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Dear Colleagues,
On behalf of the UEG Scientifi c Committee, I would like to take 
this opportunity to thank you most sincerely for your contribu-
tion as an abstract reviewer for the original programme of UEG 
Week Barcelona 2019. The abstract reviewing process is a crucial 
aspect, ensuring the scientifi c quality and relevance of UEG Week. 
I know just how much time and eff ort reviewing abstracts takes, 
but without your expertise we would not have achieved the excel-
lence in the abstract-based sessions, and UEG Week would not 
be the top international digestive diseases meeting that it has 
become today. 
Thank you! 
We received a number of 3,421 abstracts in total for UEG Week 
2019. In total, 2,443 abstracts were accepted, giving an acceptance 
rate of 71,5%. 366 abstracts will be delivered as oral presenta-
tions and 2,077 as posters. I am even more pleased to tell you 
that standards have again reached a very high level and we can 
expect most interesting research and great presentations. This 
high volume and high standard confi rm that UEG Week is the 
most important forum at which to present your best research.
Letter of Thanks 
for UEG Week 2019 Reviewers
We have received 87 video cases and 358 clinical cases which 
were formally evaluated by the Scientifi c Committee for presenta-
tion in Barcelona. As in previous years, late breaking abstracts 
have been scored by the Scientifi c Committee.
 The quality of reviewing this year was excellent, but if you have 
any further (positive or negative) comments, please do let us 
know! Finally, but most importantly, thanks to all investigators 
both within and outside Europe who have submitted their re-
search to the meeting, and who are clearly contributing to mak-
ing UEG Week Barcelona 2019 such a great success!
Herbert Tilg
Chair of the UEG Scientifi c Committee
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Opening Session: Part I
08:00 – 10:00 / Hall 6
OP001 TOP-DOWN INFLIXIMAB SUPERIOR TO STEP-UP IN 
CHILDREN WITH MODERATE-TO-SEVERE CROHN’S DISEASE - A 
MULTICENTER RANDOMIZED CONTROLLED TRIAL
Jongsma M.M.E.1, Cozijnsen M.1, van Pieterson M.1, de Meij T.2, 
Norbuis O.3, Groeneweg M.4, Wolters V.5, Wering H.6, Hojsak I.7, 
Kolho K.-L.8, Hummel T.9, Stapelbroek J.10, van der Feen C.11, 
Van Rheenen P.12, Wijk M.2, Teklenburg-Roord S.3, Escher J.C.1, 
Samsom J.13, de Ridder L.1
1Erasmus MC Sophia Children’s Hospital, Dept. of Paediatric 
Gastroenterology, Rotterdam, Netherlands, 2Amsterdam UMC - Locatie 
VUmc, Paediatric Gastroenterology, Amsterdam, Netherlands, 3Isala Hospital, 
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Introduction: In newly diagnosed paediatric Crohn’s Disease (CD) patients 
current guidelines instruct to start exclusive enteral nutrition (EEN) or oral 
prednisolone in combination with immunomodulators to achieve remis-
sion. Infl iximab (IFX) is proven to be highly eff ective in paediatric CD pa-
tients, but only used once patients are refractory, the so called step-up 
(SU) treatment strategy. 
However, evidence is emerging IFX is more eff ective the sooner it is initi-
ated. We hypothesize that initiation of IFX directly, i.e. top-down (TD) aft er 
diagnosis of moderate-to-severe CD, results in higher long term remission 
rate.
Aims & Methods: Aim: To compare effi  cacy of TD and SU treatment in new-
ly diagnosed moderate-to-severe paediatric CD 
Methods: For this international randomized controlled trial (RCT) 100 
patients aged 3-17 years, with new-onset, untreated CD with weighted 
paediatric CD activity index (wPCDAI) > 40 were included in 12 centres. 
All patients were randomly assigned to TD or SU treatment. TD treatment 
consisted of 5 IFX (CT-P13) infusions of 5 mg/kg (0, 2, 6, 14, 22 weeks) com-
bined with azathioprine (AZA). Aft er 5 infusions, IFX was stopped while 
continuing AZA. SU treatment consisted of induction therapy with EEN 
or oral prednisolone (at physician and patient/parents discretion) com-
bined with AZA as maintenance treatment. In both groups, IFX could be 
(re)started on predefi ned conditions. Primary endpoint of this study was 
sustained clinical remission (wPCDAI < 12.5) at week 52 without need for 
additional therapy or surgery. Secondary endpoints included patient rate 
using IFX at week 52, as well as clinical remission, endoscopic detection 
of mucosal healing (SES-CD < 3) and low fecal calprotectin levels (< 250 
ug/g) at week 10.
Results: Three out of 100 patients didn’t start with the study aft er random-
ization (n=97; TD:50 vs SU:47). There were no signifi cant diff erences within 
the two groups at baseline. Median age was 15.0 years [IQR 11.7-16.6] in TD, 
and 14.2 years [IQR 12.0-16.3] in the SU group. 54% and 57% were males, 
and median wPCDAI was 55 [IQR 45-65] and 57.5 [IQR 47.5-67.5]) in the TD 
vs SU group, respectively. 
For preliminary analysis of the primary endpoint data of 75/97 patients 
were available. At week 52, TD treatment resulted in sustained clinical 
remission for 18/37 [49%] of the patients compared to 5/38 [13%] of SU 
patients (p=0.001). Aft er induction therapy IFX was (re)started in 13/37 
[35%] TD patients compared to 27/38 [70%] SU patients within 52 weeks 
(p=0.001). Two patients underwent surgical resection (ileocecal resection), 
one in each treatment group. 
At week 10, TD resulted in signifi cant more patients in clinical remission 
(TD: 24/41 [59%] vs SU: 15/42 [36%], p=0.037) as well as endoscopic re-
mission (47/97 consented to repeated endoscopy; TD: 17/28 [61%]; medi-
an SES-CD 0 [IQR 0-5] vs SU: 5/29 [17%]; median SES-CD 6 [IQR 3-15.5], 
p=0.001). Lastly, signifi cantly more TD patients had a low fecal calprotectin 
level (n=44; TD: 9/23 [39%] vs SU: 4/21 [19%], p=0.005).
Conclusion: We are the fi rst to compare TD IFX to SU treatment in an RCT of 
paediatric CD patients. Although this analysis is preliminary, TD treatment 
was superior to SU in achieving sustained clinical remission (wPCDAI < 
12.5) without the need for additional therapy or surgery at week 52. More-
over, at week 10, signifi cantly more TD patients were in clinical and endo-
scopic remission and had low calprotectin levels compared to SU patients.
Disclosure: Nothing to disclose 
OP002 DEFINING THE CLONAL ORIGIN, EXPANSION RATE 
AND CLONAL DIVERSITY OF INTESTINAL METAPLASIA IN THE 
HELICOBACTER-INFECTED HUMAN STOMACH
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Introduction: Over half the world’s population is chronically infected with 
Helicobacter pylori, the main risk factor for gastric cancer (GC). Chronic 
infection provokes a mutagenic cascade involving extensive metaplastic 
remodelling of the gastric mucosa. Although gastric intestinal metaplasia 
(GIM) is an accepted pre-cursor lesion to GC, its origins, evolution and 
neoplastic potential remain unclear. An understanding of the stem cell 
dynamics and clonal diversity of GIM may allow targeted endoscopic sur-
veillance to patients at greatest risk of progression to GC.
Aims & Methods: Our objective was to develop a quantitative understand-
ing of the initiation, expansion, and clonal diversity of GIM in the chroni-
cally infl amed stomach. We developed a unique workfl ow to visualise 
and trace the clonal initiation and expansion of GIM in patients’ tissues. 
Analysis of en face embedded gastric mucosa from cancer patients (n=12) 
who underwent gastrectomy reveals a mosaic patchwork of islands of GIM. 
Using patch size dynamics, 3D modelling, and whole exome sequencing 
(WES) we quantifi ed the clonal expansion and genetic diversity of GIM. 
Comparison was made with normal gastric mucosa from patients under-
going sleeve gastrectomy for weight loss (n=12).
Results: Tracing the cellular origin of GIM in 3D, we demonstrate for the 
fi rst time that GIM originates from a single stem cell within a single gastric 
gland. These metaplastic lineages expand within the gastric gland, display 
all cellular lines of intestinal epithelial diff erentiation (enterocyte, goblet 
cells, etc) and rapidly colonise singular glandular units. Direct quantifi ca-
tion of the competitive advantage of these metaplastic lineages at single 
cell resolution shows that metaplastic stem cell lineages display biased 
drift . Patch size dynamics of neutral clonal markers in chronically infl amed 
gastric mucosa reveals a tenfold increased clonal expansion rate when 
compared to non-infl amed mucosa. Analysis of the patch size dynamics 
of GIM reveal that its clonal expansion rate is increased further by another 
order of magnitude. Finally, we have carried out whole exome sequencing 
(WES) to reconstruct the clonal phylogeny of patches of GIM and assess the 
mutation burden within metaplastic patches. Our analysis shows that the 
mutation burden of GIM is comparable to mature gastric cancer with some 
patches showing arm level copy number variation. Together, these data 
show that H. pylori provokes a massive adaptive radiation of metaplastic 
cellular clones, greatly accelerating the selection and expansion of mutant 
lineages.
Conclusion: This work reveals that the metaplastic phenotype confers a 
fi tness advantage at the level of the individual stem cell. The markedly 
exaggerated expansion rate of GIM explains the time-dependent transfor-
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OP004 EFFECTS OF FAECAL MICROBIOTA TRANSPLANTATION 
IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS): A 
RANDOMISED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY
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Introduction: The intestinal bacterial profi le in IBS patients diff ers from 
that of the healthy subjects with a low diversity (dysbiosis) (1,2,3). Mi-
crobiota dysbiosis in IBS patients is believed to play an important role in 
the pathophysiology of this disorder (3). Faecal microbiota transplantation 
(FMT) has been tried in two double-blind placebo-controlled studies (4,5). 
While the fi rst study showed improvement of the IBS symptoms, the other 
study did not show any eff ect at all. The present study was conducted to 
study the eff ect of FMT using a single donor with a favourable microbiota 
profi le.
Aims & Methods: A randomised, double-blind placebo-controlled study 
was conducted, where 164 IBS patients were randomised to either pla-
cebo, 30 g transplant or 60 g transplant in ratio 1:1:1. The primary out-
come was a reduction in the IBS-symptoms defi ned as a decrease in the 
IBS-SSS total score with ≥50 points 3 months aft er FMT. The secondary 
outcome was a reduction in the Dysbiosis index (DI) and a change in the 
intestinal bacterial profi le 3 months following FMT. Abdominal symptoms, 
fatigue and quality of life were assessed by the IBS-SSS and Birmingham 
IBS symptom, fatigue Assessment Scale, IBS-Quality of Life and the Short-
Form Dyspepsia index Questionnaires. Gut bacterial analysis was done 
using a commercially available test, GA-map Dysbiosis Test® (Genetic 
Analysis AS, Oslo, Norway).
Results: The response to FMT occurred in 23.6, 75.9 and 87.3% of patients 
received placebo, 30 g and 60 g transplant, respectively. This was accom-
panied by a signifi cant improvement in fatigue and quality of life in these 
patients. Symptom remission (SSS≥175 points) occurred in 5.5, 35.2 and 
47.3% in placebo, FMT 30 g and FMT 60 g groups, respectively. Similarly, 
a signifi cant clinical improvement in fatigue (FAS≥4 points) was found in 
21.8, 53.7 and 52.7% of patients received placebo, FMT30 g and FMT 60 g, 
respectively. The corresponding fi gures for the quality of life (IBS-QoL≥14 
points) were 7.3, 61.1 and 58.2%. DI did not decrease signifi cantly in pa-
tients received FMT or placebo. The intestinal bacterial profi les changed in 
both groups received 30 and 60 g transplant, but not in the placebo group.
Conclusion: FMT is an eff ective treatment for patients with IBS. A well-de-
fi ned donor with normal DI and favourable specifi c microbial signature is 
essential for the success of FMT. Response to FMT increases with increased 
dose. There was a signifi cant diff erence in the intestinal bacterial profi le 
between responders and non-responders, which might be used to identify 
candidates for FMT.
References: 
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ing irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 12: 439-
445, 2018. 
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mation of the gastric mucosa into a competitive fi eld of cancer precursor 
lineages. Clonal genetic diversity may be a potential marker for GC pro-
gression risk in chronic gastritis patients.
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OP003 THE NEUROPEPTIDE RECEPTOR ACTIVITY MODIFYING 
PROTEIN (RAMP)1 PROMOTES LIVER REGENERATION BY 
REGULATING YES-ASSOCIATED PROTEIN (YAP) ACTIVITY DURING 
ACUTE OR CHRONIC LIVER INJURY
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Introduction: The adult liver has a high capacity to regenerate aft er acute 
injury. In addition, chronic liver damage in patients with liver fi brosis trig-
gers proliferation of residual hepatocytes and, thus, prevents liver failure. 
The liver is innervated by sensory nerves containing the neuropeptide 
calcitonin gene-related peptide (CGRP) that binds to the receptor activity-
modifying protein (RAMP)1.
Aims & Methods: We aim to investigate whether the neuropeptide CGRP 
is able to modulate liver regeneration upon partial hepatectomy and dur-
ing hepatic fi brosis. Wild type and RAMP1 defi cient mice were subjected 
either to 70% partial hepatectomy (PH) or were injected with carbon tetra-
chloride (CCl4) for four weeks to induce chronic liver fi brosis. The de novo 
synthesis of CGRP receptor components in liver tissues of both models was 
determined by quantitative RT-PCR. Hepatocyte proliferation was quanti-
fi ed using Ki67- and BrdU-specifi c immunohistochemistry, and cell cycle 
regulatory components were analyzed by western blot and quantitative 
RT-PCR. Sirius Red staining was performed in order to assess collagen 
fi bers deposition within hepatic parenchyma. Protein expression of fi brotic 
markers, such as α-SMA and collagen, was evaluated by western blot. 
Involvement of CGRP/RAMP1 in the Hippo pathway was tested by the pres-
ence of global or active YAP, as well as global and active YAP-regulators 
LATS1/2 and MOB1 using western blot analysis. To investigate the direct 
eff ect of CGRP signaling on hepatocytes or intact liver tissue in vitro, we 
stimulated primary hepatocytes or precision-cut liver slices with CGRP and 
analyzed YAP signaling components by detecting global and phosphory-
lated YAP protein by western Blot analysis.
Results: Liver injury induced through partial hepatectomy or CCl4-injec-
tion caused a sustained upregulation of hepatic CGRP mRNA and a late 
increase of RAMP1 expression. During liver fi brosis absence of RAMP1 
impairs collagen fi bers deposition as well as expression of α-SMA and 
Collagen Type 1 proteins. RAMP1 defi ciency severely delayed recovery of 
organ mass upon PH, and inhibited hepatocyte proliferation and cell cycle 
progression in both liver injury models. Mechanistically, expression of the 
Hippo pathway-regulated transcriptional coactivator YAP was decreased 
in livers of RAMP1-defi cient mice following either partial hepatectomy or 
4-weeks’ CCl4 injection. RAMP1 defi ciency impaired nuclear localization 
of YAP protein in hepatocytes and upregulation of YAP target genes in 
regenerating livers. Phosphorylation of YAP on Ser127 and Ser397, which 
promote YAP cytoplastic retention and extranuclear degradation, was 
found to be elevated in RAMP1-defi cient livers in both models. Consis-
tently, phosphorylation of the YAP kinases LATS1/2 as well as MOB1 was 
upregulated. Stimulation of primary hepatocytes or precision-cut liver 
slices with the neuropeptide CGRP corroborated our in vivo results in an 
in vitro setting and demonstrates that CGRP/RAMP1 signaling positively 
regulates YAP activity.
Conclusion: Our study identifi es the neuropeptide CGRP signaling via its 
receptor RAMP1 as a previously unrecognized inducer of YAP activity in 
liver regeneration upon acute and chronic injury.
Disclosure: Nothing to disclose 
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OP005 REAL-WORLD SAFETY OF VEDOLIZUMAB AND ANTI-TNF 
THERAPIES IN BIOLOGIC-NAÏVE ULCERATIVE COLITIS AND CROHN’S 
DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
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Introduction: The GEMINI phase III clinical trials showed a favourable safe-
ty profi le for vedolizumab (VDZ) in treating patients (pts) with moderate-
to-severely active ulcerative colitis (UC) and Crohn’s disease (CD), however 
real-world studies are needed comparing the safety of VDZ to anti-tumour 
necrosis factors (anti-TNF) agents.
Aims & Methods: The objective was to compare the safety of VDZ and anti-
TNF agents in a real-world cohort of biologic (bio)-naïve pts with UC or CD. 
This was a multi-country (Canada, Greece and the United States), retro-
spective chart review study of bio-naïve pts (≥18 years old) with ≥ 6 months 
follow-up, initiating treatment (Tx) with VDZ or an anti-TNF [adalimumab, 
infl iximab, golimumab, certolizumab pegol] between May 2014 and March 
2018. Data were collected from Tx initiation to earliest of death, chart ab-
straction date or 6 months post-Tx discontinuation (Canada only). Serious 
adverse events (SAEs) and serious infections (SIs) (defi ned as either life 
threatening, requiring hospital admission, resulting in signifi cant disabil-
ity/incapacity, or recorded in the chart as an important medical event) oc-
curring from Tx initiation up to fi ve half-lives post-Tx discontinuation were 
assessed. Incidence rates (per 100 person-years [PYs]) of SAEs and SIs were 
estimated. A Cox proportional hazards model adjusted for baseline charac-
teristics was used to compare incidence rates between Tx cohorts. Adjusted 
hazard ratios (HR) with 95% confi dence intervals (CI) are reported.
Results: This study included 1,095 pts (VDZ: 598 [UC: 380; CD: 218]; anti-
TNF: 497 [UC: 224; CD: 273]) from 42 sites. Compared to anti-TNF pts, the 
VDZ cohort were older (mean [SD] age [years]: VDZ, 47.9 [17.4]; anti-TNF, 
39.6 [15.2] [p< 0.01]), were proportionately more male (male: VDZ, 56.9%; 
anti-TNF, 49.9% [p=0.02]) and had a longer disease duration (median 
[range: min-max] disease duration [years]: VDZ, 5.0 [0.04- 54.0]; anti-TNF, 
2.0 [< 0.1 - 49.0] [p< 0.01]). Median (range: min-max) follow-up (months) 
was: VDZ, 15.3 (3.0-47.0); anti-TNF, 16.3 (3.5-51.0). Incidence rates of fi rst 
occurrence (per 100 PY [95% CI]) of SAEs (VDZ: 4.6 [3.5-6.8]; anti-TNF: 10.3 
[9.5-14.9]) and SIs (VDZ: 2.6 [1.9-4.4]; anti-TNF: 7.0 [5.9-10.2]) were sig-
nifi cantly lower in VDZ versus anti-TNF pts (adjusted HR: SAE, 0.42 [0.27-
0.66]; SI, 0.33 [0.18-0.58]). Similar trends were shown when data were 
stratifi ed by UC and CD, separately (Table 1). 
  Ulcerative Colitis Crohn’s Disease
Outcome
Vedolizumab 
IR (95% CI) 
N=380
Anti-TNF 
IR (95% CI) 
N=224
Adjusted 
Hazard Ratio 
(95% CI)
Vedolizumab 
IR (95% CI) 
N=218
Anti-TNF 
IR (95% 
CI) N=273
Adjusted 
Hazard Ratio 
(95% CI)
Serious 
Adverse 
Events
3.8 
(2.6-6.2)
11.3 
(8.9-17.5)
0.34 
(0.19-0.63)*
3.0 
(1.8-5.0)
5.7 
(3.5-9.4)
0.47 
(0.22-1.02)
Serious 
infections
6.1 
(4.1-10.5)
9.5 
(7.7-14.5)
0.45 
(0.23-0.89)*
1.9 
(0.8-4.5)
7.9 
(5.5-11.3)
0.18 
(0.06-0.50)*
Data are incidence rates (95% CI) and hazard ratios (95% CI). Incidence rates are unadjusted 
and are per 100 person-years; hazard ratios are from adjusted Cox proportional hazards models 
(adjusted for baseline confounders: age, sex, disease duration, albumin, C-reactive protein, UC/
CD-related hospitalisations [prior 12 months] and disease severity). Indication (UC/CD) was a 
covariate for the overall analysis and was not included for disease specifi c models. CD: Crohn’s 
Disease; UC: Ulcerative colitis, IR: Incidence rate.
Half-lives for treatments: VDZ: 125days (18 weeks), Infl iximab: 47.5 days (6.8 weeks), Infl iximab-
dyyb: 47.5 days (6.8 weeks), Infl iximab-abda: 47.5 days (6.8 weeks), Adalimumab: 70 days (10 
weeks), Adalimumab-atto: 70 days (10 weeks), Golimumab: 70 days (10 weeks), Certolizumab 
pegol: 70 days (10 weeks). *Signifi cant diff erence between VDZ and Anti-TNF cohorts based on 
adjusted HRs.
[Table 1. Safety Pro le of Vedolizumab and Anti-TNF Therapies in Real-World 
Biologic-Naïve Ulcerative Colitis and Crohn’s Disease Patients]
Lastly, the proportion of pts who experienced gastrointestinal (GI) infec-
tions was signifi cantly higher among anti-TNF versus VDZ pts (4.4% versus 
1.5%, respectively, p< 0.01).
Conclusion: Bio-naïve pts treated with VDZ had a signifi cantly lower like-
lihood of experiencing SAEs and SIs, including GI infections, than those 
treated with anti-TNF therapies. These data support a favourable safety 
profi le of VDZ versus anti-TNF in bio-naïve infl ammatory bowel disease pts 
in real-world clinical practice. 
Disclosure: The study was funded by Takeda Pharmaceuticals Company Ltd. 
BB, AY, UK and GM received honoraria from Takeda Pharmaceuticals Com-
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from Takeda Pharmaceuticals Company Ltd. TL, CL, AN, CK, SS, DD and HP 
are employees of Takeda Pharmaceuticals Company Ltd. 
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CANCER IN THE TOFACITINIB ULCERATIVE COLITIS PROGRAMME
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Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor 
for the treatment of ulcerative colitis (UC). We present an update on the 
integrated analysis of non-melanoma skin cancer (NMSC) events in the 
tofacitinib UC clinical programme, as of Sep 2018.
Aims & Methods: The safety of tofacitinib for the treatment of mod-
erate to severe UC was evaluated in a randomised, placebo (PBO)-
controlled induction Phase (P) 2 study (NCT00787202),1 two induction 
P3 studies (NCT01465763; NCT01458951), one maintenance P3 study 
(NCT01458574),2 and an ongoing open-label, long-term extension (OLE) 
study (NCT01470612).3 Patients (pts) were analysed as three cohorts: 
Induction (P2/P3 induction studies); Maintenance (P3 maintenance study); 
Overall (pts receiving ≥1 dose of tofacitinib 5 or 10 mg twice daily [BID] in 
P2, P3 or ongoing OLE studies). For P3 studies, a blinded independent ad-
judication committee reviewed potential NMSC. Proportions and incidence 
rates (IRs; unique pts with events per 100 pt-years [PY] of exposure) for 
NMSC were evaluated. A Cox proportional hazards model was used for risk 
factor analysis. Overall Cohort data are as of Sep 2018.
Results: 1124 pts were evaluated for NMSC (P3 studies only), with 2399 PY 
of tofacitinib exposure and up to 6.1 years of treatment. NMSC occurred in 
two Induction pts receiving tofacitinib 10 mg BID. In the Maintenance Co-
hort, the NMSC IR for pts receiving PBO was 0.97 (one pt) and was 1.91 for 
tofacitinib 10 mg BID (three pts) (Table). In the Overall Cohort, the NMSC 
IR for tofacitinib-treated pts was 0.78 (19 pts): 0.82 for pts receiving a pre-
dominant dose (PD) of 10 mg BID (defi ned as an average daily dose ≥15 
mg; 15 pts) and 0.67 for pts receiving a PD of 5 mg BID (an average daily 
dose < 15 mg; four pts). Ten pts had squamous cell carcinoma (SCC) and 
12 pts had basal cell carcinoma (BCC); three pts had both SCC and BCC. No 
NMSC was metastatic or led to study discontinuation. Of all tofacitinib-
treated pts with NMSC, seven had prior NMSC history, 18 had prior use 
of thiopurines and 15 had prior tumour necrosis factor inhibitor (TNFi) 
exposure. The Overall Cohort showed higher IRs for subgroups of pts aged 
≥50 years (1.93 [95% confi dence interval (CI) 1.08, 3.19]) vs 40 to < 50 years 
(0.74 [95% CI 0.20, 1.89]), 30 to < 40 years (0.00 [95% CI 0.00, 0.58]) and 
< 30 years (0.00 [95% CI 0.00, 0.77]), and for pts with prior TNFi treatment 
(1.23 [95% CI 0.69, 2.04]) vs those without (0.33 [95% CI 0.09, 0.84]), or 
prior immunosuppressant use (0.99 [95% CI 0.59, 1.57]) vs those without 
(0.16 [95% CI 0.00, 0.90]). Cox regression selected prior NMSC (hazard 
ratio [HR] 10.95; 95% CI 3.72, 32.24; p< 0.0001) and age (HR per 10-year 
increase 2.10; 95% CI 1.41, 3.13; p=0.0003) as signifi cant risk factors for 
NMSC.
Conclusion: NMSC events were infrequent in the tofacitinib UC programme, 
and were more likely to occur in pts with prior NMSC and with increasing 
age, known risk factors for the development of NMSC.4 NMSC IRs were 
similar to those reported for tofacitinib in other indications, including for 
tofacitinib in rheumatoid arthritis,5 and for biologic UC treatments.6 
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OP007 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE 
COLITIS: ANALYSIS OF INFECTION RATES IN THE TOFACITINIB 
ULCERATIVE COLITIS CLINICAL PROGRAMME
Winthrop K.L.1, Loft us Jr. E.V.2, Baumgart D.C.3, Salese L.4, Thorpe A.J.4, 
Lawendy N.4, Chan G.4, Pedersen R.D.4, Reinisch W.5
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Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor 
for the treatment of ulcerative colitis (UC). The safety of tofacitinib for the 
treatment of moderate to severe UC was evaluated in an 8-week induc-
tion Phase 2 study (NCT00787202),1 two 8-week induction Phase 3 studies 
(OCTAVE Induction 1 & 2; NCT01465763 & NCT01458951) and a 52-week 
maintenance Phase 3 study (NCT01458574),2 plus an ongoing, open-label, 
long-term extension (OLE) study (OCTAVE Open, NCT01470612).3 Here, we 
present an update on infections observed in the tofacitinib UC clinical pro-
gramme as of Sep 2018.4,5
All NMSC Induction Cohort(8 weeks)
Maintenance Cohort 
(52 weeks)
Overall 
Cohort
(≤6.1 years)
 
Placebo 
(N=282)
Tofacitinib
10 mg BID 
(N=938)
Placebo 
(N=198)
Tofacitinib
5 mg BID 
(N=198)
Tofacitinib
10 mg BID 
(N=196)
Tofacitinib
All
(N=1157)
Age (years), 
mean (SD)
41.4 
(14.4)
41.3 
(13.8)
43.4 
(14.0)
41.9 
(13.7)
43.0 
(14.4)
41.3 
(13.9)
Exposure, 
PYa
40.39 158.37 103.20 148.77 156.80 2398.6
Pts with 
events, n 
(%)a
0 (0.0) 2 (0.2) 1 (0.5) 0 (0.0) 3 (1.5) 19 (1.7)b
IR (95% CI)a
0.00
(0.00, 9.13)
1.26
(0.15, 4.56)
0.97
(0.02, 5.40)
0.00
(0.00, 2.48)
1.91
(0.39, 5.59)
0.78
(0.47, 1.22)
Data are as of Sep 2018 for the Overall Cohort (OLE study database not locked)
aAdjudicated data do not include data from the P2 Study (A3921063; NCT00787202); 
bIncluding fi ve pts from the P3 Induction and Maintenance Cohorts
BID, twice daily; CI, confi dence interval; IR, incidence rate (unique patients with events 
per 100 PY of exposure); N, number of patients randomised and treated; N/A, not 
applicable; NMSC, non-melanoma skin cancer; OLE, open-label, long-term extension; P, 
Phase; pts, patients; PY, patient-years
[Table. Demographics, and proportions and IRs for all NMSC events, for the 
Induction, Maintenance and Overall Cohorts]
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2. Sandborn WJ et al. N Engl J Med 2017; 376: 1723-1736. 
3. Lichtenstein GR et al. Am J Gastroenterol 2018; 113 (Suppl 1): Abstract 571.
4. Marcil I and Stern RS. Arch Dermatol 2000; 136: 1524-1530.
5. Cohen SB et al. Ann Rheum Dis 2017; 76: 1253-1262.
6. FDA Advisory Committee Meeting sNDA 203214. FDA 2018: Supplement 
018 (available at www.fda.gov).
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Inc and TARGET PharmaSolutions. L Baidoo has received research support 
and advisory board fees from Pfi zer Inc, and speaker’s bureau fees from 
Takeda. 
W Reinisch has received research support, consultancy fees, advisory board 
fees and speaker’s bureau fees from Abbott Laboratories, AbbVie, Aesca, 
Centocor and MSD; consultancy fees, advisory board fees and speaker’s 
bureau fees from Astellas, Celltrion, Danone Austria, Elan, Ferring, Mit-
subishi Tanabe Pharma Corporation, Otsuka, PDL, Pharmacosmos, Scher-
  Induction Cohort Maintenance Cohort Overall Cohort 
 
Placebo 
(N=282; 44.8 PY) 
Tofacitinib 10 mg 
BID 
(N=938; 156.2 PY) 
Placebo (N=198; 
100.4 PY) 
Tofacitinib 5 mg BID 
(N=198; 146.2 PY) 
Tofacitinib 10 mg 
BID (N=196; 154.3 
PY) 
PD Tofacitinib 5 mg 
BID (N=197; 595.5 
PY) 
PD Tofacitinib 10 
mg BID (N=960; 
1808.1 PY) 
Tofacitinib All
(N=1157; 2403.6 PY) 
AEs (all), n (%) 155 (55.0) 515 (54.9) 149 (75.3) 143 (72.2) 156 (79.6) 183 (92.9) 793 (82.6) 976 (84.4)
Infections (all), 
n (%), IR [95% CI]b
43 (15.2) 196 (20.9)
48 (24.2),
58.16 [42.88, 77.12]
71 (35.9),
62.54 [48.85, 78.89]
78 (39.8),
72.82 [57.56, 90.88]
131 (66.5),
46.76 [39.10, 55.49]
498 (51.9),
53.45 [48.86, 58.35]
629 (54.4),
51.90 [47.92, 56.12]
Serious infections, 
n (%), IR [95% CI]b
0 (0.0) 8 (0.9)
2 (1.0),
1.94 [0.23, 7.00]
2 (1.0),
1.35 [0.16, 4.87]
1 (0.5),
0.64 [0.02, 3.54]
8 (4.1), 
1.32 [0.57, 2.61]
35 (3.6), 
1.89 [1.32, 2.63]
43 (3.7),
1.75 [1.27, 2.36]
OIs, n (%), 
IR [95% CI]b,c,d
0 (0.0) 3 (0.3)
1 (0.5),
0.97 [0.02, 5.42]
2 (1.0),
1.36 [0.16, 4.92]
4 (2.0),
2.60 [0.71, 6.65]
8 (4.1), 
1.37 [0.59, 2.71]
20 (2.2), 
1.09 [0.66, 1.68]
28 (2.5),e 
1.16 [0.77, 1.67]
Non-herpes-zoster 
OIs, n (%), 
IR [95% CI]b,c,d
0 (0.0) 1 (0.1)
0 (0.0),
0.00 [0.00, 3.57]
0 (0.0),
0.00 [0.00, 2.48]
0 (0.0),
0.0 [0.00, 2.35]
1 (0.5),
0.16 [0.00, 0.92]
3 (0.3), 
0.16 [0.03, 0.47]
4 (0.4),
0.16 [0.04, 0.42]
Herpes zoster (all), 
n (%), IR [95% CI]b
1 (0.4) 6 (0.6)
1 (0.5),
0.97 [0.02, 5.42]
3 (1.5),
2.05 [0.42, 6.00]
10 (5.1),
6.64 [3.19, 12.22]
19 (9.6), 
3.62 [2.06, 5.35]
64 (6.7),
3.42 [2.78, 4.62]
83 (7.2),
3.57 [2.84, 4.43]
Data are as of Sep 2018 for the Overall Cohort (OLE study database not locked)
aOnly patients with events occurring within 28 days aft er the last dose are included in this table for calculation of proportion and IR; bData for the Induction Cohort are shown as n (%) due 
to the short duration (8 weeks) of the induction studies; cInfection endpoints are based on adjudicated data; adjudicated events are calculated as percentage (%), based on the number 
of patients in the studies in which adjudication was performed; dExcludes Phase 2 patients; eOf the 28 patients with OIs in the Overall Cohort, 24 had herpes zoster (herpes zoster OIs were 
either multidermatomal [2 non-adjacent or 3-6 adjacent dermatomes] or disseminated [any of: diff use rash >6 dermatomes, encephalitis, pneumonia, other non-skin organ involvement]), 1 
had cytomegalovirus infection, 1 had histoplasmosis, 1 had cytomegalovirus hepatitis and 1 had pulmonary mycosis
AE, adverse event; BID, twice daily; CI, confi dence interval; IR, incidence rate (patients with events per 100 PY of exposure); N, number of patients treated in the treatment group; n, number 
of patients with a particular AE; OI, opportunistic infection; OLE, open-label, long-term extension; PD, predominant dose; PY, patient-years
[OP007 Table. Summary of incidence of treatment-emergent infections (all causality)a in the Induction, Maintenance and Overall Cohorts]
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Aims & Methods: Patients who received placebo, tofacitinib 5 or 10 mg twice 
daily (BID) were analysed as three cohorts: Induction (Phase 2 & Phase 3 
studies, N=1220), Maintenance (Phase 3, N=592) and Overall (patients in 
Phase 2, Phase 3 & ongoing OLE studies receiving tofacitinib 5 or 10 mg 
BID, N=1157). Proportions and incidence rates (IRs; patients with events per 
100 patient-years [PY] of exposure, 95% CI) were evaluated for infections of 
special interest (including serious infections, opportunistic infections [OIs], 
herpes zoster and tuberculosis). OIs were based on review by an indepen-
dent adjudication committee. Overall Cohort data are as of Sep 2018.
Results: In total, 1157 patients received >1 dose of tofacitinib 5 or 10 mg 
BID (83% of patients received a predominant tofacitinib dose of 10 mg 
BID [average daily dose ≥15 mg]), with 2403.6 PY of tofacitinib exposure 
(median 623 days) and up to 6.1 years of treatment. In the Overall Cohort, 
the infections IR (95% CI) was 51.90 (47.92, 56.12), with nasopharyngitis 
being the most frequently occurring infection. For serious infection events, 
the IR (95% CI) for all tofacitinib-treated patients in the Overall Cohort 
(1.75 [1.27, 2.36]) was similar to those of the Maintenance Cohort (1.35 [0.16, 
4.87] for tofacitinib 5 mg BID and 0.64 [0.02, 3.54] for 10 mg BID). No seri-
ous infection events resulted in death. OIs occurred infrequently in the UC 
programme, with an Overall Cohort IR (95% CI) of 1.16 (0.77, 1.67). Of 28 
patients with OIs, the majority were patients with herpes zoster (n=24; IR 
0.99 [95% CI 0.63, 1.47]) mostly limited to skin involvement. Not all herpes 
zoster events were reported as OIs, with 83 patients overall with herpes 
zoster events (IR 3.57 [95% CI 2.84, 4.43]), of which six were classed as 
serious herpes zoster (IR 0.24 [95% CI 0.09, 0.53]).
Conclusion: Serious infections were infrequent in the UC clinical pro-
gramme and IRs in the Overall Cohort did not suggest an increasing risk 
of serious infections with longer duration of tofacitinib treatment when 
compared with IRs of the Maintenance Cohort. OIs were rare, with the 
exception of herpes zoster. The incidence of serious infections was similar 
in the Overall Cohorts of the UC and rheumatoid arthritis programmes 
(including increased risk of herpes zoster)6 and that of other UC therapies 
including biologics.7
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OP008 HIGH SEROCONVERSION RATE TO TRIVALENT INFLUENZA 
VACCINE DURING USTEKINUMAB TREATMENT IN CROHN’S DISEASE: 
RESULTS FROM A PROSPECTIVE COHORT STUDY
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Introduction: Infl uenza vaccination may be less eff ective in patients with 
infl ammatory bowel disease treated with immunosuppressive therapy, es-
pecially with combined use of anti-TNFα agents and immunomodulators. 
However, little is known regarding the eff ects of anti-IL-12/23 therapy on 
the effi  cacy of vaccination. Therefore, the aim of this study was to investi-
gate the immune response to the 2018-2019 inactivated trivalent infl uenza 
vaccine (TIV) in Crohn’s disease (CD) patients treated with ustekinumab 
(UST) as compared to CD patients treated with adalimumab (ADA) and 
healthy controls (HC).
Aims & Methods: A prospective open-label study was conducted to ex-
amine the immunogenicity of the 2018/2019 inactivated TIV in adult CD 
patients treated with UST. Patient details, disease characteristics and vacci-
nation history were recorded. Age and gender matched CD patients treated 
with ADA and healthy controls were included as control populations. Blood 
samples were drawn at 3 time points, T0: before vaccination, T1: 4 to 6 
weeks aft er vaccination and T3: 3 months aft er vaccination. Hemagglutinin 
inhibition (HI) assays for all 3 infl uenza vaccine strains (A/Michigan/2015/
H1N1; A/Singapore/2016/H3N2, B/Victoria) were performed simultaneously 
on all study samples.
Results: A total of 15 CD patients treated with UST, 14 CD patients treated 
with ADA and 20 healthy controls (HC) were included and received TIV 
between October and December 2018. In UST group, 4 patients received 
co-medication (2 MTX, 1 high-dose prednisone and 1 low-dose predni-
sone). In ADA group, 5 patients received co-medication (2 thiopurine and 
3 low-dose prednisone). Post-vaccination seroprotection rates (HI titer 
≥1:40) were high in all 3 study groups, no signifi cant diff erences between 
study groups were observed (Table 1). 
      HC ADA UST P-value overall
P-value 
ADA vs 
HC
P-value 
UST vs 
HC
P-value 
ADA vs 
UST
A/H3N2 Seroprotection rate (%) T1 100 100 100 1* 1** 1** 1**
 
Seroconversion 
rate (%) T1/T0 30.0 18.2 69.2 0.023* 0.676** 0.038** 0.019**
 
Beyer corrected 
MFI T1/T0 2.15 1.86 2.31 0.121° 0.070^ 0.624^ 0.087^
 
Beyer corrected 
MFI T3/T0 1.93 1.55 2.12 0.030° 0.026^ 0.396^ 0.017^
A/H1N1 Seroprotection rate (%) T1 100 90.9 91.7 0.280* 0.355** 0.375** 1**
 
Seroconversion 
rate (%) T1/T0 47.4 33.3 70.0 0.335* 0.687** 0.433** 0.179**
 
Beyer corrected 
MFI T1/T0 1.96 1.79 2.03 0.280° 0.451^ 0.431^ 0.091^
B/
Victoria
Seroprotection 
rate (%) T1 85.0 66.7 92.3 0.281* 0.379** 1** 0.160**
 
Seroconversion 
rate (%) T1 35.0 33.3 61.5 0.278* 1** 0.169** 0.238**
 
Beyer corrected 
MFI T1/T0 1.49 1.15 1.73 0.022° 0.307^ 0.043^ 0.008^
 
Beyer corrected 
MFI T3/T0 1.319 1.055 1.627 0.021° 0.346^ 0.036^ 0.009^
[Table 1 Immune response to seasonal trivalent in uenza vaccine in 3 study 
groups. *Fisher-F.-H. exact, **Fisher’s exact, ⁰ Kruskal-Wallis, ^Mann-
Wh.U]
Seroconversion rates (≥4-fold increase in HI titer compared to pre-vaccina-
tion) for strain A/H3N2 were signifi cantly higher at both time points in UST 
group as compared to ADA group (T1; p = 0.019, T3; p = 0.015) and HC (T1; 
p = 0.038, T3; p = 0.029). Geometric mean titres (GMT) at T1 and T3 were 
lower for all strains in ADA group, as compared to UST group and HC, and 
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reactions, delayed hypersensitivity, edema, allergy, anaphylaxis, psoriasis, 
lupus-like syndrome) were compared, as well as the rate of secondary loss 
of response (SLR).
Results: We included 939 (12%) patients who started infl iximab over 60 
years and 6,844 (88%) patients below 50 years. The rate of IAE (15% vs. 
15%, ns) and treatment withdrawal due to IAE (13% vs. 12%, ns) was simi-
lar in both groups. Neither diff erences were observed according to IAE: 
infusion reactions (8.3% vs. 8.2%), late hypersensitivity (1.4% vs. 1.2%), 
paradoxical psoriasis (0.9% vs. 1.4%) and drug-induced lupus erythema-
tosus (0.7% vs. 0.6%). Patients below 50 years were signifi cantly more 
oft en treated with concomitant immunosuppressants (57% vs. 48.1%> 60 
years, p< 0.05). In the multivariate analysis, combination with immuno-
mosuppressants (OR 0.741; 95%CI 0.64-8.5, p< 0.05) and female sex (OR 
1.8; 95%CI 1.6-2.1 p< 0.05) were the only independent predictors to de-
velop IAE. The rate of SLR was also similar in both study groups (20% vs. 
21%). Combination therapy with immunomosuppressants was the unique 
risk factor to develop SLR (OR 0.85; CI95% 0.73 to 0.98, p=0.021).
Conclusion: Elderly IBD patients who start treatment with infl iximab have 
a similar risk of developing IAE and SLR than younger patients. From this 
point of view, elderly would benefi t from combination therapy.
Disclosure: Nothing to disclose 
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Introduction: Infl ammatory bowel disease (IBD) has a high incidence in 
population of childbearing age. Ustekinumab, a fully human monoclonal 
antibody targeting the p40 subunit of interleukins 12 and 23, and vedoli-
zumab, an anti α4β7 integrin, are biologics currently used in IBD with 
immunosuppressant or anti TNF failure. Data concerning use and safety of 
these new biologics during pregnancy are scarce.
Aims & Methods: We conducted a retrospective multicenter study in the 
GETAID group and collected cases of women with IBD who received at least 
one injection of ustekinumab or vedolizumab during pregnancy or in the 
last 2 months before conception. The aims of the study were (1) to evalu-
ate pregnancy and neonatal outcomes in IBD female patients exposed to 
ustekinumab or vedolizumab during pregnancy, and (2) to observe the im-
pact of ustekinumab or vedolizumab withdrawal on disease activity during 
pregnancy and postpartum.
Results: Sixty-seven pregnancies in 62 IBD females (43 for Crohn’s disease 
and 19 for ulcerative colitis) were reported among 19 centers of the GETAID 
group. Median age at conception was 29 years. Median time between in-
troduction of ustekinumab or vedolizumab treatment and pregnancy was 
12 months. Twenty-fi ve pregnancies occurred on ustekinumab: 7 received 
signifi cantly lower for the A/H3N2 strain in ADA group as compared to HC 
(T1; p= 0.032, T3 p = 0.015). Aft er correcting for high GMTs at baseline using 
Beyer’s method, mean fold increase (MFI) in titers at T3 for A/H3N2 strain 
was signifi cantly lower in ADA group as compared to HC (p = 0.026) and 
UST group (p = 0.017). MFI for the B/Victoria strain was high in UST group 
and signifi cantly higher than in ADA group (T1; p = 0.008, T3; p = 0.009). 
Sub-analysis aft er exclusion of patients on combination therapy showed 
similar seroconversion rates.
Conclusion: Seroconversion rate to the seasonal trivalent infl uenza vaccina-
tion during ustekinumab treatment in CD patients is high, in contrast to the 
reduced rate observed for adalimumab. Patients treated with ustekinumab 
can be eff ectively vaccinated with the trivalent infl uenza vaccine. 
Disclosure: Nothing to disclose 
OP009 RISK OF IMMUNOMEDIATED ADVERSE EVENTS OR 
SECONDARY LOSS OF RESPONSE TO INFLIXIMAB IN ELDERLY 
PATIENTS WITH INFLAMMATORY BOWEL DISEASE. A COHORT STUDY 
OF THE ENEIDA REGISTRY
Calafat Sard M.1, Mañosa M.2,3, Ricart E.3,4, Nos Mateu P.3,5, Iglesias E.6, 
Vera I.7, López-San Roman A.8, Guardiola J.9, Taxonera C.10, Mínguez M.11, 
Martin-Arranz M.12, De Castro L.13, Riestra S.14, Rivero M.15, 
García-Planella E.16, Calvet X.3,17, García-López S.18, Andreu M.19, 
Gomollon Garcia F.3,20, Barrio Andrés J.21, Esteve Comas M.3,22, 
Rodríguez A.23, P. Gisbert J.3,24, Gutierrez A.25, Hinojosa J.26, Argüelles F.27, 
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Introduction: Infl iximab is one of the most used biological drugs in infl am-
matory bowel disease (IBD). Immunomediated adverse events (IAE) are 
of the most frequent reported infl iximab-related adverse events. Elderly 
patients have diff erential pharmacodynamic and pharmacokinetic charac-
teristics. 
We recently reported an increased risk of thiopurine-related AEs in this 
population; hence, it would be relevant to ascertain if combined treatment 
is adequate in this population.
Aims & Methods: Our aim was to evaluate the rate of infl iximab-related 
IAE in elderly IBD patients. Methods: All adult patients in the ENEIDA reg-
istry (a large, prospectively maintained database of the Spanish Working 
Group in IBD -GETECCU) who received a fi rst course of infl iximab treatment 
were identifi ed. Patients were selected in two cohorts regarding the age at 
the beginning of infl iximab treatment: over 60 years, and between 18 and 
50 years of age. The rates of IAE recorded in the ENEIDA database (infusion 
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ustekinumab in the last 2 months before conception, 11 received 1 injec-
tion aft er conception, and 7 stopped ustekinumab in the 2nd trimester. 
Among the 25 pregnancies occurred on ustekinumab, there were 22 (88%) 
live births, 1 elective termination and 2 spontaneous abortions. Maternal 
complications were reported in 2 women (one gestational diabetes and 
one threat of premature labor). Fetal complications were reported in 3 
pregnancies (intra uterine growth restriction). Four newborns presented 
a non severe neonatal complication (3 preterm deliveries, one low birth 
weight) and one a Tetralogy of Fallot . Forty-two pregnancies occurred on 
vedolizumab: 15 received vedolizumab in the last 2 months before concep-
tion, 16 received 1 injection aft er conception, and 11 stopped vedolizumab 
(6 during the 2nd trimester and 5 during the 3rd trimester). Among the 42 
pregnancies occurred on vedolizumab, there were 36 (86%) live births, 1 
elective termination (for Down Syndrom) and 5 (12%) spontaneous abor-
tions. Maternal complications were reported in 5 women (one cholestasis 
and 4 pre-eclampsia). Fetal complications were reported in one pregnancy 
(intra uterine growth restriction) and 13 newborns developed a neonatal 
complication (6 preterm deliveries, 6 low birth weight and one congenital 
corpus callosum hypoplasia). Concerning IBD activity, 65% of women were 
in remission at conception. Among them, only 2 patients fl ared during 
pregnancy.
Conclusion: We reported in 67 pregnancies under vedolizumab or ustekin-
umab exposition, no severe neonatal (except a cardiac malformation) and 
maternal complications. However, additional prospective evaluations re-
garding safety concerns pregnancy outcomes in patients directly exposed 
to ustekinumab or vedolizumab are needed.
Disclosure: Travelling: Janssen, Biogaran Board: Ferring Speaker: Takeda 
Therapeutic nutrition in IBD
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OP011 HIGH PHENOLIC ACID INTAKE IS A PROTECTIVE FACTOR 
FROM COLORECTAL ADENOMAS AMONG EVER-SMOKERS
Fliss Isakov N.1, Grosso G.2, Salomone F.2, Godos J.3, Shibolet O.4, Kariv R.5, 
Zelber-Sagi S.6
1Tel Aviv Sourasky Medical Center, Gastroenterology, Tel Aviv, Israel, 2Azienda 
Sanitaria Provinciale di Catania, Gastroenterology, Catania, Italy, 3Azienda 
Sanitaria Provinciale di Catania, Catania, Italy, 4Tel Aviv Medical Center, 
Gastroenterology, Tel Aviv, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv, 
Israel, 6University of Haifa, Health Promotion, Tel Aviv, Israel
Contact E-Mail Address: naomishfi @gmail.com
Introduction: Polyphenols are a family of phytochemicals, demonstrating 
anti-infl ammatory and antioxidant properties. High intake of phenolic 
acid have been linked with reduced risk of colorectal cancer (CRC) and 
adenoma, while smoking has been linked with a higher risk. However, the 
association of phenolic acids with diff erent types of colorectal adenomas 
and the interaction with smoking has yet been tested.
Aims & Methods: The aims of this study were to explore the independent 
association between phenolic acid intake and colorectal adenomas, and to 
evaluate the potential interaction with smoking. This was a case-control 
study, among consecutive subjects aged 40-70 years, undergoing colonos-
copy during 2010-2015. Cases with colorectal adenomas were compared 
to controls with no past or present polyps. Detailed information was gath-
ered regarding adenoma size, histology and anatomic location, to enable 
the defi nition of non-advanced and advanced adenomas, and their loca-
tion in the distal and proximal colon. Demographics, medical history, an-
thropometrics, smoking status, lifestyle and dietary intake was assessed. 
Data on the phenolic acid content in foods was obtained from the Phenol-
Explorer database1. High phenolic acid intake was defi ned according to 
the study sample median (214.8 mg/day). Based on the questionnaires, 
smoking status was defi ned as: never-smokers and ever-smokers (past/
current smokers). Smoking intensity was calculated in pack-years as: daily 
cigarettesXyears smoking/20. Pack years were categorized by the group 
median (≥19.55 pack-years).
Results: The analysis included 711 patients (cases of colorectal adenomas 
n=326; non-advanced adenomas n=160; advanced adenomas n=166; con-
trols n=385). High phenolic acid intake was negatively associated with 
colorectal adenomas (OR=0.60, 95%CI 0.43-0.83, P=0.003), both non-
advanced and advanced adenomas (OR=0.63, 0.42-0.95 vs. OR=0.56, 0.37-
0.86 respectively), independently of demographic, medical and lifestyle 
confounders. Associations were signifi cant with distal adenomas but not 
with proximal adenomas (OR=0.56, 0.37-0.84 vs. OR=0.71, 0.47-1.09 re-
spectively). The association was modifi ed by smoking, as high phenolic 
acid intake had a strong negative association with colorectal adenomas 
among ever-smokers but not among never-smokers 
(P for interaction=0.013) (Table 1). Furthermore, the association was also 
modifi ed by smoking intensity, as strong inverse associations were ob-
served between high phenolic acid intake and all types of colorectal ad-
enomas among participants who reported high smoking intensity (≥19.55 
pack years, Table 1).
Conclusion: Intake of phenolic-acids is negatively associated with colorec-
tal adenomas, both distal and proximal, among ever-smokers. A high 
phenolic-acid diet should be further studied as a potential mean to re-
duce smoking induced oxidative stress, and prevent adenoma-carcinoma 
pathway.
References: 1. Neveu V, Perez-Jiménez J, Vos F, Crespy V, du Chaff aut L, 
Mennen L, et al. Phenol-Explorer: an online comprehensive database on 
polyphenol contents in foods. Database (Oxford). 2010;2010:bap024.
Disclosure: Nothing to disclose 
Type of adenoma
Polyphenol intake 
mg/day
Never smokers Ever smokers
Smokers of 1.1-19.54 pack years 
among smokers
Smokers of ≥19.55 pack years 
among smokers
   
n (cases/ 
controls)
OR (95%CI), P
n (cases/ 
controls)
OR (95%CI), P
n (cases/ 
controls)
OR (95%CI), P
n (cases/ 
controls)
OR (95%CI), P
Total adenomas < 214.8 mg/day 65/87 1.00 (ref.) 122/78 1.00 (ref.) 46/38 1.00 (ref.) 76/39 1.00 (ref.)
  ≥ 214.8 mg/day 70/114
0.88 (0.54-1.44) 
0.625
70/105
0.42 (0.26-0.67) 
<0.001
41/62
0.63 (0.31-1.27) 
0.202
29/41
0.33 (0.16-0.68) 
0.003
Advanced 
adenomas
< 214.8 mg/day 35/87 1.00 (ref.) 59/78 1.00 (ref.) 17/38 1.00 (ref.) 42/39 1.00 (ref.)
  ≥ 214.8 mg/day 34/114
0.95 (0.51-1.76) 
0.888
38/105
0.54 (0.31-0.94) 
0.029
23/62
1.26 (0.50-0.31) 
0.614
15/41
0.39 (0.17-0.90) 
0.028
Non-advanced 
adenomas
< 214.8 mg/day 30/87 1.00 (ref.) 63/78 1.00 (ref.) 28/38 1.00 (ref.) 35/39 1.00 (ref.)
  ≥ 214.8 mg/day 36/114
0.88 (0.47-1.66) 
0.710
31/105
0.33 (0.18-0.60) 
<0.001
17/62
0.40 (0.16-1.05) 
0.058
14/41
0.32 (0.12-0.84) 
0.021
Distal adenomas < 214.8 mg/day 32/87 1.00 (ref.) 65/78 1.00 (ref.) 24/38 1.00 (ref.) 41/39 1.00 (ref.)
  ≥ 214.8 mg/day 32/114
0.95 (0.50-1.78) 
0.873
35/105
0.41 (0.23-0.72) 
0.002
19/62
0.52 (0.20-1.32) 
0.170
16/41
0.36 (0.15-0.85) 
0.021
Proximal 
adenomas
< 214.8 mg/day 33/87 1.00 (ref.) 57/78 1.00 (ref.) 22/38 1.00 (ref.) 35/39 1.00 (ref.)
  ≥ 214.8 mg/day 39/114
0.90 (0.48-1.66) 
0.742
35/105
0.46 (0.26-0.82) 
0.009
22/62
0.81 (0.34-1.93) 
0.816
13/41
0.28 (0.10-0.75) 
0.011
[OP011 Table. Multivariate association between high polyphenol intake and colorectal adenoma groups, according to smoking status and intensity. ]
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Compher C, Gilroy E, Nessel L, Grant A, Chehoud C, Li H, Wu GD, Bushman 
FD. Cell Host Microbe. 2017 Aug 9;22(2):247.
Disclosure: Nothing to disclose 
Modern management of oesophageal 
dysmotility: Can we do better?
10:30-12:00 / B2
OP013 FUNCTIONAL LUMEN IMAGING PROBE TOPOGRAPHY 
(FLIP) AS A SCREENING TOOL FOR ESOPHAGEAL DYSMOTILITY: 
COMPARISON TO HIGH-RESOLUTION MANOMETRY (HRM) IN 
PATIENTS WITH ESOPHAGEAL SYMPTOMS
Valdovinos Garcia L.R.1,2, Horsley-Silva J.L.1, Crowell M.D.3, Vela M.F.4
1Mayo Clinic, Gastroenterology and Hepatology, Scottsdale, United States, 
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Gastroenterología, Ciudad de México, Mexico, 3Mayo Clinic Arizona, 
Scottsdale, United States, 4Mayo Clinic, Gastroenterology and Hepatology, 
Phoenix, United States
Contact E-Mail Address: drprapul@gmail.com
Introduction: High resolution manometry (HRM) is the current gold stan-
dard for the evaluation of esophageal motility. Functional lumen imaging 
probe topography (FLIP) is a novel approach that enables assessment of 
esophago-gastric junction (EGJ) distensibility and esophageal peristalsis.
Aims & Methods: Our aim was to evaluate the agreement between FLIP 
and HRM for esophageal motility assessment, and to assess the role of 
FLIP as a screening tool for dysmotility in patients undergoing endosco-
py. Methods:FLIP and HRM were compared in patients who underwent 
both procedures. FLIP was performed with a 16 cm balloon; peristaltic 
response was assessed at 30-40-50-60 ml and classifi ed as repetitive 
antegrade contractions (RACs), repetitive retrograde contractions (RRCs), 
diminished/disordered contractile response (DDCR) or absent contractility; 
median EGJ distensibility index (DI) was calculated at 60 ml and classifi ed 
as abnormal (< 2 mm2/mmHg), indeterminate 2-3 mm2/mmHg), normal 
(> 3 mm2/mmHg). FLIP was considered normal if EGJ DI was normal and 
RACs were present without concomitant RRCs. For HRM, ten 5-ml liquid 
swallows were administered; Chicago classifi cation version 3.0 was ap-
plied for manometric diagnosis. HRM diagnoses were dichotomized as 
normal/minor disorder (normal, ineff ective esophageal motility (IEM), or 
fragmented peristalsis) or abnormal (achalasia, jackhammer esophagus, 
distal esophageal spasm (DES), EGJ outfl ow obstruction (EJGOO), absent 
contractility). Sensitivity, specifi city, and positive/negative predictive values 
for FLIP were calculated.
Results: 75 patients were included, age 17-92, 65% women. HRM was 
performed a median 18 days from FLIP. HRM diagnoses: normal/minor 
disorder 45% (28% normal, 16% IEM, 1% fragmented) and abnormal 55% 
(17% absent contractility, 16% achalasia, 15 % EGJOO, 4% Jackhammer, 3% 
DES). FLIP diagnoses: 33% normal, 77% abnormal. In patients with nor-
mal FLIP topography, HRM diagnoses were normal/minor disorder in 58% 
(52% normal and 5% IEM), absent contractility 26%, jackhammer 11%, 
EGJOO 5%. In patients with normal FLIP, HRM never showed achalasia or 
DES. Normal FLIP had 80% specifi city for HRM being normal or showing 
only minor motility disorder. When FLIP was abnormal, HRM diagnoses 
were achalasia 21.4%, normal 19.6%, IEM 19.6%, EGOO 17.9%, absent con-
tractility 14.2%, distal spasm 3.6%, jackhammer 1.8%, fragmented 1.8%); 
FLIP had sensitivity of 80% for a major motility disorder on HRM. A normal 
EGJ DI by itself had a negative predictive value of 90% for normal HRM or 
minor motility disorder. FLIP was abnormal in 100% patients with achala-
sia or DES diagnosed by HRM.
Conclusion: FLIP topography performed during sedated endoscopy ap-
pears to be a good screening tool for esophageal dysmotility, with 80% 
specifi city for normal or minor disorder on HRM, and 80% sensitivity for 
major disorder on HRM. With subsequent evolution and refi nement of FLIP 
analysis, and data confi rmation, a normal FLIP topography during endos-
copy for evaluation of esophageal symptoms may obviate the need for ma-
nometry. Likewise, HRM is clearly indicated in patients with abnormal FLIP 
topography, as the likelihood of a major motility disorder on HRM is high 
in these patients.
Disclosure: Nothing to disclose 
OP012 SHIFTS IN BACTERIAL COMMUNITY FUNCTION ARE 
ASSOCIATED WITH SHORT CHAIN FATTY ACID PATHWAYS DURING 
NUTRITIONAL THERAPY IN PEDIATRIC CROHN’S DISEASE PATIENTS
Dunn K.1, Bielawski J.2, Bjorndahl P.2, Sigall Boneh R.3, Shamir R.4, 
Wine E.5, Levine A.6, Van Limbergen J.7,8
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Netherlands, 8Tytgat Institute for Liver and Intestinal Research, Amsterdam 
Gastroenterology and Metabolism, Academic Medical Center, University of 
Amsterdam, Amsterdam, Netherlands
Contact E-Mail Address: johanvanlimbergen@dal.ca
Introduction: Changes in gut bacterial community structure are associated 
with Crohn’s Disease (CD) and response to therapy. A recently completed 
randomized controlled trial (RCT) showed improved sustained remis-
sion with the Crohn’s Disease Exclusion Diet + Partial Enteral Nutrition 
(CDED+PEN) as compared with Exclusive Enteral Nutrition (EEN)1.
Aims & Methods: We examined changes in the microbiome functional net-
work in patients reaching remission with nutritional therapy. Stool samples 
from 53 CD patients reaching remission aft er 6 weeks of dietary treatment 
were collected at weeks 0, 6 and 12 and whole shotgun sequence data 
were obtained. In total, 146 CD patient samples were combined with 26 
healthy controls (previously published by Lewis et al.2), and characterized 
using HUMAnN2. Reactions, substrates and products for genes with an 
enzymatic commission were input into an unsupervised Bayesian analysis 
of community metabolism (BiomeNet). Statistical analysis of community 
metabolism were performed using R. Non-negative matrix factorization 
(NMF) and Structural topic models (STM) were used to identify patient-
associated microbial metabotypes.
Results: Unsupervised analyses revealed two metabotypes. All healthy 
controls possessed one metabotype (M1). CD patients possessed a mixture 
of two metabotypes (M1 & M2), with mixtures related to time in treatment, 
with 48% belonging to M1 at baseline before dietary therapy. At week 6, 
the number of M1 samples had increased to 63% and further increased to 
74% M1 at week 12 which was closer to healthy controls. Among the path-
ways identifi ed within metabotypes, one diff ered substantially between 
the two metabotypes; the key reactions involve the metabolism of various 
sugars. 
Using NMF and STM, we identifi ed fi ve communities; two were predomi-
nant in M1, and the other three were predominant in M2. The communities 
identifi ed in M1 samples had high levels of Bacteroidetes, including Odori-
bacter, Alistipes, Prevotella, Barnesiella and Bacteroides as well as increases 
in Firmicute taxa Eubacterium, Ruminococcus, Oscillibacter, Clostridium, 
Faecalibacterium and Roseburia. The Proteobacteria were decreased in M1. 
M2 samples were characterized by Enterobacteriaceae. 
Genes involved in butyrate formation were also associated with M1 and 
M2. Genes involved in the 4-aminobutyrate pathway, and crotonoyl-CoA 
to butyrate pathway, (p=0.03 to 0.0001) were associated with M1. M2 was 
associated with genes involved in the acetyl-CoA pathway as well as ato 
genes (p< 0.001), involved in the degradation of SCFA.
Conclusion: Diet-induced remission samples were more similar to healthy 
controls, having shift ed away from the baseline. The functional network, 
associated with active disease, changes as patients progress to remission 
at week 6 and sustain the remission through week12. The butyrate-related 
change in community function is attributable to distinct shift s in bacte-
rial species abundance. Genes signifi cant for the M1 butyrate pathway ap-
peared to be driven by Bacteroides and Clostridium, while genes signifi cant 
for M2 butyrate pathways were driven by taxa in Enterobacteriaceae nota-
bly Citrobacter, Escherichia and Enterobacter.
References: 1. Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori 
M, Cohen S, Peleg S, Shamaly H, On A, Millman P, Abramas L, Ziv-Baran 
T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J. Crohn’s 
Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained 
Remission in a Randomized Controlled Trial. Gastroenterology 2019 in 
press. 2. Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffi  ths AM, Lee 
D, Bittinger K, Bailey A, Friedman ES, Hoff mann C, Albenberg L, Sinha R, 
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OP014 INEFFECTIVE ESOPHAGEAL MOTILITY WITH CONTRACTION 
RESERVE ON ESOPHAGEAL HIGH RESOLUTION MANOMETRY (HRM) 
IS ASSOCIATED WITH LOWER ACID EXPOSURE TIMES COMPARED TO 
ABSENT CONTRACTION RESERVE
Quader F.1, Rogers B.1, Sievers T.2, Mumtaz S.3, Lee M.4, Lu T.5, Gyawali C.P.1
1Washington University School of Medicine, Division of Gastroenterology, 
St Louis, United States, 2University of Minnesota, Minneapolis, United States, 
3Loyola University Medical Center, Chicago, United States, 4Yale University, 
New Haven, United States, 5University of Chicago, Chicago, United States
Contact E-Mail Address: farhan@wustl.edu
Introduction: Ineff ective esophageal motility (IEM) is a minor motor disor-
der that may have refl ux implications. Augmentation of esophageal body 
contraction on multiple rapid swallows (MRS) indicates presence of con-
traction reserve, which is associated with lower likelihood of late post-
operative dysphagia following antirefl ux surgery. We hypothesized that 
presence of contraction reserve in IEM will be associated with reduced 
esophageal acid burden.
Aims & Methods: Our aim was to evaluate the interrelationship between 
contraction reserve on HRM and esophageal acid burden on ambulatory 
refl ux monitoring performed off  antisecretory therapy. Esophageal HRM 
and ambulatory refl ux monitoring studies were reviewed on all patients 
undergoing both tests between 01/2016 and 12/2017 at a tertiary care re-
ferral center. Patients fulfi lling the following three HRM motor diagnoses 
(using Chicago Classifi cation 3.0 criteria) were identifi ed: normal, inef-
fective esophageal motility (IEM, ≥50% ineff ective swallows), and absent 
contractility (100% failed swallows). Single swallows (SS) and multiple 
rapid swallows (MRS) were analyzed using HRM soft ware tools assessing 
integrated relaxation pressure (IRP, normal< 15 mmHg), distal latency (DL, 
normal >4.5 s), distal contractile integral (DCI, normal 450-8000 mmHg.
cm.s), esophagogastric junction contractile integral (EGJ-CI, normal>39.3 
mmHg.cm) and EGJ morphology. Contraction reserve required mean MRS 
DCI to mean SS DCI ratio >1. Total acid exposure time (AET) was abnormal 
if >6%; thresholds utilized for upright and supine AET were 6% and 2% 
respectively. Univariate analysis was performed to determine the role of 
contraction reserve on esophageal acid burden, and multivariate regres-
sion analyses were performed to determine predictors of abnormal total, 
supine and upright acid burden in the context of contraction reserve.
Results: Study criteria were fulfi lled by 191 patients, 109 (57.1%) with nor-
mal HRM (53.6 ± 1.4, 70.7% F), 71 (37.2%) with IEM (52.2 ± 1.7, 72.7% F), 
and 11 (5.76%) with absent contractility (51.4 ± 2.5, 58.3% F). Within IEM, 
a higher proportion of patients without contraction reserve demonstrated 
upright AET >6% compared to those with contraction reserve (59.1% vs 
32.7%, p=0.04); this diff erence was not seen with supine AET, and did 
not aff ect total AET. Contraction reserve had no impact on AET in normal 
HRM and absent contractility. When the IEM group was further subdivided 
into severe IEM (8-10 ineff ective swallows, n=40) and non-severe IEM (5-7 
ineff ective swallows, n=31), the non-severe IEM category demonstrated 
signifi cantly lower proportions with abnormal AET in the presence of con-
traction reserve (30.4% vs. 75.0%, p=0.03). Abnormal AET proportions in 
non-severe IEM with contraction reserve resembled normal HRM (p=0.96), 
while that in severe IEM with or without contraction reserve resembled 
absent contractility (p=0.39). Multivariate analysis demonstrated EGJ mor-
phology to be an independent contributor to total AET in IEM (p=0.03). 
Additionally, absence of contraction reserve associated with increased total 
AET (p=0.01) in non-severe IEM, while EGJ morphology associated with 
upright AET in non-severe IEM (p=0.04), and with supine AET in severe 
IEM (p=0.02).
Conclusion: The presence of contraction reserve is associated with lower 
upright acid burden in IEM, particularly in non-severe IEM, where acid 
burden resembles that seen with normal HRM. In contrast, the acid burden 
profi le of severe IEM resembles that seen with absent contractility, regard-
less of contraction reserve. EGJ morphology is also a contributor to acid 
burden in IEM.
Disclosure: Nothing to disclose 
OP015 CODEINE INDUCES INCREASED RESISTANCE AT THE 
OESOPHAGO-GASTRIC JUNCTION IN HEALTHY VOLUNTEERS: 
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 
CROSSOVER TRIAL
Geeraerts A.1, Geysen H.1, Ballet L.1, Hofmans C.1, Omari T.2, Manolakis A.3, 
Rommel N.4, Vanuytsel T.5, Tack J.6, Pauwels A.1
1KU Leuven, TARGID, Leuven, Belgium, 2University of Adelaide, Department of 
Human Physiology, SA, Australia, 3University of Thessaly, School of Medicine, 
Department of Gastroenterology, Larissa, Greece, 4University of Leuven, 
Department of Neurosciences, Leuven, Belgium, 5KU Leuven, Department of 
Gastroenterology, Leuven, Belgium, 6University of Leuven, University Hospital 
Gasthuisberg, Gastroenterology, Leuven, Belgium
Contact E-Mail Address: annelies.geeraerts@kuleuven.be
Introduction: The adverse eff ects of short- and long-term use of opioids, 
such as codeine and morphine, on gastrointestinal transit are well known. 
More recently, studies showed that chronic opioid use may induce oesoph-
ageal dysfunction with symptoms similar to achalasia (eg. dysphagia) and 
a manometric pattern of functional oesophago-gastric junction outfl ow 
obstruction (OGJ-OO). However, little is known whether this is generalized 
or occurs only in susceptible subjects, and whether acute opioid adminis-
tration has similar eff ects.
Aims & Methods: Aft er positioning a High-Resolution impedance Ma-
nometry catheter (HRiM, Unisensor, Attikon, Switzerland), codeine (30mL 
codeine phosphate 10mg/5mL) or placebo (30mL glucose syrup) was in-
fused in the proximal stomach. Forty-fi ve minutes post-infusion, partici-
pants received diff erent volumes (5mL and 20mL) of liquid and semi-solid 
boluses, classifi ed as 0/1/2/3/4 according to the International Dysphagia 
Diet Standardization Initiative (IDDSI) classifi cation and bread (2x2cm and 
4x4cm). Blood samples were collected to detect slow morphine metaboliz-
ers. HRiM analysis was performed adhering to the Chicago classifi cation 
v3.0 (CC v3.0) using dedicated soft ware (Solar GI, Laborie, Canada). Ad-
ditionally, pressure-fl ow analysis (PFA) was performed, using the online 
soft ware platform swallowgateway.com for calculating the following met-
rics: pressure fl ow index (PFI), distension pressure emptying (DPE) as a 
measure of OGJ resistance to bolus fl ow, impedance ratio (IR) as measure 
of bolus clearance failure, distal ramp pressure (DRP) which refl ects bolus 
pressurization and distension-contraction latency (DCL), time from nadir 
impedance to peak pressure.
Results: Twenty-three HV (6 men, 38±3y) completed the study. Eight par-
ticipants were excluded from analysis: one due to biliary type pain, a 
rare side eff ect of codeine, one due to the presence of an OGJ-OO during 
placebo and six were slow metabolizers. Integrated relaxation pressure 4 
seconds (IRP4) values were signifi cantly higher aft er codeine (except for 
4x4cm bread) and distal latency (DL) values were signifi cant lower (except 
for 5mL IDDSI3). Distal contractile integral (DCI) values were similar in both 
conditions, except for IDDSI0 (5mL and 20mL). Based on the CC v3.0, acute 
infusion of codeine induced an OGJ-OO in fi ve HV (p-value=0.042). PFI val-
ues were signifi cantly higher aft er codeine infusion, for all given boluses 
except for 5mL IDDSI3 and bread 4x4cm. DPE was signifi cantly increased 
for all boluses except for 5mL IDDSI2. The DRP was signifi cantly increased 
for 5mL IDDSI0/2 and bread 4x4cm and DCL values were signifi cantly lower 
for 5mL IDDSI0/3/4 and 20mL IDDSI0 in the codeine condition. No signifi -
cant diff erences were noted for IR between placebo and codeine infusion, 
except for bread 2x2cm. Results are presented in Table 1.
 
5mL 
IDDSI0 
IRP4
5mL 
IDDSI1 
DL
5mL 
IDDSI3 
DCI
20 mL 
IDDSI0 
PFI
5 mL 
IDDSI4 
DPE
5 mL 
IDDSI2 
DRP
20 mL 
IDDSI0 
DCL
5 mL 
IDDSI3 
IR
Placebo
10 
(8 - 14)
6.8 
(6.4 - 7.4)
923 
(621 - 1281)
8.1 
(6.9 - 10.4)
21.9 
(17.9 - 27.4)
4.7 
(3 - 7.1)
4.2 
(3.7 - 4.8)
0.3 
(0.3 - 0.5
Codeine
18 
(15 - 21)
5.9 
(5.5 - 6.8)
1075 
(523 - 1568)
15.8 
(10.1 - 42)
37.7 
(31.4 - 47.6)
7.6 
(6.5 - 10.6)
2.7 
(2.5 - 3.8)
0.3 
(0.3 - 0.5)
p-value <0.0001* <0.0001* 0.2339 0.009* 0.013* 0.025* <0.0001* 0.821
[Table 1: Median (interquartile range) values of IRP4, DCI, DL, PFI, DPE, DRP, 
DCL and IR for codeine and placebo administration]
Conclusion: Acute administration of codeine increases bolus resistance at 
the OGJ in HV and is able to induce major motility disorders in a subset of 
subjects. These are mainly localized in the distal oesophagus as the IR data 
indicate no bolus clearance failure in the oesophageal body.
Disclosure: Nothing to disclose 
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OP017 A RANDOMIZED CLINICAL TRIAL ON THE THERAPEUTIC 
EFFECT OF TRPA1 AND TRPM8 AGONISTS ON THE SWALLOWING 
FUNCTION OF PATIENTS WITH OROPHARYNGEAL DYSPHAGIA
Tomsen N.1,2, Alvarez-Berdugo D.1,2, Rofes L.1,2, Arreola V.2, 
Nascimento W.2, Martin A.2, Ortega O.1,2, Cabib C.2, Bolivar Prados M.2, 
Mundet L.2, Legrand C.3, Clavé P.1,2, Michlig S.3
1Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de 
Enfermedades Hepáticas y Digestivas, Barcelona, Spain, 2Hospital de Mataró, 
Gastrointestinal Motility Laboratory, Mataró, Spain, 3Nestlé Research, 
Lausanne, Switzerland
Contact E-Mail Address: ntomsen@csdm.cat
Introduction: Oropharyngeal dysphagia (OD) is a major complain among 
older people, patients with neurological diseases or stroke patients. Clas-
sical treatment of OD is based on compensatory strategies that do not 
promote the recovery of the swallowing function. Pharyngeal sensory 
stimulation through transient receptor potential channel (TRP) agonists is 
a promising active treatment.
Aims & Methods: The main aim of this study was to assess the therapeutic 
eff ect of TRPA1 and TRPM8 agonists in improving swallowing function in 
OD patients. For this purpose, we designed a prospective, double-blind, 
randomized, interventional study (NCT02193438), in which we included 
58 patients with OD caused by ageing, stroke or neurodegenerative dis-
ease. Swallowing safety and effi  cacy and the kinematics of the swallow 
response were assessed by videofl uoroscopy (VFS) during the swallow of 
nectar boluses of a xanthan gum based thickener supplemented with a) 
756.6mM cinnamaldehyde and 70mM zinc (CIN-Zn) (TRPA1 agonists), b) 
1.6mM citral (CIT) (TRPA1 agonist) or c) 1.6mM citral and 1.3mM isopulegol 
(CIT-ISO) (TRPA1 and TRPM8 agonists). The eff ects on pharyngeal event-
related potentials (ERP) were assessed by electroencephalography dur-
ing the deglutition of two supplemented boluses with the same agonist 
the patients received during the VFS. The brain activation was determined 
with sLORETA soft ware.
Results: Compared to control series, TRPA1 stimulation with either CIN-
Zn or CIT reduced time to laryngeal vestibule closure (CIN-Zn p=0.002, 
CIT p=0.023) and upper esophageal sphincter opening (CIN-Zn p=0.007, 
CIT p=0.035). In addition, CIN-Zn reduced the penetration-aspiration scale 
score (p=0.009), the prevalence of penetrations (p=0.039), the latency of 
the P2 peak of the ERP and enhanced the brain activation of the frontal 
gyri and the transverse temporal gyrus. The combination of CIT-ISO had 
not shown any benefi cial eff ects on swallow biomechanics or neurophysi-
ological measures. No signifi cant adverse events were observed.
Conclusion: TRPA1 stimulation with CIN-Zn or CIT improves swallow re-
sponse which, in the case of CIN-Zn, is associated with an enhanced corti-
cal activation, and leads to a signifi cant improvement in swallow safety in 
patients with OD. These results set the basis to develop new active treat-
ments for OD using TRPA1 agonists, moving away from compensation to 
the recovery of the swallowing function.
Disclosure: This study was supported by a grant from Nestlé Health Science 
and presented in the 8th ESSD Congress as an oral presentation. 
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OP019 TLR4-INDUCED DYSBIOSIS PROMOTES AN EXPANSION 
OF PROTEOBACTERIA THAT INCREASES SUSCEPTIBILITY TO 
TUMORIGENESIS
Burgueno J.1, Fritsch J.1, Santander A.M.1, Maruthamutu M.1, Brito N.1, 
Fernandez I.1, Pignac-Kobinger J.1, Conner G.E.2, Abreu M.T.3
1University of Miami, Medicine, Miami, United States, 2University of Miami, 
Cell Biology, Miami, United States, 3University of Miami, Miller School of 
Medicine, Crohn’s and Colitis Center, Miami, United States
Contact E-Mail Address: joan.burgueno@gmail.com
Introduction: Dysbiosis in infl ammatory bowel diseases (IBD) and coli-
tis-associated cancer (CAC) is characterized by an increase in the rela-
tive abundance of facultative anaerobes (Proteobacteria). These bacteria 
OP016 EVALUATION OF THE HEIGHT OF THE WATER COLUMN 
RETAINED AFTER A RAPID DRINK CHALLENGE TEST (RDC) USING 
HIGH RESOLUTION IMPEDANCE MANOMETRY (HRIM) IN PATIENTS 
WITH ACHALASIA TREATED WITH PERORAL ENDOSCOPIC MYOTOMY 
(POEM)
Marin Fernandez I.1, Guarner-Argente C.2, Rodriguez M.3, Benslaiman B.3, 
Serra J.4
1University Hospital Germans, Endoscopy, Barcelona, Spain, 2Hospital 
de la Santa Creu i Sant Pau, Servei de Patologia Digestiva, Barcelona, 
Spain, 3University Hospital Germans Trias i Pujol, Motility and Functional 
Gut Disorders Unit, Badalona, Spain, 4Hospital Germans Trias I Pujol, 
Department of Gastroenterology, Barcelona, Spain
Contact E-Mail Address: gridin_8@hotmail.com
Introduction: High resolution impedance manometry (HRIM) allows si-
multaneous assessment of esophageal motility and bolus transport. Pre-
vious studies have shown that the height of the retained column aft er a 
rapid drink challenge test (RDC) correlates with the height of the barium 
column measured 5-min aft er timed barium esophagogram, with the in-
crement of the pressurization of the esophageal body and with the inten-
sity of dysphagia. However, evaluation of the height of the water column 
aft er treatment with POEM, which means a larger myotomy that is oft en 
associated with refl ux, has not been reported.
Aims & Methods: To evaluate the eff ect of treatment with POEM on the 
height of the retained water column aft er a RDC, and its correlation with 
pressurization of the esophageal body and esophageal symptoms, in pa-
tients with achalasia. 
We prospective studied 16 consecutive patients (8M, 8F, mean age 56 yr) 
diagnosed with achalasia and treated with POEM. In each patient, a 200-
ml RDC was performed before and 2-12 months aft er treatment. Pressure 
responses, height of the retained column, number and length of refl ux 
episodes were measured using HRIM. Symptoms were scored by the Eck-
ardt Scale. An upper endoscopy has been performed before treatment and 
aft er treatment.
Results: Before treatment, all patients showed an obstructive pattern of 
pressure responses characterized by pressurization of the esophageal body 
(37±7 % of time with pressure >20 mmHg, pressure gradient across the 
EGJ 20±4 mmHg) that reverted to a non-obstructive pressure pattern aft er 
POEM in all (3±1% of time with pressure >20 mmHg, pressure gradient 
across the EGJ 2±2 mmHg; p< 0.05 vs before treatment for both) and that 
was associated to clinical improvement (Eckardt score 8.0±0,6 before vs 
0.9±0,2 aft er POEM, p< 0.05). Treatment with POEM was associated to a 
reduction in the height of the water column retained immediately aft er the 
RDC, from 12±2 cm to 5±1 at 1 min aft er the RDC (before and aft er treatment 
respectively; p< 0.05), and this reduction correlated with the reduction of 
the Eckardt score (r=0.703; p=0.005). Aft er this immediate clearance of the 
bolus, 6 patients had 2.5±0.5 refl ux episodes of 29±18 sec duration (range 
4-120sec), occurring at 81.3±13.2 sec aft er the end of the RDC, leading to an 
increment in the height of the water column measured at 5 min aft er the 
RDC (1.4±0.6 cm vs 8,5±1.3 cm aft er treatment; NS). The endoscopic follow 
up showed mild esophagitis in 7 patients that did not correlate with the 
presence of refl ux aft er the RDC (p=0.622).
Conclusion: Measurement of the height of the column retained aft er a 
RDC using HRIM may objectively confi rm treatment success aft er POEM in 
patients with achalasia. However, refl ux of the ingested bolus occurs fre-
quently aft er the RDC, and needs to be carefully considered to determine 
the right timing for evaluation of bolus clearance in patients treated with 
POEM.
References: Cho et al. Am J Gastroenterol 2014;109:829, Marin et al. Neu-
rogastroenterol Mot 2018: e13438. DOI:10.1111/nmo.13438).
Disclosure: Nothing to disclose 
20 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
bloom by performing anaerobic respiration using certain substrates that 
are generated in the presence of reactive oxygen species (ROS). However, 
the interplay between the host and the microbiota that leads to dysbiosis 
is not fully understood. Our laboratory has shown that IBD dysplasia and 
colorectal adenomas overexpress toll-like receptor 4 (TLR4) in intestinal 
epithelial cells (IECs). Moreover, we have described that epithelial TLR4 
activation increases susceptibility to CAC.
Aims & Methods: In this study, we tested the hypothesis that IECs, via TLR4 
activation, provide the microbiota with ROS that can be used by Proteobac-
teria to outgrow obligate anaerobes. Furthermore, we aimed to determine 
whether TLR4-mediated susceptibility to CAC is induced by the dysbiotic 
microbiota.
IECs isolated from villin-TLR4 mice (which express a constitutively active 
form of TLR4 in IECs) and their WT littermates were analyzed for H
2
O
2
 
production (Amplex Red) and expression of NADPH oxidase 1 (Nox1) and 
dual oxidase 2 (Duox2; qPCR). Colonoids from wild-type (WT), TLR4-KO, 
Nox1-KO, and DuoxA2-KO mice were stimulated with lipopolysaccharide 
(LPS) and tested for H
2
O
2
 production in the presence of the NADPH oxidase 
inhibitor, diphenyleneiodonium. Mucosa-associated microbiota (MAM) of 
villin-TLR4 and C57Bl/6 mice was used to colonize WT germ-free mice. 
Aft er 3 weeks of engraft ment, half of the MAM-engraft ed mice were eu-
thanized to verify engraft ment via 16S sequencing, whereas the other half 
of mice underwent a chemical model of CAC by administration of azoxy-
methane followed by 3 cycles of 3% dextran sulfate sodium. Tumor burden 
and size as well as H
2
O
2 
production in IECs were measured at the end of 
the experiment.
Results: Constitutive activation of epithelial TLR4 in vilin-TLR4 mice sig-
nifi cantly increased the production of H
2
O
2
, which was accompanied by a 
marked upregulation of Nox1, Duox2, and DuoxA2 transcripts. Similarly, 
LPS stimulation in WT colonoids induced the upregulation of Nox1, Duox2, 
and DuoxA2 and the release of H
2
O
2
 in a TLR4- and NADPH oxidase-depen-
dent manner, as demonstrated by total abrogation of responses in TLR4-KO 
colonoids and in diphenyleneiodonium-treated WT colonoids. DuoxA2-KO 
colonoids showed a marked attenuation in the production of H
2
O
2
 upon 
LPS challenge, demonstrating that this NADPH oxidase drives TLR4-me-
diated production of H
2
O
2
. Villin-TLR4 MAM was characterized by an ex-
pansion in Proteobacteria that could be transmitted to WT GF recipient 
mice. In addition, this TLR4-induced microbiota caused an upregulation in 
Duox2 and DuoxA2 expression in IECs of WT germ-free recipient mice. Aft er 
the chemical model of CAC, recipient mice of villin-TLR4 MAM developed 
more tumors of bigger size when compared to C57 MAM. Consistently, IECs 
isolated from non-involved areas demonstrated higher release of H
2
O
2
 in 
villin-TLR4 MAM-recipient mice, indicating that dysbiosis increases sus-
ceptibility to CAC by promoting an oxidative milieu.
Conclusion: Our fi ndings demonstrate that TLR4 activation in IECs pro-
motes a Duox2-mediated oxidative phenotype that facilitates the blooming 
of Proteobacteria in the absence of overt infl ammation. Furthermore, we 
show that such TLR4-induced dysbiosis increased the susceptibility to CAC. 
These fi ndings suggest that the intestinal epithelium plays pivotal roles in 
promoting dysbiosis.
Disclosure: Nothing to disclose 
OP020 MYELOID CALCINEURIN IN THE CONTROL OF IMMUNE 
CHECKPOINT INHIBITION IN INTESTINAL TUMOR DEVELOPMENT
Peuker K.1, Strigli A.1, Tauriello D.2, Južnić L.1, Brosch M.1,3, Röcken C.4, 
Hampe J.1,3, Schafmayer C.5, Batlle E.2, Zeissig S.1,3
1Center for Regenerative Therapies, TU Dresden, Dresden, Germany, 2Institute 
for Research in Biomedicine (IRB Barcelona), Barcelona, Spain, 3University 
Hospital Dresden, Gastroenterologie und Hepatologie, Dresden, Germany, 4Kiel 
University, University Hospital Schleswig-Holstein, Kiel, Germany, 5University 
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Contact E-Mail Address: kenneth.peuker@crt-dresden.de
Introduction: Colorectal cancer (CRC) development is based on somatic 
mutations in tumor suppressor genes and oncogenes. Intestinal infl am-
mation is a risk factor for CRC but recent work has demonstrated that 
immunological pathways also play critical roles in the development of 
sporadic CRC, in the absence of clinically overt intestinal infl ammation. 
We have previously shown that the phosphatase calcineurin and its down-
stream mediators of the NFAT transcription factor family are active in the 
intestinal epithelium and support tumor development through promotion 
of epithelial proliferation.
Aims & Methods: Here, we asked whether calcineurin and NFAT play simi-
lar tumor-promoting roles in myeloid cells and analyzed potential syn-
ergistic eff ects of epithelial and myeloid calcineurin in intestinal tumor 
development. We studied mice with myeloid-specifi c deletion (LysM-Cre) 
of calcineurin or NFAT in the ApcMin/+ model of genetically-induced intesti-
nal tumor development as well as in an orthotopic colonic CRC model as-
sociated with liver metastasis. In addition, we analyzed 1500 human CRCs.
Results: We observed barrier dysfunction at sites of intestinal adenomas, 
which was associated with tumor infi ltration by the commensal microbiota 
and microbiota-dependent activation of calcineurin and NFAT in myeloid 
tumor-infi ltrating cells. Calcineurin-NFAT signaling in myeloid cells pro-
moted the expression of IL-6, which was associated with activation of epi-
thelial STAT3. STAT3 in turn supported tumor cell proliferation and survival 
in a cell-intrinsic manner and was also associated with dramatic induction 
of epithelial expression of the two co-inhibitory proteins B7H3 and B7H4. 
Antibody-mediated blockade or epithelial deletion of these co-inhibitory 
proteins led to an increased CD8+ cytotoxic T cell response against tumor 
cells in mice, which was associated with protection from intestinal tumor 
growth as well as the development of liver metastasis, suggesting a central 
role of myeloid calcineurin in licensing T cell responses against intestinal 
tumors. Moreover, increased expression of these immune checkpoint pro-
teins correlated with reduced CD8+ T cell infi ltration in human CRCs and 
reduced CRC-associated survival.
Conclusion: Our studies reveal a novel pathway of calcineurin-dependent 
cross-talk between epithelial, myeloid, and T cells, which promotes tumor 
development through inhibition of cytotoxic T cell responses and which is 
potentially amenable to therapeutic targeting.
Disclosure: Nothing to disclose 
OP021 SUPPLEMENTATION WITH BUTYRATE PRODUCING 
BACTERIA REDUCES TUMOR LOAD IN A MOUSE MODEL OF 
COLORECTAL CANCER
Montalban-Arques A.1, Olivares-Rivas I.1, Katkeviciute E.1, Atrott K.1, 
Busenhart P.1, Schwarzfi scher M.1, Baebler K.1, Hering L.1, Leventhal G.E.2, 
De Wouters T.3, Scharl M.1, Spalinger M.R.1
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Zurich, Switzerland, 2Institute of Technology, Department of Civil and 
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Zurich, Switzerland
Contact E-Mail Address: ana.montalban-arques@usz.ch
Introduction: Colorectal cancer (CRC) is one of the most prominent can-
cers with increasing incidence rates, and originates at the crossroad of the 
microbiome and its host. Besides genetically predisposing factors, CRC is 
strongly infl uenced by the infl ammatory status of the tissue, the presence 
of carcinogenic substances (such as microbiome metabolites), and the 
regulation of the host’s immune response. Although the link of the intesti-
nal microbiota to these functions is well established, the biological under-
standing of the modes of action is not well understood. Here, we studied 
how certain intestinal microbiota contributes to the prevention of CRC.
Aims & Methods: In a fi rst approach, colitis associated tumourus were 
induced in wild-type (WT) and RAG2-/-C57BL/6 mice via administration of 
three cycles of 1% dextran sodium sulfate (DSS) + azoxymethane (AOM). 
PBS, Peptostreptococcus stomatis or a mix of 4 butyrate-producing strains 
was supplemented via daily oral gavage on days 8-10 of each AOM/DSS 
cycle. 
Next, we used an infl ammation-independent model of CRC, where MC-38 
tumour cells were injected into the cecum wall aft er WT mice received 
PBS or the mix of butyrate-producing bacteria for three consecutive days. 
Intestinal microbiome was analyzed in stool samples before, during and 
aft er administration of the bacteria to the mice. Colon tumour and non-
tumour tissue were analyzed using RNAseq, fl ow cytometry and histology 
techniques.
Results: We found that tumour burden in the DSS/AOM model was associ-
ated with increased levels of fecal P. stomatis, but overall reduced levels of 
butyrate-producing bacteria. In DSS/AOM-treated WT mice, supplementa-
tion with P. stomatis signifi cantly enhanced tumour load when compared to 
PBS-treated controls. In contrast, only a small fraction of WT mice treated 
with butyrate producers developed tumours. Supplementation with P. sto-
matis was associated with increased intestinal infl ammation as assessed in 
endoscopy and histology aft er each AOM/DSS cycle compared to WT mice 
supplemented with butyrate producers. However, the benefi cial eff ect of 
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lines, whereby anti-CSC eff ect was further validated by assessing impact 
on tumoursphere formation. Five compounds at the IC
50
 dose robustly de-
creased the number of HT29-, SW-620- and HCT116-derived spheres. Those 
hits were tested on colorectal cancer cell lines plated in adherent condi-
tions (5,000 cells/well) and primary mouse hepatocytes (10,000 cells/well) 
for 72h using a 10-point concentration range of 0.01 - 243.00 µM and 1 
compound was excluded for potential severe hepatotoxicity. Future work 
comprises in vivo proof-of-principle experiments, hit-to-lead medicinal 
chemistry and identifi cation of precise mechanisms of action.
Conclusion: In conclusion, a novel HTS platform to test a wide range of 
candidate compounds to target CSCs was developed and validated, allow-
ing the identifi cation of potent colon cancer stem cell inhibitors. 
Supported by COMPETE (LISBOA-01-0145-FEDER-016405) and FCT 
(SAICTPAC/0019/2015).
Disclosure: Nothing to disclose 
OP023 XBP1 COORDINATES DNA DAMAGE INDUCED 
STEM CELL REPRESSION IN THE INTESTINAL EPITHELIUM VIA 
DDIT4L-DEPENDENT MTOR INHIBITION
Welz L.1, Ito G.1, Kakavand N.1, Wottawa F.1, Tran F.1,2, Lipinski S.1, 
Knight J.3, Sansom O.3, Kaser A.4, Blumberg R.5, Schreiber S.1,2, Aden K.1,2, 
Rosenstiel P.1
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Introduction: Intestinal stem cells are particularly prone to the accumu-
lation of hazardous mutations leading to malignant transformation. We 
have shown that RNase H2-mediated ribonucleotide excision repair (RER) 
preserves genomic integrity of intestinal stem cells. In the absence of 
RNase H2, intestinal epithelial cells generate DNA damage and induce a 
p53-driven suppression of the intestinal stem cell (Aden, Bartsch et al. 
2019). XBP1 encodes for a transcription factor critically involved in resolv-
ing endoplasmic reticulum (ER) stress (Kaser, Lee et al. 2008). Whether 
Xbp1-mediated signalling is directly involved in DNA damage response 
mechanisms is not known.
Aims & Methods: The aim of the study is to investigate the role of XBP1 in 
coordinating epithelial DNA damage response and p53-driven intestinal 
stem cell suppression. 
For this purpose, murine intestinal epithelial ModeK cells (iCtrl and iXbp1) 
were stimulated with the DNA-damaging agent Cytarabin A (AraC) and 
subjected to gene expression analyses, FACS cell death assays and immu-
noblot analyses. We generated conditional intestinal epithelial knockout 
of Xbp1, Rnaseh2b and the combined DKO. Intestinal organoids of derived 
from Rnaseh2b/Xbp1fl /fl , Xbp1dIEC, Rnaseh2bdIEC and Rnaseh2b/Xbp1dIEC mice 
were derived used for immunoblot analyses, colony formation assays and 
RNA sequencing. We employed Rnaseh2b/Xbp1fl /fl , Xbp1dIEC, Rnaseh2bdIEC 
and Rnaseh2b/Xbp1dIEC mice were used for in-vivo basal phenotyping of 
young (8 week) and aged (52 week) mice as well as, acute and chronic 
DSS-colitis models. Post mortem analyses included fl uorescence or IHC 
stainings, western blot analyses and gene expression analyses.
Results: Xbp1-defi ciency elevates AraC-induced DNA-damage and epithe-
lial cell death in-vitro. Untreated and DSS-treated Rnaseh2b/Xbp1dIEC mice 
exhibit display heightened amounts of DNA damage, cell death and intesti-
nal infl ammation. Compared to H2bdIEC mice, which were previously shown 
to exhibit a p53-dependent stem cell arrest that protects them from intes-
tinal carcinogenesis, Xbp1-defi ciency impairs stem cell arrest in Rnaseh2b/
Xbp1dIEC mice, leading to epithelial hyperproliferation and spontaneous in-
testinal carcinogenesis. Mechanistically, RNA sequencing of intestinal or-
ganoids (Rnaseh2b/Xbp1fl /fl , Rnaseh2bdIEC, Rnaseh2b/Xbp1dIEC and Rnaseh2b/
p53dIEC) reveals that XBP1 coordinates a p53-dependent induction of the 
DNA damage inducible transcript 4l (Ddit4l). Mechanistically, Xbp1 directs 
a Ddit4l- mediated mTOR-inhibition and dephosphorylation of the transla-
tion initiator 4E-BP1, leading tothereby determining suppression of epithe-
lial proliferation. In in-vitro intestinal organoid growth assays we demon-
strate, that pharmaceutical inhibition of the mTOR pathway by Rapamycin 
restores epithelial stem cell suppression in Rnaseh2b/Xbp1dIEC organoids.
butyrate-producing bacteria was lost in RAG2-/- mice, indicating that T-
cells are crucially involved in mediating the anti-tumour eff ect. As caus-
ative mechanisms, we found an increased number of IFNγ+ CD8+ cytotoxic 
T- cells and IFNγ+ NK cells inthe tumour tissue of WT mice supplemented 
with butyrate producers compared to control and P. stomatis groups, indi-
cating that supplementation with butyrate producers promoted increased 
anti-tumour immune responses. Further, the increase in PD-L1+/PD-L2+ 
tumour-associated macrophages was absent in those mice. 
In the cecum injection model, we found a reduction in tumour develop-
ment in mice treated with butyrate producers. Interestingly, tumours from 
mice receiving butyrate producers had a higher amount of activated CD8+ 
T cells compared to controls, while in the surrounding tumour tissue there 
were more naïve CD8+ T cells in mice supplemented with butyrate-produc-
ing bacteria, suggesting that butyrate producers induce the infi ltration and 
diff erentiation of naïve CD8+ T cells into the tumours.
Conclusion: Our results indicate that oral supplementation with selected 
butyrate producers protects from CRC tumour development via promoting 
anti-tumour T cell responses in vivo in infl ammation-dependent and in-
dependent CRC mouse models. Our fi ndings suggest that manipulation of 
the intestinal microbiota might be a promising novel approach to promote 
anti-cancer immune responses.
Disclosure: Nothing to disclose 
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CANCER STEM CELL INHIBITORS USING TUMOURSPHERES
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Introduction: Cancer stem cells (CSCs) are a subpopulation of cancer cells 
implied in tumour formation, metastasis and recurrence due to their long-
lasting properties and chemotherapy resistance.
Aims & Methods: Here, we aimed to optimize, validate and apply a high-
throughput screening (HTS) platform to identify novel molecules from large 
compound libraries that specifi cally impact on colorectal CSC phenotype.
Results: For validation of the HTS platform, HT29 human colorectal ad-
enocarcinoma cells were plated in undiff erentiated medium in ultra-low 
attachment conditions for sphere formation and treated with previously 
reported CSC-targeting agents (e.g. salinomycin; 1 µM) or traditional che-
motherapeutic agents (e.g. 5-fl uorouracil (5-FU), irinotecan and oxalipla-
tin; 1 µM) or vehicle controls. Following 7 days of incubation, the number 
and size of spheres were assessed, while cell viability was determined 
based on measurement of ATP. This screening system was tested in both 
96- and 24-well plates. Classical chemotherapeutics such as 5-FU and iri-
notecan were not able to impact on HT29-derived spheres, while the anti-
CSC agent salinomycin markedly reduced cell viability, sphere formation 
potential, as well as sphere size in both plate formats. 
Next, we proceeded with the evaluation of the eff ectiveness of ~1,420 
chemical compounds as potential anti-CSC agents from selected in-house 
and external libraries. For hit selection, a cut-off  threshold > 70% of ATP 
depletion led to 150 hits, corresponding to ~11% hit rate for the full li-
brary, with some series particularly rich in actives. Additional compounds 
decreased ATP activity under 1% and have been excluded due to even-
tual excess of toxicity and impossibility to build a dose-response curve. 
To quantitatively assess hit inhibitory potency, dose-response curves were 
built using a 10-point concentration range of 0.03 - 16.00 µM. From those, 
69 compounds showed a sigmoidal dose-response curve-fi t and a half-
maximal inhibitory concentration (IC
50
) ≤ 2 µM. Twenty-four compounds 
were further selected for testing on other colorectal cancer cell lines (SW-
620, HCT116), based on their structural diversity and predicted drug-like 
properties. Seventeen compounds displayed an IC
50
 ≤ 2 µM in both cell 
22 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Conclusion: Our data suggest a crucial role for XBP1 in directly coordinat-
ing epithelial DNA damage responses and intestinal stem cell suppression 
via a novel Ddit4l-mTOR dependent feedback mechanism.
References: Aden, K., K. Bartsch, J. Dahl, M. A. M. Reijns, D. Esser, R. 
Sheibani-Tezerji, A. Sinha, F. Wottawa, G. Ito, N. Mishra, K. Knittler, A. 
Burkholder, L. Welz, J. van Es, F. Tran, S. Lipinski, N. Kakavand, C. Boeger, 
R. Lucius, W. von Schoenfels, C. Schafmayer, L. Lenk, A. Chalaris, H. 
Clevers, C. Röcken, C. Kaleta, S. Rose-John, S. Schreiber, T. Kunkel, B. Rabe 
and P. Rosenstiel (2019). „Epithelial RNase H2 Maintains Genome Integrity 
and Prevents Intestinal Tumorigenesis in Mice.“ Gastroenterology 156(1): 
145-159.e119. Kaser, A., A.-H. Lee, A. Franke, J. N. Glickman, S. Zeissig, H. 
Tilg, E. E. S. Nieuwenhuis, D. E. Higgins, S. Schreiber, L. H. Glimcher and 
R. S. Blumberg (2008). „XBP1 Links ER Stress to Intestinal Infl ammation 
and Confers Genetic Risk for Human Infl ammatory Bowel Disease.“ Cell 
134(5): 743-756.
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OP024 STEM CELL DERIVED INTESTINAL ORGANOIDS AS AN 
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Introduction: The establishment of organoid culture systems represents 
a milestone on the route towards successful personalized medicine. In-
testinal organoids dervied from human pluripotent stem cells display es-
sential attributes of adult intestinum even composed of diff erent tissue 
types. Moreover, complex organoid structures represent a highly realistic 
testing platform for advanced toxicity assays and subsequent evaluation 
of potential toxin inhibitors. Organoids can be defi ned as 3D structures 
derived either from pluripotent or organ restricted stem cells harboring 
the ability to mimic in vivo architecture and multi lineage diff erentiation of 
terminally diff erentiated tissues. The pathogeinicity of Clostridium diffi  cile 
is mainly attributable to the production of the large protein toxins (C dif-
fi cile toxins [Tcd]) A (TcdA) and B (TcdB) and -in few bacterial strains- the 
binary enterotoxin CDT.
Aims & Methods: The toxin-inhibiting eff ect of diff erent potential pro-
teins and small molecules like albumin or VER-155008 was evaluated in 
stem cell derived induced human intestinal organoids (iHIOs). iHIOs are 
derived from hair sheet keratinocyte cultures from a healthy donor. Aft er 
cellular reprogramming towards induced pluripotent stem cells, intestine 
organoids were generated in a stepwise diff erentiation protocol. These 
organoids display basic characteristics, such as crypt-like structures and 
architecture of a polarized intestinal epithelium, of human intestine tis-
sue, containing both epithelial and non-epithelial cell types. Direct eff ects 
of clostridial toxins and potential protective eff ects of various substances 
were evaluated in a standardized approach.
Results: Toxin inhibitors like VER-155008 or Albumin decreased toxin-
mediated F-actin destruction, while cortical F-actin was clearly more pre-
served and resembled more to the structure in untreated control organ-
oids. Moreover, a clear distribution/organization of the adhesion protein 
E-cadherin mainly at the cortex of cells was observed in control miniguts 
whereas in toxin-treated organoids E-cadherin was more diff usely distrib-
uted and clustering of E-cadherin became obvious. Toxin-inhibiting treat-
ment led to reduced clustering while E-cadherin maintained its cortical 
localization comparable to control organoids.
Conclusion: iHIOs may serve as a highly advanced toxicity-screening plat-
form with essential advantages compared to pervious single cell toxicity 
assays.
Disclosure: Nothing to disclose 
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OP025 RECTAL COMPLIANCE IS AFFECTED BY ENTERIC NERVOUS 
SYSTEM AND INTERSTITIAL CELLS OF CAJAL IN MURINE SMOOTH 
MUSCLE
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Introduction: Rectal compliance, contributing to fecal storage, is diff er-
ent from the colonic propulsive movement. Abnormal rectal compliance 
is presented in many functional gastrointestinal motility disorders, such as 
irritable bowel syndrome, constipation and fecal incontinence.
Aims & Methods: This study aimed to explore the electromechanical char-
acteristics of rectal compliance in the murine rectum and investigate the 
contribution of intrinsic inhibitory neurotransmission and interstitial cells 
to rectal compliance. 
Male C57BL/6 mice, aged 8 weeks or more were used. For in vivo experi-
ments, the mice were anesthetized with isofl urane, and anorectal ma-
nometry was applied to measure rectal compliance through rectum. In 
ex vivo experiments with using murine rectum, intra-rectal pressure was 
measured in organ bath. The colonic migrating motor complex (CMMC) 
measurements and electrophysiological microelectrode recordings for 
membrane potential were performed using smooth muscle strips and 
segments. Calcium imaging was used to measure the calcium transients 
in the interstitial cells and smooth muscle cells within the rectum of the 
mice expressing a genetically encoded calcium indicator (GCaMP). Drugs 
aff ecting inhibitory neurotransmission including L-NNA and apamin were 
applied.
Results: The rectal compliance was signifi cantly decreased aft er in vitro 
intraperitoneal injection and ex vivo infusion into organ bath of L-NNA 
and apamin, respectively (p=0.002 vs 0.005; p=0.016 vs 0.015) (Fig 1). 
In ex vivo experiments, rectum did not have CMMC, and aft er treatment 
of the L-NNA or apamin in the organ bath, the rectal contractions were 
increased, not CMMC (6.19±3.98 vs 20.35 ±15.78 mN·min, p=0.031), and 
propagation of contractions from the distal colon increased (7.20±3.32 
vs 29.12±20.75 mN·min, p=0.046). In membrane potential with electric 
fi eld stimulation, inhibitory junction potential signifi cantly increased af-
ter L-NNA and apamin, respectively (17±2.9 vs 16±1.6 mV, p=0.04; 24±2.5 
vs 13±3.6 mV, p=0.02). In calcium transient of smooth muscle, AUC (area 
under the curve) in rectum was smaller than that of colon (9.36±4.57 vs 
3.49±2.58 IU·min, p=0.03), and AUC in rectum increased aft er L-NNA and 
apamin, respectively (3.79±1.93 vs 9.71±4.52 IU·min, p=0.001; 3.26±1.92 vs 
8.31±4.12 IU·min, p=0.021). In calcium transient of ICC of rectal circular 
muscle, AUC signifi cantly increased aft er L-NNA (7.39±2.52 vs 10.98±3.71 
IU·min, p=0.012).
Conclusion: Murine rectal compliance were identifi ed in the study. Enteric 
inhibitory neurotransmissions was related to the rectal compliance. ICC 
could control the rectal smooth muscle activities.
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OP026 EVALUATION OF PLASMA M2-PYRUVATE KINASE IN 
DIFFERENTIATION BETWEEN FUNCTIONAL AND ORGANIC COLONIC 
DISORDERS
Yousry M., Wahib A.A., Seif El-Nasr M.S., Eltiby D.M., Soliman G.M.M.
Al-Azhar University-Faculty of Medicine, Hepatogastroenterology and 
Infectious Diseases, Cairo, Egypt
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Introduction: M2-pyruvate kinase (M2-PK) is a key regulator of tumor 
growth and important for tumor metabolism and can dynamically regulate 
aerobic glycolsis. Diff erentiating between functional bowel disorders, such 
as irritable bowel syndrome (IBS), and organic colonic disorders such as 
infl ammatory bowel disease (IBD), colorectal polyps, and colorectal cancer 
(CRC) can oft en be diffi  cult as they present with similar and/or overlapping 
clinical presentations. The investigation and procedures to diff erentiate 
between organic and functional bowel disorders oft en incurs consider-
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OP028 DELETION OF DELTA OPIOID RECEPTORS ON NOCICEPTIVE 
SENSORY NEURONS ABOLISHES T CELL-MEDIATED ANALGESIA 
WITHOUT ALTERING INTESTINAL INFLAMMATION IN MICE
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Introduction: T lymphocytes play a pivotal role in the endogenous regula-
tion of infl ammatory visceral pain. Thus, we have previously shown that 
the local release of enkephalins by eff ector CD4+ T lymphocytes relieves 
from infl ammatory pain in the later phase of the Dextran Sulfate Sodium 
(DSS)-induced colitis model. In this model, intestinal epithelium integrity 
disruption leads to the translocation into the mucosa of bacteria which 
activate innate immune cells. This early phase of the disease results in vis-
ceral hypersensitivity. In the later phase of the disease, when the adaptive 
immune response against bacterial antigens took place, the migration of 
eff ector T lymphocytes within the colon normalizes the visceral sensitiv-
ity. This T-cell analgesic eff ect is dependent on the activation of opioid 
receptors expressed on nociceptor terminal endings by enkephalins lo-
cally released by mucosal eff ector T lymphocytes accumulating into the 
intestinal mucosa.
Aims & Methods: The aim of the study was to identify the receptor(s) for 
enkephalins (i.e. µ and δ opioid receptor subclasses) responsible for T cell-
mediated analgesia. For this purpose, we compared colitis severity, mu-
cosal T cell density and visceral sensitivity in both early and late phases of 
DSS-induced colitis in fl oxed (littermates) and conditional knockout mice 
in which each opioid receptor has been specifi cally deleted in Na
v
1.8+ sen-
sory neurons.
Results: We show that analgesia induced by T cell-derived opioids is elic-
ited via activation of δ but not µ opioid receptors expressed on peripheral 
sensory nerves. The absence of each receptor on sensory nerves did not 
change neither the infl ammatory status nor the time-course of the adap-
tive immune response.
Conclusion: Endogenous regulation of infl ammatory visceral pain by T 
cell-derived enkephalins is mediated by δ opioid receptors expressed on 
enteric Na
v
1.8+ sensory neurons
Disclosure: Nothing to disclose 
OP029 INTESTINAL MICROBIOTA AS A MEDIATOR OF LUMINAL 
PROTEOLYTIC ACTIVITY AND ALTERED INTESTINAL PERMEABILITY 
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Farrugia G.1, Grover M.1
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Introduction: Up to 15% of Campylobacter jejuni enteritis patients may de-
velop post-infection irritable bowel syndrome (PI-IBS). The mechanisms 
for PI-IBS development remain unclear. A subset of PI-IBS patients (~40%) 
have elevated proteolytic activity (PA) in their stool correlating with looser 
and more frequent bowel movements1.
Aims & Methods: Our aim was to determine microbiota associations with 
PA in PI-IBS patients and microbial mediation of PA and intestinal per-
meability using microbiota-specifi c humanized mouse model. 29 PI-IBS 
patients (Rome III) {20 females, mean (SD) age 46.8 (16.7) yrs}, 14 PI-no-
IBS controls {5 females, 50.1 (15.6) yrs} and 21 healthy volunteers (HV) {16 
females, 40.6 (13.7) yrs} were recruited. Fecal PA was assessed using FITC-
casein assay. Shotgun metagenomics was performed for microbiota assess-
able health-care costs both for patients and community health service. 
The selection of patients who should undergo colonoscopy and/or imaging 
procedures is one of the key points of the diagnostic process, which should 
avoid the abuse of invasive and costly tests as well as the underestimation 
of potentially harmful diseases.
Aims & Methods: The aim of this study is to evaluate the diagnostic value 
of plasma M2-pyruvate kinase level in diff erentiating functional colonic 
disorders (e.g: IBS) from organic colonic disorders(e.g: IBD, colorectal 
polyps and CRC).This case control study included 150 patients with dif-
ferent colonic disorders, 75 patients with IBS, 25 patients with ulcerative 
colitis (UC), 25 patients with colorectal polyp and 25 patients with CRC. We 
measured the plasma M2-PK using Enzyme-linked immunosorbent assay 
(ELIZA) in IBS patients and comparing these levels with those obtained 
from patients with UC, colorectal polyp and CRC.
Results: Our study revealed a highly signifi cant increase in plasma M2-PK 
in patients with organic colonic disorders compared to functional group 
(IBS). Using Receiver operating characteristic (ROC) curve at area under 
curve (AUC) 0.872 and cut-off  value of >3 U/ml, our overall sensitivity and 
specifi city for organic group over the functional group were 81.94% and 
83.3% respectively with 35.3% positive predictive value and 97.6% nega-
tive predictive value.
Conclusion: M2-PK is a good marker for discrimination of functional from 
organic colonic disorders (IBD and colorectal polyp, and CRC). Future re-
searches including a large studies population and long-term follow-up 
studies is recommended.
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Introduction: The Irritable Bowel Syndrome (IBS) is a functional disorder 
aff ecting up to 15% of world population. Despite its high prevalence, there 
is not a specifi c diagnostic test for this syndrome. Currently, diagnosis is 
based on the characteristic symptoms systematized in the Rome IV criteria. 
Although Rome IV criteria are mandatory, they are not enough to stablish 
the diagnosis and the patients are not exempt from going through relevant 
explorations to discard some organic pathologies which share symptom-
atology to IBS. RAID-Dx is a non-invasive test developed to positively diag-
nose IBS patients based on specifi c faecal bacterial signature.
Aims & Methods: The aim of this work was to develop a non-invasive test 
to positively diagnose IBS and demonstrate its capacity. A cohort consisting 
on 52 IBS patients and 61 healthy subjects was used to develop a specifi c 
bacterial signature. IBS patients met Rome IV criteria and H subjects were 
asymptomatic, all of them went through a colonoscopy and presented 
no valuable macroscopic lesions in the colon. Diff erent bacterial markers 
were analysed from a stool sample obtained from each subject prior to the 
diet-preparation for the colonoscopy. RAID-Dx was defi ned in a proof-of-
concept with 70% of the cohort (36 IBS patients and 43 H subjects) and the 
obtained results were validated with the remaining 30% (16 IBS patients 
and 18 H subjects).
Results: In the proof-of-concept, RAID-Dx showed high sensitivity and 
specifi city values of 91.67% and 86.05%, respectively. In addition, a Posi-
tive Predictive Value (PPV) of 84.62% and a Negative Predictive Value 
(NPV) of 92.50% for the diagnosis of IBS patients were also found.
In the validation of the defi ned bacteria signature for RAID-Dx, sensitivity 
increased up to 93.75% and specifi city decreased until 72.22%. The PPV 
were also decreased (75.00%) whereas NPV was kept similar (92.86%).
Conclusion: RAID-Dx is an accurate marker to diagnose IBS with high sen-
sitivity and specifi city, which makes it a candidate to become a standard, 
widely accepted diagnostic method of IBS.
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ment. β-diversity was summarized using Unifrac and Bray-Curtis distance 
with signifi cance assessed using nonparametric PERMANOVA method. 
Diff erentially abundant taxa were identifi ed using a multivariable linear 
model with permutation to assess statistical signifi cance, accounting for 
non-normality of abundance data. To investigate microbiome regulation of 
luminal PA, stool from a subset of these patients (n=6 stool/PA classifi ca-
tion) were used to humanize 4-week old germ-free (GF) mice (ex-GF). Six 
weeks post humanization, fecal PA and stool frequency was measured and 
serum was collected aft er administration of creatinine, 4kDa FITC-Dextran 
and 70kDa Rhodamine B-Dextran to assess in vivo permeability.
Results: 12/29 PI-IBS {8 females}, were classifi ed as High PA (>85th percen-
tile of HV, >891 BAEE/mg of protein). Compared to Low PA patient stool, 
High PA patients had signifi cantly decreased microbial diversity (Bray-Cur-
tis, PERMANOVA p< 0.001). Low PA patients had an increased abundance 
of genus Prevotella and Firmicutes and decreased abundance of Bacteri-
odes. Humanization of mice with microbiota from Low PA stool suppressed 
baseline PA of GF mice while microbiota from High PA patients resulted in 
unchanged PA from baseline (% of baseline, Low PA 17.2 ± 30.0; High PA 
100.4 ± 122.0, p< 0.05). High PA mice had increased PA at six weeks post 
humanization (BAEE units/mg protein, High PA 1570.9 ± 1834.3, Low PA 
240.5.2 ± 374.8; p< 0.05). No diff erence was observed in stool frequency 
(pellets/hr, High PA 9.4 ± 3.0; Low PA 9.0 ± 3.6); however High PA mice 
had looser pellets when scored for fecal consistency (Scored 0=normal to 
4=diarrhea, High PA 0.82 ± 0.49; Low PA 0.18 ± 0.33 p< 0.001. Permeability 
of creatinine increased only in mice humanized with High PA microbiota 
(mg/dL, High PA 0.81 ± 0.28); Low PA 0.58 ± 0.24; HV 0.51 ± 0.36 p< 0.05), 
while permeability of 4kDa FITC-Dextran increased in both Low and High 
PA humanized mice compared to HV humanized mice (mg/dL, High PA, 
19.1 ± 14.6; Low PA 23.9 ± 23.9; HV 13.7 ± 30.3 p< 0.05). Creatinine and 4kDa 
FITC-Dextran permeability positively correlated with terminal PA (Spear-
man r=0.31 and 0.27 respectively, p< 0.05).
Conclusion: High PA PI-IBS patients have signifi cantly decreased fecal 
microbial diversity. Low PA microbiota suppresses host luminal PA while 
High PA microbiota did not change host PA. Compared to Low PA micro-
biota, High PA microbiota causes increased intestinal permeability through 
the pore pathway. Therefore, microbiota may infl uence intestinal perme-
ability in PI-IBS through modulation of proteases. Supported by NIH K23 
DK 103911.
References: Edogawa S, Edwinson AL, Peters SA, et al. Serine proteases as 
luminal mediators of intestinal barrier dysfunction and symptom severity 
in IBS. Gut 2019:gutjnl-2018-317416.
Disclosure: Nothing to disclose 
OP030 CIPROFLOXACIN TREATMENT AFFECTS THE STRUCTURE 
AND ACTIVITY OF ENTERIC NERVOUS SYSTEM IN MOUSE SMALL 
INTESTINE
Caputi V.1,2, Marsilio I.1, Cerantola S.1, Renzulli C.3, Calanni F.3, 
Viscomi G.C.3, De Martin S.1, Giron M.C.1
1University of Padova, Department of Pharmaceutical and Pharmacological 
Sciences, Padova, Italy, 2University College Cork, APC Microbiome Ireland, 
Cork, Ireland, 3AlfaSigma S.p.a, Corporate R&D Department, Bologna, Italy
Contact E-Mail Address: cecilia.giron@unipd.it
Introduction: Commensal gut microbiota ensures the functional and struc-
tural integrity of enteric nervous system (ENS) circuitries. Any change of its 
composition elicited by environmental factors or drugs could disrupt ENS 
homeostasis and determine the onset of functional bowel disorders. Cip-
rofl oxacin is a synthetic broad-spectrum antimicrobial agent, belonging 
to the fl uoroquinolone family, used for treating respiratory, urinary tract, 
gastrointestinal and abdominal infections. Ciprofl oxacin usage has been 
associated with many adverse reactions, including neurotoxicity.
Aims & Methods: The aim of the present study was to evaluate the eff ect of 
ciprofl oxacin on ENS integrity and gastrointestinal motility in young mice. 
Male C57Bl/6 mice (age=9±1 weeks; N=44) were orally gavaged with cip-
rofl oxacin (50 mg/kg, suspended in 1% methylcellulose; CPX group) or 
vehicle (CNTR group) for 14 days. In CPX and CNTR animals we assessed:
i) gastrointestinal transit 30 minutes aft er intragastric administration of 
nonabsorbable-FITC-labeled dextran; 
ii) pellet frequency, measured as changes in stool output during a 60-min-
ute collection period; 
iii) stool water content; 
iv) contractile activity of isolated ileum segments, measured as changes 
in isometric muscle tension following carbachol (0.001- 100 µM), KCl (60 
mM), electric fi eld stimulation (EFS, 1-40 Hz) or inhibition in non-adren-
ergic, non-cholinergic (NANC) conditions (EFS=10 Hz, 1 µM atropine, 1 µM 
guanethidine, with or without 0.1 mM L-NAME); 
v) distribution of the neuronal HuC/D and glial S100β markers by confocal 
immunofl uorescence in ileal frozen cryosections; 
vi) neurochemical coding integrity, evaluated by acetylcholinesterase and 
NADPH-diaphorase biochemical staining in longitudinal-muscle myen-
teric plexus preparations (LMMPs).
Results: Ciprofl oxacin treatment determined a signifi cant reduction in the 
number/hour output of fecal pellets (-36±8%, N=5/group, P< 0.01) and 
increased stool water content (+32±9%, N=5/group, P< 0.01). Gastrointes-
tinal transit was delayed in CPX mice compared to CNTR mice (geometric 
center: 8.3±0.2 vs 7.3±0.2, N=6/group, P< 0.01), respectively). In vitro con-
tractility studies showed a signifi cant downward shift  of the concentration-
response curve to carbachol in CPX group (Emax=-36±5%, N=5/group, p< 
0.01) compared with CNTR group, together with a reduced KCl-induced 
excitatory responses (-32±8%, N=5/group, p< 0.05). Altered excitatory and 
inhibitory neurotransmission in CPX mice was shown by decreased EFS-
elicited contractions with a signifi cantly reduction of 10 Hz-neuronal cho-
linergic response (CPX=-67±11%, N=5/group, p< 0.01) and by an impaired 
NANC-mediated relaxation of ileal segments from CPX mice. In the ENS of 
CPX mice, increased HuC/D immunoreactivity and NADPH-d-positive cells 
(+38±2%, N=5/group, P< 0.01) in the ileum of CPX mice together with reac-
tive gliosis, evidenced by S100β immunofl uorescence distribution.
Conclusion: Ciprofl oxacin-induced gut dysbiosis determines complex 
anomalies in ENS architecture, neurochemical coding and function lead-
ing to neuromuscular dysfunction. Such neuroglial plastic changes are 
highly indicative of the negative eff ects mediated by ciprofl oxacin on the 
integrity of gut microbiota-ENS axis, possibly contributing to promote 
functional bowel disorders later in life.
Disclosure: FC, CR, GCV are employees of Alfasigma SpA. The remaining 
authors declare that the research was conducted in the absence of any 
commercial or fi nancial relationships that could be construed as a poten-
tial confl ict of interest. 
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OP031 A COMPARATIVE ANALYSIS OF DIGITAL CHOLANGIOSCOPY 
AND PROBE-BASED CONFOCAL LASER ENDOMICROSCOPY FOR THE 
MALIGNANCY DETECTION IN BILE DUCT LESIONS
Robles-Medranda C., Oleas R., Olmos J., Alcivar-Vasquez J., 
Puga-Tejada M., Baquerizo-Burgos J., Pitanga-Lukashok H.
Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Gastroenterology 
and Endoscopy Division, Guayaquil, Ecuador
Contact E-Mail Address: robertoleas@gmail.com
Introduction: The diff erentiation of malignant from the benign biliary 
lesion is challenging in clinical practice. Peroral digital cholangioscopy 
(POCS) predicts malignancy through the visual impression of biliary le-
sions; whereas, Probe-based confocal laser endomicroscopy (pCLE) via in 
vivo, real-time tissue examination. Currently, both pCLE and cholangios-
copy classifi cation systems are available; however, a comparison between 
these classifi cation systems remains unknown.
Aims & Methods: To compare the Paris classifi cation criteria (pCLE) and the 
visual impression classifi cation system (POCS) for the detection of malig-
nancy in biliary lesions. 
The following is a cross-sectional study. Data from patients referred for 
cholangioscopy and pCLE due to indeterminate biliary stricture was con-
secutively recorded and analyzed. The visual impression of biliary lesions 
during POCS were recorded following the classifi cation system proposed 
by Robles-Medranda et-al. pCLE was performed using the Cellvizio Chol-
angioFlex probe (Mauna Kea Technologies, Paris, France) during the ERCP 
procedure, and the pCLE fi ndings for the diagnosis malignancy were re-
corded according to the Paris classifi cation. pCLE videos were reviewed 
by one endoscopist, blinded to any clinical or ERCP information, and in-
dicated which descriptive criteria (Paris classifi cation) were observed in 
the videos displayed. Malignancy detection was defi ned following histo-
pathology results. A video-set of 20 patients with pCLE were evaluated for 
interobserver agreement by two endoscopists (J.O and J.A).
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contrast, some genes encoding for lymphocyte receptors were exclusively 
regulated in CD-MAT, (i.e., MS4A1, CD6, CTLA4, CD3D, CD3E, IL2RG, LAG3-
2, CD24, CD79A, CD5 and CD69), showing a diff erent pattern of immune 
cell activation in this tissue compared to the ileum. Real-time RT-PCR in 
an independent patient and control cohort confi rmed the signifi cant up-
regulation of CD79A, SM4A1 (CD20), CTLA4 and CD3D in CD-MAT compared 
to controls, with no signifi cant diff erences in IL1B and S100A8. Finally, 
immunohistochemistry and immunofl uorescence analysis confi rmed the 
large infi ltrates and localized follicular structures containing both CD3+ and 
CD20+ lymphocytes in CD-MAT.
Conclusion: Our study reveals the marked accumulation of lymphocytes 
that form disseminated aggregates, as well as well-structured lymphoid 
follicles, in the MAT associated with CD infl amed ileum, but not in controls. 
Remarkably, acute infl ammatory genes highly expressed in the ileum were 
not markedly upregulated in the adipose tissue. Our data strongly sup-
ports the role of CD-associated MAT as a site for T- and B-cell activation 
and suggests that it could also act as a reservoir of memory immune re-
sponses. Whether these antigen-specifi c responses would be detrimental 
or protective will require further study.
Disclosure: Nothing to disclose 
Gastric intestinal metaplasia: 
The premalignant stomach
10:30-12:00 / C3
OP033 RISK FACTORS FOR THE PROGRESSION OF GASTRIC 
INTESTINAL METAPLASIA IN A LOW RISK POPULATION: A 
MULTICENTER, PROSPECTIVE, COHORT STUDY
Nieuwenburg S.A.V.1, Mommersteeg M.C.1, Eikenboom E.1, Yu B.1, 
Tang T.J.2, Anten M.P.3, Prytz-Berset I.4, Witteman E.M.5, Ter Borg F.6, 
Hartog G.D.7, Bruno M.J.1, Fuhler G.M.1, Peppelenbosch M.P.1, Doukas M.8, 
Kuipers E.J.1, Spaander M.C.W.1
1Erasmus University Medical Center, Gastroenterology & Hepatology, 
Rotterdam, Netherlands, 2Ijsselland Hospital, Gastroenterology & Hepatology, 
Capelle a/d Ijsel, Netherlands, 3Sint Fransiscus Hospital, Gastroenterology 
& Hepatology, Rotterdam, Netherlands, 4More and Romsdal Trust, 
Gastroenterology & Hepatology, Alesund, Norway, 5Canisius-Wilhelmina 
Hospital, Gastroenterology & Hepatology, Nijmegen, Netherlands, 6Deventer 
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Hospital, Gastroenterology & Hepatology, Rotterdam, Netherlands, 8Erasmus 
University Medical Center, Pathology, Rotterdam, Netherlands
Contact E-Mail Address: s.nieuwenburg@erasmusmc.nl
Introduction: Gastric cancer (GC) is mostly preceded by gastric precursor 
lesions (GPL). The recently updated MAPS guideline for surveillance of GPL 
now includes the recommendation for surveillance in case of a positive 
family history for GC. However, the evidence for this recommendation and 
our tools to identify patients at risk for progression are still scarce. This 
study therefore aimed to investigate if risk factors such as family history, 
lifestyle, genetic polymorphisms, and serology at baseline are possible 
predictors for progression of GPL in low risk areas.
Aims & Methods: Patients with GPL were included in the PROREGAL study; 
a multicenter, prospective cohort study. At upper endoscopy biopsies were 
obtained from 12 standardised sites in the stomach and from visible le-
sions. These were histologically assessed according to the operative link 
on gastric intestinal metaplasia (OLGIM) system. At baseline, patients 
completed a questionnaire on family history and lifestyle factors, and fas-
tening blood samples were taken for pepsinogen and gastrin-17. All pa-
tients underwent at least two upper endoscopies. Progression of intestinal 
metaplasia (IM) was defi ned as progression of OLGIM classifi cation be-
tween follow-up (FU) endoscopies. Previously associated single nucleotide 
polymorphisms (SNPs) with H. pylori infection or GC were determined us-
ing polymerase chain reaction restriction fragment length polymorphism 
(PCR-RFLP): NCF4 (rs4821544), TLR1 (rs28393318), TLR4 (rs11536889) and 
ATG16L1 (rs2241880). Cox-regression was performed for analysis on risk 
factors. Diff erences in proportions for the presence of SNPs were calcu-
lated using z-test. For all tests a signifi cance level of 0.05 was used.
Results: 308 patients (median age 61 years, IQR 17;male 48.4%) were in-
cluded. Median FU was 48 months (IQR 24). During FU 116 (37.7%) pa-
tients showed progression of their OLGIM status and six patients (1.9%) 
developed high grade dysplasia or GC. Family history (HR 1.4; p=0.154), 
Results: Forty-three patients were included; the median age was 62.2± 
15.6 years; the 65.1% were female. The main reason for the evaluation 
was indeterminate biliary stenosis (44.18%) and suspected biliary tumor 
(55.8%). 67.44% of lesions were located in the proximal common bile 
duct. POCS visual impression detected malignancy in 76.7 % of patients, 
with a sensitivity, specifi city, PPV, and NPV of 94%, 92%, 92%, and 94%, 
respectively. pCLE detected malignancy in the 79.0% of patients, with a 
sensitivity, specifi city, PPV, and NPV of 64%, 100%, 100%, and 83%, re-
spectively. Table 1 summarizes the overall accuracy of each pCLE criteria 
for malignancy prediction. A moderate interobserver agreement for pCLE 
criteria was obtained (Κ< 60).
  Sensitivity, % Specifi city, % PPV, % NPV, %
Tick blank band (>40 um) 85 24 37 75
Thick white band 87 40 42 83
Dark clumps 69 96 90 86
Epithelium 54 50 37 67
[Table 1. Overall accuracy for each pCLE features of malignancy.]
Conclusion: The visual impression of POCS using a classifi cation system 
showed to be more sensitive than in vivo, real-time tissue examination of 
pCLE for the detection of malignancy in indeterminate biliary obstruction.
Disclosure: Nothing to disclose 
OP032 WHOLE TRANSCRIPTIONAL ANALYSIS IDENTIFIES THE 
MESENTERIC ADIPOSE TISSUE OF CROHN’S DISEASE PATIENTS AS 
SITES OF T- AND B-CELL ACTIVATION
Silva F.A.R.1, Pascoal L.B.1, Dotti I.2, Ayrizono M.L.S.1, Aguilar D.2, 
Rodrigues B.L.1, Milanski M.3, Velloso L.A.4, Fagundes J.J.1, Salas A.2, 
Leal R.F.1
1University of Campinas, Department of Surgery, Colorectal Surgery Unit, 
IBD Research Laboratory, Campinas, Brazil, 2IDIBAPS, Department of 
Gastroenterology, IDIBAPS, Hospital Clínic, CIBER-EHD, Barcelona, Spain, 
3University of Campinas, Laboratory of Metabolic Disorders, School of 
Applied Sciences, Campinas, Brazil, 4University of Campinas, Laboratory of 
Cell Signaling, School of Medical Sciences, Campinas, Brazil
Contact E-Mail Address: rafranco.unicamp@gmail.com
Introduction: Crohn´s disease (CD) is a multifactorial disease characterized 
by chronic intestinal infl ammation. The increased visceral adiposity near 
the aff ected intestinal area, of which mesenteric adipose tissue (MAT) is 
the main component, is a feature of CD. Both protective, as well as patho-
logical, roles have been attributed to this disease-associated tissue in CD.
Aims & Methods: Our aim was to understand the contribution of MAT to 
CD pathophysiology by providing a molecular and cellular signature of 
disease-associated adipose tissue in CD patients. To do that we performed 
whole transcriptional analysis by RNA sequencing (RNA-seq) of MAT and 
ileum from CD patients with active disease (CD group, n=8) and non-IBD 
controls (CTR group, n=4). The biological validation of a panel of diff er-
entially expressed genes was conducted by qPCR in 26 CD patients and 17 
non-IBD controls. Immunohistochemistry was also performed for valida-
tion analysis.
Results: RNA-seq identifi ed 17 signifi cantly regulated genes (|FC|>1.5; FDR< 
0.05) in CD-MAT compared to non-IBD controls, with a marked upregu-
lation of plasma cell genes (i.e., IGLL5, MZB1, CD79A, POU2AF1, FCRL5, 
JCHAIN, DERL3, SDC1, PIM2). A less strict statistical cutoff  value (|FC|>1.5, 
nominal p£0.05) revealed a larger list of 651 genes in CD-MAT compared 
to controls. Ingenuity Pathway Analysis of this signature revealed a sig-
nifi cant regulation of pathways related to T- and B-cell functionality. In 
contrast to MAT, transcriptional analysis of the ileum revealed a set of 849 
genes signifi cantly regulated in CD compared to non-IBD controls (|FC|>1.5; 
FDR< 0.05), and 2,654 genes when applying the lower cutoff  (nominal 
p value< 0.05). Despite the diff erences between the MAT and ileal sig-
natures of CD patients, we identifi ed a subset of 204 genes signifi cantly 
modulated in both tissues. This common signature included genes related 
to the plasma cell signature (MZB1, POU2AF1, IGLL5, JCHAIN, DERL3 and 
PIM2) that were signifi cantly up-regulated both in CD-MAT and ileum. In 
contrast, other genes that are highly increased in CD ileum such as S100A8 
and S100A9 (calprotectin), IL1B, CD14, CXCL1, CXCL8, MMP1, OSMR, all of 
which are related to an acute infl ammatory response, were exclusively 
regulated in the ileal mucosa of CD disease, but not in the adjacent MAT. In 
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smoking (HR 1.3; p=0.260), and history of Hp-infection (HR 1.1; p=0.684) 
were associated with non-signifi cant risks for progression. Alcohol use (HR 
0.8; p=0.428), serum levels of PG I/II (HR1.0; p=0.446) and gastrin-17 (HR 
1.0; p=0.908) were not associated with an increased progression risk. The 
minor allele (C) on the TLR4 (rs11536889) was negatively associated with 
progression (OR 0.4; p< 0.001), while the minor allele (G) in the ATG16L1 
(rs2241880) was positively associated with progression (OR 1.5; p=0.001).
Conclusion: This is the fi rst study to assess potential risk factors for the 
progression of IM in a low risk area. Over one third of patients showed 
progression of IM during surveillance. We did not fi nd any signifi cant risk 
factors for progression. However, SNPs in TLR4 and ATG16L1 showed sig-
nifi cant associations with progression of IM, suggesting that genetic risk 
stratifi cation may contribute to the identifi cation of patients eligible for 
surveillance.
Disclosure: Nothing to disclose 
OP034 EVOLUTION OF GASTRIC PRECANCEROUS LESIONS: A LONG 
TERM FOLLOW-UP SINGLE CENTER STUDY IN FRANCE
Chapelle N.1, Péron M.2, Quénéhervé L.3, Bourget A.4, Cauchin E.5, 
Touchefeu Y.6, Mosnier J.-F.7, Matysiak Budnik T.8
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Introduction: International guidelines recommend surveillance of gastric 
precancerous lesions (GPL), but there are limited data on the evolution of 
these lesions, especially in countries of low gastric cancer incidence. Our 
objective was to study the evolution of GPL in France.
Aims & Methods: From the cohort of 507 patients diagnosed with GPL 
[atrophic gastritis (AG), or intestinal metaplasia (IM), or low grade dyspla-
sia (LGD), or high grade dysplasia (HGD)]in our center between 2000 and 
2015, the patients fulfi lling the following criteria were identifi ed: 
1) at least one follow-up endoscopy performed aft er a minimal period of 
6 months, 
2) at each endoscopy, random gastric biopsies obtained, at least 3 from 
antrum and 2 from corpus, 
3) all biopsy material available for histological review. 
The biopsy specimens were retrieved from the hospital tissue bank and 
analysed prospectively by an expert pathologist for the presence of GPL 
and their extent (according to OLGA and OLGIM score). The type of IM 
(complete or incomplete) was also evaluated. The evolution of the lesions 
was assessed by comparing the initial and the fi nal histology. Additionally, 
for the patients with multiples endoscopies during the follow-up, a precise 
evaluation of the evolution on individual level was performed.
Results: Seventy nine patients (35 men, median age 61 years), were in-
cluded. At initial endoscopy, the GPL found were, by order of severity: AG 
in 5 patients (OLGA 1, n=4; OLGA 2, n=1), IM in 73 patients (OLGIM 1, n=39; 
OLGIM 2, n=28; OLGIM 3, n=6) and LGD in 1 patient. Thirty-seven patients 
(47%), were H. pyloripositive by histology. Among the 73 patients with IM, 
59 had IM in the antrum, 8 in the corpus, and 6 both in the antrum and in 
the corpus. Sixty patients had complete IM and 13 incomplete IM. The mean 
(±SD) follow-up period was 66 ±48 months (Min=7, Max=208), the mean 
(±SD) number of endoscopies per patient was 4±2 (Min= 2, Max = 14), and 
the total number of endoscopies performed in all patients was 341. 
At fi nal endoscopy, the GPL found were AG in 2 patients, LGD in 4 patients, 
HGD in 1 patient, adenocarcinoma (ADK) in 2 patients, IM in 58 patients 
and normal gastric mucosa (+/- superfi cial gastritis) in 12 patients. Six pa-
tients (7%) were H. pyloripositive by histology.
The comparison between the initial and fi nal endoscopy, showed stabil-
ity of GPL in 56 patients (71%), progression to more severe lesion in 10 
patients (13%) (from AG to IM in 4 patients, from IM to LGD in 3 patients, 
from IM to HGD in 1 patient, and from IM to ADK in 2 patients), and the 
regression in 13 patients (16%). Both patients who progressed to ADK had 
incomplete type of antrum IM, one OLGIM 2 and one OLGIM 3. Altogether, 
among 10 patients who progressed to more severe lesions, 6 (60%) had 
incomplete type of IM.
Among the 13 patients in whom the regression to the normal (+/-gastritis) 
gastric mucosa was observed, 9 had initially antrum limited OLGIM 1 com-
plete IM and 4 had antrum limited complete OLGIM 2 IM.
Conclusion: This study shows that: 
1) Most of the GPL remain stable over time, 
2) Antrum-limited IM, especially of incomplete type, has the highest risk of 
progression to dysplasia and cancer, 
3) Regression of IM is possible, especially for low grade (OLGIM 1) and for 
complete type.
Disclosure: Nothing to disclose 
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OP035 EUROPEAN SURVEY OF HELICOBACTER PYLORI PRIMARY 
RESISTANCE TO ANTIBIOTICS - EVOLUTION OVER THE LAST 20 YEARS
Megraud F.1, Huang D.2, Hoebeke M.2, Alix C.3, Benejat L.3, Lehours P.4, 
Glupczynski Y.5, and The H. pylori AST working group
1Hopital Pellegrin, Laboratoire de Bacteriologie, Inserm U 1053, Bordeaux 
Cedex, France, 2Université catholique de Louvain, Bacteriology Laboratory, 
CHU Namur (Site Godinne), Yvoir, Belgium, 3Hopital Pellegrin, Bacteriology, 
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Introduction: Antibiotic resistance of Helicobacter pylori is the main cause 
of failure of most current eradication regimens. As antimicrobial suscep-
tibility testing (AST) is not performed in all cases, it is important to have 
regular surveys to infer the treatments which can be used. For this pur-
pose, European surveys were performed in 1998, 2008 and we report here 
the results of 2018.
Aims & Methods: Centres were recruited on a voluntary basis, one for each 
small country (in the range of 10 million inhabitants) and several for larger 
countries. The request was to include 50 adult patients who had not re-
ceived previous eradication treatment. 
Information collected included demographic, clinical, and endoscopic re-
sults as well as AST results (clarithromycin, levofl oxacin, metronidazole, 
amoxicillin, tetracycline and rifampicin) performed by Etest or disk dif-
fusion according to a standardized procedure. Control strains were also 
made available and a 10% random sample was sent to the coordinating 
centre at the end.
Results: The crude data show 1,246 H. pylori positive patients included in 
24 centres from 19 countries (minimum: 20 cases per centre) The distribu-
tion with regard to age, gender, reason for consultation and endoscopic 
examination is in the range of what is usually observed for this type of pa-
tients. H. pylori resistance was present in 21.9% for clarithromycin, 16.6% 
for levofl oxacin, and 38.5% for metronidazole; 30 strains were reported 
as resistant to amoxicillin (2.4%), 4 to tetracycline (0.3%) and 48 to ri-
fampicin compounds (3.8%). These unusual resistance strains are now 
being controlled as well as a random sample of the other strains. The kit 
Amplidiag H.pylori (MobiDiag) will be used for clarithromycin and AST for 
the other antibiotics.
Conclusion: These results indicate a global and continuous rise in H. pylori 
primary resistance to clarithromycin but lower than in the previous decade 
(9.9% in 1998, 17.5% in 2008, and 21.9% in 2018), a slight increase to le-
vofl oxacin and a more important increase for metronidazole (from 33.1 to 
38.5% since 2008).
Disclosure: The authors acknowledge the support of bioMérieux for pro-
viding Etests and Mobidiag for providing with PCR kits. 
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Pancreatic neoplasms: Improving diagnosis 
and outcomes
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OP037 ROBOTIC PANCREATODUODENECTOMY IN THE 
NETHERLANDS: A MULTICENTER ANALYSIS OF THE FIRST 100 
PROCEDURES
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Rotterdam, Netherlands, 4St. Antonius Ziekenhuis, Nieuwegein, Netherlands, 
5Erasmus MC, Rotterdam, Netherlands
Contact E-Mail Address: c.l.m.nota@umcutrecht.nl
Introduction: Minimally invasive surgery is currently the gold standard for 
many surgical procedures. Most pancreatoduodenectomies, however, are 
still being performed through laparotomy. As conventional laparoscopy is 
limited by the rigid visual- and working axis, it might be less suited for 
complex procedures such as pancreatoduodenectomy. Potentially, the use 
of robotic technology off ers a solution. The technically enhanced articu-
lating instruments and 3D vision allow for optimal surgical dexterity, as 
needed during meticulous dissection and construction of the anastomoses 
in pancreatoduodenectomy. The aim of this study was to determine safety 
and feasibility of a robotic approach to pancreatoduodenectomy in the 
Netherlands and compare our results to recent studies reporting on the 
outcomes of open pancreatoduodenectomies.
Aims & Methods: This is a multicenter post hoc analysis of prospective 
databases from three high volume Hepato-Pancreato-Biliary (HPB) cen-
ters in the Netherlands. The fi rst 100 patients undergoing robot-assisted 
pancreatoduodenectomy were included. Primary endpoint was severe 
complication, defi ned as the occurrence of one or more of the following 
complications: ISGPS gr. B/C postpancreatectomy hemorrhage, ISGPS gr. 
B/C pancreatic fi stula, multiple or single organ failure, or death. Outcomes 
were scored during index admission. In addition, we performed a system-
atic review of observational, monocenter studies reporting on outcomes 
of > 500 open pancreatoduodenectomies, published in the past 5 years.
Results: In total, 100 consecutive patients underwent robot-assisted pan-
creatoduodenectomy. A total of 22 (22%) patients suff ered from a severe 
complication. Pancreatic fi stula (ISGPS gr. B/C) occurred in 19 (19%) pa-
tients and 9 (9%) patients suff ered from post-pancreatectomy hemorrhage 
(ISGPS gr. B/C). Delayed gastric emptying (ISGPS gr. B/C) occurred in 26 
(26%) patients. In 8 (8%) patients the procedure was converted to an open 
pancreatoduodenectomy. Seven patients (7%) underwent a relaparotomy. 
There was no postoperative in-hospital or 30-day mortality. The systematic 
review of 14 studies (n=12.708 patients) on open pancreatoduodenectomy 
demonstrated that complications occurred in 38% of all patients and reop-
erations in 7%. The weighted mean mortality was 3%.
Conclusion: These outcomes of the fi rst 100 robot-assisted pancreato-
duodenectomies demonstrate that this procedure was introduced safely 
in three hospitals in the Netherlands without postoperative mortality and 
acceptable morbidity. Clinical outcomes in this study were in line with out-
comes reported in 14 recent, large, international studies on open pancre-
atoduodenectomies.
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Introduction: Bismuth-quadruple therapy with a PPI, bismuth salts, tet-
racycline and metronidazole has resurfaced in Europe thanks to a new 
single-capsule formulation (Pylera®).
Aims & Methods: Our aim was to evaluate the effi  cacy and safety of the sin-
gle-capsule bismuth-quadruple therapy (Pylera®) in the European Registry 
on Helicobacter pylori management. Patients were systematically registered 
at an e-CRF by AEG-REDCap. Variables included: Patient’s demographics, 
previous eradication attempts, prescribed treatment, adverse events, and 
outcomes. Intention-to-treat and per-protocol analyses were performed. 
Data monitoring was performed to ensure the quality of the data
Results: So far, 30,394 patients have been included. Of these, 2,326 valid 
patients treated with single-capsule bismuth-quadruple therapy have 
been evaluated. 1,900 (81.7%) were prescribed following the technical-
sheet (10 days, 3 capsules q.i.d.), the remaining where excluded. Average 
age was 52 years, 64% women, and 13% had peptic ulcer. Table sum-
marizes results. The majority of cases (63%) were naïve. PPI type or dose 
did not infl uence eradication rate. 33% of cases suff ered from adverse 
events (severe in 3%, and only 1% withdrew treatment due to adverse 
events). Only two serious adverse events were reported: hospitalization for 
diarrhea, and an allergic reaction treated with anti-histamine drugs, both 
solved without complications.
Conclusion: Treatment with single-capsule bismuth-quadruple therapy 
(Pylera®) achieves H. pylori eradication in approximately 90% of patients 
by intention-to-treat in clinical practice, both in fi rst- and second-line, 
with a favorable safety profi le.
  Frequency Percent mITT PP
Naive 
(no previous treatment) 1,195 63% 92% 95%
2nd 412 22% 87% 90%
3rd 220 12% 84% 85%
mITT: Modi ed intention-to-treat; PP: per-protocol.
[Prescription and eradication rates of single-capsule bismuth quadruple 
therapy]
Disclosure: Prof. Gisbert has served as a speaker, consultant and advi-
sor to, or has received research funding from, Almirall, Nycomed, Astra-
Zeneca, Casen Recordati, Mayoly, and Allergan. Dr McNicholl has received 
retributions from Allergan and MSD for training activities, and he is an 
advisor for Mayoly. 
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BILIARY DRAINAGE USING METAL OR PLASTIC STENTS IN PATIENTS 
WITH PANCREATIC DUCTAL ADENOCARCINOMA
Latenstein A.1, Mackay T.2, van Huijgevoort N.3, Bonsing B.A.4, 
Bruno M.5, Verdonk R.C.6, Besselink M.G.H.7, van Hooft  J.E.8, 
Dutch Pancreatic Cancer Group
1Amsterdam UMC, Location AMC, Surgery, Amsterdam, Netherlands, 
2Amsterdam UMC, Location AMC / University of Amsterdam, Surgery, 
Amsterdam, Netherlands, 3Academical Medical Center Amsterdam, 
Gastroenterology, Amsterdam, Netherlands, 4Leiden University Medical 
Center, Leiden, Netherlands, 5Erasmus MC - University Medical Center, 
Gastroenterology, Rotterdam, Netherlands, 6St. Antonius Ziekenhuis, 
Gastroenterology and Hepatology, Nieuwegein, Netherlands, 7Amsterdam 
UMC, Department of Surgery, Amsterdam, Netherlands, 8Amsterdam UMC, 
Gastroenterology and Hepatology, Amsterdam, Netherlands
Contact E-Mail Address: a.e.latenstein@amsterdamumc.nl
Introduction: In patients with resectable pancreatic ductal adenocarci-
noma and biliary obstruction, early surgery is the preferred treatment. 
In patients with severe jaundice, neoadjuvant therapy, delayed surgical 
treatment, and acute cholangitis endoscopic biliary drainage (EBD) is oft en 
indicated. In the updated European Society of Gastrointestinal Endoscopy 
guidelines, self-expanding metal stents (SEMS) are strongly recommended 
for EBD, because of lower rates of stent dysfunction, cholangitis and en-
doscopic re-interventions as compared to plastic stents. We aimed to as-
sess the implementation of SEMS use in daily clinical practice in patients 
with resectable pancreatic head cancer undergoing EBD and the relation 
between SEMS,drainage related complications and postoperative compli-
cations.
Aims & Methods: We performed a nationwide, retrospective cohort study 
including all patients with pancreatic ductal adenocarcinoma who un-
derwent EBD prior to pancreatoduodenectomy in the mandatory Dutch 
Pancreatic Cancer Audit (January 2017 - December 2018). Patients under-
going percutaneous biliary drainage were excluded. Missing data (range 
0.-10.4%) were imputed by multiple imputation techniques in which 15 
dummy sets were created. Multivariable logistic regression models with 
adjustment for patient characteristics (sex, age, BMI, and ASA score) were 
performed to assess the association between type of stent and drainage-
related or post-operative complications. Drainage-related complications 
were pancreatitis, cholangitis, perforation, bleeding, occlusion. Postoper-
ative complications were postoperative pancreatic fi stula, delayed gastric 
emptying, postpancreatectomy hemorrhage, bile leakage, chyle leakage, 
pneumonia and wound infection.
Results: In total, 585 patient, with a mean age of 68 (standard error 0.41) 
years, were included and 321 (55%) were male. EBD was mostly per-
formed with plastic stents (331, 57%) compared to SEMS (254, 43%). Over-
all, drainage-related complications were comparable between patients 
with SEMS (18%) and plastic stents (19%). Cholangitis occurred less oft en 
in patients with SEMS compared to plastic stents (5% vs. 11%, p=0.029). 
Post-ERCP pancreatitis occurred in 9% and 8% in patients with SEMS and 
plastic stents, respectively. In multivariable logistic regression, adjusted 
for patient characteristics, SEMS was associated with lower odds of chol-
angitis (OR 0.394, 95% CI 0.176-0.881). Postoperative pancreatic fi stula oc-
curred less oft en in patients with SEMS compared to plastic stents (10% vs. 
19%, p=0.011) and this eff ect remained aft er adjustment for patient charac-
teristics in multivariable logistic regression (OR 0.568 95% CI 0.324-0.995).
Conclusion: This nationwide study shows that biliary drainage with SEMS 
placement is insuffi  ciently implemented in the Netherlands despite ex-
plicit European guideline recommendations. Importantly, this nationwide 
study confi rmed that those patients, drained with a SEMS, had a reduced 
rate of cholangitis and clinically relevant postoperative pancreatic fi stula. 
Therefore, preoperative biliary drainage using SEMS should be strongly 
promoted and this may be facilitated and accelerated by a nationwide 
implementation programme.
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Introduction: Endoscopic ultrasound-guided fi ne needle biopsy (EUS-FNB) 
has been proposed to obtain high-quality tissue samples for pancreatic 
tumors. We performed a multicenter randomized control trial comparing 
EUS-FNB with a 20-gauge Procore® needle versus a 22-gauge Acquire® 
needle. Our primary endpoint was the quantity of the obtained tissue, as 
defi ned by the mean cumulative length of tissue core biopsies per needle 
pass. The secondary aim was the tumor characterization.
Aims & Methods: Patients admitted for EUS-FNB of a pancreatic mass in 
3 endoscopy units were included. One pass was performed consecutively 
with both needles. The order of use of the 2 needles was randomized. 
Histological material was studied in a blinded manner with respect to the 
needle, and the cumulative length of tissue core biopsies per needle pass 
was determined (sum of all the target tissue core lengths as measured 
manually with a graduated ruler under microscopy assistance, on the best 
cell block section). The gold standard was based on histological diagnosis, 
surgical resection, or more than 6 months follow-up. Assuming a 4mm 
diff erence in length of tissue core biopsies (based on a previous compara-
tive study) [1], with a type-I error of 0.05 (2-sided) and a power of 0.9, the 
study required a total 60 patients.
Results: 38 men and 22 women, with a mean age of 67±9 years were in-
cluded. No adverse eff ect was noted. Final diagnosis (based in all cases on 
histology for malignant tumor, and on histology and follow-up in benign 
pathology) was adenocarcinoma in 45 cases (75%), neuroendocrine neo-
plasm in 11 cases (18%), auto-immune pancreatitis in 2 cases, and others 
in 2 cases. Histological diagnosis was achieved in 41 out of 60 patients 
(68%) with the 20-gauge Procore® pass and in 53 out of 60 patients 
(88%) with the 22-gauge Acquire® pass (P< 0.02). The mean cumulative 
length of tissue core biopsies per needle pass was signifi cantly higher with 
the 22-gauge Acquire® needle with 11.78±9.2mm versus 5.86±6.7mm for 
the 20-gauge Procore® needle (P< 0,0001).
Conclusion: Our results suggest signifi cant diff erences, with a tumor char-
acterization rate and a mean cumulative length of tissue core biopsies per 
needle pass signifi cantly higher with the 22-gauge Acquire® needle than 
with the 20-gauge Procore®.
ClinicalTrials.gov ID: NCT03567863
References: 1- Karsenti D, Tharsis G, Zeitoun JD, et al. Comparison of 
20-gauge Procore® and 22-gauge Acquire® needles for EUS-FNB of solid 
pancreatic masses: an observational study. Scand J Gastroenterol 2019
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PANCREATIC LESIONS BY GLUCOMETRIC ANALYSIS OF CYSTIC FLUID 
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Introduction: Diff erential diagnosis of pancreatic cystic lesions is required 
for an appropriate therapeutic approach. Several markers have been eval-
uated in cystic fl uid obtained by EUS-FNA, but they have shown limited 
accuracy.
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The EUS-FNA pass and CH-EUS FNA had the accuracy of diagnosis of 
86.48% and 89.18% respectively (p=NS) and the global accuracy of the two 
passes was 93.2%. The rate of false negative cases did not diff er between 
hypoenhanced or hyperenhanced lesions. No diff erence were seen for the 
results related to the location , size or tumor stage.
Conclusion: The diagnostic rate of core obtained by using 22G FNA needles 
with standard EUS-FNA and guided CH-EUS-FNA did not diff er statistically.
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Introduction: Endoscopic ultrasound-directed transgastric ERCP (EDGE) is 
an alternative to enteroscopy- and laparoscopy-assisted ERCP in patients 
with RYGB anatomy. It allows for direct access via lumen-apposing metal 
stents (LAMS) to the excluded stomach, followed by ERCP across the gas-
tro-gastric (GG) stent. 
Although short-term results are promising with technical success in the 
majority of cases, the long-term outcomes are not known. Specifi cally, the 
rate of persistent GG fi stula (GGF) is unknown.
Aims & Methods: To 
1) determine rates of long-term adverse events (AEs) aft er EDGE, with a 
focus on rates of persistent GGF; 
2) identify predictors of persistent GGF; 
3) assess outcomes of endoscopic closure when persistent GGF is encoun-
tered. 
This is a multicenter, retrospective study involving 12 centers between 
1/2014 and 10/2018. AEs were defi ned according to ASGE lexicon. Persis-
tent GGF was defi ned as UGI series or EGD showing evidence of fi stula. 
Presumptive GGF was defi ned as weight gain of 5% of total body weight 
without having objective documentation of GGF. Multivariable analysis 
was used to determine predictors of AEs.
Results: A total of 166 patients (58yr, F 80%) underwent EDGE and had a 
mean follow-up of 5.7 months. EDGE was performed in a single session in 
51% (n=85) of cases, and two sessions in 49% (81 patients). The excluded 
stomach was accessed from a transgastric location in 52% of cases and 
a transjejunal location in 48%. Technical success was achieved in 98% 
of cases (163/166) with a mean procedure time of 87 min. The LAMS was 
anchored in 21% of EDGE procedures (35/166; suturing 25, plastic double 
pigtail stents 7, hemoclips 2, and over-the-scope clip 1) with the majority 
(57%) done in a single session. Periprocedural AEs occurred in 28 patients 
(17%). Mild, moderate and severe AEs occurred in 3.1%, 11.5% and 2.4% 
of patients respectively. The 4 severe adverse events were managed lapa-
roscopically. 
Overall, mean LAMS dwell time was 47d. Initial fi stual tract closure was 
performed with suturing in 31%, OTSC in 9%, and TTS clips in 4%. In 28% 
of patients the fi stula edges were treated with APC alone without attempt-
ed closure. In 27% of patients the fi stula was left  entirely undisturbed fol-
lowing LAMS removal. GGF was identifi ed following EDGE in 12% of those 
sent for objective testing (10/85). In addition, 61 (37%) patients had pre-
sumptive GGF aft er LAMS removal. 
Following identifi cation of GGF, 70% of patients underwent a mean of 
1.2±0.8 closure attempts which at last follow-up had been successful in 
71% of cases (5/7). Univariate and multivariate analyses suggested diabe-
tes was associated with persistent GGF (OR 7.2; 1.5, 34).
Aims & Methods: Our aim was to assess the accuracy of intracystic glucose 
for the diff erential diagnosis between non-mucinous and mucinous cystic 
neoplasia (MCN). 
Prospective, observational and analytic study of patients undergoing EUS-
FNA of cystic pancreatic lesions from January to December 2018. Intracystic 
glucose concentration was evaluated on-site by glucometry. Additionally, 
fl uid samples were sent to the lab for glucose and CEA quantifi cation, 
and for cytological analysis. Diagnostic accuracy of glucose and CEA was 
evaluated by using cytology and imaging features (EUS and MRI), evalu-
ated by two expert pancreatologists blinded to glucose and CEA levels, as 
gold standard.
Results: Thirty-three patients with cystic pancreatic lesions were included 
(mean age 73 years, range 35-88 years, 17 male). Mean size of the lesions 
was 37 mms (range 11-120 mms). Final diagnosis was MCN in 21 cases (18 
branch duct IPMN, 1 main duct IPMN, 1 mucinous cystadenoma and 1 muci-
nous cystoadenocarcinoma) and non-mucinous lesions in 12 cases (4 serous 
cystadenomas, 2 cystic endocrine tumours, 4 walled-off  necrosis, 1 pseu-
docyst and 1 post-surgical collection). Intracystic glucose concentration in 
MCN was 27.3 mg/dl (5.4-49.3) and 123.1 mg/dl (93.7-152.5) in non-mucinous 
lesions (p< 0.001). Intracystic glucose quantifi cation in the lab showed an 
area under the ROC curve for the diagnosis of non-mucinous lesions of 0.93 
(0.84-1.00). Using a cut-off  point of >66 mg/dl, intracystic glucose allows 
diagnosing non-mucinous lesions with a sensitivity of 100% (72.0-100) and 
specifi city of 80.0% (58.4-91.9). Intracystic glucose could be evaluated by 
on-site glucometry in 22 cases, showing a sensitivity of 100% and specifi city 
of 75.0% for a cut-off  of 74 mg/dl, with and area under the ROC curve of 0.85 
(0.63-0.96). Compared to glucose, intracystic CEA showed an area under 
the ROC curve of 0.71 (0.52-0.87), sensitivity 72.2% (49.1-87.5) and specifi city 
81.8% (52.3-94.9) for the diagnosis of non-mucinous lesions.
Conclusion: Intracystic glucose, which can be measured on-site by glu-
cometry, is an accurate tool for the diff erential diagnosis of mucinous and 
non-mucinous cystic pancreatic lesions.
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Introduction: The contrast enhanced endosonography (CH-EUS) may visu-
alize the necrotic areas and the vessels inside the lesions. Its results com-
bined with endosonography- fi ne-needle aspiration (EUS-FNA) improves 
the diagnosis in pancreatic solid masses. Also, CH-EUS can target EUS-FNA 
(CH-EUS-FNA) which might improve the diagnostic rate of EUS-FNA, but 
their superiority was not proved in prospective studies.
Aims & Methods: to assess if the effi  ciency of the targeted contrast- en-
hanced-EUS-FNA ( CH-EUS-FNA) is superior to standard EUS-FNA in ob-
taining diagnosis or diagnosing malignancy in solid pancreatic masses 
and to evaluate whether the hypovascular aspect of the mass infl uences 
the accuracy of the diagnosis of FNA.
This randomized controlled study in one tertiar medical academic center 
included patients with the suspicion of pancreatic solid masses on trans-
abdominal ultrasound or CT scan. Two passes with 22G standard FNA nee-
dle were done in random order by using EUS-FNA or CH-EUS-FNA and the 
visible core obtained was sent for pathology analysis. The fi nal diagnosis 
was based on EUS-FNA or surgical specimen results and on following up 
data every three month by imaging methods.
Results: The study included 150 patients and two of them were lost from 
follow-up. There were 99 adenocarcinoma, 13 neuroendocrine tumors, 3 
schwanomma, 1 GIST, 3 cholangiocarcinoma, 11 metastases, 19 benign le-
sions. 
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Conclusion: The EDGE procedure is safe with a low risk of short-term and 
long-term AEs. Persistent GGF is uncommon and is independently associ-
ated with diabetes.
Disclosure: Nothing to disclose 
Endoscopy: The heat in diagnosis and therapy
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OP043 LONG-TERM OUTCOMES AFTER ENDOSCOPIC TREATMENT 
FOR BARRETT’S NEOPLASIA IN 641 PATIENTS IN A CENTRALIZED 
CARE SETTING IN THE NETHERLANDS: RECURRENT NEOPLASIA IS 
RARE AND NEOSQUAMOUS BIOPSIES DO NOT CONTRIBUTE TO ITS 
DETECTION
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Introduction: Radiofrequency ablation (RFA), with or without endoscopic 
resection (ER) is the standard of care for treatment of early neoplasia in 
Barrett´s esophagus (BE). We aimed to report durability outcomes based 
on a large cohort of patients with uniform treatment and follow-up (FU) in 
a centralized care setting.
Aims & Methods: Endoscopic therapy for BE neoplasia in the Netherlands 
is centralized in 8 expert centers, where care is provided by specifi cally and 
jointly trained endoscopists and pathologists. Uniformity of treatment/FU 
is ensured by a joint protocol and quarterly group meetings. In an ongo-
ing registry, prospectively collected treatment/FU data from all Dutch BE 
patients treated since 2008 is being registered in a uniform database. In 
the current study, we report on the completed data of 3 centers. Treatment 
indications were BE with low/high grade dysplasia (LGD/HGD) or early 
adenocarcinoma (EAC). Visible lesions were removed by ER, followed by 
RFA until complete endoscopic remission of BE and absence of intestinal 
metaplasia (CR-IM). FU consisted of high-resolution endoscopy and opti-
cal chromoendoscopy. From 2008 to 2015, FU endoscopy was done every 
3mo in year 1, followed by yearly endoscopies in year 1-5, then every 2-3 
yrs. Since 2015, FU endoscopies within the fi rst year were abandoned. Ini-
tially, 4Q-random biopsies (Bx) were obtained from NSE and cardia (i.e. < 
5mm distal from the neo-squamocolumnar junction) at every FU endos-
copy. These were abandoned in 2013 and 2016 respectively.
Outcomes: Sustained CR-neoplasia (SCR-N) aft er CR-IM, diagnostic yield 
for NSE and cardia Bx.
Results: 641 patients with median BE length C2M4 and LGD (19%), HGD 
(32%) or EAC (49%) achieved CR-IM. Over a total FU of 2,747 person years 
(median 4 (IQR 2-6) yrs and 4 endoscopies per patient), 625 (98%) pa-
tients had SCR-N. The overall annual recurrence risk was 0.6%/year, with 
a relatively low risk in year 1 (0.1%). Based on 205 pts with FU >5yrs, there 
was no decrease in the recurrence risk aft er 5 years (0.7%/year). In total, 
16 pts developed recurrent neoplasia aft er median 30mo (23-42). A more 
severe baseline histology signifi cantly increased the recurrence risk (HR 
3.1, 95%-CI 1.1-8.2). In 81% (13/16), CR-N was re-achieved aft er endoscopic 
treatment for LGD (3) HGD (4) or EAC (6), but 3 (0.5% of all pts) eventually 
progressed to advanced cancer (2 metastatic disease without BE, 1 submu-
cosal cancer identifi ed aft er an 18 months interval). The 3 cases were at 
baseline identifi ed as highly complicated due to multifocal HGD/EAC and/
or severe refl ux stenosis. All recurrences were detected as visible non-fl at 
lesions (10) or by biopsies from recurrent BE (1) or cardia (3). None of the 
5,992 NSE Bx which were obtained, contributed to detection of recurrence. 
Abandoning NSE sampling in 2013 saved approximately 10,000 Bx in our 
cohort. Cardia Bx were obtained in 1,687 endoscopies with LGD (0.2%), IM 
(7%) or no abnormalities (93%). In total, 69 pts (11%) had IM in a normal 
appearing cardia at some time point; this was reproduced in a minority 
and none progressed to dysplasia.
Conclusion: In a setting of centralized BE care, the 2-step approach of ER 
and RFA has remarkably low rates of neoplastic recurrence aft er CR-IM, 
with an annual recurrence risk comparable to the NDBE surveillance pop-
ulation. The vast majority of recurrences are detected at early stages that 
are amendable for curative endoscopic treatment. In conclusion, our data 
support more lenient FU intervals, especially in the fi rst year aft er CR-IM, 
with emphasis on careful endoscopic inspection whilst NSE biopsies can 
be abandoned.
Disclosure: Bas Weusten: Covidien (research support) and Pentax Medi-
cal (research support, speaker´s fee). Jacques Bergman: Olympus, Pentax, 
Medtronic, Ninepoint Medical, Fuji Film, CDx Diagnostics, Erbe, Boston 
Scientifi c, Cook. Other authors: no disclosures. 
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Introduction: Endoscopic submucosal dissection (ESD) is considered as 
minimum invasive treatment for large-size esophageal cancers. Howev-
er, prolonged procedure time and life-threatening adverse events are a 
crucial matter of esophageal ESD.[1] Stable view during ESD is essential 
for less adverse events and more technical success. Traction-assisted ESD 
(TA-ESD) has the potential to maintain an adequate view during the pro-
cedures.[2]
Aims & Methods: The present study was a randomized, open-label, mul-
ticenter trial done in 7 hospitals in Japan and designed to evaluate the 
impact of traction assist on the effi  cacy and safety of ESD for esophageal 
neoplasms. Eligible patients were aged at least 20 years old and had en-
doscopically diagnosed squamous cell carcinoma or basal cell carcinoma 
meeting the following all conditions:
i) tumor size ≥20 mm and
ii) clinically-diagnosed intramucosal cancer (cT1a) or slightly infi ltrating 
submucosal cancer (cT1b-SM1) according to the Japanese diagnosis and 
treatment guidelines for the esophagus.[3] 
Enrolled patients were randomized in a 1:1 allocation ratio to receive either 
conventional ESD or TA-ESD via dynamic balancing using the minimization 
method. The primary endpoint was to ascertain if there was a diff erence in 
ESD procedure time between the two groups. The pre-defi ned secondary 
endpoints were as follows: handover to another operator; frequency of 
conversion from conventional ESD to TA-ESD; en bloc resection; histologi-
cal assessment; and incidence of adverse events.
Results: From October 2016 to March 2019, 241 patients with large-size 
esophageal cancers were included in this trial and randomized. Aft er ex-
cluding patients who did not undergo treatment (conventional ESD, three; 
TA-ESD, fi ve), 233 patients were included in the analysis. ESD procedure 
time was signifi cantly shorter in the TA-ESD group (60.5 vs. 44.5 minutes, 
P< 0.001). Six (5.2%) patients in conventional ESD were converted to TA-
ESD technique to overcome technical diffi  culties during the procedure. 
Moreover, handover to another operator tended to be more frequently 
observed in the conventional ESD group (6.0% vs. 0.9%, P=0.066) Im-
portantly, perforation occurred only in conventional ESD (5 cases, 4.3%), 
resulting in discontinuation of the procedure in one patient. Conversely, 
no adverse event in the TA-ESD group. En bloc resection rate and horizon-
tal margin involvement of tumor were similar (99.1% vs. 100%, P=1.000; 
10.3% vs. 6.9%, P=0.484, respectively).
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were defi ned as adenoma and adenocarcinoma. This study was approved 
by the institutional review board of all participating institutions and was 
registered with UMIN Clinical Trial Registry (UMIN000023863).
Results: A total of 1508 patients were enrolled and 1504 patients were ran-
domly allocated to each group; 752 for WLI-LCI and 750 for LCI-WLI group. 
There was no signifi cant diff erence in demographics including age, sex, 
presence/absence of surgical history, and the ratio of current and previous 
cancer between the two groups. In the WLI-LCI group, a total of 63 gastric 
neoplastic lesions were detected, which included 37 lesions detected by 
primary WLI and 26 lesions by secondary LCI. In the LCI-WLI group, a total 
of 71 gastric lesions were detected, which included 66 lesions detected by 
primary LCI and 5 lesions by secondary WLI. Additional detection rates of 
gastric neoplasm in WLI-LCI group was signifi cantly higher than in LCI-WLI 
group; 41.3% vs 7.0%, p< 0.001. Additional detection rate of the patients 
with gastric neoplasm in WLI-LCI was also signifi cantly higher than in LCI-
WLI group; 8.0% (60/750) vs 4.8% (36/752), p< 0.05. When images of 85 
gastric cancer lesions were compared between LCI and WLI, LCI showed 
more reddish color in 56 cancer lesions and more whitish color in 17 le-
sions than WLI. All 17 lesions, which were overlooked by WLI, showed en-
hanced color contrast in LCI image. All 10 isochromatic lesions with WLI 
exhibited enhanced reddish color in LCI images.
Conclusion: Our large-scale RCT strongly suggest that LCI is superior to 
conventional WLI for detection of gastric neoplasm during upper GI endos-
copy. It is supposedly due to the characteristic color enhancement function 
of LCI. LCI may be a standard examination tool for the detection of gastric 
neoplasm for high-risk patients.
References: Ono S, Abiko S, Kato M. Linked Color imaging enhanced gastric 
cancer in gastric intestinal metaplasia. Dig Endosc 2017;29 :230-1.
Disclosure: Kato M. received funding from Fujifi lm Co. for this study. 
Takayama T received a research grant from Fujifi lm Co.. The fi nancial 
sponsor was not involved in the design of the study, analysis and inter-
pretation of the data. 
OP046 EFFICACY OF POLYGLYCOLIC ACID SHEETING WITH 
FIBRIN GLUE FOR THE TREATMENT OF PERFORATIONS RELATED TO 
GASTROINTESTINAL ENDOSCOPIC PROCEDURES: A MULTICENTER 
RETROSPECTIVE STUDY AMONG THE PGA STUDY GROUP
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Introduction: Polyglycolic acid (PGA) sheets with fi brin glue have been re-
ported to be useful for preventing perforation and delayed bleeding aft er 
endoscopic treatment [1,2]. Although they can be useful for the closure 
of perforations related to gastrointestinal (GI) endoscopic procedures, no 
large-scale multicenter treatment outcomes have been reported yet.
Aims & Methods: This is a retrospective multicenter study conducted by 
the PGA study group, which is the affi  liated study group of the Japanese 
Gastroenterological Endoscopy Society and consists of 18 institutions. 
Conclusion: TA-ESD signifi cantly reduced ESD procedure time without any 
adverse event compared with conventional ESD and should be applied for 
esophageal ESD as the standard method.
  Conventional ESD TA-ESD P value
Total procedure time, min (range) 60.5 (18-245) 44.5 (13-156) 0.000
Conversion to TA method, n (%) 6 (5.2) N/A N/A
Handover to another operator, n (%) 7 (6.0) 1 (0.9) 0.066
En bloc resection, n (%) 116 (99.1) 116 (100) 1.000
Horizontal margin involvement, n (%) 12 (10.3) 8 (6.9) 0.484
Adverse events, n (%)      
Perforation 5 (4.3) 0 (0) 0.060
Delayed bleeding 0 (0) 0 (0) 1.000
Pneumonia 0 (0) 0 (0) 1.000
Mediastinitis 1 (0.9) 0 (0) 1.000
En bloc resection and adverse events were calucurated for 117 patients in the 
conventional ESD group including one discontinuation case aft er perforation. ESD, 
endoscopic submucosal dissection; TA, traction assisted; N/A, not available
[Clinical outcomes of conventional ESD and TA-ESD]
References: 1. Repici A, Hassan C, Carlino A, Pagano N, Zullo A, Rando G, 
et al. Endoscopic submucosal dissection in patients with early esopha-
geal squamous cell carcinoma: results from a prospective Western series. 
Gastrointest Endosc 2010;71:715-21. 2. Yoshida M, Takizawa K, Suzuki S, 
Koike Y, Nonaka S, Yamasaki Y, et al. Conventional versus traction-assisted 
endoscopic submucosal dissection for gastric neoplasms: a multicenter, 
randomized controlled trial (with video). Gastrointest Endosc 2018;87:1231-
40. 3. Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, et 
al. Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus 
April 2012 edited by the Japan Esophageal Society. Esophagus 2015;12:1-30.
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OP045 LINKED COLOR IMAGING FOR THE DETECTION OF GASTRIC 
NEOPLASM IN HIGH RISK PATIENTS: A PROSPECTIVE MULTICENTER 
RANDOMIZED CONTROLLED TRIAL (LCI-FIND TRIAL)
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Japan, 5Hokkaido University Hospital, Division of Endoscopy, Sapporo, Japan, 
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Introduction: Gastric cancer remains one of the most common causes 
of cancer-related death worldwide, particularly in East Asian countries. 
Although the prevention and eradication of Helicobacter pylori infection 
decreased the incidence of gastric cancers, it is still high. Recently, image-
enhanced endoscopy (IEE) technologies including narrow-band imaging 
(NBI) and blue laser imaging (BLI) have been developed. A more recently 
developed IEE technology, linked color imaging (LCI), enhances slight color 
diff erences in hue in the red region of the spectrum, and has been re-
ported to be useful for the diagnosis of gastrointestinal (GI) diseases.
Aims & Methods: The aim of this study is to compare the detection rate of 
neoplasms in upper GI endoscopy between conventional white-light im-
aging (WLI) and LCI observation for high-risk patients. In this prospective 
multicenter randomized controlled trial (RCT), patients with a history or 
presence of esophageal or gastric neoplasms were enrolled in 19 Japa-
nese institutions between November 2016 and July 2018. Patients were 
assigned to 2 groups; primary observation with WLI followed by LCI (WLI-
LCI group) or primary LCI observation followed by WLI (LCI-WLI group). 
Additional detection rates of gastric neoplasms were compared between 
WLI-LCI and LCI-WLI groups. The characteristics of the neoplastic lesions 
additionally detected by each mode were also evaluated. The number of 
lesions detected, and endoscopic diagnosis (neoplastic or non-neoplastic) 
were recorded for each procedure during examination, and all lesions de-
tected were biopsied for histopathological diagnosis. Neoplastic lesions 
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From April 2013 to March 2018, patients with perforations related to GI 
endoscopic procedures and endoscopically closed using PGA sheeting 
with fi brin glue were extracted, and were retrospectively examined. “In-
traoperative perforation” was defi ned as a perforation through which the 
outside of the GI tract was visible during the endoscopic procedure, or as 
the case where free gas was detected outside the lumen on radiography or 
computed tomography (CT) just aft er the endoscopic procedure. Delayed 
perforation was defi ned as a perforation or symptoms appearing aft er the 
completion of the endoscopic procedure and the case where free gas was 
detected on radiography or CT, even though no perforation or symptoms 
occurred immediately aft er the completion of the endoscopic procedure. 
Perforations were fi lled with one or several pieces of PGA sheets followed 
by spraying fi brin glue using an endoscopic catheter. This procedure was 
sometimes repeated at 1- or 2-week intervals before closure.
Results: 
Intraoperative perforation: Sixty-six cases (esophagus 6, stomach 22, duo-
denum 12, and colon 26) during endoscopic procedures, including 58 en-
doscopic submucosal dissections (ESDs), 2 endoscopic mucosal resections, 
1 endoscopic submucosal resection with a ligation device, 2 endoscopic 
papillectomies, and 3 endoscopic balloon dilations, were detected. The 
median lesion and perforation diameters were 27 mm (range, 3-163 mm) 
and 5 mm (range, 1-30 mm), respectively. PGA sheets were fi lled at a me-
dian of once aft er perforation (range, 1-3). Nasal drainage and endoscopic 
clipping were performed adjunctly in 23 (35%) and 49 cases (74%) with 
PGA sheeting, respectively. Complete closure was attained in 60 cases 
(91%). The median period from the fi rst sheeting to the diet resuming was 
6 days (range, 0-23).
Delayed perforation: Twenty-four cases (esophagus 5, stomach 10, duode-
num 7, and colon 2) occurred aft er 20 ESDs, 3 dilations, and 1 Per-Oral En-
doscopic Myotomy (POEM). The median lesion and perforation sizes were 
24 mm (range, 4-58) and 5 mm (range, 1-30), respectively. PGA sheets 
were fi lled at a median of once (1-4) aft er perforation. Nasal drainage 
accompanied the procedure in 12 cases (50%) and endoscopic clipping in 
7 cases (29%). Complete closure was attained in all 24 cases (100%). The 
median period from the fi rst sheeting to the diet resuming was 10 days 
(range, 1-124 days). No adverse events related to PGA sheeting occurred 
in all the cases.
Conclusion: PGA sheeting with fi brin glue was eff ective for the treatment of 
intraoperative or delayed perforation related to GI endoscopic treatment.
References: 1] Takimoto K, Toyonaga T, Matsuyama K. Endoscopy. 
2012;44(Suppl.02):E414-E415 2] Tsuji Y, Fujishiro M, Kodashima S, et al. 
Gastrointest Endosc. 2015;81(4):906-912
Disclosure: Tsuji Y and Takimoto K: Lecture fees from GUNZE Medical Japan 
and CSL Behring 
OP047 ENDOSCOPIC SUBMUCOSAL DISSECTION VS ENDOSCOPIC 
MUCOSAL RESECTION FOR TREATMENT OF BARRETT’S RELATED 
SUPERFICIAL ESOPHAGEAL NEOPLASIA: MULTICENTER 
RETROSPECTIVE STUDY IN THE WEST
Mejia Perez L.K.1, Alaber O.2, Salmaan O.3, Chua T.4, Mehta N.5, 
Kudaravalli P.6, Pourmousavi Khoshknab M.7, Vargo J.J.8, Jang S.9, 
Dumot J.2, Aihara H.10, Gabr M.6, Ngamruengphong S.11, Fukami N.4, 
Draganov P.V.12, Chak A.2, Bhatt A.8
1Cleveland Clinic, Internal Medicine, Cleveland, United States, 2University 
Hospital, Cleveland, United States, 3University of Florida, Cleveland, United 
States, 4Mayo Clinic Arizona, Scottsdale, United States, 5Cleveland Clinic, 
Gastroenterology and Hepatology, Cleveland, United States, 6University 
of Kentucky, Lexington, United States, 7Johns Hopkins, Baltimore, United 
States, 8Cleveland Clinic Foundation Digestive Disease Institute, Cleveland, 
United States, 9Cleveland Clinic, Gastroenterology, Cleveland, United States, 
10Brigham and Women’s Hospital, Harvard Medical School, Boston, United 
States, 11Johns Hopkins University, Dept. of Gastroenterology, Baltimore, 
United States, 12University Of Florida, Gainesville, FL, United States
Contact E-Mail Address: mejiapl@ccf.org
Introduction: The diff erence in long-term outcomes of endoscopic submu-
cosal dissection (ESD) and endoscopic mucosal resection (EMR) for Bar-
rett’s related superfi cial neoplasia remain unclear.
Aims & Methods: We aimed to compare the rates of local and metachro-
nous recurrence of ESD and EMR in patients with clinically staged BE-as-
sociated high-grade dysplasia (HGD) and T1a esophageal adenocarcinoma 
(EAC). A retrospective multicenter study was performed at six academic 
hospitals in the U.S. Patients who underwent ESD with a pre-procedural 
diagnosis of BE-HGD or T1a EAC were included in the study. Data was 
collected on demographics, tumor and procedure characteristics, proce-
dure pathology, and follow-up. The main outcome was a composite of rate 
of local and metachronous recurrence. Local recurrence was defi ned as 
that appearing at a similar location as previous resection and confi rmed 
by histopathology. Flat dysplasia requiring radiofrequency ablation (RFA) 
was not included in the defi nition. Follow-up time was defi ned as months 
from initial procedure to recurrence or last follow-up visit if recurrence-
free. A time-to-event analysis was performed to evaluate recurrence. A 
Kaplan-Meier plot was constructed, and a log-rank test was used to com-
pare the groups. A Cox proportional hazard ratio regression analysis was 
performed to identify predictors of recurrence.
Results: A total of 219 patients were included. 154 underwent EMR, while 
65 underwent ESD. ESD had higher en bloc (92% vs 33%, p< .0001), R0 
(55% vs 31%, p=0.023) and curative resection rates (66% vs 32% , p< 
.0001) when compared to EMR. The 24-month local recurrence rate for 
EMR and ESD was 43.3% and 15%, respectively (p=.0007). Signifi cantly 
more endoscopic resection procedures were required to treat recurrence 
aft er EMR compared to aft er ESD. EMR, piecemeal resection, positive mar-
gins, and non-curative resection were identifi ed as predictors of recur-
rence on univariate analysis. EMR remained signifi cant aft er multivariate 
analysis (Table 2).
Conclusion: This multicenter study showed that ESD results in more defi ni-
tive treatment of BE-associated early neoplasia than EMR, with signifi cant 
lower recurrence rates and less need for repeat endoscopic therapeutic 
procedures than EMR.
Disclosure: Nothing to disclose
  Univariable Univariable Multivariable Multivariable
Factor HR 95% CI P-value HR 95% CI P value
Technique: EMR vs ESD 3.7 [1.7-9.6] 0.0003 4.1 [1.3-18.4] 0.01
En bloc resection: 
Piecemeal vs en bloc
7.6 [3.9-16.5] < .0001 1.6 [0.5-5.6] 0.42
Margins: R1 vs R0 2.6 [1.5-4.6] 0.0038 1.9 [0.9-4.4] 0.07
Lymphovascular 
invasion: Yes vs No
1.52 [0.4-9.3] 0.52 -- --
Diff erentiation: 
Well + moderate vs Poor
2.0 [0.8-5.4] 0.23 -- --
Curative resection: 
No vs Yes
6.1 [3.2-13.3] < .0001 2.6 [0.11-8.8] 0.08
[Table. Cox proportional hazard ratio regression analysis for recurrence]
 
OP048 CLINICAL CHARACTERISTICS AND RISK FACTORS OF 
UPPER GASTROINTESTINAL CANCERS MISSED DURING ENDOSCOPY: 
A NATION-WIDE REGISTRY-BASED STUDY
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Contact E-Mail Address: w.januszewicz@gmail.com
Introduction: Upper gastrointestinal (UGI) cancers, including esophageal, 
gastric and duodenal cancers, usually present at an advanced stage in the 
Western world, when the treatment options are limited and the prognosis 
is dismal. Endoscopy remains the gold standard for UGI cancer diagnosis, 
however, a signifi cant proportion of these neoplasms are missed during 
this examination. The clinical characteristics of missed UGI cancers remain 
poorly understood.
Aims & Methods: This was a retrospective registry-based study done in 
collaboration between clinicians and data analysts from Ministry of Health 
in Poland aimed to characterize patients with missed UGI cancers during 
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Introduction: Per-oral endoscopic myotomy (POEM) is as a safe and eff ec-
tive treatment for achalasia with short-term clinical response reported in 
over 80% of patients. However, long-term data are limited.
Aims & Methods: To (1)evaluate outcomes in achalasia patients at least 6 
years post-POEM and (2)identify factors associated with clinical failure. We 
conducted a retrospective review of achalasia patients at 8 tertiary-care 
centers (2 USA, 4 Europe, 2 Asia) who underwent POEM from 2010 to 2012 
with a minimum follow-up of 6 years. Response was defi ned by an Eckardt 
score of ≤3. Adverse events (AEs) were also reported and categorized by 
the ASGE lexicon for AEs. Univariable analysis was performed to deter-
mine factors associated with clinical failure.
Results: A total of 73 patients (46 females (63.0%); mean age 49.7 years) 
with at least 6 years of follow-up (type I 16, type II 15, type III 4, and un-
endoscopy. We used National Health Fund Registry (NFZ) to identify adult 
patients who underwent UGI endoscopy between 2009-2015 and had a 
subsequent diagnosis of UGI cancer. Cancers diagnosed within 1 year aft er 
endoscopy were defi ned as “prevalent” cancers, those diagnosed aft er 1 
year and within 3 years aft er UGI endoscopy were considered as “missed” 
cancers, and those diagnosed aft er 3 years were classifi ed as “latent” can-
cers. To reduce the number of miscoding errors we included only cases of 
cancer confi rmed at least twice in the registry on two subsequent occa-
sions. We used Polish National Cancer Registry (KRN) for data validation. 
Clinical characteristics of prevalent and missed cancers where compared 
using t-test and chi-square test, where appropriate, with Holm-Bonferroni 
correction. Survival data were compared by Kaplan-Meier analysis and 
log-rank test.
Results: In total, we analyzed 8,040,178 UGI endoscopies [46.3% ambula-
tory and 53.7% secondary care] performed in 3,856,210 patients [2,178,859 
females (57.7%), mean age 58.7 (±3.8) years]. Aft er excluding cancers with 
a single record in the NFZ (n=11,180) and those diagnosed before the fi rst 
registered endoscopy (n=10,171) we included 51,123 UGI cancers in the 
analysis, of which 43,388 were classifi ed as prevalent (84.9%), 3,964 as 
missed (7.8%), and 3,771 as latent cancers (7.4%). NFZ data was cross-
linked with KRN registry showing a 84.2% agreement. We observed a 
steady decline of UGI cancer incidence within the study time-frame (from 
8,881 cases in 2009 to 6,231 cases in 2015), however, the proportion of 
missed cancers remained relatively stable oscillating between 7.3% to 
8.5% in 2009-2014. Median time of missed cancer diagnosis aft er UGI en-
doscopy was 1.8 years (IQR 1.4-2.4). Gastric cancers constituted majority of 
missed cancers (81.4%), however, the miss-rate was highest for duodenal 
cancers, followed by gastric and oesophageal cancers (16.9%, 7.4% and 
5.2%, respectively). When compared to prevalent cancers, patients with 
missed UGI cancers were more commonly female (40.9% vs 33.1%, P< 
.001), less commonly resided in rural areas (30.0% vs 35.1%, P=.003) and 
were statistically younger, however, this diff erence wasn’t clinically signifi -
cant (mean age 67.5 vs 68.1, P< .001). Missed cancers had a higher survival 
rate as compared to prevalent cancers cases (5-year survival: 12.6% vs 
9.0%, P< .001). Within missed UGI cancers, oesophageal had the worst 
survival as compared to gastric and duodenal cancers [5-year survival rate: 
6.9%, 13.6% and 13.0%, respectively (P< .001)].
Conclusion: Despite declining UGI cancer incidence, proportion of missed 
UGI cancers remain stable over time. Patients with missed UGI cancers 
are more commonly female, reside more oft en in urban areas and have a 
higher survival rate than prevalent cancers. Oesophageal cancers are least 
commonly missed, however, have the poorest survival among missed UGI 
cancers.
Disclosure: Nothing to disclose 
  Patients with available data Total; total clinical response; total clinical failure Overall (n=73)
Clinical success (ES 
≤3) n=65
Clinical failure 
(ES>3) n=8 p-value
Age, years (mean±SD) 73;65;8 49.7±17.4 50.6±18.0 42.4±10.1 0.07
BMI, kg/m2 (mean±SD) 37;32;5 26.5±12.4 26.3±12.6 28.3±11.6 0.73
Female, no. (%) 73;65;8 46 (63.0) 41 (63.1) 5 (62.5) 0.99
Disease Classifi cation 73;65;8       0.005
Type 1   16 (21.9) 10 (15.4) 6 (75.0)  
Type 2   15 (20.6) 14 (21.5) 1 (12.5)  
Type 3   4 (5.5) 4 (6.2) 0 (0.0)  
Unspecifi ed   38 (52.1) 37 (56.9) 1 (12.5)  
Any prior therapy, no. (%) 73;65;8 23 (31.5) 22 (33.9) 1 (12.5) 0.42
HRM IRP, mmHg (mean±SD) 25;21;4 32.5±14.2 32.4±15.1 33.1±9.2 0.90
Pre-poem Eckhart score, mean±SD 71;65;6 7.1±2.3 7.1±2.3 7.7±2.7 0.61
Follow up time, months, median (IQR) 50;42;8 79.5 (73.9-82.6) 76.9 (73.9-82.2) 81.6 (74.7-89.1) 0.25
72 months Eckhart score (mean±SD) 73;65;8 1.1±1.1 0.9±0.8 2.5±1.8 0.04
36 months Eckhart score (mean±SD) 61;58;3 0.9±1.1 0.8±0.8 4.3±1.2 0.03
6 months Eckhart (mean±SD) 69;63;6 0.8±1.1 0.6±0.8 3.2±1.5 0.007
Patients with adverse events, no. (%) 73;65;8 16 (21.9) 16 (24.6) 0 (0.0) 0.19
Symptomatic refl ux, no. (%) 72;64;8 27 (37.5) 25 (39.1) 2 (25.0) 0.43
PPI use, no. (%) 73;65;8       0.41
Daily   23 (31.5) 22 (33.9) 1 (12.5)  
Occasionally   6 (8.2) 5 (7.7) 1 (12.5)  
Esophagitis on EGD, no. (%) 60;57;3 17 (28.3) 17 (29.8) 3 (0.0) 0.55
[OP049 Table. Clinical characteristics and outcomes in patients with clinical success versus failure.]
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specifi ed 38) were identifi ed. Median follow-up was 79.5 months (IQR 
73.9-82.6). Twenty-one (28.8%) patients had prior dilatation, 4 (5.5%) 
botulinum injection and 2 (2.7%) Heller myotomy. A total of 17 AEs oc-
curred in 16 (21.9%) patients and included: 1 arrhythmia, 1 delayed bleed-
ing, 1 esophageal leak, 3 mucosotomies, 1 subcutaneous emphysema, and 
10 symptomatic capnoperitoneum (13 mild, 2 moderate, and 2 severe). 
Clinical success was observed in 96%(66/69), 96%(67/70), 93%(65/70), 
91%(64/70), and 91%(64/70) of patients within 6, 12, 24, 36, and 48 months 
respectively. At 72 months, success was noted in 89%(65/73) of cases. Of 66 
patients with response at 6 months, only 3 (4.5%) experienced recurrence 
of symptoms. Overall, mean Eckardt score decreased from 7.1±2.3 to 1.1±1.1 
(p< 0.001) and 4sIRP pressure improved from 32.5±14.2 to 12.2±8.8 mmHg 
(p< 0.001). In univariable analysis, type I achalasia (OR 10.8, p=0.04) was 
associated with clinical failure. Four patients with clinical failure under-
went retreatment with pneumatic dilation and clinical response was noted 
in 3 (75%) of these patients. Of the remaining 4 patients who did not un-
dergo retreatment, 2 were managed conservatively and 2 were lost to fol-
low up. Aft er POEM, symptomatic refl ux was reported by 27/72 (37.5%) 
patients and esophagitis was reported in 17/60 (28.3%) of patients who 
had post-procedure EGDs.
Conclusion: This international study reports the longest follow-up of a 
POEM cohort to date. POEM is safe and provides long-term symptomatic 
relief with sustained response in almost 90% of patients.
Disclosure: Nothing to disclose 
OP050 OUTCOMES OF THE FIRST 500 PERORAL ENDOSCOPIC 
MYOTOMY FOR ESOPHAGEAL MOTILITY DISORDERS: OUTCOMES OF 
THE FIRST 500 PATIENTS WITH A MID- AND LONG-TERM FOLLOW-
UP. IN A SINGLE EUROPEAN CENTER
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Introduction: Peroral endoscopic myotomy (POEM), which combines the 
effi  cacy of surgical myotomy with the benefi ts of an endoscopic, minimally 
invasive, procedure, is now considered an eff ective treatment for esopha-
geal motility disorders. We report on the mid- and long-term outcomes of 
a large series of patients treated with POEM in a single European center.
Aims & Methods: The fi rst 500 adult patients successfully treated in our 
center between May 2011 and January 2018 were retrospectively identi-
fi ed from a prospective database, and included in this study. Patients were 
treated according to the original a standard technique describe by Inoue 
in 2010. Demographics, clinical, procedural and follow-up data were col-
lected and analysed.
Results: Mean age of patients was 51 years (18-85); 50.5% were male. 
79.4% patients were treatment naïve; 14.4% had undergone pneumatic 
dilatation, 2.6% botulin toxin injection,3.6% Heller-Dor myotomy. A total 
of 16.6% patients had a type- I achalasia, 57.2% type- II, 13.8% type- III, 
1.2% Jackhammer esophagus, 0.8% distal esophageal spasm; in 10.4% 
the achalasia type was not adequately classifi ed. POEM was completed 
in 98% of patients. Mean symptoms duration before POEM was 24±64.1 
months. Mean operative time was 62.9 minutes (19-180 minutes). Severe 
complications occurred in 5 patients (1%), but all were managed conser-
vatively. A mean follow-up of 23.7 months (3-60 months) was available 
for 96.7% of patients. Clinical success (Eckardt score ≤3) was documented 
in 98% of patients, and was 96.4%, 95.6%, and 93% aft er 6, 24 and 36 
months respectively. 13 patients with failure underwent pneumodilation 
with success, 4 have persisting symptoms aft er pneumodilation, 2 under-
went surgery.
Success was 97.5% (435/424) in achalasia-patients and 81.8% (11/2) in 
those with spastic motility disorders (p< 0.05).
An altered esophageal pH-study was documented in 31.2% patients; 
esophagitis rate was 27.7% (86.9% grade A/B; 13.1% grade C/D). 
At the date of the last follow-up, 10% of patients receive daily PPI for GERD.
Conclusion: Our results confi rm the effi  cacy of POEM in a large cohort of 
patients, with an adequate follow-up. Benefi ts of POEM seem durable, 
with and acceptable incidence and severity of iatrogenic GERD.
Disclosure: Nothing to disclose 
OP051 PERORAL ENDOSCOPIC SEPTOTOMY (POES) FOR 
TREATMENT OF ZENKER’S DIVERTICULUM: A PILOT STUDY
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Introduction: The defi nitive treatment of ZD is to transect the cricopharyn-
geal muscle to eliminate the septum between the diverticulum and the 
upper esophagus thus relieving the dysfunctional condition. In the last 
decade, a septotomy performed utilizing a fl exible endoscope has been 
reported as a safe and eff ective alternative to both open surgery and rigid 
endoscopic diverticulotomy. More recently, submucosal tunneling endo-
scopic septum division (STESD) or Z-POEM has been developed to reduce 
the risk of perforation and allow a safer, more complete cricopharyngeal 
myotomy. However, patients with short septum (≤20mm) ZD still repre-
sent a diffi  cult-to-treat subgroup of patients because of the anatomical 
limitation leading to reduced operating space for both rigid and fl exible 
endoscopic treatments or even a STESD approach.
Aims & Methods: The aim of this pilot study is to investigate the effi  cacy 
and safety of a novel alternative third space approach, called Per-Oral 
Endoscopic Septotomy (POES) to treat symptomatic patients with short-
septum ZD. The POES technique consisted of: 
1) using a hook knife, aft er submucosal injection, a 15mm mucosotomy 
performed directly on top of the diverticular septum directed along its 
long axis; 
2) dissection of the underlying submucosa to create an endoscopic win-
dow to directly visualize the muscular septum with continued submucosal 
dissection along either side of the cricopharyngeal muscle, sparing the 
overlying mucosa, to create two short tunnels; 
3) complete myotomy of the now fully exposed cricopharnyngeal muscle 
fi bres extended a 5-10 mm into the esophageal body; 
4) closure of the mucosotomy with clips.
All patients with short-septum (≤20mm) ZD who were referred to Humani-
tas Research Hospital (Rozzano, Italy) for fl exible endoscopic septotomy 
from September 2017 to present were considered for POES. Exclusion cri-
teria consisted of previous interventions for ZD, ongoing use of anticoagu-
lants and inability to provide informed consent. 
We determined pre- and post-procedural dysphagia scores using the Dak-
kak and Bennett (D&B) scale (0-4). Complete or near-complete resolution 
of symptoms (D&B 0 or 1) was the primary endpoint. Procedure-related 
adverse events according to ASGE lexicon and procedure time were also 
recorded. Follow up was carried out by patient visits or via telephone calls 
by a dedicated nurse at 24 hours, 4 weeks and then regularly every month. 
Recurrence was defi ned as new onset dysphagia with a D&B score > 1 or 
requiring re-intervention.
Results: Sixteen patients (M/F: 11/5, mean age: 64.6±14.0) underwent 
POES. All procedures were performed under deep sedation with C02 in-
suffl  ation. Mean size of ZD was 18.4±5.4 mm and mean pre-procedure 
D&B dysphagia score was 2.75±0.4. Average procedural time was 14.9±5.0 
min (range: 8-26 min). No intra- or post- procedural adverse events oc-
curred. Septal myotomy was successfully completed in all patients. There 
was complete or near-complete resolution of symptoms in 15 out of 16 
patients (93.8%) with the D&B dysphagia score dropping from 2.75±0.4 to 
0.3±0.6 (p < 0.0001). No symptomatic recurrences were reported aft er a 
mean follow up time of 8.9 ± 3.1 months (range: 6-15 months).
Conclusion: According to the preliminary results of this pilot study, third-
space approach with POES provided a very safe, effi  cient and eff ective 
treatment for this specifi c diffi  cult-to-treat group of patients with short 
septum ZD. Larger comparative studies with longer follow-up are needed 
to confi rm this preliminary data.
Disclosure: Nothing to disclose 
35Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
OP053 GUT MICROBIAL CO-ABUNDANCE NETWORKS IDENTIFY 
FUNCTIONAL HUBS FOR INFLAMMATORY BOWEL DISEASE AND 
OBESITY
Chen L.1, Collij V.2, Jaeger M.3, van de Munckhoff  I.3, Vich Vila A.2, 
Kurilshikov A.4, Gacesa R.2, Sinha T.4, Oosting M.3, Joosten L.3, Rutten J.3, 
Riksen N.3, Xavier R.5, Kuipers F.6, Wijmenga C.4, Zhernakova A.4, Netea 
M.3, Weersma R.7, Fu J.1
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Introduction: Recent studies have shown the importance of unraveling the 
role of the gut microbiota in human health and disease. While knowl-
edge is increasing on abundance diff erences in diseases like infl ammatory 
bowel disease (IBD) and obesity on microbial compositional level, it is also 
important to study the gut microbiota as an entire ecosystem. One way of 
doing this, is to study which microbial species and functional pathways 
show co-abundance networks which may also be relevant for disease.
Aims & Methods: Here, we present the largest study to date in which mi-
crobial networks are constructed from an IBD, an obesity and two general 
population cohorts. We collected metagenomics sequencing data of stool 
samples from 2,379 participants. DNA isolation was performed by using 
the same standardized procedures for all four cohorts. MetaPhlAn2 and 
HUMAnN2 tools were used to characterize the composition and functional 
pathways of the gut microbiota. Co-abundance of species or functional 
pathways were identifi ed by using pairwise Spearman correlation. The 
heterogeneity Cochran’s- Q test was used to analyze whether results were 
derived from a single cohort. A false discovery rate of < 5% was used as 
signifi cance threshold to also account for multiple testing.
Results: We established co-abundance networks that revealed 1,057 spe-
cies-species and 8,381 pathway-pathway co-abundance edges. Notable, 
113 (10.7%) of the species edges and 4,824 (57.6%) of the pathway edges 
showed signifi cant diff erences between the cohorts. The heme anaerobic 
biosynthesis pathway for example showed co-abundance with biosynthe-
sis pathways of fatty acids in the IBD cohort. Heme is a cofactor of inducing 
oxidative stress and the identifi ed fatty acids are known for their lipotoxic-
ity. This data suggests that the gut microbiota may play an important role 
in inducing gut infl ammation through biosynthesis of toxic fatty acids in 
IBD patients. Another example is the sulfur amino acids biosynthesis in 
the obesity cohort. This pathway has been recognized as potent modula-
tor of lipid metabolism. This pathway was positively correlated with fi ve 
carbohydrate degradation pathways in the obesity cohort, indicating that 
these pathways may play an important role in regulating functional dys-
biosis in obesity.
Conclusion: By performing a large microbial co-abundance network com-
paring patients with IBD, obesity and population based subjects, we show 
that not only microbial abundances but also microbial co-abundance rela-
tionships are shift ed in disease states. We show that the pathway networks 
are more diff erent than the species networks. The obesity and IBD specifi c 
networks could point to key species or functional pathways which could 
potentially be used as therapeutic targets.
Disclosure: Nothing to disclose 
OP054 FIRST LARGE SCALE EVALUATION OF THE SMALL 
INTESTINAL MICROBIOME IN PATIENTS WITH OBESITY
Leite G., Sedighi R., Celly S., Villanueva-Millan M.J., Parodi G., 
Sanchez M., Weitsman S., Barlow G., Pimentel M., Mathur R.
Cedars-Sinai Medical Center, Los Angeles, United States
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Introduction: Obesity has reached epidemic proportions globally, nearly a 
third of the world population is now classifi ed as overweight or obese. In 
2016, the prevalence of obesity was 39.8% and aff ected about 93.3 million 
adults in US. The World Health Organization (WHO) defi nes overweight 
Towards microbiome targeted therapies
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OP052 TOWARDS ANTI-INFLAMMATORY DIETARY 
RECOMMENDATIONS BASED ON THE RELATION BETWEEN FOOD AND 
THE GUT MICROBIOME COMPOSITION IN 1423 INDIVIDUALS
Bolte L.1,2, Vich Vila A.1, Imhann F.1, Collij V.2,3, Peters V.1, Fu J.2, 
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Introduction: Gut microbiota are essential for intestinal health. As mi-
crobes thrive on dietary substrates, the question arises whether we can 
nourish a protective gut fl ora. While there is increasing interest in anti-
infl ammatory capacities of isolated nutrients, little is known on the as-
sociation between dietary patterns or individual foods and gut microbial 
features. In this study, we investigated the eff ect of 160 dietary factors on 
the gut microbiome across four cohorts, comprising the general popula-
tion, patients with Crohn’s disease, ulcerative colitis, and irritable bowel 
syndrome. Connecting the diet to the gut microbiome gives us more in-
sight into the relation between diet and intestinal disease and could guide 
us towards more rational dietary interventions.
Aims & Methods: For every participant one stool sample was collected 
along with a Food Frequency Questionnaire. To reconstruct the microbiota 
composition of stool samples, microbial DNA was isolated and shotgun 
metagenomic sequencing was performed. Unsupervised cluster analyses 
were performed to identify dietary patterns associated with particular mi-
crobial clusters, using hierarchical clustering. Dietary clusters were com-
puted based on squared Euclidean distances, clusters of microbial species 
and pathways were based on Bray-Curtis dissimilarity. Next, linear mod-
els were conducted, adding caloric intake, age, sex, and sequencing read 
depth as covariates. Analyses were performed separately per cohort, fol-
lowed by a meta-analysis and heterogeneity estimation. Multiple testing 
correction was performed on the obtained p-values and a FDR < 0.05 was 
defi ned as signifi cance cut-off .
Results: We identifi ed 61 individual food items associated with 123 taxa and 
249 pathways (FDR< 5%) as well as 49 correlations between food patterns 
and microbial groups. A plant-based diet was associated with increased 
abundances of short chain fatty acid (SCFA) producing bacteria, as well as 
associated pathways of fermentation. Moreover, plant protein was associ-
ated with pathways involved in the biosynthesis of vitamins and amino 
acids (biotin, thiamine, L-ornithine) and degradation of sugar alcohols. 
While plant protein was associated with an increase in Bi dobacteria and 
a decrease in Blautia and Streptococci, the opposite was found for animal 
protein. Expectedly, low-fat fermented dairy correlated with an increase 
of Lactococcus lactis, Lactobacilli and Bi dobacterium bi dum, as well as 
pathways of peptidoglycan synthesis possessed by lactic acid bacteria. A 
pattern comprising plant protein, vegetables, fruits, cereals, nuts, wine 
and fi sh was associated with increased abundances of Roseburia hominis, 
Faecalibacterium prausnitzii and Bi dobacteria and carbohydrate ferment-
ing pathways. A cluster of wine correlated with an increased abundance 
of the Bifi dobacterium shunt, a fructose fermenting pathway. Interestingly, 
wine was also correlated with a decrease in clusters of potentially harm-
ful species, namely Bacteroides fragilis, Escherichia coli, Coprobacillus and 
Clostridium bolteae, potentially related to a high polyphenol content.
Conclusion: We show that specifi c foods are associated with the abun-
dance of gut bacteria capable of the biosynthesis of essential nutrients 
and carbohydrate fermentation to SCFAs, inferring that certain foods could 
exert mucosal protection by inducing bacteria with anti-infl ammatory 
properties. Our work provides support of the idea that the diet represents 
a therapeutic strategy for intestinal diseases, through the modulation of 
the gut microbiome.
Disclosure: Nothing to disclose 
36 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
and obesity as abnormal or excessive fat accumulation that presents a risk 
to health. In the past decade, the gut microbiome has been implicated as 
an important factor involved in obesity, but most of the research has fo-
cused on the stool microbiome and not the metabolically and functionally 
important small intestine.
Aims & Methods: In this study, we examined the small bowel microbiome 
in obese subjects. Subjects with normal weight (Body Mass Index (BMI) 
18.5 to < 25) and subjects with obesity (BMI > 30) undergoing sole up-
per endoscopy were recruited. Blood was collected before the procedure. 
Duodenal aspirates were collected using a novel sterile aspiration catheter 
technique and DNA was isolated using the MagAttract PowerSoil DNA Kit. 
Microbiota was analyzed by 16S rRNA metagenomic sequencing. Opera-
tional Taxonomic Units clustering and taxonomic analysis were performed 
with CLC Microbial Genomics Module v. 2.5. The blood levels of glucagon-
like peptide-1 (GLP-1) and leptin were determined by Luminex. The Wald 
test and Mann-Whitney test were used to determine signifi cance between 
groups.
Results: 92 normal weight subjects (controls) and 45 subjects with obe-
sity had their duodenal microbiome (DM) completely sequenced. The 
α-diversity indexes of subjects with obesity were similar when compared 
to controls (Total number, P=0.3846; Simpson’s index, P=0.4938; Shan-
non entropy, P=0.5203). The DM of subjects with obesity and controls was 
predominantly colonized by taxon from Firmicutes phylum (56-60%), fol-
lowed by Proteobacteria and Actinobacteria (19-21% and 7-11%). The rela-
tive abundance (RA) of the Bacteroidetes phylum represented less than 
6% of the total abundance in both groups and the DM Firmicutes/Bacte-
roidetes ratio in subjects with obesity was also similar when compared 
to controls (P=0.1899). However, at the family level, the RA of the families 
Lactobacillaceae and Clostridiaceae, both from Firmicutes phylum, were 
increased when compared to controls (Fold change (FC)=11.17, P=2.73E-8; 
FC=16.11, P=2.96E-10 respectively). Additionally, the RA of the Neisse-
riaceae and Pasteurellaceae families, both from Proteobacteria phylum, 
were also increased in the DM of subjects with obesity when compared 
to controls (FC=2.05, P=0.021; FC=2.28, P=0.01, respectively). Interestingly, 
the RA of the Neisseriaceae family had a positive correlation with the lev-
els of GLP-1 (Spearman r=0.193, P=0.037) and leptin (Spearman r=0.214, 
P=0.021). The RA of the Pasteurellaceae family also correlated with the 
levels of leptin (Spearman r=0.247, P=0.007). Impressively, subjects with 
obesity had higher circulating levels of GLP-1 and leptin when compared 
to controls (FC=1.14, P=0.038; FC=8.85, P< 0.0001, respectively).
Conclusion: In this fi rst study of the small bowel microbiome, marked dif-
ferences in the microbiome were seen at the family level and these diff er-
ences appeared related to incretins and hormones linked to metabolism.
Disclosure: Nothing to disclose 
OP055 DIMETHYL FUMARATE (DMF) INHIBITS PROLIFERATION 
AND MIGRATION OF HEPATOCELLULAR CARCINOMA CELLS (HCC)
Michalski M., Wiesner O., Müller-Schilling M., Gülow K.
University Hospital Regensburg, Internal Medicine I, Regensburg, Germany
Contact E-Mail Address: marlen.michalski@ukr.de
Introduction: Dimethyl fumarate (DMF) is used for treatment of psoria-
sis (Fumaderm®). Recently, we have shown that application of DMF in-
duces cell death in NF-κ B-dependent tumors. This data were confi rmed 
in a mouse model. DMF application led to a reduced tumor growth and, 
interestingly, to a reduction of metastases formation. The inhibition of 
metastasis formation was NF-κ B-independent. Thus, identifi cation of the 
molecular mechanism inhibiting metastasis formation is a challenging 
aim for future. Solid tumors, like pancreas, breast or colon carcinoma, 
show no constitutive NF-κ B activation. Interestingly, DMF also reduced the 
metastasis formation in these tumors. Since metastasis is the major cause 
of poor prognosis of HCC DMF could be an interesting new approach for a 
treatment of these.
Aims & Methods: Human liver tumor cell lines HepG2, Huh7 und Hep3B 
were treated with DMF (25 µM up to 100 µM) for up to 72 h. A luminescence 
based viability assay was performed. The assay measures the concentra-
tion of ATP via photometric quantifi cation. The concentration of ATP is con-
nected to the viability but also the active metabolism of cells. To maintain 
eff ects on metastasis formation a scratch assay with the cell lines HepG2, 
Huh7 and Hep3B were performed. The cells were treated with DMF (25 
µM up to 100 µM) and cultivated for up to 48 h. Since DMF could lead to 
cell death cell were co-treated with 50 µM zVAD an inhibitor of apoptosis. 
Migration of the cells was analyzed by microscopy. To maintain eff ects on 
proliferation HepG2 were stained with Cytopainter Cell Proliferation Stain-
ing Reagent, which stains the cytoplasm of the cells. Aft er each cell divi-
sion the dye will be divided between mother and daughter cell resulting in 
a reduced staining. The proliferation of the HepG2 cells was analyzed aft er 
24 h, 48 h, 72 h and 96 h of treatment.
Results: DMF application resulted in a time- and dose-dependent reduc-
tion of the ATP-concentration in all cell lines tested. The strongest eff ects 
were observed aft er 72 h treatment at a concentration of 100 µM DMF. In 
addition, migration of Huh7 and Hep3B were inhibited time and dose-
dependently. Migration of Hep3B was more eff ected by DMF. Inhibition of 
migration of Hep3B was already observed at a concentration of 25 µM DMF. 
At a concentration of 100 µM DMF migration of Hep3B was blocked com-
pletely. Migration of Huh7 was inhibited at a concentration of 75 µM DMF. 
Hence, migration of Huh7 was less eff ected by DMF. Migration of HepG2 
could not be detected. Since the migration of the HepG2 cells could not be 
analyzed we switched to the measurement of the proliferation. Eff ects on 
proliferation combined with the reduction of ATP in the cells could mean 
that the cells will be dormant. It could be shown that the proliferation of 
HepG2 was also time- and dose-dependent inhibited through DMF.
Conclusion: The formation of metastases is one of the major reasons why 
solid tumors like HCC display a rather high mortality rate. Here, we show 
that DMF is capable to inhibit migration and proliferation in HCC cell lines 
probably caused by energy depletion. The exact mechanism which causes 
the inhibition of migration and proliferation still needs to be investigated. 
DMF is already clinical approved used for the treatment of psoriasis and 
shows compared to anti-cancer drugs minor side eff ects. Hence, DMF 
could be used to develop treatments against metastasis formation.
Disclosure: Nothing to disclose 
OP056 DUODENAL MICROBIOME CHARACTERIZATION IN 
PATIENTS WITH OR WITHOUT HELICOBACTER PYLORI INFECTION
Cardenas P.1,2, Suarez A.1, Prado B.1, Garces D.1, Salvador I.3, Cargua O.3, 
Fornasini M.3, Cohen H.4, Baldeon M.3
1USFQ, Institute of Microbiology, Quito, Ecuador, 2University of North Carolina 
at Chapel Hill, Biology, Chapel Hill, United States, 3UTE, CENBIO, Quito, 
Ecuador, 4Clinica de Endoscopia y Gastroenterologia, Gastroenterology, 
Montevideo, Uruguay
Contact E-Mail Address: pacardenas@usfq.edu.ec
Introduction: Helicobacter pylori a common human pathogen is a risk fac-
tor for chronic gastritis, peptic ulcer and gastric cancer. Its prevalence is 
higher in developing countries mainly by inadequate hygiene on food han-
dling and preparation. H. pylori creates an alkaline environment on the 
stomach, which leads to changes in the gastric and gut microbiomes; also, 
H. pylori elicits a local immune response that could modulate gastric and 
duodenal microbiota. There is little information regarding the eff ect of H. 
pylori gastric infection on duodenal microbiota.
Aims & Methods: To conduct a culture independent metagenomic profi ling 
of duodenal microbiome on patients with and without H. pylori infection, 
matched by age, hospital and sex. 
The V3-V4 region of the 16S rRNA gene was amplifi ed and sequenced on 
MiSeq Illumina platform from a total of 74 patients in 4 diff erent hospitals 
in Quito, Ecuador. Patients were assessed for the presence of H. pylori 
through a biopsy obtained during an upper digestive endoscopy. From 
these, 34 patients had a H. pylori active infection on the gastric fundus, 
and 40 patients were negative for the bacterium. Duodenal biopsies were 
obtained in all patients, and additional epidemiological information was 
collected. Bioinformatic analysis of sequences was performed using QI-
IME2.
Results: Around 28 million bacterial sequences were obtained and 3,230 
operational taxonomic units (OTUs) were characterized among the 74 sam-
ples. On most of the samples positive for H. pylori on histological observa-
tion, there was also detected H. pylori16S rRNA on the culture-independent 
metagenomic analysis. A higher alpha diversity was encountered in the 
duodenum of H. pylori positive patients (Shannon index and observed 
OTUs diff erences between the two groups P < 0.01). Weighted UNIFRAC, 
Bray-Curtis and Jaccard beta diversity indexes also showed signifi cant dif-
ferences between groups (P < 0.05). Relative abundance of Haemophilus, 
Streptococcus, Neisseria and Prevotella spp. was higher in the H. pylori posi-
tive patients whilst a higher abundance of Ralstonia spp. was on found in 
negative ones.
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Results: The total scores for IBS-SSS and IBS-SQ were signifi cantly im-
proved (P=0.0009 and < 0.0001, respectively) 3 weeks aft er receiving FMT. 
During the same period, the densities of UGN immunoreactive cells for the 
total group and idiopathic subgroup decreased signifi cantly in the duo-
denal crypts (P= 0.049 and 0.04, respectively) but not in the villi (P= 0.5 
and 0.8, respectively), as shown in Table 1. No signifi cant changes were 
shown in the PI-IBS subgroups (Table 1). Using Pearson’s test, UGN im-
munoreactive cells density in the crypts correlated positively with diarrhea 
(r=0.97, P=0.001) and negatively with bloating (r=  -0.91, P=0.011) in the 
PI-IBS subgroup before FMT and positively with abdominal pain (r=0.63, 
P=0.029) in the total group of IBS patients aft er FMT. No correlations were 
found between the cells in the villi and IBS symptoms.
Conclusion: This is the fi rst study to show the changes in the UGN im-
munoreactive cell densities following FMT and their correlations to IBS 
symptoms (pain, bloating and diarrhea). These correlations are consistent 
with the eff ects exhibited by UGN analog that is used for the treatment of 
IBS patients (3).
References: 
1) Mazzawi T et. al. Abnormal uroguanylin immunoreactive cells density 
in the duodenum of patients with diarrhea-predominant irritable bowel 
syndrome compared to healthy control subjects. Submitted UEG Week 
2019, Abstract: A-1084-0010-00312. 
2) Rahbi H, Narayan H, Jones DJ, Ng LL (December 2012). „The uroguanylin 
system and human disease“. Clinical Science. 123 (12): 659-68. 
3) Miner PB, Jr., Koltun WD, Wiener GJ, De La Portilla M, Prieto B, Shailubhai 
K, et al. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin 
Analog, in Patients With Chronic Idiopathic Constipation. The American 
journal of gastroenterology. 2017;112(4):613-21.
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OP058 ROLE OF INTESTINAL ALKALINE PHOSPHATASE, MYOKINES 
AND MICROBIOME IN AMELIORATION OF EXPERIMENTAL COLITIS IN 
VOLUNTARY RUNNING WHEEL ACTIVITY OBESE MICE FED FAT DIET
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Introduction: Intestinal alkaline phosphatase (IAP) is an important apical 
brush border enzyme expressed throughout the gastrointestinal tract and 
secreted into both, the intestinal lumen and the bloodstream. IAP has been 
implicated in intestinal protection through dephosphorylating both ATP 
and bacterial lipopolysaccharide (LPS) released from cells during stressful 
conditions. The hypertrophied mesenteric white (mWAT) adipose tissue in 
obesity may predispose the development of colitis.
Aims & Methods: Exercise can improve colitis but the role of IAP with or 
without exercise in mucosal healing of colitis has been little studied. We 
determined the eff ects of daily intragastric treatment with IAP (50 - 200 U) 
in sixty mice fed for 6 months with high fat diet (HFD, 70% energy from fat, 
series A) and standard diet (SD, 10% energy from fat, series B) (Altromin, 
Lage, Germany) and subjected to voluntary running wheel activity on the 
course of trinitrobenzene sulfonic acid (TNBS) colitis. Mice (series A & B) 
were housed for 8 weeks in individual running wheel cages to measure 
the running distance and muscle force by grip test. Following colitis, the 
colonic blood fl ow (CBF) by Laser Doppler fl owmetry, disease activity index 
(DAI) were determined, the plasma levels of TNF-α, IL-1β, adiponectin, 
leptin, TWEAK and myokines irisin, IL-6 and FNDC5 were assessed by Lu-
minex, the expression for TNF-α, IL-1β and IL-6 mRNA was determined by 
qPCR and the gut microbiome was analyzed by Next-Generation Sequenc-
ing (NGS).
Results: TNBS caused a signifi cant increase in DAI, the signifi cant fall in 
the CBF, an increase in colonic tissue weight, the plasma levels, expression 
of IL-1β, TNF-α and IL-6 mRNA and protein (p< 0.05). In HFD mice, the 
running distance, muscle strength were reduced and the area of colonic 
damage and colonic tissue weight, the plasma IL-1β, TNF-α, TWEAK and 
leptin levels were signifi cantly increased while FND5, irisin and adipo-
nectin levels were decreased vs. SD mice. Treatment with IAP signifi cantly 
Conclusion: Duodenal microbiomes are diff erent between H. pylori positive 
and negative patients in terms of alpha diversity, beta diversity and rela-
tive OTUs abundance. Also, H. pylori infected individuals have increased 
abundance of Haemophilus, Streptococcus, Neisseria and Prevotella spp. in 
their gastric microbiome (1).
References: 1. Klymiuk, I., Bilgilier, C., Stadlmann, A., Thannesberger, J., 
Kastner, M. T., Högenauer, C., Steininger, C. (2017). The Human Gastric Mi-
crobiome Is Predicated upon Infection with Helicobacter pylori. Frontiers 
in microbiology, 8, 2508. doi:10.3389/fmicb.2017.02508
Disclosure: The current project was funded by Biocodex, USFQ and UTE, 
however the funders did not were involved in study design, patients re-
cruitment, experiments, data collection and analyses, or results interpre-
tation. 
OP057 CHANGES IN DUODENAL UROGUANYLIN IMMUNOREACTIVE 
CELLS DENSITY CORRELATE WITH SYMPTOMS OF PATIENTS 
WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME 
FOLLOWING FECAL MICROBIOTA TRANSPLANTATION
Mazzawi T.1,2, Eikrem Ø.2,3, Hausken T.2,3
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Introduction: Altered density of uroguanylin (UGN) immunoreactive (GU-
CA2B-positive) cells was found in the duodenum of patients with diarrhea-
predominant irritable bowel syndrome (IBS-D) (1). Uroguanylin activates 
guanylate cyclase to regulate electrolyte and water transport in intestinal 
epithelia (2).
Aims & Methods: The aim was to investigate the eff ect of fecal microbiota 
transplantation (FMT) on UGN immunoreactive (GUCA2B-positive) cells 
density in the duodenum of IBS-D patients. 
The study included 16 IBS patients according to Rome III criteria and four 
patients were excluded. The remaining patients (n=12, 4 females and 8 
males) were divided according to the cause into post-infectious (PI, n=6) 
and idiopathic (n=6) IBS. They completed IBS-Symptom Severity Scoring 
system (IBS-SSS) questionnaire and IBS-Symptom questionnaire (IBS-SQ) 
before and 3 weeks aft er FMT. Fecal suspension (30 g fresh feces donated 
from patients’ healthy relatives and diluted with 60 ml normal saline) was 
instilled via gastroscope into the duodenum. Biopsies were taken from 
the descending part of the duodenum before and 3 weeks aft er FMT. They 
were immunostained for UGN cells using rabbit polyclonal antibody to 
GUCA2B (LS-C371347, LSBio, Seattle, WA, USA) and quantifi ed using com-
puterized image analysis.
  Fecal microbiota transplantation  
Questionnaire Before Aft er P-value 
IBS-SSS 326.6±22.3 240.2±33.6 0.0009 
IBS-SQ 
Total score 30.8±3.3 11.6±2.1 <0.0001 
Abdominal pain 6.3±0.9 3.3±0.8 0.0012 
Bloating 7.9±0.5 3.4±0.8 <0.0001 
Diarrhea 6.4±0.9 1.2±0.4 <0.0001 
Uroguanylin immunoreactive cells density 
Total IBS group 
Villi (cells/100 epithelial cells) 44±5.5 41±2.3 0.5
Crypts (cells/mm2) 116±8 96±3 0.049 
PI-IBS 
Villi (cells/100 epithelial cells) 45.8±7.4 40.5±3.3 0.6
Crypts (cells/mm2) 108±11.8 102.5±4 0.6
Idiopathic IBS 
Villi (cells/100 epithelial cells) 42.5±8.8 40.7±3.6 0.8
Crypts (cells/mm2) 124±11 89.5±4 0.04 
Paired t test. Data are presented as the mean±SEM. IBS: irritable bowel syndrome, PI: 
post infectious, SSS: Symptom Severity Scoring system, SQ: symptom questionnaire.
[Table 1: Symptoms scores and duodenal uroguanylin immunoreactive cells 
density in IBS patients before and a er fecal microbiota transplantation]
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reduced DAI in SD and HFD mice, increased the skeletal muscle strenght as 
assessed by muscle grip test and potentiated the benefi cial ameliorating 
eff ect of exercise on colitis. IAP alone or combined with exercise increased 
the CBF and plasma levels of myokines IL-6, FND5 and irisin while plasma 
levels of IL-1β, TNF-α, TWEAK and leptin was signifi cantly diminished (p< 
0.05). In HFD mice, the reduction of Lactobacillus, Clostridium, Faecalibac-
terium and an enhanced colonization by Bacteroides, Prevotella and Helico-
bacter spp. was detected while IAP treatment reduced Bacteroides and He-
licobacter spp. and favored colonization of Lactobacillus and Bi dobacteria 
spp. compared with sedentary mice.
Conclusion: Exercise can improve the healing of experimental colitis due 
to release of protective myokines irisin, IL-6 and FND5 from working skel-
etal muscles, reduction of proinfl ammatory cytokines and normalization 
of leptin/adiponectin ratio, especially in obese mice, and 2) exogenous IAP 
ameliorates gut infl ammation, enhances eff ect of exercise and favors heal-
ing of colitis due to modifi cation of microfl ora and a potent enhancement 
in CBF. IAP may represent a novel supplementation capable of acting syn-
ergistically with moderate exercise activity in mechanism of amelioration 
of human IBD (grant No. K/PBO/000440).
Disclosure: Nothing to disclose 
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OP059 INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL 
DISEASE IN THE UK BETWEEN 2000 AND 2016 AND ASSOCIATED 
MORTALITY AND SUBSEQUENT RISK OF COLORECTAL CANCER
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Adderley N.2, Trudgill N.1
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Introduction: There is only limited and old data on the epidemiology of 
infl ammatory bowel disease (IBD), including Ulcerative Colitis (UC) and 
Crohn’s Disease (CD), in the UK. Accurate data on the IBD burden and their 
impact is crucial for service planning for patients. The aim of this study was 
to establish accurate, updated UK incidence and prevalence of IBDs and 
to quantify the risk of mortality and colorectal cancer in those with IBD.
Aims & Methods: Retrospective cohort studies and cross-sectional stud-
ies were carried out between 2000 and 2016 using data from the Health 
Improvement Network (THIN), a primary care database of 750 general 
practices representative of the UK population. Annual incidence rates and 
point prevalence among adults aged 18 years and over were calculated 
for CD and UC. Mortality and colorectal cancer (CRC) incidence rates were 
quantifi ed using a matched cohort study design, with four controls for 
each UC or CD subject, matching on age, sex and general practice between 
1995 and 2017. A multivariable Cox proportional hazards model was used 
to quantify risk of mortality adjusting for year, age-band, sex, deprivation 
level, Charlson comorbidity, smoking status and hypertension and a multi-
variable Poisson regression model was used to quantify CRC risk.
Results: 16,765 incident cases of CD and 24,410 incident cases of UC were 
observed among 8,767,641 subjects, totalling more than 61 million per-
son-years at risk (py). The incidence rate (IR) of CD was 16.3 per 100,000 
py. Females had a 30% higher incidence of CD than male subjects (Inci-
dence Rate Ration 1.30 (95% CI 1.23-1.34), p< 0.001) and all age categories 
greater than 18-30 had a lower rate of CD incidence. Overall, CD incidence 
fell by 3% (0.97 (0.96-0.97), p< 0.001) over the study period, was stable 
in subjects under 60 years, and fell by 4% in those over 60 years (0.96 
(0.95-0.97), p< 0.001). The IR of UC was 25.9 per 100,000py. Females had 
a 6% lower incidence of UC than males (0.94 (0.91-0.96), p< 0.001) and 
compared to 18-30s all older age categories had a lower rate of UC when 
adjusted by sex and year. Overall, UC incidence fell by 4% (0.96 (0.95-
0.96), p< 0.001) between 2000 and 2016. In those aged over 60, IR fell 
by 6% (0.94 (0.93-0.94), p< 0.001) over the study period, but was stable 
in those under 60. Point prevalence of CD increased from 218 to 414 per 
100,000 population between 2000 and 2016. In 2016, prevalence was 460 
and 370 for females and males respectively. UC prevalence rose from 380 
to 640 per 100,000. In 2016. prevalence was 630 and 640 in females and 
males respectively.
CRC incidence rate in the whole THIN population was 70.6 per 100,000py 
(95% CI 69.6-71.5) over the study period. IR of CRC in CD was 78.4 per 
100,000py (66.8-92.0). IR of CRC in UC was 133.3 per 100,000py (121.1-
146.8). The adjusted incidence rate ratio (IRR) of CRC was 26% higher in 
CD patients than in matched controls (1.26 (1.04-1.51), p=0,014), and was 
48% higher in those with UC (1.48 (1.32-1.67), p< 0.001). Among CD sub-
jects, mortality was 41% higher (hazard ratio 1.41 (1.35-1.47), p< 0.001) and 
among UC subjects, mortality was 17% higher (1.17 (1.14-1.21), p< 0.001).
Conclusion: IBD prevalence in the UK is more than double that which had 
been previously reported. Although incidence rates of UC and CD are sta-
ble in the under 60s, there appears to have been a fall in rates of IBD in 
older age groups. Mortality and CRC risk was higher in both UC and CD 
when compared to matched controls.
Disclosure: Nothing to disclose 
OP060 INFLAMMATORY BOWEL DISEASE ASSOCIATED 
COLORECTAL CANCER: CHARACTERISTICS AND OUTCOMES FROM 
AN ENGLISH POPULATION DATASET (2010 TO 2016)
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Introduction: Colorectal cancer (CRC) is an important complication of in-
fl ammatory bowel disease (IBD). Historic cohort studies have suggested 
that the risk of developing CRC in those with IBD (IBD-CRC) may be in-
creasing, but contemporary, population data are lacking. There is also a 
paucity of information on the clinical outcomes for these cancers, includ-
ing surgical outcomes, and whether there is any diff erence between spo-
radic and IBD-CRC.
Aims & Methods: This English population-based study examined the char-
acteristics, treatments and outcomes for CRC patients with and without IBD. 
The CORECT-R data repository holds national, linked data on CRC diagno-
sis pathways, treatments and outcomes in England. Using this resource, all 
CRC cases between 01/01/2010 and 31/12/2016 were identifi ed. A diagnosis 
of IBD (Crohn’s disease or ulcerative colitis) was defi ned by relevant ICD-10 
codes (K50-51). Study characteristics included; sex, age at diagnosis, asso-
ciated comorbidity, route of diagnosis, stage of CRC, survival in days, and 
details of any surgical resection. Multivariable logistic regression models 
assessed the relationship between IBD and post-surgical outcomes and 
death within a year of diagnosis.
Results: There were 192,000 CRC in the study period (2,992 IBD-CRC). There 
was an increase in the proportion of IBD-CRC from 1,4% in 2010 to 1.9% in 
2016 (p-value for trend < 0.01). IBD-CRC cases were signifi cantly younger 
(median age 68 years (IQR 56-78) and 73 years (IQR 64-81) respectively), 
had more associated comorbidity, and more presented as an emergency. 
There were signifi cantly more right-colonic, and more early (Stage I) and 
late (Stage IV) cancers. Aft er a major surgical resection signifi cantly more 
people with IBD were likely to be readmitted as an emergency (OR 1.30, 
95% CI 1.16-1.47), have a prolonged hospital stay (≥21 days) (OR 1.47, 95% 
CI 1.28-1.68), and die within a year (OR 1.52, 95% CI 1.32-1.77).
Conclusion: The proportion of IBD-CRC is increasing. This is may refl ect the 
rising incidence of IBD, but also decreasing rates of colectomy procedures 
leaving more people exposed to a risk of developing CRC. Outcomes for 
those with IBD-CRC appear worse than for sporadic CRC, and the cancers 
occur in younger patients. There is an urgent need to explore the diagnosis 
and management pathways for these individuals to try and explain the 
signifi cant diff erences shown here.
Disclosure: Nothing to disclose 
39Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
OP062 COURSE OF INDOLENT CROHN’S DISEASE IN A 
PROSPECTIVE EUROPEAN POPULATION-BASED INCEPTION COHORT 
WITH FIVE YEARS FOLLOW-UP - THE EPI-IBD COHORT
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Introduction: The lack of scientifi c evidence regarding the effi  cacy of 
5-aminosalicylate (5-ASA) in patients with Crohn’s disease (CD) is in sharp 
contrast to its widespread use in clinical practice. Up to one out of three of 
CD patients are treated with 5-ASA at any given time during their disease 
course, many as monotherapy, suggesting a mild phenotype. Population-
based data regarding this subgroup of patients are sparse.
Aims & Methods: The Epi-IBD cohort is a prospective population-based 
cohort of 1,289 unselected, uniformly diagnosed patients with IBD di-
agnosed from 31 centres in Europe in 2010. Clinical data were captured 
prospectively throughout the fi ve-year follow-up period. Diagnosis were 
made according to the Copenhagen Diagnostic Criteria. Patient manage-
ment was left  to the discretion of the treating gastroenterologists. Patients 
receiving 5-ASA monotherapy or in no need of medical therapy during 
the fi rst year following diagnosis were combined for the sake of analysis 
(Indolent cohort). The aim of the study was to investigate the course and 
characteristics for these patients as well as the use of 5-ASA in patients 
diagnosed with CD.
Results: A total of 488 (38%) patients were diagnosed with CD. Patient 
characteristics are shown in Table 1. Overall, 303 (62%) patients received 
5-ASA at any point during follow-up for a median duration of 28 months 
(IQR 6-60). A total of 97 (20%) patients received either 5-ASA monotherapy 
(n=80, 82%) or no medical treatment (n=17, 18%) during the fi rst year 
following diagnosis. These patients were older (p=0.03) and had less com-
plicated disease behaviour (p< 0.01) compared to the other patients but 
were otherwise similar. 
During follow-up, 4 (4%) patients in the indolent group stepped up to 
corticosteroids as their highest treatment step, 12 (12%) patients to im-
munomodulators, and 1 (1%) patient to biological therapy. Furthermore, 
19 (20%) patients were hospitalized and 5 (5%) patients needed surgery. 
Most patients in the indolent group (n=75 [80%], 15% of the total cohort) 
never needed more intense therapy during follow-up. A total of 4 (5%) 
patients diagnosed with B1 disease behaviour progressed to B2/B3 during 
follow-up.
OP061 THE RISK OF FURTHER RESECTIONAL SURGERY IN THE 
TEN YEARS FOLLOWING A FIRST RESECTION FOR CROHN’S DISEASE 
IN ENGLAND
King D.1, Coupland B.2, Dosanjh A.2, Myton J.2, Patel P.2, Trudgill N.1
1Sandwell And West Birmingham NHS Trust / University of Birmingham, 
Gastroenterology, West Bromwich, United Kingdom, 2University Hospital 
Birmingham NHS Trust, Queen Elizabeth Hospital, Informatics, Birmingham, 
United Kingdom
Contact E-Mail Address: dominic.king@nhs.net
Introduction: Most patients with Crohn’s Disease (CD) will have surgery 
during the course of their disease1, many of whom develop endoscopic 
recurrence within a year2 and may need further surgery. This study aims 
to examine the proportion, timing and factors associated with further sur-
gery following an index surgical resection.
Aims & Methods: Hospital Episode Statistics captures all patient interac-
tion with hospitals in England. Subjects were included in the study if they 
had index surgical resection between 2007 and 2016 and an International 
Classifi cation of Disease-10 (ICD-10) code of K51 (CD) on admission. A sub-
cohort was identifi ed whose index resection was colonic and whose ICD-10 
code was K501 - this was considered a Crohn’s colitis cohort. Subjects were 
followed for a maximum of 12-years and the primary outcome was further 
bowel resection. A multivariable Cox regression model assessed factors 
associated with further resection.
Results: 16,609 subjects with CD had a bowel resection: 53.7% female, 
median age 35 (IQR 26-46) years, 87.3% were white, 85.3% of subjects had 
no comorbidities (Charlson score of 0) and 11% of subjects were coded as 
having perianal disease during the study period. 70% of subjects had at 
least 5 years of follow-up and 19% had at least 10-years follow-up. Index 
surgery was performed on an emergency admission in 41.8%. The median 
number of annual index resections was 1,662 (IQR 1,617-1,682). 29.7% of 
subjects had one or more further resections during the follow-up period 
and 22% of these had more than two further resections. 48.7% of fi rst 
further resections took place within 1-year of index surgery and 54.7% of 
fi rst further operations were performed in subjects whose index surgery 
occurred during an emergency admission. Of those with 5 years follow-
up, 26.5% had one or more further resections and in those with 10 years 
follow-up, 32.4% had one or more further resections. Female subjects 
were at lower risk of further resection (HR 0.85 (95% CI 0.80-0.90), p< 
0.001), as were the older subjects 44-60 years when compared to 18-29 
year olds (0.85 (0.79-0.92), p< 0.001). Those in the least deprived quintile 
were also at lower risk (0.90 (0.82-0.99), p=0.029), as were those whose 
initial resection was done on an elective basis (0.53 (0.5-0.56), p< 0.001). 
Perianal disease was associated with a 69% increased the risk of future 
resection (1.69 (1.57-1.82, p< 0.001), and a high comorbidity score was as-
sociated with a 22% increased risk (1.22 (1.03-1.44), p=0.024). Ethnicity 
was not associated with further resection.
In the Crohn’s colitis sub-cohort, 1,933 subjects were identifi ed. 56% fe-
male, median age 36 (IQR 26-47) years and 87% white. 33% of subjects 
had further resection during follow-up, 25.6% of these subjects had 2 
or more further resections. Perianal disease was coded in 14.5% of this 
cohort. 43% of index colonic resections were performed during an emer-
gency admission and 39.5% of these subjects had further resection. An 
elective admission for index resection was associated with a decreased risk 
of future resection in the Crohn’s colitis cohort (0.68 (0.58-0.79), p< 0.001) 
whereas perianal disease was associated with an 85% increased risk (1.85 
(1.53-2.23), p< 0.001).
Conclusion: Future resection was associated with an index resection per-
formed during an emergency admission, perianal disease, male sex and 
those with greater comorbidity. Lower deprivation and older age were as-
sociated with a reduced risk of further resection. Further resectional sur-
gery remains common in CD following index bowel resection, despite the 
widespread use of biologic agents.
References: 2: Frolkis AD, Lipton DS, Fiest KM, et al. Cumulative inci-
dence of second intestinal resection in Crohn’s disease: a systematic re-
view and meta-analysis of population-based studies. Am J Gastroenterol 
2014;109:1739-48. doi:10.1038/ajg.2014.297 2: Auzolle C, Nancey S, Tran-
Minh M-L, et al. Male gender, active smoking and previous intestinal re-
section are risk factors for post-operative endoscopic recurrence in Crohn’s 
disease: results from a prospective cohort study. Aliment Pharmacol Ther 
2018;48:924-32. doi:10.1111/apt.14944
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All CD patients 
(n=488)
Indolent 
CD patients 
(n=97)
Other (n=391)
Age, years (IQR) 33 (23-49) 37 (27-58) 32 (23-47)
Males, n (%) 244 (50%) 47 (48%) 197 (50%)
Diagnostic delay, months (IQR) 4.2 (1.7-12.0) 3.6 (1.1-9.7) 4.3 (1.8-12.0)
Extraintestinal manifestations at 
diagnosis, n (%)
79 (16%) 17 (18%) 62 (16%)
Smoking at diagnosis, n (%)
Never 183 (40%) 40 (41%) 143 (37%)
Current 171 (37%) 27 (28%) 144 (37%)
Former 103 (23%) 15 (15%) 88 (23%)
Disease behaviour, n (%)
B1: non-stricturing, non-penetrating 347 (71%) 84 (86%) 263 (67%)
B2: stricturing 100 (21%) 11 (12%) 89 (23%)
B3: penetrating 41 (8%) 2 (2%) 39 (10%)
Perianal disease 46 (9%) 5 (5%) 41 (11%)
Disease location, n (%)
L1: terminal ileum 128 (77%) ) 28 (30%) 100 (26%)
L2: colon 134 (28%) 30 (32%) 104 (27%)
L3: terminal ileum + colon 111 (23% 21 (22%) 90 (23%)
L4: Upper GI 30 (6%) 7 (7%) 23 (6%)
L1-L3 + L4 76 (16%) 8 (9%) 68 (18%)
[Patient characteristics 2010-2015]
Conclusion: In this European population-based inception cohort of un-
selected CD patients, a substantial group of patients needed only mild 
or no treatment during follow-up and experienced a quiescent disease 
course. Patient stratifi cation at baseline to prevent not only under- but also 
overtreatment is important. Further studies are needed to identify clinical, 
serological or genetic markers to identify this group of patients.
Disclosure: Nothing to disclose 
OP063 EARLY SYMPTOM IMPROVEMENT WITH RISANKIZUMAB 
TREATMENT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE 
CROHN’S DISEASE: ANALYSIS FROM A PHASE 2 STUDY
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Introduction: Risankizumab (RZB), an IL-23 p19 inhibitor, has shown safety 
and effi  cacy in inducing clinical remission in patients with Crohn’s disease 
(CD) in a Phase 2 study.1 Here we assessed early symptom improvement 
during the randomized, double-blind, placebo-controlled induction phase 
of the trial.
Aims & Methods: This Phase 2 study enrolled adult patients with moder-
ate-to-severe CD with a Crohn’s Disease Activity Index (CDAI) of 220-450, 
ulcers in the ileum and/or colon, and a Crohn’s Disease Endoscopic Index 
of Severity (CDEIS) ≥7 (≥4 for patients with isolated ileitis) assessed by il-
eocolonoscopy confi rmed by a blinded central reader. Patients were ran-
domized 1:1:1 to receive intravenous RZB (200 mg or 600 mg) or placebo at 
Weeks 0, 4, and 8. Endpoints examined in this post hoc analysis included 
changes from baseline at Weeks 2, 4, 8, and 12 in CDAI, average daily stool 
frequency (SF) and average daily abdominal pain score (AP) for all pa-
tients with available data, and newly defi ned clinical remission at Week 12, 
based on symptom improvement, defi ned as SF ≤2.8 and AP ≤1, both not 
worse than baseline, in patients with baseline SF ≥4 or AP ≥2. Continuous 
endpoints were analyzed using observed case; non-responder imputation 
was used for missing data of binary endpoints. Statistical comparisons of 
median change were based on Wilcoxon rank sum test.
Results: 121 patients were randomized in the induction phase. Baseline 
characteristics were similar among treatment arms.1 Mean (SD) disease 
duration at baseline was 13.4 (9.4) years; 94.2% of patients received previ-
ous anti-TNF therapy. Signifi cant improvements in CDAI and AP were ob-
served with RZB (600 mg) versus placebo as early as Week 2 and in SF at 
Week 8 (Table). The proportion of patients with clinical remission based 
on symptom improvement was signifi cantly higher in the 600 mg RZB 
group versus placebo at Week 12 (23.7% versus 6.1%; p< 0.05), support-
ing the previously reported superiority of RZB versus placebo for inducing 
CDAI remission at Week 12 (36.6% of 600 mg RZB versus 15% of placebo; 
p< 0.05).1
Conclusion: RZB induction treatment was associated with signifi cant early 
improvements in clinical symptoms and disease activity in a highly refrac-
tory patient population with moderately to severely active CD.
  PBO RZB 200 mg RZB 600 mg
CDAI BL (median) 287.3 304.1 298.1
CDAI Median Change from BL 
Wk 2
Wk 4
Wk 8
Wk12
11.0
7.3
-2.2
-33.0
-18.0*
-37.0*
-38.9
-54.6
-42.0***
-39.3*
-68.8**
-58.8*
SFa BL (median) 5.9 5.9 6.3
SFa Median Change from BL 
Wk 2
Wk 4
Wk 8
Wk12
0.0
-0.4
-0.1
-0.4
-0.9
-1.4*
-1.2
-1.4
-0.9
-1.3
-1.2*
-1.7*
APa BL (median) 5.2 5.7 5.1
APa Median Change from BL 
Wk 2
Wk 4
Wk 8
Wk12
0.1
0.0
-0.4
-0.7
-0.6
-1.3**
-1.0
-1.5
-0.8*
-0.8*
-1.2*
-1.2
aBased on patient diaries.
*p<0.05; **p<0.01; ***p<0.001 for RZB vs PBO.
AP, abdominal pain score; CDAI, Crohn‘s Disease Activity Index; RZB, 
risankizumab; SF, stool frequency.
[Baseline values and change from baseline in median CDAI, SF, and AP over 
time with RZB versus placebo (as observed)]
References: 1. Feagan BG et al. Lancet 2017;389:1699-1709.
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extended-release upadacitinib 7.5, 15, 30, 45 mg once daily (QD) or placebo 
for 8 weeks. In the current sub-analysis, the effi  cacy of upadacitinib in 
more severe and/or more refractory patient populations was assessed. Pa-
tients who at baseline had failed ≥ 2 prior biologic agents, had pancolitis, 
and/or an Adapted Mayo score >7, were included. Pairwise comparisons 
between upadacitinib doses and placebo for the primary endpoint, clinical 
remission per Adapted Mayo Score at Week 8 (defi ned as stool frequency 
subscore ≤1, rectal bleeding subscore =0, and endoscopic subscore ≤1) and 
secondary endpoints were conducted using the Fisher’s Exact test and no 
multiplicity adjustments were applied. Non-responder imputation was 
utilized for missing values.
Results: At baseline, 142 (56.8% of the total study population) patients 
had failed ≥ 2 prior biologics, 135 (54.0%) patients had pancolitis, and 90 
(36.0%) patients had an Adapted Mayo score >7. The proportions of pa-
tients achieving endoscopic improvement, clinical response per Adapted 
Mayo score, and clinical response per Partial Mayo score were signifi cantly 
higher (nominal p-value < 0.05) with upadacitinib doses ≥30 mg QD ver-
sus the placebo group in patients who failed ≥ 2 biologics or had panco-
litis at baseline (Table). Trends of higher proportions of patients achiev-
ing clinical remission per Adapted Mayo score, endoscopic improvement, 
clinical response per Adapted Mayo score, and clinical response per Partial 
Mayo score were observed with all upadacitinib groups versus placebo in 
all the sub-analyses. 
Conclusion: In this dose-ranging induction study, upadacitinib demon-
strated greater effi  cacy compared to placebo with dose response in the 
more severe and refractory population; signifi cantly greater effi  cacy was 
demonstrated with upadacitinib at doses ≥30 mg QD for most of the end-
points evaluated.
References: 
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Organisation 2019.
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OP064 EFFICACY OF UPADACITINIB AS AN INDUCTION THERAPY 
IN SEVERE AND REFRACTORY ULCERATIVE COLITIS: SUB-GROUP 
ANALYSIS OF THE PHASE 2B STUDY U-ACHIEVE
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Introduction: An unmet need exists to fi nd eff ective therapy in more severe 
ulcerative colitis (UC) patients, especially those who have failed multiple 
therapies. The effi  cacy and safety of upadacitinib, a selective Janus Ki-
nase 1 inhibitor, has been assessed in an 8-week double-blind, placebo-
controlled, dose-ranging, phase 2b induction study in adult patients with 
moderately-to-severely active UC (U-ACHIEVE).1,2
Aims & Methods: In U-ACHIEVE, adult patients with moderately-to-se-
verely active UC as determined by the Adapted Mayo Score (5-9 points 
and centrally-read endoscopy subscore 2-3) were randomized to receive 
Endpoints, n (%) Placebo
UPA
7.5 mg QD
UPA
15 mg QD
UPA
30 mg QD
UPA
45 mg QD
Clinical remission per Adapted Mayo Score 
(SFS ≤1, RBS=0, and ES ≤1) at Week 8a 
Biologic use ≥ 2 
With pancolitis 
BL Adapted Mayo score >7
0/28
0/27
0/19
2/27(7.4)
3/25(12.0)+ 
1/17(5.9)
2/27(7.4)
4/24(16.7)*
0/18
4/30(13.3)
3/29(10.3)
1/19(5.3)
4/30(13.3)
4/30(13.3)
2/17(11.8)
Endoscopic improvement (ES ≤1) at Week 8b 
Biologic use ≥ 2 
With pancolitis 
BL Adapted Mayo score >7
0/28
0/27
0/19
3/27(11.1)
5/25(20.0)*
4/17(23.5)*
6/27(22.2)*
8/24(33.3)**
3/18(16.7)
7/30(23.3)*
7/29(24.1)*
3/19(15.8)
10/30(33.3)***
10/30(33.3)***
8/17(47.1)***
Clinical response per Adapted Mayo score 
(decrease from baseline ≥2 points and 
≥30% and in RBS ≥1 or an absolute RBS ≤1) 
at Week 8b 
Biologic use ≥ 2 
With pancolitis 
BL Adapted Mayo score >7
2/28(7.1)
3/27(11.1)
4/19(21.1)
7/27(25.9)+ 
5/25(20.0)
5/17(29.4)
10/27(37.0)*
9/24(37.5)*
7/18(38.9)
11/30(36.7)*
12/29(41.4)*
8/19(42.1)
12/30(40.0)**
13/30(43.3)**
10/17(58.8)*
Clinical response per Partial Mayo score 
(decrease from baseline ≥2 points and 
≥30% and in RBS ≥1 or an absolute RBS ≤1) 
at Week 2b 
Biologic use ≥ 2 
With pancolitis 
BL Adapted Mayo score >7
3/28(10.7)
3/27(11.1)
3/19(15.8)
5/27(18.5)
5/25(20.0)
5/17(29.4)
8/27(29.6)+ 
9/24(37.5)*
5/18(27.8)
11/30(36.7)*
12/29(41.4)*
8/19(42.1)
17/30(56.7)***
18/30(60.0)***
11/17(64.7)**
Endoscopic remission (ES=0) at Week 8b 
Biologic use ≥ 2 
With pancolitis 
BL Adapted Mayo score >7
0/28
0/27
0/19
1/27(3.7)
3/25(12.0)+ 
1/17(5.9)
0/27
0/24
0/18
0/30
3/29(10.3)
2/19(10.5)
4/30(13.3)
2/30(6.7)
2/17(11.8)
aPrimary Endpoint; bRanked Secondary Endpoints. ***, **, *, and + signifi cant at 0.001, 0.01, 0.05, and 0.1 levels, respectively.
UPA=upadacitinib; QD=once daily; SFS=stool frequency subscore; RBS=rectal bleeding subscore; ES=endoscopic subscore.
Baseline Adapted Mayo score is missing for 1 subject in upadacitinib 45 mg QD treatment group.
[OP064 Table]
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OP065 EFFICACY OF FIRST-LINE REGIMENS IN SPAIN: 
RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI 
MANAGEMENT (HP-EUREG)
Caldas Alvarez M.1, Perez Aisa M.&.2, Castro Fernandez M.3, Bujanda L.4, 
Lucendo A.J.5, Fernandez Moreno N.2, Hinojosa J.2, Rodrigo Sáez L.R.6, 
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Molina Infante J.10, Fernández Salazar L.11, Barrio Andrés J.12, Lanas A.13, 
Domínguez Cajal M.14, Perona Vincenti M.C.15, Ortuño J.16, 
Gómez Rodríguez B.J.17, Canelles Gamir P.18, Almela Notari P.19, 
González P.L.20, Modolell I.21, Botargues J.M.22, Gomez J.23, P. Nyssen O.1, 
Marin A.C.24, Garcia Donday M.1, Garre A.1, Megraud F.25, O’Morain C.26, 
McNicholl A.G.1, P. Gisbert J.1
1Hospital de La Princesa, IIS-IP and CIBERehd, Madrid, Spain, 2Agencia 
Sanitaria Costa del Sol, Málaga, Spain, 3Hospital de Valme, Digestivo, 
Sevilla, Spain, 4Hospital Donostia/Instituto Biodonostia and CIBERehd. 
Universidad del País Vasco (UPV/EHU), San Sebastián, Spain, 5Hospital 
General de Tomelloso, Dept. of Digestive Health Dept. of Gastroenterology, 
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Zaragoza University Hospital, Dept. Medicine & Gastroenterology, Zaragoza, 
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y Politècnic La Fe de Valencia and CIBERehd, Valencia, Spain, 17Hospital 
Universitario Virgen Macarena, Sevilla, Spain, 18H.G.U. Valencia, Valencia, 
Spain, 19Hospital Universitario General de Castellón, Castellon, Spain, 
20Hospital San Pedro de Alcántara, Cáceres, Spain, 21Consorci Sanitari de 
Terrassa, Barcelona, Spain, 22Hospital Universitari de Bellvitge, Digestive 
Diseases, Barcelona, Spain, 23Complejo Asistencial Universitario de Burgos, 
Burgos, Spain, 24Hospital Universitario de La Princesa, IIS-IP, and CIBERehd, 
Gastroenterology Unit, Madrid, Spain, 25Hopital Pellegrin, Laboratoire de 
Bacteriologie, Inserm U 1053, Bordeaux Cedex, France, 26Trinity College 
Dublin - Faculty of Health Sciences, Dublin, Ireland
Contact E-Mail Address: m.caldas.a@gmail.com
Introduction: The best empirical treatment prescribed against Helicobacter 
pylori (H. pylori) infection must be chosen following local effi  cacies 
previously observed. Therefore, updated data concerning Spanish results, 
obtained in daily clinical practice, is needed to meet this objective.
Aims & Methods: The aim was to analyse the effi  cacy of the most commonly 
prescribed fi rst-line therapies in a Spanish cohort. We conducted an 
observational, prospective, multicenter study, carried out in 48 Spanish 
hospitals as part of the ́ Pan-European Registry on H. pylori management´. 
The database was provided by AEG-REDCap. Gastroenterologists included 
data obtained in their clinical medical practice from February 2013 to 
January 2018. A multivariate analysis was performed considering the 
most effi  cacious therapies, and considering the sex of the patient, type 
of PPI (fi rst vs. second-generation), type of PPI dose (simple vs. double), 
treatment duration (10 vs. 14 days), compliance and penicillin allergy.
Results: 8,581 patients naive to H. pylori treatment have been included so 
far, 61% of them being women and 4% having penicillin allergy. Median 
age was 51±15 years. The therapies most frequently prescribed as a fi rst-
line therapy (all of them including a proton pump inhibitor, PPI) were: 
non-bismuth quadruple concomitant therapy (Q-NBCT, 41%), standard 
triple therapy containing clarithromycin and amoxicillin (T-CA, 34%), the 
three-in-one single capsule bismuth containing metronidazole, bismuth 
and tetracycline (Q-SINGLE, 9%), bismuth quadruple therapy containing 
clarithromycin and amoxicillin (Q-BCA, 8%), and the non-bismuth 
quadruple sequential therapy (Q-NBST, 3%). 5% of the remaining patients 
received other minority therapies. The effi  cacy of these therapies was 
analysed on a modifi ed ITT (mITT) and PP basis. The results are shown 
in Table 1, divided by 10 or 14 days duration of treatment prescription. 
Good compliance was associated with a higher effi  cacy for Q-NBCT and 
Q-SINGLE therapies (p< 0.001). Male sex and the use of second-generation 
PPIs also increased effi  cacy rates obtained with Q-NBCT (p< 0.05). None 
of the variables mentioned showed effi  cacy increase considering Q-BCA 
treatment. 
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In multivariate analysis (entering variables H. pylori status, age, gender, 
sour dairy products, cheese products, leek, 200 g vodka at a time during the 
last year, educational level, income, smoking) seropositive H. pylori status 
(OR 3.40, 95% CI 2.60-4.45, p< 0.001), age above 51 years (OR 1.59, 95% 
CI 1.27-1.99, p< 0.001), alcohol consumption (OR 1.30, 95% CI 1.02-1.64, 
p=0.03) and present smoking (OR 1.44, 95% CI 1.11-1.87, p=0.007) showed 
a positive association with decreased pepsinogen level while an inverse 
association (OR 0.72, 95% CI 0.52-0.99, p=0.05) was found with higher 
consumption of cheese and cheese products.
Conclusion: Although a few studied dietary factors showed a signifi cant 
univariate association with decreased pepsinogen level, only H. pylori 
seropositivity, advanced age, alcohol consumption and present smoking 
were independently linked to decreased pepsinogen level while higher 
consumption of cheese and cheese products showed protective eff ect to-
wards decreased pepsinogen level. Thus, suggesting that the bacterium 
and age play more important role in the development of atrophy than 
diff erent dietary factors.
Disclosure: Nothing to disclose 
OP067 “TEST AND TREAT” STRATEGY WITH UREA BREATH 
TEST: A COST-EFFECTIVE STRATEGY FOR THE MANAGEMENT OF 
HELICOBACTER PYLORI INFECTION IN SPAIN
McNicholl A.G.1, Malfertheiner P.2,3, Franceschi F.4, Liebaert F.5, Salhi H.5, 
Beresniak A.6, Gisbert J.P.7
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University Hospital, Magdeburg, Germany, 3Dept. of Medicine II, University 
Hospital, LMU, Munich, Germany, 4Policlinico Gemelli, Catholic University, 
Emergency Medicine, Roma, Italy, 5Mayoly Spindler Laboratories, Chatou, 
France, 6Data Mining International, Geneva, Switzerland, 7Hospital 
Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP) 
and CIBEREHD, Digestive Services, Madrid, Spain
Contact E-Mail Address: peter.malfertheiner@med.ovgu.de
Introduction: Helicobacter pylori (H. pylori) infection is a common chronic 
infection that is associated with upper gastrointestinal diseases. There are 
limited data from clinical trials comparing management strategies for pa-
tients with dyspepsia. Cost-eff ectiveness simulation models might help to 
identify optimal strategies and their cost-eff ectiveness.
Aims & Methods: To assess the cost-eff ectiveness of the H. pylori “Test 
and Treat” strategy, including the use of Urea Breath Test (UBT), versus 
symptomatic treatment and endoscopy fi rst-line strategy, in patients with 
dyspepsia from the Spanish healthcare system perspective. The models 
compared three strategies, namely “Test and Treat” strategy including the 
use of UBT, „Endoscopy and Treat strategy“ and „Symptomatic treatment 
strategy“. Data were derived from the European registry of H. pylori man-
agement and from the literature. Advanced simulations were conducted 
to assess cost, eff ectiveness and cost-eff ectiveness over (1) 4 weeks-time 
horizon for the eff ectiveness endpoint „Probability of dyspepsia symptoms 
relief“ and over (2) 10 years for two other eff ectiveness endpoints „Prob-
ability of gastric cancer avoided“ and „Probability of peptic ulcer avoided“. 
Probabilistic sensitivity analyses were carried out using Monte-Carlo sim-
ulations considering data distributions. Models were developed in accor-
dance with the routine Spanish medical practices and costs.
Results: Regarding the endpoint „Probability of dyspepsia symptoms re-
lief“, „Test and Treat“ was the most cost-eff ective strategy (883 € per suc-
cess) compared to „Endoscopy and Treat“ and to „Symptomatic treatment“ 
strategies (respectively 1,628€ and 990€ per success). Regarding the end-
point „Probability of gastric cancer „, the „Test and Treat“ was the most 
cost-eff ective strategy (524 € per gastric cancer avoided) compared to „En-
doscopy and Treat“ and „Symptomatic treatment“ strategies (respectively 
716€ and 696€ per gastric cancer avoided). For the endpoint „Probability of 
Peptic ulcer“, the „Test and Treat“ was also the most cost-eff ective strategy 
(421€ per peptic ulcer avoided) compared to „Endoscopy and Treat“ and 
„Symptomatic treatment“ strategies (respectively 728€ and 632€ per peptic 
ulcer avoided).
Conclusion: The “Test and Treat” strategy including the use of UBT is the 
most cost-eff ective medical approach for the management of dyspepsia. 
The results of this study should contribute to the increase of awareness 
about the usefulness of the “Test and Treat” strategy and concerning its 
benefi cial impact for patients with H. pylori-related diseases.
    mITT effi  cacy PP effi  cacy
  Duration (days)
N 
included
mITT 
(95% C.I.) N included
PP 
(95% C.I.)
Q-NBCT 10 2,142 86% (84-87%) 2,030 89% (87-90%)
  14 1,296 91% (89-92%) 1,248 92% (90-93%)
T-CA 10 1,978 82% (80-84%) 1,871 86% (84-87%)
  14 742 81% (78-83%) 675 87% (85-90%)
Q-SINGLE 10 721 86% (83-89%) 646 95% (93-97%)
Q-BCA 14 714 89% (86-91%) 669 94% (91-95%)
Q-NBST 10 231 78% (72-83%) 189 85% (79-90%)
[Table 1: E  cacy obtained by mITT and PP with the  ve more common 
treatments used as  rst-line regimens.]
Conclusion: In fi rst-line treatments, the best effi  cacy results were obtained 
with non-bismuth concomitant therapy and bismuth quadruple therapy 
containing clarithromycin and amoxicillin, both therapies used for 14 days, 
and the three-in-one single capsule, prescribed for 10 days.
Disclosure: Dr. Gisbert has served as a speaker, a consultant and advisory 
member for or has received research funding from Casen Recordati, Mayo-
ly, Allergan, Advia, Diasorin. Dr McNicholl has received retributions from 
Allergan and MSD for training activities, and he is an advisor for Mayoly. 
The remaining co-authors have no confl ict of interests to declare. 
OP066 H. PYLORI STATUS AND OLDER AGE IS MORE RELATED TO 
DECREASED PEPSINOGEN LEVEL COMPARED TO DIFFERENT DIETARY 
FACTORS
Aleksejeva J.1, Razuka-Ebela D.1, Daugule I.1, Polaka I.2, Parshutin S.2, 
Santare D.3, Ebela I.4, Murillo R.5, Herrero R.5, Park J.Y.5, Leja M.6
1University of Latvia, Faculty of Medicine, Riga, Latvia, 2University of Latvia, 
Institute of Clinical and Preventive Medicine, Riga, Latvia, 3Riga East 
University Hospital, Department of Science, Riga, Latvia, 4University of Latvia, 
Riga, Latvia, 5International Agency for Research on Cancer, Lyon, France, 
6University of Latvia, Digestive Diseases Centre Gastro, Riga, Latvia
Contact E-Mail Address: aleksejeva.jelizaveta@gmail.com
Introduction: Gastric cancer development is a multifactorial process infl u-
enced by Helicobacter pylori (H. pylori), genetics and environmental factors. 
Although there is strong evidence about the role of H. pylori and genetic 
factors in the development of gastric atrophy leading to gastric cancer, data 
about the infl uence of dietary factors on carcinogenesis remain controver-
sial. Minimally invasive way to evaluate possible gastric epithelial atrophy 
is to detect level of serum Pepsinogen (Pg) I and PgII, in particular - the 
ratio between PgI and PgII.
Aims & Methods: To analyze whether there is an association between de-
creased Pg level and diff erent dietary factors.
The study was performed within GISTAR pilot study analyzing the data of 
participants (aged 40 to 64) from the general population of Latvia from 
2013 until 2015. Participants completed a detailed questionnaire on per-
sonal characteristics and dietary habits and those who were allocated to 
the Intervention Group were tested for PgI and PgII by latex-agglutination 
test-system (Eiken Chemical, Tokyo, Japan), and H. pylori IgG group anti-
bodies by ELISA (Biohit, Finland). 
Gender, age (< 50 and ≥51 years), income (< 500 € vs. ≥500€), educational 
level (general secondary education and lower vs. professional technical 
education and higher), smoking (never vs. 100 cigarettes in the last 30 
days), the consumption frequency of diff erent products and alcohol was 
compared between participants with normal and decreased Pg level (PgI/
PgII ≤3 and PgI ≤70 ng/mL).). Statistical analyses included χ2 test and lo-
gistic regression analysis. Factors that showed association with decreased 
Pg level in univariate analysis (p< 0.09) were included in multiple logistic 
regression model adjusting for H. pylori status.
Results: In total, 1725 participants (mean age 51.62, SD± 6.741) were includ-
ed in the analysis. Decreased Pg level was identifi ed in 32.4% (559/1725) 
of individuals; it did not diff er between men and women (p=0.57) and was 
associated with age above 51 year (p< 0.001). In the univariate analysis 
decreased Pg level was inversely associated with the consumption (less 
than twice per month vs. more than once a week) of sour dairy products 
(OR 0.78; 95% CI 0.64-0.96, p=0.02), cheese and cheese products (OR 0.72; 
95% CI 0.54-0.97, p=0.03) and leek (OR 0.78; 95% CI 0.63-0.97, p=0.02). 
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Disclosure: This study was funded by Mayoly Spindler Laboratories. AGM 
has received honoraria from Allergan and Takeda for formative actions and 
is advisory board member for Mayoly Spindler; PM has received honoraria 
for consultancy from Alfasigma, Bayer Health Care, Biocodex, Danone, 
Mayoly Spindler and speaker honoraria from Bayer, Hexal/Sandoz, Sanofi , 
Takeda; FF has received honoraria for consultancy from Mayoly Spindler; 
FL and HS are employees of Mayoly Spindler; AB has received honoraria 
from Mayoly Spindler for data management and data analyses; JPG has 
received honoraria as a speaker, a consultant and advisory member for 
or has received research funding from Casen Recordati, Mayoly Spindler, 
Allergan, Advia, Diasorin. 
OP068 LEVOFLOXACIN SEQUENTIAL THERAPY VERSUS 
BISMUTH QUADRUPLE THERAPY IN THE SECOND-LINE AND 
THIRD-LINE TREATMENT OF HELICOBACTER PYLORI: 
A MULTICENTER RANDOMIZED TRIAL
Liou J.-M.1, Chen C.-C.1, Fang Y.-J.2, Lin J.-T.3, Wu M.-S.1, 
Taiwan Gastrointestinal Disease and Helicobacter Consortium
1National Taiwan University Hospital Dept. of Internal Medicine Taiwan 
Helicobacter Consortium, Dept. of Internal Medicine, Taipei, Taiwan, 
2National Taiwan University Hospital, Yun-Lin Branch, Taipei, Taiwan, 3Fu 
Jen Catholic University, School of Medicine, New Taipei City, Taiwan
Contact E-Mail Address: dtmed046@pchome.com.tw
Introduction: A recent systematic review and meta-analysis showed that 
the effi  cacy of levofl oxacin triple therapy was lower than 80% in the sec-
ond-line treatment for Helicobacter pylori (H. pylori). Our previous trial 
showed that levofl oxacin sequential therapy was superior to levofl oxacin 
triple therapy in the second-line treatment.
Aims & Methods: Therefore, we aimed tocompare the effi  cacy and safety 
of 14-day levofl oxacin sequential therapy versus 10-day bismuth quadruple 
therapy in the second-line treatment of H. pylori infection. H. pylori infected 
patients who failed aft er one treatment were eligible in this open labeled, 
multicenter, randomized trial, and were randomized to receive (1) levo-
fl oxacin sequential therapy (EAML): esomeprazole 40 mg and amoxicillin 
1 g for the fi rst 7 days, followed by esomeprazole 40 mg, metronidazole 
500 mg, and levofl oxacin 250 mg for another 7 days (all twice daily); or (2) 
bismuth quadruple therapy (BQ): esomeprazole 40mg twice daily, bismuth 
tripotassium dicitrate 300 mg four times a day, tetracycline 500mg four 
times a day, and metronidazole 500mg three times a day, for 10 days. The 
primary end point was the eradication rate in the second-line treatment 
according to intention to treat (ITT) analysis. The minimum inhibitory con-
centrations were determined by agar dilution test.
Results: A total of 560 patients have been recruited and results were avail-
able for analysis in 533 patients up to April 2019. The demographic charac-
teristics and antibiotic resistance rates were similar across the two treat-
ment groups. The eradication rate in the second line treatment were 88.3% 
(235/266) and 88.4% (236/267) in the levofl oxacin sequential therapy and 
bismuth quadruple therapy groups, respectively (p=1.000) in the ITT analy-
sis. The eradication rates were 89.7% (235/262) and 92.9% (236/254) in the 
levofl oxacin sequential therapy and bismuth quadruple therapy according 
to PP analyses, respectively (p=0.195). The effi  cacy of levofl oxacin sequen-
tial therapy, but not bismuth quadruple therapy, appeared to be aff ected 
by levofl oxacin resistance. The frequency of any adverse eff ects was higher 
in patients treated with bismuth quadruple therapy than levofl oxacin se-
quential therapy (76.4% vs. 44.1%, p< 0.001).
Conclusion: Levofl oxacin sequential therapy and bismuth quadruple ther-
apy are similarly eff ective in the second-line treatment for H. pylori infec-
tion. (Trial registration number: NCT NCT03148366).
References: 1. Chen PY, Wu MS, Chen CY, et al. Systematic review with 
meta-analysis: the effi  cacy of levofl oxacin triple therapy as the fi rst- or 
second-line treatments of Helicobacter pylori infection. Aliment Pharma-
col Ther 2016;44:427-37. 2. Liou JM, Bair MJ, Chen CC, et al. Levofl oxacin 
sequential therapy versus levofl oxacin triple therapy in the second line 
treatment of Helicobacter pylori: A randomized trial. Am J Gastroenterol 
2016; 111:381-7.
Disclosure: Nothing to disclose 
OP069 GASTRIC MICROBIOME ASSOCIATED WITH PROGRESSION 
OF GASTRIC INFLAMMATION, ATROPHY AND INTESTINAL 
METAPLASIA AFTER HELICOBACTER PYLORI ERADICATION
Sung J.J.Y.1, Coker O.O.1, Chu S.H.1, Yu J.2
1Chinese University of Hong Kong, Department of Medicine & Therapeutics, 
Hong Kong, China, 2Chinese University of Hong Kong, Department of 
Gastroenterology, Hong Kong, China
Contact E-Mail Address: jjysung@cuhk.edu.hk
Introduction: Infection with Helicobacter pylori is associated with gastric 
infl ammation and increases the risks for precancerous gastric atrophy (GA) 
and intestinal metaplasia (IM). Evidences however abound that these risks 
persist in some patients aft er H. pylorieradication.
Aims & Methods: We aimed to identify non-H. pylorigastric microbes that 
are associated with infl ammation, GA and IM post-treatment of H. pylori 
infection. Five hundred and eighty-seven H. pylori positive subjects resid-
ing in Yantai county of Shandong Province, China. A total of 295 received 
one-week course omeprazole, amoxicillin and clarithromycin (OAC) while 
292 received placebo. Subjects underwent endoscopy with biopsy at base-
line and aft er one year. Severity of infl ammation, GA and IM was graded 
according to the updated Sydney classifi cation. Progression and regression 
were defi ned as worsening or improvement, respectively, of infl ammation, 
GA or IM scores aft er one year. 
Analysis of 16S rRNA sequences was performed on a total of 404 gastric bi-
opsy samples, comprising of 102 pairs before and aft er successful H. pylori 
eradication by OAC treatment estimatedby negative rapid urease test and 
histology, and 100 pairs before and aft er placebo. Multiple linear regres-
sion, discriminant and microbial network analyses were used to identify 
microbes associated with infl ammation, GA and IM.
Results: Analysis of microbial sequences confi rmed the eradication of H. 
pyloriin OAC treated group (0.013 ±0.0018) compared to placebo group 
(0.67 ±0.028) (P< 0.00001). Principal component analysis revealed distinct 
microbial clusters and proliferation of a wide variety of bacterial species, 
refl ected by marked increase in bacterial diversity (P< 0.00001) aft er H. 
pylori eradication (Figure 1). 
Much less microbial co-occurrence was observed aft er H. pylori eradica-
tion, while microbial interactions remained largely unchanged before and 
aft er placebo treatment. In addition, without H. pylorire-infection, gastric 
infl ammation persisted in 16%, GA emerged in 33% and IM emerged in 
17% of patients one year following H. pylorieradication. 
A distinct cluster of oral bacterial genera comprising Peptostreptococcus,St
reptococcus, Parvimonas, Prevotellaand Porphyromonaswere observed to be 
associated with persistent or progressive GA and IM (P< 0.05)aft er H. pylori-
eradication.Streptococcus anginosus(P=0.012, R=0.3) and Ralstonia(P=0.02, 
R=0.25) were positively correlated with infl ammation scores and increased 
in patients with persistent infl ammation, suggesting their involvement in 
gastric infl ammation in the absence of H. pylori. 
Two probiotic bacterial species namely Roseburia inulinivorans(P=0.027) 
and Lactobacillus salivarius(P=0.04) were enriched in subjects whose gas-
tric infl ammation regressed following H. pylorieradication.
Conclusion: Oral bacterial genera Peptostreptococcus, Streptococcus, Par-
vimonas, Prevotellaand Porphyromonasare associated with the progression 
of gastric infl ammation, GA and IM following anti-H. pyloritherapy. Treat-
ment targeting these bacteria may be prescribed to patients to reduce the 
risk of developing into gastric cancer.
Disclosure: Nothing to disclose 
OP070 TIME LATENCIES OF RETREATMENT FOR HELICOBACTER 
PYLORI AND RISK OF UPPER GASTROINTESTINAL BLEEDING IN 
PATIENTS WHO FAILED INITIAL ERADICATION THERAPY
Leung W.K., Guo C.-G., Chen L., Cheung K.S.
University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong, 
China (SAR)
Contact E-Mail Address: waikleung@hku.hk
Introduction: Delays in primary eradication of H. pylori (HP) in patients 
newly diagnosed with peptic ulcer could result in higher risk of ulcer com-
plications. 
However, it remains unknown whether delays in retreatment of patients 
who failed initial HP eradication therapy would aff ect subsequent risk of 
upper gastrointestinal bleeding (UGIB).
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OP071 GENETIC STUDIES OF MRI LIVER IRON CONTENT IDENTIFIES 
LOCI REGULATING HEPCIDIN AND YIELD INSIGHTS INTO ITS LINK 
WITH HEPATIC AND EXTRAHEPATIC DISEASES
Parisinos C.1, Wilman H.R.2, Atabaki-Pasdar N.3, Kelly M.4, Thomas E.L.2, 
Naubauer S.5, Mahajan A.5, Hingorani A.D.1, Patel R.S.1, Hemingway H.1, 
Franks P.W.6, Bell J.D.2, Banerjee R.4, Yaghootkar H.7, IMI DIRECT
1UCL, London, United Kingdom, 2University of Westminster, London, United 
Kingdom, 3Skåne University Hospital, Malmo, Sweden, 4Perspectum 
Diagnostics, Oxford, United Kingdom, 5University of Oxford, Oxford, United 
Kingdom, 6Umea University, Umea, Sweden, 7University of Exeter, Exeter, 
United Kingdom
Contact E-Mail Address: c.parisinos@ucl.ac.uk
Introduction: Background and aims: Excess liver iron content is common, 
however its genetic background and link to hepatic and extrahepatic dis-
ease risk is unknown. We aimed to identify genetic variants infl uencing 
liver iron content and use genetics to understand its link to other traits 
and diseases.
Aims & Methods: First, we performed a genome-wide association study 
(GWAS) in 8,289 individuals in UK Biobank with MRI quantifi ed liver iron, 
and validated our fi ndings in an independent cohort (n=1,513 from IMI DI-
RECT). Second, we used Mendelian randomisation to test the causal eff ects 
of 29 predominantly metabolic traits on liver iron content. Third, we tested 
phenome-wide associations between liver iron variants and 770 anthropo-
metric traits and diseases.
Results: We identifi ed three independent genetic variants (rs1800562 
(C282Y) and rs1799945 (H63D) in HFE and rs855791 (V736A) in TMPRSS6) 
associated with liver iron content that reached the GWAS signifi cance 
threshold (p< 5x10-8). The two HFE variants account for ~85% of all cases 
of hereditary haemochromatosis. Mendelian randomisation analysis pro-
vided evidence that higher central obesity plays a causal role in increased 
liver iron content. 
Phenome-wide association analysis demonstrated shared aetiopathogenic 
mechanisms for elevated liver iron, high blood pressure, cirrhosis, ma-
lignancies, neuropsychiatric and rheumatological conditions, while also 
highlighting inverse associations with anaemias, lipidaemias and isch-
aemic heart disease.
Conclusion: Our study provides genetic evidence that mechanisms under-
lying higher liver iron content are likely systemic rather than organ spe-
cifi c, that higher central obesity is causally associated with higher liver 
iron, and that liver iron shares common aetiology with multiple metabolic 
and non-metabolic diseases.
Disclosure: Confl ict of Interest statement: M.K and R.B. are employees and 
shareholders of Perspectum Diagnostics. H.W. and S.N. are shareholders 
in Perspectum Diagnostics. No other potential confl icts of interest relevant 
to this article were reported. 
OP072 PORTAL ENDOTHELIAL DAMAGE IN CIRRHOSIS
Shalaby S.1, Campello E.2, Gavasso S.2, Gringeri E.3, D’Amico F.3, 
Cillo U.3, Barbiero G.4, Battistel M.4, Debora B.5, Romilda C.5, 
Zanetto A.1, Ferrarese A.1, Becchetti C.1, Sciarrone S.1, Pellone M.1, 
Gambato M.1, Germani G.1, Russo F.P.1, Burra P.1, Simioni P.2, Senzolo M.1
1Multivisceral Transplant Unit, Department of Surgery, Oncology and 
Gastroenterology, Padua University Hospital, Padua, Italy, 2Hemorrhagic 
and Thrombotic Diseases Unit, Department of Medicine (DIMED), 
University of Padua Medical School, Padua, Italy, 3Hepatobiliary Surgery 
and Liver Transplantation Unit, Department of Surgery, Oncology and 
Gastroenterology, Padua University Hospital, Padua, Italy, 4University 
Radiology, Department of Medicine, University Hospital of Padua, Padua, 
Italy, 5Padua University Hospital, Padua, Italy
Contact E-Mail Address: sarahshalaby18@gmail.com
Introduction: Cirrhotic patients show a systemic heparin-like eff ect at 
thromboelastometric tracing during infection or bleeding. Endotoxemia, 
shear stress and infl ammation may lead to endothelial damage and sub-
sequent release of endogenous heparinoids by disruption of glycocalyx. 
The endothelium of portal vein could be persistently damaged by portal 
Aims & Methods: We determined the risk of UGIB in patients who required 
retreatment for HP aft er failure of initial eradication therapy according to 
time latencies of retreatment. All HP-infected patients who had received 
the fi rst course of clarithromycin-containing triple therapy for HP between 
2003 and 2012 were identifi ed from the territory-wide electronic health 
database of the Hong Kong Hospital Authority. 
We excluded patients with prior GI cancers, surgical resection of the GI 
tract, bleeding tendency and esophageal varices. The primary outcome 
was hospitalization for non-variceal UGIB aft er the fi rst HP therapy. The 
follow-up period commenced from 60 days of the fi rst HP therapy until the 
occurrence of UGIB, death or the end of the study (30 Jun 2016). Patients 
were divided into diff erent groups according to time latencies between 
initial and fi nal HP eradication (< 3, 3-12 and >12 month). Those who did 
not require retreatment were included as reference. Covariates included 
baseline demographics, concurrent medical illnesses and medication 
uses. Time-dependent Cox proportional hazards model was used to adjust 
for confounders, in which all medications were included as time-varying 
variables. Sensitivity analyses were performed with propensity score (PS) 
matching in a ratio of 1:5 and excluding patients with baseline peptic ulcer 
or UGIB.
Results: 70,518 patients were included in this analysis (7,761 in the retreat-
ment group and 62,757 in the reference group). The median follow-up was 
7.75 years (interquartile range 5.3-10.4 years). The crude incidence rate 
of UGIB was 6.62 per 1000 person-year (95% CI 6.01-7.28) in the retreat-
ment group and 3.25 (95% CI 3.09-3.41) in the reference group. Compared 
to the reference group, patients who received retreatment have a higher 
risk of UGIB (adjusted hazards ratios [aHR] 1.90, 95% confi dence intervals 
[CI] 1.70-2.12; PS matching analysis HR 1.91, 95% CI 1.71-2.15). There was 
a progressive increase in risk of UGIB with longer latency intervals of re-
treatment (Table; aHR for < 3m: 1.17, 95% CI 0.98-1.40; 3-12m: 1.88, 95% CI 
1.48-2.39; >12m: 3.42 95% CI 2.92-3.99). Similar results were obtained with 
PS matching or aft er excluding patients with baseline peptic ulcer/GIB (HR 
2.01; 95% CI 1.72-2.36).
Conclusion: Patients who failed initial HP eradication had a 1.9-fold in-
crease in UGIB risk, which progressively increased with the time latencies 
of retreatment. Early retreatment within 3-month should be considered to 
minimize the risks of subsequent UGIB aft er failed HP eradication.
Disclosure: Nothing to disclose.
  Crude HR (95% CI)
Adjusted HR 
(95% CI)
PS matching HR 
(95%CI)
No retreatment 1.00 (reference)
All retreatment 
groups 2.10 (1.84-2.28) 1.90 (1.70-2.12) 1.91 (1.71-2.15)
<3 month 1.67 (1.40-1.98) 1.17 (0.98-1.40) 1.57 (1.31-1.87)
3-12 month 1.86 (1.47-2.35) 1.88 (1.48-2.39) 1.74 (1.37-2.21)
>12 month 2.56 (2.21-2.97) 3.42 (2.92-3.99) 2.39 (2.05-2.78)
[Risk of UGIB with di erent latency intervals between the  rst and last HP 
eradication therapies]
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hypertension, and this could correlate with the high incidence of portal 
vein thrombosis in cirrhosis. Data regarding heparin-like eff ect in the por-
tal venous system are lacking.
Aims & Methods: We consecutively enrolled adult cirrhotic patients under-
going liver transplantation (LT) or transjugular-intrahepatic-portosystem-
ic-shunt(TIPS). Rotational-thrombelastometry(ROTEM) along with evalua-
tion of endothelial dysfunction by quantifi cation of circulating endothelial-
microparticles (MP), and endotoxemia (LPS) were performed on citrated 
peripheral and portal venous blood samples of all enrolled patients.
Results: Forty-one cirrhotics (16 LT and 25 TIPS) were enrolled. ROTEM-
analysis showed similar coagulative-assets in portal blood of cirrhotic pa-
tients compared to their own peripheral blood. However, we highlighted 
the presence of a heparin-like eff ect in portal blood by heparinase ad-
dition to native test (median ɑ angle NATEM 51° (46-57) vs HEPTEM me-
dian 57° (50-59), p=0.05; median CT NATEM 678sec (576-785) vs HEPTEM 
596sec (560-651), p=0.026), which was not detected in peripheral blood 
(median angle ɑ NATEM 53° (48-58) vs HEPTEM 53° (46-63), p=0.9; medi-
an CT NATEM 782sec (560-832) vs HEPTEM 623sec (536-741), p=0.2). Addi-
tionally, an increased concentration of endothelial-MP (CD62E-MP median 
1607MP/µL (680-1885) vs 1391MP/µL (651-2031), p=0.09) and endotoxemia 
(LPS median 182.95pg/mL (149-300) vs 160.25pg/mL (103-243), p=0.005) 
were detected.
Conclusion: The detected heparin-like eff ect, supported by the increased 
levels of endotoxemia and the MP-asset could be indirect hematic signs 
of a higher local endothelial damage in cirrhotics portal vein, caused by 
portal hypertension. Portal site-specifi c endothelial damage could hamper 
its antithrombotic properties and may be an important local risk factor in 
the pathogenesis of PVT along with the already documented venous stasis.
Disclosure: Nothing to disclose 
OP073 THE EFFECT OF ESCHERICHIA COLI NF73 ON LIVER 
TRIGLYCERIDE IN NON-ALCOHOLIC FATTY LIVER DISEASE MICE 
AND THE POTENTIAL MOLECULAR MECHANISM
Zhang Y.1,2, Wang Y.1,2, Xu J.1,2,3, Wang T.1,2, Liu Y.1,2
1Peking University People’s Hospital, Department of Gastroenterology, 
Beijing, China, 2Peking University People’s Hospital, Clinical Center of 
Immune-Mediated Digestive Diseases, Beijing, China, 3Peking University 
People’s Hospital, Institute of Clinical Molecular Biology & Central 
Laboratory, Beijing, China
Contact E-Mail Address: yifanzhang@bjmu.edu.cn
Introduction: In our previous research, we isolated Escherichia coli patho-
gens NF73 (patent application NO. 201610591293.4) from the intestinal mu-
cosa of a non-alcoholic steatohepatitis (NASH) patient, and demonstrated 
that Escherichia coli NF73 increased hepatic damage in high fat diet (HFD) 
induced non-alcoholic fatty liver disease(NAFLD) mice. In this study, we 
aimed to investigate the eff ect of Escherichia coli NF73 upon hepatic triglyc-
eride metabolism and the potential molecular mechanism.
Aims & Methods: All male C57BL/6J mice (6 weeks of age) were randomly 
divided into normal group and fl ora-defi cient group, and were fed with 
HFD for 16 weeks. In the 8thweek, mice in fl ora-defi cient group were treat-
ed with a cocktail of broad-spectrum antibiotics (including ampicillin, 
vancomycin, neomycin and metronidazole) in drinking water for 2 weeks 
to diminish the intestinal bacteria, while the normal group received ster-
ile tap water. Aft er 10 weeks, both groups were further divided as HFD 
group, Escherichia coli NF73 group and Escherichia coli MG1655 group, 
treated intragastrically by Luria-Bertani (LB) medium, 1*108cfu Esherichia 
coli NF73, 1*108cfu Esherichia coli MG1655 (control bacteria) every day, 
respectively. Hepatic lipid depositions were detected by HE and oil red O 
staining. Lipid synthesis related protein expressions were determined by 
Western Blot.
Results: Escherichia coli NF73 administration induced more severe hepatic 
steatosis in normal and fl ora-defi cient mice. Notably, Escherichia coli NF73-
treated mice had higher triglyceride level, and more signifi cant liver lipid 
deposition than mice in Escherichia coli MG1655 and HFD control groups. 
It was found that Escherichia coli NF73 increased liver triglyceride levels by 
upregulating SREBP-1c expression and transcriptional activity of genes in-
volved in hepatic fatty acid synthesis (FASN, ACC). Meanwhile, Escherichia 
coli NF73 enhanced the expression of PI3K, p-AKT, mTOR and p-mTOR. The 
results indicated that Escherichia coli NF73 promoted hepatic triglyceride 
accumulation via upregulating SREBP-1c expression through the PI3K-
AKT-mTOR pathway.
Conclusion: Triglyceride accumulation induced by Escherichia coli NF73 
plays a key role in the pathological process of hepatic damage. Therefore, 
intestinal mucosal-adherent Escherichia coli NF73 might be a critical trig-
ger in the progression of NAFLD to NASH.
Disclosure: Nothing to disclose 
OP074 NOVEL CLINICAL AND GENETIC RISK FACTORS FOR EARLY 
POST-OPERATIVE THROMBOSIS IN LIVER TRANSPLANTATION
Li Y.1, Nieuwenhuis L.2, Voskuil M.1, Gacesa R.1, Hu S.1, Jansen B.1, 
Werner M.2, Blokzijl H.1, Hepkema B.3, Lisman T.2, Weersma R.K.1, 
Porte R.2, Festen E.1,4, de Meijer V.2
1University Medical Center Groningen, Department of Gastroenterology and 
Hepatology, Groningen, Netherlands, 2University Medical Center Groningen, 
Department of Hepatobiliary Surgery and Liver Transplantation, Groningen, 
Netherlands, 3University Medical Center Groningen, Department of 
Immunology, Groningen, Netherlands, 4University Medical Center Groningen, 
Department of Genetics, Groningen, Netherlands
Contact E-Mail Address: yanni19907300@gmail.com
Introduction: Post-operative thrombosis (PT) is one of the leading causes 
of graft  loss and mortality aft er liver transplantation (LT), and is associ-
ated with a plethora of donor, recipient and transplant-related risk factors. 
While clinical risk factors can largely be accounted for, better knowledge 
of genetic risk factors for PT is essential for developing targeted strategies 
to improve graft  survival.
Aims & Methods: A post-hoc analysis of a prospective cohort (www.tri-
alregister.nl - Trial NL6334) of LT recipients between 1993-2017 was per-
formed. Upon availability, donor and recipient DNA were genotyped with 
the Illumina Global Screening Array. Risk factors for early PT (< 90 days) 
were analyzed in univariate and multivariate logistic regression models. To 
study genetic risk factors for PT, we performed genome-wide association 
(GWA) analysis.
Results: A total of 1099 recipients underwent 1337 LT procedures. Only 
primary adult LT (748 [55.9%]) were included in subsequent analyses. 
Multivariate regression analyses demonstrated that smoking status of the 
donor (OR=2.505 [1.288-4.871]; P=0.007), and nonalcoholic steatohepati-
tis (NASH) in the recipient (OR=2.343 [1.057-5.193]; P=0.036) were inde-
pendent clinical risk factors for early PT. Using GWA analysis with donor 
genotypes, we identifi ed 42 genetic loci associated with increased risk of 
PT at a suggestive genome-wide signifi cance threshold (P< 5x10-05). One 
of these variants (rs1336472 [P=1.2x10-05 OR=1.84]), in a locus harboring the 
AK4 gene, has been reported as a risk variant for venous thromboembo-
lism, outside the context of LT.
Conclusion: We identifi ed donor smoking status and NASH in the recipient 
as novel clinical risk factors for early PT. Moreover, we observed that ge-
netic variation within the donor infl uences risk for early PT. These prelimi-
nary results warrant further investigation into the contribution of donor 
genetic risk factors for early PT.
Disclosure: Nothing to disclose 
OP075 ANALYSIS OF GASTROINTESTINAL SYMPTOMS, DIAGNOSTIC 
PATTERNS, AND PROVIDER PERSPECTIVE OF ACUTE HEPATIC 
PORPHYRIA AMONG EU-5 COUNTRIES
Salameh J.1, Meninger S.1, Lyn N.1, Murray S.1, Karki C.2, Krautwurst K.2, 
Mustafi na R.2, Ko J.1
1Alnylam Pharmaceuticals, Cambridge, United States, 2Ipsos LLC, Parsippany, 
United States
Contact E-Mail Address: jsalameh@alnylam.com
Introduction: Acute hepatic porphyria (AHP) is a family of rare genetic dis-
eases, the most common being acute intermittent porphyria (AIP). AHP re-
sults from enzyme defi ciencies involved in haem synthesis, leading to ac-
cumulation of neurotoxic haem intermediates, aminolaevulinic acid (ALA) 
and porphobilinogen (PBG), causing potentially life-threatening attacks 
and chronic symptoms. Patients affl  icted by AHP oft en remain without a 
proper diagnosis for up to 15 years due to lack of awareness and testing. 
First-line diagnostic biochemical tests include measuring spot urinary ALA 
and PBG as both are elevated in the majority of AHP patients.
Aims & Methods: The study aimed to describe gastroenterologists’ experi-
ence diagnosing AHP and characterize patients from the United Kingdom, 
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jaundice or biliary tract infection. EBD detachment during CS treatment 
was seen in 11 patients (45.8%) and was likely to occur from 2-3 weeks af-
ter CS initiation. 7 patients who had obstructive jaundice with serum total 
bilirubin levels more than 3.0 mg/dL were treated with CS alone without 
EBD and all of them achieved clinical improvement free from biliary tract 
infection. All the 3 patients who developed bile duct stones were treated 
with EBD. The development of bile duct cancer in ISC patients did not occur 
during follow-up.
Conclusion: EBD removal should be carried out within 2-3 weeks aft er CS 
initiation to prevent EBD detachment in ISC patients who achieved clinical 
remission by CS treatment. Obstructive jaundice due to biliary stricture can 
safely be treated with CS alone without EBD. We should be careful about 
the long-term management of ISC since bile duct stones are likely to occur 
in patients treated with EBD.
Disclosure: Nothing to disclose 
Update in cholangiocarcinoma
14:00-15:30 / E1
OP077 ENDOTHERAPY IN PATIENTS WITH PRIMARY SCLEROSING 
CHOLANGITIS: OVER 30 YEARS’ EXPERIENCE
Bove V.1,2, Molinario F.3, Tringali A.2,4, Boskoski I.2,4, Familiari P.2,4, 
Landi R.2,4, Barbaro F.2,4, Perri V.2,4, Costamagna G.2,4
1Fondazione Policlinico Universitario A. Gemelli, IRCCS, Unità Operativa 
Complessa di Endoscopia Digestiva Chirurgica, Dipartimento Scienze 
Gastroenterologiche, Endocrino-Metaboliche e Nefro-Urologiche, Roma, 
Italy, 2Università Cattolica del Sacro Cuore, CERTT - Centre for Endoscopic 
Research Therapeutics and Training, Rome, Italy, 3Federico II University, 
Gastroeterology Department, Naples, Italy, 4Fondazione Policlinico 
Universitario A. Gemelli, Roma, Italia - IRCCS, Unità Operativa Complessa di 
Endoscopia Digestiva Chirurgica. Dipartimento Scienze Gastroenterologiche, 
Endocrino-Metaboliche e Nefro-Urologiche., Roma, Italy
Contact E-Mail Address: vinbove@alice.it
Introduction: Primary Sclerosing Cholangitis (PSC) is a chronic cholestatic 
liver disease characterized by infl ammation and periductal fi brosis of the 
intrahepatic and/or extrahepatic bile ducts. Endoscopic dilation of symp-
tomatic dominant biliary strictures is a temporary therapeutic option in 
these patients frequently candidate to liver transplantation. Our experience 
over a 30-years period is reported.
Aims & Methods: Between March 1984 and April 2019, 73 patients with PSC 
(46 Males, mean age 46 ± 18 years) were identifi ed from a prospectively 
collected database. Indications for endoscopic drainage were the presence 
of symptomatic “dominant” biliary strictures located at the common bile 
duct or main hepatic confl uence. Strictures were dilated with balloon and/
or temporary plastic stents insertion. Brush cytology of dominant strictures 
was performed in patients with new onset or worsening strictures. When 
MRC was not routinely available, abdominal US and/or CT-Scan were per-
formed before ERCP.
Results: Indications for ERCP were: cholangitis (n=28, 38.3%), anicteric 
cholestasis and pruritus (n=18, 24.6%) and jaundice (n=27, 36.9%). Bile 
ducts morphology was assessed by MRC in 51 cases (69%) before ERCP.
A total of 161 ERCPs were performed in 73 pts [mean 4.3 (range 1-13)]. 
Results are summarized in table I.
One patient (0.6%) developed severe post-ERCP pancreatitis that resolved 
aft er surgical treatment.
Cholangitis recurrence requiring re-treatment occurred aft er a mean of 
28.2 months aft er stents removal and 16.6 months aft er balloon dilation.
Brush cytology was performed in 42 patients (57.5%): 4 patients (5.4 %) 
resulted positive for high grade dysplasia, 1 patient (1.3 %) for carcinoma.
A mean follow-up of 7.4 years (range 0.2-21.7) is available in 46 patients 
(63%): 29 patients (63%) had no further episodes of cholangitis, 7 (15.2%) 
underwent OLT, 3 (6.5%) died for cholangiocarcinoma, 6 (13%) died for 
unrelated other disease, 1 (2.2%) had an incidental fi nding during laparo-
scopic cholecystectomy of gallbladder cancer and is still alive.
Conclusion: According to our experience endotherapy of dominant biliary 
strictures secondary to PSC is eff ective in the long term-follow-up and can 
delay liver transplantation. Early diagnosis of cholangiocarcinoma in PSC 
is still an unsolved issue. 
Disclosure: Nothing to disclose 
France, Italy, Germany, and Spain (EU-5).EU-5 physicians (n=100) who ac-
tively managed AHP patients (with and without recurrent attacks) in the 
preceding year were recruited from 9/2017-10/2017 to complete an online 
survey collecting information on demographics, familiarity with AHP and 
diagnostic tests, perspective on symptoms important to diagnosis, referral 
patterns, and treatment preferences. Physicians also completed a chart 
review of 304 patients and reported anonymized data on demographics, 
medical history, attacks and symptoms. Data was analysed using descrip-
tive statistics.
Results: Physicians practiced a mean of 19 years, 65% worked in academic 
settings, and 19% were gastroenterologists. Gastrointestinal symptoms 
leading to AHP diagnosis included abdominal pain (88%), vomiting (63%), 
fatigue (55%), nausea (54%), weight loss (43%), and constipation (37%).
Patients were aged 40 years (mean), female (52%), with AIP (83%). AHP 
diagnostic tests gastroenterologists considered informative for diagnosis 
included urinary PBG (59) and ALA (71%); however, several non-specifi c 
tests were also commonly considered informative of AHP. For most patients 
(68%), diagnoses were assessed as uncertain (41%) or incorrect (27%). 
Misdiagnoses included non-specifi c abdominal pain (49%), irritable bow-
el syndrome (47%), Crohn’s disease (28%), diverticulitis (26%), appen-
dicitis (21%), lead poisoning (19%), and gastroesophageal refl ux disease 
(GERD) (19%). Patients had a mean of 1.9 attacks and 1.1 hospitalizations 
in the past year. Chronic symptoms included pain (60%), weakness (59%), 
fatigue (57%), anxiety (50%), nausea/vomiting (49%), constipation (39%), 
diarrhea (36%).
Conclusion: This study highlights the challenges diagnosing AHP due to 
non-specifi city of symptoms and limited understanding of diagnostic pro-
cedures. Due to the frequent presentation of gastrointestinal symptoms, 
AHP should be included in gastroenterologists’ diff erential diagnosis of 
patients presenting with non-specifi c abdominal pain. Among patients 
diagnosed with AHP, both acute attacks and chronic symptoms were re-
ported, implicating both in the disease.
Disclosure: Joseph Salameh, Sarah Murray, and John Ko are full time em-
ployees and stock holders in Alnylam Pharmaceuticals. Stephen Meninger 
and Nicole Lyn are contractors for Alnylam Pharmaceuticals. Chitra Karki, 
Katherine Krautwurst, and Renata Mustafi na are full time employees of 
Ipsos LLC. 
OP076 THE MANAGEMENT OF BILIARY STRICTURE IN IGG4-
RELATED SCLEROSING CHOLANGITIS
Miyazawa M.1, Takatori H.1, Asahina Y.1, Hayashi T.1, Kitamura K.1, 
Matsuda K.2, Inamura K.3, Komura T.4, Fuchizaki U.5, Mizukoshi E.1, 
Kaneko S.1
1Kanazawa University, Gastroenterology, Kanazawa, Japan, 2Toyama 
Prefectural Central Hospital, Internal Medicine, Toyama, Japan, 3Tonami 
General Hospital, Internal Medicine, Tonami, Japan, 4National Hospital 
Organization Kanazawa Medical Center, Gastroenterology, Kanazawa, Japan, 
5Keiju Medical Center, Gastroenterology, Nanao, Japan
Contact E-Mail Address: miyacchi_1985@yahoo.co.jp
Introduction: Although endoscopic biliary drainage (EBD) and corticoste-
roid (CS) therapy are important for the treatment of biliary stricture in 
IgG4-related sclerosing cholangitis (ISC), clinical evidences about short 
and long-term prognosis and the risk of biliary tract complications in ISC 
are still insuffi  cient. This research aimed to elucidate the appropriate way 
to manage biliary stricture in ISC.
Aims & Methods: The study enrolled ISC patients diagnosed in our hospital 
or its affi  liated institutes from January 2007 to December 2017. We reviewed 
medical records of ISC patients, such as clinical characteristics, and the 
way of treatment with EBD and/or CS. The appropriate duration of EBD 
for preventing detachment of a biliary stent was assessed. We verifi ed the 
safety of treatment with CS alone without EBD for patients with obstructive 
jaundice. We also compared the rate of biliary tract complications between 
groups treated with and without EBD.
Results: A total of 70 ISC patients with the mean age of 66.9 years were 
enrolled. The median follow-up period was 64.5 months. Autoimmune 
pancreatitis was concurrent in 98.4% and extrapancreatic biliary stric-
ture was seen in 21.9%. 64 patients (91.4%) were treated with CS and 24 
(34.3%) underwent EBD. Scheduled EBD removal aft er clinical remission 
of ISC by CS treatment was carried out in 11 patients (45.8%). 9 (81.8%) of 
11 patients underwent EBD removal within a month aft er CS initiation, all 
of which were safely carried out without early recurrence of obstructive 
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  N %
ERCP failure 2 1.24
Site of “dominant” biliary strictures    
Common bile duct 51 31.6
Hilum / intrahepatic ducts 67 41.6
Common bile duct + hilum 31 19.2
No dominant strictures / presence of 
common bile duct stones
10 6.2
Therapeutic procedures    
Balloon dilation (diameter 4-10 mm) 71 44.1
Single plastic stent 15 9.3
Multiple plastic stents (range 2 - 7) 19 10.6
Naso-biliary drains 131 81.3
[Table I. Results from 161 ERCPs in 73 patients with Primary Sclerosing 
Cholangitis.]
OP078 THE ROLE OF “ROSE” FOR ERCP-GUIDED BRUSHING ON 
INDETERMINATE BILIARY STRICTURES: EXPERIENCE OF A REFERRAL 
CENTER
Archibugi L.1, Mariani A.2, Ciambriello B.3, Zaccari P.4, Petrone M.C.5, 
Rossi G.6, Testoni S.G.G.7, Capurso G.8, Arcidiacono P.G.9
1Hospital San Ra aele, Pancreato-Biliary Endoscopy and Endosonography 
Division, Milan, Italy, 2San Ra aele Hospital, Dept. of Gastroenterology, 
Milano, Italy, 3Digestive Endoscopy AO Specialistica Dei Colli CTO, Naples, 
Italy, 4Policlinico Umberto I Sapienza University of Rome, Rome, Italy, 
5Vita-Salute San Ra aele University, Pancreato-Biliary Endoscopy and 
Endosonography Division, Milan, Italy, 6Pancreas Translational and Clinical 
Research Center, San Ra aele Scienti c Institute IRCCS, Vita S, Pancreato-
Biliary Endoscopy and Endosonography Division, Milano, Italy, 7Division 
of Gastroenterology and Gastrointestinal Endoscopy, Vita-Salute San 
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Translational & Clinical Research Center, Rome, Italy, 9Ospedale San Ra aele, 
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Contact E-Mail Address: livia.archibugi@hotmail.it
Introduction: Endoscopic Retrograde CholangioPancreatography (ERCP), 
although nowadays used only for therapeutic purposes, still has a promi-
nent diagnostic role in patients with indeterminate biliary strictures and 
no evidence of mass lesion at EUS or CT scan. The use of biliary stricture 
brushing is a safe, easy, cheap and fast way to acquire cytological speci-
men from the determination of the etiology, but the sensitivity can be as 
low as 50%. Rapid On-Site Evaluation (ROSE) of the sample has been 
used for years in referral centers for the determination of the adequacy 
of EUS-guided FNA cytological specimens, improving its sensitivity and 
specifi city. Nevertheless, there are currently no studies evaluating its role 
for ERCP brushing.
Aims & Methods: The aim of this study was to assess the diagnostic yield 
of ERCP brushing of indeterminate biliary strictures when supported by 
ROSE.
We conducted a retrospective single center study enrolling consecutive 
patients undergoing ERCP and brush cytology supported by ROSE for in-
determinate biliary strictures, including patients from January 1st 2010 to 
May 31st 2018. Data recorded included patient’s characteristics, clinical/
radiological and EUS features, ERCP features including stricture features, 
number of passages performed with the brush, fi nal cytology or histol-
ogy when biopsy was performed as an adjunct, use of cholangioscopy or 
confocal laser endomicroscopy, fi nal diagnosis aft er surgery or follow-up 
when the patient would not undergo a resection. The diagnostic yield of 
ERCP-guided brushing with ROSE was then calculated.
Results: 96 patients underwent ERCP for indeterminate biliary stenosis, 
with 50% being males, mean age 68.1 years, 80% having an extrahepatic 
biliary stricture. 90 patients underwent brushing with ROSE and were in-
cluded in the analysis, with 86.7% of patients having an adequate sample 
at ROSE. The preliminary diagnostic yield calculated showed a sensitivity 
of 80%, a specifi city of 82%, an accuracy of 81%, a positive predictive 
value of 92% and a negative predictive value of 61%.
Conclusion: The availability of ROSE in patients undergoing ERCP with 
indeterminate biliary stricture without a mass lesion increases the diag-
nostic yield of brushing, decreasing the need of further procedures, such 
as cholangioscopy and confocal laser endomicroscopy and can, therefore, 
decrease costs and increase safety.
Disclosure: Nothing to disclose 
Brave new world: Neurons vs. neuronal 
network
14:00-15:30 / Barcelona
OP079 APPLICATION OF CONVOLUTIONAL NEURAL NETWORK 
IN THE DIAGNOSIS OF THE INVASION DEPTH OF GASTRIC CANCER 
BASED ON CONVENTIONAL ENDOSCOPY
Zhu Y.1, Zhou P.-H.2, Li Q.-L.3, Wang Q.-C.4
1Zhongshan Hospital, Endoscopy Center and Endoscopy Research Institute, 
Shanghai, China, 2Endoscopy Center and Endoscopy Research Institute, 
Zhongshan Hospital, Fudan University - Zhongshan, Zhongshan Hospital, 
Shanghai, China, 3Zhongshan Hospital, Fudan University, Endoscopy Center, 
Zhongshan Hospital, Fudan University, Shanghai, China, 4University of 
California, Department of Computer Science, Irvine, China
Contact E-Mail Address: zhuyan1992521@163.com
Introduction: According to guidelines, endoscopic resection should only 
be performed for patients whose early gastric cancer invasion depth is 
within the mucosa or submucosa of the stomach regardless of lymph node 
involvement. The accurate prediction of invasion depth based on endo-
scopic images is crucial for screening patients for endoscopic resection. 
The recent fi ndings suggest that the deep learning of endoscopic images 
by convolutional neural networks (CNN) can have clinical applications. In 
particular, we suspected that a CNN might be eff ective in determining the 
invasion depth of gastric cancer and thus could be used to screen patients 
for endoscopic resection. To evaluate the ability of a CNN to determine gas-
tric cancer invasion depth, we constructed a convolutional neural network 
computer-aided detection (CNN-CAD) system based on endoscopic images 
to determine invasion depth and screen patients for endoscopic resection.
Aims & Methods: We constructed a convolutional neural network com-
puter-aided detection (CNN-CAD) system based on endoscopic images to 
determine invasion depth and screen patients for endoscopic resection. 
Endoscopic images of gastric cancer tumors were obtained from the En-
doscopy Center of Zhongshan Hospital. An artifi cial intelligence-based 
CNN-CAD system was developed through transfer learning leveraging a 
state-of-the-art pretrained CNN architecture, ResNet50. A total of 790 im-
ages served as a development dataset and another 203 images as a test 
dataset. We used the CNN-CAD system to determine the invasion depth of 
gastric cancer and evaluated the system´s classifi cation accuracy by cal-
culating its sensitivity, specifi city, and area under the receiver operating 
characteristic curve.
Results: The area under the receiver operating characteristic curve for 
the CNN-CAD system was .94 (95% confi dence interval [CI], .90-.97). At 
a threshold value of .5, sensitivity was 76.47%, and specifi city 95.56%. 
Overall accuracy was 89.16%. Positive and negative predictive values were 
89.66% and 88.97%, respectively. The CNN-CAD system achieved signifi -
cantly higher accuracy (by 17.25%; 95% CI, 11.63-22.59) and specifi city (by 
32.21%; 95% CI, 26.78-37.44) than human endoscopists.
Conclusion: We constructed a CNN-CAD system to determine the invasion 
depth of gastric cancer with high accuracy and specifi city. This system 
distinguished early gastric cancer from deeper submucosal invasion and 
minimized overestimation of invasion depth, which could reduce unneces-
sary gastrectomy.
Disclosure: Nothing to disclose 
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OP081 APPLICATION OF ARTIFICIAL INTELLIGENCE USING A 
CONVOLUTIONAL NEURAL NETWORK FOR DIAGNOSIS OF EARLY 
GASTRIC CANCER BY MAGNIFYING ENDOSCOPY WITH NARROW-
BAND IMAGING
Ueyama H.1, Nagahara A.1, Abe D.1, Oki S.1, Suzuki N.1, Ikeda A.1, 
Yatagai N.1, Akazawa Y.1, Komori H.1, Izumi K.1, Takeda T.1, Matsumoto K.1, 
Ueda K.1, Matsumoto K.1, Asaoka D.1, Hojo M.1, Yao T.2, Tada T.3
1Juntendo University School of Medicine, Department of Gastroenterology, 
Tokyo, Japan, 2Juntendo University Graduate School of Medicine, 
Department of Human Pathology, Tokyo, Japan, 3Tada Tomohiro Institute of 
Gastroproctcology, Gastroenterology, Saitama, Japan
Contact E-Mail Address: psyro@juntendo.ac.jp
Introduction: As many reports have indicated the usefulness of magnify-
ing endoscopy with narrow-band imaging (ME-NBI) for diagnosing gastric 
cancer, the magnifying endoscopy simple diagnostic algorithm for early 
gastric cancer (MESDA-G) has been proposed as a new uniform diagnostic 
system for gastric cancer by means of ME-NBI in Japan. However, although 
ME-NBI is thought to have made a huge contribution to clinical practice, 
acquiring skill at ME-NBI diagnosis using MESDA-G requires substantial 
eff ort. Recently, there has been remarkable progress in artificial intelli-
gence (AI) using deep learning and convolutional neural networks (CNNs) 
in various medical fields for diagnostic imaging. However, no reports have 
assessed the usefulness of AI using CNNs for diagnosis of early gastric 
cancer (EGC) by ME-NBI.
Aims & Methods: We aimed to develop an AI-assisted diagnostic system 
of EGC using ME-NBI images and evaluate the diagnostic accuracy of the 
AI system in diagnosing EGC. From the 745 lesions of EGC resected by 
endoscopic procedures at our hospital between April 2013 and March 
2018, 5,227 ME-NBI images using the water immersion technique at the 
maximum magnifi cation that had suffi  cient quality to permit diagnosis by 
MESDA-G were collected. ME-NBI images of gastric adenocarcinoma of 
fundic gland type and diff use-type EGC were excluded, since the diagnostic 
yield was unclear in MESDA-G. Additionally, 2,592 ME-NBI images of non-
cancerous mucosa or non-cancerous lesions that were obtained under 
the same conditions were collected. A CNN-based diagnostic system was 
pre-trained and fi ne-tuned on a dataset of 5,574 ME-NBI images (3,797 
EGCs, 1,777 non-cancerous mucosa or lesions). To evaluate the diagnostic 
accuracy, a separate test data set of 2,245 ME-NBI images (1430 EGCs, 815 
non-cancerous mucosa or lesions) was applied to the constructed CNN.
Results: The CNN required 60 s to analyze 2,245 test images. The over-
all accuracy, sensitivity, specifi city, positive predictive value and negative 
predictive value of the CNN were 98.7%, 98%, 100%, 100% and 96.6%, 
respectively. All missed images of EGCs were superfi cially depressed and 
intestinal-type intramucosal cancers that were diffi  cult to distinguish from 
gastritis even by experienced endoscopists.
Conclusion: The constructed CNN system for diagnosis of EGC could process 
many stored ME-NBI images in a short period of time and had clinically 
high diagnostic ability. A more advanced system will be developed by add-
ing the EGC images of cases that could not be diagnosed by MESDA-G and 
images of a wide variety of non-cancerous mucosa and non-cancerous 
lesions. This AI-assisted diagnostic system of EGC using ME-NBI images 
may be able to reduce the burden of endoscopists.
References: Hirasawa T et al. Application of artifi cial intelligence using a 
convolutional neural network for detecting gastric cancer in endoscopic 
images. Gastric Cancer. 2018. Shichijo S et al. Application of convolutional 
neural networks for evaluating Helicobacter pylori infection status on the 
basis of endoscopic images. Scand J Gastroenterol. 2019
Disclosure: Nothing to disclose 
OP080 NEURAL NETWORK SYSTEM FOR IDENTIFYING UPPER-
GASTROINTESTINAL ORGANS IN ENDOSCOPIC IMAGES
Igarashi S.1, Sasaki Y.2, Tatsuta T.1, Kikuchi H.1, Sawaya M.1, Chinda D.1, 
Sakuraba H.1, Mikami T.3, Matsuzaka M.2, Tanaka R.2, Fukuda S.1
1Hirosaki University, Gastroenterology and Hematology, Hirosaki, Japan, 
2Hirosaki University, Medical Informatics, Hirosaki, Japan, 3Hirosaki 
University Hospital, Division of Endoscopy, Hirosaki, Japan
Contact E-Mail Address: s.igarashi@hirosaki-u.ac.jp
Introduction: Neural networks(NNs) is the mathematical model which imi-
tates principle of action of human’s neuron in the brain. Recently, NNs is 
used for classifying images in various fi elds of medicine, for example, skin 
cancer classifi cation, diabetic retinopathy, and gastro-intestinal endosco-
pies. Image recognition using NNs has been applied for the automated 
detection of gastric cancer during gastrointestinal endoscopies.
Aims & Methods: While developing NNs system, it is necessary to conduct 
data cleansing and classify several endoscopic images to form a training 
dataset, which is time-consuming. Therefore, this study aims to develop 
an automated system for classifying the upper-gastrointestinal organs in 
large sets of endoscopic images captured under various imaging condi-
tions. For this purpose, we have developed a ten-layer NNs system. The 
NNs architecture comprises a 1530-dimensional input layer followed by 
nine fully connected affi  ne layers with batch normalization to facilitate 
training and a rectifi ed linear unit for activation. The color histogram (255 
× 3) and the spatial gradient histogram(255 × 3) obtained by Scharr edge 
fi ltering were utilized as the input layer. The training dataset comprised 
52,390 anonymized images collected from patients with gastric cancer who 
underwent upper-gastrointestinal endoscopies in our institution during 
2017/01/01 to 2017/12/31. 
A total of 35,537 cleansed upper-gastrointestinal endoscopic images (i.e., 
the training data) were manually classifi ed as white-light (WL) stomach 
(15,075), WL esophagus (1,573), WL duodenum (1,673), WL stomach with 
local indigo carmine (IC) (5,823), WL esophagus with IC (379), narrow band 
(NB) imaging stomach (7,194), and NB imaging esophagus (2,309). These 
datasets were selected by the following criteria. 1)they must include a visu-
ally identifi able each organs, esophagus, stomach, and duodenum without 
excessive blur. 2)the area of halation(blackout) must be less than 50% of 
the eff ective pixels. 3)no treatment devices should be visible with the ex-
ception of old clips. 3)there must not be any therapeutic fi ndings, such as 
markings, infusions, mucosal excisions, and massive hemorrhages. Aft er 
the NNs were trained using the training dataset, the system performance 
was evaluated by the testing dataset, which was another set of 27,862 
images, to classify the images into these eight categories. To evaluate 
the performance of the proposed system, we used the MNIST database 
28×28-pixels images of hand-written digits from 0 to 9 as a benchmark, 
which is separated into a training dataset of 60,000 examples and a test-
ing dataset of 10,000 examples.
Results: The accuracy of the classifi cation system in the training and test-
ing data were found to be 0.988 and 0.961, respectively. The accuracy of 
the system in the training and testing data when applied to the MNIST 
database reached 0.999 and 0.982, respectively.
Conclusion: Thus, it was concluded that the proposed system is eff ective 
for identifying the upper-gastrointestinal organs in endoscopic images. 
This system can be utilized as an organ identifi er to aid the process of data 
cleansing in the development of an automated lesion-detection system.
Disclosure: Nothing to disclose 
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OP082 ARTIFICIAL INTELLIGENCE FOR REAL-TIME POLYP 
LOCALISATION IN COLONOSCOPY WITHDRAWAL VIDEOS
Ahmad O.1, Brandao P.1, Sami S.2, Mazomenos E.1, Rau A.1, Haidry R.J.3, 
Vega R.3, Seward E.3, Stoyanov D.1, Lovat L.B.1,2
1University College London, Wellcome/EPSRC Centre for Interventional & 
Surgical Sciences, London, United Kingdom, 2University College London, 
Targeted Intervention, London, United Kingdom, 3University College Hospital 
London Dept. of Gastroenterology, London, United Kingdom
Contact E-Mail Address: o.ahmad@ucl.ac.uk
Introduction: There is considerable variation in polyp detection rates dur-
ing colonoscopy. Missed adenomas may contribute to interval colorectal 
cancers. Artifi cial intelligence (AI) can potentially improve ADR. Previous 
work has focussed on still images and selected video sequences which 
may be subject to bias and lack clinical utility. This pilot work assesses 
whether a convolutional neural network (CNN) developed using still im-
ages and short video sequences from a multicentre dataset using diff erent 
processors generalises eff ectively to locate polyps in new video dataset 
consisting of complete colonoscopy withdrawals (caecum to rectum).
Aims & Methods: Our group previously developed a CNN using 4664 polyp 
test frames from the MICCAI 2015 polyp detection challenge dataset. Here, 
we created a second dataset using 17 complete colonoscopy withdrawal 
videos, previously unseen by the CNN, containing 83 unique polyps con-
sisting of 83,716 frames (14,634 polyp and 69,082 non-polyp) using Olym-
pus EVIS LUCERA CV290(SL) processors and colonoscopes. White light 
frames were manually annotated by drawing bounding boxes around pol-
yps. Polyp size, morphology, histopathology and location was recorded for 
each polyp sequence (Table 1). Low quality frames (blurred/indistinguish-
able image) were excluded. Half the procedures were randomly selected 
to create a testing set consisting of 24,596 frames (4,804 polyp and 19,792 
non-polyp). A true positive was scored if the computer-generated predic-
tion overlapped with the bounding box. A false positive indicated a non-
overlapping location (more than one can occur per frame).
Results: The CNN operated at real-time video-rate achieving a sensitivity 
of 91.6% and positive predictive value 75.3% in the MICCAI challenge test 
set consisting of 196 high defi nition still images from 44 polyps. When 
the MICCAI trained CNN was tested on our previously unseen colonoscopy 
procedures, it achieved a sensitivity of 76.6% and specifi city of 78.9%. This 
CNN was fi ne-tuned by using polyp positive frames from our training data-
set. This improved sensitivity to 84.5% and specifi city to 92.5%.
Conclusion: Whilst the CNN achieved excellent results on the public still 
image dataset, it is more challenging to generalise results to complete 
colonoscopy withdrawals. Fine-tuning using our dataset led to improved 
performance. Furthermore, our procedures were performed by expert en-
doscopists, including a signifi cant proportion of right sided fl at elevated 
and subtle sessile serrated lesions which were not evaluated in recently 
published test sets. AI development should include complete colonoscopy 
withdrawals to refl ect true clinical practice and focus specifi cally on identi-
fying challenging polyps that may be overlooked by colonoscopists.
Disclosure: Nothing to disclose 
Lesions (n) 83
Mean size (mm) 5.4
Morphology (Paris Classifi cation)  
Protruded (Ip/Isp/Is) 35
Flat elevated/Flat (IIa/IIb) 48
Location  
Right Colon 58
Left  Colon 20
Rectum 5
Pathology  
High Grade Dysplasia Tubular Adenoma 1
Low Grade Dysplasia Tubular Adenoma 61
Sessile Serrated Lesion 14
Hyperplastic Polyp 7
[Polyp Details (Complete Colonoscopy Video Dataset)]
OP083 THE REAL-TIME DETECTION AND DIFFERENTIAL DIAGNOSIS 
OF COLORECTAL POLYPS IN COLONOSCOPY WITH AN ARTIFICIAL 
INTELLIGENCE ALGORITHM; A PROSPECTIVE OBSERVATIONAL STUDY
Kamba S.1, Matsui H.1, Horiuchi H.1, Tamai N.1, Ohya T.1, Tonouchi A.2, 
Fukuda A.2, Fujimoto Y.2, Kutsuna N.2, Shimahara Y.2, Sumiyama K.1
1The Jikei University School of Medicine, Department of Endoscopy, Tokyo, 
Japan, 2Lpixel Inc., Tokyo, Japan
Contact E-Mail Address: kanba@jikei.ac.jp
Introduction: For supporting detection and diagnosis of colorectal polyps 
in real time by artifi cial intelligence (AI) technology, we have developed 
AI-aided endoscopic diagnosis system (AAE). This system has been de-
veloped using Convolutional Neural Network, one of deep learning ap-
proaches. We have already reported its polyp detectability and diff erential 
diagnostic accuracy in retrospective studies using stored still images. The 
aims of this study were to validate whether the AAE could detect colorectal 
polyps which were detected by endoscopists as the gold standard, and 
to evaluate diff erential diagnostic accuracy of AAE in real time under a 
clinical setting.
Aims & Methods: AAE analyzes all image frames during a colonoscopy on 
GPU workstation, and a box-shaped alert is presented on the lesion area 
in real-time. When the endoscopist presses the freeze button at the tar-
get polyp in white light imaging (WLI), the diff erential diagnosis between 
neoplastic and non-neoplastic is made by AAE. In order to prepare the 
training data of AAE, 69,285 images were collected from 4,147 colonoscopy 
case underwent in Jikei University hospital since April 2014 to December 
2018. All training data was annotated by enclosing lesion area on each im-
age with a bounding box. Following the development of the algorithm, a 
prospective observational study was conducted at Jikei university hospital 
in January 2019. The patients who underwent colonoscopy were enrolled. 
Patients with known IBD were excluded. In this study, results of detection 
and diff erential diagnosis by AAE were displayed on a monitor separated 
from the main monitor used by endoscopists. When an endoscopist detect 
a polyp, polyp information (size, morphologic type, location and the time 
to detect a polyp) were informed to research assistants and recorded. We 
evaluated the success rate of polyp detection during colonoscopy by re-
viewing videos at the recorded time to detect a polyp. Successful polyp 
detection with AAE was defi ned when a polyp detected by endoscopists 
as gold standard could be detected by AAE within 2 seconds from the ini-
tial appearance of a polyp on a video frame. Furthermore, the diff erential 
diagnostic accuracy between neoplastic and non-neoplastic by AAE was 
analyzed only for the polyp removed endoscopically. The diff erential diag-
nosis of AAE was made by freezing the video image when an endoscopist 
judged that highly-quality closeup images would be obtained without blur.
Results: Thirty patients (with 102 polyps) were analyzed. AAE succeeded to 
detect 95 polyps (93.1%) in 102 polyps within 2 sec from their initial ap-
pearance, of which 62 polyps (65.2%) were diminutive polyps of 5 mm or 
less. The median detection time was 0.4 seconds (range 0.1 - 20.2 seconds). 
AAE was able to predict diff erential diagnosis in 58 polyps (41 neoplasm 
and 17 non-neoplasm) of 81 polyps (63 neoplasm and 18 non-neoplasm) 
endoscopically resected (71.6%). When 23 polyps in which AAE could not 
predict diff erential diagnosis were treated as misdiagnosed polyps, dif-
ferential diagnostic accuracy between neoplastic and non-neoplastic was 
sensitivity 58.7% /specifi city 77.8% /positive predict value 90.2% /nega-
tive predict value 35.0% /accuracy 63.0% in overall 81 polyps. In diagnos-
able 58 polyps, it was sensitivity 90.2% /specifi city 82.4% /positive predict 
value 92.5% /negative predict value 77.8% /accuracy 86.8%, respectively.
Conclusion: This preliminary study demonstrated that the polyp detect-
ability of AAE and diff erential diagnostic accuracy between neoplastic 
and non-neoplastic polyp were comparable to endoscopists in a real-time 
clinical setting.
Disclosure: Nothing to disclose 
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Barrett’s oesophagus
16:00-17:30 / Hall 6
OP085 DEEP LEARNING SYSTEM DETECTS BARRETT’S 
ESOPHAGUS NEOPLASIA WITH HIGH ACCURACY IN A MULTI-STEP 
TRAINING AND EXTERNAL VALIDATION STUDY
de Groof J.1, Struyvenberg M.1, van der Sommen F.2, 
van der Putten J.2, Curvers W.L.3, Zinger S.2, Pouw R.E.4, Pech O.5, 
Weusten B.L.A.M.6, Meining A.7, Neuhaus H.8, Bisschops R.9, 
Schoon E.J.10, de With P.2, Bergman J.J.4
1Amsterdam University Medical Centers, Location AMC, Gastroenterology and 
Hepatology, Amsterdam, Netherlands, 2Eindhoven University of Technology, 
Electrical Engineering, Eindhoven, Netherlands, 3Catharina Hospital, 
Gastroenterology, Eindhoven, Netherlands, 4Academic Medical Centre, 
Gastroenterology and Hepatology, Amsterdam, Netherlands, 5Krankenhaus 
Barmherzige Brüder Klinik für Gastroenterologie und Interventionelle 
Endoskopie - Klinik, Klinik für Gastroenterologie und, Regensburg, 
Germany, 6St Antonius Hospital, Dept. of Gastroenterology and Hepatology, 
Nieuwegein, Netherlands, 7University of Würzburg, Gastroenterology, 
Würzburg, Germany, 8Evangelisches Krankenhaus Düsseldorf, Dept. of 
Internal Medicine, Düsseldorf, Germany, 9Katholieke Universiteit Leuven, 
Gastroenterology, Leuven, Belgium, 10Catharina Hospital Gastroenterology 
and Hepatology, Dept. of Gastroenterology, Eindhoven, Netherlands
Contact E-Mail Address: ajdegroof@gmail.com
Introduction: Early neoplasia in Barrett’s esophagus (BE) is oft en diffi  cult 
to detect endoscopically. Computer aided detection (CAD) systems might 
be able to assist endoscopists in real-time recognition of BE neoplasia. 
Recently, CAD deep learning techniques have shown promising results in 
other fi elds.
Aims & Methods: The aim of this study was to develop a deep learning 
CAD system for endoscopic recognition of BE neoplasia using multi-step 
training followed by internal- and external validation. 
The CAD system was pre-trained via a novel approach, for which we cre-
ated a unique dataset of 494,364 labelled images of broad endoscopic 
variety, named GastroNet. The system was further trained and refi ned 
by datasets 2 and 3. Dataset 2 consisted of retrospectively collected WLE 
overview images of BE neoplasia (n=690) and non-dysplastic BE (NDBE; 
n=557). Dataset 3 consisted of prospectively collected overview images of 
BE neoplasia (n=129) and NDBE (n=168). The CAD system was constructed 
using a fully residual, hybrid ResNet-UNet model using transfer- and en-
semble learning. The system was fi rst internally validated on dataset 3, 
using 4-fold cross validation methodology. 
Finally, a fourth dataset was created for external validation. This dataset 
consisted of 40 prospectively collected WLE overview images of BE neo-
plasia and 40 WLE NDBE images from 80 patients not included in dataset 
1-3. In dataset 2-4, all NDBE images were reviewed by experts for absence 
of neoplasia. All neoplastic images were delineated by multiple experts, 
where the area with ≥1 delineation served as ground truth for training- 
and validation. 
Outcome parameters: 1) Correct classifi cation of images (neoplastic/NDBE); 
2) Correct delineation of neoplastic lesions (i.e. CAD’s delineation within 
experts delineation: delineation score); 3) Correct positioning of preferred 
biopsy location within experts delineation (red fl ag indication score).
Results: Accuracy, sensitivity, and specifi city for classifi cation of all images 
in internal validation were 88%, 88% and 89%, respectively. In the exter-
nal validation these values were 88%, 93%, and 83%, respectively. The 
CAD-delineation overlapped with the expert ground truth in all correctly 
classifi ed neoplastic cases in the external validation set, and red-fl agged 
this area in 97%.
Conclusion: We developed a deep learning CAD system for primary de-
tection of BE neoplasia, using multi-level validation. The system detected 
neoplasia with high accuracy and near-perfect delineation- and red-fl ag 
performance. These performance parameters indicate that our CAD system 
is ready for real-time, image-based testing in clinical practice.
Disclosure: This research is supported by the Dutch Cancer Society and 
Technology Foundation STW, as part of their joint strategic research 
program ‘Technology for Oncology’ A.J. de Groof: None declared M.R. 
Struyvenberg: None declared J. van der Putten: None declared F. van der 
Sommen: None declared W.L. Curvers: None declared S. Zinger: None 
declared R.E. Pouw: None declared O. Pech: Medtronic, FUJIFILM, OLYM-
PUS, Boston Scientifi c, Cook (speaker fees) B. Weusten: Pentax Medical 
(research support, speakers fees) A. Meining: OVESCO (consulting fees) 
OP084 ARTIFICIAL INTELLIGENCE FOR DETECTING DIMINUTIVE 
COLON POLYPS BASED ON AUTOMATIC COLLECTING SYSTEM FOR 
DAILY ANNOTATED DATASETS FROM THE COMMERCIALLY AVAILABLE 
ENDOSCOPY REPORTING SYSTEM
Hori K.1, Ikematsu H.1, Yamamoto Y.1, Matsuzaki H.2, Takano H.2, 
Takeshita N.2, Shinmura K.1, Yoda Y.1,2, Takemoto S.3, Yokota H.3, Yano T.1
1National Cancer Center Hospital East, Department of Gastroenterology 
and Endoscopy, Kashiwa, Japan, 2National Cancer Center Hospital East, 
Medical Device Innovation Center, Kashiwa, Japan, 3RIKEN, Image Processing 
Research Team, Wako, Japan
Contact E-Mail Address: khori@east.ncc.go.jp
Introduction: Recently, artifi cial intelligence (AI) has been shown the re-
markable progress in image recognition. The application of AI system for 
the endoscopic images are expected to be the favorable assistance. The 
recent AI progressions are primarily are based on the availability of large-
scale annotated datasets. In general, the dataset of high-quality annotated 
endoscopic images are retrospectively made by endoscopic specialist with 
much eff ort. In Japan, endoscopists make reports including selected key 
images with localized annotation at diagnosis in daily practice. Collecting 
system for daily annotated datasets from the endoscopy reporting systems 
enables continuous accumulation of high-quality annotated endoscopic 
dataset.
Aims & Methods: The aim of this study is to assess the validity of using 
daily annotated endoscopic images in constructed reporting system for 
prototype AI model for diminutive polyp detection. We constructed auto-
matic collecting system for daily annotated datasets from the endoscopy 
reporting system (NEXUS, FUJIFILM medical Co.) with Japan Endoscopy 
Database (JED) project conducted by Japan Gastroenterological Endoscopy 
Society (JGES). By the keyword of diagnostic information, we automatically 
extracted annotated endoscopic images of diminutive colon polyps which 
diagnosed between March 2018 and September 2018. To verify the collect-
ing system, we have created the AI model for detecting diminutive colon 
polyp from the collected dataset and additional collected normal colon da-
taset. The detection model was made by RetinaNet network architecture, 
which is one of the latest deep learning algorithm for object detection.
Results: We automatically collected 47391 endoscopic images of 745 colo-
noscopy and extracted 1356 key images of diminutive colon polyps with 
localized annotation which added at diagnosis. Additionally, we collected 
700 images of normal colon. To validate the quality of dataset for mak-
ing AI model, we used 1056 datasets of colon polyps and 400 images of 
normal colon for training and used 300 datasets of colon polyps and 300 
images of normal colon for validation. The sensitivity, specifi city, and ac-
curacy of our trained colon polyp detector for 300 polyp images and 300 
normal images was 95.0%, 97.7%, and 96.3%.
Conclusion: This automatic collecting system for daily annotated datasets 
enabled creating high-performance detector for diminutive colon polyps 
with reducing much eff orts of endoscopic specialists. This scheme leads 
to continuous extensive information collection infrastructure for making 
endoscopic AI diagnostic system.
Disclosure: Nothing to disclose 
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OP086 HIGH ACCURACY AND EFFECTIVENESS WITH DEEP NEURAL 
NETWORKS AND ARTIFICIAL INTELLIGENCE IN DETECTION OF EARLY 
ESOPHAGEAL NEOPLASIA IN BARRETT’S ESOPHAGUS
Hashimoto R.1, El Hage Chehade N.2, Dao T.1, Ninh A.1, Requa J.1, 
Chang K.1, Karnes W.1, Samarasena J.2
1University of California Irvine, Orange, United States, 2University of California 
Irvine, Gastroenterology, Orange, United States
Contact E-Mail Address: jsamaras@uci.edu
Introduction: The most widely used approach for surveillance of Barrett’s 
esophagus (BE) is oesophagogastroduodenoscopy. However, the visual de-
tection of early esophageal neoplasia (high grade dysplasia and T1 cancer) 
in BE with white light and virtual chromoendoscopy is still diffi  cult.
Aims & Methods: The aim of this study is to assess if a convolutional neural 
artifi cial intelligence network can aid in the recognition of early esopha-
geal neoplasia in BE.
Over 800 images from 65 patients were retrospectively collected of his-
tology-proven early esophageal neoplasia in BE containing high grade 
dysplasia or T1 cancer (Dysplasia Group). Within each image, the area of 
neoplasia was masked using image annotation soft ware by two experts in 
BE imaging. Over 800 control images were collected of either histology-
proven or confocal endomicroscopy-proven BE without high grade dyspla-
sia (Non -Dysplastic Group). 
A training set with ~1200 images split 50/50 Dysplasia/Non-Dysplasia 
was used to train the algorithm. We used a convolutional neural network 
(CNN) and hybrid algorithm design including Inception blocks to deepen 
the neural net and maximize effi  ciency and accuracy. The algorithm was 
pre-trained on ImageNet and then fi ne-tuned with the goal to provide the 
correct binary classifi cation: “Dysplastic” (1) or “Non-dysplastic” (0). Adam 
optimizer performed stochastic optimization of a binary cross-entropy loss 
function to produce a probability value between 0 and 1. A set 458 images 
unique of the training set was used for algorithm validation. 
We additionally developed an object detection algorithm which drew lo-
calization boxes in real-time around regions classifi ed as dysplasia. Test-
ing was performed for near-focus images, non-near focus (far) images, 
white light and NBI images.
Results: The CNN analyzed 458 test images (225 dysplasia/233 non-dys-
plasia) and correctly detected early neoplasia in BE cases with sensitivity 
of 95.6% and specifi city of 91.8% (Fig.1). The accuracy was 93.7% and the 
AUC was 0.94 (Fig.3). With regards to the object detection algorithm for 
all images in the validation set, the system was able to achieve a mean-
average-precision (mAP) of 0.7533 at an intersection over union (IOU) of 
0.3, Sensitivity 96.7% and Specifi city 87.6% (Fig 2). For NBI images only, 
a mAP 0.802 was achieved and mAP 0.819 with Near-focus images only.
Conclusion: Our AI model was able to detect early esophageal neoplasia 
in Barrett’s Esophagus images with 93.7% accuracy. In addition, the object 
detection algorithm was able to draw a localization box around the areas 
of dysplasia with high precision. This system appears promising and an 
algorithm of this kind may aid endoscopists detect dysplastic lesions more 
eff ectively. Real-time live video validation of the algorithm is currently un-
derway.
Disclosure: Jason Samarasena and William Karnes (Co-founders of DocBot) 
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OP087 DIFFERENCES IN IMPLEMENTATION OF GUIDELINES ON 
DIAGNOSIS AND TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EOE): 
AN OVERVIEW OF CURRENT PEDIATRIC AND ADULT GI PRACTICE IN 
EUROPE
Amil Dias J.1, Garcia-Puig R.2, Gutiérrez Junquera C.3, Papadopoulou A.4, 
Roma E.4, Kalach N.5, Oudshoorn J.H.6, Sokollik C.7, 
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Medicine, University of Ljubljana, Ljubljana, Slovenia, 16Al Jalila Children’s 
Specialty Hospital, Paediatric Gastroenterology Department, Dubai, 
United Arab Emirates, 17Vilnius University Children’s Hospital, Vilnius, 
Lithuania, 18University Children’s Hospital Skopje, Department for Pediatric 
Gastroenterohepatology, Skopje, Macedonia (Republic of), 19Institute of 
Gastroenterology, Nutrition and Liver Diseases, Schneider Children’s Medical 
Center of Israel, Petach Tikva and Sackler Faculty of Medicine, Tel Aviv 
University, Tel Aviv, Israel, 20Ghent University Hospital, Ghent, Belgium
Contact E-Mail Address: jorge.amil@outlook.pt
Introduction: Guidelines for diagnosis and treatment of Eosinophilic 
Esophagitis (EoE) have changed markedly over the last decade. An inter-
national survey, conducted by the ESPGHAN EGID Group, aimed to ana-
lyze diff erences in current practice of European Pediatric (PG) and Adult 
Gastroenterologists (AG) in their management of EoE, and to assess self-
reported adherence to guidelines.
Aims & Methods: Gastroenterologists treating children and/or adults in 
13 European countries and the United Arab Emirates were contacted and 
asked to complete a multiple-choice questionnaire to gauge physician de-
mographics, EoE diagnosis and management strategies.
Results: Of the 1232 gastroenterologists who completed the questionnaire, 
465 were PG and 697 were AG. In contrast to current guidelines on EoE 
diagnosis, only 41% of gastroenterologists (22% AG vs. 68% PG, p< 0.01) 
reported taking biopsies in patients with symptoms of esophageal dys-
function but without macroscopic endoscopic abnormalities; 92% (97% 
PG vs. 88% AG, p< 0.01) reported to take biopsies when dysphagia was 
the specifi c symptom; 81% (86.2% PG vs. 77% AG, p< 0.01) sampled mul-
tiple esophageal sites when suspecting EoE. High dose PPI administration 
(68.1% PG vs. 72.4% AG) followed by elimination diets (31.6% and 27.3% 
respectively) were the most common fi rst line treatments. Following fail-
ure of initial PPI treatment, the majority of both PG and AG opted for oral 
topical steroids (56.4% PG vs. 86.9% AG, p< 0.01), however PG utilize food 
elimination diets as second line treatment signifi cantly more oft en than 
AG (43.5% PG vs. 13.3% AG, p< 0.01). Geographic practice diff erences were 
noted, for example the highest use of high dose PPI as fi rst line treatment 
was reported in Spain while, of elimination diets, in the United Arab Emir-
ates. Although proven unreliable, 24.1% of prescribed food elimination 
diets were reported to be based on specifi c allergy testing (32.8% PG vs. 
16.3% AG, p< 0.01) and up to 83% refer their patients for allergic assess-
ment aft er diagnosis of EoE. 
Aft er initiating therapy, the majority reported monitoring therapeutic 
response endoscopically (86.3% PG vs. 69.7% AG, p< 0.01). German PG 
universally reported endoscopic follow-up while Dutch gastroenterolo-
gists were least likely to follow this approach. A greater proportion of PG 
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No diff erences were observed in terms of concomitant food allergies be-
tween non-responder and responder group: n= 18 (cow’s milk protein: 8; 
egg: 7 ; fi sh: 5; cereals: 1) vs n=7 (cow’s milk protein:2; egg: 3; fi sh: 2), re-
spectively (p= 0,19). No diff erences were observed in terms of concomitant 
atopic diseases between non-responder and responder group: 22 patients 
(asthma: 3; rhinoconjunctivitis: 3; atopic dermatitis: 1) vs 15 patients (asth-
ma: 7 ; rhinoconjunctivitis: 7; atopic dermatitis: 2), respectively (p= 0,26).
Conclusion: Trachealized esophagus,and a higher number of eosinophils 
on biopsy sample at the index endoscopy are more prevalent in PPI not 
responders and might be used to predict a lack of response to PPI and to 
guide the treatment. Conversely, a normal mucosa and a lower number of 
eosinophils on biopsy sample at the index endoscopy predict a response 
to PPI treatment.
Disclosure: Nothing to disclose 
OP089 BUDESONIDE ORODISPERSIBLE TABLETS ARE SUPERIOR TO 
MAINTAIN COMBINED CLINICAL AND HISTOLOGICAL REMISSION IN 
ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM 
THE 48-WEEKS, DOUBLE-BLIND, PLACEBO-CONTROLLED PIVOTAL 
EOS-2 TRIAL
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Hartmann D.11, Madisch A.12, Hruz P.13, Hayat J.14, von Arnim U.15, 
Bredenoord A.J.16, Schubert S.17, Müller R.18, Greinwald R.19, Schoepfer A.20, 
Attwood S.21, on Behalf of the International EOS-2 Study Group
1Swiss EoE Research Network, Gastroenterology FMH, Olten, Switzerland, 
2University Hospital Zurich, Clinic for Gastroenterology and Hepatology, Zurich, 
Switzerland, 3Hospital General de Tomelloso Dept. of Digestive Health, Dept. de 
Gastroenterologia, Tomelloso, Spain, 4Coopertion of Internal Medicine Center 
for Digestive Diseases, Hamburg, Germany, 5Klinikum Bayreuth Abt. Pathology, 
Abt. Pathologie, Bayreuth, Germany, 6Technische Universität München, II. 
Medizinsiche Klinik, München, Germany, 7USZ Zürich, Gastroenterolog y & 
Hepatology, Zürich, Switzerland, 8Hospital Universitario de La Princesa, Servicio 
de Aparato Digestivo, Madrid, Spain, 9Barcelo Viajes, Servicio Digestivo, 
Palma de Mallorca, Spain, 10Hospital 12 de Octubre, Gastroenterology, 
Madrid, Spain, 11Sana Klinikum Lichtenberg, Klinik für Innere Medizin, Berlin, 
Germany, 12CRH Clinic Siloah, Dept. of Gastroenterology, Hannover, Germany, 
13Universitätsspital Basel, Abt. Endoskopie, Basel, Switzerland, 14St. George`s 
University Hospitals, Gastroenterology, London, United Kingdom, 15Otto-Von 
Guericke University, Gastroenterology, Hepatology And Infectious Disease, 
Madgeburg, Germany, 16Academic Medical Center, AMC, In ammatory Bowel 
Disease Centre, Dept. of Gastroenterology and Hepatology, Amsterdam, 
Netherlands, 17Praxis, Berlin, Germany, 18Dr. Falk Pharma GmbH, Clinical 
Research & Development, Freiburg, Germany, 19Dr. Falk Pharma GmbH, 
Research and Development, Freiburg, Germany, 20University Hospital (CHUV), 
Dept. of Gastroenterology & Hepatology, Lausanne, Switzerland, 21Durham 
University, Health Services Research, North Tyneside, United Kingdom
Contact E-Mail Address: alex.straumann@hin.ch
Introduction: In the recent EOS-1 trial, a 6-week therapy with a novel 
budesonide orodispersible tablet (BOT), with a unique mode of delivery 
and esophageal targeting, given twice daily (1mg BID) induced clinico-
histological remission in 57% of adult patients with active eosinophilic 
esophagitis (EoE), with 93.2% achieving histological remission (1).
Aims & Methods: This maintenance study assessed the effi  cacy and safety 
of two doses of BOT vs placebo for maintaining EoE in clinico-histological 
remission over 48 weeks. In total, 204 patients being in clinico-histological 
remission at baseline were randomized (1:1:1) to a 48-weeks treatment 
with BOT 1 mg BID, BOT 0.5 mg BID or placebo.
Primary endpoint: Proportion of patients in clinico-histological remission 
aft er 48 weeks of double-blinded treatment, defi ned as fulfi lling all of the 
following criteria:
- Absence of clinical relapse (as defi ned by dysphagia or odynophagia [7-
day recall period] severity ≥4 points, confi rmed by ≥4 points on at least 1 
day during the subsequent week on the respective 010 NRS for dysphagia 
or odynophagia [24-hours recall period]),
- Lack of histological relapse (defi ned as a peak of ≥48 eos/mm2 hpf [corre-
sponding to peak of ≥15 eos/hpf] at the end of treatment (EOT) and derived 
from six biopsies (2 from each esophageal third),
- Absence of food impaction requiring endoscopic intervention,
- No need of dilation,
- No premature withdrawal for any reason.
than AG indicated that had read at least one recent international guideline 
(89% PG vs. 56% AG), but both PG and AG alike recognize the potential 
benefi t of national guidelines concerning the diagnosis and treatment of 
EoE (86% PG vs. 85% AG).
Conclusion: The general practice of pediatric and adult gastroenterologists 
diff ers and diverges from international guidelines on diagnosis as well as 
treatment of EoE. Geographic practice variations are apparent. Although 
the majority indicated awareness of recent practice standards, strategies 
to improve the implementation of current guidelines are urgently needed.
Disclosure: Nothing to disclose 
OP088 ENDOSCOPIC AND HISTOLOGIC DIFFERENCES BETWEEN 
PPI-RESPONSIVE AND NON-RESPONSIVE EOSINOPHILIC 
ESOPHAGITIS IN CHILDREN POPULATION: A TERTIARY CENTER 
EXPERIENCE
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Introduction: Eosinophilic esophagitis (EoE) is defi ned as histological fea-
tures of 15 or more eosinophils per high power resolution (hpf) without 
other causes of esophageal eosinophilia. Endoscopic and/or histologi-
cal diff erences between PPI responders and non-responders were never 
clearly defi ned. PPI-responder eosinophilic esophagitis (PPI-REE) patients 
are defi ned those patients presenting clinical and histological features of 
EoE but with a resolution of eosinophilic infi ltrate aft er a treatment of high 
dose PPI for eight weeks. Aim of this study is to evaluate if endoscopic, 
histological or constitutional feature may be specifi c of PPI responder and 
non responder patients in a pediatric population.
Aims & Methods: Non consecutive patients in children population with 
confi rmed eosinophilic esophagitis were screened. All patients have un-
dergone an initial upper GI endoscopy with esophageal biopsy and have 
had a defi nite diagnosis of eosinophilic esophagitis (eosinophilic infi ltra-
tion ≥ 15 per hpf at the esophageal biopsy). 
All patients received high dose (1mg/kg) of PPI therapy for eight weeks 
without changing the current diet. At the end of PPI treatment a second 
endoscopic look with bioptic sampling was performed to evaluate the re-
sponse to PPI treatment and to assign each patients to PPI responder or 
non responder group. Endoscopic features (stenosis, longitudinal stripes, 
trachealized esophagus, white spots) and histologic fi ndings (absolute 
number of eosinophils per hpf) at fi rst endoscopy were evaluated and 
compared between PPI- responder and non responder group . History of 
food allergies and/or atopic diseases were also recorded.
Results: Of the 64 patients screened for the analysis, 6 patients were ex-
cluded because were lost during follow up and/or they did not show at 
the second look endoscopy. Therefore, 58 patients were included in the 
fi nal analysis (mean age 10,5 years old; male: 35, female: 23). 37 patients 
were classifi ed as PPI non-responder (male:21, female:16; average age: 
11,1 years old) and 21 patients as PPI responder (male:14, female:7; average 
age: 9,5 years old). Diff erences between the 2 groups are shown in Table 
1. [Table 1]
Endoscopic characteristics Non responder (n. 37)
Responder 
(n. 21) p-value
Stenosis n 4 10.8 % n 1 4.7 % 0.39
Longitudinal stripes n 20 54.1 % n 9 42.8 % 0.29
White spot n 17 45.9 % n 8 38.1 % 0.38
Trachealized esophagus n 13 35.1 % n 1 4.7 % 0.008
Normal mucosa n 1 2.7 % n 5 23.8 % 0.02
Histological fi ndings          
15-50 eos/hpf n 8 21.6 % n 10 47.6 % 0.04
50-99 eos/hpf n 12 32.5 % n 5 23.8 % 0.35
>100 eos/hpf n 17 45.9 % n 5 23,8 % 0.007
[Table 1]
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Secondary a priori ordered endpoints (confi rmatory tested):
- Individual components of the primary endpoint,
- Proportion of patients in clinical remission at week 48/EOT defi ned by 
EEsAI-PRO ≤20,
- Proportion of patients being at week 48/EOT in clinical (NRS [7-day re-
call period] for dysphagia and odynophagia ‚0‘) AND endoscopic (EREFS 
scores: fi xed rings ‚≤1‘; exudates, furrows, and edema: all ‚0‘), AND histo-
logical remission (< 15 eos/hpf).
Further main secondary effi  cacy endpoints (exploratory) contained clini-
cal, endoscopic, and histological endpoints.
Results: Both BOT dosing groups were signifi cantly superior over placebo 
in maintaining EoE in clinico-histological remission, with no signifi cant 
diff erences between the budesonide groups in the standard effi  cacy crite-
ria (Table 1; 1.-4. endpoints). However, the higher dose was more effi  ca-
cious for achieving and maintaining clinical and endoscopic and histologi-
cal remission (Table 1; 5. endpoint). 
All further secondary endpoints confi rmed the fi ndings of the primary 
endpoint. Our study confi rmed the well-known safety profi le of topical 
budesonide for the fi rst time also over a long-term administration period 
in a randomized double-blind trial. There were no diff erences in the base-
line morning cortisol levels over 1 year between patients receiving BOT 
and placebo. Suspected symptomatic candidiasis were reported in only 
12% and 16% of patients in the high and low dose, respectively, all cases 
easily to be treated. 
    BOT 1mg BID (n=68)
BOT 0.5mg BID 
(n=68)
Placebo BID 
(n=68)
 
Primary confi rmatory endpoint: 
Number (%) patients in clinico-
histological remission aft er 48 
weeks of treatment
51 (75.0%) 
P<0.0001*
50 (73.5%) 
P<0.0001*
3 (4.4%)
1)
Secondary a priori ordered con-
fi rmatory endpoints: Number (%) 
patients with histological relapse, 
defi ned as a peak of ≥48 eos/mm² 
hpf at wk48/EOT
7 (10.3%) 
P<0.0001*
9 (13.2%) 
P<0.0001*
61 (89.7%)
2)
Mean [95%CI] change from base-
line to wk48/EOT in peak eos/
mm2 hpf
21 [5; 37] 
P<0.0001**
38 [10; 65] 
P<0.0001**
262 [208; 316]
3)
Number (%) patients with clinical 
relapse, or food impaction requi-
ring endoscopic intervention, or 
dilation during 48 weeks
5 (7.4%) 
P<0.0001*
7 (10.3%) 
P<0.0001*
41 (60.3%)
4)
Number (%) patients in clinical 
remission at wk48/EOT defi ned by 
EEsAI-PRO ≤ 20
50 (73.5%) 
P<0.0001*
49 (72.1%) 
P<0.0001*
14 (20.6%)
5)
Number (%) of patients in clinical 
AND endoscopic AND histological 
remission at week48/EOT
36 (52.9%) 
P<0.0001*
27 (39.7%) 
P<0.0001*
0 (0%)
 
Secondary exploratory endpoints: 
Number (%) of patients with deep 
histological remission defi ned 
as a peak of ‘0’ eos/mm2 hpf at 
wk48/EOT
54 (79.4%) 
P<0.0001*
52 (76.5%) 
P<0.0001*
1 (1.5%)
P-values (test for superiority vs placebo); 1-sided with Bonferroni adjusted α=0.0125 
*normal approximation test; ** Wilcoxon rank sum test
[Table 1: E  cacy endpoints]
Conclusion: Both, BOT 1mg BID and BOT 0.5mg BID were safe and highly 
superior vs placebo in maintaining EoE patients in clinico-histological re-
mission over 48 weeks. 90% of patients had a histological relapse when 
on placebo for 1 year.
References: (1) Lucendo AJ, et al. Gastroenterology 2019, DOI:https://doi.
org/10.1053/j. gastro.2019.03.025
Disclosure: Mueller R & Greinwald R are employees of Dr. Falk Pharma 
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Introduction: Eosinophilic oesophagitis (EoE) is a chronic immune-
mediated infl ammatory disorder of the oesophagus in response to a 
non-IgE-mediated food allergy. Although avoiding specifi c food triggers 
constitutes the only therapy that targets the cause of the disease, the limi-
tations of dietary therapy in clinical practice promoted the use of anti-
infl ammatory drugs, mainly swallowed topic steroids and proton-pump 
inhibitors (PPIs).
Aims & Methods: This study aims to analyse criteria for selecting a second 
line therapy for EoE patients, by a searching within the EoE CONNECT da-
tabase (a prospectively maintained registry of EoE patients from EUREOS) 
in order to improve our current knowledge about how EoE patients are 
managed in real world practice. Demographic and clinical variables were 
considered to seek on determinant factors. First and second-line thera-
pies were analysed. Frequency tables were generated for each treatment 
modality while contingency tables were analysed by chi-square test using 
GraphPad soft ware.
Results: First-line treatment data from 493 patients and second-line 
treatment data from 303 patients recruited at 9 hospitals in Spain and 1 
more in Italy were analysed. PPIs overall constituted the preferred fi rst-
line option for EoE, followed by topic steroids and dietary interventions. 
When they failed, dietary interventions (mainly empiric elimination diets) 
were the most common second-line options used for non-responders to 
PPIs (51.9%), topic steroids (43.2%) or other previous dietary approaches 
(32.1%). Among PPIs, omeprazole was the most frequently prescribed 
drug in both fi rst and second treatment lines (51.6% and 57.8%, respec-
tively). 
As for topical steroids, fl uticasone was the only drug used as a fi rst-line 
therapy, while budesonide was used in 31.4% of patients as a second-line 
steroid treatment. As for dietary intervention, empiric elimination diets 
were the preferred alternative, with six-food and two-food elimination di-
ets being the most commonly used as fi rst-line (42.9%) and second-line 
(43.6%) therapies, respectively. 
Topic steroids provided the highest eff ectiveness in terms of clinical and 
histological responses in both lines of treatment. Except for dietary thera-
pies, second-line treatments were overall more eff ective than fi rst-line 
ones. Endoscopic dilation was used in a minority of patients, most com-
monly as a second-line therapy.
Among the variables analysed, three of them were identifi ed as signifi cant 
determinants for the choice of a fi rst-line treatment: age (p< 0.001), EoE 
phenotype (p< 0.05) and hospital of origin (p< 0.001). Regarding second-
line therapies, diff erences in treatment were found also for EoE phenotype, 
recruiting hospitals and previous therapy (all p< 0.001). 
Conclusion: Most EoE patients were initially treated with PPIs, with no 
responders having a two-food elimination diet as second-line therapy. 
Patients’ age and EoE phenotype determined the choice of a fi rst-line 
therapeutic option, while phenotype and previous treatment aff ected the 
selected of second-line therapy. Preferred treatment in both lines was also 
dependant on the referral hospital.
Disclosure: Nothing to disclose
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Number (%) patients in clinico-histological remission at 
wk 6 (LOCF) 126 (69.6%)
Number (%) patients in histological remission 
(peak <16 eos/mm2 hpf) at wk 6 (LOCF) 163 (90.1%)
Number (%) patients in deep histological remission 
(‚0’ eos/mm2 hpf) at wk 6 (LOCF) 153 (84.5%)
Mean [95% CI] change in peak eos/mm2 hpf -283 [-323; -243]
Number (%) patients in clinical remission (dysphagia 
and odynophagia each ≤2 points on 0-10 points NRS) at 
wk 6 (LOCF)
136 (75.1)
Mean (SD) total modifi ed EREFS score (0-9) at wk 0 / wk 
6 (LOCF)
4 (1.6) n=181 / 
1 (1.3) n=176
Number (%) patients with all modifi ed EREFS features 
graded as ‚0’ at wk 0 / wk 6 (LOCF)
1 (0.6%) / 
72 (39.8%)
Number (%) patients with endoscopist’s overall 
assessment of ‚no signs of EoE’ at wk 0 / wk 6 (LOCF)
-- (0%) / 
101 (55.8%)
eos, eosinophils; EREFS; Endoscopic activity score; hpf, high power fi eld; 
LOCF, last observation carried forward; NRS, numerical rating scale
[Open-label induction phase (n=181 patients)]
OP092 A NOVEL BUDESONIDE ORODISPERSIBLE TABLET 
FORMULATION IS HIGHLY EFFECTIVE TO MAINTAIN ENDOSCOPIC 
INFLAMMATORY REMISSION AND EVEN COMPLETE ENDOSCOPIC 
REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: 
RESULTS FROM THE 48-WEEKS, DOUBLE-BLIND, PLACEBO-
CONTROLLED PIVOTAL EOS-2 TRIAL
Biedermann L.1, Lucendo A.J.2, Miehlke S.3, Schlag C.4, 
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University, Durham, United Kingdom, 17Swiss EoE Research Network, 
Gastroenterology FMH, Olten, Switzerland, 18University Hospital Zurich, Clinic 
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Contact E-Mail Address: luc.biedermann@usz.ch
Introduction: In the recent EOS-1 trial, a 6-week therapy with a novel 
budesonide orodispersible tablet (BOT), with a unique mode of delivery 
and esophageal targeting, given twice daily (1mg BID) induced endoscopic 
infl ammatory remission in 59% of adult patients with active eosinophilic 
esophagitis (EoE) versus 0% under placebo (1).
Aims & Methods: This maintenance study also assessed the effi  cacy of two 
doses of BOT vs placebo for maintaining EoE in endoscopic infl ammatory 
remission and in complete endoscopic remission over 48 weeks. 
In total, 204 patients being in clinico-histological remission at baseline 
were randomized (1:1:1) to a 48-weeks treatment with BOT 1 mg BID, BOT 
0.5 mg BID or placebo.
Endoscopic assessment by using the validated modifi ed EREFS score (2) 
was performed at baseline and end of treatment (EOT). Endoscopic in-
  First-line treatment Second-line treatment
Type of 
treatment
Use 
(%)
Failure to 
achieve 
clinical 
response 
(%)
Failure to 
achieve 
histological 
response 
(%)
Use 
(%)
Failure to 
achieve 
clinical 
response 
(%)
Failure to 
achieve 
histological 
response 
(%)
PPIs 76.5 28.3 45.9 29.4 15.6 30.6
Topic steroids 10.5 14.6 21.7 16.8 3.2 13.8
Dietary 
interventions
7.5 18.2 50.0 48.2 28.3 50.9
Dilation 1.6 8.3 nd 5.3 0.0 nd
Other 3.9 nd nd 0.3 nd nd
[Table 1]
OP091 A NOVEL ORAL BUDESONIDE FORMULATION IS HIGHLY 
EFFECTIVE FOR INDUCTION OF REMISSION IN PATIENTS WITH 
ACTIVE EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 6-WEEKS 
OPEN-LABEL TREATMENT PHASE OF EOS-2 TRIAL
Lucendo A.J.1, Schlag C.2, Miehlke S.3, Biedermann L.4, 
Santander Vaquero C.5,6, Hartmann D.7, Hayat J.8, Hruz P.9, 
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on Behalf of the International EOS-2 Study Group
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Gastroenterology, Tomelloso, Spain, 2Technische Universität München, 
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Medicine Center for Digestive Diseases, Hamburg, Germany, 4USZ Zürich, 
Gastroenterology & Hepatology, Zürich, Switzerland, 5Hospital Universitario 
de La Princesa, Servicio de Aparato Digestivo, Madrid, Spain, 6Barcelo Viajes, 
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Klinik für Innere Medizin, Berlin, Germany, 8St. George`s University 
Hospitals, Gastroenterology, London, United Kingdom, 9Universitätsspital 
Basel, Abt. Endoskopie, Basel, Switzerland, 10Hospital 12 de Octubre Dept. 
de Gastroenterologia, Gastroenterology, Madrid, Spain, 11Academisch Med. 
Centrum Amsterdam, Dept. of Gastroenterology, Amsterdam, Netherlands, 
12Klinikum Bayreuth Abt. Pathology, Abt. Pathologie, Bayreuth, Germany, 13Dr. 
Falk Pharma GmbH, Clinical Research & Development, Freiburg, Germany, 
14Dr. Falk Pharma GmbH, Research and Development, Freiburg, Germany, 
15Swiss EoE Research Network, Gastroenterology FMH, Olten, Switzerland, 
16University Hospital Zurich, Clinic for Gastroenterology and Hepatology, 
Zurich, Switzerland
Contact E-Mail Address: alucendo@vodafone.es
Introduction: In the recent EOS-1 trial, a 6-week therapy with a novel 
budesonide orodispersible tablet (BOT), with a unique mode of delivery 
and esophageal targeting, given twice daily (1mg BID) induced clinico-
histological remission in 57% of adult patients with active eosinophilic 
esophagitis (EoE), with 93.2% achieving histological remission (1).
Aims & Methods: We report here the effi  cacy of a 6-week open-label in-
duction (OLI) treatment with BOT 1mg BID in a large prospectively treated 
cohort of EoE patients, which was used as a feeding arm for the further 
double blind (DB) maintenance phase of the EOS-2 trial.
In total, 181 patients with clinical and histological active EoE were treated 
in the 6-week OLI phase. The major endpoint and basis for later random-
ization into the DB maintenance phase was clinico-histological remission, 
i.e. achieving clinical remission (≤2 points on numerical rating scales (0-10 
points) each for dysphagia and odynophagia on each of the 7 days prior to 
end-of-treatment) and histological remission (peak eosinophil count <16 
eos/mm2 hpf). Further study endpoints included clinical, histological re-
mission rates and change in peak eosinophil counts, beside other second-
ary effi  cacy endpoints.
Results: Clinico-histological remission of EoE was achieved in 69.6% 
(126/181) of patients aft er 6 weeks of therapy. Compared to baseline, BOT 
1mg BID achieved all assessed clinical, endoscopic or histological end-
points (Table 1). 
Conclusion: A 6-week open-label treatment with BOT 1mg BID was highly 
eff ective in bringing clinico-histological active EoE into remission. These 
fi ndings were similar and confi rm in a larger number of active EoE pa-
tients the results obtained under DB treatment with BOT 1mg BID in the 
EOS-1 study (n=88, amongst these 59 having received verum) (1).
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fl ammatory remission was defi ned as previously suggested by Greuter et 
al. (3): i.e., modifi ed EREFS subscores: fi xed rings = ´Grade 0: none´ or 
´Grade 1: mild´, exudates = ´Grade 0: none´, furrows = ´Grade 0: absent´, 
and edema = ´Grade 0: absent´. Additional EREFS subscores were also as-
sessed. Complete endoscopic remission was defi ned as all modifi ed EREFS 
features graded as ‘0’.
Results: see Table: 
 
BOT 1mg BID 
(n=68)
BOT 0.5mg 
BID (n=68)
Placebo BID 
(n=68)
Number (%) patients in endoscopic 
infl ammatory remission at baseline 48 (70.6%) 45 (66.2%) 47 (69.1%)
Number (%) patients in endoscopic 
infl ammatory remission at wk48/EOT
51 (75.0%) 
p<0.0001
49 (72.1%) 
p<0.0001
4 (5.9%)
Number (%) of patients maintaining 
endoscopic infl ammatory remission from 
Baseline to wk48/EOT
38 (79.2%) 
n=48 
p<0.0001
32 (71.1%) 
n=45 
p<0.0001
4 (8.5%) n=47
Number (%) of patients in complete 
endoscopic remission at baseline 34 (50.0%) 34 (50.0%) 35 (51.5%)
Number (%) of patients in complete 
endoscopic remission at wk48/EOT
39 (57.4%) 
p<0.0001
36 (52.9%) 
p<0.0001
4 (5.9%)
Number (%) of patients with no fi xed 
rings present at baseline 42 (61.8%) 39 (57.4%) 42 (61.8%)
Number (%) of patients with no fi xed 
rings present at wk48/EOT
47 (69.1%) 
p=0.0010
43 (63.2%) 
p=0.0098
27 (39.7%
P-values (exploratory test for superiority vs placebo; 1-sided Fisher exact test
[Endoscopic e  cacy endpoints]
Conclusion: Both BOT dosing groups were signifi cantly superior over pla-
cebo in maintaining EoE in endoscopic infl ammatory remission and even 
in complete endoscopic remission. Moreover, both BOT groups were able 
to delay or even revert fi brotic remodeling as indicated by improvement 
in fi brotic signs such as fi xed rings. 20% of patients on placebo developed 
new fi xed rings, compared to none on maintenance BOT.
References: (1) Lucendo AJ, et al. Gastroenterology 2019 (accepted for pre-
sentation as poster of distinction at DDW 2019) (2) Hirano I, et al. Gut. 
2013;62:489-95. (3) Greuter T, et al. Am J Gastroenterol. 2017;112:1527-35.
Disclosure: Mueller R & Greinwald R are employees of Dr. Falk Pharma 
GmbH 
Pathogenesis of H. pylori infection
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OP093 RE-DIFFERENTIATION OF GASTRIC CARCINOMA AFTER 
SUCCESSFUL HELICOBACTER PYLORI ERADICATION THERAPY
Urabe Y.1, Ito M.2, Tanaka S.3, Nakamura K.4, Masuda K.2, Kotachi T.3, 
Boda T.3, Ono A.2, Oka S.5, Hayes C.N.2, Chayama K.2
1Hiroshima University Hospital, Department of Regeneration and Medicine 
Medical Center for Translation and Clinical Research, Hiroshima, Japan, 
2Hiroshima University, Department of Gastroenterology and Metabolism, 
Institute of Biomedical and Health Sciences, Graduate School of Biomedical 
and Health Sciences, Hiroshima, Japan, 3Hiroshima University, Endoscopy 
and Medicine, Hiroshima, Japan, 4Hiroshima University Hospital, 
Department of Endoscopy, Hiroshima, Japan, 5Hiroshima University Hospital, 
Gastroenterology and Metabolism, Hiroshima, Japan
Contact E-Mail Address: beyan13@hiroshima-u.ac.jp
Introduction: Gastric cancer may develop aft er successful eradication of 
Helicobacter pylori,although the incidence is lower than in non-eradicated 
individuals. We previously reported that the appearance of characteristic 
epithelium with low-grade atypia (ELA) on the surface of gastric cancer 
aft er H. pylorieradication. However, whether ELA originates from cancer 
aft er re-diff erentiation or from the non-cancerous surrounding mucosa 
is unknown.
Aims & Methods: We isolated ELA regions from 10 early gastric cancer pa-
tients and analyzed the nucleotide sequences for 90 oncogenes and 35 
fusion oncogenes, comparing them with counterpart cancer tissue, normal 
gastric mucosa, and blood cell-derived DNA. Somatic mutations in each 
tissue were identifi ed by comparing them with the sequences from whole 
blood-derived DNA.
Results: Gene alterations were observed in nine of the ten patients, and 
up to 42 and 70 somatic mutations were seen in cancer and ELA samples, 
respectively. Common mutations shared between cancer and ELA tissues 
were found in eight of these nine patients. In contrast, common mutations 
between non-cancer mucosa and ELA was only detected in one patient, 
who also had common mutation between cancer and ELA. ELA-specifi c 
nucleotide substitutions were seen in seven patients. In contrast, cancer-
specifi c substitutions were only found in two patients. 18 out of 19 amino 
acid substitutions present in cancer tissue were also identifi ed in ELA. 
These results suggest that ELA originated from cancer tissue and accumu-
lated further nucleotide substitutions.
Conclusion: Diff erential diagnosis of ELA and normal mucosa should be 
carefully performed to prevent misdiagnosis of ELA as normal mucosa with 
atypia.
Disclosure: Nothing to disclose 
OP094 RECIPROCAL EXPRESSION OF 8-OHDG AND DNA 
REPAIR PROTEINS IN THE PROGRESSION OFHELICOBACTER PYLORI 
ASSOCIATED GASTRIC CANCER
Raza Y.1, Bernstein C.2, Mubarak M.3, Kazmi S.4
1University of Karachi, Department of Microbiology, Karachi, Pakistan, 
2University of Arizona, Tucson, United States, 3Institute of Urology and 
Transplantation, Karachi, Pakistan, 4Dadabhoy Institute of Higher Education, 
Karachi, Pakistan
Contact E-Mail Address: yasir.raza@uok.edu.pk
Introduction: Role of Helicobacter pylori in the establishment and progres-
sion of gastric cancer is still not well understood. It was hypothesized in 
this study to determine any possible role of H. pylori in the enhanced ex-
pression of reactive oxygen species which may result in the accumulation 
of DNA damages and escape from DNA repair enzymes activity, ultimately 
lead to the establishment and progression of gastric cancer.
Aims & Methods: Gastric tissues from dyspeptic patients (n=300), normal 
individuals (n=100) and gastric cancer patients (n=100) were analyzed im-
munohistochemically for PMS2 and ERCC1 expression in comparison with 
the presence or absence of H. pylori infection and 8-OHdG occurrence.
Results: Regression analysis of 8-OHdG, PMS2 and ERCC1 expressions 
showed the reciprocal relation between 8-OHdG and PMS2 (r=-0.964) /
ERCC1 (r=-0.967). Statistical analyses including mean rank determination, 
mean comparisons and spearman coeffi  cient analysis, of PMS2 and ERCC1 
expression in gastric tissues collected from dyspeptic and gastric cancer 
patients also confi rmed the reciprocal relation observed between expres-
sion of these proteins and cagA -ve/cagA +ve H. pylori infection. Intestinal 
type gastric cancer were highly defi cient for both proteins, which may sug-
gest the presence of critical role of cagA +ve H. pylori in transforming gas-
tritis into precancerous lesions and then into intestinal type gastric cancer 
by causing impairment in NER and MMR systems.
Conclusion: Findings of this study can suggest the possible involvement 
of cagA +ve H. pylori in enhanced expression of 8-OHdG and decreased 
expression of PMS2 and ERCC1, resulting in the progression of intestinal 
type gastric cancer.
Disclosure: Nothing to disclose 
OP095 CD44V9-POSITIVE CANCER STEM CELL IS DEVELOPED 
FROM CAPZA1 OVER-EXPRESSING CELL INDUCED BY OXIDATIVE 
STRESS
Kato C.1, Tsugawa H.2, Suzuki H.3,4
1Keio University School of Medicine, Tokyo, Japan, 2Keio University School of 
Medicine, Department of Biochemistry, Tokyo, Japan, 3Keio University School of 
Medicine, Medical Education Center, Tokyo, Japan, 4Tokai University School of 
Medicine, Department of Gastroenterology and Hepatology, Kanagawa, Japan
Contact E-Mail Address: chihirokato202113@gmail.com
Introduction: It is known that CD44 variant 9 (CD44v9) is a splicing variant 
of cancer stem cell marker and CD44v9 expression is strongly associated 
with the recurrence of early gastric cancer (Br. J. Cancer 109:379-386, 2013). 
However, the mechanism of CD44v9 expression in H. pylori-infected gas-
tric mucosa has not been clarifi ed. Although translocated Helicobacter 
pylori-derived CagA is usually degraded by autophagy, it specifi cally ac-
cumulates in CD44v9-positive cancer stem cells (Cell Host Microbe 12:764-
777, 2012). 
We recently reported that CAPZA1 functions as a negative regulator of the 
autophagy, and thereby translocated CagA accumulates in CAPZA1-over-
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Results: Four high frequent AACs in N-terminal region of East Asian CagA 
were detected in our previous 40 H. pylori sequence data and the two AACs 
(V356A, Y677F) out of four were demonstrated the reproducible specifi c-
ity using validation dataset (20 strains of East Asian CagA vs 20 strains of 
the others) obtained from National Center for Biotechnology Information 
(NCBI). 
Aft er the mutant tertiary structure of CagA refl ecting these two specifi c 
AACs being made by SWISS-MODEL server, the docking simulations of 
CagA with PS were performed. As a result, there is no signifi cant diff er-
ence of ΔG between control CagA and mutant CagA. On the other hand, in 
docking simulation of CagA with α5β1 integrin, the total energy of complex 
of mutant CagA with α5β1 integrin was signifi cantly lower than that of 
control CagA (p < 0.01). 
This result indicates that the complex of mutant CagA with α5β1 integrin 
is more stable than that of control. Therefore, these two AACs signifi cantly 
increase the binding affi  nity of CagA to α5β1 integrin and may contribute 
to the high virulence of East Asian CagA.
Conclusion: Two novel AACs which can be the candidates relating to the 
pathogenicity of CagA were detected in N-terminal region of East Asian 
CagA.
Disclosure: Nothing to disclose 
OP097 HELICOBACTER PYLORI INFECTION INHIBITS NOTCH 
SIGNALLING IN GASTRIC EPITHELIAL CELLS AND THE GASTRIC 
MUCOSA
FitzGerald R.1, Windle H.1, Kelleher D.2, Douglas A.R.1, O’Morain C.1, 
McNamara D.1, Smith S.1
1Trinity College Dublin, School of Medicine, Dublin, Ireland, 2University of 
British Columbia, Faculty of Medicine, Vancouver, Canada
Contact E-Mail Address: fi tzger4@tcd.ie
Introduction: Helicobacter pylori infects approximately 4.4 billion people 
worldwide and poses a major health burden due to its association with 
chronic gastritis, ulcers, gastric cancer and mucosa-associated lymphoid 
tissue lymphoma. Disease progression is correlated with host and bacte-
rial factors. Increasing H. pylori antibiotic resistance has led to a decrease 
in eradication success using current therapies. A deeper understanding of 
host-pathogen interaction is vital to uncover alternative therapeutic strat-
egies. The Notch pathway is highly conserved and central to numerous 
biological processes including cell diff erentiation, proliferation and sur-
vival. Notch signalling is essential for normal function of gastric epithelial 
cells (1) and dysregulation is associated with infl ammatory conditions and 
gastric cancer (2). The role of Notch signalling in H. pylori pathogenesis is 
not fully understood.
Aims & Methods: The aim of the study was to monitor expression of Notch 
signalling pathway components during H. pylori infection and assess the 
role of the virulence factors CagA and VacA. AGS gastric epithelial cells 
were infected with H. pylori 60190 or isogenic CagA and VacA mutant 
strains. Cells were lysed at 0, 3 and 6 hours post-infection and total RNA 
was isolated. RNA was also isolated from antral biopsies of H. pylori-in-
fected and uninfected patients. Patients were classifi ed as infected if 2 of 3 
test results (rapid urease test, histology, culture) were positive. Expression 
of Notch pathway genes was measured using reverse transcription quan-
titative PCR. Changes in expression were evaluated using the compara-
tive CT method. Results were normalised to GAPDH levels, and expressed 
relative to uninfected cells. IL-8 was measured as a positive control. The 
Student’s T-test and Mann-Whitney U-test were used to compare gene ex-
pression in cell culture samples and biopsies, respectively. A P value of < 
0.05 was considered signifi cant.
Results: H. pylori 60190 infection led to a signifi cant increase in IL-8 mRNA 
expression in AGS cells, together with a signifi cant decrease in the produc-
tion of several Notch pathway components, including Notch receptors; 1 
and 3, Notch ligands; Jagged 1, Jagged 2 and Delta-like 1, as well as Notch 
target genes Hes1 and Hey1. A similar level of reduction was also observed 
following infection with H. pylori 60190 lacking functional CagA or VacA. 
In all, biopsy samples from 25 H. pylori-infected and 17 uninfected patients 
were analysed (mean age 50.8 ± 12.9 versus 49.8 ± 17.5 years, respectively; 
P=0.82). Histology fi ndings reported chronic gastritis in all of the H. pylori-
infected patients. A signifi cant decrease in the median expression levels 
of Notch 4 (46%; P=0.02), Jagged 2 (39%; P=0.01), Hes1 (38%; P=0.02) 
and Hey1 (45%; P=0.03) was observed in the gastric mucosa of H. pylori-
infected patients compared to uninfected controls.
expressing cells (Autophagy 15:242-258, 2019). The present study was con-
ducted to examine the generating mechanisms of CAPZA1-overexpressing 
cells that lead to the production of CD44v9-positive cancer stem cells.
Aims & Methods: CAPZA1 expression levels in gastric mucosa were evalu-
ated using H. pylori-infected Mongolian gerbils. Lipid peroxidation and 
protein carbonylation in the H. pylori-infected mucosa were evaluated on 
the basis of malondialdehyde and protein carbonyl levels, respectively. Ex-
pression mechanisms of CAPZA1 were examined by western blotting and 
chromatin immunoprecipitation. CD44v9 expressions were evaluated by 
western blotting and immunohistochemistry.
Results: In CAPZA1-overexpressing cells infected with H. pylori, CD44v9 ex-
pression was enhanced due to accumulation of CagA oncoprotein. CD44v9-
expressing cells were detected among cells strongly stained for CAPZA1 in 
H. pylori-infected gastric mucosa of Mongolian gerbils and human gas-
tric cancer tissues. Moreover, CAPZA1-overexpressing cells infected with 
H. pylori exhibited enhanced expression of Sal-like protein 4 (SALL4) and 
Krüppel-like factor 5 (KLF5), which encode reprogramming factors. Our 
fi ndings show that CD44v9-expressing cancer stem cells arise from CAP-
ZA1-overexpressing cells following CagA accumulation. We subsequently 
examined the induction mechanisms of CAPZA1 expression. The levels of 
CAPZA1 expression in the gastric mucosa of H. pylori-infected Mongolian 
gerbils were signifi cantly higher than that in uninfected gastric mucosa. 
In H. pylori-infected gastric mucosa, a signifi cant linear correlation was 
observed between CAPZA1 expression and lipid peroxidation (r = 0.614, 
p < 0,005). CAPZA1 expressions in AGS cells were increased in the dose-
dependent manner by the treatment with H
2
O
2
 or Di-tert-butyl peroxide. 
Such increased expression of CAPZA1 was abolished by treatment with N-
Acetyl-L-cysteine. These results show that CAPZA1 expression is enhanced 
by oxidative stress stimulus.
Conclusion: CAPZA1-overexpressing cells behave as progenitor cells for 
CD44v9-positive cancer stem cells. Oxidative stress in H. pylori-infected 
gastric mucosa could increase CAPZA1 expression.
Disclosure: Nothing to disclose 
OP096 THE CANDIDATES OF THE AMINO-ACID POLYMORPHISM 
IN N-TERMINAL REGION OF EAST ASIAN CAGA RELATING TO THE 
PATHOGENIC FUNCTION OF CAGA
Hayashi H., Inoue J., Oyama K., Tanaka T., Tanaka S., Ikegawa T., 
Kodama Y.
Kobe University Graduate School of Medicine, Gastroenterology, Kobe, Japan
Contact E-Mail Address: hhayashi@med.kobe-u.ac.jp
Introduction: The cytotoxin-associated gene A (CagA) is generally accepted 
to be the most important virulence factor of Helicobacter pylori and in-
creases the risk of developing gastric cancer. Especially, infection of H. py-
lori with East Asian CagA which includes EPIYA-D segment in C-terminal 
region signifi cantly increases the risk of the incidence of gastric cancer 
than the other type of CagA. Though there are many studies analyzing 
the amino acid polymorphism of East Asian CagA in C-terminal region 
surrounding EPIYA motif, much less works about the amino-acid polymor-
phism in N-terminal region relating to the high virulence of East Asian 
CagA have been done.
Aims & Methods: The aim of this study is to detect the amino acid poly-
morphisms in N-terminal region of East Asian CagA which will result in 
the strong pathogenesis of East Asian CagA in sillico. First, our previous 
whole-genome sequencing (WGS) data of H. pylori deposited in DNA Data 
Bank of Japan (DDBJ) were downloaded. Aft er sequence reads of 40 H. 
pylori strains being mapped to reference using CLC Genomics Workbench, 
40 H. pylori strains were classifi ed by the EPIYA segment type and divided 
into two groups, East Asia group including 37 strains and the other group 
including 3 strains. Specifi c single nucleotide variants (SNVs) and amino 
acid changes (AACs) in East Asia group were detected with the tool of 
Fisher Exact test. 
Next, possible infl uence of the specifi c AACs existing in N-terminal region 
of East Asian CagA on the functions of CagA were evaluated with in silico 
simulation model. The tertiary structure of mutant CagA refl ecting the 
specifi c AACs was made by SWISS-MODEL server using crystal model of 
CagA (Protein Data Bank (PDB)-ID:4DVY). The docking simulations of CagA 
with phosphatidylserine (PS) were performed by Swiss-Dock. The docking 
simulations of CagA with α5β1 integrin were performed by ClusPro. The 
energy of each docked model, ΔG (kcal/mol) and total energy (kJ/mol) 
respectively, was calculated and analyzed by Wilcoxon test using JMP 10.
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Conclusion: H. pylori infection inhibits Notch signalling in gastric epithe-
lial cells, independent of the CagA and VacA virulence factors. Decreased 
Notch signalling was also observed in the gastric mucosa of infected pa-
tients. Further experiments will be necessary to fully elucidate the role of 
decreased Notch signalling in H. pylori pathogenesis.
References: 1. Kim T-H, Shivdasani RA. Notch signaling in stomach 
epithelial stem cell homeostasis. Journal of Experimental Medicine. 
2011;208(4):677-88. 2. Wu X, Liu W, Tang D, Xiao H, Wu Z, Chen C, et al. 
Prognostic values of four Notch receptor mRNA expression in gastric can-
cer. J Scientifi c reports. 2016;6:28044.
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Zhang H.1, Dai Y.2, Shen H.1, Yang J.1, Zhang X.1, Wang W.3
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Introduction: Large epidemiological studies and meta-analyses have dem-
onstrated an inverse association between Helicobacter pylori (H.pylori) 
infection and the risk of developing infl ammatory bowel diseases (IBD). 
Our previous study has demonstrated H.pylori infection can modulate Th17/
Treg balance to protect against colitis. Colitis associated colon cancer (CAC) 
is one of the most common cause of death in IBD patients. Compared with 
hereditary and sporadic colon cancer, the pathogenic mechanisms of CAC 
involve the crosstalk among tumor cells, tumor stromal cells and immune 
cells. The diff erentiation balance between Th17 and Treg cells palys signifi -
cant role in the CAC. Thus, we speculate H.pylori infection might ameolio-
rate the severity of CAC by regulating Th17/Treg balance.
Aims & Methods: The aim of this work was to investigate whether H.pylori 
infection may infl uence the severity of CAC in a mouse model of early 
colorectal carcinogenesis by modulating Th17/Treg balance. C57BL/6 mice 
received azoxymethane (AOM) i.p. at a dose of 10 mg/kg body weight to 
induce dysplasia and then received 4 cycles of 2% DSS, each separated by 
14 days of regular water. All mice were sacrifi ced 90 days aft er the fi rst 
AOM injection to perform histology, fl ow cytometry analysis and immu-
nohistochemistry of colonic mucosa. The tumor number and tumor load 
were counted for each group. Immunohistochemical staining for BrdU was 
performed to evaluate the proliferative activity of colonic epithelial cells. 
Flow cytometry was used to determine the percentage of Th17, IL10+Treg, 
IL17+Treg and tumor associated macrophages (TAM) in colon. The m-RNA 
expression of Th17 and Treg associated cytokines (IL6, IL10, IL17A, IL23, 
TGFβ).
Results: AOM/DSS treatment resulted in the formation of colon tumors in 
both H.pylori infected and non-infected mice. Compared with non-infected 
group, H.pylori infected mice exhibited less tumor number and tumor load 
(7.83±2.64 vs 5.00±1.51, P< 0.05 and 18.68±4.56 vs 9.04±3.40, P< 0.05). 
In accordance, BrdU staining revealed signifi cantly decreased proliferative 
activity in both tumor and peri-tumor tissues (44.62±4.38 vs 27.65±3.24, P< 
0.05 and 10.69±1.42 vs 4.45±1.24, P< 0.05). Flow cytometry study revealed 
lower Th17 and IL17+Treg cells percentage in the colon of H.pylori infected 
group mice, showing an inhibited Th17 cell diff erentiation by H.pylori infec-
tion (3.52±0.32 vs 1.16±0.20, P< 0.05 and 0.30±0.02 vs 0.22±0.02, P< 0.05). 
In turn, H.pylori infected mice exhibited higher IL10+Treg cells percentage 
in colon (0.42±0.02% vs 0.58±0.03%, P< 0.05), which might involve in 
the protective mechanism against colon cancer. In addition, we found that 
H.pylori infected group also presented lower TAM percentage in colon tis-
sues (21.81±1.06 vs 13.46±0.42, P< 0.05). Accordingly, Th17 cells associated 
cytokines ( IL17, IL6 and IL23) decreased in infected group, whereas Treg 
cells associated cytokines ( IL10 and TGFβ) increased signifi cantly.
Conclusion: Our data demonstrated that H.pylori infection might antago-
nize the process from colitis to CAC in CAC mouse model. This eff ect is 
likely mediated via regulating Th17/Treg balance by modulating TAM in 
colon cancer.
Disclosure: All authors have declared no confl icts of interest. 
IBD: Health care and patient-reported outcomes
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Introduction: Patient experience with healthcare is positively associated 
with clinical eff ectiveness and patient safety in a wide range of diseases. 
Infl ammatory bowel diseases (IBD) are chronic and disabling conditions 
involving the gastrointestinal tract. Besides, the quality of information 
given by the physician to patients and the development of shared decision 
processes may be helpful to improve confi dence and adherence in IBD 
management. The aim of this study was to assess experience of patients 
with IBD on their disease, their treatment and the relationship with their 
physician.
Aims & Methods: We performed a nationwide cross-sectional survey in 42 
tertiary centers in France and Belgium affi  liated to the GETAID from No-
vember 26th to December 2nd 2019, on consecutive outpatients with IBD. A 
standardized self-administered anonymous questionnaire was completed 
by each patient. The recorded data included patients, IBD and treatment 
characteristics combined with multiple-choice questions and 10-point Lik-
ert scales regarding patient global assessment of clinical remission, daily 
life IBD burden, treatment adherence, information on IBD, doctor-patient 
relationship, overall satisfaction, patient-self management, concerns about 
their treatment, knowledge on biosimilars and alternative management.
Results: A total of 2011 outpatients with IBD responded to the survey (930 
men; median age 40.0 (29.0-52.0) years; median IBD duration 10.5 (4.5-
18.5) years; 67.8% of patients with Crohn’s disease). Most of the patients 
were treated with biological agents (63.9%) or immunomodulator (8.5%). 
Patient global assessment of clinical remission was noted in 49.9% and 
daily life IBD burden score was 5.2 ± 2.9. Assessment of doctor-patient 
relationship considering IBD and IBD treatment knowledge and doctor-
patient relationship was good ranging from 7.4 to 8.3 (table 1) associated 
with a high adherence to treatment (9.1 ± 2.2). 
Alternative sources of information about ongoing treatment and IBD was 
mainly obtained from internet in 62.9% and 79.8%, respectively, and from 
general practitioner in 54.3% and 61.4%. Indeed, patients with IBD re-
ported consulting their general practitioner 2.6 ± 3.9 times a year in addi-
tion to their gastroenterologist. Lost working days were frequent in 71.2% 
of patients accounting for 0.8 working day loss per years. Complementary 
medicine was used by 28.2% of patients including 19.4% on a regular 
basis. Knowledge about biosimilars was poor (20.4%) and associated with 
a low acceptance rate (21.4%). 
Main concerns about IBD treatment were the fear of adverse events (47.4%) 
and lack and/or loss of effi  cacy (32.9%), while the absence of any concerns 
was observed in 24.4%. Claim for prospective access to complementary 
and alternative healthcare professionals were noticed in 89.2% including 
dietician (24.9%), sports coach (22.0%), psychotherapist (14.6%), sexolo-
gist (9.4%) and social worker (8.5%).
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Total 
(n=536)
No 
treatment 
(n=138)
5-ASA 
(n=113)
Immuno-
modulator 
(n=112)
Anti-TNF 
(n=112)
Vedoli-
zumab 
(n=29)
Ustekinumab 
(n=16)
Crohn´s 
disease, n(%)
286 (53) 83 (60) 12 (11) 66 (59) 91 (71) 19 (66) 15 (94)
Disease 
duration, 
median years 
(IQR)
11 (5-20) 12 (6-21) 10 (4-20) 11 (5-20) 12 (6-20) 14 (5-20) 11 (7-15)
Disease 
activity, n (%)
122 (23) 28 (20) 17 (15) 28 (25) 32 (25) 7 (24) 10 (63)
Perianal 
disease, n 
(%)
32 (11) 10 (12) 2 (2) 5 (8) 10 (11) 2 (10) 3 (20)
Prior bowel 
resection, 
n (%)
143 (27) 57 (41) 3 (3) 26 (23) 40 (31) 7 (24) 10 (63)
Severe 
absenteeism, 
n (%)
36 (7) 8 (6) 2 (2) 3 (3) 13 (10) 4 (14) 6 (38)
Severe 
presenteeism, 
n (%)
85 (16) 23 (17) 6 (5) 16 (14) 29 (23) 6 (21) 5 (31)
Severe overall 
WP loss, n 
(%)
115 (22) 30 (22) 8 (7) 20 (18) 38 (30) 9 (32) 10 (63)
[Table 1. Baseline characteristics]
Conclusion: In this large IBD cohort, 7%, 16% and 22% of patients had 
severe absenteeism, presenteeism and overall WP loss. Major risk factors 
for WP loss were perianal disease and disease activity, resulting in high 
indirect costs. Patients using ustekinumab had the highest yearly indirect 
costs, patients on 5-ASA the lowest, which is most likely related to the 
number of patients with disease activity and perianal disease within these 
groups. A substantial proportion of indirect costs are related to presentee-
ism.
Disclosure: This work was sponsored by dr. Falk Pharma Benelux B.V. 
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Introduction: ICONIC is the largest prospective, multi-country, observa-
tional study assessing disease burden in adults with ulcerative colitis (UC) 
under routine care over a 2-year period. The study assessed quality of life 
and disease burden using standard Infl ammatory Bowel Disease (IBD) pa-
tient reported outcome measures as well as a visual measure of disease-
associated suff ering, Pictorial Representation of Illness & Self-Measure 
(PRISM). The fi nal analysis of the study is presented.
Aims & Methods: Adult patients with early UC (diagnosed ≤36 months) 
were enrolled irrespective of disease severity or treatment. Patient visits 
occurred every 6 months (+/- 3months) for 2 years. The primary objective 
was to evaluate PRISM as a tool to assess disease-associated suff ering in 
patients with UC. Lower PRISM scores represent a greater suff ering as-
sociated with illness. The correlation between patient and physician per-
ception of disease was also assessed. Patient self-assessments included 
PRISM, Patient Health Questionnaire-9 (PHQ-9), Short IBD Questionnaire 
(SIBDQ), and patient-modifi ed Simple Clinical Colitis Activity Index (P-
SCCAI). Physician assessments included clinical parameters, PRISM, and 
SCCAI. Data are presented as-observed. Mean diff erences between patient 
and physician measures, and diff erences between the 2-year and fi rst vis-
its were calculated using Wilcoxon signed-rank test. Correlation between 
PRISM and SIBDQ, PHQ-9, and SCCAI were performed using Spearman 
correlation.
Results: A total of 1806 patients were enrolled and fulfi lled the selection 
criteria; 53.8% female, mean (SD) age 38.5 (14.6) years; 336 (18.6%) dis-
continued the study. At the 2-year visit, data were available for 1265 pa-
Knowledge about IBD 7.4 ± 1.2
Suffi  cient information about ongoing treatment 8.1 ± 2.1
Overall satisfaction about ongoing treatment 7.6 ± 2.5
Adherence to ongoing treatment 9.1 ± 2.2
Overall satisfaction on doctor-patient relationship 8.3 ± 2.2
[Table 1]
Conclusion: In 2011 outpatients with IBD followed-up in tertiary care cen-
tres, we observed a high level of satisfaction, adherence and knowledge 
about IBD and IBD treatment. However, we highlight several fi elds that 
still need improvement: knowledge and acceptance of biosimilars, access 
to complementary and alternative healthcare professionals, loss of work 
productivity and concerns about eff ectiveness and safety of IBD treatment.
Disclosure: This study was funded by Abbvie
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Introduction: Infl ammatory bowel disease (IBD) negatively impacts work 
productivity (WP). Most studies focus on absence from work (absentee-
ism), while on the job productivity loss (presenteeism) is present in more 
than 30% of patients. Indirect costs, defi ned as expenses incurred from 
WP loss due to IBD, have not been thoroughly studied in economic evalu-
ations.
Aims & Methods: The aim of the WORK-IBD study was to determine predic-
tors for WP loss and estimate corresponding indirect costs. Crohn’s disease 
(CD) and ulcerative colitis (UC) patients that attended the outpatient clinic 
of four hospitals between May 1st and August 31st 2017 were invited. WP loss 
was measured using the Work Productivity and Activity Impairment ques-
tionnaire, disease activity using the patient-reported Harvey Bradshaw 
Index or Simple Clinical Colitis Activity Index. Severe absenteeism, presen-
teeism and overall WP loss were defi ned as ≥ 50% work time missed, ≥ 
50% on the job productivity loss, and ≥ 50% overall work impairment (ab-
senteeism plus presenteeism) in the previous week, respectively. Annual 
indirect costs were calculated based on hourly wage data from Statistics 
Netherlands (CBS) 2017, percentages WP loss, contract hours per week and 
47 weeks worked annually.
Results: In total, 1590 IBD patients were invited, 768 (48%) responded (119 
not eligible, 86 declined) and 536 were included (58% female, 53% CD) 
with a median age and disease duration of 45 (33-53) and 11 (5-20) years 
(table 1). Severe absenteeism, presenteeism and overall WP loss was re-
ported by 36 (7%), 85 (16%) and 115 (22%) of patients, respectively. Eight 
(7%) patients using mesalamine (5-ASA), 20 (18%) using immunomodula-
tors, 26 (30%) on anti-TNF monotherapy, 12 (29%) on combination therapy, 
9 (32%) on vedolizumab, 10 (63%) on ustekinumab and 30 (22%) without 
maintenance treatment reported severe overall WP loss. Risk factors for 
severe WP loss were disease activity (OR 6.6, 95% CI 3.6-12.1) and perianal 
disease (OR 3.7, 95% CI 1.5-8.7), whereas 5-ASA treatment was associated 
with a lower risk (OR 0.2, 95% CI 0.0-0.8). Median costs per patient for ab-
senteeism, presenteeism and overall WP loss were €0 (0-0), €0 (0-8430) 
and €1905 (0-10537), respectively. Median costs due to overall WP loss 
were €0 (0-6734) for patients using 5-ASA, €1143 (0-8767) for immuno-
modulators, €3810 (0-14875) for anti-TNF monotherapy, €3049 (0-16859) 
for combination therapy, €5603 (0-15771) for vedolizumab, €10350 (3049-
28201) for ustekinumab and €762 (0-9146) for patients without treatment. 
Costs were higher for patients with disease activity and perianal disease 
(€13,338 vs 0, p< 0.001 and €14363 vs 2382, p=0.001).
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tients. The most common reasons for discontinuation were did not attend 
routine visit and lost to follow-up. At baseline, 37.0% and 12.9% of pa-
tients were assessed by the physician to have moderate or severe disease, 
respectively. At the 2-year visit, the physician assessments were 13.4% of 
patients with moderate disease and 2.5% with severe disease. Mean ± 
SD patient-reported PRISM score and P-SCCAI were signifi cantly diff er-
ent than the physician measures, with patients reporting a higher disease 
burden than that perceived by the physician (patient PRISM: 5.1 ± 2.5 and 
physician PRISM: 5.6 ± 2.4; p< 0.0001; P-SCCAI: 2.5 ± 2.8 and SCCAI: 1.3 ± 
2.1; p< 0.0001; Table). A high correlation was observed between patient 
and physician PRISM scores and between P-SCCAI and SCCAI. Mean ± SD 
scores for PHQ-9 and SIBDQ were 4.2 ± 4.6 and 55.7 ± 11.6, respectively. 
Patient PRISM scores were moderately correlated with SIBDQ, PHQ-9, and 
P-SCCAI (Table).
Signifi cant diff erences in mean ± SD scores between the 2-year visit and 
the fi rst visit were observed for all measures (PHQ-9: -1.8 ± 5.5; P-SCCAI: 
-1.6 ± 4.0; SCCAI: -1.5 ± 3.2, SIBDQ: 6.8 ± 13.9; patient PRISM: 1.2 ± 3.0; 
physician PRISM: 1.3 ± 2.9; p< 0.0001 for all measures).
  SIBDQ PHQ-9
PRISM 
(physician)
P-SCCAI 
(patient)
PRISM (patient), r (p-value)
0.56 
(0.0001)
-0.43 
(<0.0001)
0.63 
(<0.0001)
-0.50 
(<0.0001)
SCCAI (physician), r (p-value)
Not 
determined
Not 
determined
-0.48 
(<0.0001)
0.67 
(<0.0001)
PRISM=Pictorial Representation of Illness & Self- Measure, SCCAI=Simple Clinical Colitis 
Activity Index; SIBDQ=Short Infl ammatory Bowel Disease Questionnaire, PHQ-9=Patient 
Health Questionnaire-9.
[Table. Spearman correlation coe  cients between selected instruments at 
the  nal visit.]
Conclusion: PRISM may be a valuable tool to assess disease burden in 
patients recently diagnosed with UC. Although patient and physician mea-
sures of disease related suff ering and disease severity were strongly cor-
related, the perception of UC-related burden signifi cantly diff ered between 
physician- and patient- assessments. These discrepancies between patient 
and physician ratings warrant further investigation.
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Introduction: The chronic impairment of health related quality of life 
(HrQoL) is of high relevance in patients with ulcerative colitis (UC). Many 
patients perceive a treatment regime solely based on drug therapy as lim-
ited. A standardised multimodal lifestyle-modifi cation program including 
modules in mind-body medicine, naturopathic self-help strategies, herbal 
treatments and dietary counseling shows promising fi rst evidence to lower 
the burden of disease and increase patients HrQoL.
Aims & Methods: Ninety-seven patients with ulcerative colitis in clinical 
remission and impaired HrQoL were randomly assigned to a 10 week com-
prehensive lifestyle-modifi cation program or a control group that received 
a single workshop of intense training in naturopathic self-help strategies 
(Table 1). 
  Lifestyle-modifi cation (n = 47) Control (n = 50)
Age years 50.28 ± 11.90 (18 - 74) 45.54 ± 12.49 (19-71)
Female n (%) 34 (72.3) 35 (70)
Weight 72.79 ± 14.90 (52-100) 70.24 ± 16.86 (49.6 - 150)
Anamnestic pattern n (%)    
Proctitis 14 (29.8) 15 (30)
Left -sided colitis 17 (36.2) 15 (30)
Pancolitis 13 (27.7) 17 (34)
Missing 3 (6.4) 3 (6)
Time since diagnosis years 18.04 ± 12.00 (2 - 46) 14.76 ± 10.99 (1 - 43)
Smokers n (%) 2 (4.3) 3 (6)
Married n (%) 33 (70.2) 39 (78)
Blood parameters    
Leucocytes 6.40 ± 1.70 6.73 ± 4.38
Thrombocytes 272.26 ± 81.69 269.98 ± 72.68
Blood sedimentation rate 9.17 ± 10.55 9.54 ± 11.99
C-reactive protein .36 ± .67 .29 ± .58
[Table 1. Sociodemographic and clinical characteristics at baseline.]
Patients were randomized using stratifi ed block randomization (Strata: 
sex, azathioprine and biologics). Primary outcome was disease-specifi c 
total HrQoL at week 12 (Infl ammatory Bowel Disease Questionnaire; IBDQ). 
Secondary outcomes included IBDQ sub-scores, generic HrQoL (SF-36), 
disease activity (Rachmilewitz clinical activity index, fecal lactoferrin, and 
fecal calprotectin), microbiome, and safety. In 31 patients additional en-
doscopy with histology was performed pre and post intervention.
Results: In both groups, a relevant increase in HrQoL (>16 in the IBDQ) 
at week 12 was achieved. In the Intention-to-treat analysis, the interven-
tion group showed signifi cantly higher improvement on the IBDQ subscale 
Bowel Symptoms (p=.045) and the SF36 mental health index (p=.002). In 
the Per Protocol (PP) analysis (pts who attended ≤50% of the interven-
tion and screening failures were excluded), 37 patients in the intervention 
group and 43 patients in the self-care group were analyzed. Within the 
PP analysis, the LSM group showed a signifi cant higher response in the 
IBDQ global score (p=.034; mean IBDQ=172.8) as well as the IBDQ systemic 
subscore (p=.034) and the IBDQ emotional subscore (p=.004) indicating a 
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Functional Domain 
(0-12)
Bowel Domain
(0-16)
Baseline
N 479 479
Mean (SD) 6.41 (2.13) 8.23 (2.56)
Median 6.43 8.43
Min, max 1.43, 11.43 1, 13
Week 14
N 421 421
Mean (SD) 4.21 (2.35) 5.83 (3.07)
Median 4.14 5.85
Min, max 0, 11.43 0.43, 13.75
Change from Baseline at Week 14
N 334 334
Mean (SD) -2.28 (2.55) -2.45 (2.89)
Median -2.08 -2.28
Min, max -9.86, 6.01 -10.43, 4.72
CD-PRO/SS, Crohn’s Disease Patient-Reported Outcomes Signs and Symptoms; SD, 
standard deviation.
[Table. Baseline, Week 14, and Change from Baseline in CD-PRO/SS Scores 
by Domain]
References: 1. Higgins PDR et al. J Patient Rep Outcomes. 2018;2:24. 2. Eu-
ropean Medicines Agency (EMA). Letter of Support for the development of 
Patient-Reported Outcomes tools for use as an endpoint in Infl ammatory 
Bowel Disease (IBD) clinical trials. April 2019.
Disclosure: PDR Higgins has nothing to disclose. K DeBusk is employee 
of and shareholder in Genentech/Roche and employee of Bristol-Myers 
Squibb (outside submitted work). R Jacob, A Hassanali, Z Sharafali, and A 
Matsui are employees of Genentech. YS Oh is employee of and shareholder 
in Genentech/Roche. 
OP104 IMPACT OF BIOLOGIC TREATMENT OF ULCERATIVE COLITIS 
ON HEALTHCARE RESOURCE UTILIZATION IN US PATIENTS
Naegeli A.1, Hunter T.1, Dong Y.2, Choong C.2, Crandall W.2
1Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, 
Indianapolis, United States, 2Eli Lilly and Company, Indianapolis, United 
States
Contact E-Mail Address: naegelian@lilly.com
Introduction: This study compared healthcare resource utilization (HCRU) 
among Ulcerative Colitis (UC) patients currently receiving biologics and UC 
patients not currently receiving biologics.
Aims & Methods: Adult (18+ years) patients with ≥1 UC diagnosis code (ICD-
9: 556.x; ICD-10:K51.x) from January 1, 2017 to December 31, 2017 were in-
cluded in this retrospective analysis of medical and pharmacy claims data 
from the IBM Marketscan Commercial, Medicaid, and Medicare-Supple-
mental Claims database. Patients with a Crohn’s Disease diagnosis were 
excluded from this study. Subgroups analyses were conducted to compare 
UC patients prescribed biologics and UC patients not prescribed biologics 
during 2017. A two-sample t-test was conducted to compare continuous 
variables and chi-squared tests were used to compare categorical vari-
ables.
Results: A total of 62,146 UC patients were included in this analysis; 7,705 
patients (12.4%) were prescribed a biologic and 54,441 (87.6%) were not 
prescribed a biologic. Biologic users were more likely to be male (50.6% 
vs. 45.6%; p<0.0001) and younger (mean age: 42.94 vs. 49.88 years; 
p<0.0001) when compared to patients not prescribed a biologic. Biologic 
users were more likely to be prescribed immunomodulators (24.2% vs. 
7.9%; p<0.0001), 5-ASAs (50.7% vs. 48.5%; p=0.0004), corticosteroids 
(47.7% vs. 29.5%; p<0.0001), and opioids (41.5% vs. 40.0%; p=0.0132). Bi-
ologic users were also more likely to have gastroenterologist visits (76.9% 
vs. 62.0%; p<0.0001), however patients not prescribed biologics were 
more likely to have ER visits (28.4% vs. 25.6%; p<0.0001) and inpatient 
hospital visits (13.6% vs. 15.8%; p<0.0001).
Conclusion: Medication use was higher among UC biologic users, however 
UC patients not prescribed biologics had higher HCRU.
Disclosure: Nothing to disclose 
higher HrQoL. No signifi cant group diff erence was shown regarding en-
doscopy (p=.451) and histology (p=.406), disease activity (CAI p=.239), fecal 
Lactoferrin (p=.648) or fecal Calprotectin (p=.751). In addition, there was no 
signifi cant diff erence in the fecal microbiota.
Conclusion: UC patients benefi t from defi ned non-pharmacological treat-
ment modules. A comprehensive lifestyle-modifi cation program improves 
quality of life in patients with ulcerative colitis, while no eff ects were 
shown on disease activity in this group of patients in clinical remission. 
The results suggest that patients have to attend more than 50% of the 
training sessions of the 10 week lifestyle-modifi cation program. Trial reg-
istration: Clinicaltrials.gov (NCT02721823).
Disclosure: Research grant: Steigerwald Arzneimittelwerke GmbH, Falk 
Foundation; TechLab, Dr. Willmar Schwabe; Repha GmbH biologische 
Arzneimittel Lecture: Falk Foundation; MSD Sharp&Dohme GmbH; Repha 
GmbH biologische Arzneimittel; Ardeypharm GmbH; Celgene GmbH; Dr. 
Willmar Schwabe Advisory board: Medizinverlage Stuttgart; Steigerwald 
Arzneimittelwerke GmbH; Repha GmbH; Ferring Arzneimittel GmbH; 
Sanofi  
OP103 RESPONDER DEFINITIONS FOR THE CROHN’S DISEASE 
PATIENT-REPORTED OUTCOMES SIGNS AND SYMPTOMS (CD-PRO/
SS) TOOL USING PATIENTS WITH CROHN’S DISEASE TREATED WITH 
ETROLIZUMAB
Higgins P.D.R.1, DeBusk K.2,3, Jacob R.4, Hassanali A.2, Sharafali Z.2, 
Oh Y.S.2, Matsui A.2
1University of Michigan, Ann Arbor, United States, 2Genentech, Inc., South 
San Francisco, United States, 3Bristol-Myers Squibb, Lawrenceville, United 
States, 4Roche Products Limited, Welwyn Garden City, United Kingdom
Contact E-Mail Address: phiggins@med.umich.edu
Introduction: Clinically relevant patient-reported outcome (PRO) tools are 
important for evaluating treatment effi  cacy. Available PRO instruments 
used in Crohn’s disease (CD) have limitations in evaluating the full extent 
of disease components, appropriately quantifying clinical symptoms, and 
adequately capturing the patient perspective. The Crohn’s Disease Patient-
Reported Outcomes Signs and Symptoms (CD-PRO/SS) is the fi rst CD PRO 
tool developed with input from health authorities, patients, and clinical 
experts.1 In April 2019, the EMA released a letter supporting use of the CD-
PRO/SS as an end point in IBD clinical trials.2 Here, we propose responder 
defi nitions for the CD-PRO/SS using data from patients with moderate-to-
severe CD treated with etrolizumab in BERGAMOT (NCT02394028).
Aims & Methods: In BERGAMOT (Phase 3 trial), aTNF-naive and aTNF-
experienced patients with CD were treated with etrolizumab 105 mg, 210 
mg, or placebo SC every 4 weeks during a 14-week induction phase. Co-
hort 1 (blinded) and cohort 2 (open-label) were analysed independently, 
encompassing all treatments. Data reported are from the pooled analysis. 
The CD-PRO/SS consists of 2 separately scored scales: a 3-item functional 
domain and a 3-item bowel domain. The domain score is equal to the 
sum of the item scores, which were calculated as an average of ≥ 4 out of 7 
days before every induction visit. Mininum clinically important diff erences 
(MCID) were calculated using distributional- and anchor-based methods 
on a reduction of ≥ 16 points in the Infl ammatory Bowel Disease Question-
naire, ≥ 70 points in the Crohn’s Disease Activity Index (CDAI), and ≥ 100 
points in the CDAI at week 14.
Results: As of September 2018, the CD-PRO/SS scores from patients with 
non-missing data (67.4% aTNF-experienced; cohort 1 n=215; cohort 2 
n=264) were pooled for analysis (Table). Based on a reduction of ≥ 70 
CDAI and ≥ 100 CDAI, the MCID from anchor-based method were 2.5 and 
2.7, respectively, for the functional domain and 3.1 for the bowel domain 
regardless of treatment arm. Preliminary responder defi nitions for the CD-
PRO/SS were a reduction ≥ 2.5 for the functional domain and ≥ 3.0 for the 
bowel domain that were determined through triangulation. Using these 
cutoff s, 45% of patients were responders based on the functional domain 
and 41% of patients were responders based on the bowel domain. 
Conclusion: The proposed responder defi nitions determined from 479 pa-
tients show that a clinically meaningful response on the CD-PRO/SS are a 
reduction of ≥ 2.5 in the functional domain or ≥ 3.0 in the bowel domain. 
These defi nitions for the CD-PRO/SS will be confi rmed in the ongoing etro-
lizomab Phase 3 CD studies for use in both clinical trials and practice to 
assess a clinically meaningful improvement.
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Management of patients with portal 
hypertension
16:00-17:30 / C3
OP105 SELECTIVE ACTIVATION OF STAT1-DEPENDENT 
APOPTOSIS IN HEPATIC STELLATE CELLS BY RILPIVIRINE AS A NEW 
THERAPEUTIC OPTION FOR LIVER FIBROSIS
Martí-Rodrigo A.1, Moragrega Á.B.1, Gruevska A.1, Fernández-Iglesias A.2, 
Gracia-Sancho J.2, Esplugues J.V.1,3,4, Apostolova N.1,3, Blas-Garcia A.5
1University of Valencia, Department of Pharmacology, Valencia, Spain, 
2IDIBAPS Biomedical Research Institute - CIBERehd, Liver Vascular Biology 
Research Group, Barcelona Hepatic Hemodynamic Laboratory, Barcelona, 
Spain, 3CIBERehd, Valencia, Spain, 4FISABIO, Valencia, Spain, 5FISABIO - 
University of Valencia, Department of Pharmacology, Valencia, Spain
Contact E-Mail Address: alberto.marti-rodrigo@uv.es
Introduction: Liver fi brosis is a common clinical outcome of all chronic 
liver diseases. Its current incidence is achieving pandemic dimensions and 
the lack of eff ective therapeutic options represent a major health problem 
worldwide. Among the wide range of signaling pathways that contribute 
to the progression of this pathology, JAK-STAT1 and JAK-STAT3 have been 
recently proposed as interesting therapeutic targets since they play a key 
role in the regulation of cell proliferation and cell death in both parenchy-
mal and non-parenchymal cells. Rilpivirine (RPV) is a widely used antiret-
roviral drug that not only is considered safe in chronic treatments but also 
has been associated with an improvement in the lipid profi le and glycemic 
control of HIV-infected patients aft er switching from other antiretroviral 
regimens.
Aims & Methods: We aimed to study the role of RPV in the progression 
of chronic liver damage as well as the involvement of JAK-STAT1 and JAK-
STAT3 signaling pathways in this process, especially focusing on its actions 
on hepatic stellate cells (HSC) and hepatocytes.
To do this, a nutritional model of nonalcoholic fatty liver disease (NAFLD) 
and a CCl
4
-induced liver fi brosis model (both in C57BL/6 mice) were used; 
RPV was daily administered at clinical doses. Human cell lines of hepa-
tocytes (Hep3B) and HSC (LX-2), as well as primary human HSC (hHSC) 
were also treated with RPV. Standard molecular biology and histology 
techniques were used to assess the progression of liver damage and the 
activation of STATs. Gene silencing and conditioned medium experiments 
were carried out to evaluate the implication of STAT1 and STAT3 as well as 
the crosstalk between diff erent cell types in response to RPV.
Results: RPV signifi cantly reduced hepatic infl ammation and fi brosis in 
vivo, and produced an increase of STAT3 activation in hepatocytes and of 
STAT1 in HSC. These eff ects were accompanied by augmented numbers of 
proliferating hepatocytes and apoptotic HSC. In vitro, RPV did not directly 
alter the viability or STAT3 activation in hepatocytes, but it did induce a 
clear pro-apoptotic eff ect in LX-2 cells, together with a decrease in STAT3 
and collagen 1 protein expression, and an increase in STAT1 activation. 
Interestingly, this selective cytotoxic eff ect completely disappeared when 
STAT1 was silenced. In addition, STAT3 was activated in hepatocytes incu-
bated with conditioned medium from apoptotic LX-2 cells. All these results 
were reproduced in hHSC.
Conclusion: The hepatoprotective eff ect of RPV is directly mediated by the 
selective STAT1-dependent induction of apoptosis in HSC. Additionally, RPV 
activates STAT3 in hepatocytes, increasing its proliferation and favoring 
liver regeneration. These eff ects could be of great clinical relevance in the 
development of new eff ective therapies for liver diseases with a fi brotic 
component.
Disclosure: Nothing to disclose 
OP106 EUS-GUIDED PORTAL PRESSURE GRADIENT 
MEASUREMENT SAFELY PERFORMED WITH EUS-GUIDED LIVER 
BIOPSY: ENDOHEPATOLOGY IN PRACTICE
Samarasena J., El Hage Chehade N., Hashimoto R., Chang K.
University of California Irvine, Gastroenterology, Orange, United States
Contact E-Mail Address: jsamaras@uci.edu
Introduction: The portal pressure gradient (PPG) is useful to predict the 
development of complications of portal hypertension (PH). Recently, we 
showed the feasibility and safety of a simple novel technique for Endo-
scopic ultrasound (EUS) guided PPG measurement (PPGM) in a pilot study. 
EUS-guided liver biopsy (EUS-LB) has been shown to be a safe and eff ec-
tive alternative to percutaneously or Interventional Radiology performed 
liver biopsy for the diagnosis of liver disease.
Aims & Methods: We aimed to assess feasibility and safety of concomitant 
EUS-guided PPGM with EUS-LB in a single session. Secondarily, we aimed 
to evaluate the correlation between PPG and clinical markers of PH in an 
expanded clinical series.
This was a retrospective study of EUS-PPGM at single tertiary endoscopy 
center that enrolled 51 consecutive patients suspected of liver cirrhosis be-
tween February 2014 and October 2017.
Results: Technical success rate of EUS-PPGM was 100% without any severe 
adverse events. PPG ranged from 0 to 27.3 mm Hg. There was excellent cor-
relation between PPG and clinical parameters of PH including the pres-
ence of clinical features of cirrhosis (11.26 vs 3.14 mmHg, p < 0.001), varices 
(14.94 vs 4.09 mmHg, p < 0.001), portal hypertensive gastropathy (14.37 vs 
5.23 mmHg, p < 0.001), and thrombocytopenia (10.91 vs 4.81 mmHg, p = 
0.0027). Platelet count also had a moderate negative correlation with PPG (R 
= -0.579). EUS-guided liver biopsies were performed in 35 patients (68.6%). 
All biopsies were deemed adequate for achieving histologic diagnosis by 
our pathologists. There were no early or late major adverse events.
Conclusion: EUS-guided PPG measurement using a 25-gauge needle and 
compact manometer correlates well with clinical markers of portal hy-
pertension and appears safe in this study with an expanded selection of 
patients. EUS-LB can be performed safely at the same session as EUS-
PPGM further adding value to the endoscopic evaluation of the patient 
with liver disease.
Disclosure: Presented at DDW 
Expanding the horizons for early colonic cancer
16:00-17:30 / F2
OP107 COVERT CANCER IN COLONIC POLYPS: SIZE DOES MAKE A 
DIFFERENCE!
Hossain E.1, Thayalasekaran S.1, Varytimiadis L.2, Arndtz S.3, 
Abdelrahim M.1, Subramaniam S.1, Bhandari P.4
1Queen Alexandra Hospital, Gastroenetrology, Portsmouth, United Kingdom, 
2Evaggelismos, Gastroenterology, Athens, Greece, 3Queen Alexandra 
Hospital, Endoscopy, Portsmouth, United Kingdom, 4Portsmouth University 
Hospital, Dept. of Gastroenterology, Portsmouth, United Kingdom
Contact E-Mail Address: ejaz.hossain@gmail.com
Introduction: Colorectal polyps with overt endoscopic features of invasive 
cancer are referred for surgery. However, polyps without overt features 
might still harbour cancer. We aim to identify incidence of such covert 
cancers in colorectal polyps to see if the ‘resect and discard’ strategy could 
be extended beyond diminutive polyps.
Aims & Methods: We analysed outcomes of all patients who underwent 
screening colonoscopy between January 2007 to December 2018 and were 
found to have polyps. Data was prospectively collected on an online en-
doscopy reporting system and pathology reporting system. A using multi-
nomial logistic regression.
Results: A total of 15906 polyps were removed at colonoscopy over the 
specifi ed period. Mean size was 7.3 mm (range: 1 to 120 mm) with 82.5% 
polyps being < 10mm in size. 86.6% of all polyps were non pedunculated 
and 56.3% polyps were located in the left  colon and rectum. The size, site, 
morphology and histology of these polyps is shown in table 1.
A histopathological diagnosis of polyp cancer was made in 104 /15906 
polyps (0.65%). 94/104 polyp cancers (90.25%) were associated with non 
pedunculated morphology [OR 1.45, 95%CI 0.75-2.78 p=0.005]. 
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program analysed all images, and the fi nal conclusion regarding the polyp 
was based on the averaged results. Then the results of the AI-DSS were 
compared to the fi nal histology. Thus, we achieved 82.35% accuracy with 
81.82% sensitivity, 83.33% specifi city, 90% PPV, 71.43% NPV.
Conclusion: AI-DSS is able to predict the advanced histology of the polyp 
and diff erentiate between adenomas with low- and high-grade dysplasia 
with high accuracy. This soft ware can support everyday clinical decisions 
and even the training of endoscopists. Due to the nature of deep learning 
neural networks, accuracy of the soft ware could be further increased with 
a higher number of polyp images. The soft ware does not require medical 
expertise.
Disclosure: Nothing to disclose 
OP109 ENDOSCOPIC SUBMUCOSAL DISSECTION FOR COLORECTAL 
MALIGNANT POLYPS. RESULTS OF A PROSPECTIVE MULTICENTER 
WESTERN COHORT
Uchima H.1,2,3, Herreros de Tejada A.4, Múgica F.5, Ramos-Zabala F.6, 
Eduardo A.7, Rosón P.8, De la Peña J.9, Teran A.9, Rodríguez Sánchez J.10, 
García D.11, Amorós Tenorio A.11, Sánchez-Yagüe A.12, Del Pozo-García A.13, 
Dolz Abadia C.14, Fernández-Esparrach M.G.15, Santiago-Garcia J.4, 
Nogales Rincón O.16, Alvarez Delgado A.17, Cortes H.18, Duran R.19, 
Marín-Gabriel J.13, ESD Interest Group. Endoscopic Resection Working 
Group of the Spanish Society of Digestive Endoscopy
1Teknon Medical Center, Gastroenterology (GI Endoscopy Unit), 
Barcelona, Spain, 2Hospital Universitario Doctor Josep Trueta de Girona, 
Gastroenterology (GI Endoscopy Unit), Girona, Spain, 3Hospital Germans 
Trias i Pujol, Badalona, Spain, 4Hospital Puerta de Hierro Majadahonda, 
Madrid, Spain, 5Hospital de Donostia, San Sebastián, Spain, 6Hospital 
Universitario HM Montepríncipe, Servicio de Aparato Digestivo, Madrid, 
Spain, 7Complejo Hospitalario de Navarra, Pamplona, Spain, 8Hospital 
Quirón Salud Malaga, Malaga, Spain, 9Hospital Marqués de Valdecilla, 
Santander, Spain, 10Hospital General de Ciudad Real, Gastroenterology, 
Ciudad Real, Spain, 11Hospital Universitario Nuestra Señora de Candelaria, 
Endoscopy, Santa Cruz de Tenerife, Spain, 12Hospital Costa del Sol, 
Gastroenterology, Marbella, Spain, 1312 de Octubre University Hospital, 
Dept. of Gastroenterology, Endoscopy Unit, Madrid, Spain, 14Son Llatzer, 
Palma de Mallorca, Spain, 15Hospital Clinic de Barcelona, Inst. de Malaties 
Digestives, Barcelona, Spain, 16Hospital Gregorio Marañon Dept. de 
Endoscopia Digestiva, Madrid, Spain, 17University Hospital of Salamanca 
Dept. of Gastroenterology, de Salamanca Endoscopist &, Salamanca, Spain, 
18San Juan de Dios Medical Center, Santurce, Spain, 19Servidigest Center, 
Barcelona, Spain
Contact E-Mail Address: hugoikuo@hotmail.com
Introduction: Endoscopic submucosal dissection (ESD) allows en bloc re-
section of early gastrointestinal tumours regardless of size, with an en bloc 
resection rate in colon around 91.7%
1
, thus allowing an adequate histo-
logical examination. This is important in the resection of malignant polyps 
(those who invade the submucosal layer) as they carry a risk for LNM, that 
can be stratifi ed in high or low risk according to the histological features.
Aims & Methods: Our aim was to describe the feasibility, technical success, 
en bloc resection rate and complications of ESD for colorectal malignant 
polyps in a western cohort.
We analyzed all the cases of colorectal ESD performed in polyps with his-
tology showing submucosal or deeper invasion (at least pT1), that were 
recruited in 19 centers between January 2016 and January 2019 in a pro-
spective Spanish study. 
Stata soft ware was used for statistical analysis. Categorical data were ex-
pressed as frequencies and percentages. Comparative data according to 
location was analyzed. Categorical data was compared using Pearson´s 
chi-squared test, and cuantitative data was compared with T student test.
Results: From a total of 851 colorectal ESDs, 58 (6.8 %) cases with submu-
cosal or deeper invasion were evaluated. 
Mean age of patients was 68 years old, being male 72%. ASA score was I-II 
in 39 patients, III in 18 and IV in 1.
The lesions were located in rectum n=21 (36%), sigmoid n=10 (17%), de-
scending colon n=8 (13.7%), splenic fl exure=2 (3.4%), transverse colon n=4 
(7%), hepatic fl exure n=3 (5%), ascending colon n=7 (12%), and cecum 
n=3 (5%).
Complete resection of the lesion was achieved in 48 cases (82.7%). The en 
bloc resection rate was 70.7% (n= 41). When comparing the results of ESD 
for malignant polyps according to location, the en bloc resection rate was 
No cancer was found in polyps < 5mm in size. However, the cancer inci-
dence was 4/2365 (0.17%) in polyps 6-10mm [OR 1.10 95% CI 1.09-1.12, 
p<0.001], 58/1793 (3.25%) in polyps 10-30mm and 42/973 (4.30%) in pol-
yps > 30mm in size. Risk of developing in cancer in polyps >10mm was sig-
nifi cantly higher than in polyps 6-10 mm [OR 21.1 95% CI 7.9-58, p< 0.001].
89 cancers were found in the left  colon and rectum compared with 15 can-
cers in the right colon (85.5% vs 14.5%) [OR 1.98, 95%CI 0.9-3.1 p=0.007]. 
All 4 cancers found in the 6-10mm category were non-pedunculated pol-
yps in left  colon.
Size
Propor-
tion %
Morp hology % Location % Dysplasia %
   
Pedun-
culated
Non pedun-
culated
Right 
Colon
Left  
Colon
None LGD HGD Cancer
< 5mm 
(N= 10775)
67.74 3.7 96.3 50.3 49.7 34.0 65.40 0.60 0.0
6-10mm 
(N= 2365)
14.87 31.75 68.25 30.8 69.2 21.33 74.44 4.06 0.17
10-30mm 
(N=1793)
11.27 46.9 53.1 31.0 69.0 12,20 68.89 15.67 3.25
>30mm 
(N= 973)
6.12 14.08 85.92 24.0 76.0 10.10 69.50 16.10 4.30
[Table 1]
Conclusion: We have demonstrated that the prevalence of covert cancer in 
colorectal lesions < 5mm is negligible and that of polyps 6-10 mm is very 
low (0.17%). All these cancers were in non-pedunculated polyps in left 
colon.This means that the ‘resect and discard’ strategy could be extended 
to 6-10 mm polyps in right colon and potentially to pedunculated polyps 
in left  colon.
Cancer risk, however, increased more than 20 fold in polyps between 1-3 
cm (3.25%) and 25 fold in polyps > 3 cm (4.3%). This calls for careful 
resection (preferably en-bloc) and retrieval of these polyps to obtain all 
prognostic information.
Disclosure: Nothing to disclose 
OP108 APPLICATION OF ARTIFICIAL INTELLIGENCE AND DEEP 
LEARNING ALGORITHM IN THE PREDICTION OF ADVANCED 
HISTOLOGY OF COLORECTAL ADENOMAS
Lovasz B.D.1, Oczella L.2, Szalai M.2, Dubravcsik Z.3, Kiss E.4, Schmiedt P.5, 
Zsobrák K.2, Madácsy L.2
1Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 
2Endo-Kapszula Health Center and Endoscopy Unit, Székesfehérvár, Hungary, 
3Bacs-Kiskun County Hospital, Gastroenterology & Endoscopy, Kecskemét, 
Hungary, 4Szent Imre Hospital, Budapest, Hungary, 5Endo-Kapszula Health 
Center and Endoscopy Unit, Budapest, Hungary
Contact E-Mail Address: endomabt1@gmail.com
Introduction: Recognition of high grade dysplasia or intramucosal malig-
nancy in colorectal polyps is of critical importance before polypectomy to 
ensure that the optimal operative endoscopic method is selected for the 
removal. This is currently mainly based on expert opinions. Therefore, we 
developed an artifi cial intelligence-based decision support system (AI-
DSS) that can diff erentiate between low- and high-grade dysplasia or in-
tramucosal neoplasia in adenomatous polyps.
Aims & Methods: In the present study our aim was to analyze the eff ective-
ness and accuracy of an AI-DSS in the prediction of advanced histology. We 
took still images from videos (colonoscopy containing colorectal adenomas 
with low- and high-grade dysplasia). We enrolled 1033 HD images of a 
total of 91 polyps (85 patients, 57.45% male, 56.4 average age), and we 
set up and trained a deep learning model with these images. The images 
went trough a pre-process algorithm, images of malignancies (invasive 
cancer), and low-quality images were excluded from both the train and 
test sets. Using the Gradient-weighted Class Activation Mapping (Grad-
CAM) technique, the soft ware can visually explain via a „heatmap” which 
areas on the image contained key information for the decision.
Results: We trained the neural network with 480 images of 55 polyps with 
a histological diagnosis of low-grade dysplasia and 457 images of 41 pol-
yps with high-grade dysplasia. 119 images of 17 polyps (7 with low-grade 
and 5 with high-grade dysplasia + 2 with intramucosal carcinoma) were 
used for the test set. The test group had more images of each polyp, the 
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higher in the rectosigmoid compared to the rest of the colon (83.9% vs 
55.5% respectively, p=0.02).
There were 10 (17%) aborted procedures due to technical reasons (2/10), 
perforation (2/10) or muscle retracting sign (6/10).
The mean size of the resection was 38.3mm x 30.7mm (CI 95% 33.9-42.7 for 
major axis, and 26.1-35.2 for minor axis). 
Submucosal fi brosis was absent (F0) in 18 cases, it was mild (F1, white 
web-like structure in the submucosa) in 17 cases and there was severe 
fi brosis (F2, “white submucosa”) in 23 cases (39.66%). 
There were 6 (10%) intraprocedural bleeding, 3 (5%) delayed bleeding, 
10 (17%) intraprocedural perforations and 2 (3.4%) delayed perforations.
There were a total of 30 (51.7%) surgeries: 19 (63% of surgeries) due to 
high risk histologic features, 10 for aborted ESD (mainly due to muscle 
retracting sign as discussed before), and 1 for delayed perforation.
There were 2 pT2 and 1 pT3 cases diagnosed aft er surgery due to aborted 
ESD. 
LNM were positive in 6 cases (5 pT1N1 and 1 pT2N1).
Regarding the need for surgery, it was much lower aft er ESD in the rectum 
than in the colon, with 8 surgeries (38%) in rectum vs 22 surgeries (59%) 
in colon, p= 0.03.
Conclusion: ESD for malignant polyps in the distal colon (sigmoid and rec-
tum) shows better results compared to more proximal locations. 
In a Western population, the en bloc resection rate for malignant polyps 
proximal to sigmoid location is lower than expected for colorectal ESD ac-
cording to current literature.
LST Granular G. Nodular Mixed =18 G. Homogeneous = 2
LST NonGranular NG Pseudodepressed=15 NG Flat = 4
0-Is 13
0-Ip 1
0-IIc or 0-IIc component 4
0-IIb 1
[Morphology of the lesions]
References: Fujiya M, Tanaka 1, Dokoshi T, et al. Effi  cacy and adverse events 
of EMR and endoscopic submucosal dissection for the treatment of colon 
neoplasms: a meta-analysis of studies comparing EMR and endoscopic 
submucosal dissection. Gastrointest Endosc 2015;81:583-95
Disclosure: Nothing to disclose 
OP110 ENDOSCOPIC FULL-THICKNESS RESECTION IS FEASIBLE FOR 
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Introduction: For T1 colorectal cancer (CRC), endoscopic resection is an 
attractive alternative for surgical resection due to substantially lower 
morbidity and mortality. However, conventional polypectomy for T1 CRC 
oft en leads to suboptimal histologic risk assessment and colonic ESD is 
challenging. Exact risk stratifi cation with certainty about resection margin 
status and the presence of histologic risk factors for lymph node metastasis 
(LNM) is crucial for further decision making. Allowing transmural resec-
tion, endoscopic full-thickness resection (eFTR) could potentially serve as 
a valid diagnostic and therapeutic primary treatment option for T1 CRCs as 
well as completion treatment aft er previous incomplete resection of low-
risk T1 CRCs.
Aims & Methods: The aim of this study was to determine the technical 
success, clinical success and safety of eFTR for T1 CRCs. In our prospective 
multicenter cohort of all eFTR procedures performed between September 
2015 and April 2019 in 21 Dutch hospitals, we evaluated all T1 related pro-
cedures. This included primary treatment for lesions with optical diagnosis 
of T1 CRC and secondary treatment aft er previous (potentially) incomplete 
resection of T1 CRC. To determine technical success, we studied the num-
ber of macroscopic complete (no macroscopic evidence of residual lesion 
judged by the endoscopist) en bloc resections. Other outcomes were clini-
cal success (R0 resection with tumor-free lateral and deep resection mar-
gins and possibility of discrimination between high-risk versus low-risk 
T1 CRCs) and adverse events. A lesion was defi ned as high-risk if one of 
the following risk factors was present: poor diff erentiation, lymphatic or 
vascular invasion, deep submucosal invasion (≥1000 µm) or incomplete 
resection (R1/Rx resection).
Results: We included 247 procedures. Indications for eFTR were primary 
resection for suspected T1 CRCs (n=81) and re-resection aft er previous in-
complete resection of T1 CRCs (n=166). Technical success of all procedures 
was achieved in 85.4% (n=211/247). No histopathology was obtained in 
6.1% (n=15/247), because the lesion either could not be reached or re-
tracted into the cap. In the remaining 232 cases amenable to eFTR, R0 
resection rate was 88.8% (n=206/232). Final histopathology confi rmed re-
sidual adenocarcinoma in 33.2% (n=77/232). Subgroup analysis showed 
adenocarcinoma in 85.5% (n=65/76) aft er primary resection and in 7.7% 
(n=12/156) aft er previous incomplete resection. Discrimination between 
high-risk versus low-risk T1 CRC was achieved in 97.4% (n=75/77). Low-
risk T1 CRC was identifi ed in 22.1% (n=17/77) and high-risk T1 CRC in 75.3% 
(n=58/77). In 46.6% (27/58) of the high risk cases, deep submucosal in-
vasion was identifi ed as the only risk factor for LNM. Additional surgery 
was performed in 41.4% (n=24/58) of the high risk cases, of which 87.5% 
(n=21/24) had no residual cancer or LNM. Endoscopic surveillance strategy 
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OP112 FULL-THICKNESS RESECTION BY USING LAPAROSCOPY 
ENDOSCOPY COOPERATIVE SURGERY (LECS) TO OVERCOME THE 
LIMITATIONS OF ENDOSCOPIC RESECTION FOR COLORECTAL 
NEOPLASMS
Tamegai Y.1, Fukunaga Y.2
1Cancer Institute Hospital, Endoscopy, Tokyo, Japan, 2Cancer Institute 
Hospital, Gastroenterological Surgery, Tokyo, Japan
Contact E-Mail Address: yoshiro.tamegai@jfcr.or.jp
Introduction: We established a new procedure, laparoscopy endoscopy co-
operative surgery (LECS) applied with endoscopic submucosal dissection 
(ESD) technique to overcome the limitations of endoscopic resection for 
colorectal tumors. In this report, we clarify the feasibility of performing 
a safe full-thickness resection with an adequate surgical margin by LECS 
procedure.
Aims & Methods: We performed full-thickness resection for 18 colorectal 
tumors in 18 patients (male: female 11:7; mean age, 65.8 years) by LECS. 
The clinicopathological outcomes of these 18 cases and the feasibility of 
full-thickness resection were evaluated retrospectively. 
The indications for LECS were as follows: 1) intramucosal cancer and ade-
noma (Vienna Classifi cation; Category 3, 4) accompanied by severe fi brosis 
in the submucosal layer (tumor recurrence aft er endoscopic or surgical re-
section), 2) intramucosal cancer and adenoma involving the diverticulum 
or appendix, and 3) intraluminal or intramural growth-type submucosal 
tumors.
Results: We successfully performed full-thickness resection using LECS in 
18 cases (intramucosal cancer [n=6], adenoma [n=10], schwannoma [n=1], 
and gastro-intestinal stromal tumor [GIST] [n=1]. The mean tumor size was 
22.2mm (range, 8-41mm). LECS was successfully performed in 18 all cases 
without conversion to open surgery; the R0 rate was 100%. The indica-
tions for LECS were as follows: involvement of the appendix (n=7), tumor 
accompanied by severe fi brosis (n=5), involvement of a diverticulum (n=3), 
submucosal tumor (n=2), and poor endoscopic operability (n=1). We ex-
perienced no adverse events (e.g., grade 3 or more of Clavien-Dindo clas-
sifi cation), and the mean hospital stay was 6.4(range, 4 to 12) days. All 
patients who were followed for ≥6 months (mean, 37.3 months; range, 
11-80 months) showed no residual/local recurrence. Thus, the use of the 
ESD technique in LECS, can achieve a safe oncological margin in cases 
involving colorectal tumors.
Conclusion: LECS was a safe, feasible, minimally-invasive procedure that 
achieved the full-thickness resection of colorectal tumors and which 
showed excellent clinical outcomes.
References: [1] Fukunaga Y, Tamegai Y, Chino A, et al: New technique of en 
bloc resection of colorectal tumor using laparoscopy and endoscopy coop-
eratively (laparoscopy and endoscopy cooperative surgery - colorectal). Dis 
Colon Rectum 2014; 57, 2: 267-271 [2] Tamegai Y, Fukunaga Y, Suzuki S, et al: 
Laparoscopic and endoscopic surgery (LECS) to overcome the limitations 
of endoscopic resection for colorectal tumors. Endoscopy Int open 2018; 
06: E1477-E1485
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OP113 STEP-UP FECAL MICROBIOTA TRANSPLANTATION: 
TARGETING COMPLAINTS IN CROHN’S DISEASE
Xiang L.1, Ding X.1, Li Q.1, Li P.1, Wu X.2, Dai M.2, Zhang F.1
1the Second A  liated Hospital of Nanjing Medical University, Medical Center 
for Digestive Disease, Nanjing, China, 2The Second A liated Hospital of 
Nanjing Medical University, Nanjing, China
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Introduction: The benefi ts of fecal microbiota transplantation (FMT) in 
Crohn’s disease (CD) is unclear.
Aims & Methods: This real-world study aims to evaluate FMT’s potential 
therapeutic targets in CD. FMT for CD as a registered trial (NCT01793831) 
was performed from October 2012 to December 2017. Clinical response 
was assessed at 1 month and 3 months aft er step-up FMT. We defi ned 
seven major complaints and recorded them as 1 (yes) or 0 (no) in the long-
term follow up for each patient, which include abdominal pain, diarrhea, 
was initiated in 46.6% (n=27/58). The overall adverse event rate was 8.5% 
(n=21/247), with emergency surgery in 2.4% (n=6/247) for 2 immediate and 
4 delayed perforations.
Conclusion: eFTR is a feasible and safe treatment for T1 CRCs, both as 
primary treatment and secondary treatment aft er previous incomplete 
resection. eFTR delivers optimal histology for risk assessment and leads to 
R0 resection rate in 88.8% overall, avoiding surgery in most cases. Further 
studies focussing on long term outcomes need to clarify the role of eFTR 
for scars aft er previous incomplete resection and as a primary treatment 
method for deep submucosal invasive T1 CRC.
Disclosure: Nothing to disclose 
OP111 LONG-TERM OUTCOMES IN 944 T1 COLORECTAL CANCER 
AFTER ENDOSCOPIC AND SUGICAL RESECTION
Kimoto Y.1, Ohata K.2, Matsuhashi N.3
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Introduction: Lymph node metastasis (LNM) occurs in 6-12% of patients 
with T1 colorectal cancer (T1-CRC). In some studies, the depth of submu-
cosal invasion, histological type, lymphovascular invasion, and tumor 
budding have been reported as risk factors for nodal metastasis, and the 
remainders were classifi ed into high-risk group. Recent studies reported 
that invasion depth only has no clinical impact to LNM of CRC. pT1b CRCs 
have a good prognosis if treated along guidelines. However, the high rate 
of recurrence has been reported in rectal pT1b CRCs when they were fol-
lowed it up without additional surgical resection (SR). Therefore we aim 
to examine the recurrence rate and clinicopathological features associated 
with invasive recurrence aft er endoscopic resection for T1 CRC, in particular 
in rectum.
Aims & Methods: A total of 944 patients with T1 CRCs treated by endoscopic 
resection (ER) or SR from January 2000 to April 2018 at our unit were 
analyzed retrospectively. The exclusion criteria were as follows; 1) patients 
with FAP, HNPCC, or IBD, 2) patients with active malignant diseases in 
any other organs, 3) patients with synchronous or metachronous advanced 
colorectal cancer, 4) patients with T1a-CRCs treated by primary SR and 5) 
follow up periods. We evaluated the invasive recurrence rate and clinico-
pathological features of 883 T1-CRCs.
Results: A total of 883 patients were involved according to criteria of this 
study (median follow-up period: 76 months). Of 883 patients, 246 patients 
underwent ER alone, 60 of 246 patients were followed-up without ad-
ditional SR. 251 patients underwent ER+SR, and 386 patients underwent 
primary SR. 246 patients in ER alone were divided into 186 patients in ER-L 
(Low risk) and 60 patients in ER-H (High risk). 637 patients in SR (ER+SR 
and primary SR) were divided into 281 patients in SR-L (Low risk) and 356 
patients in SR-H (High risk). In ER alone, 2 patients were cancer death. 
The outcomes of ER-L and ER-H were that 0% vs 8.3% (5 of 60 patients) in 
recurrence rate (RR). ER-H was tended to be higher in recurrence than ER-
L. In 5 patients with recurrence in ER-H, tumor location were all rectum. 
In 637 patients in ER+SR and primary SR, Synchronous LNM occurred in 
10.5%. The outcomes of SR-L and SR-H were that 3.9% (11 of 280 patients) 
vs 15.7% (56 of 357 patients). SR-H was tended to be higher in Synchro-
nous LNM than SR-L, and a sub-analysis showed that primary treatment 
and lymph invasion and vascular invasion were equivalent to the risk fac-
tors of Synchronous LNM (p< 0.01). In SR, 4 patients were cancer death. 
The outcomes of SR-L and SR-H were that 0% vs 2.2% (8 of 357 patients) 
in RR. Synchronous LNM was the only factor that contributed signifi cantly 
to increase recurrence in SR (p< 0.01).
Conclusion: pT1b CRCs have a good prognosis if treated along guidelines. 
The invasive recurrences for T1 CRC in our study was 1.5% overall. Our 
results suggested that a risk factor of recurrences in ER alone was only 
rectum. Therefore surgery should be considered in addition to ER regard-
less of the risk factors in pT1b rectal CRCs. We didn’t experience recurrence 
in SR-L, but experienced 8 recurrences (2.2%) in SR-H. So careful follow-
up is required even in high-risk group undergoing surgery that included 
lymph node dissection.
Disclosure: Nothing to disclose 
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hematochezia, fever, steroid-dependence, enterocutaneous fi stula, active 
perianal fi stula. Step-up FMT strategy includes: step 1: single FMT; step 2: 
≥ 2 FMTs; step 3: FMT(s) followed by immunosuppressant or enteral nutri-
tion. Potential predictors for non-response to FMT were analyzed.
Results: Totally 174 patients completed follow-up. Median follow-up was 
28 (IQR 12-47) months. 74.7% (130/174) and 67.2% (117/174) of patients 
achieved clinical response at one month and three months aft er FMT. The 
total complaint score decreased signifi cantly at 3, 6, 12, 24, 36 months 
aft er FMT. 71.9% (100/139), 68.3% (95/139), 64% (89/139), 56.5% (65/115), 
and 52.2% (47/90) of patients had abdominal pain improvement at 3, 6, 
12, 24, 36 months aft er FMT, respectively. 61.4% (89/145), 57.9% (84/145), 
53.8% (78/145), 44.4% (52/117), 42.2% (38/90) of patients had diarrhea 
improvement at 3, 6, 12, 24, 36 months aft er FMT, respectively. 55% (11/20) 
of steroid-dependent patients were able to discontinue steroids aft er FMT. 
Disease duration > 2 years (p = 0.011) was associated with poor response 
to FMT.
Conclusion: Step-up FMT strategy could be an eff ective therapeutic option 
for CD-related complaints.
Disclosure: Nothing to disclose 
OP114 PERIANAL LESIONS IN CROHN’S DISEASE AT DIAGNOSIS: 
ANALYSIS OF EPIMAD REGISTRY FROM 2007 TO 2012 IN A 
POPULATION BASED-STUDY
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Introduction: Perianal lesions (PL) aff ect up to 26% of Crohn´s disease (CD) 
patients in the fi rst two decades aft er diagnosis and are associated with 
poor outcomes.1 Data concerning evaluation and clinical management of 
PL at diagnosis are limited.2,3
Aims & Methods: To perform a population based-study to characterise CD 
patients presenting with PL at diagnosis and describe their initial diagno-
sis and assoicated therapeutic management.
All CD patients diagnosed between 2007 and 2012 were extracted from 
a French multi-centre prospective registry (EPIMAD Registry).4 PL were 
defi ned as the presence of fi stula or abscess at CD diagnosis. For all pa-
tients with PL at diagnosis, complementary data were collected via a stan-
dardised questionnaire through examination of gastroenterologist and 
surgeon records by a university proctologist. The following variables were 
described: clinical examination, perianal resonance imaging (magnetic 
resonance imaging [MRI]), echo-endoscopy, examination under general 
anesthesia (GA) and medical and/or surgical management within the fi rst 
three months aft er CD diagnosis. Associated factors with PL at CD diagnosis 
were identifi ed using a multivariate logistic regression.
Results: Among the 2,906 patients with CD diagnosed between 2007 to 
2012, 116 (4%) had PL at CD diagnosis. Forty-four percent of patients were 
women, the median age at diagnosis was 25 years (IQR: 19-39) and 51 
(45%) patients had a previous history of PL. Ileocolonic CD (L3) was pre-
dominant in 51 patients (47%); one patient (1%) had only perianal involve-
ment and 51% of patients presented rectal lesions. Patients could present 
one or more PL: 81% had fi stula (including 12 rectovaginal fi stulas) and 
58% had abscess; one patient (1%) had anal stenosis. An examination un-
der GA was performed in 50% of patients, MRI in 34% of patients and an 
echo-endoscopy in 1 case. For initial therapeutic management of CD: 63% 
of patients received antibiotics, 42% 5-ASA and 47% steroids. Twenty-sev-
en percent of patients received azathioprine, 29% anti-TNF therapy (87% 
infl iximab) and 13 (12%) patients received combination therapy. Surgery 
was performed in 64 patients (57%) with 41 abscess drainages, 25 seton 
drainages, 16 fi stulotomy and 2 diverting ileostomy. Multivariate logistic 
regression analysis found that male sex (p = 0.006), an absence of ab-
dominal pain (p = 0.003) and colonic location (p = 0.02) were signifi cantly 
associated with the presence of PL at CD diagnosis.
Conclusion: In this large population-based study, the proportion of pa-
tients with PL at CD diagnosis was 4%. Male sex, absence of abdominal 
pain, and colonic location were associated with the presence of PL at CD 
diagnosis. Surgery was performed in over half of the cases. An immuno-
suppressant, anti-TNF or combination therapy was respectively prescribed 
for 27%, 29% and 12% of cases, refl ecting the current approach for treat-
ing CD patients with PL. Further exploration of treatment options aft er CD 
diagnosis is warranted.
References: 1. Schwartz DA, Loft us EV Jr, Tremaine WJ, et al. Gastroen-
terology 2002;122: 875-880. 2. Gomollón F, Dignass, A, Annese V, et al. 
J Crohns Colitis 2016;11: 3-25. 3. Gottgens KW, Jeuring SF, Sturkenboom 
R, et al. Eur J Gastroenterol Hepatol 2017;29: 595-601. 4. EPIMAD (2019) 
Retrieved from http://epimad.chru-lille.fr/historique/index.html. (Last ac-
cessed: April 2019).
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OP115 THE DETECTION OF ESOPHAGEAL SQUAMOUS CELL 
CARCINOMA IN ENDOSCOPIC MOVIES BY THE ARTIFICIAL 
INTELLIGENCE USING CONVOLUTIONAL NEURAL NETWORKS
Shiroma S.1, Yoshio T.1, Aoyama K.2, Ishiyama A.1, Tsuchida T.1, Fujisaki J.1, 
Tada T.3
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Introduction: Esophageal cancer is the eighth most common cancer world-
wide, and the sixth cause of death. When esophageal cancer is diagnosed 
in advanced stage, it will require highly invasive treatments and its prog-
nosis will be poor, thus it is important to detect in early stage. In recent 
years, artifi cial intelligence (AI) using deep learning has made remarkable 
progress in various medical fi elds, and we had reported the great ability of 
artifi cial intelligence to detect esophageal cancer including squamous cell 
carcinoma (SCC) and adenocarcinoma in still pictures.
Aims & Methods: We demonstrated the diagnostic ability of AI to detect 
superfi cial esophageal SCC in movies.
We retrospectively collected 8428 training still images of esophageal can-
cer that was histologically proven to be SCC or adenocarcinoma, including 
6026 white light imaging (WLI) and 2402 narrow band imaging (NBI), from 
Cancer Institute Hospital, Tokyo, Japan from 2014 to 2017. These images 
were used to develop deep learning through a convolutional neural net-
works (CNNs) to detect esophageal cancer. 
Then we prepared 80 test movies of 40 patients both in WLI and in NBI, 
including 20 patients with 22 superfi cial esophageal SCC and 20 patients 
with no esophageal cancer to evaluate the accuracy of AI diagnosis. All 
cases of esophageal cancer were confi rmed to have no other cancer using 
WLI, NBI, iodine staining, and follow-up endoscopy aft er the treatment.
In the movies, we inserted endoscopy from cervical esophagus to esopha-
gogastric junction in the speed of 2cm /sec. AI diagnosed SCC when the 
lesions were detected for 0.06 sec.
Results: The AI correctly diagnosed 81.8% (18/22) of esophageal cancers 
both in WLI and in NBI. Of them, 45.4% (10/22) of cancers were diagnosed 
with WLI and 77.2% (17/22) with NBI. In contrast, the AI misdiagnosed 31 
non-cancerous lesions, which caused low positive predictive value (PPV) 
(36.7%). However, these sensitivity and PPV in movies were not so diff er-
ent from in still pictures (sensitivity 98%, positive predictive value 54%). 
The misdiagnosed lesions included scars of endoscopic resection (3 le-
sion), esophagogastric junction (7 lesions), shadows of esophageal lumen 
(15 lesions). Infl ammation of esophageal mucosa (6 lesions). This can be 
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re-epithelialization was 6 weeks (range, 5-14). Dysphagia score deterio-
rated to 1 to 2 in 31.8% (8/44), but showed a fi nal score of 0 aft er complete 
re-epithelialization in 93.1% (41/44). No severe adverse events occurred.
Conclusion: The esophageal TA-fi lling method is highly eff ective for 
preventing severe stenosis aft er subcircumferential esophageal ESD, and 
the procedure is simple, feasible, and safe. However, grade 2 or higher 
resection has a high risk for stenosis.
References: 1. Shibagaki K, Ishimura N, Oshima N, et al. Esophageal 
triamcinolone acetonide-fi lling method: a novel procedure to prevent 
stenosis aft er extensive esophageal endoscopic submucosal dissection 
(with videos). Gastrointest Endosc 2018;87:380-89. 2. Katada C, MutoM, 
Manabe T, et al. Esophageal stenosis aft er endoscopic mucosal resection 
of superfi cial esophageal lesions. Gastrointest Endosc 2003;57:165-9. 3. 
Hashimoto S, Kobayashi M, Takeuchi M et al. The effi  cacy of endoscopic 
triamcinolone injection for the prevention of esophageal stricture aft er 
endoscopic submucosal dissection. Gastrointest Endosc 2011;74:1389-93. 4. 
Hanaoka N, Ishihara R, Takeuchi Y, et al. Intralesional steroid injection to 
prevent stricture aft er endoscopic submucosal dissection for esophageal 
cancer: a controlled prospective study. Endoscopy. 2012;44:1007-11. 5. 
Knyrim K, Wagner HJ, Bethge N. A controlled trial of an expansile metal 
stent for palliation of esophageal obstruction due to inoperable cancer. N 
Engl J Med 1993;329:1302-7.
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OP118 COMPARABLE LONG-TERM OUTCOMES OF ENDOSCOPIC 
SUBMUCOSAL DISSECTION AND ESOPHAGECTOMY FOR EARLY 
ESOPHAGEAL SQUAMOUS CELL NEOPLASIA: A SYSTEMATIC REVIEW 
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Introduction: Endoscopic submucosal dissection (ESD) has become treat-
ment of choice for superfi cial esophageal squamous cell neoplasia (ESCN) 
owing to the minimal invasiveness and high rate of complete resection. 
However, it is not clear whether ESD has similar long-term outcome com-
pared to esophagectomy.
Aims & Methods: This study is aimed to evaluate the long-term outcomes 
of ESD with comparison of that to esophagectomy in patients with super-
fi cial ESCN. Comprehensive literature search and review were conducted 
using PubMed, Cochrane Library, and ProQuest databases through January 
2019. The inclusion criteria were studies having > 20 cases and reporting 
survival data longer than 3 years with ESD for superfi cial ESCN. The exclu-
sion criteria were those with incomplete data, or inability to extract data 
from mixture results with adenocarcinoma or other treatment modality. All 
extracted data were present and analyzed either with the original format 
or following appropriate calculation. The primary outcomes were over-
all survival, disease free survival and disease specifi c survival at 3 and 5 
years. Secondary outcomes included adverse events, R0 resection, locore-
gional recurrence and distal metastasis. Meta-analyses were performed 
with hazard ratio (HR) for survival analysis and odds ratio (OR) for other 
variables using appropriate models and expressed with 95% confi dence 
interval (CI).
Results: Total 21 eligible retrospective studies and 3796 patients were in-
cluded. Among these, 5 studies compared ESD and esophagectomy and the 
others only reported the outcome with endoscopic treatment. For all the 
cases of ESD, the distribution of tumor invasion depth was 52.0% for m1-
m2, 43.2% for m3-sm1 and 4.7% sm2 or deeper; however, up to 35.6% of 
cases had discrepancy between clinical and pathological stage. The mean 
R0 resection rate was 92%, and proportion of lesions exceeding 50% 
and 75% of circumference were 36.5% and 8.6%. The local recurrence, 
metachronous recurrence and nodal/distal metastasis rate of ESD were 
1.8%, 8.5%, and 3.3% respectively. Severe complication of ESD included 
perforation (3.4%) and stricture (9.5%), although endoscopic treatment 
was successful in most cases, the median sessions of balloon dilatation 
ranged from 2-8 and more procedures were necessary for cervical lesions. 
corrected by deep learning about each normal structure and benign lesion, 
which will surely reduce false positives and improve the PPV signifi cantly. 
Furthermore, because endoscopists will never think esophagogastric junc-
tion or shadows of esophageal lumen as cancer, considering the practical 
use of this system, this PPV is not so high but acceptable. 
The missed cancers were less than 1 cm in size or in background infl am-
mation. It was very diffi  cult to detect these lesions with WLI or NBI even by 
experienced endoscopist in the movies, because of their speed and indis-
tinguishable lesions.
Conclusion: AI could detect superfi cial esophageal SCC in movies with high 
sensitivity, same as in still pictures. This system would well support en-
doscopists in real time during endoscopic examinations in the near future.
Disclosure: Nothing to disclose 
OP116 WITHDRAWN
OP117 CLINICAL EFFICACY OF THE ESOPHAGEAL TRIAMCINOLONE 
ACETONIDE-FILLING METHOD: A NOVEL STENOSIS-PREVENTIVE 
PROCEDURE AFTER EXTENSIVE ESOPHAGEAL ENDOSCOPIC 
SUBMUCOSAL DISSECTION
Shibagaki K.1, Yuki T.2, Taniguchi H.3, Kotani S.4, Ishimura N.4, Ishihara S.4
1Shimane University Hospital, Dept. of Gastroenterology, Izumo, Japan, 
2Matsue Red Cross Hospital, Matsue, Japan, 3Tottori Municipal Hospital, 
Tottori, Japan, 4Shimane University Hospital, Izumo, Japan
Contact E-Mail Address: shibagaki@zb.wakwak.com
Introduction: Endoscopic submucosal dissection (ESD) for extensive esoph-
ageal carcinomas causes severe esophageal stenosis requiring endoscopic 
balloon dilation (EBD), but a standard prophylactic treatment has not been 
established. As a novel procedure for the local steroid administration, we 
developed the esophageal Triamcinolone Acetonide (TA)-fi lling method. 
This method fi lls the esophagus with a saline solution containing 80 mg 
TA for a certain time to infi ltrate the drug evenly into extensively resected 
surface [1].
Aims & Methods: The aim of this study is to analyze the clinical effi  cacy 
and safety of the esophageal TA-fi lling for stenosis-prevention aft er ex-
tensive esophageal ESD. We enrolled a total of 44 consecutive patients 
with esophageal cancer requiring subcircumferential ESD, which is three 
quarters of the circumference or more horizontal resection but not cir-
cumferential. They had no previous treatment for the lesions, such as 
endoscopic resection or radiation therapy. Esophageal TA-fi lling was 
performed the day aft er ESD and one week later, and follow-up endos-
copy was performed every 2 weeks until complete re-epithelialization. 
We treated severe stenosis preventing endoscope passage with EBD and 
additional TA-fi lling, and mild stenosis allowing endoscope passage with 
additional TA-fi lling only.
Primary endpoint was the incidence of severe stenosis, which is report-
edly 66% to 75% aft er subcircumferential ESD without any preventive pro-
cedure [2-4]. Setting the clinically meaningful preventive eff ect to 30% 
incidence reduction, we determined lower boundary of the target inci-
dence value at 40%. Secondary endpoints were total number of EBDs, 
execution rate of additional TA-fi lling, time to initial stenosis and complete 
re-epithelialization without stenosis, dysphagia score, and adverse events. 
Dysphagia score was estimated based on 5 grades: each grade of 0, 1, 2, 
3, and 4 denoted the ability to eat a normal diet, some solid foods, only 
semisolid foods, liquids only, and nothing, respectively [5]. The horizontal 
resection range of ESD was divided into three grades (grade 1; ≥ 9/12 and < 
10/12 , grade 2; ≥ 10/12 and < 11/12 , grade 3; ≥ 11/12 but not circumferential), 
and analyzed statistically for correlation with the endpoints.
Results: All lesions in 44 enrolled patients were resected en bloc. The hori-
zontal resection grade was grade 1 in 19 patients, grade 2 in 14, and grade 
3 in 11. All patients concretely followed the study protocol. The median size 
of the lesions and the resected specimens was 38 (22-70) mm and 52 (32-
85) mm, respectively. 
The incidence of severe stenosis was 6.8% (3/44; 1.4%-18.6%), which was 
suffi  ciently lower than target incidence value, showing a statistically ac-
ceptable stenosis-preventive eff ect. EBD was performed median 2 (1-3) 
times in these 3 patients. 10 patients demonstrated mild stenosis. Time 
to initial stenosis was median 3 (3-5) weeks, and rate of additional TA-
fi lling was 29.5% (13/44); 5.2% (1/19) for grade 1 resection, 28.5% (4/14) 
for grade 2, and 63.6% (7/11) for grade 3 (P< .05). Median time to complete 
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Overall survival and cancer specifi c survival at 5-year were 88% and 99%. 
In terms of the comparison between ESD and esophagectomy, there were 
no diff erence in the 5-year overall survival (HR = 0.66, 95% CI 0.39 - 1.11) 
and recurrence free survival (HR = 1.52, 95% CI = 0.74 - 3.09). Despite 
the similar perioperative mortality rate in both groups, the adverse events 
were remarkably lower in ESD group (19.8% vs. 44.0%, OR = 0.29, 95% 
CI = 0.19 - 0.43).
Conclusion: For superfi cial ESCN, ESD is highly eff ective with less morbid-
ity than esophagectomy. It should be considered as the fi rst line treatment 
in centers with expertise.
  Yamauchi (2017)
Yuan 
(2018)
Min 
(2018)
Takeuchi 
(2018)
Zhang 
(2018)
Case Number
ESD = 54, 
OP = 51
ESD = 69, 
OP = 47
ESD = 120, 
OP = 120
ESD = 73, 
OP = 54
ESD = 322, 
OP = 274
Lesion size 
(Median, mm)
Not 
recorded
ESD = 45.9, 
OP = 52.1
ESD = 17, 
OP = 16.4
ESD = 20, 
OP = 32
ESD = 26, 
OP = 20
Lesions > 3/4 
circumference
Not 
recorded
ESD = 18, 
OP = 23
Not 
recorded
ESD = 13, 
OP = 22
Not 
recorded
R0 resection 
(%)
Not 
recorded
ESD 92.7%, 
OP = Not 
recorded
Not 
recorded
ESD 78.1%, 
OP 88.9%
ESD 91.9%, 
OP 98.2%
Adverse events 
(%)
ESD 29.6%, 
OP = 49.1%
ESD 43.4%, 
OP = 72.3%
ESD 18.5%, 
OP = 55.5%
ESD 10.9%, 
OP = 38.8%
ESD 15.8%, 
OP = 31.3%
M1-M2 invasion
Not 
recorded
ESD = 52, 
OP = 24
ESD = 64, 
OP = 63
ESD = 10, 
OP = 7
ESD = 107, 
OP = 24
M3-Sm1 invasion
Not 
recorded
ESD = 17, 
OP = 23
ESD = 35, 
OP = 37
ESD = 41, 
OP = 18
ESD = 215, 
OP = 250
Sm2 or deeper
Not 
recorded
ESD = 0, 
OP = 0
ESD = 21, 
OP = 20
ESD = 22, 
OP = 29
ESD = 0, 
OP = 0
Lymphovascular 
invasion
Not 
recorded
ESD = 1, 
OP = 0
ESD = 16, 
OP = 9
ESD = 17, 
OP = 31
ESD = 11, 
OP = 36
[Baseline characteristics in studies comparing the outcomes of ESD and 
esophagectomy]
References: 1.Ono et al. Gastrointestinal endoscopy. 2009;70(5):860-6. 
2.Takahashi et al. Gastrointestinal endoscopy. 2010;72(2):255-64 3.Toyona-
ga et al. Surgical endoscopy. 2013;27(3):1000-8. 4.Joo et al. Gut and liver. 
2014;8(6):612-8. 5.Nakagawa et al. American journal of gastroenterology. 
2014;109(3):348-56. 6.Ikeda et al. Internal medicine. 2015;54(22):2803-
13. 7.Kim et al. Gut and liver. 2015;9(4):470-7. 8.Probst et al. Endoscopy. 
2015;47(2):113-21. 9. Tsujii et al. Endoscopy. 2015;47(9):775-83. 10.Park et al. 
The Korean journal of internal medicine. 2016;31(6):1064-72. 11.Park et al. 
Clinical endoscopy. 2016;49(2):168-75. 12.Lizuka et al. Endoscopy interna-
tional open. 2017;5(8):E736-e41. 13.Nagami et al. Digestive and liver disease 
2017;49(4):427-33. 14.Yamauchi et al. UEG 2017 Spain. 2017;5(5 Supplement 
1):A361. 15.Baisi et al. Surgical endoscopy. 2018, Epub ahead of print. 
16.Berger et al. Endoscopy. 2019 Apr;51(4):298-306. 17.Furue et al. Surgi-
cal endoscopy. 2018, Epub ahead of print. 18.Min et al. Gastrointestinal 
endoscopy. 2018;88(4):624-33. 19.Qi et al. Endoscopy. 2018;50(9):839-45. 
20.Takeuchi et al. Gastrointestinal endoscopy. 2018;88(3):456-65. 21.Zhang 
et al. Clinical gastroenterology and hepatology. 2019;17(1):73-81.e3.
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OP119 LASTING SYMPTOMS AFTER ESOPHAGEAL RESECTION 
(LASER) - EUROPEAN MULTI-CENTER CROSS-SECTIONAL STUDY
Markar S.1, Zaninotto G.2, Lagergren P.3, Castoro C.4, Elliott J.5, Klevebro F.3, 
Van Berge Henegouwen M.6, Huddy J.7, Alfi eri R.4, Scarpa M.8, 
Gisbertz S.S.6, Johar A.9, Van Hillegersberg R.10, Ruurda J.P.11, Findlay J.12, 
Maynard N.13, Antonowicz S.13, Murphy C.5, Pera M.14, Reynolds J.5, 
Piessen G.15, Mariette C.16, Nilsson M.17, Sanders G.18, Ariyarathenam A.18, 
Jaunoo S.19, Matthijsen R.20, Lagarde S.M.21, Wijnhoven B.P.L.22, 
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7Imperial College, Department of Surgical Oncology and Technology, London, 
United Kingdom, 8Veneto Institute of Oncology (IOV-IRCCS), Esophageal 
and Digestive Tract Surgical Unit, Regional Centre for Esophageal Disease, 
Padova, Italy, 9Karolinska Institutet, Stockholm, Sweden, 10University Medical 
Center Utrecht, Utrecht, Netherlands, 11UMC Utrecht, Utrecht, Netherlands, 
12Oxford University Hospitals NHS Trust, Oxford, United Kingdom, 13Oxford 
University Hospitals, Churchill Hospital, Oxford OesophagoGastric Centre, 
Oxford, United Kingdom, 14Universitat Autònoma de Barcelona, Barcelona, 
Spain, 15University Hospital C. Huriez Place de Verdun, Lille, France, 
16University Hospital Claude Huriez, Department of Digestive and Oncological 
Surgery, Lille, France, 17Karolinska Institutet, Karolinska University Hospital, 
Stockholm, Sweden, 18Plymouth Hospitals NHS Trust, Plymouth, United 
Kingdom, 19Three Counties Oesophago-Gastric Centre, Gloucester, United 
Kingdom, 20Tildburg Hospital, Netherlands, Netherlands, 21Academic Medical 
Center, Department of Surgery, Rotterdam, Netherlands, 22Erasmus MC 
Rotterdam, Department of Surgery, Rotterdam, Netherlands, 23Norfolk and 
Norwich University Hospital, Norwich, United Kingdom, 24Royal Marsden 
Hospitals NHS Trust, London, United Kingdom
Contact E-Mail Address: s.markar@imperial.ac.uk
Introduction: Long-term functional outcomes and the associations to 
health-related quality of life (HRQOL) aft er esophagectomy is largely un-
known.
Aims & Methods: This multi-center European study aimed to identify the 
most prevalent symptoms, and those with the greatest impact upon HRQOL 
among patients surviving more than one-year aft er esophagectomy for 
cancer, and to develop a clinically relevant tool. 
Twenty European centers participated in the study. Patients who under-
went esophagectomy for esophageal cancer between 2010 and 2015, 
and were disease-free at least one year postoperatively were invited to 
complete the LASER questionnaire, EORTC-QLQ30 and OG25. LASER ques-
tionnaire items that were associated with a poor HRQOL as identifi ed by 
EORTC-QLQC30 and OG25 were identifi ed by multivariable linear and lo-
gistic regression analysis and combined to form a tool, which was tested 
using receiver operating characteristics curve analysis.
Results: A total of 876 of 1081 invited patients responded to the question-
naire, giving a response rate of 81%. Of these, 66.9% stated in the last 
6 months they had had symptoms associated with their esophagectomy 
and 52.4% of patients had sought medical treatment for their symptoms. 
Ongoing weight loss was reported by 10.4% of patients while 32.4% was 
struggling to maintain their body weight, and 18.8% of patients required 
supplemental oral nutrition. Only 13.8% of patients returned to work with 
the same activities as before. 
Three LASER symptoms in multivariate analysis were correlated with poor 
HRQOL; pain on scars on chest (Odds ratio (OR) 1.27; 95% CI 0.97-1.65), low 
mood (OR 1.42; 95% CI 1.15-1.77) and reduced energy or activity tolerance 
(OR 1.37; 95% CI 1.18-1.59). The areas under the curves for the development 
and validation datasets were 0.81±0.02 and 0.82±0.09 respectively.
Conclusion: The three key symptoms identifi ed in this study should be fur-
ther validated, and could be used in clinical practice to identify patients 
who require increased long-term term support in survivorship.
Disclosure: Nothing to disclose 
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OP120 ENDOSCOPIC THERAPY REPLACES SURGERY FOR CLINICAL 
T1 OESOPHAGEAL CANCER IN THE NETHERLANDS: A NATIONWIDE 
POPULATION-BASED STUDY
Noordzij I.C.1, Hazen M.L.2, Verhoeven R.H.A.3, Schoon E.J.1
1Catharina Hospital, Gastroenterology and Hepatology, Eindhoven, 
Netherlands, 2Elkerliek Hospital, Gastroenterology and Hepatology, Elkerliek, 
Netherlands, 3Netherlands Comprehensive Cancer Organisation, Research & 
Development, Utrecht, Netherlands
Contact E-Mail Address: irma.noordzij@catharinaziekenhuis.nl
Introduction: Oesophageal cancer is the eight most common cancer world-
wide and the sixth leading cause of cancer related mortality. The inci-
dence of oesophageal cancer increases worldwide. Recent studies showed 
comparable survival aft er endoscopically or surgically treated oesophageal 
cancer in the United States and Asia. Survival aft er endoscopic resection 
or surgery of oesophageal cancer has not been investigated in a Dutch 
population.
Aims & Methods: This study will provide insight into the treatment and 
survival for patients with clinical T1 oesophageal and cardia cancer over a 
fi ft een-year period between 2000 and 2014 in the Netherlands. Data were 
obtained from the nationwide population-based Netherlands Cancer Reg-
istry (NCR). All patients diagnosed with clinical in situ and T1 oesophageal 
or cardia cancer without lymph node or distance metastasis during the 
study period were extracted from the NCR. Primary outcome parameters 
were the trends in treatment modalities over time and relative survival of 
each treatment regime.
Results: A total of 1822 patients were diagnosed with a clinical in situ 
or T1 oesophageal or cardia cancer in the Netherlands between Janu-
ary 2000 and December 2014. Patients with metastatic disease (n=285) 
and/or unknown lymph node metastasis (n=513) were excluded. In total 
of 1020 patients were included. Almost half of the patients receive endo-
scopic therapy (44.9%), around a third underwent surgery (35.1%) and 
twenty per cent underwent other treatment (12.3%) or no treatment et al 
(7.7%). Patients who underwent surgery were signifi cantly younger than 
patients treated with endoscopic therapy (median 64 years vs. 67 years; p 
< 0.0001). There were signifi cantly more oesophagus carcinoma resected 
with endoscopic therapy compared to cardia carcinoma (96.1% vs. 79.6%; 
p < 0.0001) and the group with endoscopic therapy signifi cantly had a 
clinical in situ tumour more oft en (p< 0.0001). The proportion of patients 
who received endoscopic treatment increased from 2.5% in 2000 to 64.1% 
in 2014. During the same period the proportion of patients who received 
surgery decreased from 57.5 to 17.1%. 
The 5-year relative survival of all patients with clinical in situ or T1 oe-
sophageal or cardia cancer was 70%. The 5-year relative survival aft er 
endoscopic therapy was 85% and aft er surgery 78%. Relative excess risk 
analyses showed signifi cant diff erence in survival between patients in the 
endoscopic therapy group and patients in the surgery group aft er adjust-
ment for age, sex, clinical TNM classifi cation, morphology and tumour 
location (RER 1.80; CI interval 1.20-2.70; p< 0.001). In subgroup analysis, 
the 5-year relative survival of all patients with T1 oesophageal or cardia 
cancer was 66%. The 5-year relative survival aft er endoscopic therapy was 
81%, aft er surgery 73%. Relative excess risk analyses for the subgroup 
T1 oesophageal or cardia cancer showed signifi cant diff erence in survival 
between patients in the endoscopic therapy group and patients in the 
surgery group aft er adjustment for age, sex, clinical TNM classifi cation, 
morphology and tumour location (RER 1.71; CI interval 1.14-2.55; p< 0.01).
Conclusion: Our results demonstrate an increase in endoscopic resections 
and a decrease of surgical treatment for in situ and T1 oesophageal/car-
dia cancer between 2000-2014 in the Netherlands. The relative 5-years 
survival aft er endoscopic treatment is high (85%) and signifi cantly higher 
when compared to surgery (78%) which is diff erent from previous studies.
Disclosure: Nothing to disclose 
Diff erent faces of microbiota along the digestive 
tract
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OP121 COMPOSITION AND FUNCTION OF GUT MICROBIOTA 
AFFECTS THE RESPONSE RATE AND SURVIVAL OF MELANOMA 
PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS
Gacesa R.1,2, T. Wind T.3, Vich Vila A.1,2, J. de Haan J.3, Jalving M.3, 
A.P. Hospers G.3
1University Medical Center Groningen (UMCG), Gastroenterology, Groningen, 
Netherlands, 2University Medical Center Groningen (UMCG), Genetics, 
Groningen, Netherlands, 3University Medical Center Groningen (UMCG), 
Comprehensive Cancer Centre, Groningen, Netherlands
Contact E-Mail Address: r.gacesa@umcg.nl
Introduction: Immune checkpoint inhibitors (ICIs) have demonstrated 
strong clinical benefi t in patients with irresectable cutaneous melanoma, 
with now an increased 1-year survival of up to 70%. Approximately 40% 
of patients, however, do not respond to ICI therapy, while 25% of patients 
develop serious adverse events. Previous studies in animal models and 
small-scale human studies identifi ed a link between composition of gut 
microbiota and response to ICI therapy, but these studies showed low 
concordance and did not take into account common confounders such as 
patient sex, age, BMI as well as medications that alter composition of gut 
microbiom.
Aims & Methods: The aim of this study was to assess the eff ect of composi-
tion and function of gut microbiota on the response rate and survival of 
ICI-treated melanoma patients, while taking into account known factors 
that infl uence the composition of gut microbiome. 
This study employed a strictly protocolized collection procedure to obtain 
high-quality fresh-frozen stool samples from 25 patients with metastatic 
melanoma before the start of ICI therapy. Twelve of these patients went 
on to respond to ICI therapy. Metagenomic shotgun sequencing was used 
to obtain a high-resolution profi le of the gut microbiome composition 
and biochemical pathways encoded in the microbiome. Composition (192 
bacterial taxa) and function (260 pathways) of microbiota were tested for 
association with ICI response, overall survival, and progression-free sur-
vival using multivariate associations with linear models (implemented in 
MaAsLin toolkit). These models included known factors that infl uence gut 
microbiota: age, sex, BMI, tumor M-stage (AJCC version 8), LDH-level (> 
250 U/L vs. < 250 U/L), previous anti-melanoma therapy, type of therapy 
(anti-PD1 or anti-PD-1/anti-CTLA-4 combination), antibiotic use (yes/no), 
proton pump inhibitor use (yes/no) and colitis during ICI therapy (yes/no, 
any grade).
Results: We observed no diff erences in alpha-diversity and bacterial prev-
alence between responders and non-responders (p-value > 0.05). Multi-
variate analysis identifi ed 68 taxa and 17 microbial pathways that showed 
diff erential abundance between responders and non-responders (FDR < 
0.05), including previously reported associations with Veillonella parvula, 
Bacteroides thetaiotaomicron, Akkermansia muciniphila, Escherichia coli and 
Actinomyces odontolyticus. In addition, multiple taxa were associated with 
overall or progress-free survival, including Streptococcus parasanguinis 
(Overall survival HR: 6.9), Peptostreptococcaceae Family (Overall survival 
HR: 0.11, Progression-free survival HR: 0.18) and B. massiliensis (Progres-
sion-free survival HR: 3.79).
Conclusion: This study shows that composition and function of the gut mi-
crobiom infl uences the response to immune checkpoint inhibitors (ICIs) 
in patients with cutaneous melanoma. This suggests that manipulation of 
gut microbiota might be viable strategy to improve the response to ICIs.
Disclosure: Nothing to disclose 
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OP123 ALTERATIONS IN FUNGAL MICROBIOTA AFTER 
CHOLECYSTECTOMY IN PATIENTS
Xu J.1,2,3, Ren X.1,4, Zhang Y.1,2, Zhang Y.4,5, Chen G.1,2, Huang Q.1,2, Liu Y.1,2
1Peking University People’s Hospital, Department of Gastroenterology, 
Beijing, China, 2Clinical Center of Immune-Mediated Digestive Diseases, 
Peking University People’s Hospital, Beijing, China, 3Institute of Clinical 
Molecular Biology & Central Laboratory, Peking University People’s Hospital, 
Beijing, China, 4Peking University People’s Hospital, Clinical Center of 
Immune-Mediated Digestive Diseases, Beijing, China, 5Peking University 
People’s Hospital, Department of Gastroenterology, Beijing, China
Contact E-Mail Address: yi.wen.zhang@foxmail.com
Introduction: Fungal microbiota of the gastrointestinal tract is aff ected by 
many factors, such as pH, diet. Aft er cholecystectomy, the gut physico-
chemical environment changes, and the fungal microbiota may change 
accordingly. Notably, few reports focused on gut fungal microbiota aft er 
cholecystectomy. Therefore, we tended to investigate the diff erences and 
composition characteristics of gut fungal microbiota in patients aft er cho-
lecystectomy.
Aims & Methods: We called on 104 people for this study, including 52 
healthy controls (HC) and 52 post-cholecystectomy (PC) patients. 9 of the 
52 PC patients accompanied with precancerous lesions and colorectal can-
cer (preCA_CRC). Fecal samples of all patients were collected for internal 
transcribed spacer (ITS) 3-4 rDNA amplicons sequencing to profi le the 
overall structure of the fecal fungal microbiota. Based on the Operational 
Taxonomic Units (OTUs), fungal composition and the correlation analysis 
with environmental factors were analyzed, respectively.
Results: Fungal richness in PC patients was similar to the one in HC, but 
the composition was quite diff erent. The abundance of exogenous patho-
gens Alternaria, Aspergillus and opportunistic pathogen Candida increased 
signifi cantly; while Malassezia, Vanrija and protective genus Ganoderma 
had a remarkable reduction in PC patients. Indicspecies analysis showed 
that Candida glabrata and Aspergillus unassigned were characteristic spe-
cies of PC patients, and Candida albicans was a characteristic species of 
HC. Previous studies suggested that Candida glabrata displayed more viru-
lence factors, triggering host cell damage. The intraspecifi c competition of 
Candida may play an important role, and Candida albicans may suppress 
the growth of Candida glabrata in HC. About 10 kinds of indexes were col-
lected as environmental factors for correlation analysis with fungal com-
position. As a result, we found that the duration aft er cholecystectomy 
was an independent factor, which mainly aff ected the composition of the 
fungal microbiota. Addtionally, according to the presence or absence of 
precancerous lesions and CRC, we divided PC patients into preCA_CRC and 
nonCA. We found that preCA_CRC patients had lower fungal richness than 
the nonCA patients with statistical diff erence. In addition, most species 
were reduced in abundance, such as Pleosporales unassigned, Sordariales 
unassigned and Gibberella zeae.
Conclusion: Our study showed a specifi c gut fungal composition in PC 
patients. The duration aft er cholecystectomy was an important environ-
mental factor which aff ected fungal microbiota. It was suggested that the 
duration aft er cholecystectomy may be associated with the risk of relative 
diseases. The abundance of Candida glabrata may be associated with clini-
cal long-term outcome in patients aft er cholecystectomy.
Disclosure: Nothing to disclose 
OP124 NEXT-GENERATION SEQUENCING OF FAECAL 
MICROBIOTA IN ULCERATIVE COLITIS PATIENTS TOGETHER WITH 
CONSANGUINEOUS AND NON-CONSANGUINEOUS RELATIVES
Fukuda K., Takasu A., Okuyama S., Okamoto T., Ikeya T.
St. Luke’s International Hospital, Gastroenterology, Tokyo, Japan
Contact E-Mail Address: fukukats@luke.ac.jp
Introduction: The gut microbiota has been recognized as a relevant fi n-
gerprint to predict the development of infl ammatory bowel disease (IBD) 
like ulcerative colitis (UC). Accordingly, inter-individual variation in the gut 
microbial community may refl ect inter-individual variation in the risk of 
developing IBD or other diseases. 
Further recently, the Next-Generation Sequencing (NGS) has been vali-
dated for determining bacterial species in faecal samples. Essentially, NGS 
is a molecular biology sequencing technique for the precise identifi cation 
and assessment of bacterial species.
OP122 THE EFFECTS OF F. PRAUSNITZII ON CANDIDA ALBICANS 
GROWTH AND PATHOGENICITY AND RELATED MECHANISMS
Mao X.1, Zhang H.2, Qiu X.1
1First A  liated Hospital of Nanjing Medical University, Nanjing, 
China, 2Nanjing Medical University, First A  liated Hospital, Dept. of 
Gastroenterology, Nanjing, China
Contact E-Mail Address: 2214403564@qq.com
Introduction: Infl ammatory bowel disease (IBD), including ulcerative coli-
tis (UC) and crohn´s disease (CD). The pathogenesis of the disease is com-
plex. It is believed that genetic, environmental, intestinal microbes and 
immune factors are involved in the occurrence and development of IBD, 
especially the intestinal fl ora disorder has become a research hotspot in 
recent years. The reduction of Faecalibacterium prausnitzii (F. prausnitzi) 
and the increase of the opportunistic pathogen Candida albicans are one 
of the important features of intestinal fl ora disorder in patients with IBD. 
Many studies have shown that Faecalibacterium prausnitzii and its su-
pernatant can improve intestinal infl ammation, regulate dysbacteriosis, 
maintain the homeostasis of the intestinal microenvironment, etc. In-
testinal bacteria and fungi infl uence each other in many ways.Therefore, 
exploring the interactions between intestinal bacteria and fungi and its 
role in the development of IBD is of great signifi cance to understand the 
intestinal micro-ecological environment.
Aims & Methods: F. prausnitzii and its supernatant were co-cultured with 
Candida albicans in vitro to observe the eff ects of F. prausnitzii and its 
supernatant on Candida albicans growth, hyphal and hydrolytic enzyme 
production capacities. To investigate whether F. prausnitzii and its super-
natant can inhibit the growth and reproduction of Candida albicans by 
stimulating the expression of infl ammasomes (NLRP6) and antimicrobial 
peptides (LL-37/BD-2/BD-3) and tight junction proteins(ZO-1, occludin) in 
intestinal epithelial cell.
Results: 
1. It was found that the amount of C.albicans with F. prausnitzii and its 
supernatant co-cultured were signifi cantly decreased compared with the 
control group by plate counting method. 
2. It was found that the expressions of Hyphae-Specifi c Genes (BCR1, CD-
C24b, ECE1, HGC1, HWP1 and EFG1) and production of hyphal phase CA 
were inhibited and hydrolytic enzyme production capacities (Ep, Sap, and 
Ha)were dcreased when F. prausnitzii and its supernatant were co-cul-
tured with CA. 
3. Western blot analysis showed that F. prausnitzii and its supernatant may 
inhibit the growth of CA by stimulating IEC secretion of NLRP6, ASC, IL-1β/
IL-18 and antibacterial peptides BD-2 and BD-3, but caspase-1 and LL-37 
had no signifi cant eff ect. 
4. Western blot analysis showed that F. prausnitzii and its supernatant may 
enhance the intestinal mucosal barrier function by promoting the expres-
sion of IEC tight junction protein (occludin, zo-1).
Conclusion: F. prausnitzii and its supernatant have inhibitory eff ects on CA. 
The direct eff ects are as follows: inhibiting CA growth and reproduction, 
inhibiting the expression of CA Hyphae-Specifi c Genes (BCR1, CDC24b, 
ECE1, HGC1, HWP1 and EFG1), reducing production of hyphal phase CA, re-
ducing the production of CA hydrolytic enzyme production capacities (Ep, 
Sap, and Ha). The indirect eff ect is by stimulating the expression of NLRP6, 
ASC, IL-1β/IL-18, BD-2, BD-3 and the tight junction proteins occludin and 
ZO-1 in IEC to inhibition the growth of CA.
Disclosure: Nothing to disclose 
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Aims & Methods: This study was to analyse faecal bacteria and establish a 
biomarker of disease activity in ulcerative colitis (UC) patients. The subjects 
were 82 patients with UC together with 61 healthy relatives as controls. 
Twenty-fi ve patients had active UC (group I) and 57 had quiescent UC; 29 
with mild infl ammation in the large intestine (group II), and 28 without 
infl ammation (group III). The patients’ relatives were consanguineous 
(group IV, n=33), and non-consanguineous (group V, n=28). Faecal bacte-
ria between groups I to V were compared by the t-test. The Discriminant 
Score (Ds) for each subject together with the quantity and the diversity of 
each bacterial variant which had signifi cant diff erence were calculated. 
The Discriminant analysis in all fi ve groups was done for Species. We cal-
culated the Discriminant Score (Ds) in each case.
Results: We obtained 1011 varieties of bacteria as Phyla, Class, Order, Fam-
ily, Genera and Species. 648 bacteria that were not considered important 
were excluded. The t-statistic was done on 363 bacteria between groups I 
to V. Signifi cant diff erence was calculated in 18 Species, 10 Genera, and 4 
Families. The Discriminant analysis was done on these 18 Species from all 
groups. The Ds value showed an increasing tendency in this order: group 
I < group II < group III < group IV < group V. Signifi cant diff erence was 
calculated for group I vs group II, vs group III, vs group IV, and vs group V 
(P< 0.01); group V vs group I, vs group II, vs group III (P< 0.01), indicating 
a strong association between gut microbial species and the development 
of UC. 
The diversity of Bacteroides Genus was higher in group V, but the quan-
tities of Bacteroides Genus and the Bacteroides fragilis were higher in 
group I. Further, in group I, the amount of Bacteroides fragilis was in-
creased, but the diversity of Bacteroides Genus was decreased, while in 
group V, the opposite result was observed. It’s very interesting, and the 
balance can be key point between Bacteroides fragilis and the diversity of 
Bacteroides in UC activity. Considering Genus, Anaerococcus, Finegoldia 
and Peptoniphilus were dramatically increased in group I compared with 
group V. All these bacteria belong to Clostridiales Family XI. Incertae Sedis.
Conclusion: In this study, we compared 363 bacteria between active UC 
patient (groups I) to control (group V), signifi cant diff erence was calculated 
in 18 Species, 10 Genera, and 4 Families. To our knowledge, this is the fi rst 
report on so many bacteria being related to UC activity. Additionally, the 
Ds related to UC, or otherwise absence of UC in the fi ve groups. Potentially, 
Ds might be a clinically relevant biomarker of disease activity in UC. This is 
the fi rst application of the NGS and the Ds to the study of microbiota in UC 
patients, consanguineous and non-consanguineous relatives. Moreover 
we could obtain a lot of interesting results the quantity and the diversity 
of the bacteria, especially Bacteroides. Clinical trial No: UMIN000017103
Disclosure: Nothing to disclose 
OP125 STRAIN LEVEL ANALYSIS OF KLEBSIELLA PNEUMONIA 
SHOWS ASSOCIATION WITH INFLAMMATORY BOWEL DISEASE AND 
DISEASE SEVERITY
Gacesa R.1,2, Vich Vila A.1,2, Collij V.1,2, Imhann F.1,2, Kurilshikov A.1,2, Fu J.2, 
Wijmenga C.2, Zhernakova A.2, McLean P.3, Giallourakis C.3, Schneider J.3, 
Weersma R.1
1University Medical Center Groningen (UMCG), Gastroenterology, Groningen, 
Netherlands, 2University Medical Center Groningen (UMCG), Genetics, 
Groningen, Netherlands, 3Takeda Pharmaceuticals Inc., Gastrointestinal 
Drug Discovery Unit, Cambridge, United States
Contact E-Mail Address: r.gacesa@umcg.nl
Introduction: Klebsiella pneumoniae (KP) is a bacterium mainly found in 
the human oral cavity, but also inhabiting human skin and gut. While it 
is primarily associated with bacterial infl ammation of the lung recent re-
search has identifi ed that KP-strains can cause ulcerative colitis (UC) -like 
pathology in germ-free mice. The prevalence and abundance of KP in IBD 
patients has not been studied in detail, and it is unknown if strain compo-
sition of KP diff ers between healthy individuals and IBD patients. It is also 
unclear which specifi c KP strains are associated to clinical characteristics 
of IBD such as disease severity and location.
Aims & Methods: Aim of this study was to identify if KP is associated 
with infl ammatory bowel disease in humans, and to identify IBD-specifi c 
strains of KP. 
The study utilised whole metagenome sequencing to study the gut micro-
biota of 447 IBD patients (291 Crohn’s disease cases and 156 cases with ul-
cerative colitis) and 933 population-based controls. Species-level composi-
tion of metagenomes was determined by aligning metagenomic reads to 
a database of unique marker genes, while KP strains were identifi ed and 
quantifi ed using reference-based approaches utilising genomes of 276 KP 
strains and 10,484 other bacterial species. Prevalence, relative abundance, 
and diversity of KP were tested against IBD-related clinical phenotypes, 
while unsupervised clustering and dimensionality-reduction approaches 
were used to study strain composition.
Results: Prevalence and relative abundance of KP were found to be signifi -
cantly increased (p-value < 1.0*10-4) in the gut of IBD patients (prevalence 
≈ 10%) when compared to the general population (prevalence ≈ 2%), with 
a trend of increased prevalence of KP in more severe cases of UC (panco-
litis, severe colitis, and patients who underwent colonic resection). Strain 
identifi cation was considered if the relative abundance of a specifi c strain 
was above 10% of the total KP content in the sample. In total, 54 strains 
of KP were identifi ed and quantifi ed, of which 33 were found only in IBD 
patients (18 in UC, 6 in CD and 9 in both CD and UC patients). Our results 
also show concordance with previous in-vitro studies: Two KP strains pre-
viously described to cause UC-like pathology and strong immune response 
in mice (strains KP-700603 and KP-2H7) were found to be specifi c to gut of 
UC patients in our cohorts.
Conclusion: We demonstrate the increase in prevalence of KP in the gut mi-
crobiome of IBD patients, and show that certain strains of KP are specifi c 
to IBD patients. Thus, KP may be involved in IBD and has a potential to be 
exploited as novel target for alleviating the severity of the disease.
Disclosure: This study was partially funded by Takeda Pharmaceuticals 
Inc., United states. 
OP126 RISK OF GASTRIC CANCER AFTER HELICOBACTER PYLORI 
ERADICATION IN DIABETES MELLITUS PATIENTS: A TERRITORY-WIDE 
STUDY WITH PROPENSITY SCORE ANALYSIS
Cheung K.S.1, Chan E.W.2, Chen L.2, Seto W.K.2, Wong I.C.2, Leung W.K.2
1University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong, 
China (SAR), 2University of Hong Kong, Hong Kong, Hong Kong, China (SAR)
Contact E-Mail Address: mongolhorse2002@gmail.com
Introduction: Whether diabetes mellitus (DM) increases gastric cancer (GC) 
risk remains controversial in prior studies due to inadequate adjustment 
for important risk factors including Helicobacter pylori(HP) infection, glyce-
mic control, concomitant medication usage and cancer sites.
Aims & Methods: We aimed to investigate whether type II diabetes mellitus 
(DM) increased GC risk in patients aft er HP treatment.
This was a territory-wide cohort study of patients aged ≥45 years who had 
received clarithromycin-based triple therapy for HP between 2003 and 2012. 
Data were retrieved from the public electronic health database. Observation 
started from HP therapy to GC diagnosis, death or end of study (December 
2015). Exclusion criteria included type I DM, GC diagnosed within fi rst year 
of HP therapy, prior GC or gastrectomy, and failure of HP eradication. The-
adjusted hazard ratio (aHR) of GCwith DM was calculated by Cox model with 
propensity score regression adjustmentfor 20 covariates (age, sex, smoking, 
alcoholism, past history of gastric and duodenal ulcers, other comorbidities 
[atrial fi brillation, ischemic heart disease, congestive heart failure, chronic 
renal failure, cirrhosis, stroke, hypertension and obesity] and medications 
[aspirin, non-steroidal anti-infl ammatory drugs (NSAIDs), cyclooxygen-
ase-2 (COX-2) inhibitors, and proton pump inhibitors (PPIs)]).
Results: Of 46,460 eligible patients, 6,900 (14.9%) had DM. During a me-
dian follow-up of 7.1 years (IQR:4.8-9.8) with 337,313 person-years, 153 
(0.33%) developed GC at a median age of 72.4 years (IQR:63.8- 82.6). 
There were 31 (20.3%) cardia cancers and 88 (57.5%) non-cardia cancers, 
while the remaining 34 (22.2%) cases did not have site specifi ed.DM was 
associated with an increased GC risk (adjusted HR:1.67; 95% CI:1.08-2.58). 
This association was biased towards null if concomitant medication us-
age was not adjusted (adjusted HR:1.30; 95% CI:0.85-1.99), with the most 
infl uential eff ect from statins (Table). On the other hand, HR increased to 
1.92 (95% CI:1.28-2.90) without adjusting for comorbidities.Stratifi ed anal-
ysis shows the risk was increased for cardia cancer only (aHR:3.40, 95% 
CI:1.45-7.97), in those with suboptimal DM control (time-weighted average 
HbA1c ≥6.0%; aHR:1.68, 95% CI: 1.07-2.63) and metformin non-users (aHR 
2.59, 95% CI 1.41-4.74).
Conclusion: Type II DM was associated with an increased GC risk among 
HP-eradicated patients, in particular cardia GC and those with suboptimal 
DM control. Inadequate adjustment for concomitant medications and co-
morbidities could potentially bias the results in previous studies.
Disclosure: Nothing to disclose 
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Several models have been developed to distinguish these two diseases; 
however, no studies have externally validate these scores using data from 
the same cohort.
Aims & Methods: To validate existing scoring systems which used clinical, 
endoscopic and pathological fi ndings in diff erentiating ITB from CD based 
on data from the same cohort.
We retrospectively collected data from patients newly diagnosed ITB and 
CD in 5 referral-centers in Thailand and Hong Kong. Clinical data was 
reviewed from medical records. Endoscopic and pathological fi ndings 
were reviewed by endoscopists and pathologist blinded to the diagno-
sis. The data was applied to published scoring systems including score 
from Lee et al (Endoscopy 2006;38:592-7), Makharia et al (Am J Gastro-
enterol 2010;105:642-51), Jung et al (Am J Gastroenterol 2016;111:1156-64) 
and Limsrivilai et al (Am J Gastroenterol 2017;112:415-27). The performance 
of each score was evaluated with the area under the receiver operating 
characteristic curve (AuROC) and were compared to each other using the 
DeLong test.
Results: Of the 590 patients assessed, 163 patients had ITB, and 427 pa-
tients had CD. The mean age was 51.8 years in ITB and 36.6 years in CD 
(p<0.01). Fift y-four percent in ITB and 61% in CD were male (p=0.49). Ap-
plying the data to Lee’s score which used only endoscopic fi ndings, 149 
patients (27%) obtained the score of zero in which the score could not con-
clude the diagnosis. In the remaining 394 patients, the sensitivity, specifi c-
ity, and accuracy of the score for the diagnosis of ITB was 96%, 47%, and 
61.2%, respectively. The AuROC was 0.713. By including clinical presenta-
tion, Jung’s score and Limsrivilai’s score were validated. The AuROC was 
0.850 and 0.858, respectively. The diff erence between these two scores 
was not signifi cantly diff erent (p=0.75), but both performed superiorly than 
endoscopic score (p<0.01). By including pathological fi ndings, Makharia’s 
score and Limsrivilai’s score were validated. The AuROC based on the data 
of 82 patients with available pathology review was 0.628 and 0.900, re-
spectively. The diff erence was signifi cant (p<0.01). The summary of each 
model performance in each cohort was shown in Table 1.
Conclusion: In a multi-center study across two diff erent TB endemic areas, 
scoring systems which combined more potential parameters and diag-
nostic modalities performed better in diff erentiating ITB from CD. Further 
prospective studies to validate the model including more diagnostic mo-
dalities such as computed tomography enterography or serological tests 
are warranted.
Disclosure: Nothing to disclose 
  No. of patients without DM and GC
No. of patients 
with DM and GC HR 95% CI p-value
All variables 
adjusted for
39,560 (GC = 117) 6,900 (GC=36) 1.67 1.08 - 2.58 0.021
Statins not adjusted 
for
39,560 (GC = 117) 6,900 (GC=36) 1.43 0.93 - 2.19 0.101
Statins and aspirin 
not adjusted for
39,560 (GC = 117) 6,900 (GC=36) 1.32 0.86 - 2.02 0.203
All drugs not 
adjusted for
39,560 (GC = 117) 6,900 (GC=36) 1.30 0.85 - 1.99 0.234
Comorbidities not 
adjusted for
39,560 (GC = 117) 6,900 (GC=36) 1.92 1.28 - 2.90 0.002
Subgroup analysis
Metformin use
Yes 39,560 (GC=117) 6,379 (GC=32) 1.28 0.74 - 2.20 0.378
No 39,560 (GC=117) 521 (GC=4) 2.59 1.42 - 4.74 0.002
Time-weighted average HbA1c level
HbA1c ≥ 6.0% 39,560 (GC=117) 6,379 (GC=32) 1.68 1.07 - 2.63 0.025
HbA1c < 6.0% 39,560 (GC=117) 521 (GC=4) 1.99 0.71 - 5.54 0.188
Cancer site*
Cardia 39,462 (GC=19) 6,876 (GC=12) 3.40 1.45 - 7.97 0.005
Non-cardia 39,513 (GC=70) 6,882 (GC=18) 1.53 0.84 - 2.78 0.161
Non-carida + 
unspecifi ed site
39,541 (GC=98) 6,888 (GC=24) 1.33 0.80 - 2.23 0.271
DM, diabetes mellitus; GC, gastric cancer; HR, hazard ratio; 95% CI, 95% confi dence 
interval; NSAIDs, non-steroidal anti-infl ammatory drugs; COX-2, cyclooxygenase-2; PPIs, 
proton pump inhibitors; HbA1c, hemoglobin A1c * total cancer cases = 153 (non-cardia: 
88, cardia: 31, unspecifi ed: 34)
[Association between diabetes mellitus and gastric cancer (propensity score 
regression adjustment)]
OP127 VALIDATION OF SCORING SYSTEMS FOR DIFFERENTIATING 
INTESTINAL TUBERCULOSIS FROM CROHN’S DISEASE UTILIZING 
CLINICAL, ENDOSCOPIC AND PATHOLOGICAL FINDINGS: 
A MULTICENTER STUDY FROM THAILAND AND HONG KONG
Limsrivilai J.1, Choon Kin L.2, Prueksapanich P.3, Harinwan K.4, 
Sudcharoen A.1, Cheewasereechon N.5, Aniwan S.3, Wetwittayakhlang P.5, 
Pongpaibul A.6, Pausawasdi N.1, Charatcharoenwitthaya P.7, Ng S.C.2
1Siriraj Hospital, Dept. of Medicine, Bangkok, Thailand, 2Chinese University 
of, Hong Kong, Institute of Digestive Disease, Medicine and Therapeutics, 
Hong Kong, Hong Kong, China (SAR), 3Chulalongkorn University, Dept. 
of Internal Medicine, Bangkok, Thailand, 4Phramongkutklao Hospital, 
Bangkok, Thailand, 5Prince of Songkla University, Dept. of Internal Medicine, 
Songkla, Thailand, 6Mahidol University Siriraj Hospital, Dept. of Pathology, 
Bangkok, Thailand, 7Siriraj Hospital Dept. of Medicine, Bangkok, Thailand
Contact E-Mail Address: alimsrivilai@gmail.com
Introduction: Diff erentiating between Intestinal tuberculosis (ITB) and 
Crohn’s disease (CD) is a diagnostic challenging in TB-endemic areas. 
Authors Country Thai n=242 (137 CD, 105 ITB)
Hong Kong n=348 
(290 CD, 58 ITB)
Thai & Hong Kong n=590 
(427 CD, 163 ITB) Scores
Lee, Endoscopy 
2006;38:592-7
South 
Korea
For Dx of ITB (242 pt, 
TB prevalence 43%) Sen 
96% Spec 32% Accuracy 
61.3% PPV 54% NPV 89% 
(48 pt inconclusive)
For Dx of TB (301 pt, 
TB prevalence 13%) Sen 
96% Spec 56% Accuracy 
61% PPV 25% NPV 99% 
(101 pt inconclusive)
For Dx of ITB (543 pt, 
TB prevalence 29%) Sen 
96% Spec 47% Accuracy 
61.2% PPV 43% NPV 96% 
(149 pt inconclusive)
8 parameters of endoscopic fi ndings +1 for 4 fi ndings favoring CD 
(Longitudinal ulcer, cobblestone, aphthous, anorectal lesions) 
-1 for 4 fi nding favoring ITB (Transverse ulcer, patulous IC, 
pseudopolyps, < 4 segmental involvement) Sum of score: > 0 = CD, 
< 0 = ITB, 0 = inconclusive
    Area under area under the ROC curve  
Makharia GK*, Am 
J Gastroenterol 
2010;105:642-51
India
0.628 (0.511 - 0.746) (44 CD 
and 38 ITB)
0.708 (0.630 - 0.787) (180 
CD, 35 ITB)
0.671 (0.605 - 0.737) (224 CD 
and 73 ITB)
- 2.5 × involvement of sigmoid colon - 2.1 × blood in stool + 2.3 × 
weight loss - 2.1 × focally enhanced colitis + 7
Jung Y, Am J 
Gastroenterol 
2016;111:1156-64
South 
Korea
0.810 (0.757 - 0.863) (135 
CD, 105 ITB)
0.857 (0.793 - 0.921) (205 
CD, 38 ITB)
0.850 (0.815 - 0.886) (340 
CD, 143 ITB)
1/[1+e-(-4.423+0.037×age+2.226×sex-2.203×diarrhea+2.345×tran_
ring-1.911×longitudinal-2.123×sigmoid+5.606×pul_tbc)] 
Limsrivilai, Am J Gastroenterol 2017;112:415-27 (Score from meta-analysis of each signifi cant fi nding, please go to bit.ly/ITBvsCD)
Clinical   0.741 (0.678 - 0.804) 0.766 (0.701 - 0.831) 0.766 (0.723 - 0.809)  
Endoscopy   0.769 (0.712 - 0.826) 0.735 (0.671 - 0.800) 0.786 (0.748 - 0.824)  
Clinical and endoscopy   0.833 (0.783 - 0.883) 0.849 (0.793 - 0.904) 0.858 (0.825 - 0.892)  
Clinical, endoscopy, 
and pathology*
  0.853 (0.806 - 0.900) 0.814 (0.752 - 0.876) 0.861 (0.828 - 0.894)  
[OP127 Table 1]
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Primum non nocere: Making ERCP safer
08:30-10:00 / B2
OP128 ADDING INTRAVENOUS SOMATOSTATIN TO RECTAL 
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) IN 
PREVENTION OF POST - ENDOSCOPIC RETROGRADE CHOLANGIO 
PANCREATOGRAPHY (ERCP) PANCREATITIS IN HIGH RISK PATIENTS
Norouzi A.1, Besharat S.2, Ghasempoori S.E.3, Tavassoli S.3, Amiriani T.4, 
Pooshani A.2, Ezabadi Z.1
1Golestan Research Center of Gasteroentrology and Hepatology (Grcgh), 
Golestan University of Medical, Internal Medicine, Gorgan, Iran (Islamic 
Republic of), 2Golestan University of Medical Sciences, Gorgan, Iran (Islamic 
Republic of), 3Golestan University of Medical Sciences (GOUMS), Gorgan, 
Iran (Islamic Republic of), 4Arya Sun Co., Management Dept., Tehran, Iran 
(Islamic Republic of)
Contact E-Mail Address: norouzi54@gmail.com
Introduction: Endoscopic Retrograde CholangioPancreatography (ERCP) is 
used frequently for treatment of pancreatobiliary diseases. Pancreatitis is 
one of most frequent complication of ERCP. Pharmacologic measures have 
been studied for preventing this complication. Somatostatin use has been 
proposed by previous studies but with inconclusive results.
Aims & Methods: Regarding the prevalence and importance of pancreatitis 
aft er Endoscopic Retrograde Cholangio Pancreatography (ERCP), present 
study was conducted to evaluate the eff ect of adding intravenous soma-
tostatin to indomethacin on the incidence of pancreatitis aft er ERCPIn this 
clinical trial study, 240 patients with primary diagnosis of pancreatobiliary 
disorders with high risk features of post RCP pancreatitis (patient related, 
operator dependent or procedure dependent) who were referred to the 
main academic hospital of Golestan province, Northeast of Iran for di-
agnostic and therapeutic ERCP during March 2018 to February 2019 were 
included. They were randomly divided into 2 groups to receive either intra-
venous somatostatin plus rectal indomethacin (group A, N=120) or rectal 
indomethacin plus normal salin (group B, N=120).
Serum amylase was evaluated 2 and 18 hours aft er ERCP and the length 
of hospitalization or complications had been recorded. Independent t-test 
was used to compare means and Chi-2 test was used to compare qualita-
tive variables.
Results: Amounts of dye injection, duration and time of cannulation were 
not signifi cant diff erent between two groups (p>0.05). Signifi cant diff er-
ence was noted between the two groups in amylases aft er 2 hours (147.66 
vs 198.88 U/L) and 18 hours (124.14 vs 166.55 U/L). Results showed 4.2% 
pancreatitis in group A and 15% in group B (p = 0.004).
Conclusion: It can be concluded that the administration of somatostatin 
during and aft er ERCP could signifi cantly decrease the risk of pancreatitis 
and hyperamylasemia between the two groups.
Disclosure: Nothing to disclose 
OP129 INDIRECT TREATMENT COMPARISON OF USTEKINUMAB 
VERSUS OTHER ADVANCED THERAPIES IN MODERATE TO SEVERE 
ULCERATIVE COLITIS AFTER 1 YEAR
Welty M.1, Mesana L.1, Padhiar A.1, Naessens D.2, Diels J.3, van Sanden S.3, 
Pacou M.1
1AMARIS, London, United Kingdom, 2Janssen-Cilag, Beerse, Belgium, 
3Janssen Pharmaceutica NV, Beerse, Belgium
Contact E-Mail Address: dnaessen@its.jnj.com
Introduction: Indirect evidence on the relative effi  cacy of ustekinumab in 
moderate to severe ulcerative colitis (UC) to other therapies is needed to 
better inform decision-makers. An indirect treatment comparison (ITC) 
was performed to compare the 1-year effi  cacy of therapies in non-biologic 
failure and biologic failure UC patients.
Aims & Methods: Randomised controlled trials reporting induction and 
maintenance clinical effi  cacy of anti-tumour necrosis factors (infl iximab 
[IFX], adalimumab [ADA], golimumab [GOL]), vedolizumab (VDZ), tofaci-
tinib (TOF) or ustekinumab (UST) were identifi ed by a systematic literature 
review through MEDLINE, MEDLINE IN PROCESS, Embase and Cochrane up 
to the 28th March 2019. Analyses were conducted for clinical response (de-
crease in baseline total Mayo score ≥30% and ≥3 points, decrease in rectal 
bleeding subscore ≥1, or rectal bleeding subscore 0 or 1) and clinical remis-
sion (total Mayo score ≤2 points, no individual subscore >1 [defi nitions with 
rectal bleeding subscore of 0 were also included]) in each population. Due 
trial design diff erences, comparisons of maintenance data alone would 
be biased. To mimic an ITT-based approach, maintenance data from trials 
with re-randomised response designs were re-calculated to correspond to 
treat-through arms including responders at induction and non-induction 
responders. UST effi  cacy was calculated for patients starting on the ~6 mg/
kg IV regimen. For trials with only short-term placebo (PBO) rates or miss-
ing data for PBO non-responders, end of 1-year placebo-to-placebo rates 
were externally imputed. Bayesian ITCs were conducted to obtain posterior 
distribution probabilities for UST to perform better than its comparators 
by population. In the non-biologic failure population, maintenance doses 
were pooled as no dose-response was apparent.
Results: Six trials were included in the non-biologic failure population ITC 
[1,2,3,4,5,6], and four included in the biologic failure ITC [1,2,3,4]. Imputed rates 
for the PBO responders and non-responders in the non-biologic failure 
group were derived from multiple trials and were consistent. UST given 
as a 1-year regimen showed higher probabilities of both clinical response 
and remission versus all treatments in the non-biologic failure group, with 
Bayesian probabilities of UST being better than active therapies ranging 
between 91% (VDZ) to 100% (ADA) doses for response and 82% (VDZ) 
to 99% (ADA) for remission, respectively. In the biologic failure group, 
the probabilities of UST being better than each active treatment were all 
higher than 80% for response with the exception of TOF with 10mg in 
maintenance, and remission was similar between the therapies.
Conclusion: Results of the 1-year ITC indicate a higher likelihood of re-
sponse and remission on UST in non-biologic failure population versus 
comparators, especially versus anti-TNFs. In biologic failure patients, re-
sults were more uncertain due to smaller sample sizes and data limita-
tions, though a higher likelihood of response to UST versus most compara-
tors was observed.
Treatments sequence 
(induction - maintenance)
Clinical response Median 
OR [95% CrI] Pr UST 
~6mg/kg - UST 90mg 
pooled (Q8W and Q12W) vs.
Clinical remission Median 
OR [95% CrI] Pr UST 
~6mg/kg - UST 90mg 
pooled (Q8W and Q12W) vs.
VDZ 300mg - VDZ 300mg 
pooled (Q4W and Q8W)
1.93 [0.75 ; 4.82] 91.45% 1.47 [0.65 ; 3.34] 82.34%
IFX pooled - IFX pooled 
(5mg/kg and 10mg/kg)
2.62 [1.22 ; 5.60] 99.31% 1.89 [0.83 ; 4.30] 93.52%
GOL 200/100mg - GOL pooled 
(50mg Q4W and 100mg Q4W)
3.76 [1.90 ; 7.57] 99.99% 1.99 [0.93 ; 4.26] 96.27%
ADA 160/80/40mg - ADA 
40mg EOW
4.76 [2.25 ; 10.16] 100% 2.43 [1.10 ; 5.41] 98.55%
TOF 10mg - TOF pooled 
(5mg and 10mg)
2.27 [1.06 ; 4.86] 98.21% 1.51 [0.64 ; 3.52] 83.00%
PBO - PBO 8.70 [5.03 ; 15.40] 100% 5.11 [2.83 ; 9.51] 100%
QXW: every X weeks, EOW: every other week, Pr: probability for ustekinumab to perform 
better than the comparator
[Table 1 ITC results in the non-biologic failure population]
References: [1]Janssen. A Phase 3, Randomized, Double-blind, Placebo-
controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Ef-
fi cacy of Ustekinumab Induction and Maintenance Therapy in Subjects with 
Moderately to Severely Active Ulcerative Colitis (44-Week Clinical Study Re-
port). Research & Development (2018). [2]Feagan BG, Rubin DT, Danese S, 
Vermeire S, Abhyankar B, Sankoh S, James A and Smyth M. Effi  cacy of ve-
dolizumab induction and maintenance therapy in patients with ulcerative 
colitis, regardless of prior exposure to tumor necrosis factor antagonists. 
Clinical Gastroenterology and Hepatology. 201;15:229-239. [3]Sandborn 
WJ, Van Assche G, Reinisch W, Colombel JF, D´Haens G, Wolf DC, et al. 
Adalimumab induces and maintains clinical remission in patients with 
moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142(2):257-
65. [4]Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, 
et al. Tofacitinib as induction and maintenance therapy for ulcerative coli-
tis. New England Journal of Medicine. 2017;376(18):1723-36. [5]Rutgeerts P, 
Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infl iximab 
for induction and maintenance therapy for ulcerative colitis. New England 
Journal of Medicine. 2005;353(23):2462-76. [6]Sandborn WJ, Feagan BG, 
Marano C, Zhang H, Strauss R, Johanns J, et al. Subcutaneous golimumab 
induces clinical response and remission in patients with moderate-to-
severe ulcerative colitis. Gastroenterology. 2014;146(1):85-95.
Disclosure: Margaux Welty, Laura Mesana, Amie Padhiar, and Maud Pacou 
are consultants for Janssen Pharmaceutica NV Dominik Naessens, Suzy van 
Sanden, and Joris Diels are all employees of Janssen Pharmaceutica NV 
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Aims & Methods: We aimed to identify the incidence of and risk factors for 
PEP in emergency ERCP. We performed a prospective study of 3914 patients 
undergoing diagnostic and therapeutic ERCP at fi ve Japanese institutions 
between April 2015 and May 2017. The exclusion criteria were as follows: 
active pancreatitis, choledochojejunostomy, inability to approach a pa-
pilla, and inspection only of the pancreatic duct (PD). In this study, emer-
gency ERCP was defi ned as unscheduled inspections performed within 
and beyond regular working hours. A diagnosis of PEP was made when 
two of the following three conditions were met: (1) serum amylase levels 
greater than three times the upper limit of the normal range at each insti-
tution, (2) persistent abdominal pain for more than 24 h, and (3) evidence 
of pancreatitis on computed tomography. In the fi rst study, we compared 
the incidence and characteristics of PEP between emergency and elective 
ERCP. In the second study, we determined the predictive risk factors for PEP 
in emergency ERCP using univariate and multivariate analyses.
Results: In total, 3,410 patients were enrolled in this study. < Study 1> PEP 
developed in 44 of 800 (5.5%) cases and 190 of 2,418 (7.9%) cases in the 
emergency and elective groups, respectively. No signifi cant diff erence was 
noted in the incidence of PEP between the two groups (odds ratio [OR], 
0.73; 95% confi dence interval [CI], 0.52-1.03; P = 0.07 ). Endoscopic sphinc-
terotomy, pre-cutting, stone removal, endoscopic papillary balloon dilata-
tion (EPBD), and intraductal ultrasound were more frequently performed 
in the elective group than in the emergency group (P < 0.001); while biliary 
stent placement was signifi cantly more common in the latter group (P < 
0.001) . In addition, a considerably longer procedure time (40.2min. vs 
30.8min.;P < 0.001) and higher number of endoscopists with more than 5 
years of experience (P = 0.02) were noted in the elective group than in the 
emergency group. < Study 2> The multivariate analysis showed that the 
following factors increased the risk for PEP in emergency ERCP: contrast 
medium injection into the PD (OR, 2.56; 95% CI, 1.30-5.03; P = 0.005), 
more than four cannulation attempts (OR, 5.72; 95% CI, 2.61-12.50; P < 
0.0001), and EPBD (OR, 9.24; 95% CI, 2.13-40.10; P < 0.0001).
Conclusion: No signifi cant diff erence was noted in the incidence of PEP 
between emergency and elective ERCP. For noninvasive methods, a proce-
dure time less than 30 minutes is acceptable even for a trainee with less 
than 5 years of experience during the emergency ERCP. The contrast medi-
um injection into the PD necessitates close monitoring, particularly when 
more than four cannulation attempts are required; furthermore, surgeons 
should refrain from performing EPBD in emergency ERCP.
Disclosure: Nothing to disclose 
OP132 A NOVEL SINGLE-USE DUODENOSCOPE HAD 
COMPARABLE PERFORMANCE RATINGS TO REUSABLE 
DUODENOSCOPES IN A RANDOMIZED BENCH STUDY
Ross A.S.1, Bruno M.J.2, Kozarek R.1, Petersen B.T.3, Pleskow D.K.4, 
Sejpal D.V.5, Slivka A.6, Moore D.5, Panduro K.7, Peetermans J.8, Insull J.8, 
Rousseau M.8, Tirrell G.P.8, Muthusamy V.R.7
1Virginia Mason Medical Center, Department of Gastroenterology, Seattle, 
United States, 2University Medical Center Rotterdam, Department of 
Gastroenterology & Hepatology, Rotterdam, Netherlands, 3Mayo Clinic, 
Division of Gastroenterology and Hepatology, Rochester, United States, 
4Beth Israel Deaconess, Division of Gastroenterology, Boston, United 
States, 5Zucker School of Medicine at Hofstra/Northwell, Division of 
Gastroenterology, Manhasset, United States, 6University of Pittsburgh 
Medical Center, Department of Gastroenterology, Hepatology, and Nutrition, 
Pittsburgh, United States, 7University of California, Vatche and Tamar 
Manoukian Division of Digestive Diseases, Los Angeles, United States, 
8Boston Scienti c, Marlborough, United States
Contact E-Mail Address: raman@mednet.ucla.edu
Introduction: Multidrug-resistant (MDR) infectious outbreaks are a major 
global concern.1 Duodenoscope contamination during reuse and reprocess-
ing is one of many potential nosocomial sources of patient-to-patient trans-
mission of pathogenic MDR organisms. Duodenoscope reprocessing guide-
lines are evolving and impose a signifi cant economic burden to hospitals. 
In addition, guideline adherence alone cannot prevent duodenoscope con-
tamination because the current cleaning paradigm for duodenoscopes is 
ineff ective.2 In this context, single-use duodenoscopes could off er benefi ts. 
No single-use duodenoscope is currently available in gastroenterology 
clinical practice. Similar performance to reusable duodenoscopes is a 
prerequisite to considering further investigation of a single-use duodeno-
scope for endoscopic retrograde cholangiopancreatography (ERCP).
OP130 META-ANALYSIS OF RANDOMIZED TRIALS OF 
POST-ERCP PANCREATITIS AFTER EARLY AND LATE NEEDLE-KNIFE 
SPHINCTEROTOMY IN DIFFICULT BILIARY CANNULATION
Dubravcsik Z.1, Szepes A.Z.1, Szalai M.2, Lovasz B.D.3, Schmiedt P.2, 
Zsobrák K.2, Madácsy L.1,2
1Bacs-Kiskun County Hospital, Gastroenterology & Endoscopy, Kecskemét, 
Hungary, 2Endo-Kapszula Health Center and Endoscopy Unit, Szekesfehervar, 
Hungary, 3Semmelweis University, 1st Department of Medicine, Budapest, 
Hungary
Contact E-Mail Address: dubravcsikzs@gmail.com
Introduction: Needle-knife sphincterotomy (NKS) and prolonged cannula-
tion attempts are both considered as risk factors for post-ERCP pancreatitis 
(PEP). Previous meta-analyses compared the eff ect of early precut versus 
persistent cannulation attempts on PEP.
Aims & Methods: Our aim was to analyze the eff ect of early versus late NKS 
on PEP in diffi  cult biliary cannulation. MEDLINE/PubMed, EMBASE were 
searched. Only randomized controlled trials (RCT) containing data of early 
(< 10 minutes of cannulation attempts and/or < 5 inadverent pancreatic 
duct cannulation) and late (additional 10 minutes of attempts) NKS were 
selected and analyzed.
A subgroup of patients where cannulation attempts were prolonged but 
NKS was not needed served as the prolonged cannulation group. Pooled 
estimates of PEP were analyzed using odds (OR) and risk ratios (RR), and 
number needed to treat (NNT) was calculated.
Results: 6 RCTs were found, but only 3 RCTs were included in the meta-
analysis (3 excluded: 2 used prophylactic pancreatic stenting which could 
alter the eff ect of NKS; and only moderate and severe PEP were analyzed in 
1 RCT). NKS was used early in 310 and late in 220 patients. In 216 patients 
prolonged standard cannulation was used. PEP occurred in 14/310 (4.06%) 
vs. 29/220 (12.23%) vs. 14/216 (9.47%) patients. 
The cannulation success rates were 272/310 (86%) in early NKS vs. 187/220 
(80.7%) in late NKS groups. Regarding PEP, our meta-analysis showed a 
signifi cantly increased risk, when NKS was used late compared to ear-
ly (OR=3.21 (95% CI: 1.65-6.23; p=0.0006); RR=2.92 (95% CI: 1.57-5.39; 
p=0.0006); NNT=11.54). When NKS is applied late aft er prolonged cannu-
lation attempts, it further increases the risk of PEP compared to prolonged 
cannulation only (OR=2.19 (95% CI: 1.12-4.27; p=0.0214); RR=2.03 (95% CI: 
1.11-3.74; p=0,0225); NNT=14.9).
Conclusion: Early, but not late precut NKS is safe in diffi  cult biliary can-
nulation when used by experts. The incidence of PEP of early NKS is half 
compared to prolonged cannulation and third compared to late NKS. We 
suggest using early precut sphincterotomy in diffi  cult biliary cannulation 
and/or using other preventive methods (eg. prophylactic pancreatic stents 
or rectal indomethacin) to lower PEP rates.
Disclosure: Nothing to disclose 
OP131 IS THERE A DIFFERENCE IN THE INCIDENCE AND 
CHARACTERISTICS OF POST-ERCP PANCREATITIS BETWEEN 
EMERGENCY AND ELECTIVE ERCP?: A PROSPECTIVE MULTICENTER 
STUDY
Nakai Y.1, Itokawa Y.1, Kusumoto K.1, Endoh B.2, Chikugo K.2,3, 
Doi T.4, Kawakami T.4,5, Suzuki T.4, Suzuki A.6, Inatomi O.7, 
Bamba S.8, Kusaka T.1, Kokuryu H.1, Mizumoto Y.2, Tanaka K.6, 
SOSUI Study Group
1Kyoto-Katsura Hospital, Digestive Disease Center, Department of 
Gastroenterology and Hepatology, Kyoto, Japan, 2Kyoto Medical Center, 
Department of Gastroenterology, Kyoto, Japan, 3Teine Keijinkai Hospital, 
Hokkaido, Japan, 4Japanese Red Cross Kyoto Daiichi Hospital, Center 
Department of Gastroenterology, Kyoto, Japan, 5Municipal Turuga 
Hospital, Fukui, Japan, 6Kyoto Second Red Cross Hospital, Department 
of Gastroenterology, Kyoto, Japan, 7Shiga University of Medical Science, 
Division of Gastroenterology, Otsu, Japan, 8Shiga University of Medical 
Science, Division Of Gastroenterology, Otsu, Japan
Contact E-Mail Address: digestivenews@yahoo.co.jp
Introduction: Post-endoscopic retrograde cholangiopancreatography 
(ERCP) pancreatitis (PEP) is a potentially serious complication. Risk factors 
for PEP aft er elective ERCP have been reported. ERCP is oft en performed 
urgently, but the diff erence in the risk factors for PEP between elective and 
emergency ERCP remains unclear.
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Aims & Methods: The aim of this study was for 6 expert ERCP endoscopists 
to compare performance characteristic ratings of a novel single-use duo-
denoscope to those of 3 marketed reusable duodenoscopes.
Beginning in March 2017, 9 laboratory animal studies were conducted to 
develop a single-use duodenoscope intended to bring a familiar design 
with a minimal learning curve. Prototype revisions based on physician 
feedback led to the fi rst-generation single-use duodenoscope used in 
the current study. Also based on physician feedback, a handmade, fully 
synthetic ERCP anatomical bench model was developed for use in ERCP 
simulation testing.
In January 2019, a bench study with randomized block design was conduct-
ed in which the 6 endoscopists rated the performance of the single-use 
EXALT Model D duodenoscope (Boston Scientifi c, Marlborough, USA) and 
3 reusable duodenoscopes (Q180V (Olympus, Japan), ED-3470TK (Pentax, 
Japan), ED-530XT (Fujifi lm, Japan) to complete 4 simulated ERCP tasks: 
guidewire locking (single-use and one reusable duodenoscope only), 
plastic stenting, metal stenting, and basket sweeping. Each task was per-
formed once with each duodenoscope model. Task completion rates and 
times, and subjective performance ratings on a scale of 1 (worst) to 10 
(best) were compared among duodenoscopes using non-parametric tests 
with adjustment for multiple comparisons.
Results: Task completion rates were 100% for all 4 duodenoscopes. Me-
dian task completion time ranged from 1.5 to 8.0 minutes per task. Overall 
performance (Table) and tip control (medians 9.0-10.0, P=0.77 among all 
4 duodenoscopes) were rated similarly among the duodenoscopes tested. 
Task 
Number
EXALT Model D Q180V ED-3470TK ED-530XT P value
1 9.0 (8.0-10.0) 9.0 (8.0-10.0) -- -- 1.00
2 8.5 (8.0-9.0) 10.0 (8.0-10.0) 9.0 (8.0-10.0) 9.0 (8.0-10.0) 0.14
3 8.5 (8.0-9.0) 9.5 (8.0-10.0) 8.0 (8.0-9.0) 9.5 (8.0-10.0) 0.11
4 8.5 (8.0-10.0) 9.0 (8.0-10.0) 9.0 (8.0-10.0) 9.0 (8.0-10.0) 0.74
[Table: Median ratings (range) for overall performance ]
The 2 duodenoscopes capable of guidewire locking both received median 
ratings of 10 for that function (P=0.14 for diff erence in subtask ratings). 
Among all 4 duodenoscopes, navigation/pushability was rated lower for 
the single-use duodenoscope (medians 8.0, 10.0, 9,0, 9.0 respectively, 
P<0.01). Image quality was rated lower for one of the reusable duode-
noscopes (ED-3470TK) (medians 8.0, 9.0, 9.0, 9.0 respectively, P< 0.01) 
compared to the other duodenoscopes tested.
Conclusion: In a comparative bench study including 4 simulated ERCP 
tasks, performance ratings were similar for the new single-use duode-
noscope and 3 brands of reusable duodenoscopes. A multicenter clinical 
study of the safety, feasibility and effi  cacy of the new single-use duodeno-
scope is warranted.
References: 1. Cassini A, Hogberg LD, Plachouras D, et al. Attributable 
deaths and disability-adjusted life-years caused by infections with antibi-
otic-resistant bacteria in the EU and the European Economic Area in 2015: 
a population-level modelling analysis. Lancet Infect Dis 2019;19:56-66. 2. 
Hutfl ess SM, Kalloo AN. Commentary on the 2016 Multi-Society Task Force 
Endoscope Reprocessing Guidelines. Gastroenterology 2017;152:494-6.
Disclosure: ASR: consulting fees and research funding from Boston Sci-
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initiated grants from Boston Scientifi c Corporation, Cook Medical, Pentax 
Medical and 3M, and consultant fees from Mylan; RK: research support 
from Boston Scientifi c Corporation; BTP: consultant/investigator relation-
ship with Boston Scientifi c Corporation, consultant fees from Olympus 
America, Advanced Steriliz Products and GI Medical; DKP: consultant fees 
from Boston Scientifi c Corporation, Olympus, Fuji and Nine Point Medical; 
DVS: consulting/research relationship with Boston Scientifi c Corporation, 
consultant fees from Olympus; AS: research funding from Boston Scientifi c 
Corporation and Olympus; DM: consultant fees from Boston Scientifi c Cor-
poration; JP, JI, MR and GPT are full-time employees of Boston Scientifi c 
Corporation; VRM: consulting fees and research funding from Boston Sci-
entifi c Corporation. 
OP133 ERCP IN BABIES: LOW RISK OF POST-ERCP-PANCREATITIS 
- RESULTS FROM A EUROPEAN MULTICENTER SURVEY
Goetz M.1,2, Andersen P.3, Bergman J.J.4, Frei N.4, Kähler G.5, Martus P.6, 
Dechêne A.7
1Universitätsklinikum Tübingen, Interdisziplinäre Endoskopie, Tübingen, 
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3Universitätsklinikum Tübingen, Interdisziplinäre Endoskopie, Tübingen, 
Germany, 4Academic Medical Centre, Gastroenterology and Hepatology, 
Amsterdam, Netherlands, 5University Medical Center Mannheim, Endoscopy, 
Mannheim, Germany, 6Universität Tübingen, Tübingen, Germany, 
7Universitätsklinik Essen Gastroenterologie und Hepatologie, Klinik für 
Gastroenterologie und Hepatologie, Essen, Germany
Contact E-Mail Address: philipp.andersen@student.uni-tuebingen.de
Introduction: ERCP is rarely performed in newborns, and the risk of post-
ERCP-pancreatitis (PEP) has not been defi ned in this age group. We there-
fore performed a European multicenter analysis of PEP rates and risk fac-
tors in children ≤1-year-old.
Aims & Methods: Based on a sample size estimation, 135 consecutive ER-
CPs in 126 children ≤1-year-old were evaluated from fi ve European centers. 
All ERCP and clinical reports were reviewed manually for PEP and as-
sociated risk factors. All ERCPs were performed by endoscopists with high 
ERCP expertise.
Results: No PEP was observed (0/126, 0.0%, CI 0-2.9%) despite formal 
presence of multiple risk factors and despite lack of PEP prophylaxis (ex-
cept one patient having received a pancreatic duct stent). The PEP rate 
was signifi cantly lower than the PEP rate expected in adults with similar 
risk factors.
Conclusion: : ERCP in ≤1-year-old children is safe in terms of PEP. The PEP 
risk is signifi cantly lower in children ≤1-year-old than in adults, therefore 
no PEP prophylaxis seems to be needed in young children. Risk factors 
from adults may not apply to children under 1 year. Reluctance to perform 
diagnostic ERCP in suspected biliary anomalies should not be based on 
presumed PEP risk.
Disclosure: Nothing to disclose 
New impulses in management of gastroparesis
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OP134 THYMIDINE PHOSPHORYLASE ABNORMALITIES AND 
GASTROINTESTINAL VASCULAR CHANGES IN GENETIC AND 
SPORADIC FORMS OF SEVERE DYSMOTILITY
Boschetti E.1, Costa R.2, Papa V.2, Cenacchi G.2, Rinaldi R.3, D’Angelo R.3, 
Carelli V.4, Pironi L.1, Tugnoli V.2, Clavenzani P.5, Sternini C.6, 
Stanghellini V.1, De Giorgio R.7
1University of Bologna, Department of Medical and Surgical Science, 
Bologna, Italy, 2University of Bologna, DIBINEM, Bologna, Italy, 3St. Orsola-
Malpighi Hospital, Bologna, Italy, 4University of Bologna, Bologna, Italy, 
5University of Bologna, DIMEVET, Bologna, Italy, 6David Ge en School of 
Medicine UCLA, Division of Digestive Diseases, Departments of Medicine and 
Neurobiology, Los Angeles, United States, 7University of Ferrara, Ferrara, Italy
Contact E-Mail Address: elisa.boschetti@unibo.it
Introduction: Mitochondrial neurogastrointestinal encephalomyopa-
thy (MNGIE) is an extremely rare autosomal recessive disease caused by 
thymidine phosphorylase (TP) enzyme defect. Normally, TP converts the 
nucleosides thymidine and deoxyuridine into respective nucleotides. In 
MNGIE these nucleosides accumulate in most tissues and induce toxic ef-
fects leading to mitochondrial DNA (mtDNA) abnormalities. MNGIE pa-
tients show severe gastrointestinal (GI) dysmotility and neurological im-
pairment, resulting in a poor quality of life and fatal outcome. Although 
permanent tissue replacement of TP (via either liver or hematopoietic cell 
transplantation) is the best way to stably revert the biochemical imbalance, 
transplanted patients do not recover the poor BMI and may dye for GI mas-
sive bleeding. The liver transplant follow-up suggests that the phenotype 
directly linked to the accumulation of nucleosides seems to be reversible, 
while other mechanisms underlying non-reversible GI damage may oc-
cur. During the conversion of nucleosides TP produces 2-deoxy-D-ribose-
1-phosphate (dRP) that has been demonstrated to be the chemotactic 
agent inducing endothelial progenitor cells to form/repair blood vessels. 
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collected utilising the Brisbane Aseptic Biopsy Forceps (MTW, Germany) 
to avoid the luminal and working channel contamination of tissue, and 
total DNA was extracted. Tissue bacterial density was normalised to hu-
man DNA by qPCR using Bacteria-Domain 16S rRNA gene- and beta-actin 
gene-specifi c primers, respectively. Based upon on all available clinical 
data, patients were categorised as FGID or non-FGID. The FGID and non-
FGID groups were compared utilising non parametric testing, and Spear-
man correlation to determine the relationships between disease category 
and the respective variables. In addition, Receiver Operator Curves (ROC) 
for the variables that were signifi cantly diff erent for FGID and non-FGID 
provided areas under the curve for comparison.
Results: SAGIS symptom scores, the symptom response to the nutrient 
challenge, and the tissue bacterial load were all signifi cantly greater (all 
P< 0.005) in FGID patients as compared to non FGID patients (Table 1). 
  SAGIS-score Nutrient challenge score
Bacterial load, 
ratio
Gastric emptying, 
t-lag (min)
Non-FGID 10.8 (±12.9) 204 (±190) 0.04 (±0.11) 116.0 (±37.3)
FGID 30.6 (±15.1)# 458 (±399)* 0.20 (±0.5)# 115.8 (±29.3)
#P< 0.001, *P< 0.005
[Table 1. GI symptom severity, symptom response to nutrient challenge, 
bacterial load (ratio of 16s RNA:β actin) and t-lag gastric emptying]
There was no diff erence with regard to gastric emptying. SAGIS score 
(r=0.62, P< 0.001), nutrient challenge score (r=0.41, p< 0.001) and bacte-
rial load (r=0.342, p< 0.001) were linked to FGID, whereas gastric emptying 
was not (r=0.024, p>0.8). For the total SAGIS score the AUC was .892 (95% 
CI 0.83-0.954), for the nutrient challenge score 0.74 (95%CI .64-0.83), bac-
terial load (0.71 (95%CI 0.61-0.80).
Conclusion: In patients referred to a tertiary setting for assessment and 
treatment, self-reported symptom severity, response to a standardised 
nutrient challenge and small intestinal bacterial load but not gastric emp-
tying rate diff erentiate patients with functional and non-functional symp-
toms. Further studies need to explore the utility of these simple tests to 
better tailor diagnostic and therapeutic interventions for patients present-
ing with chronic unexplained GI symptoms.
Disclosure: Nothing to disclose 
OP136 EFFECT OF RIKKUNSHITO ON GASTROINTESTINAL MOTILITY 
AND UPPER GASTROINTESTINAL SYMPTOMS - THE FIRST STUDY IN A 
BELGIAN FUNCTIONAL DYSPEPSIA POPULATION
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Tack J.6
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Introduction: Functional dyspepsia (FD) is a common chronic gastrointesti-
nal (GI) disorder. Rikkunshito, a traditional Japanese Kampo medicine, has 
shown effi  cacy in improving FD symptoms in controlled trials in Japan. Its 
putative benefi t for European patients has never been investigated. Fur-
ther, its exact mechanism of action is incompletely elucidated.
Aims & Methods: This study aimed to examine the eff ect of rikkunshito on 
gastric motility and GI symptom perception in FD patients with postpran-
dial distress syndrome (PDS) subtype in a randomized, placebo-controlled, 
cross-over study. Aft er a 2-week run-in period, during which adequate 
symptom intensity was confi rmed, patients were treated with rikkunshito 
(2.5g t.i.d.) and matching placebo for 4 weeks, separated by a 4-week 
washout period. Symptom severity was assessed by the Leuven Postpran-
dial Distress Scale (LPDS) diary throughout the study. At baseline and at 
the end of both treatment arms, intragastric pressure (IGP) was assessed 
using high-resolution manometry aft er an overnight fast. Thirty minutes 
aft er study medication intake, a liquid meal was infused intragastrically at 
a constant speed (60 mL/min) until full satiation. IGP measurement con-
tinued until 2 hours aft er the liquid meal. GI symptoms were scored on a 
100mm visual analogue scale every 10 minutes. At baseline, before and 
aft er each treatment period, the PAGI-SYM (patient assessment GI symp-
In MNGIE patients the conversion does not take place. In order to exert its 
eff ect dRP has to be locally released, hence vascular changes may occur in 
the GI tract of MNGIE patients.
Aims & Methods: This study was designed to explore the enteric submuco-
sal microvasculature in the jejunal of MNGIE patients in comparison with 
asymptomatic GI controls (CTR) and non-MNGIE patients with well charac-
terized severe dismotility (SD) and normal TP activity. 
Jejunal full thickness biopsies were collected from n=4 MNGIE (4M, 24-32 
yrs); n=10 CTR (7M, 30-73 yrs) and n=21 SD (9M; 16-75). Formalin fi xed-par-
affi  n embedded tissue sections were stained with orcein to identify, mea-
sure and count blood vessels. Vessels were subdivided in 4 classes: >300 
µm (large); 300-101 µm (medium); 100-51 µm (small) and < 50 µm (very 
small). Snap frozen tissue was used to quantify TP protein expression.
Results: MNGIE patients showed two times more submucosal vessels/mm2 
(P< 0.05) vs. CTR, while SD showed only a non signifi cant trend to in-
crease. In contrast the area of submucosa occupied by vascular tissue was 
about half in MNGIE (P< 0.01) and SD (P< 0.001) vs. CTR. The percentage of 
the small vessels (< 50 µm) in CTR was very low ~19%, whereas drastically 
increased in SD (43%; P< 0.001) and MNGIE (54%; P< 0.01). Conversely, 
the percentage of higher diameter vessels (>300 µm) in CTR was ~15 % 
and in SD and MNGIE patients decreased up to 7% and 5% (P< 0.01 and 
P< 0.05), respectively. Medium vessels (300-101 µm) represented the 40% 
of vessels in CTR and decreased to 25% and 17% in SD and MNGIE patients 
(P< 0.001 and P< 0.01). The TP amount showed a signifi cant decrease in 
the jejunum of SD patients (P< 0.0001).
Conclusion: Our results indicate that, compared to CTR, MNGIE and SD vas-
culature showed quantitative abnormalities likely related to the absence/
lower TP conversion. This study addressed the abnormal vascularization 
in the small intestine of genetic (MNGIE) and sporadic SD as a possible 
contributory mechanism underlying gut dysfunction in these severe condi-
tions.
Disclosure: Nothing to disclose 
OP135 DIAGNOSTIC YIELD OF SYMPTOM SEVERITY, VISCERAL 
SENSORY TESTING, SMALL INTESTINAL, BACTERIAL LOAD AND 
GASTRIC EMPTYING FOR THE DIAGNOSIS OF FUNCTIONAL 
GASTROINTESTINAL DISORDERS
Shah A.1,2, Morrison M.3,4, Koloski N.A.2,3,5, Hansen T.3, Walker M.M.6, 
Jones M.P.7, Talley N.J.5, Holtmann G.J.2,3,8
1Princess Alexandra Hospital, Queensland Health, Department of 
Gastroenterology and Hepatology, Brisbane, Australia, 2University of 
Queensland, School of Medicine, Brisbane, Australia, 3Princess Alexandra 
Hospital, Gastroenterology & Hepatology, Brisbane, Australia, 4University 
of Queensland, Brisbane, Australia, 5University of Newcastle, Faculty of 
Health & Medicine, Callaghan, Australia, 6University of Newcastle, Dept. 
of Anatomical Pathology, Newcastle, Australia, 7Macquarie University 
Psychology, Psychology, North Ryde, Australia, 8Australian Gastrointestinal 
Research Alliance (AGIRA), Newcastle, Australia
Contact E-Mail Address: ayesha17@gmail.com
Introduction: Patients presenting with functional gastrointestinal disorders 
(FGIDs) frequently report debilitating symptoms which may be more se-
vere than symptoms experienced by patients with organic intestinal dis-
ease. While presence or absence (i.e. symptom pattern) is generally used 
to categorise patients with FGIDs, the role of symptom intensity to catego-
rise and diagnose patients has not been tested. In addition, alterations of 
gastrointestinal sensory function, altered motility and bacterial dysbiosis 
are considered to play key roles in FGID pathophysiology.
Aims & Methods: In this study we aimed to explore the diagnostic yield 
of severity of self-reported GI symptoms, visceral sensory testing, qPCR to 
quantify small intestinal mucosal bacterial load and gastric emptying in 
diff erentiating functional from organic GI disease. We recruited 284 pa-
tients (150 female, 95 patients with FGID (68 functional dyspepsia (FD)/IBS 
overlap, 21 FD, 3 IBS), 118 organic disease (43 Crohn’s disease, 48 ulcerative 
colitis (UC), 16 UC/primary sclerosing cholangiopathy (PSC), 4 PSC alone, 
9 other) and 71 patients with a positive stool occult blood test without 
structural lesions). Aft er informed consent, type and severity of GI symp-
toms were recorded using a standardized valid questionnaire (SAGIS). Pa-
tients underwent a nutrient challenge test and the cumulative symptom 
response to a standardised test meal (Ensure, 600 cc) were recorded. In 
addition, gastric emptying of a solid test meal was measured utilising 13C-
octanoic breath testing. During endoscopy, mucosal tissue samples were 
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toms), VSI (visceral sensitivity index) and SF-NDI (short form Nepean dys-
pepsia index) questionnaires were completed. Data were analyzed using 
mixed models.
Results: Thirty-four patients were randomized in the study, of which 11 
dropped-out, resulting in 23 fully evaluable patients (33±14 y, 22.7±3.22 
kg/m2). The IGP was numerically, although not signifi cantly, lower aft er 
rikkunshito compared to both baseline and placebo (mean diff erence: 1.51 
mmHg, p< 0.221; 2.19mmHg, p=0.132, respectively). No signifi cant diff er-
ences were found in gastric accommodation, nutrient volume tolerance 
and symptoms assessed during IGP measurements. An exploratory sub-
group analysis, comparing patients on PPI (7 patients) and off  PPI (16 pa-
tients), showed that the numerical diff erence in IGP was driven by the 
patients who were not on PPI treatment. However, no signifi cant diff erence 
was observed between both subgroups. Early satiation, bloating and epi-
gastric pain, scored on the LPDS diary, decreased aft er rikkunshito com-
pared to baseline (p< 0.025 for all). However, comparable symptom im-
provement occurred aft er placebo (p< 0.045 for all; NS between groups). 
Exploratory subgroup analysis on overall LPDS symptom scores revealed 
signifi cant improvement aft er rikkunshito for the patients off  PPI (p=0.021) 
and aft er placebo for the patients on PPI (p=0.006). Total PAGI-SYM scores 
were equally improved aft er rikkunshito and placebo compared to base-
line (p< 0.001 and p< 0.001, respectively; NS between groups). Placebo, 
but not rikkunshito, signifi cantly improved frequency, severity and both-
ersomeness of SF-NDI scores compared to baseline (p< 0.008 for all). No 
signifi cant changes in VSI scores occurred. No adverse reactions occurred.
Conclusion: Rikkunshito did not alter gastric accommodation and nutrient 
volume tolerance. Treatment with rikkunshito improved upper GI symp-
toms in FD patients but a similarly high placebo eff ect was observed us-
ing the LPDS diary, PAGI-SYM and SF-NDI. Rikkunshito was safe and well 
tolerated. Exploratory analyses indicate potentially better responses in 
patients who are not on concomitant PPI treatment.
Disclosure: Nothing to disclose 
OP137 TRADIPITANT, A NOVEL NK-1 RECEPTOR ANTAGONIST, 
SIGNIFICANTLY IMPROVED NAUSEA AND OTHER SYMPTOMS OF 
GASTROPARESIS IN A PHASE II TRIAL
Carlin J., Lieberman V., Dahal A., Keefe M., Xiao C., Birznieks G., 
Polymeropoulos M.
Vanda Pharmaceuticals, Inc, Research & Development, Washington, United 
States
Contact E-Mail Address: jesse.carlin@vandapharma.com
Introduction: A phase II multicenter, randomized, double-blind, placebo-
controlled trial with gastroparesis subjects demonstrating delayed gastric 
emptying and moderate to severe nausea were randomized to receive oral 
85mg tradipitant bid or placebo (1:1) for four weeks. Of the 152 patients, 
60% of patients had idiopathic and 40% had diabetic gastroparesis.
Aims & Methods: The primary outcome was change in average nausea 
score from baseline, measured using the 5-point Gastroparesis Core 
Symptom Daily Diary (GCSDD). Overall gastroparesis symptoms were eval-
uated using the Gastroparesis Cardinal Symptom Index (GCSI), and Patient 
Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-
SYM).
Results: A statistically signifi cant and clinically meaningful improvement 
in nausea and overall gastroparesis symptoms was observed in patients 
on tradipitant. Subjects receiving tradipitant had a signifi cant decrease in 
their average nausea score compared to placebo with LS mean diff erence 
(95% CI) of -0.53 (-0.92, -0.13, p=0.0099) as well as a signifi cant increase 
in nausea free days (28.8% increase on tradipitant compared to 15.0% 
increase on placebo, p=0.0160). A clinically meaningful response of 1-point 
or more improvement on the GCSI total score was observed in 46.0% of 
patients on tradipitant compared to 24.2% of patients on placebo.
Conclusion: Tradipitant treatment resulted in statistically and clinically 
meaningful improvements in nausea and overall gastroparesis symptoms. 
Tradipitant was well tolerated with comparable rates of adverse events 
between tradipitant and placebo groups. These robust effi  cacy results sug-
gest tradipitant has the potential to become a fi rst line pharmacological 
treatment for gastroparesis.
Disclosure: All authors are employees of Vanda Pharmaceuticals, Inc. 
OP138 EFFICACY OF VELUSETRAG TREATMENT IN PATIENTS WITH 
IDIOPATHIC GASTROPARESIS: SUBGROUP ANALYSIS OF A PHASE 2B 
STUDY
Abell T.1, Kuo B.2, Esfandyari T.3, Canafax D.4, Tacchi R.5, Grimaldi M.5, 
Viscomi G.5, Renzulli C.5, Zhou K.4, Nguyen D.4, Barnes C.4, McCallum R.6
1University of Louisville, Louisville, United States, 2Massachusetts General 
Hospital, Boston, United States, 3University of Kansas Medical School, Kansas 
City, United States, 4Theravance Biopharma US, Inc., South San Francisco, 
United States, 5Alfasigma S.p.A., Bologna, Italy, 6Texas Tech University Health 
Science Center - Paul L. Foster School of Medicine, Department of Internal 
Medicine and Center for Neurogastroenterology and GI Motility, El Paso, 
United States
Contact E-Mail Address: kaitlynf@alphabiocom.com
Introduction: Velusetrag (VEL) is a highly selective oral 5-hydroxytryp-
tamine receptor type 4 agonist with demonstrated prokinetic eff ects 
throughout the gastrointestinal tract. A phase 2b trial evaluated VEL ef-
fi cacy and safety in patients with idiopathic or diabetic gastroparesis; this 
subanalysis assessed eff ects of VEL vs placebo on symptoms and gastric 
emptying in only patients with idiopathic gastroparesis.
Aims & Methods: Patients with baseline 24-hour Gastroparesis Cardinal 
Symptoms Index (GCSI-24H) 7-day mean composite score ≥2.5 and delayed 
gastric emptying based on scintigraphy (GES) or gastric emptying breath 
test were randomized, stratifi ed by gastroparesis type, to receive oral VEL 
5, 15, or 30 mg, or placebo, once daily in the morning, in parallel for 12 
weeks and followed for another 2 weeks. Symptoms were assessed daily 
using the GCSI-24H, a daily version of the GCSI including nausea/vomiting, 
postprandial fullness/early satiety, and bloating subscales. Gastric emp-
tying was evaluated at day 28 by the same test used for screening. The 
primary effi  cacy outcome was change from baseline to week 4 in 7-day 
mean GCSI-24H composite score in patients receiving each dose of VEL vs 
placebo. Key secondary outcomes included change from baseline to day 28 
in gastric emptying assessed by GES in patients receiving VEL vs placebo, 
and safety and tolerability of VEL in patients with idiopathic gastroparesis.
Results: Of 228 randomized patients who received study drug and had 
evaluable effi  cacy data, 112 had idiopathic gastroparesis: 29 patients re-
ceived VEL 5 mg, 24 received VEL 15 mg, 31 received VEL 30 mg, and 28 
received placebo. The majority of patients were female (85%); mean age 
was 45.4 (range, 19-73) years, and mean baseline GCSI-24H total score 
was 3.1 (standard deviation, 0.51) points (n=111). GES was assessed in 58 
patients.
Change from baseline GCSI-24H composite score at weeks 4 and 12 showed 
an inverse dose response, with larger treatment eff ects vs placebo for VEL 
5 mg vs 15 or 30 mg. In patients receiving VEL 5 mg, GCSI-24H composite 
score decreased from baseline signifi cantly at week 4 (treatment diff erence 
[95% confi dence interval (CI)], −0.6 [−1.08, −0.05] points; nominal p=0.03) 
and numerically at week 12 (treatment diff erence [95% CI], −0.6 [−1.19, 
0.00] points; nominal p=0.05]) relative to placebo. All GCSI-24H symptom 
subscale scores in patients receiving VEL 5 mg vs placebo decreased from 
baseline in week 1 of treatment, stabilized or decreased through week 6, 
and were stable through week 12. No tachyphylaxis was observed. Gastric 
emptying assessed by GES improved from baseline to day 28 in 9/13 pa-
tients receiving VEL 5 mg, 13/13 receiving VEL 15 mg, and 16/16 receiving 
VEL 30 mg vs 6/16 patients receiving placebo. Gastric emptying normalized 
(< 10% GES hour 4 retention) in all patients receiving VEL 15 mg and 81% 
receiving VEL 30 mg vs 0% receiving VEL 5 mg or placebo.
VEL was generally well tolerated. The most common adverse events (AEs) 
across all treatment arms were diarrhea, nausea, and headache. Numeri-
cally greater proportions of patients receiving VEL 5, 15, or 30 mg vs pla-
cebo had diarrhea (13.8%, 30.8%, and 19.4%, respectively, vs 7.4%) and 
nausea (6.9%, 7.7%, and 19.4%, respectively, vs 3.7%).
Conclusion: VEL treatment for 12 weeks reduced gastroparesis symptoms, 
with greatest eff ect for the 5-mg dose; demonstrated gastroprokinetic ac-
tivity at all doses; and was well tolerated in patients with idiopathic gas-
troparesis. Future phase 3 studies will further evaluate VEL effi  cacy in this 
population.
Disclosure: TLA is a consultant to Theravance Biopharma, Inc.; an inves-
tigator for Vanda, Allergan, Anylam, Censa, and Theravance Biopharma 
R&D, Inc.; a reviewer for Up To Date; an Editor of MedStudy, Neuromodu-
lation, and Wikistim; and a founder of ADEPT-GI. BK reports grant fund-
ing from AstraZeneca; Evidera; Gelesis, Inc.; Genzyme; GSK; Medtronic; 
Takeda; Theravance Biopharma R&D, Inc.; and Vanda; and personal fees 
from Actavis Pharma, Inc.; AstraZeneca; Biogen; Entrega; Forest Pharma-
78 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
pain, role limitations due to physical health and emotional problems, 
energy/fatigue, emotional well-being, and general health were not sta-
tistically signifi cant (p>0.05). Comparison of GES results before and aft er 
G-POEM showed that gastric emptying rate normalized in 55% of patients 
and the mean 4-hr gastric retention percentage decreased signifi cantly 
from 39.4 ± 20.4 to 18.3 ± 24.8 (p< 0.001). A total of 4 AEs occurred: 3 
capnoperitoneum and 1 mucosotomy, all rated as mild according to the 
ASGE lexicon. The 3 capnoperitoneum cases were treated by needle de-
compression, while the inadvertent mucosotomy was successfully treated 
by stent deployment.
Conclusion: With high technical success rate, limited adverse events, and 
high clinical effi  cacy, G-POEM appears to be a feasible and promising 
therapeutic intervention for management of refractory gastroparesis.
Disclosure: Nothing to disclose 
Advances in endoscopy and faecal testing for 
IBD and cancer
08:30-10:00 / B5
OP140 LOCATION BUT NOT SEVERITY OF ENDOSCOPIC LESIONS 
AT BASELINE INFLUENCES ENDOSCOPIC HEALING RATES IN CROHN’S 
DISEASE PATIENTS TREATED WITH INFLIXIMAB: A POST-HOC 
ANALYSIS OF THE TAILORIX TRIAL
Riviere P.1, D’Haens G.R.2, Peyrin-Biroulet L.3, Baert F.4, Lambrecht G.5, 
Pariente B.6, Bossuyt P.7, Buisson A.8, Oldenburg B.9, Vermeire S.10, 
Laharie D.1
1Bordeaux University Hospital, Gastoenterology and Nutrition, Pessac, 
France, 2AMC Amsterdam In ammatory Bowel Disease Centre, Amsterdam, 
Netherlands, 3Nancy University Hospital, Lorraine University, Hépato-
Gastroentérologie, Nancy, France, 4Az Delta, Dept of Gastroenterology, 
Roeselare, Belgium, 5AZ Damiaan, Gastroenterology, Oostende, Belgium, 
6Lille University, Gastroenterology, Lille, France, 7Imelda Ziekenhuis, 
Bonheiden, Belgium, 8CHU Estaing Clermont-Ferrand, Dept. of 
Gastroenterology, Clermont-Ferrand, France, 9University Medical Center 
Utrecht, Utrecht, Netherlands, 10University Hospital Leuven, Dept. of 
Gastroenterology, Leuven, Belgium
Contact E-Mail Address: pauline.riviere@chu-bordeaux.fr
Introduction: Whether severity and location of endoscopic lesions may in-
fl uence the likelihood of endoscopic healing in Crohn’s disease patients 
treated with anti-TNF is poorly known. We assessed rates of endoscopic 
healing in CD patients responding to infl iximab (IFX) in combination with 
an immunomodulator at the end of the induction period and at one year 
according to baseline endoscopic fi ndings (severity of lesions and their 
location).
Aims & Methods: We conducted a post-hoc analysis of the endoscopic 
data prospectively collected in the TAILORIX study, a randomized trial in-
vestigating treatment with IFX based on biomarkers and therapeutic drug 
monitoring in biologic-naïve patients with an active luminal CD (1). All 
patients had endoscopic ulcerations at inclusion. Ileo-colonoscopies were 
performed at week 0, 12 and week 54. Endoscopic healing was defi ned as 
absence of ulcers, complete endoscopic remission as either CDEIS< 3 or 
SES-CD< 3, and endoscopic response as >50% decrease in CDEIS or SES-
CD scores. Individual segments (ileum, right colon, transverse colon, left  
colon and rectum) were centrally read and scored separately for healing 
and response.
Results: Of the 122 patients included in the trial, the 75 patients who re-
ceived IFX until week 54 and underwent ileocolonoscopy at week 0, 12 
and week 54 could be analysed (median (interquartile range) disease 
duration: 6 (1-67) months), corresponding to 234 diseased segments (il-
eum n=47, right colon n=46, transverse colon n=46, left  colon n=54, rec-
tum n=41) at baseline. Thirty-fi ve patients with early discontinuation of 
IFX during the study and 12 with missing ileocolonoscopy at week 12 or 
54 were excluded. Overall at weeks 12 and 54, 32 (43%) and 54 (72%) 
patients displayed endoscopic healing, 54 (72%) and 64 (85%) complete 
endoscopic remission and 63 (84%) and 69 (92%) endoscopic response, 
respectively. The severity of endoscopic lesions at inclusion did not af-
fect endoscopic outcomes: endoscopic healing rates at weeks 12 and 54 
were similar among patients with deep ulcerations at baseline and those 
with only superfi cial ulcerations (20/50 (40%) vs.12/25 (48%), p=0.68 and 
35/50 (70%) vs.19/25 (76%), respectively, p=0.79), as well as complete en-
ceuticals; Gelesis, Inc.; Genzyme; GLG; GSK; Ironwood Pharmaceuticals; 
Medtronic; Takeda; and Theravance Biopharma R&D, Inc. TE reports noth-
ing to disclose. DC, KZ, and CNB are former employees of Theravance Bio-
pharma US, Inc. RT, MG, GCV, and CR are employees of Alfasigma S.p.A. 
DDN is an employee of Theravance Biopharma US, Inc., and shareholder 
of Theravance Biopharma, Inc. RM reports grant funding from Allergan 
Pharma; Medtronic Corp.; Takeda Pharma; Vanda Pharma; Theravance 
Biopharma R&D, Inc.; and Evoke Pharma; and personal fees from Salix 
Pharma. 
OP139 GASTRIC PERORAL ENDOSCOPIC MYOTOMY (G-POEM) FOR 
THE TREATMENT OF REFRACTORY GASTROPARESIS: RESULTS FROM 
THE FIRST INTERNATIONAL PROSPECTIVE TRIAL
Vosoughi K.1, Ichkhanian Y.1, Benias P.2, Miller L.S.2, Aadam A.A.3, 
Triggs J.3, Law R.4, Chaves D.5, Draganov P.V.6, Kotzev A.I.7, El Halabi M.8, 
Sanaei O.1, Brewer Gutierrez O.I.1, Pandolfi no J.9, Kalloo A.N.1, 
Khashab M.A.1
1Johns Hopkins Medical Institution, Division of Gastroenterology and 
Hepatology, Baltimore, United States, 2Long Island Jewish Medical Center, 
Northwell Health System, Division of Gastroenterology, Zucker School of 
Medicine at Hofstra/Northwell, New Hyde Park, United States, 3Northwestern 
University, Division of Gastroenterology, Chicago, United States, 4University of 
Michigan, Division of Gastroenterology, Ann Arbor, United States, 5Faculdade 
de Medicina da Universidade de São Paulo, Gastroenterologia, Unidade 
de Endoscopia Gastrointestinal, São Paulo, Brazil, 6University of Florida, 
Division of Gastroenterology, Hepatology and Nutrition, Gainesville, United 
States, 7University Hospital ‘Alexandrovska’, Medical University, Clinic of 
Gastroenterology, So a, Bulgaria, 8American University of Beirut, Department 
of Medicine, Beirut, Lebanon, 9Northwestern University, Department of 
Medicine, Feinberg School of Medicine, Chicago, United States
Contact E-Mail Address: kvosoug2@jhmi.edu
Introduction: Gastric per-oral endoscopic myotomy (GPOEM) was fi rst 
reported in 2013 for the treatment of gastroparesis. Early data suggested 
effi  cacy of the procedure; however, data from prospective multicenter 
studies are currently lacking.
Aims & Methods: The aim of this study is to prospectively evaluate the 
effi  cacy and safety of G-POEM in patients with gastroparesis refractory 
to conventional medical treatment. This is a multicenter study involving 
6 tertiary centers (5 US, 1 South America) between 11/2015 and 11/2018. 
Adult patients with refractory gastroparesis, defi ned as failing prior 
conventional medical therapy, and confi rmed by gastric emptying study 
(GES).The primary outcome was clinical success, defi ned as at least one 
score decrease in total Gastroparesis Cardinal Symptom Index (GCSI) with 
more than a 25% decrease in at least 2 sub-scales. Secondary outcomes 
were quality of life based on Short Form 36 (SF-36) and improvement of 
gastric motility assessed by GES. Data were collected before the procedure 
and 1 month, 3 months, 6 months, and 12 months aft er the procedure. GES 
was performed before and aft er G-POEM.
Results: A total of 73 patients with refractory gastroparesis (51 female 
[70 %]; median age 44yr) underwent G-POEM during the study period. 
The most common etiologies were idiopathic 29 (39.7 %), post-surgical 
26 (35.6 %), and diabetes 18 (24.7 %). All procedures were technically 
successful. Clinical success was achieved in 57.9 % and 36.8% of patients 
at 6 and 12 months, respectively. Repeated measures ANOVA showed 
that the mean GCSI score and nausea/vomiting and bloating subscores 
improved signifi cantly over follow-up intervals (table 1). 
GCSI subscales, 
mean ± SD
Preproce-
dural
1 month 
aft er 
procedure
3 months 
aft er 
procedure
6 months 
aft er 
procedure
12 months 
aft er 
procedure
p-value
Nausea/
vomiting
2.69 ± 1.29 1.44 ± 1.32 1.22 ± 1.4 1.54 ± 1.21 1.72 ± 1.48 0.17
Early satiety 2.76 ± 1.19 1.21 ± 1.14 1.12 ± 1.25 1.47 ± 1.12 1.67 ± 1.17 0.04
Bloating 3.65 ± 1.44 1.98 ± 1.72 1.58 ± 1.68 2.2 ± 1.7 2.06 ± 1.57 0.06
Total 2.96 ± 1.05 1.57 ± 1.14 1.39 ± 1.23 1.62 ± 1.14 1.84 ± 1.12 0.015
[Improvement of GCSI and its sub-scales, a er G-POEM]
Quality of life generally improved aft er G-POEM. Subscales with signifi -
cant improvement were Physical functioning (p=0.043), social functioning 
(0.024), and health change (0.005); however, the improvement of bodily 
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doscopic remission rates (35/50 (70%) vs.19/25 (76%), p=0.79 and 43/50 
(86%) vs.21/25 (84%), respectively, p=1.00) and endoscopic response rates 
(44/50 (88%) vs.19/25 (76%), p=0.32 and 46/50 (92%) vs.23/25 (92%), re-
spectively, p=1.00). The location of endoscopic lesions aff ected endoscopic 
outcomes: disappearance of deep ulcerations was lower in the ileum 
than in the colon both at weeks 12 (18/23 (78%) vs.57/57 (100%), p < 0.01) 
and 54 (20/23 (87%) vs.57/57 (100%), p=0.02). Consistently, a segmental 
CDEIS< 3 was less frequent in the ileum than in the colon at weeks 12 and 
54 (51% vs.80%, p< 0.01 and 70% vs.94%, p< 0.01, respectively). No dif-
ference was observed between disappearance rates of colonic and rectal 
deep ulcerations (p=0.17). No diff erence of segmental remission rates was 
observed between colonic and rectal lesions at weeks 12 and 54 (80% 
vs.68%, p=0.10 and 94% vs.90%, p=0.42, respectively).
Conclusion: In biologic-naive CD patients treated with IFX combo therapy 
during one year, severity of endoscopic lesions at baseline does not infl u-
ence healing rates at short- and long-term. Healing rate was lower for 
ileal than for colonic lesions.
References: 1. D’Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pari-
ente B, et al. Increasing Infl iximab Dose Based on Symptoms, Biomarkers, 
and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, 
and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s 
Disease. Gastroenterology. 2018 Apr;154(5):1343-1351.e1.
Disclosure: Abbvie, Amgen. 
OP141 ASSESSING MUCOSAL BARRIER FUNCTION IN VIVO WITH 
CONFOCAL LASER ENDOMICROSCOPY CAN PREDICT MAJOR CLINICAL 
EVENTS IN IBD PATIENTS WITH HIGH SENSITIVITY
Rath T.1, Klenske E.2, Atreya R.1, Fischer S.2, Zundler S.2, Hartmann A.3, 
Neurath M.F.1
1University Hospital Erlangen, Ludwig Demling Endoscopy Center of 
Excellence, Erlangen, Germany, 2University Hospital Erlangen, Department of 
Medicine 1, Erlangen, Germany, 3University Hospital Erlangen, Department of 
Pathology, Erlangen, Germany
Contact E-Mail Address: timo.rath@uk-erlangen.de
Introduction: Probe-based confocal laser endomicroscopy (pCLE) enables 
in vivo microscopic imaging during ongoing endoscopy. Further, pCLE en-
ables visualization of mucosal barrier dysfunction (MBD) in patients with 
infl ammatory bowel diseases (IBD). With this, pCLE is the only technology 
allowing functional imaging within the GI tract in IBD patients.
Aims & Methods: Here we evaluated whether assessment of MBD by pCLE 
can accurately predict major clinical events (MCE) in IBD patients. IBD pa-
tients in clinical and endoscopic remission were prospectively enrolled. 
pCLE was performed initially and subsequently patients were followed-up 
for at least 12 months. During follow-up major clinical events (MCE= IBD-
related hospitalization, need for surgery, need for initiation of systemic 
corticosteroids, immunosuppressants or biologics, escalation of existing 
biologic therapy) were recorded.
Results: 60 patients were prospectively included (37 Crohn’s disease [CD], 
23 ulcerative colitis [UC]) with a median age of 38 years (range 19-68). CLE-
scoring showed strong correlation with histopathology (r≥0.75, p≤0.05) 
with an almost perfect interobserver agreement of pCLE fi ndings among 
diff erent readers (Kappa >0.8). MBD as assessed with pCLE in the terminal 
ileum showed 100% sensitivity (95% CI, 77-100), 75% specifi city (95% CI, 
47-92) and 88% accuracy in CD patients and 83.3% sensitivity (95% CI, 
50.8-97.1), 81.8% specifi city (95% CI, 47.8-96.8) and 82.6% accuracy in 
UC patients for predicting MCEs during the 12 month follow-up. In those 
patients with MBD in the colon, sensitivity, specifi city and accuracy for pre-
dicting MCEs with pCLE were 91.7% (95% CI, 59.8-99.6), 72.8% (95% CI, 
39.3-92.7) and 82.6%, respectively.
Conclusion: By assessing MBD in vivo, pCLE allows to predict MCE in IBD 
patients in clinical end endoscopic remission with very high sensitivity. 
Therefore, pCLE can be used to eff ectively time and personalize anti-in-
fl ammatory treatment in IBD patients.
Disclosure: Nothing to disclose 
OP142 CROHN´S DISEASE LESIONS DETECTION BY SMALL-BOWEL 
CAPSULE ENDOSCOPY: AN AUTOMATIC DEEP LEARNING METHOD
de Maissin A.1, Vallée R.2, Normand N.2, Coutrot A.2, Mouchere H.2, 
Trang C.1, Bourreille A.1
1Universitary Hospital of Nantes, Gastro-Enterology - IMAD, Nantes, France, 
2University of Nantes, École Polytech, UMR CNRS 6004, LS2N Équipe IPI, 
Nantes, France
Contact E-Mail Address: astriddemaissin@gmail.com
Introduction: Detection of abnormalities in small-bowel capsule endos-
copy (SBCE) is challenging and time consuming. Although Crohn´s disease 
(CD) is one of the main indications to perform SBCE, at the era of deep 
learning, few effi  cient computer-aided detection methods have been es-
tablished. 
We aimed to develop an artifi cial intelligence system based on deep learn-
ing to automatically detect CD lesions in SBCE.
Aims & Methods: An attention based-deep convolutional neural network 
(ACNN) system has been trained, using two databases, CrohnIPI and a 
public national database, CAD-CAP. The CrohnIPI database encompassed 
images extracted from Pillcam® SB2 and SB3 videos of patients with a 
known or suspected CD, in whom a SBCE was performed between 2013 
and 2018 in our department. Pathologic frames have been annotated as 
follow: aphtoid ulceration, ulceration between 3 and 10mm, ulceration 
over 10mm, stenosis, erythema and edema. Lesions were not localized or 
delineated into the image. Pathologic and normal images were not select-
ed in regard of their cleanliness or lighting. The CAD-CAP public database 
was used for the Gastrointestinal Image ANAlysis deep-learning challenge 
in 2018. It contains normal, vascular and infl ammatory frames. 
The whole original CrohnIPI’s images were randomly split into three 
groups: 70% for the training phase, 10% for the validation phase and 
20% for the test phase. The training phase was performed 10-times with 
random split of data to get a robust 10 folds cross-validation. CAD-CAP’s 
images were split into the same three groups as follow: 80%, 20% and 
10%. For this database, no cross-validation was done. We assessed our 
ACNN performance by calculating accuracy, sensitivity and specifi city for 
each database using an independent dataset from the one used for train-
ing.
Results: The CrohnIPI database was composed of 1628 normal frames and 
1590 containing CD lesions, acquired from 63 videos of 54 patients. The 
pathologic dataset contained 1281 ulcerations, 419 erythema, 64 stenosis 
and 428 edemas. Note that one frame could contain several lesions. The 
CAD-CAP database contained 600 images of each type (normal, vascu-
lar and infl ammatory). Our classifi er reached 90.85% accuracy, 91.47% 
specifi city and 90.22% sensitivity on our own dataset, CrohnIPI. The accu-
racy, specifi city and sensitivity for the CAD-CAP database were respectively 
99.67%, 100% and 98.97%.
Conclusion: We developed a new system based on a CNN to automatically 
detect CD lesions in images obtained from SBCE. The AI system showed a 
better performance on a selected frames national database. The promising 
performance of this ACNN paves the way for a complete computer-aided 
diagnosis system that could support physician´s clinical practice. Future 
work is aiming to train our ACNN on entire videos and developing an ap-
plication that could permits a collaborative annotation.
Disclosure: Nothing to disclose 
OP143 A PATIENT SELF-MADE ONE STEP QUICK FAECAL TEST 
IMPROVES DIAGNOSTIC ACCURACY FOR DETECTING ENDOSCOPIC 
ACTIVITY COMPARED WITH FAECAL CALPROTECTIN ALONE IN 
INFLAMMATORY BOWEL DISEASE PATIENTS
Velamazan R.1, Hijos G.1,2, Martí R.3, Arechavaleta S.2,4, Chueca E.2,4, 
Lué A.1,2,4, Sostres C.1,2,4, Lanas A.1,2,4, Gomollon F.1,2,4
1Hospital Clinico Universitario Lozano Blesa, Zaragoza, Spain, 2Instituto de 
Investigación Sanitaria Aragón (IIS Aragón), Zaragoza, Spain, 3Universidad 
de Zaragoza, Zaragoza, Spain, 4Centro de Investigación Biomédica en Red en 
el Area de Enfermedades Hepáticas y Digestivas (CIBERehd), Zaragoza, Spain
Contact E-Mail Address: raulvs92@gmail.com
Introduction: Faecal Calprotectin (FC) has a good correlation with infl am-
matory activity in Infl ammatory Bowel disease (IBD). Faecal occult blood 
test (FOBT) has demonstrated eff ectiveness detecting colorectal cancer or 
precancerous lesions in screening programs, but it’s value for monitoring 
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sions arising within the extent of infl ammation, between 01 January 2005 
and 30 June 2016. Patients with incomplete endoscopic resection at in-
dex endoscopy, no follow-up endoscopy/colectomy, and those with other 
CRC-predisposing conditions (e.g. polyposis) were excluded. Patients were 
followed up until the date of colectomy, or the last endoscopy up to 31 
December 2018. Survival analyses were performed using Kaplan-Meier 
estimation and Cox proportional hazards models.
Results: 236 patients met the inclusion criteria, with a median patient age 
of 64 years (range 28-88) and median 23 year duration (range 1 - 57) of 
diagnosed UC, at index endoscopy. CRC was found in the endoscopy resec-
tion specimens of 7 patients; 5 underwent colectomy in the following 18 
months, with the other two remaining CRC-free and on active monitoring.
For the remaining 229 patients, the median patient follow-up time of post-
resection was 5.2 years, with a median 4 follow-up endoscopies per pa-
tient. There was a median 12.2 months until fi rst follow-up endoscopy for 
patients with their largest lesion < 10mm, and median 6.2 months until 
fi rst follow-up endoscopy for those with lesion(s) >=10mm. 22% of patients 
underwent resection of multiple lesions at their fi rst procedure. Of the 
1,259 total endoscopies, only 2 resulted in complications requiring hospi-
talisation (post-polypectomy bleeding).
In these 229 patients, the risks of fi rst dysplasia recurrence at 1 and 5 years 
were 27.4% and 59.2% respectively. Colectomy risks at 1 and 5 years were 
3.5% and 8.3% respectively in patients with the largest index lesion is < 
10mm (n=142), and 8.0% and 26.4% respectively for patients with lesion(s) 
>10mm (n=87, log-rank p< 0.001). In all but 1 patient who required surgery 
for UC severity, colectomies were performed either for neoplastic progres-
sion to CRC, or for endoscopically unresectable dysplasia. CRC was de-
tected in 45% of colectomy specimens (17/38).
Multivariate Cox proportional hazards analysis demonstrates that lesion 
size >=10mm (HR = 2.16 [1.06 - 4.4, 95% CI]) and non-polypoid shape (HR 
= 3.2 [1.51 - 6.4, 95% CI]) were signifi cant predictors of future colectomy 
(model log-rank p=0.02). Covariates for the presence of multifocal dyspla-
sia, high grade dysplasia, pseudopolyposis, patient age, IBD duration, PSC 
and serration were statistically insignifi cant. Of note, patients with LGD 
resected by endoscopic submucosal dissection (n=15) and piecemeal EMR 
(n=40) had similar risk of future colectomy (p=0.94).
Conclusion: With over 1,272 patient-years of data, this is the largest study of 
endoscopic resection in IBD, and the fi rst to correlate resection outcomes 
with clinical & endoscopic characteristics. While endoscopic dysplasia re-
section is safe and eff ective, over 25% of patients with lesions larger than 
10mm ultimately required a colectomy within 5 years despite ostensibly 
complete dysplasia resection at index endoscopy, highlighting the impor-
tance of long-term surveillance and counseling these patients, who face 
the ongoing possibility of surgery.
References: Laine L, Kaltenbach T, Barkun A et al. SCENIC international 
consensus statement on surveillance and management of dysplasia in 
infl ammatory bowel disease. Gastroenterology. 2015 Mar; 148(3):639-651
Disclosure: Nothing to disclose 
OP145 PROGRESSIVE REDUCTION OF COLORECTAL CANCER 
INCIDENCE AND MORTALITY IN THE CZECH REPUBLIC: EFFECT OF 
SUBSTANTIAL TARGET POPULATION COVERAGE BY EXAMINATIONS?
Suchanek S.1, Grega T.2, Ngo O.3,4, Májek O.3,5, Zavoral M.6
1Military University Hospital, Department of Internal Medicine, Prague 6, 
Czech Republic, 2First Faculty of Medicine of Charles University and Military 
University Hospital, Prague, Department of Internal Medicine, Prague 6, 
Czech Republic, 3Institute of Biostatistics and Analyses, Faculty of Medicine, 
Masaryk University, Brno, Czech Republic, 4Institute of Health Information 
and Statistics of the Czech Republic, Uherčice, Czech Republic, 5Institute 
of Health Information and Statistics of the Czech Republic, Brno, Czech 
Republic, 6Military University Hospital Prague, Department of Internal 
Medicine, Prague 6, Czech Republic
Contact E-Mail Address: stepan.suchanek@uvn.cz
Introduction: The organized non-population based National Colorectal 
Cancer (CRC) Screening Program in the Czech Republic was running since 
year 2000. In January 2014, the transition to population-based setting has 
been implemented. Currently, the annual immunochemical fecal occult 
blood test (FIT) is off ered at the age 50 - 54, followed by FIT+ colonos-
copy, if positive. In age of 55, there is a choice of either FIT biennially 
or screening colonoscopy in 10 years interval. Besides these preventive 
colonoscopies, adenomas and colorectal cancers might be found out and 
IBD activity is less well established. Other faecal biomarkers, including 
faecal lactoferrin or faecal transferrin, are less used in clinical practice. 
Quick faecal tests, performed by patients at home or in the outpatients 
clinic, may be a useful strategy to monitor closely the disease activity.
Aims & Methods: To evaluate the diagnostic accuracy for detecting infl am-
matory colorectal mucosal activity of a one-step combo card faecal test 
for the simultaneous semi-qualitative detection of human haemoglobin 
(hHb), human transferrin (hTf), human calprotectin (hCp) and human lac-
toferrin (hLf) in samples of IBD patients. 
Methods: Consecutive IBD patients referred for colonoscopy according to 
our center protocol, who complete colonic examinations and returned 
stool samples, were prospectively recruited. Certest FOB+Transferrin+Ca
lprotectin+Lactoferrin® (Certest Biotec S.L, Zaragoza, Spain), a coloured 
chromatographic inmmunoassay for the simultaneous semi-qualitative 
detection of hHb, hTf, hCp and hLf, was performed. 
Endocoscopic activity was defi ned using endoscopic MAYO score in Ulcer-
ative Colitis (UC), and SES-CD score for Crohn’s Disease (CD).Clinical activ-
ity was evaluated by MAYO partial score in UC and Harvey-Bradshaw Index 
in CD. Laboratory data (C reactive protein, albumin, white blood cell count) 
were collected. 
Positive and negative predictive values (PPV, NPV), sensitivity and specifi c-
ity and area under ROC curve (AUROC) for each marker and for the diff er-
ent combinations for the detection of endoscopic activity were calculated.
Results: 106 patients (56,6% female, median age 52 years, IQR 42-61) were 
fi nally included. 54 (50,9%) with UC and 52 (49,1%) with CD. Median time 
since diagnosis was 14 years (IQR 9-20). 24 (22.6%) patients report clinical 
activity, while endoscopic activity was detected in 42 patients (39.6%). No 
signifi cant diff erence was observed in C reactive protein mean levels ac-
cording to the presence of endoscopic activity. 
Diagnostic accuracy for hHb, hCp, hTf, hLf and its combination are sum-
marized in Table 1.
AUROC were 0.62 (95% CI: 0.5-0.73) for C reactive protein and 0.83 (95% 
CI: 0.75-0.91) for the combination of the 4 biomarkers.
Test Negative test
Positive 
test PPV NPV Sensitivity Specifi city
hCp 23 83 49.3% 95.6% 97.6% 34.3%
hHb 73 33 75.8% 76.7% 59.5% 87.5%
hTf 79 27 70.4% 70.8% 45.2% 84.9%
hLf 78 28 82.1% 75.6% 54.7% 92.1%
All negative 19 87 48.3% 100% 100% 29.7%
All positive 93 13 100% 68% 30.9% 100%
[Table 1.]
Conclusion: FC alone is a good biomarker to rule out endoscopic activity in 
IBD, but with a low PPV. The one step quick simultaneous determination 
of 4 faecal biomarkers with the same kit improves the accuracy of FC alone 
for detecting patients with high risk of endoscopic activity.
Disclosure: Nothing to disclosure 
OP144 LONG-TERM OUTCOMES FOLLOWING ENDOSCOPIC 
RESECTION OF NEOPLASTIC LESIONS IN ULCERATIVE COLITIS: 
A LARGE SINGLE-CENTRE RETROSPECTIVE STUDY
Al Bakir I.1,2, Curtius K.2, Kabir M.3, Saunders B.3, Suzuki N.3, 
Thomas-Gibson S.3, Wilson A.3, Moorghen M.4, Graham T.2, Hart A.1
1St. Mark’s Hospital, In ammatory Bowel Disease Unit, Harrow, United 
Kingdom, 2Barts Cancer Institute, Centre for Tumour Biology, London, United 
Kingdom, 3St. Mark’s Hospital, Wolfson Unit for Endoscopy, Harrow, United 
Kingdom, 4St. Mark’s Hospital, Pathology Department, Harrow, United 
Kingdom
Contact E-Mail Address: i.albakir@qmul.ac.uk
Introduction: Patients with ulcerative colitis (UC) are enrolled into sur-
veillance programs for the early detection of precursor dysplasia and 
colorectal cancer (CRC). The SCENIC1 consensus recommends endoscopic 
resection of amenable dysplastic lesions; however, long-term patient 
outcomes, particularly for larger and/or non-polypoid lesions, remains 
poorly defi ned.
Aims & Methods: We conducted a retrospective observational study at St. 
Mark’s Hospital to identify all patients with Montreal classifi cation E2 & 
E3 UC who underwent endoscopic resection of dysplastic & serrated le-
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treated with diagnostic colonoscopy. Between years 2000 and 2015, sig-
nifi cant reduction of the CRC incidence (18.4 %) and mortality (32.4 %) 
was observed.
Aims & Methods: Estimation of the overall coverage of the screening target 
population (aged 50+) in the Czech Republic by available tests: FIT, screen-
ing colonoscopy or diagnostic colonoscopy. The analysis was performed 
using the newly available database (National Registry of Reimbursed 
Health Services), which contains individual data on reimbursed healthcare 
in the Czech Republic. Overall coverage was assessed over a three-year 
period 2015-2017.
Results: The CRC screening target population consists of 4,056,641 individ-
uals. The FITs were performed in 1,758,596 individuals (43.4 %), screening 
colonoscopies in 36,387 individuals (0.9 %) and diagnostic colonoscopies 
in 268,701 individuals (6.6 %). The overall target population coverage in 
the Czech Republic reached 50.9 % (women 52.0 %, men 49.5 %), highest 
in the age group of 65 - 69 years. The coverage is heterogenous among the 
regions (44.6 - 58.2 %), lowest in the capital city.
Conclusion: The overall target population coverage of CRC screening and 
diagnostic tests (50.9 %) has reached the recommended level according 
to the European guidelines (45-60 %). The most common examination is 
FIT, but signifi cant part of screening target population (6.6.%) has been 
examined with diagnostic colonoscopy. The high number of preventive and 
diagnostic colonoscopies might be the reason for the observed CRC inci-
dence and mortality reduction in the Czech Republic.
Disclosure: Nothing to disclose 
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OP146 MUCOSAL MOLECULAR SIGNATURES DIFFER BETWEEN 
ULCERATIVE COLITIS PATIENTS WITH OR WITHOUT RESPONSE TO 
VEDOLIZUMAB THERAPY
Bamias G.1, Gazouli M.2, Xourafas V.3, Zacharopoulou E.4, Tsoukali E.5, 
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Introduction: The anti-integrin monoclonal antibody vedolizumab has 
been successfully incorporated in the treatment algorithms for moderate 
to severe ulcerative colitis. A substantial percentage of patients, however, 
do not respond to this agent and fail to achieve sustained clinical remis-
sion. The identifi cation of mucosal or systemic molecular biomarkers that 
could predict response to vedolizumab is urgently needed to facilitate bet-
ter patient selection.
Aims & Methods: In a prospective study we aimed to identify mucosal mo-
lecular signatures with predictive value for response to vedolizumab in 
patients with ulcerative colitis. To accomplish our aim, mucosal biopsies 
were obtained at baseline, i.e. before commencement of vedolizumab, 
from pre-defi ned involved areas during lower GI endoscopy. 
Total RNA was extracted and the mRNA expression for several infl amma-
tory mediators were examined with an RT² Profi ler PCR Array Gene Ex-
pression array (Qiagen). Baseline transcriptomic profi les were compared 
between patients who were subsequently responders to scheduled ve-
dolizumab treatment until week 54 and patients who failed to respond to 
vedolizumab. A signifi cant diff erence was considered when there was a 
>2-fold increase or decrease in expression and a P value of < 0.05 for the 
comparison between the 2 groups.
Results: To compare baseline transcriptomic profi les, overall, we assessed 
10 patients who continued vedolizumab treatment and were in clinical re-
mission at week 54 and 10 patients who failed treatment with vedolizum-
ab. Mucosal mRNA signatures at baseline diff ered between the two groups 
of patients. In particular, we identifi ed eight genes that were signifi cantly 
upregulated at baseline in non-responders (CD40LG, CXCL10, LTB, IL-23A, 
CXCL9, SELE, CEBPB, CXCL5) and 9 genes that were signifi cantly down-
regulated (CXCL6, CCL4, CCL5, NR3C1, TNFSF14, CCL24, CCL2, CD14, CSF1). 
The top two mostly diff erentiated genes between the two groups were 
CD40LG (37-fold increase in non-responders, P= 0.000961) and CXCL6 (20-
fold decrease in non-responders, P= 0.0035).
Conclusion: Using a targeted transcriptomic profi ling approach we were 
able to identify, at baseline, several diff erentially expressed infl amma-
tory mediators in the colonic mucosa of patients with ulcerative colitis 
who were responders or non-responders aft er 54 weeks of vedolizumab 
therapy. If these results are replicated in larger cohorts they could pro-
vide reliable predictive biomarkers for better pre-treatment stratifi cation 
of patients and for optimization of their clinical response to vedolizumab.
Disclosure: This study has been funded by an IISR from Takeda to G.B. 
OP147 ANTI-INFLAMMATORY GUT MICROBIAL PATHWAYS ARE 
DECREASED DURING CROHN’S DISEASE EXACERBATIONS
Klaassen M.A.Y.1,2, Imhann F.1,2, Collij V.1,2, Fu J.1,3, Wijmenga C.2, 
Dijkstra G.1, Festen E.A.M.1,2, Gacesa R.1,2, Vich Vila A.1,2, Weersma R.K.1,2
1University Medical Center Groningen, Gastroenterology and Hepatology, 
Groningen, Netherlands, 2University Medical Center Groningen, Genetics, 
Groningen, Netherlands, 3University Medical Center Groningen, Pediatrics, 
Groningen, Netherlands
Contact E-Mail Address: marjolein.klaassen@outlook.com
Introduction: Crohn’s disease (CD) is a chronic infl ammatory disorder of 
the gastrointestinal tract characterized by alternating periods of exacerba-
tion and remission. We hypothesized that changes in the gut microbiome 
are associated with CD exacerbations, and therefore aimed to correlate 
multiple gut microbiome features to CD disease activity.
Aims & Methods: Fecal microbiome data generated using whole-genome 
metagenomic shotgun sequencing of 196 CD patients were of obtained 
from the 1000IBD cohort (one sample per patient). Patient disease activity 
status at time of sampling was determined by re-assessing clinical records 
three years aft er fecal sample production. Fecal samples were designated 
as taken ‘in an exacerbation’ or ‘in remission’. Samples taken ‘in remis-
sion’ were further categorized as ‘before the next exacerbation’ or ‘aft er 
the last exacerbation’, based on the exacerbation closest in time to the 
fecal production date. CD activity was correlated with gut microbial com-
position and predicted functional pathways via logistic regressions using 
MaAsLin soft ware.
Results: In total, 105 bacterial pathways were decreased during CD exac-
erbation (FDR< 0.1) in comparison to the gut microbiome of patients both 
before and aft er an exacerbation. Most of these decreased pathways exert 
anti-infl ammatory properties facilitating the biosynthesis and fermenta-
tion of various amino acids (tryptophan, methionine and arginine), vita-
mins (ribofl avin and thiamine) and short-chain fatty acids (SCFAs).
Conclusion: CD exacerbations are associated with a decrease in micro-
bial genes involved in the biosynthesis of the anti-infl ammatory media-
tors ribofl avin, thiamine and folate and SCFAs, suggesting that increasing 
intestinal abundances of these mediators might provide new treatment 
opportunities. These results were generated using bioinformatic analyses 
of cross-sectional data and need to be replicated using time-series and 
wet lab experiments.
Disclosure: Nothing to disclose 
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OP149 HISTOLOGIC REMISSION AND MUCOSAL HEALING IN A 
PHASE 2 STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY 
TO SEVERELY ACTIVE ULCERATIVE COLITIS
Pai R.1, Canavan J.B.2, Tuttle J.3, Durante M.3, Arora V.3, Milch C.3, 
Harpaz N.4, D’Haens G.5, Sands B.E.6, Sandborn W.7
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Introduction: Interleukin (IL)-23 is a key cytokine in infl ammatory bowel 
disease pathogenesis. Mirikizumab (miri), a p19-directed IL-23 antibody, 
demonstrated effi  cacy and was well-tolerated during 12 weeks of induc-
tion followed by an additional 40 weeks of maintenance treatment in a 
phase 2 randomized clinical trial (NCT02589665) in patients with ulcerative 
colitis (UC). The histologic results at Week 12 induction and Week 52 main-
tenance are presented here.
  Induction Treatment Groups
  Placebo
(N=63)
Mirikizumab
50 mg EB IV
Q4W (N=63)
Mirikizumab
200 mg EB IV 
Q4W (N=62)
Mirikizumab
600 mg IV
Q4W (N=61)
Mean (SD) unless 
otherwise specifi ed Baseline Characteristics
Age, years 42.62 
(13.47)
41.83 (14.06) 43.35 (14.75) 42.44 (13.71)
Male, n (%) 36 (57.1) 38 (60.3) 37 (59.7) 38 (62.3)
Disease duration, years 9.5 (9.6) 8.2 (7.2) 9.0 (9.0) 6.0 (5.7)
Previous biologic use, 
n (%) 40 (63.5) 39 (61.9) 40 (64.5) 38 (62.3)
Mayo Score, n (%)
6-8 27 (42.9) 24 (38.7) 27 (44.3) 26 (42.6)
9-12 36 (57.1) 38 (61.3) 34 (55.7) 35 (57.4)
  Induction Period, Study Week 12
Histologic remission, n (%) 11 (17.5) 9 (14.3) 28 (45.2) 21 (34.4)
% Diff erence vs PBO 
(95% CI) --- -3.2 (-15.9, 9.6) 27.7 (12.2, 43.2) 17.0 (1.8, 32.1)
  Maintenance Treatment Groups
 
Mirikizumab
200 mg SC
Q4W (N=47)
Mirikizumab
200 mg SC
Q12W (N=46)
  Maintenance Period, Study Week 52
Histologic remissiona, n (%) 31 (66.0) 17 (37.0)
Durable histologic 
remissionb, n (%) 20 (42.6) 9 (19.6)
Mucosal healingc, n (%) 23 (48.9) 11 (23.9)
aHistologic remission: Geboes histologic subscores of 0 for neutrophils in lamina propria, 
neutrophils in epithelium, and erosion or ulceration parameters.
bDurable histologic remission: histologic remission at both Week 12 and 52.
cMucosal healing: Histologic remission + endoscopic improvement (Mayo endoscopic 
subscore=0 or 1).
[Table 1.]
OP148 EARLY HISTOLOGIC IMPROVEMENT DEMONSTRATED WITH 
ORAL OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY 
ACTIVE CROHN’S DISEASE IN THE STEPSTONE TRIAL
Feagan B.G.1, D’Haens G.R.2, Usiskin K.3, Liu J.3, Pai R.K.4
1Robarts Clinical Trials Inc., Gastroenterology, London, Canada, 2AMC 
Amsterdam In ammatory Bowel Disease Centre - Academic Medical Center, 
AMC Amsterdam In ammator, Amsterdam, Netherlands, 3Celgene Corp, 
Summit, United States, 4Mayo Clinic, Scottsdale, United States
Contact E-Mail Address: brian.feagan@robartsinc.com
Introduction: Ozanimod, an oral immunomodulator that selectively tar-
gets S1P
1
 and S1P
5
, has demonstrated effi  cacy and safety in ulcerative coli-
tis (UC) (Sandborn NEJM 2016) and is being evaluated in active Crohn’s 
Disease (CD). The aim of the STEPSTONE study was to examine histologic, 
endoscopic, and clinical outcomes, and safety of ozanimod in adults with 
CD.
Aims & Methods: STEPSTONE was an open-label uncontrolled phase 2 
multicenter trial of ozanimod for 12 weeks, followed by an extension pe-
riod. Patients with active CD (Crohn’s Disease Activity Index [CDAI] score 
220-450, total simple endoscopic score for CD [SES-CD] ≥6 [or in isolated 
ileum disease SES-CD ≥4]) received ozanimod 1 mg daily. Ileo-colonic en-
doscopic biopsies (perpendicular to the mucosal surface at the edge of 
the largest ulcer or in the most severely aff ected area in segments without 
ulcers) were obtained from the terminal ileum and 4 colonic segments at 
baseline and Weeks 12 and 52 for assessment of histologic change. A post 
hoc analysis of histology data through week 12 are reported here, based 
on a 02-Oct-2017 interim data cut. The Robarts Histopathology Index (RHI) 
is a validated, reproducible, and responsive index that incorporates four 
histological descriptors (severity of chronic infl ammatory infi ltrate, the 
number of lamina propria neutrophils, the number of neutrophils in the 
epithelium, and the severity of erosions or ulceration), each of which is 
objectively graded from 0 to 3 (Mosli Gut 2017).
Results: Sixty-nine patients were enrolled. At baseline, mean age was 38 
years, mean SES-CD was 13, mean CDAI score was 321, and mean RHI 
was 16.3. Mean CD duration since diagnosis was 9 years, with 54% of 
patients having had prior exposure to biologic therapy (i.e., anti-TNF-α, 
vedolizumab). Table 1 presents the mean change in RHI for paired seg-
ments from baseline to Week 12 in the overall study population and in 
subgroups of patients with or without prior exposure to biologic therapy 
and by segment. Through 12 weeks, most non-serious and serious adverse 
events appeared to be related to underlying moderate to severe CD. No 
new safety signals were identifi ed.
Conclusion: Results of the STEPSTONE trial demonstrated early histologic 
improvements among patients with moderately to severely active CD who 
were treated for 12 weeks with ozanimod. These improvements were seen 
in the patients with and without prior biologic exposure and across all 
segments.
Study Group N (ITT N=69) Mean (Standard Deviation)
Overall Population 52 -4.5 (9.48)
Biologic Exposure    
Prior Biologic Exposure 30 -4.0 (8.59)
Biologic Naïve 22 -5.1 (10.75)
Segment (analysis includes patients 
with baseline segment scores of >3)
   
Ileum 30 -5.3 (8.58)
Rectum 26 -8.2 (10.59)
Left  Colon 24 -8.1 (11.38)
Right Colon 19 -4.5 (12.63)
Transverse Colon 17 -2.3 (9.29)
[Table 1: Change from Baseline in Robarts Histopathology Index (RHI) Score 
at Week 12 - Observed Cases, Intent-to-Treat Population]
References: Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induc-
tion and maintenance treatment for ulcerative colitis. N Engl J Med. 
2016;374(18):1754-1762. Mosli MH, Feagan BG, Zou G, et al. Development 
and validation of a histological index for UC. Gut. 2017;66(1):50-58.
Disclosure: Brian G. Feagan: AbbVie, Actogenix, Albireo, Amgen, Astra-
Zeneca, Avaxia Biologics, Baxter, Biogen Idec, Boehringer Ingelheim, 
BMS, Calypso, Celgene, Elan, EnGene, Ferring Pharma, Roche/Genentech, 
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Aims & Methods: Patients were randomized 1:1:1:1 to receive intravenous 
placebo (PBO), miri 50mg or 200mg with possibility of exposure-based 
dose increases, or fi xed miri 600mg every 4 weeks (Q4W), with effi  -
cacy assessment at Week 12. Patients who achieved clinical response to 
miri at Week 12 were re-randomized 1:1 to a double-blind maintenance 
treatment with miri 200mg subcutaneously (SC) Q4W or every 12 weeks 
(Q12W), and were treated through Week 52. Endoscopy was performed 
at Weeks 0, 12, and 52, with biopsy of the sigmoid colon obtained at 
the most aff ected area lying at least 30 cm from the anal verge. Glass 
slide sections of the biopsies, stained with hematoxylin and eosin for 
histologic evaluation, were digitized and centrally read by one of two 
gastrointestinal pathologists with scoring performed using the Geboes 
Score. Histologic remission was defi ned as Geboes histologic subscores 
of 0 for neutrophils in lamina propria, neutrophils in epithelium, and 
erosion or ulceration parameters.
Results: Greater proportions of patients who received 200 or 600mg of 
miri achieved histologic remission at 12 Weeks compared to PBO (PBO: 
17.5% [95% CI: 8.1-26.8]; miri 50mg: 14.3% [95% CI: 5.6-22.9]; 200mg: 
45.2% [95% CI: 32.8-57.5]; 600mg: 34.4% [95% CI: 22.5-46.3]. Of the pa-
tients who continued onto the maintenance period, 66.0% and 37.0% of 
patients in miri 200mg Q4W and Q12W groups, respectively, achieved his-
tologic remission at Week 52. Moreover, 42.6% (Q4W) and 19.6% (Q12W) 
of patients had durable histologic remission throughout the maintenance 
period, and 48.9% (Q4W) and 23.9% (Q12W) achieved mucosal healing 
(histologic remission plus endoscopic improvement).
Conclusion: Patients treated with miri achieved and sustained histologic 
remission over 52 weeks of treatment. These are the fi rst histologic data 
with an IL-23 p19 targeted antibody in patients with UC.
Disclosure: Study was funded by Eli Lilly and Company. 
OP150 HISTOLOGIC IMPROVEMENT WITH VEDOLIZUMAB VS 
ADALIMUMAB IN ULCERATIVE COLITIS: RESULTS FROM VARSITY
Peyrin-Biroulet L.1, Colombel J.-F.2, Loft us, Jr E.3, Danese S.4, 
Abhyankar B.5, Chen J.6, Rogers R.6, Lirio R.A.6, Bornstein J.6, Sands B.E.7, 
Schreiber S.8
1Nancy University Hospital, Nancy, France, 2Icahn School of Medicine at 
Mount Sinai, New York, United States, 3Mayo Clinic College of Medicine, 
Rochester, United States, 4Humanitas University, Milan, Italy, 5Takeda, 
London, United Kingdom, 6Takeda, Cambridge, United States, 7Icahn School 
of Medicine at Mount Sinai, Division of Gastroenterology, New York City, 
United States, 8University-Hospital Schleswig-Holstein, Kiel, Germany
Contact E-Mail Address: peyrinbiroulet@gmail.com
Introduction: Histologic remission is associated with superior long-term 
clinical outcomes in ulcerative colitis (UC). VARSITY, the fi rst head-to-head 
comparison of biologic agents in UC (NCT02497469; EudraCT 2015-000939-
33), showed superior clinical remission and endoscopic improvement at 
Week 52 with vedolizumab (VDZ), a gut-selective, humanised, α
4
β
7
 in-
tegrin monoclonal antibody, vs adalimumab (ADA), a systemic, human, 
anti-tumour necrosis factor (anti-TNF) monoclonal antibody.1 Both VDZ 
and ADA were generally safe and well-tolerated.1 This analysis compared 
histologic improvements with VDZ vs ADA in VARSITY.
Aims & Methods: Patients with moderately to severely active UC were 
randomised 1:1 to active VDZ intravenous (IV) infusions (300 mg)/placebo 
subcutaneous (SC) injections or placebo IV/active ADA SC (160/80/40 mg). 
Prespecifi ed histologic exploratory endpoints included histologic remis-
sion (Geboes score < 2 or Robarts Histopathology Index [RHI] score < 3) 
and minimal histologic disease activity (Geboes score < 3.2 or RHI score < 
5) at Week 14 and Week 52. Histologic remission was also assessed based 
on previous anti-TNF use.
Results: A total of 769 patients received ≥1 dose of VDZ (n=383) or ADA 
(n=386). Median (range) duration of exposure was 477 (127, 630) days for 
VDZ and 420 (71, 454) days for ADA. Mean (standard deviation) baseline 
histologic disease activity was similar between groups (Geboes: VDZ, 15.0 
[4.92]; ADA, 15.1 [5.03]; RHI: VDZ, 19.5 [8.74]; ADA, 19.6 [8.89]). Histologic 
remission induced by VDZ at Week 52 was greater than with ADA in the 
overall (Geboes or RHI), anti-TNF naïve (Geboes or RHI), and anti-TNF fail-
ure (RHI only) groups (Table). Histologic remission at Week 14 favoured 
VDZ over ADA, with larger diff erentiation when using RHI (Table). VDZ 
also outperformed ADA in achieving minimal histologic disease activity at 
Weeks 14 and 52 (Table).
Conclusion: VARSITY showed that use of VDZ, compared with ADA, 
achieved higher rates of histologic remission and minimal histologic dis-
ease activity at Weeks 14 and 52 in patients with moderately to severely 
active UC. These data support the use of VDZ over ADA in UC.
References: 1. Schreiber S, et al. J Crohns Colitis. 2019;13(suppl 1):S612-
S613. Abstract OP34.
Disclosure: Silvio Danese: Lecture fee(s): AbbVie, Ferring, Hospira, Johnson 
and Johnson, Merck, MSD, Takeda, Mundipharma, Pfi zer Inc, Tigenix, UCB 
Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer 
Ingelheim; Consultancy: AbbVie, Ferring, Hospira, Johnson and Johnson, 
Merck, MSD, Takeda, Mundipharma, Pfi zer Inc, Tigenix, UCB Pharma, Vi-
for, Biogen, Celgene, Allergan, Celltrion, Sandoz, Boehringer Ingelheim ; 
Edward V. Loft us Jr.:EVL has received fi nancial support for research from: 
AbbVie, Takeda, Janssen, UCB, Amgen, Pfi zer, Genentech, Celgene, Recep-
tos, Gilead, MedImmune, Seres Therapeutics, and Robarts Clinical Trials; 
and has served as a consultant for AbbVie, Takeda, Janssen, UCB, Am-
gen, Pfi zer, Eli Lilly, Celltrion Healthcare, Allergan, Bristol-Myers Squibb, 
Celgene, Gilead, Genentech, and Boehringer Ingelheim. Jean-Frederic 
Colombel: Consultancy/advisory board membership: AbbVie, Amgen, 
Boehringer Ingelheim, Celgene Corporation, Celltrion, Enterome, Ferring, 
Genentech, Janssen Pharmaceuticals, Medimmune, Merck & Co., Pfi zer, 
Protagonist, Second Genome, Seres, Takeda, Theradiag; Speaker: AbbVie, 
Ferring, Takeda, Shire; Research support: AbbVie, Genentech, Takeda; 
Stock options: Intestinal Biotech Development, Genfi t.; Laurent Peyrin-
Biroulet: LPB has received consulting fees from Merck, AbbVie, Janssen, 
Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Therakos, Pharma-
cosmos, Pilège, BMS, UCB-pharma, Hospira, Celltrion, Takeda, Biogaran, 
Boehringer Ingelheim, Lilly, Pfi zer, HAC-Pharma, Index Pharmaceuticals, 
Amgen, and Sandoz; Lecture fees from Merck, AbbVie, Takeda, Janssen, 
  Adalimumab SC 160/80/40 mg (n=386)
Vedolizumab IV 
300 mg (n=383)  
Adalimumab SC 
160/80/40 mg (n=386)
Vedolizumab IV 
300 mg (n=383)  
Parameter Histologic Remission (Geboes Score <2), n (%) Diff erence (95% CI) P value Histologic Remission (RHI Score <3), n (%) Diff erence (95% CI) P value
Overall, Wk 14 12 (3.1) 19 (5.0) 1.8 (-0.9 to 4.6)a 0.1944 62 (16.1) 98 (25.6) 9.5 (3.8 to 15.2)a 0.0011
Anti-TNF naïve, Wk 14 12 (3.9) 16 (5.3) 1.3 (-2.0 to 4.7)b 0.4348 58 (19.0 82 (27.0) 8.0 (1.3 to 14.6)b 0.0198
Anti-TNF failure, Wk 14 0 3 (3.8) 3.8 (-11.9 to 19.5)b 0.1180 4 (4.9) 16 (20.3) 15.3 (0.1 to 30.6)b 0.0038
Overall, Wk 52 12 (3.1) 40 (10.4) 7.3 (3.8 to 10.8)a <0.0001 77 (19.9) 144 (37.6) 17.6 (11.3 to 23.8)a <0.0001
Anti-TNF naïve, Wk 52 11 (3.6) 40 (13.2) 9.6 (5.2 to 13.9)b <0.0001 69 (22.6) 121 (39.8) 17.2 (9.9 to 24.4)b <0.0001
Anti-TNF failure, 
Wk 52
1 (1.2) 0 -1.2 (-16.9 to 14.5)b 1.0000 8 (9.9) 23 (29.1) 19.0 (7.1 to 31.0)b 0.0022
Parameter Minimal Histologic Disease Activity (Geboes Score <3.2), n (%)  
Minimal Histologic Disease Activity (RHI 
Score <5), n (%)  
Overall, Wk 14 49 (12.7) 81 (21.1) 8.4 (3.2 to 13.6)a 0.0017 94 (24.4) 143 (37.3) 12.9 (6.5 to 19.4)a <0.0001
Overall, Wk 52 53 (13.7) 128 (33.4) 19.6 (13.8 to 25.5)a <0.0001 99 (25.6) 162 (42.3) 16.6 (10.0 to 23.1)a <0.0001
[OP150 Table. Histologic Remission and Minimal Histologic Disease Activity]
aAdjusted treatment diff erence and nominal P value: based on the Cochran-Mantel-Haenszel method, stratifi ed by concomitant use of oral corticosteroids (Yes/No) and prior use of anti-TNF 
therapy (Yes/No); vedolizumab versus adalimumab.
bAdjusted treatment diff erence and nominal P value: based on the Cochran-Mantel-Haenszel method, stratifi ed by concomitant use of oral corticosteroids (Yes/No) or the Fisher´s exact method 
if the numerator is ≤5; vedolizumab versus adalimumab.
CI, confi dence interval; IV, intravenous; RHI, Robarts Histopathology Index; SC, subcutaneous; TNF, tumour necrosis factor-alpha.
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16; by wk 40-72, 47.2% (n = 17) had responded and 22.2% (n = 8) were in 
remission. Overall, the mean Mayo endoscopic subscore of 2 (SD, 0.1) was 
maintained from baseline to wk 40-72.
 
Ontamalimab overall 
(n = 101)
Mean (SD) Age, years 39.2 (12.5)
Sex, n (%) male 62 (61.4)
Anti-TNF naïve, n (%) 51 (50.5)
Mean time since UC diagnosis, years 7.89 (6.8)
Number (%) of patients in clinical remission 17 (16.8)
Mean (SD) total Mayo score 5.1 (2.7)
Mean (SD) partial Mayo score 3.1 (2.1)
Mean (SD) concentration of hsCRP (mg/dL) (n = 98) 0.7 (1.1)
Mean (SD) concentration of fecal calprotectin (µg/g) (n = 90) 1746 (2950)
[Table 1. Patient demographics and characteristics at TURANDOT II baseline.]
Conclusion: Mucosal healing, response and remission persisted in a subset 
of patients who continued ontamalimab treatment up to 72 wks and un-
derwent surveillance endoscopies between wks 40 and 72. These fi ndings 
support study of ontamalimab in on-going phase 3 trials.
Disclosure: Study funding was provided by Pfi zer and Shire, a Takeda com-
pany. Medical writing support was provided by Emily Colbeck, of Pharma-
Genesis London, London, UK, and funded by Shire, a Takeda company. CB - 
Employee, Stockholder at Shire. FC - Previous employee at Pfi zer. Previous 
employee, Stockholder at Shire. SD - Consultant for Abbott Laboratories, 
AbbVie, AstraZeneca, Schering Plough, Takeda Millennium. Lecturer for 
Ferring, MSD, UCB Pharma. Advisory Board Member for MSD. KJG - Con-
sultant for Pfi zer, Shire. MGreguš - Consultant / Speaker for AbbVie, Alfa 
Wasserman, Ferring, Hospira, Janssen, MSD, Pfi zer, Takeda. Development 
of educational materials for Alfa Wasserman, Egis, Hospira, MSD, Takeda, 
Vifor. MGoetsch - Employee, Stockholder at Shire. XH - Clinical Research for 
AbbVie, Abivax, Alphasigma, Cellgène, Gilead, Eli Lilly, Enterome, Janssen, 
InDex Pharmaceuticals, Pfi zer, Roche, Salix, Takeda, Theravance. Advisory 
Board member for AbbVie, Abivax, Arkopharma, Astellas, Janssen, Nutri-
cia, Pfi zer, Roche, Takeda. Lecturer for AbbVie, ARARD, Arkopharma, Bax-
ter, Bristol Myers Squibb, Ferring, Janssen, MSD, Nutricia, Pfi zer, Sanofi -
Advantis, Takeda, Tillots. MK - Speaker for AbbVie, Sanofi , Takeda, Ferring, 
Egis. Congress support for AbbVie, Egis, Ferring. Grant/Research Support 
for Egis. WR - Research funding from AbbVie, MSD. Speaker for AbbVie, 
Astellas, Celltrion, Ferring, Janssen, Merck Sharp, Dohme, Mitsubishi Ta-
nabe Pharma Corporation, Pfi zer, Pharmacosmos, Schering-Plough, Shire, 
Takeda, Therakos. Consultant for AbbVie, Amgen, Astellas, Avaxia, BioCli-
nica, Biogen Idec, Boehringer Ingelheim, Celgene, Celltrion, Covance, Dr. 
Falk Pharma GmbH, Ferring, Galapagos NV, Genentech, Gilead Sciences, 
ICON, InDex Pharmaceuticals, Inova, Janssen, Johnson, Johnson, Lipid 
Therapeutics, LivaNova, Mallinckrodt, MedImmune, Merck Sharp, Dohme, 
Millennium, Mitsubishi Tanabe Pharma Corporation, Novartis, Parexel, 
Pfi zer, Pharmacosmos, Philip Morris Institute, Provention Bio, Robarts 
Clinical Trials, Roland Berger GmBH, Sandoz, Schering-Plough, Second 
Genome, Seres Therapeutics, Sigmoid, Takeda, Therakos, TiGenix, Zea-
land. Advisory board member for AbbVie, Amgen, Astellas, Biogen Idec, 
Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Cellerix, Celltrion, 
Galapagos NV, Genentech, Inova, Janssen, Johnson, Johnson, Mitsubishi 
Tanabe Pharma Corporation, Merck Sharp, Dohme, Pfi zer, Pharmacosmos, 
Sandoz, Schering-Plough, Takeda, Zealand. MS - Advisory Board Member, 
Speaker for AbbVie, Janssen, Pfi zer, Takeda. Advisory Board Member for 
Celgene, MSD. Speaker for Shire. Advisory Board Member, Grant/Research 
Support for Ferring. Grant/Research Support for Orphan. 
Takeda, Ferring, Norgine, Tillots, Vifor, Therakos, Mitsubishi, and HAC-
Pharma; Brihad Abhyankar :Former employee of Takeda; Jingjing Chen: 
Employee of Takeda; Raquel Rogers: Employee of Takeda; Richard A. 
Lirio: Employee of Takeda; Jeff rey D. Bornstein: Employee of Takeda; Ste-
fan Schreiber: On-spot consultancy fees from AbbVie, Celltrion, Janssen, 
Merck, Pfi zer, Roche, and Takeda; Bruce E. Sands: Consulting fees from 4D 
Pharma, Abbvie, Allergan Sales, Amgen, Arena Pharmaceuticals, Boeh-
ringer Ingelheim, Capella Biosciences, Celgene, EnGene, Ferring, Gilead, 
Janssen, Lilly, Lyndra, MedImmune, Oppilan Pharma, Otsuka, Palatin Tech-
nologies, Pfi zer, Progenity, Rheos Medicines, Seres Therapeutics, Synergy 
Pharmaceuticals, Takeda, Target PharmaSolutions, Theravance Biopharma 
R&D, TiGenix, Vivelix Pharmaceuticals, and WebMD; research funding from 
Celgene, Pfi zer, Takeda, Janssen. 
OP151 LONG-TERM MUCOSAL HEALING, CLINICAL RESPONSE 
AND CLINICAL REMISSION IN PATIENTS WITH ULCERATIVE COLITIS 
TREATED WITH THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION 
MOLECULE-1 (MADCAM-1) ANTIBODY ONTAMALIMAB (SHP647): 
RESULTS FROM THE OPEN-LABEL EXTENSION STUDY TURANDOT II
Danese S.1, Sandborn W.J.2, Reinisch W.3, Hébuterne X.4, Kłopocka M.5, 
Tarabar D.6, Vaňásek T.7, Greguš M.8, Hellstern P.A.9, Kim J.S.10, 
Sparrow M.11, Gorelick K.J.12, Goetsch M.13, Bliss C.14, Gupta C.15, Cataldi F.14, 
Vermeire S.16
1Humanitas University, Milan, Italy, 2University of California San Diego, 
La Jolla, United States, 3Medical University of Vienna, Vienna, Austria, 
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Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, 
6Clinic of Gastroenterology and Hepatology, Military Medical Academy, 
Belgrade, Serbia, 7Charles University Hospital, Hradec Králové, Czech 
Republic, 8Gastroenterology Center, Nitra, Slovakia, 9Nature Coast Clinical 
Research, Inverness, United States, 10Seoul National University College of 
Medicine, Seoul, Korea (Republic of), 11Alfred Hospital, Melbourne, Australia, 
12Zymo Consulting Group, Newtown Square, United States, 13Shire, a Takeda 
Company, Zug, Switzerland, 14Shire, a Takeda Company, Lexington, United 
States, 15Cytel Inc, Cambridge, United States, 16University Hospitals Leuven, 
Leuven, Belgium
Contact E-Mail Address: silvio.danese@hunimed.eu
Introduction: Ontamalimab (SHP647), a human monoclonal IgG
2
 antibody, 
targets endothelium expressed mucosal addressin cell adhesion mol-
ecule-1 (MAdCAM-1), to reduce lymphocyte homing to the gastrointestinal 
(GI) tract. In the TURANDOT II trial, ontamalimab was well-tolerated and 
clinical benefi t was seen up to 144 wks in patients with ulcerative colitis 
(UC). This abstract reports long-term mucosal healing, response and re-
mission in a subset of patients in TURANDOT II.
Aims & Methods: TURANDOT II (NCT01771809) is a phase 2, 2-part open-
label (OL) extension study of ontamalimab in patients with moderate-to-
severe UC who received placebo or ontamalimab 7.5, 22.5, 75 or 225mg 
subcutaneously (sc) in the feeder study (TURANDOT). At TURANDOT II 
baseline (TURANDOT wk 12), patients were randomized to ontamalimab 
75 or 225mg sc every 4 wks for 72 wks (OL1). Dose escalation from 75 to 
225mg was permitted between wks 8 and 72 in cases of clinical exacer-
bation or no response. In OL2, patients received 75mg every 4 wks for 
72 wks. Endoscopies were carried out at wk 16 for all patients, and a 
subset of patients undergoing routine cancer surveillance underwent at 
least one follow-up endoscopy between wks 40 and 72 of OL1: all endos-
copies were centrally-read. Mucosal healing (Mayo endoscopy subscore 
≤1), clinical remission (total Mayo score ≤2, no subscore >1) and clinical 
response (≥3-point decrease in total Mayo score from TURANDOT base-
line, ≥30% change; ≥1-point decrease in or ≤1 rectal bleed absolute score) 
were measured.
Results: Of 330 patients in TURANDOT II, 101 had follow-up endoscopies 
(Table 1), 25.7% (n = 26) of whom had mucosal healing at TURANDOT II 
baseline. At week 16, 43.6% of patients (n = 44) had mucosal healing, and 
75% of these patients (n = 33) maintained mucosal healing up to week 40-
72. Of the 65 responders in TURANDOT, 37 (56.9%) had mucosal healing 
at both wk 16 and at wk 40-72. Of 36 non-responders, 19.4% (n = 7) and 
25% (n = 9) achieved mucosal healing at wk 16 and wk 40-72, respectively. 
Of the responders, 89.2% (n = 58) maintained response and 41.5% (n = 
27) were in remission at wk 16; at wk 40-72, 81.5% (n = 53) maintained 
response and 50.8% (n = 33) were in remission. Of non-responders, 61.1% 
(n = 22) achieved response and 13.9% (n = 5) achieved remission by wk 
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Optimising treatment strategies in pancreatitis 
and pancreatic cancer
08:30-10:00 / E1
OP152 DOUBLE PIGTAIL PLASTIC STENTS ARE CHEAPER AND 
AS EFFECTIVE AS LUMEN APPOSING METAL STENT FOR THE 
ENDOSCOPIC DRAINAGE OF WALLED-OFF NECROSIS: A CASE 
CONTROL STUDY
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Hospital, Department of Digestive Diseases, Stockholm, Sweden, 5Karolinska 
University Hospital, Gastrocentrum, Stockholm, Sweden, 6Karolinska 
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Sweden, 8Karolinska Institutet, CLINTEC, Division of Surgery, Department of 
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Contact E-Mail Address: robbie.valente@gmail.com
Introduction: The presence of infected walled off  necrosis (WON) increases 
morbidity and mortality in severe acute pancreatitis. In the last years, en-
doscopic drainage has gained increased attention as part of step-up ap-
proach, through the creation of a controlled fi stula between the upper 
gastrointestinal tract and the pancreatic necrotic collection. The patency 
of fi stula is allowed by endoscopic stenting and, for this purpose, double 
pigtail plastic stents have been traditionally used. In the last years lumen 
apposing metal stents (LAMS) have been proposed. By harboring a wid-
er diameter, they are supposed to allow better necrotic tissue clearance 
through the execution of multiple sessions of endoscopic necrosectomy. 
Despite a substantial higher initial cost, a non-unequivocally demonstrat-
ed safety and a still unclear eff ectiveness, lumen apposing metal stents 
have progressively gained wide spread in clinical practice. Few and mostly 
heterogeneous studies have compared double pigtail plastic stents and 
lumen apposing metal stents in terms of short and long-term outcomes. 
Most of previous studies lacked methodological rigorous designs and have 
either considered mixed cohorts of patients (WON plus pseudocyst), or 
have retrospectively investigated extremely inhomogeneous cohorts of pa-
tients with WON.
Aims & Methods: To compare short and long-term outcomes of plastic 
double pigtail versus lumen-apposing metal stents for the endoscopic 
drainage of infected walled-off  necrosis. Single-center, 1:1 case-control 
study. Patients who have undergone drainage of infected or highly sus-
pected infected pancreatic necrosis through lumen-apposing metal stents 
(cases) or double pigtail plastic stents (controls) were compared. Controls 
date up to 2016, when our center used exclusively double pigtail stents; 
cases date from 2016 onwards, when endoscopic necrosectomies were 
performed exclusively using lumen-apposing metal stents.
Results: 15 cases and 15 matched controls were enrolled at Karolinska Uni-
versity Hospital, Stockholm, Sweden, between 2011 and 2017. Cases and 
controls were homogeneous in terms of etiology and clinical characteris-
tics. 93.0% of cases and 86.7% of controls were clinically successful, with-
out any signifcant diff erences in rates of infection, bleeding and stent mi-
gration (respectively 13.3% vs 21.4%; p=0.65; 13.3% vs 0%; p=0.48; 13.3% 
vs 7.1%; p=1.00), nor of the need for additional percutaneous or surgical 
treatments (33.3% vs 13.3%; p=0.39). Cases however display a signifi cantly 
prolonged mean hospital stay (90.2 days vs 18.5 days; p< 0.01) and a high-
er mean number of endoscopic procedures per patient (1.5 vs 4.8; p< 0.01).
Conclusion: We fi nd that double pigtail stents are not inferior to lumen-
apposing metal stents in the treatment of pancreatic WON, and are thus to 
be favored as a cheaper yet equally eff ective strategy.
Disclosure: Urban Arnelo received an unrestricted grant from Boston Sci-
entifi c. Other authors declare no confl icts of interests 
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Sinha S.K.1, Gupta V.3, Yadav T.D.3, Dutta U.1, Kochhar R.1
1Post Graduate Institute of Medical Education and Research, 
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Introduction: A pro-active protocol that involves frequent catheter upsizing 
and insertions has been shown to improve the clinical success of percu-
taneous catheter drainage (PCD). However, there are a limited number of 
studies with small sample size.
Aims & Methods: In this large cohort, we aim to compare the outcomes 
of pro-active protocol in patients with acute pancreatitis (AP) and necrotic 
collections with a published PCD data. 
Consecutive patients with AP who underwent PCD with a pro-active proto-
col between January 2018 and January 2019 were included. The pro-active 
protocol was defi ned as PCD of all the drainable collections aft er an indi-
cation of drainage was identifi ed. This was followed by frequent upsizing 
with the aim to drain the entire collections including both the liquid and 
the necrotic component. The outcomes were compared with patients from 
a retrospective published cohort who underwent PCD between January 
2011 and December 2017. Outcome measures included need for surgery, 
mortality, intensive care unit (ICU) stay, hospital stay and complications.
Results: 110 patients underwent PCD with a pro-active protocol. Their out-
come was compared with that of 375 patients who had undergone PCD be-
tween 2011 and 2017. There was no signifi cant diff erence in the age, gender, 
and etiology of AP between the two groups. A fewer number of patients in 
the pro-active group required ICU admission (34.5 % vs. 61%, p< 0.001). 
Patients in the pro-active PCD group had a signifi cantly reduced length of 
hospital stay, and ICU stay (27.45±14.2 vs. 36.59±22.49 days; p=0.001and 
4.12 ± 8.5 vs. 11.5± 13.6 days; p< 0.001 respectively). However, there was no 
signifi cant diff erence in terms of mortality and need for surgical interven-
tion between the two groups (p=0.558 and 0.153 respectively). The rate of 
complications was also comparable.
Conclusion: Pro-active PCD protocol results in reduced length of hospital 
stay, and ICU stay and can reduce hospitalization costs.
Disclosure: Nothing to disclose 
OP154 SUPERIORITY OF ENDOSCOPIC INTERVENTIONS OVER 
MINIMALLY INVASIVE SURGERY FOR INFECTED NECROTIZING 
PANCREATITIS: A META-ANALYSIS OF RANDOMIZED TRIALS
Bang J.Y.1, Wilcox C.M.2, Arnoletti J.P.3, Varadarajulu S.1
1AdventHealth Orlando, Center for Interventional Endoscopy, Orlando, 
United States, 2University of Alabama at Birmingham, Gastroenterology & 
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Introduction: Infected necrotizing pancreatitis is a highly morbid disease 
managed either by minimally invasive surgery or endoscopy-based treat-
ment approaches. This meta-analysis was conducted to compare clinical 
outcomes between patients treated using either approach.
Aims & Methods: MEDLINE and EMBASE were searched to identify all ran-
domized trials that compared minimally invasive surgery and endoscopy-
based interventions for the treatment of infected necrotizing pancreatitis. 
The main outcome measure was to compare rates of complications or 
death during 6-months of follow-up.
Results: Three studies (184 patients; Bakker OJ et al. PENGUIN trial, JAMA 
2012; van Brunschot S et al. TENSION trial, Lancet 2018; Bang JY et al. 
MISER trial, Gastroenterology 2018) met inclusion criteria (Table). While 
there was no signifi cant diff erence in mortality (14.5 vs. 16.1%, risk ratio 
(RR) 1.02, p=0.96), complications of new onset multiple organ failure (5.2 
vs. 19.7%, RR=0.34, p=0.045), enterocutaneous fi stula/perforation (3.6 vs. 
17.9%, RR=0.34, p=0.034) and pancreatic fi stula (4.2 vs. 38.2%, RR=0.13, p< 
0.001) were signifi cantly lower for endoscopy compared to minimally in-
vasive surgical treatment approaches. Also, the length of hospital stay was 
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Aims & Methods: Anonymized data from patients who underwent pan-
creatoduodenectomy aft er PBD for periampullary cancer (i.e. pancreatic 
ductal adenocarcinoma, distal cholangiocarcinoma, ampullary cancer) 
between Jan 2017 and Dec 2018 were extracted from the mandatory, na-
tionwide, Dutch Pancreatic Cancer Audit. Patients who underwent (radio)
chemotherapy prior to pancreatoduodenectomy were excluded from the 
analysis. Patients were stratifi ed by time from PBD to surgery into group: 
A; short (< 4 weeks), B; intermediate (4 - 8 weeks), and C; long (> 8 
weeks). The primary outcome was the rate of major postoperative compli-
cations, defi ned as any complication classifi ed as Clavien-Dindo grade ≥3 
within 30 days aft er pancreatoduodenectomy. Secondary outcomes were 
the rate of PBD-related complications and overall complications. PBD-re-
lated complications were pancreatitis, cholangitis, perforation, bleeding, 
stent occlusion or exchange. Overall complications included PBD-related 
complications and major postoperative complications. A logistic regres-
sion analysis was performed, adjusted for age, gender, body mass index, 
ASA-score, texture of the pancreas and diameter of the pancreatic duct, 
to assess the association between time from PBD to pancreatectomy and 
major postoperative complications.
Results: In total, 539 patients were included aft er PBD prior to pancre-
atoduodenectomy, group A 221 (41%), group B 251 (47%), and group C 67 
(12%) patients, respectively. The median time between PBD and surgery 
was 56 days (range 5 - 555 days). The rate of PBD-related complications 
was 15%, with similar outcomes in the three patient groups (group A 13% 
vs. group B 16% vs. group C 16%; P = 0.697). Major postoperative compli-
cation (Clavien Dindo ≥ 3) rate was 26% and did not diff er between the 
three groups (group A 25% vs. group B 25% vs. group C 38%; P = 0.096). 
The 30-day mortality rate was 2.2%. The overall complication rate was 
69% , with similar outcomes in the three patient groups (group A 67% vs. 
group B 71% vs. group C 70%; P = 0.574). In the multivariable analysis, the 
duration of preoperative biliary drainage was not associated with a greater 
risk of major postoperative complications.
Conclusion: The risk for major postoperative complications aft er pancre-
atoduodenectomy is not infl uenced by the interval between preoperative 
biliary drainage and the surgical procedure.
Disclosure: Nothing to disclose 
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Introduction: About 30-40% of patients with pancreatic cancer present 
with locally advanced pancreatic cancer (LAPC). Clinical outcomes are 
mostly described in highly selected patient cohorts.
signifi cantly shorter for endoscopy as compared to surgery (standardized 
mean diff erence (SMD) -0.41, p=0.01). There was no signifi cant diff erence 
in intrabdominal bleeding (6.2 vs. 12.3%, RR=0.60, p=0.58), new onset 
diabetes (22.1 vs. 27.3%, RR=0.78, p=0.38) or pancreatic exocrine insuf-
fi ciency (39.5 vs. 57.8%, RR=0.99, p=0.96) between the cohorts.
Conclusion: An endoscopic treatment approach, as compared to minimally 
invasive surgery, signifi cantly reduces complications in patients with in-
fected necrotizing pancreatitis. 
Outcome measure Number of patients (n)
Pooled estimate: 
mean % (95% CI)
Pooled 
risk ratio 
(95% CI)
p-value
 
Endo-
scopy
Surgery Endoscopy Surgery    
Major complications 
or death
95 89
25.8 
(7.9 - 49.7)
50.8 
(33.5 - 68.0)
0.46 
(0.17 - 1.27)
0.136
Major complications 
or death (inc. 
pancreatic fi stula in 
all studies)
95 89
26.4 
(7.5 - 51.7)
57.0 
(38.7 - 74.4)
0.44 
(0.19 - 1.01)
0.053
Death 95 89
14.5 
(8.3 - 22.1)
16.1 
(5.0 - 31.8)
1.02 
(0.42 - 2.51)
0.963
New onset Multiple 
organ failure
95 89
5.2 
(1.7 - 10.4)
19.7 
(6.1 - 38.7)
0.34 
(0.12 - 0.98)
0.045
Enterocutaneous 
fi stula/perforation
95 89
3.6 
(0.2 - 11.2)
17.9 
(10.8 - 26.3)
0.34 
(0.13 - 0.92)
0.034
Pancreatic fi stula 86 83
4.2 
(0.4 - 11.8)
38.2 
(19.9 - 58.5)
0.13 
(0.04 - 0.37)
<0.001
Intraabdominal 
bleeding
95 89
6.2 
(0.2 - 27.0)
12.3 
(3.5 - 25.4)
0.60 
(0.10 - 3.59)
0.575
Endocrine pancreatic 
insuffi  ciency
85 79
22.1 
(14.1 - 31.3)
27.3 
(18.0 - 37.7)
0.78 
(0.45 - 1.36)
0.380
Exocrine pancreatic 
insuffi  ciency
85 79
39.5 
(3.7 - 84.5)
57.8 
(17.8 - 92.5)
0.99 
(0.66 - 1.48)
0.962
Length of hospital 
stay (days)
85 79 - -
SMD -0.41 
(-0.71 to 
-0.095)
0.010
[Table. Summary of pooled outcome measures and risk ratios]
Disclosure: Ji Young Bang and Shyam Varadarajulu are Consultants for 
Boston Scientifi c Corp. and Olympus American Inc. 
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Introduction: Obstructive jaundice is a frequent symptom in patients with 
periampullary cancer. Preoperative biliary drainage (PBD) is indicated in 
patients with cholangitis, severe jaundice (serum bilirubin > 250 µmol/L), 
intended neoadjuvant chemotherapy and with extended waiting time for 
defi nitive surgical treatment due to logistic reasons. Several studies sug-
gest to delay surgery until 4-8 weeks aft er PBD to allow for recovery of the 
liver and immune function but consensus is lacking. The aim of this study 
is to investigate the relation between time from PBD to pancreatoduode-
nectomy and (major) postoperative outcomes in patients who underwent 
resection for periampullary cancer.
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Aims & Methods: This study aims to give an overview of treatment and 
survival within an unselected, consecutive cohort of patients with LAPC. 
Prospective multicenter study including consecutive patients with LAPC ac-
cording to Dutch Pancreatic Cancer Group (DPCG) criteria between 04/2015-
12/2017 from 14 centers. The decision to start treatment was based on the 
advice of the multidisciplinary team meeting followed by patient consul-
tation of a medical oncologist. Restaging of CT-scans was performed by 
a nationwide expert panel aft er two months of systemic treatment. The 
panel evaluated response according to RECIST criteria, resectability and 
eligibility for clinical trials.
Results: In total, 422 patients were included, of whom 325 (77%) start-
ed chemotherapy, 84 (20%) received best supportive care (BSC) and 13 
(3%) started other primary treatments. Most patients started FOLFIRINOX 
(n=252, 60%), 32 patients (8%) were treated with gemcitabine plus nab-
paclitaxel and 41 (10%) with gemcitabine monotherapy. 309 patients were 
restaged of whom 33 (11%) had a partial response, 221 (72%) had stable 
disease and 55 (18%) had progressive disease. A total of 34/422 patients 
(8%) underwent a resection. Median overall survival (mOS) in all patients 
was 10 months (95%CI 9-11) In patients treated with FOLFIRINOX, nab-
paclitaxel plus gemcitabine or gemcitabine monotherapy, mOS was 14 
(95%CI 12-16), 9 (95%CI 7-11), and 9 months (95%CI 8-10) respectively. 
Resected patients had a mOS of 23 months (95%CI 12-34).
Conclusion: In a large prospective multicenter cohort of LAPC, median 
overall survival was 10 months, 60% received FOLFIRINOX treatment and 
8% were eligible for a resection aft er neoadjuvant chemotherapy with 
promising survival. Since treatment allocation bias cannot be excluded 
future randomized studies are needed.
Disclosure: Nothing to disclose 
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PAIN MANAGEMENT IN PATIENTS WITH PANCREATIC CANCER
Damm M.1, Kölsch A.-K.1, Weniger M.2, Lampert C.2, Beer S.3, Schorn S.4, 
Moir J.5, Michl P.1, Ceyhan G.O.6, Rosendahl J.7
1University Hospital Halle, Department of Internal Medicine I, Halle, 
Germany, 2Ludwig-Maximilians-University, Department of General, Visceral, 
and Transplantation Surgery, Munich, Germany, 3Leipzig University, 
Leipzig, Germany, 4Klinikum Rechts der Isar der TU München, Allgemein- 
und Viszeralchirurgie, Munich, Germany, 5Freeman Hospital, HPB Unit, 
Newcastle upon Tyne, United Kingdom, 6Technische Universität München, 
Chirurgische Klinik und Poliklinik, München, Germany, 7University Clinic 
Halle (Saale) - Department of Internal Medicine I, University Clinic Halle 
(Saale), Department of Internal Medicine I, Halle (Saale), Germany
Contact E-Mail Address: marko.damm@uk-halle.de
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is associated with 
moderate to severe cancer-related pain in most patients, as it has a high 
rate of neural invasion. Despite WHO management guidelines for pain 
management, more than 50% of cancer patients worldwide still expe-
rience pain. One-third of these patients don’t receive an adequate pain 
treatment. This data indicates that there is a need for more investigations 
in this fi eld. Especially for patients with PDACan adequate pain therapy 
is essential to maintain the quality of life as they are oft en in a palliative 
situation with very limited life expectancy.
Therefore we conducted this study to investigate the occurrence of pain 
and the quality of pain management in patients with PDAC.
Aims & Methods: A multi-center, prospective, cross-sectional study with 
the aim to evaluate the quality of care in patients with PDAC. The level 
of pain and the impact of pain on functioning was assessed by the brief 
pain inventory. Additionally insuffi  cient pain treatment (undertreatment) 
and possible determinants (e.g. patient characteristics, disease character-
istics, tumour therapy) were registered. Undertreatment was defi ned as a 
negative PMI (pain management index), which is a score constructed upon 
the patients level of worst pain substracted from the most potent level of 
analgesic drug therapy. To investigate the impact of e.g. changes in tumor 
therapy or disease progression on pain and pain therapy we conducted an 
follow up aft er a minimum of 4 weeks.
Results: We recruited 128 patients with histologically proven PDAC. 44% of 
the patients were female and the mean age was 68 yrs. 77 patients (60%) 
were questioned while hospitalised and 51 patients (40%) in the outpa-
tient department or private practice. 50 patients (39%) had resectable 
pancreatic cancer, whereas 22 patients (17%) had locally advanced disease 
(LAPC) and 56 patients (44%) metastatic disease (mPDAC). A total of 79 
patients suff ered from pain regularly (62%). 90% of these patients showed 
an impaired quality of life. Patients in an more advanced disease stage 
(LAPC, mPDAC) suff ered more frequently from pain (77%) than patients 
with resectable disease (38%). Most common locations of pain were the 
epigastric area (72%), the lumbar region (34%) and the lower abdomen 
(22%). 30 patients (38%) showed an insuffi  cient pain treatment (under-
treatment). Interestingly, undertreatment was more frequent in resectable 
disease (58%) than in LAPC (41%) or mPDAC (21%). Furthermore patients 
with high performance status (ECOG 0: 55%; ECOG 1: 37%) showed a high-
er rate of undertreatment than patients with a low performance status 
(ECOG 2: 18%, ECOG 3: 25%). Until now 60 patients (47%) have completed 
the follow up aft er a median of 2,2 months. The proportion of patients 
with pain has not changed markedly (57%), but untertreatment was less 
frequent (18%) compared to the fi rst interview.
Conclusion: The preliminary results of this ongoing study confi rm that 
there is a high percentage of patients with PDAC suff ering from pain. De-
spite comprehensive pain management guidelines we can show that the 
amount of patients aff ected from undertreatment is still very high. Fur-
thermore, our data indicates that especially patients in an early disease 
stage and with high performance status will need a better pain manage-
ment in the future. 
When the study will have collected more patient data, we’ll might be able 
to identify other determinants of undertreatment and thereby help to im-
prove the pain management in PDAC patients.
Disclosure: Nothing to disclose 
Novel therapeutic approaches in microscopic 
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OP158 MICROBIOTA RESTORATION THERAPEUTIC CANDIDATES 
FOR PREVENTING RECURRENT CLOSTRIDIUM DIFFICILE INFECTIONS: 
SIMILAR 6-MONTH OUTCOMES FOR ENEMA-ADMINISTERED RBX2660 
AND ORAL CAPSULE-ADMINISTERED RBX7455
Blount K.1, Khanna S.2, Pardi D.2, Jones C.1, Mische S.1, Shannon B.3, 
Deych E.3
1Rebiotix Inc., Roseville, United States, 2Mayo Clinic, Gastroenterology and 
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Introduction: Recurrent Clostridium di  cile infections (rCDI) are a public 
health threat and linked to intestinal microbiome disruption. In response 
to the need for a standardized, FDA-approved treatment, numerous mi-
crobiota-based drugs are being evaluated to restore a healthier microbi-
ome and reduce recurrence. Herein we compare data from clinical trials of 
RBX2660 and RBX7455, two dosage forms of an investigational standard-
ized, stabilized microbiome restoration therapeutic currently under study 
for potential FDA approval.
Aims & Methods: This comparison includes a large multicenter, open-label 
Phase 2 trial of RBX2660 (administered by enema; n=149) and a single-
center, open-label Phase 1 investigator-sponsored trial of RBX7455 (ad-
ministered by room-temperature-stable oral capsules in 3 dosing regi-
mens; n=30). Both trials had similar participant populations. The RBX2660 
trial included multi-recurrent CDI participants while the RBX7455 trial 
included fi rst- and multi-recurrent CDI participants (n=17 and 13, respec-
tively). For both trials, primary effi  cacy was defi ned as absence of recur-
rent CDI at 8 weeks aft er the last study treatment. Safety and durability 
were further assessed at 6 months. Microbiome restoration was assessed 
by shallow-shotgun sequencing of pre- and post-treatment stool samples 
and product samples, followed by calculation of a previously reported pro-
totype Microbiome Health Index (MHI) that expresses collective changes in 
taxonomic composition.
Results: Primary effi  cacy was 80% for RBX2660 and 90% for RBX7455. 
Among primary treatment responders in the RBX2660 trial evaluable at 6 
months (n=109), 97% were CDI occurrence-free at 6 months. All primary 
responders in the RBX7455 trial remained CDI occurrence-free at 6 months. 
Reported safety was similar between the studies. In addition, mcrobiome 
changes were similar between the studies, characterized by a predomi-
nance of Gammaproteobacteria/Bacilli-class bacteria before treatment and 
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Patients receiving 1-3 infusions of FMT had a higher cure rate than patients 
receiving only vancomycin (OR 3.2 (1.1; 9.2), p = 0.05) with a NNT of 3.5. 
The cure rate for one infusion of FMT was 48 % (30 - 67 %) and 68 % (49 
- 83 %) for 1-2 infusions. 
We found no diff erence between the effi  cacy of RBT and vancomycin (OR 
1.6 (0.6; 4.5)) or FMT and RBT in a superiority-analysis (OR 2.1 (0.7; 6.4)), 
but could not show non-inferiority between FMT and RBT either (diff er-
ence in cure rate: 15.8 % (-43 %; 12 %)). 
Recruitment for the RCT was terminated aft er the interim-analysis for lo-
gistic reasons.
Conclusion: Rectally applied faecal microbiota transplantation was supe-
rior to oral vancomycin in treating recurrent Clostridium di  cile infection, 
but multiple infusions were oft en needed. The eff ect of rectal bacterio-
therapy with 12 gut bacteria appeared similar to both faecal microbiota 
transplantation and vancomycin, but the study had insuffi  cient power for 
non-inferiority analysis. Rectal bacteriotherapy could be a safe alterna-
tive in treating recurrent Clostridium di  cile infection, but further RCTs are 
needed.
References: 1. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal in-
fusion of donor feces for recurrent Clostridium diffi  cile. N Engl J Med. 
2013;368(5):407-415. doi:10.1056/NEJMoa1205037 2. Cammarota G, Ma-
succi L, Ianiro G, et al. Randomised clinical trial: faecal microbiota trans-
plantation by colonoscopy vs. vancomycin for the treatment of recurrent 
Clostridium diffi  cile infection. Aliment Pharmacol Ther. 2015;41(9):835-
843. doi:10.1111/apt.13144 3. Tvede M, Rask-Madsen J. Bacteriotherapy for 
chronic relapsing Clostridium diffi  cile diarrhoea in six patients. Lancet. 
1989;1(8648):1156-1160. doi:10.1016/S0140-6736(89)92749-9 4. Tvede M, 
Tinggaard M, Helms M. Rectal bacteriotherapy for recurrent Clostridium 
diffi  cile-associated diarrhoea: results from a case series of 55 patients in 
Denmark 2000-2012. Clin Microbiol Infect. 2015;21(1):48-53. doi:10.1016/j.
cmi.2014.07.003 5. Emanuelsson F, Claesson BEB, Ljungström L, Tvede M, 
Ung K-A. Faecal microbiota transplantation and bacteriotherapy for recur-
rent Clostridium diffi  cile infection: A retrospective evaluation of 31 patients. 
Scand J Infect Dis. 2014;46(2):89-97. doi:10.3109/00365548.2013.858181
Disclosure: Michael Tvede owns MT MicroSearch, that manufactures the 
bacteria mix for RBT. All other authors have nothing to disclose. 
OP160 RIDINILAZOLE REDUCES RECURRENCE OF CLOSTRIDIUM 
DIFFICILE INFECTION WITH MINIMAL IMPACT ON THE GUT 
MICROBIOTA
Duperchy E.1, Vickers R.1, Roblin D.1, Freeman J.2, Wilcox M.2
1Summit Therapeutics, Abingdon, United Kingdom, 2Leeds Teaching 
Hospitals, NHS Trust, Leeds, United Kingdom
Contact E-Mail Address: esther.duperchy@summitplc.com
Introduction: Recurrence of Clostridium di  cile infection (rCDI) is a par-
ticular concern with signifi cant impacts on patient welfare and healthcare 
resources. Ridinilazole (RDZ) is a novel targeted spectrum antibiotic under 
investigation to treat CDI and reduce rCDI. Here translation of in vitro data 
to clinical trial data is reviewed.
Aims & Methods: Susceptibility testing was performed to CLSI standards 
with vancomycin (VAN), metronidazole (MTZ) and fi daxomicin (FDX) as 
comparators. The Phase 2 clinical trial was a double-blind, randomised, 
study of 100 patients assigned 1:1 to 10 days RDZ 200 mg BID or VAN 125 mg 
QID treatment. Primary endpoint was sustained clinical response (SCR), 
defi ned as cure at end of therapy (EOT) and no rCDI for the next 30 days. 
Primary analysis population was the modifi ed intent-to-treat (MITT); all 
randomised subjects with a diagnosis confi rmed by presence of free toxin. 
Relative eff ects of RDZ and VAN on the gut microbiota was examined by 
sequencing 16S rDNA amplicons from stool collected at baseline, days 5, 
10, 25 and end of study. Bioinformatic analyses were performed in QIIME.
Results: Across 4 studies RDZ C. di  cile (N=439) MIC range was 0.015-
0.5µg/mL with no major diff erences by ribotype or resistance phenotype. 
RDZ and FDX were less active against Gram negative anaerobes, especially 
B. fragilis group, than VAN and MTZ. RDZ had limited activity against Gram 
positive anaerobes. The Phase 2 clinical study exceeded its primary end-
point (MITT), with RDZ shown to be superior on SCR to VAN with rates of 
66.7% and 42.4%, respectively. Superiority on SCR was driven by a re-
duction in rCDI for RDZ (14.3%) compared with VAN (34.8%). Microbiota 
analysis showed at RDZ EOT that signifi cant relative abundancy reduc-
tions were limited to 2 Firmicute families including Peptostreptococcaceae 
(includes C. di  cile). In contrast VAN at EOT resulted in signifi cant losses 
predominance of Bacteroidia/Clostridia-class bacteria aft er treatment. The 
change in compositional microbiome as expressed via the MHI from before 
to aft er treatment was statistically signifi cant for both studies.
Conclusion: Two clinical studies confi rm similar safety, durable effi  cacy, 
and microbiome restoration for RBX2660 and RBX7455 microbiota restora-
tion therapies. These 6-month outcomes suggest that microbiome resto-
ration for preventing rCDI can be comparably eff ective via enema or oral 
administration routes. Since the manufacture of both products is standard-
ized and adheres to quality control specifi cations, these results represent 
an important advance towards FDA-approved microbiome therapeutics. 
Ongoing placebo-controlled studies will expand upon these data.
Disclosure: This analysis was funded by Rebiotix Inc., Roseville, MN, USA. 
OP159 CURE OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION 
WITH A MIX OF 12 GUT BACTERIA, FAECAL MICROBIOTA 
TRANSPLANTATION OR ORAL VANCOMYCIN: RESULTS FROM AN 
OPEN-LABEL MULTICENTRE RANDOMISED CONTROLLED TRIAL
Rode A.A.1,2, Chehri M.2,3,4, Heno K.K.5, Krogsgaard L.R.1, Helms M.2,5, 
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Petersen A.M.2,3,4, Bytzer P.1,2
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Denmark, 3Hvidovre University Hospital, Department of Clinical Microbiology, 
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Introduction: Faecal microbiota transplantation (FMT), i.e. transfer of stool 
from a healthy donor to a recipient, is an eff ective treatment for recurrent 
Clostridium di  cile infection (rCDI)1,2 but there are concerns on safety and 
long-term risks. Using a mix of specifi ed microorganisms instead of donor 
stool could be a solution. Rectal bacteriotherapy (RBT) using a mix of 12 
well-characterised gut bacteria has a reported effi  cacy for rCDI at 64-88 
% in case series but has not been evaluated in a randomised controlled 
trial (RCT).3-5
Aims & Methods: An open-label multicentre RCT compared the effi  cacy of 
FMT, RBT and oral vancomycin for rCDI. We hypothesized that FMT and RBT 
were superior to vancomycin and that RBT was non-inferior to FMT (non-
inferiority margin: 5% diff erence in cure rate). 
All consecutive patients with a positive test for Clostridium di  cile (CD) 
were screened for eligibility May 2017 - March 2019 at two centres cover-
ing eastern Denmark, including primary care. Patients with rCDI, defi ned 
as diarrhoea and a positive CD-test aft er at least one treatment course for 
CDI, were eligible. Patients with life expectancy <3 months, other GI infec-
tions or GI-disease with diarrhoea, concomitant antibiotic use or severe 
immune defi ciency were excluded.
Patients were stratifi ed according to number of recurrences (fi rst vs. mul-
tiple recurrences) and randomly allocated 1:1:1 to FMT, RBT or vancomycin 
by computer-generated stratifi ed block randomisation. The FMT and RBT 
groups were pre-treated with vancomycin for 7-14 days. Both FMT and RBT 
was applied rectally. FMT was applied once but, if needed, repeated twice 
within two weeks. RBT was applied on three consecutive days. Patients 
in the vancomycin-group received 14 days of vancomycin, but for patients 
with multiple recurrences, this was continued with tapering for additional 
fi ve weeks.
The primary outcome was clinical cure, defi ned as absence of CDI dur-
ing 90 days of follow-up. We planned an interim analysis of the primary 
outcome aft er 90 participants. Treatments were compared with Mantel-
Haentzel odds ratios (95 % CI) and χ2-tests with adjustment for stratifi -
cation in the superiority analysis. Non-inferiority was evaluated with the 
diff erence in cure rates (95 % CI).
Results: Cure rates for FMT, RBT and vancomycin in the interim-analysis 
(n=90) are shown in Table 1. 
FMT, 1-3 infusions (n = 31) RBT (n = 29) Vancomycin (n = 30)
22 (71 %), (52 - 86 %) 16 (55 %), (36 - 74 %) 13 (43 %), (25 - 63 %)
[Table 1 - Clinical cure at 90 days (Intention-to-treat analysis): n (%), 
(95% CI)]
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(oft en to below detection) in 4 Firmicutes families: Peptostreptococcaceae, 
Ruminococcaceae, Erysipelothrichaceae and Lachnospiraceae. A 70% drop 
in Actinobacteria, and greater than 3 log decrease in Bacteroidetes, abun-
dance were also observed. These changes were associated with a 25-fold 
increase in Proteobacteria abundance, in particular Enterobacteriaceae.
Conclusion: These data demonstrate targeted C. di  cile activity with RDZ 
both in vitro and in CDI patients. Preservation of the microbiome likely 
contributed to the low rate of recurrence, and superior effi  cacy on SCR, 
compared to vancomycin. Further clinical development is warranted.
Disclosure: E. Duperchy, R. Vickers and D. Roblin: Summit Therapeutics´ 
Employees; Hold stock options; M. Wilcox: Consultant Summit Therapeu-
tics; J. Freeman: Research Contractor Summit Therapeutics. 
OP161 MOLECULAR CLASSIFICATION OF COLLAGENOUS COLITIS 
BY WHOLE-GENOME SEQUENCING
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Trondheim, Norway, 5Wallenberg Centre for Molecular Medicine, Linköping, 
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Introduction: Collagenous colitis (CC) is a common, infl ammatory bowel 
disease that deteriorates the patients’ quality of life due to chronic watery 
diarrhoea. Treatment with the locally active glucocorticoid budesonide is 
eff ective in inducing clinical remission. However, how budesonide restores 
water homeostasis in the gut is unknown. To address this question, we 
performed genome-wide RNA sequencing (RNAseq) analysis on mucosal 
samples from diff erent CC patient populations.
Aims & Methods: We collected colonic biopsy samples from healthy 
controls and CC patients with active disease. Additionally, we obtained 
matched samples from budesonide-responsive patients (clinical remis-
sion) under treatment with budesonide (9mg/d for 8 weeks), as well as 
biopsies from budesonide-refractory patients (n=9 patients/group). Ul-
cerative colitis (UC) samples were included as a separate control. Total 
RNA was isolated for library construction and RNA sequencing (RNAseq). 
Whole genome expression data was processed using the R statistical soft -
ware, and analysed by principal component analysis (PCA), linear models 
with least square regression, and empirical Bayes moderates t statistics. 
Results were corrected using the Benjamini-Hochberg FDR method, with 
an adjusted p value < 0.05 considered to be statistically signifi cant. Gene 
ontology (GO) analysis was performed in Cytoscape, using the ClueGO and 
CluePedia packages.
Results: Unsupervised PCA of all samples identifi ed three principal com-
ponents which separated sample groups into distinct clusters of gene 
expression, explaining 31% of the transcriptional variation. One of the 
components (8% of the variation) clearly demarcated UC samples from 
healthy controls and CC. Remarkably, mucosal samples from budesonide-
refractory patients exhibited a discrete RNA expression profi le that was 
distinct from all other groups. Moreover, PCA of budesonide-responsive 
persons revealed two principal components (24% of the variation) that 
separated these sample groups.
Subsequent analysis of diff erentially regulated genes showed that the 
expression of 395 genes was altered in patients with active CC patients 
compared to healthy controls, and that these were evenly split into 201 
up- and 194 down-regulated genes. GO analysis of these genes indicat-
ed that up-regulated genes were mainly involved in immune response, 
whereas metabolic pathway genes were down-regulated. In samples from 
budesonide-treated patients, 75 genes were diff erentially regulated com-
pared to controls. These genes were found to regulate glycogen metabo-
lism and mineral absorption. A paired comparison of the matched active 
CC patients and budesonide-treated patients showed a dysregulation of 
337 genes. A GO analysis of these genes were dominated by categories 
covering carboxylic acid transmembrane transport, protein ubiquitination 
and immune response. Finally, genes dysregulated in refractory CC were 
mostly associated with the transport of secretory proteins.
Conclusion: Our analyses suggest that collagenous colitis is a transcrip-
tionally homogeneous disease that can be characterised by means of dif-
ferential gene expression. We were able to identify unique gene expres-
sion profi les that describe patient sub-populations, also with regard to 
their treatment response. Interestingly, transcriptome analysis indicates 
that budesonide-refractory CC may be a discrete disease entity, which may 
explain the lack of treatment response. Further study of the transcriptional 
landscape of CC may reveal pathogenic mechanisms and therapeutic vul-
nerabilities for this common, debilitating infl ammatory bowel disease.
Disclosure: CEH and AM have received an unrestricted research grant from 
Ferring Pharmaceuticals (Switzerland). The remaining authors do not have 
any confl icts of interest. 
OP162 CRITICAL ROLE OF AQUAPORIN 8 IN COLLAGENOUS COLITIS
Escudero-Hernández C.1, Koch S.1,2, Münch A.3
1Linköping University, Clinical and Experimental Medicine, Linköping, 
Sweden, 2Wallenberg Centre for Molecular Medicine, Linköping, Sweden, 
3Universitetssjukhus, Gastroenterology, Linköping, Sweden
Contact E-Mail Address: celia.escher@gmail.com
Introduction: Collagenous colitis (CC) patients experience chronic watery 
diarrhoea that eff ectively can be treated by budesonide, a locally acting 
glucocorticoid. The diarrhoeal mechanism in CC is unclear, as well as 
budesonide’s mode of action. We hypothesize that aquaporin (AQP) water 
channels are critical in the development of watery diarrhoea in CC; hence, 
they are highly important proteins in CC pathogenesis that could be tar-
geted by new drugs.
Aims & Methods: Colonic biopsy samples from controls (n=27), active CC 
patients (n=26), matched CC patients under treatment with budesonide 
(9mg for 8 weeks; n=18), and refractory CC patients (active disease despite 
6mg budesonide for more than 12 weeks; n=15) were collected at the local 
university hospital, and either preserved in AllProtect for subsequent gene 
analyses or embedded in paraffi  n. Total RNA was isolated for analysis of 
the AQP genetic expression profi les (AQPs 0-12) by quantitative polymerase 
chain reaction (qPCR); whereas paraffi  n embedded samples were used 
for fl uorescent staining of AQP8 and subsequent analysis by confocal mi-
croscopy. AQP8 protein levels in the apical membrane of colonic epithelial 
cells were determined by computer-assisted image analysis using ImageJ. 
Non-parametric Mann-Whitney (for unpaired samples) or Wilcoxon (for 
paired samples) statistical tests with Monte Carlo algorithm were used to 
analyze the results in SPSS.
Results: Gene expression of AQPs 8 and 11 was signifi cantly downregu-
lated in all CC patient sets when compared to control samples. In patients 
that achieved clinical remission under budesonide treatment, AQP 8 and 
11 levels were increased compared to their corresponding pre-treatment 
samples. In contrast, budesonide-refractory patients had similar AQP gene 
expression levels as non-matched patients with active CC. The gene ex-
pression of the remaining AQPs (AQP0-7, AQP10, and AQP12) did not sig-
nifi cantly change in any group.
Protein levels of AQP8 were further studied by confocal microscopy in the 
apical side of intestinal epithelia of all CC patient groups. As with gene 
expression, AQP8 protein levels were signifi cantly decreased in active CC 
patients. Budesonide treatment increased AQP8 protein in the mucosa, 
albeit not to the same level as in the control group. Curiously, budesonide-
refractory CC patients had similar AQP8 protein levels as controls.
Conclusion: Aquaporin 8 is signifi cantly downregulated in active CC. Both 
AQP8 gene and protein expression are partially restored aft er treatment 
with budesonide, which is suffi  cient to achieve clinical remission. In 
budesonide-refractory patients, AQP8 gene expression is decreased, while 
its protein levels do not change when compared to controls. Therefore, 
we conclude that AQP8 has a critical role in active CC leading to malab-
sorption of water in the colon which could represent a novel diarrhoeal 
pathomechanism.
Disclosure: CEH and AM have received an unrestricted research grant from 
Ferring Pharmaceuticals (Switzerland). 
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week 12 had histological response. The only patient who achieved clini-
cal and histological remission was on combination therapy with IFX and 
azathioprine. Five patients were switched to another anti-TNFα in second-
line therapy and two subsequently reached clinical remission. Two pa-
tients received vedolizumab for loss of response, it was successful in one. 
All treatment lines confounded, seven patients (50%) and eight patients 
(57.1%) were in clinical remission at week 12 and 52, respectively. Six ad-
verse events have been reported, including a serious one (anaphylactoid 
reaction with anti-IFX antibodies).
Conclusion: To date, this is the biggest case series evaluating the effi  cacy 
and safety of anti-TNFα in refractory MC. Anti-TNFα therapies appear to 
be eff ective and could represent a suitable option in highly refractory MC 
patients.
Disclosure: Nothing to disclose 
Randomised controlled trials in IBD II
10:30-12:00 / A3
OP164 EFFICACY OF UPADACITINIB AS AN INDUCTION THERAPY 
FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE 
COLITIS, WITH OR WITHOUT PREVIOUS TREATMENT FAILURE OF 
BIOLOGIC THERAPY: DATA FROM THE DOSE-RANGING PHASE 2B 
STUDY U-ACHIEVE
Panaccione R.1, D’Haens G.R.2, Sandborn W.J.3, Ghosh S.4, Schreiber S.5, 
Tanida S.6, Zhou W.7, Cataldi F.7, Pugatch D.7, Huang B.7, Xie W.7, Higgins P.8
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4Institute Of Translational Medicine, Institute of Translational Medicine, 
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I - UKSH, Kiel, Germany, 6Nagoya City University Graduate School of Medical 
Sciences, Nagoya, Japan, 7AbbVie Inc., North Chicago, United States, 
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Contact E-Mail Address: rpanacci@ucalgary.ca
Introduction: Upadacitinib (UPA), a Janus kinase 1 (JAK1) selective inhibi-
tor, shows promise as a future treatment option for ulcerative colitis (UC). 
Initial data analyses from an 8-week, double-blind, placebo (PBO)-con-
trolled, dose-ranging, Phase 2b induction study in patients with moder-
OP163 EFFICACY AND SAFETY OF ANTI-TNFα THERAPY IN 
BUDESONIDE REFRACTORY, DEPENDENT OR INTOLERANT 
MICROSCOPIC COLITIS: A FRENCH REGISTRY
Boivineau G.1, Zallot C.2, Amiot A.3, Zerbib F.4, Plastaras L.5, Thibault P.6, 
Boivineau L.7, Peyrin-Biroulet L.8, Vuitton L.9
1CHU Besancon, Gastro-Enterology, Besancon, France, 2Nancy University 
Hospital, Lorraine University, Hepatogastroenterology, Nancy, France, 3Henri 
Mondor Hospital, APHP, Gastroenterology, Creteil, France, 4CHU de Bordeaux 
- Hôpital Haut Leveque, Hépato-Gastroentérology, Bordeaux, France, 5CHU 
Colmar, Colmar, France, 6Jura-Sud Hospital, Hepatogastroenterology, Lons-le-
Saunier, France, 7Hôpital Saint Eloi, CHRU Montpellier, Montpellier, France, 
8Nancy University Hospital Inserm U 954, Gastroenterology, Vandoeuvre les 
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France
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Introduction: Currently, budesonide is the best documented treatment for 
microscopic colitis (MC); however, relapses, even aft er maintenance thera-
py, remain high, and some patients become intolerant or refractory. Tumor 
necrosis factor (TNF) α antagonists have revolutionized the management 
of infl ammatory bowel diseases (IBD) and may represent an interesting 
option in refractory MC patients. The aim of the study was to evaluate the 
effi  cacy and safety of anti-TNFα in refractory MC in France.
Aims & Methods: Budesonide refractory, intolerant or dependent MC pa-
tients treated with anti-TNFα agents (infl iximab (IFX), adalimumab (ADA)) 
in the French Groupe d’étude thérapeutique des aff ections infl ammatoires 
du tube digestif (GETAID) centers were included in the registry. The data 
was collected from october 2018 to february 2019. Clinical remission was 
defi ned by strictly less three daily bowel movements, and clinical response 
by an improvement in stool frequency ≥ 50%.
Results: Fourteen patients were included, 7 received IFX and 7 received 
ADA. Maintenance therapy was prescribed in 13/14 patients with a median 
duration of 10 months. Clinical remission without steroids at week 12 was 
reached in 5/14 patients (35.7%): 5/7 (71.4%) in the IFX group and 0/7 in 
the ADA group. Clinical response at week 12 was reached in 6/7 patients in 
the IFX group and 3/7 patients in the ADA group. Clinical response at week 
52 was obtained in 7/14 (50%) patients. A 36.4% and 68.1% reduction 
rate was observed in mean daily stools at weeks 12 and 52, respectively. 
Histological response, evaluated in nine patients, was complete in 11.1% 
and partial in 44.4%. All patients in clinical remission at week 12 achieved 
histological response; conversely, none of the patients in clinical failure at 
Treatment groups Clinical Remission per Adapted Mayo Scorea Endoscopic Improv
b Endoscopic Remissionc Clinical Response per Adapted Mayo Scored Histologic Improv
e Clinical Response per 
Partial Mayo Scoref 
  Week 8 Week 2
  Primary endpoint Secondary endpoints
All, n (%) Placebo n=46 0 1 (2.2) 0 6 (13.0) 3 (6.5) 7 (15.2)
  UPA 7.5 mg QD n=47 4 (8.5) 7 (14.9)* 3 (6.4) 14 (29.8)* 15 (31.9)** 11 (23.4)
  UPA 15 mg QD n=49 7 (14.3)* 15 (30.6)*** 2 (4.1) 22 (44.9)*** 25 (51.0)*** 18 (36.7)*
  UPA 30 mg QD n=52 7 (13.5)* 14 (26.9)*** 5 (9.6)* 23 (44.2)*** 23 (44.2)*** 19 (36.5)*
  UPA 45 mg QD n=56 11 (19.6)** 20 (35.7)*** 10 (17.9)** 28 (50.0)*** 27 (48.2)*** 31 (55.4)***
Bio-IR, n 
(%)
Placebo n=34 0 0 0 2 (5.9) 3 (8.8) 5 (14.7)
  UPA 7.5 mg QD n=34 2 (5.9) 3 (8.8) 1 (2.9) 8 (23.5) 7 (20.6) 6 (17.6)
  UPA 15 mg QD n=36 3 (8.3) 9 (25.0)** 0 13 (36.1)** 15 (41.7)** 11 (30.6)
  UPA 30 mg QD n=40 4 (10.0) 8 (20.0)** 1 (2.5) 13 (32.5)** 15 (37.5)** 15 (37.5)**
  UPA 45 mg QD n=42 5 (11.9) 11 (26.2)*** 5 (11.9) 17 (40.5)*** 20 (47.6)*** 22 (52.4)***
Non-Bio-IR, 
n (%)
Placebo n=12 0 1 (8.3) 0 4 (33.3) 0 2 (16.7)
  UPA 7.5 mg QD n=13 2 (15.4) 4 (30.8) 2 (15.4) 6 (46.2) 8 (61.5)** 5 (38.5)
  UPA 15 mg QD n=13 4 (30.8) 6 (46.2) 2 (15.4) 9 (69.2) 10 (76.9)*** 7 (53.8)
  UPA 30 mg QD n=12 3 (25.0) 6 (50.0) 4 (33.3) 10 (83.3)* 8 (66.7)** 5 (41.7)
  UPA 45 mg QD n=14 6 (42.9)* 9 (64.3)** 5 (35.7)* 11 (78.6)* 7 (50.0)** 9 (64.3)*
Intent-to-treat population, non-responder imputation aSFS ≤1, RBS = 0, endoscopic score ≤1. bEndoscopic subscore ≤1. cEndoscopic subscore = 0. dDecrease from BL ≥2 points and ≥30%, 
plus RBS decrease ≥1 or absolute RBS ≤1. eDecrease from BL in Geboes score. fMayo score excluding endoscopic subscore; defi ned as decrease from BL in the Partial Mayo Score ≥2 points 
and ≥30% from BL, plus decrease in RBS ≥1 or absolute RBS ≤1. Improv, Improvement; RBS, rectal bleeding subscore; SFS, stool frequency subscore ***, **, *statistically signifi cant at 
0.001, 0.01, and 0.05 levels, respectively, for UPA versus PBO
[OP164 Table: Clinical e  cacy in the overall patient population and in Bio-IR and non-Bio-IR patients]
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ately to severely active UC suggest that UPA is generally well tolerated 
with signifi cantly greater effi  cacy compared with PBO.1 In this subgroup 
analysis, effi  cacy was assessed in patients who either had an inadequate 
response, loss of response, or intolerance to biologic therapies (Bio-IR), or 
were non-Bio-IR.
Aims & Methods: Adult patients with moderately to severely active UC 
(Adapted Mayo Score [Mayo score without Physician Global Assessment] 
5-9 points) and centrally read Mayo Endoscopy Subscore ([MES] 2-3) were 
randomized to receive extended-release UPA 7.5, 15, 30, 45 mg, or PBO 
once daily (QD) for 8 weeks. Patients were stratifi ed by previous biologic 
use, baseline (BL) corticosteroid use, and BL Adapted Mayo Score (≤7/>7). 
Effi  cacy measures (defi ned in Table) were the primary endpoint of Clinical 
Remission per Adapted Mayo Score at Week 8, and secondary endpoints 
were Endoscopic Improvement, Endoscopic Remission, Clinical Response 
(CR) per Adapted Mayo Score, Histologic Improvement (all Week 8), and 
CR per Partial Mayo Score (Week 2). Pairwise comparisons between UPA 
doses and PBO for effi  cacy endpoints were conducted using the Cochran-
Mantel-Haenszel test stratifi ed by randomization factors. Non-responder 
imputations were utilized for missing values.
Results: A total of 250 patients were randomized with a mean (SD) age 
of 42.3 (14.2) years and a disease duration of 8.2 (2.5) years. At BL, 74.4% 
were Bio-IR, 36% had an Adapted Mayo Score >7, and 79% had a MES 
of 3. At Week 8, a UPA dose-response relationship was observed for all 
effi  cacy endpoints in the overall population, and in each of the two sub-
populations. The highest effi  cacy rates were observed with UPA 45 mg QD 
treatment for the majority of the endpoints, which were all signifi cant for 
the non-Bio-IR group analyses and in the majority of the Bio-IR group 
analyses. While the non-Bio-IR subpopulation was small, effi  cacy rates 
were numerically higher than in the Bio-IR subpopulation. Adverse events 
leading to discontinuation were similar across the overall UPA groups, and 
numerically higher in the PBO group.1
Conclusion: Upadacitinib showed a dose response in Bio-IR and non-Bio-
IR patients with moderately to severely active UC, with numerically greater 
effi  cacy in the non-Bio-IR population. Patient numbers were small in both 
groups and the fi ndings need to be confi rmed in larger Phase 3 studies. 
References: 1. Sandborn WJ, et al. UEGW 2018, #OP195
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OP165 EARLY CLINICAL RESPONSE AND REMISSION WITH 
VEDOLIZUMAB VERSUS ADALIMUMAB IN ULCERATIVE COLITIS: 
RESULTS FROM VARSITY
Danese S.1, Loft us, Jr E.2, Colombel J.-F.3, Peyrin-Biroulet L.4, 
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Introduction: VARSITY is the fi rst head-to-head trial comparing the effi  cacy 
and safety of 2 biologic therapies, vedolizumab (VDZ) and adalimumab 
(ADA), in patients with moderately to severely active ulcerative colitis 
(UC). We previously reported signifi cantly higher rates of clinical remis-
sion (31.3% vs 22.5%; p=0.0061) and endoscopic improvement (39.7% vs 
27.7%; p=0.0005) at Week 52 with VDZ vs ADA.1 Here we report data on 
early response and remission within the fi rst 14 weeks, as well as durable 
clinical remission.
Aims & Methods: VARSITY was a phase 3b, randomised, double-blind, 
double-dummy, active-controlled study (NCT02497469; EudraCT 2015-
000939-33). As predefi ned, exploratory endpoints, we examined early 
clinical response and remission, along with the durability of remission. 
Clinical response was defi ned as reduction in complete Mayo score of ≥3 
points and ≥30% (or partial Mayo score reduction of ≥2 points and ≥25% 
from baseline if sigmoidoscopy was not performed), with a decrease in 
rectal bleeding subscore of ≥1 point or absolute rectal bleeding subscore 
of ≤1 point. Clinical remission was defi ned as complete Mayo score of ≤2 
(or partial Mayo score ≤2 points if sigmoidoscopy was not performed) and 
no individual subscore >1 point. Patients who were in clinical remission at 
Week 14 and Week 52 were considered as having achieved durable clinical 
remission.
Results: A total of 769 patients received ≥1 dose of VDZ (n=383) or ADA 
(n=386). Baseline characteristics were comparable between the 2 groups. 
A trend for separation in clinical response started to emerge at Week 6 fa-
vouring VDZ vs ADA. Clinical response at Week 14 favoured VDZ vs ADA (257 
[67.1%] vs 177 [45.9%]; treatment diff erence 21.2%). A greater number of 
patients achieved clinical remission at Week 14 on VDZ vs ADA (102 [26.6%] 
vs 82 [21.2%]; treatment diff erence 5.3%). Patients on VDZ achieved high-
er rates of durable clinical remission (70 [18.3%] vs 46 [11.9%]); labora-
tory results correlated with these fi ndings. Post-hoc analyses showed a 
larger mean (standard deviation) change of C-reactive protein (CRP) from 
baseline to Week 14 (-32.88 [155.77] nmol/L VDZ vs -3.35 [260.82] nmol/L 
ADA) and to Week 52 (-50.87 [174.76] nmol/L VDZ vs -37.21 [169.17] nmol/L 
ADA) in favour of VDZ. Greater mean declines in faecal calprotectin (FCP) 
levels were seen in patients on VDZ compared to ADA (Week 14: -1,551.3 
[6,236.70] mg/kg VDZ vs -1,167.6 [4,647.67] mg/kg ADA; Week 52: -2,187.3 
[7,440.42] mg/kg VDZ vs -1,846.6 [4,560.55] mg/kg ADA).
Conclusion: Patients on VDZ had numerically higher rates of both clinical 
response and clinical remission by Week 14 compared with ADA. Those 
patients on VDZ also achieved higher rates of durable clinical remission 
compared with ADA. CRP and FCP results correlated with these fi ndings. 
These data on early clinical response and clinical remission, as well as 
durable remission, further support the use of VDZ over ADA in patients 
with moderately to severely active UC.
References: 1. Schreiber S, et al. J Crohns Colitis. 2019;13(suppl 1):S612-
S613. Abstract OP34.
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Introduction: Few data are available so far to select the best therapeutic 
option aft er failure of a fi rst subcutaneous anti-TNF agent in ulcerative 
colitis (UC). The objective of the present study was to compare the effi  cacy 
of infl iximab (IFX) and vedolizumab (VDZ) in UC patients who stopped a 
fi rst subcutaneous anti-TNF agent.
Aims & Methods: Consecutive UC patients who started IFX or VDZ from 
February 2009 to November 2018 in 12 French referral centres aft er receiv-
ing at least one injection of adalimumab or golimumab have been in-
cluded in a retrospective study. Inclusion corresponded to the fi rst admin-
istration of IFX or VDZ. Outcomes were rate of clinical remission (defi ned 
as a partial Mayo score - PMS - ≤ 1) at week 14, survival without treatment 
discontinuation, and survival without any UC-related event (treatment dis-
continuation, colectomy, acute severe UC or hospitalization). Predictors of 
clinical remission at week 14 were determined by multivariate analysis 
logistic regression.
Results: Among the 225 patients included [133 (59%) male; median age: 41; 
InterQuartileRange: 27-55) years; median PMS was 6/9 (5-8)], 154 (68%) 
received IFX and 71 (32%) VDZ aft er failure of a fi rst subcutaneous anti-TNF 
agent. At inclusion, patients treated with IFX were signifi cantly more oft en 
men, having more recent UC and more primary non-response to the fi rst 
anti-TNF (116 (77%) in the IFX group, 44 (62%) in the VDZ group), were 
more oft en admitted for the current fl are, received more combotherapy 
and had a higher median PMS [6 (5-8)] as compared to those treated with 
VDZ [5.5 (3-7)]. At week 14, 40 (26%) patients treated with IFX were in 
clinical remission as compared to 35 (49%) patients treated with VDZ (p< 
0.01; odds ratio (OR): 2.77; 95%-confi dence interval (95%CI): 1.54; 4.99). 
Aft er adjustment on baseline characteristics, the diff erence between both 
drugs was nearly signifi cant (OR 2.12; 95%CI: 0.95-4.80; p=0.07). With a 
median follow-up duration of 115 (55-165) months, survival rates without 
treatment discontinuation at 1 year and 3 years were 86% and 69% for 
patients receiving IFX, and 97% and 91% for those receiving VDZ (p< 0.01). 
Survival rates without UC-related event at 1 year and 3 years were 85% and 
67% with IFX and 93% and 87% with VDZ (p< 0.01).
OP166 EFFICACY AND SAFETY OF MIRIKIZUMAB (LY3074828) 
IN A PHASE 2 STUDY OF PATIENTS WITH CROHN’S DISEASE
Sands B.1, Sandborn W.2, Peyrin-Biroulet L.3, Higgins P.4, Hirai F.5, 
Belin R.6, Gomez Valderas E.6, Miller D.6, Morgan-Cox M.6, Naegeli A.6, 
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Tokyo, Japan
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Introduction: Mirikizumab (Miri; interleukin [IL]-23p19 antibody) is a hu-
manized, immunoglobulin G4 monoclonal antibody specifi cally targeting 
the p19 subunit of the IL23 cytokine. Prior studies have shown Miri to have 
effi  cacy in psoriasis and ulcerative colitis. We assessed safety and effi  cacy 
of Miri with a Phase 2, multicenter, randomized, parallel-arm, double-
blind, placebo (PBO)-controlled trial (NCT02891226) in patients with mod-
erate-to-severely active Crohn’s disease (CD).
Aims & Methods: At baseline, subjects (N=191) were randomized with a 
2:1:1:2 allocation across 4 treatment arms (200, 600, 1000mg Miri, and 
PBO, administered intravenously (IV) at Weeks 0, 4, and 8). The primary 
objective was to evaluate superiority of Miri to PBO in inducing endoscopic 
response, defi ned as 50% reduction from baseline in Simple Endoscopic 
Score for Crohn´s disease (SES-CD), at Week 12. Secondary objectives in-
cluded clinical remission by Patient-Reported Outcomes (PRO remission), 
endoscopic remission, and safety, with Crohn´s Disease Activity Index 
(CDAI) assessed as an exploratory endpoint. Treatment comparisons of 
the primary endpoint and other effi  cacy variables were conducted using a 
logistic regression analysis with treatment, geographic region, and prior 
biologic CD therapy use included in the model, with a 2-sided alpha level 
of 0.10 considered signifi cant.
Results: Baseline characteristics were similar among treatment groups. 
At Week 12, endoscopic response rates were signifi cantly greater 
for all Miri groups compared to PBO, with 25.8% (8/31[95%CI: 10.4-
41.2], p=0.079), 37.5% (12/32[95% CI: 20.7-54.3], p=0.003), and 43.8% 
(28/64[95%CI: 31.6-55.9], p< 0.001) patients in the 200, 600, and 1000mg 
groups, respectively, achieving endoscopic response compared to 10.9% 
(7/64[95%CI: 3.3-18.6]) of PBO patients. Endoscopic remission was 
achieved in 15.6 and 20.3% of patients treated with 600 and 1000mg Miri 
(p=0.032 and p=0.009, respectively; 200mg p=0.241), versus 1.6% of PBO. 
Likewise, PRO remission rates were greater in 200, 600, and 1000mg Miri 
groups (12.9% [4/31], p=0.346; 28.1% [9/32], p=0.005 and 21.9% [14/64], 
p=0.025, respectively), versus 6.3% PBO. CDAI response was greater in all 
Miri groups (200mg: 48.4%, p=0.015; 600mg: 56.3%, p=0.001; 1000mg: 
42.2%, p=0.026) versus 23.4% of PBO and CDAI remission rates greater in 
the 600 and 1000mg Miri groups (200mg: 16.1%, p=0.321; 600mg: 40.6%, 
p< 0.001; 1000mg: 26.6%, p=0.013) versus 9.4% of PBO. The frequencies 
of serious adverse events (SAEs) and treatment-emergent adverse events 
(TEAEs) across treatment groups (SAEs: 0-9.4%, TEAEs: 58.1-65.6%) were 
similar to PBO (SAEs: 10.9%, TEAEs: 70.3%) and consistent with the previ-
ous safety profi le.
Conclusion: These data affi  rm the effi  cacy of Miri in the induction of statis-
tically signifi cant and clinically meaningful improvements in clinical and 
endoscopic outcomes. Sustained effi  cacy and safety are being evaluated in 
the maintenance phase of this study.
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Conclusion: Aft er failure of a fi rst subcutaneous anti-TNF agent, patients 
treated with VDZ achieved more clinical remission at week 14 and less 
UC-related events - including treatment discontinuation, colectomy, acute 
severe UC and hospitalization - than those treated with IFX. Such results 
have to be confi rmed by head-to-head trials.
Disclosure: Nothing to disclose 
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Introduction: Management of intra-abdominal abscess complicating 
Crohn’s disease (CD) is challenging. Surgery with delayed intestinal resec-
tion is oft en recommended in this situation.
Aims & Methods: The aim of this study was to estimate the success rate 
of adalimumab (ADA) in patients with CD complicated by intra-abdominal 
abscess, aft er complete resolution of sepsis and abscess, and to identify 
predictive factors of success.
We performed a multicentre, prospective, observational cohort study in 
patients with CD complicated by intra-abdominal abscess. Patients pre-
viously treated with an anti-TNF at the time of abscess occurrence, and 
patients with post-operative abscesses were not eligible. Patients with 
complete resolution of sepsis and abscess confi rmed by MR enterography 
(MRE) at baseline were included and received 160 mg of ADA at W0, 80 
mg at W2, and then 40 mg every 2 weeks. The primary endpoint was ADA 
success at W24 defi ned as no steroids use aft er the 12th week following 
inclusion, no intestinal resection, no abscess recurrence and no clinical 
relapse (CDAI > 220 or HBI > 4 and CRP > 10 mg/L at two consecutive visits). 
Baseline factors associated with ADA success were identifi ed using the 
logistic regression model.
Results: From April 2013 to December 2017, 190 patients from 27 GETAID 
centers were screened. Seventy-three patients were excluded, and 117 
were analysed for the primary endpoint. Median age at inclusion was 28 
years (inter-quartile range [IQR]:24-36), 58 (50%) patients were male and 
39 (35%) were active smokers. Median disease duration before abscess 
occurrence was 2.4 (0-58.7) months. Thirty-three (28%) patients had been 
previously exposed to thiopurines. Small bowel CD was responsible for 
intra-abdominal abscess in 101 (86%) patients. The median size of abscess 
was 25 (18-40) mm. MRE at baseline showed a visible fi stula tract in 67 
(58%) patients. Eleven (9%) patients had a percutaneous drainage of the 
abscess and 114 (97%) patients received antibiotics for a median duration 
of 21.5 (8-31) days. Fift y-nine (50%) patients had an exclusive enteral nu-
trition, 12 (10%) an exclusive parenteral nutrition and 28 (24%) oral feed-
ing. Median CRP and albumin level at inclusion aft er abscess resolution 
were 5 (2-9) mg/L and 39 (36-43) mg/L, respectively. At W24, 83/117 (71%) 
patients achieved ADA success. Ten (9%) patients underwent an intestinal 
resection. At least one serious adverse event was reported in 40 patients, 
with relapse of intra-abdominal abscess in 10 patients, other infections 
in 7 patients, and gastrointestinal disorders including CD worsening in 
27 patients. No death was reported. In multivariate analysis, predictive 
factors of ADA success were a mural high signal intensity on T2-weighted 
MRE (Odds ratio[OR]=2.92; 95% Confi dence interval [CI]:1.06-7.99; p=0.04), 
active smoking (OR=0.37; 95%CI: 0.14-1.00; p=0.05) and CRP level at ADA 
initiation (OR=0.98; 95%CI: 0.96-1.00; p=0.11).
Conclusion: In this prospective cohort of CD patients complicated by intra-
abdominal abscess, ADA success was observed in 71% of cases at W24. 
During this period, 9% of cases had an abscess recurrence and 9% needed 
an intestinal resection. No death was reported. Non-smoking status, low 
CRP level and active signs of infl ammation on MRE at ADA initiation were 
associated with ADA success at W24.
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Introduction: The UNIFI maintenance study was a Phase 3, double-blind, 
placebo-controlled, randomized-withdrawal study in pts with moderate 
to severely active ulcerative colitis (UC) who failed conventional or bio-
logic therapy and were in clinical response 8 weeks aft er receiving a single 
ustekinumab (UST) IV induction dose. In this study, patients were random-
ized to placebo, UST 90 mg SC q8w or q12w.
Aims & Methods: To examine the relative effi  cacy of the UST 90 mg SC 
q8w or q12w maintenance regimens, subgroup analyses were performed 
for clinical outcomes of clinical remission, symptomatic remission, and 
endoscopic improvement at Week 44 for patients who did and did not 
achieve these endpoints at the start of maintenance. Additionally, analyses 
of clinical remission and endoscopic improvement at Week 44 based on 
pre-specifi ed cut-points of the concentrations of infl ammatory biomarkers 
(CRP [≤3 mg/L, >3 mg/L] and fecal calprotectin [≤250 mg/kg, >250 mg/kg]) 
at maintenance baseline were conducted.
Results: For patients who had achieved clinical remission, symptomatic 
remission, or endoscopic improvement at maintenance baseline, effi  cacy 
of UST q8w and UST q12w regimens for the respective endpoint at Week 44 
was similar (Table 1). By contrast, for patients who did not achieve clini-
cal or symptomatic remission or endoscopic improvement at maintenance 
baseline, UST q8w demonstrated greater effi  cacy than UST q12w for that 
endpoint at Week 44. 
Patients with low infl ammatory burden marked by CRP ≤3 mg/L at main-
tenance baseline achieved similar effi  cacy at Week 44 with UST q8w and 
q12w dosing regimens as measured by clinical remission and endoscopic 
improvement (Table 1). By contrast, patients with high infl ammatory bur-
den, marked by CRP>3 mg/L at maintenance baseline, achieved greater 
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from the National Surgery Quality Improvement Program (NSQIP) partici-
pant use data specifi c fi le 2014-2016. NSQIP includes prospective validated 
30-day outcomes and anonymized data for patients undergoing major 
surgery in more than 500 hospitals. The primary outcome in this study 
was short term surgical morbidity and mortality. The patients were di-
vided into 4 groups, those who underwent surgery at days 0, 1, 2, 3+ for 
AC. We used the chi square test or Fisher’s exact (when one or more cells 
had an expected frequency lower than 5) to compare categorical variables 
between groups 0 and groups 1,2 and 3+ respectively. We used the inde-
pendent t-test for continuous variables. We performed multivariate logistic 
regression to evaluate the association between the timing of surgery aft er 
admission and 30-days postoperative outcomes. We included confounders 
into the models based on both clinical and statistical signifi cance.
Results: A total of 21,392 patients were included. Laparoscopic approach 
was used in 86% of cases. Patients who performed their operation at 3+ 
were signifi cantly older and had worse baseline clinical status prior to op-
eration. The overall morbidity (including wound infection, cardiac and re-
spiratory complications, urinary infections, thromboembolism and sepsis) 
occurred in 1439 patients (6.82%), while 1-month rebleeding and mortality 
occurred in 457 (2.1%) and 185 (0.9%) patients. On univariate analysis, 
all morbidity events and mortality increased signifi cantly with increased 
surgery timing from admission (Table 1). 
Adjusted ORs (95% CI)
  Days from hospital admission to operation p-value
  0 (n=8906) 1 (n=6952) 2 (n=2605) 3+ (n=2929) 1 vs 0 2 vs 0 3+ vs 0
Mortality Reference 0.99 
(0.62 - 1.56)
1.38 
(0.83 - 2.30)
1.57 
(1.01 - 2.44)
0.96 0.21 0.05
Composite 
Morbidity Reference
0.79 
(0.68 - 0.93)
0.81 
(0.66 - 0.99)
0.99 
(0.82 - 1.19)
0.004 0.04 0.89
Bleeding Reference 1.14 
(0.86 - 1.49)
1.41 
(1.03 - 1.94)
1.83 
(1.39 - 2.43)
0.36 0.03 <0.0001
Return to OR Reference 0.86 
(0.66 - 1.13)
0.76 
(0.53 - 1.09)
1.07 
(0.79 - 1.45)
0.28 0.14 0.67
[Adjusted 30-day outcomes]
Compared to patients who underwent surgery at day 0, and aft er adjusting 
for confounders (table 1), patients who underwent surgery at day 1 and day 
2 had a signifi cantly slightly lower composite morbidity. No signifi cant dif-
ference among the four groups in the need for reoperation was noted. The 
bleeding rate was signifi cantly higher in patients who were operated at 
day 2, and was highly signifi cant in the 3+ group. Patients who underwent 
surgery at day 3+ had a signifi cantly higher mortality rate.
Conclusion: Early cholecystectomy performed aft er 72 hours from admis-
sion was associated with higher mortality and rebleeding. Our results sup-
port the “golden 72 hours window “for surgery in AC.
Disclosure: Nothing to disclose 
OP171 A NEW ENDOSCOPIC TRANSPAPILLARY GALLBLADDER 
DRAINAGE COMBINED WITH INTRADUCTAL ULTRASONOGRAPHY 
FOR PATIENTS WITH ACUTE CHOLECYSTITIS
Sagami R.1, Hayasaka K.2, Ujihara T.2, Nakahara R.2, Murakami D.2, 
Iwaki T.2, Suehiro S.1, Katsuyama Y.2, Harada H.1, Amano Y.3
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Introduction: Endoscopic transpapillary gallbladder drainage (ETGBD) is a 
useful drainage technique for acute cholecystitis, although this method is 
technically diffi  cult.
Aims & Methods: When ETGBD is combined with intraductal ultrasonog-
raphy (IDUS), the orifi ce of the cystic duct (CD) in the common bile duct is 
more easily detected, and the CD is more easily cannulated. The aim of the 
present study is to evaluate the effi  cacy and feasibility of ETGBD with IDUS 
compared to ETGBD alone. 
A hundred patients with acute cholecystitis requiring ETGBD were recruit-
ed between January 2015 and December 2017. The fi rst consecutive 50 out 
of 100 patients were treated by ETGBD without IDUS, and the following 
consecutive 50 patients were treated by ETGBD with IDUS. The primary 
outcome was technical success rate.
effi  cacy at Week 44 with UST q8w versus q12w dosing over the endpoints. 
Generally similar trends were seen in patients with fecal calprotectin mea-
surements for low (≤ 250 mg/kg) and high (>250 mg/kg) infl ammatory 
burden at maintenance baseline.
Conclusion: Among patients with a clinically meaningful response to a 
single IV induction dose of UST, maintenance treatment with UST q8w or 
q12w demonstrated similar effi  cacy at Week 44. By contrast, the effi  cacy of 
UST q8w at Week 44 was greater than the q12w regimen for patients with 
higher infl ammatory burden or who did not achieve clinical or symptom-
atic remission or endoscopic improvement at week 8. These data suggest 
that multiple clinical measures can help inform the decision on the most 
appropriate maintenance dosing regimen for UST in the treatment of pa-
tients with UC.
  Patients attaining outcome at maintenance baseline
Patients not attaining outcome 
at maintenance baseline
Endpoint
Placebo 
SCa
UST 90 
mg q12w
UST 90 
mg q8w
Placebo 
SCa
UST 90 
mg q12w
UST 90 
mg q8w
Clinical remissionb
37.8% 
(17/45)
70.0% 
(28/40) *
65.8% 
(25/38) *
19.2% 
(25/130)
28.8% 
(38/132)
37.7% 
(52/138) *
Symptomatic 
remissionc
51.6% 
(63/122)
73.0% 
(89/122) *
73.1% 
(87/119) *
30.2% 
(16/53)
36.0% 
(18/50)
56.1% 
(32/57) *
Endoscopic 
improvementd
35.2% 
(25/71)
60.3% 
(41/68) *
64.9% 
(37/57) *
24.0% 
(25/104)
32.7% 
(34/104)
44.5% 
(53/119) *
 
Subjects with CRP ≤3 mg/L at 
maintenance baseline
Subjects with CRP >3 mg/L at 
maintenance baseline
Endpoint
Placebo 
SCa
UST 90 
mg q12w
UST 90 
mg q8w
Placebo 
SCa
UST 90 
mg q12w
UST 90 
mg q8w
Primary effi  cacy 
analysis set
111 121 111 60 49 65
Clinical remission at 
Week 44b
29 
(25.4%)
53 
(43.8%)*
50 
(45.0%)*
13 
(21.7%)
12 
(24.5%)
27 
(41.5%)*
Endoscopic 
improvement at Week 
44d
33 
(28.9%)
57 
(47.1%)*
59 
(53.2%)*
17 
(28.3%)
16 
(32.7%)
31 
(47.7%)*
a: Patients who were in clinical response to ustekinumab IV induction dosing and were 
randomized to placebo SC on entry into this maintenance study
b: A Mayo score ≤2 points, with no individual subscore >1.
c: Mayo stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0.
d: A Mayo endoscopy subscore of 0 or 1.
* Nominal p-value < 0.05.
[Table 1. Clinical Outcomes at Week 44 by Maintenance Baseline Status for 
the Outcome]
Disclosure: Drs. Panaccione, Peyrin-Biroulet, Danese, Leong, Arasarad-
nam, Rowbotham, Abreu, and Sands are all investigators for Janssen Re-
search & Development, LLC Drs. Marano,O’Brien, Szapary, Zhang, Johanns 
are all employees of Janssen Research & Development, LLC. 
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OP170 INFLUENCE OF EARLY CHOLECYSTECTOMY TIMING FOR 
ACUTE CHOLECYSTITIS ON SHORT TERM SURGICAL MORBIDITY AND 
MORTALITY: A NSQIP DATABASE ANALYSIS
Daniel F.1, Malaeb M.1, Hosni M.1, Tamim H.2, Mailhac A.2, Khalife M.3, 
Faraj W.3, Jamali F.3
1American University of Beirut Medical Center, Division of Gastroenterology, 
Department of Internal Medicine, Beirut, Lebanon, 2American University of 
Beirut Medical Center, Biostatistics Support Unit, Clinical Research Institute, 
Beirut, Lebanon, 3American University of Beirut Medical Center, Surgery, 
Beirut, Lebanon
Contact E-Mail Address: fd21@aub.edu.lb
Introduction: There is growing evidence that supports early cholecystec-
tomy is associated with better outcomes. Nonetheless, the exact timing of 
early cholecystectomy is still yet to be determined.
Aims & Methods: To elucidate the optimal timing of early cholecystectomy 
and determine the outcomes of patient undergoing early versus delayed 
same admission cholecystectomy in patients with acute cholecystitis. 
We studied all patients undergoing open or laparoscopic cholecystectomy 
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Results: The technical success rate of ETGBD with IDUS was signifi cantly 
higher than that of ETGBD without IDUS (92.0% [46/50] vs 72.0% [36/50], 
P= 0.014). There was no signifi cant diff erence between the procedure 
lengths of both groups (74.0 minutes [10-140] vs 65.6 minutes [14-215], p 
= .219). Complication rates of ETGBD with IDUS were signifi cantly higher 
than those of ETGBD without IDUS (6.0% vs 0% P< .001); however, IDUS 
technique-related complications such as pancreatitis were found in only 
one case.
Conclusion: ETGBD with IDUS may be one of the best therapeutic methods 
for patients with acute cholecystitis.
Disclosure: Nothing to disclose 
OP172 ENDOSCOPIC ULTRASOUND VS ENDOSCOPIC 
TRANS-PAPILLARY VS PERCUTANEOUS GALLBLADDER DRAINAGE 
IN HIGH-RISK ACUTE CHOLECYSTITIS PATIENTS: A SYSTEMATIC 
REVIEW AND COMPARATIVE META-ANALYSIS
Mohan B.1, Khan S.2, Trakaroo S.3, Ponnada S.4, Jayaraj M.5, 
Asokkumar R.6, Adler D.7
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Tucson, United States, 2University of Arizona/Banner University Medical 
Center, Tucson, United States, 3St Vincent Charity Medical Center, Cleveland, 
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United States, 6Singapore General Hospital, Gastroenterology, Singapore, 
Singapore, 7University of Utah School of Medicine, Gastroenterology and 
Hepatology, Salt Lake City, United States
Contact E-Mail Address: babupmohan@gmail.com
Introduction: Endoscopic transpapillary gallbladder drainage (ETGBD) and 
endoscopic ultrasound guided gallbladder drainage (EUSGBD) are alter-
native to percutaneous gallbladder drainage (PCGBD) in the management 
of acute cholecystitis unfi t for surgery. Data comparing these modalities 
are limited and have reported confl icting results.
Aims & Methods: We searched multiple databases from inception through 
December2018 to identify studies that reported on ETGBD, EUSGBD, and 
PCGBD in the management of acute cholecystitis high risk for surgery. Our 
goals were to compare the pooled rates of technical success, clinical suc-
cess, adverse events, and disease recurrence.
Results: 13 studies (815 patients), 12 studies (506 patients), and 8 studies 
(1484 patients) were treated by ETGBD, EUSGBD, and PCGBD respectively. 
Baseline patient characteristics were comparable between the groups. Age 
ranged from 65 to 85 years with 61% males. The pooled technical and 
clinical successes of EUSGBD was statistically superior to ETGBD [95.9% 
(95% CI 91-98.1, I2=6.4) vs 80.3% (95% CI 67.4-89, I2=68), p=0.001; 96.7% 
(95% CI 94.1-98.1, I2=0) vs 88.6% (95% CI 84.3-91.8, I2=42.3), p=0.001; 
respectively]. Bleeding and perforation was statistically more with EUS-
GBD [3.8% (95% CI 2.3-6.2, I2=0) vs 1.6% (95% CI 0.7-3.2, I2=0), p=0.03; 
4.4% (95% CI 2.8-6.9, I2=0) vs 1.7% (95% CI 0.9-3.4, I2=0), p=0.004; re-
spectively], whereas pancreatitis was statistically more with ETGBD [6.4% 
(95% CI 4.1-9.8, I2=27.3 vs 0, p=0.001]. Pooled clinical success of EUSGBD 
was statistically superior to PCGBD [96.7% (95% CI 94.1-98.1, I2=0) vs 90% 
(95% CI 85.7-93.1, I2=37.6), p=0.001], whereas the pooled rate of techni-
cal success was comparable (Table).Pooled rate of disease recurrence was 
comparable between the groups (Table).
(95% CI, I2) Technical success Clinical Success Adverse events Recurrence
ETGBD
80.3% 
(67.4-89, 68)
88.6% 
(84.3-91.8, 42.3)
9.8% 
(5.3-17.2, 40.7)
3.6% 
(1.9-6.6, 17.1)
EUSGBD
95.9% 
(91-98.1, 6.4)
96.7% 
(94.1-98.1, 0)
12.1% 
(6.9-20.2, 7.9)
4.5% 
(2.7-7.4, 0)
PCGBD
94.7% 
(85.7-98.1, 95.3)
90% 
(85.7-93.1, 37.6)
18.4% 
(9.9-31.5, 93.7)
7.5% 
(4.7-11.6, 48.6)
p-value of statistical signifi cance
ETGBD vs 
EUSGBD
0.001 0.001 0.69 0.66
ETGBD vs 
PCGBD
0.03 0.53 0.2 0.1
EUSGBD vs 
PCGBD
0.91 0.001 0.37 0.1
ETGBD: endoscopic transpapillary gallbladder drainage, EUSGBD: endoscopic ultrasound 
guided gallbladder drainage, PCGBD: percutaneous gallbladder drainage
[Summary of pooled results]
Conclusion: EUSGBD demonstrates superior clinical success when com-
pared to ETGBD and/ or PCGBD in the treatment of acute cholecystitis in 
surgically unfi t patients. Based on our analysis, EUSGBD should be con-
sidered the fi rst line approach for treating patients with acute cholecystitis 
who are high risk for surgery and preferable be done in high volume cen-
ters due to signifi cant but rare adverse events.
Disclosure: Nothing to disclose 
OP173 EVALUATIONS OF SEVERITY ASSESSMENT FOR ACUTE 
CHOLECYSTITIS : JAPAN-TAIWAN COLLABORATIVE MULTICENTER 
STUDY FOR ACUTE CHOLECYSTITIS
Yokoe M.1, Takada T.2, Hwang T.-L.3, Endo I.4, Chen M.-F.5, 
Japan-Taiwan Research Group for Acute Cholecystitis
1Japanese Red Cross Nagoya Daini Hospital, General Internal Medicine, 
Nagoya, Japan, 2Teikyo University Hospital, Tokyo, Japan, 3Chang Gung 
University, Taoyuan, Taiwan, 4Yokohama City University, Yokohama, Japan, 
5Chang Gung Memorial Hospital, Taoyuan, Taiwan
Contact E-Mail Address: masa45a@gmail.com
Introduction: Acute cholecystitis is a disease frequently encountered in 
daily practice presenting with right hypochondrial pain as the main symp-
tom. Tokyo Guidelines 2013 (TG13) have already been recognized as the 
severity assessment criteria to be recommended in today’s medical care 
for acute cholecystitis all over the world. Severe acute cholecystitis was 
defi ned as acute cholecystitis accompanying organ dysfunctions directly 
related to poor prognosis. Exactly acute cholecystitis is basically not a dis-
ease with a high mortality. However, it was thought that guidelines should 
make it clear that adequate management with appropriate use of severity 
assessment criteria for acute cholecystitis does lead to improved patients’ 
prognosis.
Aims & Methods: The aim for this study was validation of the clinical im-
pact of TG13 severity assessment criteria for acute cholecystitis. The study 
was designed as Japan-Taiwan collaborative multicenter retrospective 
study of acute cholecystitis from 2011 to 2013. Based on the data, we inves-
tigated the TG13 severity assessment criteria by analyzing the correlations 
between grade and prognosis, surgical procedures, and histopathology, in 
addition between the numbers of organ dysfunctions and mortality.
Results: A total of 5,459 patients in 154 Japanese and Taiwanese institu-
tions were included in our study. Of the 5,459 patients, 4,716 were from 
Japan and 743 from Taiwan. With exclusion criteria of missing data, 1,099 
patients were excluded and a fi nal total of 4,360 patients were included 
for this study. A Study revealed that 30-day overall mortality rate was 1.1% 
for Grade I, 0.8% for Grade II, 5.4% for Grade III. The 90-day mortality rate 
was 1.0% for Grade I, 0.8% for Grade II, 5.6% for Grade III. The mortality 
rate for Grade III was signifi cantly higher than lower grades (P < 0.001). 
The relationship between the numbers of organ dysfunctions and 30-day 
mortality was investigated, the greater the numbers of organ dysfunction, 
the higher the mortality rate (P < 0.001). However, the mortality rate var-
ied depending on the number of organ dysfunction (3.1-25%). Especially 
neurological dysfunction and Respiratory dysfunction were considered 
as a signifi cant poor prognostic factor on 30-day mortality (P < 0.001). 
With respect to the surgical procedures, laparoscopic cholecystectomy was 
signifi cantly selected for Grade I patients (P < 0.001), and the higher the 
grade, the more likely open cholecystectomy was performed (P < 0.001). 
Pathological fi ndings research revealed that Gangrenous cholecystitis and 
Chronic cholecystitis were signifi cantly diagnosed with higher grade of 
TG13 severity assessment (P < 0.001).
Conclusion: This international multicenter investigation between Japan 
and Taiwan revealed that severe acute cholecystitis judged by TG13 severity 
assessment criteria were exactly worse conditions with organ dysfunctions 
and it would have possible to be poor prognosis. As a result, it would be 
better performance for the management of acute cholecystitis with using 
TG13 severity assessment criteria on emergency room and aft er admission. 
TG13 for AC would be providing great impact in actual clinical practice.
References: Takada, et al. TG13: Updated Tokyo Guidelines for the man-
agement of acute cholangitis and cholecystitis. J Hepatobiliary Pancreat 
Sci. 2013 Jan;20(1):1-7. Yokoe, et al. TG13 diagnostic criteria and severity 
grading of acute cholecystitis (with videos).J Hepatobiliary Pancreat Sci. 
2013 Jan;20(1):35-46.
Disclosure: Nothing to disclose 
96 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
come the disadvantages of minimally invasive liver resection. The proce-
dure is not time-consuming and its applications can reduce the postopera-
tive complication rate in robotic liver surgery.
Disclosure: Nothing to disclose 
Basic science: The intestinal epithelium and IBD
10:30-12:00 / B5
OP176 THE EFFECT OF ULCERATIVE COLITIS RELATED CIRCRNA 
CIRC-SOD2 ON INTESTINAL EPITHELIAL BARRIER
Wang T.1, Zhang Y.2, Liu Y.1
1Peking University People’s Hospital, Department of Gastroenterology, 
Beijing, China, 2Peking University People’s Hospital, Biobank, Beijing, China
Contact E-Mail Address: 1428695100@qq.com
Introduction: To explore the dysregulated circRNAs and mRNAs profi les in 
infl amed ulcerative colitis (UC) colorectal mucosa and identify the crucial 
circRNAs associated with UC. To clarify the roles and potential mechanisms 
of the key circRNA involved in intestinal epithelial barrier.
Aims & Methods: 
1. CircRNAs microarray and mRNAs microarray were used to determine 
the diff erences of circRNAs and mRNAs between 5 paired infl amed UC 
colorectal tissues and normal colorectal tissues; 
2. To predict the functions and involved pathways of dysregulated circRNAs 
and mRNAs with bioinformatics tools and identify the critical circRNA; 
3. Quantitative real-time polymerase chain reaction (qRT-PCR) was ap-
plied to examine the expression of candidate circRNAs in extended UC 
colorectal tissues and colon epithelial cell models; 
4. Fluorescence in Situ Hybridization(FISH) was performed to confi rm the 
cellular location in UC tissues; 
5. Construct overexpressed circ-SOD2 vector and transfected into Caco2 
cells to object the infl uences of circ-SOD2 in intestinal epithelial barrier; 
6. Detect epithelial barrier related proteins such as CLDN-8, ZO-1 and oc-
cludins with Western Blotting aft er circ-SOD2 vector transfected; 
7. Build a network included circRNAs, microRNAs and mRNAs to predict 
the potential role mechanisms of circ-SOD2 in intestinal epithelial barrier.
Results: 
1. The microarray assays indicated that 110 upregulated and 152 down-
regulated circRNAs and 1004 upregulated, 865 downregulated in mRNAs; 
2. The functional analysis of diff erentially expressed circRNAs derived pa-
rental genes found that these parental genes were involved in HIF1-α, Rap1 
signaling pathway and cellular adhesion; 
3. Multiple dysregulated circRNAs were validated in UC with qRT-PCR and 
hsa_circ_0004662 derived from SOD2 gene was upregulated signifi cantly 
(named as circ-SOD2) and related to the severity of UC; 
4. circ-SOD2 mostly located in colon epithelial and increased aft er the 
treatment of infl ammation factors in vitro; 
5. The overexpression of circ-SOD2 in Caco2 cells led to TEER decreased, 
FITC-dextran permeability improved, microvillus and tight junction re-
duced; 
6. Overexpressed circ-SOD2 in Caco2 cells caused that epithelial related 
protein CLDN-8 was decreased; 
7. The potential mechanism of the role of circ-SOD2 in intestinal epithelial 
barrier was that circ-SOD2 harbored some microRNAs such as hsa-miR-
424-5p, hsa-miR-497-5p, hsa-miR-935, hsa-miR-16-5p, hsa-miR-152-3p 
to control the downstream mRNAs.
Conclusion: The profi le of circRNAs and mRNAs in infl amed UC colorec-
tal tissues changed signifi cantly, among them, circ-SOD2 had an obvious 
decrease. Additionally, the overexpression of circ-SOD2 caused the injury 
of intestinal epithelial barrier and its possible mechanisms were that circ-
SOD2 regulated the expression of CLDN-8 directly or bound microRNAs to 
control target mRNAs indirectly.
Disclosure: Nothing to disclose 
OP174 IS SELECTIVE HISTOPATHOLOGIC EXAMINATION OF THE 
GALLBLADDER PERMISSIBLE?
Corten B.J.G.A.1, de Savornin Lohman E.2, Leclercq W.K.G.1, 
Roumen R.M.H.1, Verhoeven R.3, van Zwam P.H.4, de Reuver P.R.2, 
Dejong C.H.C.5, Slooter G.6
1MMC Veldhoven, Surgery, Veldhoven, Netherlands, 2Radboudumc, Surgery, 
Nijmegen, Netherlands, 3IKNL, Eindhoven, Netherlands, 4PAMM, Pathology, 
Veldhoven, Netherlands, 5Maastricht University Medical Centre, Maastricht, 
Netherlands, 6Maxima Medical Centre, Surgical Oncology, Veldhoven, 
Netherlands
Contact E-Mail Address: bartcorten@gmail.com
Introduction: Necessity of routine histopathologic examination of gallblad-
ders has been debated for the past decades. Implementation of a selective 
histopathologic policy is hampered by fear of missing small carcinoma in 
macroscopically normal gallbladders. We wanted to investigate how gall-
bladder cancer was detected and identifi ed. We aimed to identify GBC in 
macroscopically normal gallbladders and to what extend these malignan-
cies might have had clinical consequences.
Aims & Methods: Using the Dutch Cancer Registry all patients were re-
viewed with diagnosis of gallbladder cancer between 2004 and 2015 in 
the South region of the Netherlands, a population of 2.3 million people. 
We identifi ed all patients that had unexpected malignancies operated for 
benign gallstone disease. Based on clinical and pathological report we 
determined whether malignancies were macroscopically suspected or de-
tected by microscopy only. In patients with GBC only detected by histopa-
thology tumour stage and clinical consequence were summarized.
Results: A total of 205 malignancies of the gallbladder were identifi ed. In 
75 patients there was no suspicion of gallbladder cancer prior to surgery. 
Of these 37, the surgeon described a tumour in the operation report. In 38 
there was no mention of abnormalities in the operation report. 8 gallblad-
ders would probably been send for histopathologic examination based on 
diffi  culties during surgery (e.g. conversion or excessive gallbladder em-
physema) or clinical indication (e.g. Mirizi syndrome). Pathologic exami-
nation identifi ed macroscopic abnormalities in 23 cases. In the remaining 
7 specimens there were no macroscopic abnormalities and samples were 
taken at random. None of these patients received additional treatment. 
In the same time period histological gallbladder examination occurred in 
31902.
Conclusion: We present one of the largest single study cohort of histo-
pathologic gallbladder examination and relation to gallbladder cancer. 
The major part of the invasive gallbladder cancers showed macroscopic 
abnormalities peroperatively. Over a decade, in a population of 2.3 million 
people, histology alone resulted in a change of treatment plan in just one 
patient. Therefore, selective histopathology seems a feasible policy and 
would reduce costs and pathological workload.
Disclosure: Nothing to disclose 
OP175 THE APPLICATION OF INDOCYANINE GREEN-FLUORESCENCE 
IMAGING DURING ROBOTIC LIVER RESECTION: A CASE-MATCHED 
STUDY
Marino M.V.1,2
1Azienda Ospedaliera, Ospedali Riuniti Villa So a-Cervello, Emergency 
and General Surgery, Palermo, Italy, 2Hospital Universitario Marqués de 
Valdecilla, General Surgery, Santander, Spain
Contact E-Mail Address: marco.vito.marino@gmail.com
Introduction: The ICG-fl uorescence properties are progressively gaining 
momentum in the HPB surgery. However, the exact impact of ICG applica-
tion on surgical outcomes is yet to be established.
Aims & Methods: Twenty-fi ve patients who underwent ICG-fl uorescence 
guided robotic liver resection were case matched in a 1:1 ratio to a cohort 
who underwent standard robotic liver resection.
Results: In the ICG group six additional lesions not diagnosed by preopera-
tive workup and intraoperative ultrasound were identifi ed and resected. 
Four of the lesions proved to be malignant. Despite the similar operative 
time (288 vs 272 min, p= 0.778), the risk of postoperative bile leakage (0% 
vs 12%, p= 0.023), R1 resection (0% vs 16%, p= 0.019) and readmission 
(p= 0.023) was reduced in the ICG group compared with the no-ICG group.
Conclusion: The ICG-fl uorescence is a real time navigation tool which en-
able surgeons to enhance visualization of anatomical structures and over-
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OP177 GPX4 RESTRICTS ENVIRONMENTALLY-INDUCED COLITIS
Grabherr F.1, Mayr L.1, Schwärzler J.1, Reitmeier I.1, Moschen A.1, Ran Q.2, 
Tilg H.1, Adolph T.E.1
1Medical University of Innsbruck, Department of Internal Medicine I, 
Innsbruck, Austria, 2University of Texas Health Science Center, Department of 
Cell Systems and Anatomy, San Antonio, United States
Contact E-Mail Address: felix.grabherr@student.i-med.ac.at
Introduction: Glutathione Peroxidase 4 (GPX4) is an antioxidative enzyme, 
which particularly reduces lipid peroxides and is the key regulator of a 
novel cell death pathway called ferroptosis which is characterised by un-
controlled lipid peroxidation (LPO) [1,2]. A recent study demonstrated that 
deletion of GPX4 in myeloid cells of mice, leads to increased susceptibility 
to chemical induction of colitis [3]. However, the role of intestinal epithelial 
GPX4 in intestinal homeostasis remains unclear.
Aims & Methods: We aimed to study a role for epithelial GPX4 in the con-
trol of intestinal homeostasis.
We crossed Gpx4 /  mice with Villin-Cre+ mice to obtain Gpx4 /wt VillinCre+ 
(Gpx4+/-IEC) mice that lack one allele of Gpx4 specifi cally in intestinal epithe-
lial cells. In these mice colitis was induced with three percent dextran so-
dium sulfate (DSS) in drinking water for fi ve consecutive days followed by 
three days of tap water. Mice were dissected three days aft er withdrawal 
of DSS. Disease severity was assessed by comparing the colon length and 
the histology score.
Results: Gpx4+/-IEC mice had signifi cantly reduced colon lengths aft er DSS-
colitis compared to wild type littermates, indicative for severe colitis. This 
fi nding was corroborated by histopathological evaluation, which showed 
that mice lacking one allele of GPX4 exhibited more severe infl ammation 
in their colons aft er colitis induction with DSS.
Conclusion: Intestinal epithelial GPX4, a central antioxidative enzyme in 
cells, protects mice against infl ammation in the large intestine. So far, the 
mechanisms how GPX4 interacts with infl ammatory pathways remain un-
known, but it presents a promising target for future anti-infl ammatory 
therapies.
References: 1 Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev 
EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapop-
totic cell death. Cell 2012;149:1060-72. 2 Stockwell BR, Friedmann Angeli 
JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: A Regulated 
Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 
2017;171:273-85. 3 Canli Ö, Nicolas AM, Gupta J, Finkelmeier F,Goncharova 
O, Pesic M, et al. Myeloid Cell-Derived Reactive Oxyben Species Induce 
Epithelial Mutagenesis, Cancer Cell 2017; 32(6):869-883
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OP178 BACTERIA INDUCE THE RELEASE OF PROALGESIC LIPIDS 
BY EPITHELIAL CELLS
Petitfi ls C.1, Pujo J.2, Lefaouder P.3, Cenac N.4
1Digestive Health Research Institute, Toulouse, France, 2Digestive Health 
Research Institute, Gastroenterology, Toulouse, France, 3Institute of 
Cardiovascular and Metabolic Diseases, Lipidomic plateform, Toulouse, 
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Introduction: Irritable bowel syndrome is the most common functional 
intestinal disorder. It is characterized by visceral hypersensitivity and an 
altered gut transit that are associated with a gut microbiota dysbiosis. 
Among the studied pronociceptive mediators, host and bacterial lipid 
compounds have been described as major regulators of visceral hyper-
sensitivity.
Aims & Methods: The aim of our study was to identify the role of the host 
and bacterial lipids interplay on visceral hypersensitivity. To diff erentiate 
bacterial and host lipids, Escherichia coli were cultivated in a minimal me-
dium with 13C- glucose as unique source of carbon, leading to the pro-
duction of 13C-labelled bacterial lipids. Bacterial lipid extracts were added 
at the apical side of polarized intestinal epithelial cells (caco2) cultured 
in transwell. Twenty four hours aft er treatment, quantifi cation by high-
resolution mass spectrometry of the 13C-labelled lipids from the bacteria 
and the unlabeled lipids from the epithelial cells in the basolateral com-
partment allowed us to determine epithelial and bacterial lipids that could 
potentially be in contact with nerve endings. Lipid quantifi cation by liquid 
chromatography coupled to tandem mass spectrometry was performed in 
the colon of germ free and conventional mice. We then assessed the ability 
of the epithelial and bacterial lipids found in the basolateral compartment 
to increase intracellular calcium concentration in primary culture of mouse 
sensory neurons.
Results: Amongst the uniformly 13C-labelled bacterial lipids, we identifi ed 
long chain fatty acids, from 10 to 18 carbons, hydroxylated on the 3rd car-
bon with or without a double bound, and aminolipids in the bacterial 
culture. Twenty four hours aft er treatment by bacterial lipids at the apical 
side of the transwells, we quantifi ed an increase of the concentration of 
bacterial C10-3OH, C12AsnOH and C14AsnOH as well as epithelial 9,10-Di-
HOME and 12,13-DiHOME in the basolateral compartment. Similar results 
were obtained when the bacterial lipids were unlabeled, meaning that 
these results were not due to the labelling. We found a signifi cantly lower 
concentration of 9,10- and 12,13-DiHOME in the colon of germ-free mice, 
strengthening the link between the microbiota and the host production 
of those lipids. Bacterial lipids and 12,13-DiHOME did not activate sensory 
neurons. In contrast, the 9,10-DiHOME induced calcium fl ux in sensory 
neurons. This eff ect was inhibited by a pretreatment of the neurons with a 
TRPV1 antagonist (AMG9810).
Conclusion: Our study show that bacterial lipids induce the release of po-
tentially proalgesic lipids by epithelial cells. Lipid metabolism could be the 
link between dysbiosis and visceral pain in IBS.
Disclosure: Nothing to disclose 
OP179 CONTRIBUTION OF FULL FIELD OPTICAL COHERENCE 
TOMOGRAPHY (FF-OCT) FOR THE STUDY OF THE DIGESTIVE 
EPITHELIAL BARRIER IN PATIENTS WITH SPINA BIFIDA
Olivier R.1, Quénéhervé L.2, Mosnier J.-F.3, Bossard C.4, Bouguen G.5, 
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Introduction: Full Field Optical Coherence Tomography (FF-OCT) is an ex 
vivo imaging technique, with micrometric resolution, usually reserved for 
imaging biological environments (1) (2). It allows rapid acquisition of ex 
vivo tissue images on a cellular scale, and therefore represents an attrac-
tive approach for analysis of human samples such as endoscopic biopsies. 
Adult patients with Spina Bifi da (SB) oft en have digestive disorders (3) 
whose pathophysiology is poorly known and remains to be explored. The 
objective of this study was to evaluate the feasibility and relevance of FF-
OCT in the study of the morphology of the intestinal epithelial barrier from 
colonic biopsies of patients with SB.
Aims & Methods: FF-OCT analyses were performed on fi xed colonic biop-
sies of SB patients and healthy volunteers (HV), collected during a short 
colonoscopy. Biopsies were scanned using the Light-CT scanner (LLTech, 
Paris, France). This device allows to produce contrast images in grayscale 
(axial resolution 1µm, frequency 75Hz), with the possibility of making a 
mosaic in order to obtain a maximum examination fi eld of 25mm. The 
analyse depth is adjustable, with a maximum depth of several millime-
ters and the possibility of performing a three-dimensional reconstruction 
of the specimen. 2 biopsies per patient/HV were analyzed. The diff erent 
morphological criteria studied in FF-OCT were: the average density of the 
connective tissue, the number of crypts, the average area of the crypts, the 
total area of the crypts, the average roundness of the crypts, the average 
circularity of the crypts and the average of the major axis/small axis of the 
crypts. These data were compared with each other by a Student t-test. A 
standard histological analysis was also performed.
Results: Data from 36 adult SB and 16 HV patients were analyzed. Among 
SB patients: 26 (72%) had abdominal pain, 6 (17%) faecal incontinence, 
the average number of stools was 3/week. The appearance of the mucosa 
was macroscopically healthy in endoscopy and the standard anatomo-
pathological study found no abnormalities. The connective tissue density 
in FF-OCT was signifi cantly decreased in Spina Bifi da patients: p < 0.0001. 
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OP181 ACTIVE EPITHELIAL SERINE PROTEASES ARE PRODUCED BY 
INTESTINAL EPITHELIUM TO CONTROL MUCOSAL BIOFILMS
Motta J.-P.1, Sagnat D.2, Guiraud L.1, Edir A.1, Bonnart C.3, Sebbag M.1, 
Rousset P.1, Alric L.4, Dufour A.5, Verdu E.F.6, Serino M.1, Oswald E.7, 
Deraison C.8, Vergnolle N.9
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Toulouse, France, 4CHU Toulouse, Toulouse, France, 5University of Calgary, 
Calgary, Canada, 6McMaster University, Hamilton, Canada, 7INRA INSERM, 
Toulouse, France, 8Digestive Health Research Institute, U 1220 IRSD, 
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Introduction: Proteolytic homeostasis is observed at the surface of intesti-
nal mucosa and is known to be disrupted in diseases (infl ammatory bowel 
disease, infection or irritable bowel syndrome)(1-3). Here, we investigated 
how mucosal proteolytic homeostasis might control microbial biofi lms 
present at the intestinal epithelium surface.
Aims & Methods: Our aim was to determine if epithelial proteases could 
control microbial biofi lm composition, and structure.
We measured proteolytic activity and protease expression at mucosal sur-
faces in mouse and human tissues, and in monolayers of human epithelial 
cell lines. We studied the biophysical structure, biomass and microbial 
composition of biofi lms at mucosal surfaces, or grown on synthetic solid 
surfaces. For the latest, we used cultured mucosa-associated microbiota 
from 4 healthy human colon biopsies. Mucosal proteolytic activity was 
modulated by the use of selective protease inhibitors in vivo and in vitro. 
Finally, N-terminomics/TAILS approaches were used to identify protease 
cleavages in human complex microbial biofi lms.
Results: We report that healthy human and mouse colon epithelium are 
a major source of active serine proteases, released in the lumen. Using 
germ-free animals, we demonstrated that mucosal serine proteases were 
directly regulated by the presence of commensal microbiota. Specifi c inhi-
bition of luminal serine protease activity caused macro-, microscopic dam-
age and transcriptomic alterations of genes involved in host-microbiota in-
teractions. Further, luminal serine protease inhibition impaired the spatial 
segregation of microbiota biofi lms, allowing bacteria to invade the mucus 
layer and to translocate across the epithelium, but had no obvious eff ect 
on microbiota composition. Epithelial proteases cleaved the biofi lm matrix 
of reconstituted mucosa-associated human microbiota, and can alter in a 
concentration-dependent manner the biofi lm biomass.
Conclusion: We demonstrate a previously unknown physiological role for 
epithelial proteases that constrains biofi lms at mucosal surfaces. Our dis-
covery points to an important role for proteolytic homeostasis at the in-
testinal mucosal surface with regards to biofi lm organization and invasive 
behavior.
References: 1- Motta JP et al. Sci. Trans. Med. 2012 2- Motta JP et al. 
Gastroenterology 2011 3- Denadai-Souza A. et al. Sci. Rep. 2018
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Colonic ESD: Does size matter?
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OP182 BRIDGE FORMATION METHOD IN COLORECTAL 
ENDOSCOPIC SUBMUCOSAL DISSSECTION
Abe M.1, Kudo S.1, Hayashi T.1, Ishigaki T.2, Okumura T.3, Sato Y.2, 
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Introduction: Colorectal endoscopic submucosal dissection(ESD) is becom-
ing an established procedure, diffi  cult cases still exist. As eff ective traction 
for approaching to submucosal layer can reduce diffi  culty of ESD proce-
No signifi cant diff erences were found concerning, per section, the num-
ber of crypt p = 0.4210, the average crypt area p = 0.2332, the total crypt 
area p = 0.2391, the average crypt roundness p = 0.7906, the average crypt 
circularity p = 0.09 and the average major/small crypt axis measurement 
mean p = 0.3463.
Conclusion: Morphological abnormalities of the intestinal epithelial barri-
er could be detected by FF-OCT in adult Spina Bifi da patients. This innova-
tive technique allows the precise quantitative study of specifi c histological 
parameters and therefore provides additional information to the classical 
anatomopathological study.
References: 1- Beaurepaire E, Boccara AC, Lebec M, Blanchot L, Saint-
Jalmes H. Full-fi eld optical coherence microscopy. Opt Lett. 1998; 23: 244-
246 2- Dubois A, Vabre L, Boccara AC, Beaurepaire E. High-resolution 
full-fi eld optical coherence tomography with a Linnik microscope. Appl 
Opt. 2002; 41: 805-812. 3- Brochard C, Peyronnet B, Dariel A, Ménard H, 
Manunta A, Ropert A, Neunlist M, Bouguen G, Siproudhis L.Bowel Dys-
function Related to Spina Bifi da: Keep It Simple. Dis Colon Rectum. 2017 
Nov;60(11):1209-1214.
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OP180 MIR-124A MEDIATES THE IMPAIRMENT OF INTESTINAL 
EPITHELIAL INTEGRITY BY TARGETING ARYL HYDROCARBON 
RECEPTOR IN CROHN’S DISEASE
Zhao X.1, Li J.1, Zhang H.2
1First A  liated Hospital of Nanjing Medical University, Dept. of 
Gastroenterology, Nanjing, China, 2First A  liated Hospital of Nanjing 
Medical University, Nanjing Medical University, Dept. of Gastroenterology, 
Nanjing, China
Contact E-Mail Address: zhaoxj91718@163.com
Introduction: Aryl hydrocarbon receptor [AHR] is a transcription factor, 
which induced by various ligands. AHR palsys a important role in the im-
mune response. Meanwhile, activation of AHR can attenuate epithelial 
barrier dysfunction. The expression level of AHR is downregulated and 
miR-124a is upregulated in Crohn’s Disease [CD]. How to modulate the 
AHR expression during the development of CD has yet to be thoroughly 
expounded.
Aims & Methods: The expression levels of miRNA and AHR protein were 
determined in Caco-2 monolayers and inflamed colon from patients with 
CD by RT-PCR and western blot analysis. Combining miRNA target predic-
tion soft wares, we verifi ed microRNAs that targeted AHR. Trans-epithelial 
electrical resistance [TEER] and fl uorescein isothiocyanate [FITC]-dextran 
were used to assess the permeability of the Caco-2 cell monolayers. The 
wild type [WT], miR-124a-Nju and AHR knockout mice were induced colitis 
using TNBS enema. Colitis mice using anti-miR-124a to inhibit miR-124a 
expression. We evaluated the intestinal infl ammation and determined 
miR-124a, AHR and tight junction [TJ] proteins levels in mice of diff erent 
treated groups.
Results: miRNA profi les of colon samples from CD patients were diff erent 
with normal controls. There was an negative correlation between miR-124a 
and AHR protein levels in infl amed colon tissues from active CD patients. 
In vitro studies [Caco2 monolayers] revealed that: the downregulated AHR 
and TJ proteins were induced by TNF-α or miR-124 mimic. Meanwhile, 
TNF-α or miR-124a mimic induced-hyperpermeability via overexpression 
of the miR-124a, which was abrogated by miR-124a inhibitor. In vivo stud-
ies [colitis model mice] demonstrated that: miR-124-1-Nju and AHR-/- mice 
using TNBS enema had more severe intestinal infl ammation than WT coli-
tis mice. MiR-124-1-Nju and AHR-/- mice experienced severely intestinal 
barrier dysfunction, which was ameliorated aft er administrating anti-miR-
124a in miR-124a-Nju mice but not in AHR-/- mice.
Conclusion: This study suggested that miR-124a can cause intestinal bar-
rier dysfunction and induce intestinal infl ammation via supressing AHR. 
Furthermore, we will explicate the exact molecular mechanisms for CD.
Disclosure: Nothing to disclose
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dure, the normal mucosa on both lateral sides of lesion is used for natural 
traction. it is called the Bridge Formation Method (BFM). We present the 
procedure of BFM and comparison of treatment results of BFM group and 
non-BFM group in our hospital.
Aims & Methods: From January 2009 to December 2018, colorectal ESD 
was performed in 1577 lesions consecutively at our hospital. There were 
867 cases for the BFM group and 710 cases for the non-BFM group. Flush 
Knife(FUJIFILM) and Distal attachment(Olympus) were used as the main 
devices. The procedure is as follows: 
1) Make a mucosal incision on the anal side of lesion, 
2) Advance submucosal dissection without mucosal incison of both lateral 
sides, 
3) Make a mucosal incision on oral side of lesion and fi nish almost sub-
mucosal dissection, 
4) Open the tunnel and bridge will be completed, 
5) At last make a mucosal incision on both lateral sides. 
The diff erence from the normal tunnel method is that almost submucosal 
dissection under the tumor is completed before mucosal incision on both 
lateral sides of lesion.
Results: In comparison with BFM group and non-BFM group, Aver-
age tumor size[27.0 ± 19.5 mm vs 25.0 ± 13.5 mm, P=0.017], morphology 
0-Is, 0-IIc, laterally spreading tumor-granular(LST-G), laterally spread-
ing tumor-non granular(LST-NG) [3.6%, 1.1%, 30.9%, 64.5% vs 1.7%, 
0.3%, 50.7%, 47.3%, P=0.000], localization [colon: rectum, 84.1%:15.9% 
vs 85.4%:14.6%, P=0.528], submucosal(SM) invasion≥1000µm [13.5%, 
117/867 vs 3.9%, 28/710, P = 0.000], en block resection rate [99.6%, 864/867 
vs 97.6%,693/710, P=0.000], R0 resection rate [98.2%, 851/867 vs 97.0%, 
689/710, P=0.181], average dissection speed [28.5 ± 17.2mm²/ min vs 24.9 ± 
18.3 mm²/ min, P < 0.001], perforation rate [1.4%, 12/867 vs 1.8%, 13/710, 
P=0.546], post-bleeding rate [1.4%, 12/867 vs 0.8%, 6/710, P = 0.351].
In BFM group, average tumor size was signifi cantly larger than non-BFM 
group, and the ratio of LST-NG was higher. 
There was no signifi cant diff erence in the localization of the lesions. The 
rate of SM massive invasion and en block resection rate were signifi cantly 
higher in BFM group. R0 resection rate was higher in the BFM group but 
there was no statistically signifi cant diff erence. Average dissection speed 
was signifi cantly faster in the BFM group, and there was no signifi cant dif-
ference in perforation rate and post-bleeding rate. 
The results in the BFM group that the ratio of LST-NG is high and the high 
SM massive invasion rate suggests the degree of fi brosis in submucosal 
layer is high, so treatment diffi  culty is high. Despite under these condi-
tions, the average dissection speed in the BFM group was signifi cantly 
faster, and the en block resection rate was signifi cantly higher.
Conclusion: The results suggests the usefulness of BFM is to leave the nor-
mal mucosa on both lateral sides of lesion for using the natural traction to 
the last of ESD. BFM enables stable manipulation under the lesion without 
using dedicated traction device, and dissection at an appropriate depth 
will be easier. Therefore, BFM is versatile method appropriate from normal 
lesions to diffi  cult lesions.
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Introduction: Endoscopic submucosal dissection (ESD) of colorectal lesions 
can be diffi  cult due to submucosal fi brosis, a thin muscularis or a poorly-
controlled colonoscope. To overcome these obstacles, the pocket-creation 
method (PCM) was developed and may be an ideal strategy for resecting 
all types of colorectal lesions. 
However, there are no randomized clinical trials to date assessing the ef-
fi cacy of the PCM for ESD of routine colorectal lesions compared with the 
conventional method (CM).
Aims & Methods: This study was designed as a randomized controlled 
parallel clinical trial in three tertiary-care hospitals. Patients with colorec-
tal neoplasms ≥20mm were enrolled and randomly allocated to PCM or 
CM. Patients were excluded if lesions were suspicious for deep (≥1mm) 
submucosal invasion; spread to the ileocecal valve, appendiceal orifi ce or 
diverticulum; recurrent lesions aft er endoscopic resection; infl ammatory 
bowel disease or familial adenomatous polyposis; and/or a bleeding ten-
dency. Randomization was conducted to minimize diff erences in lesion 
morphology, location (colon or rectum), and institution. The primary end-
point was ESD completion rate. “Completion” was defi ned as achieving an 
en-bloc resection within 3 hours, without changing the assigned strategy. 
Procedures were not complete with interruption of the ESD procedure for 
≥10 minutes, severe injury to the muscularis, or perforation/penetration. 
Secondary endpoints were en-bloc resection rate, cutting time, dissection 
speed and adverse events.
Results: A total of 121 patients were enrolled and randomly allocated to 
CM or PCM. Seven patients were excluded aft er randomization, and 59 
patients for PCM and 55 patients for CM fi nally included. Patient demo-
graphics and lesion characteristics showed no signifi cant diff erences be-
tween the two groups. The completion rate was signifi cantly higher in 
the PCM group compared to the CM group ( 93% [55/59] vs. 73 % [40/55]; 
P = .01). In contrast, en-bloc resection rates, cutting time and dissection 
speed were not signifi cantly diff erent comparing the two groups. Analysis 
of subgroups showed the PCM was better for colon lesions (P = .003), 
lesions 30 mm or larger (P = .03), lateral spreading tumor granular type 
or protruded morphology (P = .009), treatment in institution A (P = .001) 
and non-expert endoscopists (P = .003).The incidence of adverse events 
was similar in the two groups (delayed bleeding one in each group, and 
perforation one in the CM group). All adverse events were treated success-
fully with endoscopy.
Conclusion: The resection completion rate using the PCM is signifi cantly 
higher than the CM. The PCM is useful for routine ESD of colorectal lesions, 
not only for diffi  cult lesions. 
  PCM Group (n=59) CM Group (n=55)
Male/female Male (%) 
Female (%)
34 (58%) 25 (42%) 33 (60%) 22 (40%)
Median age (range, years) 70 (41-92) 68 (42-86)
Location- Cecum, Ascending, 
Transverse, Descending, 
Sigmoid, Rectum
8 (14%), 19 (33%), 9 (15%), 
2 (3%), 10 (17%), 11 (19%)
9 (16%), 16 (29%), 9 (16%), 
1 (2%), 8 (15%), 12 (22%)
Morphology- LST-G, 
Protruded, LST-NG
31 (53%), 3 (5%), 25 (42%) 28 (51%), 6 (11%), 21(38%)
Median estimated tumor 
size (range, mm)
30 (18-75) 30 (20-80)
Operator- Expert, Non-expert 27 (46%), 32 (54%) 28 (51%), 27 (55%)
Institution- A, B, C 27 (46%), 19 (32%), 13 (22%) 24 (44%), 14 (25%), 17 (31%)
[Baseline data of the treatment groups]
Disclosure: Dr. Yamamoto has patents for the double-balloon endoscope 
produced by Fujifi lm Corp. He also serves as a consultant for and has re-
ceived honoraria, grants, and royalties from Fujifi lm Corp. All other au-
thors disclosed no fi nancial relationships relevant to this publication. 
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OP185 IS THE SMSA SCORE ACCURATE ENOUGH TO 
PREOPERATIVELY PREDICT SUBOPTIMAL CLINICAL OUTCOMES 
IN COLORECTAL ENDOSCOPIC SUBMUCOSAL DISSECTION (CR-ESD)? 
A MULTICENTER SPANISH PROSPECTIVE STUDY
Marín-Gabriel J.1,2, Herreros de Tejada A.3,4, Zapata-Morcillo E.5, 
Ramos-Zabala F.6, Albéniz-Arbizu E.7, Rosón-Rodríguez P.8, 
Terán-Lantarón Á.9, Rodríguez Sánchez J.10, García-Romero D.11, 
Amorós Tenorio A.12, Sánchez-Yagüe A.13, Uchima Koecklin H.14, 
Del Pozo-García A.J.15, Dolz Abadia C.16, Fernández-Esparrach M.G.17, 
Santiago Garcia J.18, Nogales Rincón O.19, Alvarez Delgado A.20, 
Cortés-Pérez H.21, Durán-Bermejo R.22, Cañete Á.1, Arribas-Anta J.23, 
ESD Interest Group. Endoscopic Resection Working Group of the Spanish 
Society of Digestive Endoscopy
112 de Octubre University Hospital, Department of Gastroenterology, 
Endoscopy Unit, Madrid, Spain, 2HM Sanchinarro University Hospital, 
Gastroenterology. Endoscopy Unit, Madrid, Spain, 3Puerta de Hierro-
Majadahonda University Hospital, Gastroenterology. Endoscopy Unit, 
Majadahonda, Spain, 4MD Anderson Cancer Center, Madrid, Spain, 
5Donostia University Hospital, Gastroenterology. Endoscopy Unit, San 
Sebastián, Spain, 6Hospital Universitario HM Montepríncipe, Servicio de 
Aparato Digestivo, Boadilla del Monte, Spain, 7Complejo Hospitalario de 
Navarra, Servicio Aparato Digestivo, Pamplona, Spain, 8Hospital Quirón 
Salud Malaga, Gastroenterology. Endoscopy Unit, Malaga, Spain, 9Marques 
de Valdecilla University Hospital, Santander, Spain, 10Hospital General de 
Ciudad Real, Gastroenterology, Ciudad Real, Spain, 11Ntra. Sra. Candelaria 
University Hospital, Santa Cruz de Tenerife, Spain, 12Hospital Universitario 
Nuestra Señora de Candelaria, Endoscopy, Santa Cruz de Tenerife, Spain, 
13Hospital Costa del Sol, Gastroenterology, Marbella, Spain, 14Hospital 
Germans Trias i Pujol / Teknon Medical Center, M, Barcelona, Spain, 
15Hospital Universitario 12 de Octubre, Gastroenterology. Endoscopy Unit, 
Madrid, Spain, 16Son Llatzer, Palma de Mallorca, Spain, 17Hospital Clinic de 
Barcelona, Inst. de Malaties Digestives, Barcelona, Spain, 18Nottingham 
University Hospitals, Endoscopy, Majadahonda, Spain, 19Hospital Gregorio 
Marañon Dept. de Endoscopia Digestiva, Madrid, Spain, 20University Hospital 
of Salamanca Dept. of Gastroenterology, de Salamanca Endoscopist &, 
Salamanca, Spain, 21Hospital Urduliz, Digestivo, Madrid, Spain, 22Servidigest 
Institute, Gastroenterology. Endoscopy Unit, Barcelona, Spain, 23Hospital 
Universitario Doce de Octubre, Gastroenterology, Madrid, Spain
Contact E-Mail Address: josecarlos.marin@salud.madrid.org
Introduction: The SMSA (size, morphology, site, access) polyp scoring sys-
tem is a method for stratifying the diffi  culty of polypectomy. It was devel-
oped by an expert consensus using the Delphi method.
Aims & Methods: 
1. To assess the ability of SMSA to predict CR-ESD suboptimal clinical out-
comes (SCOs): excessive duration of the procedure and percentages of 
piecemeal resections, aborted procedures and complications. 
2. To develop a new preoperative model to predict those SCOs and com-
pare its performance with that of the SMSA.
Consecutive patients were enrolled in a prospective multicenter Spanish 
CR-ESD registry since January 2016 to October 2018. We analyzed 585 cases 
in 19 hospitals. The overall ability of the scores to discriminate between 
those who developed SCOs and those who did not was assessed by the 
area under the ROC curve.
Results: Overall, 221 cases (38%) developed any of the predefi ned SCOs. 
There were 13 aborted procedures (2.2%), 92 piecemeal resections 
(16.1%), 86 intraprocedural perforations (14.7%), 19 delayed perforations 
(3.4%) and 37 delayed bleedings (6.6%). There were 40 SMSA2 (6.8%), 
189 SMSA3 (32.3%) and 356 SMSA4 (60.8%) lesions. Surprisingly, SMSA2 
lesions were signifi cantly associated with piecemeal resections (SMSA2 vs 
SMSA3/4: 27.5% vs. 14.8%; OR= 0.5; CI95%: 0.2-0.9; p= 0.04). Statisti-
cally signifi cant diff erences were observed between intraprocedural per-
forations and SMSA3/4 lesions (SMSA2 vs. SMSA3/4: 2.5% vs. 15.6%; OR= 
7.2; IC95%: 1.01-53.1; p= 0.02). We did not observe statistically signifi cant 
association between higher SMSA scores and duration of the procedure > 
240 min., aborted procedures or delayed complications. The AUROC of the 
SMSA score >= 3 was 0.51 (CI95%: 0.46-0.55). Thus, an alternative logistic 
regression model was designed. It included signifi cant variables that were 
associated with the predefi ned outcomes in the univariate analysis: case 
load < 10 lesions: OR=4.5 (CI95%: 1.5-13.2; p= 0.007), poor manoeuvrabil-
ity, OR=1.6 (CI95%: 1.1-2.2; p= 0.007), size > 30 mm, OR=1.5 (CI95%: 1.01-
2.2; p= 0.02), LST-G mixed type with a nodule > 10 mm, OR=2.8 (CI95%: 
1.1-7.1; p= 0.03) and previous endoscopic electrosurgical treatment, OR=2.2 
OP184 COLONIC ESD WITH DOUBLE-CLIP TRACTION: 
A REVOLUTION COMING FROM EUROPE!
Jacques J.1, Albouys J.2, Brule C.2, Bordillon P.2, Rivory J.3, Legros R.4, 
Ponchon T.5, Sautereau D.6, Pioche M.7
1CHU Limoges, Hepato-Gastro-Enterology, Limoges, France, 2University 
Hospital Limoges, Limoges, France, 3Hopital Edouard Herriot, Lyon, France, 
4CHU Limoges, Limoges, France, 5Edouard Herriot University Hospital, 
Dept. of Digestive Diseases, Lyon, France, 6CHU Limoges Gastroentérologie, 
Limoges, France, 7Hospices Civils de Lyon, Gastroenterology and Endoscopy, 
Lyon, France
Contact E-Mail Address: jeremiejacques@gmail.com
Introduction: ESD in the colon is more challenging technically than other 
locations. 
This diffi  culty explain poor results of colonic RSD (except rectal cases) out-
side of japan with a low R0 resection rate, a high perforation rate and 
a long procedure time. Due to these bad results most European experts 
promotes piece-meal EMR instead of ESD for the endoscopic treatment of 
large benign colonic lesions.
Recently we presented our new systematic strategy for colonic ESD by 
countertraction by clips and rubber band that considerably facilitates the 
procedure. Here, we report a large prospective case series of colon ESD 
using this strategy.
Aims & Methods: Prospective consecutive sudy of all colonic ESD per-
formed prospectively two experts centers from April 2017 (First Colonic ESD 
with clips and rubber band) to April 2019. Since the fi rst case of colonic 
ESD with clips and rubber band in April 2017, all cases of colonic ESD were 
performed using this strategy.
Primary Endpoint: Monobloc, RO and curative resection rate.
Secondary Endpoints: Perforation rate, risk factors in multivariate analy-
sis of Perforation, R0 resection and Optimal ESD (defi ned by R0 resection 
without perforation and faster than 20mm2/min).
Results: 618 colorectal ESD were performed in the study period. Rectal 
cases (180) were excluded. About the 438 remaining colonic cases, ap-
pendiceal lesions, recurrent or partial resection lesions, dysplasia on IBD 
lesions and lesions invading diverticula were excluded. Finally 374 cases 
were included in the study performed by 4 operators in to experts centers.
Lesions were SMSA 4 in 82% of cases with a mean size of 55 mm. Mean 
duration procedure was 67 min with a min speed of resection at 38,7 mm2/
min. 63% of the lesions were located above the splenic fl exure.
Primary Endpoint: Monobloc, R0 and curative resection rate were respec-
tively 96%, 83% and 81%.
Secondary Endpoint:
- Perforation rate was 4,6%.
-predictive factors of optimal ESD were one operator (OR 3,9; p< 0,0001) 
and no F2 fi brosis (OR 4,3 p=0,0003), and ESD performed in 2018 à 2019 
(OR 7; p=0,0004) in multivariate analysis.
- predictive factors of non R0 resection were presence of perforation (OR 
0,32; p=0,05) and intense fi brosis (OR 0,30; p= 0,008).
- predictive factors of perforation were intense fi brosis (OR 18,4; p=0,03) 
and big size of the lesion (OR 1,037; p< 0,0001) in multivariate analysis.
Conclusion: Systematic countertraction using a double clip and rubber 
band facilitates colon ESD. Speed of ESD is twice as reported by recent Jap-
anese teams using Pocket creation Method whereas oncologic results are 
similar. This strategy should become the standard for colon ESD and help 
to widespread colonic ESD. Our results feeds the debate between piece-
meal EMR and ESD for the treatment of large colonic superfi cial lesions.
Disclosure: Nothing to disclose 
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(CI95%: 1.06-4.6; p= 0.03). The AUROC for this multivariate model was 0.61 
(CI95%: 0.57-0.66). The diff erence between both AUROCs was statistically 
signifi cant (p< 0.00001).
Conclusion: The SMSA score was useless to predict CR-ESD SCOs. A new 
score based on a multivariate logistic regression model showed a slightly 
better discrimination ability to predict these suboptimal events.
      Univariate Multivariate
Variable
Yes 
(n= 221)
No 
(n=364)
OR 
(CI 95%)
p
OR 
(CI 95%)
p
Size > 3 cm 151 (68.3) 219 (60.2) 1.43 (1.01-2.0) 0.04 1.55 (1.08-2.24) 0.02
LST-G mixed type 
nodule > 10 mm
13 (6) 8 (2.2) 2.78 (1.13-6.8) 0.02 2.83 (1.13-7.07) 0.03
Previous 
electrosurgery
18 (8.1) 15 (4.1) 2.06 (1.02-4.2) 0.04 2.21 (1.06-4.62) 0.03
Poor 
manoeuvrability
122 (55.2) 163 (4.8) 1.52 (1.08-2.1) 0.01 1.60 (1.13-2.25) 0.008
Case load < 10 12 (5.4) 5 (1.4) 4.12 (1.43-11.8) 0.005 4.48 (1.51-13.2) 0.007
[Suboptimal clinical outcomes. Univariate and multivariate analysis]
Disclosure: Nothing to disclose 
OP186 ENDOSCOPIC CLIPPING CLOSURE FOR PREVENTING 
POST-ESD COAGULATION SYNDROME AND PERFORATION 
(CLIPEC STUDY): A MULTICENTER, SINGLE-BLIND, RANDOMISED 
CONTROLLED TRIAL
Iwai T.1, Shimura T.2, Nomura S.2,3, Mizuno Y.4, Yamada T.4, Ebi M.5, 
Hirata Y.6, Katano T.2, Nishie H.2, Mizushima T.7, Nojiri Y.2, Togawa S.8,9, 
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2Nagoya City University Graduate School of Medical Sciences, Department 
of Gastroenterology and Metabolism, Nagoya, Japan, 3Nagoya City West 
Medical Center, Department of Gastroenterology, Nagoya, Japan, 4Japanese 
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Japan, 5Aichi Medical University School, Department of Gastroenterology, 
Nagakute, Japan, 6Kasugai Municipal Hospital, Department of 
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Department of Gastroenterology, Nagoya, Japan, 9Social Insurance Chukyo 
Hospital, Department of Gastroenterology, Nagoya, Japan, 10Nagoya City East 
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Contact E-Mail Address: towonder66@gmail.com
Introduction: Endoscopic submucosal dissection (ESD) has been widely 
applied as an endoscopic treatment for superfi cial colorectal neoplasms, 
however some complications occasionally occur aft er ESD, including de-
layed perforation and post-ESD coagulation syndrome (PECS). The PECS 
reveals abdominal pain, infl ammation and fever without perforation aft er 
ESD, but the exact cause and epidemiology of PECS remain unknown. We 
thus conducted a randomized controlled trial (CliPEC study) to assess use-
fulness of endoscopic clipping closure for prevention of PECS and delayed 
perforation.
Aims & Methods: CliPEC study is a multicenter, single-blind randomized 
controlled trial. Patients who will receive ESD for superfi cial colorectal 
neoplasms were prospectively enrolled, and randomly allocated to ESD 
followed by endoscopic clipping closure (the closure group) and non-clo-
sure (the non-closure group), stratifying by institution and tumor size. Ac-
cording to pre-planned protocol, this study was analyzed for full analysis 
set: patients who could not endoscopically resect tumor and develop to 
perforation during ESD were excluded from this analysis. All participants 
routinely received computed tomography (CT) scan and blood examination 
on day 1 aft er ESD and pain severity was assessed on day 1-3 aft er ESD us-
ing visual analogue scale (VAS). PECS was defi ned as VAS ≥30mm, a raise 
of VAS ≥20mm from baseline, BT ≥37.5ºC or WBC ≥10,000/µl aft er ESD. 
Delayed perforation was defi ned as PECS accompanied with peri-luminal 
air (minor) or intra-abdominal free air (major).
Primary endpoint of this study was the rate of PECS and delayed perfora-
tion. Pre-planned sample size was 320 patients by estimating that clipping 
closure decrease the rate of PECS and delayed perforation from 15% to 
5% with overall 2-sided-α and β errors of 0.05 and 0.20, and allowing 
an approximate 10% dropout rate. According to O’Brien Fleming type α 
spending rule, 2 sided α levels of 0.0056 and 0.044 were defi ned for the 
interim and fi nal analysis, respectively. 
(University Hospital Medical Network Clinical Trials Registry, Number: 
UMIN000027031)
Results: At the planned interim analysis with a half of study enrollment, 
this trial was terminated by recommendation of the independent data and 
safety monitoring committee because conditional power with superiority 
of closure to non-closure (0.12%) was less than pre-planned futility limit 
of 20% in the interim analysis.
In total, 181 patients were enrolled from April 2017 to August 2018 at 10 
Japanese institutions, and 155 patients aft er exclusion (2: protocol vio-
lation for criteria, 3: consent withdrawal, 9: perforation during ESD, 12: 
no-completion of ESD) were fi nally analyzed including 71 patients in the 
closure group and 84 patients in the non-closure group. Patient and tumor 
characteristics were well balanced between 2 groups. The rate of PECS and 
delayed perforation was 23.9% (PECS: 19.7%, delayed perforation: 4.2%) 
in the closure group and 15.5% (PECS: 11.9%, delayed perforation: 3.6%) 
in the non-closure group, respectively (P=0.184). All cases with delayed 
perforation were within minor criteria, and all patients with PECS and 
delayed perforation were conservatively improved without emergency sur-
gery. Interestingly, 15.5% (13/84) in the non-colure group and 9.9% (7/71) 
in the closure group revealed simple extra-luminal air without any symp-
toms aft er ESD.
Conclusion: Endoscopic clipping closure could not reduce the incidence 
of PECS and delayed perforation aft er colorectal ESD. Colorectal ESD has 
been safely managed in a clinical practice.
Disclosure: Nothing to disclose 
OP187 COVERT CARCINOMA AMONG RECTAL ESD SPECIMEN IS 
HIGH: A EUROPEAN TERTIARY CENTER PROSPECTIVELY COLLECTED 
EXPERIENCE
Figueiredo Ferreira M.1, Bucalau A.-M.2, Huberty V.3, Verset L.4, Maris C.5, 
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Jules Bordet, Bruxelles, Belgium, 5Erasme Hospital, ULB, Department of 
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Chirurgie Digestive, Bruxelles, Belgium
Contact E-Mail Address: mariana.fi g.ferreira@gmail.com
Introduction: Endoscopic resection (ER) represents the treatment of choice 
for superfi cial rectal lesions. Careful assessment of the lesions is crucial for 
decision making in order to optimize outcomes for the patient. Endoscopic 
submucosal dissection (ESD) is becoming increasingly common in Western 
countries and is currently proposed by the European Society of Gastroin-
testinal Endoscopy (ESGE) for the resection of large lesions due to the risk 
of harbouring a superfi cial invasive cancer 
The rate of covert SMIC (unpredicted submucosal invasive cancer found on 
the specimen) has been described among endoscopic mucosal resection 
(EMR) specimen but is poorly known for rectal ESD in Europe.
Aims & Methods: In the current study, we aim to evaluate the rate of co-
vert carcinoma among ESD specimen. Furthermore, we assess the effi  cacy 
and safety of this treatment approach in one European academic tertiary 
center. 
Clinical and technical data from Erasme Hospital (Brussels) was systemati-
cally and prospectively collected from June 2015 to March 2019. Covert car-
cinoma is defi ned as no suspicion of cancer in the rectal lesion based on 
pit pattern analysis and pre-ESD biopsies if available. Complete resection 
(R0) is defi ned as no carcinoma and no adenoma on the margins. Curative 
resection is defi ned as en bloc R0 resection of a superfi cial lesion, well-
diff erentiated adenocarcinoma (G1/G2), sm1 (≤1mm submucosal invasion, 
with no lymphovascular invasion, as defi ned by the ESGE). Procedure-as-
sociated complications and recurrence rate were also assessed.
Results: Fift y-seven patients, mostly men (57.9%), with a mean age of 67 
[30-85] years underwent ESD for a superfi cial rectal lesion. Most of the 
lesions were laterally spreading tumors (64.9%), large buldging polyps 
representing 28.1%, mostly located in the upper rectum (> 5 cm from the 
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SSCAI was 4 (IQR: 2-5). Amongst the separate IBD-disk items ‘the lack of 
energy’-item had the highest mean score: 5.3 (SD: 3), whereas the ‘sexual 
dysfunction’-item had the lowest score: 2.4 (SD: 2.6). There was a signifi -
cant strong correlation between SCCAI and the cumulative score of all IBD 
disk items (r=0.68), regulating defecation (r=0.60), interpersonal relations 
specifi cally (0.61) and lack of energy (r=0.62) (all p< 0.0001). The correla-
tion with the other items were moderate to weak (r< 0.6).
Conclusion: This is the fi rst study prospectively validating the use of the 
IBD-disk in a large cohort. Correlation with disease activity was strong in 
UC and moderate in CD. Since lack of energy was the dominant item of the 
IBD disk and an overall weak correlation between the standard activity 
indices and psychosocial items, the IBD-disk provides a more detailed and 
holistic evaluation of the patient with IBD.
References: 1. Ghosh S, Louis E, Beaugerie L, et al. Development of the IBD 
Disk: A Visual Self-administered Tool for Assessing Disability in Infl amma-
tory Bowel Diseases. Infl amm Bowel Dis 2017;23:333-340.
Disclosure: MB received travel grants from Takeda. LP received travel 
grants from Abbvie, Ferring and Takeda. PB has received educational 
grants from AbbVie, Mundipharma, Janssen and Pfi zer; speaker fees from 
AbbVie, Takeda, Pfi zer and Janssen; and advisory board fees from Hospira, 
Janssen, MSD, Mundipharma, Sandoz, Pentax, Abbvie, Takeda. All other 
authors declare no confl icts of interest. 
OP189 CT-SCOUTTM PLATFORM, THE DIGITAL SOLUTION TO 
BOOST PATIENT RECRUITMENT IN INFLAMMATORY BOWEL DISEASE 
CLINICAL TRIALS: A MULTICENTER PROSPECTIVE OBSERVATIONAL 
COMPARATIVE STUDY INVOLVING 134 SITES AND 644 PATIENTS IN 6 
COUNTRIES
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Introduction: The main issue to validating new molecules in the fi eld of 
IBD is insuffi  cient patient enrollment into clinical trials, resulting in pre-
mature trials termination and cost increase. CT-SCOUT™ platform is a web-
based solution built by the GETAID to help clinicians to pre-screen poten-
tial candidates at their site and facilitating the coordination of the research 
team. It is customized per site giving access to all academic and selected 
industrial trials in active recruitment period.
Aims & Methods: The aim of the current assessment was to evaluate the 
added value of CT-SCOUT™ platform in patient enrollment in industrial 
IBD clinical trials. We conducted a prospective, multicenter, open-label, 
observational study in equipped sites in France and in non-equipped sites 
in diff erent countries participating to two phase 3 trials evaluating the ef-
fi cacy and safety of etrolizumab in ulcerative colitis (UC, Hickory) and in 
Crohn’s disease (CD, Bergamot) participants previously exposed or naïve 
to anti-TNF. Patients’ recruitment in the 21 sites in France equipped with 
CT-SCOUT™ at the time of studies launch was compared to the 113 sites 
non-equipped with the app located in 4 European countries [Belgium 
(n=14), Germany (n=41), Spain (n=19), United Kingdom (n=26)] and in Is-
rael (n=13). The primary endpoint was the mean patient randomization 
rate per site for both studies. Secondary endpoints included mean number 
of patients screened and randomized in Hickory, Bergamot and in both 
studies. Patients who signed study informed consent (screened) and those 
fi nally randomized were compared in sites equipped and non-equipped 
with CT-SCOUT™ using one-way ANOVA followed by post-hoc Tukey test 
and Mann-Whitney test.
Results: During the observational period of 27 months (Sept 2015 - Dec 
2018), 644 and 289 patients were screened and randomized in 134 sites in 
Hickory and Bergamot trials, respectively. There were 307 and 149 patients 
in 78 sites for Hickory, and 337 and 140 patients for Bergamot in 102 sites. 
The mean numbers of included and randomized patients were signifi cant-
ly higher in equipped centers compared to non-equipped centers in both 
pooled and separate analysis (Table 1).
anal margin: 61.4%), with a mean size of 49 [10-130] mm. Endoscopic 
characterization revealed mainly Paris O-Is-IIa lesions (58%). Mean dura-
tion of the procedure was 136 [41-480] minutes.
En bloc resection was achieved in 98.2% of patients and R0 resection in 
58.9%. Histopathological examination displayed (31.6%, 18/57) adeno-
carcinomas comprising 50% (9/18) pTis tumors, 39% (7/18) pT1sm2/sm3 
and 11% (2/18) T2 lesions. Curative oncological resection was obtained in 
44.4% (8/18) of patients with carcinoma. All the pTis and 3 of the pT1sm2/
sm3 were not suspected to be carcinoma at the fi rst evaluation giving a 
covert carcinoma rate of 21% (12/57) and a covert SMIC rate of 5% (3/57).
Three out of 4 patients proposed for complementary surgery underwent 
a surgical treatment and the histopathological examination showed no 
residual tumor on the specimen nor on lymphadenopathies. 
Altogether, 95% of the patients had no complication needing an inter-
vention: 2 presented delayed bleeding managed endoscopically and one 
patient presented stenosis that was calibrated aft er one balloon dilation.
A 6 months endoscopy follow-up was obtained in 22 patients disclosing 
a free-recurrence rate of 100%, in favor of coagulation artefacts on the 
specimen seeing the 58% R0 (no adenoma on margins) rate.
Conclusion: ESD for superfi cial rectal lesions is showing favorable results 
in terms of effi  cacy and safety. A 21% rate of covert carcinoma among 
rectal large polyps underline the added value of using ESD compared to 
piece-meal resections.
Disclosure: Nothing to disclose 
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OP188 THE IBD-DISK PROVIDES A DETAILED DISEASE ACTIVITY 
AND DISABILITY ASSESSMENT IN PATIENTS WITH INFLAMMATORY 
BOWEL DISEASE: THE IBD-DISK VALIDATION AND PERFORMANCE 
STUDY
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Introduction: Various instruments have been developed to assess infl am-
matory bowel disease (IBD)-related disability, but these tools are oft en 
time consuming and diffi  cult to use in an outpatient setting. The IBD Disk 
is a fast and self-administered 10-item visual instrument developed to 
overcome these limitations1. Data on the correlation of the IBD disk with 
standard activity indices are lacking.
Aims & Methods: The aim of this study was to validate the performance of 
the IBD Disk in clinical practice and to correlate the IBD disk with standard 
clinical activity indices in IBD. 
We prospectively evaluated consecutive patients with IBD in an outpatient 
setting between April 1th 2018 and December 31th 2018. All patients com-
pleted the questionnaire of the IBD disk (10 items scored from 0 to 10). In 
addition, the stool frequency and abdominal pain patient reported out-
come (PRO-2) of the Clinical Disease Activity Index were assessed for pa-
tients with Crohn’s disease (CD), whereas the Simple Clinical Colitis Activity 
Index (SCCAI) was used for patients with ulcerative colitis (UC) and IBD 
unspecifi ed (IBD-U). All questionnaires were recorded by an e-health pre-
assessment digital tool before the actual clinical visit. Correlation analysis 
between the scores was performed using Pearson’s product-moment cor-
relation coeffi  cient.
Results: Two hundred fi ft y two evaluations were performed amongst 146 
patients (83 CD, 59 UC, 4 IBD-U). In patients with CD, the median PRO-2 
score was 4.7 (IQR: 1.6-10). Amongst the separate IBD-disk items, the ‘lack 
of energy’-item had the highest mean score: 4.8 (SD: 3.1), whereas the 
‘negative impact on interpersonal relations’-item had the lowest score: 
2.1 (SD: 3). 
There was a signifi cant moderate correlation between the PRO-2 and the 
cumulative score of all IBD disk items (r=0.53), abdominal pain (r=0.56), 
regulating defecation (r=0.59), interpersonal relations (0.41) and educa-
tion/work (r=0.48) (all p< 0.0001). The correlation with the other items 
were weak to very weak (r< 0.4). In patients with UC or IBD-U, the median 
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The mean number of patients randomized in Hickory in CT-SCOUT™ sites 
has been increased by 4.04 folds as compared to non-equipped sites 
(p< 0.001). The mean number of patients randomized in Bergamot in 
CT-SCOUT™ sites has been increased by 1.88 folds as compared to non-
equipped sites (p=0.009).
Conclusion: This is the fi rst multicentric international study to demonstrate 
a dramatic increase in patient recruitment in IBD clinical trials, with ran-
domization rates twice to four times higher during Crohn’s disease and ul-
cerative colitis in sites equipped with the app versus those non-equipped. 
CT-SCOUT™ appears to be a promising and easy-to-use digital solution to 
the global issue of patient enrollment in clinical trials in reducing clini-
cal trial duration, and allowing new drug candidates to be available to 
patients earlier.
 
French sites 
equipped with 
CT-SCOUTTM
Sites from other 
countries non-equipped 
with CT-SCOUTTM
p
Screened in both studies (UC + CD) 7.55 3.05 p<0.001
Randomized in both studies (UC + CD) 3.79 1.28 p<0.001
Screened in Hickory (UC) 9.17 3.14 p<0.001
Randomized in Hickory (UC) 5.17 1.28 p<0.001
Screened in Bergamot (CD) 5.94 2.95 p=0.003
Randomized in Bergamot (CD) 2.41 1.28 p=0.003
[Table 1]
References: 1 Use of digital technology to boost patient recruitment in in-
fl ammatory bowel disease clinical trials. J Crohns Colitis, 2017; 1027 (doi: 
10.1093/ecco-jcc/jjx002.177)
Disclosure: Nothing to disclose 
Holistic management of IBD patients
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OP190 EPIGENETIC PROFILING OF BLOOD FROM PATIENTS WITH 
PRIMARY SCLEROSING CHOLANGITIS AND ULCERATIVE COLITIS 
COMPARED TO PATIENTS WITH ULCERATIVE COLITIS AND HEALTHY 
CONTROLS
de Krijger M.1,2, Li Yim A.Y.F.3, Henneman P.3, Wildenberg M.E.2, 
de Jonge W.J.2, Ponsioen C.Y.1
1Amsterdam UMC, University of Amsterdam, Department of Gastroenterology 
and Hepatology, Amsterdam, Netherlands, 2Amsterdam UMC, University of 
Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam, 
Netherlands, 3Amsterdam UMC, University of Amsterdam, Department of 
Clinical Genetics, Genome Diagnostics Laboratory, Amsterdam, Netherlands
Contact E-Mail Address: m.dekrijger@amsterdamumc.nl
Introduction: The aetiology of primary sclerosing cholangitis (PSC) is un-
known. The concurrence of PSC and infl ammatory bowel disease (IBD) 
has led to various hypotheses linking these two disease entities, e.g. the 
aberrant gut-lymphocyte homing in IBD contributing to PSC. This mecha-
nism may be due to genetic predisposition of the host and/or epigenetic 
changes in circulating lymphocytes. Epigenetic changes in blood cells have 
been described in the context of IBD: the DNA methylome of patients with 
ulcerative colitis (UC) diff ers from patients with Crohn’s disease (CD) and 
healthy controls (HC) (1).
Aims & Methods: We hypothesized that the peripheral blood DNA methy-
lome of patients with concurrent PSC and UC is distinct from that of UC 
patients without PSC and healthy controls.
DNA was isolated from peripheral blood samples from 18 PSC-UC and 17 UC 
patients, as well as 12 healthy controls. Only male patients were selected, 
and groups were matched for age (mean age 41, 40 and 40 years for PSC-
UC, UC and HC, respectively), UC duration (15 and 11 years for PSC-UC and 
UC patients, respectively) and medication use (all PSC-UC and UC patients 
used Mesalazine, 50% used Thiopurins and none used biologicals). Aft er 
bisulfi te conversion, DNA methylation was determined using the Illumina 
HumanMethylation Infi nium BeadChip (850K) EPIC microarray. Addition-
ally, in a hypothesis driven approach, changes in genes associated with 
PSC from previous genome wide association studies (GWAS) as well as 
genes involved in lymphocyte traffi  cking were assessed (2, 3).
Results: In a non-biased approach, no signifi cantly diff erentially methyl-
ated positions (DMPs) or regions (DMRs) were identifi ed when comparing 
PSC-UC with UC or HC. Principal component analysis revealed no clear 
separation or clustering of the diff erent groups, and no statistically signifi -
cant diff erences were found when comparing PSC-UC with UC or PSC-UC 
with HC. 
In a hypothesis driven analysis, 52 genes associated with PSC, identifi ed 
from previous studies, were specifi cally analysed. We observed that two 
genes, BACH2 and ASAP2, were signifi cantly diff erentially methylated in 
PSC-UC compared to UC patients. In addition, comparison of PSC-UC with 
healthy controls showed that the genes FOXP1, UBASH3A, BACH2, DDIT4, 
CD28, TNFAIP6, SOCS3 and ITGB1 were diff erentially methylated, although 
eff ect sizes were limited (< 20%).
Conclusion: We observed only limited diff erences in the genome-wide DNA 
methylomes that were associated with the presence of PSC. We conclude 
that the total peripheral blood methylome does not discriminate PSC-UC 
from UC alone. The diff erential methylation of BACH2, a gene that plays a 
role in regulating memory T-lymphocyte diff erentiation, is of interest in 
the context of mistargeted lymphocyte homing in PSC, and could be an 
interesting target for further studies.
References: (1) McDermott E, Ryan EJ, Tosetto M, Gibson D, Burrage J, 
Keegan D, et al. DNA Methylation Profi ling in Infl ammatory Bowel Dis-
ease Provides New Insights into Disease Pathogenesis. J Crohns Colitis. 
2016;10(1):77-86. (2) Chung BK, Hirschfi eld GM. Immunogenetics in primary 
sclerosing cholangitis. Current opinion in gastroenterology. 2017;33(2):93-
8. (3) Aoki CA, Dawson K, Kenny TP, Gershwin ME, Bowlus CL. Gene expres-
sion by PBMC in primary sclerosing cholangitis: evidence for dysregulation 
of immune mediated genes. Clin Dev Immunol. 2006;13(2-4):265-71.
Disclosure: AYFLY is an employee at GSK. MEW received Speaker fees from 
Takeda, Tillotts, research grants from Glaxo Smith Kline CYP received re-
search grants form Takeda, speaker’s fees from Takeda, Tillotts, and Ab-
bvie, and consultancy fees form Takeda and Pliant. 
OP191 IMMUNOGENICITY OF USTEKINUMAB IN PATIENTS WITH 
CROHN’S DISEASE: RESULTS FROM THE IM-UNITI STUDY
Sandborn W.J.1, Sands B.E.2, Nussbaum J.3, Oortwijn A.4, Gasink C.5, 
Jacobstein D.6, Gao L.-L.7, Adekokun O.J.7, de Villiers W.8, Ghosh S.9
1University of California, San Diego, United States, 2Icahn School of Medicine 
at Mount Sinai, Division of Gastroenterology, New York, United States, 
3Janssen Scienti c A airs, LLC, Immunology-GI, Horsham, United States, 
4Janssen Biologics BV, Leiden, Netherlands, 5Janssen Scienti c A airs, LLC, 
Horsham, United States, 6Janssen Research & Development, Immunology 
Development GI, Spring House, United States, 7Janssen Research & 
Development, LLC, Spring House, United States, 8Stellenbosch University, 
Stellenbosch, South Africa, 9Institute of Translational Medicine, Birmingham, 
United Kingdom
Contact E-Mail Address: wsandborn@ucsd.edu
Introduction: Patients (pts) with moderately to severely active Crohn’s dis-
ease (CD) who completed induction treatment with IV ustekinumab (UST) 
were eligible for a study of maintenance treatment with SC UST or placebo 
(PBO). Previous analyses of randomized pts who did not undergo dose 
adjustment in the maintenance study showed that rates of antibody for-
mation were higher for those who received a single IV UST induction dose 
and SC PBO maintenance (4.9%) than those who received IV UST induc-
tion and SC UST maintenance (2.9% and 2.0% for q12w and q8w groups, 
respectively). The aim of this analysis was to further characterize pts who 
had antibodies to UST in the maintenance study, including randomized 
and nonrandomized pts.
Aims & Methods: In the induction trials (UNITI-1, n=741; UNITI-2, n=628), 
pts were randomly assigned to a single dose of IV PBO or UST (130 mg or 
~6 mg/kg). Pts who responded to UST induction were randomly assigned 
to SC PBO or UST 90mg (q12w or q8w) at Wk 0 of the maintenance study 
(IM-UNITI) (n=397). Randomized pts who lost response between Wks 8 
and 32 were eligible for dose adjustment to UST 90mg q8w. Nonrandom-
ized pts (n=884) received SC UST q12w or UST q8w. Blood samples drawn 
at baseline and Wk 6 in the induction trial and Wks 12, 24, 36, and 44 in 
the maintenance trial were evaluated for antibodies to UST using a vali-
dated, drug-tolerant electrochemiluminescence immunoassay. Analysis 
set included all pts who were treated in the maintenance study, received 
≥1 dose of UST induction or maintenance, and had ≥1 sample evaluable for 
antibodies from induction Wk 6 through maintenance Wk 44.
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OP192 EFFECT OF ANTI-TNF-α TREATMENT IN PRIMARY 
SCLEROSING CHOLANGITIS
Hedin C.R.H.1,2, Sado G.3, Lytvyak E.4, Mason A.L.4, Montano-Loza A.5, 
Gerussi A.J.6, Thorburn D.6, Nilsson E.7, Larsson G.8, Moum B.A.9, 
van Munster K.N.10, Ponsioen C.Y.10, Levy C.11, Nogueira N.12, Bowlus C.L.13, 
Gotlieb N.B.14, Shibolet O.14, Lynch K.D.15, Chapman R.W.15, Rupp C.16, 
Vesterhus M.17, Jørgensen K.K.18, Rorsman F.19, Schramm C.20, Sabino J.21, 
Vermeire S.21, Zago A.22, Cazzagon N.22, Marschall H.-U.23, Ytting H.24, 
Ben Belkacem ‎K.25, Chazouilleres O.25, Almer S.1,2, Bergquist A.1,2, IPSCSG
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Division of Medicine, Oslo, Norway, 9Oslo University Hospital, Ullevål, 
Department of Gastroenterology and Hepatology, Division of Medicine, Oslo, 
Norway, 10Academic Medical Center, Department of Gastroenterology and 
Hepatology, Amsterdam, Netherlands, 11University of Miami Miller School 
of Medicine, Division of Hepatology, Miami, United States, 12University of 
Miami, Schi  Center for Liver Diseases, Miami, United States, 13University of 
California Davis, Division of Gastroenterology and Hepatology, Department of 
Internal Medicine, Sacramento, United States, 14Sourasky Medical Center and 
Tel Aviv University, Department of Gastroenterology and Hepatology, Tel Aviv, 
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of Gastroenterology and Hepatology, Leuven, Belgium, 22University of 
Padova, Department of Surgery, Oncology and Gastroenterology, Padova, 
Italy, 23Sahlgrenska Academy and University Hospital, Department of 
Molecular and Clinical Medicine, Institute of Medicine, Gothenburg, Sweden, 
24Rigshospitalet, Department of Medical Gastroenterology, Hvidovre Hospital 
and Department of Hepatology, Copenhagen, Denmark, 25Saint-Antoine 
Hospital, French Reference Center for In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and French Network for Rare Liver Diseases (FILFOIE), Paris, France
Contact E-Mail Address: charlotte.hedin@ki.se
Introduction: Few patients with primary sclerosing cholangitis and infl am-
matory bowel disease (PSC-IBD) are exposed to anti-TNF-α drugs due to 
the oft en mild nature of the IBD. This study assessed the eff ect of anti-
TNF-α drugs on liver function and their effi  cacy in treating IBD in in PSC-
IBD patients. The eff ect of anti-TNF-α drugs in liver transplant (LTx) PSC-
IBD was also considered.
Aims & Methods: A retrospective analysis of 141 PSC-IBD patients receiving 
anti-TNF-α at 20 sites across Europe and North America was carried out 
via the International PSC Study Group (IPSCSG). Eighty-nine (63%) were 
male, 84 (60%) had UC, 52 (37%) had CD and 5 (4%) had indetermi-
nate colitis; 110 (78%) received infl iximab (IFX) and 31 (22%) adalimumab 
(ADA). Eff ects on alkaline phosphatase (ALP), IBD activity (response de-
fi ned endoscopically or where endoscopic data were lacking clinical re-
sponse as determined by physician assessment, or calprotectin < 250 µg/g 
or ≥30% drop in calprotectin; remission defi ned as endoscopic healing, or 
where endoscopic data were lacking, as clinical remission as determined 
by physician assessment), PSC related symptoms, and adverse events were 
recorded. Linear regression analyses were carried out to identify signifi -
cant predictors of ALP during anti-TNF-α treatment.
Results: Lever biochemistry was available for 90 patients during the fi rst 
4 months of treatment of which 67 (74%) received IFX and 23 (26%) ADA. 
There was no signifi cant diff erence in the proportion of patients with 
raised ALP at baseline between IFX (n=40, 60%) and ADA (n=13, 57%, 
p=0.50[CH1] ). Patients treated with IFX experienced a median 4% reduc-
tion (IQR -25 to +19%, n=67) in ALP compared with median 15% (IQR -29 to 
-4%, n=23) reduction for ADA, (p=0.035). This diff erence was also appar-
ent at 12 months, although non-signifi cant (IFX median 2% reduction in 
Results: Of the 914 pts who received UST in the induction trials, 2(0.2%) 
were positive for antibodies through Wk 8. Of the 1,154 pts who were 
treated in the maintenance study, received UST in the induction or main-
tenance study, and had samples that were appropriate for antibody test-
ing, 27(2.3%) had antibodies detected through Wk 44. Among the 27 pts 
who were positive for antibodies, 7 had at least one sample with high 
titers (>1:800), 7 had positive samples at ≥3 visits including Wk 44, and 7 
were receiving immunomodulators at baseline (Table). No pts had infu-
sion or injection-site reactions at the visit they were positive for antibod-
ies. Among pts who were receiving UST maintenance, median trough UST 
serum concentrations at the visits of the positive antibody results were 
0.18 and 0.72 µg/mL for pts whose highest antibody titers were >1:800 and 
≤1:800, respectively.
Conclusion: Antibodies to UST were uncommon in pts with CD who re-
ceived induction and maintenance treatment with UST. When antibodies 
did occur, they were usually transient and low titer.
    Nonresponders to IV Induction  
 
Responders 
to UST IV 
induction 
→PBOa
Placebo IV 
and UST 
maintenance 
→q12wb
UST IV and UST 
maintenance 
→q8wc
Total
Analysis setd 396 284 474 1,154
Patients positive for 
antibodies to UST, n (%)e
14 (3.5%) 4 (1.4%) 9 (1.9%) 27 (2.3%)
Before any UST dose 1 1 0 2
1 visit then negative 8 0 2 10
Wk 44 only 1 1 0 2
Safety follow-up visit only 0 0 1 1
2 visits then negative 3 1 0 4
Wks 36 and 44 only 0 1 0 1
≥3 visits including Wk 44 1 0 6 7
Received 
immunomodulators at 
baseline
4 1 2 7
Total number of positive 
antibody test results, n
23 6 29 58
Patients with highest 
antibody titer >1:800, n (%)
2 2 3 7
a Includes patients who were in clinical response to ustekinumab IV induction and were 
randomized in the maintenance study to ustekinumab or placebo.
b Includes patients who did not respond to IV placebo induction, were not randomized 
in the maintenance study, received ustekinumab 130 mg IV at Week 0 of the maintenance 
study, achieved clinical response at Week 8, and initiated ustekinumab 90 mg SC q12w.
c Includes patients who did not respond to IV ustekinumab induction, were not 
randomized in the maintenance study, received ustekinumab 90 mg SC at Week 0 of the 
maintenance study, achieved clinical response at Week 8, and initiated ustekinumab 90 
mg SC q8w.
d Patients who were treated in the maintenance study, received ≥1 dose of ustekinumab 
in either the induction or maintenance studies, and had ≥1 samples that were evaluable 
for antibodies from induction Week 6 through maintenance Week 44.
e Patients who had at least 1 positive sample at any time from induction Week 6 through 
maintenance Week 44.
[Summary of antibody to ustekinumab status through Wk 44 of the 
maintenance study for pts who were treated with ustekinumab induction or 
maintenance]
Disclosure: William J. Sandborn, MD, Bruce E. Sands, MD, Willem J. de 
Villiers, MD, PhD, Subrata Ghosh, MD are all investigators for Janssen Re-
search & Development, LLC Jeannette Nussbaum, PhD, MS is an employee 
of Janssen Pharmaceuticals Alessandra Oortwijn, MD, PhD is an employee 
of Janssen Europe Christopher Gasink, MD is an employee of Janssen Sci-
entifi c Aff airs, LLC Douglas Jacobstein, MD,Long-Long Gao, PhD, Omoniyi 
J. Adekokun, MS, RPh, are all employees of Janssen Research & Develop-
ment, LLC 
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ALP (IQR -20 to +32%, n=56), ADA median 20% reduction (IQR -32 to +9%, 
p= 0.084, n=16)). In regression analysis normal ALP at baseline (p < 0.01), 
treatment with ADA (p=0.090) and European site (p=0.083) were found to 
be predictive of lower ALP, (F(3,61)=18.86, p< 0.001) R2= 0.47. IBD-response 
rate to anti-TNF-α treatment was 48% and the remission rate was 23%. 
There was no diff erence between IFX and ADA in the frequency of PSC 
symptoms aft er drug exposure. Ten additional patients who underwent 
LTx prior to anti-TNF-α were analysed: neither ALP nor bilirubin changed 
signifi cantly during the study, however the small numbers precluded com-
parison of IFX and ADA. The proportion of post-LTx patients whose IBD 
responded to anti-TNF-α was not signifi cantly diff erent compared with 
non-LTx patients, (p=0.69). Data regarding the eventual reasons for anti-
TNF-α discontinuation were available for 72 patients who were exposed 
to anti-TNF-α for a median of 415 days (IQR 176-1735). The most common 
reasons for anti-TNF-α discontinuation were primary IBD non-response 
(30%) and adverse event (32%). Reasons for stopping anti-TNF-α were 
also similar between LTx and non-LTx patients.
Conclusion: Serum ALP improved during treatment with ADA but not IFX 
in PSC-IBD patients, indicating possible advantages for ADA in treating 
PSC patients with IBD. There is no obvious explanation for this diff erence 
between the two anti-TNF-α agents. However, overall IBD-response rates 
to anti-TNF-α appeared to be lower than in the absence of PSC. Post-LTx 
patients had similar IBD-response rates to anti-TNF-α drugs and similar 
adverse events compared with non-LTx patients.
Disclosure: Nothing to disclose 
OP193 IDENTIFICATION OF RISK FACTORS ASSOCIATED WITH LOSS 
OF RESPONSE TO USTEKINUMAB IN CROHN’S DISEASE
Hanauer S.B.1, Sands B.E.2, Feagan B.G.3, Oortwijn A.4, van Kruchten R.4, 
Laliman V.5, Izanec J.6, Adedokun O.J.7, Gao L.-L.8, Sloan S.9, Gasink C.6, 
Targan S.10, de Villiers W.11, Rutgeerts P.12, Colombel J.-F.13, Ghosh S.14
1Feinberg School of Medicine, Northwestern University, Chicago, 
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Kingdom
Contact E-Mail Address: ghoshs@bham.ac.uk
Introduction: Ustekinumab (UST) therapy induced and maintained re-
sponse and remission in patients with moderate-to-severe Crohn’s dis-
ease (CD) in induction, maintenance, and 2-year extension trials in the IM-
UNITI program. Secondary loss of response (LoR) was observed in some 
patients during follow-up. This post-hoc analysis aims to characterize and 
identify potential predictors of LoR through 2 years of UST (Wk 96).
Aims & Methods: The analysis included initial responders (IR) to UST IV at 
Wk 8 who were randomized to 90 mg SC UST q8w or q12w maintenance 
therapy and delayed responders (DR: responders at Wk 16 aft er not achiev-
ing clinical response at Wk 8; subsequently received UST q8w). LoR was 
defi ned as CDAI score ≥220 and a ≥100-point increase in CDAI score from 
Wk 8 or 16. Discontinuation due to lack of effi  cacy was also considered LoR, 
while patients who discontinued for other reasons were excluded from 
the analysis. Baseline (BL), Wk 8, and Wk 16 variables were described for 
LoR and no LoR patients. Univariate and multivariate logistic regression 
modeling was conducted on BL and Wk 8/16 variables.
Results: This analysis included 473 patients, of whom 191 (40.4%) met cri-
teria for LoR through Wk 96: 36.6% among IR randomized to UST q8w, 
37.6% among IR randomized to UST q12w, and 43.8% among DR on q8w 
dosing. Patients with LoR versus patients without LoR during follow-up 
had higher mean CDAI scores at BL and at Wk 8 (321.6 [SD 60.6]and 227.8 
[SD 108.3] vs 305.7 [61.6] and 184.5 [90.75] and higher FeCal at Wk 8 (622.5 
[SD 1065.5) vs 446.7 [SD 671.2]). In addition, LoR was more frequent among 
patients with previous anti-TNF exposure (72.2%) and no use of 5-ASA 
(71.2%). Univariate analysis identifi ed higher CDAI at induction and main-
tenance BL, lower delta CDAI aft er induction, Wk 8 FeCal levels, previous 
anti-TNF exposure and previous TNF failure as factors associated with in-
creased risk for LoR (Table 1). Serum UST levels and concomitant IMM use 
were not identifi ed as potential predictors of LoR. At multivariate analysis, 
only CDAI at maintenance baseline (OR: 1.42; 1.14-1.77), and previous TNF 
failure (OR: 2.05; 1.15-3.65) remained signifi cant predictors of LOR.
Conclusion: Throughout 2 years of follow up, secondary LoR occurred in 
~40% of initial or delayed responders to UST. Patients with higher CDAI 
at maintenance BL, and history of previous anti-TNF failure were found 
to be at increased risk for LoR. UST levels were not helpful as potential 
predictors of LoR and concomitant use of IMM did not reduce the risk of 
LoR during UST therapy.
Predictors of LoR (vs no LoR) by Univariate Logistic Regression Model
  OR 95% CI p-value
Induction baseline CDAI (per 100-points) 1.52 1.13, 2.05 0.0063
Maintenance baseline CDAI (per 
100-points)
1.56 1.28, 1.88 <0.0001
Delta CDAI induction/ Maintenance (per 
100-points)
1.40 1.13, 1.72 0.0016
FeCal levels at Week 8 (per 100 mg/kg) 1.03 1.00, 1.05 0.040
Previous TNF exposure 2.13 1.44, 3.16 0.0002
Previous TNF failure 2.46 1.69, 3.58 <0.0001
Predictors of LoR (vs no LoR) by Multivariate Logistic Regression Model
  OR 95% CI p-value
Maintenance baseline CDAI score (per 
100-points)
1.42 1.14, 1.77 0.0021
Previous TNF exposure 1.06 0.58, 1.94 n.s.
Previous TNF failure 2.46 1.15, 3.65 0.015
[Table 1: Predictors of LoR (vs no LoR): univariate and multivariate logistic 
regression models]
Disclosure: Drs. Hanauer, Sands, Feagan, Targan, de Villiers, Rutgeerts, 
Colombel, and Ghosh are all investigators for Janssen Research & Develop-
ment, LLC Dr. Laliman is a consultant to Janssen Research & Development, 
LLC Drs. Oortwijn and van Kruchten are employees with Janssen Biologics 
BV Drs. Izanec and Gasink are employees of Janssen Scientifi c Aff airs, LLC 
Drs Adedokun and Gao are employees of Janssen Research & Develop-
ment, LLC Dr. Sloan is an employee of Janssen Global Services, LLC 
OP194 SERUM METABOLOMIC FINGERPRINT OF ULCERATIVE 
COLITIS (UC) PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS 
(PSC) CAN DISCRIMINATE THEM FROM UC PATIENTS WITHOUT PSC
Hassanzadeh Keshteli A.1, Chibbar R.1, Mandal R.2, Wishart D.2, 
Madsen K.1, Dieleman L.A.1
1University of Alberta, Medicine, Edmonton, Canada, 2University of Alberta, 
Biological Sciences, Edmonton, Canada
Contact E-Mail Address: ahassanz@ualberta.ca
Introduction: Primary sclerosing cholangitis (PSC) is a chronic, cholestatic, 
idiopathic liver disease that can progress to end-stage liver disease, cir-
rhosis and cholangiocarcinoma. It is strongly associated with infl ammatory 
bowel disease, especially ulcerative colitis (UC). It is still unknown why 
some UC patients develop PSC or why UC patients with PSC are at higher 
risk of colorectal cancer development.
Aims & Methods: In the present study, we aimed to compare the serum 
metabolomic profi les of UC patients with PSC to UC patients without PSC 
in order to explore the underlying pathophysiological mechanisms and 
to identify PSC-related biomarkers. Fasting serum samples were collected 
from a group of adult UC patients with confi rmed diagnosis of PSC and 
a group of UC patients without PSC who were matched for diff erent de-
mographic and clinical characteristics. Metabolomic assessment was done 
using nuclear magnetic resonance (NMR) spectroscopy and direct infu-
sion/liquid chromatography tandem mass spectrometry (DI-LC MS/MS).
Results: Forty-nine UC patients were recruited (24 with PSC and 25 with-
out PSC). Their mean age was 42.9±15.6 years and 62% of them were 
men. Forty-seven (94%) patients had a history of pan-colitis and 20% of 
them were on biologic medications. Fift y-three and 129 metabolites were 
identifi ed and quantifi ed using NMR and DI-LC MS/MS, respectively. In 
the multivariate analysis using partial least squares discriminant analysis, 
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  IV FCM (n=92) Oral FM (n=86) Diff erence (FM-FCM)
      %* Risk diff erence (95% CI)
Mean ± SD Hb at 
baseline, g/dL
10.11 ± 1.077 10.02 ± 0.997    
Mean ± SD Hb at 
Week 12, g/dL
13.12 ± 1.456 12.68 ± 1.544    
LSM (95% CI) 
diff erence (baseline 
to Week 12), g/dL
3.02 (2.71-3.32) 2.69 (2.37-3.01)  
-0.32 (-0.76 to 0.11), 
p=0.142
Hb responder rate at 
Week 12, n (%)
77 (84) 64 (74) 10
-0.1 (-0.2 to 0.0), 
pnoninf=0.023
≥2 g/dL increase in 
Hb at Week 12, n (%)
70 (76) 59 (69) 7
-0.1 (-0.2 to 0.0), 
p
noninf
=0.027
Hb normalisation at 
Week 12, n (%)
72 (78) 52 (60) 18
-0.2 (-0.3 to -0.0), 
p
noninf
=0.338
*Noninferiority limit set at 20%. CI, confi dence interval; FCM, ferric carboxymaltose; FM, 
ferric maltol; Hb, haemoglobin; IV, intravenous; LSM, least-squares mean; p
noninf
, p value 
for noninferiority; SD, standard deviation.
[Haemoglobin endpoints at 12 weeks (per-protocol population)]
Tackling the NAFLD/NASH epidemics
10:30-12:00 / F2
OP196 POSITIVE RESULTS FROM REGENERATE: A PHASE 3 
INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED STUDY 
EVALUATING OBETICHOLIC ACID TREATMENT FOR NONALCOHOLIC 
STEATOHEPATITIS
Younossi Z.1,2, Ratziu V.3, Loomba R.4, Rinella M.5, Anstee Q.6, 
Goodman Z.1, Bedossa P.7, Geier A.8, Beckebaum S.9,10, Newsome P.11, 
Sheridan D.12, Trotter J.13, Knapple W.14, Lawitz E.15, Kowdley K.16, 
Montano-Loza A.17, Boursier J.18, Mathurin P.19, Bugianesi E.20, 
Mazzella G.21, Olveira A.22, Cortez-Pinto H.23, Graupera I.24, Orr D.25, 
Gluud L.L.26, Dufour J.-F.27, Shapiro D.28, Campagna J.29, Zaru L.28, 
MacConell L.28, Shringarpure R.30, Harrison S.31, Sanyal A.J.32, 
on Behalf of the REGENERATE Study Investigators
1Betty and Guy Beatty Center for Integrated Research, Inova Health System, 
Claude Moore Health Education and Research Building, Falls Church, United 
States, 2Chronic Liver Disease Foundation, Falls Church, United States, 
3Hôpital Pitié Salpêtrière, Dept. of Hepatology and Gastroenterology, Paris, 
France, 4University of California, San Diego, United States, 5Feinberg School 
of Medicine, Northwestern University, Chicago, United States, 6Newcastle 
University, Institute of Cellular Medicine, Newcastle, United Kingdom, 
7Université Paris-Diderot Hopital Beaujon Dept. of Pathology, Paria, France, 
8University of Wuerzburg, Wuerzburg, Germany, 9St. Josef-Krankenhaus 
Kupferdreh, Essen, Germany, 10University Hospital Münster, Münster, 
Germany, 11University of Birmingham, Birmingham, United Kingdom, 
12Derriford Hospital, University Hospital Plymouth, Plymouth, Devon, United 
Kingdom, 13Baylor Health, Liver Consultants of Texas, Dallas, United States, 
14Arkansas Gastroenterology, North Little Rock, United States, 15University 
of Texas Health Science Center, The Texas Liver Institute, San Antonio, 
United States, 16Swedish Liver Center, Seattle, United States, 17Division of 
Gastroenterology and Liver Unit, University of Alberta, Edmonton, Canada, 
18Centre Hospitalier Universitaire, Service d’Hépato-GastroEntérologie, Angers, 
France, 19CHRU Lille Service MADN Hopital Huriez, Lille, France, 20AOU Città 
della Salute e della Scienza University of Torino, Medical Sciences, Torino, 
Italy, 21University of Bologna, Bologna, Italy, 22Hospital Universitario La Paz, 
Madrid, Spain, 23Faculdade de Medicina de Lisboa, Centro Hospitalar Lisboa 
Norte, HSM, Laboratório de Nutrição, Dept. de Gastroenterologia, Lisbon, 
Portugal, 24Hospital Clinic de Barcelona, Barcelona, Spain, 25Auckland City 
Hospital, Gra on, Auckland, New Zealand, 26Gento e Hospital, University of 
Copenhagen, Consultant, Hvidovre, Denmark, 27University of Bern, Institute 
für Klinische Pharmakologie, Bern, Switzerland, 28Intercept Pharmaceuticals, 
San Diego, United States, 29Intercept, San Diego, United States, 30Intercept 
Pharmaceuticals, Inc., San Diego, United States, 31Pinnacle Clinical Research 
Center, San Antonio, United States, 32Virginia Commonwealth University, 
Translational Research, Richmond, United States
Contact E-Mail Address: igraupe@clinic.cat
Introduction: Obeticholic acid (OCA), an FXR agonist, improved both fi bro-
sis and histologic features of nonalcoholic steatohepatitis (NASH) in the 
Ph2 FLINT study.
serum metabolome of UC patients with PSC were signifi cantly distinctive 
from those without PSC. Increased 2-oxoglutaric acid, ethanol, alpha-ke-
toglutaric acid, phosphatidylcholines and decreased alpha-aminobutyric 
acid, malonic acid, and glutamine were among the most important meta-
bolic changes in UC patients with PSC that could diff erentiate them from 
patients without PSC.
Conclusion: This is the fi rst study indicating that metabolomic profi ling 
in UC patients can discriminate between patients with and without PSC. 
The discriminatory metabolites are involved in host cellular energy me-
tabolism, as well as amino acid and fatty acid metabolism and are likely 
involved in PSC pathogenesis and its complications in UC.
Disclosure: Nothing to disclose 
OP195 ORAL FERRIC MALTOL VERSUS INTRAVENOUS FERRIC 
CARBOXYMALTOSE FOR THE TREATMENT OF IRON-DEFICIENCY 
ANAEMIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: 
A MULTICENTRE PHASE 3B, OPEN-LABEL RANDOMISED 
CONTROLLED TRIAL
Howaldt S.1, Martinez N.2, Domènech E.3, Sampson M.4
1MVZ für Immunologie, Hamburg, Germany, 2Gastroenterology Research 
of America, San Antonio, United States, 3Hospital Germans Trias i Pujol, 
Gastroenterology Unit, Badalona, Spain, 4Shield Therapeutics plc, London, 
United Kingdom
Contact E-Mail Address: howaldt@hafced.de
Introduction: Iron-defi ciency anaemia (IDA) is a serious complication of 
infl ammatory bowel disease (IBD), resulting from infl ammation, chronic 
mucosal blood loss and iron malabsorption. Treatment of IDA involves 
iron-replacement therapy, oft en with oral agents; however, use of stan-
dard oral ferrous iron (Fe2+) compounds may be limited by poor iron bio-
availability and adverse events, in which case patients require intravenous 
(IV) iron. Ferric maltol (FM), a chemically stable complex of ferric iron 
(Fe3+) and maltol, provides another oral option formulated to improve ab-
sorption and reduce adverse events. FM is eff ective and well tolerated in 
patients with IBD (Gasche et al. In amm Bowel Dis 2015;21:579-588) but no 
head-to-head studies between FM and IV iron have been done.
Aims & Methods: 
Objectives: To compare the effi  cacy and safety of oral FM and IV iron (ferric 
carboxymaltose [FCM]) in the treatment of IDA in patients with IBD.
Methods: This prospective, multicentre, phase 3b, open-label randomised 
controlled trial (EudraCT 2015-002496-26) included patients aged ≥18 years 
with confi rmed IBD and IDA (haemoglobin [Hb] 8.0-11.0 g/dL for women, 
8.0-12.0 g/dL for men AND either ferritin < 30 ng/mL or ferritin <100 ng/mL 
with transferrin saturation < 20%). Patients were randomised to 12 weeks 
of oral FM 30 mg twice daily or IV FCM administered according to standard 
prescribing information. Treatment could continue for up to 52 weeks. 
Effi  cacy was assessed in all randomised patients (intention-to-treat [ITT] 
population) and in patients without serious protocol deviations (per-
protocol population; PP). The primary endpoint was Hb responder rate 
defi ned as the proportion of patients achieving either a 2 g/dL increase 
in Hb or normalisation of Hb (women ≥12 g/dL; men ≥13 g/dL) at Week 
12, with a noninferiority limit set to 20% in either the ITT or the PP 
population.
Results: Mean ± SD treatment exposure was 30.2 ± 17.94 weeks for FM and 
15.5 ± 15.60 weeks for FCM. The PP population included 178 patients (FM 
n=86; FCM n=92). At 12 weeks, the PP responder rate was 74% with FM 
and 84% with FCM; the diff erence was therefore well within the 20% non-
inferiority limit (p=0.023; Table). In the safety population (FM n=127; FCM 
n=120), 118 patients had treatment-emergent adverse events (FM n=75, 
59%; FCM n=43, 36%), of which 15 were severe (FM n=11; FCM n=4). For 
FM, most cases were gastrointestinal (n=40, 31%). For FCM, most cases 
were infections/infestations (n=22, 18%). No serious adverse events re-
lated to study treatment were reported. Fourteen patients discontinued 
because of adverse events (FM n=13; FCM n=1).
Conclusion: This fi rst comparative trial shows noninferiority of oral FM ver-
sus IV FCM in improving Hb aft er 12 weeks of treatment. Both treatments 
were well tolerated, with safety profi les as expected from previous studies. 
FM may therefore be an appropriate alternative to IV iron for treatment 
of IDA in IBD, even in patients in whom other oral iron therapy is not an 
option.
Disclosure: Nothing to disclose 
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Aims & Methods: : This Month 18 pre-specifi ed interim analysis of the on-
going Ph3 REGENERATE study evaluated the eff ect of OCA on liver histology 
in patients with biopsy-confi rmed NASH. Patients with NASH and fi brosis 
stages F2-3 (ITT), and an exploratory group of F1 patients with metabolic 
syndrome, were randomized to placebo, OCA 10 mg, or OCA 25 mg QD. Pri-
mary endpoints were fi brosis improvement (≥1 stage) with no worsening 
of NASH, or NASH resolution with no worsening of liver fi brosis per liver 
biopsy. The safety population included all randomized and dosed patients 
(F1-3, N=1968). Clinical outcomes will be evaluated at the end-of-study.
Results: The ITT population included 931 patients (placebo [n=311], OCA 
10 mg [n=312] or OCA 25 mg [n=308]), comprised of 44% F2 and 56% 
F3. Baseline characteristics were well-balanced across groups. Results in 
Table. The primary fi brosis endpoint was met by 11.9% placebo, 17.6% OCA 
10 mg (p=0.0446 vs placebo), and 23.1% OCA 25 mg (p=0.0002 vs placebo) 
patients (ITT). The primary NASH endpoint was not statistically signifi cant 
(ITT). More patients on OCA 25 mg showed improvements in hepatocellu-
lar ballooning (p=0.0011 vs placebo) and lobular infl ammation (p=0.0322 
vs placebo). Dose-dependent reductions in ALT, AST and GGT were ob-
served. Pruritus was the most common AE (19% placebo, 28% OCA 10 mg, 
51% OCA 25 mg) and was predominantly mild to moderate in severity (se-
vere pruritus: < 1% placebo, < 1% OCA 10 mg, 5% OCA 25 mg). More OCA 
25 mg patients discontinued due to pruritus (< 1% placebo, < 1% OCA 10 
mg, 9% OCA 25 mg; protocol mandated discontinuation of treatment with 
severe pruritus). SAEs occurred in 11% placebo, 11% OCA 10 mg and 14% 
OCA 25 mg patients. Increases in LDLc with OCA were observed by Week 4, 
but approached baseline by Month 18 (OCA 25 mg: LS mean change Wk4 
+22.6 mg/dL, M18 +4.0 mg/dL). Cardiovascular SAEs were similar across 
groups (2% placebo, 1% OCA 10 mg, 2% OCA 25 mg). Cholelithiasis or 
cholecystitis were reported in 1% placebo, 1% OCA 10 mg and 3% OCA 25 
mg patients. Hepatic disorder SAEs were uncommon but occurred more 
frequently in OCA 25 mg patients (< 1%). Three deaths occurred; none were 
considered treatment-related (placebo n=2; OCA 25 mg n=1).
Primary: ITT Population (F2 + F3) Placebo (n=311)
OCA 10 mg 
(n=312)
OCA 25 mg 
(n=308)
Fibrosis improvement + no worsening of NASH 11.9%
17.6% 
(p=0.0446)
23.1% 
(p=0.0002)
NASH resolution + no worsening of fi brosis 8.0%
11.2% 
(p=0.1814)
11.7% 
(p=0.1268)
Improvement in hepatocellular ballooning 23.2%
27.2% 
(p=0.2423)
35.1% 
(p=0.0011)
Improvement in lobular infl ammation 35.7%
39.1% 
(p=0.3380)
44.2% 
(p=0.0322)
Overall study discontinuations (ITT): 16% Placebo, 17% OCA 10 mg, 15% OCA 25 mg
[REGENERATE Table]
Conclusion: Treatment with OCA 25 mg improved liver fi brosis, key his-
tologic features of steatohepatitis and liver biochemistry, demonstrating 
consistent effi  cacy with an overall AE profi le similar to previous studies.
Disclosure: Nothing to disclose 
OP197 MOUSE AND HUMAN ADULT LIVER - DERIVED BIPOTENT 
DUCTAL ORGANOIDS FUNCTIONALLY RECAPITULATE LIVER 
STEATOSIS
Raabe T., McCarron S., Abbey D., Hand N., Quiroz-Figueroa K., Rader D., 
Olthoff  K., Shaked A., Bathon B.
University of Pennsylvania, Perelman School School of Medicine, Medicine, 
Philadelphia, United States
Contact E-Mail Address: raabe@pennmedicine.upenn.edu
Introduction: Recently both mouse and human adult liver - derived bi-
potent ductal organoids (consisting of adult ductal stem cells) have been 
described and shown capable of diff erentiation from the biliary state to 
the hepatic state. Although such hepatically diff erentiated organoids have 
been shown to accumulate lipids in the presence of fatty acids, the mo-
lecular pathways regulating lipid metabolism in organoids are not known. 
To determine if adult liver-derived organoids can be a useful experimental 
model for mouse and human liver steatosis we set out to functionally char-
acterize the metabolic pathways governing lipid accumulation in mouse 
and human organoids and compare them to known steatotic pathways 
including the Trib1 defi cient genetic mouse model of steatosis. The Trib1 
-/- mouse model is likely relevant for at least a subset of steatotic patients 
because several GWAS studies strongly correlate Trib1 down - regulating 
mutations with high plasma LDL levels, high plasma triglyceride levels, 
coronary artery disease and steatotic liver disease. Indeed, Trib1’s suspect-
ed role in metabolic syndrome has been functionally proven by Trib1 liver 
specifi c ko mouse models which also show that Trib1 acts at least in part 
through upregulation of the liver specifi c transcription factor C/EBPalpha 
which in turn causes metabolic syndrome (Bauer et al 2015 J Clin Invest 
125:3809-18). It has also been convincingly demonstrated that HepG2 liver 
cancer cells feature strongly reduced levels of C/EBPalpha which in turn 
induces over expression of the transcriptional co-activator YAP, the main 
eff ector of the Hippo pathway, through direct physical interaction of C/
EBPalpha with YAP (Wang et al 2013, Mol Cell 2:221-225).
Aims & Methods: Using Trib1-/- mouse liver - derived bipotent ductal or-
ganoids, we present here evidence that Trib1 defi ciency - mediated upreg-
ulation of C/EBPalpha may in turn further down regulate normal - already 
low - YAP activity in hepatically diff erentiated organoids. YAP is the main 
eff ector of the evolutionary conserved Hippo pathway that regulates liver 
size, regeneration and some aspects of liver pathogenesis.
Results: We show that almost complete absence of YAP leads to a defi -
ciency of the hepatically diff erentiated organoids to dediff erentiate back to 
proliferating ductal organoids, consistent with the well documented block 
of liver regeneration caused by low YAP activity levels. Most importantly, 
experimentally induced downregulation of YAP in hepatically diff erenti-
ated normal organoids phenocopies the lipid droplet accumulation and 
reduced uptake of LDL seen in Trib1-defi cient hepatic organoids. Consistent 
with this, drugs that upregulate YAP activity partially rescue Trib1 defi cien-
cy - mediated lipid accumulation and low LDL uptake. To our knowledge 
this is the fi rst time YAP activity has been implicated in the regulation of 
steatosis.
Importantly, we present evidence that YAP activating drugs, which can also 
alleviate liver fi brosis in mice, can partially rescue experimentally induced 
steatosis in human organoids. Further, we show that liver - derived organ-
oids from NASH patients, but not normal donors, spontaneously recapitu-
late lipid accumulation in the absence of experimental steatotic stimulus.
Conclusion: We conclude that normal and steatotic human liver- derived 
organoids can be used to study important aspects of patient steatosis, and 
may be useful in future patient specifi c screens for antisteatotic drugs.
Disclosure: Nothing to disclose 
IBS treatment
10:30-12:00 / Barcelona
OP198 CONSEQUENCES OF CHANGING TO THE ROME IV 
DIAGNOSTIC CRITERIA FOR IRRITABLE BOWEL SYNDROME 
AMONG PEOPLE LIVING WITH THE CONDITION
Black C.J.1,2, Yiannakou Y.3, Houghton L.A.2, Ford A.C.1,2
1St James’s University Hospital, Department of Gastroenterology, Leeds, 
United Kingdom, 2University of Leeds, Institute of Medical Research at St 
James’s, Leeds, United Kingdom, 3County Durham and Darlington, NHS 
Foundation Trust, Durham, United Kingdom
Contact E-Mail Address: chrisjamesblack4@gmail.com
Introduction: Irritable bowel syndrome (IBS) is a common condition with a 
prevalence in the community of 10%. The diagnosis is made using symp-
tom-based diagnostic criteria. There are few studies examining implica-
tions of applying the Rome IV criteria for IBS, in preference to the previous 
gold standard, the Rome III criteria. We conducted a cross-sectional survey 
of over 1000 individuals who self-identifi ed as having IBS in order to ex-
amine this issue.
Aims & Methods: We collected complete demographic, symptom, mood, 
and psychological health data from 1375 adults who self-identifi ed as 
having IBS, but who were not recruited from a referral population. We 
applied both the Rome III and the Rome IV criteria simultaneously to 
examine what proportion met each of these diagnostic criteria for IBS. 
We measured the level of agreement between the Rome III and Rome 
IV criteria, and assessed for presence of an alternative functional bowel 
disorder in individuals who no longer met diagnostic criteria for IBS with 
the more restrictive Rome IV criteria. Finally, we compared characteristics 
of individuals who met only Rome III criteria with those who met Rome 
IV criteria.
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gastroenterology specialist (SC) or multi-disciplinary (MD) clinic, the 
latter comprising gastroenterologists, dieticians, gut-hypnotherapists, 
psychiatrists and behavioural (“biofeedback”) therapists situated in the 
same clinic simultaneously. At the MD clinic all patients initially saw a 
gastroenterologist and were then referred to allied clinicians as felt ap-
propriate. Outcomes were assessed at clinic discharge or at 9 months. 
The primary outcome was global symptom improvement: “slightly better” 
(4/5) or “much better” (5/5) on a 5-point Likert scale. Secondary outcomes 
included gut symptoms (Gastro-Intestinal Symptom Severity Index (GISSI), 
condition-specifi c symptom scores [IBS: Irritable Bowel Severity Scoring 
System (IBS-SSS), functional dyspepsia: Nepean Dyspepsia Index (NDI)], 
psychological well-being (Hospital Anxiety and Depression Scale - HADS), 
and Quality of Life (Euro-QOL: EQ-5D).
Results: 
Patient disposition: 188 patients (mean age 39, 63% female) were ran-
domised, of whom 144 (46 SC and 98 MD) had suffi  cient outcome data and 
form the basis of this modifi ed intention to treat analysis. 59% had IBS, 
27% functional dyspepsia, the remainder other FGIDs. In the MD clinic, 61 
patients (62%) saw at least one allied clinician. Median clinic visits were 
2 in SC and 6 in MD (p< 0.01), and time to discharge 226 and 179 days, 
respectively (p=NS). 
Outcome: The primary outcome was achieved in 57% versus 84%, re-
spectively (p< 0.01). Patients scoring “much better” was 28% versus 51% 
(p=0.01). 
Conditions: ≥50 point decrease in IBS-SSS in IBS patients: 38% v 66% 
(P=0.02), and ≥ 50% decrease in NDI in functional dyspepsia patients 27% 
v 46% (P=0.47). 
Symptoms: Whole group ≥50% drop in GISSI sub-scores was 20% v 38% 
for refl ux, 26% v 44% for nausea and vomiting, 17% v 42% for constipa-
tion, 22% v 43% for diarrhoea (all P< 0.04), but not signifi cantly diff erent 
for abdominal discomfort or dyspepsia. HADS score decreased from base-
line to discharge in MD but not SC: SC 14.4 vs 13.7 (p=0.28) v MD 14.5 vs 11.5 
(P< 0.01); HADS at discharge 13.7 v 11.5 (P=0.09), respectively. Baseline v 
discharge EQ-5D quality of life: SC 70 vs 70 (P=0.17) v MD (67 vs 75 (P< 0.01); 
EQ-5D at discharge 70 v 75 (P< 0.01).
Conclusion: In this randomised, controlled trial multi-disciplinary care was 
signifi cantly superior to standard gastroenterologist-only care in patients 
with a functional gastro-intestinal disorder. Multi-disciplinary care based 
in a single clinic provided superior improvement in global symptoms, spe-
cifi c conditions, specifi c symptoms, psychological well-being, and quality 
of life. Superior outcomes were achieved over a shorter time, but with 
more clinic visits. The pragmatic study design that included all referrals 
supports the generalisability to gastroenterological practice. Consideration 
should be given to providing routine multi-disciplinary care for these con-
ditions.
References: 1. Basnayake, C. , Kamm, M. A., Salzberg, M. , Stanley, A. , 
Khera, A. , Burrell, K. , Wilson O’Brien, A. , Hebbard, G. and Thompson, A. 
J. (2019), Outcome of hospital outpatient treatment of functional gastroin-
testinal disorders. Intern Med J, 49: 225-231. doi:10.1111/imj.14067
Disclosure: Nothing to disclose 
OP200 PELVIC FLOOR BIOFEEDBACK IS EFFECTIVE TREATMENT 
FOR BLOATING IN FUNCTIONAL GASTROINTESTINAL DISORDERS 
WITH OUTLET DYSFUNCTION
Iovino P.1, Neri M.C.2, D’Alba L.3, Santonicola A.1, Cidoni F.4, Chiarioni G.5
1University of Salerno, Department of Medicine, Surgery & Dentistry, Scuola 
Medica Salernitana, Salerno, Italy, 2Pio Albergo Trivulzio Hospital, Milano, 
Italy, 3San Giovanni Addolorata Hospital, Roma, Italy, 4AOUI Verona, 
Gastroenterologia B, Verona, Italy, 5AOUI Verona, Gastroenterology, Verona, 
Italy
Contact E-Mail Address: chiarioni@tin.it
Introduction: It has been suggested that biofeedback may improve bloat-
ing in constipation due to dyssynergic defecation (DD) (1). However, data 
on diff erent functional gastrointestinal disorders (FGID) are lacking.
Aims & Methods: Aim of our study was to evaluate the effi  cacy of pelvic 
fl oor biofeedback for severe bloating unresponsive to diet advise in FGID 
patients. 
Materials and methods: Sixty-nine consecutive FGID patients consulting 
for bloating as main complaint were considered for the study. Four refused 
and were excluded. All the 65 remaining patients reported bloating as not 
improved by NICE diet advise augmented by lactose abstinence accord-
Results: In total, 1080 (78.9%) of 1368 individuals with IBS met the Rome 
III criteria. In contrast, only 811 (59.1%) of 1373 individuals with IBS met 
the Rome IV criteria. Agreement between the criteria was only moderate 
(Kappa = 0.50). The reasons for not meeting the Rome IV criteria for IBS 
among those meeting the Rome III criteria are shown in Table 1.
 
Reported abdominal 
discomfort, rather than 
abdominal pain (%)
Reported abdominal 
pain, but not at the 
required frequency (%)
Other 
reasons 
(%)
Met Rome III criteria, but 
not Rome IV criteria, for IBS 
(n = 286)
26 (9.1) 253 (88.5) 7 (2.4)
Rome IV functional 
constipation (n = 33)
3 (9.1) 29 (87.9) 1 (3.3)
Rome IV functional diarrhea 
(n = 118)
9 (7.6) 108 (91.5) 1 (0.8)
Rome IV functional 
abdominal bloating (n = 68)
6 (8.8) 61 (89.7) 1 (1.5)
Rome IV unspecifi ed 
functional bowel disorder 
(n = 67)
8 (11.9) 55 (82.1) 4 (6.0)
[Table1: Reasons for not meeting the Rome IV criteria for IBS among those 
meeting the Rome III criteria]
Among those who no longer had IBS according to the Rome IV criteria, 
33 (11.5%) met Rome IV criteria for functional constipation, 118 (41.3%) 
functional diarrhoea, 68 (23.8%) functional abdominal bloating or disten-
sion, and 67 (23.4%) an unspecifi ed functional bowel disorder. Individuals 
with Rome IV-defi ned IBS had more severe symptoms, and higher levels of 
mood disorder and poor psychological health, compared with those who 
only met the Rome III criteria for IBS (P < 0.001).
Conclusion: Changing from the Rome III criteria to Rome IV IBS has sub-
stantial implications, both for individuals who believe they suff er from IBS, 
and for the spectrum of disease severity seen. Understanding the impact 
of these changes on clinical trials of novel agents in IBS will be important. 
Of those individuals with Rome III IBS who did not meet the Rome IV crite-
ria for IBS, only 11.5% were reclassifi ed into another functional bowel dis-
order where licensed and evidence-based therapies are available, namely 
functional constipation. In contrast, the treatment of people with functional 
diarrhoea, functional bloating, and unspecifi ed functional bowel disorder 
relies on off -label therapies with only anecdotal evidence for their effi  cacy. 
Alternatively, these individuals could still be treated as if they have IBS. If 
use of the Rome IV criteria for IBS makes these conditions more prevalent, 
this highlights the need for rigorous randomised controlled trials (RCTs) of 
neuromodulators, probiotics, anti-diarrheals, and other agents in these 
disorders. 
Disclosure: Nothing to disclose 
OP199 OPTIMAL DELIVERY OF CARE FOR FUNCTIONAL 
GASTRO-INTESTINAL DISORDERS: RANDOMISED CONTROLLED 
TRIAL OF STANDARD GASTROENTEROLOGIST VERSUS 
MULTI-DISCIPLINARY CARE (THE MANTRA STUDY)
Basnayake C.1,2, Kamm M.A.1,2, Stanley A.1, Wilson-O’Brien A.2, Burrell K.1, 
Lees-Trinca I.1, Khera A.1,2, Kantidakis J.1, Wong O.1, Fox K.1, Talley N.J.3, 
Liew D.4, Salzberg M.1, Thompson A.J.1,2
1St Vincent’s Hospital, Melbourne, Gastroenterology, Melbourne, Australia, 
2University of Melbourne, Medicine, Melbourne, Australia, 3University of 
Newcastle, Faculty of Health & Medicine, Callaghan, Australia, 4Monash 
University, School of Public Health and Preventative Medicine, Melbourne, 
Australia
Contact E-Mail Address: cbbasnayake@gmail.com
Introduction: Functional gastrointestinal disorders (FGIDs) are common 
and costly to treat. Only a minority of patients are symptomatically im-
proved with standard gastroenterologist care1. Many patients have psy-
chological morbidity, yet despite psychological, behavioural and dietary 
therapies being well validated in these conditions, gastroenterology ser-
vices do not provide them as part of integrated routine care.
Aims & Methods: We aimed to determine whether standard or multidis-
ciplinary care provides the best clinical outcome for patients with a FGID. 
In a single hospital setting consecutive new referrals of patients with a 
Rome IV criteria-defi ned FGID were randomised 1:2 to a standard care 
109Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
ing to a 5 point likert scale (range worse-major improvement/cure) and 
rated symptom severity VAS score >24 on a 100-mm scale. All 65 subjects 
underwent electromyography (EMG) testing of pelvic fl oor muscle function 
on straining by a surface EMG anal plug and rectal balloon expulsion test 
(BET) with a 16F Foley catheter infl ated with 50 ml of tepid water. BET 
was considered failed if the balloon could not be evacuated within two 
minutes (2). A biofeedback protocol previously used for constipation due 
to DD was provided in all patients by a registered nurse who was unaware 
of the physiology results (3). Primary study aims were a) subjective report 
of fair-major improvement from baseline, b) >50% reduction of bloating 
VAS score from baseline. Secondary aim was achievement of successful 
BET. Dropouts (4 patients total, 2 BET failure) were included in the analysis 
with the last observation carried forward. Clinical and physiology follow-
up visits were scheduled at 1-3-6 months post-treatment.
Results: All sixty-fi ve patients (56 Female, mean age 41 years) completed 
the biofeedback protocol and attended the fi rst follow-up visit. Most of 
the patients were aff ected by functional bloating (43.5%) or constipation 
predominat irritable bowel syndrome (27.5%), according to Rome III Cri-
teria. DD was diagnosed in 32 patients (59%) (failed BET, EMG evidence of 
paradoxical contraction of the pelvic fl oor muscles on straining), 4 patients 
(6.3%) were discordant (failed BET, EMG evidence of pelvic fl oor muscle 
relaxation on straining), while the remaining 29 patient (43.8%) showed 
normal defecation pattern. As a whole, 35/65 patients (53.8%) met both 
primary aims at 1-3-6 month follow-up (McNemar non parametric test, 
p< 0.0001). According to BET results, 30/36 (83.3%) patients who failed 
BET at baseline evaluation met both primary aims at 1-3-6 month follow-
up intervals compared with 5/29 (17.2%) patients with successful BET (chi 
square p< 0.001). A strong correlation between adequate relief and a 
>50% reduction of VAS bloating score was observed (r=1.00). In the failed 
BET group, 30/36 (83.3%) patients learned to evacuate the balloon within 
two minutes at all follow-up intervals (Friedman test for non-parametric 
data p>0.001), while no physiology modifi cations was observed in the suc-
cessful BET group from baseline evaluation.
Conclusion: Pelvic fl oor biofeedback aimed to improve defecation eff ort is 
eff ective treatment for severe bloating in FGID with comorbid outlet dys-
function. Dyssynergic defecation may present without prevalent obstructed 
defecation and/or constipation symptoms.
References: 1) Baker J, et al. Abdominal Symptoms Are Common and Ben-
efi t from Biofeedback Therapy in Patients with Dyssynergic Defecation. 
Clinical and Translational Gastroenterology 2015; 6, e105; 2) Chiarioni G, 
et al. Validation of the balloon evacuation test: reproducibility and agree-
ment with fi ndings from anorectal manometry and electromyography. Clin 
Gastroenterol Hepatol 2014;12:2049-54. 3) Chiarioni G, et al. Biofeedback 
is superior to laxatives for normal transit constipation due to pelvic fl oor 
dyssynergia. Gastroenterology 2006;130:657-664.
Disclosure: Chiarioni G is a Member of the Anorectal Committe of the 
Rome Foundation. No COI to be disclosed for all of the remaining Authors 
OP201 HUMAN MILK OLIGOSACCHARIDES IMPROVE ALL 
THE CENTRAL SYMPTOMS OF IRRITABLE BOWEL SYNDROME: 
A MULTI-CENTER, OPEN LABEL TRIAL
Palsson O.S.1, Peery A.2, Seitzberg D.3, Amundsen I.4, McConnell B.5, 
Simrén M.6
1University of North Carolina at Chapel Hill, Dept. of Medicine, Chapel 
Hill, United States, 2University of North Carolina at Chapel Hill, Dept. of 
Medicine, Division of Gastroenterology and Hepatology, Chapel Hill, United 
States, 3Glycom, Clinical Dept., Hørsholm, Denmark, 4GlycomA/S, Hørsholm, 
Denmark, 5Glycom A/S, Clinical, Preclinical and Business Development, 
Horsholm, Denmark, 6Sahlgrenska University Hospital, Dept of Internal 
Medicine, Gothenburg, Sweden
Contact E-Mail Address: olafur_palsson@med.unc.edu
Introduction: Altered gut microbiota is increasingly seen as a potential 
factor in irritable bowel syndrome (IBS) pathophysiology. Human milk oli-
gosaccharides (HMOs) have been shown in healthy adults to increase the 
abundance of bifi dobacteria1, which are reported to be depleted in IBS2. 
HMOs may also have benefi cial impact on gut motility and visceral pain3.
Aims & Methods: We aimed to assess the potential for HMOs to support 
normal bowel habits and improve other bowel symptoms of IBS. A multi-
center, open label trial was conducted in clinical patients with IBS (Rome 
IV criteria plus physician diagnosis) at 17 sites across the United States. 
The subjects took 5 grams of the HMOs 2’fucosyllactose (2’FL) and lacto-N-
neotetraose (LNnT) in a 4:1 mix daily by mouth for 12 weeks. Bowel habits, 
IBS symptoms and quality of life were assessed at baseline and every 4 
weeks during the intervention. Results were analyzed with Intention-to-
Treat (ITT) methodology (last observation carried forward for non-com-
pleters), using repeated measures Analysis of Variance.
Results: A total of 317 subjects (70.7% females; mean age 44.0 years, range 
18-93 years) received the study product; 136 with constipation predominant, 
85 with diarrhea predominant, 95 with mixed, and 1 with unspecifi ed IBS. 
The full twelve week intervention was completed by 245 subjects. In the 
ITT analyses, the subjects showed a signifi cant reduction in total percent-
age of abnormal bowel movements (Bristol Stool Form Scale types 1, 2, 6, 
or 7) from baseline to 12 weeks (means and 95% CI: 89.8% [88.1%-91.5%] 
vs. 54.9% [51.4%-58.4%]) as well as substantial reductions in overall IBS 
Symptom Severity Score (327 [317-337] vs. 128 [117-139]), abdominal pain 
severity (62.5 [60.1-64.9] vs. 25.4 [22.6-28.2] and bloating severity (56.8 
[53.8-59.8] vs. 23.2 [20.5-25.8]), and improvement in health-related qual-
ity of life (IBS-QOL scores: 50.4 [48.0-52.8] vs. 74.6 [72.3-76.9]): p< 0.0001 
for all changes. The degree of therapeutic response was similar in all IBS 
subtypes, and most of the symptom improvement occurred in the fi rst 4 
weeks of intervention (see Table 1). Younger age was predictive of greater 
improvement in stool consistency and abdominal pain severity. The study 
product tested was well tolerated by most patients. The only common side 
eff ects were mild GI symptoms such as abdominal discomfort, distension 
and fl atulence.
Conclusion: Our fi ndings suggest that oral supplementation with 2’FL 
and LNnT HMOs can provide nutritional support that signifi cantly reduces 
abnormal stool consistency, abdominal pain and bloating and improves 
health-related quality of life in IBS suff erers of all subtypes. However, the 
results from this open label trial need to be followed up by a randomized 
controlled trial.
Percentage of abnormal bowel movements in the past 4 weeks measured by Bristol 
Stool Form Scale
  Overall (n=317) IBS-C (n=136) IBS-D (n=85) IBS-M (n=95)
Baseline 88.0 [86.4-89.7] 84.9 [82.4-87.5] 87.5 [84.0-91.1] 93.1 [90.3-95.8]
Week 4 59.2* [56.5-62.0] 55.5* [51.3-59.8] 54.6* [49.3-59.9] 68.2* [63.7-72.8]
Week 8 56.5* [53.5-59.5] 53.5* [49.1-57.8] 56.2* [50.4-62.1] 61.3* [55.3-67.3]
Week 12 56.3* [53.2-59.4] 49.3* [44.8-53.8] 60.0* [54.4-65.6] 62.8* [56.8-68.9]
Total IBS Symptom Severity Score
  Overall (n=317) IBS-C (n=136) IBS-D (n=85) IBS-M (n=95)
Baseline 323 [314-332] 316 [302-329] 322 [305-339] 332 [314-349]
Week 4 178* [167-188] 164* [148-180] 181* [163-198 195* [174-215]
Week 8 150* [140-161] 136* [121-151] 155* [136-174] 165* [142-188]
Week 12 144* [133-155] 118* [103-134] 155* [138-172] 170* [146-193]
*signi cantly di erent from baseline at p<0.0001.
[Table 1. Changes in abnormal bowel movement percentage and IBS 
Symptom Severity Score (IBS-SSS) throughout the trial (ITT analyses; 
means [95% CI])]
References: [1] Elison, E., et al., Oral supplementation of healthy adults 
with 2´-O-fucosyllactose and lacto-N-neotetraose is well tolerated and 
shift s the intestinal microbiota. Br J Nutr, 2016. 116(8): p. 1356-1368. [2] 
Rajilić-Stojanović, M., et al., Intestinal microbiota and diet in IBS: causes, 
consequences, or epiphenomena? The American Journal of Gastroenterol-
ogy, 2015. 110(2): p. 278-287. [3] Bienenstock, J., et al., Fucosylated but not 
sialylated milk oligosaccharides diminish colon motor contractions. PLoS 
One, 2013. 8(10): p. e76236.
Disclosure: Dorthe Seitzberg, Ingvild Dybdrodt Amundsen and Bruce Mc-
Connell are employed at Glycom A/S, Denmark, which funded this trial. 
Olafur Palsson, Anne Peery and Magnus Simren received research support 
from Glycom A/S related to the trial. 
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OP203 THE EFFECTS OF HUMAN MILK OLIGOSACCHARIDES ON 
BIFIDOBACTERIA AND GASTROINTESTINAL SYMPTOMS IN IRRITABLE 
BOWEL SYNDROME PATIENTS: A PARALLEL, DOUBLE BLIND, 
RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Iribarren C.1,2, Törnblom H.2, Aziz I.2, Magnusson M.K.1, Sundin J.2, 
Vigsnaes L.3, Amundsen I.4, McConnell B.5, Seitzberg D.6, Öhman L.1, 
Simrén M.2
1University of Gothenburg. Institute of Biomedicine, Microbiology and 
Immunology, Göteborg, Sweden, 2University of Gothenburg. Institute of 
Medicine, Internal Medicine and Clinical Nutrition, Göteborg, Sweden, 
3Glycom A/S, Business Development, Hoersholm, Denmark, 4GlycomA/S, 
Hørsholm, Denmark, 5Glycom A/S, Clinical, Preclinical and Business 
Development, Horsholm, Denmark, 6Glycom, Clinical Department, Hørsholm, 
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Contact E-Mail Address: cristina.iribarren.gomez@gu.se
Introduction: Gut microbiota alterations seem to be a relevant factor in the 
pathophysiology of irritable bowel syndrome (IBS). Therefore, modulating 
the gut microbiota by using prebiotics, such as human milk oligosaccha-
rides (HMO), might infl uence gastrointestinal (GI) symptoms through their 
eff ect on specifi c gut bacteria. However, the safety and tolerance of HMO 
have not been assessed in IBS patients. Thus, we aimed to determine the 
dose of a HMO mix of 2’-O-Fucosyllactose (2’FL) and Lacto-N-neotetraose 
(LNnT) that increased fecal bifi dobacteria abundance in IBS patients with-
out aggravating overall GI symptoms.
Aims & Methods: We performed a parallel, double-blind, randomized, 
placebo-controlled trial in an IBS patient cohort diagnosed according to 
the Rome IV criteria. We studied the eff ects of 5g and 10g doses of 4:1 mix 
of 2’FL and LNnT (2’FL/LNnT) compared to placebo (powdered glucose) af-
ter 4 weeks of oral intake, followed by a 4 weeks wash-out period. Gastro-
intestinal Symptom Rating Scale-IBS (GSRS-IBS) and fecal samples were 
collected at baseline, at the end of intervention and the washout period. 
Fecal bifi dobacteria abundance was analyzed by the GA-mapTM platform 
technology. Non-parametric analysis were performed between and within 
intervention groups.
Results: We included 61 IBS patients, (41 women; median age 45 (19 - 73) 
years); 27 IBS with diarrhea, 14 IBS with constipation and 20 mixed IBS. 
During the intervention phase, two patients, one from the placebo group 
and one from the 10g group, discontinued prematurely (aft er 2 weeks of 
intervention) due to worsening symptoms. 
As can be seen in table 1, the bifi dobacteria abundance diff ered between 
the groups aft er the intervention period, with higher abundance in the 
10g group compared with the other intervention groups (p< 0.05). Within-
group comparisons demonstrated a signifi cant increase in bifi dobacteria 
abundance in the 10g group at the end of the intervention period com-
pared to baseline (p=0.018). 
  Placebo (n=21)
5g 2´FL/LNnT 
(n=20)
10g 2´FL/LNnT
 (n=20)
#p- 
value
  Baseline Week 4 Baseline Week 4 Baseline Week 4  
Log 
bifi doacteria 
abundance*
3.77 
(± 1.48)
3.78 
(±1.62)
4.81 
(± 0.89)
4.86 
(± 0.99)
4.21 
(± 1.34)
5.03 
(± 1.00)
< 0.05
GSRS-IBS scores*
Total score
49.76 
(± 10.04)
41.71 
(± 10.43)
45.15 
(± 7.99)
43.06 
(± 13.43)
52.55 
(± 8.41)
48.42 
(± 11.65)
ns
Constipation 
score
6.05 
(± 3.47)
5.24 
(± 2.84)
3.70 
(± 2.45)
4.33 
(± 3.43)
5.35 
(± 4.17)
4.68 
(± 3.33)
ns
Abdominal 
pain score
8.57 
(± 1.99)
7.76 
(± 2.17)
8.10 
(± 2.71)
7.06 
(± 3.39)
9.20 
(± 1.64)
8.53 
(± 2.61)
ns
Bloating score
14.00 
(± 3.54)
11.94 
(± 3.99)
12.35 
(± 4.00)
11.61 
(± 4.54)
15.10 
(± 3.02)
14.16 
(± 4.07)
ns
Diarrhea score
15.52 
(± 4.39)
11.94 
(±4.17)
15.35 
(± 4.78)
14.83 
(±4.97)
17.20 
(± 5.21)
15.95 
(± 6.92)
ns
Satiety score
5.62 
(± 3.41)
4.82 
(± 3.43)
5.65 
(± 2.81)
5.22 
(± 2.69)
5.70 
(± 3.34)
5.11 
(± 2.71)
ns
*Data shown as mean (±sd). #p-values refl ecting comparisons between the three groups 
(placebo, 5g and 10g 2´FL/LNnT) aft er the intervention (week 4), relative to baseline.
[Table 1. Fecal bi dobacteria abundance and gastrointestinal symptom 
severity (GSRS-IBS scores) at baseline and a er the intervention (week 4).]
OP202 THE EFFICACY OF LACTIBIANE IKI (BIFIDOBACTERIUM 
LACTIS LA 304, LACTOBACILLUS SALIVARIUS LA 302, LACTOBACILLUS 
ACIDOPHILUS LA 201) IN REDUCING ABDOMINAL SYMPTOMS 
AND INFLAMMATORY BIOMARKERS IN ACUTE UNCOMPLICATED 
DIVERTICULATIS
Petruzziello C.1, Marannino M.2, Migneco A.3, Franceschi F.2, Ojetti V.4
1Fondazione Policlinico A. Gemelli, Emergency Medicine, Roma, Italy, 
2Policlinico Gemelli, Catholic University, Emergency Medicine, Roma, Italy, 
3Emergency Medicine, Roma, Italy, 4Policlinico A. Gemelli Internal Med. and 
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Introduction: Diverticular Disease (DD) is the most frequent abnormality in 
the digestive tract mainly in developed countries.
Most of people suff ering from DD are asymptomatic, while 20% experi-
ence abdominal symptoms and eventually complications, episodes of di-
verticulitis or bleeding. 
Acute Uncomplicated Diverticulitis (AUD) is defi ned as the infl ammation of 
a colon diverticulum, oft en involving colic wall and pericolic fat. Conven-
tional treatment of AUD includes antibiotic therapy, usually Ciprofl oxacin 
and Metronidazole, fasting and fl uid therapy.
Although several studies have been performed aimed at evaluating the 
clinical effi  cacy of probiotics in AUD, no defi nitive results have been 
achieved yet.
Aim of our pilot study is to test the effi  cacy of Bi dobacterium Lactis LA 304, 
Lactobacillus Salivarius LA 302, Lactobacillus Acidophilus LA 201 (Lactibiane 
IKI, Biocure), in association with conventional antibiotics in treating AUD 
compared to conventional antibiotic therapy.
Aims & Methods: We enrolled 84 (25M/59F mean age 61,5 +- 11,5 years) 
consecutive patients who came to the Emergency Department of Founda-
tion Policlinico A. Gemelli Hospital with a diagnosis of AUD. All patients 
performed routine blood test, dosage of C-Reactive Protein value and they 
were then randomly divided into two groups.
Group A (42 patients, 10M/32F mean age 32,23 +- 10,3 years) was treated 
with ciprofl oxacin 400mg twice a day and metronidazole 500mg three 
times a day for one week, with a supplementation of Lactibiane IKI twice 
a day for 10 days.
Group B (42 patients, 15M/27F mean age 59,01 +- 11,3 years) was treated 
with ciprofl oxacin 400mg twice a day and metronidazole 500mg three 
times a day for one week.
All patients fi lled a daily Visual Analog Scale (VAS) for abdominal pain, 
with a range value from 0 (asymptomatic) to 10, and C-RP value was de-
termined on admission and at discharge.
Primary outcome of the study is the reduction of abdominal pain and in-
fl ammatory markers (C-RP) in the group treated with Lactibiane IKI sup-
plementation.
Results: All patients completed the study. No side eff ect were observed.
As regards the VAS values: between day 1 and 3, group A decreased 4.07 
points of vas scale, group B decreased 2.79 points of vas scale (p=0,0002); 
between day 1 and 5 group A decreased 6.3 points of vas scale, group B 
decreased 4.85 points of vas scale (p< 0,0001); between day 1 and 7 group 
A decreased 7.26 points of vas scale, group B decreased 6.1 points of vas 
scale (p < 0,0001); between day 1 and 10 group A decreased 7.8 points of 
vas scale, group B decreased 7.2 points of vas scale (p=0,048). 
Regarding C-RP value, the mean decrease between the admittance value 
and aft er 72h was 49 mg/l for group A and 21,8 mg/l for group B (p=0,006). 
Finally, group A has a mean of 88,8 +- 17 hours (3,7 days) of hospitaliza-
tion in BOU, meanwhile group B has a mean of 101 +- 20 hours (4,2 days) 
(p< 0,05).
Conclusion: Our study showed that the supplementation with Lactibiane 
IKI in the standard AUD therapy signifi cantly reduce abdominal pain and 
infl ammatory markers compared to control group.
These interesting results could be due to its anti-infl ammatory activity, 
already well documented in the IBD therapy. Larger studies are needed to 
validate its use in the clinical practice.
Disclosure: Nothing to disclose 
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However, aft er the 4 weeks washout period no diff erence between the 
groups was detected. Overall GI symptom severity (GSRS-IBS total score) 
or individual GI symptoms did not diff er between the groups aft er the 
treatment (ns, non-signifi cant). However, tendencies towards improve-
ments of GI symptom severity within the groups were observed at the end 
of the intervention (week 4). The 10g group showed a trend towards re-
duction in overall GI symptom severity (GSRS-IBS total score) compared 
to baseline (p=0.076), whereas the placebo group showed reduction of 
overall GI symptom severity, bloating and diarrhea at the end of the inter-
vention (p< 0.05 for these comparisons). No symptom deterioration was 
seen in any of the groups.
Conclusion: In conclusion, 10g HMO dose of 2’FL/LNnT mix is able to in-
duce the growth of the benefi cial bacteria Bi dobacterium in patients with 
IBS without aggravating gastrointestinal symptoms. This approach may be 
worthwhile to restore IBS gut microbiota towards a healthy profi le.
Disclosure: Nothing to disclose 
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Introduction: Data on the preclinical stage of ulcerative colitis (UC) are 
sparse. At diagnosis, UC oft en shows a modest increase in systemic in-
fl ammatory markers like C-reactive protein (CRP). However, a subclinical 
infl ammation with elevated levels of CRP and interleukin-6 (IL6) in se-
rum have been observed several years before diagnosis [1]. First-degree 
relatives, including healthy twin siblings, also display elevated levels of 
some infl ammatory markers as a consequence of shared genetic and en-
vironmental risk factors [2]. It is reasonable to believe that the preclinical 
infl ammation, refl ecting early pathogenic mechanisms, ultimately leads to 
a diagnosis of UC.
Aims & Methods: We aimed to deeper examine the systemic preclinical 
infl ammation in UC using a comprehensive set of protein markers. Cases 
with UC were identifi ed at clinical follow-up of a prospectively collected 
population-based cohort of healthy individuals from northern Sweden. 
Plasma samples from cases and controls were subjected to proximity ex-
tension assay for relative quantifi cation of 92 protein markers of infl am-
mation. Results were validated in an inception cohort of treatment naïve, 
newly diagnosed patients with UC (n=101) vs. healthy controls (n=50). In 
addition, to examine the impact of shared genetic and environmental fac-
tors, a cohort of healthy mono- and dizygotic twin siblings of twins with UC 
(n=41) and matched healthy controls (n=37) were explored.
Results: Pre-diagnostic plasma samples from 72 cases who later in life de-
veloped UC and 140 controls, matched for gender, age, year of health sur-
vey and area of residence, were identifi ed (table 1). Six proteins were sig-
nifi cantly upregulated (p< 0.05) in pre-diagnostic UC compared to matched 
healthy controls. A receiver-operating curve based prediction model using 
the six protein markers combined with sex, age, smoking status and time 
to diagnose was set up for validation. The model discriminated newly di-
agnosed, treatment naïve UC cases from healthy controls (AUC=0.96; CI 
0.93-0.98). An AUC of 0.73 (CI 0.62-0.84) was observed when the model 
was applied to healthy twin siblings vs. healthy controls and four out of 
six proteins were upregulated similarly as in the pre-diagnostic samples. 
The relative levels of the six proteins showed an intermediate upregulation 
in pre-diagnostic samples and samples from healthy twin siblings com-
pared to samples at diagnosis of UC. Only one protein showed a signifi cant 
correlation with time to diagnosis in the pre-diagnostic samples. Using 
pathway analysis, the six protein upregulations pointed towards subclini-
cal infl ammation in UC being caused by dysregulation of four immune 
pathways.
Conclusion: This is the fi rst comprehensive characterisation of preclinical 
systemic infl ammation in UC. Infl ammatory proteins were upregulated 
several years prior to diagnosis of UC and to some extent these alterations 
were also seen in healthy twin siblings of UC patients. Characterisation of 
the preclinical stage of UC could pave the way for identifi cation of predic-
tive biomarkers and preventive strategies.
  Ulcerative colitis n=72
Controls 
n=140
BMI (IQR) 25.0 (23.2-27.5) 25.5 (23.1-27.8)
Sex; male (%) 34 (47.2) 64 (45,7)
Smoking status, current (%) 22 (30.6) 22 (30.6)
Median (range) age at sample (years) 50 (30-70) 50 (30-70)
Median (range) age at diagnosis (years) 54 (31-75)  
Disease extent (%)    
Proctitis (E1) 16 (22.2)  
Left -sided colitis (E2) 28 (38.9)  
Extensive colitis (E3) 28 (38.9)  
[Table 1. Clinical and demographic characteristics (before diagnose >1 year).]
References: 1. Lochhead P, Khalili H, Ananthakrishnan AN, Richter JM, 
Chan AT. Association Between Circulating Levels of C-Reactive Protein 
and Interleukin-6 and Risk of Infl ammatory Bowel Disease. Clinical gas-
troenterology and hepatology : the offi  cial clinical practice journal of the 
American Gastroenterological Association. 2016;14(6):818-24 e6. PubMed 
PMID: 26844874 2. Zhulina Y, Hahn-Stromberg V, Shamikh A, Peterson CG, 
Gustavsson A, Nyhlin N, et al. Subclinical infl ammation with increased 
neutrophil activity in healthy twin siblings refl ect environmental infl uence 
in the pathogenesis of infl ammatory bowel disease. Infl ammatory bowel 
diseases. 2013;19(8):1725-31. PubMed PMID: 23669399.
Disclosure: DB, EA, PK, DR, JH; Nothing to disclose CE has received consul-
tant/lecture fees from AbbVie, Janssen, Takeda. J. Halfvarson has received 
consultant/lecture fees from Abbvie, Celgene, Celltrion, Ferring, Hospira, 
Janssen, Medivir, MSD, Pfi zer, Prometheus, Sandoz, Shire, Takeda, Tillotts 
Pharma, and Vifor Pharma and grant support from Janssen, MSD, and 
Takeda 
OP205 OVERALL AND CAUSE-SPECIFIC MORTALITY IN 
MICROSCOPIC COLITIS: A DANISH NATIONWIDE MATCHED 
COHORT STUDY
Nyboe Andersen N.1, Munck L.K.2,3, Hansen S.4, Jess T.5, Wildt S.2,3
1Gento e Hospital, Department of Internal Medicine, Copenhagen, Denmark, 
2Zealand University Hospital Køge, Internal Medicine, Køge, Denmark, 
3Faculty of Health and Medical Sciences, University of Copenhagen, 
Department of Clinical Medicine, Copenhagen, Denmark, 4Centre for 
Clinical Research and Prevention, Frederiksberg and Bispebjerg Hospital, 
Copenhagen, Denmark, 5Statens Serum Institut, Department of Epidemiology 
Research, Copenhagen S, Denmark
Contact E-Mail Address: nynne@nyboeandersen.com
Introduction: Microscopic colitis (MC) is a chronic infl ammatory disease 
characterized by watery diarrhea and characteristic histological fi ndings 
in the setting of a normal macroscopic appearance of the colonic mucosa. 
The etiology is assumedly multifactorial and smoking is a known risk fac-
tor. 
The disease course in MC is generally considered benign. However, the 
long-term natural history remains largely unknown and the risk of death 
in these patients has not been systematically evaluated.
Aims & Methods: Using Danish nationwide registry information, we aimed 
to investigate the overall and cause-specifi c mortality in a large consecu-
tive and unselected cohort of patients with MC.
All patients with an incident diagnosis of MC from 2001-2017 were identi-
fi ed from the national pathology and patient registry. Patients were sub-
categorized according to subtype of MC, lymphocytic colitis (LC) and col-
lagenous colitis (CC).
Overall and cause-specifi c mortality in patients with MC was compared 
with that of an age and sex matched cohort from the general population 
(controls) in a variable 1:10 ratio. The relative risk of death was analyzed 
with Cox regression models, estimating both crude and comorbidity-ad-
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nomograms and threshold probabilities of 0-0.3 for LNM or 0-0.2 for LIM 
were the most benefi cial for predicting LNM and LIM with our nomograms. 
Receiver operating characteristic curves indicated good discrimination in 
the training set (area under the curve [AUC] = 0.667, 95% CI=0.661-0.673) 
and the testing set (AUC=0.658, 95% CI=0.649-0.667) for the LNM nomo-
gram and encouraging performance in the training set (AUC=0.766, 95% 
CI=0.760-0.771) and the testing set (AUC=0.825, 95% CI=0.818-0.832) for 
the LIM nomogram.
Conclusion: In conclusion, based on the clinical risk factors identifi ed in a 
large population-based cohort, we established the fi rst practical nomo-
grams that can objectively and accurately predict individualized risk of 
LNM and LIM. Moreover, the internal cohort validation results demonstrate 
that the two nomograms perform well and have high accuracy and reli-
ability. Our nomograms were demonstrated to be clinically useful in DCAs, 
and they should therefore help clinicians to improve individual treatment, 
make clinical decisions and guide follow-up management strategies for 
patients with early colon carcinoma.
Disclosure: Nothing to disclose 
OP207 LPA-INDUCED GPR35 SIGNALLING IN MACROPHAGES 
RESULTED IN ALTERED CYTOKINE EXPRESSION AND MODULATION 
OF COLITIS
Kaya B.1, Cuadra C.D.2, Hruz P.3, Villablanca E.J.2, Niess J.H.1,3
1University of Basel, Department of Biomedicine, Basel, Switzerland, 
2Karolinska Institute, Department of Medicine, Immunology and Allergy Unit, 
Stockholm, Sweden, 3St. Clara Hospital and University Hospital Basel, Basel, 
Switzerland
Contact E-Mail Address: berna.kaya@unibas.ch
Introduction: Host- or bacterial-derived metabolites orchestrate immune 
responses in infl ammatory bowel diseases through G protein-coupled re-
ceptors. Genome-wide association studies indicated that polymorphisms 
in GPR35 are associated with an increased risk of ulcerative colitis (UC) 
and primary sclerosing cholangitis (1). The chemokine CXCL17, the tryp-
tophan metabolite kynurenic acid (KNA) and the phospholipid derivative 
lysophosphatidic acid (LPA) have been suggested as potential ligands (2). 
GPR35 also interacts with the sodium potassium pump to ensure electro-
chemical gradients in epithelial cells (3). The endogenous ligand and cell 
type in which GPR35 signaling modulate intestinal infl ammation is rather 
unexplored.
Aims & Methods: To investigate GPR35 in macrophages the mouse lines 
GPR35tdTomato, GPR35Ko and GPR35ΔCX3CR1, in which tamoxifen injection 
silences GPR35 expression in CX3CR1+macrophages have been created. Po-
tential ligands were screened in Gpr35.2-defi cient zebrafi sh.
Results: In situ hybridization of Gpr35.2 in zebrafi sh 120 hours post fertil-
ization revealed restricted Gpr35.2expression in the intestine. Ex vivo im-
aging of GPR35tdTomato / CX3CR1-GFP double reporter animals showed 
GPR35 expression by intestinal epithelial cells and CX3CR1+ macrophages. 
Flow cytometry confi rmed that monocytes but not B cells, T cells and in-
nate lymphoid cells express GPR35. During the development of monocytes 
into gut macrophages GPR35 expression is down-regulated, which can be 
discriminated in GPR35-positive and -negative macrophages with higher 
Tnf, Il1band Il23expression by GPR35-positive macrophages. Gpr35 expres-
sion is regulated by the microbiota as antibiotic-treated zebrafi sh and mice 
as well as germ-free mice have reduced GPR35 expression. Conversely, 
TNBS-colitis in zebrafi sh, DSS-colitis in mice induced GPR35 expression 
in macrophages, and increased numbers of GPR35-positive macrophages 
were present in infl amed regions of UC patients. Potential agonistic li-
gands of GPR35, were screened with a Chinese Hamster Ovary (CHO)-K1 
GPR35 Gi cell line, that stably overexpressed human GPR35 coupled to an 
inhibitory G protein which inhibits forskolin-induced cAMP accumulation 
in response to GPR35 agonists. LPA and CXCL17 but not KYNA inhibited 
forskolin-induced cAMP production, and the potential candidate LPA was 
further tested in Gpr35.2-defi cient zebrafi sh. As macrophages express oth-
er lysophophospatic acid receptors bone marrow-derived macrophages 
from GPR35Ko mice were stimulated with GPR35. LPA induced tnf,Ilband 
Ila production in macrophages and induced macrophage migration in a 
GPR35-dependent manner. Increased expression of autotaxin, which con-
verts lysophosphatidylcholine into LPA, was observed in zebrafi sh and 
mice undergoing intestinal infl ammation. In agreement with the potential 
activation of GPR35 during colitis, GPR35-defi cient mice have increased 
DSS-colitis severity. The deletion of GPR35 in CX3CR1+ macrophages in-
justed hazard ratios (HRs) with 95% confi dence intervals (CIs). Analyses 
were stratifi ed according to sex, age at diagnosis and subtype of MC.
Results: A total of 14.024 patients with MC of whom 42% had LC were 
identifi ed. The mean age at diagnosis was 63.6 years for patients with LC 
and 67.0 years for CC and patients were predominantly female (64.4% of 
LC patients and 74.4% of CC patients). 
During follow up, 3047 patients with MC died compared to 26.395 in the 
control group, unraveling a 25% signifi cantly increased risk of death (HR 
1.25; 95% CI, 1.20-1.30) in crude analyses. The mortality was attenuated 
in analyses adjusted for comorbidity, however, the relative risk remained 
signifi cantly augmented (HR 1.08; 95% CI, 1.04-1.13). Stratifying accord-
ing to MC subtype, crude analyses showed a signifi cantly increased risk of 
death in both patients with LC (HR 1.30; 95% CI, 1.22-1.39) and CC (HR 1.21; 
95% CI, 1.16-1.27). Again, the risk of death, although reduced, remained 
signifi cant increased, in comorbidity-adjusted analyses (HR
LC 
1.13; 95% CI, 
1.06-1.20 and HR
CC 
1.06; 95% CI, 1.00-1.11). 
Compared to matched controls, patients with MC were more likely to die 
due to infections, diabetes, ischemic heart diseases and chronic lung dis-
eases.
Conclusion: In an unselected large nationwide cohort of MC patients, the 
risk of death was signifi cantly increased compared to the background pop-
ulation. The increased mortality was largely, but not entirely, associated 
to an increased burden of comorbidities and patients with MC were more 
likely to die from smoking-related diseases. 
The increased mortality associated with a diagnosis of MC, as observed 
in our study, is however unexpected and needs to be confi rmed in other 
large cohorts.
Disclosure: Nothing to disclose 
OP206 NOVEL NOMOGRAMS TO PREDICT LYMPH NODE 
METASTASIS AND LIVER METASTASIS IN PATIENTS WITH EARLY 
COLON CARCINOMA
Yan Y., Mao K., Zhang J., Wang J., Xiao Z.
Sun Yat-Sen University, Hepatobiliary Surgery of Sun Yat-Sen Memorial 
Hospital, Guangzhou, China
Contact E-Mail Address: yanyc@mail2.sysu.edu.cn
Introduction: The poor prognosis and frequent recurrence of colon carci-
noma might be related to lymph node metastasis (LNM) and distant me-
tastasis. Advanced colon carcinoma (stage III or IV) is diagnosed when 
LNM or distant metastasis occurs, regardless of the pathologic T (pT) clas-
sifi cation. Studies have indicated that 27.3% of patients diagnosed with 
colon carcinoma develop liver metastasis (LIM) during the course of their 
disease. We attempted to develop and validate nomograms to predict LNM 
and LIM in patients with early colon carcinoma (pT1+pT2) .
Aims & Methods: A total of 32,819 patients who underwent surgery be-
tween 2004 and 2015 for pT1 or pT2 colon carcinoma were enrolled in the 
study and divided into a training set (n=21880) in an earlier period and a 
validation set (n=10939). Univariable and multivariable analysis were used 
to identify independent risk factors predictive of LNM and LIM in the SEER 
discovery set. All variables were screened using the forward stepwise se-
lection method in a multivariate binary logistic regression model. Cali-
bration curves were plotted to validate the accuracy and reliability of the 
nomograms by the Hosmer-Lemeshow test. The predictive performance of 
the nomograms was measured by a receiver operating characteristic (ROC) 
curve.The predictive accuracy and clinical values of the nomograms were 
measured by decision curve analysis (DCA) by calculating the net benefi ts 
at each risk threshold probability. The predictive nomograms were further 
validated in the internal testing set.
Results: LNM was present in 3111 of 21880 patients (14.2%) and 30 of 10939 
patients (14.5%) in the training and testing sets, respectively. LIM occurred 
in 1.5% of patients in the training set and 1.2% of patients in the testing 
set. In the correlation analysis, fi ve variables, namely, histological grade, T 
classifi cation, tumor size, serum CEA level and overall survival, were sig-
nifi cantly correlated (P< 0.001) with LNM and LIM in both the training and 
testing sets. Based on the independent risk factors identifi ed in the multi-
variate regression analysis, two nomograms were developed to predict the 
possibility of LNM (marital status, histological grade, histological type, T 
classifi cation, tumor size and serum CEA level) and LIM (age, histological 
grade, tumor size, serum CEA level and N classifi cation). The calibration 
curves showed perfect agreement between nomogram predictions and ac-
tual observations. DCAs indicated the clinical usefulness of the prediction 
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dicated that GPR35 signaling in macrophages is critical for the increased 
severity of DSS colitis. GPR35 deletion in macrophages resulted in reduced 
tnf production by macrophages. As TNF regulates CYP11A1 and CYP11B1ex-
pression required for extraadrenal corticosterone synthesis, the silencing 
of GPR35 in macrophages was associated with reduced intestinal CYP11A1 
and CYP11B1 expression.
Conclusion: LPA-induced GPR35-signalling in macrophages modulates 
cytokine responses and colitis. The depletion of GPR35 in macrophages 
resulted in increased DSS colitis severity associated with reduced CYP11A1 
and CYP11B1expression involved in extraadrenal corticosterone synthesis.
References: 1. Ellinghaus, D et al. Hepatology. 2013; 58(3):1074-83 2. Mil-
ligan G. Br J Pharmacol. 2018;175(13):2543-2553. 3. Schneditz, G et al. Sci 
Signal. 2019;12(562)
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OP208 EFFICACY AND SAFETY OF UPADACITINIB AS AN 
INDUCTION THERAPY FOR PATIENTS WITH MODERATELY-TO-
SEVERELY ACTIVE ULCERATIVE COLITIS: COMBINED RESULTS 
FROM 382 SUBJECTS IN THE PHASE 2B STUDY U-ACHIEVE
Higgins P.D.R.1, Hébuterne X.2, Siffl  edeen J.3, Zhou W.4, Cataldi F.4, Xie W.4, 
Lacerda A.4, Danese S.5
1University of Michigan, Ann Arbor, United States, 2Service de Gastro-
Entérologie et Nutrition Clinique, Université de Nice-Sophia-Antipolis, Nice, 
France, 3University of Alberta, Edmonton, Canada, 4AbbVie Inc., Chicago, 
United States, 5Istituto Clinico Humanitas, Milan, Italy
Contact E-Mail Address: phiggins@med.umich.edu
Introduction: The effi  cacy and safety of upadacitinib (UPA), an oral Janus 
Kinase 1-selective inhibitor, were assessed in an 8-week double-blind, 
placebo-controlled, dose-ranging phase 2b induction study (part 1) in pa-
tients with moderately-to-severely active ulcerative colitis (UC) who had 
inadequate response, loss of response, or intolerance to corticosteroids, 
immunosuppressives, or biologic therapies.1,2 During the analysis of part 1, 
additional patients were enrolled in part 2 to avoid interrupting the study 
activities and to provide a suffi  cient number of clinical responders for the 
maintenance portion of the study.
Aims & Methods: We present the effi  cacy and safety of the combined re-
sults of part 1 and part 2 of U-ACHIEVE.
Adult patients with moderately-to-severely active UC (Adapted Mayo Score 
5-9 points and centrally-read endoscopy subscore 2-3) were randomised 
in a 1:1:1:1:1 ratio to receive extended-release UPA 7.5, 15, 30, 45mg once 
daily (QD) or placebo for 8 weeks (N=250). In part 2, an additional 132 
patients were randomised to UPA 30 or 45mg QD with 1:1 allocation for 
8 weeks. Pairwise comparisons between UPA doses and placebo for the 
primary endpoint of clinical remission per Adapted Mayo Score at Week 8 
(defi ned as stool frequency subscore ≤1, rectal bleeding subscore =0, and 
endoscopic subscore ≤1) and ranked secondary endpoints were conducted 
using the Cochran-Mantel-Haenszel test stratifi ed by previous biologic use, 
baseline corticosteroid use, and baseline Adapted Mayo score. No multi-
plicity adjustments were applied. Non-responder imputation was utilized 
for missing values in 13% of patients. Treatment emergent adverse events 
(AEs) were reported from fi rst dose of study drug to up to 30 days aft er 
last dose.
Results: A total of 382 patients were randomised with a mean (SD) age 
of 42.7 (14.3) years and a disease duration of 8.4 (7.4) years. The primary 
endpoint of clinical remission, and secondary endpoints of endoscopic im-
provement, clinical response per Adapted Mayo score, clinical response 
per Partial Mayo score, endoscopic remission, and histologic improvement 
were signifi cantly higher with UPA doses ≥30mg QD compared to placebo 
(Table). Incidences of AEs and AEs leading to discontinuation were similar 
across UPA groups, and numerically higher in the placebo group. Rates 
of serious AEs were 10.9%, 0%, 4.1%, 4.3% and 4.9% for placebo and 
UPA 7.5, 15, 30, and 45mg QD, respectively. Serious infections occurred in 
patients receiving placebo (4.3%, n=2), 15mg QD (2.0%, n=1), 30mg QD 
(0.9%, n=1), and 45mg QD (1.6%, n=2). One case of herpes zoster and one 
case of pulmonary embolism (PE)/deep vein thrombosis (DVT) with UPA 
45mg QD were reported. The case of PE/DVT was reported 26 days aft er 
study drug discontinuation due to UC worsening and hospitalization. No 
deaths were reported.
Conclusion: In this combined analysis, primary and ranked secondary end-
points consistently met statistical signifi cance with UPA doses ≥ 30mg QD 
compared with placebo in patients with moderately-to-severely active UC. 
These results are consistent with the part 1 intention-to-treat analysis.1,2 
UPA was well-tolerated, and no new safety signals were identifi ed com-
pared to previous studies of UPA.3
References: 
1. Sandborn, W.J., et al. Presentation #OP195. United European Gastroen-
terology (UEG) Week 2018.
2. Sandborn, W.J., et al. Presentation #OP14. European Crohn´s and Colitis 
Organisation 2019.
3. Burmester et al., Lancet 2018; 391(10139):2503-12.
Disclosure: P.D.R. Higgins: consultancy fees from AbbVie, PRIME Medical 
Education, UCB, Takeda, Amgen, Lilly, Lycera, research funding from Jans-
sen, AbbVie, Pfi zer, Lilly, UCB, Takeda, Janssen, Arena, NIH, and CCF.
X. Hébuterne: Clinical Research: AbbVie, Abivax, Alphasigma, Cellgène, 
Gilead, Eli Lilly, Enterome, Janssen, InDex Pharmaceuticals, Pfi zer, Roche, 
Salix, Takeda, and Theravance. Advisory Boards: AbbVie, Abivax, Ar-
kopharma, Astellas, Janssen, Nutricia, Pfi zer, Roche and Takeda. Lecture 
fees: AbbVie, ARARD, Arkopharma, Baxter, Bristol Myers Squibb, Ferring, 
Janssen, MSD, Nutricia, Pfi zer, Sanofi -Advantis, Takeda, and Tillots.
J. Siffl  edeen: consultancy and/or speaking honoraria fees from AbbVie 
Inc, Janssen Pharmaceuticals, Allergan, Takeda, Ferring Pharmaceuticals, 
Shire, Pfi zer. Educational grants from AbbVie Inc.
S. Danese: has served as a speaker, consultant and/or advisory board mem-
ber for AbbVie, Actelion, Alphawasserman, Astra Zeneca, Cellerix, Cosmo 
Pharmaceuticals, Ferring, Genentech, Grunenthal, Johnson&Johnson, Mil-
lennium, Merck & Co., NovoNordisk, Nycomed, Pfi zer, Pharmacosmos, 
Schering-Plough, Salix, Takeda, UCB Pharma, and Vifor.
W. Zhou, F. Cataldi, W. Xie, and A. Lacerda are Abbvie employees; may 
own AbbVie stock and/or options
Role of authors and sponsor: The authors and AbbVie scientists designed 
the study, and analysed and interpreted the data. AbbVie funded the re-
search and provided writing support. All authors contributed to the devel-
opment of the content. The authors and AbbVie reviewed and approved 
the abstract; the authors maintained control over the fi nal content.
Acknowledgements: AbbVie and the authors thank the patients who 
participated in the study and all study investigators for their contributions. 
Ramona Vladea, PhD, of AbbVie Inc., provided medical writing support in 
the development of this abstract. 
Endpoints, n (%) PlaceboN=46
UPA
7.5 mg QD
N=47
UPA
15 mg QD
N=49
UPA
30 mg QD
N=117
UPA
45 mg QD
N=123
Clinical remission per 
Adapted Mayo Score (SFS 
≤1, RBS=0, and ES ≤1) at 
Week 8a
0 4(8.5) 7(14.3)* 25(21.4)*** 22(17.9)**
Endoscopic Improvement 
(ES ≤1) at Week 8b
1(2.2) 7(14.9)* 15(30.6)*** 40(34.2)*** 42(34.1)***
Clinical response per 
Adapted Mayo score 
(decrease from baseline 
≥2 points and ≥30% and 
in RBS ≥1 or an absolute 
RBS ≤1) at Week 8b
6(13.0) 13(27.7)+ 22(44.9)*** 63(53.8)*** 65(52.8)***
Clinical response per 
Partial Mayo score 
(decrease from baseline 
≥2 points and ≥30% and 
in RBS ≥1 or an absolute 
RBS ≤1) at Week 2b
7(15.2) 11(23.4) 18(36.7)* 52(44.4)*** 63(51.2)***
Endoscopic remission 
(ES=0) at Week 8b
0 3(6.4)+ 2(4.1) 19(16.2)** 20(16.3)**
Histologic improvement 
(any decrease from 
baseline in Geboes score) 
at Week 8b
3(6.5) 16(34.0)** 25(51.0)*** 55(47.0)*** 62(50.4)***
aPrimary Endpoint; bRanked Secondary Endpoints
***, **, *, and + signifi cant at 0.001, 0.01, 0.05, and 0.1 levels, respectively compared with 
placebo
UPA=upadacitinib; QD=once daily; SFS=stool frequency subscore; RBS=rectal bleeding 
subscore; ES=endoscopic subscore
[Table]
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OP210 MULTICENTER PROSPECTIVE RANDOMIZED STUDY TO 
COMPARE ENDOSCOPIC TREATMENT OF STRICTURES IN CROHN´S 
DISEASE: SELF-EXPANDING METAL STENTS VS ENDOSCOPIC 
BALLOON DILATION. PROTDILAT STUDY
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Introduction: Endoscopic Balloon Dilation (EBD) is the established endo-
scopic treatment for short strictures in Crohn´s Disease (CD). Self-expand-
ing metallic stents (SEMS) have been used for the treatment of refractory 
strictures with good results in patients that failed to dilation.
Hypothesis: Endoscopic treatment of strictures in CD by placing a SEMS is 
more eff ective than EBD.
Aims & Methods: Objectives: 
1)To compare the effi  cacy and safety of endoscopic treatment (SEMS vs 
EBD) in CD patients with stenosis; 
2) To perform a comparative cost study.
Methods: Randomized, prospective, multicenter clinical trial of patients 
with CD and obstructive symptoms with stenosis < 10 cm and refractory to 
medical treatment. We exclude patients with stenosis previously treated 
with SEMS and/or EBD in the previous year and with stenosis no acces-
sible to colonoscopy. The main outcome was to determine the effi  cacy of 
the endoscopic treatment defi ned by the percentage of patients free of a 
new therapeutic intervention (EBD, SEMS or surgery) due to symptomatic 
recurrence at one year of follow-up. Those who failed the endoscopic pri-
mary treatment were crossed over to the other endoscopic option. A direct 
cost study was done.
Results: A total of 99 patients from 19 Spanish hospitals were randomized, 
19 were excluded because they did not fulfi l the inclusion criteria. Eighty 
patients, 39 women, with a median age of 45 (IQR: 38-54.7) were fi nally 
included. The primary treatment was 39 SEMS and 41 EBD for ITT analysis. 
In 42.5% of the cases the stenosis was in the anastomosis site whereas 
in 57.5% were de novo strictures. The median length of the strictures was 
3.4 cm (IQR: 2-5.5). No diff erences related to demographic, disease, treat-
ment and stenosis characteristics were found between the two groups. 
The success rate of EBD and SEMS was 80.5% and 51.3%, respectively (Ad-
justed OR, 3.5; 95% CI, 1.3-9.6; p=0.016). In a subanalysis of patients with 
strictures >3 cm diff erences between the 2 endoscopic procedures disap-
peared (EDB: 66.7% vs SEMS: 63.6%). In multivariate analysis of patients 
with EBD, the only variable associated with the success was the length of 
the stricture (OR, 1.05; 95% CI, 1.01-1.10; p=0.038). A 6.3% adverse events 
were reported without diff erences between the two treatments. Only 3 
complications were related to endoscopic procedure (1 perforation in each 
therapy arm, 1 mild self-limited hemorrhage in EBD group). The average 
OP209 PROMINENCE OF ILEAL MUCOSA ASSOCIATED 
MICROBIOTA TO PREDICT POST-OPERATIVE ENDOSCOPIC 
RECURRENCE IN CROHN´S DISEASE
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Gastroenterology, Clermont-Ferrand, France, 6Amiens University Hospital, 
Gastroenterology Department, Amiens, France, 7Saint-Louis Hospital 
International Program to Develop New Indexes in Cr, Lille, France, 8Saint 
Louis Hospital, Paris, France, 9Hopital Beaujon, Asnieres, France, 10CHU Lyon, 
Lyon, France, 11Hopital Saint-Louis APHP, Université Denis Diderot Paris 7, 
Gastroenterology, Paris, France, 12Gastroenterology & Nutrition Department, 
Gastroenterology and Nutrition Unit, Paris, France
Contact E-Mail Address: harry.sokol@aphp.fr
Introduction: Following ileal resection for Crohn’s disease (CD), recurrence 
is very frequent. Although several clinical risk factors of recurrence have 
been identifi ed, predicting relapse remains challenging. Performing an il-
eocolonoscopy within the fi rst year aft er surgery is currently recommended 
to assess endoscopic recurrence and adjust the treatment.
Aims & Methods: We took advantage of a large prospective multicentric 
cohort to investigate the role of the ileal mucosa-associated microbiota 
in post-operative endoscopic recurrence. This is a prospective study per-
formed in 9 centers of the REMIND group, collecting clinical and biological 
data at time of surgery and of endoscopy (performed at 6 months). Ileal 
mucosa-associated microbiota was analyzed by 16S sequencing (MiSeq, 
Illumina) at the time of surgery and/or of endoscopic evaluation in 201 
patients (288 samples in total) prospectively recruited in France. The ob-
tained sequences (rarefi ed to 5000 read/sample) were analyzed using the 
Qiime pipeline to assess composition, alpha and beta diversity. Linear dis-
criminant analysis eff ect size (LEfSe) pipeline was used to identify bacterial 
taxa diff erentially represented. We used logistic regression and Random 
Forest to evaluate the role of the gut microbiota at the time of surgery to 
predict endoscopic recurrence (defi ned by a Rutgeerts score >i1).
Results: Among the 201 patients included: 98 (49%) were male, mean age 
at surgery was 35 years (SD 12), 66 patients (33%) were active smoker at 
time of surgery, 39 patients (19%) had a previous resection, and 47 patients 
(23%) had perianal lesions. Indication for surgery was stricturing disease 
(116), penetrating disease (71). Aft er surgery, 48 patients received thio-
purines, and 68 patients received anti-TNF therapy. The microbiota was 
composed of bacteria from the Firmicutes, Proteobacteria, Bacteroidetes, 
Actinobacteria and Fusobacteria phyla. As expected, antibiotics treatment 
within one month before surgery had a dramatic impact on microbiota 
composition (Anosim, p < 0.0001) and diversity (Shannon index mean 4.3 
± 0.1 vs 3.7 ± 0.2, p=0.006). Ileal mucosa-associated microbiota exhibits 
profound changes following surgery in CD. Compared to non-recurrence 
setting, endoscopic recurrence was associated with strong changes in il-
eal mucosa-associated microbiota that were highly reminiscent of those 
observed generally in ileal CD compared to healthy subjects with a reduc-
tion in alpha diversity, increase in several members of the Proteobacteria 
phylum and decrease in several members of the Lachnospiraceae and the 
Ruminococcaceae families within the Firmicutes phylum. At the time of 
surgery, we identifi ed several bacterial taxa associated with endoscopic 
recurrence and that can better predict relapse than usual clinical risk fac-
tors (ROC Curve, Area under the curve, AUC: 97.1% [93.8%-100%] and 
81.0% [60.8%-100%] in the whole population and in the validation set 
respectively).
Conclusion: Surgery has an important impact on ileal-mucosa associ-
ated microbiota. Post-operative endoscopic recurrence is associated with 
changes in microbiota composition and alpha diversity. The gut microbiota 
has the potential to predict post-operative evolution and recurrence.
Disclosure: This study has been supported by grants from MSD France, 
Association François Aupetit, the Helmsley Charitable Trust and INSERM 
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cost for EBD patient was 802.83 euros (average 1.3 dilations) and for SEMS 
patients was 1827.06 euros (cost analysis of fi rst 55 randomized patients). 
A total of 20 patients were crossed over to the other endoscopic option; 
13 patients completed the follow-up (10 SEMS and 3 EBD initial failure 
crossed over to EBD and SEMS respectively) with a fi nal success of 10/10 in 
rescue EBD treatment and 1/3 in rescue SEMS treatment.
Conclusion: The EDB is more eff ective than SEMS for CD strictures, with 
a good safety profi le of both treatments. In addition, EBD is a more cost-
eff ective than SEMS. The length of the stricture is the only factor related 
to EBD success. The clinical scenario in which SEMS could be useful is 
strictures >3 cm. ClinicalTrials.gov NCT 02395354.
Disclosure: Dra. Carme Loras. Research grants as PI: 1. Spanish National 
Institute of Health grants: FIS PI13/01226. PROTDILAT STUDY (2014-2017) 
2. Grant from the Foundation of Spanish Society of Digestive Endoscopy 
PROTDILAT STUDY (2013) 3. Grant from the Catalan Society of Gastroen-
terology for intensifi cation of research activity 2015. Dr. Joan B Gornals: 
Consultor for Boston Scientifi c. Boston Scientifi c has funded the study in-
surance. Taewoong Medical has funded the stents used in the study. 
OP211 RIFAMYCIN SV-MMX® FOR ACUTE UNCOMPLICATED 
DIVERTICULITIS? RESULTS OF INNOVATIVE ANTIBIOTIC THERAPY 
FROM A PROSPECTIVE DOUBLE-BLIND, PLACEBO-CONTROLLED 
STUDY
Kruis W.1, Poskus T.2, Böhm G.3, Bunganic I.4, Racz I.5, Fratila O.-C.6, 
Barbara G.7, Nacak T.8, Greinwald R.8
1Evangelisches Krankenhaus Kalk, University of Cologne, Abt. fü Innere 
Medizin, Köln, Germany, 2Vilnius University Hospital Santariskiu Klinikos, 
Kaunas, Lithuania, 3Gastroenterologist in Private Practice, Ludwigshafen, 
Germany, 4Gastro I, s.r.o., Presov, Slovakia, 5Petz Aladár County and Teaching 
Hospital, 1st Department of Medicine and Gastroenterology, Györ, Hungary, 
6Spital Clinic Judetean de Urgenta Oradea, Oradea, Romania, 7University of 
Bologna, Department of Medical and Surgical Sciences, Bologna, Italy, 8Dr. 
Falk Pharma GmbH, Research & Development, Freiburg, Germany
Contact E-Mail Address: wolfgang.kruis@googlemail.com
Introduction: Traditionally, guidelines recommended bowel rest and an up 
to 10-day treatment regime with a broad-spectrum antibiotic in acute un-
complicated diverticulitis (AUD). Recent studies have questioned this com-
mon strategy. However, placebo-controlled studies are lacking, and if ef-
fective, the duration of treatment is unclear. We conducted a double-blind 
trial, studying therapeutic benefi ts of the novel broad-spectrum, poorly 
absorbed antibiotic Rifamycin SV multi-matrix (MMX®) in comparison to 
placebo.
Aims & Methods: The aim was to compare effi  cacy and safety of two doses 
of Rifamycin SV-MMX® versus placebo (PLC) in the oral treatment of AUD. 
This was an exploratory, double-blind, double-dummy, randomized multi-
center trial, with three treatment groups: (I) Rifamycin SV-MMX® 400mg 
BID (RIF800), (II) Rifamycin SV-MMX® 600mg TID (RIF1800) and (III) pla-
cebo (PLC). Out-patients with AUD proven by cross-sectional imaging and 
biomarkers were randomly assigned to one of the three treatment groups 
for a 10-day oral treatment. The primary endpoint was treatment success 
(required absence of fever, left  lower quadrant pain, CRP improvement 
and absence of complications) at day 10. Key secondary endpoint was com-
plete treatment success (required a normalization of CRP in addition) at 
days 0, 3, 7 and 10.
Results: A total of 201 patients qualifi ed for the full analysis set (FAS). Main 
baseline characteristics were: 60% female, mean age 58.6 years, mean 
BMI 29.1 kg/m², mean CRP 40.5 mg/l and intensity of abdominal left  lower 
quadrant pain of 5.6 cm (on a 10 cm visual analogue scale). The proportion 
of patients with treatment success at day 10 was numerically higher in the 
RIF800 group (62.2%) than in the PLC group (47.5%) (p=0.06) (Table 1). 
In a subgroup of patients with > 3 days of symptoms prior to start of the 
therapy both Rifamycin groups reached higher complete treatment success 
rates at day 10 compared to placebo, which was statistically signifi cant for 
the RIF800 group (Table 1). In addition, both Rifamycin groups achieved 
statistically signifi cant higher complete treatment success rates at day 3 
compared to placebo (p< 0.05) (Table 1). It is to be noted that none of 
the placebo treated patients had complete treatment success at day 3. No 
unexpected side eff ects occurred and the rate of adverse events did not 
diff er among groups. 
  Number (%) of patients
  RIF800 (n=82) RIF1800 (n=79) Placebo (n=40)
Treatment Success at day 10 51/82 (62.2%) / 
p=0.06
39/79 (49.4%) / 
p=0.42
19/40 (47.5%)
Complete Treatment Success at day 
10 for subgroup with >3 days of 
symptoms
16/30 (53.3%) / 
p=0.01
16/42 (38.1%) / 
p=0.08
1/12 (8.3%)
Complete Treatment Success at day 3 9/82 (11%) / 
p=0.03
10/79 (12.7%) / 
p=0.02
0/40 (0%)
[Table 1: Results from clinical e  cacy endpoints (FAS)]
Conclusion: Overall, antibiotic treatment with Rifamycin SV-MMX® trended 
to demonstrate therapeutic superiority over placebo in acute uncompli-
cated diverticulitis. It was faster than placebo in achieving complete treat-
ment success, with most pronounced eff ect already at day 3. The subgroup 
of patients with more than 3 days of symptoms of AUD benefi tted most 
from the Rifamycin treatment. The preferred dosis of Rifamycin seems to 
be 400mg BID. Rifamycin SV-MMX® was safe and well tolerated.
Disclosure: The following authors have fi nancial relationship with a com-
mercial interest: Wolfgang Kruis received lecture fees and travel costs by 
Dr. Falk Pharma GmbH. Roland Greinwald and Tanju Nacak received salary 
(employment) by Dr. Falk Pharma GmbH. 
OP212 PRECLINICAL AND CLINICAL EFFICACY OF OLORINAB, 
A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE FULL AGONIST 
OF THE CANNABINOID TYPE 2 RECEPTOR FOR THE MANAGEMENT 
OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE
Yacyshyn B.1, Brierley S.M.2, Lindstrom B.3, Adams J.3, Turner S.3, 
English B.A.3, Stauber K.3, Higgins P.D.R.4
1University of Cincinnati, Cincinnati, United States, 2Visceral Pain 
Research Group, Flinders University, SAHMRI, Adelaide, Australia, 3Arena 
Pharmaceuticals, Inc, San Diego, United States, 4University of Michigan, Ann 
Arbor, United States
Contact E-Mail Address: phiggins@med.umich.edu
Introduction: Abdominal pain is common in patients with infl ammatory 
bowel diseases (IBDs), including Crohn’s disease (CD), and available treat-
ments oft en fail to relieve this pain. Cannabinoid receptors can modulate 
visceral pain; however, clinical development of non-selective agonists is 
limited by unwanted psychoactive eff ects. Olorinab is a highly selective full 
agonist of the cannabinoid type 2 receptor (CB
2
) and showed low blood-
brain barrier penetration in rodents. Reported here, preclinical evalua-
tion assessed whether olorinab reduced visceral hypersensitivity in a rat 
model of IBD (colitis), and a randomized, open-label, multi-centre, phase 
2a study evaluated olorinab in patients with quiescent CD experiencing 
abdominal pain.
Aims & Methods: In preclinical study, colitis was induced using 12 mg 
2,4,6-trinitrobenzene sulfonic acid (TNBS) in 35% ethanol in rats, applied 
rectally. Vehicle or olorinab (3 or 30 mg/kg) was given twice daily for 5 
days in control or colitis rats beginning 1 day aft er TNBS. Visceral mech-
ano-sensitivity was measured in vivo as visceromotor responses (VMR) to 
colorectal distension (CRD; distension pressures 0-80 mm Hg). Colonic 
nociceptor fi ring was measured ex vivo.
In the phase 2a study, subjects aged 18-66 years with quiescent CD (simple 
endoscopic score-CD < 10 or faecal calprotectin < 500 µg/g) experiencing 
abdominal pain, defi ned as weekly average abdominal pain score (AAPS) 
≥4 on a scale of 0 (no pain) to 10 (worst possible), were randomly assigned 
1:1 to 25 or 100 mg oral olorinab 3 times a day (TID) for up to 8 weeks. 
Primary objectives were safety and tolerability. Effi  cacy endpoints included 
change in AAPS from baseline week (BL) to weeks 4 and 8, change in AAPS 
from pre-dose to 1.5 hours post-dose, and proportion of clinical respond-
ers (≥30% reduction in weekly AAPS from BL).
Results: Visceral hypersensitivity was observed in vehicle-treated colitis 
rats with higher VMR to CRD vs healthy controls (P< 0.05 at 20 mm Hg; P< 
0.01 at 40-80 mm Hg). Colitis rats treated with olorinab had lower VMR 
to CRD vs their vehicle-treated counterparts (P< 0.001, N=9/group). Con-
trol rats treated with olorinab did not show altered VMR to CRD (P>0.05, 
N=8-11/group). Olorinab reduced colonic nociceptor hypersensitivity in a 
concentration-dependent manner via CB
2
.
In the phase 2a study (N=14), AAPS signifi cantly improved at weeks 4 and 
8 from BL. Change in AAPS from BL to the time of peak concentration 
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the ‘Tofacitinib All’ group were: serious infections 1.61 (1.10, 2.27); her-
pes zoster (all) 3.35 (2.58, 4.27); major adverse cardiovascular events 0.15 
(0.03, 0.44); malignancies excl. non-melanoma skin cancer (NMSC) 0.85 
(0.50, 1.36); and NMSC 0.81 (0.46, 1.32), with no clustering of malignancy 
type; IRs by dose are shown in the Table. No new safety risks were identi-
fi ed. At Month 36 (NRI-LOCF) in the 5 and 10 mg BID groups, respectively, 
55.9% and 32.2% of pts were in remission, 62.5% and 35.8% had mucosal 
healing, and 65.8% and 38.9% showed clinical response.
Conclusion: In pts with moderate to severe UC in the OLE study with up to 
5.5 years of treatment, no new safety risks emerged vs those observed in 
earlier analyses of the OLE study2 or with tofacitinib in rheumatoid arthri-
tis. Effi  cacy data from the OLE study continue to support long-term effi  cacy 
with tofacitinib 5 or 10 mg BID up to 36 months beyond Wk52 of OCTAVE 
Sustain.
 
Tofacitinib 5 mg BID 
(N=175; 454 PY)
Tofacitinib 10 mg BID
(N=769; 1550 PY)
Tofacitinib All 
(N=944; 2004 PY)
  n (%) IR (95% CI) n (%) IR (95% CI) n (%) IR (95% CI)
Serious 
infectionsa
6 (3.4)b
1.33
(0.49, 2.89)
26 (3.4)c
1.69
(1.10, 2.48)
32 (3.4)
1.61
(1.10, 2.27)
Herpes zoster 
(all)a
11 (6.3)
2.49
(1.24, 4.45)
53 (6.9)d
3.61
(2.70, 4.72)
64 (6.8)
3.35
(2.58, 4.27)
MACEe,f 2 (1.1)g
0.44
(0.05, 1.59)
1 (0.1)h
0.06
(0.00, 0.36)
3 (0.3)
0.15
(0.03, 0.44)
Malignancies 
excluding 
NMSCe,f
5 (2.9)i
1.11
(0.36, 2.58)
12 (1.6)j
0.78
(0.40, 1.35)
17 (1.8)
0.85
(0.50, 1.36)
NMSCe,f 5 (2.9)
1.12
(0.36, 2.61)
11 (1.4)
0.72
(0.36, 1.29)
16 (1.7)
0.81
(0.46, 1.32)
Data are as of Sep 2018, database not locked
IRs were calculated as the number of unique patients with events per 100 PY
aEvents that occurred >28 days aft er the last dose of study drug were excluded for 
calculation of proportion and IR; bThree events were reported as severe (number of 
events): appendicitis (1), gastroenteritis norovirus (1), necrotising fasciitis (1); cThirteen 
events were reported as severe (number of events): appendicitis (3), arthritis bacterial 
(1), atypical pneumonia (1), herpes zoster (2), herpes zoster meningitis (1), mastoiditis 
(1), meningitis viral (1), osteomyelitis (1), sinusitis (1), wound infection (1); dFour events 
were reported as severe; eAll events, including those outside the 28-day risk period, 
were included for calculation of proportion and IR; fAdjudicated events; gMACE (number 
of events): acute myocardial infarction (1), cerebellar haemorrhage (1); hAn event of 
cerebrovascular accident; iMalignancy (number of events): breast cancer (2), cervical 
dysplasia (1), diff use large B-cell lymphoma (1), pulmonary mass (1); jMalignancy 
(number of events): acute myeloid leukaemia (1), adenocarcinoma of colon (2), cervical 
dysplasia (1), cholangiocarcinoma (1), cutaneous leiomyosarcoma (1), Epstein-Barr virus-
associated lymphoma (1), essential thrombocythaemia (1), hepatic angiosarcoma (1), 
invasive ductal breast carcinoma (1), malignant melanoma (1), renal cell carcinoma (1)
AE, adverse event; BID, twice daily; CI, confi dence interval; IR, incidence rate; MACE, 
major adverse cardiovascular events; N, number of patients who received ≥1 dose of 
study drug; n, number of patients with the specifi ed event within the given category; 
NMSC, non-melanoma skin cancer; OLE, open-label, long-term extension; PY, patient-
years
[Table. Proportions and IRs of AEs of special interest in the OLE study]
References: 1. Sandborn WJ et al. N Engl J Med 2017;376:1723-1736. 
2. Lichtenstein GR et al. Am J Gastroenterol 2018; 113 (Suppl 1): Abstract 571.
Disclosure: GR Lichtenstein has received research support and consultancy 
fees from Celgene, Salix/Valeant, Shire and UCB; research support from 
Janssen Orthobiotech; consultancy fees from Abbott/AbbVie, Cellceutix, 
Ferring, Gilead, Luitpold/American Regent, Merck, Pfi zer Inc, Prometheus, 
Romark and Takeda; and other fees from Am J Gastroenterol: ACG, Clin Adv 
Gastroenterol and Gastroenterol Hepatol: Springer Science and Business 
Media, University of Pennsylvania, Janssen Orthobiotech, Pfi zer Inc, 
Takeda, Luitpold/American Regent, Merck, Romark, McMahon Publishing, 
Up-To-Date and SLACK Inc. 
EV Loft us Jr. has received research support and consultancy fees from 
AbbVie, Amgen, Celgene, Janssen, Pfi zer Inc, Takeda and UCB; research 
support from Genentech, Gilead, MedImmune, Robarts Clinical Trials and 
Seres; consultancy fees from Allergan, Bristol-Myers Squibb, Celltrion 
Healthcare, and Eli Lilly; and is a shareholder of Exact Sciences.
A Soonasra, N Lawendy, G Chan, H Zhang, W Wang and AJ Thorpe are 
employees and shareholders of Pfi zer Inc. S Bloom has received advisory 
board fees from AbbVie, Janssen, Pfi zer Inc and Takeda. 
(1.5 hours post-dose) during week 8 was -4.6 on an 11-point scale (N=11; 
P< 0.001). The proportion of clinical responders was 85% (11/13) at week 
4 and 100% (11/11) at week 8 among evaluable subjects. Adverse events 
(AEs) occurred in 4/6 (67%) and 6/8 (75%) subjects who received 25 mg 
and 100 mg TID, respectively, and were generally mild to moderate with 
limited duration. AEs in ≥2 subjects included drug hypersensitivity, pain 
in extremity, and hypomagnesaemia; 2 serious AEs (pneumonia, worsen-
ing interstitial pneumonia) occurred in 1 subject and were not considered 
treatment related. There were no discontinuations due to AEs, and no clin-
ically signifi cant changes in vital signs or laboratory results were observed.
Conclusion: Olorinab, a highly selective full agonist of CB
2
, showed pre-
clinical effi  cacy in reducing visceral hypersensitivity in a rat model of IBD. 
Olorinab-treated subjects with quiescent CD experiencing abdominal pain 
had an improvement in AAPS without psychoactive eff ects in phase 2a. 
These preclinical and clinical results support further clinical development 
of olorinab for the treatment of abdominal pain.
Disclosure: B.Y. has received grant support from Merck and advisory board 
honoraria for Arena; S.M.B. is a consultant to Arena Pharmaceuticals; B.L., 
J.A., B.E., and K.S. are employees and shareholders of Arena Pharmaceu-
ticals; P.D.R.H. has received grants from NIH, CCF, AbbVie, Janssen, Takeda, 
Genentech, and Pfi zer and advisory board honoraria for Lycera, and Arena 
Pharmaceuticals. 
Paradigm shift s in IBD treatment
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OP213 TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE 
TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF 
AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.5 
YEARS OF TREATMENT
Lichtenstein G.R.1, Loft us Jr. E.V.2, Soonasra A.3, Lawendy N.3, Chan G.3, 
Zhang H.3, Wang W.3, Thorpe A.J.3, Bloom S.4
1Division of Gastroenterology, Perelman School of Medicine at the 
University of Pennsylvania, Philadelphia, PA, United States, 2Division of 
Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United 
States, 3P zer Inc, Collegeville, PA, United States, 4University College London 
Hospitals NHS Foundation Trust, London, United Kingdom
Contact E-Mail Address: loft us.edward@mayo.edu
Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor 
for the treatment of ulcerative colitis (UC). Tofacitinib safety and effi  cacy 
were demonstrated in patients (pts) with moderate to severe UC in 3 Phase 
3, randomised, placebo-controlled studies,1 and are being further evalu-
ated in an ongoing open-label long-term extension (OLE) study.2
Aims & Methods: We present an update (as of Sep 2018) on previously pre-
sented safety and effi  cacy data2 from the ongoing OLE study (NCT01470612; 
database not locked) in pts who completed or demonstrated treatment fail-
ure in OCTAVE Sustain (NCT01458574) or were non-responders in OCTAVE 
Induction 1/2 (NCT01465763/NCT01458951). Eligibility was determined per 
Week (Wk)8 data from OCTAVE Induction 1/2, or Wk52 (for completers) or 
early-termination data from OCTAVE Sustain. Pts in remission (total Mayo 
score ≤2, no individual subscore >1, rectal bleeding subscore 0) at Wk52 
of OCTAVE Sustain (per central read) were assigned tofacitinib 5 mg twice 
daily (BID) in the OLE study; all others were assigned 10 mg BID. At Month 
2, all pts underwent endoscopy, and induction non-responders were man-
dated to withdraw if they did not show clinical response. Incidence rates 
(IRs) for adverse events (AEs) of special interest were calculated as the 
number of unique pts with events per 100 pt-years (PY). Effi  cacy endpoints 
were derived from Mayo score per local read, with non-responder imputa-
tion for missing data at all visits but last observation carried forward aft er 
a pt advanced to the next study (NRI-LOCF).
Results: Of 944 pts who received ≥1 dose of study drug (for up to 5.5 years), 
175 (18.5%) received tofacitinib 5 mg BID and 769 (81.5%) received tofaci-
tinib 10 mg BID (total PY exposure 454 and 1550, respectively). In total, 
337 (35.7%) pts discontinued due to insuffi  cient clinical response, and 78 
(8.3%) discontinued due to AEs excl. worsening UC. AEs, serious AEs and 
severe AEs occurred in 764 (80.9%), 162 (17.2%) and 109 (11.5%) pts, re-
spectively (Table). The most frequent AE classes were infections and infes-
tations (52.1%) and gastrointestinal disorders (43.3%). The most frequent 
AEs were nasopharyngitis (20.3%), worsening UC (19.5%) and increased 
blood creatine phosphokinase (10.8%). IRs (95% confi dence interval) in 
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OP214 INTERLEUKIN-6 TRANS-SIGNALLING INHIBITION WITH 
OLAMKICEPT (SGP130FC) IN ACTIVE IBD RESULTS IN EARLY UNIQUE 
MOLECULAR SIGNATURES PREDICTING CLINICAL REMISSION AND 
DIFFERENTIATING FROM REMISSION INDUCTION BY VEDOLIZUMAB 
OR INFLIXIMAB
Aden K.1, Conrad C.2, Bernardes J.P.3, Tran F.4, Hoeper H.3, Sommer F.3, 
Nikolaus S.5, Lokau J.6, Garbers C.6, Rose-John S.7, Röcken C.8, 
Waetzig G.H.9, Rosenstiel P.10, Schreiber S.11
1IKMB + First Medical Department, Kiel University, Kiel, Germany, 2UKSH Kiel, 
Kiel, Germany, 3Institute of Clinical Molecular Biology Christian-Albrechts-
University of Kiel, Kiel, Germany, 4Institute of Clinical Molecular Biology, 
University of Kiel, Cell Biology, Kiel, Germany, 5Univers.-Klinik Schleswig-
Holstein, Campus Kiel, Kiel, Germany, 6Universität Magdeburg, Magdeburg, 
Germany, 7Universität Kiel, Institute of Biochemistry, Kiel, Germany, 8UKSH 
Kiel, Department of Pathology, Kiel, Germany, 9Conaris Research Institute, 
Kiel, Germany, 10Kiel University, University Hospital Schleswig-Holstein, 
Institute of Clinical Molecular Biology (IKMB), Kiel, Germany, 11Universität 
Kiel UKSH, Medizinische Abt. I, Kiel, Germany
Contact E-Mail Address: k.aden@ikmb.uni-kiel.de
Introduction: The cytokine interleukin-6 (IL-6) regulates many important 
immunological processes. Many IL-6-mediated eff ects are attributed to 
classic IL-6 signalling, i.e., binding of IL-6 to a membrane receptor com-
plex consisting of the specifi c IL-6 receptor (IL-6R) expressed mainly on 
hepatocytes and leukocytes and the ubiquitously expressed signal-trans-
ducing co-receptor gp130.In contrast, chronic infl ammation is mediated by 
trans-signalling, in which a complex of circulating soluble IL-6R isoforms 
(sIL-6R) together with IL-6 can engage virtually every body cell by binding 
to the ubiquitous gp130 co-receptor. The fusion protein olamkicept (sgp-
130Fc, FE 999301, ola) is a cytokine trap that selectively neutralizes IL-6/
sIL-6R complexes and hence intercepts trans-signalling.
Aims & Methods: The aim of this study was to i) identify early molecular 
response patterns in Ola treated IBD patients and ii) to compare these 
with response patterns from Infl iximab or Vedolizumab treated patients in 
order to identify ola-specifi c signatures of clinical response. 
Samples were obtained from a multi-centre, open-label, Phase IIa, explor-
atory proof-of-concept trial administering ola over 12 weeks by intravenous 
infusion in patients with active IBD. 16 patients with IBD (CD=7, UC=9) re-
ceived 600 mg ola every 2 weeks from week 0 to a maximum of 12 weeks. 
For multi-modal molecular assessment, blood, stool, and biopsies from 
the sigmoid colon were collected twice before (screening, week 0) and at 
several time points (+4 h, +24 h, 2 weeks, 6 weeks, and 14 weeks) aft er 
ola infusion. Phosphorylation of STAT3 was assessed in colonic biopsies by 
immunohistochemistry and with an in vitro PBMC stimulation assay to in-
vestigate target engagement. Integrated omics analysis was based on RNA 
sequencing (blood, sigmoid colon) and 16s rRNA/DNA (stool) data sets. 
Ola-induced mucosal transcriptome signatures were compared with mu-
cosal transcriptome signatures from anti-TNFa(infl iximab, IFX, n=12) and 
anti-a4b7 integrin (vedolizumab, VDZ, n=18) treated patients undergoing 
the same protocol to identify drug-specifi c signatures of clinical remission.
Results: RNAseq analysis revealed compartment-specifi c transcriptomal 
response (blood vs. sigmoid colon) to ola exposure. Ola induced pro-
nounced downregulation of infl ammation-associated transcripts starting 
at +4 h aft er initial drug infusion in PBMCs coinciding with inhibition of in 
vitropSTAT3 phosphorylation induced by stimulation with a IL-6/sIL-6R fu-
sion protein (hyper-IL6). Importantly, mucosal STAT3 phosphorylation and 
expression of infl ammatory transcripts in the intestinal mucosa showed 
signifi cant downregulation at week 2 timepoint, being highly predictive 
of later clinical and endoscopic remission. By comparing ola-induced 
transcriptomal signatures associated with clinical remission with mucosal 
signatures in remission induced by IFX- (n=12) or VDZ- (n=18), we could 
defi ne common as well as olamkicept-specifi c mucosal transcriptional sig-
nature of clinical remission.
Conclusion: The study demonstrates the utility of molecular response map-
ping in early drug development by comprehensive multi-omics assess-
ments using mucosal biopsies and peripheral blood samples. In-depth 
molecular analysis of IL-6 trans-signalling inhibition in humans represents 
a novel therapeutic principle for the management of IBD. The delineation 
of drug-specifi c remission signatures in the intestinal mucosa may early 
identify patient populations with diff erential response to specifi c anti-
cytokine classes of drugs.
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Introduction: It is unclear whether vedolizumab therapy can be discon-
tinued in patients with infl ammatory bowel disease (IBD) aft er achieving 
clinical remission. The aim of this study was to assess the risk of relapse 
aft er vedolizumab therapy was discontinued in patients with IBD.
Aims & Methods: We performed a retrospective observational study, col-
lecting data from 21 tertiary centers in France affi  liated to the GETAID from 
January 2017 to April 2019, on consecutive patients with IBD treated with 
vedolizumab in clinical remission for at least 3 months who discontinued 
vedolizumab therapy. Disease activity was assessed using the Harvey-
Bradshaw Index for Crohn’s disease (CD) and the partial Mayo Clinic score 
for ulcerative coliits (UC). Relapse was defi ned as partial Mayo Clinic score 
≥ 3 and/or a stool frequency or rectal bleeding subscores of >1 for UC and 
Harvey-Bradshaw index >4 for CD and the initiation of second line therapy. 
Relapse-free survival was studied with Kaplan-Meier method, log-rank 
test and Cox regression model. Patients were censured when vedolizumab 
was reintroduced despite persistence of clinical remission.
Results: 95 patients (24 male; median age: 32.5 [IQR 27.3-42.4] years; 58 
with CD) were included in the present study. Before discontinuation, the 
median duration of vedolizumab therapy was 17.5 [10.6-25.4] months. 
Patients discontinued vedolizumab therapy for pregnancy in 37 cases 
(38.9%), adverse events in 26 (27.4%), by their own choice in 24 (25.3%) 
and reimbursement issue in 8 (8.4%). At baseline, Harvey-Bradshaw in-
dex and partial Mayo Clinic score was 1.7 ± 1.4 and 0.9 ± 1.1, respectively. 
Only 6 (6%) were still treated with immunomodulator when they discon-
tinued vedolizumab therapy. Aft er a median follow-up period of 11.2 (5.8-
17.7) months, 61 of the 95 patients experienced a relapse. Four patients 
were retreated with vedolizumab aft er pregnancy in three cases and ovar-
ian cyst work up in one, with a mean delay of 0.7 ± 0.5 years. The prob-
abilities of relapse-free survival were 83%, 59% and 36% at 6, 12 and 18 
months, respectively. The multivariate analysis demonstrated that patients 
with CRP level < 5 at the time of vedolizumab discontinuation (OR = 0.56, 
CI95%[0.33-0.95], p = 0.03) and patients who discontinued vedolizumab 
by their own choice (OR = 0.41, CI95%[0.21-0.80], p = 0.009) were less 
likely to experience relapse. Among the 61 relapsers, vedolizumab was 
re-introduced in 24 cases permitting to re-induce steroid-free clinical re-
mission aft er 14 weeks in 71%. Aft er a median follow-up of 11.0 [5.4-13.3] 
months, 15 (62.5%) patients were still in clinical remission on vedolizumab 
therapy.
Conclusion: Almost two thirds of patients with IBD who discontinued ve-
dolizumab therapy while achieving clinical remission experienced a re-
lapse within 1 year aft er discontinuation of vedolizumab. Normal CRP level 
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profi le was similar between the HIR and SIR groups, including AEs of spe-
cial interest (< 1% across both groups).
Conclusion: In SERENE-UC, there was no additional benefi t of the HIR at 
Wk 8 beyond the approved SIR. Both induction dosing regimens of ADA 
demonstrated similar clinical and endoscopic effi  cacy. Both dosing regi-
mens were generally safe and well tolerated. The maintenance portion of 
the study is ongoing.
Endpoints (Wk 8), n (%) Adalimumab HIR (n=512)
Adalimumab SIR 
(n=340) p-value
1. Endoscopic improvementa (endoscopic 
subscore of 0 or 1)
159 (31.1) 92 (27.1) 0.182
2. Fecal calprotectin < 150 mg/kg 115 (22.5) 67 (19.8) 0.283
3. IBDQ response (increase of IBDQ ≥ 16 
from BL)
342 (66.8) 207 (60.9) 0.063
4. Clinical response per full Mayo Scorea,b 241 (47.1) 136 (40.0) 0.034*
5. Endoscopic remissiona (endoscopic 
subscore of 0)
67 (13.1) 34 (10.0) 0.162
*Nominal p-value < 0.05. aEndoscopy scored via a central reading protocol. bClinical 
response per full Mayo Score: Decrease from baseline in the full Mayo Score ≥ 3 points 
and ≥ 30% from baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1. BL, 
baseline; HIR, higher induction dosing regimen; IBDQ, Infl ammatory Bowel Disease 
Questionnaire; RBS, rectal bleeding score; SIR, standard induction dosing regimen 
[Ranked secondary e  cacy endpoints]
References: 1. Reinisch W et al. Gut 2011;60:780-7. 2. Reinisch W et al. 
Infl amm Bowel Dis 2013;19:1700-9. 3. Sandborn WJ et al. Gastroenterology 
2012;142:257-65.
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(< 5 mg/L) and patients’ choice rather than pregnancy, adverse events and 
reimbursement issues was associated with a lower probability of relapse. 
Aft er re-introduction of vedolizumab therapy, more than two thirds of pa-
tients achieved steroid-free clinical remission aft er 14 weeks.
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Introduction: Adalimumab (ADA) is eff ective and well tolerated in inducing 
and maintaining clinical remission in adult patients (pts) with ulcerative 
colitis (UC).1-3 We report results from the 8 wks induction period of SE-
RENE-UC (NCT02065622), comparing two ADA dosing regimens: a higher 
induction dosing regimen (HIR) and a standard induction dosing regimen 
(SIR).
Aims & Methods: SERENE-UC is a Phase 3, double-blind, randomized mul-
ticenter study of higher versus standard ADA dosing regimens for induc-
tion and maintenance therapy in adult pts with moderately to severely 
active UC. Pts were randomized 3:2 to receive either the HIR (160 mg at 
Wks 0, 1, 2, and 3, followed by 40 mg at Wks 4 and 6) or the SIR (160 mg 
at Wk 0 and 80 mg at Wk 2, followed by 40 mg at Wks 4 and 6) of ADA. 
At randomization, pts were stratifi ed by baseline corticosteroid use and 
previous infl iximab (IFX) use. All pts who entered the study on oral corti-
costeroids were mandated to begin steroid taper at Wk 4. 
The primary effi  cacy endpoint for the induction study was the proportion 
of patients in the intent to treat population achieving clinical remission, 
defi ned as full Mayo Score ≤2 with no subscore >1, at Wk 8. The endo-
scopic component of the Mayo Score was scored via a central reading 
protocol. ADA trough serum concentrations were measured at Wks 2, 4, 
and 8. Exposure-response (ER) modelling was performed using NONMEM 
7.3 for the overall population and the ER relationship (ERR) was compared 
with the ULTRA 2 study.3 Non-responder imputation was used for miss-
ing values. Safety assessment included collection of adverse events (AEs), 
vital signs, and laboratory data.
Results: In total, 852 pts were randomized, 512 and 340 into the HIR and 
the SIR, respectively. Baseline demographics were generally balanced 
across the two treatment groups; overall, mean UC disease duration was 
7.2 (7.1) years, 87.1% of pts were biologic-naïve (12.9% had prior IFX ex-
perience with initial response and subsequent inadequate response or in-
tolerance), and 58.7% of pts were receiving corticosteroids. There was no 
signifi cant diff erence in clinical remission rate at Week 8 between the HIR 
and SIR (13.3% vs 10.9%, respectively; p=0.273). 
The Table displays results for secondary effi  cacy endpoints. ADA trough 
concentrations were higher in the HIR versus the SIR (mean [SD] = 39.2 
[20.7] and 10.8 [5.2] µg/mL at Wk 4 and 19.3 [9.5] and 8.0 [4.9] µg/mL at Wk 
8, respectively) and the levels for the SIR were comparable to those previ-
ously reported in ULTRA 2. Higher ADA concentrations were associated 
with higher clinical remission rate; however, modeling results indicated 
shallower ERR in this study compared with ULTRA 2. The observed safety 
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EVERY 4 TO EVERY 8 WEEKS IN PATIENTS WITH ULCERATIVE COLITIS 
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Introduction: Ulcerative colitis (UC) and Crohn’s disease (CD) are chronic 
diseases generally requiring long-term maintenance therapy. Vedolizum-
ab (VDZ) is a humanised monoclonal antibody targeting α
4
β
7
 integrin to 
reduce lymphocyte migration to the gut. VDZ was eff ective and well toler-
ated with 8-wk (Q8W) and 4-wk dosing (Q4W) in CD and UC in the GEMINI 
Phase 3 studies and with Q4W dosing in the GEMINI long-term safety (LTS) 
study. Aft er GEMINI LTS, an extended access program (XAP) with Q8W dos-
ing was initiated. Data from patients (pts) who reduced VDZ dosing from 
Q4W to Q8W are limited. From the XAP pharmacokinetics (PK) substudy, 
we report clinical effi  cacy, PK, and safety for pts who reduced VDZ fre-
quency from Q4W to Q8W.
Aims & Methods: VDZ XAP (NCT02743806) is a prospective, open-label, 
multinational, interventional study to provide pts access to VDZ and moni-
tor safety. Eligible pts were on VDZ 300mg IV Q4W during GEMINI LTS with 
continued clinical benefi t. In XAP, VDZ frequency was reduced to 300mg IV 
Q8W and pts were followed for 56 wk; return to Q4W dosing was allowed 
based on physician’s assessment of pt clinical status and Medical Monitor 
approval. Blood samples for PK analyses were obtained at enrolment (last 
Q4W dosing visit) and wks 8, 16, and 56; serum VDZ was measured using a 
validated ELISA. Clinical remission was defi ned as Harvey-Bradshaw Index 
(HBI) ≤4 for pts with CD and partial Mayo score ≤2 with no subscore >1 for 
pts with UC. Clinical response aft er restarting Q4W dosing was defi ned as 
decreased HBI of ≥3 from XAP baseline, or decreased partial Mayo score of 
≥2 and ≥25% from baseline with a decrease of ≥1 point in rectal bleeding 
subscore (RBS) from baseline or an RBS of ≤1 point.
Results: A total of 167 pts (88 CD, 79 UC) enrolled in the XAP-PK substudy. 
Overall, pts had a median of 6.5 y (range, 4.4-10.0) of prior VDZ use; 69% 
of pts were anti-TNF naïve at VDZ initiation in prior studies. Of pts with CD 
and UC, 91% and 92%, respectively, completed the 56-wk substudy, with 
86% and 90% remaining on Q8W dosing. Rates of clinical remission and 
corticosteroid (CS)-free clinical remission in pts remaining on Q8W were 
stable through wk 56 (Table). Four pts with CD and 2 pts with UC returned 
to Q4W dosing; 3 of 4 CD pts regained clinical response. Pts remaining on 
Q8W VDZ through wk 56 had low CRP levels that were stable over time; 
2.2 mg/L and 1.7 mg/L at baseline and wk 56 for CD pts and 2.2 mg/L and 
1.2 mg/L for UC pts. Median trough VDZ was 43.6 µg/mL at baseline and 
10.4 µg/mL at wk 56 in pts with CD and 42.4 µg/mL and 13.3 µg/mL in pts 
with UC. Adverse events (AEs) related to VDZ were infrequent; no new or 
serious AEs related to VDZ were reported.
  Baseline Week 8 Week 16 Week 56
  CD UC CD UC CD UC CD UC
Clinical remission, % 84.0 95.8 84.2 91.5 83.8 91.2 82.7 94.4
CS-free remission, % 78.7 91.5 78.9 87.3 78.4 86.8 76.0 91.5
CRP, median, mg/L 2.4 1.8 1.9 1.6 2.2 1.2 2.6 1.2
Trough VDZ, median, 
µg/mL
43.6 42.4 16.2 18.6 12.6 14.2 10.4 13.3
CD, Crohn’s disease; CRP, c-reactive protein; CS, corticosteroid; Q8W, every 8 weeks; UC, 
ulcerative colitis; VDZ, vedolizumab.
[Table. E  cacy, Safety and PK in CD (N=76) and UC (N=71) Patients Who 
Remained on Q8W Dosing for 56 Weeks]
Conclusion: In a clinically stable cohort, high pt persistence was observed 
aft er reducing dose frequency from VDZ Q4W to Q8W. High clinical and CS-
free remission rates were maintained for 56 wk. Return to Q4W dosing was 
necessary in only a few pts and half of them regained clinical response af-
terwards. VDZ trough concentrations decreased from baseline as expected. 
AEs were consistent with previous reports.
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Introduction: Endoscopic ultrasound-guided fi ne needle aspiration (EUS-
FNA) cytology is a widely used method for the diagnosis of pancreatic 
neoplasms. Liquid-based cytology (LBC) analysis has been developed to 
overcome the disadvantages of conventional smear cytology (CS) in which 
contaminants such as blood, mucin, necrosis and artefactual aggregation 
of lymphoid cells, block the background of cytology slides [1]. The aim of 
this study was to evaluate the effi  cacy of LBC in the diagnosis of pancreatic 
neoplasms compared to CS.
Aims & Methods: We randomly assigned patients with suspected pancre-
atic cancer who required histologic confi rmation to receive EUS-FNA cytol-
ogy by either LBC or CS for the fi rst pass. Nineteen to 25G needles (median 
22G) were used at the discretion of each echoendoscopist. The second pass 
was performed with the technique not used for the fi rst pass, and the last 
pass was allocated to core biopsy. The cytology slides were independently 
reviewed by two pathologists, and the diagnostic accuracy of the CS and 
LBC method was assessed for the primary outcome. Secondary outcomes 
included the sensitivity, specifi city, positive predictive value (PPV), and 
negative predictive value (NPV) for each method. Gold standard was de-
fi ned as the fi nal diagnosis of combined results from CS, LBC, core biopsy, 
and surgically obtained histology or at least 6 months follow-up for benign 
lesions. The sample size was calculated to determine the noninferiority of 
LBC compared to CS regarding diagnostic accuracy with acceptable margin 
of 10%. The reported accuracy of CS was approximately 90% [2]. With an 
alpha level of 5%, 90% power, and a droprout rate of 15%, the planned 
sample size was 170 cases.
Results: From April 2018 to March 2019, a total of 170 patients were en-
rolled in this study. Mean age was 64.8 years (range 37 - 88), and 95 
patients (55.9%) were male. The median size of masses was 3.0cm (range 
1.3-11.0), and the lesions were located as follows: 59 (34.7%) in the head, 
24 (14.1%) in the uncinated process, 38 (22.4%) in the body, 40 (23.5%) in 
the tail, and 8 (4.7%) in the junction of the body and tail. Of the 170 cases, 
165 lesions were malignant: pancreatic ductal adenocarcinoma (n = 163), 
neuroendocrine carcinoma (n = 2), and 5 lesions were benign conditions 
associated with chronic pancreatitis. No statistically signifi cant diff erences 
were observed in age, sex, needle gauges, tumor size, and tumor location 
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Results: Among the 273 operated patients, 176 were included in the fi -
nal analysis. In the BD-IPMN displaying HGD cancer the prevalence of GF 
subtype was signifi cantly lower when compared to other subtypes (3.8% 
vs 100%, p=0.007). PB subtype was much more prevalent (66.7% vs 4%, 
p=0.02). The prevalence of HGD/cancer was not signifi cantly higher for cyst 
dimension above 40 mm (25% vs 44%, p=0.62). 
At univariable logistic regression analysis PB phenotype was associated 
with an increased risk of displaying HGD/C (OR 47.21; 95% CI 1.8-1184.7, 
p=0.01). In the MD-IPMN group displaying HGD/C the prevalence of GF 
subtypes was signifi cantly lower when compared to other subtypes (45.4% 
vs 74.4%, p=0.001), while I subtype was much more prevalent (70.7% vs 
46.2%, p=0.007). 
No statistically signifi cant diff erences were found for PB and O subtypes. 
At univariable logistic regression analysis GF was associated with a de-
creased risk of displaying HGD/C (OR 0.29; 95% CI 0.12-0.66, p=0.003) 
while I subtype was associated with higher risk (OR 2.85 95% CI 1.29-6.28, 
p=0.009). At multivariable logistic regression analysis adjusted even for 
MPD diameter GF subtype was confi rmed to be associated to a decreased 
risk (OR 0.37 95% CI 0.15-0.95, p=0.03).
Conclusion: GF subtype associated with a decreased risk of HGD/C in BD-
IPMN and in MD IPMN irrespectively from cyst dimension and MPD di-
ameter. Intestinal subtypes might be associated to an increased of HGD/
cancer risk in MD IPMNs and pancreatobiliary might be associated to an 
increase risk of HGD/cancer in BD IPMNs
Disclosure: Nothing to disclose 
OP220 UPDATED INTERNATIONAL CANCER OF THE PANCREAS 
SCREENING (CAPS) CONSORTIUM GUIDELINES ON THE 
MANAGEMENT OF PATIENTS WITH INCREASED RISK FOR FAMILIAL 
PANCREATIC CANCER
Overbeek K.A.1, Canto M.I.2, Bartsch D.3, Brand R.E.4, Carrato A.5, 
del Chiaro M.6, Farrell J.J.7, Fishman E.K.8, Fockens P.9, Gress T.M.10, 
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Contact E-Mail Address: k.overbeek@erasmusmc.nl
Introduction: The international Cancer of the Pancreas Screening (CAPS) 
Consortium has recommended specifi c guidelines for the management of 
individuals with increased risk of pancreatic cancer (high-risk individuals; 
HRI) arising from a familial clustering of the disease or associated with 
germline mutations.
Aims & Methods: Our aim was to update the 2013 CAPS consensus guide-
lines on the management of HRI. A modifi ed Delphi approach was used, 
consisting of a systematic review of the literature, an international multi-
disciplinary development workgroup meeting, and two rounds of online 
voting. Based on pre-defi ned criteria, experts in the fi eld of familial pan-
creatic cancer were invited to vote on statements using a 7-point Likert 
scale. An a priori threshold of 75% agreement (‘Strongly agree’ or ‘Agree’) 
was used to establish consensus statements.
between the two groups. The diagnostic accuracy, sensitivity, specifi city, 
PPV, and NPV of LBC versus CS were 87.4% versus 83.9%, 87.1% versus 
83.3%, 100% versus 100%, 100% versus100%, and 16.0% versus 16.1% 
(Table 1). When LBC combined with core biopsy, the diagnostic accuracy for 
pancreatic cancer was higher than that of LBC only (95.3% versus 87.4%, 
p = 0.01). There were 3 (1.76%) and 9 (5.29%) unsatisfactory samples for 
diagnosis in LBC and CS, respectively. Blood clots were much less observed 
in LBC than in CS (0.59% versus 64.1%), and the nuclear feature was simi-
larly preserved in two groups.
Conclusion: Our study shows diagnostic utility of LBC was comparable to 
that of CS. Cytomorphologic features of ductal adenocarcinoma in LBC did 
not signifi cantly diff er from those in CS, and less frequent bloody back-
grounds allow better visibility in LBC method.
Characteristic Accuracy % (n/N)
Sensitivity % 
(n/N)
Specifi city % 
(n/N)
PPV % 
(n/N)
NPV (%) 
(n/N)
LBC 87.4 (146/167) 87.1 (142/163) 100 (4/4) 100 (142/142) 16.0 (4/25)
CS 83.9 (135/161) 83.3 (130/156) 100 (5/5) 100 (130/130) 16.1 (5/31)
p value 0.37 0.34 0.99 0.99 0.99
[Table 1. Comparisons of operative characteristics]
References: 1. Hoda, R.S., C. VandenBussche, and S.A. Hoda, Liquid-Based 
Specimen Collection, Preparation, and Morphology, in Diagnostic Liquid-
Based Cytology. 2017, Springer Berlin Heidelberg: Berlin, Heidelberg. p. 
1-12. 2. Yeon, M.H., et al., Comparison of liquid-based cytology (CellPrep-
Plus) and conventional smears in pancreaticobiliary disease. The Korean 
journal of internal medicine, 2018. 33(5): p. 883-892.
Disclosure: Nothing to disclose 
OP219 ROLE OF HISTOLOGICAL SUBTYPES ON THE RISK 
OF HIGH GRADE DYSPLASIA CANCER IN OPERATED IPMNS: 
A LARGE SINGLE CENTER STUDY
Anzillotti G.1, Vespasiano F.2, Rangelova E.3, Halimi A.4, Tisone G.5, 
Arnelo U.6, Anselmo A.7, Scandavini C.M.2, Del Chiaro M.8, Löhr M.9, 
Valente R.4
1Karolinska University Hospital, HBP Unit, Stockholm, Sweden, 2Karolinska 
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4Karolinska University Hospital and Karolinska Institutet, Department of 
Surgery CLINTEC, HPB Disease Unit, Stockholm, Sweden, 5University of 
Rome Tor Vergata, Roma, Italy, 6Karolinska Institutet, CLINTEC, Division of 
Surgery, Department of Upper Gastrointestinal Diseases, Stockholm, Sweden, 
7University of Rome Tor Vergata, Hepatobiliary and Transplant Unit, Roma, 
Italy, 8University of Colorado Anschutz Medical Campus, Division of Surgical 
Oncology, Department of Surgery, Denver, United States, 9Karolinska Institutet, 
Center for Digestive Diseases, Stockholm, Sweden
Contact E-Mail Address: giuseppeanzillotti94@gmail.com
Introduction: Intraductal papillary mucinous neoplasms (IPMNs) suff er 
from low preoperative diagnostic accuracy. No method is available to ac-
curately predict the grade of dysplasia of an IPMNs before surgery. Branch 
duct IPMNs (BD-IPMNs) and main duct-involving IPMNs (MD IPMNs) dis-
play diff erent risks of progression to cancer and have diff erent manage-
ments according to guidelines. IPMNs can also display diff erent histologi-
cal subtypes such as pancreatobiliary (PB) gastro foveolar (GF) oncocitic 
(O) and intestinal (I). The infl uence of such subtypes on the risks of harbor-
ing high-grade dysplasia cancer (HGD/C) in relation to diff erent kinds of 
IPMNs is unknown.
Aims & Methods: To investigate the risk of HGD/C according to diff erent 
histological subtypes. Single center, retrospective study on a prospectively 
collected cohort of patients operated for suspect malignant IPMN between 
2007 and 2017 at HPB Disease Unit, Karolinska Hospital, Stockholm. Data 
about demographics, known risk factors for PDAC, pathological features 
were recorded. The inclusion criterion was the presence of histologically 
proved IPMNs. The exclusion criteria were the presence of a synchronous 
PDAC, positive margins for high grade dysplasia/cancer, or unknown histo-
logical subtype. Chi square and fi sher test were used to analyze categorical 
variables, and statistically signifi cant results were evaluated through sex 
and age adjusted univariable and multivariable logistic regression anal-
ysis. A sub-analysis was performed in BD and MD-IPMNs to assess the 
prevalence of diff erent subtypes and the risk of harboring HGD/C.
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was snap frozen < 10 minutes aft er collection and stored at -80°C. DNA 
extraction was compared between the NucleoSpin and Maxwell cfDNA 
kit. The yield of DNA (Quant-iT dsDNA Assay), the cfDNA/gDNA-ratio (i.e. 
75bp/300bp-ratio; qPCR) and %mutated KRAS (dPCR; KRAS Multiplex Kit) 
were compared. Exosomes were isolated and analyzed with Nanoparticle 
Tracking Analysis (NTA). Total protein, cytokine and (pancreas specifi c) 
PLA2G1B concentrations were quantifi ed with Lowry assay and ELISA. Or-
ganoids were grown, based on Broutier et al.2, from cellular content of 
PJ. Also, usefulness of a protease or superase inhibitor was tested. For 
statistical analysis, either a Friedman’s or Wilcoxon signed-rank test was 
performed.
Results: Presence of pancreatic content was confi rmed by PLA2G1B in all 
PJ collection methods (32 samples, 8 individuals), with exception of 6 FPC 
samples that were collected with a catheter. The NucleoSpin kit resulted in 
a higher DNA concentration and cfDNA/gDNA-ratio (p=0.025, p< 0.0001) 
than the Maxwell kit. Collection through the endoscopic channel dur-
ing the second time period resulted in the highest yield of DNA (p=0.017, 
p=0.039), albeit with a lower cfDNA/gDNA ratio (p=0.039). cfDNA/gDNA 
ratio was highest in the fi rst four minutes (P=0.002); independent of col-
lection technique. Mutated KRAS was detected in all samples (%mutated 
KRAS: 0.09-1.01); indiscriminate of DNA extraction technique, collection 
technique or duration.
Exosomes (size range: 81.6-244.6 nm, 2 FPC kindreds) were present in 
all 8 analyzed samples. Yields were highest in samples collected with a 
catheter. The overall protein concentration of PJ collected through the en-
doscopic channel during the fi rst four minutes was highest (64 samples, 
p=0.02). IL-8, IL10, IFN-γ and TGF-β concentrations did not diff er between 
the collection methods. IL-6, IL-13 and TNF-α were not detectable. 16/65 
(25%) PJ samples that were seeded for organoids grew into organoids, of 
which 85% had been collected in the fi rst four minutes. The addition of 
inhibitors to PJ during collection did not improve any of the biomarkers 
tested.
Conclusion: We show feasibility of DNA, exosome and protein quantifi ca-
tion and organoid growth from PJ. Duodenal collection during EUS in the 
fi rst four minutes aft er secretin injection resulted in a high yield of cfDNA, 
exosomes, proteins and organoids. According to PLA2G1B concentrations, 
the use of a catheter did not result in higher yields or a more concentrated 
collection of PJ.
References: 1. K.A. Overbeek, I.J.M. Levink, I.C.A.W. Konings, F. Harinck, B. 
Koopmann, M.G.E. Ausems, A. Wagner, P. Fockens, B. Groot Koerkamp, 
M.G.H. Besselink, M. van der Vlugt, F.P. Vleggaar, J.W Poley, D.L. Cahen, 
J.E. van Hooft , M.J. Bruno. On behalf of the Dutch Familial Pancreatic Can-
cer Surveillance Study work group. 12 years of prospective pancreatic can-
cer surveillance: results of the dutch nationwide program in high-risk indi-
viduals. Abstract, UEGW. 2019. 2. Broutier L, Andersson-Rolf A, Hindley CJ, 
Boj SF, Clevers H, Koo BK et al. Culture and establishment of self-renewing 
human and mouse adult liver and pancreas 3D organoids and their genetic 
manipulation. Nat Protoc. 2016;11(9):1724-43.
Disclosure: Djuna Cahen is a member of the Tramedico clinical advisory 
board. 
OP222 NEW THERAPEUTIC METHOD FOR UNRESECTABLE 
PANCREATIC CANCER - THE IMPACT OF HIGH-INTENSITY FOCUSED 
ULTRASOUND (HIFU) THERAPY
Sofuni A., Fujita M., Asai Y., Tsuchiya T., Ishii K., Tanaka R., Tonozuka R., 
Honjo M., Mukai S., Nagai K., Yamamoto K., Matsunami Y., Kurosawa T., 
Kojima H., Itoi T.
Tokyo Medical University, Gastroenterology & Hepatology, Tokyo, Japan
Contact E-Mail Address: a-sofuni@amy.hi-ho.ne.jp
Introduction: Even with recent advances in the diagnostic imaging technol-
ogy, most cases of pancreatic cancer (PC) are diagnosed at an unresectable 
stage. The therapeutic eff ect of chemotherapy and chemoradiotherapy for 
unresectable PC was not satisfactory. High-intensity focused ultrasound 
(HIFU) is expected as new advanced therapy for unresectable PC. HIFU 
therapy with chemotherapy is being promoted as new method to control 
local advance by ablation tumor.
Aims & Methods: We have evaluated the therapeutic eff ect of HIFU therapy 
in locally advanced and metastatic PC. We treated PC patients by HIFU as 
optional local therapy as well as systemic chemo / chemo-radiotherapy, 
with whom an agreement was obtained in adequate IC, from the end of 
2008 in our hospital. 
Results: 76 experts, from 7 disciplines, 11 countries and 4 continents, com-
pleted two rounds of voting (response rate 84%). Consensus was reached 
on more statements than the previous guidelines (55 versus 34). The goals 
of surveillance (to identify T1N0M0 margin-negative pancreatic cancer and 
high-grade dysplastic precursor lesions) remained unchanged. 
Experts now also agreed that surveillance should commence at least by the 
age of 50 or 10 years younger than onset in the family, or when diabetes 
develops. There was still no agreement on the age to stop surveillance. 
Added as eligible for surveillance were CDKN2A p16 mutation carriers 
without a pancreatic cancer family history, and ATM mutation carriers with 
one aff ected fi rst-degree relative. Experts also agreed that baseline sur-
veillance should still include both endoscopic ultrasound (EUS) and MRI/
MRCP, and not CT, ERCP, or abdominal ultrasound. 
Both modalities should also be used for follow-up, but there was no con-
sensus on whether to alternate these modalities, or on the optimal sur-
veillance intervals when lesions are detected. Serum carbohydrate antigen 
19-9 was recommended when worrisome features are found on imaging. 
Fasting blood glucose testing should be performed routinely, a new di-
agnosis of diabetes should prompt for immediate investigations. In HRI 
below 50 years of age, a new diagnosis of diabetes should lead to initia-
tion of surveillance. 
The surveillance interval in case of no or low-risk fi ndings should be 12 
months. EUS-fi ne needle aspiration is recommended for detected cysts 
with worrisome features, solid lesions ≥5 mm, or main pancreatic duct 
strictures (with or without associated mass). Main areas of disagreement 
included if and how surveillance should be performed for hereditary pan-
creatitis, and the management of indeterminate lesions.
Conclusion: Surveillance is recommended for selected HRI to detect early 
pancreatic cancer and its high-grade precursors, and should be performed 
in expertise centers, by multidisciplinary teams, preferably within a re-
search setting.
Disclosure: JEH received research funding from Abbott and Cook Medical; 
she is a consultant to Boston Scientifi c, Cook Medical, and Medtronics. DLC 
is a consultant to Tramedico. MJB received research funding from Boston 
Scientifi c, Cook Medical, Pentax Medical, 3M; he is a consultant to Boston 
Scientifi c, Cook Medical, Pentax Medical, Mylan, MediRisk, and Medicom. 
PF is a consultant to Olympus, Cook Medical, Ethicon Endosurgery and re-
ceived research funding from Boston Scientifi c. REB has received research 
funding from Immunovia and Freenome. The other authors have nothing 
to disclose. 
OP221 METHODOLOGY OF PANCREATIC JUICE COLLECTION 
FROM THE DUODENUM FOR BIOMARKER DISCOVERY AND EARLY 
DETECTION OF PANCREATIC CANCER
Levink I.J.M.1, Nesteruk K.1, Visser D.I.1,2, Sieuwerts A.M.1, 
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Fuhler G.M.4, Bruno M.J.5
1Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, 
Netherlands, 2VU Medical Center, Gastroenterology and Hepatology, 
Amsterdam, Netherlands, 3Erasmus University MC, Gastroenterology, 
Amsterdam, Netherlands, 4Erasmus University MC, Gastroenterology 
and Hepatology, Rotterdam, Netherlands, 5University Medical Center, 
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Contact E-Mail Address: i.levink@erasmusmc.nl
Introduction: Pancreatic cancer (PC) is a deadly disease for which early 
detection of high-grade precursor lesions provides the only chance of cure. 
Surveillance by imaging (even EUS and MRI combined) in individuals at 
risk to develop PC does not enable timely detection1. Hence, there is an 
urgent need for reliable biomarkers. Pancreatic juice (PJ) is a promising 
biomarker source as it is in direct contact with the pancreatic ductal epi-
thelial lining from which PC arises.
Aims & Methods: We aimed to determine the technique and duration of 
duodenal PJ collection aft er secretin stimulation that results in the highest 
yield of cell-free DNA, exosomes for miRNA analysis, proteins and cells 
(organoid growth). 
PJ from patients suspected of sporadic PC and high-risk individuals, un-
der surveillance for hereditary predisposition for PC (FPC), was collected 
from the duodenum during EUS aft er secretin stimulation. For each sub-
ject, two collection techniques (i.e. suction by a through-the-scope cath-
eter positioned close to the ampulla or the endoscopic channel) and two 
time periods (i.e. the fi rst and second four minutes) were compared. PJ 
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ductal adenocarcinoma using the Kaplan-Meier method. The Cox propor-
tional hazards model was used to evaluate known predictors of overall 
survival. A prediction model, based on tumor diff erentiation, resection 
margin, lymph node ratio and adjuvant therapy, was constructed.
Results: Overall, 3,082 patients were included with a median age of 67 
years (IQR 60-73). Median overall survival was 18 months (95%CI 17-18 
months) with a 5-year survival of 15%. The probability of 5-year survival 
aft er resection increased from 15% directly aft er resection to 23%, 42%, 
61% and 82% per additional year survived (1, 2, 3 and 4 years, respectively, 
Table 1). The created nomogram had an optimism-adjusted C-statistic of 
0.64 (95% CI 0.63-0.65). The probability to achieve 5-year survival, when 
measured 1 year aft er surgery, varied from 1 to 58% depending on the 
patient- and tumor characteristics included in the nomogram.
  Survival probability to reach X years
Given years of 
survival 0 1 2 3 4 5 6 7 8
Number at risk 3082 2054 1001 585 367 246 176 125 88
0 100 67 37 25 18 15 13 12 10
1   100 55 38 28 23 20 17 15
2     100 68 50 42 36 31 28
3       100 74 61 53 46 41
4         100 82 71 62 55
5           100 86 75 67
Each column represents the years survived from surgery and each row represents the 
percentage to reach a certain total survival time from that point of survived years. For 
example, if a patient has survived 2 years aft er surgery, the probability to achieve 3-year 
survival aft er surgery is 68% and to achieve 5-year survival aft er surgery is 42%.
[Table 1. Conditional survival from the time of pancreatic resection in 3,082 
patients, given 1 to 5 years survival a er surgery]
Conclusion: This nationwide study showed the added value of conditional 
survival for patient who underwent resection for pancreatic ductal adeno-
carcinoma. A nomogram was created to provide insight to patients regard-
ing their survival probabilities during follow-up. It could be recommended 
to inform pancreatic cancer patients about CS, especially those who survive 
the fi rst year aft er resection.
Disclosure: Nothing to disclose 
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OP224 THE BRANCHED-CHAIN AMINO ACID TRANSPORTER 
CD98 HEAVY CHAIN FACILITATES THE DEVELOPMENT OF COLONIC 
MACROPHAGES ASSOCIATED WITH DECREASED APOPTOSIS IN 
MACROPHAGE PROGENITORS
Wuggenig P.1, Hruz P.2, Roux J.1, Niess J.H.2,3
1University of Basel, Department of Biomedicine, Basel, Switzerland, 2St. 
Clara Hospital and University Hospital Basel, Basel, Switzerland, 3University 
of Basel, Basel, Switzerland
Contact E-Mail Address: philipp.wuggenig@unibas.ch
Introduction: Monocytes and macrophages maintain the integrity of the 
gut by clearing apoptotic cell bodies and microorganisms that have crossed 
the epithelial barrier (1,2).A comprehensive macrophage development is 
critical for gut macrophages, which evolve from blood monocytes through 
a ‘monocyte waterfall’-developmental trajectory (3,4). The underlying 
mechanisms of the macrophage development in the gut remains elusive.
Aims & Methods: To assess the role of branched-chain amino acids for the 
development of gut macrophages, we generated an inducible knock-out 
mouse model for the branched-chain amino acid transporter CD98hc in 
CX3CR1+intestinal macrophages.
Results: CD98hc is highly expressed on monocyte-macrophage dendritic 
cell progenitors, the common monocyte progenitors, and the monocytes 
in the bone marrow. In the gut, extravasated monocytes, intermediates of 
the ‘monocyte waterfall’-development and macrophages express CD98hc. 
Stimulation of bone marrow-derived macrophages with LPS + IFN-γ (M1 
conditions) or with IL-4 + IL-13 (M2 conditions) did not change CD98hc 
This study took approval of member of ethic society of our hospital. HIFU 
device used is FEP-BY02 (Yuande Bio-Medical Engineering Co.LTD., China). 
The subjects were 176 PC patients, i.e. 88 cases in stage III, 88 cases in 
stage IV. Performance status (PS) was PS:0 ; 85, PS:1; 87, and PS:2; 4 cases. 
Gender ratio was 90 male and 86 female. Mean age was 64.0±11.8 years, 
The details of therapy before HIFU treatment (overlap) was radiochemo-
therapy in 42, chemotherapy in 97, arterial infusion chemotherapy in 5, 
immunotherapy in 8, operation in 22, Irreversible electroporation (IRE) in 
3 ,and BSC in 13 cases.
Results: All tumors were visualized by HIFU monitor system. Tumor loca-
tion was head in 49, uncus in 21, body in 73, body~tail in 7, tail in 4, and 
others (recurrence) in 22 cases. Treatment data was followed; mean tumor 
size before and aft er therapy was 33.3±10.9 and 33.8±11.7 mm, mean treat-
ment sessions: 2.1±0.7 times, mean total treatment time: 89.4±66.8 min, 
mean total number of irradiation: 1709.6±1125.7 shots. 
The eff ects of HIFU therapy were the following; the rate of complete tumor 
ablation was 90.3 %, the rate of symptom relief eff ect was 63.8%, the ef-
fectiveness of primary lesion was CR:0, PR:21, SD:105, PD:47 cases, primary 
disease control rate (DCR) more than SD was 71.0%. The therapy aft er HIFU 
treatment was operation in 8, chemotherapy in 143, immunotherapies in 
4, and best supportive care (BSC) in 22 cases. MST aft er diagnosis in HIFU 
with chemotherapy and chemotherapy alone (100 patients in our hospital) 
was 772.3 vs 346.6 days, respectively (p< 0.05). 
The mean duration to HIFU therapy from the diagnosis (including the pre-
therapy period) was 391.5 ± 390.0 days (median: 288.5 days). MST aft er 
HIFU therapy was 379.8 days. Combination therapy of HIFU with chemo-
therapy was better result than common chemotherapy alone.
Conclusion: This study suggested that HIFU therapy has the potential of 
new method of combination therapy for PC.
Disclosure: Nothing to disclose 
OP223 PREDICTING CONDITIONAL SURVIVAL DURING 
FOLLOW-UP AFTER RESECTION FOR PANCREATIC CANCER: 
A POPULATION-BASED STUDY
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Introduction: Pancreatic ductal adenocarcinoma is one of the most lethal 
cancers. Survival estimates are traditionally calculated from the time of 
diagnosis or at the time of surgery. Since many patients with pancreatic 
ductal adenocarcinoma decease within the fi rst year, 5-year overall or 
relative survival estimates change considerably when surviving the fi rst 
years postoperatively. Conditional survival (CS) accounts for the time al-
ready survived aft er resection and may be more informative for patients. 
This population-based study aims to assess CS and to develop a nomo-
gram predicting 5-year survival at a predefi ned period aft er resection of 
pancreatic ductal adenocarcinoma.
Aims & Methods: Patients with resected pancreatic ductal adenocarcinoma 
were included from the Netherlands Cancer Registry (2005-2016). Condi-
tional survival was calculated as the probability of 5-year survival in pa-
tients who already survived 1, 2, 3 and 4 years aft er resection of pancreatic 
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Results: In TNFΔARE mice, ileal infl ammation correlated with reduced PC 
granularity and diff use lysozyme (Lyz) staining. Impaired PC function was 
further indicated by diminished expression of the ISC-niche factor (Dll4) 
and antimicrobial peptides (Ang4, Defa5). Ileal tissue sections from CD 
patients confi rmed distorted PC appearance in infl amed regions. Most 
importantly, the appearance of a low-granular PC and re-localization of 
Lgr5+ cells in non-infl amed tissues predicted disease recurrence of CD 
patients aft er surgical resection. Parallel to PC dysfunction, the intesti-
nal epithelium developed signs of an activated mitochondrial unfolded 
protein response and loss of stemness indicated by reduced expression 
levels of Lgr5 in the crypt base of TNFΔARE mice as well as CD patients. ISC-
specifi c deletion of HSP60 led to elevated numbers of dysfunctional PC and 
transient reduction of Lgr5 expression, confi rming the importance of mi-
tochondrial homeostasis in regulating PC function and ISC maintenance. 
Increased numbers of Lgr5+-Lyz+ cells and HSP60--Lyz+ cells together with 
absence of apoptosis or necrosis at the crypt base indicated diff erentiation 
of ISC into dysfunctional PC upon mitochondrial impairment.
Underlining the importance of mitochondrial function for ISC niche main-
tenance, inhibition of mitochondrial respiration using oligomycin in mu-
rine and human intestinal organoids decreased expression of Lgr5 and 
antimicrobial peptides (Lyz and Defa5). In line with reduced stemness in 
vivo, TNFΔARE mice-derived crypts were not able to give rise to organoids ex 
vivo. However, DCA-mediated inhibition of glycolysis, forcing cells to shift  
to mitochondrial respiration, reverted the oligomycin-mediated distortion 
of PC functions in organoids and rescued TNFΔARE mice-derived crypt cul-
tures to form sustainable organoids.
Conclusion: We provide evidence that mitochondrial impairment drives the 
stem cell niche towards a dysfunctional PC phenotype, and is predictive for 
disease recurrence of CD patients aft er surgical resection. Maintenance of 
mitochondrial respiration may represent a novel drug target to antagonize 
PC dysfunction in the pathogenesis of CD.
Disclosure: Nothing to disclose 
OP226 ULCERATIVE COLITIS IS CHARACTERIZED BY AN INTENSE 
AND DYSFUNCTIONAL MUCOSAL AND SYSTEMIC B CELL RESPONSE
Uzzan M.1,2, Martin J.2,3, Rosenstein A.2, Mesin L.4, Singh H.2, 
Tokuyama M.2, Ungaro R.2, Grasset E.2, Cerutti A.2, Ko M.2, Kenigsberg E.2, 
Merad M.2, Magri G.5, Colombel J.-F.6, Victora G.4, Mehandru S.2
1Hôpital Beaujon, APHP, Gastroenteroogy, Clichy, France, 2Mount Sinai 
Hospital, New York City, United States, 3CHU Nantes, Nantes, France, 
4Rockefeller University, New York City, United States, 5Hospital del 
Mar, Barcelona, Spain, 6Icahn School of Medicine at Mount Sinai, 
Gastroenterology, New York City, United States
Contact E-Mail Address: mathieuuzzan@gmail.com
Introduction: The lack of clear B-cell associated drivers of mucosal infl am-
mation and the failure of the Rituximab trial in ulcerative colitis (UC) has 
largely dampened the enthusiasm for B-cell focused research in Infl am-
matory Bowel Diseases. However, emerging data as well clues in existing 
literature suggest that the humoral immune system participates in and 
perhaps drives the pathophysiology of UC.
Aims & Methods: In the present study, we systematically examined the B 
cell phenotype and function in patients with UC.
Blood and colonic biopsies were collected from UC patients as well as 
healthy controls at the Mount Sinai hospital. B cells were characterized 
using multiparameter fl ow cytometry and immunohistochemistry. In a 
subset of patients we examined the heavy chain immunoglobulin gene 
(IgH) repertoire at the single-cell level. We also deciphered the B cell tran-
scriptomic profi le and key B-cell clusters as well as their interactions with 
other cell types using single-cell RNA sequencing (10x genomic) in the 
colonic mucosa.
Results: We enrolled 65 active UC patients, 15 patients with quiescent dis-
ease and 30 healthy controls from whom we obtained blood samples. 58% 
of the patients were not under any immunomodulator. Whereas there were 
no changes in the frequency of CD19+ B cells and B cell subsets in blood, cir-
culating plasmablasts (CD19+/intCD27+CD38hi) were markedly expanded in 
active UC patients (0.56% vs 0.12%, p< 0.0001). They up-regulated the β7-
intregrin and CXCR3 while down-regulating β1-integrin. Both IgA and IgG 
plasmablasts were expanded in circulation. Expansion of β7+plasmablasts 
correlated with disease activity and systemic infl ammation. Subsequent 
analyses of plasma cells in the colonic mucosa, from 20 infl amed mucosa, 
19 non-infl amed mucosa from UC patients and 13 healthy colonic biopsies, 
expression. As tissue-resident macrophages develop from the yolk sac, 
the CD98hc expression was determined in the embryonic yolk sac (E8.5), 
Kupff er cells and Langerhans cells. The macrophages of the yolk sac re-
vealed a lower CD98hc expression compared to the tissue-resident Kupff er 
cells and Langerhans cells. We next generated an inducible knock-out 
mouse system. CD98hcΔCX3CR1mice were generated by breeding Cx3cr-
1CreERmice with CD98hcfl ox/fl oxmice for the tamoxifen-inducible silencing of 
CD98hc. Tamoxifen-injection into CD98hcΔCX3CR1mice lead to the deletion in 
colonic macrophages and liver Kupff er cells but not in Langerhans cells. 
The deletion ofCD98hc in macrophages attenuated the severity of dextran 
sodium sulfate (DSS) induced-colitis clinically, endoscopically, and his-
tologically. Aft er quality fi ltering, a total of 3,213 (1863 control and 1,350 
CD98hc cKO) cells were obtained for scRNA-seq. 
The observation of cells on a principal component analysis (PCA) or tSNE 
visualization, patterns of expression of cluster-specifi c genes, hypervari-
able genes and arbitrarily chosen monocytes and macrophages marker 
genes suggested a diff erentiation trajectory from monocytes to macro-
phages. The calculation of the relative proportion of control and CD98hc-
defi cient cells, across clusters and across the PCA space, indicated an en-
richment of CD98hc-defi cient cells in monocyte clusters, which was also 
apparent when the relative proportions of control and CD98hc-defi cient 
cells projected on the nodes of FlowSOM trees. 
These results indicate a block in the ‘monocyte waterfall’-development to 
mature macrophages in the colonic lamina propria of tamoxifen-treated 
CD98hcΔCX3CR1mice. To further gain insights into molecular mechanisms 
involved in the developmental arrest in CD98hc defi cient macrophages, 
we looked for genes diff erentially expressed between tamoxifen- or corn 
oil-treated CD98hcΔCX3CR1mice within each cluster along the developmental 
trajectory. The “pseudo-bulk” samples used for this analysis indicated an 
enrichment of apoptosis-associated genes, such as Bcl2l11, Tnf,andOsm in 
tamoxifen-treatedCD98hcΔCX3CR1mice. Consequently, the numbers of macro-
phages but not monocytes were signifi cantly reduced aft er CD98hc silenc-
ing, which is highly expressed in biopsies of patients with quiescent and 
active ulcerative colitis or Crohn’s disease.
Conclusion: Our results demonstrate that the deletion of CD98hc results in 
a developmental arrest of intestinal macrophages. CD98hc plays a pivotal 
role in the development of intestinal macrophages.
References: 1. Smythies, LE et al. J Clin Invest 115, 66-75 (2005). 2. Kamada, 
N et al. J Clin Invest 118, 2269-2280 (2008) 3. Bain CC et al. Mucosal Immu-
nol 6, 498-510 (2013) 4. Schridde A et al. Mucosal Immunol 10, 1387-1399.
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OP225 MITOCHONDRIAL IMPAIRMENT IN CROHN’S DISEASE 
DRIVES INTESTINAL STEM CELL TRANSITION TOWARDS 
DYSFUNCTIONAL PANETH CELLS
Khaloian Sarnaghi S.1, Rath E.1, Hammoudi N.2, Gleisinger E.1, Berger E.1, 
Metwaly A.1, Waldschmitt N.1, Allez M.2, Haller D.1,3
1Technische Üniversität München (TUM), Nutrition and Immunology, 
Freising-Weihenstephan, Germany, 2APHP, Hôpital Saint Louis, 
Gastroenterology, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité 
University, Paris, France, 3Technische Universität München, ZIEL Institute for 
Food & Health, Freising, Germany
Contact E-Mail Address: sevana.khaloian@tum.de
Introduction: Altered intestinal epithelial cell (IEC) homeostasis is associ-
ated with chronic intestinal pathologies like infl ammatory bowel diseases 
(IBD). Paneth cells (PC) reside in close proximity to Lgr5+ intestinal stem 
cells (ISC) localized at the crypt base, supporting epithelial renewal/homeo-
stasis. PC produce antimicrobial peptides and niche factors necessary for 
the maintenance of Lgr5+ ISCs. Impaired PC function contributes to the ileal 
pathogenesis of Crohn’s disease (CD). The aim of this study was to char-
acterize the role of mitochondrial function on the ISC niche including PC.
Aims & Methods: To determine the impact of mitochondria on the ISC 
niche, we used a mouse model for CD-like ileitis (TNFΔARE mice), and ileal 
tissue samples from CD patients. Impact of mitochondrial impairment on 
ISC and PC was evaluated in mice with a tamoxifen-inducible ISC specifi c 
knockout for the mitochondrial chaperone Hsp60 (Hsp60ΔISC). Small intes-
tinal organoids from mice and humans were generated to illustrate altera-
tions of stem cell and PC phenotypes aft er treatment with dichloroacetate 
(DCA) and oligomycin. In addition, we performed transcriptional analyses, 
in situ hybridization, and immunostaining (IHC and IF) in tissue sections 
and organoid cultures to dissect molecular mechanisms.
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Conclusion: Defects in XIAP are associated with loss of Paneth cells and 
increased susceptibility to chemical and microbiota-induced intestinal 
infl ammation. As such, these data provide novel insight into the mecha-
nisms that link XIAP mutations to intestinal infl ammation and highlight 
the microbiota as a potential therapeutic target in patients with XIAP mu-
tations and CD.
Disclosure: Nothing to disclose 
OP228 THE TRANSCRIPTOMIC LANDSCAPE OF HUMAN COLONIC 
ORGANOIDS AND ITS REMODELLING BY CANONICAL CYTOKINES 
PROVIDES KEY FUNCTIONAL AND CLINICAL INSIGHTS INTO 
INFLAMMATORY BOWEL DISEASE
Pavlidis P.1,2, Tsakmaki A.3, Cozzetto D.4, Kottoor S.1, Digby-Bell J.1, 
Constable L.1, Niazi U.4, Saqi M.4, Lombardi G.5, Hayee B.1,6, Bewick G.3, 
Powell N.1,2
1King’s College London, Centre for In ammation Biology and Cancer 
Immunology, London, United Kingdom, 2Guy’s and St Thomas’ Hospital, 
London, United Kingdom, 3King’s College London, Diabetes Research 
Group, London, United Kingdom, 4BRC Bioinformatics Core, London, United 
Kingdom, 5King’s College London, Immunoregulation, London, United 
Kingdom, 6Kings College Hospital, Gastroenterology, London, United 
Kingdom
Contact E-Mail Address: polychronis.pavlidis@kcl.ac.uk
Introduction: The immune- epithelial interactions are central in our cur-
rent understanding of infl ammatory bowel disease (IBD) pathogenesis. 
Cytokines have been shown to play an integral part in this cross-talk, with 
some considered pro-infl ammatory (e.g. IFNγ, TNFα) and others protec-
tive (e.g. IL22).
Aims & Methods: Since most of the work informing our current under-
standing of cytokine mediated epithelial responses is based on pre-clinical 
models we set out to defi ne and compare the transcriptional programmes 
regulated by the canonical cytokines IFNγ(TH1), IL13 (TH2), IL17A(TH17), IL22 
(TH22) and TNFα, as a pro-infl ammatory control, in human colonic organ-
oids (colonoids) and associate them to disease phenotypes and therapeu-
tic trajectories in IBD.
Whole transcriptome profi ling of cytokine treated human colonoids (n=4) 
was performed using the Illumina platform. Pathway analysis was per-
formed using the Ingenuity database while gene set variation analysis 
(GSVA) and weighted gene correlation network analysis (WGCNA) were 
used to associate cytokine regulated modules to phenotypes by interrogat-
ing whole biopsy transcriptomic profi les of our own UC cohort (n=16) and 
reposited datasets (GSE16879, n=73, GSE23597, n=206). Flow cytometry of 
human intestinal lamina propria mononuclear cells (LPMC) corroborated 
our transcriptomic analysis while the functional relevance of our fi ndings 
was confi rmed by using the TRUC model of colitis.
Results: A large functional overlap was found between IFNγ, IL22 and TNFα 
transcriptional programmes with key pathogenic pathways upregulated by 
all three cytokines (e.g. IL6, NF-kB, TREM1, TLR signalling, acute phase re-
sponse, neutrophil chemotaxis). GSVA revealed enrichment of all cytokine 
regulated transcriptional modules in active infl ammation while there was 
no diff erence in activated module number or type between UC and colonic 
CD. Intriguingly, patients with the same endoscopic activity had a gradi-
ent of activated cytokine regulated modules. Those with ≥2 modules en-
riched had a higher risk of non-response to anti-TNFα therapy in both IBD 
phenotypes [relative risk: 2.9, 95%CI(1.7, 6)]. A strong, positive correlation 
was seen between IL22, IFNγ and TNFα enrichment scores which was also 
validated by identifying a population of polyfunctional CD4+ T cells be-
ing enriched in the mucosa of IBD patients with active disease producing 
all three cytokines. WGCNA revealed a neutrophil chemotaxis chemokine 
module to be the pathway most strongly associated with anti-TNFα non-
response. This module was primarily upregulated by IL22 and TNFα. In a 
TNFα and IL22 dependent model of colitis IL22 blockade downregulates 
the same chemokine module and improves colitis while the use of a neu-
trophil chemokine receptor (CXCR2) blocker abrogates disease.
Conclusion: Our study provides novel insights into the human gut im-
mune-epithelial interactome and paves the way for a more granular im-
munophenotyping of IBD. It highlights that the simultaneous activation of 
modules regulated by multiple canonical cytokines is associated with non-
response to anti-TNFα. Targeting of these shared pathogenic pathways 
may hold the key to overcoming non-response to biological therapies.
Disclosure: Nothing to disclose 
revealed the reshaping of the B cell landscape in the infl amed mucosa. In-
deed, short-lived plasma cells (CD45+CD19+CD27+CD38hi) and Ki67+ plas-
mablasts were massively expanded in the infl amed mucosa along with 
an increased frequency of naïve and germinal center B cells. The study of 
the IgH gene sequencing from single-cell sorted short-lived plasma cells 
showed the skewing of isotype toward an increase of IgG and a decrease of 
IgA2 in UC. In addition, their repertoire diversity was signifi cantly reduced. 
Further, clones sequenced from UC patients presented more somatic hy-
permutations and a longer complementary-determining region 3 (CDR3) 
suggesting a reduced maturation state.
Single-cell RNA sequencing of lamina propria cells demonstrated the 
highly proliferative state of colonic plasmablasts during active UC that 
were also increased in frequency while virtually absent in healthy controls. 
IgG plasma cells expressing the chemokine receptors CXCR4 were also 
found in greater frequency in the infl amed mucosa. These changes in the 
antibody-secreting cells compartment were accompanied by an increase 
in naïve and germinal center B cells as well as in a cluster of CXCL13-
expressing T cells.
Conclusion: We show that an intense and acute B cell response is ongoing 
in active UC as evidenced by the expansion of circulating β7+plasmablasts 
that leads to an increase of short-lived PC and highly proliferative plasma-
blasts in the colonic mucosa. This B cell response likely participates in the 
infl ammatory process as they have skewed isotype usage, they diff eren-
tially express chemokine receptors and they have modifi ed IgH gene fea-
tures. This study, along with key recent works, suggests a potential interest 
in targeting specifi cally intestinal antibody-secreting cells as a therapeutic 
strategy in UC.
Disclosure: Nothing to disclose 
OP227 MUTATIONS IN THE X-LINKED INHIBITOR OF APOPTOSIS 
PROTEIN PROMOTE SUSCEPTIBILITY TO MICROBIOTA-INDUCED 
INTESTINAL INFLAMMATION
Gopalakrishnan S.1, Zeissig Y.2,3, Strigli A.1, Basic M.4, Muders M.3,5, 
Baretton G.3, Baines J.6, Bleich A.4, Hampe J.1,3, Zeissig S.1,3,7
1TU Dresden, Dresden, Germany, 2UKSH Kiel Abt. für Allg. Kinderheilkunde, 
Dr., Kiel, Germany, 3University Clinic Carl-Gustav Carus Dresden, Dresden, 
Germany, 4Hannover Medical School, Hannover, Germany, 5University Clinic 
Bonn, Bonn, Germany, 6Max Planck Institue for Evolutionary Biology, Plön, 
Germany, 7University Hospital Schleswig-Holstein, Department of Medicine I, 
Kiel, Germany
Contact E-Mail Address: szeissig@gmail.com
Introduction: Mutations in the gene encoding the X-linked inhibitor of 
apoptosis protein (XIAP) form the basis for one of the most common Men-
delian forms of Crohn’s disease. However, the mechanisms which link XIAP 
mutations to CD are poorly understood.
Aims & Methods: We investigated Xiap-/- mice and wildtype (WT) litter-
mates under constitutive conditions in a specifi c pathogen-free (SPF) envi-
ronment as well as upon exposure to dextran-sodium sulfate (DSS) or the 
pathobiont Helicobacter hepaticus.
Results: Defi ciency in XIAP was associated with a selective loss of Paneth 
cells as a result of increased Paneth cell death. Remaining Paneth cells 
showed ultrastructural defects, including aberrant positioning of granules, 
nuclear condensation and fragmentation, and loss of mitochondrial struc-
ture. 
This was associated with reduced abundance of Paneth cell-derived anti-
microbial peptides and impaired bacterial control associated with dense 
colonization of intestinal crypts by commensal bacteria, increased abun-
dance of mucosa-adherent bacteria and an altered intestinal microbial 
composition. Under SPF conditions, these alterations were not suffi  cient 
to elicit spontaneous intestinal infl ammation. 
However, upon exposure to the pathobiont Helicobacter hepaticus, Xiap-/- 
mice showed impaired clearance of Helicobacter hepaticus and developed 
granulomatous ileitis, which was not observed in WT littermates. Recon-
stitution of antimicrobial activity by adenoviral delivery of alpha defensin 
5 restored the clearance of Helicobacter hepaticus in Xiap-/- mice and pre-
vented ileal granuloma formation. 
Moreover, in accordance with long range eff ects of Paneth cell-derived 
antimicrobial peptides in the colon, Xiap-/- mice showed increased suscep-
tibility towards DSS compared to WT mice. Intriguingly, DSS also elicited 
ileal pathology such as villus blunting in Xiap-/- mice, which was not ob-
served in WT mice.
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OP229 IDENTIFICATION OF A CYTOTOXIC CD127+ INNATE 
LYMPHOID CELL SUBSET THAT IS EXPANDED IN PATIENTS WITH 
CROHN’S DISEASE
Krabbendam L.1, Kradolfer C.M.A.1, Teunissen M.B.M.1, Buskens C.J.2, 
Bemelman W.A.2, Spits H.1, Bernink J.H.J.1
1Amsterdam UMC, Location AMC, Experimental Immunology, Amsterdam, 
Netherlands, 2Amsterdam UMC, Location AMC, Surgery, Amsterdam, 
Netherlands
Contact E-Mail Address: l.krabbendam@amc.nl
Introduction: Crohn’s disease is an infl ammatory disorder within the in-
testines as a consequence of dysregulated immune responses. Innate 
Lymphoid Cells (ILCs), including helper ILCs and Natural Killer (NK) cells, 
regulate intestinal homeostasis and provide protective immunity, but also 
contribute to pathology when not properly controlled. 
Previously we demonstrated that the increased frequency of non-cytotoxic 
IFN-y-producing ILC1s in Crohn’s disease resection specimen inversely cor-
related with a decreased frequency of ILC3s, while the frequency of NK 
cells were not altered1,2 .
Aims & Methods: Combining fl ow cytometry, ex vivo culture methods, and 
whole transcriptomic analysis methods of human fetal, non-infl amed and 
Crohn’s disease resection specimen, we demonstrate here the identifi ca-
tion of a previously unrecognized population of cytotoxic IFN-y-producing 
ILC in the intestinal lamina propria, that are distinct from NK cells.
Results: These cells are characterized by the expression of the ILC-defi ning 
markers CD127 (also known as IL7Rα) and CD200R1. 
In addition, these cells express CD94, a marker that was previously thought 
to be restricted to NK cells. This ILC population is highly increased in in-
fl amed intestinal resection specimen when compared to non-infl amed 
tissue and was virtually absent in fetal intestines or peripheral blood. 
Ex vivo cloning experiments demonstrated that conventional helper ILCs, 
including ILC3s and ILC1s, acquired the cytotoxic, IFN-y-producing CD94+ 
phenotype when exposed to IL-12, a cytokine that is prominently abundant 
in infl amed intestines of Crohn’s disease patients. 
We furthermore demonstrated that the identifi ed cell population induced 
cell death of K562 target cells at a similar degree as NK cells whereas CD94- 
ILC1 and ILC3 failed to kill these target cells
Conclusion: Taken together, we have identifi ed a population of cytotoxic 
and IFN-γ-producing ILCs that is expanded at the expense of ILC3s in in-
fl amed intestines of Crohn’s disease patients where they may contribute 
to pathology.
References: 1. Bernink, J.H., Peters, C.P., Munneke, M., te Velde, A.A., Mei-
jer, S.L., et al. (2013) Human Type 1 Innate Lymphoid Cells accumulate in 
infl amed mucosal tissues. Nat. Immunol. 14, 221-229 2. Bernink J.H., Krab-
bendam, L., Germar, K., de Jong, E., Gronke et al. (2015) Interleukin-12 and 
-23 Control Plasticity of CD127+ Group 1 and Group 2 Innate Lymphoid Cells 
in the Intestinal Lamina Propria. Immunity. 43(1), 146-160
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OP230 INCREASED SENSITIVITY OF COUGH REFLEX IS NOT THE 
MECHANISM OF COUGH ATTRIBUTED TO LARYNGOPHARYNGEAL 
REFLUX
Duricek M.1, Banovcin P.1, Liptak P.1, Hyrdel R.1, Kollarik M.2
1Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 
Martin, Slovakia, Gastroenterology Clinic, Martin, Slovakia, 2Morsani 
College of Medicine, University of South Florida, Department of Molecular 
Pharmacology & Physiology, Tampa, United States
Contact E-Mail Address: martin.duricek@gmail.com
Introduction: Coughing is oft en attributed to laryngophayngeal refl ux 
(LPR). It is assumed that acid in the gastroesophageal refl ux (GER) that 
reaches the laryngopharyngeal area stimulates or sensitizes respiratory 
nerve terminals mediating cough. This premise allows for formulation 
of several testable hypotheses. If the stimulation of respiratory nerves by 
acidic LPR is responsible for coughing then a) acidic LPR should correlate 
with coughing, b) proton pump inhibitor (PPI) treatment should reduce 
both coughing and acidic LPR. On the other hand, if sensitization of re-
spiratory nerves by acidic LPR is responsible for coughing then a) cough 
sensitivity should correlate with coughing, b) PPI treatment should reduce 
both coughing and cough sensitivity. Here we addressed these hypotheses.
Aims & Methods: Consecutive patients referred for suspected LPR were 
evaluated and those with positive refl ux symptom index (RSI>13) and/or 
refl ux fi nding score (RFS >7) were enrolled. LPR was inferred from pharyn-
geal refl ux. Pharyngeal refl ux was evaluated by simultaneous pharyngeal 
and distal esophageal 24-hour pH/impedance. Pharyngeal refl ux events 
with the maximum drop of pH at levels 6.0, 5.5, 5.0, 4.5, and 4.0 were 
determined to perform analysis independent of the assumption how acidic 
pharyngeal refl ux is required to infl uence cough. Cough refl ex sensitivity 
was determined as the lowest concentration of capsaicin causing at least 
2 coughs (C2) by single breath capsaicin inhalation challenge using dou-
bling capsaicin concentrations (0.49-1000µM). For statistical analysis C2 
values were -log transformed. Troublesome coughing was evaluated on 
the scale 0-5.
Results: 27 patients diagnosed with LPR were enrolled. The number of 
pharyngeal refl ux events (median[interquartile range]) with pH 6.0, 5.5, 
5.0, 4.5 and 4.0 was 14[8-21], 4[2-7], 1[0-2], 1[0-1] and 0[0-1], respectively. 
There was no correlation between coughing and the number of pharynge-
al refl ux episodes at any pH level (Pearson coeffi  cients R ranged from -0.17 
to 0.23, P=NS). There was also no correlation between coughing and the 
cough refl ex sensitivity C2 (R=-0.1, P=NS). 17 patients completed PPI treat-
ment. In 11 patients RSI was normalized by PPI (PPI-responders). In PPI-
responders the troublesome cough was substantially reduced by >60% 
(2.3±0.6 vs. 0.9±0.1, P< 0.01). However, strikingly, there was no change in 
cough refl ex sensitivity in PPI-responders. The capsaicin C2 threshold was 
13[1.6-32]µM vs. 7.8[3.1-19]µM before and aft er PPI (P=0.11). Furthermore, 
PPI treatment did not appreciably reduce acidic pharyngeal refl ux.
Conclusion: The lack of correlation between the cough sensitivity and 
coughing and the lack of change in cough sensitivity despite substantial 
improvement of coughing by PPI strongly argue that an increased cough 
refl ex sensitivity is not the mechanism of cough attributed to LPR. Dual 
pharyngeal and distal esophageal 24-hour pH/impedance monitoring 
did not identify simple relationship between acidic refl ux and coughing 
suggesting that this relationship is more complex. Supported by VEGA 
1/0304/19.
Disclosure: Nothing to disclose 
OP231 RISK FACTORS OF FUTURE ONSET OF REFLUX ESOPHAGITIS: 
A LONGITUDINAL CASE-CONTROL STUDY USING LONG-TERM HEALTH 
CHECKUP RECORDS IN JAPAN
Kamiya T.1, Osaga S.1, Joh T.2, Haruma K.3, GERD Society in Japan
1Nagoya City University Graduate School of Medical Sciences, Department 
of Medical Innovation, Nagoya, Japan, 2Gamagori City Hospital, Internal 
Medicine, Gamagori, Japan, 3Kawasaki Medical School, Kurashiki, Japan
Contact E-Mail Address: kamitake@med.nagoya-cu.ac.jp
Introduction: Refl ux esophagitis (RE) is a disease in which the refl ux of 
gastric contents into the esophagus causes superfi cial erosion of the mu-
cosa of the lower esophagus, and its prevalence and burden have recently 
increased Risk factors of RE proposed in previous studies included obesity, 
being male, hiatal hernia, absence of atrophic gastritis, advanced age, 
diabetes drinking smoking, metabolic syndrome, Helicobacter pylori (H. 
pylori) negative, However, these risk factors of RE have been investigated 
in many cross-sectional studies, little is known about predictive factors 
associated with future onset of RE. We investigated time courses of clini-
cal parameters before RE onset by a longitudinal case-control study using 
long-term health checkup records.
Aims & Methods: We conducted a retrospective study using to investigate 
factors associated with future RE onset using long-term health checkup 
records in Japan. We used health checkup records between April 2004 and 
March 2014 at nine institutions in Japan. Subjects who were newly diag-
nosed as RE between April 2009 and March 2014 were included in the 
analysis as case subjects. For each case subject, two subjects who had no 
RE diagnosis between April 2004 and March 2014 and were matched for 
age, sex, and participating institutions with the corresponding case were 
included as control subjects. The time courses of clinical parameters of 
RE subjects were compared with those of control group by the restricted 
maximum likelihood method for repeated measures or multivariate logis-
tic analysis. We also implemented cross-sectional comparisons for each of 
the fi ve years prior to RE onset.
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acid exposure (< 4.2%) was not diff erent between the exacerbation and 
non-exacerbation groups (11 of 21 patients vs. 4 of 7 patients respectively). 
Similarly, gastric pH< 4 time% was not diff erent between groups (88.6% 
[77.4-92.7] vs 85.9% [78.8-90.6]). There were no signifi cant correlations 
between AET/gastric pH< 4 time% and the severity of the exacerbation of 
each symptom on stopping PPIs. Other MII-pH parameters (the number of 
refl ux episodes, proximal extent, and bolus exposure time%) did not show 
signifi cant diff erence.
Conclusion: Our study shows that exacerbation of refl ux symptoms aft er 
the discontinuation of PPIs occurs in the majority of patients. However, this 
appears to occur regardless of whether there is excessive esophageal acid 
exposure, and in at least half is associated with completely normal AET. 
Not just heartburn, but all recorded upper GI symptoms exacerbated on 
stopping PPI in most patients. The results suggest that acid-independent 
mechanisms may have a role in symptom exacerbation on stopping PPI. 
One potential hypothesis is that sudden withdrawal of PPI-related anti-in-
fl ammatory eff ects induce hypersensitivity of the GI viscera. Further studies 
are required.
Disclosure: Daniel Sifrim receives research grants from Reckitt Benckiser 
UK, Jinshan Technology China and Alfa Sigma, Italy. Philip Woodland re-
ceives research grants from Reckitt Benckiser UK, and consultancy fees 
from Reckitt Benckiser UK and Dr Falk Pharma UK 
OP233 ABNORMAL POST REFLUX SWALLOW INDUCED 
PERISTALTIC WAVE (PSPW) INDEX ON PH-IMPEDANCE MONITORING 
ASSOCIATES WITH HYPOMOTILE ESOPHAGEAL MOTOR PATTERNS ON 
ESOPHAGEAL HIGH RESOLUTION MANOMETRY (HRM)
Rogers B.1, Rengarajan A.2, Cicala M.3, Ghisa M.4, Quader F.5, 
Penagini R.S.6, De Bortoli N.7, Mauro A.8, Ribolsi M.9, Savarino E.V.10, 
Gyawali C.P.5
1Washington University School of Medicine, St. Louis, United States, 
2Washington University, Internal Medicine, Saint Louis, United States, 
3Università Campus Bio Medico, Gastroenterologia, Rome, Italy, 4Azienda 
Ospedaliera di Padova, DISCOG - UOC Gastroenterologia, Vedelago, Italy, 
5Washington University School of Medicine, Division of Gastroenterology, 
St Louis, United States, 6Università degli Studi di Milano, Dipto. di 
Gastroenterologia/Dipto. di Scienze Mediche, Milan, Italy, 7University of Pisa, 
Dept. of Gastroenterology, Pisa, Italy, 8University of Milan, Gastroenterology 
and Endoscopy Unit, Milano, Italy, 9University of Rome Tor Vergata, 
Rome, Italy, 10University of Padua, Department of Surgery, Oncology and 
Gastroenterology, Padua, Italy
Contact E-Mail Address: bdrogers@wustl.edu
Introduction: Post-refl ux Swallow-induced Peristaltic Wave (PSPW) partici-
pates in refl ux clearance through primary peristalsis, and abnormal PSPW 
index is a marker for higher refl ux burden on pH impedance monitoring. 
Impaired primary esophageal body peristalsis on HRM also associates with 
abnormal refl ux burden; peristalsis can augment following multiple rapid 
swallows (MRS), termed contraction reserve. The relationship between 
PSPW and esophageal body contraction metrics on HRM in the context of 
refl ux disease remains unknown.
Aims & Methods: Our aim was to determine whether a relationship existed 
between PSPW and esophageal body contraction patterns on HRM in pa-
tients being evaluated for refl ux disease. Clinical presentation, HRM, and 
ambulatory pH-impedance studies performed on patients with persisting 
refl ux symptoms were reviewed from fi ve centers (4 in Europe and 1 in 
US) for this preliminary report. Incomplete studies, achalasia, esophageal 
outfl ow obstruction, and prior foregut surgery were exclusions. HRM stud-
ies were analyzed according to CC 3.0, and proportions of intact (distal 
contractile integral, DCI>450 mmHg.cm.s), fragmented (intact with ≥5 cm 
breaks), ineff ective (DCI< 450 mmHg.cm.s), and failed (DCI< 100 mmHg.
cm.s) were recorded. The ratio of MRS esophageal body contraction vigor 
(using distal contractile integral, DCI) to mean contraction vigor from sin-
gle swallows >1 defi ned presence of contraction reserve. Total, upright and 
supine acid exposure time (AET) were extracted from pH-impedance stud-
ies (abnormal when total AET>6%, upright AET>6% and supine AET>2%). 
PSPW was defi ned as an antegrade swallow within 30 s of completion of 
an impedance detected refl ux episode, and PSPW index was calculated as 
the proportion of refl ux episodes with PSPW on the 24 hour pH impedance 
study. Univariate comparisons, ANOVA, and linear regression were utilized 
to investigate potential correlations between PSPW index and contraction 
patterns.
Results: Initial data were obtained from 230,056 individuals, and 2,066 
RE subjects and 4,132 control subjects were fi nally included in the analy-
sis. The time courses of body mass index (BMI) (p < 0.001), abdominal 
circumference (AC) (p < 0.001), fasting blood sugar (FBS) (p = 0.039), se-
rum triglyceride (TG) (p = 0.010), glutamate oxaloacetate transaminase 
(p = 0.044), glutamic pyruvic transaminase (GPT) (p = 0.005), γ-glutamyl 
transpeptidase (p < 0.001), and percentages with acid refl ux symptoms (p 
= 0.004), feeling of fullness (p = 0.019), and hiatal hernia (p < 0.001) in 
the RE group were signifi cantly worse than in the control group. In cross-
sectional comparisons at the year of RE onset, BMI (p < 0.001), AC (p < 
0.001), FBS (p = 0.006), systolic blood pressure (p = 0.011), TG (p < 0.001), 
uric acid (p = 0.002), GOT (p < 0.001), GPT (p < 0.001), γ-GTP (p < 0.001), 
amount of alcohol (p < 0.001), smoking (p = 0.008), and percentage with 
acid refl ux symptoms (p < 0.001), feeling of fullness (p = 0.046), hiatal her-
nia (p < 0.001), hypertension (p = 0.003), and hyperlipidemia (p = 0.044) 
in the case group were higher than in the control group, and high-density 
lipoprotein cholesterol (p = 0.007) and percentage with atrophic gastritis 
(p < 0.001) in the case group were lower. Among them, BMI, AC, TG, GPT, 
and percentages with acid refl ux symptoms and atrophic gastritis showed 
signifi cant diff erences for fi ve years prior to RE onset consecutively be-
tween the groups.
Conclusion: The RE group displayed a more rapid worsening of the clinical 
parameters associated with lifestyle diseases, including obesity, diabetes, 
hyperlipidemia, and fatty liver compared with the non-RE group. These 
results suggest that RE is a lifestyle disease and thus lifestyle guidance may 
help to prevent RE onset.
Disclosure: Nothing to disclose 
OP232 EXACERBATION OF GASTROESOPHAGEAL REFLUX 
SYMPTOMS AFTER DISCONTINUATION OF PROTON PUMP INHIBITORS 
IS NOT ASSOCIATED WITH INCREASED ESOPHAGEAL ACID EXPOSURE
Hoshikawa Y., Nikaki K., Sonmez S., Yazaki E., Sifrim D., Woodland P.
Barts and the London School of Medicine and Dentistry, Queen Mary 
University of London, Wingate Institute of Neurogastroenterology, London, 
United Kingdom
Contact E-Mail Address: y.hoshikawa@qmul.ac.uk
Introduction: Almost universally, proton pump inhibitors (PPIs) are used 
for initial management of heartburn symptoms. Aft er an initial PPI course, 
there is oft en an attempt to stop medication. However, it is a very common 
complaint that refl ux symptoms exacerbate on stopping PPIs. Mechanisms 
have been postulated as resumption of esophageal acid exposure and re-
bound acid hypersecretion, however data on this are limited.
Aims & Methods: We aimed to study the impact of stopping long-term 
PPIs in patients with heartburn, and its association with esophageal acid 
exposure on objective testing.
We prospectively evaluated patients with heartburn on long-term PPIs 
(>8 weeks), referred to the Royal London Hospital Upper GI Physiology 
Unit. All completed an online questionnaire following a minimum of a 
7-day PPI discontinuation. The questionnaire addressed presence and ex-
acerbation of symptoms (heartburn, regurgitation, epigastric pain/burn, 
and excessive belch/bloating) since stopping PPI. Patients were asked if 
heartburn symptom had exacerbated since stopping PPI (yes/no). In those 
who had exacerbation, symptom intensity and frequency were assessed 
on a 10 point Likert scale (0 = no exacerbation of symptoms; 10 = extreme 
symptom exacerbation). Then, all patients underwent High Resolution 
Manometry (HRM) and 24-hour multichannel impedance pH study (MII-
pH) based on our standard protocol. We measured esophageal acid expo-
sure time (AET), the number of total refl ux and proximal extent episodes, 
esophageal bolus exposure time%, and gastric pH < 4 time %. All data 
are presented as median with interquartile range. We used Fisher exact 
test for comparison of ratios, Mann-Whitney U test for the comparison of 
continuous variables, and Spearman´s Rank Correlation Coeffi  cient for in-
vestigating correlations.
Results: 28 patients were studied. Aft er stopping PPIs, 21 patients (75%) 
had exacerbation of heartburn (“exacerbation group”), 7 patients had no 
exacerbation of heartburn (“non-exacerbation group”). Heartburn exac-
erbation severity in the exacerbation group was rated as mean 6.72 out of 
10 on the Likert scale. These patients also reported similar exacerbation of 
epigastric pain, bloating and belching. AET in the exacerbation group was 
not signifi cantly higher than in the non-exacerbation group (3.5% [1.7-
8.7] vs 3.4% [1.6-7.5], NS). The proportion of patients with physiological 
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Results: Of 269 patients (53.1 ± 0.9 yr, 62% F), abnormal AET proportions 
were found in 77 (28.6%), 111 (41.2%), and 108 (40.1%) for total, upright 
and supine AET, respectively. Median PSPW index was 0.50, range 0.04-
0.89. PSPW index declined progressively with increasing proportions of 
hypomotile patterns (p< 0.001 for each comparison by ANOVA, Table); 
there was corresponding increase in AET (p< 0.001 for each comparison 
by ANOVA). MRS data was available for 140 patients, of which 76.4% had 
contraction reserve. There was no direct correlation between PSPW index 
and presence or absence of contraction reserve. However, within ineff ec-
tive esophageal motility, PSPW was more robust when post MRS DCI was 
≥1000 mmHg.cm.s compared to < 1000 mmHg (0.50±0.02 vs. 0.43 ±0.3, re-
spectively, p=0.049) When controlling for physiologic acid burden, regres-
sion analysis demonstrated positive correlation between AET and PSPW 
index (p≤0.02 for each comparison).
  100% intact
<50% 
ineff ective
50-70% 
ineff ective
≥80% 
ineff ective
Absent 
contractility
PSPW index* 0.60±0.02 0.54 ±0.02 0.52±0.14 0.46±0.03 0.42±0.44
Total AET* (%) 4.5±0.90 5.0±0.5 6.4±1.7 6.9±1.1 12.3±3.7
Upright AET* (%) 4.5±0.6 5.6±0.1 6.5±1.8 7.7±1.0 11.6±3.6
Supine AET* (%) 3.8±1.3 4.3±0.8 5.7±1.9 6.1±1.7 13.2±6.0
*p < 0.001 across groups by ANOVA
[Comparison of PSPW index and acid burden across esophageal body motor 
patterns]
Conclusion: PSPW index correlates with esophageal body motor pattern, 
and both associate with abnormal refl ux burden. Abnormal PSPW index 
demonstrates a corresponding gradient of hypomotility on HRM, suggest-
ing that both PSPW and HRM complement evaluation of neuromuscular 
integrity of esophageal motor function.
Disclosure: Nothing to disclose 
OP234 EXTENDED BRAVO STUDIES (UP TO 96HOURS) INCREASES 
DIAGNOSTIC YIELD OF GASTRO-ESOPHAGEAL REFLUX DISEASE 
(GERD) IN PATIENTS WITH NORMAL MULTICHANNEL INTRALUMINAL 
IMPEDANCE-PH (MII-PH) STUDIES
Chia C.T.W.1, Miah I.2, Jafari J.2, Wong T.2
1Tan Tock Seng Hospital, Gastroenterology & Hepatology, Novena, Singapore, 
2Guy’s and St Thomas’ Hospital, London, United Kingdom
Contact E-Mail Address: tzechris@gmail.com
Introduction: MII-pH catheter studies measure both acid and non-acid 
refl ux and are considered nowadays to be the gold standard in the diag-
nosis of GERD. Wireless pH capsule (Bravo) may increase the diagnostic 
yield of standard 24hr catheter-based studies with prolonged monitoring 
by overcoming the limitation of day-to-day refl ux variability and patients 
are able to perform activities of daily living without the discomfort of the 
nasal catheter. This study aims to assess the additional diagnostic yield of 
extended Bravo recordings (up to 96 hours) in patients with negative 24hr 
MII-pH results.
Aims & Methods: A total of 44 patients with typical GERD symptoms but 
negative 24hr MII-pH studies off  proton pump inhibitor(PPI) were referred 
for Bravo capsule studies. Bravo studies were performed off  PPI over an 
extended period beyond 48hrs (up to 96hrs). Bravo cases positive for AET 
were analysed using the Bravo ‘Worst Day Analysis’ (WDA) and ‘Average 
Day Analysis’ (ADA). Reference values for MII-pH and Bravo equivalent 
were adopted from internationally established studies (Table 1). Subgroup 
analyses were subsequently made on cohorts whose MII-pH showed nor-
mal AET with (A) normal number of total refl ux events (TRE), (B) normal 
number of non-acid refl ux (NAR) events and (C) increased number of NAR 
events. Subgroups (B) and (C) have normal number of acid refl ux events. 
Statistical analysis was performed using SPSS.
Results: study group (male=14, female=30) with a mean age of 48 years, 
successfully completed Bravo studies up to 96 hours in 77.3% and beyond 
48 hours in 97.7%. Using the WDA and ADA respectively, Bravo (AET cut-off  
>4.2%) captured an additional 59.1% and 43.2% of patients with increased 
AET (p< 0.001) in cases with normal AET on MII-pH. In MII-pH subgroups 
(A), (B) and (C), Bravo WDA was able to reveal an additional positive AET 
of 61.8%(p< 0.001), 60.9%(p< 0.001) and 50.0%(p=0.016) respectively 
compared to MII-pH while Bravo ADA showed a similar albeit smaller ad-
ditional yield of 44.1% (p< 0.001), 43.5% (p< 0.002) and 35.7% (not sig-
nifi cant). Results were similar using other internationally published Bravo 
AET limits of >4.4% and >5.3%. Inclusion of symptom refl ux association 
in Bravo cases with increased AET also showed additional diagnostic yield 
over MII-pH ranging from 42.9-47.7% (p≤0.031) across all subgroups.
Conclusion: Extended Bravo studies managed to procure a diagnosis of 
GERD in more than half of cases with an initial normal MII-pH but persis-
tent symptoms. Half of the patients with increased NAR events on MII-pH 
also showed positive acid refl ux on prolonged testing using Bravo. This 
additional yield has the potential to alter diagnosis from functional heart-
burn/hypersensitive esophagus to GERD in diffi  cult cases and aff ect man-
agement by intensifying acid suppression therapy.
Disclosure: Nothing to disclose 
OP235 ROLE OF REFLUX IN THE PATHOGENESIS OF EOSINOPHILIC 
ESOPHAGITIS -COMPREHENSIVE APPRAISAL WITH OFF- AND ON-PPI 
IMPEDANCE-PH MONITORING
Frazzoni M.1, Penagini R.S.2, Frazzoni L.3, De Bortoli N.4, Mauro A.5, 
Tolone S.6, Bertani H.7, Marsico M.8, Conigliaro R.9, Savarino E.V.10
1Baggiovara Hospital, Digestive Pathophysiology Unit, Modena, Italy, 
2Università degli Studi di Milano Dipto. di Gastroenterologia, Dipartimento 
di Scienze Mediche, Milan, Italy, 3S.Orsola-Malpighi Hospital, Department 
of Medical and Surgical Sciences, Bologna, Italy, 4University of Pisa, Dept. 
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6University of Campania, Surgery, Naples, Italy, 7Nuovo Ospedale Civile 
S. Agostino Endoscopy Unit, Dr., Baggiovara, Italy, 8Policlinico Hospital, 
Department of Specialized Medicine, Modena, Italy, 9Emilia Viaggi s.n.c., 
Dr., Casalecchio di Reno, Italy, 10University of Padua, Department Of Surgery, 
Oncology And Gastroenterology, Padua, Italy
Contact E-Mail Address: edoardo.savarino@gmail.com
Introduction: The relationship between eosinophilic esophagitis (EoE) 
and gastroesofageal refl ux disease (GERD) has not been fully elucidated, 
as well as the mechanisms of response to proton pump inhibitor (PPI) 
therapy. Comprehensive assessment of refl ux by impedance-pH monitor-
ing could clarify these issues
Aims & Methods: A prospective multicenter study comparing EoE and 
GERD patients with healthy controls was carried out. Patients were evalu-
ated off - and on- PPI; impedance-pH appraisal included chemical clear-
ance, assessed with post-refl ux swallow-induced peristaltic wave (PSPW) 
index, and mucosal integrity measured with mean nocturnal baseline im-
pedance (MNBI) in the distal and mid esophagus
Results: Sixty consecutive EoE patients entered the study, and were com-
pared to 60 age- and sex-matched healthy controls and to 60 typical 
GERD cases. Number of total and acid refl uxes were higher while PSPW 
index and distal MNBI were signifi cantly lower in EoE than in healthy 
controls. On therapy, all refl ux parameters and MNBI improved in the 40 
PPI-responsive EoE cases but PSPW index was the only variable indepen-
dently associated with PPI responsiveness (OR 1.143, 95% CI 1.049-1.247, 
P=0.002). In PPI-refractory patients, number of total refl uxes and PSPW 
index were not modifi ed by therapy. Distal MNBI improved much more in 
PPI-responsive than in PPI-refractory cases. Off -PPI, MNBI values in mid 
and distal esophagus were comparably low in PPI-refractory but not in 
PPI-responsive EoE
Conclusion: Refl ux plays a role in the pathogenesis of EoE, more relevant 
in PPI-responsive cases. PPIs mainly act by improving chemical clearance, 
i.e. by an anti-refl ux action, thus supporting their long-term prescription 
in PPI-responsive EoE
Disclosure: Nothing to disclose 
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OP237 ARTIFICIAL INTELLIGENCE IDENTIFIES BARRETT’S 
NEOPLASIA WITH HIGH ACCURACY USING NBI-ZOOM VIDEOS: 
A MULTICENTER INTERNATIONAL STUDY
Struyvenberg M.1, de Groof J.1, van der Putten J.2, van der Sommen F.2, 
Baldaque-Silva F.3, Bisschops R.4, Schoon E.J.5, Curvers W.5, de With P.2, 
Bergman J.1
1Amsterdam UMC, Location AMC, Gastroenterology & Hepatology, 
Amsterdam, Netherlands, 2Eindhoven University of Technology, Electrical 
Engineering, Eindhoven, Netherlands, 3Karolinska University Hospital, 
Gastrocentrum, Stockholm, Sweden, 4Katholieke Universiteit Leuven, 
Gastroenterology, Leuven, Belgium, 5Catharina Hospital Gastroenterology 
and Hepatology, Dept. of Gastroenterology, Eindhoven, Netherlands
Contact E-Mail Address: m.r.struyvenberg@amc.uva.nl
Introduction: The endoscopic diagnosis of Barrett’s esophagus (BE) neo-
plasia generally consists of primary detection in overview, followed by 
targeted inspection using Narrow Band Imaging (NBI). Endoscopists have 
diffi  culties evaluating NBI-zoom imagery, resulting in suboptimal diag-
nostic accuracy and poor inter-observer agreement. Computer-aided diag-
nosis (CAD), using deep learning techniques, has shown promising results 
in gastrointestinal endoscopy. Therefore, we envisioned that CAD might 
be able to assist endoscopists in the interpretation of NBI-zoom imagery. 
Aim To demonstrate feasibility of a deep-learning CAD system for the eval-
uation of unaltered NBI-zoom videos in BE.
Aims & Methods: We used a step-wise approach using 4 diff erent endo-
scopic datasets to train our deep learning network (ResNet-UNet hybrid 
architecture). First, our CAD system was pre-trained using 494,364 la-
belled images of a variety of endoscopic imagery, named GastroNet. Next, 
690 BE neoplasia and 557 non-dysplastic (ND)BE white light endoscopy 
overview images were used for refi nement training. To further improve 
the CAD system, we used 71 NDBE and 112 neoplastic NBI-zoom images 
from 50 non-dysplastic and 50 neoplastic patients. Finally, the CAD sys-
tem was trained and validated with a fourth prospectively-collected, and 
histologically-confi rmed, dataset of 77 NDBE and 37 neoplastic (high grade 
dysplasia/adenocarcinoma) unaltered NBI-zoom videos. Performance was 
evaluated using fourfold cross-validation. Majority voting by the CAD sys-
tem was applied in our automated video analysis, in which a video was 
classifi ed as neoplastic if more than 50% of its sequential frames were 
suspicious for neoplasia. The primary outcome was reported as diagnostic 
accuracy of the CAD system for classifi cation of neoplastic BE in NBI-zoom 
images and videos.
Results: The CAD system demonstrated an accuracy, sensitivity and speci-
fi city for detection of BE neoplasia using NBI-zoom images of 84%, 88%, 
and 78%, respectively. In total, 18873 individual video frames were ana-
lyzed by the CAD system. Accuracy, sensitivity and specifi city for BE neo-
plasia detection using NBI-zoom videos were 93% (106/114), 86% (32/37), 
97% (75/77). Mean assessment time per video was 0.64 seconds (SD ± 
0.02), corresponding to 391 frames per second.
Conclusion: We are the fi rst to report high diagnostic accuracy on prospec-
tively-collected and histologically-confi rmed unaltered NBI-zoom videos 
with fast corresponding assessment time, thereby showing feasibility of 
neoplasia characterization in BE using CAD systems. Future work will fo-
cus on optimizing our current CAD system and validation using separate 
prospectively-collected datasets.
Disclosure: J.J. Bergman: NinePoint Medical, Fuji Film, Olympus, Pentax, 
CDx diagnostics, Cernostics, Medtronic, Erbe, Boston Scientifi c, Cook. 
Big data to robotics
14:00-15:30 / F2
OP236 A THREE-DIMENSIONAL PRINTED PELVIC MODEL IS USEFUL 
FOR LATERAL PELVIC NODE DISSECTION IN RECTAL CANCER
Hojo D., Murono K., Nozawa H., Kawai K., Hata K., Tanaka T., 
Nishikawa T., Yasutaka S., Kaneko M., Sasaki K., Emoto S., Ishii H., 
Sonoda H., Ishihara S.
Tokyo University, Surgical Oncology, Tokyo, Japan
Contact E-Mail Address: daisuke.hojo.a1mb1083@gmail.com
Introduction: In patients with advanced lower rectal cancer, the complex 
pelvic anatomy renders lateral pelvic node dissection (LPND) challenging. 
Though laparoscopic and robotic surgery have decreased the invasiveness 
of LPND, the absence of tactile sensation increases the risk of blood vessel 
and nerve injury. Recently, three-dimensional (3D) printing of models for 
preoperative simulation or intraoperative navigation has been described 
for liver [1], kidney [2], and pancreas surgery [3]. Subjective assessments 
have confi rmed the utility of 3D-printed models for understanding spatial 
anatomy.
Aims & Methods: We evaluated the utility of printing a 3D pelvic model 
for LPND.
We included 22 patients who underwent LPND for rectal cancer between 
June 2017 and February 2019. Using CT scans, 3D pelvic images and models 
were constructed and printed, respectively. Thirty colorectal surgeons sub-
jectively evaluated the utility of 3D pelvic models based on a 5-point Likert 
scale questionnaire (1 = strongly disagree to 5 = strongly agree). 
Production of the 3D pelvic model
A colorectal surgeon constructed a 3D image from 0.5-mm thin-slice im-
ages obtained using an enhanced multi-detector CT. The organ structure 
was manually segmented to defi ne the region of interest on each CT slice 
in the axial view and converted into a stereolithography fi le to generate the 
3D virtual model. The 3D models were printed with white polylactic acid 
of 2.85-mm diameter using an 3D Printer. The models were fi nalized by 
removing the support fi lament and were coloured manually.
Results: 
Patient characteristics: The patients included 13 males and nine females; 
of these, fi ve underwent open surgery, 12 underwent laparoscopic sur-
gery and fi ve underwent robotic surgery. LPND was performed on the left  
side in eight patients, right side in seven patients and bilaterally in seven 
patients. Lateral pelvic lymph node metastasis was observed in 19 sides. 
Questionnaire results: The average Likert score for the question ‘Would a 3D 
model be useful for understanding pelvic anatomy?’ was 4.7. Cases with 
enlarged pelvic lymph nodes (4.8 ± 0.44) scored higher than those without 
metastasized lymph nodes (4.4 ± 0.77, p = 0.02). For spatial comprehension 
of pelvic anatomy, 3D models scored higher (4.83) than 3D images (4.36, p 
< 0.001). The ease of use of 3D models and images were scored 4.20 and 
4.60, respectively (p = 0.015).
Production time of 3D pelvic models: With experience, the 3D image recon-
struction time decreased to 150 min. The printing time for the model was 
approximately 22 h, and the fi nalizing time was approximately 1 h. In total, 
it took about a day to produce one 3D pelvic model.
Conclusion: 3D pelvic models helped to understand pelvic anatomy for 
LPND.
References: [1] Oshiro Y, Mitani J, Okada T, et al. A novel three-dimensional 
print of liver vessels and tumors in hepatectomy. Surg Today 2017; 47: 521-
524. [2] Chandak P, Byrne N, Coleman A, et al. Patient-specifi c 3D Printing: 
A Novel Technique for Complex Pediatric Renal Transplantation. Ann Surg 
2019; 269: e18-e23. [3] Marconi S, Pugliese L, Botti M, et al. Value of 3D 
printing for the comprehension of surgical anatomy. Surg Endosc 2017; 31: 
4102-4110.
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Evidence-based improvements in surgical 
outcomes
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OP238 PRETREATMENT TUMOR-DNA SEQUENCING OF KIT AND 
PDGFRA IN ENDOSONOGRAPHY-GUIDED BIOPSIES OPTIMIZES THE 
PREOPERATIVE MANAGEMENT OF GASTROINTESTINAL STROMAL 
TUMORS
Hedenström P.1, Nilsson B.2, Nilsson O.3, Sadik R.4
1Sahlgrenska Universitetssjukhuset, Division of Gastroenterology, 
Department of Internal Medicine, Göteborg, Sweden, 2Sahlgrenska 
Universitetssjukhuset, Department of Surgery, Göteborg, Sweden, 
3Sahlgrenska Universitetssjukhuset, Department of Pathology, Göteborg, 
Sweden, 4Medicinkliniken, Alingsås Lasarett, Sjövik, Sweden
Contact E-Mail Address: per.hedenstrom@vgregion.se
Introduction: Down-sizing tyrosine kinase inhibitor (TKI) therapy increases 
the chance of organ-preserving, radical resection in selected patients with 
gastrointestinal stromal tumor (GIST). We aimed to evaluate systematic, 
immediate DNA-sequencing of KIT and PDGFRA in pretreatment GIST-
tissue to guide downsizing TKI-therapy and optimize pre-operative tumor 
response.
Aims & Methods: All patients being candidates for downsizing therapy 
of a suspected GIST [the study cohort (SC)] were prospectively included 
January 2014 - March 2018. Patients were subjected to pretreatment, 
endosonography-guided fi ne-needle biopsy (EUS-FNB) or transabdomi-
nal ultrasound-guided needle biopsy (TUS-NB) followed by immediate 
tumor-DNA-sequencing (< 2 weeks). A historic (2006-2013) reference 
cohort (RC) underwent work-up without sequencing before downsizing 
imatinib (n=42). The rate of optimal downsizing therapy (Thera
OPT
) was 
calculated and the induced tumor size reduction (TR
max
, %) was evalu-
ated by CT-scan.
Results: The success rate of pretreatment tumor-DNA-sequencing in the 
study cohort (n=81) was 77/81 (95%) [EUS-FNB: 71/74 (96%); TUS-NB: 6/7 
(86%)] with mutations localized in KIT (n=58), in PDGFRA (n=18), or nei-
ther gene, WT, (n=5). In patients with a fi nal indication for down-sizing 
therapy, the Thera
OPT
 was higher in the SC compared with the RC, 61/63 (97 
%) vs 33/42 (79 %), p=0.006, leading to a signifi cantly higher TR
max
 (32 %) 
vs (19 %), p=0.001, among patients treated with standard dose imatinib.
Conclusion: Pretreatment endosonography-guided biopsy sampling fol-
lowed by immediate tumor-DNA sequencing of KIT and PDGFRA is highly 
accurate and valuable for the guidance of downsizing TKI-therapy in GIST. 
This approach minimizes the maltreatment with inappropriate regimens 
and leads to improved tumor size reduction before surgery.
Disclosure: Nothing to disclose 
OP239 IMMUNONUTRITION TO IMPROVE THE QUALITY OF LIFE 
OF UPPER GASTROINTESTINAL CANCER PATIENTS UNDERGOING 
NEOADJUVANT TREATMENT PRIOR TO SURGERY (NEOIMMUNE): 
DOUBLE BLIND RANDOMIZED CONTROLLED MULTI-CENTER 
CLINICAL TRIAL
Markar S.1, Mariette C.2, Piessen G.2, NEOIMMUNE
1Imperial College London, Department of Surgery & Cancer, London, United 
Kingdom, 2Claude Huriez University Hospital, Lille, France
Contact E-Mail Address: s.markar@imperial.ac.uk
Introduction: Malnutrition, is very frequent in oesophagogastric cancers, 
and is associated with negative outcomes including increased morbidity, 
poor tumour response, poor tolerance to treatment and decreased quality 
of life (QOL). Immunonutrition in gastro-intestinal cancer surgery has been 
shown to effi  cient in perioperative period in reducing the risk of infectious 
complications.
Aims & Methods: The aim of this randomized controlled trial was to evalu-
ate if immunonutrition during neoadjuvant treatment prior to surgery will 
improve patients’ QOL, reduce postoperative morbidity and reduce haema-
tological and mucosal toxicities. 
Study Design: Double blind randomized controlled multi-center clinical 
trial. Included patients had untreated non-metastatic Upper GI tumor, 
aged 18 ≥years with a life expectancy of >3months. The study was powered 
for 80% power to detect a diff erence in EORTC-QLQC30 with standard de-
viation of 15 between the groups, permitting 179 randomized to received 
immunonutrition with IMPACT® formula and 179 randomized to receive an 
isocaloric control during neoadjuvant therapy. The primary end-point for 
the study was QOL as measured by the EORTC-QLQ-C30. Secondary end-
points included diarrhoea, mucositis, haematologic toxicity, nutritional 
status, compliance and response to neoadjuvant therapy, postoperative 
morbidity and length of hospital stay. 
Statistical Analysis: An intention-to-treat analysis will be employed, and 
univariate analysis (ANOVA) was performed to compare scores, with an 
analysis of co-variance using ANCOVA also performed. 
n° EUDRACT: 2011-A00716-35
Results: The study was terminated prior to completion of recruitment at 
the interim analysis stage, as reviewers felt the sample size was underes-
timated given the true eff ect of IMPACT formula. 300 patients were ran-
domized; 148 to the IMPACT group and 152 to the control-formula group. 
Patient groups were well balanced in terms of age, sex, ethnicity, BMI, 
clinical tumour stage, utilisation of neoadjuvant therapy and medical co-
morbidities. 
No signifi cant diff erences between groups in changes, at diagnosis and 
30 days postoperatively, were identifi ed in global health score (p=0.112) 
and time to global health deterioration (p=0.527), physical functioning 
(p=0.976), role functioning (p=0.777), emotional functioning (p=0.545), 
cognitive functioning (p=0.207), social functioning (p=0.968) and fatigue 
score (p=0.920). No signifi cant diff erences in changes, at diagnosis, aft er 
neoadjuvant therapy and 30 days postoperatively were seen in pain, nausea 
and vomiting, dyspnea, insomnia, appetite loss and change in bowel habit. 
Analysis of EORTC-OG25 in changes 30-days postoperatively showed with 
IMPACT® improvements in time to pain and discomfort (p=0.007). Multi-
variate analysis for global health score deterioration showed no signifi cant 
eff ect of IMPACT® administration (Hazard ratio = 1.18; 95% confi dence in-
terval 0.843 to 1.652). 
Within the IMPACT® group toxicity during neoadjuvant treatment, tumor 
regression, postoperative complications, length of hospital stay and sur-
vival were unaff ected.
Conclusion: The results of this large multi-center blind RCT fail to demon-
strate any large benefi t in terms of HRQOL to the utilization of immunonu-
trition during neoadjuvant therapy in patients with esophageal or gastric 
cancer. Furthermore no signifi cant improvements were observed in sec-
ondary outcomes including 30-day postoperative complications.
Disclosure: Nothing to disclose 
OP240 LAPAROSCOPIC VERSUS OPEN GASTRECTOMY FOR 
GASTRIC CANCER, RESULTS OF A MULTICENTER PROSPECTIVELY 
RANDOMIZED CONTROLLED TRIAL (LOGICA-TRIAL)
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Wijnhoven B.P.L.4, de Steur W.O.5, Kouwenhoven E.A.6, Wassenaar E.B.7, 
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Introduction: Open gastrectomy is the preferred surgical approach for 
gastric cancer worldwide. This procedure is associated with considerable 
morbidity. Meta-analyses have shown an advantage in short-term out-
comes of laparoscopic gastrectomy compared to open procedures, with 
similar oncologic outcomes. However, the included series are mostly from 
Asia with early gastric cancer. It is unclear whether these results can be ex-
trapolated to the Western population with mostly advanced gastric cancer. 
In this randomized controlled multicenter trial from the Netherlands, we 
assessed the outcomes of laparoscopic versus open gastrectomy.
Aims & Methods: Between 2015-2018, patients with resectable (cT1-4a, N0-
3b, M0) gastric adenocarcinoma were randomly assigned to either laparo-
scopic (105 patients) or open (105 patients) gastrectomy, in 10 participating 
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life in the ramosetron treatment group. Ramosetron (Irribow®) treatment 
may be applied for selective patients who had severe symptoms of anterior 
resection syndrome aft er rectal cancer surgery.
References: 1. Emmertsen KJ, Laurberg S. Low anterior resection syndrome 
score: development and validation of a symptom-based scoring system for 
bowel dysfunction aft er low anterior resection for rectal cancer. Ann Surg 
2012;255:922-8
Disclosure: This study was supported by the Grant of Clinical Research 
Institute, Seoul National University Hospital (Grant No: 0620164120) from 
Dona-A Parmaceutical Co. Kore 
OP242 MULTICENTER, RANDOMIZED CONTROLLED TRIAL OF 
NASOGASTRIC TUBE WITH WATER-SOLUBLE CONTRAST AGENT 
VERSUS LONG TUBE FOR SMALL BOWEL OBSTRUCTION
Nishie H.1, Shimura T.1, Katano T.1, Iwai T.2, Itoh K.3, Ebi M.4, Mizuno Y.5, 
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Introduction: Small bowel obstruction (SBO) is a frequently occurred gas-
trointestinal emergency and the most frequent cause is adhesion aft er 
abdominal surgery, accounting for 50-80%. Gastrointestinal decompres-
sion is applied to SBO without any fi ndings of strangulation and ischemia. 
Decompression with nasogastric tube (NGT) is a standard treatment for 
SBO in Western countries based on the old small trial that showed no 
signifi cant diff erences between NGT and long tube (LT). On the other hand, 
LT seemed to be more eff ective than NGT in a recent Asian trial. Moreover, 
some studies have reported that administration of water-soluble contrast, 
gastrografi n, thorough NGT (NGT-G) is useful for determining indication 
of surgical treatment and it is more eff ective treatment than NGT alone. 
However, there have been no comparative studies between LT and NGT-G. 
We thus conducted a randomized controlled trial to evaluate the effi  cacy of 
NGT-G for patients with SBO.
Aims & Methods: In this multicenter, open label, randomized controlled tri-
al, patients with SBO from 11 Japanese institutions were randomly assigned 
by a computer-based randomization to receive LT or NGT-G between July 
2016 and November 2018. Patients who assigned to the NGT-G group could 
receive LT placement appropriately, when SBO is not improved over 24 h. 
The primary end point was non-inferiority of NGT-G to LT for non-surgery 
rate (treatment success rate). According to pre-planned protocol, effi  cacy 
analysis was on the basis of initially randomized group (intention-to-treat 
analysis). Based on the results of previous studies, we estimated 85% 
non-surgery rate of both groups, and 95.3% CI lower limit of -15% non-
surgery rate would be accepted as a lower margin for inferiority with NGT-
G to LT because the previous lowest success rate of LT was 70%. According 
to O’Brien Fleming type α spending rule, 1 sided α levels of 0.0015 and 
0.0235 were defi ned for the interim and fi nal analysis, respectively. Hence, 
pre-planned sample size was 220 overall 1-sided-α and β errors of 0.025 
and 0.20, and allowing an approximate 10% dropout rate.
Results: In total, 224 patients with SBO were enrolled to this trial and 223 
patients aft er exclusion of 1 consent withdrawal were fi nally analyzed in-
cluding 111 patients in the LT group and 110 patients in the NGT-G group. 
Baseline characteristics including laboratory data and physical fi ndings 
were well balanced between 2 groups. The treatment success rate without 
non-surgical management was 87.4% in the LT group and 91.1% in the 
NGT-G group, and diff erence between LT and NGT-G was 3.7% (95.3% CI; 
-5.55 to 12.91; non-inferiority P= 0.00002923). Among 112 patients in the 
NGT-G group, 86 patients improved by NGT-G alone (86.7%), 16 patients 
did by NGT-G followed by LT and 10 patients underwent surgery. Non-
surgery rate of NGT-G alone was signifi cantly lower than LT (P=0.039).
centers in the Netherlands. Inclusion criteria were age ≥18 years, European 
Clinical Oncology Group performance status 0, 1 or 2 and informed con-
sent. The primary outcome was postoperative hospital stay (days). Sec-
ondary outcome were postoperative morbidity and mortality, oncologic 
outcome, readmissions, quality of life and cost-eff ectiveness.
Results: This is a late breaking abstract. The last study patient was oper-
ated on in November 2018. The data are not yet mature at the moment of 
writing this abstract. We would like to present our primary endpoint and 
secondary endpoints at the UEGWEEK 2019
Conclusion: See above
Disclosure: Nothing to disclose 
OP241 RANDOMIZED CONTROLLED TRIAL ASSESSING THE 
EFFECTIVENESS OF 5-HT3 RECEPTOR ANTAGONIST (RAMOSETRON 
(IRRIBOW®)) FOR THE TREATMENT OF ANTERIOR RESECTION 
SYNDROME IN MALE PATIENTS WITH RECTAL CANCER
Ryoo S.-B.1, Park J.W.1, Lee M.A.1, Kwon Y.-H.1, Lee K.-Y.2, Lim H.-K.1, 
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Introduction: Anterior resection syndrome, including fecal urgency, fre-
quency and incontinence can develop aft er sphincter-saving surgery for 
rectal cancer in 60-90% of the patients, but there has been no eff ective 
treatment.
Aims & Methods: We performed a randomized controlled trial to assess 
the eff ectiveness of ramosetron (Irribow®), a 5-HT
3
 receptor antagonists, 
for the treatment of anterior resection syndrome.
Male patients with symptoms of anterior resection syndrome aft er rectal 
cancer surgery (aft er ileostomy take-down if ileostomy was performed) 
were enrolled and randomly assigned to take the ramosetron (Irribow®) 
5mg daily (n=48) or conservative treatment (n=50) for 1 month. Low an-
terior resection syndrome (LARS) score1 was calculated by questionnaire 
before and aft er 1 month aft er treatment. Primary endpoint was the dif-
ference in proportion of severe LARS. The study design was a superiority 
test with 30% of diff erence margin, 80% of power and 5% type I error. 
Analyses were based on the intension-to-treat population. Secondary end-
point was the diff erence of patients’ quality of life by the questionnaire of 
EORTC QLQ-C30. This study is registered with ClinicalTrials.gov, number 
NCT02869984.
Results: The mean age was 61.4±9.3 and 59.9±9.9 years in the ramose-
tron and control group, respectively (p=0.927). Tumor distance from the 
anal verge was 6.9±3.8 and 7.9±4.3cm (p=0.254) and stage of the tumor 
was not diff erent between the two groups (Stage III/IV, 20 (41.7%) vs 17 
(34.0%), p=0.434). The mean LARS score (36.0±5.9 vs 34.4±6.8, p=0.215) 
and stool frequency (12.6±7.7 vs 12.6±7.2, p=0.987) before treatment were 
also similar. 
All patients had more than 4 times/day of stool frequency before treat-
ment. The LARS score signifi cantly decreased to 29.6±9.3 aft er 1 month 
in ramosetron group (p< 0.001) and the LARS score aft er 1 month in the 
ramosetron group was signifi cantly lower than control group (29.6±9.3 vs 
34.6±7.6, p=0.004). The mean changes in LARS score (1 month - baseline) 
was -6.48 in ramosetron, compared to 0.16 in control group (p<0.001). 
The proportions of severe LARS (LARS score, ≥30) aft er 1 month was 
58.3% (n=28/48) in ramosetron group vs 82.0% (n=41/50) in the control 
group, with the diff erence of 23.7% being statistical signifi cance (95% 
CI=5.58~39.98%, p=0.011). The stool frequency aft er 1 month was 7.1/day 
and 10.5/day in the ramosetron and control group (p=0.004), and the pa-
tients who had the stool frequency less than 4 times/day were 13 (27.1%) 
in ramosetron compared to only 1 (2.0%) in the control group (p< 0.001). 
The quality of life aft er 1 month was signifi cantly better in ramosetron 
group in terms of general health status (70.7±18.6 vs 62.7±17.5, p=0.031), 
physical functioning (88.6±11.25 vs 82.4±17.18, p=0.038), emotional func-
tioning (90.5±11.78 vs 81.5±20.98, p=0.011) and cognitive functioning 
(91.7±12.4 vs 85.0±17.6, p=0.032).
Conclusion: Although we did not reach the intended superiority margin 
of 30% with ramosetron (Irribow®) treatment for anterior resection syn-
drome, our results showed signifi cantly better LARS score and quality of 
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Expectedly, median insertion time was much shorter in the NGT-G group 
than in the LT group (1 min vs. 25 min; P= 0.0001). No signifi cant diff er-
ences were found for relief time of abdominal symptoms and duration 
of hospitalization between 2 groups. In the LT and NGT-G arms, adverse 
event rates ≥ grade 3 were 1.8% and 0% (P=0.247) and the mortality rates 
were 0.91% and 0% (P=0.498), respectively.
Conclusion: NGT-G is an eff ective alternative to LT as the fi rst-line treat-
ment for SBO. Sequential strategy, NGT-G followed by LT, would be a novel 
standard treatment for SBO.
(University Hospital Medical Network Clinical Trials Registry, Number: 
UMIN000022669)
Disclosure: Nothing to disclose 
OP243 ENDOSCOPIC ULTRASOUND VS PERCUTANEOUS 
MANAGEMENT OF POST-OPERATIVE PANCREATIC FISTULA: 
A SYSTEMATIC REVIEW AND META-ANALYSIS
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Introduction: Post-operative pancreatic fi stula (POPF) is a diffi  cult to man-
age complication with signifi cant morbidity and mortality. Mortality rates 
as high as 40% have been reported. Surgical and percutaneous drainage 
(PCD) are the usual fi rst line of treatment. Studies have reported endo-
scopic ultrasound and/or standard endoscopy (END) guided management 
of POPF with confl icting results. Data comparing the outcomes of END vs 
PCD in POPF management is limited.
Aims & Methods: We conducted a comprehensive search of multiple elec-
tronic databases and conference proceedings (earliest inception through 
September 2018) to identify studies that reported on the clinical outcomes 
of END and PCD in the management of POPF. Our goal was to estimate and 
compare the pooled rates of technical success, clinical success, adverse 
events and POPF recurrence with END and PCD. The collected data was 
matched between the END and PCD management groups. The baseline 
patient characteristics, symptomatology, indication for surgery, time-to-
drain placement, and the number of drains used were comparable be-
tween the groups. Meta-analysis was conducted using the comprehensive 
meta-analysis soft ware.
Results: 4 studies (99 patients) reported outcomes with EUS and/or endos-
copy (END) in POPF management, and 4 studies (225 patients) reported 
outcomes with PCD in POPF management.1. 
Technical success: The pooled rate of technical success in END-POPF was 
97.6% (95% CI 88.4-99.5, I2=0) and in PCD-POPF was 95.2% (95% CI 84.1-
98.7, I2=63.4%). The diff erence was not statistically signifi cant, p=0.52.2. 
Clinical success: The pooled rate of clinical success in END-POPF was 
90.8% (95% CI 82.3-95.5, I2=0%) and in PCD-POPF was 78.0% (95% CI 
70.5-84.0, I2=0%). The diff erence was statistically signifi cant, p=0.02.3. 
Adverse events: There were a total of 2 adverse events and 7 recurrences 
in END-POPF group, and a total of 8 adverse events and 17 recurrences in 
PCD-POPF group.The pooled rate of adverse events in END-POPF was 4.9% 
(95% CI 1.7-13.1, I2=0%) and PCD-POPF was 5.9% (95% CI 3.4-10.0, I2=0%). 
There was no statistical signifi cance to the diff erence, p=0.74. Data was 
insuffi  cient to calculate pooled rates of recurrence in the groups.
POPF (95% CI, I2) EUS/END PCD P-value
Technical Success 97.6% (88.4-99.5, 0) 95.2% (84.1-98.7, 63.4) 0.52
Clinical Success 90.8% (82.3-95.5, 0) 78% (70.5-84, 42.5) 0.02
Adverse Events 4.9% (1.7-13.1, 0) 5.9% (3.4-10, 0) 0.74
[Summary of pooled results. POPF(pancreatic post-operative  stula), 
EUS(endosonography), END (endoscopy) PCD (percutaneous drainage)]
Conclusion: Our meta-analysis shows that endoscopic ultrasound and/or 
standard endoscopy guided management of POPF gives signifi cantly bet-
ter clinical success as compared to PCD. Use of standard endoscopy in the 
management of pancreatic fi stula is outdated. Well-conducted direct-com-
parison studies are needed evaluating endoscopic ultrasound to PCD in 
the treatment of POPF. Indirect comparison, variability in the type of stents 
used, variability in the number of repeat procedures, and heterogeneity 
were the limitations of our study.
Disclosure: Nothing to disclose 
Duodenal fl at mucosa: Coeliac and beyond
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OP244 USE OF MICRO-CT IMAGING OF INTESTINAL BIOPSIES TO 
IMPROVE THE DIAGNOSTICS OF CELIAC DISEASE
Virta J.1, Lindfors K.1, Tamminen I.1, Kaukinen K.1, Popp A.1, Hiltunen P.2, 
Hannula M.1, Hyttinen J.1, Kurppa K.3
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Introduction: Traditional histopathology is too inaccurate for early stage 
mucosal injury and short-term challenge studies in celiac disease, and 
the oft en misoriented biopsies are prone to wrong interpretation. X-ray 
microtomography (micro-CT) is an imaging technique which could provide 
freely orientable 3D images for accurate measurements of mucosal mor-
phometry and surface areas. We investigated the use of micro-CT in the 
examination of small-bowel biopsies.
Aims & Methods: Duodenal samples from 12 endoscopies were selected for 
the micro-CT imaging. The specimens represented celiac disease patients 
with diff erent stages of injury and nondiagnosed subjects with morpho-
logically normal mucosa. The micro-CT procedure was tested with variable 
staining solutions, source voltages and fi lters to optimize the practicability 
and resolution. The data were reconstructed into digital 3D images and 
virtually cut for measurement of villous length crypt depth ratios. Muco-
sal surface areas were measured utilizing computer-assisted point cloud 
analysis. The results were compared with routine histopathology and 
quantitative histomorphometry performed with paraffi  n-embedded biop-
sies.
Results: Practical staining and imaging protocol with optimal resolution 
was accomplished using specifi c I
2
E-solution, 100 kV acceleration voltage 
and 10W source power. Micro-CT imaging was feasible both for previ-
ously taken paraffi  n biopsies and fresh biopsies. It was also possible to do 
routine histopathology aft er the imaging. The formed 3D images allowed 
freely orientable digital images for exact morphometry and demonstrated 
duodenal injury in samples interpreted as normal in traditional histology. 
Furthermore, micro-CT enabled reproducible measurements of the mu-
cosal surface areas, which makes it possible to detect previously indistin-
guishable diff erences between samples e.g. minor changes during gluten-
free diet.
Conclusion: We established a unique micro-CT method for digital analysis 
of duodenal biopsies. The improved diagnostic accuracy and possibility to 
measure biologically meaningful surface areas provide a powerful tool for 
future clinical and pharmaceutical studies.
Disclosure: Nothing to disclose 
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Trends in treatment and detection of upper GI 
bleeding
16:00-17:30 / B2
OP246 OUTCOMES OF UPPER GASTROINTESTINAL BLEEDING ARE 
SIMILAR BETWEEN DIRECT ORAL ANTICOAGULANTS AND VITAMIN K 
ANTAGONISTS: A SUB-GROUP ANALYSIS OF A FRENCH PROSPECTIVE 
MULTICENTER STUDY
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Introduction: Management of oral anticoagulants remains challenging 
during upper gastrointestinal bleeding (UGIB). Outcomes of UGIB are not 
worse in patients treated with vitamin K antagonists (VKA) but a reversion 
of the anticoagulation can be easily done contrary to direct oral anticoagu-
lants (DOACs) (1). DOACs belong to a new therapeutic class with confl icting 
results on the associated risk of UGIB that might be increased (2). Later 
studies showed a diff erent bleeding risk according to the type of DOACs 
(3,4), but data are mostly retrospective with a low level of evidence. This 
study aimed to describe epidemiology, endoscopic management and out-
comes of UGIB in patients treated with anticoagulants.
Aims & Methods: From November 2017 to October 2018 a prospective mul-
ticenter study in French general hospitals enrolled all consecutive patients 
with UGIB. Data were collected with an e-CRF. All patients treated with an 
anticoagulant at the time of the UGIB were retrieved from the cohort and 
assessed. Main outcomes were mortality at 6 weeks, rebleeding during 
the fi rst 6 weeks and need for non-endoscopic treatment (surgery, radio-
embolisation).
Results: Among the 2498 patients included, 475 (19%) had an oral an-
ticoagulant: 267 (56.2%) with VKA (Warfarin 67 (25%), Fluindione 200 
(75%)) and 208 (43.8%) had DOACs (Dabigatran 21 (10%), Rivaroxaban 114 
(55%), Apixaban 73 (35%)). This subgroup of patients consisted of 65% 
men, mean age was 78.2 and mean Charlson score was 3.2. Aspirin was 
ongoing for 100 patients (21%), and 55 (11.6%) had other antiplatelets 
agent (APA). Baseline characteristics were broadly similar between VKA 
and DOACs except for the association of kidney failure and cirrhosis. Gas-
troscopy was performed in 470 patients (98.9%), described as normal in 
73 (15.3%) and showed active bleeding in 117 (24.9%). The aetiology of 
UGIB was peptic for 289 (60.8%) patients, portal hypertension for 43 (9%), 
vascular and tumoral for 41 (8.6%) and 27 (5.7%), respectively, without 
diff erence between VKA and DOACs. Endoscopic treatment was performed 
in 128 (26.9%) patients; bleeding resolution was possible in 95 (20%). The 
mortality rate at 6 weeks was 12.4% (59 patients) (VKA 16.1%, DOACs 7.8%, 
p< 0,01). Factors associated with mortality by univariate analysis were 
Charlson index ≥5, anticoagulation by VKA, presence of shock at admis-
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Introduction: Causes of SNVA can be grouped as CD- and non-CD related. 
Despite several sets of international guidelines on CD, there is no consen-
sus on how to approach subjects with seronegative CD. Coeliac lympho-
gram has been advocated as a useful tool in doubtful CD cases.
Aims & Methods: To evaluate the accuracy of the increase in CD3+ T-cell 
receptor gamma delta+ (TCRγδ) intraepithelial lymphocytes (IEL), with or 
without the concomitant decrease of CD3- IEL, in samples of duodenal mu-
cosa for the diagnosis of CD in patients with SNVA.
Seventy-four consecutive patients with SNVA were included (45.3±2.5 
years; 67% women). Serum anti-TG2 was negative in all cases. In all of 
them, duodenal biopsies to assess TCRγδ+ and CD3- IEL by fl ow cytom-
etry were obtained at the index endoscopy. The increase in TCRγδ+ plus 
decrease in CD3- IEL defi ned the coeliac lymphogram. CD was diagnosed 
on the basis of a clinical and histological remission aft er a GFD. Sensitivity 
(S), specifi city (Sp), positive and negative likelihood ratios (LR) were calcu-
lated. Values of +LR >10 and -LR < 0.10 were associated with a convincing 
diagnostic evidence.
Results: CD was diagnosed in 46 patients, and non-coeliac SNVA in 28. 
Non-coeliac causes of SNVA were: olmesartan (8), giardiasis (4), Crohn’s 
disease (2), other enteropathies (6), and idiopathic (8). CD patients were 
younger (39±3 vs. 55±3 yrs; p=0.001), more oft en showed HLA-DQ2/8 
(97.6% vs. 61%; p=0.002), and had a more severe histology (61% vs. 32% 
Marsh 3b-c; p=0.056), as compared to non-coeliac SNVA. Coeliac lympho-
gram was associated with a S of 87% (95% CI, 73-95), Sp of 96.4% (CI, 
80-100), +LR of 24.3 (CI, 3.5-167) and -LR of 0.13 (CI, 0.06-0.28). Evaluating 
only TCRγδ+ yielded a S of 91% (CI, 78-97), Sp of 86% (CI, 66-95), +LR of 6.4 
(CI, 2.6-16) and -LR of 0.10 (0.04-0.26). Two olmesartan enteropathies and 
1 giardiasis had an isolated increase in TCRγδ+ and another olmesartan 
enteropathy presented with the coeliac lymphogram.
Conclusion: The coeliac lymphogram assessed by fl ow cytometry in duode-
nal biopsy samples was associated with a high level of diagnostic evidence 
either against or in favour of CD in patients with SNVA.
Disclosure: Nothing to disclose 
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sion, peptic lesion in endoscopy, Rockall Score >2 and Blatchford ≥14; only 
Charlson index remained signifi cant in the multivariate analysis (OR 4.14, 
p< 0.0001). Re-bleeding happened in 56 patients (11.8%) (VKA 30 (11.2%), 
DOACs 26 (12.5%), p=0.71). By multivariate analysis: co-medication with 
APA was associated with a higher risk (OR 2.72, p=0,009) whereas beta-
blockers were protective (OR=0.41, p=0,0072). Non-endoscopic treatment 
was performed in 18 (3.8%) patients (VKA 10 (2.1%), DOACs 8 (1.6%) 
p=0.95).Tumoral origin of the bleeding was the only factor associated by 
multivariate analysis (OR=6.66, p=0.0064).
Conclusion: DOACs do not alter outcomes of UGIB as compared to VKA. 
Comorbidities and associated treatment seem to be the most important 
factors worsening prognosis of UGIB.
References: 1. Nahon S, Hagège H, Latrive JP, Rosa I, Nalet B, Bour B, et 
al. Epidemiological and prognostic factors involved in upper gastrointesti-
nal bleeding: results of a French prospective multicenter study. Endoscopy. 
2012 Nov;44(11):998-1008. 2. Ruff  CT, Giugliano RP, Braunwald E, Hoff man 
EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the effi  cacy and 
safety of new oral anticoagulants with warfarin in patients with atrial fi bril-
lation: a meta-analysis of randomised trials. Lancet Lond Engl. 2014 Mar 
15;383(9921):955-62. 3. Abraham NS, Noseworthy PA, Yao X, Sangaraling-
ham LR, Shah ND. Gastrointestinal Safety of Direct Oral Anticoagulants: A 
Large Population-Based Study. Gastroenterology. 2017;152(5):1014-1022.e1. 
4. Miller CS, Dorreen A, Martel M, Huynh T, Barkun AN. Risk of Gastrointes-
tinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagu-
lants: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 
Off  Clin Pract J Am Gastroenterol Assoc. 2017 Nov;15(11):1674-1683.e3.
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Introduction: Upper gastrointestinal bleeding (UGIB) is a leading cause 
of morbidity with a 7% mortality in the United Kingdom (UK). Upper GI 
tumours account for 2-4% of UGI bleeds. These patients are oft en chal-
lenging to treat due to the diff use nature of the neoplastic bleeding le-
sions, high bleeding recurrence rates and the signifi cant transfusion re-
quirements with a resultant poor quality of life. Hemospray (Cook Medical, 
North Carolina, USA) is a novel haemostatic powder for GI bleeding. 
The primary aim was to look at the outcomes of all UGIBs secondary to 
tumoural bleeding who had Hemospray therapy in 14 centres worldwide.
Aims & Methods: Data was prospectively collected on the use of hemo-
spray from specialist centres in the UK, France, Germany and the USA 
(Jan’16-March’19). Hemospray was used during emergency endoscopy for 
UGIBs secondary to upper GI tumours at the discretion of the endoscopist 
as a monotherapy, dual-therapy with standard haemostatic techniques 
or rescue therapy once standard methods have failed. Haemostasis was 
defi ned as the cessation of bleeding within 5 minutes of the application 
of hemospray. Rebleeding was defi ned as a sustained drop in Hb (>2g/l), 
haematemesis or melaena with haemodynamic instability aft er the index 
endoscopy.
Results: 84 patients with UGIB secondary to tumours of the GI tract were 
recruited (57 males, 27 females, 24/84 (29%) oesophageal, 56/84 (67%) 
gastric, 4/84 (5%) doudenal). The median Blatchford score at baseline for 
all patients was 10 (IQR, 7-12). The median rockall score was 8 (IQR,7-9). 
The median size of lesions was 25mm (IQR, 11-40mm). 
Immediate haemostasis was achieved in 81/84 (96%) of patients, 11/70 
(16%) patients had a rebleed, 2/73 (3%) patients died within 7 days, 14/73 
(19%) patients died within 30 days (all-cause mortality). Based on the 
baseline average total rockall score, the expected rebleed rate is 25-40%, 
and expected mortality rate was 40-45% in our cohort.
Haemostasis was achieved in 51/51 (100%) patients in the hemospray 
monotherapy group, 16/19 (84%) patients in the combination therapy 
group and 8/8 (100%) of patients in the rescue therapy group (Table 1). 
  Monotherapy (n=57)
Combination therapy 
(n=19)
Rescue therapy 
(n=8)
Haemostasis 57/57 (100%) 16/19 (84%) 8/8 (100%)
Median Rockall score 8 (IQR,7-9) 8 (IQR, 7-9) 7 (IQR, 5-8)
Median Blatchford score 10 (IQR, 7-12) 9 (IQR, 7-15) 11 (IQR, 10-13)
Rockall 7 and 8: Predicted re-bleed rate: 25-40%
Re-bleed 7/49 (14%) 3/13 (23%) 1/8 (13%)
Rockall 7 predicted mortality rate: 20-30%, Rockall 8 predicted mortality rate: 40-45%
7-day mortality 2/49 (4%) 0 0
30-day mortality 10/49 (20%) 4/16 (25%) 0
[Outcomes in the di erent hemospray subgroups]
100% (4/4) haemostasis was achieved in the duodenal tumour cohort, 
98% (55/56) in the gastric cohort and 92% (22/24) haemostasis in the 
oesophageal tumour group. The highest rebleed rate was in duodenal tu-
mours, 1/4 (25%), and highest all cause 30-day mortality in the oesopha-
geal tumour group, 7/20 (35%).
Conclusion: Hemospray is an eff ective endoscopic tool for achieving im-
mediate hamostasis in UGIBs secondary to upper GI tumours, which are 
generally considered diffi  cult bleeds to treat, with 100% haemostasis lev-
els and lowest re-bleed levels in the monotherapy group.
When considering average rockall score the rebleed and mortality rate is 
better than predicted rates. Haemostasis is achieved in the majority allow-
ing for patient stabilization and thereby providing time for patients to have 
urgent surgery or radiotherapy to treat the underlying tumour.
Disclosure: Nothing to disclose 
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Introduction: A new hemostatic adhesive powder (UI-EWD) was developed 
to improve the high re-bleeding rate and technical challenge in applica-
tion of current available hemostatic powders.
Aims & Methods: The aim of current study was to assess the performance 
of UI-EWD in nonvariceal upper gastrointestinal bleeding (NVUGIB). 
A total of 56 consecutive patients receiving UI-EWD for endoscopic hemo-
stasis in NVUGIB were retrospectively reviewed. UI-EWD was used as a 
monotherapy. The main outcomes were success rate of immediate hemo-
stasis and rate of re-bleeding within 30 days. Outcomes were analyzed by 
reviewing patient medical records.
Results: The etiology of bleeding was post-endoscopic therapy bleed-
ing in 46 (82.1%), peptic ulcer in 8 (14.3%), tumor in 1 (1.8%) and other 
in 1 (1.8%). The UI-EWD was successfully applied at bleeding site in all 
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morbidity and mortality, particularly in the elderly and those with co-mor-
bidities in whom capsule endoscopy is well tolerated. To our knowledge, 
this is the fi rst randomised controlled trial in this context.
Outcome Capsule endoscopy (n=11)
Colonoscopy 
(n=9)
Packed Red Blood Cells (n), Mean (SD) 2.0 (2.4) 2.9 (3.1)
Length of stay (days), Mean (SD) 8.7 (3.9) 8.3 (2.7)
Number of other investigations required, Mean (SD) 1.2 (0.4) 0.9 (0.6)
[Table 1. Secondary Outcomes]
References: 1. Laine L, Shah A. Randomized trial or urgent vs. elective colo-
noscopy in patients hospitalized with lower GI bleeding. American Journal 
of Gastroenterology 2010; 105: 5969-41 2. Raju G, Gerson L, Das A, Lewis B. 
American Gastroenterological Association (AGA) institute technical review 
on obscure gastrointestinal bleeding. Gastroenterology 2007; 133: 1697-717. 
3. Delvaux M, Fassler I, Gay C. Clinical usefulness of the endoscopic video 
capsule as the initial intestinal investigation in patients with obscure di-
gestive bleeding: validation of a diagnostic strategy based on the patient 
outcome aft er 12 months. Endoscopy 2004; 36: 1067-73. 4. Schlag C, Menzel 
C, Nennstiel S, Neu B, Phillip V, Schuster T, Schmid R, Delius S. Emergency 
video capsule endoscopy in patients with acute severe GI bleeding and 
negative upper endoscopy results. Clinical Endoscopy 2015; 81:889-895
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Introduction: Although small-bowel angioectasia is frequently diagnosed 
via capsule endoscopy (CE) in patients with obscure gastrointestinal bleed-
ing, a computer-aided detection method has not been established. We 
aimed to construct an artifi cial intelligence system with deep learning that 
can automatically detect angioectasia in CE images.
Aims & Methods: We retrospectively examined 169 patients (training im-
age set: 141 patients, validation image set: 28 patients) with small-bowel 
angioectasia diagnosed via CE and 20 patients with no abnormal fi ndings 
on CE at Hiroshima University Hospital, the University of Tokyo, and Sendai 
Kousei Hospital. CE was performed using a PillcamTMSB2 or SB3 CE device 
(Covidien Japan Inc., Tokyo, Japan). We trained a deep convolutional neu-
ral network (CNN) system based on Single Shot Multibox Detector, using 
2,237 CE images of angioectasia. For a validation image set, 10,488 inde-
pendent images were prepared. Of these, 488 images showed angioecta-
sia in the small-bowel, and 10,000 images showed normal mucosa in the 
small-bowel. We manually annotated all of angioectasia with rectangular 
bounding boxes in the validation set. The trained CNN also shaped the 
region of angioectasia with rectangular bounding boxes in the validation 
set and outputted the probability score of angioectasia (range, 0-1). We 
evaluated the ability of CNN to discriminate between whether each image 
included angioectasia or not using the probability score. In addition, we 
evaluated the ability of CNN to identify angioectasia correctly. The receiver 
operating characteristic (ROC) curve was plotted by varying the threshold 
of the probability score, and the area under the curve (AUC) was calcu-
lated for assessing the discrimination. The sensitivity, specifi city, positive 
predictive value, and negative predictive value of CNN’s ability to detect 
angioectasia were calculated, using cut-off  values for the probability score 
according to the Youden index.
Results: The AUC of CNN used to detect angioectasia was 0.999. The cut-off  
value for the probability score was 0.36. At this cut-off  value, the sensitiv-
ity, specifi city, positive predictive value, and negative predictive value of 
cases. The success rate of immediate hemostasis was 96.4% (54/56). Re-
bleeding within 30 days occurred in 2/54 (3.7%) of patients who achieved 
immediate hemostasis. The adverse event related to use of UI-EWD was 
not occurred.
Conclusion: UI-EWD had a high success rate for immediate hemostasis 
in NVUGIB when used as monotherapy and showed promising result in 
prevention of re-bleeding.
References: 1 Hearnshaw SA, Logan RF, Lowe D, et al. Acute upper gas-
trointestinal bleeding in the UK: patient characteristics, diagnoses and 
outcomes in the 2007 UK audit. Gut 2011; 60: 1327-1335 2 Barkun AN, Bar-
dou M, Kuipers EJ, et al. International consensus recommendations on the 
management of patients with nonvariceal upper gastrointestinal bleeding. 
Ann Intern Med 2010; 152: 101-113 3 Yau AHL, Ou G, Galorport C, et al. Safety 
and effi  cacy of Hemospray® in upper gastrointestinal bleeding. Canadian 
Journal of Gastroenterology and Hepatology 2014; 28: 72-76 4 Smith LA, 
Stanley AJ, Bergman JJ, et al. Hemospray application in nonvariceal upper 
gastrointestinal bleeding: results of the Survey to Evaluate the Application 
of Hemospray in the Luminal Tract. J Clin Gastroenterol 2014; 48: e89-e92
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Introduction: A proportion of patients with suspected acute upper gastro-
intestinal bleed (UGIB) characterised by malaena or malaena and hae-
matemsis, have a negative initial gastroscopy.The traditional approach is 
to perform colonoscopy as the second investigation, however diagnostic 
yield is low.1,2 Small bowel bleeding is likely in this cohort. Capsule en-
doscopy can safely and eff ectively visualise small bowel bleeding with 
high sensitivity in the acute setting.3,4The aim of this study is to investi-
gate whether capsule endoscopy is superior to colonoscopy as a second 
investigation in patients with suspected UGIB but negative initial gas-
troscopy.
Aims & Methods: This is a single centre randomised control trial, which 
commenced in June 2017. Local ethics approval was obtained (ID 31035). 
Informed consent was obtained from all patients. All patients admitted 
to our hospital with acute bleeding as defi ned above but with negative 
gastroscopy were considered for the study. Patients who consented for the 
study were then randomised to either capsule endoscopy or colonoscopy 
as the second investigation. If the test was not diagnostic, the patient 
underwent the other investigation or other interventions as clinically re-
quired. Our primary outcome was the diagnostic yield of each modality. 
Secondary outcomes measured were length of stay, transfusion require-
ments and number of diagnostic tests required. We also recorded baseline 
patient characteristics.
Results: 20 patients have been randomised to date, 12 males and eight 
females. Mean age was 69 years and baseline patient characteristics were 
similar in both groups. 11 patients received capsule endoscopy and nine 
patients received colonoscopy as the second investigation aft er negative 
gastroscopy. Diagnostic yield was 91% in the capsule endoscopy arm and 
22% in the colonoscopy arm. Six out of nine patients in the colonoscopy 
group underwent subsequent capsule endoscopy, which was normal in 
four cases and in the other two revealed mid small bowel angioectasia 
and a jejunal diverticulum. Table 1 highlights secondary outcome data. 
12-month data was available for four patients from the colonoscopy group 
and four patients from the capsule group. One patient from each group 
was readmitted to hospital with recurrent GI bleeding, though neither re-
quired further investigation. Regrading complications in our cohort, one 
patient had capsule retention without obstruction due to strictures. Two 
had incomplete capsule studies with capsule passing within 48 hours. One 
diagnosed a gastrointestinal stromal tumour in the gastric antrum and the 
second temporarily retained in a small bowel diverticulum.
Conclusion: Data from our study suggests capsule endoscopy has a sig-
nifi cantly higher diagnostic yield than colonoscopy in patients with sus-
pected acute UGIB and negative gastroscopy. It is well established that an 
early capsule study is crucial in making a timely diagnosis of small bowel 
bleeding and allows early intervention. This is expected to decrease overall 
135Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
CNN were 98.8%, 99.1%, 84.3%, and 99.9%, respectively. The sensitivi-
ties of CNN for angioectasia Type 1a and Type 1b were 83.3% (15/18) and 
99.4% (467/470). The detectability of small-bowel angioectasia Type 1b 
by CNN is signifi cantly higher than the detectability of type 1a (P< 0.001). 
False-negative images (n=6) were classifi ed into two categories based on 
the cause of the false-negative read: poorly focused (67%, 4/6) and later-
ality or partialness (33%, 2/6). On the other hand, false-positive images 
(n=90) were classifi ed into fi ve categories based on the reason as follows: 
vascular dilation of normal mucosa (40%, 36/90), foam (30%, 27/90), 
fold (18%, 16/90), debris (9%, 8/90), and normal mucosa (3%, 3/90). The 
trained CNN required 323 seconds to evaluate the images, with an aver-
age speed of 32.5 images per second. The correct discrimination rate was 
83.3% (15/18) in Type 1a and 98.9% (465/470) in Type 1b. The cause of 
incorrect discrimination for angioectasia was bleeding from angioectasia 
Type 1b. The correct discrimination rate for small-bowel angioectasia Type 
1b by CNN is signifi cantly higher than the detectability of Type 1a (P=0.002).
Conclusion: We developed and validated a new system based on CNN to 
automatically detect angioectasia in CE images. This may be the crucial 
step for a daily-use diagnostic soft ware for CE images to reduce the bur-
den on the physicians and oversight.
Disclosure: Nothing to disclose 
OP251 CLINICAL PERFORMANCE OF A NEW SOFTWARE TO 
AUTOMATICALLY DETECT ANGIOECTASIAS IN SMALL BOWEL 
CAPSULE ENDOSCOPY
Costa D.1,2, Vieira P.3, Pinto C.2, Arroja B.1, Leal T.1, da Silva Mendes S.1, 
Lima C.3, Gonçalves R.1, Rolanda C.1,2
1Hospital de Braga, Gastroenterology, Braga, Portugal, 2Life and Health 
Sciences Research Institute (ICVS), School of Medicine, University of Minho, 
Braga, Portugal, 3CMEMS-Uminho Research Unit, University of Minho, 
Braga, Portugal
Contact E-Mail Address: dc.dalilacosta@gmail.com
Introduction: Video Capsule Endoscopy (VCE) revolutionized the diagnosis 
and management of obscure gastrointestinal bleeding, though the rate of 
detection of small bowel lesions by the physician is still disappointing. Our 
group developed a novel algorithm (CMEMS-Uminho1) to automatically 
detect angioectasias which display greater accuracy in VCE static frames 
than other methods previously published.
Aims & Methods: We aimed to evaluate the algorithm overall performance 
and assess its diagnostic yield and usability in clinical practice. Algorithm 
overall performance was determined using 54 full-length VCE recordings. 
To assess its diagnostic yield and usability in clinical practice, 38 VCE ex-
aminations with the clinical diagnosis of angioectasias consecutively per-
formed (2017-2018) were evaluated by three physicians with diff erent ex-
periences. CMEMS-Uminho algorithm was also applied. The performance 
of CMEMS-Uminho algorithm was defi ned by a positive concordance be-
tween a frame automatically selected by the soft ware and a study inde-
pendent capsule endoscopist.
Results: Overall performance in complete VCE recordings was 77,7% and 
diagnostic yield was 94,7%. There were signifi cant diff erences between 
physicians in regard to global detection rate (p< 0,001), detection rate per 
capsule (p< 0,001), diagnostic yield (p=0,007), true positive rate (p< 0,001), 
time (p< 0,001) and speed viewing (p< 0,001). The application of CMEMS-
Uminho algorithm signifi cantly enhanced all readers’ global detection rate 
(p< 0,001) and the diff erences between them were no longer observed.
Conclusion: CMEMS-Uminho algorithm detained a good overall perfor-
mance and was able to enhance physicians’ performance, suggesting a 
potential usability of this tool in clinical practice.
References: 1. Vieira P, Silva C, Costa D, Vaz I, Rolanda C, Lima C (2019) 
Automatic Segmentation and Detection of Small Bowel Angioectasias in 
WCE Images. Annals of Biomedical Engineering. doi: 10.1007/s10439-019-
02248-7
Disclosure: Nothing to disclose 
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OP252 LONG-TERM EVOLUTION OF HEPATOCELLULAR ADENOMAS 
AT MR IMAGING FOLLOW-UP
Vernuccio F.1,2, Ronot M.3, Dioguardi Burgio M.3, Cauchy F.4, Dokmak S.5, 
Soubrane O.4, Valla D.-C.6, Zucman-Rossi J.7, Paradis V.8, Vilgrain V.3
1University of Palermo, Promozione della Salute, Materno-Infantile, di 
Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”, Palermo, 
Italy, 2Hopital Beaujon, APHP, Université; Denis Diderot, Clichy, France, 
3Hopital Beaujon, Radiology, Clichy, France, 4Hopital Beaujon, Department 
of Liver Transplantation and Hepatobiliary Surgery, Clichy, France, 5Hopital 
Beaujon, APHP, Université Denis Diderot, Clichy, France, 6Hôpital Beaujon, 
Hepatology, Clichy, France, 7INSERM, Paris, France, 8Beaujon Hospital, 
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Contact E-Mail Address: federicavernuccio@gmail.com
Introduction: Hepatocellular adenomas (HCAs) are rare benign liver tu-
mors. Guidelines recommend continued surveillance for patients diag-
nosed with HCAs, but these recommendations are mainly based on small 
series or experts’ opinion. The aims of this study were to analyze the long-
term course of evolution of HCAs including solitary and multiple lesions, 
and to identify predictive features of progression.
Aims & Methods: We retrospectively included consecutive patients with 
pathology-proven (i.e., biopsy or surgery) and subtyped solitary and mul-
tiple HCAs between January 2004 and December 2015. Exclusion criteria 
were: 
(a) preoperative or follow-up MR imaging was not available; 
(b) patients treated with locoregional therapies or transplantation, and 
lack of pretreatment MR imaging follow-up; 
(c) inadequate MR imaging protocol.
Reference standard was pathologic analysis. For each patient the follow-
ing information were assessed: 
(a) aspect of non tumoral liver; 
(b) subtype of HCA according to the updated classifi cation published by 
Nault J et al; 
(c) hemorrhage and malignant foci within the lesion. 
All MR exams performed by each patient were analyzed by two radiolo-
gists with expertise on liver imaging. 
Tumor evolution was evaluated using the Response Evaluation Criteria in 
Solid Tumors (RECISTv1.1) thresholds.
Results: Our fi nal study population consisted of 118 patients (mean age, 
40 ± 10 years; range 18-69 years, 10 men and 108 women), including 41 
patients with a solitary HCA and 77 patients with multiple HCAs.
In 44 HCAs with micro- and/or macroscopic hemorrhage detected at pa-
thology, 26 were infl ammatory, 8 were HNF-1α inactivated, 5 were sonic-
hedgehog, 4 were ß-catenin mutated exon 3 and 1 was ß-catenin mutated 
exon 7-8. Malignancy was detected among ß-catenin mutated HCAs in fi ve 
patients with ß-catenin mutation -four with ß-catenin mutation in exon 3 
and one with ß-catenin mutated in exon 7-8 HCA -, and two patients with 
infl ammatory HCAs. 
Median follow-up of the entire study population was 5.0 years, and it was 
not signifi cantly diff erent between the solitary and multiple HCAs cohorts 
(5.1 years vs. 4.9 years, respectively, p= 0.624). 
Overall, 37 of 41(90%) patients with solitary HCAs and 55 of 77 (71%) pa-
tients with multiple HCAs showed stable or regressive disease (i.e. >30% 
size decrease). Aft er resection of solitary HCAs, new lesions appeared only 
in 2 of 29 (7%) patients, both with HCAs at-risk of malignancy (i.e. ß-
catenin mutated HCAs or foci of malignancy within the tumor). 
Patients with multiple HNF-1α inactivated HCAs showed a higher rate of 
progression compared to patients with multiple infl ammatory HCAs (11 of 
26 [42.3%] vs. 7 of 37 [18.9%], p= 0.043).
Patients with progressive disease had a lower weight and BMI at diagno-
sis. Of note, neither surgery nor presence of ß-catenin mutated subtype 
had an impact on progression (p= 1.000, p= 0.667), while presence of mul-
tiple HCAs was associated with higher probability of progressive disease 
compared to solitary HCAs (22/77 [28.6%] vs. 4/41 [10.8%], respectively; 
p= 0.020). However, the number of lesions at diagnosis in patients with 
multiple HCAs was not signifi cantly associated with progressive disease 
(p= 0.541).
Conclusion: Seventy-eight percent of HCAs showed long-term stability or 
regression. Aft er resection of solitary HCAs, tumor progression occurred 
only in HCAs at-risk of malignancy. Patients with multiple HCAs were more 
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OP254 MIR-21 IS INCREASED IN EXPERIMENTAL AND HUMAN 
NASH-ASSOCIATED HCC, CONTRIBUTING TO HEPATOCARCINOGENESIS
Rodrigues P.M.1, Afonso M.B.2, Simão A.L.2, Islam T.2, Gaspar M.M.2, 
O’Rourke C.J.3, Andersen J.B.3, Santos-Laso Á.4, Jimenez-Agüero R.4, 
Eizaguirre E.4, Bujanda L.4, Pareja M.J.5, Banales J.M.4,6,7, 
Rodrigues C.M.P.2, Castro R.E.2
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Introduction: The molecular mechanisms governing the progression of 
non-alcoholic steatohepatitis (NASH) towards hepatocellular carcinoma 
(HCC) remains elusive. We have recently shown that concomitant miR-
NA-21 (miR-21) ablation and farnesoid X receptor (FXR) activation prevents 
NASH development in mice.
Aims & Methods: Here, we aimed to evaluate the role of miR-21 in NASH-
associated carcinogenesis. miR-21 expression was evaluated in two inde-
pendent cohorts of patients. In the San Sebastian cohort (n=160), RNA was 
isolated from formalin-fi xed, parafi n-embbeded liver biopsies obtained 
from obese patients. miR-21 expression was measured by qPCR and corre-
lated with histopathological and serological fi ndings. In the TCGA cohort, 
miR-21 expression was evaluated by miRNA sequencing (miRseq) using 
liver samples from patients with NASH-associated HCC obtained aft er sur-
gical resection (n=19) and compared with surrounding liver tissue (n=50). 
In parallel, wild-type (WT) and miR-21 KO C57BL/6N mice were fed either 
a choline-suffi  cient, amino acid-defi ned control diet (CSAA; n=28) or a 
choline-defi cient, amino acid-defi ned diet (CDAA; n=28) for 32 and 66 
weeks. Serum was collected for biochemical analyses and liver samples 
processed for histological analysis and measurement of miR-21, its targets 
and metabolic relevant genes, as well as pro-infl ammatory/pro-fi brogenic 
cytokines. A profi ler PCR array was used to evaluate the expression of liver 
cancer-related genes.
Results: miR-21 levels were increased with disease severity (steatosis, 
lobular infl ammation, ballooning, fi brosis and NAS score) while no cor-
relation with serum data was observed in the San Sebastian cohort. Note-
worthy, miR-21 levels were markedly increased in the tumor tissue of pa-
tients with NASH-HCC, when compared with surrounding liver in the TCGA 
cohort. WT mice fed the CDAA diet for 32 weeks developed macrovesicular 
steatosis, hepatocyte ballooning, NASH and fi brosis, concomitantly with 
accumulation of perivascular lymphoid cells and macrophage agglomer-
ates. CDAA-fed miR-21 KO mice exhibited increased activation of PPARal-
pha target genes, augmented mitochondrial activity and decreased fatty 
acid serum levels, compared with WT mice. Aft er 66 weeks, all WT mice on 
the CDAA diet developed at least one preneoplastic nodule (~5.2 nodules/
animal), with one animal developing trabecular HCC. miR-21 expression 
was increased in CDAA-fed mice and further increased in HCC, concomi-
tantly with decreased expression of its targets (PTEN, PDCD4, CDK2AP1 and 
PPARalpha). In addition, livers presented with mitochondrial dysfunction, 
hyperplastic foci and anisokaryosis, as well as phenotypically altered and 
highly proliferative (Ki-67 positive) hepatocytes. Increased levels of pro-
infl ammatory/fi brogenic markers were particularlly evident in pre-neo-
plastic liver tissues, alongside higher activation of oncogenic pathways. 
Strikingly, CDAA-fed miR-21 KO mice for 66 weeks displayed serum ALT 
levels similar to control animals and, compared with CDAA WT-fed mice, 
the NAS score (< 5); number of liver nodules (~2.3 nodules/animal); he-
patocyte profl iferation and expression of oncogenes were all signifi cantly 
reduced, with the pro-infl ammatory/fi brogenic milleau reversed to almost 
baseline controls.
Conclusion: Overall, activation of the miR-21 pathway appears to con-
tribute to NASH-associated carcinogenesis, with its inhibiton halting HCC 
development. Targeting miR-21 may constitute an appealing therapeutic 
approach to ameilorate NASH and its progression towards HCC. (PTDC/
BIM-MEC/0895/2014, PTDC/MED-PAT/31882/2017, SFRH/BD/88212/2012, 
SAICTPAC/0019/2015 FCT, PT).
Disclosure: Nothing to disclose 
likely to show progressive disease, with HNF-1α inactivated HCAs being the 
most common subtype showing progression.
References: 1. European Association for the Study of the Liver (EASL) EASL 
Clinical Practice Guidelines on the management of benign liver tumours. 
J Hepatol 2016; 65:386-398. 2. Bonder A, Afdhal N. Evaluation of liver le-
sions. Clin Liver Dis 2012;16: 271-283. 3. Karhunen PJ. Benign hepatic tu-
mours and tumour like conditions in men. J Clin Pathol 1986; 39:183-188. 
4. Nault JC, Couchy G, Balabaud C, et al. Molecular Classifi cation of Hepa-
tocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant 
Transformation. Gastroenterology 2017; 152:880-894. 5. Van Aalten SM, De 
Man RA, Ijzermans JNM, Terkivatan T. Systematic review of haemorrhage 
and rupture of hepatocellular adenomas. British Journal of Surgery 2012; 
99:911-916. 6. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocel-
lular adenoma management and phenotypic classifi cation: the Bordeaux 
experience. Hepatology 2009; 50:481-489
Disclosure: None related to this study Dominique Valla discloses the fol-
lowing not related to this study: Laboratoire Servier : “Liver safety commit-
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OP253 HEPATOCYTE-SPECIFIC DELETION OF MTOR ACCELERATES 
LIVER TUMOR GROWTH
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Introduction: The mTOR protein is an essential component of mTORC1 and 
mTORC2, two multi-protein complexes of central importance for the regu-
lation of cell proliferation, metabolism and autophagy. Activation of the 
mTOR pathway is frequently found in cancer, resulting in the notion that 
targeting mTOR represents a useful approach for cancer therapy. Of note, 
mTOR inhibitors have thus far failed to demonstrate signifi cant antipro-
liferative effi  cacy in the majority of cancer types. It is therefore of pivotal 
importance to better understand the functional signifi cance of the mTOR 
protein for the pathogenesis of cancer.
Aims & Methods: We sought to characterize the cell type-specifi c role of 
mTOR for the pathogenesis of primary and secondary liver tumors. To this 
end, we established a liver epithelial cell (LEC)-specifi c knock-out (KO) of 
mTOR via the Cre/loxP-system (termed mTORLEC mice). We characterized 
the growth of primary (non-alcoholic steatohepatitis-associated hepato-
cellular carcinoma (NASH-HCC)) and secondary (colorectal cancer liver 
metastasis (CRC-LM)) liver tumors in mTORLEC mice compared to wildtype 
controls.
Results: mTORLEC mice were viable and developed normally, arguing for 
a non-essential role of mTOR in LECs for hepatic development. Strikingly, 
tumor nodules in both the NASH-HCC as well as the CRC-LM model were 
signifi cantly larger in mTORLEC mice compared to controls. As both primary 
and secondary liver tumors were aff ected, we hypothesized that the KO of 
mTOR in LECs resulted in the formation of a pro-tumorigenic microenvi-
ronment in the liver. To further analyze this, we determined the expression 
of pro-infl ammatory genes in WT versus KO livers. While the expression of 
COX-2, HIF-1a, TNF-a and IL-6 was not aff ected, IL-1b gene expression was 
found to be signifi cantly higher in the livers of mTORLEC mice. Furthermore, 
mTORLEC mice displayed periportal leukocyte accumulation that was absent 
in livers from wildtype mice. The functional relevance of this fi nding for 
the accelerated liver tumor formation in mTORLEC mice is currently being 
evaluated by us.
Conclusion: We show an unexpected acceleration of liver tumor growth 
upon functional deletion of mTOR specifi cally in liver epithelial cells. These 
results argue against the widely accepted perception of mTOR as an eli-
gible target for cancer therapy. Our results add a further layer of complex-
ity to the biology of mTOR and suggest that cell and tissue type-specifi c 
factors need to be considered in order to comprehend the complexity of 
mTOR.
Disclosure: The authors declare no competing interests 
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OP255 GENOME-WIDE ASSOCIATION STUDY OF LIVER CORRECTED 
T1 MAGNETIC RESONANCE IMAGING IDENTIFIES A MISSENSE 
VARIANT IN SLC39A8 AND YIELDS NEW INSIGHTS INTO MECHANISMS 
UNDERLYING LIVER INFLAMMATION AND FIBROSIS
Parisinos C.1, Wilman H.R.2, Thomas E.L.2, Hemingway H.1, Yaghootkar H.3, 
Banerjee R.4
1UCL, London, United Kingdom, 2University of Westminster, London, United 
Kingdom, 3University of Exeter, Exeter, United Kingdom, 4Perspectum 
Diagnostics, Oxford, United Kingdom
Contact E-Mail Address: c.parisinos@ucl.ac.uk
Introduction: Steatohepatitis and subsequent fi brosis aff ect approximately 
one in ten middle-aged adults, and are progressive conditions which in 
turn may lead to cirrhosis, hepatocellular carcinoma and death.[1] The 
genetic background of steatohepatitis and fi brosis is unknown since liver 
biopsy is an invasive procedure with signifi cant risks. 
A promising, non-invasive proxy measure of liver infl ammation and fi -
brosis is corrected T1 (cT1) magnetic resonance imaging (MRI). cT1 MRI 
measures are associated with histological liver fi brosis and liver disease 
outcomes. cT1 MRI has already been used as a non-invasive outcome in 
randomised controlled trials for NASH,[2] and is an established technique 
for the assessment of myocardial fi brosis.
Aims & Methods: In this study, we aimed to explore the genetic suscepti-
bility underlying hepatic cT1 MRI measures as a proxy for underlying ste-
atohepatitis and fi brosis. 
We used data from the UK Biobank study which is a prospective study 
of 500,000 individuals recruited at age 40-69 years old across the UK. 
We derived cT1 measures from abdominal MRI scans in 2,501 unrelated 
participants. We divided our data into a discovery set of 2,289 white Brit-
ish individuals and a validation set of 212 European but not white-British 
individuals.
We performed a genome-wide association study (GWAS) in 2,289 white 
British individuals from UK Biobank using 11,977,111 imputed variants. We 
adjusted for age, sex, BMI and principal components. We performed a 
sensitivity analysis where we adjust for all the covariates except BMI. We 
validated the GWAS signifi cant variants (p-value < 5x10-8) in our validation 
set of 212 European but not white-British individuals.
Results: The GWAS of liver cT1 MRI measures in 2,289 unrelated individuals 
of white British ancestry identifi ed one independent variant that reached 
GWAS signifi cant threshold (rs13107325 in SLC39A8, p = 3.44 x 10-32). The 
missense G > T variant (rs13107325) was associated with 0.67 standard de-
viations (SD) higher cT1 measures (95% confi dence interval [0.56, 0.78]). 
In our validation set, the association between rs13107325 and cT1 measures 
was replicated (p = 0.002). 
The same missense G > T variant has been shown previously to be associ-
ated with higher alcohol intake, higher blood pressure, higher body-mass 
index, lower brain grey matter volume, less diverse human microbiome 
composition, higher risk of schizophrenia and higher risk of Crohn’s dis-
ease.[3-5]
Conclusion: We identifi ed a highly signifi cant, novel association between 
a G > T missense variant in SLC39A8 and cT1 MRI liver measures, a non-
invasive marker of fi brosis and infl ammation, in an unselected, prospec-
tive, population-based cohort. Validation is required in larger independent 
cohorts.
SLC39A8 encodes ZIP8, a divalent cation importer capable of transporting 
zinc, iron, manganese and selinate, and is one of the most pleiotropic 
genes in the human genome. Hepatic ZIP8 defi ciency in mice was previ-
ously associated with liver infl ammation and fi brosis, as well as neoplastic 
changes consistent with hepatocellular carcinoma.[6] 
Future studies are needed to determine whether interventions targeting 
pathways regulated by SLC39A8 might be attractive therapeutic options to 
prevent liver disease in at risk individuals.
References: 1) Costas, Javier. 2018. “The Highly Pleiotropic Gene SLC39A8 as 
an Opportunity to Gain Insight into the Molecular Pathogenesis of Schizo-
phrenia.” American Journal of Medical Genetics. 177 (2): 274-83. 2) Elliott, 
Lloyd T., Kevin Sharp, Fidel Alfaro-Almagro, et al. 2018. “Genome-Wide 
Association Studies of Brain Imaging Phenotypes in UK Biobank.” Nature 
562 (7726): 210-16. 3) Harrison, Stephen A., Stephen J. Rossi, Angelo H. 
Paredes, et al. 2019. “NGM282 Improves Liver Fibrosis and Histology in 12 
Weeks in Patients with Nonalcoholic Steatohepatitis.” Hepatology , Febru-
ary. https://doi.org/10.1002/hep.30590 4) Li, Dalin, Jean-Paul Achkar, Talin 
Haritunians, et al. 2016. “A Pleiotropic Missense Variant in SLC39A8 Is As-
sociated With Crohn’s Disease and Human Gut Microbiome Composition.” 
Gastroenterology 151 (4): 724-32. 5) Liu, Liu, Xiangrong Geng, Yihong Cai, 
Bryan Copple, et al. 2018. “Hepatic ZIP8 Defi ciency Is Associated with Dis-
rupted Selenium Homeostasis, Liver Pathology, and Tumor Formation.” 
American Journal of Physiology. Gastrointestinal and Liver Physiology 315 
(4): G569-79. 6) Williams, Christopher D., Joel Stengel, Michael I. Asike, 
et al. 2011. “Prevalence of Nonalcoholic Fatty Liver Disease and Nonalco-
holic Steatohepatitis among a Largely Middle-Aged Population Utilizing 
Ultrasound and Liver Biopsy: A Prospective Study.” Gastroenterology 140 
(1): 124-31.
Disclosure: RB and HW are shareholders in Perspectum Diagnostics. RB is 
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Introduction: Today, sarcopenia is widely considered as a factor infl uenc-
ing the prognosis in the liver transplant. Among the various available 
methods, the analysis of muscle mass on a single CT slice at L3 level is 
currently considered the gold standard for the diagnosis while other meth-
ods are currently a matter of investigation.
Aims & Methods: Our aim was to evaluate the prognostic role of sarcope-
nia assessed through the analysis of muscle mass of the whole abdomen 
by means of a volumetric-CT analysis. 
We evaluated 101 pre-transplant CT scans (venous phase) of adult patients 
with cirrhosis who underwent LT between 01/01/2016 and 31/10/2018 at 
our centre. We measured the muscle volume of the abdomen, using a 3D 
method, from the iliac crests to the base of the heart, excluding visceral 
content by segmentation. Images were analyzed with Volume Viewer soft -
ware (GE Medical Systems). Abdominal muscle volume was indexed by 
height squared (cm3/m2). The lower quartile of indexed muscle volume 
in the analyzed population was set as a cut-off  for signifi cantly reduced 
muscle mass. A Cox proportional regression-model was used for post-LT 
survival analysis.
Results: 80 subjects were male (79.2%). The mean age of the study popu-
lation was 54.8 ± 10.3 years. The prevalent etiology was alcoholic liver 
cirrhosis (31.7%) followed by HCV (21.8%), cholestatic liver disease (11.9%) 
and HBV (10.9%). HCC was present in 41.6% of subjects. The mean MELD 
score was 16.8 ± 7.4. Volumetric cut-off s for lower quartile of indexed ab-
dominal muscle volume were 583.7 cm3/m2 for women and 629.9 cm3/m2 
for men. A statistically signifi cant diff erence in post-LT survival was found 
using these cut-off s in the study population as an indicator of signifi cant 
sarcopenia (HR 7; 95% CI 2.3-21.6, p = 0.001).
Conclusion: Muscle mass estimate assessed by volumetric analysis appear 
to be a reliable predictor of post-LT mortality. 3D analysis has the advan-
tage of analyzing a wider portion of the body compared with the standard 
single-CT slice methods so providing a more reliable estimate of whole-
body muscle mass. This method should be further investigated in larger 
cohorts to confi rm its diagnostic performance compared with the standard 
bi-dimensional analysis.
Disclosure: Nothing to disclose 
OP257 LIVER DISORDER DUE TO PD-1 INHIBITORS IN THE CLINICAL 
SETTING
Okuyama S., Takasu A., Oguri N., Honda H., Okamoto T., Shiratori Y., 
Ikeya T., Takagi K., Nakamura K., Fukuda K.
St. Luke’s International Hospital, Gastroenterology, Tokyo, Japan
Contact E-Mail Address: shuoku@luke.ac.jp
Introduction: Recently, cases in which immune checkpoint inhibitors 
are administered as a new option for the treatment of cancer have been 
increasing. They are known to lead to immune-related adverse events 
(hereaft er referred to as ‘irAEs’), but the actual state of liver disorders as 
irAEs in clinical settings are not clear. We studied the liver disorders in 
cases where Nivolumab and Pembrolizumab were administered in our 
hospital.
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improvement across multiple metabolic parameters (weight -5.0 kg, 
p<0.001, BMI -2.4 kg/m2, p<0.001, HOMA-IR -4.7, p=0.003, ALT -7.9 U/l, 
p=0.008, MRI-PDFF -44.2%, SBP -4.0 mmHg, p 0.344, DBP -2.0 mmHg, 
p=0.475)(Table 1).
Conclusion: Single endoscopic DMR, combined with liraglutide and life-
style counseling, may eff ectively eliminate the need for insulin therapy in 
T2D while improving glucose regulation and overall metabolic health. This 
treatment approach is a promising alternative that appears to shift  insulin-
treated T2D patients to a state of better overall metabolic health.
Disclosure: Nothing to disclose 
  Baseline (n=12) 6 months (n=10)* p-value
Age 61 ± 8    
Daily insulin dose (IU) 37 ± 28 0  
Weight (kg) 96 ± 23 91 ± 22 <0.001
HbA1c (mmol/mol) 58.5 ± 5.4 52.3 ± 6.2 0.002
Insulin (pmol/l) 120 ± 60 64 ± 49 0.011
HOMA-IR 8.1 ± 4.4 3.4 ± 3 0.003
ALT (U/l) 25.9 ± 8.7 18 ± 4.8 0.008
MRI-PDFF % (change)† 8.5 ± 4.6 5.2 ± 3.2 (-44.2) 0.064
Data are mean ± standard deviation. Data represent measurements at baseline and 
6 months aft er initiation of the combined approach of DMR (Duodenal Mucosal 
Resurfacing), liraglutide and lifestyle counselling instead of basal insulin. BMI: Body 
Mass Index, HbA1c: Glycated hemoglobin A1c, FPG: Fasting Plasma Glucose, HOMA-IR: 
Homeostatic Model Assessment of Insulin Resistance, AST: Aspartate Transaminase, ALT: 
Alanine Transaminase, ABPM: 24-hour ambulatory blood pressure monitoring, SBP: 
Systolic Blood Pressure, DBP: Diastolic Blood Pressure, MMT: Mixed Meal Test, AUC: Area 
under the curve, iAUC: Incremental area under the curve. P-values based on paired 
student’s t-tests (n=10 vs. n=10). *Two subjects were excluded in whom insulin was 
reintroduced based on high HbA1c levels at 6 months. †Data at 6 months from 7 patients
[Table 1. Baseline characteristics and 6 months follow-up measurements]
OP259 DECREASED INTESTINAL ACETYLCHOLINESTERASE IN 
PATIENTS WITH DIABETES: AN IN VIVO STUDY WITH 11C-DONEPEZIL 
PET/CT
Klinge M.1, Borghammer P.2, Lund S.3, Fedorova T.2, Knudsen K.2, 
Haase A.-M.1, Krogh K.4
1Aarhus University Hospital, Department of Hepatology and Gastroenterology, 
Aarhus N, Denmark, 2Aarhus University Hospital, Department of Nuclear 
Medicine and PET centre, Aarhus N, Denmark, 3Aarhus University Hospital, 
Department of Internal Medicine and Endocrinology, Aarhus N, Denmark, 
4Aarhus University Hospital Neurogastroenterology Unit, Department of 
Hepatology and Gastroenterology, Aarhus N, Denmark
Contact E-Mail Address: mettewklinge@gmail.com
Introduction: Gastrointestinal (GI) neuropathy is a serious complication to 
diabetes mellitus (DM). Most intrinsic and extrinsic neurons controlling GI 
motility are cholinergic with nerve endings located within the myenteric 
plexus. Radioactive Donepezil binds with high affi  nity to acetylcholinester-
ase in the synaptic cleft s and thereby serve as an in vivomarker of cholin-
ergic innervation.
Aims & Methods: Nineteen patients with DM type 1 and GI symptoms 
were compared to nineteen age and gender-matched HC by means of 11C-
Donepezil PET/CT scan and validated questionnaires for assessment of GI 
symptoms. 
In the present study we aimed to compare the density of cholinergic inner-
vation of the gut in patients with DM and healthy controls (HC) by means 
of 11C-Donepezil PET/CT.
Results: All Patients had severe GI symptoms when assessed by standard 
questionnaires. Compared to HC, the DM patients had signifi cantly larger 
volumes of the small intestine (DM: median 557 cm3interquartile range 
(IQR 446-697) vs. HC median: 448 cm3(IQR 341-518) (p< 0.01)) while their 
11C-Donepezil PET signal was lower (DM: median 7.09 SUV (IQR 5.94-7.99) 
vs. HC: median 9.51 SUV (IQR 7.48-10.85) (p= 0.04)).In the colon, diff er-
ences did not reach statistical signifi cance (DM: median 1064 cm3(IQR 
882-1312) vs. HC: median 939 cm3(IQR 785-1008) (p= 0.13)) (DM: median 
1.20 SUV (IQR 1.05-1.36) vs. HC: median 1.33 SUV (IQR 1.19-1.57) (p= 0.07)). 
Furthermore, DM patients had reduced pancreatic volume (DM: median 53 
cm3(IQR 41-69) vs. HC: median 98 cm3(IQR 82-110) (p< 0.01)) and 11C-Done-
pezil PET signal of the pancreas (DM: median 13.14 SUV interquartile range 
(IQR 9.58-15.82) vs. HC: median 21.46 SUV (IQR 18.97;24.06) (p< 0.01)).
Aims & Methods: The subjects were 103 patients (male, 74; female, 29) 
who were given Nivolumab and/or Pembrolizumab from July 2015 to Feb-
ruary 2019. Seventy patients were given Nivolumab (hereaft er ‘group N’), 
31 patients were given Pembrolizumab (hereaft er ‘group P’), and 2 patients 
were given the two drugs separately (hereaft er ‘group NP’). Carcinomas 
studied were 65 cases of lung cancer, 7 cases of renal cancer, 6 cases of 
stomach cancer, 5 cases of malignant melanoma, and 20 cases of other 
cancers. We reviewed whether or not there was presence of liver disorder 
aft er the administration of the drugs, and on how they were managed aft er 
the liver disorder manifested.
Results: Liver disorder was found in 5 patients in group N (7.1%); 2 of them 
had grade 1, and 3 of them had grade 3. In the 2 patients with grade 1, 
Nivolumab was continued but the liver disorder remitted spontaneously. In 
2 patients with grade 3, Nivolumab was discontinued and the liver disorder 
remitted. In the 1 patient with grade 3, mPSL was given with Nivolumab 
continued, but the liver disorder did not improve, but when Nivolumab was 
discontinued, the liver disorder improved. In group P, liver disorder was 
found in 3 patients (9.7%); 2 of them had grade 1 and 1 had grade 3. 
In 1 patient with grade 1, Pembrolizumab was continued, but the liver dis-
order remitted spontaneously. In the other patient with grade 1, Pembro-
lizumab was discontinued because of another severe irAE, and with the 
administration of PSL 1mg/kg, the disorder remitted. As the patient with 
grade 3 did not remit rapidly aft er administering PSL 60mg (1mg/kg), my-
cophenolate mofetil (hereaft er MMF) was added, with which the disorder 
remitted. Aft er then, MMF was discontinued, and PSL was decreased to 
10mg, aft er which the liver disorder relapsed. MMR 1g was resumed, and 
the liver disorder improved. Liver disorder was not found in the NP group. 
None of the 8 patients who developed liver disorder had history of autoim-
mune disease.
Conclusion: Among patients with mild liver disorder, there were many in 
whom administration of PD-1 inhibitors could be continued. In patients 
with severe liver disorder, discontinuation of the drugs was required in 
all of them, but all of them remitted by the discontinuation of the drug 
and administration of immunosuppressive agents. There were also pa-
tients whose liver disorder relapsed by a decrease in the dosage of the 
immunosuppressive agents.
Disclosure: Nothing to disclose 
Intestinal epithelium in health and disease
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OP258 DUODENAL MUCOSAL RESURFACING (DMR) COMBINED 
WITH GLP-1-RA MAY ELIMINATE INSULIN THERAPY AND IMPROVE 
METABOLIC HEALTH IN TYPE 2 DIABETES
Van Baar A.C.G.1, Meiring S.1, Smeele P.1, Vriend T.2, Holleman F.3, 
Soeters M.R.3, Tijssen J.G.P.4, Nieuwdorp M.5, Bergman J.J.G.H.M.1
1Amsterdam UMC (Location AMC), Gastroenterology and Hepatology, 
Amsterdam, Netherlands, 2Amsterdam UMC (Location AMC), 
Nutrition, Amsterdam, Netherlands, 3Amsterdam UMC (Location AMC), 
Endocrinology, Amsterdam, Netherlands, 4Amsterdam UMC (Location AMC), 
Epidemiology, Amsterdam, Netherlands, 5Amsterdam UMC (Location AMC), 
Vascular Medicine, Amsterdam, Netherlands
Contact E-Mail Address: a.c.vanbaar@amc.nl
Introduction: Duodenal mucosal resurfacing (DMR) is an endoscopic inter-
vention in which the duodenal mucosa is ablated by hydrothermal energy. 
DMR improves glycemic control in type 2 diabetes (T2D) through altered 
metabolic signaling from the duodenum causing insulin sensitization. We 
studied the feasibility of eliminating insulin therapy in T2D by combining 
DMR with GLP-1r agonism (liraglutide) and lifestyle counseling.
Aims & Methods: Single arm, single center study in 16 insulin treated T2D 
patients (HbA1c ≤64 mmol/mol; basal insulin < 1U/kg/day, c-peptide ≥0.5 
nmol/l). Day 1, DMR is administered and insulin therapy discontinued. Day 
14, liraglutide is introduced (titrated to 1.8 mg/day) and life style counsel-
ing is administered throughout. Primary endpoint: percentage of patients 
free of insulin and HbA1c ≤59 mmol/mol at 6 months.
Results: Enrolment has been completed (n=16) and 12 patients have 
reached 6 months with 10/12 (83%) insulin-free and able to maintain gly-
cemic control (HbA1c -6.2 mmol/mol, p=0.002, FPG -2.5 mmol/l, p=0.086, 
AUC glucose MMT -916 mmol/l*min, p<0.001, iAUC glucose MMT -332 
mmol/l*min, p< 0.001, peak glucose MMT -3.9 mmol/l, p<0.001), with 
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Conclusion: We found that patients with DM and severe bowel symptoms 
had distended small intestines and reduced cholinergic innervation of the 
gut. 11C-Donepezil PET/CT holds promise as a non-invasive method for in 
vivoassessment of dysmotility and intestinal neuropathy in DM.
Disclosure: Nothing to disclose 
OP260 MEMBRANE MUCIN MUC17 IS A NOVEL INTESTINAL 
BARRIER COMPONENT REGULATED BY BACTERIAL SIGNALS
Layunta E., Jäverfelt S., Dolan B., Pelaseyed T.
University of Gothenburg, Medical Biochemistry, Gothenburg, Sweden
Contact E-Mail Address: elena.layunta@gmail.com
Introduction: Intestinal epithelium defends the host against environmen-
tal insults while permitting nutrient extraction and graft ing of microbiota. 
Contact with bacteria and bacterial products at early stages of life is neces-
sary for intestinal maturity and priming of intestinal epithelial cells (IECs) 
as well the host immune system1. However, there is critical knowledge 
gap concerning how the host senses the gut microbiota. Membrane mucin 
Muc17 is a dynamic glycoprotein expressed on apical membrane of IECs, 
where it extends up to 1 µm into the intestinal lumen2. We suggest that 
Muc17 is an ideal docking site for gut bacteria and could act as a novel 
epithelial immune receptor in intestine. However, the regulation of Muc17 
remains unknown.
Aims & Methods: The aim of this work is to determine the role of Muc17 
in intestinal barrier function. Ileum of wild type postnatal mice, human 
enterocyte-like Caco-2 cells and intestinal organoids were used as experi-
mental models. Expression of Muc17 and epithelial barrier genes were in-
vestigated using immunofl uorescence, quantitative RT-PCR and western 
blot.
Results: Establishment of an adult microbiota is a critical event in postna-
tal intestinal development. Consequently, we asked if the emergence of an 
adult-type microbiota upon weaning regulates Muc17. In adult mice with 
a conventional microbiota, Muc17 covers the apical membranes of IECs in 
the small intestine and colon. 
In stark contrast to adult animals, Muc17 was restricted to intracellular 
vesicles in the ileum of neonatal mice, and localized to apical surfaces 
only aft er the suckling-weaning transition, at postnatal day P21. In order 
to gain insight in the epithelial program(s) underlying Muc17 maturation, 
we assessed expression of epithelial barrier genes and cytokines during 
postnatal development (P9-P33). We observed a specifi c increase in Muc17 
expression with age, reaching a peak at P24. 
Other upregulated genes were the cytokines Il-22 and Ifn-γ and antimicro-
bial proteins such as Reg3-β, Reg3-γ and Zg16. However, Toll-like recep-
tors (TLRs) and downstream regulators were unaff ected in ileum during 
the suckling-weaning transition. 
Next, we investigated the signaling pathways downstream of Il-22 and 
Ifn-γ in epithelial-only intestinal organoids. Only stimulation of organoids 
with Il-22, Ifn-γ or the combination of Il-22 and Ifn-γ upregulated Muc17, 
whereas ligands for TLRs did not elevate Muc17 levels.
Conclusion: In summary, our study shows that Muc17 is associated with 
important genes that form the epithelial barrier in the small intestine. 
Expression of Muc17 and antimicrobial peptides is regulated by cytokines 
Il-22 and Ifn-γ produced by immune cells in the lamina propria, generat-
ing a robust epithelial barrier against the gut microbiota. We suggest that 
the establishment of this epithelial barrier, including membrane mucin 
Muc17, requires environmental signals from an adult-type consortium of 
microbiota.
References: 1. Knoop KA et al., Microbial antigen encounter during a pre-
weaning interval is critical for tolerance to gut bacteria. Sci Immunol. 2017 
Dec 15;2(18). pii: eaao1314. 2. Pelaseyed T et al., The mucus and mucins 
of the goblet cells and enterocytes provide the fi rst defense line of the 
gastrointestinal tract and interact with the immune system. Immunol Rev. 
2014 Jul;260(1):8-20.
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OP261 XBP1 GOVERNS ENDOPLASMIC RETICULUM STRESS DRIVEN 
STING SIGNALING IN THE INTESTINAL EPITHELIUM
Wottawa F.1, Stengel S.2, Kakavand N.1, Ito G.3, Windross S.4, Paludan S.4, 
Blumberg R.S.5, Schreiber S.6, Aden K.7, Rosenstiel P.8
1Institute of Clinical Molecular Biology, Kiel, Germany, 2IKMB, UKSH, Kiel, 
Germany, 3Institute of Clinical Molecular Biology Christian-Albrechts-
University of Kiel, Gastroenterology & Hepatology, Kiel, Germany, 4Aarhus 
University Hospital, Aarhus, Denmark, 5Brigham and Women’s Hospital, 
Boston, United States, 6Universität Kiel UKSH Medizinische Abt. I - UKSH, 
Kiel, Germany, 7IKMB + First Medical Department, Kiel University, Kiel, 
Germany, 8Kiel University, University Hospital Schleswig-Holstein, Institute of 
Clinical Molecular Biology (IKMB), Kiel, Germany
Contact E-Mail Address: f.wottawa@ikmb.uni-kiel.de
Introduction: Endoplasmic reticulum stress (ER-stress), defective au-
tophagy and a dysbiotic microbiota are hallmarks of infl ammatory bowel 
disease (IBD) pathophysiology. Recent fi ndings indicate that Stimulator of 
Interferon Genes (STING) might be involved in IBD pathophysiology in a 
mechanism involving excessive IFN-I secretion and consecutive necroptotic 
cell death[i][ii][iii]. To which extent IBD risk genes involved in the ER-Stress 
axis such asXBP1are necessary to coordinate intrinsic STING activation is 
not known.
Aims & Methods: We hypothesized that STING signaling might be dys-
regulated in context of ER-stress and infl ammation in the intestinal epi-
thelium. We therefore investigated the crosstalk between ER-stress and 
the STING pathway, focussing on the IRE1/XBP1 branch of the unfolded 
protein response (UPR) as hypomorphic XBP1 variants have been shown 
to cause ER-stress and thereby confer risk for IBD[i]. Intestinal organoids 
were derived from IBD patients and tested on their ability to induce ER-
stress driven STING signaling. RNA sequencing data from biopsies were 
analysed for correlation of ER-stress and STING singaling signatures in 
context of IBD. Mice with a conditional epithelial deletion of Xbp1and/or 
Atg16l1(Xbp1ΔIEC,Xbp1/Atg16l1ΔIEC ) were used to study STING signaling in 
context of ER-stress and defective autophagy. STING signaling was induced 
either chemically, via dsDNA or using vita-PAMPs such as L. monocyto-
genes or cytomegaliavirus.
Results: Analysis of ileal biopsies and human organoids from IBD patients 
revealed a strong correlation of ER-stress marker genes and STING ex-
pression in a disease-dependent manner with highest upregulation in 
infl amed tissue. Surprisingly, ER-stress induction itself via TM treatment 
induced robust STING-dependent IFN-I induction. In contrast, chronic ER-
stress in Xbp1-defi cient intestinal epithelial cells lead to STING degrada-
tion and subsequently impaired pathogen induced IFN-I production. These 
fi nding were confi rmed in vivo, as the STING/IFN-I pathway was strongly 
impaired in Xbp1ΔIECmice. Mechanistically, we show that impaired STING-
dependent IFN-I induction was due to Atg16l1-driven autophagic removal 
of STING, as STING-dependent IFN-I induction was partially recovered in 
the Xbp1/Atg16l1ΔIEC mice and organoids.
Conclusion: Our data suggests that the STING/IFN-I pathway is tightly reg-
ulated by ER-stress in intestinal epithelial cells. Mechanistically, acute ER-
stress directly induces IFN-I release via STING activation. In contrast, chron-
ic ER-stress, such as in the context of Xbp1 defi ciency, induces autophagy-
dependent STING degradation and renders epithelial cells vulnerable to 
bacterial or viral infections. Hence our data implicate a novel mechanism 
of the IBD risk gene XBP1on epithelial defense response against pathogens 
and provides an interesting link to explain the drastically increased vulner-
ability of IBD patients towards intestinal viral infections
References: Howell, Kate Joanne, et al. „DNA methylation and transcription 
patterns in intestinal epithelial cells from pediatric patients with infl am-
matory bowel diseases diff erentiate disease subtypes and associate with 
outcome.“ Gastroenterology 154.3 (2018): 585-598. Samie, Mohammad, et 
al. „Selective autophagy of the adaptor TRIF regulates innate infl amma-
tory signaling.“ Nature immunology 19.3 (2018): 246. Aden, Konrad, et al. 
„ATG16L1 orchestrates interleukin-22 signaling in the intestinal epithelium 
via cGAS-STING.“ Journal of Experimental Medicine 215.11 (2018): 2868-
2886. Kaser, Arthur, et al. „XBP1 links ER stress to intestinal infl ammation 
and confers genetic risk for human infl ammatory bowel disease.“ Cell 134.5 
(2008): 743-756.
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tion. Finally, we also evaluated whether the PANDA test can be used for 
monitoring the gut barrier function in 30 patients under treatment with a 
new oxygenated simethicone emulsion (6).
Results: A notably lower number of platelets was found in heparinized 
blood compared to EDTA-anticoagulated blood from patients with a gut 
barrier dysfunction but not from healthy volunteers. These results sug-
gested that when LPS translocates into blood, it binds to platelets leading 
to a preactivated state in which they have a lower threshold to be aggre-
gated in presence of heparin. In order to confi rm this hypothesis, LPS was 
added to heparinized and EDTA-anticoagulated blood samples collected 
from both groups. LPS led to a signifi cant reduction of platelet counts only 
in heparinized blood samples from control subjects but not in patients 
where the LPS-binding sites on platelets could already be saturated. LPS 
did not infl uence platelet number in EDTA-blood samples at all. 
Moreover, platelet’s aggregation can not be attributed to the higher Ca2+ 
concentration in heparinized samples compared to EDTA-blood samples. 
If this were so, how can we explain the lack of aggregation in heparinized 
blood from control subjects? Furthermore, in blood samples from some 
patients either the platelet number in citrated blood was very similar to 
that of heparinized blood or platelet counts found in heparinized blood 
were even lower than those of hirudin-blood samples in spite of the same 
external Ca2+ concentration in these samples. 
Finally, we have investigated whether PANDA test could be useful for 
monitoring the reconstitution of gut barrier function. We found that the 
platelet’s number in heparinized blood was notably lower compared to 
EDTA-blood before beginning of treatment. 
However, the diff erence in platelet’s number in presence of these both an-
ticoagulants decreased notably during the course of a simethicone treat-
ment.
Conclusion: Our results demonstrated that PANDA test can be used for 
screening LPS-loaded platelets as an indirect diagnostic biomarker for 
increased intestinal permeability and also for monitoring the gut barrier 
function during the treatment of gastrointestinal diseases.
References: 1. Laukoetter MG, Nava P, Nusrat A. Role of the intestinal bar-
rier in infl ammatory bowel disease. World J Gastroenterol 2008;14:401-407. 
2. Kopp F, Kupsch S, Schromm AB. Lipopolysaccharide-binding protein is 
bound and internalized by host cells and colocalizes with LPS in the cyto-
plasm: Implications for a role of LBP in intracellular LPS-signaling. Biochim 
Biophys Acta 2016;1863:660-672. 3. Ståhl Al., et al., 2006. Lipopolysaccha-
ride from enterohemorrhagic Escherichia coli binds to platelets through 
TLR4 and CD62 and is detected on circulating platelets in patients with 
hemolytic uremic syndrome. Blood 108:167-176. 4. Zhang G, Han J, Welch 
E, Ye R, Voyno-Yasenetskaya T,Malik AB, Du X, Li Z. LPS stimulates platelet 
secretion and potentiates platelet aggregation via TLR4/MyD88 and the 
cGMP-dependent protein kinase pathway. J Immunol 2009;182:7997-8004. 
5. Gao C, Boylan B, Fang J, Wilcox D, Newman D and Newman P. Hepa-
rin promotes platelet responsiveness by potentiating αIIbβ3-mediated 
outside-in signaling. Blood 2011;117:4946-4952. 6. Meier R, Steuerwald M. 
2007. Review of the Therapeutic use of simethicone in gastroenterology. 
Schweiz. Zschr. Ganzheits Medizin 19:380-387.
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OP262 HYPERSENSITIVITY TO OXIDATIVE LYSOSOME DAMAGE 
CAUSES DEATH OF ENTEROCYTES IN MICROVILLUS INCLUSION 
DISEASE
Leng C.1, W. Overeem A.1, Carton-Garcia F.2, Klappe K.1, Cui Y.1, 
Gabius H.-J.3, S. Zuhorn I.1, Arango D.2, van IJzendoorn S.4
1University of Groningen, Groningen, Netherlands, 2Universitat Autònoma 
de Barcelona, Barcelona, Spain, 3Ludwig-Maximilians-University, Munich, 
Germany, 4University Medical Center Groningen, Groningen, Netherlands
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Introduction: Microvillus inclusion disease (MVID) is a fatal enteropathy, 
characterized by intractable diarrhea and malabsorption associated with 
unexplained villus atrophy. MVID is caused by mutations in MYO5B encod-
ing myosin-Vb, known for its role in the recycling of cell surface proteins. 
Although recycling and degradation pathways of cell surface proteins are 
connected, the impact of the loss of myosin-Vb on the degradative route 
remains unclear.
Aims & Methods: The aim of this study was to investigate the impact of 
myosin-Vb loss-of-function on the late endo-lysosomal system.Immuno-
labeling on tissues of MVID patients with MYO5B mutations and Myo5B 
knockout mice was performed, together with functional studies in a MVID 
cell model to address causal relationships between phenotypes and myo-
sin-Vb expression and underlying mechanisms.
Results: Loss of myosin-Vb had a profound impact on the late endolyso-
somal system, causing 
1) alterations in the morphology and spatial distribution of late endo-
lysosomes, 
2) the accumulation of iron in lysosomes, 
3) an iron-mediated hypersensitivity to oxidative stress-induced lysosome 
membrane rupture and 
4) resultant cell death. 
The availability of the small GTPase rab7 was identifi ed as a ratelimit-
ing factor for the development of the late endo-lysosomal phenotype. Iron 
chelation and antioxidant treatment restored the phenotype.
Conclusion: Myosin-Vb, concurrent with its role in plasma membrane ho-
meostasis, is important for late endolysosomal homeostasis. Hypersensi-
tivity of myosin-Vb-depleted cells to oxidative lysosomal membrane per-
meabilization and cell death should be considered part of MVID pathogen-
esis. This property underlies a potential clinically relevant and druggable 
mechanism to explain the extensive villus atrophy in MVID.
Disclosure: Nothing to disclose 
OP263 NEW AND SIMPLE DIAGNOSTIC TEST FOR INCREASED 
INTESTINAL PERMEABILITY BASED ON PLATELET COUNT
Lopez M.1,2, Nowak G.3
1Löwen Apotheke, Giessen, Germany, 2Instituto Venezolano de 
Investigaciones Cienti cas, Centro de Bio sica y Bioquimica, Caracas, 
Venezuela (Bolivarian Republic of), 3University Hospital Jena, Jena, Germany
Contact E-Mail Address: melopez73@hotmail.com
Introduction: The main pathological process associated to increased in-
testinal permeability is the translocation of toxic products, predominantly 
endotoxins/lipopolysaccharides (LPS) from the intestinal tract into the mi-
crocirculation (1). 
In the bloodstream, LPS is distributed in varying proportions bound by 
LPS-binding protein, several other acute phase proteins, lipoproteins, 
soluble CD14, and even more relevant for our study, by cells bearing TLR4 
such as platelets (2,3). LPS leads to preactivated platelets that have a 
lower threshold to be aggregated in presence of the physiological ago-
nists, thrombin and collagen, but also by other molecules such as hepa-
rin (4,5).
Aims & Methods: The aim of this study was to validate a simple, fast and 
reliable test for screening LPS-loaded platelets as an indirect biomarker 
for increased intestinal permeability. This test named PANDA (acronym for 
PlAtelet’s Number in Diff erent Anticoagulants) consists in the measure-
ment of the mean platelet number in blood samples collected into EDTA 
and heparin. 
To explore this issue, we analyzed the platelet number from patients with 
gastrointestinal diseases and a group of healthy persons in blood samples 
anticoagulated with EDTA or heparin, but also in presence of hirudin or 
citrate in order to investigate the contribution of Ca2+ in platelet’s aggrega-
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Improving colorectal cancer screening
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OP264 ADENOMA DETECTION RATE IN ASYMPTOMATIC FECAL 
IMMUNOCHEMICAL TEST POSITIVE COHORTS: A SYSTEMATIC 
REVIEW AND META-ANALYSIS
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Introduction: Adenoma detection rate (ADR) is a well-accepted quality in-
dicator of screening colonoscopy and is defi ned as the proportion of pa-
tients who have one or more adenoma detected while undergoing screen-
ing colonoscopy. In a recent guideline, the US multi society task force on 
CRC prevention proposed an ADR benchmark of >35% for females and 
>45% for males in fecal immunochemical test (FIT) positive asymptomatic 
population. This, however, is based out of low quality evidence.
Aims & Methods: We conducted this meta-analysis to estimate the pooled 
threshold of ADR in FIT-positive asymptomatic population undergoing 
colonoscopy. We conducted a comprehensive search of several databases 
and conference proceedings including PubMed, EMBASE, Google-Schol-
ar, LILACS, and Web of Science databases (earliest inception to January 
2019). We followed the Preferred Reporting items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines, by using predefi ned protocol, 
to identify studies reporting the detection of adenoma by colonoscopy 
in FIT-positive population. Random-eff ects model was used for analysis. 
Heterogeneity between study-specifi c estimates was calculated using Co-
chran Q statistical test and I2 statistics. Publication bias was ascertained, 
qualitatively, by visual inspection of funnel plot and quantitatively, by the 
Egger test.
Results: From an initial total of 480 studies, 73 records were screened and 
48 full-length articles were assessed. 21 studies were included in the fi -
nal analysis. All included patients were aged more than 50 years. In the 
included 21 studies, 129,975 cases were positive for FIT, of which 105,731 
cases underwent a screening colonoscopy. 50,247 cases were identifi ed 
with a colorectal adenoma, 12,343 cases were diagnosed with advanced 
adenoma, and 4,211 cases were diagnosed with colorectal cancer. The 
pooled rate of adenoma detection rate (ADR) in FIT-positive asymptom-
atic individuals was 45.4% (95% CI 37.3-53.8, I2=99.8). The pooled rate of 
advanced adenoma detection rate (aADR) was 19.4% (95% CI 14.2-25.8, 
I2=99.6) and the pooled rate of colorectal cancer detection rate (CDR) was 
3.8% (95% CI 2.8-5.0, I2=97.9). Based on visual inspection of the funnel 
plot as well as quantitative measurement that used the Egger regression 
test, there was no evidence of publication bias (Egger’s p-value=0.37).
Conclusion: From a total of 21 good quality studies that evaluated 129,975 
participants, we report a pooled adenoma detection rate (ADR) of 45.4%, 
a pooled advanced-ADR of 19.4%, and a pooled CDR of 3.8% in FIT-posi-
tive asymptomatic individuals. To the best of our knowledge, this study is 
the largest and most up-to-date meta-analysis reporting on the pooled 
results of colonoscopy fi ndings in FIT-positive asymptomatic population.
Disclosure: Nothing to disclose 
OP265 THE PREDICTIVE EFFECT OF A HIGH-QUALITY SINGLE 
NEGATIVE SCREENING COLONOSCOPY IN INDIVIDUALS WITH FAMILY 
HISTORY OF COLORECTAL CANCER EXCEEDS 10 YEARS
Pilonis N.1, Franczyk R.2, Wieszczy P.3, Didkowska J.4, Wojciechowska U.4, 
Pisera M.5, Rupinski M.6, Bugajski M.7, Regula J.8, Kaminski M.F.9
1Maria Sklodowska-Curie Institute - Oncology Center, Department of 
Oncological Gastroenterology, Warsaw, Poland, 2Maria Sklodowska-
Curie Memorial Cancer Centre and Institute of Oncology, Department 
of Gastroenterological Oncology, Warsaw, Poland, 3Medical Center for 
Postgraduate Education, Department of Gastroenterology, Hepatology and 
Clinical Oncology, Warsaw, Poland, 4National Cancer Registry of Poland, 
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 
Warsaw, Poland, 5Maria Sklodowska-Curie Memorial Center and Institute 
of Oncology, Gastroenterology & Hepatology, Warsaw, Poland, 6The Maria 
Skłodowska Curie Memorial Cancer Centre, Klinika Gastroenterologii 
Onkologicznej, Warsaw, Poland, 7Olympus Polska, Warsaw, Poland, 8Maria 
Sklodowska-Curie Memorial Cancer Centre and Institute o Oncology, 
Department of Gastroenterology, Warsaw, Poland, 9Maria Sklodowska-Curie 
Memorial Center and Institute of Oncology, Department of Gastroenterology, 
Warsaw, Poland
Contact E-Mail Address: nastazja@gmail.com
Introduction: Despite limited evidence, current guidelines recommend to 
repeat screening colonoscopy in individuals with family history (FH) of 
colorectal cancer (CRC) every 5 years.
Aims & Methods: To assess the long-term risk (>5 years) of CRC and CRC 
death in individuals with and without a family history of colorectal cancer 
(at least one fi rst-degree relative with CRC) aft er high- and low-quality 
single negative screening colonoscopy, as compared with the general 
population. 
We conducted an analysis of the database records of all colonoscopies 
performed between October 1st 2000, and December 31st 2011 as part of 
the Polish CRC screening program. 
All subjects with and without FH of CRC who underwent a single negative 
colonoscopy (defi ned as the absence of any neoplastic lesions) were iden-
tifi ed and followed for CRC and CRC death through the National Cancer 
Registry over the median of 10.2 years and up to 17.4 years. High-quality 
colonoscopy was defi ned as an examination with cecal intubation, ad-
equate bowel preparation (very good, good or suffi  cient per the Aronch-
ick scale) performed by an endoscopist with an adenoma detection rate 
≥20%. Standardized incidence and mortality ratios (SIRs and SMRs) were 
calculated by comparing the observed values against the values for the 
general Polish population.
Results: Out of 206,685 individuals who underwent screening colonoscopy 
with a negative result, we identifi ed 40,798 individuals with FH of CRC. 
Overall, throughout a 17.4-year period following a high-quality single neg-
ative colonoscopy there was no signifi cant diff erence in risk of CRC and CRC 
death between subjects with FH of CRC and those without FH of CRC (high-
quality screening colonoscopy yielded SIR of 0.33 (95% CI, 0.19-0.53) and 
SMR of 0.04 (95% CI, 0.00-0.24) in subjects with FH of CRC and SIR of 0.24 
(95% CI, 0.19-0.30) and SMR of 0.17 (95% CI, 0.11-0.25) in subjects without 
FH of CRC. Among individuals with FH who underwent high-quality colo-
noscopy, the risk of colorectal cancer and colorectal cancer death between 
5 and 10 years aft er examination did not diff er signifi cantly from the earlier 
period of observation (Table 1).
 
  Years following negative colonoscopy
  0-5.0 5.1-10.0 Entire follow-up period 0-5.0 5.1-10.0
Entire follow-
up period
  Individuals with family history of CRC Individuals without family history of CRC
High-quality 
colonoscopy  
SIR (95% CI) 0.23 (0.08-0.50)
0.40 
(0.17-0.79)
0.33 
(0.19-0.53)
0.19 
(0.13-0.27)
0.30 
(0.22-0.42)
0.24 
(0.19-0.30)
SMR (95% CI) 0.08 (0.00-0.46)
0.00 
(0.00-0.41)
0.04 
(0.00-0.24)
0.09 
(0.04-0.18)
0.21 
(0.11-0.36)
0.17 
(0.11-0.25)
Low-quality 
colonoscopy  
SIR (95% CI) 0.57 (0.39-0.81)
1.04 
(0.77-1.37)
0.79 
(0.64-0.96)
0.36 
(0.30-0.43)
0.63 
(0.54-0.72)
0.52 
(0.47-0.57)
SMR (95% CI) 0.24 (0.09-0.52)
0.82 (0.48-
1.29)
0.50 
(0.33-0.72)
0.17 
(0.11-0.24)
0.51 
(0.40-0.64)
0.38 
(0.32-0.45
[SIRs and SMRs of individuals with and without FH of colorectal cancer according 
to the quality and the time from single negative screening colonoscopy]
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OP267 EFFICACY AND TOLERABILITY OF SINGLE DOSE VS. SPLIT 
DOSE POLYETHYLENE GLYCOL FOR COLONIC PREPARATION IN 
CHILDREN: A RANDOMIZED CONTROL STUDY
Tripathi P.R., Poddar U., Yachha S.K., Sen Sarma M., Srivastava A.
Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Dept. of Pediatric 
Gastroenterology, Lucknow, India
Contact E-Mail Address: parijattripathi1986@gmail.com
Introduction: Polyethylene glycol (PEG) solution is the most eff ective colon 
cleansing agent but volume related adverse eff ects are common. Though 
split-dose PEG is used in adults, there is no pediatric study so-far compar-
ing split-dose with single-dose PEG.
Aims & Methods: The aim of this study was to fi nd the effi  cacy and toler-
ability of split-dose as compared to single-dose PEG for bowel preparation 
in pediatric patients. 
Consecutive children (1-18 years) were randomized into either single-dose 
or split-dose PEG. Single-dose group received 4000mL/1.73m2 PEG solu-
tion day before colonoscopy while split-dose group received half dose day 
before and the remaining half on the day of colonoscopy. Eff ectiveness of 
bowel preparation was assessed on Aronchik scale, by the endoscopist 
who was blinded to the type of preparation. Inter-observer variability was 
analyzed by comparing with independent scoring by the blinded trained 
endoscopy-nurse. The trial was registered with Clinical Trials Registry of 
India. (Trail number 2017/08/009303).
Results: Of the 220 randomized children, 179 completed the study (split-
dose: 93, single-dose: 86) The mean age of the study population was 138.12 
(57.84) months (72.6% males). Age, gender distribution, body surface area 
(BSA), volume of PEG solution ingested, proportion of in-patients and pre-
vious history of colonoscopy were comparable between the single-dose 
and split-dose PEG groups. The effi  cacy of bowel preparation was bet-
ter with split-dose (satisfactory preparation: 76.34% vs. 43.02%, p< 0.001) 
with almost perfect inter-observer agreement (k=0.803). Nausea, vomiting 
and sleep disturbance were signifi cantly less in split-dose than single-
dose group (p< 0.05). Split-dose patients were able to drink PEG solution 
faster (p=0.002). Total sleep duration and uninterrupted sleep duration 
was also better in split-dose group as compared to single-dose (p=0.001).
Parameters Single dose PEG (N=86)
Split dose 
PEG (N=93) P value
Mean duration of drinking (SD) in hours 5.15 (1.18) 4.65 (0.93) 0.002
Pain abdomen, n (%) 7 (8.1) 3 (3.2) 0.199
Abdominal distension, n(%) 6 (7) 2(2.2) 0.156
Vomiting, n (%) 36(41.9) 21(22.6) 0.007
Sleep disturbance,n(%) 49(57) 13(14) 0.001
Mean duration uninterrupted sleep (SD) 
in hours
4.23 (1.83) 6.05 (1.34) 0.001
Last stool liquid consistency, n (%) 72(83.7) 90(96.8) 0.003
Satisfactory preparation (Excellent and 
Good on Aronchik score), n (%)
37(43.02) 71(76.34) <0.001
Ileoscopy, n(%) 83(96.5) 93(100) 0.109
[Comparisons of tolerability and e  cacy between single dose versus split 
dose Polyehylene glycol]
Conclusion: Split-dose PEG is more eff ective than single-dose for colono-
scopic preparation in pediatric population. At the same time it causes low-
er volume related side eff ects of bowel preparation and improved sleep 
quality which are of paramount importance for children.
Disclosure: Nothing to disclose 
Conversely, low-quality screening colonoscopy was not associated with a 
signifi cant reduction in colorectal cancer risk among the individuals with 
FH of colorectal cancer between 5 and 10 years aft er colonoscopy. 
Conclusion: Our results suggest that 5-year screening interval for individu-
als with FH of CRC could be safely prolonged to 10 years providing that the 
quality of baseline colonoscopy was high.
Disclosure: JR received honoraria/consultation fees from Ipsen, Polphar-
ma, Takeda, Alfa Sigma, Krka, Promed, and travel grant from Abbvie and 
Alfa Wassermann. MFK recived honoraria/consultation fees from Olympus, 
Fujifi lm, Alfa Sigma and Norgine. 
OP266 SHOULD ADENOMA DETECTION RATES BE AGE BASED?
Sayers R.1, Choon X.Y.1, Selby I.1, McNair A.2
1Queen Elizabeth Hospital, Core Medical Trainee, London, United Kingdom, 
2Queen Elizabeth Hospital, Consultant Gastroenterologist, London, United 
Kingdom
Contact E-Mail Address: ross.sayers2@nhs.net
Introduction: Adenoma detection rate (ADR) is a measure of the quality 
of the colonoscopic examination, and in the UK a minimum target of 15% 
has been set for the whole population. Given the pathogenesis of adeno-
mas, colonoscopists who examine a higher proportion of younger patients 
might be expected to encounter fewer adenomas, and as such not produce 
equivalent ADRs to those dealing predominantly with older patients.
Aims & Methods: We set out to establish ADRs in patients of diff erent age 
groups. We interrogated the endoscopy reporting system at a District Gen-
eral Hospital in South London over a 3-year period. We divided the pa-
tients into three age groups, and then determined the crude rate of polyp 
detection for each. From each age group we selected a sample of 100 con-
secutive patients who had polyps on their colonoscopy, and reviewed the 
histological diagnoses to determine the proportion of polyps which were 
clinically important i.e. adenomas, sessile or serrate lesions, and carcino-
mas. Chi-square testing was used to compare the diff erent age groups for: 
the crude polyp detection rates, the rate of clinically important lesions in 
our samples, and the extrapolated number of clinically important lesions 
for the 3-year data set.
Results: A total of 7928 colonoscopies were performed in this time pe-
riod. Table 1 below summarises the lesion detection rates in the three age 
groups examined.
  20-39 year old 40-59 year old 60-90 year old
Total number of colonoscopies 
performed 639 2519 4770
Number of colonoscopies in 
which polyps were detected 102 605 1662
Crude rate of polyp detection
16.0% p value 
(20-39yo vs. 40-
59yo) <0.001
24.0% p value (40-
59yo vs. 60-90yo) 
<0.001
34.8% p value (20-
39yo vs. 60-90yo) 
<0.001
Number of adenomas, sessile 
or serrated lesions, and 
carcinomas in a sample of 100
49 67 76
Predicted rates of clinically 
important polyps
7.8% p value (20-
39yo vs. 40-59yo) 
<0.001
16.1% p value (40-
59yo vs. 60-90yo) 
<0.001
26.5% p value (20-
39yo vs. 60-90yo) 
<0.001
[Table 1]
Conclusion: Our data suggests there is a signifi cant diff erence in ADRs in 
diff erent age groups, and that clinically important polyps are more likely 
to be found in older people. This adds to the body of evidence that ADRs 
increase with age. Future key performance indicators for colonoscopies 
should take this into account.
References: Kaminski MF, Regula J, Kraszewska E, Polkowski M, 
Wojciechowska U, Didkowska J, Zwierko M, Rupinski M, Nowacki MP, 
Butruk E. Quality indicators for colonoscopy and the risk of interval cancer. 
N Engl J Med. 2010 May 13;362(19):1795-803. doi:10.1056/NEJMoa0907667. 
Corley, DA., et al. Adenoma Detection Rate and Risk of Colorectal Cancer 
and Death. N Engl J Med 2014; 370:1298-1306 DOI: 10.1056/NEJMoa1309086 
Diamond SJ, Enestvedt BK, Jiang Z, et al. Adenoma detection rate in-
creases with each decade of life aft er 50 years of age. Gastrointest Endosc. 
2011;74(1):135-40.
Disclosure: Nothing to disclose 
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OP268 WATER EXCHANGE (WE) SIGNIFICANTLY INCREASES 
DETECTION RATE OF SESSILE SERRATED POLYPS COMPARED WITH 
AIR (AI) OR CARBON DIOXIDE (CO2) INSUFFLATION - POOLED DATA 
ANALYSIS OF THREE RANDOMIZED CONTROLLED TRIALS
Leung F.1, Leung J.2, IWATERS, International Water Aided Techniques in 
Endoscopy (Education) and Research Society
1Sepulveda Ambulatory Care Center, VAGLAHS, David Ge en School of 
Medicine at UCLA, Medicine, North Hills, United States, 2Sacramento 
VAMC, VA Northern California Healthcare System, UC Davis Medical Center, 
Medicine, Mather, United States
Contact E-Mail Address: felixleung@socal.rr.com
Introduction: Important advances were made in understanding the im-
pact of water exchange (WE) colonoscopy in the past decade. The cardinal 
feature and key to the success of WE is, during the insertion phase, the 
near-complete suction removal of infused water used to aid insertion.1 
A network meta-analysis in 2018 summarized the data and reported that 
WE provided the highest adenoma detection rate2; but the impact on the 
detection rate of sessile serrated polyps was not addressed. These lesions 
can be found anywhere in the colon and are more common in the proximal 
and right colon. The endoscopic features of sessile serrated polyps make 
their real-time identifi cation challenging. Given their subtle appearance 
and their defi nite potential for transformation to malignancy, a method 
that enhances their endoscopic detection is desirable. 
The fi nding of sessile serrated polyps was mentioned in several random-
ized controlled trials (RCTs) comparing WE with air (AI) or carbon dioxide 
(CO2) insuffl  ation.
Aims & Methods: By pooling the data in three RCTs3-5 to minimize the pit-
fall of type II error, the aim of this report is to assess the impact of WE 
(vs. AI or CO2) on detection rate of sessile serrated polyps. Three RCTs 
with data on sessile serrated polyps when the standardized WE method 
was compared with AI or CO2 insuffl  ation were identifi ed. Demographic 
and procedural data were tabulated. Data on sessile serrated polyps were 
pooled and analyzed.
Results: Table 1 summarizes the studies selected for pooled analysis based 
on available data. WE signifi cantly increased detection rate of sessile ser-
rated polyps from 3.2% to 4.9% (*P=0.0054, Fisher Exact test).
Conclusion: The pooled data show WE signifi cantly increased detection 
rate of sessile serrated polyps. The improved outcome adds value to colo-
noscopy performed with the WE method. The enhanced value justifi es in-
corporation of WE into colorectal cancer screening programs, to set the 
stage for future studies to assess the impact of WE on minimizing the de-
velopment of colorectal cancers.
  Pooled Data of References 3, 4, 5
Method Water Exchange Air Insuffl  ation
No. of patients 2053 2043
No. of colonoscopists 20 20
Mean age, year 57 57
Male, no. (%) 1088 (53%) 1121 (55%)
Screening, no.(%) 865 (42%) 919 (45%)
Cecal intubation no. (%) 2020 (98%) 2001 (98%)
Withdrawal time (min) 7.1 to 20 7.2 to 22
Bowel prep regimen Split-dose Split-dose
Sessile polyp detection rate 101/ 2053 (4.9%)* 65/2043 (3.2%)
[Table 1: Details of randomized controlled trials selected for analysis]
References: 1. Leung FW, et al. Water infusion without near-complete re-
moval during insertion by any other name is still water immersion (WI). 
Gastrointestinal Endoscopy 2019;89(3):599-601. 2. Fuccio L, et al. Water 
exchange colonoscopy increases adenoma detection rate: a systematic 
review with network meta-analysis of randomized controlled studies. 
Gastrointest Endosc. 2018;88(4):589-597. 3. Garborg K, et al. Water ex-
change versus carbon dioxide insuffl  ation in unsedated colonoscopy: a 
multicenter randomized controlled trial. Endoscopy. 2015 Mar;47(3):192-9. 
4. Jia H, et al. Water exchange method signifi cantly improves adenoma 
detection rate: a multicenter, randomized controlled trial. Am J Gastro-
enterol. 2017;112(4):568-576. 5. Leung JW, et al. A prospective RCT com-
paring combined chromoendoscopy with water exchange (CWE) vs. water 
exchange (WE) vs. air insuffl  ation (AI) in adenoma detection in screening 
colonoscopy. United European Gastroenterology J. 2019 Feb. https://doi.
org/10.1177/2050640619832196
Disclosure: Nothing to disclose 
OP269 FACTORS ASSOCIATED WITH MECHANICAL AND SYSTEMIC 
ADVERSE EVENTS AFTER COLONOSCOPY (FRANCE, 2010-2015)
Laanani M.1, Weill A.1, Blotiere P.O.1, Pouchot J.2, Carbonnel F.3, Coste J.4
1French National Health Insurance, Dept. of Public Health Studies, Paris, 
France, 2Paris Descartes University and Assistance Publique-Hôpitaux de 
Paris, Internal Medicine Unit, Paris, France, 3CHU Bicetre, Dept. de Hepato-
Gastroenterologie, Le Kremlin Bicetre, France, 4Paris Descartes University and 
Assistance Publique-Hôpitaux de Paris, Biostatistics and Epidemiology Unit, 
Paris, France
Contact E-Mail Address: franck.carbonnel@aphp.fr
Introduction: More than one million colonoscopies are performed every 
year in France. They are associated with risks of mechanical and systemic 
serious adverse events (SAEs).
Aims & Methods: In this study, we attempted to identify the factors as-
sociated with mechanical (colonic perforation, gastrointestinal bleeding, 
splenic injury) and systemic (shock, myocardial infarction, stroke, pulmo-
nary embolism, acute renal failure, urolithiasis) SAEs aft er colonoscopy. 
We analysed data from the French national claims databases (SNDS). A 
total of 4,088,799 patients, 30 years or older, undergoing a fi rst screening 
or diagnostic colonoscopy between 2010 and 2015 were identifi ed. SAE 
rates were estimated, and risk factors associated with SAEs were identifi ed 
using multilevel logistic regression models, adjusted for patient, colonos-
copy, endoscopist, and facility characteristics.
Results: Perforation rates ranged from 3.5 (stringent defi nition) to 7.3 
(broad defi nition) per
10,000 procedures, bleeding rates ranged from 6.5 to 23.1 per 10,000 
procedures, and splenic injury rates ranged from 0.20 to 0.34 per 10,000 
procedures. The 5-day SAE incidence rate was 2.8/10,000 procedures 
for shock, 0.87/10,000 for myocardial infarction, 1.9/10,000 for stroke, 
2.9/10,000 for pulmonary embolism, 5.5/10,000 for acute renal failure, 
and 3.3/10,000 for urolithiasis. 
Increasing age was associated with an increasing incidence of mechanical 
and systemic SAEs. Cancer andcardiovascular comorbidities were associ-
ated with mechanical SAEs. A higher number of pre-existing conditions 
was associated with shock and acute renal failure. Polypectomy, especially 
of polyps larger than 1 cm, was associated with an increased risk of perfo-
ration (OR=4.1; 95% CI, 3.4-5.0) and bleeding (OR=13.3; 95% CI, 11.7-15.1). 
Mechanical SAEs were associated with the endoscopist’s experience, while 
systemic SAEs were more frequent in public hospitals than in private clin-
ics.
Conclusion: SAEs related to colonoscopy are more frequent in older pa-
tients and in those with comorbidities. Systemic SAEs are more frequent 
in public hospitals, refl ecting patient selection processes. The risk of both 
mechanical and systemic SAEs should be taken into account when decid-
ing colonoscopy, particularly in elderly patients with multiple pre-existing 
conditions
Disclosure: Franck Carbonnel received personal fees from Medtronic for 
board participation 
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OP271 TERMINAL ILEUM THICKNESS IS A PREDICTIVE MARKER 
FOR INFLIXIMAB THERAPY IN CROHN´S DISEASE
Albshesh A.1, Ungar B.2, Ben-Horin S.3, Eliakim A.4, Kopylov U.5, 
Carter D.6,7
1Sheba Medical Center Dept. of Gastroenterology, Ramat Gan, Israel, 
2Gastroenterology Institute, Ramat Gan, Israel, 3University of Tel Aviv, Sheba 
Medical Center, Gastroenterology, Tel Hashomer, Israel, 4Sheba Medical 
Center, Dept. of Gastroenterology, Ramat Gan, Israel, 5Chaim Sheba Medical 
Center, Gastroenterology, Ramat Gan, Israel, 6Sheba Medical Center, 
Gastroenterology, Ramat Gan, Israel, 7Tel Aviv University, Sackler Faculty of 
Medicine, Tel Aviv, Israel
Contact E-Mail Address: ahmad.albshesh@sheba.health.gov.il
Introduction: While achieving mucosal healing has been associated with 
long-term response to therapy of Crohn’s disease (CD), little is known 
about the signifi cance of terminal ileum (TI) transmural thickness in pre-
dicting of clinical outcomes.
Aims & Methods: In this retrospective chart review, we examined the cor-
relation between transmural TI thickness during maintenance phase (week 
14 and above) and the clinical outcome of CD in a cohort of patients treated 
with infl iximab. Intestinal ultrasonography (IUS) was used in all patients to 
determine TI transmural thickness. TI transmural response was defi ned as 
TI< 4mm. Treatment failure was defi ned as treatment discontinuation due 
to ineffi  cacy, dose escalation, or surgery. IUS parameters and clinical data 
were assessed during follow up.
Results: Sixty CD patients receiving infl iximab therapy (60% male, mean 
age 32.6 years, mean duration of disease-9.6 years, 92% anti-TNF-naïve) 
were included in the study. All patients had ileal or ileo-colonic disease. 
Thirty nine patients (65%) achieved transmural response. The mean dura-
tion of follow-up was 11.2 months. Aft er a median follow-up of 9.5 months, 
22(36.6%) patients developed treatment failure. On univariate analysis, 
the only variables associated with treatment failure were: TI thickness of 
3.1 (3.62-6.72) mm vs 1.4 (1.8-3) mm, p value <0.0001 in patients with and 
without treatment failure, respectively, and IFX trough level (IFX-TL) of 6.6 
(0.13-6.97) mcg/ml vs 3.9 (3.9-7.8) mcg/ml level, p = 0.008. There was a 
signifi cant correlation between failure to achieve transmural response and 
treatment failure (18/24 (75%) vs 4/36 (11.1%) in patients with treatment 
failure and without treatment failure, respectively (OR-17.55 95%, CI -4.0-
76, p=0.02). Other than IFX-TL and TI- thickness there were no clinical or 
demographic parameter that were associated with the risk of treatment 
failure. 
On multivariate analysis, only terminal ileum thickness> 4 mm was as-
sociated with the risk of treatment failure (p= 0.002); IFX-TL did no retain 
statistical signifi cance on multivariate analysis (P= 0.695)
Conclusion: Our fi ndings suggest that failure to achieve transmural re-
sponse to infl iximab can predict subsequent treatment failure in CD pa-
tients, indicating transmural response as a potential novel valuable thera-
peutic target.
Disclosure: Nothing to disclose 
OP272 TRANSMURAL HEALING ASSESSED USING MRI IS 
ASSOCIATED WITH BETTER OUTCOMES AND IS A POTENTIAL 
THERAPEUTIC TARGET IN PATIENTS WITH CROHN´S DISEASE
Buisson A.1, Vignette J.2, Bommelaer G.2, Pereira B.2, Hordonneau C.2
1CHU Estaing Clermont-Ferrand, Dept. of Gastroenterology, Clermont-
Ferrand, France, 2CHU Clermont Ferrand Service de Médecine Digestive et 
Hépato-biliaire, Clermont-Ferrand, France
Contact E-Mail Address: a_buisson@hotmail.fr
Introduction: The poor acceptability of repeated colonoscopies limits the 
use of endoscopic mucosal healing as therapeutic target in patients with 
Crohn’s disease (CD). MRI is better accepted than endoscopy, is able to 
perform a concomitant transmural assessment of ileocolonic infl ammation 
and to detect CD complications.
Aims & Methods: We aimed to evaluate whether transmural healing as-
sessed using MRI scores was associated with decreased risk of surgery, 
hospitalization and therapeutic intensifi cation in patients with CD. 
From a database including all the consecutive patients who performed 
anMRI to assess luminal CD between January 2012 and June 2018 in our 
IBD unit, we selected all the patients with CD (> 18 yearsold) who under-
went two MRI with: 
New ways to predict response in IBD
16:00-17:30 / E1
OP270 EARLY DYNAMICS OF PERIPHERAL BLOOD GENE 
EXPRESSION AND DNA METHYLATION PREDICT RESPONSE 
TO ANTI-TNFA THERAPY IN A PROSPECTIVE MULTI-OMICS 
ANALYSIS IN IBD PATIENTS
Mishra N.1, Aden K.2, Blase J.I.1, Conrad C.3, Nikolaus S.4, Rey G.5, 
Dermitzakis M.5, Schreiber S.6, Rosenstiel P.1
1Kiel University, University Hospital Schleswig-Holstein, Institute of Clinical 
Molecular Biology (IKMB), Kiel, Germany, 2IKMB + First Medical Department, 
Kiel University, Kiel, Germany, 3Kiel University, Department of General 
Internal Medicine, Kiel, Germany, 4Univers.-Klinik Schleswig-Holstein, 
Campus Kiel, Kiel, Germany, 5University of Geneva, Department of Genetic 
Medicine and Development, Geneva, Switzerland, 6Universität Kiel UKSH 
Medizinische Abt. I - UKSH, Universität Kiel UKSH Medizinische Abt. I, Kiel, 
Germany
Contact E-Mail Address: n.mishra@ikmb.uni-kiel.de
Introduction: Biologics targeting tumor necrosis factor α (TNFα) are suc-
cessfully used to treat chronic immune mediated diseases including in-
fl ammatory bowel disease (IBD). However, the utility of these therapies 
is signifi cantly impacted by high primary and secondary non-response 
rates. Hence, it is crucial to fi nd biomarkers that could predict therapeutic 
response before or in the initial stages of the treatment. Here, we aim to 
understand the dynamic molecular changes that lead to remission in IBD 
patients newly receiving anti-TNFα therapy.
Aims & Methods: In total 14 biologic-naïve IBD patients, who underwent 
fi rst time anti-TNFα treatment with infl iximab, were recruited into a mo-
lecular medicine study with a dense sampling scheme at the University 
Hospital Kiel for hypothesis generation and 45 patients for confi rmation of 
fi ndings. Clinical response was assessed using symptom based clinical dis-
ease scores (HBI/MAYO) and endoscopy. In the hypothesis generation co-
hort, 7 patients attained remission within a time frame of 14 weeks. Whole 
blood from the patients before and 4, 24, 72 hours, 2, 6 and 14 weeks aft er 
therapy was collected. RNA and DNA isolated from the 98 blood samples 
were used for systematic multi-OMICS profi ling including RNA sequencing 
and DNA methylation profi ling by EPIC arrays, respectively.
Results: We found that target engagement of anti-TNFα led to fast and 
drastic downregulation of overall gene expression in the whole blood 
transcriptome irrespective of therapy outcome. Pairwise comparisons and 
impulse-modelling identifi ed a higher number of diff erentially expressed 
genes in patients who later attained remission. Co-expression analysis 
identifi ed gene modules involved in innate immune response and infl am-
matory response showing diff erent expression profi les in remission and 
non-remission groups. These modules were characterized by decrease in 
expression in the early timepoints (24h to 2 weeks) in the remission group. 
763 out of 3889 remission associated genes correlated signifi cantly with 
diff erentially methylation variable positions (MVPs), indicating a potential 
epigenetic control of remission-associated gene modules. The identifi ed 
methylation sites were enriched for binding motifs of transcription factors 
related to immune and infl ammatory processes such as BATF, NFKB, STAT3 
and CEBPB. Selected pairs of diff erentially expressed transcripts and MVPs 
were verifi ed in a confi rmatory cohort of 45 IBD patients receiving fi rst 
time treatment with infl iximab or vedolizumab, demonstrating overlap-
ping and unique signals between biologics.
Conclusion: We show that successful induction of remission through anti-
TNFα therapy drastically alters the whole blood transcriptome and methy-
lome in the fi rst 2 weeks during therapy initiation. Our results suggest that 
transcriptional changes associated with remission are highly dynamic in 
nature and might be partially regulated by epigenetic mechanisms. The 
contrast of gene modules integrated across Omics-layers can be used to 
decipher predictive molecular signatures of remission. Further clinical 
studies are required to evaluate the utility of such signatures for clinical 
decisions between continuation of therapy and early switching to other 
MOA.
Disclosure: Nothing to disclose 
145Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
1) objective signs of infl ammation on the 1st MRI, 
2) the second MRI performed to assess therapeutic effi  cacy, 
3) follow-up > 6 months and no surgery between the two MRI.
All the patients underwent MRI assessing the small bowel and the colon 
using a standardized protocol (no bowel cleansing the day before and no 
colonic distension). Complete transmural healing was defi ned as normal-
ization of MRI. Partial transmural healing was defi ned as a decrease of 
at least 25 % of Clermont score or MaRIA in each active segment. Results 
were expressed as Hazard Ratio (HR) and 95% confi dence interval [95% 
CI].
Results: Overall, 443 patients undergoing 889 MRI were screened for the 
study. Among them 274 patients were included (mean age 33.1 ± 15.8 
years, median CD duration = 7.0 [2.013.0] years, 36.4 % smokers, 31.4 % 
prior intestinal resection, L1 = 51.5 %, L2 = 5.5 % and L3 = 43.1 %, 25.9 % 
perianal lesions, 35,4 % stricturing CD and 31.0 % fi stulizing CD). At the 
time of the second MRI, the patients received one or several medications 
among: steroids (6.3 %), immunosuppressants (45.2 %), antiTNF agents 
(65.7 %) or ustekinumab (2.6 %). The median interval between the 2 IRM 
was 9.2 months [6.0 - 14.1].
Overall, 53 patients had a CD-related bowel resection, 72 patients (26.3 
%) required CD-related hospitalization and 163 patients (59.5 %) needed 
therapeutic intensifi cation (median follow-up = 14.9 mois [4.3 - 31.4]). In 
multivariate analysis (Cox model), complete or partial transmural healing 
was associated with reduced risk of surgery (HR = 0.13 [0.05 - 0.38] ; p < 
0.001), of subsequent hospitalization (HR = 0.25 [0.11- 0.56] ; p = 0.001) 
and therapeutic intensifi cation (HR = 0.08 [0.03 - 0.20] ; p < 0.001). Com-
plete transmural healing showed a lower risk of therapeutic intensifi cation 
compared to partial transmural healing (p < 0.05).
Conclusion: Transmural healing assessed using MRI scores is associated 
with favourable outcomes in patients with CD and should be used as ther-
apeutic target both in daily practice and clinical trials.
Disclosure: Nothing to disclose 
OP273 MOLECULAR TRAJECTORIES OF REMISSION IN 
BIOLOGICS THERAPY OF IBD: PRIVATE DRUG SPECIFIC-SIGNATURES 
VS. COMMON TRANSCRIPT MODULES
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Introduction: Infl ammatory bowel disease (IBD) is characterized by inad-
equate destructive immune responses fueled by a complex dysregulation 
of the mucosal cytokine network. Targeted therapies block pivotal patho-
physiological principles (e.g. cytokines, signalling, leukocyte adhesion). 
Currently, no biomarkers for predicting or defi ning molecular remission 
across therapies are available, although it can be assumed that disease 
control with mucosal healing -regardless of the drug-specifi c MOA- is 
characterized by a shared molecular signature across therapies. Currently, 
the dynamics of shared gene expression networks (e.g. remodelling of 
extracellular matrix, epithelial regeneration) associated with molecular 
remission is unclear. A blueprint of unifying principles of molecular re-
mission is needed to disentangle drug-specifi c immunological network 
alterations associated with existing and novel compounds. The aim of this 
study thus was to identify a drug-independent core expression signature 
in mucosal biopsies that might be applicable for an early prediction of 
molecular remission.
Aims & Methods: Patients with IBD that were treated with various bio-
logics, including anti-TNFa (Infl iximab, IFX), a4b7-integrin antagonist 
(Vedolizumab, VDZ) were enrolled into a prospective clinical and molecu-
lar characterization program with multiple planned endoscopies (up to 
10 endoscopies over 14 weeks) and RNASeq from intestinal biopsies. In 
addition, Additional data were included from Phase IIa molecular medi-
cine following the same setup and clinical trial in which Olamkicept (OLA), 
a sgp130Fc fusion protein specifi cally inhibiting the IL-6 trans-signaling 
pathway was administered open label. In all cases, biopsies from the sig-
moid colon were collected before (0h) and at several time points (+4h, 
+24h, 2 weeks, 6 weeks, and 14 weeks) aft er drug exposure. In total 55 
patients were analyzed (UC: 29, CD: 26) and were exposed to the following 
biologic therapies (IFX: 19, VDZ: 20, OLA: 16). 36% of patients achieved 
clinical remission, whereas 21% were clear failures
Results: All investigated biologic treatments downregulated genes starting 
at 2 weeks aft er treatment. Importantly, this downregulation preceded the 
attenuation of clinical response parameters (HBI, Mayo). The majority of 
early downregulated genes were highly drug-specifi c and showed little 
overlap between the diff erent biologic treatments; with only 1% of down-
regulated genes being shared amongst treatments at week 2, 2% at week 
6, while at week 14 21% of all downregulated genes detected were shared 
between one or more treatments.
We identifi ed a core set of eight diff erentially expressed genes, which were 
downregulated in mucosal tissues at week 14 in all remission patients in a 
drug-independent manner. These genes comprised e.g. Toll-like receptor 
2 (TLR2), chemokine receptor 2 (CXCR2) and a cytokine receptor (CSFR). 
Importantly, using this 8-gene score, we were able to defi ne a threshold 
of the dynamic behavior of the marker set that was able to predict clinical 
remission status already at week 2.
Conclusion: Our data indicate that diff erent biologic therapies produce 
private transcriptomal signatures. However, changes also comprise drug-
independent longitudinal changes of specifi c transcript modules, which 
were already detectable at an early timepoint (i.e. week 2) and were pre-
dictive of clinical remission at week 14. A prospective multicenter clini-
cal study is ongoing to evaluate whether this information can be used to 
develop a “treat and test” strategy to decide already at early timepoints of 
exposure, which therapy is best for a patient.
Disclosure: Nothing to disclose 
OP274 INTEGRIN EXPRESSION CHANGES ON THE T CELL SUBSETS 
INFLUENCE THE RESPONSE TO VEDOLIZUMAB IN INFLAMMATORY 
BOWEL DISEASE PATIENTS
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Introduction: Vedolizumab is a gut-selective alpha4beta7 integrin inhibitor 
approved for the treatment of Ulcerative Colitis (UC) and Crohn’s disease 
(CD). The exact mechanism of action remains to be unraveled and there 
is no consensus whether the response to vedolizumab is associated with 
integrin expression profi les of the innate, adaptive immunity or both. Re-
sponse prediction to vedolizumab is particularly relevant since it is a rather 
slow-acting molecule.
Aims & Methods: We investigated whether baseline levels and/or early 
changes in the integrin-expressing T cell subsets during the induction 
phase can predict the response to vedolizumab in infl ammatory bowel 
disease (IBD) patients. 
In this prospective multi-centric study, 71 patients with CD (n=28) or UC 
(n=43) with moderate-to-severe disease were included at the start of ve-
dolizumab treatment. The response to vedolizumab was determined on 
a clinical, biochemical and endoscopic level at the end of the induction 
phase (week (W)14). The clinical response was defi ned as a drop in the 
Harvey Bradshaw index (HBI) of at least 3 points for CD and a reduction 
in Mayo score of at least 3 points with no rectal bleeding for UC. The bio-
chemical response was defi ned as a 50% reduction of CRP or when the 
CRP normalized (< 10 mg/l) for CD and a 50% reduction or normalization 
(< 250mg/g) of calprotectin for UC. The endoscopic response was evalu-
ated positive when there was a drop of at least 1 point in the SES-CD score 
for CD or the endoscopic Mayo score for UC. During the induction phase, 
peripheral blood mononuclear cells (PBMCs) were collected at W0, W2, 
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change shows an extensive perturbation of microbial metabolic coopera-
tivity, which discriminates between anti-TNFα remitter and non-remitter. 
Inferred microbial metabolite exchange indicates e.g. altered inter-micro-
bial metabolism of SCFA. Stool metabolomics validated increased butyrate 
to be associated with remission status.
Conclusion: We show that anti-TNFα treatment increases the gut microbial 
diversity and coupling of cross-feeding metabolic interactions towards the 
state of healthy individuals. Assessment of metabolic interactions in re-
sponders and non-responders to therapy may identify predictive microbial 
metabolite markers as well as aid our understanding how the intestinal 
microbiota modulates therapy outcome in IBD.
Disclosure: Konrad Aden has received funding from Pfi zer to execute parts 
of this study. The grant did not aff ect study design at any time point. All 
other authors have nothing to disclose 
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OP276 AGE, OVERWEIGHT AND INITIAL CYST SIZE ARE 
ASSOCIATED WITH THE RISK OF PROGRESSION OF BD-IPMN 
UNDERGOING FOLLOW-UP
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Introduction: Current guidelines do not suggest personalizing the follow-
up of BD-IPMN without suspicious signs of malignancies according with 
their initial features of with patients’ characteristics. Furthermore, the 
need to maintain follow-up (FU) in the long-term is debated.
Aims & Methods: To investigate the occurrence of progression of the cys-
tic lesions and of Worrisome Features (WF) constituting a relative indica-
tion for surgery and analyse factors associated with them in a prospective 
cohort of IPMN-BD under FU. Data on BD-IPMNs diagnosed 2003-2017, 
without any indication for surgery at diagnosis and under FU in two insti-
tutions, were input in a prospective database containing initial patients’ 
and cysts’ characteristics. The primary outcome was the progression of 
the cyst defi ned as either an increased cyst’s size (>2 mm), development 
of a new cyst or appearance of any indication for surgery. Occurrence of 
WF was separately considered as a secondary outcome. Fisher test and 
Student’s t-test were used to analyze categorical and continuous variables. 
Survival probability was calculated with the Kaplan-Meier curve and Cox 
analysis employed to calculate hazard ratios (HR). A p< 0.05 was consid-
ered statistically signifi cant.
Results: Of 530 BD-IPMN with mean age of 65.2 years, 62.4% were female, 
54.7% were multifocal and the initial mean size of the largest cyst was 14.3 
mm. The mean length of FU was 58.9 months. 32 deaths were recorded, of 
which 3 pancreas-related. 265 patients had any progression (50%) and 82 
(15.5%) developed WFs or HRS; 13 patients were operated (2.8%) of whom 
5 had a carcinoma. The rate of progression and occurrence of WFs were 
101.9/1000 p-y and 31.5/1000 p-y. The mean time to any progression was 
43.7 months and the mean time to WFs was 54.2 and 14% of patients de-
veloped the fi rst progression event and 4.5% WF or HRS aft er 60 months. A 
ROC curve identifi ed the cut-off  of 15 mm as best discriminator of progres-
sion (sensitivity 67.9%, specifi city 44.5%) and of WF/HRS appearance (sen-
sitivity 64.6%, specifi city 67.2%). In a multivariate Cox regression analysis, 
among initial patients’ and cysts’ characteristics: age (HR 1.01 per year; 
95%CI 0.99-1.02; 0.060), BMI>25 (HR=1.32; 95%CI 1.02-1.71; 0.030), and 
cyst diameter >15mm (HR 1.32; 95%CI 1.03-1.69; 0.025) were associated 
with any progression. Only age (HR 1.026; 95%CI 1.00-1.048; 0.022) and 
W6, W10 (only CD) and W14, before vedolizumab administration. Variation 
between the diff erent centers was reduced by isolating the cells 6h aft er 
blood collection. The PBMCs were analyzed by fl ow cytometry to evaluate 
the CD4+/CD8+ Alpha4Beta7+, Alpha4Beta1+, AlphaEBeta7+ and Alpha-
EBeta1+ T cell populations. Based on the distribution of the data, statistics 
were performed by an independent sample t-test or a Mann-Whitney U 
test.
Results: The fl ow cytometry analyses revealed that only the CD4+ Alpha-
4Beta7+ T cell subset at baseline was signifi cantly increased in UC patients 
with a favorable clinical (P= 0.042), biochemical (P=0.025) and endoscopic 
response (P= 0.054). This was not the case in CD. In CD, the baseline num-
ber of CD4+ Alpha4Beta1+ T cells was lower in clinical (P= 0.094) and 
biochemical responders (P= 0.004). In addition, lower baseline CD4+ Al-
phaEBeta1+ T cells and the CD8+ AlphaEBeta1+ T cells were also associated 
with a biochemical response in CD (P= 0.032 and P= 0.025), respectively. 
No other signifi cant baseline or delta change diff erences were identifi ed 
between the responders and non-responders in the other investigated T 
cell subsets in both UC and CD.
Conclusion: This prospective cohort study showed that in UC patients, clini-
cal, biochemical and endoscopic response to vedolizumab treatment is as-
sociated with a high number of CD4+ Alpha4Beta7+ T cells in circulation 
at baseline. In CD patients, the relationship is less clear and the response 
is rather linked to a low number of Beta1+ T cells. A second cohort is be-
ing recruited to confi rm our fi ndings. The fi nal aim is to build a predictive 
model that is feasible for use in clinical practice.
Disclosure: Support provided by Takeda. 
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Introduction: An impaired interplay of the mucosal immune system and 
gut microbiota plays a critical role in the pathogenesis of human chronic 
infl ammatory bowel disease (IBD).The impact of targeted cytokine block-
ade on intestinal microbial communities is still poorly understood. Here, 
we investigate the eff ect of anti-TNFα treatment on gut microbial com-
munity structure and functional properties in a prospective, longitudinal 
two-step study. We correlate our fi ndings to therapeutic outcome and in-
vestigate fecal metabolite patterns associated with microbiota shift s upon 
therapy initiation.
Aims & Methods: We recruited two cohorts of patients initiating anti-TNFα 
therapy. Cohort #1 included IBD (n=12) and rheumatic disease (RD; n=17) 
patients who were exposed to anti-TNFα therapy were enrolled for longi-
tudinal stool sampling at baseline and 2, 6 and 30 weeks aft er therapy in-
duction. Specifi city of the fi ndings was assessed in an independent cohort 
#2 of 23 IBD patients (13 UC, 10 CD) treated with anti-TNFα or anti-α4β7 
integrin. Intestinal microbial community structures were studied by V3-
V4 16S rRNA gene amplicon sequencing. In-silico analysis of metabolic 
interactions among microbial species were performed to identify key me-
tabolites indicative of clinical remission status. Stool metabolomics was 
performed in a subset of samples to validate functional predictions associ-
ated with therapy outcome.
Results: anti-TNFα treatment restores microbial diversity in IBD patients, 
but not RD patients. Assessment of microbial diversity indices is not suit-
able for the diff erentiation between remission and non-remission status 
in IBD patients. In contrast, in-silico analysis of microbial metabolite ex-
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initial cyst diameter>15mm (HR 3.35; 95%CI 2.12-5.30; < 0.0001) were as-
sociated with development of WFs or HRS during follow-up. Sex, smoking, 
family history of any cancer or of pancreatic cancer, alcohol intake and 
multifocal cysts were not associated with progression risk, while previous 
diabetes was signifi cant only at the univariate analysis.
Conclusion: In this cohort of BD-IPMNs, the rate of progression and of 
occurrence of WFs were 10% and 3% per year. A quote of these events 
occurred aft er 5 years of negative FU. Age, overweight and initial cyst 
size>15mm are predictors of progression. These data support the role of 
metabolic factors in determining progression of BD-IPMNs and off er the 
opportunity to tailor follow-up intervals based on simple criteria available 
at diagnosis.
Disclosure: Nothing to disclose 
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Introduction: Oxaliplatin-based regimens have shown promising antitu-
mor activity in digestive neuroendocrine tumors (NETs), however the avail-
able data are limited. Our aim was to assess the tumor response and sur-
vival in a large series of patients treated with oxaliplatin and 5-fl uorouracil 
(FOLFOX) for advanced digestive NETs.
Aims & Methods: All patients with advanced well-diff erentiated digestive 
NETs treated with at least 3 cycles of FOLFOX between 2004 and 2018 in 
12 centers of the French GTE, were retrospectively included. Best response 
according to the RECIST 1.1 criteria, progression-free survival (PFS) and 
overall survival (OS) were evaluated. The prognostic factors for PFS were 
investigated by multivariate analysis using a Cox proportional hazard 
model including variables with a p value ≤ 0.20 in univariate analysis.
Results: One hundred and forty-nine patients were included. Primary tu-
mor location was pancreas (n=88), small intestine (n=37), stomach (n=7), 
rectum (n=4) and unknown without lung tumor at CT scan (n=13). Par-
tial response rate was of 31% for pancreatic NETs, 13% for small intestine 
NETs, 14% for gastric NETs, 25% for rectal NETs and 38% for unknown 
primary NETs. Median PFS were, respectively, 9, 9, 14, 4 and 6 months, and 
median OS were 30, 28, 31, 25 and 15 months. Signifi cant poor prognostic 
factors for PFS aft er FOLFOX in digestive NETs were: progressive disease 
(HR=2.5, p=0.018), hepatic involvement > 50% (HR=1.8, p=0.009), prior 
targeted therapy (HR=1.5, p=0.048) and rectal primary tumor (HR=4.2, 
p=0.01). Among pancreatic NETs, the 9 insulinomas had a 22 months PFS 
versus 9 months for the others (p=0.025), and serum glucose normaliza-
tion was obtained in 8 out of 9 cases.
Conclusion: FOLFOX has a promising clinical activity, especially in insuli-
nomas.
Disclosure: Nothing to disclose 
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Introduction: Although ERCP is the reference standard, the optimal ap-
proach to effi  cient treatment of diffi  cult bile duct stones is not standard-
ized. While single operator cholangioscopy-guided laser lithotripsy (SOC-
LL) and large balloon sphincteroplasty (LBS) are eff ective rescue tech-
niques, their precise roles in the treatment algorithm is unclear.
Aims & Methods: To evaluate the role of SOC-LL and LBS for the treatment 
of diffi  cult bile duct stones.
Patients with diffi  cult bile duct stones were randomized to undergo SOC-
LL or LBS. Diffi  cult bile duct stones were defi ned as stones (≥12mm) that 
failed retrieval attempts using balloons or baskets and required advanced 
interventions. The main outcome measure was procedural effi  ciency de-
fi ned as the ability to achieve ductal clearance without the need to cross-
over to alternate treatment modality or require adjunctive mechanical 
lithotripsy. The secondary outcome measure was treatment costs.
Results: 66 patients were randomized equally to either cohort over a 2-year 
period. There was no signifi cant diff erence in stone size (median, 15mm 
[IQR 12-18] vs. 14mm [IQR 12-15], p=0.097), number of stones (median, 3 
[IQR 1-4] vs 3 [IQR 1-4, p=0.92]) or stone-duct size ratio (stone size/diam-
eter of distal common bile duct in mm; median, 1.5 [IQR 1.0-1.8] vs. 1.3 [IQR 
1.0-1.3], p=0.098) between the SOC-LL and LBS cohorts, respectively. More 
patients randomized to LBS required mechanical lithotripsy (33.3 vs. 3.0%, 
p=0.001) or cross-over to SOC-LL (27.3 vs. 6.1%, p=0.021) to achieve ductal 
clearance. On multivariate logistic regression analysis, aft er adjusting for 
patient demographics, stone characteristics and procedure details, not us-
ing SOC-LL (OR 13.5 [95% CI, 3.11-58.4], p=0.001) and stone-duct size ratio 
≥1.2 (Odds ratio (OR) 5.0 [95% CI, 1.21-20.6], p=0.026) were signifi cantly 
associated with procedural ineffi  ciency. Although the procedural cost for 
SOC-LL was higher, there was no signifi cant diff erence in total treatment 
costs between cohorts by generalized linear models (SOC-LL $16,684 vs. 
LBS $10,626; p=0.097).
Conclusion: When standard maneuvers fail, utilizing SOC-LL for the treat-
ment of diffi  cult bile duct stones should be the preferred fi rst-line ap-
proach, particularly when size of the stone exceeds that of the distal bile 
duct.
Disclosure: Ji Young Bang, Shyam Varadarajulu and Robert Hawes are 
Consultants for Boston Scientifi c Corp. and Olympus America Inc. 
OP279 EUS-DIRECTED TRANSGASTRIC ERCP (EDGE) VS 
LAPAROSCOPIC ASSISTED ERCP (LA-ERCP) VS ENTEROSCOPY 
ASSISTED ERCP (E-ERCP): A SINGLE CENTER EXPERIENCE
Mohy-ud-din N.1, Carleton N.2, Syed A.3, Antoury C.2, Kulkarni A.2, 
Farah K.2, Dhawan M.2, Thakkar S.4, Kochhar G.5
1Allegheny Health Network, Medicine Institute, Pittsburgh, United States, 
2Allegheny Health Network, Pittsburgh, United States, 3Allegheny Health 
Network, Gastroenterology, Pittsburgh, United States, 4Allegheny Health 
Network, Gastroenterology, Sewickley, United States, 5Allegheny Health 
Network, Gastroenterology & Hepatology, Pittsburgh, United States
Contact E-Mail Address: drkochhar@gmail.com
Introduction: EUS-directed Transgastric ERCP (EDGE) is a novel technique 
for managing pancreaticobiliary diseases in patients with a history of 
Roux-en-Y Gastric Bypass (RYGB). Laparoscopic-assisted ERCP (LA-ERCP) 
and Enteroscopy-assisted ERCP (E-ERCP) are the current standard of care 
and these procedures can be challenging with limited success.
Aims & Methods: The aim of this study was to compare outcomes of EDGE, 
LA-ERCP and E-ERCP at a single tertiary-care academic center. Patients 
with a history of RYGB who underwent these procedures between Janu-
ary 2015 and March 2019 were included. Patient demographics, procedure 
time, technical success and complications of each group were recorded. 
Technical success was defi ned as cannulation of the intended duct. ‘Dif-
fi culty of procedure’ was defi ned as level of diffi  culty documented by per-
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Under EUS-guidance, the left  and right PVs were identifi ed. Aft er verifying 
fl ow signal by Doppler, a 19-gauge EUS-FNA needle was advanced trans-
hepatically into the portal vein and two sets of 9 ml aliquots of blood 
were aspirated. The puncture site was then be monitored under EUS for 
3 minutes to observe for any bleeding before the needle was withdrawn. 
Epithelial-derived CTCs were sorted magnetically based on expression of 
epithelial cell adhesion molecules. Only those with a proper morphology 
and found to be CD45 negative and positive for cytokeratins 8 and 18 were 
considered to be CTCs.
Results: This prospective, single-centre study was performed in the Prince 
of Wales Hospital in Hong Kong between December 2016 and March 2019. 
56 patients with stage 2 and 3 colorectal carcinomas were recruited. Tech-
nical success was 100% and none of the patients suff ered from adverse 
events. The colonic tumors were located in the ascending colon (11%), 
transverse colon (11%), descending colon (7%), sigmoid colon (50%), rec-
tum (21%). 85% of the patients had T2 and T3 tumours and 42.9% were 
node positive. CTCs were obtained in 80.5% of the PVA and 37.5% in pe-
ripheral blood. The mean (S.D.) of CTCs obtained by EUS-guided PVA was 
signifi cantly higher than that in peripheral blood samples [154.6 (213.4) vs 
6.78 (11.2), P< 0.0001].
Conclusion: This study has shown that EUS-guided PVA to be a safe, fea-
sible and eff ective method in collecting CTCs for enumeration and charac-
terisation in colonic cancer. More CTC’s were obtained from the portal vein 
and the numbers were signifi cantly higher than that of peripheral blood. 
Further studies are required to be performed to evaluate its potential as 
a prognostic marker for survival and liver metastasis in colorectal cancer 
patients.
References: 1. Cristofanilli M, Budd G, Ellis M et al. Circulating Tumor Cells, 
Disease Progression, and Survival in Metastatic Breast Cancer. New Eng-
land Journal of Medicine. 2004;351(8):781-791. doi:10.1056/nejmoa040766 
2. Catenacci D, Chapman C, Xu P et al. Acquisition of Portal Venous Cir-
culating Tumor Cells From Patients With Pancreaticobiliary Cancers by 
Endoscopic Ultrasound. Gastroenterology. 2015;149(7):1794-1803.e4. 
doi:10.1053/j.gastro.2015.08.050
Disclosure: Nothing to disclose 
OP281 CLINICAL IMPORTANCE OF COLONOSCOPY IN PATIENTS 
WITH EARLY GASTRIC CANCER TREATED BY ENDOSCOPIC 
SUBMUCOSAL DISSECTION (COMPARISON WITH PATIENTS WITH 
POSITIVE FECAL IMMUNOCHEMICAL TEST RESULTS)
Yamaguchi Y., Ebi M., Tashiro T., Yamamoto K., Ozeki T., Sugiyama T., 
Adachi K., Hijikata Y., Ogasawara N., Funaki Y., Sasaki M., Kasugai K.
Aichi Medical University School, Department of Gastroenterology, Nagakute, 
Japan
Contact E-Mail Address: twist619@me.com
Introduction: Second primary cancers are a leading cause of morbidity and 
mortality among cancer survivors all over the world. Colorectal neoplasms 
are the most commonly observed tumors in patients with gastric cancer.
Aims & Methods: We examined the usefulness of colonoscopy (CS) for pa-
tients undergoing gastric endoscopic submucosal dissection (ESD). Of the 
312 patients who underwent ESD for early gastric cancer in the 3 years 
between January 2015 and December 2017, 143 patients receiving CS were 
included (ESD group) in this study. And 874 asymptomatic patients who 
underwent CS because of positive fecal immunochemical test (FIT) during 
the same period were selected (FIT group). Propensity score matching was 
used to adjust baseline characteristics (BMI, alcohol, smoking, diabetes 
mellitus, hypertension, hyperlipidemia, liver disease, renal failure and 
other organs cancer) between two groups. In this study, we compared with 
the background of two groups and statistically analyzed.
Results: The total number of colorectal neoplasm were found in 90 cases 
(62.9%) in the ESD group, on the other hand, 81 cases (56.6%) in the FIT 
group (p=0.012). Advanced adenoma and carcinoma (AAC) were found 30 
cases (20.1%) of ESD group and 16 cases (11.2%) of FIT group (p< 0.01).
Conclusion: In patients undergoing gastric ESD, CS appears to be necessary 
for detecting synchronous double neoplasms.
Disclosure: Nothing to disclose 
forming endoscopist or defi ned as diffi  cult if there was performance of 
precut sphincterotomy or >2 failed attempted cannulations of intended 
duct. Statistical analysis was performed using SPSS 23 (IBM, Armonk, NY).
Results: Forty-eight patients (18 EDGE, 19 LA-ERCP and 11 E-ERCP) were 
included in this study. Mean procedure time for EDGE patients was 72 ± 
27 minutes, compared to 150 ± 58 and 108 ± 39 minutes for LA-ERCP and 
E-ERCP, respectively (p= < 0.01). The diffi  culty level was recorded as ‘not 
diffi  cult’ for 100% (18/18) of EDGE procedures, compared to 79% (15/19) for 
LA-ERCP and 45% (5/11) for E-ERCP patients (p=< 0.01). Technical success 
for EDGE was 100% (18/18) compared to 89% (17/19) and 82% (9/11) for LA-
ERCP and E-ERCP, respectively (p=0.21). While none of the EDGE patients 
developed post-procedure pancreatitis, this was observed in 5% (1/19) of 
LA-ERCP and 9% (1/11) of E-ERCP patients (p=0.47). The hospital length of 
stay was shorter for EDGE patients at 1.09 days, compared to 2.35 and 3.47 
days for LA-ERCP and E-ERCP, respectively (p=0.04).
  EDGE (n=18) LA-ERCP (n=19) E-ERCP (n=11) p-value
Age (mean) 61.78 +/- 11 61.52 +/- 13 68 +/- 16 0.39
Gender (F) 78% (14) 68% (13) 64% (7) 0.69
Indications:       0.96
Choledocholithiasis 39% (7) 68% (13) 27% (3)  
CBD Dilation 28% (5) 0% (0) 9% (1)  
PD Dilation 11% (2) 0% (0) 0% (0)  
Biliary leak/sludge/stricture 28% (5) 0% (0) 27% (3)  
Cholangitis 0% (0) 5% (1) 18% (2)  
Pancreatitis 0% (0) 11% (2) 18% (2)  
Papillary stenosis 0% (0) 5% (1) 0% (0)  
[Baseline Characteristics of patients]
Conclusion: Our study indicates that EDGE is characterized by signifi cantly 
shorter procedure time and lower rates of procedural diffi  culty when com-
pared to LA-ERCP and E-ERCP. We also observed non-statistically signifi -
cant trend towards superior safety and effi  cacy profi le of EDGE.
Disclosure: Nothing to disclose 
Risk assessment, diagnosis and management 
in colon cancer
16:00-17:30 / Barcelona
OP280 EUS-GUIDED PORTAL VENOUS BLOOD ACQUISITION 
FOR CIRCULATING TUMOUR CELLS IN PATIENTS WITH COLORECTAL 
CANCER
Chan J.H.Y.1, Wong C.S.C.2, Ng S.S.M.3, Mak T.1, Wong E.Y.K.4, Chan C.M.3, 
Teoh A.1
1Chinese University of Hong Kong, Surgery, Hong Kong, Hong Kong, China 
(SAR), 2Hong Kong Polytechnic University, Department of Health Technology 
and Informatics, Hong Kong, Hong Kong, China (SAR), 3Chinese University of 
Hong Kong, Hong Kong, Hong Kong, China (SAR), 4Hong Kong Polytechnic 
University, Hong Kong, Hong Kong, China (SAR)
Contact E-Mail Address: joeychan72@hotmail.com
Introduction: Analysis of circulating tumour cells (CTCs) has potential to 
be a prognostic marker for metastasis in diff erent types of cancer (1). As 
opposed to peripheral blood collection, the use of endoscopic ultrasound 
(EUS) to acquire portal venous blood (PVA) for circulating tumour cells 
(CTC) enumeration has only been described for pancreatic cancer. The role 
of EUS- PVA in enumerating CTC’s for other types of cancer is uncertain.
Aims & Methods: Hence, the aim of the current study is to perform a fea-
sibility study on EUS PVA for enumerating and characterising CTC’s in pa-
tients suff ering from colorectal cancers. We hypothesise that EUS-guided 
PVA is safe, feasible and eff ective in obtaining CTC. 
Patients suff ering from stage 2 to 4 colorectal carcinomas were recruited. 
Recruited patients had one 9 ml aliquots of peripheral blood collected at 
the same time of the EUS procedure. The patient then underwent EUS-PVA 
and two sets of 9 ml aliquots of portal venous blood were collected (PVB). 
During EUS-PVA, the liver was fi rst assessed for presence of occult me-
tastasis from the duodenum (right lobe) and also the stomach (left  lobe). 
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OP282 BACTERIAL ALTERATIONS IN POST-CHOLECYSTECTOMY 
PATIENTS ARE ASSOCIATED WITH COLORECTAL CANCER
Ren X.1,2, Xu J.1,3,4, Zhang Y.1,3, Zhang Y.2,5, Chen G.1,3, Huang Q.1,3, Liu Y.1,3
1Peking University People’s Hospital, Department of Gastroenterology, 
Beijing, China, 2Peking University People’s Hospital, Clinical Center of 
Immune-Mediated Digestive Diseases, Beijing, China, 3Clinical Center of 
Immune-Mediated Digestive Diseases, Peking University People’s Hospital, 
Beijing, China, 4Institute of Clinical Molecular Biology & Central Laboratory, 
Peking University People’s Hospital, Beijing, China, 5Peking University 
People’s Hospital, Department of Gastroenterology, Beijing, China
Contact E-Mail Address: vera_ren11@outlook.com
Introduction: Previous studies showed that cholecystectomy increased the 
enterohepatic recirculation rates and the secretion rate of bile acids, which 
made an increased exposure of the bile acid pool to gut bacteria. How-
ever, what kind of alteration aft er cholecystectomy in patients was unclear. 
Moreover, many meta-analyses also indicated inconsistent incidences of 
colorectal cancer (CRC) in patients aft er cholecystectomy. Thus, our study 
was to investigate the changes and roles of bacterial microbiota aft er cho-
lecystectomy and tried to clarify the clinical signifi cance of the changes.
Aims & Methods: 104 subjects were recruited for two groups, post-chole-
cystectomy patients (PC, n=52) and healthy controls (HC, n=52). 9 of PC pa-
tients had precancerous lesions and CRC (preCA_CRC), which confi rmed by 
colonoscopy mucosal pathology. The demographic data and basic clinical 
data of each group were recorded. Qualifi ed stool samples were collected 
for 16S rRNA gene V3-4 region amplicons seqencing to profi le the overall 
structure of the bacterial microbiota. Based on the Operational Taxonomic 
Units (OTUs), bacterial composition, functional annotation, and the cor-
relation with environmental factors were analyzed respectively.
Results: The species richness of gut bacterial microbiota was increased in 
PC patients, and the composition was quite changed. At the genus level, 
the abundance of Bacteroides, Parabacteroides which took part in bile acid 
metabolism and Prevotella which could promote infl ammation increased; 
the abundance of Faecalibacterium which participated in butyrate and 
short-chain fatty acids biosynthesis and Bi dobacterium which could in-
hibit infl ammation decreased. Megamonas funiformis and Lactobacillus 
mucosae were characteristic species which could distinguish PC patients 
from HC. Functional analysis showed that pathways in cancer, especially 
in CRC, were enriched in PC group. We collected about 10 kinds of indexes 
as environmental factors for correlation analysis with bacterial compo-
sition. Furthermore, the duration aft er cholecystectomy was the critical 
factor, which mainly aff ected the composition of the bacterial microbiota. 
Although there was no statistical diff erence, preCA_CRC patients had lower 
species richness than the subjects of the cancer-free patients aft er chole-
cystectomy. The abundance of Sutterella and Flavonifractor, two protective 
genera further decreased in preCA_CRC patients, additionally, the abun-
dance of Megamonas funiformis was signifi cantly negatively correlated 
with the progression of CRC.
Conclusion: Our study showed a specifi c alteration in PC patients, and the 
duration aft er cholecystectomy was the critical factor which aff ected the 
bacterial composition. Megamonas funiformis was not only the characteris-
tic species of PC patients, but also associated with the progression of CRC. 
These fi ndings suggest that it is necessary to pay more attention to the 
long-term follow-up of PC patients, and Megamonas funiformis may play a 
pivotal role in related-disease studies.
Disclosure: Nothing to disclose 
OP283 COLORECTAL CANCER DRIVES LOSS OF SIRP ALPHA AND 
INCREASED CD103 ON LAMINA PROPRIA DENDRITIC CELLS IN 
MACROSCOPICALLY HEALTHY COLONIC MUCOSA: A PATHWAY FOR 
IMMUNE EVASION?
Pring E.1,2, Durant L.3, Noble A.3, Gould L.4, Fletcher J.4, Dilke S.3, 
Malietzis G.5, Athanasiou T.2,6, Jenkins J.T.7, Knight S.C.8
1St Mark’s Hospital and Imperial College London, Surgery and Cancer, 
London, United Kingdom, 2BiCyCLE Research Group, Imperial College, 
London, United Kingdom, 3Imperial College, London, United Kingdom, 4St 
Mark’s Hospital, London, United Kingdom, 5St. Marks Hospital, Surgery, 
London, United Kingdom, 6Imperial College St Mary’s Hospital, London, 
United Kingdom, 7St Marks Hospital, London, United Kingdom, 8Imperial 
College London, Immunology, London, United Kingdom
Contact E-Mail Address: etpring@doctors.org.uk
Introduction: Dendritic cells (DC) are the major antigen presenting cells 
of the immune system and orchestrate downstream cellular immune 
responsesorchestrate the cellular immune response. Within the colonic 
mucosa, DC populations can be subdivided based on expression of SIRP-
alpha (CD172a) and CD103 (alpha E integrin). SIRP-alpha inhibits Fc recep-
tor mediated functions in cells bearing its receptor (CD47) and in doing 
so recognises the CD47 expressing cell as “self”. SIRP-alpha expressed on 
myeloid cells (DCs and macrophages), via the CD47/SIRP-alpha axis, plays 
an essential role in “self” recognition, protecting healthy cells from phago-
cytosis. 
CD103 is a mucosal tissue marker and CD103+DC play a vital role in main-
taining intestinal immune homeostasis by promoting protective immune 
responses, including upregulation of gut-homing markers on T cells thus 
inducing a “tolerogenic” immune response. CD103 expressing DCs are re-
sponsible for upregulating CCR9 and α4β7 - cell surface markers on T cell 
subtypes essential for homing to mucosal surfaces including the gut.
Aims & Methods: The aim of this study was to explore the eff ect colorectal 
cancer has on this important immunological axis in the gut and in doing 
so identify a further pathway by which cancer evades the immune system.
Colonic biopsies were taken from macroscopically healthy mucosa in 
disease free subjects (n=12) at colonoscopy and colorectal cancer (CRC) 
patients (n=8) at the time of surgery. Lamina-propria leucocytes were 
isolated by enzymatic tissue digestion which was performed in a two 
stage process with DTT and EDTA followed by collagenase and liberase. 
Cell surface staining was performed using fl uorochrome antibodies for 
SIRP-alpha and CD103. Expression of SIRP-alpha and CD103 on DCs was 
examined by fl ow cytometry.
Results: Proportions of CD103-veSIRPa+ve and CD103+SIRPa+ DC popu-
lations were signifi cantly reduced in the CRC group (p< 0.0001 and p< 
0.0002) whilst CD103+veSIRPa-ve and CD103-veSIRPa-ve DC populations 
were signifi cantly increased in the CRC group (p< 0.0015 and p< 0.0001).
Conclusion: Many cancers themselves highly express CD47 which allows 
evasion of the cellular immune response. Herein we demonstrate changes 
to DC signalling in cancer perhaps reducing an appropriate aggressive re-
sponse to CRC by loss of SIRP-alpha expression. Notably these immuno-
logical changes are taking place in what appears “healthy” bowel tissue 
away from the tumour site.
Disclosure: Nothing to disclose 
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OP286 DEVELOPMENT AND VALIDATION OF A PATIENT 
REPORTED OUTCOME MEASUREMENT IN ACUTE PANCREATITIS: 
THE PAN-PROMISE STUDY
de-Madaria E.1, Sánchez-Marin C.1, Carrillo I.2, Chooklin S.3, Mejuto R.4, 
Mauriz V.4, Márta K.5, Hegyi P.6, Barbu S.7, Lauret-Braña E.8, Gomes A.P.9, 
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Contact E-Mail Address: madaria@hotmail.com
Introduction: The development of clinical trials in acute pancreatitis (AP) 
is limited by the absence of adequate outcome variables. Organ failure 
(OF) and mortality are infrequent, so thousands of patients are needed to 
detect diff erences among treatment arms. Despite being the patients the 
center of the medical act, their assessment is rarely considered.
Aims & Methods: PAN-PROMISE aims to develop and validate a Patient Re-
ported Outcome Measurement scale (PROMS) in AP. Reliability, content va-
lidity, apparent, construct and empirical validity indexes were calculated. 
Firtsly, a qualitative study was carried out in patients and gastroenterolo-
gists from 2 centers; 7 symptoms were retrieved and the PROMS instrument 
was designed (PROMISE scale). 
Aft erwards, an international prospective multicenter cohort (29 centers 
from 15 countries, 527 patients) was performed to validate the instrument. 
PROMISE scale was measured in the 1st 24h, 48h, 5th and 7th day, at dis-
charge and 15d aft er discharge.
Results: The 7 items of PROMISE are grouped into a coherent measure 
giving rise to a single dimension with factor saturations of the items that 
exceed the minimum of 0.50: between 0.63 and 0.75, explained variance 
45.1% in the mild cases and 0.57-0.73, variance explained 43.3% in the 
moderate-to-severe cases. The internal consistency of the relationships 
between the items exceeds the degree of adjustment required for a new 
instrument of this type: Cronbach’s Alpha= 0.77 in mild cases and 0.76 in 
moderate-to-severe. The stability of the measurement calculated by test-
retest (at discharge and 15d aft er discharge) confi rms the reproducibility of 
the measurement with values  in the Student’s T statistic without statistical 
signifi cance, p> 0.05 (the clinical improvement at discharge is sustained 
aft er an adequate temporary period). The total PROMISE score was directly 
related to the health status score of the EORTC QLQ-C30 quality of life scale 
(beta -1.34, 95% CI -2.55, -0.13). PROMISE allows detecting changes in 
the clinical evolution of patients during hospital admission: total value 
OP285 IS DECOMPRESSING STOMA BETTER THAN STENT AS 
BRIDGE TO SURGERY FOR LEFT-SIDED OBSTRUCTIVE COLON 
CANCER? A NATIONWIDE, PROPENSITY-SCORE MATCHED ANALYSIS
Veld J.1, Amelung F.2, Borstlap W.1, van Halsema E.1, Consten E.2, 
Siersema P.3, ter Borg F.4, van der Zaag E.5, de Wilt H.3, Fockens P.1, 
Bemelman W.1, van Hooft  J.E.1, Tanis P.1
1Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, 
2Meander Medical Center, Amersfoort, Netherlands, 3Radboud University 
Medical Center, Nijmegen, Netherlands, 4Deventer Hospital, Deventer, 
Netherlands, 5Gelre Hospital, Apeldoorn, Netherlands
Contact E-Mail Address: j.v.veld@amc.uva.nl
Introduction: Bridge to elective surgery with self-expandable stent (SEMS) 
placement is still a debated alternative to emergency resection of left -
sided obstructive colon cancer (LSOCC) because of oncological concerns. 
Another bridge to surgery strategy is decompressing stoma construction. 
However, studies comparing decompressing stoma and SEMS are scarce. If 
we could directly compare these two methods, we may improve treatment 
and consequently health-related outcomes such as mortality and morbid-
ity in patients with LSOCC.
Aims & Methods: Our aim was to directly compare decompressing sto-
ma and SEMS as bridge to surgery strategies for LSOCC. All patients with 
LSOCC who were treated with curative intent between 2009 and 2016 were 
included from the Dutch ColoRectal Audit, a prospective, (mandatory) 
national registry. Additional diagnosic, procedural, and long-term out-
come data were retrospectively collected through individual patient fi les. 
Patients with locally advanced tumours were excluded from the analysis. 
Following propensity-score matching, patients treated with a decompress-
ing stoma were compared with patients treated with SEMS placement as 
bridge to surgery.
Results: Seventy-fi ve of 77 Dutch hospitals completed data of 345 de-
compressing stoma and 229 SEMS patients treated with curative intent. 
Propensity-score matching resulted in two groups of each 121 patients. 
Median follow-up was 36 (IQR 15-59) months and 31 (IQR 15-56) months, 
respectively (p=0.593). Decompressing stoma patients showed more pri-
mary anastomoses (86% versus 75%, p=0.024), more stomas aft er resec-
tion (67% versus 29%, p< 0.001), fewer major resection-related complica-
tions (6% versus 15%, p=0.023), and more reinterventions including stoma 
reversal (58% versus 28%, p< 0.001). Following decompressing stoma and 
SEMS, 3-year locoregional recurrence was 12% and 19% (HR 0.62, 95% CI 
0.30-1.28, p=0.200), 3-year disease free survival 64% and 57% (HR 0.90, 
95% CI 0.61-1.33, p=0.600), and 3-year overall survival 78% and 72% (HR 
0.77, 95% CI 0.48-1.22, p=0.260), respectively.
Conclusion: This nationwide, propensity-score matched study comparing 
decompressing stoma and SEMS for non-locally advanced LSOCC revealed 
both advantages and disadvantages of either of the two bridging tech-
niques. Based on the currently available evidence, there is no scientifi c 
basis to recommend one over the other.
Disclosure: J.V. Veld, F.J. Amelung, W.A.A. Borstlap, E.E. van Halsema, 
E.C.J. Consten, P.D. Siersema, F. ter Borg, E.S. van der Zaag, J.H.W. de Wilt, 
P. Fockens, W.A. Bemelman, J.E. van Hooft , and P.J. Tanis have no confl icts 
of interests or fi nancial ties to disclose for this specifi c study. The study was 
funded by unrestricted research grants from Citrienfonds and Dutch Cancer 
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of the scale (maximum 35) at admission 33.1 48h 19.6, 5ºd 11.1, 7ºd 7.7, at 
discharge 5.3 (p < 0.0001). Mild cases presented lower scores in the evolu-
tion than moderate-to-severe severe ones (p < 0.001) except at discharge.
Conclusion: The PROMISE scale satisfi es standardized criteria of reliability 
and validity. PROMISE can be used to test new therapeutic interventions 
in AP to detect diff erences in the patients´ assessment of their symptoms.
Disclosure: Nothing to disclose 
OP287 PRELIMINARY DATA OF THE PINEAPPLE-P STUDY: 
30-80% OF ACUTE PEDIATRIC PANCREATITIS IS NOT DIAGNOSED 
DUE TO THE LOW AWARENESS
Mosztbacher D.1,2, Parniczky A.2,3, Juhász M.F.2, Tél B.1, Erős A.1, Nagy A.4, 
Tokodi I.5, Kaán K.1, Horváth E.1, Ila V.6, Tóth A.7, Demcsák A.7,8, 
Kadenczki O.9, Ocskay K.2, Dohos D.2, Szentesi A.2,10, Hegyi P.2,10, 
Hungarian Pancreatic Study Group
1Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary, 
2University of Pécs, Institute for Translational Medicine & 1st Department 
of Medicine, Pécs, Hungary, 3Heim Pál National Insitute of Pediatrics, 
Translational Medicine, Budapest, Hungary, 4University of Pécs, Department 
of Pediatrics, Pécs, Hungary, 5Szent György Teaching Hospital of County Fejér, 
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Contact E-Mail Address: dora.mosztbacher@gmail.com
Introduction: Abdominal pain is one of the most common complaints in 
childhood and it is responsible for 10-20% of emergency visits. One of 
the causes of abdominal pain in children is acute pancreatitis (AP). Our 
retrospective data collection shows that the prevalence of acute pediatric 
pancreatitis (APP) depends on the diagnostic awareness, hence ranges be-
tween 0.2-1.14% in children with abdominal pain.
Aims & Methods: The aim of the PINEAPPLE-P study is to estimate the real 
worldwide incidence of APP in children with abdominal pain. Further-
more, we would like to develop an EBM guideline to establish a scoring 
system in order to evaluate the necessity of diagnostic steps for APP in 
children with abdominal pain. Patients were divided into two groups: 1) 
abdominal pain with APP (APP group) 2) abdominal pain without APP 
(non-APP group). PINEAPPLE (Pain In Early phase of Pediatric Pancreati-
tis) is a registered (ISRCTN35618458), observational, multinational clinical 
trial (http://www.ncbi.nlm.nih.gov/pubmed/26641250). In the PINEAPPLE-
P subtrial detailed patient data are collected, serum pancreatic enzyme 
measurement (sPEM) and abdominal imaging are performed prospective-
ly for children with abdominal pain turning up at ER units. Until now 769 
patients have been enrolled.
Results: 1.7% (13/769) of the children with abdominal pain was diagnosed 
with APP. The diagnosis was based on the fulfi lment of all three diagnos-
tic criteria (abdominal pain, sPEM elevation more than three times upper 
limit of normal, alteration on imaging characteristic for AP) in 6 patients 
(46.2%). Beside the abdominal pain in 5 cases (38.5%) the sPEM eleva-
tion and in 2 cases (15.4%) the imaging were positive for APP. Epigastric 
(46.2%) and left  upper abdominal pain (23.1%) occurred signifi cantly more 
oft en in children with APP than in non-APP group (p=0.004, p=0.01). Pa-
tients with APP had abdominal pain for signifi cantly longer period of time 
than non-APP patients (151.4±256.8 hours vs 70.2±140.9 hours; p=0.0043). 
Signifi cantly more patients had positive family history for pancreatitis in 
APP group compared to non-APP group (53.8% vs 13.8%; p< 0.0001). Posi-
tive family history of pancreatitis and upper abdominal pain outstanding 
more than 3 days were characteristic for APP.
Conclusion: The real incidence rate of APP is 1.7%. Diagnostic workup for 
APP should be performed in children with upper abdominal pain out-
standing more than 3 days and positive family history for pancreatitis.
Disclosure: Nothing to disclose 
OP288 THE ROLE OF HBSAG LEVELS IN THE OUTCOMES OF 
NON-CIRRHOTIC PATIENTS WITH HBEAG-NEGATIVE CHRONIC 
HEPATITIS B WHO DISCONTINUE LONG-TERM ANTIVIRAL THERAPY
Papatheodoridi M.1, Hadziyannis E.2, Orfanidou A.3, Zachou K.4, 
Kourikou A.5, Tzakou A.6, Manolakopoulos S.7, Dalekos G.8, 
Hadziyannis S.6, Papatheodoridis G.9
1Medical School, National and Kapodistrian University of Athens, 
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National and Kapodistrian University of Athens, Hippokratio General 
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School of National and Kapodistrian University of Athens, Laiko General 
Hospital, Department of Gastroenterology, Athens, Greece, 4University of 
Thessaly, Hepatology, Larissa, Greece, 5Hippokratio General Hospital, 2nd 
Department of Internal Medicine, Athens, Greece, 6Liver Clinic, Athens, 
Greece, 7Ippokratio, 2nd Department of Internal Medicine, Agia Paraskevi, 
Greece, 8University Hospital Larisa, Department of Pathology, Larisa, Greece, 
9University Medical School Hippokration Hospital, Academic Department of 
Gastroenterology, Athens, Greece
Contact E-Mail Address: margarita.gpap@gmail.com
Introduction: HBsAg serum levels at the end of treatment (EOT) have been 
associated with subsequent HBsAg loss in patients with HBeAg- nega-
tive chronic hepatitis B (CHBe-) who discontinue long-term nucleos(t)ide 
analogues (NA). However, their prognostic value for predicting post-NA 
relapse remains uncertain. This study assessed relapse, retreatment and 
HBsAg loss rates based on HBsAg levels at EOT in a large cohort of non-
cirrhotic CHBe- patients from 4 liver clinics in Greece.
Aims & Methods: The study included 136 patients (M/F: 87/49, age: 55±23 
years) who discontinued NA therapy aft er a minimum on-NA virological 
remission of 5.65± 2.39 years and had at least 12 months of post-NA fol-
low-up. Patients with coinfection, cirrhosis, cancer or liver transplantation 
were excluded. Patient characteristics before therapy as well as ALT, HBV 
DNA and HBsAg levels at EOT and post-NA were recorded. Patients were 
divided in 3 groups based on EOT HBsAg levels: A:≤100 IU/mL, B:>100-
1000 IU/mL, C>1000 IU/mL. Study endpoints were virological relapse (HBV 
DNA>2000 IU/mL), clinical relapse (HBV DNA>20,000 IU/mL & ALT>ULN), 
retreatment and HBsAg loss.
Results: The median post-NA follow-up was 20 (IQR: 14-66) months. Cu-
mulative rates of virological relapse did not diff er signifi cantly among pa-
tients of group A, B, C being 46%, 62%, 46% at 6 and 51%, 67%, 77% 
at 12 months, respectively (log-rank, P=0.25). Cumulative rates of clinical 
relapse were signifi cantly diff erent among groups A, B, C and were 16%, 
30%, 36% at 6 and 16%, 30%, 44% at 12 months, respectively (log-rank, 
P=0.03). No new case of clinical relapse was observed aft er 12 months and 
only two cases of virological relapse were observed between 12 and 24 
months of post-NA follow-up. Cumulative retreatment rates diff ered sig-
nifi cantly between group A, B, C being 8%, 18%, 29% at 6 and 8%, 22%, 
32% at 12 months, respectively (log-rank, P=0.01). Finally, cumulative rates 
of HBsAg loss also diff ered signifi cantly among groups A, B, C being 40%, 
9%, 7% at 12 months, respectively (log-rank, P< 0.001).
Conclusion: Post-NA outcomes diff er signifi cantly in CHBe- patients with 
diff erent EOT HBsAg. Patients with EOT HBsAg ≤100 IU/mL have signifi cant-
ly lower risk of clinical relapse or retreatment and higher probability of 
HBsAg loss. Therefore, non-cirrhotic CHBe- patients with HBsAg ≤100 IU/
mL can safely stop antiviral therapy and oft en achieve post-NA functional 
cure (HBsAg loss) in the fi rst 12 months aft er discontinuation.
Disclosure: Nothing to disclose 
OP289 SIMULTANEOUS BARIATRIC SURGERY AND LIVER 
TRANSPLANT ASSOCIATED WITH WORSE OUTCOMES
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Introduction: Obesity is directly linked with development of non-alco-
holic steatohepatitis (NASH), which is one of the leading indications for 
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OP290 ITALIAN MULTICENTRIC SURVEY ON DAILY PRACTICE 
FOR AUTOIMMUNE PANCREATITIS: CLINICAL PRESENTATION, 
DIAGNOSIS, TREATMENT AND EVOLUTION TOWARD PANCREATIC 
INSUFFICIENCY
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Introduction: Autoimmune pancreatitis (AIP) is a peculiar form of chronic 
pancreatitis of presumed autoimmune etiology. Several guidelines have 
been published in recent years. An attempt to unify the diff erent guide-
lines have hesitated in the International Consensus Diagnostic Criteria 
(ICDC) guidelines for AIP. However the application of these guidelines 
can be complex and articulated. Furthermore the natural history, the best 
treatment strategy and the fi nal evolution of this relatively new disease is 
not well known.
Aims & Methods: The aim of this study is to analyze, in a large cohort of 
patients from several Italian centers, representative of all national area, the 
daily practice in “real lyfe” regarding AIP, in terms of diagnosis, treatments, 
relapses, long-term outcomes and adherence to the ICDC guidelines. This 
observational multicenter retrospective survey was promoted and coordi-
nated by the Italian Association of Hospital Gastroenterologists (AIGO), and 
was endorsed by AISP (Italian Association for the Study of the Pancreas).
Data from 173 AIP patients from 14 diff erent institutions in Italy, distributed 
along the entire national territory, were retrospectively analyzed.
Results: 106 patients were classifi ed as type 1 AIP, 48 as type 2 AIP and 19 as 
AIP-Not Otherwise Specifi ed. Epidemiological, clinical, radiological, sero-
logical characteristics, relapses and outcome were similar to the previously 
reported ones for diff erent types of AIP. However, in our cohort endoscopic 
histology was available merely in 86/173 (49.7%). Pancreatic EUS-FNA/B cy-
to-histology was obtained more frequently in AIP1 (57/106 patients, 53.8%) 
compared with AIP2 (13/48 patients, 27.1%) (p< 0.01), and was judged diag-
nostic for AIP in 43/57 (75.4%) AIP1, 10/13 (76.9%) AIP2 (p= 0.91).
EUS-FNA/B of the pancreas was performed mostly in the focal form of AIP 
(85% of cases).
liver transplantation (LT). Bariatric surgery (BS) in the pre-LT setting has 
emerged as a successful treatment option for obesity, which improves 
transplant-free survival and other outcomes, or is used as a way to de-
crease the BMI and positively infl uence the patient’s transplant candidacy 
status. BS at the time of transplant (i.e. Sleeve Gastrectomy) has been ar-
gued to decrease costs, length of stay (LOS), stress and pain in small stud-
ies. To date, larger studies examining outcomes lack.
Aims & Methods: The aim was to determine inpatient outcomes of patients 
undergoing simultaneous BS and LT compared to LT alone. Case-control 
study using the 2012-2016 NIS. All patients with ICD9-10CM procedural 
codes for LT were included. Patients who did not undergo BS with a BMI< 
30kg/m2, and patients undergoing LT aft er having undergone BS during 
the same admission were excluded. The cohort was stratifi ed into two 
groups depending on whether they had undergone simultaneous BS at the 
time of LT or not. Primary outcome was determining the odds of inpatient 
mortality in patients undergoing simultaneous BS at the time of LT com-
pared to patients who underwent LT alone. Secondary outcomes included 
determining inpatient morbidity, resource utilization, hospital length of 
stay (LOS), and infl ation-adjusted total hospital costs and charges. Multi-
variate regression analyses were used to adjust for age, gender, Charlson 
Comorbidity Index, income in patient zip code, hospital region, location, 
size and teaching status.
Results: A total of 32,580 patients were identifi ed as having LT in the study 
period, of which 255 underwent simultaneous BS. The mean patient age 
was 30.1 years in patients who underwent simultaneous BS compared to 
55.7 years in patients who underwent LT alone (49% and 39% were fe-
male, respectively). For the primary outcome, patients undergoing simul-
taneous BS had adjusted mortality odds of 14.01 (p< 0.01) compared to 
patients undergoing LT alone. 
For the secondary outcomes, patients with simultaneous BS also had in-
creased odds of shock and total parenteral nutrition (TPN), compared to LT 
alone. Patients undergoing simultaneous BS had increased additional ad-
justed hospital costs, additional hospitalization charges and LOS (Table 1).
Variable Adj. OR / Adj. Mean 95%CI p-value
Inpatient Mortality 14.05 4.76-41.49 <0.01
Shock 5.73 2.36-13.91 <0.01
TPN 9.42 2.58-34.34 <0.01
AKI 0.73 0.37-1.43 0.36
Multi-organ failure 1.04 0.56-1.98 0.89
ICU 1.55 0.75-3.24 0.24
Additional Adjusted Costs $177,698 93309,262088 <0.01
Additional Adjusted Charges $555,072 283609,826536 <0.01
Additional Adjusted LOS (days) 29.1 16.7,41.4 <0.01
[Adjusted odds ratio and additional adjusted means in patients undergoing 
simultaneous BS at the time of LT compared to patients undergoing LT 
alone.]
Conclusion: Patients undergoing simultaneous bariatric surgery at the 
time of liver transplant display increased odds of inpatient mortality, mor-
bidity, hospital costs, charges and length of hospitalization during the in-
dex admission for liver transplant. The outcomes may vary signifi cantly 
with existing studies, as not only sleeve gastrectomies were included in 
this study, but all varieties of bariatric surgical procedures. This may refl ect 
the burden that an additional surgical procedure may impose on patients 
undergoing a liver transplant. Large prospective studies are needed to bet-
ter elucidate the outcomes of patients not only during the index admission 
for liver transplant, but also in the longer term.
Disclosure: Nothing to disclose 
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In the overall cohort an endoscopic histology diagnostic for AIP was ob-
tained in only 61/173 (35.2%) of patients. 
Most patients (123/173, 71.1%) were initially treated with steroids with a 
success rate of 92%. A maintenance steroid therapy was administered in 
31/123 (25.2%).
Immunosuppressant drugs were rarely used (10.9%) and Rituximab in 
only 1.7%. 
Steroid trial for diagnosis of AIP was performed in only 75/173 patients 
(43.3%) of patients and it was considered positive, in accordance to ICDC 
criteria, in 70/75 (93.3%). 
Applying the ICDC criteria to our cohort of patients, a diagnostic mismatch 
in sub-classifi cation between type 1 and type 2 AIP was founded in about 
one-third of cases, and 26 (15.2%) patients did not have enough diagnostic 
criteria for any type of AIP. 
Fecal elastase-1 was evaluated in 31.2%, and it was pathologic in 59.2% 
of cases.
Conclusion: In our cohort of AIP patients, although diagnosis and clas-
sifi cation for subtype was frequently possible, the low use of histology and 
steroid trial for diagnosis of AIP is probably responsible for a mismatch 
in subclassifi cation. These fi ndings showed that the ICDC Criteria for AIP 
are diffi  cult to apply in daily-clinical practice, confi rming what previously 
observed by other authors, and the need for modifi cation and simplifi ca-
tion of such criteria. 
The majority of patients received steroids as initial treatment and as main-
tenance therapy, with a very high response rate. Immunosuppresants and 
Rituximab were rarely used.
Finally, the rate of exocrine pancreatic insuffi  ciency development is not 
routinely investigated during the follow up of AIP, but is rather common in 
AIP patients. Fecal elastase test is inexpensive, non-invasive, and largely 
available, its use should be recommended.
Disclosure: Nothing to disclose 
OP291 PRECISION ONCOLOGY IN PANCREATOBILIARY CANCERS: 
A LONGITUDINAL STUDY
Sadaps M., Estfan B., Khorana A., Sohal D.
Cleveland Clinic, Hematology-Oncology, Cleveland, United States
Contact E-Mail Address: sadapsm@ccf.org
Introduction: Next-generation sequencing is widely used to identify thera-
peutic options for advanced cancer patients, but its utility in patients with 
pancreatobiliary cancer is not fully understood. We evaluated the rate of 
biologically actionable mutations and their impact on therapeutic deci-
sion-making in patients with pancreatobiliary cancers.
Aims & Methods: We conducted a retrospective cohort study of patients 
seen at Taussig Cancer Institute, Cleveland Clinic between 2013-16 with in-
curable solid tumor malignancies, in whom FoundationOne™ (Cambridge, 
MA) tumor genomic profi ling was ordered. Genomics tumor board (GTB) 
recommendations and treatment decisions (on label, off  label, or clinical 
trials) based on said recommendations were reviewed.
Results: Six hundred patients with solid tumor malignancies were includ-
ed, of whom 53 had pancreatobiliary malignancies. For these, median age 
was 59.6 years, 62.2% (33/53) of patients were female, 86.8% (46/53) were 
Caucasian, and 11.3% (6/53) were African American. Eight samples (15.1%) 
had inadequate tissue. Twenty-seven (60%) had biologically actionable 
alterations. Of these, 21 were recommended treatment including clinical 
trials (N=19) or off -label drugs (N=2). The most common actionable targets 
for therapy were FGFR (5/21) and CDKN2 (3/21). Of patients with recom-
mendations, only two (9.5%) received genomics-driven therapy compared 
to 31.7% (86/271) of patients with other solid tumor malignancies (p=0.03). 
One received an IDH1 inhibitor and a second received dabrafenib and tra-
metinib for a BRAF alteration; both on clinical trials. At time of last follow-
up, best responses were unknown and partial response, respectively. 
Unavailability of local clinical trials (9.5%) and clinical trial ineligibility 
(9.5%) (i.e. low performance scores, other co-morbidities) were common 
reasons for lack of actionability.
Conclusion: Benefi t from next-generation sequencing in the pancreatobili-
ary population is low with only 4.4% of tested patients eventually receiving 
genomics-based therapy. Benefi t to patients will not improve until access 
to clinical trials is enhanced and/or patients are evaluated for these trials 
earlier in the course of their disease, when their functional status is likely 
to be higher.
Disclosure: Nothing to disclose 
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Introduction: Primary sclerosing cholangitis (PSC) is a rare infl ammatory 
bile duct disease closely associated to infl ammatory bowel disease (IBD). 
The lifetime risk for cholangiocarcinoma is 10-20%. The risk for gallblad-
der cancer and colorectal cancer is also increased. The risk for extra intes-
tinal cancer is less studied.
Aims & Methods: The aim of the present study was to evaluate risk of all 
cancers in a large well-defi ned cohort of PSC patients in Sweden. We have 
performed a national prospective matched cohort study of 1769 PSC pa-
tients from six university hospitals in Sweden. All patients were diagnosed 
according to accepted criteria. The cohort was linked to the national reg-
isters of cancer, death and the patient register. Through Statistics Sweden 
we were provided with up to ten controls for each PSC patient matched for 
sex, age and residence at time of diagnosis.
Patients were followed from one year aft er date of PSC diagnosis (index 
date) until date of fi rst cancer diagnosis, liver transplantation, death, emi-
gration date or the 31stof December 2016.
Kaplan Meier method was used to evaluate the cumulative risk of the dif-
ferent subgroups of cancer in PSC patients and their controls. In addition, 
we calculated sub distribution hazard ratio (SHR) using competing risks 
regression model.
Results: Aft er exclusion, using index date, end of follow up or censoring 
events, 1430 PSC patients remained for fi nal analyzis. Mean patient follow 
up time was 15.3 years (range 0.02-47.0). A concomitant IBD diagnosis was 
present in 88 % of the PSC patients. The hazard ratio for any cancer was 3.3 
(95 % CI 2.9-3.7) in PSC patients compared to their matched controls. The 
risk of hepatobiliary cancer (cholangiocarcinoma, hepatocellular cancer 
and gallbladder cancer), pancreatic cancer, colorectal cancer, ventricular 
cancer, non-melanoma skin cancer and lymphoma was increased in PSC 
patients compared to their matched controls.
Conclusion: In this large cohort of well-defi ned PSC patients from Sweden 
we show, for the fi rst time, an increased risk of ventricular cancer, non-
melanoma skin cancer and lymphoma. The previously known high risk of 
hepatobiliary and colorectal cancer was confi rmed.
Disclosure: Nothing to disclose 
OP293 THE DIAGNOSTIC YIELD OF MAPPING BIOPSY AND 
ITS IMPACT ON SURGICAL CURABILITY IN EXTRAHEPATIC 
CHOLANGIOCARCINOMA
Takahara N.1, Nakai Y.2, Suzuki Y.1, Inokuma A.1, Oyama H.1, Kanai S.1, 
Suzuki T.1, Sato T.1, Hakuta R.2, Ishigaki K.1, Saito K.1, Saito T.1, Hamada T.1, 
Mizuno S.1, Kogure H.1, Tada M.1, Koike K.1
1The University of Tokyo, Dept. of Gastroenterology, Tokyo, Japan, 2The 
University of Tokyo, Dept. of Endoscopy and Endoscopic Surgery, Tokyo, 
Japan
Contact E-Mail Address: naminatsu.takahara@gmail.com
Introduction: Surgery with negative tumor margin (R0 resection) off ers 
survival benefi ts in patients with extrahepatic cholangiocarcinoma (ECC). 
Accurate preoperative diagnosis, especially for longitudinal cancer spread 
is required to plan an optimal surgery to achieve R0 resection. However, 
the diagnostic yield of transpapillary mapping biopsy (MB) for possible 
surgical ductal margins (PSDMs) and its impact on the operative curability 
remains unclear.
Aims & Methods: Between 2003 and 2018, 190 patients with ECC (85 peri-
hilar and 105 distal) who underwent surgical resection aft er preoperative 
evaluation with ERCP were retrospectively examined. PSDMs were deter-
mined according to the planned surgery, and the diagnostic yield of MB 
for PSDMs was assessed based on the resected specimens as the gold 
standard. We also compared the operative curability in patients with and 
without preoperative MB for PSDMs.
Results: A total of 186 preoperative MB procedures were performed in 75 
patients, and 242 samples were obtained from PSDMs under fl uoroscopic 
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up, 3 (60%) were irresectable (survival 1-4 months), two of which had 
presented as symptomatic interval carcinomas, of which one appeared to 
have arisen separately from the known side branch IPMN. One of the 5 un-
derwent an irradical resection (T3N1M0, survival 18 months), and one was 
radically resected (T1N0M0, alive, 18 months aft er diagnosis). The overall 
median survival for the 6 deceased PDAC patients was 11 (IQR 30) months.
Conclusion: In this relatively young cohort of individuals at high risk for 
PDAC, timely identifi cation of relevant resectable lesions proved chal-
lenging with surveillance based on imaging alone with EUS and MRI. 
The quantitative eff ect of surveillance on resectability rates and survival 
remain diffi  cult to assess because of the limited number of cases and pos-
sible lead-time bias. Biomarkers may hold better promise to improve the 
outcome of surveillance in individuals at high risk for PDAC.
Disclosure: PF is a consultant to Olympus, Cook Medical, Ethicon Endo-
surgery and received research funding from Boston Scientifi c. DLC is a 
consultant to Tramedico. JEH received research funding from Abbott and 
Cook Medical. She is a consultant to Boston Scientifi c, Cook Medical, and 
Medtronics. MJB received research funding from Boston Scientifi c, Cook 
Medical, Pentax Medical, 3M. He is a consultant to Boston Scientifi c, Cook 
Medical, Pentax Medical, Mylan, MediRisk, and Medicom. The other au-
thors have nothing to disclose. 
or cholangioscopic guidance. Among them, 88% (177/201) of samples ob-
tained under fl uoroscopic guidance included suffi  cient materials for the 
diagnosis (86% and 96% at the possible proximal and distal margin, re-
spectively). On the other hand, 80% (88/110) of samples obtained under 
cholangioscopic guidance included suffi  cient materials (79% and 100% at 
the proximal and the distal margin, respectively). When MB for 75 proxi-
mal and 24 distal margins aft er radical surgical resection (33 pancreatico-
duodenectomy, 24 hepatectomy, and 18 hepatopancreatoduodenectomy) 
was evaluated, MB under fl uoroscopic guidance provided the diagnostic 
accuracy of 65 % and 67 % at proximal and distal margins, respectively. 
On the other hand, MB under cholangioscopic guidance provided the di-
agnostic accuracy of 61% and 72 % at proximal and distal margins. Macro-
scopic residual cancer was observed in 20% (17% at the proximal margin, 
6% at the distal margin) and R0 resection rate was 48%. MB for PSDMs 
was associated with an improved R0 resection rate (56% vs 43%, P = 0.08) 
and a lower incidence of macroscopic residual cancer at the surgical ductal 
margins (12% vs 20%, P = 0.10).
Conclusion: MB for PSDMs improved the possibility of curative resection 
in patients with ECC. Insuffi  cient sampling for the proximal margin may 
result in the limited accuracy of the MB, especially under the cholangio-
scpoic guidance. The dedicated devices for MB should be developed.
Disclosure: Nothing to disclose 
OP294 13 YEARS OF PROSPECTIVE PANCREATIC CANCER 
SURVEILLANCE: RESULTS OF THE DUTCH NATIONWIDE PROGRAM 
IN HIGH-RISK INDIVIDUALS
Overbeek K.A.1, Levink I.J.M.1, Konings I.C.A.W.1, Harinck F.2, 
Koopmann B.1, Ausems M.G.E.3, Wagner A.4, Fockens P.5, 
Groot Koerkamp B.6, Besselink M.G.H.7, van der Vlugt M.5, 
Vleggaar F.P.8, Poley J.W.4, Cahen D.L.1, van Hooft  J.E.5, Bruno M.J.9, 
The Dutch Familial Pancreatic Cancer Surveillance Study Group
1Erasmus University Medical Center, Gastroenterology & Hepatology, 
Rotterdam, Netherlands, 2University Medical Center Rotterdam, Erasmus 
Medical Centre, Rotterdam, Netherlands, 3University Medical Center Utrecht, 
Utrecht, Netherlands, 4Erasmus University Medical Center, Rotterdam, 
Netherlands, 5Amsterdam UMC, Department of Gastroenterology & 
Hepatology, Amsterdam, Netherlands, 6Erasmus University Medical Center, 
Department of Surgery, Rotterdam, Netherlands, 7Amsterdam UMC, 
Department of Surgery, Amsterdam, Netherlands, 8Univ. Medisch Centrum 
Utrecht, Department of Gastroenterology & Hepatology, Utrecht, Netherlands, 
9University Medical Center Rotterdam, Department of Gastroenterology & 
Hepatology, Rotterdam, Netherlands
Contact E-Mail Address: k.overbeek@erasmusmc.nl
Introduction: Surveillance of individuals at high risk for pancreatic ductal 
adenocarcinoma (PDAC) may reduce pancreatic cancer-related mortality.
Aims & Methods: Our aim was to determine the yield of a nationwide pan-
creatic cancer surveillance program in high-risk individuals in the Nether-
lands during a 13-year follow-up. From 2006 through 2019, asymptomatic 
individuals with an estimated more than 10-fold increased lifetime PDAC 
risk were enrolled. Surveillance commenced at the age of 50 or 10 years 
younger than cancer onset in the family, and ended at the age of 75. Sur-
veillance was performed every 12 months with both MRI and EUS. For wor-
risome features the surveillance interval was shortened to 3 or 6 months 
or surgery was performed.
Results: 344 individuals from 229 families were enrolled (mean age 54 (SD 
10.0) years, 44% male). 156 (45%) were germline mutation carriers and 
188 (55%) were familial pancreatic cancer kindred. They were followed for 
a median of 44 (IQR 74) months and a total of 1616 person-years. Cystic 
lesions were found in 185 (54%) participants, which were ≥1 cm in 43 
(13%). 14 (4.1%) participants underwent surgery for a suspect lesion (3 at 
baseline, 11 during follow-up). Pathological results in these patients re-
vealed PDAC in 4 patients, low-grade precursor lesions in 7, a 5-mm neu-
roendocrine tumor in 1, autoimmune pancreatitis in 1, and no lesion in the 
resected specimen in 1. In total, 7 (2%) patients developed PDAC (median 
age 56 years, IQR 23). Two were diagnosed at baseline and underwent 
resection. Histology revealed a margin negative T2N1M0 and T1N0M0. Both 
patients died aft er 32 months. Another 5 individuals developed PDAC dur-
ing follow-up, all of whom had prior abnormalities visible on both EUS 
and MRI (presumed side branch IPMN in 4, an indeterminate lesion in 2, 
a moderately dilated common bile duct in 1, and a main pancreatic duct 
stricture without visible mass in 1 case). Of the 5 PDACs detected at follow-
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What’s hot in cold snaring
08:30-10:00 / A1
OP295 REAL TIME DIAGNOSTIC ACCURACY OF BLUE LIGHT 
IMAGING WITH MAGNIFICATION (BLI) IN THE CHARACTERISATION 
OF SESSILE SERRATED POLYPS (SSPS) AND ADVANCED HISTOLOGY 
WITHIN COLO-RECTAL POLYPS
John S.1, Ostrowski S.1, Neumann H.2,3
1Gold Coast University Hospital, Gastroenterology and Hepatology, Southport, 
Australia, 2University Medical Center Mainz, Interventional Endoscopy Center, 
I. Medizinische Klinik und Poliklinik, Mainz, Germany, 3Bond University, 
Medicine, Robina, Australia
Contact E-Mail Address: sneha.john@health.qld.gov.au
Introduction: Blue light imaging (BLI) is a novel modality for image en-
hanced endoscopy. Using the short wavelength of the absorption spectrum 
of haemoglobin and specifi c white light spectral colours emitted by 4 LED 
lights enhances the visualisation of vascular and surface pattern morphol-
ogy within colonic polyps. In addition, magnifi cation endoscopy with BLI is 
expected to enhance characterization and detection of advanced pathology 
such as high grade dysplasia (HGD) or submucosal invasion. Our study 
aims to assess the accuracy of BLI in characterizing SSPs and its ability to 
accurately predict advanced pathology.
Aims & Methods: A retrospective analysis was performed of a prospectively 
collected database in a single tertiary hospital. Hospital ethical board ap-
proval was obtained and informed consent was attained from all patients. 
Data from all colonoscopy utilising BLI and magnifi cation were collected 
for 12 months from October 2017.Data was collected on polyp location, size, 
morphology and polyp type and presence of advanced pathology. Mucous 
cap, indefi nite margins, type 2 open pits and dilated branching vessels 
were used as additional criteria for predicting SSPs. Endoscopic prediction 
was compared to histology to determine accuracy.
Results: 155 polyps were assessed in 68 procedures during the study pe-
riod. Of these, 112 (72%) were in the proximal colon, 28 in the distal colon 
(18%) and 15 (10%) in the rectum. 62 polyps were diminutive (40%) and 
17 were 6-10 mm (11%). 76 polyps were >10mm in size (49%) of which 43 
were between 20-50 mm and 12 were >50 mm in size. 65 polyps were of 
Paris 1s morphology (41.9%), 80 were Paris 2a (50.3%) and 10 had com-
bined morphology. BLI with magnifi cation detected 55 SSPs of which 54 
were confi rmed at pathology (sensitivity 98.1%, specifi city 99%, PPV 98%, 
NPV 99%, accuracy 98.7%). Adenomas were predicted in 100 polyps with 
HGD in 11 polyps and submucosal invasion in 6 polyps. Pathology con-
fi rmed submucosal invasion in all predicted polyps but did not detect HGD 
in 2 lesions. Pathology identifi ed an additional 2 proximal colon polyps 
with focal HGD and 1 small focus of early submucosal invasion in a >50 
mm polyp where endoscopy predicted HGD. Detailed results are in table 1.
Polyp characterisation Sensitivity Specifi city PPV NPV
SSP 98.1( 90-99) 99 (94-99) 98 (89-99) 99 (95-100)
Advanced pathology( 
HGD + SM invasion)
88 (62-97) 98 (94-99) 88 (62-97) 98 (94-99)
SM invasion 85 (42-99) 100 (96-100) 100 (51-100) 99 (95-99)
[Table 1]
Conclusion: As a novel modality, BLI with magnifi cation has enhanced 
ability to visualise and characterize vascular and pit pattern morphology 
of colo-rectal polyps. Our study utilised these features and specifi c criteria 
for SSPs for accurate prediction of polyp type and advanced pathology. 
The results indicate high diagnostic accuracy for BLI in diff erentiation of 
SSPs as well as prediction of HGD and submucosal invasion. Prediction of 
advanced pathology is crucial in determining the ideal therapeutic strat-
egy. Our study highlights the potential use of BLI and magnifi cation in this 
regard.
Disclosure: Nothing to disclose 
OP296 CONTINUOUS ANTICOAGULATION AND COLD SNARE 
POLYPECTOMY VERSUS HEPARIN BRIDGING AND HOT SNARE 
POLYPECTOMY IN PATIENTS ON ANTICOAGULANTS WITH 
SUBCENTIMETER POLYPS: A RANDOMIZED CONTROLLED TRIAL
Yamada S.1, Mabe K.2, Shimodate Y.3, Shinji Y.4, Iwatate M.5, 
Kawamura T.6, Hotta K.7, Nagaike K.8, Ikezawa N.9, Yamasaki T.10, 
Komeda Y.11, Asai S.12, Abe Y.13, Akamatsu T.14, Sakakibara Y.15, 
Ikehara H.16, Kinjo Y.17, Ohta T.18, Kitamura Y.19, Shono T.20, Inoue T.21, 
Ohda Y.22, Kobayashi N.23, Tanuma T.24, Sato R.25, Sakamoto T.26, 
Harada N.27, Chino A.28, Ishikawa H.29, Nojima M.30, Uraoka T.31, 
Takeuchi Y.32, Madowazu Study Group
1Ishikawa Prefectural Central Hospital, Kanazawa, Japan, 2Hokkaido 
University Hospital Dept. of Endoscopy, Sapporo, Japan, 3Kurashiki Central 
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Division of Endoscopy DBC Study Group, Shizuoka, Japan, 8Suita Municipal 
Hospital, Suita, Japan, 9Kobe University Hospital, Gastoroenterology, Kobe, 
Japan, 10Osaka City General Hospital, Gastroenterology, Osaka, Japan, 
11Kindai University Faculty of Medicine, Gastroenterology and Hepatology, 
Osaka, Japan, 12Tane General Hospital, Osaka, Japan, 13Utsunomiya Memorial 
Hospital, Tochigi, Japan, 14Japan Red Cross Wakayama Medical Center, 
Gastroenterology and Hepatology, Wakayama, Japan, 15National Hospital 
Organization Osaka National Hospital, Osaka, Japan, 16Nihon University 
School of Medicine, Tokyo, Japan, 17National Cancer Center Hospital Dept. 
of Endoscopy, Naha, Japan, 18Kansai Rosai Hospital, Amagasaki, Japan, 
19Nara City Hospital, Nara, Japan, 20Kumamoto University, Kumamoto, 
Japan, 21Osaka General Medical Center, Gastroenterology, Osaka, Japan, 
22Hyogo College of Medicine, Nishinomiya, Japan, 23Tochigi Cancer 
Center, Utsunomiya, Japan, 24Teine Keijinkai Hospital, Sapporo, Japan, 
25Sapporo Higashi Tokushukai Hospital, Sapporo, Japan, 26National Cancer 
Center Hospital, Tokyo, Japan, 27National Hospital Organization Kyushu 
Medical Center, Fukuoka, Japan, 28Cancer Institute Hospital Division of 
Gastroenterology, Tokyo, Japan, 29Kyoto Prefectural University of Medicine, 
Osaka, Japan, 30University of Tokyo, Tokyo, Japan, 31Gunma University 
Graduate School of Medicine, Gastroenterology and Hepatology, Maebashi, 
Japan, 32Osaka International Cancer Institute, Gastrointestinal Oncology, 
Osaka, Japan
Contact E-Mail Address: s.yamada@kdp.biglobe.ne.jp
Introduction: Management of anticoagulants for patients undergoing pol-
ypectomy is still controversial, and cold snare polypectomy (CSP) is re-
ported as a less hemorrhagic procedure.
Aims & Methods: To investigate the effi  ciency of continuous administra-
tion of anticoagulants with CSP (CA+CSP) compared to periprocedural 
heparin bridging with hot snare polypectomy (HB+HSP) for subcentimeter 
colorectal polyps. Patients taking anticoagulants (warfarin or direct oral 
anticoagulants) and having at least one non-pedunculated subcentimeter 
colorectal polyp. Patients were randomly assigned to undergo HB+HSP or 
CA+CSP. Follow-up of patients was performed 28 days postoperatively. The 
primary endpoint was incidence of polypectomy-related major bleeding: 
i) poorly controlledintra-proceduralbleedingor ii) post-polypectomy bleed-
ing requiring endoscopic hemostasis.
Results: A total of 184 patients were enrolled, with 90 allocated to the 
HB+HSP group, 92 to the CA+CSP group, and 2 refusals. The occurrence 
of polypectomy-related major bleedingin the HB+HSP and CA+CSP groups 
was 12.0% [95% confi dence interval (CI), 5.1 to 19.1] and 4.7% [95% CI, 0.2 
to 9.2], respectively. Inter-group diff erence for the primary endpoint was 
+7.3% with the lower limit of two-sided 90% CI of 0.4% [95% CI, -1.0 to 
15.7], which demonstrated non-inferiority of CA+CSP. The mean procedure 
time for each polypand hospitalization periodwere longer in the HB+HSP 
group than in the CA+CSP group.
Conclusion: CA+CSP for subcentimeter colorectal polyps in patients tak-
ing anticoagulants did not increase the incidence of polypectomy-related 
major bleedingcompared with HB+HSP, with a shorter procedure time and 
hospitalization period.
Disclosure: Nothing to disclose 
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OP298 INCOMPLETE RESECTION OF 4-20MM COLORECTAL 
POLYPS WHEN USING COLD SNARE POLYPECTOMY
von Renteln D.1, Benard F.2, Camara R.2, Barkun A.3, Bouin M.2, 
Bouchard S.4, Deslandres É.2, Faulques B.5, Panzini B.2, Weber A.2, 
Sidani S.6, Leduc R.2, Pohl H.7
1Centre Hospitalier Universitaire de Montreal, Gastroenterology, Montreal, 
Canada, 2Centre Hospitalier Universitaire de Montreal, Montreal, Canada, 
3McGill University Health Center, Montreal, Canada, 4Montreal University 
Center, Montreal, Canada, 5Centre Hospitalier Universitaire de Montreal, 
Gastroenterologie, Ville Mont Royal, Canada, 6McMaster University, 
Medicine, Hamilton, Canada, 7White River Junction VA Medical Center, New 
Hampshire, United States
Contact E-Mail Address: fl orence_benard@hotmail.com
Introduction: Cold snare polypectomy has been recently been recommend-
ed as preferred polypectomy approach for up to 10mm colorectal polyps. 
We were interested to evaluate expansion of cold snare polypectomy for up 
to 20mm colorectal polyps and associated effi  cacy and safety.
Aims & Methods: This prospective studyincluded adults (age 45-80) pre-
senting for a screening, surveillance or diagnostic colonoscopy at one aca-
demic center. The primary endpoint was the Incomplete Resection Rates 
(IRR) for 4-20mm neoplastic colorectal polyps. Secondary outcomes in-
cluded technical feasibility of cold snare polypectomy and associated com-
plication rates. “Easy” polypectomy was defi ned as immediate polyp re-
section upon fi rst closure of the snare while “diffi  cult” was defi ned as hav-
ing to open and close the snare multiple times and/or using mechanical 
force (e.g. guillotine technique)to complete the cold snare polyp removal. 
Incomplete resection was defi ned by the presence of remnant tissue in 
marginal biopsies aft er polypectomy.
Results: The study included 413 patients (mean age 63; female 48.2%). 
Polyp and adenoma detection rates were 54.5% and 36.4%, respectively. 
A total of 182 colorectal polyps 4-20mm were found and initial removal 
was attempted using cold snare. In 75.3% cold snare resection was easy, 
in 12.1% diffi  cult and in 9.9% conversion was required. The IRR for ad-
enomatous polyps was 14.8%. The IRR for neoplastic polyps was 16.8%. 
Among neoplastic polyps incomplete resection was more frequent for SSP 
(36.4%) than for adenomatous polyps (14.8%, p=0.018). The IRR for hy-
perplastic polyps was 20.0%. The IRR for all 4-20mm polyps (combining 
neoplastic and hyperplastic polyps) was 17.6%. The risk of incomplete re-
section varied with polyp size (15.8% for 4-5 mm, 22.2% for 6-9 mm and 
15.8% for 10-20 mm) and incomplete resection occurred more frequently 
when immediate polyps resection was diffi  cult (IRR 42.1%). Intraproce-
dural bleeding requiring endoscopic intervention (treatment with clip or 
injection) occurred in 4.4%.
Conclusion: In this multi-endoscopist study using systematic cold snare 
polypectomy for up to 20mm colorectal polyps IRR was found more oft en 
than in other recent studies reporting outcomes for cold snare polypecto-
my. Technical diffi  culty to resect the polyp was associated with higher IRRs.
Disclosure: Daniel von Renteln is supported by a “Fonds de Recherche 
du Québec Santé” career development award and has received research 
funding from ERBE, Ventage and Pentax and is a consultant for Boston 
Scientifi c and Pendopharm. 
OP297 THE SAFETY OF COLD SNARE POLYPECTOMY FOR PATIENTS 
ON ANTITHROMBOTIC THERAPY
Kimoto Y.1, Ohata K.2, Matsuhashi N.1
1NTT Medical Center Tokyo, Endoscopy, Tokyo, Japan, 2NTT Medical Center, 
Gastroenterology/Endoscopy, Shinagawa-ku, Japan
Contact E-Mail Address: kimoto.yoshiaki@icloud.com
Introduction: Cold snare polypectomy (CSP) is a more effi  cacious and safer 
polypectomy technique without electrocautery, therefore it is widely used 
for the removal of subcentimeter polyps. Recent studies have revealed that 
delayed post-polypectomy bleeding (DPPB) and perforation are few ob-
served in CSP. The use of antithrombotic agents for prophylaxis or treat-
ment of thromboembolic events is expected to increase with the aging of 
the population. The management of antithrombotic agent use in patients 
undergoing CSP is a very important issue in clinical practice. However 
the safety of CSP in patients who are currently on antithrombotic therapy 
haven’t been fully evaluated.
Aims & Methods: The aim of this study was to elucidate the safety of CSP 
in patients who are currently on antithrombotic therapy. 3341 consecutive 
patients with colorectal polyps were removed by CSP between March 2016 
and March 2019. We retrospectively assessed the characteristics of polyps, 
the histological results, the rates of DPPB. DPPB was defi ned as signifi cant 
bleeding requiring endoscopic treatment within 2 weeks aft er CSP.
Results: 6236 polyps in 3341 patients (male/female; 2511/830) were re-
moved by CSP. There were 1310 polyps (21.4%) in 621 patients (antiplatelets 
agent users 403, anticoagulants agent users 172 and both agent users 64) 
in the antithrombotic group, and this group was divided into two groups: 
the continuation group (group A; 637 polyps, 339 patients) and the inter-
ruption group (group B; 569 polyps, 282 patients). And there were 5030 
polyps (79.6%) in 2720 patients in the non-antithrombotic group (group 
C). The baseline characteristics of the lesions (size, location, morphology, 
resection number, and institution) in three groups weren’t signifi cantly dif-
ferent in univariate or multivariate analyses. As for adverse events, the 
overall rate of DPPB was 0.18% (6/3341). DPPB occurred 0.59% (2/339) in 
group A, 0.35% (1/282) in group B, 0.11% (3/2720) in group C, showing no 
signifi cant diff erences from three groups (p = 0.09). In the rates of DPPB 
of the antithrombotic group (group A and group B), there were no signifi -
cant diff erences depending upon the antithrombotic agents used (warfarin 
group, DOAC group, antiplatelet group, multiple antithrombotic group). 
Of the 6 cases of DPPB in CSP, 3 cases were located in sigmoid colon, all 
polyps were more than 5mm in diameter. Patients in the antithrombotic 
group in whom DPPB occurred included 2 aspirin users with 2 polyps and 
1 aspirin plus rivaroxaban user with 2 polyps. All DPPB occurred within 24 
hours, and transfusion and surgery were not necessary. In all cases, no 
perforation and fetal adverse events were occurred.
Conclusion: It is noteworthy that continued use of all of the antithrombotic 
agents in patients undergoing CSP didn’t increase the risk of DPPB, even in 
patients receiving multiple antithrombotic agents. Thus, CSP can be per-
formed with a high level of safety, even in patients receiving antithrom-
botic agents. In addition, there were no signifi cant diff erences of rates of 
DPPB between the continuation group and the interruption group. So our 
results suggest that we may not be necessary for cessation of the anti-
thrombotic therapy in CSP, and it is possible to reduce the risk of throm-
boembolism. In the future, prospective, randomized studies are necessary 
to confi rm our results.
Disclosure: Nothing to disclose 
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OP299 CLINICAL IMPORTANCE OF COLD POLYPECTOMY 
DURING INSERTION PHASE IN LEFT SIDE COLON AND RECTUM: 
A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL 
(PRESECT STUDY)
Teramoto A.1, Aoyama N.2, Ebisutani C.3, Matsumoto T.4, Machida H.5, 
Yoshida S.6, Uchima N.7, Utsumi T.8, Tochio T.9, Hirata D.1, Iwatate M.1, 
Hattori S.1, Fujita M.1, Sano W.1, Sano Y.1
1Sano Hospital, Gastrointestinal Center, Kobe, Japan, 2Aoyama Clinic, 
Department of Gastroenterology, Kobe, Japan, 3Hyogo Prefectural Kakogawa 
Medical Center, Department of Gastroenterology, Kakogawa, Japan, 4Akashi 
City Hospital, Department of Gastroenterology, Akashi, Japan, 5Machida 
Gastrointestinal Hospital, Department of Internal Medicine, Osaka, Japan, 
6National Hospital Organization Kobe Medical Center, Department of 
Gastroenterology, Kobe, Japan, 7Urasoe General Hospital, Gastrointestinal 
Center, Urasoe, Japan, 8Kyoto University Graduate School of Medicine, 
Department of Gastroenterology and Hepatology, Kyoto, Japan, 9Suzuka 
General Hospital, Department of Gastroenterology, Suzuka, Japan
Contact E-Mail Address: akira_teramoto@hotmail.com
Introduction: Although small and diminutive colorectal polyps are oft en 
found unintentionally during insertion phase (IP) of colonoscopy, removal 
of polyps during IP is not common in the current practice. These polyps, 
especially in the left  side colon are oft en challenging to re-detect during 
withdrawal phase (WP) and may even become undetectable. As time-con-
sumption of the re-inspection process is not negligible, instant resection of 
polyps should be considered. With the global spread of cold polypectomy 
and carbon dioxide (CO
2
) gas insuffl  ation, polypectomy during IP became 
less of a burden to endoscopists.
Aims & Methods: The aim of this prospective multi-centre randomized trial 
was to investigate the clinical benefi ts of instant removal of polyps upon 
scope insertion. We have set the primary outcome as total procedure time 
to confi rm that polypectomy during IP facilitates the entire colonoscopy 
procedure and improves time effi  ciency. Secondary outcomes include the 
number of missed or ‘hiding’ polyps. Hiding polyp is defi ned as a polyp 
detected during insertion, however lost in withdrawal phase which was 
eventually found aft er re-inspection. 
Patients with at least one target lesion (adenomas or SSAP < 10mm, hy-
perplastic polyps 6mm < 10mm in left  side colon) detected during IP were 
divided into two groups and received cold snare or forceps polypectomy 
under CO2 gas insuffl  ation: study group removed polyps during both IP 
and WP, where control group removed polyps during WP only. Patients 
were randomized into the two groups as soon as a target lesion is detected 
during IP. 20 senior endoscopists from 7 institutions were involved in this 
trial.
Results: A total of 1451 patients were recruited for the trial from April 2018 
to March 2019. 300 (26.2%) patients had at least one detectable target le-
sion during IP, and 220 patients (120 in study group, 100 in control group) 
were eligible for full assessment. Mean total procedure time was signifi -
cantly shorter (18:51 vs 22:18, -15.4%, p=0.0004) and mean pure cecal intu-
bation time was similar between two groups (7:25 vs 7:33 p=0.9318). Mean 
number of polyps resected per patient was 2.1 in both groups. In the con-
trol group, out of 107 polyps found during IP, 48 polyps (44.8%) were not 
found in the fi rst withdrawal action and 7 (6.5%) polyps were completely 
lost. Time consumption for re-searching these hiding or missed polyps 
was 2:54 in average. One case (1%) of delayed post-polypectomy bleeding 
in control group was reported as an adverse event.
 
Polypectomy upon 
insertion and 
withdrawal
Polypectomy 
upon withdrawal 
only
P-value
n 120 100 NA
Total number of polyps 254 210 0.9011
Mean number of polyps per patient 2.1 2.1 NA
Mean total procedure time (min:sec) 18:51 22:18 0.0004
Mean pure cecal intubation time 
(min:sec) 7:26 7:27 0.9318
Mean polypectomy time (min:sec) 2:03 1:59 0.7562
Number of ‚hiding’ polyps NA 41(38.3%) NA
Number of missed polyps NA 7 (6.5%) NA
[Main outcomes of PRESECT study.]
Conclusion: Polypectomy during IP in the left  side colon improves the time 
effi  ciency of colonoscopy and reduces total procedure time without expe-
riencing any disadvantages.
Disclosure: Nothing to disclose 
OP300 COLD SNARE POLYPECTOMY VS HOT SNARE 
POLYPECTOMY VS (APC) FOR SMALL(5-9MM) LEFT-SIDED 
COLORECTAL POLYPS: A PROSPECTIVE RANDOMIZED TRIAL
Varytimiadis L.1, Viazis N.2, Kyriakopoulos G.3, Argyrakos T.3, 
Papanikolaou I.S.4, Tribonias G.5, Pontas C.6, Papastergiou V.7, 
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Introduction: The optimal technique for the removal of small colorectal 
polys is debatable. We aimed to compare the recurrence rates among three 
endoscopic treatment modalities for 5-9mm left -sided colorectal polyps.
Aims & Methods: Consecutive adults referred for elective colonoscopy 
(1/2015-1/2018) who had at least one polyp of eligible size (5-9mm) located 
distally to the splenic fl exure were randomly assigned (1:1:1) to one of three 
treatment modalities: 1) cold snare polypectomy (CSP), 2) hot snare polyp-
ectomy (HSP) and 3) APC ablation (50-60W, fl ow: 2lt/min). The polyp site 
was marked with endoscopic tattoo and a follow-up colonoscopy with scar 
biopsies was performed 6-18 months aft er the index procedure. Outcomes 
were the polyp recurrence rate and the occurrence of complications.
Results: A total of 119 patients were enrolled, of whom 112 (62.5% males, 
mean age 61.1±9.9 years) with 121 polyps (CSP: 39, HSP: 45, APC: 37) re-
turned for follow-up colonoscopy. The mean polyp size was 6.7±0.91mm, 
58% were located in the sigmoid, 33% in the rectum and 8% in the 
descending colon. The majority of polyps resected by CSP or HSP were 
histopathologically proven to be neoplastic (tubular adenomas: 25.9%, 
tubulovillous adenomas: 11.1%, sessile serrate adenomas/polyps: 17.5%). 
No cases of delayed bleeding or perforation occurred in the study. Scar 
biopsies at follow-up colonoscopy (performed aft er a mean interval of 
13.4 ±3.8 months) revealed a total of 6 (4.96%) cases of polyp recurrence, 
showing no signifi cant diff erence among the three treatment groups [CSP: 
3/39 (7.7%), HSP: 1/45 (2.2%), APC: 2/37 (5.4%), P=0.51).
Conclusion: CSP, HSP and APC ablation are eff ective and safe treatment 
modalities for 5-9mm left -sided colorectal polyps. The present random-
ized study could not detect any diff erences in the polyp recurrence rates 
among the three endoscopic techniques.
Disclosure: Nothing to disclose 
What causes (recurrent) acute pancreatitis?
08:30-10:00 / B2
OP301 ETIOLOGY OF CHRONIC PANCREATITIS IN CHILDREN - 
ANALYSIS OF 423 CASES
Oracz G., Kolodziejczyk E., Mianowska A., Rakowska M., Kierkuś J.
Childrens Memorial Health Inst., Dep. Of Gastroenterology, Hepatology, 
Feeding Disorders and Pediatrics, Warsaw, Poland
Contact E-Mail Address: grzegorz@oracz.pl
Introduction: Chronic pancreatitis (CP) is of a rare occurrence in childhood. 
The etiology of CP in children is varied and includes anatomic anomalies, 
gene mutations, metabolic disorders and others.
Aims & Methods: The aim of this study was to investigate the etiologi-
cal aspects of CP in children from well-defi ned homogenous single-centre 
cohort. 423 children with CP (aged: 0.6-18 years; mean 10; F-220, M-203) 
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respectively). HL increased the risk for moderately severe AP, for local com-
plications (OR = 1.552) and for renal failure (OR = 2.166). DM increased the 
risk of systemic complications, though, the diff erence was not signifi cant. 
In the independent eff ect analysis, only HT was an independent risk fac-
tor for mortality and severity (OR=5.900, p=0.020 and OR=3.895, p=0.001 
respectively). OB is an independent risk factor for renal failure (OR=2.968, 
p=0.007), HT for respiratory failure (OR=2.667, p=0.024) and renal failure 
(OR=7.565, p=0.007) and HL for fl uid collections (OR=1.415, p=0.037) and 
diabetes as a complication (OR=2.373, p=0.013). 
In the joint eff ect analysis, the rate of severe AP elevates with the number 
of MetS factors (2.6%, 4.7%, 6.1%, 8.5% and 6.0% with 0, 1, 2, 3 and 4 
factors respectively).
Conclusion: MetS factors increase the risk of mortality, severe AP and com-
plications. Hypertension proved to be an independent risk factor for mor-
tality and severity of AP. The more MetS factors are present, the higher is 
the risk of worse outcome in AP.
Disclosure: Nothing to disclose 
OP303 QUANTIFYING THE RISK OF DRUG INDUCED PANCREATITIS 
WITH ACE INHIBITORS AND STATINS USING A LARGE ELECTRONIC 
MEDICAL RECORD PLATFORM
Sandhu D.1, Twohig P.2, Thakkar S.3, Dulai P.4, Gardner T.5, Kochhar G.6
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Introduction: Acute pancreatitis (AP) is one of the most common causes 
of gastrointestinal-associated hospitalizations in the United States, with 
mortality rates as high as 30% for acute severe pancreatitis. Angiotensin-
converting enzyme inhibitors (ACEi) and hydroxymethylglutaryl-coenzyme 
A reductase inhibitors, also known as ‘statins’, are oft en prescribed to pa-
tients with hypertension and hyperlipidemia and have been implicated in 
causing AP. The quantitative risk for AP and incremental risk when used 
together is unknown.
Aims & Methods: Using IBD Explorys (1999-2019), a HIPAA-enabled web 
platform that includes clinical data from over 63 million unique individu-
als with accompanying lab data, we aimed to quantify the risk for drug-
induced AP with ACEi and statins. AP cases were identifi ed using a combi-
nation of ICD and SNOMED codes, and AP episodes secondary to alcohol, 
gallstones, triglycerides or common class 1 drugs associated with AP were 
excluded. Odds ratios (OR) with corresponding 95% confi dence intervals 
(CI) are reported.
Results: A total of 280,740 patients with AP meeting our inclusion criteria 
were identifi ed, the majority of which had been exposed to statin alone 
(32%), ACEi alone (31%), or both (19%). Among all patients exposed to 
these medications, AP was observed in 1.5% (n=90,120/5,959,500) of pa-
tients exposed to statin alone, 1.9% (n=86,870/4,705,640) of patients ex-
posed to ACEi alone, and 1.9% (n=54,590/2,879,850) of patients exposed 
to both a statin and ACEi. Compared to the general population, exposure 
to these medications conferred a 5-6 fold increased risk for AP not related 
to alcohol, gallstones, triglycerides, or common class 1 drugs associated 
with AP. (Table 1)
Medication Odds Ratio Confi dence interval (95%)
HMG-CoA reductase inhibitor (statin) 4.97 (4.93, 5.01)
ACE inhibitor 6.12 (6.07, 6.17)
ACEi + Statin 5.72 (5.67, 5.78)
[Table !: Odds ratio (with 95% con dence intervals) for acute pancreatitis 
with exposure to a statin, ACE inhibitor, or both]
Conclusion: Approximately 1.5-2% of patients exposed to a statin or ACEi 
develop AP, and exposure to these medications is associated with a 5-6 
fold increased risk for developing AP not attributed to alcohol, gallstones, 
triglycerides, or other drugs commonly associated with AP.
Disclosure: Nothing to disclose 
hospitalized between 1988 and 2019 were enrolled into the study. The di-
agnosis of CP was established according to INSPIRE recommendations. 
Clinical and epidemiological data were recorded and analyzed. All pa-
tients were screened for mutations in the high-risk genes associated with 
CP (CFTR, CTRC, PRSS1, SPINK1, CPA1, CEL-HYB). All children had preceding 
imaging studies, including US, CT, MRCP and/or ERCP.
Results: Gene mutations were found in 279 children (66%) (SPINK1 muta-
tion in 118 children, CTRC in 108 patients, CFTR in 61 patients, PRSS1 in 
55 children, CEL-HYB in 8 and CPA1 in 4; 75 pts (17.7%) have 2 or more 
mutations).
Anatomic anomalies of pancreatic duct were diagnosed in 69 patients 
(16.3%) (43-pancreas divisum, 9-ansa pancreatica, 7-ABPU, 2-two main 
pancreatic ducts, 8-other). 
Toxic-metabolic risk factors were found in 63 children (14.9%) with chronic 
pancreatitis, with dominance of lipid disturbances. Hyperlipidemia was 
present in 35 patients (8.3%), including isolated in 15 patients (3.5%) and 
coexisting with obesity/metabolic syndrome in 20 (4.7%). CP associated 
with medication was present in 15 (3.5%) children (mostly with anti-
epilepsy drugs). Alcohol abuse history was present in 7 (1.7%) patients. 
Smoking (>5 cigarettes/day) history was present in 8 (1.8%) children. Five 
patients (1.2%) from these groups had history of both- alcohol abuse and 
cigarettes smoking. Chronic renal failure was present in 4 (1%), mitochon-
drial cytopathies in 2 (0.5%) and hypercalcemia (hyperparathyroidism) in 
2 (0.5%) patients with CP. 
CP was associated with biliary tract diseases in 38 patients (8.9%). Auto-
immune pancreatitis was diagnosed in 14 children (3.3%). Idiopathic CP 
was diagnosed in 37 children (8.7%).
Conclusion: 1. Gene mutations and anatomic anomalies of pancreatic duct 
are the most common etiologic factors of CP in children.
2. CP is a multifactorial disease.
3. Our data demonstrate the need for genetic testing in children with CP.
Disclosure: Nothing to disclose 
OP302 METABOLIC SYNDROME FACTORS WORSEN THE OUTCOME 
OF ACUTE PANCREATITIS
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Introduction: Several studies have confi rmed the eff ect of obesity (OB), 
hyperlipidemia (HL) and diabetes mellitus (DM) on the outcome of acute 
pancreatitis (AP). However, there is no data regarding the association be-
tween hypertension (HT) and the outcome of AP. Furthermore, no study 
has examined yet the independent eff ects of these four factors, neither the 
eff ect of their diff erent combinations.
Aims & Methods: Our aim is to understand how these four factors of meta-
bolic syndrome (MetS) and their combinations eff ect the outcome of AP.
The Hungarian Pancreatic Study Group has prospectively collected clinical 
data from AP patients between 2012 and 2017. Our cohort contains 1257 
cases from 28 centers of which 906 cases had information on all four ex-
amined factors of MetS. For the individual eff ect analysis, patient groups 
were formed based on the WHO classifi cation of BMI and the presence of 
other MetS factors, namely HT, HL and DM. Logistic regression was per-
formed to analyze the independent eff ects of these four factors. For the 
joint eff ect analysis, patient groups were defi ned according to the combi-
nations of the MetS factors.
Results: OB and HT signifi cantly increased the risk for severe AP (OR=2.153 
and OR=2.3861 respectively). OB and HT patients stayed signifi cantly longer 
in the hospital (10.4d vs. 12.1d, p=0.008 and 10.5d vs. 11.8d, p=0.020) and 
had increased risk for systemic complications (OR = 1.993 and OR=2.830 
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OP304 DEVELOPMENT OF A MODEL TO DETERMINE THE RISK 
OF RECURRENCE OF ACUTE BILIARY PANCREATITIS BEFORE 
CHOLECYSTECTOMY: A MULTICENTRE, RETROSPECTIVE COHORT 
STUDY
de la Iglesia-Garcia D.1,2, Martínez-Moneo E.3, Mejuto-Fernandez R.1,2, 
Gendive-Martin N.3, Mauriz-Barreiro V.1,2, Santamaria-Vicario I.3, 
Calviño-Suárez C.1,2, Sanfelix-Carrasco M.3, Monteserin-Ron L.1,2, 
Roa-Esparza I.3, Lariño-Noia J.1,2, Iglesias-Garcia J.1,2, 
Dominguez-Muñoz J.E.1,2
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Introduction: International guidelines of acute pancreatitis (AP) recom-
mend cholecystectomy during the index admission of patients with acute 
biliary pancreatitis (ABP). This recommendation is not consistently fol-
lowed, thus increasing the risk of recurrence of ABP.
Aims & Methods: Our aim was to develop a model to determine the risk of 
recurrence of ABP to prioritise patients on surgical waiting list. 
Multicentre, retrospective cohort study of patients with a fi rst episode of 
ABP from January 2010 to December 2015. Biliary aetiology was defi ned by 
the presence of stones, or sludge/microlithiasis in the CBD or gallbladder 
at abdominal ultrasound, EUS or MRCP, together with the absence of AP 
relapse aft er cholecystectomy. Laboratory liver tests (AST, ALT, AP, GGT and 
bilirubin) at admission were recorded. Primary outcome was the risk of 
ABP recurrence during the six-month period aft er the fi rst episode. Sur-
vival analysis was performed using the Kaplan-Meier method. Cox regres-
sion analysis was performed to calculate hazard ratios (HR). Signifi cant 
risk factors associated with the risk of ABP recurrence were scored accord-
ingly and three risk categories (low, intermediate and high) were defi ned.
Results: 498 patients with a fi rst episode of ABP were included. Median 
time to cholecystectomy was 136 days (range 72-206 days). Patients wait-
ing more than 6 months for cholecystectomy were excluded. 352 patients 
were fi nally included (mean age 67.6 years, range 51.6 to 77,4, 199 female). 
ABP relapsed in 89 patients (25.3%). Serum alkaline phosphatase (AP), 
previous endoscopic sphincterotomy (EE) and the severity of the fi rst epi-
sode of ABP were signifi cantly associated with ABP recurrence. Scores as-
signed identifi ed patients with ABP who recur with a c-statistic of 0.59 
(95% CI, 0.55-0.64, p<0.001), HR 2.64 (95% CI 1.61-4.32). Patients in the 
high, intermediate and low risk group had a recurrence rate of 30.7%, 
18.7% and 0%, respectively.
Level of Alkaline Phosphatase Points
0 to 263 (Normal limit) 5
264 to 526 (2 ULN) 4
527 to 789 (3 ULN) 3
790 to 1052 (4 ULN) 2
> 1052 0
Severity of AP  
Mild AP 4
Moderate AP 2
Severe AP 0
ERCP  
No 4
Yes 0
   
   
Low risk: 4 to 8 points Intermediate: 9 to 11 points High risk: 12 to 13 points
[RABP Score]
Conclusion: A score system (recurrence acute biliary pancreatitis -RABP- 
score) based on serum levels of AP at admission, EE and severity of AP 
allows identifying patients with ABP at low, intermediate and high-risk 
groups of recurrence. This score might be used to prioritise patients in 
surgical waiting list for cholecystectomy.
Disclosure: Nothing to disclose 
OP305 INVESTIGATING THE EARLY PHASE OF CHRONIC 
PANCREATITIS: THE GOULASH PLUS TRIAL PROTOCOL AND THE 
RESULTS OF THE FIRST 14 MONTH
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Introduction: Acute pancreatitis (AP) is an infl ammatory condition, which 
can lead to late consequences. In 20 % of patients recurrent AP (RAP) de-
velops and in 7-12 % chronic pancreatitis (CP) will occur. However, we do 
not have suffi  cient information to establish an evidence-based statement 
to defi ne early CP, or how to prevent its development.
Aims & Methods: The aim of the GOULASH-PLUS study is to understand the 
infl uencing factors and to determine, which parameters should be mea-
sured to detect the early phase of CP. 
This is an observational prospective follow-up study of the GOULASH-trial. 
Patients’ selection: individuals enrolled in the GOULASH study will be ap-
proached and asked to join this longitudinal study. Participants will be 
followed up at 1-2-3-4-5 and 6 years aft er the episode of AP. Anamnes-
tic data will be collected by the following questionnaires: i) FFQ ii) SF-36 
iii) physical activity questionnaire iv) stress questionnaire. Genetic tests 
will be performed for the genes already known to be associated with CP. 
The exocrine pancreatic, liver and kidney functions will be determined by 
several laboratory tests, stool sample analyses and imaging will be per-
formed. The endocrine function will be measured by an oral glucose toler-
ance test (OGTT) and HbA1C. Blood and stool samples will be stored in 
the biobank for later measurements. Now, the participation in the fi rst 14 
months and the changes in the endocrine function were analyzed.
Results: During the fi rst 14 months 93 out of the 126 patients attended the 
fi rst year control, thus the enrolment rate was 73.8 %. Their mean age 
was 54+13.3 years and 57 (61.2%) were male. Mild, moderate and severe 
AP was observed in 69 (74%), 19 (21%) and 5 (5%) patients during their 
index admission. Out of 18 (19.4%) of them was admitted with recurrent AP 
episode. At the fi rst year follow-up, 9 patients were newly diagnosed with 
diabetes, and 21 patients had impaired glucose tolerance. The incidence of 
diabetes increased aft er the fi rst year of AP from 12.9% to 22.7%, at 45.3% 
of the patient´s carbohydrate metabolism disorder could be detected. Pa-
tients who were admitted with moderate or severe AP were more likely to 
develop diabetes (5 from 24 patients; 20.8%) than patients with mild AP 
(4 from 69 patients; 5.8%).
Conclusion: The development of carbohydrate metabolism disorder is 
frequent in AP, it shows correlation with the severity of AP, therefore the 
follow-up of these patients is likely to be benefi cial.
Disclosure: Nothing to disclose 
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databases, and internal evaluations. Tumor-normal comparisons were 
used to defi ne somatic versus germline, and MAFs were calculated for 
each.
Results: A total of 234 patient samples from 17 institutions were analyzed. 
Of these, 12 (5.1%) had predicted deleterious germline variants involving 
8 diff erent genes: BRCA1 (n = 3), CHEK2 (n = 3), ATM (n = 1), MLH1 (n = 1), 
MUTYH (n = 1), PALB2 (n = 1), SMAD4 (n = 1), TP53 (n = 1). For most somatic 
alterations, the MAFs were found to be greater than the germline deleteri-
ous alterations, with the latter approaching ~50% in most cases.
Conclusion: This multi-institutional study identifi es 5% of patients with 
pancreatic cancer to have deleterious germline alterations. Somatic variant 
testing, particularly when paired with germline, can be used as a screen-
ing method for genetic counseling referrals, especially with MAF analyses 
of paired tumor-normal samples.
Disclosure: Nothing to disclose 
OP308 GENE CO-EXPRESSION NETWORK ANALYSIS OF 
PRECURSOR LESIONS IN FAMILIAL PANCREATIC CANCER
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Introduction: An estimated fraction of up to 10% of all pancreatic cancers 
is attributed to familial pancreatic cancer (FPC) with an accumulated life-
time risk of up to 38.5% for pancreatic ductal adenocarcinoma (PDAC) 
(1). The process of progression from pre-malignant lesions to the forma-
tion of invasive PDAC is thought to take around 10 years (2). High grade 
Pancreatic Intraepithelial Neoplasia (PanIN) are aggressive pre-malignant 
lesions, associated with elevated risk for progressing to PDAC (3-5). To 
date, no genetic mutations with strong association to FPC related PanIN 
lesions are known. A thorough depiction of dysregulated gene activity in 
high grade PanIN lesions in patients with FPC can help to characterize 
the molecular events during the development and progression of familial 
PanIN lesions to PDAC.
Aims & Methods: We performed weighted gene co-expression network 
analysis (WGCNA) to identify genes associated with FPC related PanIN le-
sions using gene expression profi les of 33,000 genes measured by Aff yme-
trix GeneChip HG-U133 arrays on 13 pancreatectomy specimens with PanIN 
lesions (stage 2-3) from FPC patients, 6 pancreatectomy specimens with 
PDAC from sporadic pancreatic cancer (SPC) patients, and 4 specimens of 
normal donor pancreatic tissue (6). Microarray data were analyzed using 
R package WGCNA.
Results: WGCNA detected co-expressed genes as modules/clusters and 
summarized each module by a representative gene: the module ei-
gengene. Correlation analysis identifi ed 2 up-regulated modules or co-
expressed gene clusters (p< 1e-05) and 2 down-regulated modules (p< 
1e-05) in FPC compared to SPC. The upregulated gene modules include 
5 signifi cant genes (p< 1e-06) consisting of FMO4, FMO2, CORO1B, TPP1, 
CIB4. 
The down-regulated gene modules include 170 signifi cant genes (p< 1e-
06), among them 13 highly signifi cant genes (p< 1e-10) consisting of: CO-
L10A1, SAMD9, PLPP4, COMP, POSTN, IGHV4-31, THBS2, MMP9, FNDC1, HOPX, 
TMEM200A, INHBA, SULF1. The down-regulated modules are signifi cantly 
enriched for Gene Ontology (GO) terms functionally related to: extracel-
lular structure organization, cell-substrate junction, focal adhesion, col-
lagen binding, extracellular vesicle, etc. In addition, we identifi ed common 
modules shared by both FPC and SPC - with 2 commonly up-regulated 
modules (p< 4e-12) and 1 commonly down-regulated module (p< 1e-17) as 
compared with normal pancreatic tissue. 
The common up-regulated modules include 1054 highly signifi cant genes 
(p< 1e-06) with 14 top signifi cant genes (p< 1e-16) consisting of: ID2B/ID2, 
OGFOD1, COL3A1, HOPX, SULF1, ELK3, HLA-DRB1, PMP22, CYAT1, PLPP4, CO-
L1A2, SFRP4, SPARC, THBS2. In the common down-regulated module, 214 
genes were diff erentially expressed in comparison with normal pancreatic 
tissue (p< 1e-06), among them 15 were top signifi cant genes (p< 1e-12) 
consisting of: UTP14A, PGM3, SLC1A4, PHGDH, MRM3, GMPPA, SNORD14D, 
NSA2, NUBP1, CCT4, IGBP1, FMOD, AADAC, ASNS, LANCL2. The common 
down-regulated module is enriched for GO terms related to functions in: 
cotranslational protein targeting to membrane, peptide metabolic process, 
structural constituent of ribosome, etc.
OP306 ACUTE PANCREATITIS AND MUCIN PHENOTYPE OF 
INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF PANCREAS
Tanaka T.1, Masuda A.2, Yamada Y.1, Ikegawa T.3, Kobayashi T.4, Sakai A.5, 
Shiomi H.5, Kodama Y.3
1Kobe University Hospital, Division of Gastroenterology, Kobe University 
Graduate School of Medicine, Kobe, Japan, 2Kobe Graduate School of 
Medicine, Division of Gastroenterology, Department of Internal Medicine, 
Kobe, Japan, 3Kobe University Hospital, Kobe, Japan, 4Kobe University, 
Gastroenterology, Kobe, Japan, 5Kobe University Graduate School of 
Medicine, Gastroenterology, Kobe, Japan
Contact E-Mail Address: t_takeshi0808@yahoo.co.jp
Introduction: Acute pancreatitis (AP) occasionally occurred in patients with 
intraductal papillary mucinous neoplasm (IPMN). The infl uence of mucin 
phenotype of IPMN on the occurrence of AP remains controversial.
Aims & Methods: We investigated the relationship between mucin phe-
notype of IPMN and AP, including pancreatic hyperenzymemia. This study 
included 163 patients with IPMN who had surgery at our hospital between 
January 2000 and December 2016. The relationship between mucin phe-
notype of IPMN and AP (or pancreatic hyperenzymemia) was investigated. 
Mucin phenotype of IPMN was classifi ed as Gastric type (G type: N=101), 
Intestinal type (I type: N=45), Pancreatobiliary type (PB type: N=11) and 
Oncocystic type (O type: N=2).
Results: 11% (18/163) of IPMN cases developed AP and 55.6% (10/18) of 
AP cases have recurrent episode (2-4 times). Age, gender, BMI, diabetes, 
alcohol consumption (more than 50g/day), drinking habits, and smok-
ing status (current smoking) were not associated with the incidence of 
AP. In addition, there was no association of the incidence of AP with the 
diameter of main pancreatic duct, mural nodules, and the diameter of 
IPMN. In mucin phenotype, AP was signifi cantly more frequently occurred 
in pancreatobiliary type (PB type: with AP vs. without AP, 27.8% [5/18] vs. 
4.1% [6/145], P = 0.003) and intestinal type (I-type: with AP vs. without AP, 
50.0% [9/18] vs 24.8% [36/145], P = 0.046). In the 5 cases of PB type with 
AP, 4 cases were intraductal mass in the main pancreatic duct, and 1 case 
had the compression of the main pancreatic duct by the intraductal mass in 
the branch pancreatic duct. In Intestinal IPMN cases with AP, 88.9% (8/9) 
had dilated main pancreatic duct by hyper mucin production. The eleva-
tion of serum pancreatic enzymes (serum amylase, serum lipase, serum 
elastase-I) was not signifi cantly related to mucin phenotype of IPMN.
Conclusion: PB type and intestinal type IPMN were signifi cantly associ-
ated with AP. PB type sometimes display intraductal mass with poor mucin 
production in the main or branch pancreatic duct, while intestinal type 
is characterized by abundant mucin production. These mucin phenotype 
might be closely associated the occurrence of AP in IPMN.
Disclosure: Nothing to disclose 
From bench to bedside in pancreatic cancer
08:30-10:00 / B3
OP307 A MULTI-INSTITUTIONAL STUDY ASSESSING PREVALENCE 
OF DELETERIOUS GERMLINE MUTATIONS IN PANCREATIC CANCER
Sadaps M.1, Funchain P.2, Heald B.2, Huether R.3, Pitt J.3, White K.3, 
Khorana A.2, Sohal D.2
1Cleveland Clinic, Hematology-Oncology, Cleveland, United States, 2Cleveland 
Clinic Foundation, Cleveland, United States, 3Tempus, Cleveland, United 
States
Contact E-Mail Address: sadapsm@ccf.org
Introduction: Pancreatic cancer is being increasingly associated with germ-
line implications. Some large single-center studies have reported results 
ranging from 3.9% to 19.8% of patients found to have germline variants 
[Shindo, JCO 2017; Lowery, JNCI 2018].
Aims & Methods: We aim to further delineate prevalence of deleterious 
germline mutations in pancreatic cancer using a multi-institutional data 
set. We also aim to analyze predictive factors such as mutant allele fre-
quency (MAF, in %) in germline versus somatic calls. We sequenced 23 
genes in DNA prepared from clinical tissue and blood specimens submit-
ted to Tempus Labs. Germline variants and somatic variants were pro-
cessed separately. Germline variants were determined to be deleterious 
through the sum eff ect of a combination of in silico predictors, population 
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Conclusion: The diff erential molecular pathology of FPC and SPC involves 
multiple co-expressed gene clusters signifi cantly enriched for GO terms in-
cluding functions in extracellular activities and focal adhesion. Meanwhile, 
both FPC and SPC share strong gene co-expression patterns functionally 
related to intracellular activities. These fi ndings provide reference for ge-
nomic characterization of the molecular events during the development 
and progression of PanIN lesions to PDAC in FPC.
References: 1. Brune KA, Lau B, Palmisano E, Canto M, Goggins MG, Hruban 
RH, et al. Importance of age of onset in pancreatic cancer kindreds. Journal 
of the National Cancer Institute. 2010;102(2):119-26. 2. Yachida S, Jones S, 
Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late dur-
ing the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114-
7. 3. Diaz KE, Lucas AL. Familial Pancreatic Ductal Adenocarcinoma. The 
American journal of pathology. 2019;189(1):36-43. 4. Hruban RH, Canto 
MI, Goggins M, Schulick R, Klein AP. Update on familial pancreatic can-
cer. Advances in surgery. 2010;44:293-311. 5. Welinsky S, Lucas AL. Famil-
ial Pancreatic Cancer and the Future of Directed Screening. Gut and liver. 
2017;11(6):761-70. 6. Crnogorac-Jurcevic T, Chelala C, Barry S, Harada T, 
Bhakta V, Lattimore S, Jurcevic S, Bronner M, Lemoine NR, Brentnall TA. 
Molecular analysis of precursor lesions in familial pancreatic cancer. PLoS 
One. 2013;8(1):e54830. doi: 10.1371/journal.pone.0054830.
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OP309 GASTROKINE 1 AND 2 IN PANCREATIC CARCINOGENESIS: 
ONE FAMILY WITH TWO DISTINCT ROLES?
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Gupta A.1, Wanner-Seleznik G.1, Graf R.1
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Introduction: Late detection of pancreatic ductal adenocarcinoma (PDAC) 
and limited treatment options lead to poor survival of PDAC patients. A 
better understanding of the pathomechanism of PDAC development will 
help identify new therapeutic approaches. An early event during tumori-
genesis is the development of pre-malignant lesions such as pancreatic 
intraepithelial neoplasia (PanIN). While studying a K-Ras driven mouse 
model (KC mice) of PDAC, which recapitulates the stepwise progression of 
pancreatic cancer, we serendipitously identifi ed Gastrokine 1 (GKN1) and 
Gastrokine 2 (GKN2) in early PanIN lesions. Importantly, we confi rmed the 
presence of GKN1 and GKN2 in human pancreatic premalignant lesions. 
GKNs are proteins derived from gastric epithelium, where they maintain 
gastric homeostasis and act as tumor suppressors. Therefore, we aim to 
investigate the function of this PanIN-specifi c GKN1 and GKN2 expression, 
to understand the early events that underlie the development of premalig-
nant lesions leading to pancreatic carcinogenesis.
Aims & Methods: We intercrossed KC mice with GKN1-/- or GKN2-/- mice. 
GKN1-/- KC, GKN2-/- KC and GKN+/+ KC pups were analyzed at the age of 
3- and 9 months to quantify PanIN lesions and assess tumor development 
via histology. Furthermore, qRT-PCR and western blots were used to ana-
lyze genes and proteins (relevant for apoptosis, EMT or tissue remodeling 
and stroma composition) involved in tumorigenic processes. For all com-
pared groups we analyzed the proliferation index and measured diff erenc-
es in pancreatic cyst sizes. In vitro, acinar transdiff erentiation experiments 
were performed with cells isolated from all groups. A lentiviral construct 
overexpressing mouse GKN1 or GKN2 was generated to transduce Panc02 
mouse pancreatic cancer cells to confi rm the results in-vitro.
Results: Absence of GKN1 or GKN2 dramatically accelerated the develop-
ment of PanIN lesions in KC mice. 3 months old GKN1-/-KC and GKN2-/-KC 
mice showed more extensive ADM and PanIN lesions compared to GKN+/+ 
KC mice, coinciding with signifi cant upregulation of genes involved in 
PanIN development, cytokine and chemokine expression as well as tissue 
remodeling. Interestingly, the mRNA expression analysis also revealed a 
signifi cant diff erence in apoptosis regulation in GKN1-/- KC mice. Analysis 
of cleaved Caspase-3, FAS protein and activated cleaved Caspase-8 point 
towards a decreased apoptosis in the absence of GKN1 and suggests a 
possible involvement of GKN1 in the activation of the extrinsic apoptotic 
pathway. The histological comparison at 9-months showed that GKN1-/- 
KC mice developed a collagen-rich dense stroma around the pancreatic 
lesions compared to sparse stroma in KC animals. GKN1-/- KC mice showed 
an increased tumor incidence (40.7% vs 13%) and a more diff erentiated 
tumor phenotype. On the other hand, the histological evaluation shows 
that 9 month old GKN2-/- KC mice display a change of pancreatic tissue 
architecture resulting in big cystic lesions. In context of tumor incidence, 
GKN2-/-KC mice reveal a comparable incidence to GKN+/+ KC mice.
Conclusion: We conclude that the absence of GKN1 or GKN2 leads to ac-
celerated PanIN development. Based on our results, we suggest that GKN1 
infl uences apoptosis avoidance at an early age through the extrinsic apop-
tosis pathway. Apoptosis avoidance and development of a dense stromal 
reaction in later stages leads to an increased tumor incidence. GKN2 plays 
an important role in maintaining pancreatic architecture during PanIN for-
mation, especially infl uencing the cyst size and proliferation.
Disclosure: Nothing to disclose 
OP310 HOW DOES INTESTINAL TYPE INTRADUCTAL PAPILLARY 
MUCINOUS NEOPLASM EMERGE?
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Introduction: Intestinal intraductal papillary mucinous neoplasms (IPMNs) 
are oft en concurrent with gastric type components, and gastric IPMNs are 
assumed the origin of intestinal IPMNs. However, the molecular mecha-
nism underlying the development and evolution of intestinal IPMN is not 
known.
Aims & Methods: To establish the molecular progression model of intesti-
nal IPMN, we performed triple staining for CDX2, MUC2, and alcian blue, 
as intestinal diff erentiation markers, and double immunostaining for p21 
and Ki-67, as cell cycle regulatory markers, on 61 intestinal IPMNs. Mu-
tation analyses of KRAS and GNAS of intestinal and gastric components, 
individually, were performed using droplet digital PCR (QX200, Bio-Rad) 
and targeted amplicon sequencing (Ion S5, Thermo Fisher) in 25 cases.
Results: Histologically, intestinal features appear gradually in gastric 
type neoplasms those being IPMNs (n=32, 54%) or incipient PanIN-like 
lesions (n=20, 30%) in size. Triple staining for CDX2, MUC2 and alcian 
blue revealed that CDX2 expression appeared to precede MUC2 expres-
sion and morphological changes into intestinal phenotypes in gastric type 
epithelia. With MUC2 expression, intestinal morphological features, such 
as elongated nuclei, high-columnar epithelia, and nuclear stratifi cation, 
became obvious. Cytoplasmic alcian blue-positive mucin and papillary 
growth seemed to become prominent as MUC2 expression increased. 
These results suggest that CDX2 may induce the characteristic biochemical 
and morphological transition of gastric-type epithelia into intestinal-type 
epithelia. 
Expression of p21 and Ki-67 seemed to be accelerated by CDX2 expression 
as follows: the labeling index of p21 was 17.9±24.0% in gastric IPMNs and 
52.4±22.1% in intestinal IPMNs (p< 0.05). The labeling index of Ki-67 was 
4.3±1.9% in gastric IPMNs and 34.0±16.8% in intestinal IPMNs (p< 0.05). 
Double immunostaining for p21 and Ki-67 revealed that p21 positive cells 
tended to distribute in apex while Ki-67 positive cells did base of papil-
lae, which resembles those in normal intestinal mucosa. Hence, intestinal 
IPMNs may have an adenomatous phase, in which the balance of diff er-
entiation and proliferation of neoplasm is regulated. This regulated trend 
seemed to disappear with the progression of grade and development of 
invasion (low-grade IPMN versus high-grade IPMN, p< 0.05, and versus 
invasive cancer, p< 0.05).
Finally, all intestinal IPMNs concurrent with gastric IPMN (n=18) or with 
incipient PanIN-like lesions (n=7) shared identical KRAS and GNAS pro-
fi les with the gastric type epithelia. Intestinal IPMNs seemed to arise from 
GNAS/KRAS mutant (n=14, 78%) and GNAS mutant (n=4, 22%) gastric 
IPMNs. Also, intestinal IPMNs seemed to arise from GNAS/KRAS mutant 
(n=4, 57%) and GNAS mutant (n=3, 43%) incipient PanIN-like lesions, 
namely incipient IPMNs. Variant allele frequencies (VAFs) of GNAS and 
KRAS increased with the transition of gastric IPMNs into intestinal IPMNs 
as follows: VAFs of GNAS in gastric and intestinal IPMNs were 20.8±15.3% 
and 40.2±18.4% (p< 0.05, n=18), respectively. VAFs of KRAS in gastric and 
intestinal IPMNs were 23.1±12.1% and 33.8±12.4% (p< 0.05, n=14), respec-
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screening. Collectively, the discovery of GKNs opens up avenues to test 
these proteins in patient cohorts and to further study their role in PanIN 
and PDAC development.
Disclosure: Nothing to disclose 
OP312 PANCREATIC CANCER CELLS ACCESS NERVES VIA 
TGFBETA1-MEDIATED TRANSDIFFERENTIATION OF PERINEURAL 
EPITHELIAL CELLS INTO MESENCHYMAL-LIKE CELLS
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Introduction: Mechanisms of “neural invasion” in pancreatic cancer are 
widely unclear. Classically, cancer cells are assumed to actively break or 
mechanically disrupt the perineural barrier to fi nd access into nerves. 
However, for this hypothesis to be true, the cancer cells would need to 
exert destructive-toxic eff ects on the cells that compose the perineural bar-
rier. Here, we hypothesized an alternative mechanism of cancer cell entry 
into nerves, i.e. the “transdiff erentiation” of perineural epithelial cells of 
the outermost nerve sheath in the cancer micro-environment.
Aims & Methods: Human perineural epithelial cells were cultured with-
in the supernatants of diff erent human pancreatic cancer cell lines and 
analyzed for markers of epithelial-mesenchymal-transition (EMT). The 
integrity of the perineural epithelial cell linings was analyzed in human 
pancreatic cancer tissues by quantitative immunohistochemistry of circum-
ferential perineural GLUT1 staining. Transcriptomic arrays were performed 
with perineural epithelial cells to decipher the transcriptomic changes in 
the cancer-induced transdiff erentiation process. Levels of diff erent EMT in-
ducers were analysed by ElLISA within pancreatic cancer cell supernatants. 
Genetically engineered mice with precursors of pancreatic cancer (p48-
Cre;LSL-KrasG12D/“KC”) and pancreas-specifi c TGFbeta1 overexpression 
(KC;TGFbeta1ov+/) were analysed for the perineural integrity.
Results: Treatment of human perineural epithelial cells (HPEC) with su-
pernatants of three diff erent human pancreatic cancer cell lines resulted 
in morphological alterations in the perineural cells that were reminiscent 
of EMT. Accordingly, cancer-conditioned perineural epithelial cells overex-
pressed Vimentin and N-Cadherine, and downregulated E-cadherine. The 
transcriptomic analysis of the cancer-conditioned, perineural epithelial 
cells revealed expression changes that pointed out towards an EMT signa-
ture. Among the diff erent potential mediators of EMT, the only factor that 
was specifi cally enriched in the supernatants of human pancreatic cancer 
cell lines was TGFbeta1. Accordingly, increasing concentrations of TGFbeta1 
in the culture medium of human perineural epithelial cells resulted in 
prominent EMT-like changes in the perineural cells. In human pancreatic 
cancer tissues, GLUT1-expressing perineural epithelial barrier cells were 
widely lost as opposed to the intact barrier around nerves in normal pan-
creas. Moreover, analysis of the perineural integrity in KC;TGFbeta1ov+/ 
revealed prominent loss of perineural integrity upon TGFbeta1 overexpres-
sion when compared to KC mice.
Conclusion: Cancer cell-induced transdiff erentiation of perineural epithe-
lial cells seems to be the initial mechanistic event that enables pancreatic 
cancer cell access into nerves. In this context, TGFbeta1 signaling seems to 
be of paramount importance in mediating neural invasion in pancreatic 
cancer and is thus of potential therapeutic relevance.
Disclosure: Nothing to disclose 
tively. Moreover, VAFs of GNAS and KRAS increased from incipient IPMN 
foci (7.5±6.9% and 3.5±3.7%) to mature intestinal IPMNs (47.1±16.1% and 
42.8±13.0%, n=7 and n=3, p< 0.05 and p=0.0702).
Conclusion: Intestinal IPMNs may arise in GNAS-mutant gastric type IPMNs, 
in which CDX2 is supposed to play a critical role in the process of intestinal 
diff erentiation and progression by inducing the expression of MUC2 and 
p21 with some unknown growth-promoting molecules.
Disclosure: Nothing to disclose 
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Introduction: Current diagnostic methods are unable to detect pancreatic 
ductal adenocarcinoma (PDAC) at early, possibly treatable stages. Such 
early event in the malignant transformation is the development of pancre-
atic intraepithelial neoplasia (PanIN), the most common PDAC precursor. 
PanINs are classifi ed according to their grade of dysplasia into PanIN-1A, 
PanIN-1B, PanIN-2 and PanIN-3. Molecular events occurring in the step-
wise progression from premalignant PanIN lesions to PDAC develop-
ment are largely unknown. A detailed knowledge of the critical biological 
changes responsible for pancreatic tumorigenesis is essential for the de-
velopment of early diagnostic and preventive strategies. 
The aim of our project is the identifi cation of such key processes through 
the characterization of PanINs, focusing on two proteins - gastrokine 1 and 
gastrokine 2- that has so far not been shown in the pancreas. Gastrokines 
(GKNs) have been almost exclusively described in the stomach with a sug-
gested role in gastric epithelial homeostasis and as tumor suppressor.
Aims & Methods: First, a comprehensive gene expression analysis was 
performed in human PanIN samples. The results were validated with 
qRT-PCR in an independent cohort of pancreatic cancer patients. The pres-
ence of GKNs was verifi ed by immunohistochemistry (IHC). The KRAS gene 
driven KC (p48+/Cre;Kras+/G12D) mouse model is a well-established model 
for pancreatic cancer, recapitulating the morphological features of PDAC 
development. Pancreatic tissues of KC mice were characterized by whole 
genome microarray analysis, qPCR, western blotting and IHC. Using a 3D 
mouse primary acinar cell culture model, we induced acinar cell transdif-
ferentiation, to test GKNs expression. GKNs in mouse pancreatic juice were 
detected with mass spectrometry and in serum by western blot.
Results: Molecular analysis of patient samples and KC pancreas revealed 
high expression of gastrokines (GKN1 & GKN2) on dysplastic cells. GKN1 
and GKN2 are co-expressed specifi cally on low-grade PanIN lesions (Pan-
IN1B and PanIN2) in human and mice, where their expression is restricted 
to the cytoplasm of dysplastic epithelium. These proteins are absent in 
healthy acinar and ductal cells, as well as on tumor cells. Also high grade 
PanIN lesions are negative for GKNs. 
We further assessed if infl ammation can drive GKNs expression, howev-
er infi ltrating infl ammatory cells in human and mouse samples do not 
express GKNs. Furthermore, GKNs are undetectable in mouse models of 
pancreatic infl ammation. Analysis of KC mice revealed continuous increase 
in GKNs from 4-52 weeks of age corresponding to an increase in the PanIN 
harboring area. During in-vitro transdiff erentiation, expression of GKNs 
increased progressively parallel to the number of newly formed lesions in 
the culture. We confi rmed secretion of GKNs in the pancreatic juice, and 
detected GKNs in the serum of KC mice. We further observed the presence 
of GKN1 in human pancreatic cyst fl uid in some IPMNs and PDAC with 
cystic component.
Conclusion: In this study, for the fi rst time, we report association of gas-
trokines with early pancreatic cancer precursors in human and mouse 
pancreatic tissues. Their progressive increase in developing PanIN lesions 
and their secretion in serum, pancreatic juice and cyst fl uid suggest that 
gastrokines could become promising biomarker(s) in PDAC diagnostic or 
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Towards early diagnosis of gastric cancer
08:30-10:00 / E1
OP313 COMPREHENSIVE BIOINFORMATIC ANALYSIS OF 
ABERRANTLY EXPRESSED PROFILES OF MIRNAS AND LNCRNAS 
WITH THE ASSOCIATED CERNA NETWORK IN GASTRIC CANCER
Zhou X.
Jiangsu Province Hospital, Dept. of Gastroenterology, Nanjing, China
Contact E-Mail Address: zhouxiaoying0926@sina.cn
Introduction: Increasing evidence has highlighted the critical roles of miR-
NAs as biomarkers and therapeutic targets for cancer. MiRNAs are also 
regarded as a major part of competing endogenous RNA (ceRNA) net-
work due to its regulation on protein-coding gene expression by acting as 
sponges. However, functional roles of miRNA-mediated ceRNAs in gastric 
cancer (GC) remain unclear.
Aims & Methods: To clarify relevant potential mechanisms, we compre-
hensively compared the expression profi les of mRNAs, lncRNAs and miR-
NAs between 55 GC tissues and 55 non-tumor tissues, based on GEO da-
tabases. Then, we selected most relevant genes through GO and pathway 
analysis, together with target gene prediction. We also set up a ceRNA 
network through the certain algorithm.
Results: 299 lncRNAs and 1118 mRNAs were identifi ed as aberrantly ex-
pressed in all of the four databases (GSE67354, GSE78775, GSE79973 and 
GSE19826). Aft er screening by GO and pathway analysis, 364 signifi cant 
mRNAs were selected (p< 0.05) and they had correlations with tumorigen-
esis and/or progression of GC. Further screening was performed using tar-
geting gene prediction and 179 mRNAs were chosen. Then, a dysregulated 
miRNA-associated ceRNA network was successfully constructed, which 
inculdes 70 lncRNAs, 11 miRNAs and 112 mRNAs. Finally, 2 out of the 11 
dysregulated miRNAs functioned as prognostic biomarkers for GC patients 
according to the overall survival analysis, which is a higher expression of 
hsa-miR-125-5p and hsa-miR-130-3p represented a lower prognosis rate 
(P=0.0259 and 0.0236, respectively). We then examined the miRNAs’ ex-
pression in our 30 GC tissues and 30 controls. MiR-125 and miR-130 were 
both decreased in GC tissues.
Conclusion: Our study identifi ed novel miRNAs as candidate prognostic 
biomarkers and potential therapeutic targets for GC, based on large-scale 
sample size. More importantly, the newly identifi ed ceRNA network will 
be benefi cial for improving the understanding of miRNA-mediated ceRNA 
regulatory mechanisms in the pathogenesis of GC.
Disclosure: Nothing to disclose 
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FOR THE EARLY DETECTION OF GASTRIC CANCER
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Introduction: Gastric cancer (GC) is one of the most common malignancies 
in the world. Although endoscopy is a gold standard for the diagnosis 
of this disease, comprehensive screening endoscopy would be invasive, 
expensive and could result in signifi cant complications. To date, there is a 
signifi cant lack of useful GC biomarkers. We thus conducted this study to 
discover non-invasive biomarkers for the early diagnosis of GC, consisting 
of urinary microRNAs (miRNAs).
Aims & Methods: A cohort of 306 patients composed of 153 patients with 
GC and 153 age- and sex-matched healthy controls (HCs) were randomly 
divided into three groups: the discovery cohort (4 pairs); the training co-
hort (95 pairs); the validation cohort (54 pairs). Moreover, age- and sex- 
matched 32 pairs with serum samples were also enrolled in the serum 
cohort.
Results: Baseline clinical characteristics were well balanced and no sig-
nifi cant diff erences were noted except for H. pylori status. More than 60 % 
of patients with GC were stage I and around 50 % could undergo curative 
endoscopic resection in this study. 
A miRNA microarray analysis detected 22 urinary miRNAs with signifi cant-
ly aberrant expressions between the two groups in the discovery cohort. 
Two miRNAs, miR-6807-5p and miR-6856-5p, were found to be highly 
expressed in the urine of GC patients compared to HCs in the training co-
hort. A multivariate analysis has demonstrated that urinary levels of these 
2 miRNAs were independent biomarkers for diagnosis of GC, as well as H. 
pylori status
In the validation cohort, urinary miR-6807-5p and miR-6856-5p showed 
signifi cantly higher expression levels in the GC group, and the combina-
tion biomarker panel of miR-6807-5p, miR-6856-5p, and H. pylori status 
also showed excellent diagnostic performance (AUC = 0.885). In addition, 
serum levels of miR-6807-5p and miR-6856-5p were signifi cantly higher 
in the GC group.
Conclusion: A novel biomarker panel consisted of urinary miR-6807-5p, 
miR-6856-5p, and H. pylori status enabled early and non-invasive detec-
tion of GC.
Disclosure: Nothing to disclose 
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Introduction: High mortality from gastric cancer is related to the late mani-
festation of its symptoms. A blood-based non-invasive biomarker with the 
ability to detect all stages of gastric cancer could signifi cantly improve pa-
tient outcomes.
Aims & Methods: We aimed to develop a novel serum miRNA assay for 
diagnosis of gastric cancer.
We developed a multi-target miRNA assay from a discovery study involving 
892 gastric cancer and control subjects from Singapore and Korea. Using 
RT-qPCR, we quantifi ed the expressions of 578 serum miRNAs and con-
structed a 12-miR biomarker panel through multi-variant data analysis. 
The results were generated with the use of a logistic-regression algorithm, 
with the value of 40 or more considered to be positive. We subsequently 
validated this multi-miR assay in a large prospective cohort. The cohort 
included subjects of all ethnicities (Chinese, Malay, Indian, and others) 
age 40 years old and above presenting with an indication for upper GI 
endoscopy at the National University Hospital and Tan Tock Seng Hospital, 
Singapore between 2013 and 2016. All participants had undergone endos-
copy. In addition to miRNA profi ling, sera was routinely assayed for H. 
pylori antibodies with Western Blot Assay (MP BIOMEDICALS, USA), as well 
as levels of pepsinogen I and II using latex agglutination turbidimetric 
immunoassay kit (Eiken, Japan). The performance of the miRNA assay was 
compared with serological markers such as H.pylori antibody and Pepsino-
gen index. A positive serum Pepsinogen index was defi ned as pepsinogen 
I level ≤70 ng/ml and a pepsinogen I/II ratio ≤3.0. All participants had 
given informed consent.
Results: Out of the 4566 subjects with the mean age of 57±10, 53% were 
male, 76% were Chinese, 55% were H.pylori serology positive, and 5.3% 
were positive for Pepsinogen index. There were 125 gastric cancer cases 
detected. The 12-miR assay achieved an Area-Under-Curve (AUC) of 0.84, 
signifi cantly outperforming (p-value< 0.01) that of H.pylori (AUC of 0.64) 
and Pepsinogen index (AUC of 0.57). The sensitivity of the miRNA assay in 
detecting early (stage 0-2) and late (stage 3-4) stage gastric cancer was 
82.6% (95% CI, 68.6% to 92.2%) and 88.4% (95% CI, 78.4% to 94.9%) 
respectively at a specifi city of 70.0% (95% CI, 67.8% to 71.9%). In com-
164 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
(2016). 4. Robinson, J. T. et al. Integrative genomics viewer. Nature bio-
technology 29, 24-26, https://doi.org/10.1038/nbt.1754 (2011).
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OP317 ENDOSCOPIC THREE CATEGORICAL DIAGNOSIS OF 
HELICOBACTER PYLORI INFECTION USING LINKED COLOR IMAGING 
AND DEEP LEARNING: A SINGLE-CENTER PROSPECTIVE STUDY
Nakashima H.1, Kawahira H.2, Kawachi H.3, Sakaki N.1
1Foundation for Detection of Early Gastric Carcinoma, Gastroenterology, 
Tokyo, Japan, 2Jichi Medical University, Medical Simulation Center, Tochigi, 
Japan, 3Cancer Institute Hospital, Japanese Foundation for Cancer Research, 
Department of Pathology, Tokyo, Japan
Contact E-Mail Address: naka2515@gmail.com
Introduction: Helicobacter pylori (HP) eradication is a critical therapeutic 
approach to reduce gastric cancer mortality. In Japan, 1.5 million people 
undergo HP eradication annually. Three categories of HP infection sta-
tus that coexist in the Japanese society are identifi ed, i.e., non-infection 
(without a history of infection, HP_0), current infection (HP_1), and aft er 
eradication treatment (HP_2). Despite successful HP eradication, the risk 
of gastric cancer persists for patients who already show progression of 
mucosal atrophy and intestinal metaplasia1). Because each category shows 
a diff erent risk of developing gastric cancer, diagnosis to stratify examinees 
into three categories is important. The authors fi nd it benefi cial to create 
a novel computer-aided endoscopic diagnosis (CAD) system for classifying 
HP infection status using linked color imaging (LCI) and deep learning 
(DL)2). LCI is a new image-enhanced endoscopic technique that enhances 
slight diff erences in mucosal color, whereas DL is a machine learning tech-
nology that imitates the neural network of the brain.
Aims & Methods: This prospective study aims to create a CAD system that 
can classify HP infection status into three categories using LCI and DL. The 
candidate subjects were examinees who underwent esophagogastroduo-
denoscopy (EGD) and who were tested for serum HP antibodies (HPab) or 
urea breath test (UBT) at our medical clinic. This study grouped the sub-
jects under three categories: non-infection (HPab < 3 U/ml, n = 121, HP_0), 
current infection (HP ab ≥10 U/ml, n = 144, HP_1), and aft er eradication 
(UBT < 2.5 ‰, n = 119, HP_2). HP eradication treatment was performed 
at our clinic. All 384 subjects were allocated to a training group (n= 294; 
HP_0 = 91, HP_1 = 114, and HP_2 = 89) or a test group (n = 90; HP_0 = 30, 
HP_1 = 30, and HP_2 = 30) to evaluate the diagnostic accuracy of CAD. From 
the training group, 12,836 LCI pictures linked with HP infection status were 
generated. The accuracy of CAD was assessed by comparing the output 
data from the test group with the actual data on HP infection status. The 
endoscopic equipment was EG-L 580 NW or EG-6400 N (Fujifi lm Co.). The 
DL model with 22 deep convolutional layers for CAD was adopted. R (ver-
sion 3.3.2.) was used for statistical analyses.
Results: The areas under the curve of receiver operating characteristics of 
the CAD were 0.90 (HP_0; 95% CI, 0.833-0.959), 0.82 (HP_1; 95% CI, 0.727-
0.905), and 0.73 (HP_2; 95% CI, 0.612-0.852).
Conclusion: Patients aft er HP eradication show negative reaction in most 
noninvasive HP infection tests; therefore, we cannot distinguish HP_0 from 
HP_2. In such a case, EGD is the only objective examination to achieve 
three categorical classifi cations because EGD recognizes mucosal atrophy 
and intestinal metaplasia of patients with eradicated HP. The CAD system 
demonstrated good accuracy in classifying HP infection status into three 
categories using LCI. In particular, the accuracy of HP non-infection with 
very low risk of gastric cancer was excellent. The authors infer that reduc-
ing EGD examination for HP_0 category can help simplify gastric cancer 
screening programs.
References: 1)Kobayashi M, Sato Y, Terai S. Endoscopic surveillance of gas-
tric cancers aft er Helicobacter pylori eradication. World J Gastroenterol. 
2015; 21(37): 10553-10562. 2)Nakashima H, Kawahira H, Kawachi H, Sakaki 
N. Artifi cial intelligence diagnosis of Helicobacter pylori infection using 
blue laser imaging-bright and linked color imaging: a single-center pro-
spective study. Annals of Gastroenterology. 2018; 31: 462-468
Disclosure: Nothing to disclose 
parison, H.pylori showed a sensitivity of 80.4% at a specifi city of 44.3% 
whereas the Pepsinogen index showed sensitivity of 18.2% at a specifi city 
of 95.0%. Using the miRNA assay as a pre-screening tool could potentially 
reduce number of endoscopy needed by 62% in detecting one case of 
gastric cancer.
Conclusion: Our serum miRNA panel is a useful, non-invasive screening 
test for gastric cancer. It can reduce unnecessary diagnostic endoscopy too.
Disclosure: Nothing to disclose 
OP316 CELL-FREE DNA AMOUNT AND MUTATION PROFILE 
ANALYSIS FOR GASTRIC CANCER PATIENTS
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Introduction: Cell-free DNA (cfDNA) is released into the blood stream in 
various ways including at the death of cells or by active secretion. CfDNA 
also harbors genetic aberrations from malignant tissue (1). It was shown 
that cfDNA could be a powerful disease state and relapse monitoring 
analyte (2). New minimally invasive diagnostic procedures for circulating 
molecules are in demand because standard diagnostics are not able to 
analyze the cancer mutation profi le changes over the course of treatment. 
However, there is a lack of comparative studies conducted in gastric cancer 
comparing tumor tissue DNA and cfDNA mutation profi les.
Aims & Methods: The aim of a study was to compare tumor tissue DNA and 
cfDNA mutation profi les and evaluate correlation of cfDNA amount and 
TNM stage for gastric cancer patients.
The study was approved by the Kaunas regional biomedical research ethics 
committee (No. Nr. BE-2-10). Gastric cancer tissue and blood were col-
lected from 30 patients who were recruited at the Department of Gastro-
enterology, Lithuanian University of Health Sciences Hospital during the 
period 2010 - 2018. Tumour tissue was obtained from the primary lesion 
of the resected specimen or biopsy and stored at -80˚C. Peripheral blood 
was drawn using a K2EDTA tubes at admission (before surgery). Sequenc-
ing libraries were prepared using TrueSeq Nano Libraries and samples 
of cfDNA pilot study were done in two replicates. Genomic DNA (gDNA) 
of tumor tissue and cfDNA were analyzed for mutations in cancer related 
genes using xGen Pan-Cancer Panel (IDT) consisting of 7816 xGen Lock-
down Probes spanning 800 kb of the human genome, for enrichment of 
127 signifi cantly mutated genes implicated across 12 tumor tissue types 
for deeper sequencing coverage. Libraries were pair-end sequenced on 
an Illumina NextSeq 500. Individual reads were mapped to hg19 using 
BWA mem keeping only primary mappings. Variant calling for stand-alone 
plasma samples was performed using VarDict which enables scaling lin-
early to sequencing depth and ultra-deep sequencing application to detect 
tumor DNA circulating in blood. Strand fi lter was enabled to reduce false 
positive variants originating from only one strand. All variants were anno-
tated using Variant Eff ect Predictor (3) and validated using the Integrative 
Genomics Viewer (4).
Results: Overall, 16 patients had mutations detected in gastric cancer 
related genes. Most frequently mutated genes in our study were TP53, 
BRCA2, NOTCH1, CHECK2, ERBB4 and KRAS. Yield of cfDNA is signifi cantly 
increased for gastric cancer patients compared to healthy controls and 
generally corelated with gastric cancer TNM stage (R=0.55, p=0.012).
Conclusion: Our results demonstrate moderate correlation of total cfDNA 
amount and tumor stage. cfDNA refl ects mutation profi le in gastric cancer 
tissue DNA therefore may enable cfDNA analysis for monitoring disease 
stage of gastric cancer patients.
References: 1. Bettegowda, C. et al. Detection of circulating tumor DNA in 
early- and late-stage human malignancies. Science translational medi-
cine 6, 224ra224, https://doi.org/10.1126/scitranslmed.3007094 (2014). 2. 
Phallen, J. et al. Direct detection of early-stage cancers using circulating 
tumor DNA. Science translational medicine 9, https://doi.org/10.1126/sci-
translmed.aan2415 (2017). 3. McLaren, W. et al. The Ensembl Variant Eff ect 
Predictor. Genome Biology Jun 6;17(1):122, doi:10.1186/s13059-016-0974-4 
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OP318 EFFICACY OF LINKED COLOR IMAGING IN SCREENING 
INTESTINAL METAPLASIA AND EARLY GASTRIC CANCER: 
A MULTICENTER RANDOMIZED CONTROL CLINICAL TRIAL
Liu Y.1, Sun X.1, Min M.2
1307 Hospital of PLA, Academy of Military Medical Science, Gastroenterology, 
Beijing, China, 2307 Hospital of Chinese People’s Liberation Army, 
Gastroenterology, Beijing, China
Contact E-Mail Address: minmin823@sina.com
Introduction: Minor mucosal lesions in the stomach are prone to be 
missed under white light (WL) endoscopy. Linked color imaging (LCI) can 
improve the endoscopic diagnosis, and LCI-based endoscopic criteria were 
proposed. We conducted this randomized clinical trial to investigate LCI’s 
diagnostic effi  cacy for gastric intestinal metaplasia (GIM) and early gastric 
cancer (EGC)/high-grade intraepithelial neoplasms (HGINs).
Aims & Methods: Consecutive adult patients who had indications for 
gastroduodenoendoscopy were selected and randomly divided into two 
groups. In Group A (n=914), the patients received the WL endoscopy fol-
lowed by LCI endoscopic examination. In Group B (n=914), the patients 
received LCI, followed by the WL mode for gastroscopy. The diagnostic ef-
fi cacies of LCI and WL were evaluated and compared.
Results: LCI was superior to WL in diagnosing EGC/HGINs. GIM was mani-
fested as “Purple in Mist” (PIM) under LCI. For GIM, the accuracy, sensitiv-
ity, specifi city, positive predictive value (PPV) and negative predictive value 
(NPV) [95% confi dence interval] of WL were lower than those of LCI (0.676 
[0.654-0.699] vs. 0.877 [0.861-892]; 0.650 [0.612-0.688] vs. 0.870 [0.843-
0.896]; 0.693 [0.664-0.721] vs. 0.880 [0.862-0.898]; 0.564 [0.527-0.600] 
vs. 0.784 [0.753-0.815]; and 0.764 [0.736-0.792] vs. 0.931 [0.916-0.946], re-
spectively). For diff erentiated EGC/HGINs, the accuracy, sensitivity, speci-
fi city, PPV and NPV of LCI were higher than those of WL (0.770 [0.729-0.812] 
vs. 0.664 [0.626-0.703]; 0.825 [0.726-0.923] vs. 0.632 [0.506-0.577]; 0.761 
[0.716-0.806] vs. 0.668 [0.627-0.709]; 0.367 [0.284-0.451] vs. 0.175 [0.122-
0.227]; and 0.963 [0.940-0.985] vs. 0.942 [0.918-0.966], respectively).
Conclusion: Our data supported the idea that LCI could improve the endo-
scopic diagnosis of GIM and EGC/HGINs, which can be used for screening 
and surveillance (ClinicalTrials.gov ID: NCT03092414).
Disclosure: Nothing to disclose 
Biomarker-based classifi cation of IBD
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OP319 POLYGENIC RISK SCORES IDENTIFY GENETIC AETIOLOGY 
OF INFLAMMATORY BOWEL DISEASE PHENOTYPES BEYOND KNOWN 
DISEASE SUSCEPTIBILITY LOCI
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Introduction: Genome-wide association studies (GWAS) have greatly im-
proved our understanding of the genetic background of infl ammatory 
bowel disease (IBD), with up to 240 genetic susceptibility loci identifi ed. 
Clinical disease phenotypes are very heterogeneous and are, rather than 
the disease itself, the main determinant of patient well-being. However, 
only few genetic contributors to disease phenotypes have been identifi ed 
through conventional GWAS. Polygenic risk scores (PRS), which aggregate 
the eff ects of thousands of trait-associated genetic variants discovered in 
GWASs, are powerful tools to estimate individual-specifi c genetic propen-
sities and predict outcomes, even when used in relatively small deeply-
phenotyped cohorts. In this present study, we use polygenic risk scores 
of twelve IBD-affi  liated traits to uncover mechanisms which contribute to 
clinical phenotypes.
Aims & Methods: Detailed clinical characteristics of patients with IBD 
were obtained from two independent cohorts (cohort A: n=1,097 and co-
hort B: n=2,697). All patients were genotyped using the Global Screening 
Array, and over 12 million genetic variants were imputed using the Hap-
lotype Reference Consortium panel. PRS were constructed for CD, UC and 
ten diff erent traits and their associations with IBD disease phenotypes 
were evaluated using linear regression models. Signifi cant (P< 0.05 aft er 
10,000 rounds of permutation) PRS-phenotype associations identifi ed in 
cohort A were put forward for replication in cohort B followed by a meta-
analysis.
Results: In total, six PRS-phenotype associations remained signifi cant 
aft er permutation and were replicated in the independent cohort. The 
composite genetic risk for CD susceptibility showed association with the 
subphenotype fi brostenotic CD (Montreal B2 [R2 = 4.6%; P = 4.0E-7]) and 
ileocaecal resection (R2 = 4.3%, P =6.3E-11), and remained signifi cantly as-
sociated aft er correcting for CD disease location and age at diagnosis, even 
aft er excluding known contributing factors (NOD2, MST1 and MHC). The 
composite UC susceptibility genetic risk (R2 = 6.5%; P = 2.9E-4) and pri-
mary sclerosing cholangitis susceptibility (PSC) genetic risk (R2 = 1.3%; P = 
1.2E-3) were associated with colonic CD (Montreal L2). Moreover, polygenic 
scoring revealed shared genetic aetiology of affi  liated diseases: polygenic 
risk for rheumatoid arthritis was associated with ulcerative proctitis (Mon-
treal E1) (R2 = 3.6%; P = 2.3E-4) and coeliac disease genetic risk (R2= 2.6%; 
P = 1.4E-4) was associated with PSC. The polygenic risk for development of 
pulmonary fi brosis was nominally signifi cantly associated with the risk of 
fi brostenotic CD in both cohorts (R2 = 1.5%, [cohort A: unadjusted P= 0.018 
and unadjusted P = 0.02 [cohort B]).
Conclusion: The cumulative genetic burden of CD is associated with more 
complicated clinical disease phenotypes, suggesting biological signals 
beyond known genome-wide signifi cant disease susceptibility genetic 
variants. We validate the putatively shared genetic aetiology of PSC and 
UC with colonic CD. Moreover, our results suggest shared genetic aetiol-
ogy between the development of pulmonary fi brosis and fi brostenotic CD. 
These results further our understanding of specifi c IBD phenotypes and 
might be used to better stratify patients or to provide new therapeutic 
targets.
Disclosure: Nothing to disclose 
OP320 GENOME-WIDE ANALYSES IDENTIFY NOVEL GENETIC 
VARIANTS THAT INTERACT WITH TOBACCO SMOKE AND AFFECT 
RISK FOR DEVELOPMENT OF INFLAMMATORY BOWEL DISEASE
Visser F.C.W., Voskuil M., Bourgonje A.R., Li Y., Weersma R.K., 
Festen E.A.M.
University Medical Center Groningen, Department of Gastroenterology and 
Hepatology, Groningen, Netherlands
Contact E-Mail Address: f.c.w.visser@umcg.nl
Introduction: Infl ammatory Bowel Disease (IBD) is characterized by a com-
plex etiology with an interplay between genetic, environmental, micro-
bial, and immunologic factors. A divergent eff ect of smoking behavior in 
the two subtypes of IBD, Crohn’s Disease (CD) and Ulcerative Colitis (UC), 
supports the existence of gene-environment interactions (GxE). Several 
genetic variants have already been found to interact with tobacco smoke 
in modifying the risk for IBD. However, in previous studies, gene-smoking 
interactions in IBD were detected based on genome-wide Immunochip-
data with poor coverage. Therefore, we performed a case-only study using 
over 12 million genetic variants with an excellent genome-wide content 
from Illumina Global Screening Array (GSA).
Aims & Methods: In this study, we aimed to identify novel gene-smoking 
interactions that could potentially aff ect IBD, CD or UC. Genetic data were 
obtained from 1,097 IBD patients (CD n= 500, UC n = 402) of European 
ancestry of the University Medical Center Groningen (UMCG) through GSA. 
Aft er quality control (QC) and imputation 12,130,010 genetic variants were 
available for genome-wide association studies. Smoking status was de-
fi ned as ‘never smoking’, ‘ever smoking’, ‘current smoking’ or ‘former 
smoking’. Multivariable logistic regression analyses (age- and sex-adjust-
ed) were performed to compare diff erent groups of smokers (ever vs never 
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Results: Overall, 419,858 cis-eQTLs were found to be signifi cant in gut tis-
sue, aft er adjusting for infl ammation eff ect (FDR< 0.05). We replicated 
84.22% of these in the publicly available intestinal dataset of the Gen-
otype-Tissue Expression (GTEx) consortium, showing robustness of our 
method. The infl ammation-interaction analysis revealed 1.140 infl am-
mation-dependent cis-eQTLs in 157 unique genes (FDR< 0.1). We identi-
fi ed infl ammation-dependent cis-eQTLs involving known IBD-risk genes 
(IL26, HLA-DQA1, HLA-DQA2, TNFSF11), cytokines and growth factors (DKK1, 
FGF12, PENK, STC2), and genes encoding immune cell receptor (segments) 
(IL17RB, TRAV34, TRAV8, TREML4). Enrichment analyses of the associated 
genes revealed that infl ammation-dependent cis-eQTL genes are mainly 
involved in immune responses and ion transport.
Conclusion: In this study we identify genetic variants that infl uence muco-
sal gene expression in patients with IBD, both dependent and independent 
of infl ammation status. We observe that the infl ammation-dependent cis-
eQTL genes are mainly involved in immune responses, which suggests that 
diff erences in the genetic background of patients drive diff erences in the 
mucosal immune response in IBD. Overall, our results show local and con-
text specifi c cis-eQTLs, which are potential leads for understanding disease 
pathogenesis and drug target identifi cation.
Disclosure: Nothing to disclose 
OP322 MICROBIOME AND FECAL BIOMARKERS CAN DIAGNOSE 
AND CLASSIFY INFLAMMATORY BOWEL DISEASE
Gacesa R.1,2, Vich Vila A.1,2, Collij V.1,2, Imhann F.1,2, Wijmenga C.2, 
Jonkers D.M.A.E.3, Kurilshikov A.2, Fu J.2, Zhernakova A.2, Weersma R.2
1University Medical Center Groningen (UMCG), Gastroenterology, Groningen, 
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Introduction: Irritable Bowel Syndrome (IBS) and Infl ammatory Bowel 
Diseases (IBD) are chronic disorders of the gut, with prevalence exceed-
ing 10% in the European population. Currently, these diseases are fre-
quently diagnosed by exclusion of other gastrointestinal disorders using 
multiple, oft en invasive, clinical procedures. The only biomarker for IBD 
currently utilised in clinical practice is fecal calprotectin test (FCal), which 
has high sensitivity but suff ers from moderate specifi city. Improvements 
in metagenomic sequencing have enabled cost-effi  cient profi ling of gut 
microbiota, opening an opportunity to utilise the gut microbiome for di-
agnosis of IBD and IBS. In addition, our previous research identifi ed that 
fecal measurements of human beta defensin 2 (HBD2) and Chromogranin 
A (ChrA) proteins are associated with composition of gut microbiota and 
diagnosis of IBS.
Aims & Methods: The primary aim of this study was to use features of 
microbiome and fecal biomarkers FCal, HBD2 and ChrA to train models 
for non-invasive diagnosis of IBD and IBS. Secondary aim was to test if 
gut microbiome can be utilised to classify type of IBD (Crohn’s disease vs 
ulcerative colitis) and clinical parameters of the disease (such as disease 
activity and location).
We used whole metagenome sequencing to analyse composition and 
function of microbiome of fecal samples of 181 IBS patient, 380 IBD cases 
and 859 healthy controls (HC), and measured HBD2, FCal and ChrA in 
all samples. A total of 521 microbiome features (244 bacterial taxa and 
277 biochemical pathways) were used to train machine-learning classi-
fi ers (random forests, support vector machines and neural networks) for 
classifi cation of samples as HC, IBD or IBS cases, and to classify type of 
IBD (Crohn’s disease (CD) vs Ulcerative colitis (UC)), clinical parameters of 
the disease (based on Montreal classifi cations), and disease activity. The 
models were put forward for validation on a dataset generated using 16S 
sequencing to assess the reproducibility of the approach.
Results: Fecal measurement of HBD2 showed high predictive power for 
diff erentiating between IBD vs IBS (Sensitivity = 0.9, Specifi city = 0.8, Area 
under ROC curve (AUC) = 0.89), outperforming FCal (Sensitivity = 0.85, 
Specifi city = 0.6, AUC = 0.79). The ChrA, however, showed low predictive 
power (Sensitivity = 0.6, Specifi city = 0.55, AUC = 0.57). Additionally, com-
bining HBD2 and FCal increased the predictive power above individual 
biomarkers (Sensitivity = 0.9, Specifi city = 0.85, AUC = 0.94). 
Models trained using microbiome features demonstrated predictive power 
in line with HBD2 (AUC = 0.88) with an added advantage classifi cation of 
smokers, current vs never smokers, former vs never smokers, and current 
vs never and former smokers). All analyses were performed in the total 
IBD cohort, and for CD and UC separately.
Results: We observed an overall number of 2,109 statistically signifi cant (p< 
5.0x10-5) single nucleotide polymorphisms (SNPs). However, some SNPs 
referred to unknown genes or belonged to the same gene. Five signifi -
cant SNPs, rs1878558 (SLCO3A1), rs6680523 (RASSF5), rs7141581 (SLC25A21), 
rs6818043 (ARHGAP10), and rs240952 (REV3L) were detected within loci 
that were previously associated with nicotine dependence or diff erences in 
smoking cessation. The directions of their odds ratios (ORs) indicated that 
our phenotype data were reliable. We detected several signifi cant SNPs 
that refer to immune regulating pathway genes (e.g. rs6680523 RASSF4, 
rs11738246 LNPEP, rs74660825 PRKCB, rs144226221 CBLB, and rs160357 
CREB5). Many other signifi cant SNPs that we detected refer to dopaminer-
gic signaling genes, calcium-associated genes, and nucleic acid binding 
genes.
Several nominally signifi cant SNPs (p < 0.01) had an opposite OR direc-
tion in CD and UC: 216 SNPs in ever vs never smokers, 97 SNPs in current 
vs never smokers, 202 SNPs in former vs never smokers, and 98 SNPs in 
current smokers vs never and former smokers. The results imply that a 
smoking associated SNP protects against the one subtype of IBD, whereas 
the same gene-smoking interaction increases the risk for development of 
the other subtype of IBD.
Conclusion: In this study, we identifi ed multiple novel genetic variants that 
interact with smoking status and aff ect the risk for development of IBD, 
CD or UC. In our cohort of 1,097 IBD patients, we were able to reproduce 
smoking-associated genetic risk variants that have previously been identi-
fi ed in non-diseased populations. We detected genetic risk variants that 
yielded an opposite direction in CD and UC, thus indicating a distinct ef-
fect of gene-smoking interactions on disease development. Our results, 
especially the divergent eff ect of gene-smoking interactions in CD and UC, 
provide a better insight into the contribution of gene-smoking interactions 
to the etiology of IBD.
Disclosure: Nothing to disclose 
OP321 INTEGRATION OF WHOLE-EXOME SEQUENCING, 
GENOME WIDE GENOTYPING AND RNA SEQUENCING OF 
INTESTINAL BIOPSIES IN INFLAMMATORY BOWEL DISEASE 
IDENTIFIES INFLAMMATION-DEPENDENT EFFECTS
Hu S.1, Uniken Venema W.T.C.1, Westra H.J.1, Voskuil M.D.1, Vich Vila A.1, 
Li Y.1, Ruggero B.1, Daly M.J.2, Xavier R.J.3, Dijkstra G.1, Festen E.A.M.1, 
Weersma R.K.1
1Universitair Medisch Centrum Groningen, Groningen, Netherlands, 2Broad 
Institute, Boston, United States, 3Massachusetts General Hospital, Boston, 
United States
Contact E-Mail Address: dhu.sxhu@hotmail.com
Introduction: Infl ammatory bowel disease (IBD) is a chronic immune-
mediated disease, characterized by intermittent infl ammation in the gas-
trointestinal tract. Although currently >240 genetic risk loci are known to 
be associated with this disease, it is still poorly understood how these 
genetic variants contribute to disease development. The eff ect of genetic 
variation on gene expression (defi ned as expression quantitative trait loci— 
cis-eQTLs) has mostly been studied by combining GWAS and transcriptome 
data from peripheral blood. However, the importance of studying these 
eQTLs in the disease- tissue and in the right disease- context is increasingly 
being recognized. We set out to examine the eff ect of genetic variants on 
gene expression in intestinal mucosal biopsies of IBD patients, in both in-
fl amed and non-infl amed conditions, to identify infl ammation-dependent 
eQTLs.
Aims & Methods: We collected 299 snap-frozen intestinal biopsies from 
171 IBD patients, 113 deriving from non-infl amed tissue and 186 from in-
fl amed tissue. Mucosal transcription profi les were determined by RNA-
sequencing and genotypes were obtained by Whole Exome Sequencing 
(WES) combined with Genome Wide Screening Array (GSA) data. In total, 
28,746 genes and SNPs located in +/- 500kb genomic regions surround-
ing these genes were included for identifying cis-eQTLs. cis-eQTLs were 
identifi ed using linear mixed models and by regressing out the eff ect of 
potential confounding variables as visualized in the fi rst 18 Principle Co-
ordinates. To explore the eff ect of genetic variants in the context of infl am-
mation, we then assessed the cis-eQTLs in infl amed versus non-infl amed 
tissue.
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disease location (AUC = 0.82 for classifi cation of colonic vs ileal disease) 
and type of disease (AUC = 0.88 for classifi cation of UC vs CD). Finally, 
integration of biomarkers and microbiome features further increased the 
predictive power of the model (Sensitivity and Specifi city > 0.9, AUC > 0.95 
for IBD vs IBS). Models build on metagenomic-sequencing data replicated 
well by using 16S data (and vice-versa), with Sensitivity and Specifi city 
within 10% of the original model.
Conclusion: We demonstrate that HBD2 is a novel biomarker for IBD with 
potential to improve specifi city of IBD diagnosis, especially when com-
bined with FCal. Additionally, we show that features of gut microbiome, in 
combination with already used fecal biomarkers, are strong predictors for 
diff erentiating IBD and IBS, with additional potential of classifying location 
and type of IBD. These results have a potential to improve non-invasive 
pre-screening for IBD in clinical practice.
Disclosure: Nothing to disclose 
OP323 USEFULNESS OF ACP 353 (ANTI-CROHN´S DISEASE PEPTIDE 
353) AS A NEW BIOMARKER IN THE DIAGNOSIS OF INFLAMMATORY 
BOWEL DISEASE: A MULTICENTER STUDY
Yoshioka S.1, Mitsuyama K.2, Hirai F.3, Esaki M.4, Araki T.5, Morita M.5, 
Yoshimura T.5, Mori A.5, Yamauchi R.6, Kuwaki K.5, Torimura T.1
1Kurume University School of Medicine, Division of Gastroenterology, 
Department of Medicine, Kurume, Japan, 2Kurume University, Division of 
Gastroenterology, Kurume, Japan, 3Fukuoka University Chikushi Hospital, 
In ammatory Bowel Disease Center, Chikushino, Japan, 4Saga University 
Hospital, Department of Endoscopic Diagnostics and Therapeutic, Saga, 
Japan, 5Kurume University School of Medicine, Kurume, Japan, 6Kurume 
University, Medicine, Fukuoka, Japan
Contact E-Mail Address: askx5y@gmail.com
Introduction: We isolated an antigenic peptide (TCP 353) specifi c for pa-
tients with Crohn’s disease (CD) from the blood using the phage display 
method and found that its antibody titer (ACP 353) would be a biomarker 
specifi c for CD (Clin Exp Immunol 2011 and J Gastroenterol 2014). In mul-
ticenter studies, we have clarifi ed the specifi city of TCP for novel serum 
biomarkers centered on ACP 353. Here, we analyzed the specifi city of ACP 
353 IgG for CD and the improvement in the diagnostic ability of the com-
bination of ACP 353 IgG and a novel serum biomarker and examined its 
usefulness in the diagnosis of infl ammatory bowel disease (IBD).
Aims & Methods: Subjects were patients with intestinal diseases who 
visited Kurume University Hospital, Fukuoka University Chikushi Hospital 
and Kyushu University Hospital between December 2016 and September 
2017. ACP 353 IgG, glycoprotein 2 (GP2) IgG and antibodies against Sac-
charomyces cerevisiae (ASCA) IgG levels were mesured as a marker for CD 
and proteinase 3- antineutrophil cytoplasmic antibody (PR3-ANCA) and 
myeloperoxidase (MPO)-ANCA levels as a marker for ulcerative colitis (UC).
Results: There were 334 patients, including 108 with CD, 88 with UC, 23 
with IBD-unclassifi ed (IBD-U), 32 with other intestinal diseases (Irritable 
bowel syndrome, etc.), and 83 healthy people. The cutoff  value was posi-
tive above the mean human healthy value plus 3 SD. The mean ± SE/posi-
tive rates of ACP 353 were as follows: CD, 54.7 ± 34.8 U/mL/34.3%; UC, 1.6 
± 0.15 U/mL/1.1%; IBD-U, 1.41 ± 0.12 U/mL/0%, others, 1 .19 ± 0.1 U/mL/0%; 
and healthy, 2.14 ± 0.06 U/mL/0%. The sensitivities/specifi cities of the 
markers were as follows: ACP 353 IgG, 34.3/97.8; GP2 IgG, 36.1/98.2; and 
ASCA IgG, 15.7/96.5 for CD, PR3-ANCA, 31.8/96.3; and MPO-ANCA, 0/100 
for UC. Next, the specifi city of the biomarker was fi xed at 95%, and the 
sensitivity was compared. The sensitivities (%) of the biomarkers were as 
follows: ACP353 IgG, 34.3; GP2 IgG, 42.6; ASCA IgG, 26.9; ACP 353 IgG + 
GP2 IgG + ASCA IgG, 41.7; and ACP 353 IgG + GP 2 IgG + ASCA IgG + PR3-
ANCA, 63.
Conclusion: The high specifi cities of the IBD novel biomarkers ACP 353, 
GP2 and PR3-ANCA were demonstrated. In the future, with the aim of 
multi-facility joint research on a nationwide scale, we would like to clarify 
the usefulness of new biomarkers centered on ACP 353 for the Japanese 
population.
Disclosure: Nothing to disclose 
OP324 MYENTERIC PLEXITIS AND POST-OPERATIVE 
RECURRENCE IN CROHN’S DISEASE: THE ROLE OF ENTERIC GLIAL 
CELLS AND INTER-CELLULAR ADHESION MOLECULE-1
Le Berre C.1, Pabois J.2, Durand T.2, Durieu E.2, Rolli-Derkinderen M.2, 
Bossard C.3, Podevin J.3, Neunlist M.4, Neveu I.2, Naveilhan P.2, 
Bourreille A.5
1CHU de Nantes Hôtel Dieu, Gastro-Entérologie, Nantes, France, 2UMR 
1235 - Faculté de Médecine, Nantes, France, 3CHU de Nantes Hôtel Dieu, 
Nantes, France, 4Inserm U 1235, Nantes, France, 5Hopital Hotel Dieu et HME, 
Gastroenterologie, Nantes Cedex, France
Contact E-Mail Address: philippe.naveilhan@univ-nantes.fr
Introduction: Half of Crohn´s disease (CD) patients require surgery within 
20 years of diagnosis, and post-operative recurrence (POR) is frequent. 
Among the risk factors of POR, the presence of myenteric plexitis (≥ one 
immune cell in contact with myenteric ganglia) at the proximal resection 
margin has been incorporated in the European guidelines. However, this 
criterion is rarely used, as little is known about the involved mechanisms. 
Our objectives were to determine which cells of the enteric nervous system 
interact with T cells, and to identify the molecules responsible for these 
interactions.
Aims & Methods: Our objectives were to determine which cells of the en-
teric nervous system interact with T cells, and to identify the molecules 
responsible for these interactions. 
In vivo: 29 patients (20 CD, 9 cancer) who underwent an ileocolonic resec-
tion were included. Full-thickness slices of the proximal resection margin 
were analysed by immunohistochemistry (IHC) to identify enteric glial cells 
(S100β), neurons (Hu) and T cells (CD3, CD4, CD8). T cells in contact with 
ganglia of the myenteric plexus were counted on each slide.
In vitro: To analyse neuro-immune interactions, human enteric glial cells 
(EGC) were co-cultured with T cells which were activated by anti-CD3/CD28 
antibodies beforehand. To determine the impact of infl ammatory condi-
tions, EGC were pre-treated with lipopolysaccharide (LPS) or IL-1β/TNFα 
(IT). Immunocytochemistry (ICC) was used to analyse the adhesion of T 
cells to EGC. The expression of adhesion molecules was determined by 
qPCR, western blot and ICC.
Results: IHC showed the presence of T cells, CD4+ and CD8+, in contact with 
EGC of myenteric ganglia in both CD and control patients. The number of 
T cells per ganglion was signifi cantly higher in CD patients (5.6 ± 0.9) as 
compared to controls (1.2 ± 0.2) (p< 0.001), with a threshold of 1.7 T cell per 
ganglion, and was twice higher in CD patients suff ering from POR (7.1 ± 1.4) 
as compared to those in whom CD did not recur (3.6 ± 0.9) (p=0.175). POR 
was systematic above 7.7 T cells per ganglion.
In vitro, pre-treatment of EGC with LPS and IT signifi cantly increased the 
number of T cells in contact with EGC, respectively by a factor of 2.7 (± 
0.7) (p< 0.01) and 2.1 (± 0.3) (p< 0.01) as compared to the control condi-
tion. These infl ammatory stimuli were associated with an overexpression 
of ICAM-1 in EGC as measured by qPCR, while the expression of MAdCAM 
and NCAM was not increased. This upregulation of ICAM-1 was confi rmed 
at the protein level.
Conclusion: Our results indicate that T cells interact with EGC in vitro and 
in vivo. These interactions are increased under infl ammatory conditions 
and are associated with an upregulation of ICAM-1. This suggests a role of 
EGC in the formation of plexitis, possibly through the binding of LFA-1 to 
ICAM-1. Further experiments will be carried out to confi rm this possibility.
Disclosure: Nothing to disclose 
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OP326 FACTORS PREDICTING MISSED DIAGNOSES OF 
OESOPHAGOGASTRIC CANCER: A CASE CONTROL STUDY OF 
PATIENTS HAVING GASTROSCOPY
Tai F.W.D.1, Wray N.1, Hopper A.1, Sidhu R.1, McAlindon M.2
1Royal Hallamshire Hospital, Academic Unit of Gastroenterology and 
Hepatology, She  eld, United Kingdom, 2Royal Hallamshire Hospital, 
Dept. of Gastroenterology, She  eld, United Kingdom
Contact E-Mail Address: david.tai@nhs.net
Introduction: There are unprecedented pressures facing endoscopy ser-
vices worldwide. In the United Kingdom, there has been an over 40% in-
crease in gastroscopy and 80% increase in colonoscopy delivery in the last 
10 years. Oesophagogastric (OG) cancers diagnosed in patients who have 
had a gastroscopy within the preceding three years are considered to have 
had cancers missed and occur in 11% cases in the Western population [Me-
non and Trudgill, EIO 2014]. We examine patient, endoscopist and service 
level factors that may aff ect rates of missed OG cancers.
Aims & Methods: Patients diagnosed with OG cancer who had undergone 
gastroscopy within the preceding three years (the cases) were identifi ed 
from endoscopy and OG cancer databases between January 2013 and De-
cember 2017 at Sheffi  eld Teaching Hospitals, Sheffi  eld, United Kingdom. 
Patient factors (age, gender, location of missed cancer and indication for 
gastroscopy), endoscopist factors (professional background, training sta-
tus, procedural volume and use of sedation) and service pressures (num-
ber, types and time of procedures) at the time of the index procedure 
(at which a missed cancer is presumed) were examined and compared 
to two control groups. The fi rst comprised the cases at the time of their 
subsequent diagnostic gastroscopy to control for patient factors. However, 
lesions in this group would be more endoscopically obvious than early 
cancers which are typically smaller, more focal lesions. Therefore a second 
control group comprised patients diagnosed as having benign focal lesions 
(of ≤ 10mm) matched (in terms of endoscopist, procedural date, patient 
age, gender and location of cancer) to each of the cases.
Results: We identifi ed 627 patients diagnosed with oesophageal (50.9%) 
and gastric (48.8%) cancer of whom there were 48 (7.7%) cases consid-
ered to have missed cancers in the preceding three years. Missed gastric 
cancer was more common in male patients (OR 3.0, 95% CI 1.32- 6.91). 
There were fewer cases of missed oesophageal cancer amongst those who 
were examined for dysphagia (OR 0.16, 95% CI 0.05 - 0.50), but more 
cases amongst those examined for anaemia (OR 5.36, 95% CI 1.87 - 15.41). 
Univariate analysis suggested that greater total numbers of procedures 
(on lists including upper and lower endoscopy) or greater number of gas-
troscopies on a list, or gastroscopy only lists, were associated with missed 
cancers. However, only greater total numbers of procedures were associ-
ated with missed cancers on multivariate analysis (OR 2.16, 95% CI 1.19 
- 3.91). When missed cancer cases were compared to the control group 
in which benign focal lesions were diagnosed, only a greater number of 
procedures on a list (OR 1.25, 95% CI 1.02 - 1.52) was associated with a 
risk of a missed lesion. There was no association between use of sedation, 
endoscopist experience or professional background or time of day and risk 
of missed cancers.
Conclusion: 7.7% of patients diagnosed with OG cancer could have been 
diagnosed and treated earlier. Our study suggests that there may be risk 
of missed pathology during gastroscopy performed on more populated 
endoscopy lists. The use of sedation, endoscopist background, or time of 
procedure did not increase the risk of missed cancer procedures.
References: Menon S, Trudgill N. How commonly is upper gastrointestinal 
cancer missed at endoscopy? A meta-analysis. Endosc Int Open 2014; 2(2): 
E46-50.
Disclosure: Nothing to disclose 
Highlights in oesophageal cancer: What’s hot?
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OP325 DETECTION OF BARRETT’S ESOPHAGUS BY MOLECULAR 
ENDOSCOPIC IMAGING USING NANOPARTICLES
Ahmed S.1, Chowdhury E.H.2, Galle P.R.3, Neumann H.4
1University Hospital Mainz, Interdisciplinary Endoscopy, Mainz, Germany, 
2Je rey Cheah School of Medicine and Health Sciences, Monash University 
Malaysia, Kualalampur, Malaysia, 3I. Medical Clinic and Polyclinic, University 
Hospital Mainz, Mainz, Germany, 4I. Medical Clinic and Polyclinic, University 
Hospital Mainz, Interdisciplinary Endoscopy, Mainz, Germany
Contact E-Mail Address: shakil.ahmed@unimedizin-mainz.de
Introduction: Barrett’s esophagus (BE) is recognized as a premalignant 
condition of esophageal cancer. Despite recent advancements in treatment 
strategies its prognosis is still very poor. Early detection may allow for more 
eff ective surveillance. Endoscopic surveillance for detecting premalignant 
lesions in BE is challenging because of their fl at appearance without any 
noticeable morphological change. Molecular endoscopic imaging (MEI) 
allows for in vivo visualization and characterization of biological processes 
that occur on a cellular or sub-cellular level. Several MEI studies in the 
past using fl uorescent-labeled antibodies were carried out to detect dis-
ease-specifi c targets. However, antibodies may confer allergic reactions, 
and their diff usion across epithelial borders and delivery to target struc-
tures is slow due to their high molecular weight. In contrast, nanoparticles 
have high surface area to volume ratio and no apparent toxicity. Therefore 
functionalizing the surface of nanoparticle with antibodies and stronger 
fl uorophores allow for targeting minute amounts of structures. In addition 
they can also be loaded with ligands to multiple biomarkers. To date, no 
data is available on the use of nanoparticles for MEI
Aims & Methods: To assess the diagnostic applicability of MEI with 
nanoparticles for diagnosis of Barrett’s esophagus. In addition, the results 
were compared with traditional MEI using specifi c labeled Muc-2 antibod-
ies and standard histopathology.
Patients undergoing endoscopic surveillance of known Barrett’s esopha-
gus were recruited for the study. First, careful inspection of the Barrett’s 
segment was performed with high-defi nition white-light imaging and 
chromoendoscopy. Then biopsies were collected from the Barrett’s muco-
sa and rinsed in PBS. Aft erwards, biopsy specimens were incubated with 
FITC labeled Muc-2 antibodies or biodegradable, pH sensitive nanopar-
ticles coupled with FITC conjugated Muc-2 antibodies. Aft er washing in 
PBS to remove unbound antibody, MEI was performed using the probe-
based confocal imaging system. Squamous epithelium and gastric tissue 
samples were considered as controls. Fluorescence intensity from Barrett’s 
mucosa and control specimens were compared, followed by histological 
confi rmation.
Results: 30 specimens were successively analyzed. Squamous epithelium 
or gastric mucosa showed no antibody binding demonstrating the high 
specifi city of the technique. Fluorescence signals were noted for tradi-
tional MEI using Muc-2 antibodies in intestinal type Barrett’s metaplasia 
corresponding to goblet cells in the histopathological examination. A sig-
nifi cantly higher fl uorescence was found with nanoparticles coupled with 
FITC conjugated Muc-2 antibodies. MEI with nanoparticles for prediction of 
Barrett’s metaplasia was consistent in all cases with histological analyses.
Conclusion: This is the fi rst study showing the feasibility of using nanopar-
ticles for molecular endoscopic imaging. Highly-specifi c nanoparticles can 
visualize Barrett’s metaplasia more effi  ciently than conventional MEI. With 
the unique potential of nanoparticles allowing coupled to multiple bio-
markers, future research is focused to identify diff erent grades of dysplasia 
in aff ected patients. In addition, NPs can be loaded with cytotoxic materi-
als to apply for targeted therapy.
Disclosure: Nothing to disclose 
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OP327 LONG-TERM OVERALL SURVIVAL AFTER ENDOSCOPIC 
MUCOSAL RESECTION FOR ESOPHAGEAL HIGH-GRADE DYSPLASIA 
AND EARLY ADENOCARCINOMA: A NATIONWIDE REGISTRY LINKAGE 
STUDY
Al-Kaabi A.1, van der Post R.S.2, Verhoeven R.3, Siersema P.D.1
1Radboud University Medical Center, Gastroenterology and Hepatology, 
Nijmegen, Netherlands, 2Radboud University Medical Center, Pathology, 
Nijmegen, Netherlands, 3Netherlands Cancer Registry, Netherlands 
Comprehensive Cancer Organization (IKNL), Utrecht, Netherlands
Contact E-Mail Address: aliak87@gmail.com
Introduction: Endoscopic therapy, particularly endoscopic mucosal re-
section (EMR), is recommended by current guidelines for patients with 
esophageal high-grade dysplasia (HGD) or early adenocarcinoma (EAC). 
Long-term outcome data based on large cohorts is limited. In this study, 
we aimed to evaluate the long-term outcome of EMR in patients with 
esophageal HGD/EAC based on nationwide data from daily clinical prac-
tice. We also investigated factors associated with overall survival.
Aims & Methods: Registered patients in the period 2005-2015 with HGD/
EAC of the esophagus or gastroesophageal junction treated with EMR were 
identifi ed from the Netherlands Cancer Registry (NCR). Clinicopathological 
data, including age at diagnosis, year of treatment, disease stage, surgical 
resection and vital status were retrieved from the NCR. Through record 
linkage with the nationwide Dutch Pathology Registry (PALGA), additional 
pathological data were obtained. Patients with no available pathology 
reports of an EMR specimen were excluded. The primary outcome was 
overall survival. 
Secondary outcomes were the number of en-bloc resections, R0-resec-
tions (margins free from dysplasia/EAC) and proportion having undergone 
surgical resection. Estimated overall survival rates were compared with 
log-rank analysis. Multivariable Cox regression models were used to in-
vestigate the association between clinicopathological variables and overall 
survival.
Results: A total of 898 primary EMR procedures for HGD/EAC were in-
cluded. The mean age at diagnosis was 67 [±10.5] years, median follow-up 
time 4.8 [IQR 3.0-6.8] years. Local tumor stage aft er primary EMR was 12% 
HGD (pTm1), 68% intramucosal (pTm2-3) and 21% submucosal (pTsm1-3) 
EAC, with 10-year overall survival rates of 73%, 58% and 49%, respectively 
(p<0.001, see table 1). In total, 118 patients (21%) had an en-bloc EMR with 
42% complete resection rate. 
Following piecemeal EMR (mean specimens 3.3 [±2.6]), R0-resection of 
the vertical margins was 73%. R0-resections increased over time from 
53% in 2005 to 75% in 2015. Aft er radical EMR without lymphovascular 
invasion, 28/558 (5%) underwent surgical resection during follow-up (4% 
intramucosal vs 14% submucosal EAC, (p<0.001). Factors associated with 
overall survival were pTsm1-3 (HR 2.5, 95% CI 1.4 - 4.4), pTm2-3 (HR 1.9, 
95% CI 1.1 - 3.3), presence of signet ring cells (HR 1.7, 95 CI% 1.0 - 2.7), 
lymphovascular invasion (HR 1.6, 95 CI% 1.0 - 2.5), R1-resection (HR 1.5, 
95% CI 1.1 - 2.0), age (HR 1.1, 95 CI% 1.0 - 1.1) and surgical resection (HR 
0.5, 95% CI 0.3 - 0.8).
  Overall R0-resection R1-resection
pT stage 5-year OS
10-year 
OS
5-year 
OS
10-year 
OS
5-year 
OS
10-year 
OS
m1 (HGD) 88% 73% 89% 75% 86% 67%
m2-3 76% 58% 79% 61% 69% 51%
sm1-3 65% 49% 80% 57% 55% 44%
[Table 1. Overall survival (OS) rates according to radicality of primary EMR.]
Conclusion: EMR is a highly eff ective treatment for esophageal HGD/EAC 
with excellent long-term survival in daily clinical practice. Pathologic fac-
tors, i.e. depth of tumor invasion, presence of signet ring cells and lympho-
vascular invasion, were the strongest predictors of poor overall survival.
Disclosure: Nothing to disclose 
OP328 CONDITIONAL SURVIVAL IN PATIENTS WITH RESECTABLE 
ESOPHAGEAL CANCER
Hagens E.R.C.1, Feenstra M.L.1, van Berge Henegouwen M.I.1, 
Hulshof M.C.C.M.2, van Laarhoven H.3, Gisbertz S.S.1
1Amsterdam UMC, Location AMC, University of Amsterdam, Cancer Center, 
Surgery, Amsterdam, Netherlands, 2Amsterdam UMC, Location AMC, 
University of Amsterdam, Cancer Center, Radiotherapy, Amsterdam, 
Netherlands, 3Amsterdam UMC, Location AMC, University of Amsterdam, 
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Introduction: Most provided survival rates in current literature are static, 
calculated from the day of surgery. But as time proceeds aft er surgery, the 
risk of death in esophageal cancer patients changes. Conditional survival 
accounts for the time already survived aft er surgery and may be informa-
tive in addition to conventional estimates during follow-up.
Aims & Methods: The aim of this study was to assess conditional survival 
in esophageal cancer patients and to design a nomogram predicting the 
conditional probability of survival for esophageal cancer patients aft er 
surgery. Consecutive patients with esophageal cancer who received neo-
adjuvant chemoradiation followed by an esophagectomy between January 
2004 and 2019 in the Amsterdam UMC, location AMC, The Netherlands 
were included in this retrospective study. Patients with distant metastases, 
who underwent salvage surgery, or who died within 30 days aft er resec-
tion due to complications were excluded. Conditional survival was defi ned 
as the probability of surviving “y” years aft er already surviving for “x” 
years. The used formula was: CS
(x|y)
 = S
(x+y)
/S
(x)
 with S
(x)
 representing the 
overall survival at “x” years. Cox proportional hazard models were used 
to evaluate predictors for overall survival. A nomogram was constructed 
to predict 5-year survival directly aft er surgery and given 1-, 2-, 3- and 
4-years survival aft er surgery, based on the coeffi  cients of the predictors in 
the multivariable Cox proportional hazard model, using a penalized LAS-
SO (Least Absolute Shrinkage and Selector Operator) method. C-statistic 
which is presented with optimism adjusted for by bootstrapping.
Results: 660 patients were included in this study. The median overall 
survival was 46.4 months (95%CI 39.1 - 53.8). The probability to achieve 
5-year overall survival aft er resection increased from 46% directly aft er 
surgery to 55%, 67%, 79% and 88% per additional year survived. The 
more years patients have already survived, the better their chances of ad-
ditional years of survival are. This increase fl attens aft er more years have 
passed. The conditional overall survival probability is shown in table 1. 
ypN-stage was the strongest predictor for overall survival in multivariable 
analysis (HR 2.53, 95%CI 1.90 - 3.36; HR 3.17, 95%CI 2.27 - 4.43 and HR 
6.50, 95%CI 4.28 - 9.87, respectively for ypN1, ypN2, ypN3 with ypN0 as 
reference, all p< 0.001), followed by pulmonary complications (HR 1.16, 
95%CI 1.88 - 0.002, p=0.002), cardiac comorbidity (HR 1.27, 95%CI 1.01 
- 1.60, p=0.040) and ypT-stage (HR for ypT2-3 in relation to ypT0 1.461, 
95%CI 1.02 - 2.09, p=0.039). These variables were included in the nomo-
gram. The nomogram predicted 5-year survival using these predictors and 
number of years already survived with a C-statistic of 0.70.
Total years of 
survival
Years already survived by patients
  0 1 2 3 4 5 6 7
1 83              
2 69 83            
3 58 69 84          
4 52 62 75 90        
5 46 55 67 79 88      
6 41 49 60 71 79 90    
7 38 46 55 66 73 83 93  
8 33 40 48 58 64 73 81 88
[Table 1. Conditional survival estimates]
Conclusion: The proposed nomogram showed an accurate prediction of 
survival in patients aft er esophageal cancer surgery, taking the years al-
ready survived aft er surgery into account. This nomogram can be helpful 
in counselling patients in the follow-up aft er surgery.
Disclosure: Nothing to disclose 
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OP330 IRRADIATION STENTS PROLONG SURVIVAL 
COMPARED TO REGULAR STENTS IN END-STAGE ESOPHAGEAL 
CANCER: META-ANALYSIS AND SYSTEMATIC REVIEW
Tinusz B.1, Soós A.1, Hegyi P.1, Sarlós P.2, Szapáry L.1, Erős A.1, Feczák D.1, 
Szakács Z.1, Márta K.1, Erőss B.1
1Institute for Translational Medicine, Medical School, University of Pécs, 
Pécs, Hungary, 2University of Pécs, Department of Gastroenterology, 1st 
Department of Medicine, Medical School, Pécs, Hungary
Contact E-Mail Address: tinuszben@gmail.com
Introduction: Esophageal cancer is the eighth most common cancer 
worldwide and the sixth leading cause for cancer-related mortality. Such 
high mortality underlines the importance of palliative treatment options. 
Currently, there are no universally accepted international guidelines on 
whether additional oncological treatment is required besides stenting in 
the palliative care of esophageal cancer.
Aims & Methods: Our aim was to compare the eff ectiveness and safety 
of stent insertion alone to stent insertion combined with any modality of 
active oncological treatment in the palliative care of esophageal cancer.
A meta-analysis and systematic review were performed according to the 
PRISMA Statement. We searched 6 databases (PubMed, EMBASE, the 
Cochrane Library, Web of Science, clinicaltrials.gov, and the WHO Global 
Health Library) for papers on the palliative treatment of esophageal can-
cer. Patients receiving stent insertion only (control group) were compared 
to patients receiving chemotherapy, radiotherapy, chemo-radiotherapy or 
brachytherapy in addition to stent treatment (intervention group). Meta-
analytical calculations were performed by using STATA v15.1. For mean 
survival time and grade of dysphagia within 3 days of stenting weighted 
mean diff erences (WMD) were calculated. For complications of stenting 
(such as chest pain, hemorrhage, deaths due to hemorrhage, stent migra-
tion and restenosis, tracheoesophageal fi stula formation and development 
of pneumonia) pooled odds ratios (OR) were calculated. WMDs and ORs 
were interpreted with 95% confi dence intervals (CI). The protocol of the 
study was registered prior on PROSPERO under the registration number 
CRD42018093921.
Results: Out of 9038 articles yielded by our search, 11 met the pre-defi ned 
inclusion and exclusion criteria. These contained a total of 838 esophageal 
cancer patients, out of which 374 and 464 patients belonged to the inter-
vention and control groups, respectively. Patients in the intervention group 
had signifi cantly longer mean survival time (WMD, 1.56; 95% CI, 0.66-
2.46). This signifi cance was still present when analyzing the subgroup of 
patients where irradiation stents were utilized as intervention (WMD, 1.93; 
95% CI, 0.78-3.09), however, the signifi cance disappeared when only look-
ing at patients receiving other modalities of oncological treatment (WMD, 
0.72; 95% CI -1.26-2.70). We found no signifi cant diff erence in any compli-
cations of stenting between the two groups. Our systematic review sug-
gested that additional treatment is more eff ective in the long-term relief of 
dysphagia than stenting alone.
Conclusion: Our results indicate that the utilization of irradiation stents 
prolong the survival of patients in the palliative treatment of esophageal 
cancers as compared to conventional stent insertion. Moreover, additional 
oncological treatment may be more eff ective in the long-term relief of dys-
phagia as compared to stenting alone. Further studies are warranted.
Disclosure: Nothing to disclose 
OP329 DYNAMICS OF BODY COMPOSITION PARAMETERS 
IN RESECTED PATIENTS WITH ADENOCARCINOMA OF THE 
ESOPHAGOGASTRIC JUNCTION TYPE 1 AND 2
Petrova G.1, Bachmann J.2, Pradhan R.2, Friess H.1, E. Martignoni M.2, 
Prokopchuk O.1
1Klinikum rechts der Isar, Department of Surgery, Munich, Germany, 
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Contact E-Mail Address: gabriela.petrova06@yahoo.de
Introduction: Preoperative sarcopenia is a predictor of poor prognosis of 
esophageal cancer aft er esophagectomy. and can infl uence surgical com-
plications. Less is known about the infl uence of surgical resection on body 
composition. The aim of this study is to examine the dynamics of body 
composition parameters of resected patients with adenocarcinoma of the 
esophagogastric junction (AEJ) Siewert type I and II.
Aims & Methods: 172 patients with AEJ Siewert type I and II who under-
went esophagectomy in the Department of Surgery, Klinikum Rechts der 
Isar, 2007-2009 and 2014-2015, were screened for this retrospective study. 
Computed tomography (CT) images prior to surgery (timepoint 1, T1) as 
well as 6 (T2) and 12 months (T3) aft er esophagectomy were assessed us-
ing Slice-O-Matic® soft ware version 4.3. Following body compositions pa-
rameters were estimated: subcutaneous adipose tissue area index (SATI), 
visceral tissue area index (VATI), intramuscular tissue area index (IMATI), 
total adipose tissue area index (TATI), as well as skeletal muscle mass in-
dex (SMAI). 157 patients had CT at T1, and only 59 patients had CTs at T1, T2, 
and T3. Sarcopenia was defi ned by consensus thresholds before surgery 
with the cut-off  points for SMI (skeletal muscle tissue area index) < 52.4 
cm2/m2 for male and < 38.5 cm2/m2 for female patients.
Results: Preoperative sarcopenia occurred in 53% of patients. 76% of pa-
tients were sarcopenic 6 months and 72% 12 months aft er surgery. Sarco-
penic and non-sarcopenic groups diff er in absolute and relative weight 
loss, BMI, albumin, hemoglobin, SMAI and SATI, but not in cholinester-
ase, c-reactive protein, TATI, VATI and IMATI. Median survival rate was 3,9 
(range: 0.2-11.3) years in the non-sarcopenic group and 2,8 (range: 0.2-
11.2) years in the sarcopenic group (p = 0.006). The median values for 
decrease in body composition parameters 6 months aft er surgery were for 
TATI 55 cm/m2 (50%) in non-sarcopenic group and 52 cm2/m2 (51%) in 
sarcopenic group, for VATI 32 cm/m2 (64%) in both non-sarcopenic group 
and sarcopenic groups, for SATI 19 cm/m2 (33%) in non-sarcopenic group 
and 16 cm2/m2 (39%) in sarcopenic group, for IMATI 1 cm/m2 (33%) in 
non-sarcopenic group and 1 cm2/m2 (20%) in sarcopenic group, for SMAI 
5 cm/m2 (9%) in non-sarcopenic group and 2 cm2/m2 (4%) in sarcopenic 
group. 
The median values for decrease in body composition parameters 12 
months aft er surgery were for TATI 60 cm/m2 (55%) in non-sarcopenic 
group and 46 cm2/m2 (46%) in sarcopenic group , for VATI 35 cm/m2 
(70%) in non-sarcopenic group and 31 cm/m2 (62%) in sarcopenic group, 
for SATI 21 cm/m2 (36%) in non-sarcopenic group and 14 cm2/m2 (34%) in 
sarcopenic group, for IMATI 1 cm/m2 (33%) in non-sarcopenic group and 1 
cm2/m2 (20%) in sarcopenic group, for SMAI 4 cm/m2 (7%) in non-sarco-
penic group and 2 cm2/m2 (4%) in sarcopenic group. The signifi cant dif-
ferences between sarcopenic and non-sarcopenic groups were observed 
regarding change in SMAI (sarcopenic group lost less skeletal muscle 6 
and 12 months aft er surgery), as well as change in IMATI (sarcopenic group 
lost less intramuscular adipose tissue 6 months aft er surgery) and SATI 
(sarcopenic group lost less subcutaneous adipose tissue 12 months aft er 
surgery).
Conclusion: To our knowledge, it is the fi rst study demonstrating dra-
matical loss of adipose and skeletal muscle tissue 6 and 12 months af-
ter esophagectomy in AEJ Siewert type I and II patients. No signifi cant 
changes in body composition parameters occur between 6 and 12 months 
aft er surgery.
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OP331 FECAL SCFA MEASUREMENT AND MICROBIOME 
METABOTYPE SHIFTS IN NUTRITIONAL THERAPY OF PEDIATRIC 
CROHN’S DISEASE
Levine A.1, Dunn K.2, Gerasimidis K.3, Bjorndahl P.4, Svolos V.3, 
Bielawski J.4, Sigall Boneh R.5, Wine E.6, Van Limbergen J.7,8
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Kingdom, 4Dalhousie University, Mathematics & Statistics, Halifax, Canada, 
5Edith Wolfson Medical Center, Dept. of Pediatric Gastroenterology and 
Nutrition, Jerusalem, Israel, 6University of Alberta, Pediatric Gastroenterology 
and Nutrition, Edmonton, Canada, 7Amsterdam University Medical Centers 
- Emma Children’s Hospital, Pediatric Gastroenterology and Nutrition, 
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Introduction: Changes in gut bacterial community structure are associated 
with Crohn’s Disease (CD) and response to therapy. A recently completed 
randomized controlled trial (RCT) showed improved sustained remis-
sion with the Crohn’s Disease Exclusion Diet + Partial Enteral Nutrition 
(CDED+PEN) as compared with Exclusive Enteral Nutrition (EEN)1. Whole 
metagenome analysis paired with metabolite assays can help elucidate 
how changes in abundance impact microbiome function.
Aims & Methods: To examine changes in the functional network and fe-
cal SCFA concentration in CD patients reaching remission aft er 6 weeks of 
nutritional therapy (n=53). Stool samples were collected from patients at 
weeks 0, 6 and 12 and whole shotgun sequence data were obtained. Stool 
SCFA analysis was available for 128 samples (48 patients). Mann-Whitney 
U (unpaired) and Wilcoxon signed rank tests (for paired samples) were 
used to compare SCFA measurements at diff erent time points.
In total 146 CD patient samples were combined with 26 healthy controls 
(Lewis et al.2), and characterized using HUMAnN2. Reactions, substrates 
and products for genes with an enzymatic commission were input to an 
unsupervised Bayesian analysis of community metabolism (BiomeNet). 
Statistical analysis of community metabolism and SCFA concentrations 
were performed using R. Non-negative matrix factorization (NMF) and 
Structural topic models (STM) were used to identify patient-associated mi-
crobial metabotypes.
Results: Unsupervised analyses revealed two metabotypes. All healthy 
controls possessed one metabotype (M1). CD patients possessed a mixture 
of two metabotypes (M1 & M2), with mixtures related to stage of treatment. 
CD patients achieving remission showed a steady increase in the M1 contri-
bution as nutritional therapy progressed. 
Fecal SCFA concentrations did not change signifi cantly across the 3 time-
points in CDED+PEN, but there was a signifi cant drop in butyrate in the 
EEN group compared with CDED+PEN at week 6 (p=0.00028).
However, SCFA concentrations were associated with M1 and M2 mixtures 
in patients. M1 was associated with higher concentrations in butyrate 
(p=0.012), valerate (p=1.2e-6) and iso-butyrate (p=0.008). Genes involved 
in the 4-aminobutyrate, and crotonoyl-CoA to butyrate pathways, (p=0.03 
to 0.0001) were associated with M1 and a diff erent pattern of associated 
genes was identifi ed in M2. Changes in fecal SCFA concentrations, though 
associated with M1, were not associated with clinical remission at week 6 
in CDED+PEN. In EEN, there was a signifi cant drop between week 0 and 
week 6 in butyrate concentration (Mann-Whitney p=0.0018 and Wilcoxon 
signed rank test p=0.0046).
The butyrate-related change in community function is attributable to shift s 
in bacterial species abundance, notably Bacteroides and Clostridium.
Conclusion: Diet-induced remission samples were associated with a 
metabotype that characterized healthy controls and genes involved in the 
4-aminobutyrate pathway, and crotonoyl-CoA to butyrate pathway. Al-
though the higher concentrations of butyrate and other SCFA, associated 
with M1, agree with past work suggesting that butyrate levels are associ-
ated with reduced infl ammation, we did not measure an increase in fecal 
butyrate in the CDED+PEN group. 
Conversely, remission achieved with EEN is associated with a decrease in 
butyrate at week 6. An expansion of Firmicutes and decrease in Proteo-
bacteria was observed in both diets by week 6. This suggests that other 
metabolic processes are important in the microbiome community function 
shift  associated with achieving remission.
References: 1. Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori 
M, Cohen S, Peleg S, Shamaly H, On A, Millman P, Abramas L, Ziv-Baran 
T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J. Crohn’s 
Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained 
Remission in a Randomized Controlled Trial. Gastroenterology 2019 in 
press. 2. Lewis JD, Chen EZ, Baldassano RN, Otley AR, Griffi  ths AM, Lee 
D, Bittinger K, Bailey A, Friedman ES, Hoff mann C, Albenberg L, Sinha R, 
Compher C, Gilroy E, Nessel L, Grant A, Chehoud C, Li H, Wu GD, Bushman 
FD. Infl ammation, Antibiotics, and Diet as Environmental Stressors of the 
Gut Microbiome in Pediatric Crohn´s Disease. Cell Host Microbe. 2017 Aug 
9;22(2):247.
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MICROBIOTA INTERACTIONS IN THE CONTEXT OF INFLAMMATORY 
BOWEL DISEASE
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Introduction: A large number of host genetic factors, as well as changes 
in the gut microbiota, are known to determine etiology and pathogenesis 
of infl ammatory bowel disease (IBD). The knowledge on the interaction 
between these two factors is, however, still limited. In order to character-
ize these interactions, in depth determination of the host genetics and gut 
microbiota is necessary. Here we aimed to identify genetic factors relevant 
for maintenance of the gut microbiome in the context of IBD.
Aims & Methods: We performed whole exome sequencing of the host ge-
nome, and whole genome shotgun sequencing of fecal samples of 524 IBD 
patients and 939 controls from population-based cohort. The interaction 
between exonic variants, microbial taxa and metabolic pathways was ex-
plored using a four step approach: 1) Bidirectional meta-analysis between 
the two cohorts to identify common variants 2) A targeted meta-analyses 
of IBD risk loci and protein truncating variants (PTVs) 3) A gene-based 
burden test to detect rare mutations that aff ect microbial features, and 4) 
an interaction analysis to identify IBD-specifi c microbial quantitative trait 
loci (mbQTLs).
Results: We tested 170,000 protein coding variants and 641 microbial fea-
tures and identifi ed 25 associations between genetic variants and gut mi-
crobial features (FDR< 0.05). Among common variants, a strong mbQTL 
was observed for deletion near the IBD-risk IL17REL gene that was corre-
lated to Alistipes indistinctus abundance, which is known to be decreased 
in IBD patients. The gene-based burden test revealed that mutations in an 
IBD-related gene CYP2D6, a major component of phase I drug metabolism, 
were associated with decreased level of bacterial biosynthesis of vitamin K 
(PWY-5838). Moreover, GPR151 gene, known to be protective against obe-
sity and type II diabetes, was found to be associated with a decrease in 
bacterial degradation of glucose. The interaction analysis revealed another 
association between TNFSF15 and glycogen degradation specifi c to IBD.
Conclusion: We performed the largest, high resolution, genome-microbi-
ome association study to date, that utilizes whole exome sequencing and 
metagenomics sequencing methods. Disease specifi c interactions were 
explored in the context of IBD, including the eff ect of risk loci and protein 
truncating variants. These results highlight the importance of host genetics 
in the maintenance of gut microbiome homeostasis critical for prevention 
of IBD.
Disclosure: Nothing to disclose 
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OP334 IMPACT OF 41 COMMONLY USED DRUGS ON THE 
COMPOSITION, METABOLIC FUNCTION AND RESISTOME OF THE 
GUT MICROBIOME
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Introduction: The human gut microbiota composition is infl uenced by 
numerous factors including medication. Moreover, there is increasing 
evidence that the gut ecosystem plays an essential role in drug responses 
and effi  cacy. To further understand these drug-microbiota interactions in 
the context of polypharmacy, we studied the relations between commonly 
used drugs and gut microbial changes in the general population as well as 
in patients aff ected by gastrointestinal disorders.
Aims & Methods: We performed metagenomics sequencing of 1883 fresh 
frozen fecal samples from three independent cohorts: 
1) a population-based cohort, 
2) patients with infl ammatory bowel disease and 
3) patients with irritable bowel syndrome intermixed with healthy controls. 
Taxonomic and potential metabolic profi les were predicted for all sam-
ples. In each cohort, we investigated diff erences between drug users and 
non-users in two steps: fi rst, by looking at the eff ect of single medication 
use, and second, considering the use of multiple drugs per participant. 
Finally, cohort-specifi c results were combined in a meta-analysis using an 
inverse-variance-based approach.
Results: Out of 41 drugs categories, 18 were associated with changes in 
gut microbiota composition and/or function, with proton-pump inhibitors 
(PPIs), metformin, antibiotics and laxatives having the largest impact. Aft er 
correcting for polypharmacy, seven drug categories remained signifi cant 
(FDR< 0.05), and associated to changes in 46 taxa and pathways. For ex-
ample, the abundance of Eubacterium ramulus was associated with the use 
of SSRI antidepressants. The gut microbiota of PPI users was characterized 
by an increased abundance of upper gastrointestinal tract bacteria and by 
the increase of fatty acid biosynthesis pathways. While these changes in 
microbial functions were mainly driven by the expansion of Streptococcus 
species in the fecal samples of PPI users, in metformin users an enrich-
ment of Escherichia coli-derived metabolic pathways was observed. The 
use of oral steroids was associated with an enrichment of methanogenic 
bacteria. Methanogenic bacteria have been associated with obesity and 
an increase in BMI, a known side eff ect of oral steroids use. Finally, we 
identifi ed an increase in antibiotic resistance mechanisms related to eight 
diff erent medication categories
Conclusion: We provide evidence for extensive changes in taxonomic struc-
ture, metabolic activity and resistome in relation to commonly used drugs. 
Changes in the gut microbiota can increase the risk of enteric infections, 
obesity and other disorders, therefore, these associations need to be func-
tionally investigated given the importance of the gut microbiota in health 
and the widespread use of many drugs.
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Introduction: Dysbiosis and metabolic alterations of the gut microbiome 
have been implicated in infl ammatory bowel diseases (IBD). The aim 
of this study is to identify functional microbiome signatures associated 
with disease outcome or response to therapy in patients with IBD, and to 
mechanistically characterize their pathogenic potential using gnotobiotic 
humanized mice and an integrative multi-omics approach.
Aims & Methods: We studied 35 Crohn’s disease (CD) patients for a period 
of 5-years aft er autologous hematopoietic stem cell transplantation (HSCT) 
therapy. Fecal samples were collected both at baseline and at diff erent 
time points during follow-up. To characterize changes in gut microbiome 
and metabolome, we performed 16S rRNA gene sequencing, global 16S 
predicted metagenomes, shotgun metagenomic sequencing and untarget-
ed metabolomics. To address the functional impact of microbial dysbiosis, 
we established a humanized IBD mouse model by colonizing germfree 
(GF) Il-10-/- mice with selected fecal samples from CD patients at diff erent 
disease states.
Results: Temporal fl uctuations in gut microbiota composition and me-
tabolite profi les refl ected the individual patient-related variations and the 
diff erences in disease activity. Fecal microbiome of patients with active 
disease was enriched in microbial taxa involved in sulfur metabolism such 
as Eschericia Shigella and Fusobacterium as well as a high proportion of 
sulfate reducing bacteria such as Desulfovibrio and Campylobacter. Fecal 
metabolic profi ling confi rmed an increased abundance of sulfated metab-
olites (bile acids, polyphenols and biogenic amines). Predicted metage-
nomes from 16S rRNA gene profi ling revealed enrichment of functional 
genes associated with sulfate and ion transport system metabolism in IBD 
patients with active disease. In contrast, increased abundance of several 
basic biosynthetic processes correlated with remission. Transplantation of 
microbiota from patients with active or inactive disease was reproduc-
ibly suffi  cient to recreate disease phenotype in recipient Il-10-/- GF mice. 
Humanized mice refl ected the dysbiotic features of their respective human 
donors and infl ammation was driven by a variety of individual community 
profi les. Using a machine-learning algorithm, we identifi ed a microbiome 
signature that discriminates infl amed from non-infl amed humanized mice 
characterized by an overabundance of Bacteroides fragillis and Desulfovi-
brio. In accordance with the signature identifi ed in humans, enrichment 
of sulfated metabolites was indicative for infl amed phenotypes, together 
with an abundance of genes mapping to sulfate metabolism, Type II, IV 
and VI secretion systems. Integration of microbiota and metabolite pro-
fi les from human and mice improved the predictive modelling of disease 
outcome signifi cantly and identifi ed a network of functionally relevant 
bacteria-metabolite interactions linked to disease activity in CD.
Conclusion: Our data prove that despite the heterogeneity of CD patients 
gut microbiome at the taxonomic level, shared functional signatures cor-
relate with disease severity. Multi-omics data integration improved the 
clinical outcome prediction and identifi ed a signature involving sulfur me-
tabolism and detoxifi cation to be relevant in disease outcome.
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OP335 BACTEROIDES FRAGILIS IS MORE PREVALENT IN CROHN’S 
DISEASE EXACERBATIONS WHILE STRENGTHENING THE INTESTINAL 
EPITHELIAL BARRIER IN A STRAIN-DEPENDENT MANNER
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Introduction: Crohn’s disease (CD) is a chronic relapsing infl ammatory 
gastro-intestinal disease with a high disease burden. Until today, the 
pathophysiology is not completely understood. Next to host genetics and 
environmental factors, impaired intestinal barrier function and microbiota 
seem to play a role in the onset and course of CD. Among others, Bacte-
roides fragilis has frequently been associated with CD. In addition, recom-
binant B. fragilis toxin (Bft ) was found to disrupt the intestinal epithelial 
barrier in vitro by cleaving the adherens junction protein E-cadherin. Fur-
thermore, Ubiquitin was found as a potential virulence factor, acting on 
host immune response.
Aims & Methods: This study aims to investigate the role of B. fragilis in the 
pathophysiology of CD, focusing on prevalence and its interaction with the 
intestinal epithelial barrier. 
To investigate the presence of B. fragilis, B. fragilis toxin (Bft ) and Ubiquitin, 
we selected 183 CD patients with active or remissive state from our ex-
tensive population-based IBD South Limburg cohort. Disease activity was 
determined by faecal calprotectin levels (< 100 µg/g = remission; ≥250 
µg/g = exacerbation) and faecal DNA was investigated by qPCR. Data were 
analysed using Chi-square test. 
To examine the impact of B. fragilis on the intestinal epithelial barrier, 
we subsequently cultured and isolated six B. fragilis strains with various 
genetic profi les of b  and ubiquitin from two healthy subjects, three CD 
patients and one ATCC strain (25285). Diff erences in coding sequences and 
secreted metabolites between bacterial strains were examined by whole-
genome sequencing using MiSeq and Nuclear Magnetic Resonance (NMR) 
Spectroscopy, respectively. Next, bacteria-free culture supernatant as well 
as outer membrane vesicles (OMVs) were isolated and luminally applied 
to colonic adenocarcinoma-derived Caco-2 cell monolayers. Aft er 24 h in-
cubation, the diff erence in transepithelial electrical resistance (TEER) was 
determined and compared to the vehicle control.
Results: B. fragilis prevalence was 15 % higher (p<0.023) in active CD pa-
tients compared to remission. B  and ubiquitin prevalence was compara-
ble in both groups. Interestingly, TEER results demonstrate that luminally 
applied concentrated culture supernatant of b  positive B. fragilis strains 
increased the TEER (p<0.001) compared to b  negative strains or vehicle 
control, suggesting an improved epithelial integrity. This eff ect even over-
ruled tight junction-dependent barrier disruption by TNF-α and IFN-γ. 
However, isolated OMVs of b  positive or b  negative strains did not show 
any alterations in TEER. Among the B. fragilis genomes 160 to 18875 SNPs 
were observed (Split Kmer Analysis). b  positive and b  negative strains 
cannot be discriminated by other known coding sequences than the patho-
genicity island, containing b  and Metalloprotease II. NMR analysis did not 
reveal clear diff erences in metabolic profi les between the supernatants of 
the strains.
Conclusion: This study confi rms in a large well-defi ned patient cohort that 
B. fragilis, but not b  or ubiquitin positive strains specifi cally, is more prev-
alent in active CD, suggesting that it might play a role in exacerbations. 
Surprisingly, B. fragilis components did not impair the epithelial barrier 
and components of b  positive strains even improved intestinal barrier 
function, which warrants further investigation. This unexpected fi nding 
stresses the relevance of extending current research on the functional role 
of relevant microorganisms.
Disclosure: Nothing to disclose 
OP336 GUT MICROBIOTA IN PRIMARY SCLEROSING CHOLANGITIS 
IS CHARACTERIZED BY SPECIFIC COMPOSITION OF FUNGI
Bajer L.1, Galanova N.2, Macinga P.1, Brezina J.1, Kostovcik M.2, 
Kostovcikova K.2, Spicak J.1, Kverka M.2, Drastich P.1
1IKEM, Hepatogastroenterology, Prague, Czech Republic, 2Institute of 
Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
Contact E-Mail Address: lukasbajer1@gmail.com
Introduction: Primary sclerosing cholangitis (PSC) is a progressive disorder 
of biliary tree which can lead to end-stage liver disease, liver transplanta-
tion or even death. Colitis accompanying PSC (in up to 80% of patients) 
is considered to be a phenotype of IBD infl ammatory bowel disease (IBD) 
distinct from ulcerative colitis (UC) and is oft en referred to as PSC-IBD. 
Gut microbiota presumably plays an important role in both PSC and IBD 
pathogenesis. Several recent studies described the features of gut bacterial 
microbiota composition in PSC. However, disruption of gut fungal micro-
biota (mycobiota) has not yet been properly investigated.
Aims & Methods: The aim of this study was to characterize gut mycobiota 
composition in patients with PSC, PSC-IBD and UC. Stool samples were 
prospectively collected and relevant clinical data obtained from 109 study 
participants: 50 PSC patients with (n = 38) or without (n = 12) concomitant 
IBD, 32 controls with UC and 27 healthy controls (HC). Aft er standardised 
DNA extraction, amplifi cation and library preparation, sequencing of the 
ITS1 gene was performed using Illumina MiSeq platform. Acquired data 
were processed in QIIME employing MaAsLin and LEfSe tools for analysis 
of the output results.
Results: Mycobial profi les did not reveal signifi cant shift s between the 
study groups when calculated for various alpha - diversity indices (Shan-
non, Chao 1, Simpson, Observed OTUs). Furthermore, there was no statisti-
cally signifi cant distinction among phenotypes when describing beta - di-
versity with both Bray - Curtis and Binary Jaccard index. However, PSC was 
characterized by high relative abundance of several genera as compared 
to healthy controls: Candida (5.2% vs 2.5%), Lysurus (20.7% vs 11.7%) and 
Cladosporium (1.2% vs 0.6%). Furthermore, relative abundance of genus 
Rhodosporidium clearly distinguished PSC-IBD from UC (14.4% vs 2.8%). 
Such diff erences were further tracked down to the species level, identify-
ing major taxa responsible for respective shift s: Candida albicans, Lysurus 
cruciatus, Cladosporium herbarum and Rhodosporidium Babjevae. Subse-
quent multivariate analysis determined high abundance of Cladosporium 
herbarum sp. to be tightly associated with presence of PSC (p ≤ 0.05).
Conclusion: PSC is characterized by specifi c features of gut fungal microbi-
ota composition. Intestinal mycobiota profi les diff er between IBD subphe-
notypes (PSC-IBD and UC). High abundance of Cladosporium herbarum sp. 
(exceedingly common plant pathogen) in PSC may suggest an association 
with certain dietary habits.
Disclosure: Nothing to disclose 
Seeing is believing: Improving polyp detection
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OP337 IMPROVED ADENOMA DETECTION WITH ENDOANGEL: 
A RANDOMIZED CONTROLLED TRIAL
Yu H.1, Wu L.1, Hu S.2
1Renmin Hospital of Wuhan University, Gastroenterology, Wuhan, China, 
2Wuhan University, School of Resources and Environment, Wuhan, China
Contact E-Mail Address: yuhonggang@whu.edu.cn
Introduction: Colonoscopy is a pivotal procedure in the detection and di-
agnosis of lower gastrointestinal lesions. However, there are signifi cant 
variations in colonoscopy performance among endoscopists, impairing 
the discovery of colorectal cancers and precursor lesions. The aim of this 
study was to construct a real-time quality improving system, ENDOANGEL, 
to monitor real-time withdrawal speed, time colonoscopy insertion and 
withdrawal, and remind endoscopists of blind spots caused by scope slip-
ping, and evaluating its eff ectiveness in improving the adenoma yield of 
everyday colonoscopy.
Aims & Methods: ENDOANGEL system was developed using the methods 
of deep neural networks and perceptual hash algorithm. Patients referred 
because of health examination, symptoms, surveillance were recruited 
from Renmin hospital of Wuhan University. Enrolled patients were ran-
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OP339 IMPACT OF DIGITAL PATIENT REINFORCEMENT ON 
HIGH QUALITY COLONOSCOPY PREPARATION IN CRC SCREENING: 
RESULTS FROM THE MULTI-CENTER COLOPRAPP-STUDY
Walter B.1, Frank R.1, Ludwig L.2, Dikopoulos N.2, Hann A.1, Mayr M.3, 
Neu B.3, Mayer B.4, Meier B.5, Caca K.6, Seuff erlein T.1, Meining A.1
1Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany, 
2Gastroenterologische Schwerpunktpraxis, Dornstadt, Germany, 
3Krankenhaus Landshut-Achdorf, Medizinische Klinik II, Landshut, 
Germany, 4Universität Ulm, Institut für Epidemiologie und Medizinische 
Biometrie, Ulm, Germany, 5Klinikum Ludwigsburg, Klinik für Innere Medizin, 
Gastroenterologie, Hämato-Onkologie, Pneumologie, Diabetologie und 
Infektiologie, Ludwigsburg, Germany, 6Klinikum Ludwigsburg, Abt. für Innere 
Medizin, Ludwigsburg, Germany
Contact E-Mail Address: benjamin.walter@uniklinik-ulm.de
Introduction: Suffi  cient bowel preparation is crucial for successful screen-
ing and surveillance colonoscopy. However, the rates of inadequate 
preparation are still high. We investigated the eff ects of reinforced patient 
education using a smartphone application for colonoscopy preparation in 
CRC-screening.
Aims & Methods: In this prospective, endoscopist-blinded, multi-center 
study standard instructions pertaining to split-dose preparation were pro-
vided orally and in a written format to all patients during the initial appoint-
ment. Patients (n=500) were randomly assigned (1:1) to group that received 
reinforced education starting 3 days before the colonoscopy (APP group) or 
control group without further education. The primary outcome was qual-
ity of bowel preparation according to the Boston Bowel Preparation Scale 
(BBPS). The secondary outcomes included polyp and adenoma detection 
rate (PDR, ADR), compliance with low fi bre diet and split-dose laxative in-
take and patients’ perceived discomfort of the preparation procedure.
Results: The mean BBPS score was signifi cantly higher in the APP group 
(7.6±0.1) than in the control group (6.7±0.1) (p< 0.0001). The percentage of 
patients with insuffi  cient bowel preparation was signifi cantly lower in the 
APP group (8%) than in the control group (17%) (p=0.002). The ADR was 
signifi cantly higher in the APP group (35 vs. 28%) (p=0.0081). Signifi cantly 
more fl at adenomas were detected in the right colon in the APP group 
(p=0.004). Using the smartphone application was accompanied by a lower 
level of discomfort during preparation and a higher rate of compliance 
regarding correct laxative intake and diet restrictions.
Conclusion: Reinforced patient education using a smartphone application 
for optimized bowel preparation during the fi nal 3 days before colonos-
copy increased bowel cleanliness, adenoma detection and reduced dis-
comfort in CRC screening and surveillance patients.
Disclosure: B. Walter: Consultancies for Norgine Pharma 
OP340 LINKED COLOR IMAGING IMPROVES DETECTION 
RATE OF SESSILE SERRATED ADENOMA/POLYP IN THE COLON: 
A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
Muguruma N.1, Fujimoto D.1, Kawaguchi T.1, Kagemoto K.1, Teramae S.1, 
Kida Y.1, Wada H.1, Nakamura F.1, Fujino Y.1, Kitamura S.1, Okamoto K.1, 
Miyamoto H.1, Tanahashi T.1, Sato Y.2, Takayama T.1
1Tokushima University Graduate School of Biomedical Sciences, Department 
of Gastroenterology and Oncology, Tokushima, Japan, 2Tokushima University 
Graduate School of Biomedical Sciences, Department of Community 
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Contact E-Mail Address: muguruma.clin.med@gmail.com
Introduction: Colorectal cancer (CRC) is one of the leading causes of can-
cer deaths worldwide. Endoscopic surveillance for premalignant polyps in 
the colorectum is a crucial strategy for reducing CRC-related mortality. It 
has been reported that colorectal polyps in the right-side colon are oft en 
missed during conventional colonoscopy. Sessile serrated adenoma/polyp 
(SSA/P) predominantly occurs in the right-side colon, and is a precursor 
lesion of the cancer with microsatellite instability. It is more diffi  cult to 
detect SSA/P with conventional colonoscopy than adenomatous lesion be-
cause SSA/P commonly presents as a fl at and faded color lesion. To im-
prove endoscopic sensitivity in detection of SSA/P is putative for reduction 
of mortality of CRC. Linked color imaging (LCI) is a novel image-enhanced 
endoscopy that emphasizes color contrast between red and white areas 
and has been widely used for the diagnosis of gastrointestinal diseases 
including neoplastic lesions.
domly assigned to ENDOANGEL-assisted colonoscopy (EAC) and normal 
colonoscopy (NC). The primary end point was the adenoma detection rate 
(ADR) in colonoscopy with or without ENDOANGEL.
Results: 388 and 391 patients were analyzed in EAC and NC respectively. 
ADR was signifi cantly higher in EAC compared with the NC (13.56% vs 
21.91%, P = 0.049). Polyp detection rate (PDR) was signifi cantly increased 
from 37.08% to 51.29% with the assistance of ENDOANGEL (P < 0.001). 
Mean withdrawal was 2.32 minute longer with EAC (P < 0.001), with no 
diff erence in caecal intubation rate or insertion time. There was no signifi -
cant adverse event.
Conclusion: ENDOANGEL signifi cantly improved adenoma yield in colonos-
copy and could be used to improve the quality of everyday endoscopy.
Disclosure: Nothing to disclose 
OP338 ENDOCUFF-ASSISTED COLONOSCOPY VS STANDARD 
COLONOSCOPY ON ADENOMA DETECTION RATE IN ROUTINE 
PRACTICE: A CLUSTER-RANDOMIZED CROSSOVER TRIAL ON 2058 
PATIENTS
Karsenti D.1, Tharsis G.1, Perrot B.2, Cattan P.1, Tordjman G.1, Venezia F.1, 
Zrihen E.1, Gillot D.1, Gillet A.1, Hagege C.1, Samama J.1, Etienney I.1, 
Lab J.-P.3, Guigui B.3, Zago J.3, Burtin P.4, Cavicchi M.1
1Clinique de Bercy, Gastroenterology, Charenton le Pont, France, 2Nantes 
University Hospital, Methodology Unit, Nantes, France, 3Clinique de Bercy, 
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France
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Introduction: Endocuff  Vision (ECV) is a device supposed to improve polyp 
detection. This device has recently changed with the marketing of a second 
generation (ECV) very diff erent from the fi rst (Endocuff  Device). If interest 
of the fi rst generation of this device is still debated, little data is avail-
able on the second generation. The aim of this study was to evaluate the 
interest of ECV on adenoma detection rate (ADR) in routine colonoscopy. 
The secondary aim was to determine in which endoscopists the ECV is the 
most useful.
Aims & Methods: This cluster-randomized crossover trial compared endo-
cuff -assisted (ECV+) to standard colonoscopy (ECV-). Randomization de-
termined which team (of 11 endoscopists each, matched on ADR, age and 
activity volume) started with ECV + and which team by ECV-. A switch of 
the 2 teams was made at half of the inclusions. 
The main criterion was ADR. Secondary objectives were polyp detection 
rate (PDR), advanced neoplasia detection rate (ANDR) and serrated polyp 
detection rate (SPDR).
Results: 2058 patients were included (1032 ECV- vs 1026 ECV+). Both 
groups were comparable except for age (58.5±13y vs. 59.25±12y, P=0.001). 
ADR was signifi cantly improved in ECV group in multivariate analysis (OR 
1.49, CI95% 1.2-1.82, P=10-5). Benefi t of ECV was signifi cant for PDR (46.2% 
vs 37.7%, P< 0.001) but not for ANDR (11.1% vs 9.2%, P=0.17) nor SPDR 
(12.5% vs 11.9%, P=0.74). 
Regarding ADR upon physicians, ECV signifi cantly improved ADR in the 
medium (42 vs. 30%, P=0.005) and high detectors (46 vs. 32%, P< 0.001) 
groups but not in the low detectors group (31 vs. 26%, P=0.16).
Conclusion: We showed a signifi cant increase in ADR and PDR in ECV 
group with a gain of approximately 10%. This benefi t was signifi cant in 
medium and high detectors, but not in low detectors. In contrast, we did 
not show signifi cant impact of ECV on ANDR and SPDR.
Trial registered at ClinicalTrials.gov (NCT03344055)
Disclosure: Nothing to disclose 
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Aims & Methods: This study aimed to evaluate the utility of LCI for SSA/P 
detection in a prospective randomized controlled trial (RCT) and was con-
ducted at Tokushima University Hospital between 2015 and 2018. Patients 
underwent modifi ed back-to-back colonoscopies with white light image 
(WLI) and LCI. Patients were randomly allocated to 1 of the 2 arms at a 
1:1 ratio using a sealed envelope method: (A) WLI-LCI group: fi rst inspec-
tion with WLI followed by a second inspection with LCI; (B) LCI-WLI group: 
fi rst inspection with LCI followed by a second inspection with WLI. Polyps 
detected during the fi rst inspection were removed by snare or biopsied. 
Polyps detected during the second inspection were classifi ed as addition-
al polyps, and were also removed or biopsied. The primary outcome of 
the study was the additional SSA/P detection rate in WLI-LCI and LCI-WLI 
groups. The secondary outcomes were the positive detection rate for ad-
ditional SSA/P lesions in the second inspection per subject and the mor-
phological features of additionally detected SSA/P.
Results: A total of 60 patients participated the clinical trial and 52 were 
eligible; 26 each in the WLI-LCI and LCI-WLI groups. There was no statis-
tically signifi cant diff erence in inspection time, bowel preparation score, 
patients´ characteristics between the 2 groups. In the WLI-LCI group, 32 
SSA/P were detected in the fi rst inspection and 9 were additionally de-
tected. In the LCI-WLI group, 34 SSA/P were detected in the fi rst inspection 
and 1 was additionally detected. The additional detection rate of SSA/P in 
the second inspection in the WLI-LCI group was signifi cantly higher than 
that in the LCI-WLI group (21.9% vs 2.9%, p< 0.05). The prevalence of 
additional SSA/P lesions in the second inspection per subject was sig-
nifi cantly higher in the WLI-LCI group versus the LCI-WLI group (30.8% vs 
3.8%, p< 0.05). The SSA/P lesions of smaller, non-mucus, same color as 
the background mucosa, and located at the transverse colon were detected 
more frequently in the second inspection with LCI. It was indicated that 
hyperplastic polyp and adenoma in the right colon were also additionally 
detected in the second inspection in the WLI-LCI group by the sub-analysis.
Conclusion: This RCT results demonstrated the superiority of LCI to WLI 
in SSA/P detection by highly improved additional detection rate of SSA/P. 
Our data will be warranted by a multicenter, larger-scale trial recruiting 
a more general patient population to compare detectability of SSA/P with 
LCI and WLI. The study was registered at the University Hospital Medical 
Information Network-Clinical Trials Registry (UMIN 000017599).
References: Fujimoto D, Muguruma N, Okamoto K, Fujino Y, Kagemoto K, 
Okada Y, Takaoka Y, Mitsui Y, Kitamura S, Kimura T, Miyamoto H, Bando Y, 
Sonoda T, Takayama T. Linked color imaging enhances endoscopic detec-
tion of sessile serrated adenoma/polyps. Endosc Int Open. 2018.
Disclosure: Tetsuji Takayama received a research grant from FUJIFILM Co. 
The fi nancial sponsor was not involved in the design of the study, analysis 
and interpretation of the data. 
OP341 MICROVESSELS OBSERVATION IN COLORECTAL 
ENDOCYTOSCOPY IS USEFUL IN PREDICTING PATHOLOGICAL 
DIAGNOSIS
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Introduction: To date, narrow-band imaging　(NBI) could make it pos-
sible to analyze the surface microvessels of colorectal lesions for diff er-
entiating neoplasms from non-neoplasms and for predicting the histro-
pathological diagnosis. Endocytoscopy (EC) is the next generation of ultra-
magnifi cation endoscopy that allow visualization of the glandular structure 
and cellular atypia in vivo. In addition, when using EC with NBI (EC-NBI), 
it enables in vivo observation of blood vessels in more detail compared 
to conventional magnifi cation power without the use of any dye solution.
Aims & Methods: The study included 502 patients who underwent com-
plete colonoscopy and endoscopic or surgical treatment between April 
2006 and June 2016. A total of 669 lesions (61 Non-neoplastic polyps, 372 
adenomas, 75 intramucosal cancer, 21 slightly invasive submucosal cancer 
(SMs) and 140 massively invasive submucosal cancer.) were retrospectively 
evaluated. We used the Kudo classifi cation for the degree of submucosal 
invasion and classifi ed cancers accordingly(1). SMs cancer without vessel 
permeation does not metastasize. In contrast, SMm lesions show a sub-
stantial proportion (~10%) of lymph node metastasis. We named the ultra-
magnifi ed microvessel fi ndings as endocytoscopic vascular (ECV) pattern 
and classifi ed into the following 3 groups: EC-V1, the surface microvessels 
were very fi ne obscure; EC-V2, the surface microvessels were more clearly 
seen and showed a regular vessel network, and their caliber and arrange-
ment were uniform; and EC-V3, the surface microvessels were thick, and 
their caliber and arrangement were non-homogeneous.
Results: The sensitivity, specifi city and accuracy of EC-V1 for diagnosis of 
hyperplastic polyp were 91.8%, 98.7% and 98.1%, respectively. Similarly 
the sensitivity, specifi city and accuracy of EC-V3 for diagnosis of SMm were 
82.1%, 98.3% and 94.9%, respectively
Conclusion: Endocytoscopic vascular pattern was useful for predicting the 
histopathology of colorectal lesions.
Disclosure: Nothing to disclose 
OP342 EFFECT OF PRECEDING BIOPSY ON THE RESULTS 
OF ENDOSCOPIC SUBMUCOSAL DISSECTION FOR COLORECTAL 
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Introduction: Forceps biopsies are usually performed before endoscopic 
submucosal dissection (ESD) for colonic laterally spreading tumors (LSTs). 
However, preceding biopsy is commonly believed to possibly inhibit com-
plete tumor resection by causing blurring of tumor borders and tissue 
fi brosis.
Aims & Methods: The aims were to investigate whether the preceding bi-
opsy of colorectal LST aff ects complete endoscopic tumor resection and in-
creases the risk of complications. We retrospectively reviewed the medical 
records of patients with colorectal LSTs who underwent ESD at our center 
during an 8-year period. Patients were divided into two groups according 
to whether they underwent biopsy of the tumor before ESD. In addition, 
the characteristics of patients and tumors, including the completeness of 
tumor resection, were investigated.
Results: Of 288 patients (174 men) enrolled in this study, 194 (67.4%, pre-
ceding biopsy group) underwent biopsies before ESD, whereas 94 (32.6%, 
no biopsy group) did not. There were no signifi cant diff erences in age, 
sex, comorbidity, medication history, tumor location, and fi nal pathologic 
result between both groups. Tumor size was larger (p=0.002) and LST-G 
tumor was more common (p=0.003) in the preceding biopsy group than in 
the no biopsy group. No signifi cant diff erence was seen in ESD outcomes, 
including procedure time, hospitalization period, incidence of complica-
tions, en bloc resection rate, resection margin status, and incidence of 
surgical operation, between both groups.
Conclusion: Biopsy of LST is commonly performed before endoscopic re-
section. Contrary to popular belief, it does not increase the incomplete 
tumor resection rate and incidence of complications.
Disclosure: Nothing to disclose 
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Introduction: Non-coeliac gluten or wheat sensitivity (NCWS) describes 
a condition by which ingestion of wheat products induce gastrointestinal 
symptoms, in the absence of coeliac disease or wheat allergy. Symptoms 
of epigastric pain and post-prandial fullness are oft en described by these 
patients, demonstrating some overlap of symptomology with functional 
dyspepsia (FD). In addition, an association between FD and foods con-
taining wheat components have been reported in a number of obser-
vational studies; however, the mechanism behind this link has not been 
elucidated.
Aims & Methods: This study aimed to examine whether antigens present 
in gluten or gliadin could provoke an immune response from duodenal 
mononuclear cells isolated from patients with FD. 
Lamina propria mononuclear cells (LPMCs) were isolated from duodenal 
biopsies taken from patients with FD diagnosed by Rome III criteria (n=14) 
and non-dyspeptic controls (n=8). The cells were cultured and exposed to 
gluten (1 mg/mL) or gliadin (1mg/mL) for 24 hours. The supernatant was 
collected and a cytometric bead array used to analyse the concentrations 
of Th1, Th2 and Th17 cytokines (IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, and IL-
17a).
Results: When LPMCs were stimulated with gliadin, a signifi cant increase 
in the concentration of IL-17a was produced from FD patient cells compared 
to non-FD controls (p=0.047). There was no signifi cant response observed 
for IL-17a in response to gluten for FD or control. When the cohort was 
classifi ed by self-reported NCWS, FD patients with NCWS had increased 
IL-17a concentrations when compared to non-FD controls with no NCWS 
(p=0.0001). Interestingly, FD patients without NCWS had signifi cantly in-
creased IL-17a levels when compared to the NWCS positive FD group when 
treated with both gluten (p=0.002) and gliadin (p=0.009). 
Stimulation with gluten produced a decreased TNF level trending towards 
signifi cance (p=0.061) in FD patients when compared to controls. FD pa-
tients with NCWS had signifi cantly decreased levels of TNF compared to 
controls with NCWS (p=0.006) and controls without NCWS (p=0.030). An 
increase in TNF level in FD patients without NCWS compared to FD patients 
with NCWS was approaching signifi cance (p=0.052).There was no change 
in TNF level following exposure to gliadin.
Conclusion: Gluten and gliadin, components of wheat, stimulate immune 
responses from duodenal LPMCs from FD patients, characterised by an in-
crease in IL-17a concentration and a decrease in TNF levels in cell culture 
supernatants. 
These results indicate that NCWS may be a subtype of FD, and that dietary 
antigens from wheat products may induce symptoms of FD in some. The 
increased IL-17 concentration in cells from FD patients following stimula-
tion with gliadin suggests Th17 immune pathways warrant further inves-
Enteropathies: From bench to bedside
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Introduction: Excessive amounts of bile acids (BAs) entering the colon due 
to bile acid malabsorption (BAM) cause chronic bile acid diarrhoea (BAD). 
The 75Selenium homocholic acid taurine (SeHCAT) test is the “gold stan-
dard”, but is not generally available. Fibroblast growth factor 19 (FGF19) is 
the ileal hormone providing feedback inhibition of BAs and one possible 
biomarker of BAM that demonstrate a correlation with SeHCAT, but little is 
known about the mechanisms of dysregulation in patients with infl amma-
tory bowel disease (IBD), IBD aft er ileal resection (IBD-IR), irritable bowel 
syndrome with diarrhea (IBS-D) and microscopic colitis (MC).
Aims & Methods: The aim was to evaluate the diagnostic accuracy of se-
rum levels of FGF19, total free faecal bile acids (TFFBA) for fi nding BAM in 
patients active IBD, IBD in remission, IBD aft er ilea resection, IBS-D and 
MC. Methods: We enrolled 109 adult patients with chronic diarrhoea and 
11 healthy controls who underwent standard laboratory tests, colonoscopy, 
serum FGF19, fecal calprotectin (FC), TFFBA. Patients were divided into 
six groups: 30 patients with active IBD, 21 patients with IBD in remission, 
21 patients with IBD aft er surgery (IBD-IL), 23 patients with IBS- D, 14 pa-
tients with MC and 11 healthy control subjects. Fasting serum FGF19, TFFBA 
were measured by ELISA test and FC by the quantitative immunochromato-
graphic method
Results: Diagnosis of BAM based on levels of FGF19 below 30 pg/ml was 
confi rmed in 65 of 109 patients (59,6%) and excluded in 44 (40,4.%) com-
pare to healthy controls. Mean levels of FGF19 in patients with IBD active 
were 263.06 pg/mL, IBD remission were 367.2 pg/mL, IBD-IR were 57.1 pg/
mL, IBS-D were 447,5 pg/mL, MC were 403,7 pg/mL and healthy controls 
were with 585,6 pg/mL (p- 0,003, Welch test). A cut-off  concentration of 
FGF19 of 136,7 pg/mL or lower identifi ed patients with active IBD and diar-
rhea attributable to BAM with 70.9% sensitivity, 72,7% specifi city and an 
AUROC 0.79 (p-0,005). The number of IBD patients in remission with up 
to 4 bowel movements daily was 16 (76.2%) and concentration of FGF19 
below 136,7 pg/ml were in 76,2% of the patients, which corresponds with 
BAD as a co-factor in the diarrhea pathogenesis in these IBD patients. A 
cut-off  concentration of FGF19 of 32,88 pg/mL or lower identifi ed patients 
with IBD-IL and MC with diarrhea attributable to BAM with 90,5% sensitiv-
ity, 81,8% specifi city and an AUROC 0.93 (p< 0.01).
The overall sensitivity and specifi city of FGF19 for fi nding BAM in patients 
with IBD and MC compare to healthy controls were 76.2% and 72,7%, re-
spectively for a cut-off  value of 136,7 pg/ml., which will lead to accurate 
prediction of BAM in 72% of the IBD and MC patients. In patients with IBS-
D, serum concentration of FGF19 shows no signifi cant diff erence compare 
to healthy controls (p-0,71). TFFBA shows no signifi cant diff erence between 
all the groups and compare to healthy controls.
Conclusion: BAM is common and very under-diagnosed condition in pa-
tients with chronic diarrhea. FGF19 could be used for screening biomarker 
for BAM in patients with IBD, IBD aft er surgery (ileal resection) and MC, 
because there is eff ective additional treatment with bile acid binder’s for 
this patients. We observed signifi cantly lower serum concentrations of 
FGF19 in patients with IBD with IR, compared to healthy controls. A cut-
off  concentration of FGF19 below of 30,04 pg/mL identifi es patients with 
diarrhea likely attributable to BAM with an AUROC value of 0.93. Further 
bigger studies are needed to establish the effi  cacy of FGF19 in patients 
with suspected bile acid malabsorption.
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tigation in NCWS and FD. Further characterisation of these antigens as 
potential triggers for a subset of FD could allow for the elucidation of the 
immune mechanisms driving symptom onset and subtle infl ammation in 
patients.
Disclosure: Nothing to disclose 
OP345 MAST CELL DENSITY AND MAST CELL-NERVE 
INTERACTIONS CORRELATE WITH SEVERITY OF ABDOMINAL 
PAIN AND BLOATING IN PATIENTS WITH NON-CELIAC 
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Introduction: Non-celiac gluten/wheat sensitivity (NCG/WS) is character-
ized by gastrointestinal (GI) and extra-intestinal symptoms triggered by 
gluten-containing foods. Hitherto, despite many eff orts, diff erent aspects 
of this disorder, i.e. epidemiology, pathophysiology, diagnostic biomark-
ers and mechanisms underlying symptom generation remain unsolved. 
Furthermore, the overlap of clinical signs with functional GI disorders, 
including functional dyspepsia (FD) and irritable bowel syndrome, make 
the diagnosis of NCG/WS challenging in daily practice. Based on the hy-
pothesis that innate, more than adaptive, immunity is involved in NCG/WS, 
we designed this study aimed to investigate the role of neuro-immune 
interactions in GI symptom generation in patients with NCG/WS, focusing 
on the upper gut, specifi cally on duodenal submucosal neurons and mast 
cells (MCs).
Aims & Methods: Patients with self-reported NCG/WS (n=34), celiac dis-
ease (CD; n=28), FD (n=13) and healthy controls (HC; n=24) were recruited 
and examined with upper GI endoscopy to obtain routine duodenal biop-
sies. NCG/WS and CD patients were recruited according to the diagnostic 
work-up, including serological and genetic tests and histopathological 
evaluation, while FD patients were selected based on Rome IV criteria. 
All subjects were invited to fi ll an appropriate symptom questionnaire 
(modifi ed GI symptom rating scale). Submucosal whole-mount prepara-
tions were analyzed by immunohistochemistry to obtain quantitative data 
on neuronal and MC density and the percentage of MC in close vicinity 
to submucosal nerve endings. Appropriate statistical tests were applied 
to compare the three groups in terms of symptoms, neuronal and MCs 
density and MCs-nerves distance (D). These results were correlated to the 
clinical features.
Results: There were signifi cant diff erences among the three pathologi-
cal groups in terms of the number of GI symptoms (P< 0.0001) and the 
presence and severity of bloating and abdominal pain (P< 0.0001), with 
NCG/WS groups showing the highest scores. Bowel habit changes were 
similar among the three groups (P=0.08). Immunohistochemistry showed 
absence of neuronal cells abnormalities in the enteric submucosal plexus 
of all the three pathological groups. In NCG/WS, MCs density was not dif-
ferent from HC, while was slightly increased vs. CD (P=0.07), and signifi -
cantly decreased vs. FD (P< 0.05). The percentage of MCs close to nerves 
(D< 15 mm) was similarly increased in all three pathological groups vs. HC 
(P< 0.001). Specifi cally, we identifi ed that in NCG/WS, CD, and FD patients, 
60% of the total MCs present in the tissues were localized in the range of 
15 mm from the closest nerve fi ber. 
Moreover, 45% of the total MCs were localized in the range of 5 mm, as 
opposed to the 20% found in HC. In NCG/WS, MCs infi ltration correlated 
to bloating (P=0.001) and abdominal pain severity (P=0.03), and the per-
centage of MCs in proximity to neurons correlated with the number of GI 
symptoms (D< 5 mm; P=0.05), bloating and abdominal pain severity (D< 
15um; P=0.01). In FD MC density correlated to the number of GI symptoms 
(P=0.03) and with the presence of pain (P=0.05). In NCG/WS, CD and FD, 
MCs density and MC-nerve spatial relation did not correlate to bowel habit.
Conclusion: This study provided a morphological basis indicating that sub-
mucosal MCs infi ltration and MCs-nerve interactions in the upper GI tract 
of NCG/WS patients contribute to patient reported GI symptoms generation 
and maintenance, i.e. abdominal pain and bloating severity.
Disclosure: Nothing to disclose 
OP346 THE IMPACT OF CLINICAL PRESENTATION OF COELIAC 
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Introduction: Due to a broader use of serological screening tests, more 
coeliac disease (CD) patients with non-classical presentation have been 
diagnosed during the past decades. However, limited awareness of the 
diversity of clinical presentation of CD among health care professionals 
(HCP) contributes to continued frequently missed diagnoses.
Aims & Methods: The aim of our study was to assess the impact of the 
clinical presentation on diagnostic delays in children with CD in Central 
European (CE) region.
Paediatric gastroenterologists (PaedGI) in fi ve CE countries retrospectively 
submitted anonymised medical records of all their symptomatic patients 
aged < 19 years with CD diagnosis in 2016. Based on clinical presenta-
tion, patients were classifi ed as classical CD (presenting with signs and 
symptoms of malabsorption), non-classical CD (any other symptoms) and 
dermatitis herpetiformis Duhring (DHD). Classical CD patients were subdi-
vided into those with and those without diarrhoea, and non-classical CD 
into those with gastrointestinal and those with non-gastrointestinal symp-
toms (appetite loss, fatigue, irritability, headache, joint pain, skin rash (not 
DHD)). 
We analysed diagnostic delays in relation to clinical presentation at di-
agnosis. Diagnostic delays were calculated as the time gap between fi rst 
CD related symptoms to confi rmed CD diagnosis, and subdivided into the 
duration between fi rst symptoms and fi rst visit to the PaedGI, and from this 
visit to fi nal diagnosis. Kruskal-Wallis H test with post hoc tests were used 
for the analysis (IBM SPSS Statistics 22.0 for Windows).
Results: Data from 393 symptomatic children (65% female) from Croatia, 
Hungary, Germany, Italy and Slovenia were included (Table 1). Median 
age at diagnosis was 7 years (range 7m-18.5y). Patients with classical CD 
tended to have a slightly shorter median diagnostic delay (6m) compared 
to those with non-classical CD (7m) and DHD (8m) (NS). Further analysis 
showed that the median duration from fi rst symptoms to the fi rst visit to 
the PaedGI was the same (5m) in children with classical CD (n=264) and 
non-classical CD (n=122) whereas it tended to be slightly longer (7m) in 
children with DHD (n=7) (NS). Median duration from the fi rst visit to the 
PaedGI to the confi rmation of CD was found to be signifi cantly longer in 
non-classical compared to classical presentation (p< 0.05). 
Within classical CD group longer diagnostic delay was found in patients 
without diarrhoea (8m) compared to those with diarrhoea (5m) (NS), 
which can be attributed to signifi cantly longer duration from symptoms to 
PaedGI in patients without diarrhoea (6m) compared to those with diar-
rhoea (4m) (p< 0.05). 
In patients with non-classical CD, diagnostic delay with GI symptoms was 
slightly longer (7m) compared to non-GI symptoms (6m) (NS).
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and make the correct diagnosis. The courses and Web-App are accessible 
via www.celiacfacts.eu (English), www.zoeliakie-verstehen.de (German), 
www.coeliakia.info (Hungarian), www.poznam-celiakijo.com (Slovenian), 
www.sveocelijakiji.hr (Croatian) and www.celiachia-info.it (Italian). Pre-
liminary data of the evaluation show a signifi cant knowledge improve and 
high user satisfaction.
Conclusion: The online courses “Celiac Facts“ increase the knowledge 
of celiac disease among health care practitioners and patients while the 
Web-App facilitates a correct diagnosis. These innovative tools may im-
prove patient care. More language versions are intended.
Disclosure: The Focus IN CD project was funded by Interreg CENTRAL 
EUROPE (European Regional Development Fund), project no. CE111 
OP348 A DURUM WHEAT VARIETY-BASED PRODUCT IS EFFECTIVE 
IN REDUCING SYMPTOMS IN PATIENTS WITH NON-CELIAC GLUTEN 
SENSITIVITY: A DOUBLE-BLIND RANDOMIZED CROSS-OVER TRIAL
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Mora V.1, Fanali C.1, Leonetti A.1, Benedettelli S.2, Mele M.C.1, 
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Introduction: Patients with non-celiac gluten sensitivity (NCGS) do not have 
celiac disease but their symptoms improve aft er a gluten-free diet. How-
ever, to date, it is uncertain if the gluten or other components of the wheat 
are responsible for these symptoms.
Aims & Methods: The aim of this study was to compare the eff ects of an 
organic durum wheat variety and of a standard commercial wheat in pa-
tients with known NCGS. 
We performed a double-blind randomized cross-over trial of 42 patients 
(mean age 45 years, 8 men) with NCGS diagnosed according to the Salerno 
criteria and adherence to GFD for at least 12 weeks from screening. En-
rolled subjects were randomly assigned to one the following groups of 
treatment: A) a 2-week diet with Senatore Cappelli wheat variety pasta; 
B) a 2-week diet with standard commercial pasta. Then, aft er a 2-week 
washout period on gluten-free diet, each patient crossed over to the other 
treatment group. Symptoms were assessed through a modifi ed version of 
the Gastrointestinal Symptom Rating Scale (GSRS), tailored on NCGS.
Results: Between April 2018 and July 2018, 42 patients with NCGS were 
enrolled in the study (70.6% female) 34 patients completed the study. 
Patients reported lower overall symptoms scores aft er eating Senatore 
Cappelli pasta than standard pasta (p=0.03), and also signifi cantly lower 
scores in several specifi c gastrointestinal and extra-intestinal symptoms 
aft er eating Senatore Cappelli pasta than standard pasta specifi cally bloat-
ing (p=0.04), abdominal distention (p=0.004), eructation (p=0.01), fl atus 
(p=0.02), feeling of incomplete evacuation (p=0.001), dermatitis (p=0.01) 
and limb numbness (p=0.03).
Conclusion: In our study patients with NCGS experienced lower gastro-
intestinal and extra-intestinal symptom scores aft er eating the Senatore 
Cappelli wheat variety than a standard commercial wheat. Should our 
preliminary results be confi rmed by further studies, new dietary alterna-
tives may be available to patients with NCGS, with consequent health, eco-
nomic, and social benefi ts
Disclosure: Nothing to disclose 
Video Case Session
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OP349 GEL IMMERSION ENDOSCOPY FOR COLONIC DIVERTICULAR 
BLEEDING
Ikeya T., Yamamoto K., Yoshimoto T., Takasu A., Oguri N., Okamoto T., 
Shiratori Y., Okuyama S., Takagi K., Nakamura K., Fukuda K.
St. Luke’s International Hospital, Gastroenterology, Tokyo, Japan
Contact E-Mail Address: takaike@luke.ac.jp
Introduction: Diverticular bleeding(DB) is most common cause of lower 
gastrointestinal bleeding. Despite 75% of diverticular bleeding achieve he-
mostasis naturally, 25% of DB have the stigmata of recent hemorrhage(SRH) 
  Classical CD
Non-classical 
CD Skin DHD
Number of patients N=393 (%) 264 (67.2%) 122 (31.0%) 7 (1.8%)
Time from fi rst symptom until fi rst visit 
to PaedGI Median (range) 5m (0-10y) 5m (0-6y) 7m (1m-1.5y)
Time from fi rst visit to PaedGI until 
diagnosis* Median (range) 1m (0-2.5y) 1mỻ (0-5y) 1m (0-1m)
Time from symptoms to diagnosis 
(diagnostic delay) Median (range) 6m (0-10y) 7m (0-6y) 8m (1m-1.5y)
PaedGI - paediatric gastroenterologist; m - month; y - year; DHD - dermatitis herpetiformis 
Duhring *p<0.05 ỻsigni cance (p<0.05) vs Classical CD
[Diagnostic delays and clinical presentation of coeliac disease]
Conclusion: Clinical presentation at CD diagnosis has some, although rela-
tively small eff ect on diagnostic delays. Delays were longer in patients pre-
senting with non-classical symptoms or dermatitis herpetiformis Duhring 
compared to malabsorption. Lack of awareness about diff erent clinical 
presentations of CD may contribute to prolonged delays. Further eff orts to 
raise the awareness and knowledge among HCPs appear necessary.
*Study was co-fi nanced by Interreg CE programme (CE 111, Focus IN CD)
Disclosure: Nothing to disclose 
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Introduction: Celiac disease (CD) requires a life-long gluten-free diet to 
treat symptoms and avoid long-term health consequences. A correct and 
early diagnosis is of utmost importance. However, many health-care pro-
fessionals (HCPs) have poor knowledge of CD, leading to impaired patient 
care. Most patients seek more details on CD online with the risk of misin-
formation. To improve this situation we developed online courses on CD 
within the „Focus IN CD“ project (Interreg Central Europe Projekt CE111).
Aims & Methods: Twelve project partners from Germany, Slovenia, Hun-
gary, Italy & Croatia developed free, autodidactic online-courses with com-
prehensive, understandable, varied and evidence-based content, tailored 
to the target group. Project partners and external reviewers revised the 
draft s before the online implementation. Adult patients, parents of pedi-
atric patients, and HCPs are currently evaluating the courses before and 
aft er their use by completing anonymous online questionnaires. A Web 
based App was planned to provide detailed pathways and explanations for 
physicians to diagnose CD during childhood and adolescence.
Results: The courses contain written explanations illustrated by graphics, 
interactive elements, explain movies, self-tests and a dictionary. The HCP’s 
course comprises two units (background & diagnosis, treatment & follow-
up), published in parallel to diagnostic guidelines of the European Society 
of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) up-
dated in 2019. The patient’s course includes four units (background, diag-
nosis, treatment, living with CD) and explains the medical background in 
lay terms. Furthermore, the Web-App provides two separate pathways for 
the generalist (GP/ paediatrician) and the specialist (pediatric gastroenter-
ologist) according to the new ESPGHAN guidelines. Therefore the physi-
cian can easily follow the diagnostic fl ow scheme by choosing the relevant 
options while getting background information and advice how to proceed 
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and need treatment such as Endoclips and Endoscopic Band Ligation(EBL). 
SRH includes active bleeding, non bleeding visible vessels and adherent 
clots. Compared with left  sided DB, right sided DB tends to be massive 
bleeding.1) In Asia, right sided DB is more common than left  sided DB.2) In 
massive bleeding cases, it’s diffi  cult to identify the SRH due to inappropri-
ate endoscopic view with a large amount of bleeding and clot. Therefore 
to achieve hemostasis in DB, to get clear endoscopic fi led is important. 
Although water jet endoscopy was one of the good device, active bleeding 
and fl esh clot make water muddy immediately and disturb good visual 
fi led.Gel immersion endoscopy has been reported to achieve hemostasis 
besides diffi  cult visual fi led in gastrointestinal bleeding.3)
Aims & Methods: Our aim is to confi rm the eff ectiveness of gel immersion 
endoscopy for the massive DB case.
Results: The case was 72 year old female who admitted our hospital with 
massive hemotochezia. CT scan revealed the extravasation at hepatic fl ex-
ure. Urgent colonoscopy was performed aft er bowel preparation.Because 
of massive bleeding and clot, it was diffi  cult to identify SRH. So Gel(OS-1 
jelly: Otsuka Pharmaceuticals Factory, Tokushima, Japan) was used to get 
clear view. We injected the OS-1 gel through the BioShield irrigator(US 
Endoscopy, Mentor, Ohio).Gel clean the visual fi led instead of clot.Aft er 
Gel injection, bleeding source was seen clearly. Small non bleeding visible 
vessel was identifi ed. Then marking clip was done. Colonoscopy was re-
inserted with Endoscopic Band Ligation(EBL) device.EBL was successfully 
done and hemostasis was achieved. At the top of EBL lesion, visible vessel 
was confi rmed.
Conclusion: Gel immersion endoscopy was eff ective technique in massive 
diverticular bleeding.
References: 1)Khoury W. Massive and recurrent diverticular hemorrhage, 
risk factors and treatment. Int J Surg 2016; 33: 136-139 2) Imaeda H. The 
Burden of Diverticular Disease and Its Complications: West versus East. 
Infl amm Intest Dis 2018; 3: 61-68 3) Yano T. Gel immersion endoscopy: 
a novel method to secure the visual fi eld during endoscopy in bleeding 
patients. Gastrointestinal Endoscopy 2016;83(4):
Disclosure: Nothing to disclose 
OP350 ENDOSCOPIC RESECTION OF A CHOLEDOCOCELE
Grillo S., Cavina M., Iori V., Cecinato P., Sassatelli R.
Azienda USL-IRCCS Reggio Emilia, Gastroenterology, Reggio Emilia, Italy
Contact E-Mail Address: simone.grillo89@gmail.com
Introduction: Coledococele is a very rare fi nding in upper GI endoscopy 
and it is liable to endoscopic resection only in a few times.
Aims & Methods: A 17 years old caucasian man referred to our endoscopic 
unit for a recent episode of pancreatits. A MRCP showed regular caliber 
of the common bile duct, with an isolated cystic-like dilatation of its dis-
tal part. Our preliminary duodenoscopy and EUS detected a pre-papillary 
choledococele of 25-30 mm containing 3 biliary stones and ascribable to 
the biliary dilatation type III, according to the Todani classifi cation.
Results: The choledococele was handled like an ampulloma and removed 
en-bloc with the hot snare; it was too large to pass through the oesopha-
geal lumen, so we cut it in the stomach and took it out in two parts. At 
the cut edge the biliary and pancreatic orifi ce could be clearly seen: we 
performed both sphinterotomies and decided to proctect the Wirsung ori-
fi ce against the risk of pancreatitis using a plastic stent. At the end of the 
procedure, the cut edge was closed by two clips.
Conclusion: The control aft er 2 months showed the spontaneous expulsion 
of the pancreatic stent and a regular scar of the papillary area.
Disclosure: Nothing to disclose 
OP351 HOW TO MODIFY THE AXIS OF A SEMS PLACED FOR 
GASTRIC ANTRAL NEOPLASIA: A SIMPLE TRICK
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Introduction: Self-expandable metallic stents (SEMSs) may be used to ef-
fectively palliate malignant gastric outlet obstructions (GOOs), but their 
utility and effi  cacy in patients with gastric antral neoplasia in not com-
pletely clear. One of the reason why gastric SEMS can be ineffi  cacy is possi-
bly due to the impact of the proximal end of the stent to the great curvature 
of the gastric body.
Aims & Methods: .The aim of our treatment was the modifi cation of the 
proximal part of the SEMS, to restore the normal anatomy of the stomach.
Three patients unfi t for surgery underwent SEMS placement for gastric an-
tral neoplasia (two F of 25 and 56 years old and one M 57 years old). In 
the fi rst patients a SEMS 22 x 90 mm was placed, in the second a 22 x 60 
mm and in the third patient a 22 x 90 mm was placed inside a previous 
22 x 60 mm
Results: Because of the normal anatomy of the stomach, aft er placing a SEMS 
for gastric antral neoplasia, the proximal end of the stent can bit on the great 
curvature of the gastric body. This can results in a GOO due to the impact of 
the stent. With a standard clip we catch the upper part of the proximal end of 
the stent, closing the clip inside the mesh of the body of the SEMS. This trick 
allow to the upper part of the stent the completely modifi cation of the axis, 
restoring the normal anatomy of the stomach. All of the patients restart oral 
intake the day aft er without any complication or vomiting.
Conclusion: In presence of gastric antral neoplasia causing GOO under-
gone SEMS placement, the modifi cation of the axis of the stent with a 
standard clip is a simple trick to restore the normal anatomy, allowing to 
the patients a correct oral intake.
Disclosure: Nothing to disclose 
OP352 ACETIC ACID IN COMBINATION WITH BLUE LIGHT IMAGING: 
A NEW METHOD TO IMPROVE THE DETECTION OF RECURRING 
SESSILE SERRATED LESIONS IN THE COLON
Yamamoto S., Varkey J., Hedenström P.
Sahlgrenska Universitetssjukhuset, Division of Gastroenterology, Department 
of Internal Medicine, Göteborg, Sweden
Contact E-Mail Address: shun0515suke@gmail.com
Introduction: Sessile serrated lesions (SSLs) have a high risk of incomplete 
endoscopic resection, and any recurrent lesion at the site of resection is 
oft en diffi  cult to delineate due to the development of mucosal scars in 
the area.1 Our previous experience have demonstrated that acetic acid (AA) 
spray along with indigocarmine is of substantial benefi t for the delineation 
of SSLs.2 Recently, a new image enhanced endoscopy technique, blue light 
imaging (BLI), has been developed and the benefi ts in assessing colonic 
polyps has been reported.3 Nevertheless, the combined use of AA and BLI 
has not yet been presented.
Aims & Methods: The aim is to describe the fi rst experience of AA and BLI 
in two recurrent SSLs. 
Colonoscopy with a magnifying function and BLI (EC-760ZP-VM, Fujifi lm 
Co., Tokyo, Japan) was used. The acetic acid (5%) was diluted in lukewarm 
water to derive a solution with a concentration of 1.7%. The solution was 
sprayed directly through the working channel of the endoscope on to the 
suspicious lesions. Thereaft er the polyps were assessed and characterized 
prior to endoscopic removal.
Results: Acetic acid improved the visibility of the recurrent SSLs in both 
cases. In combination with BLI, the delineation of the lesion was more 
easily performed, and thus facilitated precise and radical resection, which 
was achieved in both cases. The use of acetic acid in a concentration of less 
than 2% was safe and no adverse events were recorded.
Conclusion: The combination of acetic acid and BLI could be an excellent 
method to improve the visualization of recurrent SSLs and thereby increas-
ing the possibility to perform complete endoscopic resections. The acetic 
acid spray was both easy to prepare and use.
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OP354 MUCOSAL ENTRY DEHISCENCE AND ESOPHAGEAL LEAK 
AFTER POEM
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Introduction: Per-oral endoscopic myotomy (POEM) has been a minimally 
invasive technique for the treatment of achalasia. While most of the cases 
in the Northern are performed for idiopathic achalasia, in our country the 
majority of the patients treated with POEM are Chagasic patients. Many 
of them have per-oral endoscopic myotomy aft er recrudescence of dys-
phagia many years aft er surgical esophagogastric myotomy with partial 
fundoplication.
Aims & Methods: To present the case and the treatment of mucosal entry 
dehiscence and esophageal leak aft er a per-oral endoscopic myotomy.
Results: A 49 years old female with advanced Chagas achalasia present-
ing recurrence of dysphagia (Eckardt 6) 15 years aft er a cardiomyotomy 
and partial fundoplication was submitted to POEM. Control esophagogram 
the next day showed no leak. However, she presented a severe vomit-
ing episode. Liquids were introduced the following day, and the patient 
discharged asymptomatic on the postoperative day 3. Aft er 48 hours, she 
returned complaining about chest pain and vomiting. Physical examina-
tion and leukogram were normal. Computed tomography (CT) with oral 
contrast showed dehiscence of the mucosal entry (mucosotomy) in the 
esophagus and esophageal blocked leakage to the posterior mediastinum. 
Broad-spectrum antibiotics, proton-pump inhibitor (PPI) and placement 
of nasoenteric feeding tube were adopted. Follow-up CT aft er 10 days 
showed the persistence of the esophageal leakage. Upper gastrointestinal 
endoscopy (UGE) showed a proximal mucosotomy on the mucosal entry 
topography with fi brin clots and an hemoclip inside it. The hemoclip was 
pulled-out and then the endoscope advanced inside the tunnel. A distal 
orifi ce communicating the submucosal tunnel to the esophageal lumen 
was identifi ed 3 centimeters forward, guiding the drainage of the esopha-
geal leakage and preventing the formation of fl uid collection. Section of 
the mucosal fl ap over the submucosal tunnel was the therapeutic choice 
as previous surgery fi brosis and infl ammatory tissue around blocked the 
leakage and contained the infection. PPI and sucralfate were prescribed. 
Liquid diet was introduced 2 days aft er and the patient discharged with 
semi-liquid diet 4 days aft er. The patient was asymptomatic 30 days aft er 
the new procedure, and UGE revealed a small amount of fi brin over the 
blocked wall. PPI was maintained and pasty diet introduced. UGE aft er 
90 days showed the blocked wall almost wholly re-epithelialized and Los 
Angeles B esophagitis. Due to improving but still present refl ux the patient 
is still on PPI and will have a 6-months UGE control.
Conclusion: Mucosal fl ap section could be safely performed as the leakage 
was blocked. Avoiding severe vomiting aft er POEM is an important step to 
prevent mucosal entry dehiscence. Previous surgery for achalasia may be a 
factor that helps block esophageal leakage in case of mucosotomy.
Disclosure: Nothing to disclose 
OP355 MULTIPLE BULBAR NEUROENDOCRINE TUMORS RESECTED 
BY PRE-PYLORIC TUNNELING ESD
Bucalau A.-M.1, Maris C.2, Eisendrath P.1, Deviere J.1, Lemmers A.1
1Erasme University Hospital, Gastroenterology, Hepatopancreatology and 
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Contact E-Mail Address: bucalauanamaria@yahoo.com
Introduction: A 61 years-old patient underwent an esophagogastroduo-
denoscopy (EGD)for epigastric pain. It revealed multiples sub-mucosal 
lesions of the duodenal bulb, between 5 and 16 mm, the two largest be-
ing juxta-pyloric. Biopsies revealed grade I neuroendocrine tumors (Rindi 
I, Ki67< 2%). Work-up included an endoscopic ultrasound that showed a 
T1 tumor with no regional lymphadenopathies and a positron emission 
tomography-computed tomography (PET/CT) scan using 68Ga-DOTA-TATE 
(somatostatin [SST]-analog)that came back negative.
References: 1 Pohl H, et al. Incomplete polyp resection during colonoscopy-
results of the complete adenoma resection (CARE) study. Gastroenterology. 
2013;144:74-80. 2 Yamamoto S, et al. Acetic acid-indigocarmine mixture for 
evaluating the margins of sessile serrated adenomas/polyps. Dig Endosc. 
2017;29:817-8. 3 Bisschops R, et al. BASIC (BLI Adenoma Serrated Inter-
national Classifi cation) classifi cation for colorectal polyp characterization 
with blue light imaging. Endoscopy. 2018;50:211-20.
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OP353 SALINE-IMMERSION THERAPEUTIC ENDOSCOPY (SITE) 
FACILITATED UNROOFING OF A LARGE, SYMPTOMATIC ILEAL LIPOMA 
AT DOUBLE-BALLOON ENTEROSCOPY (DBE)
Pelucchi M., Murino A., Lazaridis N., Coppo C., Costa D., Despott E.J.
Royal Free Unit for Endoscopy, The Royal Free Hospital and University 
College London (UCL) Institute for Liver and Digestive Health, Endoscopy, 
London, United Kingdom
Contact E-Mail Address: nikos.lazaridis@gmail.com
Introduction: Lipomas of the gastrointestinal (GI) tract are common, be-
nign and usually present as innocuous fi ndings. Larger ones (>2cm in di-
ameter), particularly those involving the ileum, may present with clinical 
symptoms such as abdominal pain (caused by intussusception) and iron 
defi ciency anaemia (IDA) or obscure GI bleeding (OGIB) (caused by overly-
ing mucosal ulceration); these cases warrant intervention and oft en end 
up being referred for surgery. We describe a minimally invasive endoscop-
ic alternative to surgical resection for the management of these lesions.
Aims & Methods: A 60-year-old man presented with recurrent, cramp-
ing abdominal pain and OGIB. A magnetic resonance enterography (MRE) 
revealed a 2.5 cm submucosal lesion in the distal ileum, in keeping with 
a large lipoma. In light of these fi ndings and the clinical presentation, we 
perform a saline-immersion retrograde DBE under conscious sedation, for 
further evaluation and minimally invasive, defi nitive endotherapy.
At DBE the lesion was identifi ed at around 40cm proximal to the ileocaecal 
valve. The endoscopic appearances revealed a 2.5 cm sessile submucosal, 
lumen-fi lling lesion with a positive ‘pillow sign’. Although the overlying 
mucosa appeared mostly unremarkable, a small, healed ulcer (which 
would account for the patient’s IDA and OGIB) was identifi ed on the me-
dial surface of the lesion. 
Endotherapy was deemed feasible and this was facilitated by the buoyancy 
properties provided by SITE. In order to reduce the risk of perforation and 
bleeding, an endoscopic loop ligating device was fi rst deployed tightly at 
the base of the lesion. A ball-tip, needle-type endoscopic submucosal dis-
section (ESD) knife was then used to incise and unroof the lesion. This 
allowed for exposure and spontaneous extrusion of the lipomatous tissue 
(already under pressure from the loop-lighting device). Saline-immersion 
allowed for maintenance of a clear visual fi eld, through avoidance of 
clouding of the endoscopic lens and fl otation of extruded micelles of fatty 
tissue. A submucosal tattoo and a clip were placed as endoscopic and 
radiological markers, respectively. The procedure was performed under 
antibiotic cover. No signifi cant immediate, early or late adverse events 
were encountered.
Results: Histopathological examination of retrieved tissue showed mature 
adipocytes with fi brofatty submucosal changes, in keeping with a submu-
cosal lipoma. No dysplasia or sarcomatous transformation was identifi ed. 
The patient’s symptoms have resolved completely post-endotherapy.
Conclusion: Our case demonstrates the safety and usefulness of minimally 
invasive endotherapy of symptomatic large ileal lipomas. The combination 
of DBE with SITE-facilitated unroofi ng, aft er securing the lipoma’s base 
with a loop-ligation device, allows for safe, spontaneous extrusion of the 
benign lipomatous tissue and avoids the need for operative surgery in 
symptomatic patients.
Disclosure: Dr Despott and Dr Murino receive research/ education sup-
port from Aquilant Medical, Fujifi lm, Olympus, Pentax Medical, Boston 
scientifi c and GI supply. All others authors have no confl icts of interest to 
disclosure. 
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Aims & Methods: Aft er discussion in the multidisciplinary oncological 
board, a decision was made to perform an endoscopic submucosal dis-
section (ESD) of the largest tumors, followed by an endoscopic mucosal 
resection (EMR) for the remaining small lesion.
Results: Knowing the close contact between the two largest bulbar NETs 
and the pylorus, the procedure was started with gastric submucosal tun-
neling 2 cm proximal from the pylorus according to the pocket-ESD meth-
od, to be able to reach the deep submucosa of the juxta-pyloric bulb in a 
tangential axis with the ESD knife. The dissection was conducted alongside 
the pylorus sphincter before digging under the Brunner glands under the 
NET lesions. A clip and thread traction system was set up on the fl ap aft er 
lateral opening, followed by distal incision. En-bloc, complete endoscopic 
resection was achieved with a tiny bulbar muscular tear easily closed by 
clips.
The patient had no symptoms aft er the resection. Histopathological exami-
nation of the specimen showed 3 grade I neuroendocrine tumors. Lateral 
margins were free from malignancy, while one of the vertical margins was 
in contact with the tumor cells. There was no lymphovascular invasion and 
the lesion was classifi ed pT2mNx. Given the well diff erentiation of the tu-
mor, endoscopic follow-up was proposed. The patient underwent control 
EGD at three months and resection of the small remaining lesion by cap-
band-assisted EMR. At that time no recurrence was discovered.
Conclusion: Pre-pyloric tunneling ESD is feasible and safe for bulbar sub-
mucosal lesions.
Disclosure: Nothing to disclose 
OP356 ENDOSCOPIC SUTURING TO REDUCE THE RISK OF 
COMPLICATIONS AFTER ENDOSCOPIC SUBMUCOSAL DISSECTION 
OF A RECURRENT RECTAL POLYP
Belletrutti P.J., Maselli R., Palma R., Galtieri P.A., Spadaccini M., Repici A.
Humanitas Clinical and Research Center and Humanitas University, Digestive 
Endoscopy Unit, Rozzano (MI), Italy
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Introduction: Recurrent colorectal polyps present a challenge for the en-
doscopist due to the presence of submucosal fi brosis. In these cases, endo-
scopic mucosal resection (EMR) is oft en unsuccessful thus submucosal dis-
section (ESD) is the preferred technique. The risk of muscle layer damage 
and subsequent perforation is increased in performing ESD for recurrent 
colorectal polyps. As such, wound closure aft er resection may reduce the 
risk of complications.
Aims & Methods: This video demonstrates closure of a rectal ESD defect 
using an overstitch device designed for use with a fl exible endoscope. A 
74 year-old man presented with a recurrent laterally-spreading tumor 
(LST) in the mid-rectum (initial size 65mm with pathology showing focal 
high-grade dysplasia). Previous piecemeal EMR had been performed but 
at follow-up endoscopy 6 months later a large recurrent adenoma was 
identifi ed. We anticipated signifi cant submucosal fi brosis particularly in 
the scarred center of the lesion. 
Furthermore, the previous histology and location of the lesion predicted 
an increased risk for covert submucosal invasion thus ESD would likely be 
the best option for a complete en bloc resection. If indeed the center of the 
lesion was tethered to the muscle layer, we further anticipated some de-
gree of muscle injury during ESD so we were prepared to close the defect 
via endoscopic suturing.
Results: A detailed examination of the lesion under high-defi nition white-
light, linked-color imaging and blue-light imaging in addition to opti-
cal zoom + under water magnifi cation revealed a mid-rectal 40x30mm 
granular-type LST with Paris type IIa+IIc morphology and Kudo IIIL/IV pit 
pattern. Standard ESD was then performed using a HybridKnife (ERBE Ele-
ktromedezin, GE) by incising the mucosa around the lesion followed by 
stepwise ESD. As anticipated, the center of the lesion was adherent to the 
muscularis propria thus very careful dissection was required with cutting 
of some superfi cial muscle fi bres in this area to preserve an en bloc resec-
tion. No major bleeding or intra-procedural perforation occurred. 
Aft er ESD was completed, further examination of the resection bed re-
vealed no defi nite signs of deep muscle injury or perforation. However, 
given there was intentional incision of the muscle layer in the center of 
the lesion, wound closure was optimal. The resected area was too large 
to attempt clip closure therefore we elected to perform endoscopic sutur-
ing using an overstitch device (Apollo Endosurgery Inc., USA). Two run-
ning sutures were completed to tightly appose the edges of the resection 
bed and completely seal the mucosal defect. Total procedure time was 
165 minutes. No delayed complications occurred. Final pathology revealed 
low-grade dysplasia only.
Conclusion: Endoscopic suturing is a viable option when full closure of a 
mucosal defect is desired.
Disclosure: Nothing to disclose 
OP357 ENDOSCOPIC MECHANICAL LITHOTRIPSY FOR SIGMOID 
GALLSTONE ILEUS
Nawaz F., Ahmed M.
Good Hope Hospital, Gastroenterology, Birmingham, United Kingdom
Contact E-Mail Address: dr.faisal2013@yahoo.com
Introduction: Gallstone ileus is an uncommon condition accounting for 
1-4% of all causes of mechanical intestinal obstruction. The usual site for 
stone impaction is the terminal ileum or ileo-caecal valve. Intestinal ob-
struction caused by gallstone impaction in the large bowel is a very rare 
entity. We present a case of colonic gallstone ileus, at the level of sigmoid 
colon, which was successfully treated with endoscopic mechanical litho-
tripsy.
Aims & Methods: A 60 year old man was admitted with a 5 day history of 
upper colicky abdominal pain, high grade fever and darkening of urine. 
Initial blood tests showed, WBC 9.8 x10^9/L, CRP 270 mg/L, Bilirubin 
44mmol/L, ALT 48 iu/L, and Alkaline phosphatase 170 iu/L (NR< 130). An 
ultrasound scan of abdomen and MRCP showed multiple stones in the 
gallbladder and in the common bile duct. Hence, an ERCP was performed 
2 days later and strangely, 4 litres of fl uid was seen in the stomach despite 
a prior overnight fast. Aft er aspirating the fl uid, the pylorus was found 
to be widely patent and two small ulcers were noted in the duodenum 
just proximal to the normal looking ampulla. Aft er a wire guided bili-
ary cannulation, the cholangiogram confi rmed common bile duct stones. 
A sphincterotomy was performed and the bile duct stones were extract-
ed with a balloon catheter. However, the fi nal occlusion cholangiogram 
showed a possible cholecysto-duodenal fi stula. Despite a successful ERCP, 
the patient failed to show clinical improvement and developed vomiting 
and abdominal distension with a rise in the WBC to 28x10^9/L. A CT scan 
2 days aft er the ERCP confi rmed a cholecysto-duodenal fi stula together 
with dilated small bowel loops and a large gallstone impacted in the sig-
moid colon. Hence, a fl exible sigmoidoscopy was performed confi rming 
the presence of a 3cm gallstone obstructing the narrow sigmoid colon. Ini-
tially, a large polypectomy snare was used to grasp the stone but it was not 
possible to extract the stone through the narrow sigmoid colon. Therefore, 
a 3cm diameter Olympus Lithocrush Basket was used to crush the gallstone 
into smaller pieces, which then passed spontaneously.
Results: The patient recovered and went home two days later.
Conclusion: Gallstone ileus involving the large bowel is an uncommon 
condition. The stone usually fi stulates from the gallbladder directly to the 
colon rather than to the duodenum as in this case. Colonic gallstone ileus 
is usually seen in old age and in patients with multiple co-morbidities 
where surgical intervention is associated with an increased risk of morbid-
ity and mortality. Hence, less invasive techniques such as colonoscopy with 
mechanical lithotripsy of the impacted gallstone should be tried prior to 
considering surgical intervention.
Disclosure: Nothing to disclose 
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precancerous lesions. One-hundred and two non-ampullary duodenal 
premalignant lesions including 95 intestinal-type tumors (90 intestinal-
type adenomas and 5 intestinal-type non-invasive carcinomas) and 7 
gastric-type tumors (2 pyloric gland adenomas and 5 non-invasive car-
cinomas) as well as adjacent normal tissues (n = 15) from 102 individu-
als were investigated. According to the revised Vienna classifi cation, in-
testinal-type tumors were classifi ed as 32 Category 3 tumors (low grade 
adenomas) and 63 Category 4 tumors (high grade adenomas and non-
invasive carcinomas). 
Also, gastric-type tumors were classifi ed as 2 Category 3 tumors (pyloric 
gland adenomas) and 5 Category 4 tumors (non-invasive carcinomas). Af-
ter extracting DNA from formalin-fi xed paraffi  n embedded (FFPE) sections, 
we assessed the methylation status of CpG island methylator phenotype 
(CIMP) markers including CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1 
as well as MLH1 using bisulfi te pyrosequencing. A cutoff  value of 15% was 
used to defi ne genes as methylation-positive. Tumors were defi ned as 
CIMP-positive when methylation was detected in two or more out of fi ve 
methylation markers.
Results: Tumors with CIMP were seen in 20 intestinal-type tumors (21.1%) 
and 3 gastric-type tumors (42.9%), respectively. In intestinal-type tumors, 
prevalence of CIMP-positive lesions was higher in non-invasive carcino-
mas (40%) than in adenoma (20.2%) or normal mucosa (0%, P < 0.01). 
In gastric-type tumors, CIMP was detected more frequently in non-invasive 
carcinomas (60%) than in normal mucosa (0%, P < 0.01). As for intestinal-
type tumors, prevalence of CIMP-positive lesions was signifi cantly higher 
in Category 4 tumor than in normal mucosa (25.8% vs. 0%, P = 0.03). As 
for methylation levels of each cancer-associated gene, we found that the 
methylation levels of CACNA1G, NEUROG1, RUNX3, and SOCS1 were signifi -
cantly higher in intestinal-type non-invasive carcinomas than in intestinal-
type adenomas or normal mucosa. However, there were no signifi cant 
diff erences when intestinal-type tumors were classifi ed according to the 
revised Vienna classifi cation.
Conclusion: Genome-wide hypermethylation of cancer-associated genes 
estimated by CIMP were associated with development of non-invasive 
carcinomas other than adenoma formation during carcinogenesis of non-
ampullary duodenal precancerous lesions. Especially for intestinal-type 
tumors, epigenetic silencing of CACNA1G, NEUROG1, RUNX3, and SOCS1 
was signifi cantly associated with development of non-invasive carcinomas 
from adenomas.
Disclosure: Nothing to disclose 
OP360 TLR4-DRIVEN SPONTANEOUS TUMORIGENESIS IS 
MEDIATED BY MICROBIAL-INDUCED EPITHELIAL PRODUCTION 
OF REACTIVE OXYGEN SPECIES
Burgueno J.1, Fritsch J.1, Santander A.M.1, Brito N.1, Pignac-Kobinger J.1, 
Conner G.E.2, Fernandez I.1, Abreu M.T.3
1University of Miami, Medicine, Miami, United States, 2University of Miami, 
Cell Biology, Miami, United States, 3University of Miami, Miller School of 
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Introduction: Duodenal adenocarcinoma (DA) is a rare malignancy with a 
poorly defi ned pathogenesis. Previous studies have identifi ed histopatho-
logical similarities between DA and colorectal cancer (CRC) as well as an 
increased risk in CRC patients to develop DA. We have shown that toll-like 
receptor 4 (TLR4), a receptor for Gram negative bacteria, is overexpressed 
in intestinal epithelial cells (IECs) of CRC patient adenomas. To mimic over-
activation of epithelial TLR4 in an animal model, we developed the villin-
TLR4 mice, which express a constitutively active form of TLR4 under the 
promoter of villin. 
In this model, we have demonstrated that epithelial TLR4 signaling in-
duces gut dysbiosis, production of reactive oxygen species (ROS), and in-
creased susceptibility to colitis-associated cancer. Furthermore, we have 
also reported that these mice develop spontaneous duodenal adenomas 
before 12 weeks of age.
Aims & Methods: Here, we took advantage of this spontaneous model of 
DA to test the hypothesis that epithelial TLR4 activation promotes tumor 
initiation by shaping the microbiome and inducing reactive oxygen species 
(ROS). Villin-TLR4 mice and their wild-type (WT) littermates were either 
rederived into germ-free conditions or treated with the ROS scavenger 
apocynin from birth. At 12 weeks, mice were euthanized and tumor area 
in vilin-TLR4 mice was measured. IECs from non-involved areas were iso-
Oncology: Basic mechanisms
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OP358 THE CHICK EMBRYO CHORIOALLANTOIC MEMBRANE 
ASSAY: IN OVO MODEL FOR PERSONALIZED ASSESSMENT AND 
EVALUATION OF THE MOST EFFECTIVE THERAPEUTIC APPROACH 
IN CANCER THERAPY
Shapira S.1, Bogin O.2, Kazanov D.2, Bedny F.3, Hershkovizh D.3, Itzhaki A.4, 
Brazowski E.3, Arber N.5
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Introduction: “Personalized medicine,” is tailoring and maximize medical 
treatment to a single person.
Aims & Methods: To generate a personalized, quick and reliable screening 
system for eff ective evaluation of diff erent therapeutic options using 3D 
tumors in a „humanized egg“.
At day 3, 2ml of albumin was pulled out from fertilized eggs to separate 
the CAM from the eggshell and a small window in the eggshell has been 
made. On day 6-7, single cells suspension or tissues, derived from cancer 
patients, were transplanted onto the CAM and visible tumors were devel-
oped („CAM-PDX“). Human immune cells were inoculated on day 9-10 and 
then drugs, mAbs and Immuno/chemo-therapy, were applied via the yolk 
sac. Tumor growth was measured, weighted, stained and monitored by 
caliper and IVIS imaging platform.
Results: Histology and IHC analysis confi rmed that the established tumors 
retained their characteristics. Positive Ki-67 staining confi rmed that cancer 
cells proliferate while the treated tumors showed reduced staining. Anti-
CD24 mAb, FOLFOX and cetuximab, given as single agent or combinations, 
successfully inhibited CRC cells growth (by 70-75%). Detection of active 
caspase-3 confi rmed these results. Biopsies from human specimens, were 
successfully established and expanded by serial passages allows genera-
tion of bio-bank. The stimulated human PBMCs demonstrated enhanced 
proliferation in vitro and in ovo, even aft er 5 days in the egg.
Conclusion: The CAM is an ideal, eff ective, economical and powerful av-
atar-based precision medicine approach to predict the best protocol for 
cancer therapy.
Disclosure: Nothing to disclose 
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Contact E-Mail Address: sawada1046@gmail.com
Introduction: Because duodenal epithelial tumors are rare, their biological 
and clinical characteristics are not yet fully understood.
Aims & Methods: To clarify the molecular and clinicopathological charac-
teristics of non-ampullary duodenal lesions, we assessed DNA methyla-
tion of cancer-associated genes in a cohort of non-ampullary duodenal 
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lated by EDTA chelation and analyzed for H
2
O
2
 production by means of 
Amplex Red and expression of NADPH oxidase 1 (Nox1) and dual oxidase 2 
(Duox2) transcripts by means of qPCR.
Results: Constitutive activation of epithelial TLR4 signifi cantly increased 
the expression of Nox1, p22 phox, Duox2, and DuoxA2 transcripts in vil-
lin-TLR4 IECs when compared to those of WT littermates. Rederivation of 
villin-TLR4 into germ-free conditions signifi cantly reduced the epithelial 
expression of DuoxA2, which was accompanied by a signifi cant reduction 
in the production of H
2
O
2
. In the absence of a microbiota, duodenal tumor 
initiation was abrogated in 5 out of the 6 mice and the tumor area was 
dramatically reduced in the only mouse that developed DA. Chronic ad-
ministration of apocynin did not inhibit epithelial NADPH oxidase activity 
or expression, but signifi cantly reduced the tumor area in 5 out of the 8 
mice and prevented tumor formation in 3 out of the 8 mice, demonstrating 
that ROS play an important role in this model of tumorigenesis.
Conclusion: Our fi ndings demonstrate that TLR4-driven spontaneous tu-
morigenesis is dependent on the presence of a microbiota that induces 
DuoxA2 upregulation and the release of ROS. In addition, our observations 
suggest that similar to CRC, DA is also dependent on the microbiota. We 
speculate that TLR4 activation induces dysbiosis, which in turn feeds for-
ward ROS production by IECs, leading to tumor initiation.
Disclosure: Nothing to disclose 
OP361 YAP/TAZ PLAYS A POTENTIAL ROLE IN TUMOR 
INITIATION IN THE INTESTINE AND CAN BE REGULATED BY THE 
MICROENVIRONMENT
Pastula A.1, Janssen K.-P.1, Steiger K.1, Slotta-Huspenina J.1, 
Friedman R.A.2, Ruiz M.1, Ehmer U.1, Quante M.3
1Klinikum rechts der Isar Technische Universität München, Munich, Germany, 
2Columbia University, New York City, United States, 3Medizinische Klinik II, 
Klinikum rechts der Isar, Munich, Germany
Contact E-Mail Address: agnieszka.pastula@wp.pl
Introduction: The stromal microenvironment plays a key role in regulating 
adult stem cell niches and can play a dual role in tumor development. De-
pending on the tissue context, stromal cells may either promote or inhibit 
tumor growth, however the precise cellular and molecular mechanism 
remain largely unknown.
Aims & Methods: We aimed to identify tumor initiation signaling 
pathway(s) that is regulated by the stromal microenvironment. To study 
this, we employed wild type and mutated (Apc+/1638N) murine intestinal 
organoid cultures and crypt-myofi broblast co-cultures, microarray analy-
sis, real-time PCR and immunohistochemistry staining of human colorec-
tal cancer samples.
Results: Microarray analysis revealed that genes associated with YAP sig-
naling are upregulated in both mutated intestinal organoids and wild type 
organoids from an indirect crypt-myofi broblast co-cultures, that was con-
fi rmed with real-time PCR. Inhibition of YAP signaling with cytochalasin D 
resulted in reduced number and decreased diameter of tumor-like crypts 
(spheroids). Immunohistochemistry staining of human colorectal cancer 
samples showed that strong activation YAP/TAZ in dysplastic epithelium 
correlated with strong infi ltration of aSMA+ stromal cells.
Conclusion: We discovered that YAP/TAZ signaling in the intestinal epi-
thelium can be regulated either intrinsically by an oncogenic mutation or 
extrinsically by secreted factors from the stromal microenvironment. This 
study highlights the important role of the microenvironment in regulating 
epithelial cell plasticity and suggests that aSMA+ stromal cells can contrib-
ute to tumor initiation. Therefore, aSMA+ stromal cells should be consid-
ered in the future as cellular targets for anti-cancer therapies.
Disclosure: Nothing to disclose 
OP362 COMPREHENSIVE MOLECULAR ANALYSIS 
IDENTIFIES DRIVER MUTATIONS IN METASTASES OF SPORADIC 
WELL-DIFFERENTIATED NEUROENDOCRINE TUMOURS OF THE 
SMALL INTESTINE
Samsom K.1, van Veenendaal L.2, Roepman P.3, Kodach L.1, Steeghs N.2, 
Meijer G.1, Kuhlmann K.4, Verbeek W.5, Tesselaar M.2, van den Berg J.1
1Antoni van Leeuwenhoek/Netherlands Cancer Institute, Pathology, 
Amsterdam, Netherlands, 2Antoni van Leeuwenhoek/Netherlands Cancer 
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Contact E-Mail Address: k.samsom@nki.nl
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) represent 
a heterogeneous group of rare tumours. At present, the genetic make-up 
of SI-NETs is poorly elucidated. In contrast to adenocarcinomas and neu-
roendocrine carcinomas (NECs), well diff erentiated SI-NETs are relatively 
indolent tumours. NECs share oncogenic pathways with adenocarcinomas 
whilst SI-NETs are mutationally quiet. The prognosis and treatment of SI-
NETs is currently based on traditional criteria, which do not predict clini-
cal outcomes for individual patients nor provide a rationale for targeted 
therapy.
Aims & Methods: The aim is to perform a comprehensive genetic char-
acterization of metastatic SI-NETs. This study, which is largely based on 
genomic tumour data collected as part of the Center of Personalised Can-
cer Treatment (CPCT) study from patients of the Netherlands Cancer Insti-
tute, entails whole genome sequencing (WGS) of 29 metastasized SI-NETs 
(group 1) and next generation panel sequencing (NGS) of 7 SI-NET liver 
metastases (group 2). Diagnosis was confi rmed by histopathological ex-
amination according to the WHO classifi cation of neuroendocrine tumours 
(NETs) 2018. For group 1, WGS included assessment of somatic mutations 
in all cancer related driver genes (>500), somatic copy number variations, 
gene disruptions (including gene fusions), tumour mutational burden 
(TMB) and microsatellite status. In group 2, NGS was performed in a di-
agnostic setting with a cancer hotspot mutation panel of 58 genes. Our 
cohort consisted of metastatic well-diff erentiated SI-NETs of which 19% 
(7/36) were grade 1, 69% (25/36) grade 2 and 11% (4/36) grade 3. Associa-
tion between tumour grade and genetic features was assessed using the 
Man-Whitney U test.
Results: Somatic mutations were identifi ed in 66% of SI-NETs by WGS 
(n=29) and 43% by NGS (n=7). Of SI-NET metastases (n=36), 36% showed 
driver mutations in tumour suppressor genes (e.g. TP53, RB1, ATM, CD-
KN1B, CTNNB1, SMAD2) and 8% of metastases showed mutations in proto-
oncogenes (KRAS, NRAS, MET). In group 1 (N=29), allelic loss of chromo-
some 18 was present in 63%. Other recurrent events were complete loss of 
CDKN2A and CDKN1B (both 7%). All tumours in group 1 were microsatellite 
stable (median 0.029, IQR 0.022-0.046) and showed low TMB (median 
1.10, IQR 0.86-1.33). Solely 13% of all driver mutations unveiled by WGS 
would have been detected using panel NGS. No association between tu-
mour grade and genetic characteristics was found.
Conclusion: Metastasized SI-NETs are mutationally quiet tumours and al-
lelic loss of chromosome 18 is common, which is in accordance with ear-
lier studies on primary SI-NETs. Surprisingly, 44% of metastasized well 
diff erentiated SI-NETs harbour driver mutations in proto-oncogenes and 
tumour suppressor genes. Thus, the presence of driver mutations is not 
exclusive to neuroendocrine carcinomas or adenocarcinomas and does not 
contribute to the distinction between well diff erentiated NETs and poorly 
diff erentiated NECs during pathological assessment. Targetable genetic 
alterations were detected in 19% of patients, including the BRCAness, the 
cyclin D/cyclin-dependent kinases 4 and 6 -retinoblastoma protein and the 
HGF/MET pathway, rendering these patients eligible for targeted therapy 
which provides them with new treatment options. These mutations may be 
missed in the routine clinical setting when hot-spot NGS panels are used. 
In the immediate future, we will continue to assess the additional value of 
WGS in SI-NETs in terms of biomarker identifi cation, additional standard 
treatment options and eligibility for trial inclusion.
Disclosure: Nothing to disclose 
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OP365 EVALUATING THE ACCURACY OF DISCHARGING PATIENTS 
FROM SURVEILLANCE FOR GASTRIC PREMALIGNANT LESIONS 
ACCORDING TO THE MAPS GUIDELINE IN A LOW RISK POPULATION: 
A PROSPECTIVE COHORT STUDY
Mommersteeg M.1, Nieuwenburg S.1, den Hollander W.2, 
Holster L.1, den Hoed C.M.1, Capelle L.3, Tang T.J.4, Anten M.-P.5, 
Berset I.P.6, Witteman E.M.7, ter Borg F.8, den Hartog B.9, Doukas M.10, 
Bruno M.J.1, Peppelenbosch M.P.1, Fuhler G.M.1, Kuipers E.J.1, 
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Introduction: Intestinal type gastric cancer follows a cascade of prema-
lignant lesions which makes gastric cancer suitable for screening and 
surveillance. The Management of epithelial precancerous conditions and 
lesions in the stomach (MAPS) guideline (fi rst published in 2012 and re-
vised in 2019) advises an histological-led diagnosis by performing random 
biopsies, in order to stage the extent and severity of premalignant gastric 
lesions, and determine if surveillance is recommended. No surveillance is 
deemed necessary for atrophic gastritis (AG) or intestinal metaplasia (IM) 
limited to either antrum or corpus. However, random biopsies may not 
properly refl ect the extent of the lesions. The aim of this study was to as-
sess the appropriateness of discharging patients from further surveillance 
according to the guideline in daily practice.
Aims & Methods: Patients were included from the multicenter, prospec-
tively followed PROREGAL cohort initiated in 2009 in which patients were 
identifi ed with AG, IM and/or dysplasia of the gastric mucosa at index 
endoscopy (t0). In the PROREGAL protocol each patient underwent a fi rst 
surveillance endoscopy with random biopsies one year aft er the index en-
doscopy (t1), and in case no high or low grade dysplasia was present, a 
second surveillance endoscopy was performed three years aft er the in-
dex endoscopy (t2). Further surveillance interval was in accordance with 
the MAPS guideline. For the current study, patients excluded from further 
surveillance according to MAPS-2012 were re-invited to undergo a follow-
up endoscopy aft er three years (t3). Patients were included in the current 
study 1) if they met the MAPS-2012 or MAPS-2019 guideline recommenda-
tions to stop surveillance based on the outcome of the latest endoscopy (t1 
or t2), and 2) underwent a subsequent follow-up endoscopy (t2 or t3) not 
included in the guideline recommendations. An inappropriate discharge 
from follow-up was defi ned if premalignant gastric lesions were present 
at t2 or t3 that gave reason to resume surveillance.
Results: The PROREGAL cohort comprises 334 patients. Between 2009 and 
2019,113 patients were supposed to be discharged according to MAPS-2012 
but underwent follow up endoscopy according to the PROREGAL protocol. 
In 38/113 (33.6%; 95%CI 25.2-43.2) patients (progressions of) gastric le-
sions for which surveillance is recommended were found at t2 or t3. If 
MAPS-2019 was followed, inclusion increased to 173 patients who were 
supposed to be discharged from surveillance. In 62/173(35.8%; 95%CI 
28.8-43.5) of these patients, gastric lesions for which surveillance is rec-
ommended were present at t2 or t3. In two cases high grade dysplasia 
(both corpus) and in one case gastric adenocarcinoma of the angulus was 
diagnosed.
Conclusion: 1/3rd of patients who are discharged from gastric cancer sur-
veillance according to MAPS recommendations appeared to be misclassi-
fi ed as low risk according to results found at follow-up endoscopy. Three 
of them had developed high grade dysplasia or gastric cancer. Therefore 
improvement of endoscopic and histological staging of premalignant gas-
tric lesions is warranted.
Disclosure: Nothing to disclose 
OP363 REGULATION OF LYMPHANGIOGENESIS BY PANETH 
CELLS IN NORMAL PHYSIOLOGY AND EXPERIMENTAL PORTAL 
HYPERTENSION
Hassan M.1, De Gottardi A.1,2, Moghadamrad S.1,2
1University Hospital of Berne, Biomedical Research, Hepatology, Berne, 
Switzerland, 2University Hospital of Berne, Visceral Surgery and Medicine, 
Berne, Switzerland
Contact E-Mail Address: sheida.moghadamrad@dbmr.unibe.ch
Introduction: The mesenteric lymphatic network contributes to the trans-
port of fl uid and intestinal mucosal associated immune cells along the 
gut-liver axis. We have previously reported a decrease in intestinal vas-
cularization and number of Paneth cells along with diminished lymphan-
giogenesis in absence of intestinal microfl ora 1. However, the association 
of Paneth cells with the regulation of lymphatic vascular development is 
unknown.
Aims & Methods: We hypothesized that Paneth cells, as part of the innate 
intestinal immune system, regulate the development of lymphatic vessels 
and aff ect portal pressure under the control of intestinal bacteria. 
We induced Paneth cell depletion in Math-1 Lox/LoxVillcreERT2 mice by in-
jecting three consecutive doses of tamoxifen and performed partial portal 
vein ligation (PPVL) to induce portal hypertension. Aft er 14 days, intestinal 
and mesenteric lymphatic vessels were assessed by immunohistochemistry 
(IHC) using lymphatic vessel endothelial hyaluronic acid receptor 1(Lyve-1) 
antibody. The lymphatic vessels were quantifi ed using Metamorph to cal-
culate pixel ratio. Expression of genes involved in the regulation of lym-
phatic vessels was evaluated by RT2 profi ler PCR array in intestinal tissue. 
Additionally, the expression of specifi c genes involved in lymphangiogen-
sis was evaluated separately by quantitative PCR. Intestinal organoids from 
control and Paneth cell depleted mice were exposed to diff erent bacterial 
derived products. Proteomic analysis of conditioned media was performed 
using MaxQuant to analyse diff erentially regulated proteins in lymphan-
giogenesis in the absence of Paneth cells and/or in portal hypertension.
Results: Portal pressure was signifi cantly attenuated in Paneth cell deplet-
ed mice compared to control mice aft er PPVL (n=11/group, 9.78±1.23 cmH
2
O 
vs 11.45±1.41 cmH
2
O, respectively, p<0.002). Depletion of Paneth cells re-
sulted in a signifi cantly decreased density of lymphatic vessels compared 
to control as assessed by IHC (n=5, pixel ratio), in the intestine (0.176% 
±0.12 vs 0.367%±0.15, p=0.01) and in the mesentery (0.160%±0.06 vs 
0.404%±0.20 p=0.001). Quantitative PCR showed a decreased expression 
of genes involved in the regulation of lymphangiogenesis, including VEGF-
C, VEGF-D, VEGF-A, Nrp2, Angpt-2, Tie-1, Tie-2, TGF-α, HGF and CXCL-1 in 
Paneth cell depleted mice. Moreover, the expression of specifi c markers 
of lymphangiogenesis such as transcription factor Prox-1 or growth factor 
VEGFR3 and protein FOX-C2 were signifi cantly decreased in Paneth cell 
depleted mice aft er PPVL. In the absence of Paneth cells, proteomic analy-
ses showed a signifi cant downregulation of several proteins involved in 
lymphatic vessel development and morphogenesis, as well as in processes 
of lipid metabolism and transport.
Conclusion: In the absence of Paneth cells, the intestinal and mesenteric 
lymphatic vessel networks were signifi cantly underdeveloped. This was as-
sociated with an attenuated portal hypertension. These fi ndings suggest 
that Paneth cells not only play an antimicrobial role in the intestine, but 
also contribute to the regulation of lymphatic vessels and portal pressure.
References: 1. Moghadamrad S, McCoy KD, Geuking MB, et al. Attenu-
ated portal hypertension in germ-free mice: Function of bacterial fl ora on 
the development of mesenteric lymphatic and blood vessels. Hepatology 
2015;61:1685-95.
Disclosure: The authors declare no confl ict of interest. These data has been 
presented as an e-poster in ILC-2019 in Vienna. 
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OP366 DIFFERENTIAL EXPRESSION OF LONG NON-CODING RNA 
HOTAIR IN GASTRIC CANCER AND PRENEOPLASTIC CONDITIONS
Petkevicius V.1, Steponaitiene R.2, Thon C.3, Skieceviciene J.2, 
Malfertheiner P.3, Kupcinskas J.1, Link A.3
1Lithuanian University of Health Sciences, Department of Gastroenterology, 
Kaunas, Lithuania, 2Institute for Digestive Research, Lithuanian University 
of Health Sciences, Kaunas, Lithuania, 3Otto-von-Guericke University 
of Magdeburg, Gastroenterology, Hepatology and Infectious Diseases, 
Magdeburg, Germany
Contact E-Mail Address: vytenis.petkevicius@gmail.com
Introduction: HOTAIR is long non-coding RNAs that plays an important 
role in gene regulation and has been shown to be upregulated in various 
tumors, including gastric cancer (GC). Recent studies reported that high 
expression of HOTAIR can promote tumor growth in vitro infl uencing pa-
tient prognosis including worse survival.
Aims & Methods: The aim of this study was to evaluate HOTAIR expres-
sion in preneoplastic gastric conditions and GC as well as to assess the 
clinicopathological and prognostic value of HOTAIR in GC patients. HO-
TAIR expression was analyzed in tissue samples of 81 GC patient (paired 
samples from tumor and corresponding adjacent gastric mucosa), 50 atro-
phic gastritis (AG) patients, 22 chronic gastritis (NACG) patients, and 16 
controls. In addition, HOTAIR expression was evaluated in serum of 23 GC 
patients. Samples were obtained from 2 University hospitals in Lithuania 
and Germany. Total RNA was extracted using RNeasy Plus Universal Mini 
Kit. Quantitative HOTAIR expression analysis was performed using SYBR 
Green assay. HOTAIR expression was further correlated with genome-wide 
methylation using surrogate LINE-1 methylation by bisulfi te pyrosequenc-
ing. GC patient’s survival was evaluated using Kaplan-Meier analyses.
Results: HOTAIR was undetectable in histologically confi rmed normal gas-
tric mucosa samples from control group and NACG. HOTAIR expression 
was found in 24% of patients with AG. The HOTAIR positivity was strongly 
related to intestinal metaplasia (64.7%) and expression was positively 
associated with the grade of intestinal metaplasia (p< 0.001). Paired GC 
samples analysis revealed higher positivity rate of HOTAIR in tumor tissue 
compared to adjacent gastric mucosa (65.4% vs 8.6%, p< 0.001). HOTAIR 
was only sporadically detectable in serum samples of GC patients; how-
ever, with very low level of reproducibility. 
Overall, tumor positivity for HOTAIR expression was associated with shorter 
overall survival in GC patients compared to patients without detectable 
HOTAIR expression; however, the diff erence did not reach statistical sig-
nifi cance (p=0.074). HOTAIR positive tumors showed lower genome-wide 
LINE-1 methylation level compared to HOTAIR negative tumors (p=0.024).
Conclusion: Our data provide a novel evidence for a distinct expression 
pattern of HOTAIR in gastric mucosa. HOTAIR expression increases in step-
wise manner in correlation to progression of preneoplastic condition of 
Correa´s cascade. These results indicate that HOTAIR might be involved in 
the development of GC.
Disclosure: Nothing to disclose 
OP367 INVESTIGATION OF MECHANISTIC ROLE OF HOTAIR AND 
PCDH10 IN GASTRIC CARCINOGENESIS
Seo S.I.1, Yoon J.H.2, Lee S.K.2
1Hallym University College of Medicine, Internal Medicine, Seoul, Korea 
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Introduction: Long non-coding RNA (LncRNA)s are rapidly emerging as 
new players in cancer biology and contribute to epigenetically to regulate 
DNA methylation. HOX transcript antisense intergenic RNA (HOTAIR) is one 
of the well-studied lncRNAs that regulate gene expression by mediating 
the modulation of chromatin structure. Protocadherin 10 (PCDH10) is well-
known tumor suppressor genes and aberrant methylation of the PCDH10 is 
a frequent event in gastric cancers.
Aims & Methods: We aimed to investigate the epigenetic mechanism of 
lncRNA HOTAIR related with PCDH10 in gastric cancer. 
Materials and methods: We collected 30 fresh gastric cancer tissue and 
paired adjacent gastric tissue samples and we used gastric cancer cell 
lines. We investigated mechanism of HOTAIR on apoptosis, cell prolifera-
tion, cell cycle analysis as indicators of carcinogenesis and metastasis of 
gastric cancer. We analyzed expression of HOTAIR and PCDH10 in gastric 
cancer tissues and paired adjacent gastric tissue and perform methylation-
specifi c PCR to identify the interaction between HOTAIR and PCDH10 in 
cancer cell line.
Results: The expression of HOTAIR was found to be higher in gastric can-
cer tissue compared with adjacent non-tumor gastric tissue. Using MKN 
28 and MKN 74 cells, we demonstrated that HOTAIR repressed apoptosis, 
was associated with cell cycle progression, and controlled the invasion and 
migration of gastric cancer cells. PCDH10 expression was signifi cantly de-
creased in gastric cancer tissues compared with adjacent non-tumor gas-
tric tissue. The treatment of siHOTAIRs increased the transcriptional level of 
PCDH10, furthermore, PCDH10 protein was also upregulated by siHOTAIRs 
in gastric cell lines. We observed that HOTAIR induced PCDH10 methylation 
in gastric cell lines via methylation-specifi c PCR.
Conclusion: We identifi ed a novel epigenetic mechanism involving the 
methylation of PCHD10 by lncRNA HOTAIR in gastric cancer and demon-
strated that the HOTAIR modulated cell proliferation and the invasion and 
migration of gastric cancer cell We identifi ed a novel epigenetic mecha-
nism involving the methylation of PCHD10 by lncRNA HOTAIR in gastric 
cancer and demonstrated that the HOTAIR modulated cell proliferation and 
the invasion and migration of gastric cancer cell.
Disclosure: Nothing to disclose 
OP368 CLINICAL AND MOLECULAR CHARACTERIZATION OF EARLY 
ONSET GASTRIC CANCER (≤ 50 YEARS): ANALYSIS OF A NATIONAL 
MULTICENTRE STUDY
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Introduction: Gastric adenocarcinoma (GC) is a common tumour with high 
morbidity and mortality. Although most GCs are sporadic, familial aggre-
gation can be observed in approximately 10% of cases and hereditary GC, 
i.e. in the context of a germline mutation, accounts up to 5% of all cases. 
Only 7% of patients are diagnosed before age 50. The clinical and molecu-
lar characteristics of early onset GC had been poorly described.
Aims & Methods: To describe the clinical, histological and molecular char-
acteristics of early onset GC (≤ 50 years old).
From 1999 through 2018, patients with early onset GC were retrospectively 
recruited at 4 Spanish centres. Personal and, family history, tumour-re-
lated information and tumour immunohistochemistry (IHC) of DNA mis-
match repair proteins (MMR) (MLH1, MSH2, MSH6 and PMS2) status were 
registered. Germinal genetic analysis was performed in patients who met 
criteria of a hereditary syndrome associated with GC (ie. hereditary diff use 
gastric cancer, Peutz-Jeghers syndrome, Lynch syndrome, familial adeno-
matous polyposis, hereditary breast and ovarian syndrome, juvenile pol-
yposis and Li -Fraumeni syndrome).
Results: 308 patients were included, 118 (38%) were women. The median 
age at diagnosis was 43 years (range 17-50). The tumours were located 
mainly at body and antrum, 55% and 25% respectively. Histologically, 75% 
were diff use, 17% intestinal and 18% mixed or unclassifi able. An advanced 
stage (III/IV) at diagnosis was present in 78% cases. With regard to envi-
ronmental risk factors: and Helicobacter pylori infection was detected in 
24/82 (29%) cases, 78/167 (46%) patients had regular smoking habit and 
51/105 (20%) were moderate/severe alcohol consumers. 
Family history was available in 108 cases: familial aggregation of GC was 
present in 15 (13.8%) cases and 5 (4.6%) met criteria for familial GC. IHC 
of MMR was performed in 88 (28.5%) tumours: 3/88 (3.4%) showed loss 
of expression in MLH1/PMS2, without an associated germline mutation. 
Fift een genetic analyses were performed, detecting a germline mutation 
in 3 (20%) cases: BRCA2, TP53 and CDH1 (Table 1).
Conclusion: Most of early-onset GCs are histologically diff use and diag-
nosed at an advanced stage. In this subgroup of patients, DNA mismatch 
repair system defi ciency is an infrequent event and likely not very useful. 
Familial aggregation is present only in 13% of cases; however, in 20% 
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OP370 ENDOSCOPIC TREATMENT OF EARLY GASTRIC 
NEOPLASIA IN THE WEST : EXPERIENCE FROM THREE EUROPEAN 
TERTIARY CENTRES
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Portsmouth, United Kingdom, 7Queen Alexandra Hospital, Endoscopy, 
Portsmouth, United Kingdom, 8Hirslanden Clinic Center of Gastroenterology, 
Gastroenterology, Zurich, Switzerland, 9Ist. Clinico Humanitas Rozzano, Dept. 
of Gastroenterology, Milano, Italy
Contact E-Mail Address: mohamed.abdelrahim@nhs.net
Introduction: Endoscopic submucosal dissection (ESD) is a technique fi rst 
developed in Japan to enable en-bloc endoscopic resection of early gastric 
neoplasia. The high prevalence of gastric neoplasia allowed for greater 
opportunity to train and refi ne the technique in the Far East. The same is 
not applicable to the West where the prevalence of gastric neoplasia is low.
Aims & Methods: We aim to review the effi  cacy and safety of ESD for early 
gastric neoplasia from three large European referral centres. Data was 
prospectively collected on an electronic database. We analysed this data-
base and patient’s electronic record. Parameters related to ESD outcome 
were collected.
Results: A total of 175 gastric neoplasia were resected between 2009 and 
2017 (152 ESD, 23 hybrid ESD), 51.4% were in proximal stomach. Mean size 
was 29mm. Only 13 (7.42%) were sub-epithelial lesions. Table (1) shows 
outcomes and procedure-related complications. The overall en-bloc re-
section, R0 (deep), and R0 (deep and lateral) rates were 92.5%, 83.4%, 
and 61% , respectively. Proximal location of the lesion was a predictor for 
R1 outcome (p value 0.011). Size of the lesion was not signifi cantly related 
to the R0 rate. The overall adverse event rate was 11.3%. There was no 
30-day procedure related mortality. Recurrence at 3 months occurred in 
7 patients (4%).
Conclusion: This is the largest western gastric ESD series, demonstrating 
the feasibility and safety of this technique in an European setting. Despite 
the low R0 rate, our recurrence rate is low and comparable to Japanese 
data.Reasons behind good clinical outcome (very low recurrence) despite 
an average technical outcome (R0) remains uncertain.This raises a pos-
sibility that in the west, R-1 should not automatically be considered as an 
indication for surgery.
Disclosure: PB received research grants and honorarium from Pentax, Bos-
ton, Fuji, Olympus, and 3D Matrix. 
OP371 SHORT- AND LONG-TERM OUTCOMES OF GASTRIC 
ENDOSCOPIC SUBMUCOSAL DISSECTION FOR ABSOLUTE-INDICATION 
LESIONS AND EXPANDED-INDICATION LESIONS
Konishi H., Kuwai T., Moriuchi R., Wada K., Tao K., Miura R., Tamaru Y., 
Kusunoki R., Yamaguchi A., Kouno H., Kohno H.
National Hospital Organization Kure Medical Center and Chugoku Cancer 
Center, Gastroenterology, Kure, Japan
Contact E-Mail Address: hirox2x4@gmail.com
Introduction: Endoscopic submucosal dissection (ESD) is an eff ective treat-
ment method for early gastric neoplasms, and its indication is being ex-
panded. According to 2018 Japanese gastric cancer treatment guidelines, 
for diff erentiated-type gastric cancer (>2 cm without UL, ≤ 3cm with UL) 
treatment, expanded-indication of ESD became absolute-indication. Ex-
panded-indication for undiff erentiated-type gastric cancer (≤2 cm) is also 
expected to become an absolute-indication. These claims were based on 
evidence from high-volume centers, and it is important to check their ap-
plicability to actual clinical practice.
Aims & Methods: Our study aimed to evaluate and compare the clinical 
outcomes of ESD to early gastric cancers for absolute-indication lesions 
and that for expanded-indication lesions. The subjects were 490 patients 
who collectively presented with 574 early gastric cancers diagnosed with 
absolute-indication lesions or expanded-indication lesions. All patients 
underwent ESD at our hospital between June 2007 and August 2018. The 
of the patients who meet criteria for genetic study, a germline mutation 
is found (BRCA2, CDH1, TP53). These results demonstrate that early-onset 
GC has a marked genetic heterogeneity, reinforce the importance of an 
adequate genetic counselling (complete family history) and enhance the 
emerging use of multigene panels.
Disclosure: Nothing to disclose 
Age at 
diagnosis Gender 
Family history 
of GC 
Family history of 
other tumours IHC 
Germline gene 
mutation 
40 Female No Breast Ovarian MMR+ BRCA2 
38 Male Yes No MMR+ CDH1 
34 Male No Breast Colon MMR+ TP53 
[Table 1: Characteristics of patients with germline gene mutation]
OP369 CHARACTERISTICS AND RISK FACTORS OF INTERVAL 
GASTRIC NEOPLASMS DETECTED IN SCREENING ENDOSCOPY AMONG 
ASYMPTOMATIC HEALTHY ADULTS
Lim J.H.1, Song J.H.1, Chung S.J.1, Chung G.E.1, Kim J.S.1,2
1Seoul National University Hospital Healthcare System Gangnam Center, 
Internal Medicine, Seoul, Korea (Republic of), 2Seoul National University 
College of Medicine, Department of Internal Medicine and Liver Research 
Institute, Seoul, Korea (Republic of)
Contact E-Mail Address: limz00@gmail.com
Introduction: In Korea, where gastric cancer is highly prevalent, regular 
upper endoscopy every other year is recommended for gastric cancer (GC) 
screening among individuals over 40 years old. However, even under such 
regular screening endoscopy, some are still diagnosed to have advanced 
gastric neoplasms.
Aims & Methods: This study was designed to identify characteristics and 
risk factors of interval gastric neoplasms detected in screening endoscopy. 
Medical records of individuals who were newly diagnosed with gastric 
neoplasms in screening upper gastrointestinal endoscopy between Janu-
ary 2004 and May 2016 were reviewed. Among them, those who had pre-
vious endoscopy within 2 years were enrolled. Their endoscopic fi nding, 
family history of GC, cigarette smoking, and Helicobacter pylori (H. pylori) 
infection status were analyzed. Those with positive results in anti-H. pylori 
IgG, CLO test or histologic fi ndings of H. pylori were considered to have H. 
pylori infection.
Results: During the study period, 625 patients were newly diagnosed with 
gastric neoplasm. Among them, 300 patients underwent previous endos-
copy within 2 years (median 12 months; Interquartile range: 11-15 months). 
Three patients with previous gastrectomy or unclear fi nal pathology were 
excluded. Among the 297 neoplasms, 246 were endoscopically treatable 
gastric neoplasms (ET-GN) and 51 were endoscopically untreatable gastric 
neoplasms (EUT-GN) according to the criteria for endoscopic submucosal 
dissection. About 80% of EUT-GNs were undiff erentiated cancers (40/51) 
and about 30% of them showed submucosal invasion (13/40). EUT-GN 
were less commonly located at the antrum compared with ET-GN (29.4% 
vs. 58.1%, p < 0.001) and their median size was 2.0 cm. In multivariable 
analysis, EUT-GN was highly related with age < 60 (OR, 2.091; 95% CI, 
1.028-4.255, p = 0.042), H. pylori infection (OR, 2.814; 95% CI: 1.195-6.625, 
p 0.018), and absent or mild atrophic gastritis (OR, 2.673; 95% CI, 1.251-
5.724, p = 0.011). Overall and disease-free survival were not signifi cantly 
diff erent between the two groups, however, EUT-GN showed a tendency of 
short disease-free survival.
Conclusion: Current screening interval of 2 years seems unsatisfactory to 
detect rapid-growing gastric neoplasms, such as undiff erentiated cancers, 
early enough. Those neoplasms tended to develop in young adults with 
current H. pylori infection without severe atrophic gastritis. More intense 
screening is warranted for subgroup of young adults with H. pylori infec-
tion even if they do not have gastric atrophy.
Disclosure: Nothing to disclose 
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patients were segregated into two groups: absolute-indication lesions 
(group A: 294 patients with 331 collective lesions) and expanded-indica-
tion lesions (group B: 233 patients with 243 collective lesions). We evalu-
ated the clinicopathological fi ndings, and short- and long-term outcomes 
including the local and distant recurrence rates, and overall survival (OS) 
and disease-specifi c survival (DSS) rates.
Results: The patients’ mean ages were 72.9 years (group A) and 71.4 years 
(group B), and the male-to-female ratios were 232/62 (group A) and 177/56 
(group B). The mean tumor size in group B (22.9 mm) was signifi cantly 
larger than that of group A (10.2 mm) (p < 0.01). Histopathological fi ndings 
revealed that the rates of diff erentiated-type were 100 % (331/331) in group 
A and 88.9 % (216/243) in group B (p < 0.01). Regarding tumor depth, 
intramucosal carcinomas were 100 % (331/331) in group A and 81.9 % 
(199/243) in group B, and shallow submucosal invasive carcinomas (< 500 
µm) were 0 % (0/331) in group A and 18.1 % (44/243) in group B (p < 0.01). 
The en bloc resection rates were 99.7 % (330/331) in group A and 95.9 
% (233/243) in group B (p< 0.01), and the curative resection rates were 
98.5 % (326/331) in group A and 93.8 % (228/243) in group B (p< 0.01). 
Regarding adverse events, postoperative hemorrhage rates were 2.42 % 
(8/331) in group A and 4.94 % (12/243) in group B, and perforation rates 
during the procedure were 0.30 % (1/331) in group A and 0.82 % (2/243) in 
group B. There were no signifi cant diff erences in adverse events. Regard-
ing long-term outcomes, the local and distant recurrence rates were 0.30 
% (1/331) and 0 % (0/331) in group A and 0.41 % (1/243) and 0 % (0/243) in 
group B, respectively (n.s.). Regarding survival analysis, the mean follow-
up periods in group A and group B were 55.1±35.6 and 47.0±35.4 months, 
respectively. The 3- and 5-year OS rates were 92.7 % and 90.1 % in group 
A, and 94.1 % and 88.7 % in group B (using the Kaplan-Meier method 
and long-rank test), respectively. The 5-year DSS rates were 100 % in both 
groups. No signifi cantly diff erence was observed in the survival rates.
Conclusion: The short-term outcomes of expanded-indication lesions were 
inferior to those of absolute-indication lesions, despite both being accept-
able. In addition, expanded-indication lesions had excellent long-term 
prognosis, equivalent to absolute-indication lesions. Therefore, expansion 
of the indication of gastric ESD to actual clinical practice is appropriate.
Disclosure: Nothing to disclose 
OP372 DO THE SUPPRESSION OF PROLIFERATIVE CAPACITY 
OF GASTRIC CANCER CELLS DUE TO HELICOBACTER PYLORI 
ERADICATION AFFECT THE FINDINGS OF MICROSURFACE PATTERNS 
ON MAGNIFYING ENDOSCOPY WITH NARROW-BAND IMAGING?
Kojima K., Uchita K., Iwasaki T., Iwamura S.
Kochi Red Cross Hospital, Gastroenterology, Kochi, Japan
Contact E-Mail Address: kozikozima22@gmail.com
Introduction: In Japan, Helicobacter pylori (HP) eradication therapy is al-
ready spread, but gastric cancer is frequently detected, even aft er eradi-
cation (post-eradication gastric cancer). The detection of lesions or the 
diagnosis of the margin of the lesions is considered to be more diffi  cult 
in post-eradication gastric cancer than in HP-uneradicated gastric cancer. 
Regarding the underlying reason, it has been reported that the Ki-67 index 
is low in post-eradication gastric cancer, indicating that the proliferative 
capacity of tumor cells is suppressed [1-3]. However, whether diff erences 
in cell proliferative capacities between post-eradication and uneradicated 
gastric cancer are associated with the microsurface pattern (MSP) has not 
been determined.
Aims & Methods: This study included 122 lesions of diff erentiated early 
gastric cancer (63 lesions of post-eradication gastric cancer and 59 lesions 
of uneradicated gastric cancer) treated with endoscopic submucosal dis-
section (ESD) at our hospital between January 2014 and December 2017. 
Under magnifying endoscopy with narrow-band imaging (M-NBI), all le-
sions were resected in an en bloc fashion by using ESD. The middle sec-
tions of the resected specimens were immunostained for Ki-67 (MIB-1). 
The Ki-67 index was then calculated and compared to determine whether 
it was diff erent between post-eradication and uneradicated gastric cancer. 
In addition, according to the MSP using the vessel plus surface classifi ca-
tion system, the lesions were divided into the following 4 groups: group 
A of post-eradication gastric cancer with a regular MSP, group B of post-
eradication gastric cancer with an irregular MSP, group C of uneradicated 
gastric cancer with a regular MSP, and group D of uneradicated gastric 
cancer with an irregular MSP. In each group, the Ki-67 index was calcu-
lated and analyzed using the Tukey-Kramer test to determine whether the 
cell proliferative capacity was associated with M-NBI fi ndings.The Ki-67 
index was defi ned as a value calculated using the following formula: Ki-
67-positive cell count / total epithelial cell count per magnifi cation of 200 
times. To match the result for the visible range of NBI, the index was cal-
culated in an area that was located 200 µm from the superfi cial portion of 
the mucous membrane.
Results: The mean Ki-67 index score of all the lesions was 24.8% for post-
eradication gastric cancer and 38.2% for uneradicated gastric cancer. The 
score was signifi cantly lower for the former (P < 0.001), suggesting that 
eradication suppressed the proliferative capacity of tumor cells. According 
to the MSP fi ndings, there were 20 lesions in group A (31.7%), 43 lesions 
in group B (68.3%), 5 lesions in group C (8.5%), and 54 lesions in group 
D (91.5%). The mean Ki-67 index scores were 19.6% in group A, 27.1% in 
group B, 31.6% in group C, and 38.8% in group D. The Ki-67 index scores 
in groups A and B were signifi cantly lower than the score in group D (P < 
0.001 and P < 0.01, respectively), whereas no signifi cant diff erence in the 
scores was observed between groups A and B. No association was de-
tected between decreased Ki-67 index scores due to eradication and MSP 
fi ndings.
Conclusion: In post-eradication gastric cancer, the Ki-67 index was gener-
ally lower than in uneradicated gastric cancer, and the proliferative ca-
pacity of the tumor cells was suppressed. However, M-NBI did not show 
any association between diff erent MSP fi ndings and the cell proliferative 
capacity. The previously reported view appeared unlikely.
References: 1. Kodama M et al. Endoscopic and immunohistochemical 
characteristics of gastric cancer with versus without Helicobacter pylori 
eradication. Digestion. 2018;97:288-297. 2. Shichijo S et al. Characteris-
tics and predictors of gastric cancer aft er Helicobacter pylori eradication. 
World J Gastroenterol. 2018;24(20):2163-2172. 3. Kitamura Y et al. Charac-
teristic epithelium with low-grade atypia appears on the surface of gastric 
cancer aft er successful Helicobacter pylori eradication therapy. Helico-
bacter. 2014;19(4):289-295.
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P0002 InTerLeukIn 10 Induced senescence Of hePaTIc 
sTeLLaTe ceLLs vIa sTaT3-P53/P21 sIgnaL PaThWay TO 
aTTenuaTe LIver fIBrOsIs
Huang Y., Chen M., Guo Q., Wang X.
Fujian Medical University Union Hospital, Department of Gastroenterology, 
Fuzhou, China
contact e-Mail address: 2003huangyh@sina.com
Introduction: Hepatic fibrosis is a wound healing process which results in 
deposition of excessive abnormal extracellular matrix (ECM) in response 
to chronic liver injury[1].Activated hepatic stellate cells (HSCs) are the ma-
jor sources of ECM, therefore, phenotype reversion or retardation of pro-
liferation or induction of senescence in activated HSCs is an appropriate 
therapeutic strategy for liver fibrosis[2].Cytokine plays an important role in 
senescence of activated HSCs. Our previous studies have shown that inter-
leukin-10 (IL-10) attenuates the carbon tetrachloride (CCL
4
) - and porcine 
serum-induced liver fibrosis in rats. However, little is known about the 
mechanism of IL-10 regulated anti-fibrosis and activated HSCs senescence.
aims & Methods: To uncover the underlying pathway by which IL-10 me-
diates activated HSCs senescence to attenuates liver fibrosis.Rat liver fi-
brosis was induced by intraperitoneal injection of 40% CCL
4 
dissolved in 
olive oil (2 mL/kg) twice a week. From the 4th week, rIL-10 plasmid DNA 
was transferred into fibrotic rats for 5 weeks by hydrodynamics-based 
transfection (HBT). Hematoxylin and eosin stain, Masson and Sirius Red 
stain were used to evaluate degree of fibrosis; α-smooth muscle actin and 
senescence-associated-β-galactosidase (SA-β-Gal) stain were used to de-
tect senescence of activated HSCs in fibrotic liver. In vitro, primary rat HSCs 
isolated by collagenase perfusion and density gradient centrifugation were 
cultured for 7 d and then treated with or without IL-10 for 24h. Cell prolif-
eration, cell cycle, SA-β-Gal activity and expression of senescent marker 
protein P53 and P21 were detected to analyze the senescence of activated 
HSCs. Pifithin-α (a specific inhibitor of P53) or Cryptotanshinone (a specific 
inhibitor of signal transducers and activators of transcription 3) was used 
to block expression of P53 or p-STAT3 signal transduction in primary HSCs 
or HSC-T6 cells presence/absence of IL-10, respectively. SA-β-Gal stain and 
Western Blot analysis was used to detect HSCs senescence and expression 
of signaling protein p-STAT3/ STAT3 and senescence marker protein P53 
and P21.
results: In vivo, IL-10 gene treatment by HBT attenuated inflammatory 
response, deposition of collagen and numbers of activated HSCs and 
enhanced the activity of SA-β-Gal in fibrotic liver and then promoted 
senescence of activated HSCs. In vitro, IL-10 treatment inhibited the cell 
proliferation, blocked the cell cycle, and increased the activity of SA-β-Gal 
and the expression of senescence marker protein P53 and P21. Blocking 
expression of P53 with Pifithin-α reduced the number of SA-β-Gal positive 
HSCs and protein expression of P53 and P21. IL-10 treatment also increased 
the expression of total STAT3 and p-STAT3 and promoted p-STAT3 translo-
cation from cytoplasm to nucleus. Blocking p-STAT3 with cryptotanshinone 
reduced protein expression of p-STAT3, STAT3, P53 and P21 and the number 
of SA-β-Gal positive activated HSCs.
conclusion: IL-10 gene treatment attenuates CCL
4
-induced liver fibrosis by 
promoting the senescence of activated HSCs and underlying mechanism is 
that IL-10 could up-regulate the expression of senescence protein P53 and 
P21 in activated HSCs via STAT3 pathway.
references: [1] K.S. Nallagangula, S.K. Nagaraj, L. Venkataswamy, M. 
Chandrappa, Liver fibrosis: a compilation on the biomarkers status and 
their significance during disease progression, Future Science OA 4 (2018) 
O250. [2] D. Ezhilarasan, E. Sokal, M. Najimi, Hepatic fibrosis: It is time to 
go with hepatic stellate cell-specific therapeutic targets, HEPATOB PAN-
CREAT DIS 17 (2018) 192-197.
disclosure: Nothing to disclose 
P0003 cd1d as a dIrecT, nkT ceLL-IndePendenT reguLaTOr 
Of hePaTIc LIPId MeTaBOLIsM and InfLaMMaTIOn In 
nOnaLcOhOLIc faTTy LIver dIsease
Ceriotti C.1, Wang Y.1,2, Rudolph M.1, Brosch M.1,3, Hampe J.1,4, Zeissig S.1,3
1Center for Regenerative Therapies Dresden (CRTD), Dresden, Germany, 
2Max Planck institute for Cellular Biology and Genetics, Dresden, Germany, 
3University Medical Center Dresden, Technische Universität Dresden, 
Medical Department 1, Dresden, Germany, 4University Hospital Dresden, 
Gastroenterologie und Hepatologie, Dresden, Germany
contact e-Mail address: chiara.ceriotti@tu-dresden.de
Introduction: Natural Killer T (NKT) cells recognize lipid antigens in the 
context of the atypical MHC class I protein CD1d. Based on the study of 
mice deficient in CD1d, which lack both CD1d and NKT cells, recent work 
has suggested a critical role of NKT cells in the regulation of metabolic 
and inflammatory progression in nonalcoholic fatty liver disease (NAFLD). 
However, since CD1d can associate with a substantial proportion of cellular 
lipids and can compete with other substrates for lipid transfer proteins, 
we asked the question of whether CD1d may directly regulate hepatic lipid 
metabolism and inflammation in an NKT cell-independent manner.
aims & Methods: To examine potential NKT cell-independent roles of CD1d 
in hepatic metabolism, CD1d-proficient and CD1d-deficient littermates 
were analyzed on a Rag1-/- background, thus lacking mature T and B cells 
including NKT cells. Analyses were performed both on a high fat diet (HFD, 
60% kcal from fat, for 16 weeks) and control diet. Hepatic, adipose tissue, 
and plasma lipids were analyzed by shotgun lipidomics. Hepatic cytokine 
levels (qPCR), lipid droplet distribution (oil red O staining), hepatocyte 
damage (alanine aminotransferase (ALT)), and glucose metabolism were 
evaluated.
results: CD1d-deficiency on a Rag1-/- background was associated with a 
selective decrease in hepatic levels of triglycerides on normal diet and tri-
glycerides and cholesterol esters on HFD. Hepatic TNFα expression was 
increased in response to a HFD with significantly lower expression of 
TNFα in CD1d-deficient Rag1-/- compared to CD1d-proficient Rag1-/- mice. 
Accordingly, serum ALT activity was lower in CD1d-deficient compared to 
CD1d-proficient Rag1-/- mice. Moreover, CD1d-deficient Rag1-/- mice had 
reduced levels of fasting glucose in response to a HFD, compared with 
CD1d-proficient mice.
conclusion: Our data demonstrate that CD1d can regulate hepatic lipid and 
carbohydrate metabolism in an NKT cell-independent manner and pro-
mote hepatic inflammation in response to a metabolic challenge. Liver 
export of TG and CE from hepatocytes is regulated by the microsomal tri-
glyceride transfer protein (MTP) which loads neutral lipids onto apolipo-
protein B (ApoB) to assemble very low density lipoproteins (VLDL). Since 
MTP is also responsible for lipid transfer onto CD1d, we hypothesize that 
CD1d-dependent regulation of hepatic lipid metabolism results from com-
petition between CD1d and ApoB for lipid transfer activity of MTP. This 
hypothesis is currently being experimentally addressed.
disclosure: Nothing to disclose 
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liver fibrosis test predicts transplant-free survival in primary sclerosing 
cholangitis, a multi-centre study. Liver Int. 2017 Oct;37(10):1554-1561 4. 
Bettenworth D, Rieder F. Pathogenesis of Intestinal Fibrosis in Inflamma-
tory Bowel Disease and Perspectives for Therapeutic Implication. Dig Dis. 
2017;35(1-2):25-31.
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P0005 rILPIvIrIne-Induced anTI-InfLaMMaTOry effecTs 
In LIver dIseases InvOLve The acTIvaTIOn Of sTaT6 sIgnaLIng 
PaThWays In MacrOPhages
Moragrega Á.B.1, Martí-Rodrigo A.1, Gruevska A.1, Esplugues J.V.1,2,3, 
Apostolova N.1,3, Blas-Garcia A.1,2,3
1Universidad de Valencia, Farmacologia, Valencia, Spain, 2FISABIO - 
Universidad de Valencia, Farmacologia, Valencia, Spain, 3CIBER de 
Enfermedades Hepáticas y Digestivas (CIBERehd), Valencia, Spain
contact e-Mail address: angela.moragrega@uv.es
Introduction: Rilpivirine (RPV) is an antiretroviral drug widely used in anti-
HIV therapy, which is generally considered safe for the liver and not associ-
ated with hepatotoxicity in these patients. Although there are few data on 
the effects of this drug on the liver in the presence of other chronic hepatic 
complications, our group has previously described that treatment with RPV 
induces a clear anti-steatotic, anti-inflammatory and anti-fibrotic effect in 
murine models of non-alcoholic fatty liver disease (NAFLD) and fibrosis 
induced by carbon tetrachloride (CCl
4
).
aims & Methods: To determine the molecular mechanisms by which RPV 
exerts its anti-inflammatory properties in chronic liver diseases, focusing 
on its actions on hepatic macrophages. 
In vivo, the effects of RPV on the progression of NAFLD in a nutritional 
model in C57BL/6 mice (12 weeks) and in a model of CCl
4
-induced fibrosis 
(4 weeks) were analyzed. In vitro, monocyte-derived macrophages (MDMs) 
were obtained from human peripheral blood mononuclear cells isolated 
from healthy donors. MDMs were treated with clinically relevant concen-
trations of RPV (1-8 µM) for 48 h. The molecular routes involved were stud-
ied using RT-PCR, Western Blot and determinations of enzymatic activity.
results: The data obtained in both animal models revealed the anti-in-
flammatory potential of RPV, reducing the gene expression of pro-inflam-
matory markers (TNFα, IL1β, Caspase 1 and NLRP3), as well as the activity 
of the MPO enzyme and the macrophage infiltration into the liver. In ad-
dition, RPV significantly decreased the activation of the NF-κB and NLRP3 
inflammasome pathways, and induced the expression of LXRα. RPV also 
increased the hepatic expression of Stat6, Pparg and Arg1 in our mouse 
models. Interestingly, STAT6/PPARG/ARG1 pathway activation by RPV was 
confirmed in MDMs, showing a positive correlation in vitro.
conclusion: Beyond its well-described role in antiretroviral therapy, RPV 
has a clear anti-inflammatory effect in different models of chronic liver 
diseases, associated with its actions on liver macrophages and the activa-
tion of STAT6-mediated pathways. Our results may be clinically relevant in 
the management of chronic liver diseases such as NAFLD, although more 
studies are needed to clarify the mechanisms involved.
disclosure: Nothing to disclose 
P0006 fIBrOgenesIs Of nOnaLcOhOLIc sTeaTOhePaTITIs 
BegIns arOund chOLesTerOL-Laden MacrOPhage In The 
exPerIMenTaL MOuse MOdeL
Ichimura M., Oya T., Tsuneyama K.
Tokushima University, Pathology and Laboratory Medicine, Tokushima, 
Japan
contact e-Mail address: ichimura.mayuko@tokushima-u.ac.jp
Introduction: The pathogenesis of fibrosis in nonalcoholic steatohepatitis 
(NASH) may be different from that in viral hepatitis since they show dif-
ferent histopathological findings of fibrosis.The major feature of NASH-
related fibrosis is elongation of fine fiber around living cells rather than 
remarkable necrosis. The mechanisms involved in progression to fibrosis 
remain largely unknown, thus therapies to prevent or delay the disease 
progression remain limited.
aims & Methods: We examined the pathogenesis of fibrosis using mice 
fed with our new diet which could induce fibrotic NASH. Nine-week-old 
male A/J mice were fed with the high-fat/cholesterol/cholate (HFCC) diet 
or standard chow for nine weeks.
P0004 InfLaMMaTOry BOWeL dIseases dO nOT affecT 
enhanced LIver fIBrOsIs TesT reLIaBILITy In assessIng LIver 
fIBrOsIs
Cococcia S.1, Giuffrida P.2, Caprioli F.3, Pastorelli L.4, Mazza S.3,5, 
Lenti M.V.6, Delliponti M.7, Vecchi M.5, Pinzani M.8, Rosenberg W.9, 
Di Sabatino A.10
1IRCCS Ospedale San Matteo, Gastroenterology, Pavia, Italy, 2San Matteo 
Hospital Foundation, University of Pavia, First Department of Medicine, 
Pavia, Italy, 3University of Milan, Fisiopatologia Medico-Chirurgica e dei 
Trapianti, Olgiate Olona, Italy, 4IRCCS Policlinico San Donato, Department 
of Gastroenterology and Gastrointestinal Endoscopy, San Donato Milanese, 
Italy, 5University of Milan, Milano, Italy, 6Fondazione IRCCS Policlinico 
San Matteo, University of Pavia, First Department of Internal Medicine, 
Alessandria, Italy, 7IRCCS Policlinico S. Matteo, Pavia, Italy, 8UCL Institute for 
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Introduction: The Enhanced Liver Fibrosis (ELF) test was established in 
2004 as a non-invasive serum test for liver fibrosis based on an algorithm 
that combins measurements of the concentration of three markers of fibro-
sis, hyaluronic acid (HA), tissue inhibitor of matrix metalloproteinases-1 
(TIMP-1) and aminoterminal propeptide of type III procollagen (PIIINP). 
Since then, a series of studies has demonstrated the validity of ELF as a 
diagnostic and prognostic tool in a variety of chronic liver diseases (CLD), 
including primary sclerosing cholangitis (PSC). Nevertheless, in these 
studies, exacting protocols were followed that excluded patients with fi-
brogenic co-morbidities involving organs other than the liver to avoid any 
confounding of the relationship between ELF and liver fibrosis. Inflam-
matory bowel diseases (IBD) are known to cause fibrotic changes of the 
bowel wall and to be associated to liver diseases, especially PSC in patients 
affected by ulcerative colitis (UC).
aims & Methods: In order to investigate whether IBD may confound ELF 
test results in the assessment of liver fibrosis in CLD patients, we prospec-
tively collected data of IBD patients who did not have liver disease followed 
up at three IBD centres in North Italy since 2008. A cohort of healthy con-
trols (HC) was enrolled over the same period. Demographic and clinical 
data were recorded and sera were storred for ELF testing. Serum samples 
were then processed in the same laboratory (iQur Limited), and the impact 
of IBD on ELF results was investigated by comparing the ELF scores of par-
ticipants with different IBD phenotypes between IBD groups and healthy 
controls (HC). Data were analysed with the IBM SPSS software.
results: Overall, 137 patients suffering from IBD, comprising 107 Crohn’s 
disease (CD) and 31 by ulcerative colitis (UC), (mean age 36±15 years; M:F 
ratio 1.5:1) were consecutively enrolled (mean disease duration 84±89.9 
months) as well as 27 healthy volunteers (mean age 32±11.3 years; M:F 
ratio 1:1) as a control group. The ELF results of IBD patients (mean 8.38 ng/
ml, sd 1.03) were compared to those of HC (mean 8.13 ng/ml; sd 0.78) and 
no significant difference was found (p=0.15). Furthermore, each CD pheno-
type was compared to the whole recruited population, and no significant 
difference was found between these groups and the rest of the cohort (lu-
minal p=0.16; stricturing p=0.09; penetrating p=0.97). No significant differ-
ence was highlighted in direct comparison between phenotypes. Likewise, 
UC patients’ ELF results were compared to those of the rest of the recruited 
population and no significant difference emerged (p=0.31). No correlation 
was found between ELF score and either gender or age. Disease activity, 
measured at sampling in 70 CD (Crohn’s disease activity index, CDAI) and 
27 UC patients (Clinical Activity Index. CAI), showed no correlation with ELF 
score (r
s
=0.07; p=0.52 in CD and r
s
=0.005, p=0.98 in UC).
conclusion: We found that the ELF score is not influenced by IBD, regard-
less of CD phenotype or IBD clinical activity, and thus, it can be used as a 
reliable tool to detect and follow up liver fibrosis in CLD patients.
references: 1. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schup-
pan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ; European Liver Fi-
brosis Group. Serum markers detect the presence of liver fibrosis: a cohort 
study. Gastroenterology. 2004 Dec;127(6):1704-13 2. Vesterhus M, Hov JR, 
Holm A, Schrumpf E, Nygård S, Godang K, et al. Enhanced Liver Fibrosis 
Score Predicts Transplant-Free Survival in Primary Sclerosing Cholangitis. 
Hepatology. 2015; 62:188-197. 3. de Vries EMG, Färkkilä M, Milkiewicz P, 
Hov JR, Eksteen B, Thorburn D, Chazouillères O, Pares A, Nygård S, Gilja 
OH, Wunsch E, Invernizzi P, Carbone M, Bernuzzi F, Boberg KM, Røsjø H, 
Rosenberg W, Beuers UH, Ponsioen CY, Karlsen TH, Vesterhus M. Enhanced 
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results: Histological steatohepatitis including steatosis, lobular inflamma-
tion and fibrosis (stage 1 or 2) were seen in A/J mice fed the HFCC diet. 
Some of the blue-stained fibers by azan stain were surrounding bright 
and multinuclear giant cells. These cells were positively stained by mac-
2, suggesting that they were macrophages. A polarized light microscope 
identified cholesterol crystals characterized by a Maltese cross inside their 
macrophages. Platelet-derived growth factor (PDGF) is secreted by acti-
vated macrophages and activates stellate cells to become myofibroblast 
that produces collagen fibers. We observed PDGF-receptorβ-positive cell, 
that is myofibroblast, surrounded the giant cells. Histological severity in-
cluding fibrosis and the number of giant cells dose-dependently worsened 
with increasing cholesterol intake.
conclusion: Cholesterol-phagocytic macrophage could be a key player of 
development of fibrosis in NASH. Our model could capture the onset of 
NASH fibrosis and could be suitable for evaluation of drug efficacy target-
ing macrophages.
disclosure: Nothing to disclose 
P0007 LIver fIBrOsIs WITh TWO-dIMensIOnaL shear Wave 
eLasTOgraPhy In PaTIenTs WITh PrIMary BILIary chOLangITIs
Yan Y., Xing X., Yang L., Yang J.
West China Hospital of Sichuan University, Department of Gastroenterology 
and Hepatology, Chengdu, China
contact e-Mail address: yuling.yan@scu.edu.cn
Introduction: Primary biliary cholangitis (PBC) is a slowly progressive 
cholestatic disease. The accurate evaluation the degree of liver fibrosis is 
important for determining medical management and prognosis of PBC pa-
tients. Although liver biopsy remains the reference standard to assess liver 
fibrosis, it is limited by its invasiveness and potential complications [1].
Recently, Two-dimensional shear wave elastography (2D-SWE), a noninva-
sive method for measuring liver stiffness has been developed with several 
advantages. First, it can be used to measure liver stiffness values on the 
basis of anatomic information to avoid nontarget structure and elastic ar-
tifacts and to improve measurement reliability. Second, it can be used in 
patients with ascites. This method has good diagnostic accuracy for the 
staging of liver fibrosis in patients with chronic liver disease [2-4]. How-
ever, studies focused on patients with PBC are relatively rare and all of 
them include not only PBC, but also other autoimmune etiology related 
chronic liver disease [5].
Therefore, this retrospective study is to investigate the diagnostic accuracy 
of 2D-SWE for the noninvasive staging of liver fibrosis in patients with PBC 
by using histologic analysis as a reference standard.
aims & Methods: To investigate the diagnostic accuracy of 2D-SWE for the 
noninvasive staging of liver fibrosis in patients with PBC by using histo-
logic analysis as a reference standard. Patients with PBC who underwent 
liver biopsy and 2D-SWE were consecutively enrolled. Spearman’s correla-
tion was applied to evaluate the correlation between Liver stiffness (LS) of 
2D-SWE and liver fibrosis stage by liver biopsy Receiver operating charac-
teristic (ROC) curves were constructed to assess the overall accuracy and to 
identify optimal cut-off values.
results: The characteristics of the diagnostic performance were deter-
mined for 120 patients with PBC. Spearman’s correlation between LS of 
2D-SWE and liver fibrosis stage was 0.686,p< 0.001. The areas under the 
ROC curves of significant fibrosis (≥ S2), severe fibrosis (≥ S3), and cirrhosis 
(S4) were 0.799, 0.902, and 0.942, respectively. and the optimal cut-off 
values associated with significant fibrosis, severe fibrosis, and cirrhosis 
were 8.45kPa, 10.9kPa and 14.05 kPa, respectively. 2D-SWE showed sensi-
tivity of 72.4% and specificity of 73% for significant fibrosis, sensitivity of 
86.8% and specificity of 84.1% for severe fibrosis, sensitivity of 86.7% and 
specificity of 86.7% for cirrhosis.
conclusion: 2D-SWE shows promising diagnostic performance for assess-
ing liver fibrosis stages in patients with PBC, especially for severe fibrosis, 
and cirrhosis.
references: 1. Rockey, D.C., et al., Liver biopsy. Hepatology, 2009. 49(3): p. 
1017-44. 2. Gao, Y., et al., Liver Fibrosis with Two-dimensional US Shear-
Wave Elastography in Participants with Chronic Hepatitis B: A Prospec-
tive Multicenter Study. Radiology, 2018. 289(2): p. 407-415. 3. Herrmann, 
E., et al., Assessment of biopsy-proven liver fibrosis by two-dimensional 
shear wave elastography: An individual patient data-based meta-analysis. 
Hepatology, 2018. 67(1): p. 260-272. 4. Zhuang, Y., et al., Two-dimensional 
Shear-Wave Elastography Performance in the Noninvasive Evaluation of 
Liver Fibrosis in Patients with Chronic Hepatitis B: Comparison with Se-
rum Fibrosis Indexes. Radiology, 2017. 283(3): p. 873-882. 5. Zeng, J., et 
al., Non-invasive assessment of liver fibrosis using two-dimensional shear 
wave elastography in patients with autoimmune liver diseases. World J 
Gastroenterol, 2017. 23(26): p. 4839-4846.
disclosure: Nothing to disclose 
P0008 cIrcuLaTIng BLOOd MIcrOBIOMe sIgnaTures In 
PaTIenTs WITh LIver cIrrhOsIs and POrTaL hyPerTensIOn
Gedgaudas R.1, Skieceviciene J.2, Franke A.3, Gelman S.4, Streleckiene G.5, 
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1Lithuanian University of Health Sciences, Gastroenterology, Kaunas, 
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Research, Kaunas, Lithuania, 6Lithuanian University of Health Sciences, 
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contact e-Mail address: r.gedgaudas@gmail.com
Introduction: Studies from recent years have shown that intestinal micro-
biome is linked to the development of liver cirrhosis and disease related 
complications. Portal hypertension (PH) is a complication of advanced liver 
disease that causes blood retention in the portal vein system. PH leads to 
increased intestinal permeability (“leaky gut”), translocation of bacteria 
and their metabolites into the blood. In the last two years, studies have 
shown changes in circulating microbiome in patients with liver disease, 
however, circulating microbiome in patients with PH has not been as-
sessed yet.
aims & Methods: 
aim of the study: To detect changes in circulating blood microbiome in 
patients with portal hypertension.
Tasks of the study: 
1. To determine composition of circulating blood microbiome in patients 
with portal hypertension. 
2. To asses differences of circulating blood microbiome between patients 
and healthy control subjects. 
3. To asses changes in circulating blood microbiome in relation to the de-
gree of portal hypertension.
Methods: Study cohort included 58 patients with liver cirrhosis and 46 
healthy control (HC) subjects. Collection of biological material (blood plas-
ma samples from hepatic and peripheral venous blood from liver cirrhosis 
patients and peripheral venous blood from HC subjects) also measure-
ments of hepatic venous pressure gradient (for liver cirrhosis patients) was 
performed at Department of Gastroenterology of Lithuanian University of 
Health Sciences, Kaunas Clinics. Bacterial DNA from blood plasma samples 
was obtained using QIAamp Circulating Nucleic Acid (Qiagen) isolation 
kit. 16S rRNA gene sequencing of V1-V2 variable regions was used to de-
termine bacterial composition. Raw sequencing data was processed into 
the table of amplicon sequencing variants through DADA2 workflow. Data 
analysis was performed using publicly available R statistic packages.
results: Taxonomic composition analysis at the phylum level revealed that 
blood microbiome was predominated by Proteobacteria (66.3%, 58.3%, 
53.91%), Bacteroidetes(10.8%, 13.2%, 12.5%), Actinobacteria(12%, 10.8%, 
11.5%) and Firmicutes (10.9%, 17.6%, 22%) in samples from peripheral 
blood of HC subjects, peripheral blood of PH patients and blood from 
hepatic vein of PH patients respectively. α-diversity was not significantly 
different between HC and PH patients, nor between different compart-
ments in PH patients (Shannon index - 4.02, 4.22, 4.15, p >0.05). Bacterial 
community structure did not show significant clustering between neither 
HC and PH patients nor between different compartments in PH patients. 
Differential abundance analysis revealed differently abundant genera be-
tween HC and PH patients with an increase in abundance of Tepidimonas, 
Enterobacter, Prevotella, Parabacteroides in PH patients. Subgroup analysis 
of PH patients with different degree of PH revealed no significant differ-
ences in composition at phylum level, α-diversity or β-diversity, however 
Parasutterella genus was found to be differentialy abundant with increas-
ing levels in patients with higher degree of PH.
conclusion: Circulating blood microbiota comprises of four main phyla 
- Proteobacteria, Bacteroidetes, Actinobacteria and Firmicutes. Genera of 
Tepidimonas, Enterobacter, Prevotella, Parabacteroides was found to be in-
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(3) Researchers and clinicians should inform participating patients and 
healthy volunteers about the outcome of the research.
disclosure: Nothing to disclose 
P0010 InfecTIOns In cIrrhOsIs: a changIng ePIdeMIOLOgIc 
seTTIng
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Padua, Italy, 3University of Padova, Department of Surgery, Oncology and 
Gastroenterology Sciences, Padova, Italy, 4University of Padua, Department 
of Surgery, Oncology and Gastroenterology, Padova, Italy, 5Multivisceral 
Transplant Unit/Gastroenterology, Department of Surgery, Oncology and 
Gastroenterology, Padua University Hospital, Padua, Italy, 6University of 
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contact e-Mail address: monica.pellone91@gmail.com
Introduction: : Bacterial and fungal infections represent a leading cause 
of decompensation and death in hospitalized patients with cirrhosis. Even 
if a great proportion of infections in cirrhosis are culture-negative, the 
analysis of microbiological findings is of utmost importance to assess local 
epidemiology, prevalence of multidrug resistant (MDR) strains and there-
fore address early empirical therapy.
aims & Methods: To retrospectively analyze epidemiology of culture-pos-
itive infections (CP-I) in a cohort of hospitalized patients with cirrhosis.
All patients with cirrhosis consecutively admitted at Multivisceral Trans-
plant Unit, Padua University Hospital, over 2 years period, were enrolled. 
Amongst patients with infection we analyzed CP-I in relation to epidemi-
ology of fungal and bacterial strains and clinical outcome. Bacterial or 
fungal colonizations were not included.
results: One-hundred ninety-two patients during 433 hospitalizations 
were analyzed in the study period. 156 CP-I (fungal/bacterial 15/139) oc-
curred in 77 (40.1%) patients (M/F 51/26, median [IQR] age 55.3 [13] years, 
48% alcohol-related disease, 22% viral-related; 36.3% waitlisted for liver 
transplantation; Child-Pugh and MELD score 11 [3] and 24 [12], respectively. 
82% CP-I were hospital-acquired, being the urinary tract (38,9%) and 
blood (23,4%) the most common sources. 
Amongst bacterial CP-I, gram positive (G+) strains occurred more fre-
quently than gram negative (G-) ones (56.2% vs 43.8%). 
Enterococcus faecium, E. Coli and Enterococcus faecalis accounted for 
26.7%, 16.5% and 13.6% of all bacterial CP-I. Prevalence of MDR CP-I was 
35.5% (32,5% amongst G+ and 37,5% amongst G-). 
Considering fungal infections, they were mostly from the urinary tract and 
caused by Candida spp. 
17 out of 77 patients experienced an episode of sepsis-related multiorgan 
failure requiring ICU admission. In-hospital transplant free survival was 
55.8%.
conclusion: Identification of infective agent in about half of hospitalized 
patients with decompensated cirrhosis. The increasing prevalence of gram 
positive and MDR bacterial strains, should be taken into account for anti-
biotic stewardship and early empiric therapy.
disclosure: Nothing to disclose 
P0011 characTerIzaTIOn Of BIOPsy PrOven nOn-aLcOhOLIc 
faTTy LIver dIsease In heaLThy nOn-OBese and Lean 
IndIvIduaLs
Eshraghian A., Nikeghbalian S., Malek-Hosseini S.A.
Avicenna Center for Medicine and Organ Transplant, Shiraz, Iran (Islamic 
Republic of)
contact e-Mail address: eshraghiana@yahoo.com
Introduction: Non-alcoholic fatty liver disease (NAFLD) is frequently seen 
among non-obese overweight individuals and more interestingly among 
lean subjects (those with normal body mass index). This study aimed to 
investigate prevalence and risk factors of NAFLD based on liver biopsy in a 
cluster of healthy non-obese and lean individuals.
creased in patients with portal hypertension compared to healthy controls. 
Parasutterella genus was associated with higher degree of portal hyper-
tension.
disclosure: Nothing to disclose 
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Introduction: Faecal sample collection is crucial for gut microbiome re-
search and its clinical applications. However, while patients and healthy 
volunteers are routinely asked to provide stool samples, their attitudes 
towards sampling remain largely unknown. Here we investigate the atti-
tudes of 780 Dutch patients, including participants in a large Inflammatory 
Bowel Disease (IBD) cohort, and population controls, to identify barriers 
to sample collection and provide recommendations for gut microbiome 
researchers and clinicians.
aims & Methods: We sent questionnaires designed in cooperation with the 
psychologist of our IBD centre including questions about living situation, 
experiences with faecal sample collection, information about the type of 
toilet and perceptions of storing faecal samples in their freezer to 660 IBD 
patients and 112 non-gastroenterology patients who had previously been 
approached to participate in gut microbiome studies. 
The questionnaire recipients in the IBD cohort comprised both patients 
previously willing to collect a stool sample for research (n=577, IBD-Will-
ing) and patients previously not willing to do so (n=83, IBD-Unwilling). 
We also conducted 478 brief interviews with participants in our general 
population cohort who had collected stool samples. Statistical analysis of 
the data comprising Fisher’s exact tests and Chi-square tests was per-
formed using R.
results: 97.4% of respondents reported that they had willingly partici-
pated in stool sample collection for gut microbiome research, and most 
respondents (82.9%) and interviewees (95.6%) indicated willingness to 
participate again, with motivations for participating being mainly altruistic 
(57.0%). Most patients thought the collection process was easy (84.9%). 
Only 26.2% of the patients who responded felt the collection of faecal 
samples was dirty and most of the population controls interviewed per-
ceived faecal sample collection as ‘not inconvenient at all’ (49.8%) or ‘not 
inconvenient’ (28.7%). 
A minority of respondents (19.1%) did not understand why the faecal sam-
ple needed to be frozen according to our protocol. This is an important 
observation because the clarity of the written instructions was associated 
with future willingness to collect stool samples (P=0.046), and knowing 
the purpose of freezing stool (stopping bacterial growth) was associated 
with future willingness to freeze the stool samples (P=0.003). Responses 
indicated that storing stool samples in a home freezer for a prolonged 
time was the main barrier to participation (52.6%), but clear explanations 
of the sampling procedures and their purpose increased willingness to 
collect and freeze samples (P=0.046, P=0.003).
conclusion: In conclusion, patients and healthy controls experience some 
barriers to participate in stool sample collection project. To account for 
participant concerns, we wrote the following four recommendations: 
(1) Gut microbiome researchers and clinicians should explain why their 
collection protocol was designed in a specific way. 
(2) In studies where a time-series of many stool samples needs to be col-
lected and frozen, researchers should consider providing participants with 
a small freezer. 
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aims & Methods: In a cross-sectional study, adult (>18 years) healthy in-
dividuals who were first degree relatives of patients who had undergone 
liver transplantation between July 2012 and October 2018 were included. 
Liver biopsy was performed, as a routine pre-transplant work-up, for all 
the study participants to evaluate liver histology before living donor. Non-
obese individuals were those with body mass index (BMI) < 30 Kg/m2. 
Lean individuals were defined as participants with BMI < 25 Kg/m2.
results: Totally 310 patients were included. Seventy six individuals (24.5 
%) had NAFL and 30 patients (9.67 %) had non-alcoholic steatohepatitis 
(NASH) among non-obese population. In univariate analysis, higher BMI, 
serum cholesterol, LDL, ALT, alkaline phosphatase and uric acid were asso-
ciated with NAFLD in non-obese individuals (P< 0.05). In regression analy-
sis, higher BMI and LDL were independently associated with NAFLD in 
non-obese individuals (P< 0.05). In multivariate regression analysis, only 
higher BMI was marginally associated with NASH in non-obese compared 
to those without NASH (Odds ratio: 2.52, 95 % CI: 0.097-6.54; P=0.05). 
Totally, 246 individuals were lean. 55 individuals (22.3 %) had NAFL and 20 
individuals (8.2 %) had NASH in their liver biopsies. In univariate analysis, 
serum triglyceride, cholesterol, LDL, ALT, alkaline phosphatase and uric 
acid were associated with NAFL among lean individuals (P< 0.05). In re-
gression analysis, serum uric acid was associated with NAFL (Odds ratio: 
1.70, 95 % CI: 1.18- 2.45; P=0.004) and NASH in lean individuals (Odds 
ratio: 1.98, 95 % CI: 1.27- 3.10; P=0.003).
conclusion: NAFLD/NASH is prevalent even in a healthy lean population 
when evaluated by liver biopsy. Higher BMI and serum uric acid were two 
major risks of NAFLD/ NASH in non-obese and lean individuals.
univariate Multivariate analysis
  With NASH Without NASH P-value OR 95 % CI P-value
Age (year) 31.88 ± 6.64 32.64 ± 7.19 0.668      
Sex (m/f) 10/10 95/131 0.636      
BMI (kg/m2) 22.47 ± 2.1 21.76 ± 2.15 0.747      
FBS 90.84 ± 9.77 88.93 ± 10.56 0.450      
TG 152.15 ± 79.00 99.81 ± 57.25 <0.001 1.004 0.99-1.01 0.334
Cholesterol 181.95 ± 35.82 168.62 ± 37.20 0.127      
HDL 44.76 ± 9.42 46.67 ± 11.50 0.508      
LDL 105.58 ± 36.10 97.89 ± 30.51 0.329      
AST 23.80 ± 12.50 20.01 ± 7.18 0.037 1.020 0.96-1.08 0.518
ALT 27.55 ± 13.43 19.37 ± 11.54 0.003 1.005 0.96-1.04 0.834
ALK.Phos 205.35 ± 76.25 194.43 ± 66.08 0.486      
Uric acid 4.93 ± 1.40 3.50 ± 1.14 <0.001 1.98 1.27- 3.10 0.003
[Characteristics of lean patients with and without NASH]
references: 1. Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello 
M, Consonni D, Di Marco V, Cammà C, Mensi L, Dongiovanni P, Valenti 
L, Craxì A, Fargion S. Liver and Cardiovascular Damage in Patients With 
Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral 
Obesity. Clin Gastroenterol Hepatol 2017; 15(10):1604-1611.e1. 2. Golabi P, 
Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients With Lean 
Nonalcoholic Fatty Liver Disease Are Metabolically Abnormal and Have a 
Higher Risk for Mortality. Clin Diabetes 2019; 37(1):65-72.
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Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common 
hepatic disease worldwide. Possible role of genetic factors, involved in the 
NAFLD development and course is discussed. The aim of the study was to 
investigate distribution of glutathione-S-transferase T1 (GSTT1) and GSTM1 
null genotypes in NAFLD patients and their association with cytokine and 
adipokine profiles.
aims & Methods: The deletion polymorphism of GSTT1 and GSTM1 genes 
was studied in 104 NAFLD patients and 45 healthy individuals (control 
group). Biochemical parameters, tumor necrosis factor-α (TNF-α), inter-
leukin 10 (Il-10), transforming growth factor-β
1
, leptin, adiponectin blood 
levels were investigated.
results: Among the NAFLD patients deletion of the GSTT1 gene was estab-
lished in 18 individuals (17.3%), normal genotype in 86 patients (82.7%). 
In the group of healthy individuals, the deletion of the GSTT1 gene was 
observed in 6 cases (13.3%), normal genotype in 39 (86.7%), which was 
not significantly different from the distribution of the genotypes among 
NAFLD patients. 
The deletion of GSTM1 gene among NAFLD patients was diagnosed in 52 
cases (50.0%), normal genotype was observed in 52 patients (50.0%). 
In the control group, the deletion of the GSTM1 gene was detected in 23 
individuals (51.1%), normal genotype - in 22 (48.9%), which also was 
not significantly different from the distribution of genotypes in NAFLD 
patients.
Higher direct bilirubin level in the blood by 18.5% (p = 0.049) was found 
in NAFLD patients with null genotype of the GSTT1 gene, as compared to 
patients with normal genotype. The analysis of probable dependence of 
pro- and anti-inflammatory cytokines and adypokine content on the dele-
tion polymorphism of the GSTT1 gene in NAFLD patients showed a two-fold 
(p = 0.01) higher TNF-α level in the blood of patients with null genotype 
as compared to patients with normal genotype of the GSTT1 gene. Higher 
concentration of leptin in the blood at 37.1% (p = 0.04) was observed in 
patients with null-genotype of GSTM1 gene in comparison with patients 
with normal genotype.
conclusion: Distribution of GSTT1 and GSTM1 null genotypes in NAFLD pa-
tients did not differ significantly from healthy individuals. However NAFLD 
patients null genotype carriers were characterized by more aggravated 
changes of proinflammatory TNF-α and those with deletion of GSTM1 gene 
by higher leptin plasma levels as compared to patients with normal geno-
types of proper genes.
disclosure: Nothing to disclose 
P0013 The MechanIsM Of negaTIve reguLaTIOn Of faBP1 By 
nf-kB/IL-6 On InvasIOn and MeTasTasIs Of hePaTOceLLuLar 
carcInOMa
An F.1, Lin Y.1, Wu X.2
1Wuxi People’s Hospital Affiliated to Nanjing Medical University, Department 
of Gastroenterology, Wuxi, China, 2Wuxi People’s Hospital Affiliated to 
Nanjing Medical University, Wuxi, China
contact e-Mail address: wdf8025@163.com
Introduction: Breaking the homeostasis of lipid metabolism is a key risk 
factor for invasion and metastasis of hepatocellular carcinoma (HCC). The 
synthesis, transport and catabolism of free fatty acids (FFA) are regulated 
by fatty acid-binding proteins (FABPs). The biological role of FABPs in 
regulating free fatty acid (FFA) synthesis and metabolism in tumorigenesis 
and development is one of the hotspots in the basic and clinical research 
of tumor microenvironment. 
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conclusion: We found that SERPINA1 rs17580 confers an increased risk 
of developing liver fibrosis, while SERPINA1 rs28929474 and HSD17B13 
rs10433937 are not associated with liver injury.
disclosure: Nothing to disclose 
P0015 c282y/h63d cOMPOund heTerOzygOsITy causes 
sIgnIfIcanTLy eLevaTed IrOn OverLOad and assOcIaTed 
dIseases
Hasan S.M.M., Farrell J., Borgaonkar M.
Memorial University Dept. of Medicine, Medicine, St. John’s, Canada
contact e-Mail address: mhasan@mun.ca
Introduction: Hereditary Hemochromatosis (HH) occurs due to mutations 
in the HFE gene. Homozygosity for the C282Y mutation is the most common 
genotype found in HH patients. Other genotypes are found less frequently 
in HH patients, indicating variable degrees of penetrance. We studied the 
penetrance of patients with the C282Y/H63D genotype in developing clini-
cally significant iron overload and iron overload-related disease.
aims & Methods: We have completed a retrospective analysis on every 
individual within Newfoundland & Labrador (NL) who were diagnosed 
as C282Y/H63D compound heterozygote between 1996 and 2009 through 
molecular genetics study. Data collection was completed in St. John’s, 
NL using electronic health records on multiple clinically relevant param-
eters - ferritin, transferrin saturation, aspartate aminotransferase (AST) 
levels, alanine aminotransferase (ALT) levels and liver biopsy results. As 
available, data were collected for up to 10 years following the initial mo-
lecular genetics study to assess the development of iron overload and as-
sociated clinical sequelae. Iron overload categories were classified based 
on previously published definitions from the HealthIron Study (Allen et 
al., 2008). Evidence of ironoverload-related disease was the most severe 
category and required both documented iron overload with concurrent 
development of hepatocellular carcinoma, cirrhosis or fibrosis on liver 
biopsy, tenderness/effusion of the second and third metacarpophalangeal 
joints, elevated AST (>45 IU/L) or ALT (>40 IU/L) levels, or by diagnosis of 
symptoms associated with HH by a physician. Documented iron overload 
was determined by serum ferritin >1000 µg/L, or hepatic iron staining 3 
or 4. Provisional iron overload was determined by elevated serum fer-
ritin and transferrin saturation: >300 µg/L and >55% for men and post-
menopausal women, >200 µg/L and >45% for premenopausal women, 
respectively. Patients who did not meet the criteria for either documented 
or provisional iron overload were considered to have no evidence of clini-
cally significant iron overload.
results: Between 1996 and 2009, 275 individuals in NL tested positive 
for C282Y/H63D compound heterozygosity. However, only 247 individu-
als had electronic health records available for review. At baseline, 4% of 
all patients exhibited iron overload-related disease on the background of 
documented iron overload. Including these individuals, 8.1% of all pa-
tients met the criteria for documented iron overload, while an additional 
16.2% met the criteria for provisional iron overload. The remaining 75.7% 
of all patients at baseline did not show any evidence of iron overload. 
When the data from the next 10 years were analyzed, the proportion of 
patients with iron overload-related disease on the background of doc-
umented iron overload increased to 5.3%. Including these individuals, 
the total number of patients with documented iron overload increased 
to 10.1%, while the proportion of patients with provisional iron overload 
increased to 23.1%. As a result, the number of patients with no evidence 
of iron overload decreased to 66.8% at the end of our study period. Look-
ing specifically at the development of iron overload-related disease, one 
patient with documented iron overload and two patients with provisional 
iron overload at baseline progressed to iron overload-related disease 
throughout our study.
conclusion: C282Y/H63D compound heterozygosity is associated with in-
creased iron overload and this results in iron overload-related disease in a 
significant proportion of patients.
references: Allen KJ, Gurrin LC, Constantine CC, et al. Iron overload-related 
disease in HFE hereditary hemochromatosis. N Engl J Med 2008; 358:221-
30.
disclosure: Nothing to disclose 
It has been found that the expression of FABPs can be regulated by the 
signal pathway of NF-kappa B/IL-6. The specific mechanism of action is 
not clear.
aims & Methods: Immunohistochemistry was used to detect the expres-
sion of liver fatty acid-binding proteins (L-FABP, FABP1) and P65 on HCC 
tissue microarray. Lentivirus with high or low expression of FABP1 was 
used to infect Huh7 cell line in vitro. The effects of different FABP1 ex-
pression on lipid synthesis, invasion and metastasis of cancer cells were 
further studied, meanwhile, apoptosis was detected by flow cytometry. 
Affymetrix Gene Chip microRNAs Arrays gene chip were used to analyze 
the expression profile of miRNAs in the Huh7 and HepG2 cells induced by 
IL-6, and RT-PCR was used to verify the results of microarray. Bioinformat-
ics analysis was used to predict target genes of miRNAs, western-blot and 
fluorescent reporter assay were used to study the target genes. Finally, the 
role of miR-603 in the proliferation and invasion of HCC cells were studied 
by Edu Assay kit and transwell methods.
results: The expression of FABP1 in cancer tissues was significantly lower 
than that in adjacent tissues in nearly 90% HCC patients, and the expres-
sion level of FABP1 in adjacent tissues was correlated with the survival time 
of HCC patients (P < 0.01). The FABP1 could be absorbed by Huh-7 cells and 
the intracellular lipid synthesis was enhanced in the Huh7 cells with FABP1 
over expression, but the down regulation of FABP1 can decreased the lipid 
synthesis. Flow cytometry study showed that the over expression of FABP1 
can improve the apoptosis of HCC cells. The microarray results showed that 
the expression profile of miRNAs was significantly changed in the Huh7 
and HepG2 cells induced by IL-6. RT-PCR results showed that the miR-603 
was up-regulated in HCC tissues when compared with adjacent tumor tis-
sues. Bioinformatic method revealed that there were 7 binding sites in the 
region 1424-1431 of miRNA-603 to FABP1 3’UTR. In vitro cell studies, it was 
showed that high expression of miR-603 could inhibit the expression of 
FABP1 protein. Furthermore, it was showed that high expression of miR-
603 could promote the proliferation and migration of HCC cells.
conclusion: NF-KB/IL-6 can negatively regulate FABP1 expression through 
miR-603. High expression of FABP1 can promote lipid synthesis in HCC 
cells and enhance the lipotoxicity, then inhibit invasion and metastasis of 
cancer cells.
disclosure: The authors declare that they have no competing interests. 
P0014 serPIna1 and hsd17B13 gene varIanTs In LIver 
fIBrOsIs and cIrrhOsIs
Basyte-Bacevice V.1, Skieceviciene J.2, Valantiene I.1,2, Sumskiene J.1, 
Petrenkiene V.1, Kondrackiene J.1, Petrauskas D.1, Lammert F.3, 
Kupcinskas J.1,2
1Lithuanian University of Health Sciences, Gastroenterology Department, 
Kaunas, Lithuania, 2Lithuanian University of Health Sciences, Institute for 
Digestive Research, Kaunas, Lithuania, 3Saarland University Medical Center, 
Saarland University, Department of Medicine II, Homburg, Germany
contact e-Mail address: vbacevice@gmail.com
Introduction: Previous studies identified single nucleotide polymorphisms 
(SNPs) of the SERPINA1 gene as risk factors for developing liver cirrhosis 
of different aetiology and HSD17B13 gene variant association with reduced 
chronic liver disease risk.
aims & Methods: In this study, we tried to evaluate SERPINA1 rs28929474 
and rs17580 SNPs association with the risk of hepatic fibrosis or liver cir-
rhosis and HSD17B13 rs10433937 SNP protective trait against chronic liver 
injury. The study was conducted at the Department of Gastroenterology 
in Lithuanian University of Health Sciences Hospital and included 302 pa-
tients with liver cirrhosis, 127 patients with liver fibrosis, and 548 controls. 
SNPs were genotyped by quantitative PCR, using TaqMan allelic discrimi-
nation assays. Adjusted p value of < 0.016 was considered significant.
results: Genotype distributions of SERPINA1 and HSD17B13 SNPs were in 
Hardy-Weinberg equilibrium. SERPINA1 rs28929474 was not associated 
with liver fibrosis or cirrhosis. HSD17B13 rs10433937 also showed no sig-
nificance to liver injury, but genotype GG showed tendency to be protec-
tive against liver fibrosis (aOR 0.37, p=0.03). SERPINA1 rs17580 was associ-
ated with higher risk of developing hepatic fibrosis (aOR 3.42, p=0.001) 
and showed tendency towards development of liver cirrhosis (aOR 2.59, 
p=0.02). 
Moreover, SERPINA1 rs17580 genotype AT was also associated with in-
creased liver fibrosis risk (aOR 3.28, p=0.008) and showed tendency to 
increased liver cirrhosis risk (aOR 2.55, p=0.02).
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P0016 PrevaLence Of sMaLL InTesTInaL BacTerIaL 
OvergrOWTh syndrOMe In PaTIenTs WITh nOn-aLcOhOLIc 
faTTy LIver dIsease/nOn-aLcOhOLIc sTeaTOhePaTITIs: 
a crOss-secTIOnaL sTudy
Gkolfakis P.1, Tziatzios G.1, Papanikolaou I.S.1, Xirouchakis E.2, 
Panayiotides I.3, Dimitriadis G.D.1, Mathur R.4, Pimentel M.4, 
Giamarellos-Bourboulis E.J.5, Triantafyllou K.1
1Attikon University Hospital, National and Kapodistrian University of Athens, 
Medical School, Hepatogastroenterology Unit, 2nd Department of Internal 
Medicine & Research Unit, Athens, Greece, 2Department of Gastroenterology 
and Hepatology, Athens Medical Palaio Faliron General Hospital, Athens, 
Greece, 32nd Department of Pathology, National and Kapodistrian University 
of Athens, Medical School, Attikon University Hospital, Athens, Greece, 
4Medically Associated Science and Technology (MAST) Program, Cedars-
Sinai, Los Angeles, United States, 54th Department of Internal Medicine, 
National and Kapodistrian University of Athens, Medical School, Athens, 
Greece
contact e-Mail address: pgkolfakis@med.uoa.gr
Introduction: Non-alcoholic fatty liver disease (NAFLD) is a multifactorial 
wide-spectrum disorder. Small intestinal bacterial overgrowth (SIBO) is 
characterized by the increase in the number and/or type of colonic bac-
teria in the upper gastrointestinal tract. SIBO through energy salvage and 
inflammation induction could be considered one pathophysiological factor 
for NAFLD development and progression.
aims & Methods: Consecutive patients with histological, biochemical or 
radiological diagnosis of any stage of NAFLD (NAFLD, NASH, cirrhosis) un-
derwent upper gastrointestinal endoscopy. Duodenal juice (2cc) was aspi-
rated from the 3rd-4thpart of duodenum in sterile traps. SIBO was defined 
as ≥103aerobes CFU/ml of duodenal aspirate and/or presence of colonic 
type bacteria. Patients without any liver disease undergoing gastroscopy 
due to GERD comprised the healthy control (HC) group. Concentrations 
(pg/ml) of tumor necrosis factor-alpha (TNFα), interleukin (IL)-1βand IL-6 
were also measured in the duodenal fluid. The primary endpoint was to 
compare SIBO prevalence among patients with different disease stages 
and healthy controls.
results: We enrolled 125 patients (51 NAFLD, 27 NASH, 17 cirrhotics and 
30 HC) aged 54±11.9yrs and weight 88.3±19.6kg (NAFLD vs. HC 90.7±19.1 
vs. 80.8±19.6kg, p=0.02). Overall, SIBO was diagnosed in 23/125 (18.4%) 
patients, with Gram (-) bacteria being the predominant species (14/23; 
60.8%, Table). SIBO prevalence was higher among NAFLD/NASH or cirrho-
sis subjects compared to HC (14/78; 17.9% vs. 1/30; 3.3%, p=0.04 and 8/17; 
47.1% vs. 1/30; 3.3%, p< 0.001, respectively). Patients with NASH had high-
er SIBO prevalence (6/21; 22.2%) compared to NAFLD individuals (8/51; 
15.7%), but this difference did not reach statistical significance. Among pa-
tients with liver disease, cirrhotics had a higher SIBO prevalence compared 
to NAFLD/NASH individuals (47.1% vs. 17.9%, p=0.02). Mean concentration 
of TNF-a, IL-1b and IL-6 did not differ among the different groups.
conclusion: The prevalence of SIBO is significantly higher in patients with 
NAFLD compared to healthy controls, and SIBO is more prevalent in cir-
rhotics compared to uncomplicated NAFLD or NASH individuals.
disclosure: Nothing to disclose 
P0017 nOnaLcOhOLIc sTeaTOhePaTITIs: an InfrequenT 
enTITy In The WesTern WOrLd?
Gamelas V.1, Simões G.1, Santos S.1, Vasconcelos Loureiro R.2, Silva M.2, 
Calinas F.2
1Centro Hospitalar Universitário de Lisboa Central EPE, Gastroenterology, 
Lisboa, Portugal, 2Centro Hospitalar Universitário de Lisboa Central EPE, 
Lisboa, Portugal
contact e-Mail address: veronicagamelas@gmail.com
Introduction: The incidence of nonalcoholic Steatohepatitis (NASH) is 
rising, along with the increase of associated risk factors, specially over-
weight, in the Western world. The diagnosis requires an exhaustive study 
of liver disease, whereby its frequency based on population studies is diffi-
cult to determine. The relative prevalence among all causes of liver disease 
may be elucidative.
aims & Methods: The aim of this study is to evaluate the burden of NASH in 
a hepatology consultation and to characterize this population of patients.
It was performed a retrospective observational study of consecutive pa-
tients observed in a Hepatology consultation, by three different doctors, in 
a central hospital of Lisbon in the year of 2017. 
Patients with nonalcoholic fatty liver disease (NAFLD) and NASH were 
studied. NASH diagnosis was established based on the existence of he-
patic steatosis and ALT elevation and after exclusion of other etiologic fac-
tors for liver disease (including an alcohol consumption <20 and 30 g/
day for women and men, respectively). Cirrhosis was determined based 
on histologic findings, unequivocal imaging or hepatic elastography 
(FibroScan)>14kPa.
results: Among the 1268 patients analyzed, 69 (5.4%) had NAFLD, of 
whom 56 (4.4%) had NASH [age 56.7 ± 14.4; 27 (48.2%) female].
Twenty-five (44.6%) patients had type 2 diabetes mellitus; 32 (57.1%) hy-
pertension; 40 (71.4%) dyslipidemia. All patients were overweight (BMI 
31.1 ± 5.8, min.25.1- max.39.5 kg/m2).
Sixteen (28.6%) patients were cirrhotic. The initial ALT was 65±48 (20-234) 
U/L.
Among patients with NASH, 54% lost weight. Normalization of ALT was 
found in 84% (21/25) of those who lost weight.
Patients with ALT normalization had a weight loss that did not differ sig-
nificantly from those who did not normalize ALT (10.3 ± 12% and 9.2 ± 
5.36%, respectively, p = 0.46).
conclusion: NASH has a low prevalence in hepatology consultation. How-
ever, cirrhosis occurs in a significant proportion of those patients. The pre-
scription of diet and lifestyle changes has a role in this patients.
disclosure: Nothing to disclose 
P0018 evaLuaTIOn Of The Presence Of hePaTIc sTeaTOsIs 
Measured By caP-fIBrOscan In PaTIenTs WITh PsOrIasIs
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Gonzalez R.2, Cano V.2, Eiris N.3, Alvarez B.2, Jorquera F.2, Linares P.2
1Complejo Asistencial Universitario de León, Gastroenterology, Leon, 
Spain, 2Complejo Asistencial Universitario de León, Leon, Spain, 3Complejo 
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contact e-Mail address: ruben.perez.fernandez@outlook.es
Introduction: Different studies have reported a high prevalence of non-
alcoholic fatty liver disease (NAFLD) in patients with psoriasis, using ana-
lytical, histological or ultrasound evaluations. To date, there are no studies 
that analyze the usefulness of CAP-fibroscan and the assessment of body 
composition by bioimpedance in this group of patients.
aims & Methods: Knowing the prevalence of hepatic steatosis (HS) in pa-
tients with Pso and HA using CAP-fibroscan and analyze the relationship 
with serological indices, anthropometric, analytical and body composi-
tion variables: fat mass index (FMI) and visceral fat (VF) measurements by 
electrical bioimpedance (BIE). Prospective study of patients with PS and 
HA from our hospital. Anthropometric, analytical, elastometric and body 
composition variables were collected.
results: Descriptive analysis: 107 patients were recognized (45% women), 
mean age 48.4 ± 12.7 years. 80% with PSo and 20% HA. 
Anthropometry: 4.7% were overweight and 57% were obese (100% HA 
and 83.9% Pso). The mean BMI was 27.1 ± 7.6. 56% had a high waist cir-
cumference (WC) (69% women and 45% men). 
Comorbidity: 17% HBP, 7% diabetes, 25% dyslipidemia and 29% metabolic 
syndrome (MtS). 
CAP-Fibroscan: 56% had moderate-severe HS (CAP> 248 dB / m) and 
31.4% severe (CAP> 280 dB / m). 
Liver Stiffnes: 74% were F0-1, 20% F2, 3% F3 and 3% F4. BIE: 69% had 
high FMI levels (63.3% women vs 86.7% men) and 43% VF (66.7% women 
vs 23.3% men). 
Inferential analysis: There was a good correlation between HS measured 
by CAP and anthropometric parameters (WC and BMI), serological indexes 
FLI and HSI, and FMI and VF (p < 0.05). 
Patients with HA were younger, more obese, with > liver stiffness (LS),> 
CAP,> FLI,> FMI and> VF than patients with Pso (p < 0.05). Women with HS 
had > LS 7.8 vs 5.4 KPa (p < 0.05). Patients with comorbidity had higher 
HS, higher score in FLI and HSI,> LV and >% FMI and high VF and a higher 
average age. 
The hypertensive males had a VF high in 100% vs non-hypertense (p < 
0.05). The high VF in males was significantly higher in terms of age (54 vs 
39.7 years), BMI (37.3 vs 30.7), CAP (260 vs 226.8), FLI and HSI index, and 
the same occurred with the high FMI and age (54 vs 31.1), BMI (36.6 vs 
30.38) and the FLI and HSI index. 
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conclusion: In conclusion, these hormones are potentially valuable tools 
for non-invasive stratification of patients with NAFLD. In particular, leptin 
might discriminate the presence of NAFLD, while IGF-1 could be a bio-
marker of advanced fibrosis. Further studies should analyze these hor-
mones in a lean NAFLD control group and the performance of multivariate 
analysis to assess the impact of confounding factors and the potential of 
combined biomarker parameters. 
Supported by COMPETE2020 (PTDC/MED-FAR/29097/2017), FCT (PD/
BD/135467/2017), European Commission Research Executive Agency 
(H2020-MSCA-RISE-2016-734719) and APEF/MSD (Bolsa de Investigação 
APEF/MSD 2017).
disclosure: Nothing to disclose 
P0020 cheMerIn as a nOn-InvasIve seruM Marker fOr 
dIagnOsIng and gradIng Of nOn-aLcOhOLIc faTTy LIver 
dIsease
Byoumy E., Mohamed A., Ibrahim W., El-shafie A., Salama M., 
Abdelrahman G., Ibrahim M.
Ain Shams University, Faculty of Medicine, Internal Medicine Department, 
Cairo, Egypt
contact e-Mail address: drmmsalama@hotmail.com
Introduction: Patients with nonalcoholic fatty liver disease (NAFLD) and 
advanced liver fibrosis are at the highest risk for progressing to end-stage 
liver disease. Thus, identifying the severity of liver fibrosis is of major im-
portance in guiding the subsequent management of patients. Efforts have 
been made to identify noninvasive indicators of liver fibrosis in patients 
with NAFLD. Chemerin is a recently described adipokine involved in adipo-
genesis and insulin resistance.
aims & Methods: We aimed to assess the diagnostic value of serum 
chemerin in comparison to NAFLD fibrosis score as a non-invasive method 
for diagnosing and grading of NAFLD. Sixty patients with NAFLD were in-
cluded. They were categorized into 3 equal subgroups according to the 
grade of fatty liver by ultrasonography. Thirty healthy subjects were in-
cluded as controls. Serum chemerin level was measured by enzyme-linked 
immunoassay.
results: Serum chemerin level was significantly higher in patients with 
NAFLD than controls (227.38 ± 44.72 vs. 87.58 ± 28.47 ng/ml, respectively, 
p≤ 0.001); moreover, it correlated positively with the grade of fatty liver (p≤ 
0.001). Serum chemerin correlated positively with NAFLD fibrosis score (r 
= 0.988; p ≤ 0.001), age (r = 0.571; p≤ 0.001), BMI (r = 0.972; p ≤ 0.001), 
serum cholesterol (r = 0.942; p≤ 0.001), serum triglycerides (r = 0.915; p≤ 
0.001), random blood sugar (r = 0.486; p≤ 0.001), AST (r = 0.963; p≤ 0.001), 
ALT (r = 0.960; p≤ 0.001), and total bilirubin (r = 0.740; p≤ 0.001), and cor-
related negatively with platelets (r = -0.827; p≤ 0.001) and total proteins (r 
= -0.290; p≤ 0.006). 
For NAFLD diagnosis, serum chemerin at a cutoff > 147.8 ng/ml had area 
under the receiver operating characteristics curve (AUROC) = 1.000, con-
fidence interval (CI) 95% = 1.00 - 1.00, and p≤0.001, and NAFLD fibrosis 
score at a cutoff > - 2.8 had AUROC = 1.000, CI 95% = 1.00 - 1.00, and p 
≤0.001. Additionally, serum chemerin level above 245 ng/ml cutoff value 
can detect extensive fibrosis (F3-F4), with AUROC = 1.00, CI 95% = 1.00 - 
1.00, sensitivity and specificity 100%. Cases within NAFLD fibrosis score 
gray zone had a significantly higher serum chemerin compared with cases 
below the gray zone, with mean level 213.83 (± 13.74) vs. 114.48 (± 35.41) 
ng/ml, respectively, p≤ 0.001.
conclusion: In NAFLD patients, serum chemerin level is correlated with 
fatty liver grade. This study suggests that chemerin is comparable to NAFLD 
fibrosis score as regards detection and grading of NAFLD and of a useful 
utility especially in patients within NAFLD fibrosis score gray zone.
disclosure: Nothing to disclose 
Moderate-severe HS (CAP> 248 dB / m) was significantly associated with 
BMI, FLI, HSI, VF and the presence of MtS (p < 0.05). Patients with MtS had 
a CAP> 248dB / m in 76.2% vs 46.9% (p < 0.05).
conclusion: The prevalence of moderate-severe HS by CAP in patients with 
Pso and HA in our series is 56% and this is associated with the pres-
ence of obesity, MtS, cardiovascular comorbidity and high fat mass. Up 
to 25% have advanced fibrosis data. This group of patients would have to 
be evaluated in the Hepatology units for NAFLD screening and to rule out 
significant liver disease.
disclosure: Nothing to disclose 
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BIOMarkers In nOn-aLcOhOLIc faTTy LIver dIsease
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Introduction: Non-alcoholic fatty liver disease (NAFLD) encompasses a 
spectrum of conditions from the benign hepatic steatosis to non-alcoholic 
steatohepatitis (NASH), which may progress to liver cirrhosis and/or he-
patocellular carcinoma. The gold standard method to distinguish steatosis 
from NASH is liver biopsy. 
However, this is an invasive procedure with risk of complications, which 
provides a two-dimensional estimation of a particular biopsy, and is 
subjected to individual evaluation by a pathologist. All these limitations 
prompt the need to discover and validate new accurate diagnostic bio-
markers.
aims & Methods: Here, we aimed to assess the performance of circulat-
ing levels of adiponectin, leptin and insulin-like growth factor-I (IGF-1) as 
potential non-invasive biomarkers in NAFLD. Serum levels of adiponectin, 
leptin and IGF-1 were evaluated in discovery (n = 59) and validation (n = 
145) cohorts of morbidly obese patients, with clinical and biopsy-proven 
diagnosis of NAFLD, using specific enzyme-linked immunosorbent assays. 
Hormone levels were correlated with histology findings, clinical parame-
ters, presence of comorbidities and PNPLA3 genotype. Sera of disease-free 
individuals, lean and obese, were also analyzed in both cohorts (n = 20 
and n = 32, validation and discovery cohorts, respectively).
results: The results showed that in the discovery cohort, adiponectin 
was significantly lower in patients with NASH compared to steatosis (p < 
0.05) or healthy individuals (p < 0.01), and the area under the receiver-
operating characteristic (AUROC) was 0.79 (95% CI = 0.62 - 0.96; p < 0.01). 
The same trend was observed in the validation cohort. Further adipo-
nectin decreased with histologic severity of steatosis (p < 0.005), inflam-
mation and fibrosis (p < 0.05), and showed an inverse correlation with 
serum alanine aminotransferase (ALT) and triglycerides (p = 0.0023 and 
p = 0.0055, respectively), supporting a role for this hormone in NAFLD 
pathophysiology. 
In both cohorts, leptin levels were significantly increased in patients with 
steatosis or NASH when compared to healthy lean controls (p < 0.005 and 
p <0.0001), showing an AUROC of ~ 0.9 (p < 0.05 and p < 0.0001 for dis-
covery and validation cohorts, respectively). Circulating leptin levels were 
similar between lean and obese controls, suggesting that obesity is not 
a confounding factor. Finally, although IGF-I concentrations were signifi-
cantly diminished in patients with steatosis or NASH, compared with con-
trols (p < 0.05) in the discovery cohort, IGF-1 levels were similar between 
control individuals and patients with NAFLD in the validation cohort. Strik-
ingly, IGF-1 levels were significantly lower in more severe fibrosis (p < 
0.005) in the validation cohort, with an AUROC value of 0.71 (95% CI = 
0.6 - 0.82; p < 0.01).
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P0021 sysTeMIc exPressIOn and sIgnIfIcance Of neuTrOPhIL 
exTraceLLuLar TraP (neT) cOMPOnenTs In aLcOhOLIc LIver 
dIsease
Kasztelan-Szczerbinska B.1, Rycyk A.1, Surdacka A.2, Roliński J.2, 
Michalak A.1, Szczerbinski M.3, Cichoz-Lach H.1
1Medical University of Lublin, Department of Gastroenterology with 
Endoscopy Unit, Lublin, Poland, 2Medical University of Lublin, Department of 
Clinical Immunology, Lublin, Poland, 3Public, Academic Hospital Number 4, 
Gastroenterology with Endoscopy Unit, Lublin, Poland
contact e-Mail address: beata.szczerbinska@op.pl
Introduction: Neutrophils release neutrophil extracellular traps (NETs) as 
a defense strategy in response to broad-spectrum infections, but also to 
sterile triggers. NETs consist of a DNA scaffold decorated with antimicrobial 
peptides (AMPs) including cathelicidin (LL37) and α-defensins (HNP1-3), 
and enzymatically active proteases including peptidyl arginine deiminase 
type 4 (PAD-4). NET components possess pleiotropic immunomodulating 
potential. Damage-associated molecular patterns (DAMPs), such as high 
mobility group box 1 (HMGB1), stimulate NET formation. Susceptibility to 
infections and inflammatory dysregulation are hallmarks of alcoholic liver 
disease (ALD).
aims & Methods: We aimed to investigate the systemic concentrations of 
NET components such as LL37, HNP1-3, and PAD-4, and the NET promoter 
HMGB1 in patients with ALD and assess their implications in the disease 
course. 
62 patients with ALD /51 males, 11 females, aged 48,94 ± 10,29/ were 
prospectively recruited and assigned to subgroups based on their 1/ gender, 
2/ severity of liver dysfunction according to Child-Pugh and Model of End-
Stage Liver Disease (MELD) scores, and modified Maddrey’s Discriminant 
Function (mDF) 3/ presence of ALD complications, and followed for 30 
days. 24 age- and sex-matched healthy volunteers served as the control 
group. Selected plasma components of NETs and HMGB1were quantified 
using immunoenzymatic ELISAs. Correlation coefficients between their 
blood concentrations and (i) markers of systemic inflammation [the 
neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), white 
blood cell (WBC) and neutrophil (NEUT) counts], (ii) liver dysfunction 
severity scores (Child-Pugh, MELD, mDF), and (iii) ALD complications were 
calculated. The receiver operating curves (ROC) and their areas under 
the curve (AUCs) were checked in order to assess the accuracy of the NET 
component expression in predicting the degree of liver failure and the 
development of ALD complications.
results: Systemic concentrations of HNP1-3, PAD-4, and HMGB1 were 
significantly increased in patients with ALD in comparison with controls. 
However, LL37 was significantly elevated only in the subgroup of ALD 
patients with WBC count above 15 cells/µL compared with controls and ALD 
patients with WBC count equal or below 15 cells/µL. No gender-related 
differences in NET components and HMGB1 concentrations were found. 
HNP1-3 levels correlated with MELD and mDF scores. ALD subgroups 
with MELD>20 and mDF>32 presented with significantly higher HNP1-3 
concentrations. HNP1-3 levels revealed a good predictive AUC for the hepatic 
encephalopathy and ascites development (0.81 and 0.74, respectively), and 
for the survival (0.87) in patients of above 40 years of age. PAD-4 levels 
correlated with standard markers of inflammation (CRP, WBC, NEUT) and 
revealed a good predictive AUC (0.76) for the survival in the whole ALD 
group. No correlations of HMGB1 concentrations with markers of systemic 
inflammation, liver parameters, and ALD complications were found.
conclusion: Our results reveal that systemic blood levels of NET components 
and the NET promoter are elevated in ALD patients and support the value 
of HNP1-3 and PAD-4 as biomarkers in the ALD assessment. PAD-4 seems to 
be an inflammatory mediator, while HNP1-3 the disease severity indicator. 
HNP1-3 and PAD-4 may be potentially applied as predictors of the patients’ 
survival in ALD. The significance of LL37 and HMGB1 concentrations in 
patients with ALD requires further investigation.
disclosure: Nothing to disclose 
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P0024 rOLe Of POLyMOrPhIsMs rs37972 rs37973 Of The 
gLccI1 gene In MOrTaLITy Of MexIcan PaTIenTs WITh aLcOhOLIc 
hePaTITIs
Lopez Perez R.Y., Perez Hernandez J.L., Arellanes Robledo J., 
de León Rendon J.L., Manjarrez Marti D.A., Hernandez Fuentes S., 
Montes Aparicio A.V., Rosas Madrigal S., Perez Carrion J.I., 
Higuera de la Tijera M.F.
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Introduction: Alcoholic hepatitis (AH) has a mortality of 25-50%, but in 
some Mexican studies it reaches around 60%. Only steroid treatment im-
pacts in AH mortality. Genetic polymorphisms (SNPs) rs37972 and r37973 
of GLCCI1 gene have shown influence in steroids treatment response in 
various inflammatory pathologies.
aims & Methods: To determine if SNPs rs37972 and r37973 of GLCCI1 gene 
confers lack of response to steroid treatment and higher mortality in pa-
tients with severe AH.A case-control study was conducted in 71 Mexican 
mestizo patients with severe AH. The SNPs rs37972 and r37973 of GLCCI1 
gene were determined from genomic DNA by endpoint PCR. The demo-
graphic and clinical features of AH patients were collected and the re-
sponse to steroid treatment was evaluated using the Lille model and its 
mortality. The data was analyzed with the statistical package SPSS V25.
results: Of patients included: 62 were men (87.3%) treated with steroids. 
46.5% of the patients presented response to treatment with steroids. Mor-
tality at 24 weeks was 49.3%. The C allele of SNP rs370972 (p = 0.01 [OR 
0.41 (IC95% 0.21-0.81), TT genotype of SNP rs370972 (p = 0.001 [OR 0.02 
(95% CI 0.00-0.40) and AA of SNP rs37973 (p = 0.035 [OR 0.48 (95% CI 
0.24-0.95), were shown as protective factors for early mortality (28 days). 
In evaluating mortality at 24 weeks we observed that the AG genotype 
of SNP rs370973 (p = ≤0.001 [OR = 13.22 (IC95% 4.72-36.78)]) and CT of 
SNP rs370972 (p = ≤0.001 [OR 12.0 (IC95% 4.46-32.28)) conferred higher 
mortality in AH patients. No association was found between the response 
to steroids treatment and SNPs rs370973 and rs370972 of GLCCI1 gene (p = 
1.00 [IC95% 0.52 - 1.95]) in patients with AH.
conclusion: Genetic polymorphisms of GLCCI1 gene impact in mortality 
of Mestizo-Mexican patients with AH. For our knowledge, this is the first 
study worldwide that associates the of the GLCCI1 genetic polymorphisms 
in patients with AH.
references: Me. Alcoholic Hepatitis a comprehesive of pathogenesis anda 
treatment. World J Gastroenterol. 2014 May ; 20 )(20) (6279: 6286). EASL 
Clinical Guidelines Management of alcohol liver disease. J Hepatol. 2012 
57; 399(0).
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P0025 day-4 LILLe scOre In earLy PredIcTIOn Of 
cOrTIcOsTerOId resPOnse fOr PaTIenTs WITh severe 
acuTe aLcOhOLIc hePaTITIs
Foncea C.G., Popescu A., Cotrau R., Belintan P., Moga T., Sirli R., 
Danila M., Sporea I.
Victor Babes University of Medicine, Department of Gastroenterology and 
Hepatology, Timisoara, Romania
contact e-Mail address: foncea.camelia@gmail.com
Introduction: In addition to general supportive care, corticosteroids are 
indicated for patients with severe acute alcoholic hepatitis (SAH), defined 
by a Maddrey`s discriminat function (MDF) score >32 [1]. 
However, patients on corticosteroid therapy have a high risk of developing 
infections and other complications, especially during hospitalization. The 
introduction of Lille score helps in finding the steroid responders (< 0.45) 
and non-responders (>0.45) after 7 days of treatment [2]. 
The aim of this study is to evaluate whether using Lille score at day 4 
(LM4) is as useful as Lille at day 7 (LM7), in order to determine response 
to therapy earlier.
aims & Methods: A retrospective study was performed including all pa-
tients with SAH during October 2015-March 2019 in a tertiary Department 
of Gastroenterology and Hepatology. All consecutive patients with SAH and 
MDF >32, without contraindications to corticosteroids were enrolled. All 
patients received 40 mg of Prednisone per day and response was assessed 
with LM4 and LM7, according to the validated cut-off (< 0.45 responder and 
>0.45 non responder).
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P0027 The frequency and IMPacT On MOrTaLITy Of 
InfecTIOns In acuTe aLcOhOLIc hePaTITIs
Foncea C.G., Popescu A., Belintan P., Moga T.V., Cotrau R., Sirli R., 
Danila M., Sporea I.
Victor Babes University of Medicine, Department of Gastroenterology and 
Hepatology, Timisoara, Romania
contact e-Mail address: foncea.camelia@gmail.com
Introduction: Acute alcoholic hepatitis is a cause of immune system dys-
function which increases the risk of infection, especially bacterial infections 
[1]. Infection screening in patients with acute alcoholic hepatitis is begin-
ning to be a strategy in order to identify every minimal infection and to 
start treatment as soon as possible. The aim of this study was to identify the 
frequency and impact of infections in a cohort of acute alcoholic patients.
aims & Methods: A retrospective cohort study was performed on a group 
of 79 patients with acute alcoholic hepatitis hospitalized from January 2015 
to March 2019 in a tertiary Department of Gastroenterology and Hepatol-
ogy. For this study we analyzed the frequency of infections occurring in 
these patients and their predominant location by performing hemocul-
tures, sputocultures, urocultures, chest R-ray and ascitic fluid examination. 
The severe form of acute alcoholic hepatitis was defined by a Maddrey`s 
discriminat function (MDF) score >32 [2] and response to corticosteroid 
therapy was assesd by Lille score after 7 days of treatment (LM7 < 0.45 
responders and >0.45 non-responders) [3].
results: Out of all the 79 patients with acute alcoholic hepatitis (10 female 
and 69 male, with a mean age 53±9.5 years), 40/79 (50.6%) had severe 
acute alcoholic hepatitis with a MDF score >32 and 32/79 (40.5%) had a 
bacterial infection. All patients had liver cirrhosis (LC), 25/32 (78%) Child 
Pugh C score. The most common infectious agent incriminated was Klebsi-
ella spp. 11/40 (27.5%) with pulmonary location.
In the MDF>32 group, 17/40 (42.5%) patients had infections, while in the 
MDF< 32 group 15/39 (38.5%) patients had infections (p=0.719), with no 
significant difference between the two groups. 
17/32 (53%) patients had MDF>32 and received corticosteroid therapy. 7/17 
(41.1%) were responders (LM7 < 0.45) and 10/17 (58.9%) non-responders 
(LM7 >0.45), with a total mortality rate of 41.1%, 2/17 (11.7%) from the re-
sponder group and 5/17 (29.4%) from the non-responder group (p=0.2083), 
with no significant difference in mortality between the two groups.
The overall mortality was 25.3%, significantly higher in the group with in-
fections, 19% as compared to the group without infections, 6.3% (p=0.016).
conclusion: Patients with acute alcoholic hepatitis have higher risk of in-
fections and the association of infections with LC generates higher mortal-
ity, regardless the response to corticosteroid therapy.
references: 1. Grand Rounds: Alcoholic Hepatitis J Hepatol. 2018 
Aug;69(2):534-543. doi: 10.1016/j.jhep.2018.05.001. Epub 2018 Jun 13. 2. 
Aspasia S. Soultati et al. Predicting utility of a model for end stage liver 
disease in alcoholic liver disease.World J Gastroenterol. 2006 Jul 7; 12(25): 
4020-4025. 3. Louvet A. et al. The Lille model: a new tool for therapeutic 
strategy in patients with severe alcoholic hepatitis treated with steroids. 
Hepatology. 2007 Jun;45(6):1348-54
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1Barts Health NHS Trust, Acute Medicine, London, United Kingdom, 2Barts 
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contact e-Mail address: fakhirah@gmail.com
Introduction: Immune checkpoint inhibitors (ICIs) are a new class of sys-
temic anti-cancer treatment which function by targeting the inhibitory 
mechanisms on the hosts’ immune system, inducing an immune-medi-
ated anti-tumour effect. ICIs have improved outcomes for a subset of pa-
tients with advanced cancer such as metastatic melanoma. However, im-
mune activation is not specific to cancer cells and often results in off-target 
immune-related adverse events. Hepatitis occurs in 5-10% of patients 
on single agents ipilimumab, nivolumab, and pembrolizumab therapy, 
and 25-30% of patients treated with ipilimumab/nivolumab combination 
therapy. We wanted to review baseline characteristics of patients with ICI 
induced transaminitis, and other causes associated other than treatment.
results: A total of 40 patients out of 79 (50.6%) with acute alcoholic hep-
atitis had MDF>32 and received corticosteroid therapy (5 female and 35 
male, mean age 51±9.2 years). All included patients had liver cirrhosis, 
28/40 (70%) had Child Pugh C score. The median value MDF was 59.35±30. 
The mean value for Lille score at 4 days was 0.65±0.31, vs 0.5±0.35 for Lille 
score at 7 days, p=0.041. There was no difference between the proportion 
of patients with a responder Lille score value at 4 days versus 7 days (35% 
vs 45%, p=0.36).
conclusion: LM4 could be used instead of LM7 in predicting the response 
to corticosteroids therapy in SAH to avoid a prolonged use of this therapy.
references: 1.Aspasia S. Soultati et al. Predicting utility of a model for end 
stage liver disease in alcoholic liver disease.World J Gastroenterol. 2006 
Jul 7; 12(25): 4020-4025. 2. Louvet A. et al. The Lille model: a new tool for 
therapeutic strategy in patients with severe alcoholic hepatitis treated with 
steroids. Hepatology. 2007 Jun;45(6):1348-54.
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P0026 cOMBInaTIOn Of gLycyrrhIzIn and n-aceTyLcysTeIne: 
BenefIT OuTcOMe In a MurIne MOdeL Of aceTaMInOPhen-
Induced LIver faILure
Minsart C.1,2, Rorive S.3,4, Quertinmont E.1, Lemmers A.1,2, Gustot T.1,2,5
1Université Libre de Bruxelles, Laboratory of Experimental Gastroenterology, 
Brussels, Belgium, 2ULB Erasme Hospital, Department of Gastroenterology, 
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Erasme Hospital, Department of Pathology, Brussels, Belgium, 4DIAPATH-
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Unit 1149, Paris, France
contact e-Mail address: charlotte.minsart@erasme.ulb.ac.be
Introduction: Acetaminophen overdose is the most frequent cause of drug-
induced liver failure in the developed countries. Despite substantial prog-
ress in the understanding of the mechanism of hepatocellular injury, N-
acetylcysteine remains the only effective treatment if administered within 
8 to 10 hours of ingestion of the overdose. Thus, other hepatoprotective 
drugs are needed for the delayed treatment of acetaminophen-induced 
hepatotoxicity. Glycyrrhizin, an aqueous extract of licorice root, is also 
known to have hepatoprotective effects.
aims & Methods: This study aimed to investigate the efficacy of the com-
bination of glycyrrhizin and N-acetylcysteine compared to N-acetylcysteine 
alone in the prevention of liver toxicity in a murine model of acetamin-
ophen-induced liver injury. Mice fasted for 15h were treated with acet-
aminophen (500mg/kg) by intraperitoneal injection and separated into 
following groups: glycyrrhizin (200mg/kg), N-acetylcysteine (150mg/kg) 
and glycyrrhizin/N-acetylcysteine. In all groups, mice were sacrificed 12h 
following acetaminophen administration. Hematological analyses, histo-
pathological parameters and survival rates were compared between vari-
ous groups.
results: Consistent with earlier data, intraperitoneal administration of ac-
etaminophen in mice induced a severe liver injury characterized by release 
of alanine aminotransferase and centrilobular hepatocyte necrosis. Treat-
ment with glycyrrhizin, N-acetylcysteine or N-acetylcysteine/glycyrrhizin 
combination, at the same time of acetaminophen, decreased significantly 
alanine aminotransferase levels and necrosis score. At this stage, the N-
acetylcysteine/glycyrrhizin combination was as effective as N-acetylcyste-
ine alone. Delayed administration, two hours or six hours after acetamino-
phen challenge, induced significant decrease of hepatocytes necrosis in 
group of mice treated with N-acetylcysteine/glycyrrhizin combination (p< 
0,01) compared to other groups. Furthermore, the administration of N-
acetylcysteine/glycyrrhizin combination was found to be associated with 
better survival rates. The results showed that treatment with N-acetylcyste-
ine/glycyrrhizin combination prevented significantly (p< 0,001) mice mor-
tality compared to N-acetylcysteine alone. Potential interference between 
N-acetylcysteine/glycyrrhizin treatment and acetaminophen metabolism, 
was evaluated and we have not demonstrated significantly differences be-
tween groups of mice.
conclusion: Compared with N-acetylcysteine given alone, concomitant 
administration of glycyrrhizin decreased the liver necrosis score and im-
proved the survival during acetaminophen-induced liver injury in mice. 
These results suggest for the first time that the combination of an antioxi-
dant like N-acetylcysteine and an anti-inflammatory drug like glycyrrhizin 
prevented the liver damage induced by acetaminophen intoxication.
disclosure: Nothing to disclose 
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aims & Methods: We carried out a prospective review of patients with 
metastatic melanoma on immune checkpoint inhibitors who developed 
transaminitis at our tertiary oncology centre between March 2018 and Feb-
ruary 2019. Data are analysed based on demographics, diagnosis, immu-
notherapy regime, factors that would cause transaminitis such as alcohol 
history, pre-existing liver disease, and known liver metastasis. Transami-
nase elevation is graded based on CTCAE (Common Terminology Criteria 
for Adverse Events): Grade 1 is ALT or AST rise up to 3 times the upper limit 
of normal (ULN), grade 2 is 3-5 times the ULN, grade 3 is 5-20 times the 
ULN, grade 4 is more than 20 times the ULN. Patient’s outcome is assessed 
by response to immunosuppressive treatment, length of immunotherapy 
treatment break, and immunotherapy discontinuation or change to next 
line of treatment.
results: Out of 89 patients treated with ICIs (22 on combination ipilim-
umab/nivolumab therapy and 67 on single agent therapy of ipilimumab 
or pembrolizumab), 16.9% (n=15) had a rise in ALT. Of these, 8/15 had 
ocular melanoma, 6/15 had cutaneous melanoma, 1/15 had mucosal mela-
noma. 66% (n=10) patients received combination treatment and the rest 
had single agent treatment. 9/15 patients had liver metastasis at baseline. 
3/15 had grade 1 transaminitis at presentation, 5/15 had grade 2, 7/15 had 
grade 3, and none presented with grade 4. The median time from first 
dose of ICI to ALT rise is 43 days (range 23-635). The majority of patients 
(8/15) developed transaminitis after 2 cycles of ICI. More patients on com-
bination treatment had an ALT rise compared to single agent (10/22 vs. 
5/62), which was statistically significant (p=0.0002). 
1/15 had newly diagnosed active hepatitis B on investigations (positive 
HepBsAg, anti-HBc and anti-HBe) after ALT rise. 9 patients underwent 
imaging of liver and 3 had contributing reasons for ALT rise, including 
hepatic steatosis (n=1), progressive liver disease (n=1) and portal vein 
thrombosis (n=1). 
7/15 were able to continue ICI therapy, with a median break of treatment of 
91 days. Patients with contributory reasons for ALT rise other than just ICI 
induced had a longer break off of treatment (115 days vs 78 days).
conclusion: We conclude that the % of patients within our Trust with hepa-
totoxicity from immune therapy is in line with published data. From this 
study we believe it is essential to review for other causes of ALT rise in 
patients treated with ICI, including hepatitis A, B, & C serology (essen-
tial prior to commencement of ICI), as well as liver imaging for the pres-
ence of liver metastasis, steatosis and portal vein thrombosis. Consistent 
with published literature, we find that patients on combination treatment 
were significantly more likely to develop ALT rise compared to single agent 
therapy (p=0.0002).
references: Haanen J., et al. Management of toxicities from immunothera-
py: ESMO Clinical Practice Guidelines for diagnosis treatment and follow-
up. Annals of Oncology, 2017;28((suppl_4)):p. iv119-iv142. National Cancer 
Institute, National Institutes of Health, U.S. Department of Health and Hu-
man Services. Common Terminology Criteria for Adverse Events (CTCAE) 
Version 4.0. [last accessed March 16, 2015];NIH publication # 09-7473. Pub-
lished May 29, 2009; Revised Version 4.03 June 14, 2010
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Introduction: The relationship between non-alcholic fatty liver disease 
(NAFLD) and erectile dysfunciton (ED) still is not clear. Pathogenesis of ED 
is multifactorial with a leading cause of endothelial dysfunction. Hyperten-
sion, obesity, diabetes, abnormal lipid profile are risk factors for sexual 
dysfunction and also they are components of metabolic syndrome. In this 
cross-sectional study we aimed to investigate the relationship between 
NAFLD and ED.
aims & Methods: We enrolled the male patients who were following up 
with NAFLD in our out-patient clinic. NAFLD diagnosis was established 
with imaging modalities such as ultrasound, computer tomography and 
magnetic resonance imaging and exclusion of other causes of hepatos-
teatosis. Sociodemographic, anthropometric and biochemical data were 
recorded for each patient. Index of Erectile Dysfunciton (IIEF) question-
naire fulfilled by each patients and score equal or under 21 accepted as in-
creased risk for ED and referred to the urology specialist. Each patient was 
examined by same urologist for further evaluation of the etiology of ED.
results: A total of 136 patients enrolled to the study. Mean age was 45.64 
± 11.55 years. One hundred and twenty patients (88.2%) were married, 13 
patients (9.6%) were single and 3 patients (2.2%) were divorced. Grade 1 
hepatosteatosis found in 41patients (30,1%), grade 2 hepatosteatosis was 
found in 65 patients (47,8%), grade 3 hepatosteatosis was found in 23 pa-
tients (16.9%) and grade 4 hepatosteatosis was found in 2 (1,5%) patients 
with USG. NAFLD diagnosis was established with MRI in 3 patients and 
with CT in 2 patients. Metabolic syndrome was seen in 48 patients (35.3%). 
Mean body mass index was 30.04 ± 5.27 kg/m², mean height was 172.48 
± 6.88 cm, mean weight was 89.95 ± 17.25 kg, mean waist circumference 
was 106.02 ± 13.40 cm and mean hip circumference was 106.27 ± 9.37 cm. 
IIEF point was below the cut-off score in 68 patients (50.0%) and these pa-
tients were referred to urologist for confirmation of ED and further investi-
gation of etiologies and treatment. Forty-eight patients were evaluated by 
the urologist and ED was not confirmed in only 5 patients. Psychogenic ED 
was found in 19 patients (39.6%), vasculogenic ED was found in 35 patients 
(72.9%), drug-related ED was found in 3 patients (6.3%) and neurogenic 
ED was found in 6 patients(12.5%). Seventeen patients had more than one 
etiology for ED at the same time, 29 (21.3 %) patients described premature 
ejaculation and 4 (2.9%) patients described loss of sexual desire. Medical 
treatment was prescribed to 36 patients (75 %) for ED.
conclusion: Erectile dysfunction may have a relation with NAFLD. IIEF 
questionnaire is a very practical and reliable screening tool for detection 
of ED. Presence of erectile dysfunction disrupts patient’s quality of life and 
may cause psychiatric disorders. Awareness of ED in NAFLD patients is 
important for the early diagnosis and treatment of patients.
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Introduction: Well-defined guidelines for the treatment of portal vein 
thrombosis (PVT) in patients with cirrhosis do not exist due to lack in 
robust data. Treatment options include low molecular weight heparin 
(LMWH), vitamin K antagonists (VKAs), and the newer oral anticoagulants 
(NOACs). Anticoagulation safety has been an issue in patients with cirrho-
sis, and the best choice of anticoagulation is unknown.
aims & Methods: We conducted a comprehensive search of multiple da-
tabases and conference proceedings (through November 2018) to identify 
studies that reported on the use of LMWH, VKAs, and NOACs in the treat-
ment of PVT in patients with cirrhosis. Goals were to evaluate the pooled 
rate of treatment success and bleeding with LMWH, VKAs, and NOACs, and 
compare the outcomes.
results: From a total of 744 patients (17 studies), 648 were treated with 
some form of anticoagulation and 96 were control. 155, 315, and 70 pa-
tients were treated with LMWH, VKAs, and NOACs respectively. Baseline 
characteristics were comparable among the groups. Age ranged from 41 to 
71 years with a predominantly male population. 144 patients were Childs 
A, 182 Childs B, and 121 Childs C.Pooled rate of treatment responders with 
anticoagulation was 66.7% (95% CI 58.3-74.1, I2=72.7) and with control was 
26% (95% CI 14.2-42.7, I2=36.7). The difference was statistically significant, 
p=0.001. Pooled rate of bleeding was similar between these two groups 
(7.8%, 95% CI 4.5-13.3 and 15.4%, 95% CI 4.3-42.7, p=0.33).Pooled rates of 
treatment success and bleeding events were comparable between LMWH, 
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failure (OR 4.7) CI (2 - 10.7), Early re- bleeding (OR 7120)CI(555 - 92583), 
Not taking NSBBS (OR .024)CI (0.004 - 0.220) , INR (OR 2.5 )CI (1.1 - 6.4 ), 
and CRP (OR 1.05 CI (1 - 1.012) as P- value for all< 0.05.
conclusion: Liver disease severity scores performed better than bleeding 
risk scores. 
I MELD score with cut off value ≥ 40.5 is most specific predictor for 6 weeks 
mortality after acute variceal bleeding. 
On Age, HCC, Renal failure, CRP and early re-bleeding are risk factors to 
predict six weeks mortality in variceal bleeding while taking NSBBs de-
crease mortality.
references: * Roayaie S et al. PALBI-An objective score based on platelets, 
albumin and bilirubin stratifies HCC patients undergoing resection and 
ablation better than Child’s classification, Hepatology 2015; 62: 624A. • 
Rockall TA et al. Risk assessment after acute upper gastrointestinal hemor-
rhage. Gut 1996; 38: 316-21. • Saltzman JR, et al. A simple risk score accu-
rately predicts in-hospital mortality, length stay, and cost in acute upper GI 
bleeding. Gastrointest Endosc. 2011;74:1215-1224 • Blatchford O et al. A risk 
score to predict need for treatment for upper gastrointestinal hemorrhage. 
Lancet 2000, 356: 1318-1321.
disclosure: Nothing to disclose 
P0032 hIgher-dOse Of LevOcarnITIne May cOnTrIBuTe 
TO an earLy reMIssIOn Of hyPeraMMOneMIa In PaTIenTs 
WITh LIver cIrrhOsIs
Moriya A.1, Kawaji H.1, Mashima S.1, Iwasaki Y.2, Ando M.1
1Mitoyo General Hospital, Dept. of Gastroenterology, Kanonji, Japan, 2Health 
Service Center, Okayama University, Okayama, Japan
contact e-Mail address: moriyaakio@gmail.com
Introduction: Patients with liver cirrhosis often develop carnitine deficien-
cy due to decreased intake from the diet and decreased biosynthesis in 
the body; and further, their carnitine pools in skeletal muscle are often 
reduced due to sarcopenia. Carnitine deficiency contributes to hyperam-
monemia and hepatic encephalopathy. Administration of levocarnitine ac-
tivates the urea cycle, promotes ammonia metabolism, and relieve hepatic 
encephalopathy; however, the optimum dose of levocarnitine in patients 
with liver cirrhosis has not been well established. We hypothesized that 
administration of higher-dose of levocarnitine might promptly fill up the 
carnitine pool in the body and lead to an early remission of hyperammo-
nemia and other symptoms in comparison to administration of lower-dose 
levocarnitine.
aims & Methods: We aimed to compare the effect on hyperammonemia by 
the dose of levocarnitine in Japanese patients with liver cirrhosis. Out of 
the 83 patients who received levocarnitine, we included 46 cases (29 men 
and 17 women; median age, 68 years old) those who had hyperammone-
mia (at or above 70 µg/dl) at baseline and had follow-up study of serum 
ammonia levels. We stratified the initial levocarnitine dose into < 1500 mg/
day (lower-dose group, n = 36) and 1500 mg/day or more (higher-dose 
group, n = 10). We performed a 2:1 matching according to the propensity 
score calculated from age, sex and ALBI score [1]. We compared them for 
the improvement of serum ammonia levels to below 70 µg/dl in 6 weeks, 
using Fisher’s exact test and the Cox proportional hazard model.
results: No adverse event related to levocarnitine administration was ob-
served. In 6 weeks from the start of levocarnitine administration, 17 cases 
(47%) in the lower-dose group and 6 cases (60%) in the higher-dose 
group improved serum ammonia levels to below 70 µg/dl. After matching, 
the median (interquartile range) of serum ammonia levels at baseline, 
ALBI score, and the initial levocarnitine dose were 134 (52) µg/dl, -1.3492 
(0.3528), and 750 (62) mg/day in the lower-dose group (n = 20) and 149 
(124) µg/dl, -1.3402 (0.4941), and 1750 (500) mg/day in the higher-dose 
group (n = 10), respectively. Remission of hyperammonemia in 6 weeks 
was observed more often in the higher-dose group than in the lower-
dose group, although the difference was not statistically significant (60% 
vs. 30%, P = 0.1391). The longitudinal analysis adjusted for the concomi-
tant medication (branched-chain amino acid, rifaximin, and zinc acetate) 
showed that the higher-dose group had a significantly earlier ammonia 
normalization than the lower-dose group (adjusted hazard ratio, 4.087; 
95% confidence interval, 1.169-12.289; P = 0.0275).
conclusion: Administration of levocarnitine 1500 mg/day or more signifi-
cantly remitted hyperammonemia compared with the lower dose. It may 
contribute to a rapid recovery from symptoms caused by carnitine defi-
ciency.
VKAs, and NOACs (Table-1). On meta-regression analysis, Child-Pugh clas-
sification did not seem to affect the treatment success and/ or the bleeding 
outcomes. The calculated 2-sided p-value of intercept was 0.39, Childs A 
was 0.15, Childs B was 0.11, and Childs C was 0.15.
(95% cI, I2) Treatment responders Bleeding
All anticoagulants 66.7% (58.3-74.1, 72.7) 7.8% (4.5-13.3, 66.2)
LMWH 60.7% (40.2-77.9, 57) 7.2% (4.5-16.6, 0)
VKA 66.0% (52.9-76.9, 80.7) 9.3% (3.8-20.6, 78.2)
NOAC 76.7% (44.6-93.4, 88.5) 7.9% (3.7-24.0, 30.3)
Control 26% (14.2-42.7, 36.7) 15.4% (4.3-42.7, 0)
p-value of statistical significance
All anticoagulants 
vs control
0.001 0.33
LMWH vs VKA 0.63 0.74
NOAC vs LMWH 0.35 0.86
NOAC vs VKA 0.5 0.9
LMWH: low molecular weight heparin, VKA: vitamin K antagonists, 
NOAC: novel oral anticoagulants
[Summary of pooled results]
conclusion: Our study demonstrates that anticoagulation is effective and 
safe in the treatment of PVT in patients with cirrhosis. Bleeding is not in-
creased in treatment group compared to control group. Due to their similar 
and comparable outcomes, NOACs may be offered as a first line treatment 
based on patient preferences. Limitations of our study were the compara-
tively small sample size of patients on NOACs, heterogeneity, and indirect 
comparison. Well-conducted studies are warranted to ascertian the role of 
NOACs in the treatment of PVT in patients with cirrhosis.
disclosure: Nothing to disclose 
P0031 MuLTIvarIaTe anaLysIs Of rIsk facTOrs fOr 
MOrTaLITy In acuTe varIceaL BLeedIng
Elfayoumy M.1, Mohammed El Tabbakh M.2, Badra G.2, Rewisha E.2, 
Waked I.2
1National Liver Institute, Hepatology and Gastroenterology, Menoufia, Egypt, 
2National Liver Institute-Menoufia University, Menoufia, Egypt
contact e-Mail address: elfayomymarwa@gmail.com
Introduction: Acute variceal bleeding in liver cirrhosis is an immediate life-
threatening condition and a major complication of portal hypertension.
aims & Methods: The aim of this study is to evaluate bleeding risk scores 
and other risk factors for predicting six-week mortality in patients with 
acute variceal bleeding.
We prospectively evaluated 703 consecutive patients admitted with endo-
scopically proven acute variceal hemorrhage (71.4% males, mean age 58 
± 10.3 years), 43% admitted with first attack of hematemesis, 14.1% Child-
Turcotte-Pugh (CTP) A, 47.2% CTP B, 38.7% CTP C, 38.3% had HCC. 
All patients received antibiotics and vasoactive drugs. Endoscopic treat-
ment was individualized. The outcome was the 6-week mortality. Bleeding 
was controlled in 422 patients (59.9%) and 210 patients died (29.8%), (122 
(17.4%) during hospitalization, 69 patients from causes not related to the 
acute hemorrhage (9.8%)). Rebleeding occurred in 281 patients (39.9%) 
after the first week. Disease severity scores (platelet-albumin-bilirubin (P-
ALBI), ALBI, MELD, IMELD, MELD-Na, and UMELD) and bleeding risk scores 
(GB score, admission Rockall, AIMS 65 and APASL score) were calculated 
on admission and the full Rockall score following endoscopy. Demograph-
ic, clinical and laboratory data and the calculated scores were compared 
between survivors and non-survivors.
results: Different bleeding risk scores were calculated and the significant 
were (the platelet-
albumin-bilirubin (P-ALBI), ALBI, MELD, IMELD, MELD-Na, UMELD with 
the best score I MELD with AUC 0.863);The AUC of different scores is shown 
in table (1).
Then Demographic, clinical and laboratory data were compared between 
survivors and non-survivors, Multivariate models showed that Age (age> 
60 years) (OR 2.6, CI (1.2 - 5.6), presence of HCC (OR 8.9) CI(3.1 - 26.1),Renal 
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references: [1] Johnson PJ, et al. Assessment of liver function in patients 
with hepatocellular carcinoma: a new evidence-based approach-the ALBI 
grade. J Clin Oncol. 2015;33:550-8.
disclosure: Nothing to disclose 
P0033 sarcOPenIa heLPs PredIcT The rIsk Of hePaTIc 
encePhaLOPaThy and TransPLanTaTIOn-free survIvaL 
afTer TransjuguLar InTrahePaTIc POrTOsysTeMIc shunT 
In cIrrhOsIs
Zhu Y.1, Luo X.1, Wang X.1, Yang J.2, Yan Y.3, Yang L.1
1Sichuan University West China Hospital, Department of Gastroenterology 
and Hepatology, Chengdu, China, 2West China Hospital of Sichuan University, 
Department of Gastroenterology, Chengdu, China, 3West China Hospital 
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Introduction: Hepatic encephalopathy (HE) remains one of the most com-
mon challenges after transjugular intrahepatic portosystemic shunt (TIPS). 
Sarcopenia was associated with clinical outcomes of patients with cirrho-
sis. This study was aimed to evaluate the association between preopera-
tive sarcopenia and the incidence of HE and liver transplantation (LT)-free 
survival after TIPS with covered stents.
aims & Methods: Preoperative CT images taken at the 3rd lumbar vertebra 
from 189 patients were quantified for definition of sarcopenia. Incidence of 
sarcopenia and post-TIPS HE, LT-free survival and the association between 
them were analyzed.
results: Sarcopenia was present in 74 (39.2%) patients. HE occurred in 
64 patients (33.9%) after a median time of 17.7 (IQR 4.5-28.8) months 
follow-up. Patients with sarcopenia had a significantly higher incidence 
of HE (p=0.009) and tended toward lower LT-free survival (p=0.082) than 
nonsarcopenic patients. The SSA score including sarcopenia (OR=1.776, 
p=0.024), sodium (OR=1.112, p=0.003) and age (OR=1.032, p=0.006) yielded 
a concordance statistic (C-statistic) of 0.714 for predicting overall HE. 
The BSA score including bilirubin (OR=1.025, p=0.014), sarcopenia 
(OR=2.495, p=0.025) and albumin (OR=1.186, p< 0.001) generated a higher 
C-statistic (0.770, 95% CI 0.689-0.850) than MELD (0.639, 95% CI 0.539-
0.739), MELDNa (0.685, 95% CI 0.583-0.787), MELD-sarcopenia (0.681, 95% 
CI 0.565-0.797) and MELD-L3SMI (0.644, 95% CI 0.538-0.750) for overall 
LT-free survival. The BSA score showed better discriminative performance 
in earlier months after TIPS. Both scores gave excellent C-statistics at 3-, 
6- and 12-month for corresponding outcomes.
conclusion: Preoperative sarcopenia independently increased incidence of 
HE and decreased LT-free survival after TIPS. Clinical scores including sar-
copenia provided excellent discriminative performances for predicting the 
risk of post-TIPS HE and LT-free survival.
disclosure: Nothing to disclose 
P0034 hOW TO IdenTIfy cIrrhOTIc PaTIenTs In need 
Of PaLLIaTIve care?
Leal T.1, Brites R.2, Fernandes D.1, Costa D.1, da Silva Mendes S.1, 
Caetano A.C.1, Arroja B.1, Gonçalves R.1
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Introduction: In end-stage liver disease, in order to select patients requir-
ing Palliative care (PC) the Poor Prognosis Screening Criteria for Inpatients 
with Cirrhosis (PPSCIC) were developed. The presence of 3 criteria (out of 
the following 5: Child-Pugh score C, more than two admissions within the 
last 6 months, ongoing alcohol use in the context of known alcohol-related 
liver disease, unsuitability for liver transplantation, World Health Organi-
zation Performance status 3 or 4) should prompt referral to PC.
aims & Methods: The aim of this study is the external validation of PPSCIC 
and its comparison to other prognostic scores, such as the Child-Pugh, 
UKELD and MELD-Na scores. Patients admitted to the Gastroenterology 
Department with liver cirrhosis, from July 2013 to December 2017 were re-
viewed. Those without previous diagnosis and with missing information 
were excluded. The PPSCIC, Child-Pugh, UKELD and MELD-Na at admis-
sion were assessed. 
The defined outcomes were mortality at 6 months and mortality at 12 
months. The area under the curve (AUC) of the different receiver operating 
characteristic (ROC) curves was calculated.
results: A total of 260 admissions were selected from 214 different pa-
tients. The majority of the admissions were of male patients (n=194; 
74.6%) and the mean age was 60.9±10.7 years. The median value for the 
Child-Pugh score was 10 (range 5-15), 19 (range 7-47) for MELD-Na and 55 
(range 43-77) for the UKELD score. Regarding PPSCIC, 75 (28.8%) patients 
had 1 criterion, 70 (26.9%) had 2 criteria, 50 (19.2%) presented with 3 
criteria and only 11 (4.2%) had 4 criteria. A total of 54 (20.8%) patients 
had no PPSCIC. The AUC for mortality at 6 months was 0.68 (95% CI: 0.61-
0.74, p< 0.001) for PPSCIC, 0.67 (95% CI: 0.60-0.74, p< 0.001) for Child-
Pugh, 0.74 (95% CI: 0.68-0.80, p< 0.001) for MELD-Na and 0.75 (95% CI: 
0.69-0.81, p< 0.001) for UKELD. The best cut-off point for PPSCIC was >1, 
presenting a sensitivity of 65.7% and specificity of 59.5%. The AUC for 
mortality at 12 months was 0.66 (95% CI: 0.59-0.72, p< 0.001) for PPSCIC, 
0.67 (95% CI: 0.60-0.73, p< 0.001) for Child-Pugh, 0.73 (95% CI: 0.67-0.79, 
p< 0.001) for MELD-Na and 0.74 (95% CI: 0.69-0.80, p< 0.001) for UKELD. 
The best cut-off point for PPSCIC was also >1, with a sensitivity of 61.7% 
and specificity of 59.3%.
conclusion: The performance of PPSCIC in predicting mortality at 6 months 
and mortality at 12 months as a surrogate for benefit in PC was modest. 
Moreover, the optimal cut-off identified (>1) was different from the previ-
ously reported (>2). In fact, other prognostic scores such as the UKELD 
or MELD-Na revealed a greater ability to predict mortality. Therefore, the 
PPSCIC does not seem to be a useful tool to select patients in need of PC 
in our population.
disclosure: Nothing to disclose 
P0035 effIcacy Of aTOrvasTaTIn PLus asa In cOMParIsOn 
WITh aTOrvasTaTIn aLOne On LIver funcTIOn and degree Of 
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a randOMIzed dOuBLe BLInd cLInIcaL TrIaL
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Introduction: To evaluate efficacy of combination of Aspirin and atorvas-
tatin in comparison with atorvastatin alone for improvement of liver fibro-
sis and function among cases of cryptogenic cirrhosis.
aims & Methods: In this randomized double blind clinical trail, 40 pa-
tients with cryptogenic liver cirrhosis randomly allocated to receive either 
atorvastatin plus ASA or atorvastatin alone for a six months period and 
compared for viewpoint of liver function and stiffness thereafter.
results: Overall 33 cases with cryptogenic cirrhosis included. After ran-
domization, 16 participants in group A and 17 in group B evaluated for 
final analysis. Average age of patients in group A & B were 50.3± 11.2 and 
47.9± 10.6 and average BMI of participants in 2 groups were 30.7± 4.2 and 
30.8± 3.1 respectively. 12 patients in group A (75%) and 14 cases in group 
B (82%) were male. The baseline demographic characters of 2 groups 
were similar. 
After 6 months of intervention, the decrease in average ALT level was 
not significant in group A (atorvastatin + ASA) while this item in group 
B (atorvastatin + placebo) was meaningful (P=0.009). Average Child 
score of participants in both groups improved significantly (P= 0.0001 & 
0.002 respectively) and also the liver stiffness measurement by Fibroscan 
proved a significant decrease (group A; P< 0.001 & group B; P=0.007) . 
Despite significant decrease in degree of liver stiffness and Child score, 
there was not any significant difference between 2 groups (P= 0.982 & 
0.611 respectively).
conclusion: While atorvastatin is efficacious in improvement of liver fibro-
sis and function among cryptogenic cirrhotics, adding aspirin is unable 
to potentiate its positive effects although this issue worth to further be 
clarified in future studies.
disclosure: Nothing to disclose 
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sorbent Assay (ELISA), the sensitivity of the assay was 6.25 IU/ml. Human 
active betatrophin was analyzed by ELISA technique, the sensitivity of the 
assay was 0.4 ng/ml.
results: Insulin resistance was observed in 70% of cirrhotic patients 
(HOMA-IR= 4 (IQR= 0.50 - 10); p= 0.005). Determinants of insulin resis-
tance were age (p= 0.572, OR= 1.02), cirrhosis (p= 0.019, OR= 4.58) and 
higher betatrophin level (p= 0.165, OR= 1.04). Subjects with IR had higher 
betatrophin level than subjects without IR with median level (IQR) of 17.75 
(10 - 23.75) vs. 8 (3.75 - 15) ng/ml, respectively, (p= 0.006). 
In the overall cohort, betatrophin level correlated with fasting blood sugar 
(r= 0.521; p <0.001), fasting insulin (r= 0.495; p <0.001) and HOMA-IR (r= 
0.405; p= 0.001). Betatrophin level was significantly higher in cirrhotic 
patients than controls [17.8 (8 - 30) vs. 8 (4 - 12) ng/ml, respectively, (p 
<0.001)]. Besides, Child-Pugh C patients had higher betatrophin level than 
Child-Pugh B patients [22.5 (13.25 - 40.25) vs. 15 (6.25 - 19.13) ng/ml, re-
spectively, (p= 0.035)]. 
Moreover, the highest level of betatrophin was detected in patients with 
severe ascites followed by moderate and mild ascites [35 (13.13 - 55.25) 
vs. 18.75 (15 - 25) vs. 13 (2.63 - 17.25) ng/ml, respectively, (p= 0.052)]. In 
the cirrhosis group, betatrophin level correlated positively with Child-Pugh 
classification (r= 0.381; p= 0.038), MELD score (r= 0.496; p= 0.005), INR (r= 
0.385, p= 0.035), and total bilirubin (r= 0.388, p= 0.034), and correlated 
negatively with platelets (r= -0.418, p= 0.022).
conclusion: Plasma betatrophin is increased in cirrhotic patients; in addi-
tion, this increase is correlated with disease severity, as well as the emer-
gence of insulin resistance.
disclosure: Nothing to disclose 
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Introduction: Acute on chronic liver failure (ACLF) is a clinical syndrome 
characterized by acute liver decompensation in patients with cirrhosis as-
sociated with at least one extrahepatic organ failure. This situation is fre-
quently encountered during hospitalizations for complicated cirrhosis by 
variceal bleeding.
aims & Methods: The aim of the study was to determine the prevalence and 
predictors factors of ACLF development in patients with variceal bleeding. 
A retrospective study was conducted collecting all cirrhotic patients admit-
ted to the hepatology unit for variceal bleeding over 2-years period. We 
excluded patients with hepatocellular carcinoma. The diagnosis of ACLF 
was defined according to the criteria of CANONIC study; Grade 1: Isolated 
kidney failure or isolated organ failure associated with renal dysfunction 
(creatinine ≥15mg and < 20mg) and/or hepatic encephalopathy grade 1 or 
2, or cerebral failure associated with renal dysfunction (creatinine ≥15mg 
and < 20mg); Grade 2: two organ failures; Grade 3: Three organ failures 
or more. In subgroup analysis, patients classified into 2 groups: with or 
without ACLF, were compared.
results: Overall sixty-nine cirrhotic patients hospitalized for variceal bleed-
ing were included with a sex ratio H/F=1.2. The mean age was 59 years old. 
The average stay at hospital was 15 days (extremes: 5-36 days). Causes of 
cirrhosis were: hepatitis C (43%), hepatitis B (23%), nonalcoholic steato-
hepatitis (15%) and primary biliary cholangitis (13%). 
Average evolution of the cirrhosis was 4 years (extremes: 6 months-10 
years). 44% of patients admitted for variceal bleeding developed ACLF. 
There was no difference of the demographics data between the two 
groups. In patients with ACLF, grade 1 was the most common (52.8%) fol-
lowed by Grade 2 (40.6%) and Grade 3 (2%). 
Bacterial infection was found in 65% of ACLF-reported patients: urinary 
tract infection (33%), Spontaneous bacterial peritonitis (26%), and pul-
monary infection (23%). Intra-hospital mortality was of 50.5% in patients 
P0036 resPOnse Of LIver and sPLeen sTIffness TO POrTaL 
Pressure LOWerIng drugs In a raT MOdeL Of cIrrhOsIs
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contact e-Mail address: elshaarawy.omar@stadtmission-hd.de
Introduction: Liver stiffness (LS) is increasingly used to screen for liver fi-
brosis, in addition, spleen stiffness (SS) is an established parameter to 
assess portal hypertension which is tightly related to the hemodynamics of 
blood flow and vascular resistance. Little is known about the response of 
LS and SS to vasoactive substances.
aims & Methods: We here studied LS and SS in an TAA-induced cirrhosis 
rat models after exposure to various vasoactive drugs using a miniaturized 
Fibroscan platform (µFibroscan). 
We induced cirrhosis in 47 wildtype 8 weeks old adult male Wistar rats 
with 200 mg/Kg dosage of Thioacetamide (TAA) through intraperitoneal 
injection of 50 mg/ml solution 2 times per week for 6 weeks. The six 
groups consisted of control (sodium chloride), metoprolol, udenafil, enal-
april, terlipressin and carvidelol. LS and SS were measured by µFibroscan 
(Echosens, Paris). The rats underwent general anesthesia with isoflurane 
inhalation. After anesthesia, abdominal aorta, inferior vena cava and por-
tal vein were cannulated with 24-gauge cannula and connected to Power 
lab device (AD instruments) to continuously measure the mean arterial 
pressure (MAP), heart rate (HR) and portal vein pressure (PVP). Drugs 
were injected systemically and data were collected at time points 0, 15 
and 30 mins.
results: LS and SS was significantly higher in TAA treated rats than in the 
control group (23.8 vs 3.8 kPa and 19.6 vs 47.8 kPa, P< 0.0001). In addition, 
they had significantly bigger and heavier spleens (6 vs 4 cm and 2.7 vs 1 
gm, P< 0.0001, respectively). In all drugs, LS and SS followed tightly the 
change of the portal vein pressure (r=0.681and 0.622, P< 0.01, respec-
tively). Also, SS was significantly correlated with spleen size and weight 
(r=0.723 and 0.663, respectively< 0.01). Noteworthy, a significant decrease 
of PVP ranging from 22% to 34% (P< 0.05) was seen after 15 to 30 minutes 
with metoprolol, udenafil, enalapril and carvedilol which was accompa-
nied with a significant decrease in LS and SS ranging from 18.2 to 44% (P< 
0.05). (see the Table) Interestingly, with terlipressin, LS and SS only slightly 
decreased which could be explained by counteracting PVP and MAP. Thus, 
while PVP decreased by 20% (P< 0.001), MAP increased by 35% (P< 0.001). 
Overall, carvedilol showed the best response regarding the decrease of 
PVP, LS and SS. Of note, the heart rate increased after metoprolol and 
udenafil injection (ca. 10%, P< 0.05), while it decreased in response to 
terlipressin and carvedilol by ca 30% (P< 0.01).
conclusion: LS and SS strongly correlates to PVP and responded differently 
to various vasoactive drugs. Combined non-invasive LS and SS measure-
ment could be useful to monitor the patient’s response and compliance to 
portal pressure lowering drugs.
disclosure: Nothing to disclose 
P0037 BeTaTrOPhIn seruM LeveL Is POsITIveLy cOrreLaTed 
WITh InsuLIn resIsTance and dIsease severITy In cIrrhOTIc 
PaTIenTs
Salama M., Abdelrahman G.
Ain Shams University, Faculty of Medicine, Internal Medicine Department, 
Cairo, Egypt
contact e-Mail address: drmmsalama@hotmail.com
Introduction: Insulin resistance (IR) is frequently associated with chronic 
liver disease. There has been an increase interest about betatrophin and 
its involvement in the compensatory response to insulin resistance.
aims & Methods: To investigate the correlation of betatrophin level with 
insulin resistance and disease severity in cirrhotic patients. Sixty candi-
dates were included and categorizes into two groups, cirrhosis group: 
thirty liver cirrhosis patients and control group: thirty healthy controls with 
matched age and sex. We excluded patients with any medical condition or 
receiving treatment affecting glucose metabolism. The severity of cirrho-
sis was classified according to Child Pugh classification and MELD score. 
Insulin resistance was assessed by the Homeostasis Model Assessment 
(HOMA-IR). Serum insulin was determined by Enzyme Linked Immuno-
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with ACLF grade 2 and 3. Independent predictors of ACLF were high MELD 
at admission (p = 0.04), bacterial infection (p < 0.001) and recurrent bleed-
ing (p = 0.06).
conclusion: In our study, ACLF affects almost half of hospitalized patients 
for variceal bleeding and is associated with a short-term mortality. High 
MELD at admission, bacterial infection and bleeding recurrence are pre-
dictive factors for the occurrence of ACLF.
disclosure: Nothing to disclose 
P0041 PrOLOnged draInage Increases cOMPLIcaTIOns 
Of Large vOLuMe ParacenTesIs In refracTOry ascITes
Lum J.H.M.1, Thurairajah P.1, Kumar R.1, Tan J.1, Teo E.K.1, Wong Y.J.2
1Changi General Hospital, Department of Gastroenterology & Hepatology, 
Singapore, Singapore, 2Changi General Hospital, Dept. of Gastroenterology 
and Hepatolgy, Singapore, Singapore
contact e-Mail address: johnathan.lum@mohh.com.sg
Introduction: Large volume paracentesis (LVP) is a common procedure 
for symptom relief among patients who have advanced cirrhosis with re-
fractory ascites. Prolonged ascitic drainage beyond 24 hours is frequently 
practised due to the concern of acute kidney injury (AKI) and circulatory 
dysfunction following LVP. 
While prolonged drain duration could lead to secondary bacterial perito-
nitis (SeBP), only limited data correlates the duration of ascitic drainage 
with the prevalence of SeBP.
aims & Methods: We aim to study the correlation between the duration of 
LVP and the prevalence of SeBP among cirrhotic patients with refractory 
ascites. All cirrhotic patients who underwent LVP in our institution from 
2014 to 2017 were studied. Patients diagnosed with primary spontaneous 
bacterial peritonitis were excluded. SeBP was diagnosed based on ascitic 
fluid analysis with neutrophil count >250 cells/mm3 or positive ascitic fluid 
culture following recent paracentesis within 7 days. 
Standard dose of albumin infusion was given during LVP as per EASL 
guidelines. Baseline data on patient demographic, duration and complica-
tions of LVP were collected. Cases were censored at death, liver transplant 
or last follow-up. Analyses were performed using chi-squared test and Cox-
regression models using SPSS 23.0.
results: A total of 131 patients underwent LVP were followed-up for 1806 
patients-month. The median age was 68.0 years and 86 (65.6%) were 
male. The median Model for End-Stage Liver Disease (MELD) score was 15; 
54.2% and 45.8% were Child-Pugh class B and C respectively. The median 
duration of ascitic drainage was 2 days. 
Overall prevalence of SeBP among these patients was 5.3%. Among pa-
tients with SeBP, 71.4% grew resistant organisms from ascitic fluid culture. 
Ascitic drainage beyond 24 hours significantly increased the prevalence 
of SeBP (0% vs 8.9%, p=0.026). Patients who developed SeBP had high-
er Child-Pugh scores (10.3±0.8 vs 9.5±1.2, p=0.027), higher MELD scores 
(17.1±1.8 vs 15.1±5.4, p=0.028), and lower serum albumin levels (22.1±3.89 
vs 25.9±5.46 g/L, p=0.044). 
When subgroup analysis was performed among patients with Child-Pugh 
scores of more than 9, drainage beyond 24 hours remained a significant 
predictor for SeBP (0% vs 17.9%, p=0.040). SeBP was also associated with 
higher risk of AKI following LVP (57.1% vs 16.1%, p=0.006) and longer in-
patient stay (39.0 vs 12.5 days, p=0.024). 
The 30-days readmission rate (p=0.508) and 6-month survival (p=0.327) 
were similar in patients with and without SeBP. The volume of ascitic fluid 
drained and the amount of intravenous albumin infusion given were not 
associated with AKI during LVP.
conclusion: Ascitic drainage beyond 24 hours increases the risk of SeBP. 
As SeBP is associated with resistant organisms, higher risk of renal im-
pairment and longer inpatient stay, ascitic drain removal within 24 hours 
should be considered especially among patients who have advanced cir-
rhosis with Child-Pugh scores of more than 9.
disclosure: Nothing to disclose 
P0042 carOTId arTery sTIffeness In LIver cIrrhOsIs 
PaTIenTs
Scarpellini E.1, Sanguigni S.2, Tiberi S.2, Svegliati Baroni G.3, Rasetti C.4, 
Paci C.2, Ragno M.2, Santori P.4
1TARGID, Leuven, Belgium, 2San Benedetto General Hospital, Neurology, 
San Benedetto del Tronto, Italy, 3Politechnic University of Marche, 
Gastroenterology, Ancona, Italy, 4San Benedetto General Hospital, Internal 
Medicine, San Benedetto del Tronto, Italy
contact e-Mail address: scarpidio@gmail.com
Introduction: Liver stiffness assessment is considered a valid biomarker 
of cirrhosis.Carotid artery stiffness (CAS) assessment is the new gold-
standard in cardiovascular and cerebral-vascular events risk-definition. In 
fact, it has replaced intima-media thickness measurement, not devoid of 
technical bias. 
In LC, Hepatic encephalopathy (HE) is a frequent complication of decom-
pensated liver cirrhosis (LC) of any cause and can overlap very often with 
Wernicke -Korsakoffsyndrome (WK), due to alcohol addiction.
aims & Methods: Thus, we aimed to verify whether CAS decompensation 
could correlate with LC staging and/or HE/WK. 
We consecutively enrolled LC patientsadmitted to the hepatology outpa-
tient clinicof the Internal Medicine Unit of San Benedetto del Tronto Gen-
eral Hospital.They underwent a full LC and anophthalmic artery (OA) and 
CAS study at the outpatient Neurosonologic Unit of our hospital.Presence 
of HE and/or WK was assessed by MOCA, Digit and Stroop tests by a dedi-
cated psychologist.
results: We consecutively enrolled 24 LC patients (20 with alcoholic 
abuse, 2 with HCV- and 2 with HBV-infection, 6 of metabolic origin; mean 
age 64.7±10.3 years,6 F, BMI 28.1±1.1 Kg/m2). Cirrhotic patients had sig-
nificantly higher CAS index values vs. healthy subjects (beta 9.91±3.0, EP 
128.45±39.30 kPa, AC 0.87±0.19mm2/kPa, AI 16.46±5.2%, PvW 6.62±1.16 m/
sec,all p<0.05). 
More in detail, beta positively correlated with BMI (r=0.63); AC positively 
correlated with Child (r=0.67) and with OA PI (r=0.58); pvW inversely cor-
related with Child (r=-0.61). CAS parameters did not significantly correlate 
with HE and/or WK presence/grading.
conclusion: This prospective single-center study showed for the first time 
the significant correlation between CAS derangement and LC staging, 
comorbiditiesand cerebral flow characteristics.These preliminary results 
suggest the possible use of CAS as biomarker for LC patients follow-up 
and management.
disclosure: Nothing to disclose 
P0043 cIrrhOTIc PaTIenTs: Is There any rOLe TO 
MaLnuTrITIOn In PredIcTIng MOrTaLITy?
Meixedo Arieira C.V.1,2,3, Dias de Castro F.1,2,3, Magalhães J.L.T.M.1,2,3, 
Marinho C.1,2,3, Berkeley Cotter J.1,2,3
1Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal, 
2Life and Health Sciences Research Institute (ICVS), School of Medicine, 
University of Minho, Braga/Guimarães, Portugal, 3ICVS/3B’s PT Government 
Associate Laboratory, Braga/Guimarães, Portugal
contact e-Mail address: catia_arieira@hotmail.com
Introduction: Protein-caloric malnutrition and sarcopenia are common 
conditions in liver cirrhosis and are associated with poor prognosis and 
decreased survival. 
However, it remains to be enlightened whether deficient nutritional status 
predicts mortality in liver cirrhosis.
aims & Methods: aim: To compare if the incorporation of sarcopenia into 
the Meld score (Meld-Psoas) may improve the prediction of mortality in 
liver cirrhosis when compared to Meld and Meld-Na scores.
Methods: retrospective study, included cirrhotic patients with computed 
abdominal tomography study between 2007 and 2017. Analytical param-
eters (creatinine, total bilirubin, INR and sodium) were analyzed and the 
transverse diameter of the right psoas muscle (TPMT) was determined at 
the cross-sectional level of L3-L4. The analytical parameters were collected 
within ± 7 days of the abdominal tomography. 
The Meld-Psoas score: ([0.2xMELD] - [0.08xTPMT / height] +2), MELD and 
MELD-Na were calculated. A descriptive analysis and a ROC curve was 
performed to compare the predictive capability of each score to predict 
mortality at 6 weeks, 3, 6 and 12 months.
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conclusion: Although SUS is a validated score including bowel wall thick-
ness and color Doppler parameters, in our population was not capable 
to predict with good accuracy endoscopic activity. CEUS is an emerging 
technique that must be considered routinely part of the entire sonographic 
evaluation in CD with good diagnostic accuracy for bowel inflammation.
disclosure: Nothing to disclose 
P0045 TargeTed vIsuaLIzaTIOn Of ceLL adhesIOn MOLecuLes 
In PaTIenTs WITh LIver cIrrhOsIs By MOLecuLar endOscOPIc 
IMagIng
Ahmed S.1, Chowdhury E.H.2, Galle P.R.3, Neumann H.4
1University Hospital Mainz, Interdisciplinary Endoscopy, Mainz, Germany, 
2Jeffrey Cheah School of Medicine and Health Sciences, Monash University 
Malaysia, Kualalampur, Malaysia, 3I. Medical Clinic and Polyclinic, University 
Hospital Mainz, Mainz, Germany, 4I. Medical Clinic and Polyclinic, University 
Hospital Mainz, Department of Interdisciplinary Endoscopy, Mainz, Germany
contact e-Mail address: shakil.ahmed@unimedizin-mainz.de
Introduction: The degeneration of intestinal barrier integrity plays a pivotal 
pathophysiological role in patients with liver cirrhosis leading to bacterial 
translocation and the development of complications including spontane-
ous bacterial peritonitis, hepatic encephalopathy, hepatorenal syndrome, 
progression of liver injury and hepatocellular carcinoma. Previous studies 
have shown the potential of molecular endoscopic imaging (MEI) for iden-
tification of disease specific molecular alterations in patients with chronic 
inflammatory bowel disease and colorectal polyps. To date, no data is 
available on the applicability of MEI for cirrhotic patients.
aims & Methods: To assess the diagnostic applicability of MEI for diagnosis 
of intestinal barrier function in patients with liver cirrhosis. Afterwards the 
results of compensated and decompensated patients and controls were 
compared. 
Patients with confirmed liver cirrhosis and control patients undergoing 
surveillance gastroscopy were recruited for the study. A total of 20 samples 
were obtained from duodenum of the enrolled patients. Specimen were 
first washed with PBS and then incubated with FITC labeled Claudin-1 and 
Connexin-43 antibodies. After washing in PBS to remove unbound anti-
body, MEI was performed using the probe-based confocal imaging system 
with a scan rate of 12 frames per second and a scanning field of 30,000 
pixels. Similar examinations were performed with specifically developed 
biodegradable and pH sensitive inorganic nanoparticles conjugated with 
FITC labeled antibodies. After MEI, specimens were fixed in 10% formalin 
and processed for immunohistochemical analysis.
results: Specific fluorescence signals were observed in all samples stud-
ied, including cirrhotic patients and controls. Claudin-1 and Conexin-43 
signals were highest in controls. Reduced expression was found in cir-
rhotic patients. Alterations were more apparent in decompensated pa-
tients compared to the compensated liver cirrhotic patients. Of note, MEI 
was achieved with both, traditional antibody staining and by means of 
nanoparticles.
conclusion: Molecular endoscopic imaging of cell adhesion molecules in 
patients with liver cirrhosis is feasible and showed reduced expression in 
decompensated patients. The data indicated that an impaired gut barrier 
function in patients with liver cirrhosis might be related to disease specific 
complications. 
Next studies should focus to assess the impact of pharmaceutical ther-
apies, like that of non-selective beta-blockers, on the intestinal barrier 
function. Moreover, MEI might help in developing new specific risk scores 
for cirrhotic patients.
disclosure: Nothing to disclose 
results: 78 patients were included, 76.2% male gender with mean age 
of 56.5±11.6 years. 89.7% of the patients presented alcoholic cirrhosis. 46 
patients (59%) presented ascites and 10 (12.8%) hepatic encephalopathy. 
Patients presented a median creatinine of 0.89 (0.4-3.89)mg/dl, a bilirubin 
of 1.6 (0.25-18.61) mg/dl, INR of 1.4 (0.9-3.3) and sodium of 138.0 (123-145) 
meq/l. Regarding the scores, they presented a median Meld of 13.0 (6-43), 
a Meld-Na+ of 14.0 (6-42) and Meld-Psoas of 3.1 (1.32-9.4). 
Meld-Psoas presented an AUROC of 0.90 (0.81-0.95, CI95%), 0.87 (0.77 
-0.93) and 0.86 (0.77- 0.93) and 0.87 (0.78-0.94) predicting mortality at 6 
weeks, 3, 6 and 12 months respectively. 
Meld presented an AUROC of 0.88 (0.79-0.94), 0.83 (0.73-0.91), 0.83 (0.73- 
0.91) and 0.84 (0.74-0.91) predicting mortality at 6 weeks, 3, 6 and 12 
months respectively. 
Meld Na+ presented an AUROC of 0.87 (0.78-0.94), 0.82 (0.72-0.90), 0.82 
(0.72-0.90), 0.84 (0.74-0.91) predicting mortality at 6 weeks, 3, 6 and 12 
months respectively.
Meld-Psoas of 0.71 predicts 6 week mortality with a sensitivity of 100% and 
a specificity of 71%.
conclusion: The incorporation of sarcopenia in Meld score (Meld-Psoas) 
presented an excellent accuracy in predicting mortality of cirrhotic pa-
tients, in particular 6 week mortality, superior than the observed in previ-
ous scores (Meld, Meld-Na+).
disclosure: Nothing to disclose 
P0044 MOnITOrIng InfLaMMaTOry acTIvITy In crOhn’s 
dIsease: sIMPLe uLTrasOnOgraPhIc scOre versus ceus WhIch 
One TO use?
Meixedo Arieira C.V.1,2,3, Monteiro S.1,2,3, Dias de Castro F.1,2,3, 
Magalhães J.L.T.M.1,2,3, Leite S.1,2,3, Moreira M.J.1,2,3, Berkeley Cotter J.1,2,3
1Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal, 
2Life and Health Sciences Research Institute (ICVS), School of Medicine, 
University of Minho, Braga/Guimarães, Portugal, 3ICVS/3B’s PT Government 
Associate Laboratory, Braga/Guimarães, Portugal
contact e-Mail address: catia_arieira@hotmail.com
Introduction: Gastrointestinal Ultrasound (GIUS) is increasingly being used 
in Crohn’s Disease (CD) as an essential tool in monitoring inflammatory 
activity, given its low cost and the absence of ionizing radiation exposure. 
In 2017 emerged a simple ultrasonographic score (SUS) that allows the 
accurate noninvasive assessment of inflammatory activity based on 2 pa-
rameters: bowel wall thickness (bwt) and color Doppler.
aims & Methods: The aim of this study was therefore to compare the accu-
racy of bowel GIUS with SUS versus Contrast Enhanced Ultrasound (CEUS) 
in predicting inflammatory activity in ileocolonoscopy. 
All CD patients underwent a conventional GIUS directed to terminal ileum 
followed by a CEUS using a microbubble contrast agent (SonoVue®). GIUS 
examinations were performed using a Hitachi HI VISION Avius®, employ-
ing a linear abdominal transducer. Qualitative and quantitative param-
eters from the sonographic analysis included maximum bowel wall thick-
ness (bwt), semi-quantitative analysis of vascularity pattern by Doppler 
GIUS and quantitative measurement of contrast bowel wall enhancement 
using CEUS (peak intensity). SUS was calculated according to the authors 
= (0.0563xbw1) + (2.0047xbtw2) + (3.0881xbwt3) + (1.0204xdoppler1) + 
(1.5460xdoppler2).
Disease activity was assessed by ileocolonoscopy (reference) and patients 
were graded as inactive (normal or mild disease) or active (moderate or 
severe inflammation).
results: Thirty known CD patients were included, 60% female with me-
dian age 33.5 (17-63) years. Regarding endoscopic disease severity, 14 
(46.7%) patients presented inactive disease and 16 (53.3%) patients were 
classified as active disease. 
Median bwt was 6.1 (3-13) mm and Doppler intensity was absent in 1 pa-
tient (3.3%), mild in 7 patients (23.3%) and moderate to severe in 22 pa-
tients (73.3%). Patients presented a median SUS of 5.1 (0.1-12.4) and was 
not different between patients with active or inactive disease (p=0.50) with 
a poor capability to predict endoscopic activity in ileoscopy (AUROC 0.6, 
95% CI 0.38-0.75).
Regarding CEUS, the median peak intensity was 10.9 (2.5-44) and was re-
lated with disease severity (p=0.005) with a good capability to predict en-
doscopic activity in ileoscopy (AUROC 0.8, 95% CI 0.61-0.92). We found that 
peak intensity of 7.8 is the optimal cut off point predicting active disease 
with a sensitivity of 87.5% and a specificity of 71.4%.
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P0046 hePaTITIs B screenIng PrIOr TO cheMOTheraPy In The 
MIddLe easT: a reTrOsPecTIve cOhOrT sTudy
Bizri A.R.1, Ziade N.2, Hosni M.2
1American University of Beirut Medical Center, Infectious Diseases, Beirut, 
Lebanon, 2American University of Beirut Medical Center, Gastroenterology 
and Hepatology, Beirut, Lebanon
contact e-Mail address: nz28@aub.edu.lb
Introduction: The global burden of hepatitis B virus (HBV) infection has 
been increasingly recognized, placing it among the 20 most common 
causes of mortality worldwide. Lebanon is considered to be of moderate 
endemicity. Acute infection in immunocompetent adults resolves spon-
taneously in the vast majority of cases. HBV DNA persists in all affected 
individuals, rendering them susceptible to reactivation in certain immu-
nosuppressive conditions. 
Reactivation can be asymptomatic or manifest as fatal fulminant hepatitis. 
Most international guidelines recommend HBV screening for patients an-
ticipated to receive immunosuppressive therapy.
aims & Methods: To determine screening rates and modalities of HBV 
screening in patients receiving chemotherapy at the American University of 
Beirut Medical Center (AUBMC), a leading tertiary care center in Lebanon 
and the Middle East, and compare it to the international recommenda-
tions. To establish local national guidelines for HBV screening in patients 
planned to receive chemotherapy. A retrospective cohort review of elec-
tronic medical records of all adult patients who received chemotherapeu-
tic agents on the hematology-oncology service at AUBMC between June 
2015 and June 2016 was performed. The information retrieved from the 
records included patient demographics, type of malignancy (solid organ 
or hematological), and if the patients underwent hematopoietic stem cell 
transplantation (HSCT) in case of hematological malignancies. The labora-
tory tests performed for HBV screening were reviewed and documented. 
Adequate screening was defined as performing all of the following tests: 
HBsAg, anti-HBs Abs, and anti-HBc Abs (total). Statistical analysis in-
cluded simple descriptive statistics (using % for categorical variables and 
mean for continuous variables).
results: A total of 1547 patients were initially screened. 277 were excluded 
from the study (221 were younger than 18, and 56 did not receive chemo-
therapy). Most of the patients were males (579 ,45.6%), and 691 (54.4%) 
were females with a mean age of 56 (range 18 to 96). The majority of the 
included patients had solid organ malignancies (888, 70%), and the rest 
(382, 30%) had hematologic malignancies, of whom 111 underwent HSCT. 
Of those included, 303 (24%) patients were screened by at least one test 
for HBV. 42 (3.3%) were adequately screened (7 in solid organ malignan-
cies, and 35 in hematologic malignancies, including 19 of HSCT patients); 
45 (3.5%) were tested only for HBsAg and anti-HBs Abs; 8 (0.6 %) for anti-
HBs Abs alone; 50 (3.9%) for HBsAg and anti-HBc Abs; and 158 (12.4%) 
for HBsAg alone. Of those tested, 25 patients were positive for at least one 
serological test. HBV DNA was performed on 20 of them.
screening 
test perfor-
med
none per-
formed
at least 1 
test per-
formed
hBsag 
only
anti-hBs 
abs only
hBsag 
and anti-
hBs abs
hBsag 
and anti-
hBc abs
hBsag, 
anti-hBsabs, 
anti-hBc abs 
(combination)
Hematologic 
malignancy 141 (36.9%)
241 
(63.1%)
123 
(32.2%) 3 (0.8%) 38 (9.9%)
42 
(11.0%) 35 (9.2%)
Solid malig-
nancy
826 
(93.0%) 62 (7.0%)
35 
(3.9%) 5 (0.6%) 7 (0.8%) 8 (0.9%) 7 (0.8%)
[Hepatitis B screening patterns among solid and hematologic malignancies; 
HBsAg: HBV surface antigen]
conclusion: Rates of screening for HBV prior to chemotherapy in a tertiary 
care center in the middle east are still low. When performed, screening 
was not always complete and adequate. Also, patients with hematologic 
malignancies were more likely to be screened. There is an urgent need 
to implement a better screening policy at AUBMC. Increased awareness 
among physicians is required and establishing a standardized protocol for 
pre-chemotherapy screening and management is needed at the institu-
tional and national levels.
disclosure: Nothing to disclose 
P0047 TreaTMenT OuTcOMes Of hePaTITIs c vIrus 
recOMBInanT fOrM 2k/1B WITh sOfOsBuvIr Based regIMens 
In geOrgIa
Zakalashvili M.1, Weizenegger M.2, Telia T.1, Metreveli S.1, Abramishvili N.1, 
Rtskhiladze I.1, Zarkua J.1, Gish R.3, Metreveli D.1
1Medical Center Mrcheveli, Hepatology-Gastroenterology Department, Tbilisi, 
Georgia, 2Medizinisches Versorgungszentrum Dr. Limbach & Kollegen, 
Heidelberg, Germany, 3Stanford University Medical Center, Division of 
Gastroenterology and Hepatology, Department of Medicine, Stanford, United 
States
contact e-Mail address: jabazarqua@gmail.com
Introduction: The estimated prevalence of hepatitis C virus (HCV) infection 
in the Republic of Georgia is one of the highest in the world. Interestingly, 
latest data suggest, that up to 20% of all genotypes (GT) in Georgia be-
long to the HCV intergenotypic recombinant form 2k/1b (RF_2k/1b), which 
appears to show the highest prevalence of this recombinant virus so far 
reported worldwide.
aims & Methods: The aim of our study was to define optimal treatment 
regimen for RF_2k/1b within hepatitis C virus elimination project in Geor-
gia.
We retrospectively analyzed the data of GT2 patients identified by INNO-
LiPA VERSANT HCV Genotype 2.0 in Medical Center Mrcheveli from May 
2015 to May 2016. Partial genome sequencing of core and NS5B regions 
was performed for identification of RF_2k/1b variants before treatment. All 
interferon eligible recombinants were treated with Sofosbuvir (SOF) plus 
Pegilated Interferon (PegINF) plus Ribavirin (RBV) for 12 weeks and inter-
feron ineligible patients with SOF/RBV 24 weeks. We compare SVR12 rates 
of RF_2k/1b to pure GT2 treated with SOF/RBV-12 or SOF/RBV-20 (depend-
ing on presence of cirrhosis). Also we performed regenotyping and par-
tial sequencing of core and NS5B region in randomly selected 20 samples 
from 95 GT2 (by INNO-LiPA VERSANT) treatment failures from other medi-
cal centers treated with SOF/RBV 12 or SOF/RBV 20 weeks.
From May 2016, after SOF/LDV became available, all RF1_2k/1b patients 
were treated with SOL/LDV+RBV for 12 weeks, irrespective of liver damage, 
like GT2 patients. Only RBV ineligible patients receiving RBV free regimen 
- SOF/LDV for 12 weeks, like GT1 patients.
results: A total number of 67 HCV GT2 samples by INNO-LiPA were ana-
lyzed, in which 43 (64%) RF_2k/1b were identified. Antiviral therapy in 23 
out of 24 GT2 patients with SOF/RBV for 12 or 20 weeks (depending on 
presence of cirrhosis) was initiated and SVR12 rates was achieved in 22/23 
(96%) patients. 36 out of 43 RF_2k/1b patients were treated with either 
SOF/PegINF/RBV for 12 weeks (n=24) or with SOF/RBV for 24 weeks (n=12) 
depending on interferon eligibility criteria. 23/24 (96%) patients achieved 
SVR 12 rates in interferon-containing group and 9/12 (75%) patients in 
group without interferon.
From unspecified genotype 2a/2c patients (n=446) who were treated with 
SOF/RBV for 12 or 20 weeks depending on presence of cirrhosis, 95/446 
(21%) relapsed. Partial genome sequencing of core and NS5B regions of 
20 randomly selected samples from 95 treatment failed patients was per-
formed. All samples were consistent to RF_ 2k/1b.
From May 2016 to May 2018, after introduction of SOF/LDV regimen, a total 
number of 336 RF1_2k/1b patients were treated. 30 (9%) of patients lost 
from follow-up. 
From total 306 patients, SVR12 were achieved in 303 patients (99%)
From 306 patients, in 294 patients, who were treated with SOF/LDV+RBV 
for 12 weeks, SVR rate were achieved in 292 (99%) patients.
From 306 patients, in 12 RBV ineligible patients, who were treated with 
SOF/LDV- 12 week, SVR rate were achieved in 11 (92%) patients.
conclusion: Our findings suggest that treatment of RF_2k/1b patients with 
SOF/PegINF/RBV for 12 weeks was more effective than with SOF/RBV for 
24 weeks (p = 0.061). 
Also we can conclude, that SVR12 rate was significantly higher in GT2 pa-
tients, confirmed by sequencing, treated with SOF/RBV 12 or 20 weeks than 
in unspecified GT2, who were treated with the same regimen (p < 0.05). 
Treatment of HCV RF_2k/1b with SOF/LDV regimen with or without RBV is 
as effactive as GT1 patients.
references: Zakalashvili M, Zarkua J, Weizenegger M, et al. Identification 
of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia. Liver Int. 
2018;38:451‐457 Messina JP, Humphreys I, Flaxman A et al. Global distri-
bution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 
61:77-87. Mitruka K, Ward JW, Averhoff F et al. Launch of a Nationwide Hep-
atitis C Elimination Program--Georgia, 2015 Jul 24;64(28):753-7. Kalinina 
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P0049 BaseLIne LIver sTeaTOsIs exceeds advanced 
fIBrOsIs as a PredIcTOr Of POOr OuTcOMe In chrOnIc 
hePaTITIs c PaTIenTs WITh susTaIned vIrOLOgIc resPOnse
Peleg N.1,2, Issachar A.3, Sneh-Arbib O.3, Cohen-Naftaly M.3, Braun M.3, 
Leshno M.4, Shlomai A.3
1Rabin Medical Center, Division of Gastroenterology and Hepatology, Petach 
Tikava, Israel, 2Tel Aviv University, Sackler School of Medicine, Tel Aviv, 
Israel, 3Rabin Medical Center, Liver Institute, Petach Tikva, Israel, 4Tel Aviv 
University, Tel Aviv, Israel
contact e-Mail address: p.peleg@gmail.com
Introduction: Sustained virological response (SVR) results in reduced in-
cidence of hepatocellular carcinoma (HCC) and mortality among chronic 
hepatitis C (CHC) patients with advanced fibrosis. Both advanced fibrosis 
and liver steatosis (LS) may coexist in CHC patients.
aims & Methods: The present study was design in order to evaluated the 
individual effects of LS and advanced fibrosis on a composite outcome of 
all-cause mortality and HCC in CHC patients with SVR following direct-
acting antivirals (DAA) treatment. In the study we retrospectively evaluated 
515 consecutive CHC patients who achieved SVR following treatment with 
DAA, with a mean follow up of 24 months. Baseline liver fibrosis was as-
sessed by transient elastography and LS was validated by at least 3 inde-
pendent ultrasonographic examinations.
results: 211 of 515 patients (41%) had baseline LS. The incidence rate of of 
HCC were 2.61 cases (95% C.I 2.47 - 2.85) of HCC per 100 person-years in 
all the cohort, and 5.23 cases (95% C.I 4.85 - 5.71) per 100 person-years in 
patients who had LS. In addition, patients with LS had a higher cumulative 
rates of all-cause mortality and HCC at 2 years of follow up compared to 
patients without LS (15.75% and 2.79%, respectively p < 0.001), although 
they did not have increased incidence of advanced fibrosis or cirrhosis. 
Consistently, multivariate analysis showed that LS was associated with a 
significant 7.5-fold increased risk of all-cause mortality and HCC (HR 7.51, 
95% C.I 3.61 - 13.36, p < 0.001) even upon adjustment to the components of 
the metabolic syndrome, whereas advanced fibrosis showed only a trend 
toward statistical significance (HR 2.32, 95% C.I 0.97 - 6.59, p = 0.06). 
Finally, when divided into four groups according to fibrosis and steatosis 
status at baseline, patients who had both LS and advanced fibrosis had 
the highest risk to develop the composite outcome (HR 17.56, 95% C.I 2.37 
- 75.11, p = 0.005) while the presence of LS without advanced fibrosis at 
baseline was also significantly associated with the composite outcome (HR 
9.21, 95% C.I 1.11 - 62.53, p = 0.030). Interestingly, the presence of ad-
vanced fibrosis without LS was not significantly associated with the com-
posite outcome of all cause mortality and HCC (HR 1.96, p = 0.538).
conclusion: LS is a major predictor of all-cause mortality and HCC in pa-
tients who achieved SVR following DAA treatment regardless of fibrosis 
stage. These patients should be rigorously screened for HCC.
disclosure: Nothing to disclose 
P0050 cOMParaTIve sTudy fOr reTreaTIng PaTIenTs WhO 
faILed TO PrIOr sOfOsBuvIr/ dacLaTasvIr regIMen: an OPen 
LaBeLed randOMIzed TrIaL
Mekky M.A.1, Abdel-Malek M.O.1, Abbas W.A.2, Osman H.A.3, Hetta H.F.4,5
1Assiut University Hospital, Tropical Medicine and Gastroenetrology, Assiut, 
Egypt, 2Assiut University Hospital, Department of Internal Medicine, Division 
of Digestive Diseases, Assiut, Egypt, 3South valley University, Tropical 
Medicine, Qena, Egypt, 4Assiut Univeristy, Microbiology and Immunology, 
Assiut, Egypt, 5University of Cincinnati College of Medicine, Department of 
Internal Medicine, Division of Digestive Diseases, Cincinnati, United States
contact e-Mail address: momar7619@gmail.com
Introduction: Treating HCV patients with NS5A-containg protocols such as 
sofosbuvir/ daclatasvir (SOF/DCV) regimens is still very effective. However, 
a minute number of patients may experience treatment failure. Retreating 
those patients is still challenging due to the possibility of NS5A resistance-
associated substitutions (RASs).
aims & Methods: To compare the results of re-treating those patients with 
2 different protocols.
Methods: From a total of 4585 patients treated with sofosbuvir/ daclatas-
vir± ribavirin regimen for 12 weeks, only 92 patients (2%) failed to achieve 
sustained virologic response at week 24 (SVR-24). Eighty patients were 
randomly re-treated either by Sofosbuvir(400mg)/Daclatasvir(60mg)/ 
O, Norder H, Mukomolov S et al. A natural intergenotypic recombinant of 
hepatitis C virus identified in St. Petersburg. J Virol 2002; 76(8):4034-4043. 
Hedskog C, Doehle B, Chodavarapu K et al. Characterization of hepati-
tis C virus intergenotypic recombinant strains and associated virological 
response to sofosbuvir/ribavirin. Hepatology 2015; 61(2):471-480. Susser 
S, Dietz J, Schlevogt B, et al. Origin, prevalence and response to therapy 
of hepatitis C virus genotype 2k/1b chimeras. J Hepatol. 2017; ttps://doi.
org/10.1016/j.jhep.2017.05.027 Zarkua J, Zakalashvili M, Metreveli D, Identi-
fication of recombinant strains in HCV genotype 1 and 3: Is it needed? Liver 
Int. 2018; DOI: 10.1111/liv.13729
disclosure: The authors report no conflicts of interest. 
P0048 safeTy and effIcacy Of a LOW MOnITOrIng 
TreaTMenT sTraTegy, WITh secOnd generaTIOn 
dIrecT-acTIng anTIvIraLs, In hcv MOnO InfecTed PaTIenTs 
WIThOuT cIrrhOsIs: a POrTuguese reaL LIfe cOhOrT
Figueiredo L.M., Carvalho R., Nuno Costa M., C Branco J., Amorim S., 
Beirão S., Alberto S., Martins A.
Hospital Prof. Doutor Fernando Fonseca, Department of Gastroenterology, 
Amadora, Portugal
contact e-Mail address: luisa_mmfigueiredo@hotmail.com
Introduction: The 2ndgeneration direct acting antivirals (DAAs) brought 
hope regarding elimination of chronic hepatitis C (CHC), as a global Pub-
lic Health issue. Further simplification of on treatment surveillance will 
save costs and help physicians in scaling up treatment, representing an 
improvement in the “cascade of care” framework. Real life data, about 
efficacy and safety of low monitoring strategies, is sparse and necessary.
aims & Methods: Prospective study with CHC patients, treated for the first 
time with DAAs, without ribavirine, between January 2017 and March 2018, 
without on treatment scheduled visits and laboratory monitoring. Exclu-
sion criteria were: fibrosis stage F4, hepatocellular carcinoma, HIV or HBV 
coinfection and ongoing additive substance abuse. The outpatient clinic 
had 1 consultant hepatologist, 3 gastroenterology assistants and 2 hepatol-
ogy nurses. 
All patients had a complete baseline medical and nurse evaluation. A di-
rect telephonic number for on demand nurse consultation was available. 
A medical visit, with laboratory and viral load evaluation, was scheduled 
12 weeks after the end of treatment.
results: 82 enrolled patients (63% male; 41-78 years); Genotype distribu-
tion: G1 - 38 (47% 1b), G3 - 23, G4 - 10 and G5 - 1. Treatment regimens were 
chosen according to EASL guidelines at the time: 65 were sofosbuvir based 
and 17 protease inhibitor based (29% pan genotypic).
Only one patient discontinued treatment (lost to follow up) and 4 forgot-
ten blood collection for RVS12, despite attending the medical visit. Minor 
adverse events were 0,02%, without any serious adverse events. 
None of the patients required on treatment medical visits. Sustained viro-
logical response (SVR12) was 94% (77/82) in intention to treat and 100% 
(77/77) in per protocol analysis.
conclusion: In this real life cohort cohort of “easy to treat patients”, a low 
monitoring treatment stategy, was safe and achieved high adherence and 
efficacy, without virologic failures. These results support the adoption of 
simplified treatment surveillance protocols, whenever possible, as a cost-
effective tool in the achievement of CHC elimination goals.
references: 1- Shahid I, AlMalki WH, Hassan S et al Real-world challeng-
es for hepatitis C virus medications: a critical overview. Crit Rev Micro-
biol. 2018 Mar;44(2):143-160 2- VanOpdorp JR, Ferrentino N, Strader DB, et 
al Utility of laboratory monitoring during hepatitis C treatment with riba-
virin-free direct acting antiviral regimens. J Viral Hepat. 2019 doi: 10.1111/
jvh.13083. 3- Marco VD, Alberti A, Angarano G et al Optimising manage-
ment of patients with hepatitis C virus in the age of direct-acting antivirals: 
results of a Delphi consensus Eur Rev Med Pharmacol Sci 2018; 22 (20): 
7024-7033. 4- Kapadia SN, Marks KM Hepatitis C Management Simplifi-
cation From Test to Cure: A Framework for Primary Care Providers. Clin 
Ther. 2018 Aug;40(8):1234-1245. 5- EASL Recommendations on Treatment 
of Hepatitis C 2018 Journal of Hepatology 2018 vol. 69 j 461-511
disclosure: Nothing to disclose 
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Simeprevir(150mg)/Ribavirin (SIM-group, n=40) versus Sofosbuvir(400mg) 
/Ombitasvir(25mg)/ Paritaprevir(150mg) /Ritonavir(100mg) /Ribavirin 
(OPr-group, n=40) for 12 weeks. All recruited patients were compensated 
cirrhosis. Patients with decompansated liver, HBV co-infection and hepa-
tocellular carcinoma (HCC) were excluded. The mean duration for re-start 
new treatment was 12±3 weeks.
results: In SIM-group, SVR-24 was 92.5% (n=37) and 3 patients failed to 
achieve SVR. In OPr-group, SVR24 was 90% (n=36) and 4 patients failed. 
All failed-to-treat patients were males, F3/F4 fibrosis score, and diabetic. 
No major adverse events were reported.
conclusion: Re-treating patients with previous NS5A failure is possible and 
safe with satisfactory results.
references: ClinicalTrials.gov ID: NCT03549832
disclosure: Nothing to disclose 
P0051 PredIcTOrs Of deTecTIOn Of hBv In PBMcs aMOng 
naIve PaTIenTs WITh seruM hBv-dna negaTIvITy
Meshaal A.K.1, Osman H.A.2, Hetta H.F.3,4, Mekky M.A.5
1Assiut Al-Azhar University, Microbiology Department, Faculty of Science, 
Assiut, Egypt, 2South Valley University, Tropical Medicine, Qena, Egypt, 
3University of Cincinnati College of Medicine, Department of Internal 
Medicine, Division of Digestive Diseases, Cincinnati, United States, 4Assiut 
University, Microbiology and Immunology, Assiut, Egypt, 5Assiut University 
Hospital, Tropical Medicine and Gastroenetrology, Assiut, Egypt
contact e-Mail address: doc_mekky0000@yahoo.com
Introduction: Studies tackled the extra-hepatic reservoir of hepatitis B vi-
rus (HBV), especially in those with negative peripheral viremia, are still 
scarce.
aims & Methods: Therefore, we aimed to investigate the presence of HBV 
DNA in peripheral blood mononuclear cells (PBMCs) and evaluate different 
factors affecting this. 
Patients and methods: Between January 2018 and December 2018, a cross-
sectional study was designed to include all consecutive patients with 
proven CHB. From these cases, naive patients (without previous treatment) 
with persistently negative HBV viremia were selected. HBV DNA was tested 
in PBMCs All cases were tested also for anti-HBc-Ab, HBe-Ag, HBe-Ab and 
HCV-Ab, and quantitative HBs-Ag (qHBs-Ag). Assessment of hepatic stiff-
ness score measurements was done by Fibroscan.
results: A total of 1650 naive CHB patients were recruited. Out of them, 
320 (19.4%) patients (75% were male [n=240], mean age was (38.4 ±12.8 
years) have a persistently negative serum real-time PCR for HBV-DNA 
without previous treatment experience. More than half of them (n=170, 
53.1%) exhibited positive HBV-DNA in PBMCs. The mean Log10 of quan-
titative HBV-DNA by PCR in PBMCs was 5.1±0.3 IU/ML. HCV co-infection 
was found in 30 patients (17.6%). Most of them had insignificant fibrosis 
scores (less than F2). The multivariate Logistic regression analysis for pre-
diction of presence of detectable HBV-positive viremia in PBMCs yielded 
the following risk factors (OR): The presence of HBV anti-core (OR =37.2), 
presence of HCV-RNA (OR =1.7) and RNA (OR =1.7) and a log
10
 of qHBs-Ag 
more than 3 (OR =1.1).
conclusion: A considerable number of patients with negative plasma HBV 
DNA are still harboring subtle form of virus within remote extra-hepatic 
compartments. So, dual testing for both plasma and PBMCs is mandatory 
especially in epidemiologic studies.
disclosure: Nothing to disclose 
P0052 Off TraIL TreaTMenT Of héPaTITIs c WITh heMOdIaLyIs 
PaTIenTs, resuLTs Of an aLgerIan cOhOrT
Haouam M.A.1, Boumendjel M.1, Hammada T.2
1CHU Constantine, Hépato-gastro-Entérologie, Constantine, Algeria, 2CHU 
Constantine, Constantine, Algeria
contact e-Mail address: m.a_haouam@hotmail.com
Introduction: There is a constant growth in the number of hemodialysis 
patients in our country with a prevalence of 23,8% of infection with hepa-
titis C1, unfortunatly there is no adapted treatment for this population in 
Algeria; With the risk of contamination that increases with time2 and the 
complication that goes with it, we had to treat our patients with the anti-
viral therapy in our disposal.
aims & Methods: Highlight the difficulties associated with the manage-
ment of hemodialysis patients with viral hepatitis C (VHC), particularly with 
the unavailability of adapted drugs in some countries like Algeria. 
Prove the effectiveness of current therapies outside consensual indications.
A prospective descriptive study, including all patients treated for (VHC) on 
dialysis over a period of one year (January 2017-January 2018).
29 patients were treated, all included in our study.
The treatment was: Sofosbuvir 400mg / Ledipasvir 90mg +/- Ribaverine 
for 12 or 24 weeks.
The treatment was taken after each dialysis.
All patients received a complete clinical examination, a biological assess-
ment with genotype identification and an assessment of liver fibrosis (fi-
broscan / fibrotest).
Regular monitoring every 4 weeks with assessment of tolerance, compli-
ance, transaminases and blood count was performed.
A viral load was requested in pre-therapeutic, end of treatment and 12 
weeks after the end of treatment.
results: Total number of patients was 29, of whom 28 were naive to any 
treatment.
The mean age was 46 ± 20 years, with a sex ratio of close to 1
Average viral load of 500 * 10³ / ml (4.7Log)
We had to treat 7 cirrhotic patients, 5 patients had a treatment duration 
of 24 weeks (hemoglobin < 10g / dl); the remaining two were treated in 
combination with Ribaverine for 12 weeks.
Genotype 1b was found in 100% of patients.
We had 96% sustained viral response (SVR)
Only one patient had a positive viral load at week 12 (naïve non-cirrhotic 
patient). 
28% of patients complained of headache, asthenia and only one case of 
severe anxiety was reported.
100% of the group treated with Ribaverine benefited from an optimization 
of Erythropietine injections.
No patient had to stop the treatment.
conclusion: The renal clearance of Sofosbuvir makes it difficult to handle 
in patients with IRCT, however our study shows that with close and strict 
monitoring we get a sustained viral response in more than 95% of patients 
with no significant side effects, however more exhaustive studies, with 
dosage of active metabolites should be conducted to support our results.
references: (1) : National Algerian survey MSRH-IPA2008 on 7502 samples 
(2) : High Prevalence of Infection in Dialysis and Multi-Transfused Patients 
Involving Diverse and Novel Virus VariantsAug 2012
disclosure: Nothing to disclose 
P0053 assOcIaTIOn Of geneTIc POLyMOrPhIsM Of TOLL LIke 
recePTOrs2( TLr2) and (TLr4) WITh suscePTIBILITy TO hcv 
InfecTIOn, resPOnse TO TreaTMenT and PrOgressIOn TO 
hePaTOceLLuLar carcInOMa In cIrrhOTIc PaTIenTs
El-Bendary M.1, Neamatallah M.2, Elalfy H.3, Besheer T.4, 
Abd El-Maksoud M.4, Elhammady D.4, Abed S.4, Elegezy M.4, Kandeel L.5, 
Eldeib D.4, Mousa N.4, Abd El-Hafeez M.4, El-Gilany A.-H.4, Esmat G.6
1Mansoura Faculty of Medicine-Mansoura University, Tropical Medicine and 
Hepatology, Mansoura, Egypt, 2Mansoura Faculty of Medicine-Mansoura 
University, Medical Biochemistry, Mansoura, Egypt, 3Mansoura University, 
Endemic Medicine and Hepatlogy, Mansoura, Egypt, 4Mansoura Faculty of 
Medicine-Mansoura University, Mansoura, Egypt, 5Shrbeen Fever Hospital-
Ministry of Health, Mansoura, Egypt, 6Cairo University, Cairo, Egypt
contact e-Mail address: mmelbendary@gmail.com
Introduction: Chronic hepatitis C virus (HCV) infection is a major cause of 
chronic liver disease, leading to progressive hepatic fibrosis with long-
term progression to cirrhosis and hepatocellular carcinoma (HCC). 
HCV has different effects on TLR pathway stimulation which enhances 
proinflammatory cytokine production leading to liver damage and viral 
persistence by evasion of the immune response . Lipopeptide complexes of 
the HCV core protein were found to stimulate the innate immune response 
via TLR2 and TLR4. Many studies have shown that genetic variation in TLRs 
may affect susceptibility to infections.
aims & Methods: In the current study 9 of single-nucleotide polymor-
phisms (SNPs) and haplotypes of SNPs in TLR 2 and TLR4 were investi-
gated to clarify their association with clinical outcome of hepatitis C, re-
sponse to treatment, progression to cirrhosis and development of HCC. In 
this study a total of 3295 individuals from 725 families were recruited and 
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conclusion: Successful eradication of HCV results in significant LSM im-
provement; the best improvement occurs in F2 patients. But as the major-
ity of cirrhotics are still at risk for liver decompensation and hepatocellular 
carcinoma development despite achieving SVR-12, early detection and 
treatment are highly recommended.
disclosure: Nothing to disclose 
P0055 sIMPLe scOre fOr PredIcTOrs Of hePaTOceLLuLar 
carcInOMa Occurrence afTer hePaTITIs c vIrus eradIcaTIOn 
By dIrecT-acTIng anTIvIraL TreaTMenT
Tani J.1, Morishita A.1, Moriya A.2, Ogawa C.3, Deguchi A.4, Takaguchi K.5, 
Masaki T.1, Kagawa Liver Disease Study
1Faculty of Medicine, Kagawa University, Dept. of Gastroenterology 
and Neurology, Miki-cho, Japan, 2Mitoyo General Hospital, Dept. of 
Gastroenterology, Kanonji, Japan, 3Takamatsu Red Cross Hospital, Dept. 
of Gastroenterology and Hepatology, Takamatsu, Japan, 4Kagawa Rosai 
Hospital, Division of Gastroenterology, Marugame-shi, Japan, 5Kagawa 
Prefectual Central Hospital, Hepatology, Takamatsu, Japan
contact e-Mail address: georget@med.kagawa-u.ac.jp
Introduction: Hepatitis C virus (HCV) infection is a high risk factor related to 
liver cirrhosis (LC) and the occurrence of hepatocellular carcinoma (HCC). 
Interferon (IFN) / Ribavirin (RBV) combination treatment for hepatitis C 
was performed as a standard treatment, but the cure rate remains poor. 
n recent years, Direct Acting Antivirals (DAA) has been developed against 
HCV infection, and currently the IFN-free DAA treatment dramatically im-
proves the cure rate to more than 90% and is also safe to use for patients 
with HCV. Patients with HCV treated with DAA still exhibited the occurrence 
of HCC. Therefore, the aim of this study is to identify predictors of hepato-
cellular carcinoma occurrence after DAA treatment.
aims & Methods: The remaining task is to predict the risk of HCC in infected 
patients with HCV after obtaining SVR with IFN-free DAA treatment. The 
patient grouping with high risk of HCC need closed surveillance program. 
Therefore, to establish a simple scoring system using general clinical data 
to predict the risk of HCC after 12 week SVR (SVR 12) following DAA treat-
ment, we evaluated the clinical features of patients who acquired SVR12 
by DAA administration retrospectively.Of 1454 HCV-infected patients from 
September 2014 to November 2018, we enrolled 1088 who achieved sus-
tained virologic response (SVR) and had no history of HCC treatment. We 
analyzed the incidence of HCC and predictors contributing to HCC occur-
rence after DAA treatment using patient background and blood tests be-
fore and after DAA treatment.
results: During this study, HCC developed in 26 cases. The incidence of 
HCC was 0.61 %, 1.88 %, 2.82 %, and 3.71 % at 0.5,1, 1.5 and 2 years at the 
end of DAA treatment respectively. Multivariate analysis identified Male 
gender (HR=1.1902; 95% CI 1.0155- 1.3946; P=0.0316) and AFP at the start 
(HR=1.0023; 95% CI 1.0002 - 1. 0049; P=0.0330) as independent factors 
that contributed to HCC occurrence after DAA treatment. The cut-off value 
of AFP at the start of DAA treatment was set as 6.0 ng/mL, based on the 
ROC value for developing HCC based on the serum AFP level at the start of 
DAA treatment noted in the original set (sensitivity 0.8400 and specificity 
0.6315, area under the curve 0.743). Using these factor, our novel scoring 
system (0 to 2 points) was developed. The incidence of HCC at 2 year was 
0.52% in 0 points group, 2.37% in 1 points group and 11.77% in 2 points 
group.
conclusion: Male gender and AFP ≥6 at the start of DAA treatment were 
the independent predictors for developing HCC after DAA treatment. For 
patients with these risk factors, we consider that our novel score of this 
study is very simple to perform before DAA treatment.
disclosure: Nothing to disclose 
categorized as Chronic HCV (CHC) , Spontaneous virus clearance (SVC) and 
control groups . The treated patients were classified into responders (RST) 
and non responders (NRST) .In addition to patients with liver cirrhotic(LC) 
and Hepatocellular carcinoma(HCC) were also included. All subjects were 
genotyped for 5 snips of TLR 2 and 4 snips of TLR4 and their haplotypes 
using allelic discrimination real-time PCR.
results: The carriage of minor alleles in different TLR 2 SNPs is associated 
with HCV chronicity compared to sponatenous clearance (SVC)group.The 
peak of association was observed with the A allele of rs13105517 s. 
The peak of risk of HCC was observed with allele C of rs3804099 (<0.0001). 
A strong association was also detected for the carriage of T allel of 
rs1816702 and the allele A of both rs13105517 and rs1898830 (P<0.008, 
0.00001, and 0.0002 respectively). 
Finally, a strong association was found with allele T of rs1816702 and allele 
C of rs3804099 in non-responder compared to that of responder group 
(P<0.0001 and 0.0029 respectively). 
As regard TLR4 the peak of risk of chronicity was observed with the C allele 
of rs10116253 in addition to a strong association of allele A of rs5030728 
and allele G of rs4986790 in CHC compared to that of SVC group( p<0.0001, 
<0.0001 and 0.0022) respectively. However no association with T allel of 
rs4986791 . The carriage of minor alleles of three SNPs of TLR4 was associ-
ated with HCC compared to that of cirrhotic group. The peak of risk with 
C allele of rs10116253 while a strong association was observed for allele A 
of rs5030728 and allele T of rs4986791 in HCC group compared to that of 
LC group( p< 0.001) . The carriage of rare allele of different SNPs of TLR4 
was significantly higher in non-responder group compared to that of re-
sponder group (p<0.0001) with peak at allele A of rs5030728. 
A signification association of haplotype CAGT of TLR4 and ATAC of TLR2 
with CH and HCC groups in comparison to others.
conclusion: There is an association of minor alleles of TLR2 and TLR4 with 
outcome of HCV infection, response to therapy and development of HCC in 
cirrhotic patients ,especially the allele A of rs13105517 and allele C of TLR4 
rs10116253 are strongly associated with HCV chronicity and development 
of HCC.
disclosure: This research was funded by Science and Technology Devel-
opment Foundation (STDF), Project NO. 1784 (TC/2/Health/2009/hep-1.3.) 
P0054 effecT Of dIrecT acTIng anTIvIraL TheraPy 
fOr hePaTITIs c- InfecTed PaTIenTs On changes In The 
ParaMeTers Of LIver fIBrOsIs PrOgressIOn
Rofaeil B., Elfeki M. Abdelfattah, Kamel M. Farid
Beni Suef Specialized Hospital, Gastroenterology and Hepatology, Beni Suef, 
Egypt
contact e-Mail address: beshokemo@yahoo.com
Introduction: Liver fibrosis is the most important prognostic factor in chron-
ic hepatitis C virus (HCV) patients, and Egypt shows the highest worldwide 
HCV prevalence. Recently, direct acting antivirals (DAAs),medicines with 
direct activity against HCV, were introduced for treatment of HCV with very 
favorable results regarding viral cure, but liver fibrosis is still an unre-
solved problem. Our study was done to assess to what degree viral cure 
results in regression of liver fibrosis
aims & Methods: The aim of this study was to investigate the degree of 
liver stiffness measurement (LSM) improvement after successful HCV 
eradication.This study included 100 chronic HCV Egyptian patients, and 
was conducted at The Egyptian Liver Foundation-Beni Suef, from August 
1, 2017 till February 1, 2018. LSM was obtained by FibroScan® before start-
ing direct acting antiviral (DAA) treatment, after the end of 12 weeks of 
treatment, and after achieving sustained virological response-12 (SVR-12). 
Based on baseline LSM, patients were stratified into F2, F3 and F4 groups 
(METAVIR), as F0-F1 patients were excluded. LSM and laboratory data after 
the end of treatment and after achieving SVR-12 was compared with that 
before starting therapy in each fibrosis group, p-value =0.050 was statisti-
cally significant.
results: Following DAA treatment, 100 patients achieved SVR-12. Mean 
baseline LSM dropped from 13.5 to 10.1 kPa post-SVR12; the maximum 
change occurred in F2 patients 84.3% versus 84.2%, 43.3% in F3, and F4 
patients respectively (p< 0.001). At baseline, 30 patients were in the F4 
group; only 11 (43.3%) regressed to non-cirrhotic range (< 12.5 kPa), while 
19 (56.7%) were still cirrhotic despite achieving SVR-12 (p< 0.001). Patients 
showed significant improvement in Platelets count and decreased ALT lev-
els after achieving SVR (p< 0.001).
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P0056 safeTy and effIcacy Of The use Of generIc 
sOfOsBuvIr and dacLaTasvIr In The TreaTMenT Of naïve 
chrOnIc hePaTITIs c In hIv/hcv genOTyPe 4 cO-InfecTed 
PaTIenTs: an egyPTIan reaL- LIfe exPerIence
Cordie A.1, Kamal W.2, Elsharkawy A.1, Abdel Alem S.1, Mashaal S.3, 
Abdellatif Z.1, Kamel S.4, Abdel Aziz H.5, Kandeel A.2, Esmat G.1
1Cairo University Hospitals, Endemic Hepatogastroenterology and Infectious 
Diseases Department, Cairo, Egypt, 2Ministry of Health and Population, 
Preventive Sector, Cairo, Egypt, 3Cairo University Hospitals, Clinical Pathology 
Department, Cairo, Egypt, 4Ministry of Health and Population, Imbaba Fever 
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Introduction: HIV and HCV co-infection is associated with an increased risk 
of poor health outcomes, mostly due to the negative effects of HIV infection 
on the natural history of HCV. HIV infection is associated with higher rates 
of HCV replication and therefore higher risk of development of liver fibro-
sis, decompensated cirrhosis and hepatocellular carcinoma. In Egypt, ac-
cording to several clinical trials and real-life data, the use of utterly generic 
sofosbuvir and daclatasvir combination with or without generic ribavirin 
was well tolerated and associated with high response rate in genotype 4 
(GT4) HCV mono-infected patients with different stages of liver disease. 
However, data are lacking regarding efficacy and safety in HIV/HCV-GT4-
co-infected patients.
aims & Methods: This prospective cohort study was conducted in the pe-
riod between May 2017 and January 2019. From a wide spectrum of pa-
tients seeking Direct Acting Antivirals (DAAs) in Kasr Al-Aini Viral Hepatitis 
Center (KAVHC), Cairo University Hospitals, Cairo, Egypt, 50 HIV/HCV-GT4 
co- infected patients were offered generic sofosbuvir and an adjusted dose 
of daclatasvir according to the antiretroviral therapy (ART) without ribavi-
rin for 12 weeks. 
All patients were HCV treatment naïve, with CD4 count ≥100 cells/mm3 
and eligible for HCV treatment according to the national guidelines. The 
13 patients who were naive to both ART and DAAs with CD4 count > 500 
cells/mm3, were advised to receive DAAs firstly. Patients’ demographics, 
laboratory data (complete blood cell counts, serum alanine and aspar-
tate aminotransferase, total bilirubin and serum creatinine), and adverse 
events (AEs) were analyzed at baseline, week 4, 8, 12 on treatment and at 
follow-up week 4 and 12. Sustained viral response (SVR12) was defined 
as an undetectable HCV RNA 12 weeks after the end of treatment (EOT). 
Changes in HIV PCR, CD4 count and liver stiffness measurement (LSM) by 
transient elastography at week 12 post- treatment were assessed in com-
parison to baseline.
results: The mean patients age was 34.6±10 years, 41 were males (82%), 
46% reported intravenous drug use and 26% had significant liver fibrosis 
(≥F2). SVR12 was achieved in 48 of 50 patients (96%). SVR12 rates were 
comparable either the patients were receiving ART or not and either had 
significant liver fibrosis (≥F2) or not (All p >0.1). AEs occurred in 44 (88%) 
patients. Most frequent AEs: fatigue (32%), headache (20%), and nausea 
(12%) were mild with spontaneous recovery after EOT. No serious AEs, 
treatment discontinuation due to AEs or deaths were reported. HIV viral 
load suppression was not compromised in the patients stable on ART. All 
patients experienced a CD4 count increase during HCV treatment (p=0.01). 
LSM showed a significant decline at week 12 post-treatment when com-
pared to baseline (7.5±5.2 vs. 6.33±3.1 kPa, p< 0.01).
conclusion: Administration of generic daclatasvir and sofosbuvir without 
ribavirin for 12 weeks irrespective of liver fibrosis stage was safe and highly 
effective for HCV treatment naïve HIV/HCV-GT4-co-infected patients. So, 
patients with HIV-HCV co-infection are no longer considered as a special 
‘hard to treat’ population in the real-life settings.
disclosure: Nothing to disclose 
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Introduction: Acute liver injury (ALI) is determined as liver insult resulting 
in liver damage characterized by ALI or AST ≥x10 ULN, INR ≥1.5, without 
hepatic encephalopathy in absence of pre existing liver disease. There is 
paucity of literature available over cohort of ALI patient, who is vulnerable 
to develop poor outcome i.e. acute liver failure (ALF) and death. In this 
study we have determined the characteristic of cohort of ALI patients plus 
the risk factors predicting the poor outcome.
aims & Methods: Patients meeting criteria of ALI prospectively enrolled, 
while patients with comorbid condition affecting short term mortality 
e.g. with hepatocellular carcinoma were excluded. These patients were 
followed until complete recovery, acute liver failure (ALF), death, or liver 
transplantation (LT). Two subgroup analyses -one with patients with INR 
≥1.5-≤1.9 vs. with INR ≥2 and second subgroup analysis with respect to pa-
tients with and without death was performed to see the difference among 
independent variables. Finally using linear regression model the factors 
responsible for death were determined.
results: A total of 110 patients were enrolled from January 2013 to De-
cember 2017 for final analysis. Mean age was 35.1± 18.0, and 50 (45.5%) 
were males. The common etiology of ALI was HEV 39 (35%), followed by 
HAV 23 (20%), DILI among 12 (10.8%), ischemic hepatitis among 10 (9%), 
indeterminate etiology among 3 (2.7%), and paracetomol only among 2 
(1.8%) of patients. The common symptom at presentation was fever 49 
(44.5%), Nausea/Vomiting (N/V) among 49 (44.5%) followed by jaundice 
among 47 (42.7%). A total of 27 (24.5%) patients developed at least one 
of poor outcome i.e. ALF, death or LT, while rest recovered liver insult. Of 
27 patients 19 (17.27%) patients developed ALF. Out of 19 ALF patients, 8 
patients died, one underwent LT, and 10 recovered spontaneously. A total 
of 14 patient died-8 have ALF initially and 6 patients without intermediate 
phase of ALF. Out of 14 who died, 4 had HEV, 3 had ischemic hepatitis, 
3 with indeterminate cause, two patients with HAV-HEV and dengue in-
fection respectively. On subgroup analysis among groups-one with INR 
≥1.5-≤1.9 (n=40), and second with ≥ 2 (n=70), showed difference in terms 
of jaundice (9 (22.5%) vs. 38 (54.2%) p 0.002), WBC (6.9 vs. 11 p < 0.001), 
GGT (150 vs. 61.5 p < 0.001), and development of poor outcome (3 (7.5%) 
vs. 24 (34.2%) p 0.002). 
On regression analysis, there were no factors which were found to be re-
sponsible for having INR ≥2. On subgroup analysis with respect to death-a 
group with death (n=14) vs. a group without death (n=96) showed differ-
ence in INR of ≥2 (13 vs. 1 p 0.01), frequent ALOC (10 (71.4%) vs. 4 (4.1%) 
p 0.04), less frequent N/V (1 (1%) vs. 10 (71) p 0.002), raised PT ( 33 vs. 22 
p 0.003), raised WBC (16.2x103 vs. 10.4x103 p 0.003), raised AST (5166 vs. 
1834 IU/L p 0.004), raised Creatinine (2.6 vs. 1.1 mg/dl p 0.002), and longer 
length of hospital stay ( 8.36 vs. 5.04 days p 0.019) were statistically dif-
ferent among groups. 
However, on linear regression AST (OR 1.0 (1.0-1.0) p 0.03), creatinine (OR 
1.42(1.04-1.95) p 0.02), and length of hospital duration (OR 1.12(1.004-1.25) 
p 0.04) were found to be the predictors of death.
conclusion: ALI is a severe disease culminating in to poor outcome in 
among one fourth of patients. More than half of patient with ALF can re-
cover spontaneously; however, death is inevitable among rest of patients 
unless an immediate LT is performed. Patients with severely raised AST, 
acute renal deterioration and longer hospital stay are vulnerable to de-
velop poor outcome.
disclosure: Nothing to disclose 
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Fib4= [Age (yr.) × AST (IU/L)/platelet count (109/L) × ALT (IU/L) ]. We classi-
fied cases according to LSM into, F0-1: < 7.1 KPa, ≥F2: ≥7.1 - < 9.5 KPa, ≥F3: 
≥9.5 - < 12.5 KPa, and F4: ≥12.5 KPa.
results: All patients achieved SVR12 (100%). M2BPGi, LSM, FIB-4 and PA-
PAS index decreased significantly at SVR12 [9 vs. 6.7 ng/mL (p< 0.001), 11.4 
vs. 9.5 kPa (p=0.002), 1.8 vs. 1.3 (p< 0.001) and 2.2 vs. 2.1 (p=0.010), re-
spectively]. M2BPGi correlated positively with LSM at baseline and SVR12 
(r= 0.326; p= 0.003 and r= 0.612; p< 0.001, respectively), while no cor-
relation was observed with FIB4 or PAPAS index. At baseline, M2BPGi 
was the best marker to distinguish patients with F4, F0-2 from F3-4 and 
F0-1 from F2-4 with AUROC of 0.801, 0.730 and 0.763, respectively, (P< 
0.001). At SVR12, when compared with FIB4 and PAPAS index, M2BPGi 
had the greatest AUROC for differentiating patients with F4, F3, F0-2 from 
F3-4 and F0-1 from F2-4 with AUROC of 0.844, 0.893, 0.891 and 0.750, 
respectively, (P< 0.001).
conclusion: Serum M2BPGi is an accurate and reliable marker for the as-
sessment and grading of liver fibrosis before and after DAAs therapy for 
CHC patients. This diagnostic capability is superior to FIB4 and PAPAS in-
dex. This approach could be clinically feasible for therapeutic and inves-
tigational utility if this measurement application is commercially realized.
disclosure: Nothing to disclose 
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Introduction: Several concerns have arisen regarding cardiac toxicity after 
the Food and Drug Administration published the warning about the seri-
ous slowing of the heart rate of amiodarone when taken in combination 
with direct acting antivirals (DAAs). Currently, little is known about the 
possible drug-related cardiotoxicity of DAAs.
aims & Methods: To investigate the occurrence of cardiac adverse effects of 
DAAs if not coadministered with amiodarone in chronic hepatitis C (CHC) 
patients. We included 60 CHC patients who were eligible for DAAs therapy. 
They were equally categorized into 2 groups according to the presence of 
risk factors for cardiac disease such as diabetes, hypertension and obesity. 
Group I included patients without risk factors for cardiac disease, while 
group II included patients with risk factors for cardiac disease. We ex-
cluded patients with diagnosed cardiovascular disease, under treatment 
with amiodarone or other heart-rate lowering drugs and those with ab-
normal echocardiographic or ECG findings. All patients were treated with 
sofosbuvir and daclatasvir for 12 weeks. We compared echocardiographic 
findings, ECG and lipid profile of all patients at baseline and after achieve-
ment of sustained virological response at 12 weeks after completion of 
treatment (SVR12).
results: All patients achieved SVR12 (100%). Heart rate slowed significant-
ly at SVR12 than baseline with median (IQR) of 55 (40 - 70) vs. 70 (60 - 80) 
beats/min, respectively, (p=0.001). In group I, bradycardia and 1st degree 
heart block occurred in 8 (26.6%) and 4 (13.3%) patients, respectively, (p< 
0.05). Ten (33.3%) and 7 (23.3%) patients in group II developed bradycar-
dia and 1st degree heart block, respectively, (p=0.001). Concerning the lipid 
profile at SVR12, we detected a significant difference between both groups 
as regards serum levels of cholesterol, low density lipoprotein (LDL) and 
triglycerides (p< 0.001). Serum triglycerides level increased significantly in 
both groups at SVR12 compared with baseline; as mean level in group I 
was 140 ± 8.56 vs. 126.13 ± 20.80 mg/dl, respectively, (p= 0.01), and mean 
level in group II was 185.67 ± 12.94 vs. 125.13 ± 20.33 mg/dl, respectively, 
(p< 0.001). Serum cholesterol level in group II increased significantly at 
SVR12 compared with baseline with mean level of 280.20 ± 34.68 vs. 185.73 
± 34.93 mg/dl, respectively, (p< 0.001). 
Additionally in group II, LDL serum level increased significantly at SVR12 
compared with baseline with mean level of 185.80 ± 2.31 vs. 151.00 ± 13.06 
mg/dl, respectively, (p< 0.001).
conclusion: Cardiac adverse effects of DAAs are possible irrespective of the 
presence of cardiac disease or coadministration with amiodarone. Physi-
cians’ awareness of this risk is mandatory for optimizing patients’ care.
disclosure: Nothing to disclose 
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Introduction: Treatment of chronic Hepatitis C (HCV) with directly acting 
antivirals (DAAs) can lead to sustained virological response (SVR) in nearly 
95% of patients. Treatment efficacy and safety in elderly patients has not 
been extensively studied.
aims & Methods: We retrospectively analyzed treatment efficacy and safety 
in HCV patients ≥ 80 years of age who consecutively received DAAs at the 
Humanitas Research Hospital between 2015 and 2018. DAAs were given 
following the EASL recommendations.
results: During the study period 976 patients received DAA treatment in 
our center, 40 patients (4.1%) were ≥80 years old and were included in 
the study. Their mean age was 81.8 years (80-88), 25 patients were fe-
male (62%), HCV genotype 1b (29 patients 72.5%) and 2 (10 patients 25%) 
were the most prevalent HCV genotypes. Advanced fibrosis (F3-F4) defined 
by transient elastography was present in 21 (52.5%), six patients had CPT 
score >A5 and 8 (20%) had previously failed IFN based treatment. Sofos-
buvir based therapies (SOF/LDV, SOF/VEL and SOF + RBV) were given to 21 
patients (52.5%), Paritaprevir/Ombitasvir/Dasabuvir was used in 3, G/P in 
7 (17.5%) and Grazoprevir/Elbasvir in 9 (22.5%). Concomitant medications 
were common in our cohort with 39 patients (97.5%) taking at least 1 drug 
and 23 (57.5%) taking 4 or more concomitant drugs. In 3 cases concomi-
tant therapy had to be modified to start DAA treatment for potential sig-
nificant Drug interactions. Five patients reported side effects during treat-
ment, side effects were always mild and no serious adverse events were 
reported, no patient discontinued treatment prematurely. Seven patients 
are still completing the follow-up and could not be assessed for SVR. In 
the remaining 33 patients a SVR was achieved in 32 (97%). The only treat-
ment failure was a patient lost to follow-up after the End of treatment visit.
conclusion: Our study shows that DAA treatment in HCV Patients older than 
80 years of age is safe and effective. Due to high rate of comorbidities DDI 
need to be carefully assessed before starting treatment.
disclosure: Nothing to disclose 
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Introduction: Assessing liver fibrosis is important for predicting the effi-
cacy of direct acting antivirals (DAAs) and patient prognosis. Non-invasive 
techniques to assess liver fibrosis are becoming important. Recently, se-
rum Mac-2 binding protein glycan isomer (M2BPGi) was developed as a 
non-invasive marker for liver fibrosis.
aims & Methods: The aims of this study were (1) to evaluate the diag-
nostic accuracy of serum M2BPGi to predict the grade of liver fibrosis in 
patients with chronic hepatitis C (CHC) at baseline and after achievement 
of a sustained virological response at 12 weeks after completion of treat-
ment (SVR12) by DAAs and (2) to compare the results with fibrosis score 
(FIB4) and PAPAS index. This study included 85 patients with CHC. For 12 
weeks duration, 65 patients were treated with sofosbuvir and daclatasvir, 
and 15 patients were treated with sofosbuvir, daclatasvir and ribavirin. We 
measured M2BPGi, PAPAS index, FIB4 and liver stiffness measurements 
(LSM) at baseline and SVR12. Serum M2BPGi was measured by M2BPGi 
ELISA kits, with detection range 0.625 - 20 ng/ml, sensitivity 0.1 ng/ml, 
intra-assay, and inter-assay coefficient of variation less than 15%. PAPAS 
index (platelets/age/phosphatase/AFP/AST) formula= Log (index+1) = 
0.0255 + 0.0031 × age (years) + 0.1483 × log {ALP (U/L)} + 0.004 × log {AST 
(U/L)} + 0.0908 × log {AFP (ng/L) + 1} - 0.028 × log {platelet count (109/L)}. 
LSM was performed using Fibroscan (Echosens, 502 Touch, Paris, France). 
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Introduction: Hepatocellular carcinoma (HCC) is the fifth most common 
cancer in the world and the most common cancer in Egypt.(1)
Incidence of HCC recurrence after curative therapies without HCV treat-
ment ranges widely among different studies. Cabibbo et al.(2) conducted a 
meta-analysis of 11 studies evaluating the HCC recurrence in HCV untreated 
patients after curative HCC treatment using surgical resection or radiofre-
quency ablation for tumors ≤3cm. The meta-analysis found probabilities of 
HCC recurrence to be 20% at 1 year and 47% at 2 years. Data regarding HCC 
recurrence after directly acting antivirals (DAAs) treatment are debatable.
aims & Methods: Our aim was to study the 2-year recurrence rate of HCC 
in HCV patients who were treated using radiofrequency ablation (RFA) 
or microwave ablation (MWA) at our unit during 2016 and then received 
DAAs. This retrospective study included all Child-Pugh A and B patients 
with HCV related < 5 cm single or multiple HCCs up to 3 lesions without any 
vascular invasion or lymph node or distant metastasis who were treated 
using RFA or MWA at the Hepatobiliary Unit, University of Alexandria in 
the period from 1/1/2016 to 31/12/2016 and then received DAAs for HCV after 
ensuring no residual or recurrent HCC on triphasic CT scan. Triphasic CT 
scans were performed for all paients 4 weeks after the ablation procedure 
and every 12 weeks from the date of the ablation procedure thereafter ac-
cording to our unit protocol. Those with any other cause of chronic liver 
disease, those who received previous HCC treatments and those with pre-
vious DAAs exposure were excluded. After these exclusions, data from 52 
patients were analyzed. Significance of the obtained results was judged 
at the 5% level.
results: Out of the 52 patients, 2 patients were died and 4 patients were 
lost for follow up before any HCC recurrence. The tumor recurrence rate at 
1 year after tumor ablation among the remaining 46 patients was 30% (14 
patients) and became 47.8% (22 patients) by the end of the second year.
Tumor recurrence at 6 months after tumor ablation among those who had 
started DAAs before that time was 22.2% (8 out of 36 patients) while no 
one out of the 16 patients who started DAAs later experienced tumor recur-
rence during that period but this difference was not statistically significant 
(P=0.06). All of the 8 patients had started DAAs just 4 weeks after tumor 
ablation and the recurrence was multicentric in 50% of them.
On comparing HCC recurrence between those who started DAAs earlier 
than 12 weeks from the HCC ablation procedure and those who started 
DAAs 12 weeks or more after it, the 1-year HCC recurrence was 31.3% in 
the first group (10 out of 32) and 20 % in the second group (4 out of 20) 
(p=0.591) while the 2-year HCC recurrence was 43.8% in the first group (14 
out of 32) and 40% in the second group (8 out of 20) (p=0.722)
conclusion: Although our study included both modified Child-Pugh A and 
B classes and included lesions up to 5 cm, HCC recurrence rates were 
nearly similar to that previously reported in the era before DAAs and so we 
can conclude that DAAs usage after ensuring complete HCC ablation us-
ing a reliable imaging technique doesn’t seem to increase HCC recurrence 
rates. HCC recurrence rates didn’t differ significantly between those who 
started DAAs early after tumor ablation and those who started them later 
but we recommend a randomized controlled trial to confirm this point.
references: 1- Ibrahim AS, Khaled HM, Mikhail NN, et al. Cancer incidence 
in Egypt: Results of the National Population-Based Cancer Registry Pro-
gram. J Cancer Epidemiol. 2014;2014:437971. 2- Cabibbo G, Petta S, Barbàra 
M, et al. A metaanalysis of single HCVuntreated arm of studies evaluating 
outcomes after curative treatments of HCVrelated hepatocellular carcino-
ma. Liver International. 2017;37:1157-66.
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Introduction: Autoimmune hepatitis is an autoimmune disorder involving 
the liver with several systemic manifestations. The link between autoim-
mune hepatitis and autoimmune thyroid disorders has been investigated 
with controversial results. The aim of the study was to assess whether an 
association exists between autoimmune hepatitis and thyroid dysfunction
aims & Methods: Using the medical database of EMMS the Nazareth 
Hospital, we compared the proportion of hypo and hyperthyroidism be-
tween patients with autoimmune hepatitis and age-matched and gender-
matched controls in a cross-sectional study. Univariate analysis was per-
formed using Chi-square and student t-test and a multivariate analysis 
was performed using a logistic regression model.
results: One hundred and sixty three autoimmune hepatitis patients 
and 1,104 age-matched and gender-matched controls were included in 
the study. The average age was 44.12 ± 10.5 (18-74). Fifty-seven patients 
(64.6%) were females. The proportion of hypothyroidism among autoim-
mune hepatitis patients was increased in comparison with controls (17.7vs. 
4.98%, respectively, p-value < 0.001), as was hyperthyroidism (3.24 and 
1.23% respectively, p-value < 0.001). Autoimmune hepatitis revealed an in-
dependent association with hypothyroidism on multivariate analysis (Odd 
Ratios 1.324, 95% Confidence Intervals 1.21-1.38),but not with hyperthy-
roidism.
conclusion: Autoimmune hepatitis patients have a higher proportion of 
hypothyroidism in comparison with matched controls. Physicians treating 
autoimmune hepatitis subjects should consider screening for thyroid dys-
function on a regular basis.
disclosure: Nothing to disclose 
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Introduction: Autoimmune marker can be present in serum healthy sub-
jects as well as among patients whit autoimmune and non-autoimmune 
disorder. The prevalence of autoimmune markers in tatty liver patients var-
ies considerably.
aims & Methods: Patients with fatty liver disease were compared with age 
and sex-matched controls regarding the proportion of autoimmune mark-
ers deduction in a case-control study. Chi-square and t-tests were used for 
univariate analysis and a logistic regression model was used for multivari-
ate analysis. The study was performed utilizing the medical database of 
Clalit Health Services.
results: The study included 519 patients with fatty liver and 2,187 age and 
sex-matched controls. The proportion of autoimmune markers detection 
in patients with fatty liver was increased compared with the prevalence 
in controls (19.52% and 4.68%, respectively, P< 0.001). In a multivariate 
analysis, fatty liver disease was associated with autoimmune markers de-
tection (odds ratio 2.542, 95% confidence interval 2.254-2.879).
conclusion: Patients with fatty liver disease have a greater proportion of 
autoimmune markers detection than matched controls.
disclosure: Nothing to disclose 
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brate 160mg/day in addition to UDCA for 16 weeks. Biochemistry data and 
UK-PBC risk scores at 5-, 10- and 15- years were compared at baseline and 
after 16 weeks of treatment. In addition, the baseline fibroscan score and 
serologies were noted.
results: .Median serum ALP levels decreased significantly at 16 weeks. 
However there was no significant improvement in the 5-, 10- and 15-year 
UK-PBC risk scores. 1 patient was cirrhotic and 1 patient had Autoimmune 
hepatitis(AIH)/PBC overlap syndrome. No significant adverse events were 
reported.
conclusion: This study found the use of fenofibrate in combination with 
UDCA to be effective in improving serum ALP in PBC patients with a sub-
optimal response to UDCA monotherapy within 16 weeks. However, this 
did not appear to translate to significant reductions in the estimated prob-
ability of liver-related death or need for liver transplantation. Further stud-
ies are needed to evaluate if fenofibrate can be a viable alternative to 
bezafibrate as second line therapy for patients with PBC and suboptimal 
response to ursodeoxycholic acid.
references: 1. Corpechot C, et al. Early primary biliary cirrhosis: biochemi-
cal response to treatment and prediction of long-term outcome. J Hepatol. 
2011;55:1361-1367 2. Corpechot et al. A Placebo-Controlled Trial of Bezafi-
brate in Primary Biliary Cholangitis. N Engl J Med. 2018 Jun 7;378(23):2171-
2181
disclosure: Nothing to disclose 
P0067 WIThdraWn
P0068 asParTaTe-β-hydrOxyLase PrOMOTes cancer 
MeTaBOLIc sWITch vIa P53-dePendenT suPPressIOn Of 
MITOPhagy In hePaTOceLLuar carcInOMa
Xue R.1,2, Wu J.2, Meng Q.2
1Peking University Cancer Hospital and Institute, Department of 
Gastrointestinal Oncology, Beijing, China, 2Beijing You-an Hospital, Capital 
Medical University, Beijing, China
contact e-Mail address: xueran2@sina.com
Introduction: Metabolic reprogramming is widely observed during he-
patocellular carcinoma (HCC) development. Mitophagy constitutes an 
important target for interventions seeking tomanipulate cell fate during 
metabolic reprogramming. Aspartate-β-hydroxylase (ASPH) was one of 
the most differentially expressed genes in HCC. However, the relationship 
between ASPH and cancer metabolic reprogramming remains uncharac-
terized.
aims & Methods: In the this study, we aimed to explore the relationship of 
ASPH in the P53-dependent mitophagy, characterized the impact of ASPH 
on tumor metabolic reprogramming. 
We constructed HCC animal model and HCC anoxic autophagy model, 
using lentivirus to deliver ASPH to HepG2 cell line and the CRISPR/Cas9 
system to knockout ASPH, so that we can assess the effect of ASPH on mi-
tophagy, characterized cancer metabolic reprogramming in HCC. Besides, 
we uncovered the biological mechanism of ASPH-induced mitophagy and 
cancer metabolic reprogramming using western blotting, RT-PCR, electron 
microscopy, immunofluorescence and transient transfection of a GFP-LC3-
expressing construct.
results: In this study, ASPH down-regulated the expression of P62, and 
improved the expression of P53, Atg5, Atg7 and LC3-II/LC3-I. Meanwhile, 
ASPH also significantly inhibited the expression of TOMM20, which reflects 
the oxidative phosphorylation level of tumor cells. In addition, ASPH regu-
lated tumor metabolism reprogramming in HCC hypoxic autophagy model, 
including increased levels of glycolysis and pentose phosphate pathways, 
with the up-regulation of GLUT1, PKM2 and G6PD. However, ASPH did not 
affect the level of lipid metabolism and lactic acid metabolism based on 
the the expressions of MCT1, ACC and ACLY. Futhermore, ASPH also signifi-
cantly decreased the expressions of BNIP3 and NIX proteins in HCC.
conclusion: Our finding suggests that ASPH regulates metabolic repro-
gramming via P53-dependent signaling pathway in HCC. This study will 
provide a reliable theoretical basis for the application of ASPH as an effec-
tive target for HCC treatment.
disclosure: Nothing to disclose 
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PaThWay In auTOIMMune hePaTITIs
Fan X.1, Men R.1, Shen M.1, Wang T.1, Ye T.1, Yan Y.2, Yang L.1
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Introduction: Autoimmune hepatitis (AIH) is distinctly characterized by 
massive immune cell-mediated hepatocyte destruction. Here, we investi-
gated the effect of glucocorticoids on concanavalin A (Con A)-induced ex-
perimental autoimmune hepatitis (EAH) mice and in vitro to demonstrate 
the important role of hepatocytes.
aims & Methods: C57BL/6 mice were injected intravenously with ConA (20 
mg/kg) to generate a model of EAH. Glucocorticoids was injected intra-
gastric administration 0.5 h after the ConA administration. The apoptosis 
cells percentage, levels of serum serum liver enzymes, inflammatory cy-
tokines, pathology and other marker proteins were determined 12 h after 
ConA injection. In vitro, primary hepatocyte and the LO2 cell lines were 
used to examine the susceptibility of hepatocytes to ConA challenge and 
explore the underlying mechanisms. We then treated the hepatocytes with 
ConA, 3-methyladenine (3-MA), and glucocorticoids. The apoptosis rates, 
mitochondrial membrane potential (ΔΨm), reactive oxygen species (ROS) 
level, the expression of autophagy-related proteins, the formation of au-
tophagosomes and expression of Akt/p-Akt and mTOR/p-mTOR protein 
were detected.
results: Treatment with glucocorticoids reduced apoptosis cells percent-
age, levels of serum liver enzymes, inflammatory cytokines, and attenuat-
ed histopathological damage in EAH mice. Autophagy may play an impor-
tant role in EAH. In vitro, the increased apoptosis rates, decreased ΔΨm 
level, ROS imbalance and elevated autophagy level were observed under 
treatment with ConA. The expression of p-Akt and p-mTOR was inhibited 
during this process. Glucocorticoids protected against Con A-induced he-
patocyte apoptosis, decreased the autophagy related protein expression, 
decreased autophagosome formation and up-regulated the level of p-Akt 
and p-mTOR.
conclusion: We provided evidence that underlying mechanisms of hepato-
cytes involved in the progression of AIH. Glucocorticoids could ameliorate 
Con A-induced liver injury by regulating autophagy and apoptosis on he-
patocytes via PI3K/AKT/mTOR signaling pathway.
disclosure: Nothing to disclose 
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P0066 effIcacy Of fenOfIBraTe add-On TheraPy 
fOr PaTIenTs WITh PrIMary BILIary chOLangITIs and a 
suBOPTIMaL resPOnse TO ursOdeOxychOLIc acId
Ching S.Y.1, Kaliyaperumal K.1, Yang W.L.2
1Tan Tock Seng Hospital, Gastroenterology and Hepatology, Singapore, 
Singapore, 2Tan Tock Seng Hospital Gastroenterology and Hepatology, Dept. 
of Gastroenterology, Singapore, Singapore
contact e-Mail address: siewyi.ching@mohh.com.sg
Introduction: Oral ursodeoxycholic acid (UDCA) at 13-15mg/kg/day is the 
first line pharmacotherapy for all patients with primary biliary cholangitis 
(PBC). However up to 40% of PBC patients have a suboptimal response to 
UDCA monotherapy as defined by validated criteria, and have been shown 
to be at higher risk of disease progression to cirrhosis, need for liver trans-
plant, and death (1). Due to their peroxisome proliferator-activated recep-
tor (PPAR)-mediated anti cholestatic effects, evidence of the biochemical 
efficacy of add-on therapy with bezafibrate has been demonstrated in pa-
tients with ALP >1.67x upper limit normal(ULN) and/or bilirubin elevated 
< 2x ULN (2). However data evaluating the efficacy of fenofibrate, a more 
commonly used fibrate, is limited.
aims & Methods: To evaluate the efficacy of fenofibrate in patients with 
PBC and a suboptimal response to UDCA monotherapy. 
This was a retrospective analysis of 5 patients with PBC and serum alkaline 
phosphatase (ALP) 1.5x ULN despite at least 12 months of UDCA mono-
therapy (median treatment duration 90.2 months). They received fenofi-
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P0069 PrOTecTIve effecT Of BIOfaBrIcaTed TrIanTheMa 
POrTuLacasTruM sILver nanOParTIcLes agaInsT 
hePaTOceLLuLar carcInOMa
Yadav E.
SHUATS, Pharmaceutical Sciences, Allahabad, India
contact e-Mail address: hiwalekta@gmail.com
Introduction: Over the recent years, nanoparticle approach for targeted 
drug delivery is considered as a promising therapeutic method to improve 
the potential of antitumor agents. Trianthema portulacastrum (TP) leaves 
have been utilized as a strong hepatoprotective in Indian traditional me-
dicinal system.
aims & Methods: Current study was designed to biofabricate, characterize 
and evaluate protective effect of TP extract mediated silver nanoparticles 
(AgTPNPs) against diethylnitrosamine (DEN) induced hepatocarcinoma in 
rat model. AgTPNPs were synthesized by co-precipitation method and dif-
ferent characterization techniques confirmed the formation of spherical 
crystalline nanoparticles with size range of 50-80 nm. FTIR results showed 
the existence of possible bioactive functional groups of phytoconstituents 
in the synthesized AgTPNPs. Liver damage in rats was induced with a 
single dose of DEN (200 mg/kg) as well as double dose of phenobarbital. 
Simultaneously, animals were administered with AgTPNPs at two dose 
levels (10 and 20 mg/kg p.o.) for 16 weeks. At the end of study, serum 
biomarkers, hematological status, antioxidants enzymes, proinflammatory 
cytokines, i.e., tumor necrosis factor-α, interlukin-6, interlukin-1β, and 
nuclear factor kappa beta (NF-kB), were examined to assess the protective 
effect of AgTPNPs. Histological studies were also undertaken to assess the 
outcomes of current study.
results: Results demonstrated that DEN significantly induced the hepa-
tocellular carcinoma in each group, which was significantly reversed (p 
< 0.001) by AgTPNPs in a concentration dependent manner. A significant 
reduction in level of serum hepatic and non-hepatic marker enzymes, 
oxidative stress and different inflammatory markers via direct and indirect 
inhibition of NF-kB expression were observed in rats administered with 
AgTPNPs. Histopathological study further supported the significant hepatic 
cellular structure recovering effect.
conclusion: Collectively, results demonstrated that AgTPNPs potentially 
ameliorated the damaging effects of DEN induced hepatocellular carci-
noma and it can be utilized as an effective nano technology based anti-
cancer approach.
disclosure: Nothing to disclose 
P0070 esTrOgen-Induced ePIgeneTIc sILencIng Of IrOn 
MeTaBOLIsM-reLaTed genes reduces The grOWTh POTenTIaL 
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Introduction: Hepatocellular carcinoma (HCC) is the second most common 
type of cancer in men and seventh in women. Several lines of evidence 
suggest that estrogen (E2) plays a protective role against HCC. In that, 
male-to-female incidence ratio is between 2:1 to 4:1, women of premeno-
pausal age are less prone to HCC and respond more positively to chemo-
therapy as compared with postmenopausal women and E2 treatment in 
hepatocellular carcinoma (Hep-G2) cell cultures induces significant levels 
of apoptosis. That said, the exact mechanism underlying this protective ef-
fect of E2 against HCC is not well understood. Recent work has shown that 
E2 modulates the expression of multiple iron metabolism-related (IRM) 
genes and disrupts intracellular iron homeostasis in cancer cells. However, 
how E2 disrupts the expression of IRM genes and whether this has any 
bearing on the protective role of E2 against HCC is yet to be addressed.
aims & Methods: Given that epigenetic modifications are involved in regu-
lating gene expression, we hypothesized that E2 could disrupt intracellular 
iron metabolism by inducing epigenetic modifications in select IRM genes. 
To test this hypothesis, the UCSC genome browser was used to analyze the 
CpG islands (CGI) on the promoter regions of core IRM genes. Further-
more, Hep-G2, gastric cancer (AGS) and breast adenocarcinoma (MCF7) 
cell lines were used to investigate the effect of E2 on IRM gene expression. 
DNA methylation was assessed by PCR, methylation-specific (MSP)-PCR, 
western blotting and flow cytometry. Histone modification was assessed 
by chromatin immunoprecipitation (ChIP) and western blotting. Cell pro-
liferation and cell cycle analysis were performed to assess the functional 
significance of E2- disrupted intracellular iron metabolism.
results: Both ferritin heavy chain-1 (FTH1) and transferrin receptor-1 (TFR1) 
genes were identified as having CGIs in their promoter region. E2 (20nM) 
treatment induced DNA methylation and inhibited the expression of FTH1 
and TFR1 in HepG2 cells. De-methylation treatment with 5-Aza-dC rescued 
the downregulation of FTH1 and TFR1 in HepG2 cells but not in AGS or MCF7 
cells. DNMT3B, PRMT5 and methylated-Histone 4 (H4R3me2s) upregulated 
in E2-treated HepG2 cells. The siRNA knockdown of PRMT5 inhibited E2-
induced methylation of histone H4R3. Furthermore, E2 treatment recruited 
PRMT5 and H4R3me2s on FTH1 but not on TFR1, as suggested by ChIP as-
say data. The siRNA knockdown of PRMT5 and DNMT3B were required 
to block the inhibitory effect of E2 on FTH1, however, knock-down of the 
only DNMT3B inhibited E2 induced-downregulation of TFR1. Suggesting 
FTH1 silencing requires coordination of both, histone methylation and DNA 
methylation, whereas, TFR1 is silenced only by DNA methylation. Lastly, 
siRNA knockdown of FTH1 and TFR1 in Hep-G2 cells resulted in the de-
creased intracellular labile iron pool, which was associated with cell cycle 
arrest and reduced cell growth and proliferation.
conclusion: These findings clearly suggested that E2 disrupts intracellular 
iron metabolism by inducing histone and/or DNA methylation events that 
silences the FTH1 and TFR1 genes and that such changes were associated 
with cell cycle arrest and reduced cell growth.
disclosure: Nothing to disclose 
P0071 saT-2 hyPOMeThyLaTIOn as an earLy dIagnOsTIc 
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Introduction: Hepatocellular Carcinoma (HCC) is the most frequent subtype 
of primary liver cancer, accounting for approximately 85% of total clinical 
cases. In the past 20 years, the HCC incidence, in the United States, was 
increased by three times with a 5-year survival rate lower than 12%. The 
prevalence of HCC in Africa is higher than the rest of the world due to the 
high incidence of chronic hepatitis C virus (HCV) infection which is usually 
undiagnosed until late stages.< br>The precise molecular pathogenesis 
of HCC is very complicated and heterogeneous, leading to a delay in its 
diagnosis and treatment. Owing to the low sensitivity and specificity of the 
currently existing tumor biomarker tests (e.g., AFP) for the early detection 
of HCC, most patients are diagnosed and treated at advanced stages of the 
disease, which greatly affects the response to the available therapy and 
leads to poor prognosis. Thus, improving early disease detection may help 
to achieve a better clinical outcome for liver cancer patients.
Epigenetic analyses determine how the environmental factors interact with 
the genome, and thus, inducing gene expression modifications without af-
fecting the gene sequence. Epigenetic transformations, such as alteration 
of DNA methylation, have been noticed in multiple cancers including HCC. 
Therefore, they could serve as excellent biomarkers for carcinogenesis risk 
estimation, diagnosis, and prognosis.
aims & Methods: The current study was designed to investigate the po-
tentiality of SAT-2 methylation alteration for the early detection of HCV-
induced HCC and to provide key insights into the epigenetic molecular 
mechanisms regulating HCC development and progression. 
Twenty healthy controls, 40 chronic HCV patients, 40 HCV-associated cir-
rhotic patients, and 50 HCV-HCC patients were enrolled in this study. Pa-
tients were subjected to full history taking, complete clinical examination, 
routine laboratory investigations, serological detection of HCV, AFP mea-
surement, radiological examination (e.g abdominal ultrasonography with 
Doppler examination, spiral CT, and Child’s Pugh scoring and grading), 
and SAT-2 methylation analysis by Methy-Light PCR assay following bisul-
fite conversion of the extracted DNA from patients’ blood samples.
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of HCC in NAFLD that is followed at a later step by STAT3 phosphorylation 
and cMyc expression. This hypothesis is currently under investigation in a 
larger study.
disclosure: Nothing to disclose 
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Introduction: 14 million patients worldwide are affected by hepatocellular 
carcinoma (HCC), the most common primary malignant neoplasia of the 
liver (85 - 90%) with the third highest tumor mortality. Thus, novel diag-
nostic and therapeutic options are indispensable. The insulin like growth 
factor (IGF) system promotes growth and cell survival via IGF binding 
to the IGF receptor. Insulin like growth factor binding proteins (IGFBPs) 
control IGF availability by competitive binding of IGF, therefore limiting 
proliferative IGF effects. Thus, the impact of IGFBP2 on HCC cell viability, 
proliferation and migration was evaluated and effects of IGFBP2 signaling 
on the efficacy of HCC-relevant therapeutics were analyzed.
aims & Methods: IGF secretion and surface levels of IGF receptors were 
analyzed in the human HCC cell line Hep3B. Cells were cultured with re-
combinant IGFBP2 (100 -1000 ng/ml). Then, cell viability was measured 
by MTS assay, proliferation was determined by flow cytometry and cell 
migration was analyzed using a wound healing model. Activation of the 
IGF pathway was also determined by milliplex assay. Moreover, efficacy of 
the HCC-relevant therapeutics bleomycin, sorafenib, regorafenib and len-
vatinib in combination with different IGFBP2 concentrations was analyzed 
by measuring cell death using flow cytometry. Varying IGFBP2 levels were 
obtained by overexpression and knockdown of IGFBP2. Overexpression of 
IGFBP2 was verified by Western Blot, while knockdown of IGFBP2 was con-
trolled using qPCR and ELISA.
results: Hep3B cells displayed an intact IGF system, indicated by constant 
IGF secretion over 96 hours and surface expression of IGF receptors. Large-
ly, cell viability increased in a time-dependent fashion. Most pronounced 
effects of up to 115% were observed after 96 h using 100 - 500 ng/ml 
IGFBP2 . Highest proliferation rates were induced by IGFBP2 concentra-
tions between 100 - 250 ng/ml with a significant increase of up to 18% 
after 48 h compared to the control. Concordantly, IGFBP2 concentrations 
between 100 and 500 ng/ml resulted in enhanced cell migration after 
only 16 hours. Interestingly, analysis of the IGF pathway after treatment 
with recombinant IGFBP2 resulted in no significant changes in activation 
compared to the untreated control. IGFBP2 protein levels were fivefold 
increased after overexpression of IGFBP2. Knockdown of IGFBP2 resulted 
in a more than 90% decrease on RNA level and a reduced secretion of 
more than 60% after 72 h. Remarkably, with all HCC-relevant therapeutics, 
cell death behaved contrariwise to IGFBP2 concentration. Reduced IGFBP2 
concentrations, generated by knockdown, resulted in enhanced cell death. 
In contrast, a decrease of cell death rates was observed in IGFBP2-over-
expressing cells. IGFBP2 knockdown in cells hereby significantly increased 
cell death when treated with bleomycin and regorafenib (7,4% and 23,5% 
after 48 h). Correspondingly, IGFBP2 overexpressing cells displayed a de-
crease in cell death of 11% after incubation with sorafenib.
conclusion: Although being regarded as growth-limiting factor within the 
IGF-system, recombinant IGFBP2 exerted proliferative effects on HCC cells. 
Since an induction of IGF signaling was not observed, the exact mecha-
nisms of action need further elucidation. Nonetheless, IGFBP2 also af-
fected the efficacy of HCC relevant therapeutics. We therefore hypothesize 
that IGFBP2 has further functions independent of its role within the IGF 
system and elucidation of those is essential for our understanding and 
treatment of HCC.
disclosure: Nothing to disclose 
P0074 WIThdraWn
results: The percent of methylated reference (PMR) of SAT-2 methylation 
was calculated for all samples. A significant reduction was noticed in the 
cirrhotic and hepatocellular carcinoma groups in comparison to the con-
trol and chronic HCV groups. The mean ± standard deviation of the PMR 
values were 38.58 ± 0.11 % in the control group, 41.18 ± 0.068 % in the 
chronic HCV group, 26.23 ± 0.086 % in the cirrhotic group, 27.28 ± 0.16 % 
in the HCC group.
conclusion: Decreased DNA methylation of SAT-2, in blood samples, can be 
used as a reliable diagnostic tool for liver cirrhosis and hepatocarcinogen-
esis development in HCV-chronically infected patients.
references: 
1) Fan G, Tu Y, Chen C, Sun H, Wan C, Cai X. DNA methylation biomarkers 
for hepatocellular carcinoma. Cancer Cell Int. 2018; 1 8:140. 
2) Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, Ehrlich 
M, Laird PW. Analysis of repetitive element DNA methylation by Methy-
Light. Nucleic Acids Res. 2005; 33(21):6823-36.
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Introduction: Nonalcoholic fatty liver disease (NAFLD) is associated with 
the metabolic syndrome and is rapidly becoming one of the major causes 
of hepatic cirrhosis and hepatocellular carcinoma (HCC). There are no reli-
able biomarkers to predict the risk of HCC in patients with NAFLD. The 
protein hepatocyte nuclear factor 4 alpha (HNF4α) has been recently iden-
tified as a central gene in the pathogenesis of nonalcoholic steatohepatitis 
(NASH), a subset of NAFLD characterized by inflammation with increased 
risk for cirrhosis and HCC over NAFLD. There are two different isoforms of 
HNF4α, P1-HNF4α and P2-HNF4α. P2-HNF4α is expressed in fetal liver but 
is not usually expressed in livers of normal adult. 
However, it has been reported to be expressed in HNF4α-positive HCC. 
Phosphorylation of STAT3 (p-STAT3) and induction of cMyc has been pro-
posed to be major contributor to HCC progression.
aims & Methods: The aim of this study was to determine the relationships 
between p-STAT3, cMyc and P2-HNF4α xpression in biopsies from livers 
with NAFLD as potential biomarkers of HCC risk. 
Formalin-fixed paraffin-embedded liver biopsies from 50 patients with 
NAFLD were included in this study. Sections were stained for P1-HNF4α, 
P2-HNF4α, p-STAT3 and cMyc using standard immunohistochemistry 
staining protocols. The staining results were correlated with each other 
and with clinicopathologic features. Statistical analysis was performed us-
ing two-tailed Fisher’s exact test; p < 0.05 is considered significant.
results: All 50 biopsies, except one, were positive for nuclear expression of 
P1-HNF4α. Twenty-nine (58%) cases were positive for nuclear expression 
of P2-HNF4α, 6 (12%) were positive for nuclear p-STAT3 and 5 (10%) were 
positive for nuclear cMyc. 
There was no significant correlation between P2-HNF4α, p-STAT3 or 
cMyc expression and inflammation grade or fibrosis stage. All 6 (100%) 
p-STAT3-positive cases were also positive for P2-HNF4α. P-SAT3-positive 
cases were more likely to be positive for P2-HNF4α than p-STAT3-negative 
cases (100% vs 42%, p = 0.03). Four of the 5 cMyc-positive cases were also 
positive for P2-HNF4α. 
Although cMyc-positive cases were more likely to be positive for P2-HNF4α 
than cMyc-negative cases the difference was not statistically significant 
(80% vs 56%, p = 0.38). p-STAT3-positive cases were more likely to be also 
cMyc-positive (67% vs 2%, p = 0.0003).
conclusion: Our results strongly suggest that STAT3 phosphorylation occurs 
in livers with NAFLD only in the subset with P2-HNF4α expression, and 
cMyc expression is strongly correlated with STAT3 phosphorylation. We hy-
pothesize that P2-HNF4α expression is an early event in the development 
216 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
P0075 cLInIcaL IMPLIcaTIOns Of afP LeveLs In PaTIenTs 
Of hePaTOceLLuLar carcInOMa In a referraL cancer cenTre 
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Nutrition, Mumbai, India
contact e-Mail address: vaneet.jearth@gmail.com
Introduction: α-fetoprotein (AFP) is the most studied and used marker in 
Hepatocellular carcinoma (HCC). It is used to predict prognosis, assess re-
sponse to therapy and more controversially as a screening tool along with 
abdominal ultrasound in patients with hepatitis or cirrhosis who are at 
risk for HCC. However, not all HCC secrete elevated amounts of AFP into 
the serum.
aims & Methods: Aim-To explore the relationship between AFP and vari-
ous clinical variables including Barcelona Clinic Liver Cancer (BCLC) stage 
at presentation in patients with HCC.
Methods-Clinical data of 547 prospectively accrued patients with untreated 
HCC in an ongoing study at our liver clinic between June 2017 and Feb 2019 
was analysed. Demographic and clinical features, investigation results in-
cluding routine labs and imaging reports regarding HCC size, extent of tu-
mour (Single lobe /Bilobar), extra hepatic spread, macro vascular invasion 
and BCLC stage at presentation were recorded. Patients were divided into 
three groups according to different cutoff values for serum AFP: Group A (< 
10 ng/mL, N=103); Group B (10-400 ng/mL, N=151) and Group C (>400 ng/
mL, N=293). As per aetiology patients were divided into Hepatitis B /Hepa-
titis C related (HBHC) or Non Hepatitis B or Hepatitis C related (NBNC) HCC.
results: 19% (n=103) patients had normal or low serum AFP values (< 10 
ng/mL). Mean age at presentation in years (±SD) was 57 (±13.3), 59 (±11.9), 
54 (±12.6) in group A, B and C respectively. As per aetiology, 53 % of pa-
tients in Group A were HBHC HCC as compared to 63 % in group C (p 
=0.146). Mean AFP was higher in HBHC HCC as compared to NBNC but this 
was not statistically significant (p= .367). 
Patients in group A had significantly higher mean albumin (p=0.008), 
lower mean Bilirubin (p=< 0.001), lower mean INR (p=0.003) and smaller 
mean tumour size (p=0.002) as compared to group B and C. 25 % (n=26) 
of patients in Group A had evidence macro vascular invasion (MVI) as com-
pared to 40% (60) in group B and 59% (n=172) in group C (p=< 0.001). 
Patients with MVI (n=260) had significantly highly mean AFP in ng/mL 
(98088.49) as compared to patients without it (n=287, 40555.41 p=0.003). 
Patients in Group A had significantly lower incidence of extra hepatic me-
tastases (EHM) (12.6 %) as compared to Group B (19.2 %) and C (28.6%, 
p=0.04). Serum AFP levels differed significantly (P < 0.001) in the BCLC 
stage D vs. stage A and B.
Parameter group a group B group c p value
HBHC/NBNC n (%)
55 (53.4 ) /48 
(46.6)
85 (56.3)/66 
(43.4)
185 (63.1)/108 
(36.9)
.146
Albumin (g/dL) Mean 
(± SD)
3.61 ± 0.62 3.38 ± 0.58 3.41 ± 0.58 0.008
INR 1.12 ± 0.21 1.17 ± 0.22 1.22 ± 0.30 0.003
Bilirubin(mg/dL) Mean 
(± SD)
1.59 ± 2.11 1.74 ± 1.42 2.5 ± 3.95 <0.001
Size of largest 
lesion(cm) Mean 
(± SD)
7.83 ± 3.66 8.38 ± 3.53 9.19 ± 3.45 0.002
Extent of tumour n (%) 
Single lobe/Bilobar
67 (65)/36 
(35)
87(57.6)/64 
(42.4)
142 (48.5)/151 
(51.5)
0.01
BCLC (n) O/A/B/C/D 1/16/47/29/10 2/10/61/61/17 1/6/66/162/58 <0.001
Cirrhosis n(%) Yes/No
74 (71.8)/29 
(28.2)
124 (82.1)/27 
(17.9)
229 (78.1)/64
(21.9)
0.15
Macro vascular 
invasion n(%) Yes/No
26 (25.2)/77 
(74.8)
60 (39.7)/91 
(60.3)
172 (58.7) /121 
(41.3)
<0.001
Extra hepatic 
Metastasis n(%) 
Yes/No
13 (12.6)/90 
(87.4)
29 (19.2)/122
(80.8)
84 (28.6)/209
(71.4)
0.04
[Comparisons among AFP (ng/mL) groups in HCC patients (n=547)]
conclusion: Comparisons between patients with AFP levels < 10, 10-400, 
>400 ng/ml showed that increasing AFP levels were associated with an 
increased percentage of MVI and EHM and ineligibility for any curative 
treatment. AFP is still a reasonably reliable prognostic serum marker es-
pecially in resource limited settings. However even advanced HCC can have 
normal to low serum AFP. In these patients, non-AFP prognostic markers 
are needed, especially for small HCCs.
disclosure: Nothing to disclose
P0076 OuTcOMes Of hePaTIc resecTIOn (hr) versus 
Trans arTerIaL cheMOeMBOLIzaTIOn (Tace) fOr sOLITary 
Large hePaTOceLLuLar carcInOMa: a sysTeMIc revIeW 
and MeTa-anaLysIs
Gopalakrishnan Ravikumar N.P.1, Sannapaneni S.2, Martinez A.3
1University at Buffalo, Internal Medicine, Buffalo, United States, 2Texas 
Health Presbyterian Hospital, Dallas, United States, 3University at Buffalo, 
Buffalo, United States
contact e-Mail address: ravikumar.naveen1@gmail.com
Introduction: Hepatocellular Carcinoma (HCC) is the sixth most common 
cancer and second most common cause of cancer-related death in the 
world. Common treatment modalities for large HCC (>/=5 cm) are Hepatic 
Resection (HR) and Trans arterial Chemoembolization (TACE). However, 
the most optimal treatment option for treating solitary large HCC (>/= 5 
cm) remains controversial.
aims & Methods: In our study we aimed to compare long-term survival 
outcomes of HR versus TACE for solitary HCC.The meta-analysis was per-
formed using the Preferred Reporting Items for Systematic Reviews for 
Meta-Analysis (PRISMA) guidelines. We searched PubMed, Embase, Co-
chrane library, Medline, Google Scholar and Science Citation Index for 
studies comparing HR with TACE for solitary HCC >/=5cm between 2008-
2018. Keywords used were “Hepatocellular carcinoma”, “liver cell carci-
noma”, “hepatic resection” or “liver resection” and “Trans arterial Che-
moembolization” or “TACE”. Quality of studies was assessed by Method-
ological Index for Non-Randomized Studies (MINORS). Statistical analysis 
was performed using Review Manager version 5.3 (RevMan) software. The 
primary outcome was overall survival (OS) rates at 1,3 and 5 years.
results: Using the pre-defined search strategy, 6 retrospective cohort stud-
ies were included in the meta-analysis. The analysis was performed on a 
total of 1488 patients, 784 (53%) underwent Hepatic resection (HR), 704 
(47%) were treated with TACE. OS rates in HR 1,3 and 5 were 87,69 and 57 
% respectively. OS rates in the TACE group at 1,3, and 5 years were 71, 49, 
and 33% respectively. The pool hazard ratio for 3 year OS rate was 0.63 
(95% CI 0.51-0.69, P< 0.0001). The pooled hazard ratio for 5 year OS rate 
was 0.57 (95% CI 0.45-0.79, P=0.003).
conclusion: Based on the analysis, we conclude that the patients who un-
derwent HR have a significantly higher 3 and 5 year overall survival rate 
than TACE alone. Hence, HR can be safe and effective in patients with soli-
tary large HCC. TACE can be considered in patients with contraindications 
to HR. However, larger prospective trials are needed to prove this.
disclosure: Nothing to disclose 
P0077 seruM vascuLar endOTheLIaL grOWTh facTOr as a 
TuMOur Marker fOr hePaTOceLLuLar carcInOMa In PaTIenTs 
WITh hcv-reLaTed LIver cIrrhOsIs
Alzamzamy A.1, Elsayed H.2, Abd Elraouf M.2, Eltoukhy H.2, Megahed T.3
1Military Medical Academy, Department of Gastroenterology and Hepatology, 
Cairo, Egypt, 2Faculty of Medicine for Girls, Al-Azhar University, Department 
of Internal Medicine, Cairo, Egypt, 3Military Medical Academy, Department of 
Clinical Pathology, Cairo, Egypt
contact e-Mail address: dr_zamzamy@hotmail.com
Introduction: Hepatocellular carcinoma (HCC) is the sixth commonest can-
cer and the fourth leading cause of cancer death, accounting for 8.2% of 
cancer-related deaths worldwide. Being a vascular tumor, vascular endo-
thelial growth factor (VEGF) plays a vital role in HCC pathogenesis, growth, 
and spread.
aims & Methods: The aim of this study was to determine the accuracy of 
serum VEGF and VEGF/PLT as tumour markers for early detection of HCC in 
patients with hepatitis C virus (HCV)-related liver cirrhosis. We conducted 
a prospective cohort study on HCV patients attending the outpatient and 
inpatient divisions of Gastroenterology & Hepatology Department. Patients 
were classified into three groups: HCC group, cirrhosis group, and HCV 
without cirrhosis (control group). 
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study showed that ALBI was better than CTP in detecting death from HCC.
conclusion: We found that both CTP and ALBI have significant inverse re-
lationship with HCC survival. However, ALBI grading system discriminates 
HCC survival better than CTP. ALBI does not require clinical assessment as 
in CTP score and hence is not subjective to assessment variability between 
clinicians. ALBI is easier to apply as a prognostic test for HCC survival.
references: 1. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment 
of liver function in patients with hepatocellular carcinoma: a new evi-
dence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8. 
2. Hiraoka A, Michitaka K, Kumada T, et al. Validation and Potential of 
Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 
46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More 
Detailed Evaluation of Hepatic Function. Liver Cancer. 2017;6(4):325-336. 3. 
Chen B, Lin S. Albumin-bilirubin (ALBI) score at admission predicts pos-
sible outcomes in patients with acute-on-chronic liver failure. Medicine 
(Baltimore). 2017;96(24):e7142. 4. Lee PC, Chen YT, Chao Y, et al. Validation 
of the albumin-bilirubin grade-based integrated model as a predictor for 
sorafenib-failed hepatocellular carcinoma. Liver Int. 2018;38(2):321-330. 5. 
Hiraoka A, Kumada T, Kudo M, et al. Albumin-Bilirubin (ALBI) Grade as 
Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan 
Society of Hepatology: A Comparison with the Liver Damage and Child-
Pugh Classifications. Liver Cancer. 2017;6(3):204-215.
disclosure: Nothing to disclose 
P0079 WIThdraWn
P0080 deveLOPMenT and exTernaL vaLIdaTIOn Of 
PrOgnOsTIc nOMOgraMs In hePaTOceLLuLar carcInOMa 
PaTIenTs: a POPuLaTIOn Based sTudy
Yan Y., Mao K., He C., Wang J., Xiao Z.
Sun Yat-Sen University, Hepatobiliary Surgery of Sun Yat-Sen Memorial 
Hospital, Guangzhou, China
contact e-Mail address: yanyc@mail2.sysu.edu.cn
Introduction: Hepatocellular carcinoma (HCC) is the sixth most common 
cancer and the second most deadly cause of cancer mortality worldwide. 
Improvements in treatment strategies have markedly improved the overall 
survival (OS) and cancer-specific survival (CSS) of HCC patients, although 
the long-term survival rate remains low. We attempted to construct and 
validate novel nomograms to predict OS and CSS in HCC patients.
aims & Methods: A total of 15394 HCC patients were included in the study 
and randomly divided into a discovery set (n=10262) and an internal test-
ing set (n=5132) obtained from the Surveillance, Epidemiology, and End 
Results (SEER) database. We used a univariate Cox regression analysis to 
screen for clinicopathological risk factors for OS and CSS in the SEER dis-
covery set. We further performed multivariate Cox regression analysis to 
screen for important risk factors. All variables were screened using the 
forward stepwise selection method in a Cox multivariate analysis regres-
sion model. Based on univariate and multivariate Cox regression analyses, 
we identified independent risk factors for OS and CSS. Concordance in-
dexes (c-indexes) were used to evaluate model discrimination. Calibra-
tion plots were constructed to validate the accuracy and reliability of the 
nomograms. The predictive accuracy and clinical values of the nomograms 
were measured by decision curve analysis (DCA).
results: The 1-, 3- and 5-year OS rates were 63.99%, 40.91%, 30.78% and 
80.10%, 58.36%, 45.19% in the SEER and the SYMH cohorts, respectively. 
The median CSS durations in the above four sets were 1230, 1200, 1200 
and 1701 days, respectively; while the 1-, 3- and 5-year CSS rates were 
73.12%, 54.25%, 45.42% and 88.68%, 69.70%, 50.23% in the SEER and 
the SYMH cohorts. The c-index for the OS prediction nomogram was 0.753 
(95% CI, 0.745-0.761) based on age, sex, race, marital status, histologi-
cal grade, TNM stage, tumor size, and surgery performed in the discov-
ery set, while the c-indexes for TNM stage, histologic grade and tumor 
size for OS prediction were 0.555 (95% CI, 0.547-0.563), 0.654 (95% CI, 
0.646-0.662), and 0.618 (95% CI, 0.612-0.624), respectively. Similarly, Our 
CSS nomogram with a c-index of 0.748 (95% CI, 0.740-0.756) was higher 
than the c-indexes for TNM stage, grade and tumor size. The calibration 
curves fit well. DCA showed that the two nomograms provided substan-
tial clinical value. Based on risk stratification by the nomograms, in the 
low-, intermediate- and high-risk subgroups, the 1-year OS rates were 
85.59%, 52.78%, and 20.57%, the 3-year OS rates were 63.72%, 22.64%, 
All patients were clinically evaluated, and were subjected to the follow-
ing investigations: CBC, Liver functions test, renal functions test, HCV viral 
markers including HCV-RNA PCR, quantitative measurement of AFP, VEGF 
and VEGF/PLT, in addition to abdominal U/S and dynamic imaging study 
for HCC patients. 
Data of the three study groups were compared by the ANOVA or Kruskal 
Wallis test. Sensitivity, specificity, optimal cut off values and diagnostic ac-
curacy were calculated, and ROC curves were constructed for AFP, VEGF, 
and VEGF/PLT.
results: Our study included one hundred patients (HCC group: n=40, cir-
rhosis group: n=30, and control group: n=30). HCC patients had signifi-
cantly higher serum VEGF and VEGF/PLT levels than the non-HCC groups 
(P=0.001). Serum VEGF and VEGF/PLT showed significant positive cor-
relations with HCC tumor size, stage, vascular invasion and Child Pugh’s 
classification. Moreover, a VEGF cut off value of 250 pg/ml provided 80% 
sensitivity and 81.7% specificity for discriminating HCC patient from non-
HCC patients in comparison to AFP (65%, 83.33%, respectively). Similarly, 
the ratio of VEGF/PLT provided sensitivity and specificity of 77.5% and 80%, 
respectively which is higher than the accuracy provided by AFP. The com-
bination of AFP, VEGF, and VEGF/PLT increased the accuracy for diagnosing 
HCC to >95%.
conclusion: In HCV patients, serum VEGF and VEGF/PLT either separately 
or in combination with AFP are reliable biomarkers for early and accurate 
detection of HCC.
references: Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal 
A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and 
Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal 
for clinicians. 2018 Sep 12; doi: 10.3322/caac.21492.
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P0078 aLBuMIn-BILIruBIn grade (aLBI) suggesTs BeTTer 
PrOgnOsTIc MOdeL Than chILd TurcOTTe Pugh (cTP) scOre In 
PredIcTIng survIvaL frOM hePaTOceLLuLar carcInOMa (hcc)
Bannaga A.1, Arasaradnam R.P.2
1University Hospital Coventry and Warwickshire, Warwick Medical School, 
Gastroenterology, Coventry, United Kingdom, 2University Hospital Coventry 
and Warwickshire, Dept. of Gastroenterology, Surrey, United Kingdom
contact e-Mail address: aymanbannaga@yahoo.com
Introduction: HCC is the second most frequent cause of cancer related 
death globally. CTP score is composed of bilirubin level, albumin level, 
prothrombin time, severity of ascites, and degree of hepatic encephalopa-
thy. Among these five parameters, severity of ascites and hepatic encepha-
lopathy are assessed by clinician and are subjective in certain degree. 
The albumin-bilirubin (ALBI) grade system consists of only albumin and 
bilirubin levels. ALBI has been suggested by Johnson et al1 as a simpler 
and more objective way to estimate liver function for patients with HCC. 
ALBI = (log10 bilirubin × 0.66) + (albumin × -0.085), where bilirubin is 
in µmol/L and albumin in g/L. ALBI ≤-2.60 or Grade 1 (showed median 
survival 18.5-85.6 months), ALBI >-2.60 to ≤-1.39 or Grade 2 (showed me-
dian survival 5.3-46.5 months) and ALBI >-1.39 or grade 3 (showed median 
survival 2.3-15.5 months).
aims & Methods: To identify predictors of overall survival in HCC patients 
and validate ALBI grading system in our patients. Using the hospital infor-
matics system, we retrospectively analysed all HCC cases between Decem-
ber 2013 and December 2018. We calculated CTP scores and ALBI grades at 
the time of diagnosis and compared them to HCC survival after diagnosis. 
The analysis was done using the IBM SPSS Statistics software version 25. 
Survival analysis was performed using the Kaplan-Meier (KM) method. We 
also performed receiver operating characteristic (ROC) analysis between 
the ALBI grades, CTP scores and death from HCC
results: Total of 121 HCC patients were identified. 82 patients (67.8%) had 
liver cirrhosis at time of diagnosis. Majority of the patients had relatively 
good liver function (Child A 64.5%, Child B 24% and child C 11.5%). There 
was a significant negative relationship between both CTP score and ALBI 
grade and survival (p < 0.05). Mean and median survival for ALBI grade 
1 were 37.7 and 26 months, ALBI grade 2 were 13.4 and 6 months and for 
ALBI grade 3 were 4.5 and 3 months. Mean and median survival for CTP 
score A were 26.3 and 15 months ,CTP score B were 9.6 and 5 months and 
for CTP score C were 3.2 and 2 months. Visually the KM curves showed bet-
ter discriminative performance for ALBI grade than CTP score. In addition, 
comparison of ROC curves of CTP and ALBI for outcome of death in the 
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and 4.38%, the 1-year CSS rates were 90.69%, 59.95%, and 23.39%, and 
the 3-year CSS rates were 75.23%, 31.18%, and 6.88%, respectively. In-
ternal validation produced c-indexes of 0.758 and 0.752 for OS and CSS, 
respectively, while external validation in the Sun Yat-sen Memorial Hos-
pital (SYMH) cohort produced a c-indexes of 0.702 and 0.686 for OS and 
CSS, respectively.
conclusion: Based on the clinical risk factors identified in a large pop-
ulation-based cohort, we established practical prognostic nomograms 
that can objectively and accurately predict long-term OS and CSS in HCC 
around the world. Moreover, the internal and external cohort validation 
results demonstrate that these nomograms perform very well and have 
high accuracy and reliability. Our nomograms may enable more accurate 
individualized predictions of OS and CSS to help doctors better formulate 
individual treatment and follow-up management strategies.
disclosure: Nothing to disclose 
P0081 sOrafenIB fOr PaTIenTs WITh recurrenT 
hePaTOceLLuLar carcInOMa afTer LIver TransPLanTaTIOn: 
InTrInsIc resIsTance Or nOT?
Tovoli F.1, Di Costanzo G.G.2, Sansone V.1, Magini G.3, Sacco R.4, 
Pressiani T.5, Trevisani F.1, Tortora R.2, Bucci L.1, Lucà M.G.3, Bolondi L.1
1Università di Bologna - Policlinico Sant’Orsola, Department of Medical 
and Surgical Sciences, Bologna, Italy, 2Cardarelli Hospital, Department of 
Transplantation - Liver Unit, Napoli, Italy, 3Papa Giovanni XXIII Hospital, 
Gastroenterology and Transplant Hepatology, Bergamo, Italy, 4Azienda 
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Introduction: The use of sorafenib in patients with hepatocellular carci-
noma (HCC) recurring after orthotopic liver transplantation (OLT) may be 
challenging. Increased toxicity from interaction with immunosuppressants 
are a common issue. Also, poor outcomes have been reported. However, 
it has not been investigated whether these outcomes derive from a dire 
clinical presentation or from a resistance to sorafenib.
aims & Methods: We aimed to compare the overall survival (OS) of 
sorafenib-treated post-OLT HCC with that other sorafenib-treated HCCs. 
We analyzed a large retrospective-prospective database gathering the 
clinical data of 487 patients from 6 Italian centres, who were prescribed 
with sorafenib between 2008 and 2017. Eighteen patients with HCC re-
curring after OLT were identified. A propensity score analysis comparing 
their clinical and tumor characteristics with those of 90 matched controls 
(sorafenib in patients without OLT) was performed. Propensity score in-
cluded performance status, alfa-fetoprotein >400 ng/ml, macrovascular 
invasion, extrahepatic spread.
results: Characteristics of the OLT patients and matched controls are re-
ported in Table 1.
  OLT patients (n=18)
sorafenib controls 
(n=90) P
Males 16 (88.9%) 80 (88.9%) 1.000
Age 59 (56-67) 65 (62-74) 0.101
Performance status  
- ECOG-PS 0 14 (77.8%) 71 (78.9%) 1.000
- ECOG-PS 1 4 (22.2%) 19 (21.1%)  
BCLC stage  
- Intermediate 4 (22.2%) 21 (22.2%) 1.000
- Advanced 14 (77.8%) 69 (73.8%)  
Macrovascular invasion 2 (11.1%) 16 (17.8%) 1.000
Extrahepatic spread 13 (72.2%) 65 (72.2%) 1.000
Alfa-fetoprotein>400 ng/ml 4 (22.2%) 19 (21.1%) 1.000
[Table 1]
Immunosuppressant in OLT patients included: everolimus (n=10), tacrolim-
us (n=4), sirolimus (n=2), cyclosporine (n=2). Toxicities were similar in the 
two groups.The median treatment duration [4.5 months (95%CI 3.0-6.1) vs 
5.9 months (95% CI 4.0-7.9), p=0.344] was comparable as well as the rate 
of radiologic disease control (44.4 vs 52.5%, p=0.323). Finally, the OS was 
also similar [11.5 months (95%CI 9.2-13.8) vs 13.5 months (95%CI 9.7-17.3) , 
p=0.725] in OLT and non-OLT groups, respectively. 
conclusion: Extrahepatic spread was common in patients with HCC recur-
ring after OLT, possibly reflecting the negative effects of immunomodu-
lation.. However, once sorafenib was started, treatment duration, radio-
logical response and OS were comparable with those of controls. The 
prognosis of these patients seems to be more influenced by their clinical 
presentation rather than by a reduced efficacy of sorafenib.
references: 1) Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cor-
done G, Gentiluomo M, Belli LS. Adverse events affect sorafenib efficacy in 
patients with recurrent hepatocellular carcinoma after liver transplanta-
tion: experience at a single center and review of the literature. Eur J Gas-
troenterol Hepatol. 2013 Feb;25(2):180-6. 2) Vitale A, Boccagni P, Kertusha 
X, Zanus G, D’Amico F, Lodo E, Pastorelli D, Ramirez Morales R, Lombardi 
G, Senzolo M, Burra P, Cillo U. Sorafenib for the treatment of recurrent 
hepatocellular carcinoma after liver transplantation? Transplant Proc. 2012 
Sep;44(7):1989-91 3) Mancuso, A., Mazzola, A., Cabibbo, G., Perricone, G., 
Enea, M., Galvano, A., Zavaglia, C., Belli, L. and Cammà, C. Survival of 
patients treated with sorafenib for hepatocellular carcinoma recurrence 
after liver transplantation: A systematic review and meta-analysis, Diges-
tive and Liver Disease 2015, 47(4), pp. 324-330.
disclosure: Nothing to disclose 
P0082 “cheMO-vacaTIOn PerIOd” gaIned By adjuvanT 
hePaTecTOMy fOr synchrOnOus BILaTeraL MuLTIPLe 
cOLOrecTaL LIver MeTasTasIs
Natsume S., Shimizu Y., Senda Y., Okuno M., Kinoshita T.
Aichi Cancer Center, Gastroenterological Surgery, Nagoya, Japan
contact e-Mail address: snatsume@aichi-cc.jp
Introduction: Recently, number of patients with synchronous bilateral 
multiple colorectal liver metastasis (SBM-CRLM) who underwent adjuvant 
hepatectomy (AH) is increasing. In such cases, surgery is often performed 
as one choice of multidisciplinary therapy even for patients with low possi-
bility of complete cure. It is because most surgeons or medical oncologists 
consider that “chemo-vacation period” gained by AH have some possibility 
to give a positive impact for the patients’ quality of life (QOL) and second 
line treatment. However, there has been no reports investigating actual 
period of “chemo-vacation”.
aims & Methods: The aim of this study is to investigate the surgical out-
come of resected cases for SBM-CRLM and to clarify the “chemo-vacation 
period”.
35 patients who underwent AH (2013-2018) for SBM-CRLM were examined. 
R0 or R1 resection was achieved in all patients. Chemo-vacation period 
was defined as the duration between the latest date of pre or post-op-
erative chemotherapy and the date of re-inducing chemotherapy for the 
post-operative recurrence.
results: The median number of liver metastasis was 7 (range; 2-30). Ana-
tomical hepatectomy was performed for 25 patients (71.4%). The median 
hospitalization after AH was 12 days and there was no mortality. Recur-
rence was developed in 16 patients (45.7%). The median recurrence fee 
survival time, 3-year recurrence free survival rate and 3-year overall sur-
vival rate were 428 days, 48.2% and 87.1%, respectively. Re-induction of 
chemotherapy for the recurrence was done in 9 patients. In these cases, 
the median “chemo-vacation period” was 155 days.
conclusion: Although post-operative recurrence was occurred in high rate, 
overall survival rate was relatively good. AH gained about 5 months of 
“chemo-vacation period” even in cases with recurrence.
disclosure: Nothing to disclose 
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August 2014 and October 2018. We attempted to perform biliary cannula-
tion for DBE-ERCP using conventional techniques, including wire-guided 
cannulation or pancreatic guidewire placement with conventional guide-
wire (0.025 or 0.035 inch) in the first 10 min. When the endoscopists found 
the procedure challenging, they were permitted to switch to GTW after 10 
min to achieve cannulation and change the guidewire to GTW after 60 min 
from initiation of the procedure. DBE-ERCP-difficult-patients were defined 
as those who underwent biliary cannulation with GTW. Selective biliary 
cannulation was performed under fluoroscopic control.
results: The 20 consecutive ERCP-naive patients with altered gastrointes-
tinal anatomy included 14 males and 6 females. The age (median [range]) 
was 77 [59-88] years. Twelve patients had common bile duct stones, 7 had 
malignant biliary strictures, and 1 had primary sclerosing cholangitis. All 
endoscopists, except one expert, were inexperienced in DBE-ERCP, despite 
more than 5 to 10 years of experience in ERCP (3 experts with more than 
10 years and 5 trainees with 5-10 years). The conventional technique was 
successful in 55% (11/20) patients (con group), while it was unsuccessful 
in 1 case owing to worse clinical conditions during this procedure (un-
used GTW). Although 40% (8/20) patients who failed the biliary cannu-
lation were considered DBE-ERCP-difficult-patients, the GTW technique 
was successful for biliary cannulation in 100% (8/8) cases (GTW group). 
Consequently, the overall success rate improved from 55% to 95% (19/20 
patients). The reaching time to the blind end was not significantly different 
between the con group and GTW group (25 [12-69] min and 22 [15-38] min, 
respectively). The cannulation time (the time from advancement of the 
cannula out of the endoscope channel to the successful deep cannulation) 
in the con group was 8.8 [3-47] min. Although the switched time (the time 
from advancement of the cannula out of the endoscope channel to that 
when switched to GTW) in the GTW group was 38 [15-61] min, the cannula-
tion time after switch to GTW was 3.8 [1.2-15] min and significantly shorter 
than that before switch to GTW (P=0.01, Wilcoxon signed-rank test).
conclusion: Although the biliary cannulation in DBE-ERCP with altered 
gastrointestinal anatomy was difficult for inexperienced endoscopists in 
DBE-ERCP, the salvage technique using a micro guidewire can facilitate 
this procedure.
disclosure: Nothing to disclose 
P0085 a PrOsPecTIve sTudy Of TeMPOrary PLaceMenT Of a 
fuLLy-cOvered MeTaL sTenT fOr refracTOry BenIgn BILIary 
sTrIcTure
Sato T.1, Kogure H.1, Nakai Y.2, Inokuma A.1, Suzuki Y.1, Oyama H.1, 
Kanai S.1, Suzuki T.1, Nakamura T.1, Ishigaki K.1, Hakuta R.1, Saito K.1, 
Saito T.1, Takahara N.1, Hamada T.1, Mizuno S.1, Yamada A.1, Tada M.1, 
Isayama H.3, Koike K.1
1University of Tokyo, Gastroenterology, Tokyo, Japan, 2University of Tokyo, 
Endoscopy and Endoscopic Surgery, Tokyo, Japan, 3Juntendo University, 
Gastroenterology, Tokyo, Japan
contact e-Mail address: tatsusatou-tky@umin.org
Introduction: Endoscopic treatment utilizing balloon dilation and plastic 
stent placement has been established as a standard of care for benign 
biliary strictures (BBS). However, patients with recurrent or refractory 
strictures necessitate long duration of endoscopic, percutaneous or even 
surgical treatment.
aims & Methods: The aim of this prospective exploratory trial was to evalu-
ate the effectiveness and safety of temporary placement of a fully-covered 
self-expandable metal stent (FCSEMS) for patients with refractory BBS, 
especially with biliary anastomotic stricture after living-donor liver trans-
plantation (LDLT) and hepaticojejunostomy anastomotic strictures (HJAS). 
We included patients with refractory BBS defined as strictures resistant 
to balloon dilation and plastic stent placement longer than six months. 
FCSEMS (Niti-S Kaffes stent, Taewoong medical, Gyeonggi-do, South Ko-
rea) was placed endoscopically and removed after 3 months. In cases with 
HJAS, FCSEMS was placed under double-balloon endoscope-assisted en-
doscopic retrograde cholangiopancreatography. The primary outcome was 
a rate of stricture resolution at FCSEMS removal. The secondary outcomes 
included rates of stricture recurrence and adverse events. The trial was 
registered to UMIN-CTR (UMIN000022164).
results: A total of 30 patients were eligible for this study between Septem-
ber 2016 and February 2018. The major causes of BBS were 13 LDLT, and 
12 HJAS, and the other etiology of BBS included 1 post-cholecystectomy, 2 
chronic pancreatitis and 1 post-hepatectomy. The location of BBS was dis-
P0083 rIsk facTOrs fOr syMPTOMaTIc gaLLsTOne dIsease 
afTer rOux-en-y gasTrIc ByPass
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Introduction: Patients with morbid obesity are at risk for symptomatic 
gallstone disease after bariatric surgery. Up to 15% of patients will de-
velop biliary symptoms within two years after surgery. Although bariatric 
surgery is performed widely nowadays, specific risk factors for gallstones 
have not been well defined. Therefore, we aimed to identify risk factors for 
symptomatic gallstone disease after laparoscopic Roux-en-Y gastric bypass 
(LRYGB).
aims & Methods: We conducted a case-control study of patients who 
underwent a LRYGB between 2013 and 2015 in the MC Slotervaart (Am-
sterdam, The Netherlands). Primary endpoint was symptomatic gallstone 
disease defined as the need for cholecystectomy because of postoperative 
biliary symptoms within two years after surgery. We selected for each case 
two controls without symptomatic gallstone disease after surgery. Logis-
tic regression analyses were used to identify risk factors for symptomatic 
gallstone disease.
results: Between 2013 and 2015, 1780 primary LRYGBs were performed. 
We identified 233 (13.1%) cases who developed symptomatic gallstones 
after a median [IQR] of 9 [5-14] months, and 466 controls. Younger age [OR 
(95% CI) 0.98 (0.96-0.99)], female gender [OR 1.83 (1.06-3.17)], Caucasian 
ethnicity [OR 1.82 (1.10-3.02)], higher percent total weight loss (%TWL) at 
12 months [OR 1.06 (1.04-1.09)] and preoperative pain syndrome [OR 2.72 
(1.43-5.18)] were associated with an increased risk for symptomatic gall-
stones. In a subgroup of patients who developed symptomatic gallstones 
within 9 months, preoperative statin use was associated with a reduced 
risk [OR 0.27 (0.09-0.78)].
conclusion: In our study, higher %TWL and preoperative pain syndrome 
were associated with an increased risk of symptomatic gallstones besides 
the traditional risk factors female gender and Caucasian ethnicity. Most 
factors can be used to identify high-risk patients, who might benefit from 
preventive measures. Whether statins can protect bariatric patients from 
developing gallstones should be investigated prospectively.
disclosure: Nothing to disclose 
P0084 saLvage TechnIque fOr dOuBLe-BaLLOOn 
enTerOscOPy-assIsTed endOscOPIc reTrOgrade 
chOLangIOPancreaTOgraPhy usIng a MIcrO guIdeWIre
Mori A., Yumura T., Hayashi S., Hachiya H., Shibuya T., Ohashi N.
Ichinomiya Nishi Hospital, Dept. of Gastroenterology, Ichinomiya, Japan
contact e-Mail address: a-mori@anzu.or.jp
Introduction: Double-balloon enteroscopy-assisted endoscopic retrograde 
cholangiopancreatography (DBE-ERCP) in patients with altered gastroin-
testinal anatomy is a technically difficult procedure. Particularly, biliary 
cannulation in DBE-ERCP may be challenging for even endoscopic retro-
grade cholangiopancreatography (ERCP) experts because the endoscopic 
maneuver of double-balloon enteroscopy (DBE) is different from that of 
conventional duodenal endoscopy. On the contrary, micro guidewire (GT 
wire; 0.016-inch, 300 cm, TERUMO, Japan; GTW) designed for super-se-
lective angiography is reported to assist in difficult biliary cannulation in 
ERCP (UEGW 2017 and 2018). Hence, we developed a novel biliary cannula-
tion technique using GTW for DBE-ERCP.
aims & Methods: We aimed to assess the usefulness of GTW in the salvage 
technique for biliary cannulation using DBE-ERCP. We studied 20 consecu-
tive ERCP-naive patients with altered gastrointestinal anatomy between 
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tal in 2, proximal or IHBD in 16, and at the site of bilio-enteric anastomosis 
in 12. A median time from initial biliary drainage to FCSEMS placement 
was 25.5 months (interquartile range [IQR] 11.0-45.1). FCSEMS was placed 
in 29 patients except one developing cholangitis prior to FCSEMS place-
ment. One patient needed premature FCSEMS removal due to cholangitis 
on day 65. Finally, a total of 28 patients completed a planned indwell-
ing period of 90 days and all FCSEMS were successfully removed without 
difficulty. The rate of stricture resolution at FCSEMS removal was 96.6%. 
Stricture recurrence occurred in 10.7% during a median follow-up period 
of 15.6 months (IQR 12.0-22.1). Adverse events were observed in 10.3%: 5 
cholangitis (3 moderate and 2 mild), 1 pancreatitis (moderate) and 1 intra-
abdominal air (moderate).
conclusion: Temporary placement of FCSEMS was a feasible and effective 
treatment option for refractory BBS such as anastomotic strictures after 
LDLT and HJAS.
disclosure: Nothing to disclose 
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National University, Department of Internal Medicine, Daegu, Korea 
(Republic of), 2Kyungpook National University Hospital/Korea of Republic/
Kyungpook National University, Daegu, Korea (Republic of)
contact e-Mail address: hero797@hanmail.net
Introduction: Although, cholecystectomy is the treatment of choice for cho-
lecystitis, many patients with comorbidities cannot undergo this surgical 
treatment. Percutaneous transhepatic gallbladder drainage (PTGBD) is the 
other treatment option for these patients. However, afterward, removing 
of PTGBD is not easy due to relative high risk of recurrent cholecystitis.
aims & Methods: The aim of our study is to evaluate the role of endo-
scopic sphincterotomy on reducing the recurrence of cholecysitis. The pa-
tient who underwent PTGBD due to cholecystitis between January 2011 and 
April 2018 in Kyungpook National University Hospital, Republic of Korea 
were retrospectively analyzed. After improvement of acute cholecystitis by 
PTGBD, scheduled removal of PTGBD was conducted. We compared re-
currence rate between endoscopic sphincterotomy group with observation 
group after removal of PTGBD.
results: Among total of 1,148 PTGBD cases, patients scheduled for cho-
lecystectomy, follow up duration of less than 1 year, loss of follow up, no 
removal of PTGBD, direct trauma or cancer related cholecystitis, prior 
sphincterotomy before PTGBD, percutaneous transhepatic biliary drainage 
with balloon dilatation at bile duct sphincter, and secondary cholecystitis 
were excluded. 126 patients were enrolled in this study. Among them, 40 
patients underwent endoscopic sphinterotomy after PTGBD. The other 86 
patients were treated without a specific procedure. The PTGBD was re-
moved after improvement of PTGBD. The median interval between PTGBD 
and sphincterotomy was 108 days (range, 0-1,988). The total recurrence 
rate of cholecystitis was 15.1% (19/126) in the median follow-up period of 
1,159 days (range, 369-2,774 days). There was no difference of recurrence 
rate between endoscopic sphincterotomy and observation group by using 
Kaplan-Meier curves with the log-rank test (P=0.807). There was a ten-
dency of shorter duration of recurrence in observation group than endo-
scopic sphincterotomy group (mean±SD days; 830±603.1 vs. 1,033±669.9, 
p=0.093). However, this difference is not significant statistically. The only 
factor that increase recurrent cholecystitis was the presence of gallstone 
(P=0.048, by Kaplan-Meier analysis).
conclusion: Endoscopic sphincterotomy do not reduce recurrent cholecys-
titis that treated by PTGBD. Other strategies for reducing recurrent chole-
cytitis should be investigated for patients who cannot undergo cholecys-
tectomy and need PTGBD.
disclosure: Nothing to disclose 
P0087 PneuMOBILIa and an aBsence Of InTrahePaTIc BILe 
ducT dILaTaTIOn are PredIcTOrs Of anasTOMOTIc PaTency 
afTer chOLedOchOjejunOsTOMy
Yokoyama K.1, Yano T.1, Ushio J.1, Tamada K.1, Lefor A.2, Yamamoto H.1
1Jichi Medical University, Department of Gastroenterology, Shimotsuke, 
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Introduction: Cholangitis due to anastomotic strictures after choledochoje-
junostomy are treated with double-balloon endoscopic retrograde cholan-
giography (DBERC) and dilatation. However, some patients with cholangi-
tis did not show anastomotic strictures on endoscopic findings.
aims & Methods: 
aim: To evaluate predictors of anastomotic strictures in patients after cho-
ledochojejunostomy.
Methods: We reviewed 367 patients with surgically altered biliary anatomy 
evaluated by DBERC from January 2007 to March 2017. We anticipated stric-
tures at the choledochojejunostomy in 76 patients due to cholangitis or 
obstructive jaundice (21 after biliary resection, 21 after pancreaticoduo-
denectomy, and 34 after living donor liver transplantation). Anastomotic 
patency was evaluated in association with the following factors: fever, 
persistent cholangitis, elevation of liver enzymes, bilirubin, or CRP, pneu-
mobilia of the intrahepatic bile ducts (IHBD), retained fluid in the afferent 
limb, dilatation of IHBD (>5mm) on computed tomography (CT) scan, and 
stones in the IHBD.
results: Of 76 patients who underwent DBERC for suspicion of anasto-
motic stricture, 64 had a stricture at the anastomosis, and 12 did not. In 
univariate analysis, normal serum liver enzyme levels (p=0.028), absence 
of IHBD dilatation (p=0.037) and pneumobilia (p< 0.01) were significantly 
associated with anastomotic patency. In multivariate analysis, pneumobi-
lia (p=0.01, Odds Ratio [OR]7.01) and absence of IHBD dilatation (p=0.026 
OR0.06) were independent predictors of anastomotic patency. The combi-
nation of these two factors were significantly associated with anastomotic 
patency (p< 0.01, OR 0.03).
conclusion: Pneumobilia and the absence of IHBD dilatation on CT scan 
are predictors of anastomotic patency. Patients with both factors are highly 
likely to have a patent anastomosis and can usually be treated without 
endoscopic or surgical procedure.
disclosure: Nothing to disclose 
P0088 PredIcTOrs Of cOnfIrMed cOMMOn BILe ducT 
sTOnes afTer a POsITIve InTra-OPeraTIve chOLangIOgraM 
durIng chOLecysTecTOMy: LaBOraTOry, radIOLOgIc, and 
deMOgraPhIc facTOrs
Shaib Y.1, Hosni M.2, Tarhini H.3, Hassoun L.2, Al Masri S.4, Hallal A.4
1American University of Beirut, Medicine/Gastroenterology, Beirut, Lebanon, 
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Beirut, Lebanon, 3American University of Beirut Medical Center, Beirut, 
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contact e-Mail address: mnh23@mail.aub.edu
Introduction: Among patients with symptomatic gallstones, initial evalu-
ation of suspected choledocholithiasis includes serum liver biochemical 
tests and transabdominal ultrasound. Patients with intermediate prob-
ability of choledocholithiasis undergo further evaluation with either pre-
operative EUS or an IOC. However, the incidence of false positive results is 
increasing, thus subjecting patients for unnecessary interventions.
aims & Methods: Our aim in is to evaluate the correlation between pre-
operative and intra-operative findings with the presence of a CBD stone 
on ERCP.
This is a retrospective review of chart study, where all patients who un-
derwent IOC during their same stay laparoscopic cholecystectomy at the 
American University of Beirut Medical Center, Lebanon between 2010 
and 2018. All patients who were admitted for gallstone related LC were 
scanned. Patients with a positive IOC (filling defect, non-passage of con-
trast to duodenum, or dilated CBD that didn’t resolve upon surgical ma-
nipulation) who were further followed with ERCP or EUS for suspected 
CBD stone were included. The subjects were divided into 2 groups, those 
with a confirmed CBD stone and those with a false positive IOC. Data col-
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cholithiasis is associated with severe complications such as cholangitis 
and acute pancreatitis. The endoscopic retrograde cholangiopancreatog-
raphy (ERCP) is the treatment of choice for choledocholithiasis, but is as-
sociated with 5-10% risk of complications. Therefore, an accurate selection 
of patients with high probability of having choledocholithiasis is essential 
in the management of this population.
The guide of the American Society of Gastrointestinal Endoscopy (ASGE) 
have proposed criteria to stratify patients into low, intermediate and high 
risk of choledocholithiasis using variables readily available in clinical prac-
tice. The objective of the present study was to establish the diagnostic ac-
curacy of these criteria, as well as to evaluate the presence of additional 
variables that are associated with the presence of choledocholithiasis.
aims & Methods: A cross-sectional cohort study was conducted at San 
Martin de La Plata Hospital during the period between 2017 and 2019. All 
patients older than 15 years referred for ERCP with suspected choledo-
cholithiasis that met ASGE criteria of high and intermediate risk of cho-
ledocholithiasis were considered for inclution. Presence of stone at ERCP 
served as criteria standard.
results: During the study period, 653 patients met inclusion criteria. Of the 
645 patients in high risk for choledocholithiasis group, 451 were found to 
have stones during ERCP (69.9%). Of the 8 patients at intermediate risk 
for choledocholithiasis, 5 were found to have stones during ERCP (62.5%); 
P-value for the difference between groups = 0.703. The diagnostic accuracy 
for choledocholithiasis in the high-risk group was 70%, and for the inter-
mediate risk group it was 30%. 
The presence of choledocholithiasis on pre-ERCP imaging presented 1.5 
times more probability of having stones at ERCP compared with those who 
did not have it (OR: 2.49, 95% CI 1.49-4.16), being the strongest predic-
tor of choledocholithiasis. In a multivariate logistic regression analysis, an 
increase of alkaline phosphatase (ALP) above normal value was found as 
an additional variable (OR: 2.09, 95% CI 1.32-3.34). The time between the 
pre-ERCP imaging with evidence of choledocholithiasis and the evidence 
of choledocholithiasis at ERCP was 9 days (5-19), and 12 days (7-21) in pa-
tients without evidence of choledocholithiasis at ERCP (p = 0.0423).
  Predictor Or cI 95%
  Elevated transaminases 0.67 (0.41-1.06)
  Elevated ALP 2.09 (1.32-3.34)
ERCP indication Suspected choledocholithiasis Reference  
  Suspected ascending cholangitis 2.32 (0.92-7.12)
  Suspected gallstone pancreatitis 0.37 (0.11-1.21)
  Choledocholithiasis 2.7 (1.59-4.60)
[multivariate logistic regression analysis]
conclusion: The use of ASGE criteria to predict the likelihood of cho-
ledocholithiasis are useful in high-risk patients and can be used in daily 
practice. The evidence of choledocholithiasis in imaging is the strongest 
predictor associated with the presence of stones at ERCP. The increase of 
serum ALP is an additional variable related to the presence of choledocho-
lithiasis at ERCP.
disclosure: Nothing to disclose 
P0090 IdenTIfIcaTIOn Of MaLIgnanT BILIary sTrIcTures vIa 
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eLecTrOnIc nOse: a PILOT sTudy
Obst W.1, Canbay A.E.1, Weigt J.2
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Introduction: Determination the dignity of biliary strictures in patients 
with obstructive jaundice can be challenging. Present procedures still have 
difficulties to differentiate between malignant and benign strictures and 
other methods are needed to avoid wrong diagnoses. One novel diagnostic 
tool could be the profiling of volatile organic compounds (VOCs) in exhaled 
breath via training an artificial neural network (ANN) that showed promis-
ing results in previous studies detecting other malignant tumours.
lected included: patient’s age, gender, pre-operative laboratory results, 
pre-operative abdominal imaging (EUS, right abdominal ultrasound, or CT 
abdomen), IOC findings and post LC ERCP results were included. We used 
McNemar’s test, paired t test, and conditional logistic regression analysis 
to compare the two groups.
results: During the specified period, the files of 685 patients who had IOC 
during LC were scanned. Among those, 35 patients were found to have a 
positive IOC and were followed up endoscopically. The average age of our 
population was 52 ± 20 years, with a female predominance of 62.9% (22 
patients). 
The most common indication for LC was cholecystitis (17, 49%) followed by 
cholelithiasis (15, 43%). The most common IOC finding was “non-passage 
of contrast to the duodenum” with 29 patients, followed by filling defect in 
19 patients. CBD stone was confirmed in 25 patients (71.40%). 
Comparing the 2 groups, patients who had CBD stone were older, and 
were more likely to have a normal serum liver biochemical test (table). 
On pre-op imaging, none of the patients who had a false positive result 
had CBD dilation. Regarding IOC findings, dilated CBD on IOC was signifi-
cantly associated with the presence of CBD stone on further investigations 
(p=0.028). On multivariate analysis, dilated CBD on IOC, was found to be 
an independent predictor of a CBD stone with OR= 9 [1.0-82.5, p=0.052].
demographics and Operative variables no evidence of cBd stones (n=10)
cBd stone 
(n=25) p-value
age, mean (sd) 46 (16) 54 (21) 0.253
gender (female), n (%) 7 (70%) 15 (60%) 0.709
Pre-operative asT (Iu/L), mean (sd) 69 (89) 131 (160) 0.154
Pre-operative aLT (Iu/L), mean (sd) 131 (210) 170 (243) 0.646
Pre-operative alkaline phosphatase 
(Iu/L), mean (sd) 194 (197) 168 (164) 0.722
Pre-operative ggT (Iu/L), mean (sd) 152 (180) 192 (232) 0.591
Pre-operative lipase (Iu/L), mean (sd) 45 (42) 157 (530) 0.329
Pre-operative total bilirubin (mg/dL), 
mean (sd) 1 (2) 1 (1) 0.749
Pre-operative imaging      
cBd dilation on any imaging, n (%) 0 (0%) 7 (33%) 0.142
IOc abnormality      
dilated cBd, n (%) 1 (10%) 13 (52%) 0.028
filling defect, n (%) 7 (70%) 12 (48%) 0.285
non-passage of contrast to duodenum, 
n (%) 6 (60%) 15 (60%) 1.000
[Clinical characteristics of IOC positive patients who were followed up 
endoscopically.]
conclusion: IOC findings are important in guiding the post-operative man-
agement of patients with suspected CBD stones. A dilated CBD on IOC is 
the strongest predictor of CBD stones and should prompt further investi-
gations.
disclosure: Nothing to disclose
P0089 assesMenT Of cOnsensus crITerIa fOr 
chOLedOchOLIThIasIs: are They usefuL In The cLInIcaL 
PracTIce?
Sciarretta M.1, Vargas Y.2, Tufare F.3, Baldoni F.3, Yantorno M.3, Vitale L.3, 
Ojeda E.1, Talani A.2, Perron N.S.1, Fasano M.V.4, Correa G.J.3, Villaverde A.3
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Martin, La Plata, Argentina, 3HIGA San Martin, La Plata, Argentina, 4Instituto 
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contact e-Mail address: tinchosc@hotmail.com
Introduction: Biliary lithiasis is a condition that affects about 15% of the 
population in Europe and North America. In 10-15% of cases it is compli-
cated by the presence of choledocholithiasis, which is suspected in the 
scenarios of symptomatic cholelithiasis and acute biliary pancreatitis, as 
well as other presentations such as de novo lithiasis in cholecystectomized 
patients. In Argentina, the prevalence of choledocholithiasis in patients 
undergoing cholecystectomy with or without suspicion is 15.1%. Choledo-
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aims & Methods: Aim of this pilot study is to investigate the diagnostic 
performance of a handheld electronic nose by analysing VOC patterns in 
exhaled breath of patients with malignant and benign biliary obstruction.
In this prospective study we included 107 patients with obstructive jaun-
dice. 
Before an invasive procedure (endoscopy or surgery) was performed, ex-
haled breath of all patients was sampled and processed using an elec-
tronic nose device (Aeonose™, The eNose Company, Zutphen, The Nether-
lands). Only patients with histologically confirmed diagnosis or with bile 
duct stones were considered in the analysis and divided into two groups: 
malignant and benign biliary obstruction. 
The electronic nose measurement data obtained were used for training 
an ANN and cross-validated using the ‘Leave-10%-Out’ technique. Patient 
characteristics, including laboratory values, were documented and anal-
ysed statistically.
results: 60 patients with malignant (cholangiocarcinoma, pancreatic can-
cer, liver metastases, hepatocellular carcinoma) and 47 patients with be-
nign (bile duct stones, chronic pancreatitis, primary sclerosing cholangitis, 
postoperative) biliary stenosis were compared. The trained ANN was able 
to distinguish between the two groups with an accuracy of 0,79 and an 
area under the curve of 0,82. The sensitivity and specificity were 80 (95% 
confidence interval [CI] 0,67-0,89) and 0,77 (95% CI 0,62-0,87), respective-
ly. The positive predictive value to diagnose correctly a malignant biliary 
stricture was found to be 0,81.
conclusion: The use of an electronic nose in combination with a competent 
ANN can be a new non-invasive diagnostic tool in the discrimination of 
obscure bile duct strictures. However further training is needed to improve 
the accuracy of the ANN.
disclosure: Nothing to disclose 
P0091 sIngLe-OPeraTOr PerOraL chOLangIOscOPy-guIded 
LIThOTrIPsy fOr dIffIcuLT BILIary sTOnes: a PrOsPecTIve 
MuLTIcenTer sTudy
Moreira M.1, Fernandes J.1,2, Alexandrino G.3, Araújo T.1, Lourenço L.3, 
Horta D.3, Bana e Costa T.4, Lopes L.1,5,6, Canena J.3,7
1Santa Luzia Hospital - Unidade Local de Saúde Alto Minho, 
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Introduction: ERCP is the first choice for the removal of biliary stones. In 
difficult stones, advanced therapeutic techniques, such as electrohydraulic 
lithotripsy (EHL) and laser lithotripsy (LL) have been proposed. Recently, 
the availability of single-operator cholangioscopy (SOC) turned these tech-
niques more accessible and easier to perform.
aims & Methods: We sought to evaluate the clinical efficacy and safety of 
SOC guided-lithotripsy using EHL or LL in patients with complex biliary 
stones.
A prospective study was carried out in 4 hospitals, comprising 45 con-
secutive patients with complicated biliary stones treated with SpyGlass DS 
(Boston Scientific, Marlborough, United States) guided-lithotripsy using 
EHL or Holmium LL. We analyzed the complete cleaning of the ducts, the 
incidence of adverse events, the impact of the number of stones and its 
location on clinical success, and the performance of the 2 lithotripsy mo-
dalities.
results: 37 patients (82.22%) had common bile duct/common hepatic duct 
stones, 5 patients (11.11%) had a single cystic stump stone and 3 patients 
(6.66%) had intrahepatic stones. 37 patients (82.22%) were successfully 
treated in one procedure and the remaining 8 patients (17.77%) required 
additional sessions to obtain cleaning of the ducts. 28 patients were treat-
ed with LL: 24 (85.71%) achieved clinical success in a single session with 
a single laser fiber. 17 patients were treated with LEH: 7 patients (41.17%) 
were clinically successful in a single 1-fiber session; 6 patients required 2 
fibers to obtain ductal cleansing in a single session.
Complications were mild in 7/45 (15.55%) patients and included fever (n = 
5), cholangitis (n = 1), and mild pancreatitis (n = 1).
conclusion: SOC guided-lithotripsy using EHL or LL in patients with difficult 
biliary stones is very effective and is associated with transient and mild 
complications. Although further studies are needed there is an apparent 
advantage in the use of laser technology.
disclosure: Nothing to disclose 
P0092 gaLL sTOne PancreaTITIs OuTcOMes In The eLderLy
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Introduction: Gallstone pancreatitis is the most common cause of pan-
creatitis in the United States. Little is known about outcomes of gallstone 
pancreatitis in the elderly population. We aimed to examine the associa-
tion of age with outcomes and management of acute gallstone pancre-
atitis
aims & Methods: A retrospective study utilizing the 2014 National Inpatient 
Sample (NIS) database was performed. All Adult patient hospitalizations 
with a diagnosis of acute pancreatitis and gallstones were included in this 
study. We excluded hospitalizations with a diagnosis of acute pancreatitis 
from any other identifiable etiology. The outcome data including presence 
of organ failure, inpatient surgical procedures, length of hospital stay and 
mortality were obtained. Patient and outcome characteristics were com-
pared using the Mann U Whitney test for non-normally distributed data 
and logistic regression was used to examine associations of elderly age 
with outcomes. We controlled for hospitalizations, patient and hospital-
level characteristics.
results: We identified 55,285 hospitalizations that met our inclusion crite-
ria. 66% were ≤ 65 years compared to 33% > 65 years. Whites accounted 
for more admissions in both age groups (72% for age > 65 and 52% for 
age ≤ 65 years). Females had more episodes of acute gallstone-related 
pancreatitis (69% for ≤ 65 years and 61% for > 65 years). 58% of hospital-
izations were in patients > 65 years with ≥ three comorbidities. 
Endoscopic retrograde cholangiography (ERCP) was performed in 33% of 
hospitalizations > 65 years versus 20% of hospitalizations ≤ 65 years. 62% 
of hospitalizations ≤ 65 years had a cholecystectomy compared to only 
44.7% in patients > 65 years. Finally, median length of stay was shorter in 
hospitalizations ≤ 65 years (4 days vs. five days; p-value < 0.001) compared 
to 65 and older.
On multivariable analysis, hospitalizations > 65 years were twice as likely 
(AOR 2.2, 95% CI 1.8- 2.8) to have acute kidney injury compared to hospi-
talizations ≤ 65 years. 
There was no significant difference between having an acute respiratory 
failure (AOR 1.18, 95% CI 0.92 - 1.50) or need for mechanical ventilation 
(AOR 1.14, 95% CI 0.77-1.67) in patients > 65 compared to their counterparts 
≤ 65 years. Patients > 65 years were 22% more likely (AOR 1.22, 95% CI 1.06 
-1.41) to receive an ERCP but 31% less likely (AOR 0.69, 95% CI 0.61 - 0.79) 
to have a cholecystectomy (laparoscopic or open). Patients > 65 years were 
two times higher mortality (AOR 2.95, 95% CI 1.59 - 5.56) during hospital-
ization for acute pancreatitis compared to patients ≤ 65 years.
conclusion: Results from our study show significant disparities in hospi-
talization outcomes in elderly patients. Hospitalizations with age > 65 had 
fewer cholecystectomies done during index admission compared to age ≤ 
65 years. Similarly, significantly more comorbidities, end organ damage 
(AKI), and increased mortality was associated with elderly patients with 
acute gall stone pancreatitis.
disclosure: Nothing to disclose 
P0093 IMPrOvIng The dIagnOsTIc yIeLd Of BILIary Brush 
cyTOLOgy In PancreaTOBILIary cancers: a sIngLe cenTre 
exPerIence
Selvaraj E.1, Lei I.1, Rendek A.2, Collantes E.2, Hughes C.2, Bailey A.1
1Oxford University Hospitals NHS Foundation Trust, Gastroenterology, Oxford, 
United Kingdom, 2Oxford University Hospitals NHS Foundation Trust, Cellular 
Pathology, Oxford, United Kingdom
contact e-Mail address: emmanuel_selvaraj@hotmail.com
Introduction: The diagnostic sensitivity of brush cytology for malignant 
biliary stricture has typically reported to be low (6-64%). The perceived 
futility coupled with the emergence of endoscopic ultrasound (EUS) and 
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P0094 a nOveL aPPrOach fOr sTudy Of PancreaTIc ducTs 
In MIce
Gál E.1, Dolensek J.2, Stozer A.2, Ébert A.1, Venglovecz V.1
1University of Szeged, Department of Pharmacology and Pharmacotherapy, 
Szeged, Hungary, 2University of Maribor, Institute of Physiology, Maribor, 
Slovenia
contact e-Mail address: eleonorcika@gmail.com
Introduction: Tissue slice technique offers several benefits compared to 
isolated cells that helps us to understand (patho)physiology of several 
organs in situ. The most prominent feature are intact homotypic in het-
erotypic interactions within the tissue. In the pancreas, this technique has 
been successfully applied to study acinar and endocrine islet cells; how-
ever, has never been used to investigate ductal function. Since pancreatic 
ductal epithelial cells (PDECs) play essential role in the physiology of the 
pancreas, our aim was to apply this technique to pancreatic ductal cells 
and thus study these cells in a more in vivo physiological conditions.
aims & Methods: 8-16 weeks old C57BL/6 mice were used for the prepa-
ration of pancreatic tissue slices. Low-melting point agarose was retro-
gradely injected into the common bile duct that served as a scaffold for 
further manipulation. For morphological studies, agarose-embedded tis-
sue was further subjected to 15 µm thick cryosectioning. In order to visu-
alize pancreatic ducts cystic,Giemsa dye was added to the agarose that 
was injected into the ductal tree and visualized using light microscopy 
or fibrosis transmembrane conductance regulator (CFTR) immunostaining 
was performed. For functional calcium imaging, agarose-embedded tis-
sue was immediately cut to 140 µm thick tissue slices; these were loaded 
with OGB-1 AM.
results: Giemsa staining has shown, that the injected agarose reaches the 
head and body of
the pancreas, but not the tail. Strong CFTR expression was detected at the 
apical membrane of the ductal cells and acini, whereas islet cells were 
completely negative for CFTR. In order to induce changes in intracellular 
calcium concentration ([Ca 2+ ] i ) chenodeoxycholic acid (CDCA,1mM) was 
used. Administration of CDCA, for 5 minutes, caused a robust, revesible 
increase in ([Ca 2+ ] i in most of the investigated ducts.
conclusion: Our results confirm that the pancreas tissue slice technique 
is suitable for the functional investigation of PDECs. The morphology of 
the PDECs was not disturbed by the tissue preparation and PDECs express 
functional membrane proteins; moreover, PDECs routinely responded to 
physiological stimuli. The main advantage of this approach is that allows 
us to examine many PDECs simultaneously, and in an intact milieu of 
neighbouring cells in situ, a more natural condition compared to other 
in vitro approaches; additionally it allows to study heterotypic interactions 
with other cell types, such as the acini or the endocrine pancreas allowing 
for broad spectra of pathophysiological testing.
disclosure: Nothing to disclose 
P0095 cOrreLaTIOn BeTWeen PancreaTIc T1 vaLues usIng 
MOdIfIed LOOk-LOcker InversIOn recOvery (MOLLI) sequence 
and PancreaTIc exOcrIne and endOcrIne funcTIOn
Ashihara N.1, Watanabe T.1, Yamada A.2
1Shinshu University School of Medicine, Second Department of Internal 
Medicine, Matsumoto, Japan, 2Shinshu University School of Medicine, 
Department of Radiology, Matsumoto, Japan
contact e-Mail address: kenta55226@gmail.com
Introduction: Quantifying myocardial T1 values has been useful for detect-
ing and characterizing fibrotic appearance in myocardial infarction, fo-
cal scars, and non-ischemic cardiomyopathies. Since pancreatic exocrine 
function decreases with chronic pancreatic fibrosis advancement, this 
study examined the correlation between pancreatic T1 values and pancre-
atic exocrine and endocrine insufficiency.
aims & Methods: Thirty-two patients underwent abdominal contrast MRI 
in our department between October 2017 and February 2019. We evaluated 
T1 values with the MOLLI sequence, pancreatic exocrine insufficiency (PEI) 
by fecal elastase 1 (FE1) values, and pancreatic endocrine insufficiency us-
ing fasting insulin levels.
fine needle aspiration (FNA) with a higher reported sensitivity (74%), has 
curbed the enthusiasm to obtain brush cytology in suspected pancreatico-
biliary malignancies.
aims & Methods: This retrospective study aims to investigate the diagnostic 
yield of biliary brush cytology following introduction of changes to practice 
in 2015 at a single centre tertiary hospital. The changes implemented in 
the laboratory were: (i) increased care in preparing specimens with the 
appointment of a chief cytology biomedical scientist, (ii) careful levelling 
through cell block in an attempt to reveal more entrapped tissue, and (iii) 
downsizing in cytopathology team to three dedicated pathologists to in-
crease experience by maximising exposure to more cases. Endoscopic ret-
rograde cholangiopancreatography (ERCP) operators were simultaneously 
encouraged to perform targeted vigorous brushing of strictures to increase 
cellular yield. All adult patients who had an index brush cytology for bili-
ary stricture at ERCP from 1st January 2014 to 30th September 2018 were 
identified. Repeat brushing and ampullary sampling were excluded. Elec-
tronic patient record was searched for histocytopathology data, radiology 
report, multidisciplinary team (MDT) meeting outcome and clinic letters. 
Patients were considered to have a malignant outcome if (i) subsequent 
biopsy, FNA or resection confirmed primary or metastatic disease, or (ii) 
there was unequivocal radiological or clinical progression of malignant 
disease. Patients were considered to have a benign outcome if (i) subse-
quent resection was benign, or (ii) clinical follow-up for a minimum of 
6 months was uneventful. Cytology positive was defined as confirmed or 
suspicious malignant. Cytology negative was defined as atypical, negative 
or non-diagnostic. Sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) were calculated. Differences in yield 
between cancers were compared using chi-squared test.
results: 201 patients met the inclusion criteria. Mean age at presenta-
tion was 69.5 years (60% male). Cytological diagnosis were as follows: 
malignant 48.2%, suspicious 11.1%, atypical 14.1%, negative 25.6% and 
non-diagnostic 1.0%. 78.6% of biliary strictures were cancers with 54.4% 
pancreatic, 36.1% cholangiocarcinoma, 3.8% gallbladder, 1.9% ampullary 
and 3.8% metastatic or other. Diagnostic test characteristics for detecting 
cancer before (2014-15) and after (2016-18) changes in practice are pre-
sented in Table 1. Marked improvement in sensitivity was noted (68.7% 
vs 83.0%). A slight drop in specificity and PPV was due to a false positive 
result in a patient with primary sclerosing cholangitis. There were no sta-
tistically significant difference in brush cytology yield between pancreatic 
cancer and cholangiocarcinoma (P=0.84).
  sensitivity (%) specificity (%) PPv (%) nPv (%) accuracy (%)
2014-15 66.7 100.0 100.0 44.4 75.0
2016-18 83.0 96.3 98.7 61.9 86.0
[Table 1: Diagnostic performance for detecting cancer in index biliary 
brushing of 201 patients before(2014-15) and after(2016-18) changes to 
practice.]
conclusion: The sensitivity of biliary brush cytology for the detection of 
malignant biliary strictures in our centre is higher than reported in the lit-
erature with excellent PPV. Multifaceted changes in practice and workforce 
restructuring can produce comparable yield to EUS FNA. Biliary brush cy-
tology remains a valuable tool in diagnosing pancreatobiliary cancers with 
no difference in yield between pancreatic cancer and cholangiocarcinoma.
references: Burnett AS, Calvert TJ, Chokshi RJ. Sensitivity of endoscopic 
retrograde cholangiopancreatography standard cytology: 10-y review of 
the literature. J Surg Res 2013;184:304-11. Burnett AS, Bailey J, Oliver JB, 
et al. Sensitivity of alternative testing for pancreaticobiliary cancer: a 10-y 
review of the literature. J Surg Res 2014;190:535-47.
disclosure: Nothing to disclose 
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results: Median cohort (9 male, 23 female) age was 71 (range: 49-84) 
years. Eighteen patients had pancreatic cysts, 3 had alcohol-induced 
chronic pancreatitis, 3 had pancreatic cancer, and 8 possessed other pan-
creatic features (autoimmune pancreatitis: 2, acute pancreatitis: 2, bile 
duct tumor: 2, idiopathic chronic pancreatitis: 1, healthy control: 1). 
A significant negative correlation was found between T1 and FE1 values 
(r=0.69, p< 0.01), with none between T1 and fasting insulin levels in the 
non-insulin administration group (r=0.044, p=0.85). T1 values were signif-
icantly higher in the insulin administration group than in the non-insulin 
group (1655.5 vs. 898.9 msec, p< 0.01).
conclusion: Pancreatic T1 values correlated with pancreatic exocrine func-
tion and might be useful in PEI diagnosis.
disclosure: Nothing to disclose 
P0096 dIfferenTIaL PhOsPhOryLaTIOn Of 
MITOgen-acTIvaTed PrOTeIn kInases assOcIaTed TO 
The OBesTaTIn/g-PrOTeIn cOuPLed recePTOr 39 (gPr39) 
sIgnaLIng PaThWay In huMan PancreaTIc sTeLLaTe ceLLs
Estevez-Perez L.1, Leal-Lopez S.1, Seoane-Mosteiro C.2, 
Gallego-Gomez R.3,4, Löhr M.5, Dominguez-Muñoz J.E.3,6, 
Perez-Camiña J.2, Pazos-Randulfe Y.1
1Health Research Institute of Santiago de Compostela, Gastroenterology, 
Santiago de Compostela, Spain, 2Health Research Institute of Santiago de 
Compostela, Cell Endocrinology, Santiago de Compostela, Spain, 3Health 
Research Institute of Santiago de Compostela, Santiago de Compostela, 
Spain, 4University of Santiago de Compostela, Department of Morphological 
Sciences, Santiago de Compostela, Spain, 5Karolinska Institutet, Center for 
Digestive Diseases, Stockholm, Sweden, 6University Hospital of Santiago de 
Compostela, Gastroenterology, Santiago de Compostela, Spain
contact e-Mail address: yolanda.pazos.randulfe@sergas.es
Introduction: Obestatin, a peptide derived from preproghrelin, and its 
receptor GPR39 have been described in the endocrine pancreas. Recent 
works show that obestatin exogenous administration accelerates the re-
covery in the course of ischemia/reperfusion-induced or cerulein-induced 
acute pancreatitis in rats. These data revealed the possible role on the 
recovery of the injured pancreas via the regulation of the activated pan-
creatic stellate cells, accordingly to the regenerative and/or protector role 
previously described for obestatin in the pancreas. The obestatin/GPR39 
system regulates the proliferation, migration and invasion of the activated 
pancreatic stellate cells (aRLT-PSCs), as well as the expression of epitheli-
al-mesenchymal transtition and angiogenesis markers. Our goal is to de-
termine signaling mechanisms triggered by obestatin in these pancreatic 
stellate cells.
aims & Methods: The aim of the present wotk is to determine the signal-
ing mechanisms triggered by obestatin in the activated pancreatic stellate 
cells RLT-PSC. 
To investigate the intracellular signalling pathways activated downstream 
of GPR39 in aRLT-PSC cells in response to obestatin (100 nM, 5 min), the 
degree of the differential activation of mitogen-activated protein kinases 
(MAPK) was analysed by a analysed by using a human phospho-MAPK 
array kit. 
This protein array comprised 26 MAPKs and other serine/threonine kinas-
es. The results were validated by immunoblot.
results: Out of the 26 kinases analysed in the human phospho-MAPK ar-
ray kit, 9 were differentially phosphorylated/dephosphorylated (P < 0.05, 
P <0.01, P <0.001) in the obestatin-treated (100 nM, 5 min) compared to 
the untreated RLT-PSCs. To examine by western blot the activation/inhi-
bition observed on the previous MAPK array, the aRLT-PSCs cells were 
stimulated with obestatin (100 nM) for the indicated times (5-120 min). 
CREB (~39.5%), ERK2 (~33.60%), glycogen synthase kinase-3 (GSK-3) α/β 
(~34.3%) and GSK-3β (~26.8%) exhibited increased phosphorylation fol-
lowing obestatin treatment. Additionally, the proteins HSP27 (~56.55%), 
p38α (~61.95%), p38β (~58.92%), p38δ (~56.86%) and RSK1 (~37.77%) 
were partially inhibited in response to obestatin.
conclusion: The obestatin/GPR39 system regulated the activation/inhibi-
tion of a kinase panel in the aRLT-PSCs cells, in which ERK1/2 and Akt were 
the key signalling nodes. These facts agree with the previously described 
signalling pathway for the obestatin/GPR39 system. Indeed, the obestatin-
GPR39 activation triggers two routes in parallel: 
1) the metabolic ERK1/2 pathway, by sequential activation of Gi, PI3K, and 
novel PKCε and characterized mainly by its proliferative role; and 
2) the Akt pathway, mediated by β-arrestin 1 and cross-activation of EGFR, 
of which S6K1 is the final protein triggering effects of cell growth, prolif-
eration and differentiation.
disclosure: Nothing to disclose 
P0097 MuTanT hnf6 PerTurBs The PancreaTIc PrOgenITOr 
and BeTa-ceLL PrOgraM LeadIng TO varIOus TyPes Of 
dIaBeTes In huMans
Heller S.1, Costa I.2, Böhm B.3, Julier C.4, Kleger A.5
1Ulm University, Internal Medicine I, Ulm, Germany, 2RWTH Aachen 
University Medical School, Aachen, Germany, 3LKC School of Medicine, 
Nanyang Technological University, Singapore, Singapore, 4Inserm UMR-S 
958, Faculté de Médecine Paris Diderot, Paris, France, 5Universitätsklinik 
Ulm, Internal Medicine 1, Ulm, Germany
contact e-Mail address: alexander.kleger@uni-ulm.de
Introduction: Diabetes represents a major burden with continuously rising 
incidence and socioeconomic impact worldwide. Insufficient glucose ho-
meostasis initiates a plethora of complications at multiple sites of the hu-
man body. Interestingly, several genes responsible for monogenic diabetes 
(rare variants) are additionally associated with multifactorial diabetes (fre-
quent variants) pointing towards a shared disease mechanism.
aims & Methods: Genetic screening of human diabetic cohorts and healthy 
controls was performed. HNF6 was deleted in human pluripotent stem 
cells using CrisprCas9 techniques followed by subsequent pancreatic dif-
ferentiation and thorough step-wise OMICS analysis.
results: Here, we identify the transcription factor HNF6 as a novel dia-
betes-causing gene. In one index patient an HNF6 mutation leading to a 
truncated protein caused neonatal diabetes, pancreatic hypoplasia, and 
early death. High-throughput targeted sequencing of different diabetic pa-
tient cohorts linked HNF6 mutations to early onset type 2 diabetes (T2D). 
To dissect the underlying mechanism, various human HNF6 null pluripo-
tent stem cells (hPSC) were differentiated toward the pancreatic lineage 
complemented with stage-specific ATAC-, ChIP- and RNA-sequencing to 
investigate chromatin and gene binding as well as expression dynamics. 
Specifically, HNF6 shapes the differentiation of the pancreatic endoderm 
toward the pancreatic progenitor stage by binding a large set of pancreatic 
enhancers and opening stage-specific chromatin clusters for endocrine 
priming. HNF6 null hPSCs failed to activate NKX6.1 leading to a dramati-
cally reduced number of pancreatic progenitors with intrinsic defects to 
activate the endocrine program. Mechanistically, we found protein-protein 
interaction of HNF6 with other core factors of the islet program and a high 
correlation of target gene binding. Specifically, T2D causing HNF6 variants 
show a perturbed activation of an NKX6.1 enhancer which is crucial for 
isletogenesis. In addition, HNF6 interacts with NKX2.2 to foster NKX2.2 
transcription, one of the earliest and most broadly expressed islet tran-
scription factors.
conclusion: Our study reveals distinct HNF6 mutations being detrimental 
for a spectrum of diabetes types in humans and expands our knowledge 
how HNF6 shapes the isletogenesis program.
disclosure: Nothing to disclose 
P0098 PancreaTIc sTIffness vaLues usIng a POInT shear 
Wave eLasTOgraPhy TechnIque In PaTIenTs WITh heaLThy 
Pancreas
Popa A., Sirli R.L.D., Mare R.G., Danila M.V., Popescu A., Sporea I.
Victor Babes University of Medicine, Department of Gastroenterology and 
Hepatology, Timisoara, Romania
contact e-Mail address: gastro.popa@gmail.com
Introduction: In the current literature, there is only a small number of 
studies that have evaluated the utility of point share wave elastography for 
pancreatic assessment.
aims & Methods: To assess the feasibility of Virtual Touch Quantification 
(VTQ) elastography for pancreas assessment, as well as the mean pancre-
atic stiffness values in healthy subjects.
We included 70 subjects (52.8% women, 47.2% men, average BMI=25.9±4.9 
kg/m2, average age 46.8±18.4 years) with a normal pancreatic ultrasound 
aspect and with no history of pancreatic disease or diabetes, in whom 
elastography measurements were performed with a Siemens Acuson 
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P0100 PredIcTIng reLaPse In IdIOPaThIc acuTe PancreaTITIs. 
Is There a PLace fOr eus?
Valverde-López F.1, Ortega-Suazo E.J.2, Jiménez-Rosales R.3, 
Martínez-Cara J.G.4, Redondo-Cerezo E.5
1’La Merced’ Hospital, Gastroenterology and Hepatology, Sevilla, 
Spain, 2Virgen de las Nieves University Hospital, Gastroenterology and 
Hepatology, Granada, Spain, 3Hospital Universitario Virgen de Las Nieves, 
Gastroenterology, Granada, Spain, 4Virgen de las Nieves University Hospital, 
Granada, Spain, 5Hospital Virgen de las Nieves, Digestive Diseases, Granada, 
Spain
contact e-Mail address: fcovalverde89@gmail.com
Introduction: Natural history of idiopathic acute pancreatitis (IAP) is com-
plex although diagnosing the etiology is a mainstay to prevent furthers 
episodes. The efficacy of endoscopic ultrasound (EUS) as a diagnostic tool 
to establish etiology has been proven in many studies but its role as a 
predictor of recurrence has not been deeply assessed.
aims & Methods: Our aim is to assess the predictive ability of EUS and 
several clinical factors on recurrent episodes of acute pancreatitis. Patients 
referred to our unit for EUS after a first episode of IAP or recurrent IAP 
were recruited. We retrospectively analyzed data such as sex, age, liver en-
zymes (ALT and ALP) on hospital admission in the index episode, previous 
cholecystectomy, smoker condition and recurrence rates. Patients were 
considered to have IAP after an initial normal study including abdominal 
ultrasound, no evidence of significant alcohol consumption, normal tri-
glyceride levels out of an acute episode, and blood tests. Either ERCP or 
cholecystectomy were performed when stones were found in EUS in com-
mon bile duct or gallbladder respectively. When EUS findings suggested 
chronic pancreatitis or other etiology, patients underwent conservative 
management and clinical follow up. Patients were followed until death 
and those lost to follow up were excluded.
results: We recruited 106 patients from 2010 until 2016 and they were fol-
lowed until 2018 (mean follow up of 53.59±27.79 months). Clinical and en-
dosonographic factors assessed are shown in table 1. 
  Total n = 106
recurrence 
n = 29 (27.4%)
no recurrence n 
= 77 (72.6%) p
Current or previous smoker, n (%) 37 10 (34.4) 27 (35) n.s
Normal ALT and ALP, n (%) 56 20 (68.9) 36 (46.7) 0.04
Male, n (%) 52 16 (55.1) 36 (46.7) n.s
No lithiasis on EUS 54 21 (72.4) 33 (42.8) <0.01
Age < 65, n (%) 65 22 /75.8) 43 (55.8) 0.06
Previous cholecistectomy, (%) 28 13 (44.8) 15 (19.4) <0.01
[Clinical and endosonographic factors. ALT: Alanine transaminase. ALP: 
Alkaline phosphatase. EUS: endoscopic ultrasound]
In the univariate analysis, we found that normal ALT or ALP by the time 
of admission and a previous cholecystectomy raised the probability of re-
lapse (p=0.04, p < 0.01 respectively). Patients aged below 65 years old 
showed higher recurrence rate than older ones with a p value almost sig-
nificant (p=0.06). Furthermore, findings different than lithiasis in the bili-
ary tract on EUS also had a higher probability of a relapse (p< 0.01). When 
logistic regression was performed, we found that age under 65 years old 
(OR 3.56; CI 95% 1.21-10.44; p=0.02), previous cholecystectomy (OR 3.19; CI 
95% 1.11- 9.17; p=0.03) and normal EUS or findings different than lithiasis 
in gallbladder or common bile duct (OR 2.87; CI 95% 1.04 - 7.87; p=0.04) 
were all independent risk factor for recurrence
conclusion: Far beyond sheer endosonographic findings, physicians per-
forming EUS for IAP assessment might be concerned about etiological di-
agnosis and also about prognosis and future management. Beyonds its 
role in diagnosis of biliary conditions that lead to an ERCP or cholecys-
tectomy or its ability in diagnosis of chronic pancreatitis, in combination 
with other factors such as age or the presence of a gallbladder in situ, EUS 
can provide predictive information about recurrence. Our study shows that 
patients aged under 65 years old, with a previous cholecystectomy and 
no stones on EUS entail a high risk of relapse. All this information should 
be taken into account by pancreatologists in order to decide whether a 
closer clinical monitoring is needed or if some patients could be spared 
from follow-up, although further multicenter studies should be done in 
this setting.
disclosure: Nothing to disclose 
S2000 Virtual Touch ultrasound system (Siemens AG, Erlangen, Germany) 
using a 4CI transducer. For each patient, 10 valid VTQ measurements of the 
pancreatic parenchyma were performed under fasting conditions. Reliable 
measurements were defined as a median value of ten pancreas stiffness 
measurements with a success rate ≥60% and an interquartile range in-
terval < 30%.
results: Out of 70 subjects, reliable measurements were acquired in 61 
subjects (87.1%) by means of VTQ elastography. The mean pancreas stiff-
ness values in healthy subjects was 1.26 m/s ± 0.1 m/s, CI 95% (1.24-1.28). 
There were no significant differences between the mean pancreas stiffness 
in men vs. women 1.25 m/s ± 0.09 m/s, CI 95% (1.21-1.28) vs. 1.28 m/s ± 0.1 
m/s CI 95% (1.25-1.31) (p=0.103).
conclusion: VTQ can be a useful tool for pancreas quantification character-
ized by a good feasibility (87.1%) in healthy subjects. The mean pancreas 
stiffness values in healthy individuals was 1.26 m/s ± 0.1m/s.
disclosure: Nothing to disclose 
P0099 MuscLe ParaMeTers cOrreLaTe WITh 
severITy durIng acuTe PancreaTITIs unLIke ParaMeTers 
Of un-InvOLved faT dePOTs
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15Martin Luther University Halle-Wittenberg, Halle, Germany, 16University 
Clinic Halle (Saale), Department of Internal Medicine I, Halle, Germany
contact e-Mail address: jonas.rosendahl@medizin.uni-leipzig.de
Introduction: Acute pancreatitis (AP) is a frequent disorder with a consid-
erable risk of morbidity and mortality. Obesity has been reported to influ-
ence severity of AP. Recent studies indicate that the volume and distribu-
tion of visceral adipose tissue correlates with worse outcome.
aims & Methods: The aim of this study was to investigate the associa-
tion of adipose and muscle parameters with the severity grade of AP. In 
total 454 patients were recruited from an established European cohort and 
two German centres. The first contrast-enhanced computed tomography of 
each patient was reviewed for radiological uninvolved adipose and muscle 
tissue parameters at L3 level. Associations between these parameters and 
disease severity were analysed through univariate and multivariate logistic 
regression analysis. The predictive capacity of the parameters was investi-
gated using Receiver Operating Characteristic (ROC) curves.
results: No distinct variation was found between the AP severity groups 
in neither adipose tissue parameters (p-values 0.97 and 0.1 for visceral 
and subcutaneous fat) nor visceral muscle ratio (p-value 0.14). However, 
muscle mass and mean muscle attenuation differed significantly with p-
values of 0.037 and 0.003 respectively. In multivariate analysis low muscle 
attenuation was associated with severe AP with an odds ratio of 4.09 (CI: 
1.61-10.36; p-value 0.003). No body parameter presented sufficient predic-
tive capability in ROC curve analysis.
conclusion: Our results demonstrate that a low muscle attenuation level 
measured during acute pancreatitis is associated with an increased risk of 
severe AP, unlike parameters of uninvolved adipose tissue. Further pro-
spective studies will help identifying underlying mechanisms and charac-
terize the influence of body composition parameters on AP.
disclosure: Nothing to disclose 
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P0101 cOMBInaTIOn Of InTravenOus hydraTIOn and 
IndOMeThacIn suPPOsITOry Is The MOsT effecTIve TheraPy 
fOr The PrevenTIOn Of POsT-ercP PancreaTITIs - a neTWOrk 
MeTa-anaLysIs
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contact e-Mail address: katalin.martak@gmail.com
Introduction: Acute pancreatitis as a complication of endoscopic retrograde 
cholangiopancreatography (PEP) has substantial morbidity and mortality. 
The ESGE 2014 and the HPSG 2015 guidelines suggest (i) administration of 
diclofenac or indomethacin and (ii) placement of a prophylactic pancreas 
stent to prevent PEP. The beneficial effect of hydration in the prevention of 
PEP has been shown, however, its effectiveness compared to other treat-
ments has never been analyzed.
aims & Methods: Our aim was to compare the efficacy of different fluid 
therapies and indomethacin suppository used in PEP prevention.
A network meta-analysis was performed on randomized trials identified 
from Pubmed, Embase and Cochrane Library. Studies reporting a com-
parison of at least two treatment options (hydration/indomethacin) and 
no treatment were included with at least 10 patients. The incidence rate of 
PEP and its severity were used as outcome parameters. Bayesian network 
meta-analysis with WinBUGS and NetMetaXL (Markov chain Monte Carlo 
method) was performed. Treatment ranking was performed based on the 
calculation of the surface under the cumulative ranking (SUCRA). Odd 
ratios (95%CI) for the dichotomous data and random effect model were 
used. PROSPERO reg.no.: CRD42018112698.
results: 16/954 studies with a total number of 6070 ERCP were analyzed. 
The event rate of PEP was 616 (10.15%). Six treatment combinations (LR-
lactated ringer alone, NS-normal saline alone, IND-indomethacin alone, 
NT-no treatment, LR+IND, NS+IND) were found and analyzed. The most 
effective treatment modality was LR+IND (SUCRA: 0.9069), the second was 
NS+IND (SUCRA: 0.8135), the third was LR (SUCRA: 0.6572), the fourth was 
NS (SUCRA: 0.2911), the fifth was IND (SUCRA: 0.2696) and the last one was 
NT (SUCRA:0.06173). The analysis showed that LR+IND is significantly more 
effective in PEP prevention than NS (OR=0.06; 95%CI: 0.00-0.69), IND 
(OR=0.05; 95%CI:0.00-0.64) and NT (OR=0.03;95%CI: 0.00-0.41) alone; 
NS+IND is also significantly more effective than NS (OR=0.12; 95%CI:0.02-
0.60), IND (OR=0.09; 95%CI 0.01-0.73), and NT (OR=0.05;95%CI:0.01-0.45). 
However, LR or NS are not significantly better than IND alone.
conclusion: Hydration in combination with indomethacin is more effective 
than hydration or indomethacin alone for PEP prevention.
disclosure: Nothing to disclose 
P0102 ManageMenT Of severe acuTe PancreaTITIs PaTIenTs 
By enOxaParIn
Chuklin S., Chooklin S., Shershen G.
Lviv Regional Clinical Hospital, Surgery, Lviv, Ukraine
contact e-Mail address: serhii.chuklin@gmail.com
Introduction: The problem of acute pancreatitis treatment in the pres-
ent time remains unsolved, and the main difficulty is to assist patients 
with severe disease. Despite the success of diagnostics, intensive care, 
improved methods of surgical treatment, mortality in this category is 30-
50%. Processes of inflammation and coagulation are enhanced each oth-
er and played the important role in the pathogenesis of severe forms of 
pancreatitis. Therefore, in the complex treatment of this group of patients 
it is important to use drugs with anticoagulant and anti-inflammatory 
properties.
aims & Methods: We used enoxaparin in the treatment of 31 patients with 
severe acute pancreatitis (SAP) (control group included 26 patients). The 
drug was administered at a dose of 1 mg/kg subcutaneously once daily for 
12-14 days. We are not observed the complications.
results: The use of enoxaparin in patients with SAP contributes to the im-
provement of hemostasis and had an anti-inflammatory effect. Enoxaparin 
is improved the condition of SAP patients, considering APACHE II assess-
ment (from 11.94 ± 1,39 to 6.96 ± 1.63; control group from 12.42 ± 1.42 
to 10.18 ± 1.44, p < 0.05) and severity of organ dysfunction (SOFA) (from 
5.74 ± 1.39 to 1.04 ± 1.60; control group from 5.38 ± 1.36 to 3.05 ± 1.21; p< 
0.05). Three (9.68%) patients with SAP in enoxaparin group are died, and 
8 (30.77%) patients in control group (χ 2 =4.04; p=0.0445). We operated 
the 14 (45.16%) patients in main group, and 9 (34.62%) patients in control 
group (χ 2 =0.65; p=0.4149). Two patients (14.29%) died in enoxaparin 
group, and 4 (44.44%) in control group (χ 2 =2.58, p=0.1079).
conclusion: Enoxaparin improves outcomes in patients with severe acute 
pancreatitis. Enoxaparin application reduced inflammation processes and 
procoagulantive status, improved the condition of patients, reduced the 
mortality level.
disclosure: Nothing to disclose 
P0103 cLInIcaL OuTcOMe Of endOscOPIc TreaTMenT 
Of syMPTOMaTIc sTerILe WaLLed-Off necrOsIs
Boxhoorn L.1, Fritzsche J.A.1, Haal S.2, Fockens P.1, van Hooft J.E.1, 
de Jonge P.J.F.3, Poley J.W.3, Bruno M.J.3, Voermans R.P.1, 
Dutch Pancreatitis Study Group
1Amsterdam UMC, Department of Gastroenterology & Hepatology, 
Amsterdam, Netherlands, 2Amsterdam UMC, locatie AMC / University 
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Introduction: The majority of patients with symptomatic sterile walled-off 
necrosis (WON) can be treated conservatively. Endoscopic drainage might 
be considered in case of persisting symptoms, but frequently results in 
complications such as iatrogenic infection. To date, no study that solely 
focusses on the management of symptomatic sterile WON has been pub-
lished.
aims & Methods: We aimed to evaluate clinical outcome of patients who 
underwent endoscopic drainage of symptomatic sterile WON. We per-
formed a retrospective analysis of patients with symptomatic sterile WON 
who were drained endoscopically between November 2001 and August 
2018 in two Dutch tertiary referral hospitals. Primary endpoint was iat-
rogenic infection, defined as need for endoscopic transluminal necrosec-
tomy. Secondary endpoints were total number of re-interventions, post-
procedural complications, clinical success and hospital stay. Factors as-
sociated with iatrogenic infection were identified by multivariable logistic 
regression analysis (stepwise selection method).
results: The study cohort consistent of 62 patients (56% male, mean age 
53 years). Indications for intervention were abdominal pain (66%), gastric 
outlet obstruction (47%), jaundice (21%) and failure to thrive (29%). Iatro-
genic infection occurred in 45 patients (73%). A median of 2 endoscopic, 
surgical or radiological re-interventions (IQR 0.25 - 4) per patient were 
performed as a result of iatrogenic infection. Post-procedural complica-
tions included bleeding (5%) and stent migration (2%). Thirty patients 
(48%) were re-admitted and one patient died within 30 days after the 
index procedure as a consequence of iatrogenic infection. Follow-up data 
regarding clinical outcome was available for 51 patients (median follow-
up 14 months, IQR 6 - 38). Forty-four patients (86%) had complete res-
olution of symptoms at 1-year follow-up, but 6 patients (12%) reported 
ongoing symptoms of abdominal pain (n=4), nausea (n=1) and failure to 
thrive (n=1). Higher percentage necrosis in WON significantly increased the 
probability of developing iatrogenic infection (odds ratio = 35.36, 95%CI 
4.06 - 1048.34).
conclusion: This is the first study to evaluate clinical outcome of patients 
that were treated endoscopically for symptomatic sterile WON. Clinical 
success was achieved in almost all patients, but at the costs of multiple 
invasive procedures. Treatment of symptomatic sterile WON should there-
fore only be performed in patients in whom conservative management is 
no longer expected to result in symptom relief.
disclosure: Nothing to disclose 
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P0105 IdIOPaThIc acuTe PancreaTITIs In PaTIenTs WITh 
InfLaMMaTOry BOWeL dIsease: a MuLTIcenTrIc cOhOrT sTudy
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Introduction: Idiopathic acute pancreatitis (IAP) in patients with inflamma-
tory bowel disease (IBD) is not well characterized.
aims & Methods: Retrospective study conducted at 9 Spanish centres and 
approved by the Ethics Committee of the steering centre. All patients with 
IBD and a first episode of acute pancreatitis (AP) from 1998 to 2018 were 
included. The primary aim was to describe the incidence, characteristics 
and natural history of AP labelled as idiopathic (unexplained after anam-
nesis, initial laboratory study and abdominal ultrasound) in patients with 
IBD. Secondary aims included: proportion of IAP in which a cause was 
found after additional diagnostic work-up, risk of AP recurrence, chronic 
pancreatitis, and fulfillment of autoimmune pancreatitis criteria during 
follow-up. Data were collected and managed using AEG-REDCap™ elec-
tronic data capture tool.
results: We identified 185 patients with IBD (53% male; 68.7% Crohn’s dis-
ease) and a first episode of AP. The cause of AP was: drug-induced in 109 
(59%) patients, idiopathic in 38 (20.6%), gallstones in 34 (18.4%), alcohol 
in 2 (1%) and post ERCP in 2 (1%). AP severity in IAP group was moderate 
in 15.8% and there were no severe cases; in non-IAP patients AP was mild 
in 93.8%, moderate in 4.8% and severe in 1.4% (p=0.04). Ulcerative colitis 
was significantly more frequent in the IAP group compared to other causes 
(56.2% vs. 23.1%, p< 0.001). 
Occurrence of AP before the diagnosis of IBD was more frequent in IAP 
patients compared to non-IAP (21% vs. 3.4%, p=0.001), and median time 
from IAP to IBD diagnosis was 7.5 months (1.7-18). Further diagnostic work-
up was performed in 16/38 (42%) patients without an identifiable cause 
at presentation (magnetic resonance cholangiopancreatography in 13, en-
doscopic ultrasound in 7, and both in 4 patients), and an etiological diag-
nosis was reached in 6/16 (37.5%): 2 biliary, 3 autoimmune and 1 groove 
pancreatitis. 
Five-year risk of AP recurrence was significantly higher in IAP group than 
in non-IAP group (28% vs. 5.1%, p< 0.001), with a median time to first 
recurrence of 4.4 months (2.9-12.2). Six of the eleven (54.5%) IAP patients 
in which AP reoccurred presented more than one recurrence. 
Diagnosis of chronic pancreatitis was more frequent in IAP patients than in 
non-IAP group (5.2% vs. 0.6%, p=0.04) after a median time of follow-up 
of 6.2 years (3-10). At the last available visit a probable diagnosis of au-
toimmune pancreatitis type 2 was established in 5/38 patients of the IAP 
group (13.1%) and in one patient of the non-IAP group (0.6%), p=0.002.
conclusion: IAP represents one out of five cases of AP in patients with 
IBD, it is significantly more frequent in patients with ulcerative colitis and 
presents a high risk of recurrence. Additional imaging studies after a first 
episode of IAP in IBD patients identify a cause in more than one third.
disclosure: Nothing to disclose 
P0104 raTe Of earLy readMIssIOn In acuTe PancreaTITIs as 
a quaLITy Marker - exPerIences Of a TerTIary care unIT
Illés D.1, Hegyi P.2, Czakó L.1
1University of Szeged, First Department of Medicine, Szeged, Hungary, 
2University of Pecs, Centre for Translational Medicine, Pecs, Hungary
contact e-Mail address: illes.dora@med.u-szeged.hu
Introduction: Acute pancreatitis (AP) is one of the most common hospitali-
sation-indicating gastrointestinal diseases. Usually, the clinical manifesta-
tion of AP is mild, but unfortunately, the mortality of severe AP reaches 
30%. The early (< 30 days) readmission rate is a quality indicator of the 
treatment of AP, which correlates with the long-term outcome of the dis-
ease: it is the strongest prognostical factor of 1-year mortality.
aims & Methods: To investigate the rate and cause of the early readmission 
among patients treated with AP at our clinic. 
Our retrospective study was conducted among patients (>18 years old) 
treated with AP between January 2010 and December 2018 at the First De-
partment of Medicine, University of Szeged. Personal data were collected 
from the Hungarian Pancreas Register and medical history data from the 
patient recording system (eMedsol). AP cases by whom unplanned read-
mission happened in 30 days were investigated. Beside epidemiological 
data, the cause of the AP, the mean time elapsed till readmission, its 
cause, duration and outcome were studied. Data of biliary - and non-
biliary AP were compared concerning the above mentioned parameters, 
separately.
results: 647 patients were admitted because of AP (57% men, mean age: 
57,7±13 years). Of them, 28 (4,33%) patients had early readmission (mean 
elapsed time: 13,5±8 days). The etiology of AP in these 28 cases was: id-
iopathic in 46,4%, biliary in 28,5% and dietary in 10,7%. 50% of these 
cases were mild based on the Atlanta classification. By differentiating the 
cases according to biliary - non-biliary etiology the number of moderately 
severe AP cases was significantly higher in the non-biliary group (2 vs. 
12, respectively; p=0,048). The most common causes of early readmission 
were pancreatic (walled off necrosis, pseudocyst) in 32,1%, biliary (cho-
lecystitis, cholangitis) in 28,6% and recurrence in 17,8% of the cases. By 
investigating the biliary - non-biliary AP cases separately, the indication 
of readmission showed a significant difference: the cause of readmission 
was biliary in 65,5% and in 15% in the two groups, respectively (p=0,042). 
In case of non-biliary AP, readmission happened because of pancreatic 
cause in 35% and recurrence in 25% of the cases. None of the readmitted 
patients needed intensive-care treatment. 50% of cases with pancreatic 
complications needed surgical treatment. There was no mortality bounded 
to hospital treatment, 75% of the patients were safely emitted to their 
home after readmission.
conclusion: The rate of early readmission in our clinic is very low com-
pared to the international data. In case of biliary AP, we need to perform 
index cholecystectomy in line with the international guidelines to avoid 
readmission, hospitalisation and increasing hospital costs.
references: S. Munigala et al. Predictors for early readmission in acute 
pancreatitis (AP) in the United States (US) e A nationwide population 
based study. Pancreatology 17 (2017) 534-542
disclosure: Nothing to disclose 
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P0106 earLy OraL refeedIng In acuTe PancreaTITIs
Liebe R.1, Molnar E.1, Gellért B.2, Sahin P.1
1Jahn Ferenc Hospital, Gastroenterology, Budapest, Hungary, 2Central and 
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Miskolc, Hungary
contact e-Mail address: rebekaliebe@gmail.com
Introduction: In recent guidelines of acute pancreatitis treatment there is a 
strong agreement that enteral nutrition should be started in severe cases 
within 48 hours (1, 2, 3). In contrast, most guidelines do not contain any 
information on the optimal timing of oral refeeding after enteral nutrition. 
Some recently published data shows that early oral refeeding could be 
beneficial as it shortens the lengths of hospital stay and does not result in 
higher number of clinical complications and mortality (4, 5).
aims & Methods: Early enteral nutrition in severe cases of acute pancre-
atitis improved mortality rate at our department in 2015. From 2018 we 
started to adopt an early oral refeeding approach to patients with acute 
pancreatitis. Early oral refeeding after enteral nutrition meant initiation 
of oral administration as soon as the patients experienced significant im-
provement of their abdominal pain and passed their CRP peak. Our aim 
was to compare the mortality rate before and after the change of thera-
peutical strategy regarding the timing of oral refeeding.
Particular emphasis was placed on patients who reached a modified Ran-
son score of minimum 2 as most of them were fed enterally. The modified 
Ranson score meant adding an extra point to the conventional Ranson 
score when the patient had severe abdominal pain. 
We examined 220 cases of acute pancreatitis retrospectively who were 
treated in our department in 2018 and compared the data to the mortality 
rate of 2015 by two-sample T-test. The occurrence of early and late compli-
cations, the amount of fluid infusion in the first 24 hours of the treatment 
and the consumption of enteral formulas in 2015 and 2018 were compared 
as well.
results: In 107 cases the patients reached a modified Ranson score of mini-
mum 2 in 2018. This group had a mortality of 7.8% which was not signifi-
cantly higher than the 3.9% mortality of 2015 (p=0.17).
In 49 cases the patients reached a modified Ranson score of minimum 3 
in 2018. This group had a mortality of 10.2% which was not significantly 
higher than the 5.56% mortality of 2015 (p=0.28).
The overall mortality rate of acute pancreatitis was 3.63% in 2018 which is 
concordant with the international data (6).
We experienced a significant decrease in the average fluid infusion given in 
the first 24 hours in both the modified Ranson 2 (3462,96ml vs. 3021,05ml; 
p=0,000001) and modified Ranson 3 (3472,22ml vs. 3083,33ml; p=0,0006) 
groups.
Consumption of enteral formulas has decreased by 38.84% from 2017 to 
2018, and thus saving EUR 1814.
conclusion: The early initiation of oral refeeding did not result in a signifi-
cantly higher rate of mortality.
However, the mortality rate of 2018 was higher than the mortality rate of 
2015 which we attribute to the significantly lower amount of fluid infusion 
in the first 24 hours of the treatment.
Earlier oral refeeding is more tolerable for patients and it is more cost-
effective as it results in shorter hospital stay and lower consumption of 
enteral formulas.
references: 1. Tenner, S., et al., American College of Gastroenterology 
guideline: management of acute pancreatitis. Am J Gastroenterol, 2013. 
108(9): p. 1400-15; 1416; 2. IAP/APA evidence-based guidelines for the 
management of acute pancreatitis. Pancreatology, 2013. 13(4 Suppl 2): p. 
e1-15.; 3. Yokoe, M., et al., Japanese guidelines for the management of 
acute pancreatitis: Japanese Guidelines 2015. J Hepatobiliary Pancreat Sci, 
2015. 22(6): p. 405-32.; 4. Zhao XL, Zhu SF, Xue GJ, et al. Early oral refeed-
ing based on hunger in moderate and severe acute pancreatitis: A pro-
spective controlled, randomized clinical trial. Nutrition 2015; 31: p.171-175.; 
5. Masayasu, H., et al., Timing of oral refeeding in acute pancreatitis: A 
systematic review and meta-analysis, United European Gastroenterology 
Journal, 2016, Vol. 4(6) 725-732; 6. Carnovale, A., et al., Mortality in Acute 
Pancreatitis: Is It an Early or a Late Event?, JOP. J Pancreas (Online) 2005; 
6(5):438-444.
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as earLy chrOnIc PancreaTITIs: a MeTaanaLysIs Of 21,186 
PaTIenTs
Soós A.1,2, Hegyi P.J.1, Szakács Z.1, Mikó A.1, Mátrai P.1, Erőss B.1, 
Hegyi P.1,3,4
1Institute for Translational Medicine, Medical School, University of Pécs, Pécs, 
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Medicine, First Department of Medicine, Pécs, Hungary, 4University of 
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contact e-Mail address: soos.alexandra5622@gmail.com
Introduction: Chronic pancreatitis (CP) is an irreversible end -stage disease 
of the pancreas. The diagnosis is usually delayed when testing potential 
pharmacological interventions is not possible, therefore it is not surpris-
ing, that very small amount of clinical trials are performed. It is an unmet 
need to diagnose the disease much earlier before the morphological and 
functional deterioration develop.
aims & Methods: Our aim was to systematically review the literature and 
investigate whether recurrent acute pancreatitis (RAP) can be considered 
as early CP. A meta -analysis was performed using the preferred reporting 
items for systematic review and meta -analysis
protocol (PRISMA P). MEDLINE, Scopus, EMBASE and the Cochrane Library 
databases were searched for articles in which RAP and either of AP or 
CP were compared. Data on etiology, gender ratio and smoking were ex-
tracted from the eligible articles. Pooled estimates were calculated with 
random effects model by using DerSimonian-Laird method. All meta- 
analytical calculations were performed using Stata 15.1 data analysis and 
statistical software (Stata Corp LLC, College Station, TX, USA).
results: 21186 patients’ data from 23 articles were collected. Biliary etiol-
ogy was significantly higher in group AP than in RAP or CP (OR: 2.40, 
95% CI:1.29 -4.46; OR:5.53, 95% CI:2.76- 11.07 respectively). However, the 
significant difference in terms of biliary etiology disappeared between 
RAP and CP (OR: 0.81, 95% CI: 0.40 -1.63) suggesting that RAP is more 
similar to CP than to AP. 
More male were suffering from CP than AP (OR:1.93, 95% CI: 1.32- 2.82 
); RAP than AP (OR: 1.31, 95% CI: 1.04- 1.64) and CP than RAP (OR: 1.42, 
95% CI: 1.15 -1.76) suggesting that RAP is a transition between AP and CP. 
The same transition pattern was observed in the amount of smoking (OR: 
3.28, 95% CI: 1.96- 5.49; OR: 1.37, 95% CI: 1.11 -1.70; OR: 2.23, 95% CI: 1.81- 
2.75, respectively) and alcohol etiology (OR: 3.85, 95% CI: 2.61- 5.67; OR: 
2.02, 95% CI: 1.30 -3.15; OR: 1.93, 95% CI: 1.26- 2.97, respectively).
conclusion: The above patterns of etiology, gender ratio and smoking sug-
gest that recurrent acute pancreatitis is a transit disease between AP and 
CP. Therefore, RAP can be considered as early chronic pancreatitis. De-
tailed large cohort analysis is necessary to determine the number of recur-
rences, which should define and be incorporated into the nomenclature of 
early chronic pancreatitis.
disclosure: Nothing to disclose 
P0108 The cOMBInaTIOn Of The aBdOMInaL vIsceraL faT 
area and age Is a usefuL PredIcTOr Of MOrTaLITy In severe 
acuTe PancreaTITIs PaTIenTs
Higaki Y.1, Nishida T.1, Hayashi S.1,2, Chang L.1, Kuriki S.1, Aochi K.1, 
Meren E.1, Sakamoto T.1, Tomita R.1, Osugi N.1, Sugimoto A.1, Takahashi K.1, 
Nakamatsu D.1, Mukai K.1, Matsumoto K.1, Yamamoto M.1, Fukui K.1, 
Inada M.1
1Toyonaka Municipal Hospital, Gastroenterology & Hepatology, Toyonaka, 
Japan, 2Hayashi Clinic, Gastroenterology and Internal Medicine, Suita City, 
Japan
contact e-Mail address: yuhi55114@gmail.com
Introduction: The mortality rate for severe acute pancreatitis (SAP) is ex-
tremely high. Several scoring systems have been developed for predict-
ing adverse outcomes in AP, such as the APACHE-II and Japan severity 
score by summing nine factors including age. However, each score has 
certain shortcomings or complex using a lot of parameters. Obesity is a 
well-known risk factor for acute pancreatitis and reported to be related to 
mortality by meta-analysis. In the present study, we aimed to evaluate the 
impact of abdominal visceral fat area (VFA) on mortality due to SAP and 
performed the prognostic stratification using VFA.
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one could speculate the inflammatory nature of familial Mediterranean 
fever may confer increased proclivity in triggering the acute pancreatitis 
inflammatory process. Familial Mediterranean fever is a relatively rare ge-
netic disease and as such large population based studies have never been 
conducted, thus future studies will be needed to better understand the 
association between acute pancreatitis and familial Mediterranean fever.
a) variable aOr 95%cI p-value
Acute Pancreatitis 1.73 1.10-2.71 0.02
Mortality 5.27 0.70-39.51 0.11
AKI 3.11 0.98-9.92 0.05
Shock 2.69 0.35-20.47 0.34
ICU 3.14 0.67-14.60 0.15
Multi-organ failure 3.38 1.13-10.13 0.03
ERCP 0.90 0.20-4.01 0.89
B) Variable aMean 95%CI p-value
Additional Adjusted Costs -$1,421 -6355,3512 0.57
Additional Adjusted Charges -$12,383 -27143,2377 0.10
Additional Adjusted Length of Stay (days) -1.4 -3.2,0.4 0.14
[A) Adjusted Odds Ratio of Acute Pancreatitis and outcomes in patients with 
FMF. B) Resource Utilization in patients with acute pancreatitis and FMF.]
disclosure: Nothing to disclose 
P0110 cT -severITy Index can PredIcT The severITy Of acuTe 
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Introduction: Based on the revised Atlanta classification, the severity of 
acute pancreatitis (AP) may be mild, moderate or severe. The management 
of the moderate and severe forms of the disease with necrosis and mul-
tiorgan failure remains a challenge. To predict the severity and mortality 
of AP different scoring systems are used. The aim of the study is to inves-
tigate, if the computed tomography severity index (CTSI) of AP can predict 
severity and mortality similar to other scoring systems.
aims & Methods: A systematic search was performed in 3 databases, 
Pubmed, Embase and the Cochrane Library. Articles were selected if they 
(1) provided data from patients with AP, included different severities of the 
disease; (2) if they used CTSI or mCTSI and/or another prognostic score 
(Ranson, BISAP, APACHE II, CRP) for the evaluation of severity or mortality 
of the disease (3) if they contained the absolute numbers of true positive, 
false negative, false positive and true negative test results, or area under 
the curve (AUC) for severity or mortality of AP. Diagnostic odds ratios with 
95% confidence intervals were calculated. The statistical analysis was per-
formed with Stata 14 software using the METANDI module.
results: From the 319 found articles, 36 articles were included in our 
meta analysis, these contain data of 6280 patients. From the 36 articles, 
11 contained AUC data about mortality. The pooled AUC for the prediction 
of mortality was 0.79 (95% CI 0.73 0.86) for CTSI; 0.87 (95% CI 0.83 0.90 
for BISAP; 0.80 (95% CI 0.72 0.89) for mCTSI; 0.73 (95% CI 0.66 0.81) for 
CRP level; 0.87 (95% CI 0.81 0.92) for Ranson score; and 0.91 (95% CI 
0.88 0.93) for APACHE II score. The AUC for the prediction of severity of AP 
were 0.80 (95% CI 0.76 0.85) for CTSI; 0.79, (95% CI 0.72 0.86) for BISAP; 
0.83 (95% CI 0.75 0.91) for mCTSI; 0.73 (95% CI 0.64 0.83) for CRP level; 
0.81 (95% CI 0.75 0.87) for Ranson score and 0.80 (95% CI 0.77 0.83) for 
APACHE II score.
aims & Methods: This study was a retrospective single-center cohort study 
that examined a total of 108 consecutive patients with SAP from April 2009 
till March 2018. They were diagnosed with SAP according to the Japanese 
diagnostic criteria and graded by the Japan severity score (JSS). VFA at the 
umbilical level were manually assessed by computed tomography scan us-
ing the image analysis system, SYNAPSE VINCENT (Fujifilm, Tokyo, Japan). 
We studied the mortality of patients with SAP according to clinical char-
acteristics including VFA. Receiver operating characteristic (ROC) curve 
analysis was used to determine the cut-off values for predicting mortality 
due to SAP.
results: The median age was 62 years (IQR 50, 75), 67% male. The me-
dian JSS and CTseverity socre was 1 (QR 0.25, 3), 2 (QR 2, 2) based on the 
Japanese severity scoring system for acute pancreatitis. The cause of AP 
was gallstone-related in 32 (30%) patients, alcohol abuse in 42 (40%) 
patients, idiopathic in 10 (9.5%) patients, and the others. The median hos-
pital stay was 29 days (IQR 20, 43). During hospital stay, 14 patients de-
veloped walled-off necrosis. Nine patients (9/108, 8.3%) died in hospital. 
Our analysis for mortality demonstrated that the age, JSS, and VFA cut-off 
values were 72 years (AUC: 0.773), 4 (AUC: 0.865) and 167cm2 (AUC: 0.684), 
respectively. The mortality rates of patients with older age (>72), higher JSS 
(>4), and larger VFA( >167) were significantly higher than those with young-
er (22.9% vs 1.4%, P=0.0005), lower JSS (40.3% vs 3.3%, P=0.0002), and 
smaller VFA (21.1% vs 5.6%, P=0.0492). We generated 4 groups using the 
combination of age and VFA cut-off varlues and evaluated mortality rates 
in each group (AgeOld VFTHigh group; 50% (4/8), AgeOld VFTSmall; 15%(4/27), 
Ageyong VFTLarge 0%(0/10), AgeYong VFTSmall; 1.6%(1/61), respectively).
conclusion: Larger VFA was significantly associated with poor prognosis 
in elderly patients with SAP. Therefore, the combination of age and VFA at 
diagnosis of SAP may easily provide prognostic stratification.
disclosure: Nothing to disclose 
P0109 faMILIaL MedITerranean fever assOcIaTed WITh 
eLevaTed Odds Of acuTe PancreaTITIs
Kroner P.T.1, Kesler A.M.2, Corral J.E.2, Raimondo M.3
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Introduction: Familial Mediterranean Fever (FMF) characterized by fever 
and serosal inflammation. Up to 95% of patients have episodic abdominal 
pain secondary to peritoneal inflammation. Gastrointestinal manifesta-
tions of patients with FMF may be under reported due to a frequent history 
of abdominal pain in this group of patients leading to a delay in diagnosis. 
In particular, acute pancreatitis (AP) in patients with FMF has only been 
described in rare case reports.
aims & Methods: The aim of this study is to determine if there is an as-
sociation between FMF and Acute Pancreatitis by examining inpatient 
prevalence.
Case-control study using the NIS 2007-2015, the largest public inpatient 
database in the US. All patients with ICD9CM codes for FMF were included. 
None were excluded. The primary outcome was determining the asso-
ciation between FMF and AP. Secondary outcomes included determining 
inpatient mortality, morbidity (AKI, shock, ICU stay, TPN), resource utiliza-
tion (ERCP and abdominal imaging), hospital length of stay (LOS), and 
inflation-adjusted total hospital costs and charges. Multivariate regression 
analyses were used to adjust for age, gender, Charlson Comorbidity Index, 
income in patient zip code, hospital region, location, size and teaching 
status.
results: A total of 3,956,807 patients with AP were identified and propen-
sity matched for selected covariates, of which 96 had FMF. The mean age 
was 53 years, and 49.5% were female. For the primary outcome, patients 
with FMF had increased adjusted odds (aOR: 1.73, p=0.02) of having AP. For 
secondary outcomes, patients with FMF had higher adjusted odds of AKI 
(aOR:3.11, p=0.05), and multi-organ failure (aOR:3.38,p=0.03) compared 
to the general population. There was no significant difference in mortality, 
or hospital costs, charges, or length of stay (LOS). All adjusted odds, and 
means are shown in Table 1.
conclusion: Patients with familial Mediterranean fever had higher adjust-
ed odds of having acute pancreatitis, along with higher odds of AKI, and 
multi-organ failure. It is difficult to determine what contributes to the as-
sociation between acute pancreatitis and familial Mediterranean fever, but 
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conclusion: The APACHE II scoring system had significantly higher predic-
tive value for mortality than CTSI or CRP level (p=0.001; p< 0.001 respec-
tively), while the AUC for CTSI was not statistically different from the AUC 
for BISAP, mCTSI, CRP or Ranson criteria. There was no statistical differ-
ence between the different scoring systems in the prediction of the severity 
of AP. CTSI is an easily calculated feasible scoring system for AP, which can 
predict the severity of AP, similar to the other scoring systems.
disclosure: Nothing to disclose 
P0111 eus-ThrOugh-The-needLe TechnOLOgIes In The 
dIagnOsIs and MaLIgnancy deTecTIOn Of PancreaTIc cysTs: 
a cOMParaTIve sTudy BeTWeen dIfferenT TechnOLOgIes
Robles-Medranda C., Olmos J.I., Oleas R., Baquerizo-Burgos J., 
Puga-Tejada M., Del Valle R., Alvarado-Escobar H., Pitanga-Lukashok H.
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Introduction: Endoscopic ultrasound (EUS) have limitations to differentiate 
neoplastic from non-neoplastic pancreatic cysts.
aims & Methods: aim: to define the role of through-the-needle technolo-
gies such as: fiberoptic probe, needle-based confocal laser-endomicrosco-
py (nCLE) and EUS-through-the-needle microforceps biopsy (mFB) in the 
diagnosis of pancreatic cyst malignancy. 
Methods: a retrospective analysis of a prospectively collected database 
(Jan-2013 to Mar-2018). Patients ≥18 years submitted for diagnostic work-
up of pancreatic cyst lesions at our institution were included. Pancreatic 
solid lesions were excluded. Malignancy was defined in accordance to en-
doscopic criterion, histopathology (Fukuoka criteria) and 6-months follow-
up. Patients were allocated into two cohorts: patients evaluated via EUS 
alone, and those with EUS plus an additional method. The sample size of 
20 patients per-cohort was estimated through the accuracy described for 
EUS-through-the-needle micro forceps biopsy, with a 5% margin error 
and a 95% confidence interval. Baseline characteristics per cohort was 
confirmed through the corresponding hypothesis test. Agreement between 
EUS malignancy detection and follow-up was stablished for each method 
via univariate and multivariate binary logistic regression (Odds Ratio, OR). 
The overall diagnostic accuracy for malignancy detection was determined 
for each diagnostic method. An off-line inter-observed analysis (IOA) of 
EUS criteria was performed by two endoscopists (JO and RV) using a ran-
domized EUS-image-set, calculated through Cohen Kappa (k). A p-value < 
0.05 was considered statistically significant. Data analysis was performed 
on R v.3.4.3.
results: 129 cases were included. In 82/129 patients, EUS was performed 
with an additional diagnostic method: EUS-FNA (21/82), nCLE (44/82), di-
rect intracystic mFB (36/82), cystoscopy (27/82). The median age was 67 
years, 90 (69%) female, 46 (36%) lesions were on pancreatic head. There 
were no statistical association between baseline characteristics and study 
cohorts. Agreement between EUS malignancy detection and follow-up 
was 58.6% higher when associated with nCLE, direct intracystic mFB or 
cystoscopy [62/82 (75.6%) vs. 8/47 (17%); OR=15.11, 95% CI 6.06-37.65; p< 
0.001]. Multivariate analysis confirmed a highest malignancy detection is 
reached when nCLE (OR=8.441, 95% CI 2.698-33.081; p< 0.001) and direct 
intracystic mFB are performed (OR=3.425, 95% CI 1.104-11.682; p=0.038), 
with a sensitivity, specificity, PPV, NPV and observed agreement of 78%, 
100%, 100%, 89% and 92% (k=82%; p< 0.001) (table 1). 
  eus (n = 47) eus + ncLe (n = 44)
eus + mfB (n 
= 36)
eus + ncLe + mfB 
(n = 26)
sensitivity 7/7 (100%; 
59-100)
8/9 (89%; 
52-100)
7/8 (88%; 
47-100)
7/9 (78%; 40-97)
specificity 1/40 (3%; 0-13) 30/35 (86%; 
70-95)
23/28 (82%; 
63-94)
17/17 (100%; 
80-100)
Positive Preditive 
value
7/46 (15%; 
6-29)
8/13 (62%; 
32-86)
7/12 (58%; 
28-85)
7/7 (100%; 59-
100)
negative Predictive 
value
1/1 (100%; 
3-100)
30/31 (97%; 
83-100)
23/24 (96%; 
79-100)
17/19 (89%; 67-99)
Observed 
agreement 8/47 (17%) 38/44 (86%) 30/36 (83%) 24/26 (92%)
cohen kappa (k) 0% (p=0.672) 64% (p<0.001) 59% (p<0.001) 82% (p<0.001)
[Table 1. Overall diagnostic accuracy for determining malignancy [n/T  
(%; 95% CI)]]
IOA (k) of EUS level of confidence, borders, lobularity, walls, diagnosis and 
microcyst component were 29%, 30%, 17%, 4%, 53% 54%, respectively. 
conclusion: EUS-through-the-needle direct intracystic mFB and nCLE im-
proves malignancy detection in pancreatic cysts.
disclosure: Nothing to disclose 
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Introduction: Endoscopic ultrasound (EUS) is a pivotal exam in the evalu-
ation of pancreatic cystic lesions (PCLs). During EUS it is also possible to 
perform fine needle aspiration (FNA) and analysis of the cystic fluid, which 
is helpful in the diagnostic process while it is still controversial if it has 
an impact on the management of these patients. Histological samples 
acquired by through-the-needle microforceps biopsy (TTNB) have been 
demonstrated to improve the diagnostic yield of EUS sampling of PCLs. 
However, available data is limited to the interobserver agreement among 
pathologists in evaluating such samples is still unknown.
aims & Methods: Consecutive patients with PCLs were retrieved were re-
trieved from the databases of participating centers between May 2016 and 
July 2017. TTNB slides with worrisome features were retrieved and inde-
pendently evaluated for specimen adequacy, presence of lining epithe-
lium, grade of epithelial dysplasia, presence of ovarian type stroma, and 
specific diagnosis by six expert pathologists from six different tertiary care 
centers. Cohen’s kappa and Gwet’s AC1 coefficients were used to assess 
interobserver agreement, with 95% confidence intervals.
results: 40 TTNB slides were retrieved and evaluated in the study period. 
An almost perfect agreement were observed for specimen’s adequacy 
[87%, kappa 0.16 (95% CI:0.05;0.27) and AC1 0.82 (95% CI:0.79;0.98)], 
presence of lesional epithelium [92%, kappa 0.61 (95% CI:0.51;0.86) 
and AC1 0.90 (95% CI:0.86-0.92)], epithelial dysplasia [97%, 0.43 (95% 
CI:0.18-0.67) and AC1, 0.97 (95% CI:0.95-0.99)] and ovarian-like stroma 
[93%, kappa 0.76 (95% CI:0.68-0.83) and AC1 0.90 (95% CI:0.86-0.93)]. 
When considering all diagnoses separately, a moderate to substantial 
agreement (68%) was observed [AC1 0.62 (95% CI:0.57-0.67)], similarly 
to what was found for mucinous cysts versus serous cyst adenoma versus 
other diagnoses (overall agreement, 76%; kappa, 0.62, 95% CI:0.57-0.88, 
AC1, 0.65 95% CI:0.59-0.70) and for mucinous cysts vs. all other diagno-
ses (overall agreement, 87%, kappa 0.73, 95% CI: 0.68-0.80), AC1 0.74, 
95% CI:0.68-0.84). The agreement for diagnosis of mucinous cystic neo-
plasm vs. intraductal mucinous papillary neoplasm was almost perfect 
(overall agreement 94.0%, kappa 0.88, 95% CI:0.81-0.95, AC1 0.88, 95% 
CI:0.81-0.95).
conclusion: Interobserver agreement between expert pathologists in the 
evaluation of TTNB samples from PCLs with worrisome feature was close 
to perfection for all the evaluated parameters, except the definitive diag-
nosis. When mucinous cystic lesions were compared versus all other diag-
noses the agreement became substantial, thus indicating that TTNB speci-
men can provide important information for PCLs management decisions.
disclosure: Nothing to disclose 
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aims & Methods: The aim of this study was to present our initial experi-
ence with microbiopsies from pancreatic cysts by quantifying the size and 
cellular content of the biopsies and subject the biopsies to NGS. Microbi-
opsies from 27 patients were reviewed with regards to clinical data and 
histopathology. The biopsies were processed and areas of H&E stained 
tissue and numbers of neoplastic epithelial cells on the glass slides were 
measured digitally using a slide scanner. Of the 27 biopsies, 23 were sub-
jected to NGS using a 50 gene cancer hotspot panel detecting point muta-
tions in frequently altered genes such as KRAS, GNAS and BRAF.
results: Of the 27 patients, 19 were IPMNs, 3 SCNs, 2 pseudocysts, 2 were 
non-diagnostic with regards to histopathology, and 1 was excluded due to 
scarce material. Mean age was 70.9 years. The cysts were mostly located 
in the head of the pancreas and were predominantly side-branch IPMNs 
of gastric subtype with low grade dysplasia. A median of 3 biopsies were 
obtained with a mean cross size of 1,046 µm and a mean area of 997,102 
µmm2. 
A total of 23 out of 27 biopsies were subjected to NGS, excluding pseudo-
cysts and the biopsy with insufficient material. Furthermore, one biopsy 
was excluded due to insufficient amount of DNA after DNA-extraction. The 
biopsies subjected to NGS had a mean cell count of 308 cells. The NGS 
analysis yielded DNA with a mean mapped reads of 742,807 base pairs, 
mean of sequencing depth of 3,429 and a mean uniformity of 98.4%. Six-
teen IPMNs harbored mutations in genes regulating cell cycle and repair, 
and three were without mutations. 
Most frequent mutations were found in KRAS and GNAS, and these were 
often concomitant. Three SCNs were without mutations, while a non-
diagnostic microbiopsy, with regards to histology, harbored a KRAS and 
TP53 mutation and was deemed malignant after clinical follow up. Three 
patients underwent surgery, and the mutated genes detected in the mi-
crobiopsies were confirmed in the resected specimens. We additionally 
identified a GNAS mutation in one of the resected specimens which was 
not identified in the corresponding initial microbiopsy.
conclusion: Microbiopsies offer sufficient tissue for histopathological ex-
amination as well as NGS. The latter identified mutations in genes fre-
quently seen in IPMNs and thus, NGS of microbiopsies is a promising 
method that has the potential to improve diagnostic decision making. Fur-
ther studies in this field are needed to validate the results.
references: 1. Kromrey ML, Bulow R, Hubner J, et al. Prospective study 
on the incidence, prevalence and 5-year pancreatic-related mortality of 
pancreatic cysts in a population-based study. Gut. 2018;67(1):138-45. 2. 
Brugge WR, Lauwers GY, Sahani D, et al. Cystic neoplasms of the pan-
creas. The New England journal of medicine. 2004;351(12):1218-26. 3. Eu-
ropean evidence-based guidelines on pancreatic cystic neoplasms. Gut. 
2018;67(5):789-804.
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Introduction: Pancreatic cystic lesions (PCL) is a frequent finding on cross-
sectional imaging. Mucinous cystic neoplasms (MCNs) and intraductal 
papillary mucinous neoplasms (IPMNs) have malignant potential. The 
differential diagnosis of malignant pancreatic cystic lesions is frequently 
difficult.
aims & Methods: The aim of our study was to evaluate the accuracy of 
preoperative clinical markers in differential diagnosis of malignant PCL 
Ninety seven patients who underwent pancreas resection for PCL were 
between 2008 and 2018 reviewed retrospectively (mean age 56.5 years, 
range 21-79; 52 females). 14 were IPMNs (9 - benign lesions, 5 malignant), 
34 were serous cystoadenomas (SCA) and 34 MCNs (19 - benign lesions, 
15 malignant), 27 pseudocysts. The following factors on association with 
malignant PCL were assessed with logistic regression analysis: age, sex, 
localization of cyst, cyst size, neutrophil to lymphocyte index (NLI), se-
rum carbohydrate antigen 19-9 (CA19-9) and the presence of enhanced 
P0113 carcInOeMBryOnIc anTIgen LeveL In The PancreaTIc 
juIce Is effecTIve In MaLIgnancy dIagnOsIs and PredIcTIOn 
Of fuTure MaLIgnanT TransfOrMaTIOn Of InTraducTaL 
PaPILLary MucInOus neOPLasM Of The Pancreas
Hayakawa H., Fukasawa M., Takano S., Shindo H., Takahashi E., 
Hirose S., Kawakami S., Sato T., Enomoto N.
University of Yamanashi, First Department of Internal Medicine, Chuo City, 
Japan
contact e-Mail address: hhayakawa@yamanashi.ac.jp
Introduction: The present study aimed to determine the ability of diagnos-
ing malignancy and predicting malignant transformation in patients with 
IPMN using carcinoembryonic antigen (CEA) level in the pancreatic juice.
aims & Methods: We enrolled patients with IPMN who underwent en-
doscopic retrograde pancreatography (ERP) between 2002 and 2018. We 
examined the ability of diagnosing malignancy in 63 patients who under-
went surgery (surgical group). 
Furthermore, we examined the value of predicting malignant transforma-
tion in 52 patients who underwent follow-up for over 1 year after ERP 
(follow-up group).
results: In the surgical group, the overall sensitivity and specificity of CEA 
level (≥97 ng/ml) in the pancreatic juice for diagnosing malignancy were 
45% and 100%, respectively. The specificity was excellent for all IPMN 
types; however, the sensitivity was highest in main duct type, followed by 
mixed type and branch duct type. 
In the follow-up group, malignant transformation was observed in four 
patients (7.7%) during the follow-up, and the median time until malig-
nant transformation was 58 months. High CEA level in the pancreatic juice 
demonstrated a statistically significant difference in multivariate analysis 
and was found to be an independent predictor of malignant transforma-
tion (hazard ratio, 17; P = 0.02). The cumulative malignant transformation 
rate was significantly higher in the high CEA group than that in the low 
CEA group (5-year cumulative malignant transformation rates, 69% vs. 
0%, P < 0.001).
conclusion: CEA level in the pancreatic juice is useful not only in diagnos-
ing malignancy but also in predicting future malignant transformations in 
IPMN patients receiving follow-up.
disclosure: Nothing to disclose 
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Introduction: Risk stratification of pancreatic cysts presents a diagnostic 
challenge for the multidisciplinary team, and the incidence of these le-
sions is on the rise due to an increased use of cross sectional imaging (1). 
Mucinous cysts such as Intraductal Papillary Mucinous Neoplasms (IPMNs) 
and Mucinous Cystic Neoplasms harbor malignant potential and may de-
velop into pancreatic ductal adenocarcinoma. Conversely, Serous Cystic 
Neoplasms (SCNs) are considered benign (2). 
Endoscopic Ultrasound Examination (EUS) with fine needle aspiration 
(FNA) of cyst fluid has been the preferred method for imaging as well as 
tissue procurement of pancreatic cysts (3). 
Interpretation of cytology samples from pancreatic cysts is challenging. A 
novel microbiopsy forceps used in conjunction with EUS-FNA procedure 
offers new opportunities for histological examination of tissue from pan-
creatic cysts as well as Next Generation Sequencing (NGS), whereby iden-
tification of mutated genes controlling cell cycle and arrest may provide 
biomarker information in the risk assessment of pancreatic cysts.
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intracystic mass on computed tomography. The receiver operating charac-
teristic (ROC) curve and area under the ROC curve (AUC) were applied to 
determine the best cutoff values for baseline NLI.
results: The NLI in patients with benign PCL (1,85 ± 0,94) was significantly 
lower than that in patients with malignant PCLs (2,93 ± 2, 45, P=0,008). 
The optimal cut-off value of NLI for predicting malignant PCLs was 1,876 
(AUC=0,684). In multivariable analysis NLI>1,876 (OR: 5,857; 95 % CI: 
1,872- 18,326; P = 0,002), CA 19-9 > 37 U/ml (OR: 17,333; 95 % CI: 4,984 
- 60,273; P = 0,0001) and the presence of enhanced intracystic mass on 
computed tomography (OR: 7,333; 95 % CI: 2,319 - 23,186; P = 0,0007) were 
independent factors of malignant PCL. Sensitivity, specificity and accuracy 
of the combination of NLI>1,876, CA 19-9 > 37 U/ml. and the presence of 
enhanced intracystic mass in predicting malignant PCL is 71,4%, 95,6% 
and 86,5% respectively
conclusion: Combination of NLI>1,876 CA 19-9 > 37 U/ml. and the presence 
of enhanced intracystic mass on computed tomography is an effective pre-
dictor of malignant PCL
disclosure: Nothing to disclose 
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Pham K.C.-D.1,2
1Haukeland University Hospital, Department of Medicine, Bergen, Norway, 
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3Haukeland University Hospital, Department of Pathology, Bergen, Norway, 
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Introduction: Current diagnostic tools are insufficient to distinguish mu-
cinous from non-mucinous cystic lesions in the pancreas. Since these 
lesions have different malignancy potential, it is crucial to establish a 
diagnosis to provide relevant follow-up and timely intervention. In this 
feasibility study, we used a through-the-needle biopsy forceps to obtain 
histology specimens from the cyst wall in addition to cyst fluid analyses of 
cystic pancreatic lesions.
aims & Methods: Adult patients with pancreatic cysts ≥15 mm were in-
cluded prospectively after a multi-disciplinary-team evaluation of CT and/
or MRI images from November 2016-March 2019. The entire pancreas was 
examined with EUS and the size, position and morphology of the cystic 
lesion was recorded. A 19G EUS needle was used to puncture the cysts and 
a Moray Micro biopsy-forceps (US Endoscopy, OH, USA) was introduced 
through the needle, and 2-4 biopsies were obtained from the cyst wall un-
der EUS guidance. The patients received prophylactic antibiotics, and from 
2018 additional NSAIDs and 1 l Ringer acetate i.v. prior to procedure. The 
specimens were examined by a dedicated pathologist. Finally, cyst-fluid 
was aspirated for cytology, CEA, amylase and biobank. All patients were 
observed for one day post procedure.
results: 34 patients were considered for micro-biopsies: 5 patients were 
not included due to age (1) solid lesions (1), inability to visualise needle 
(1), small cyst size and ongoing double antiplatelet therapy (1). 29 patients 
were included and one patient needed repeated procedure. 30 procedures 
were performed. 17 of patients were male, 12 female, median age was 68 
years (33-77). Average cyst size: 33 x 25 mm. Twenty two of 29 patients 
were asymptomatic and only 4 had cyst related symptoms. Diagnostic bi-
opsy specimen was obtained in 23/29 (79,3%) of the cases, whereas cytol-
ogy was diagnostic in only 5/29 (17,2%). In five of the procedures (5/30), 
post-procedure pancreatitis occurred and had to be treated conservatively 
over 4-11 days of hospitalisation. All patients recovered without sequelae. 
1/29 patients underwent surgery and postoperative histology confirmed 
the histology obtained by EUS microbiopsy (MCN, low grade dysplasia). 
Two patients developed inoperable carcinoma, both were found unfit for 
surgery due to tumor progression. Both these patients had cyst-fluid CEA 
>2000 at the time of the procedure. The other patients are currently under 
observation.
conclusion: EUS-guided micro-biopsies of cystic pancreatic lesions is fea-
sible and increases diagnostic performance significantly compared to cytol-
ogy. The procedure carries a risk for post-procedure pancreatitis that must 
be considered, and patients should be selected carefully for this procedure.
disclosure: Speaker honoraria: GE healthcare, Conference participation: 
Pharmacosmos, US equipment: Samsung Medison. 
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P0118 ePIgeneTIc reguLaTIOn Of aPOPTOTIc PrOTease 
acTIvaTIng facTOr-1Is assOcIaTed WITh WOrse survIvaL 
and PrOgnOsIs In PancreaTIc cancer
Lukosiute-Urboniene A.1, Gasianec A.2, Dauksa A.1, Gulbinas A.1, 
Dambrauskas Z.1
1Lithuanian University of Health Science, Kaunas, Lithuania, 2Vytautas 
Magnus University, Kaunas, Lithuania
contact e-Mail address: ausra.urboniene2@lsmuni.lt
Introduction: Apoptotic protease activating factor-1 (Apaf-1) is a critical 
regulator of the intrinsic pathway of apoptosis. Recent studies suggest that 
inactivation of the Apaf-1 by DNA methylation processis common event 
in numerous cancer types including pancreatic ductal adenocarcinoma 
(PDAC). In addition, restoring physiological levels of Apaf-1 by5-aza-2’-
deoxycytidine (Decitabine) - a specific inhibitor of DNA methylation, mark-
edly enhances chemosensitivity and rescues the apoptotic defects associ-
ated with Apaf-1 loss. While the ability of DNA hypermethylation to silence 
tumor suppressor genes in cancer is well established, how genes are tar-
geted for this aberrant DNA methylation in PDAC is still unclear.
aims & Methods: The aim of our study is to determine the association of 
APAF-1 expression with clinicopathological parameters and prognosis in 
PDAC and to assess the possible epigenetic APAF-1 regulation mechanism 
by DNA methylation process. 
Data of 56 patients after pancreatoduodenectomy for PDAC between 2011- 
2016 were analyzed. Patient’s mRNA expression levels of APAF-1 was com-
pared with normal pancreatic tissue and the correlations with clinicopatho-
logical parameters were analyzed. The Kaplan-Meier method and log-rank 
tests were used for survival analysis. Additionally, two linear pancreatic ad-
enocarcinoma cell lines Capan2 and MiaPaca2 were treated with Decitabine 
(1mM, 5mM, 10mM concentrations) and APAF-1 mRNA expression,apoptotic 
activity and viability were evaluated after 0, 24, 48 and 72 hours.
results: The RT-PCR analysis revealed that APAF-1 mRNA expression was 
significantly lower in PDAC when compared to normal pancreatic tissue 
(p=0.002). The expression of APAF-1 mRNA was correlated with tumor 
stage, lymph-node metastases, lymphatic and vascular invasion (p< 0.05). 
Furthermore,survival analysis revealed that patients with higher APAF-1 
expression were doing better in tested cohort group (p=0.033). Univariate 
analysis revealed that higher T stage, lymph-node metastases, perineu-
ral and lymphatic invasion were assessed as significant factors for shorter 
survival in PDAC patients (p< 0.05). After 24 h treatment with Decitabine 
(1mMand 5mM conc.) the increased expression of Apaf-1 was detected in 
the most of thePDAC cells and it decreased gradually with increased incuba-
tion period when compared with control group.
Decitabine inhibited the cells’ proliferations and viability of Capan2 and 
MiaPaCa2 cells gradually with increased drug’s concentration and incuba-
tion time. The strongest apoptosis rates were obtained after incubation for 
48 h in the Capan2 cells despite concentrations rates of Decitabine, while 
MiaPaCa2 cells showed the highest apoptotic activity starting from 24 hours 
that intensify progressively throughout all concentrations. Presumably, 
Decitabine reduces APAF-1 methylation and restores its expression, thus 
reactivating its functions.
conclusion: Present study shows that downregulation of pro-apoptotic 
Apaf-1 gene is associated with worse prognosis in PDAC.Our results sug-
gest that the tumor-suppressive effect of Decitabine may result from the 
reactivation of silenced Apaf-1 through demethylation.
disclosure: Nothing to disclose 
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results: By using a genome wide unbiased approach we were able to 
establish the chemokines CCL20 and CX3CL1 as central NF-kB target genes 
mediating therapy resistance. Both chemokines are acting in a paracrine 
fashion, leading to an increased recruitment of inflammatory cells which 
in turn mediate apoptosis resistance of PDAC cells. By the use of an or-
thotopic syngeneic transplantation PDAC model, we further dissected the 
relevance of the observed cancer-immune cell interaction and strengthen 
the value of such onco-immuno-crosstalk to tailor novel precise therapeu-
tic interventions.
conclusion: In conclusion, our data show a functional role of NF-kB-con-
trolled chemokine pathways in PDAC TRAIL resistance. 
The demonstrated therapy induced cross-talk of cancer cells with immune 
cells impairs the intended treatment response, pointing out the need of nov-
el bi-specific treatments, which target tumor cells as well as immune cell.
disclosure: Nothing to disclose 
P0121 Txnrd2 defIcIency Leads TO LOW ras-acTIvITy 
and decreased TuMOr deveLOPMenT In a krasg12d - drIven 
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Introduction: Reactive Oxygen Species (ROS) and oxidative defense sys-
tems are believed to play a pivotal role in pancreatic cancer development. 
Recent results show the driving force of ROS in the development of pan-
creatic ductal adenocarcinoma (PDAC), yet the role of key regulators of 
ROS remains elusive. We set out to investigate the impact of mitochondrial 
Thioredoxin reductase (Txnrd2) deletion on mitochondrial ROS (mtROS) 
and KrasG12D - driven pancreatic carcinogenesis in a mouse model.
aims & Methods: Genetically engineered mice (GEM) were kept in ap-
propriate housing facilities according to German animal welfare law until 
tumor development or designated time points, respectively. Sections from 
pancreas and primary metastatic sites as well as macroscopically patho-
logical organs were fixed and processed by H&E staining and immuno-
histochemistry. Also, tumor cells were isolated and further experiments 
were performed in cell culture. Methods such as qRT-PCR, Western Blot 
analysis, cellular oxygen consumption analysis, protein activity pulldowns, 
proliferation and colony formation assays, in vivo stainings, Flow cytom-
etry and others were performed to investigate the objective.
results: At 12 weeks and, to a lesser degree, also in 24 weeks, we observed 
an increase in ADM (acinar-to-ductal metaplasia) and PanIN (pancreatic 
intraepithelial neoplasia) lesions in KrasG12D; Txnrd2ΔPanc mice compared to 
KrasG12D control mice. Despite this initial increase in precursor lesions, , 
tumor incidence was significantly lower compared to KrasG12D control mice. 
In order to gain insight into the mechanism behind this apparent dis-
crepancy, we investigated cancer cell lines isolated from these GEM. We 
observed impaired proliferation and colony formation. This reduced pro-
liferation could be linked to impairments in cell cycle, concerning mainly 
the S-Phase. ROS and some antioxidant enzymes were increased, how-
ever, the oxidative state of the cells remained balanced. Although we also 
detected a higher mitochondrial copy number in Txnrd2-deficient cells, 
measurement of mitochondrial bioenergetics showed no impairment of 
mitochondrial function and comparable O
2
-consumption and extracellular 
acidification rates, respectively.
Interestingly, we found lightly decreased levels of mRNA-levels of RAS-
isoforms, which led us to investigate RAS abundance and activity, where 
we could observe significant alterations in cell lines deficient of Thiore-
doxin Reductase 2.
conclusion: Although there are further experiments to be pursued, we 
believe to have gained insight into the mechanisms behind the observed 
phenotype of reduced tumor incidence in KrasG12D; Txnrd2ΔPanc mice.
disclosure: Nothing to disclose 
P0119 MIr-23B-3P PrOMOTes PancreaTIc cancer ceLL 
TuMOrIgenesIs and MeTasTasIs ThrOugh The PTen/PI3k/akT 
sIgnaLIng PaThWay
An F.1, Zhang Y.2, Chen D.2
1Wuxi People’s Hospital Affiliated to Nanjing Medical University, Department 
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Introduction: The microRNA (miRNA) miR-23b-3p plays an important role 
in tumor growth, proliferation, invasion, and migration. However, the role 
and mechanism of miR-23b-3p in pancreatic cancer (PC) development re-
main largely unknown.
aims & Methods: RT-PCR was applied to verified the serum miR-23b-3p 
expression, Immunohistochemical (IHC) and western-blot were used to 
detect the proteins expression, MicroRNAs (miRNAs) mimic and inhibitor 
were used to change the expression levels of miR-23b-3p and the PANC-1 
cell lines was used for in vitro studies, the targeted gene was verified by 
luciferase reporter assay as well as western-blot. Finally, the subcutane-
ous tumor xenograft model and the living image system were used for the 
in vivo studies.
results: In this study, we found that the serum miR-23b-3p level was el-
evated in PC patients along with upregulation of phosphoinositide 3-ki-
nase (PI3K) and phospho-protein kinase B (p-Akt), suggesting the possible 
involvement of miR-23b-3p and PI3K/Akt signaling in PC development. 
In addition, miR-23b-3p was induced in response to interleukin-6 (IL-6), 
which is involved in PC progression. Overexpression of miR-23b-3p by an 
miR-23b-3p mimic, on the other hand, activated PI3K/Akt signaling in PC 
cells, as evidenced by miR-23b-3p-induced upregulation of phosphati-
dylinositol (3,4,5)-trisphosphate (PIP3) and p-Akt as well as downregula-
tion of phosphatase and tensin homolog (PTEN). MiR-23b-3p downregu-
lated PTEN through directly targeting the 3ʹ-untranslated region (3ʹUTR) of 
PTEN mRNA. Importantly, overexpression of miR-23b-3p by a miR-23b-3p 
agomir promoted PC cell-derived tumor growth and liver metastasis in a 
xenograft mouse model, along with activated PI3K/Akt signaling. In con-
trast, knockdown of miR-23b-3p by an miR-23b-3p antagomir suppressed 
tumor growth and metastasis as well as PI3K/Akt signaling activity. 
Furthermore, the mice in vivo imaging experiment showed over expression 
of miR-23b-3p can enhance the total fluorescence signals from regions of 
interest (ROI), and it was demonstrated that the fluorescence signals were 
stronger in the lung and heart when compared with control.
conclusion: These results suggest that miR-23b-3p enhances PC cell tu-
morigenesis and metastasis at least partially through the PTEN/PI3K/Akt 
signaling pathway. Therefore, targeting miR-23b-3p or PTEN/PI3K/Akt sig-
naling may be a potential therapeutic strategy against PC.
disclosure: The authors declare that they have no competing interests. 
P0120 nf-kaPPaB cOnTrOLLed cheMOkIne sIgnaLLIng 
reguLaTes OncO-IMMunO crOssTaLk and aPOPTOsIs 
resIsTance In PancreaTIc cancer
Geismann C.1, Gundlach J.P.2, Hauser C.2, Schreiber S.3, Arlt A.4
1University Hospital Schleswig-Holstein, Campus Kiel, Department of 
Internal Medicine 1, Kiel, Germany, 2University Hospital of Schleswig-
Holstein, Campus Kiel, Department of Surgery, Kiel, Germany, 
3Universität Kiel UKSH, Medizinische Abt. I, Kiel, Germany, 4University 
Hospital of Schleswig-Holstein, Campus Kiel, Department of Medicine, 
Kiel, Germany
contact e-Mail address: aarlt@1med.uni-kiel.de
Introduction: Pancreatic ductal adenocarcinoma (PDAC) exhibit one of the 
worst survival rates of all cancers. For the majority of patients, a “curative” 
intended resection is not feasible and the response rates to palliative ther-
apeutic approaches remain highly unsatisfactory. One hallmark of PDAC 
is a profound desmoplastic stroma reaction consisting of fibroblasts, en-
dothelial and immune cells essentially contributing to therapy resistance 
of PDAC. It is known that inflammation and tumorigenesis are function-
ally connected and controlled by the NF-kB signaling pathway, mediating 
apoptosis resistance.
aims & Methods: Analyzing the role of NF-kB controlled chemokine sig-
naling in apoptosis resistance of PDAC using unbiased expression profiling 
followed by translational functional analysis.
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P0122 The effIcacy Of reIc/dkk-3 gene TheraPy fOr 
PancreaTIcOBILIary carcInOMa
Uchida D.1, Shiraha H.1, Tanaka E.2, Kato H.1, Ohyama A.1, Okada H.1
1Okayama University Hospital, Okayama, Japan, 2Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
Okayama, Japan
contact e-Mail address: pt77172s@okayama-u.ac.jp
Introduction: The reduced expression in immortalized cells (REIC)/Dkk-3 
gene is down-regulated in various malignant tumors. Previous study re-
vealed that the REIC/Dkk-3-expressing adenoviral vector (Ad-REIC) was 
found to induce cancer-selective apoptosis, and anti-tumor immunity.
aims & Methods: We applied Ad-REIC to treatments of pancreaticobiliary 
carcinoma.The cell proliferation and the apoptotic effect of Ad-REIC were 
evaluated by MTT assayin the pancreatic cancer cell lines (ASPC1 and MIA-
PaCa2) and cholangiocarcinoma cell lines (TFK-1 and G-415). Ad-LacZ was 
used as a control. The apoptosis signal was assessed by western blotting. 
Additionally, the effect of combined therapy with Ad-REIC and chemo-
therapy agents (gemcitabine, and cisplatin) was assessedin vitro. We also 
established the drug-resistant cancer cells (gemcitabine-resistant ASPC1, 
cisplatin-resistant TFK-1),and assessed the therapeutic effects of Ad-REIC 
therapy for drug-resistant cancer cells. The effects of Ad-REIC in vivo were 
assessed using the mouse xenograft model.
results: Ad-REIC inhibited cell growth in pancreaticobiliary cancer 
cell lines (ASPC1:31.9±8.8%, MIAPaCa2:39.7±11.6%, TFK-1:64.5±1.7%, 
G-415:48.4±4.1%). Anti-tumor effect of Ad-REIC was further enhanced 
in combination with chemotherapy agents (ASPC1:29.1±6.8%, MIAPa-
Ca2:19.7±3.1%, TFK-1:50.0±5.3%, G-415:22.0±2.0%). Ad-REIC also induced 
apoptosis inthe gemcitabine-resistant ASPC1 (62.7±1.3%), and the cisplat-
in-resistant TFK-1 (58.0±1.3%). The anti-tumor effect may be causedby the 
stimulation of c-Jun-N-terminal kinase pathway. Ad-REIC also achieved 
tumor growth inhibition in the mouse xenograft model (ASPC1: 60.7±9.9%, 
G-415: 43.8±22.6%).
conclusion: Ad-REIC induced apoptosis and inhibited tumor growth in the 
pancreaticobiliary cancer including drug-resistant cancer cells. REIC/Dkk-3 
gene therapy could be an attractive therapeutic tool for the pancreatico-
biliary cancer.
disclosure: Nothing to disclose 
P0123 sMarT drug-deLIvery sysTeMs fOr PancreaTIc 
cancer TreaTMenT
Gonzalez-Valdivieso J.1, Garcia Sampedro A.2, Arias F.J.1, Pereira S.P.2, 
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Introduction: Pancreatic cancer is a lethal disease partly due to poor drug 
delivery and acquired resistance to therapy. Nanotechnology have shown 
promise in a wide range of biomedical applications. In particular, nanopar-
ticles have been used to achieve controlled drug delivery and to improve 
treatment efficacy. The protein kinase B, also known as Akt, is overex-
pressed in many types of cancers, including pancreatic cancer. This protein 
plays a key role in multiple cellular processes such as cell proliferation and 
cell death. Targeting Akt is a highly attractive anti-cancer strategy and dif-
ferent Akt inhibitors are now in clinical development for cancer therapy.
aims & Methods: In this project, we have developed novel polymeric 
nanoparticles formed by elastin-like recombinamers (ELRs) carrying a 
small peptide inhibitor of the protein kinase Akt. We have evaluated the 
kinetic uptake and subcellular localisation of these carriers by flow cytom-
etry and confocal microscopy, respectively. Moreover, we have determined 
the effectiveness of the loaded nanoparticles to inactivate both established 
pancreatic cancer cell lines and clinically relevant patient-derived cells by 
MTT assays and LIVE/DEAD staining. The specific inhibition of phospho-Akt 
and the activation of cell death pathways after incubation with the loaded 
nanoparticles were evaluated by western blot analysis and protein array-
based approaches.
results: We corroborated that the ELR polymer was able to self-assemble 
into smart nanoparticles with a mean diameter of 72 nm when the tem-
perature was increased above 16°C. Accumulation of nanoparticles into the 
cells was validated by flow cytometry. Confocal microscopy showed a lyso-
somal localisation of these nanoparticles. Cell viability and metabolic ac-
tivity were significantly reduced after incubation with loaded nanoparticles 
in a time- and concentration-dependent fashion. Moreover, nanoparticles 
inhibited phosphorylation of Akt protein, blocked NFĸB signalling pathway 
and triggered caspase 3-mediated apoptosis.
conclusion: Hence, the use of these novel polymeric nanoparticles could 
lead to the development of more effective pancreatic cancer treatment op-
tions focused on the inhibition of Akt. The combination of these inhibitors 
with other treatment strategies could improve treatment outcomes.
disclosure: Nothing to disclose 
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Introduction: We have previously described in an humanized mouse model 
of nasopharyngeal carcinoma that an anti-Galectin-9 (Gal-9) monoclonal 
antibody (mAb) is able to significantly limits tumor growth by specifically 
inhibiting the suppressive activity of human natural Tregs (Patent WO: 
WO2015185875). Herein, we propose to use this new specific active im-
munotherapy in a pancreatic cancer mouse model (KRASG12D), insofar as 
a high Treg prevalence has been described and correlated to the tumor 
progression of pancreatic cancer.
aims & Methods: Gal-9 expression was analysed by immunohistochemis-
try on pancreas isolated from the KRASG12D mouse model. Treg infiltration 
was analyzed by flow cytometry after digestion (GentleMACS) of pancreas 
isolated from the KRASG12D
For in vitro study we used four PDAC cancer cell lines Capan-1, Capan-2, 
MIAPaCa-2, Panc-1 and perfomed RT-qPCR, Immunofluorescence, West-
ern-blot, flow cytometry and ELISA to validate Gal-9 expression and secre-
tion.
results: Gal-9 expression was confirmed by immunohistochemistry on 
pancreas isolated from the KRASG12D mouse model. This Gal-9 expression 
level has been correlated to the progression of pre-cancerous lesions. 
Furthermore, an increase of Tregs prevalence has been observed in this 
transgenic model at a systemic and intratumoral level. Very interestingly, 
we also showed that 
(i) murine Tregs expressed Gal-9 (flow cytometry, immunofluorescence 
and western-blot),
(ii) anti-Gal9 mAb neutralized the immunosuppression induced by recom-
binant murine Gal-9 (proliferation assays) and 
(iii) anti-Gal9 mAb neutralized the suppressive activity of murine Tregs 
(MLR assay).
Further investigations performed on four human pancreatic cancer cell 
lines (Capan-1, Capan-2, MIAPaCa-2, Panc-1) have also confirmed the Gal-
9 expression at a genomic (RT-qPCR), proteomic (Immunofluorescence, 
Western-blot and flow cytometry) and secreting (ELISA) level. Moreover 
public data from ‘Gene Expression Omnibus’ showed a high level of Gal-9 
transcript in the pancreas of PDAC patients which is associated with de-
creased overall survival.
conclusion: Our preliminary results suggest that the use of an anti-Gal-9 
mAb could be considered as a new anti-tumoral immunotherapy targeting 
Tregs in the pancreatic cancer.
disclosure: Presented at: 5th European Congress of Immunology (ECI), 
September 2-5, 2018 in Amsterdam 
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aims & Methods: For this purpose, the RESPECT-study - a multinational, 
retrospective database - was screened for patients receiving either FO-
FIRINOX (FFx) or Gemcitabine/nab-paclitaxel (GNP). Subsequently, patient 
outcomes were compared between young and elderly patients using a cut-
off age of 63 years(Comparison1) and 70 years (Comparison 2).
results: 48.5% and 23.7% of all patients receiving NTx were older than 
63 and 70 years. In both groups younger patients preferably undergo FFx 
(Comparison 1: 83.1% vs. 69.7%; p=0.063; 
Comparison 2: 81.8% vs. 57.6%; p=0.005) with more NTx cycles (Compari-
son1: 6.58 vs. 5.66; p=0.057). Although dose reduction of NTx was more 
common in elderly patients in Comparison 1 (n=10/11.2% vs. n=23/23.9%; 
p=0.003), resectability (Comparison 1: n=71/79.8% vs. n=57/75.0%; 
p=0.575; 
Comparison 2: n=102/77.3% vs. n=26/78.8%; p=1.000) did not differ be-
tween both groups. Importantly, median survival (Comparison 1: 29.867 
vs. 23.1; p=0.406, Comparison 2: 28.0 vs. 21.0; p=0.499), overall survival of 
resected patients (Comparison 1: 36.0 vs. 28.0; p=0.453, 
Comparison 2: 35.0 vs. 26.0; p=0.378) and progression-free-survival time 
(Comparison 1: 22.0 vs. 19.0; p=0.730, Comparison 2: 23.0 vs. 15.0; p=0.095) 
did not relevantly differ.
conclusion: Results suggest that NTx is also feasible in elderly patients suf-
fering from pancreatic cancer with an adequate resection rates, oncologi-
cal response and overall survival.
disclosure: Nothing to disclose 
P0129 can dIgITaL skeLeTaL MuscLe Index PredIcT PaLLIaTIve 
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Introduction: An endoscopic ultrasound guided biopsy (EUS-B) is required 
prior to treatment with palliative chemotherapy for patients with suspect-
ed pancreatic ductal adenocarcinoma (PDAC). Given the urgency of treat-
ment, EUS-B is often done prior to oncological assessment after which a 
significant proportion of patients do not take up chemotherapy. Low skel-
etal muscle index (SMI), termed sarcopenia, is common in PDAC and has 
been associated with poor outcomes.
aims & Methods: We aimed to assess if novel digital software can calcu-
late SMI using a computerised tomography (CT) image to predict palliative 
chemotherapy uptake in patients with suspected PDAC, and streamline 
EUS-B. Patients who underwent an EUS-B showing PDAC between Jan 
2016 and Dec 2017 with a CT scan performed within a month prior to biopsy 
were included in the study. SMI was calculated by a single slice CT image 
taken at the level of the third lumbar vertebra. 
Software was used to identify skeletal muscle (sliceOmatic, Tomovision). 
Sarcopenia was defined as SMI< 41(female) and < 53 cm2/m2(male). Body 
mass index (BMI), performance status, demographic data were also com-
pared between patients that went on to receive chemotherapy and those 
who did not.
results: EUS-Bconfirmed PDAC in 85 eligible patients during the study 
(median age 70;41-84 years). A total of 61/85(71%) of patients received at 
least one dose of chemotherapy. Sarcopenia was present in 57/85 (57.6%). 
Despite a raised BMI of >25 in 41/85 (48.1%) of the patients, sarcopenia 
was present in 25 (61.0%) of them. 
Patients who did not take up chemotherapy had a lower SMI (40.5 vs 45.2 
cm2/m2,p=0.04) and a poorer mean performance status (1.25 vs 0.7: t-test 
p=0.002). There was no difference in BMI (26.8 vs 24.6 p=0.10) in patients 
that did and did not take up chemotherapy. No patients with a perfor-
mance status of 3 (n=3) or age >80 (n=5) proceeded to chemotherapy. In 
those having chemotherapy, survival was higher in non-sarcopenic pa-
tients compared to sarcopenic patients (11.8 vs 7.7 months, p=0.04). Sur-
vival was similar in sarcopenic patients having chemotherapy and non-
sarcopenic patients who did not have chemotherapy (7.7 vs 7.4 months 
p=0.5). Patients with performance status ≥2 and sarcopenia were much 
less likely to receive chemotherapy compared to those with performance 
status 0-1 without sarcopenia (83.9% vs 37.5%, p=0.02).
P0125 dna sequencIng Of cyTOPaThOLOgIcaLLy IncOncLusIve 
eus-guIded fIne needLe asPIraTes frOM sOLId PancreaTIc 
LesIOns susPIcIOus fOr MaLIgnancy cOnfIrMs eus dIagnOsIs
Plougmann J.1, Klausen P.1, Toxværd A.2, Abedi A.1, Kovacevic B.1, 
Gásdal Karstensen J.1, Poulsen T.S.2, Kalaitzakis E.1, Høgdall E.2, 
Vilmann P.1
1Copenhagen University Hospital Herlev, Gastro Unit, Division of Endoscopy, 
Herlev, Denmark, 2Copenhagen University Hospital Herlev, Department of 
Pathology, Herlev, Denmark
contact e-Mail address: julie.isabelle.plougmann@regionh.dk
Introduction: Endoscopic ultrasound (EUS) with fine-needle aspiration 
(FNA) is inconclusive in up to 10-15% of patients with solid pancreatic 
lesions (SPLs). We aimed to investigate whether supplementary genetic 
analyses with whole exome sequencing add diagnostic value in patients 
with SPLs suspicious of malignancy but inconclusive EUS-FNA.
aims & Methods: Thirty-nine patients, who underwent EUS-FNA of a SPL 
were retrospectively included. Three groups were defined: 16 (41.0%) 
had suspected malignancy on EUS confirmed by cytology (malignant), 13 
(33.3%) had suspected malignancy on EUS but benign cytology (incon-
clusive), and 10 (25.6%) had benign EUS imaging and cytology (benign). 
Areas with highest epithelial cell concentrations were macro-dissected 
from the FNA smears from each patient, and extracted DNA was used for 
whole exome sequencing by Next Generation Sequencing of a selected 
gene panel including 19 genes commonly mutated in cancer. Final diagno-
sis was verified by surgery or clinical follow-up.
results: Pathogenic mutations in KRAS, TP53, and PIK3CA differed signifi-
cantly between the three groups (p< 0.001, p=0.018 and p=0.026, respec-
tively). Pathogenic mutations in KRAS and TP53 were predominant in the 
inconclusive (54% and 31%, respectively) and malignant groups (81.3% 
and 50%, respectively) compared to the benign group (0%). Malignant 
and inconclusive diagnoses correlated strongly with poor overall survival 
(p< 0.001).
conclusion: Whole exome sequencing of genes commonly mutated in pan-
creatic cancer may be an important adjunct in patients with SPLs suspi-
cious for malignancy on EUS but with uncertain cytological diagnosis.
disclosure: Nothing to disclose 
P0126 WIThdraWn
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P0128 OncOLOgIcaL OuTcOMe Of currenT neOadjuvanT 
TheraPy regIMes In eLderLy PaTIenTs sufferIng frOM 
PancreaTIc cancer - resuLTs Of The resPecT-sTudy
Weniger M.1, Moir J.2, Damm M.3, Maggino L.4, Kordes M.5, Rosendahl J.6, 
Ceyhan G.O.7,8, Schorn S.9, RESPECT- Study Group
1Ludwig-Maximilians-University, Department of General, Visceral, and 
Transplantation Surgery, Munich, Germany, 2Freeman Hospital, HPB Unit, 
Newcastle, United Kingdom, 3University Hospital Halle/Saale, Department 
of Gastroenterology, Halle, Germany, 4University of Verona, Unit of 
General and Pancreatic Surgery - The Pancreas Institute, Padova, Italy, 
5Karolinska Institutet, CLINTEC, Stockholm, Sweden, 6University Clinic 
Halle (Saale), Department of Internal Medicine I, Halle (Saale), Germany, 
7Technische Universität München, Chirurgische Klinik und Poliklinik, 
München, Germany, 8Department of General Surgery, School of Medicine, 
Acibadem Mehmet Ali AydinUniversitylar, Istanbul, Turkey, 9Klinikum Rechts 
der Isar der TU München, Allgemein- und Viszeralchirurgie, Munich, 
Germany
contact e-Mail address: stephan_schorn@yahoo.de
Introduction: The worldwide number of people aged older than 60 years 
will more than triple by the year 2050. As a consequence, the absolute and 
relative number of elderly patients requiring oncological therapy for ma-
lignant diseases will rise leading to the question whether currently prac-
ticed treatment regimes can be applied in patients of higher age or should 
be adopted to age. Here, data on the impact of neoadjuvant therapy(NTx) 
in elderly patients with pancreatic cancer is lacking.
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conclusion: Patients with PDAC and a performance status of ≥2 and low 
SMI were significant less likely to take up chemotherapy and had poorer 
survival. SMI measurement could act as part of a decision tool to assess 
suitability of patients to triage patients for rapid EUS-B, or clinical assess-
ment prior to considering chemotherapy.
disclosure: Nothing to disclose 
P0130 rOLe Of adIPOnecTIn LeveLs In TuMOr sTagIng and 
survIvaL PredIcTIOn In PancreaTIc cancer PaTIenTs
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Introduction: There is increasing evidence that adipose tissue-derived hor-
mones may significantly influence the growth and proliferation of tumor 
cells. We recently demonstrated the potential diagnostic role of changed 
adipokines levels in patients with pancreatic cancer (PC). However, the 
role of adiponectin in tumor proliferation in PC patients has not been well 
studied before.
aims & Methods: The aims of the study were to analyze plasma concentra-
tions of adiponectin in PC patients and to compare these concentrations 
to clinicopathological parameters. Baseline levels of serum adiponectin 
were determined in 50 consecutive patients with PC and followed up for 
the median period of 18 months. 50 Control subjects were matched to 
case patients by age, sex and BMI. The association between variables 
were evaluated using nonparametric Spearman’s correlation test. Logistic 
regression analysis was used to evaluate the association of independent 
variables with one dependet variable.Receiver operating characteristics 
(ROC) analysis was employed to calculate the area under the curve (AUC). 
Survival analysis used the Kaplan-Meier curve.
results: Overall median adiponectin concentrations were lower in PC pa-
tients versus control subjects (3.33 vs 6.62 mg/L, p< 0.001). Strong inverse 
correlation between adiponectin concentrations and tumor size (r= -0.934, 
p< 0.01) and Ca 19-9 levels (r= -0.495, p< 0.01) in PC patients were ob-
served. Logistic regression analysis demonstrated that low adiponectin 
levels were independent predictors of tumor size (beta= -0,018,p< 0.001) 
and metastatic disease (OR=0.573,p< 0.005). At ROC analysis the diagnos-
tic profiles of adiponectin for detecting matastatic disease (AUC 0.924; 
sensitivity 82%;specificity 93%) among PC patients was high. Kaplan-Mei-
er global survival analysis revealed that low adiponectin levels were as-
sociated with poorer survival compared to patients with high adiponectin 
levels (log-rank (c2): 5.02, p< 0.001).
conclusion: This study identified, for the first time, an inverse correla-
tion between adiponectin levels, tumor size and Ca 19-9 levels suggest-
ing a potential role of adiponectin as an indicator of disease progression.
Furthermore these results suggest, that serum adiponectin levels might 
provide prognostic information in predicting survival in PC patients. The 
potential role of adiponectin levels as an adjunctive indicator of advanced 
PC disease requires further evaluation.
disclosure: Nothing to disclose 
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Introduction: Recent advances in treatment of pancreatic adenocarcinoma 
are leading to an increasing use of neoadjuvant therapy before surgery, 
even in borderline resectable disease. This could increase the number of 
patients who need pancreatic biopsy, until now reserved to unresectable 
pancreatic cancer or metastatic dIsease.
Current guidelines suggest that an histological diagnosis of adenocarcino-
ma of the pancreas can be made using fine-needle aspiration (FNA) biopsy 
with either endoscopic ultrasonography (EUS) guidance (preferred) or com-
puted tomography (CT). EUS-FNA is highly sensitive and specific for solid 
lesions and provides the benefit of additional staging information at time of 
biopsy: lymph node staging, vascular invasion, and prediction of resectabil-
ity. Altough effective, EUS-FNA requires narcosis and is an expensive pro-
cedure. Percutaneous ultrasound-guided fine needle Biopsy (US-FNB) is a 
widely accepted procedure to study retroperitoneal and various abdominal 
lesions butit is not recommended for diagnosis of pancreatic cancer.
We aimed to assess the sensitivity, specificity, accuracy, safety and effec-
tiveness of US-FNB in patients with suspected pancreatic lesions
aims & Methods: In our prospective study we enrolled consecutive pa-
tients with a solid pancreatic lesion suspected for malignancy. All patients 
underwent, if possible, US-FNB and diagnosis of malingnancy was con-
firmed at follow-up, either at surgery or by the evolution of disease (eg: 
systematic therapy, death, development of metastatic lesions). Sensitivity, 
specificity and side effects were estimated.
results: Out of 90 patient, US FNB was technically feasible in 81 patients. 
60 patients were diagnosed with malignancy lesions (in detail 55 were 
pancreatic adenocarcinomas, 2 metastasis, 3 neuroendocrine tumor). 6 
patients had mass growing pancreatitis. The sensitivity of US-FNB was 
80%, specificity was 100% and accuracy 82%. Only 2 adverse effects were 
registered: a case of mild abdominal pain and a case of self-limiting ab-
dominal bleeding.
conclusion: In our study the sensitivity, specificity and accuracy in pancre-
atic lesions of US-FNB are equal to EUS-FNA. US-FNB is safe and effective. 
We do not registered any important side effect and procedure was usually 
well tolerated by patient. Not requiring narcosis and using simple dispos-
able equipment US-FNB is also a cheaper technique than EUS-FNA. We 
suggest to evaluate its use as a valid alternative to endoscopic biopsy.
disclosure: Nothing to disclose 
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Introduction: Worrisome features detected in high-risk individuals partici-
pating in a pancreatic cancer surveillance program, warrant for intensified 
surveillance or, occasionally, surgery.
aims & Methods: Our aim was to determine the patient-reported burden 
of such intensified surveillance and/or surgery, and to assess post-oper-
ative quality of life. In the course of our pancreatic cancer surveillance 
program, participants completed questionnaires including the Hospital 
Anxiety and Depression Scale (HADS, subscales range 0-21) and the Cancer 
Worry Scale (CWS, ranges 8-32). For individuals who underwent intensi-
fied surveillance (without leading to surgery), questionnaires before in-
tensified surveillance, during, and ≥3 weeks after the decision to return 
to regular follow-up were analyzed. In addition, those who underwent 
intensified surveillance in the last 3 years, or surgery at any time, were 
invited for a semi-structured telephone interview.
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aims & Methods: We retrospectively reviewed the data regarding 131 PC 
patients who received NACRT using gemcitabine or TS-1 at our institution 
between August 2012 and July 2017. We excluded the patients who did 
not receive preoperative biliary drainage and those who did not receive 
surgery. The definition of time to RBO was the period from the stent place-
ment to the recurrence of biliary obstruction according to TOKYO crite-
ria 2014. Analysis of time to RBO was performed using the Kaplan-Meier 
method and differences were evaluated with the log-rank test.
results: 58 patients (pts) were included. Median age was 66; 62.1% were 
male; median tumor size was 22mm. All biliary obstruction was caused by 
pathologically-proven pancreatic head cancer. Operative procedures were 
pancreaticoduodenectomy (n=51), total pancreatectomy (n=2) and bypass 
surgery (n=5). Median time from the initial biliary drainage to surgery 
was 133 days. The study patients received preoperative biliary drainage 
in 2.9 times on average (once 10 pts; twice 12 pts; three times 20 pts; four 
times 8 pts; five-seven times 10 pts). Biliary drainage were plastic stents 
in 128 cases (75.7%), endoscopic nasal biliary drainage (ENBD) in 37 cases 
(21.9%), SEMS in 2 cases (1.2%) and percutaneous biliary drainage in 2 
cases (1.2%). SEMS was placed after radiotherapy was completed. The 
ERCP-related complication rate was 1.8% (mild pancreatitis 2; bile duct 
injury 1). These complications were relieved with conservative treatment. 
Two mild pancreatitis was observed in the cases of 7-Fr plastic stent place-
ment. 
RBO occurred in 80 times (occlusion 70; distal migration 10). Cholangitis 
was observed at the time of RBO in 66.3% (53/80). 33.9% (20/58 pts) ex-
perienced the delay of chemotherapy due to RBO. 11.9% (7/58 pts) suffered 
from the delay of radiation due to RBO. Surgery was not delayed because 
of RBO. Median time to RBO of plastic stents was significantly longer in 10 
Fr (107 days) than 49 days in 7 Fr (p=0.005) and 62 days in 8.5 Fr (p=0.030).
conclusion: In this study primarily using plastic stents, PC patients receiv-
ing NACRT experienced preoperative biliary drainage in 2.9 times on aver-
age. 10Fr plastic stents were significantly associated with longer patency 
compared with smaller-diameter plastic stents. Larger-diameter plastic 
stents could decrease RBO and the delay of chemotherapy and radiation 
without increasing adverse events.
disclosure: Nothing to disclose 
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Introduction: The neuroendocrine neoplasia (NEN) were considered an 
heterogeneity disease in term of somatostatin receptor expression, uptake 
contrast enhancement in CT scan evaluation, FDG uptake, and heterogene-
ity of proliferative index especially for patients with multiple metastases. 
Tumor heterogeneity can be difficult to capture and quantify with tradi-
tional imaging tools. The recent tendency of radiology is to research re-
producible parameters, extracted from the images and standardized. The 
technical term to explain this strand is “Radiomics”. It is possible to obtain 
an objective evaluation in addiction to traditional subjective evaluation, 
using TexRAD, software of CT-Texture Analysis, that refers to mathemati-
cal methods used to analyze the attenuation value of each voxel and their 
distribution within the region of interest (ROI) to obtain a measure of the 
intralesional heterogeneity.
aims & Methods: Compare CT-texture analysis and CT features of liver me-
tastases (mets) in pancreatic and non-pancreatic NENs according to tumor 
grading. CE-CT images of liver mets in NEN patients were analysed by 3D 
CT texture analysis. These parameters were evaluated during arterial and 
portal phase: mean attenuation, standard deviation, skewness, kurtosis, 
entropy, mean of positive pixels and Tx_sigma. Lesions delta enhancement 
was also calculated. The CT exams were performed before the beginning 
of any medical treatment.All patients had G1 or G2 a tumor according with 
WHO classification.
results: Twenty-five patients non pancreatic NENs (NP-NENs) and 23 pa-
tients pancreatic (PNENs) were included in the study.
results: 34 individuals underwent intensified surveillance, of which 20 re-
turned multiple questionnaires (response rate 59%) and 12 were invited 
for an interview, to which eight consented (response rate 67%). Of those 
who underwent surgery, 10 were interviewed (response rate 91%). The 
total cohort consisted of 31 individuals (12 (39%) male, median age 52 (IQR 
13) years), 16 (52%) familial pancreatic cancer kindreds and 15 (48%) gene 
mutation carriers.
During the intensified surveillance period, cancer worries increased sig-
nificantly (median CWS 14, IQR 7), as compared to before (median 12; IQR 
9, P=0.007) or after (median 11, IQR 7, P=0.014), but eventually returned 
back to baseline (P=0.823). General anxiety and depression scores were 
low (both median 5, IQR 5) and not significantly influenced by the intensi-
fied surveillance period (P>0.100). 
Of the 8 interviewed participants, 5 (63%) had perceived the extra visits as 
more burdensome or stressful than the regular visits, and 5 still experi-
enced increased worries. They regarded intensified surveillance as some-
thing positive (2), neutral (2), negative but necessary (3) or negative (1).
Of the 10 operated patients (median 43 months since surgery, IQR 63), 
5 underwent a pancreatoduodenectomy and 5 a distal pancreatectomy. 
Pathology revealed one T1 pancreatic ductal adenocarcinoma, 7 prema-
lignant lesions (PanIN 1-2 or IPMN with low-moderate grade dysplasia), 
and 2 cases of benign disease (neuroendocrine tumor and autoimmune 
pancreatitis). 
Afterwards, 20% developed diabetes and 70% steatorrhea. Patients 
judged their recovery as good (fast, no complications, 20%), fair (minor 
complications and/or longer recovery time than anticipated, 50%), or poor 
(major complications, 30%). Median quality of life scores (SF-12 PCS 56 
and MCS 52) were not different from age-matched reference data from the 
general population. 
After surgery, patients’ attitude towards surveillance was unchanged 
(60%) or became more positive (40%), but never more negative. Knowing 
the pathological outcome, when asked if surgery had been justified, only 
20% disagreed and all would again have chosen to undergo surgery.
conclusion: In individuals at high risk for pancreatic cancer, intensified 
surveillance transiently increased cancer worries, without affecting gen-
eral anxiety or depression. 
Although pancreatic surgery led to substantial co-morbidity, quality of life 
was similar to the general population, and surgery did not negatively af-
fect the attitude towards surveillance.
disclosure: DLC is a consultant to Tramedico. PF is a consultant to Olym-
pus, Cook Medical, Ethicon Endosurgery and received research funding 
from Boston Scientific. JEH received research funding from Abbott and 
Cook Medical; she is a consultant to Boston Scientific, Cook Medical, and 
Medtronics. MJB received research funding from Boston Scientific, Cook 
Medical, Pentax Medical, 3M; he is a consultant to Boston Scientific, Cook 
Medical, Pentax Medical, Mylan, MediRisk, and Medicom. The other au-
thors have nothing to disclose. 
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PreOPeraTIve BILIary draInage Is sIgnIfIcanTLy assOcIaTed 
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Introduction: Neoadjuvant therapy has been investigated in the patients 
with resectable and borderline resectable pancreatic cancer (PC). In 
neoadjuvant chemotherapy, self-expandable metallic stents (SEMS) was 
reported to be superior to plastic stents for endoscopic biliary decom-
pression. However, preoperative biliary drainage in PC patients receiving 
neoadjuvant chemoradiotherapy (NACRT) has not been fully examined. 
We mainly used plastic stents for biliary drainage in PC patients receiving 
NACRT because metallic stent placement during external irradiation could 
cause infiltration of inflammatory cells and fibrosis due to scattering of 
X-ray. In this study, we examined recurrent biliary obstruction (RBO) of 
preoperative biliary drainage and evaluated how the diameter of plastic 
stents impacts on time to RBO.
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Comparing liver mets from pNENs and non-pNENs,CT texture analysis 
showed that the parameter “skewness” was significantly higher in non-
pNENs (p-value< 0.05).This data was also confirmed when subgroup anal-
ysis according with grading system (G1 vs G2) was performed.The param-
eter “mean” was significantly higher in pNENs compared with non-pNENs 
(p=0,0066). Furthermore, the “delta enhancement” was significantly 
higher (p-value< 0.05) in liver mets from pNENs.”Entropy” and “Kurtosis” 
assessed during arterial phase were associated with higher risk of death 
by Cox analysis (p< 0.05).
conclusion: This study shows that liver metastases from pNENs and non-
pNENs have different CT features in terms of texture parameters. The use 
of radiomics in NENs could be used by the physician to plan the therapy 
strategy.
disclosure: Nothing to disclose 
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Introduction: Contrast-enhanced harmonic endoscopic ultrasonography 
(CEH-EUS) can be used for differential diagnosis of pancreatic lesions by 
evaluating microvascular circulation and patterns of contrast enhance-
ment1-3. However, routine use of CEH-EUS is limited by its high cost, the 
lack of contrast agent availability and expertise with this technique. Direc-
tional eFLOW (D-eFLOW) (Aloka Co., Ltd., Tokyo, Japan) was introduced as 
a new high-definition modality for blood flow that detects blood flow in 
microvessels4. Since it uses built-in functions, it needs no additional cost 
and takes less time for examination.
aims & Methods: The purpose of this study was to investigate the use-
fulness of D-eFlow compared with CEH-EUS for differential diagnosis of 
pancreatic solid lesions, especially neuroendocrine tumors. From Janu-
ary 2016 to February 2019, a total of 34 patients who received EUS and 
D-eFLOW examination to evaluate pancreatic and peripancreatic masses 
were analyzed, retrospectively.
results: Of 34 patients, D-eFLOW was performed in 34 patients and CEH-
EUS was performed in 32 patients. Histological diagnosis was confirmed 
in 19 patients by EUS-FNA and/or surgery. Concerning the detection of 
the neuroendocrine tumors, D-eFLOW had higher sensitivity to CEH-EUS 
(100% vs. 91.7%), lower specificity (33.3% vs. 50.0%), lower positive pre-
dictive value (76.5% vs. 78.6%), higher negative predictive value (100% vs. 
75%) and higher accuracy (78.9% vs. 77.8%). There was a good correla-
tion between the D-eFLOW and CEH-EUS to evaluating the vascularity of 
tumors (correlation coefficient 0.683, p < 0.05).
conclusion: In conclusion, D-eFLOW can be considered as an alternative 
method to CEH-EUS for the evaluation of pancreatic and peripancreatic 
solid tumors.
references: 1. Kitano M, Sakamoto H, Matsui U, et al. A novel perfusion 
imag¬ing technique of the pancreas: contrast-enhanced harmonic EUS 
(with video). Gastrointest Endosc 2008;67:141-150. 2. Kitano M, Sakamoto 
H, Matsui U, et al. Contrast-enhanced endoscopic ultrasound. Digestive 
Endoscopy 2014;26(Suppl. 1): 79-85 3. Fusaroli P, Spada A, Mancino MG, 
Caletti G. Contrast harmonic echo-endoscopic ultrasound improves accu-
racy in diagno¬sis of solid pancreatic masses. Clin Gastroenterol Hepatol 
2010;8:629-634.e1-2. 4. Das K, Kudo M, Kitano M, et al. Diagnostic value 
of endoscopic ultrasound-guided directional eFLOW in solid pancreatic le-
sions. J Med Ultrasonics 2013;40:211-218.
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Introduction: We previously reported in a prospective multicenter trial 
that endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) using 
25-gauge needles with a core trap provides histological samples of ad-
equate quality for diagnosing and grading pancreatic neuroendocrine tu-
mors (PNET) (UMIN000010021).
aims & Methods: Since the number of surgical cases increased thereaf-
ter, we conducted further detailed examination in this study. Consecutive 
patients with hypervascular solid pancreatic masses, suspected as PNET 
on imaging modalities, who presented to ten Japanese referral centers 
from June 2016 to November 2017 were prospectively recruited. All patients 
underwent EUS-FNB using 25-gauge needles with a core trap (EchoTip 
ProCore, Cook Medical, Bloomington, Indiana, USA). After the mass was 
punctured, the slow-pull technique was used for biopsy. The specimen 
obtained by first pass was used for this study. The entire specimen was 
inserted into a formalin bottle and processed for histological analysis. All 
tissue samples were brought to a single facility where experienced pa-
thologists reviewed them.
results: A total of 52 patients (male/female: 24/28, median age: 63 years) 
were enrolled in this study. The technical success rate of EUS-FNB was 
100% and tissue acquisition rate for histological analysis was 86.5%. 
There were no complications related to EUS-FNB. Thirty-six patients sub-
sequently underwent pancreatic resection, and 31 patients were diagnosed 
as PNET (G1=28, G2=3, tumor size: 3 to 26 mm, median tumor size: 11 
mm) by evaluation of the surgical specimen. The sensitivity, specificity and 
accuracy of EUS-FNB for the histological diagnosis of PNET were 82.1%, 
100% and 84.8%, respectively. Sensitivity of EUS-FNB was 80% for tumors 
smaller than 10 mm, 91.7% for tumors 10 to 20 mm in size, and 80% for 
those larger than 20 mm. Sensitivity of EUS-FNB via transgastric access 
(median tumor size: 11 mm) was 84.6%, that via transduodenal bulb ac-
cess (median tumor size: 15.5 mm) was 50%, and that via transduodenal 
2nd portion access (median tumor size: 11 mm) was 90%. Although the 
sensitivity of EUS-FNB via transduodenal bulb access was low, the tumors 
were not smaller than those for the other route. The concordance rate of 
PNET grading by EUS-FNB with grade of the resected tumor was 82.6%.
conclusion: EUS-FNB using a 25-gauge needle with a core trap via a single 
pass offers high accuracy for diagnosing and grading small PNET.
disclosure: Nothing to disclose 
P0137 unaWereness Of hyPOgLycaeMIa In PaTIenTs WITh 
InsuLInOMa
Nosáková L.1, Banovcin P.1, Ďuriček M.1, Uhrík P.2, Hyrdel R.1
1Jessenius Faculty of Medicine, Gastroenterology Clinic, Martin, Slovakia, 
2Clinic for Internal Medicine and Gastroenterology, University Hospital 
Martin, Gastroenterology and Internal Medicine, Martin, Slovakia
contact e-Mail address: lenka.bubernakova@gmail.com
Introduction: Insulinoma is rare, but definitely most common functional 
neuroendocrine tumor of pancreas. In almost all cases there are benign 
239Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
should be noted, that the patient’s age >65 years at diagnosis (P < 0.001), 
primary tumor size greater than 25 mm (P = 0.02), the presence of syn-
chronous metastases (P = 0.03) and the presence of a Ki67> 5% (P = 0.04) 
were evidenced as independent factors of adverse prognosis.
conclusion: The clinical presentation and biological behavior of IP-NETs is 
considerably variable. Consistent with previously published series of cases, 
age less than 65 years, primary tumor size and absence of locoregional 
disease, angioinvasion and metastases are associated with a better prog-
nosis.
disclosure: Nothing to disclose 
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P0139 LOng-TerM OuTcOMes Of endOscOPIc suBMucOsaL 
dIssecTIOn versus LaParOscOPIc resecTIOn fOr gasTrIc 
sTrOMaL TuMOrs Less Than 2 cM
Meng Y., Liu S.
Guangdong Provincial Key Laboratory of Gastroenterology, Department 
of Gastroenterology, Nanfang Hos, Department of Gastroenterology, 
Guangzhou, China
contact e-Mail address: 1031294787@qq.com
Introduction: Gastrointestinal stromal tumors (GISTs) is the most common 
mesenchymal gastrointestinal tumor, which accounts for about 2% of all 
the gastrointestinal tumors.The age-adjusted yearly incidence rate of GISTs 
was about 6.8 per million, with 54% men and 46% women.
aims & Methods: Laparoscopic resection (LAP) and endoscopic submu-
cosal dissection (ESD) is commonly used to remove small gastrointestinal 
stromal tumors (GISTs). However, whether LAP or ESD has more efficient 
outcome for small GISTs is controversial. Therefore, our Aim was to evalu-
ate the efficacy of ESD and LAP for small GISTs and provided long-term 
outcomes of the two methods.
Methods: All data from 398 patients who underwent ESD or LAP for small 
GISTs (between 2008 and 2019) were collected from Nanfang hospital, 
Guangzhou, China. We made telephone calls to collect information about 
their recurrence rate. Clinicopathological characteristics, recurrence rate 
and surgical outcome were collected and blindly measured for each pro-
cedure.
results: Among the 398 patients, 234 (58.79%) received ESD treatment, 
and 164 (41.21%) received LAP treatment. The clinicopathological charac-
teristics of the patients were well balanced. There was no significant dif-
ference between LAP and ESD groups according to gender, age, tumor size 
and location. There was also no significant difference in follow-up time 
(6.65±1.84 years in ESD vs. 6.19±1.53 years in LAP group, P=0.24). However, 
there was a significant difference between the two groups in operating 
time (61.42 ± 32.85min vs. 78.68 ± 39.76 min, P=0.03), estimated blood 
loss (6.58 ± 12.16 ml vs. 16.35 ± 17.06 ml, P=0.02) and hospital stay (5.07 ± 
2.15 days vs. 9.84 ± 3.80 days, P< 0.001). The complication rate (defined 
as perforation or massive hemorrhage) showed no significant difference 
among ESD and LAP group (2.14% vs. 1.22%; P=0.85). The recurrence rate 
of ESD and LAP group was 2.56% and 1.22%; P=0.56. Meanwhile, Kaplan-
Meier curves for disease-free survival test showed no significant difference 
between two groups (P=0.86).
conclusion: Long-term follow-up showed that ESD can be a more prefera-
ble technique for resection of small gastric stromal tumors compared with 
LAP. However, long-term randomized controlled trials are further needed.
disclosure: Nothing to disclose 
and sporadic. Clinical manifestation include various symptoms of hypogly-
caemia, which is the result of insulin overproduction. Paradoxically, there 
is some patients without any clinical sign of hypoglycaemia. This patients 
suffer from unawereness of hypoglycaemia. In our work, we focus on pres-
ence of this syndrom in patients with insulinoma. Our aim was identify 
these patients, because unawereness hypoglycaemia is serious condition, 
which has a great influence life, and can be even life threatening.
aims & Methods: Analysis of retrospective clinical and biochemical data 
was used to create file of patients. We evaluated every patient with con-
firmed insulinoma (biochemically, with localization technique) from 1996 
to 2019 hospitalized in our department. During admission we asked pa-
tient about clinical presentations, duration of hardships and presence of 
spontaneous loss of conciousness. After admission, every patient under-
went 72-hour fasting test on intensive unit care with monitoring vital signs, 
levels of blood glucose level, C-peptis and IRI. From this file of patients 
we selected and focus on patients with documentated episode of clini-
cally silent hypoglycaemia. After reaching the blood glucose level under 
2,2 mmol/l, we took blood for examination of C-peptid and IRI levels, gave 
patient gucose parenterally and stopped fasting test. These patient was 
monitoring closely during whole diagnostic procedure, and were reffered 
to surgical treatment as soon as it was possible
results: From 1996 to 2019 there were overall 23 patients with confirmed 
diagnosis of insulinoma. The number of patients with unawereness hy-
poglycaemia events was 7 (30,43%), 4 men and 3 women. The mean age 
of our patiens was 50 years (from 30 to 69 years). All of these patients 
suffer from severe episodes of hypoglycaemia without any accompanying 
symptoms during hospitalization in our department. We detected hypogly-
caemia either accidentally during measurement profile of glucose or when 
patient loss of consciousness. Mean levels of blood glucose during fasting 
test was 1,79 mmol/l (from 2,4 to 1). Paradoxically, none of these patients 
had increased levels of C-peptid and IRI during fasting test.
conclusion: Until now, unawereness of hypoglycaemia was descripted only 
in patients with diabetes mellitus. In our work, we found presence of this 
syndrom in patients with insulinoma. These patients suffered from severe 
episodes of hypoglyceamia without any accompanying symptomts and 
they are also at risk of sudden death.
disclosure: Nothing to disclose 
P0138 PrOgnOsTIc and survIvaL facTOrs Of InTesTInaL 
and PancreaTIc neurOendOcrIne TuMOrs (IP-neTs): The 
exPerIence Of a TerTIary referraL cenTer
Saraiva M.1, Brozzi L.2, Dias E.3, Cardoso H.4, Macedo G.5
1Centro Hospitalar São João, Gastroenterology, Porto, Portugal, 2The 
Pancreas Institute, G.B. Rossi University Hospital, Department of Medicine, 
Gastroenterology and Digestive Endoscopy Unit, Verona, Italy, 3Centro 
Hospitalar São João, Porto, Portugal, 4Centro Hospitalar São João, Baguim 
do Monte, Portugal, 5World Gastroenterology Organisation, Milwaukee, 
United States
contact e-Mail address: miguelmascarenhassaraiva@gmail.com
Introduction: Intestinal and pancreatic neuroendocrine tumors (IP-NETs) 
represent a rare group of neoplasias, with an incidence of approximately 
0.5 in 100,000 inhabitants, constituting a small percentage of intestinal 
and pancreatic neoplasias. The clinical presentation and biological behav-
ior is extremely variable, reflecting large differences in survival, depending 
on the location, type of primary tumor, metastization and other multiple 
factors.
aims & Methods: In this study, we evaluated the location, type of primary 
tumor as well as other relevant clinical and pathological aspects with im-
pact on the global and disease-free survival. We retrospectively evaluated 
89 patients with intestinal and pancreatic neuroendocrine tumors with a 
confirmed pathological diagnosis between 2008 and 2019. Patients with 
MEN1 (Type1 Multiple Endocrine Neoplasia) or Von Hippel-Lindau syn-
drome were excluded.
results: The most frequent primary site was pancreatic (47% -57%) and 
intestinal (42 patients-47%). The majority of patients were female (60%). 
The mean age at diagnosis was 53.8 years (range 22-87 years). The median 
survival was 138 months. Regarding the existence of metastases at the 
time of diagnosis (synchronous or metachronous), they were present in 37 
patients (42%). Regarding the therapeutic approach, patients underwent 
surgery (54%), surgery + chemotherapy (40%) or chemotherapy alone 
(6%), Survival was higher in patients submitted to surgery (P < 0.001). It 
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P0140 endOscOPIc MucOsaL resecTIOn In The uPPer 
gasTrOInTesTInaL TracT: 22-year exPerIence In a sIngLe 
cenTer
Frasca Rodrigues C.1, Vieira Coelho N.H.2, Teixeira C.R.3, Conrado L.3, 
Coelho N.4, Castilho PInto R.5
1Fugast, Dept. of Endoscopy, Porto Alegre, Brazil, 2Hospital Moinhos 
de Vento, Endoscopy Unit and Pancreas Group, porto alegre, Brazil, 
3Fugast, Porto Alegre, Brazil, 4Fundacao Riograndense Universitaria, de 
Gastroenterologia, Porto Alegre, Brazil, 5Fugast, de Gastroenterologia, 
PORTO ALEGRE, Brazil
contact e-Mail address: crfrasca@hotmail.com
Introduction: Endoscopic mucosal resection (EMR) has proven to be a safe 
and effective technique to locally remove lesions confined to the mucosa, 
with the advantage of providing a complete specimen for histological 
analysis.
aims & Methods: We aim to report our 22-year outcome data to measure 
resection success and complication rates in EMR procedures performed in 
a single center. 
We retrospectively reviewed 176 EMR procedures (157 patients) performed 
in our endoscopic department from March 1, 1997 to December 10, 2018. 
Procedures were performed using Olympus and Fujinon singlechannel or 
dual-channel endoscopes with a cap or band-ligation. Endoscopic ultra-
sound was performed with linear scopes, radial scopes, or miniprobes 
in most patients. Recurrent cancer was re-treated (with additional EMR) 
when necessary.
results: Of 157 patients, 93 (59.2%) were men. Mean patient age was 66.7 
(SD, 11.0) years. Fourteen patients underwent more than 1 EMR procedure, 
for a total of 176 EMRs analyzed. Mean follow-up was 52.3 months. Gastric 
adenocarcinoma was diagnosed in 31.8% of patients (50/157), followed 
by esophageal squamous cell carcinoma in 17.8% (28/157), esophageal 
adenocarcinoma (Barrett esophagus) in 14.0% (22/157), and duodenal ad-
enocarcinoma in 8.9% (14/157). Figure 1 shows a case of esophageal ad-
enocarcinoma (Barrett esophagus) treated with EMR using band-ligation. 
The remaining 43 patients were diagnosed with benign lesions, including 
neuroendocrine tumors, hamartomas, granular cell tumors, and gastric 
heterotopia in the esophagus. En bloc resection was possible in 88.5% 
(139/157) of patients; the remaining 18 patients underwent piecemeal EMR. 
Eleven (7.0%) patients had recurrent lesions during follow-up: 3 esopha-
geal adenocarcinomas (Barrett esophagus) and 8 gastric adenocarcino-
mas. Bleeding occurred in 21 (13.3%) patients, successfully controlled with 
hemoclips. Perforations occurred in 3 (1.9%) patients; 2 of them required 
surgery. No procedure-related death was observed during the follow-up 
period.
conclusion: Our long-term outcome data demonstrate that EMR is a safe 
and effective therapy for high-grade dysplasia and early upper gastroin-
testinal neoplasia. However, careful follow-up is particularly necessary in 
cases of local recurrence, when additional EMR is required.
disclosure: Nothing to disclose 
P0141 TraInIng effecT Of arTIfIcIaL InTeLLIgence IMage 
cLassIfIer On The PerfOrMances Of junIOr endOscOPIsTs 
In PredIcTIng hIsTOLOgy Of gasTrIc LesIOns
Lui T.K.-L.1, Wong K.K.Y.2, Mak L.L.Y.1, To E.W.P.1, Tsui V.W.M.1, Deng Z.3, 
Guo J.3, Li N.3, Cheung M.K.S.1, Leung W.K.1
1University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong, 
China (SAR), 2University of Hong Kong, Department of Computer Science, 
Hong Kong, Hong Kong, China (SAR), 3University of Hong Kong-Shenzhen 
Hospital, Department of Medicine, Shenzhen, China
contact e-Mail address: luikaluen@gmail.com
Introduction: Accurate endoscopic prediction of the histology of a sessile 
gastric lesion requires training and expertise, which may not be widely 
available. The use of artificial intelligence (AI) assisted image classifier has 
been shown to have high accuracy on endoscopic diagnosis. We evaluated 
the potential training effects of our recently developed AI assisted image 
classifier on histological prediction of gastric lesions by junior endosco-
pists.
aims & Methods: An AI image classifier was built on a convolutional 
neural network with 5 convolutional layers and 3 fully connected layers 
Resnet backbone. It was first trained by 2,000 endoscopic images of both 
non-neoplastic and neoplastic gastric lesions, as verified by final histology 
of either multiple biopsies or total endoscopic resection. The endoscopic 
images were all obtained by high-definition endoscopy series (Olympus 
GIF-HQ290 and CV-290 video system). Gastric pathology was based on the 
WHO classification with neoplastic lesions defined as the presence of gas-
tric dysplasia, adenoma or carcinoma in the most severe histology of the 
lesion. For each gastric lesion, around 10 regions of interest (ROI) were 
randomly selected in a pixel of at least 300 x 300 dpi. The independent 
validation set consisted of 1000 endoscopic NBI images from 100 gastric 
lesions. The validation set was also reviewed by six junior endoscopists 
who had performed more than 1,000 upper endoscopies and with training 
on NBI. The first part of validation set was first commented by all endosco-
pists and then the prediction of AI was disclosed to three of them (Group A 
endoscopists) while the remaining three (Group B endoscopists) were not 
provided this information. All the endoscopists then reviewed the 2nd part 
of the validation set.
results: The overall accuracy of AI was 90.4% (95%CI: 88.6%-92.2%) with 
sensitivity 97.3% (95%CI: 95.8-98.7%), specificity 84.1% (95%CI: 80.9-
87.2%), PPV 84.9% (95%CI: 81.8-87.8%), NPV 97.1% (95%CI: 95.6-98.7%) 
and area under the ROC (AUROC) 0.91 (95%CI: 0.89-0.93). AI was more 
confident in the prediction of non- neoplastic lesions than neoplastic le-
sions (84.5% vs 81.6%, p< 0.01). AI was superior to all junior endoscopists 
in term of accuacy and AUROC in both validation sets. (Table 1) The per-
formance of the 3 endoscopists who had been revealed the AI finding of 
1st validation set (Group A endoscopists), significantly improved on the 2nd 
validation set (69.3% to 74.7%; p =0.003). However, there was no signifi-
cant improvement on performance for those who were not disclosed the 
AI findings (Group B endoscopists). 
conclusion: ]The trained AI image classifier based on non-magnified NBI 
images can accurately predict the presence of neoplastic component of 
sessile gastric lesions. The use of AI image classifier can also hasten the 
learning curve of junior endoscopists on histologic prediction of gastric 
lesions.
disclosure: Nothing to disclose 
  aI group a endoscopists group B endoscopists
1st 
validation 
set
  Endoscopist I Endoscopist II Endoscopist III Group A Endoscopists Endoscopist IV Endoscopist V Endoscopist VI Group B Endoscopists
accuracy
(95%cI)
91.2%
(85.9%-95.0%)
69.9% 
(65.6%-73.6%)
65.6% (61.2%-69.8%)
69.6%
(65.6%-73.7%)
69.4%
(67.0%-71.7%)
69.4%
(65.3%-73.4%)
74.4% 
(70.6%-78.2%)
61.0%
(57.5%-66.2%)
68.2%
(65.9%-70.6%)
aurOc
(95%cI)
0.93
(0.89-0.97)
0.72 
(0.68-0.77)
0.68 (0.63 -0.73) 0.68 (0.63 -0.73) 0.69 (0.67-0.72) 0.68 (0.63 -0.73) 0.76 (0.71 -0.80) 0.63 (0.58 -0.69) 0.69 (0.66-0.72)
2nd 
validation 
set
                 
accuracy
(95%cI)
90.4%
(85.9%-95.0%)
73.6% 
(69.7%-77.4%)
78.0%
(74.4%-81.6%)
74.0%
(70.1%-77.8%)
74.7%
(72.5%-77.0%)
70.0%
(65.9%-74.0%)
67.2%
(63.1%-71.3%)
66.0%
(61.9%-70.2%)
67.7%
(65.3%-70.1%)
aurOc
(95%cI)
0.90
(0.87-0.93)
0.75 
(0.71 -0.80)
0.78 (0.73 -0.82) 0.73 (0.69 -0.78) 0.75 (0.72-0.77) 0.68 (0.63-0.73) 0.68 (0.64-0.73) 0.67 (0.62-0.71) 0.67 (0.65-0.70)
[P0141 Table. Performances of the AI image classifier vs junior endoscopists]
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were re-bleeding, duration of hospitalization, need for blood transfusion 
and death. Patients who required blood transfusions or suffered composite 
clinical outcomes were considered high-risk patients. Rockall scoring sys-
tem, Glasgow-Blatchford score (GBS) and AIMS65 scores were calculated 
for each patient. The sensitivity and specificity of the scoring systems were 
calculated. The areas under the receiver operating characteristic curve 
(AUC) of the scores were compared.
results: There were 100 patients in the study; of whom 76 were men and 
24 were women. The mean age was 59.39±7.7 years. Endoscopy was done 
for all of them and the three scores were calculated. Rebleeding was ob-
served in 35 patients. A total of 83 patients received blood transfusions and 
19 patients unfortunately died within 1-month follow up period. The three 
scores were compared to each other as regards our outcomes by using the 
ROC curves as shown in figures.
conclusion: AIMS65 was superior for predicting the re-bleeding, GBS 
score was superior for predicting the need for blood transfusion and no 
significant difference was detected as regard duration of hospitalization 
and mortality among the three scores.
disclosure: Nothing to disclose 
P0144 fOrWard vIeWIng LInear (fvL) versus curved 
LInear-array (cLa) echOendOscOPes fOr saMPLIng and 
draInage Of PancreaTIc and uPPer gI suB-ePITheLIaL LesIOns
Sharma P.1, Baniya R.2, Jamil L.3
1Yale New Haven Health System, Gastroenterology, Bridgeport, United States, 
2Our Lady of the Lake Regional Medical Center, Internal Medicine, Baton 
Rouge, United States, 3Cedars-Sinai Medical Center, Gastroenterology, Los 
Angeles, United States
contact e-Mail address: prabinsharmaa@hotmail.com
Introduction: Curved linear-array [CLA] echoendoscopes and forward-
viewing linear [FVL] echoendoscopes are used in sampling and draining of 
upper GI subepithelial lesions and pancreatic lesions. FVL echoendoscopes 
were designed to overcome the limitations of the CLA echoendoscopes. 
Only a few prospective studies have compared the 2 types of endoscopes 
in terms of safety, efficacy, procedure duration and ease of the procedure.
aims & Methods: We aimed to review the currently available data that 
compare the CLA echoendoscope with FVL echoendoscope in terms of 
technical success rates, diagnostic yield, diagnostic accuracy and proce-
dure time.
results: A total of 3 prospective studies met the inclusion criteria for this 
meta-analysis. A total of 260 procedures were analyzed, which included 
130 FVL and 130 CLA. There were no significant differences in the technical 
success rates and diagnostic yield (OR, 0.77; 95% CI, 0.14-4.40, P= 0.77 and 
OR, 1.21, 95% CI, 0.6- 2.44, p= 0.6), Similarly, there was no significant dif-
ference in diagnostic accuracy (OR, 0.81; 95% CI, 0.38-1.71, p=0.57). How-
ever, procedure time was significantly less for the FVL group compared to 
CLA (MD, -2.88, 95% CI -4.53 - -1.22, p= 0.0006).
conclusion: Both forward-viewing and curved linear-array echoendo-
scopes have similar technical success rate, diagnostic yield and accuracy in 
sampling and draining upper GI sub-epithelial and pancreatic lesions. FVL 
echoendoscopes provide the benefit of shorter procedural time.
disclosure: Nothing to disclose 
P0145 hyBrId endOscOPIc suBMucOsaL dIssecTIOn vs 
cOnvenTIOnaL endOscOPIc suBMucOsaL dIssecTIOn In The 
TreaTMenT Of earLy gasTrIc neOPLasMs: a MuLTI-cenTer 
reTrOsPecTIve anaLysIs
Esaki M.1,2,3, Suzuki S.1,2, Horii T.1,2, Ichijima R.1, Kusano C.1,2, Ikehara H.1, 
Ihara E.3, Gotoda T.1
1Nihon University School of Medicine, Division of Gastroenterology and 
Hepatology, Department of Medicine, Tokyo, Japan, 2Yuri-Kumiai General 
Hospital, Akita, Japan, 3Kyushu University, Department of Medicine and 
Bioregulatory Science, Graduate School of Medical Sciences, Fukuoka, 
Japan
contact e-Mail address: esaki_saiseikai@yahoo.co.jp
Introduction: Endoscopic submucosal dissection (ESD) is a technically dif-
ficult and time-consuming procedure. Hybrid ESD (H-ESD) combines cir-
cumferential incision with partial submucosal dissection and subsequently 
P0142 The search, cOaguLaTIOn and cLIPPIng (scc) 
MeThOd TO PrevenT deLayed BLeedIng afTer gasTrIc 
endOscOPIc suBMucOsaL dIssecTIOn
Azumi M., Takeuchi M., Miida S., Hojo Y., Yoshikawa S., Kohisa J.
Nagaoka Red Cross Hospital, Gastroenterology, Niigata, Japan
contact e-Mail address: az2948@yahoo.co.jp
Introduction: Delayed bleeding is an important complication after gas-
tric endoscopic submucosal dissection (ESD). Post-ESD coagulation (PEC) 
involving prophylactic cauterization of visible blood vessels at the ulcer 
floor is widely performed to prevent delayed bleeding after endoscopic 
therapy. The bleeding rate with this approach has been reported to be 
3-5.5%.The search, coagulation, and clipping (SCC) method, which in-
volves observing the ulcer floor, identifying blood vessels, and cauterizing 
and clipping respective blood vessels, appears to be a good approach to 
prevent bleeding after ESD. However, its safety and efficacy are unclear. 
We compared the SCC method with post-ESD coagulation (PEC) to clarify 
the safety and efficacy of the SCC method for preventing delayed bleeding 
after gastric ESD.
aims & Methods: This retrospective study included 601consective patients 
(669 lesions) who underwent gastric ESD.97 patients treated with anti-
thrombotic therapy (97/601 16.1%). Delayed bleeding was defined as clini-
cal post-ESD bleeding with hematemesis, melena, or anemia progression 
that required endoscopic examination aside from the one scheduled dur-
ing second-look endoscopy.Multivariate analysis was performed to iden-
tify the significant independent factors associated with delayed bleeding 
and we performed propensity score matching (PSM) to reduce the effect of 
procedure-selection bias of SCC method. Explanatory variables consisted 
of location, specimen size, antithrombotic agents, procedure time, and 
heparin placement.
results: Of the 601 patients, 217 underwent PEC and 384 underwent SCC. 
According to the clinical pathway, the second-look endoscopy was per-
formed for all cases. One patient presented bleeding in the stomach during 
second-look endoscopy.Delayed bleeding was significantly less common in 
the SCC group than in the PEC group (10/384 2.6% vs. 16/217 7.4%; P = 
0.011) Among 97 patients treated with antithrombotic therapy, the delayed 
bleeding rate was lower in the SCC group than in the PEC group; however, 
the difference was not significant (4/61 6.6% vs. 5/36 13.9%;P = 0.285). 
Multivariate logistic regression analysis indicated that SCC methods and 
heparin placement were independent and significant factors affecting the 
delayed bleeding (SCC methods: P = 0.011;heparin placement ;P = 0.004). 
PSM was performed in 154 patients in the PEC group and SCC group. There 
was a significant difference in the incidence of bleeding in the PEC and SCC 
groups (2/154 1.3% vs. 12/154 7.8%;P = 0.011). No patient had perforation/
bleeding associated with the SCC method.
conclusion: Our findings suggest that the SCC method is a simple, safe, 
and effective approach for preventing delayed bleeding after gastric ESD.
references: Takizawa K, Oda I, Gotoda T, Yokoi C, Matsuda T, Saito Y, et 
al.Routine coagulation of visible vessels may prevent delayed bleeding af-
ter endoscopic submucosal dissection—an analysis of risk factors. Endosco-
py. 2008;40:179-83. Azumi M, Takeuchi M, Koseki Y, Kumagai M, Kobayashi 
Y, Takatsuna M , et al.The search, coagulation, and clipping (SCC) method 
prevents delayed bleeding after gastric endoscopic submucosal dissection. 
Gastric Cancer. 2018 Sep 28.
disclosure: Nothing to disclose 
P0143 cOMParIsOn Of rIsk scOrIng sysTeMs In PaTIenTs 
WITh acuTe varIceaL uPPer gasTrOInTesTInaL BLeedIng
Dawoud H.1, Hakim H.2, Goda T.1, Altonbary A.2
1Mansoura Faculty of Medicine, Mansoura University, Critical Care, 
Mansoura, Egypt, 2Mansoura Specialized Medical Hospital, Gastroenterology 
and Hepatology, Mansoura, Egypt
contact e-Mail address: hzhzhkhk@yahoo.com
Introduction: The aim of this study was to compare the performance of dif-
ferent scoring systems (Rockall scoring system, Glasgow-Blatchford score 
and AIMS65) in predicting outcomes in patients with acute variceal bleed-
ing.
aims & Methods: Data were collected prospectively over a 6-month period 
in the emergency department of a university hospital. Adult patients with 
upper GI bleeding from variceal sources were included. Clinical outcomes 
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snaring using a single device. H-ESD is potentially a simpler and shorter 
procedure. Here, we report the short-term outcomes of H-ESD for early 
gastric neoplasms.
aims & Methods: The aim of this study is to compare short-term outcomes 
of H-ESD for early gastric neoplasms with those of conventional ESD (C-
ESD). In this multi-center retrospective study, we reviewed the charts of 
patients with early gastric neoplasms within 20 mm in diameter treated 
with H-ESD or C-ESD between January 2017 and October 2018 at three hos-
pitals. Propensity score matching was performed to reduce biases. Short-
term outcomes including the procedure time, the en-bloc resection rate, 
the complete resection rate, and the rate of adverse events (perforation/
delayed bleeding) were evaluated.
results: Among 215 patients, 29 were in the H-ESD group and 186 were 
in the C-ESD group. Twenty-nine pairs were created by propensity score 
matching. In the H-ESD group, 82.8% of lesions met the original absolute 
indication (limited to 20 mm in diameter dominated by differentiated ad-
enocarcinoma without ulcer) for endoscopic resection. As a result, H-ESD 
required a significantly shorter median procedure time (H-ESD: 20 [in-
terquartile range, 12-27] min vs C-ESD: 40 [30-50] min; P < 0.001). Other 
outcomes were similar among two groups and no significant differences 
were observed (En-bloc resection rate; 100% in both groups, Complete 
resection rate; 100% vs 93.1%, P = 0.49, Adverse event rate; 0% vs 3.4%, 
P = 1).
conclusion: H-ESD achieved significantly shorter procedure time with high 
curability without increase in adverse events. Therefore, H-ESD should be 
selected for gastric neoplasms within original absolute indication.
disclosure: Nothing to disclose 
P0146 usefuLness Of 3-dIMensIOnaL fLexIBLe endOscOPy 
In The dIagnOsIs Of gasTrIc ePITheLIaL neOPLasIa
Higuchi K., Kaise M., Koizumi E., Kirita K., Noda H., Umeda T., Akimoto T., 
Omori J., Goto O., Iwakiri K.
Nippon Medical School, Department of Gastroenterology, Bunkyo-ku, Japan
contact e-Mail address: k-higuchi@nms.ac.jp
Introduction: 3-dimensional (3D) visualization offers better depth recogni-
tion than 2-dimensional (2D) visualization. There are some reports that 3D 
rigid endoscopy in surgical fields can shorten the procedure time and re-
duce the complications. In contrast, the prototype of 3D flexible endoscopy 
has already been developed, and we have reported that it has reduced 
technical complications during endoscopic submucosal dissection (ESD), 
especially in trainees. 3D visualization might be effective in the diagnosis 
of cancer extent because it facilitates more clearly the recognition of rug-
gedness and shape of lesions than 2D.
aims & Methods: To explore the feasibility of 3D visualization in the en-
doscopic diagnosis, we conducted a study to compare 2D and 3D endos-
copy in the diagnosis of early gastric cancers (EGCs) and gastric adenomas. 
Study participants (3 experts and 6 trainees) who do not know clinical 
information of target lesions performed pre-ESD endoscopic assessment 
of EGCs and adenomas under 2D and 3D observation. In the 3D endoscopy 
system, 2D and 3D visualization under white light imaging or narrow band 
imaging are quickly changed by a food pedal. In the next, they made elec-
trocautery markings on a half of demarcation line of EGCs and adenomas 
under 2D images at first, and on other half under 3D. 
The markings under 2D and 3D were performed in half of the anterior 
and posterior wall side respectively, which side they would be on was 
randomly assigned. Thereafter, target lesions were resected by ESD. After 
procedure, participants answered visual analog scaled (VAS; 0-10, worst 
to best) questionnaire on ease of recognition of lesion morphology / lesion 
extent / total endoscopic cognition and technical ease of electrocautery 
marking under 2D and 3D visualization. 
The main endpoint was accuracy of ESD marking, which derived from the 
pathological distance between the demarcation line and the markings in 
the excised specimens. This study was conducted after an approval of the 
institutional review board of our hospital.
results: Enrolled 24 EGCs and 2 adenomas (median tumor size, 13 mm, 
range 3 - 32 mm) were 4 of type 0- IIa, 3 of type 0-IIb and 19 of type 0-IIc, 
and the types of histology of EGCs were 20 well differentiated adenocar-
cinomas, 3 signet-ring cell carcinomas and a poor differentiated adeno-
carcinoma. The distance between the demarcation line and electrocautery 
marking under 3D visualization was significantly shorter than under 2D 
(1.04 ± 0.79 mm vs 1.93 ± 1.92 mm, respectively, P = 0.040). In VAS, the 
recognition of lesion morphology under 3D was easier than 2D (8.54 ± 1.10 
vs 4.96 ± 1.56, respectively, P < 0.001), and that of lesion extent under 3D 
was easier than 2D (8.00 ± 1.20 vs 5.12 ± 1.66, respectively, P < 0.001). And 
ease of total endoscopic cognition under 3D (8.15 ± 1.26) was significantly 
higher than 2D (5.35 ± 1.72) (P < 0.001). Additionally, technical ease of 
electrocautery marking under 3D was higher than 2D (7.35 ± 1.32 vs 5.27 ± 
1.40, respectively, P < 0.001).
conclusion: 3D endoscopy was more accurate than 2D in the endoscopic 
diagnosis of extent of EGCs and adenomas. Furthermore, 3D visualization 
enhanced the quality of recognition of ruggedness and extent of lesions, 
and facilitated technically electrocautery marking before ESD. In flexible 
endoscopy, not only the efficiency and accuracy of procedure but also the 
quality of diagnosis is very important. Combined with previous results on 
3D-enhanced improvement of ESD performance, 3D endoscopy is the key 
technological innovation in diagnosis and treatment of GI.
disclosure: Nothing to disclose 
P0147 cOMPLIcaTIOns Of The sharP-POInTed fOreIgn BOdy 
IngesTIOn: a PredIcTIve MOdeL
Xiao X., Huang Z., Wu H.
West China Hospital, Sichuan University, Gastroenterology Department, 
Chengdu, China
contact e-Mail address: xxuenk@gmail.com
Introduction: Foreign body ingestion is a common emergency with little 
complication, but with the penetrating nature, sharp-pointed objects 
have a high risk in making esophageal perforation and subsequent death. 
Emergency endoscopy is the recommended treatment and sharp-pointed 
foreign body retrieval is a challenge for even highly experienced gastro-
enterologist. To date, there is no clear risk algorithm available for sharp-
pointed foreign body ingestion. It is important to identify the risk factors in 
order to mitigate potential morbidity and improve prognosis.
aims & Methods: In this single-center, retrospective study, 190 consecu-
tive patients complained of sharp-pointed foreign body ingestion, and 
referred to gastroenterology department of West China Hospital between 
August 2018 and February 2019 were included. Patients data, include age, 
gender, foreign body type, ingestion duration (from ingestion to taking 
endoscopy), computed tomography (CT) features and gastroscopy findings 
were recorded and analyzed with univariable analysis. Logistic regression 
and conditional inference tree were applied to develop a predictive model. 
Complications of sharp-pointed foreign body ingestion were classed into 
four ordered categories, including none or edema, erosion, ulcer and per-
foration. We aimed to recognize risk factors for the complications of sharp-
pointed foreign body ingestion, and help clinicians to decide the role and 
timing of endoscopic intervention.
results: Of the 190 patients, 182 had taken gastroscopy (96%). The width 
of sharp-pointed foreign body was identified as an independent risk factor 
for complications (OR=3.10, 95%CI: 2.33-5.55, P< 0.001). Conditional infer-
ence tree analysis was used to construct a risk stratification algorithm for 
complications. The sharp-pointed foreign body width of 1.9cm was the key 
discriminator (P< 0.001), and the subsequent split was ingestion duration 
of 24 hours (P=0.003). Therefore, patients could be stratified into four risk 
groups: low risk (width≦1.9cm), moderate risk I (2.5cm≧width>1.9cm and 
duration≦24hours), moderate risk II (width>2.5cm, duration≦24hours), 
and high risk (width>1.9cm, duration>24hours). To test the accuracy of 
conditional inference tree in predicting complications, receiver operating 
characteristic curve was drawn, and the area under the curve was 0.703 
(95%CI: 0.543-0.862, P=0.009). In high risk group, the specificity in pre-
dicting perforation was 83.2% and sensitivity was 60%. We also examined 
the accuracy of CT in recognizing perforation, the specificity was 95.2%, 
and the sensitivity was 20%.
conclusion: The width of sharp-pointed foreign body is the main risk factor 
for complications. Our predictive model including width and ingestion du-
ration could help to differentiate the patient with a high risk in perforation.
disclosure: Nothing to disclose 
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P0149 LOng-TerM OuTcOMes Of endOscOPIc suBMucOsaL 
dIssecTIOn fOr undIfferenTIaTed earLy gasTrIc cancer, 
BeyOnd exPanded crITerIa
Ryu C.B.1, Lee M.S.2, Bae J.Y.3, Lee J.Y.2
1Soon Chun Hyang University School of Medicine, Department of Internal 
Medicine, Bucheon, Korea (Republic of), 2Soonchunhyang University College 
of Medicine, Department of Internal Medicine, Bucheon, Korea (Republic 
of), 3Seoul Medical Center, Department of Internal Medicine, Seoul, Korea 
(Republic of)
contact e-Mail address: ryuchb@gmail.com
Introduction: Expanded indication of endoscopic submucosal dissection 
(ESD) for intramucosal undifferentiated early gastric cancer (EGC) up to 2 
cm without lymphovascular invasion have been accepted. However, pre-
operative measurement of the tumor was completely not as same as post-
operative one and if the postoperative tumor size would be a little more 
than 2 cm with R0 resection, additional surgery recommaded absolutely. 
Without Intramucosal undifferentiated early gastric cancer (EGC) up to 2cm 
in size without ulceration has been treated by endoscopic submucosal dis-
section (ESD) because the incidence of lymph node metastasisis negligible.
aims: The aim of this retrospective study was to analyze the long-term 
outcomes of ESD carried out to treat undifferentiated EGC in two groups ( 
group A: up to 2 cm, group B: 2-3 cm)
Patients and methods: Between January 2001 and March 2015, 104 patients 
with undifferentiated early gastric cancer (EGC) including poorly differenti-
ated adenocarcinoma (PD, n=66) or signet ring cell carcinoma (SG, n=38) 
on preoperative biopsy underwent ESD (group A: 71cases, group B: 33cas-
es), Total ESD speciemens were evaluated en bloc resection, R0 resection, 
and curative resection (CR) and to evaluate long term outcome, annual 
endoscopic surveillance with biopsy and CT scan were done.
Long-term outcomes analyzed in the 79 patients with undifferentiated EGC 
who had undergone ESD between 1999 and 2008.
Short-term outcomes were evaluated in the remaining 97 patients with 
undifferentiated EGC.
results: M/F was 40/31 and 17/16. Mean follow up period in group A and 
B were 61.10 ± 38.12, 60.79 ±47.75. Mean age in group A and B were 52.90 
±13.62, 57.00 ±12.25. 
En bloc in group A and B were achieved in 92.9%, 90.9 % of patients, 
respectively (NS). 
R0 resection in were achieved in 87.3 %, 51.5 % of patients, respectively 
(p< 0.05). 
Curative resection was 83.0 % in group A and group B was not include 
this definition.
Postoperative bleeding, perforation during the procedure, and delayed 
perforation were no significantly different in both groups, respectively. 
Recurrence in group A and B were 5.6 %(n=4), 18.1 % (n=6), retrospec-
tively (p< 0.01). All cases with lateral margin positive required additional 
ESD (n=2), desctructive therapy (n=3), or surgery (n=4) and no recurrence 
happened. No patient died of gastric cancer.
conclusion: In group B, R0 resection rate was lower than group A but R0 
resection in both group were not different recurrence rate with long term 
follow up. Carefully, undifferented EGC with 2 to 3 cm in a size recom-
mended ESD.
disclosure: Nothing to disclose 
P0150 cOMParaTIve sTudy Of esd and surgIcaL resecTIOn 
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Ryu C.B.1, Lee M.S.2, Bae J.Y.3
1Soonchunhyang University School of Medicine, Department of Internal 
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Introduction: Endoscopic resection for gastric subepithelialtumors(SETs) 
originated from the muscularispropria (GSET-PM) has offered less invasive 
alternatives to surgical resection.
aims & Methods: The aims of this study were to compare endoscopic 
subtumoraldissection(ESD) with surgical resection for the removal of 
GSET-PM. This study involved 17 patients with GSET-PM removed by ESD 
P0148 cLInIcaL sIgnIfIcance Of urgenT endOscOPy fOr 
gasTrOduOdenaL PerfOraTIOn
Asayama N., Nagata S., Shigita K., Aoyama T., Fukumoto A., Mukai S.
Hiroshima City Asa Citizens Hospital, Hiroshima, Japan
contact e-Mail address: a-s-ayama@hotmail.co.jp
Introduction: Gastroduodenal perforation, a condition representative of 
acute abdomen, is potentially life-threatening if left unattended, and thus 
early diagnosis and treatment are necessary. The standard treatment for 
gastroduodenal perforation is surgery. In some cases, however, operative 
findings reveal spontaneous closure where the perforation site is already 
sealed, indicating that surgery was not necessary. An accurate diagnosis 
by urgent endoscopy is therefore required before choosing between surgi-
cal and conservative management. 
There is presently no consensus regarding the role of urgent endoscopic 
examination for gastroduodenal perforation in Japan.
aims & Methods: The aim of the study was to evaluate the clinical signifi-
cance of urgent endoscopy for gastroduodenal perforation. We retrospec-
tively investigated 156 cases of gastroduodenal perforation in 154 patients 
(111 men, 45 women; mean age 59±19 years) at Hiroshima City Asa Citizens 
Hospital between December 2005 and December 2018. 
We performed urgent endoscopy for the sole purpose of identifying the 
location of perforation and confirming the size of the perforation in order 
to shorten the examination time. All procedures were performed using CO
2
 
insufflation with a surgeon standing by in case of complications.
results: The primary location of gastroduodenal perforation was the stom-
ach in 42 cases and the duodenum in 114 cases. For 40 of the 42 cases of 
gastric perforation (95.2%) and 100 of the 114 cases of duodenal perfora-
tion (87.7%), urgent endoscopy was performed on admission to diagnose 
the primary disease and confirm the exact perforation site. For gastric per-
foration, the endoscopic diagnosis was gastric ulcer in 32 cases, gastric 
carcinoma in 5, malignant lymphoma (ML) in 1, and perforation due to fish 
bone ingestion in 1. 
Regarding the clinical course of the 42 gastric perforation cases, 31 (73.8%) 
underwent surgery (25 gastric ulcers, 5 gastric cancer, and 1 ML) and 11 
(26.2%) were managed conservatively (8 gastric ulcers, 1 terminal case of 
gastric cancer, 1 ML, and 1 perforation due to fish bone ingestion). 
Of these 11 cases managed conservatively, 9 cases were successful while 2 
cases required delayed emergency surgery because of progression of peri-
tonitis. It is necessary to rule out the presence of malignant tumor for cases 
of gastric perforation. For duodenal perforation, the endoscopic diagnosis 
was duodenal ulcer in all 114 cases. For the clinical course of these 114 
cases, 62 cases (54.4%) underwent surgery while 52 cases (45.6%) were 
managed conservatively. 
Of the 52 cases managed conservatively, 48 cases (92.3%) were success-
ful while 3 cases (7.7%) required delayed emergency surgery because of 
progression of peritonitis. There was 1 fatal case where the patient had 
presented in shock on admission. 
We compared clinical factors between the cases of successful conservative 
management and those that required surgery plus the fatal case. Multi-
variate analysis revealed that localized abdominal pain (with no perito-
neal signs) (odds ratio [OR] 0.25; 95% confidence interval [CI] 0.08-0.75; 
p<0.01) and perforation diameter ≤ 5 mm (OR 0.13; 95% CI 0.04-0.36; 
p<0.01) were significant independent clinical factors associated with suc-
cessful conservative management of duodenal ulcer perforation. No com-
plications of urgent endoscopy were observed.
conclusion: Urgent endoscopy in gastroduodenal perforation enabled di-
agnosis of the primary disease and determination of the perforation site, 
and was considered useful in deciding the management strategy.
references: 1. Tanaka R, Kosugi S, Sakamoto K, et al. Treatment for perfo-
rated gastric ulcer: a multi-institutional retrospective review. J Gastrointest 
Surg. 2013;17:2074-81 2. Satoh K, Yoshino J, Akamatsu T, et al. Evidence-
based clinical practice guidelines for peptic ulcer disease 2015. J Gastro-
enterol. 2016;51:177-94.
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and 76 patients who underwent curative surgical resection. ESD was at-
tempted in GSET-PM with well marginated tumors which was below 5cm 
and showed an endoluminal growth pattern according to endoscopic 
ultrasound(EUS) finding.
results: ESD group were more likely to have upper portion(10/17, 58.8%) 
and surgery group were more likely to have mid portion(41/76, 53.8%)
(p=0.039). ESD group were smaller median tumor size (25.6 mm vs 35.9 
mm, p=0.037) and higher endoluminal ratio (58.5±9.1 % vs 45.8±15.4 %, 
p=0.002). ESD group were mostly to have Yamada type III (10/17, 58.8%) 
and surgery group were mostly Yamada type I (52/76, 68.4%)(p< 0.001). 
Complete resection by ESD was lower than by surgical resection (82.4% vs 
100%, p< 0.001). In ESD group, 3 performed surgical resection after ESD (1 
incompletely resection and 2 uncontrolled bleeding) and 1 showed perfo-
ration was completely resected with endoscopic closure. In surgery group, 
complications occurred in 6 patients (1 leakage, 1 stricture, 1 hernia and 
bowel obstruction, 1 wound infection and 2 worsened general condition 
after surgery). Although surgery group were lower in complication rate 
than ESD group (p=0.006), severity of complications were higher in the 
surgery group and there were no mortalities in the ESD group compared 
with 2 in the surgery group. There was no statistical difference of recur-
rence and the follow-up period between two group.
conclusion: ESD can be one of good options for the resection of endolu-
minal GSET-PM and could be replace treatment by surgical resection in 
Yamada type III with a high endoluminal ratio.
disclosure: Nothing to disclose 
P0151 effIcacy Of POLygLycOLIc acId sheeTIng WITh 
fIBrIn gLue fOr gasTrOInTesTInaL fIsTuLas: a MuLTIcenTer 
reTrOsPecTIve sTudy Of The POLygLycOLIc acId (Pga) sTudy 
grOuP
Matsuura N.1, Takimoto K.2, Tsuji Y.3, Takizawa K.4, Morita Y.5, Takeuchi Y.1, 
Nagami Y.6, Hirasawa K.7, Araki H.8, Yamaguchi N.9, Aoyagi H.10,  
Matsuhashi T.11, Iizuka T.12, Saegusa H.13, Yamazaki K.14, Hori S.15,  
Mannami T.16,17, Hanaoka N.18,19, Mori H.20, Ono H.4, PGA Study Group
1Osaka International Cancer Institute, Gastrointestinal Oncology, 
Osaka, Japan, 2National Hospital Organization Kyoto Medical Center, 
Gastroenterology, Kyoto, Japan, 3Graduate School of Medicine, University of 
Tokyo, Gastroenterology, Tokyo, Japan, 4Shizuoka Cancer Center, Division of 
Endoscopy, Shizuoka, Japan, 5Kobe University Hospital, Kobe, Japan, 6Osaka 
City University, Graduate School of Medicine, Gastroenterology, Osaka, 
Japan, 7Yokohama-City Medical Center, Endoscopy, Yokohama, Japan, 8Gifu 
University Hospital, Gastroenterology, Gifu, Japan, 9Nagasaki University 
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Introduction: Anastomotic leakage, which is one of the complications of 
surgical operations, sometimes causes a refractory fistula despite conser-
vative therapy, including local drainage and decompression of the diges-
tive tract. If a refractory fistula cannot be healed, a highly invasive reop-
eration may be performed in the end. Fistulas can occur after not only 
anastomotic leakage but also other situations, including cancer chemo-
radiation therapies (CRT). Polyglycolic acid (PGA) sheets (Neoveil; Gunze, 
Kyoto, Japan) with fibrin glue (Beriplast P Combi-Set; CSL Behring Pharma, 
Tokyo, Japan) have been reported to be useful for preventing perforations 
and delayed bleeding after endoscopic treatment [1,2]. Although it can be 
useful for closure of fistulas related to gastrointestinal cancer operation or 
chemoradiation therapies [3], large-scale multicenter treatment outcomes 
have not been reported.
aims & Methods: Patients with GI fistulas endoscopically closed using PGA 
sheeting with fibrin glue between April 2013 and March 2018 in 18 institu-
tions in the PGA study group, which is the affiliated study group of the 
Japanese Gastroenterological Endoscopy Society, were identifiedand retro-
spectively analyzed. Fistula is defined as the communication between the 
digestive tract and other areas (thoracic cavity, mediastinum, bronchus, 
abdominal cavity, etc.). Fistulas were filled with one or several pieces of 
PGA sheets followed by spraying fibrin glue using an endoscopic catheter. 
The procedure was repeated several times at 1- or 4-week intervals before 
fistula closure, and accompanied by nasal or percutaneous drainages, and 
endoscopic clipping as appropriate for each case.
results: Fistula: Forty-five cases (hypopharyngeal/esophageal cancer 21, 
gastric cancer 3, pancreatic cancer 1, colon cancer 3, prostate cancer 1, 
and communicating organs: chest cavity 5, mediastinum 4, bronchus 10, 
abdominal cavity 6, and others 20) were extracted. The median fistula di-
ameter was 5 mm (range 1-20 mm). Thirty-six cases were related with 
operations; and 9, with other conditions, including CRT. PGA sheets were 
filled at a median of 2 times (range 1-10). CRT was performed before sur-
gery in 13 cases (29%). Infections caused by fistulas were suspected in 
12 cases (22%) because pus was observed in the fistulas. Percutaneous 
drainage was performed in 26 cases (58%); nasal drainage, in 14 (31%); 
and endoscopic clipping, in 16 (36%). Complete closure was attained in 25 
cases (56%). The median period until resuming diet after starting sheeting 
was 16 days (range 1-222 days) in the closed cases. No statistically sig-
nificant differences in total protein level, fistula size, performance status, 
accompanying drainage, and the period between fistula occurrence and 
start of sheeting and fistula closure. Eleven deaths occurred, which were 
not related to PGA sheeting.
conclusion: Endoscopic PGA sheeting can be expected to achieve conser-
vative closure and inhibit highly invasive reoperation for more than half 
of fistula cases.
references: 1] Takimoto K, Toyonaga T, Matsuyama K. Endoscopic tissue 
shielding to prevent delayed perforation associated with endoscopic sub-
mucosal dissection for duodenal neoplasms. Endoscopy 2012; 44 (Suppl. 
02): E414 - E415 2] Tsuji Y, Fujishiro M, Kodashima S, et al. Polyglycolic 
acid sheets and fibrin glue decrease the risk of bleeding after endoscopic 
submucosal dissection of gastric neoplasms (with video). Gastrointest En-
dosc. 2015;81:906-12 3] Matsuura N, Hanaoka N, Ishihara R, et al. Polygly-
colic acid sheets for closure of refractory esophago-pulmonary fistula after 
esophagectomy Endoscopy 2016; 48: E78-E79
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Introduction: Endoscopic submucosal dissection(ESD) is a standard treat-
ment treatment of intramucosal gastric neoplasms. However, still only 
highly skilled operators can perform ESD safe. One of those reason is 
that there is no proper counter-traction during procedure. Recently, our 
research team devised revolute joint-based auxiliary transluminal endo-
scopic robot (REXTER). In this study, we evaluated the clinical feasibility of 
our REXTER in a live porcine model and identify the safety and efficacy of 
unskilled operator performing ESD.
aims & Methods: We perform ESD was performed to imaginary gastric 
lesions in nonsurvival porcine models using our novel robotic asstivie de-
vice. EAR can be mounted on GIF-Q260 endoscope and can be passed 
through overtube to porcine stomach, making it possible for clinical use. 
We devided two groups, conduected by experts and novice. We measured 
the time required to complete the ESD and complications involving perfo-
ration and significant bleeding in each group.
results: Total 16 cases of ESD were done. 6 cases were conduected by 
experienced endoscopist and 10 cases by unskilled endoscopist. Procedure 
time between operator groups was similar. There was no significant time 
difference between operator group. There was no incidence of perforation 
and significant bleeding.
conclusion: Our endosopic assitive robot showed feasibility and its safety. 
Our robotic device could be helpful, especially in unskilled endoscopicst.
disclosure: Nothing to disclose 
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P0154 WhITe LIghT IMagIng MOrPhOLOgIcaL feaTures and 
MagnIfyIng endOscOPy WITh narrOW Band IMagIng fOr The 
OPTIcaL dIagnOsIs Of suPerfIcIaL nOnaMPuLLary duOdenaL 
ePITheLIaL TuMOrs
Kakushima N., Yoshida M., Takizawa K., Yabuuchi Y., Kawata N., 
Kishida Y., Ito S., Imai K., Hotta K., Ishiwatari H., Matsubayashi H., Ono H.
Shizuoka Cancer Center, Division of Endoscopy, Shizuoka, Japan
contact e-Mail address: kakushin-tky@umin.ac.jp
Introduction: Optical diagnosis of superficial nonampullary duodenal epi-
thelial tumors (SNADETs) is important in guiding the treatment strategy.
aims & Methods: The aim of this study was to compare the treatment out-
comes based on optical diagnosis using white light imaging (WLI) mor-
phological features and magnifying endoscopy with narrow band imaging 
(MNBI).We retrospectively analyzed endoscopic and pathological data on 
SNADETs treated at a tertiary cancer center between Feb. 2010 to Jan. 2019. 
We made a decision tree model for WLI and MNBI diagnosis. Optical diag-
nosis of high-grade dysplasia (HGD) or carcinoma with WLI were defined 
based on WLI scoring system (WLS) [1] as total score of 3 points or higher; 
1 point for lesion diameter >10mm, heterogeneous/no lobulation, mixed 
type morphology/presence of depression, isochromatic, respectively, and 
2 points for red color. Diagnosis of HGD/carcinoma using MNBI was based 
on MNBI pattern diagnosis [2]: >2 patterns of MNBI within a lesion or 
presence of the pattern of obscure surface structure with abnormal ves-
sels. Ideal treatments were cold snare polypectomy (CSP) for low-grade 
dysplasia (LGD) < 10mm, endoscopic mucosal resection (EMR), endoscopic 
submucosal dissection (ESD) or surgery for lesions >10mm or HGD/car-
cinoma. We compared the ideal treatment based on optical diagnosis to 
actual treatment results.
results: A total of 197 patients with 218 lesions who were pre-operatively 
diagnosed as SNADETs were included for analysis. Final histology included 
non-tumor 12(5%), LGD 53 (24%), HGD 20(9%), intramucosal carcinoma 
124 (57%) and submucosal invasive carcinoma 9 (4%). Proportions of ideal 
treatment for LGD < 10mm based on WLS, MNBI and WLS with MNBI were 
89%, 79% and 97%. For HGD/carcinoma, they were 89%, 90% and 96%. 
Diagnostic accuracy of WLS and MNBI was 84% and 80%, respectively. 
When the diagnosis was similar between WLS and MNBI, the accuracy 
was 94%.
conclusion: Both WLI and MNBI were useful to select appropriate treat-
ment for SNADETs. A high diagnostic accuracy was achieved when both 
WLI and MNBI showed similar results.
references: [1] Kakushima N, et al. A simple endoscopic score system 
to differentiate between duodenal adenoma and carcinoma. Endosc Int 
Open. 2017;5:E763-E768. [2] Kakushima N, et al. Magnified endoscopy with 
narrow-band imaging for the differential diagnosis of superficial non-am-
pullary duodenal epithelial tumors. Scand J Gastroenterol 2019;54:128-134.
disclosure: Nothing to disclose 
P0155 cIrcuLarITy In endOscOPIc uLTrasOnOgraPhy 
IMagIng as a usefuL dIagnOsTIc IndIcaTOr Of 
gasTrOInTesTInaL sTrOMaL TuMOurs: a reTrOsPecTIve 
anaLysIs In 51 gasTrIc cases
Goto O.1,2, Akimoto T.1,2, Koizumi E.1, Higuchi K.1, Noda H.1, Omori J.1, 
Kaise M.1, Yahagi N.2, Iwakiri K.1
1Nippon Medical School, Department of Gastroenterology, Tokyo, Japan, 2Keio 
University, School of Medicine, Division of Research and Development for 
Minimally Invasive Treatment, Cancer Center, Tokyo, Japan
contact e-Mail address: o-goto@nms.ac.jp
Introduction: Gastrointestinal stromal tumour (GIST) should be accurately 
diagnosed to determine the treatment strategy for submucosal tumours 
(SMTs). Although endoscopic ultrasonography (EUS)-guided fine-needle 
aspiration is a standard option to diagnose SMTs, it is more or less invasive 
and less satisfactory due to technical difficulties or possible insufficient 
volume of specimen. Therefore, a non-interventional diagnostic method 
using imaging modality is still expected.
aims & Methods: We hypothesise that GISTs can be distinguished from 
other SMTs based on the shape of the tumours in EUS images because 
GISTs generally appear round, whereas leiomyoma, a counterpart of dif-
ferential diagnosis in gastric SMTs, appear craggy. Therefore, this study 
aims to investigate the potential diagnostic ability of EUS findings by using 
P0153 cLInIcaL OuTcOMes Of endOscOPIc IncIsIOnaL TheraPy 
fOr TreaTIng BenIgn esOPhageaL sTrIcTure: cOMParIsOn 
WITh BaLLOOn dILaTIOn and sTenT PLaceMenT
Pih G.Y., Kim D.H., Na H.K., Lee J.H., Ahn J.Y., Jung K.W., Choi K.D., 
Song H.J., Lee G.H., Jung H.-Y.
Asan Medical Center, Gastroenterology, Seoul, Korea (Republic of)
contact e-Mail address: lalila721@gmail.com
Introduction: Benign esophageal stricture has been treated with endo-
scopic methods including balloon dilation, stent placement. Despite these 
treatment modalities, recurrent refractory esophageal stricture impairs 
patient’s quality of life. Recently endoscopic incisional therapy was re-
ported as an another treatment option for benign esophageal stricture.
aims & Methods: We investigated the efficacy and safety of endoscopic 
incisional therapy (EIT) compared to balloon dilation (BD) and stent place-
ment in treating benign esophageal stricture. Subjects who underwent 
balloon dilation, stent placement and EIT as a first-line treatment for 
benign esophageal stricture between January 2009 and December 2017 
were eligible. Patients treated with different treatment modality from ini-
tial event for recurrent stricture were excluded. In addition, combination 
treatment more than two modalities concurrently were also excluded. All 
the patients were administered the same treatment modality as first when 
the stricture recurred. The medical records were retrospectively reviewed 
and clinical characteristics were investigated. Stricture was defined as an 
inability to pass a conventional endoscope.
results: Of total 49 patients, 31 were in BD group, 7 were in stent group 
and 11 were in EIT group. There was no significant difference among three 
groups in median age and procedure time. Most common indications for 
BD group and EIT group was esophagojejunostomy anastomotic stricture, 
10 patients (32.3%) and 4 patients (36.4%), respectively. In stent group, 
radiation therapy induced stricture of 4 patients (57.1%) was most com-
mon indication of procedure. Among three groups, there were no signifi-
cant difference in re-stricture rate (p=0.697, 41.9% in BD group, 28.6% in 
stent group and 27.3% in EIT group) and interval to the second stricture 
(p=0.239, median 46 days in BD group, 215 days in stent group and 46 
days in EIT group). Median follow up period was 699 days in BD group, 
540 days in stent group and 395 days in EIT group. Subgroup analysis of 
esophagojejunostomy anastomotic stricture group showed lower recur-
rence rate in EIT group compared to BD group (0% vs. 30%, p=0.505). 
There was no procedure related complication reported including bleeding, 
perforation and pneumothorax in three groups.
 
Balloon 
dilatation 
group (n=31)
stent group 
(n=7)
eIT group 
(n=11) P value
Age (medina, IQR) 62 (51-69) 61 (55-66) 67 (56-73) 0.680
Sex (male/female) 23/8 6/1 6/5 0.316
Procedure time, minutes 8 (7-12) 9 (8-15) 6 (2-14) 0.243
Restricture rate 13 (41.9%) 2 (28.6%) 3 (27.3%) 0.697
Interval to the 2nd stricture, 
days
46 (13-90) 215 (133-297) 46 (14-93) 0.239
Recurrence number 
(median, IQR)
0 (0-2) 0 (0-1) 0 (0-1) 0.589
Follow up period, days 699 (219-1752) 540 (305-774) 395 (86-552) 0.123
RT-induced stricture 2 (6.5%) 4 (57.1%) 2 (18.2%)  
Short segment stricture 25 (80.6%) 2 (28.6%) 8 (72.7%) 0.024
[Table 1. Baseline patient characteristics and treatment outcome]
conclusion: EIT is a feasible, safe and effective treatment modality with 
acceptable long term patency for benign esophageal strictures especially 
in short segment stricture such as anastomotic stricture and expected to be 
an alternative treatment to balloon dilation or stent placement.
disclosure: Nothing to disclose 
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tumour circularity. A total of 51 gastric cases with SMTs 20-50 mm in di-
ameter, diagnosed as possible GISTs by EUS and surgically removed there-
after, were retrospectively collected at two institutions. In each lesion, one 
EUS still image showing the maximal area was selected, and the circularity 
of each lesion, a surrogate indicator of roundness calculated as four pi 
times the area divided by the perimeter squared (0-1, 1 = a true circle), 
was assessed using ImageJ (ver. 1.50e; National Institutes of Health, USA) 
by tracing the rim of the lesion. The mean circularity between GISTs and 
other SMTs were compared, and its diagnostic utility, by investigating a re-
ceiver operating characteristics (ROC) curve, as well as diagnostic accuracy 
were evaluated. In addition, circularity between GISTs and leiomyoma was 
compared as a sub-analysis.
results: In 51 SMT cases, 31 GISTs were included. The mean circularity in 
GISTs and others were 0.85 ± 0.07 and 0.69 ± 0.11, respectively, with statis-
tical significance (p < 0.01). In the ROC curve, a cut-off value of 0.83 with 
0.91 in the area under the curve showed maximum diagnostic accuracy 
(84.3%), with sensitivity and specificity of 80.6% and 90.0%, respectively. 
The mean circularity in eight cases of leiomyomas was significantly lower 
than the mean circularity in GISTs (0.63, p < 0.01).
conclusion: These retrospective data suggest that circularity calculated us-
ing EUS imaging can be used as a non-invasive diagnostic discriminator in 
gastric GISTs with high accuracy rate, particularly from leiomyomas. How-
ever, further prospective analysis is expected.
disclosure: Nothing to disclose 
P0156 rOLe Of endOscOPy In susPIcIOn Of aTrOPhIc 
gasTrITIs WITh and WIThOuT InTesTInaL MeTaPLasIa In 
cOMParIsOn TO hIsTOPaThOLOgy
Ibrahim Mohamed H.1, Ahmed Sakr A.2, Shams El Dein Mohamed A.3, 
A. Kasemy Z.4, Saad Hassan M.5
1Faculty of Medicine-Menoufia University, Tropical Medicine, Shebeen El-
Kom, Egypt, 2Faculty of Medicine-Menoufia University, Tropical Medicine 
Department, Shibin El-kom-Menoufia, Egypt, 3Faculty of Medicine-Menoufia 
University, Pathology, Shebeen El-Kom, Egypt, 4Faculty of Medicine-
Menoufia University, Public Health and Community Medicine Department, 
Shibin El-Kom, Egypt, 5Shibin El-Kom Fever Hospital, Hepatology and 
Gastroenterology, Shibin El-Kom, Egypt
contact e-Mail address: aymanahmedsakr@gmail.com
Introduction: Atrophic gastritis(AG) and intestinal metaplasia(IM) are es-
tablished premalignant gastric lesions. Many studies using conventional 
white-light endoscopy(CWLE) documented a poor correlation between 
esophagogastroduodenoscopy(EGD) and histopathological(HP) findings 
for detection of precancerous gastric lesions. However, in daily practice, 
CWLE is still used.
aims & Methods: Bridging the gap between endoscopy and HP in detec-
tion of chronic gastritis, AG and IM. This was a prospective single-center 
study involved 150 patients with endoscopic criteria of chronic gastritis, AG 
or IM selected from 300 patients with upper gastrointestinal symptoms 
who were referred for Upper GI endoscopy and met the criteria of chronic 
gastritis, AG or IM. They were classified into 3 groups according to HP 
results of gastric biopsies from targeted lesions (GI chronic non-atrophic 
gastritis n=86, GII AG n=42 and GIII IM n=26). Routine HP using updated 
Sydney system and H.pylori detection in gastric biopsies using Giemsa 
stain were done. We correlated the endoscopic criteria of chronic gastritis, 
AG and IM with the HP results.
results: The sample included (73males & 75 females) with ages ranged17-75 
years and mean± SD was41.96 ± 15.95. GI, GII &GIII were [42 patients 
(28%),82 patients (54.7%) and 26 patients (17.3%)], respectively. Smok-
ing, DM, chronic NSIDs use, current H.pylori infection, and family history 
of H. pylori were highly statistically significant among the 3 groups with 
higher incidence of AG and IM in patients who had positive family history 
of H.pylori infection (p value < 0.001). However, age and previous H.pylori 
therapy were not significant among the groups. We correlated the stan-
dardized endoscopic findings in each group, diffuse mottling was more 
common in GI (74.3%, P< 0.001), visible submucosal vessels, atrophic 
mucosa and atrophic gastric folds predominated in GII (75.6,82.3&73.1%(P 
0.005,0.4 &< 0.01)), respectively. Whitish raised lesions were more spe-
cific in GIII (85.7%)with highly statistically significant difference between 
the groups(P< 0.001). H.pylori was the most etiologic agent in all groups 
132/150 patients (90%) (p-0.001). EGD could truly diagnose 36 out of 42 
patients diagnosed by HP in GI,71/82 in GII and 14/26 in GIII, the sensitivity 
and specificity of endoscopic suspicion of chronic gastritis was (86&88% in 
GI), (87&85% in GII) and (54% &100% in GII) with statistically significant 
difference between the 3 groups(p-0.001). The logistic regression model 
for risk factors was statistically significant, χ2= 25.74 and 49.32 respec-
tively, p < 0.001. The model explained 61.0 and 70% (Nagelkerke R2) of the 
variance in AG or IM and correctly classified 86.3, 85.3% of cases respec-
tively. Smokers were 36.72 and 23.73 times more likely to exhibit AG or IM. 
Current H. Pylori infection was associated with an increased likelihood of 
exhibiting AG.
conclusion: CWLE has a high sensitivity and specificity for suspicion of 
chronic gastritis and AG, but low sensitivity and very high specificity for IM 
and can be used as a bridge or an alternative to HP especially with high-
definition endoscopy. Targeted biopsies with image enhanced endoscopic 
techniques may be more practical than updated Sydney protocol.
disclosure: Nothing to disclose 
P0157 The aPPLIcaTIOn Of arTIfIcIaL InTeLLIgence usIng a 
cOnvOLuTIOnaL neuraL neTWOrk fOr deTecTIng head and 
neck cancer In endOscOPIc IMages
Yamaguchi K.1,2, Kawada K.1,2, Aoyama K.3, Matsui T.1,2, Okada T.1,2, 
Hoshino A.1,2, Tokairin Y.1,2, Nakajima Y.1,2, Kinugasa Y.2, Kumagai Y.4, 
Tada T.5
1Tokyo Medical and Dental University, Esophageal Surgery, Tokyo, Japan, 
2Tokyo Medical and Dental University, Gastrointestinal Surgery, Tokyo, Japan, 
3AI Medical Service, Tokyo, Japan, 4Saitama Medical Center, Saitama Medical 
University, Digestive Tract and General Surgery, Kawagoe, Japan, 5Tada 
Tomohiro Institute of Gastroproctcology, Gastroenterology, Saitama, Japan
contact e-Mail address: kyama713@gmail.com
Introduction: Head and neck squamous cell carcinoma is typically diag-
nosed at an advanced stage, and the prognosis for patients is poor. Re-
cently, image-enhanced endoscopy (IEE) has become popular as a new 
diagnostic modality for the early detection of superficial head and neck 
cancer. However, it is difficult for inexperienced endoscopists to detect 
superficial head and neck cancer because the observation of the laryn-
gopharyngeal sites is not a standard procedure with esophagogastroduo-
denoscopy. Image recognition using artificial intelligence (AI) with deep 
learning through convolutional neural networks (CNNs) has dramatically 
improved and been applied increasingly frequently to medical fields for 
diagnostic imaging.
aims & Methods: The aim of this study is to investigate the utility of AI 
for diagnosing head and neck cancers. A CNN-based diagnostic system 
was constructed based on the Single Shot MultiBox Detector architecture 
and trained using 5163 endoscopic images of laryngopharyngeal cancer. 
To evaluate the diagnostic accuracy, an independent test set of 1775 la-
ryngopharyngeal images collected from 68 consecutive patients with 75 
laryngopharyngeal cancer lesions was applied to the constructed CNN.
results: The CNN correctly diagnosed 72 of 75 laryngopharyngeal cancer 
lesions with an overall accuracy of 91.4%, and 4 of 6 non-cancerous le-
sions were diagnosed as benign. The two missed benign lesions were 
papilloma and lymphoid follicles. The three missed malignant lesions 
were superficial hypopharyngeal cancer (n=2) and laryngeal cancer (n=1). 
The sensitivity, specificity, positive predictive value, and negative predic-
tive value in terms of the lesions were 96.0%, 66.7%, 97.3%, and 57.1%, 
respectively, and the accuracy, sensitivity, and specificity in terms of the 
endoscopic images were 83.0%, 83.3% and 79.2%, respectively. The CNN 
required 47 seconds to analyze 1775 test images.
conclusion: This CNN system for detecting laryngopharyngeal cancer was 
able to process numerous stored endoscopic images in a very short time 
with clinically relevant diagnostic ability. It may be applicable to daily clin-
ical practice, where it can help reduce the burden on endoscopists.
disclosure: Nothing to disclose 
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P0159 PrevenTIve effecT Of PPIs aLOne, PPIs PLus 
cyTOPrOTecTIve agenT, and h2ra PLus cyTOPrOTecTIve 
agenT On BLeedIng afTer endOscOPIc suBMucOsaL 
dIssecTIOn: a PrOsPecTIve randOMIzed cOnTrOLLed TrIaL
Lee J.Y., Jang J.S.
Dong-A University, Gastroenterology, Busan, Korea (Republic of)
contact e-Mail address: ljyhateo@gmail.com
Introduction: ESD is the most effective treatment for early gastric cancer or 
gastric adenoma. However, the major complication of ESD is postoperative 
bleeding from ulcers after the procedure.
aims & Methods: This study aimed to evaluate the preventive effect of us-
ing a proton pump inhibitor (PPI) alone, a PPI+rebamipide combination 
therapy, and an H2 receptor antagonist (H2RA)+rebamipide combination 
therapy on bleeding after endoscopic submucosal dissection (ESD). 
In total, 210 patients who underwent ESD from April 2015 to July 2016 
in Dong-A University Hospital were randomly assigned to the PPI-alone 
therapy group, the PPI+rebamipide combination therapy group, or the 
H2RA+rebamipide combination therapy group. We excluded patients who 
were lost to follow-up or who had diagnoses other than early gastric can-
cer or gastric adenoma. Twenty-eight days after ESD, we evaluated the 
ulcer bleeding ratio, gastric pH, ulcer residual ratio, and ulcer stage.
results: This study included 149 patients (PPI-alone group: 43 patients, 
PPI+rebamipide group: 61 patients, H2RA+rebamipide group: 45 patients). 
The post-ESD bleeding ratio was not significantly different among the three 
groups (p=0.264). The ulcer residual ratios were 34.5±21.4%, 24.8±18.8%, 
and 27.6±20.2% in the PPI alone, PPI+rebamipide, and H2RA+rebamipide 
groups, respectively (p=0.05).
conclusion: There was no difference in delayed bleeding after ESD among 
the PPI-alone, PPI+rebamipide, and H2RA+rebamipide groups at 28 days; 
however, PPI+rebamipide was significantly more effective in reducing the 
ulcer residual ratio.
disclosure: Nothing to disclose 
P0160 OPPOrTunIsTIc deTecTIOn Of OesOPhagOgasTrIc 
neOPLasTIc and Pre-neOPLasTIc LesIOns durIng screenIng 
cOLOnOscOPy PrOgraM - a WOrThWhILe sTraTegy?
Lau W.L.J.1, Khoo M.J.W.2, Leong X.H.2, Lim T.Z.3, Shabbir A.4, Yeoh K.-G.5, 
Koh C.J.5, So J.B.Y.4
1National University Hospital, General Surgery, Singapore, Singapore, 2Yong 
Loo Lin School of Medicine, Singapore, Singapore, 3National University 
Hospital, Singapore, Singapore, 4National University Health System, 
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contact e-Mail address: joellauwenliang@hotmail.com
Introduction: Endoscopic screening for colon cancer is generally accepted 
for screening for colorectal cancer, whereas endoscopic screening for oe-
sophagogastric (EG) cancer alone is not cost-effective in countries with 
low to intermediate incidence of gastric cancer. The utility of offering an 
opportunistic upper endoscopy during a screening colonoscopy was evalu-
ated as a potential strategy for detection of early EG neoplastic and pre-
neoplastic lesions.
aims & Methods: A retrospective review of a prospective database in a 
tertiary hospital was performed. Patients with age>40 who underwent 
opportunistic screening upper endoscopy and colonoscopy in the same 
session from January 2015 to December 2017 were included. Patients who 
underwent upper endoscopy for indications such as dyspepsia, weight loss 
and anaemia were excluded. EG neoplastic lesions were defined as EG 
carcinomas, and pre-neoplastic lesions were defined as Barret’s oesopha-
gus, intestinal metaplasia (IM), or atrophic gastritis.
results: Out of 9,566 patients who underwent simultaneous upper en-
doscopy and colonoscopy, we identified 1,414 patients who underwent 
screening upper endoscopy. On colonoscopy, 491 (34.7%) patients had ad-
enomatous polyps detected, and colorectal malignancy was detected in 20 
patients (1.4%).
From our cohort, 179 (12.7%) patients undergoing opportunistic screening 
upper endoscopy had EG neoplastic and pre-neoplastic lesions. Of these, 
IM was found in 146 (10.3%) patients with 112 (7.9%) focal IM while 21 
(1.4%) had extensive IM. Atrophic gastritis was detected in 23 (1.6%) pa-
tients. Also, 19 (1.3%) patients were found to have Barrett’s oesophagus 
P0158 endOscOPIc gradIng Of gasTrIc InTesTInaL 
MeTaPLasIa (eggIM) usIng narrOW Band IMagIng endOscOPy 
WITh nOn-MagnIfIed and MagnIfIed OBservaTIOn
Kawamura M., Kikuchi T., Nagasaki F., Nomura E., Suzuki N., Hiratsuka T., 
Oyama H.
Sendai City Hospital, Department of Gastroenterology, Sendai, Japan
contact e-Mail address: dq8m-kwmr@asahi-net.or.jp
Introduction: Gastric intestinal metaplasia (GIM) is known to associated 
with a risk of gastric cancer. Recent studies suggest the endoscopic find-
ings with narrow band imaging (NBI) (light-blue crest (LBC), white opaque 
substance (WOS)) correlate to histological GIM, and are useful markers 
for a cancer risk according to the classification of endoscopic grading of 
GIM (EGGIM). However LBC, WOS are originally reported under magnified 
endoscopic observation, it is unknown the differece in classifying EGGIM 
between non-magnified NBI (non-M-NBI) and magnified NBI (M-NBI) ob-
servation.
aims & Methods: To investigate the difference in classifying EGGIM be-
tween non-M-NBI and M-NBI observation, 100 consecutive patients who 
underwent NBI endoscopy were enrolled. Helicobacter pylori (HP) infec-
tion and the endoscopic grading of gastric atrophy were investigated. Us-
ing a high resolution endoscopy (Model GIF-H260Z or H290Z, OLYMPUS 
Co.), four areas in each stomach (greater and lesser curvature in each 
corpus and antrum) were evaluated under non-M-NBI and M-NBI (with 
moderate-high magnification) observation. The presence of LBC and WOS 
were defined into three groups (score 0 (none), 1 (focal, ≤30%), or 2 (ex-
tensive, >30%)). Furthermore, using the combination of presence of LBC, 
WOS, or tubulo-villous pattern, endoscopic GIM score was classified ac-
cording to above three groups. Resulting from the sum of endoscopic GIM 
score in each of the four areas, EGGIM was defined into stage 0/I/II/III/IV 
according to total score 0/1-2/3-4/5-6/7-8. The concordance rate and the 
weighted kappa value of LBC, WOS and EGGIM were analyzed between 
non-M-NBI and M-NBI observation.
results: Fifty-nine patients were defined as present positive for HP in-
fection, 20 were past infected, 21 were uninfected subjects. Endoscopic 
grading of atrophy were none-mild in 46 patients, moderate in 38 and 
severe in 16. Of total evaluated 400 areas, LBC score 0, 1 and 2 were found 
in 202 (50.5%), 148 (37.0%) and 50 (12.5%) areas with non-M-NBI, while 
223 (55.7%), 131 (32.8%) and 46 (11.5%) areas with M-NBI observation, 
respectively. WOS score 0, 1 and 2 were found in 315 (78.7%), 53 (13.3%) 
and 32 (8.0%) areas with non-M-NBI, while 322 (80.4%), 47 (11.8%) and 
31 (7.8%) areas with M-NBI observation, respectively. Several cases with 
whitish mucus or marginal of tubulo-villous surface structure (marginal 
turbid band (MTB)) were misdiagnosed as presence of LBC with non-M-
NBI. The concordance rate between non-M-NBI and M-NBI were 75.8% 
in LBC score and 94.5% in WOS score. The strength of agreement showed 
good reproducibility between non-M-NBI and M-NBI observation (weight-
ed kappa value of 0.77 in LBC score and 0.90 in WOS score). The EGGIM 
were classified as follows: stage 0, I, II, III and IV were 18, 26, 26, 21 and 9 
patients with non-M-NBI, while 27, 21, 32, 15 and 5 patients with M-NBI, 
respectively. Several cases with a discordance in the EGGIM were found 
because of difference in a capability of evaluated field between non-M-
NBI and M-NBI observation. The concordance rate of EGGIM were 76%, 
and the weighted kappa value showed substantial agreement with 0.72 
between non-M-NBI and M-NBI observation.
conclusion: Using high resolution NBI endoscopy, non-M-NBI and M-NBI 
observation showed good agreement on evaluation of the endoscopic 
findings associated with GIM (LBC, WOS, EGGIM). Non-M-NBI observa-
tion for EGGIM, with capability of a wide range view, may have a similar 
potential for assessment of an individual risk of gastric cancer as M-NBI 
observation.
references: Esposito G, Pimentel-Nunes P, Angeletti S et al. Endoscopic 
grading of gastric intestinal metaplasia (EGGIM): a multicenter validation 
study. Endoscopy 2018; 21[Epub ahead of print] doi: 10.1055/a-0808-3186
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with one high-grade dysplasia which was resected endoscopically. Early 
stage gastric cancers were diagnosed in three patients (0.2%) who under-
went surgery. Two were T1bN0 and one was T2N0. Another patient was 
diagnosed with early MALT lymphoma.
On multivariate regression, independent risk factors for upper GI neoplas-
tic and pre-neoplastic lesions in this population include age > 50 (Risk 
Ratio (RR) 2.18, 95%CI 1.15 - 4.14), p = 0.018) and having a family history 
of first-degree relative with gastric cancer (RR 1.60, 95% CI 1.03 - 2.48, p 
= 0.035). 
Hence, using this strategy, the number needed to detect an incidental neo-
plastic or pre-neoplastic EG lesion is 7.90. At a cost of USD$500/upper 
endoscopy, it would cost $3950 per lesion detected.
Patient group number needed to scope
cost per diagnosis 
($usd)
All opportunistic OGDs 7.90 3,950
Age above 50 7.42 3,710
Family History of Gastric Cancer (1st Degree) 5.65 2,825
Any one risk factor 7.74 3,870
[Table 1]
conclusion: This observational cohort suggests the potential utility of in-
corporating upper endoscopy into an established screening colonoscopy 
program, for the purpose of detecting EG neoplastic and pre-neoplastic le-
sions in countries with intermediate risk. All pathologies detected are early 
lesions. In addition, this strategy may be more acceptable to patients as 
they are already planned for colonoscopy. Further studies are worthwhile 
to verify these observations. 
disclosure: Nothing to disclose 
P0161 PerOraL endOscOPIc MyOTOMy as rescue-TheraPy 
afTer IneffecTIve heLLer MyOTOMy: a sIngLe cenTre 
reTrOsPecTIve exPerIence
Quarta Colosso B.M., Shimamura Y., Ikeda H., Abad M.R.A., Nishikawa Y., 
Ueno A., Tanabe M., Sumi K., Tomida H., Onimaru M., Inoue H.
Showa University Koto Toyosu Hospital, Digestive Diseases Center, Tokyo, 
Japan
contact e-Mail address: quarta.colosso@gmail.com
Introduction: Heller Myotomy has been the treatment of choice for pa-
tients with achalasia for the past decades. Since 2008, Peroral Endoscopic 
Myotomy (POEM) has demonstrated excellent outcome and became the 
primary form of minimally invasive treatment in many centers. Although 
Heller myotomy is still being performed worldwide with excellent results, 
there are patients who are refractory to the surgical procedure.
aims & Methods: The aim of this study is to assess the safety and efficacy 
of POEM as a rescue therapy in those cases in which Heller myotomy was 
not effective. This is a retrospective study from a prospective database in a 
tertiary referral single center from April 2015 to April 2019. All patients in-
cluded in the study had undergone POEM after ineffective Heller myotomy. 
All underwent gastroscopy, barium esophagogram, and high resolution 
manometry, as well as CT Scan to rule out obstructive lesions at the junc-
tion prior to POEM. The approach during POEM was either anterior or 
posterior depending on patient’s anatomy and scar of surgical myotomy. 
To rate the effectiveness of the procedure, we used Eckardt score and Sat-
isfaction scale (a numeric scale from 1 to 10, 10 to express maximum satisfac-
tion) upon second month follow up. Symptomatic patients were defined 
as those with Eckardt score≥3 or those who complained of high intensity 
symptoms even with Eckardt score <3. Outcome measures were as follows: 
1. Clinical Success: post-POEM Eckardt score <3 or Satisfaction scale >7; 
2. Technical Success: complete execution of myotomy; 
3. Major Adverse Events: vital-sign instability, intensive care unit (ICU) stay, 
hospital readmission, conversion to open surgery, invasive postoperative 
procedure, blood transfusion, or prolonged (> 5 days) hospitalization for 
functional impairment.
Exclusion Criteria: patients who did not present for routine second month 
follow-up post POEM.
results: Thirty-six patients underwent POEM after ineffective Heller my-
otomy. Three patients were excluded because of exclusion criteria and a 
total of 33 patients were analyzed. Twenty-two patients had laparoscopic 
approach and 11 patients with open approach in previous Heller myotomy. 
Thirty patients presented with Eckardt score>3 and 4 patients had high 
intensity symptoms. Based on Modified Chicago Classification, the type of 
achalasia seen were as follows: Type I/II/III= 21/2/2, and 8 unclear cases. 
We distinguished Straight Type from Sigmoid Type (1 vs 32) based on bar-
ium esophagogram. 
All cases achieved Technical Success. Clinical Success was observed in 
81.8% of patients. Eckardt score and Satisfaction scale were as follows: 
Eckardt score < 3 in 23 patients (69.6%), =3 in 2 patients (6.0%), and >3 in 
7 patients (21.2%), Unknown in 1 patient (3.0%). Satisfaction scale ≥7 in 19 
patients (57.5%), < 7 in 2 patients (6.0%), Unknown in 12 patients (36.3%). 
No patients experienced Major Adverse Events. There were few cases with 
discrepancy in Eckardt score and Satisfactory scale: 2 patients with Eckardt 
score = 3 and Satisfaction scale = 9, 1 patient with Eckardt score = 4 and 
Satisfaction scale = 7, 1 patient with Eckardt score = 2 with Satisfaction 
scale = 6.
conclusion: According to our study, POEM can be considered a safe and 
effective rescue therapy in symptomatic patients with prior history of sur-
gical myotomy. In addition, there seems to be no differences in risks in 
performing POEM after either laparoscopic or open Heller myotomy and 
clinical success was achieved in majority of patients.
disclosure: Inoue H is an advisor of Olympus Corporation and Top Corpo-
ration. He has also received educational grants from Olympus Corp., and 
Takeda Pharmaceutical Co. All other authors have no conflict of interests 
to declare. 
P0162 esOPhageaL cLeansIng BefOre POeM - a sIMPLe and 
effecTIve TechnIque
Desai P.N.1, Kabrawala M.V.2, Patel C.3
1Surat Institute of Digestive Sciences, Endoscopy, Surat, India, 2Surat Institute 
of Digestive Sciences, Gastroenterolgy, Surat, India, 3Surat Institute of 
Digestive Sciences, Surat, India
contact e-Mail address: drp_desai@hotmail.com
Introduction: Pre - procedural preparation varies from center to center. No 
standard method prescribed.
Conventionally, patients are put on clear liquids for 48 to 72 hours pre 
POEM. Then an endoscopic lavage is given the previous day. This is very 
cumbersome and we need a better less cumbersome preparation method
aims & Methods: To devise a simple yet effective method for pre-procedur-
al preparation for poem.
Methods: 100 cases between 2017 and 2019 with Achalasia Cardia were 
included. A Pre POEM Score for the condition of oesophageal mucosa was 
devised.
Pre POeM score:
Grade 1: Clean esophagus 
Grade 2: Presence of fluid and froth + crumpled / puckered but normal 
mucosa
Grade 3: Presence of fluid and froth, no food residue + intermittent 
esophageal candidiasis 
Grade 4: Presence of fluid and froth with minimal food residue +/- 
esophageal candidiasis
Grade 5: Extensive food residue with candidial infection
Patients dived in two groups: A and B
Group A: 50 patients: Prepared with 48 hours clear liquids, 24 hours nil 
orally and endoscopic lavage the day before. 
Group B: Our new preparation. Warm water and a carbonated drink al-
teranately every 15 to 20 minutes for 12 hours prior to 6 hours before the 
procedure. No pre procedure lavage. 
To assess anesthesia aspiration risk, while intubation in POEM, we devised 
an ‘Anesthesia Risk Score’ 
1. Normal risk with no fluid regurgitation
2. Minimal fluid regurgitation requiring suction once
3. Significant fluid regurgitation requiring continuous suction
4. Food and fluid regurgitation needing emergency measures 
Using this we compared Group A and B in terms of requirement of lavage
- procedure time
- anaesthesia aspiration risk
- Length of hospital stay
- adverse events and 
- cost effectiveness
results: In the patients who had Grade 2 and Grade 3 pre-POEM score, the 
lumen clearance at the time of POEM procedure was found to be optimum 
in both the groups
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The correlation between NBI targeted biopsies and histological findings 
was statistically significant (p< 0.001) with a Kappa coefficient of 0.81. 
EGGIM was associated with an increase of NBI diagnosis of dysplasia (odd 
1.384; p=0.025). However, as EGGIM increases the odd of correlation be-
tween NBI and histological dysplasia decreases in 42% (odd 0.58; p = 
0.041). 
We report 15 gastric non polypoid lesions (Paris classification 0-IIa, 0-IIb 
and 0-IIc). Applying NBI, we established a concordance with histological 
dysplasia diagnosis of 100%.
conclusion: NBI targeted biopsies presented a statistically significant 
correlation with histological findings, acknowledging an almost perfect 
agreement with a Kappa coefficient of 0.81. Applying NBI on non-polypoid 
lesions identified in WLE increases the rate of histological concordance, 
we report a 100% concordance. NBI is an accurate tool that, in the hands 
of experienced endoscopists, can lead to an easy identification of gastric 
dysplasia, with high concordance with histological findings.
disclosure: Nothing to disclose 
P0164 endOscOPIc suBMucOsaL dIssecTIOn Of The 
OesOPhagus and OesOPhagOgasTrIc juncTIOn fOr earLy 
neOPLasIa: WILL IT Be The fuTure?
Félix C., Mendo R., Pereira I., Rodrigues J.P., Barreiro P., Chagas C.
Centro Hospitalar Lisboa Ocidental, Gastrenterology, Lisbon, Portugal
contact e-Mail address: sfelixcatarina@gmail.com
Introduction: Endoscopic submucosal dissection (ESD) is an endoscopic 
technique widely employed in Asia for resection of oesophagus and oe-
sophagogastric junction (EGJ) neoplasms. In the West, ESD of these loca-
tions is limited to a very few centres.
aims & Methods: This study aims to report the feasibility, safety and effec-
tiveness of ESD for the treatment of oesophagus and EGJ early neoplasms 
in a Western centre. 
We conducted a prospective data analysis of all consecutive oesophageal 
and EGJ lesions treated by ESD from October 2014 to November 2018. Lo-
cation, en bloc, pathological complete resection (R0) and curative rates, 
procedure time, complications and local recurrence were evaluated.
results: Thirty lesions were included from 28 patients (65-year-old [39-
84]; M/F=23/5): 9 squamous cell neoplasms, 6 neoplasms in Barrett’s 
oesophagus, 12 gastric cardia neoplasms, 2 granular cell tumours and 1 
oesophageal papilloma (proximal oesophagus n=3, medial oesophagus 
n=8, distal oesophagus n=6, EGJ n=13). The median size of the resected 
specimen was 42mm (12-88). En bloc resection was achieved in all resect-
ed lesions (29/29; 1 resection was considered non-feasible due to invasion 
detected during the procedure). Circumferential dissection was performed 
in 6/29 lesions (21%). R0 was accomplished in 24/29 (83%) and resection 
was considered curative in 19/29 (66%). Reasons to non-curative resection 
were: poorly differentiated cardiac gastric adenocarcinoma (n=1), R1 (n=1), 
deep submucosal invasion (n=6) and Rx (n=2). There were no immediate 
complications such as bleeding or perforation; in the curative resected 
group, stenosis was diagnosed in 1 patient submitted to a circumferential 
resection and was managed endoscopically. No recurrence was observed 
within a mean follow-up of 18 months (3-53).
conclusion: This study represents one of the largest series of oesophageal 
and EGJ ESD in the West. Although representing the initial experience, ESD 
for oesophageal and EGJ lesions was efficient and extremely safe.
disclosure: Nothing to disclose 
P0165 a sTudy Of IMPrOvIng IMage PrOcessIng TO reduce 
cOLOr nOIses In Oxygen saTuraTIOn IMagIng endOscOPy
Nishihara K.1, Hori K.1, Saito T.2, Omori T.2, Yoda Y.1, Sunakawa H.1, 
Minamide T.1, Suyama M.1, Yamamoto Y.1, Shinmura K.1, Ikematsu H.1, 
Yano T.1
1National Cancer Center Hospital East, Gastroenterology and Endoscopy, 
Kashiwa, Japan, 2Imaging Technology Center, FUJIFILM Corporation, Tokyo, 
Japan
contact e-Mail address: kenishih@east.ncc.go.jp
Introduction: Oxygen saturation (OS) imaging (FUJIFILM Corporation, To-
kyo, Japan) is a novel endoscopic technology which can directly measure 
the tissue oxygen saturation (Sto2) of the surface of gastrointestinal tract 
• In patients with Grade 4 score 
- Group A : two patients required additional wash prior to POEM
- Group B : all patients had good luminal clearance
• In patients with Grade 5 score 
- Group A: all four patients required an additional wash prior to POEM
- Group B: one of the patients required wash prior to POEM. 
• All patients had successful esophageal clearance with both approaches. 
• Group B patients had 
- Avoidance of an additional endoscopic procedure for esophageal lavage 
- Decreased risk of aspiration.
- Decreased exposure to anesthesia/ sedation. 
- Decrease in the total POEM procedure time 
- Total cost to the patient was significantly decreased 
- Duration of the hospital stay was reduced
conclusion: The new simple protocol of giving warm water and a carbon-
ated drink just 12 hours before keeping the patient nil orally for anaes-
thesia 
- reduces the starvation time for the patient to 6 hours and hence, im-
proves compliance. 
- reduces one more procedure for esophageal lavage
- reduces the anaesthesia risk of aspiration during induction
- reduces the exposure to anaesthesia 
- and reduces the hospital stay and is cost effective 
We can have a randomised trial to prove the effectiveness of this simple 
protocol in a larger study.
characteristics group a group B
Duration Of Symptoms, Median, months 4(1-60) 6(1-60)
Mean IRP mm Hg (Median) 17.6 (10.4-52.2) 24.2 (12.4- 65.6)
Type I Achalasia; n (%) 22 (44) 35 (70)
Type II Achalasia; n (%) 18 (36) 10 (20)
Type III Achalasia; n (%) 10 (20) 5 (10)
Grade I Mucosa; n (%) 14 (28) 12 (24)
Grade II Mucosa; n (%) 13 (26) 21 (24)
Grade III Mucosa; n (%) 13 (26) 21 (42)
Grade IV Mucosa; n (%) Gr V; n (%) 6 (12) 4 (8) 7(12) 4 (8)
[Findings]
references: •J Neurogastroenterol Motil, Vol. 18 No. 4 October, 2012 •Jour-
nal of Clinical Gastroenterology: June 1998 - vol 26 - Issue 4 p 239 •Clin 
Radiol 1986 Nov;37(6):589-92.
disclosure: Nothing to disclose 
P0163 narrOW-Band-IMagIng: a reLIaBLe IndIcaTOr 
Of gasTrIc dysPLasIa
Magalhaes R.1,2,3, Boal Carvalho P.2,3,4, Rosa B.2,3,4, Cotter J.2,3,4
1Hospital Senhora da Oliveira, Gastrenterology, Guimarães, Portugal, 2Life 
and Health Sciences Research Institute (ICVS), School of Medicine, University 
of Minho, Braga, Portugal, 3ICVS/3B’s, PT Government Associate Laboratory, 
Guimarães/Braga, Portugal, 4Hospital Senhora da Oliveira, Gastrenterology, 
Guimarães, Portugal
contact e-Mail address: rui.magalhaes.med@gmail.com
Introduction: Gastric cancer is a major health concern worldwide, with 
significant morbidity and mortality rates. In western society, screening 
remains controversial regarding cost-efficiency issues. NBI (narrow-band-
imaging) is a virtual chromoendoscopy tool that has been associated with 
higher detection of gastric premalignant conditions in comparison with 
white-light endoscopy (WLE). Endoscopic grading of gastric intestinal 
metaplasia (EGGIM) is a NBI grading score for metaplasia.
aims & Methods: Assess the correlation between NBI and histological di-
agnosis of gastric dysplasia.
Retrospective, single center study, including consecutive patients that un-
derwent upper endoscopy complemented with NBI for gastritis surveil-
lance, from October 2016 to Jan 2019. Our cohort was analyzed by descrip-
tive, parametric and non-parametric SPSS tools.
results: We included 71 upper endoscopies complemented with NBI evalu-
ation, 40 men (56.3%) with a mean age of 62 years old. Gastric dysplasia 
was detected, histologically, in 23 cases (32.4%).
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without any additional drugs or devices.Its principle is recognizing the dif-
ference in optical absorption spectra between oxy- and deoxy-hemoglobin 
by emitting two kinds of lasers from endoscopy. This imaging technology is 
expected to contribute to research into cancer biology which leads to clini-
cal benefit such as prediction to efficacy of chemotherapy or radiotherapy. 
OS imaging supply the StO2 mapping in real time, however, the measure-
ment of StO2 is difficult in some cases of advanced gastrointestinal cancer 
due to covered blood or necrotic tissue. 
Therefore, the algorism for discrimination between tumors and noises due 
to blood or necrotic tissue on tumors is necessary to measure the precise 
StO2 in OS imaging.
aims & Methods: To construct the algorithms for discriminating between 
tumors and its adhered substances using white light imaging (WLI) of gas-
trointestinal cancer, and validate the utility of it in OS imaging.
We classify color of tumors and its adhered substances in WLI into follow-
ing 2 classes of 4 types (red points: red tumors (83 points) and blood (68 
points); white area: white tumors (79 points) and white coat (89 points)), 
and plotting is made at each place in 50 endoscopic tumor images in 
upper digestive tract. As a result, we create scatter diagram using color 
data (RGB value) in WLI, which its X axis is ln(R/G) value and Y axis is 
ln(B/G) value. The minimum and maximum value of the X and Y axes of 
each classes, and linear function as discriminating algorithm for each 
types of areas is constructed by calculating scatter diagram to adjust color 
noises. Discriminating algorithms are verified by using validation data-
sets prepared separately from 15 images out of 50 images in this study, 
and classified each datasets into tumor and color noises. In addition, the 
comparison of StO2 value of the tumors and that of its adhered substances 
is conducted in the images of gastrointestinal tumors captured using OS 
imaging.
results: We randomly selected 50 cases consisting of advanced gastric 
cancer (n=30) and advanced esophageal cancer (n=20) who are simul-
taneously evaluated with WLI and SO imaging, and images are analyzed. 
The calculated algorithms for each areas were as follows: algorism for red 
area; 0.388≤x≤2.610, -0.842≤y≤0.157, Y< 0.77X-1.440; algorithms for white 
area; 0.119≤x≤1.079, -0.577≤y≤0.172, and Y< -0.32X+0.10. In validation da-
tasets of 15 images, each algorithms showed the discriminating accuracy 
between noise due to ad and tumor in red and white area of 87.8% and 
86.0%, respectively.
The analysis resulted that StO2 values (median, [range]) of the area rec-
ognized as tumor and adhered substances by algorithms are follows: all 
captured red area; 75.9%, [44.6.-100.0], red adhered substances; 77.6%, 
[44.6-100.0 ], red tumor; 74.9%, [62.0-86.9], all captured white area; 
66.1%, [42.1-100.0], white adhered substances; 71.4%, [42.1-100.0], white 
tumor: 64.8%, [54.2-71.4]. Analysis of StO2 revealed that the values of tu-
mors except for adhered substances were distributed more specific com-
paring with that of whole tumor.
conclusion: The algorithm for discriminating between tumors and its ad-
hered substances based on the annotated information using WLI can be 
useful for precising StO2 measurement of 
gastrointestinal cancer in OS imaging.
references: nothing
disclosure: Nothing to disclose 
P0166 cOMParIsOn BeTWeen endOscOPIc Band LIgaTIOn 
and argOn PLasMa cOaguLaTIOn fOr The TreaTMenT Of 
gasTrIc anTraL vascuLar ecTasIa: a sysTeMaTIc revIeW 
WITh MeTa-anaLysIs
Cubisino R.1, Losurdo G.1, Scalisi G.2, Perri F.3
1University of Bari, Section of Gastroenterology, Dept. Emergency and 
Organ Transplantation, Bari, Italy, 2Presidio Osp Garibaldi Nesima, 
Gastroenterology, Catania, Italy, 3Casa Sollievo della Sofferenza Hospital, 
Gastroenterology, San Giovanni Rotondo, Italy
contact e-Mail address: rossellacubisino@gmail.com
Introduction: Gastric antral vascular ectasia (GAVE) is a condition charac-
terized by diffuse mucosal vascular ectasia causing chronic gastrointestinal 
blood loss and anemia. It is more common in patients with cirrhosis as 
well as chronic kidney disease, hematologic malignancies, scleroderma, 
systemic lupus erythematosus and other autoimmune diseases. Since 
GAVE is a cause of anemia in the above mentioned chronic illnesses, it 
is important to ensure a treatment that may reduce the morbidity related 
to GAVE in such patients. Argon plasma coagulation (APC) is one of the 
most widespread endoscopic technique for GAVE, however endoscopic 
band ligation (EBL) has gained increasing interest. Therefore we aimed to 
perform a meta-analysis of studies comparing EBL versus APC.
aims & Methods: A literature search was performed in February 2019 us-
ing the following string: (GAVE OR gastric antral vascular ectasia OR wa-
termelon stomach AND band ligation AND APC. We selected only studies in 
which a direct comparison of EBL and APC was performed. For dichotomic 
variables, odd ratios (OR) and 95% confidence intervals (95% CI) were 
calculated according to the Mantel-Haenszel method. For continuous vari-
ables we calculated mean differences (MD). Heterogeneity was estimated 
by chi-square test and, if present, a random effect model was chosen, 
otherwise a fixed effect model was used. Statistical significance was set at 
p < 0.05 and the RevMan 5.3 software was used. All procedures followed 
PRISMA guidelines.
results: Five studies were selected, enrolling overall 207 patients (93 EBL 
and 114 APC). Pooled effectiveness of EBL was 91.4%, statistically greater 
than 57.9% of APC (OR=8.4; 95% CI 3.45-20.43; p< 0.001, no heteroge-
neity, fixed effect). Complication rate was 27.2% and 13.0% for EBL and 
APC respectively, not statistically different (OR=3.09, p=0.28). EBL allowed 
a fewer number of endoscopy sessions than APC with a p value close to 
significance (MD=-1.28 95% CI -2.62-0.05; p=0.06). With EBL, the mean 
number of transfused blood units was lower than for APC (MD=-1.55; 95% 
CI -3 to -0.09; p=0.04; random effect for high heterogeneity). Post-treat-
ment hemoglobin levels were higher in the EBL group than in APC group 
(MD=0.43; 95% CI 0.11-0.75; p=0.009 fixed effect, no heterogeneity) and, 
in comparison to baseline hemoglobin, EBL showed a significantly higher 
increase in levels than APC (p=0.02).
conclusion: EBL was more effective than APC in treating GAVE since a 
better control of anemia, a fewer number of red cell transfusions, and a 
higher rise in hemoglobin levels were achieved. A non significant trend 
showed that less endoscopic sessions were required with EBL which could 
be proposed as a potential cost-effective modality compared to APC. How-
ever, the low number of patients enrolled in this analysis prompts the 
development of further randomized trials aiming to evaluate EBL and APC 
for GAVE treatment.
disclosure: Nothing to disclose 
P0167 rOBOT cOnTrOLLed MagneT-assIsTed caPsuLe 
gasTrOscOPy Is BeTTer TOLeraTed and accePTed By PaTIenTs 
Than fLexIBLe gasTrOscOPy
Tai F.W.D.1, Ching H.L.1, McAlindon M.2
1Royal Hallamshire Hospital, Academic Unit of Gastroenterology and 
Hepatology, Sheffield, United Kingdom, 2Royal Hallamshire Hospital, Dept. of 
Gastroenterology, Sheffield, United Kingdom
contact e-Mail address: david.tai@nhs.net
Introduction: Gastroscopy is performed commonly but often poorly toler-
ated. Capsule endoscopy is well tolerated. Robot controlled magnet as-
sisted capsule endoscopy (MACE) allows control of a capsule endoscope 
resulting in a non-invasive endoscopic examination of the upper GI tract. 
No controlled comparisons of patient tolerance and acceptability between 
MACE and gastroscopy have been performed. Post procedure Endoscopy 
Concerns Scale (ECS) scores correlate with patient acceptance after gas-
troscopy [Condon 2008, Can J Gastro]. We assess tolerance and acceptabil-
ity of MACE compared to OGD using the ECS.
aims & Methods: Patients referred for the endoscopic investigation of 
dyspepsia were recruited. Upper GI MACE examinations were performed 
followed by oral or transnasal gastroscopies. Questionnaires examined pa-
tients’ tolerance to and acceptability of the endoscopies. Paired differences 
between median distress and ECS scores are reported (p< 0.0001***, p< 
0.01**)
results: Thirty eight (oral n=33, transnasal n=5) patients were recruited 
(median age 50, female 74%, sedated in 36.4% of oral gastroscopy). All 
patients tolerated MACE adequately with minimal discomfort in 16%. Gas-
troscopy was adequately tolerated in 63% with the remaining reporting 
moderate or severe discomfort. There was less distress (1 - 10: not at all 
- extremely) caused by: discomfort during (1 vs 5***), discomfort after (1 
vs 2***) and pain during (1 vs 2***) the procedures, gagging (1 vs 6***), 
choking (1 vs 4.5***), bloating (1 vs 2**) and swallowing the capsule vs. 
insertion of the scope (1 vs 4***) with MACE compared to gastroscopy. The 
overall pre-procedure ECS score (28 vs 50 points***) and post-procedure 
ECS score (13 vs 32 points***) was lower after MACE compared to gastros-
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clinical success. The procedure appears to be relatively safe, and a mini-
mally invasive alternative to surgery in expert hands. Further prospective 
studies and technique standardisation are warranted to generalise these 
results.
disclosure: Nothing to disclose 
P0169 endOscOPIc and cLInIcOPaThOLOgIcaL feaTures 
Of nOn-aMPuLLary duOdenaL TuMOr Based On The MucIn 
PhenOTyPes
Akazawa Y.1, Ueyama H.1, Tsuyama S.2, Abe D.1, Oki S.1, Suzuki N.1, 
Ikeda A.1, Yatagai N.1, Komori H.1, Izumi K.1, Takeda T.1, Matsumoto K.1, 
Ueda K.1, Matsumoto K.1, Asaoka D.1, Mariko H.1, Yao T.2, Nagahara A.1
1Juntendo University School of Medicine, Gastroenterology, Tokyo, Japan, 
2Juntendo University Graduate School of Medicine, Human Pathology, Tokyo, 
Japan
contact e-Mail address: yakazawa@juntendo.ac.jp
Introduction: Superficial non-ampullary duodenal epithelial tumors (SNA-
DET) are relatively rare. In a few studies, the association between clini-
copathological features and mucin phenotypes was analyzed, and they 
reported that the gastric phenotype of SNADET showed more aggressive 
biological behavior than those of the intestinal phenotype [1-3]. However, 
the association between mucin phenotypes and endoscopic features in 
SNADET has not been well elucidated.
aims & Methods: We aimed to clarify the clinicopathological and endo-
scopic features including conventional white-light imaging (WLI) and 
magnifying endoscopy with narrow-band imaging (M-NBI) findings based 
on the mucin phenotypes. We collected 65 lesions of SNADET which were 
resected by endoscopic procedures at our hospital between February 2013 
and November 2017. Eleven lesions were excluded as follows; 3 lesions 
with insufficient histopathological evaluation due to specimen damage, 
1 lesion diagnosed cancer arising from juvenile polyp, and 7 lesions with 
unclassifiable mucin phenotype. The remaining 54 lesions were classified 
into two groups immunohistochemically: the gastric predominant pheno-
type (GPP) and the intestinal predominant phenotype (IPP). Endoscopic 
and clinicopathological findings were compared between the two groups.
results: There were 11 lesions of the GPP and 43 lesions of the IPP. All 
lesions of the GPP were located in the first portion (100%, 11/11), while le-
sions of IPP were located more often in the second portion (72.1%, 31/43) 
(p< 0.01). The mean tumor size of the GPP was larger than that of the IPP 
(14.4 mm [range: 7-25] vs. 10.2 mm [2-30], p< 0.05). Type 0-I (72.7%, 8/11 
vs. 5/43, 11.6%, p< 0.01), reddish color (72.7%, 8/11 vs. 16/43, 37.2%, p< 
0.05), lobular/granular pattern (81.8%, 9/11 vs. 4.7%, 2/43, p< 0.01), cat-
egory 4/5 (mucosal high-grade neoplasia/submucosal invasion by carci-
noma) in Vienna classification (81.8%, 9/11 vs. 30.2%, 13/43, p< 0.01) were 
observed more frequently in the GPP than in the IPP. No significant differ-
ences were observed in terms of the mean age (GPP vs. IPP=67.3 years vs. 
65.2 years, p=0.72), gender (male/female=9/2 in GPP, 26/17 in IPP, p=0.29), 
operative method (EMR/ESD=8/3 in GPP, 30/13 in IPP, p=1.00). M-NBI find-
ings were assessed in 48 lesions. All lesions showed demarcation line 
(DL) clearly (100%, 48/48). White opaque substance (WOS) (22.2%, 2/9 
vs. 89.7%, 35/39, p< 0.01) and light blue crest (LBC) (0%, 0/9 vs. 43.6%, 
17/39, p< 0.05) were less frequently observed in the GPP than in the IPP. 
Vessels within epithelial circle pattern (VEC) (66.7%, 6/9 vs. 17.9%, 7/39, 
p< 0.01), dense pattern (55.6%, 5/9 vs. 2.6%, 1/39, p< 0.01), and dilatation 
of intervening part (DIP) (100%, 9/9 vs. 12.8%, 5/39, p< 0.01) were more 
frequently observed in the GPP than in the IPP.
conclusion: Endoscopic and clinicopathological features of the GPP were 
as follows: located in the first portion, reddish color, type 0-I, lobular/
granular pattern, VEC, dense pattern, DIP, and high frequency of the cat-
egory 4/5 in Vienna classification. On the other hand, those of the IPP were 
as follows: located in second or third portion, whitish color, type 0-IIa or 
IIc, WOS, LBC, and high frequency of the category 3. These features are 
useful to distinguish the mucin phenotypes of SNADET.
references: 1. Toba T, Inoshita N, Kaise M, Nomura K, Kuribayashi Y, Tanaka 
M, Yamashita S, Furuhata T, Kikuchi D, Matsui A, Mitani T, Iizuka T, Hoteya 
S (2018) Clinicopathological features of superficial non-ampurally duode-
nal epithelial tumor; gastric phenotype of histology correlates to higher 
malignant potency. J. Gastroenterol. 53:64-70. 2. Ushiku T, Arnason T, Fu-
kayama M, Lauwers GY (2014) Extra-ampullary duodenal adenocarcinoma. 
Am. J. Surg. Pathol. 38:1484-1493. 3. Hida R, Yamamoto H, Hirahashi M, 
Kumagai R, Nishiyama K, Gi T, Esaki M, Kitazono T, Oda Y (2017) Duodenal 
copy suggesting patients are more accepting of MACE before and after the 
procedure compared to gastroscopy. There was a reduction in pre-proce-
dure ECS after both MACE (median difference -15 ***) and gastroscopy (-18 
***) suggesting procedures are not as distressing as initially anticipated, 
however 32% of patients report a higher ECS after gastroscopy whereas all 
patients reported a lower ECS after MACE. 
All patients would undergo, or advise a friend to undergo MACE again 
given the same medical circumstances compared to 71% and 79% of pa-
tients when undergoing gastroscopy. All patients would have MACE as a 
screening test for cancer compared to 79% of patients when undergoing 
gastroscopy. If biopsies were required after MACE, patients would require 
a further gastroscopy. When asked, in retrospect after having both proce-
dures, if the chance of requiring biopsies was 1:20, 1:10, 1:5, 1:4 and 1:2, 
91%, 91%, 82%, 73% and 73% of patients respectively would prefer to 
have initial MACE.
conclusion: Patients better tolerate, are more accepting of and prefer 
MACE over gastroscopy. Where biopsies are required, patients would 
still prefer capsule endoscopy initially. Cost effectiveness of this approach 
should be examined.
references: Condon A, Graff L, Elliot L, Ilnyckyj A. Acceptance of colonosco-
py requires more than test tolerance. Can J Gastroenterol 2008; 22(1): 41-7.
disclosure: Nothing to disclose 
P0168 endOscOPIc uLTrasOund-guIded gasTrO-enTerIc 
anasTOMOsIs: a sysTeMaTIc revIeW and MeTa-anaLysIs
Antonelli G.1, Kovacevic B.2, Gasdal Karstensen J.3, Kalaitzakis E.2,4, 
Vanella G.1, Hassan C.5, Vilmann P.2
1Sapienza Università di Roma at Sant’Andrea University Hospital, Digestive 
and Liver diseases Unit, Roma, Italy, 2Copenhagen University Hospital Herlev, 
Gastro Unit, Division of Endoscopy, Copenhagen, Denmark, 3University 
Hospital Hvidovre, Gastro Unit, Hvidovre, Denmark, 4University Hospital of 
Heraklion, University of Crete, Department of Gastroenterology, Heraklion, 
Greece, 5Nuovo Regina Margherita Hospital, Digestive Endoscopy Unit, 
Rome, Italy
contact e-Mail address: giulio.antonelli@gmail.com
Introduction: Endoscopic ultrasound (EUS)-guided gastro-enteric anasto-
mosis using lumen-apposing metal stents (LAMS)is emerging as an alter-
native, minimally invasive therapy for treating gastric outlet obstruction 
(GOO), as well as restoring bowel continuity in patients with surgically 
altered anatomy. Literature on this subject is heterogeneous, with variable 
reporting of techniques and outcomes.
aims & Methods: Our aim was to perform a meta-analysis of published 
data on EUS-guided enteric anastomosis, providing a pooled estimate of 
technical and clinical outcomes. 
The protocol was registered in PROSPERO (Reg. no. CRD42018111110). 
PubMed, Embase, Scopus, and Web of Science databases were searched 
until February 2019 for studies describing at least 5 patients undergoing 
EUS guided enteric anastomosis. Screening of titles/abstracts, full-text 
review, and data extraction was performed independently by two of the 
authors. Data regarding indication, technique, technical and clinical suc-
cess, adverse events, and follow-up were collected. PRISMA methodology 
was used. Pooled technical and clinical success rates as well as pooled 
adverse events rates were calculated. Study quality, publication bias, and 
heterogeneity were explored.
results: Twelve studies including 290 patients were included, published 
between 2016 and 2019. All studies but one were retrospective. The main 
procedure indication was GOO (62.4%), followed by need for ERCP (27.9%) 
in patients with gastric bypass surgery. Direct puncture technique was the 
most frequently adopted (68.2%). The pooled technical success rate (12 
studies, 290 patients) was 93.5% [95% confidence interval (CI) 89.7-6.0%; 
I2:0%], while the clinical success rate (11 studies, 260 patients) was 90.1% 
[95% CI 85.5-93.4%; I2:0%]. The pooled total adverse events rate was (11 
cohorts, 261 patients) was 11.7% [95% CI 8.2-16.6; I2:0%]. When stratified 
for adverse event severity, the mild/moderate pooled adverse event rate 
was 10.6% [95% CI 7 -15.6; I2:3.4%], while the severe/fatal adverse event 
rate was 2.9% [95% CI 1.4-6; I2:0%]. Mean procedure time was 63.5±35.7 
minutes, and mean length of hospital stay was 4.9±2.7 days.
No publication bias or significant heterogeneity was found, although some 
included studies were graded as low quality.
conclusion: EUS-guided enteric anastomosis, when performed by expert 
endoscopists in tertiary referral centres, has a high rate of technical and 
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Neoplasms of Gastric Phenotype: An Immunohistochemical and Genetic 
Study With a Practical Approach to the Classification. Am. J. Surg. Pathol. 
41:343-353.
disclosure: Nothing to disclose 
P0170 cOMParIsOn Of MedIcaL cOsT BeTWeen duOdenaL 
and gasTrIc esd
Mizutani M.1,2, Kato M.1,2, Tsutsumi K.2, Kiguchi Y.2, Akimoto T.2, 
Takatori Y.2, Fukuhara S.3, Nakayama A.2, Maehata T.2, Kanai T.1, Yahagi N.2
1Keio University School of Medicine, Department of Internal Medicine, 
Division of Gastroenterology and Hepatology, Tokyo, Japan, 2Keio University 
School of Medicine, Division of Research and Development for Minimally 
Invasive Treatment, Cancer Center, Tokyo, Japan, 3Keio University School of 
Medicine, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan
contact e-Mail address: marimizutani6@gmail.com
Introduction: Duodenal ESD (D-ESD) is reported to be technically difficult 
and at high risk of adverse events such as bleeding and perforation. Thus, 
it is expected D-ESD would require more medical cost than gastric ESD 
(G-ESD), however, actual costs of D-ESD are still unknown, since there are 
only few studies.
aims & Methods: The aim of this study was to analyze the actual cost of 
D-ESD and compare with G-ESD, including analysis according to the ele-
ments of procedure .This is a single-center, retrospective cross-sectional 
survey,Medical costs were calculated among patients who underwent D-
ESD or G-ESDfrom July 2016 to June 2017. Medical costs were calculated in 
summation of the costs of anesthesia, costs of devices for procedure, costs 
of materials to prevent adverse events, costs of intervention for adverse 
events, and hospitalization costs. Hospitalization costs were extracted in 
reference to the “diagnosis procedure combination” reimbursement sys-
tem in Japan. The costs of devices and materials were calculated from the 
number of items actually used from medical records. We analyzed by using 
Wilcoxon rank sum test and a p value < 0.05 was considered statistically 
significant.
results: A total of 49 cases of D-ESD and 107 cases of G-ESD were included 
in the study. Total medical costs in D-ESD group was significantly higher 
than in G-ESD group. As for the breakdown, the costs of the anesthesia, 
costs of materials to prevent adverse events, and hospitalization costs were 
significantly higher in D-ESD group than in G-ESD group, whereas there 
was no difference between two groups for costs of devices used for treat-
ment and the additional treatment for the adverse events (Table1). 
costs (€) g-esd (n=107) d-esd (n=49) P value
Median costs of anesthesia, 
Eur [range]
55 [8-1,079] 142 [27-3,230] <0.001
Median costs of devices for 
procedure, Eur [range]
328 [208-584] 328 [208-584] 0.338
Median costs of prevention 
for adverse events, Eur 
[range]
0 [0-697] 86 [0-839] <0.001
Median costs of intervention 
for adverse events, Eur 
[range]
0 [0-756] 0 [0-3416] 0.904
Median hospitalization costs 
of, Eur [range]
1,800 [1,297-14,546] 2,086 [1.420-15,119] <0.001
Median total medial costs, 
Eur [range]
2,498 [1,795-12,971] 3,232 [2,243-22,219] <0.001
[Table1: Actual medical costs during hospitalization for ESD]
conclusion: The medical costs of D-ESD are more expensive than G-ESD, 
especially for the anesthesia and prevention for adverse events.
disclosure: Nothing to disclose 
P0171 drug adMInIsTraTIOn WITh PercuTaneOus 
endOscOPIc gasTrOjejunOsTOMy: a nOveL TreaTMenT 
OPTIOn fOr ParkInsOn’s dIsease
Yamashita K.1, Tsuboi Y.2, Fujioka S.2, Okada H.1, Mishima T.2, Shiwaku H.1, 
Ohmiya T.1, Hasegawa S.1
1Fukuoka University Faculty of Medicine, Department of Gastroenterological 
Surgery, Fukuoka, Japan, 2Fukuoka University Faculty of Medicine, 
Department of Neurology, Fukuoka, Japan
contact e-Mail address: matubara666@gmail.com
Introduction: The incidence of Parkinson’s disease (PD) sharply increases 
with age and, due to the progressive aging of the world’s population, the 
number of affected individuals is likely to exponentially increase in the 
near future. However, it is difficult to maintain therapeutic plasma concen-
trations of levodopa after oral levodopa administration in patients with ad-
vanced PD due to the narrow therapeutic range and delayed gastric empty-
ing. Levodopa-carbidopa intestinal gel (LCIG) therapy, a new drug delivery 
system for patients with advanced PD, has been covered by insurance in 
Japan since September 2016. LCIG is administered by using a percutaneous 
endoscopic gastrojejunostomy (PEG-J) system and helps maintain thera-
peutic plasma concentrations of levodopa. However, the LCIG administra-
tion cannot be achieved without PEG-J, which is the main hindrance to its 
introduction. Additionally, close collaboration between neurologists and 
gastroenterologists is very important.
LCIG therapy was introduced in our hospital in January 2017. This study 
investigated the usefulness and safety of the LCIG treatment system.
aims & Methods: In LCIG therapy, a nasojejunal (NJ) feeding tube is in-
dwelled and a test administration of LCIG is performed. After confirming 
reactivity and tolerability, gastrostomy is performed by the “pull” method 
and a PEG-J tube is inserted. We examined 11 patients who underwent 
LCIG therapy at our hospital from January 2017 to September 2018. The 
initial six cases used PEG-J tube insertion with the standard procedure, 
while the more recent five cases used it with the modified procedure. The 
modified procedure for placement of the PEG-J tube is as follows: after 
guiding the PEG-J tube to the jejunum with the grasping forceps using 
an endoscope, pull back only the endoscope to the stomach leaving the 
PEG-J tube with grasping forceps at the jejunum. Then, release the PEG-J 
tube and pull back the grasping forceps to the stomach. This method will 
prevent interference between the PEG-J tube and the endoscope.
results: Out of the 11 patients, three were male and eight were female, and 
the mean age was 69.5±6.4 years old. Placement of the NJ tube was per-
formed in eight patients, and, in three patients, the NJ tube placement was 
skipped, and gastrostomy and PEG-J were performed. The operation time 
for the placement of the NJ tube was 13.1±4.8 minutes (9 to 20 minutes), 
and for gastrostomy and the placement of the PEG-J, it was 45.6±28.4 min-
utes (20 to 120 minutes). PEG-J could be safely performed in all patients. 
The operation time for gastrostomy and the placement of the PEG-J of the 
modified procedure (27±6.7 min) was significantly shorter than that of the 
standard procedure (61.0±30.7 min) (p< 0.05). All patients responded well 
to LCIG regarding neurological outcomes.
conclusion: Although there are differences among the currently used 
PEG-J systems, the LCIG treatment system could be used without major 
problems. Moreover, the modified procedure could shorten the operation 
time for gastrostomy and the placement of the PEG-J. For its introduction, 
the close collaboration between the neurologist and the co-medical staff 
proved to be important. The LCIG treatment system is a new and useful 
treatment option for PD and requires understanding and cooperation on 
the part of endoscopists.
disclosure: Nothing to disclose 
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results: Fifty-eight patients (mean age 71.5 years, F/M ratio 1.5:1) have 
been evaluated over the study period. Of 53 patients undergoing PEG-
J placement at our Unit, no immediate AEs were reported. Short-term 
(within 30 days) AEs (1 kinking, 3 dislocations, and 1 obstruction of the 
jejunal extension) occured in 5 patients (9.43%); while delayed (after 30 
days) AEs (2 obstructions, 3 tube malfunctions, and 1 pyloric ulcer) were 
registered in 6 patients (11.32%). The median duration of the original PEG-
J was 10.66 months (range 1-24 months). 
Of the 113 tube replacement performed, no immediate AEs were registered 
and only in 2 cases (1,76%) a second procedure was necessary within the 
first 30 days due to dislocation of jejunal extension. A delayed AE occurred 
in 21 cases (18,58%; 6 obstructions, 2 buried bumper syndromes, 6 dislo-
cations, 7 malfunctions). The median duration was 10.96 months (range 
1-34 months). 
The risk of developing an AE was not reduced if tube replacement was 
performed electively (p=0.96). No serious complications were reported.
conclusion: Differently from what is stated in previous literature (Devos, 
French Duodopa Study Group, 2009), PEG-J placement is a safe procedure, 
particularly in patients with PD. An elective tube replacement after one 
year is not strictly recommended, since the durability is variable among 
patients and an elective replacement does not significantly reduce the 
number of following AEs.
disclosure: Nothing to disclose 
P0174 LanreOTIde and endOscOPIc gasTrOsTOMy In 
InTesTInaL OccLusIOn frOM gynaecOLOgIcaL cancers: 
avIanO naTIOnaL cancer InsTITuT exPerIence
Cannizzaro R.1, Giorda G.2, Fornasarig M.1, Maiero S.1, Magris R.1, 
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Introduction: Bowel obstruction represents a common condition of gyn-
aecological cancer. The aim of this study was to evaluate the efficacy of a 
combined treatment with the somatostatin analogue Lanreotide and per-
cutaneous endoscopic gastrostomy (PEG) in the clinical management of 
advanced ovarian cancer with intestinal occlusion.
aims & Methods: 93 consecutive patients with advanced abdominopelvic 
carcinomatosis were enrolled in the study between November 1998 and 
December 2012. In particular, we investigated safety and efficacy of soma-
tostatin analogue lanreotide, 30 mg every 10-14 days, alone or in combi-
nation with PEG.
results: Seventy-seven patients were treated with Lanreotide, and 27 of 
them underwent also PEG. The median age was 52,3 years, and the me-
dian follow-up was 13 months. After 2 lanreotide administrations, we ob-
served reduction of nausea in 56.3% of patients, of vomiting in 52.7%, 
of abdominal distension in 60%, and of colic pain in 67.2%. In no cases, 
drug-related side effects were observed. In patients who received lanreo-
tide and PEG, there was a significant reduction in gastrointestinal secre-
tions, with a real benefit for the patient also during the home care.
conclusion: The integrated and combined treatment with Lanreotide 30 
mg and PEG is effective in patients with advanced abdominopelvic cancers. 
A constant overall benefit for the quality of life was observed and the con-
trol of symptoms, which is very important especially during the home care 
follow-up of terminal patients.
disclosure: Nothing to disclose 
P0172 POsTOPeraTIve BLeedIng rIsk afTer gasTrIc 
endOscOPIc suBMucOsaL dIssecTIOn durIng anTIThrOMBOTIc 
TheraPy
Yamauchi K., Nagahara T., Suto K., Seki H., Yasuhara H., Jinnno H., 
Moriya A., Nakatsu M., Ando M.
Mitoyo General Hospital, Gastroenterology, Kanonji, Japan
contact e-Mail address: yamauchi.kenji@hotmail.com
Introduction: Little is known about the safety of gastric endoscopic submu-
cosal dissection (ESD) during antithrombotic therapy. In 2017, after several 
guideline updates, the Japan Gastroenterological Endoscopy Society rec-
ommended ESD under the continuation of aspirin/warfarin for patients 
with high thrombotic risk.
aims & Methods: We aimed to evaluate the post-ESD bleeding rate and risk 
factors in patients receiving antithrombotic therapy. The medical records 
of 622 patients with gastric neoplasms treated by ESD at Mitoyo General 
Hospital between April 2009 and December 2018 were retrospectively ana-
lysed. The following patient/tumour clinical parameters were analysed: 
age, sex, comorbidities, antithrombotic drug type, antithrombotic drug 
management (complete cessation, continued, or heparin replacement), 
macroscopic findings, location, invasion depth, resected specimen diam-
eter, and operative time. Post-ESD bleeding was defined as an episode of 
hematemesis/melena or a decrease in haemoglobin (>2 g/dL).
results: Of 622 patients, 140 underwent ESD during antithrombotic therapy. 
The post-ESD bleeding rate was significantly higher in patients receiving 
therapy than in those not receiving therapy (22.4% vs 5.4%, P=0.009; log-
rank test). In a multivariate analysis, the combined use of antiplatelet and 
anticoagulant drugs (odds ratio [OR] 13.1, 95% confidence interval [95%CI] 
1.3-132) and tumours in the lesser curve (OR 0.28, 95%CI 0.08-0.99) were 
significant risk factors for post-ESD bleeding, while antithrombotic therapy 
continuation/cessation was not.
conclusion: Gastric ESD under the continuation of aspirin/warfarin is ac-
ceptable. However, the combined use of antiplatelet and anticoagulant 
drugs is associated with a higher risk of post-ESD bleeding.
references: Kato M, Uedo N, Hokimoto S, Ieko M, Higuchi K, Murakami K, 
et al. Guidelines for Gastroenterological Endoscopy in Patients Undergoing 
Antithrombotic Treatment: 2017 Appendix on Anticoagulants Including Di-
rect Oral Anticoagulants. Digestive endoscopy : official journal of the Japan 
Gastroenterological Endoscopy Society. 2018;30(4):433-40.
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P0173 safeTy and duraBILITy Of Peg-j: a sIngLe-cenTre 
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contact e-Mail address: sara.cococcia@gmail.com
Introduction: Percutaneous endoscopic gastrostomy with jejunal extension 
(PEG-J) is currently the gold standard for delivering levodopa-carbidopa 
duodenal infusion therapy in patients suffering from Parkinson’s disease 
(PD). Data regarding the safety and durability of PEG-J are still lacking. Aim 
of this study was to review short- and long-term safety of PEG-J first posi-
tioning and any tube replacement in a cohort of patients with PD referred 
to our Endoscopy Unit.
aims & Methods: We retrospectively collected data from 58 patients (53 with 
PD and 5 with other neurological conditions) with a PEG-J referred to our 
Endoscopy Unit between March 2010 and August 2018 (53 underwent PEG-J 
placement in our Unit, 5 patients elsewhere). We used descriptive statistics 
to define prevalence of short- and long-term adverse events (AEs) related to 
PEG-J placement or after any tube replacement. As many substitutions were 
performed electively, as suggested by the PEG-J manufacturers, Chi-square 
with Yates’ correction was used to compare the number of AEs following 
tube replacement on either a programmed or on an urgent basis.
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P0175 rIsk facTOrs fOr BacTereMIa afTer LOW rIsk 
endOscOPIc PrOcedures WITh a fOcus On neuTrOPenIa
Isenberg Y.1, Zamstein N.2, Horesh N.3, Bar-Yoseph H.4
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contact e-Mail address: yoniisenberg15@gmail.com
Introduction: risk for bacteremia following endoscopic procedures varies 
among studies. A low neutrophil count is considered by some to be a risk 
factor. We assessed risk factors for bacteremia in low risk endoscopic pro-
cedures and risk for post procedural complications in neutropenic patients.
aims & Methods: A retrospective analysis of all inpatients undergoing low 
risk endoscopic procedure (esophago-gastro-duodenoscopy (EGD), short 
colonoscopy and colonoscopy) between 2005-2018 with a neutrophil level 
taken within 72 hours prior to procedure at our hospital. Data was re-
trieved using MDClone’s query engine and was manually validated. Neu-
tropenia was defined as neutrophil level < 1000 cell/µl. Primary outcome 
was new onset bacteremia within 48 hours after the procedure. Secondary 
composite endpoints in patients with neutropenia included mortality with-
in 7 days of the procedure, new onset of fever, bacteremia or hemodynamic 
instability within 48 hours following the procedure. As a comparator in-
vasive procedure, rate of new onset bacteremia was estimated following 
bronchoscopic procedures. Mean comparison for numerical variables was 
done using t-test. Categorical variables were compared using either a 
Chi-squared test or Fisher’s exact test. The multivariate logistic regres-
sion models were built by using stepwise forward selection and backward 
elimination.
results: 13168 patients were included, out of which 167 procedures were 
performed in the setting of neutropenia. The mean age was 61 years and 
EGD was the most common procedure (56%). Post-procedural bacteremia 
was recorded in 103 (0.8%) and 7 (4.2%) of the general cohort and patients 
with neutropenia, respectively. Neutropenia (OR 3.2), low albumin level 
(OR 0.33), male gender (OR 1.71), older age (OR 1.02), fever before proce-
dure (OR 2.09) and ICU/hematologic department settings were associated 
with increased risk for bacteremia in the general study population, in both 
univariate and multivariate analysis. A multivariate model including these 
factors was predictive of bacteremia (AUC 0.82, 95% CI 0.78-0.88). Bac-
teremia was associated with increased risk of mortality. Among patients 
with neutropenia, secondary composite endpoints were more frequent in 
patients admitted to the hematology department and with low albumin 
level. Antibiotics or granulocyte stimulating factor before procedure were 
not associated with a decreased risk for adverse outcomes. In comparison 
with GI endoscopic procedure, the risk for bacteremia was significantly 
higher among patients that underwent bronchoscopy (1.85% vs. 0.78%, 
respectively), but not significant among neutropenic patients undergoing 
these procedures (1.8% vs. 4.2%, respectively).
conclusion: we report a low incidence of post-endoscopic bacteremia in 
our center. Low neutrophil level was found to be a risk factor for bacte-
remia. A model highly predictive of bacteremia was developed. Further 
studies to assess these factors are needed.
disclosure: Nothing to disclose 
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LOss-a BrazILIan sTudy
Hoff A.1,2, Barrichello S.3, Galvao M.4, Queiroz Sander B.5, 
Fittipaldi-Fernandez R.J.6
1Angioskope, Bariatric Endoscopy, São Paulo, Brazil, 2Angioskope, Bariatric 
Endoscopoy, São José dos Campos, Brazil, 3Healthme Clinic, Endoscopy, 
Sao Paulo, Brazil, 4ABC Medical School, São Paulo, Brazil, 5Sander Medical 
Center, Bariatric Endoscopy, Belo Horizonte, Brazil, 6Endogastro Med Service, 
Digestive Endoscopy, Rio de Janeiro, Brazil
contact e-Mail address: nathoff@yahoo.com
Introduction: Adjustable Balloon Therapy (ABT) is an effective minimal 
invasive technique for weight loss, proven widely. However, there is no 
published study comparing results using:1- Non-modified volume during 
the 12-month treatment;2-Submitted to upward adjustment with a fixed 
volume; 3-Associated with Liraglutide and 4- A combination of items 2 
and 3.
aims & Methods: From December 2016 to December 2017 were analyzed 
159 patients (mean age 37.96±22.15, female 77.85%) who underwent and 
completed the 12-month therapy. 40 patients maintained initial volume 
until retrieval (IGB group). 35 received Liraglutide daily, initiated one 
month after implant, mean dose 2,18±0,53 mg for 9 consecutive months 
(LG group). 53 underwent the upward adjustment with 200 ml of sterile 
saline (mean 166days ±17,11 after placement) (UP group). 34 were sub-
mitted to both Liraglutide and upward adjustment (LGUP group). 3 in 
the UP and 1 in the LGUP group excluded. Percentage Total Body Weight 
Loss(%TBWL), Percentage Excess Weight Loss(%EWL), Body Mass Index 
(BMI) difference analyzed after balloon retrieval by the Kruskal-Wallis and 
the Wilcoxon test. The p set to ≤.005
results: 
  IgB grOuP Lg grOuP LguP grOuP uP grOuP
(F)BMI-(I)BMI 6.14±1.99 7.72±2.42 7.69±1.84 5.97±2.21 #
%TBWL 18.18±3.66 22.53±3.64**** 22.1±3.31**** 17.14±4.68
%EWL 71.66±18.45 86.62±25.09* 80.56±15.96 61.82±16.34**
[Results]
#p=0.0205;****p<0.0001;*p=0.0252;**p=0.0392
conclusion: The LG and the LGUP group presented the highest %TBWL, 
%EWL and BMI difference and had no statistical difference between, em-
phasizing Liraglutide efficiency. However, complications regarding upward 
adjustment should be considered. Liraglutide costs should be summed up.
disclosure: Nothing to disclose 
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nOrMaL dIgesTIve MucOsa: a PrOMIsIng TOOL fOr The sTudy 
Of The dIgesTIve BarrIer
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1University Hospital of Nantes, Digestive Disease Institute, Nantes, France, 
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Introduction: Full-field optical coherence tomography (FF-OCT) is a non-
invasive imaging technique, based on interferometry, allowing dynamic 
acquisition of images of ex vivo specimens on a microscopic scale.
aims & Methods: 
The aim of this study was to demonstrate the feasibility of imaging normal 
digestive biopsies using FF-OCT.
We enrolled adult subjects scheduled for an endoscopy with biopsies, 
who had no history of digestive disease. We a posteriori excluded patients, 
whose biopsies showed abnormal aspects at pathological examination. 
Four biopsies were sampled, 2 for pathological examination, 2 for im-
mediate FF-OCT analysis, from 5 different locations: esophagus, gastric 
antrum, gastric fundus, duodenum or colon. Fresh biopsies were scanned 
using the LL-Tech benchtop scanner in order to perform an optical slicing 
beneath the tissue surface at selected depths (static mode) and a mea-
surement of intracellular activity data (dynamic mode). Biopsies were then 
fixed in formaldehyde, sliced in a longitudinal plane parallel to the surface 
and stained using hematoxylin-eosin. FF-OCT images and pathological 
slides were then reviewed with the assistance of a senior pathologist.
results: We enrolled 25 patients with normal biopsies of the esophagus 
(n=5), gastric fundus (n=10), gastric antrum (n=10), duodenum (n=7) and 
colon (n=6). Specific histological structures of each organ were clearly 
identified in 100% of FF-OCT images. For instance, the cellular structure of 
esophageal squamous epithelium with papillae, gastric crypts and glands, 
duodenal villi and colonic crypts was clearly seen at a 1µm resolution.
conclusion: FF-OCT allows a morphological and functional analysis of di-
gestive tissues on fresh routine endoscopic biopsies, at a subcellular scale. 
It is a promising tool for the study of the digestive barrier.
disclosure: Nothing to disclose 
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aims & Methods: Data collection was performed on the clinical outcomes 
from the patients who underwent colorectal resection against malignant 
colorectal obstruction between January 2012 and June 2018. A total of 22 
patients were included in this analysis. Eleven patients received SEMS 
placement as BTS (Group A), and 11 patients received nasal ileus tube or 
emergency surgery (Group B). We retrospectively investigated the techni-
cal and clinical success rates of SEMS placement, the short-term outcomes 
(postoperative complication rate and 30-day mortality rate) and the long-
term outcomes (progression free survival and overall survival).
results: The mean age of the patients was 71 years (group A) and 77 years 
(group B), respectively. The male-to-female ratios were 3:8 (groupA) and 
9:2 (group B). Tumor sites (cecum/ ascending/ transverse/ descending/ 
sigmoid/ rectum) were 0/1/1/2/5/2 (group A) and 5/0/3/1/1/1 (group B). The 
pStages (I/II/III/IV) were 0/4/4/3 (group A) and 0/1/5/5(group B), which 
were no significant differences between the two groups (p=0.308). In group 
A, the technical and clinical success rates for SEMS was 100% (11/11) and 
91% (10/11). There was one case of stent perforation, but it was coinciden-
tally detected during the elective operation. Regarding of the short-term 
outcomes, the postoperative complication rate was 9% (p=0.269), and the 
postoperative 30-day mortality rate was 0%. As for long-term outcomes, 
there were no significant statistical differences between the two groups in 
progression free survival (p=1.000) and overall survival (p=0.768), using 
the Kaplan-Meier method and long-rank test.
conclusion: In our institute relatively high technical and clinical success 
rates were observed after SEMS placement. There were no significant dif-
ferences of short-term and long-term outcomes between the two groups. 
These findings may suggest that the SEMS as BTS might be one of the op-
tions as long as the placement is successfully performed.
disclosure: Nothing to disclose 
P0181 adenOMa deTecTIOn WITh chrOMO-endOscOPy usIng 
OraL IndIgO carMIne
Kawanishi K., Maekita T., Kitano M.
Wakayama Medical University, Second Department of Internal Medicine, 
Wakayama, Japan
contact e-Mail address: amurosyaa218@yahoo.co.jp
Introduction: Colonoscopy is currently the reference method to detect 
colorectal neoplasia, yet some adenomas remain undetected. Indigo car-
mine staining with various methods has shown interesting results for re-
ducing this miss rate.
aims & Methods: The aim of this study was to determine if the standard 
colonoscopy prep followed by oral indigo carmine intake shows the in-
crease in the adenoma detection rate (adenoma and adenocarcinoma; 
ADR) and the mean number of adenomas per patient (MAP).
We introduced the oral indigo carmine technique to every subject and 
prospectively collected the data, and also performed retrospective review 
of endoscopic reports and medical charts of consecutive patients who un-
derwent colonoscopy before introducing this technique to compare the 
results.
results: 211 subjects were included in the study (105 in indigo group). The 
ADR was not significantly different between the groups; 44.8% in the in-
digo group versus 41.5% in the standard colonoscopy group (odds ratio, 
1.15; 95% confidence interval, 0.9 - 1.52, p = 0.33). MAP was significantly 
greater in the indigo group (1.1) than in the standard colonoscopy group 
(0.81; p = 0.008). For advanced adenomas, the results were 10 (9.5%) and 
7 (6.6%), respectively (p = 0.13).
conclusion: The routine use of oral indigo carmine does not lead to higher 
ADR regardless of higher MAP.
disclosure: Nothing to disclose 
P0179 LOW resIdue dIeT durIng 3 days versus 1 day In 
PreParaTIOn fOr cOLOnOscOPy fOr POPuLaTIOn screenIng 
Of cOLOrecTaL cancer: nOnInferIOrITy randOMIzed cLInIcaL 
TrIaL
Machlab S.1, Brunet E.1, Martínez-Bauer E.1, López P.2, García-Iglesias P.1,3, 
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Introduction: To improve participation in the population screening pro-
gram for colorectal cancer, to guarantee the quality of the exploration and 
to reduce its impact on the patient, it is necessary to provide the safest 
and most tolerable preparation. Although numerous studies have been 
conducted to determine which is the best purgative preparation and its ad-
ministration regimen, no randomized study has been published regarding 
the number of days of low residue diet. Both the European and American 
guidelines give little concrete and low quality recommendation regarding 
the number of days stating “no more than 24 hours” and “several days” 
respectively.
aims & Methods: To assess the efficacy and tolerance to a low-residue 
diet during a day in a comparison with three days in participants referred 
to screening colonoscopy. An equivalence margin of 5% was defined and 
a low diet was assigned during a day (Group A) or three days (Group B, 
control) without other differences in preparation. Participants with chronic 
constipation were given bisacodyl 10mg the night before the colonosco-
py. Boston scale was used to determine the bowel cleansing. Inadecuate 
preparation was defined as a puntuation lesser than 2 in any segment. A 
Likert scale was used for assesing the tolerance to the diet. We present the 
results of a intermediate analysis of the study.
results: We included 210 participants in group A and 211 in group B. An 
adequate randomization was achieved without observing differences in 
age, sex, BMI, treatment with antidepressants, cirrhosis, reduced mo-
bility or constipation. Neither in the time elapsed from the end of the 
preparation until the start of the colonoscopy. In group A 2 participants 
had an inadecuate preparation versus 10 (4.7%) in group B. This is a 
difference of -3, 78% (-6, 88, -1.12% CI 90% unilateral) (p < 0.05). In 
trems of tolerance to diet, group A obtained a maximum tolerance score 
(Likert 1) in 48.5% against 29.9% in B (p < 0.05), while there were no 
significant differences in tolerance to the evacuating preparation, Likert 
1 36.9% Vs. 29.4% (p> 0.05). There were also no differences in the ad-
enoma detection rate, 66.7% vs. 67.8%, nor in the withdrawal time with 
a median of 13 minutes vs. 14 (p> 0.05). In group B, cecal intubation was 
not achieved due to poor cleansing in 5 participants, whereas that did 
not occur in group A.
conclusion: The results of this intermediate analysis show that for the 
preparation of the screening colonoscopy a low residue diet for 1 day is 
noninferior to 3 days and offers a better tolerance.
disclosure: Nothing to disclose 
P0180 The uTILITy Of seLf-exPandaBLe MeTaLLIc sTenT 
as a BrIdge TO surgery agaInsT MaLIgnanT cOLOrecTaL 
OBsTrucTIOn
Akabane M., Kuroda T., Nagaoki Y., Fukuhara T., Hirata D., Tamura T.
Mazda Hospital, Gastroenterology, Hiroshima, Japan
contact e-Mail address: makisky1110@yahoo.co.jp
Introduction: Self-expandable metallic stent (SEMS) placement for ma-
lignant colorectal obstruction has been available from 2012 in Japan. On 
the other hand, SEMS placement as a bridge to surgery (BTS) is not rec-
ommended as a standard treatment of symptomatic left-sided malignant 
colonic obstruction in the European Society of Gastrointestinal Endoscopy 
Clinical Guideline. This is because there have been some concerns that 
SEMS placement has association with worse disease-free and overall sur-
vival. Therefore, we retrospectively investigated the treatment results.
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P0182 a 10-year exPerIence WITh BOWeL PreParaTIOn: 
PredIcTOrs and cOLOnOscOPy OuTcOMes Of InadequaTe 
BOWeL cLeansIng. a Large cOhOrT sTudy
Abu Baker F.1, Mari A.2, Gal O.1, Suki M.1, Ovadia B.1, Kopelman Y.1
1Hillel Yaffe Medical Center, Gastroenterology and Hepatology, Hadera, Israel, 
2Nazareth EMMS Hospital, Department of Gastroenterology, Nazareth, Israel
contact e-Mail address: fa_fd@hotmail.com
Introduction: The last decade brought in an outstanding advancement in 
endoscopic equipment and awareness of colonoscopy quality indicators. 
However, inadequate bowel preparation is still the main obstacle for a 
complete, thorough and quality procedure in a sizable mass of patients, 
constituting one of the most leading indications for repeated procedures. 
In the current study we aimed to identify risk factors associated with in-
adequate bowel preparation and better characterize these patients in our 
practice.
aims & Methods: a retrospective, large cohort, single centre study. Elec-
tronic reports of colonoscopy procedures over a 10-year period were re-
vised. Patients were divided based on the quality of bowel preparation 
into adequate and non- adequate bowel preparation groups. Multivariate 
analysis was performed to identify variables associated with inadequate 
bowel preparation including age, sex, setting (inpatient/outpatient), 
preparation regimen and procedures’ indications. We also examined the 
effect of inadequate preparation on colonoscopy outcome and quality in-
dicators.
results: 28725 patients were included in the study. Of these, 6702 (23.3%) 
had inadequate bowel preparation. In multivariate analysis, increased age 
(OR= 1.015, 95% CI= 1.013-1.017; P< 0.01), male gender (OR =1.353, 95% 
CI=1.286-1.423; P< 0.01) and minority population (OR =1.635, 95%CI=1.531-
1.746; P< 0.01) were significantly associated with inadequate bowel 
preparation. Inpatient setting was among the most prominent factors as-
sociated with poor bowel preparation (OR= 2.018, 95%CI 1.884-2.163; P 
value< 0.01). In regard to procedures’ indications, significant associations 
with inadequate preparation were recorded for constipation (OR =1.373, 
95%CI=1.24-1.519; P< 0.01), rectal bleeding (OR = 1.473, 95%CI= 1.355-
1.602) and surveillance procedures after colonic resection (OR = 1.266, 
95%CI= 1.089-1.472). Evaluation of procedure’s outcome and quality in-
dicators revealed that adequate bowel preparation was associated with 
enhanced polyp detection rate (26.8% vs 23.6%; OR= 1.22, 95% CI= 1.109-
1.347; P< 0.01), increased colorectal cancer detection rate (2.8% vs. 2.4% 
OR= 1.402, 95% CI=1.146-1.716; P< 0.01), as well as increased cecal (96.4% 
vs. 73.5%; OR= 2.243, 95% CI= 2.095-2.403) and terminal ileum detection 
rates (8.1% vs. 5.4%; OR= 1.243, 95% CI= 1.088-1.434), when compared to 
inadequate preparation.
conclusion: In this large cohort study we outlined various factors associ-
ated with inadequate bowel preparation. Further study is underway to 
examine tailored preparation regimens in this population.
disclosure: Nothing to disclose 
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Introduction: Transanal endoscopic microsurgery (TEM) is a well-estab-
lished local resection method. Although TEM is a useful and less invasive 
treatment, it has been reported to be associated with local recurrence 
rates of 3% to 19%. Occasionally surgical treatment such as low anterior 
resection or abdominal perineal resection may be required for such re-
current rectal lesions, however, they can have severe effects on patients’ 
postoperative quality of life. Recently, several studies have demonstrated 
the usefulness of endoscopic submucosal dissection (ESD) for residual or 
locally recurrent colorectal lesions after endoscopic treatment. However, 
the utility of ESD for recurrent rectal lesions after TEM has not been fully 
investigated.
aims & Methods: Aim of this study was to evaluate the feasibility and safe-
ty of ESD for recurrent rectal lesions after TEM. This study was performed 
at Kobe University Hospital and Kishiwada Tokushukai Hospital, which are 
tertiary referral centers in Japan. It examined the outcomes of 10 consecu-
tive lesions in 9 patients, who underwent ESD between January 2006 and 
March 2018 for recurrent rectal lesions after TEM. The target lesions were 
preoperatively assessed via conventional and magnified chromoendo-
scopic examinations. As ESD technique, after TEM procedures involving 
full-thickness resection, the resultant fibrosis can be so severe that the 
border between the submucosa and muscle layer, and sometimes even 
that between the inner circular and outer longitudinal muscles, is invis-
ible. In such cases, dissecting at the assumed level of the submucosal layer 
would carry a risk of cutting into the lesion, so we employed the previously 
reported peranal endoscopic myectomy (PAEM) technique.
results: All lesions were successfully resected en bloc, and the R0 resec-
tion rate was 90%. The median sizes of the resected specimens and tu-
mors (range) were 44 mm (21-70) and 27.5 mm (5-60), respectively. In 
present study, the PAEM technique was used to treat 4 lesions, and all of 
them had negative vertical margins. The pathological diagnoses included 
4 adenomas and 6 cancerous lesions. The cancerous lesions included 5 
cases of mucosal cancer and 1 case of SM1 cancer. No adverse events oc-
curred. There was no recurrence during the follow-up period (median du-
ration: 25 months).
conclusion: ESD for recurrent rectal lesions after TEM achieved en bloc re-
section for all lesions without any complications. ESD appears to be a safe 
and feasible treatment for recurrent rectal lesions after TEM.
references: Toyonaga T, Ohara Y, Baba S et al. Peranal endoscopic my-
ectomy (PAEM) for rectal lesions with severe fibrosis and exhibiting the 
muscle-retracting sign. Endoscopy 2018 Ito S, Hotta K, Imai K et al. Treat-
ment strategy for local recurrences after endoscopic resection of a colorec-
tal neoplasm. Surg Endosc 2018
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Turan A.1, Didden P.2, Siersema P.D.1, Van Geenen E.J.M.1
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2University Medical Center Utrecht, Utrecht, Netherlands
contact e-Mail address: ayla.turan@radboudumc.nl
Introduction: Flat and sessile colorectal adenomas are often resected en-
doscopically using endoscopic mucosal resection (EMR). Delayed bleeding 
after EMR occurs in up to 10% of patients. Recently, a multicenter study 
reported a significant decreased delayed bleeding (DB) rate after prophy-
lactic clipping (PC) in right sided colonic lesions >2cm. As PC is associated 
with significant costs, its use is considered not cost-effective for small (< 
2cm) polyps and left sided polyps. The practice of PC is not yet widely ad-
opted in guidelines and clinical practice.
aims & Methods: Our aim was to determine which predefined variables 
contribute to using PC in an international group of endoscopists. We per-
formed an international survey study among endoscopists, structured as 
an online discrete choice experiment (DCE) with a choice based conjoint 
analysis. The survey was conducted in 428 gastroenterologists of the Dutch 
Association of Gastroenterology and Hepatology. Additionally, 69 interna-
tional EMR experts were contacted and invited to forward the survey to 
other colleagues with EMR experience. Relevant variables hypothesized 
to influence decision-making for PC were selected by a panel of four EMR 
experts and included previous DB, periprocedural anticoagulant use, polyp 
size, morphology, location, intra-procedural bleeding and visible vessel(s) 
in the wound surface. Respondents answered ten sets of three hypotheti-
cal case scenarios with various option combinations of all of these vari-
ables, each time choosing only one scenario for PC. Alternatively, it was 
possible to choose a ‘none’-option if they wouldn’t use PC in any of the 
scenarios. Part-worth utility scores and importance weights were calcu-
lated for each level of the variables with a Hierarchical Bayes regression 
analysis and compared between subgroups using a T-test. Subsequently, 
considerations that were posed by participants in the comment section of 
the survey were analyzed quantitatively.
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references: Mori H, Kobara H, Nishiyama N. et al. Novel effective and re-
peatedly available ring-thread counter traction for safer colorectal endo-
scopic submucosal dissection. Surg Endosc 2017; 31(7): 3040-3047
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P0186 an InTernaTIOnaL survey Of uPTake and BarrIers 
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Introduction: Optical real-time diagnosis (=resect-and-discard strategy) is 
an alternative to histopathology for diminutive colorectal polyps. However, 
clinical adoption of this approach seems sparse and we were interested 
in evaluating potential clinical uptake and barriers for implementation of 
this approach.
aims & Methods: We conducted an international survey using the “Google 
forms” platform. Nine endoscopy societies distributed the survey. Survey 
questions measured current clinical uptake and barriers for implement-
ing the resect-and-discard strategy, perceived cancer risk associated with 
diminutive polyps and potential concerns with using CT-colonography as 
follow-up, as well as non-resection of diminutive polyps.
results: 808 endoscopists participated in the survey. 84.2% (95% CI 
81.6%-86.7%) of endoscopists are presently not using the resect-and-dis-
card strategy and 59.9% (95% CI 56.5%-63.2%) do not believe that the 
resect-and-discard strategy is feasible for implementation in its current 
form. European (38.5%) and Asian (45%) endoscopists had the highest 
rates of resect-and-discard practice, while Canadian (13.8%) and American 
(5.1%) endoscopists had some of the lowest implementation rates. 80.3% 
(95% CI 77.5%-83.0%) of endoscopists believe that using the resect-and-
discard strategy for diminutive polyps will not increase cancer risk. 48.4% 
(95% CI 45.0%-51.9%) of endoscopists believe that leaving diminutive 
polyps in place is associated with increased cancer risk. This proportion 
was slightly higher (54.7%; 95% CI 53.6%-60.4%) when asked if current 
CT-colonography screening practice might increase cancer risks.
conclusion: Clinical uptake of resect-and-discard is very low. Most endosco-
pists believe that resect-and-discard is not feasible for clinical implementa-
tion in its current form. The most important barriers for implementation 
are fear of making an incorrect diagnosis, assigning incorrect surveillance 
intervals and medicolegal consequences.
disclosure: Phillipe Willems, Roupen Djinbachian, Saskia Ditisheim, Sinan 
Orkut, Heiko Pohl, Alan Barkun, Mickael Bouin and Bernard Faulques 
have no conflicts of interest relevant to this paper to declare. Daniel von 
Renteln is supported by a “Fonds de Recherche du Québec Santé” career 
development award and has received research funding from ERBE, Vent-
age, Pendopharm and Pentax and is a consultant for Boston Scientific and 
Pendopharm. The findings, statements, and views expressed are those of 
the authors and do not represent the views of the Department of Veterans 
Affairs or the United States Government. 
results: The survey was completed by 190 endoscopists with experience 
in EMR from 17 different countries. In total, 6.8% of respondents would 
not use PC in any of the simulated situations, whereas 30.9% never chose 
the none-option in the survey. Except for polyp type (flat, sessile, mixed 
type), all tested variables were significant in the decision-making for PC 
with P< 0.01. 
The most important factor was anticoagulant use, accounting for 22.5% 
in decision-making, followed by intra-procedural bleeding (16.3%), polyp 
size (16.2%), polyp location (15.9%), visible vessel(s) (13.5%) and previous 
DB (10%). Small polyps < 2 cm were considered eligible for PC by 14% of 
the responders in the presence of high-weighing factors such as antico-
agulant use. In a subgroup analysis, no significant differences in impor-
tance weights were found when comparing high with low to moderately 
experienced EMR endoscopists. 
Qualitative analysis showed that other variables, not included in the sur-
vey, were also considered in clinical decision making, such as technical 
possibility of clipping, prophylactic coagulation of visible vessels and dis-
tance of patient’s residence to the hospital.
conclusion: PC after EMR is commonly considered useful by endoscopists, 
usually based on known risk factors for DB. 
Anticoagulant use was the most important factor in decision-making to 
perform PC, independent of the experience of the endoscopist. Nonethe-
less, although not considered cost-effective, 1 in 7 EMR endoscopists also 
apply PC for adenomas < 2 cm.
disclosure: Nothing to disclose 
P0185 effIcacy Of cOunTer TracTIOn usIng a cLIP WITh 
a LOOPed Thread fOr cOLOrecTaL endOscOPIc suBMucOsaL 
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contact e-Mail address: inchan0701@gmail.com
Introduction: Colorectal endoscopic submucosal dissection (ESD) remains 
a difficult endoscopic procedure. Several traction methods have been re-
ported that enable an appropriate view of the submucosal layer; however, 
almost all these methods have limitations regarding preparation, delivery, 
ease or cost. We have reported a treatment strategy for colorectal ESD us-
ing a clip with a looped thread, which has been developed to resemble a 
ring-shaped thread counter traction. 
Our original counter traction does not require any special tools or devices 
and can be carried out without the removal and reinsertion of a scope. 
Additionally, this method is very easy and only requires thirty seconds to 
make one looped thread.
aims & Methods: This study was performed to evaluate the efficacy of our 
traction method.
A 3-0 nylon suture and a clip (HX-610-135; Olympus, Tokyo, Japan) were 
used as the material. Between January 2017 and November 2018, colorectal 
ESD was carried out on 90 lesions. These lesions were allocated either 
to the group before introduction of the looped thread counter traction 
(non-looped thread; NLT) (n=66) or to the group after introduction (looped 
thread; LT) (n=24). We retrospectively investigated the background factors, 
treatment outcomes and complications.
results: We achieved en bloc resections of all lesions. No significant dif-
ferences were detected in the background factors or in the procedure time 
(P=0.298). The median time of the LT group (65 min) was shorter than that 
of the NLT group (80 min). There were 3 cases of perforation during ESD in 
the NLT group compared to 0 cases in the LT group (P=0.287). There were 4 
cases of post-ESD bleeding (1-7 days after ESD) in the NLT group compared 
to 2 cases in the LT group (P=0.749).
conclusion: No significant differences were detected in the treatment out-
comes and complications in this study. But we think this traction method 
is useful, and we suggest that this counter traction method may be a su-
perior method for colorectal ESD because the length of the thread can 
be adjusted and more clips or looped thread can be added as needed to 
maintain an appropriate view of the submucosal layer. Good visualization 
of the submucosal layer can prevent perforation and bleeding during ESD. 
The greatest advantages of this traction method include the low cost and 
ease. This method is readily available not only in high-volume centres but 
also in general hospitals. In this report, we demonstrate how to make the 
looped thread, how to tie the thread to a clip and how to carry out this 
traction method.
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P0187 The cLInIcaL OuTcOMes Of endOscOPIc resecTIOn fOr 
LOcaL recurrence cases resecTed By cfP In PaTIenTs WITh 
dIMInuTIve POLyPs
Kuwai T.1, Yamada T.2, Toyokawa T.3, Iwase H.4, Kudo T.5, Esaka N.6, 
Kagaya T.7, Yamashita H.8, Hosoda Y.9, Watanabe N.10, Harada N.11
1National Hospital Organization Kure Medical Center and Chugoku 
Cancer Center, Gastroenterology, Kure, Japan, 2Osaka Rosai Hospital, 
Gastroenterology & Hepatology, Sakai, Japan, 3National Hospital 
Organization Fukuyama Medical Center, Gastroenterology, Fukuyama, 
Japan, 4National Hospital Organization Nagoya Medical Center, Dept of 
Gastroenterology, Nagoya-shi, Japan, 5National Hospital Organization 
Takasaki General Medical Center, Dept of Gastroenterology, Takasaki-shi, 
Japan, 6Kyoto Medical Center, Dept of Gastroenterology, Kyoto, Japan, 
7National Hospital Organization Kanazawa Medical Center, Gastroenterology, 
Ishikawa, Japan, 8National Hospital Organization Okayama Medical Center, 
Gastroenterology, Tsukubo-gun, Japan, 9National Hospital Organization 
Saitama National Hospital, Gastroenterology, Wako-shi, Japan, 10National 
Hospital Organization Mie Chuo Medical Center, Gastroenterology, Tsu-
shi, Japan, 11Kyushu Medical Center, National Hospital Organization, 
Gastroenterology, Fukuoka, Japan
contact e-Mail address: toshiokuwai@gmail.com
Introduction: Cold forceps polypectomy (CFP) is often used to remove 
diminutive colorectal polyps. It has few adverse events and can be im-
plemented using routine biopsy techniques. In addition, jumbo biopsy 
forceps are considered superior to standard ones in removing colorectal 
polyps. Examining the margin of resected regions using narrow band im-
aging (NBI)-enhanced endoscopy can also improve complete resection 
rate. However, even in such cases using Jumbo forceps in NBI-enhanced 
endoscopy, local recurrence occurs in few cases. In such cases, lesions 
have to be treated again and clinical outcomes are still unknown.
aims & Methods: We investigated clinical outcomes of treatment for pa-
tients with local recurrence of diminutive polyps resected by jumbo for-
ceps biopsy in NBI endoscopy. This multicenter, prospective, single-arm 
observational study was conducted at 11 institutes of the National Hos-
pital Organization in Japan between January 2015 and September 2018 
(UMIN000015969). In total, 503 patients, aged 20-75 years, with diminu-
tive polyps (≤5 mm) were prospectively assessed, and 1015 polyps were 
resected by jumbo forceps biopsy in NBI endoscopy. Among these, 955 le-
sions from 471 patients were followed-up 1 year post-CFP to examine local 
recurrence in the polypectomy sites (follow-up rate; 94.1%). Finally, local 
recurrence occurred in 18 patients (20 lesions, 2.1%), who were enrolled in 
this study. We analyzed clinicopathological characteristics of primary and 
local recurrent lesions, as well as short- and long-term clinical outcomes 
of treatment for local recurrent lesions including resection rates, adverse 
events, and re-recurrence rate.
results: The patients consisted of 12 men (67%) and 6 women (33%) with 
a median age of 68.5 years (49-74). The mean primary polyp size was 
3.9±0.9 mm. The number of resected primary polyps in the right and left 
colon were 12 (60%) and 8 (40%), respectively. The histological diagnoses 
of the primary resected polyps were low-grade adenomas in all cases, and 
the rate of one-bite polypectomy was 55% (11/20). Immediate bleeding oc-
curred in 1 case; delayed bleeding or perforations were not observed. The 
mean size of local recurrent polyps was 1.5±0.6 mm; all were less than 3 
mm. Re-CFP successfully managed local recurrent polyps in all cases, and 
the rate of one-bite polypectomy was 90% (18/20). The histological diag-
noses of local recurrent polyps were low-grade adenomas in all cases; no 
adverse events occurred in any cases. Additionally, 16 of 18 patients (18/20 
lesions) were subjected to a 1-year follow-up examination with colonos-
copy (follow-up rate; 88.9%), and no re-recurrence occurred in any cases 
(0/18).
conclusion: The local recurrence rate of diminutive polyps in CFP by jumbo 
forceps biopsy in NBI endoscopy was acceptable. When local recurrence 
occurred, the size was small, and it could be treated using re-CFP.
disclosure: Nothing to disclose 
P0188 screenIng cOLOnOscOPy fIndIngs and cOMPLIcaTIOns 
In a MuLTI-cenTer sTudy In The unITed sTaTes
Dominitz J.1,2, Robertson D.3,4, Ahnen D.J.5, Beed A.6, Boardman K.7, 
Del Curto B.7, Guarino P.8, Imperiale T.9, Johnson G.6, Kyriakides T.6, 
LaCasse A.3, Larson M.1, Lieberman D.10,11, Provenzale D.12,13, Shaukat A.14, 
Sultan S.14, Planeta B.6, CONFIRM Study Investigators
1VA Puget Sound Health Care System, Gastroenterology Section, Seattle, 
United States, 2University of Washington School of Medicine, Division of 
Gastroenterology, Seattle, United States, 3White River Junction VA Medical 
Center, Gastroenterology, White River Junction, United States, 4Geisel School 
of Medicine at Dartmouth, Hanover, United States, 5University of Colorado, 
Denver, United States, 6VA Cooperative Studies Program, West Haven, United 
States, 7VA Cooperative Studies Program, Albuquerque, United States, 8Fred 
Hutchinson Cancer Research Center, Seattle, United States, 9Roudebush VA 
Medical Center, Indianapolis, United States, 10Portland VA Medical Center, 
Portland, United States, 11Division of Gastroenterology and Hepatology, 
Oregon Health and Science University, Portland, United States, 12Durham VA 
Medical Center, Durham, United States, 13Duke University Medical Center, 
Duke Cancer Institute, Durham, United States, 14Minneapolis VA Medical 
Center, Minneapolis, United States
contact e-Mail address: jason.dominitz@va.gov
Introduction: The Colonoscopy vs. Fecal Immunochemical Testing (FIT) in 
Reducing Mortality from Colorectal Cancer (CONFIRM) Study, a randomized 
study comparing annual FIT vs. colonoscopy in average risk adults aged 
50-75, recently completed enrollment and is now following participants 
for cancer outcomes.
aims & Methods: To determine 1) findings on baseline colonoscopy, 2) fac-
tors associated with baseline neoplasia and 3) 30 day complication rate. 
Advanced adenoma (AA) was defined as any adenoma ≥1cm, with high 
grade dysplasia or with villous histology. Univariable logistic regression 
was used to determine the association between baseline variables and 
findings of adenomas, advanced adenomas, and sessile serrated lesions 
(SSLs). See table for full variable list. Variables found to be significant at 
p≤0.1 were included in a multivariable logistic regression model, stratified 
by site. Participants found to have colorectal cancer were excluded from 
this analysis as this study is ongoing. Coordinators reviewed medical re-
cords and telephoned participants to determine complications. All serious 
adverse events (SAEs) were recorded, as were non-serious adverse events 
(AEs) deemed to be at least possibly related to colonoscopy.
results: 15,806/17,340 colonoscopies were complete with cecal intubation 
(97.3%) and adequate preparation (92.4%). Polyps were found in 66.0%. 
Among those without polyps, mean withdrawal time was 11.1 minutes. 
Non-gastroenterologists were less likely to detect polyps (0.65; 95% CI 
0.58-0.77) and adenomas (Table). Trainee involvement was associated 
with higher polyp detection (1.24; 95% CI 1.14, 1.35). Factors associated 
with adenoma and AA are shown in the table. Factors associated with 
AA included age, male sex, smoking and alcohol use. Black race, college 
degree, NSAIDs and prior colonoscopy were inversely associated with AA. 
Independent predictors of SSL’s included BMI and smoking; while Blacks 
had 62% reduced odds of SSL’s. Former aspirin use was associated with 
adenomas, but this finding was modified by age. 
There were 235 SAEs reported (1.3%), with 52 related (0.36%) and 38 pos-
sibly related (0.25%) to colonoscopy, including 31 serious bleeding events 
(.18%), 31 cardiovascular events (.18%) and 5 perforations (.03%). 585 AEs 
were reported (2.9%), most (84%) were mild, 15% were moderate and 
0.1% were severe,
conclusion: Our study confirms the importance of several demographic 
and environmental risk factors for adenomas, AA and SSL. AEs and SAEs 
related to colonoscopy occur in approximately 3% and 0.5% of colonos-
copies, respectively. 
The first two authors are co-first authors. 
disclosure: Nothing to disclose
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P0189 usefuLness and safeTy Of cOLOrecTaL hyBrId esd 
and PrecuTTIng eMr usIng a nOveL MuLTIfuncTIOnaL snare 
fOr ssPs
Tamaru Y., Kuwai T., Moriuchi R., Wada K., Konishi H., Tao K., Miura R., 
Kusunoki R., Yamaguchi A., Kouno H., Kohno H.
National Hospital Organization Kure Medical Center and Chugoku Cancer 
Center, Gastroenterology, Kure, Japan
contact e-Mail address: tamaru.yuzuru.vh@mail.hosp.go.jp
Introduction: Precutting endoscopic mucosal resection (EMR) and hybrid 
endoscopic submucosal dissection (ESD) have the advantages of decreased 
procedure time and perforation risk. Recently, a novel multifunctional 
snare (SOUTEN; Kaneka Medics, Tokyo, Japan) to enable easy and time-
efficient hybrid ESD, involving circumferential incision and partial submu-
cosal dissection, followed by snare resection, was introduced. The SOUTEN 
snare combines an 18.5-mm snare loop with a 1.5-mm needle-knife and 
a knob-shaped tip attached to the top of the snare loop. Sessile serrated 
polyps (SSPs) are increasingly recognized as a significant contributor to the 
epidemiologic burden of colorectal cancer; therefore, it is desirable that 
SSPs are resected en bloc for reliable histologic assessment of the resected 
specimen. We sometimes experience difficult SSP cases for en bloc EMR, 
in which the polyps are more than 20 mm in size or in which the border 
of the lesion is difficult to identify. Until now, there have been few reports 
regarding the outcomes of precutting EMR and hybrid ESD using SOUTEN 
for SSPs.
aims & Methods: The aim of this study was to evaluate the usefulness and 
safety of colorectal hybrid ESD and precutting EMR for SSPs using SOUTEN. 
We analyzed 14 SSPs in 12 patients (2 male and 10 female, mean age: 
69.1 years) who underwent hybrid ESD or precutting ESD using SOUTEN 
at our hospital between May 2018 and March 2019. The clinicopathological 
characteristics, en bloc resection rate, histological complete resection rate, 
curative resection rate, tumor size, specimen size, procedure time, and 
adverse event rate were evaluated.
results: Of the 14 lesions, 1 (7%) was located in the cecum, 6 (43%) in the 
ascending colon, 6 (43%) in the transverse colon, and 1 (7%) in the de-
scending colon. All lesions had a 0-IIa macroscopic polyp morphology, and 
all lesions were histopathologically identified as SSPs (low grade). Among 
the treatment methods, the hybrid ESD-to-precutting EMR ratio was 8/6. 
The mean tumor and specimen sizes were 18.2 mm, and 24.5 mm, respec-
tively. The en bloc, histological complete, and curative resection rates were 
100% (14/14), 100% (14/14), and 100% (14/14), respectively. The median 
procedure time was 16.5 minutes. There was no bleeding, perforation, or 
stricture postoperatively.
conclusion: Hybrid ESD/precutting EMR using SOUTEN for SSPs is a safe 
and effective treatment option because of sufficient submucosal swelling 
after injection of the submucosal layer. A prospective study with a large 
number of cases should be conducted in the future to validate our results.
disclosure: Nothing to disclose 
P0190 cOLOn cLeansIng effIcacy and safeTy Of 1L 
ner1006 In PaTIenTs WITh MILd TO MOderaTe renaL 
IMPaIrMenT: POsT hOc anaLysIs Of randOMIsed Phase 3 
cLInIcaL TrIaLs
Alvarez Gonzalez M.A.1, Mokashi S.2, Hassan C.3
1Hospital del Mar, Barcelona, Spain, 2Norgine, Medical, Harefield Middlesex, 
United Kingdom, 3Nuovo Regina Margherita Hospital, Gastroenterology, 
Rome, Italy
contact e-Mail address: marcoalgo@gmail.com
Introduction: Only polyethylene glycol (PEG) bowel preparations are rec-
ommended for patients with renal failure. This post hoc analysis of ran-
domised phase 3 clinical trials assessed the colon cleansing efficacy of 
the first 1L PEG, NER1006, in renally impaired versus non-renally impaired 
patients [1-3].
aims & Methods: Patients received split dosing regimens of NER1006, 
either day-before (PM/PM), overnight (PM/AM), or morning-only (AM/
AM). Cleansing efficacy was assessed by treatment blinded central readers 
using the Harefield Cleansing Scale (HCS). The efficacy analysis included 
patients with a documented renal status and colonoscopy data. Patients 
were stratified into creatinine clearance rate (CrCl) groups: normal renal 
function (≥90 mL/min), mild renal insufficiency (≥60 to < 90 mL/min), or 
  adenoma n=7,222 (45.7%)
advanced adenoma 
n=1,481 (9.4%)
sessile serrated 
Lesion 
n=589 (3.7%)
Baseline Variable Multivariable Multivariable Multivariable
Age, per year (mean 59.2) 1.05 (1.04-1.05) 1.04 (1.03-1.05) 1.01 (1.00-1.03)
Female 
(ref=Male, 93.4%)
0.48 (0.41-0.56) 0.66 (0.49-0.89) NS on univariable
Race: 
White (72.9%)
Black (22.7%)
AI/AN (0.7%)
Asian (1.7%)
Other (2.0%)
Ref
0.80 (0.73-0.88)
0.80 (0.55-1.18)
0.77 (0.59-1.01)
1.09 (0.84-1.42)
Ref 
0.81 (0.70-0.93)
1.12 (0.61-2.05)
0.64 (0.38-1.08)
1.12 (0.75-1.65)
Ref 
0.38 (0.28-0.50)
1.20 (0.52-2.75)
0.77 (0.38-1.58)
0.74 (0.38-1.45)
Ethnicity:
Non-Hispanic (87.7%)
Hispanic (12.1%)
Ref
 
0.81 (0.71-0.93) 
NS on univariable NS on univariable
Education: 
≤ High School (27.0%) 
Some College (34.9%) 
College Degree (37.8%)
Ref
0.93 (0.86-1.02)
0.90 (0.83-0.99)
Ref
0.95 (0.83-1.09)
0.85 (0.73-0.97)
NS on univariable
BMI, per unit (mean 30.3) 1.02 (1.01-1.02) NS on univariable 1.02 (1.01-1.04)
2° Relative with CRC: 
none (96.0%
)
At least one (4.0%)
Ref 
0.97 (0.82-1.15)
Ref 
0.91 (0.67-1.24)
Ref 
0.61 (0.36-1.05)
Aspirin Use: Never (51.1%)
Former Use (7.8%)
Current Use (41.0%)
Ref 
4.57 (1.54-13.56)
1.60 (0.87-2.97)
NS on univariable NS on univariable
NSAID Use: 
Never (57.4%)
Former use (9.8%)
Current use (32.8%)
Ref 
1.04 (0.92-1.16)
0.84 (0.78-0.90)
Ref 
0.88 (0.72-1.07)
0.87 (0.77-0.98)
NS on univariable
Statin Use: 
Never (53.9%)
Former use (6.4%)
Current use (39.6%)
Ref
1.11 (0.96-1.27)
1.14 (1.06-1.23)
NS on univariable NS on univariable
Smoking: 
Never (38.7%)
Former Smoker (38.9%)
Current Smoker (22.4%)
Ref
1.16 (1.07-1.25)
1.65 (1.51-1.81)
Ref
1.29 (1.12-1.47)
1.78 (1.54-2.07)
Ref
1.38 (1.13-1.69)
1.68 (1.34-2.12)
ETOH/day, per drink (mean 
0.78)
1.03 (1.01-1.05) 1.04 (1.01-1.07) NS on univariable
METs/day, per unit (mean 14.5) 1.00 (0.99-1.00) NS on univariable NS on univariable
Age*Aspirin Usage/Never 
Age*Formerly takes 
Aspirin 
Age*Currently takes Aspirin
Ref
0.98 (0.96-0.99)
0.99 (0.98-1.00)
NS on univariable NS on univariable
Specialty: 
Gastroenterologist (89.2%)
Non-Gastro (8.5%)
Ref
0.73 (0.64-0.85)
NS on univariable NS on univariable
Trainee Involved: 
No (64.7%)
Yes (35.2%)
Ref
1.19 (1.09-1.29)
Ref
1.11 (0.99-1.25)
Ref
1.19 (1.00-1.42)
Colonoscopy at VA: 
Yes (99.0%)
No (1.0%)
NS on univariable NS on univariable
Ref
1.53 (0.61-3.80)
Prior Colonoscopy: 
No (72.6%)
Yes (27.2%)
NS on univariable
Ref
0.65 (0.57-0.75) 
NS on univariable
[P0188 Table. Predictors of Colonoscopy Findings (OR; 95% Confidence 
Interval)]
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moderate renal insufficiency (≥30 to < 60 mL/min). Patients with severe 
renal insufficiency were excluded.
results: Among 1134 randomised patients, 1016 were assessed for efficacy 
(renal status; 692 mild/moderate, 324 normal). No significant difference 
was observed in the overall cleansing success rates in mild and moderate 
versus normal (Table). Safety was assessed in 1028 patients. The types of 
TEAEs were generally consistent between mild and moderate and normal. 
The most common TEAEs in all patient groups were gastrointestinal i.e. 
nausea, vomiting and dehydration. There were numerically more TEAEs 
in patients with moderate renal insufficiency versus normal. However, this 
may reflect the patients’ disease state.
conclusion: The current efficacy and safety findings support the use of 
NER1006 as a bowel preparation in patients with mild to moderate renal 
impairment.
successful overall colon 
cleansing using the hcs
Mild to moderate 
renal impairment: 
crcl 30-<90 mL/min
normal renal function: 
crcl 90+ mL/min P value
MORA PM/AM N=262 96% (183/190) 97% (69/71) 0.63
MORA AM/AM N=270 91% (182/200) 91% (62/68) 0.52
DAYB PM/PM N=236 64% (91/142) 67% (61/91) 0.68
NOCT PM/AM N=255 92% (147/160) 94% (88/94) 0.69
[Percentage of NER1006 patients with successful overall colon cleansing 
using the HCS in patients with renal-impairment vs normal renal function.]
references: 1. Bisschops R et al. Endoscopy 2019; 51(1):60-72 2. DeMicco MP 
et al. Gastrointestinal Endoscopy 2018; 87(3):677-687 3. Schreiber S et al. 
Endoscopy 2019; 51(1):73-84
disclosure: Marco Antonio Alvarez-Gonzalez: An investigator in the MORA 
study and has received honoraria from Norgine for Advisory Board atten-
dance and from Casen-Recordati for speaking and teaching Soniya Mo-
kashi: Employee of Norgine. Cesare Hassan: An investigator in the DAYB 
study and received honoraria from Norgine Ltd. for advisory board atten-
dance; no other conflicts of interest. 
P0191 feasIBILITy Of ILeaL InTuBaTIOn In cOLOnOscOPy WITh 
endOcuff: a PrOsPecTIve OPen LaBeL cOMParIsOn
Sawatzki M., Borovicka J., Baumeler S.
Kantonsspital, Gastroenterology, St. Gallen, Switzerland
contact e-Mail address: sawatzki@sunrise.ch
Introduction: Endocuff (EC) is a mucosal exposure device attached to the 
distal tip of the colonoscope. Adenoma detection rate (ADR) can be im-
proved with EC and the examination time (without reducing the ADR) can 
be reduced (1,2). The use of EC influencing the ileum intubation rate (IIR) 
has been investigated in only two studies as secondary endpoint with con-
tradictory results (3,4).
aims & Methods: We prospectively analysed the use of an EC and ileum 
intubation at the Kantonsspital St. Gallen in Switzerland between January 
to December 2018 performed by 3 experienced endoscopists and 1 train-
ee. Scientific data security were approved by the local ethics commission 
(EKSG14/099). EC was only applicated for screening or follow-up colonos-
copy. The withdrawal time had to be at least 6 minutes. Significance was 
calculated with the Fishers Exact Test. Adenoma detection rate (ADR) was 
determined.
results: We included 570 patients, median age 60 years (range 21-94), 
51% were male. Of the 570 colonoscopies, 63% were performed with EC 
(n=359). Colonoscopy with EC and intubation of the terminal ileum was 
achieved in 85.8% (308 of 359 patients). Without EC, the ileum was in-
tubated in 82% (173 of 211 patients). There was no significant difference 
(p=0.234). ADR with EC was 45% and without EC 43%, p< 0.00001. IIR for 
the trainee (n=87) was 71% with EC and 76% without EC (p=0.81).
conclusion: Colonoscopy with the use of Endocuff achieved the same ileum 
intubation rate as without Endocuff. The need of ileum intubation there-
fore is not an argument against the use of Endocuff. In contrast, the ADR 
significantly improves with the use of an EC.
references: 1. Rex DK, Slaven JE, Garcia J, et al. Endocuff Vision Reduces In-
spection Time Without Decreasing Lesion Detection in a Randomized Colo-
noscopy Trial. Clin Gastroenterol Hepatol 2019. Available at: https://linkin-
ghub.elsevier.com/retrieve/pii/S1542356519300357 [Accessed February 18, 
2019]. 2. Williet N, Tournier Q, Vernet C, et al. Effect of Endocuff-assisted 
colonoscopy on adenoma detection rate: meta-analysis of randomized 
controlled trials. Endoscopy 2018;50:846-860. 3. Floer M, Biecker E, Fitzlaff 
R, et al. Higher Adenoma Detection Rates with Endocuff-Assisted Colo-
noscopy - A Randomized Controlled Multicenter Trial. PLoS ONE 2014;9. 
Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4255000/ 
[Accessed February 18, 2019]. 4. González-Fernández C, García-Rangel D, 
Aguilar-Olivos NE, et al. Higher adenoma detection rate with the endocuff: 
a randomized trial. Endoscopy 2017;49:1061-1068.
disclosure: Nothing to disclose 
P0192 1L ner1006 IMPrOves hIgh-quaLITy cOLOn cLeansIng 
versus sTandard BOWeL PreParaTIOns: POsT hOc anaLysIs 
Of Phase 3 cLInIcaL TrIaLs usIng reaL-WOrLd cLeansIng 
assessMenT By sITe endOscOPIsTs
Gschossmann J.1, Amlani B.2, Repici A.3
1Klinikum Forchheim, Dept. of Internal Medicine, Forchheim, Germany, 
2Norgine, Medical Affairs, Harefield, United Kingdom, 3I st. Clinico 
Humanitas Rozzano, Dept. of Gastroenterology, Milano, Italy
contact e-Mail address: juergen.gschossmann@klinikum-forchheim.de
Introduction: Colonoscopy requires bowel cleansing; high-quality cleans-
ing facilitates lesion detection. NER1006 is a 1L polyethylene glycol (PEG) 
bowel preparation. This post hoc analysis of three randomised trials in-
vestigated cleansing efficacy assessed, as in clinical practice, by site en-
doscopists [1-3].
aims & Methods: Patients received either a 2-day evening/morning regi-
men of NER1006 (N2D), 2L PEG+ascorbate (2LPEG), or oral sulfate solu-
tion (OSS); or day-before NER1006 (NDB) or sodium picosulfate plus 
magnesium citrate (SPMC). Morning-only NER1006 (N1D) dosing was also 
evaluated. Cleansing was assessed by treatment-blinded site endoscopists 
using the Harefield Cleansing Scale (HCS). This analysis included only 
patients with self-reported 100% treatment adherence. Overall cleansing 
success (HCS grade A or B), overall high-quality cleansing success (HCS 
grade A), and the proportion of high-quality segments (HCS 3-4) per treat-
ment population were analysed.
results: Among 1985 randomised patients, 1367 were included (Table). 
Overall cleansing success was higher with N2D than 2LPEG (97.5% vs 
93.0%) and more patients had overall high-quality cleansing with N2D 
and N1D than 2LPEG (72.1% and 68.4% vs 56.0%). N2D delivered more 
overall high-quality cleansing than OSS (77.3% vs 69.8%). Overall cleans-
ing success was higher with NDB than SPMC (74.5% vs 62.9%) and more 
patients achieved HCS Grade A with NDB than SPMC (29.0% vs 12.0%). 
More high-quality segments were demonstrated with N2D and N1D ver-
sus 2LPEG (87.1% and 84.4% vs 76.3%), with N2D versus OSS (89.5 % vs 
84.4%) and with NDB than SPMC (60.3% vs 47.0%).
conclusion: When assessed by site-endoscopists NER1006 delivers greater 
high-quality, HCS grade A, cleansing than 2LPEG, OSS, or SPMC.
Phase 3 trial MOra nOcT dayB
cleansing success N2D N1D 2LPEG N2D OSS NDB SPMC
split dosing regimen Overnight
Morning 
only
Overnight Overnight Overnight
Day 
before
Day 
before
sample size: n 204 193 200 225 225 145 175
Overall cleansing 
success hcs grades 
a+B, n/n (%)
199/204 
(97.5)
180/193 
(93.3)
186/200 
(93.0)
211/225 
(93.8)
210/225 
(93.3)
108/145 
(74.5)
110/175 
(62.9)
Overall cleansing 
success, P-value
P=0.016 P=0.459   P=0.424   P=0.012  
Overall high-quality 
cleansing success hcs 
grade a, n/n (%
147/204 
(72.1)
132/193 
(68.4)
112/200 
(56.0)
174/225 
(77.3)
157/225 
(69.8)
42/145 
(29.0)
21/175 
(12.0)
Overall high-quality 
cleansing success; 
P-value
P<0.001 P=0.006   P=0.035   P<0.001  
high-quality segments 
hcs 3-4, n/n (%); 
P-value
888/1020 
(87.1)
814/965 
(84.4)
763/1000 
(76.3)
1007/1125 
(89.5)
950/1125 
(84.4)
437/725 
(60.3)
411/875 
(47.0)
high-quality segments; 
P-value
P<0.001 P<0.001   P<0.001   P<0.001  
[High-quality colon cleansing as assessed by site endoscopists in patients 
with self-reported 100% treatment adherence]
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conclusion: UEMR featured an improved R0 resection rate of 10-20-mm 
colorectal polyps without increasing procedure time or the adverse event 
rate. UEMR procedure and polyp size < 15 mm were independently related 
to R0 resection.
references: 1) Yamashina T, Uedo N, et al. Comparison of Underwater 
versus Conventional Endoscopic Mucosal Resection of Intermediate-Size 
Colorectal Polyps. Gastroenterology 2019, in press
disclosure: Nothing to disclose 
P0194 PredIcTIOn Of cOLOn adenOMa PaThOLOgy By 
aPPLIcaTIOn Of arTIfIcIaL InTeLLIgence
Choi S.J.1, Kim E.S.1, Kim Y.J.2, Choi K.2, Kim S.1, Lee K.W.1, Jeon H.J.1, 
Kim S.H.1, Jang S.1, Kim S.H.1, Lee J.M.1, Choi H.S.1, Keum B.1, Jeen Y.T.1, 
Lee H.S.1, Chun H.J.1, Kim C.D.1
1Korea University College of Medicine, Department of Internal Medicine, 
Seoul, Korea (Republic of), 2Korea Institute of Science and Technology, Seoul, 
Korea (Republic of)
contact e-Mail address: spring0107@naver.com
Introduction: Detection and diagnosis of colon adenoma have long been 
emphasized in reducing colon cancer incidence. Since confirmation of the 
colon cancer diagnosis is by pathology, there has been lots of efforts to find 
and diagnose the colonic lesion more precisely before histological analy-
sis. To spot the polyp and predict its pathology more accurately, there has 
been not only promising imaging technique development but also several 
studies using artificial intelligence for polyp recognition and its classifica-
tion. The aim of this study is to develop computer-aided diagnostic system 
for colon adenoma.
aims & Methods: We labeled the colonoscopic data into 4 classes accord-
ing to the final pathology; Normal, Low-grade dysplasia, High-grade dys-
plasia, and Adenocarcinoma. The total number of colonoscopic pictures 
was 2507; Normal, 903; Low-grade dysplasia, 738; High-grade dysplasia, 
459; and Adenocarcinoma ,407, and we separated them into the train set 
and the test set. We removed unnecessary black pads from the original 
images, and we resized our data into 224 by 224 for modeling.
results: We used a ResNet50 model pre-trained with Imagenet data to 
classify the adenoma. The model we used classified the class with 86% 
accurary. We used a few data augmentation methods to improve the data 
and utilized heatmap technique to explain the results. We also compared 
our data with the classification pilot test results from 6 endoscopists.
conclusion: The trained model successfully distinguished the colon adeno-
ma pathology. There should be follow up studies to detect and diagnose 
the colon adenoma in real-time practice.
disclosure: Nothing to disclose 
P0195 usefuLness Of MagnIfyIng narrOW-Band IMagIng 
endOscOPy and MagnIfyIng chrOMOendOscOPy fOr dIagnOsIs 
Of sessILe serraTed adenOMa/POLyP WITh dysPLasIa/
carcInOMa
Murakami T.1, Sakamoto N.1, Fukushima H.1, Ueyama H.1, Matsumoto K.1, 
Shibuya T.1, Yao T.2, Nagahara A.1
1Juntendo University School of Medicine, Department of Gastroenterology, 
Tokyo, Japan, 2Juntendo University School of Medicine, Department of 
Human Pathology, Tokyo, Japan
contact e-Mail address: t-murakm@juntendo.ac.jp
Introduction: Sessile serrated adenoma/polyp (SSA/P), an early precursor 
lesion in the serrated neoplasia pathway [1], is now considered a major 
contributor to the failure of colonoscopy in the prevention of colorectal 
cancers, known as “interval cancer” [2]. Therefore, accurate diagnosis of 
SSA/P and its dysplastic components is endoscopically important. How-
ever, the usefulness of magnifying endoscopy for serrated lesions with 
dysplastic changes has not yet been fully elucidated.
aims & Methods: The aim of this study was to verify the usefulness of 
magnifying narrow-band imaging (NBI) endoscopy and magnifying chro-
moendoscopy for the diagnosis of SSA/P with dysplasia/carcinoma. Among 
the endoscopically or surgically resected lesions pathologically diagnosed 
as SSA/P with dysplasia or invasive carcinoma at Juntendo University Hos-
pital (Tokyo, Japan) between 2011 and 2018, 73 (from 73 patients), includ-
ing 44 low-grade dysplasia (LGD), 17 high-grade dysplasia (HGD), and 12 
references: 1. Bisschops R et al. Endoscopy 2019; 51(1):60-72 2. DeMicco MP 
et al. Gastrointestinal Endoscopy 2018; 87(3):677-687 3. Schreiber S et al. 
Endoscopy 2019; 51(1):73-84
disclosure: Jürgen Gschossmann: Has been on the speaker list for Norgine 
and has served on Norgine advisory boards Bharat Amlani: Employee of 
Norgine Alessandro Repici: Has received research grants from Norgine 
P0193 underWaTer endOscOPIc MucOsaL resecTIOn 
IMPrOves r0 resecTIOn raTe Of 10-20-MM cOLOrecTaL POLyPs: 
resuLTs Of a MuLTIcenTer randOMIzed cOnTrOLLed TrIaL
Kawamura T.1, Uedo N.2, Yamashina T.2,3, Akasaka T.2,4, Iwatsubo T.2, 
Nakatani Y.5, Akamatsu T.5, Takeuchi Y.2, Fujii S.6, Kusaka T.6, 
Shimokawa T.7
1Kyoto Second Red Cross Hospital, Dept. of Gastroenterology, Kyoto, Japan, 
2Osaka International Cancer Institute, Dept. of Gastrointestinal Oncology, 
Osaka, Japan, 3Osaka Red Cross Hospital, Dept. of Gastroenterology and 
Hepatology, Osaka, Japan, 4National Hospital Organization, Osaka National 
Hospital, Dept. of Gastroenterology and Hepatology, Osaka, Japan, 5Japanese 
Red Cross Society Wakayama Medical Center, Dept. of Gastroenterology 
and Hepatology, Wakayama, Japan, 6Kyoto Katsura Hospital, Dept. of 
Gastroenterology and Hepatology, Kyoto, Japan, 7Wakayama Medical 
University, Dept. of Clinical Study Support Center, Wakayama, Japan
contact e-Mail address: kawamurat@kyoto2.jrc.or.jp
Introduction: Endoscopic mucosal resection (EMR) with submucosal in-
jection is widely performed to remove colorectal polyps, and underwater 
EMR (UEMR) without submucosal injection has been reported to be useful 
for large colorectal polyps. We recently reported the results of a multi-
center randomized controlled trial that compared R0 resection rates of 10-
20-mm colorectal polyps between UEMR and conventional EMR (CEMR)1).
aims & Methods: This study aimed to reveal independent predictors for R0 
resection by post hoc analysis of the multicenter randomized controlled 
trial conducted at five Japanese institutions (UMIN000018989). Patients 
aged ≥20 years with 10-20-mm colorectal mucosal lesions (adenoma, 
intramucosal adenocarcinoma, or sessile serrated adenoma/polyp) were 
randomly assigned to the UEMR or CEMR group. Only the most proximal 
lesion was registered. Exclusion criteria were as follows: pedunculated 
lesions, residual lesions after endoscopic resection, inflammatory bowel 
disease, familial polyposis, electrolyte abnormality, coagulopathy, or se-
vere organ failure. In the CEMR group, mucosal resection was performed 
with submucosal injection in an environment of air or carbon dioxide. In 
the UEMR group, the colonic lumen was filled with water and EMR was 
performed without submucosal injection. The intergroup difference in R0 
resection rates was the primary endpoint. Multivariate logistic regression 
analysis was used for comparison of the R0 and non-R0 groups.
results: A total of 214 patients were enrolled between February 2016 and 
December 2017. Finally, 108 in the UEMR group and 102 patients in the 
CEMR were analyzed in an intention-to-treat analysis. The R0 resection 
rate of the UEMR group (69% [74/108; 95% confidence interval (CI), 59-
77%]) was significantly higher than that of the CEMR group (50% [51/102; 
95% CI, 40-60%]) (p = 0.011). There was no significant intergroup differ-
ence in median procedure time (165 vs. 175 s) or adverse events rate (2.8% 
vs. 2.0%). Multivariate analysis revealed that procedure (UEMR vs CEMR: 
odds ratio, 2.24 [95% CI, 1.24-4.03]) and tumor diameter (≥15 mm vs < 15 
mm: odds ratio, 0.56 [95% CI, 0.31-0.99]) were independent factors of R0 
resection rate (Table).
  Odds ratio [95% cI] P value
Procedure UMER/EMR 2.24 [1.24, 4.03] 0.007
Endoscopist Non-expert/expert 0.83 [0.46, 1.49] 0.530
Sex Male/female 1.21 [0.65, 2.24] 0.550
Tumor diameter ≥15 mm/<15 mm 0.56 [0.31, 0.99] 0.048
Morphology Superficial/sessile 0.95 [0.50, 1.81] 0.890
Age ≥70 y/<70 y 0.80 [0.44, 1.45] 0.460
Location Rectum 1.00 0.244
  Right-sided colon 0.93 [0.30, 2.87]  
  Left-sided colon 1.70 [0.52, 5.52]  
[Results of multivariate analysis for R0 resection]
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submucosal invasive carcinoma (SIC), were assessed. We retrospectively 
evaluated magnifying NBI endoscopic and magnifying chromoendoscopic 
findings using the Japan NBI Expert Team (JNET) system [3] and Kudo’s pit 
pattern classification [4], respectively.
results: The clinicopathological and endoscopic characteristics of the stud-
ied lesions are summarized in Table 1. All the groups were more frequently 
located in the proximal colon. The SSA/P-SICs tended to be larger than the 
SSA/P-LGDs and SSA/P-HGDs. As for the JNET classification with magnify-
ing NBI endoscopy, 63 SSA/P lesions (86%) exhibited type 1 and type 2A, 
2B, or 3, corresponding to SSA/P and dysplasia/carcinoma, respectively. 
The pit pattern analysis revealed that 61 SSA/P lesions (84%) had a combi-
nation of types II (including type II-open) and III
L
, IV, V
I
, or V
N
 pit patterns, 
corresponding to SSA/P and dysplasia/carcinoma, respectively. Further-
more, both magnifying NBI endoscopy and magnifying chromoendoscopy 
had high sensitivity (90%) for diagnosing SSA/P with dysplasia/carcinoma.
conclusion: Our findings suggest that the use of magnifying NBI endos-
copy and magnifying chromoendoscopy might be useful for the diagnosis 
of SSA/P with dysplasia/carcinoma. This increased awareness may also 
improve recognition and complete resection of SSA/Ps with dysplasia or 
invasive carcinoma, and reduce the rates of interval cancer.
variable ssa/P-Lgd (n = 44)
ssa/P-hgd 
(n=17)
ssa/P-sIc 
(n = 12)
Age (years) * 62 ± 11 (35 - 82) 68 ± 9 (51 - 81) 72 ± 6 (60 - 79)
Sex: Male / Female 23 / 21 8 / 9 3 / 9
Location: Proximal / Distal 
colon
35 / 9 14 / 3 11 / 1
Size of tumour (mm) 14 ± 7 (6 - 35) 14 ± 7 (6 - 33) 20 ± 16 (6 - 65)
Macroscopic type:      
0-Ip / 0-Isp / 0-Is / 0-IIa / 
0-IIa+Is / 0-IIa+IIc
1 / 4 / 2 / 16 / 19 / 2 - / 3 / 2 / 10 / 2 / - - / 2 / 1 / 5 / 1 / 3
JNET classification **:      
Type 1 only 6 (13%) 4 (24%) -
Type 1 + Type 2A 36 (82%) 8 (47%) 2 (17%)
Type 1 + Type 2B 2 (5%) 5 (29%) 8 (67%)
Type 1 + Type 3 - - 2 (17%)
Pit pattern classification ***:      
Type II only 10 (23%) 2 (12%) -
Type II + Type IIIL or IV 34 (77%) 9 (53%) 3 (25%)
Type II + Type VI or VN - 6 (35%) 9 (75%)
Age and size of tumor are represented as mean ± SD (range).
* SSA/P-LGD vs SSA/P-HGD, P < 0.05; SSA/P-LGD vs SSA/P-SIC, P = 0.002
** SSA/P-LGD vs SSA/P-SIC, P < 0.001; SSA/P-HGD vs SSA/P-SIC, P = 0.024
*** SSA/P-LGD vs SSA/P-HGD, P < 0.001; SSA/P-LGD vs SSA/P-SIC, P < 0.001
[Table 1. Clinicopathological and endoscopic characteristics of colorectal 
lesions studied.]
references: 1. O’Brien MJ, Yang S, Mack C, et al. Comparison of microsatel-
lite instability, CpG island methylation phenotype, BRAF and KRAS status 
in serrated polyps and traditional adenomas indicates separate pathways 
to distinct colorectal carcinoma end points. Am J Surg Pathol. 2006; 30: 
1491-1501. 2. Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite in-
stability in interval colon cancers. Gastroenterology. 2006; 131: 1700-1705. 
3. Sano Y, Tanaka S, Kudo SE, et al: Narrow-band imaging (NBI) magnify-
ing endoscopic classification of colorectal tumors proposed by the Japan 
NBI Expert Team. Dig Endosc. 2016; 28: 526-533. 4. Kudo S, Tamura S, 
Nakajima T, et al. Diagnosis of colorectal tumorous lesions by magnifying 
endoscopy. Gastrointest Endosc. 1996; 44: 8-14.
disclosure: Nothing to disclose 
P0196 effecTIveness and TOLeraBILITy Of very-LOW-vOLuMe 
PreParaTIOn fOr cOLOnOscOPy: a PrOsPecTIve, MuLTIcenTer 
OBservaTIOnaL sTudy
Maida M.F.1, Morreale G.1, Sinagra E.2, Sferrazza S.3, Manganaro M.1, 
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Introduction: The effectiveness of bowel cleansing is essential for a quality 
colonoscopy since it affects diagnostic accuracy and adenoma detection 
rate. Recently, a very-low-volume 1L PEG-ASC solution (Plenvu®; Norgine, 
Harefield, UK) has been introduced on the evidence arising from three par-
allel phase 3 randomized controlled trials showing non-inferiority respect 
to comparators [1-3].
aims & Methods: This study aimed to assess the effectiveness and toler-
ability of novel 1L PEG preparation compared to 4L and 2L PEG solutions 
in a real-life setting and to evaluate independent factors associated with a 
bowel cleansing success. 
All in- and out-patients aged 18 years and over scheduled for a screen-
ing, surveillance or diagnostic colonoscopy, after an afternoon only or 
afternoon/morning 1, 2 or 4L PEG-based preparation were consecutively 
enrolled from September 2018 to February 2019 in 5 Italian centres. Bow-
el cleansing was assessed through the Boston Bowel Preparation Scale 
(BBPS), a bowel cleansing success was defined as a total BBPS≥6 with a 
partial BBPS≥2 in each colon segment and a high-quality cleansing of the 
right colon as a partial BBPS=3. Tolerability was evaluated through a semi-
quantitative scale with a score ranging from 0 to 10. Safety was monitored 
through adverse event (AE) reporting.
results: 1289 patients meeting inclusion criteria were enrolled in the 
study. The mean age was 60.5±14.1 years with an equal gender balance, 
and the main indications of colonoscopy in 58% of cases were screening 
and surveillance for CRC.Overall, 490 patients performed a 4L PEG prepa-
ration (Selgesse®), 566 a 2L PEG cleansing (Moviprep® or Clensia®) and 
233 a 1L PEG preparation (Plenvu®). 
Overall, bowel cleansing by BBPS was 6.3±1.5, 6.2±1.5 and 7.3±1.5 (p< 
0.001) while right colon cleansing was 1.7±0.6, 1.6±0.6 and 2.1±0.6 (p< 
0.001) for 4L, 2L and 1L PEG preparation respectively. A bowel cleansing 
success was achieved in 72.4%, 74.5% and 90.1% (p< 0.001), while an 
high-quality cleansing of the right colon in 15.5%, 11.7% and 39.5% (p< 
0.001) for 4L, 2L and 1L PEG preparation groups, respectively.
The 1L preparation was the most tolerated compared to the 2 and 4L PEG 
solutions, with an average score of 7.8±1.7 vs 7.1±2.0 and 7.3±2.0 (p< 0.001) 
respectively, in the absence of serious adverse events within any of the 
three groups.
At multivariate analysis, age (OR = 0.98, 95% CI = 0.97-0.99; P = 0.02), 
absence of diabetes (OR = 1.51, 95% CI = 1.01-2.25; P = 0.04), adequate 
cleansing at previous colonoscopy (OR = 2.37, 95% CI = 1.37-4.09; P = 
0.002), afternoon-morning split regimen (OR = 2.52, 95% CI = 1.65-3.83; 
P < 0.001), low-fiber diet for at least 3 days preceding colonoscopy (OR = 
2.31, 95% CI = 1.61-3.31; P< 0.001), colonoscopy within 5 hours after the end 
of the preparation(OR= 2.16, 95% CI = 1.30-3.60; P= 0.003) and tolerability 
score (OR = 1.22, 95% CI = 1.14-1.31; P< 0.001) were independently associ-
ated with a bowel cleansing success.
conclusion: The novel 1L PEG-ASC solution (Plenvu®) presents greater ef-
fectiveness compared to higher-volume PEG preparation in terms of over-
all bowel cleansing and high-quality cleansing of the right colon with the 
advantage of a higher adherence and a significantly better tolerability pro-
file respect to comparators. In the next future, this new very-low-volume 
solution will be useful to improve the tolerability of bowel preparation, 
increasing at the same time the adherence to CRC screening and surveil-
lance programs.
references: 1) DeMicco MP, Clayton LB, Pilot J, et al. Novel 1 L polyethyl-
ene glycol-based bowel preparation NER1006 for overall and right-sided 
colon cleansing: a randomized controlled phase 3 trial versus trisulfate. 
GastrointestEndosc. 2018;87:677-687. 2) Bisschops R, Manning J, Clayton 
LB, et al. Colon cleansing efficacy and safety with 1 L NER1006 versus 2 L 
polyethylene glycol + ascorbate: a randomized phase 3 trial. 3) Schreiber 
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results: Fifteen colorectal hybrid ESD procedures were conducted success-
fully in three pigs (five hybrid ESD each). The en bloc resection rate of 
colorectal hybrid ESD was 100% (15/15). The average size of the colorec-
tal hybrid ESD is 10.00±1.86 mm. No adverse event was found during the 
procedure or one week after resection. The endoscopic examination one 
week after the resection showed all wound being healing. In the pathology 
evaluation, superficial muscularis propria damage was found in one case 
(1/15, 6.67%), which was covered with exudate. 
Other fourteen postoperative wounds showed healing of the ulcer. Elev-
en gastric hybrid ESD procedures were performed. The en bloc resection 
rate of gastric hybrid ESD was 100% (11/11). The average size of the gastric 
hybrid ESD was 17.18±9.00mm. No procedure related adverse event was 
found.
conclusion: The new all in one snare is feasible and safe in gastric and 
colonic hybrid ESD in porcine model. It can save the numbers of endo-
scopic accessories using during hybrid ESD procedure and simplify the ESD 
procedure. Further study in human is awaited
disclosure: Nothing to disclose 
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Introduction: The development of the procedure questionnaire, by the Eu-
ropean Colonoscopy Quality Investigation (ECQI) Group, has been previ-
ously described in posters presented at United European Gastroenterology 
Week, 2015 and 2016.
aims & Methods: To investigate the factors associated with adequate bow-
el preparation using questionnaire responses from across Europe. Data 
collection is an ongoing process. We analysed data collected between 
2/6/16 and 30/4/18.
A stepwise multivariable logistic regression analysis was performed to in-
vestigate which factors are associated with achievement of adequate bow-
el preparation, defined as a Boston Bowel Preparation Scale (BBPS) score 
≥6. Analysis was performed on the following variables: age over or under 
50; gender; body mass index (BMI) categories; inpatient/outpatient status; 
reason for procedure; use of bowel preparation; whether the patient fol-
lowed instructions; proportion of bowel preparation consumed; total vol-
ume of fluid consumed; time period since last dose of bowel preparation; 
dosing regimen; time of day colonoscopy was performed.
results: Data were collected on 6455 procedures, of which whether bowel 
preparation was adequate (BBPS≥6) or not could be determined in 6236. 
Of these, there were 2884 procedures where the results of all selected vari-
ables were known: adequate bowel preparation was achieved in 86.96% 
of these procedures.
The first five variables most associated with adequate bowel clearance 
were, in order:
1. Patient following instructions (89.1% vs. 54.3%, p< 0.0001).
2. Split-dosing or same-day regimen (89.5% split-dosing and 90.8% 
same-day vs. 77.9% evening, p=0.004).
3. Outpatient status (88.4% vs. 77.3% inpatient, p< 0.0001).
4. Age < 50 years (93.3% vs. 85.3% > 50 years, p< 0.0001).
S, Baumgart DC, Drenth JPH, et al. Colon cleansing efficacy and safety with 
1 L NER1006 versus sodium picosulfate with magnesium citrate: a random-
ized phase 3 trial.
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Introduction: The current study aimed at comparing the effects of diltiazem 
gel, an antispasmoic drug with local pain-reducing effects, with lidocaine 
gel in patients undergoing flexible rectosigmoidoscopy.
aims & Methods: This double-blinded, randomized, clinical trial was 
performed on 80 patients who were potential candidates for rectosig-
moidoscopy. After obtaining the informed consent, the patients randomly 
assigned to one of the lidocaine gel (2 mL) or diltiazem gel (2 mL) group, 
10 minutes prior to rectosigmoidoscopy. The level of pain in the patients 
during the procedure was measured using the visual analogue scale 
(VAS) and the results were recorded. The data were analyzed using paired 
samples t-test and independent t-test as well as analysis of covariance 
(ANOVA) with SPSS version 18. P-value < 0.05 was considered the level 
of significance.
results: Of 80 patients, 35 (43.75%) were male and 45 (56.25%) female 
with a mean age of 51.45 ± 15.21 years. The most frequent indications 
for rectosigmoidoscopy were abdominal pain (46.3%) and rectorrhagia 
(31.3%). The mean VAS score for pain reported by the patients in the lido-
caine and diltiazem groups were 3.97 ± 2.89 and 2.60 ± 2.36, respectively. 
The VAS score for pain in the diltiazem group was significantly lower than 
of the lidocaine group (P = 0.023).
conclusion: The application of local diltiazem gel around the anus, in spite 
of no side effects, can effectively reduce the pain and discomfort in patients 
during rectosigmoidoscopy.
disclosure: Nothing to disclose 
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Introduction: Endoscopic submucosal dissection (ESD) has a higher rate 
of en bloc resection rate, more accurate histological evaluation and lower 
rate of local recurrence compared with endoscopic mucosal resection 
(EMR). However, the technical difficulty limits its use in western country. 
To overcome the drawback, various modified techniques have been ap-
plied. Among them, ESD with snaring (by the name of hybrid ESD) is the 
most commonly used technique.
aims & Methods: We designed a new multifunctional snare to simplify hy-
brid ESD procedure. The new rotatable device has the following functions: 
submucosal injection, needle knife, snare and argon plasma coagulation 
(APC). Animal study on porcine model was used to test its feasibility and 
safety in gastric and colorectal hybrid ESD. Artificial colorectal lesions of 
proximately 10mm and artificial gastric lesions of about 15mm were cre-
ated by APC function of the new device. Hybrid ESD was done as following 
: initial mucosal pre-cut, submucosal injection, circumferential cutting , 
snare and APC the wound. The wound was checked one week after hybrid 
ESD. Then, pigs were sacrificed and necropsy performed.
The primary outcome is the en bloc resection rate. The secondary out-
comes are the intra- and postoperative adverse event rate (bleeding and 
perforation). The wound healing one week after resection was also as-
sessed by pathology.
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5. Lower time period between procedure and last intake of bowel prepa-
ration (mean 6.1 hours vs. 8.0 hours in those with inadequate bowel 
preparation, p=0.0030).
conclusion: Patients following instructions is the most important factor as-
sociated with achieving adequate bowel clearance followed by using a 
split-dosing or same-day regimen.
disclosure: Amaro A, Agrawal A, Hünger M, Petruzziello L, Ono A, Jover 
R, Toth E: Consultant & advisory board participant to Norgine. Spada C: 
Consultant fee from Norgine. Brink L: Consultancy & Advisory Board par-
ticipant to Norgine, AMBU. Fischbach W: Consultancy & Advisory Board 
participant to Norgine; Speaking - Abbott, Bio Merieux, Falk; Advisory 
speaking - Aptalis, Fresenius Biotech, Pfizer; Advisory - Boehringer Ingel-
heim, med update. Kinnunen U: Consultant & advisory board participant 
to Norgine and Olympus (European NBI Expert Training Group). Riemann 
JF: In terms of ECQI, consultant to Norgine, otherwise no conflict of inter-
est. Amlani B: Employee of Norgine. Koulaouzidis A: No relevant conflict 
of interest. Patai A: No conflict of interest. Pecere S: No conflict of interest. 
P0200 endOscOPIc ManageMenT Of nOn-dIMInuTIve POLyPs: 
OBservaTIOns frOM The eurOPean cOLOnOscOPy quaLITy 
InvesTIgaTIOn quesTIOnnaIre
Amaro P.1, Agrawal A.2, Brink L.3, Fischbach W.4, Fuccio L.5, 
Hünger M.6, Kinnunen U.7, Koulaouzidis A.8, Ono A.9, Petruzziello L.10,11, 
Toth E.12, Riemann J.F.13,14, Amlani B.15, Spada C.16, 
on Behalf of the ECQI Group
1Coimbra University Hospital, Coimbra, Portugal, 2Doncaster Royal 
Infirmary, Doncaster, United Kingdom, 3Herlev Hospital, Herlev, Denmark, 
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for Internal Medicine, Würzburg, Germany, 7Tampere University Hospital, 
Tampere, Finland, 8The Royal Infirmary of Edinburgh, Edinburgh, United 
Kingdom, 9Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, 
Spain, 10Fondazione Policlinico Universitario A.Gemelli IRCCS, Digestive 
Endoscopy Unit, Rome, Italy, 11Università Cattolica del Sacro Cuore, Centre 
for Endoscopic Research Therapeutics and Training - CERTT, Rome, Italy, 
12Skåne University Hospital, Lund University, Malmö, Sweden, 13Director em. 
Klinikum Ludwigshafen, Ludwigshafen, Germany, 14Chairman, LebensBlicke 
Foundation for the Prevention of Colorectal Cancer, Ludwigshafen, 
Germany, 15Norgine, Harefield, Middlesex, United Kingdom, 16Fondazione 
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Introduction: The development of the procedure questionnaire, by the 
European Colonoscopy Quality Investigation (ECQI) Group, has been pre-
viously presented at United European Gastroenterology Week, 2015 and 
2016.1,2 Management of pathology is a domain of colonoscopy quality ac-
cording to European Society of Gastrointestinal Endoscopy (ESGE) perfor-
mance measures.3
aims & Methods: To assess the endoscopic interventions performed in pro-
cedures where a non-diminutive polyp was recorded. Data collection is an 
ongoing process: we analysed data collected between 2/6/16 and 30/4/18.
results: Of 6445 procedures, 2621 reported a polyp (40.7%). Polyp size was 
missing in 35 procedures, leaving 2586 procedures with at least one polyp 
of known size. 
Polyps >5 mm: 1294 procedures reported at least one polyp >5mm: 1156 
reported an endoscopic intervention (89.3%), 136 reported that there was 
no endoscopic intervention (10.5%) while 2 did not answer (DNA, 0.15%).
Of the 138 procedures with a polyp >5mm that did not report an endoscopic 
intervention, there was one procedure in which an immediate complica-
tion (vascular syncope) was reported (132 stated there were no immediate 
complications, 5 DNA), and 37 who reported a requirement for a non-
routine (immediate) repeat procedure (no 93, DNA 8). The reasons for a 
repeat procedure were: 20 further treatment or intervention required, 8 
insufficient bowel preparation, 3 pathology encountered, 2 adjustment of 
blood-thinning medication required prior to intervention, and one case 
each of refused consent for polypectomy, referral to specialised hospital, 
pain and unsafe procedure.
Polyps ≥20 mm (polyp size ≥20 mm is a subset of >5 mm): There were 
280 procedures with a polyp ≥20 mm recorded. Of these procedures 227 
(81.1%) reported an endoscopic intervention while 53 (18.9%) reported 
that they did not perform an endoscopic intervention. Tattooing was only 
reported in 28 procedures (10%). 
Of the 53 reporting no endoscopic intervention, one reported an imme-
diate complication (vascular syncope), while 50 reported no immediate 
complication and 2 DNA. A requirement for an immediate (non-routine) 
repeat procedure was reported in 19 procedures (no 33, DNA 1): 9 further 
treatment or intervention required, 5 insufficient bowel preparation, 3 pa-
thology encountered, one referral to specialised hospital for endoscopic 
mucosal resection and one unsafe procedure.
conclusion: In procedures reporting non-diminutive polyps, no immediate 
endoscopic intervention was reported in over 1 in 10 procedures, rising 
to nearly one in five for procedures reporting a polyp ≥20 mm. The ESGE 
specifies that “In patients undergoing removal of colorectal nonpedun-
culated lesions 20mm in size or larger, or with suspicious macroscopic 
features regardless of size, the resection site should be tattooed to improve 
future re-location of the resection site”. This should be done in 100% of 
cases.3 Our findings indicate that tattooing rates are very low, being re-
ported in only 10% of procedures recording a polyp ≥20 mm.
Type of endoscopic intervention Polyp size >5 mm, number, n=1156 
Polyp size ≥20 mm, 
number, n=227 
Endoscopic mucosal resection 154 58
Endoscopic submucosal dissection 14 6
Polypectomy (complete) 1012 159
Polypectomy (incomplete) 18 10
Argon plasma coagulation 4 1
Biopsy 41 21
Tattooing 40 28
Note: Biopsies performed were not necessarily related with polyp resection.
[Endoscopic interventions in procedures with non-diminutive polyps 
(multiple options possible). Note: polyp size ≥20 mm is a subset of >5 mm.]
references: 1. Riemann JF et al. Poster PO160: UEGW 2015, Oct 24-28: Bar-
celona. 2. Jover R et al. Poster PO165: UEGW 2016, Oct 15-19: Vienna. 3. 
Kaminski et al. Endoscopy 2017; 49: 378-397.
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fee from Norgine. Brink L: Consultancy & Advisory Board participant to 
Norgine, AMBU. Fischbach W: Consultancy and Advisory Board participant 
to Norgine; Speaking - Abbott, Bio Merieux, Falk; Advisory speaking - Ap-
talis, Fresenius Biotech, Pfizer; Advisory - Boehringer Ingelheim, med up-
date. Kinnunen U: Norgine and Olympus (European NBI Expert Training 
Group. Riemann JF: In terms of ECQI, consultant to Norgine, otherwise no 
conflict of interest. Amlani B: Employee of Norgine. Fuccio L: No conflict of 
interest. Koulaouzidis A: No relevant conflict of interest. 
P0201 sessILe serraTed LesIOns deTecTIOn WITh 
endOcuff-assIsTed cOLOnOscOPy - a randOMIzed 
cOnTrOLLed TrIaL
Costa Santos M.P., Palmela C., Gouveia C., Gomes C., Roque Ramos L.M., 
Fidalgo C., Nunes J., Loureiro R., Barjas E., Oliveira H., Torres J., Cravo M., 
Oliveira Ferreira A.
Hospital Beatriz Ângelo, Gastroenterology, Loures, Portugal
contact e-Mail address: mariapiacostasantos@gmail.com
Introduction: Sessile serrated lesions (SSL) have been associated with in-
terval colorectal cancer (CRC) since they present a faster carcinogenesis 
and are more difficult to detect than adenomas. Several techniques have 
been developed to increase the sensitivity of colonoscopy, namely the En-
docuff. Studies demonstrated that Endocuff-assisted colonoscopy improves 
adenoma detection rate. Still, the available data of its’ effectiveness in 
detecting SSL is very limited. The aim of this study was to compare the 
effectiveness in SSL detection of Endocuff-assisted colonoscopy versus con-
ventional colonoscopy.
aims & Methods: We performed a randomized controlled trial that in-
cluded patients undergoing elective colonoscopy between June 2018 and 
March 2019. Patients were randomly assigned in two groups before the 
procedure: 1) Endocuff-assisted colonoscopy; 2) Conventional colonos-
copy. The procedures were performed with high definition endoscopes. 
The primary endpoint was the mean number of SSL with ≥ 10 mm per 
colonoscopy.
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any individual segment), while protruded lesion reporting was generally 
higher in higher BMI groups (p< 0.0001 overall and in all individual seg-
ments): BMI < 18.5 17.9%, 18.5-< 25 30.5%, 25-< 30 40.0%, 30-< 35 45.6%, 
≥35 42.8%. 
Flat lesions were more commonly reported in inpatients (inpatients 16.2% 
vs 10.7% outpatients, p< 0.0001), this was significant in the left (p=0.004) 
and right (p< 0.0001) segments but not the transverse segment (p=0.256). 
Protruded lesions were more common in outpatients (inpatients 29% vs 
33.4% outpatients, p=0.023), however, this was not significant in any in-
dividual segments. 
The reporting of flat lesions was significantly higher in procedures report-
ing adequate bowel clearance (11.4% vs 8.0%, p=0.004), this was signifi-
cant in the left (p=0.016) and right (p=0.01) segments but not the trans-
verse segment (p=0.354). Conversely, reporting of protruded lesions was 
not changed according to bowel cleansing adequacy (p=0.317).
conclusion: Flat lesions are less commonly reported than protruded le-
sions. They are significantly less likely to be reported than protruded le-
sions in the left colon segment compared with the transverse and right 
segments. Reporting of flat lesions was not associated with BMI, while 
higher BMI was associated with increased reporting of protruded lesions. 
Flat lesions were more likely to be reported in inpatients while protruded 
lesions were more likely in outpatients. Reporting of protruded lesions 
was not affected by adequacy of bowel clearance while flat lesion report-
ing was higher in procedures reporting adequate bowel clearance.
references: 1. Riemann JF et al. Poster PO160: UEGW 2015, Oct 24-28: Bar-
celona. 2. Jover R et al. Poster PO165: UEGW 2016, Oct 15-19: Vienna.
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fee from Norgine. Brink L: Consultancy & Advisory Board participant to 
Norgine, AMBU. Fischbach W: Consultancy and Advisory Board participant 
to Norgine; Speaking - Abbott, Bio Merieux, Falk; Advisory speaking - Ap-
talis, Fresenius Biotech, Pfizer; Advisory - Boehringer Ingelheim, med up-
date. Kinnunen U: Norgine and Olympus (European NBI Expert Training 
Group). Riemann JF: In terms of ECQI, consultant to Norgine, otherwise no 
conflict of interest. Amlani B: Employee of Norgine. Fuccio L: No conflict of 
interest. Koulaouzidis A: No relevant conflict of interest. 
P0203 Is adenOMa deTecTIOn raTe IncreasIng In PaTIenTs 
yOunger Than age 50?
Wonaga A., Gutierrez B., Cassella F., Graciano J., Fernandez J.L., Viola L.A.
Centro Integral de Gastroenterologia, Gastroenterology, Buenos Aires, 
Argentina
contact e-Mail address: awonaga@gmail.com
Introduction: Some data in the literature suggest that adenoma detection 
rate (ADR) in patients younger than age 50 has increased with the passage 
of years, with figures ranging between 4.7% and 24.1%. These observa-
tion gives cause for the start of colorectal cancer (CRC) screening at earlier 
ages.
aims & Methods: aim: To compare the ADR in two populations belonging 
to two periods separated by eight years. 
Methods: We retrospectively studied patients younger than 50 years old 
who underwent a colonoscopy in an endoscopy center from Buenos Aires, 
Argentina; 204 from May to October 2009 (group 1) and 709 from January 
2016 to May 2017 (Group 2). We recorded the following data: age, sex, 
indication of colonoscopy [low risk screening, high risk screening (family 
antecedents of CRC) and due to symptoms or surveillance], ADR and ad-
enocarcinoma detection rate (ACDR). Detection rates were compared using 
a x2 or a Fisher test as appropriate.
results: Ninety six (47.1 %) patients from group 1 and 337 (47.5%) from 
group 2 were men (NS). Mean age was 40.4 +/- 7.5 years in group 1 and 
39.1 +/- 7.5 years in group 2 (P = 0,03). In group 1, the indication of colo-
noscopy was low risk screening in 45 patients, high risk screening in 41, 
and symptoms or surveillance in 118. In group 2, the indication of colonos-
copy was low risk screening in 116 patients, high risk screening in 97, and 
symptoms or surveillance in 496. In the total population, 20 adenomas 
were detected in group 1 (ADR 9.8%) and 66 in group 2 (ADR 9.3%) (P = 
0.93). No adenocarcinoma was detected in group 1 (ACDR 0%) and 5 were 
detected in group 2 (ACDR 0.7%) (P = 0.59). In low risk screening patients, 
7 adenomas were detected in group 1 (ADR 15.6%) and 22 in group 2 (ADR 
19.0%) (P = 0.81). In high risk screening patients, 5 adenomas were de-
tected in group 1 (ADR 12.2%) and 12 in group 2 (ADR 12.3%) (P = 1.00). 
results: 170 patients were included, 57% male, with mean age of 62.4±9.9 
years. In per protocol analysis, 81 (48%) patients performed Endocuff-as-
sisted colonoscopy and 89 (52%) conventional colonoscopy. There were no 
differences in cecal intubation rate (99% vs 94%, P=0.214), in mean cecal 
intubation time (7.3 ± 4.1 vs 8.0 ± 4.3 minutes, P=0.260) nor in withdrawal 
time (12.3 ± 5.3 vs 13.1 ± 6.7 minutes, P=0.373) between procedures with 
and without Endocuff. SSL detection rate was higher in Endocuff-assisted 
colonoscopy group (9% vs 2%, P=0.027), as well as the mean number of 
SSL detected per colonoscopy (0,2 ± 0,5 vs 0,02 ± 0,1, P=0,021). There were 
no differences in the mean number of SSL ≥ 10 mm between groups (0.04 
± 0.2 vs 0.02 ± 0.1, P=0.577). There were also no differences in adenoma 
detection rate (72% vs 67%, P=0.554) nor in the mean number of adeno-
mas detected per colonoscopy (1.8 ± 2.4 vs 1.7 ± 2.2, P=0.785). The rate of 
adverse events was similar between groups (1% vs 1%, P=0.999).
conclusion: Endocuff-assisted colonoscopy increases SSL detection rate 
and the mean number of SSL per colonoscopy, but not the mean number 
of SSL ≥ 10 mm.
disclosure: Nothing to disclose 
P0202 assOcIaTIOn Of PaTIenT facTOrs WITh fLaT and 
PrOTruded LesIOn rePOrTIng: OBservaTIOns frOM The 
eurOPean cOLOnOscOPy quaLITy InvesTIgaTIOn 
quesTIOnnaIre
Toth E.1, Amaro P.2, Agrawal A.3, Brink L.4, Fischbach W.5, Fuccio L.6, 
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Introduction: The development of the procedure questionnaire, by the Eu-
ropean Colonoscopy Quality Investigation (ECQI) Group, has been previ-
ously described.1,2
aims & Methods: To assess the patient factors associated with flat and 
protruded lesion reporting, as defined by Paris classification. Data col-
lection is an ongoing process: we analysed data collected between 2/6/16 
and 30/4/18. Adequate bowel clearance was defined as a Boston Bowel 
Preparation Score (BBPS) ≥6.
results: Of 6445 procedures, 2621 reported a polyp in at least one seg-
ment (40.7%). Protruded lesions were reported in 2160 procedures and 
flat lesions were reported in 692 procedures. In procedures with polyps 
reported, the proportion with flat lesions was significantly lower in the left 
colon segment than either transverse or right colon segments (p< 0.0001).
  right Transverse Left any segment
Any polyp 1328 723 1645 2621
Flat lesion 346 181 329 692
Protruded lesion 1012 544 1346 2160
[Table. Procedures in which a polyp was reported by type and colon 
segment]
Reporting of both flat and protruded lesions varied by age (generally in-
creasing with increasing age, p< 0.0001 overall and in all individual seg-
ments). Reporting also increased for both flat and protruded lesions in 
those who had received a previous total colonoscopy within the last 5 
years (p< 0.0001, significant in all segments): flat lesions 13.8% vs 9.8%; 
protruded lesions 38.7% vs 29.2%. Flat lesion reporting was not associ-
ated with body mass index (BMI, kg/m2) (p=0.667 overall, not significant in 
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In patients who underwent endoscopy due to symptoms or surveillance, 8 
adenomas were detected in group 1 (ADR 6.8%) and 32 in group 2 (ADR 
6.4%) (P = 0.83).
conclusion: We did not find significant differences in the ADR of both 
groups, independently of the indication of colonoscopy, suggesting that 
ADR has not increased with the passage of years. ACDR neither differs but 
we cannot reach any conclusion due to the very low prevalence of CRC.
disclosure: Nothing to disclose 
P0204 saLIne-IMMersIOn TheraPeuTIc endOscOPy (sITe) 
cOMBIned WITh The POckeT-creaTIOn MeThOd (PcM) fOr 
endOscOPIc suBMucOsaL dIssecTIOn (esd) Of gasTrIc and 
cOLOrecTaL LesIOns: exPerIence frOM a TerTIary referraL 
cenTre In LOndOn
Despott E.J., Coppo C., Lazaridis N., Costa D., Koukias N., Murino A.
Royal Free Hospital & UCL School of Medicine, Royal Free Unit for Endoscopy 
& Centre for Gastroenterology, UCL Institute for Liver & Digestive Health, 
London, United Kingdom
contact e-Mail address: claudiacoppo@icloud.com
Introduction: Endoscopic submucosal dissection (ESD) is now widely ac-
cepted as a potentialy curative, minimally invasive alternative to major 
surgery for the endoscopic management of superficial gastric and colorec-
tal neoplasms. Due to its several advantages, in our institution, we use the 
pocket-creation method (PCM) for ESD as described by Yamamoto H. et al. 
(1). Since 2017, we have combined this with saline-immersion therapeutic 
endoscopy (SITE), since in our experience, this further facilitates PCM ESD 
by improving view quality (through refractive magnification, and minimal 
lense fogging) and lesion lifting, through buoyancy.
aims & Methods: The aim of our study is to review our centre’s experience 
of SITE-PCM-ESD cases. Demographic, endoscopic, histopathological data 
of patients treated by SITE-PCM-ESD were prospectively collected from July 
2017 to April 2019.
results: ESDs were performed in 35 patients (15 women), mean age: 64.8 
years. Three lesions (8.6%) were removed from the stomach, 1 from the 
caecum (2.86%), 6 from the ascending colon (17.14%), 14 from the sigmoid 
colon (40%) and 11 from the rectum (31.40%). En-bloc pure SITE-PCM-ESD 
resection was achieved in 23 patients (65.7%); in 3 patients (8.6%) the 
procedure was not completed due to the suspicion of invasive malignancy 
and these patients were referred for surgery. Finally, in 9 cases (25.7%) the 
technique was converted in an endoscopic mucosal resection (EMR) due to 
time constraints. One of the 3 patients who were referred for surgery did 
not undergo any further intervention due to risks associated with underly-
ing comorbidities. In 1 of the other 2 cases the histopathology after surgery 
confirmed our suspicion of malignancy. 
Details of the cases managed by pure SITE-PCM-ESD are described as fol-
lows. Median specimen size was of 45,1 mm (12-100mm). Histopathologi-
cal examination showed: 1) 1 villous adenoma with low grade dysplasia, 2) 
8 tubular adenoma with low grade dysplasia, 3) 3 tubular adenoma with 
high grade dysplasia, 4) 1 tubulovillous adenoma with high grade dyspla-
sia, 5) 10 tubulovillous adenoma with low grade dysplasia, 6) 1 adenocar-
cinoma, 7) 4 neuroendocrine tumors (2 G1 rectal NET, 1 G1 gastric NET and 
1 G2 gastric NET), 8) 1 serrated adenoma with low grade dysplasia 9) 1 hy-
perplastic gastric polyp and 10) 1 sessile serrated lesion without dysplasia. 
R0 resection rate was 90.32 %. Lymphovascular infiltration was suspected 
in the one case of malignancy (3.12%). Two patients suffered from early 
post-procedural rectal bleeding, warranting further endotherapy (clip 
placement and haemospray application); no further complications were 
identified. To date, 16 patients (51.6%) have completed 3 months’ and 12 
patients (38.7%) have completed 6 months’ endoscopic follow-up respec-
tively; none of these patients have had any evidence of disease recurrence.
conclusion: Our series of SITE-PCM ESD showed favorable results in term 
of efficacy and safety. Further comparative randomised control studies are 
required to further evaluate potential advantages of this technique.
references: 1. Hayashi Y, Sunada K, Takahashi H, Shinhata H, Lefor AT, 
Tanaka A, Yamamoto H. Pocket-creation method of endoscopic submuco-
sal dissection to achieve en bloc resection of giant colorectal subpeduncu-
lated neoplastic lesions. Endoscopy. 2014;46 E421-2.
disclosure: Dr Despott and Dr Murino receive research/education support 
from Aquilant Medical, Fujifilm, Olympus and Pentax Medical. All other 
authors have no conflicts of interest to disclosure. 
P0205 effIcacy, safeTy and resecTIOn OuTcOMes Of 
endOscOPIc suBMucOsaL dIssecTIOn fOr The TreaTMenT Of 
suPerfIcIaL cOLOrecTaL neOPLasIa In an endOscOPy referraL 
cenTer
Fiori G., Bravi I., Ravizza D., Trovato C., De Roberto G., Giunta M., 
Crosta C.
European Insitute of Oncology, IRCCS, Division of Endoscopy, Milan, Italy
contact e-Mail address: ivana.bravi@ieo.it
Introduction: Endoscopic submucosal dissection (ESD) is the preferred re-
section technique in eastern countries for superficial colorectal neoplasia 
larger than 2 centimeters in size and/or suspicious of submucosal super-
ficial invasion. Only few data on ESD for colorectal neoplasia have been 
published in western countries.
aims & Methods: We aimed to assess the safety, efficacy and resection 
outcomes of ESD for the treatment of large colorectal lesions in our cen-
ter. We retrospectively collected medical data of consecutive patients who 
underwent colorectal ESD between 2015 and 2018 from a prospectively re-
corded database. Patients with inflammatory bowel diseases and familiar 
polyposis were excluded.
results: Ninety five lesions in 94 patients were included in the study (42 
males, median age 69 years). Median lesion size was 30 mm. 82 (86.3%) 
were naïve lesions, whereas 13 (13.7%) were recurrent or remnant lesions. 
24 (25.3%) lesions were located in the right colon, 21 (22.1%) in the left 
colon, 50 (52.6%) in the rectum. Naïve lesions were defined as laterally 
spreading tumors (LSTs) granular homogeneous, 2 (2.4%), LSTs granular 
mixed, 26 (31.7%), LSTs non granular, 37 (45.1%), sessile polyps, 17 (20.7%). 
Histology revealed 77 (81%) benign adenomatous lesions (with high grade 
dysplasia in 87%), while submucosal invasive cancer (SMIC) was present 
in the remaining 18 (19%) lesions. All SMICs were deeply invasive (>1000 
µm). 
En-bloc resection was possible in 71 (74.7%) lesions: 65/82 (79.3%) naïve 
and 6/13 (46.1%) non naïve. In 21(22.1%) lesions piecemeal ESD had to be 
performed. In the remaining 3 lesions (2 naïve), resection was stopped 
because of non-lifting. 
Complications occurred in 13/95 (13.7%) lesions: 6 (6.3%) post-procedural 
bleedings (no one needed blood transfusion) and 7 (7.4%) intra-procedur-
al perforations. Only one patient (1.05%) underwent surgical management 
for complication (i.e. perforation). 
R0 resection was obtained in 58/71 lesions: 54/60 (90%) adenomas and 
4/11 (36.4%) SMICs. R1 was due to positive vertical margins in 2/60 (3.33%) 
adenomas and in 7/11 (63.6%) SMICs, positive lateral margins in 3/60 
(5.0%) adenomas, both vertical and lateral positive margins in 1/60 (1.7%) 
adenomas. 
14/18 (77.8%) patients with SMIC underwent surgery; in 10/14 (71.4%) of 
them surgical specimen was negative for neoplasia. The remaining 4 pa-
tients were not operated for comorbidities or refusal. 
57 patients had 1-4 surveillance colonoscopies (SCs): 43 of the en-bloc 
resection group (EBG) and 14 in the piecemeal resection group (PMG). 
Recurrence was observed in 2/43 (4.6%) EBG patients and in 3/14 (21.4%) 
PMG patients. Recurrence occurred in 2/47 (4.2%) naïve lesions and in 
3/10 (30%) non naïve lesions. All recurrences were successfully treated 
endoscopically.
conclusion: In our experience ESD is a safe technique for the treatment of 
large superficial colorectal neoplasia, with an acceptable risk of complica-
tions and a low recurrence rate considering benign lesions. Despite our 
adherence to the current guidelines for ESD in the treatment of superficial 
colorectal neoplasia, none of the SMICs of our series had a curative treat-
ment because all of them were deep invasive cancers.
disclosure: Nothing to disclose 
P0206 recTaL reTrOfLexIOn: Is IT reaLLy necessary?
Giunta M., Tamayo D., Trovato C.M., Ravizza D., Bravi I., de Roberto G., 
Fiori G., Crosta C.
European Institute of Oncology, Division of Endoscopy, Milan, Italy
contact e-Mail address: mariangela.giunta@ieo.it
Introduction: Rectal retroflexion (RR) is a commonly performed maneuver 
during lower gastrointestinal (GI) endoscopy even if poor evidence sup-
ports its diagnostic and clinical value and international guidelines do not 
agree to consider it as a key performance measure.
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P0207 assOcIaTIOn Of asPecTs Of PrOcedure WITh 
rePOrTIng Of fLaT and PrOTruded LesIOns: OBservaTIOns 
frOM The eurOPean cOLOnOscOPy quaLITy InvesTIgaTIOn 
quesTIOnnaIre
Ono A.1, Amaro P.2, Agrawal A.3, Brink L.4, Fischbach W.5, Fuccio L.6, 
Hünger M.7, Kinnunen U.8, Koulaouzidis A.9, Petruzziello L.10,11, 
Riemann J.F.12,13, Toth E.14, Amlani B.15, Spada C.16, on Behalf of the ECQI 
Group
1Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, 2Coimbra 
University Hospital, Coimbra, Portugal, 3Doncaster Royal Infirmary, Doncaster, 
United Kingdom, 4Herlev Hospital, Herlev, Denmark, 5Gastroenterologie 
und Innere Medizin, Aschaffenburg, Germany, 6S.Orsola-Malpighi 
University Hospital, Bologna, Italy, 7Private Practice for Internal Medicine, 
Würzburg, Germany, 8Tampere University Hospital, Tampere, Finland, 9The 
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom, 10Fondazione 
Policlinico Universitario A.Gemelli IRCCS, Digestive Endoscopy Unit, Rome, 
Italy, 11Università Cattolica del Sacro Cuore, Centre for Endoscopic Research 
Therapeutics and Training - CERTT, Rome, Italy, 12Director em. Klinikum 
Ludwigshafen, Ludwigshafen, Germany, 13Chairman, LebensBlicke Foundation 
for the Prevention of Colorectal Cancer, Ludwigshafen, Germany, 14Skåne 
University Hospital, Lund University, Malmö, Sweden, 15Norgine, Harefield, 
Middlesex, United Kingdom, 16Fondazione Poliambulanza, Brescia, Italy
contact e-Mail address: ono.akiko@gmail.com
Introduction: European Society of Gastrointestinal Endoscopy (ESGE) 
guidelines recommend the routine use of high-definition (HD) white light 
colonoscopy for detection of colorectal neoplasia in the average popula-
tion.1 The development of the procedure questionnaire, by the European 
Colonoscopy Quality Investigation (ECQI) Group, has been previously de-
scribed.2,3
aims & Methods: To assess how aspects of a procedure associate with 
reporting of flat and protruded lesions, according to Paris classification. 
Data collection is an ongoing process: we analysed data collected between 
2/6/16 and 30/4/18.
results: Of 6445 procedures, 2621 reported a polyp in at least one segment 
(40.7%). Protruded lesions were reported in 2160 procedures and flat le-
sions in 692 procedures. In procedures with polyps reported, the propor-
tion with flat lesions was significantly lower in the left colon segment than 
either transverse or right colon segments (p< 0.0001).
Use of HD equipment significantly increases reporting of both flat lesions 
(13.2% vs 5.5%, p< 0.0001) and protruded lesions (35.8% vs 23.6%, p< 
0.0001). HD equipment significantly increases the proportion of flat lesions 
in procedures where polyps are reported (p< 0.0001): significant in right 
(p=0.004) and left (p=0.0054) segments, but not the transverse segment 
(p=0.0933). 
Chromoendoscopy was increasingly used when both flat lesions (23.4% 
vs 7.9%, p< 0.0001) and protruded lesions (61.4% vs 27.2%, p< 0.0001) 
were reported. Where polyps are detected, the proportion of flat lesions 
increases with the use of chromoendoscopy (p=0.0005): significant in 
transverse (p=0.0172) and left (p=0.0337) segments, but not the right seg-
ment (p=0.1176).
The use of assistive technology significantly increases flat lesion reporting 
(21.3% vs 10.3%, p< 0.0001), significant in all segments. Higher rates were 
seen with the use of Endocuff (38.5%) and cap-assisted (23.9%) versus 
when other assistive technologies were used (19.8%). Assistive technology 
does not influence reporting of protruded lesions (p=0.712).
The reporting of flat (p=0.019) and protruded (p=0.015) lesions varies 
according to the time of day the procedure was performed. Flat lesion 
reporting was highest in the morning (07:00-11:59): 13.9% vs 11.3% af-
ternoon (12:00-17:59) vs 8.4% evening (18:00-19:59). However, this was 
not significant in individual segments: right (p=0.321), transverse (p=0.063) 
and left (p=0.069). Conversely, protruded lesion reporting was higher in 
the evening and afternoon than morning: morning 30.1% vs afternoon 
33.8% vs evening 39.2%. This was significant in the transverse segment 
(p=0.008), but not the right (p=0.62) and left (p=0.065) segments.
conclusion: Use of HD equipment improves the reporting of both flat and 
protruded lesions. Furthermore, its use relatively increases the reporting 
of flat lesions, particularly in the left colon segment, where flat lesions are 
less reported. Chromoendoscopy was increasingly used when both types of 
lesion were reported, and also relatively increased the proportion of flat le-
sions. Use of assistive technology improves detection of flat but not protrud-
ed lesions. Reporting of flat lesions is higher in the morning, while pro-
truded lesions are more commonly reported in the afternoon and evening.
aims & Methods: The aim of this study was to assess the diagnostic yield 
of RR for neoplastic and non-neoplastic ano-rectal lesions, compared with 
straight view examination. The RR complications rate and the variables 
associated with complications were also evaluated. We prospectively en-
rolled all consecutive patients undergoing lower diagnostic GI endoscopy 
between June 2018 and February 2019 in our Institute. In all patients the 
endoscopist performed first straight view examination of rectum and anal 
canal and then RR. Mayor complications included perforation and bleed-
ing needing endoscopic treatment. Mucosal injury without bleeding or 
with self-limited bleeding and pain during and after the maneuver were 
considered minor complications.
results: A total of 1600 patients (woman, 59%), undergoing 1419 colonos-
copies and 181 proctosigmoidoscopies were included. RR was successful 
in 1572 patients (98%). In 28 patients (2%) RR was unsuccessful or not 
performed because of narrow rectum or because the maneuver was not 
tolerated by the patients. 
One hundred and seventeen lesions were detected in 117 patients (7.4%): 
91 lesions were identified on both retroflexion and straight view (77.7%), 23 
lesions only on retroflex view (19.6%) and 3 lesions only on straight view 
(2.5%). The 117 identified lesions were: 13 malignant anal or rectal lesions 
(3 squamous anal cancers, 2 distal rectal adenocarcinoma, 1 melanoma, 
1 distal rectal gastrointestinal stromal tumor, 5 ano-rectal infiltrations by 
gynecologic cancer and 1 rectal infiltration by urologic cancer) (0.8%), 4 
high-risk adenoma (0.3%), 7 low-risk adenoma (0.4%), 25 high-grade 
anal intraepithelial neoplasia (AIN) (1,6%), 20 low-grade AIN (1.3%), 27 
hyperplastic polyps (1.7%), 21 non-neoplastic lesions -ulcerations, angio-
dysplasia, mucosal findings of ulcerative proctitis- (1.3%). 
Lesions identified only by RR were 2 out of 13 (15%) malignant anal and 
rectal lesions (1 squamous anal cancer and 1 rectal infiltration by gyne-
cologic cancer), 1 out of 4 (25%) high-risk adenoma, 2 out of 7 (16%) 
low-risk adenoma, 4 out of 25 (16%) high-grade AIN, 6 out of 20 (30%) 
low-grade AIN, 6 out of 27 (22%) hyperplastic polyps and 2 out of 21 (9%) 
non-neoplastic lesions.No major complications occurred. There were 161 
(10%) minor complications which consisted of mild or moderate pain dur-
ing RR (78%) and self-limited bleeding associated with mild or moderate 
pain (22%). Multivariate analysis identified age < 61 years and endoscope 
diameter as factors correlated to the presence of minor complications (p-
value respectively 0.007 and 0.037) while sex and previous pelvic surgery 
and/or radiotherapy did not correlate to the occurrence of complications.
conclusion: In our experience RR identified a low but significant number 
of neoplastic lesions undetected by straight view. Thus, considering that 
RR has a low rate of not significant complications and it is fast, repeatable 
and low cost, its use should be recommended in the clinical practice dur-
ing lower GI endoscopy.
disclosure: Nothing to disclose 
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references: 1. Kaminski et al. Endoscopy 2014;46:435-49. 2. Riemann JF et 
al. Poster PO160: UEGW 2015, Oct 24-28: Barcelona. 3. Jover R et al. Poster 
PO165: UEGW 2016, Oct 15-19: Vienna.
disclosure: Ono A, Amaro A, Agrawal A, Hünger M, Petruzziello L, Toth E: 
Consultant & advisory board participant to Norgine. Spada C: Consultant 
fee from Norgine. Brink L: Consultancy & Advisory Board participant to 
Norgine, AMBU. Fischbach W: Consultancy and Advisory Board participant 
to Norgine; Speaking - Abbott, Bio Merieux, Falk; Advisory speaking - Ap-
talis, Fresenius Biotech, Pfizer; Advisory - Boehringer Ingelheim, med up-
date. Kinnunen U: Norgine and Olympus (European NBI Expert Training 
Group: Riemann JF: In terms of ECQI, consultant to Norgine, otherwise no 
conflict of interest. Amlani B: Employee of Norgine. Fuccio L: No conflict of 
interest. Koulaouzidis A: No relevant conflict of interest. 
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P0209 TIMe PLannIng and LearnIng curve Of 
endOscOPIc suBMucOsaL dIssecTIOn In The cOLOrecTuM: 
resuLTs frOM an exPerT WesTern cenTer
Dang H., Dang Q., van der Kraan J., Dekkers N., Hommes D.W., 
Langers A.M.J., Hardwick J.C.H., Boonstra J.J.
Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, 
Netherlands
contact e-Mail address: h.dang@lumc.nl
Introduction: Endoscopic submucosal dissection (ESD) in the large bowel 
has gained considerable popularity in Asian countries. However, ESD has 
been slow to be taken up by Western endoscopists due to the technical 
complexity and time-consuming nature of the procedure. We have evalu-
ated the learning curve and time planning outcomes of ESDs in an expert 
Western center.
aims & Methods: Medical records of all patients undergoing ESD at Leiden 
University Medical Center till 1 January 2019 were retrospectively reviewed. 
We used multiple linear regression to identify independent risk factors for 
longer ESD duration.
results: In total, 97 ESDs were performed by two expert endoscopists. The 
median size of the resected lesions was 45 mm (range 8-130). Median 
dissection speed was 8.5 cm2 per hour (range 0.3-31.8) and did not signifi-
cantly differ between the two endoscopists. Dissection speed significantly 
increased per 10 ESDs by 0.8 cm2 per hour on average (p = 0.003). 
The amount of time scheduled for the procedure was ≤ 120 minutes in 31 
patients, 121-239 minutes in 32 patients and ≥ 240 minutes in 34 patients. 
Median ESD duration was 160 minutes (range 30-720); scheduled time was 
exceeded > 1 hour in 12 cases (3, 4 and 5 in the ≤ 120, 121-239 and ≥ 240 
minutes planning group respectively). 
Time exceeding of > 1 hour was associated with a higher rate of conver-
sion to piecemeal resection (5/12 vs. 7/85; p = 0.006). Size of the lesion 
was the only independent risk factor for longer ESD duration (β = 23.0; 
p < 0.001).
conclusion: Although the dissection speed gradually increases with the 
amount of ESDs performed, ESD planning should mainly be based on the 
size of the lesion to be resected. Accurate time scheduling of ESDs may 
eventually lead to higher en bloc resection rates and easier implementa-
tion of ESD in Western endoscopy centers.
disclosure: J.J. Boonstra is a consultant of Boston Scientific. All other au-
thors declare no potential conflicts of interest 
P0210 OuT Of hOur cOLOnOscOPy; Is The quaLITy as gOOd 
as In hOur cOLOnOscOPy?
Afify S.1,2, Archer T.1, Thoufeeq M.1, El Desouky E.3
1Sheffield Teaching Hospitals, Gastroenterology, Sheffield, United Kingdom, 
2National Hepatology and Tropical Medicine Institute, Gastroenterology, 
Cairo, Egypt, 3National Cancer institute, Biostatistics, Cairo, Egypt
contact e-Mail address: drshima202@yahoo.com
Introduction: Colonoscopy is the ‘gold standard’ investigation for assess-
ment of the large bowel which detects and prevents colorectal cancer1, as 
well as non-neoplastic conditions. The Joint Advisory Group (JAG) on GI 
Endoscopy suggests monitoring key performance indicators such as ce-
cal intubation rate (CIR) and the adenoma detection rate (ADR)2.3. There 
has been a drive to increase utilization of endoscopy units nationwide by 
offering out of hours (OOH) endoscopy to deal with increasing service de-
mands. Our aim was to investigate the quality of colonoscopies carried out 
during evening and Saturday lists in our unit and compare against BSG 
standards of quality for colonoscopies.
aims & Methods: We retrospectively collected and analyzed demographical 
and procedure related data for non- screening colonoscopies performed 
between January 2016 and April 2018. Procedures were grouped accord-
ing to the day of the week and timing of session (weekday, evening and 
Saturday). We also compared those performed by advanced colonoscopist 
and non-advanced colonoscopist. Advanced colonoscopist was defined as 
a BCSP colonoscopist or an advanced EMR colonscopist.
results: There were a total of 17653 colonoscopies that were carried out, 
56.8% (n=10025) were less than 70 years. Table 1 summarizes the differ-
ences between weekdays, evening and Saturdays’ colonoscopies regard-
ing the CIR and ADR. We noted that the KPIs (ADR, CIR) met the JAG stan-
dards. Advanced colonoscopists had better KPIs when compared to the 
non-advanced colonoscopists. (Table1)
    Weekdays evenings saturdays  
    No. Rate% No. Rate% No. Rate% P Value
Total ADR 14200 28.9 1391 24.4 2062 24.2 <0.001a
  CIR   90.5   90.7   91.3 0.508
Advanced 
colonoscopist
ADR 1728 44.2 135 32.6 334 34.7 <0.001a
  CIR   94.5   97   95.2 0.411
Non-advanced 
colonoscopist
ADR 12472 26.7 1256 23.5 1728 22.1 <0.001a
  CIR   89.9   90.0   90.5 0.741
Advanced vs. 
Non-advanced 
colonoscopist
p value 
ADR
<0.0001   0.019   0.001    
 
P value 
CIR
<0.0001   0.007   0.005    
[Table 1]
conclusion: JAG standards were maintained during colonoscopies done 
on weekdays, evening and Saturdays. Advanced colonoscopists had higher 
CIR and ADRs.Other units should explore the options of doing planned 
OOH colonoscopies to meet service demands.
references: 1 Rex, D.K., et al., Colonoscopic miss rates of adenomas deter-
mined by back-to-back colonoscopies. Gastroenterol, 1997. 112: p. 24-28. 2 
Bowles, C.J.A., et al., A prospective study of colonoscopy practice in the UK 
today: are we adequately prepared for national colorectal cancer screen-
ing tomorrow? Gut, 2004. 53: p. 277-283. 8. 3 Gavin, D., et al., The National 
Colonoscopy Audit: a nationwide assessment of the quality and safety of 
colonoscopy in the UK. Gut, 2013. 62: p. 242-249
disclosure: Nothing to disclose 
P0211 cOMParIng The safeTy and effIcacy Of cOLd snare 
POLyPecTOMy fOr sMaLL cOLOrecTaL neOPLasMs TO eMr and 
cOnvenTIOnaL POLyPecTOMy
Bensuleiman Y.1, Ikezawa N.2, Kado T.1, Andou J.1, Ishida T.1, 
Furumatu K.1, Toume M.1, Kazunari S.1, Yukako M.1, Kohashi S.1, 
Tanaka T.1, Nakai T.1, Oonishi K.1, Yoshida S.1
1Akashi Medical Center, Gastroenterology, Akashi, Japan, 2Kobe University, 
Gastroenterology, Kobe, Japan
contact e-Mail address: sato_yahaya@hotmail.com
Introduction: Cold snare polypectomy (CSP) has been performed world-
wide as a safe endoscopic treatment for colorectal neoplasms compared 
with EMR and conventional polypectomy. However, in post-cold polypec-
tomy, it is considerably difficult to evaluate pathological examination be-
cause of failed polyp retrieval and unclear cut margin. Incomplete resec-
tion is one of the most common causes that results in local recurrence after 
endoscopic treatment for colorectal neoplasms. The aim of this study is to 
assess the safety, efficacy, bleeding risk and problems of CSP compared 
with EMR and conventional polypectomy for small colorectal neoplasms.
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conclusion: Colonoscopy performed with PE was safe and no adverse 
events during and/or after the procedure occurred. Compared to standard 
colonoscope and paediatric colonoscope, PE is longer, thinner and more 
flexible and these features make it more suitable to complete a colonos-
copy in tricky patients. Moreover, PE is a less expensive option compared 
to SBE and DBE (which require the overtube-balloon equipment and pa-
tient’s X-ray exposure during fluoroscopic guidance) and it allows to per-
form operative endoscopy compared to less invasive alternatives, such as 
computed tomographic virtual colonoscopy and capsule endoscopy. 
Our results suggest that PE is a useful and valid alternative to standard 
scope in difficult cases, especially those related to fixed/angulated colon 
and in female gender.
disclosure: Guido Costamagna is a member of the Advisory Board of Olym-
pus, Tokyo, Japan; the other authors have no conflict of interest to declare. 
P0213 dIfferenT rIsk facTOrs fOr deLayed 
POsTPOLyPecTOMy BLeedIng In PaTIenTs WITh a sIngLe 
POLyPecTOMy versus MuLTIPLe POLyPecTOMIes durIng 
a One-TIMe cOLOnOscOPy
Chen C.-W.1, Lin W.-R.1, Chiu C.-T.2
1Linkou Chang Gung Memorial Hospital, Gastroenterology and Hepatology, 
Taoyuan, Taiwan, 2Chang Gung Memorial Hospital, Gastroenterology and 
Hepatology, Taoyuan, Taiwan
contact e-Mail address: 8902088@adm.cgmh.org.tw
Introduction: Colorectal cancer (CRC) is a common and lethal disease. Pol-
ypectomy can prevent the development of CRC. Although polypectomy is 
a safe procedure, there is still 1% bleeding rate after polypectomy. During 
screening colonoscopy, patients may have more than one colon polyp to 
remove in one-time colonoscopic procedure. 
However, data on the rate of delayed postpolypectomy bleeding (PPB) and 
risk factors for multiple polypectomies during a one-time colonoscopic 
procedure are limited.
aims & Methods: The aim of the study was to evaluate the risk of de-
layed PPB of multiple polypectomies in a one-time colonoscopy. From Jan 
2015, to Jan, 2017, patients who underwent snare polypectomy in a referral 
center of northern Taiwan for polyp’s size between 6 and 20 millimeters 
(mm) were enrolled in this study. The PPB event was defined as the pre-
sentation of a bloody stool 14 days after the polypectomy and followed by 
repeat colonoscopic interventions. The demography of patients and the 
polyp characteristics were recorded. Descriptive statistics and frequency 
distributions were calculated. The data were analyzed by using either the 
Mann-Whitney U test for continuous variables or chi-square test for cat-
egorical variables. Univariate and multivariate logistic regressions were 
used to examine the risk factors of delay PPB. Statistical significance was 
defined as p value < 0.05.
results: A total of 1188 patients were enrolled in this study. 888 (74.8%) 
patients underwent a single polypectomy during one-time colonoscopy, 
and 300 (25.2%) patients underwent ≥ 2 polypectomies during a one-time 
colonoscopy. There were 616 (69.4%) male patients in the single polyp-
ectomy group and 231 (77.0%) in the multiple polypectomies group. The 
median age in the single polypectomy group was 59 years (range: 19-
96 years) and 61 years (range:20-96 years) in the multiple polypectomies 
group. 
The mean polyp size in both groups was 8 millimeters without statistically 
difference. The overall delay PPB was 1.1 %. Compared to the single polyp-
ectomy group, the bleeding rate in the multiple polypectomies group was 
significantly higher. (3.3% vs 0.3%; p=0.02) In the univariate regression 
analysis for bleeding risk factors, increases in the polyp size were signifi-
cantly associated with delayed PPB in the single polypectomy group. (OR: 
1.3, 95% CI:1.03-1.65, p=0.02).
In the multiple polypectomies group, female was significantly associated 
with delayed PPB (OR: 3.7, 95% CI:1.05-12.93, p=0.04) and a history of 
anti-platelet/coagulant agent use was a borderline factor for delayed PPB 
(OR: 4.85, 95% CI:0.99-23.69, p=0.05). The patients’ age, polyp location, 
polyp morphology, polyp pathology, prophylactic hemoclipping, and the 
endoscopists’ experience were not found to be significant risk factors for 
delayed PPB in either group. 
By adjusting for sex, polyp size and history of anti-platelet/coagulant 
agent use in the multivariate regression analysis, polyp size was still an 
independent factor for delayed PPB in the single polypectomy group. (OR: 
1.30, 95% CI:1.02-1.65, p=0.03) Female and history of anti-platelet/coagu-
aims & Methods: We retrospectively analyzed a total of 5,991 lesions in 
3548 consecutive patients who underwent CSP, EMR or conventional pol-
ypectomy for non-pedunculated polyps up to 10 mm in size at the Akashi 
Medical Center, Hyogo, Japan, from May 2013 to July 2017. 
When lesions were found, we used chromoendoscopy and narrow band 
imaging (NBI) in all cases and included a magnifying examination if mag-
nifying endoscopy was possible to use. Endoclip was performed when the 
oozing did not decline even after one minute of observation in CSP, on the 
other hand in EMR or conventional polypectomy it depended on operator’s 
decision. We evaluated patient characteristics, clinicopathological features 
of the polyps, complications, polyps retrieval, and pathological complete 
resection rates for neoplasm lesions. The data were statistically analyzed.
results: CSP was performed on (n=1381; 2518polyps), EMR was performed 
on (n=1820; 2888polyps), conventional polypectomy was performed on 
(n=347; 584polyps) .Patient characteristics and clinicopathological features 
of the polyps did not show significant differences in three groups. Polyp 
size was significantly smaller in CSP group compared with the EMR group 
(3.89 ± 1.39vs 6.40 ± 2.04 mm, p< 0.01), and conventional polypectomy 
group (3.89 ± 1.39vs 5.19 ± 2.18 mm, p< 0.01). The retrieval rate for polyps 
was significantly lower in CSP group compared with EMR and conven-
tional polypectomy group at (n=2035; 94.4 % vs n=2786; 99% p< 0.01), 
and (n=2035; 94.4 % vs n=547; 97.3% p= 0.01), respectively. Pathological 
complete resection rate of the neoplasm lesions was significantly lower in 
CSP compared with EMR at (73 % vs 86% p< 0.01), but were identical to 
conventional polypectomy group (73 % 76% p= 0.15). No significant differ-
ence in delayed bleeding requiring endoscopic hemostasis in CSP group 
compared with EMR and conventional polypectomy group at (n=1; 0.05 % 
vs n=6; 0.21% p= 0.12), and (n=1; 0.05 % vs n=1; 0.31% p= 0.31), respec-
tively. The rate of using endoclip was significantly lower in CSP compared 
with EMR and conventional polypectomy at (n=51; 0.2 % vs n=1884; 67% 
p< 0.01), and (n=51; 0.2 % vs n=51; 9.1% p< 0.01), respectively.
conclusion: CSP tended to conduct for significantly smaller lesions with 
lower polyp retrieval rate and lower rate of using endoclip compared with 
EMR and conventional polypectomy in this study. Delayed bleeding in CSP 
required endoscopic hemostasis was seen in only one case and perfora-
tion was not observed. Thus, CSP could be a safer and more convenient 
method for small colonic neoplasia compared with EMR and conventional 
polypectomy, On the other hand, pathological complete resection rates 
were significantly lower compared with EMR. Consequently, these findings 
highlight the importance of meticulous inspection of the remnant tumor 
via endoscopy after CSP to avoid unnecessary future local recurrence.
disclosure: Nothing to disclose 
P0212 use Of enTerOscOPe WIThOuT The OverTuBe In 
IncOMPLeTe cOLOnOscOPIes
Purchiaroni F.1, Conti S.2, Valerii G.2, Costamagna G.2, Riccioni M.E.2
1Policlinico Universitario Agostino Gemelli, Gastrointestinal Endoscopy Unit, 
Rome, Italy, 2Università del Sacro Cuore, Rome, Italy
contact e-Mail address: flaminia.purchiaroni@hotmail.it
Introduction: Colonoscopy is the gold standard diagnostic method for 
colorectal cancer screening. The quality of such procedure depends on dif-
ferent factors, including endoscopist’s skills and caecal intubation rate. 
Despite the progress in the endoscopy technology field, a small percentage 
of colonoscopies is still incomplete. The reasons for that are mostly associ-
ated to anatomic features, such as fixed, angulated, long and loopy colon, 
intra-abdominal adherences and female gender. To overcome such dif-
ficulties, the usefulness of scopes different from conventional colonoscope, 
such as paediatric colonoscope, gastroscope, single and double balloon 
enteroscope (SBE and DBE), has been shown in literature.
aims & Methods: Our retrospective study aims to evaluate the caecal in-
tubation rate using a push enteroscope (PE) without the overtube in pa-
tients who previously underwent an incomplete procedure with a standard 
colonoscope. 
47 adult patients, mostly female (77%), who previously underwent an in-
complete colonoscopy with a standard colonoscope, were retrospectively 
enrolled through the analysis of a dedicated database. The enteroscope 
used was the Olympus Enteropro Single Balloon SiF-Q180 with no over-
tube. Complete colonoscopy was defined as successful caecal intubation.
results: The use of PE led to a complete procedure in 91% of patients (43 
over 47). The most frequent reason (75%) for an incomplete procedure 
even with the use of PE was a fixed and angulated colon (3 over 4 patients).
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lant agent use were independent factors for delayed PPB in the multiple 
polypectomies group (OR: 4.07, 95% CI:1.14-14.47, p=0.03; OR: 5.54, 95% 
CI:1.09-27.94, p=0.03 respectively).
conclusion: When performing ≥ 2 polypectomies during a one-time colo-
noscopic procedure, the rate of delayed PPB significantly increases. Polyp 
size was a risk factor for delayed PPB in single polypectomy. Female and 
history of anti-platelet/coagulant agent use were risk factors for delayed 
PPB in multiple polypectomies.
disclosure: Nothing to disclose 
P0214 cLInIcaL and PaThOLOgIcaL characTerIsTIcs Of 
adenOMaTOus POLyPs In Lynch syndrOMe
Hatamori H., Chino A., Ide D., Saito S.
Cancer Institute Hospital of Japanese Foundation for Cancer Research, 
Gastroenterology, Tokyo, Japan
contact e-Mail address: kyoen_miss2009@hotmail.co.jp
Introduction: Lynch Syndrome (LS) is an autosomal dominant disorder 
caused by germline mutations in DNA mismatch repair genes such as 
MLH1, MLH2, MSH6 and PMS2, and patients with LS have an increased risk 
of developing colorectal cancer. While adenoma-carcinoma sequence is 
accelerated in patients with LS, the characteristics of adenomatous polyps 
in patients with LS are not precisely known.
aims & Methods: A total of 325 consecutive adenomatous polyps in pa-
tients with LS removed by colonoscopy between June 2005 and May 2018 
were retrospectively reviewed. In addition, we defined adenomatous pol-
yps with advanced pathological features including high grade adenomas, 
intramucosal carcinomas, and superficial submucosal invasive carcinomas 
(submucosal invasion depth < 1000 µm) as index lesions and compared 
the prevalence and clinical characteristics of the index lesions between pa-
tients with LS and a control group. As the control group, the adenomatous 
polyps in patients without LS, Familial Adenomatous Polyposis, or Inflam-
matory Bowel Disease removed by colonoscopy between January 2015 and 
December 2015 at our institute were reviewed.
results: One hundred and fifty five polyps (48%) were located in proximal 
colon, 114 polyps (35%) at distal colon and 56 polyps (17%) at rectum. The 
median polyp size was 5 mm (range 2-40 mm) and 229 polyps (71%) were 
non-polypoid type. The percentage of carcinomas were 1%, 7%, 69% and 
86% for polyps of diameter < 5 mm, 5 ≤ X< 10 mm, 10 ≤ X< 20 mm and 20 
≤ mm, respectively. 
The percentage of the index lesions was significantly higher in LS group 
(26%) than in the control group (15%) (P < 0.0001). The percentage of the 
index lesions according to the location (proximal colon, distal colon and 
rectum) was 32%, 33% and 41%, respectively in LS group. The mean age ± 
SD at the index lesions removal was significantly younger in LS group (59 ± 
13 years) than in the control group (67 ± 11 years) (P < 0.0001). The median 
polyp size of the index lesions was significantly smaller in LS group (7 mm, 
range, 3-30 mm) than in the control group (10 mm, range, 1-120 mm) (P 
< 0.0001), which was applicable to the size of each histology including 
high grade adenoma, intramucosal carcinoma and superficial submucosal 
invasive carcinoma. Non-polypoid polyp was significantly more common 
macroscopic type of the index lesions in LS group (63%) than in the control 
group (30%) (P < 0.0001).
conclusion: The adenomatous polyps in patients with LS, especially great-
er than 10 mm, showed higher degree of dysplasia than sporadic ones. 
The index lesions in patients with LS were smaller and more often non-
polypoid morphology than sporadic ones. The percentage of index lesions 
was comparable at any part of the colon in patients with LS and this result 
suggest the adenoma-carcinoma sequence in patients with LS should be 
similarly accelerated between proximal and distal colon.
disclosure: Nothing to disclose 
P0215 endOscOPIc anaLysIs Of MIcrOsTrucTures Of The 
cOLOn MucOsa On The edge Of The POsT-resecTIOn defecT 
as a Measure Of PrevenTIng recurrence Of POLyPs afTer 
a cOLd POLyPecTOMy
Ageykina N.1, Fedorov E.2,3, Oleynikova N.3, Malkov P.3, Danilova N.3, 
Kharlova O.3
1Medsi Clinic, Endoscopy, Moscow, Russian Federation, 2Pirogov Russian 
National Research Medical University, Moscow, Russian Federation, 
3Lomonosov Moscow State University, Moscow, Russian Federation
contact e-Mail address: ageykina.natalia@yandex.ru
Introduction: To identify the residual tissue after the cold snare polypecto-
my, it is necessary to know an endoscopic view of the unchanged structure 
on the edge of the post-resection defect. This is the prevention of tumor 
recurrence.
aims & Methods: To assess the usefulness of endoscopic removal of small 
(less than 10 mm) colon polyps with a cold snare on the basis of endo-
scopic microstructural analysis of the edges of the post-resection defect.
In 74 patients (22 men and 52 women) aged 28 to 84 years (59.3 ± 3.6 
years), 103 colon polyps were detected. These were up to 10mm in size and 
no more than 5mm in height, without endoscopic signs of severe dysplasia 
or cancer. Most of the polyps (81/103; 78.7%) were of flat-elevated form, 
type 0-IIa, of which 10 (9.7%) had a depression, type 0-IIa+c; and were of 
polypoid form 21/103; 20.3%. 
The polyps were resected with a cold snare and in all cases the edges of 
the defect were evaluated for the absence of residual tissue. A complete 
endoscopic analysis of the microstructures and the capillary vessels of the 
mucosa was performed on the edge of the post-resection defect, and was 
then compared to the histological image.
results: The endoscopic criteria followed post cold snare resection in or-
der to check its success were: endoscopic visualization on the edge of the 
post-resection defect of 1) parallel crypts and 2) the pit pattern of only type 
I (S. Kudo). 
This was observed in 93 (90.3%) cases. In 10 (9.7%) cases, single extended 
modified crypts were found, with violation of their parallelism, which was 
a sign of residual tissue. In these cases, a combined removal technique 
was used - a cold snare, supplemented with biopsy forceps for the purpose 
of radical intervention. 
During endoscopic examination of the post-resection defects in the rec-
tum, we noted differences in the location of the crypts of the rectum in the 
anorectal junction and in the range of 1-2 cm proximity to it, compared 
to the orderly arrangement of crypts in the colon. In this area, the loss 
of parallelism of the crypt is determined; the irregularity of the structure 
giving the impression of “falling crypts” It is noted that this feature of 
the structure complicates the differential diagnosis of normal and residual 
tumor tissue.
An endoscopic assessment of the capillary network of the colon mucosa 
was performed, as a result of which it was determined that the possi-
bilities of endoscopic analysis in vivo have advantages over histological 
examination, where it is difficult to trace the course of blood vessels. Flat-
elevated polyps have capillary vessels that are small in diameter, which 
significantly reduces the risk of bleeding when removed by a cold snare 
resection when up to 10 mm in size. This was confirmed by a slight capil-
lary leakage of blood in 101 (98.1%) cases, which stopped independently, 
on average, after 2-3 minutes. In 2 (1.9%) cases, due to the reception of 
anticoagulant therapy, the period of capillary thrombosis varied from 5 to 
10 minutes. In these patients, the defects were clipped to prevent delayed 
bleeding. 
Follow-up colonoscopies were performed on 11 (10.7%) patients: neither 
advanced adenomas, nor interval cancers were detected.
conclusion: A detailed assessment of the edges of the post-resection defect 
of the mucosa after cold snare resection provides a reliable diagnosis of 
the complete success of the endoscopic intervention and the possibility of 
removing residual tumor tissue (if present) immediately after its comple-
tion, and therefore reduces the number of recurrence of tumors.
disclosure: Nothing to disclose 
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ously established UC patients in sustained corticosteroid-free (≥6 months) 
clinical remission (defined as partial Mayo score of ≦1) and mucosal heal-
ing (defined as Mayo endoscopic subscore of 0 or 1) undergoing endo-
scopic evaluation using EC between October 2016 and September 2018 at 
the Digestive Disease Center of the Showa University Northern Yokohama 
Hospital. Exclusion criterion was patients with medical history of any pre-
vious surgical colon resection. The EC images to evaluate were selected by 
an endoscopist (M.O.) who was blinded to clinical, histological, and endo-
scopic information. Another expert endoscopist (Ya. M.) evaluated the im-
ages according to endocytoscopic findings, and the cohorts were classified 
into either ‘Healing’ or ‘Active’ group according to endocytoscopic find-
ings. The main outcome measure was the difference of clinical relapse-
free rates compared between 2 groups. The differences of clinical relapse-
free rates depending on the extent of disease (extensive colitis, left-sided 
colitis, and proctitis) were also investigated as sub-analysis. Cohorts were 
followed until the end of the study in March 2019 or until relapse. Clinical 
relapse was defined as the presence of rectal bleeding together with any 
treatment intervention.
results: A total of 178 patients were included as the study cohorts. 6 were 
not completed to be followed until the end of the study. 172 patients, who 
were followed for 12 months on average, were analyzed. 104 being classi-
fied in the ‘Healing’ group, and 68 in the ‘Active’ group. In the follow up 
period, 3.8% (4/104) relapsed in the ‘Healing’ group, and 22.1% (15/68) in 
the ‘Active’ group. The ‘Healing’ group had a significantly higher clinical 
relapse-free rate compared with the ‘Active’ group (Log rank test: P< 0.01). 
In sub-analysis, it also revealed that the ‘Healing’ group had a significantly 
higher clinical relapse-free rate with the ‘Active’ group in extensive colitis, 
and left sided colitis (P< 0.01, and P=0.02, respectively) and not signifi-
cantly in proctitis. (P=0.59).
conclusion: Endocytoscopy has potential to predict short-term relapse in 
patients with clinical and endoscopic remission.
disclosure: Nothing to disclose 
P0219 endOscOPIc suBMucOsaL dIssecTIOn fOr recTaL 
neOPLasIa: safeTy and effIcacy In a eurOPean cenTre
Félix C., Mendo R., Pereira I., Chivia J., Rodrigues J.P., Barreiro P., 
Chagas C.
Centro Hospitalar Lisboa Ocidental, Gastrenterology, Lisbon, Portugal
contact e-Mail address: sfelixcatarina@gmail.com
Introduction: The efficacy of endoscopic submucosal dissection (ESD) has 
been well documented, however Western data on colorectal ESD is limited 
and its role for colorectal lesions is, at present, not well defined. Neverthe-
less, the rectum is recognized as a particular segment and ESD may play 
an important role in avoiding a major surgery.
aims & Methods: This study aims to report the feasibility, safety and ef-
fectiveness of ESD for treating premalignant and early malignant rectal 
lesions in a Western centre. 
We conducted a prospective data analysis of all consecutive rectal lesions 
treated by ESD between 2013 and 2019. En bloc, pathological complete 
resection (R0) and curative rates, procedure time, complications and local 
recurrence were evaluated.
results: Included 114 lesions from 111 patients (mean age 69,0±9,8 years 
old; M/F=71/40). Morphologically, lesions were laterally spreading tumour 
(LST) granular homogeneous (n=19), LST granular mixed (n=61), LST non-
granular (n=15) and protruded lesions (n=19). Median size of the resected 
specimen was 50mm (13-156) and mean resection time was 107±89,1min. 
En bloc resection was achieved in 91,9% (102/111) of the resected lesions 
(3 resections were considered non-feasible). R0 resection was accom-
plished in 81 cases (73 %) and resection was considered curative in 78 
cases (70%). Complications occurred in 15 procedures (13%): 7 immediate 
minor bleedings, 1 immediate perforation and 7 delayed bleedings. In the 
resected group, asymptomatic stenosis was diagnosed in 2 patients whose 
resection was >90% of the rectal circumference. All complications were 
managed conservatively or endoscopically. Of the 78 curative resections, 
53 were followed up and median follow-up time was 12 months (1 - 74) 
revealing 1 recurrence (2 %).
conclusion: To the best of our knowledge, this study represents the third 
largest series of rectal ESD in the West, showing that rectal ESD can achieve 
a high rate of en bloc and R0 resection, safely.
disclosure: Nothing to disclose 
P0217 arTIfIcIaL InTeLLIgence-assIsTed POLyP deTecTIOn 
fOr cOLOnOscOPy
Mochizuki K.1, Kudo S.1, Misawa M.1, Mori Y.2, Ogawa Y.3, Maeda Y.1, 
Takeda K.1, Matsudaira S.1, Ichimasa K.1, Nakamura H.1, Ishigaki T.3, 
Toyoshima N.1, Kudo T.1, Hisayuki T.1, Hayashi T.1, Wakamura K.1, Baba T.1, 
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Introduction: A previous meta-analysis has shown that approximately 26% 
of neoplastic diminutive polyps are missed in single colonoscopies. We have 
developed a computer-aided detection (CADe) system assisted by artificial 
intelligence (AI) to reduce this failure and the resulting deaths from cancer. 
Research on CADe has been increasing in recent years, but most of it focuses 
on learning and analysis of still images. We think that the use of spatio-tem-
poral data is essential for learning, improving, and evaluating AI systems. In 
this study, we compiled a database of many endoscopic videos and used it to 
develop a CADe system. We then evaluated its performance.
aims & Methods: To develop the CADe system, we retrospectively collected 
colonoscopy videos from study participants who underwent colonoscopies 
in our institution from April 2018 to August 2018. We collected 1,089 colo-
noscopy videos with a total duration of 2,716,720 frames (514,240 polyp-
positive frames and 2,202,480 polyp-negative frames) and constructed a 
new algorithm based on 3D convolutional neural networks with residual-
blocks. To evaluate our system, we also retrospectively collected 96 colo-
noscopy videos from 96 consecutive participants between August 2018 and 
October 2018.The exclusion criteria were advanced colorectal cancer and 
inflammatory bowel disease. Expert endoscopists annotated the presence 
of polyps in each frame of each video, and this annotation was treated as 
the gold standard for the presence of polyps to determine the sensitivity 
and specificity.
results: Seventy-one patients had a total of 152 polyps and 25 patients 
were free from polyps. The median polyp size was 4(3-5) mm, the CADe’s 
sensitivity was 89% and the specificity was 75%. The sensitivity to polyps 
under 5 mm was 88%. Morphologically, the sensitivity to protruded polyps 
was 90% and to flat polyps was 88%. There was no significant difference 
between the sensitivities to protruded and flat polyps.
conclusion: The CADe we developed by learning spatio-temporal data had 
a high sensitivity regardless of the size and morphology of the polyp, and 
may improve the adenoma detection rate.
disclosure: Nothing to disclose 
P0218 endOcyTOscOPy cOMBIned WITh narrOW-Band 
IMagIng fOr PredIcTIOn Of cLInIcaL reLaPse In PaTIenTs 
WITh uLceraTIve cOLITIs
Maeda Y.1, Kudo S.-E.2, Ogata N.2, Mori Y.2, Misawa M.2, Ogawa M.2, 
Ogawa Y.3, Ichimasa K.2, Nakamura H.2, Kudo T.2, Hayashi T.4, 
Wakamura K.2, Inoue H.5, Ohtsuka K.6
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kanagawa yokohamashi, Japan, 2Showa University Northern Yokohama 
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Department, Tokyo, Japan
contact e-Mail address: yasuharumaeda610@hotmail.com
Introduction: Some patients with ulcerative colitis (UC) clinically relapse 
in the short term despite white light endoscopic mucosal healing was 
achieved. We developed a novel index using endocytoscopy (EC: ×520 
ultramagnifying colonoscopes providing both microvascular and crypt 
sharpness visualization of colorectal mucosa after application of the nar-
row-band imaging).
aims & Methods: The aim of this retrospective cohort study was to evaluate 
clinical efficacy of endocytoscopy for prediction of future clinical relapse in 
patients with sustained remission. The study cohorts were including previ-
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P0220 The accuracy Of WavsTaT versIOn 4 OPTIcaL BIOPsy 
fOrcePs In characTerIzIng cOLOrecTaL POLyPs Less Than 10 
MM: a PrOsPecTIve BLInded sTudy
Sin C.W.1, Mohammed N.2, Sood R.3, Venkatachalapathy S.V.4, 
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Leeds, United Kingdom, 6Leeds Institute for Biomedical and Clinical Sciences, 
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Introduction: WavSTAT Version 4 (WavSTAT4) Optical biopsy (designed by 
SpectraScience Inc, California, USA) represents a novel means of predict-
ing histology based on laser-induced autofluorescence spectroscopy. Po-
tentially, this could replace standard histological assessments of colonic 
polyps < 10mm in size. We present our final findings following the pre-
liminary study in 2016.
aims & Methods: The primary aim of this study was to demonstrate the 
accuracy of WavSTAT4 in characterizing colorectal polyps< 10mm. The sec-
ondary aim looked at comparing the real time diagnostic performance of 
WavSTAT version 4 with endoscopic assessment and a combination of both. 
Patients attending the endoscopy unit for lower gastrointestinal endoscopy 
as requested by their responsible physician were approached to participate 
in the study. Adult patients aged above 18 years were included. Patients 
with known active inflammatory bowel disease or colorectal cancer were 
excluded from the study. Polyps < 10mm were assessed in real time by 
high definition white light, NBI and WavSTAT4 optical biopsy forceps. Stan-
dard techniques were used for polypectomy. Histopathological specimens 
were read separately by two expert GI pathologists blinded to the results 
of the NBI and WavSTAT4 assessments. The primary outcome measure was 
the negative predictive value in distinguishing adenomatous from non-
adenomatous colorectal polyps. The secondary outcome measure was the 
accuracy of on-site recommended surveillance intervals.
results: 136 patients participated in this study. A total of 211 polyps (199 < 
10mm, 12 >10mm) were found in 79 patients (51 males, 28 females). The 
mean age was 65 (range 28-95 years). 50 patients were excluded from 
the study (no polyps in 38 patients, device failure in 8 patients, 4 polyps 
not retrieved). A further 7 patients were not included due to missing data. 
15 polyps were not included in the final analysis due to discrepancies be-
tween the histological analysis of the two pathologists. 
  WavsTaT 4 alone % (95% cI)
WLe + nBI 
assessment % 
(95% cI)
algorithmic 
approach % 
(95% cI)
Sensitivity 93.8 (86.0-97.9) 86.2 (76.7-92.3) 93.8 (86.0-97.9)
Specificity 45.4 (35.6-55.8) 82.2 (73.3-89.0) 77.2 (67.8-85.0)
NPV 90.2 (79.3-95.7) 88.3 (81.2-92.9) 94.0 (86.9-97.4)
PPV 57.7 (53.0-62.2) 79.3 (71.4-85.4) 76.5 (69.4-82.4)
Surveillance interval 
(% correctly coded)
67.9 88.5 87.2
Surveillance interval 
(% of patients called 
earlier)
32.1 11.5 12.8
[Diagnostic performance of Wavstat4, Endosocpic assessment and combined 
algorthmic assessment for characterization of colorectal polyps less than 
10mm]
WavSTAT4 had a high NPV of 90.2% and was more sensitive (93.8%) com-
pared to endoscopic assessment (NPV 88.3%, sensitivity 86.3%). WavSTAT4 
however lacked specificity and was poor for hyperplastic recto-sigmoid 
polyps and only accurately predicted surveillance intervals in 67.9% of pa-
tients. Due to this we implemented an algorithmic approach where pol-
yps proximal to the recto-sigmoid were classified according to WavSTAT4, 
whereas the endoscopic classification used only if Wavstat4 prediction was 
as an adenomatous polyp in the recto-sigmoid area. With this combined 
algorithmic approach the NPV was 94.0% which met the PIVI thresholds 
and improved correctly predicted surveillance intervals to 87.2% of pa-
tients. 
conclusion: This study has shown that WavSTAT4 reached the threshold to 
“resect and discard” however only correctly predicted surveillance inter-
vals in 67.9% of patients. When utilizing an algorithmic approach combin-
ing WavSTAT4 and endoscopic assessment a higher NPV was achieved with 
87.2% achieving accurate surveillance intervals.
disclosure: Nothing to disclose 
P0221 an excLusIve PerfOrMance vaLIdaTIOn On 
LaTeraLLy sPreadIng TuMOr and sessILe serraTed 
adenOMa In cOLOnOscOPy IMages and vIdeOs Of deeP 
LearnIng POLyP deTecTIOn sysTeM
Zhou G.1, Liu X.1, Berzin T.M.2, Glissen Brown J.R.2, Li L.1, Zhou C.1, Guo Z.1, 
Lei L.1, Xiong F.1, Pan Y.1, Wang P.1
1Sichuan Academy of Medical Sciences & Sichuan Provincial People’s 
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contact e-Mail address: wangpuhuaxi@qq.com
Introduction: Evidences have shown that automatic polyp detection sys-
tem using deep learning can achieve both high sensitivity and specificity 
in colonoscopy images and videos, and with real-time assistance of this 
CADe system, the ADR/PDR can be improved in realistic colonoscopy set-
tings. However, the detection performance of this system on colon laterally 
spreading tumor and sessile serrated adenoma, which are with higher 
miss rate and malignancy potential, has not been specifically investigated.
aims & Methods: A real-time automatic polyp detection system based 
on deep learning was validated on colonoscopy images and videos from 
a large-scale of consecutive patients in a previous study1, in which the 
system has the sensitivity and specificity both above 94%. In this study, 
the system was validated exclusively on laterally spreading tumor (LST) 
and sessile serrated adenoma (SSA). 1451 LST images from 182 patient 
(92(50.55%) female; age, mean(s.d.):63.21(11.52)) are collected between 
July 2015 and January 2019, 82 SSA videos from 26 patients (7(26.92%) 
female; age, mean(s.d.):50.81(10.07)) were collected between September 
2018 and January 2019. The per-frame sensitivity and per-lesion sensitivity 
were calculated.
  LsT Image dataset ssa video dataset
Data acquisition* July2015-January2019 September2018- January 2019
Content* * 1451 images containing LST
82 colonoscopy video clips, each 
with a SSA appearing from the 
beginning until the end. 12.59 min 
in total and 17.99s per polyp on 
average
Device* * * Olympus and Fujifilm Olympus and Fujifilm
Patient 
demographics
182 patients,92(50.55%) female; 
age, mean(s.d.):63.21(11.52)
26 patients,7(26.92%) female; age, 
mean(s.d.):50.81(10.07)
Polyp histology
Total LST number 194(100%) 
Carcinoma 23(11.86%) SSAP 
14(7.22%) Adenomatous 
147(75.77%) Advanced Adenoma 
135(69.59%) Hyperplastic and 
Inflammatory 10(5.15%)
Total SSA number42(100%) SSAP 
42(100%)
Polyp location
Rectum 74(38.14%) Sigmoid 
colon 24(12.37%) Descending 
colon, including splenic flexure 
10(5.15%) Transverse colon 
29(14.95%) Ascending colon, 
including hepatic flexure 
43(22.16%) Cecum 14(7.22%)
Rectum 9(21.43%) Sigmoid colon 
11(26.19%) Descending colon, 
including splenic flexure 3(7.14%) 
Transverse colon 11(26.19%) 
Ascending colon, including hepatic 
flexure 7(16.67%) Cecum 1(2.38%)
Polyp size (cm) size, mean(s.d.):2.33(1.11)
Small(≤0.5) 29(69.05%) Moderate 
(>0.5&<=1) 12(28.57%) Large (>1) 
1(2.38%)
* All datasets were acquired from the Endoscopy Center of Sichuan Provincial People’s 
Hospital of China. * * Resolution of images and videos are 704 × 576, 1,920 × 1,080 or 
1,280 × 1,024. * * * Olympus EVIS LUCERA CV260 (SL)/CV290 (SL) and Fujifilm 4400/4450 
HD. NA, not applicable.
[Patient demographics and polyp characteristics for the validation datasets]
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conclusion: This study demonstrated the clinical significance of an FH of 
CRC in FDRs as a risk factor for ACN in a younger asymptomatic screened 
population aged 40 to 54 years. This result reemphasizes the importance 
of careful attention to an FH of CRC in FDRs, especially in CRC screening of 
younger populations. In contrast, an FH of CRC in FDRs may have a weaker 
impact for relatively older screened populations aged 55 to 69 years, ex-
cept for those with two or more affected FDRs.
references: 1. Schoenfeld P. Gastroenterology. 2018; 155: 1298-1300. 2. 
Schoen RE, et al. Gastroenterology. 2015; 149: 1438-45.
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Introduction: Current guidelines regarding surveillance after screen-
ing colonoscopy assume adequate bowel preparation. Management and 
follow-up intervals of patients with suboptimal or inadequate cleansing 
is unknown, with early surveillance being recommended especially after 
colonoscopy with poor preparation.
aims & Methods: To determine the diagnostic yield of early repeat colo-
noscopy in patients with suboptimal bowel preparation in screening colo-
noscopy, regarding adenoma detection rate (ADR), advanced adenoma 
detection rate (AADR) and colorectal cancer detection rate (CRCDR). Also, 
to identify which factors existing on index colonoscopy are associated with 
the presence of advanced adenomas or colorectal cancer on repeat colo-
noscopy.
We performed an observational cross-sectional study by collecting data 
from men and women who underwent screening colonoscopy with subop-
timal bowel preparation and then repeat colonoscopy within one year from 
May 2012 to August 2017 at Hospital General Universitario of Alicante. Ad-
equate bowel preparation was defined as a score of 2 or 3 in every colonic 
segment according to the Boston Bowel Preparation Scale (BBPS). Patients 
with a score of 1 at any segment were considered to have a suboptimal 
preparation. Patients with a BBPS score of 0 at any segment or incomplete 
examination were excluded. Adenoma detection rate, advanced adenoma 
detection rate and colorectal cancer detection rate were analyzed at both 
index and repeat colonoscopy.
results: Of the 2474 patients who underwent screening colonoscopy at our 
center during this period, 314 (12.7%) were reported to have a suboptimal 
preparation, with an initial adenoma detection rate of 65%, advanced ad-
enoma detection rate of 48% and colorectal cancer detection rate of 3.8%. 
Of the 259 (82.5%) patients who underwent repeat colonoscopy, subopti-
mal cleansing persisted in 22 (9%). Among these patients, adenoma de-
tection rate was 38’9%, advanced adenoma detection rate was 15% and 
no colorectal cancer was detected.
After index colonoscopy, 155 (49.4%) patients had post-polypectomy sur-
veillance recommendation in 3 years and 159 (50.6%) in 10 years. However, 
after repeat colonoscopy, recommendation changed from 10 to 3 years in 
15% of the patients with previous 10 years surveillance recommendation. 
The number of colonoscopies needed to repeat to change a surveillance 
recommendation was 15.
Total BBPS or presence of advanced adenoma at index colonoscopy were 
not associated with the presence of advanced adenoma at repeat colo-
noscopy. In the per-segment analysis, only the left colon was found to 
have a higher advanced adenoma detection rate at repeat examination in 
those patients with suboptimal preparation in that segment at index study 
(p=0’036).
conclusion: Patients with suboptimal bowel preparation in screening colo-
noscopy present a high rate of advanced adenomas in repeat colonoscopy, 
with major changes in post-polypectomy surveillance recommendations. 
These findings support a recommendation for early repeat (within 1 year) 
colonoscopy in patients with a BBPS of 1 in any colonic segment at screen-
ing colonoscopy.
disclosure: Nothing to disclose 
results: 1) For LST image dataset, the system achieved an overall sensitivity 
of 94.28% (1368/1451). the sensitivity for LST-G(H), LST-G(M), LST-NG(F), 
LST-NG(PD) was 94.24% (360/382), 98.41% (681/692), 86.56% (322/372) 
and 100% (5/5) respectively. 2) for SSA video dataset, the system achieved 
an overall per-frame-sensitivity of 84.10% (15883/18885). This real-time 
system processed 25 frames per second.
conclusion: This study demonstrated that a local feature oriented auto-
matic polyp detection system could detect laterally spreading tumor and 
sessile serrated adenoma with high sensitivity comparable with general 
polyps. This CADe system has a higher sensitivity on granular lesions com-
pared to flat lesions and the per-frame sensitivity in videos for small SSAP 
should be further improved.
disclosure: Nothing to disclose 
P0222 cLInIcaL sIgnIfIcance Of faMILy hIsTOry Of 
cOLOrecTaL cancer In fIrsT-degree reLaTIves as a 
rIsk facTOr fOr advanced cOLOrecTaL neOPLasIa In 
asyMPTOMaTIc screened POPuLaTIOns aged 40 TO 54 
years and 55 TO 69 years
Sekiguchi M.1,2,3, Nakamura K.1,2, Kakugawa Y.2, Tomizawa Y.4, Saito Y.2, 
Matsuda T.1,2,3
1National Cancer Center Hospital, Cancer Screening Center, Tokyo, Japan, 
2National Cancer Center Hospital, Endoscopy Division, Tokyo, Japan, 3Center 
for Public Health Sciences, National Cancer Center, Division of Screening 
Technology, Tokyo, Japan, 4Harborview Medical Center, University of 
Washington, Division of Gastroenterology, Seattle, United States
contact e-Mail address: masekigu@ncc.go.jp
Introduction: The clinical significance of a family history (FH) of colorectal 
cancer (CRC) in first-degree relatives (FDRs) as a risk factor for colorectal 
neoplasia is still inconclusive.1 Several recent studies have suggested that 
the influence of an FH of CRC in FDRs as a risk factor in CRC screening 
weakens as the age of the screened population increases (≥55 years)2. 
Even for younger screened populations (< 55 years), the relationship be-
tween an FH of CRC in FDRs and the risk of colorectal neoplasia remains 
incompletely understood.
aims & Methods: This study was performed to investigate the relationship 
between an FH of CRC in FDRs and the presence of advanced colorec-
tal neoplasia (ACN) in asymptomatic screened individuals aged 40 to 54 
and 55 to 69 years. Data from screened individuals aged 40 to 54 years 
(n=2,263) and 55 to 69 years (n=2,621) who underwent their first-ever 
screening colonoscopy at our institution from February 2004 to March 2013 
were used. None of the screened individuals had an FH of hereditary CRC. 
Data on the following baseline characteristics of the study participants 
were extracted: age; sex; history of smoking, drinking, and nonsteroidal 
anti-inflammatory drug use; body mass index; and presence of diabetes 
mellitus. The relationship between the presence of FDRs with CRC and the 
presence of ACN was examined using the chi-square test. A multivariate 
logistic regression analysis incorporating all of the above-mentioned fac-
tors was also performed to calculate the odds ratio (OR) of an FH of CRC in 
FDRs for the presence of ACN adjusted by the other factors.
results: Of 2,263 screened individuals aged 40 to54 years, 249 (11.0%) 
had FDRs with CRC. No significant difference in the baseline characteristics 
was observed between these 249 individuals and the other 2,014 individu-
als without affected FDRs. The prevalence of ACN was significantly higher 
among the individuals with than without affected FDRs (5.6% vs. 1.6%, 
respectively; P< 0.01). Despite this significant relationship, no statistically 
significant association was observed between the presence of ACN and 
the number of affected FDRs or presence of younger affected FDRs (< 60 
years). The OR of the presence of affected FDRs for ACN, which was ad-
justed by all other baseline characteristics, was 3.6 [95% confidence inter-
val (CI), 1.9-6.8; P< 0.01] in the screened population aged 40 to 54 years. 
Among the 2,621 screened individuals aged 55 to 69 years, 291 (11.1%) had 
FDRs with CRC, and the prevalence of ACN was not significantly differ-
ent between these 291 individuals and the other 2,330 individuals without 
affected FDRs (5.8% vs. 5.8%, respectively; P=0.95). The adjusted OR of 
the presence of affected FDRs for ACN was 1.0 (95% CI, 0.6-1.7; P=0.94). 
Despite this lack of a significant association, individuals with two affected 
FDRs (n=23) showed a significantly higher prevalence of ACN (17.4%) than 
those with one or no affected FDRs (5.7%) in the population aged 55 to 
69 years (P=0.04). In this population, no significant association was found 
between the presence of affected FDRs aged < 60 years and ACN.
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P0224 achIeveMenT Of eurOPean sOcIeTy Of 
gasTrOInTesTInaL endOscOPy PerfOrMance Measures: 
OBservaTIOns frOM The eurOPean cOLOnOscOPy quaLITy 
InvesTIgaTIOn quesTIOnnaIre
Spada C.1, Agrawal A.2, Amaro P.3, Brink L.4, Fischbach W.5, Hünger M.6, 
Jover R.7, Kinnunen U.8, Koulaouzidis A.9, Ono A.10, Patai Á.11, Pecere S.12,13, 
Petruzziello L.12,13, Toth E.14, Amlani B.15, Riemann J.F.16,17
1Fondazione Poliambulanza, Brescia, Italy, 2Doncaster Royal Infirmary, 
Doncaster, United Kingdom, 3Coimbra University Hospital, Coimbra, Portugal, 
4Herlev Hospital, Herlev, Denmark, 5Gastroenterologie und Innere Medizin, 
Aschaffenburg, Germany, 6Private Practice for Internal Medicine, Würzburg, 
Germany, 7Hospital General Universitario de Alicante, Alicante, Spain, 
8Tampere University Hospital, Tampere, Finland, 9The Royal Infirmary of 
Edinburgh, Edinburgh, United Kingdom, 10Hospital Clínico Universitario 
Virgen de la Arrixaca, Murcia, Spain, 11Markusovszky University Teaching 
Hospital, Szombathely, Hungary, 12Fondazione Policlinico Universitario A. 
Gemelli IRCCS, Digestive Endoscopy Unit, Rome, Italy, 13Università Cattolica 
del Sacro Cuore, Centre for Endoscopic Research Therapeutics and Training 
- CERTT, Rome, Italy, 14Skåne University Hospital, Lund University, Malmö, 
Sweden, 15Norgine, Harefield, Middlesex, United Kingdom, 16Director em. 
Klinikum Ludwigshafen, Ludwigshafen, Germany, 17Chairman, LebensBlicke 
Foundation for the Prevention of Colorectal Cancer, Ludwigshafen, Germany
contact e-Mail address: cristianospada@gmail.com
Introduction: The development of the procedure questionnaire, by the Eu-
ropean Colonoscopy Quality Investigation (ECQI) Group, has been previ-
ously described in posters presented at United European Gastroenterology 
Week, 2015 and 2016.
aims & Methods: To investigate the quality of colonoscopy in current clini-
cal practice, through the use of online questionnaires, compared with re-
cently published European Society of Gastrointestinal Endoscopy (ESGE) 
key performance measures. Data collection is an ongoing process. We 
analysed data collected between 2/6/16 and 30/4/18.
results: 6445 colonoscopies were documented by 84 practitioners across 
12 European countries.
Adequate bowel preparation was defined as Boston Bowel Preparation 
Scale score ≥6 (ESGE minimum standard ≥90%). From our data (data un-
available for 209, 3.2%), 84.2% (n = 5427) of procedures had adequate 
bowel cleansing.
Caecal intubation rate (ESGE minimum standard of ≥90% of all diagnostic 
and screening colonoscopies visualise the whole caecum, where indica-
tion exists). The caecum was the intended endpoint in 69.4% of proce-
dures (ileum 28.1%, anastomosis 1.3%, data unavailable 1.2%). For those 
colonoscopies where the caecum was the intended endpoint (n = 4473), 
94.7% reported reaching the caecum but only 77.5% (3281/4234) of those 
stated endpoint photo-documentation.
Polyp detection rate (PDR) (ESGE minimum standard ≥40% of screening 
and diagnostic colonoscopies performed in those aged 50 years or older). 
At least one polyp was detected in 40.7% (1357/3335) of qualifying proce-
dures.
Withdrawal time from caecum to anal canal and inspection of the entire 
bowel mucosa at negative (no biopsy or therapy) screening or diagnostic 
colonoscopy (ESGE minimum standard mean 6 minutes). Of the 1150 quali-
fying procedures providing data, the overall mean (± SD) withdrawal time 
was 7.8 ± 3.1 minutes, the median withdrawal time was 7 minutes.
conclusion: Our findings indicate that while minimum standards for PDR 
and withdrawal time are being met, they are not achieved for adequate 
bowel clearance, or photo-documentation of caecal intubation.
disclosure: Spada C: Consultant fee from Norgine. Agrawal A, Amaro A, 
Hünger M, Petruzziello L Ono A, Jover R, Toth E: Consultant & advisory 
board participant to Norgine. Brink L: Consultancy & Advisory Board par-
ticipant to Norgine, AMBU. Fischbach W: Consultancy & Advisory Board 
participant to Norgine; Speaking - Abbott, Bio Merieux, Falk; Advisory 
speaking - Aptalis, Fresenius Biotech, Pfizer; Advisory - Boehringer Ingel-
heim, med update. Kinnunen U: Consultant & advisory board participant 
to Norgine and Olympus (European NBI Expert Training Group). Riemann 
JF: In terms of ECQI, consultant to Norgine, otherwise no conflict of inter-
est. Amlani B: Employee of Norgine. Koulaouzidis A: No relevant conflict 
of interest. Patai A: No conflict of interest. Pecere S: No conflict of interest. 
P0225 The sIgnIfIcance Of cLOsure Of The MucOsaL defecT 
afTer cOLOrecTaL endOscOPIc suBMucOsaL dIssecTIOn
Takita M., Ohata K., Nobuyuki M.
NTT Medical Center Tokyo, Gastroenterology, Tokyo, Japan
contact e-Mail address: myc0p1asm@mail.goo.ne.jp
Introduction: Because of the technical difficulty of colorectal endoscopic 
submucosal dissection (ESD), injury to the muscularis layer or perforation 
might occur during the procedure. The efficacy of closure of the mucosal 
defect after colorectal ESD is unknown. We investigated the significance of 
mucosal defect closure after colorectal ESD.
aims & Methods: We investigated 403 consecutive cases of colorectal ESD 
performed between January 2016 and March 2019 by an expert with an 
experience of >500 colorectal ESD procedures. We divided the patients into 
two groups; one for which mucosal defect closure was done (group C), and 
another for which mucosal defect closure was not performed (group N), 
and investigated their clinical outcomes. The closure was defined as the 
closure of the entire mucosal defect.
results: Because of muscularis layer injury or perforation, 49 patients 
(12.2%) underwent closure of the mucosal defect and were classified into 
group C. Of these cases, 40 (81.6%) were closed using conventional clip 
and 9 (18.4%) were closed using over-the-scope clip (OTSC), respective-
ly. The closure time was significantly shorter in conventional clip cases 
(6.7±3.2 vs. 22.4±7.3 min, P< 0.01) compared with OTSC cases. 
On the other hand, all OTSC cases had a perforation or a widely exposed 
muscularis layer. One group C patient and 3 group N patients had delayed 
perforation (2.0% vs. 0.8%, P=0.41). 
The one case in the group C patient was closed with OTSC. The clini-
cal outcomes were not significantly different between groups, as fol-
lows: maximum temperature after the procedure (C vs. N: 37.2±0.5°C vs. 
37.2±0.5°C, P=0.91), white blood cell count on postoperative day 1 (POD1) 
(8055±2708/µL vs. 8252±2419/µL, P=0.60), and C-reactive protein level on 
POD1 (1.22±1.39 vs. 1.19±1.66 mg/dL, P=0.89). However, the incidence of 
abdominal pain was lower in group C than in group N (16.3% vs. 17.8%, 
P=0.80).
conclusion: Our results suggest that when perforation or muscularis layer 
injury occurs in colorectal ESD, a favorable course, similar to that of cas-
es without such complications, can be obtained if the mucosal defect is 
closed.
disclosure: Nothing to disclose 
P0226 endOBILIary radIOfrequency aBLaTIOn fOr 
refracTOry BenIgn sTrIcTure: a PILOT BIcenTrIc sTudy
Privat J.1, Donatelli G.2, Demmak H.1, Keita A.1
1Hopital de Vichy, Endoscopy, Vichy, France, 2Hôpital Privé des Peupliers, 
Ramsay Générale de Santé, Unité D’ Endoscopie Interventionnelle, Paris, 
France
contact e-Mail address: jocelyn.privat@ch-vichy.fr
Introduction: Endoscopic treatment of benign biliary stricture (BBS) re-
mains challenging with 15% of recurrence ater metallic or multiple plastic 
stenting. We experimented endobiliary radiofrequency ablation (ERFA) 
with the aim to eradicate biliary fibroplasia endoscopically. We report our 
first experience of ERFA in the management of refractory BBS.
aims & Methods: 8 patients with BBS (5 postoperative strictures, 2 chronic 
inflammatory strictures and 1 post stenting stricture) were treated from 
august 2014 to march 2018. All had previously unsuccessful endoscopic 
treatment with dilatations (1,75 [0-3]) and plastic or metallic stenting dur-
ing a median of 18 months (9-48). Bipolar ERFA was delivered at power of 
10 W for 90 seconds per stricture segment, followed by a 10 mm balloon 
dilatation without stent placement. Data were collected on technical suc-
cess (ERFA delivery), clinical success (stricture resolution), adverse events 
and follow-up.
results: ERFA was performed in 8 patients (7 men) with a median age of 
56 years (range 20-81). All patients had stricture resolution after ERFA. No 
severe adverse event occurred with only a case of short abdominal mild 
pain. The median follow-up is 31 months.
BBS resolution without the need for further stenting was achieved in 6 
patients. The 2 patients with inflammatory stricture had BBS relapse after 
initial resolution at 10 and 12 months, one underwent surgery, the other 
metallic stenting for 9 months with no further relapse at 2 years.
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several databases including PubMed, EMBASE, Google-Scholar, Scopus 
and Cochrane Review (from 1960 to October 2018). Random-effects model 
was used for analysis. Heterogeneity between study-specific estimates 
was calculated using Cochran Q statistical test and I2 statistics. Publication 
bias was ascertained, qualitatively, by visual inspection of funnel plot and 
quantitatively, by the Egger test.
results: Our initial search yielded 3201 results. After excluding non-english 
literature and duplicates, 1936 studies were screened and 12 met inclusion 
criteria. A total of 396 patients with recurrent acute pancreatitis and ab-
normal manometry findings were included from these studies in the final 
analysis. The interventions performed were as follows: endoscopic biliary 
sphincterotomy in 212 (53.5%), endoscopic pancreatic sphincterotomy in 
19 (4.8%) and dual biliary and pancreatic sphincterotomy in 165 (41.6%) 
patients. Technical success ranged from 99 to 100%.The pooled estimate 
for clinical success following index sphincterotomy was 68.4% (95% CI 
57.6-77.4; I2=71.4%). Lone endoscopic biliary sphincterotomy was success-
ful in 43/60 (71.6%) patients. The pooled estimate for proportion of pa-
tients with post-ERCP pancreatitis was 23.2% (95% CI 16.6-31.4; I2=44.4%). 
The follow up duration ranged from 6 months (the shortest) to 120 months 
(the longest). There was no evidence of publication bias, based on funnel 
plot analysis and Egger’s test.
conclusion: Our study highlights the utility and clinical efficacy of endo-
scopic sphincterotomy in patients with recurrent acute pancreatitis sec-
ondary to functional biliary sphincter of Oddi disorder. We conclude that 
68.4% of patients improved after endoscopic sphincterotomy and that it 
can be considered in patients with recurrent acute pancreatitis.
disclosure: Nothing to disclose 
P0229 WIThdraWn
P0230 assessMenT Of The hOuse cLassIfIcaTIOn 
fOr gradIng endOscOPIc reTrOgrade 
chOLangIOPancreaTOgraPhy cOMPLexITy
Leal T., Gonçalves B.M., Ferreira A., Costa R.S., Arroja B., Gonçalves R.
Hospital de Braga, Gastroenterology, Braga, Portugal
contact e-Mail address: tiago.afleal@gmail.com
Introduction: In order to grade the complexity of Endoscopic Retrograde 
Cholangiopancreatography (ERCP) there are many scores available, the 
most used being the one developed by the American Society of Gastrenter-
ology Endoscopy (ASGE).
aims & Methods: The aim of this study was to evaluate a new classification 
(HOUSE) and to compare it with ASGE’s. The ERCPs performed between 
2015 and 2018 in our center were retrospectively reviewed. Repeated pro-
cedures in the same hospital admission and ERCPs in which cannulation 
was not attempted were excluded. We assessed HOUSE and ASGE clas-
sification scores, complications (pancreatitis, cholangitis, bleeding and 
perforation) and global technical success (GTS) - cannulation of the duct 
of interest, complete stone clearance and drainage of the duct of interest.
results: A total of 900 ERCP were selected (mean age 71,6 ± 21,9 years ; 
51,4% women), comprising 673 patients. According to the HOUSE clas-
sification, 765 (85%) ERCP were class 1, 86 (9,6%) class 2 and 49 (5,4%) 
class 3. The distribution by the ASGE classification was the following: 137 
(15,2%) grade 1, 425 (47,2%) grade 2, 320 (35,6%) grade 3 and 18 (2%) 
grade 4. The GTS rate was significantly higher in less complex procedures 
according to the HOUSE (1 - 91,0%; 2 - 82,6%; 3 - 81,6%; p=0,009) and 
ASGE classification (1 - 98,5%; 2 - 92,7%; 3 -83,4%; 4 - 61,1%; p < 0,01). 
The overall complication rate was 10,0%, with an increasing complica-
tion incidence observed in more complex procedures as determined by 
the HOUSE (8,8%; 15,1%; 20,4%; p=0,008) and ASGE classification (5,8%; 
8,2%; 13,8%; 16,7%; p=0,019). The correlation between the two scores was 
poor (ρ=0,239; p< 0,01).
conclusion: Both scores accurately graded the complexity of ERCP. As com-
plexity of procedures rises, GTS decreases while complications increase. 
These scores may be useful to compare technical success and complica-
tions between centers and endoscopists according to complexity as well as 
to stratify endoscopy training.
disclosure: Nothing to disclose 
conclusion: ERFA appears to be a safe and effective treatment for refractory 
BBS, especially for postoperative strictures. Further studies are warranted.
references: Hu B. et al. Dig Endosc. 2014 Jul;26(4):581-5.
disclosure: Nothing to disclose 
P0227 assessMenT Of ercP usIng a shOrT-TyPe 
sIngLe-BaLLOOn enTerOscOPe fOr PaTIenTs WITh 
surgIcaLLy aLTered gasTrOInTesTInaL anaTOMy
Tanisaka Y., Ryozawa S., Mizuide M., Harada M., Fujita A., Ogawa T.
Saitama Medical University International Medical Center, Gastroenterology, 
Saitama, Japan
contact e-Mail address: tanisaka@saitama-med.ac.jp
Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) 
in patients with surgically altered anatomy is technically challenging. We 
performed ERCP in such patients using a short single-balloon enteroscope 
(Short-SBE, Olympus), which has a 3.2-mm working channel and a 152-cm 
working length and for which conventional accessories are available. This 
study aimed to assess the efficacy and safety of ERCP using a Short-SBE in 
patients with surgically altered anatomy.
aims & Methods: The present retrospective study included 144 patients 
(range, 32-93 years) and 236 procedures comprising Roux-en-Y recon-
struction (105 patients and 141 procedures), Billroth II gastrectomy (21 
patients and 40 procedures), and reconstruction by the modified Child 
method (18 patients and 55 procedures) performed using a Short-SBE. The 
success and complication rates of each procedure were evaluated.
results: The blind end was reached in 95.3% of procedures (225/236). Of 
the failed procedures, five were caused by jejunum invasion. Among 225 
procedures in which the blind end was reached, cholangiography was suc-
cessfully performed 92.9% of procedures (209/225). Treatment was suc-
cessful in 87.3% of procedures (206/236). Successfully performed thera-
peutic interventions included nasobiliary drainage (n = 3), plastic stent 
placement (n = 51), self-expandable metallic stent placement (n = 27), and 
stone extraction (n = 102) using endoscopic sphincterotomy (n = 5) en-
doscopic papillary balloon dilation (n = 11), endoscopic papillary large-
balloon dilation (n = 39), and anastomosis dilation (n=22). Complications 
that occurred in 6.8% of procedures (16/236) included intestinal perfora-
tion (n = 1), mucosal laceration (n = 1), mild pancreatitis (n = 8), and mild 
cholangitis (n = 6).
conclusion: ERCP using a short-SBE is effective and safe in patients with 
surgically altered anatomy.
disclosure: Nothing to disclose 
P0228 TO cuT Or nOT TO cuT - cLInIcaL effIcacy Of 
endOscOPIc sPhIncTerOTOMy In recurrenT acuTe 
PancreaTITIs frOM funcTIOnaL BILIary sPhIncTer Of OddI 
dIsOrder - a sysTeMaTIc revIeW and MeTa-anaLysIs
Chandan S.1, Mashiana H.1, Mohan B.2, Dhindsa B.3, Braseth A.4, 
Sayles H.5, Jha L.1, Singh S.1, Adler D.6
1University of Nebraska Medical Center, Gastroenterology and Hepatology, 
Omaha, United States, 2University of Arizona/Banner University Medical 
Center, Internal Medicine, Tucson, United States, 3University of Nevada, 
Internal Medicine, Las Vegas, United States, 4University of Nebraska Medical 
Center, Internal Medicine, Omaha, United States, 5University of Nebraska 
Medical Center, Biostatistics, College of Public Health, Omaha, United 
States, 6University of Utah School of Medicine, Therapeutic Endoscopy, 
Gastroenterology and Hepatology, Salt Lake City, United States
contact e-Mail address: harmeet.mashiana@unmc.edu
Introduction: Functional biliary sphincter of Oddi disorder, previously 
referred to as sphincter of Oddi dysfunction, is an established cause of 
recurrent acute pancreatitis which is defined as two or more episodes of 
documented acute pancreatitis per year. Data on the efficacy of endoscopic 
sphincterotomy in preventing future episodes of pancreatitis is limited.
aims & Methods: We performed a systematic review and meta-analysis 
to evaluate the clinical efficacy of index endoscopic sphincterotomy in 
patients with recurrent acute pancreatitis secondary to manometrically 
proven functional biliary sphincter of Oddi disorder. Our goal was to as-
sess reduction in episodes of pancreatitis following sphincterotomy, and 
not to assess chronic pain in these patients. We conducted a search of 
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P0231 endOscOPIc TreaTMenT sTraTegIes fOr BILIary 
jejunaL anasTOMOTIc sTenOsIs
Hosono K., Kurita Y., Hasegawa S., Sato T., Kubota K., Nakajima A.
Yokohama City University Hospital, Department of Gastroenterology and 
Hepatology, Yokohama, Japan
contact e-Mail address: hiro1017@yokohama-cu.ac.jp
Introduction: Although treatment by balloon endoscopy for benign biliary 
duct jejunal anastomotic stenosis after biliary reconstruction has been 
reported useful, there is currently no standardized treatment strategy. In 
this report, we have examined the treatment strategy and results at our 
facility.
aims & Methods: We examined a total of 248 cases in 99 patients who 
underwent ERCP during single balloon endoscopy (SBE) with a diagnosis 
of cholangitis after biliary reconstruction from March 2013 to March 2019 
in our hospital. After reaching the anastomotic site, direct-viewing obser-
vation was performed for diagnosis of benign or malignant disease, and 
biopsy was performed if malignancy was suspected. 
A practical classification of endoscopic and retrograde cholangiographic 
appearance of hepaticojejunostomy strictures (K. Mönkemüller et al. WJG 
2011; 3: 213-9) was used to evaluate the biliary-jejunal anastomotic site. 
The strictures were classified into Type A (small opening), B (large), C 
(normal), D (2 holes) and S (constriction upstream from the anastomotic 
site) according to endoscopic findings at the anastomosis site, and com-
bined with the cholangiogram Type 0 (no stenosis), 1 (short stenosis), 2 
(long stenosis), 3 (intrahepatic bile duct stenosis). 
As a treatment strategy, only balloon dilatation was performed for Type A1 
and S1, and balloon dilation plus plastic stent placement was done for A2 
and S2; cases of Type B / C / D without stenosis were left untreated. In cas-
es of stent placement, replacement was repeated every 2-3 months, and 
the stent was removed, if expansion was good. If endoscopic treatment 
was not possible, percutaneous transhepatic biliary drainage (PTBD) or 
EUS-guided biliary drainage (EUS-BD) was performed.
results: The overall arrival rate to the bile duct jejunal anastomosis site 
was 97/99 (97.9%). Malignant recurrence at the anastomotic site was 
found in 15/97 (15.4%) among the achieved cases. A total of 82 benign 
cases were observed, and the classification of anastomotic findings was 
A1: 30 cases, A2: 10 cases, B / C / D: 1/30/5 cases, S1: 3 cases, S2: 1 case and 
complete stenosis. 2 cases showed dissection of the bile duct jejunal anas-
tomosis. The endoscopic treatment completion rate was 80/82 (97.5%) and 
balloon dilation was performed in 44/80 cases (55%). Among the A1 and 
S1 cases, intrahepatic stones were present in 16/33 cases (48.8%). Stent 
placement was performed in 12/80 cases (15%), and 10 cases (83.3%) suc-
ceeded in having the stent removed. PTBD was performed in 2 cases and 
EUS-BD in 2 cases.
conclusion: Balloon endoscopy enables direct observation of biliary jeju-
nal anastomoses and is useful for diagnosis, differentiation and treatment 
of benign and malignant cases. 
However, the classification and treatment consensus of anastomotic ste-
nosis are still inadequate, so in the future it would be desirable to study a 
larger number of cases.
disclosure: Nothing to disclose 
P0232 a reTrOsPecTIve anaLysIs TO assess The IMPOrTance 
Of dOIng a BILIary sPhIncTerOTOMy as a MeThOd TO Increase 
and sIMPLIfy cannuLaTIOn success raTe Of The MaIn 
PancreaTIc ducT
Desai P.N.1, Kabrawala M.V.2, Patel C.3, Bhatt K.3, Mangukiya D.3, 
Surat Institute Of Digestive Sciences
1Surat Institute of Digestive Sciences, Endoscopy, Surat, India, 2Surat Institute 
of Digestive Sciences, Gastroenterolgy, Surat, India, 3Surat Institute of 
Digestive Sciences, Surat, India
contact e-Mail address: drp_desai@hotmail.com
Introduction: MPD cannulation is the prime requisite for any pancreatic 
endotherapy during an ERCP. 
Lot of techniques are described for difficult bile duct cannulation, but very 
few for pancreatic duct cannulation. Usually in cases with chronic pancre-
atitis, acute on chronic pancreatitis or cases of acute pancreatitis followed 
by ductal leaks, the duodenum and peri ampullary region are edematous 
and makes MPD cannulation difficult. 
We found that in difficult cases where MPD could not be cannulated easily 
and if we could get the wire into the CBD first, doing a wide biliary sphinc-
terotomy improved the success of cannulation of the MPD without using 
any more sophisticated techniques.
aims & Methods: Aim was to prove that doing a biliary sphincterotomy 
improves PD cannulation success.
Data of all cases (1206) for pancreatic ERCP from October 2008 to May 2018 
in our tertiary care centre was studied. 
All cases done by a single operator always using the wire guided technique. 
When MPD could not be cannulated in three attempts, or MPD not 
cannulated directly in 10 minutes or wire going in CBD first were studied
In failed MPD cannulation - we attempted to cannulate the CBD first or 
when wire went in CBD first inadvertently during an MPD cannulation, 
we did a biliary sphincterotomy wide enough to separate the biliary and 
pancreatic orifices and then cannulated the MPD with a cannula and a 
glide wire.
results: 
Number of ERP 1206
Successful direct MPD cannulation 982 ( 81.4%)
Difficult Cannulation 224 (18.6%)
CBD cannulated first inadvertently 199 out of 224 ( 88.9%)
Biliary Sphincterotomy done 199 (100%)
Successful MPD Cannulation after biliary sphincterotomy 185 (92.9%)
Failed MPD cannulation after biliary sphincterotomy 14 (7.03%)
Pancreas Divisum found
10 out of 14 failed 
cannulations (71.4%)
Failed MPD cannulation overall 25 out of 1206 (2.07%)
[Table 1]
conclusion: If direct MPD cannulation is difficult, cannulating the CBD first 
and doing a prior biliary sphincterotomy improves the MPD cannulation 
success rate - from 81.4% to 92.9%. 
Of those cases with failed MPD cannulation after biliary sphincterotomy, 
71.4% cases had pancreas divisum which was not detected on MRCP or 
prior imaging. 
Those who could not be cannulated at all were subjected with either EUS 
guided drainage or surgery.
disclosure: Nothing to disclose 
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P0234 deTecTIOn Of aPnea ePIsOde usIng nOveL 
MaInsTreaM caPnOgraPhy sysTeM Is feasIBLe durIng 
eus and ercP-reLaTed PrOcedure WITh cO2 InsuffLaTIOn: 
a reTrOsPecTIve sTudy
Iwasaki E.1, Takimoto Y.1, Minami K.1, Noda M.1, Tamagawa H.1, 
Katayama T.1, Kawasaki S.1, Seino T.1, Horibe M.1, Fukuhara S.2, 
Masaoka T.1, Ogata H.2, Kanai T.1
1Keio University School of Medicine, Division of Gastroenterology and 
Hepatology, Department of Internal Medicine, Tokyo, Japan, 2Keio University 
School of Medicine, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, 
Japan
contact e-Mail address: iwaiwa2007@gmail.com
Introduction: Hypoxemia is the most frequent adverse effect of sedation 
during endoscopic procedures [1]. Hypoxemia can lead to unexpected car-
diac arrest and/or brain injury. It has been reported that hypoxemia fol-
lows apnea during sedation, and as such, early detection of apnea might 
decrease hypoxemia [2]. However, the ESGE guideline recommended that 
capnography should be considered during non-anesthesiologist admin-
istration of Propofol in specific situations including high risk patients, 
intended deep sedation, and long procedures [3] A previous report re-
vealed that the detection of EtCO
2
 during full endoscopic procedures us-
ing the available sidestream capnometer was difficult because of block-
age of the sampling tube with saliva, undetectable shallow breathing, or 
tachypnoea. Many previous studies reported that severe adverse events 
could not be prevented using the unreliable capnometer [4-6]. Thus, we 
developed a novel mainstream capnometer bite block system (cap-ONE 
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results: In Group A, the rates of cytologic malignancy were as follows: 
non-WF, 0% (0/6); WF, 9.1% (3/33); and HRS, 56.3% (9/16). In 4 patients 
with HRS, PJC was negative but surgery was performed, leading to defini-
tive diagnosis of IPMC. Finally, the rate of malignant IPMN in the patients 
with HRS was 81.3% (13/16). Notably, the sensitivity and accuracy of PJC in 
patients with WF were 100% and 100%, respectively, because the patients 
with negative PJC could be observed without progression. In Group B, ERP 
was performed in the cases with main pancreatic duct (MPD) stenosis or 
hypoechoic lesion that was separately detected by endoscopic ultrasound 
(EUS) or magnetic resonance cholangiopancreatography.The rates of cyto-
logic malignancy in Group B was 23.8% (5/21). In 3 patients, PJC was nega-
tive but EUS-guided fine needle aspiration revealed PDAC. Therefore, the 
concomitant PDAC rate was 38.1% (8/21) ( 3, Stage 0; 4, Stage IA; 1, Stage 
IV). PEP frequency was 7.3% (4/55) and 23.8% (5/21) in Group A and Group 
B, respectively. All 9 patients were composed of branch duct (BD)-IPMN 
without MPD dilatation. Except for 4 patients who died of other diseases, 
all patients in the two groups were alive after surgery at a median follow-
up of 15 months (range 2-120 months).
conclusion: In patients suspected of IPMN-derived PDAC with WF, PCJ might 
have important roles in determining the appropriate treatment choice. In 
patients suspected of concomitant PDAC, careful follow-up examinations 
of the whole pancreas are needed for the early PDAC diagnosis regardless 
of IPMN type. Nevertheless, we should consider BD-IPMN without MPD 
dilatation as a risk factor of PEP.
disclosure: Nothing to disclose 
P0236 ehL fOr BILe ducT sTOnes under dIrecT 
chOLangIOscOPy WITh sBe In PaTIenTs WITh surgIcaLLy 
aLTered anaTOMy
Kida M.1, Haegawa R.2, Kaneko T.2, Yamauchi H.2, Iwai T.1, Okuwaki K.2, 
Imaizumi H.1
1Kitasato University, Endoscopy & Gastroenterology, Sagamihara, Japan, 
2Kitasato University Hospital, Endoscopy & Gastroenterology, Sagamihara, 
Japan
contact e-Mail address: m-kida@kitasato-u.ac.jp
Introduction: Nowadays Endoscopic treatment of Bile duct stones in pa-
tients with surgically altered anatomy have become popular with enteros-
copy-ERCP. We have retrospectively investigated surgically altered patients 
with bile duct stones which were treated by Electrohydrolic lithotripsy(EHL) 
under direct single balloon enteroscopy(SBE).
aims & Methods: We have reviewed medical records from 2009 to 2018 
and finally found consecutive 159 cases of bile duct stones with surgically 
altered anatomy. Averaged age is 71.5y/o and male: female is 117(75%): 
42(25%). The group of Roux-en-Y(R-Y) with gastrectomy were 95 cases 
which included gastric cancer 87cases and 8 others, R-Y without gastrec-
tomy were 29 cases which included biliary cancer 12 cases, maljunction 8 
cases, and 9 others, PD were 35 cases(53 sessions) which included pan-
creas cancer 20 cases, biliary cancer 7 cases and 8 others. Generally we 
started to treat these patients with enteroscopy-ERCP which were mainly 
short-type single-balloon enteroscopy(SBE). In case of large stone, we di-
late the papilla by 15-18mm CRE balloon, then directly insert SBE into bile 
duct and crash the stones by EHL under SBE guidance.
results: The rate of blind reach end and success rate were 88/95 cas-
es(92.6%) and 79/81 cases(97.6%) in the Roux-en-Y(R-Y) with gastrectomy 
group, 28/29 cases(96.6%) and 28/28 cases(100%) in R-Y without gas-
trectomy, 34/35 cases(94.3%), and 33/33 cases(100%) in pancreato-duo-
denectomy, respectively. Totally 140/159 cases(88%) were treated by SBE 
which included 13 cases(8%) of EHL treatment by directly inserted SBE and 
remained 6 cases by surgery, 4 cases by PTBD, 2 cases by EUS-HGS, and 
conservative 7 cases. The adverse events were 3.1% in pancreatitis, 0.7% in 
bile leakage, 1.7% in perforation, and 1.1% in bleeding.
conclusion: We concluded that EHL under direct cholangioscopy per-
formed safely in 13/159(8%) and totally 140/159(88%) of bile duct stones 
were treated by enteroscopy-ERCP in surgically altered anatomy cases,
disclosure: Nothing to disclose 
P0237 WIThdraWn
bite block, YG-227T; Nihon Kohden Corporation, Tokyo, Japan) designed 
to detect either nasal or oral tidal flow, with the EtCO
2
 detector placed on 
the bite block without a sampling tube. The detector was not dislodged 
during the endoscopic procedure because the bite block was tightly fixed. 
A small-scale pilot study revealed the reliable detection of end-tidal EtCO
2
 
using our system [7]. This is a feasibility study for the novel mainstream 
capnometer system in a larger cohort.
aims & Methods: Non-intubated patients undergoing ERCP and EUS-re-
lated procedures with CO2 insufflation under intravenous sedation with 
midazolam 0.25mg and pethidine 35mg were enrolled retrospectively dur-
ing 2017 to 2018. EtCO2 was monitored continuously during the procedure 
using a mainstream capnometer system. The accuracy of total respiratory 
count using wave form analysis was evaluated using software (Nihon Ko-
hden Tokyo, Japan).
results: We enrolled 125 patients (age, 65.4±12.8; American Society of An-
esthesiologists [ASA] class 1, n=81 and ASA 2, n=44; ERCP, n= 31 and EUS, 
n=94). Measurement of EtCO
2
 concentration was possible from the start to 
the end of the procedure in all 125 cases. No measurement failure, bite 
block disruption, or adverse event related to the capnometer was found. 
Of the patients, 53.6% (67/125) had an apnoea episode. The mean time 
to the first apnoea episode was 9:56±1:47 min after sedation. The inci-
dence of apnoea episode within 5 min after sedation was 52.3% (35/67). 
No relationship was found between the incidence of apnoea episode and 
comorbid diseases, smoking habit, alcohol consumption, or sleep medica-
tion addiction in the univariate analysis.
conclusion: The detection rates of respiration and apnoea episodes were 
higher than those in previous reports. The novel mainstream capnometer 
system is reliable and feasible for use during EUS- and ERCP-related pro-
cedures even under CO
2
 insufflation.
references: [1] Qadeer MA, Lopez AR, Dumot JA et al. Hypoxemia during 
moderate sedation for gastrointestinal endoscopy: causes and associa-
tions. Digestion 2011; 84: 37 [2] Lynn LA, Curry JP. Patterns of unexpected 
in-hospital deaths: a root cause analysis. Patient safety in surgery 2011; 5: 
3 [3] Dumonceau JM, Riphaus A, Schreiber F et al. Non-anesthesiologist 
administration of propofol for gastrointestinal endoscopy: European So-
ciety of Gastrointestinal Endoscopy, European Society of Gastroenterology 
and Endoscopy Nurses and Associates Guideline--Updated June 2015. 
Endoscopy. 2015; 47: 1175 [4] Yamamori S, Takasaki Y, Ozaki M et al. A 
flow-through capnometer for obstructive sleep apnea. Journal of clinical 
monitoring and computing 2008; 22: 209 [5] Klare P, Reiter J, Meining A et 
al. Capnographic monitoring of midazolam and propofol sedation during 
ERCP: a randomized controlled study (EndoBreath Study). Endoscopy 2016; 
48: 42 [6] Qadeer MA, Vargo JJ, Dumot JA et al. Capnographic monitoring of 
respiratory activity improves safety of sedation for endoscopic cholangio-
pancreatography and ultrasonography. Gastroenterology 2009; 136: 1568 
[7] Takimoto Y, Iwasaki E, Masaoka T et al. Novel mainstream capnometer 
system is safe and feasible even under CO2 insufflation during ERCP-relat-
ed procedure: a pilot study. BMJ Open Gastroenterol. 2019 e000266.
disclosure: Nothing to disclose 
P0235 vaLue Of PancreaTIc juIce cyTOLOgy usIng 
endOscOPIc reTrOgrade PancreaTOgraPhy In PaTIenTs 
susPecTed Of MaLIgnanT InTraducTaL PaPILLary MucInOus 
neOPLasM
Yokode M., Hanada K., Kurihara K., Shimizu A., Minami T.
Onomichi General Hospital, Gastroenterology, Onomichi, Japan
contact e-Mail address: ykdmstk0428@gmail.com
Introduction: Pancreatic juice cytology (PJC) can provide strong evidence of 
malignant intraductal papillary mucinous neoplasm (IPMN), resulting in 
appropriate management. However, routine endoscopic retrograde pan-
creatography (ERP) for PJC is not recommended in IPMN patients because 
of the low sensitivity and the risk of post-ERP pancreatitis (PEP).
aims & Methods: We aimed to elucidate what types of IPMN gain benefit 
of PJC using ERP. From April 2007 to April 2018, we reviewed medical re-
cords of 76 IPMN patients who underwent PJC using ERP in our hospital. 
IPMN-derived pancreatic ductal adenocarcinoma (PDAC) was suspected in 
55 patients (Group A); 21 patients were suspected of having concomitant 
PDAC (Group B). Group A patients were further classified as having high-
risk stigmata (HRS) (n=16), worrisome features (WF) (n=33), and non- WF 
(n=6) according to the International Consensus Guidelines 2012. We evalu-
ated the cytology results, rate of malignant IPMN, PEP frequency and post-
operative prognosis.
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P0238 dIagnOsTIc uTILITy Of a neW endOscOPIc scraPer fOr 
BILIary sTrIcTures
Akao J., Itoh T., Nagao K., Tahara J., Takayama Y., Shimizu K., Tokushige K.
Tokyo Women’s Medical University, Gastroenterology, Shinjuku-Ku, Japan
contact e-Mail address: akao.junichi@twmu.ac.jp
Introduction: The endoscopic transpapillary bile duct brushing cytology 
and biliary forceps biopsy with endoscopic retrograde cholangiopancre-
atography are generally performed for pathological diagnosis of biliary 
strictures. The sensitivity of the conventional cytology and biopsy was re-
ported to be 30% to 81%. The diagnosis of biliary strictures is difficult, 
especially of those caused by pancreatic cancer. Therefore, endoscopic 
transpapillary pancreatic juice cytology and endoscopic ultrasound-guided 
fine needle aspiration are performed for diagnosis.
aims & Methods: The Trefle (Piolax Medical Devices, Yokohama, Japan) is 
a new device that consists of looped metallic wires to scrape and aspirate 
the tissue along with bile juice.The aim of the study was to compare the 
diagnostic performance of the new device with that of conventional cytol-
ogy and biopsy. A total of 196 cases with biliary stricture underwent trans-
papillary biopsy and cytology between 2012 and 2018, of which 74were 
diagnosed using the new device.We retrospectively analyzed the diagnos-
tic utility of the new device compared with that of conventional cytology 
and biopsy.
results: The locationsof biliary strictureswereperihilar in 56 cases and dis-
tal in140. Of the 196 cases, 138 were diagnosed with a malignant stricture. 
Ninety-two cases had biliary cancer, whereas 46 had pancreatic cancer. 
The sensitivity of the new device and the conventional cytology and biopsy 
was 61% and 52%, respectively. Seven cases were diagnosed with malig-
nant strictures using the new device, although they were not diagnosed 
during the conventional cytology and biopsy. In the cases with biliary stric-
tures caused by pancreatic cancer, the sensitivity of the new device and the 
conventional cytology and biopsy was 59% and 32%, respectively.
conclusion: Our study suggests that the new device was more useful than 
conventional cytology and biopsy for the pathological diagnosis of biliary 
strictures, especially those caused by pancreatic cancer.
disclosure: Nothing to disclose 
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contact e-Mail address: hayashishiro1976@yahoo.co.jp
Introduction: Medical radiation provides us many benefits not only in diag-
nosis but also therapeutic procedure. On the other hand, its adverse effect 
becomes non-negligible concerns. Even a low dose exposure can affect the 
carcinogenesis in proportion to radiation exposure (RE) dose according to 
the Linear no-threshold model. Likewise, it is also important for medical 
staffs. Therefore, we have to recognize the proper use of medical radiation. 
In the field of gastroenterology, ERCP represents the major procedures un-
der fluoroscopic guidance. However, we gastroenterologist do not know 
enough about the basis of RE nor how much we actually use in each ERCP.
aims & Methods: The aim of this study is to assess the actual RE dose in 
ERCP and its affecting factors.
This is a retrospective, single-center cohort study of consecutive patients 
who underwent ERCP with the fluoroscopic unit (EXAVISTA, Hitachi..co) 
between Oct 2012 and Mar 2018. All ERCP procedures were categorized by 
disease sites into 4 types: common bile duct stone (CBDS), distal malig-
nant biliary obstruction (DMBO), proximal malignant biliary obstruction 
(PMBO), and the Others. A total of 1543 ERCP procedures excluding proce-
dures with missing data, were analyzed. We measured total fluoroscopy 
time (FT, sec), dose area product (DAP, mGycm2) and air kerma (AK, mGy).
results: The mean age was 73.9±10.8 years, and 663 patients were female 
(43%). 729 patients (47%) had a native papilla. ERCP procedures were 
performed for the purpose of treating CBDS (N=761,49%), DMBO (N=275, 
18%), PMBO (N=324,21%), or other diseases (N=183, 12%).Median AKs in 
all case/ CBDS/ DMBO/ PMBO were 133/ 139/ 100/ 166 mGy, respectively. 
In a similar fashion, median DAPs were 15.1/ 15.2/ 12.2/ 20.0 Gycm2, and 
median FTs were 639/ 623/ 526/ 794 sec. Dunn’s multiple comparison test 
revealed that PMBO showed significantly the largest DAP, AK, and FT, com-
pared with DMBO (p< .0001/ p< .0001/ p< .0001, respectively) and, com-
pared with CBDS (p=.0006/ p< .0001/ p< .0001, respectively). Among them, 
DMBO showed significantly the smallest DAP, AK and FT (p=.0015/ p=0.012/ 
p=.0068 than CBDS). Among all procedurs, the highest level of AK was 2.1 
Gy in a PMBO case. Twelve cases (0.8%) were over 1Gy. Of them, 8 cases 
were PMBO including 3 cases with CBDS.
conclusion: DAP, AK and, FT in PMBO were significantly larger than CBDS 
and DMBO. The disease sites significantly influenced the RD during ERCP. 
Some cases mainly in PMBO showed extremely high level of RE.
disclosure: Nothing to disclose 
P0240 hydraTIOn WITh LacTaTed rInger’s sOLuTIOn 
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chOLangIOPancreaTOgraPhy
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Introduction: Pancreatitis after retrograde cholangiopancreatography 
(PEP) is one of the most frequent and serious complications of this explo-
ration. It has been reported that rectal diclofenac, aggressive hydration 
with lactated ringer’s solution alone or together with rectal indomethacin 
prior to exploration decreases the number of PEP.
We conducted a retrospective study in consecutive patients who under-
went ERCP and were given rectal diclofenac prior to exploration or lactated 
ringer during and after or both interventions (lactated ringer’s solution 
plus diclofenac) to assess whether there is reduction in the number of PEP 
in the treated groups.
aims & Methods: All consecutive patients who have undergone ERCP since 
2009 have been included. Until June 2012, they did not receive any type 
of prophylactic treatment (Group I). As of this date, rectal diclofenac 100 
mg was placed before the start the exploration (Group II). Since January 
2016 they were treated with intravenous infusion of lactated Ringer 200 
ml / hour during the procedure and 4 hours after the procedure. In those 
patients in whom the pancreas was cannulated, they also received 500 ml 
of lactated Ringer in 30 minutes postexploration (Group III). Subsequently, 
from January 2017, patients received the same IV infusion of lactated Ringer 
during and after the exploration plus diclofenac 100 mg rectal before the 
procedure (Group IV). 1,896 ERCPs were included: 725 patients group I, 530 
Group II, 227 Group III and 414 Group IV. The risk factors for PEP and PEP 
cases that were defined by consensus criteria were recorded.
results: The average age of the patients was 70.7 years. 53.1% were male 
and 46.9% female. There were 65 PEP (3.4%), 3.4% of which correspond-
ed to group II, 2.9%, to group I, 3.5% to group III and 4.3% to group IV 
(p, 640). 38.4% of all patients had one or more risk factors for PEP. The 
bivariate analysis relating the influence of the various factors under study 
on the likeliness of PEP development no differences were seen according 
to diclofenac administration status, acute hydration with lactated ringer 
nor with both treatments. Wirsung stent placement had no influence. PEP 
risk was increased by pancreatic duct cannulation and biliary sphincter-
otomy increased risk by a factor of 1.13 (95% CI: 0.55-2.34). In the logistic 
regression analysis the variable found to be significantly associated with 
PEP included Wirsung cannulation (with guidewire, contrast or both - OR 
3,09 (95% CI: 1,45-6.58), OR 2,05 (95% CI: 0,81-5,17), and OR 4,57 (95% CI: 
2.47-8.45), respectively), 83). Age younger than 75 years would increase 
risk by a factor of 2.35 (95% CI: 1.14-4.83). Hydratation plus diclofenac 
played no role in our cohort
conclusion: In this study hydration with lactated ringer’s solution com-
bined with rectal diclofenac does not prevent the occurrence of PEP in our 
patients.
references: Lactated Ringer’s solution in combination with rectal indo-
methacin for prevention of post-ERCP pancreatitis and readmission: a pro-
spective randomized, double-blinded, placebo-controlled trial. Mok SR, 
Ho HC, Shah, P, Patel M,Gaughan JP, Elfant AB. Gastrointest Endosc 2017; 
85: 1005-1013
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The aim of our study is to evaluate the success rate, clinical results and 
length of hospital stay of single stage treatment of gallstones and CBDS by 
laparo-endoscopic rendez-vous.
aims & Methods: From April 2000 to April 2019 a total of 495 elective 
patients (mean age 65 years, range 18-92, M/F 235/260) underwent single 
stage treatment of gallstones and CBDS by laparo-endoscopic rendez-vous 
technique. All patients were diagnosed preoperatively by MRCP or EUS and 
informed about alternative methods of treatment and potential complica-
tions related to laparo-endoscopic rendez-vous technique.
results: Cholecystectomy and common bile duct drainage were achieved 
in 494 cases of 495. 
The transcystic-transpapillar guidewire access was achieved in 448 of 495 
(90.5%). In 46 of 495 patients (9.3%) we successfully performed intraop-
erative ERCP. We registered one case in which it was necessary a percuta-
neous drainage due to distal biliary stenosis (0.2%).
The conversion rate to an open cholecystectomy was 1.8% (9/495) because 
of previous abdominal surgery (7 pts) and unknown gallbladder cancer (2 
pts). The mean ERCP operative time was 35 minutes (range 15-120 min). 
A biliary plastic stent was placed in 61 patients (12.3%) due to anatomic 
alteration of biliary tract (1 pt, 0.2%), not complete stone extraction (40 
pts, 8%), giant lithiasis in elderly patients (17 pts, 3.4%) or biliary fistula (2 
pts, 0.4%). One patient dead after the procedure for severe acute pancre-
atitis. Of the 495 patients who underwent laparo-endoscopic rendez-vous 
6 patients (1.2%) suffered by major complications (lesions of the biliary 
tract=5 (1%); severe acute pancreatitis=3 (0.6%); retroperitoneal bleed-
ing=2 (0.4%). Eleven patients (2.2%) underwent minor complications 
(bleeding=11). The mean length of hospitalization was 3 days.
conclusion: Single stage treatment of gallstones and CBDS by laparo-en-
doscopic rendez-vous technique is a safe and effective method with low 
risk of postoperative pancreatitis. One-step treatment is more comfortable 
for patients and also shortens the mean hospital stay.
disclosure: Nothing to disclose 
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) 
plays major role in pancreaticobiliary disorders, however; its use in acute 
biliary pancreatitis (ABP) is a very debatable issue. 
The aim of this work was to study the safety and efficacy of ERCP in ABP.
aims & Methods: Patients presented with ABP were prospectively included 
and subjected to ERCP procedure after full clinical and investigational 
work up as per the policy of Qena university hospital. Diagnosis of AP 
was based on presence of deep-seated epigastric pain, at least triple-fold 
rise of pancreatic amylase and/or lipase, and radiologic findings of AP 
including edema, fluid collection or necrosis as detected by abdominal 
ultrasound (US) and computerized tomography (CT). Biliary aetiology of 
AP was confirmed by a triple-fold rise of ALT with detection of CBD stone(s) 
or mud in abdominal imaging.
To distinguish patients with concomitant cholangitis from those without 
cholangitis, the included patients were then classified into two groups: 
group (A) with concomitant cholangitis as defined as right upper quadrant 
pain, serum bilirubin ≥ 3 mg/dl and temperature ≥ 38 C, and group (B) 
patients without cholangitis who did not fulfill these criteria. ERCP proce-
dures were performed by experienced ERCP endoscopist with more than 
500 procedures performed.
results: A total of 78 ABP patients were included, mean age: 40.7±13, 42 
(54%) were females.
Clinical presentations on admission were; abdominal pain in 78 (100%), 
nausea in 55 (70.5%), jaundice in 44 (56.4%), vomiting in 43 (55 %) and 
fever in 35 (44.9%). 
All patients were subjected to ERCP within 24 hours from the onset of pain. 
The cannulation technique was: wire-guided cannulation (WGC) in 56 pa-
tients (72%), transpapillary fistulotomy (TPF) in 18 (23%) and transpapil-
P0241 evaLuaTIOn Of a neW MeTaL BILIary sTenT Of 12-MM 
dIaMeTer: a case cOnTrOL sTudy
Decoster C.1, Caillol F.1, Pesenti C.1, Ratone J.P.1, Zemmour C.2, Bories E.1, 
Winkler J.1, Debourdeau A.1, Giovannini M.1
1Institute Paoli-Calmettes, Endoscopy, Marseille, France, 2Institute Paoli-
Calmettes, Statitstics, Marseille, France
contact e-Mail address: claire.decoster@hotmail.fr
Introduction: : Biliary stent allows pre-operative or palliative drainage of 
malignant biliary stenosis, and biliary calibration in case of benign steno-
sis. Currently, by expert agreement, the diameter is 10-mm for metal stent. 
Since 2017, larger stent have been marketed in France and are approved for 
the biliary drainage of benign and malignant biliary stricture. These new 
12-mm diameter stent could reduce the risk of recurrent biliary obstruction 
(RBO) and therefore increase the stent patency. The aim of our study was 
to compare whether the patency of 12-mm diameter stent was better than 
a conventional 10-mm.
aims & Methods: From April 2017 and April 2018, 2 patients per month 
with benign or malignant biliary stricture were treated with metallic bili-
ary stent, covered or uncovered, of 12-mm diametre (length 4 or 6-cm). 
Control patients treated with stent of 10-mm diametre were identified in 
our center database over the same period. These patients were paired 
based on age (per decade), stricture etiology (i.e., benign or malignant) 
and type of stent (i.e., covered or non covered). Primary endpoint was time 
before RBO. Secondary endpoints were technical success rate and adverse 
events rate (< 1 month).
results: From April 2017 to April 2018, we included 24 patients in the 12-
mm group (sex ratio 1.8/1; mean age 71 years) and 48 patients in the con-
trol group (sex ratio 1.6/1; mean age 68.8 years).
In each group, 75% of patients were treated for malignant stricture, 
mainly due to pancreatic adenocarcinoma. There was no statistically sig-
nificant difference between the two groups in terms of sex, Karnofsky 
index and initial total bilirubin level. The median follow-up time was 7.49 
months in the 12-mm group compared to 8.8 months in the 10-mm group 
(p=0.042). Technical success rate was 95.8% and 100% in the 12 and 10-
mm groups respectively. The only failure was due to a stent dysfunction 
during the placement requiring its immediate replacement. Median time 
to RBO was 5.9 months in the 12-mm group vs. 8.3 months in the 10-
mm group (p=0.27). In the malignant stricture subgroup, RBO occurred 
after 6.1 months and 17.1 months in the 12 and 10-mm group respectively 
(p=0.05). The adverse events rate in the month following the biliary stent 
placement was 25% (n=6/24) in the 12-mm group and 2% (n=1/48) in the 
control group without significant difference. In the 12-mm group, there 
were two grade II, one grade IIIa and three grade V adverse events ac-
cording to the Dindo-Clavien classification. The only adverse event in the 
10-mm group was grade II (acute pancreatitis). When new biliary drain-
age was required, it was done endoscopically in 100% of cases for both 
groups.
conclusion: This case-control study does not show better permeability 
of 12-mm diameter metal biliary stent. This result seems to be true re-
gardless of the etiology of biliary stricture and particularly in the group 
of malignant strictures. The placement of 12-mm diameter stent in benign 
stricture should be better evaluated. New prospective studies must be con-
ducted to investigate the efficacy and safety of these stent.
disclosure: Nothing to disclose 
P0242 LaParO-endOscOPIc rendez-vOus ManageMenT Of 
gaLLsTOnes and cOMMOn BILe ducT sTOnes: a Large case 
serIes
Lauri A.1, Lattanzio R.2, Vittorini V.3, Navarra L.3, Caterino G.3, Rando G.1
1Gastroenterology and Digestive Endoscopy Unit, Department of Medicine, 
Pescara, Italy, 2Surgical Endoscopy Unit, Surgery, Pescara, Italy, 3General 
Surgery Unit, Surgery, Pescara, Italy
contact e-Mail address: adrianolauri1@gmail.com
Introduction: Biliary lithiasis is an endemic condition in both Western and 
Eastern countries, affecting 20% of the general population. In up to 20% 
of cases, gallstones are associated with common bile duct stones (CBDS), 
which are asymptomatic in up to one half of cases. 
The ideal management of CBDS in the era of laparoscopic cholecystectomy 
is still controversial: multiple modalities have been applied with success. 
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lary papillotomy in 4 patients (5%) with impacted stone at the papillary 
orifice. Definite stones were extracted in 74 patients (94%) while the rest 
of patients had only debris. The mean cannulation time was 13.6 minutes 
and the mean total procedure time was 68.4 minutes. 
Our result showed a statistically significant difference among means of 
all biochemical parameters at baseline, 24-hours post-ERCP and at the 
time of discharge. The mean values of ALT, AST, ALP, total bilirubin, direct 
bilirubin, pancreatic amylase and lipase were: 261 U/L, 178 U/L, 252.5 U/L, 
5.1 mg/dl, 3.3 mg/dl, 1013 U/L, 1404 U/L at baseline versus 180, 105, 178, 
2.7, 1.7, 367, 918 one-day post-ERCP and 98, 69, 137, 1.6, 0.5, 84, 716 at 
discharge time.
At baseline; 18 patients had mild abdominal pain, 52 had moderate and 
8 had sever while after ERCP 76 patients were pain-free, 1 patient had 
worsening of her pain from mild to moderate and another patient had 
the same moderate intensity pain. Both patients were young-age females 
with serum bilirubin < 3 mg/dl, BISAP score of 2 at admission, and without 
cholangitis. Biliary access was achieved via WGC after a relatively-long 
cannulation time of 17 and 23 minutes, and prolonged total procedure time 
of 98 and 103 minutes respectively. Both were managed medically for 5 
and 7 days then were discharged.
No reported serious complications in our study.
conclusion: In the setting of acute biliary pancreatitis, either with or with-
out cholangitis, ERCP is safe and efficient procedure when performed by 
experienced hands and at the optimal time.
disclosure: Nothing to disclose 
P0244 a POPuLaTIOn-Based anaLysIs: WhO dOes recTaL 
IndOMeThacIn In POsT-ercP PancreaTITIs heLP?
Syed A.1,2, Thakkar S.3, Farah K.1, Dhawan M.1, Kulkarni A.1, Kochhar G.4
1Allegheny Health Network, Gastroenterology, Pittsburgh, United States, 
2Case Western Reserve University - School of Medicine, Internal Medicine, 
Cleveland, United States, 3Allegheny Health Network, Gastroenterology, 
Sewickley, United States, 4Allegheny Health Network, Gastroenterology & 
Hepatology, Pittsburgh, United States
contact e-Mail address: aslam.syed@ahn.org
Introduction: Pancreatitis (PEP) post endoscopic retrograde cholangiopan-
creatography (ERCP) is a severe complication, with an incidence rate rang-
ing between 1.3 - 24.4%. Many studies have shown that indomethacin 
effectively decreases post-ERCP pancreatitis (PEP). However, it is unclear 
which demographics are effected most, and the role of indomethacin in 
these populations. Additionally, large population-based studies reporting 
the effectiveness of rectal indomethacin are limited. This study aims to re-
port populations who pose a higher than average-risk of PEP, and describe 
the role of indomethacin in these patients.
aims & Methods: A population-based study was conducted using a cloud-
based, HIPPA-enabled web platform called Explorys (IBM, New York) to 
collect aggregated de-identified electronic health records. At the time of 
the study, Explorys had access to over 62 million unique records. Data was 
obtained using ICD-9 code criteria for ERCP’s, acute pancreatitis (pancre-
atitis within 7 days of ERCP), and inclusion of rectal indomethacin formu-
laries. Relative risk (RR) with 95% confidence intervals (CI) in a random 
effect model was used for aggregated subgroup outcome data based on 
associated factors or patient characteristics to identify populations who 
may benefit most from rectal indomethacin.
  PeP [n=23,920]
PeP with rectal 
Indomethacin [n=3,320]
relative risk 
[95% cI] P
Age, n [%]        
18-65 12,150 [51] 1,920 [58] 1.11 [1.04, 1.18] 0.0011
> 65 11,630 [49] 1,390 [42] 0.68 [0.63, 0.72] < 0.0001
Gender, n [%]        
Female 13,560 [57] 2,020 [61] 0.96 [0.90, 1.02] 0.1660
Male 10,360 [43] 1,300 [39] 0.76 [0.71, 0.81] < 0.0001
Race, n [%]        
Caucasian 18,890 [79] 2,820 [85] 1.50 [1.37, 1.64] < 0.0001
African-American 2,840 [12] 340 [10] 0.25 [0.22, 0.27] < 0.0001
Hispanic 1,509 [7] 220 [7] 1.05 [0.93, 1.20] 0.4150
[Role of Rectal-Indomethacin in Post-ERCP Pancreatitis (PEP)]
results: A total of 112,290 patients underwent ERCP, of which 23,920 (21%) 
developed PEP. We found a higher risk of PEP development in younger 
patients (18-65), African-Americans and Hispanics (P< 0.001). Rectal in-
domethacin decreased rates of PEP in patients > 65 [RR 0.68 (95% CI; 
0.63-0.72), P< 0.0001] and African-Americans [RR 0.25 (95% CI: 0.22-0.27), 
P< 0.0001]. Indomethacin did not affect the risk of PEP in the younger 
population and Caucasians.
conclusion: Rectal indomethacin decreases rates of post-ERCP pancreati-
tis in the elderly, and African-Americans. Given our study found African-
Americans have higher rates of PEP, clinicians need to be aware and vigi-
lant to provide rectal indomethacin in these populations, where benefit 
was greatest.
disclosure: Nothing to disclose 
P0245 endOscOPIc sPhIncTerOTOMy fOLLOWed By 
Large BaLLOOn dILaTIOn In The exTracTIOn Of Large 
chOLedOchOLIThIasIs
Del Olmo Martinez L.1, Velayos Jiménez B.2, Almaraz A.3
1Hospital Clinico, Gastroenterology, Valladolid, Spain, 2Hospital Clinico 
Universitario, Gastroenterology, Valladolid, Spain, 3Facultad de Medicina, 
Medicina Preventiva y Salud Pública, Valladolid, Spain
contact e-Mail address: ldelolmo@yahoo.es
Introduction: Endoscopic sphincterotomy (ES) is the standard therapy in 
common bile duct (CBD) stones extraction. Large stones (≥ 10 mm) or 
multiple stones extraction may be challenging after ES alone. Endoscopic 
sphincterotomy followed by large balloon dilation (ESLBD) has been de-
scribed as an alternative to ES in these indications.
The aim of this study was to determine the therapeutic outcomes and safe-
ty of ESLBD compared with ES for large CBD stone extraction.
aims & Methods: This is a retrospective study in which 323 consecutive 
patients who presented with choledocholithiasis >10 mm from January 
2011 to December 2018 have been analyzed. In 249 ES was performed and 
the extraction of the stones was attempted. 74 patients were treated with 
ESLBD. Data for each patient and exploration were collected in an Excel 
sheet, and later analyzed using the IBM SPSS Statistics 20 software pack-
age. Simple statistical applications were applied in order to determine 
whether significant differences exist in comparison groups. We used chi-
square test to compare proportions and categorical variables. Non-para-
metric Mann-Whitney U-test was applied in order to compare continuous 
variables. All comparisons were deemed to be statistically significant if P 
values were less than 0.05.
results: The comparison of variables of two groups are expressed in Table 
1. 
varIaBLes es n=249 esLBd n=74 p
Mean Age 75,81 75,82 0,828
Older than 75 Years(%) 59,3 60,8 0,893
Mean Number Stones 2,9 3,45 0,154
Size Major Stone (mm) 11,91 13,26 0,029
Male/Female (%) 52,2/47,8 50/50 0,792
Dilatation bile duct (%) 89,6 95,9 0.107
Full extraction stones (%) 68,7 69,9 0,887
Adverse Events (%) 2 0 0,593
[Comparison variables of ES and ESLBD groups]
78 (31.3%) of patients in ES group required repeat ERCP for stone clear-
ance and in 70 large biliary dilation (LBD) was performed. In 22 (30.1%) 
of ESLBD group it was not possible to extract the stones and 11 had repeat 
LBD for complete duct clearance. Larger stone size (12.7 mm vs 16.3 mm, 
P < 0.001), multiple stones (3 vs 4 P < 0.06) were significant predictors of 
failed duct clearance at ERCP. Procedure related adverse events included 5 
cases (2%) in ES group and none in ESLBD group (P< 0.593).
conclusion: In our study ESLBD and ES clear bile stones with equal ef-
ficacy. However, ESLBD achieves the removal of larger stones in the initial 
ERCP with few adverse effects.
references: Endoscopic Papillary Large Balloon Dilation Versus Endoscopic 
Sphincterotomy for Retrieval of Large Choledocholithiasis: A Prospective 
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biliary drainage training model using three-dimensional printing bile duct 
and mixed gelatin material. Endoscopic Ultrasound. 2017;6(Suppl 1):S26-S.
disclosure: Nothing to disclose 
P0247 endOscOPIc Band LIgaTIOn WIThOuT resecTIOn Of 
sMaLL sIzed suBePITheLIaL TuMOrs: resuLTs In shOrT-MedIuM 
fOLLOW uP TerM Of a MuLTIcenTer PrOsPecTIve sTudy 
(BandIng-seT)
Bas-Cutrina F.1, Consiglieri C.F.2, Loras C.3, Huertas C.4, Ballester R.5, 
Guarner-Argente C.6, Pardo A.7, Andújar X.3, Albert M.4, González-Huix F.5, 
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Barcelona, Catalonia, Spain, 3Hospital Universitari Mútua de Terrassa, 
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contact e-Mail address: francescbas15@gmail.com
Introduction: The endoscopic band ligation (EBL) without resection com-
bined with a single-incision needle-knife (SINK) biopsy is a little reported 
option in the management of subepithelial tumours (SET).
aims & Methods: The main aim was to determine the efficacy of this tech-
nique. Secondary aims: to evaluate its safety and the diagnostic yield of 
biopsy. 
Methods: Prospective multicenter study. Inclusion criteria: SET≤15-mm, 
confirmed by endoscopic ultrasound (EUS). Technical success: complete 
EBL of the SET plus SINK biopsy. Clinical success: total disappearance of the 
SMT. Clinical controls: recovery at first 6 hours, calling at 48 hours and 7 
days. EUS control at 4-6 weeks and 12 months. Clinical-Trials.gov register: 
NCT03247231.
results: Seventy-two cases (49% of the sample calculation); EUS control 
4-6 weeks n=59. Esophagus n=5, stomach n=52, duodenum n=14, rectum 
n=1. SET medium size: 9.6-mm (4.5-15 mm). EBL technical success: 85% 
(n=61/72). Clinical success at 4-6 weeks: 93% (n=55/59), overall clini-
cal success: 79% (n=55/70). SET dependence of superficial vs deep layer 
subanalysis: technical success 90% vs 71%; overall clinical success 86% 
vs 62%. SET≤10-mm vs >10-mm: technical success 100% vs 63%; overall 
clinical success 98% vs 52%. Pathological diagnosis: 64% (35/55); no dif-
ferences between SET-size, SET-layer, or number or biopsies. Three mild 
adverse events (4%): bleeding, pain, mucosal intraprocediment laceration. 
Incidences: epigastralgy (6h: 29%; 24-48h: 26%; 7-days: 13%; 4-6 weeks: 
2%).
conclusion: Preliminary results in the short-medium follow up term indi-
cate that EBL of small SET, supplemented with SINK biopsy, seems to be 
a feasible and safe technique. The limitations of its technical and clinical 
success seem to be associated with the SET size and deep layers depen-
dence.
  superficial layer deep layer seT ≤10-mm seT >10-mm
yes technical 
success 46 (90%) 15 (71%) 42 (100%) 19 (63%)
nO technical 
success 5 (10%) 6 (29%) 0 (0%) 11 (37%)
yes clinical 
success 42 (95%) 13 (87%) 40 (98%) 15 (83%)
Overall nO clinical 
success 7 (14%) 8 (38%) 1 (2%) 14 (48%)
[Technical and clinical success subanalysis]
references: [1] Faulx AL, Kothari S, Acosta RD et al. The role of endoscopy in 
subepithelial lesions of the GI tract. Gastrointest Endosc 2017; 85: 1117-1132. 
[2] Arezzo A, Verra M, Miegge A, Morino M. Loop-and-let-go technique 
for a bleeding, large sessile gastric gastrointestinal stromal tumor (GIST). 
Endoscopy 2011; 43: E18-19. [3] Binmoeller KF, Shah JN, Bhat YM, Kane 
Randomized Trial. Omar MA1, Abdelshafy M2, Ahmed MY2, Rezk AG2, Taha 
AM2, Hussein HM2. J Laparoendosc Adv Surg Tech A. 2017 Jul;27(7):704-709.
disclosure: Nothing to disclose 
P0246 evaLuaTIOn Of a nOveL, nOn-fLuOrOscOPIc, 
aLL-arTIfIcIaL MOdeL fOr endOscOPIc uLTrasOund guIded 
BILIary draInage TraInIng (Tage-2)
Siripun A.1, Chantarojanasiri T.2, Ratanachuek T.3, Kongkam P.4, 
Thai Association for Gastrointestinal Endoscopy (TAGE)
1Bangkok Hospital, Dept. of Internal Medicine, Bangkok, Thailand, 2Rajavithi 
Hospital, Internal Medicine, Bangkok, Thailand, 3Rajavithi Hospital, 
Bangkok, Thailand, 4Chulalongkorn University Dept. of Internal Medicine, 
Bangkok, Thailand
contact e-Mail address: aroon1979@gmail.com
Introduction: Endoscopic ultrasound guided biliary drainage (EUS-BD) is 
a useful method after failed ERCP yet need expertise in performing the 
procedure. Hands on model for EUS-BD training has been developed to 
improve trainee’s skill but previous models required fluoroscopy and in-
cluded ex-vivo animal organs.We reported an all-synthetic interventional 
EUS training model (TAGE-1) and now a newer model (TAGE-2) has been 
developed.
aims & Methods: This study aims to evaluate TAGE-2 model during the 
hands on workshop. We developed a non-fluoroscopy, all-artificial model 
for EUS-BD which included both hepaticogastrostomy (HGS) and choledo-
choduodenostomy (CDS). We launched TAGE-2 in two international EUS 
hands on workshops and gave a questionnaire to the participants. 10 as-
pects of EUS-BD was assessed scored from 1 to 4, with score 1 = poor, 2 = 
fair, 3 = good, 4 = excellent, by both the expert (> 300 experiences of EUS 
FNA) and the trainee during the workshop. The trainees were divided into 
a beginner (< 50 cases of EUS) and an experienced (≥50 cases of EUS FNA).
results: The evaluation scores for EUS guided HGS and CDS are shown in 
table 1. Almost all items were graded as good to excellent, especially for 
the needle visibility, guidewire manipulation and stent deployment. How-
ever, the puncture sensation in EUS-CDS and contrast visibility in EUS-HGS 
are still graded fair to good by the experienced and the expert, respectively.
conclusion: We developed a non-fluoroscopic, all-artificial model for EUS 
BD training which provided good training hands on for therapeutic EUS, 
especially for the steps and maneuverability of the instruments.
evaluated 
items
hgs 
beginner 
(23)
hgs 
experi-
enced 
(2)
hgs 
expert 
(3)
hgs 
overall 
(28)
cds 
beginner 
(36)
cds 
experi-
enced 
(5)
cds 
expert 
(4)
cds 
overall 
(45)
Anatomical 
correlation 3 3 3 3 3 3 3 3
Bile duct 
identification 4 3 3 3 3 3 3.5 3
Needle 
visibility 4 3 4 4 4 4 4 4
Puncture 
sensation 3 3 3.5 3 3 3 2.5 3
Contrast 
injection 3 2.5 3.5 3 4 3 4 4
Guidewire 
manipulation 3 3 3 3 4 3 3 3
Tract dilation 
(dilation 
catheter)
3 3 3.5 3 4 3 4 4
Stent insertion 3 3 3.5 3 4 3.5 3 4
Overall 4 3.5 3 4 4 4 3.5 4
[Median evaluation score of TAGE-2 model for Endoscopic ultrasound guided 
hepaticogastrostomy (EUS-HGS) and choledochoduodenostomy (EUS-CDS).]
references: 1. Dhir V, Itoi T, Pausawasdi N, Khashab MA, et al. Evaluation 
of a novel, hybrid model (Mumbai EUS II) for stepwise teaching and train-
ing in EUS-guided biliary drainage and rendezvous procedures. Endosc 
Int Open. 2017;5(11):E1087-E95. 2. Dhir V, Itoi T, Fockens P, et al. Novel ex 
vivo model for hands-on teaching of and training in EUS-guided biliary 
drainage: creation of “Mumbai EUS” stereolithography/3D printing bile 
duct prototype (with videos). Gastrointest Endosc. 2015;81(2):440-6. 3. 
Pinyoteppratarn R, Ratanchuek T. POSTER ABSTRACTS: THERAPEUTIC: P-
THER-02: A realistic, simple, inexpensive endoscopic ultrasound-guided 
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SD. Suck-ligate-unroof-biopsy by using a detachable 20-mm loop for the 
diagnosis and therapy of small subepithelial tumors (with video). Gastro-
intest Endosc 2014; 79: 750-755. [4] Hwang JH, Konda V, Abu Dayyeh BK et 
al. Endoscopic mucosal resection. Gastrointest Endosc 2015; 82: 215-226. 
[5] Zang D, Lin Q, Shi R et al. Ligation-assisted endoscopic submucosal 
resection with apical mucosal incision to treat gastric subepithelial tumors 
originating from the muscularis propria. Endoscopy 2018; 50: 1180-1185.
disclosure: Nothing to disclose 
P0248 The safeTy and The effIcacy Of sIngLe-sessIOn 
esOPhagOgasTrOduOdenOscOPy and endOscOPIc uLTrasOund 
usIng neWLy deveLOPed endOscOPe: a PrOsPecTIve 
InTervenTIOn sTudy
Uchida D.1, Kato H.2, Matsumoto K.2, Matsumi A.2, Saragai Y.2, Tomoda T.2, 
Horiguchi S.2, Okada H.2
1Okayama University Hospital, Gastroenterology, Okayama, Japan, 2Okayama 
University Hospital, Okayama, Japan
contact e-Mail address: pt77172s@okayama-u.ac.jp
Introduction: Endoscopic ultrasound (EUS) is useful for obtaining high-
resolution images of pancreaticobiliary diseases but is not readily avail-
able for a physical checkup. Recently, a new ultrasonic endoscope (EG-
580UR; FUJIFILM) capable of simultaneously performing esophagogastro-
duodenoscopy (EGD) and EUS was developed. In this study, we evaluated 
the safety and efficacy of single-session EGD and EUS for the detection 
of upper-gastrointestinal and pancreaticobiliary diseases using this newly 
developed ultrasonic endoscope.
aims & Methods: A total of 148 patients scheduled to undergo upper-gas-
trointestinal screening using an endoscope were prospectively included. 
All patients were examined using EUS together with EGD using EG-580UR. 
The primary endpoint was the safety of the procedures, and the secondary 
endpoints were the prevalence of diseases, basal imaging capability of 
EUS, correlation between the prevalence of pancreatic diseases and back-
grounds, and procedure time. Imaging capability was scored as 0 (invis-
ible) to 2 (sufficient visualization to evaluate the organs clearly) in each 
region.
results: Intraoperative hypotension occurred as an adverse event of intra-
venous anesthesia in one patient, however her hypotension was reversed 
rapidly with the administration of ephedrine, and she recovered from an-
esthesia without further symptoms. The prevalence of pancreaticobiliary 
diseases was as written below; pancreatic cysts: 32 patients, early chronic 
pancreatitis: 25 patients, gallbladder polyps: 22 patients, adenomyomato-
sis: 9 patients, gallbladder stone: 13 patients, bile duct stone: one patient. 
The prevalence of upper-gastrointestinal diseases was as written below; 
esophagitis: 51 patients, esophageal polyp: 3 patients, chronic gastritis: 69 
patients, gastric ulcer scar: oneb patient, gastric polyp: 23 patients, gastric 
submucosal tumor: 8 patients, duodenal ulcer scar: 8 patients, duode-
nal submucosal tumor: 2 patients. There were no features of malignancy 
of pancreaticobiliary and upper-gastrointestinal findings in any patients. 
Swollen abdominal lymph nodes was detected in one patient incidentally, 
and EUS-guided fine-needle aspiration was performed, which revealed 
the lesion to be follicular lymphoma. The mean EUS imaging scores of 
each section were 1.95 (pancreatic head and papilla), 2.0 (pancreatic 
body), 1.99 (pancreatic tail), and 1.89 (common bile duct and gallblad-
der). The age, history of diabetes mellitus, and smoking history were sig-
nificantly associated with the prevalence of pancreatic diseases. Median 
procedure time was 21 minutes.
conclusion: Performing EGD and EUS simultaneously using the new ul-
trasonic endoscope is tolerable and safe for upper-gastrointestinal and 
pancreaticobiliary screening.
disclosure: Nothing to disclose 
P0249 The “TWIsT-needLe” - a neW cOncePT fOr endOscOPIc 
uLTrasOund-guIded fIne needLe-BIOPsy
Hann A.1, Walter B.1, Epp S.1, Ayoub Y.2, Meining A.1
1Ulm University, Department of Internal Medicine I, Ulm, Germany, 2Cairo 
University, Faculty of Medicine, Cairo, Egypt
contact e-Mail address: a.hann@posteo.de
Introduction: Endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) 
represents a standard method for tissue acquisition of lesions adjacent 
to the gastrointestinal wall. 19-gauge needles acquire more tissue than 
needles with a smaller diameter, but are often unable to penetrate solid, 
rigid masses. In this study we evaluate a novel prototype that links forward 
movement of the needle to rotation of the needle tip.
aims & Methods: Two needle-models that generate either a regular axial 
movement or a combination of axial movement with rotation of the needle 
tip were compared ex vivo for measurement of pressure needed to pen-
etrate artificial tissue. Furthermore, a standard 19-gauge EUS-FNB needle 
was compared to a modified model (“Twist Needle”) in an ex vivo model 
to measure the amount of tissue obtained.
results: Pressure measurements using the rotating needle revealed that 
significantly less pressure is needed for penetration compared to the 
regular axial movement (mean ± SEM; 3.7 ± 0.3 N vs. 5.5 ± 0.3 N). Using 
the modified 19-gauge “Twist Needle” did not diminish tissue acquisition 
measured by surface amount compared to a standard needle (37 ± 5 mm² 
vs. 35 ± 6 mm²).
conclusion: The method of rotation of an EUS-FNB needle tip upon for-
ward movement requires less pressure for penetration but does not di-
minish tissue acquisition. Hence, the concept of our “Twist Needle” may 
potentially reduce some of the current limitations of standard EUS-FNB.
disclosure: Nothing to disclose 
P0250 dOes endOscOPIc uLTrasOund-guIded fIne needLe 
BIOPsy usIng a franseen needLe reaLLy Offer hIgh 
dIagnOsTIc accuracy and POOr PuncTure PerfOrMance?
Fujita A., Ryozawa S., Mizuide M., Tanisaka Y., Harada M., Ogawa T.
Saitama Medical University International Medical Center, Department of 
Gastroenterology, Hidaka, Japan
contact e-Mail address: a.fujita0628@gmail.com
Introduction: Endoscopic ultrasound-guided fine needle aspiration (EUS-
FNA) was first reported in 1992 and is now used for a wide range of le-
sions. This widely used non-surgical biopsy procedure provides safe, con-
sistent results under ultrasound guidance.
A recent meta-analysis of pancreatic lesions showed that EUS-FNA was a 
modality producing excellent diagnostic accuracy, and EUS-FNA has now 
been established as an important modality for the histopathologic diag-
nosis of pancreatic lesions. This modality is not, however, without unre-
solved issues, including the need for by-lesion needle selection, the need 
for availability of rapid onsite evaluation (ROSE), and the need for skilled 
endoscopists.
New clinical applications for biopsies are on the horizon, such as genetic 
diagnostics and anticancer drug-sensitivity assays in addition to conven-
tional diagnostics. Such applications will inevitably require collection of 
an adequate tissue volume to achieve better diagnostic accuracy. In EUS-
FNA, 19-G needles are useful for histologic diagnostics, providing suf-
ficient sample for immunostaining, but the greater puncture resistance 
encountered at this size increases the difficulty of the procedure. This has 
left users wanting smaller-gauge needles that could collect comparable 
volumes of tissue. In 2016, the Franseen needle emerged as a fine needle 
biopsy (FNB) device with the potential to provide better histologic diagnos-
tic accuracy than conventional FNA needles. This device, however, remains 
under-researched. 
We recently evaluated the diagnostic accuracy and utility of EUS-FNB per-
formed with a 22-G Franseen needle for solid pancreatic lesions, com-
paring the results to those obtained through EUS-FNA with conventional 
needles.
aims & Methods: This study aimed to investigate the diagnostic accuracy 
and utility of EUS-FNB performed using a Franseen needle on solid pan-
creatic lesions.
This study included 132 consecutive lesions sampled by EUS-FNA using a 
22-G conventional needle and 93 consecutive lesions evaluated by EUS-
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most cases. Given the high sensitivity for cancer in clinical practice, our 
results also suggest that quality benchmarks for EUS-FNA should be re-
evaluated.
references: 1. Wani S, Wallace MB, Cohen J et al. Quality indicators for EUS. 
Gastrointest Endosc 2015;81(1):67-80. 2. Hewitt MJ, McPhail MJW, Possamai 
L et al. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a 
meta-analysis. Gastrointest Endosc 2012;75:319-31. 3. Sonnenberg A, Ro-
driguez SA, Faigel DO. Diagnostic ascertainment of suspicious pancreatic 
masses: a threshold analysis. Clin Gastro Hep 2008;6:1162-1166.
disclosure: Nothing to disclose 
P0252 The dIagnOsTIc accuracy Of endOscOPIc uLTrasOund 
versus endOscOPIc reTrOgrade chOLangIOPancreaTOgraPhy 
In evaLuaTIng cOMMOn BILe ducT dILaTaTIOn Of 
undeTerMIned eTIOLOgy deTecTed By aBdOMInaL uLTrasOund
A. Faheem H.1, Helal E.1, Abdel Aziz A.2, El.Ansary M.3, 
Darwish El-Talkawy M.3, Ragab K.3, Abd El-Hameed M.3, Gamal A.3, 
Ibrahim M.3, Fayed M.2
1Ain Shams University, Gastroenterology, Hepatology and Endoscopy, Cairo, 
Egypt, 2Theodor Bilharz Research Institute, Tropical Medicine, Cairo, Egypt, 
3Theodor Bilharz Research Institute, Gastroenterology, Hepatology and 
Endoscopy, Cairo, Egypt
contact e-Mail address: doc_hobafaheem@yahoo.com
Introduction: The aim of the diagnostic evaluation of bile duct obstruction 
is to differentiate benign from malignant lesions and to stage the tumor 
in cases of malignancy. Endoscopic retrograde cholangiopancreatography 
(ERCP) helps in detecting the stricture location especially in the lower parts 
of biliary tract. Endoscopic ultrasound (EUS) is another modality which is 
safe when performed at a center with an experienced endosonographers. 
Isolated dilated CBD on abdominal ultrasound (US) is still in need to be 
probably assessed.
aims & Methods: Our aim was to compare the accuracy of endoscopic 
ultrasound (EUS) to endoscopic retrograde cholangiopancreatography 
(ERCP) in the diagnosis of dilated common bile duct of undetermined eti-
ology detected by abdominal ultrasound. Methods: we conducted a retro-
spective study on 139 patients referred to TBRI (Theodor Bilharz Research 
Institute) over the period of 2 years. 80 patients were included in the study 
and 59 were excluded due to insufficient endoscopic details. All patients 
with dilated CBD of indeterminate etiology by US who underwent EUS and 
ERCP were enrolled to compare between the accuracy of both as a diag-
nostic tool.
results: Our study included 43 (53.7%) males and 37 (46.2%) females, with 
a mean (±SD) age of 52.01 (±12.15). The mean (±SD) of CBD diameter de-
tected by US was 12.38 (±2.65). In comparison between ERCP and EUS in 
diagnosing pathological causes of CBD dilatation. EUS was statistically sig-
nificant than ERCP with (p value < 0.001*). Diagnosis of CBD dilatation by 
EUS was as follows: 40 cases had malignant stricture, 28 cases had stones, 
10 cases had benign stricture, and prominent CBD with no obstruction was 
in only 2 cases. While diagnosis of CBD dilatation by ERCP was as follows: 
26 cases had indeterminate stricture, 24% cases had stones, another 24% 
cases had malignant stricture, 4 cases had prominent CBD with no obvious 
obstruction, and 2 cases had benign stricture. 
FNA-EUS/biopsy sample was conducted on 44 cases only and the results 
were as follows: 36 cases had malignant stricture, 5 cases had chronic 
nonspecific inflammation, and 3 cases had benign non inflammatory stric-
ture. In relation between FNA \ Biopsy sample results and pathological 
causes of CBD dilatation diagnosed by EUS and ERCP, there was statisti-
cally significant relation between FNA \ Biopsy sample results and findings 
of EUS and ERCP (with p-value< 0.001* in both), while diagnosis of CBD 
dilatation by EUS on those 44 cases was as follows: 36 cases (81.82 %) 
had malignant stricture, 6 cases (13.64%) had benign stricture and 2 cases 
(4.55%) had microlithiasis. While the diagnosis of CBD dilatation by ERCP 
was as follows: 21 cases (47.73%) had benign stricture, 19 cases (43.18%) 
had indeterminate stricture, 2% cases (4.55%) had stones, 1 case (2.27%) 
had benign stricture, and another 1 case had prominent CBD with no obvi-
ous obstruction. 
FNB using a 22-G Franseen needle to evaluate solid pancreatic lesions at 
our medical center between July 2013 and October 2018. Patient data were 
analyzed retrospectively.
results: Diagnostic accuracy was significantly higher in the Franseen nee-
dle group (Group F; 91.4%, 85/93) than in the conventional needle group 
(Group C; 80.3%, 106/132; P=0.02). In Group F, diagnostic accuracies for 
pancreatic head lesions, lesions sampled by transduodenal puncture, and 
relatively large lesions >20 mm in diameter were 97.9% (47/48), 97.8% 
(45/46), and 93.3% (70/75), respectively. These values were significant-
ly higher than in Group C (P < 0.001, 0.002, and 0.04, respectively). In 
terms of differentiating benign from malignant lesions, Group C showed 
78.3% sensitivity (94/120), 100% specificity (12/12), 100% positive pre-
dictive value (94/94), and 31.6% negative predictive value (12/38), while 
Group F showed values of 89.9% (71/79), 100% (14/14), 100% (71/71), and 
63.6%(14/22), respectively. Sensitivity and negative predictive value were 
better in Group F.
conclusion: Using a Franseen needle for EUS-FNB of solid pancreatic le-
sions offers superior diagnostic accuracy to conventional FNA regardless 
of the lesion site.
disclosure: Nothing to disclose 
P0251 The sensITIvITy and negaTIve PredIcTIve vaLue Of 
eus-fna Of PancreaTIc Masses In PracTIce: can We ruLe OuT 
PancreaTIc cancer?
Faigel D., Pannala R., Nguyen C., Villa N., Fukami N.
Mayo Clinic, Gastroenterology, Scottsdale, United States
contact e-Mail address: faigel.douglas@mayo.edu
Introduction: EUS-FNA is commonly performed to establish a tissue diag-
nosis of pancreatic cancer. Performance metrics for FNA of solid masses in-
clude diagnostic yield ≥70% and sensitivity for malignancy ≥85%.(1) These 
benchmarks were based on a meta-analysis of 33 studies from 1997-2009 
reporting an average sensitivity of 85% but with a range among these 
studies of 54-95%.(2) Our previously published threshold analysis sug-
gests that this level of sensitivity may have inadequate negative predictive 
value (NPV) to affect management.(3)
aims & Methods: Objective: Review a tertiary center’s clinical experience 
with EUS-FNA of pancreatic masses and calculate the sensitivity and NPV 
for pancreatic cancer.
Methods: This study was granted an IRB exemption from review. As part of 
our quality assurance program, all EUS-FNA procedures of solid pancreas 
masses from calendar years 2013 and 2014 were identified. All procedures 
were performed by 1 of 3 experienced endosonographers using Olympus 
echoendoscopes and processors and 22g or 25g FNA needles (Boston Sci-
entific, Cook Medical) using a no suction technique. Rapid on-site evalua-
tion for adequacy was performed by trained cytotechnicians after staining 
with toludine blue. Final pathology was determined by cytopathologists 
after review of pap stained slides and cell block material. Only cytology 
that was diagnostic was considered a true positive (suspicious was consid-
ered negative). Follow-up was done by chart review. False negatives had 
subsequent biopsy or clinical follow-up diagnostic of pancreatic cancer. 
True negatives ether had an alternative diagnosis established at FNA, by 
resection or biopsy, or adequate clinical follow-up indicative of a benign 
condition.
results: 120 patients underwent EUS-FNA for pancreatic masses. Patients 
with a preprocedure or a pre-FNA endosonographic diagnosis of a cystic 
lesion without a solid mass were excluded. 102 (85%) were positive for 
malignancy. 18 patients with a negative cytology had median follow-up 
of 695 days. Of these 18, 4 were subsequently diagnosed with cancer (3 
adenocarcinoma, 1 NET). The EUS-FNA was diagnostic of a benign etiology 
in 6 (AIP, ectopic spleen, 4 benign cystic lesions). Of the 8 without cancer 
and with a non-diagnostic EUS-FNA (median follow-up 830 days), 3 had 
surgical resections with pathology revealing benign cystic lesions, 2 had 
resolution of the lesion on repeat imaging, and 3 had chronic pancreatitis 
with no progression on at least 2 years of follow-up. The sensitivity of EUS 
FNA for cancer was 102/106 = 96%. The NPV was 14/18 = 78%.
conclusion: EUS-FNA of pancreatic masses using modern techniques and 
rapid on-site evaluation has improved in the last 10 years. Our previously 
published threshold analysis indicated that if the post-test probability of 
cancer was ≥43% then surgery should be done.(3) With a NPV=78% and 
a post-test probability of 22%, a negative FNA should prompt additional 
testing and follow-up as opposed to proceeding with surgical resection in 
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  ercP eus chi-square
fna / 
Biopsy 
(only 44 
cases)
eus ercP chi-square
  N (%) N (%) X2 P-value N (%) N (%) N (%) X2 P-value
stone 24 
(30%)
28 
(35%)
     
2 
(4.5%)
2 
(4.5%)
FNA / Biopsy 
and EUS
Indeterminate 
stricture
26 
(32.5%)
0 (0%)        
19 
(43.1%)
68.444 <0.001*
Benign 
stricture
2 
(2.5%)
10 
(12.5%)
36.308 < 0.001* 3 (6.8%)
6 
(13.6%)
1 
(2.2%)
FNA / Biopsy and 
ERCP
Malignant 
stricture
24 
(30%)
40 
(50%)
   
36 
(81.8%)
36 
(81.8%)
21 
(47.7%)
33.868 <0.001*
Prominent 
cBd no 
obstruction
4 (5%)
2 
(2.5%)
       
1 
(2.2%)
   
chronic 
non-specific 
inflammation
        5(11.3%)        
Total 80 
(100%)
80 
(100%)
    44 (100%)
44 
(100%)
44 
(100%)
   
[Table (1): Descriptive data of the study]
conclusion: Our study revealed the superiority of EUS over ERCP in diag-
nosing CBD dilatation of undetermined etiology detected by abdominal 
US.
disclosure: Nothing to disclose 
P0253 PrOPhyLacTIc endOscOPIc uLTrasOund guIded 
gaLLBLadder draInage In PaTIenTs WITh unresecTaBLe 
MaLIgnanT BILIary OBsTrucTIOn and cysTIc ducT OrIfIce 
InvOLveMenT: a randOMIzed cOnTrOL TrIaL
Robles-Medranda C., Oleas R., Olmos J., Nebel J., Puga-Tejada M., 
Baquerizo-Burgos J., Pitanga-Lukashok H.
Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Gastroenterology 
and Endoscopy Division, Guayaquil, Ecuador
contact e-Mail address: robertoleas@gmail.com
Introduction: Biliary self-expandable metal stents (SEMS) are a palliative 
therapy for malignant biliary obstruction (MBO); however, acute chole-
cystitis is a described adverse event. Tumor involvement to the orifice of 
the cystic duct (OCD) is a major predictive factor for acute cholecystitis 
after SEMS placement. Endoscopic ultrasound guided gallbladder drain-
age (EUS-GBD) have been reported for the acute cholecystitis treatment; 
however, the role of primary EUS-GBD for acute cholecystitis prophylaxis 
remains unknown.
aims & Methods: A single-center, randomized control-trial. Primary EUS-
GBD was performed using a 3.8 mm therapeutic echoendoscope and a lu-
men apposing metal stent (Hot Axios™ Stent and Electrocautery Enhanced 
Delivery System, Boston Scientific, MA) after conventional biliary drainage 
with SEMS. In the other arm, patients were submitted to conventional bili-
ary drainage using SEMS without primary EUS-GBD. A sample size of 11 
patients per group was estimated, considering the clinical success of EUS-
GBD vs. percutaneous transhepatic gallbladder drainage (92% vs. 86%) 
and, a type I & II errors of 10% and 20%, respectively. Baseline character-
istics were described and compared with their corresponding hypothesis 
testing. The primary outcome of the study was the occurrence of acute 
cholecystitis after randomization and assed-up to 12 months or death. 
Secondary endpoints were the length of hospitalization and the median 
relative survival. Time-to-event analysis for acute cholecystitis and relative 
survival were estimated through Competing Risk Analysis and Cox Regres-
sion, respectively. A p- value < 0.05 was considered statistically significant. 
Data analysis was performed using R.
results: 23 patients were included: 12/23 in the primary EUS-GBD group 
and 11/23 in the control group. No reintervention was required in the pri-
mary EUS-GBD group; whereas, four patients from the control group de-
veloped acute cholecystitis: three patients were treated via laparoscopic 
cholecystectomy at the day 16, 7 and 1, after randomization. One patient in 
control group developed acute cholecystitis and was rejected to surgery at 
the day 100, being switched and treated with EUS-GBD. The median length 
of hospitalization in days was inferior in patients treated with primary 
EUS-GBD. The one-year acute cholecystitis-free survival rate was 91.7% 
for primary EUS-GBD compared to 36.4% in the control group (HR 0.117; 
0.014-0.958, p=0.016). No difference in the median relative survival was 
detected among groups 2.4 months for primary EUS-GBD vs 2.8 months in 
the control group (HR 0.837; 0.308-2.272, p=0.727) (table 1). 
  Primary eus-
gBd (n = 12)
control group 
(n = 11)
p-
value 
Age (years), median (IQR) 63.9 (52.4 - 
71.9)
71.6 (67.9 - 
81.7)
0.037
Sex (female), n (%) 9 (75.0) 7 (63.6) 0.444
Primary tumor, (cholangiocarcinoma/mali-
gnant pancreas tumor)
8/4 8/3 0.555
Middle-distal common bile duct tumor 
obstruction, n (%)
5 (41.7) 1 (9.1) 0.112
Size of the lesion (mm), median (IQR) 27.5 (15 - 30) 23.5 (20 - 35) 1.000
Covered/Uncovered metal stent, n (%) 8/4 6/5 0.543
Hospitalization days, median (IQR) 1 (1-3) 3 (0-27) 0.054
One-year acute cholecystitis-free survival 
rate, n (%)
11/12 (91.7) 4/11 (36.4) 0.016
One-year relative survival rate, n (%) 8/12 (66.7) 9/11 (81.8) 0.727
[Table 1. Baseline characteristics & study outcomes per groups.]
conclusion: Primary EUS-GBD prevent the development of acute cholecys-
titis after SEMS placement in patients with MBO and tumor involvement of 
the orifice of the cystic duct.
references: Clinical trial number: NCT03729882.
disclosure: Nothing to disclose 
P0254 endOscOPIc uLTrasOund guIded TheraPy Is 
suPerIOr TO endOscOPIc TheraPy fOr gasTrIc varIceaL 
BLeedIng: a sysTeMaTIc revIeW and cOMParaTIve MeTa-
anaLysIs
Mohan B.1, Chandan S.2, Khan S.3, Dosala S.3, Trakaroo S.4, Kassab L.5, 
Ponnada S.6, Asokkumar R.7, Adler D.8
1University of Arizona/Banner University Medical Center, Internal 
Medicine, Tucson, United States, 2University of Nebraska Medical Center, 
Gastroenterology and Hepatology, Omaha, United States, 3University of 
Arizona/Banner University Medical Center, Tucson, United States, 4St Vincent 
Charity Medical Center, Internal Medicine, Cleveland, United States, 5Mayo 
Clinic, Hospital Medicine, Rochester, United States, 6Carilion Roanoke 
Medical Center, Roanoke, United States, 7Singapore General Hospital, 
Gastroenterology, Singapore, Singapore, 8University of Utah School of 
Medicine, Salt Lake City, United States
contact e-Mail address: kassab.lena@mayo.edu
Introduction: Gastric varices (GV) are less common and rupture less often 
than esophageal varices (EV). However, once ruptured, GV bleeding is dif-
ficult to control and carries a higher mortality than EV bleeding in the set-
ting of portal hypertension. Treatment options include direct endoscopic 
(END) glue injection and endoscopic ultrasound (EUS) guided glue and/ 
or coil injection. The role of EUS in the treatment of GV is not established.
aims & Methods: We conducted a comprehensive search of several data-
bases (inception to Dec 2018) to identify studies that evaluated the use of 
END and EUS in the treatment of GV. Our goals were to estimate and com-
pare the pooled rates of treatment efficacy, GV obliteration, GV recurrence, 
early re-bleeding (< 120hrs), and late re-bleeding (>120hrs) with END and 
EUS. Our secondary goals were to analyze the adverse events with these 
two modalities in the treatment of GV.
results: Total of 44 studies (2777 patients) were included. 26 studies (2196 
patients), 8 studies (231 patients), 7 studies (303 patients), and 3 studies (47 
patients) were treated with END-glue, EUS-glue, EUS-glue/coil, and EUS-
coil respectively. Mean age range was between 40 and 65 years, with 68% 
of males. N-butyl-2-cyanoacrylate and 2-octyl-cyanoacrylate were the most 
commonly used glue. 28% had GOV1, 49% had GOV2, and 23% had IGV1 
(Sarin classification). 63% of the patients had cirrhosis. 30% were due to 
alcohol, 31% due to viral hepatitis, and the rest were due to other causes. 
11% of the included patients had hepatocellular carcinoma.Complete GV 
obliteration was significantly higher with EUS-coil/glue as compared to 
END-glue [(89% (95% CI 66.3-97.1, I2=62.4) vs 57.1% (38.2-74.1, I2=94.3), 
p=0.03].GV recurrence was significantly lower with EUS-coil/glue as com-
pared to END-glue [(3.1% (95% CI 0.9-10.3, I2=0) vs 22.6% (95% CI 13.8-34.9, 
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results: Among 1124 with CP, 210 patients (60% males, mean age 62.7 
years) with CP and pancreatic masses met the inclusion criteria and were 
enrolled. In the FNA group (110 patients), a correct diagnosis was obtained 
in all but 18 cases (diagnostic accuracy 83.6%, sensitivity 69.5%, specificity 
100%, PPV 100%, NPV 73.9%); by contrast, among 100 patients undergo-
ing FNB, a correct diagnosis was obtained in all but 7 cases (diagnostic 
accuracy 93%, sensitivity 86.8%, specificity 100%, PPV 100%, NPV 87%) 
(p=0.03, 0.03, 1, 1 and 0.07, respectively). At binary logistic regression, 
focal pancreatitis (OR 4.9;p< 0.001), higher Ca19-9 (OR 2.3;p=0.02) and 
FNB (OR 2.5;p< 0.01) were the only independent factors associated with a 
correct diagnosis.
conclusion: EUS-FNB is effective in the differential diagnosis between 
pseudotumoral masses and solid neoplasms in CP, showing higher diag-
nostic accuracy and sensitivity than EUS-FNA. EUS-FNB should be con-
sidered the preferred diagnostic technique for diagnosing cancer in the 
setting of CP.
disclosure: Nothing to disclose 
P0256 hIgh PerfOrMance Of a neW franseen needLe fOr 
endOscOPIc uLTrasOund-guIded fIne-needLe BIOPsy In sOLId 
LesIOns: a MuLTIcenTer sTudy
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Introduction: Endoscopic ultrasound-guided fine needle aspiration (FNA) 
is the standard choice to samplegastrointestinal/pancreatic lesions. EUS-
FNA is accurate when rapid on-site evaluation (ROSE) is performed, but 
ROSE is not always available. EUS- guided fine needle biopsy (EUS-FNB) 
can give a a better chance to reach a diagnosis providing more tissue. It 
is not simple to use 19-gauge needles especially in transduodenal settings 
for risk of complications. A new needle for EUS-FNB, the Acquire needle is 
available from 2016. Data for pancreatic and non pancreatic solid lesions 
are available but these are based only on small sample size studies.
aims & Methods: The aim of our study is to perform a retrospective evalu-
ation of all sampling procedures performed using the 22/25 gauge Acquire 
needle in patients with solid lesions.We performed a retrospective analy-
I2=77.1), p=0.002].Late re-bleeding was significantly lower with EUS-coil/
glue as compared to END-glue [(6.4% (95% CI 2.7-14.7, I2=0) vs 20% (14.7-
26.6, I2=89.30, p=0.01].The pooled rates of immediate treatment efficacy and 
early re-bleeding were comparable between the treatment modalities. The 
pooled rate of all adverse events, sepsis, distant embolism, fever, pain, and 
death due to GV rebleeding were similar between the groups. No difference 
was noted between EUS-glue and END-glue. (Table)
conclusion: EUS guided treatment of GV with simultaneous use of coil/
glue seems to give superior long term clinical benefits as compared to 
END-glue with comparable immediate treatment efficacy and similar risk 
to early-rebleeding. Well-conducted studies are warranted to further es-
tablish the role of EUS-coil/glue treatment in GV.
disclosure: Nothing to disclose 
P0255 eus-guIded TIssue acquIsITIOn In chrOnIc 
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Introduction: Endoscopic Ultrasound (EUS)-guided fine needle aspiration 
(FNA) sensitivity for malignancy in parenchymal masses of patients with 
concurrent chronic pancreatitis (CP) has been reported to be unsatisfac-
tory.
aims & Methods: The aim of the present study was to directly compare 
the diagnostic accuracy of EUS-FNA and EUS-fine needle biopsy (FNB) 
in differentiating between inflammatory masses and malignancies in the 
setting of CP. We performed a retrospective analysis of prospective, multi-
centric databases of all subjects with pancreatic masses and clinical-radio-
logical-endosonographic features of CP who underwent EUS-FNA or FNB.
(95% cI, I2) all eus modalities eus-glue eus-coil eus-coil/glue end-glue
Immediate treatment 
efficacy
93.6% (85-97.4, 59.5), 
p=0.17
92.3% (74-98, 54.4), p=0.44 86.2% (38.4-98.4, 6.5), 
p=0.99
96.5% (85.3-99.2, 61.5), 
p=0.1
86.4% (75.3-93, 96.1)
Complete GV obliteration 84.7% (66.8-93.8, 84.2), 
p=0.03
89.8% (57.4-98.3, 28.8), 
p=0.07
NC 89% (66.3-97.1, 62.4), 
p=0.03
57.1% (38.2-74.1, 94.3)
GV recurrence 6.1% (2.6-13.7, 51.4), 
p=0.006
12.4% (4-32.3, 18.8), p=0.29 NC 3.1% (0.9-10.3, 0), p=0.002 22.6% (13.8-34.9, 77.1)
Early rebleeding (<120 hrs) 6.8% (4.1-11.1, 13.2), p=0.43 5.9% (2.8-12, 0), p=0.83 NC 9% (4.1-18.4, 64.2), p=0.25 5.4% (4.2-6.8, 17.8)
Late rebleeding (>120hrs) 10.6% (6.3-17.3, 45.7), p=0.03 14.2% (6.6-27.9, 68.2), 
p=0.39
14.7% (4-42, 0), p=0.63 6.4% (2.7-14.7, 0), p=0.01 20% (14.7-26.6, 89.3)
Total adverse events 16.5% (9.7-26.9, 83.1), 
p=0.48
27.4% (13.8-47, 81.7), p=0.07 5.5% (0.9-26.8, 0), p=0.3 11.7% (5-25.3, 79.5), p=0.79 13% (8.5-19.5, 87.7)
Sepsis 2.5% (1.3-4.9, 0), p=0.91 2.8% (1.1-7.3, 0), p=0.65 4% (0.7-20.4, 0), p=0.53 1.7% (0.5-5.4, 0), p=0.74 2.4% (1.5-3.8, 53.6)
Distant organ embolism 4.1% (1.9-8.6, 40.6), p=0.22 3.4% (1-10.5, 0), p=0.52 4% (0.5-26.4, 0), p=0.92 4.9% (1.5-14.9, 70.8), p=0.27 2.2% (1.2-4.1, 70.9)
Fever 2.9% (1.3-6.2, 0), p=0.57 3.5% (1.1-10.5, 0), p=0.95 4% (0.5-24.9, 0), p=0.92 2% (0.5-6.9, 0), p=0.4 3.8% (2.1-6.7, 84.3)
Pain 4.3% (2.1-8.6, 29.9), p=0.3 4% (1.3-11.5, 0), p=0.51 4% (0.5-24.5, 0), p=0.68 4.7% (1.6-13.2, 67.9), p=0.36 2.7% (1.5-4.7, 73.4)
Death due to GV rebleeding 6% (3.3-10.6, 28.9), p=0.3 8.8% (3.7-19.5, 62), p=0.13 4.7% (0.9-21, 0), p=0.87 4% (1.5-10.3, 0), p=0.97 4.1% (2.7-6.2, 57.5)
EUS: endosonography, END: direct endoscopy, GV: gastric varices, All p-values are in comparison to END-glue. NC: not calculated due to limited data
[P0254 Table. Summary of pooled results.]
286 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
sis of prospective, multicentric databases in 5 Italian Endoscopic centres, 
including all consecutive patients with solid lesions who underwent EUS 
between June 2016 and October 2018. All lesions localized at pancreas, 
nodes, biliary, kidney/liver masses, periduodenal/perigastric abdominal 
masses were enrolled in the study. Features of masses and technical de-
tails of FNB were recorded.
results: 450 patients (60.2% males, mean age 64,3) were enrolled. EUS-
FNB was performed using the 22 and 25 gauge Acquire needle. The bi-
opsies was done transgastrically in 190 (42%)cases and transduodenally 
in 260 (58%) ones. A mean of 2.2 ± 0.32 passes per lesion site were per-
formed, without any complication. A tissue core biopsy sample for his-
tological evaluation was obtained in 438 (97%) cases. In all the cases, 
the specimens were useful for cytological analysis too. Acquire sensitivity, 
specificity and diagnostic accuracy were 98.8%,100% and 98.7% respec-
tively
conclusion: EUS-FNB using the 22 and the 25-gauge Acquire needle has a 
very high accurancy and is useful to achieve histological sample in almost 
all the patients
disclosure: Nothing to disclose 
P0257 eus-guIded ThrOugh-The-needLe MIcrOfOrcePs 
BIOPsy fOr The dIagnOsIs Of PancreaTIc cysTIc LesIOns: 
hOW Many sPecIMens shOuLd Be reTrIeved?
Crinò S.F.1, Bernardoni L.1, Brozzi L.1, Barresi L.2, Malleo G.3, Salvia R.3, 
Marchegiani G.3, Frulloni L.1, Sina S.4, Parisi A.4, Remo A.5, Larghi A.6, 
Gabbrielli A.1, Manfrin E.4
1The Pancreas Institute, G.B. Rossi University Hospital, Gastroenterology and 
Digestive Endoscopy Unit, Department of Medicine, Verona, Italy, 2Istituto 
Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT), 
Endoscopy Service, Department of Diagnostic and Therapeutic Services, 
Palermo, Italy, 3The Pancreas Institute, University of Verona Hospital Trust, 
Unit of General and Pancreatic Surgery, Verona, Italy, 4GB Rossi University 
Hospital, Department of Diagnostic and Public Health, Verona, Italy, 5Mater 
Salutis Hospital Legnago, Departiment of Pathology, Verona, Italy, 6IRCCS, 
Fondazione Policlinico Universitario A. Gemelli, Digestive Endoscopy Unit, 
Rome, Italy
contact e-Mail address: lorenzo.brozzi89@gmail.com
Introduction: Accurate diagnosis of pancreatic cystic lesions (PCLs) is of 
paramount importance to guide the decision-making process and reduce 
the rate of inappropriate resection.
Endoscopic ultrasound (EUS)-guided through-the-needle biopsy (TTNB) 
has been reported to improve diagnostic yield compared with cytology 
[1-3]. However, TTNB technique is not yet standardized and the minimum 
number of visible specimen to be retrieved is unknown
aims & Methods: The aim of this single center retrospective study was to 
evaluate the diagnostic yield of TTNB according to the number of macro-
scopically visible samples acquired.
All consecutive patients with PCLs with risk features (cyst >3 cm, thickened 
wall, 5-9 mm main pancreatic duct, increased size during follow-up, and 
mural nodules) who underwent TTNB between May 2016 and July 2018 
were included. TTNB procedures were performed following an internal 
protocol established with the pathologists whereby the acquisition of three 
samples, when possible, was set as a standard. Each acquired specimen 
was placed separately in formalin vials.
Diagnostic yield of one, two, or three TTNB macroscopically visible speci-
mens was analyzed and compared with fluid cytology at four levels: capa-
bility of differentiating mucinous vs nonmucinous cysts, ability to obtain a 
cyst-lining epithelium, definition of the grade of dysplasia, and definition 
of specific cyst histotype.
results: Sixty-one patients (M/F 14/47; mean age 50.2 ± 14.7 years) were 
included. PCLs were located in the head, body, and tail in 18 (29.5%), 
23 (37.7%), and 20 (32.8%) cases, respectively. The mean size was 40.7 ± 
14.2mm. Overall, 179 TTNB specimens were evaluated (in four cases, intra-
cystic bleeding impeded collection of the third specimen). Specimens were 
judged adequate for histological evaluation in 164 (91.6%) cases. A 100% 
histological adequacy was reached by two samples (p=0.05 versus one).
In the cytological samples, cyst epithelium was present in 27 (44.2%), the 
distinction between mucinous and nonmucinous cysts was possible in 30 
(49.2%), the grade of dysplasia was established in 25 (41%), and a specific 
diagnosis of cyst type was achieved in 5 (7.9%) cases.
Compared with cytology, one TTNB specimen improved only the possibility 
of defining cyst histotype (p< 0.0001), whereas two specimens increased 
all four diagnostic categories (p< 0.003). Two specimens also increased 
diagnostic yield compared with one sample (p< 0.085). The collection of 
a third sample did not improve the value of any diagnostic level (Table 1). 
A specific diagnosis was reached in 74% of patients with two histological 
samples. The diagnostic reliability of TTNB compared with surgical histol-
ogy was 90% (18/20 patients). The two TTNB nonconcordant cases were 
mucinous non-neoplastic cysts according to TTNB, resulting in mucinous 
cystic neoplasms with surgical histology. The rate of adverse events was 
22.9% (10 cases of intracystic bleeding, 2 mild acute pancreatitis, 1 peri-
pancreatic bleeding and 1 transitory fever).
conclusion: Two TTNB macroscopically visible specimens allowed reach-
ing a 100% histological adequacy and a specific diagnosis in 74% of pa-
tients. The collection of a third specimen did not add any additional infor-
mation, and should be avoided in order to possibly decrease the risk of 
adverse events.
references: 1. Barresi L, Crinò SF, Fabbri C, et al. Endoscopic ultrasound-
through-the-needle biopsy in pancreatic cystic lesions: A multicenter 
study. Dig Endosc. 2018 May 29 2. Kovacevic B, Karstensen JG, Havre RF, 
et al. Initial experience with EUS-guided microbiopsy forceps in diagnos-
ing pancreatic cystic lesions: A multicenter feasibility study (with video). 
Endosc Ultrasound. 2018 Nov-Dec;7(6):383-388 3. Yang D, Trindade AJ, 
Yachimski P, et al. Histologic Analysis of Endoscopic Ultrasound-guided 
Through the Needle Microforceps Biopsies Accurately Identifies Mucinous 
Pancreas Cysts. Clin Gastroenterol Hepatol. 2018 Nov 21. doi: 10.1016/j.
cgh.2018.11.027. [Epub ahead of print]
disclosure: Nothing to disclose 
diagnostic level 
(possibility to define) citology n (%)
One specimen at 
TTnB n (%)
Two specimens at 
TTnB n (%)
Three specimens at 
TTnB n (%)
P value (citology vs 
one specimen)
P value (citology vs 
two specimens)
P value (one vs two 
specimens)
P value (two vs 
three specimens)
Histologic adequacy na 56 (91.8) 61 (100) 61 (100) na na 0.05 NS
Mucinous Vs 
Nonmucinous
30 (49.2) 38 (62.3) 48 (78.7) 51 (83.6) 0.201 0.001 0.073 0.644
Presence of epithelial 
lining
27 (44.2) 32 (52.4) 44 (72.1) 48 (78.6) 0.468 0.003 0.039 0.528
Grade of dysplasia 25 (41) 31 (50.8) 42 (66.8) 46 (75.4) 0.363 0.003 0.064 0.545
Specific diagnosis 5 (7.9) 35 (57.4) 45 (73.8) 48 (78.6) <0.0001 <0.0001 0.085 0.671
[P0257 Table:1 Histologic adequacy and four levels of diagnostic yield according to cytology and the number of retrieved specimens]
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results: We demonstrated that the MWST group had a significantly bet-
ter histological diagnostic accuracy (84.85%) than DRST group (73.19%, P 
=0.0013). In subgroup analysis, the MWST group reached a 91.59% histo-
logical diagnostic accuracy for non-pancreatic masses and achieved a sig-
nificantly superiority for all lesions >20 mm. Furthermore, the MWST pro-
vided a better specimen adequacy and less blood contamination whether 
it was chosen as the first pass or not.
conclusion: In this prospective study of sampling solid masses, we found 
using MWST resulted in significantly better histology than DRST, especially 
for the masses >20 mm. Two passes of MWST provided adequate tissue 
for non-pancreatic lesions. The specimen quality collected by MWST was 
superior to DRST regardless of sequence selection bias. Trials registration: 
NCT02789371.
disclosure: Nothing to disclose
  drsT group % (95% cI)
MWsT group % 
(95% cI) P value
Overall diagnostic accuracy      
All lesions (n=269) 89.22 (84.89-92.66) 92.94(89.19-95.69) 0.13043
Pancreatic (n=161) 86.34 (80.05-91.23) 91.30(85.84-95.16) 0.15714
Non-pancreatic (n=108) 93.52 (87.10-97.35) 95.37(89.53-98.48) 0.55245
Histological diagnostic accuracy      
All lesions (n=269) 73.19(67.05-78.74) 84.85(79.94-88.95) 0.0013*
Pancreatic (n=161) 68.84(60.41-76.45) 80.25(73.16-86.17) 0.0240*
Non-pancreatic (n=108) 79.38(69.97-86.93) 91.59(84.63-96.08) 0.0127*
[Comparison of diagnostic accuracy between DRST group and MWST group]
P0260 dOuBLe guIdeWIre TechnIque usIng a dOuBLe LuMen 
cannuLa fOr InTervenTIOnaL eus
Nakai Y.1, Suzuki Y.2, Inokuma A.2, Kanai S.2, Oyama H.2, Suzuki T.2, 
Nakamura T.2, Sato T.2, Hakuta R.2, Ishigaki K.2, Saito K.2, Saito T.2, 
Hamada T.2, Takahara N.2, Mizuno S.2, Kogure H.2, Tada M.2, Koike K.2
1University of Tokyo, Endoscopy and Endoscopic Surgery, Tokyo, Japan, 
2University of Tokyo, Gastroenterology, Tokyo, Japan
contact e-Mail address: ynakai-tky@umin.ac.jp
Introduction: There are a few reports on the use of double guidewire 
(DGW) technique to facilitate multiple drainage placement for EUS-guided 
drainage of pancreatic fluid collections (PFC). However, this technique can 
provide advantages other than multiple drainage placement during inter-
ventional EUS, such as scope stabilization, support for stone extraction or 
device insertion.
aims & Methods: Consecutive patients who underwent interventional EUS 
between Feb 2012 and Apr 2019 were retrospectively reviewed. The rate 
and purposes of DGW technique, and clinical outcomes were evaluated. 
A double lumen cannula (UDLC: Uneven Double Lumen Cannula, Piolax 
Medical, Kanagawa, Japan) was used to achieve DGW technique. UDLC 
has two separate lumens (0.025” and 0.035”) with a tip diameter of 3.6 
Fr. DGW technique was performed as follows; Puncture using a 19-gauge 
FNA needle under EUS guidance, insertion of a 0.025” guidewire (GW), 
followed by UDLC insertion, preloaded with a 0.035” GW, over the 0.025” 
GW, and then, advancement of a 0.035” GW. A 0.035” stiff GW was used 
when multiple drainage placement is planned or when support for scope 
stabilization, antegrade stone extraction or device insertion is needed, 
while a 0.035” hydrophilic GW was used when negotiation of the stric-
ture is necessary. After achieving DGW insertion, EUS-guided interventions 
were completed.
results: During the study period, 252 interventional EUS procedures were 
performed: 51 pancreatic cyst drainage (PCD), 82 hepaticogastrostomy 
(HGS), 8 choledochoduodenostomy (CDS), 37 gallbladder drainage (GBD), 
36 rendezvous (RV), 19 antegrade stone treatment (AG), 13 pancreatic duct 
drainage (PD) and 6 abscess drainage (AD). Among those 252 cases, DGW 
technique was used in 82 cases (32.5%). The reasons for DGW technique 
were multiple drainage placement in 61 cases (21PCD, 32 GBD, 5 HGS, 2 
AD, 1 PD), scope stabilization in 10 (5 HGS, 3 PD, 1 GBD, 1 AD), support 
for stone removal in 4 AG, support for device insertion in 8 (4 HGS, 2 PD, 
1 AG, 1 RV) and safety GW placement in 5 (3 guidewire manipulation for 
stricture passage and 2 stent placement). DGW technique was utilizes as 
a salvage technique after single guidewire procedure in 17 (20.7%) and 
as a primary technique in 65 (79.3%). Insertion of UDLC and DGW were 
P0258 case serIes Of eus guIded BILIary draInage as a 
neWLy adOPTed TechnIque fOr BILIary OBsTrucTIOn In a 
TerTIary care cenTer
Hoppmann N.1, Harris P.1, Hingorani N.1, Mitchell R.1, Ahmed A.2, 
Kyanam Kabir Baig K.R.1
1University of Alabama at Birmingham, Gastroenterology & Hepatology, 
Birmingham, United States, 2University of Alabama at Birmingham, 
Gastroenterology & Hepatology - Interventional Endoscopy, Hoover, United 
States
contact e-Mail address: nhoppmann@uabmc.edu
Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) is 
often the procedure of choice for drainage of biliary obstruction; how-
ever, this technique may not be feasible in all patients. Percutaneous tran-
shepatic biliary drainage (PTBD) is another option but is associated with 
high morbidity and post procedural complications. Endoscopic ultrasound 
(EUS), initially a diagnostic procedure, has evolved into a therapeutic op-
tion in patients with failed ERCP. EUS can be performed immediately af-
ter attempted ERCP, thereby providing a potentially immediate solution. 
This project focuses on the implementation of EUS guided biliary drainage 
(EUS-BD) as a new technique for relieving biliary obstruction in patients 
with failed ERCP in a tertiary care center.
aims & Methods: A prospective analysis of patients with biliary obstruction 
and failed ERCP requiring EUS-BD was conducted between November 2017 
to February 2019. Indication for intervention and reason for failed ERCP 
were noted. Patients’ clinical improvement, laboratory data, and proce-
dural complications were documented 1 month after the procedure.
results: Twenty-six patients (M/F, 14/12; median age 68) underwent EUS-
BD. Twenty-five patients required drainage secondary to a malignancy 
while 1 was for choledocholithiasis. ERCP failure was due to clinical in-
stability in 1 patient with severe aortic stenosis (4%), inaccessible papilla 
in 13 patients (50%), and inability to cannulate the papilla in 12 patients 
(46%). 
The procedure was technically successful in 20 patients with the remaining 
6 requiring PTBD. In patients with successful EUS-BD, there was one com-
plication with a patient requiring ICU admission for Klebsiella bacteremia. 
Clinical success, in the form of reduced total bilirubin or improvement of 
obstructive symptoms, was noted in 100% of patients following successful 
EUS-BD.
conclusion: Our study shows that EUS-BD is a technique that offers high 
clinical and technical success rates and low complication rates. The learn-
ing curve is short when performed in the hands of an experienced endos-
copist. Furthermore, EUS-BD provides immediate solution for failed ERCP 
rather than investigating other therapeutic options. 
Further studies are required to establish outcomes in patients with EUS-
BD and comparison of this technique to potential alternative solutions 
such as PTBD or surgery. One limitation of this case series is the majority 
of cases are specific to distal biliary obstruction caused by malignancy.
disclosure: Nothing to disclose 
P0259 cOMParIng MOdIfIed WeT sucTIOn versus dry 
sucTIOn TechnIques In eus-fna fOr sOLId LesIOns: a 
PrOsPecTIve, MuLTIcenTer, randOMIzed cOnTrOLLed TrIaL
Wang R., Wang Y., Cheng B.
Tongji Hospital, Tongji Medical College, Huazhong University of Science and 
Technology, Department of Gastroenterology and Hepatology, Wuhan, China
contact e-Mail address: wangrh1988@126.com
Introduction: The optima sampling techniques for endoscopic ultrasound 
(EUS) -guided fine-needle aspiration (FNA)are not standardized. We con-
ducted a prospective, multicenter, randomized controlled trial comparing 
the modified wet suction technique (MWST) and the dry suction technique 
(DRST) for sampling the solid lesions in the pancreas, mediastinum and 
abdomen.
aims & Methods: A total of 296 patients from 4 endoscopic centers were 
randomized in a ratio of 1:1 to receive either DRST or MWST as the first 
pass during EUS-FNA procedure. For Group A (n=134), the pass sequence 
was DRST - MWST - DRST - MWST versus MWST - DRST - MWST - DRST 
for Group B (n=135). The outcome measures were the diagnostic yield and 
specimen quality.
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both successful in 100%. Adverse events related to DGW technique were 
not observed. Preplanned intervention was technically successful in 75 
cases (91.5%). The reasons for preplanned procedure failure were failed 
multiple drainage placement in 3 and failed GW passage in 4 (3 rescue 
transmural drainage and 1 technical failure). Among 17 cases with salvage 
DGW technique, preplanned intervention was achieved only after DGW 
technique in 13 (76.5%).
conclusion: DGW technique using UDLC during interventional EUS was 
useful for multiple drainage placement as well as support for stone re-
moval and device insertion.
references: Seewald S, Thonke F, Ang TL, et al. One-step, simultane-
ous double-wire technique facilitates pancreatic pseudocyst and abscess 
drainage (with videos). Gastrointest Endosc. 2006 Nov;64(5):805-8. Ang 
TL, Teo EK, Fock KM. EUS-guided drainage of infected pancreatic pseudo-
cyst: use of a 10F Soehendra dilator to facilitate a double-wire technique 
for initial transgastric access. Gastrointest Endosc. 2008 Jul;68(1):192-4. Itoi 
T, Itokawa F, Tsuchiya T, et al. EUS-guided pancreatic pseudocyst drain-
age: simultaneous placement of stents and nasocystic catheter using 
double-guidewire technique. Dig Endosc. 2009 Jul;21 Suppl 1:S53-6. Nakai 
Y, Kogure H, Koike K. Double‐guidewire technique for endoscopic ultra-
sound-guided pancreatic duct drainage. Dig Endosc. 2019;31 Suppl 1:65-6.
disclosure: Nothing to disclose 
P0261 fOcussed endOscOPIc uLTrasOund resuLTs In 
PaTIenTs WITh unexPLaIned dILaTaTIOn Of cOMMOn BILe ducT 
and Or PancreaTIc ducT
Parihar V.1, Offiah G.2, Bashir Y.2, Karl H.3, Ryan B.4
1Tallaght Hospital, Gastroenterology, Dublin, Ireland, 2Trinity College Dublin, 
Dublin, Ireland, 3James Connolly Memorial Hospital, Gastroenterology, 
Dublin 15, Ireland, 4Adelaide and Meath Hospital, Department of 
Gastroenterology, Dublin 24, Ireland
contact e-Mail address: vikpar37@yahoo.com
Introduction: Unexplained dilation of the common bile duct (CBD) and 
pancreatic duct (PD) or both on abdominal imaging are amongst the most 
common indications for endoscopic ultrasound (EUS).
aims & Methods: Patients referred for EUS for dilated CBD and/or PD from 
2012 to 2016 for whom LFTs were available, were included in the study. 
CBD dilatation was defined as CBD diameter greater than 7mm at any 
place while PD diameter more than 4 mm in the head and 3 mm in the 
body and tail was considered dilated.To investigate if derangement of liver 
function tests (LFTs) is associated with positive findings on EUS to explain 
the cause for the dilated ducts.
results: : We examined a total of 2179 EUS procedures, of which 404 pa-
tients met the study criteria. 293/404 had elevated LFTs [defined as eleva-
tion of one of these: bilirubin, ALT, ALKP or GGT] and 111/404 had normal 
LFTs. 74% of patients had more than one imaging modality before the EUS. 
EUS found a cause of dilated duct in >50% of cases in both the groups. In 
patients with CBD dilatation alone, elevated bilirubin was associated with 
finding a significant finding on EUS (p< 0.027) (66%). In those with CBD 
and PD dilatation, raised bilirubin (p< 0.022) and Alkaline Phosphatase 
(p< 0.018) were associated with positive findings (39% and 62%respec-
tively).
conclusion: The presence of raised bilirubin +/- concurrent ALKP rise was 
statistically more likely to have a cause found for the dilated duct on EUS. 
EUS detected undiagnosed pathology in unexplained duct dilation even in 
the presence of normal LFTs. We recommend early access to a diagnostic 
EUS in the diagnostic pathway of patients with dilated CBD and or PD.
references: Smith I, Monkemuller K, Wilcox CM. Incidentally Identi-
fied Common Bile Duct Dilatation. Journal of Clinical Gastroenterology. 
2015;49(10):810-5. Malik S, Kaushik N, Khalid A, Bauer K, Brody D, Slivka 
A, et al. EUS yield in evaluating biliary dilatation in patients with normal 
serum liver enzymes. Digestive diseases and sciences. 2007;52(2):508-12.
disclosure: Nothing to disclose 
P0262 endOscOPIc uLTrasOund feaTures assOcIaTed WITh 
MaLIgnancy and aggressIveness Of nOn-hyPOvascuLar 
sOLId PancreaTIc LesIOns: resuLTs frOM a PrOsPecTIve 
OBservaTIOnaL sTudy
Crinò S.F.1, Brandolese A.1, Vieceli F.1, Paiella S.2, Conti Bellocchi M.C.1, 
Manfrin E.3, Bernardoni L.1, D’Onofrio M.4, Marchegiani G.5, Larghi A.6, 
Frulloni L.1, Landoni L.5, Gabbrielli A.1
1The Pancreas Institute, G.B. Rossi University Hospital, Gastroenterology and 
Digestive Endoscopy Unit, Verona, Italy, 2The Pancreas Institute, University 
of Verona Hospital Trust, Department of General and Pancreatic Surgery, 
Verona, Italy, 3The Pancreas Institute, G.B. Rossi University Hospital, 
Department of Diagnostics and Public Health, Verona, Italy, 4The Pancreas 
Institute, G.B. Rossi University Hospital, Department of Radiology, Verona, 
Italy, 5The Pancreas Institute, G.B. Rossi University Hospital, Department of 
General and Pancreatic Surgery, Verona, Italy, 6Fondazione Policlinico A. 
Gemelli, IRCCS, Digestive Endoscopy Unit, verona, Italy
contact e-Mail address: brandoqui@yahoo.it
Introduction: Non-hypovascular (i.e., isovascular or hypervascular) pat-
terns can be observed in solid pancreatic lesions (SPLs) with different di-
agnoses with different prognosis and management.
aims & Methods: The primary aim was to identify lesion features on en-
doscopic ultrasound (EUS) associated with malignancy/aggressiveness 
in this setting of patients. Secondary aims were EUS-tissue acquisition 
(EUS-TA) outcome and safety. In a prospective observational study we 
included consecutive patients with one or more non-hypovascular SPLs 
detected on cross-sectional imaging and referred for EUS-TA. Exclusion 
criteria were hypovascular pattern on contrast-harmonic EUS, concomitant 
chronic pancreatitis, and lesion of nonpancreatic origin. Lesion features 
(size, site, margins, echotexture, vascular pattern, and upstream dilation 
of the main pancreatic duct) were recorded. Malignancy/aggressiveness 
was determined by one or more of the follows: a) evidence of carcinoma at 
biopsy/surgical histology; b) signs of local aggressiveness (perineural in-
vasion, lymphovascular invasion, microscopic tumor extension/infiltration 
or evidence of metastatic lymph nodes) at surgical specimen; c) radiologic 
detection of lymph nodes or distant metastases; d) tumor growth >5mm/12 
months. Uni- and multivariate analyses were performed to assess the pri-
mary aim.
results: Among 174 patients evaluated, 154 (M/F 70/84, mean age 58.7 
years ± 13.1) with 161 SPLs were enrolled. SPLs were located in the head/
uncinate, body, and tail in 50 (31.1%), 55 (34.1%), and 56 (34.8%) cases, 
respectively. Mean lesion size was 18.8 mm ± 10.6. Fifty-six lesions (34.8%) 
were resected and 105 (65.2%) underwent follow-up for a median period 
of 20 months (range 12-32 months). Overall, 40 (24.8%) lesions were de-
fined malignant/aggressive and 121 (75.2%) benign. Irregular margins and 
size >20mm were independent factors associated with aggressiveness in 
multivariate analysis (p< 0.001, OR=5.2 and p=0.003, OR=2.1, respectively). 
Irregular margins and size >20mm predicted malignancy/aggressiveness 
with an accuracy of 81% and 74%, respectively. A subgroup analysis evalu-
ating neuroendocrine tumors (NET) (N=92) and non-NETs (N=60) was per-
formed (Table 1) revealing that in non-NET group only irregular margins 
were associated with malignancy/aggressiveness. 
EUS-TA sensitivity, specificity and accuracy were 91.6%, 100%, and 92%, 
respectively. The rate of adverse events was 4%.
conclusion: Our study demonstrated that irregular lesion margins are an 
independent factor useful in predicting malignancy/aggressiveness of 
isovascular and hypervascular SPLs. Size >20mm should be considered a 
warning feature only when a diagnosis of NET is confirmed. EUS-TA is safe 
and highly accurate in this setting and should be largely adopted for the 
differential diagnosis of these lesions.
disclosure: Nothing to disclose 
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patients with EUS-BD drainage were included. It could be a drainage by 
EUS-BD alone or in combination with another technique, for initial drain-
age or re-intervention. Clinical characteristics of patients, stenosis and 
drainage were collected. The percentage of liver drained, the complication 
rate in the month following the procedure using Clavien-Dindo classifica-
tion, the number of re-interventions, the length of hospitalisation were 
analyzed.
results: Among the 139 patients of the registry, 20 patients were included 
(10 women and 10 men). The mean patient age was 68 years. 7 patients 
had an obstruction by cholangiocarcinoma and 13 by metastasis. 4 patients 
had type II stenosis according bismuth classification, 7 type IIIA, 2 IIIb and 
7 type IV. The mean invasion of liver was 24%. 
No patient had ascites or duodenal stenosis but 2 patients had a modified 
anatomy. EUS-hepaticogastrostomy (EUS-HGS) was the only one EUS-BD 
technique used. 16 patients had EUS-HGS for initial drainage: 2 EUS-HGS 
alone due to a right liver invasion and 14 combined with another tech-
nique : 11 combined with ERCP, 2 with Percutaneous transhepatic drainage 
(PCTD) and 1 with ERCP and PCTD. 
The mean percentage of drained liver was 86%. The average number of 
stents was 2.8. The early complication rate was 31%( n=5) mainly angio-
cholitis (n=4) with 3 grade II and 2 grade III. The mean hospital length 
was 8 days.
The EUS-HGS combined with PCTD was performed in 2 patients with modi-
fied anatomy. One of this patient had a right-left drainage by hepaticogas-
trostomy combined without complication.
For EUS-HGS/ERCP combined drainage , 5 were performed during the 
same session and 6 in two sessions .Hospitalisation length was 7,4 days 
and 8,3 days respectively. It was mainly type IIIa (n=5) and type IV (n=5) 
stenosis.There was no difference between the complication rate (n=1), the 
number of endoscopic reintervention (n=3) and the percentage liver drain-
age (96% vs 97% respectively). 
4 patients had EUS-HGS as re-intervention with 3 situations : One patient 
had rescue drainage by EUS-HGS because of pancreatitis associated with 
angiocholitis. Two patients had an EUS-HGS in the follow-up because of 
the progression of the disease (Day 183 and day 303) and 1 patient needed 
EUS-HGS to drain the left liver not initially drained. In the registry,11 pa-
tients had an undrained left liver due to ERCP failure or left liver atrophy. 
Only this patient needed additional drainage.
conclusion: EUS-BD is a feasible and safe technique for initial drainage 
and for re-intervention procedures. EUS-HGS/ERCP combination seemed 
to be useful in cases of complex stenosis, especially type IIIa , and could be 
performed in one or two sessions.
references: 1.Caillol et al. Palliative endoscopic drainage of malignant ste-
nosis of biliary confluence: Efficiency of multiple drainage approach to 
drain a maximum of liver segments. UEG journal, 2018.
disclosure: Nothing to disclose 
P0265 IncIdence and rIsk facTOrs Of adverse evenTs afTer 
eus-guIded fna Or fnB fOr PancreaTIc sOLId LesIOns
Ishigaki K.1, Nakai Y.2, Oyama H.1, Kanai S.1, Suzuki T.1, Nakamura T.1, 
Sato T.1, Hakuta R.1, Saito K.1, Saito T.1, Takahara N.1, Hamada T.1, 
Mizuno S.1, Kogure H.1, Tada M.1, Koike K.1
1Graduate School of Medicine, the University of Tokyo, Gastroenterology, 
Tokyo, Japan, 2The University of Tokyo, Endoscopy and Endoscopic Surgery, 
Tokyo, Japan
contact e-Mail address: ishigakikazunaga@yahoo.co.jp
Introduction: Recently, EUS-guided fine-needle biopsy (EUS-FNB) of pan-
creatic solid lesions has been developed in the hopes of obtaining core 
tissue samples for histological evaluation. However, data with regard to 
the adverse events (AEs) of EUS-FNB are scarce.
aims & Methods: We conducted a retrospective study to identify the AE rate 
of EUS-FNB and compare with that of EUS-FNA in patients with pancreatic 
solid lesions. Consecutive patients who underwent EUS-FNA/B for pancre-
atic solid lesions between Jan 2017 and Aug 2018 at the University of Tokyo 
Hospital were retrospectively studied. Inclusion criteria were patients who 
underwent EUS-FNA using mainly 22-gauge FNA needle (Expect, Boston 
Scientific Japan, Tokyo, Japan) and EUS-FNB using mainly 22-gauge FNB 
needle (Acquire, Boston Scientific Japan) for pancreatic solid lesions. 
About 10-20 strokes after application of 10-cc suction were similarly per-
formed during EUS-FNA/B. The frequency of AEs after EUS-FNA/B of pan-
creatic solid lesions were compared and a multivariate logistic regression 
P0263 endOLuMInaL uLTrasOund versus MagneTIc 
resOnance IMagIng In assessMenT Of recTaL cancer 
afTer neOadjuvanT TheraPy
Ghoneem E.1,2, Hakim H.3, Ragab K.4, Zuhdy M.5, Metwally I.5, Shiha G.1,6, 
Abdel Ghaffar A.7, Abd El Ghaffar Saleh M.8
1Specialized Medical Hospital, Faculty of Medicine, Mansoura University, 
Hepatogastroenterology and Endoscopy, Mansoura, Egypt, 2Egyptian Liver 
Research Institute and Hospital (ELRIAH), Hepatogastroenterology and 
Endoscopy, Mansoura, Egypt, 3mansoura university, gastro-hepatology, 
Mansoura, Egypt, 4Theodor Bilharz Research Institute, Cairo, Egypt, 
5Oncology Center Mansoura University, Mansoura, Egypt, 6Egyptian 
Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt, 
7Specialized Medical Hospital, Faculty of Medicine Mansoura University, 
Hepatogastroenterology and Endoscopy, Mansoura, Egypt, 8Oncology Center 
Mansoura University, Oncosurgery, Mansoura, Egypt
contact e-Mail address: ghoneem_84@yahoo.com
Introduction: Accurate tumor staging guides the choice of treatment mo-
dality and suggest the prognosis of rectal cancer. EUS and magnetic reso-
nance imaging (MRI) are used indistinctly in the pretherapeutic workup of 
rectal cancer. Post neoadjuvant therapy interpretation of response in both 
MRI and EUS retains some difficulty due changes seen in the peritumoral 
region because of the effects of chemoradiation such as edema, inflamma-
tion, necrosis, and fibrosis lead to a hypoechoic appearance which mimics 
the primary tumor, leading to frequent overstaging.
aims & Methods: To compare the performance of EUS and MRI in assess-
ment of locoregional staging of anorectal cancer after neoadjuvant therapy.
Up till now, we have twenty-eight (16 male, 12 female) were included in 
the study. Histopathological staging after surgery were used as reference 
for comparing the yield of locoregional staging for EUS and MRI. EUS and 
MRI were done 1 month after completion of neoadjuvant therapy.
results: Regarding Post-Surgical T staging, there were eight patients with 
early tumor (T2=6 and T1=2) and twenty patients with locally advanced 
tumor (T3= 20 and No T4), while N staging, there were sixteen patients 
with negative nodes and twelve with positive nodes (N1= 7 and N2= 5). 
Regarding T staging; The sensitivity, specificity and accuracy of EUS (95%, 
72%, 89.29%) was significantly higher than MRI (70%, 50%, 64.29%) for 
detecting early and locally advanced tumor. Also, EUS had a high statistical 
significant difference for detection of lymph nodes across MRI (sn 83.33%, 
sp 62.5% and acc 71.43% vs 54.55%, 52.94%, 53.57 ).
conclusion: EUS appears more accurate in locoregional staging of rectal 
carcinoma after neoadjuvant therapy compared to MRI in rectal carcinoma.
references: Uberoi, A. S., & Bhutani, M. S. (2018). Has the role of EUS in 
rectal cancer staging changed in the last decade?. Endoscopic ultrasound, 
7(6), 366.
disclosure: Nothing to disclose 
P0264 feasIBILITy Of endOscOPIc uLTrasOund guIded 
BILIary draInage fOr unresecTaBLe MaLIgnanT hILar BILIary 
sTrIcTures
Winkler J.1, Caillol F.2, Bories E.3, Ratone J.P.2, Pesenti C.2, Debourdeau A.4, 
Pizzicannella M.5, Decoster C.6, Giovannini M.2
1Institut Paoli Calmettes, Gastroenterology, Marseille, France, 2Institut 
Paoli-Calmettes, Endoscopy, Marseille, France, 3Institut Paoli-Calmettes, 
Marseille, France, 4CHU de Montpellier, Gastroentérologie et Transplantation 
Hépatique, Montpellier, France, 5Campus Bio-Medico University, Endoscopic 
Unit, Cienzano di Roma, Italy, 6AP-HM Hôpital de la Timone, Marseille, 
France
contact e-Mail address: jerome.winkler@hotmail.fr
Introduction: Biliary drainage is the main palliative therapeutic measure 
for unresectable malignant hilar biliary strictures (MHS) and survival is 
highly correlated to the volume of drained liver1.Endoscopic ultrasound-
guided biliary drainage (EUS-BD) has emerged as an alternative technique 
for primary drainage or as rescue technique after failed endoscopic retro-
grade cholangiography (ERCP).
aims & Methods: The aim of this study was to demonstrate the feasibility 
of EUS-BD in MHS, both as the initial and rescue procedure. 
This study is a single center retrospective work based on prospective data 
of patients included between January 2015 and September 2018 for biliary 
drainage of inoperable malignant hilar obstruction. For this analysis, only 
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analysis for AE rate was performed to clarify the risk factors of AE. AEs 
were graded according to the ASGE lexicon’s severity grading system.
results: A total of 221 patients were included to this study. The median age 
was 69 (24-91) years, and 148 patients were male. The median diameter of 
lesions was 20 (3-72) mm and location was in the head in 85 (38%). The 
median number of passes were 4 (2-8). The final diagnoses were pancre-
atic cancer in 122 (55%), neuroendocrine tumor in 16 (7%), autoimmune 
pancreatitis in 33 (15%). The rate of patients with tumor size>20mm was 
significantly higher in the FNB group (FNA: 39%, FNB: 67%, P< 0.01), and 
the rate of patients who had been punctured through the normal pancre-
atic parenchyma was higher in the FNA group (FNA: 69%, FNB: 42%, P< 
0.01). Ten (4.5%) patients out of 221 patients had AEs (pancreatitis in 8 
and pancreatic fistula in 2). Five patients had asymptomatic hyperamyla-
semia. The AE rates was 5.2/4.2 % in the FNA/B group and there was no 
statistically significant difference between these two groups. According to 
the ASGE lexicon’s severity grading system, 6 cases were mild and 4 cases 
were moderate. The median extended length of hospital stay in patients 
with AEs was 3.5 (2-7) days. In one case of EUS-FNA group, endoscopic 
naso-pancreatic drainage was performed for moderate pancreatic fistula 
which had improved in 4 days. In a multivariate logistic regression analy-
sis for AE rate, the head location of the lesions was the only statistically 
significant factor for AEs of EUS-FNA/B (HR 4.3, 95% CI 1.05-17.4, P=0.04). 
EUS-FNB (HR 1.2, 95% CI 0.31-4.85, P=0.76), the puncture through the nor-
mal pancreatic parenchyma (HR 1.3, 95% CI 0.30-5.96, P=0.71) and tumor 
size>20mm (HR 0.30, 95% CI 0.06-1.32, P=0.11) were not the statistically 
significant factors for AEs.
conclusion: In our retrospective analysis, the total AE rate of EUS-FNA/B 
was 4.5%, and EUS-FNB was not the statistically significant factor for AE 
in patients with pancreatic solid lesions.
references: non
disclosure: Nothing to disclose 
P0266 exPerIence usIng raPId On-sITe evaLuaTIOn 
Of BIOPsIes OBTaIned By eus- guIded fna PerfOrMed 
By cyTOPaThOLOgy-TraIned endOscOPIsTs
Arango L.1, Bolivar D.2, Diaz C.3, Ferreira E.J.4, Sanchez A.5, 
Ricardo Gonzales Pathologyst
1University of Caldas, Union de Cirujanos S A S, Advanced Endoscopy, 
Manizales, Colombia, 2University of Caldas, Manizales, Colombia, 3Union 
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Introduction: Biopsy by Fine-Needle Aspiration guided by ultrasonography 
(EUS-FNA) with rapid on-site evaluation (ROSE) by cytopathologists im-
proves diagnostic capacity of the EUS. We have investigated the usefulness 
of ROSE performed by endoscopists with cytopathology training to assess 
whether the samples were adequate or not adequate.
aims & Methods: Between March and October 2015, 49 patients with solid 
or cystic lesions of the gastrointestinal tract were taken to EUS-FNA. Two 
endoscopists with short training in cytopathology performed the ROSE and 
they categorized samples obtained as adequate or not adequate; the re-
sults were compared with the evaluation of a pathologist, using the same 
criteria to assess concordance.
results: A high concordance of a proper reading between the endoscopist 
and pathologist in first EUS-FNA (EUS-FNA 1) (Kappa agreement measure 
81%, sig = 0.000) and second EUS-FNA (EUS-FNA 2) (Kappa agreement 
measure 78%, sig = 0.001) was found.
conclusion: Endoscopists can acquire basic skills in cytopathology to per-
form the ROSE, and the findings are consistent with those made by a pa-
thologist. This strategy can contribute to obtaining adequate samples for 
cytopathology diagnosis and improve EUS-FNA diagnostic capacity. Basic 
cytopathology should be included as a subject in endosonography and 
endoscopy programs.
disclosure: Nothing to disclose 
P0267 endOscOPIc radIOfrequency aBLaTIOn as fOcaL 
TheraPy fOr PancreaTIc MeTasTasIs frOM renaL ceLL 
carcInOMa: a MOnOcenTrIc exPerIence
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Thomassin J.6, Brunelle S.7, Walz J.4, Salem N.4, Giovannini M.8, Gravis G.4
1Paoli Calmettes Institute, Oncology, Marseille, France, 2Paoli Calmettes 
Institute, Endoscopy, Marseille, France, 3Paoli Calmettes Institute, 
Department of Endoscopy, Marseille, France, 4Paoli Calmettes Institute, 
Marseille, France, 5Paoli Calmettes Institute, Urology, Marseille, France, 
6Paoli Calmettes Institute, Pathology, Masrseille, France, 7Paoli Calmettes 
Institute, Radiology, Marseille, France, 8Paoli-Calmettes, Dept. of Endoscopy, 
Marseille Cedex 9, France
contact e-Mail address: fcaillol@free.fr
Introduction: Pancreatic metastasis (PM) from renal cell carcinoma (RCC) 
are rare but associated with good prognosis. The usual management of 
PMis surgery or tyrosine kinase inhibitor (TKI) with sides effects. Endo-
scopic radiofrequency ablation (ERFA) is a very innovative approach to fo-
cally treat deep metastasis and could be a relevant technic to control PM 
from RCC.
aims & Methods: We report a monocentric, prospective analysis for local 
control and toxicity in patients treated by ERFA for progressive PM from 
RCC. ERFA was performed under general anesthesia, with a linear EUS 
scope and a 19 G RFA needle; time of ablation was short (30sec to 1 mn), 1 
or 2 shots were needed to ablate a 2 cm lesion.
results: 7 pts from Paoli-Calmettes Institute (France) were recruited be-
tween May 2017 and December 2018.Median age was 72y [69-73], 4/7 fe-
male, ECOG 0-1 (100%). The median time from diagnosis to PM was 14 
years [9.98-22.18], median number of PM was 2 [1-3], 5/7 was documented 
by histology and all were classified as progressive before ERFA. PM local-
izations was: head in 40%, body 40%, tail 20% and average size was 14 
mm before treatment [4 - 35]. 86% of pts (6/7) had other mRCC spread, 5/7 
received systemic treatment and 2 of them were on therapy at ERFA time (1 
TKI, 1 Nivolumab). Two pts had ERFA as the only treatment for oligometa-
static RCC. We performed 17 ERFA procedures over 14 PM. Median number 
of ERFA sessions was 2/patient [1-3]. With a median follow up of 18 months 
[4.6-35.6], 50% of treated PM displayed a complete response, 15% a par-
tial response and 20% a stable disease at the last CT-evaluation. Only 
two patients were considered as progressive disease revealing 86% of PM 
focal control. One patient treated by TKI during procedure, developed a 
paraduodenal abscess 2 months after ERFA and was drained endoscopi-
cally and one with biliary prothesis developed hepatic abscesses few days 
after ERFA. Acute side effects like pancreatitis or life-threatening bleeding 
was not experienced. PM with size <20mm had the best focal control rate.
conclusion: ERFA is feasible and displays an excellent local control for 
PM without any major side effect. However, TKI should be stop before the 
procedure to avoid complications. ERFA could be a valuable option, less 
morbid than pancreas resection for progressive PM.
disclosure: Nothing to disclose 
P0268 LOng-TerM OuTcOMes Of TreaTMenT decIsIOn 
Based On The severITy Of sMaLL BOWeL caPsuLe endOscOPy 
fIndIngs In PaTIenTs WITh crOhn’s dIsease: a sIngLe-cenTre 
cOhOrT sTudy In jaPan
Nasuno M., Tanaka H., Nakamura K., Sugiyama K., Miyakawa M., 
Motoya S.
Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan
contact e-Mail address: nasunomasanao@gmail.com
Introduction: There are few reports on the impact of small bowel capsule 
endoscopy (SBCE) findings on clinical outcomes in patients with Crohn’s 
disease (CD). In particular, the relevance of SBCE findings to the treatment 
decision in patients with CD has not been adequately evaluated. Likewise, 
an appropriate SBCE score to support treatment decision has not been 
determined.
aims & Methods: The aim of this study was to better understand the long-
term outcomes of treatment initiative based on the severity of SBCE find-
ings and compare with the routinely used SBCE scores in patients with CD. 
We retrospectively compiled the data on patients with CD who underwent 
an initial SBCE between January 2015 and December 2017. Patients with 
ileostomy or colostomy, without lesions in the small intestine together with 
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aims & Methods: All patients that underwent a CCE (PillCam 2, MedTron-
ics, United States) in France have been enrolled from January 2011 to May 
2016 in a prospective manner in the ONECC cohort. All CCE and colonos-
copy reports have been systematically collected and data analysis has been 
only performed on complete data. All enrolled patients had an annual 
phone-call during the study with a standardized questionaire until May 
2017.
results: The results of CCE in 689 patients from 14 different medical cen-
ters (7 teaching hospitals, 7 general hospitals) were analyzed. The median 
time of follow-up was of 3 years (0-7). The median age was of 70 years old 
(min 16- max 96). The main indication for CCE was represented by anaes-
thesia or colonoscopy contraindication (n=307; 44.6%). Bowel cleansing 
was considered satisfying (Excellent or Good) in 69.2% of CCE (n=477/689). 
CCE were considered complete in 442 cases (64.2%) and 337 examina-
tions (48.5%) were both complete and associated with a satisfying bowel 
preparation. A polyp was identified in 295 CCE (42.8%) among which 189 
(27.4%) were classified as significant (i.e. ≥6mm or ≥3 polyps). Following 
CCE, a colonoscopy was indicated in 40.5% of patient (279/689) and per-
formed for 32.7% (225/689). The main indications to perform a colonosco-
py following CCE were the diagnosis of a significant polyp on CCE (139/279; 
49.8%), an incomplete examination or with unsatisfying bowel prepara-
tion (73/279; 26.1%) or the diagnosis of a non-significant polyp (30/279; 
10.7%). The 2 main reasons for failure to perform colonoscopy for patients 
with a significant capsule were the refusal of the patient (19/52, 36.5%) 
and anesthesia contraindication (16/52, 30.8%). Twenty-two CCE (4,6%) 
were followed by the diagnosis of an advanced adenoma with high-grade 
dysplasia or CRC. Colonoscopy and CCE were concordant for the diagnosis 
of polyp with advanced dysplasia (location and size) in 84.4% of cases 
(27/32). Discrepancies were mainly explained by an incomplete CCE as-
sociated with a distal lesion of the sigmoid colon or rectum identified in 
the colonoscopy (4/5 of non concordant observations; 80%). At the end 
of follow-up, 115 patients were dead (16.7%) and a total of 40 advanced 
dysplasia were diagnosed. Performing a colonoscopy after a CCE with a 
significant polyp or an incomplete CCE would allow the diagnosis of 97.5% 
(39/40) of all advanced adenoma in the ONECC cohort.
conclusion: In patients with a satisfying preparation and complete colonic 
examination a normal CCE is a reassuring result to exclude adenoma with 
advanced dysplasia. This real-life practice cohort shows that the decision 
after a positive colon capsule endoscopy takes into account patient status 
and the nature of capsule abnormalities in mostly old patients.
references: 1. Spada, C. et al. Colon capsule endoscopy: European Society 
of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 44, 527-536 
(2012). 2. Enns, R. A. et al. Clinical Practice Guidelines for the Use of Video 
Capsule Endoscopy. Gastroenterology 152, 497-514 (2017).
disclosure: This study was funded by Medtronics that provided Colon Cap-
sule PillCam2, funded for e-CRF constitution, and for a clinical research 
assistant that reviewed all CCE and colonoscopy reports. 
those who received new medications within three months after SBCE were 
excluded. SBCE findings were evaluated using the Lewis and Capsule En-
doscopy CD Activity Index (CECDAI) scores. Intervention was defined as an 
additional treatment involving budesonide, prednisolone, elemental diet, 
immunomodulators, anti-tumor necrosis factor agents or intestinal resec-
tion. The rate of treatment intervention within one year since the initial 
SBCE was assessed. Receiver operating characteristic (ROC) curves were 
constructed, and the area under the ROC curve (AUC) was calculated to de-
termine the cut-off values for the Lewis and CECDAI scores at baseline that 
required treatment intervention within one year. Further, the cumulative 
rates of treatment intervention, following the initial SBCE, were estimated 
using the Kaplan-Meier method. Further, the rates of treatment interven-
tion within one year and the cumulative rates of treatment intervention 
were compared using univariate analysis, stratified according to the deter-
mined cut-off value of Lewis and CECDAI scores.
results: A total of 94 patients were included in this study (median age, 26.1 
years; 22 female). The median CD activity index was 111, and the median 
C-reactive protein was 0.10 mg/dL. The median Lewis and CECDAI scores 
were 258.5 and 6.0, respectively. The rate of treatment intervention within 
one year was 11.7%. The ROC curve showed that the cut-off values of Lewis 
and CECDAI score were 645.0 (AUC = 0.803; 95% confidence interval [CI] 
0.677 to 0.930; 85.5% specificity, 63.6% sensitivity) and 8.0 (AUC = 0.831; 
95% CI 0.742 to 0.921; 66.3% specificity, 100.0% sensitivity), respectively. 
There was no significant differences between the AUC of Lewis scores and 
that of CECDAI scores (P = 0.705). The rates of treatment intervention within 
one year with Lewis score ≥645.0 and CECDAI score ≥8.0 were significantly 
higher than with Lewis score < 645.0 (36.8% vs. 5.3%, P = 0.001) and 
CECDAI score < 8.0 (28.2% vs. 0%, P < 0.001), respectively. The 1-, 2- and 
3-year cumulative rates of treatment intervention were 12%, 27% and 31%, 
respectively. The 3-year cumulative rates of treatment intervention accord-
ing to the Lewis score were < 645.0, 22% and ≥645.0, 61%, respectively (P 
< 0.001). Similarly, the 3-year cumulative rates of treatment intervention 
according to the CECDAI score were < 8.0, 15% and ≥8.0, 52%, respectively 
(P < 0.001).
conclusion: Both, the Lewis and the CECDAI scores had moderate accuracy 
to allow decision making in the treatment of patients with CD following 
the initial SBCE. However, the Lewis and CECDAI scores equally predicted 
the therapeutic intervention. A cut-off value of Lewis score ≥645.0 and 
CECDAI score ≥8.0 significantly predicted the long-term outcomes of treat-
ment intervention.
disclosure: Maki Miyakawa has received lecture fees from JIMRO Co. Ltd. 
Hiroki Tanaka has received lecture fees from JIMRO Co. Ltd., AbbVie GK, EA 
Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyorin Pharmaceutical 
Co. Ltd. and Mitsubishi Tanabe Pharma Corporation. Satoshi Motoya has 
received lecture fees from Mitsubishi Tanabe Pharma Corporation, Mochi-
da Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K. and Takeda Phar-
maceutical Co. Ltd.; and has received research grants from Pfizer Japan 
Inc., Janssen Pharmaceutical K.K. and from Takeda Pharmaceutical Co. Ltd. 
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Introduction: Colon capsule endoscopy (CCE) allows non-invasive explo-
ration of colon mucosa. It has been proposed as an alternative to colo-
noscopy for average-risk colorectal cancer (CRC) screening patients with 
contraindications or unwilling to undergo colonoscopy and/or with an 
incomplete colonoscopy.1,2 However relevance of CCE in a real-life practice 
and its short and long-term impact on clinical decisions have never been 
described. A prospective national cohort of CCE, the ONECC cohort, has 
been developed to assess these questions.
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P0270 nOMencLaTure and seManTIc descrIPTIOn 
Of uLceraTIve and InfLaMMaTOry LesIOns seen In 
crOhn’s dIsease In sMaLL BOWeL caPsuLe endOscOPy: 
an InTernaTIOnaL deLPhI cOnsensus sTaTeMenT
Leenhardt R.1, Buisson A.2, Boureille A.3, Marteau P.1,4, Koulaouzidis A.5, 
Li C.6, Keuchel M.7, Rondonotti E.8, Toth E.9, Plevris J.N.10, Eliakim A.11, 
Rosa B.12, Triantafyllou K.13, Elli L.14, Wurm-Johansson G.15, Ellul P.16, 
Perez-Cuadrado-Robles E.17, McNamara D.18, Cavallaro F.19, Spada C.20, 
Cholet F.21, Beaumont H.22, Fernández-Urién Sainz I.23, Kopylov U.24, 
McAlindon M.25, Németh A.26, Niv Y.27, Panter S.28, Tontini G.E.29, 
Yung D.E.30, Rahmi G.31, Saurin J.C.32, Dray X.33
1Sorbonne University, Hepato-Gastroenterology and Digestive Endoscopy, 
APHP, Saint Antoine Hospital, Paris, France, 2CHU Estaing Clermont-
Ferrand, Gastroenterology, Clermont-Ferrand, France, 3University of 
Nantes Hospital, IMAD, Gastroenterology, Nantes, France, 4Lariboisiere 
Hospital, Hepato-Gastroenterology, Paris, France, 5The Royal Infirmary 
of Edinburgh, Centre for Liver & Digestive Disorders, Edinburgh, United 
Kingdom, 6Sorbonne University, Hepato-Gastroenterology, Paris, France, 
7Bethesda Krankenhaus Bergedorf, Klinik für Innere Medizin, Hamburg, 
Germany, 8Ospedale Valduce Gastroenterology Unit, Gastroenterology, 
Como, France, 9Lund University, Gastroenterology - Surgery, Malmo, 
Sweden, 10The Royal Infirmary of Edinburgh, Gastroenterology, Edinburgh, 
United Kingdom, 11Sheba Medical Center, Gastroenterology, Ramat 
Gan, Israel, 12Universidade do Minho, Hospital Senhora da Oliveira, 
Gastroenterologia, Guimarães, Portugal, 13Medical School, Athens University, 
2nd Dept of Internal Medicine and Research Institute, Alimos, Greece, 
14Fondazione IRCCS Ca Granda, Center for Prevention and Diagnosis of 
Celiac Disease, Milano, Italy, 15Skåne University Hospital, Gastroenterology 
- ClinicalSciences, Malmö, Sweden, 16Mater Dei Hospital, Msida, Malta, 
17Cliniques Universitaires Saint-Luc, Gastroenterology, Bruxelles, Belgium, 
18Tallaght Hospital, Gastroenterology, Dublin, Ireland, 19Foundation IRCCS 
Ca Granda Policlinico, San Donato M.Se, Italy, 20Catholic University Rome, 
Digestive Endoscopy Unit, Rome, Italy, 21Chu La Cavale Blanche, Endoscopy 
Unit, Brest, France, 22VU Medical Center, Gastroenterology, Amsterdam, 
Netherlands, 23Hospital de Navarra, Gastroenterology, Pamplona, Spain, 
24Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 
25Royal Hallamshire Hospital, Gastroenterology, Sheffield, United Kingdom, 
26Skåne University Hospital, Malmö, Sweden, 27Rabin Medical Center, Tel 
Aviv University, Gastroenterology, Petach Tikva, Israel, 28South Tyneside 
Hospital, Gastroenterology, East Boldon, United Kingdom, 29IRCCS Policlinico 
San Domato, Gastroenterology and Digestive Endoscopy Unit, San Donato 
Milanese, Italy, 30The Royal Infirmary of Edinburgh, Edinburgh, United 
Kingdom, 31Hôpital Européen Georges Pompidou, Gastroenterology, Paris, 
France, 32Hospices Civils de Lyon, Lyon Cedex 03, France, 33Paris 6 University 
and APHP, Saint Antoine Hospital, Hepatology and Gastroenterology, Paris, 
France
contact e-Mail address: xavier.dray@aphp.fr
Introduction: Nomenclature and description of small bowel (SB) ulcer-
ative and inflammatory (UI) lesions in capsule endoscopy (CE) are scarce 
in the medical literature. Interobserver variability in interpreting the find-
ings remains a major limitation for the assessment of severity of mu-
cosal lesions with a potential negative impact on clinical care, training 
and research regarding SBCE. Our aim is to establish a consensus on the 
nomenclature and the description of UI lesions seen in SBCE in Crohn’s 
Disease (CD).
aims & Methods: An international panel of experienced SBCE readers was 
formed during the 2016 UEGW meeting. A core group of 5 CE and inflam-
matory bowel disease (IBD) experts established an internet-based three-
round Delphi consensus, but did not participate in voting process. The core 
group built illustrated questionnaires including various still frames of SB 
UI CE lesions obtained from CD patients. A group of 27 other experts was 
asked to rate and comment different proposals on the nomenclature and 
the description of the most frequent SB UI lesions. A 6-point rating scale 
(varying from ‘strongly disagree’ to ‘strongly agree’) was used in succes-
sive rounds. The consensus was reached when at least 80 % voting mem-
bers scored the statement within the ‘agree’ or ‘strongly agree’.
results: A 100% participation rate was obtained for all rounds. Consensual 
nomenclature and descriptions were reached for the seven following UI 
lesions: aphthoid erosion, deep ulceration, superficial ulceration, stenosis, 
edema, hyperemia and denudation. 
nomenclature description % nomenclature/ description
Aphthoid erosion
Diminutive loss of epithelial layering with a 
white center and a red halo, surrounded by 
normal mucosa
85.2/96.3
Deep ulceration
Frankly deep loss of tissue compared to the 
surrounding swollen / oedematous mucosa, with 
a whitish base
96.3/85.2
Superficial 
ulceration
Mildly depressed loss of tissue with a whitish 
bottom, whose features fit neither with that 
of aphthoid erosion nor with that of deep 
ulceration, as previously defined
81.5/85.2
Stenosis
Narrowing of the intestinal lumen withholding 
or delaying the passing of the videocapsule 
(therefore, to be evaluated on a video)
100.0/88.9
Edema Enlarged / swollen / engorged villi 85.2/81.5
Hyperemia Area of reddish villi 96.3/81.5
Denudation
Reddish (but not whitish) mucosal area where 
villi are absent
81.5/81.5
[International Delphi Consensus on the nomenclature and descriptions of 
ulcerative and inflammatory lesions seen in IBD during SBCE.]
conclusion: Consensual nomenclature and descriptions of the most fre-
quent SB UI lesions seen in CD in CE have been reached by an international 
group. These terms and descriptions are useful in daily practice, for teach-
ing and for medical research purposes.
disclosure: Xavier Dray has acted as a consultant for Alfasigma; Bouchara 
Recordati; Boston Scientific, Fujifilm, Medtronic, and Pentax 
P0271 cOLOn caPsuLe endOscOPy: an effIcIenT cOMPLeMenT 
fOr IncOMPLeTe cOLOnOscOPIes
Magalhaes R.1,2,3, Xavier S.1,2,3, Boal Carvalho P.1,2,3, Rosa B.1,2,3, 
Moreira M.J.1,2,3, Cotter J.1,2,3
1Hospital Senhora da Oliveira, Gastroenterology, Guimarães, Portugal, 2Life 
and Health Sciences Research Institute (ICVS), School of Medicine, University 
of Minho, Braga, Portugal, 3ICVS/3B’s, PT Government Associate Laboratory, 
Guimarães/Braga, Portugal
contact e-Mail address: rui.magalhaes.med@gmail.com
Introduction: Colonoscopy is the gold standard for visualization of the colon 
during colorectal cancer screening. A colonoscopy is considered complete 
when cecum is reached. Completion rates, on some series, are described 
as low as 81% for mixed indications. Colon capsule endoscopy (CCE) is 
approved for complementing incomplete colonoscopies, with completion 
rates up to 90%, and it could help to detect additional relevant colonic and 
extracolonic findings.
aims & Methods: To assess the value of CCE on incomplete colonoscopies: 
complementation rates and incremental diagnostic yields.
Retrospective, single center study, including consecutive patients that un-
derwent CCE for incomplete colonoscopy, from April 2015 to October 2018. 
Our cohort was analyzed by descriptive and parametric SPSS tools.
results: We included 55 patients submitted to CCE after an incomplete 
colonoscopy. Included 46 women (83.6%) with a mean age of 67 years old. 
CCE were complete in 64% of the patients, however, in almost 90%, we 
reach total colon visualization, considering both exams.
The three main indications for primary colonoscopy were colorectal car-
cinoma screening (49.1%), followed by positive fecal occult blood test 
(14.5%) and post-polipectomy surveillance (14.5%). 
Significant endoscopic findings were identified in 44 (80%) CCE, namely, 
colon diverticula (61.8%) followed by polyps (29.1%), angiectasias (9.1%) 
and erosions (9.1%).
From the 16 CCE with diagnosis of colon polyps, three lesions (18.5%) had 
more than 10mm. Polyps were mainly found on left colon (12.7%).
Seven patients performed colonoscopy after CCE (12.7%), and in 6 (85.7%) 
the intended lesions were identified and treated: 5 polypectomies and 
1 fulguration with argon plasma. Therefore, 87.3% of the patients won’t 
need additional investigation after CCE.
There were no CCE retentions or other complications associated to the pro-
cedure.
conclusion: CCE is useful and well tolerated, an important tool to be used 
to increase colonic diagnostic yield with direct impact on therapeutic in-
terventions.
disclosure: Nothing to disclose 
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P0273 POLyeThyLene gLycOL PurgaTIves PrIOr TO sMaLL 
BOWeL caPsuLe endOscOPy IMPrOve dIsTaL sMaLL BOWeL 
vIsuaLIsaTIOn
Tai F.W.D.1, Wray N.1, Healy A.1, Thurston V.1, Hookey L.2, McAlindon M.3
1Royal Hallamshire Hospital, Academic Unit of Gastroenterology and 
Hepatology, Sheffield, United Kingdom, 2Kingston General Health Research 
Institute, Division of Gastroenterology, Department of Medicine, Queen’s 
University, Kingston, Canada, 3Royal Hallamshire Hospital, Dept. of 
Gastroenterology, Sheffield, United Kingdom
contact e-Mail address: david.tai@nhs.net
Introduction: Bowel purgatives are common practice prior to small bowel 
capsule endoscopy (SBCE). The use of Polyethylene glycol (PEG) laxatives is 
suggested to improve SB visualisation quality and diagnostic yield [Kotwal, 
Eur J Gastro Hep 2014]. However, this finding is not completely consistent, 
with other studies suggesting no clear benefit of PEG preparation over 
clear fluids only [Hookey, GIE 2017]. Therefore, unlike colonoscopy where 
the routine use of split dose bowel preparation to improve right colon 
cleansing has become a standard of care [Flemming, GIE 2012], the benefit 
and timing of purgatives prior to SBCE is unknown. We report the interim 
results from a clinical trial comparing the use of split dose PEG and single 
dose PEG against clear fluids only.
aims & Methods: Adult patients referred for SBCE were invited to partici-
pate and subject to exclusion criteria, were randomised to control (clear 
fluids only), single dose PEG (2L PEG at 6am on the day of the exam) 
and split dose PEG (1L PEG at 7pm the day before and 6am on the day 
of the exam). Briefly, the mean red to green colour intensity from SBCE 
procedure colour bars were used to calculate a computed assessment of 
cleansing (CAC) scores described elsewhere [Van Weyenberg, Endoscopy 
2011]. The CAC is a validated 10 point scoring system (0-10; least - most 
clean) used to assess small bowel visualisation quality. CAC scores are 
reported as mean ± SEM and student t-tests performed to compare the 
means.
results: A total of 78 patients (35% male, mean age 48±2.0) were includ-
ed (split n=28, single n=24 and control n=26). Intention to treat analysis 
show that split dose PEG preparation results in significantly greater mean 
CAC score in the distal quartile (5.58±0.16) of the small bowel compared 
to control (4.78±0.30; p=0.02). No differences in the overall, first, second 
and third quartile CAC score of the small bowel was found between con-
trol and PEG groups. Complete ingestion of PEG preparation occurred in 
88% and 77% of single vs split dose (p=0.33). Subgroup analysis showed 
that amongst patients that completed preparation successfully, those ran-
domised to both split dose (5.52±0.20; p=0.01) and single dose (5.64±0.18, 
p=0.003) PEG had a significantly greater mean CAC score in the distal 
quartile of the small bowel compared to control (4.58±0.28).
P0272 The rOLe Of cOLOn caPsuLe endOscOPy In cOLOrecTaL 
cancer screenIng: a sysTeMaTIc revIeW
Vuik F.E.R.1, Nieuwenburg S.A.V.1, Moen S.1, Spada C.2,3, Senore C.4, 
Kuipers E.J.1, Spaander M.C.W.1
1Erasmus MC University Medical Center, Department of Gastroenterology and 
Hepatology, Rotterdam, Netherlands, 2Poliambulanza Foundation, Digestive 
Endoscopy and Gastroenterology Unit, Brescia, Italy, 3Catholic University 
Rome - Digestive Endoscopy Unit, Catholic University Rome, Digestive 
Endoscopy unit, Rome, Italy, 4AO Città della Salute e della Scienza, CPO 
Piemonte, Torino, Italy
contact e-Mail address: f.vuik@erasmusmc.nl
Introduction: Colorectal cancer (CRC) screening programs have been im-
plemented in many countries in order to decrease CRC incidence and mor-
tality. Primary colonoscopy and fecal immunochemical testing (FIT) are 
the most commonly used screening modalities. An alternative screening 
instrument is second generation colon capsule endoscopy (CCE). Although 
the accuracy of CCE has already been proven in several trials, information 
on its performance in a screening population remains scarce.
aims & Methods: We therefore performed the first systematic review on 
the role of CCE as a CRC screening tool. A systematic search was conducted 
until November 2018 to retrieve studies from Embase, Web of Science, 
Medline Ovid and Cochrane Central according to the PRISMA guideline. 
Studies with patients participating in a population colorectal screening 
were included. Studies using first generation CCE were excluded.
results: Literature search retrieved 499 studies, of these 11 studies met the 
inclusion criteria. The included studies focused on FIT-positive screening 
populations (n=7) or opportunistic screening populations (n=4). In total 
1792 subjects were included. The participation rate ranged between 4.2% 
and 17.4% (Table 1). The polyp detection rate of CCE varied from 63% to 
74%. Complete CCE led to detection of 16/17 (94%) CRCs. Sensitivity of CCE 
for polyps ranged between 75% and 92.8% and specificity between 65.3% 
and 99%. Bowel preparation was adequate in 70% to 92% and comple-
tion rate varied from 57% to 88%. No adverse events with CCE were re-
ported in the included studies.
conclusion: CCE is a safe and effective diagnostic tool for the detection of 
cancer and polyps in a screening population. Bowel preparation is ade-
quate in most studies, but the low completion rates affect the performance 
of CCE. More studies are needed to determine the role of CCE as screening 
instrument. 
disclosure: Nothing to disclose 
study characteristics quality indicators yield
Study Type screening
Participation, N 
(participation 
rate %)
Bowel preparation and 
booster regimen
Adequate bowel 
preparation (%)
Completion 
rate CCE (%)
DR CCE (%) 
a = Polyp b 
= CRC
DR OC (%) 
a = Polyp b 
= CRC
Sensitivity CCE (%) 
a= Polyp>5mm b= 
Polyp>9 mm
Specificity CCE (%) 
a= Polyp>5mm b= 
Polyp>9 mm
Groth 2012
Opportunistic, 
primary OC
90 (4.2)
2L PEG evening + 1L PEG 
morning. NaP, water
88 82 a:- b:- a:- b:- a:- b:- a:- b:-
Holleran 2014 FIT based screening 62
4L PEG split dose. 
Sodium picosulfate
92 73 a:69 b:100 a:58 b:100 a:- b:- a:- b:-
Suchanek 2014
Opportunistic, 
primary OC or FIT
225 - 90 - a:- b:100 a:51 b:100 a:79 b:88 a:97 b:99
Rondonotti 2014 FIT based screening 50 (8.2)
2L PEG split dose + 1L 
water. NaP, water
70 90 a:- b:- a:- b:- a:88.2 b:92.8 a:87.8 b:91.7
Romero 2015 FIT based screening 53 - - 81 a:- b:100 a:82 b:100 a:87 b:88 a:88 b:94
Rex 2015
Opportunistic, 
primary OC
695
4L PEG split dose. Sulfate 
solution, water
80 92 a:- b:75 a:- b:100 a:87 b:85 a:94 b:97
Suarez 2016 FIT based screening 88 - 82 81 a:- b:100 a:- b:100 a:- b:- a:- b:-
Kobaek-Larsen 
2017
FIT based screening 253 (17.4)
2L PEG + 3L water split 
dose. Moviprep, water
85 57 a:74 b:64 a:64 b:100 a:- b:87 a:- b:92
Hassan 2018 FIT based screening 203
4L PEG split dose. NaP, 
water, gastrografin
89 88 a:- b:- a:- b:- a:89.7 b:87.2 a:65.3 b:87.9
Voška 2018
Opportunistic, 
primary FIT
54
3L PEG evening + 1L PEG 
morning. NaP, water
- - a:- b:100 a:69 b:100 a:82 b:75 a:88 b:93
Pioche 2018 FIT based screening 19 (5.0)
Day -2: 4L PEG Day -1: 3L 
PEG Day 0: 1L PEG. NaP, 
water
74 68 a:63 b:100 a:- b:100 a:- b:- a:- b:-
[P0271 Table 1. Overview of the 11 included studies reporting on the quality indicators and yield of CCE in a screening population.]
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conclusion: The use of split dose laxatives improves the visualisation qual-
ity of the distal small bowel. Initial results may suggest that the PEG dose 
in the morning of the procedure improves distal quartile visualisation.
references: Kotwal VS, Attar BM, Gupta S, Agarwal R. Should bowel prep-
aration, antifoaming agents, or prokinetics be used before video capsule 
endoscopy? A systematic review and meta-analysis. Eur J Gastroenterol 
Hepatol 2014; 26(2): 137-45. Hookey L, Louw J, Wiepjes M, et al. Lack of ben-
efit of active preparation compared with a clear fluid-only diet in small-
bowel visualization for video capsule endoscopy: results of a randomized, 
blinded, controlled trial. Gastrointest Endosc 2017; 85(1): 187-93. Flemming 
JA, Vanner SJ, Hookey LC. Split-dose picosulfate, magnesium oxide, and 
citric acid solution markedly enhances colon cleansing before colonoscopy: 
a randomized, controlled trial. Gastrointest Endosc 2012; 75(3): 537-44.
disclosure: Nothing to disclose 
P0274 Is IT POssIBLe TO TreaT The angIOdysPLasIas 
fOund In PaTIenTs WITh OBscure gasTrOInTesTInaL BLeedIng 
suBjecTed TO sMaLL BOWeL caPsuLe endOscOPy?
Viazis N.1, Tziortziotis I.1, Tsoukali E.2, Pontas C.1, 
Hatzievangelinou C.1, Gkeros F.1, Filippidis G.1, Karampekos G.1, Vraka M.1, 
Archavlis E.1, Christidou A.1, Mela M.1, Mantzaris G.3
1Evangelismos Hospital, Gastroenterology, Athens, Greece, 2Evangelismos 
Hospital, Department of Gastroenterology and Hepatology, Koropi, Greece, 
3Evangelismos Hospital, 1st Dept. of Gastroenterology, Athens, Greece
contact e-Mail address: nikos.viazis@gmail.com
Introduction: Angiodysplasias of the small intestine is reported to be the 
most common cause of obscure gastrointestinal bleeding (OGIB). The aim 
of our study was to identify whether it is possible to treat the bleeding due 
to angiodysplasias found in patients with OGIB subjected to small bowel 
capsule endoscopy (SBCE).
aims & Methods: Retrospective analysis of prospectively collected data 
[March 2003 - March 2019] from 5771 patients that were subjected to SBCE 
in our Department, which is a tertiary referral centre for this test. Among 
these patients, 3403 were subjected to the test for the investigation of 
OGIB. All these patients were referred to our Department for OGIB after a 
reported negative gastroduodenoscopy and a negative colonoscopy.
results: By SBCE angiodypslasias were found in 1652 of 3403 patients 
(48.5%). Of these lesions 224 (13.5%) were actively bleeding at the time 
of testing and were localized in the proximal gastrointestinal tract (stom-
ach or the first/second part of the duodenum) (n=12, 5.3%), the proximal 
jejunum (n=62, 27.6%), the distal jejunum (n=49, 21.8%), the proximal 
ileum (n=41, 18.3%), the distal ileum (n=42, 18.7%), and the right colon 
(n=18, 8.0%). 
Therapeutic intervention by Argon-Plasma Coagulation (APC) cauterization 
was possible in 6 patients with gastric or duodenal angiodysplasias, in 7 
patients with angiodysplasias in the right colon, and in 31 patients with 
angiodysplasias in the proximal jejunumn (using a push enteroscope), 
since in the remaining patients angiodysplasias were not seen during re-
peat endoscopy. 
Therefore, in total, angiodysplasias were endoscopically treated in 44 pa-
tients (2.6%), among the 1652 initially revealed through SBCE.
conclusion: Angiodysplasias are seen in the majority of patients with ob-
scure gastrointestinal bleeding subjected to SBCE; however therapeutic in-
tervention is possible only in a small minority of them, especially if double 
balloon endoscopy is not available.
disclosure: Nothing to disclose 
P0275 negaTIve sMaLL BOWeL vIdeO caPsuLe endOscOPy 
fOr OccuLT gasTrOInTesTInaL BLeedIng PredIcTs a LOW 
rIsk Of suBsequenT InPaTIenT adMIssIOn WITh uPPer 
gasTrOInTesTInaL BLeedIng
Rajagopalan A., Venugopal K.
Royal Perth Hospital, Gastroenterology and Hepatology, Perth, Australia
contact e-Mail address: arvind.raja@gmail.com
Introduction: Small bowel video capsule endoscopy (SBVCE) is the inves-
tigation of choice for occult gastrointestinal bleeding (OGIB) following a 
negative gastroscopy and colonoscopy. Approximately 50-55% of these 
tests are negative, however the long-term outcome of this cohort of pa-
tients is not well described.
aims & Methods: aim: To assess the long-term clinical impact of a negative 
SBVCE in patients with OGIB.
Methods: A retrospective review of all patients who underwent SBVCE at 
an Australian tertiary health service between 1st January 2012- 31st Decem-
ber 2017 was performed. The gastrointestinal Procedure Reports database 
was reviewed for listed indications of ‘anaemia’ or ‘iron deficiency’. Demo-
graphic data (including medication history) was determined by reviewing 
the medical record. 
Primary outcome measure was hospital admission secondary to gastro-
intestinal bleeding within 1 year of negative SBVCE, with secondary out-
come measure being further endoscopic investigation of iron deficiency 
anaemia or gastrointestinal bleeding within 1 year. Statistical analysis was 
performed using GraphPad Prism software (version 8.02).
results: 429 cases were initially identified. 13 were excluded due to cap-
sule retention in upper gastrointestinal tract, whilst a further 209 excluded 
due to either additional presence of overt gastrointestinal bleeding or a 
positive capsule result (Significant angioma burden, ulcers, small bowel 
Crohn’s Disease and small bowel tumors). 
207 cases were included for final assessment. 110 (53%) female, median 
age 61 years (range 17-91). 18 (9%) had a history of non-steroidal anti-in-
flammatory use, 41 (20%) reported aspirin use, 17 (8%) other antiplatelet 
agents and 15 (7%) were using other anticoagulation at the time of SBCE. 
Regarding the primary outcome measure, 7 (3%) of patients were admit-
ted to hospital within 1 year of negative SBVCE. 11 (6%) of patients had re-
peat endoscopic investigation (8 patients had negative studies, 2 patients 
had gastric antral vascular ectasia and 1 patient had a duodenal angioma). 
3/62 patients receiving antiplatelet or anticoagulant therapy were admit-
ted to hospital compared to 4/145 not receiving these therapies. The odds 
ratio for readmission when on anticoagulation was 1.7 (95% confidence 
interval 0.44-6.8), when compared to patients not on anticoagulation - 
although this did not reach statistical significant (p = 0.44). No patient had 
multiple admissions.
conclusion: Negative SBVCE for occult GI bleeding carries a low risk for 
subsequent hospital admission due to overt GI bleeding within 1 year of 
the study. In addition, there is a low risk of requiring further endoscopic 
investigations.
disclosure: Nothing to disclose 
P0276 The neW generaTIOn Of exPress vIeW Is hIghLy 
accuraTe and Is effecTIve TO reduce caPsuLe endOscOPy 
readIng TIMe
Piccirelli S.1,2, Mussetto A.3, Bellumat A.4, Cannizzaro R.5, Pennazio M.6, 
Pezzoli A.7, Bizzotto A.1, Fusetti N.7, Valiante F.4, Spada C.1,2
1Fondazione Poliambulanza Istituto Ospedaliero, Department of Medicine, 
Gastroenterology and Endoscopy, Brescia, Italy, 2Catholic University Rome 
- Digestive Endoscopy Unit, Catholic University Rome, Digestive Endoscopy 
unit, Rome, Italy, 3Azienda AUSL Ravenna Dept. of Gastroenterology, 
Ravenna, Italy, 4Presidio Osp. Feltre, Feltre, Italy, 5Centro di Riferimento 
Oncologico di Aviano (CRO), IRCCS, S.O.C. di Gastroenterologia, Oncological 
Gastroenterology, Aviano, Italy, 6City of Health and Science University 
Hospital, University Division of Gastroenterology, Turin, Italy, 7Dip. 
Gastroenterologia-Epatologia, Ospedale Sant’Anna, Ferrara, Italy
contact e-Mail address: stefania.piccirelli@gmail.com
Introduction: Capsule Endoscopy (CE) is a first-line diagnostic test in pa-
tients with suspected small bowel bleeding (SSBB). One of the main limi-
tation of CE is reading that might be time consuming. In order to overcome 
such limitation, innovative types of reading software have been developed. 
A new generation reading algorithm (Express-View by MiroCam) has re-
cently released with the aim to reduce CE reading time by removing im-
ages based upon their similarity and effectively reducing the number of 
images for the review, without affecting the diagnostic yield. Accuracy and 
impact on reading time are unknown.
aims & Methods: Primary aim was to evaluate the accuracy of the new 
generation Express View in patients with SSBB. Secondary objective was 
to evaluate the reading time with the Express View compared to standard 
reading. This is a per patient, interim analysis including 48 patients with 
SSBB prospectively enrolled in 5 centers. All patients underwent small-
bowel CE (MC 1200, Intromedic, Republic of Korea). CE reading was ini-
tially performed in the standard mode according to the ESGE capsule en-
doscopy technical guidelines. A second reading was performed using the 
Express View (EV) mode by an external, blinded reader. For each lesion, 
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liquid diet in relation to the QI (8.13 ± 1.56 vs. 7.47 ± 1.97, p=0.05) and the 
QE cleansing grades (excellent: 15.4% vs. 13.8%, good: 48.1% vs. 39.7%, 
reasonable: 25% vs. 27.6%, poor: 11.5% vs. 19%, p = 0.67). The diagnostic 
yield was not different between the 2 protocols (PEG: 58.8% vs Clear liquid 
diet: 55.2%, p=0.7).
conclusion: The use of a PEG solution did not show to affect the small-
bowel cleansing in CE when evaluated by QI and QE Brotz scales, and did 
not affect the diagnostic yield of CE.
disclosure: Nothing to disclose 
P0278 cOMParIng The effIcacy and safeTy Of MeTaL versus 
PLasTIc sTenTs In PreOPeraTIve BILIary draInage
Roberts A.1, Jaya J.2, Thakur U.2, Aldridge O.3, Pilgrim C.3, Wong E.4, 
Tan E.4, Fox A.4, Le S.T.T.5, Croagh D.2
1Monash Health, Gastroenterology, Clayton, Australia, 2Monash Health, 
Surgery, Melbourne, Australia, 3Alfred Health, Surgery, Melbourne, 
Australia, 4Eastern Health, Surgery, Box Hill, Australia, 5Monash Medical 
Centre Gastroenterology and Hepatology, Gastroenterology, Melbourne, VIC, 
Australia
contact e-Mail address: atr444@gmail.com
Introduction: There is conflicting evidence regarding whether routine pre-
operative biliary drainage (PBD) should be performed if clinically war-
ranted prior to a pylorus-preserving pancreaticoduodenectomy (PPP) for 
resectable pancreatic head cancer. In addition, there are limited studies 
that investigated whether PBD with metal or plastic biliary stents have 
differing impacts on PBD-related complication rates, post PPP surgical 
outcomes, and healthcare resource utilisation.
aims & Methods: An Australian multicentre retrospective cohort study was 
conducted which included patients who underwent PBD prior to PPP from 
2010 to 2019. Patients included received PBD based on one or more of: 
cholangitis defined by revised Tokyo guidelines, level of total bilirubin ≥40 
µmol/L, expected time to operation ≥7 days, or receiving neoadjuvant che-
motherapy.
The aim of this study was to compare PBD with fully covered self-expand-
able metal stent (FCSEMS) compared to plastic stents in terms of the rate 
of endoscopic reintervention, stent related complication and surgical com-
plications in patients with resectable pancreatic head cancer who later 
underwent a PPD.
results: 106 patients underwent PBD. 32 patients (30.19%) received a FC-
SEMS versus 74 (69.81%) with plastic). The mean age was 66.75 ± 9.79 
years, 47.17% were male and the baseline bilirubin was 184.91 ± 113.59 
µmol/L. Both FCSEMS and plastic effectively reduced bilirubin (Δ140.04 ± 
113.04 µmol/L from baseline) with no difference between the FCSEMS arm 
and the plastic arm (Δ134.56 ± 108.35 µmol/L vs Δ152.19 ± 123.74 µmol/L, 
p-value:0.47). 
There was no difference in the PBD complication rates in the FCSEMS and 
plastic stent groups respectively: readmission (p-value=0.40), pancreatitis 
(p-value=0.25), cholangitis (p-value=0.35), haemorrhage (p-value=0.51), 
stent occlusion without cholangitis (p-value=0.09), and reintervention 
with either ERCP or PTC (p-value=0.21). There were no cases of stent re-
lated perforation. There was also no difference in the post-operative com-
plication rates including surgical or biliary leaks, infection, haemorrhage 
or return to theatre in the FCSEMS and plastic stent groups.
On multivariate logistic regression analysis, the stent type was not an inde-
pendent risk factor of endoscopic or post-operative complication or death. 
On multivariate linear regression analysis, the stent type was not an in-
dependent risk factor for increased length of stay for those readmitted for 
a stent related complication. The resection histopathology showed pan-
creatic adenocarcinoma (69.81%), neuroendocrine (2.83%), autoimmune 
pancreatitis (0.94%) and other primary malignancy (26.42%).
conclusion: Both FCSEMS and plastic PBD stents were comparable in nor-
malising bilirubin pre-PPP. There were no statistically significant differ-
ence in pre or post-operative complications or healthcare resource utilisa-
tion between the two groups apart from the increased upfront cost of the 
FCSEMS. The cost benefit in using plastic stents in preference to FCSEMS 
may be an important consideration where there are clinical indications for 
PBD or long wait times for surgical management of resectable pancreatic 
head cancer.
disclosure: Nothing to disclose 
the time of visualization, nature, and relevance according to the Saurin 
classification were collected. For the accuracy evaluation, the Express View 
reading was compared to the standard reading (SR) that was considered 
gold standard. In case of discrepancies between SR and EV reading, ac-
curacy parameters were re-evaluated after a consensus reading that was 
performed by two experienced investigators (>500 cases) and that was 
considered the gold standard. Reading time (gastric + small bowel) was 
also evaluated after selection of the first gastric, duodenal and cecal land-
marks. In case of incomplete enteroscopy, the last recorded image was 
considered as landmark.
results: On a total of 48 patients, 47 performed VCE examination while 
one patient had gastric capsule retention. Enteroscopy was complete (i.e 
cecal visualization) in 43 patients (91.5%). In 33 out of 47 patients (70.2%) 
both SR and EV mode were in agreement for type of lesion and local-
ization, while in the remaining 14 patients (29.8%) the EV reading was 
discordant compared to the gold standard (i.e. SR). Sensitivity, specific-
ity, PPV, and NPV of EV reading after the initial evaluation were 71.8%, 
66.6%, 82%, 52.6%, respectively. After the consensus reading, in 12 out of 
14 patients with discordant reports (n=5 SR-EV+, n=4 SR+EV-, n=3 SR+EV+ 
but no comparable lesions) EV was reclassified to be able to properly de-
tect the lesion and the disagreement was considered related to a reader-
misinterpretation. In the remaining 2 patients (4.2%), EV mode missed 
relevant lesions (1 patient with significant ileal erosions and 1 with a vas-
cular malformation). 
After consensus reading reclassification, EV mode sensitivity, specificity, 
NPV and PPV were 94.6%, 100%, 83.3% and 100% respectively. The mean 
reading time at SR and EV was 84.13 ± 53.63 min and 14.79 ± 11.2 min, 
respectively (p< 0.001).
conclusion: The preliminary results of this study suggest that the new gen-
eration Express View algorithm shows excellent accuracy and significantly 
reduces CE reading time.
disclosure: Nothing to disclose 
P0277 cOMParIsOn Of sMaLL-BOWeL cLeansIng BeTWeen 2 
PreParaTIOn PrOTOcOLs In caPsuLe endOscOPy (ce)
Ribeiro Gomes A.C.1, Pinho R.T.2, Ponte A.3, Rodrigues A.3, Sousa M.4, 
Silva J.C.5, Afecto E.6, Carvalho J.7
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Portugal, 4Centro Hospitalar Vila Nova de Gaia e Espinho, Gastroenterology, 
Vila Nova de Gaia, Portugal, 5Centro Hospitalar Vila Nova de Gaia/Espinho, 
Gastroenterology, Vila Nova de Gaia, Portugal, 6Centro Hospitalar Gaia 
Espinho, Serviço de Gastroenterologia, Vila Nova de Gaia, Portugal, 7Centro 
Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal
contact e-Mail address: catarina.rib.gomes@gmail.com
Introduction: The European Society of Gastrointestinal Endoscopy recom-
mends that a solution such as polyethylene glycol (PEG) should be used 
prior to a capsule endoscopy (CE), since it allows a better mucosal visual-
ization and increases the diagnostic yield. However, it is still controversial 
which is the best enteric preparation. In the current literature, some series 
showed similar results between a PEG solution and a clear liquid diet on 
the day before the CE.
aims & Methods: The aim of this study was to compare Brotz’s enteral 
cleansing scales between two enteric preparation protocols in patients 
undergoing CE. The authors performed a retrospective single-center 
analysis of CE. Patients with active bleeding and whose capsule did not 
reach the cecum were excluded from the study. The enteric preparation 
protocols were (1) clear liquid diet on the previous day plus 8 hour fasting, 
(2) 2 liters of PEG solution plus simeticone. The CE videos were graded 
regarding the level of cleanliness according to 2 grading scales devel-
oped by Brotz et al previously described: a) quantitative index (QI), which 
grades the level of cleanliness with a score ranging from 0 to 10 and b) 
qualitative evaluation (QE), which grades the degree of cleanliness as ex-
cellent, good, fair and poor. The diagnostic yield between the 2 protocols 
was also evaluated.
results: 110 CE were analyzed, 52.7% (n=58) were female, with a mean age 
of 56.1 years-old (± 18). 52.7% (n=58) of the patients had the clear liquid 
diet protocol and 47.3% (n=52) the PEG protocol. Sex, age and indica-
tion for CE were not significantly different between the two protocols. In 
addition, there were no significant differences between the PEG and the 
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P0279 eus-guIded TransjejunaL draInage WITh 
fOrWard-vIeWIng echOendOscOPe In The PaTIenTs 
WITh aLTered anaTOMy
Iwai T.1, Kida M.2, Okuwaki K.1, Yamauchi H.1, Kaneko T.1, Hasegawa R.1, 
Imaizumi H.1, Koizumi W.1
1Kitasato University School of Medicine, Sagamihara-City, Japan, 2Kitasato 
University, Endoscopy & Gastroenterology, Sagamihara, Japan
contact e-Mail address: t-iwai@kitasato-u.ac.jp
Introduction: Forward-viewing echoendoscope (FV-ES) was originally de-
signed for therapeutic procedures, particularly for pseudocyst drainage. 
The advantage of FV-ES is that it enables the axial application of force 
during needle insertion and accessory device deployment. Although other 
big advantage of FV-ES is its easier manipulation throughout the GI tract 
due to forward viewing, a wider angulation rage, and short length of the 
hard tip, there are few reports on EUS-guided transjejunal anastomotic 
drainage for the patients with altered anatomy. The advantages of this 
technique are that we can approach both biliary systems and it is a 1-step 
procedure (no need for Rendezvous method) and it is not performed 
through the abdominal cavity.
aims & Methods: We evaluated the feasibility of the EUS-guided choledo-
chojejunostomy (EUS-CJS) and pancreaticojejunostomy (EUS-PJS) with 
FV-ES (TGF-UC260J; Olympus, Tokyo, Japan) for the patients with surgi-
cally altered anatomy from Feb 2015 through Mar 2019 in our institution, 
retrospectively.
results: A total of 7 cases with surgically altered anatomy were received 
transjejunal anastomotic drainage with FV-ES. All of them were after pan-
creaticoduodenectomy with modified Child reconstruction. The indication 
for drainage was complete stricture of the hepaticojejunal anastomosis in 
6 cases and the pancreaticojejunal anastomosis in one case. The success 
rate of reaching the target site at afferent limb is 100% (7/7) and median 
reaching time was 6 min (4-17). EUS-CJS and bile duct stent placement 
was succeeded in 66.7% (4/6). Erroneous puncture of unintended bile 
duct in one case and impossibility to pass by mechanical dilatation de-
vice in one case, in which cautery dilation catheter was not applied due 
to major vessels close to the puncture site on EUS. Both were rescued 
by percutaneous transhepatic biliary drainage. EUS-PJS and pancreatic 
duct stent placement was succeeded in one case (1/1). No adverse events 
related to the procedure were happened such as sever bile or pancreatic 
juice leakage.
conclusion: EUS-CJS and PJS with FV-ES is feasible in the patients with 
modified Child’s reconstruction after pancreaticoduodenectomy and they 
can be safe and effective method in case of complete stricture of the anas-
tomotic site.
disclosure: Nothing to disclose 
P0280 dOuBLe sTenTIng has BeTTer OuTcOMes Than 
dOuBLe surgIcaL ByPass In The case Of cOMBIned MaLIgnanT 
duOdenaL and BILIary OBsTrucTIOn: a MeTa-anaLysIs and a 
sysTeMaTIc revIeW
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Introduction: Data about efficacy of palliative double stenting of malignant 
duodenal and biliary obstruction are limited.
aims & Methods: Systematic literature search was performed to assess 
feasibility and optimal method of double stenting of malignant duodenal 
and biliary obstruction compared to surgical double bypass in terms of 
technical and clinical success, adverse events, reinterventions, and sur-
vival. Seventy-two retrospective and 8 prospective studies published until 
July 2018 were enrolled. Event rates with 95% confidence intervals were 
calculated.
results: Technical and clinical success rates of double stenting were 97% 
(95-99%) and 92% (89-95%), respectively. Clinical success of endoscopic 
biliary stenting was higher than that of surgery (97% [94-99%] vs 86% 
[78-92%]) in an older population (67.9 years [67.0-68.9 years] vs 63.7 
years [62.3-65.0 years]). Double stenting was associated with less ad-
verse events (13% [8-19%] vs 28% [19-38%]) but more frequent need for 
reintervention (21% [16-27%] vs 10% [4-19%]) than double bypass. No 
significant difference was found between technical and clinical success 
and reintervention rate of endoscopic retrograde cholangiopancreatog-
raphy (ERCP), percutaneous transhepatic drainage (PTD) and endoscopic 
ultrasound guided biliary drainage (EUS-BD). ERCP was associated with 
the least adverse events (3% [1-6%]), followed by PTD (10% [0-37%]) and 
EUS-BD (23% [15-33%]).
conclusion: Substantially high technical and clinical success can be 
achieved with double stenting also in elderly. ERCP is recommended as 
first choice for biliary stenting as part of double stenting. Prospective com-
parative studies with well-defined outcomes and cohorts are needed.
disclosure: Nothing to disclose 
P0281 effIcacy and safeTy Of endOscOPIc draInage 
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Introduction: Endoscopic ultrasound (EUS)-guided drainage is considered 
the gold standard for the treatment of symptomatic peripancreatic fluid 
collections (PFCs). Both lumen-apposing metal stents (LAMS) and double 
pigtail plastic stents (DPPS) can be deployed once access in the collection 
is achieved.
aims & Methods: In this retrospective study we aimed to evaluate the ef-
ficacy and safety of EUS-guided drainage of PFCs. Data from consecutive 
patients undergoing drainage in 8 European centers were retrospectively 
retrieved. Characteristics of PFC, type of stent, technical success (successful 
stent deployment), clinical success (satisfactory drainage), rate of early ad-
verse events, drainage duration and complications on stent removal were 
evaluated.
results: 96 patients [69 men (72%), 57.8±12.8yrs] underwent drainage 
from 2016 to 02.2019. A pancreatic pseudocyst (PC) and a walled-off ne-
crosis (WON) was drained in 62 and 34 patients, respectively. LAMS were 
used in 76 (79.2%) patients; DPPS in 20 (20.8%) of them. In 75 patients 
(78.1%) PFC was located in the body or tail of the pancreas with a mean di-
ameter of 12±5cm. In 86 cases (89.6%) the transgastric approach was used 
to access the PFC. For all above characteristics no difference was detected 
between PC and WON (p>0.1). Among LAMS, the 15mm diameter was cho-
sen in 57 (75%) of the cases. Overall, 30 DPPS were used [median 2(1-3)]; 
the most common diameters were 10Fr (15/30, 50%) and 7Fr (12/30, 40%). 
A successful deployment was possible in 92 (95.8%) of the cases with no 
difference regarding either the PFC type (p=0.13) or the type of stent (p=1). 
Clinical success was achieved in 88 (92%) of the patients; PC had better 
response than WON (62/62 vs. 6/32, p=0.001, respectively). Type of stent 
did not affect the rate of clinical success (p=0.61).
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P0283 reInTervenTIOn fOr sTenT OccLusIOn afTer 
PLaceMenT Of MuLTIPLe seLf-exPandaBLe MeTaLLIc sTenTs 
fOr MaLIgnanT hILar BILIary OBsTrucTIOn
Kitamura H., Hijioka S., Hisada Y., Harai S., Yoshinari M., Maruki Y., 
Ohba A., Nagashio Y., Kondo S., Morizane C., Ueno H., Okusaka T.
National Cancer Center Hospital, Hepatobiliary and Pancreatic Oncology 
Division, Tokyo, Japan
contact e-Mail address: kita3channel.ssh@gmail.com
Introduction: Endoscopic reintervention for stent occlusions following the 
placement of multiple self-expandable metallic stents (SEMS) for malig-
nant hilar biliary obstruction (MHBO) is challenging, and the appropriate 
drainage method have not yet been clarified. We aimed to clarify a suit-
able reintervention method for stent occlusions following placement of 
multiple SMES for MHBO.
aims & Methods: Between October 2017 and March 2019, 41 patients with 
MHBO underwent reintervention for stent occlusion after placement of 
multiple SEMS. We retrospectively evaluated the technical and function-
al success rates of the reintervention, and the time to recurrent biliary 
obstruction (RBO). The treatment strategy of reintervention was the first 
choice via ERCP, and EUS-BD was performed/co-administered in cases 
when transpapillary drainage was insufficient.
results: Re-intervention was performed in 41 of 118 cases (34.7%) that 
were indwelled with multiple SEMS for hilar region stenosis. The median 
age of the patients was 59 ± 11.5 years, and the patients comprised of 27 
men and 17 women. Etiologies included cholangiocarcinoma in 17 cases, 
gallbladder cancer in 6, pancreatic cancer in 5, and others in 13. Bismuth 
classification were type II in 15 patients (36.6%), type III in 17 patients 
(41.5%), and type IV in 9 patients (21.9%). Regarding the methods used 
for the placement of the initial SEMS, 28 cases (68.2%) underwent SBS and 
13 cases (31.7%) underwent PSIS. In 24 (58.5%) and 17 (41.5%) cases, 2 and 
3 areas were drained. 
As a result, the technical and functional success rates of re-intervention 
were 82.9% (34/41) and 90.2% (37/41), respectively. In SBS group, the 
technical and functional success rates were 82.2% (23/28) and 92.3% 
(26/28), and in PSIS group, these were 84.6% (11/13) and 92.3% (12/13). 
In dranage for 2 areas group, the technical and functional success rates 
were 79.2% (19/24) and 91.7% (22/24), and in dranage for 3 areas group, 
these were 88.2% (15/17) and 94.1% (16/17). ERCP was performed in 25 
cases, EUS-BD (all EUS-HGS) in 13, and ERCP+ EUS-BD in 3 (EUS-HGS in 2, 
EUS-HDS in 1). Stent for re-intervention was used Plastic stents(PS) for 3 
cases, PS + SEMS for 2, and SEMS for 36. The median time to RBO was 109 
days. The time to RBO tended to be longer in the EUS-BD group compared 
to that of the ERCP group (116 days vs. 78 days; long-rank test, p = 0.076). 
There was no significant difference in examination time (72.2 vs. 79.4, p = 
0.52). In the ERCP group, mild acute pancreatitis was observed in 3 cases 
(12%). In the EUS-BD group, the stent straying into the gastric wall was 
observed in 1 patient (postoperative 59 days), intraabdominal abscess (CT-
CAE v5.0 grade 3) in 1, and hemorrhage from the puncture site (CTCAE 
v5.0 grade 2) in 1.
conclusion: When considering reintervention for MHBO, EUS-BD has a 
long patent period and can be used as a new reintervention method.
disclosure: Nothing to disclose 
P0284 endOscOPIc TreaTMenT Of acuTe chOLecysTITIs In 
POOr surgIcaL candIdaTes Is cOsT-effecTIve
Corral J.E.1, Das A.2, Kroner P.T.3, Gomez V.3, Wallace M.B.3
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States, 2Arizona Center of Digestive Health, Gilbert, United States, 3Mayo 
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contact e-Mail address: corral.juan@mayo.edu
Introduction: Endoscopic gallbladder drainage is an alternative to percu-
taneous gallbladder drainage (PGBD) to treat acute cholecystitis in poor 
surgical candidates. Treatment is achieved through retrograde transpap-
illary gallbladder drainage (ERC-GBD) or endosonographic gallbladder 
drainage (EUS-GBD), and offers similar success rates with less adverse 
events. No cost-effectiveness analysis has compared these three strategies.
aims & Methods: We aim to compare the clinical and cost determinants 
of three treatment alternatives for acute cholecystitis in subjects who were 
deemed poor surgical candidates for cholecystectomy.
An early complication was evident in 16 (16.8%) of the cases. The most 
common adverse event was bleeding (n=5, 5.2%) followed by obstruction 
of the stent causing inflammatory reaction (n=4, 4.2%), perforation (n=3, 
3.1%) and migration necessitating stent replacement (n=3, 3.1%). More 
complications were noted in the LAMS group (n=14, 18.7%) compared to 
DPTS group (n=2, 10%) but this difference did not reach statistical signifi-
cance (p=0.51). PFC type was also not related to the rate of early complica-
tions [9/62, 14.5% vs. 7/33, 21.2% for PC and WON, respectively (p=0.41)]. 
10/16 adverse events were handled conservative while 6 patients received 
further intervention to treat the adverse event. All 5 bleeding episodes 
were recorded in the LAMS group with 4 patients undergoing emboli-
zation. All but one patients recovered completely. The mean duration of 
drainage was 61.1±67 days, but was significantly longer for the DPTS group 
compared to that of LAMS [98.5±47.7 vs. 54±68.2; p=0.007, respectively]. In 
LAMS group, stent removal was intended in all cases while in the DPPS 
group 4 cases received indwelling stent placement. On stent removal 9 
(11.8%) complications were recorded in the LAMS group compared to none 
in the DPPS. Buried stent syndrome (n=6, 7.9%) was the most common 
complication on stent removal followed by bleeding (n=3, 3.9%). PFC type 
did not affect the complication rate on removal.
conclusion: EUS-guided drainage of PFCs using LAMS or DPPS is associ-
ated with high percentages of technical and clinical success. Early adverse 
events are similar between the two types of drainage and not affected by 
the type of collection. Drainage using LAMS is of shorter duration, but 
severe complications occur more frequently on stent removal, regardless 
of the type of PFC.
disclosure: Nothing to disclose 
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Introduction: Inoperable biliary cancer with hilar biliary stenosis has a 
poor prognosis and requires multiple drainage of complicated stenoses. 
Radiofrequency ablation (RFA) for the bile duct was recently reported to 
be effective in ensuring the long-term stent patency and affording a good 
prognosis. Many reports on biliary RFA have been retrospective studies of 
distal biliary obstruction including a variety of etiologies, such as a pan-
creatic cancer, biliary cancer, and metastasis of the lymph node and other 
organ cancers.
aims & Methods: We prospectively evaluated the feasibility and short-term 
outcomes of endoscopic biliary RFA for malignant hilar biliary obstruction 
(MHBO) caused by biliary cancer. The primary outcomes of the study were 
the technical success of RFA with the bilateral placement of a self-expand-
able metallic stent (SEMS) and complications within 30 days after the pro-
cedures. Bilateral biliary stenting for MHBO was performed by the partial 
stent-in-stent method using a thin delivery system of the SEMS after RFA.
results: Twelve patients (10 men; 70.8 ± 6.0 years of age) were enrolled 
in the study between May 2017 and March 2019. Hilar bile duct cancer was 
diagnosed in 11 patients (92%), while 1 had gallbladder cancer (8%). The 
Bismuth classification of biliary stenosis was III and IV in 7 (58%) and 
5 (42%). The mean stricture length was 39.1 ± 14.6 mm. Before RFA, all 
patients underwent biliary drainage once in 2 patients (17%), twice in 9 
patients (75%), and 3 times in 1 patient (8%). The technical success rate for 
RFA with SEMS placement was 100%. The mean number of ablations was 
5.4 ± 1.1. Post-procedural adverse events occurred in 4 patients (33%; 3 
with fever and 1 with cholecystitis). The patients with a fever improved im-
mediately with conservative treatment. The case of cholecystitis required 
percutaneous aspiration of the gallbladder three days after the procedure 
and was suspected to have been influenced by the SEMS placement, as the 
stent was placed across the cystic duct without ablation of the duct.
conclusion: The short-term outcomes of RFA for MHBO were suitable. Fur-
ther preoperative studies are needed to confirm the efficacy of RFA with 
bilateral placement of a SEMS for MHBO.
disclosure: Nothing to disclose 
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A cost-effectiveness analysis compared three strategies: PGBD, ERC-GBD 
and EUS-GBD. A decision tree was created comparing clinical outcomes 
during the first three months after hospitalization. All subjects included 
were considered poor surgical candidates based on comorbidities, and 
subsequently managed with bowel rest, intravenous fluids and antibiotics 
without improvement. 
Effectiveness was a composite of length of hospitalization plus additional 
hospital care due to adverse events or readmissions (measured in hospital 
days). Costs of care were obtained from the National Inpatient Sample 
and published literature. Outcomes estimates (e.g. procedure complica-
tions and readmissions) were obtained from published literature. Primary 
analysis was performed from the health care perspective. 
Cost-effectiveness was compared to the national average cost of one hos-
pital bed per diem as reference. One-way sensitivity analyses and Monte 
Carlo simulations were generated to evaluate effect modifying variables.
results: Analysis of a hypothetical cohort of patients considered poor can-
didates for cholecystectomy showed that the cost effectiveness of endo-
scopic therapies was superior to PGBD. Compared to PGBD, ERC-GBD was 
a cost-saving strategy and EUS-GBD was cost effective, requiring $1,312 per 
hospitalization day averted. Both interventions were acceptable under the 
cost of one-hospital-bed per diem ($2,338 national average). Compared to 
ERC-GBD, EUS-GBD required spending $8,950 more per hospitalization 
day averted. 
Sensitivity analyses showed that our model was notably affected by LAMS 
price, length of stay for patients managed conservatively, and length of 
stay for patients requiring laparoscopic cholecystectomy. Cost effectiveness 
was minimally affected by variations in technical success rates of endo-
scopic procedures. One-way sensitivity analysis showed that a decrease 
of LAMS price (to $780) could potentially make EUS-GBD the dominant 
strategy. 
The Monte Carlo simulation included a variable range of therapeutic suc-
cess rates. ERC-GBD was cost effective in the majority of simulation trials, 
and was under the cost of one hospitalization day. ERC-GBD ceased being 
cost effective when willingness to pay for a new intervention was greater 
than $10,000. ERC-GBD remained more cost effective than EUS-GBD in the 
Monte Carlo simulation.
Analysis from a societal perspective added $6,264 for PGBD, $4,659 for 
ERC-GBD, and $4,543 for EUS-GBD over 3 months. Loss of productivity days 
represented approximately 60% of the additional costs. Cost-effectiveness 
results did not change from the primary analysis; EUS-GBD remained cost 
effective, with $762 per hospital day averted compared to PGBD.
conclusion: Endoscopic treatment for acute cholecystitis is cost-effective 
compared to PGBD, favoring ERC-GBD over EUS-GBD. Further efforts are 
needed to make endoscopic treatments available in more medical centers, 
reduce equipment costs and shorten inpatient care.
disclosure: Nothing to disclose 
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Emara E.1,2, Elhawash E.2,3, Aboelezz M.4, Mansour H.4, Hegab S.4, 
Nour Eldin N.E.2, Naguib N.2, Hegab S.3, Abdel-Kerim A.3, Vogl T.2
1Kafrelsheikh University, Gastrointestinal Radiology, Kafr El-Sheikh, Egypt, 
2Frankfurt University Hospital, Diagnostic and Interventional Radiology, 
Frankfurt, Germany, 3Alexandria University, Diagnostic and Interventional 
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Introduction: Image-guided percutaneous thermal ablation can be used 
for treatment of non-operable primary and metastatic lung tumors. These 
techniques are based on heating effect on the tissue around a percutane-
ous applicator causing coagulative necrosis of the tumor cells. Microwave 
ablation (MWA) is a commonly used locoregional interventional procedure 
in treatment of pulmonary tumors with satisfactory outcome.
aims & Methods: To study the efficacy of MWA in treatment of colorectal 
pulmonary metastases. 
Patients and methods: A total of 47 patients (22 men and 25 women; mean 
[± SD] age, 63.8 ± 14.6 years; range, 30-91 years) with 68 inoperable lung 
metastases of colorectal origin (Mean tumor size15 ± 9.0 mm) were treated 
with MWA under guidance of CT-Fluoroscopy using conscious sedation ac-
cording to the guidelines from November 2008 to October 2017.
Diagnosis of lung metastases relied on chest CT with contrast (Somatom 
Sensation 64; Siemens, Erlangen, Germany with scanning parameter: 
5-mm collimation, 30 mAs, and 120 kVand 5-mm section thickness) and 
lung biopsy. 
Follow-up post ablation by chest CT was done after 24 hours, three months, 
six months, one year and every 6 months onwards to determine treatment 
response. Patients were either adequately ablated (no residual tumor ac-
tivity) or had local progression (residual tumor activity). Local progression 
was considered when the lesion became of larger size or expressed mor-
phological changes in its shape such as protrusion or, irregular, scattered, 
nodular or eccentric focus arising from the margin in addition to denovo 
lesion showing contrast uptake. Survival rates were calculated from the 
time of the first ablation session, with the use of Kaplan-Meier and log-
rank tests. Changes in the size and volume of the ablated lesions were 
measured using the Kruskal-Wallis method.
results: Forty four lesions (64.7%) showed complete response to treatment 
and 24 lesions (35.3%) had local progression (residual activity). The me-
dian time to local tumor progression was 7.6 months. The median survival 
was 31.5 months for patient underwent MWA according to the Kaplan-
Meier test. The overall survival rate at 1, 2, and 4 years was 83.5%, 68.2%, 
and 16.5%, respectively.
The progression-free survival rate at 1, 2, 3, and 4 years was 53.9%, 28.8%, 
10.0%, and 1.0%, respectively. 
Successful tumor ablation was significantly more frequent for lesions with 
a maximal axial diameter of 3 cm or smaller than for lesions greater than 3 
cm in maximal axial diameter (P =.0001). There were no deaths during the 
procedure and the mortality rate within 6 months after ablation was 0%.
Early postablation complications included pneumothorax (10.3%), pain 
(8.8%), hydroneumothorax (5.8 %), pulmonary hemorrhage (5.8%) and 
postablation syndrome (2.9%). An intercostal chest tube was applied in 
one (14.2%) of the 7 sessions with pneumothorax. No significant long term 
complications were seen.
conclusion: Pulmonary CT-guided microwave ablation therapy for man-
agement of pulmonary metastases of colorectal origin is safe and effec-
tive minimally invasive option and can improve local tumor control and 
survival rate in patients who are not candidate for surgical resection. The 
efficacy of the ablation is determined by the size and location of the tumor 
in relation to the hilar structures.
disclosure: Nothing to disclose 
P0286 aPParenT dIffusIOn cOeffIcIenT In evaLuaTIng earLy 
TreaTMenT resPOnse afTer cT-guIded MIcrOWave aBLaTIOn 
fOr InOPeraBLe cOLOrecTaL PuLMOnary MeTasTases
Emara E.1,2, Elhawash E.2,3, Aboelezz M.4, Mansour H.4, Hegab S.4, 
Nour Eldin N.E.2, Naguib N.2, Hegab S.3, Abdel-Kerim A.3, Vogl T.2
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Frankfurt, Germany, 3Alexandria University, Diagnostic and Inteventional 
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Introduction: Microwave ablation (MWA) is a commonly used locoregional 
thermal ablation technique in treatment of primary and secondary pulmo-
nary tumors. There is growing evidence that apparent diffusion coefficient 
(ADC) value can be used in evaluating early MWA therapeutic efficacy in 
treatment of pulmonary tumors and thus represent a reliable predictor of 
tumor recurrence after treatment.
aims & Methods: To determine the early treatment response of lung MWA 
in patients with colorectal pulmonary metastases using ADC value. 
Patients and methods: A total of 47 patients (22 men and 25 women; mean 
[± SD] age, 63.8 ± 14.6 years; range, 30-91 years) with 68 lung lesions 
of colorectal origin were retrospectively included, and were treated with 
MWA according to the guidelines during the period from November 2008 
to October 2017. 
All lesions were evaluated by diffusion weighted imaging (DWI) and ADC 
value measurement before and 24 hours after MWA. DWI was obtained us-
ing axial a single-shot echoplanar imaging with two b-values (50,400, 800 
mm2/s) using 3 tesla MRI machine. Quantitative ADC maps were calculated 
using commercially available software and an imaging workstation. 
Diagnosis of lung tumors relied on chest CT and/or MRI with contrast. Fol-
low-up post ablation by chest CT and/or MRI with ADC value measurement 
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up using contrast enhanced MRI to evaluate local tumor control based on 
modified Response Evaluation Criteria for Solid Tumors (mRECIST) and the 
survival was evaluated using Kaplan-Meier method.
results: The mean and median survival was 42.5 and 28 months (CI: 27.3-
57.6 and 15.3-40.7 respectively). The initial local tumor response follow-
ing 3 TACE was stable (10%), partial response (80%), progressive (10%) 
and complete remission (0%) and final effect was 13.3%, 16.7%, 63.3% 
and 6.7% respectively. Local lesion response following thermal ablation 
was complete resolution of the targeted lesion in 47/73 lesions (64.4%) 
and incomplete response at the rest. 6.2% (2/30) patients developed local 
complication following thermal ablation.
Significant correlation has been found between the size of the targeted 
lesion and the response with better results at diameter ranging from 10-
50 mm. However no significant correlation was found between the device 
type and the ablation outcome.
conclusion: Combined targeted local liver therapy has a potentiality to pro-
vide safe therapeutic option for irresectable or recurrent cholangiocarci-
noma and may affect the overall patients’ survival as well.
disclosure: Nothing to disclose 
P0288 endOvascuLar Pressure MeasureMenTs TO assess 
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PaTIenTs susPecTed Of havIng chrOnIc MesenTerIc IscheMIa
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Introduction: Chronic mesenteric ischemia (CMI) is an invalidating disease 
causing severe complaints of postprandial abdominal pain and weight 
loss. CMI is most often caused by stenosis of one or more mesenteric ar-
teries, a frequent finding in the general population with a prevalence ris-
ing to up to 67% in patients >80 years of age(1). The abundant collateral 
mesenteric circulation protects the bowel against ischemia, creating a di-
agnostic challenge since CMI only occurs when the collateral circulation is 
insufficient. Revascularization is performed after multidisciplinary group 
discussion amongst gastroenterologists, vascular surgeons and interven-
tional radiologists of the patient’s history, radiological imaging and result 
of a functional test. Treatment decisions are especially challenging in pa-
tients with a single vessel mesenteric stenosis, since 27% does not experi-
ence an improvement of symptoms after successful revascularization(2). 
An assessment of hemodynamic significance of a stenosis to determine 
clinical relevance and support treatment decision could be of great value 
in these patients. Endovascular pressure measurements to assess the se-
verity and clinical relevance of a stenosis have been validated in coronary 
and renal arteries and are widely used to guide treatment decision in clini-
cal practice(3,4). No conclusive data on clinical applicability of pressure 
measurements in the mesenteric arteries exist.
aims & Methods: The aim of this single center, retrospective cohort study 
was to identify clinically significant mesenteric stenosis by correlating 
mesenteric pressure measurements with clinical success after stenting of 
the celiac artery (CA) or superior mesenteric artery (SMA). All consecu-
tive patients planned for endovascular mesenteric artery treatment with 
pressure measurements between April 2015 and May 2017 were included. 
Pressure measurements were performed before and after intra-arterial 
administration of a vasodilator (nitroglycerin). For both series of mea-
surements the pressure gradient over the stenosis and the pressure distal 
to the stenosis divided by the aortic pressure (Pd/Pa) were calculated. 
Clinical success was defined as an improvement of symptoms and or 
weight gain.
results: In total 41 endovascular mesenteric procedures with pressure 
measurements were performed in 37 patients (mean age 67.7±10.8 years, 
62% female). The measured Pd/Pa without vasodilator in patients with an 
isolated CA or SMA stenosis or an inferior mesenteric artery and either CA 
or SMA stenosis(N=24), significantly differed between patients with clini-
cal success after stenting (N=18), median 0.885 (IQR 0.735-0.904) versus 
patients without clinical success 0.923 (0.897-0.958), p=0.040. After ad-
ministration of a vasodilator differences increased further with a Pd/Pa 
of 0.703 (0.598-0.769) in patients with clinical success and 0.827 (0.818-
was done after 24 hours, three, six months, one year and every 6 months 
onwards to determine responsive cases (no residual tumoral activity) and 
local progression cases with residual tumor activity. Local progression was 
considered when the lesion became of larger size or expressed morpho-
logical changes in its shape such as protrusion or, irregular, scattered, 
nodular or eccentric focus arising from the margin in addition to denovo 
lesion showing contrast uptake. Immediate changes in ADC values were 
compared to the net response based on CT and/or MRI follow-up.
results: Forty four lesions (64.7%) responded to ablation and twenty four 
lesions (35.3%) had shown local progression (residual tumor activity). ADC 
values were significantly higher in lesions that responded to MWA than in 
non-responding lesions. 
The mean ADC value before treatment was 0.8 ± 0.2 × 10−3 mm2/s (mean 
± SD), while after treatment it was 1.7 ± 0.3× 10−3 mm2/s with a statistically 
significant difference (P = 0.001) for the responsive group .
The mean ADC of the local progression group before treatment was 0.7 ± 
0.2×10̵³mm²/s , and increased after treatment to reach 1.4 ± 0.3×10̵³mm²/s 
with a statistically significant difference (P = 0.001).
The mean ADC value before treatment didn’t show significant difference 
between responding (0.8 ± 0.2 × 10−3 mm2/s) and local progression 
group(0.7 ± 0.2×10̵³mm²/s; P = 0.857). 
There is statically significant difference in mean ADC value between re-
sponsive group (was 1.7 ± 0.3× 10−3 mm2/s) and local progression group 
(1.4 ± 0.3×10̵³mm²/s) after ablation (P =0.001)
A cut-off ADC value (1.42) has been suggested as a reference point to pre-
dict the response after ablation with 66.67 % Sensitivity, 84.21% Specificity, 
66.7% PPV& 84.2% NPV.
conclusion: ADC value calculated from DWI performed 24 hours post 
treatment is a good quantitative measurement for early prediction of the 
therapeutic efficacy of MWA in treatment of patients with inoperable lung 
metastases of colorectal origin and can be used as good alternative to CT 
imaging in early immediate post ablation follow-up before morphological 
changes in tumor become detectable on conventional CT and/or MRI.
disclosure: Nothing to disclose 
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Introduction: Intrahepatic cholangiocarcinoma (ICC) constitutes around 
30% of all hepatic malignant neoplasms and considered the second most 
common primary malignant hepatic tumor following hepatocellular carci-
noma. ICC is often diagnosed at an advanced stage; associated with poor 
prognostic outcomes and 5-year survival less than 5%.
conventional transarterial chemoembolization (TACE) have been recently 
applied in cases of ICC. Microwave and radiofrequency are minimal inva-
sive procedures have also been proved to be effective safe therapeutic mo-
dalities in case of various hepatic tumors including HCC and liver deposits 
aiming to decrease tumor burden by inducing local coagulative necrosis; 
still their therapeutic value in case of ICC not clearly defined.In the last 10 
years, we implemented TACE, local thermal ablative methods, and com-
bined treatment protocols as minimal invasive palliative procedures aim-
ing to limit the disease process and improve survival rates.
aims & Methods: To assess the combined role of local thermal ablation 
and transarterial-chemoembolization in cases of irresectable intrahepatic 
choloangiocarcinoma. 
Methods & Materials: Retrospective analysis for 32 patients with CCC from 
Januar 2007 till December 2017, in which 11 males (34.4 %) and 21 (65.6 %) 
females with mean age 59.2 years (25-86) with either irresectable (22/32, 
68.8%) or recurrent lesions (10/32, 31.3%) managed by at least three 
sessions of TACE (3-26, mean 9) with local thermal ablation for overall 
73 lesions with mean size 21 mm (10-74) with either laser (9/73, 12.3%), 
radiofrequency (8/73, 11%) or microwave (56/73, 76.7%) devices. Follow 
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0.906) in patients without, p=0.009. The pressure gradient showed similar 
differences, without vasodilator 17.5 (11.0-29.0) vs. 8.0 (4.0-15.0), p=0.047 
and after vasodilator 36.0 (21.0-40.0) vs. 20.0 (9.0-21.0), p=0.041. A Pd/Pa 
after vasodilator with a cut-off ≤0.8 proved to be the best predictor of clini-
cal success with a sensitivity of 86% and specificity of 83% (AUC=0.869).
conclusion: Endovascular pressure measurements seem a promising tool 
to assess the clinical relevance of mesenteric artery stenoses and hence 
may be helpful in making treatment decisions. Pressure measurements in 
a larger cohort are needed to verify the results of this study.
references: 1. Mensink PB, Moons LM, Kuipers EJ. Chronic gastrointesti-
nal ischaemia: shifting paradigms. Gut. 2011;60(5):722-37. 2. van Dijk LJD, 
Moons LMG, van Noord D, Moelker A, Verhagen HJM, Bruno MJ, et al. 
Persistent symptom relief after revascularization in patients with single-
artery chronic mesenteric ischemia. J Vasc Surg. 2018. 3. Aboyans V, Ricco 
JB, Bartelink MEL, Bjorck M, Brodmann M, Cohnert T, et al. Editor’s Choice 
- 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arte-
rial Diseases, in collaboration with the European Society for Vascular Sur-
gery (ESVS). Eur J Vasc Endovasc Surg. 2018;55(3):305-68. 4. Neumann FJ, 
Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 
ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention. 
2019;14(14):1435-534.
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Introduction: Irreversible Electroporation (IRE) of the pancreas is an in-
creasingly used method for unresectable pancreatic cancer that can be 
used in cytoreduction followed by surgical treatment and shows promising 
results in palliative care. 
IRE is an ablative technique where electric pulses cause damage the cell 
membrane leading to apoptosis. It is claimed that IRE is not causing ther-
mal effect comparing to radiofrequency and microwave ablation.
The early assessment of signal intensity changes after IRE could provide 
information on actual processes occurring in the ablation zone.
aims & Methods: The study aims to assess the MR (Magnetic Resonance) 
images performed before and up to 7 days after IRE to evaluate the early 
post IRE changes in signal intensities in the ablation zone with a special 
emphasis on thermal effect and vascularization in the ablated zone.
We retrospectively analyzed the MRI studies of 24 patients (10 F, 14M, aged 
35-71) with unresectable pancreatic cancer during or shortly after che-
motherapy. IRE was performed under general anesthesia percutaneously 
or during open surgery with the use of 4-6 electrodes (AngioDynamics) 
placed in pairs at a maximum distance of 20mm between each other, 90 
pulses of 90us (maximum 1500V/cm) were delivered per pair of electrodes.
The MR images were performed on 1,5T and 3T scanners one day before 
IRE procedure, on the 1st and 7th day after. The standard protocol for pan-
creas was performed including T1-weighted images (T1W), T2-weighted 
images (T2W), Diffusion Weighted Images (DWI), ADC (Apparent Diffusion 
Coefficient) maps, Dynamic Contrast Enhancement (DCE) images with sub-
traction series. The qualitative and quantitative assessment of the obtained 
images was performed.
results: The signal intensity in the ablated zone on T1 Fat Saturation (Fat-
Sat) after contrast media administration with subtraction was in the range 
0-6,25 (Mean 2,03, SD 1,83). The ADC values after IRE were significantly 
higher compared to pre IRE measurements. These trends were found like-
wise on different MR scanners (1,5, 3T).
The signs of thermal effect, e.g., areas of electrodes placement were found 
in 83,3% of patients. They were seen as small, hypointense zones close to 
electrodes on T1-weighted fat saturation contrasted enhanced images in 
the coronal plane.
conclusion: Lower (close to zero) SI values in the ablated zones on T1 FatSat 
images after contrast media aministration images with subtraction proves 
that vascular bed within the ablation zone was completely damaged. The 
growth of ADC values after IRE is the effect of cellular water displacement 
to intercellular space what is a sign of cytolysis. IRE can create a thermal 
effect on exposed tissues.
disclosure: Nothing to disclose 
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Introduction: The duodenal neuroendocrine tumors (dNETs) are arising 
from the cell of the mucosal layer and often small and confined to the 
superficial layer. Surgery and endoscopic resection are both considered 
appropriate; however, there are critical hurdles to both modalities in real 
practice. Laparoscopic surgery has a difficulty to determine precise tumor 
location, and endoscopic resection has high risks for bleeding, perfora-
tion, and incompleteness. In our study, we compared the treatment out-
comes of endoscopic full-thickness resection assisted laparoscopic surgery 
(EFTRLS).
aims & Methods: The electronic medical record database was reviewed at 
a university hospital (Yeouido St. Mary’s Hospital), Seoul, Korea. A total of 
33 patients were found to be diagnosed during the last 10 years, from June 
2008 to Dec 2018.
results: Among the 35 patients with dNETs, 12 were excluded, follow-up 
loss (3), transfer-out (2), treatment refusal (2), invisible after forceps biopsy 
(2), poorly differentiated histology (2), and the presence of metastatic le-
sion (1). Twenty-three patients who showed well-differentiated histology, 
less than 2 mitosis per 10 HPF and less than 3% of Ki-67 index, under-
went excision of tumors. Sixteen were treated with endoscopic resection, 
3 with surgery only and 4 with EFTRLS. Resection margin involvement was 
none in the EFTRLS group compare to other single modality groups (0% 
[0/4 cases] vs 19% [3/16 endoscopic resection] vs 33% [1/3 surgery only]). 
One endoscopically treated patient had a macroscopic residual tumor and 
needed additional surgery. Two patients of endoscopic resection group 
experienced perforation and underwent surgery. Tumor recurrence and 
metastasis were not reported during the study period in all patients.
conclusion: EFTRLS provides a precise and secure safety margin of tumor 
resection and abolishes the risk of uncontrolled bleeding and perforation. 
EFTRLS has the advantage in the oncological completeness and patient 
safety over either endoscopic resection alone or surgery alone.
disclosure: Nothing to disclose 
P0292 cLInIcaL vaLue Of Per-OraL endOscOPIc MyOTOMy 
(POeM) fOr achaLasIa (ac)
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Manan A.4
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of Shihezi University, Department of Surgery, Shihezi, China, 3Lanzhou 
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Life Sciences, Lanzhou, China
contact e-Mail address: rjwqrali@yahoo.com
Introduction: Achalasia (AC) is a clinically rare disease of lower esopha-
geal inflammatory changes and myenteric plexus injury has been treated 
by medication, surgical and endoscopic methods. During the pathological 
process, the lower esophageal sphincter (LES) contracts, leading to food 
retention, and esophageal peristalsis, constriction and expansion. Clinical 
symptoms include dysphagia, food reflux, nausea, vomiting, chest pain, 
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P0294 a sIngLe cenTer evaLuaTIOn On IMPLeMenTaTIOn 
Of seLecTIve PaThOLOgIc exaMInaTIOn Of The gaLLBLadder
Corten B.1, Leclercq W.K.G.1, Roumen R.M.H.1, van Zwam P.H.2, 
Slooter G.D.1
1MMC Veldhoven, Surgery, Veldhoven, Netherlands, 2PAMM, Pathology, 
Veldhoven, Netherlands
contact e-Mail address: bartcorten@gmail.com
Introduction: Historically, all gallbladders are send for histopathologic ex-
amination following cholecystectomy to exclude presence of malignancy. 
Several hospitals switched to a selective histopathologic (Sel-HP) policy 
to reduce unnecessary pathological workload. Our aim was to evaluate 
the evolution of a Sel-HP policy and determine safety and cost reduction.
aims & Methods: A single center retrospective study was conducted from 
January 2012 to December 2017 in a teaching hospital in the Netherlands. 
All gallbladders were macroscopically examined by the surgeon or resi-
dent. Consequently, they decided which cases required additional histo-
pathologic evaluation. We reviewed the number of gallbladders send for 
pathologic examination. To identify missed GBC we reviewed the Nether-
lands Comprehensive Cancer Organisation (IKNL) registry to detect GBC in 
patients of whom the gallbladder was not send for histopathology.
results: Out of the 2271 patients, 1083 (47.7%) were selected for additional 
histopathology to assess the presence of malignancy. Percentage of gall-
bladders selected for histopathologic examination decreased from 83% 
in the first year to 38% in the last year. Six (0.26%) gallbladder cancers 
(GBC) were discovered, 7 times (0.31%) a low grade dysplasia and 3 times 
(0.13%) an intestinal metaplasia of the gallbladder. During follow-up, no 
patient was found to have GBC recurrence after Sel-HP. Our policy imple-
mentation reduced medical cost and saved over €65 000.
conclusion: The strategy of a Sel-HP policy decreased the number of re-
ferred gallbladders to the department of pathology by roughly 60%, while 
no GBC cases were missed and therefore appears to be safe and leads to 
significant cost reduction.
disclosure: Nothing to disclose 
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Introduction: Pancreatoduodenectomy is a high-risk surgical procedure, 
after which one complication may provoke a sequence of adverse out-
comes. To improve quality of care after pancreatoduodenectomy, initiatives 
are required to mitigate the impact of separate complications. To allow 
prioritization of such initiatives, the aim of this study was to quantify the 
attribution of individual complications to postoperative mortality, organ 
failure, prolonged hospital stay and unplanned readmissions after pancre-
atoduodenectomy in a national cohort.
aims & Methods: Data from all consecutive patients undergoing pancre-
atoduodenectomy from January 2014 to December 2017 were extracted 
from the mandatory nationwide Dutch Pancreatic Cancer Audit. 
and severe malnutrition. The drug and surgical treatments have many 
disadvantages such as, easy-to-relapse, high cost and complications, and 
the patient’s intolerance. Contrary to the above-mentioned methods, the 
Peroral endoscopic myotomy POEM, a new endoscopic treatment of AC has 
been affirmed with the short-term efficacy. However, there are few reports 
on long-term efficacy of POEM. The study aims to evaluate the short-term, 
medium- and long-term effects of POEM analyzing the clinical data of 59 
patients with AC in the second hospital from 2012 to 2018.
aims & Methods: 
Objective: To explore the short-term and long-term clinical efficacy of per-
oral endoscopic myotomy (POEM) and its postoperative complications in 
the treatment of achalasia (AC).
Methods: The retrospective clinical study of 59 patients who underwent 
POEM was conducted from Jan. 2012-April 2018 in the Endoscopy Center of 
Lanzhou University Second Hospital. The short-term and long-term clini-
cal efficacy, complications and changes in the clinical manifestations was 
comparatively analyzed according to the Eckardt scoring system before and 
after achalasia (AC) management by POEM.
results: All the 59 patients underwent 100% successful POEM, in which the 
disorder duration ranges from 4-380 months. The follow-up times were 
6-89 months, respectively. The pre-operative and post-operative Eckardt 
score was 6.45±1.63, 0.52±0.56 (P<0.05), respectively. The patients, who 
were follow-up 12 month, mean Eckardt score was 0.61. Post-operative 
weight gain was 9.92±5.97kg). The post-operative complications were ob-
served in 5 cases (8.4%) and 1 case (1.69%) was successfully treated con-
servatively, whereas 23 cases (38.9%) presented with gastro-esophageal 
reflux.
conclusion: The short-term and long-term clinical efficacy of POEM is safe 
and effective in the treatment of achalasia (AC).
disclosure: Nothing to disclose 
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Introduction: Based on the anatomy-function-pathology (AFP) classifica-
tion, the recurrence rate of A2 and A3 hiatal hernia after laparoscopic fun-
doplication (LF) is higher than A1, a mesh is used to reinforce the esopha-
geal hiatus.
aims & Methods: The aim of this study is to report the surgical out-
comes and treatment strategies in our institution. The subjects were 
509 patients (mean age 55.2±16.6 years, 209 women) who underwent 
primary LF for hiatal hernia from January 1995 to November 2018. These 
patients were divided into the 3 groups by A factor of AFP classification 
(A1:A2:A3=285:148:76). We assessed the patients’ background, pathologi-
cal condition, surgical outcome, recurrence rate and changes in surgical 
procedure.
results: The median age (years) of the patients in each group was 
A1:A2:A3=46:63:74 and the size of the hernia increased in proportion to 
the age (p< 0.001). Female ratio was significantly higher in A3 (p< 0.001). 
Preoperative reflux esophagitis was severe in A2 (p< 0.001) and opera-
tion time (min) became longer by the hernia size (A1:A2:A3=135:165:191, p< 
0.001), but the amount of bleeding was minimum in each group (p=0.753). 
The incident rate (%) of intraoperative complications in A3 was significant-
ly higher (A1:A2:A3=9:8:23, p=0.005). The recurrence rate of hiatal hernia 
after LF was 13% (68/509), and the recurrence rate (%) was increased 
by the hernia size (A1:A2:A3=12:18:24, p=0.043). Therefore, we introduced 
reinforcement of the hiatus using mesh since February 2011 for cases with 
A2 and A3, from 75 years old and above, BMI 28 or more. After that, the 
recurrence rate of A2 markedly decreased to 3% (1/37, p=0.001), but that 
of A3 was still high (8/34=24%) and no effect was obtained by mesh re-
inforcement (p=1).
conclusion: Mesh reinforcement decreased the recurrence rate of A2 pa-
tient. Further improvement is necessary for A3 patients, and now the fixa-
tion of the anterior wall of the stomach and the abdominal wall is added.
disclosure: Nothing to disclose 
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conclusion: We found a small increased risk of per-/postoperative compli-
cations comparing out-of-hours surgery to daytime surgery. The conver-
sion rate was significantly higher in the out-of-hours group. The operative 
time was significantly lower when surgery was performed out-of-hours.
disclosure: Nothing to disclose 
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Introduction: Prolonged postoperative ileus (PPOI) represents a frequent 
complication following colorectal surgery, affecting approximately 10%-
15% of these patients(1).
aims & Methods: This systematic review and meta-analysis aimed to eval-
uate the perioperative risk factors for PPOI.
Study conducted in accordance with the PRISMA Statement. Pubmed, Em-
base, Scielo and LILACS databases were searched from inception to No-
vember 2018 for studies that evaluated primary clinical data regarding the 
analysis of risk factors for PPOI after colorectal surgery. Heterogeneity was 
assessed with the I2 measure of inconsistency. The Newcastle-Ottawa scale 
was used for bias assessment within studies, and the Grading of Recom-
mendations Assessment, Development an Evaluation (GRADE) approach 
was used for quality assessment of evidence on outcome levels. According 
to the AMSTAR 2 tool, this meta-analysis was ranked with a high method-
ological quality.
results: Fifty-six studies were included, of which forty-two were assessed 
in the meta-analysis, comprising a total of 131,034 patients that underwent 
colorectal surgery from 1997 to 2017. From these, 25838 (19.71%) devel-
oped PPOI. Significant risk factors for PPOI development were male sex (OR 
1.56;95%CI 1.25-1.94), age (MD 3.17;95%CI 1.63-4.71), cardiac comorbidities 
(OR 1.65;95%CI 1.24-2.20), previous abdominal surgery (OR 1.44; 95%CI 
1.19, 1.75) and open approach (OR 2.47;95%CI 1.77-3.44). Included studies 
evidenced a moderate heterogeneity. The quality of evidence was regarded 
as low-moderate according to the GRADE approach.
conclusion: Multiple factors as demographic characteristics, past medical 
history and type of approach can increase the risk of developing PPOI in 
colorectal surgery patients. The knowledge of these will allow a more ac-
curate assessment of PPOI risk in order to take measures to decrease its 
impact in this population.
references: 1.) Wolthuis AM, et al. Incidence of prolonged postoperative 
ileus after colorectal surgery: a systematic review and meta-analysis. 
Colorectal Dis. 2016;18(1):O1-9.
disclosure: Nothing to disclose 
P0298 The “TIMe-Of-day” effecT On 30-day MOrTaLITy fOr 
eLecTIve aBdOMInaL surgery
Lee J.1, Kim M.H.1, Kim D.-R.2, Suh B.3, Oh H.-K.1
1Seoul National University Bundang Hospital, Department of Surgery, 
Seongnam, Korea (Republic of), 2Seoul National University College 
of Medicine, Seoul, Korea (Republic of), 3Seoul National University 
Graduate School of Convergence Science and Technology, Department of 
Transdisciplinary Studies, Seoul, Korea (Republic of)
contact e-Mail address: pippi0531@naver.com
Introduction: Emphasis on systematic approaches to patient safety has led 
to many studies demonstrating worse outcomes in the absence of sup-
porting staff, especially during the night. This so called “time-of-day” ef-
fect has shown conflicting results based on the hospital setting, type of 
surgery, supporting system, or country studied.
aims & Methods: The purpose of this study was to investigate the time-
of-day effect on 30-day mortality for elective abdominal surgery patients 
in a tertiary care center. All patients receiving elective abdominal surgery 
between May 2003 and Feb. 2018 at Seoul National University Bundang 
Hospital were included in the study. Patients were evaluated by the start-
ing time of the surgery received and grouped into first- surgery and non-
first-surgery. To reduce the effects of confounding variables an inverse 
Using a modified Poisson regression model, adjusted risk ratios were 
calculated for the association of each of the individual complications (i.e. 
postoperative pancreatic fistula, postpancreatectomy hemorrhage, bile 
leakage, delayed gastric emptying, wound infection and pneumonia) with 
each of the study outcomes (i.e. in-hospital mortality, organ failure, pro-
longed hospital stay and unplanned readmission). Complications were 
defined according to the International Study Group of Pancreatic Surgery. 
Prolonged hospital stay was defined as exceeding the 75th percentile in this 
cohort (i.e. longer than 18 days). 
Risk adjusted population attributable fractions (PAF) were calculated for 
each complication-outcome pair while adjusting for patient- and treat-
ment related factors and the presence of other complications in individual 
patients. The PAF represents the percentage of an outcome that could be 
prevented in a theoretical scenario where a specific complication would 
be eliminated completely and is therefore particularly useful in prioritizing 
quality improvement initiatives.
results: Overall, 2620 patients were analyzed. A total of 1672 patients 
(63.8%) experienced complications after pancreatoduodenectomy, leading 
to an in-hospital mortality of 3.6% (95 patients), organ failure in 7.6% (198 
patients), and an unplanned readmission of 16.2% (427 patients). Post-
operative pancreatic fistula and postpancreatectomy hemorrhage had the 
greatest independent impact on both mortality and organ failure. 
Complete elimination of these complications would lead to a 25.7% [95% 
CI 13.4-37.9%] and 32.8% [95% CI 21.9-43.8%] decrease in mortality and 
a 21.8% [95% CI 12.9-30.6%] and 22.1% [95% CI 15.0-29.1%] decrease 
in organ failure, respectively. Delayed gastric emptying had the greatest 
independent impact on prolonged hospital stay (risk adjusted PAF 27.6% 
[23.5-31.8%]). 
The reasons of unplanned readmission remained largely unexplained in 
this analysis. The impact of other evaluated complications on the study 
outcomes was relatively small.
conclusion: Interventions to improve clinical outcome after pancreatic 
resection may have the greatest effect when focused on prevention and 
treatment of postoperative pancreatic fistula and postpancreatectomy 
hemorrhage, because these complications have the most impact on both 
mortality and organ failure. To reduce prolonged hospital stay, initiatives 
to decrease delayed gastric emptying should be explored.
disclosure: Nothing to disclose 
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Introduction: A way to avoid the delay of surgery for patients with acute 
cholecystitis is to perform laparoscopic cholecystectomy 24/7. Existing data 
on the safety of out-of-hours operations are conflicting and large studies 
regarding this are few.
aims & Methods: The aim of this study was to investigate if out-of-hours 
laparoscopic cholecystectomy is associated with a higher rate of complica-
tions. 
We used the Swedish Registry of Gallstone Surgery and Endoscopic 
Retrograde Cholangiopancreatography (GallRiks). Data from patients 
registered for laparoscopic cholecystectomy due to acute cholecystitis, 
between 2006-2017 was collected. Out-of-hours surgery was defined as 
starting 7 pm - 7 am on weekdays or any time during weekends (Fri-
day 7 pm - Monday 7 am). A multivariate logistic regression analysis was 
performed to assess the risk of complications, with time of procedure as 
independent variable. 
We also analyzed the rate of conversion to open surgery and rate of pro-
cedures exceeding 120 minutes. Adjustments were made for sex, age, BMI 
and ASA score.
results: Altogether 13165 procedures were included in the analysis. The 
adjusted Odds Ratio (OR) for complications, comparing the out-of-hours 
procedures compared to daytime surgery, was 1.14 (95% CI 1.01-1.27, 
p=0.03). OR for conversion to open surgery was 2.07 (1.89-2.27, p< 0.001) 
and OR for operative time exceeding 120 minutes was 0.50 (0.46-0.54, p< 
0.001).
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domonas aeruginosa isolation progressed to POPF. These results suggest 
that Pseudomonas aeruginosa is related to POPFs. The results are consis-
tent with our previous vitro research [2]. Therefore, such cases should be 
handled with extreme caution.
references: 1. Kato D, Sasaki T, Yamashita K, et al. Drain selection reduces 
pancreatic fistulae risk: a propensity-score matched study. Hepatogas-
troenterology 2015; 62: 485-492. 2. Yamashita K, Sasaki T, Itoh R, et al. 
Pancreatic fistulae secondary to trypsinogen activation by Pseudomonas 
aeruginosa infection after pancreatoduodenectomy. J Hepatobiliary Pan-
creat Sci 2015; 22: 454-462.
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Introduction: Management of anastomotic dehiscence after colorectal 
surgery is a severe complication. EVT (Endoscopic Vacuum Therapy) is a 
promising therapeutic approach, being able to reduce both morbidity and 
mortality.
aims & Methods: The primary endpoint of this series was to analyze ef-
ficacy and feasibility of EVT in the management of anastomotic leakage 
after colorectal surgery. This is a prospective single center study evaluating 
consecutive patients referred for EVT for anastomotic dehiscence. Patients 
were excluded in case of small cavity (i.e. < 1 cm) or circumferential anas-
tomotic defect. All patients were treated with the same EVT. A preliminary 
endoscopic evaluation was performed in order to define size and shape 
of dehiscence. Then, the sponge was modeled to fit the cavity and ad-
vanced through a 12 mm overtube into the dehiscence. After removal of 
the overtube, the sponge was connected to a suction bottle at a 150 mmHg 
negative vacuum. After a mean 3-days interval, the sponge was removed 
and replaced until healing process was achieved (i.e cavity < 1 cm covered 
by granulating tissue). In order to maintain the healing process, further 
endoscopic curettages were performed until full resolution of the cavity 
(disappearance of anastomotic leakage at endoscopy). Treatment failure 
was defined as persistence of cavity during follow up and/or no sign of 
tissue granulation and/or infection signs. Procedures were performed un-
der conscious sedation, according to our internal safety protocol and ASA 
score. All patients signed the informed consent.
results: 14 patients with low colorectal anastomosis dehiscence were eval-
uated between October 2017 and April 2019: 2 were excluded (< 1 cm de-
fect) and treated with pig tail drainage. 12 patients (M=11; F=1) (median age 
of 70 y.o. - R 40-86) were included. Indications for EVT were Hartmann’s 
stump insufficiency (n=6), anastomotic leakage after Laparoscopic Total 
Mesorectal Excision (Lap-TME) (n=3) and anastomotic dehiscence after 
Trans-anal Total Mesorectal Excision (TaTME) (n=3). A total of 169 sponges 
were placed in 12 patients with a median number of 12,5 (R 4-31) per pa-
tient. Overall, full resolution was achieved in 6 patients in a median time of 
97 days (range, 15-160). 4 patients had an initial healing process followed 
by a subsequent deterioration requiring EVT reinsertion: 1 patient finally 
had a full resolution of the cavity, a treatment failure was observed in 1, 
while the remaining 2 patients died during EVT for neoplastic progression 
(n=1) and septic complications (n=1). The remaining 2 patients had a treat-
ment failure. No EVT-related complications were observed.
conclusion: EVT seems to be a feasible and safe treatment with a high 
success rate in patients with large colorectal anastomotic dehiscence. It 
represents a minimally invasive alternative to surgical re-treatment.
disclosure: Nothing to disclose 
probability treatment weighting (IPTW) propensity score analysis was 
done utilizing 51 variables. These variables included baseline character-
istics (age, BMI, ASA class, residential and education status, alcohol and 
smoking status), baseline vital signs and lab results (blood pressure, pulse 
rate, body temperature, blood cell count, liver function tests, electrolyte 
tests), surgery type (minimal invasive surgery, cancer vs. non-cancer op-
eration, anesthesia type), whether the patient underwent post-operative 
ICU care, and operation year. The primary outcome was 30-day mortality.
results: Out of a total of 66,606 patients receiving abdominal surgery, 
58,649 (88.1%) were elective procedures. There was a total of 110 (0.19%) 
30-day mortalities (first-surgery: 20/15,285, 0.13%; non-first-surgery: 
90/43,364, 0.21%). There were more cancer surgeries in the first-surgery 
group, and the patients were of older age and higher ASA class. The two 
groups were well rounded in the IPTW adjusted population. Undergoing 
first-surgery was found to be protective against 30-day mortality (Rela-
tive risk (first vs. non-first) = 0.58 95%CI[0.35-0.96], P = 0.033). In the 
numbers-needed-to-treat analysis, the calculated absolute difference was 
0.088% and translated to 1 additional mortality for every 1,142 patients 
treated.
conclusion: Receiving the first surgery may be protective for 30-day mor-
tality in elective abdominal surgeries. Further large-scale population stud-
ies are needed to evaluate these findings.
disclosure: Nothing to disclose 
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Introduction: Pancreatoduodenectomy (PD) is one of the most technically 
demanding operations, and thus, a challenge for surgeons. Postoperative 
pancreatic fistula (POPF) is the most severe postoperative complication of 
pancreatic surgery, and is recorded in 6-16% of patients. Some studies 
have shown that bacterial contamination in abdominal discharge is as-
sociated with the development of pancreatic fistula after PD. Moreover, 
we previously found that retrograde infections can be prevented and the 
incidence and severity of pancreatic fistulae reduced by using a closed 
drainage system following PD [1]. In another study, we showed that infec-
tion with Pseudomonas aeruginosa during the perioperative period in PD 
activates pancreatic juice secretion and induces the progression of pancre-
atic fistulae to higher grade fistulae [2]. However, thus far, the clinical rela-
tionship between POPF and the bacterial strain involved remains unclear. 
Therefore, this study was performed to assess the relationship between 
POPF following PD and the bacterial strain involved in a clinical setting.
aims & Methods: The data for 82 consecutive patients who had undergone 
PD at Fukuoka University Hospital between January 2009 and July 2014 
were retrospectively analysed to review patient characteristics and peri-
operative and postoperative parameters. We compared the clinicopatho-
logic features between patients with bacterial contamination of drainage 
fluid and those without bacterial contamination of drainage fluid. We also 
examined the relationship between POPF and bacterial contamination of 
drainage fluid, according to bacterial strain.
results: In total, 82 patients who underwent PD were divided into 2 
groups: 57 patients to the bacterial contamination negative group and 25 
patients to the bacterial contamination positive group. The incidence of 
preoperative cholangitis was significantly higher in the bacterial contami-
nation positive group (p=0.014). The incidence of Grade B/C POPF was sig-
nificantly higher in the bacterial contamination positive group than in the 
bacterial contamination negative group (44.0% vs. 0.0%; p< 0.001). Soft 
gland texture and bacterial contamination of intra-abdominal discharge 
were found to be risk factors for POPF (odds ratio: 9.00; odds ratio: 43.94, 
respectively). The incidence of Grade B/C POPF was significantly higher in 
patients harbouring Pseudomonas aeruginosa than in patients harbouring 
bacteria other than Pseudomonas aeruginosa (p=0.005).
conclusion: Our findings suggest that bacterial contamination of intra-
abdominal discharge plays an important role in the risk for the develop-
ment of pancreatic fistulae. Therefore, bacterial infection control is very 
important in the perioperative PD period. Herein, all cases involving Pseu-
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Introduction: Hybrid minimally invasive esophagectomy (HMIE) has been 
shown to reduce major postoperative complications compared with open 
esophagectomy (OE) for esophageal cancer.
aims & Methods: The aim of this study was to compare short- and long-
term health-related quality-of-life (HRQOL) following HMIE and OE within 
a randomized controlled trial. 
We performed a multicentre, open-label, randomised controlled trial at 13 
study centres between 2009 and 2012. Patients aged 18-75 years old with 
resectable cancers of the middle or lower third of the oesophagus were 
randomized to undergo either transthoracic OE or HMIE. Patients were 
followed-up every six months for three years postoperatively and global 
health assessed with EORTC-QLQC30 and esophageal symptoms assessed 
with EORTC-OES18.
results: The short-term reduction in global HRQOL at 30-days specifically 
role functioning (-33.33 (HMIE) vs. -46.3 (OE); P=0.0407) and social func-
tioning (-16.88 (HMIE) vs. -35.74 (OE); P=0.0003) was less substantial in 
the HMIE group. At two years, social functioning had improved following 
HMIE to beyond baseline (+5.37) but remained reduced in the OE group 
(-8.33) (P=0.0303). At two years, increases in pain were similarly reduced 
in the HMIE compared with the OE group (+6.94 (HMIE) vs. +14.05 (OE); 
P=0.018. However at three-years there were no statistical significant differ-
ences between treatment groups in changes from baseline HRQOL.
conclusion: HMIE reduces the short-term adverse effects upon global 
health from esophagectomy compared to an open approach, with some 
persistence of these improvements up to two years. This HRQOL effect may 
be mediated by a reduction in postoperative complications following HMIE.
disclosure: Nothing to disclose 
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P0304 fIve year audIT Of endOscOPIc suBMucOsaL 
dIssecTIOn (esd) In daILy cLInIcaL PracTIce
Pytlik D.1, Netzer P.1,2
1GastroZentrum Netzer AG, Bern, Switzerland, 2Lindenhofspital, Bern, 
Switzerland
contact e-Mail address: domip@students.unibe.ch
Introduction: ESD provides a modern endoscopic resection technique with 
a high rate of en bloc resections for lesions in the upper and lower gastro-
intestinal tract (GIT). It is recommended for high grade dysplasia (HGD) or 
superficial early cancer and other lesions with a diameter > 10 mm where 
common snare resection is difficult to perform.
aims & Methods: Our aim was to report our experience and results of 
ESD in the GIT in daily clinical practice over a five year period in a Swiss 
private hospital. Therefore we retrospectively analysed 302 ESD cases (cs) 
of 268 patients (pts) that have had at least one ESD resection. All ESD were 
performed by one experienced endoscopist (PN).
results: In the last 5 years 302 ESD in 268 pts were performed and now 
analysed (136 f, mean age 64.4). Further surgery after ESD was needed in 
27 cs (9%). Of these, 19 cs (6.3%) were ESD-related: 15 (5%) ESD were not 
P0301 endOscOPIc ManageMenT Of BarIaTrIc surgery 
cOMPLIcaTIOns: LOng-TerM resuLTs Of 830 cOnsecuTIve 
PaTIenTs In a sIngLe cenTer exPerIence
Donatelli G.1, Vergeau B.2, Cereatti F.3, Privat J.4, Tuszynski T.2, Derhy S.2, 
Dumont J.-L.2
1Hôpital Privé des Peupliers, Ramsay Générale de Santé, Unité D’ Endoscopie 
Interventionnelle, Paris, France, 2Hôpital Privé des Peupliers, Ramsay 
Générale de Santé, Paris, France, 3Ospedale di Cremona, Endoscopy Unit, 
Cremona, Italy, 4Hopital de Vichy, Endoscopy Unit, Vichy, France
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Introduction: Surgery is the gold standard treatment of morbid obesity and 
its related co-morbidities. However early or late surgical related adverse 
events(AE) occurs in 4 to 25% of patients requiring, in most cases, re-
interventions. Endoscopy is an effective treatment especially if it is per-
formed soon after occurrence of AE. However a comprehensive evalua-
tion of long-term results and need for revisional surgery after endoscopic 
management is lacking.
aims & Methods: The aim of this study is to report overall results and long-
term outcomes of patients underwent to endoscopic management for AE 
following bariatric surgery in a tertiary interventional endoscopic center. 
From January2013 to April2019, 830 consecutive patients(640F), average 
age 44(17 - 72), underwent upper GI endoscopy for suspected AE following 
obesity surgery. 
651 patients underwent Sleeve Gastrectomy, 167 gastric-by-pass(98 Roux-
en-Y and 69 Omega)(GBP)and 12 had lap-band. 168 patients presented an 
AE after revisional bariatric surgery.
358 patients were addressed for sepsis due to supposed leak(extravasation 
of medium contrast). 
226 patients presented dysphagia due to GI stenosis.
201 subjects presented fistula(abnormal communication between two re-
epithelized structures or skin due to previous placement of surgical drain-
age). 
28 patients had a perigastric intra-abdominal collection. 
12 patients had partial intragastric migration of gastric band.
5 presented weight regain following GBP for enlargement of G-J anas-
tomosis. Endoscopic management according to the different type of AE 
were one or an association of the following: endoscopic internal drain-
age, septotomy, stenting with Lumen apposed metal stent, Argon plasma 
coagulation(APC) anastomotic remodeling and trans-oral lap band abla-
tion. 
Clinical success was defined as follows: leak and fistula: no medium con-
trast extravasation, no chemistry tests alterations no need for prolonged 
antibiotics therapy. Stricture: adequate passage of medium contrast at 
swallow study or easy crossing of the stricture with a standard gastro-
scope. Lap band migration:uneventful removal. Loss of excess weight after 
G-J anastomotic remodeling with APC. Long term clinical success was con-
sidered after a minimum follow up of more than 18 months.
results: 89 patients underwent endoscopy after one week from index 
surgery(5,13 ± 1,92days), 451 between 8 and 42days(19,63 ± 9,17), 93 
patients between 43 and 91days(60,34 ± 13,07) and 197 after more than 
91days(854,93 ± 1170,37). Overall mean period was of 223days(0-2100) from 
index surgery.
70 patients(8.4%) presented normal findings at upper endoscopy.
An average of 6 endoscopic sessions(1-31) were needed to achieve AE reso-
lution in 72%(598) of patients. At long follow up (more than 18 months) 
16%(96 out 598) of patients healed were lost whereas. 8%(66) are still 
under treatment. 
Overall mortality was of 0,6%(5 out 830) whereas overall AE related to en-
doscopic treatment was of 2%(15)namely bleeding, stent migration with/
or perforation. 3 patients with perforation required emergency surgery. 
11.%(91 patients) underwent revisional surgery either for endoscopic treat-
ment failure or poor quality of life after an average of 331days(15 - 1400).
conclusion: According to this large case series endoscopy plays a pivotal 
role in the management of AE following bariatric surgery guaranteeing 
good results with low morbidity and mortality rates avoiding emergency 
surgery in 65% of cases. However several endoscopic sessions are needed. 
Long-term follow up showed that 11% of patients require, revisional sur-
gery, either in case of endoscopic clinical success.
disclosure: Nothing to disclose 
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P0305 a case-MaTched sTudy On eus-guIded draInage Of 
WaLLed-Off necrOsIs usIng 20MM vs 15MM LuMen aPPOsIng 
MeTaL sTenTs: Is BIgger BeTTer?
Ichkhanian Y.1, Parsa N.2, Vosoughi K.3, Nieto J.4, Powers P.5, 
Mitsuhashi S.6, Abdelqader A.7, Hadzinakos G.8, Anderloni A.9, 
Fugazza A.10, James T.11, Arlt A.12, Ellrichmann M.13, Aparicio Tormo J.R.14, 
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Introduction: EUS-guided placement of lumen apposing metal stents 
(LAMS) for the drainage of walled-off necrosis (WON) has gained popular-
ity due to ease of placement, wide bore and anti-migration properties. 
Traditionally, the 10mm and 15mm diameter LAMS have been used. The 
20mm diameter LAMS was recently introduced and provides 300% and 
78% greater cross-sectional area as compared to the 10mm and 15mm 
stents, respectively. Therefore, it is plausible that the 20mm stent may re-
sult in improved efficacy. Nonetheless, the larger flanges may theoreti-
cally increase risk of adverse events (AEs) (e.g. bleeding). It is currently 
unknown how the 20mm and 15mm LAMS compare in terms of efficacy 
and safety.
aims & Methods: To compare the 15 mm and 20 mm LAMS for the treat-
ment of symptomatic WON in terms of technical success, clinical success 
and AEs. This was a retrospective comparative study at 21 centers (16 US, 
4 Europe, 1 South America) between 04/14 and 10/18. Adult patients with 
WON who underwent EUS-guided drainage with 15 mm or 20 mm LAMS 
were identified. Patients with 20mm LAMS were matched to those with 
15mm LAMS by age, gender, and route of LAMS insertion (trans-gastric vs 
trans-duodenal) with a ratio of 1:2. Univariable analysis was performed 
to compare technical success, clinical success and AE rates between the 
two groups.
completed due to technical problems (missing lifting sign, difficult ana-
tomical situations, difficult pts conditions), 4 due to severe adverse event 
(SAE). 8 (2.6%) were not ESD-related: 6 due to unfavourable histology, 2 
recurrences. Major SAE occurred in 15 cs (5%) and consisted of perforation 
(9 cs, 3%), delayed bleeding (4 cs 1.3%) or infection (2 cs, 0.7%).
From the further analysis 18 (6%) cs with a not completed ESD were ex-
cluded.
Of these 18, 13 had subsequent surgical resections, 2 had a second ESD in 
the follow up and 2 snare resections were performed. 1 needed no further 
resection.
The definitive study population consisted of the remaining 284 ESD-cs in 
254 pts. The median lesion size was 3 cm (0.8-8), median intervention 
time was 14 min (5-111).
Follow-up was performed according to current guidelines and took place 
between 1 and 59 months after ESD. So far, local recurrence was found in 
11 cs (3.9%).
Esophagus: 23 ESD (8%) were performed (1x surgery due to unfavourable 
histology (histo)): 2 showed an adenocarcinoma. 9 showed Barret’s mu-
cosa, of which 6 had HGD. 2 showed superficial squamous cell carcinoma 
pT1a. In 10 other benign lesions were found.
Stomach: 76 ESD (27%) were performed (3x surgery: 1 due to unfavourable 
histo, 1 delayed perforation, 1 recurrence). 4 GIST. 11 hyperplastic polyps. 11 
ectopic pancreatic tissue (1 combined with a hamartoma). 7 inflammatory 
fibroid polyps (Vanêk’s Tumour). 3 NET. 1 solitary nodal malign lymphoma. 
39 other benign lesions.
Duodenum: 14 ESD (5%) were performed (no further surgery). 4 adenoma, 
of which 1 with HGD. 1 NET. 1 Peutz-Jeghers Polyp. 8 other benign lesions.
Colon above sigmoid: 79 ESD (28%) were performed (4x surgery: 2 due to 
delayed perforation, 1 unfavourable histo, 1 technical reasons). 1 had no 
histo (lost). 68 showed adenoma, of which 3 with HGD. 10 other benigne 
lesions.
Sigma: 23 ESD (8%) were performed (1x surgery due to delayed perfo-
ration). 1 adenocarcinoma pT1 which was successfully treated by ESD. 21 
adenoma, of which 6 with HGD. 1 retention “juvenile” polyp.
Rectum: 69 ESD (24% of all ESD) were performed, (4x surgery: 3 due to 
unfavourable histo, 1 due to recurrence). 5 showed adenocarcinoma. 1 
showed squamous cell dysplasia AIN III. 48 adenoma, of which 19 showed 
HGD. 15 other benign lesions.
conclusion: ESD is a safe technique in daily clinical practice if performed 
by experienced endoscopists. With a high rate of successfully treated HGD 
and carcinoma it appears to be a favourable choice of treatment for such 
lesions.
disclosure: Nothing to disclose 
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results: A total of 306 patients (31% F; mean age 55.1 yr) underwent EUS-
guided WON (mean size 107mm) drainage (204 with 15 mm LAMS; 102 with 
20 mm LAMS). The most common etiology of WON was gallstone pancre-
atitis (39.2%), most common indication for drainage was abdominal pain 
(54.9%), and most common location was pancreas body (53.9%). Baseline 
characteristics of patients and WON in both groups were equivalent. The 
technical success of LAMS placement of the 15mm and 20mm stents were 
similar (100%). At 6-month follow-up, the rate of clinical success with 
resolution of WON was similar in the two groups (92.1% vs 91.6%; p 0.85). 
The mean number of endoscopic necrosectomy sessions required for WON 
resolution was lower in the 20mm LAMS group compared with the 15mm 
LAMS group (0.8% vs 1.5%, p < 0.001). The need for additional interven-
tion for WON resolution, including nasocystic drainage and percutaneous 
drainage, was not significantly different (Table 1). 
A total of 31 (15.2%) AEs events developed in patients with 15mm LAMS 
and 22 (21.6%) AEs developed patients with 20mm LAMS (mild AE 2% vs 
2%, moderate AE 13.2% vs 17.6%, p=0.30, severe AE 0% vs 2%; p 0.11, 
p=0.11, 15 mm and 20 mm, respectively) and were comparable without 
significant difference (3.4% vs. 4.9% with bleeding, 1.5% vs. 1% with 
infection, 4.4% vs. 4.9% with stent occlusion; 6.4% vs. 6.9% with stent 
migration; p 0.61).
conclusion: The 20mm LAMS carries similar efficacy and safety profile to 
the 15mm stent, while requiring significantly less necrosectomy sessions. 
  Total (n=306)
20 mm LaMs 
(n=102)
15 mm LaMs 
(n=204) p-value
Technical Success, n (%) 306 (100) 102 (100) 204 (100)  
Clinical Success, n (%) 281 (91.8) 94 (92.1) 187 (91.6) 0.85
Total number of direct 
endoscopic necrostomy
1.8 (8.2) 1.3 (0.8) 2.1 (1.5) <0.001
WON recurrence requiring 
intervention, n(%)
25 (8.2) 8 (7.9) 17 (8.4) 0.22
Surgical necrostomy 1 (0.3) 1(0.9) 0 0.24
Endoscopic stent placement 18 (5.8) 6 (5.8) 12 (5.8) 0
Percutaneous catheter 
placement
6 (1.9) 1 (0.9) 5 (2.4) 0.38
Length of hospital stay (days), 
mean (SD)
12.5 (25) 15.4 (27.6) 10.9 (23.2) 0.13
Follow-up duration 5.8 2.7 (SD, 2.6) 7.3 (SD 9.5) <0.001
[Clinical Outcomes of WON drainage using 20mm LAMS vs 15mm LAMS]
disclosure: Vivek Kumbhari. MD: Consultant for Medtronic, Reshape Life-
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port from ERBE and Apollo Endosurgery Vikesh K Singh. MD MSc: Consul-
tant for Abbvie, Novo Nordisk, advisory board participant for Akcea Mouen 
A Khashab. MD: Consultant for Boston Scientific, Olympus America and 
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P0306 PancreaTIc ducT sPhIncTerOTOMy: a vaLuaBLe 
TechnIque aPPLIed TO dIffIcuLT cOMMOn BILe ducT 
cannuLaTIOn
Abasolo H.1, Rosello D.E.2, Gabriel E.1
1Cebu Doctors’ University Hospital, Department of Internal Medicine- Section 
of Gastroenterology, Cebu City, Philippines, 2Cebu Doctors’ University 
Hospital, Department of Surgery, Cebu City, Philippines
contact e-Mail address: herlyn.abasolo@gmail.com
Introduction: Pancreatic duct sphincterotomy, a technique referred also as 
transpancreatic precut sphincterotomy, has been used to access difficult 
cannulation of CBD with an immediate success rate of 60-90%1. The aim 
of this study is to present a single center’s experience of such technique 
along with its success rate, indications and identified complications.
aims & Methods: Eighty three patients who underwent endoscopic ret-
rograde cholangiopancreatography using pancreatic duct sphincterotomy 
technique to access the CBD was retrieved from the endoscopy unit’s 
patient’s record from January 2014 to December 2018. Only 72 were ret-
rospectively analyzed due to the unavailability of charts. Pancreatic duct 
sphincterotomy was used on cannulations that were deemed difficult and 
when initial standard technique failed.
results: The success rate of CBD cannulation was 96.4%, while failed ac-
cess to CBD was only 3.6%. A periampullary diverticulum, an anatomic 
obstacle to sphincterotomy, was noted among 27% of successfully can-
nulated patients. Procedure-related complications was 18% in which 
bleeding (mild: 2.7%, moderate:4.1%) and pancreatitis (mild:8.3%, mod-
erate:4.2%) were the only ones identified while 81.9% did not have any 
complications.
conclusion: Pancreatic duct sphincterotomy is an effective technique for 
difficult bile duct cannulation with minimal mild to moderate bleeding 
and pancreatitis as the only procedure-related complication.
disclosure: Nothing to disclose 
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P0307 sacraL nerve sTIMuLaTIOn InhIBITs The 
MaPk/nf-κB sIgnaLIng PaThWay and PrOMOTes 
Treg -Th1/Th17 ceLL BaLance and seLf-reneWaL 
Of enTerIc nervOus sysTeM In TnBs-Induced 
InfLaMMaTIOn In raTs
Meng Y.1,2, Liu S.3, Chen J.1
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Introduction: The IBD includes Crohn’s disease (CD) and ulcerative colitis 
(UC). The common characteristic of IBD is chronic relapsing of inflamma-
tion of the gastrointestinal tract. It is thought that IBD results from an ab-
errant and continuing immune response to the microbes in the gut, cata-
lyzed by the genetic susceptibility of the individual.2,4,6-trinitrobenzene 
sulfonic acid (TNBS) is known to induce inflammation through triggering 
the MAPK/NF-κB pathway and activation of T helper cells. Recently, sacral 
nerve stimulation (SNS) was reported to exert an anti-inflammatory effect 
on TNBS-induced colitis. 
The aim of this study was to investigate whether the SNS anti-inflamma-
tory effect was mediated via the MAPK/NF-κB signaling pathway and/or 
balancing Th1/17-Treg cells. Meanwhile, we also explored if SNS could alter 
self-renewal of neurons in myenteric plexus.
aims & Methods: Forty male Sprague-Dawley (SD) rats were implanted 
wire electrodes unilaterally at sacral nerve (S3). One week later, the rats 
were administrated with TNBS intra-rectally. Five days later, 20 of the rats 
were treated with SNS 1 hour daily for 10 days with the optimized param-
eters derived from previous studies and the other 20 rats were treated 
with sham-SNS (exactly the same setting but SNS at 0mA). Additional 20 
rats were treated with intra-rectal injection of saline, serving as controls. 
Animal behaviors and various inflammatory factors were assessed by the 
disease activity index (DAI), macroscopic score, microscopic score, fluores-
cence-activated cell sorter and western blot. Longitudinal muscle myen-
teric plexus (LMMP) was studied by immunohistochemistry.
results: 1) Compared with saline group, the TNBS treatment substantial-
ly induced inflammation, increased the percentage of Th1 cells (4.71% ± 
1.18% vs. 8.87% ± 2.32%, P=0.03), Th17 cells (8.78% ± 1.95% vs. 12.35% ± 
1.61%, P=0.02) and Treg cells (10.15% ± 3.57% vs. 15.73% ± 2.81%, P=0.04); 
it also increased p-ERK/ERK by 3.3 folds (P< 0.01) and p-JNK/JNK by 21.7 
folds (P< 0.001) and increased nuclear translation of NF-κB p65 by 4.5 
folds (P< 0.01); 2) compared to sham-SNS, SNS significantly decreased DAI 
(area under the curve: 64.3 ± 3.8 vs. 49.5 ± 3.2, P< 0.01), microscopic scores 
(4.6 ± 1.1 vs. 2.7 ± 0.8, P=0.04) and macroscopic scores (5.85 ± 0.9 vs. 2.55 ± 
0.6, P=0.03) and normalized the colon length(16.05 ± 1.6 cm vs. 14.33 ± 1.3 
cm, P< 0.05); 3) in colon tissues, compared with sham-SNS, SNS reduced 
the percentage of Th1 cells (8.87 ± 2.32% to 5.40 ± 1.39%, P=0.04) and Th17 
cells (12.35 ± 1.61% to 9.75 ± 1.17%, P=0.04) but increased Treg cells (15.73 
± 2.81% to 20.15 ± 2.24%, P=0.03); 4) SNS reduced the percentage of the 
phosphorylation of MAPKs compared to Sham-SNS (p-ERK/ERK: 22.5%, 
P=0.03; p-JNK/JNK: 25.6%, P=0.04) and prevented the nuclear transloca-
tion of NF-κB p65 by 41.7% (P=0.02, vs. sham-SNS); 5) the percentage 
of choline acetyltransferase (ChAT) neurons were decreased by TNBS but 
reversed by SNS (19.06±2.07% to 25.68±3.56%, P=0.02). The percentage of 
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P0309 free faTTy acId recePTOr TyPe 4 LIgands aLLevIaTe 
InTesTInaL InfLaMMaTIOn In MIce
Salaga M., Bartoszek A., Binienda A., Fabisiak A., Krajewska J.B., 
Niewinna K., Mosinska P., Tarasiuk A., Fichna J.
Medical University of Lodz, Dept. of Biochemistry, Lodz, Poland
contact e-Mail address: macieks100@wp.pl
Introduction: Diet is considered an important pathological trigger in in-
flammatory bowel diseases (IBD), as feeding habits can affect intestinal 
permeability and efficient clearance of bacterial antigens, consequently 
influencing the immune system. Moreover, high incidence of IBD was re-
ported in western, developed countries which is likely related to the in-
creasing environmental pollution, as well as “westernization” of the popu-
lations’ diet and lifestyle (e.g. diet rich in animal fat and protein and low 
in fiber), all of which significantly affect individuals’ immune response. 
Free Fatty Acid receptors (FFARs), expressed on the intestinal epithelial 
cells, belong to the family of luminal-facing receptors that are responsive 
to nutrients (nutrient-sensing receptors). They are possibly involved in the 
maintenance of gut function and implicated in IBD.
aims & Methods: The objective of this study was to test the anti-inflam-
matory activity of synthetic agonists of FFARs in mouse models of colitis. 
Therapeutic activity of GW9508 (FFAR1 agonist), 4-CMTB (FFAR2 agonist), 
AR420626 (FFAR3 agonist) and GSK137647 (FFAR4 agonist) was investigat-
ed in two models of semi-chronic colitis: induced by trinitrobenzenesul-
fonic acid (TNBS) mimicking Crohns disease as well as induced by DSS that 
recapitulates ulcerative colitis in humans. Body weight, macroscopic score, 
ulcer score, colon length, weight and thickness, as well as myeloperoxi-
dase (MPO) activity were recorded. Expression of FFAR1, 2, 3 and 4 in the 
colon was compared between control and colitic animals.
results: We found that expression of FFAR1 is significantly elevated while 
FFAR2 reduced in the inflamed colon. Systemic administration of GSK137647 
(FFAR4 agonist; 1 mg/kg, twice daily) attenuated both TNBS-induced and 
DSS-induced colitis in mice, as indicated by significantly reduced body 
weight loss as well as macroscopic parameters and MPO activity. The ac-
tion of GSK137647 was blocked by pretreatment with selective FFAR4 an-
tagonist AH 7614 (5 mg/kg, twice daily).
conclusion: This is the first investigation evaluating the anti-inflammatory 
activity of FFAR agonists and showing that pharmacological intervention 
targeting FFAR4, which is a sensor of medium and long chain fatty acids, 
attenuates intestinal inflammation. Further experiments evaluating the 
signaling pathways triggered by FFAR4 stimulation are pending.
disclosure: Nothing to disclose 
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Aly E.1, Moez P.2, Header D.1, Abd Elaaty K.1
1Alexandria Faculty of Medicine, Internal Medicine Department, 
Gastroenterology and Endoscopy Unit, Alexandria, Egypt, 2Alexandria 
Faculty of Medicine, Clinical Pathology Department, Alexandria, Egypt
contact e-Mail address: ezzatali64@yahoo.com
Introduction: : Inflammatory bowel disease (IBD) consists of 2 main disor-
ders: ulcerative colitis (UC) and Crohn’s disease (CD). IBD is characterized 
by chronic, uncontrolled inflammation of the intestinal mucosa. Although 
major advances have improved the understanding of the multifactorial 
influence of genetic, environmental, microbial, and inflammatory deter-
minants of IBD, the etiology of the disease still confusing. The diagnosis is 
based on a combination of disease history, colonscopy, inflammatory bio-
markers, radiological and histological evaluation.Most biomarkers used 
are not disease specificand not reliable, but reflect generalized inflam-
mation.
aims & Methods: The aim of the work is to identify serum proteomic pro-
files of IBD cases and correlating this profile with the other diagnostic 
markers and activity of the disease.We performed a study with 101serum 
samples collected from patients classified in 3 groups (31 Crohn’s, 37 ulcer-
ative colitis, 33 healthy controls) according to accredited criteria. They were 
subjected to: complete history taking, thorough clinical examination, Lab 
investigations ( routine, fecalcalprotectin, ANCA, ASCA), endoscopy (upper, 
lower), histopathology, imaging were done. plasma proteomic pattern of 
IBD patients and control subjects was determined using matrix-assisted 
nitric oxide synthase (NOS) neurons was increased by TNBS but decreased 
by SNS (17.21 ± 1.27% to 13.34 ± 1.63%, P=0.03).
conclusion: SNS is effective in inhibiting colon inflammation through the 
inhibition of the MAPK/NF-κB pathway, balancing of Th1/Th17-Treg cells, 
and also improving the LMMP neuronal self-renewal and regeneration.
disclosure: Nothing to disclose 
P0308 BerBerIne IMPrOved exPerIMenTaL chrOnIc cOLITIs 
vIa reguLaTIng InTerferOn-γ and IL-17a PrOducIng LaMIna 
PrOPrIa cd4+T ceLLs ThrOugh aMPk acTIvaTIOn
Takahara M., Takaki A., Hiraoka S., Koike K., Inokuchi T., Yasutomi E., 
Oka S., Yamasaki Y., Kinugasa H., Harada K., Okada H.
Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, Department of Gastroenterology, Okayama, Japan
contact e-Mail address: m_takahara009@yahoo.co.jp
Introduction: A herbal medicine, berberine (BBR), which is used as an 
anti-diarrhea medicine in Japan, is known as an AMPK activator to show 
various kinds of action such as diabetes control and anti-tumor response. 
Recently, BBR has been reported to elicit anti-inflammatory response of 
CD4+ T cells resulting in improvement of experimental chronic inflamma-
tory diseases such as multiple sclerosis and may be of potential therapeu-
tic utility in the treatment of immune-mediated diseases. Inflammatory 
bowel disease (IBD) is also immune-mediated diseases characterized by 
a chronic inflammation of the gastrointestinal tract. Inflammatory lamina 
propria (LP) CD4+ T cells are acknowledged as critical factors in the patho-
genesis of IBD. Some reports showed the anti-inflammatory response of 
BBR against experimental colitis models, however, detailed analysis of 
BBR against LP CD4+ T cells including anti-inflammatory mechanisms have 
not been performed.
aims & Methods: To investigate the effect of BBR against LP CD4+ T cells of 
IBD, we conducted a T cell transfer model of chronic colitis in which SCID 
mice were injected with CD4+CD45RBhigh T cells resulting in T cell mediated 
colitis. The excised colitic LP CD4+ T cells were used for in vitro experiments 
(1) and the chronic colitis model mice were used for in vivo experiments 
(2). 
(1) In in vitro experiments, we stimulated colitic LP CD4+ T cells by PMA/
Ionomycin to induce interferon (IFN)-γ and interleukin (IL)-17A produc-
tion. With this model, we investigated the effect of BBR connecting AMPK 
pathway and immune system activation. To investigate the effect of AMPK 
activation on immune system, AMPK agonist AICAR and antagonist Com-
pound C were added to the culture. 
(2) In in vivo experiments, the colitic mice were fed with BBR and subjected 
to the mechanism investigation.
results: (1) When colitic LP CD4+T cells were cultured with BBR, the fre-
quency of IFN-γ and IL-17A producing cells reduced and the activation of 
AMPK was induced by Western blotting (WB). When colitic LP CD4+T cells 
were cultured with AMPK agonist, (AICAR) or antagonist, Compound C 
(C.C), AICAR significantly suppressed and C.C significantly increased induc-
tions of IFN-γ and IL-17A producing cells frequency. WB analysis showed 
AICAR significantly activated and C.C significantly inactivated AMPK activi-
ties. Metabolic assay showed BBR suppressed oxidative phosphorylation 
(OXPHOS) and ATP production in colitic LP CD4+T cells. 
(2) The BBR fed mice showed reduced severity of colitis with significant 
reduction of IFN-γ and IL-17A producing cells frequency. This effect was 
induced by AMPK activations of colitic LP CD4+T cells.
conclusion: BBR elicited anti-inflammatory response in colitic LP CD4+T 
cells via AMPK activation possibly induced by OXPHOS inhibition. AMPK 
activation of LP CD4+T cells could be a new therapeutic target of IBD and 
BBR might be a good candidate.
disclosure: Nothing to disclose 
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laser desorption/ionization (MALDI) TOF MS analysis, all serum samples 
were subjected to solid-phase extraction (SPE). We analyzed the spectra 
obtained from all the samples using ClinProTool.
results: There was a statistical significant difference of the serum pro-
teome profiles of UC group in comparison to health volunteers, Also there 
was a statistical significant difference of the serum proteome profiles of 
crohn’s group in comparison to health volunteers, we used Support Neural 
Network (SNN), Genetic algorithms (GA) to analyse proteomic profile of 
UC and CD cases versus control cases respectively. (64, 76) signals were 
identified by the ClinProt software with a statistically different area for UC, 
Crohn’s disease respectively. There was a statistical significant difference 
between active versus inactive UC group and Crohn’s disease group.
conclusion: Advances in mass spectrometry and bioinformatics have al-
lowed capturing and selecting the signal of thousands of small, low mo-
lecular weight peptides.The pattern of these peptides holds the promise of 
distinguishing disease states and providing clinically important informa-
tion such as prognosis, response to therapy, or even targets of therapy.
disclosure: Nothing to disclose 
P0311 sT2+/IL-33 resPOnsIve ceLLs PrOMOTe TuMOrIgenesIs 
In cOLITIs-assOcIaTed cOLOrecTaL cancer
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Introduction: It is now well-established that IL-33 and its receptor, ST2, 
are important factors in the pathogenesis of IBD. Emerging evidence also 
suggests its critical role in epithelial proliferation and the potential con-
tribution to inflammation-driven tumorigenesis that can lead to colorectal 
cancer (CRC).
aims & Methods: The aim of our study was to characterize the precise con-
tribution of IL-33/ST2 axis in the azoxymethane (AOM)/dextran sodium sul-
fate (DSS) model of colitis-associated CRC. C57/BL6 wild-type (WT), IL-33 
KO, ST2 KO and CD73 KO mice were given a single dose of AOM (7.4 mg/kg) 
followed by two cycles of 3% DSS for 7d in drinking water. Disease Activity 
Index (DAI), as well as endoscopic and histological evaluation of colons 
were performed. IHC, immunofluorescence (IF) and qPCR were done on 
full-thickness colons for IL-33 and ST2 localization and identification, as 
well as mRNA expression, respectively. FACS analysis was performed on 
cell suspensions from resected, isolated polyps and qPCR for Vimentin, 
Desmin, αSMA, CD34, CD31, CD73 was completed on sorted cells in order 
to functionally characterize ST2+/IL-33 responsive cells.
results: IL-33, ST2L, and sST2 mRNA transcripts were dramatically elevated 
in AOM/DSS-treated WT mice vs. controls. IHC of treated WT mice revealed 
localization of IL-33 to the colonic epithelium and to cells within the LP 
morphologically consistent with tissue macrophages. ST2 staining was lo-
calized to the intestinal epithelium in tissues immediately adjacent to tu-
mors, while within the tumors themselves, ST2+ cells displayed a spindle/
fibroblast-like morphology with a unique distribution throughout the pol-
yps. Little to no staining for both IL-33 and ST2 was present in controls. Us-
ing IF, ST2 co-localized with αSMA in polyps; however, ST2 staining was not 
exclusive for αSMA+ cells. FACS analysis showed a distinct population of 
CD45+ hematopoietic cells consisting of CD3/CD8+ cytotoxic T cells (CTLs), 
CD19+ B-lymphocytes, CD11b+CD11c- and CD11b+CD11c+ myeloid cells. ST2 
was mainly expressed by CTLs, and CD11b+CD11c- and CD11b+CD11c+ my-
eloid cells. Non-hematopoietic cells (CD45-) also expressed ST2. At qPCR, 
CD45-ST2+ and CD45+ST2+ expressed significantly elevated levels of CD73 
vs. ST2- cells. AOM/DSS treatment in IL-33, ST2 KO and CD73KO mice re-
sulted in a significant decreased polyp number and size vs. WT, with colo-
noscopy revealing the development of protruding lesions with abnormal 
vascular patterns, suggesting pre-tumorous lesions in WT mice, while all 
KO mice showed their absence with a more impressive mucosal inflamma-
tion, likely due to reduced epithelial proliferation and repair caused by the 
deficiency of IL-33 signaling.
conclusion: Our results suggest that the IL-33/ST2 axis promotes tumori-
genesis in colitis-associated CRC through the activation of CD73.
disclosure: Nothing to disclose 
P0312 reguLaTIOn Of InTesTInaL ePITheLIaL hOMeOsTasIs 
By The IBd rIsk gene ccny
Da Silva-Heil S., Koch S., Molinas A.
Wallenberg Centre for Molecular Medicine (WCMM) and Department of 
Clinical and Experimental Medicine (IKE), Linköping University, Linköping, 
Sweden
contact e-Mail address: stephanie.da.silva@liu.se
Introduction: Inflammatory bowel diseases (IBD) are recurring inflamma-
tory disorders characterized by chronic dysregulation of the intestinal epi-
thelium. The etiology of IBD is still unknown. CCNY, encoding Cyclin Y, has 
previously been identified as a putative risk gene in Crohn’s disease and 
Ulcerative Colitis1; however, the function of CCNY in the gut is unknown. 
We have shown that Cyclin Y is a critical activator of the Wnt/beta-catenin 
signalling pathway, which controls stemness and proliferation in intestinal 
epithelia2. We thus investigated whether CCNY regulates epithelial homeo-
stasis and wound repair in the gut.
aims & Methods: To address the role of CCNY in intestinal epithelia, we 
used a RNA interference based loss-of-function approach in model cell 
lines HEK 293T, SW48 and HCT 116 cells. Wnt signalling activity was as-
sayed by a Topflash luciferase reporter assay following siRNA-mediated 
depletion of CCNY in model cell lines. In addition, we generated transgenic 
mice with deletion of Ccny specifically in intestinal epithelial cells. These 
animals were subjected to the dextran sulphate sodium (DSS) model of 
intestinal injury (acute, 5 days of DSS) and repair (recovery, 5 days of DSS 
followed by 5 days of plain drinking water), which mimics human Inflam-
matory Bowel Diseases3. In addition to the in vitro experiments, we deter-
mined daily colitis progression and epithelial homeostasis in mice using 
an established disease activity index, histopathological analyses (haema-
toxylin-eosin staining, crypt length measure) and proliferation markers. 
Animal were weighed daily.
results: In contrast to non-intestinal model epithelial cells, loss-of-func-
tion of CCNY did not reduce Wnt signalling activity in intestinal HCT116 
and SW48 cell lines. Accordingly, CCNY depletion did not impair epithelial 
proliferation or stemness in vitro. Ccny mutant mice did not present any 
changes compared to controls regarding proliferation, crypt length or his-
topathology. Moreover, markers of Wnt activity and cell proliferation were 
unchanged in Ccny mutant mice compared to their littermate controls, and 
we observed no changes in disease activity indexor weight loss of the ani-
mals during both acute intestinal inflammation or after recovery.
conclusion: Our results thus far suggest that IBD risk gene CCNY is dispens-
able for intestinal epithelial homeostasis. The apparent uncoupling of Cy-
clin Y from Wnt signalling in the gut is the subject of ongoing investigation 
in our lab. In addition, we continue to investigate the possible contribution 
of CCNY to epithelial regeneration following colitis.
references: 1 Franke A. et al., Sequence variants in IL10, ARPC2 and multi-
ple other loci contribute to ulcerative colitis susceptibility, Nat Genet. 2008 
Nov;40 (11):1319-23. doi: 10.1038/ng.221 2 Koch S. et al., Post-transcription-
al Wnt Signaling Governs Epididymal Sperm Maturation, Cell. 2015 Nov 
19;163(5):1225-1236. doi: 10.1016/j.cell.2015.10.029 3 Wirtz S. et al., Chemi-
cally induced mouse models of acute and chronic intestinal inflammation, 
Nat Protoc. 2017 Jul;12(7):1295-1309. doi: 10.1038/nprot.2017.044
disclosure: Nothing to disclose 
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inflammation of the previously normal small bowel comprising the pouch 
(pouchitis). Pouchitis may be a model for the development of intestinal 
inflammation with features resembling CD.
aims & Methods: To compare the microbiome and its functions across 
different phenotypes of IBD, faecal samples were obtained from patients 
with a pouch, diagnosed according to accepted criteria and inflammatory 
biomarkers were detected. Shotgun metagenomics was applied and mi-
crobiome data was analyzed using specifically designed bioinformatics 
pipelines. Outcomes were compared to metagenomic data from two inde-
pendent cohorts, PRISM and LifeLines DEEP-NLIBD both comprised of CD 
and UC patients and healthy-controls.
results: Samples from 78 patients with a pouch (40 normal pouch, 38 
pouchitis) were analysed and compared to data of 88 patients with CD 76 
with UC and 56 healthy controls. PCoA analysis based on bacterial species 
and enzymes profiles showed substantial overlap between patients with a 
normal pouch, pouchitis and CD. Taxonomic and functional variation cor-
related (Spearman r=0.5, P< 0.05) with inflammation (faecal calprotectin) 
and samples were stratified according to phenotype, from healthy controls 
to UC, CD, patients with a normal pouch and pouchitis (highest inflamma-
tion). Area under the curve of 0.9 (mean) was achieved for three IBD phe-
notypes classifier and was the highest for patients with a pouch. Most of 
the misclassified pouch patients’ samples were labelled as CD. Escherichia 
coli and several Streptococcus and Veillonella species were significantly 
more abundant in IBD phenotypes compared to healthy controls, while pa-
tients with a pouch, especially with pouchitis presented the highest levels 
(median relative abundance of E. coli: 13% compared to 4% in CD, 2.7% in 
UC and 0.3% in healthy, P=4x10-18). In contrast, beneficial bacteria such 
as Eubacterium rectale, Roseburia inulinivorans, Faecalibacterium praus-
nitzii, Ruminococcus bromii and Bacteroides species were depleted in pa-
tients with a pouch, especially in pouchitis (E. rectale: 1.2%, 6.9%, 5.5%, 
and 10.8%; R. bromii: 0.13%, 1.2%, 2.3% and 4.2%; F. prausnitzii: 2.7%, 
3.3%,, 7.3% and 6.5% in pouch, CD, UC, and healthy controls, respectively, 
P< 0.05). Microbial enzymes related to protection against oxidative stress: 
glutathione-disulfide reductase, peroxiredoxin and nitric-oxide dioxygen-
ase were enriched in patients with a pouch. Moreover, numerous meta-
bolic pathways were associated with IBD phenotypes. Specifically: heme 
biosynthesis with a pouch, CD and UC; NAD salvage with a pouch, aromat-
ic amino-acid biosynthesis and starch degradation with healthy controls 
(lowest in patients with a pouch).
conclusion: Major metabolic and microbial signatures common to IBD 
patients as well as several that are phenotype-specific were identified. 
Robust bacterial taxonomic and functional overlap supports resemblance 
between a pouch and CD. Oxidative stress and virulence pathways are 
associated with IBD, specifically with pouch, while beneficial metabolic 
pathways are decreased. Patients with pouchitis harbour a distinct signa-
ture characterized by intensified dysbiosis.
disclosure: Nothing to disclose 
P0315 TheraPeuTIc effecT Of auTOPhagy MOduLaTIOn In 
InTesTInaL fIBrOsIs
Cosin-Roger J.1, Ortiz-Masia D.2, Canet F.3, Calatayud S.3, Barrachina M.D.3
1Unidad Mixta Facultad de Medicina-Hospital Dr Peset, FISABIO, 
Pharmacology, Valencia, Spain, 2CIBERehd-Univ. de Valencia, Medicina, 
Valencia, Spain, 3University of Valencia, Pharmacology, Valencia, Spain
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Introduction: Intestinal fibrosis is a common complication of Crohn’s Dis-
ease (CD) patients characterized by an obstruction of the intestinal lumen 
which requires surgery. Several single nucleotide polymorphisms in au-
tophagy-related genes associated to CD have been identified. Although 
autophagy is impaired in CD patients, the relevance of autophagy in intes-
tinal fibrosis is still not well elucidated.
aims & Methods: We aim to analyze the effect of pharmacological modula-
tion of autophagy in the development of murine intestinal fibrosis. 
Murine intestinal fibrosis was induced using the heterotopic transplant 
model. Segments of 1cm colon from mice were subcutaneously transplant-
ed into the neck of a recipient mice and collected after 7 days. Recipient 
mice were treated with a daily injection of 3-MA (10mg/kg) or rapamy-
cin (1.25 mg/kg). Expression of intestinal inflammation, fibrosis and EMT 
markers were analyzed by qPCR and protein levels of autophagy mark-
ers by Western Blot. Collagen layer was evaluated by Sirius Red Stain-
ing. Intestinal resections from CD patients were obtained and expression 
P0313 nOTch sIgnaLIng rOLe In The PeneTraTIng BehavIOr 
In crOhn’s dIsease
Ortiz-Masia D.1, Cosin-Roger J.2, Coll S.3, Alos R.4, F. Navarro-Vicente F.5, 
Calatayud S.6, Barrachina M.D.6
1CIBERehd-Universitat de València, Dept. de Medicina, València, Spain, 
2Unidad Mixta Facultad de Medicina-Hospital Dr Peset, Pharmacology, 
València, Spain, 3CIBERehd-Universitat de València, Phamacology, Valencia, 
Spain, 4Hospital de Sagunto, Sagunto, Spain, 5Hospital de Manises, Manises, 
Spain, 6CIBERehd-Universitat de València, València, Spain
contact e-Mail address: jesus.cosin@uv.es
Introduction: Fibrosis and fistula development constitute the main com-
plications associated to Crohn’s disease. Notch signalling has been im-
plicated in lung, kidney, liver and cardiac fibrosis and in various disease 
conditions such as scleroderma.
aims & Methods: We aim to analyse here the pattern of NOTCH ligands, 
receptors and effectors expression in surgical resections from stenotic and 
fistulizing CD patients and to determine the potential role of these ligands 
in favouring fistula and fibrosis. CD patients (n= 52) were categorized ac-
cording to Montreal classification (age at diagnosis, location and behav-
iour). mRNA was isolated from resections of patients presenting a strictur-
ing (B2, n=26) or a penetrating (B3, n=15) behaviour or from unaffected 
mucosa of patients with colorectal cancer (control, n=15). The expression of 
Notch ligands, receptors, and effectors (HES1 and MATH1) was determined 
by RT-PCR or WB. The dates are showed as mRNA expression of NOTCH li-
gands and receptors vs. the housekeeping gene β-ACTIN in intestinal mu-
cosa and values correspond to mean ΔCT (CT target - CT housekeeping) ± 
SEM. Significant differences vs the respective Non-IBD patients are shown 
by *P< 0.05 or **P< 0.05 and vs B2 CD patients by #P< 0.05. Correlations 
between data were analysed using Pearson’s correlation coefficient (*p < 
0.05).
results: The expression of NOTCH3 and NOTCH4 receptors was significant-
ly higher in intestinal samples from B3 CD patients (14. 8±0.3**#, and 
9.6±0.9**#, respectively) than in controls (17.4±0.2, and 13.4±0.3, respec-
tively) or B2 CD patients (16.0±0.3*, and 11.5±0,3*, respectively), but only 
NOTCH3 expression was up-regulated in crypts in the penetrating group 
(Control:14.5±0.5; B2: 15.3±0.5; B3: 12.4±0.3*#). The fistulizing group pre-
sented a generalized overexpression of NOTCH ligands (JAG2, DLL3 and 
DLL4) compared with controls and among them, only DLL3 expression 
was up-regulated in the penetrating group (Control: 0.39±0.05 A.U.; B2: 
0.31±0.04 A.U.; and B3:0.81±0.18*# A.U.). Similar levels of HES1 and MATH1 
mRNA expression were detected between different groups while protein 
levels of HES1 were higher in the fistulising group than in control or ste-
notic groups (3.4±0.1 A.U*#, 2.8±0.2 A.U and 2.0±0.1 A.U, respectively).
The expression of DLL3 significantly correlated with FSP1 (r=0.77, P=0.04*), 
DESMIN (r=0.80, P=0.03*), and SNAIL1 (r=0.59, P< 0.04*), only in intesti-
nal tissue from the fistulizing CD group.
conclusion: Activation of the Notch signalling pathway is detected in 
Crohn’s disease patients with a penetrating (B3) behaviour compared with 
those with a structuring (B2) phenotype and it may be involved in fistula 
development over fibrosis.
disclosure: Nothig to disclosure 
P0314 MIcrOBIaL MeTagenOMIc sIgnaTures reveaL 
dysBIOTIc dIfferences and sIMILarITIes BeTWeen 
InfLaMMaTOry BOWeL dIseases
Dubinsky V.1, Reshef L.1, Rabinowitz K.2,3, Godny L.2,3, Yadgar K.2,3, 
Gophna U.1, Dotan I.3,4
1Tel Aviv University, School of Molecular Cell Biology and Biotechnology, Tel 
Aviv, Israel, 2Rabin Medical Center, Felsenstein Medical Research Center, 
Petah Tikva, Israel, 3Rabin Medical Center, Division of Gastroenterology, 
Petah Tikva, Israel, 4Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, 
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contact e-Mail address: dani.dubinsky@gmail.com
Introduction: The etiology of inflammatory bowel diseases (IBD) includ-
ing Crohn’s disease (CD) and ulcerative colitis (UC) involves an aberrant 
immune response towards the gut microbiome in genetically susceptible 
individuals. Approximately 25% of patients with UC may undergo total 
large bowel resection (proctocolectomy) followed by creation of a reser-
voir (“pouch”) from the normal small bowel. Most will develop de-novo 
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of p62, Col1a1, α-SMA, Snail1 and Snail2 was analyzed by qPCR. Results 
are expressed as fold induction (mean±SEM, n≥5). Statistical analysis was 
performed with one-way ANOVA followed by Newman-Keuls test. Correla-
tions were analyzed with the Spearman coefficient.
results: Intestinal grafts 7 days after surgery exhibited a reduced autophagic 
flux since higher levels of p62 and lower levels of phospho-MTOR and LC3 
were detected compared with intestinal grafts at day 0. The inhibition of 
autophagy by 3-MA and the activation of autophagy by rapamycin were 
also confirmed by WesternBlot. As shown in Table 1, grafts obtained 7 
days after surgery from 3-MA-treated mice exhibited a significant increase 
in the expression of proinflammatory, profibrotic and EMT genes and a 
significant thicker collagen layer after Sirius Red Staining. Of interest, 
grafts 7 days after transplantation obtained from rapamycin-treated mice 
showed a significant reduction in the expression of proinflammatory, 
profibrotic and EMT genes and a significant reduction in the thickness of 
the collagen layer after Sirius Red Staining. In intestinal resections from CD 
patients, the expression of p62 positively correlates with the expression of 
Col1a1 (r
Spearman
=0.6098, P=0.004), α-sma (r
Spearman
=0.5168, P=0.041), Snail1 
(r
Spearman
=0.4112, P=0.0003) and Snail2 (r
Spearman
=0.4410, P=0.0009). 
  Tnf-α IL-1β cOx-2 col1a1 col3a1 col4a1 snail1 snail2 Itgb6
Graft day 0
1.1
±0.2
1.6
±0.8
1.1
±0.2
1.2
±0.4
2.6
±1.9
1.1
±0.3
1.0
±0.1
1.0
±0.1
1.1
±0.2
Graft day 7
50.5
±7.5
243.7
±35.9
103.1
±22.3
41.3
±9.3
166.9
±61.4
2.7
±0.8
11.6
±1.5
3.7
±0.7
2.7
±0.4
Graft day 7 + 
3-MA
102.9
±22.9
425.4
±84.9
174.5
±46.2
74.2
±9.2
2005.0
±1229.0
11.7
±1.7
21.1
±4.6
7.3
±1.8
7.7
±1.9
Graft day 7 
+ Rap
24.1
±6.2
132.8
±33.5
36.2
±9.3
9.5
±1.9
40.6
±17.9
4.1
±1.1
7.5
±1.3
1.8
±0.5
1.9
±0.5
[Table 1: Expression of proinflammatory, profibrotic and EMT genes in 
intestinal grafts analyzed by qPCR.]
conclusion: Pharmacological modulation of autophagy modulates intes-
tinal inflammation and fibrosis since the inhibition of autophagy exac-
erbates intestinal inflammation and fibrosis whereas an autophagy acti-
vation reduces the intestinal fibrosis. In addition, in intestinal resections 
from CD patients the expression of autophagy markers correlates with the 
expression of pro-fibrotic and pro-EMT genes, which led us to suggest that 
pharmacological modulation of autophagy might be a new therapeutic 
option for intestinal fibrosis.
disclosure: Nothing to disclose 
P0316 TOBaccO aLkaLOId assessMenT In acuTe and 
recOvery dss-Induced cOLITIs fuLL huMan IMMune sysTeM 
hu-MOuse MOdeL
Lo Sasso G.1, Verhaeghe C.2, Sierro N.1, Martin F.1, Guedj E.1, Merg C.1, 
Kondylis A.1, Ivanov N.V.1, Tabruyn S.P.2, Peitsch M.C.1, Hoeng J.1
1PMI R&D, Philip Morris Products S.A, Neuchatel, Switzerland, 2TransCure 
bioServices, Archamps, France
contact e-Mail address: giuseppe.losasso@pmi.com
Introduction: Cigarette Smoke (CS) contains many compounds that exert 
biological effects, increasing the risk of cardiovascular and pulmonary dis-
eases as well as carcinogenesis in exposed individuals. Moreover, smok-
ing in Crohn’s Disease patients is associated with greater disease activity, 
increased requirement for immunosuppressant, and early post-operative 
recurrence. 
However, epidemiological and clinical evidence from robust case-con-
trolled studies points to an inverse association between smoking and the 
onset and development of ulcerative colitis (UC). The biological mecha-
nisms responsible of the underlined smoking effects on UC progression 
remain largely elusive. Several studies have demonstrated the anti-inflam-
matory action of cholinergic agonists, such as the main tobacco alkaloid, 
nicotine. 
However, contrasting results have been observed in clinical and non-
clinical studies addressing the role of nicotine in UC, opening new ques-
tions on the molecular mechanisms at the base of the intrinsic nicotinic 
anti-inflammatory activity and the possible involvement of other tobacco 
alkaloids in the observed reduced severity of UC. 
In the present study, we aimed to investigate the potential anti-inflam-
matory activity of nicotine and another tobacco alkaloid (PMI001) in a full 
human immune system Hu-Mouse colitis model.
aims & Methods: NOD/Shi-scid/IL-2Rγ null immunodeficient mice were 
engrafted with functional cord blood-derived human CD34+ hematopoietic 
stem cells. During the 14 weeks following cell injection, the engrafted hu-
man stem cells developed fully functional human dendritic cells, granu-
locytes, NK cells, macrophages, and monocytes as well as B and T lym-
phocytes. After complete maturation, mice were treated with nicotine or 
PMI001 for two weeks. Colitis was induced by adding 3% dextran sulfate 
sodium (DSS) over seven days, and mouse necropsy was performed after 
DSS treatment (acute model) or five days after DSS removal (recovery mod-
el). Disease-specific endpoint analysis (global clinical score, colon length, 
body weight loss, diarrhea, rectal bleeding), immune-phenotyping, colon 
histopathological assessment, and colon transcriptomics were performed.
results: Data analysis revealed that nicotine significantly reduces all the 
associated acute colitis symptoms (diarrhea, rectal bleeding, and body 
weight loss) and improves colitis-specific endpoints (colon length, global 
clinical score). Moreover, histopathological analysis confirmed a signifi-
cant reduction of colon inflammation, tissue damage, and mononuclear 
cell infiltration upon nicotine treatment. Finally, nicotine significantly im-
proved the survival of mice; no mortality was observed compared to the 
vehicle group. The tobacco alkaloid PMI001 showed a similar, although 
generally weaker, effectiveness trend. Further molecular analyses are on-
going to investigate the molecular mechanisms implicated in the disease 
progression.
conclusion: The risks of smoking far outweigh any possible benefit, thus 
smoking cessation must be considered as a first step toward well-being 
and healthy status. However, tobacco constituents, such as nicotine or oth-
er alkaloids, may exert positive effects in the context of UC, thus represent-
ing molecules to further investigate. Using a full human immune system 
mouse models, the current study enabled the investigation of possible mo-
lecular mechanisms responsible for the attenuation of UC by tobacco alka-
loids, providing therapeutic opportunities for the treatment of the various 
pathological conditions with an inflammatory component.
disclosure: The research described in this abstract was sponsored by Philip 
Morris International. 
P0317 exPerIMenTaL TnBs cOLITIs MOdeL In cynOMOLgus 
Macaques assessed LOngITudInaLLy By cOLOnOscOPy, 
hIsTOPaThOLOgy and PeT/cT: a PILOT sTudy
Pohl C.1, Mirakhur K.1, Kohnken R.1, Voorbach M.1, Reuter D.1, Guo Q.1, 
Jacobson P.1, Wurbel M.2, Lynch G.2, Finnema S.1, Luo Y.1, 
Westmoreland S.2, Slavin A.2, Makidon P.1
1AbbVie Inc., North Chicago, United States, 2AbbVie Bioresearch Center, 
Worcester, United States
contact e-Mail address: calvin.pohl@abbvie.com
Introduction: We have developed and longitudinally characterized a non-
human primate (NHP) macaque model of chemical colitis for the purpose 
of testing efficacy of mucosal healing therapies in a highly translational 
model.
aims & Methods: Disease induction and progression was assessed by clini-
cally relevant modalities, including white light colonoscopy, histopathol-
ogy, and positron emission tomography/computed tomography (PET/CT). 
Utilizing four cynomolgus macaques, colitis was initiated and maintained 
with endoscopic application of the hapten 2,4,6-trinitrobenzenesulfonic 
acid (TNBS) on Day 0 (100mg), D7 (50mg), and D14 (50mg), and muco-
sal health was assessed and scored by colonoscopy at baseline (14 days 
before D0), D7, D14, D17, D21, D28, and D48. Histopathology from colonos-
copy guided mucosal pinch biopsies was performed at baseline, D17, D28, 
and D42 and quantified using a modified Geboes score. To assess colonic 
mucosal inflammation non-invasively, we quantified maximum standard-
ized uptake value (SUV-max) signals of the radio-ligand, 18F-fluorode-
oxyglucose ([18F]FDG), a glucose metabolism marker, in two cynomolgus 
macaques at baseline, D17, D21, D28, and D42. To account for background 
signal, SUV-max values were collected from PET images that had been 
gated relative to the baseline PET image for each subject.
results: Colonoscopy revealed ulcers, mucosal friability, luminal narrow-
ing, and mucosal edema, which were significantly increased in severity 
relative to baseline (mean score=0.25) on D14 (mean score=6.6, p=0.029), 
D17 (mean score=8.3, p< 0.005) and D21 (mean score=7.3, p< 0.054); how-
ever, mucosal changes assessed by colonoscopy were not significantly 
different on D28 (mean score=5.08, p=0.174) or D42 (mean score 2.25, 
p=0.478). Histological evaluation demonstrated epithelial changes com-
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(227.6) individuals as compared to CD (181.7) and HC (205.4) (p=0.01) . Eight 
bacterial genera displayed significantly different abundances across the 
groups. CD microbiome was characterized by higher abundances of Bac-
teroides and Intestinibacter and lower abundances of Faecalibacterium and 
Odoribacter than HC and HFDR microbiomes. The microbiota composition 
of HFDR harboured specific microbial features such as higher representa-
tion of Coprococcus, Gemmiger and Clostridium IV and an almost undetect-
able presence of Haemophilus. At the species level Coprococcus catus, Co-
prococcus comes, Gemmiger formicilis, Eubacterium siraeum and Clostridium 
leptum were significantly more abundant in the microbiota of HFDR as 
compared to CD and HC. E. coli strains isolated from CD patients and HFDR 
presented higher invasion ability to intestinal epithelial cells compared to 
E. coli strains isolated from HC. AIEC strains are mostly distributed among 
B2 phylogroup. No association was found between these microbiota fea-
tures and ASCA measurements as well as fecal calprotectin levels.
conclusion: Our study depicts the presence of specific microbial features 
within the microbiota of healthy individuals with higher risk of CD on-
set. Healthy relatives of CD patients exhibited higher microbiota richness 
and higher abundances of numerous bacterial taxa than CD patients but 
also healthy controls. These specific microbial features (mostly bacteria 
known to produce short-chain fatty acids, such as butyrate or formate) may 
counterbalance potential host impairments such as genetic predisposition. 
Furthermore, healthy relatives harbour more invasive E. coli strains than 
healthy controls. Since healthy relatives microbiome differ from that of 
healthy individuals, therapeutic approaches focusing on bacteria specifi-
cally associated with healthy relatives microbiome may be more appropri-
ate to correct the microbiota dysbiosis in CD.
references: 1: Ramos G.P. and Papadakis K.A., Mayo Clinic Proceedings, 
2019.
disclosure: Nothing to disclose 
P0319 PaTIenTs WITh crOhn’s dIsease exhIBIT a 
dysreguLaTed LyMPhOcyTe resPOnse TO cOrTIcOsTerOIds: 
IMPLIcaTIOns In sTress-Induced dIsease aggravaTIOn and 
faILure Of TheraPy
Nemirovsky A.1, Elyahu Y.2, Ilan K.2, Vinogradov E.2, Sarid O.2, 
Slonim-Nevo V.2, Schwartz D.2, Odes S.3, Monsonego A.1, 
Israeli IBD Research Nucleus (IIRN)
1Ben Gurion University of the Negev, The Shraga Segal Department of 
Microbiology, Immunology and Genetics, Faculty of Health Sciences; 
Zlotowski Center for Neuroscience; Regenerative Medicine and Stem Cell 
Research Center; and The National Institute of Biotechnology in the Negev, 
Beer Sheva, Israel, 2Ben Gurion University of the Negev, Beer Sheva, Israel, 
3Ben-Gurion University of the Negev, Gastroenterology, Beer Sheva, Israel
contact e-Mail address: doronsh90@gmail.com
Introduction: Crohn’s disease (CD) is a chronic inflammatory bowel disease 
engendering both psychological and physiological stresses. Our previous 
studies demonstrated that prolonged stress and chronic inflammation 
cause dysregulation of glucocorticoid (GC) signaling in different immune 
subsets, with consequent reduced sensitivity to GCs, so-called steroid re-
sistance, and a shift towards a more aggressive immune response. The 
present study aims to identify and characterize patterns of steroid resis-
tance in adult CD patients.
aims & Methods: We analyzed leukocyte subset distribution, functionality 
and their responsiveness to GCs using peripheral blood mononuclear cells 
(PBMCs) isolated from CD patients (mean age 35 years, mild-moderate 
disease activity with a Harvey-Bradshaw Index in the range 6-15) and from 
age- and sex-matched healthy controls. PBMCs underwent stimulation 
with anti-CD3 without or with methylprednisolone (MP, 1-10,000 ng/ml) 
followed by measuring secreted levels of IL-2 (24 hours), IL-10 (48 hours), 
IFN-γ (48 hours), and IL-17 (72 hours) with ELISA. In addition, PBMCs were 
activated with PMA/ionomycin for 6 hours and analyzed for cytokine pro-
duction with flow cytometry. Finally, non-activated PBMCs were analyzed 
for lymphocyte subsets such as naïve, exhausted, regulatory (Tregs) and 
effector memory T cells.
results: MP in increasing doses caused a progressive reduction of PBMC 
cytokine production; the effect was less in CD (n=8) than in controls (n=8). 
For IL2 and IL10 the difference became statistically significant at MP 1000 
ng/ml (Table). MP in increasing doses caused a progressive reduction 
of TNFα producing cells in the CD8 population. The effect was less pro-
nounced in CD (n=4) than controls (n=4). The difference became statis-
pared to baseline (mean score=0) including ulceration, loss of goblet cells, 
and epithelial hyperplasia, which were observed on D17 (mean score=5, 
p=0.005) and D28 (mean score=2, p=0.120). Inflammatory changes includ-
ed increased numbers of neutrophils and eosinophils and increased oc-
currence of intra-epithelial leukocytes, which were observed on D17 (mean 
score=2.5, p=0.060) and D28 (mean score=2.5, p=0.041). By D42, epithelial 
and inflammatory changes had resolved. TNBS application increased [18F]
FDG, SUV-max signal on D17 by 6-fold and on D21 by 3-fold compared to 
baseline; however, SUV-max was not increased compared to baseline at 
D28 and D42.
conclusion: The pathological features and feasibility for longitudinal and 
clinically relevant assessment demonstrate the translational strength of 
this NHP, TNBS colitis model. Further, the duration of significant, quantifi-
able pathology should provide a window for the immediate evaluation of 
therapeutic interventions, targeting mucosal healing and inflammation.
disclosure: The design, study conduct, and financial support for the study 
were provided by AbbVie. AbbVie participated in the interpretation of data, 
review, and approval of the publication. Dr. Anthony Slavin was a scientist 
at AbbVie at the time of the study. All other authors are AbbVie employees. 
P0318 sPecIfIc faecaL MIcrOBIOMe feaTures In heaLThy 
IndIvIduaLs WITh hIgher rIsk Of crOhn’s dIsease OnseT
Mondot S.1, Chevarin C.2, Cornu M.3, Sarter H.4,5, Colombel J.-F.6, 
Savoye G.7, Ruemmele F.8, Mosca A.9, Ley D.10,11, Desreumaux P.3,12, 
Borderon C.13, Beaugerie L.14, Buisson A.15, Collins M.16,17, Sendid B.18, 
Barnich N.19, Lepage P.1, Gower-Rousseau C.3,4, MAGIC Study Group
1Institut National de la Recherche Agronomique (INRA), Micalis Institute, 
Jouy-en-Josas, France, 2M2isH Laboratory, Clermont-Ferrand, France, 
3Lille Inflammation Research International Center, UMR 995 Inserm, 
CHU Lille, Lille University, Lille, France, 4Lille University Hospital, Public 
Health, Epidemiology and Economic Health, Registre Epimad, Lille, France, 
5Public Health, Epidemiology, Prevention Unit, Epimad Registry, Lille 
University Hospital, Lille, France, 6Icahn School of Medicine at Mount Sinai, 
Gastroenterology, New York City, United States, 7Hopiaux de Rouen, Hépato 
Gastro Entérologie, Rouen, France, 8Universite Sorbonne, Paris-Cite Hospital, 
Paris, France, 9Assistance Publique-Hôpitaux de Paris, Hôpital Robert 
Debré, Service de Gastroentérologie Pédiatrique, INSERM et Université Paris 
Diderot, Paris, France, 10CHU, Lille University, Pediatric Gastroenterology, 
Hepatology and Nutrition, Lille, France, 11CHU, Lille University, Lille 
Inflammation Research International Center, UMR 995 Inserm, Lille, France, 
12Gastroenterology Unit, Lille University Hospital, Lille, France, 13CHU Estaing 
Clermont-Ferrand, Clermont-Ferrand, France, 14Saint-Antoine Hospital 
AHPD and Paris 6 University, Gastroenterology, Paris, France, 15CHU Estaing 
Clermont-Ferrand, Gastroenterology, Clermont-Ferrand, France, 16Bicêtre 
Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Gastroenterology, 
Le Kremlin-Bicêtre, France, 17University Paris-Saclay, Faculté de Médecine, Le 
Kremlin-Bicêtre, France, 18CHRU Lille, Microbiology, Lille, France, 19Université 
Clermont Auvergne, M2iSH, Clermont-Ferrand, France
contact e-Mail address: stanislas.mondot@inra.fr
Introduction: Crohn’s disease (CD) is a multi-factorial disorder and familial 
aggregation of CD has long been recognized. In first-degree relatives of 
patients suffering from IBD, the relative risk for disease onset can be up 
to 5-fold higher than that in unaffected families1. The interplay between 
impaired host genetics, defective immune system components and altered 
gut microbiome composition is often pointed out as the main drivers of 
CD pathogenesis.
aims & Methods: We included 112 individuals comprising adult CD patients 
in clinical remission (n=33; time to diagnosis < 2 years), their healthy first 
degree relatives (HFDR; n=46) and matched healthy controls (HC; n=33). 
Our objectives were to identify microbial features within the microbiota 
composition of HFDR that were discriminant from CD and HC and to cor-
relate them to host inflammatory markers such as faecal calprotectin. The 
faecal microbiota composition, diversity and estimated loads were as-
sessed by 16S rRNA gene sequencing and quantitative PCR. Other CD-as-
sociated biomarkers (serum IgG and IgA ASCA and faecal calprotectin) and 
Adherent-Invasive Escherichia coli (AIEC) detection in stool samples and 
their respective phylotyping/invasiveness classification) were evaluated.
results: Estimated bacterial loads were similar between the different 
groups (CD=9.8, HC=10.2, HFDR=10; log10 CFU/g). Microbial diversity was 
not lower in CD or HFDR (CD=0.91, HC=0.90 and HFDR=0.93; Simpson in-
dex). Microbiota richness (number of observed OTUs) was higher in HFDR 
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tically significant at MP 10000 and 100000 ng/ml (Table). Non-activated 
PBMCs analyzed for lymphocyte subsets such as naïve, exhausted, regula-
tory (Tregs) and effector memory T cells did not demonstrated differences 
between CD (n=4) and controls (n=4).
  fold of steriod sensitivity decrease in cd patients
  MP, ng/ml 1 10 100 1000 10000 100000
IL2 production mean (p)
1.040 
(0.63)
1.306 
(0.15)
1.587 
(0.07)
2.391 
(0.049)
2.2105 
(0.049)
 
Il1 production mean (p)
1.191 
(0.28)
1.328 
(0.19)
1.379 
(0.36)
1.462 
(0.05)
1.341 
(0.11)
 
  Fold of steroid resistance in CD patients
relative TNFα 
production by CD8
average(p)
1.129 
(0.57)
1.905 
(0.14)
1.241 
(0.41)
1.049 
(0.64)
8.445 
(0.03)
3.031 
(0.01)
[Cytokine production after MP stimulation]
conclusion: In CD patients certain immune cell subsets demonstrated a 
loss of steroid sensitivity. This may be indicative of a dysregulated hypo-
thalamus-pituitary-adrenal (HPA) axis, which phenomenon may contrib-
ute to the disease process itself and moreover augur an inadequate re-
sponse to corticosteroid therapy.
disclosure: Nothing to disclose 
P0320 acTIvaTIOn Of aryL hydrOcarBOn recePTOr 
aTTenuaTes InTesTInaL InfLaMMaTIOn By enhancIng 
Irf4 MedIaTed MacrOPhage M2 POLarIzaTIOn
Li J.1, Zhao X.2, Zhang H.2
1The First Affiliated Hospital of Nanjing Medical University, Department 
of Gastroenterology, Nanjing, China, 2First Affiliated Hospital of Nanjing 
Medical University, Department of Gastroenterology, Nanjing, China
contact e-Mail address: nylijiajia@126.com
Introduction: Inflammatory bowel diseases (IBDs) are characterized by a 
functional dysregulation of immune cells, among which macrophages play 
an indisputable role. Macrophages could undergo opposite polarization 
under different conditions thus exerting pro-/anti-inflammatory effects. 
Aryl hydrocarbon receptor (AhR), a ligand-dependent transcription fac-
tor, is implicated in intestinal inflammation by regulating both innate and 
adaptive immune response, but the relationship between AhR and macro-
phages in inflammatory bowel diseases has not been investigated.
aims & Methods: We investigated the distribution of macrophages in co-
lonic tissue of patients with active IBDs and assessed the effects of AhR 
activation in trinitrobenzenesulfonic acid (TNBS)-induced colitis in mice 
and on the polarization of bone marrow derived macrophages (BMDMs). 
Macrophage IRF4 expression was measured and IRF4 siRNA was used to 
explore the potential mechanism behind AhR mediated macrophage po-
larization.
results: Compared with normal controls, there are fewer M2 macrophages 
in colonic tissue of patients with active IBDs. Experimentally, intra-colonic 
administration of 6-formylindolo [3,2-b] carbazole (FICZ), an AhR agonist, 
protected against TNBS-induced colitis ,manifested by less frequency of 
diarrhea and bloody stool and less weight loss. This protection was as-
sociated with the increase of M2 macrophages and the release of IL-10 in 
the intestine. In vitro, FICZ enhanced the expression of M2 related hall-
marks like Ym-1, Fizz1 and CD206, and increased the production of anti-
inflammatory mediators. Furthermore, FICZ mediated M2 polarization was 
accompanied by an induction of IRF4 expression, and IRF4 silencing using 
siRNA significantly impaired M2 polarization.
conclusion: In conclusion, AhR activation reduces the severity of colitis and 
the inflammatory process via enhancing macrophage M2 polarization, and 
this effect could be mediated by the induction of IRF4 expression. These 
findings provide insight into the mechanisms of colonic inflammation and 
could lead to new therapeutic strategies for IBDs.
disclosure: Nothing to disclose 
P0321 PLasMa cOncenTraTIOn Of LIPOPrOTeIn (a) and 
ITs reLaTIOnshIP WITh InfLaMMaTIOn In PaTIenTs WITh 
InfLaMMaTOry BOWeL dIsease
Zhao X., Li J., Zhang H.
The First Affliated Hospital of Nanjing Medical University, Department of 
Gastroenterology, Nanjing, China
contact e-Mail address: zhaoxj91718@163.com
Introduction: Inflammatory bowel disease (IBD) patients have increased 
risk of cardiovascular disease (CVD). Dyslipidemia is a confirmed risk fac-
tor for CVD. The purposes of this retrospective study were to examine the 
lipid and lipoprotein profiles in patients with IBD, investigate the relation-
ship between disease severity and lipid and lipoprotein profiles, and also 
analyze influence factors.
aims & Methods: Three hundred seven consecutive Crohn’s disease (CD) 
patients and 235 consecutive ulcerative colitis (UC) patients were included 
in this retrospective study. We retrieved patients’ clinical and laboratory 
parameters from their medical records. The control group (n=167) com-
prised clinically healthy subjects from the same geographic region as the 
IBD study group. Total cholesterol (TC), triglyceride (TG), high-density li-
poprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), 
and lipoprotein (a) (Lp (a)) levels were analyzed in relation to disease ac-
tivity. Tukey’s post-hoc test, Mann-Whitney U test, and Pearson’s or Spear-
man’s coefficient were used in the statistical analyses.
results: Compared to the controls, patients with CD and UC had lower 
TC, TG, HDL-C, and LDL-C levels. This lipid pattern was more prominent 
in patients with CD than in those with UC. Furthermore, TC, HDL-C, and 
LDL-C levels were negatively associated with the Crohn’s Disease Activity 
Index (CDAI) and Mayo scores. Additionally, patients with CD had higher 
Lp (a) levels than in those with UC and the controls. Patients with active CD 
had higher Lp (a) concentrations than those with inactive CD, and the Lp 
(a) levels were positively associated with the CDAI, C-reactive protein level 
(CRP), and erythrocyte sedimentation rate (ESR).
conclusion: Lower TC, TG, HDL-C, and LDL-C levels are demonstrated in 
patients with IBD (particular CD) compared to normal controls and are 
negatively correlated with the disease activity. Conversely, higher Lp (a) 
concentrations are observed in patients with CD, and they are positively 
correlated with CDAI. Inflammation may induce dyslipidemia in IBD. Fur-
thermore, a more efficient method for diagnosing and treating dyslipid-
emia is warranted in patients with IBD.
disclosure: Nothing to disclose 
P0322 reduced cdx2 exPressIOn In ILeOcOLOnIc BIOPsIes 
frOM PaTIenTs WITh InfLaMMaTOry BOWeL dIsease
Younes M.1,2, DuPont A.2,3, Ertan A.2,3
1The University of Texas Health Science Center at Houston McGovern Medical 
School, Pathology and Laboratory Medicine, Houston, United States, 
2Memorial Hermann Hospital-TMC, Houston, United States, 3The University of 
Texas Health Science Center at Houston McGovern Medical School, Medicine 
Section of Gastroenterology, Hepatology and Nutrition, Houston, United 
States
contact e-Mail address: mamoun.younes@uth.tmc.edu
Introduction: The caudal-related homeobox transcription factor 2 (CDX2) 
plays an important role in intestinal epithelial differentiation, prolifera-
tion, migration, and adhesion. Coskun and colleagues previously reported 
that CDX2 was downregulated in ulcerative colitis, showed that TNF-are-
duces CDX2 mRNA and protein levels in cultured Caco-2 colon epithelial 
cells, in a dose-dependent manner, and this effect was significantly re-
duced by adding the anti-TNF-a drug infliximab to the culture medium 
(Biochim. Biophys. Acta. 2011;1812:283-9).
aims & Methods: The aim of this study was to determine whether CDX2 is 
reduced in Crohn’s disease (CD) and whether CDX2 levels are affected by 
anti-TNF-a treatment. 
Sections of formalin-fixed paraffin-embedded ileocolonic biopsy tissues 
from 6 biologics-naiive patients with Crohn’s disease (CD), 16 patients with 
CD treated with anti-TNF-a (CD-T), 7 biologics-naiive patients with ulcer-
ative colitis (UC), and 7 biopsies without significant distortion or active 
inflammation (controls), were stained by immunohistochemistry (IHC) for 
CDX2. The inflammation activity was scored on a scale from 0 (no activ-
ity) to 3 (erosion/ulceration) using a modified Riley Histological Activity 
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P0324 PrOTeOMIc Markers Of resPOnse TO anTI-Tnf 
drugs In crOhn’s dIsease
Medina Medina R.1, Flores E.I.2, Benitez J.M.3, Marín Pedrosa S.2, 
Salgueiro Rodriguez I.1, Ferrín Sánchez G.1, Linares Luna C.I.1, 
González Rubio S.1, Soto Escribano P.2, Gros Alcalde B.3, Moral C.4, 
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García Sánchez M.D.V.2, Aguilar Melero P.1
1IMIBIC/Hospital Universitario Reina Sofía, Córdoba, Spain, 2Reina Sofia 
University Hospital, Córdoba, Spain, 3Reina Sofia University Hospital, 
Gastroenterology, Córdoba, Spain, 4IMIBIC, Córdoba, Spain
contact e-Mail address: rmedina@soportevital.es
Introduction: 
Therapy with anti-TNF has improved notably the management of Crohn’s 
disease (CD). However, 25-40% of patients treated with these drugs lose 
response long-term. In addition, these treatments are expensive and not 
without risk of adverse events. Therefore, it is essential to identify reliable 
markers that will select those patients who can benefit of anti-TNF drugs, 
thus improving their efficacy and safety.
aims & Methods: A consecutive cohort of CD patients, who were naïve 
to anti-TNF therapy, were enrolled and followed up during 12 months. 
Demographic, analytical, nutritional and physiopathology were recorded. 
Patients were stratified according to clinical response as follows: a) Non-
primary response (NPR) at 12 weeks post-treatment; b) loss of response 
(LR) within 12 months; c) sustained clinical response (SCR). In addition, 
plasma samples were collected previously to anti-TNF treatment and fur-
ther analysed by SWATH proteomics, in order to identify potential bio-
markers of response to anti-TNF. Anova or Kruskal-Wallis tests were used 
for analysis, according to data distribution. Functional pathways of identi-
fied biomarkers was analysed by DAVID Bioinformatics Resources 6.7.
results: 54 CD patients were included. 77.3% showed a SCR. However, 
4.5% of patients had NPR and 18.2 % LR. Patients with recent diagnosis 
of CD (< 12 months) were less likely to achieve SCD. Indeed, the interval 
from diagnosis to anti-TNF therapy was shorter in patients NPR (0± 0) as 
compared with LR (9.9 ± 5.9 years) and SCR (6.32±8.0 years) (p=0.04).We 
have identified as NPR factors, the early use of antiTNF during the first 
year of diagnosis (NPR: 0±0 vs LR: 9.9±5.9 and SCR: 6.32±8.0) (p=0.043). 
Increased blood leucocytes count before treatment was also associated 
with NPR (NPR: 13.7±2.1 vs LR: 8.4±2.3 and SCR: 7.6±2.9) (p=0.018). In ad-
dition, we have identified the overweight as a factor of losing response 
during the first year of treatment (BMI: NPR: 24.5± 7.5, LR: 27.6± 4.6 vs SCR: 
23.4± 3.6) (p=0.036). As potential biomarkers of primary response we have 
identified 18 proteins upregulated, related to hemostasis and metabolism 
of carbohydrates, all of them with p≤0.009 and a fold change ≥ 2.4. 17 of 
these proteins are regulated by acetylation. 
In addition, 4 proteins were potential biomarkers of loss of response 
(p≤0.05 and fold change from 0.5 - 1.4). 2 of them related to lipids me-
tabolism.
conclusion: Early need for anti-TNF and increased blood leucocytes count, 
probably related to a more severe disease, are associated with NPR. Over-
weight is associated with secondary loss of response to anti-TNF. In addi-
tion, hemostasis, metabolism of carbohydrates and lipids may be involved 
in the response to anti-TNF in CD.
disclosure: Nothing to disclose 
P0325 The effecT Of PaI-1 On endOPLasMIc reTIcuLuM 
sTress In raTs WITh InfLaMMaTOry BOWeL dIsease
Haitao H., Wen L., Xia W.
Hangzhou First People`s Hospital, Department of Gastroenterology, 
Hangzhou, China
contact e-Mail address: hhthzcn@126.com
Introduction: Studies have shown that long-term, severe endoplasmic re-
ticulum stress (ERS) exceeds regulatory capacity of cells, and activation 
of the unfolded protein response (UPR) will cause a large number of un-
folded and misfolded proteins to deposit in the endoplasmic reticulum. 
Induction of apoptosis leads to an immune response that causes an im-
mune imbalance. Among them, cytokines TNF-α, IL-1, IL-6, IFN-γ and BIP 
play a key role in the pathogenesis of IBD. Plasminogen Activator Inhibitor 
1 (PAI-1) is an irreversible inhibitor of tissue-type Plasminogen Activator 
(tPA) and urokinase Plasminogen Activator (uPA). 
Score (HAS). The level of CDX2 expression was determined using the image 
analysis software OTMIAS; the expression levels of CDX2 are given in OT-
MIAS Units (OU). Statistical analysis was performed using Prism statistical 
analysis software.
results: There was no significant correlation between CDX2 levels and 
(HAS). Compared to the control group (mean 21.13), CDX2 expression was 
reduced in CD (mean 5.2, p = 0.0147) and in CD-T (mean 8.137, p = 0.0176). 
CDX2 expression was also reduced in UC, but this was not statistically sig-
nificant (mean 11.89, p = 0.1625). Biopsies from CD-T patients had only 
slightly higher mean CDX2 expression (8.137) compared to CD (5.2, p = 
0.4797).
conclusion: CDX2 levels in ileocolonic epithelial cells are significantly re-
duced in biopsies from patients with CD compared to controls, confirm-
ing what has been previously reported in UC. However, treatment with 
anti-TNF-adid not significantly impact the levels of CDX2 expression in CD 
suggesting that other inflammatory mediators may be involved in CDX2 
downregulation, in addition to TNF-a. Lack of correlation between CDX2 
levels and HAS suggests that CDX2 downregulation may be more related 
to the chronic inflammation than a direct response to acute inflammation.
disclosure: Mamoun Younes: President of, and owns significant shares in, 
Olive Tree Media, LLC, the maker of the quantitative image analysis soft-
ware OTMIAS used in this study. All other authors: No conflicts. 
P0323 The anTI-InfLaMMaTOry effecTs Of nIcLOsaMIde On 
cyTOkInes PrOduced By PBMcs derIved frOM IBd PaTIenTs
Shivaji U.N.1,2, Jeffery L.E.1,2, Batis N.3, Iacucci M.1,4, Ghosh S.1,4
1NIHR Birmingham Biomedical Research Centre, Birmingham, United 
Kingdom, 2Institute of Immunology and Immunotherapy, University of 
Birmingham, Birmingham, United Kingdom, 3Institute of Cancer and 
Genomic Sciences, University of Birmingham, Birmingham, United Kingdom, 
4Institute of Translational Medicine, University of Birmingham, Birmingham, 
United Kingdom
contact e-Mail address: doctoruday80@gmail.com
Introduction: Despite considerable progress in IBD therapies, at least half 
of the treated patients fail to reach remission. Monoclonal antibody thera-
pies are associated with immunogenicity. Niclosamide is a salicylide which 
has been used as an anti-helminthic drug and minimally absorbed from 
the gastrointestinal tract. It has been shown to have anti-inflammatory 
properties and is currently repurposed for use in head and neck cancer. 
We aimed to study its effects on immune cells ex vivo and potential for 
repurposing in IBD.
aims & Methods: Peripheral blood mononuclear cells (PBMCs) from the 
bloods of 6 IBD patients were cultured with or without stimulation with 
0.5µg/ml antiCD3 (clone OKT3). Niclosamide was prepared in dimethyl 
sulfoxide (DMSO) and diluted into culture medium at 0.25mM and 0.5mM. 
Effect of niclosamide upon cell survival and T cell activation was measured 
at 1 day by flow cytometry analysis of activation markers CD69, CD25 and 
CTLA-4. At six days, cells were re-stimulated with PMA and ionomycin in 
the presence of Brefeldin A and expression of cytokines IL-17A, TNFα, IFNγ 
and IL-2 measured by flow cytometry. Data was analysed by Flowjo and 
significance tested by Friedman Analysis.
results: Niclosamide was not toxic to cells at the concentrations tested 
and did not alter the frequencies of CD4+ and CD8+ T cells, CD19+ B cells 
or CD14+ monocytes in unstimulated cells. However, niclosamide reduced 
CD4 and CD8 T cell activation indicated by a significant decrease in the 
frequency of CD4+ cells expressing CTLA-4 and CD25 and CD69 and CD25 
by CD8+ cells. This resulted in a significant decrease in T cell number at six 
days (P=0.0120). Furthermore, it significantly inhibited expression of pro-
inflammatory cytokines IL-17, IFNγ, TNFα and IL-2 by CD4 and CD8+ T cells.
conclusion: Niclosamide has a strong anti-inflammatory effect on T cells 
from IBD patients with no significant cell toxicity seen at concentrations 
used. The significant reduction in cytokine levels known to be involved in 
IBD make it a potential drug that could be used in IBD.
disclosure: Nothing to disclose 
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Studies have shown that PAI-1 is involved in the inflammatory process of 
IBD [4], but the relationship between its specific gene expression and the 
involvement of related cytokines in the ERS process is still unclear.
aims & Methods: In this study, we will investigate the effect of PAI-1 gene 
on ERS in rats with inflammatory bowel disease.
12 Wistar normal rats were randomly divided into 2 groups: Control 
group(n=6) and IBD group(n=6); 12 PAI-1 knock out rats were randomly 
divided into 2 groups: Knock out PAI-1 control group(n=6) and Knockout 
PAI-1+IBD group(n=6). The model of IBD was induced by 2,4,6-trinitroben-
zene sulfonic acid (TNBS)/absolute ethanol; The pathological grade was 
evaluated using HE staining; The gene transcriptional levels of PAI-1, IL-6, 
IFN-γ, BIP were measured by Quantitative Real-time PCR (qRT-PCR); The 
protein expression levels of PAI-1, IL-6, IL-10, IFN-γ, BIP, p-IRE1α, p-JNK, 
JNK were measured by western blot.
results: 1.Pathological examinations showed severe changes of colonic tis-
sue and inflammation in IBD rats whereas relieved symptoms were found 
in PAI-1 knock out rats with IBD.
2. Compared with the control group, the transcription levels of the in-
flammation-related factors IL-6, IL-10, IFN-γ and BIP in the colon tissue 
of rats in the IBD group were significantly up-regulated (p< 0.01), and the 
transcription level of PAI-1 gene was significantly up-regulated (p< 0.01). 
Compared with the IBD group, the transcription levels of PAI-1, IL-6, IL-
10, IFN-γ and BIP genes in Knock out PAI-1+IBD group were significantly 
down-regulated (p>0.01).
3. Compared with the Control group, the PAI-1 protein expression in the 
colon tissue of the IBD group was significantly increased, and the protein 
expression levels of PAI-1, IL-6, IL-10, IFN-γ, BIP, p-IRE1α, p-JNK, JNK were 
Significantly up-regulated. Compared with Knockout PAI-1 control group, 
there was no significant difference in PAI-1 protein expression of Knock out 
PAI-1+IBD group, the protein expression levels of PAI-1, IL-6, IL-10, IFN-γ, 
BIP, p-IRE1α, p-JNK, JNK of Knock out PAI-1+IBD group were significantly 
up-regulated. Compared with the IBD group, the protein expression lev-
els of PAI-1, IL-6, IL-10, IFN-γ, BIP, p-IRE1α, p-JNK, JNK were significantly 
down-regulated in the Knock out PAI-1+IBD group.
conclusion: This study explored the interaction of PAI-1 in inflammatory 
response and endoplasmic reticulum stress. It is concluded that the ex-
pression of PAI-1 gene is positively correlated with tissue inflammation and 
endoplasmic reticulum stress in IBD rats, which may promote the develop-
ment of inflammatory bowel disease.
references: [1] Engel MA,Neurath MF. New pathophysiological insights 
and modern treatment of IBD [J].Gastroenterology,2010,45(6):571-583. [2] 
Corazzari M, Rapino F, Ciccosanti F, et al. Oncogenic BRAF induces chronic 
ER stress condition resulting in increased basal autophagy and apoptotic 
resistance of cutaneous melanoma[J]. Cell Death & Differentiation, 2015, 
22(6):946-958. [3]Abdel Salam AG,Ata HM,Aalman TM,et al.Potential ther-
apeutic utility of mesenchymal stem cells in inflammatory bowel disease 
in mice [J].Int Immunopharmacol,2014,22(2):515-521. [4] Shaghaghi, Z; 
Bonyadi, M; Somi, MH; et al.Association of plasminogen activator inhibi-
tor-1 gene polymorphism with inflammatory bowel disease in Iranian Azeri 
Turkish patients.[J].Saudi J Gastroenterol.2014,20(1):54-58. [5]Iba T, Thachil 
J. Clinical significance of measuring plasminogen activatorinhibitor-1 in 
sepsis[J]. J Intensive Care. 2017,5:56. [6]Ole D. Laerum, Martin Illemann, 
Arne Skarstein,et al. Crohn’s Disease But Not Chronic Ulcerative Colitis In-
duces the Expression of PAI-1 in Enteric Neurons[J]. Am J Gastroenterol. 
2008,103(9):2350-2358. 2015,24(3):253-256. [9]Richardson CE,Kooistra 
T,Kim DH.An essential role for XBP-1 inhostprotection against immune 
activation in C.elegans[J].Nature,2010,463(7284):1092-1095． [10]Sano R 
, Reed J C . ER stress-induced cell death mechanisms[J]. Biochimica et 
Biophysica Acta (BBA) - Molecular Cell Research, 2013, 1833(12):3460-3470.
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Introduction: Evidence for the role of the gut microbiota in the develop-
ment and progression of Crohn’s disease (CD) is increasing. So far, gut 
microbiome studies in patients with CD have focused on characterising 
the changes in bacterial abundances. Clinical, environmental factors and 
inflammation can influence not only the microbial composition in the gut 
but also its total bacterial biomass. However, the total number of bacteria 
in a sample is rarely considered when investigating the relation between 
microbiome and gastrointestinal diseases.
aims & Methods: We hypothesize that combining sequencing data with 
absolute quantification of the gut microbiota (e.g. the number of bacteria 
per gram of feces) provides better insight in disease heterogeneity and 
improves the accuracy of gut microbiome studies in diseases such as IBD.
We collected 140 fecal samples from a cohort of 70 patients with CD, taken 
at two time points with an interval of three weeks. Microbial densities 
were calculated by fluorescence in situ hybridization. Microbiota composi-
tion was estimated by shotgun metagenomic sequencing. Phenotypic data, 
such as medication use and surgery, was obtained from clinical records. 
PERMANOVA analysis was used to estimate the explained variance of each 
phenotype on the microbiome composition. Differences between disease 
phenotypes and microbial loads were calculated using a Wilcoxon-test. 
To estimate the confounding effect of absolute bacterial quantification, 
metagenome-wide associations were then recalculated adjusting for bac-
terial cell counts.
results: Patients with CD showed a large variation in gut bacterial densi-
ties, which is independent of disease activity, measured as the level of 
fecal calprotectin (rho=0.05, P=0.53). Differences in microbial loads ex-
plained most of the variation in microbiome composition between samples 
(R2=10%, P = 0.0001). Higher densities were related with an increased 
compositional abundance of beneficial bacteria, such as F.prausnitzii and 
R.intestinalis, while lower microbial loads were associated with an expan-
sion of potentially pathogenic bacteria such as E.coli and R.gnavus. Patients 
with intestinal resections showed lower microbial loads (P= 5.94E-06), al-
though the latest resection occurred, on average, 11 years before sample 
collection. Interestingly, by using the concentration of DNA extracted in 
combination with the bacterial richness per sample we can capture ~40% 
of the variation in the number of bacteria per gram of fecal material. Cor-
recting for bacterial densities in the microbe-trait associations allowed 
us to increase the specificity of microbiome-wide association studies and 
therefore pinpoint relevant species in CD sub-phenotypes, such as the as-
sociation between F.prausnitzii and clinical resections in the ileum.
conclusion: The number of bacteria in the gut of patients with CD show 
a large variation between individuals. Lower microbial densities are cor-
related with the expansion of pathogenic bacteria and associated with in-
testinal resection. For specific conditions or sub-phenotypes in the context 
of IBD, adding bacterial quantification to metagenomics sequence data 
reveals potential false positive and false negative findings. The differences 
in bacterial loads should be considered when exploring the gut microbiota 
of patients with CD, both as a separate major indicator of gut health and as 
correction factor for microbe-phenotype association.
disclosure: Nothing to disclose 
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of bowel inflammation and cancer on the expression of the most popular 
internal controls: ACTB, GAPDH, and B2M in whole blood is unknown, 
although at least GAPDH occurred to be tightly regulated and suspected of 
supporting cancer growth, challenging its suitability as reference.
aims & Methods: We designed our present study to find and validate optimal 
reference genes for whole blood transcriptom studies involving patients with 
CRC and IBD, active and non-active (1), and to examine and compare the 
effect, if any, bowel cancer and inflammation might have on the expression 
of popular HKG in whole blood (2).Stability of ACTB, B2M, GAPDH, HPRT1, 
SDHA, and TBP expression in blood from controls, colorectal cancer, and 
active inflammatory bowel disease patients was evaluated in RT-qPCR using 
NormFinder, geNorm, BestKeeper, and comparative ΔCt method and vali-
dated by comparison with absolute quantification of IL1β and CCL4.
results: HPRT1, SDHA and TBP were superior normalizers for whole blood 
in CRC and IBD. The highest variability was in active IBD. B2M was sig-
nificantly lower in CRC but higher in IBD. GAPDH was higher in CRC and 
IBD. ACTB and GAPDH corresponded with CRC advancement (ρ=0.52 and 
ρ=0.53) and with clinical activity in Crohn’s disease (ρ=0.44 and ρ=0.57) 
and ulcerative colitis (GAPDH: ρ=0.72). ACTB, B2M, and GAPDH correlated 
with circulating inflammatory/angiogenic indices, differently in IBD and 
CRC. In IBD, ACTB positively correlated with CRP, B2M with FGF2 and 
MIP1α, and GAPDH with CRP, IL1β, IL4, IL8, IL12, G-CSF, and TNFα. In CRC, 
ACTB positively correlated with IL1β, IL6, IL8, FGF2, G-CSF, GMCSF, MIP1α, 
and TNFα and GAPDH with IL1β, IL6, FGF2, G-CSF, GM-CSF, MIP1α, and 
TNFα, and B2M negatively with FGF2, G-CSF, and TNFα.
conclusion: The expression of frequently used normalizers for whole blood 
transcriptomic analysis, that is, GAPDH, ACTB, and B2M, is directionally 
affected by bowel inflammation and cancer, rendering them unsuitable 
as reference in CRC and IBD. The expression of HPRT1, SDHA and TBP was 
stable across CRC and IBD patients allowing for their recommendation as 
normalizers in studies involving both groups of patients.
disclosure: Nothing to disclose 
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Introduction: Clinical trials suggest that vagus nerve stimulation pres-
ents an alternative approach to classical immune suppression in Crohn’s 
disease. T-cells capable of producing acetylcholine (ChAT+ T-cells) in the 
spleen are essential mediators of the anti-inflammatory effect of vagus 
nerve stimulation. Besides the spleen, ChAT+ T-cells are found abundantly 
in Peyer’s patches of the small intestine. However, the role of ChAT+ T-cells 
in colitis pathogenesis is unknown.
aims & Methods: The aim of this study was to investigate the role of ChAT+ 
T-cells in experimental models of colitis. We made use of CD4creChATfl/fl 
mice (CD4ChAT-/- mice), lacking ChAT expression specifically in CD4+ T-cells. 
Littermates (ChATfl/fl mice) served as controls. We used three experimen-
tal colitis models: 1) Acute dextran sulphate sodium (DSS)-induced colitis: 
7 days of 2% DSS in the drinking water; 2) A resolution model of DSS-
induced colitis: 5 days of 2% DSS in the drinking water followed by 7 days 
without DSS; 3) T-cell transfer colitis using CD4+CD45RBhigh T-cells as donor 
cells. Outcome measures included bodyweight loss, endoscopy and histol-
ogy score, colon weight and intestinal cytokine levels.
results: In acute DSS-induced colitis, CD4ChAT-/- mice showed attenuated 
colitis and lower intestinal inflammatory cytokine levels compared to ChAT-
fl/fl mice. In contrast, in the resolution model of DSS-induced colitis, CD-
4ChAT-/- mice showed a worsened colitis recovery and augmented colonic 
histological inflammation scores and inflammatory cytokine levels as com-
pared to ChATfl/fl mice. In the T-cell transfer model, T-cells from CD4ChAT-/- 
mice induced a similar level of colitis compared with ChATfl/fl T-cells.
conclusion: Our results indicate that ChAT+ T-cells aggravate the acute in-
nate immune response upon mucosal barrier disruption in a DSS-induced 
colitis model, while they are supporting the later resolution process of 
this innate immune driven colitis. Surprisingly, ChAT expression in T-cells 
seems redundant in the context of T-cell driven colitis.
P0327 auTOPhagy InducTIOn Of InTesTInaL ePITheLIuM 
aLLevIaTe cOLITIs In dss MOdeL MIce
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Introduction: Crohn’s disease (CD) and ulcerative colitis, generally known 
as inflammatory bowel disease (IBD), are chronic, relapsing and refrac-
tory disorders of the intestine. The pathogeneses of IBD is still not clear. 
Autophagy is a required system to maintain cellular homeostasis by dis-
assembling unnecessary or dysfunctional components in the cytoplasm, 
and plays an important role in recovery from inflammation and bacterial 
infection of intestinal epithelium. Involvement of autophagy-related genes 
such as Atg16L1, NOD2 and LRRK2 has also been reported in the onset of 
CD. Therefore, we investigate the effect of autophagy induction on the al-
leviation of colonic inflammation.
aims & Methods: The modulators of autophagy were screened by in vi-
tro screening assay from compound library derived from food and herbal 
medicine. Autophagy induction was examined using autolysosome forma-
tion in MEF cell line. The modulator of autophagy screened by in vitro as-
say was administrated to the acute dextran sulfate sodium (DSS)-induced 
colitis model mice and the effect was evaluated by weight reduction, colon 
length and histopathological examination.
results: From screening assay, 3 compounds showed autophagy induction 
and relieving colitis. The administration of one compounds derived from 
herbal medicine (named SO) significantly prevent weight loss, colonic 
shortening and infiltration of inflammatory cells. SO induced autophago-
some formation in Caco2 (human intestinal epithelium cell line) by con-
centration dependency. Western blotting assay showed the expression of 
representative autophagy marker LC3 was high in the epithelium and en-
hanced by administration of SO. Immunohistological examination showed 
high expression of LC3- II in the intestinal epithelium after administration 
of SO in colitis model mice.
conclusion: We identified 3 autophagy modulators which has effects of 
autophagy induction and relieving colitis. SO which has high activity for 
inducting autophagy induced the effect of alleviation colitis through au-
tophagy induction of intestinal epithelium. 
disclosure: Nothing to disclose 
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Introduction: Inflammatory bowel disease (IBD) and colorectal cancer 
(CRC) evoke response from circulating immune cells and analyzing gene 
expression patterns in whole blood, owing to its availability, might be ad-
vantageous over more relevant but less accessible bowel tissues. The effect 
316 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
references: Rosas-Ballina et al. Acetylcholine-synthesizing T cells relay 
neural signals in a vagus nerve circuit. Science (New York, NY) 334: 98-101, 
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late antimicrobial peptide expression and microbial diversity. Am J Physiol 
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Introduction: The family of Free Fatty Acid Receptors (FFARs), specific G 
protein-coupled receptors consist of four members: FFAR1-4, where each 
responds to different chain length fatty acids (FAs). It was reported that 
FFAR ligands may reduce inflammatory states, thus FFARs have become 
a potential new target in inflammatory bowel disease (IBD). IBD is a het-
erogeneous disorder characterized by chronic, relapsing, inflammation in 
the gastrointestinal tract, consisting of ulcerative colitis (UC) and Crohn’s 
disease (CD). Neither CD nor UC are fatal diseases but both are debilitat-
ing with a wide range of symptoms. One of IBD symptoms is secretory 
diarrhea, which occurs when secretion of water and electrolytes into the 
intestinal lumen exceeds its absorption. The movement of fluid between 
the intestinal lumen and blood is driven by the active transport of ions, 
thus restoration of this process in IBD patients could be beneficial as the 
chronicity of symptoms leads to decrease in patient’s quality of life.
aims & Methods: The aim of this study was to evaluate the effects of FFAR1- 
4 agonists on epithelial ion transport in isolated mouse colon stimulated 
by Forskolin (FSK) and Veratridine (VER) and compare between groups 
comprising healthy control and 3% Dextran Sulfate Sodium (DSS)-treated 
mice.
Male c57 mice were randomly divided into healthy control group and 
group treated with 3% DSS in drinking water. Epithelial ion transport was 
examined using Ussing Chambers. Changes in ion flux were determined 
on the basis of short-circuit current (ΔIsc) in isolated mouse colon exposed 
to FFAR1-4 and stimulated with FSK or VER.
results: ΔIsc values were reduced in inflamed tissues as compared to con-
trols in all colon samples stimulated with FSK. Incubtion of healthy tissue 
with FFAR1 and FFAR2 agonists caused significant (p< 0.05) reduction of 
ΔIsc induced by FSK. On the other hand, FFAR3 agonist caused significant 
ΔIsc decrease in inflamed colon tissue stimulated with FSK. FFAR1 and 
FFAR2 agonists lowered, but FFAR3 and FFAR4 agonists increased ion 
transport in control tissues stimulated with VER. Incubation of DSS-treated 
mouse colon tissue with FFAR1, 2 and 4 agonists diminished ΔIsc caused 
by VER.
conclusion: FFAR agonists differentially affect the ion transport in healthy 
and inflamed colon tissue. The varying effects depend not only on the re-
ceptor but also on the modulator of ion flux (FOR or VER). These differ-
ences may be explained by the activation of various intracellular pathways 
by FFAR agonists, which need further investigation. 
To summarize, we suggest that it is possible to develop treatment in a 
form of specialized diet enriched with specific FFAR ligands which could 
ameliorate symptoms of IBD associated with disrupted transport across 
intestinal epithelium.
disclosure: Nothing to disclose 
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Introduction: The cytokines IL-12 and IL-23 are elevated in ulcerative colitis 
(UC), and genetic association suggests that they play causative roles in the 
disease. Ustekinumab (UST), an anti-IL-12p40 monoclonal antibody that 
binds both cytokines, is an effective therapy for moderate-to-severe UC. 
We previously observed a partial normalization of UC disease signatures 
in colonic biopsy gene expression and serum protein levels following UST 
induction therapy.1 However, the molecular effects of maintenance UST 
therapy in UC patients are unknown.
aims & Methods: We evaluated the molecular effects of UST in the UNIFI 
Phase 3 maintenance study of UST in moderate-to-severe UC (n=961). Sub-
jects in response to UST 8 weeks after intravenous induction were ran-
domized to receive maintenance treatment with subcutaneous placebo, 
UST 90 mg every 8 (q8w) weeks, or UST 90 mg every 12 weeks (q12w). 
Colonic biopsy mRNA and serum samples from the first ~60% of patients 
treated in the UNIFI phase 3 induction study2 were analyzed, with equal 
representation of patients with or without a history of biologic therapy 
failure (Table 1). Biopsy and serum samples from healthy subjects were 
analyzed as controls.
results: At Week 44 after the start of maintenance therapy, the expression 
of colonic genes dysregulated in UC was altered towards normal levels 
in all treatment groups, with the greatest improvements among those 
receiving UST and those in clinical remission (p< 0.05 for maintenance 
Week 44 versus start of maintenance). No dose effect was observed be-
tween q8w and q12w UST treatment arms, and no significant improve-
ments in disease signature occurred in non-responders to placebo or UST. 
Ustekinumab maintenance therapy magnified the normalization of serum 
proteins following UST induction; among subjects receiving q8w UST who 
were in remission at Week 44, the proteins IFNγ, IL-17A, MMP3, and SAA 
reached concentrations comparable to those seen in healthy controls. Sim-
ilar trends occurred in subjects in remission following q12w UST and to a 
lesser degree among UST-treated subjects not in remission at Week 44. 
Among subjects receiving placebo maintenance therapy who were in re-
mission at Week 44, the disease-associated serum proteins that decreased 
following UST induction were not further reduced during maintenance. 
As previously observed in the induction studies, UST maintenance did not 
reduce serum TNF levels.
conclusion: UST maintenance therapy suppressed IL-12 and IL-23-related 
serum proteins and promoted normalization of the UC disease transcrip-
tomic profile. These results provide insight into the molecular mechanisms 
associated with the efficacy of UST maintenance therapy.
  Biopsy mrna (550 uc and 18 healthy cntl)
serum Protein 
(574 uc and 50 healthy cntl)
Analytes Affymetrix HG U133 PM arrays
12 serum markers: 
• Matrix metalloproteinases: MMP-1,3,9 • 
Cytokines and cytokine receptors: 
IFNy, IL-17A, IL-22, IL-10, IL-2R, TNFa, 
TNFR1 
• Acute Phase Reactant: SAA Inflammatory 
marker: NGAL
Methods
Generalized linear model (GLM) 
& Gene Set Variation Analysis
GLM
Time points
Screening, induction Week 8 
(maintenance Week 0), and 
maintenance Week 44
-
Significance 
cutoffs
|fold change| > 1.5x and 
p < 0.05
-
[Table 1. Biopsy mRNA and serum protein assessments in UNIFI]
references: 1.K Li, et al. Molecular Response to Ustekinumab in Moderate-
to-severe Ulcerative Colitis by Serum Protein and Biopsy Gene Expression 
Analysis: Results from the UNIFI Phase 3 Induction Study. Presented at 
ECCO 2019, March 6-9, 2019, Copenhagen, DK.
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resonance (1H NMR) spectroscopy was used to acquire urinary metabolic 
data from 74 CD patients and 100 controls. 19 of the CD group and 48 of 
the controls had at least one significant co-morbidity (diabetes, asthma, 
hypertension). Multivariate analysis was performed using OPLSDA. Uni-
variate analysis was also performed to assess whether bacterial associated 
metabolites, as demonstrated in previous studies (1), were significantly 
different in CD patients compared to controls. These metabolites were hip-
purate, alanine, citrate, P-cresol, phenyacetylglutamine (PAGn), and di-
methylglycine (DMG).
results: OPLSDA analysis showed statistically significant separation be-
tween CD patients and controls irrespective of the presence of co-mor-
bidities. Model 1 compares CD patients to healthy controls (H). Models 2 
and 3 include CD patients with at least one other co-morbidity (CDWC), 
and Model 3 includes non-CD patients with another co-morbidity in the 
control group (C).
Univariate analysis showed that the bacterial associated metabolites hip-
purate, citrate, P-cresol, DMG, and PAGn changed with statistical signifi-
cance between CD groups and controls irrespective of the presence of co-
morbidities.
conclusion: The pattern of change in discriminating metabolites appear to 
be preserved in models separating CD from controls when patients with 
co-morbidities are included in the models, and these groups can be sig-
nificantly separated with multivariate analysis. It is likely the effect of mi-
crobial disturbance is still measurable with this technique in a real world 
cohort.
Model n r2x q2 P value cv-anOva
Metabolites driving 
model in cd
1 CD : H 106 (54 : 52) 0.085 0.231 0.014
hippurate↓ alanine↓ citrate↓ 
P.cresol↑ PAGn↑ DMG↓ 
leucine↓ aspartate↓
2 CDWC : H 128 (74 : 54) 0.100 0.175 0.057
hippurate↓ alanine↓ citrate↓ 
P.cresol↑ PAGn↑ DMG↓
3 CDWC : C 174 (74 : 100) 0.037 0.093 <0.001
hippurate↓ alanine↓ citrate↓ 
P.cresol↑ PAGn↑ DMG↓ 
sucrose↑
[Table 1. - OPLSDA Models of CD groups vs controls]
references: (1) Williams, 2009. AJG). (2) Lu, 2013. Front. Med.
disclosure: Nothing to disclose 
P0334 The IMPacT Of uLceraTIve cOLITIs On quaLITy Of LIfe 
and PrOducTIvITy acrOss eurOPe, a Burden Of ILLness sTudy
Lobo A.1, Rose A.2, Finnegan A.3, Hayee B.4, Limdi J.K.5, 
Peyrin-Biroulet L.6, Sturm A.7, Fiorino G.8, Burish J.9, Terry H.10, 
Avedano L.11, Tucknott S.12, Noone D.2, Evans J.2
1Sheffield Teaching Hospitals, Sheffield, United Kingdom, 2HCD Economics, 
Health Economics, Daresbury, United Kingdom, 3University of Chester, 
Chester, United Kingdom, 4Kings College Hospital, Gastroenterology, London, 
United Kingdom, 5The Pennine Acute Hospitals NHS Trust, Gastroenterology, 
Bury, Greater Manchester, United Kingdom, 6Nancy University Hospital 
Inserm U954 Dept. of Hepato-Gastroenterology, Department of 
Gastroenterology, Vandoeuvre les Nancy, France, 7DRK Kliniken Berlin I 
Westend, Gastroenterology, Berlin, Germany, 8IRCCS Humanitas, IBD Center, 
Rozzano, Italy, 9North Zealand Hospital, Copenhagen, Denmark, 10Crohns 
and Colitis UK, Hatfield, United Kingdom, 11European Federation of Crohn’s 
& Ulcerative Colitis Association EFCCA, EFCCA CEO, Brussels, Belgium, 
12IBDrelief, Shoreham-by-Sea, United Kingdom
contact e-Mail address: jonathan.evans@hcdeconomics.com
Introduction: Ulcerative Colitis (UC) has a significant impact on quality of 
life, ability to work and making career choices and often a negative psy-
chosocial impact on patients’ lives. The wider implications to psychoso-
cial well-being and activities of daily living challenge existing paradigms 
which are currently limited to clinical “remission” and regard surgery in 
some instances as being “curative”. There is an urgent need for studies 
assessing health-related quality of life (HRQoL) even as modern biological 
therapies redefine our perceptions of disease control. 
The Living with Ulcerative Colitis: Identifying the socioeconomic burden in 
Europe (LUCID) study was a descriptive, retrospective, cross-sectional, Eu-
ropean (France, Germany, Italy, Spain, United Kingdom, Denmark, Norway, 
2.BE Sands, et al. Safety and Efficacy of Ustekinumab Induction Therapy in 
Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 
3 UNIFI Study. Presented at ACG 2018, October 9, 2018, Philadelphia, PA, 
USA.
disclosure: Drs.Li, Yang, Hayden, Strawn, Wadman, Bhagat, Marano, and 
Friedman are all employees of Janssen Research & Development, LLC 
P0332 effecTs Of MaTrIx MeTaLLOPrOTeInase (MMP)-7, 
MMP-13 and caThePsIn g On The InTegrITy and funcTIOn Of 
anTI-TuMOur necrOsIs facTOr (Tnf)-α and anTI-InTegrIn 
BIOLOgIc agenTs
Jones S.1, Sobande T.1, Curciarello R.2, Ferreyra M.2, Docena G.2, 
Tremelling M.3, Watson A.3, Macdonald T.1, Biancheri P.3
1Barts & The London School of Medicine and Dentistry, Blizard Institute, 
Queen Mary University of London, Centre for Immunobiology, London, 
United Kingdom, 2University of La Plata, Institute of Immunologic and 
Physiopatological Studies, CONICET, La Plata, Argentina, 3Norwich Medical 
School, University of East Anglia, Gastroenterology and Gut Biology, 
Norwich, United Kingdom
contact e-Mail address: paolo.biancheri@gmail.com
Introduction: Biologic therapy is highly effective in inflammatory bowel 
disease (IBD), however a significant proportion of patients fail to respond, 
and mechanisms underlying primary non-responsiveness are unclear. We 
have previously observed that proteolytic degradation by MMP (matrix me-
talloproteinase)-3 and MMP-12, which are up-regulated in IBD inflamed 
mucosa, may contribute to primary non-responsiveness to anti-tumour 
necrosis factor (TNF)-α agents in IBD.1 We hereby investigated the effect 
of other proteases on the integrity and function of anti-TNF-α and anti-
integrin agents.
aims & Methods: We co-incubated increasing concentrations of activated 
recombinant human MMP-7, MMP-13, and Cathepsin G with the anti-TNF-α 
agents Infliximab, Adalimumab, and Etanercept, or with the anti-integrin 
agent Vedolizumab, and we subsequently analysed the cleavage reaction 
products by Western blotting. Using a reporter cell line, we evaluated the 
effect of recombinant human proteases on the ability of anti-TNF-α agents 
to neutralise soluble TNF-α.
results: Infliximab, Adalimumab and Vedolizumab were not degraded by 
MMP-7, MMP-13, or Cathepsin G. Etanercept was degraded in a concentra-
tion-dependent manner by MMP-7 and MMP-13, but not by Cathepsin G. 
Degradation by MMP-7 and MMP-13 did not significantly impair the ability 
of Etanercept to neutralise soluble TNF-α.
conclusion: Despite being known to cleave immunoglobulins,2 MMP-7 and 
MMP-13 do not appear to impair the integrity and function of Infliximab 
and Adalimumab. In keeping with our previous findings, Etanercept ap-
pears to be highly susceptible to the action of proteases.
references: 1. Biancheri P, et al. Gastroenterology 2015;149:1564-74. 2. 
Brezski RJ, et al. MAbs 2010;2:212-20.
disclosure: Nothing to disclose 
P0333 effecT Of cO-MOrBIdITIes In crOhn’s dIsease 
assOcIaTed urInary MeTaBOLIc PrOfILes
Powles S.T.R.1,2, Gallagher K.I.1, Hicks L.C.1,2, Chong L.W.L.1,2, Swann J.R.3, 
Holmes E.3, Williams H.R.T.1,2, Orchard T.R.1,2
1Imperial College London, Division of Digestive Diseases, London, United 
Kingdom, 2Imperial College Healthcare NHS Trust, Gastroenterology, London, 
United Kingdom, 3Imperial College London, Division of Integrative Systems 
Medicine, London, United Kingdom
contact e-Mail address: s.powles@imperial.ac.uk
Introduction: Distinct metabolic signatures have been detected in urine 
that differentiate Crohn’s disease (CD) from controls in multiple studies, 
with consistent discriminatory metabolites derived from bacteria and co-
bacterial pathways (1). Multiple other diseases have also been found to 
affect the urinary metabolome, and many of these relate to changes in 
bacterial associated metabolites (2).
aims & Methods: The aim of this study was to examine whether the same 
metabolite changes that have been previously shown are present in a real 
life cohort of CD patients, and if these patients could be distinguished 
from controls despite the presence of co-morbidities. Nuclear magnetic 
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Poland, Romania and Turkey), multi-site bottom-up prevalence-based 
Burden of Illness research study carried out by HCD Economics and the 
University of Chester in partnership with Crohn’s and Colitis UK.
aims & Methods: The aim of this study was to explore the impact of UC on 
patients’ HRQoL and productivity. Patients were recruited through Gastro-
enterologists (surveyed between August 2018 - February 2019) and split 
into two population cohorts; Arm 1: Patients with moderate or severe UC 
status at initiation of documentation period (12 months prior the index 
date) and Arm 2: Patients with moderate or severe UC that achieved mild 
UC or remission at initiation of documentation period. Each patient was 
invited to complete a public patient involvement and engagement (PPIE) 
form. The PPIE included patient reported outcome measures (PROMs) 
to capture intangible costs using the work productivity and impairment 
(WPAI) questionnaire, which quantifies work time missed, work impair-
ment and activity impairment, and HRQoL using the EQ5D. The EQ5D pro-
duces a utility score of the patients current HRQoL from five domains, with 
1 denoting perfect health and 0 denoting death.
results: 1,658 patients completed the PPIE form. Of these patients, 9 pa-
tients did not have their UC status recorded so could not be assigned to 
an arm. Out of these patients, 1,001 patients (60.7%) were categorised into 
arm 1 with 648 patients (39.3%) categorised into arm 2. 994 patients from 
arm 1 and 638 patients from arm 2 completed the EQ5D with a mean score 
of 0.81 (0.17 SD) and 0.86 (0.16 SD) respectively. The mean WPAI scores for 
arm 1 (n=602) were 0.11 (0.25 SD) for work time missed (absenteeism), 
0.24 (0.21 SD) for impairment (presenteeism), 0.28 (0.24 SD) for work im-
pairment and 0.27 (0.24 SD) for activity impairment. The mean WPAI scores 
for arm 2 (n=368) were 0.01 (0.19 SD) for work time missed (absenteeism), 
0.24 (0.18 SD) for impairment (presenteeism), 0.2 (0.21 SD) for work im-
pairment and 0.18 (0.2 SD) for activity impairment.
conclusion: Our preliminary results show that UC has implications on 
HRQoL and work productivity for all patients with UC, ranging from 
those in remission or mild disease to those with moderate or severe 
UC, underpinning the need for more holistic and inclusive definitions of 
care and disease control. Further analysis, to understand the impact of 
ulcerative colitis on patients, is ongoing to address this important and 
unmet need.
references: Rubin, D. T., Siegel, C. A., Kane, S. V., Binion, D. G., Panac-
cione, R., Dubinsky, M. C., … Hopper, J. (2009). Impact of ulcerative colitis 
from patients’ and physicians’ perspectives: Results from the UC: NOR-
MAL survey. Inflammatory Bowel Diseases, 15(4), 581-588. https://doi.
org/10.1002/ibd.20793
disclosure: The LUCID study was funded internationally by educational 
grants from Pfizer and Eli Lilly and in the UK by Celgene. The study was 
governed by an expert reference group consisting of the authors. 
P0335 rIsk Of reOccurrence Of PerIanaL fIsTuLas In 
PaTIenTs WITh crOhn’s dIsease In The unITed sTaTes - a 
reTrOsPecTIve cLaIMs daTaBase sTudy
Patel H.1, Latremouille-Viau D.2, Serre D.2, Lissoos T.1, Null K.D.1, Owen G.3, 
Campbell-Hill S.4
1Takeda Pharmaceuticals USA, Inc., Deerfield, United States, 2Analysis Group, 
Inc., Montreal, Canada, 3Takeda UK Ltd., London, United Kingdom, 4Takeda 
International, UK Branch, London, United Kingdom
contact e-Mail address: sarah.campbell-hill@takeda.com
Introduction: Perianal fistulas (PAF) in patients with Crohn’s disease (CD) 
are associated with morbidity and impaired quality of life. Limited data is 
available on the risk of PAF among patients with CD and long-term PAF 
relapse rates.
aims & Methods: To describe characteristics of patients with CD and PAF, 
and rates of PAF reoccurrence (a proxy for disease relapse including both 
relapse of previous fistula and development of new fistula). A retrospective 
cohort study on US adult patients with CD identified in an US administra-
tive claims database (2001-2018) was conducted. Patients with PAF were 
identified using diagnosis or procedure codes in medical claims. A PAF 
episode, starting from the first PAF occurrence, was defined as consecutive 
PAF-related codes ≤120 days of each other. PAF reoccurrence was defined 
as a new PAF-related code occurring after a PAF-free period of ≥180 days 
(proxy for remission) following the end of the first PAF episode. Time from 
the 180-day PAF-free period to PAF reoccurrence was estimated using KM 
analyses. A similar analysis was conducted in CD patients with a PAF-free 
period of ≥360 days.
results: 5,482 patients with a PAF-free period of ≥180 days after their first 
PAF episode were included (CD-PAF cohort; mean age=43.8 years and pro-
portion of males=51.8%). Over a mean follow-up duration of 2.6 years, 
28.8% had a PAF reoccurrence. Estimated rates of PAF reoccurrence in 
these CD-PAF patients were 23.7%, 32.0%, 42.1% and 47.8% at 1, 2, 5, and 
10 years, respectively (Table 1).
In the 12 months before first PAF occurrence, 70.8% of CD-PAF patients re-
ceived non-biologic therapies: corticosteroids (46.5%), antibiotics (44.4%), 
aminosalicylates (5-ASA) (32.5%) and immunomodulators (IMDs)/immu-
nosuppressants (IMs) (21.1%); 25.3% used ≥1 biologic therapy; and 19.2% 
had ≥1 CD-related surgery. In the 4 months after first PAF occurrence, 
66.5% of CD-PAF patients received non-biologic therapies: antibiotics 
(39.6%), corticosteroids (30.3%), 5-ASA (27.4%) and IMDs/IMs (22.1%); 
31.8% used ≥1 biologic therapy; and 47.2% had ≥1 CD-related surgery.
In patients with a longer PAF-free period of ≥360 days (CD-PAF360 cohort), 
a numerically lower proportion had a PAF reoccurrence (20.5%) and es-
timated rates of reoccurrence were numerically lower at every time point 
(32.6% at 5 years and 39.4% at 10 years) vs the CD-PAF cohort. 
cohort (n)
duration of 
follow-up, 
mean [a]
Patients 
with Paf 
reoccurrence, 
n (%)
kM 
analyses
3 
months
6 
months
1 
year
2 
years
5 
years
10 
years
CD-PAF 
(N=5,482)
2.6 years 1,578 (28.8%)
KM rates 
[b,c]
10.0% 16.0% 23.7% 32.0% 42.1% 47.8%
CD-PAF 
(N=5,482)
2.6 years 1,578 (28.8%)
Patients 
at risk, N
4,478 3,771 2,824 1,702 494 85
CD-PAF360 
(N=3,764)
2.7 years 771 (20.5%)
KM rates 
[b,c]
5.2% 9.2% 14.5% 21.7% 32.6% 39.4%
CD-PAF360 
(N=3,764)
2.7 years 771 (20.5%)
Patients 
at risk, N
3,236 2,824 2,162 1,360 422 67
[a] Duration of follow-up starts from the end of the PAF-free period following the first PAF episode
[b] KM rates of PAF reoccurrence from the end of the PAF-free period of 180 days (CD-PAF) or 360 days 
(CD-PAF360) following the first PAF episode. KM rates are estimated at given time points and represent 
cumulative incidence accounting for right censoring
[c] Similar findings were observed in the sensitivity analysis defining a PAF episode as all consecutive 
PAF within 180 days of each other (vs. 120 days)
[Table 1. Kaplan-Meier rates of reoccurrence of perianal fistulas among 
patients with Crohn’s disease]
conclusion: In this retrospective US claim database analysis, the 5-year 
and 10-year rates of PAF reoccurrence following PAF remission of ≥180 
days were 42.1% and 47.8% among patients with CD, respectively. Patients 
achieving longer-term remission (≥360 days) had numerically lower rates 
of PAF reoccurrence. Future studies should examine the impact of disease 
severity and treatment on long-term rates of PAF reoccurrence.
disclosure: HP, TL, KDN, GO and SC-H are employees of Takeda. DLV and 
DS are employees of Analysis Group, Inc., which has received consulting 
fees from Takeda. 
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in CU. One third of patients are hospitalized in the first year after diagnosis 
and over 5% undergo surgery. Our results highlight the high burden of 
IBD as well as the important challenges faced by health-care systems to 
manage this costly and complex disease.
  cumulative incidence of exposure to treatments (%)
Treatments 6 months 12 months
  UC CD p UC CD p
Mesalazine (%) 89 36 <0.01 99 40 <0.01
Steroids (%) 35 70 <0.01 40 75 <0.01
Immunomodulators 
(%)
7 38 <0.01 11 50 <0.01
Biologics (%) 7 13 <0.01 11 31 <0.01
Surgery (%) 1 8 <0.01 2 11 <0.01
[Table 1. Cumulative incidences of exposure to different therapeutic options  
in Crohn’s disease (CD) and ulcerative colitis (UC) patients]
disclosure: M. Chaparro has served as a speaker, or has received research 
or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, 
Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma. JP Gis-
bert has served as a speaker, a consultant and advisory member for or has 
received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, 
Biogen, Takeda, Janssen, Roche, Celgene, Ferring, Faes Farma, Shire Phar-
maceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro 
Pharma, Otsuka Pharmaceutical, Vifor Pharma. 
P0337 WIThdraWn
P0338 TIMe Trends Of crOhn’s dIsease In caTaLOnIa frOM 
2011 TO 2017. IncreasIng use Of BIOLOgIcs cOrreLaTes WITh a 
decrease In surgIcaL requIreMenTs. a POPuLaTIOn-Based 
sTudy In caTaLOnIa
Brunet E.1, Melcarne L.1, Vela E.2, Cleries M.2, Pontes C.2,3, Hernández L.1, 
Soria A.1, Vives J.1, Grau G.1, Pedregal P.1, Lira A.1, Machlab S.1, 
Garcia-Iglesias P.1, Gallach M.1, Vergara M.1,3,4, Villoria A.1,3,4, Calvet X.1,3,4
1Parc Tauli, Digestive, Sabadell, Spain, 2Servei Català de la Salut, Barcelona, 
Spain, 3Universidad Autónoma de Barcelona, Bellaterra, Spain, 4CIBERehd, 
Madrid, Spain
contact e-Mail address: eduardbrunet91@gmail.com
Introduction: Data from clinical trials suggest that biological drugs might 
improve the outcomes in Crohn disease (CD) by reducing the need for sur-
gery or hospitalization. Data on the trends in biological drugs use and 
outcomes in CD patients are scarce.
aims & Methods: The aim of this study was to valuate the time-trends of 
the prescription of biological drugs and other treatments for Crohn’s dis-
ease (CD), and its relationship with outcomes as surgery and hospitaliza-
tion in Catalonian population. 
All patients with CD included in the Catalan Health Surveillance System 
(including data on more than 7.5 million individuals) from 2011 to 2017 
were identified. The exposures to different IBD treatments was retrieved 
from the electronic dispensation records. Time trends for surgery and hos-
pitalization were also described and correlated with treatment. The statis-
tical analysis was carried out using the statistical package R, version 3.4.3.
results: The use of salicylates, corticosteroids and immunosuppressant 
treatment decreased from 2011 to 2017 from 28.8% to 17.1%, 15.8% to 
13.7%, and 32.9 to 29.6%, respectively. Biological treatments increased 
from 15.0% to 18.7%. Adalimumab was the most prescribed (1604 pa-
tients, 52% of all biologics in 2017). Ostomy rates per 1000 patients/year 
decreased from 13.2 in 2011 to 9.8 in 2017. Corresponding figures for surgi-
cal resection decreased from 24.1 to 18.0. The rate of the CD-related hospi-
talizations per 1000 patients/year decreased from a 92.7 to a 72.2.
conclusion: Use of biological drugs increased from 15.0% to 18.7% from 
2011 to 2017. During the same periods we observed an improvement in the 
outcomes of CD
patients.
disclosure: Nothing to disclose 
P0336 ePIdeMIOLOgy, cLInIcaL characTerIsTIcs, evOLuTIOn 
and TreaTMenTs In neWLy dIagnOsed InfLaMMaTOry BOWeL 
dIsease (IBd): resuLTs frOM The naTIOnWIde ePIdeMIBd sTudy 
Of geTeccu
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Casanova M.J.1, Ceballos D.5, Esteve M.6, Fernández H.7, Ginard D.8, 
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EpidemIBD Group
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Galdakao, Spain, 5Hospital Universitario de Gran Canaria Dr. Negrín, 
Gastroenterology Unit, Las Palmas, Spain, 6Hospital Universitari Mutua 
Terrasa, Gastroenterology Unit, Tarrasa, Spain, 7Hospital San Pedro, 
Gastroenterology Unit, Logroño, Spain, 8Hospital Universitari Son Espases, 
Gastroenterology Unit, Palma de Mallorca, Spain, 9Hospital Clínico 
Universitario “Lozano Blesa”, IIS Aragón and CIBERehd, Gastroenterology 
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Unit, Oviedo, Spain, 13Hospital Universitario Marqués de Valdecilla, 
Gastroenterology Unit, Santander, Spain, 14Hospital Universitario San 
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Unit, Murcia, Spain, 18Universidad Autónoma de Madrid/IdiPaz and 
CIBERESP, Preventive Medicine and Public Health, Madrid, Spain
contact e-Mail address: mariachs2005@gmail.com
Introduction: Updated data on the incidence, evolution and treatment 
strategies used in IBD management in South Europe is needed. This is the 
largest study on the recent epidemiology of IBD in Spain.
aims & Methods: 
i) To assess the incidence of IBD in Spain; 
ii) to describe the main epidemiological and clinical characteristics of pa-
tients at diagnosis and the evolution of the disease; and iii) to explore the 
use of treatments in the biological era.
Prospective and population-based nationwide registry. Adult patients 
diagnosed with IBD ¾Crohn’s disease (CD), ulcerative colitis (UC) or IBD 
unclassified (IBD-U)¾ during 2017 in the 17 Spanish regions were includ-
ed and will be followed-up for 5 years after diagnosis. Treatment was 
grouped into 5 categories: mesalazine (oral or topical), steroids (intrave-
nous, oral or topical), immunomodulators (thiopurines, methotrexate or 
cyclosporine), biologics (anti-TNF, vedolizumab or ustekinumab) and sur-
gery. Cumulative incidence of exposure to each of the studied treatments 
was estimated by Kaplan-Meier curves.
results: 3,627 incident cases of IBD diagnosed during 2017 from 108 centres 
covering over 22 millions of adult inhabitants (about 50% of the Spanish 
population) comprise the study cohort. 
The overall incidence (per 100.000 person-years) of IBD was 16: 7.5 for CD, 
8 for UC, and 0.5 for IBD-U. 46% of patients had CD and 50% UC. Diagno-
sis delayed was significantly longer in CD than in UC (5 vs. 2 months, p< 
0.01). The proportion of patients with symptoms at diagnosis was higher 
in UC (94 vs. 89%, p< 0.01). 
On the opposite, the proportion of patients with family history of the dis-
ease (18 vs. 13%, p< 0.01), smoking habit (38 vs. 12%, p< 0.01) and extraint-
estinal manifestations (12.5 vs. 6%, p< 0.01) were significantly higher in CD 
than in UC. At diagnosis, 18% of CD patients had structuring or fistulising 
behaviour and 64% of UC patients had pancolitis or left-sided colitis. 27% 
of patients were hospitalized during a median follow-up of 10 months 
(35% of CD and 22% of UC patients, p< 0.01). 
During follow-up, 33 (2.4%) CD patients progressed to a more severe phe-
notype, and 2 (0.01%) UC patients to more extensive involvement. The cu-
mulative incidences of the different treatments are shown in table 1.
conclusion: The incidence of IBD in Spain is relatively high and similar to 
figures reported in Northern Europe. IBD patients require the use of sub-
stantial diagnostic and therapeutic resources, which are higher in CD than 
320 UEG Journal | Abstract Book
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P0339 PrevaLence Of InfLaMMaTOry BOWeL dIsease (IBd) 
In a cOLOrecTaL cancer POPuLaTIOn screenIng PrOgraM
Bezzio C.1, Arena I.2, Nucci G.D.2, Della Corte C.2, Devani M.3, 
Manes G.2, Mandelli E.2, Morganti D.2, Omazzi B.2, Redaelli D.2, 
Reati R.4, Saibeni S.4
1ASST Rhodense, Gastroenterlogy, Milano, Italy, 2ASST Rhodense, Rho, Italy, 
3Ospedale G. Salvini, Milano, Italy, 4ASST Rhodense, Gastroenterology Unit, 
Rho, Italy
contact e-Mail address: cribezzio03@yahoo.it
Introduction: in general, IBD are diagnosed in subjects with gastrointesti-
nal symptoms, despite this a diagnostic delay is often observed. However 
IBD may also be present in asymptomatic subjects. In these cases, diagno-
sis may be further delayed, incidentally done or missed.
aims & Methods: we analyzed an electronic database of a regional 
colorectal cancer population screening program offered to subjects from 
50 to 70 years old with faecal occult blood. From 1 September 2013 to 31 
August 2018, among subjects who underwent colonoscopy in a single hos-
pital, we identified subjects with endoscopic findings suggestive of IBD. Of 
these, we retrieved histological findings as well as information on other 
examinations and possible therapeutic decisions.
results: 3972 subjects undergoing to colonoscopy were enrolled. In 46 
(1.16%) subjects (24 men, mean age ± SD 60.3 ± 6.8 years) endoscopic 
findings suggestive of IBD were present: 35 of CD and 11 of UC; none of 
these subjects were taking oral anticoagulants or NSAIDs and reported 
gastrointestinal symptoms. After a median follow-up of 12 months (range 
2-58), a definitive diagnosis of IBD was done in 13 subjects (0.33%). Of 
these, 3 already underwent to colonoscopy in the context of the same pro-
gram and 1 showed familiarity for IBD. Nine were diagnosed with CD (7 
men, 60.0 ± 6.6 years) and 4 with UC (3 men, 59.1 ± 6.9 years). In CD 
population, 4 patients showed colonic, 4 ileal and 1 ileo-colonic location; 1 
was treated with steroids and then with vedolizumab, 1 with steroids and 
then with azathioprine, 1 with 5-ASA, 1 with Budesonide, while 5 did not 
receive any therapy. In UC population, 2 patients showed extension limited 
to rectum and 2 to rectum and sigmoid colon; all patients started therapy 
with 5-ASA, 1with systemic steroids and Vedolizumab.
conclusion: prevalence of IBD in a colorectal cancer population screening 
program is 0.33%. IBD diagnosis can be missed in asymptomatic subjects, 
but only 1 out of 4 subjects with endoscopic findings suggestive of IBD is 
eventually diagnosed as affected by CD or UC.
disclosure: Nothing to disclose 
P0340 guT MIcrOBIOMe Of PaTIenTs WITh uLceraTIve cOLITIs
Kupaeva V.1, Shapina M.V.2, Nanaeva B.3, Boldyreva M.4, 
Loranskaya I.5
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Gastroenterology, Moscow, Russian Federation, 2Lomonosov Moscow State 
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contact e-Mail address: victoriakupaeva@gmail.com
Introduction: The etiology of inflammatory bowel diseases (IBD), including 
ulcerative colitis (UC), has not been established. The role of microbiota 
in the development of intestinal wall inflammation is still unclear. Can 
dysbiosis be one of the causes of the disease, or is it a consequence of it? 
We still do not know.
aims & Methods: Our study was prospective aimed to evaluate the com-
position of the gut transient and mucosal microbiome in various forms 
of UC by real-time polymerase chain reaction (RT-PCR). None of patients 
had received antibiotics or probiotics previously. Stool samples and mu-
cosal biopsies were collected for each participant immediately frozen until 
analysis. 70 patients with UC were included. The median age was 40±14.4 
years (range 18-69). 43 were female (61.4%), 27 - male (38.6%). Dura-
tion of the disease was 7.22±6.9 years (range 0.5-38). Extensive colitis was 
diagnosed in 78.6% cases (n=55), left-sided colitis - 21.4% (n=15). Acute 
UC was found in 3 (4.3%) patients, relapsing course of the disease in 29 
(41.4%) and remitting course in 38 (54.3%) patients. The activity of the UC 
(Truelove-Witts classification) was variable: mild - 38 (54.3%), moderate 
- 14 (20%) and clinical remission - 18 (25.7%). PCR diagnostics of stud-
ied samples was carried out using a DT-96 amplificator (DNA-Technology, 
Russia). The non-parametric Mann-Whitney test was performed to calcu-
late the confidence.
results: Using RT-PCR, the following bacterial phylotypes were isolated: 
Firmicutes, Bacteroidetes, Actinobacteria, Euryarchaeota, Fusobacteriaceae, 
Verrucomicrobia, and Proteobacteria. When comparing the microbial com-
position in stool samples and mucosal biopsies of the affected parts of 
the intestine in left-sided UC were revealed the following differences. 
The total bacterial mass of biopsies (4.736) is less compared to the to-
tal bacterial mass of fecal samples (7.240) (p< 0.05). In stool samples 
the concentration of Methanobrevibacter spp (p< 0.05), Fusobacteria-
ceae (p< 0.05), Akkermansia muciniphila (p=0.0441), Staphylococcus spp 
(p=0.0002), Anaerococcuscus spp (p=0.0308), Helicobacter spp (p < 0.05), 
Bdelovibrio (p=0.0017), Suterella wadsworthensis (p=0.0295), Pseudomo-
nas spp (p< 0.05), Campylobacter spp (p< 0.05), Mageebacillus indolicus 
(p< 0.05), Clostridium leptum gr- (p=0.0025) was significantly less. The 
number of Lactobacillus spp is reduced in the biopsy compared to stool 
samples (p=0.0434). The difference in the microbes’ concentration in stool 
samples and biopsies from unaffected sections in left-sided UC is similar 
to the above data (p< 0.05). 
The content of Clostridium leptum gr- is significantly reduced in the in-
flamed part of the intestine (p=0.03). In patients with extensive UC, when 
comparing stool samples and biopsies, a significant decrease in the con-
centration of 15 species in stool samples (p< 0.05) was found. The number 
of Lactobacillus spp is reduced in the biopsies compared to stool samples 
(p< 0.05).
conclusion: In any form of UC, stool samples significantly reduced mi-
crobes’ concentration in types Euryarchaeota, Fusobacteriaceae, Verruco-
microbia, and Proteobacteria. The content of Lactobacillus spp in the af-
fected areas of the intestine has been reduced. Transient microbiota differs 
in composition from the mucosal and does not reflect the real microbial 
diversity of mucosal microbiome. Its definition in routine practice is not 
diagnostically significant. The composition of mucosal microbiota of the 
right and left sections of large intestine in left-sided UC was not signifi-
cantly different.
disclosure: Nothing to disclose 
P0341 assessMenT Of endOTheLIaL funcTIOn and 
cardIOvascuLar rIsk In cOexIsTIng InfLaMMaTOry BOWeL 
dIsease and exTraInTesTInaL ManIfesTaTIOns:PreLIMInary 
daTa Of a PrOsPecTIve sTudy
Carparelli S.1, Losurdo G.2, Cecere A.3, Girasoli C.3, Clemente F.3, 
Scicchitano P.3, Ierardi E.1, Ciccone M.M.3, Principi M.4, Di Leo A.1
1Section of Gastroenterology, DETO, University of Bari, Dr., Bari, Italy, 
2University of Bari, Emergency and Organ Transplantation, Bari, Italy, 
3Policlinico di Bari, Bari, Italy, 4Policlinico di Bari, Dr., Bari, Italy
contact e-Mail address: carparelli.sonia@gmail.com
Introduction: Inflammatory bowel diseases (IBD) can be considered as sys-
temic conditions for the possible involvement of extraintestinal manifesta-
tions (EIMs). Previous studies showed that patients with IBD in an active 
phase have an increased cardiovascular (CV) risk compared to healthy con-
trols. Flow-mediated dilation (FMD) of brachial artery and carotid intima-
media thickness (IMT) are ultrasound, validated techniques, which assess 
endothelial function and atherosclerosis. We aimed to assess CV risk in IBD 
patients with EIMs in order to evaluate a possible influence of extraintes-
tinal inflammatory activity.
aims & Methods: We enrolled 56 consecutive subjects with an established 
diagnosis of IBD associated with EIMs and 20 patients with IBD without 
EIMs as control group. The first group was subsequently divided into 4 
subgroups on the bases of disease activity (patients with both active or 
inactive IBD and EIMs, patients with intestinal symptoms and no signs of 
EIM and vice versa). Patients were screened for common CV risk factors 
and underwent FMD and IMT evaluation. 
We performed Kruskal-Wallis test, followed by Dunn’s post-hoc test for 
multiple comparisons for analysis of continuous variables. Spearman’s test 
was used for correlation analysis.
results: FMD and IMT values showed no statistically significant difference 
in any group (P=0.64 and P=0.65) nor when we considered only the pres-
ence of active or inactive EIM (control group vs active or vs inactive EIM, 
P=0.44 and P=0.29). FMD showed no correlation with patients’ and dis-
ease characteristics, while IMT correlated with BMI (p< 0.0001).
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P0343 assOcIaTIOn Of vITaMIn d sTaTus WITh IrOn 
defIcIency and hePcIdIn seruM exPressIOn In PaTIenTs 
WITh InfLaMMaTOry BOWeL dIsease
Stallhofer J.1, Veith L.1, Probst P.2, Diegelmann J.1, Breiteneicher S.1, 
Schnitzler F.3, Olszak T.4, Brand S.5, Török H.1, Beigel F.1
1University Hospital, LMU Munich, Department of Medicine II, Munich, 
Germany, 2Faculty of Medicine, LMU Munich, Chair of Biometrics and 
Bioinformatics, IBE, Munich, Germany, 3Praxisklinik München-Pasing, 
Munich, Germany, 4Klinikum Fürstenfeldbruck, Academic Teaching Hospital, 
LMU Munich, Munich, Germany, 5Kantonsspital St. Gallen, St. Gallen, 
Switzerland
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Introduction: Vitamin D deficiency and iron deficiency are common comor-
bidities in inflammatory bowel disease (IBD) and linked to complications 
like osteoporosis and anemia, respectively1. There is emerging evidence 
that active vitamin D may enhance intestinal iron absorption and prevent 
iron deficiency and iron deficiency anemia by direct suppression of hepci-
din mRNA transcription2,3.
aims & Methods: To investigate a potential influence of vitamin D status 
on iron metabolism, iron deficiency and iron deficiency anemia in IBD, 
25-hydroxyvitamin D levels, 1,25-dihydroxyvitamin D levels, hepcidin se-
rum concentrations, biochemical markers of iron status (serum iron, 
ferritin, transferrin, transferrin saturation) and hemoglobin levels were 
measured in 104 adult patients with IBD (67 patients with Crohn’s disease 
[CD] and 37 patients with ulcerative colitis [UC]). Multivariate logistic and 
linear regression models included age, gender, body mass index, smoking 
status, disease activity and C-reactive protein levels as covariables when 
assessing the association of vitamin D levels with iron deficiency, iron defi-
ciency anemia, hemoglobin levels and biochemical markers of iron status. 
Patients, who were substituted with iron during the last 30 days, were 
excluded from the study. For iron substitutions dating back longer than 
30 days (up to three months), a corresponding categorical covariable was 
introduced in a multivariate confirmatory model. For categorical consider-
ations, vitamin D deficiency was defined as 25-OH-vitamin D < 20 ng/ml. 
Iron deficiency and iron deficiency anemia in IBD were defined according 
to ECCO guidelines.
results: In multivariate logistic regression models controlling for age, 
gender, body mass index, smoking status, disease activity and C-reactive 
protein levels, lower 25-hydroxyvitamin D levels were significantly associ-
ated with iron deficiency in patients with IBD (β [SE] = - 0.064 [0.030], P 
= 0.029). In multivariate linear regression models, vitamin D deficiency 
was significantly associated with decreased levels of ferritin (β [SE] = 0.25 
[0.11], P = 0.024) and transferrin saturation (β [SE] = 8.41 [4.07], P = 0.044) 
in IBD. IBD patients with lower 25-hydroxyvitamin D levels exhibited sig-
nificantly lower serum iron levels (β [SE] = 0.94 [0.42], P = 0.029) and fer-
ritin levels (β [SE] = 0.013 [0.0059], P = 0.037). Moreover, multivariate lin-
ear regression models showed a significant negative association of higher 
1,25-dihydroxyvitamin D : 25-hydroxyvitamin D ratios with lower hepcidin 
serum levels in IBD (β [SE] = - 4.31 [1.67], P = 0.012). For CD, multivari-
ate linear logistic regression analysis revealed a significant association 
of increased concentrations of active 1,25-dihydroxyvitamin D with higher 
transferrin saturation levels (β [SE] = 0.43 [0.18], P = 0.027). In CD patients, 
there was a significant positive correlation of 25-hydroxyvitamin D levels 
with iron (Kendalls Tau 0.17, P < 0.05), ferritin (Kendalls Tau 0.18, P < 0.05) 
and transferrin saturation (Kendalls Tau 0.21, P < 0.05). Furthermore, lev-
els of active 1,25-dihydroxyvitamin D correlated positively with transferrin 
saturation in patients with CD (Kendalls Tau 0.21, P < 0.05).
conclusion: Vitamin D deficiency in IBD patients correlates significantly 
with parameters indicating iron deficiency. An optimized vitamin D sta-
tus may ameliorate iron deficiency in IBD, potentially by downregulation 
of hepcidin serum expression, suggesting a beneficial role for vitamin D 
substitution. Further interventional studies are warranted to prove this 
hypothesis.
references: 1. Hwang, C., Ross, V. & Mahadevan, U. Micronutrient deficien-
cies in inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis 
18, 1961-1981. 2. Moran-Lev, H., et al. Vitamin D Decreases Hepcidin and 
Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease 
Pediatric Patients- A Prospective Study. J Crohns Colitis (2019). 3. Smith, 
E.M. & Tangpricha, V. Vitamin D and anemia: insights into an emerging 
association. Curr Opin Endocrinol Diabetes Obes 22, 432-438 (2015).
disclosure: Nothing to disclose 
conclusion: Our study showed no difference in CV risk in IBD patients 
with a concomitant EIM. However, it cannot address definite conclusions , 
since the lack of statistically significant differences is probably due to the 
small sample size. Therefore, we should obtain a clear picture about the 
possible relationship between CV risk and EIM in IBD only when the results 
will involve an adequate sample size.
disclosure: Nothing to disclose 
P0342 InadequaTe ferTILITy and Pregnancy knOWLedge 
Is reLaTed TO vOLunTary chILdLessness In PaTIenTs WITh 
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Introduction: Inflammatory bowel diseases (IBD) are frequently diag-
nosed in individuals who are in the reproductive period. Lack of fertility 
and pregnancy-related knowledge leads to subsequent voluntary child-
lessness, although pregnancy outcome is favorable in the majority of IBD 
patients that plan pregnancy when the disease is in remission.
aims & Methods: The aim of the study was to investigate specific reproduc-
tive knowledge in patients with IBD. In this study 165 female IBD patients 
(aged 20 to 74) treated in the Clinic for Gastroenterology and Hepatology 
Clinical center of Serbia and Clinical center of Vojvodina completed a stan-
dardized questionnaire consisting of demographic characteristics, preg-
nancy, and abortion data, IBD phenotype and therapy. Disease-related 
pregnancy knowledge was assessed using Crohn’s and colitis pregnancy 
knowledge score (CCPKnow). CCPKnow consists of 18 questions and scores 
lower than 7 are considered poor. Patients were divided according to the 
diagnosis into the group with ulcerative colitis (UC) and Crohn’s disease 
(CD). These two groups were further stratified according to the occurrence 
of pregnancy after IBD diagnosis.
results: We analyzed data from 165 IBD patients (73 UC, 92 CD). In UC 
group 23 (31.5%) and in CD group 32 (34.9%) were childless. After IBD was 
diagnosed a total of 48 pregnancies occurred. In 17 UC patients, there were 
24 pregnancies while in CD patients a total of 18 women had 24 pregnan-
cies. Statistically, a significant difference was shown in UC patients when 
the average number of children was compared between groups with and 
without pregnancy after IBD diagnosis (2.05 vs.0.94, p< 0.001). The aver-
age age at diagnosis in UC patients who gave birth after IBD diagnosis 
was 24±6 compared to 37±13years in the group who did not give birth after 
IBD diagnosis (p< 0.001). Average CCPKnow score surprisingly did not dif-
fer between the two groups (6.82 vs. 5.76 p>0.05). CD patients who were 
pregnant after diagnosis were significantly younger (p< 0.001) compared 
to those who did not (21±7 vs 33±12, respectively) and they had an average 
of 1.5 children compared to 0.96 in those who did not have children after 
IBD was diagnosed (p< 0.05). The CCPKnow score was higher in patients 
that had children after IBD diagnosis although the difference did not reach 
statistical significance (7.61 vs. 5.31, p=0.051). The average number of chil-
dren in mothers on biological therapy was 1.0 on infliximab (IFX) and 0.96 
on adalimumab (ADA).
conclusion: : Our study confirmed that voluntary childlessness is common 
in female patients with IBD. The CCPKnow score is extremely low in the 
examined population and is not related to the decision to have children 
after IBD diagnosis. Patients who had children after IBD was diagnosed 
were significantly younger at diagnosis and had more children than those 
who remained childless after IBD was diagnosed. There is an urgent need 
to improve pregnancy and fertility-related knowledge in IBD patients in 
Serbia.
disclosure: Nothing to disclose 
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Introduction: People with inflammatory bowel disease (IBD) are exposed 
to multiple risk factors for cognitive impairment, including inflammation, 
nutritional deficiencies, depression, pain and vascular damage. Further-
more, reduced productivity and subjective cognitive difficulties are highly 
prevalent in people with IBD. To date, however, the presence of neurocog-
nitive deficits in people with IBD has not been systematically evaluated.
aims & Methods: Using a PRISMA systematic review and meta-analysis, 
we tested for domain-specific neurocognitive deficits in people with IBD 
compared to healthy controls. We systematically searched EMBASE, Web 
of Knowledge, Medline, CINAHL, PsycINFO and grey literature from incep-
tion to 31 December 2018 for cross-sectional- and longitudinal studies 
comparing cognitive function in adults with IBD versus healthy controls. 
According to DSM-5 classification, cognitive measures were stratified by 
domains of executive function (including working memory), attention, 
perceptual-motor, learning and recall, language, social cognition, as well 
as premorbid IQ. For any cognitive domain reported by 3 or more studies, 
we performed random-effects meta-analysis using STATA 15.0 to calculate 
the standardised mean difference (SMD) between IBD and control groups; 
higher scores reflected better performance. Where a single study used 
multiple measures within a single domain, we averaged the effect sizes. 
Between-study heterogeneity was assessed using the I2 statistic; publica-
tion bias estimated using Egger’s intercept test; and study quality assessed 
using the IBD-modified Newcastle-Ottawa scale. For significant findings, 
we used Monte-Carlo permutation tests for meta-regression to test the fol-
lowing potential moderators of cognitive impairment: age, sex (% female), 
IBD disease duration, depressive symptoms (% of maximum questionnaire 
score) and years of formal education.
results: Of 8287 articles screened, 11 were included, of which 3-, 6-, and 
1 were of high, moderate and low quality respectively. All studies were 
cross-sectional; none specifically recruited older adults; and 6-, 1-, and 
4 recruited populations with Crohn’s disease, ulcerative colitis and mixed 
IBD respectively. The sample (n=674 people) had mean age 39.9 years and 
60.2% were female. Despite no difference between groups in premorbid 
IQ (p=0.13), the IBD group showed deficits compared to healthy controls in 
attention (pooled effect size (ES) = -0.40 [95% confidence interval -0.69 to 
-0.10], p=0.009, I2=4.3%) and executive function (pooled ES = -0.38 [-0.70 
to -0.07], p=0.017, I2=20.3%), including specifically in working memory 
(pooled ES = 0.73 [-1.09 to -0.37], p< 0.001, I2=0%). By contrast, deficits in 
learning and recall were inconsistent (pooled ES = -0.50 [-1.08 to 0.08], 
p=0.089, I2=72.8%) and data for other cognitive domains insufficient for 
meta-analysis. There was no evidence of publication bias. Although there 
were no significant moderators of cognitive impairment, power of meta-
regression was limited by low between-study heterogeneity.
conclusion: Despite comparable premorbid IQ, people with IBD show 
small-to-moderate deficits in attention and overall executive function, 
including large deficits in working memory. Such deficits may impact ad-
versely on productivity. Longitudinal studies are required to test the course 
of neurocognitive deficits - including specifically in older adults - whilst 
testing the biological and psychological pathways that can be modified to 
improve cognitive function in people with IBD.
disclosure: Nothing to disclose 
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Introduction: Inflammatory Bowel Disease (IBD) incidence rates seem to 
be stabilised in adults in industrialised countries unlike in the paediatric 
population.
aims & Methods: The aim of this study was to describe changes in inci-
dence and phenotypic presentation of adult-onset IBD in northern France 
during a 27-year period. All adult-onset IBD patients (≥ 17 years at IBD 
diagnosis) were issued from the EPIMAD population-based IBD registry 
in France between 1988 and 2014. Standardized incidence rates were cal-
culated for Crohn’s Disease (CD) and Ulcerative Colitis (UC) in the whole 
population, and separately according to age and gender. Digestive location 
was defined according to the Montreal classification.
results: 17,686 incident IBD cases were recorded including 10,206 CD 
(58%), 6,839 UC (39%) and 640 IBD unclassified (IBDU) (4%). Median age 
at diagnosis was lower in CD (28 years, interquartile range (IQR) [22-40]) 
than in UC (36, IQR[27-49]) (p<0.0001). Age at diagnosis was stable in time 
for both diseases (p=0.37 in CD and p=0.52 in UC). Females were younger 
at diagnosis than men, especially in UC : respectively 28 IQR[21-39] vs 29 
IQR[22-40] in CD (p<0.0001) and 33 IQR[26-45] vs 39 IQR[28-51] (p<0.0001) 
in UC. The proportion of females were significantly higher in CD (females/
males = 1.36) conversely to UC (females/males = 0.84) (P<0.0001). Sex ratio 
was stable over time in CD (p=0.28) and changed in UC with an inver-
sion from 0.70 in 1988-1990 to 1.10 in 2012-2014 (p=0.001). Median time 
between onset of symptoms and IBD diagnosis was consistently 3 months 
IQR[1-6]. Mean annual incidence was 13.5/105 95% Confidence Interval 
(95%CI) [13.3 - 13.7] for IBD overall, 7.5/105 95%CI[7.4 - 7.7] for CD, 5.4/105 
95%CI[5.3 - 5.6] for UC and 0.51/105 95%CI[0.46 - 0.55] for IBDU. From 
1988-1990 to 2012-2014, a continuous increase in incidence of CD was ob-
served while that of UC stayed stable: for CD from 5.5 to 7.9/105 (+44%, p< 
0.0001) and for UC at 5.4/105. The most important increase of IBD incidence 
rate was in young women (17-39 years): average percent change of +1.9% 
per year in CD (p< 0.0001) and +1.7% per year in UC (p< 0.0001). In CD, 
over time, pure colonic location (L2) decreased from 41% (1988-1990) to 
25% (2012-2014), while pure ileal (L1) and ileo-colonic (L3) locations in-
creased from 20% to 26% and from 39% to 49%, respectively (p< 0.0001). 
During the same period, explorations of the small bowel increased from 
76% to 86%. In UC, proctitis (E1) and left sided colitis (E2) represented 
38% and 37% of the locations.
conclusion: In this French population-based study, CD incidence increases 
continuously during a 27-year period, especially CD with ileal involvement, 
while UC incidence remains stable. These results highlight the difference 
in immunopathology between each CD phenotype. Moreover, CD and UC 
incidence rates rise mostly in young women (17-39 years), suggesting that 
one or more strong environmental factors may predispose the women to 
IBD.
disclosure: Nothing to disclose 
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aims & Methods: We conducted a systematic review with meta-analysis 
of population-based studies to compare the phenotypic characteristics of 
UC in Latin America with UC in Hispanic-Americans in the U.S. We also 
aimed to compare phenotype of UC across Latin American countries. Phe-
notype was defined using the Montreal classification. A systematic search 
was conducted using MEDLINE and EMBASE. Google Scholar was used to 
search for unpublished data. 
Inclusion criteria: 
(i) studies describing the phenotype of UC in Latin America and Hispanics 
in the U.S. 
(ii) age equal to or greater than 18 years. 
Exclusion criteria: 
(i) prevalence or incidence studies not describing phenotype. 
A random effects model was chosen “a priori” for analysis of pooled pro-
portions.
results: A total of 4,627 studies were screened. There were 34 studies from 
9 countries in Latin America and 7 studies from Hispanics in the U.S. This 
included 4,082 patients with UC from Latin America and 390 Hispanic pa-
tients with UC in the U.S. 
The predominant phenotype in Latin America was proctitis (E1) with 
a pooled proportion of 0.37 (95% CI 0.28-0.45, I2 98.2%), as compared 
with 0.08 (95% CI 0.05-0.11, I2 18%), p=0.003, in the U.S. Extensive coli-
tis (E3) was present in two-thirds of Hispanics in the U.S. as compared 
with only one-third of Latin Americans, p<0.001. There was no difference 
in the prevalence of left-sided colitis (E2) in Latin America and the U.S, 
with nearly one-third of patients showing this phenotype in both regions, 
p=0.82. Among the Latin American countries, Cuba and Puerto Rico had 
the highest frequency of proctitis with nearly two-thirds of patients show-
ing this phenotype. Left-sided colitis was more frequent in Colombia (0.39, 
95% CI 0.34-0.45) and Peru (0.36, 95% CI 0.29-0.44), whereas, extensive 
colitis was more frequent in Argentina (0.67, 95% CI 0.59-0.75) and Mexico 
(0.54, 95% CI 0.51-0.57). 
variables countries of Origin n Prevalence
95 % 
confidence 
Interval
I 
squared
es P 
value 
(%)
Meta 
regression p 
value
E1: Proctitis
Latin 
America
33 0.37 0.28 0.45 98.2 0.003
 
Hispanic 
Americans
6 0.08 0.05 0.11 18.06  
E2: Left-
sided colitis
Latin 
America
30 0.27 0.23 0.32 91.11 0.815
 
Hispanic 
Americans
5 0.26 0.15 0.38 82.01  
E3: 
Extensive 
Colitis
Latin 
America
34 0.38 0.32 0.44 95.26 <0.001
 
Hispanic 
Americans
6 0.64 0.52 0.77 84.01  
[Phenotypic Characteristics of Ulcerative Colitis in Hispanics from Latin 
America versus the United States]
conclusion: The phenotype of UC varies between Latin America and the 
U.S. Proctitis was more frequent in Latin America, whereas, extensive coli-
tis was the predominant phenotype in Hispanics from the U.S. This may 
suggest that Hispanics that develop UC in the U.S. have a more aggressive 
form of the disease. In Latin America, Cubans and Puerto Ricans have a 
milder form of UC as compared with Argentinians and Mexicans who are 
more likely to have extensive disease. Further research is warranted to 
determine underlying genetic, environmental and dietary factors which 
may account for these differences.
disclosure: Nothing to disclose 
P0346 InfLaMMaTOry BOWeL dIsease Is assOcIaTed WITh 
a hIgher rIsk Of renaL cancer
Kochhar G.1, Syed A.2,3, El-Hachem S.2, Abdul-Baki H.2, Chintamaneni P.2, 
Thakkar S.2, Shen B.4, Dulai P.5
1Allegheny Health Network, Gastroenterology & Hepatology, Pittsburgh, 
United States, 2Allegheny Health Network, Gastroenterology, Pittsburgh, 
United States, 3Case Western Reserve University - School of Medicine, 
Internal Medicine, Cleveland, United States, 4Cleveland Clinic, 
Gastroenterology, Cleveland, United States, 5University of California San 
Diego, Gastroentrology, San Diego, United States
contact e-Mail address: drkochhar@gmail.com
Introduction: Inflammatory bowel disease (IBD) including ulcerative coli-
tis (UC) and Crohn’s disease (CD) has been implicated as a precursor to 
extra-intestinal cancers. Recent studies have shown an increased risk of 
renal cancer. 
The aim of our study is to conduct a population-based study to explore 
the risk of renal cancer in IBD, and evaluate the role of IBD associated 
medications.
aims & Methods: A population-based study was conducted using a cloud-
based, HIPPA-enabled web platform called Explorys (IBM, New York) to 
collect aggregated de-identified electronic health records. At the time of 
the study, Explorys had access to over 62 million unique records. Data 
was obtained using ICD-9 code criteria for Crohn’s disease, ulcerative 
colitis, and malignant neoplasm of the kidney. Each cohort was further 
evaluated for baseline patient characteristics and usage of IBD-associated 
medications, including corticosteroids, biologics, and immunomodula-
tors. All-cause mortality was also reported. Comparisons were reported 
for relative risks (RR) with 95% confidence intervals (CI) in a random 
effect model.
results: Renal cancer was more common in patients with both UC [RR 
3.51 (95% CI: 3.29-3.74), P< 0.0001] and CD [RR 3.45 (95% CI: 3.25-3.66), 
P< 0.0001] vs. the general population. Patients over the age of 65, males, 
and Caucasians with CD had an increased risk of renal cancer. Patients 
over the age of 65, males, Caucasians and African-Americans with UC had 
an increased risk of renal cancer. In patients with CD, subsequent renal 
cancer had an increased risk in the setting of corticosteroids [RR 2.45 (95% 
CI: 2.12-2.82), P< 0.001], biologics [RR 1.86 (95% CI: 1.65-2.10), P< 0.001], 
and immunomodulators [RR 1.37 (95% CI: 1.19-1.58), P< 0.001]. In patients 
with UC, renal cancer risk was elevated in patients on corticosteroids [RR 
2.24 (95% CI: 1.92-2.62), P< 0.001], biologics [RR 1.61 (95% CI: 1.41-1.83), 
P< 0.0001] and immunomodulators [RR 1.44 (95% CI: 1.20-1.72), P< 0.001]. 
All-cause mortality was higher in patients with renal cancer in patients 
with CD [RR 3.91 (95% CI: 3.35-4.56), P< 0.0001] and UC [RR 3.55 (95% CI: 
3.01- 4.19), P< 0.0001].
conclusion: Risk of renal cancer is higher in patients with ulcerative colitis 
and Crohn’s Disease. All-cause mortality risk is significantly higher in pa-
tients with UC and CD with renal cancer.
disclosure: Nothing to disclose 
P0347 PhenOTyPIc characTerIsTIcs Of uLceraTIve 
cOLITIs In LaTIn aMerIcans versus hIsPanIcs frOM The 
unITed sTaTes: a sysTeMaTIc revIeW WITh MeTa-anaLysIs
Satiya J.1, Contreras A.2, Zuckerman M.3, Dodoo C.4, Dwivedi A.4, Avalos D.5
1University of Miami, Internal Medicine, Atlantis, United States, 2Texas 
Tech University Health Sciences Center, Division of Internal Medicine, El 
Paso, United States, 3Texas Tech University Health Sciences Center, Division 
of Gastroenterology, El Paso, United States, 4Texas Tech University Health 
Sciences Center, Division of Biostatistics & Epidemiology, El Paso, United 
States, 5Digestive Medicine Associates LLP, Miami, United States
contact e-Mail address: jinen19@gmail.com
Introduction: Latin America has been experiencing a rise in the prevalence 
and incidence of inflammatory bowel disease. Environmental and dietary 
changes may be contributing to this rise. Ulcerative colitis (UC) is more 
common than Crohn’s disease in Latin America, but it is unclear whether 
the phenotype seen in Latin America is similar to the one seen in Hispan-
ics residing in the United States (U.S.), two locations with distinct envi-
ronmental and dietary exposures. In addition, it is yet to be determined 
whether there are major differences in the phenotype of ulcerative colitis 
across Latin America.
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P0348 TrefOIL facTOr 3 Is hIghLy PredIcTIve Of cOMPLeTe 
MucOsaL heaLIng IndePendenTLy and In cOMBInaTIOn WITh 
c-reacTIve PrOTeIn In PaTIenTs WITh uLceraTIve cOLITIs
Nakov R.1, Velikova T.2, Nakov V.3, Gerova -Nankova V.4, Tankova L.5
1Clinic of Gastroenterology, Queen Yoanna University Hospital, 
Gastroenterology, Sofia, Bulgaria, 2University Hospital Lozenetz, Laboratory 
of Clinical Immunology, Sofia, Bulgaria, 3Tsaritsa Joanna University Hospital, 
Gastroenterology, Sofia, Bulgaria, 4University Hospital Queen Joanna, 
Gastroenterology, Sofia, Bulgaria, 5University Hospital Sofia, Clinic of 
Gastroenterology, Sofia, Bulgaria
contact e-Mail address: radislav.nakov@gmail.com
Introduction: Trefoil factors (TFFs) include a family of three mucin-associ-
ated peptides secreted by goblet cells in the intestinal mucosa. They have 
a key role in maintaining mucosal barrier integrity and are up-regulated 
at the site of mucosal damage. It has recently been suggested that serum 
levels of TFF3 can predict disease activity and reflect mucosal healing (MH) 
in ulcerative colitis (UC) patients with minimal disease activity. However, 
its potential to predict complete MH independently or in combination with 
other biomarkers has never been addressed.
aims & Methods: In the current study we aimed to evaluate the role of 
trefoil factor 3 (TFF3) as a marker for complete MH in patients with UC. 116 
consecutive UC patients were enrolled. TFF3 levels were measured by ELI-
SA and were compared to clinical activity, assessed by Lichtiger Index, fecal 
calprotectin (FCP) and C-reactive protein (CRP) levels. Colonoscopy was 
performed in all the patients and the findings were graded according to 
Mayo endoscopic score (EMS) and UC endoscopic index of severity (UCEIS).
results: TFF3 levels were significantly correlated with Lichtiger Index (r = 
0.736, p < 0.001), EMS (r = 0.811, p < 0.001), UCEIS (r = 0.820, p < 0.001), 
FCP (r = 0.696, p < 0.001) and CRP (r=0.405, p < 0.001). The TFF3 cut-off 
level of 6.74 ng/ml indicated complete MH (EMS = 0; UCEIS =0) with a 
sensitivity and specificity of 0.879 and 0.869, respectively (area under the 
curve (AUC), 0.927; 95% confidence interval, 0.877-0.976). The DeLong’s 
test revealed no significant difference between the AUC of TFF3+CRP and 
the AUC of FCP (Z = 1.717, p = 0.086), AUC of TFF3+FCP (Z = 1.908, p = 
0.056), and AUC of TFF3+CRP+FCPP (Z = 1.915, p = 0.056). However, the 
AUC of TFF3+CRP showed significant difference with the AUC of TFF3 (Z = 
2.210, p = 0.027) and the AUC of CRP (Z = 3.145, p = 0.002) for predicting 
complete MH.
conclusion: TFF3 levels correlated significantly with clinical activity, endo-
scopic indices, CRP and FCP. TFF3 is highly predictive marker of complete 
MH independently and in combination with CRP in patients with UC
disclosure: Nothing to disclose 
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contact e-Mail address: gabrieledragoni89@gmail.com
Introduction: Prevention of post-operative recurrence (POR) is a contro-
versial field in Crohn’s disease. Despite evidence for some clinical risk 
factors favoring POR (previous ileocolonic resections, extensive resection, 
penetrating disease, active smoking), there is no total agreement among 
guidelines[1-2] on initiation of postoperative prophylactic therapy, preferred 
drug as well as on the modality and timing of POR assessments.
aims & Methods: Our aim was to obtain an international perspective on 
the current adopted therapies and strategies (immediate postoperative 
prophylaxis versus endoscopy-driven) with regard to prevention of POR. 
A 11-question anonymous survey was proposed to all gastroenterologists 
participating at various ECCO pre-meeting workshops in March 2019.
results: Data from 168 participants were collected (participation rate 
24%). Median gastroenterology experience was 8 years [IQR 4-14 years], 
65% junior (≤10 years of practice), 35% senior (>10 years). The major-
ity were European (67%), while the remainder were representatives of 19 
countries across all five continents. Most participants (60%) were working 
in an academic hospital. 
Post-operative endoscopic evaluation to assess POR was routinely per-
formed within 12 months by 87% of respondents. This was the same for 
patients who do or do not receive immediate postoperative prophylactic 
therapy. After a first endoscopy without POR, 89% of physicians reported 
following up patients with a combination of clinical examination, lab test 
and fecal calprotectin, and 45% considered endoscopy as a routine assess-
ment modality. Comparison between young and senior gastroenterologists 
did not show any statistical difference (p>0.05).
Most respondents (60%) reported starting medical prophylaxis against 
POR in naïve patients if 1 or more risk factors are present, while 16% of 
respondents would prescribe immunoprophylaxis even in patients without 
risk factors. Only 20% of participants reported that they would wait for 
endoscopic proof of recurrence (Rutgeerts score ≥i2) before starting im-
munomodulators. Data were similar between young and senior gastroen-
terologists (p>0.05). 
In regard to the class of drug, the number of POR risk factors lead the ma-
jority (59%) to prescribe biologics over immunosuppressants. Among bio-
logics, 98% of respondents having access to anti-TNF reported a routine 
use of them in this setting, while 62% and 56% of physicians with access 
to vedolizumab and ustekinumab respectively prescribed these drugs for 
POR prophylaxis.
In the specific clinical context of perianal disease, fistulizing phenotype or 
concomitant colonic disease, most of the participants reported adopting an 
immediate POR prophylaxis in 98%, 85% and 88% of cases, respectively. 
Conversely, a significant number of respondents were more prone to an 
endoscopy-driven treatment in the elderly (42%) and in long-standing dis-
ease after failure of thiopurines (51%). No significant difference (p>0.05) 
in post-operative approach was registered in these scenarios between 
young and experienced gastroenterologists.
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conclusion: IFN-g and TGF-b1 may be useful to identify AZA responders 
and IL8 and IL6 levels could be good predictors of response to both bio-
logical and immunosuppressive drugs. Our study is a first step for tailored 
therapy in IBD patients.
disclosure: Nothing to disclose 
P0351 MeasurIng InfLIxIMaB drug LeveLs cOnsIsTenTLy: 
aLIgnMenT TO The 1sT InTernaTIOnaL sTandard MaTerIaL 
(nIBsc 16/170) usIng IdkMOnITOr® InfLIxIMaB drug LeveL 
eLIsa Leads TO an Increase In The Measured InfLIxIMaB 
cOncenTraTIOn
Nice R.1, Perry M.2
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contact e-Mail address: rachel.nice@nhs.net
Introduction: Measuring the concentration of infliximab drug levels in IBD 
patients is widely practiced. Variability between assays has previously 
been a problem as inconsistent results are obtained between different 
laboratories, depending on the methodology and manufacturer used. 
Introduction of the 1st International Standard infliximab material (NIBSC 
16/170) should allow for alignment of the methods for measuring inflix-
imab, and ultimately more consistent results between laboratories. 
Immundiagnostik has aligned the IDKmonitor® Infliximab drug level ELI-
SA by re-calibrating with the International Standard infliximab material 
(NIBSC 16/170). The impact of this change upon clinical results is explored.
aims & Methods: The aim of this work is to determine the change in the 
measured concentration of infliximab using the IDKmonitor® Infliximab 
drug level ELISA kit before and after alignment with the 1st International 
Standard infliximab (NIBSC 16/170).
Serum samples received through the routine infliximab monitoring service 
(n=80) were measured using the IDKmonitor® Infliximab drug level ELISA, 
using kits manufactured before and after calibration with the 1st Inter-
national Standard infliximab (NIBSC 16/170). Regression and correlation 
results were obtained.
results: Regression analysis of results before and after the calibration 
provide are good (R2 = 0.99). Correlation of the data shows that when 
aligned to the 1st International Standard infliximab (NIBSC 16/170), the 
measured concentration of infliximab is higher than that obtained with the 
kit manufactured before the calibration (i.e. post calibration result = 1.35x 
pre-calibration result + 0.81).
conclusion: International standardisation of infliximab drug level con-
centrations is now possible due to the introduction of the 1st International 
standard infliximab. This is a step change towards consistency of measur-
ing infliximab drug levels. 
However, clinicians who are using this test for monitoring need to be 
aware of this change and consider patient results carefully in the light of 
this information.
disclosure: Nothing to disclose 
P0352 LeveLs Of seruM free ThIOLs are suPerIOr TO fecaL 
caLPrOTecTIn In PredIcTIng endOscOPIc dIsease acTIvITy In 
InfLaMMaTOry BOWeL dIsease
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Introduction: Oxidative stress is considered to play a pivotal role in the 
pathogenesis of Inflammatory Bowel Diseases (IBD). Serum free thiol 
groups (R-SH) reliably reflect systemic oxidative stress, since they are 
readily oxidized by reactive species. Endoscopic examination is the gold 
standard to determine disease activity in IBD. In clinical practice, fecal cal-
protectin (FC) levels are most widely used as surrogate marker for endo-
scopically proven disease activity. 
However, its diagnostic accuracy and applicability are still subject to de-
conclusion: Clinicians are well aware of the risk of POR in Crohn’s disease 
and tight endoscopic control within twelve months is often proposed. After 
a first ileocolonoscopy without POR, most respondents reported relying 
on fecal calprotectin for routine monitoring. The surprisingly high rate of 
immediate postoperative prophylactic therapy with biologics, even in the 
absence of clear endoscopic recurrence or clinical risk factors for POR, 
highlights the need for a randomized trial comparing immediate prophy-
laxis with endoscopy-driven therapy.
references: [1] Paolo Gionchetti, Axel Dignass, Silvio Danese, et al., on 
behalf of ECCO; 3rd European Evidence-based Consensus on the Diagnosis 
and Management of Crohn’s Disease 2016: Part 2: Surgical Management 
and Special Situations, Journal of Crohn’s and Colitis, Volume 11, Issue 2, 
1 February 2017, Pages 135-149 [2] Nguyen GC, Loftus EV Jr, Hirano I, et al., 
AGA Institute Clinical Guidelines Committee. American Gastroenterologi-
cal Association Institute Guideline on the Management of Crohn’s Disease 
After Surgical Resection. Gastroenterology. 2017 Jan;152(1):271-275
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Introduction: There is a rising interest in identifying easy to dose disease 
markers to predict response to therapy in inflammatory bowel disease 
(IBD) patients.
Several markers have been studied, but none of them has been validated.
aims & Methods: The aim of our study was to understand the role of in-
flammatory interleukins in predicting the response to immunosuppressive 
or biological therapy. A monocentric prospective study was conducted. 
Forty IBD patients who needed to start immunosuppressive or biologi-
cal drugs were included. For each patient serological levels of interleukin 
(IL)1-B, IL4, IL6, IL8, Il10, IL12p70, IL17, IFN-gamma, TNF-alfa, TGF-beta-1 
were dosed at the time of enrollment (T0) and after three months of im-
munosuppressive or biological therapy (T3). To dose these cytokines, mul-
tiplex Bio-Plex® system was used.
results: Among the 40 enrolled patients, 32 (80%) were suffering from 
Crohn’s disease (CD) and 8 from Ulcerative Colitis (UC); the mean age was 
46.6 years (18-79 years). 
IL1-B T0 was detectable only in CD patients (mean value 0.05 pg/ml), with 
no difference due to illness localization. 
Serological T0 TNF-a levels correlated with pre-treatment endoscopic ac-
tivity: among patients with moderate or severe endoscopical activity me-
dian value was 20.94 pg/ml while among mild activity or remission group 
median value was 13 pg/ml (p=0,034).
T0 IL8 levels correlated both with pre-treatment fecal calprotectin (p=0,03; 
r= 0.437) and endoscopic activity (median value 28,07 pg/ml for moderate 
to severe activity vs 5,79 pg/ml median value for mild activity/remission; 
p=0,023)
T0 TGF-b1 levels were significantly lower in CD patients than in UC patients 
(p = 0.0076). 
Low levels of IL6 at T0 (< =0.54 pg/ml) predicted a negativization of fecal 
calprotectin after three months of adalimumab (ADA) administration (area 
under the curve [AUC] = 0.89; p=0,001; sensitivity = 72.7%; specificity = 
100%). Low levels (median value = 0.54 pg/ml) of T0 IL6 correlated with 
a higher probability to response to azathioprine (AZA) too (p = 0.049). T0 
IL6 >=0.9 pg/ml correlated with higher response to vedolizumab (VEDO). 
Patients who responded to AZA had undetectable T0 serological levels of 
IFN-g, while the ones who did not respond had a median IFN-g level of 
0.11 pg/ml (p = 0.043). 
T0 serological levels of TGF-b1 correlated with response to AZA (< 4.7 pg/
ml) and to ADA (>6.57 pg/ml) (p = 0.027). 
Low IL12p70 levels predicted a better response to therapy at all (p = 
0.0095), but not for each drug separately. 
T0 IL8 levels predicted response to vedolizumab therapy: at ROC curve 
analysis we observed for >6,6 pg/ml levels of IL8 a response to VEDO in all 
patients (AUC = 1; sensitivity 100%; specificity 100%; p=0.0001).
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bate. Systemic biomarkers for disease activity are urgently sought to im-
prove disease activity monitoring and to avoid repeated endoscopic ex-
amination.
aims & Methods: In this study, we aimed to establish concentrations of 
serum free thiols in IBD and assessed their potential utility as a discrimi-
nating biomarker for different grades of endoscopic disease activity. Serum 
free thiol concentrations were measured in 78 IBD patients (31 patients 
with Crohn’s disease (CD) and 47 patients with ulcerative colitis (UC)) and 
50 healthy controls, adjusted for serum albumin. Albumin-adjusted serum 
free thiols were analyzed for associations with clinical and biochemical 
disease parameters. Endoscopic disease activity was assessed by the Sim-
ple Endoscopic Score for CD (SES-CD) and Mayo endoscopic subscore for 
UC, that were merged to create an IBD composite endoscopy score. Non-
parametric ROC estimation with cross-validated areas under the curves 
(AUCs) was used to assess the discriminative value of serum free thiols 
regarding the degree of endoscopic disease activity (n=54) and to com-
pare this to fecal calprotectin (n=28) in patients for which those data were 
available.
results: Mean serum free thiol concentrations were significantly decreased 
in both CD and UC as compared to healthy controls (19.4±3.1 and 17.8±3.4 
vs. 21.1±1.9 µmol/g of albumin, P < 0.001). Albumin-adjusted serum free 
thiols significantly inversely associated with age (r = -0.49, P < 0.01), plate-
let counts (r = -0.29, P < 0.01) and fecal calprotectin levels (r = -0.32, P 
< 0.05). Patients with severe endoscopic disease activity demonstrated 
significantly lower serum free thiol concentrations compared to patients 
having mild disease activity (16.2±3.1 vs. 20.4±3.4 µmol/g of albumin, P < 
0.01). Finally, serum free thiols highly accurately discriminated between 
mild and moderate-to-severe disease activity, better than fecal calprotec-
tin (FC) levels (AUC=0.87, P < 0.001 vs. AUC=0.76, P < 0.05, respectively). 
After cross-validation, serum free thiols maintained their predictive ac-
curacy (AUC=0.89, P < 0.001).
conclusion: Serum free thiols are reduced in IBD as compared to healthy 
controls and strongly correlate with the degree of endoscopic disease ac-
tivity. Quantifying systemic redox status in IBD may be a promising, mini-
mally invasive strategy to monitor IBD disease activity. Future studies are 
warranted to further explore free thiols as potential biomarker for IBD 
disease activity in larger, prospective patient cohorts and serially assess 
their predictive value in relation to disease course and therapeutic inter-
ventions.
disclosure: Nothing to disclose 
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Introduction: Diagnosis of inflammatory bowel disease (IBD) require com-
bination of patient history and physical examination in association with 
laboratory, endoscopic, histologic, and radiographic investigations. Al-
though ileocolonoscopy is the preferred method of diagnosis, assessing 
disease extent, activity and follow up after therapy but repeated endoscopy 
is neither practical nor feasible, being invasive, time consuming, and not 
always well tolerated or accepted. 
Therefore, employment of non-invasive biomarkers is needed. No single 
marker is ideal. Many studies focus on fecal calprotectin (FC) in IBD and 
confirm its value in diagnosis, disease activity evaluation, effect evalua-
tion, and relapse monitor.
Neopterin, is a metabolite of cyclic guanosine monophosphate that is re-
leased by activated T lymphocytes and macrophages after induction by 
interferon γ. Neopterin release from activated macrophages may provide, 
at least theoretically by its intrinsic mechanism of release, an advantage 
over calprotectin which is not secreted and represents a neutrophil-de-
rived protein.
aims & Methods: ts specificity and sensitivity to To investigate the relation 
between fecal neopterin (fNeo) excretion and IBD clinical and endoscopic 
activity indices and compare its specificity to that of fecal calprotectin.
60 patients were included: 30 patients with ulcerative colitis (UC) (15 clini-
cally in remission, 15 active ) and 30 patients with Crohn’s disease (CD) (15 
clinically in remission, 15 active ) and 20 healthy control subjects. 
FC and fNeo were detected in stool samples by enzyme-linked immuno-
sorbent assay (ELISA).
The following indices were calculated at enrollment: for Crohn’s disease 
the Crohn’s disease activity index (CDAI) and simple endoscopic score for 
Crohn’s disease (SES-CD); for ulcerative colitis, Simple Clinical Colitis Activ-
ity Index (SCCAI) and ulcerative colitis endoscopic index of severity (UCEIS).
results: Among UC patients, fNeo was higher in those with either clini-
cally active or inactive disease than in control subjects ( P=0.001, P=0.040 
; for active and inactive disease vs. controls respectively) but there was no 
significant difference between both UC groups (P=0.225). For CD patients, 
fNeo concentration was higher in those with active disease than in those 
with inactive diseas (P< 0.001) or healthy controls (P=0.001). Nonsignifi-
cant trends toward greater fecal neopterin concentration were observed 
with increased colonic disease involvement. Neopterin was not found to 
be significantly correlated with all laboratory tests done (Heamoglobin, 
platelets, white blood cells, ESR, CRP, serum albumin, fecal calprotectin). 
fNeo was significantly correlated with CDAI (r=0.604, P< 0.001) , SES-CD 
(r=0.600, P< 0.001) in CD patients but not with SCCAI, UCEIS in UC patients. 
fNeo was found to have comparable sensitivity and overall accuracy to FC 
in predicting endoscopic disease activity in CD patients but less in UC and 
combing both stool tests together increases the sensitivity and specificity 
of either alone.
conclusion: Stool neopterin could be used to assess disease activity in CD 
but not in UC patients as it correlates positively with disease activity indi-
ces in CD but not in UC. Thus its measurement represents a novel reliable 
biomarker useful to detect and monitor the severity of mucosal affection in 
CD patients more than UC.
disclosure: Nothing to disclose 
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during follow-up (OR 1.3 CI 95% 1-1.6 p = 0.033). In contrast, they exhibit 
fewer abscesses (OR: 0.6 (95% CI: 0.5-0.9), p = 0.001) and have less fa-
milial history of inflammatory bowel disease (OR 0.7 CI 95% 0.6 -0.9 p = 
0.008).
conclusion: In the most extensive series of upper digestive tract involve-
ment in CD, it is shown that they present a more evolved disease at CD 
diagnosis, suggesting that these patients may be diagnosed late on time. 
Consequently, they are more refractory to treatments, requiring more 
frequently anti-TNF treatment. Chronic anaemia due to iron loss in the 
absence of endoscopic findings should be suspicious of upper CD involve-
ment. Diagnostic and specific treatment strategy for these patients must be 
considered including signs that allow a high rate of suspicion and a rapid 
therapeutic escalation.
disclosure: Nothing to disclose 
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Introduction: Up to one third of patients with acute severe ulcerative coli-
tis (ASUC) will fail intravenous steroid (IVS) treatment, requiring rescue 
therapy with cyclosporin (Cys), infliximab (IFX), or colectomy. Even with the 
best available therapy, over 1/3 of these patients will still require surgery. 
Long -term outcomes of steroid responsive (SR) patients have seldom been 
studied. We hypothesize that this subgroup of patients also presents an 
unfavorable short and long term prognosis.
aims & Methods: We hypothesize that SR patients also presents an unfa-
vorable short and long term prognosis.
Retrospective multicenter study including patients fulfilling Truelove and 
Witts criteria for ASUC. Response to IVS was determined by the attending 
physician between the 3rd and 5th day of admission. Patients were then 
classified as steroid non responders (SNR) or SR. A cohort of consecutive 
patients admitted with a flare of Ulcerative colitis but without criteria for 
ASUC served as a control group (CG). Endpoints included the need for bio-
logics, surgery or both in the 5 years following discharge.
results: 253 patients were included, 170 (67.2%) with ASUC (SNR: 47, SR: 
123) and 83 controls. 53.4% were male with median age of 33 (18- 80). 
Although SR patients presented lower surgical rates than SNR patients 
(13.9% vs 53.2%, P< 0.001) they were substantially higher than in the CG 
(0%, P< 0.001). Of note, 70.6% of surgeries in SR patients occurred within 
one year after discharge. Furthermore, 40.6% of SR patients were subse-
quently readmitted with a flare of colitis requiring biologics or surgery in 
44.0% and 28.0% of cases, respectively. Concerning treatment escalation, 
SR patients required less biologic therapy than SNR (36.7% vs 91.5%, P< 
0.001) but more so than patients in the CG (18.1%, P< 0.001). Likewise, a 
composite endpoint of any unfavorable outcome was more common in SR 
patients than in the CG (44.9% vs 18.1%, P< 0.001). Time to event analysis 
showed that SR patients reached an unfavorable outcome sooner than the 
CG (logrank test P< 0.001).
conclusion: Patients with ASUC present an unfavorable prognosis, even 
after an adequate response to IVS. Early therapy intensification should 
strongly be considered in these patients as almost half develop unfavor-
able outcomes.
disclosure: Nothing to disclose 
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Introduction: Patients with upper (L4) and diffuse (L1 + L4) Crohn’s disease 
(CD) may have a more aggressive and refractory disease course. However, 
evidence on this particular sub-type of patients is scarce. Clinical guide-
lines do not offer specific protocols on how to manage them.
aims & Methods: To identify the clinical characteristics, therapeutic re-
quirements and complications that are independently associated with an 
upper digestive tract CD involvement. 
Retrospective study of cases and controls matched (1: 2) by sex and age 
in patients with CD (L4 or L1 + L4: cases; L1 or L3: controls) of the ENEIDA 
database (49 hospitals). The small intestine was evaluated with radiologic 
and/or endoscopic examination, and complex perianal disease was ex-
cluded. Clinical variables: pattern, severity, anaemia; Complications: ste-
nosis, fistula, abscess, perforation and digestive bleeding; Therapeutic 
requirements: use of antiTNF, second line biologic drug, 1 or more biologi-
cal treatment, iv iron, blood transfusions, enteral nutrition, endoscopic/
radiological treatments, surgeries and hospitalisations were investigated. 
A logistic regression analysis with those significant variables in univariate 
analysis (SPSS) was performed.
results: 941 cases and 1882 controls were identified. Multivariate analysis 
showed that cases were independently associated to a stricturing pattern 
at disease diagnose (OR: 1.3 (95% CI: 1-1.6), p = 0.028), anaemia due to 
iron loss (OR: 1.9 (95% CI: 1,3-2.7), p < 0.002), more extensive involvement 
(> 30cm) (OR: 2.7 (95% CI: 2.2-3.3), p < 0.0001), and the use of anti-TNF 
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Bernardo S.1, Simões C.1, Fernandes S.R.2, Gonçalves A.R.3, Baldaia C.4, 
Valente A.I.5, Moura dos Santos P.M.4, Araujo Correia L.2, Marinho R.T.6
1Hospital Santa Maria, Centro Hospitalar Lisboa Norte, Gastroenterology, 
Lisboa, Portugal, 2Hospital Santa Maria, Centro Hospitalar Lisboa Norte, 
Lisboa, Portugal, 3Serviço de Gastroenterologia, Lisboa, Portugal, 4Hospital 
Santa Maria, Gastroenterology, Lisboa, Portugal, 5Hospital Santa Maria, 
Gastroenterology and Hepatology Intensive Care Unit, Gastroenterology, 
Porto, Portugal, 6Hospital de Santa Maria, Medical School of Lisbon, Lisboa, 
Portugal
contact e-Mail address: soniamcb@hotmail.com
Introduction: There is increasing evidence supporting the use of therapeu-
tic drug monitoring (TDM) of anti-TNF therapies in Crohn’s disease (CD) 
following loss of response. However, the potential benefit of proactive TDM 
is still unknown 1-4.
aims & Methods: To study the pharmacokinetics and clinical benefits as-
sociated with a proactive TDM strategy in CD.
Patients completing Infliximab (IFX) induction were assigned to a proac-
tive TDM protocol (pTDM). Before the 4th infusion and before every 2 infu-
sions, IFX drug levels and anti-drug antibodies were measured using a 
drug sensitive assay (Theradiag®, Lisa Tracker). Treatment was proactively 
escalated aiming at a trough level of 3-7 ug/ml. A retrospective cohort of 
patients treated with IFX but without TDM was used as a control group 
(noTDM). Endpoints included the need for IBD-related surgery and hos-
pitalization, treatment discontinuation, and mucosal healing (absence of 
ulceration in non-operated patients or Rutgeerts score < i2 in operated 
patients) at 2 years of follow-up. Patients with major bowel surgery, drug 
holiday and primary IFX non-response were excluded.
results: 185 patients were included in the study (35 in the pTDM and 150 in 
the noTDM group); Baseline characteristics were non-significant between 
groups. A median (range) of 3 (1-7) drug/anti-drug measurements were 
collected in the pTDM group over the 2-year period. The median (range) 
IFX trough levels and anti-drug antibodies were 5.80 µg/ml (0.03-16.4) 
and 0 U/mL (0-200.0), respectively. Pharmacokinetic analysis showed a 
significant correlation between IFX trough levels and C-reactive protein 
(ρ= -0.197, P= 0.01), fecal calprotectin (ρ= -0.344, P= 0.004) and anti-drug 
antibodies (ρ= -0.220, P= 0.003). Higher trough levels were associated 
with higher rates of mucosal healing (7.25 µg/ml (1.9-14) vs 2.9 µg/ml 
(0.03-7); P= 0.02, AUROC= 0.83), magnetic resonance enterography nor-
malization (7.25 µg/ml (3.75-14) vs 2.14 µg/ml (0.03-7); P< 0.001, AUROC= 
0.92) and transmural healing (7.5 µg/ml (3.75-14) vs 2.6 µg/ml (0.03-7.66); 
P= 0.015, AUROC= 0.88). 
After 2 years of follow-up, pTDM patients presented higher rates of treat-
ment escalation (74.3% vs 20.7%, P< 0.001) and mucosal healing (77.1% 
vs 46.7%, P= 0.01), but similar rates of hospitalization (P= 0.534), surgery 
(P= 0.241) and treatment discontinuation (P= 0.212). pTDM patients were 
less likely to reach any of the former outcomes (66.0% vs 45.7%, P= 0.033). 
In regression analysis only proactive TDM (OR 0.44 95%CI 1.52-8.54; P= 
0.04) and immunomodulation (OR 0.35 95%CI 1.17-4.63; P= 0.016) were 
independently associated with mucosal healing. Immunomodulation did 
not influence IFX trough levels (P= 0.456) and anti-drug antibodies (P= 
0.150), and was not associated with improved rates of mucosal healing (P= 
0.182) in the pTDM group.
conclusion: Higher IFX trough levels were associated with lower inflam-
matory biomarkers and higher rates of endoscopic and radiologic healing. 
In comparison with a cohort under conventional management, proactive 
TDM was unable to show a difference in the rates of surgery, hospitaliza-
tion and treatment discontinuation but significantly improved the rates of 
mucosal healing at 2-years. As several studies have shown that mucosal 
healing reduces the rates of surgery and hospitalization in the long-term, 
we hypothesize that a longer follow-up would significantly improve our 
results.
In conclusion, improved IFX pharmacokinetics were associated with better 
disease control. Proactive TDM was associated with higher rates of muco-
sal healing than a conventional non-TDM based management.
references: 1- Vande Casteele N, Ferrante M, Van Assche G, et al. Trough 
concentrations of infliximab guide dosing for patients with inflammatory 
bowel disease. Gastroenterology. 2015 Jun;148(7):1320-9.e3. 2- D’Haens G, 
Vermeire S, Lambrecht G, et al. Increasing Infliximab Dose Based on Symp-
toms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clin-
ical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active 
Luminal Crohn’s Disease. Gastroenterology. 2018 Apr;154(5):1343-1351.e1. 
3- Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman 
MT, Cheifetz AS. Improved Long-term Outcomes of Patients With Inflam-
matory Bowel Disease Receiving Proactive Compared With Reactive Moni-
toring of Serum Concentrations of Infliximab. Clin Gastroenterol Hepatol. 
2017 Oct;15(10):1580-1588.e3. 4- Papamichael K, Vajravelu RK, Vaughn BP, 
Osterman MT, Cheifetz AS. Proactive Infliximab Monitoring Following Re-
active Testing is Associated With Better Clinical Outcomes Than Reactive 
Testing Alone in Patients With Inflammatory Bowel Disease. J Crohns Coli-
tis. 2018 Jun 28;12(7):804-810
disclosure: Nothing to disclose 
P0357 a neW InsIghT Of LIquId BIOPsy fOr IBd-assOcIaTed 
neOPLasIa
Kinugasa H.1, Nouso K.1,2, Terasawa H.1, Hirai M.3, Yamamoto S.1, Oka S.1, 
Yasutomi E.1, Yamasaki Y.1, Inokuchi T.1, Takahara M.3, Harada K.1, 
Hiraoka S.1, Okada H.1
1Okayama University Hospital, Department of Gastroenterology, Okayama, 
Japan, 2Okayama City Hospital, Okayama, Japan, 3Okayama University, 
Department of Gastroenterology and Hepatology, Okayama, Japan
contact e-Mail address: gyacy14@yahoo.co.jp
Introduction: IBD-associated cancer and high grade dysplasia (HGD) are 
sometimes difficult to diagnose, because the patients with IBD-associated 
cancer do not have any characteristic symptoms and the tumor cannot be 
detected easily because of their inflammatory background. To overcome 
the weakness of the current methods for the diagnosis of IBD-associated 
cancer and HGD, we tried to develop “liquid biopsy” with blood based 
on the concept of non-invasive diagnostic method with circulating tumor 
DNA.
aims & Methods: Ten patients with IBD-associated cancer and HGD were 
enrolled in this study. Tumors and paired non-tumor tissues obtained from 
10 patients were analyzed for mutations of 48 oncogenes (Cancer panel; 
Haloplex, Agilent Technology) using next generation sequencing (NGS; Il-
lumina, San Diego, CA, USA). Blood from 10 patients was also analyzed 
for the mutations with droplet digital PCR (ddPCR; BioRad, Hercules, CA, 
USA). Each sample was obtained prior to the treatment. As negative con-
trols, 10 tissues and blood samples of IBD patients without neoplasia were 
analyzed for mutations of the 48 oncogenes in the same way.
results: The median (range) age was 49 (34-83) years and the male/female 
ratio was 0.67 (4/6). Of the 10 cases, 7 were IBD-associated cancer and 3 
were IBD-associated HGD. Five, three, and two patients were diagnosed as 
stage 0 (which contained HGD), stage I, and stage III, respectively. We set 
the cut-off value at 5% for rare mutation rate based on the results of con-
trol samples to avoid false positive. Seven of 10 (70%) tumor tissue sam-
ples were positive for the mutations. TP53, KRAS, and PIK3CA mutations 
were detected in 5/10 (50%), 1/10 (10%) and 1/10 (10%) respectively. The 
frequency of the amino acid changes in each gene were as follows: TP53 
(20.9%; R136H), TP53 (25.0%; C110W), TP53 (8.5%; H140Q), TP53 (31.1%; 
R150W), TP53 (12.8%; R141H), KRAS (40.0%; G12V) and PIK3CA (34.1%; 
R88Q). In these seven patients, the same mutations were detected in all 
blood samples. On the other hand, blood samples of the remaining 3 pa-
tients without the mutations in tissue did not show any mutations either. 
Concordance rate with mutations between tissue and blood was 100%. 
Blood analysis for the mutations indicated that sensitivity, specificity, posi-
tive predictive value (PPV) and negative predict value (NPV) were 70%, 
100%, 100% and 76.9%, respectively. None of negative control samples 
showed any mutations.
conclusion: Mutations in tumor could be detected in blood using digital 
PCR with high PPV (100%). Liquid biopsy with blood may help us to diag-
nose IBD-associated cancer and HGD non-invasively.
disclosure: Nothing to disclose 
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maceutical, Takeda pharmaceutical; MT: Abbvie, Tanabe Mitsubishi, Jans-
sen Pharmaceutical, EA Pharma, Nippon Kayaku, Kyorin; TK: EA Pharma, 
Sekisui Medical, Thermo Fisher Scientific 
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Introduction: Inflammatory bowel disease (IBD) patients are in higher risk 
of developing colorectal cancer (CRC) than general population. Studies 
show that surveillance with chromoendoscopy (CE) detects a higher num-
ber of dysplastic lesions, allowing their endoscopic resection and therefore 
preventing CRC. It also saves costs by avoiding non-targeted biopsies. We 
aimed to assess the endoscopic results from follow-up CE in IBD patients 
with diagnose of dysplasia.
aims & Methods: We carried out a retrospective data collection from IBD 
patients who have had dysplastic lesions in surveillance chromoendosco-
py, which were performed in our hospital from January 2013 to November 
2018. Demographic and clinical data were assessed at the time of the first 
CE, as well as endoscopic findings in this CE and in the first follow-up CE.
results: 320 chromoendoscopies were performed, all of them using Indigo 
Carmine 0.2% and spray catheter Olympus.
41 patients show dysplastic lesions in the initial CE. Most of them were 
male (75.5%), with median age 58 years old (23.8-77.4) and familiar his-
tory of colorectal cancer was found on 26.7% of them. Ulcerative colitis was 
more frequent than Crohn’s disease (84%), most patients had extensive 
colitis (79%) and an average age of evolution of the disease of 16 years. 
17% were in treatment with biological drugs, 23.7% with immunomodula-
tors and 80% with salicylates, at an average dose of 2.33 g/d. 12 patients 
(30%) had already had dysplasia in previous colonoscopies, all of them 
were visible lesions and they were treated endoscopically.
In the initial chromoendoscopy, an average of 2.89 dysplastic lesions with 
an average size of 8 mm was detected, 76.9% were flat lesions (0-IIa or 
0-IIb from Paris classification) and 86% were completely removed endo-
scopically. Most of them were located distal to the splenic flexure (72%). 
80% were tubular adenomas with low grade dysplasia (LGD); there were 
2 cases of high grade dysplasia (HGD) and one case of adenocarcinoma.
At this time we have performed 25 follow-up CE and new dysplasic lesions 
were found in 39% of them, with an average of 3.25 lesions, < 10 mm in 
size, 75% in distal location. 50% of the visible lesions were tubular adeno-
mas LGD, 12.5% serrated adenomas LGD and 12.5% hyperplasic. 
In our analysis we found that those patients with flat lesions 0-IIa in 
the baseline chromoendoscopy have more frequent dysplastic lesions in 
the revision compared to those with lesions 0Is (78.6% vs 0%, p=0.035). 
Bowel cleanliness also influenced the number of lesions detected, as we 
found that those patients whose Boston was < 8 in the baseline CE have a 
greater number of lesions in the next CE (16 vs. 8; p=0.005)
conclusion: Surveillance with chromoendoscopy in IBD patients with pre-
vious dysplastic lesions detects new dysplasia in 30% of cases. Low grade 
dysplasia was the most frequent histology within the removed lesions. 
Finding higher number of lesions, 0-IIa lesions or worse bowel prepara-
tion (Boston < 8) in the first chromoendoscopy predicts having a higher 
number of lesions on the follow-up in our sample.
disclosure: Nothing to disclose 
P0360 hIgh InfLIxIMaB exPOsure Increases The rIsk Of 
InfecTIOn
Landemaine A.1, Petitcollin A.1, Brochard C.2, Miard C.1, Le Balc’h E.1, 
Dewitte M.1, Belissant E.1, Siproudhis L.1, Bouguen G.3
1CHU Pontchaillou, Rennes, France, 2CHU Rennes, Services des Maladies de 
L’Appareil Digestif, Rennes, France, 3CHU Pontchaillou, Service des Maladies 
de l’Appareil Digestif, Rennes, France
contact e-Mail address: amandine.landemaine@chu-rennes.fr
Introduction: Infliximab (IFX) increases the risk of infection in patients with 
inflammatory bowel diseases (IBD), but the relationship between drug ex-
P0358 usefuLness Of LeucIne-rIch aLPha-2-gLycOPrOTeIn 
(Lrg) TO MOnITOr The effIcacy Of adaLIMuMaB TreaTMenT In 
PaTIenTs WITh uLceraTIve cOLITIs (PLaneT sTudy)
Iijima H.1, Mizuno S.2, Shinzaki S.1, Matsuoka K.3, Tanaka H.4, 
Takeshima F.5, Kato S.6, Torisu T.7, Nakagawa M.8, Nakamura S.9, 
Yoshimura N.10, Kobayashi T.11, Shiotani A.12, Hirai F.13, Hiraoka S.14, 
Matsuura M.15, Suzuki Y.3, Watanabe M.16, Takehara T.1, Matsumoto T.17, 
Naka T.18, Kanai T.2
1Osaka University Graduate School of Medicine, Department of 
Gastroenterology and Hepatology, Suita, Japan, 2Keio University,School of 
Medicine, Tokyo, Japan, 3Toho University Sakura Medical Center, Sakura, 
Japan, 4Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan, 
5Nagasaki University, Nagasaki, Japan, 6Saitama Medical Center Saitama 
Medical University, Kawagoe, Japan, 7Kyushu University, Fukuoka, Japan, 
8Chiba University, Chiba, Japan, 9Hyogo College of Medicine, Osaka, Japan, 
10Tokyo Yamate Medical Center, Tokyo, Japan, 11Kitasato University Kitasato 
Institute Hospital, Tokyo, Japan, 12Kawasaki Medical School, Okayama, Japan, 
13Fukuoka University, Fukuoka, Japan, 14Okayama University, Department 
of Gastroenterology and Hepatology, Okayama, Japan, 15Kyoto University, 
Kyoto, Japan, 16Tokyo Medical and Dental University, Gastroenterology and 
Hepatology, Tokyo, Japan, 17Iwate Medical University, Internal Medicine, 
Morioka, Japan, 18Kochi University, Kochi, Japan
contact e-Mail address: hiijima@gh.med.osaka-u.ac.jp
Introduction: Leucine-rich alpha-2 glycoprotein (LRG) is an acute phase 
protein induced by various inflammatory cytokines. Naka et al. has recent-
ly reported that LRG is an effective biomarker for inflammatory diseases, 
such as inflammatory bowel diseases (IBD). In this study, we prospectively 
measured serum LRG in patients with ulcerative colitis (UC), who were 
treated with adalimumab. We also analyzed the correlation of serum LRG 
with other disease activity markers.
aims & Methods: This is a multicenter prospective observational study 
[Predictor and Biomarker; LRG (leucine rich alpha-2 glycoprotein) for In-
flammatory Bowel Disease Treatment with Adalimumab: PLANET study 
(UMIN000019958)]. Active UC patients with Mayo score of 6 or more were 
recruited for the standard adalimumab treatment. Serum LRG levels were 
measured by latex turbidimetric immunoassay before and at 12, 24 and 
52 weeks after the initiation of adalimumab. Partial Mayo score (PMS), 
fecal calprotectin (fCP) and C-reactive protein (CRP) were evaluated at the 
same time point, and severity of colonic inflammation was evaluated by 
Mayo endoscopic subscore (MES) and Ulcerative Colitis Endoscopic Index 
of Severity (UCEIS) at 12 and 52 weeks. This study was funded by Eisai 
Co., Ltd.
results: Forty-seven patients with UC (27 males, 20 females; age 40.6 ± 
14.4; disease duration 6.9 ± 6.7 years; left-side colitis 16 cases, total colitis 
30 cases, right-side/segmental colonic type 1 case) were registered. 
The serum LRG level was 23.6 ± 10.4 µg/ml before the treatment (n = 46), 
and was decreased to 13.9 ± 5.5 µg/ml at 12 weeks (n = 37), 12.5 ± 5.0 µg/ml 
at 24 weeks (n = 31), and 13.1 ± 5.0 µg/ ml at 52 weeks (n = 27). 
The levels of LRG and CRP were significantly correlated with pre-treatment 
PMS, MES and UCEIS (PMS, r = 0.503; MES, r = 0.534; UCEIS, r = 0.394 for 
LRG: PMS, r = 0.440; MES, r = 0.538; UCEIS, r = 0.365 for CRP). 
In addition, LRG and fCP were significantly correlated with MES (LRG, r = 
0.429; fCP, r = 0.448) and UCEIS (LRG, r =0.608; fCP, r = 0.512) at 12 weeks. 
LRG and fCP were significantly correlated with PMS at 52 weeks (LRG, r = 
0. 398; fCP, r = 0.494). 
At week 52, however, fCP was the only parameter, which was significantly 
correlated with UCEIS (r = 0.640). When serial data were put into an analy-
sis, LRG was the best correlated with PMS and UCEIS (PMS, r = 0.408; 
UCEIS, r = 0.301).
conclusion: LRG is a novel serum biomarker which can reflect disease ac-
tivity possibly better than CRP and fCP in UC patients with adalimumab 
treatment.
disclosure: HI: AbbVie, EA Pharma, EisaiMitsubishi Tanabe Pharma, 
Mochida pharmaceutical, Kyorin pharmaceutical, Janssen, Zeria phar-
maceutical, Takeda pharmaceutical,, Sekisui Medical. AbbVie, Kissei, 
Nippon Kayaku; SS: Abbvie, Tanabe Mitsubishi, Janssen Pharmaceutical; 
KM: EA Pharma, Thermo Fisher Scientific,Sekisui Medical, Alfresa Phar-
ma; SK:Abbvie, Tanabe Mitsubishi, Janssen; TK: Kyorin, Abbvie, Eli Lilly, 
Pfizer Inc., Janssen, Takeda Pharmaceutical, Medtronic, Gilead Sciences 
Inc., Alfresa Pharma Corporation and Celltrion; MM: Tanabe Mitsubishi, 
Abbvie, JIMRO, EA Pharma, Kyorin, Mochida, Nippon Kayaku; SH:Tanabe 
Mitsubishi, Eiken Chemical; TT: Mitsubishi Tanabe , AbbVie, Mochida phar-
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posure, mostly estimated by the trough level of IFX (TLI), and infections 
remains controversial. The present study aimedtoassess factors associated 
with infection among IFX-treated patients, including pharmacokinetic 
data.
aims & Methods: All IBD patients receiving the IFXmaintenance regimen 
from November 2016 to April 2017 were screened and prospectively fol-
lowed. Patients during induction phase of treatment at baseline or who 
interrupted the treatment during the study period were excluded. Clini-
cal and biological data, infectious events and the TLI were collected at 
each infusion visit.IFX exposure was estimated by the area under the curve 
(AUC) of the drug concentration using pharmacokinetic modelling,andthen 
the individual exposure over the 6-month period was estimated by the 
sum of the AUC (ΣAUC). Independent risk factors of infection were identi-
fied by logistic regression.
results: Among the 288 patients treated with infliximab during the study 
period, 209 patients were included: 102 men (49%), mean (±SD) age 39 
(±14) years old, 159 Crohn’s disease (76%). A total of 54 (26%) patients 
received a combination therapy. The mean TLI was 5.46 mg/Land the mean 
ΣAUC was 3938 (±1427) mg.d/L, corresponding to a mean period of IFX 
exposure of 24.7 (±3.5) weeks.A total of 215 infections were collected from 
640 infusionvisits (63 [29%]bacterial infections, 143 [67%]viral infections 
and 9 [4%] fungal infections).At least one infection occurred in 123 patients 
(59%), more than one infection in 64 patients (30 %), and 46 patients 
(22%) received antibiotics. Three factors were independently associated 
with infection after a multivariate analysis: smoking (OR=2.05, p=0.046), 
IBD flare-up (OR=2.71, p=0.0060) and a high ΣAUC of IFX (>3234 mg.d/L)
(OR=2.02, p=0.02). The ΣAUC was higher in patients with infection than 
in patients without infection (p=0.04) and correlated with the numberof 
infections (p=0.04). The trough concentration of IFX alonewas not associ-
ated with infection.
conclusion: Almost two-thirds of patients treated with IFX developed an 
infectionover the 6-month follow-up,and this risk was individually related 
to increasedcumulative drug exposure. These results encourage starting 
therapeutic de-escalation for patients in remission, guided by drug moni-
toring.
disclosure: GB received lecture fees from Abbvie, Ferring, MSD, Takeda 
and Pfizer and consultant fees from Takeda, Janssen. LS received lecture 
fees from Abbvie, Ferring and MSD. LS received consultant fees from Take-
da and Ferring. CB received lecture fees from Ipsen. AP received lecture 
fees from Hospira. AL, CM, MD and EB declare no conflict of interest. 
P0361 usefuLness Of caPsuLe endOscOPy In PaTIenTs WITh 
crOhn’s dIsease In reMIssIOn
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Yamamoto N.2, Higashiyama M.2, Sanomura Y.2, Hiramoto T.2, Hiraga Y.3
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Prefectural Hospital, Hiroshima, Japan, 3Hiroshima Prefectural Hospital, 
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contact e-Mail address: naishikyo1@hph.pref.hiroshima.jp
Introduction: No biomarkers can effectively predict the clinical prognosis 
of Crohn’s disease (CD) in remission. Capsule endoscopy (CE) is known as 
a direct examination that can detect minute lesions of the mucous mem-
brane. However, the consensus on the relevance of CE findings and the 
subsequent course of disease remains to be determined.
aims & Methods: CE was performed after the patency capsule (PC) proce-
dure to verify the patency of the small intestinal tract in patients with CD 
in remission, and the relationship between CE findings and prediction of 
clinical prognosis was evaluated. 
A total of 45 patients with small intestine type and small intestine-colon 
type CD in remission phase underwent CE after the PC procedure from Oc-
tober 2010 to December 2017 (27 men, 18 women; average age, 34.9 years). 
All patients had CD activity index (CDAI) of < 150 (average, 92.7). Patients 
were divided into “active group” with small or longitudinal ulcers detected 
by CE and “non-active group” without ulcer, and the relationship between 
the two groups was examined according to disease duration, CDAI value, 
and C-reactive protein (CRP) value. In addition, occurrence of “exacerba-
tion” requiring change or strengthening of treatment was determined, and 
its relationship with CE findings was evaluated.
results: Among the 45 patients, 35 (77.8%) were confirmed to have pat-
ent small intestines by PC and subsequently underwent CE. Incidents of 
capsule retention in the small intestine were not observed. Among the 
35 patients who underwent CE, 12 (34.3%) were included in the “active 
group” and 23 (65.7%) in the “non-active group.” The disease durations 
were 82.8 and 142.1 months and the CDAI values were 100.8 and 88.3 in the 
“active group” and “non-active group,” respectively, without significant 
differences. CRP values were 1.04 and 0.53, respectively, which were sig-
nificantly higher in the “active group” than those in the “non-active group” 
(p < 0.05). “Exacerbation” occurred in 6 (50%) and 2 (8.7%) patients, re-
spectively, which was significantly higher in the “active group” than those 
in the “non-active group” (p < 0.01).
conclusion: CE was safely performed in 77.8% of patients with CD in remis-
sion after performing the PC procedure. The CRP value was significantly 
associated with the active phase of the small intestinal mucosa as detected 
by CE. Exacerbation rate was significantly higher in the “active group” than 
those in the “non-active group.” CD in remission may be exacerbated even 
in clinical remission when an active phase of small intestinal mucosa is 
detected by CE, and thus, the treatment should be strengthened. These 
findings suggested that CE is a useful examination procedure to predict the 
clinical prognosis in patients with CD in remission.
disclosure: Nothing to disclose 
P0362 deMOgraPhIc feaTures Of uLceraTIve cOLITIs 
PaTIenTs as PredIcTOrs Of resPOnse TO adsOrPTIve 
granuLOMOnOcyTaPheresIs as reMIssIOn InducTIOn TheraPy: 
a reTrOsPecTIve assessMenT Of TreaTMenT OuTcOMes
Tanaka T.1, Goishi H.2, Iiboshi T.2, Kajihara T.2, Miura T.2
1Akitsu Prefectural Hospital, Dept. of Gastroenterology, Hiroshima, Japan, 
2Akitsu Prefectural Hospital, Hiroshima, Japan
contact e-Mail address: tomotaka@c.do-up.com
Introduction: Inflammatory bowel disease (IBD) is associated with elevated 
myeloid lineage leucocytes, which show activation behaviour1 including 
the CD14+CD16+DR++ phenotype known as proinflammatory monocytes 
and a major source of tumour necrosis factor-α.2 Accordingly selective 
depletion of myeloid leucocytes by granulomonocytapheresis (GMA) with 
an Adacolumn is expected to promote remission and enhance drug ef-
ficacy. However, hitherto studies in IBD have reported contrasting efficacy 
outcomes, ranging from an 85%3 to statistically insignificant.4 Patients’ de-
mographic features should guide to select responder patients.
aims & Methods: In ulcerative colitis patients, we were interested to iden-
tify relevant demographic features, which potentially could indicate a fa-
vourable response to GMA. Therefore, in a retrospective setting, we looked 
at the baseline clinical and endoscopic features of responders and non-
responders to adsorptive GMA in 146 consecutive ulcerative colitis patients 
who had undergone GMA as remission induction therapy, 74 steroid naive, 
70 steroid dependent, and 2 steroid refractory. Patients had received up 
to an 11 GMA sessions over 10 weeks. At entry and week 12, patients were 
clinically and endoscopically evaluated, allowing each patient to serve as 
her or his own control. Clinical activity index (CAI) ≤4 was defined as re-
mission. Biopsies from endoscopically detectable inflamed mucosa were 
processed to see the impact of GMA on leucocytes within the mucosa.
results: At entry, the average CAI was 12.8, range 10-17. Ninety-four pa-
tients (64.1%) had responded to GMA, 53 of 74 steroid naïve (71.6%), 40 of 
70 steroid dependent (57.1%), and 1 of the 2 steroid refractory cases. On av-
erage remission was sustained for 8.6 months in steroid naïve patients and 
for 10.4 months in steroid dependent cohort. Mucosal biopsies revealed 
that infiltrating leucocytes were mostly neutrophils and monocytes. There 
was a marked reduction of infiltrating leucocytes in the biopsies from the 
responder patients. Patients with extensive deep UC lesions together with 
loss of the mucosal tissue at the lesions were non-responders. Patients 
with the first UC episode were identified as the best responders (100%), 
followed by steroid naive patients. Further, a short duration of active UC 
prior to GMA marked a patient as a likely responder.
conclusion: Patients who responded well to GMA attained a favourable 
long-term clinical course. GMA was more effective if applied immediately 
after a relapse than after a lag time. In general, GMA is favoured by pa-
tients for its safety profile and for being a non-drug remission induction 
option. Patients with extensive deep ulcers, with long duration of UC re-
fractory to multiple pharmacologics are unlikely to benefit from GMA. In 
therapeutic settings, knowing baseline features, which may identify re-
sponder patients should help to avoid futile use of medical resources.
references: 1. McCarthy DA, et al. Peripheral blood neutrophils in inflam-
matory bowel disease: morphological evidence of in vivo activation in ac-
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conclusion: LRG is a novel serum biomarker for CD, which specially repre-
sents endoscopic activity of the disease. LRG may be superior to CRP and 
fCP for monitoring CD under adalimumab treatment.
disclosure: Shinzaki S; Mitsubishi Tanabe Pharma, AbbVie, Mochida phar-
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chida Pharmaceutical Co. Ltd., Gilead Sciences Inc., Nippon Kayaku Co. 
Ltd., JIMRO Co. Ltd., ZERIA Pharmaceutical Co. Ltd., Astellas, Asahi Kasei 
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Hiraoka S; Mitsubishi Tanabe Pharma, and Eiken Kagaku. Matsuura M; Ab-
bvie, Mitsubishi Tanabe Pharma, JIMRO, EA Pharma, Kyorin Pharmaceuti-
cal, Mochida Pharmaceutical, and Nippon Kayaku. Takehara T; Mitsubishi 
Tanabe Pharma, AbbVie, Mochida pharmaceutical, and Takeda pharma-
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Sekisui Medical, and Thermo Fisher Scientific. 
P0364 ManageMenT Of InfLaMMaTOry BOWeL dIsease 
PaTIenTs In The eMergency deParTMenT: a french naTIOnaL 
cOnsensus
Hebuterne X.1,2, Peyrin-Biroulet L.3,4, Hausfater P.5,6, Emergency IBD Group
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Introduction: Inflammatory bowel diseases (IBD) are conditions of unpre-
dictable evolution. Despite recent therapeutic progress, particularly since 
the arrival of biologics, visits to the emergency department (ED) by IBD 
patients remain frequent and two-thirds of the ED visits lead to hospital 
admission.
There are currently no guidelines on the actions to be taken when an 
IBD patient visits the ED: urgent CT scan, hospitalization, or discharge. 
Certain situations can sometimes lead to unnecessary hospitalizations or, 
on the contrary, to an inappropriate discharge. The aim of this study was 
to define criteria to help in the decision-making process in IBD patients 
visiting ED.
aims & Methods: To address this problem, after a systematic literature 
review, a Delphi consensus on the actions to be taken when an IBD patient 
visits the ED was organized in France. Three experts (2 gastroenterologists 
and 1 emergency physician) built an initial list of criteria which, if met, 
could lead either to an emergency CT scan prescription or to a hospitaliza-
tion. An Internet-based two-round Delphi consensus was constructed and 
a panel of 119 healthcare professionals (68 gastroenterologists, 42 emer-
gency physicians and 9 nurses) were asked to rate each criterion according 
to a 4-point rating scale (from ‘strongly agree’ to ‘strongly disagree’) and 
to propose additional criteria. Consensus was reached for one criterion 
when at least 75% of voting members scored the statements ‘strongly 
agree’ or ‘agree’. 
After the first round a national web conference was organized to pres-
ent and discuss the results and to build the list of criteria for the second 
round. The first round took place between 21st November and 5th Decem-
ber 2018 and the second round between 19th December 2018 and 15th 
January 2019.
results: 86 healthcare professionals took part in the first round of vot-
ing and 58 in the second round. For both Crohn’s disease and ulcerative 
colitis, consensus was reached on ‘IV morphine titration, ‘fever’, ‘vomiting’, 
‘laboratory-confirmed signs of dehydration’, ‘anoperineal abscess’, ‘hae-
modynamic instability’ as criteria for hospitalisation. The criteria ‘suspect 
abdomen’, ‘bowel resection in the past 30 days’ and ‘bowel obstruction’ 
reached consensus both for hospitalization and emergency CT scan. Re-
garding biological criteria, consensus was reached on ‘haemoglobin < 9 
tive disease. Clin Exp Immunol 1991; 86: 489-93. 2. Belge KU, et al. The 
proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF. J 
Immunol 2002;168:3536-42 3. Cohen RD. Treating ulcerative colitis without 
medications - look mom, no drugs. Gastroenterology 2005;128:235-36. 4. 
Sands BE, et al. A randomized, double-blind, sham-controlled study of 
granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenter-
ology 2008;135:400-09.
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Introduction: Leucine-rich alpha-2 glycoprotein (LRG) is an acute phase 
protein induced by various inflammatory cytokines. Naka T. et al. has re-
cently reported that the serum level of LRG is an effective biomarker to 
reflect the activity of chronic inflammatory diseases, such as inflammatory 
bowel disease. In the present study, we prospectively analyzed the levels 
of serum LRG in patients with Crohn’s disease (CD) who were treated with 
adalimumab. We also analyzed the correlation of LRG levels with conven-
tional disease activity markers.
aims & Methods: This is a multicenter prospective observational study 
[Predictor and biomarker; LRG (leucine rich alpha-2 glycoprotein) for 
inflammatory bowel diseasetreatment with Adalimumab: PLANET study 
(UMIN000019958)]. Active CD patients with Crohn’s disease activity index 
(CDAI) score of 220 or more were recruited for the standard adalimumab 
therapy. Serum LRG levels were measured by latex turbidimetric immu-
noassay before and at 12, 24 and 52 weeks after adalimumab treatment. 
CDAI score,C-reactive protein (CRP) and fecal calprotectin (fCP) levels were 
evaluated at the same time point, and the severity of intestinal inflamma-
tion was evaluated by Simple endoscopic score for Crohn’s disease (SES-
CD) before and at 24 and 52 weeks after adalimumab treatment.
results: Thirty-four patients with CD (24 males, 10 females; age 29.5 ± 
14.0; disease duration 4.5 ± 6.6 years; ileocolitis 27 cases, ileitis 3 cases, 
colitis 4 cases) were registered. The serum LRG level was 32.5 ± 13.6 µg/ml 
before treatment (n = 34), and it decreased to 17.3 ± 9.4 µg/ml at 12 week 
(n = 33), 18.7 ± 11.7 µg/ml at 24 week (n = 31), and 15.8 ± 8.1 µg/ ml at 52 
week (n = 28). 
LRG levels were significantly correlated with CDAI at 12, 24 and 52 weeks 
(12 week, r = 0.440; 24 week, r = 0.743; 52 week, r = 0.554). CRP levels 
were significantly correlated with CDAI before treatment, and at 24 and 
52 weeks (pre, r = 0.375; 24 week, r = 0.622; 52 week, r = 0.597). fCP was 
correlated with CDAI only at 52 week (r = 0.600). 
In addition, LRG was significantly correlated with SES-CD before treatment 
(r = 0.391). LRG, CRP and fCP were significantly correlated with SES-CD at 
24 week (LRG, r = 0.563; CRP; r = 0.470, fCP, r = 0.659), and LRG (r = 0.697) 
and fCP (r = 0.593) were significantly correlated with SES-CD at 52 weeks. 
When serial data were put into an analysis, LRG was the most highly cor-
related with CDAI and SES-CD (CDAI, r = 0.660; SES-CD, r = 0.636).
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g/dL or decrease of ≥ 2 g/dL’ and ‘acute renal failure’ as criteria in favour 
of hospitalization and ‘very high CRP’ for an emergency CT scan. The final 
checklist is presented in Table 1.
conclusion: A French group of experts reached a multidisciplinary con-
sensus on a list of clinical and biological criteria which could be used in 
daily practice when an IBD patient is admitted to the ED. It is hoped that 
the use of this list will improve management of IBD patients visiting ED. 
Future studies will be conducted to evaluate the use and the impact of 
this new tool.
criteria for immediate hospitalisation
clinical criteria
• Suspect abdomen
• IV morphine titration
• Fever
• Vomiting
• Laboratory-confirmed signs of dehydration
• Bowel resection in the past 30 days
• Anoperineal abscess
• Bowel obstruction
• Haemodynamic instability
Laboratory criteria • Haemoglobin <9 g/dL or decrease of ≥ 2 g/dL
• Acute renal failure
criteria for emergency cT scan
clinical criteria
• Suspect abdomen
• Bowel resection in the past 30 days
• Bowel obstruction
Laboratory criteria • Very high CRP
[Final checklist]
disclosure: XH: Abbvie, Abivax, Alphasigma, ARARD, Arkopharma, Astel-
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Sanofi-Advantis, SAlix, Takeda, Theravance, Tillots LPB: Merck, Abbvie, 
Janssen, Genentech, Ferring, Tillots, Vifor, Pharmacosmos, Celltrion, Take-
da, Biogaran, Boerhinger-Ingelheim, Lilly, Pfizer, Index Pharmaceuticals, 
Amgen, Sandoz, Celgene, Biogen, Samsung Bioepis, Alma, Sterna, Nestlé, 
Enterome, Mylan, HAC-Pharma PH : Janssen 
P0365 hePaTOBILIary ManIfesTaTIOns In PaTIenTs WITh 
InfLaMMaTOry BOWeL dIsease
Chabib F.-Z., Benelbarhdadi I., Ajana F.-Z.
Ibn Sina University Hospital, Medical Unit C, Rabat, Morocco
contact e-Mail address: dr.chabib.fatimazahra@gmail.com
Introduction: Hepatobiliary manifestations in IBD (chronic inflammatory 
bowel diseases) are common. The most common is steatosis and the most 
specific is primary sclerosing cholangitis (PSC).
aims & Methods: The objectives of the study are: to evaluate the frequency 
of these anomalies, and enumerate the different etiologies as well as their 
consequences on the management of IBD.This is a 26-year retrospective 
study [1990 -2016], which includes patients with IBD who presented with 
at least one biological and / or morphological hepatobiliary abnormality.
results: Out of 1157 patients followed up, 109 patients had at least one 
liver anomaly, being an incidence of 9.42%. The average age of our pa-
tients was 37 years with extremes [13 years, 69 years], the female sex was 
predominant [68 women, 41 men] with a sex F / H ratio of 1.6. Crohn’s 
disease was the predominant type of IBD (93 cases of Crohn’s, 13 cases 
of UC, 3 cases of indeterminate colitis). Clinically, 89% of patients were 
asymptomatic. The biological assessment found cytolysis in 37% of cases, 
cholestasis in 21%, both in 6% of cases and normal in 36% of cases. Ab-
dominal ultrasound was performed for all patients . Magnetic resonance 
cholangiopancreatography was performed in 15.6% of cases (17 cases) and 
found: an aspect suggestive of sclerosing cholangitis in 8 cases and nor-
mal in 9 cases. Puncture Biopsy of the liver was performed in 28.45% of 
cases (27 cases). The etiologies were as follows: hepatocellular toxicity in 
30,25% (33 cases) (24 cases under thiopurines , 6 cases under methotrex-
ate (MTX), 3 cases under salicylic agent and one case under anti bacillary), 
a steatosis in 26.21% (27 cases), an infectious origin in 15.6% (17 cases) (16 
cases of viral hepatitis B or C, 1 case of hepatic abscess), primary sclerosing 
cholangitis (PSC) in 9.18% ( 10 cases), vesicular lithiasis (VL) in 11.9% (13 
cases), autoimmune hepatitis type I in 2.75% (3 cases), hepatic angioma 
in 3.66% of cases (4 cases). ), 1 case (0.91%) of liver metastasis of adeno-
carcinoma in the retained rectum after colectomy for ulcerative colitis and 
undetermined origin in 5.42% (6 cases) . transitory anormalies were noted 
in 6.42% of cases (7 cases). 13 cases of our patients associate 2 anomalies 
at the same time. Therapeutic drug hepatotoxicity led to the decrease of 
the dose in 42.4% (14 cases) and to stop definetely the medicament in 
question in 57.58% (19 cases) with either a therapeutic abstention in as-
ymptomatic patients or a change to another therapeutic molecule: from 
one purine agent to another or to MTX, MTX or salicylic to a purinic agent. 
PSC cases were treated by ursodeoxycholic acid. The cases of steatosis im-
proved once the disease stabilized. Treatment of autoimmune hepatitis 
was similar to that of IBD combined with corticosteroid therapy followed 
by azathiopirine. The case of liver metastasis was followed by surgical re-
section followed by chemotherapy. For the other patients a specific treat-
ment was applied. The evolution was good in all patients.
conclusion: Hepatobiliary manifestations in patients with IBD are frequent 
, the incidence in our study is 9.42%. as it’s showed it range from benign 
diseases and side effects of the treatement to malignant disorders . Early 
diagnosis by a monitoring of liver function at regular intervals is important 
because of the therapeutic implications for the overall management of pa-
tients . Additionally, we should not forget the search for common causes of 
liver disease as well as for the general population.
disclosure: Nothing to disclose 
P0366 The InTra-IndIvIduaL varIaBILITy Of fecaL 
caLPrOTecTIn In PaTIenTs WITh gI-syMPTOMs
Netzer S.1, Behrouz S.1, Mehr-Rahimi S.1, Moriconi F.1, Wilhelmi M.1, 
Netzer P.1,2
1GastroZentrum Netzer AG, Bern, Switzerland, 2Lindenhofspital, Bern, 
Switzerland
contact e-Mail address: serainanetzer@rocketmail.com
Introduction: Levels of faecal calprotectin (FC) are used to distinguish be-
tween functional and organic gastrointestinal disease. In routine clinical 
practice, we have observed intra-patient variability in FC measurements 
made during a short time period. This may indicate that the detection 
assay is not as reliable as originally presumed. To evaluate this variability 
more closely, we retrospectively analysed FC measurement data from a 
selected patient cohort.
aims & Methods: Our aim was to systematically assess the variability in 
the levels of FC measured within a defined period of time in patients with 
either a functional or organic gastrointestinal disorder. We searched our 
electronic patient database for all patients with a gastrointestinal disorder, 
independent of diagnosis, who had at least three FC measurements made 
within a 10-day period.
results: Of 404 patients who fulfilled the search criteria and were includ-
ed in the study analysis, there were 284 women (70%) with a mean age 
(range) of 45.8 (11 to 90 years). Based on the commonly recommended cut-
off value of 50 µg/g for most European countries, 144 patients (35.6%) had 
three values below the cut-off level and 150 (37.1%) had all three values 
above the cut-off. Therefore, 110 patients (28.1%) showed a variability in FC 
levels, which included values considered normal as well as pathological. 
The range analysis for this patient group showed: 48 patients(43.6%) with 
the range < 50 µg/g; 33 (30%) within 50-99 µg/g; 11 (10%) within 100-199 
µg/g; 9 (8.2%) within 200-500 µg/g; and 8 pts (7.3%) with values > 500 
µg/g. Large variability was also seen in a sub-analysis of three patient 
groups categorised either with an organic disease (232, 57.4%), functional 
disease (153, 37.9%) or uncertain diagnosis (19, 4.7%). In patients with 
an organic disease, 66 (28.4%) had FC values below and above the cut-
off, whereas there were 30 (19.6%) and 11 (58%) patients with normal 
and pathological values in the groups defined with a functional disease 
and uncertain diagnosis, respectively. Further analysis showed variability 
in patients with three elevated values: 21 (14%) in the range < 50 µg/g; 
25 (16.7%) within 50-99 µg/g; 33 (22%) within 100-199 µg/g; 38 (25.3%) 
within 200-499 µg/g; 19 (12.7%) within 500-1000 µg/g; and 14 (9.3%) with 
levels > 1000 µg/g. When the cut-off was increased to 100 µg/g, 92 patients 
(22.6%) had values below and above the cut-off. By applying a cut-off of 
150 µg/g, the number of patients with both normal and pathological val-
ues decreased to 62 (15.4%). Age and gender did not have any significant 
influence on the data analysis.
conclusion: We were able to show a relevant variability in FC values 
measured in our patients. More than one quarter of the patients (28%) had 
levels of FC deemed both normal and pathological within the sampling time 
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envisage that the top five recommendations will be a useful tool for en-
hancing patient-doctor relationship and provide a better care, especially 
among non-IBD experts.
references: 1. Nguyen GC et al. Modified Delphi process for the develop-
ment of choosing wisely for inflammatory bowel disease. Inflamm Bowel 
Dis 2017;23:858-865. 2. Montano N et al. The Italian Society of Internal 
Medicine choosing wisely campaign. Intern Emerg Med 2016;11:1125-1130.
disclosure: Nothing to disclose 
P0368 OPPOrTunIsTIc InfecTIOn In PaTIenTs WITh 
InfLaMMaTOry dIsease usIng BIOLOgIcaL TheraPy. 
(PrOsPecTIve sTudy)
Bismara Cury D.H.
Harvard, Gastroenterology, Campo Grande / MS, Brazil
contact e-Mail address: didiacury@gmail.com
Introduction: Infection by clostridium difficile has been related in patients 
who were in hospital and making use of antibiotics therapy. 
Up till now , such an infection has not been seen in patients making use of 
biological and without history preview of hospitalization or antibiotic and 
who are in remission.
aims & Methods: We investigated the incidence of parasitosis as well as 
clostridium difficile in the faeces of patients with inflammatory bowel dis-
ease during the course of three years of monotherapy with TNF inhibitors 
(infliximab and adalimumab) or thiopurines ( azathioprine)Prospective 
study with patients in follow-up at a referral center of inflammatory bowel 
diseases , who were in remission (endoscopic and clinical), with no previ-
ous hospitalisation or use of antibiotics, but undergoing treatment with 
biological therapy for at least six months. The results were compared with 
those of patients with inflammatory disease not using immunosuppressive 
agents.
results: Of the total sample of 329 (212 Crohn’s disease, 117 ulcerative 
colitis) patients undergoing biological therapy, 81.13% tested positive for 
clostridium B versus 18.87% of those only taking immunosuppressants (p< 
0.0001) OR 4.956 CI 1.96-8.39, demonstrating that patients on TNF inhibi-
tors were four times more likely to be affected by clostridium (p=0.0002). 
In contrast, no positivity was observed for parasitosis. 
No predominance was observed among the biologics (adalimumab/inf-
liximab), p=0.79.
conclusion: Patients undergoing biological therapy are more susceptible 
to becoming infected with clostridium, and not only those hospitalised or 
receiving antibiotics. This study points to the importance of clostridium 
research in this specific group of patients.
disclosure: Nothing to disclose 
P0369 cOnfOcaL Laser endOMIcrOscOPy reveaLs 
dIfferenTIaL resPOnse In PaTIenTs WITh acTIve 
uLceraTIve cOLITIs undergOIng anTI-InTegrIn cOMPared 
TO anTI-Tnf-aLPha TheraPy
Ellrichmann M.1, Bethge J.2, Aust G.3, Schulte B.3, Arlt A.4, Nikolaus S.5, 
Aden K.6, Schreiber S.2
1University Hospital Schleswig-Holstein, Interdisciplinary Endoscopy, Medical 
Department 1, Kiel, Germany, 2UKSH Kiel, Medizinische Abt. I, Kiel, Germany, 
3University Hospital Schleswig-Holstein, Kiel, Germany, 4University Hospital 
of Schleswig-Holstein, Campus Kiel, Department of Medicine, Kiel, Germany, 
5Univers.-Klinik Schleswig-Holstein, Campus Kiel, Kiel, Germany, 6IKMB + 
First Medical Department, Kiel University, Kiel, Germany
contact e-Mail address: mark.ellrichmann@uksh.de
Introduction: Endoscopic quantification of inflammation in ulcerative coli-
tis (UC) is limited to superficial criteria. Mucosal healing is only validated 
after 8 weeks of treatment and therefore cannot predict early therapy re-
sponse in UC patients undergoing biological therapy with either anti-in-
tegrin or anti-TNF-alpha antibodies. Confocal Laserendomicroscopy (CLE) 
allows real-time visualisation of dynamic changes of the mucosal anatomy 
and might therefore be a reliable tool for an exact quantification of inflam-
mation in UC.
aims & Methods: To evaluate CLE for dynamic quantification of the level of 
inflammation in UC patients undergoing biological therapy (Vedolizumab 
(VDO) or Infliximab (IFX)) as a marker for early therapy response. 
period. The range for patients with all three measured values above the 
cut-off of 50 µg/g was relatively large, which creates significant difficulties 
in analysing the results. By applying a higher cut-off of 100 or 150 µg/g, the 
number of patients with normal and elevated values was reduced, which 
suggests that a higher cut-off may be more pertinent. Our analysis also 
raises the question of whether a single measurement is sufficient to form 
the basis for clinical decision. We suggest that, as withoccult blood, three 
measurements could be performed. All three values in conjunction with a 
clear picture of patient symptoms should enable the clinician to determine 
further treatment procedures. To clearly define recommendations for 
clinical practice, a large prospective study is needed.
disclosure: Nothing to disclose 
P0367 are We chOOsIng WIseLy In InfLaMMaTOry BOWeL 
dIsease care? The Ig-IBd chOOsIng WIseLy caMPaIgn
Lenti M.V.1, Armuzzi A.2, Castiglione F.3, Fantini M.C.4, Fiorino G.5, 
Orlando A.6, Pugliese D.7, Rizzello F.8, Vecchi M.9, Di Sabatino A.10, IG-IBD
1Fondazione IRCCS Policlinico San Matteo, University of Pavia, I Department 
of Internal Medicine, Alessandria, Italy, 2Complesso Integrato Columbus 
Catholic University, Internal Medicine and Gastroenterology, Rome, Italy, 
3Federico II University, Naples, Italy, 4University of Rome ‘Tor Vergata’, 
Department of System Medicine - Gastroenterology, Rome, Italy, 5IRCCS 
Humanitas, IBD Center, Rozzano, Italy, 6United Hospitals ‘Villa Sofia-
Cervello’, Palermo, Italy, 7Università Cattolica del Sacro, Cuore Roma, Rome, 
Italy, 8Policlinico Sant’Orsola Malpighi, Bologna, Italy, 9IRCCS Policlinico 
San Donato, Milan, Italy, 10IRCCS Policlinico S. Matteo, Prima Clinica Medica, 
Pavia, Italy
contact e-Mail address: marcolenti1986@yahoo.it
Introduction: Since it started in 2012 in the USA, the Choosing Wisely 
campaign promoted by the American Board of Internal Medicine has rap-
idly spread all over the world, involving all medical subspecialties. The 
campaign aims at promoting the clinician-patient relationship, identify-
ing procedures, tests, and treatments that are commonly used in routine 
practice, but necessity of which should be questioned or discussed. The 
Canadian inflammatory bowel disease (IBD) Network has recently carried 
out the first choosing wisely campaign for IBD. However, it was carried out 
with a top-down approach, involving only 14 expert gastroenterologists. 
A choosing wisely campaign conducted in a broader scientific community 
could promote a more rationale, clinically-oriented, management for pa-
tients suffering from IBD.
aims & Methods: Between May 2018 and March 2019 we carried out the 
choosing wisely campaign involving regular members of the Italian Group 
for the Study of IBD (IG-IBD). Modified Delphi process was applied. All 
IG-IBD members were asked to submit through SurveyMonkey five state-
ments starting with “Do not…” addressing any management strategy, 
procedure, or treatment the necessity of which should be questioned or 
discussed. As a second step, all the proposed recommendations were 
evaluated by a group of seven senior members and three young members 
(panellists) who prioritised each item, giving a score from 1 to 10 (1=lowest 
priority, 10=maximum priority). The ten recommendations with the highest 
score were prioritised again by all IG-IBD members with the same scor-
ing system. The top five list of the IG-IBD choosing wisely campaign was 
identified.
results: Overall, 101 members (mean age 42±12; 62 males), working in 
both academic (57%) and non-academic (43%) hospitals, participated in 
the campaign. Most participants were gastroenterologists (92%), followed 
by internists (4%), surgeons (2%), and paediatricians (2%). In the second 
step, before selecting the top ten recommendations, panellists merged 
together and rephrased similar statements, and consensus was reached 
after discussion through email. The top five “Do not…” recommendations 
are as follow: 1. Do not use corticosteroids for maintenance therapy, or 
without a clear indication (score 9.08); 2. Do not forget venous thrombo-
embolism prophylaxis in hospitalised patients with active disease (score 
8.9); 3. Do not treat perianal Crohn’s disease with biologics without prior 
surgical evaluation (score 8.66); 4. Do not discontinue IBD-related medica-
tions during pregnancy unless specifically indicated (score 8.63); 5. Do not 
delay surgery (8.4).
conclusion: The IG-IBD promoted a choosing wisely campaign with a 
bottom-up approach, thus reflecting the most compelling, but yet unmet, 
needs in the care of IBD across Italy. Despite the growing number of guide-
lines, uncertainties still exist in day-by-day clinical practice. We therefore 
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90 patients (54m) with active UC were recruited for probe based CLE (Cell-
vizio) in the sigmoid colon before and 2/4/6/14 weeks(wk) after initiation 
of therapy with IFX (46 patients) or VDO (44 patients). The following CLE 
criteria were quantified: Mucosal barrier dysfunction, vascular alteration, 
changes of crypt architecture, inflammatory cell infiltrate. Data were cor-
related to endoscopic Mayo scores and histological activity indices. Data 
are presented as mean±SD.
results: Response to therapy (defined as clinical remission at wk 14) was 
achieved in 73.9% (30/46) of IFX patients and 70.5% (31/44) of VDO pa-
tients. At baseline, fluorescin accumulated in the mucosa after 8.9±6.1sec. 
In patients with later response to both therapies time to accumulation 
significantly decelerated within 2 wk to 14.8±5.2sec compared to patients 
without response (9.6±5.4sec.; p=0.03). Capillary diameters were dilated 
up to 16.3±3.2µm prior to initiation of biological therapies. In case of ther-
apy response a reduction in the capillary diameter of 20.2% (13.65±3.2µm, 
p=0.001) was observed within the first two weeks of treatment.
Crypts were significantly enlarged up to an outer diameter of 114.1±21.2µm 
at baseline and showed a significant shrinkage in response to therapy 
(92.9±12.3µm; p=0.01). Endoscopic Mayo score revealed no significant dif-
ferences at wk 2 between responders and non-responders. 
In patients not responding to biological therapy pCLE criteria did not show 
significant changes after 2 wk of treatment.
Though both therapy groups exhibited significant changes of pCLE crite-
ria between response and non-response patients, changes were mark-
edly higher in the IFX group compared to the VDO groups after 2 wk of 
treatment. Thereafter, no significant changes were observed between the 
groups.
conclusion: Dynamic pCLE criteria allow a reliable quantification of the 
level of inflammation in UC. The assessed criteria proved to be predictive 
for therapy response already after 2 wk of treatment and preceded mucosal 
healing by far. Of note, dynamic, intramucosal changes occur significantly 
earlier in patients undergoing IFX therapy compared to VDO.
disclosure: Nothing to disclose 
P0370 assessMenT Of IBd-dIsk In a PrOsPecTIve 
MuLTIcenTer cOhOrT Of PaTIenTs WITh InfLaMMaTOry BOWeL 
dIsease
Tadbiri S.1, Nachury M.2, Serrero M.3, Bouhnik Y.4, Filippi J.5, Roblin X.6, 
Bourrier A.7, Bouguen G.8, Franchimont D.9, Savoye G.10, Buisson A.11, 
Louis E.12, Nancey S.13, Abitbol V.14, Reimund J.-M.15, Dewit O.16, Vuitton L.17, 
Laharie D.18, Amiot A.19
1APHP, Gastroenterology, Courbevoie, France, 2Lille University Hospital, Lille, 
France, 3Hopital Nord, Gastroenterology, Marseille, France, 4CHU Beaujon 
Dept. of IBD and Nutrition, Dept. of Gastroenterology, Clichy, France, 5Hopital 
de l’Achet, Dept. de Gastroenterologie et Nutrition Oncologie, Nice Cedex 3, 
France, 6University of St. Etienne Dept. de Gastroenterologie, Saint Etienne, 
France, 7Saint-Antoine Hospital AHPD and Paris 6 University, Dept. of 
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Introduction: The IBD-disk is a 10-item visual tool assessing the disease 
burden in patients with inflammatory bowel diseases (IBD) with no vali-
dation to date. In a cohort of patients with IBD, we aimed to determine 
the correlation between the IBD-disk and each of its components with the 
daily-life IBD burden.
aims & Methods: A one-week cross-sectional cohort study has been con-
ducted in 42 tertiary centers in France and Belgium affiliated to the GETAID 
in November 2019 recruiting all consecutive outpatients with IBD. Patients 
fulfilled a self-administered anonymous standardized questionnaire col-
lecting data on patients’, IBD and treatment characteristics. Patients were 
asked to complete each component of the IBD-disk on 10-point Likert 
scales (0 = no burden ; 10 = maximal burden) assessing abdominal pain, 
body image, education and work, emotions, energy, interpersonal interac-
tions, joint pain, regulating defecation, sexual functions, and sleep) rang-
ing from 0 to 100 as well as a 10-point Likert scale assessing the daily-life 
IBD burden. The objective of the study was to determine the correlation 
between the IBD-disk score and the daily-life IBD burden, using Pearson’s 
correlation coefficient. 
Secondary objectives were to determine the correlation between each 
component of the IBD-disk score and the daily-life IBD burden. A multi-
variate linear regression was carried out to investigate the effect of each 
IBD-disk score component on daily life IBD burden scale. In addition, we 
evaluated completion rate as well as patient satisfaction for IBD-disk.
results: A total of 2011 outpatients with IBD responded to the survey (930 
men; median age 40.0 (29.0-52.0) yrs; median IBD duration 10.5 (4.5-18.5) 
yrs; 67.8% of patients with Crohn’s disease). Patient global assessment of 
clinical remission was noted in 49.9%. Completion of the IBD-disk was 
complete in 1484 (73.8%) cases and partial (>5 items) in 220 (10.9%). It 
was considered as easy to complete by 88.4% of patients. The mean IBD-
disk score was 39.0 ± 23.2. After removing 29 outliers, a significant cor-
relation was found between IBD-disk score and daily-life IBD burden scale 
(r=0.65, p< 0.001). 
A significant correlation was found between 5 IBD-disk score components 
(abdominal pain, regulating defecation, education/work, emotions and 
energy) and daily-life IBD burden (r>0.50). Based on multivariate linear 
regression analysis, we build a modified 5-item IBD-disk score (education 
and work x3 + regulating defecation x2 + abdominal pain + energy + emo-
tions) ranging from 0 to 80 with the highest correlation with daily-life IBD 
burden (r=0.68, p< 0.001). 
The receiver operating characteristic (ROC)- curves analysis indicated a 
good performance to predict the absence of clinical remission (AUROC 0.70 
95%CI[0.66-0.72], p< 0.001) and a significant daily-life IBD burden (0.82 
[0.80-0.84], p< 0.001) with an optimal cut-off above 30. 
Subgroup analysis of patients in clinical remission revealed a significant 
burden (score >5) in many dimension of burden: body image (33%), edu-
cation/work (34%), emotions (40%), energy (55%), interpersonal interac-
tions (17%), sexual functions (23%), and sleep (47%).
conclusion: The IBD-disk had a good completion rate and demonstrated a 
close correlation with daily-life IBD burden in a large multicentre cohort of 
IBD patients. Our results suggest that the IBD-disk could be a valuable tool 
in routine practice to assess daily-life IBD burden. Although a simplified 
5-item IBD-disk demonstrated better performance to assess IBD burden, 
the overall score, the IBD-disk allows to explore all dimensions of IBD 
burden.
disclosure: This study was funded by a grant from ABbvie 
P0371 IncIdence and sIgnIfIcance Of faTIgue In PaTIenTs 
WITh IBd
Kokkotis G., Bekiari D., Gizis M., Perlepe N., Gagas F., Athanasiou V., 
Kounadis G., Xourafas V., Bamias G., Koutsounas I.
3rd Internal Medicine clinic, University of Athens, Gastrenterology, Athens, 
Greece
contact e-Mail address: gkokkot@gmail.com
Introduction: Fatigue is common in IBD patients, even in clinical remission 
and adversely affects the quality of life. For this reason, it has been sug-
gested to use fatigue questionnaires as PROs (patient reported outcomes). 
We aimed to study the degree of fatigue in IBD patients and identify factors 
that are positively or negatively related to its presence.
aims & Methods: Patients with IBD (men: 48.7%, Crohn’s Disease: 65.8%, 
age: 39.7yrs median, 18.1-72 yrs range), with a regular f-up in our Depart-
ment completed the Fatigue Severity Scale, IBD Fatigue self assessment 
1 & 2, short IBDQ and Short Health Scale upon consensus. Two groups 
of patients were studied: Group A, patients attended the IBD outpatient 
clinic (111 patients / 127 questionnaires) and Group B, patients attended the 
infusion center for biological therapy (45 patients / 256 questionnaires). 
The SPSS-23 statistical program was used to identify correlations between 
fatigue and various clinical-laboratory parameters of patients.
results: Problematic fatigue (FSS> 36) was reported by 45.9% of patients. 
No difference was observed between Crohn’s disease and Ulcerative Coli-
tis or between the two groups of patients. There were statistically sig-
nificant correlations between fatigue and disease activity (R = 0.452, P 
335Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
ment of the agreement for both scores, this study suggested that EMES 
could be a feasible diagnostic tool for disease activity assessment and tai-
lored therapy.
disclosure: Nothing to disclose 
P0373 sOMaTIc dIsTress syMPTOMs are assOcIaTed WITh 
hIgher dIsease acTIvITy In crOhn’s PaTIenTs
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(IIRN)
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Israel, 5Soroka Medical Center, Gastroenterology and Hepatology, Beer 
Sheva, Israel
contact e-Mail address: doronsh90@gmail.com
Introduction: Patients with Crohn’s disease (CD) struggle continuously 
with chronic somatic symptoms that could bring about emotional distress. 
Previous studies have mostly focused on the symptoms of depression and 
anxiety [1]. The present study evaluates a possible role of somatic distress 
(previously termed somatization) due to perceived bodily sensations (e.g., 
numbness, dizziness, chest pain), in addition to depression and anxiety, in 
exacerbating disease activity among adult patients with CD.
aims & Methods: A cross-sectional analysis was performed on unselected 
CD patients (age >18years) attending for routine follow-up at a teaching 
hospital. Clinical disease activity was assessed by the Harvey-Bradshaw 
Index (HBI) [2]. Anxiety, depression and somatic distress symptoms were 
measured using the self-report Brief Symptom Inventory questionnaire 
[3]. Socio-economic status (SES) was self-declared on a Likert scale [4]. 
Path analysis models tested the contribution of depression, anxiety and 
somatic distress to disease activity, in the whole cohort and across socio-
demographic groups.
results: The cohort was composed of 494 CD patients, mean age 38.0 
±13.8 yr., women 58%. Declared SES was: bad 20%, medium 50%, high 
30%. Among the three dimensions of distress symptoms, somatic distress 
was the only significant predictor of increased HBI for the entire sample 
(Table). The effect of somatic distress on HBI was stronger in men than 
women, but there were no gender differences in the effects of depression 
or anxiety on HBI. The effect of somatic distress on HBI was stronger for 
individuals with low SES (vs. medium SES) and for patients who had re-
cently endured a stressful life event (vs. those who did not). In contrast, no 
such differences were found in the effect of depression or anxiety on HBI 
across these subgroups.
conclusion: Somatic distress is more strongly related than depression and 
anxiety to disease activity in CD. The association between somatic distress 
and HBI was especially strong for men, for patients with a recent stress-
ful life event and for patients with low SES. We suggest that screening for 
emotional distress arising from perceived bodily sensations should be part 
of CD care. Further investigation will determine whether somatic distress 
symptoms are causal for elevated markers of inflammation, and whether 
psychological interventions designed to manage somatic distress could 
improve outcomes for IBD patients.
  all gender ses stressful life event
    Men Women Low Medium High No Yes
β Somatic 
distress
0.65*** 0.91*** 0.52*** 0.91*** 0.48*** 0.67*** 0.32 .0.72***
β 
Depression
0.11 0.20 0.06 -0.15 0.14 0.47 0.29 0.05
β Anxiety -0.23 -0.53** -0.11 -0.17 -0.15 -0.74 -0.28 -0.22
[Effect of somatic distress, depression and anxiety on HBI: Summary of path 
coefficients across socio-demographic groups (** p<.01, *** p<.001)]
references: 1. Mikocka-Walus A, Knowles SR, Keefer L, et al. Controversies 
revisited: A systematic review of the comorbidity of depression and anxiety 
with inflammatory bowel diseases. Inflamm Bowel Dis 2016; 22(3):752-62. 
2. Bennebroek Evertsz, F. B., Hoeks, C. C., Nieuwkerk, P. T., et al. Develop-
ment of the patient Harvey Bradshaw index and a comparison with a clini-
<0.001), HGB (R = -0.318, P < 0.001) and albumin (R = -0.172, P = 0.039). 
Fatigue was significantly associated with quality of life based on the short 
IBDQ and SHS questionnaires (R = -0.544, P < 0.001 and R = 0.426, P < 
0.001 respectively). There was also a statistically significant relationship 
of both fatigue and quality of life with parameters such as female sex (P 
< 0.01), arthralgia (P < 0.05) and biological agent treatment (P < 0.05). 
Sequential measurements showed that the quality of life and fatigue rate 
were consistently maintained in patients with remission under biological 
therapy.
conclusion: In the group of IBD patients we studied, a significant correla-
tion with various clinical characteristics was observed. The presence of 
fatigue is a factor associated with poor quality of life for patients.
disclosure: Nothing to disclose 
P0372 InTer-OBserver agreeMenT Of uLceraTIve cOLITIs 
“exTended MayO endOscOPIc scOre (eMes)” WIThIn a 
MuLTIcenTer InfLaMMaTOry BOWeL dIsease (IBd) TeaM WOrk
Contaldo A.1, Bianchi F.P.2, Losurdo G.3, Iannone A.3, Albano F.4, 
Allegretta L.5, Bossa F.6, De Tullio N.7, Della Valle N.8, Fiorella S.9, 
Hadad Y.10, Mazzuoli S.11, Paiano P.12, Rispo A.13, Stasi E.14, Tursi A.15, 
Tafuri S.2, Di Leo A.3, Principi M.16
1Section of Gastroenterology, DETO, University of Bari, Dr., Lecce, Italy, 
2Department of Biomedical Science and Human Oncology, University 
of Bari ‘Aldo Moro’, Bari, Italy, 3Section of Gastroenterology, DETO, 
University of Bari, Dr., Bari, Italy, 4University of Bari, Bari, Italy, 5Division of 
Gastroenterology, ‘Santa Caterina Novella’ Hospital, Galatina (LE), Galatina, 
Italy, 6Casa Sollievo della Sofferenza Hospital, Gastroenterology, Bari, Italy, 
7Miulli Hospital, Acquaviva delle Fonti, Italy, 8Gastroenterologia Universit 
Azienda Ospedali Riuniti, Foggia, Italy, 9Padre Pio Hospital, Division of 
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Giovanni Panico, Medicine, Tricase (Le), Italy, 11Silvia Mazzuoli, Bari, Italy, 
12Division of Gastroenterology, ‘Veris Delli Ponti’ Hospital, Scorrano (LE), 
Scorrano, Italy, 13University ‘’Federico II’’of Naples, Dept. Clinical Medicine 
and Surgery, Naples, Italy, 14IRCCS DE BELLIS, Gastroenterology and Digestive 
Endoscopy, Rome, Italy, 15ASL BAT Gastroenterology Service, Gastroenterology 
Service, Andria, Italy, 16Policlinico di Bari, Bari, Italy
contact e-Mail address: contaldoantonella@gmail.com
Introduction: Ulcerative colitis (UC) endoscopic scores decode and translate 
mucosal damage and into a numeric value to reach inter/intra-observer 
standardization and variability reduction. At this regard, we elaborated 
a new UC endoscopic score i.e. the “Extended Mayo Endoscopic Score 
(EMES)”. In this study, we evaluated its inter-observer agreement within a 
multicenter IBD endoscopy experts team and compared EMES concordance 
with that of Mayo score.
aims & Methods: Sixteen UC consecutive patients underwent follow-up 
colonoscopy. Sixteen videos were recorded during instrument withdrawal 
phase. They were anonymously loaded on a web platform realized by 
SEM web-service, FORMEDICA Scientific Learning srl, Lecce, Italy. Thirteen 
endoscopists were allowed to access by a personal account in order to 
evaluate UC activity using both Mayo and EMES scores from April to May 
2018. EMES has the peculiarity to depict in every colon segment (ascend-
ing, transverse, descending, sigmoid and rectum) the following features: 
erythema (0: absent, 1: mild, 2: moderate, 3: severe); vascular pattern (0: 
normal, 1: reduction, 2: disappearance); erosions (0: absent, 1: from 1 to 5, 
2: 6 to 10, 3:>10); ulcers (0: absent, 1: from 1 to 5, 2: 6 to 10, 3:>10).
The weighted Fleiss’ kappa (k) with 95% confidence interval (CI) and the 
p-value defined the Interrater agreement for global EMES, for every colon 
segment EMES and for Mayo score. Agreement was considered poor if k< 
0; slight for k=0-0.2; fair for k=0.21-0.4; moderate for k=0.41-0.6; substan-
tial dor k=0.61-0.8; almost perfect for k=0.81-1. STATA MP14 software was 
used.
results: The interobserver agreement degree of EMES score was moder-
ate even if statistically significant (k= 0.56; 95% CI= 0.46 - 0.67; p< 0.001). 
Every colon segment showed the following agreement degrees: ascending 
(k= 0.46; 95% CI= 0.32 - 0.60; p< 0.001); transverse (k= 0.48; 95% CI= 
0.29 - 0.67; p< 0.001); descending (k= 0.49; 95% CI= 0.35 - 0.64; p< 0.001); 
sigmoid (k= 0.52; 95% CI= 0.39 - 0.65; p< 0.001); rectum (k= 0.55; 95% 
CI= 0.42 - 0.69; p< 0.001) (figure 1). Mayo score result was similar to EMES 
global agreement (k= 0.53; 95% CI= 0.39 - 0.66; p= 0.001).
conclusion: EMES and Mayo score showed a moderate, but significant 
global agreement. Despite the evidence of the need of a further improve-
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cian based Harvey Bradshaw index assessment of Crohn’s disease activity. 
J Clin Gastroenterol 2013; 47: 850- 856. 3. Derogatis, L. R., & Melisaratos, 
N. The brief symptom inventory: An introductory report. Psychol Med 1983; 
13: 595-605. 4. Slonim-Nevo V, Sarid O, Friger M, Schwartz D, Chernin E, 
Shahar I, Sergienko R, Vardi H, Rosenthal A, Mushkalo A, Dizengof V, Ben-
Yakov G, Abu-Freha N, Munteanu D, Gaspar N, Eidelman L, Segal A, Fich A, 
Greenberg D, Odes S; Israeli IBD Research Nucleus (IIRN). Effect of psycho-
social stressors on patients with Crohn’s disease: threatening life experi-
ences and family relations. Eur J Gastroenterol Hepatol. 2016; 28:1073-1081.
disclosure: Nothing to disclose 
P0374 MIndfuLness-Based cOgnITIve InTervenTIOn 
IMPrOves WOrk PrOducTIvITy and acTIvITy IMPaIrMenT 
aMOng crOhn’s dIsease PaTIenTs. a randOMIzed 
cOnTrOLLed TrIaL
Schwartz D.1,2, Goren G.3, Sergienko R.4, Greenberg D.5, Abu kaf H.1,2, 
Friger M.6, Sarid O.3, Slonim-Nevo V.3, Odes S.2, Israeli IBD Research 
Nucleus (IIRN)
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contact e-Mail address: doronsh90@gmail.com
Introduction: Crohn’s Disease (CD) is a chronic debilitating inflammatory 
intestinal disease causing lifetime medical problems. It was shown to af-
fect patients’ ability to work and perform everyday leisure activities. We 
assessed whether a specifically designed Cognitive Behavioral Mindfulness 
Intervention (CBMI) as an add-on treatment, could improve work produc-
tivity and leisure activities in CD patients.
aims & Methods: Unselected adult CD patients with mild to moderate 
disease activity (4< HBI < 16) attending for routine follow-up at the out-
patients’ department of a university-affiliated tertiary hospital were en-
rolled consecutively into a prospective randomized controlled study. Pa-
tients were randomized to CBMI (Intervention group) or were wait-listed 
(Control group). CBMI was taught to Intervention group patients by trained 
therapists, using SKYPE in weekly hour-long sessions over an 8-week pe-
riod. Medical details were collected by study physician and medical treat-
ment was uninterrupted. Patients’ clinical status was scored by the Harvey 
Bradshaw Index (HBI). Treating physicians were blinded to randomization. 
Patients completed the Work Productivity and Activity Impairment (WPAI) 
Questionnaire, which assesses their ability to work and perform leisure 
activities in the previous week while coping with their disease. The WPAI 
generates four scores: Absenteeism - missed work d\t CD; Presenteesism 
- reduced on-the-job effectiveness; Work productivity loss -overall work 
impairment; Activity Impairment - degree CD affected regular leisure ac-
tivities. HBI and WPAI were again completed three months from baseline.
results: The cohort consisted of 41 patients, 20 in the Intervention Group 
(IG) and 21 in the Control Group (CG). Of the IG and CG patients 65% and 
62% were female, the mean (SD) age was 36 (14.4) and 34 (10.8) years, 
mean (SD) disease duration was 9.7 (10.1) and 9.7 (8.9) years, 10% and 
14.3% were smokers, baseline mean HBI was 9.14 and 8.5, and employ-
ment rates were 71.4% and 85.0% respectively. Three months from base-
line HBI decreased by 3.35 in the IG vs 1.95 in the CG. Absenteeism de-
creased from 25.4% to 4.6% in the IG (P=0.06) and increased from 15.1% 
to 21.8% in the CG (P=0.55). Presenteesism decreased from 52.1% to 24.3% 
in the IG (P=0.027) and from 43.3% to 38.0% in the CG (P=0.63). Work 
productivity loss decreased from 57.0% to 26.9 % in the IG (P=0.021) and 
from 49.8% to 45.2% in the CG (P=0.46). Activity impairment decreased 
from 47.0% to 29.0% in the IG (P=0.018) and from 51.9% to 48.6% in the 
CG (P=0.51).
conclusion: Work productivity is significantly improved by a specifically de-
signed CBMI. This intervention should be added to the treatment options 
for better outcomes in CD.
disclosure: Nothing to disclose 
P0375 evaLuaTIOn Of The dIagnOsTIc vaLue Of fecaL 
caLPrOTecTIn In The ManageMenT Of crOhn’s dIsease: 
MOrOccan exPerIence
Chabib F.-Z., Benelbarhdadi I., Ajana F.-Z.
Ibn Sina University Hospital, Medical Unit C, Rabat, Morocco
contact e-Mail address: dr.chabib.fatimazahra@gmail.com
Introduction: To limit the repetition of colonoscopies, which are not appre-
ciated by patients, non-invasive tools have been developed. Among them, 
fecal calprotectin is the non-invasive reference biomarker for assessing 
endoscopic activity in Crohn’s disease (CD).
aims & Methods: The objective of our study is to evaluate the performance 
of fecal calprotectin for the detection of endoscopic activity in patients with 
Crohn’s disease .This is a single-center retrospective study that includes 
patients with CD. Inclusion criteria: Patient with both fecal calprotectin and 
ileocoloscopy. Fecal calprotectin was measured by ELISA and expressed 
in mg / kg. Criterion of judgment : Endoscopic remission: CDEIS < 6 and 
Rutgeert score < i2. Statistical analysis was performed using Medcalc V9 
software. The diagnostic evaluation of (calpro) was performed by the ROC 
curve. For each value, the sensitivity (Se), the specificity (Spe), the posi-
tive predictive value (VPP) and the negative predictive value (VPN) were 
determined. The best threshold value of (calpro) corresponds to the value 
having a better sensitivity for a better specificity.
results: A total of 70 patients were included in this study. There are 54 
women and 16 men; the couple calprotectin-fecal-ileocoloscopy was per-
formed 90 times. According to the Montreal classification: the localiza-
tion is distributed as follows: L1 = 17.8%, L2 = 20% , L3 = 62.2% and the 
phenotype is distributed as follows: B1 = 50%, B2 = 37.8%, B3 = 12 , 2%. 
Clinically: 76.6% were asymptomatic. The analysis of the area under the 
curve ROC revealed a diagnostic value estimated at 70% (confidence inter-
val [0.589 - 0.788]). The best detection threshold for the endoscopic activity 
was 150 mg / kg. This threshold demonstrated the following performances: 
Se = 72.97%, Spe = 71.70%, VPP = 64.3%, VPN = 79.2%. If we take oper-
ated patients separately, the analysis of area under ROC curve found an 
estimated diagnostic value of 72% (confidence interval [0.544 - 0.859]). 
The best detection threshold for endoscopic activity was 127 mg / kg . This 
threshold demonstrated the following performance: Se = Se = 66.67%, Spe 
= 78.57%, VPP = 82.4%, VPN = 61.1%.
conclusion: Measurement of fecal calprotectin have a diagnostic value ac-
ceptable for the diagnosis and monitoring of endoscopic remission in pa-
tients with Crohn’s disease. In our study, the optimal threshold was 150 mg 
/ kg and 127 mg/kg in operated patients. This threshold value presented a 
better sensitivity for a better specificity.
disclosure: Nothing to disclose 
P0376 arTIfIcIaL neuraL neTWOrk as an assIsTanT In 
The dIfferenTIaL dIagnOsIs BeTWeen uLceraTIve cOLITIs 
and crOhn’s dIsease
Bakulin I.1, Skalinskaya M.2, Skazyvaeva E.1, Mashevskii G.3, 
Shelyakina N.3, Smirnov A.4
1SZGMU na I.I.Mechnikov, Gastroenterology and Dietology, Saint Petersburg, 
Russian Federation, 2SZGMU na I.I.Mechnikov, Gastroenterology and 
dietology, Saint Petersburg, Russian Federation, 3St. Petersburg State 
Electrotechnical University ‘LETI’ n.a. V.I. Ulyanov, Department of 
Biotechnical Systems, Saint Petersburg, Russian Federation, 4SZGMU 
na I.I.Mechnikov, Department of Operative and Clinical Surgery with 
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contact e-Mail address: igbakulin@yandex.ru
Introduction: Due to the lack of a “gold standard” in the diagnosis of IBD, 
the differential diagnosis between ulcerative colitis (UC) and Crohn’s dis-
ease (CD) can be difficult. The complexity of the short-term diagnosis, but 
its extreme necessity, the lack of uniform criteria for diagnosis, but at the 
same time high social and medical significance, require the development 
of new algorithms and methods for identifying and differentiating the 
forms of IBD.
aims & Methods: We have created an artificial neural network (ANN) of 
the multilayer perceptron type using the Neural Network Toolbox applica-
tion from the MATLAB application package. Three types of images were 
used to train the ANN: the norm of the endoscopic picture of the colon, 
the endoscopic pictures of UC and CD. The first stage is the training of an 
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mococcal vaccines, HPV and HiB vaccines. These results will serve as a 
starting point for establishing determinants of suboptimal adherence 
within the studied population. Ultimately, targeted education programs 
can be developed.
references: [1] The Impact of Inflammatory Bowel Disease in Canada. 2018 
Final Report and Recommendations. [2] Selby L, Kane S, Wilson J, et al. 
Receipt of preventive health services by IBD patients is significantly lower 
than by primary care patients. Inflamm Bowel Dis. 2008;14:253-258. [3] 
Mao EJ, Sheibani S, Martin C, Bloomfeld RS, Isaacs K, Saha S, Mahadevan 
U. Preventive Health Care Among Postpartum Women With Inflammatory 
Bowel Disease: Results From the PIANO Registry. Inflamm Bowel Dis. 2019 
Mar 14;25(4):797-802.
disclosure: (1) Dr. Cynthia Seow: Advisory Boards: Janssen, Abbvie, Takeda, 
Ferring, Shire, Pfizer Speaker: Janssen, Abbvie, Takeda, Ferring, Shire Edu-
cational grants: Janssen (2) Dr. Bellal Jubran: None (3) Nastaran Sharifi: 
None 
P0378 reLaTIOn BeTWeen 6-ThIOguanIne nucLeOTIdes 
and red ceLL Mean cOrPuscuLar vOLuMe, WhITe BLOOd ceLL, 
neuTrOPhIL and LyMPhOcyTe cOunT In PaTIenTs TreaTed WITh 
azaThIOPurIne and 6-MercaPTuPurIne
Zad M.1, Do C.2, Mahy G.3
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contact e-Mail address: ali6351@gmail.com
Introduction: Inflammatory bowel disease (IBD) is caused by dysregulated 
immune responses, thus thiopurine drugs, 6-mercaptopurine (6-MP) and 
prodrug Azathiopurine (AZA) are indicated in refractory and steroid-de-
pendent patients. Due to narrow therapeutic ranges, risks of myelosup-
pression and liver toxicity, these drugs require therapeutic monitoring of 
metabolites. The 6-Thioguanine nucleotide (6-TGN) metabolite is pre-
dominant during therapeutic efficacy (235-460 pmol/8x108 erythrocytes), 
whereas 6-Methylmercaptopurine (6-MMP) correlates with toxicity. Moni-
toring is associated with significant laboratory costs and a more cost-ef-
fective surrogate marker is desirable. As thiopurines cause lymphopenia 
and increased mean corpuscular volume (MCV), it has been postulated 
that these may be clinically useful in determining 6-TGN levels, and thus 
therapeutic efficacy of immunomodulatory treatment.
aims & Methods: To investigate the correlation between 6-TGN levels in 
relation to MCV, white blood cell count (WBC), neutrophil and lymphocyte 
count in patients treated with thiopurines.
We retrospectively analysed an electronic database of IBD and non-IBD 
patients from 2008 to 2017 who were treated with thiopurines (either 6-MP 
or AZA) in a regional Australian hospital. A total of 931 laboratory results 
were consecutively obtained, with some patients having repeated blood 
tests. Pearsons correlation was performed between 6-TGN and MCV levels. 
Laboratory results were grouped with those < 235 pmol/8x108 erythrocytes 
(below therapeutic level, n=403) and those ≥235 pmol/8x108 erythrocytes 
(above therapeutic level, n=528). Unpaired t-test was used to compare 
the MCV, WBC, neutrophil and lymphocyte levels of these two groups. The 
value of these surrogate markers to distinguish shunters (6-TGN < 260, 
6-MMP > 5700) vs. non-shunters (6-TGN ≥ 260, 6-MMP ≤5700) was also 
assessed.
results: Results showed that a positive statistically significant correlation 
existed between 6-TGN and MCV levels (r=0.3219, p< 0.0001) within our 
dataset. The odds ratio of therapeutic levels of 6-TGN (≥235 pmol/8x108 
erythrocytes) found in patients with MCV ≥92 fl was 2.79 (95% CI 2.13, 3.67) 
(p< 0.0001), compared to patients with MCV < 92 fl. Patients above thera-
peutic 6-TGN level had a mean MCV of 92.66 fl, compared to MCV 89.1 fl 
(p< 00001) in patients below therapeutic 6-TGN (< 235 pmol/8x108 erythro-
cytes). Therapeutic patients also had a mean WBC of 6.59 x109/L (p=0.0012), 
neutrophil count of 4.37 x109/L (p=0.0211) and lymphocyte count of 1.53 
x109/L (p=0.033), which were statistically lower levels than non-therapeutic 
patients at 7.16 x109/L, 4.73 x109/L and 1.64 x109/L respectively. The mean 
MCV (95 fl) and WBC (5.915 x109/L) of shunters was statistically different 
to the mean MCV (90.91 fl) and WBC (6.885) of non-shunters (p=0.0001 
and p=0.0131 respectively). The mean neutrophil and lymphocyte count 
between shunters and non-shunters was non-significant.
conclusion: The results from this study show that there is a statistically 
significant correlation between 6-TGN and MCV levels. Patients with above 
therapeutic 6-TGN levels have statistically higher MCV levels and statisti-
artificial neural network to distinguish the presence or absence of pathol-
ogy (29 images of the “normal colon”, 14 images of the CD, and 15 - UC). 
The second stage is the training of the network in the task of differentiating 
IBD. The network was trained on an array of 124 images (62 images of each 
class of pathologies). Each image was previously converted to grayscale 
mode, and then into a matrix of pixels. A vector with the number of ele-
ments equal to the size of the image was fed to the input of the perceptron.
results: To solve the problem of identifying pathology, a perceptron was 
built with 32,2784 input neurons, 10 hidden neurons and 2 output neu-
rons, which represent the conclusion that the image belongs to one of two 
classes: norm or pathology. To solve the problem of differentiating CD and 
UC, a perceptron was created with 364500 input neurons (this value was 
determined by the image resolution) and 2 output neurons, representing 
the conclusion that the image belongs to one of two classes: ulcerative 
colitis or Crohn’s disease. ANN studied no more than three times, because 
then there was a decrease in accuracy.
The best result in the differentiation of pathologies was shown by a neural 
network of the type MP 364500: 364500-20-2: 2, the overall recognition 
accuracy of which was 96.8%. However, on the control sample, the ac-
curacy was 84.2%.
The effectiveness of the created artificial neural network in relation to the 
differentiation of the forms of IBD (UC / CD) can be judged by the criteria: 
specificity (Sp) 78.2%, sensitivity (Se) 93.1%, accuracy (Ac) 85.7%.
conclusion: At present, it is planned to further refine the models obtained 
in order to increase the reliability of their estimates. In particular, it is 
planned to train the network on a larger array of endoscopic images, in-
cluding those with higher resolution, as well as the use of other types of 
networks, in particular, the radial basis function. The resulting ANN can 
be used to solve the problems of classifying endoscopic images of the in-
testine for the presence of IBD, as well as to differentiate between Crohn’s 
disease and ulcerative colitis.
disclosure: Nothing to disclose 
P0377 suBOPTIMaL adherence TO vaccInaTIOn In PregnanT 
PaTIenTs WITh InfLaMMaTOry BOWeL dIsease On BIOLOgIcs
Jubran B.1, Sharifi N.2, Seow C.3
1University of Calgary, Internal Medicine, Calgary, Canada, 2University of 
Calgary, Calgary, Canada, 3University of Calgary, Gastroenterology, Calgary, 
Canada
contact e-Mail address: bellal.jubran@ahs.ca
Introduction: Inflammatory bowel disease (IBD) affects 0.7% of the Canadi-
an population[1]. Studies have suggested that preventative health services 
are received at a significantly lower rate for IBD patients than the general 
population[2]. Further, many IBD patients are young, female and of child-
bearing age. Recent data has demonstrated that despite having multiple 
health care providers, post partum individuals with IBD have suboptimal 
health care maintenance rates, with lower self-reported rates of vaccina-
tion[3]. We determined adherence to vaccination in pregnant women with 
IBD by linking a provincial database to a dedicated IBD pregnancy registry.
aims & Methods: To determine the proportion of pregnant women with 
IBD on biologics who received key vaccines, which included Hepatitis A 
and B, pneumococcal vaccines 13 and 23, the diphtheria, tetanus and acel-
lular pertussis (dTap) vaccine, human papilloma virus (HPV) vaccine, and 
the hemophilus influenza (HiB) vaccine. Adherence was based on serolog-
ical documentation of immunity and/or electronic public health provincial 
vaccination records.
results: Records of 115 IBD patients who were pregnant and on a biologic 
in the study period of 2012-2018 were reviewed. The median age of pa-
tients studied was 32 years (IQR 6). Of these patients, 23% had ulcerative 
colitis (UC), 2% had indeterminate colitis, and 75% had Crohn’s disease 
(CD). 87% were on an anti TNF-alpha biologic (infliximab, adalimumab 
or golimumab), 7% were on vedolizumab and 6% on ustekinumab. Our 
results show that 70% had either serological evidence of immunity or reg-
istry reported vaccination to Hepatitis B. 37% had serological or registry 
reported evidence of Hepatitis A vaccination. With the pneumococcal vac-
cine, 2% had records of the Prevnar 13 vaccine with 35% having received 
the Pneumovax 23 vaccine. When it came to the dTap vaccine, 78% had 
evidence of vaccination. The recorded rate of a complete HPV vaccine was 
4% while exposure to the hemophilus influenza (HiB) vaccine was 14%.
conclusion: Our study suggests deficiencies in rates of vaccination in the 
pregnant IBD population on biologics, particularly hepatitis A, the pneu-
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cally lower levels of WBC, neutrophils and lymphocytes. Further, there are 
statistically significant odds that patients managed on thiopurines with 
MCV ≥92 fl have a therapeutic 6-TGN level. This indicates that it may be 
possible to use these markers as surrogates for expensive 6-TGN levels in 
patients treated with thiopurines. Further, this study suggests that shunt-
ers have a statistically higher mean MCV and WBC.
disclosure: Nothing to disclose 
P0379 BaMBOO jOInT-LIke aPPearance In sTOMach - an 
endOscOPIc BIOMarker Of crOhn’s dIsease. a PrOsPecTIve 
case cOnTrOL sTudy
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contact e-Mail address: kgracapakulska@gmail.com
Introduction: Crohn’s disease (CD) is a chronic inflammatory condition that 
typically involves the ileocecal region; but the whole gastrointestinal (GI) 
tract can be affected. Lesions in the upper GI tract are increasingly diag-
nosed. It was suggested that lesions in the stomach, with a bamboo joint-
like appearance (BJA) might be an endoscopic biomarker for CD. However, 
the reported prevalence of upper GI tract involvement in CD varies greatly 
and diagnostic significance of BJA remains to be defined. A majority of 
European studies were retrospective and did not refer to the presence of 
BJA in stomach.
aims & Methods: Our aim was to investigate the prevalence, characteristic 
and clinical importance of upper gastrointestinal involvement in a patients 
with CD, with special focus on the lesion named bamboo joint like ap-
pearance. A prospective, case control study was conducted. 144 patients 
were included into the study, 72 with CD ( 37 female, 35 male) and 72 
gender and age matched non IBD controls. The endoscopy was performed 
by experienced physician using a high definition endoscope with narrow 
band imaging.
results: The upper gastrointestinal tract was involved in 43 out of 72 (59.7 
%) patients with CD. Most commonly stomach was affected ( n=37; 51.4 
%), followed by duodenum (n=21; 29.2% ) and esophagus ( n=9; 12.5 %). 
16 (22.2%) of CD patients had BJA in proximal part of gastric body or/and 
fundus . BJA was present irrespectively of the patient’s sex, age, location 
of the disease, and medications taken. BJA was absent in control group 
(statistically significant difference with study group, p=0.00025).
conclusion: The upper gastrointestinal involvement in Crohn’s disease is 
common phenomenon. The most commonly affected area is the stomach 
with a specific lesion for CD, the bamboo joint like appearance. This find-
ing may help to identify individuals at high risk for CD using only gastro-
duodenoscopy.
references: 1.Yokota K, Saito Y, Einami K, Ayabe T, Shibata Y, Tanabe H, et 
al. A bamboo joint-like appearance of the gastric body and cardia: possible 
association with Crohn’s disease. Gastrointest Endosc. 1997;46(3):268-72. 2. 
Kuriyama M, Kato J, Morimoto N, Fujimoto T, Okada H, Yamamoto K. Spe-
cific gastroduodenoscopic findings in Crohn’s disease: Comparison with 
findings in patients with ulcerative colitis and gastroesophageal reflux dis-
ease. Dig Liver Dis. 2008;40(6):468-75. 3.Horjus Talabur Horje CS, Meijer 
J, Rovers L, van Lochem EG, Groenen MJ, Wahab PJ. Prevalence of Upper 
Gastrointestinal Lesions at Primary Diagnosis in Adults with Inflammatory 
Bowel Disease. Inflamm Bowel Dis. 2016;22(8):1896-901. 4.Greuter T, Piller 
A, Fournier N, Safroneeva E, Straumann A, Biedermann L, et al. Upper 
Gastrointestinal Tract Involvement in Crohn’s Disease: Frequency, Risk Fac-
tors, and Disease Course. J Crohns Colitis. 2018;12(12):1399-409.
disclosure: The project is financed from the program of the Minister of Sci-
ence and Higher Education under the name “Regional Initiative of Excel-
lence” in 2019-2022 project number 002 / RID / 2018/19 amount of financ-
ing 12 000 000 PLN” 
P0380 POInT-Of-care TesTIng sysTeM fOr fecaL 
caLPrOTecTIn deTecTIOn In The TeLeMOnITOrIng Of 
PaTIenTs WITh InfLaMMaTOry BOWeL dIseases
Malícková K., Pešinová V., Bortlík M., Ďuricová D., Machková N., 
Hrubá V., Lukáš M., Vašátko M., Lukáš M.
ISCARE IVF & Charles University, Clinical & Research Center for Inflammatory 
Bowel Disease, Prague, Czech Republic
contact e-Mail address: kmali@seznam.cz
Introduction: Telemedicine refers to the professional monitoring of pa-
tients and the transmission of medical information remotely via informa-
tion technologies. The first Czech study of the remote monitoring of IBD 
patients called “IBD Assistant” was launched at the IBD Clinical & Research 
Centre ISCARE IVF in 2018. The inclusion criteria for the study were as fol-
lows: (1) a diagnosis of Crohn’s disease or ulcerative colitis, (2) remission 
of the disease verified by endoscopy conducted during the 12 months prior 
to the start of the study, (3) age > 18 years, (4) user-level computer literacy 
with the possibility of regular use of an online smartphone, and (5) the 
subject’s own email address. 
The exclusion criteria were (1) lacking knowledge of the Czech language, 
(2) a diagnosis of IBD within the 3 months preceding the start of the study, 
(3) pregnancy, (4) ongoing biological treatment, and (5) hospitalisation 
in the preceding 3 months due to exacerbation of IBD symptoms. In ad-
dition to monitoring the patients’ subjective complaints, the occurrence 
of defined clinical signs and treatment adherence, the best-known and 
most widely used biomarker of gut inflammation - fecal calprotectin (FC) 
measurement - were integral parts of the project.
aims & Methods: Quality assessment of the home-based CalproSmart 
(CALPRO, Norway) FC test in the telemonitoring of patients with inflam-
matory bowel disease (IBD).
One hundred FC values were compared. The first data set was measured by 
patients using the home-based CalproSmart test, and the second data set 
was obtained using standard fluoroimmunoassay (FIA) in a clinical labo-
ratory. The principle of CalproSmart measurement is lateral flow analysis. 
Its measurement range is 70-1,500 µg/g. Expert measurements were con-
ducted by using the ELiA Calprotectin Phadia (Thermo Fisher Scientific, 
USA) diagnostic kit. The measurement range of the analysis is 0-6,000 
µg/g.
results: Spearman’s correlation coefficient r = 0.895 (p = 0.0004) and 
weighted Cohen’s kappa 0.835 indicate good correlation of two data sets 
measured by different measurement systems; see Table 1.
    Lfa (calprosmart)
    LOW MODERATE HIGH
  LOW 53 6 0
fIa (Phadia) MODERATE 2 32 1
  HIGH 0 1 5
FIA - fluoroimmunoassay; LFA - laminar flow analysis; LOW - concentrations of fecal 
calprotectin up to 200 µg/g; MODERATE - concentrations of fecal calprotectin between 
201 and 500 µg/g; HIGH - concentrations of fecal calprotectin over 500 µg/g; Unweighted 
kappa = 0.814; Weighted kappa = 0.835; Standard error of kappa = 0.055; 95% 
confidence interval: from 0.706 to 0.923; The strength of agreement is considered „very 
good.”
[Table 1. LFA and FIA performance results in terms of Cohen’s kappa 
coefficient]
conclusion: The home-based FC test CalproSmart is well-suited to qualita-
tive FC analysis in the telemonitoring of patients with IBD. It cannot replace 
standard laboratory FC measurements, but such performance is not re-
quired for the home-based kit.
acknowledgements: Supported by the IBD-Comfort Endowment Fund.
disclosure: Nothing to disclose 
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fection. IGRA results are often indeterminate, resulting in the need for 
repeat testing and a potential delay in commencing appropriate manage-
ment. Disease activity and corticosteroid treatment have previously been 
shown to be associated with indeterminate IGRA results. We hypothesise 
that there is a positive correlation between systemic inflammation and 
indeterminate IGRA results.
aims & Methods: We performed a case-control study of 268 IBD (5 IBDU, 48 
UC, 215 CD) patients who underwent pre-biologic IGRA testing at our ter-
tiary IBD referral centre. We compared various phenotypic, disease activity 
and treatment characteristics of patients who had a determinate IGRA with 
those who had an indeterminate IGRA results. Biochemical disease activity 
was evaluated using CRP, platelet count and albumin measured within one 
week of IGRA testing. We also aimed to assess whether treatment setting 
(inpatient vs outpatient) affected IGRA results. The Mann-Whitney U and 
Chi-Square tests were used to compare the two groups.
results: Of the 268 included patients, 42 (16%) had an indeterminate IGRA 
and the remaining 226 (84%) were determinate: 215 negative, 11 positive 
(table 1). 
We observed that a significantly higher proportion of patients with an in-
determinate IGRA results were on corticosteroid therapy (50% vs 15.5%, 
p< 0.0001) and were inpatients (52% vs 5%, p=<0.0001) at the time of 
testing. We also found that patients with an indeterminate result had a 
higher median CRP (25 vs 5mg/L, p=<0.0001) and platelet count (412 vs 
330x109/L, p=<0.0001) as well as a lower albumin (35 vs 44g/L, p=<0.0001). 
There was no significant difference in the proportion of patients in each 
group who were receiving immunomodulators at the time of testing (55% 
indeterminate IGRA vs 61% determinate IGRA, p=0.48).
  Indeterminate Igra (n=42)
determinate Igra 
(n=226) p
Characteristic
IBD phenotype, UC:CD:IBDU 15:24:3 33:191:2  
Use of immunomodulators 23 (55%) 137 (61%) 0.48
Use of steroids 21(50%) 35 (16%) <0.0001
Treatment setting- inpatient 22 (52%) 12 (5%) <0.0001
Disease activity
Median CRP (mg/L) 25 5 <0.0001
Median albumin (g/L) 35 44 <0.0001
Median platelet count (x109/L) 412 330 <0.0001
[Table 1. Univariate analyses of associations with an indeterminate IGRA 
result]
conclusion: Our results demonstrate that patients with more active IBD 
are significantly more likely to have an indeterminate IGRA test than those 
with less active disease. IGRA testing may be of limited diagnostic utility 
in the context of hospitalised patients and those receiving corticosteroids. 
These factors should be taken into account by clinicians when considering 
how to manage patients with indeterminate IGRA requiring escalation to 
a biologic. In patients with factors known to contribute to indeterminate 
IGRA testing, low risk of TB and a normal chest radiograph, clinicians may 
decide to proceed with biologic treatment rather than delay. If possible, 
IGRA testing should be carried out prior to the initiation of corticosteroid 
therapy.
disclosure: Nothing to disclose 
P0384 adherence TO TheraPy InfLaMMaTOry BOWeL dIsease 
OBserved In MOscOW cLInIcaL scIenTIfIc cenTer
Knyazev O.1,2, Babayan A.1, Kagramanova A.1
1The Loginov Moscow Clinical Scientific Centre, Department of Inflammatory 
Bowel Diseases, Moscow, Balaschiha, Russian Federation, 2AbbVie, 
Department of Inflammatory Bowel Diseases, Moscow, Russian Federation
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Introduction: Inflammatory bowel diseases (IBD) are chronic autoimmune 
inflammatory diseases with intestinal lesions and external manifestations. 
The concept of permanent life-long medication is the cornerstone in the 
treatment of IBD. Depending on the dosage regimen prescribed, the pa-
tient is injected with a dose and an interval between doses.
P0381 seruM TrOugh sB5 LeveLs: a cOMParIsOn Of TWO 
dIfferenT IMMunOassays fOr The MOnITOrIng Of BIOsIMILar 
adaLIMuMaB TreaTMenT In PaTIenTs WITh InfLaMMaTOry 
BOWeL dIsease
Malícková K., Bortlík M., Ďuricová D., Machková N., Hrubá V., Lukáš M., 
Vašátko M., Mitrová K., Kostrejová M., Lukáš M.
ISCARE IVF & Charles University, Clinical & Research Center for Inflammatory 
Bowel Disease, Prague, Czech Republic
contact e-Mail address: kmali@seznam.cz
Introduction: SB5 is a biosimilar monoclonal antibody adalimumab for the 
treatment of patients with inflammatory bowel disease (IBD). Only minor 
differences in clinically inactive components are allowable in biosimilars 
compared to reference products. However, even a small difference in the 
molecular structure can lead to different behavior of the biosimilar drug in 
analytical systems for the detection of serum drug trough levels.
aims & Methods: Although monitoring of adalimumab serum trough lev-
els hold an important significance in treatment modalities and clinical 
outcome during the treatment, no data about monitoring of drug serum 
trough levels in IBD patients treated with SB5 are present to date. There-
fore, we would like to compare recombinant human TNFa -based (rhTNFa) 
ELISA kit for the adalimumab trough levels detection with results obtained 
from the system based on the monoclonal antibody towards an original 
adalimumab. 
Sixty-two IBD serum samples from patients on maintenance treatment 
with SB5 (40 mg subcutaneously every two weeks) were analyzed. Sera 
form IBD Blood Bank established according to the Ethics Committee of 
ISCARE (Nr 2015/Ia) were used. SB5 trough levels were measured by the 
standard enzyme immunoassay (ADALIMUMAB ELISA ImmunoGuide, REF: 
IG-AA103) based on recombinant human TNFa (rh TNFa). Moreover, the 
same serum samples were analyzed by RIDAScreen ADM Monitoring (R-
Biopharm, REF: G09043) based on the highly specific monoclonal antibody 
towards original adalimumab MA-ADM40D8 isolated and characterized at 
the KU Leuven.
Data were analyzed by Statistica 13.3. (TIBCO). The strength and direction 
of association between two variables were assessed by Spearman’s rank 
order correlation coefficient. The Kruskal-H test was used for comparing 
two cohorts of concentration values.
results: Of 62 serum samples, 54 were patients with Crohn’s disease and 8 
patients with ulcerative colitis, 36 were women and 26 were men, median 
age was 41.5 years. Excellent quantitative agreement was observed be-
tween adalimumab trough levels measured by rhTNFa-based, and mono-
clonal antibody-based kits, r = 0.804, P < 0.0001. Non-parametric Kruskal 
Wallis test have shown that medians of trough levels concentrations in two 
data groups are not different, p = 0.363.
conclusion: rh-TNFa-based ELISA kit and monoclonal antibody-based 
ELISA kit for measuring SB5 trough levels showed similar overall perfor-
mance. and were in very good mutual quantitative agreement. This would 
provide valuable information on the possibility of using these assays as 
monitoring tools during treatment with biosimilar adalimumab. 
acknowledgements: Supported by the IBD-Comfort Endowment Fund.
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P0383 facTOrs cOnTrIBuTIng TO IndeTerMInaTe 
InTerferOn-γ reLease assay resuLTs In InfLaMMaTOry BOWeL 
dIsease PaTIenTs undergOIng Pre-BIOLOgIc TuBercuLOsIs 
screenIng
Bi C.J.1, Sadler C.1, Makaranka S.1, Potter J.L.2, Samaan M.A.1, Parker H.1, 
Kettle R.1, Whitley L.1, Di Caro S.1, Rahman F.1, Mehta S.1, Vega R.1, 
Seward E.1, McCartney S.1, Bloom S.1
1University College London Hospital, Department of Gastroenterology, 
London, United Kingdom, 2University College London Hospital, Department of 
Respiratory Medicine, London, United Kingdom
contact e-Mail address: claudia.sadler@nhs.net
Introduction: IFN-γ release assays (IGRA) are routinely used in patients 
with Inflammatory Bowel Disease (IBD) prior to initiation of biologic 
monoclonal antibody treatment to screen for latent tuberculosis (TB) in-
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aims & Methods: To assess adherence to the treatment of diseases in pa-
tients with Crohn (CD) and ulcerative colitis (UC), observed in the depart-
ment of inflammatory bowel disease. 
Materials and methods. The study included 55 (45.8%) men and 65 (54.2%) 
women older than 18 years, 70 (58.3%) patients with UC, 50 (41.7%) with 
CD, who attend treatment and examination in the department of inflam-
matory bowel diseases. Patient adherence to therapy is evaluated using 
the Moriska-Green test, the results of which all patients were divided into 
two groups: the first group - patients with low adherence treatment (LAT); 
the second group - patients with high adherence to treatment (HAT).
results: It was shown that patients with high adherence to therapy were 
78 (65.0%) versus 42 (35.0%), respectively (p <0.001). In the group of pa-
tients with HAT, women predominate - 26 (61.9%) versus 16 (30.1%) men 
(p <0.001). In the group of HAT, patients with CD 30 (71.4%) also prevail 
against 12 (28.6%) patients with UC (p <0.001). It was established that 
in the group of HAT, patients receiving 5-aminosalicylic acid preparations 
(5-ASA) 23 (54.8%) and biological preparations (BP) - 15 (35.7%) predomi-
nate. In the LAT group, patients with the necessary immunosuppressors 
and glucocorticosteroids prevail - 54 (69.3%), against patients receiving 
5-ASA and BP - 24 (30.7%) (p <0.001). The frequency of exacerbations of 
diseases was higher in the LAT group - 52 (66.6%), versus 13 (30.9%) in the 
HAT group (p <0.001). The frequency of surgical interventions in patients 
with CD was higher in the LAT group - 15 (75.0%) versus 5 (16.6%) in the 
HAT group (p <0.001). A significant difference between the groups was 
noted when it was possible to obtain drugs in the preferential provision 
(38.5%) in the HAT group versus 40 (51.3%) LAT groups (p <0.001). It was 
shown that the patient has no age, no educational and socio-economic 
status.
conclusion: Among patients with IBD, examined in the department of in-
flammatory bowel diseases, 65% have a low commitment to taking pre-
scribed medications. Low adherence of treatment is associated with factors 
such as the use of systemic immunosuppressants and glucocorticosteroids 
in therapy, complications during CD, the frequency of exacerbations of IBD. 
Female sex is reliably associated with high adherence to treatment, the 
presence of drugs in the preferential provision.
disclosure: Nothing to disclose 
P0385 PreLIMInary anaLysIs Of uTILIsaTIOn and cLInIcaL 
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Introduction: Anti-tumour necrosis factor α (anti-TNFα) drugs infliximab 
(IFX) and adalimumab (ADL) are effective treatments for inflammatory 
bowel disease (IBD) and have greatly improved outcomes for many in-
dividuals. However, treatment effects are not universally favourable with 
primary non-response (PNR) to treatment occurring in up to 30% and 
secondary loss of response (SLR) in up to 46% of IFX and ADL treated 
IBD cohorts (1,2).Therapeutic drug level and anti-drug antibody monitor-
ing (TDM) has emerged as a useful tool for optimising the effectiveness of 
these drugs, identifying individuals who may benefit from dose or treat-
ment frequency adjustments to regain control of disease after relapse, or 
even to prevent PNR or SLR.
aims & Methods: Ensuring safe and effective use of biologic medicines 
has been identified as a key priority for NHS Scotland. Inequity and incon-
sistency of access to TDM across the nation was recognised as a barrier 
to delivering best practice and so a nationally commissioned TDM service 
was established in January 2018 to support clinical practice, providing uni-
versal access to TDM for IBD services across Scotland. A service webpage 
was developed to provide guidance on testing strategies and interpreta-
tion of TDM results (3). Preliminary data and initial clinical observations 
from the first year of the service have now been collated. Data collection 
and analysis of results regarding usage and clinical impact of the service 
were identified as key outcome measures to assess service success and 
sustainability.
An automated search of clinical data and test results recorded within the 
clinical biochemistry electronic results management system was conduct-
ed to identify all TDM tests performed between 01/01/2018 and 31/12/2018. 
Outcomes for descriptive analysis included the number of samples re-
ceived and processed, overall testing population, service utilisation by 
Health Board, and the number and results of TDM tests performed per 
patient. TDM results were interpreted according to published guidance on 
the service webpage and comparison was made with previously published 
data (4).
results: 3609 specimens were received for testing, from 13 of the 14 Scot-
tish Health Boards. 3561 drug level (DL) tests were performed; 1786 IFX, 
1775 ADL. 2717 total antidrug anti-body (TABT) tests and 681 free antidrug 
anti-body tests (FABT) were performed according to service protocol. 2791 
individuals had one or more TDM tests during the 12-month period, of 
whom 541 were tested twice or more (range 2-5). 
    INFLIXIMAB ADALIMUMAB  
Drug level by 
category
Supratherapeutic 
DL > 8mcg/ml
546 (30.6%) 708 (39.9%)
Supratherapeutic DL 
> 10 mcg/ml
 
Therapeutic DL 
≥3<8.1mcg/ml
738 (41.3%) 636 (35.8%)
Therapeutic DL 
≥5<10.1 mcg/ml
 
Sub-therapeutic 
DL < 3mcg/ml
502 (28.1%) 431 (24.3%)
Sub-therapeutic DL 
< 5 mcg/ml
TABT by 
category
Negative 
(<10 AU/ml)
791 (54.2%) 905 (71.9%) Negative (<10 AU/ml)
 
Positive 
(>10 AU/ml)
668 (45.8%) 353 (28.1%) Positive (>10 AU/ml)
FABT by 
category
Negative 
(< 5AU/ml)
376 (82.8%) 176 (77.6%) Negative (<10 AU/ml)
 
Positive 
(> 5 AU/ml)
78 (17.2%) 51 (22.4%) Positive (>10 AU/ml)
[Table 1 - IFX & ADL DL, TABT and FABT results by category as defined in 
service guidance (AU/ml = Arbitrary Units/ml)]
conclusion: TDM has been enthusiastically embraced with rapid uptake 
of testing in IBD. It is estimated that > 50% of individuals treated with 
IFX or ADL have been tested at least once in the first year. DL results were 
found to be similar to previously published data, as were rates of antibody 
positivity. The large volume of data generated by the service may pro-
vide additional evidence regarding the utility of TDM in predicting clinical 
response. Next steps are to conduct a comparative effectiveness analysis 
where proactive vs reactive TDM testing strategies will be compared, with 
the primary outcome measure being the proportions of patients with SLR.
references: 1. Ben-Horin S and Chowers Y. Review article: loss of response 
to anti-TNF treatments in Crohn’s disease. Alimentary Pharmacology & 
Therapeutics, 33: 987-995. doi:10.1111/j.1365-2036.2011.0461. 2. Osterman 
MT, Haynes K, Delzell E, et al. Comparative effectiveness of infliximab and 
adalimumab for Crohn’s disease. Clin Gastroenterol Hepatol 2014;12:811-
817 3. Scottish Biologic Therapeutic Drug Monitoring Service https://www.
nhsggc.org.uk/about-us/professional-support-sites/biochemistry/biologi-
cal-therapy-monitoring/ 4. Kennedy NA, Heap GA, Green HD et al. Predic-
tors of anti-TNF treatment failure in anti-TNF-naive patients with active 
luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet 
Gastroenterology and Hepatology (2019). https://doi.org/10.1016/S2468-
1253(19)30012-3.
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conclusion: Tofacitinib demonstrated significant induction efficacy vs 
placebo for both subgroups of patients with and without baseline corti-
costeroid use. Proportions of HZ, SIs and OIs in OCTAVE Induction 1 & 2 
were generally similar for both subgroups of patients with and without 
baseline corticosteroid use; however, the relatively small number of events 
and short duration of follow-up (8 weeks) are limitations of this analysis. 
references: 1. Rubin DT et al. Am J Gastroenterol 2019; 114: 384-413.
disclosure: GR Lichtenstein has received research support and consultancy 
fees from Celgene, Salix/Valeant, Shire and UCB; research support from 
Janssen Orthobiotech; consultancy fees from Abbott, AbbVie, Cellceutix, 
Ferring, Gilead, Luitpold/American Regent, Merck, Pfizer Inc, Prometheus, 
Romark and Takeda; and other fees from Am J Gastroenterol: ACG, Clin 
Adv Gastroenterol and Gastroenterol Hepatol: Springer Science and Busi-
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Takeda, Luitpold/American Regent, Merck, Romark, McMahon Publish-
ing, Up-To-Date and SLACK Inc. BL Cohen has received consultancy fees 
from AbbVie, Alfasigma, Celltrion, Ferring, Grifols, Janssen, Pfizer Inc and 
Sublimity Therapeutics; and other fees from Allergan (expert witness). L 
Salese, A Soonasra, I Modesto, W Wang, DA Woodworth, G Chan, D Quirk 
and C Su are employees and shareholders of Pfizer Inc. L Peyrin-Biroulet 
has received lecture and consultancy fees from AbbVie, Amgen, Biogen, 
Celltrion, Ferring, Janssen, Merck, Pfizer Inc, Samsung Bioepis, Takeda and 
Tillotts; and consultancy fees from Alma, Biogaran, Boehringer Ingelheim, 
Celgene, Eli Lilly, Enterome, Genentech, Index Pharmaceuticals, Nestlé, 
Sandoz, Sterna and Vifor. 
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Introduction: Treatment options for inducing/maintaining clinical remis-
sion in moderate to severe ulcerative colitis (UC) include biologic thera-
pies. Yet, in some patients, biologics are less effective over time due to 
immunogenicity and fail to maintain remission. Hence, dose escalations 
(dose intensifications or more frequent dosing) may be considered. Previ-
ous studies assessing dose escalations in biologic therapies have mainly 
focused on one biologic, predominantly adalimumab (ADA) or infliximab 
(INF); therefore, there is a need for data relating to other biologic thera-
pies and also for comparative data.
aims & Methods: This study aimed to estimate the frequency and extent of 
dose escalations in patients with UC in Germany initiated on biologic ther-
apy. A retrospective, longitudinal cohort design was employed utilising 
de-identified German statutory health insurance (SHI) claims data within 
the Health Risk Institute database. Adult patients (18+ years of age) with 
UC (ICD-10 K51) but without Crohn’s disease (ICD-10 K50) were indexed 
(Jan 2013-Dec 2015) on biologic therapy initiation (ADA, golimumab [GOL], 
INF or vedolizumab [VED]) with a 24-month follow-up. Patients had to be 
continuously insured by SHI and have no record of biologic therapy in the 
prior 12 months. 
Daily doses (in milligrams [mg]) were calculated as a quotient of dose 
prescribed and duration between prescriptions/administrations (in days). 
Dose escalations were defined as an increase in daily dose of ≥50% com-
pared with the recommended maintenance daily dose (ADA = 2.86, GOL = 
3.57, INF = 6.25 [70 kg assumed], VED = 5.36) following induction period. 
De-escalations were defined as a daily dose equal to or below the recom-
mended maintenance daily dose. Time to dose escalation (from start of 
maintenance) and subsequent de-escalation were calculated.
results: In total, 304 patients were identified (mean age 42.9 years, 56.3% 
male), and 56% of patients had sufficient data to assess dose escalations. 
Of those, over half (59%) of patients received a dose escalation, occurring 
after a mean of 58.5 days (see Table). A significant difference (P< 0.0001) 
in the frequency of dose escalations was observed across index biolog-
ics, with 73% of patients initiated on ADA receiving a dose escalation. 
Patients initiated on INF were escalated, on average, to over four times the 
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Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibi-
tor for the treatment of ulcerative colitis (UC). Oral corticosteroids are an 
acknowledged induction therapy, but are associated with side effects in-
cluding infections.1
aims & Methods: We evaluated induction efficacy and infection risk with 
tofacitinib 10 mg twice daily (BID) treatment based on baseline corticoste-
roid use in tofacitinib UC induction studies. Remission (total Mayo score 
≤2, no individual subscore >1, rectal bleeding subscore 0), mucosal heal-
ing (Mayo endoscopic subscore ≤1) and clinical response (decrease from 
baseline total Mayo score of ≥3 points and ≥30%, and decrease in rectal 
bleeding subscore of ≥1 point or absolute rectal bleeding subscore of 0 
or 1) were evaluated in two 8-week, Phase 3 tofacitinib induction stud-
ies (OCTAVE Induction 1 & 2; NCT01465763 & NCT01458951; pooled data). 
Induction studies allowed stably dosed corticosteroids (25 mg/day maxi-
mum). Efficacy and safety data were summarised by oral corticosteroid use 
at induction baseline (BLC-Yes/No). Infections of interest included herpes 
zoster (HZ), serious infections (SIs), and adjudicated opportunistic infec-
tions (OIs).
results: Of 1139 patients (placebo: n=234; 10 mg BID: n=905) in OCTAVE 
Induction 1 & 2, 525 (46.1%) were on corticosteroids at baseline (< 15 
mg daily dose: 32.8%; ≥15 mg daily dose: 67.2%). A statistically signifi-
cant treatment effect of tofacitinib 10 mg BID vs placebo was observed 
for remission, mucosal healing and clinical response at Week 8, for both 
subgroups of patients with and without baseline oral corticosteroid use 
(Table). Differences vs placebo were numerically greater for patients not 
receiving oral corticosteroids at baseline. In OCTAVE Induction 1 & 2, infec-
tions of interest occurred with similar frequency among both subgroups of 
patients: the proportion of placebo-treated patients with HZ was 0.8% for 
BLC-No vs 0.0% for BLC-Yes; and 0.2% for BLC-No vs 1.0% for BLC-Yes with 
10 mg BID. The proportion of placebo-treated patients with SIs was 0.0% 
for BLC-No vs 0.0% for BLC-Yes; and 1.0% for BLC-No vs 0.2% for BLC-Yes 
with 10 mg BID. The proportion of placebo-treated patients with OIs was 
0.0% for BLC-No vs 0.0% for BLC-Yes; and 0.2% for BLC-No vs 0.5% for 
BLC-Yes with 10 mg BID.
%
(n/n)
Placebo
(n=234) 
Tofacitinib
10 mg BId (n=905) 
difference from 
placebo (95% cI) 
Remission - oral CS use at 
baseline (No) 
5.0
(6/121)
18.1
(89/493)
13.1**
(7.9, 18.2)
Remission - oral CS use at 
baseline (Yes) 
7.1
(8/113)
17.0
(70/412)
9.9**
(4.0, 15.9)
Mucosal healing - oral CS 
use at baseline (No) 
7.4
(9/121)
28.2
(139/493)
20.8***
(14.6, 26.9)
Mucosal healing - oral CS 
use at baseline (Yes) 
20.4
(23/113)
32.0
(132/412)
11.7*
(3.0, 20.4)
Clinical response - oral CS 
use at baseline (No) 
26.4
(32/121)
54.0
(266/493)
27.5***
(18.5, 36.5)
Clinical response - oral CS 
use at baseline (Yes) 
35.4
(40/113)
61.9
(255/412)
26.5***
(16.5, 36.5)
Data are FAS, NRI, central read endoscopy. 95% CI for differences from placebo are 
based on the normal approximation for the difference in binomial proportions
*p<0.05; **p<0.01; ***p<0.0001 vs placebo based on Cochran-Mantel-Haenszel chi-
square test
BID, twice daily; CI, confidence interval; CS, corticosteroid; FAS, full analysis set; N, 
number of patients in treatment group; n, number of patients with efficacy response; 
NRI, non-responder imputation
[Table. Summary of efficacy at Week 8 in OCTAVE Induction 1 and 2 by oral 
CS use at baseline (yes/no)]
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recommended dose. Patients initiated on VED were escalated to double 
the recommended dose. Two-fifths (41%) of patients who received a dose 
escalation received a subsequent de-escalation.
conclusion: A large proportion of patients required dose escalations to 
manage their UC. The prevalence and timing of dose escalations differed 
significantly between biologic therapies, with the largest proportion of 
dose escalations observed for ADA. These data suggest that many patients 
may require dose escalations to achieve and maintain remission when 
being treated with current biologic therapies. Further advanced treatment 
options that remain effective for this patient population without the need 
for dose escalations may be warranted.
Outcomes Total(n=169)
ada
(n=49)
gOL
(n=27)
Inf
(n=75)
ved
(n=18)
Dose escalation, 
n (%)a
99 (59) 36 (73) 5 (19) 49 (65) 9 (50)
Time to escalation (days), 
mean (SD)b
58.5 (106.4) 17.0 (30.1) 82.2 (115.8) 80.5 (118.0) 91.2 (179.5)
Dose at escalation (mg/
day), mean (SD)
- % increase relative to 
maintenance dosec
N/A
N/A
8.1 (5.6)
182%
13.1 (7.7)
268%
27.3 (41.4)
336%
9.8 (0.9)
83%
Subsequent de-
escalation,
n (%)d
41/99 (41) 11/36 (31) <5 26/49 (53) <5
Time to de-escalation 
(days),
mean (SD)
75.7 (104.7) 31.8 (32.2) - 102.5 (122.7) -
Dose at de-escalation 
(mg/day), mean (SD)
- % of maintenance dosec
N/A
N/A
2.2 (0.5)
77%
-
-
5.2 (0.7)
84%
-
-
aP<0.0001; bP=0.0316; cRecommended maintenance dose: ADA = 40 mg/2 weeks, GOL = 
100 mg/4 weeks, INF = 5 mg/kg/8 weeks, and VED = 300 mg/8 weeks; dP=0.0386 (ADA 
vs INF only)
-, data not presented as sample size <5 (due to data protection requirements applied by 
board of SHIs); ADA, adalimumab; GOL, golimumab; INF, infliximab; N/A, not applicable; 
SD, standard deviation; 
SHI, statutory health insurance; VED, vedolizumab
[Table. Dose escalations and de-escalations by index biologic therapy]
disclosure: A Dignass has received research support from Institut für Ge-
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Janssen, Roche/Genentech, Sandox/Hexal and Takeda; and other fees from 
ECCO (travel support), Falk (review participation), Falk Foundation, Takeda, 
Thieme and Wiley (manuscript preparation) and Ferring and Tillotts (edu-
cational presentation development). J Waller and R Wood have received 
research support from Pfizer Inc and are employees of Adelphi. JC Cappel-
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shareholders of Pfizer Inc. A Kisser has received research support from, 
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Introduction: Biologic therapies for the treatment of moderate to severe 
ulcerative colitis (UC) provide relevant options for achieving clinical re-
mission. Yet, in some patients, they do not induce and/or maintain clini-
cal response or remission as monotherapy. Thus, concomitant treatment 
with steroids and/or immunosuppressants (IMs) is required. Given the 
long-term safety profile associated with these therapies, it is important to 
understand concomitant steroid/IM use in this patient population to deter-
mine how biologics are being used in combination with other therapies to 
achieve response/remission in UC.
aims & Methods: This study explores the concomitant use of steroids and 
IMs in patients with UC in Germany initiated on biologic therapy. A retro-
spective, longitudinal cohort design was employed utilising de-identified 
German statutory health insurance (SHI) claims data within the Health Risk 
Institute database. Adult patients (18+ years of age) with UC (ICD-10 K51) 
but without Crohn’s disease (ICD-10 K50) were indexed (Jan 2013-Dec 2015) 
on biologic therapy initiation (adalimumab [ADA], golimumab [GOL], inf-
liximab [INF] or vedolizumab [VED]) with a 24-month follow-up (FU). Pa-
tients had to be continuously insured by SHI and have no record of biologic 
therapy in the prior 12 months (baseline).
Steroid use (oral only) and IM use were observed in the FU period and 
stratified by whether steroids/IMs had been received prior to biologic ini-
tiation or not (ie newly initiated). Descriptive statistics are reported and 
Chi-squared or Fisher’s exact tests were used to assess statistical signifi-
cance of outcomes across index biologics.
results: In total, 304 patients were identified (mean age 42.9 years, 56.3% 
male). Only a quarter of patients (26%) did not require any treatment with 
steroids in the FU period (see Table). Prednisolone was the most frequently 
observed steroid (88%) among steroid users. Approximately two-fifths of 
patients (41%) received treatment with IMs in the FU period, with azathio-
prine being the most frequently observed IM (77%). Most IM users (72%) 
had received an IM in the baseline period, whilst 28% newly initiated an 
IM following biologic initiation.
conclusion: Steroid use was high following biologic initiation, with only 
a quarter of patients being steroid-free. Over a quarter of IM users were 
newly initiated on IM treatment following biologic initiation. These data 
suggest that control with biologic monotherapy is often insufficient treat-
ment, highlighting the need for further advanced treatment options for 
this patient population.
Outcomes, n (%) Total(n=304)
ada
(n=125)
gOL
(n=47)
Inf
(n=114)
ved
(n=18)
Steroid users 
Prednisolonea 
Prednisonea Budesonidea,b 
Methylprednisolonea 
Hydrocortisonea
224 (74) 
197 (88)
47 (21)
45 (20)
<5
<5
98 (78) 
88 (90)
23 (23)
17 (17)
<5
<5
36 (77) 
31 (86)
6 (17)
10 (28)
0
0
78 (68) 
69 (88)
17 (22)
11 (14)
<5
<5
12 (67) 
9 (75)
<5
7 (58)
0
0
Newly initiated steroid 
in FUa
24 (11) 11 (11) <5 7 (9) <5
IM users Azathioprinec 
Methotrexatec 
Mercaptopurinec 
Tacrolimusc
126 (41) 
97 (77)
20 (16)
14 (11)
5 (4)
59 (47) 
41 (69)
14 (24)
8 (14)
<5
17 (36) 
12 (71)
<5
<5
<5
46 (40) 
40 (87)
<5
<5
<5
<5 
<5
0
0
0
Newly initiated IM in FUc 35 (28) 13 (22) <5 17 (37) -
aOf all steroid users; bP=0.0049; cOf all IM users
-, data not presented as sample size <5 (due to data protection requirements 
applied by board of SHIs); ADA, adalimumab; FU, follow-up; GOL, golimumab; IM, 
immunosuppressant; INF, infliximab; 
SHI, statutory health insurance; VED, vedolizumab
[Table. Concomitant steroid and IM use by index biologic therapy]
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0.990]; p=0.0460), were significantly associated with clinical remission at 
Week 8. In addition, PMS at Week 4 (OR [95% CI] 0.572 [0.345, 0.948]; 
p=0.0302) was significantly associated with clinical response at Week 8.
conclusion: These post-hoc analyses of a Phase 2 study showed that de-
creases as early as Week 2 in FCP levels and PMS, and as early as Week 
4 in CRP levels, may be predictors of improved clinical and endoscopic 
outcomes in patients with moderately to severely active UC treated with 
tofacitinib 10 mg BID, although definitive conclusions cannot be drawn due 
to low patient numbers.
references: 1. Sandborn WJ et al. Gastroenterology 2016; 150: 96-102. 
2. Sandborn WJ et al. N Engl J Med 2012; 367: 616-624.
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Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor 
for the treatment of ulcerative colitis (UC). Monitoring of liver enzymes, 
lipids, absolute neutrophil count (ANC), absolute lymphocyte count (ALC) 
and haemoglobin (Hg) is recommended in patients (pts) with UC treated 
with tofacitinib.1
aims & Methods: We investigated the changes in laboratory parameters 
in pts with moderately to severely active UC treated with tofacitinib in OC-
TAVE Open, an ongoing Phase 3, open-label, long-term extension (OLE) 
study (NCT01470612; data as of Sep 2018, database not locked). Pts who 
had completed or demonstrated treatment failure in the OCTAVE Sustain 
maintenance study, or those who were non-responders after completing 
OCTAVE Induction 1 or 2, were eligible for inclusion in the OLE study. Pts 
who were in remission at the end of OCTAVE Sustain were assigned to 
tofacitinib 5 mg BID; all other pts were assigned to tofacitinib 10 mg BID 
in the OLE study. Changes from baseline values in the OLE study for liver 
enzymes, lipids, ANC, ALC and Hg at Month 36 were evaluated (observed 
data). The proportions of pts with laboratory values meeting protocol 
criteria for discontinuation (two sequential: aspartate aminotransferase 
[AST] or alanine aminotransferase [ALT] elevations ≥3× upper limit of 
normal [ULN] with ≥1 total bilirubin value ≥2× ULN or signs or symptoms 
consistent with hepatic injury; AST or ALT elevations ≥5× ULN; ANC < 750/
mm3; ALC < 500/mm3; or Hg < 8.0 g/dL or >30% decrease from baseline) 
were assessed. The proportions of pts with investigator-defined hyperlipi-
daemia treatment-emergent adverse events (TEAEs), and with a change in 
lipid-lowering agent (LLA), were also reported.
results: Changes from OLE study baseline in liver enzymes, lipids, ANC, 
ALC and Hg at Month 36 in pts treated with tofacitinib 5 and 10 mg twice 
daily (BID) are presented in the Table. With regard to meeting protocol 
criteria for discontinuation, 2.9% and 1.0% of pts treated with tofacitinib 
5 and 10 mg BID, respectively, met the criteria for liver enzyme elevations; 
0.6% and 1.4% of pts treated with tofacitinib 5 and 10 mg BID, respec-
tively, met the criteria for ALC; 0 and 0.1% of pts treated with tofacitinib 5 
and 10 mg BID, respectively, met the criteria for ANC; and 0 and 1.4% of 
pts treated with tofacitinib 5 and 10 mg BID, respectively, met the criteria 
for Hg. Hyperlipidaemia TEAEs were experienced by 1.7% of pts treated 
with tofacitinib 5 mg BID and 1.2% of pts treated with tofacitinib 10 mg 
BID. Furthermore, 8.0% and 6.6% of pts treated with tofacitinib 5 and 
P0389 faecaL caLPrOTecTIn LeveLs, c-reacTIve PrOTeIn 
LeveLs and ParTIaL MayO scOre as earLy PredIcTOrs Of 
cLInIcaL and endOscOPIc OuTcOMes In aduLT PaTIenTs WITh 
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Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor 
for the treatment of ulcerative colitis (UC). Faecal calprotectin (FCP) levels 
were shown to correlate with clinical and endoscopic outcomes at Week 
8 in patients with moderately to severely active UC receiving tofacitinib in 
a Phase 2 study.1
aims & Methods: In these post-hoc analyses, we aimed to determine if 
FCP levels, C-reactive protein (CRP) levels or partial Mayo score (PMS) can 
be early predictors of clinical or endoscopic outcomes in a Phase 2, ran-
domised, double-blind, placebo-controlled, parallel group, multicentre 
study (NCT00787202).2 FCP levels and PMS at baseline, Week 2 and Week 
4, and CRP levels at baseline and Week 4, were analysed based on wheth-
er patients with moderately to severely active UC treated with tofacitinib 
10 mg twice daily (BID) had clinical response, clinical remission, mucosal 
healing or endoscopic remission at Week 8. Univariate logistic regression 
analyses were performed to evaluate if FCP levels (log transformed), CRP 
levels (log transformed) or PMS were associated with clinical and endo-
scopic outcomes.
results: In patients treated with tofacitinib 10 mg BID (N=28), numeri-
cally greater decreases from baseline were observed in FCP levels and 
PMS at Weeks 2 and 4 in patients who achieved clinical response, clinical 
remission, mucosal healing and endoscopic remission at Week 8 vs those 
who did not achieve these clinical or endoscopic outcomes. FCP levels at 
Week 2 were decreased by >50% from baseline in patients who achieved 
endoscopic remission. Furthermore, numerically greater decreases from 
baseline were observed in CRP levels at Week 4 in patients who achieved 
clinical response and mucosal healing at Week 8 vs those who did not 
achieve these clinical or endoscopic outcomes (Table). 
  Tofacitinib 10 mg BId (n=28) 
 
fcP,
geometric mean (sd) 
crP,
geometric mean 
(sd) 
PMs,
mean (sd) 
  Baseline Week 2 Week 4 Baseline Week 4 Baseline Week 2 Week 4 
Clinical responseb 
Yes (N=19) 
No (N=9)
350.3(7.2)
352.4(4.4)c
221.8(5.7)
443.3(6.8)
195.0(5.0)d 
502.8(1.6)
4.7(5.5)e 
4.6(3.2)
1.1(5.2)
2.7(5.4)
5.4(1.5)
5.6(1.6)
2.6(1.8)f 
4.0(2.5)
1.8(1.5)d 
3.8(2.3)
Clinical remissiong 
Yes (N=15) 
No (N=13)
317.1(8.6)
398.3(3.9)h
214.0(6.2)
373.5(5.8)
203.0(5.5)i 
360.8(2.6)
3.7(5.5)j 
6.1(3.7)
0.8(4.3)
3.1(5.4)
5.0(1.9)
6.0(0.8)
1.8(1.7)h 
4.2(1.8)
1.4(1.4)i 
3.6(2.0)
Mucosal healingk 
Yes (N=19) 
No (N=9)
341.0(7.5)
375.7(3.9)c
257.0(6.5)
324.9(5.6)
221.4(4.5)d 
395.5(3.0)
5.3(5.3)e 
3.8(3.4)
1.2(5.5)
2.3(5.2)
5.3(1.8)
5.9(0.6)
2.4(2.1)f 
4.2(1.9)
1.9(1.7)d 
3.6(2.2)
Endoscopic 
remissionl 
Yes (N=9) 
No (N=19)
815.7(5.3)
230.1(5.9)e
385.9(5.2)
236.9(6.5)
444.5(4.0)m 
225.4(4.0)
3.8(6.7)c 
5.2(4.0)
0.9(4.8)
1.9(5.6)
5.8(1.5)
5.3(1.6)
2.3(2.0)c 
3.5(2.2)d
1.5(1.7)c 
2.9(2.0)e
aFAS, observed case; bClinical response was defined as a decrease from baseline total Mayo score of ≥3 
points and ≥30%, plus a decrease in rectal bleeding subscore of ≥1 point or an absolute rectal bleeding 
subscore of 0 or 1; cN=8; dN=17; eN=18; fN=16; gClinical remission was defined as a total Mayo score of ≤2, 
with no individual subscore >1; hN=12; iN=13; jN=14; kMucosal healing was defined as a Mayo endoscopic 
subscore of 0 or 1; lEndoscopic remission was defined as a Mayo flexible proctosigmoidoscopy subscore 
of 0; mN=7
BID, twice daily; CRP, C-reactive protein; FAS, full analysis set; FCP, faecal calprotectin; N, number of 
patients in the analysis population; PMS, Partial Mayo Score; SD, standard deviation
[Table. FCP levels, CRP levels and PMS in patients treated with tofacitinib 10 
mg BID, by Week 8 efficacy endpointsa]
In patients treated with tofacitinib 10 mg BID, logistic regression results 
showed that PMS at Week 2 (odds ratio [OR] [95% confidence interval 
(CI)] 0.496 [0.288, 0.856]; p=0.0117) and Week 4 (OR [95% CI] 0.463 [0.251, 
0.853]; p=0.0135), and CRP levels at Week 4 (OR [95% CI] 0.582 [0.342, 
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10 mg BID, respectively, had a new LLA added, and 2.3% and 1.7% of pts 
treated with tofacitinib 5 and 10 mg BID, respectively, had their LLA dose 
increased.
conclusion: No major changes from OLE study baseline were observed 
in the laboratory parameters recommended for monitoring in pts treated 
with tofacitinib up to Month 36. In addition, the proportions of pts meeting 
protocol criteria for discontinuation for liver enzymes, ANC, ALC or Hg, with 
hyperlipidaemia TEAEs or with a change in LLA, were evaluated and were 
low in both tofacitinib treatment groups. Due to the dose assignment in 
the OLE study, the pt populations in the treatment arms differ in terms of 
their baseline remission status. 
        Tofacitinib 5 mg BId       Tofacitinib 10 mg BId
  n Mean (sd) n Mean (sd)
Liver enzymes 
ALT (IU/L) 
AST (IU/L)
79
79
5.32 (20.57)
5.10 (26.02)
296
295
7.47 (18.54)
7.51 (14.86)
Lipids 
Cholesterol (mg/dL) 
HDL cholesterol (mg/dL) 
LDL cholesterol (mg/dL) 
Triglycerides (mg/dL)
83
83
81
82
-5.88 (36.85)
-2.44 (9.48)
-4.06 (32.23)
3.31 (62.14)
314
314
312
314
20.76 (43.76)
6.69 (16.46)
11.90 (36.43)
11.91 (61.54)
Blood cells 
Hg (g/dL) 
ALC (103/mm3) 
ANC (103/mm3)
79 
79 
79
0.17 (0.98) 
-0.23 (0.50)
0.01 (1.83)
295
289
289
0.99 (1.64)
-0.54 (0.66)
-1.02 (2.37)
Data are as of Sep 2018, database not locked
ALC, absolute lymphocyte count; ALT, alanine aminotransferase; ANC, absolute 
neutrophil count; AST, aspartate aminotransferase; BID, twice daily; HDL, high-density 
lipoprotein; Hg, haemoglobin; LDL, low-density lipoprotein; N, number of patients with 
non-missing data; OLE, open-label, long-term extension; pts, patients; SD, standard 
deviation; UC, ulcerative colitis
[Table. Change from OLE study baseline in clinical laboratory parameters at 
Month 36 in pts with UC treated with tofacitinib (observed data)]
references: 1. European Medicines Agency. 2018. Xeljanz (tofacitinib ci-
trate) - summary of product characteristics. Available at: https://www.
medicines.org.uk/emc/medicine/33167.
disclosure: GY Melmed has received consultancy fees from AbbVie, Boeh-
ringer Ingelheim, Celgene, Genentech, Janssen, Medtronic, Pfizer Inc, 
Takeda and UCB; and has received research support from Prometheus. 
S Chang has received consultancy fees from Oshi Health and Shire.
N Kulisek, H Fan, N Lawendy, E Maller and A Soonasra are employees and 
shareholders of Pfizer Inc. 
PM Irving has received research support from Janssen, MSD and Takeda; 
lecture and consultancy fees from AbbVie, Janssen, MSD, Pfizer Inc, Takeda 
and Warner Chilcott; lecture fees from Falk, Ferring, Shire and Tillotts; and 
consultancy fees from Arena Pharmaceuticals, Eli Lilly, Genentech, Ho-
spira, Pharmacosmos, Samsung Bioepsis, Sandoz, Topivert, VH2 and Vifor. 
P0391 ITeM-LeveL IMPrOveMenTs In InfLaMMaTOry BOWeL 
dIsease quesTIOnnaIre scOres In PaTIenTs WITh uLceraTIve 
cOLITIs TreaTed WITh TOfacITInIB InducTIOn TheraPy
Dubinsky M.C.1, DiBonaventura M.2, Fan H.3, Bushmakin A.G.4, 
Cappelleri J.C.4, Maller E.3, Thorpe A.J.3, Salese L.3, Panés J.5
1Icahn School of Medicine at Mount Sinai, New York, United States, 2Pfizer 
Inc, New York, United States, 3Pfizer Inc, Collegeville, United States, 4Pfizer 
Inc, Groton, United States, 5Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, 
Barcelona, Spain
contact e-Mail address: jpanes@clinic.ub.es
Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor 
for the treatment of ulcerative colitis (UC). The effect of tofacitinib treat-
ment on Inflammatory Bowel Disease Questionnaire (IBDQ) domains has 
been reported in patients with UC in OCTAVE Induction 1 & 2 and OCTAVE 
Sustain, with significant improvements observed in all domains vs pla-
cebo.1 However, the effect of tofacitinib on the individual items within each 
IBDQ domain has not been analysed previously.
aims & Methods: We examined the effect of induction treatment with to-
facitinib 10 mg twice daily (BID) on individual IBDQ items in adults with 
moderate to severe UC. Data were pooled from OCTAVE Induction 1 & 2 
(NCT01465763 & NCT01458951), which were identical, randomised, 8-week, 
double-blind, Phase 3 studies.2 The IBDQ was self-administered by pa-
tients at baseline, Week 4 and Week 8, and has four domains, with indi-
vidual items within each domain. The IBDQ domains are bowel symptoms 
(10 items), systemic symptoms (5 items), emotional function (12 items) 
and social function (5 items), with higher scores indicating better health-
related quality of life (HRQoL).1,3 Change from baseline in IBDQ items was 
analysed for tofacitinib 10 mg BID vs placebo using a linear mixed-effects 
model, with treatment, study, prior tumour necrosis factor inhibitor treat-
ment, corticosteroid use at baseline, geographical region, week, treatment 
by week interaction, and baseline score as fixed effects, and patients as a 
random effect. No multiplicity adjustment was performed for this ad-hoc 
analysis.
results: Significant improvements (p< 0.05) were observed in all IBDQ 
items with tofacitinib 10 mg BID vs placebo at Weeks 4 and 8. The larg-
est treatment differences within each domain were reported as follows: 
‘bowel movements been loose’ at Weeks 4 and 8, and ‘problem with rectal 
bleeding’ at Week 8 (all 1.1), for the bowel symptoms domain; ‘getting a 
good night’s sleep’ at Week 4 (0.8) and Week 8 (0.9), for the systemic 
symptoms domain; ‘fear of not finding a washroom’ at Week 4 (0.6) and 
Week 8 (0.8), and ‘felt embarrassed’ and ‘felt angry’ at Week 4 (both 0.6), 
for the emotional function domain; and ‘avoid attending events’ at Week 4 
(0.8) and Week 8 (1.0), and ‘difficulty doing leisure/sports’ at Week 8 (1.0), 
for the social function domain (Table).
conclusion: Tofacitinib treatment resulted in improvements vs placebo in 
all bowel-related symptoms, systemic symptoms, emotional functioning 
and social functioning IBDQ items, highlighting the broad impact of to-
facitinb on all aspects of HRQoL. The greatest numerical improvements 
across all items were reported for ‘bowel movements been loose’ and 
‘problem with rectal bleeding’. This analysis provides an informative and 
useful perspective on which components of the IBDQ domains are the most 
improved following tofacitinib induction therapy, which may help to facili-
tate patient-physician dialogue. 
IBdq item,
LsM (se) Week 4 Week 8 
 
Placebo
(N=231) 
Tofacitinib
10 mg BID
(N=881) 
Placebo
(N=218) 
Tofacitinib
10 mg BID
(N=849) 
Bowel symptoms 
Bowel movement frequencya 
Bowel movements been loose
Problem with rectal bleedingb 
1.1 (0.1)
0.7 (0.1)
1.3 (0.1)
2.1 (0.1)† 
1.8 (0.1)† 
2.3 (0.1)† 
1.3 (0.1)
1.0 (0.1)
1.6 (0.1)
2.2 (0.1)† 
2.1 (0.1)† 
2.7 (0.1)† 
systemic symptoms 
Feeling fatigued or tired
Felt generally unwellc 
Getting a good night‘s sleep
0.7 (0.1)
0.9 (0.1)
0.7 (0.1)
1.1 (0.1)† 
1.4 (0.1)† 
1.5 (0.1)† 
0.8 (0.1)
1.0 (0.1)
0.8 (0.1)
1.4 (0.1)† 
1.6 (0.1)† 
1.7 (0.1)† 
emotional function 
Fear of not finding a washroom
Felt embarrassedb 
Felt angryb
0.9 (0.1)
0.7 (0.1)
0.4 (0.1)
1.4 (0.1)† 
1.4 (0.1)† 
1.1 (0.0)† 
0.9 (0.1)
0.9 (0.1)
0.5 (0.1)
1.7 (0.1)† 
1.6 (0.1)† 
1.1 (0.1)† 
social function 
Delay/cancel social engagementsc 
Difficulty doing leisure/sportsd 
Avoid attending eventsc
0.8 (0.1)
0.9 (0.1)
0.5 (0.1)
1.4 (0.1)† 
1.6 (0.1)† 
1.3 (0.1)† 
0.8 (0.1)
1.0 (0.1)
0.5 (0.1)
1.5 (0.1)† 
2.0 (0.1)† 
1.5 (0.1)† 
†p<0.0001 vs placebo
aWeek 4: placebo N=227, tofacitinib 10 mg BID N=862; Week 8: placebo N=213, tofacitinib 
10 mg BID N=832; bWeek 4: tofacitinib 10 mg BID N=879; Week 8: tofacitinib 10 mg BID 
N=848; cWeek 4: tofacitinib
10 mg BID N=880; Week 8: tofacitinib 10 mg BID N=848; dWeek 4: tofacitinib 10 mg BID 
N=880
BID, twice daily; IBDQ, Inflammatory Bowel Disease Questionnaire; LSM, least squares 
mean;
N, number of patients evaluated; SE, standard error
[Table. Change from baseline for the IBDQ items with the top three largest 
treatment differences in each domain (full analysis set, observed case)]
references: 1. Panés J et al. J Crohns Colitis 2018; 12: 145-156. 
2. Sandborn WJ et al. N Engl J Med 2017; 376: 1723-1736.
3. Guyatt GH et al. J Clin Epidemiol 1989; 42: 403-408.
disclosure: MC Dubinsky has received research support and consultancy 
fees from AbbVie, Janssen, Pfizer Inc and Prometheus; and has received 
consultancy fees from Boehringer Ingelheim, Celgene, Eli Lilly, Genentech, 
Salix, Shire, Takeda and UCB. 
M DiBonaventura, H Fan, AG Bushmakin, JC Cappelleri, E Maller, AJ Thorpe 
and L Salese are employees and shareholders of Pfizer Inc. 
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P0393 TOfacITInIB fOr The TreaTMenT Of uLceraTIve cOLITIs: 
an uPdaTe On The anaLysIs Of MaLIgnancy raTes frOM The 
uc cLInIcaL PrOgraMMe
Lichtenstein G.R.1, Ciorba M.A.2, Rogler G.3, Quirk D.4, Thorpe A.J.4, 
Pedersen R.D.4, Lawendy N.4, Chan G.4, Panés J.5
1Perelman School of Medicine at the University of Pennsylvania, Division 
of Gastroenterology, Philadelphia, United States, 2Washington University 
in Saint Louis, Division of Gastroenterology, Saint Louis, United States, 
3University of Zürich, Department of Gastroenterology and Hepatology, 
Zürich, Switzerland, 4Pfizer Inc, Collegeville, PA, United States, 5Hospital 
Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
contact e-Mail address: jpanes@clinic.ub.es
Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibitor 
for the treatment of ulcerative colitis (UC). The safety of tofacitinib for 
the treatment of moderate to severe UC was evaluated in a randomised, 
placebo-controlled induction Phase (P) 2 study (NCT00787202),1 2 
induction P3 studies (NCT01465763; NCT01458951), 1 maintenance P3 
study (NCT01458574),2 and an ongoing, open-label, long-term extension 
(OLE) study (NCT01470612).3 Here, we present an update on the integrated 
analysis of adjudicated malignancies observed in the UC clinical 
development programme, as of Sep 2018.
aims & Methods: Patients (pts) who received placebo, tofacitinib 5 or 
10 mg twice daily (BID) were analysed as 3 cohorts: Induction (P2/P3 
induction studies, N=1220), Maintenance (P3 maintenance study, N=592) 
and Overall (pts receiving tofacitinib 5 or 10 mg BID in P2, P3 or ongoing 
OLE studies, N=1157). Proportions and incidence rates (IRs; unique pts with 
events per 100 pt-years [PY] of exposure) were evaluated for malignancies 
(excluding non-melanoma skin cancer [NMSC]) and NMSC. For Overall 
Cohort analysis, pts were categorised based on the average daily dose of 
tofacitinib: predominant dose (PD) tofacitinib 5 mg BID (average total daily 
dose < 15 mg) and PD tofacitinib 10 mg BID (average total daily dose ≥15 
mg). For P3 studies, an independent adjudication committee reviewed all 
potential malignancies. Overall Cohort data are as of Sep 2018.
  Induction cohorta Maintenance cohorta Overall cohort 
 
Placebo 
(N=282;
44.8 PY)
Tofacitinib
10 mg BID 
(N=938;
156.2 PY)
Placebo 
(N=198;
100.4 PY)
Tofacitinib
5 mg BID 
(N=198;
146.2 PY)
Tofacitinib
10 mg BID 
(N=196;
154.3 PY)
Tofacitinib
All 
(N=1157; 
2403.6 PY)
Age (years), mean 
(SD)
41.4 (14.4) 41.3 (13.8) 43.4 (14.0) 41.9 (13.7) 43.0 (14.4) 41.3 (13.9)
Prior TNFi failure, 
n (%)
124 (53.0)b 465 (51.4)c 89 (44.9) 83 (41.9) 92 (46.9) 583 (51.9)d
Prior 
immunosuppressant 
failure, n (%)
158 (67.5)b 661 (73.0)c 129 (65.2) 143 (72.2) 141 (71.9) 813 (72.3)d
Prior 
immunosuppressant 
treatment, n (%)
160 (68.4)b 683 (75.5)b 134 (67.7) 149 (75.3) 144 (73.5) 838 (74.6)d
Disease duration 
(years), mean (SD)
8.2 (6.8) 8.2 (7.0) 8.8 (7.5) 8.3 (7.2) 8.7 (7.0) 8.2 (7.0)
Malignancies 
(excluding NMSC), n 
(%), IR [95% CI]e,f,g
0 (0.0) 0 (0.0)
1 (0.5), 0.97 
[0.02, 5.39]
0 (0.0), 
0.00 [0.00, 
2.48]
0 (0.0), 
0.00 [0.00, 
2.35]
17 (1.5), 
0.69 [0.40, 
1.11]
NMSC, n (%), IR 
[95% CI]e,f
0 (0.0) 2 (0.2)
1 (0.5), 0.97 
[0.02, 5.40]
0 (0.0), 
0.00 [0.00, 
2.48]
3 (1.5), 
1.91 [0.39, 
5.59]
19 (1.7),h 
0.78 [0.47, 
1.22]
Data are as of Sep 2018 for the Overall Cohort (OLE study database not locked)
aAs per the SCS analysis convention, only events occurring within 28 days after the last dose 
are included in this Table for calculation of proportion and IR; bN=234; cN=905; dN=1124; 
eData for the Induction Cohort are shown as n (%), due to the short duration (8 weeks) of 
the induction studies; fAdjudicated data do not include data from the P2 Study (A3921063; 
NCT00787202); gOne case of breast cancer in the Maintenance Cohort (placebo arm); in the 
Overall Cohort, 17 malignancy events (excluding NMSC), including two cases of cervical cancer, 
breast cancer and adenocarcinoma of the colon, and one case each of hepatic angiosarcoma, 
cholangiocarcinoma, leiomyosarcoma, diffuse large B-cell lymphoma, Epstein-Barr virus-
associated lymphoma, malignant melanoma, renal cell carcinoma, lung cancer, invasive ductal 
breast carcinoma, essential thrombocythemia, acute myeloid leukaemia, plus secondary 
malignancies in the liver and peritoneum; hOf the 19 Overall Cohort pts with NMSC, most (17/19) 
had prior immunosuppressant failure, most (15/19) had prior treatment failure with TNFi, and 
seven had prior NMSC
BID, twice daily; CI, confidence interval; IR, incidence rate (patients with events per 100 patient-
years of exposure); N, number of patients in the treatment group; n, number of patients in a 
specified category; NMSC, non-melanoma skin cancer; OLE, open-label, long-term extension; P, 
Phase; pts, patients; PY, patient-years; SCS, summary of clinical safety; SD, standard deviation; 
TNFi, tumour necrosis factor inhibitors 
[Table. Demographics and summary of incidence of malignancies (all 
causality) among pts in the Induction, Maintenance and Overall Cohorts]
J Panés has received research support, consultancy fees and advisory 
board fees from AbbVie; research support, consultancy fees and speaker’s 
bureau fees from MSD; consultancy fees, advisory board fees and speak-
er’s bureau fees from Janssen, Pfizer Inc and TiGenix; consultancy fees and 
advisory board fees from Boehringer Ingelheim, Celgene, Genentech, Gil-
ead, GoodGut, GSK, Nestlé, Oppilan, Robarts Clinical Trials, Roche, Takeda 
and Theravance; and advisory board fees from Arena Pharmaceuticals. 
P0392 cLInIcaL cOurse and dIeTary PaTTerns aMOng 
PaTIenTs IncOrPOraTIng The auTOIMMune PrOTOcOL fOr 
ManageMenT Of InfLaMMaTOry BOWeL dIsease
Lee J.1, Pedretti C.2, Konijeti G.3
1Scripps Clinic, Department of Medicine, La Jolla, United States, 2Pacific 
College of Oriental Medicine, San Diego, United States, 3Scripps Clinic, 
Division of Gastroenterology & Hepatology, La Jolla, United States
contact e-Mail address: lee.joy@scrippshealth.org
Introduction: Elimination diets, including the autoimmune protocol (AIP), 
may improve symptoms among patients with inflammatory bowel disease 
(IBD), but limited data exist on diet efficacy and utilization.
aims & Methods: The aim of our study was to examine clinical course 
and dietary patterns of patients with IBD utilizing AIP. We conducted an 
anonymous online survey sent through electronic newsletters and support 
groups utilizing AIP. The survey assessed demographics, IBD disease activ-
ity and medication use, including use of steroids and immunosuppression 
(biologics and/or immunomodulators). Participants were asked about AIP 
utilization and food group reintroductions. Symptom measures of abdomi-
nal pain, stool frequency, and rectal bleeding were compared at baseline 
(BL, prior to starting AIP), week 6 (after starting AIP), and present, sepa-
rately for Crohn’s disease (CD) and ulcerative colitis (UC).
results: There were 78 respondents who attempted AIP for management 
of IBD. Mean age was 39.4 years (SD 11.4), with mean IBD duration 13.2 yrs 
(SD 11.4), 78% prior steroid exposure, and 35% currently on immunosup-
pression. Seventy-three percent perceived achieving clinical remission due 
to AIP, but this was more common among patients not on immunosup-
pression (76% vs. 24% on immunosuppression, p< 0.001). After starting 
AIP, 32% reported being able to discontinue steroids. AIP was initiated 
according to protocol by 73%, while 27% modified it. 
Compared to BL, 6 weeks after starting AIP more patients with CD reported 
no abdominal pain (47% vs BL 17%, P = 0.01), normal stool frequency (53% 
vs BL 30%, P < 0.01), and no rectal bleeding (90% vs 43%, P = 0.057). 
Similarly, more patients with UC reported no abdominal pain (60% vs BL 
14%, P < 0.01), normal stool frequency (47% vs BL 14%, P < 0.01), and no 
rectal bleeding (63% vs 30%, P < 0.01) 6 weeks after starting AIP, com-
pared to BL. 
Food group reintroductions were started within 0-4 weeks of starting AIP 
among 8%, while 23% reintroduced within 5-8 weeks, 24% within 2-6 
months, 23% within 6-12 months, and 13% after 12 months. Although suc-
cess of food group reintroductions varied, this did not appear to affect 
symptom improvement, with majority of patients with IBD reporting no 
abdominal pain (80%), no rectal bleeding (72%), and normal stool fre-
quency (64%) at present.
conclusion: In this retrospective study, patients utilizing AIP for manage-
ment of IBD report clinical benefit, with reduction of steroid use and im-
provement in IBD symptoms, including with food group reintroduction.
disclosure: Dr. Konijeti has previously received honoraria from Takeda, Ab-
bvie, Janssen, and Pfizer. 
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results: The Overall Cohort comprised 1157 pts with 2404 PY of tofacitinib 
exposure and up to 6.1 years of treatment (median 623 days) who received 
≥1 dose of tofacitinib 5 or 10 mg BID (Table). There were no pts with malig-
nancy events (excluding NMSC) in the Induction Cohort, 1 pt with a malig-
nancy event (excluding NMSC; placebo, breast cancer) in the Maintenance 
Cohort, and 17 pts with malignancy events (excluding NMSC) in the Over-
all Cohort (IR 0.69; 95% confidence interval [CI] 0.40, 1.11). There was no 
clustering of malignancy events (excluding NMSC) in the Overall Cohort 
(Table). Of the 17 pts with malignancy events (excluding NMSC), 3 had re-
ceived a PD of tofacitinib 5 mg BID (IR 0.49; 95% CI 0.10, 1.45) and 14 a PD 
of tofacitinib 10 mg BID (IR 0.75; 95% CI 0.41, 1.27).
NMSC was reported in 2 (0.2%) tofacitinib-treated Induction Cohort pts, 4 
Maintenance Cohort pts (3 tofacitinib 10 mg BID; IR 1.91; 95% CI 0.39, 5.59; 
and 1 placebo-treated pt; IR 0.97; 95% CI 0.02, 5.40) and 19 Overall Cohort 
pts (IR 0.78; 95% CI 0.47, 1.22; 4 had received a PD of tofacitinib 5 mg BID 
and 15 a PD of tofacitinib 10 mg BID).
conclusion: In the UC clinical programme, malignancies (including NMSC) 
were observed with tofacitinib treatment. There was no clustering of types 
of malignancy (excluding NMSC). The IR of malignancies (excluding NMSC) 
reported here is similar to that previously reported (IR 0.7; 95% CI 0.3, 
1.2),4 suggesting no treatment duration impact on the IR of malignancies 
(excluding NMSC). The IRs for malignancies (NMSC, and excluding NMSC) 
were similar to those reported for tofacitinib in pts with rheumatoid arthri-
tis5 and in pts with UC treated with biologics.6,7
references: 1. Sandborn WJ et al. N Engl J Med 2012; 367: 616-624. 
2. Sandborn WJ et al. N Engl J Med 2017; 376: 1723-1736.
3. Lichtenstein GR et al. Am J Gastroenterol 2018; 113: Abstract 571.
4. Sandborn WJ et al. Clin Gastroenterol Hepatol 2018: Epub ahead of print.
5. Cohen SB et al. Ann Rheum Dis 2017; 76: 1253-1262.
6. Sandborn WJ et al. Gastroenterology 2012; 142: 257-265.e253.
7. Sandborn WJ et al. Gastroenterology 2014; 146: 96-109.e101.
disclosure: GR Lichtenstein has received research support and consultancy 
fees from Celgene, Salix/Valeant, Shire and UCB; research support from 
Janssen Orthobiotech; consultancy fees from Abbott, AbbVie, Cellceutix, 
Ferring, Gilead, Luitpold/American Regent, Merck, Pfizer Inc, Prometheus, 
Romark and Takeda; and other fees from Am J Gastroenterol: ACG, Clin 
Adv Gastroenterol and Gastroenterol Hepatol: Springer Science and Busi-
ness Media, University of Pennsylvania, Janssen Orthobiotech, Pfizer Inc, 
Takeda, Luitpold/American Regent, Merck, Romark, McMahon Publishing, 
Up-To-Date and SLACK Inc. MA Ciorba has received lecture and consul-
tancy fees from Pfizer Inc and Takeda, and lecture fees from AbbVie and 
UCB. G Rogler has received research support, lecture fees and consultancy 
fees from AbbVie, Falk, MSD, Pfizer Inc, Takeda, Tillotts, UCB and Zeller; 
research support and consultancy fees from Augurix, Calypso, Ferring, No-
vartis, Phadia, Roche and Vifor; research support from Ardeypharm and 
Flamentera; lecture fees from AstraZeneca and Janssen; consultancy fees 
from Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Fisher, Ge-
nentech, Gilead, Janssen and Vital Solutions; is a shareholder of Nestlé, 
Novartis, Pharmabiome and Roche; and has a directorship at Pharmabi-
ome. D Quirk, AJ Thorpe, RD Pedersen, N Lawendy and G Chan are employ-
ees and shareholders of Pfizer Inc. J Panés has received research support, 
consultancy fees and advisory board fees from AbbVie; research support, 
consultancy fees and speaker’s bureau fees from MSD; consultancy fees, 
advisory board fees and speaker’s bureau fees from Janssen, Pfizer Inc 
and TiGenix; consultancy fees and advisory board fees from Boehringer 
Ingelheim, Celgene, Genentech, Gilead, GoodGut, GSK, Nestlé, Oppilan, 
Robarts Clinical Trials, Roche, Takeda and Theravance; and advisory board 
fees from Arena Pharmaceuticals. 
P0394 PredIcTOrs Of deLayed resPOnse TO TOfacITInIB: 
resuLTs Of The OcTave OPen sTudy fOr deLayed resPOnders
Regueiro M.1, Kinnucan J.A.2, Ungaro R.3, Quirk D.4, Su C.4, Lawendy N.4, 
Fan H.4, Woodworth D.A.4, Neurath M.F.5
1Cleveland Clinic, Department of Gastroenterology, Hepatology and Nutrition, 
Cleveland, United States, 2Division of Gastroenterology and Hepatology, 
Michigan Medicine, Department of Internal Medicine, Ann Arbor, United 
States, 3Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of 
Medicine at Mount Sinai, New York, United States, 4Pfizer Inc, Collegeville, 
United States, 5University of Erlangen-Nürnberg, Department of Medicine, 
Erlangen, Germany
contact e-Mail address: markus.neurath@uk-erlangen.de
Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibi-
tor for the treatment of ulcerative colitis (UC). The efficacy and safety of 
tofacitinib was shown in 3 Phase 3, randomised, placebo-controlled trials 
in patients (pts) with moderately to severely active UC.1 Pts who received 
tofacitinib 10 mg twice daily (BID) for 8 weeks in OCTAVE Induction 1 & 2 
(NCT01465763 & NCT01458951) and did not achieve clinical response could 
enter an ongoing, Phase 3, multicentre, open-label, long-term extension 
(OLE) study (NCT01470612)2 and receive tofacitinib 10 mg BID. Long-term 
maintenance data for up to 3 years of treatment in the OLE study for those 
who achieved clinical response with an additional 8 weeks of tofacitinib 
treatment (ie delayed responders) have been previously reported.3
aims & Methods: We evaluated potential predictors of delayed response, 
ie a clinical response (≥3-point and ≥30% decrease from induction study 
baseline total Mayo score, plus ≥1-point decrease in rectal bleeding sub-
score [RBS] or absolute RBS ≤1) after 16 weeks of tofacitinib 10 mg BID (8 
weeks induction plus an additional 8 weeks in the OLE study). Potential 
predictors evaluated included characteristics at baseline of OCTAVE Induc-
tion 1 & 2 and the OLE study, and at Month 1 of the OLE study. Pts were 
analysed as 3 subgroups: induction responders (pts who demonstrated 
clinical response after 8 weeks of tofacitinib 10 mg BID); delayed respond-
ers; and complete non-responders (pts who did not respond to 16 weeks 
of treatment with tofacitinib 10 mg BID).
 
Induction 
respondersa 
(n=521) 
delayed 
respondersb 
(n=148) 
complete non-
respondersc 
(n=106) 
Prior TNFi failure at OCTAVE Induction 
baseline, n (%)
237 (45.5) 85 (57.4) 66 (62.3)
Total Mayo score 
- OCTAVE Induction baseline, mean (SD)
- Mean change from OCTAVE Induction 
baseline to OCTAVE Induction Week 8 (SD)
8.8 (1.4)
-5.6 (1.7)
9.1 (1.4)
-1.0 (1.2)
9.2 (1.3)
-0.4 (1.1)
PMS 
- OLE study Month 1, mean (SD)
- Mean change in PMS from OLE baseline to 
OLE Month 1 (SD)
N/A
N/A
2.9 (1.7)d 
-2.4 (1.7)d 
5.2 (1.7)e 
-0.9 (1.6)e 
Mayo endoscopic subscore 
- OCTAVE Induction baseline, mean (SD)
- Mean change from OCTAVE Induction 
baseline to OCTAVE Induction Week 8 (SD)
2.6 (0.5)
-1.0 (0.9)
2.6 (0.5)
0.1 (0.5)
2.7 (0.5)
0.1 (0.5)
Mayo stool frequency subscore 
- OLE study baseline, mean (SD)
- OLE study Month 1, mean (SD) [mean 
change from OCTAVE Induction baseline (SD)]
N/A
N/A
2.2 (0.8)
1.4 (0.9) 
[-1.2 (0.9)]f 
2.5 (0.7)
2.4 (0.8) [-0.3 
(0.7)]e 
Mayo rectal bleeding subscore 
- OLE study baseline, mean (SD)
- OLE study Month 1, mean (SD) [mean 
change from OCTAVE Induction baseline (SD)]
N/A
N/A
1.1 (0.8)
0.5 (0.7) 
[-1.1 (0.7)]f 
1.2 (0.7)
1.1 (0.7) 
[-0.4 (0.8)]e 
C-reactive protein (mg/L) 
- OCTAVE Induction baseline, mean (SD) 
- Mean change from OCTAVE Induction 
baseline to OCTAVE Induction Week 8 (SD)
- OLE study baseline, mean (SD)
10.0 (16.6)g 
-7.3 (16.4)h 
N/A
10.8 (16.2)i 
-2.2 (18.8)i 
8.3 (15.4)
14.6 (26.9)
-3.4 (29.4)j 
11.2 (18.4)
OCTAVE Induction data are pooled data from OCTAVE Induction 1 and 2
aPts who demonstrated a clinical response following 8 weeks of tofacitinib 10 mg BID in OCTAVE 
Induction; bPts who demonstrated a clinical response following 16 weeks of tofacitinib 10 mg BID; 
cPts who did not demonstrate a clinical response following 16 weeks of tofacitinib 10 mg BID; dN=143; 
eN=104; fN=144; gN=511; hN=510; iN=146; jN=105
BID, twice daily; FAS, full analysis set; N, number of patients in the analysis population; n, number of 
patients in the category; N/A, not applicable; OLE, open-label, long-term extension; PMS, partial Mayo 
score; pts, patients; SD, standard deviation; TNFi, tumour necrosis factor inhibitor
[Table. Characteristics of induction responders, delayed responders and 
complete non-responders (FAS, observed case)]
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P0395 a MuLTIcenTrIc sTudy On The effecTIveness Of 
anTI-Tnf agenTs In syMPTOMaTIc sTrIcTurIng crOhn’s 
dIsease
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Bastón I.11, Piqueras M.12, Mena R.12, Esteba i Bech de Careda L.13, 
Suárez Ferrer C.14, Poza Cordón J.14, López A.15, Márquez Mosquera L.15, 
Arroyo M.16, Alfambra E.16, Sierra-Ausín M.17, Cano N.17, 
Delgado-Guillena P.18, Morales V.18, Aparicio J.C.19, Guerra I.20, Aulló C.21, 
Merino O.22, Rodríguez González G.E.23, Hidalgo M.A.24, Llaó J.25, 
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Frago-Larramona S.34, Benítez J.M.35,36, Calvo Moya M.I.37, 
López-Martín M.C.38, Elorza A.1, Larena A.39, Peña E.40, 
Rodríguez-Grau M.D.C.41, de Miguel-Criado J.42, Botella B.43, Olmos J.A.44, 
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26Hospital Universitario Infanta Leonor, Gastroenterology, Madrid, Spain, 
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Spain, 40Hospital Royo Villanova, Gastroenterology, Zaragoza, Spain, 
41Hospital Universitario del Henares, Gastroenterology, Coslada, Spain, 
42Hospital Universitario del Henares, Radiology, Coslada, Spain, 43Hospital 
Universitario Infanta Cristina, Gastroenterology, Parla, Spain, 44Hospital 
Universitario Rey Juan Carlos, Gastroenterology, Móstoles, Spain, 45Hospital 
Universitari Sant Joan de Reus, Gastroenterology, Reus, Spain
contact e-Mail address: iago.r.lago@gmail.com
Introduction: Approximately one half of the patients with Crohn’s disease 
may develop intestinal strictures during their lifetime. The effectiveness of 
the currently approved drugs in these stricturing complications remains 
barely known. Our aim was to determine the effectiveness of anti-TNF 
therapy for symptomatic stenosis in Crohn’s disease patients.
aims & Methods: We included adult patients with symptomatic strictur-
ing Crohn’s disease receiving their first-line anti-TNF therapy. Strictures 
were defined as constant luminal narrowing with pre-stenotic dilatation. 
We excluded those patients with previous anti-TNF exposure, surgery or 
endoscopic therapy of the stenosis. The effectiveness of the anti-TNF agent 
results: Characteristics at baseline of OCTAVE Induction 1 & 2 were gener-
ally similar between the 3 subgroups (Table). The proportion of pts with 
prior tumour necrosis factor inhibitor (TNFi) failure was numerically high-
er among complete non-responders than that among delayed responders 
(Table). Induction baseline mean C-reactive protein (CRP) was numerically 
higher in complete non-responders compared with induction responders 
and delayed responders (Table). A similar trend was observed at baseline 
of the OLE study; mean CRP value was numerically lower for delayed re-
sponders than complete non-responders (Table). At Month 1 of the OLE 
study, stool frequency subscore (SFS) and RBS were numerically lower in 
delayed responders compared with complete non-responders, and the re-
duction in partial Mayo score (PMS) from baseline of the OLE study was 
greater for delayed responders than complete non-responders (Table).
conclusion: Numerically higher proportions of complete non-responders 
and delayed responders had prior TNFi failure vs induction responders. 
In pts with UC, changes in SFS, RBS and PMS during extended induction 
treatment with tofacitinib may be indicative of the likelihood of clinical 
response. Extended treatment with tofacitinib 10 mg BID beyond the initial 
8-week induction period may be associated with clinical response in a 
subset of pts with UC who do not respond initially. This ad hoc analysis 
is limited by the small sample size and further evaluation is needed to 
confirm the findings.
references: 1. Sandborn WJ et al. N Engl J Med 2017; 376: 1723-1736.
2. Lichtenstein GR et al. Am J Gastroenterol 2018; 113 (Suppl 1): Abstract 571.
3. Rubin DT et al. J Crohns Colitis 2019; 13 (Suppl 1): Abstract DOP43.
disclosure: M Regueiro has received research support, educational grants, 
advisory board and consultancy fees from AbbVie, Janssen and Takeda; 
educational grants, advisory board and consultancy fees from Pfizer Inc 
and UCB; educational grants from Salix and Shire; and advisory board and 
consultancy fees from Amgen, Celgene, Miraca Labs and Seres. J Kinnu-
can has received consultancy fees from AbbVie, Janssen and Pfizer Inc. R 
Ungaro has received research support and consultancy fees from Pfizer 
Inc; research support from AbbVie and Boehringer Ingelheim; and con-
sultancy fees from Eli Lilly, Janssen and Takeda. D Quirk, C Su, N Lawendy, 
H Fan and DA Woodworth are employees and shareholders of Pfizer Inc. 
MF Neurath has received consultancy fees and lecture/speaker’s bureau 
fees from Janssen-Cilag; consultancy fees from Bionorica, Boehringer 
Ingelheim, e.Bavarian Health GmbH, F. Hoffmann La Roche, Genentech, 
Hexal, Index Pharmaceuticals, MSD, Pentax Europe, PPM Services, Takeda 
Pharma Vertrieb GmbH & Co. and Tillotts; and lecture/speaker’s bureau 
fees from AbbVie Deutschland, Falk Foundation and Pentax. 
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was defined as a composite outcome combining the persistence of the 
treatment and without dose or frequency intensification, with no new im-
munomodulators, surgery or endoscopic therapy during follow-up.
results: A total of 262 patients from 32 IBD Units in Spain were included. 
The main characteristics of the cohort are summarized in Table 1. The me-
dian number of stenosis per patient was 1 (range 1-9). One hundred-forty 
one patients (54%) received infliximab and 121 (46%) adalimumab. The 
treatment was considered to be effective in 81% and 60% of patients after 
6 and 12 months, respectively, while this outcome was fulfilled by 21% 
after a median follow-up of 40 months (IQR, 19-85). There were no radio-
logical findings at baseline associated with the effectiveness or the rate of 
surgery. During follow-up, anti-TNF therapy required a dose or frequency 
adjustment in 39% of patients, 12% required a new immunomodulator or 
endoscopic therapy in 4%. The proportion of subjects requiring surgery 
was 15% after 1 year, and 21% after 2 years, with an overall rate of sur-
gery of 32%. In the multivariate analysis, infliximab was associated with 
a higher rate of surgery as compared to adalimumab (OR 1.78; 95% CI, 
1,025-3,09). The anti-TNF agent was discontinued in 131 patients (50%) 
after a median of 16 months (IQR, 7.5-37), mainly due to an absence or loss 
of response (56%). A total of 88 subjects (34%) required a switch to a new 
biologic drug (72% to a second anti-TNF, 24% to ustekinumab and to 5% 
to vedolizumab).
conclusion: Anti-TNF agents are effective in approximately 20% of patients 
with Crohn’s disease complicated with symptomatic strictures, avoiding 
surgery in a relatively high proportion of cases.
characteristic Infliximab n = 141
adalimumab 
n = 121
all 
n = 262 p value
age at diagnosis, years 
Median (Iqr) 33 (25-47) 33 (23-46) 33 (25-46) 0.92
sex, female n (%) 72 (51) 67 (55) 139 (53) 0.48
disease duration, months 
Median (Iqr) 1.6 (0-59) 2.9 (0-83) 2.2 (0-71) 0.38
Perianal disease, n (%) 19 (13) 16 (13) 35 (13) 0.55
concomitant thiopurines, 
n (%) 98 (69) 24 (65) 165 (63) 0.003
Baseline crP, mg/L Median 
(Iqr) 5.3 (1.0-11.9) 3.9 (0.7-10-7) 5.3 (1.0-15) 0.26
number of stenosis per 
patient Median (Iqr)
1 (1-2) 
range 1-8
1 (1-2) 
range 1-9
1 (1-2) 
range 1-9
0.43
[Patient characteristics]
disclosure: IRL has received educational, travel support or speaker fees 
from MSD, Pfizer and Abbvie. 
P0396 cLInIcaL effecTIveness Of gOLIMuMaB In uLceraTIve 
cOLITIs: a PrOsPecTIve MuLTIcenTre sTudy Based On The 
sWedIsh naTIOnaL quaLITy regIsTry fOr IBd, sWIBreg
Eriksson C.1, Visuri I.1, Bergemalm D.1, Rundquist S.1, Vigren L.2, 
Nilsson L.3, Kärnell A.4, Hjortswang H.5, Udumyan R.6, Almer S.7, 
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of Clinical and Experimental Medicine, Linköping, Sweden, 6School of 
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Introduction: Clinical trials have demonstrated that golimumab is effective 
in anti-TNF naïve patients with ulcerative colitis.
aims & Methods: The aim of this prospective, multicentre cohort study was 
to assess the clinical effectiveness of golimumab in a real world setting. 
All patients with moderate-to-severe ulcerative colitis, defined as Mayo 
endoscopic subscore ≥2 who initiated golimumab between June 2014 and 
June 2017 at 16 Swedish hospitals were eligible for inclusion after written 
consent. Clinical characteristics, treatment, clinical, biochemical, endo-
scopic activity and quality of life measures were recorded at baseline and 
prospectively, using an electronic Case Report Form, integrated with the 
Swedish National Quality Registry for IBD (SWIBREG). Primary objective 
was clinical effectiveness at 12 weeks and 52 weeks, i.e. clinical response 
(defined as a decrease in Mayo score by ≥3 points or 30% from baseline) 
and remission (defined as a score of ≤2 with no individual subscores >1.) 
Continuous data are presented as median (interquartile range). Differ-
ences between baseline and follow-up were assessed by Wilcoxon-signed 
rank test.
results: 50 patients were included during the three-year study period. At 
study entry, 24/50 (48%) were on concomitant treatment with immuno-
modulators, 16/50 (32%) on oral corticosteroids and 27/50 (54%) on 5-ASA 
(table 1). In total, 35/50 (70%) had previously been exposed to at least one 
TNF-antagonist. The 12 and 52-week drug continuation rates were 37/50 
(74%) and 23/50 (46%), respectively. The 12-week clinical response rate 
was 14/50 (28%), the remission rate, 8/50 (16%) and the corresponding 
figures at week 52 were 13/50 (26%) and 10/50 (20%). Among patients 
who continued golimumab, the median Mayo score decreased from 7 (6-9) 
at baseline to 1 (0-5) at 52 weeks (p< 0.01) and the median faecal calpro-
tectin decreased from 862 (335-1759) µg/g to 90 (34-169) µg/g (p< 0.01). 
Consistently, quality of life improved in golimumab treated patients, with a 
significant reduction of the overall short health scale (SHS) score (p< 0.01).
 
Median age yr. (IQR) 41 (28-53)
Sex female no. (%) 25 (50)
Median disease duration yr. (IQR) 5 (2-11)
Extent no. (%)  
Proctitis (E1) 5 (10)
Left-sided colitis (E2) 19 (38)
Extensive colitis (E3) 26 (52)
Previous medications no. (%)  
Immunomodulators 46 (92)
Anti-TNF therapy 35 (70)
[Table 1. Baseline clinical and demographical characteristics of patients with 
ulcerative colitis]
conclusion: In this prospective cohort study, golimumab-treated patients, 
in Swedish clinical practice, represented a treatment refractory patient-
group, in which 70% previously were exposed to anti-TNF. Despite this, our 
results confirm that golimubab is an effective therapy in UC. 
The study was financially supported by MSD.
disclosure: CE has received consultant/lecture fees from AbbVie, Janssen, 
Takeda. IV has nothing to disclose.
DB has nothing to disclose.
SR has received speaker’s fee from Takeda.
LV has received consultant/lecture fees from Ferring, Takeda, Tillott, MSD 
and Abbivie
LN has nothing to disclose.
AK works at MSD Sweden.
HH has received consultant/lecture fees from AbbVie, Janssen, Takeda, 
Pfizer, Vifor Pharma, Tillotts and Ferring.
RU has nothing to disclose.
SA has received consultant/lecture fees from Janssen, Takeda, AbbVie, Vi-
for Pharma, Equalis, Pfizer
EH has received consultant/lecture fees from Takeda, Janssen, Abbvie, 
Pfizer.
PK has received lecture fees from Ferring, Jansen, Takeda and Otsuka.
HS has received consultant/lecture fees from Fering, Takeda, Pfizer, Tillotts, 
Janssen and Abbvie.
JH has received consultant/lecture fees from Abbvie, Celgene, Celltrion, 
Ferring, Hospira, Janssen, Medivir, MSD, Pfizer, Prometheus, Sandoz, 
Shire, Takeda, Tillotts Pharma, and Vifor Pharma and grant support from 
Janssen, MSD, and Takeda 
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duction were 72% (95% CI: 53-86%; range: 39-100%; I2=92%) and 42% 
(95% CI: 20-68%; range: 15-84%; I2=92%), respectively. At maintenance, 
the pooled estimates rates of clinical response, clinical remission, endo-
scopic response, and endoscopic remission were 69% (95% CI: 56-79%; 
range: 48-89%; I2=86%), 47% (95% CI: 25-70%; range: 28-73%; I2=93%), 
60% (95% CI: 53-67%; range: 55-77%; I2=0%), and 24% (95% CI: 19-31%; 
range: 15-31%; I2=0%), respectively. The pooled estimate of incidence rates 
of total adverse events and infections were 15.3 (95% CI: 8.7-26.8; range: 
7.2-34; I2=89%) and 3.7 (95% CI: 2.0-6.9; range: 2.2-9.0; I2=60%) per 100 
persons-years, respectively.
conclusion: Cumulative analysis of data from real-life studies confirmed 
that ustekinumab holds the potential to deserve a relevant role in the 
management of patients with Crohn’s disease with a reassuring safety pro-
file. Furthermore, its clinical effectiveness at induction seems to be higher 
in real-life observational studies compared with randomized controlled 
trials.
disclosure: FSM served as advisory board member or received lecture 
grants from for AbbVie, Biogen, MSD, Takeda Pharmaceuticals. AO served 
as advisory board member for AbbVie, MSD, Takeda Pharmaceuticals, and 
received lecture grants from AbbVie, MSD, Sofar, Chiesi, and Takeda Phar-
maceuticals. 
P0399 LOng-TerM effecT Of rIsankIzuMaB On IMPrOved 
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In PaTIenTs WITh MOderaTe TO severe crOhn’s dIsease: 
InTerIM anaLysIs Of a Phase 2 OPen-LaBeL exTensIOn sTudy
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Chen N.6, Lee W.-J.6, Ferrante M.7
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contact e-Mail address: edouard.louis@uliege.be
Introduction: The clinical and endoscopic efficacy of risankizumab (RZB), 
an IL-23 inhibitor, in patients with moderate to severe Crohn’s disease (CD) 
have been reported in the phase 2 trials of induction1 and maintenance 
phases over 52 weeks.2 Longer term outcomes were assessed from an on-
going open-label extension (OLE) study (NCT02513459).
aims & Methods: This study aims to evaluate the long-term effects of RZB 
on health-related quality of life (HRQoL) measured by the Inflammatory 
Bowel Disease Questionnaire (IBDQ) for up to 3 years from the ongoing 
phase 2 OLE study. Patients who achieved clinical response (decrease from 
baseline [BL] in CD Activity Index [CDAI] ≥100) without remission (CDAI < 
150) after Period 2 (Week 26) or clinical response and/or remission af-
ter Period 3 (Week 52) of the preceding study1,2 were enrolled to receive 
open-label RZB 180 mg subcutaneous (SC) injections every 8 weeks for 
up to 216 weeks. Patients who lost clinical response or remission after 
completion of the preceding study were re-induced with open-label RZB 
600 mg intravenous (IV) infusions at Weeks 0, 4 and 8. Patients could only 
receive subsequent RZB 180 mg SC maintenance treatment if they achieved 
response and/or remission following re-induction treatment. Percentages 
of patients with IBDQ response per minimal clinical important difference 
(MCID: increase in IBDQ total score from the induction BL ≥16); IBDQ remis-
sion (IBDQ total score ≥170); and mean change from induction BL in IBDQ 
total, domain, and selected individual scores were calculated at Weeks 0, 
24, 48, 72 and 96 with a data cut-off date of February 4, 2019. Results were 
reported as observed, and additional non-responder imputation was ap-
plied for remission/response data.
results: A total of 65 adults with CD were enrolled, including 4 patients 
who were re-induced. At BL of the preceding study, median (range) age 
34 (19-67) years and median disease duration 10 (2-38) years; 60 (92%) 
patients were previously exposed to tumour necrosis factor antagonists. 
Over 96 weeks of OLE therapy with RZB, >90% achieved IBDQ response 
and >58% of patients achieved IBDQ remission (Table, as observed). Mean 
change from induction BL to Week 0 of the OLE study was 62.5 points for 
IBDQ total score and this improvement was maintained over 96 weeks. 
This maintenance effect was also observed across all four IBDQ domains, 
with a mean change per individual item scores improved by approximately 
2 points (Table). Individual items with the greatest improvement at Week 
P0397 LuPus-LIke reacTIOns In PaTIenTs WITh 
InfLaMMaTOry BOWeL dIsease TreaTed WITh anTI-Tnfs are 
rare BuT InsIdIOus adverse evenTs: daTa frOM a Large 
sIngLe-cenTer cOhOrT
Macaluso F.S., Sapienza C., Ventimiglia M., Cottone M., Orlando A.
‘Villa Sofia-Cervello’ Hospital, IBD Unit, Palermo (Pa), Italy
contact e-Mail address: fsmacaluso@gmail.com
Introduction: The occurrence of lupus-like reactions (LLRs) may compli-
cate the management of patients with inflammatory bowel disease (IBD) 
treated with anti-TNFs. However, very few data on the incidence, predic-
tors, and clinical outcomes of LLRs have been reported.
aims & Methods: We aimed to describe all these features in a large cohort 
of IBD patients treated with anti-TNF drugs. All records of consecutive pa-
tients who started a treatment with an anti-TNF from January 2006 to June 
2018 were retrospectively reviewed. Patients were defined as having LLR 
by the presence of immunologic abnormalities (positivity for ANA and/or 
anti-ds-DNA), along with clinical features that included at least two of the 
following: arthralgia, fatigue, fever, cutaneous manifestations, or serositis, 
which had a clear temporal association with exposure to the anti-TNFs, 
and resolved without recurrence once the drug was discontinued. Univari-
able and multiple Cox proportional hazard models were used to estimate 
the association between all variables at baseline and occurrence of LLRs.
results: 760 patients (1059 total treatments with anti-TNFs) were included. 
Participants contributed a total of 2863.5 person-years of follow-up, dur-
ing which 16 cases of LLRs (2.1% of patients) were reported, with an inci-
dence rate of 5.6 per 1000 person-years. Female gender and being former 
smokers were more prevalent in the LLR group (75.0% versus 44.1%, p= 
0.02; and 18.8% versus 5.4%, p=0.037, respectively), with a hazard ratio of 
3.86 (95% CI: 1.21-12.38; p=0.023) and 4.42 (95% CI: 1.20-16.24; p=0.025), 
respectively, at Cox regression analysis adjusted for possible confounders. 
LLRs occurred after a mean of 12.0 ± 9.7 months of therapy with anti-TNFs. 
Antinuclear antibodies were universally positive, and 10 out 16 (62.5%) 
patients had also anti-ds-DNA. Arthropathy was the most frequent symp-
tom (87.5%), followed by fatigue (81.2%), and fever (31.2%). Three cases 
presented with a concomitant autoimmune hepatitis-like syndrome. The 
diagnosis of LLR was further confirmed by a re-challenge with the culprit 
agent in half of the cases. All LLRs resolved following discontinuation of 
the drug after a mean of 8.1 ± 4.2 weeks, even if 10 patients required 
corticosteroids for the control of symptoms. Five patients (31.2%) were 
switched to a second anti-TNFs, and one of them developed a second LLR.
conclusion: In this very large cohort of patients treated with anti-TNFs, 
LLRs were rare adverse events, more common in women and former 
smokers. Clinical features are non-specific and insidious. All LLRs resolved 
following discontinuation of the drug, but the use of corticosteroids was 
required in most of the cases.
disclosure: FSM served as advisory board member or received lecture 
grants from for AbbVie, Biogen, MSD, Takeda Pharmaceuticals. AO served 
as advisory board member for AbbVie, MSD, Takeda Pharmaceuticals, and 
received lecture grants from AbbVie, MSD, Sofar, Chiesi, and Takeda Phar-
maceuticals. 
P0398 effecTIveness and safeTy Of usTekInuMaB fOr 
The TreaTMenT Of crOhn’s dIsease In reaL-LIfe sTudIes: 
a MeTa-anaLysIs
Macaluso F.S.1, Maida M.2, Ventimiglia M.1, Cottone M.1, Orlando A.1
1’Villa Sofia-Cervello’ Hospital, IBD Unit, Palermo, Italy, 2’S.Elia-Raimondi’ 
Hospital, Gastroenterology Unit, Caltanissetta, Italy
contact e-Mail address: fsmacaluso@gmail.com
Introduction: The real-life value of ustekinumab in Crohn’s disease is un-
der evaluation.
aims & Methods: The aim of this single-arm meta-analysis was to estimate 
the effectiveness and safety of ustekinumab in real-life observational stud-
ies. PubMed Central/Medline and Embase, as well as reference lists of ar-
ticles, were systematically searched through December 2018. Only real-life 
observational studies were included.
results: Seven studies comprising 597 patients met the inclusion criteria. 
Almost all patients had been previously exposed to anti-TNFs. Ustekinum-
ab was administered subcutaneously at induction in all studies except 
one. The pooled estimates rates of clinical response and remission at in-
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96 from Induction BL were abdominal pain (2.7 points), abdominal cramps 
(2.7 points), bowel movement frequency (2.4 points), number of loose 
bowel movements (2.5 points), feeling unwell (2.8 points), quality of sleep 
(2.3 points) and fatigue (1.9 points).
Outcome Week 0 Week 24 Week 48 Week 72 Week 96
N (as observed) 64 65 60 52 51
IBDQ response (increase 
of IBDQ total score ≥16 
from the Induction 
Baseline), n/N (%)
As observed
NRI
60/64 (93.8)
60/65 (92.3)
59/65 (90.8)
59/65 (90.8)
57/60 (95.0)
57/65 (87.7)
47/52 (90.4)
47/65 (72.3)
47/51 (92.2)
47/65 (72.3)
IBDQ remission (IBDQ 
total score ≥170), n/N 
(%)
As observed
NRI
40/64 (62.5)
40/65 (61.5)
38/65 (58.5)
38/65 (58.5)
42/60 (70.0)
42/65 (64.6)
36/52 (69.2)
36/65 (55.4)
37/51 (72.5)
37/65 (56.9)
Total IBDQ score,
mean change ± SD
(mean change per 
item)*
62.5 ± 38.8
(1.95)
58.7 ± 35.6
(1.83)
64.1 ± 33.1
(2.00)
63.8 ± 43.4
(1.99)
62.4 ± 39.2
(1.95)
IBDQ bowel symptom 
domain, 
mean change ± SD
(mean change per 
item)*
20.4 ± 11.7
(2.04)
18.3 ± 11.6
(1.83)
20.5 ± 10.7
(2.05)
20.5 ± 12.8
(2.05)
19.1 ± 13.1
(1.91)
IBDQ systemic symptom 
domain, 
mean change ± SD
(mean change per 
item)*
11.0 ± 8.2
(2.20)
10.6 ± 7.7
(2.12)
11.7 ± 7.5
(2.34)
11.3 ± 9.0
(2.26)
10.6 ± 8.6
(2.12)
IBDQ social function 
domain,
mean change ± SD
(mean change per 
item)*
9.9 ± 6.7
(1.98)
9.1 ± 6.4
(1.82)
9.6 ± 6.1
(1.92)
10.1 ± 7.5
(2.02)
10.3 ± 5.8
(2.06)
IBDQ emotional function 
domain,
mean change ± SD
(mean change per 
item)*
21.1 ± 16.8
(1.76)
20.8 ± 15.6
(1.73)
22.3 ± 15.0
(1.86)
21.9 ± 18.3
(1.83)
22.4 ± 17.1
(1.87)
*Total number of items in IBDQ is 32: 10 items in bowel symptom domain, 5 items in systemic 
symptom domain, 5 items in social domain, and 12 items in emotional domain.
[Table. IBDQ response, IBDQ remission and mean change in IBDQ total and 
domain scores from induction BL]
conclusion: In patients with moderate to severe CD responding to RZB, 
improvements in HRQoL as measured by IBDQ were maintained over 3 
years with RZB treatment. Bowel symptoms as well as patients’ sleep 
quality and fatigue were found to have the greatest improvement with 
RZB therapy.
references: 1. Feagan BG, et al. Lancet. 2017;389:1699-1709. 2. Feagan BG, 
et al. Lancet Gastroenterol Hepatol. 2018;3:671-80.
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P0400 effIcacy and safeTy Of usTekInuMaB usIng 
endOvenOus InducTIOn In crOhn’s dIsease: reaL-WOrLd 
cLInIcaL seTTIng frOM a MuLTIcenTer OBservaTIOnaL sTudy
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contact e-Mail address: laura7ramos@gmail.com
Introduction: Randomized clinical trials have confirmed that biological 
therapy with ustekinumab (UST- amonoclonal antibody targeting inter-
leukins12 and 23) is an effective treatment to induce and maintenance of 
remission in Crohn’s disease (CD). UST using intravenous (¡v) induction in 
CD was approved in Spain in june 2017 and limited data on the efficacy and 
safety of this drug in clinical practice are available.
aims & Methods: 
aim: To assess the efficacy and safety of UST, using iv induction, in a real 
world clinical setting.
Methods: A retrospective multicenter cohort study was performed on IBD 
patients receiving iv induction dose ofUST between june 2017 and june 
2018 in five tertiary hospitals from Canary Islands (Spain). Efficacy was 
defined as clinical remission (HBI ≤4 ) at 8 weeks and 3,6 and 12 months 
and steroid withdrawal at 3and 12 months. We examined previous use of 
anti-TNF agents, need of surgery, rate of treatment discontinuation and 
adverse effects during UST treatment.
results: A total of 47 CD patients (22M/25F; mean age 29 ±11 years; A2 
85.1%, L3 59.6%/ B1 44.7%/p 44.7%) were included. Mean time from diag-
nosis to use of UST was 224 ± 323 months and 17.4% of patients were naive 
to anti-TNF and 43% had received 3 previous biological treatment. UST 
was indicated for induction of remission in 47,7% patients. Remission was 
achieved in 51.6% and 42% of patients at 8 weeks and 12 months, respec-
tively. Steroid withdrawal was obtained in 80% of patients at 3 month of 
UST treatment. Escalation treatment by administrating UST every 8 weeks 
was indicated in 80% of casesand 91% received combination treatment 
with inmunosupresants (80% azathioprine). Number of previous anti-TNF 
agents , uso of steroids when starting UST and combination treatment with 
inmunosupresant did not reach stadistical significance to associate with 
clinical response to UST. The mean time of use of UST was 6.7± 3 months 
. Biological treatment discontinuation occurred in 30 % of patients pre-
dominantly owing to lack or loss of response. Surgery was underwent in 
5 patients (10%). No adverse effects were reported and only one infection 
(infectious colitis) (2,1%) during follow-up.
conclusion: UST is a safe treatment for IBD patients but the efficacy of UST 
might be distorted due to the complex profile of IBD patients in which we 
use in routine clinical practice.
disclosure: Nothing to disclose 
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P0402 assessMenT Of PaTIenTs’ Preference fOr a neW 
auTO-InjecTIOn Pen cOMPared WITh The PrefILLed syrInge 
fOr seLf-adMInIsTraTIOn Of adaLIMuMaB In PaTIenTs WITh 
crOhn’s dIsease: a PrOsPecTIve cOhOrT sTudy
Miyakawa M.1, Tanaka H.1, Nojima M.2, Hojo H.3, Masuya K.3, Morino M.3, 
Wataya M.3, Akita I.3, Nakamura K.1, Sugiyama K.1, Nasuno M.1, Motoya S.1
1Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan, 2The University 
of Tokyo, Center for Translational Research/Division of Advanced Medicine 
Promotion The Institute of Medical Science, Tokyo, Japan, 3Sapporo Kosei 
General Hospital, Nursing Department, Sapporo, Japan
contact e-Mail address: a030086m1982@yahoo.co.jp
Introduction: In Japan, a new auto-injection pen for self-administration of 
adalimumab, which differs in shape from the conventional auto-injection 
pen used worldwide, has been available since June 2018. This pen is filled 
with the same drug solution and fitted with the same 29-gauge needle 
as the prefilled syringe. However, there are no data comparing the new 
pen and the syringe in terms of preference among patients with Crohn’s 
disease (CD). We report the results from the Comparison of Preference for 
New Auto-injection Pen Versus Prefilled Syringe in CD Patients Receiving 
Adalimumab Treatment (COMFORT).
aims & Methods: The COMFORT study was to assess the patients’ prefer-
ence for the new pen in comparison with that of the syringe of adalim-
umab using a questionnaire survey. This study was a prospective cohort 
study conducted at a single centre in Japan. Patients with CD who agreed 
to switch from the adalimumab syringe to the new pen between Sep-
tember 2018 and January 2019 were enrolled. The inclusion criteria were 
as follows: 1) patients who were self-injecting 40 mg/0.4 mL of adalim-
umab using a syringe every other week, 2) those who were treated with 
adalimumab for ≥6 weeks and had ≥1 self-injections with a syringe and 3) 
those whose date of consent was within 2 weeks from the last date of self-
injection with the syringe. The first questionnaire survey was conducted 
within 2 weeks from the last date of self-injection using the syringe, and 
the patient’s impressions of the syringe during the final self-injection were 
assessed. All patients were instructed by a nurse on how to use the pen 
after the first survey was completed. The second and third surveys were 
conducted within 1 h after the first and seventh self-injection using the 
pen, and the patients’ impressions of the pen were then investigated. Pain 
at the injection site was assessed using the visual analogue scale (VAS). 
In all surveys, VAS scores and the overall patients’ satisfaction were ex-
amined. In the second and third surveys, pain, administration time, safe 
operability, simplicity, convenience and overall assessment were investi-
gated to determine the patients’ preference for the pen, syringe or neither.
results: A total of 81 patients (median age, 33.6 years; female, 33.3%) 
were included in this study. All patients responded to the first survey, while 
73 and 64 patients responded to the second and third surveys, respec-
tively. The mean VAS score significantly decreased from 28.2 during the 
first survey to 16.7 (P < 0.001) and 19.1 (P = 0.003) during the second and 
third surveys, respectively. The proportion of patients who were satisfied 
increased sequentially from 66.7% in the first survey to 78.6% and 85.2% 
in the second and third surveys. The proportion of patients who reported 
that the pen was generally better than the syringe significantly increased 
from 69.9% in the second survey to 83.9% in the third survey (P = 0.012). 
Similarly, the proportion of patients who reported that the pen caused 
milder pain, took less time to administer, had safer operability, was sim-
pler and more convenient to use than the syringe increased from 61.6%, 
82.2%, 76.7%, 83.6% and 69.9% in the second survey to 71.4%, 87.3%, 
85.7%, 88.9% and 79.4% in the third survey, respectively.
conclusion: The new pen for self-administration of adalimumab caused 
less pain than the syringe. Further, approximately 70% of patients an-
swered that the new pen was generally better than the syringe at the first 
self-injection. In addition, the proportion of patients who preferred the 
new pen was higher at the seventh self-injection than at the first self-
injection.
disclosure: Maki Miyakawa has received lecture fees from JIMRO Co. Ltd. 
Hiroki Tanaka has received lecture fees from JIMRO Co. Ltd., AbbVie GK, EA 
Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyorin Pharmaceutical 
Co. Ltd. and Mitsubishi Tanabe Pharma Corporation. Satoshi Motoya has 
received lecture fees from Mitsubishi Tanabe Pharma Corporation, Mochi-
da Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K. and Takeda Phar-
maceutical Co. Ltd.; and has received research grants from Pfizer Japan 
Inc., Janssen Pharmaceutical K.K. and from Takeda Pharmaceutical Co. Ltd. 
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Kato M.1,2, Tanaka H.2, Nakamura K.2, Sugiyama K.2, Miyakawa M.2, 
Sakemi R.2,3, Yamashita M.1,2, Nasuno M.2, Ishii M.2,4, Motoya S.2, Itoh F.1
1St. Marianna University School of Medicine, Division of Gastroenterology 
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Introduction: In Japan, infliximab was first approved for patients with 
Crohn’s disease as an induction therapy in 2002. Subsequently, it was ap-
proved for maintenance therapy and dose escalation in 2007 and 2011, re-
spectively. However, the comparative long-term effectiveness of infliximab 
treatments in patients with Crohn’s disease at different times of initiation 
of infliximab administration is not fully established.
aims & Methods: The aim of this study was to compare the rates of dose 
escalation of infliximab, intestinal resection and retention of infliximab 
among patients with Crohn’s disease at different times of initiation of inf-
liximab administration. Data for 338 patients with luminal Crohn’s disease 
who were treated at our hospital with infliximab (5 mg/kg) for ≥14 weeks 
between January 2003 and May 2017 were retrospectively reviewed. The 
cumulative rate of the dose escalation of infliximab from 5 mg/kg to 10 mg/
kg, the rate of intestinal resection and the rate of retention of infliximab 
following the initial infliximab administration were estimated using the 
Kaplan-Meier method. Patients were categorised into three groups accord-
ing to the time of initiation of the infliximab therapy [A, 2003-2006 (n = 
83); B, 2007-2010 (n = 146) and C, 2011-2017 (n = 109)]. Patient characteris-
tics and the rates of dose escalation of infliximab, intestinal resection and 
retention of infliximab were compared among the three groups. Prognos-
tic factors related to the outcomes were evaluated using the log-rank test.
results: Of the 338 patients (median age, 29.7 years; 85 females), the 
median duration of the disease at initiation of infliximab therapy was 4.3 
years. Of the total patients, 201 patients had ileocolitis, 75 had ileitis and 62 
had colitis. In addition, 145 patients were diagnosed with non-stricturing, 
non-penetrating disease, 145 with stricturing disease and 48 with pen-
etrating disease. Perianal disease was diagnosed in 156 patients. The me-
dian C-reactive protein was 1.01 mg/dL. Prior to initiation of the infliximab 
therapy, 108 patients had undergone at least one intestinal resection and 11 
had been previously exposed to adalimumab. Concomitant treatment with 
immunomodulators (azathioprine or 6-mercaptopurine) and prednisolone 
was administered to 248 and 36 patients respectively. The 1-, 3-, 5- and 10-
year cumulative rates of dose escalation of infliximab, intestinal resection 
and retention of infliximab in all 338 patients were 16.2%, 33.7%, 42.3% 
and 52.2%, 3.4%, 9.8%, 13.8% and 21.3% and 98.2%, 93.5%, 89.8% and 
80.1%, respectively. Patients in group C had significantly shorter disease 
durations (P = 0.029) and higher rates of concomitant treatment with im-
munomodulators (P < 0.001) than those in group A. The 5-year cumulative 
rates of dose escalation of infliximab, intestinal resection and retention of 
infliximab were 54.2%, 17.1% and 88.5% in group A; 46.8%, 16.6% and 
89.1% in group B and 27.3%, 6.5% and 92.2% in group C, respectively. The 
rates of dose escalation of infliximab (P < 0.001) and intestinal resection (P 
= 0.043) in group C were significantly lower than those in groups A and B.
conclusion: The rates of dose escalation of infliximab and intestinal resec-
tion of patients with Crohn’s disease who were administered infliximab 
after 2011 were lower than those of patients who were administered inf-
liximab before 2010. Early induction of infliximab and a combined therapy 
with infliximab and immunomodulators in the 2011-2017 period may have 
contributed to the reduction in the rates of dose escalation of infliximab 
and intestinal resection.
disclosure: Maki Miyakawa has received lecture fees from JIMRO Co. Ltd. 
Hiroki Tanaka has received lecture fees from JIMRO Co. Ltd., AbbVie GK, EA 
Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyorin Pharmaceutical 
Co. Ltd. and Mitsubishi Tanabe Pharma Corporation. Satoshi Motoya has 
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da Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K. and Takeda Phar-
maceutical Co. Ltd.; and has received research grants from Pfizer Japan 
Inc., Janssen Pharmaceutical K.K. and from Takeda Pharmaceutical Co. Ltd. 
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Introduction: The efficacy of etrasimod, a once-daily, oral, selective, sphin-
gosine-1-phosphate receptor modulator as induction therapy in adult 
patients with moderate to severe ulcerative colitis (UC) was previously 
demonstrated in the 12-week phase 2, randomised, placebo-controlled, 
double-blind (DB), OASIS study (NCT02447302). This open-label extension 
(OLE) study (NCT02536404) subsequently evaluated for an additional 34 
weeks the safety and efficacy of etrasimod in achieving and maintaining 
response and/or remission in patients who completed OASIS.
aims & Methods: All patients completing the OASIS DB study were eligible 
to enrol in the OLE and receive etrasimod 2 mg QD for up to 46 weeks from 
the DB baseline, irrespective of their response or treatment during the 
DB study. Efficacy was summarized in the modified intent-to-treat (mITT) 
population evaluable cohort, which included patients with required as-
sessments who received etrasimod 2 mg throughout the OLE. Patients in 
the treat-through (TT) group received etrasimod 2 mg in both the DB and 
OLE studies. Endpoints were clinical remission (endoscopic score ≤1 [with 
absence of friability], rectal bleeding [RB] 0, and stool frequency [SF] score 
≤1 with ≥1 point decrease from DB baseline), clinical response (clinical 
remission or decrease in 3-component Mayo Clinic score [endoscopy find-
ings, RB, or SF] of ≥2 points and ≥30% decrease from DB baseline, with 
either a RB decrease of ≥1 or RB score of ≤1), and endoscopic improvement 
(subscore ≤1). All statistics are descriptive. End of treatment (EOT) was the 
last observation for each patient, occurring at week 46 (week 34 of OLE) 
for study completers or at last visit for patients who discontinued or had 
missing data.
   
By previous treatment group in 
dB study
 
dB study: 
any 
treatment
OLe:
etrasimod
2 mg
(n = 105)
dB study: 
etrasimod 
1 mg
OLe: 
etrasimod
2 mg
(n = 35)
dB study: 
etrasimod 
2 mg
OLe: 
etrasimod
2 mg
(n = 31)
dB study: 
Placebo
OLe: 
etrasimod 
2 mg
(n = 39)
Patients with clinical response, %
n
Week 12 (end of DB study)
End of treatment
  94 
 40.4 
70.2
33
39.4
75.8
28
57.1
64.3
33
27.3
69.7
Patients with clinical remission, %
n
Week 12 (end of DB study)
End of treatment
94 
 21.3 
35.1
33 
   9.1 
33.3
28
50.0
39.3
33 
   9.1 
33.3
Patients with endoscopic improvement, %
n 
Week 12 (end of DB study) 
End of treatment
96 
 26.0 
44.8
34
14.7
50.0
29
51.7
41.4
33
15.2
42.4
[Key efficacy endpoints for patients in the OLE etrasimod 2-mg group  
(mITT evaluable cohort)]
results: 118 patients (84% of DB completers) entered the OLE; 112 patients 
(safety population) received etrasimod 2 mg at any point in the OLE, of 
whom 105 patients (evaluable cohort) received etrasimod 2 mg throughout 
the OLE and 92 patients (82% of OLE enrollers) completed the OLE. At EOT, 
70% of patients had a clinical response, an increase from 40% at week 12 
(Table). Clinical response at EOT was seen in 87% (33/38) and 81% (13/16), 
respectively, of week-12 responders who received OLE etrasimod 2 mg or 
were in the 2-mg TT group; clinical remission at EOT was seen in 60% 
(12/20) and 64% (9/14), respectively, of week-12 remitters who received 
OLE etrasimod 2 mg or were in the 2-mg TT group. Median lymphocyte 
reduction from the DB baseline was 44.6% at week 12 with etrasimod 2 
mg and 42.9% at EOT in the 2-mg TT group. Of patients who received etra-
simod 2 mg at any point during the OLE, 60% (67/112) experienced ≥1 TEAE 
(most of mild or moderate severity) and 9% (10/112) discontinued study 
drug due to a TEAE (worsening UC, atrial fibrillation, or headache). Of the 
14 serious TEAEs reported in 7 patients, only 1 was considered treatment-
related (worsening UC). The impact on heart rate and atrioventricular (AV) 
conduction was minimal, with no study discontinuations related to brady-
cardia or AV block.
conclusion: Etrasimod 2 mg demonstrated sustained clinical response, 
clinical remission, and endoscopic improvement at the end of the OLE 
compared with the end of induction therapy. Etrasimod demonstrated a 
favourable long-term safety profile, with most AEs of mild to moderate 
severity; no new safety findings were reported. 
disclosure: SV has received grants from AbbVie, J&J, Pfizer, and Takeda; 
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TiGenix. MC has received consulting and/or speaking fees from AbbVie, 
Arena Pharmaceuticals, Celgene, Janssen, Medtronic, Pfizer, Takeda, 
and UCB. LP-B has received personal fees from AbbVie, Alma, Amgen, 
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Ferring, Genentech, Index Pharmaceuticals, Janssen, Lilly, Merck, Nestle, 
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P0404 nOncLInIcaL safeTy assessMenT Of Lc51-0255, an 
OraL sPhIngOsIne-1-PhOsPhaTe 1 recePTOr (s1P1) MOduLaTOr 
WITh a favOraBLe PrOfILe
Kim K.C.1, Kim J.1, Hong P.S.2, Seo D.O.1
1LG Chem, Ltd, Regulatory Toxicology Team, Drug Discovery Center, Life 
Sciences R&D, Seoul, Korea (Republic of), 2LG Chem, Ltd, Drug Discovery 
Center, Life Sciences R&D, Seoul, Korea (Republic of)
contact e-Mail address: kichankim@lgchem.com
Introduction: LC51-0255 is a highly selective and potent S1P1 modulator 
under the clinical development for the treatment of Ulcerative Colitis (UC).
The objective of this study was to evaluate the safety of LC51-0255 in non-
clinical toxicity studies with rats and monkeys.
aims & Methods: GLP toxicity studies were conducted in Sprague-Dawley 
rats and Cynomolgus monkeys. LC51-0255 was orally administered in 0.5% 
methylcellulose for up to 26 weeks in rats and 39 weeks in monkeys.
results: LC51-0255 was evaluated for 4-, 13- and 26-week repeated oral 
dosing toxicity in Sprague-Dawley rats. The no-observed-adverse-effect-
level (NOAEL) of LC51-0255 was 3 mg/kg/day in the toxicity studies in rats. 
Due to immunosuppressive nature of pharmacological effects of LC51-
0255, low leukocyte and lymphocyte counts were observed, and changes 
in organ weight and histopathology from lymphoid tissues were mainly 
observed from 10 mg/kg/day groups. But those changes showed a tenden-
cy of recovery at the end of each recovery period of the studies. Although 
there were no functional abnormalities, toxicity target organs from the rat 
studies were considered to be liver and lung, based on the changes in 
organ weight and histopathology.
In toxicokinetic analysis in rats, the values of C
max
 and AUC
0-24
 of LC51-0255 
increased in a dose proportional manner throughout the studies, and no 
clear sex-related differences were noted. Estimated human safety margins 
based on AUC
0-24
 were over 20-fold and over 30-fold for male and female 
rats, respectively.
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hip-, and wrist fractures (OR 1.34 (CI: 0.94-1.93) and OR 1.26 (CI: 0.87-1.83), 
respectively). No dose-response association was evident (OR for doubling 
of cumulative dose 1.03 (CI: 0.91-1.16). When addressing differences across 
subgroups, we generally found moderately increased ORs (1.28-1.97). 
  cases exposed/unexposed
controls exposed/
unexposed
crude odds 
ratio 95% cI
adjusted* 
odds ratio 95% cI
No use 120 / 365 460 / 976 1.00 (Ref) 1.00 (Ref)
Spinal fracture 54 / 14 128 / 74 2.29 (1.19 - 4.42) 2.15 (1.09 - 4.25)
Wrist fracture 141 / 51 386 / 181 1.29 (0.90 - 1.86) 1.26 (0.87 - 1.83)
Hip fracture 170 / 55 462 / 205 1.37 (0.97 - 1.93) 1.34 (0.94 - 1.93)
[The association between budesonide use and types of osteoporotic 
fractures.]
Cases: MC-patients with an osteoporotic fracture; Controls: MC-patients 
without fractures; matched according to age, gender and type of MC. 
*Adjusted for all comorbid conditions and co-prescribed medication.  
CI = 95% confidence interval; DDD = Defined daily dose 
conclusion: A moderate increased risk risk of osteoporotic fractures related 
to use of oral budesonide among individuals with MC was found. However, 
no dose-response association could be demonstrated. Based on present 
study we suggest using bone densitometry to periodically assess bone 
mineral density in MC patients on long-term oral budesonide to maintain 
clinical remission.
references: 1. Bonderup OK, Hansen JB, Birket-Smith L, Vestergaard V, 
Teglbjaerg PS, Fallingborg J. Budesonide treatment of collagenous colitis: 
a randomised, double-blind, placebo controlled trial with morphometric 
analysis. Gut 2003;52 (2):248-51. 2. Bonderup OK, Hansen JB, Teglbjrg PS, 
Christensen A, Fallingborg JF. Long-term budesonide treatment of collag-
enous colitis: a randomised, double-blind, placebocontrolled trial. Gut 
2009;58(1):68-72.
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from Tillotts. Jesper Hallas, Martin Thomsen Ernst, Gunnar Lauge Nielsen, 
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Introduction: LC51-0255 is a potent, selective, and orally available sphin-
gosine-1-phosphate 1 (S1P1) receptor agonist which exerts anti-inflamma-
tory effect. Once it is bound to S1P1 receptor, it is internalized from the cell 
membrane and is introduced to receptor degradation pathway, leading to 
the capture of immune cells in the secondary lymph node. We herein pres-
ent the phase 1 clinical study results of LC51-0255 as a potential treatment 
of auto-immune diseases such as ulcerative colitis (UC).
aims & Methods: A dose blocked-randomized, double-blind, placebo-con-
trolled, single and multiple dosing, dose-escalation phase 1 clinical study 
was conducted to investigate the safety, tolerability, pharmacokinetic/
pharmacodynamic (PK/PD) characteristics and food effect on the bioavail-
ability of LC51-0255 after oral administration in healthy male volunteers. 
Eligible subjects were healthy male, 19 - 45 years of age with BMI 18.0 - 
27.0 kg/m2. In the single ascending dose (SAD) study, 50 subjects (n=10/
dose group) were randomly assigned, in 4:1 ratio, to receive either LC51-
0255 (0.25 - 4 mg) or placebo, and the food effect was evaluated in LC51-
0255 2 mg dose group. In the multiple-ascending dose (MAD) study, 40 
subjects (n=10/dose group) were randomized (4:1) to receive either LC51-
0255 (0.25 - 1.5 mg) or placebo once daily for 21 days. Safety and toler-
ability assessment included adverse events (AE), electrocardiogram (ECG), 
laboratory tests, and Holter monitoring. Blood samples were collected to 
evaluate the PK and PD of LC51-0255.
To evaluate the systemic toxicity of orally administered LC51-0255 on Cyno-
molgus monkeys, 4-, 13- and 39-week toxicity studies were examined. The 
NOAEL of LC51-0255 was 3 mg/kg/day throughout the toxicity studies in 
monkeys. Similar to the rat toxicity studies, low leukocyte and lymphocyte 
counts were observed due to immunosuppressive effects of LC51-0255. 
In the spleen, organ weight loss and atrophy were observed. But those 
changes showed a tendency of recovery at the end of each recovery period 
of the studies.
Clinical signs including diarrhea and soft stool were mainly observed from 
10 mg/kg/day groups. But those signs were considered to be related to the 
physicality of the test article formulation and toxicologically insignificant. 
Although there were no functional abnormalities, toxicity target organs 
from monkey toxicity studies were considered to be liver and lung, based 
on the changes in organ weight and histopathology.
In toxicokinetic analysis in monkeys, the values of C
max
 and AUC
0-24 
of 
LC51-0255 increased in dose proportional manner on the Day 1 of dos-
ing throughout the studies. But accumulation ratio of LC51-0255 showed a 
tendency to decrease with increasing dose. From 3 mg/kg/day, the mean 
values of C
max
 and AUC
0-24 
showed similar values throughout the dosing pe-
riod. Estimated human safety margins based on AUC
0-24
 were over 20-fold 
and over 30-fold for male and female monkeys, respectively.
conclusion: LC51-0255 is a potent S1P1 modulator with high selectivity at 
S1P1 receptor versus the other S1P receptors
Nonclinical safety of LC51-0255 was assessed for genotoxicity, safety phar-
macology, general toxicity and reproductive/developmental toxicity stud-
ies, and there were no specific safety concerns. Most of findings are related 
to its pharmacological activity as a S1P1 modulator.
These safety assessments support the continuing development of LC51-
0255 for Ulcerative Colitis and other potential autoimmune disorders.
disclosure: Nothing to disclose 
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1Diagnostic Center, Section of Gastroenterology, Silkeborg, Denmark, 2Aarhus 
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Odense, Denmark, 4Aalborg University Hospital, Department of Medicine, 
Farsø, Denmark
contact e-Mail address: olebonde@rm.dk
Introduction: Budesonide is a well-established treatment of microscopic 
colitis (MC). Due to a substantial first-pass metabolism of oral budesonide 
the systemic bioavailability is low compared to other oral corticosteroids. 
This may lead to a decreased risk of adverse effects normally related to 
long-term use of corticosteroids. Due to a high risk of relapse long-term 
treatment of MC is often necessary. However, adverse effects related to 
long-term use of budesonide are of concern.
aims & Methods: The aim was to determine whether use of oral 
budesonide is associated with risk of osteoporotic fractures in patients 
with MC. Based on data from the Danish nationwide health registries, we 
conducted a case-control study nested within patients with a histologically 
verified diagnosis of MC from 2004 to 2012. Cases were individuals with 
a first-occurrence of a fracture likely caused by osteoporosis i.e.,fracture 
of hip (ICD-10: S72), wrist (S525) or spine (S220 & 320). Controls were 
patients with MC without fractures matched according to age, gender and 
type of MC. Cases were matched to controls by risk set sampling in a ratio 
of 1:3. We estimated odds ratios (ORs) for the association between ever 
use of budesonide and any osteoporotic related fractures, and for hip-, 
wrist and spinal fractures independently. Further, we investigated dose-
response associations and associations for subgroups at suspected high 
or low risk of fractures. Potential confounding was adjusted for by risk set 
sampling and regressionanalyses
results: Among 10,652 patients with a diagnosis of MC we identified 485 
cases with a first occurrence of an osteoporotic fracture as defined above. 
The majority were women (86%) and the median age was 78 years. Af-
ter adjustment for confounding, a modestly increased adjusted OR was 
observed for the overall association between use of budesonide and os-
teoporotic fractures (OR 1.39, CI: 1.09-1.76). Stratification by type of fracture 
revealed the highest risk of spinal fractures (2.15, CI: 1.09-4.25), followed 
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results: There was no serious adverse event in SAD study. Decreased heart 
rate (bradycardia) was the most common AE, and one case of asymptom-
atic 2nd degree atrioventricular block occurred after single administration 
of LC51-0255 4 mg, both of which are well-known AEs in the same class of 
S1P agonists. These AEs were well tolerated and resolved within study pe-
riod without any intervention. No clinically significant QT prolongation was 
reported in ECG and Holter monitoring. In present, MAD study is ongoing.
Systemic exposure of LC51-0255 increased dose-dependently after a single 
dose, in dose range of 0.25 to 4 mg, with the mean area under the plasma 
concentration time curves (AUC) ranging from 127.72 to 2498.99 µg·h/L. 
There was no apparent effect of food on the systemic exposure of LC51-
0255. The peak plasma concentration of LC51-0255 was observed at 3 - 4 
hours after oral administration and the mean elimination half-life was 70 
-130 hours, making it suitable for once daily administration. The fraction 
excreted into urine was less than 0.1% across all dose levels, indicating 
that the renal excretion is not the major route of elimination.
The absolute lymphocyte count (ALC), a PD biomarker, decreased dose-
dependently with the mean maximum change from baseline of ALC rang-
ing from 34 to 77%. These results showed that the pharmacodynamics 
of LC51-0255 was consistent with expected pharmacology. All dose levels 
reached its maximum pharmacodynamic effect at 6 hours post adminis-
tration except for 4 mg (10 hours). Reduced ALC levels were recovered to 
normal range during the study period.
conclusion: Overall, LC51-0255 was well tolerated at all doses tested in this 
study. Systemic exposure increased dose-dependently and PK profile was 
favorable for once daily administration. ALC displayed a dose-dependent 
reduction, showing the potential of LC51-0255 as an effective treatment 
for UC. These findings support further evaluation of LC51-0255 in phase 2 
clinical studies to determine the safe and efficacious dose in UC patients.
disclosure: Nothing to disclose
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Introduction: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, 
debilitating inflammatory bowel diseases (IBD). Medications used in the 
treatment of IBD include aminosalicylates, glucocorticoids, immunomod-
ulators, biologics, and small molecules, with each class having distinct 
characteristics a patient may consider. Research into patient preferences in 
IBD indicates that values regarding medical treatment may vary depending 
on the clinical disease phenotype.1-4 The development of a comprehensive 
descriptive system addressing all the meaningful aspects related to the 
management of IBD conditions is of utmost importance to enable a rigor-
ous analysis of patients’ preferences.
aims & Methods: We present a descriptive system that includes the most 
relevant attributes for IBD treatment decision making, focusing on the pa-
tient perspective.
A three-step approach was used to develop the descriptive system. First, 
a literature review was performed and an initial list of attributes was de-
veloped and classified within domains and categories. Second, a focus 
group meeting was conducted with eight patient representatives and nine 
gastroenterologists. Using feedback elicited from the focus group meeting, 
the research team constructed an initial draft of the descriptive system, 
including a subset of domains and attributes. Third, all participants of the 
focus group meeting participated in two-rounds of structured online in-
terviews. The structured interviews were used to refine the wording used 
for naming and defining each attribute and the levels of those attributes in 
the initial descriptive system.
results: We identified 32 eligible publications and a list of 127 attributes 
grouped into 7 domains (effectiveness, side-effects, health related qual-
ity of life [HRQoL], well-being, available evidence, administration/conve-
nience, and other) was developed. This list was discussed in the focus 
group meeting and a draft of the descriptive system containing 16 relevant 
attributes was constructed. 
The same attributes were defined for UC and CD while taking into con-
sideration that the relative weights for each disease may differ. During 
the first round of interviews, patients ranked all attributes included in the 
descriptive system and based on the second round of interviews, the final 
descriptive system containing a total of 3 domains, 10 attributes, and their 
corresponding levels was developed (Table). 
domain attribute name/descriptor
Efficacy
Abdominal pain (8 levels)
Other disease-related pain (8 levels)
Bowel urgency (4 levels)
Fatigue (4 levels)
Complications/
Risk
Risk of cancer and serious infections within the next 10 years (3 levels)
Risk of mild to moderate complications (4 levels)
Aesthetic complications related to treatment (3 levels)
Health related 
quality of life
Emotional status (3 levels)
Sexual life (3 levels)
Social life and relationships (3 levels)
[Table. Final list of attributes]
conclusion: This qualitative research shows which attributes within the 
domains of efficacy, complications/risk, and HRQoL patients value most 
when making treatment decisions. We developed a descriptive system that 
outlines the IBD treatments by means of the 10 most relevant attributes, 
which should be considered by physicians and nurses when discussing 
treatment options with a patient. These attributes will be weighted in a 
future study based on patient preferences.
references: 
1. Bewtra M, Kilambi V, Fairchild AO, Siegel CA, Lewis JD, Johnson 
FR. Patient preferences for surgical versus medical therapy for ulcer-
ative colitis. Inflamm Bowel Dis. 2014 Jan;20(1):103-14. doi: 10.1097/01.
MIB.0000437498.14804.50.
2. Almario CV, Keller MS, Chen M, Lasch K, Ursos L, Shklovskaya J, 
Melmed GY, Spiegel BMR. Optimizing Selection of Biologics in Inflamma-
tory Bowel Disease: Development of an Online Patient Decision Aid Using 
Conjoint Analysis. Am J Gastroenterol. 2018 Jan;113(1):58-71. doi: 10.1038/
ajg.2017.470. Epub 2017 Dec 5.
3. Casellas F, Herrera-de Guise C, Robles V, Navarro E, Borruel N. Patient 
preferences for inflammatory bowel disease treatment objectives. Dig Liver 
Dis. 2017 Feb;49(2):152-156. doi: 10.1016/j.dld.2016.09.009.
4. van Deen WK, Nguyen D, Duran NE, Kane E, van Oijen MG, Hommes DW. 
Value redefined for inflammatory bowel disease patients: a choice-based 
conjoint analysis of patients’ preferences. Qual Life Res. 2017 Feb;26(2):455-
465. doi: 10.1007/s11136- 016-1398-z. Epub 2016 Aug 31.
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ing compared to late/conventional treatment (OR 2.06 [95% CI: 1.35-3.15, 
n=454, P< 0.001]). A subgroup analysis for pediatrics was not feasible, but 
in the adult patient subgroup, the OR for endoscopic healing with early 
treatment was 2.21 (95% CI: 1.34-3.64, n=424, P=0.002).
  early anti-Tnf Treatmenta
Late/conventional 
Treatmenta
Odds ratio 
(95% cI) P value
 
Total 
(n)
Events 
(n)
Event 
rate
Total 
(n)
Events 
(n)
Event 
rate
   
Clinical 
Remissionb
524 341 65.1% 1589 610 38.4%
2.11 
(1.66, 2.68)
<0.001
Disease 
Relapsec
123 32 26.0% 473 227 48.0%
0.31 
(0.14, 0.68)
0.003
Endoscopic 
Healingd
200 108 54.0% 254 92 36.2%
2.06 
(1.35, 3.15)
<0.001
a Early treatment is defined as anti-TNF use <2 years of disease duration or top-down 
treatment strategy; late/conventional treatment is defined as anti-TNF use after >2 years 
of disease duration or conventional step-up treatment strategy b Definition of clinical 
remission: 3 studies used CDAI<150; 1 study used CDAI<150 plus no bowel resection 
and no steroid use; 2 studies used PCDAI≤10; 1 study used corticosteroid free remission 
c Definition of disease relapse: 1 study used increase in CDAI≥70 and an absolute 
CDAI>220; 3 studies used PCDAI>10 d Definition of endoscopic healing: 2 studies used 
SES-CD=0; 1 study used CDEIS<4 and absence of deep ulcers; 1 study used absence 
of any mucosal ulcers (including aphthous ulcers); 1 study used absence of mucosal 
ulceration; 1 study used disappearance of ulcerations, multiple erosions, bleeding and 
friability (grade 0 or 1) CDAI: Crohn‘s Disease Activity Index; PCDAI: Pediatric Crohn‘s 
Disease Activity Index; SES-CD: Simple Endoscopic Score for Crohn‘s Disease; CDEIS: 
Crohn‘s Disease Endoscopic Index of Severity
Table. Results of meta-analysis on clinical remission, relapse and endoscopic 
healing with early anti-TNF treatment versus late or conventional treatment 
in Crohn’s disease
conclusion: Early use of anti-TNF in CD patients is associated with im-
proved outcomes in clinical remission, disease relapse, and endoscopic 
healing compared to late/conventional treatment.
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Introduction: There is an unmet need for safe and effective treatment op-
tions for patients with moderate to severe ulcerative colitis (UC) who have 
intolerance to, experience an inadequate response to, or relapse of the cur-
rent recommended treatments. Many patients experience infusion or injec-
tion site reactions with biologic therapies, and immunomodulators increase 
malignancy risk, highlighting the need for new safe oral alternatives. 
Although cyclosporine (CsA) has similar safety and efficacy to infliximab 
for acute severe UC management, its use is limited due to its serious sys-
temic side effects (SSE). Sublimity has developed ST-0529, an oral formu-
lation of CsA with a diffusion-controlled mechanism of release that deliv-
ers CsA directly to diseased tissue of the ileum and colon, thereby reducing 
systemic absorption, and potentially minimising the risk of SSE and the 
need for extensive drug monitoring.
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P0409 effIcacy Of earLy anTI-TuMOr necrOsIs facTOr 
TreaTMenT In aduLT and PedIaTrIc PaTIenTs WITh crOhn’s 
dIsease: a sysTeMaTIc revIeW and MeTa-anaLysIs
Ungaro R.1, Aggarwal S.2, Topaloglu O.2, Lee W.-J.3, Clark R.3, 
Colombel J.-F.1
1Icahn School of Medicine at Mount Sinai, New York, United States, 2NOVEL 
Health Strategies, Bethesda, United States, 3AbbVie Inc., Health Economics 
and Outcomes Research, North Chicago, United States
contact e-Mail address: jean-frederic.colombel@mssm.edu
Introduction: There is an increasing body of evidence supporting earlier 
use of anti-tumor necrosis factor (anti-TNF) agents to improve outcomes 
and change the natural course of Crohn’s disease (CD). The objective of 
this study was to perform a meta-analysis to assess the impact of early 
anti-TNF use in the treatment of CD.
aims & Methods: The PubMed and Embase databases were searched for 
English language papers and conference abstracts published through 31 
December 2017. Studies were selected for inclusion if patients initiated 
anti-TNFs within 2 years of a CD diagnosis or if anti-TNFs were used before 
or with immunosuppressants (top-down) in clinical trials and retrospec-
tive observational studies based on PRISMA guidelines. Random-effects 
meta-analyses were conducted to compare clinical remission (including 
steroid-free remission), disease relapse and endoscopic healing rates with 
early anti-TNF treatment (< 2 years of disease duration or top-down treat-
ment strategy) to late/conventional treatment (defined as biologic use after 
>2 years of disease duration or conventional step-up treatment strategy in 
recently diagnosed patients).
results: A total of 3,061 records were identified, of which 39 references met 
the selection criteria for systematic review. The meta-analysis included 14 
studies that reported comparative remission, relapse and endoscopic heal-
ing rates for early vs late/conventional anti-TNF treatment. Early vs. late/
conventional anti-TNF use was more likely to result in clinical remission 
or steroid-free remission, with an odds-ratio (OR) of 2.11 (95% CI: 1.66-
2.68, n=2,113, P< 0.001). The positive results were observed in both adult 
(OR 1.97 at week 26 [95% CI: 1.53-2.53, n=803, P< 0.001]) and pediatric 
subgroups (OR 3.07 at week 52 [95% CI: 1.59-5.94, n=217, P< 0.001]). Con-
versely, early treatment with anti-TNFs was associated with reduced risk 
of relapse compared to late/conventional treatment, with an OR of 0.31 
(95% CI: 0.14-0.68, n=596, P=0.003). A subgroup analysis for adults was 
not feasible, however in the pediatric patient subgroup, the OR for re-
lapse with early treatment was 0.18 (95% CI: 0.07-0.43, n=105, P< 0.001). 
Early anti-TNF treatment was also more likely to result in endoscopic heal-
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aims & Methods: Two phase 1 and one phase 2 studies have been com-
pleted with ST-0529.[1] Phase 1 results showed that ST-0529 (dose range 
37.5-150 mg) achieves similar or higher colonic tissue concentrations of 
CsA and significantly lowers systemic CsA levels compared to continuous IV 
CsA in healthy subjects.[2],[3] Phase 2a pilot results confirmed safety of ST-
0529 75 mg once-daily in patients with mild or moderate UC after 4 weeks 
of treatment and showed a numerical increase in rates of remission and 
response with ST-0529 compared to placebo, although not statistically sig-
nificant. Post-hoc analysis found that compared to placebo, patients with 
moderate disease (35% vs 17%, p=0.0499) and moderate disease taking 
concomitant 5-aminosalicylate and/or steroids without immunosuppres-
sives (47.8% vs 17.9%, p=0.026) did significantly better on ST-0529.[4] To 
further investigate ST-0529 in UC, a phase 2b, multicentre, randomised, 
double-blind, placebo-controlled, parallel-group study will evaluate ef-
ficacy, safety and tolerability of ST-0529 in achieving clinical remission in 
subjects with moderate to severe UC. This study will also characterise the 
pharmacokinetic (PK) and pharmacodynamic (PD) profile of ST-0529 as 
well as its impact on quality of life in subjects with UC. Key inclusion cri-
teria will include a diagnosis of histologically confirmed moderate to se-
vere UC for ≥3 months defined as 3-Component Mayo Score (Mayo) of 5-9. 
Approximately 280 subjects are planned to be enrolled (40 are targeted 
for participation in a PK sub-study), randomised 1:1:1:1 (dosage regimen 
in table 1). Randomisation will be stratified according to disease sever-
ity as assessed by Mayo, prior treatment with anti-TNF therapy and corti-
costeroid use. The primary efficacy outcome will be clinical remission at 
week 12, defined as stool frequency subscore ≤1 associated with a decrease 
≥1-point, rectal bleeding subscore 0, and an endoscopic subscore ≤1 using 
Mayo. Rectal bleeding and stool frequency subscores will be calculated 
from data collected in subject diaries and endoscopic subscore provided 
by a central reader.
results: 
 
sT-0529 
dosage 1 
(n=70)
sT-0529 
dosage 2 
(n=70)
sT-0529 
dosage 3 
(n=70)
Placebo 
(n=70) 
Dosage 
regimen
18.75 mg 
twice-daily, oral 
(capsule)
37.5 mg 
twice-daily, oral 
(capsule)
75 mg 
twice-daily, oral 
(capsule)
To match 
ST-0529 dose 
twice-daily, oral 
(capsule)
Treatment 
duration
12 weeks
PK sub-study
Whole blood samples being collected at Week 2 at 0 (pre-dose), 
and at 2, 4, 6, and 8 hours post-dose (n=40)
[Table 1: Phase 2b trial overview - Test product (ST-0529) and comparator 
(placebo)]
conclusion: Orally administered ST-0529 represents a novel approach to 
attaining therapeutically relevant tissue concentrations of CsA in the colon 
and may offer an alternative for inadequate clinical response to tradition-
al therapies. The results from this trial will help identify the appropriate 
dose(s) of ST-0529 for use in phase 3 clinical studies.
references: [1]O’Donoghue D, Bloom S, Coulter I. Colon targeted, low sys-
temic absorption soluble ciclosporin in ulcerative colitis. Gut. 2013;62(Sup-
pl 2):A1.3-A2. doi:10.1136/gutjnl-2013-305143.3. 
[2]Colombel J, Coulter I, Hall J, Rosa M, McDonald B, Cullen A. P053 Tar-
geted release oral cyclosporine formulation as a potential new therapy 
for ulcerative colitis. Gastroenterology. 2019;156(3):S37-S38. doi:10.1053/j.
gastro.2019.01.109.
[3]Colombel J, Coulter I, Hall J, Rosa M, McDonald B, Cullen A. P053 Target-
ed release oral cyclosporine formulation as a potential new therapy for ul-
cerative colitis. Inflamm Bowel Dis. 2019;25(Suppl 1):S26-S26. doi:10.1093/
ibd/izy393.059.
[4]Bloom S, Iqbal T, Nwokolo C et al. OP16 A randomised, multi-centre, 
double-blind, placebo-controlled study of a targeted release oral cyclo-
sporine formulation in the treatment of mild-to-moderate ulcerative 
colitis: efficacy results. Journal of Crohn’s and Colitis. 2019;13(Suppl 1):S011-
S011. doi:10.1093/ecco-jcc/jjy222.015.
disclosure: Peter Gardzinski, Bruce Dzyngel, and Jesse Hall are employees 
and shareholders in Sublimity Therapeutics Inc. 
P0411 huMan adIPOse MesenchyMaL sTeM ceLLs MOduLaTe 
MyeLOId ceLLs TOWards an anTI-InfLaMMaTOry and 
reParaTIve PhenOTyPe: rOLe Of IL-6 and Pge2
Ortiz-Virumbrales M.1, Menta R.1, Mancheño-Corvo P.1, 
Avivar-Valderas Á.1, Herrero A.1, Dalemans W.2, de la Rosa O.1, 
Lombardo E.1
1Takeda Madrid, Cell Therapy Technology Center, Madrid, Spain, 2TiGenix NV, 
Leuven, Belgium
contact e-Mail address: maitane.ortiz@takeda.com
Introduction: Mesenchymal stem cells (MSCs) are the focus of intensive 
efforts directed towards developing cell-based therapies in immunologic 
disorders.1,2 MSCs have been shown to activate the endogenous immune 
regulatory system of the recipient to induce a therapeutic effect.1,2 Dar-
vadstrocel (DVS) is an expanded, allogeneic, adipose-derived MSC (ASC) 
therapy approved in Europe5,6 and Israel for the management of treatment-
refractory complex perianal fistula (CPAF) in patients with inactive or mild-
ly active Crohn’s disease (CD)3,4. DVS has been shown to have long-term 
success rates comparable with existing medical and surgical therapies for 
CPAF.3,4 
The mechanism of action of DVS is only partially understood.3,4 It has been 
suggested that MSCs can modulate phenotype and function of monocytes 
via prostaglandin E2 (PGE2) and interleukin 6 (IL-6) during their differen-
tiation to macrophages (Mphs) and dendritic cells.7,8,9
aims & Methods: To characterise the modulatory effect of DVS on human 
myeloid cells in vitro.
Freshly isolated human monocytes from peripheral blood were differen-
tiated in vitro towards M0 Mphs, M1 pro-inflammatory Mphs, M2 anti-
inflammatory Mphs or mature dendritic cells (mDCs) in the presence or 
absence of DVS in non-contact conditions. The phenotype and function 
of the differentiated Mphs and dendritic cells were determined by flow 
cytometry, and their secretome (sets of secreted proteins) was assessed 
by Olink technology (a proteomic analysis system based on the Proximity 
Extension Assay). The role of the soluble factors PGE2 and IL-6 was inves-
tigated using neutralisation assays.
results: The co-culture of monocytes in the presence of DVS during their 
differentiation to Mphs or mDCs resulted in polarisation towards an anti-
inflammatory and phagocytic phenotype. This was characterised by an 
increased expression of phagocytic receptors and modulation of surface 
chemokine receptors, a reduced expression of co-stimulatory and acti-
vation molecules, and a decrease in the amount of cell debris present. 
Additionally, the morphology of M1 and M2 Mphs was modulated when 
differentiated in the presence of DVS. DVS promoted an elevation of se-
creted factors with anti-inflammatory, reparative and antimicrobial func-
tions. DVS appeared, therefore, to be able to modulate monocyte cells 
towards an anti-inflammatory and reparative phenotype through secretion 
of soluble factors. Chemical inhibition of PGE2 with indomethacin resulted 
in complete neutralisation of the modulatory effect of DVS on mDC phe-
notype, whereas inhibition of IL-6 resulted in only a minor reduction of 
DVS-mediated modulation. The data indicate that PGE2 and IL-6 are the 
main soluble factors responsible for this modulatory effect.
conclusion: The results demonstrate a mechanism of the DVS-mediated 
induction of anti-inflammatory and reparative phenotypes that potentially 
modulates monocyte/Mph/mDC differentiation. The modulatory effects of 
DVS on human myeloid cells are mediated by PGE2, and to a lesser extent, 
IL-6 examined on mDCs.
references: 1. Uccelli A, Prockop DJ. Curr Opin Immunol 2010;22:768-774. 
2. English K, Wood KJ. Cold Spring Harb Perspect Med 2013;3:a015560. 3. 
Panés J, et al. Lancet 2016;388:1281-1290. 4. Panés J, et al. Gastroenterol-
ogy 2018;154:1334-1342.e4. 5. European Medicines Agency (EMA) Commit-
tee For Medicinal Products For Human Use. Alofisel, INN-darvadstrocel 
EPAR Annex I Summary of Product Characteristics. (2018). http://www.ema.
europa.eu. Accessed: April 2019. 6. Swiss Agency for Therapeutic Prod-
ucts. www.swissmedic.ch. Accessed: April 2019. 7. Kondo M, et al. Arthritis 
Rheumatol 2015;67:1250-1260. 8. Hwa Ko, J, et al. Proc Natl Acad Sci USA 
2016;113:158-163. 9. Prockop DJ, Youn Oh J. Mol Ther 2012;20:14-20.
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the Table. In the Induction and Maintenance Cohorts, 2 pts had DVT and 2 
had PE; all had received placebo in the study. In the Overall Cohort, there 
was 1 pt with DVT and 4 pts with PE; all 5 pts had received PD of tofacitinib 
10 mg BID and all events occurred during the OLE study. Pts with PE had 
the following notable medical history: 1 with prior DVT and PE, 1 with 
phlebothrombosis and stroke, 1 was receiving oral contraceptives for dys-
functional uterine bleeding, and 1 had cholangiocarcinoma and metasta-
ses to the peritoneum, and PE was the cause of death. The pt with DVT was 
diagnosed following a long-haul flight and management of an infected leg 
wound sustained in a recent motorbike accident.
conclusion: In this post-hoc analysis of pts from the OCTAVE programme, 
during tofacitinib exposure, 4 pts had PE and 1 pt had DVT. All of the events 
in pts taking tofacitinib occurred during the OLE study in pts treated with 
PD of tofacitinib 10 mg BID (83% of pts in the Overall Cohort received a PD 
of tofacitinib 10 mg BID) and with risk factors for thrombotic events. This 
post-hoc analysis is limited by small sample size and limited drug expo-
sure, and further study is needed.
references: 
1. Sandborn WJ et al. N Engl J Med 2012; 367: 616-624.
2. Sandborn WJ et al. N Engl J Med 2017; 376: 1723-1736.
3. Lichtenstein GR et al. Am J Gastroenterol 2018; 113 (Suppl 1): Abstract 571.
4. Weng MT et al. Inflamm Bowel Dis 2018; 24: 1791-1800.
5. Bernstein CN et al. Thromb Haemost 2001; 85: 430-434.
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Rheos, Seres, Synergy, Takeda, TARGET PharmaSolutions, Theravance 
Biopharma R&D, TiGenix,Vivelix; and other fees from WebMD (honoraria 
for CME program).W Reinisch: research support and consultancy/advisory 
board/speaker’s bureau fees from Abbott, AbbVie, Aesca, Centocor, MSD; 
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Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibi-
tor for the treatment of ulcerative colitis (UC). The safety of tofacitinib for 
the treatment of moderate to severe UC was evaluated in a randomised, 
placebo-controlled Phase (P) 2 induction study (NCT00787202),1 2 induc-
tion P3 studies (NCT01465763; NCT01458951), 1 maintenance P3 study 
(NCT01458574),2 and an ongoing, open-label, long-term extension (OLE) 
study (NCT01470612).3 A safety signal for pulmonary embolism (PE) was 
seen in the tofacitinib 10 mg twice daily (BID) arm of an FDA post-mar-
keting requirement study in rheumatoid arthritis designed to evaluate the 
long-term risk of major cardiovascular events and malignancy. Patients 
(pts) eligible for this ongoing, open-label, safety-endpoint-driven study 
had to be ≥50 years of age, have ≥1 cardiovascular risk factor and be on 
a stable dose of methotrexate. UC is a known risk factor for deep vein 
thrombosis (DVT) and PE, with reported incidence rates ranging from 0.07 
to 0.30 and 0.04 to 0.20, respectively.4,5 Here, we report the incidence of 
DVT and PE in the tofacitinib UC clinical programme, as of Sep 2018.
aims & Methods: Pts who received placebo, tofacitinib 5 or 10 mg BID were 
analysed in three cohorts: Induction (P2/P3 induction studies, N=1220), 
Maintenance (P3 maintenance study, N=592) and Overall (pts receiving 
tofacitinib 5 or 10 mg BID in P2, P3 or ongoing OLE studies, N=1157). DVT 
and PE events were identified using preferred terms in the Standardised 
Medical Dictionary for Regulatory Activities query ‘embolic and thrombotic 
events, venous’ and incidence rates (unique pts with events per 100 pt-
years [PY] of exposure) were evaluated. For Overall Cohort analysis, pts 
were categorised based on the average daily dose of tofacitinib: predomi-
nant dose (PD) tofacitinib 5 mg BID (average total daily dose < 15 mg) and 
PD tofacitinib 10 mg BID (average total daily dose ≥15 mg).
 
Induction cohort
(8 weeks)a
Maintenance cohort
(52 weeks)a
Overall cohort
(≤6.1 years)a,b
 
Placebo
(N=282; 
44.8 PY)
Tofacitinib 
10 mg 
BID
(N=938; 
156.2 PY)
Placebo
(N=198; 
100.4 
PY)
Tofacitinib 
5 mg BID
(N=198; 
146.2 PY)
Tofacitinib 
10 mg BID
(N=196; 
154.3 PY)
PD 
Tofacitinib 
5 mg BID
(N=197; 
595.5 PY)
PD 
Tofacitinib 
10 mg BID
(N=960; 
1801.1 PY)
Tofacitinib 
All
(N=1157; 
2403.6 PY)
DVT, n 
(%),
IR 
[95% CI]
1 (0.4), 
1.99 
[0.05, 
11.07]
0 (0.0), 
0.00 
[0.00, 
2.22]
1 (0.5), 
0.97 
[0.02, 
5.39]
0 (0.0), 
0.00 
[0.00, 
2.48]
0 (0.0), 
0.00 
[0.00, 
2.35]
0 (0.0), 
0.00 
[0.00, 
0.61]
1 (0.1),c 0.05 
[0.00, 
0.30]
1 (0.1), 
0.04 
[0.00, 
0.23]
PE, n 
(%),
IR 
[95% CI]
1 (0.4), 
1.98 
[0.05, 
11.04]
0 (0.0), 
0.00 
[0.00, 
2.22]
1 (0.5), 
0.98 
[0.02, 
5.44]
0 (0.0), 
0.00 
[0.00, 
2.48]
0 (0.0), 
0.00 
[0.00, 
2.35]
0 (0.0), 
0.00 
[0.00, 
0.61]
4 (0.4),d 
0.21 
[0.06,
 0.55]
4 (0.3), 
0.16 
[0.04, 
0.41]
For Overall Cohort analysis, pts were categorised based on the average daily dose of tofacitinib 
(placebo exposure was not included): PD tofacitinib 5 mg BID (average total daily dose <15 mg) and PD 
tofacitinib 10 mg BID (average total daily dose ≥15 mg)
aExcluding events occurring after 28 days from the last dose of the corresponding cohort; bData are as 
of Sep 2018 (OLE study database not locked); cDVT event occurred in 1 pt (58 years of age at DVT event) 
1149 days following the first dose of tofacitinib; dPE events occurred in 1 pt (25 years of age at PE event) 
with prior DVT and PE, 216 days following the first dose of tofacitinib; 1 pt (57 years of age at PE event) 
with prior phlebothrombosis and stroke, 236 days following the first dose of tofacitinib; 1 pt (70 years 
of age at PE event) with cholangiocarcinoma and metastases to the peritoneum, 383 days following the 
first dose of tofacitinib; and 1 pt (21 years of age at PE event) who was receiving oral contraceptives for 
dysfunctional uterine bleeding, 569 days following the first dose of tofacitinib
BID, twice daily; CI, confidence interval; DVT, deep vein thrombosis; IR, incidence rate; N, number of 
patients; n, unique number of patients with a particular adverse event; OLE, open-label, long-term 
extension; PD, predominant dose; PE, pulmonary embolism; pts, patients; PY, patient-years
[Table. Incidence rates (unique pts with event per 100 PY of exposure) of DVT 
and PE among pts in the Induction, Maintenance and Overall Cohorts]
results: The Overall Cohort comprised 1157 pts who received ≥1 dose of 
tofacitinib 5 or 10 mg BID, with 2404 PY of tofacitinib exposure and up to 
a maximum of 6.1 years of treatment. Results for DVT and PE are shown in 
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P0413 cLInIcaL reMIssIOn deMOnsTraTed WITh OraL 
OzanIMOd In The OveraLL POPuLaTIOn and acrOss MuLTIPLe 
suBgrOuPs Of PaTIenTs WITh MOderaTeLy TO severeLy acTIve 
uLceraTIve cOLITIs In The TOuchsTOne TrIaL
Feagan B.G.1, Sandborn W.J.2, D’Haens G.R.3, Hanauer S.B.4, Wolf D.C.5, 
Vermeire S.6, Ghosh S.7, Petersen A.8, Hua S.Y.8, Shan K.8, Liu J.8
1Robarts Clinical Trials Inc., Gastroenterology, London, Canada, 2University 
of California, San Diego, United States, 3AMC Amsterdam Inflammatory 
Bowel Disease Centre - Academic Medical Center, Amsterdam, Netherlands, 
4Feinberg School of Medicine, San Diego, United States, 5Atlanta 
Gastroenterology Associates, Atlanta, United States, 6University Hospital 
Leuven, Gastroenterology, Leuven, Belgium, 7University of Leuven, Leuven, 
Belgium, 8Celgene Corp, Summit, United States
contact e-Mail address: brian.feagan@robartsinc.com
Introduction: Ozanimod is an oral immunomodulator that selectively tar-
gets S1P
1
 and S1P
5
. TOUCHSTONE, a randomised, double-blind, placebo-
controlled phase 2 trial that evaluated patients with moderately to severely 
active ulcerative colitis (UC) showed significantly higher rates of clinical 
remission, clinical response, and endoscopic mucosal healing (Mayo en-
doscopic subscale score of 0/1) at Weeks 8 and 32 in patients assigned to 
ozanimod 1 mg compared to those who received placebo (Sandborn NEJM 
2016). The objective of this analysis was to assess clinical remission at 
Week 32 across subgroups of interest.
aims & Methods: Patients were randomised 1:1:1 and received ozanimod 1 
mg, ozanimod 0.5 mg, or placebo. Mayo score, based on stool frequency, 
rectal bleeding, mucosal appearance at endoscopy, and physician rating 
of disease activity, was calculated at baseline, end of induction (Week 8), 
and end of maintenance (Week 32). Clinical remission was defined as total 
Mayo score ≤2, with no subscore >1. A post hoc sub-group analysis evalu-
ated clinical remission rates at Week 32 according to baseline Mayo score, 
years since UC diagnosis, and body mass index (BMI).
results: A total of 197 patients were randomised and received ozanimod 1 
mg (n=67), 0.5 mg (n=65), or placebo (n=65), with 103 (52.3%) entering a 
maintenance period based on response criteria (ozanimod 1 mg, n=42; 0.5 
mg, n=36; placebo, n=25), and 91 (88.3%) completing the study. Differenc-
es in the proportion of patients in clinical remission with ozanimod 1 mg 
versus placebo by subgroup illustrate that the treatment effect favoured 
ozanimod 1 mg in every subgroup analysed (Table). 
The 95% confidence intervals for the treatment difference between ozani-
mod 1 mg and placebo exclude 0 for the overall population and subgroups 
of baseline Mayo score >8, years since UC diagnosis >6, and BMI <25 
kg/m2.
 
Treatment difference 
in Week 32 remission 
rate (Ozanimod 1mg vs 
placebo) 
95% confidence 
Limits
    Lower Upper
Clinical Remission at Week 32 
Overall 16.23% 4.67% 27.80%*
Baseline Mayo score (≤8) 14.35% -4.20% 32.89%
Baseline Mayo score (>8) 18.18% 5.02% 31.34%*
Years of UC diagnosis at baseline (≤6) 12.90% -0.07% 25.87%
Years of UC diagnosis at baseline (>6) 23.48% 1.10% 45.87%*
BMI at baseline (≥25 kg/m2) 15.44% -2.10% 32.98%
BMI at baseline (<25 kg/m2) 16.82% 1.41% 32.23%*
BMI: body mass index; ITT: intent-to-treat; NRI: non-responder imputation; UC: 
ulcerative colitis. *P<0.05.
[Clinical Remission at Week 32 by Subgroup of Interest (ITT, NRI)]
conclusion: In the TOUCHSTONE trial, ozanimod therapy was consistently 
more efficacious than placebo for induction of clinical remission across a 
wide range of patient subtypes including those with relatively long disease 
duration and high disease activity.
references: Sandborn WJ, Feagan BG, Wolf DC, D’Haens G, et al. Ozanimod 
induction and maintenance treatment for ulcerative colitis. N Engl J Med. 
2016;374(18):1754-1762.
disclosure: Brian G. Feagan: AbbVie, ActoGeniX, Albireo, Amgen, As-
traZeneca, Avaxia Biologics, Baxter, Biogen Idec, Boehringer Ingelheim, 
BMS, Calypso, Celgene, Elan, EnGene, Ferring Pharma, Roche/Genentech, 
GiCare, Gilead, Given Imaging, GSK, Ironwood, Janssen, Johnson & John-
son, Lexicon, Lilly, Merck, Millennium, Nektar, Novo Nordisk, Pfizer, Pro-
metheus, Protagonist, Celgene, Sanofi, UCB - consultant; Robarts Clinical 
Trials - director. 
P0414 LOng-TerM effIcacy and safeTy Of uPadacITInIB 
TreaTMenT In PaTIenTs WITh crOhn’s dIsease: One-year 
resuLTs Of The OngOIng Phase 2 ceLesT OPen-LaBeL 
exTensIOn sTudy
D’Haens G.1, Panes J.2, Louis E.3, Zhou Q.4, Pugatch D.4, Liu J.4, Lacerda A.4, 
Loftus Jr. E.V.5
1Amsterdam University Medical Center, Amsterdam, Netherlands, 2Hospital 
Clínic Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 3CHU de Liège et 
Université de Liège, Liège, Belgium, 4AbbVie Inc., Chicago, United States, 
5Mayo Clinic, Rochester, United States
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Introduction: Upadacitinib (UPA), an oral selective Janus kinase 1 inhibi-
tor, demonstrated clinical and endoscopic efficacy and a favourable safety 
profile as induction and maintenance treatment in patients with moderate 
to severe Crohn’s disease (CD).1,2
aims & Methods: To report the 1-year efficacy and safety results of UPA 
long-term treatment in the ongoing CELEST open-label extension (OLE) 
study.
Patients who completed the 52-week CELEST study2, either receiving dou-
ble-blind or open-label rescue treatment during CELEST, were enrolled to 
receive the once daily (QD) UPA modified release formulation for up to 8 
years; patients on double-blind therapy received 15 mg QD and those on 
open-label rescue therapy received 30 mg QD. Clinical remission 2.8/1.0, 
enhanced clinical response, CD activity index (CDAI) remission, CDAI re-
sponse 70, endoscopic remission, endoscopic response 50%, Inflamma-
tory Bowel Disease Questionnaire (IBDQ) remission, and change from 
baseline (BL) in C-reactive protein and faecal calprotectin, as defined in 
the table, were analysed at Week 0 to Month 12 (Table). 
Missing data were imputed via last observation carried forward; ob-
served-case analysis was done for the endoscopic endpoints. Adverse 
events (AEs) were collected throughout the study up to 30 days after the 
last UPA dose.
results: Of 107 patients enrolled, 76 received 15 mg QD and 31 received 30 
mg QD, with median (range) age of 40 (19, 76) years and disease duration 
10.4 (1.4, 47.4) years. At Week 0, the mean (SD) UPA exposure was 303.0 
(108.8) days. Overall, the number of patients with clinical remission, clini-
cal response, endoscopic remission, endoscopic response, and reporting 
IBDQ remission was maintained from Week 0 to Month 12 (Table). 
Incidences of AEs were 75.0% and 83.9% for UPA 15 and 30 mg QD 
groups, respectively. AEs leading to discontinuation of study drug were 
6.6% in the UPA 15 mg and 19.4% in the UPA 30 mg QD groups. Serious 
AEs occurred in patients receiving UPA 15 mg QD (10.5%) and UPA 30 mg 
QD (12.9%). 
The most frequently reported serious AE (4.7%) and AE leading to study 
drug discontinuation (4.7%) was CD. One case of serious infection was 
reported in each of the UPA treatment groups. Herpes zoster was reported 
in patients receiving UPA 15 mg QD (1.3%, n=1) and UPA 30 mg QD (6.5%, 
n=2). One case of malignancy (basal cell carcinoma) occurred in the UPA 
15 mg QD group and one case of latent tuberculosis in the UPA 30 mg 
group. 
No cases of opportunistic infection, thromboembolic event, or death were 
reported. 
conclusion: The 1-year efficacy of UPA observed after induction and main-
tenance was sustained in patients with CD. No new safety signals were 
identified.
references: 
1. Sandborn WJ, et al. Gastroenterology. 2017;152(5 Suppl 1):S1308-S1309.
2. Panes J et al. Journal of Crohn’s and Colitis. 2018; 12(S1):S238-S239.
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P0415 TheraPeuTIc InTensIfIcaTIOn In PaTIenTs WITh 
InfLaMMaTOry BOWeL dIsease - a cOMParIsOn Of dIfferenT 
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Introduction: The loss of response to biologic therapies in Inflammatory 
Bowel Disease (IBD) is common. Treatment intensification may be helpful 
in regaining response in up to 1/3 of patients. To date, there have been 
no studies comparing the need for escalation between different biological 
therapies.
aims & Methods: To compare the need and predictors of therapy escala-
tion in Crohn’s Disease (CD) and Ulcerative Colitis (UC). This was a retro-
spective cohort single center study including patients under maintenance 
therapy with Infliximab (IFX), Adalimumab (ADA), Golimumab (GLB) or 
Vedolizumab (VDZ). Patients with at least 2 years of follow-up were in-
cluded. Non-responders and patients with treatment interruption prior to 
the need of escalation were excluded.
results: 344 patients were included: 258 with CD and 86 with UC; 51,7% 
were male with mean age of 43,6±13 years. IFX: 229 (180 CD, 49 UC), ADA: 
74 (62 CD, 12 UC), GLB: 14 (all UC) and VDZ: 27 (16 CD, 11 UC). In general, the 
need for treatment escalation was superior in UC (Log Rank test, p=0.001). 
In UC, therapeutic escalation in GLB patients was less frequent than IFX 
patients (p=0.035). For CD we could not find a difference in the need of es-
calation between drugs. In multivariate analysis age, gender, localization 
and behavior of the disease and combo therapy weren’t predictors of the 
need of drug escalation during the two years of follow-up, independently 
of the biologic therapy used.
conclusion: Therapeutic intensification is more frequent and occurs earlier 
in patients with UC, regardless of the treatment used.
disclosure: Nothing to disclose 
P0416 usTekInuMaB MaInTaIned cLInIcaLLy MeanIngfuL 
IMPrOveMenT In heaLTh-reLaTed quaLITy Of LIfe In PaTIenTs 
WITh MOderaTe TO severe crOhn’s dIsease: resuLTs frOM The 
IM-unITI LOng-TerM exTensIOn
Sands B.E.1, Han C.2, Gasink C.3, Zou B.4, Targan S.5, Sandborn W.J.6, 
Feagan B.G.7
1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New 
York, United States, 2Janssen Global Services, LLC, Malvern, United States, 
3Janssen Scientific Affairs, LLC, Horsham, United States, 4Janssen Research 
& Development, LLC, Spring House, United States, 5Cedars-Sinai Med Ctr, Los 
Angeles, United States, 6University of California, San Diego, United States, 
7Robarts Clinical Trials Inc., Gastroenterology, London, Canada
contact e-Mail address: bruce.sands@mssm.edu
Introduction: The IM-UNITI study evaluated the safety and efficacy of sub-
cutaneous (SC) ustekinumab (UST) maintenance therapy in patients with 
moderately to severely active Crohn’s disease (CD) who completed induc-
efficacy endpoints uPa 15 mg qd uPa 30 mg qd
Clinical remission 2.8/1.0, n/N (%)a 
Week 0
Month 12
40/71 (56.3)
38/60 (63.3)
16/28 (57.1)
16/28 (57.1)
Enhanced clinical response, n/N (%)a 
Week 0
Month 12
59/76 (77.6)
51/63 (81.0)
24/31 (77.4)
23/31 (74.2)
CDAI remission, n/N (%)a 
Week 0
Month 12
49/76 (64.5)
41/63 (65.1)
20/31 (64.5)
18/31 (58.1)
Endoscopic remission, n/N (%)b 
Week 0
Month 12
20/69 (29.0)
22/43 (51.2)
7/28 (25.0)
10/20 (50.0)
Endoscopic response 50%, n/N (%)b 
Week 0
Month 12
39/69 (56.5)
29/43 (67.4)
15/28 (53.6)
15/20 (75.0)
IBDQ remission, n/N (%)a 
Week 0
Month 12
43/76 (56.6)
41/62 (66.1)
15/28 (53.6)
14/30 (46.7)
Change in hs-CRP from baseline to 
Month 12, mg/L, Median (range)a 
Week 0
Month 12
-4.2 (-88.4, 169.0)
-2.710 (-81.0, 33.3)
-9.9 (-93.6, 61.4)
-7.2 (-93.7, 135.0)
Change in FCP from baseline to Month 
12, mcg/g, Median (range)a 
Week 0
Month 12
-680.0 (-9560, 2621)
-650.0 (-9590, 7971)
-438.5 (-6770, 5391)
-615.0 (-7549, 3800)
aLast observation carried forward analysis; bObserved cases analysis; cBaseline (BL) of the 
CELEST study
For the LOCF analysis, any missing data was mainly due to (1) discontinuation, (2) missing visit 
(3) loss of data due to technical reason, e.g., ePro malfunction. During the study, subjects who 
met the criteria for inadequate response were allowed to dose escalate from 15 mg QD to 30 
mg QD. In the 15 mg QD group, these subjects (N=15) were removed from the 15 mg QD analysis 
after dose escalation visit.
UPA=upadacitinib; QD=once daily; CDAI=Crohn‘s disease activity index; CR=CDAI response; 
IBDQ= Inflammatory Bowel Disease Questionnaire; hs-CRP=high sensitivity C-reactive protein; 
FCP=faecal calprotectin
Clinical remission 2.8/1.0: very soft/liquid stool frequency (SF) ≤2.8 and abdominal pain (AP) 
score ≤1.0, both not worse than BL in patients with SF≥4 or AP score ≥2.0 at BL of CELEST study 
Enhanced clinical response: ≥60% reduction from BL in SF or ≥35% reduction from BL in AP 
and both not worse than BL of CELEST study 
CDAI remission: CDAI <150 
Endoscopic remission: Simplified Endoscopic Score for CD (SES-CD) ≤ 4 and at least 2-point 
reduction from BL of CELEST study and no subscore >1 
Endoscopic response 50%: SES-CD reduction >50% from BL of CELEST study or endoscopic 
remission 
IBDQ remission: IBDQ ≥170
[Clinical and endoscopic endpoints at Week 0 and Month 12 in the CELEST 
OLE study]
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tion treatment with UST. Previously, we reported the effects of UST on 
health-related quality of life (HRQoL) through Wk44. Here, we evaluated 
HRQoL through Wk140 in patients who entered the long-term extension of 
the IM-UNITI study.
aims & Methods: Patients who completed the safety and efficacy evalua-
tion at Wk44 of the maintenance study were eligible to continue their regi-
men in the extension study (placebo [PBO], UST 90 mg q12w, or UST 90 mg 
q8w). All patients who were treated in the extension study were included 
in this analysis of Inflammatory Bowel Disease Questionnaire (IBDQ) and 
SF-36 data according to the treatment they received during the extension 
study. The IBDQ is a 32-item questionnaire with 4 dimensions: bowel 
symptoms, systemic symptoms, emotional function, and social function. 
The total score ranges from 32 to 224, higher scores indicate better quality 
of life, and a change ≥16 points was defined as clinically meaningful. For 
SF-36, a change ≥5 points was defined as clinically meaningful.
results: For patients who entered the extension, mean total IBDQ scores 
and SF-36 scores at maintenance baseline were comparable across treat-
ment groups (Table). Patients who received UST maintained the improve-
ment in IBDQ and SF-36 that was achieved by maintenance baseline 
through Wk140, and those who received PBO generally worsened. Through 
Wk140, 26.5% of patients receiving PBO, 61.5% of patients receiving UST 90 
mg q12w, and 59.3% of patients receiving UST 90 mg q8w had ≥16-point 
improvements from induction baseline in IBDQ score. In addition, 10.9%, 
51.6%, and 54.2%, respectively, had ≥5-point improvements in SF-36 
physical component summary scores, and 8.7%, 43.8%, and 43.7%, re-
spectively, had ≥5-point improvements in SF-36 mental component sum-
mary scores during the same period.
conclusion: In patients who entered the long-term extension of the IM-
UNITI study, those who received SC UST maintenance generally maintained 
improvements in IBDQ and SF-36 scores that were achieved through IV in-
duction, and those who received PBO gradually lost these improvements.
Outcome Placebo sc ustekinumab 90 mg sc q12w
ustekinumab 
90 mg sc 
q8w
Patients who entered the long-term 
extension, n
151 213 354
IBDQ maintenance baseline score, mean 
(standard deviation)
165.0 (32.04) 148.0 (36.15) 151.8 (36.61)
IBDQ change from baseline to Week 140, 
mean (standard deviation)
0.8 (37.12) 19.2 (40.65) 17.6 (40.36)
SF-36 physical component maintenance 
baseline score, mean (standard 
deviation)
45.85 (7.200) 43.65 (8.189) 43.77 (8.291)
SF-36 physical component change from 
baseline to Week 140, mean (standard 
deviation)
1.19 (8.091) 3.52 (8.378) 3.90 (8.132)
SF-36 mental component maintenance 
baseline score, mean (standard 
deviation)
46.29 (10.765) 42.51 (11.466) 43.82 (11.253)
SF-36 mental component change from 
baseline to Week 140, mean (standard 
deviation)
-0.30 (11.126) 3.76 (10.712) 1.95 (11.784)
*Patients who had prohibited CD-related surgery or discontinued study agent due to 
lack of efficacy or due to an adverse event of worsening CD before week 140 had their 
induction baseline value carried forward or were considered not to have achieved the 
≥16- or ≥5-point improvement. Patients who had insufficient data at week 140 had their 
last value carried forward.
[Table: Inflammatory Bowel Disease Questionnaire (IBDQ) and SF-36 scores 
through Week 140 in patients who entered the long-term extension study*]
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opment, LLC Dr. Gasink is an employee of Janssen Scientific Affairs, LLC 
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Introduction: In the real-world settings, few studies have focused on the 
short-term effectiveness of adalimumab (ADA) therapy in patients with ul-
cerative colitis (UC). In particular, determination of demographic features 
of patients with UC who rapidly respond to ADA are relevant clinical is-
sues, but are currently unknown. We report results from our Adalimumab 
Multi-centre Cohort Study on Effectiveness in Patients with Ulcerative Coli-
tis (ADVENTURE).
aims & Methods: In the ADVENTURE study, our major interests were to 
investigate the short-term effectiveness of ADA therapy in patients with UC 
and understand the relevant prognostic factors. This was a retrospective, 
multi-centre, cohort study involving seven institutes in Japan, compiling 
data from patients with UC who had received at least one induction dose of 
160 mg of ADA between June 2013 and May 2017. Patients had to have a Li-
chtiger clinical activity index (CAI) score of ≥5 at the initial ADA administra-
tion. The CAI scores were analysed at baseline, at 2 and 12 weeks after the 
initial ADA administration. Remission was defined as CAI score ≤4, while 
response was defined as a decrease of ≥50% relative to baseline. Rapid 
responder was defined as a patient who achieved response at 2 weeks. 
The related prognostic factors in rapid responders were determined using 
univariate and multivariate logistic regression analyses. Receiver operat-
ing characteristic (ROC) curves were also constructed, and the area under 
the ROC curve (AUC) was calculated to determine the cut-off value for the 
prognostic factors of rapid response. Additionally, we looked at the rate 
of remission at 12 weeks in rapid responders, stratified by the identified 
prognostic factors.
results: A total of 91 patients were included in this study (median age, 
37.9 years; 37 female), and median duration of UC was 3.3 years. At base-
line, the median CAI score was 9, and the median platelet count was 
300 × 109/L. Prior to initiation of ADA therapy, 32 patients had previously 
been exposed to infliximab (IFX). Of the 91 patients, 37.4% and 45.1% 
achieved response at 2 weeks and remission at 12 weeks. Among these 
34 rapid responders, 82.4% (28 of 34) achieved remission at 12 weeks. 
Multivariate logistic regression analysis identified a higher platelet count 
as an independent prognostic factor for a higher rate of rapid response. 
Likewise, ROC curve showed that a platelet count cut-off value ≥312 × 
109/L (AUC = 0.725; 95% confidence interval, 0.614-0.836) was associ-
ated with a rapid response (73.7% specificity, 70.6% sensitivity). In the 
univariate analysis, the rate of rapid response with platelet count ≥312 
× 109/L (61.5%) was significantly higher than with platelet count < 312 × 
109/L (19.2%) (P< 0.001). 
Further, patients with platelet count ≥312 × 109/L showed significantly more 
rapid responses in both IFX-naive (61.5% vs. 27.3%, P = 0.016) and IFX-
exposed patients (61.5% vs. 5.3%, P = 0.001), while the proportion of rapid 
responders in IFX-exposed patients with platelet count < 312 × 109/L was 
only 5.3%. Similarly, 5.3% of the IFX-exposed patients with platelet count 
< 312 × 109/L achieved remission at 12 weeks.
conclusion: Approximately 40% of patients with UC showed a rapid re-
sponse to ADA therapy after 2 weeks. Up to an 80% of the rapid respond-
ers also achieved remission at 12 weeks. The rate of rapid response was 
significantly higher in patients with platelet count ≥312 × 109/L. However, 
in this study we found that both rapid response and remission at 12 weeks 
were difficult to attain, especially in the IFX-exposed patients with a plate-
let count of < 312 × 109/L.
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P0419 IBd BIOsIMILar TO BIOsIMILar InfLIxIMaB sWITchIng 
sTudy: PreLIMInary resuLTs
Harris C.1,2, Harris R.1,2, Young D.3, Mcdonnell M.1,2, Harvey J.4, Felwick R.2, 
Gwiggner M.2, Latter S.5, Cummings F.1,2
1University of Southampton, Faculty of Medicine, Southampton, United 
Kingdom, 2University Hospital Southampton NHS Foundation Trust, 
Department of Gastroenterology, Southampton, United Kingdom, 3University 
Hospital Southampton NHS Foundation Trust, Pharmacy Department, 
Southampton, United Kingdom, 4University of Stellenbosch, Department of 
Statistics and Actuarial Science, Stellenbosch, South Africa, 5University of 
Southampton, School of Health Sciences, Southampton, United Kingdom
contact e-Mail address: fraser.cummings@uhs.nhs.uk
Introduction: Biosimilar infliximab products have become part of routine 
clinical care for patients with IBD. As part of the regulatory process, the 
European Medicines Agency compare a biosimilar product with the origi-
nator molecule but do not compare biosimilar products with each other. 
The introduction of multiple biosimilar products into clinical practice 
means that patients maybe asked to transition from one biosimilar prod-
uct to another. Whilst Remicade™, CT-P13 and SB2 have been compared in 
a laboratory setting1, there is a paucity of clinical outcome data, as well as 
data on the patient experience of this process. The aim of this study is to 
assess the outcome of transitioning a cohort of IBD patients from CT-P13 to 
SB2 in a real world setting.
aims & Methods: IBD patients treated with CT-P13 6 or 8 weekly at a dose 
of 5mg/kg at Southampton General Hospital were approached to partici-
pate in the study. After giving informed consent, at their next routine in-
fliximab infusion they were transitioned to SB2. Demographics, disease 
history, disease activity scores (mHBI or partial Mayo), IBD Control PROM2, 
adverse events and FBC, UE, CRP, and LFTs were collected at baseline and 
week 16/18 (depending on the infusion regime). A historical cohort of CT-
P13 patients was used to assess drug persistence. SAS was used to conduct 
the analysis. Data is presented as mean +/-standard deviation. t-Test was 
performed to compare outcomes at week 0 and week 16/18.
results: 133/144 patients approached (105 CD, 28 UC) participated in the 
study with a mean duration of disease of 9.64+/-8.96 yrs and had been 
treated with infliximab for 2.96 +/-2.72 years. 89/133 were on immuno-
modulators. The mean mHBI and partial Mayo scores at week 0 vs week 
16/18 were 3.13 +/- 3.31 vs 3.15 +/- 3.17 (p=0.32) and 1.53+/-1.75 vs 0.91+/-
1.64 (p=0.15) respectively. The overall disease control component of the IBD 
control PROM at week 0 and week 16/18 for CD and UC were 74.99 +/- 23.4 
vs 78.09 +/- 19.27 (p=0.66) and 76.22 +/-23.80 vs 81.57 +/-21.21 (p=0.49) 
respectively. The treatment specific components of the IBD-Control PROM 
(Q1b, 3f, 4a, 4b and 4c) showed no significant differences between Week 
0 and Week 16/18. 7 patients stopped treatment due to therapeutic failure, 
6 due to adverse drug reactions, 2 withdrew consent, 2 were lost to follow 
up and 1 for other reasons. There was no significant difference in drug 
persistence between a historical CT-P13 treated patient cohort and the SB2 
treated patients in this study.
conclusion: The advent of multiple biosimilar infliximab molecules means 
patients maybe asked to consider transitioning from one biosimilar to 
another biosimilar. There are considerably challenges to demonstrate the 
safety of interchangeability of multiple switches between different biosim-
ilar products. This study has set out examine the outcomes of transition-
ing from one biosimilar to another biosimilar in a real world cohort of 
patients. This data suggests that there does not appear to be a detrimental 
effect on patient outcomes as assessed by disease activity, the treatment 
specific domains of the IBD-control PROM and drug persistence for at least 
4 months. Further longer term data is required in multiple large cohorts 
of patients to confirm this finding as well as examine the outcomes of 
multiple switches between biosimilar products.
references: 1. Lee et al MABS 2017 9:6, 968-977 2. Bodger et al Gut 2014 
63(7):1092-102 2. Bodger et al Gut 2014 63(7):1092-102
disclosure: This work is an Investigator initiated study funded by Biogen 
GmBH. Dr Cummings has received honorarium/consultancy fees/research 
support from Biogen, Samsung, Takeda, Abbvie, MSD, Hospira/Pfizer 
disclosure: Ryosuke Sakemi has received lecture fees from JIMRO Co. Ltd., 
AbbVie GK, EA Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Janssen 
Pharmaceutical K.K., and Mitsubishi Tanabe Pharma Corporation. Hiroki 
Tanaka has received lecture fees from JIMRO Co. Ltd., AbbVie GK, EA Phar-
ma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyorin Pharmaceutical Co. 
Ltd. and Mitsubishi Tanabe Pharma Corporation. Satoshi Motoya has re-
ceived lecture fees from Mitsubishi Tanabe Pharma Corporation, Mochida 
Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K. and Takeda Phar-
maceutical Co. Ltd.; and has received research grants from Pfizer Japan 
Inc., Janssen Pharmaceutical K.K. and from Takeda Pharmaceutical Co. Ltd. 
Maki Miyakawa has received lecture fees from JIMRO Co. Ltd. Other authors 
(Najima M, Nasuno M, Tanuma T, Ishi M, Yanagisawa H, Yamashita M, 
Toita N, Suzuki R, So S ) have no finacial relationships to disclose. 
P0418 assessIng The LeveL Of unMeT need aMOngsT 
uLceraTIve cOLITIs PaTIenTs In The unITed sTaTes and eurOPe
Kershaw J.1, Lucas J.1, Naessens D.2
1Adelphi Group, Macclesfield, United Kingdom, 2Janssen-Cilag, Beerse, 
Belgium
contact e-Mail address: dnaessen@its.jnj.com
Introduction: To assess the level of unmet need within Ulcerative Colitis 
(UC) patients currently prescribed biologic treatment and patients pre-
scribed conventional treatments in Europe and the USA.
aims & Methods: This is a real-world survey of treating Gastroenterolo-
gists and their consulting UC patients conducted in 2017 after the intro-
duction of vedolizumab to the UC market. Patients were included from 
France, Germany, Italy, Spain, the United Kingdom and the United States 
of America. Physicians completed patient record forms for the next seven 
eligible adult patients diagnosed with UC. Patient record forms contained 
details on patient demographics, clinical factors, satisfaction with control 
of condition and details on current treatment received. Only patients with 
a diagnosis of moderate-to-severe disease severity were included in the 
analysis. Patients currently receiving biologic treatment with a duration 
over 3 months allowing time for response to treatment where compared to 
patients receiving conventional treatments.
results: A total of n=1714 patients from the EU and n=619 from the US were 
included in the analysis. In the EU n=522 / US n=182 of UC patients were 
currently receiving biologic treatment and EU n= 1049 / US n=389 were 
currently receiving conventional treatment. Physicians reported in the EU 
34% / US 42% of biologic patients were not currently in remission, EU 
44% / US 57% for conventional patients. 36% of biologic patients in the EU 
and 51% in the US had experienced in the last 12 months or were currently 
experiencing a flare, 36% EU and 28% US for conventional patients. In the 
EU 71% / US 75% of biologic patients currently experienced symptoms, 
suffering a mean EU 3.2 / US 3.3 symptoms. For conventional patients EU 
77% / US 85%. Patients with symptoms suffered a mean of EU 3.8 / US 3.3 
symptoms.
conclusion: A high proportion of UC patients receiving conventional treat-
ments were not classed as currently being in remission by their physician, 
were currently experiencing symptoms and had currently or had suffered 
from a flare in the last 12 months. This was similar for patients who were 
currently receiving biologic treatment despite the introduction of vedoli-
zumab to the market.
disclosure: Jim Kershaw and James Lucas are consultants for Janssen Beer-
se, Belgium Dominik Naessens is an employee of Janssen Global, Beerse, 
Belgium 
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  Infliximab (n=91)
adalimumab 
(n=52)
Infliximab 
(2-2,5 mg/kg) (n=45)
Infliximab 
(<2mg/kg) (n=46 P value
adalimumab 
(2-2,5 mg/kg) (=36)
adalimumab 
(<2 mg/kg) (n=16) P value
Crohn Disease / Ulcerative Colitis 
(n, %)
75 (82,6%)/16 
(17,4%)
50 (96,2%)/2 
(3,84%)
37( 82,2%) /8 ( 
17,7%)
38(82,6%) /8 
(17,4%)
  36 (100%) /0 (0%) 14 (87,5%)/2 (12,5%)  
Combined treatment time (months) 
(mean,range)
36 (8-127) 37 (7-116) 37 (8-125) 35 (8-124) 0,105 40(7-67) 33( 7-116) 0,231
Serum levels mg/ml (mean, SD)
(ultimate determination)
2906 (3183) 7500 (4639) 2316 (2735) 3484 (3500) 0,08 7571.417( 5817,9) 8001,6 (5021,744) 0,4
Serum levels mg/ml ( mean, SD) 
(penultimate determination)
2594 (2398) 7797 (4519) 2186 ( 1842) 2994,63 (2803) 0,108 7827.45 (4051,1) 8470.7( 6572,1) 0,34
Fecal Calprotectin (mean, SD) 195,68 (275) 122 (141) 185 (185,9) 237 (354,6) 0,408 147.92 (228,5) 164.9 (229,6) 0,41
C-reactive protein (mean, SD)) 18,67 (119,7) 4,3 (10,4) 8,10 (19,2) 29,01 (167,3) 0,52 5.71 (12,30) 2.57 (3,7) 0,188
Response to treatment (remission/ 
response / failure) (n,%)
37(40,7%)/14
(15,4%)/40 (43,96%)
32 (61,5%) 
/10(19,2%)/10 
(19,2%)
18(40,9%) /4 (8,9%) 
/23 (51,5%)
19( 41,3%) /10 
(21,7%)/17 (37%)
p=0,174
23( 66,6%)/6 
(15,38%)/7 (17,95%)
9 
(56,25%)/4(25%)/3 
(18,25%)
0,83
Effectiveness/faulure (n,%) 51 (56%)/40 (44%)
32(76,19%)/10 
(23,8%)
22 ( 48,9%) /23 
(51,1%)
29(63,1%) /17 
(36,9%)
0,175 29 (81,8% )/7 (18,2) 13(80,6%)/3 (19,4%) 0,951
Anti-drug antibody formation (yes/
no) (n, %)
83 (91,2%)/8 
(8,79%)
0/0 (0%) 42(91,3 %)/4( 8,7%) 41( 91,1%)/4 (8,8%) 0,974 0/0 (0%) 0/0 (0%)  
[P0420Table 1. Results of the study according to the doses of thiopurines]
P0420 OPTIMIzaTIOn Of dOses Of ThIOPurInIc drugs 
(azaTIOPrIne and MercaPTOPurIne) In PaTIenTs WITh 
InfLaMMaTOry BOWeL dIsease under TreaTMenT cOMBIned 
WITh anTI-Tnf aLPha (InfLIxIMaB/adaLIMuMaB)
Lucas Ramos J.1, Suárez Ferrer C.2, Martín-Arranz M.D.3, Poza Cordón J.3, 
Martín-Arranz E.3, Andaluz Garcia I.1, Yebra Carmona J.1, Mora Sanz P.1
1Hospital La Paz, Madrid, Spain, 2Hospital Puerta de Hierro Dept. de 
Gastroenterología, Madrid, Spain, 3Hospital La Paz, Gastroenterology, 
Madrid, Spain
contact e-Mail address: jlucasr77@gmail.com
Introduction: The combination of Anti-TNF drugs with thiopurinic drugs 
in the treatment of IBD, has shown greater clinical efficacy1, serum drug 
levels in therapeutic range in a higher proportion of patients, and less 
antibody formation, than monotherapy with Anti-TNF2,3. However, the dose 
of the thiopurinic drug in combined treatments has not been clearly estab-
lished. Some authors consider that this dose could be lower than that used 
in monotherapy4(2.5 mg/kg/day).
aims & Methods: A retrospective study was performed, selecting all pa-
tients with established diagnosis of IBD in follow-up at the IBD Unit of the 
Hospital La Paz, from 2006 to 2018, who were on combined maintenance 
treatment with azathioprine and Anti-TNF. 91 patients were recruited for 
treatment with infliximab and 52 for treatment with adalimumab. Two 
groups of patients were established for both infliximab and adalimum-
ab, one with the standard dose (2-2.5 mg/kg) and one with a lower dose 
(less than 2 mg/kg). The main objectives are to evaluate the clinical and 
pharmacokinetic response: through the measurement of the levels of the 
biological drug and the formation of anti-drug antibodies(ADA) ,as well 
as the loss of clinical response (defined as the need to intensify or change 
the treatment). As secondary variables, PCR and fecal calprotectin are de-
termined.
results: In the adalimumab group, there are no statistically significant dif-
ferences in remission rates, response without remission , or failure de-
pending on the dose of thiopurines (adequate or low). If we join response 
and remission in the same group (efficacy versus failure), the low dose 
group and the standard dose group also showed no statistically significant 
differences. There are no differences between PCR and calproctectin levels 
among patients with optimal doses of thiopurines and low doses. The last 
determinations of mean adalimumab levels were not significantly different 
between groups. No ADA formation was detected.
In the infliximab group, there is no statistically significant difference in 
remission, response or failure rates depending on the dose of thiopurines 
(adequate or low). If we compare efficacy vs failure, there are no statisti-
cally significant differences depending on the dose of thiopourins. There 
are no differences between the levels of PCR and fecal calprotectin, nor in 
the formation of ADA; nor in the last two determinations of mean infliximab 
levels among patients with optimal doses of thiopurines vs lower doses. If 
we consider pharmacokinetic failure (infliximab levels < 1000 ug/ml and/
or ADA), there were also no statistically significant differences(p=0.063).
conclusion: Consistent with the findings of other studies, there are no 
differences in the pharmacokinetic characteristics or in the responses of 
patients with the biologic treatment combined with thiopurine a standard 
dose with respect to the group with low dose (< 2 mg/kg). The use of a 
lower dose of Azathioprine can provide a better tolerance of the drug, a 
better safety profile, and lower economic cost.
references: 1.-Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Prin-
cen F, et al. The association of tissue anti-TNF drug levels with serological 
and endoscopic disease activity in inflammatory bowel disease: The ATLAS 
study. Gut. 2015. Epub ahead of print 2.-Maser EA, Villela R, Silverberg MS, 
Greenberg GR. Association of trough serum infliximab to clinical outcome 
after scheduled maintenance treatment for Crohn’s disease. Clin Gastro-
enterol Hepatol. 2006;4:1248---54 3.- Colombel JF, Sandborn WJ, Reinisch 
W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al; SONIC Study Group. 
Infliximab, azathioprine, or combination therapy for Crohn’s disease. N 
Engl J Med. 2010;362:1383-95. -4. Roblin X, Boschetti G, Williet N, et al. 
Azathioprine dose reduction in inflammatory bowel disease patients on 
combination therapy: an open-label, prospective and randomised clinical 
trial.
disclosure: Nothing to disclose 
P0421 MeTa-anaLysIs: deeP reMIssIOn In IBd WITh anTI-Tnf 
agenTs
Alipour O.1, Gulati A.1, Shao L.1, Zhang B.2
1University of Southern California, Gastroenterology and Liver Diseases, Los 
Angeles, United States, 2University of California, Department of Medicine, 
Division of Gastroenterology, San Francisco, United States
contact e-Mail address: omeedalipour@gmail.com
Introduction: Clinical remission and mucosal healing have been thera-
peutic targets in the treatment of inflammatory bowel disease (IBD). 
However emerging paradigms suggest deep remission (DR) as an im-
pactful and achievable goal of therapy. Although there is no consensus 
on the definition of deep remission, many authors consider clinical re-
mission with mucosal healing with or without additional criteria as deep 
remission. Achieving deep remission may positively impact the long-term 
trajectory of disease. This meta-analysis aims to determine the rate of 
deep remission with anti-TNF agents, the oldest and most utilized biolog-
ics therapy.
aims & Methods: Using the search terms (“inflammatory bowel diseases” 
OR “IBD” OR “crohn*” OR “ulcerative colitis” OR “UC” OR “colitis”) AND 
(“mucosal healing” OR “deep remission” OR “complete remission” OR 
“full remission” OR “endoscopic remission”), 7,514 articles and abstracts 
were identified between Pubmed and EMBASE on October 1, 2018. Inclu-
sion criteria were adult IBD patients treated with anti-TNF medications, 
with report of achieving deep remission defined as at least clinical remis-
sion and mucosal healing or endoscopic remission. Exclusion criteria were 
studies focusing on pediatric patients, reporting < 10 patients, and non-
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REA PMS were collected up to the data cut-off date of 27 December 2017. 
Descriptive analyses are presented for the safety population (≥1 dose of 
CT-P13). Overall, 2813 patients were included in the safety analysis of which 
2,215 patients (78.7%) were from the EU.
results: A total of 999 UC and 1814 CD patients were included in the safety 
population. Mean age was 41.6 and 35.8 years and the mean treatment 
duration of CT-P13 was 264.6 and 266.4 days in UC and CD patients, re-
spectively. EU patients constituted 76.0% (759 patients) of the UC and 
80.3% (1456 patients) of the CD population. Thus, the results of this analy-
sis can be considered representative of real-world CT-P13 (biosimilar inf-
liximab) safety data from the EU. Overall, 27.43% and 27.78% of UC and CD 
patients, respectively, experienced at least 1 treatment-emergent adverse 
event (TEAE) and 10.01% and 10.92% of UC and CD patients, respectively, 
experienced at least 1 treatment-emergent serious adverse event (TESAE). 
A total of 8.81% and 5.68% patients discontinued treatment due to TEAEs 
in UC and CD patients respectively. Three deaths (attributed to sudden 
heart death, sepsis and unknown cause, 1 each) were reported among the 
UC patients and 1 death attributed to rupture of aneurysm of the abdomi-
nal aorta was reported among the CD patients. 
Incidences of AESIs are included in Table 1 and are aligned with the known 
safety profile of the reference product as described in the literature and 
Summary of Product Characteristics (SmPC)
(1, 2, 3, 4, 5). More specifically, active TB was reported in 2 patients (0.20%) 
and 4 patients (0.22%) in the UC and CD population, respectively. Of the 6 
patients, 1 patient was from Portugal and the remaining 5 patients were 
from Korea. Incidences of active TB and serious infections including TB 
were within the range of the reference values from observational studies 
of the reference product (incidence of active TB: 0.7% and 1.18%; incidence 
of serious infection: 8.16% and 7.3%) (1, 2, 3). 
aesI uc (n = 999) cd (n = 1814)
Serious Infection including TB 24 (2.40%) 40 (2.21%)
Active TB 2 (0.20%) 4 (0.22%)
Serum sickness 1 (0.10%) 0
Haematologic reactions 4 (0.40%) 23 (1.27%)
Systemic lupus erythematosus/ lupus-like syndrome 1 (0.10%) 3 (0.17%)
Non-haematologic malignancy 5 (0.50%) 7 (0.39%)
Hepatobiliary event 4 (0.40%) 7 (0.39%)
Intestinal or perianal abscess NA 31 (1.71%)
[Table 1. Incidence of AESIs]
conclusion: Incidence of AESIs, including active TB and serious infection, 
among IBD patients treated with CT-P13 in the 3 post-marketing studies 
were low and consistent with the known safety profile of infliximab. The 
pooled safety analysis suggests a favourable benefit-risk balance and safe-
ty profile for IBD patients treated with CT-P13 in EU.
references: 1. Delabaye I, De Keyser F. 74-week follow-up of safety of inf-
liximab in patients with refractory rheumatoid arthritis. Arthritis Res Ther. 
2010;12(3):R121. 2. Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. 
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients 
with severe long-standing refractory disease: attrition rate and evolution 
of disease activity. Arthritis Res Ther. 2010;12(3):R77 3. D’Haens G, Reinisch 
W, Colombel J-F, Panes J, Ghosh S, Prantera C, et al. Five-year Safety Data 
From ENCORE, a European Observational Safety Registry for Adults With 
Crohn’s Disease Treated With Infliximab [Remicade(R)] or Conventional 
Therapy. J Crohns Colitis. 2017 Jun 1;11(6):680-9. 4. Remicade EU product 
information https://www.ema.europa.eu/documents/product-information/
remicade-epar-product-information_en.pdf (last accessed 22 Dec 2018) 5. 
Yoneno K, Hisamatsu T, Matsuoka K, Okamoto S, Takayama T, Ichikawa R, 
et al. Risk and Management of Intra-Abdominal Abscess in Crohn’s Disease 
Treated with Infliximab. Digestion. 2014;89(3):201-208
disclosure: SJ Lee, K Baek, YJ Lee, S Lee, SG Lee, JE Park are employees of 
Celltrion, Inc. H Kim is an employee of Celltrion Healthcare, Inc. The CT-P13 
4.3 registry and Korea PMS were conducted and funded by Celltrion, Inc. 
The CONNECT-IBD study was conducted and funded by Pfizer Inc. 
English publications. Publications were independently reviewed for inclu-
sion by two authors. A third author reviewed studies not agreed upon. 
Statistical analysis was performed using OpenMetaAnalyst.
results: 14 peer-reviewed manuscripts, two of which were randomized 
control trials, with 1248 total cases were included. Most patients were 
treated with infliximab (IFX) or adalimumab (ADA). Length of follow-up 
ranged from 10 to 138 weeks. Overall, 37.7% (509/1248, CI 0.267-0.488) of 
patients achieved deep remission with anti-TNF medications. Rates of DR 
ranged from 7% to 63%. There was significant heterogeneity (I^2=94.82%, 
P< 0.001). In sub-analysis, 37.1% of patients with CD and 50.3% with UC 
achieved deep remission. 40.1% of patients on ADA and 41.1% on IFX 
achieved deep remission. Two studies (Magro 2016, Kaymak 2018) with 
histologic remission as a criteria reported only 10.1% (13/129) rate of deep 
remission combined. 
studies estimate (95% cI)
deep 
remission/
Treated
cd uc studies estimate (95% cI)
deep re-
mission/
Treated
cd uc
De Vos et 
al. 2013
0.345 
(0.245, 
0.445)
30/87   30/87 Colombel et al. 2015
0.455 
(0.371, 
0.540)
61/134 61/134  
Molander 
et al. 
2013
0.484 
(0.422, 
0.546)
122/252 79/183 43/69 Zhang et al. 2016
0.557 
(0.447, 
0.667)
44/79 44/79  
Dai et al. 
2014
0.556 
(0.489, 
0.622)
120/216 62/109 58/107 Borje et al. 2016
0.625 
(0.388, 
0.862)
10/16   10/16
Colombel 
et al. 
2014
0.194 
(0.095, 
0.292)
12/62 12/62   Zittan et al. 2016
0.483 
(0.357, 
0.610)
29/60 29/60  
Kopylov et 
al. 2015
0.143 (0, 
0.326) 2/14 2/14  
Magro et 
al. 2016
0.250 
(0.060, 
0.440)
5/20   5/20
Echarii et 
al. 2015
0.375 
(0.225, 
0.525)
15/40 15/40   Kaymak et al. 2018
0.073 
(0.024, 
0.122)
8/109 8/109  
Yu et al. 
2015
0.189 
(0.114, 
0.263)
20/106 20/106  
Munoz-
Villafranca 
et al. 2018
0.585 
(0.452, 
0.718)
31/53   31/53
Overall
0.377 
(0.267, 
0.488)
509/1248 332/896 177/352          
[Studies Reporting Rates of Deep Remission with Anti-TNF Agents]
conclusion: This study systematically reviewed the effect of Anti-TNF 
agents on achieving deep remission. Anti-TNF agents achieved deep re-
mission in IBD in 37.7% of patients, with rates similar between adalim-
umab and infliximab. Unfortunately, a lack of available trials precludes the 
comparison of IFX and ADA in UC and CD. A limitation is the heterogene-
ity amongst studies, including reported findings, variable definitions of 
deep remission, length of follow up, and concomitant medications such as 
immunomodulators. Future studies comparing anti-TNF agents to newer 
biologics with other mechanisms of action may elucidate the best treat-
ment approach for achieving deep remission.
disclosure: Nothing to disclose 
P0422 a Large POOLed safeTy anaLysIs Of 3 POsT-
MarkeTIng sTudIes cOnducTed In InfLaMMaTOry BOWeL 
dIsease PaTIenTs TreaTed WITh BIOsIMILar InfLIxIMaB (cT-P13)
Lee S.J.1, Baek K.1, Lee Y.J.1, Lee S.1, Kim H.2, Lee S.G.1, Park J.E.1
1Celltrion, Incheon, Korea (Republic of), 2Celltrion Healthcare, Incheon, Korea 
(Republic of)
contact e-Mail address: sangjoon.lee@celltrion.com
Introduction: CT-P13 (biosimilar infliximab) has well established its place 
in the treatment of rheumatoid diseases and Inflammatory Bowel Disease 
(IBD) in the European Union (EU) since gaining marketing authorisation 
in 2013. However, real-world safety data of patients with Crohn’s Disease 
(CD) and Ulcerative Colitis (UC) receiving infliximab biosimilar in the EU 
are limited. This analysis presents a pooled analysis of available UC and 
CD safety data from 3 open-label post-marketing studies.
aims & Methods: The primary objective of the analysis was to evaluate ad-
verse events of special interest (AESIs) in patients with IBD in a real-world 
setting. Safety data from the Pfizer CONNECT-IBD study (13 EU countries), 
the Celltrion CT-P13 4.3 registry (5 EU countries) and Celltrion CT-P13 KO-
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P0423 cOgnITIve BehavIOraL InTervenTIOn decreases 
PsychOLOgIcaL sTress and dIsease acTIvITy In aduLTs WITh 
crOhn’s dIsease: PreLIMInary resuLTs Of a randOMIzed 
cOnTrOLLed TrIaL
Schwartz D.1, Goren G.2, Sergienko R.2, Friger M.3, Greenberg D.2, 
Sarid O.2, Slonim-Nevo V.2, Odes S.4, Israeli IBD Research Nucleus (IIRN)
1Soroka University Medical Center, Ben Gurion University of the Negev, 
Beer Sheva, Israel, 2Ben Gurion University of the Negev, Beer Sheva, Israel, 
3Epidemiology, Ben Gurion University, Beer Sheva, Israel, 4Ben Gurion 
University of the Negev, Gastroenterology, Beer Sheva, Israel
contact e-Mail address: doronsh90@gmail.com
Introduction: Psychological stress in Crohn’s disease (CD) triggered symp-
tomatic activity independently of calprotectin levels (Targownik 2015). Pa-
tients with active CD had significantly more stress than those in remission 
(Sarid 2018). We examine whether cognitive behavioral intervention (CBI) 
can reduce psychological stress as well as disease symptoms in CD.
aims & Methods: Unselected adults (≥18 years) with active CD attending 
routine follow-up at a university hospital were randomized to enter a 
stress reduction CBI program combining cognitive behavioral and mind-
fulness techniques, or act as controls. CBI was taught by trained social 
workers in 8 on-line sessions, delivered one-to-one for 1 hour weekly over 
8 weeks. Home practice twice daily with feedback to an application was 
required. Disease activity was measured by Harvey-Bradshaw Index (HBI) 
and psychological stress by the Brief Symptom Inventory (BSI), at entry 
and at 3 months follow-up. The BSI assesses 53 symptoms in categories 
of Somatization, Obsessive-Compulsive, Interpersonal Sensitivity, Depres-
sion, Anxiety, Hostility, Phobic Anxiety, Paranoid Ideation and Psychoti-
cism. Combining the category scores yields the Global Severity Index (GSI). 
BSI range is 0-4; a higher score indicates more stress.
results: The cohort comprised 41 patients: mean age 35 years, BMI 22.7, 
disease duration 5.5 years, 63.4% female, 78% with higher education, 
88% non-smokers. Median HBI was 8.0 (range 5-16). Twenty patients were 
taught CBI and 21 were controls. There were no differences in age, gender, 
education, smoking habit and disease severity between the groups. In CBI 
patients there was a large reduction of HBI at 3 months, and significant 
decreases in all category scores except anxiety and paranoid ideation. In 
controls the drop of HBI was minor, and category scores were unchanged 
or increased. The GSI score decreased significantly in CBI, but there was no 
significant change in controls. See Table (Wilcoxon signed-ranks test, entry 
vs. 3 months. *p< .05, **p< .01).
  cBI controls
  Entry 3 months Entry 3 Months
HBI 8.0 4.0** 8.0 7.0*
Somatization 1.2 0.8* 1.1 1.3
Obsessive -Compulsive 1.1 0.8* 1.8 2.1
Interpersonal sensitivity 1.0 0.4* 1.5 1.5
Depression 1.1 0.5* 1.5 1.5
Anxiety 1.1 0.8 1.7 1.7
Hostility 0.6 0.4* 0.8 0.8
Phobic anxiety 0.4 0.2* 0.8 0.8
Paranoid ideation 1.0 0.6 1.0 1.4
Psychoticism 0.9 0.2** 0.6 1.0
GSI 1.0 0.6* 1.2 1.4
[Table 1: Median HBI and BSI values in patients taught CBI versus controls]
conclusion: Patients taught CBI demonstrated significant less psychologi-
cal stress and diminished disease activity, whereas control subjects ex-
hibited no improvement in stress measures and little change of disease 
activity. These findings may imply a role for psychological stress impacting 
disease activity in CD patients.
disclosure: Nothing to disclose 
P0424 effecTIveness and safeTy Of endOscOPIc BaLLOOn 
dILaTIOn Of cOLOrecTaL sTrIcTures In crOhn’s dIsease
Tilmant M.1, Serrero M.2, Poullenot F.3, Bouguen G.4, Pariente B.5, 
Altwegg R.6, Basile P.7, Filippi J.8, Vanelslander P.9, Buisson A.10, 
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Introduction: Endoscopic balloon dilation (EBD) is widely used to manage 
Crohn’s disease (CD) ileal stricture. However, data of EBD on inflammatory 
bowel diseases (IBD) colorectal strictures are scarce.
aims & Methods: We performed a retrospective study in 9 tertiary centers, 
including all consecutive IBD patients who underwent EBD for native or 
anastomotic colorectal stricture between 1999 and 2018. Outcomes were 
rate of technical success defined by a passable stricture at the end of the 
EBD, clinical success defined by a passable and asymptomatic stricture 
and colonic resection at the end of follow-up. Factors associated with EBD 
success were also investigated by logistic regression.
results: Fifty-seven patients (25 women, median age: 36 years, InterQuar-
tile Range, 31-48) were included. All patients had CD and 42 (74%) had 
symptomatic stricture. Regarding the 60 strictures, 52 (87%) were native 
and the most frequent location was left colon (27%). 39 (65%) measured 
less than 5 cm, 57 (95%) were non-passable by the scope and 35 (58%) 
ulcerated. 
Among the 161 EBD performed (median number of dilatations per stric-
tures: 1, IQR 1-3), technical success was observed in 123 (76%) EBD. One 
perforation occurred (0.6% per EDB and 2% per patient). After a median 
follow-up of 4.3 years [IQR 2.0-8.4], 24 patients (42%) underwent colonic 
resection, 9 (16%) had symptomatic strictures non-passable by the scope, 
11 (19%) had asymptomatic non-passable strictures and 13 (23%) had as-
ymptomatic strictures passable by the scope. 
One colon lymphoma and one colorectal cancer were diagnosed (3.5% of 
patients), respectively on endoscopic biopsies and at the time of surgery. 
None factor was associated with technical, clinical success, or surgery in-
cluding therapeutic modification.
conclusion: EBD of CD-associated colorectal strictures is feasible, efficient 
and safe as more than 50% of patients avoid surgery.
disclosure: Nothing to disclose 
P0425 BarrIers and facILITaTOrs In cOnducTIng 
TheraPeuTIc TrIaLs In InfLaMMaTOry BOWeL dIsease: 
a MOnOcenTrIc ITaLIan survey
Giubilei L., Larussa T., Suraci E., Imeneo M., Marasco R., Abenavoli L., 
Luzza F.
University of Catanzaro Magna Graecia, Health Sciences, Catanzaro, Italy
contact e-Mail address: lidiagiubilei83@gmail.com
Introduction: Anti-TNF agents and other currently available biologic drugs 
represent a valid therapeutic option for inflammatory bowel diseases (IBD). 
However, these treatments are not effective in all patients, and moreover 
the initial response diminishes over time. So, clinical therapeutic trials 
are a fundamental tool for identifying new categories of drugs useful for 
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partial Mayo score was ≤ 2. Changes in C-reactive protein, infliximab-drug 
levels, and antidrug antibodies were collected during followed up. All ad-
verse events (AEs) were monitored.
results: 
characteristics n(%) cI (95%)
Sex Men // Women 51(51) // 49(49) 40.7; 61.3 // 38.7; 59.3
Age (years, range) CD // UC
40.5 (18-77) // 
44.0 (37-53)
 
Smoking status: 
Never // Previous // 
Current
 
68 (68) // 18 (18) 
// 14 (14)
58.4; 77.6 // 9.9; 26.0 
// 6.7; 21.3
CD patients (n=64)    
Age at diagnosis: A1, 
A2, A3 // Location 
at diagnosis: 
L1,L2,L3,L3+L4 // 
Disease behavior: 
B1,B2,B3 // Perianal 
disease
A1 (<17) // A2 (17-40) 
// A3 (>40) // L1 (ileal) 
// L2 (colonic) // L3 
(ileocolonic) // L3+L4 
(upper gastrointestinal 
tract) // B1 (nonstricturing, 
nonpenetrating) // 
B2 (stricturing) // B3 
(penetrating) // Yes
8 (12.5) // 46 
(71.9) // 10 (25.6) 
// 16 (25) // 27 
(42.2) // 18 (28.2) 
// 3 (4.7) // 39 
(60.9) // 12 (18.8) 
// 13 (20.3) // 28 
(43.8)
3.6; 21.4 // 60.1; 83.7 
// 5.9; 25.3 // 13.6; 
36.4 // 29.3; 55.1 // 
16.3; 39.9 // 0.9; 13.1 
// 48.2; 73.7 // 8.4; 
29.1 // 9.7; 30.9 // 
30.8; 56.7
UC patients (n=36)    
Extent (UC): E1, E2, 
E3 // Severity: S1, S2, 
S3 // Extraintestinal 
manifestations
E1 (proctitis) // E2 
(left-sided colitis) // E3 
(pancolitis) // S1 (mild) 
// S2 (moderate) // S3 
(severe) // Yes
13 (36.1) // 11 
(30.6) // 12 (33.3) 
// 13 (36) // 17 
(47.2) // 6 (16.7) // 
10 (27.7)
19.9; 53.2 // 14.1; 46.9 
// 15.5; 50.1 // 19.9; 
53.2 // 29.5; 64.9 // 
3.1; 30.2 // 11.8; 43.8
Prior medication 
exposure: 
Thiopurines // 
Methotrexate 
// Concomitant 
medication use: 
Thiopurines // 
Methotrexate // 
Steroids
CD // UC // CD // UC // CD // 
UC // CD // UC // CD // UC
33 (51.6) // 19 
(52.8) // 20 (31.3) 
// 5 (13.9) // 27 
(42.2) // 13 (36.1) 
// 14 (21.8) // 3 
(8.3) // 10 (15.6) 
// 5 (13.9)
38.5; 64.6 // 29.7; 17.7 
// 19.1; 43.4 // 4.7; 29.5 
// 29.3; 55.1 // 19.0; 
53.2 // 10.9; 32.8 // 
1.8; 22.5 // 5.9; 25.3 // 
4.7; 29.5
Time using 
Remicade (months) 
// Time global using 
infliximab (months)
 
58 (37-80) 
median (IQR) 
// 81 (63-107) 
median (IQR)
 
[Table 1. Baseline demographics/clinical characteristics]
100 patients were included (64 CD, 36 UC). Most of them (72%) remained 
on CTP-13 and 28% of patients discontinued the therapy due to loss of 
response, adverse events or remission/mucosa healing. Remission at 18 
and 24 months occurred in 69.9% and 68.5% of patients, respectively. 
Global remission in patients with Crohn’s disease was: 79.7%, 67.7%, 67.7% 
and 65.6% to basal remission, 12 months, 18 months and 24 months, re-
spectively. Global remission in patients with Ulcerative Colitis was: 75.0%, 
74.2%, 74.2% and 74.2% to basal remission, 12 months, 18 months and 
24 months, respectively. 22% of patients received a dose increase, with 
remission being reached in 60% of them. HB score, partial Mayo score, 
C-reactive protein and infliximab-drug levels did not show significant 
changes. AEs were reported in 14% of patients.
conclusion: Most of the patients switching from infliximab original main-
tained CT-P13 at 2 years of follow-up with a good profile of effectiveness 
and safety.
disclosure: Nothing to disclose 
P0427 PaTIenTs’ PercePTIOns and unMeT needs In 
InfLaMMaTOry BOWeL dIseases: a MOnOcenTrIc ITaLIan 
survey
Giubilei L., Larussa T., Flauti D., Suraci E., Imeneo M., Marasco R., 
Abenavoli L., Luzza F.
University of Catanzaro Magna Graecia, Health Sciences, Catanzaro, Italy
contact e-Mail address: lidiagiubilei83@gmail.com
Introduction: Inflammatory bowel diseases (IBD) significantly impact the 
patient’s quality of life (QoL) and clinicians should be aware of patients’ 
perspectives and needs in the everyday life.
aims & Methods: The aim of this survey was to assess patients’ percep-
tions regarding their QoL, quality of care, and satisfaction in a local resi-
dent series of IBD patients from Southern Italy. Consecutive patients with 
ensuring clinical benefit in patients with IBD. However, a number of dif-
ficulties, still not clearly investigated, may affect the recruitment of patients 
in large clinical trials.
aims & Methods: The aim of this survey was to assess patients’ perceptions 
regarding their willingness to take part in clinical therapeutic trials in a 
local resident group of IBD patients from Southern Italy. Consecutive pa-
tients with Crohn’s disease (CD) and ulcerative colitis (UC) were recruited 
to complete a self-administered, locally validated, questionnaire dealing 
with their knowledge about clinical trials and attitude towards participa-
tion . Patients also completed the Short Inflammatory Bowel Disease Ques-
tionnaire (S-IBDQ) to investigate their quality of life (QoL). Demographic 
and clinical data were recorded.
results: Of the 132 patients who completed the survey, 38 (29%) had CD 
and 94 (71%) UC; 57% were male, the mean age was 47.8 (range 16-82) 
years and 75 (57%) had a long-standing disease (> 10 years). Sixty (45%) 
patients displayed active disease, 30 (23%) were currently on biologic 
therapy while 21 (16%) underwent surgery. More than half (65%) showed 
a poor QoL according to S-IBDQ. Sixty-six per cent were married or co-
habiting, 20% had a family history of IBD, and 78% had a high school 
diploma. 
Although few (16%) patients have previously participated in clinical re-
search, 67% claimed their willingness to take part in a clinical therapeu-
tic trial for IBD. Overall, 43% feared taking placebo, 88% would refuse if 
the drug had never been tested on humans, 24% were poor inclined to 
frequent visits, 76% were more prone to participate when the medical 
staff was always the same. Monetary remuneration and gastroenterologist 
conditioning were a motivation for participation in 34 (26%) and 27 (20%) 
patients, respectively. 
Using multivariate analysis, the chance of taking placebo was the only sig-
nificant risk factor for denying participation in a clinical trial [adjusted odd 
ratio (OR) 12.46, 95% confidence interval (CI) 7.81-50.73, p=0.000)] while 
monetary remuneration (OR:5.46, 95% CI:1.21-18.67, p=0.03) and having 
the same medical staff (OR:8.46, 95% CI:2.08-20.13, p=0.02) were predic-
tive factors of willingness to participate. Age, gender, type and duration 
of disease, current biologic therapy, prior participation, poor QoL, marital 
status, level of education, and previous surgery did not affect the decision 
to take part.
conclusion: In a native local resident series of IBD patients more than half 
of the patients were willing to participate in a clinical therapeutic trial. 
Placebo represented a barrier to enrollment while the presence of an es-
tablished medical staff and monetary compensation could be facilitative . 
Clinicians should pay attention to understanding the critical issues affect-
ing enrollment in clinical IBD therapeutic trials , in order to improve their 
quality and optimize their management.
disclosure: Nothing to disclose 
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WOrLd daTa
Belvis Jiménez M.1, Guerra Veloz M.F.2, Maldonado Perez B.3, 
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1HU Virgen Macarena, Gastroenterology, Sevilla, Spain, 2Hospital Virgen 
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Digestivo, Sevilla, Spain
contact e-Mail address: mariabelvisjimenez@gmail.com
Introduction: Several studies have reported positive outcomes for efficacy 
measures in inflammatory bowel disease patients treated with CT-P13, an 
infliximab biosimilar. Still, data from follow-up periods longer than 1 year 
are scarce. Here, we assessed the long term data of effectiveness, loss of 
response, safety and immunogenicity of switching from infliximab to CT-
P13 in patients with inflammatory bowel disease.
aims & Methods: This was a prospective single-center observational study 
in patients with moderate to severe Crohn’s disease (CD) and ulcerative 
colitis (UC) switched from infliximab original to infliximab biosimilar (CT-
P13) since March 2015 and followed up to 24 months. Montreal classifi-
cation status and previous/concomitant therapies were recorded (Table1). 
The efficacy endpoint was the change in the Harvey-Bradshaw for CD and 
partial Mayo score for UC. Clinical Remission was considered HB≤ 4 and 
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Crohn’s disease (CD) and ulcerative colitis (UC) were recruited. The survey 
consisted of the following self-administered questionnaires: the Short In-
flammatory Bowel Disease Questionnaire (S-IBDQ), the Hospital Anxiety 
and Depression Scale (HADS), the Brief Illness Perception Questionnaire 
(B-IPQ) and a questionnaire dealing with impact of IBD on patients’ life 
locally validated. Demographic and clinical characteristics were recorded. 
Multivariate logistic regression analysis (MVA) was performed to assess 
association between variables.
results: Of the 120 IBD patients who completed the survey, 34 (28%) had 
CD and 86 (72%) had UC, 73 (60%) were male, the median age was 44 
years (range 18-80), the mean body mass index (BMI) was 23.7±3.2, and 
the mean disease duration was 14±11 years. Seventy-four (62%) per cent 
were married or cohabiting, 25 (20%) had a family history of IBD, and 
90 (75%) had a high school diploma. Overall, 77 (64%) had poor QoL as 
assessed by S-IBDQ, 61 (51%) had HADS positive for anxiety/depression, 
the mean illness perception score was significantly high, and 46 (38%) 
claimed a poor sleep quality. Of 51 and 31 patients who experienced bio-
logics agents and surgery, 63% and 74% were satisfied, respectively. Par-
ticipation in therapeutic clinical would be accepted from 92% patients. 
Only 44 (37%) patients considered themselves satisfied with the relation-
ship with the family doctor, while 97 (81%) trusted their gastroenterologist. 
Independent risk factors (adjusted odd ratio, 95% confidence interval) for 
low S-IBDQ were a poor sleep quality (5.88, CI 1.8-20.2), a positive HADS 
(6.31, CI 1.93-20.6) and a high illness perception (1.13, CI 1.05-1.2). At MVA, 
age, gender, BMI, type and duration of disease, biologic therapy, surgery, 
marital status, and level of education did not affect S-IBDQ score.
conclusion: In a local resident setting of IBD patients from Southern Italy, 
more than half reported a low QoL. This was significantly associated with 
anxiety/depression, high illness perception and poor sleep quality. Biolog-
ics and surgery are well accepted from IBD patients and their willingness 
in participating to clinical trials claimed. Relationship with family doctors 
should be improved.
disclosure: Nothing to disclose 
P0428 safeTy and TOLeraBILITy Of BIOLOgIc agenTs 
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contact e-Mail address: carparelli.sonia@gmail.com
Introduction: Inflammatory bowel diseases (IBD), which include Crohn’s 
Disease (CD) and Ulcerative Colitis (UC), are chronic conditions with a re-
mitting-relapsing course. The main therapeutic goal in IBD patients is to 
induce and maintain long-term remission. Besides conventional therapy, 
biologic agents are widely and increasingly used. Such drugs, however, 
may arise safety issues due to increased risk of infections, severe infusion 
reactions and cancer. Therefore, we aimed to evaluate safety and toler-
ability of biologic drugs.
aims & Methods: We retrospectively reviewed patients followed at our 
tertiary referral center from 1999 and 2018 and treated with biologics in 
order to assess the prevalence of adverse events (AE), their characteristics 
and predictors. We used t-test or chi-squared test for univariate analysis. 
We draw Kaplan-Meier curves and used Cox regression for multivariate 
analysis and to calculate Hazard Ratio (HR) and 95% confidence intervals 
(CI).
results: Three hundred sixty patients were recruited (61.7% CD). They 
underwent 538 biologic courses overall. Male/female ratio was 209/151 
and mean age was 37.2±14.5. Eighty patients (14.9%) experienced an AE, 
mostly infusion reactions (77.5%). Additionally, we recorded 4 severe in-
fections and one case of melanoma. AEs were significantly more frequent 
in UC patients compared to CD patients (19% versus 12.3%, p=0.03). UC 
patients with AE had more severe partial Mayo (3.6±3.1 versus 2.3±3.0, 
p< 0.001) and full Mayo score (4.9±4.1 versus 3.3±4.1, p< 0.001) and extra-
intestinal manifestations were less common (21.2% versus 33%, p=0.04). 
Finally, AEs were more commonly related to infliximab (67.5% versus 41% 
for other biologic agents, p< 0.001). 
However, at multivariate analysis, none of the following factors was in-
dependently associated to AE: UC (HR=1.6, 95% CI 0.8-3.3 p=0.17), partial 
Mayo (HR=1.3 , 95% CI 0.9-1.7 p=0.14), full Mayo (HR=0.9 95% CI 0.7-1.2, 
p=0.66), extraintestinal manifestations (HR=0.7 95% CI 0.4-1.2, p=0.14) or 
type of biologic drug (p=0.45). More details are listed in table 1.
conclusion: On the basis of our data, the most common AEs of biologi-
cal therapies were hypersensitivity reactions Although there are not single 
predictors of AE, probably many factors are likely to influence each other 
and to contribute to AE onset. Further studies are needed to assess long 
term safety.
disclosure: Nothing to disclose
  univariate   Multivariate  
  HR (95% CI) p HR (95% CI) p
Disease • Crohn • RCU
1 (reference) 1.7 
(1.1-2.7)
0.03
1 (reference) 1.6 
(0.8-3.3)
0.17
Partial Mayo 1.1 (1.0-1.2) <0.001 1.3 (0.9-1.7) 0.14
Full Mayo 1.1 (1.0-1.2) 0.001 0.9 (0.7-1.2) 0.66
Extraintestinal manifestations 0.6 (0.3-1) 0.04 0.7 (0.4-1.2) 0.14
Biologic • infliximab • 
adalimumab • vedolizumab • 
golimumab
1 (reference) 0.5 
(0.3-0.8) 0.02 
(0.003-0.2) 0.8 
(0.2-2.8)
<0.001
1 (reference) 0.9 
(0.3-2.9) 0.5 (0.2-
2.0) 0.8 (0.1-7.6)
0.45
[Table 1]
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Introduction: Ustekinumab (UST) is a fully human monoclonal antibody 
against IL-12/23 approved in Brazil for the treatment of moderate-to-severe 
Crohn’s disease(CD) in November 2017. UST has demonstrated its efficacy 
in induction and maintenance therapy for patients with CD. Real world 
data regarding the efficacy and safety of UST in this population is lacking 
in our country. We hereby report our experience with UST in patients with 
moderate to severe CD.
aims & Methods: A retrospective chart review and a prospective study 
were performed including patients from eleven IBD referral centers with 
moderately to severely active CD starting on UST (IV infusions followed 
by scheduled subcutaneous [SC] injections) between November 2017 
and March2019. We accessed clinical response and remission (based on 
Harvey-Bradshaw index [HBI]), fecal calproprotectin (FC) and C-reactive 
protein (CRP) levels. Clinical response and clinical remission were defined 
by HBI decrease ≥ 3 and HBI ≤ 3, respectively. Clinical remission was ac-
cessed in weeks 0, 8, 16, 24, 32, 40, 48 and 56. CRP levels were evaluated 
in weeks 0, 8, 16, 24, 32, 40 and 48. FC levels were evaluated in weeks 0, 
8, 16 and 40.
results: One-hundred and fifty-one patients were treated with UST during 
the study period. The mean age was 38.2 years, disease duration was 10.8 
years, 57.6% had previous surgeries, 45.0% had perianal disease, 49.3% 
had anaemia, 55.7% were female, 15.9% were smokers. The majority of 
patients were treated with 90mg every 8 weeks (97.4%) during mainte-
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P0431 safeTy and effecTIveness Of granuLOcyTe and 
MOnOcyTe adsOrPTIve aPheresIs In eLderLy PaTIenTs WITh 
InfLaMMaTOry BOWeL dIsease: a MuLTIcenTre cOhOrT sTudy
Tanaka H.1, Nasuno M.1, Shibuya T.2, Osada T.3, Ito A.4, Kobayashi T.5, 
Kunisaki R.6, Hongo H.7, Tanida S.8, Hosoi E.9
1Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan, 2Juntendo 
University School of Medicine, Department of Gastroenterology, 
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Gastroenterology, Chiba, Japan, 4Tokyo Women’s Medical University, 
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City University, Graduate School of Medical Sciences, Department of 
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Introduction: There are few studies on the usefulness of granulocyte and 
monocyte adsorptive apheresis (GMA) in elderly patients with inflamma-
tory bowel disease (IBD). We report the result of the “Post-marketing sur-
veillance study on the safety and response of GMA treatment in patients 
with Crohn’s disease or ulcerative colitis with at least one special situation 
who received Adacolumn (PARTICULAR)”.
aims & Methods: The aim of this study is to investigate the safety and 
effectiveness of GMA in elderly patients with IBD who participated in the 
PARTICULAR study. This retrospective, multicentre cohort study included 
patients with ulcerative colitis (UC) or Crohn’s disease (CD) who had at 
least one special situation feature and who had received GMA therapy in 
medical institutions of Japan between November 2013 and March 2017. 
Patients with at least one special situation, including elderly patients, pa-
tients with anaemia and patients on multiple immunosuppressants (IMs) 
were enrolled. Patients ≤64 years were excluded from this study. GMA 
was performed using Adacolumn (JIMRO, Takasaki, Japan). Each patients 
received up to a maximum of 11 sessions. All adverse events (AEs) were 
recorded during the observation time interval. The safety of GMA was as-
sessed in all patients. The effectiveness of GMA was assessed in patients 
with UC with a partial Mayo (pMayo) score of ≥3. Remission was defined 
as a pMayo score of ≤2, while response was defined as a decrease in the 
pMayo score by ≥2 points and by ≥30% decrease relative to that at base-
line plus all 3 sub-scores ≤1. Patients receiving concomitant treatment with 
infliximab, adalimumab or calcineurin inhibitors were excluded from the 
effectiveness assessment.
results: A total of 125 patients (118 UC, 7 CD) from 93 institutions were 
included. The median age was 72.0 years. Fifty-one patients did not have 
any special situation, and 74 had one or more special situations. The inci-
dence rate of AEs was 11.2% in all patients. The incidence rate of AEs was 
significantly lower in patients without any special situation (3.9%) than 
in those with one or more special situations (16%). The incidence rate of 
AEs with the special situation subgroups were: 21.9% (7/32) in anaemic 
patients, 22.7% (5/22) in patients on multiple IMs, 25.0% (4/16) in patients 
with diabetes mellitus, 25.0% (4/16) in patients with ischaemic heart dis-
ease/arrhythmia, 20.0% (2/10) in hypertensive patients, 16.7% (1/6) in pa-
tients with dyslipidemia, 25.0% (1/4) in patients with liver dysfunction and 
33.3% (1/3) patients with renal dysfunction. A univariate analysis found 
the occurrence of AEs significantly higher in patients with anaemia, on 
multiple IMs, diabetes mellitus and ischaemic heart disease/arrhythmia 
than in patients without any special situation. Anaemia and multiple IMs 
were also identified as independent predictors for a higher incidence of 
AEs. The effectiveness of GMA was assessed in 92 patients with UC, show-
ing response and remission rates of 72.8% and 48.9%, respectively. The 
response and remission rates were slightly higher in patients without any 
special situation (81.0%, 52.4%) than in those with one or more special 
situations (66.0%, 46.0%).
conclusion: A rather low incidence rate of AEs (3.9%) was identified in 
elderly IBD patients treated with GMA, and not displaying any special situ-
ation, while the incidence of AEs was significantly higher in patients with 
one or more special situation (16%), which could be attributed to anaemia 
or multiple IMs. Remission and response was achieved by GMA in approxi-
mately 50% and 70% of the elderly UC patients, respectively.
disclosure: Hiroki Tanaka has received lecture fees from JIMRO Co. Ltd., 
AbbVie GK, EA Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyorin 
Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation. Taro 
nance. The majority of patients was previously exposed to biological ther-
apy (87.6%). Of these, 16 patients were naïve, 38 were previously exposed 
to one biologic, 63 exposed to two biologics and 9 exposed to three biolog-
ics. Previous biological therapies included infliximab (n=93), adalimumab 
(n=88), vedolizumab (n=11) and certolizumab pegol (n=8). Mean HBI at 
baseline was 10.1 and 73.5% of patients had HBI higher than 3 at baseline. 
At baseline mean CRP was 22.7 mg/L and mean FC was 1243.3 mg/kg. At 
week 8, 80.2% of patients achieved clinical response and 44.9% achieved 
clinical remission. Clinical remission was observed in 57.4% (week 16), in 
60.7% (week 24), in 69.8% (week 32), in 75.0% (week 40), in 63.8% (week 
48) and in 72.0% (week 56) of patients. CRP decreased to 15.1mg/L at week 
8, followed by a significant decrease until week 48 (8.1 mg/L). Sixty-three 
percent of the patients showed a decreased in the FC levels from baseline 
until week 40. However, the mean FC at week 40 was 1201.0mg/Kg, exhib-
iting a decrease of 42.3mg/Kg from baseline. Adverse events occurred in 
28.6% of patients. Twelve patients stopped UST, three due to pregnancy, 
five due to a lack of response and four due to others. No new safety signals 
were observed.
conclusion: UST therapy was successful for inducing and maintenance of 
clinical remission and improving laboratory biomarkers of disease activity 
in patients with moderate-to-severe CD and who were refractory to anti-
TNF therapy. Both UST induction and maintenance regimens until week 56 
were overall well tolerated. These results support a favorable safety and 
efficacy profile.
disclosure: Nothing to disclose 
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Introduction: CT-P13, a biosimilar of the reference product infliximab, has 
been approved for the treatment of ulcerative colitis on the basis of the 
results of trials conducted in patients with spondyloarthritis and rheuma-
toid arthritis.
aims & Methods: The objective wasto compare the effectiveness and safety 
of CT-P13 and the reference productin infliximab-naive patients with ul-
cerative colitis.
A comparative real-life equivalence cohort study was conducted using the 
French nationwide health administrative database. Infliximab-naive pa-
tients with ulcerative colitisover 15 years of age who started infliximab with 
no other indications for infliximab were included. The primary outcome 
was a composite endpoint (death, ulcerative colitis-related surgery, all-
cause hospitalization and reimbursement for other biologics). Equivalence 
was defined as a 95% confidence interval (CI) of the hazard ratio (HR) of 
CT-P13 versusthe reference product, in a multivariable marginal Cox model 
situated within prespecified margins of [0.80 to 1.25].
results: 3,112 patients were included between January 1, 2015 and June 30, 
2017: 1,434 received the reference product, 1,678 received CT-P13. Overall, 
710 patients in the reference productgroup and 743 patients in the CT-P13 
group met the composite endpoint. In multivariable analysis of the pri-
mary outcome, CT-P13 was equivalent to the reference product(HR 1.04; 
95%CI: 0.94-1.15). The number of serious infections was lower in the CT-
P13 group (HR 0.65; 95%CI: 0.48-0.88). There was no difference in the 
incidence of solid or hematologic malignancy (HR 0.81; 95%CI: 0.41-1.60).
conclusion: The effectiveness of CT-P13 is equivalent and the risk of serious 
infectionscould be lower than that of the reference product for infliximab-
naive patients with ulcerative colitis.
disclosure: Dr. Meyer, Mr. Drouin, Dr. Weill and Prof. Coste declared no 
conflict of interest. Dr. Rudant reports personal fees from CNAM during 
the conduct of the study. Prof. Franck Carbonnel received board or lecture 
fees from Enterome, MSD, BMS, Janssen, Pfizer, Abbvie, Mayoly Spindler, 
Takeda, Pileje. 
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Introduction: Few studies have assessed the safety of granulocyte and 
monocyte adsorptive apheresis (GMA) in patients with inflammatory bow-
el disease (IBD) undergoing concomitant treatment with multiple immu-
nosuppressant medications. To address this research gap, we investigated 
adverse events (AEs) associated with GMA in patients with IBD treated with 
multiple immunosuppressants who participated in the “Post-marketing 
surveillance study on the safety and response of GMA treatment in patients 
with Crohn’s disease or ulcerative colitis with at least one special situation 
who received Adacolumn (PARTICULAR)”.
aims & Methods: The aim of this study is to investigate the safety of GMA 
in patients with IBD treated with multiple immunosuppressants who par-
ticipated in the PARTICULAR study. This retrospective, multicentre cohort 
study included patients with ulcerative colitis (UC) or Crohn’s disease (CD) 
who had at least one special situation feature and who had received GMA 
therapy in medical institutions of Japan between November 2013 and 
March 2017. Patients with at least one special situation, including elderly 
patients, patients with anaemia and patients on multiple immunosup-
pressants were enrolled. GMA was performed using Adacolumn (JIMRO, 
Takasaki, Japan). Each patients received up to a maximum of 11 sessions. 
All adverse events (AEs) were recorded during the observation time inter-
val. In addition, feasibility problems (FPs) including difficulty in achieving 
blood access, technical problems related to the system operation during 
the operation of the GMA column were recorded. Any AE for which the 
causality of GMA could not be ruled out was classified as adverse device 
effect (ADE). The safety of GMA was assessed in all patients. The incidence 
of AEs was investigated relative to the number and type of immunosup-
pressants using univariate and multivariate logistic regression analyses.
results: A total of 437 patients (368 UC, 69 CD; 45.5% female) from 93 
institutions were included. Of these, 140, 169, 101 and 27 patients received 
none, 1, 2 and ≥3 immunosuppressants, respectively. Concomitant pred-
nisolone, immunomodulators, anti-tumor necrosis factor agents and 
calcineurin inhibitors were administered in 189, 151, 89 and 24 patients, 
respectively. Among all patients, AEs, ADEs and FPs were observed in 
50 (11.4%), 11 (2.5%) and 71 (16.2%) patients, respectively. AEs in ≥1% of 
patients included headache in 10 patients (2.3%), nausea/vomiting in 9 
(2.1%) and fever in 6 (1.4%). The rates of AE in patients receiving none, 1, 
2 and ≥3 immunosuppressant medications were 7.9%, 11.8%, 11.9% and 
25.9%, respectively. In multivariate logistic regression analysis, anaemia 
and concomitant immunosuppressants were independently associated 
with the incidence of AEs. Particularly, a higher number of concomitant 
immunosuppressants showed an increasing trend with odds ratios related 
to AEs. In contrast, concomitant prednisolone were associated with a re-
duced risk of AEs. Nausea/vomiting and headache were the most common 
AEs in patients on multiple immunosuppressant medications (5.6% and 
3.2%, respectively).
conclusion: Concomitant treatment with immunosuppressants was in-
dependently associated with the incidence of AEs such as nausea/vom-
iting and headache in patients with IBD receiving GMA. As the number 
of concomitant immunosuppressants increased, the incidence of AEs also 
increased. However, our data also suggest that GMA is safe in patients with 
IBD receiving prednisolone.
disclosure: Hiroki Tanaka has received lecture fees from JIMRO Co. Ltd., 
AbbVie GK, EA Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyorin 
Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation. Maki 
Miyakawa has received lecture fees from JIMRO Co. Ltd. Taro Osada has 
received research grant from JIMRO Co. Ltd. Eiji Hosoi is employee of JIMRO 
Co. Ltd. Tomoyoshi Shibuya has nothing to disclose. 
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Introduction: There are few treatment options that can be applied repeat-
edly as remission induction therapy for patients with inflammatory bowel 
disease (IBD). Granulocyte and monocyte adsorptive apheresis (GMA) is a 
treatment option for patients with IBD, which can be applied repeatedly 
as remission induction therapy. Nonetheless, currently, there is no report 
on the safety and efficacy of repeated treatment with GMA in patients with 
IBD. We report the result of the “Post-marketing surveillance study on the 
safety and response of GMA treatment in patients with Crohn’s disease or 
ulcerative colitis with at least one special situation who received Adacol-
umn (PARTICULAR)”.
aims & Methods: The aim of this study was to assess the safety and ef-
fectiveness of retreatment with GMA in patients with IBD who participated 
in the PARTICULAR study. Our retrospective, multicentre cohort study in-
cluded patients with ulcerative colitis (UC) or Crohn’s disease (CD) who had 
at least one special situation feature and who had received GMA therapy at 
93 medical institutions of Japan between November 2013 and March 2017. 
Patients with at least one special situation, including elderly patients, pa-
tients with anaemia and patients on multiple immunosuppressants were 
enrolled. Patients who received GMA for the first time were excluded. GMA 
was performed using Adacolumn (JIMRO, Takasaki, Japan). Each patients 
received up to a maximum of 11 sessions. All adverse events (AEs) were re-
corded during the observation time interval. In addition, feasibility prob-
lems (FPs) during the operation of the GMA column were recorded. The 
safety of GMA was assessed in all patients. The effectiveness of GMA was 
assessed in patients with UC with a partial Mayo (pMayo) score of ≥3. Re-
mission was defined as a pMayo score of ≤2, while response was defined 
as a decrease in the pMayo score by ≥2 points and by ≥30% decrease rela-
tive to that at baseline plus all 3 sub-scores ≤1.
results: A total of 131 patients who received GMA retreatment (109 UC, 22 
CD; 51.9% female) with a median age 41.0 years were included. Among 
all patients, 81 did not have any special situation, while 50 had at least 
one special situation, including 17 elderly, 18 with anemia and 24 on mul-
tiple immunosuppressants. AEs and FPs were observed in 9.9% and 8%, 
respectively. The FPs rate (3.7%) in the GMA retreated patients without 
any special situation was significantly lower than the rate (16.0%) in pa-
tients with at least one special situation (P=0.021). The rates of AEs and 
FPs in the elderly, patients with anaemia and those on multiple immu-
nosuppressants were 17.6% and 23.5%, 22.2% and 16.7% and 12.5% and 
8.3%, respectively. The effectiveness of GMA retreatment was assessed in 
78 patients with UC. Remission and response rates were 41.0% and 55.1%, 
respectively. There were no significant differences in the rates of remis-
sion (43.4% vs. 36.0%) and response (56.6% vs. 52.0%) between patients 
without any special situation and those with at least one special situation. 
Remission and response rates in 11 elderly, 8 with anemia and 8 on mul-
tiple immunosuppressants were 36.4% and 63.6%, 37.5% and 50.0% and 
25.0% and 37.5%, respectively.
conclusion: Relatively low rates of AEs and FPs and favourable response 
and remission rates were observed in patients who received GMA retreat-
ment. The rate of FPs in patients who received GMA retreatment without 
any special situation was significantly lower than those with special situ-
ation. Although the rate of FPs in the elderly was relatively high, approxi-
mately 60% of the elderly patients achieved response by receiving GMA 
retreatment.
disclosure: Taro Osada has received research grant from JIMRO Co. Ltd. 
Hiroki Tanaka has received lecture fees from JIMRO Co. Ltd., AbbVie GK, EA 
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Methods: Using the local databases from two referral centers, all the pa-
tients with IBD who were in clinical remission at the time they were moved 
to a spaced schedule with infliximab or adalimumab, were identified. Pa-
tients with ostomy or ileoanal pouch, indication of anti-TNF therapy for 
perianal disease, or adverse events as the main cause for spaced schedule, 
were excluded. The spaced schedule was considered successful if, at the 
end of the follow-up, the patient remained in clinical remission with the 
same spaced schedule or without biological therapy and if no return to 
the conventional schedule, dose-escalation, change to another biological 
agent, a course of systemic corticosteroids or surgery were required.
results: 85 patients were included (58 Crohn’s disease, 27 ulcerative coli-
tis/IBD unclassified). 60 were treated with infliximab (49 every 10 weeks 
and 11 every 12 weeks) and 25 with adalimumab every 3 weeks. Before the 
spaced schedule, 38% of patients had previous courses of anti-TNF, and 
7% required dose-escalation. The spaced schedule was initiated after the 
median of 25 months of anti-TNF treatment (IQR 14-49). Baseline C-reac-
tive protein (CRP) was available in all patients (95% with CRP< 5mg/L). 
Baseline faecal calprotectin was available in 31% of patients (100% < 250 
µg/g). Morphological assessment of disease activity (colonoscopy, MRI en-
terography) within 6 months before the spaced schedule was available in 
48% of patients (3% and 17% with endoscopic and RMI activity, respec-
tively). 64% were on combination therapy with an immunosuppressant at 
the beginning of the anti-TNF. The median time on spaced schedule was 
15 months (IQR 12-25). 37% of patients returned to a conventional schedule 
and 9% required dose-escalation. In 16 patients (19%) the anti-TNF was 
stopped because of sustained remission (9/22). 12 patients had available 
trough infliximab levels before the spaced schedule (median: 2.8 µg/mL 
[IQR, 1.12-4.30]) and 21 patients after two spaced doses (median: 1.6 µg/mL 
([IQR, 0.5-3.5]). 10 patients had available trough infliximab levels before 
and after the spaced schedule; with a significant decrease in drugs levels 
(p=0.007). At the end of follow-up, 50 out of 85 patients (59%) met the 
success criteria of the spaced schedule. A longer time (> 5 years) from IBD 
diagnosis to the introduction of anti-TNF treatment (RR 2.1 [IC 95% 1.1 - 
4.3]; p=0.034) and a baseline CRP >2mg/L prior to spacing (RR 3.2 [IC 95% 
1.4 - 7.5]; p=0.008), were the only independent predictive factors of the 
failure of the spacing strategy.
conclusion: Anti-TNF administration at longer intervals than those pro-
vided in the data sheet of the drug can be a convenient and cheaper al-
ternative, particularly effective in patients in whom anti-TNF treatment 
was early initiated (within 5 years from disease diagnosis) and once deep 
remission has been achieved.
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Rotondo, Italy
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Introduction: Vedolizumab is a fully humanized monoclonal antibody that 
selective binds the α4β7 integrin, recently approved for the treatment of 
patients with Inflammatory Bowel Diseases (IBD). It acts blocking the mi-
gration of circulating T-lymphocytes into inflamed gastro-intestinal tissue.
aims & Methods: Here we present a real-life experience with patients af-
fected with IBD treated with Vedolizumab.
All consecutive patients observed at a single Center (Gastroenterology De-
partment of “Casa Sollievo della Sofferenza” Hospital) treated with Ve-
dolizumab from September 2016 were included. Demographic and clinical 
data (age at disease diagnosis, disease location and duration, behavior, 
and previous therapies) were collected. We also collect clinical activity be-
fore and during therapy with Vedolizumab and concomitant medications. 
The clinical response to induction (valued by means of Harvey Bradshaw 
index and partial Mayo score for Crohn’s disease and Ulcerative Colitis 
patients respectively) was assessed after 3 months of therapy. Persistence 
of therapy with Vedolizumab was also evaluated.
results: A total of 68 patients (30 Crohn’s Disease (CD) and 38 Ulcerative 
Colitis (UC)) were included. Thirty-eight patients were male (55.8%), and 
the mean disease duration was 10.2±7.3 years and 11.8±6.8 years for CD 
and UC respectively. The majority of patients had moderate activity when 
started Vedolizumab (90% and 86.8% of those with CD and UC, respec-
tively). Fifty-two patients (76.5%) had been treated with Anti TNF alpha 
before Vedolizumab. Clinical response after three months of therapy was 
achieved in 22 CD patients (73%) and 33 UC patients (87%). Fifteen patients 
(11 CD and 4 UC) definitively discontinued Vedolizumab (9 for primary non 
response, 1 for intolerance, and five for loss of response after a mean of 
25±2.9 months of therapy - range 21-30). Fifty-two patients (76.4%) are on-
going in treatment with a mean persistence of therapy of 12.2±7,3 months 
(range 1 - 33). No significant differences for clinical response rate were 
found between patients naïve vs previous treated with anti TNF alpha (87% 
vs 83%, p=1.0), short (≤ 2 years) vs long disease duration (75% vs 83%, 
p=0.6), older (≥ 65 years) vs younger patients (70% vs 85%, p=0.1), and 
disease behavior for Crohn’s disease (66.6% of patients with B1 responded 
to Vedolizumab vs 80% both for B2 and B3, p=0.3).
conclusion: Vedolizumab was effective in patients with IBD (both CD and 
UC), irrespective of previous anti TNF alpha therapy, age of patients, dis-
ease duration and disease behavior in Crohn’s disease.
disclosure: Nothing to disclose 
P0435 sPacIng The adMInIsTraTIOn InTervaL Of anTI-Tnf 
agenTs: a vaLId sTraTegy fOr PaTIenTs WITh InfLaMMaTOry 
BOWeL dIsease?
Torres Rodríguez P.F.1, Núñez L.2, Aguilar A.1, Mañosa M.1, Mesonero F.2, 
Cañete F.1, Calafat M.1, Fernandez C.2, Cabré E.1, López-San Román A.2, 
Domènech E.1
1Hospital Universitari Germans Trias i Pujol, Aparell Digestiu, Badalona, 
Spain, 2Hospital Ramón y Cajal, Aparato Digestivo, Madrid, Spain
contact e-Mail address: paofrtr@gmail.com
Introduction: Patients with psoriasis and rheumatologic diseases are even-
tually treated with biological agents using treatment schedules with more 
spaced administrations than those approved in data sheet. These sched-
ules are cheaper, and they even might reduce the risk of adverse events. 
However, they are scarcely used in inflammatory bowel disease (IBD).
aims & Methods: 
Aim: To describe the clinical outcomes of IBD patients treated with anti-
TNF agents by means of a spacing schedule (administration interval great-
er than 8 weeks for infliximab or 2 weeks for adalimumab).
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P0436 surgery and hOsPITaLIzaTIOn raTes In 
InfLaMMaTOry BOWeL dIsease PaTIenTs In The quéBec 
PrOvIncIaL daTaBase frOM 1996 - 2015
Verdon C.1, Reinglas J.1, Coulombe J.2, Gonczi L.3, Bessissow T.1, 
Afif W.1, Vutcovici M.1, Wild G.1, Seidman E.1, Bitton A.1, Brassard P.2,4,5, 
Lakatos P.L.1,3
1McGill University Health Center, Division of Gastroenterology, Montreal, 
Canada, 2Lady Davis Research Institute, Jewish General Hospital, Centre 
for Clinical Epidemiology, Montreal, Canada, 3Semmelweis University, First 
Department of Internal Medicine, Budapest, Hungary, 4Biostatistics and 
Occupational Health, Department of Epidemiology, Montreal, Canada, 
5McGill University, Department of Medicine, Montreal, Canada
contact e-Mail address: kislakpet99@gmail.com
Introduction: Inflammatory bowel diseases (IBD), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC), are associated with high healthcare 
expenditures related to medications, hospitalisations, and surgeries. Our 
aim was to analyse disease outcomes and treatment algorithms in newly 
diagnosed IBD patients in Québec over the past 2 decades, comparing pe-
riods before and after routine public reimbursement of biologics.
aims & Methods: Overall, 34644 newly diagnosed IBD patients (CD: 20644 
or 59.5%; M:F CD: 3:4, UC: 1:1; CD < 40 years old: 46% vs. UC< 40 years 
old: 35%) were identified from the population-based health insurance da-
tabase of Québec from 1996 to 2015. The primary and secondary outcomes 
included time to and probability of first hospitalisation and first major 
surgery, and medication exposures. Prescription data were collected from 
the public prescription database (RAMQ).
results: Probability of major surgery increased after 2010 in CD (at 5 years 
after diagnosis: before and after 2010: 8% (SD: 0.2%) vs. 15% (0.6%); p< 
0.0001) and UC patients (6% (0.2%) vs. 10% (0.6%); p< 0.0001). Hospitali-
sations rates remained unchanged, but were higher in CD compared with 
UC (p< 0.0001). IBD patients on biologicals had overall lower probability of 
hospitalisations compared with other drug types (overall 5 years probabil-
ity for all IBD patients using 5-ASA: 37% (0.6%); biologicals: 31% (1.8%), 
p< 0.0001). Biologicals were more commonly prescribed in CD after 2010 
(4% (0.2%) vs. 16% (0.6%), p< 0.0001), especially in patients less than 40 
years old at diagnosis. Thiopurine exposure increased in IBD patients after 
2010 (CD: 21% (0.4%) vs. 24% (0.6%) p< 0.0001; UC: 13% (0.4%) vs. 16% 
(0.7%), p< 0.0001), while methotrexate use remained overall low (overall 
5 years probability in CD: 4% (0.1%); UC: 1% (0.1%); p < 0.0001). Cortico-
steroid exposure was unchanged before and after 2010 (CD: 31% (0.4%) 
vs. 30% (0.7%) p=0.46; UC: 31% (0.5%) vs. 34% (0.9%); p=0.03). 5-ASA 
use was higher in UC (40% (0.4%), p < 0.001), while in CD it became lower 
after 2010 (33% (0.4%) vs. 21% (0.6%), p< 0.0001).
conclusion: The probability of first hospitalizations remained unchanged 
whilst the probability of first major surgery was increased despite the 
higher and earlier use of biologicals therapies in IBD in this large pop-
ulation-based inception cohort from Québec. Overall, there was a slight 
increase in the use of thiopurines and methotrexate, while the use of cor-
ticosteroids was unchanged.
disclosure: Nothing to disclose 
P0437 anaLysIs Of uc cOLecTOMy raTes In Pre- and 
POsT- BIOLOgIc era In LOThIan, scOTLand
Jenkinson P.1, Jones G.R.1, Plevris N.1, Lyons M.2, Kirkwood K.3, Arnott I.D.1, 
Lees C.W.1
1NHS Lothian, Gastroenterology, Edinburgh, United Kingdom, 2University 
of Edinburgh, Edinburgh, United Kingdom, 3NHS Lothian, Pathology, 
Edinburgh, United Kingdom
contact e-Mail address: philipjenkinson@nhs.net
Introduction: The use of biologic therapy for UC in the UK has lagged sig-
nificantly behind that of Crohn’s disease because of restricted guidance 
from NICE (NICE Clinical Guideline 166, June 2013). Following approvals of 
anti-TNF and vedolizumab for UC in early 2015 there has been a significant 
increase in prescribing. The aim of this study was to describe trends in 
colectomy rates for UC over time spanning the pre- and post-biologic era.
aims & Methods: All patients (adult and paediatric) with a diagnosis of UC 
who received maintenance biologic treatment and/or underwent a colec-
tomy in Lothian between 1st January 2005 and 31st December 2018 were 
identified by interrogating multiple clinical and administrative databases. 
Patient phenotype, prescribing and surgical data including complications 
were extracted by manual review of the EHR. Operations were classified 
by extent of resection and by time interval from diagnosis to colectomy 
(early within 6 months vs established after 6 months from diagnosis). Lin-
ear regression and segmental regression assuming poisson variance were 
used to identify temporal changes (statistical joinpoints) in the trend of 
biologic prescription and colectomy rates. Biologic prescription and colec-
tomy rates were described per 100 UC patients, with yearly prevalence data 
obtained from the Lothian IBD Registry (Jones et al, ECCO 2019).
results: A total of 175 patients were treated with maintenance biologic 
therapy during the study (Table 1). Rates of initiation of maintenance bio-
logic therapy increased from 0.05 per 100 UC patients in 2005 to 1.26 in 
2018 (p< 0.001). For the whole study period the biologic prescription an-
nual percentage change (APC) was 30.4% (14.5-48.6% 95% CI). Rates of 
prescription of infliximab as rescue therapy remained at a steady state 
throughout the study. 
A total of 448 colectomies for UC were performed during the study period 
(Table 1). Colectomy rates per 100 UC patients fell throughout the study 
period; from 1.47 colectomies per 100 UC patients in 2005 to 0.44 in 2018 
(p< 0.001). There was a significant inflection point in the rate of change 
with a statistical joinpoint identified in 2014. The colectomy rate APC was 
-4.1% per year from 2005 to 2014 and -18.9% from 2014 to 2018 (p=0.019). 
There was no increase in complications in patients treated with biologics 
pre-operatively. 
year uc Preva-lence
colecto-
mies
1st Biologic 
prescriptions year
Popula-
tion
colecto-
mies
1st Biologic 
prescriptions
2005 2152 32 1 2012 3164 30 2
2006 2289 35 0 2013 3279 34 5
2007 2445 33 0 2014 3415 40 13
2008 2548 32 1 2015 3566 26 32
2009 2727 36 2 2016 3678 26 28
2010 2881 46 1 2017 3798 24 39
2011 3003 37 2 2018 3876 17 49
[Table 1 UC colectomy and first maintenance biologic prescription numbers 
per year]
conclusion: The increase in biologic prescribing for UC has been paral-
lelled by a significant reduction in colectomy rates without increased post-
operative complications. This is the first population based study that shows 
a reduction in colectomy rates in parallel with increased use of biologics 
for UC.
references: Jones G et al, ECCO 2019, DOP87. Multi-parameter datasets are 
required to identify the true prevalence of IBD: The Lothian IBD Registry 
(LIBDR)
disclosure: PJ has received travel support from Takeda. NP has received 
consultancy fees from Takeda and speaker fees and travel support from 
AbbVie, Takeda and Norgine. IDA has received consultancy fees from Vifor 
and travel support from Shire. CWL has received research support from 
AbbVie and Shire, consultancy fees from AbbVie, Pfizer, Dr. Falk, Hospira, 
MSD, Pharmacosmos, Takeda and Vifor, and speaker fees and travel sup-
port from AbbVie, Pfizer, Dr. Falk, Ferring, Hospira, MSD, Shire, Takeda 
and Warner-Chilcott. GRJ, KK and ML have no personal interests to declare. 
P0438 WIThdraWn
P0439 rIsk Of LaTe POsT-OPeraTIve recurrence Of 
crOhn’s dIsease In endOscOPIc reMIssIOn afTer ILeOcaecaL 
resecTIOn: a 10-year MuLTIcenTer exPerIence
Pouillon L.1,2, Amicone C.3, Remen T.2, Louis E.3, Maes S.1, Reenaers C.3, 
Germain A.2, Baumann C.2, Bossuyt P.1, Peyrin-Biroulet L.2
1Imelda Hospital Bonheiden, Gastroenterology-Hepatology, Bonheiden, 
Belgium, 2Nancy University Hospital, Vandoeuvre-lès-Nancy, France, 
3University Hospital CHU of Liège, Liège, Belgium
contact e-Mail address: lievenpouillon@icloud.com
Introduction: The Rutgeerts’ score (RS) grades the severity of signs of en-
doscopic Crohn’s disease (CD) recurrence in the postoperative patient af-
ter ileocolonic resection. Although the International Organization for the 
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P0440 assessMenT Of The need fOr The fIrsT InTesTInaL 
resecTIOn In PaTIenTs WITh crOhn’s dIsease fOLLOWIng 
dIagnOsIs: a sIngLe-cenTre cOhOrT sTudy In jaPan
Yamashita M.1,2, Tanaka H.2, Nakamura K.2, Sugiyama K.2, Kato M.1,2, 
Miyakawa M.2, Sakemi R.2,3, Nasuno M.2, Ishii M.2,4, Motoya S.2, Itoh F.1
1St. Marianna University School of Medicine, Division of Gastroenterology 
and Hepatology, Kawasaki, Japan, 2Sapporo Kosei General Hospital, 
IBD Center, Sapporo, Japan, 3Tobata Kyoritsu Hospital, Center for 
Gastroenterology, Kitakyushu, Japan, 4Fujiwara Internal Medicine Clinic, 
Okayama, Japan
contact e-Mail address: ymstmsktbssr@ac.auone-net.jp
Introduction: Studies on the natural history of Crohn’s disease (CD) show 
that up to 50% of CD patients require their first intestinal resection within 
10 years of diagnosis. In recent years, immunomodulators (IM) and anti-
tumour necrosis factor (TNF) agents have become available and used to 
treat CD worldwide, but currently, there is inadequate information regard-
ing the need when the first intestinal resection should be undertaken.
aims & Methods: The aim of this study was to investigate the time when 
the first intestinal resection becomes necessary after the diagnosis of CD 
and understand the relevant prognostic factors including concomitant ad-
ministration of IM or anti-TNF agents. We retrospectively compiled and re-
viewed the data on patients with CD who had been treated at our hospital 
between January 2010 and December 2012. Patients who were diagnosed 
with CD prior to 1989 and had undergone intestinal resection before the 
diagnosed of CD were excluded. All patients were followed until the initial 
intestinal resection was done or until March 2019. Patients who were lost 
to follow-up were censored. Patients were divided into two groups accord-
ing to the year of CD diagnosis (Group A, 1990-2001; Group B, 2002-2012). 
Between groups A and B, patients’ demographic variables were compared 
using univariate analysis. Further, the cumulative rates of the initial in-
testinal resection following the diagnosis of CD in the two groups were 
evaluated using the Kaplan-Meier method together with the log-rank test.
results: A total of 291 patients, median age, 21.7 years; 93 female were 
available for evaluation. At the diagnosis of CD, 157 patients had ileocolitis, 
84 had ileitis and 50 had colitis. Two-hundred and two patients were di-
agnosed with non-stricturing, non-penetrating disease, 75 with stricturing 
disease and 14 with penetrating disease. Perianal disease was diagnosed 
in 159 patients. During the observation period, concomitant prednisolone, 
IM (azathioprine or 6-mercaptopurine) and anti-TNF agents (infliximab 
or adalimumab) were administered to 72, 162 and 177 patients, respec-
tively. Among the 291 patients, 125 were assigned to Group A and 166 to 
Group B. The proportion of the patients diagnosed with non-stricturing, 
non-penetrating disease, stricturing disease and penetrating disease were 
60%, 33% and 7% in Group A and 77%, 20% and 3% in Group B, respec-
tively indicating that the number of patients with non-stricturing, non-
penetrating disease in Group B significantly increased compared to Group 
A, while patients with stricturing and penetrating disease decreased com-
pared with Group A (P = 0.008). Patients who had received concomitant 
treatment with prednisolone were significant lower in Group B than in 
Group A (19% vs. 34%, P = 0.007), while patients on concomitant IM or 
anti-TNF agents were significantly higher in Group B than in Group A (IM: 
66% vs. 42%, P < 0.001; anti-TNF agents: 78% vs. 44%, P < 0.001). Further, 
the cumulative rates of 1, 5, 10 and 15 years intestinal resection were 16%, 
29%, 47% and 57% in Group A and 8%, 15%, 21% and 24% in Group B, 
respectively showing that the cumulative rates of intestinal resection in 
Group B were significantly lower than in Group A (P < 0.001).
conclusion: This study showed a significant reduction in the rates of initial 
intestinal resection in patients with CD diagnosed during 2002-2012 than 
those diagnosed during 1990-2001. It is assumed that a decrease in pa-
tients with stricturing and penetrating disease and an increase in IM and 
anti-TNF agents use may have contributed to the decrease in the intestinal 
resection rate beyond 2001.
disclosure: Maki Miyakawa has received lecture fees from JIMRO Co. Ltd. 
Hiroki Tanaka has received lecture fees from JIMRO Co. Ltd., AbbVie GK, EA 
Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyorin Pharmaceutical 
Co. Ltd. and Mitsubishi Tanabe Pharma Corporation. Satoshi Motoya has 
received lecture fees from Mitsubishi Tanabe Pharma Corporation, Mochi-
da Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K. and Takeda Phar-
maceutical Co. Ltd.; and has received research grants from Pfizer Japan 
Inc., Janssen Pharmaceutical K.K. and from Takeda Pharmaceutical Co. Ltd. 
Study of Inflammatory Bowel Disease (IOBD) agreed that a RS< i2 reflects 
endoscopic remission, the risk of late post-operative disease recurrence in 
these patients remains unclear.
aims & Methods: We performed a multicenter, retrospective cohort study 
to evaluate the risk of late post-operative CD recurrence in patients who 
are in endoscopic remission after ileocaecal resection. All CD patients that 
underwent an ileocolonic resection with curative intent between 2006-
2016 were screened for eligibility in three large-volume IBD centres. Only 
those who had no signs of endoscopic recurrence (defined as RS< i2) at 
baseline assessment between month 3 and 18 after surgery were included. 
Post-operative recurrence during follow-up was defined as a composite 
endpoint of at least one of the following: clinical recurrence (i.e. new or 
worsening IBD-related abdominal pain and/or diarrhea), IBD related hos-
pitalization, development of bowel damage (i.e. new intra-abdominal fis-
tulae, abscesses and/or strictures), the need for endoscopic balloon dilata-
tion of the anastomosis, and the need for redo-surgery. Time to disease 
recurrence was estimated by Kaplan-Meier analysis, and cox regression 
analysis was used to identify potential risk factors for recurrence.
results: A total number of 86 patients (n=55 female; n=27 active smok-
ers) were included. Median (IQR) time between CD diagnosis and ileoco-
lonic resection was 6.1 (0.9-19.4) years. Seventeen (19.8%) patients had 
undergone previous surgery, while the majority (n=55, 64%) had received 
treatment with immunomodulators and/or biologicals before ileocolonic 
resection. Median (IQR) time between surgery and baseline endoscopy 
was 7 (5.7-9.5) months and forty (46.5%) patients received therapy with 
immunomodulators and/or biologicals in this period. Median (IQR) fol-
low-up time after baseline endoscopy was 3.5 (1.6-5.3) years. Based on 
the composite endpoint, late post-operative CD recurrence was seen in 
35 (40.7%) patients (Table 1). Recurrence status was comparable between 
patients with RS of i0 (20/55) or i1 (15/31) at baseline endoscopy (p=0.28), 
and independent whether or not patients had received medical therapy 
between surgery and baseline endoscopy (16/40 with therapy vs. 19/46 
without therapy; p=0.9). Median (IQR) time to disease recurrence was 
14.2 (6.3-26.1) months. No risk factor for late post-operative CD recurrence 
could be identified after bivariate cox regression analysis.
conclusion: This is the first study looking at the risk of late post-operative 
CD recurrence after ileocaecal resection with curative intent.It was seen in 
up to 40% of patients despite initial endoscopic remission, and continuous 
follow-up of this population remains therefore warranted.
Outcome parameter yes no 
Clinical recurrence, % (n) 36 (31) 64 (55)
IBD-related hospitalization, % (n) 15.1 (13) 84.9 (73)
Need for endoscopic balloon dilatation, % (n) 4.7 (4) 95.3 (82)
New intra-abdominal bowel damage, % (n) 16.3 (14) 83.7 (72)
Need for IBD-related surgery, % (n) 3.5 (3) 96.5 (83)
Composite endpoint, % (n) 40.7 (35) 59.3 (51) 
[Risk of late post-operative CD recurrence]
disclosure: Lieven Pouillon received travel fees from Abbvie, Ferring and 
Takeda. Peter Bossuyt received grants and personal fees from Abbvie; 
and personal fees from Takeda, Vifor Pharma, Hospira, Janssen, MSD, 
Mundipharma, Roche, Pfizer, and Dr Falk Benelux. Laurent Peyrin-
Biroulet received consulting fees from Merck, Abbvie, Janssen, Genentech, 
Mitsubishi, Ferring, Norgine, Tillots, Vifor, Therakos, Pharmacosmos, 
Pilège, BMS, UCB-pharma, Hospira, Celltrion, Takeda, Biogaran, 
Boerhinger-Ingelheim, Lilly, Pfizer, HAC-Pharma, Index Pharmaceuticals, 
Amgen, Sandoz, Forward Pharma GmbH and Celgene; and lecture fees 
from Merck, Abbvie, Takeda, Janssen, Takeda, Ferring, Norgine, Tillots, 
Vifor, Therakos, Mitsubishi, and HAC-pharma. All other authors declare no 
competing interests in relationship to this abstract. 
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P0441 TransanaL cLOse recTaL dIssecTIOn (Tacrd) 
PrOcTecTOMy: a neW rOad TO an OLd desTInaTIOn
Barugola G.1, Variola A.2, Bertocchi E.1, Di Ruscio M.2, Geccherle A.2, 
Ruffo G.1
1IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Surgery, Negrar, Italy, 
2IRCCS Ospedale Sacro Cuore Don Calabria Negrar, Centro delle Malattie 
Rettointestinali (IBD Unit), Negrar, Italy
contact e-Mail address: angela.variola@sacrocuore.it
Introduction: Total mesorectal excision (TME) is the gold standard resec-
tional strategy for rectal cancer. In benign diseases so called close rectal 
dissection (CRD), has been traditionally advocated to minimize damage to 
pelvic neural plexuses and complications reducing dead space, compared 
to TME. In daily practice laparoscopic CRD has never spread because af-
fects a worse visualization, a chopsticks conflict and a more difficult hemo-
stasis. Transanal approach bottom to up to the pelvis (taCRD) could allow a 
better visualization and an easily and safer hemostatic control.
aims & Methods: Aim of the study was to evaluate safety and feasibility 
of TaCRD proctectomy in our inflammatory bowel diseases (IBD) cohort. 
From January 2016 to December 2018 prospective colorectal disease data-
base maintained at IRCCS Sacred Heart - Don Calabria Hospital of Negrar 
was required to identify patients underwent taCRD proctectomy for IBD ). 
Transanal platform of choice was Gel Point Path™. We analyzed all clinical 
and operative data.
results: Nineteen patients (median age 43,6 ± 11,4, male/female 13/6, me-
dian BMI 22,3 ± 3), 16 with ulcerative colitis (UC) and 3 with Crohn’s disease 
(CD). TaCRD proctectomy was always performed when dysplasia or cancer 
are not suspected. In 9 cases an ileal pouch-anal anastomosis (ta-IPAA) 
(47,3%) was done. Operative time was 85 min (±21) in 89,1 % of patients. 
Dissection was properly carried on with radiofrequency plus hook in 69,4 
% of cases. The main intraoperative problem was smoke evacuation in 15,7 
% of cases; No bleeding was experienced neither chopstich conflict that 
led to conversion to abdominal approch. During postoperative course we 
experienced 2 complication (10,4 %); one bleeding that has been no need 
of blood transfusion (Clavien-Dindo I) and one collection, successfully 
treated with antibiotics (Clavien Dindo II). In our series taIPAA creation did 
not affect further complications .
conclusion: Our experience confirmed that TaCRD is feasible and safe with 
proper indication. It allows a less rate of complication even when per-
formed as the road to pouch creation. A next step will be the evaluation of 
functional results compared with laparoscopic TME and TaTME.
disclosure: Nothing to disclose 
P0442 LaParOscOPIc InTraOPeraTIve uLTrasOund In 
PaTIenTs WITh crOhn’s dIsease: a feasIBILITy sTudy
Botti F.1,2, Prati M.1, Montagnolo G.1, Verga V.1, Caprioli F.3, Boni L.1,3
1Fondazione Irccs Ca’ Granda Ospedale Maggiore Policlinico Milan, General 
Surgery, Milan, Italy, 2Università degli Studi di Milano, Milano, Italy, 
3Università degli Studi di Milano, Milan, Italy
contact e-Mail address: chir5mi@hotmail.com
Introduction: Transabdominal bowel ultrasound (BUS) is being increas-
ingly adopted for diagnosing and monitoring of patients with Crohn’s dis-
ease (CD), due to its wide availability and readiness. Specifically, BUS has 
been reported to accurately evaluate CD extension, activity and to detect 
presence of CD-related complications. Moreover, ultrasound elastography 
has been recently demonstrated able to quantify bowel wall fibrosis. No 
study has so far assessed feasibility and usefulness of laparoscopic bowel 
ultrasound during CD-related surgery.
aims & Methods: The aim of the study is to assess the feasibility and 
usefulness of laparoscopic bowel ultrasound during CD-related surgery. 
Consecutive CD patients undergoing their first laparoscopic surgery were 
enrolled. Intraoperative laparoscopic ultrasound was performed in the first 
stage of surgical intervention by a dedicated surgeon expert in CD-related 
surgery. A dedicated 5-10 Mhz US laparoscopic transducer with a flexible 
tip and a depth of 4-10 centimeters was used for all examinations.
results: Between March 2016 and March 2017 10 CD patients were enrolled. 
Intraoperative US was feasible in all patients (i.e. intraoperative US study of 
CD-affected tract), and no procedure-related complication was reported. 
Mean US execution time was 25 minutes (range 15-40 minutes). Median 
follow-up following surgery was 29 months (range 24-36). In all patients, 
intraoperative US was helpful for CD surgical management (Table). 
During post-operative follow-up, 1 patient experienced a grade I complica-
tion according to Clavien-Dindo while 1 patient experienced a grade IIIa 
complication. No patient underwent a second bowel resection at the end 
of follow-up
Pts (n) Intraoperative laparoscopic ultrasound-related advantage
2 Suggesting not to perform bowel resection
1 Helping to rule out CD diagnosis
2 Clarification of intestinal and mesenteric morphology
3
Identification of the exact location of CD-related complications (fistula and 
abscesses)
1 Identification and characterization of concomitant lesions
4 Clarification of imaging discrepancies
8 Exact definition of bowel resection margin
[Table 1]
conclusion: Results of the present study demonstrate that laparoscopic 
intraoperative ultrasound is feasible and safe in patients with Crohn’s dis-
ease. Our preliminary data seem to suggest that this technique may be 
helpful for CD surgical management, even if these results should be con-
firmed in a prospective study.
disclosure: Nothing to disclose 
P0443 cOLecTOMy raTes and POsTOPeraTIve cOMPLIcaTIOns 
In PaTIenTs WITh uLceraTIve cOLITIs regIsTered In a TerTIary 
cenTer
Costache R.E.1, Anda L.1, Saizu I.A.1, Stanciulea O.2, Dumitrascu T.2, 
Iacob R.1, Popescu I.2, Gheorghe L.S.1, Gheorghe C.1
1Fundeni Clinical Institute, Gastroenterology, Bucharest, Romania, 2Fundeni 
Clinical Institute, Surgery, Bucharest, Romania
contact e-Mail address: roxanaelenacostache@gmail.com
Introduction: According to disease duration, surgical intervention rate in 
patients with UC varies from 4.9% to 15.6%.1 The standard procedure is 
proctocolectomy with ieal pouch, its curative goal being limited by the 
postoperative complications, which occurs in 30% of the cases2.
aims & Methods: The purpose of our study was to asses the colectomy rates 
and the main postoperative complications in patients with UC admitted in 
a Tertiary Gastroenterology Center - Fundeni Clinical Institute, Bucharest, 
Romania - during January 2012 - March 2019. Among 592 of patients with 
UC admitted in our clinic during the mentioned period, 111 patients (18%) 
with severe disease, we retrospectively analysed the data from 28 patients 
(4.7%) who underwent surgical intervention. We extracted the data using 
our hospital information system. The mean age at diagnosis was 38 years. 
Disease extension, surgical indication, intervention type, postoperative 
and long-term complications with their specific treatment were analysed.
results: The main indications for the surgery intervention were severe, 
medically unresponsive flare (69.2%), the presence of dysplasia/adeno-
carcinoma (11.54%), toxic megacolon (7.69%), stenosis (7.69%) and ab-
cess (3.85%). The most common intervention was the restaurative proce-
dure (53.85%), followed by proctocolectomy with a permanent ileostomy 
(19.23%), hemicolectomy (15.38%) and total colectomy with ileorectal 
anastomosis (11.54%).The progression of disease extension was observed 
in 30.77% of the patients, being strongly correlated to the medical intrac-
tability (p< 0.001). Postoperatively, the most frequent complications were 
the local and systemic infections (50.00%), haemorrhage (18.75%), early 
stomal complications (12.50%), anastomotic leak (6.25%), eventration 
(6.25%) and fistulas (6.25%). 52.63% of the interventions were performed 
laparoscopically; the laparotomic procedures and also the urgent surger-
ies (23.08%) were associated with more frequent infectious complications 
(p< 0.001). Pouch-related complications (pouchitis, stenosis, pouch failure 
and irritable pouch syndrome) were the most common long-term compli-
cations - 41.67%, with a response rate to the medical treatment of 50.00%.
conclusion: The data regarding the colectomy rate registered in our clinic 
is similar to those mentioned in the literature. The timing and surgical ap-
proach have an essential role in the postoperative evolution.
references: 1. “Long-Term Colectomy Rates in Patients with Ulcerative Coli-
tis Treated with Infliximab: A Single Canadian Tertiary Care Centre’s Expe-
rience.” Journal of Crohn’s and Colitis, vol. 9, no. suppl 1, 2015, doi:10.1093/
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P0445 PreLIMInary daTa On OraL and fecaL MIcrOBIOTa 
In PaTIenTs affecTed By Lynch syndrOMe
Mannucci A.1, Zuppardo R.A.2, Ferrarese R.3, Antoci G.4, Ditonno I.4, 
Notaristefano C.2, Patricelli M.G.5, Russo Raucci A.5, Testoni P.A.2, 
Di Leo M.6, Mancini N.3, Cavestro G.M.2
1Università Vita-Salute San Raffaele, Gastroenterology and Gastrointestinal 
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University, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy, 
3Microbiology and Virology Unit, IRCCS Ospedale San Raffaele, Università 
Vita-Salute San Raffaele, Milan, Italy, 4Università Vita-Salute San Raffaele, 
Gastroenterology and Gastrointestinal Endoscopy Unit, Milano, Italy, 
5Division of Genetics and Cell Biology, Unit of Genomics for Human Disease 
Diagnosis, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy, 
6Digestive Endoscopy Unit, Division of Gastroenterology, Humanitas Clinical 
and Research Center, Department of Biomedical Sciences, Humanitas 
University, Milan, Italy
contact e-Mail address: alessandromannucci11@gmail.com
Introduction: Microbiota alterations seem to play an associated role in 
colorectal cancer (CRC) pathogenesis. Bacteroides, Fusobacterium, Salmo-
nella, Escherichia and Campylobacter have been widely studied, demon-
strating their promoting role on inflammatory environment, production of 
molecules affecting DNA stability and alteration of proliferative responses. 
Few projects are ongoing on microbiota alterations in patients affected by 
Lynch Syndrome (LS).
aims & Methods: Our aim was the characterization of oral and fecal mi-
crobiota in LS patients compared with healthy normal controls. We anal-
ized oral and fecal microbiota of 17 LS patients: 12 patients were MSH2 
mutation carriers, 3 MLH1 mutation carriers, 2 MSH6 mutation carriers. 
11 underwent on emicolectomy and one proctocolectomy for CRC, besides 
one gastric cancer, one endometrial cancer and one duodenal cancer. Total 
DNA was purified from fecal samples and oral washes. The V3-V4 region 
of the 16s rRNA gene was amplified. Purified DNA was quantified and 
libraries were diluted and mixed for pooling with unique molecular tags. 
Sequences with high quality score and length >250bp were used for the 
taxonomic analysis with QIIME software.
results: Oral wash microbiota of Lynch patients and 41 matched normal 
healthy controls were analyzed. Alpha diversity was statistically different 
between the two groups, with a lower observed otus/chao1 index in Lynch 
patients compared to controls. The unweighted beta diversity was able to 
distinguish the two populations. At the genus level, taxonomic analysis of 
oral wash samples showed a statistically significant increase of Veillonella 
(17% vs 11%) and a decrease of Neisseria (10% vs 17%) and Prevotella (3% 
vs 5%) in Lynch patients compared to control subjects. Fecal microbiota of 
Lynch patients and 21 matched normal healthy controls were analyzed. No 
statistically significant differences were observed neither in alpha diversity 
and nor in beta diversity between the two groups. Taxonomic analysis of 
fecal samples identified a statistically significant increase of Bifidobacte-
riaceae in Lynch patients compared to controls (2% vs 0%) and a slight 
increase of Enterobacteriaceae in Lynch samples (1% vs 0%).
conclusion: An increase of Veillonella and a decrease of Neisseria was ob-
served in oral wash samples of Lynch patients. In fecal samples of Lynch 
patients we observed an increase of Bifidobacteriaceae. These associations 
were described in sporadic colorectal cancer and Crohn’s disease (CD) too. 
Further study on larger groups of patients are needed to confirm or revoke 
these results.
disclosure: Nothing to disclose 
P0446 seruM MeTaBOLITe PrOfILes In acuTe radIaTIOn 
enTerITIs: an anIMaL MOdeL sTudy
Zhang Q., Zhan Q., An F., Nie H.
Wuxi People’s Hospital Affiliated to Nanjing Medical University, 
Gastroenterology, Wuxi, China
contact e-Mail address: zhang517068@126.com
Introduction: Acute radiation enteritis (ARE), a complication with radio-
therapy for pelvic and abdominal tumors, seriously undermines the life 
quality, even shortens the life span of survivors. Untargeted metabolomics 
analysis may help find the diagnostic biomarkers, metabolic mechanism 
and intervention strategies for ARE.
ecco-jcc/jju027.659. 2. Kühn, Florian, and Ernst Klar. “Surgical Principles in 
the Treatment of Ulcerative Colitis.” Viszeralmedizin vol. 31,4 (2015): 246-
50. doi:10.1159/000438894
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P0444 fecaL caLPrOTecTIn LeveLs are eLevaTed In 
TransThyreTIn aMyLOIdOsIs PaTIenTs WITh gasTrOInTesTInaL 
ManIfesTaTIOns
Nakov R.1, Sarafov S.2, Nakov V.3, Gospodinova M.4, Todorov T.5, Kirov A.5,6, 
Todorova A.5,6, Vladimirov B.7, Tournev I.2,8
1Clinic of Gastroenterology, Queen Yoanna University Hospital, 
Gastroenterology, Sofia, Bulgaria, 2Alexandrovska University Hospital, 
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Joanna University Hospital, Gastroenterology, Sofia, Bulgaria, 4Medical 
Institute of Ministry of Interior, Clinic of Cardiology, Sofia, Bulgaria, 5Genetic 
and Medico-diagnostic Laboratory “Genica”, Sofia, Bulgaria, 6Medical 
University - Sofia, Department of Medical Chemistry and Biochemistry, Sofia, 
Bulgaria, 7UMBAL Tsaritsa Joana, Gastroenterology, Sofia, Bulgaria, 8New 
Bulgarian University, Department of Cognitive Science and Psychology, Sofia, 
Bulgaria
contact e-Mail address: radislav.nakov@gmail.com
Introduction: Transthyretin amyloid (ATTR) amyloidosis is a rare systemic 
disorder characterized by amyloid deposits formed by misfolded mono-
mers of transthyretin (TTR). Gastrointestinal (GI) manifestations are com-
mon in ATTR amyloidosis, however their pathogenesis is not fully eluci-
dated.
aims & Methods: In the current study, we aimed to evaluate the diagnostic 
role of fecal calprotectin (FC) in ATTR patients with GI manifestations and 
to evaluate the role of intestinal inflammation in the pathogenesis of the 
disease. We recruited 21 consecutive ATTR amyloidosis patients and 42 sex 
and age-matched healthy controls. Presence of GI symptoms and severity 
of peripheral neuropathy had been evaluated. Colonoscopy and FC assess-
ment were performed in all subjects.
results: Mean levels of FC in ATTR amyloidosis patients 184 µg/g (30-430) 
were significantly higher then those of controls 40 µg/g (30-70), p< 0.001. 
ROC curve analysis indicated a FC cut-off level of 71 µg/g differentiates 
ATTR amyloidosis with GI manifestations from healthy subjects with 91% 
sensitivity, 100% specificity, 100% positive predictive value, 95% negative 
predictive value and 97% overall accuracy. FC values were significantly as-
sociated with the presence of neutrophilic granulocytes infiltration in the 
colonic mucosa (p=0.002), with the presence of amyloid deposits in rectal 
mucosa ( p=0.007) and the presence of diarrhea (p=0.046).
conclusion: FC levels are elevated in patients with ATTR amyloidosis with 
GI manifestations, which suggests an inflammatory component in the 
pathogenesis of the disease. The presence of elevated FC concentrations 
could help gastroenterologists to include ATTR amyloidosis in their diag-
nostic work-up
disclosure: Nothing to disclose 
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aims & Methods: ARE rat model was established through single abdomi-
nal irradiation with a gamma-ray dose of 10 Gy. The fecal condition of each 
rat was recorded. H&E staining was employed to evaluate the change in 
intestinal structure at four days after radiation. Serum from 15 ARE mod-
els and 10 controls were collected for untargeted metabolomics detection 
by ultra-high-performance liquid chromatography/quadrupole-time-of-
flight-mass spectrometry (UHPLC-Q-TOF/MS). Variable importance for the 
projection (VIP) was calculated in Orthogonal partial least squares dis-
crimination analysis (OPLS-DA) which worked together with heat map to 
categorize samples and screen metabolites. Significantly differentially ex-
pressed metabolites (VIP > 1 and P < 0.05) between ARE group and control 
group were identified. At last, Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathway analysis was employed to explore the metabolomic path-
ways affected by abdominal irradiation.
results: At two days after radiation, ARE rats showed obvious diarrhea, 
while the control rats continued to defecate normally. H&E staining re-
vealed a dramatic destruction in the intestinal villi of irradiated animals, 
which confirmed the occurrence of ARE. Based on the metabolomics data, 
6044 positive peaks and 4241 negative peaks were extracted from each 
sample. In OPLS-DA, the explanation rate for Y variable (R2Y) and predic-
tion ability (Q2) (0.998 and 0.788 in positive ion mode, 0.997 and 0.866 in 
negative ion mode) confirmed the stability and reliability of the model. The 
heat map for cluster analysis showed satisfactory discriminatory power 
between ARE rats and controls. Further analysis identified 66 significantly 
differentially expressed metabolites, ten of which changed by more than 
three folds and might be biomarkers for ARE. KEGG pathway enrichment 
analysis indicated that the differentially expressed metabolites were in-
volved in multiple different pathways, including central metabolism in 
cancer, mineral absorption, protein digestion and absorption, aminoacyl-
tRNA biosynthesis, ABC transporters, pyrimidine metabolism.
conclusion: Ten metabolites, with more than three folds change in ex-
pression, may serve as useful biomarkers for ARE. The pathways through 
which abdominal irradiation disrupts metabolic activity of intestinal cells 
may provide a clue for elucidating ARE physiopathology.
disclosure: The authors declare no conflict of interest 
P0447 LOss Of The MIcrOBIaLLy reguLaTed hexOkInase 2 In 
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Hamm J.1, Klischies K.1, Prasse D.2, Hinrichsen F.1, Mishra N.1, Messner B.1, 
Häsler R.1, Aden K.1, Schmitz-Streit R.2, Rosenstiel P.1, Sommer F.1
1University Hospital Schleswig Holstein, Institute of Clinical Molecular 
Biology, Kiel, Germany, 2Christian-Albrechts-University Kiel and University 
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contact e-Mail address: jacobhamm@me.com
Introduction: Hexokinases (HK) are a group of five isoenzymes, which 
catalyze the first step of glycolysis and thereby limit its pace. HK activity is 
tightly linked to immune responses1 and HK2 also functions as a pattern 
recognition receptor sensing a bacterial cell wall component and thereby 
mediates a pro-inflammatory response2.
aims & Methods: Our goal was to examine the function of HK2 for host-
microbiota-interactions and intestinal inflammation. To that end, we gen-
erated mice lacking Hk2 specifically in intestinal epithelial cells (Hk2-ΔIEC) 
and tested their susceptibility to acute inflammation using the dextran 
sodium sulfate (DSS) colitis model. In parallel we stimulated epithelial 
cell lines and gnotobiotic mice with bacterial strains and metabolites to 
identify bacterial agents that may modulate Hk2 expression and thereby 
intestinal inflammation.
results: Under unchallenged conditions Hk2-ΔIEC mice did not exhibit a 
major metabolic or inflammatory phenotype, whereas loss of HK2 in the 
intestinal epithelium was protective during acute inflammation. We found 
that the normal microbiota strongly regulates HK2 expression and activity. 
Additionally, we identified individual bacteria and metabolites that repress 
Hk2 expression in intestinal epithelial cells and gnotobiotic mice. We cur-
rently test whether supplementation with these bacterial factors protects 
from intestinal inflammation.
conclusion: Our data identified the microbiome as a central regulator of 
HK2 and glycolysis and thereby as a potential therapeutic target for acute 
inflammatory conditions.
references: 1 Perrin-Cocon et al. “Toll-like Receptor 4-Induced Glycolytic 
Burst in Human Monocyte-Derived Dendritic Cells Results from p38-De-
pendent Stabilization of HIF-1α and Increased Hexokinase II Expression.”, J 
Immunol, 201 (5) 1510-1521, September 01, 2018 2 Wolf et al. “Hexokinase Is 
an Innate Immune Receptor for the Detection of Bacterial Peptidoglycan.”, 
Cell 166, 624-636, July 28, 2016
disclosure: Nothing to disclose 
P0448 IMPacT Of The dIeTary POLyaceTyLenIc faLcarInOL 
and faLcarIndIOL On InfLaMMaTIOn and cOLOrecTaL cancer: 
a MechanIsTIc sTudy In a PrIMed raT MOdeL
Kobaek-Larsen M.1, Baatrup G.2, Notabi M.3, El-Houri R.3, Pipó-Ollé E.3, 
Arnspang E.3, Christensen L.4
1Odense University Hospital, Department of Clinical Science, Svendborg, 
Denmark, 2Department of Clinical Research, Surgery, Svendborg, Denmark, 
3University of Southern Denmark (SDU), Odense, Denmark, 4Allborg 
University, Alborg, Denmark
contact e-Mail address: morten.kobaek.larsen@rsyd.dk
Introduction: Colorectal cancer (CRC) development is a multistep process, 
from normal epithelial cells via inflammation to aberrant crypt foci (ACF) 
and progressive adenoma stages, to carcinomas and then metastatic dis-
ease [1, 2]. In order to reduce the incidence and consequences of CRC, ef-
fective prevention and treatment strategies need to be identified. Due to the 
long precancerous stage of identifiable disease, dietary intervention may 
exert favorable effect on polyp formation and/or inhibition of adenomas 
transformation to CRC. Recent findings indicate that long-term consump-
tion of a diet rich in vegetables may prevent the development of CRC [3]. 
For the prevention of CRC by dietary measures, vegetables such as carrots 
are highly interesting due to their content of the bioactive polyacetyle-
nic falcarinol (FaOH) and falcarindiol (FaDOH) [4]. FaOH and FaDOH have 
shown many interesting bioactivities including anti-inflammatory and cy-
totoxic activity [4-6]as well as antineoplastic effect in animal models [7, 8]. 
In this study, we demonstrate that FaOH and FaDOH prevent the develop-
ment of early neoplastic lesions in the colorectal intestine in a dose-re-
sponse relationship corresponding to the logarithmic of the concentration 
of the contents of FaOH and FaDOH in the diet. Furthermore, the results 
presented also demonstrate that FaOH and FaDOH have an effect on in-
flammatory markers and they seem to act as selective COX-2 inhibitors, 
which appears to be their main mechanism of action in relation to colon 
cancer prophylactics.
aims & Methods: The gene expression of seven inflammatory markers COX-
1, COX-2, NFκβ1, IL1β, IL6, PPARγ and TNFα in tissue from biopsies was 
analyzed by means of Real-time quantitative PCR (RT-qPCR). The biopsies 
include neoplastic tissue from the control group, receiving standard rat 
diet (SRD) without the supplement of FaOH and FaDOH and size matched 
neoplastic tissue from the test group receiving SRD supplemented with 7 
µg FaOH g-1 feed and 7 µg. Prior to the RT-qPCR, RNA from the tissue was 
extracted using QIAzol and EconoSpin column purification where after it 
was converted into complementary DNA.
results: The expression level of seven different inflammatory and cancer 
biomarkers COX-1, COX-2, TNFα, IL-6, NF-κβ, IL-1β, and PPARgamma2, 
were examined in both neoplastic and healthy tissue from biopsies ob-
tained from rats receiving either SRD or SRD supplemented with FaOH 
and FaDOH. 
Upregulation of most biomarkers, except COX-1, TNFα, and IL-1β, was ob-
served in neoplastic tissue compared to normal tissue. Contrary, a sig-
nificant downregulation in expression levels were detected in five of the 
seven biomarkers when comparing biopsies of neoplastic tissue from rats 
receiving a SRD with biopsies of neoplastic tissue from rats receiving the 
FaOH and FaDOH as a food supplement. A significant downregulation in 
the expression of TNFα, IL-6, NF-κβ, PPARγ2 and COX-2 was detected. 
The qRT-PCR analyses showed no significant difference in the expression 
level in healthy tissue for all biomarkers when the rats received FaOH and 
FaDOH as a food supplement compared to rates receiving SRD.
conclusion: Collectively, the results of the present study shows that FaOH 
and FaDOH in combination has a chemopreventive effect on CRC in a can-
cer primed rat model and that this effect is due to their inhibitory effect 
on key biomarkers in the NF-κB signaling pathway and in particular the 
downstream target COX-2. The present study therefore opens up for precise 
dietary advices to prevent this disease and to develop new selectively COX-
2 inhibitors with no or only minor side effects.
references: 1. Vogelstein and Kinzler, The multistep nature of cancer. Trends 
Genet, 1993. 9(4): p. 138-41. 2. Lucas et al., Microbiota, Inflammation and 
Colorectal Cancer. Int J Mol Sci, 2017. 18(6). 3. Leenders et al., Subtypes of 
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P0450 LOss Of PTPn2 In eITher dendrITIc ceLLs Or T ceLLs 
resuLTs In reduced TuMOr Burden In The OrThOTOPIc cOLOn 
TuMOur MOuse MOdeL
Katkeviciute E., Hering L., Montalban-Arques A., Busenhart P., Atrott K., 
Scharl M., Spalinger M.
University Hospital Zurich, USZ, Department of Gastroenterology and 
Hepatology, Zürich, Switzerland
contact e-Mail address: egle.katkeviciute@usz.ch
Introduction: In the recent years, protein tyrosine phosphatase non-re-
ceptor type 2 (PTPN2) has emerged as a potential cancer immunotherapy 
target. Our previous data demonstrate that loss of PTPN2 in dendritic cells 
(DC) or in T cells results in reduced tumour burden in the azoxymethane 
(AOM)-dextran sodium sulphate (DSS) induced model of colitis-associated 
colorectal carcinoma (CRC). However the role of PTPN2 in inflammation 
independent CRC pathogenesis has not yet been determined. Here, we 
show that tissue-specific deletion of PTPN2 in DCs or T cells results in re-
duced tumour load in the orthotopic cecum injection mouse model of CRC.
aims & Methods: Tumours were induced in mice specifically lacking PTPN2 
in either DCs (PTPN2fl/fl-CD11cCre) or T cells (PTPN2fl/fl-CD4Cre) and their WT 
littermate controls by injecting MC38 tumour cells into the mouse caecum. 
Immune cells in spleen, mesenteric lymph nodes (mLN), tumour (T) and 
tumour-adjacent normal tissue (non-T) were analysed using flow cytom-
etry and immunohistochemistry.
results: Although tumour burden varied between individuals, PTPN2fl/f-
CD11cCre and PTPN2fl/f-CD4Cre mice had clearly less and smaller tumours 
compared to their littermate controls. In turn, PTPN2-deficient mice exhib-
ited significantly increased levels of CD44+ effector/memory CD4+ and CD8+ 
T cells in spleen and mLN, indicating enhanced T cell activation. Addition-
ally, we observed increased granzyme B expression in the spleen from 
PTPN2fl/fl-CD4Cre mice compared to their littermate controls, suggesting 
increased cytotoxic/anti-tumour activity of PTPN2-deficient CD8+ T cells. 
Furthermore, expression of regulatory T cells was decreased in PTPN2-
deficient mice, showing lower effector/memory T cells suppression in 
PTPN2fl/f-CD11cCre and PTPN2fl/f-CD4Cre mice compared to their littermate 
controls. Finally, PTPN2-deficient mice presented increased levels of the 
checkpoint marker PD-1 on T cells in the spleen, further displaying highly 
increased immune response.
conclusion: Our results demonstrate an important in vivo role for PTPN2 
in the pathogenesis of inflammation independent CRC. Loss of PTPN2 in 
either DCs or T cells exerts anti-tumour effects and ultimately results in 
lower colon tumour burden. This effect is likely mediated via promoting 
anti-cancer immune responses by modulating T cell activation, cytotoxicity 
and immune checkpoint molecules expression.
disclosure: Nothing to disclose 
P0451 characTerIzaTIOn Of a neW BacTerIaL LIgand fOr 
PParγ
Petitfils C.1, Pujo J.2, Perez-Berezo T.3, Payros G.3, Barreau F.3, Blanpied C.3, 
Bertrand-Michel J.4, Oswald E.3, Dietrich G.3, Le Faouder P.4, Cenac N.3
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Introduction: Data from clinical research suggest that certain probiotic 
bacterial strains have the potential to modulate colonic inflammation in 
patients with inflammatory bowel diseases. Nonetheless, this data differs 
considerably among studies due to the probiotic bacterial strains used and 
the poor knowledge of their mechanisms of action.
aims & Methods: The aim of our study was to better characterize the mech-
anisms of the anti-inflammatory activity of Escherichia coli Nissle 1917 (EcN), 
a probiotic used for the treatment of multiple intestinal disorders. Lipids 
were extracted from pathogenic Escherichia coli (E. coli) strains UTI, Nu14, 
SP15, CFT, NC101, from an asymptomatic E. coli ABU, from a commensal E. 
coli M1/5 and from the probiotic EcN. Llipid extracts were analyzed by liquid 
chromatography coupled to high resolution mass spectrometry for identifi-
cation and by liquid chromatography coupled to tandem mass spectrometry 
(LC-MS/MS) for quantification. To assess the passage of 3-hydroxyoctade-
caenoic acid (C18-3OH) across the intestinal barrier, we used caco2 cells 
fruit and vegetables, variety in consumption and risk of colon and rectal 
cancer in the European Prospective Investigation into Cancer and Nutrition. 
Int J Cancer, 2015. 137(11): p. 2705-14. 4. Waluga et al., Pharmacological and 
dietary factors in prevention of colorectal cancer. J Physiol Pharmacol, 2018. 
69(3). 5. Christensen and Brandt, Bioactive polyacetylenes in food plants of 
the Apiaceae family: occurrence, bioactivity and analysis. J Pharm Biomed 
Anal, 2006. 41(3): p. 683-93. 6. Metzger et al., Purple carrot (Daucus carota 
L.) polyacetylenes decrease lipopolysaccharide-induced expression of 
inflammatory proteins in macrophage and endothelial cells. J Agric Food 
Chem, 2008. 56(10): p. 3554-60. 7. Kobaek-Larsen et al., Inhibitory effects 
of feeding with carrots or (-)-falcarinol on development of azoxymethane-
induced preneoplastic lesions in the rat colon. J Agric Food Chem, 2005. 
53(5): p. 1823-7. 8. Kobaek-Larsen et al., Dietary polyacetylenes, falcarinol 
and falcarindiol, isolated from carrots prevents the formation of neoplastic 
lesions in the colon of azoxymethane-induced rats. Food Funct., 2017.
disclosure: Nothing to disclose 
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exPerIence
Soufleris K.1, Fasoulas K.1, Lazaraki G.1, Kafalis N.1, Stergiou E.1, 
Vladika N.2, Tzilves D.1
1Theageneio Anticancer Hospital Thessaloniki, Gastroenterology, 
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contact e-Mail address: fasoulaskonstantinos@gmail.com
Introduction: Immunotherapy has significantly improved the traditionally 
poor prognosis of several malignant diseases including metastatic mela-
noma and Non Small Cell Lung Cancer (NSCLC), while their efficacy in a 
number of other tumor types is vigorously studied. Immune check point 
inhibition can lead to activation of autoreactive T-cells resulting in a new 
spectrum of side effects called immune-related adverse events (IRAEs). 
Gastrointestinal manifestations are common complications of immuno-
therapy, being often the cause of treatment discontinuation.
aims & Methods: We retrospectively assessed 9 patients (5 males, mean 
age: 65.4 years) admitted to the Gastroenterology Department, because 
of gastrointestinal symptoms while being on therapy with immune check-
point inhibitors for NSCLC (7 patients) and metastatic melanoma (2 pa-
tients). Two patients were treated with ipilimumab, 6 with nivolumab, and 
one with a combination treatment.
results: Diarrhoea was the most common symptom, followed by abdomi-
nal pain, fever and nausea. The mean time of symptom occurrence was 17 
weeks after initiation of immunotherapy (8-27 weeks). The colonoscopy 
findings in 6 patients were consistent with colitis with continuous in-
flammation pattern (mucosal erythema, ulcerations, loss of subepithelial 
vascular pattern and friable mucosa), while 3 patients had normal endo-
scopic findings. Cryptitis, and crypt abscesses were common pathological 
findings. Granulomas were not detected. Hospitalization was required for 
three patients as they met the Truelove-Witts criteria for acute severe coli-
tis. CRP levels were elevated in 8 cases (mean 7.3 mg/dl, 3.9 - 10.6) and 
returned to normal after the treatment. The albumin levels were decreased 
in 7 patients (mean 3.3 g/dl, 2.6 - 3.9). Seven patients were treated with 
corticosteroids and one patient received salvage therapy with infliximab 
after failure of steroid treatment. Time to symptom resolution was noted 
to be variable (ranging from 1 day to 4 weeks).
conclusion: Given the constantly expanding use of immune checkpoint 
inhibitors, it is important for the gastroenterologists to be familiar with 
the gastrointestinal IRAEs. Steroids comprise the first line of treatment, 
but salvage therapy with infliximab may be necessary in case of a steroid 
treatment failure. The role of alternative biologics, mainly vedolizumab is 
being studied. Long-term management of immune related colitis and the 
effect of infliximab on the malignant disease have to be further evaluated.
disclosure: Nothing to disclose 
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differentiated in transwell and colon biopsies in Ussing chambers. Time-
resolved fluorescence resonance energy transfer (TR-FRET)-based competi-
tive binding assay was performed to assess the C18-3OH agonist properties 
for the peroxisome proliferator activated receptor gamma (PPARγ). Mice 
received an oral administration of C18-3OH and were injected with a PPARγ 
antagonist (GW9662, IP). Concentration of C18-3OH and mRNA expression 
of genes dependent on the PPARγ activation (Fiaf and Lfabp) were quanti-
fied in mouse colons. In order to test the impact of the C18-3OH on colitis, 
mice have been submitted to DSS-induced colitis model and to oral ad-
ministration of C18-3OH. Intensity of colitis was determined by the quan-
tification macroscopic and microscopic scores, paracellular permeability, 
pro-inflammatory and pro-resolving lipids and mRNA expression of protein 
implicated in barrier functions (Zo1, Occludin, Muc2, …), chemokines (Cxcl1, 
Cxcl2,…) and cytokines (IL6, IL1β, …).
results: In EcN, we identified and quantified free long chain fatty acids 
(LCFA) from 8 to 18 carbons hydroxylated on the 3rd carbon. The concentra-
tion of C18-3OH was increased in EcN compared to other E. coli strains. 
This bacterial lipid was not able to cross caco2 cells in transwell or tis-
sue in Ussing chambers but penetrated the cells. The C18-3OH bonded the 
receptor-binding site of PPARγ. Oral administration of C18-3OH increased 
its concentration in the colon and increased Fiaf and Lfabp mRNA expres-
sion; treatment with a PPARγ antagonist inhibited these effects. C18-3OH 
treatment to mice with DSS-induced colitis significantly decreased paracel-
lular permeability, colon thickness, macroscopic and microscopic scores 
and pro-inflammatory lipid concentration compared to DSS-treated mice. 
In addition, the C18-3OH decreased Reg3γ, Zo1, Cxcl1 and Cxcl2 mRNA ex-
pression.
conclusion: The bacterial lipids C18-3OH is a agonist of PPARγ. It could 
therefore represent a new mechanism of probiotics anti-inflammatory ac-
tivities.
disclosure: Nothing to disclose 
P0452 gasTrOInTesTInaL and LIver IMMune-reLaTed 
adverse evenTs Induced By InMune checkPOInT InhIBITOr: 
a descrIPTIve OBservaTIOnaL sTudy
Sanz-Segura P.1, García Cámara P.1, Fernandez-Bonilla E.1, Bernal V.1,2
1Hospital Miguel Servet, Department of Gastroenterology, Zaragoza, Spain, 
2Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain
contact e-Mail address: paulagarciacamara@gmail.com
Introduction: Immune checkpoint inhibitors (ICIs), such as anti-CTLA-4 
and anti-PD-1 antibodies, are effective against several malignancies. They 
are associated with gastrointestinal and liver immune-related adverse 
events (GI-IrAEs and LI-IrAEs), which may be severe and lead to ICI dis-
continuation.
aims & Methods: The aim of this study is to evaluate real-world data about 
the efficacy and gastrointestinal and liver toxicity of ICIs in several cancers 
among patients who have progressed on one or more prior lines of che-
motherapy. 
Methods: All patients with advanced cancers who received at least 1 molec-
ular-targeted therapy after the failure of chemotherapy between May 2015 
and September 2018 at our center were retrospectively assessed. Informa-
tion about efficacy and toxicity was collected and analyzed. The grade of 
irAEs was defined based on the Common Terminology Criteria for Adverse 
Event (CTCAE) version 4.0.
results: 132 patients who had received ICIs were included, 32% female, 
with mean age 66.3 (SD 10.4) years. Primary tumors were as follows: 86 
(65.6%) non-small cell lung cancer; 30 (22.9%) melanoma; 12 (9.16%) 
kidney cancer; and 3 (2.29%) others tumors. ICIs therapy included atezoli-
zumab (N=13), nivolumab (N=82), pembrolizumab (N=28), durvalumab 
(N=2), ipilimumab (N=1) and combined programmed cell death protein 
1/cytotoxic T-lymphocyte-associated protein 4 antibodies (N=6). 19.6% of 
evaluable patients achieved a response. 51 (38.6%) patients developed any 
IrAEs. GI-IrAEs were observed in 17 (12.9%) patients: 9 grade 1, 6 grade 2 
and 2 grade 3. 8 out 17 (47%) needed steroids and 1 patient needed sur-
gery due to colonic perforation. 4 of 6 patients with combined treatment 
suffered from GI-IrAEs. No more treatment-related discontinuations or 
deaths occurred because of GI-IrAEs. LI-IrAEs were observed in 4 patients 
(3.03%), which all consisted of mild grade hepatitis (grade 1 and 2). 50% 
patients needed steroids and 1 patient stopped treatment. Any patient with 
combined treatment suffered from Li-IrAEs. IrAEs were no related with age 
or sex. IrAEs development did not predict response.
conclusion: GI-IrAEs are among the most commonly encounter IrAEs, 
mainly with combination treatment. LI-IrAEs are rare. Both are potentially 
life-threatening events. Their management in a multidisciplinary approach 
will help to reduce morbidity and therapy interruptions.
disclosure: Nothing to disclose 
P0453 TOxIn a and B cOMBIned WITh gLuTaMaTe 
dehydrOgenase IMMunOassays can save TOxIgenIc cuLTure 
fOr The dIagnOsIs Of cLOsTrIdIOIdes dIffIcILe InfecTIOn
Yoshimura D.1,2, Shimomura T.2, Iwasaki N.2, Inoue T.2, Suenaga K.2, 
Ochiai T.1
1Saiseikai Fukuoka General Hospital, Gastroenterology, Fukuoka, Japan, 
2Saiseikai Fukuoka General Hospital, Infection Control Team, Fukuoka, Japan
contact e-Mail address: mdyoshimura@gmail.com
Introduction: Clostridioides difficile infection (CDI) in adults is an important 
nosocomial intestinal infectious disease, which can be life-threatening. An 
efficient diagnosis of CDI is needed both for patient safety and for hospital 
cost saving. The stool toxin enzyme immunoassay (EIA) is a major method 
of laboratory rapid testing, however, its sensitivity is inadequate. On the 
other hand, the sensitivity of toxigenic culture (TC) or nucleic acid amplifi-
cation test (NAAT) is excellent, however, it costs much and may overdiag-
nose CDI. The glutamate dehydrogenase (GDH) EIA is also reported as high 
sensitivity, but the significance compared with TC is not clear.
aims & Methods: We performed a single-center prospective study to ex-
amine the effectiveness of EIAs detecting toxin A/B and GDH (C.DIFF QUIK 
CHEK, Alere), compared with selective anaerobic culture (cycloserin-cefox-
itin mannitol agar; CCMA-EX, Nissui) as the reference method (TC). During 
the period from August 2012 to December 2013, the hospitalized patients 
with unexplained and newly onset watery diarrhea (defined as more than 
3 stools/day) were included in the study. All the stool specimen was simul-
taneously tested by EIA and TC. For the positive selective culture plate, all 
the colonies in a single plate were picked up and suspended at once in 
saline, then applied to the toxin A/B EIAs. In this study, CDI was defined as 
positive with TC (both selective culture and toxin EIA).
results: A consecutive 447 stool specimens were tested. Toxin A/B EIAs 
were positive for 62 samples (13.9%), and all of them were also posi-
tive with GDH and TC. Among the 385 specimens that were negative with 
toxin A/B EIAs, 35 samples (9.1%) were positive with GDH and also with 
TC. Twenty (57.1%) out of those 35 culture positive specimens were posi-
tive with toxin tests. There was no specimen that was positive in selective 
culture while the GDH test was negative. Accordingly, the prevalence of 
CDI was 18.3% in this study. The sensitivity of the rapid test only for toxin 
A/B was 75.6%, while the combination of GDH test resulted in the positive 
predictive value of 84.5% and the negative predictive value of 100%. This 
study also proved the GDH EIA to be equivalent to TC.
conclusion: Our study indicated that the two-step combination of TC for the 
GDH negative stool samples is not needed. The combination rapid test for 
Clostridioides difficile GDH and toxins is useful that could save unnecessary 
TC costs. In accordance with the study, we have established the algorithms 
for CDI test (Figure 1). Patients positive with GDH while negative for toxin 
EIAs could be placed on preemptive contact precautions and could also be 
treated empirically until the results of TC are revealed. During the period 
from January 2014 to December 2018, 1442 stool specimens were tested, 
and 216 cases (15.0%) were diagnosed as CDI, without any nosocomial 
outbreak incident.
disclosure: Nothing to disclose 
P0454 effIcacy Of MuLTIPLex sTOOL Pcr assay fOr 
deTecTIOn Of enTerOPaThOgenIc BacTerIa In PaTIenTs WITh 
acuTe InfecTIOus dIarrhea
Ahn J.S., Seo S.I., Kang J.G., Kim H.S., Shin W.G., Jang M.K., Lee J.H., 
Kim H.Y.
Kangdong Sacred Heart Hospital, Gastroenterology, Seoul, Republic of Korea
contact e-Mail address: dks0819@kdh.or.kr
Introduction: Bacterial infections are important cause of acute infectious 
diarrhea. Conventional stool culture and microscopic examination are time 
consuming and often lack sensitivity and specificity. Recently, there has 
been substantial development of multiplex molecular assays for the de-
tection and identification of pathogens responsible for causing diarrhea.
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P0456 earLy cOnTrasT-enhanced cT BefOre cOLOnOscOPy 
sIgnIfIcanTLy IMPrOves The raTes Of IdenTIfyIng The 
resPOnsIBLe dIverTIcuLuM causIng cOLOnIc dIverTIcuLar 
BLeedIng and endOscOPIc heMOsTasIs
Mizutani S.1, Ochi M.1, Yamaguchi Y.1, Okawara H.1, Okawara A.1, 
Kakinoki N.1, Hirai S.1, Kamoshida T.1, Yanaka A.2
1Hitachi General Hospital, Gastroenterology, Hitachi, Japan, 2University of 
Tsukuba, Gastroenterology, Hitachi, Japan
contact e-Mail address: yutsudo0130@yahoo.co.jp
Introduction: Colonoscopy for colonic diverticular bleeding (CDB) within 
24 hours after hematochezia is useful to make a diagnose and perform 
therapeutic intervention, but it has problems due to the necessity of pre-
treatment and a low CDB identification rate. Intravenous contrast materi-
al-enhanced computed tomography (CT) before colonoscopy contributes 
to improvement of the rate of identifying stigmata of recent hemorrhage 
(SRH) compared with that by colonoscopy alone, but the timing of CT to 
improve the colonoscopic hemostatic rate has remained unclear.
aims & Methods: We assessed the usefulness of performing contrast-
enhanced CT early after the first hematochezia (within 6 hours) for CDB 
patients retrospectively. A diverticulum with active hemorrhage, blood 
clots, and an exposed hemorrhagic vessel was defined as the diverticulum 
responsible for CDB. The subjects were 146 CDB patients who visited our 
hospital between January 2012 and January 2018 and were examined by 
contrast-enhanced CT and then colonoscopy within 24 hours. For analysis, 
the Mann-Whitney U-test and chi-square test were used. Patients exam-
ined by contrast-enhanced CT within 6 hours and after 6 hours were des-
ignated as an early CT group (69 patients (47 %)) and elective CT group 
(77 patients (53%)), respectively. The treatment effectiveness of contrast-
enhanced CT early after the onset of CDB was investigated.
results: Ninety-nine patients (67.8%) were male and the mean age was 
72 years old (37-96 years old). There was no difference in the characteris-
tics between the early and elective CT groups. The extravasation-positive 
rate significantly improved in the early CT group compared with that in 
the elective CT group (49 vs. 27%, respectively; P=0.006). In addition, the 
colonoscopic hemostatic rate significantly improved in the early CT group 
compared with that in the elective CT group (32 vs. 13%, respectively; 
P=0.006). No adverse event after contrast-enhanced CT, such as contrast-
induced nephropathy, occurred.
conclusion: Early contrast-enhanced CT after the onset of CDB significantly 
improved the responsible diverticulum identification rate and colonoscop-
ic hemostatic rate in the early CT group. By performing contrast-enhanced 
CT in the early phase, extravasation positivity served as an index to apply 
hemostasis to the responsible diverticulum, suggesting that the responsi-
ble diverticulum was safely and accurately identified by contrast-enhanced 
CT performed early after hematochezia, which significantly contributed to 
colonoscopic control of hemorrhage.
disclosure: Nothing to disclose 
P0457 BLOOd grOuP O Is an IndePendenT rIsk 
facTOr fOr deLayed POsT-PrOceduraL BLeedIng afTer 
endOscOPIc resecTIOn fOr cOLOrecTaL TuMOrs: 
a MuLTI-cenTer case-cOnTrOL sTudy
Furuhashi H.1,2, Dobashi A.1,2, Tamai N.1,2, Shimamoto N.1,2, Ono S.1,2, 
Matsui H.1,2, Hara Y.1,3, Kobayashi M.1,3, Ohya T.1,2, Kamba S.1,2, 
Horiuchi H.1,2, Koizumi A.1,2, Kato M.1,4, Ikeda K.1,3, Arakawa H.1,5, 
Sumiyama K.1,2
1The Jikei University School of Medicine, Department of Endoscopy, Tokyo, 
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4Jikei University Katsushika Medical Center, Department of Endoscopy, Tokyo, 
Japan, 5Jikei University Kashiwa Hospital, Department of Endoscopy, Chiba, 
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contact e-Mail address: ms04furuhashi@gmail.com
Introduction: Delayed post-procedural bleeding (DPPB) is a common ad-
verse event after endoscopic resection (ER) for colorectal tumors and occa-
sionally requires additional interventions. Recently, O blood group of ABO 
blood group system has been reported as a risk factor for various bleeding 
events, but the relationship with DPPB has yet to be investigated. This 
study aimed to evaluate if the O blood group would be relevant to DPPB.
aims & Methods: In this study, we evaluated the efficacy of multiplex stool 
polymerase chain reaction (PCR) test in patients with acute infectious diar-
rhea. A total of 250 admitted patients with acute infectious diarrhea were 
recruited in Kangdong Sacred Heart Hospital from January 2016 to Decem-
ber 2018. Multiplex PCR detected 7 enteropathogenic bacteria including 
Salmonella, Campylobacter, Shigella, Escherichia coli O157:H7, Aeromonas, 
Vibrio, Clostridium difficile. We reviewed clinical and laboratory findings 
by stool multiplex PCR test and compared with those by stool culture.
results: Mean age was 49.7±20.5 years and hospital stay was 7±10.5 days. 
Multiplex stool PCR test detected much more enteropathogens compared 
with stool culture (61.2% vs. 5.2%). Of culture-positive specimens, 4% 
of those were the same pathogens detected in multiplex PCR test. Stool 
multiplex PCR detected 88 Campylobacter, 46 E. Coli H7, 16 Clostridium, 11 
Salmonella, 5 Aeromonas, 4 Shigella and 4 Vibrio. Campylobacter was the 
most common pathogen in stool PCR (88/250, 35.2%) and culture (4/10, 
40%). Stool PCR-positive patients presented more fever >38°C [72/153 
(47.1%) vs. 33/97 (34%), P=0.04) and higher C-reactive protein (CRP) at 
admission [100.9±79mg/L vs. 65.1±83mg/L, P=0.001] compared with PCR-
negative patients.
conclusion: Multiplex stool PCR test showed superior sensitivity to conven-
tional culture for detection of pathogens in acute infectious diarrhea. Stool 
PCR result may be useful to predict clinical severity of infectious diarrhea.
disclosure: Nothing to disclose 
P0455 PrOBIOTIcs fOr The PrevenTIOn Of cLOsTrIdIuM 
dIffIcILe InfecTIOn aMOng PaTIenTs undergOIng anTIBIOTIc 
TheraPy- PreLIMInary resuLTs
Popescu A., Foncea C.G., Topan M., Cotrau R., Belintan P., Moga T.V., 
Danila M., Sirli R., Sporea I.
Victor Babes University of Medicine, Department of Gastroenterology and 
Hepatology, Timisoara, Romania
contact e-Mail address: alinamircea.popescu@gmail.com
Introduction: Clostridium difficile infection (CDI), is the leading cause of 
antibiotic-associated diarrhea (AAD), a disease which increased in inci-
dence and severity over the last years. Antibiotics exposure is considered 
the most significant risk factor for CDI among eldery and hospitalized pa-
tients. Probiotics have been proposed for the prevention and treatment of 
a variety of gastrointestinal conditions, but guidelines do not recommend 
probiotic use for prevention of CDI (1). The aim of this study is to evaluate 
the efficacy of probiotics in preventing CDI.
aims & Methods: We performed an unblinded, randomized, prospective 
study (October 2018- March 2019), in which 140 patients admitted in our 
department, who fulfilled the inclusion criteria and received antibiotics, 
regardless the indications, were included. Four arms of study were creat-
ed: three probiotics and one group placebo. The patients received probiot-
ics in less than 24 hours from the first antibiotic dose, during the treatment 
and 7 days after, according to their dose indication. Strains such as Lac-
tobacillus, Clostridium Butiricum, Bacilus Mesentericus, Bifidobacterium 
and Streptococcus faecalis were used. Primary and secondary outcomes 
were frequency of AAD and CDI and adverse events.
results: Out of 140 patients, 54 female and 86 male, mean age 63±12 
years, mean hospitalization days 7.5±6.1. 35.5%(50/140) were on placebo 
and 64%(90/140) received probiotics. 16.4% received prophylaxis antibi-
otics. Among those with infection, the most frequent was urinary infec-
tion 28.2%. Other risk factors for CDI accounted were: use of proton pomp 
inhibitors 18.5%(26/140) patients, 46.4%(65/140) patients with age >65 
years, liver cirrhosis 47.1%(66/140) patients. 
13.5%(19/140) of patients developed antibiotic-associated diarrhea, 
30%(15/50) patients from the placebo group and 4.4%(4/90) patients on 
probiotics (p< 0.0001). Out of 140 patients, 4.2%(6/140) were confirmed 
with CDI, 10%(5/50) patients from placebo group and only 1.1% (1/90) pa-
tient on probiotics (p=0.013). Patients exposed to antibiotics, without tak-
ing probiotics had a higher risk of CDI: OR=9.8 CI 95% (1.12-87) p=0.039. 
None of the patients reported adverse events.
conclusion: The rate of antibiotic-associated diarrhea and CDI was signifi-
cantly lower in the probiotics group, but further studies are requiered in 
order to determine the optimal strain.
references: Christine SM Lau and Ronald S Chamberlain. Probiotics are ef-
fective at preventing Clostridium difficile-associated diarrhea: a systematic 
review and meta-analysis. Int J Gen Med. 2016; 9: 27-37.Published online 
2016 Feb 22. doi: 10.2147/IJGM.S98280
disclosure: Nothing to disclose 
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aims & Methods: This was a case-control study comparing cases who did 
and did not developed DPPB who underwent colorectal ER at four uni-
versity hospitals between January 2014 and December 2017. We enrolled 
the consecutive patients who underwent colorectal ER using any of the 
following ER techniques (EMR, ESD, cold snare/forceps polypectomy, and 
hot snare/forceps polypectomy) during the study period. We excluded the 
patients whose ABO blood group was unidentified or who underwent pro-
cedures without interrupting antithrombotic agents. We reviewed medical 
records and the endoscopy database which included the following infor-
mation: 1) ABO blood group, 2) age, 3) sex, 4) daily use of anti-platelets/
coagulants, 5) size of resected tumors, 6) the number of resected tumors, 
7) procedure. The control group consisted of all the patients who com-
pleted the treatment without DPPB. DPPB was defined as the occurrence 
of hematochezia or melena requiring blood transfusion or hemostatic in-
tervention with colonoscopy, surgery, or radiology up to 28 days after en-
doscopic resection. Univariate and multivariate logistic regression analysis 
were performed to determine the risk factor for colorectal DPPB using the 
independent variables including ABO blood group.
results: Among 10,253 consecutive patients who underwent colorectal ER, 
1,628 patients (15.9%) were excluded according to the criteria for unidenti-
fied blood group (n=1,604) and/or continued antithrombotic agents (n=25). 
A total of 8,625 patients who met the eligibility criteria were enrolled in 
the analysis. Of the 8,625 patients, 6,111 (70.9%) were male; the age was 
66.3 years ±11.4 (mean ± SD); the median number of tumors resected per 
patient was 2 (IQR, 1-3); the number of cases with a large lesion (≥20 mm) 
was 1,158 (13.4%). In total, 237 (2.75%) patients developed DPPB (the case 
group); 8,625 patients did not (the control group). In univariate analysis, O 
blood group was significantly related to increased risk of DPPB (odds ratio 
[OR], 1.57; 95% confidence interval [CI], 1.21-2.04; P=0.00079) equivalent to 
other known risk factors: younger age (< 60 years) (OR, 1.71; 95% CI, 1.31-
2.24; P=0.000097), sex (male) (OR, 1.83; 95% CI, 1.32-2.55; P=0.00034), 
the number of tumors (OR, 1.44; 95% CI, 1.10-1.89; P=0.0088), tumor-
size>2cm (OR, 1.90; 95% CI, 1.39-2.59; P=0.000057). In multivariate logistic 
regression analysis, O blood group remained as an independent risk factor 
for DPPB (adjusted OR, 1.57; 95% CI, 1.20-2.04; P=0.0009) (Table 1).
  coefficient (β)
standard 
error Wald
adjusted 
Or 95% cI P-value 
Age
< 60 
years
0.626 0.143 4.39 1.87 1.41 - 2.47 0.000011
Sex Male 0.565 0.171 3.31 1.76 1.26 - 2.46 0.00092
Use of 
antithrombotic 
agents
Yes 0.402 0.163 2.47 1.49 1.09 - 2.06 0.013
Blood group O 0.448 0.135 3.32 1.57 1.20 - 2.04 0.00091
Number of 
polyps
≥ 2 0.448 0.147 3.05 1.57 1.17 - 2.09 0.0023
Tumor-size ≥ 20mm 0.577 0.193 2.99 1.78 1.22 - 2.60 0.0028
Procedure ESD 0.490 0.302 1.63 1.63 0.90 - 2.95 0.104
[Table 1 : Multivariate analysis of risk factors for DPPB based on ABO blood 
group and other known factors]
conclusion: The patients with O blood group were associated with an in-
creased risk of DPPB. The pre-operative screening of ABO blood group may 
improve the preoperative risk assessment.
disclosure: Nothing to disclose 
P0458 effecTIveness Of TranscaTheTer arTerIaL 
eMBOLIzaTIOn fOr cOLOnIc dIverTIcuLar BLeedIng
Machida T., Fukami Y., Ishii R., Hara H., Sugiyama Y., Yonemoto Y., 
Ikemiyagi H., Yoshino K., Sakita S.
Yokohama City Minato Red Cross Hospital, Gastroenterology, Yokohama, 
Japan
contact e-Mail address: tomoyo.machida@gmail.com
Introduction: Colonic diverticular bleeding is the most common cause of 
acute severe lower gastrointestinal bleeding. Recently, it has been increas-
ing with the aging of the population and the widespread use of anti-
thrombotic drugs. Although it stops spontaneously in many cases, a small 
number of patients experience re-bleeding or shock. Persistent or acute 
massive bleeding with hemodynamic disorders sometimes requires an in-
terventional treatment. Persistent bleeding or acute massive of presenting 
with hemodynamic disorders requires an interventional treatment. In our 
institution, we perform transcatheter arterial embolization (TAE) for cases 
in which bleeding points are not able to be detected and cannot be treated 
successfully by endoscopic procedures.
aims & Methods: The aim of this study is to evaluate the effectiveness of 
TAE for colonic diverticular bleeding.
The subjects are 21 patients who were diagnosed as colonic diverticular 
bleeding and were performed endovascular treatment in our institution 
from January 2006 to December 2018. We retrospectively evaluated patient 
characteristics and clinical outcomes, including success rates of hemosta-
sis, transfusion requirement, early rebleeding, and complications.
results: In all 21 patients, endoscopic hemostasis was difficult and early 
rebleeding developed. The median time of endoscopic procedures before 
TAE was 2 times. The hemostasis by arterial embolization was successful 
in 15 patients (71.4%), while the bleeding points could not be identified in 
6 patients. In 11 cases (52.3%), an extravasation image was observed by 
angiography, and in all cases, hemostasis was succeeded by TAE.
In 4 cases no extravasation was found by angiography, but TAE was per-
formed because an approximate bleeding point could be identified by CT 
and endoscopic findings. After TAE, no recurrence of bleeding were ob-
served. In 2 patients (9.5%) intestinal ischemia was observed as adverse 
event and operation was performed.
conclusion: TAE is effective treatment for colonic diverticular bleeding in 
which endoscopic hemostasis is not successful, or in massive bleeding.
disclosure: Nothing to disclose 
P0459 uTILITy Of shOck Index fOr rIsk sTraTIfIcaTIOn In 
acuTe LOWer gasTrOInTesTInaL BLeedIng
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Introduction: Although the incidence of acute lower gastrointestinal bleed-
ing (LGB) is increasing, the predictors of outcomes are not as well stud-
ied and defined as for acute upper gastrointestinal bleeding. Several risk 
scores have been developed over the past years in order to early stratify 
patients according to the risk of complications. The shock index (SI) score 
(heart rate divided by systolic blood pressure) is a simple tool that can 
provide an assessment of hemodynamic status.
aims & Methods: The aim of this study was compare the utility of Shock In-
dex (SI) for predicting outcomes: a) Transfusion, b) Treatment (endoscopic, 
vascular embolization or surgery), c) Clinical intervention (transfusion and 
treatment), d) Rebleeding, e) Readmission and f) Mortality in patients 
with LGB between scores used for risk prediction in upper gastrointestinal 
bleeding (Glasgow- Blachford Score (GBS) and Pre-endoscopic Rockall) 
and in LGB (Oakland, Strate, Velayos and Newman scores).
International Classification of Diseases, 9 Revision, Clinical Modification 
codes for admission diagnosis were used to identify retrospectively a co-
hort of patients with acute LGB from January 2013 to December 2017 hospi-
talized to a tertiary care, university-affiliated hospital. Data were extracted 
from the electronic clinical records of the Hospital. Area under the receiver 
operating characteristic (AUROC) curve were calculated for SI and the dif-
ferent risk scores for each outcomes. AUROCs were compared with the 
DeLong method by using STATA 14.1 software (StataCorp.2015).
results: A total of 406 consecutive patients admitted with LGB were identi-
fied. Median age was 76.6 years (range 23-97), 277 (68.1%) of patients 
were older than 70 years, 219(53.8%) were men. Six (1.5%) died, 36 (8.8%) 
rebleeding, 20 (4.95) needed readmission, 110 (27%) needed transfusion, 
52 (12.5%) needed treatment ( 48 endoscopic, 4 vascular embolization, 0 
surgery). The most common source bleeding was diverticular 115 (28.3%). 
SI was not useful to predict any outcome (AUROC < 0.6). The SI was similar 
to the acute LGB scores for prediction rebleeding or readmission. The GBS 
and Oakland score was the best for predicting transfusion, need clinical 
intervention. All the risk scores were more accurate for determining need 
transfusion than need treatment or clinical intervention. 
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Fisher exact test was used.. For continuous variables we used t-test (two-
tailed). P values < 0.05 were considered statistically significant. Statistical 
analysis was performed using STATA 14.1 software (StataCorp.2015).
results: A total of 452 consecutive patients admitted with LGB were identi-
fied. Of these 348 (73.9%) were admitted during the weekday and 104 
(23.1%) during the weekend. Compared to patients admitted on a week-
day, weekend admissions had similar adverse outcomes, need transfusion 
similar, treatment or need clinical intervention and had similar re-bleed-
ing and mortality in patients with LGB.
Results are resumed in Table 1.
  Weekend 104 (23%)
Weekday 348 
(73.9%) P value
age(years) (mean± sd) 72.1 (±14.6) 73.4 (± 13.8) 0.39
gender (female) (%) 47 (45.2) 167 (48) 0.62
heart rate (mean ± sd) / systolic 
blood pressure (mean±sd)
84.52(±17.2)/ 133 
(±24.9
82.6 (±18) / 
133.1(±25.7)
0.41 / 0.93
antiplatelet /anticoagulant 21(20.2) / 39(37.5) 74 (21.3) / 127(36.5) 0.84 / 0.82
hemoglobin (gr/dl) mean (±sd) 120 (±26.5) 118 (±29.7) 0.59
Length of hospital stay (days) 
(mean ±sd) 8.38 (±7.7) 7.8 (±6.9) 0.6
Time to colonosocpy (days) 
(mean ±sd) 4.6 (±3.2) 4.5 (±2.6) 0.5
adverse outcome (%) 33(31.7) 123(35.4) 0.49
Transfusion (%) 25 (24.0) 102 (29.3) 0.29
Treatment (%) 9 (8.7) 52 (14.9) 0.10
clinical Intervention (%) 30 (28.8) 124 (35.6) 0.2
rebleeding (%) 11 (10.6) 30 (8.6) 0.54
severe Bleeding (%) 29 (27.9) 109 (31.3) 0.50
death (%) 3 (0.9) 3 (2,9) 0.14
[Table 1: Characteristics and results of patients admitted for LGB on weekend 
and weekday]
conclusion: The outcomes for patients admitted with acute lower gastro-
intestinal bleeding (LGB) no differ depending on weekend versus week-
day admission. The timing of colonoscopy no differ on weekday versus 
weekend. This study was limited by being a single institution study, which 
could lead to a sampling bias. Our findings should be reevaluated in other 
healthcare systems under the same socioeconomic conditions.
references: Gupta A, Agarwal R, Ananthakrishnan AN. “Weekend Effect” 
in Patients With Upper Gastrointestinal Hemorrhage: A Systematic Review 
and Meta-analysis. Am J Gastroenterol. 2018 Jan;113(1):13-21.
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Introduction: The use of multiple antithrombotic medications, includ-
ing anticoagulants and antiplatelet agents have been on the rise. When 
prescribed in dual or triple combinations, these regimens are considered 
complex antithrombotic therapies (CAT). CAT is frequent in patients with 
acute lower gastrointestinal bleeding (LGB). However, there is little data 
on the clinical course of patients undergoing CAT.
aims & Methods: The aim os this study was to analyze the relationship of 
CAT (dual treatment: antiplatelet - anticcoagulant or antiplatelet - anti-
platelet) and the adverse outcomes on patients with LGB.
International Classification of Diseases, 9th Revision, Clinical Modifica-
tion codes for admission diagnosis were used to identify retrospectively 
scOre
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reBLeedIng
readMIs-
sIOn
deaTh
shOck Index
0.58 
(0.51-0.64)
0.49 
(0.40-0.57)
0.55 
(0.49-0.61)
0.58 
(0.48-0.69)
0.57 
(0.45-0.69)
0.58 
(0.38-0.77)
gLasgOW-
BLaTchfOrd
0.89 
(0.85-0.92)
0.65 
(0.56-0.73)
0.82 
(0.78-0.87)
0.72 
(0.63-0.81)
0.70 
(0.58-0.82)
0.76 
(0.49-1.00)
Pre endOsc 
rOckaLL
0.70 
(065-0.76)
0.56 
(0.49-0.64)
0.68 
(0.62-0.73)
0.68 
(0.60-0.76)
0.63 
(0.51-0.75)
0.82 
(0.58-1.00)
OakLand
0.89 
(0.85-0.93)
0.63 
(0.55-0.72)
0.82 
(0.77-0.86)
0.74 
(0.65-0.83)
0.71 
(0.59-0.83)
0.78 
(0.63-0.93)
sTraTe
0.67 
(0.62-0.73)
0.60 
(0.52-0.67)
0.65 
(0.60-0.71)
0.67 
(0.59-0.76)
0.70 
(0.59-0.81)
0.56 
(0.31-0.80)
veLayOs
0.78 
(0.74-0.82)
0.65 
(0.57-0.73)
0.74 
(0.70-0.79)
0.68 
(0.60-0.76)
0.68 
(0.57-0.79)
0.80 
(0.67-0.92)
neWMan
0.78 
(0.73-0.82)
0.64 
(0.56-0.71)
0.75 
(0.70-0.79)
0.68 
(0.60-0.75)
0.67 
(0.55-0.79)
0.78 
(0.63-0.92)
[Table 1: AUROC and IC 95 % for shock index and risk scores]
conclusion: SI was not useful to predict any outcome. Both Oakland Score 
and GBS were superior for predicting transfusion or clinical intervention. 
The GBS may be and useful tool for risk stratification in LGB. If can be used 
for as common score for predicting need of clinical intervention in upper 
and lower gastrointestinal bleeding. More precise prognostic scales are 
needed in LGB.
references: Tapaskar N, Jones B, mei S, Sengupta N. Comparaison of 
clinical prediction tools and identification of risk factors for adverse out-
comes in acute lower gastrointestinal bleeding. Gastrointest Endosc. 2019 
May;89(5). Ratra A, Rassameehiran S, Parupudi S, Nugent K. Utility of the 
Shock Index and Other Risk-Scoring Tools in Patients with Gastrointestinal 
Bleeding. South Med J. 2016 Mar;109(3):178-84.
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Introduction: “Weekend effect” refers to worse outcomes among patients 
presenting to the hospital on weekends. Many different processes are re-
quired in the management of patients with acute lower gastrointestinal 
bleeding (LGB). The availability of some of these procedures may be re-
duced on weekend. The weekend effect closely reflect the organizational 
level and performances of healthcare services under “off-hour” condi-
tions, it can identify the possible deficiencies in functioning and the need 
for improvements. At present, it is not known whether there is a weekend 
effect in LGB.
aims & Methods: The primary aim of this study is to investigate whether 
adverse outcomes for patients admitted with LGB differ depending on 
weekend versus weekday admission. The secondary aim was to determine 
whether any such differences are mediated by the timing of colonoscopy.
International Classification of Diseases, 9th Revision, Clinical Modifica-
tion codes for admission diagnosis were used to identify retrospectively 
a cohort of patients with acute LGB from January 2013 to December 2017 
hospitalized to in a tertiary care, university-affiliated hospital. Data were 
extracted from the electronic clinical records of the Hospital. Time of ad-
mission was recorded defining weekend as midnight Friday to midnight 
Sunday. Hospital admissions on holydays no weekend were excluded. 
We used definition for adverse outcomes as the composite outcome: a) 
Transfusion, b) Treatment (endoscopic, vascular embolization or surgery), 
c) Clinical intervention (transfusion and treatment), d) Re-bleeding and f) 
Mortality in patients with LGB. 
Our center has endoscopy available 24 hours a day, 7 days a week. 
For discrete variables we tested for significant differences between groups 
with X2 tests If 25 %or more of cells had expected values less than 5; the 
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a cohort of patients with acute LGB from January 2013 to December 2017 
hospitalized to in a tertiary care, university-affiliated hospital. Data were 
extracted from the electronic clinical records of the Hospital. The primary 
outcome studied was severe LGIB as defined 
(1) continued bleeding in the first 24 hours of admission (transfusion ≥2 
units of packed red blood cells and/or a decrease in hematocrit ≥20%) 
and/or 
(2) recurrent bleeding after 24 hours of clinical stability (rectal bleeding 
accompanied by a further decrease in hematocrit ≥20% and/or additional 
blood transfusions and/or readmission for LGIB .Secondary outcomes in-
cluded: 
a) Re-bleeding, 
b) Transfusion requirements, 
c) Treatment (endoscopy, interventional radiology or surgery), 
d) Readmission and 
e) Death. 
Re-bleeding was defined as 
(1) clinically significant recurrent bleeding requiring repeat endoscopic or 
radiographic procedures (after initial colonoscopy) or 
(2) additional blood transfusion requirements or 
(3) a further decrease inhematocrit of 20% or more after a 24-hour period 
of stability after initial presentation. 
For discrete variables we tested for significant differences between groups 
with X2 tests If 25 %or more of cells had expected values less than 5; the 
Fisher exact test was used. P values < 0.05 were considered statistically 
significant. Differences in outcomes were expressed in odds ratio (OR) with 
95% confidence intervals (95%CI). Statistical analysis was performed us-
ing STATA 14.1 software (StataCorp.2015)
results: A total of 471consecutive patients admitted with LGB were identi-
fied 417 (88.5 %) in not CAT group versus 54 (11.5%) in CAT group . Mean 
age was 76.8 years in CAT group versus 72.6 in not CAT group, 203 (48.7%) 
were men in not CAT group and 42 (77.8 %) in patients using CAT. The most 
common source bleeding was diverticular 114 (27.3%) in not CAT group and 
ischemic colitis 13 (24.1%) in CAT group. Outcomes of patients admitted for 
lgb (with CAT treatment versus without CAT treatment) are show in Table 1. 
  WITh caT 54 (11.5%) WIThOuT caT 417 (88.5%) Or (95%Ic)
SEVERE LGB 24 (44.4) 115 (27.8) 2.1 (1.18- 3.75)
TRANSFUSION 23 (42.6) 105 (25.2) 2.21 (1.23 - 3.95)
REBLEEDING 8 (14.3) 34 (8.2) 1.96 (0.86 - 4.49)
TREATMENT 10 (18.5) 50 (12 ) 1.67 (0.79 - 3.52)
READMISSION 8 (14.3) 12 (2.9) 5.87 (2.28 - 15.1)
DEATH 0 (0) 6 (1.4) 2.1 (1.18 - 3.75)
[Table 1: Outcomes of patients admitted for LGB (with CAT treatment versus 
without CAT treatment)]
conclusion: Patients in CAT have a higher frequency of severe LGB ; trans-
fusion and readmission compared to patients without CAT. No difference 
was found between them for re-bleeding, need for treatment and death.
references: Abraham NS, Hartman C, Richardson P, Castillo D, Street RL, 
Naik AD. Risk of Lower and Upper Gastrointestinal Bleeding, Transfusions, 
and Hospitalizations with Complex Antithrombotic Therapy in Elderly Pa-
tients. Circulation. 2013 Oct 22;128(17):1869-77.
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Introduction: Gastrointestinal bleedings (GIBs) are acute events which are 
potentially severe but not always life threatening and often can be safely 
treated. There have been numerous studies reporting on the rates of GIBs 
associated with use of drugs mostly focusing on upper GIBs and data re-
garding lower GIBs (lGIBs) in the general population is limited
aims & Methods: The aim of this study was to evaluate the incidence rates 
of lGIBs and the trends overtime in the general population of Finland. Data 
from participants of prospectively conducted population-based FINRISK 
health examination surveys was utilized for this study. FINRISK enrolled 
persons aged 25-74 years, recruited by random sampling from the popu-
lation register, stratified by 10-year age group, sex and study area. The 
total number of participants in each survey was approximately 6000-8000. 
The participation rate in 1972 survey was >90% with a gradually declining 
trend to 57% in men and 67% in women in 2012. The follow-up took place 
using record linkage to the country-wide electronic health registers which 
included hospital discharge register and causes of death register. With the 
help of these national registers, the coverage of the follow-up was 100% 
for persons living in Finland. The follow-up period was from the enroll-
ment up to the onset of an lGIB leading to hospitalization, death due to 
any cause, or end of the follow-up period which was December 31st, 2016. 
Participants with a history of GIBs before the baseline were excluded from 
the analyses. Incidence rates, recurrence rates (events recorded were >30 
days apart), cause-specific mortality rates and 28-day case-fatality rates 
for lGIBs were calculated with 95% confidence intervals (CIs). The time-
trends in event rates were calculated using a log-linear poison regres-
sion model adjusting for baseline age, gender, region, and the year of 
enrollment. Age standardization was conducted using weights from the 
European standard population
results: A total of 71,068 participants were included in the study and they 
experienced 1750 incident lGIBs. The median age of participants experi-
encing lGIBs was 49.9 years and among the ones without GIBs it was 45.4 
years. The age standardized incidence rates for lGIBs in males and females 
were 1.58 and 1.29 per 1000 py, respectively. Among men, there was a 
slight increase in the early 1990’s but after that a constant decline end-
ing at the level of about one-third of those in the late 1980’s (ref. period). 
Among women, there was a steady decline over the years ending up to 
less than 15% of the rates in the late 1980’s by the end of the study period 
in 2012-16. Among incident lGIBs, the recurrence rates of lGIBs in males 
and females were 11.4 and 11.1 per 1000 py, respectively. There was a sub-
stantial random variation in the proportion of recurrent lGIBs but in gen-
eral an increasing trend was observed. Cause-specific mortality rates for 
lGIBs were the lowest in the study with 24 deaths. Cause-specific mortality 
rates in males and females were 0.01 and 0.03 per 1000 py, respectively. 
The 28 day case-fatality rates in males and females were 0.7% and 1.7%, 
respectively. Trends overtime of cause-specific mortality rates and case-
fatality rates due to lGIBs could not be calculated due to the low number 
of cases
conclusion: Overall, the age-standardized incidence rates of lGIBs are 
higher in males than in females. The rates of lGIBs have significantly de-
creased since the late 1980’s. The mortality rates due to lGIBs were in 
general low but tended to be higher in females compared to males
disclosure: Pareen Vora is an employee at Bayer AG, Berlin Germany; Gun-
nar Brobert is an employee at Bayer AB, Solna, Sweden; Veikko Salomaa 
has participated in a conference trip sponsored by Novo Nordisk and re-
ceived a honorarium for participating in an advisory board meeting (unre-
lated to the present study). Veikko Salomaa and Arto Pietilä has ongoing 
research collaboration with Bayer AG. 
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TheraPy: a reaL-WOrLd sTudy
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Universitari Vall d’Hebron & Facultat de Medicina, Universitat Autònoma 
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contact e-Mail address: lgalcala1986@gmail.com
Introduction: Gastrointestinal bleeding (GIB) is a common adverse event 
associated to anticoagulant therapy. Pivotal clinical trials have shown that 
compared to warfarin, direct oral anticoagulants (DOACs) have a similar 
efficacy to prevent thromboembolic complications, but with higher rates of 
GIB. However, real-world studies are needed to assess the risk and severity 
of GIB in patients under direct oral anticoagulant therapy.
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could reactivate the expression of SFRP1 (P< 0.05), but interference with 
EZH2 could not reactivate it (P>0.05). However, in SW480 and HCT116 cells, 
interfering with MBD2 and EZH2 at the same time was more effective than 
interfering one of them alone in restoring the expression of SFRP1, SFRP2, 
SFRP4 and SFRP5 genes (P < 0.05). We found that compared with interfer-
ing with MBD2 or EZH2 alone, interfering with MBD2 and EZH2 together 
could significantly inhibit the proliferation, migration and invasion of CRC 
cells. Flow cytometry analysis showed that simultaneous interference 
with MBD2 and EZH2 in SW480 cell was more effective than interfering 
with MBD2 or EZH2 alone in blocking cell cycle and causing more cells 
to stagnate in S phase (P < 0.05); however, in HCT116, compared with in-
terfering with MBD2 or EZH2 alone, more cells stagnated in G0/G1 phase 
when interfering with MBD2 and EZH2 at the same time (P < 0.05). In 
addition, compared with interfering with MBD2 or EZH2 alone, interfering 
with MBD2 and EZH2 in SW480 and HCT116 cells together could remarkably 
increase apoptosis (P < 0.05).
conclusion: Compared with silencing MBD2 or EZH2 alone, silencing MBD2 
and EZH2 can inhibit the proliferation of CRC cells by restoring the expres-
sion of SFRP more effectively. MBD2 and EZH2 may be potential therapeu-
tic targets for colorectal tumors, however, the regulatory mechanism of 
SFRP remains to be further studied in the future.
disclosure: Nothing to disclose 
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Introduction: Colorectal cancer (CRC) is the conclusive result of a multi-step 
phenomenon that, in most cases, goes through the adenoma-carcinoma 
sequence pathway. Some substances of plant origin have been reported to 
exert an effect in reducing intestinal neoplasm development, especially in 
animal models. In detail, silymarin, a phytoestrogen compound derived 
from milk thistle (Silybum marianum) may decrease intestinal carcinogen-
esis through both anti-oxidant and estrogen receptor-beta agonist proper-
ties. Previous studies have shown that silymarin is able to hamper intesti-
nal carcinoma (IC) development in ApcMin/+ mice and familial adenomatous 
polyposis patients with ileal pouch-anal anastomosis. Boswellia serrata is 
a plant with anti-inflammatory properties. Interestingly, boswellic acids, 
especially Acetyl-11-Keto-beta-Boswellic Acid (AKBA), a component of the 
gum resin of Boswellia serrata, has been recognized as a promising agent 
for the prevention of intestinal tumorigenesis in a mouse model of inher-
ited carcinogenesis, i. e. APC multiple intestinal neoplasia (min) animals
aims & Methods: Our aim was to assess whether an enriched nutritional 
formulation with anti-carcinogenetic properties may prevent inherited in-
testinal cancer (IC) in animal model.
Eighty male mice were used (40 wild type for diet safety test and 40 ad-
enomatous polyposis coli multiple intestinal neoplasia ApcMin/+). Forty 
ApcMin/+ mice were divided into two groups: 20 standard and 20 enriched 
diet. At the100th day, colonoscopy was performed, then animals were sac-
rificed after 10 days. In each group, four subgroups received intraperitone-
al bromodeoxyuridine (BrdU) injection. We evaluated: lesion number/size, 
histological inflammation/dysplasia/neoplasia, pro-inflammatory cytokine 
mRNA expression, BrdU/TUNEL.
results: No mice died during the safety test. Compared to standard, en-
riched diet reduced solid lesion total number (203 versus 416) and mean 
number±SD/animal (12.6±5.0 versus 26.0±8.8;p< 0.001). In enriched diet 
group a reduction in polyp size was observed (p< 0.001). Histological in-
flammation and pro-inflammatory cytokine expression were similar. Low 
grade dysplasia (LGD;p< 0.001) and intestinal carcinoma (IC;p< 0.001) ar-
eas were decreased in enriched diet. IC was observed in 100% in stan-
dard and 85% in enriched formulation assuming animals. Enriched diet 
showed higher epithelial proliferation/migration and increased apoptosis 
in normal mucosa and LGD areas (p< 0.001).
aims & Methods: We aimed to analyse the severity of GIB with DOACs, 
compared to vitamin K antagonists (VKAs) in patients admitted to the 
emergency department with GIB who were under anticoagulant therapy.
Patients under anticoagulant therapy admitted to the emergency depart-
ment with GIB were prospectively recruited from July 2016 to January 2018. 
Inclusion criteria were patients with non-valvular atrial fibrillation (NVAF) 
or thromboembolic disease treated with DOACs, and patients with AF of 
any cause, mechanical heart valve or thromboembolic disease treated with 
VKAs. Patients under heparin therapy were excluded. Clinical presenta-
tion, the need for blood transfusion, length of hospital stay, and results of 
endoscopic and radiologic studies were recorded. Severity of the bleed-
ing episode was defined though the International Society of Hemostasis 
and Thrombosis (ISTH) scale. Patients were followed up until discharge 
or death.
results: Throughout the study, a total of 208 events of GIB were docu-
mented in 178 patients: 119 events under AVKs, and 89 events under DOACs 
(Apixaban=36, Rivaroxaban=29, Dabigatran=19 Edoxaban=5). Female sex 
was more prevalent in both groups (54% in the VKA group and 59% in the 
DOAC group). Mean age in both groups was similar (VKAs: 78.6±0.9 years, 
DOACs: 80.2±0.7 years, p= ns). CHADsVASC score and previous history of 
GIB were similar in both groups, although a higher prevalence of chronic 
kidney disease in the AVK group was observed (p= 0.009) while a higher 
prevalence of chronic cerebrovascular disease was seen in the DOAC group 
(p= 0.024). Concomitant anti-platelet therapy was 16% in the VKA group, 
and 24.7% in the DOAC group (p= ns). Clinical presentation was lower GIB 
in 52.9% of the VKA group patients and 53.9% in the DOAC group (p=ns). 
According to ISTH, major bleeding was the most frequent in both groups 
(VKAs: 77.3%, DOACs: 82%; p=ns). Mean hemoglobin on admission was 
10±0.5 g/dL in the VKA group, and 10.1± 1 g/dL in the DOAC group (p=ns). 
Decrease of hemoglobin compared to last known value was 2.7±0.2 g/dL in 
the VKA group, and 3±0.2 g/dL in the DOAC group (p=ns). The mean num-
ber of packed red blood cells transfused was similar in both groups (2.26 
± 0.23 in VKA group, and 2.30 ± 0.28 in DOAC group (p=ns). No differences 
were observed in the length of hospital stay between groups.
conclusion: Gastrointestinal bleeding severity is similar in patients tak-
ing DOACs when compared to patients under VKAs therapy. Future studies 
with a higher number of patients are needed to confirm our data.
disclosure: Nothing to disclose 
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Introduction: The Secreted frizzled related proteins (SFRPs) is an extracel-
lular inhibitors of wnt pathway signaling and was found to be underex-
pressed in the early stage of colorectal tumorigenesis due to hypermethyl-
ation of the promoter. MBD2 and EZH2 are core members of MBD and PCG 
protein families respectively, which have been known as crucial proteins 
of epigenetic regulation.
aims & Methods: The aim of this study is to figure out the potential role of 
MBD2 and EZH2 proteins in colorectal cancer (CRC) and its effects on the 
transcription of SFRP. The mRNA expression of SFRPs in CRC and adjacent 
noncancerous tissues are analyzed by bioinformatics. Real-time quantita-
tive polymerase chain reaction (qRT-PCR) and western blot were used to 
detect the expression of MBD2, EZH2 and SFRPs in CRC cell lines and hu-
man normal intestinal mucosa cell NCM460. We knockdown of MBD2 and 
EZH2 using small interfering RNA (siRNA) to clear its role in the regulation 
of SFRPs gene expression. The function of MBD2 and EZH2 in cell prolifera-
tion, cycle, apoptosis and invasion was examined in CRC cell lines.
results: The mRNA expression level of SFRPs was significantly decreased 
in CRC tissues and cell lines compared to adjacent tissues and NCM460 (P< 
0.05). However, the mRNA level of EZH2 and MBD2 were highly expressed 
in CRC cell lines (P< 0.05). In SW480 cell, interference with MBD2 could 
reactivate the expression of SFRP1 (P< 0.05), but interference with EZH2 
could not reactivate it (P>0.05); Interference with EZH2 could reactivate 
the expression of SFRP2, SFRP4 and SFRP5 (P < 0.05), but interference 
with MBD2 could not activate it. In HCT116 cell, interference with MBD2 
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conclusion: Our results are promising for a chemo-preventive synergic ef-
fect of enriched formulation in inherited IC.
disclosure: Nothing to disclose 
P0466 MIcrOrna 375 reguLaTes PrOLIferaTIOn Of 
cOLOrecTaL cancer ceLLs By suPPressIng The MTdh 
exPressIOn
Han S.H., Mo J.-S., Chae S.
School of Medicine, Wonkwang University, Department of Pathology, Iksan, 
Korea (Republic of)
contact e-Mail address: chaesc@wku.ac.kr
Introduction: MicorRNAs play important roles in the pathogenesis of hu-
man diseases by down-regulation of target genes in various cells or tis-
sues. We have previously identified MicoRNA 375 (MIR375) as a colorectal 
cancer associated microRNA. It is significantly down-regulated in human 
colorectal cancer tissues. The putative MIR375 target genes were also 
identified by comparing the mRNA microarray analysis data of MIR375-
overexpressing cells with the candidate MIR375 target genes predicted by 
public bioinformatic tools.
aims & Methods: The purpose of this study is to determine the correlation 
between the MIR375 and its novel target gene, metadherin (MTDH), in hu-
man colorectal cancer cells and tissues. A luciferase reporter system was 
used to confirm the effect of MIR375 on MTDH expression. Protein or mRNA 
expression of the target gene and associated molecules were by western 
blot or qRT-PCR, respectively. Cell proliferation assays were employed us-
ing an EZ-Cytox cell viability assay kit. And flow cytometry was used to 
compare cell cycle progression.
results: MTDH is a direct target gene of MIR375. MTDH mRNA and protein 
expression levels were directly down-regulated by MIR375 mimic transfec-
tion. We observed that MIR375 down-regulated the several MTDH-medi-
ated pathways which include PIK3CA, NFκB and BRAF-MAPK-CTNNB1 in 
colorectal cancer cells. Our results showed that the cell proliferation and 
angiogenesis in colorectal cancer cells were regulated by MIR375.
conclusion: Our results indicate that MTDH is a direct target of MIR375 in 
human colorectal cancer cell lines, and suggest that the down-regulation 
of MIR375 modulates MTDH signaling pathways in human colorectal cells 
and tissues. Thus, MIR375 may have a therapeutic value in relation to hu-
man colorectal cancer.
disclosure: Nothing to disclose 
P0467 herv-hx, a neW huMan endOgenOus reTrOvIrus 
gene, PrOMOTes cOLOrecTaL cancer grOWTh and MeTasTasIs 
By acTIvaTIng WnT/β-caTenIn sIgnaLIng
Zhang M.1,2, Zheng S.2,3, Liang J.Q.4
1Second Affiliated Hospital of Zhejiang University School of Medicine, 
Department of Plastic and Reconstructive Surgery, Hangzhou, China, 
2Cancer Institute, Second Affiliated Hospital, and Ministry of Education Key 
Laboratory of Cancer Prevention and Intervention, Zhejiang University School 
of Medicine, Hangzhou, China, 3Second Affiliated Hospital of Zhejiang 
University School of Medicine, Department of Surgical Oncology, Hangzhou, 
China, 4Faculty of Medicine, Chinese University of Hong Kong, Department of 
Medicine and Therapeutics, Hong Kong, Hong Kong, China (SAR)
contact e-Mail address: zhang5621358@163.com
Introduction: Human endogenous retroviruses (HERVs) are human DNA 
sequences that are homologous to exogenous retroviruses. Accumulating 
evidence has highlighted the close correlation between colorectal cancer 
(CRC) and HERVs [1]. In a previous study, we identified and designated a 
new H family HERV (HERV-H) gene, HERV-HX, which is actively expressed 
in CRC tumor tissues as compared to adjacent normal tissues [2]. However, 
the functional and clinical significance of HERV-HX remains unexplored.
aims & Methods: This study aimed to elucidate the biological function, 
molecular mechanism and clinical significance of HERV-HX in CRC. HERV-
HX expression was assessed by TaqMan probe RT-qPCR and in situ hy-
bridization. siRNA specifically targeting HERV-HX and expression vector 
carrying the ORF of HERV-HX were used for the loss- and gain-of-function 
assays in different CRC cells. The biological functions of HERV-HX were 
determined by cell viability assay, colony formation, wound-healing mi-
gration and matrigel invasion assays, cell cycle and apoptosis flow cytom-
etry, Ki-67 and TUNEL staining. Effects of HERV-HX on tumorigenicity and 
metastasis in vivo were assessed using subcutaneous xenograft and tail 
vein injection models respectively. Protein levels were assessed by west-
ern blot and immunostaining. Protein localization was investigated by im-
munofluorescence staining and western blot. Molecular mechanism was 
investigated by RNA sequencing and pathway luciferase reporter assays.
results: HERV-HX was specifically upregulated in cell lines of colon can-
cer but not other cancer types, and was significantly upregulated in CRC 
tumors as compared to adjacent normal tissues (P< 0.0001). HERV-HX ex-
pression was not associated with age, gender, lesion location, but was 
positively associated with TNM staging (rho=0.721, P=0.0004). HERV-HX 
expression was significantly higher in samples with vs without lymph 
node or distant metastasis (P< 0.0001), while no significant difference was 
found between TNM stage I and II or between III and IV cases.
Knockdown of HERV-HX in HT29 and LoVo cells significantly suppressed 
cell viability and colony formation, induced apoptosis and cell cycle ar-
rest, and inhibited migration/invasion ability. Conversely, overexpression 
of HERV-HX in SW480 and HCT116 cells produced opposite effects. HERV-
HX expression significantly promoted tumorigenicity and also increased 
metastases to the lung and/or liver in vivo (overall metastatic rates: 53% in 
HERV-HX group vs 28% in control group). 
In concordance with the growth- and migration-promoting effects of 
HERV-HX, protein levels of cell cycle markers (p21, p27, cyclin D1 and CDK4), 
apoptosis markers (cleaved forms of caspase-8, caspase-9, caspase-3 and 
PARP), the proliferation marker PCNA and epithelial-mesenchymal tran-
sition markers (E-cadherin, N-cadherin, β-catenin, Vimentin, Slug and 
Snail) were significantly altered following knockdown or overexpression 
of HERV-HX. HERV-HX significantly activated Wnt/β-catenin signaling as 
indicated by the increased TOP/FOP luciferase activity. Importantly, exami-
nation in cells, subcutaneous xenografts and liver/lung metastatic nodules 
showed that HERV-HX increased the total level and nuclear translocation 
of β-catenin by inhibiting its phosphorylation.
conclusion: Upregulation of HERV-HX plays a pivotal role in tumor pro-
gression and metastasis of CRC. HERV-HX inhibits phosphorylation-me-
diated degradation of β-catenin, causes its cellular accumulation and 
nuclear translocation, and subsequently activates Wnt/β-catenin signaling 
to promote colorectal tumorigenesis.
references: 1. Mengwen Zhang, Jessie Qiaoyi Liang, Shu Zheng. Expres-
sional activation and functional roles of human endogenous retroviruses 
in cancers. Rev Med Virol. 2019 Mar;29(2):e2025. doi: 10.1002/rmv.2025. 2. 
Jessie Qiaoyi Liang, Jiayi Ding, Rongzhen Xu, Zefeng Xu, Shu Zheng. Iden-
tification of a novel human endogenous retrovirus and promoter activity 
of its 5’ U3. Biochem Biophys Res Commun. 2009 May;382 (2):470-4. doi: 
10.1016/j.bbrc.2009.03.058.
disclosure: Nothing to disclose 
P0468 aBrOgaTIOn Of eMILIn1 gc1q-α4β1 InTegrIn 
InTeracTIOn affecTs exPerIMenTaL cOLITIs and cOLOn 
carcInOgenesIs enhancIng LyMPhaTIc dysreguLaTIOn and 
InfLaMMaTOry cascade
Capuano A.1, Doliana R.1, Pivetta E.1, Maiero S.2, Fornasarig M.2, 
Magris R.2, Guarnieri G.2, Cannizzaro R.2, Spessotto P.1
1Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Molecular 
Oncology, Aviano, Italy, 2Centro di Riferimento Oncologico di Aviano (CRO) 
IRCCS, Oncological Gastroenterology, Aviano, Italy
contact e-Mail address: acapuano@cro.it
Introduction: Colon cancer is one of the principal types where a functional 
link between inflammation, tumor microenvironment and progression had 
been noted; colitis-associated cancer is also related to striking changes in 
the lymphatic vasculature and dysfunction in the intestinal lymphatic net-
work is a well-established feature of human inflammatory bowel disease. 
The ECM protein EMILIN1 is expressed, among several other tissues, in the 
normal colonic mucosa; it controls elastogenesis, blood pressure homeo-
stasis and is a key structural element in the maintenance of the integrity 
of lymphatic vessels. It is an adhesive ligand of α4/α9β1 integrins via its 
gC1q domain and this interaction down-regulates cell proliferation. The 
aim of this project is to analyze the possible role of EMILIN1 in inflamma-
tory colon cancer.
aims & Methods: The impact of intestinal inflammation and carcinogen-
esis was analysed in Emilin1-/ - (KO) and E933A EMILIN1 transgenic mice 
(E933A TG), in which a mutant EMILIN1, unable to be engaged by α4β1, 
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P0470 MIrnas as MOLecuLar PredIcTOrs Of resPOnse 
TO cheMOradIOTheraPy In recTaL cancer
Mourato C.1, Ourô S.2, Cardador A.1, Castro R.E.1, Albergaria D.2, Maio R.2, 
Rodrigues C.M.P.1
1Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, 
Universidade de Lisboa, Lisbon, Portugal, 2Beatriz Ângelo Hospital, Surgery 
Department, Loures, Portugal
contact e-Mail address: claudia.a.mourato@gmail.com
Introduction: Colorectal cancer (CRC) is the main tumour-related cause of 
death worldwide, being the third most common cancer, with rectal adeno-
carcinoma accounting for almost one-third of all CRC [1]. Treatment of ad-
vanced rectal cancer consists mainly in pre-operative chemoradiotherapy 
(CRT), a strategy that not always induces tumour response and that de-
creases the quality of life of patients [2]. In addition, there is no available 
method to determine whether a patient will benefit from CRT, with all pa-
tients receiving the same therapy regardless of its outcomes. Therefore, the 
possibility to predict disease progression and response of patients to CRT 
would allow its selective use, thus avoiding toxicity and associated mor-
bidity in non-responders. In this sense, microRNAs (miRNAs) with a role 
in the pathogenesis of CRC, may function as regulators of tumour response 
to therapy and are being increasingly evaluated as potential diagnostic, 
prognostic and predictive biomarkers of response to therapy [3].
aims & Methods: The aim of this work was to identify miRNAs as potential 
biomarkers of disease progression and pre-CRT predictors of pathological 
response in rectal cancer. Using a targeted approach, the expression pro-
file of single miRNAs (miR-16-5p, miR-145-5p, miR-335-5p, miR-135b-5p 
and miR-21-5p) was analysed in 94 patients with locally advanced rectal 
cancer. 14 were identified as pathological complete responders (pCR) and 
80 as pathological incomplete responders (pIR). Total RNA was isolated 
from normal (adjacent non-tumour) and tumour rectal samples tissues 
collected before and after long course CRT by biopsy and protectomy, re-
spectively. The miRNA expression profile was analysed by Real Time-PCR 
using TaqMan® Advanced miRNA assays. miR-484 was used for normal-
ization.
results: In pIR patients, miR-21-5p demonstrated higher expression (p ≤ 
0.05) in pre-CRT tumour tissue when compared with pre-CRT normal tis-
sue and the same expression profile was observed in post-CRT samples 
(p ≤ 0.01). In addition, a similar expression profile was observed in miR-
135b-5p analysis, with higher levels of miR-135b-5p in pre- and post-CRT 
(p ≤ 0.001) tumour samples when compared with normal samples. On 
the contrary, the expression profile of both miR-21-5p and miR-135b-5p 
showed the opposite tendency in pCR patients, with similar or lower miR-
NAs levels in pre-CRT tumour samples comparing with normal tissue. 
This suggests that a lower tumour expression of these miRNAs prior to 
pharmacological intervention could be indicative of a better response to 
treatment, which is also in line with the well-described oncogenic role of 
miR-21 and miR-135. On the other hand, no significant differences were 
observed in the expression profiles of miR-16-5p, miR-145-5p and miR-
335-5p between pIR and pCR patients.
conclusion: This work highlights that miRNAs are differentially expressed 
between pre- and post-CRT normal and rectal cancer tumour samples. 
Among the evaluated miRNAs, miR-21-5p and miR-135b-5p appear to be 
the most promising predictors of pre-treatment pathological complete re-
sponse and may provide new insights for consolidating discovery of bio-
markers of response to treatment.
Supported by COMPETE (LISBOA-01-0145-FEDER-016405), FCT (grant 
SAICTPAC/0019/2015) and Sociedade Portuguesa de Coloproctologia.
references: 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Je-
mal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence 
and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 
2018;68: 394-424. 2. Li Y, Wang J, Ma X, Li T, Yan Y, Xue C, et al. A review 
of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J 
Biol Sci. 2016, 12: 1022-1031. 3. Zhu Y, Peng Q, Lin Y, Zou L, Shen P, Chen F, 
et al. Identification of biomarker microRNAs for predicting the response of 
colorectal cancer to neoadjuvant chemoradiotherapy based on microRNA 
regulatory network. Oncotarget. 2016;8: 2233-2248.
disclosure: Nothing to disclose 
is deposited. Chronic colitis was induced treating mice with 2% DSS in 
the drinking water; colon tumours were induced with a single injection of 
AOM followed by three 1-week exposures to 2% DSS. Colitis and tumour 
growth were analysed over time by endoscopy; clinical scoring of colitis 
was performed applying the MEICS and DAI indexes.
results: KO and E933A-TG presented higher colitis scores and more se-
vere mucosal injury, fibrosis and inflammatory infiltrates than WT. RNAseq 
analysis confirmed the up-regulation of several inflammatory response 
genes and the down-regulation of cell-cell adhesion molecules in E933A-
TG. KO and E933A-TG mice had also higher tumour incidence, bigger 
adenomas and less survival. Whole-mount analyses on colon specimens 
demonstrated that both KO and E933A-TG lymphatic vessels are irregu-
lar, dilated and characterized by dysmorphic structures and wide lacunae. 
This abnormal network architecture leads to enhanced lymphatic dysregu-
lation, decreased lymph flow and impaired inflammatory cell drainage, 
providing a possible explanation for the reduced inflammatory resolution 
observed in KO and TG models.
conclusion: Overall these data demonstrate that EMILIN1 by virtue of its 
multifaceted functions is centrally located in the context of the develop-
ment and progression of inflammatory colon cancer. The integrity of EMI-
LIN1 is necessary to control proliferation and to guarantee the regeneration 
of competent and well functioning lymphatic vasculature .
Acknowledgments: RF-2016-02361525 grant
disclosure: Nothing to disclose 
P0469 sTudIes On PrOTease-acTIvaTed recePTOr-
dePendenT reguLaTIOn Of cOLOn sTeM ceLLs WITh The 
OrganOId MOdeL
Racaud-Sultan C.1, Coméra C.2, Rolland C.1, Bonnart C.1, Sebbag M.1, 
Deraison C.1, Mas E.1, Vergnolle N.1
1INSERM UMR-1220, Digestive Health Research Institute (IRSD), Toulouse, 
France, 2INRA UMR-1331, Toxalim, Toulouse, France
contact e-Mail address: claire.racaud@inserm.fr
Introduction: Stem cells of the colon epithelium are dysregulated in chron-
ic inflammatory diseases such as ulcerative colitis and colorectal cancer, 
both pathologies with high incidence in the population. In order to better 
understand the pathophysiology of those diseases, we used the organoid 
model to study stem cell functions and demonstrated the critical roles of 
protease-activated receptors (PAR
1
, PAR
2
, PAR
3
) in stem cell regulation.
aims & Methods: Colon crypts were isolated from WT or PAR KO male and 
female mice. Crypts were cultured in 3D conditions as organoids (colo-
noids) for one week. From day 2 to day 6 of culture, PARs were activated 
by specific agonist peptides. Number and size of colonoids were measured 
to analyze survival and proliferation of colon stem cells. Expression of PARs 
and key signaling molecules were studied by qRT-PCR and immunolabel-
ing.
results: The PAR activation by specific agonist peptides differently influ-
enced stem cell proliferation. While PAR
1
 promoted stem cell proliferation, 
PAR
2
 was found to slow down this process. Interestingly, PAR
2
 was highly 
expressed in colon primitive cells from male mice compared to females. 
Its brake on cell proliferation was specific of male sex since, in females, 
stem cell proliferation was increased by both PAR
1
 and PAR
2
 activation. This 
sexual dimorphism was linked to the PAR
2
-dependent expression of genes 
implicated in stem cell proliferative pathways. The Glycogen Synthase Ki-
nase 3beta (GSK3beta) plays a critical role in stem cell behavior and has 
been implicated in colon inflammation and cancer. Using PAR
2
 or PAR
3
 KO 
mice, we found its activation under the control of PAR
2
 and PAR
3
 and criti-
cal for male stem cell survival. Finally, better recovery of passaged male 
colonoids (further improved by PAR
2
 activation) and of primitive sorted 
male cells as colonoids suggested that male stem cells have higher resis-
tance capacities compared to females.
conclusion: Our results demonstrate that PAR
1
, PAR
2
 and PAR
3
 play specific 
roles in colon stem cell regulation that could be targeted in anti-inflam-
matory and anticancer therapies. Work is ongoing to determine the fine 
impact of PARs on stem cell differentiation and the implication of specific 
proteases in colon stem cell regulation.
disclosure: Nothing to disclose 
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P0471 a gene PaneL derIved frOM gasTrIc cancer 
TranscrIPTOMe anaLysIs dIscrIMInaTes cOLOnIc POLyPs
Bornschein J.1, Blake A.2, Leedham S.2, Bird-Lieberman E.3, 
The S:CORT Consortium
1Oxford University Hospitals, Translational Gastroenterology Unit, Oxford, 
United Kingdom, 2University of Oxford, Oxford, United Kingdom, 3Oxford 
University Hospital, Gastroenterology, Oxford, United Kingdom
contact e-Mail address: janbornschein@gmx.de
Introduction: There is ongoing debate about factors that drive pathogen-
esis of different types of colonic polyps. Several studies have reported an 
enrichment for stomach-specific genes in sessile serrated lesions in the 
right colon.
aims & Methods: Aim of the present study was to assess if a gene-panel 
derived from analysis of upper gastrointestinal cancers can discriminate 
different phenotypes of colonic polyps.RNA was extracted from 64 colonic 
samples collected as part of the S:CORT study. This comprised 15 sessile 
serrated lesions (SSL), 15 tubulo-villous adenomata from the proximal 
(right) colon (p-TVA), 14 from the distal (left) colon (d-TVA), 10 tubolo-
sessile adenomata (TSA), and 5 biopsies each from normal colonic mu-
cosa adjacent to tubolo-villous and to tubolo-serrated adenomata. RNA-
Sequencing was performed for transcriptome analysis. Data were loga-
rithmised, and 66 genes have been selected that have been identified in 
a previous study applying an unsupervised stratification to distinguish 
phenotypes of oesophago-gastric adenocarcinomas.
results: Stratification of the colonic samples according to expression of 
the 66 genes was done by using the mclust algorithm on R. This revealed 
a distribution into 4 separate groups. The “normal” samples from non-
polypoid mucosa clustered in group 3 (100.0%), without any of the polyp 
samples being represented in this group. SSL clustered in group 4 (86.7%), 
whereas both p-TVA and d-TVA clustered in groups 1 (64.3%, 46.7%, resp.) 
and 2 (35.7%, 53.3%, resp). TSA were mainly represented in group 1 
(80.0%), together with a subgroup of d-TVA and p-TVA. The phenotype 
distribution was confirmed in the principle component analysis with the 
first principle component being dominated by gastric genes (TFF2, MU-
C5AC, CTSE, CA2) and the second principle component by intestinal genes 
(CDX2, PHGR1) as well as genes involved in epithelial cell-cell interaction 
such as CLDN15 and A1CF. Phenotypic discrimination was further assessed 
by Fisher’s exact test revealing highly significant association of the dis-
tribution given by the 66 genes and histopathology results (P< 0.00001).
conclusion: A gene panel derived form upper GI adenocarcinoma can suc-
cessfully stratify phenotypes of colonic polyps. This indicates common de-
nominators that are involved in gastrointestinal carcinogenesis, most likely 
luminal pathogens. SSL, TSA and TVA in the colon can be discriminated 
by their transcriptome profile. TSA cluster with TVA, not with SSL. There 
does not seem to be a difference between classic tubulovillous adeno-
mata of proximal and distal location, but but they cluster with a subgroup 
of tubolosessile adenomata. Prospective validation of the key markers for 
immuno-histochemistry is ongoing.
disclosure: Nothing to disclose 
P0472 WIThdraWn
P0473 LInc00152 cOnTrIBuTes TO The PaThOgenesIs Of 
cOLOrecTaL cancer ThrOugh PrOMOTIng ceLL PrOLIferaTIOn 
vIa MuLTIPLe MOLecuLar PaThWays
Galamb O.1,2, Kalmár A.1,2, Sebestyén A.3, Dankó T.3, Tolnai-Kriston C.3, 
Kinga Bartak B.1, Nagy Z.B.1, Barna G.3, Tulassay Z.4, Igaz P.1, Molnar B.1
1Semmelweis University, 2nd Department of Internal Medicine, Budapest, 
Hungary, 2Hungarian Academy of Sciences and Semmewleis University, 
Molecular Medicine Research Group, Budapest, Hungary, 3Semmelweis 
University, 1st Department of Pathology and Experimental Cancer Research, 
Budapest, Hungary, 4SE II. Belgy. Klinika Belgyogyaszat, 2nd Department of 
Medicine, Budapest, Hungary
contact e-Mail address: alexandra.kalmar@gmail.com
Introduction: Long non-coding RNAs (lncRNAs) contribute to pathomech-
anism of various cancers including colorectal cancer (CRC). Altered 
LINC00152 expression in CRC was reported, but its exact localization and 
detailed role in CRC formation and progression are not well studied.
aims & Methods: We aimed to evaluate the effects of LINC00152 silencing on 
whole transcriptome in colon carcinoma cells and to analyze the DNA meth-
ylation alterations caused by LINC00152 knockdown. Tissue localization of 
LINC00152 was investigated by using in situ hybridization (ISH). LINC00152 
were silenced in SW480 colon carcinoma cells using Stealth siRNAs. Flow 
cytometric cell cycle analysis was performed using propidium-iodide DNA 
staining. The effect of LINC00152 silencing to genome-wide gene expres-
sion was studied on Human Transcriptome Array 2.0 microarrays. The 
expression of selected proteins was determined using western blot. DNA 
methylation alterations after LINC00152 knockdown were evaluated using 
Reduced Representation Bisulfite Sequencing (RRBS) method.
results: Using ISH, elevated LINC00152 expression was found in both epi-
thelial and stromal cells of CRC tissue samples. Silencing of LINC00152 
significantly suppressed cell growth compared to negative control cells 
and caused approximately two-fold increase in apoptosis (p< 0.05). Whole 
transcriptome analysis of LINC00152 silenced cells revealed significant 
underexpression of genes with oncogenic and/or metastasis promoting 
function (e.g. STC1, YES1, HES1, KLK6, PORCN) and upregulation of tumor 
suppressor genes (e.g. DKK1, PERP) (FDR p< 0.05, abs. value of logFC>1). 
Knockdown of LINC00152 significantly reduced the cyclin D1 expression 
without attenuation of phospho-S6 protein (p< 0.05). The decreased ex-
pression of PORCN and YES1 in LINC00152 silenced cells was also confirmed 
at protein levels. DNA methylation alterations after LINC00152 silencing 
could be genome-widely detected by RRBS including hypomethylation in 
SFRP4 and ALDH1A3 gene promoters.
conclusion: Our results indicate that LINC00152 lncRNA can contribute to 
CRC pathogenesis by promoting cell proliferation through upregulation 
of several oncogenes/metastatic genes in WNT, PI3K/Akt, Notch and TP53 
pathways and of cyclin D1 cell cycle progression gene, furthermore, by af-
fecting the promoter methylation status of certain CRC associated genes.
disclosure: Nothing to disclose 
P0474 faecaL IMMunOcheMIcaL TesTIng In PaTIenTs WITh 
recTaL BLeedIng: a WasTe Of TIMe?
D’Souza N.1, Benton S.2, Abulafi M.1
1Croydon University Hospital, Colorectal Surgery, Croydon, United Kingdom, 
2Southern Bowel Cancer Screening Hub, Guildford, United Kingdom
contact e-Mail address: nigel151@gmail.com
Introduction: The faecal immunochemical test (FIT) can be used to rule out 
bowel cancer. Patients with rectal bleeding (RB) have been recommended 
not to be tested with FIT due to concerns of a high false positive rate. This 
study aimed to investigate the positivity rate and diagnostic accuracy for 
colorectal cancer of FIT in patients with rectal bleeding.
aims & Methods: Patients referred from primary care in England with 
symptoms of suspected bowel cancer according to NICE NG12 guidelines 
were recruited in a prospective, ethics-approved, multicentre, diagnostic 
test of accuracy study, and were tested with FIT prior to colonoscopy. FIT 
samples were processed on the HMJACK-arc analyser. Patients were then 
split into groups, based on the presence or absence of RB symptoms. Fae-
cal haemoglobin (FHb) levels and colonoscopy findings in each group 
were analysed. Cutoffs of FHb were set at the limit of detection, calibrated 
at 2ug blood per gram of faeces (ug/g), and the limit of quantification, 
calibrated at 10ug/g. Statistical analysis was performed on Stata using the 
Kruskal-Wallis or Chi-Square tests to compare continuous and categorical 
outcomes.
results: The results of 5332 patients were analysed, of whom 1730 pre-
sented with RB with or without other associated bowel symptoms. 
Patients with RB had a higher mean faecal haemoglobin than patients 
without RB (264.6 (std. dev. 1135) vs 62.8 (std. dev. 493), p< 0.01), although 
the median value in both groups was undetectable FHb (< 2ug/g).
FHb was undetectable (< 2ug/g) in 57% (983/1730) of patients with RB 
vs 65% (2365/3602) in patients without RB (p< 0.01). Faecal haemoglo-
bin was less than 10ug/g in 75% (1289/1730) of patients with RB vs 85% 
(3065/3602) of patients without RB (p< 0.01). 
Colorectal cancer was diagnosed in 67 patients without RB, and 65 patients 
with RB. At a cut-off of 2ug/g, there were 2 missed cancers in patients 
without RB (3%) vs 2 missed cancers in patients with RB (5%, p=0.63). The 
sensitivity of FIT at a cut-off of 2ug/g for CRC was 95% in patients with RB 
vs 97% in patients without RB.
At a cut-off of 10 ug/g, there were 9 missed cancers in patients without RB 
(13%) vs 5 missed cancers in patients with RB (8%, p=0.29). The sensitivity 
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aims & Methods: Investigate the diagnostic accuracy of the FIT at cut-offs 
of 2 or 10µg/g for CRC, as well as HRA and IBD.
The study was approved by the UK Health Research Authority to recruit 
patients prospectively from multiple centers in England. Symptomatic pa-
tients meeting NICE referral criteria and awaiting colonoscopy were re-
cruited via telephone and post at over 40 hospitals, and invited to perform 
a FIT. The HM-JACKarc analyser was used to process all FIT samples. Colo-
noscopy findings of serious bowel disease ie colorectal cancer (CRC), high 
risk adenoma (HRA) and inflammatory bowel disease (IBD), were com-
pared to faecal haemoglobin (FHb) levels at cut-offs of 2 or 10 micrograms 
of blood per gram of faeces (µg/g). 2µg/g has recently been suggested 
as the limit of detection of faecal haemoglobin[2]. All clinical data un-
derwent a three-level process of quality assurance, including final checks 
by colorectal surgeons who were all accredited endoscopists. Statistical 
analysis included Chi-squared test for proportions.
results: The trial has recruited over 11 000 patients, and quality assured 
the data of 5332 patients. The prevalence of CRC was 2.5% (132/5332), 
HRA was 4.3% (230/5332) and IBD was 6.1% (326/5332). At cut-off of 2 or 
10µg/g, the sensitivity of FIT for CRC was 96.2% and 89.4% respectively. 
Significantly more cases of CRC (14 vs 5, p=0.03), HRA (107 vs 54, p< 0.01) 
and IBD (181 vs 131, p< 0.01)were missed at a cut-off of 10µg/g than 2 µg/g. 
Less patients would be triaged to colonoscopy at a cut-off of 10µg/g (81.7%) 
than 2µg/g (62.8%).
conclusion: The diagnostic accuracy of FIT suggests it could be used to 
triage symptomatic patients for further investigation. Although a cut-off of 
10µg/g permits a greater reduction in referral for colonoscopy, significantly 
more CRC, HRA and IBD is missed.
references: 
1. Westwood M, Corro Ramos I, Lang S, et al. Faecal immunochemical tests 
to triage patients with lower abdominal symptoms for suspected colorectal 
cancer referrals in primary care: a systematic review and cost-effective-
ness analysis. Southampton (UK): NIHR Journals Library; 2017 May. (Health 
Technology Assessment, No. 21.33.) Available from: https://www.ncbi.nlm.
nih.gov/books/NBK436505/ doi: 10.3310/hta21330 
2. Fraser CG, Benton SC. Detection capability of quantitative faecal im-
munochemical tests for haemoglobin (FIT) and reporting of low faecal 
haemoglobin concentrations. Clinical Chemistry and Laboratory Medicine 
(CCLM). 2018 Jul 11.
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P0477 dIgITaL chrOMOendOscOPy sysTeMs (I-scan and 
OPTIcaL enhanceMenT) fOr cOLOrecTaL POLyP PredIcTIOn: 
TheIr rOLe In The nIce cLassIfIcaTIOn
Robles-Medranda C., Soria-Alcivar M., Oleas R., Olmos J.I., 
Baquerizo-Burgos J., Puga-Tejada M., Ospina J., Alcivar-Vasquez J., 
Alvarado-Escobar H., Del Valle R., Pitanga-Lukashok H.
Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Gastroenterology 
and Endoscopy Division, Guayaquil, Ecuador
contact e-Mail address: robertoleas@gmail.com
Introduction: The validity of the narrow-band imaging international 
colorectal endoscopic (NICE) classification, using other digital chromoen-
doscopy systems remains unknown.
aims & Methods: aim: to validate the NICE classification using digital chro-
moendoscopy systems (I-scan and Optical Enhancement) for endoscopic 
colonic polyps prediction. 
Methods: consecutive adult patients referred to a tertiary-center for endo-
scopic polypectomy, or biopsy were prospectively enrolled from April 2017 
to May 2018. Lesion size, location and macroscopic features (color, vessels 
and surface pattern) were recorded. Real-time, endoscopic classification of 
polyps via NICE classification using digital chromoendoscopy systems was 
performed. All lesions were photographically recorded and then biopsied 
or resected for histology analysis (criterion standard). Accuracy, sensitiv-
ity, specificity, positive and negative predictive values for each component 
of the classification and for the overall prediction was calculated. A 30 
randomly-selected image set was collected for inter and intra-observer 
agreement analysis.
results: A total of 95 patients were enrolled, 52.6% were female. The mean 
age was 60.30 (±14.04) years. The reasons for colonoscopy were diagnostic 
(49.5% of cases), surveillance (27.4%), and screening (23.3%). The median 
Boston bowel preparation scale was 8 (range: 6-9). A total of 139 polyps 
were found during colonoscopy. 31/139 (22.3%) were located in the left 
of FIT at a cut-off of 10ug/g for CRC was 92% in patients with RB vs 87% 
in patients without RB.
conclusion: FIT can be used to triage patients with RB for investigation. 
The mean FHb level was significantly higher in patients with RB. However, 
a substantial number of patients with RB had less than 2 or 10 ug/g of FHb 
when tested with FIT, with similar sensitivity to patients without RB. This 
suggests that FIT could be used to rule out cancer in patients with RB and 
still reduce the negative colonoscopy rate.
disclosure: Nothing to disclose 
P0475 PrOTOn PuMP InhIBITOrs assOcIaTed WITh 
faLse-POsITIve resuLTs When usIng faecaL IMMunOcheMIcaL 
TesTs fOr cOLOrecTaL cancer screenIng
de la Peña Negro L.C.1,2,3, Ibañez Sanz G.1,2,4, Milà N.1,5, 
Rodríguez Moranta F.2,4, Rodríguez Alonso L.2, García M.5, Binefa G.5, 
Vidal C.5, Atencia C.1, Centelles C.2, Soriano A.2, Guardiola J.2,6, Moreno V.1,4,6
1Catalan Institute of Oncology-IDIBELL, Oncology Data Analytics Program, 
Hospitalet de Llobregat, Spain, 2Bellvitge University Hospital - DIBELL, 
Gastroenterology Department, Hospitalet de Llobregat, Spain, 3Viladecans 
Hospital, Gastroenterology Department, Viladecans, Spain, 4CIBER 
Epidemiology and Public Health, Madrid, Spain, 5Catalan Institute of 
Oncology-IDIBELL, Screening Unit, Hospitalet de Llobregat, Spain, 6University 
of Barcelona, Barcelona, Spain
contact e-Mail address: ldelapena.hv@gencat.cat
Introduction: The faecal immunochemical test (FIT) has a specificity of 
94% for colorectal cancer (CRC) screening resulting in false positive (FP) 
results. The use of proton pump inhibitors (PPI) prior to FIT could decrease 
the accuracy of the test which would lead to a reduction in the efficacy of 
CRC screening.
aims & Methods: We included participants with a positive FIT result who 
underwent total colonoscopy between 2013 and 2014. A FP result was de-
fined as having a positive FIT (≥20 µg haemoglobin per gram of faeces) 
and follow-up colonoscopy without intermediate/high-risk lesions or can-
cer. Screening data was anonymously linked to pharmaceutical dispensing 
during the study period obtained through the public data analysis pro-
gram for health research and innovation (PADRIS). PPI consumption for 
each FIT was measured according to whether the individual had collected 
prescriptions with the ATC code: A02BC for the 3 months prior to the FIT. 
Logistic regression models, adjusted for sex and age, were carried out to 
analyse whether PPI consumption increased the risk of FP.
results: We included 4253 positive FIT (4204 participants) with diagnos-
tic colonoscopy. The proportion of FP was 53.49% (45.8% in men; 54.2% 
in women). In 1019 (23.96%) FIT, the person had received PPI 3 months 
prior to testing (21.0% men; 27.8% women). PPI consumption increased 
the probability of obtaining a FP by 13% (95% CI 9.5-16.3%) from 50.4% to 
63.3% (adjusted OR: 1.65; 95% CI: 1.42 to 1.92).
conclusion: Concurrent use of PPIs at the time of FIT increases the likeli-
hood of a false positive result. The recommendation to avoid their use 
before colonoscopy could reduce up to 1 out of 8 FP.
disclosure: Nothing to disclose 
P0476 The nIce fIT sTudy InTerIM resuLTs: PrOsPecTIve, 
MuLTIcenTre, dIagnOsTIc accuracy sTudy Of The faecaL 
IMMunOcheMIcaL TesT fOr cOLOrecTaL dIsease In 5332 
syMPTOMaTIc PaTIenTs
D’Souza N.1, Benton S.2, Abulafi M.1
1Croydon University Hospital, Colorectal Surgery, Croydon, United Kingdom, 
2NHS, Bowel Cancer Screening Programme, Guildford, United Kingdom
contact e-Mail address: nigel151@gmail.com
Introduction: The faecal immunochemical test (FIT) detects the amount of 
blood in stool (faecal haemoglobin or FHb) to the nearest microgram of 
blood per gram of faeces (µg/g). A recent meta-analysis[1] reported that 
FIT could be used to rule out colorectal cancer (CRC) if less than 10µg blood 
was present per gram of faeces. We designed a powered, prospective, di-
agnostic cohort study to investigate whether this non-invasive, accurate 
and cheap test could be used rule out serious bowel disease such as CRC, 
but also high risk adenoma (HRA) and inflammatory bowel disease (IBD) 
instead of a colonoscopy.
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colon, 27/139 (19.4%) in the right colon, 26/139 (18.7%) in the transverse 
colon, 25/139 (18.0%) in the sigmoid colon, 19/139 (13.7%) in the rectum, 
and 11/139 (7.9%) in the cecum. 52/139 of the polyps (37.4%) were ≥10mm, 
44/139 (31.7%) were ≤5mm, and 43/139 (30.9%) were 6-9mm. According 
to the Paris classification: 111/139 (79.9%) were sessile polyps (Is), 19/139 
(13.7%) were pedunculated (Ip), 6/139 (4.3%) were subpedunculated, 
2/139 (1.4%) were flat elevated lesions of the mucosa, and 1/139 (0.7%) 
was flat mucosal change. According to the NICE classification, the color 
was classified as clear (73/139 [52.5%]), intermediate (60/139 [43.2%]), 
and dark (6/139 [4.3%]); the surface was subdivided into uniform pattern 
(78/139 [56.1%]), tubular pattern (57/139 [41.0%]), and amorphic pattern 
(4/139 [2.9%]); vessels were distributed as no vessels (51/139 [36.7%]), 
regular vessels (69/139 [49.6%]), and irregular vessels (19/139 [13.7%]). 
NICE types were type 1 (63/139 [45.3%]), type 2 (68/139 [48.9%)), and type 3 
(8/139 [5.8%]). Using I-scan and Optical Enhancement, NICE classification 
reached a sensitivity specificity, positive and negative predictive value of 
89%, 70%, 36% and 97%, respectively. Every NICE classification parameter 
reached an excellent inter and intra-observer agreement (>0.80 κ value) 
(table 1).
  Overall accuracy [% (95% cI)]
Interobser-
ver agree-
ment (κ)
Intraobserver 
agreement (κ)
Macroscopic 
features Sensitivity Specificity PPV NPV M.S.A. M.S.A. H.A.E. J.O.
color 68 
(45 - 86)
96 
(78 - 100)
94 
(70 - 100)
76 
(56 - 89)
0.81 0.93 0.95 0.95
vessels 55 
(32 - 77)
83 
(59 - 96)
79 
(49 - 95)
62 
(41 - 81)
0.92 0.93 0.94 0.94
surface 86 
(65 - 97)
96 
(81 - 100)
95 
(75 - 100)
90 
(73 - 98)
0.85 0.94 0.95 0.94
nIce type 89 
(52 - 100)
70 
(55 - 83)
36 
(17 - 59)
97 
(85 - 100)
0.85 0.94 0.89 0.94
[Table 1. Overall accuracy, inter and intraobserver agreement analysis of the 
NICE classification using digital chromoendoscopy systems.]
conclusion: Digital chromoendoscopy systems (I-scan and Optical en-
hancement) are useful also with NICE classification for prediction of polyps 
histology during colonoscopy.
references: ClinicalTrials.gov Identifier: NCT03155308
disclosure: Nothing to disclose 
P0478 cOMParaTIve sTudy Of greek PaTIenTs WITh cancer 
Of The LefT and rIghT cOLOn Based On cLInIcaL PresenTaTIOn, 
cOMOrBIdITy, hIsTOPaThOLOgy and MOLecuLar BIOMarkers
Kalantzis I.1, Gakiopoulou X.2, Nonni A.2, Ziras N.3, Gkoumas K.1, 
Paulaki A.2
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Introduction: The differences in histopathology and molecular biology be-
tween right and left colon cancer were first reported in the literature by 
Bufill in 1990. Since then a large number of studies have confirmed their 
differences in epidemiology, clinical presentation, comorbidity and bio-
logical behavior, which may be related to the difference in prognosis and 
overall survival between the two groups.
aims & Methods: Investigating statistically significant differences between 
Greek patients with right and left colon cancer based on clinical presenta-
tion, comorbidity, histopathology and molecular biomarkers. 144 patients 
diagnosed with colon cancer of any stage who received chemotherapy 
regimens in a Greek Oncology Hospital were included in the study. Data 
analysis was performed with the SPSS statistical package.
results: 144 patients (86 males and 58 females) participated in the study. 
100 (69.4%) patients had a primary lesion in the left and 44 (30.6%) in the 
right colon. The average age of diagnosis was 65.4 years and that of the 
BMI was 28.3 without statistically significant differences between the two 
groups. Statistically significant differences resulted from the clinical pre-
sentation of the disease, wherein patients with right colon cancer localiza-
tion were more likely to display anemia (OR=3.09, p=0.008), while patients 
with left colon cancer localization were more likely to develop bloody 
stools (OR=3.37, p=0.003) and feeling of incomplete evacuation (OR=2.78, 
p=0.05). In the case of comorbidity, patients with right primary lesion were 
more likely to receive metformin (OR=3.31, p=0.016), while marginal sig-
nificance (p=0.056) was found in coronary artery disease, where patients 
with right sided neoplasia suffered from the disease to a greater percent-
age (20.5% vs. 9% left).Statistically significant differences were also ob-
served in the histological characteristics between the two groups. On one 
hand the percentage of mucinous differentiation was higher in the right-
sided group (15,9% vs 4,0% left-sided group, p=0,035.OR=4,49), while on 
the other hand the percentage of high grade differentiation was higher in 
the group of patients with left-sided colon cancer (78% vs 56,1% right-
sided group, p=0,010.OR=2,78). Furthermore, the percentage of infiltrated 
lymph nodes was higher in the group of patients with right colon cancer 
compared with the left-sided group (N
0
 left 33,3% vs 24,3% right , N
1-3 
right 
62,2% vs 38,1% left, p=0,039) as it was also the average of removed lymph 
nodes (right 18,1 vs 14,6 left). The study of three genes (KRAS, NRAS and 
BRAF) revealed statistically significant difference only regarding the KRAS 
gene, wherein the neoplasms of the left colon had a higher percentage of 
wild type KRAS gene (65,2%), in comparison with the right colon cancer 
group (47,2%) (p=0,062, marginal significance).
conclusion: The differences in clinical presentation and symptoms of right 
and left colon cancer were confirmed. The highest rate of metformin and 
coronary artery disease in patients with right colon neoplasia may reflect 
correlation with the metabolic syndrome in this group and requires fur-
ther study. The location of colon cancer seems to play a significant role in 
the behavior of the disease. Left and right colon cancer present different 
pathogenic mechanisms, probably related to the differences in histology 
and molecular pathways between them.
references: 1. Bufill JA. Colorectal cancer: evidence for distinct genetic 
categories based on proximal or distal tumor location. Ann Intern Med. 
1990 Nov 15;113(10):779-88 2. Hansen IO, Jess P. Possible better long-term 
survival in left versus right-sided colon cancer - a systematic review. Dan 
Med J 2012;59 3. Katherine Esposito, Paolo Chiodini, Annalisa Capuano. 
Colorectal cancer association with metabolic syndrome and its compo-
nents: a systematic review with meta-analysis. Endocrine. December 2013, 
Volume 44, Issue 3, pp 634-647
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TuMOrs Of The cOLOrecTuM
Iwabuchi M., Sugimura M., Mano Y., Ukai K.
NHO Sendai Medical Center, Gastroenterology, Sendai, Japan
contact e-Mail address: s7856@snh.go.jp
Introduction: Laterally spreading tumors (LSTs) of the colorectum are clas-
sified into the following four subtypes according to their morphology ; 
granular homogeneous type (LST-GH), granular nodular mixed type (LST-
GM), non-granular flat-elevated type (LST-NGF), and non-granular pseu-
do-depressed type (LST-NGPD). Clinical features of each subtype of LSTs 
have not been fully evaluated.
aims & Methods: The aims of this study was to clarify the clinicopatho-
logical features of colorectal LSTs focusing on their subtypes. We reviewed 
clinical charts and surgical pathology files of 7229 endoscopically resected 
specimens during January 2007 and December 2018 at our institution. A 
total of 548 LSTs were detected. We examined the clinical features (mean 
age, male to female ratio, size, location, Incidence of concomitant carci-
noma) according to their subtypes.
results: Of these 548 lesions, a total of 204 (37.2%) were LST-GH, 61 (11.1%) 
LST-GM, 246 (44.9%) LST-NGF, and 37 (6.8%) LST-NGPD. Mean age of pa-
tients with each subtype was 68.4 years old for LST-GH, 67.2 for LST-GM, 
66.9 for LST-NGF, and 66.2 for LST-NGPD. Male to female ratio (M/F) was 
1.4 for LST-GH, 1.9 for LST-GM, 1.8 for LST-NGF, and 1.7 for LST-NGPD. Mean 
size of LST-GH (22.4mm) and LST-GM (26.8mm) were significantly larger 
than that of LST-NGF (17.0mm) and LST-NGPD (15.6mm). All subtypes were 
located predominantly in the proximal colon. 
Incidences of concomitant carcinomas in LST-GH, LST-GM, LST-NGF, and 
LST-NGPD were 17.6% (36 out of 204), 37.7% (23 out of 61), 16.7% (41 out 
of 246), and 51.4% (19 out of 37), respectively. Incidences of concomitant 
submucosal carcinomas in LST-GH, LST-GM, LST-NGF, and LST-NGPD were 
0.5% (1 out of 204), 13.1% (8 out of 61), 2.4% (6 out of 246), and 18.9% (7 
out of 37), respectively.
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conclusion: Created diagnostic panels, including electric, viscoelastic pa-
rameters and fatty acids of RBS membranes and BS, should be considered 
promising for early diagnosis, detection of progression of CRC.
disclosure: Nothing to disclose 
P0481 cLInIcOPaThOLOgIcaL sTudy Of serraTed LesIOns 
Of The cOLOrecTuM
Sugimura M., Iwabuchi M., Mano Y., Ukai K.
NHO Sendai Medical Center, Gastroenterology, Sendai, Japan
contact e-Mail address: sugimura.mikako.fp@mail.hosp.go.jp
Introduction: Serrated lesions of the colorectum are the precursors of mi-
crosatellite unstable carcinomas. However, their clinical and pathologic 
features are still unclear and need further exploration.
aims & Methods: The aims of this study was to clarify the clinicopatho-
logical features of colorectal serrated lesions. We reviewed clinical charts 
and pathology files of 7229 endoscopically resected specimens performed 
during January 2007 and December 2018 in our hospital. A total of 668 
serrated lesions (9.2%) resected were classified into three categories : HP 
(hyperplastic polyp), SSA/P (sessile serrated adenomas/ polyps), and TSA 
(traditional serrated adenoma), according to the WHO criteria. We exam-
ined the features of these cases and evaluate the morphologic character-
istics by using immunochemical staining for Ki-67 and the expression of 
MUCs (MUC2, MUC5AC and MUC6) in differentiating serrated lesions.
results: Of these 668 lesions, a total of 348 (52.1%) were HP, 178 (26.6%) 
SSA/P, and 142 (21.3%) TSA. Male to female ratio (M/F) was 2.28 for HP, 
0.94 for SSA/P, and 2.02 for TSA. Mean size of SSA/Ps (12.1mm) and TSAs 
(13.5mm) were significantly larger than that of HP (8.0mm) (p<0.005, re-
spectively) . SSA/Ps were located predominantly in the proximal colon, 
whereas HP and TSA were mainly located in the sigmoid colon and rectum. 
84% of SSA/Ps were flat in macroscopic appearance. SSA/Ps and HPs were 
whitish or almost the same as adjacent mucosa in color, whereas TSAs had 
a tendency to be reddish. Magnified colonoscopy showed Type II open pit 
pattern as characteristic of SSA/Ps, whereas pinecone-shaped pit pattern 
as that of TSAs. Incidences of concomitant carcinomas in HP, SSA/P, and 
TSA were 0% (0 out of 348), 3.4% (6 out of 178), and 3.5% (5 out of 142), 
respectively. Ki-67 positive cells in HP showed regular, symmetric distribu-
tion, and those in SSA/P did irregular asymmetrical pattern, whereas most 
of those cells in TSA distributed in the so-called ectopic crypts. Expression 
levels of MUC2, MUC5AC and MUC6 were significantly different between 
serrated lesions, SSA/Ps and HPs were positive for MUC5AC in comparison 
with TSAs.
conclusion: Our studies showed the three types of serrated lesions have 
their own distinct features and could be helpful to distinguish between 
them. SSA/P and TSA are premalignant lesions of colorectum and we 
should detect these lesions and completely remove endoscopically.
disclosure: Nothing to disclose 
P0482 cOLOnOscOPIc WIThdraWaL TIMes and adenOMa 
deTecTIOn raTe durIng surveILLance cOLOnOscOPy afTer 
surgery fOr cOLOrecTaL cancer
Huh C.W.1, Jung D.H.2
1Incheon St. Mary’s Hospital, The Catholic University of Korea, Department of 
Internal Medicine, Incheon, Korea (Republic of), 2Severance Hospital, Yonsei 
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contact e-Mail address: leah10042@gmail.com
Introduction: Withdrawal time (WT) and adenoma detection rate (ADR) are 
widely used quality indicators for colononoscopy. Although current guide-
line suggests a minimum withdrawal time of 6 minutes during screening 
colonoscopy, little is known about appropriate withdrawal time during 
surveillance colonoscopy after colorectal cancer (CRC) surgery.
aims & Methods: We investigated the association between WT and ADR 
during surveillance colonoscopy after CRC surgery. 
We performed a retrospective analysis of data from 1,341 subjects who un-
derwent 1st surveillance colonoscopy after curative colectomy between Jan-
uary 2013 and April 2018. The colonoscopies were performed by 8 board-
certified colonoscopists. We recorded the numbers, sizes, and histologic 
features of the neoplastic lesions detected during colonoscopy, as well as 
the duration of insertion and of withdrawal of the colonoscope during the 
conclusion: Each subtype of LSTs has distinct clinical features. LST-GM and 
LST-NGPD have higher malignant potentials than other subtypes. Espe-
cially LST-NGPD has the highest risk of invasive carcinoma regardless of 
its size. Therefore we should carefully detect these lesions and choose ap-
propriate treatment according to the subtypes.
disclosure: Nothing to disclose 
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Introduction: The aim of the work was to study the diagnostic efficiency of 
using the electric and viscoelastic parameters of red blood cells (RBC) in 
combination with the fatty acid profile (FA) of their membranes and serum 
(BS) for early diagnosis and evaluation of tumor progression in patients 
with colorectal cancer (CRC).
aims & Methods: The CRC patients (62,7±8,6 years old) included 65 pa-
tients with early stages (TNM staging I, II) and 64 with late stages (TNM 
staging III, IV) and different tumor locations. The healthy controls (n=35, 
61,7±7,5 years old) were selected by routine clinical examination. Electric, 
viscoelastic parameters of RBC were studied by dielectrophoresis, RBC 
membrane and BS FA composition were measured using GC/MS system 
triple quad Agilent 7000B (USA). 
Using the methods of statistical and inductive analysis, a population of 
logical-mathematical models was formed, from which the best model for 
each diagnostic task was chosen on the basis of the vector quality char-
acteristic.
results: In the patients with CRC RBC tended to have much lower find-
ings of the range of deformation, dipole moment, polarizability at 106 Hz, 
capacity of membranes and much higher levels of summarized findings of 
viscosity, rigidity, indices of destruction, aggregation and conductivity as 
compared to the ones in healthy subjects under study (p< 0.0001-0.02).
The diagnostic panel containing proportion of deformed cells, the ampli-
tude of RBC deformation at a frequency of 106 Hz, the summarized rigidity, 
electric conductivity - achieved high diagnostic accuracy (0.97) with AUC of 
0.95, a sensitivity of 0.97 and a specificity of 0.93 for differentiating early 
stage patients from healthy controls.
A total of 21 differentially expressed FA in RBC membrane and BS were 
identified. Each FA class demonstrated specific changing trends in CRC 
progression (down-regulation in saturated FA, monounsaturated FA 
and up-regulation in polyunsaturated FA during cancer progression) 
(p<0.0001-0.001). The combination of the above RBC electrical and vis-
coelastic parameters and the list of FA, including C18:1;c9, C20:2n-6, 
C20:3n-6, C20:4n-6, C22:4n-6, C22:5n-3, C22:6n-3 - showed the best pre-
dictive power when comparing the early stages CRC patients and late ones 
(AUC 0.80, diagnostic accuracy 0.77, sensitivity 0.76, specificity 0.78).
Metastasis was associated with significant changes in the electric char-
acteristics of erythrocytes: increase of conductivity (r=0.486, p<0.0001), 
decrease of electric membrane capacity (r=-0.548, p<0.0001), dipole mo-
ment (r=-0.527, p<0.0001) at the background of increase of PUFA, espe-
cially C22:5n-3 (r=0.355, p<0.0001) and C22:6n-3 (r= 0.252, p<0.0001 ).
The significant role of PUFA in carcinogenesis is probably related to the 
effect of their high concentrations on the immune environment (it can in-
corporate into the membrane phospholipids to alter their fluidity to inhibit 
the T-cell proliferation).
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procedure. Colonoscopists were classified as fast or slow based in their 
mean WT for colonoscopy without polypectomy. The primary outcome was 
the ADR for each colonoscopists.
results: The mean WT during colonoscopy without polypectomy was 8.1 ± 
5.6 minutes. Using 8 minutes as cutoff, we classified 5 colonoscopists as 
fast (mean WT, 6.8 ± 3.2 minutes) and 3 colonoscopists as slow (mean WT, 
10.3 ± 4.5 minutes). Each colonoscopist’s mean WT correlated with their 
ADR (r
s
=0.874, P=0.005). As compared with colonoscopists with mean 
withdrawal times of less than 8 minutes, those with mean withdrawal 
times of 8 minutes or more had higher ADR (49.1% vs. 32.2 %, P< 0.001).
conclusion: In this study, we found that a minimum of 8 minutes of WT 
was necessary during surveillance colonoscopy after surgery for CRC. Be-
cause patients who underwent CRC surgery possess high risk for meta-
chronous CRC and adenoma, ample amount of time for observation on 
colorectal mucosa is necessary.
disclosure: Nothing to disclose 
P0483 adenOMa deTecTIOn raTe In cOLOrecTaL cancer 
screenIng PrOgraMs: MasTer shOW Me The Way TO BecOMe 
a hIgh deTecTOr!
Rosa-Rizzotto E.1, Saia M.2, Caroli D.3, Zorzi M.4, Monica F.5, Narne E.4, 
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1St. Anthony Hospital Gastroenterology Unit, Internal Medicine, Padova, 
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Introduction: Although the adenoma detection rate (ADR) cut-off for colo-
noscopies after positive fecal immunochemical tests (FIT) continues to 
be a debated issue, the ADR is one of the most accepted benchmarks for 
colonoscopy quality. There is some evidence that the quality of colonscopy 
screening can be improved by educational interventions.
aims & Methods: This study aimed to analyze the effect of endoscopist-
related characteristics on colonoscopy quality indicators and to evaluate 
the factors affecting ADR patterns registered in the colorectal (CRC) screen-
ing program in the Veneto Region between 2015-2017. The following data 
about endoscopists in screening programs between 2015-2017 were col-
lected: age, sex, years as physician, specialization, annual colonoscopy 
volume. During 2010-2014, younger endoscopists (< 40 yr) underwent four 
meetings with a senior endoscopist (Cristopher Williams), to improve gen-
eral endoscopic ability and, in particular, the sensibility to detect adeno-
matous lesions. ADR was calculated for each operator. Data were analyzed 
with SPSS program.
results: During the three year period, 191 endoscopists performed a total 
of 42,706 first colonoscopies after FIT positivity. One hundred forty with 
at least 20 colonoscopies after FIT positivity/yr, (mean age 48.2yr ± 10.8yr 
(M±SD), Male 53.9%) were selected. Three hundred eight-two ADRs were 
collected during the observation period. Overall ADR was 43.7±9.5%. 
Ninety-six of the endoscopists were specialized in gastroenterology, 35 in 
general surgery, and 8 in other specialities. ADR was 44.1± 9.7% for the 
gastroenterologists, 42.7 ±9.6% for the surgeons (p=ns) and 39.5 ±7% for 
those with other specialities (p=0.033). ADR was significantly higher for 
the younger endoscopists (30-39yr 47.5%; 40-49yr 44.6%; >50yr 41.4%, 
with p< 0.001). The ADRs over the three year period were similar (44.2% 
vs 42.9% vs 43.3%, p= ns). No significant association between ADR and 
number of screening colonoscopies performed we found. When the ADR 
in 2017 of 81 endoscopists was analyzed depending on the cumulative 
number of total colonoscopies/yr, it was found that the those with > 300 
colonoscopies/yr had higher ADRs ( 35.5 ±21.4% vs 43.5±11.5%, p=0.04) in 
colonoscopies after FIT positivity/yr.
conclusion: Study findings demonstrated that junior endoscopists and 
those specialized in gastroenterology were more effective in identifying 
adenomas during screening colonscopy procedures. High annual colonos-
copy volumes and working exclusively as endoscopists but not years of 
experience or being older were associated with higher ADRs. Educational 
interventions seemed to be effective in improving sensitivity and perfor-
mance.
disclosure: Nothing to disclose 
P0484 endOscOPIsTs’ POLyP deTecTIOn raTe as a PredIcTOr 
Of LOng- TerM POsT cOLOnOscOPy cancer afTer InITIaL 
nOrMaL cOLOnOscOPy In “syMPTOMaTIc/nOn-screened 
scenarIO”
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Introduction: Polyp detection rate (PDR) is an accepted quality measure of 
colonoscopy in the average-risk population screening scenario (1).
aims & Methods: aim: We aimed to evaluate whether endoscopist’s PDR 
calculated in symptomatic/ non screened situation is associated with long 
term post colonoscopy cancer (PCC) after initial normal colonoscopy (2). 
Methods: A cohort of 16,645 symptomatic patients aged >50 years who 
underwent first-time colonoscopy in 2003-2010 was analyzed to calculate 
PDR of each endoscopists [divided into quartiles: Q1 (21.2-26.7), Q2 (27.8-
29.6), Q3 (31.4-32.1), Q4 (38.3-42.0)]. Thereafter, 9,497 patients with normal 
colonoscopy were followed for PCC through National Cancer Registry or 
death up to Dec 2017. Cox proportional analysis was calculated for PCC and 
advanced stage disease (stage III,IV).
results: During a median follow-up time of 7.58 years (interquartile range 
6.0-8.3), PCC was documented in 38 patients and advanced cancer in 19 
patients. The rate of total PCC and advanced cancer among patients that 
underwent the procedure by endoscopists with lower quartile (Q
1)
 vs. other 
quartiles (Q
2-3-4 
) was 10.0 vs. 4.4 cases/1,000 years and 5.6 vs. 2.0 cas-
es/1,000 years, p=0.012 & 0.023 respectively. After adjusting for multiple 
covariates the risk of total PCC and advanced stage CRC among subjects 
that underwent the procedure by endoscopist with lower quartile PDR was 
HR 1.97 (95%C.I. 1.03-3.78) & 2.47 (1.00-6.14) respectively.
conclusion: Symptomatic patients who undergo colonoscopy by an endos-
copist with lower quartile PDR are at significantly increased risk of total 
and advanced stage PCC. PDR is a significant predictor of PCC also in the 
non-average risk population.
references: 1. Kaminski MF, Regula J, Kraszewska E, et al. Quality indi-
cators for colonoscopy and the risk of interval cancer. N Engl J Med. 
2010;362:1795-1803. 2. Nakao SK, Fassler S, Sucandy I, Kim S, Zebley DM. 
Colorectal cancer following negative colonoscopy: is 5-year screening the 
correct interval to recommend? Surg Endosc. 2013;27:768-773
disclosure: Nothing to disclose 
P0485 shOuLd sessILe serraTed POLyPs have seParaTe 
surveILLance
O’Riordan F.1, McNamara D.1,2, Ryan B.1,2, Breslin N.1,2, O’Connor A.1,2
1Tallaght Hospital/Trinity College Dublin, Gastroenterology, Dublin, Ireland, 
2Trinity Academic Gastroenterology Group, Clinical Medicine, Dublin, Ireland
contact e-Mail address: fionaoriordan85@gmail.com
Introduction: The serrated pathway accounts for up to 30% of colorectal 
cancer (CRC). Sessile serrated polyps (SSPs) have the highest malignant 
potential of serrated lesions. SSPs occur sporadically or as part of the ser-
rated polyposis syndrome (SPS). More recently, increased CRC risk has also 
been associated with an oligo-SPS phenotype and large, ≥ 10mm lesions.
aims & Methods: Our aim was to describe and evaluate SSP character-
istics in an Irish cohort. Following ethical approval, patients with ≥ 1 SSP 
confirmed on histology between 2016-2018 were identified. Patients were 
stratified into four known risk groups: SPS defined by WHO criteria (SPS), 
≥2 SSPs with 1≥ 10 mm (Oligo-SPS), SSP ≥10 mm (Large-SSP), and all other 
SSP’s (Low-risk SSP).
results: 195 SSPs in 145 patients were identified; 4/145 (2.8%) SPS, 10/145 
(7%) Oligo-SPS, 25/145 (17 %) Large-SSP and 106/145 (73%) Low-risk SSP. 
Mean SSP size was 6.5mm. The most common SSP location was the as-
cending colon 54/195 (28%), while a significant proportion were sigmoid 
lesions 45/195 (23.1%). Overall, SSP subjects had a high synchronous polyp 
burden; ≥2 SSPs 47/145 (37%), ≥1 advanced adenoma 17/145 (12%), ≥1 non-
serrated adenoma 59/145 (41%). This did not differ significantly between 
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P0487 cOMParIsOn Of LOng-TerM OuTcOMe Of The cOLOnIc 
sTenT versus TransanaL draInage TuBe and eMergency 
surgery fOr LefT-sIded OBsTrucTIve cOLOrecTaL cancer: 
a reTrOsPecTIve MuLTI-cenTer OBservaTIOnaL sTudy
Enomoto T.1,2, Endo S.2,3, Takayasu K.2,4, Fujimoto T.2,5, Otsuka H.2,6, 
Egashira H.2,7, Koizumi K.2,8, Ebi M.2,9, Kawamura T.2,10, Saida Y.1,2
1Toho University Ohashi Medical Center, Department of Surgery, Tokyo, 
Japan, 2Japan Colonic Stent Safe Procedure Research Group, Tokyo, 
Japan, 3Aizu Medical Center, Fukushima Medical University, Department 
of Coloproctology, Fukushima, Japan, 4Kyorin University, Department 
of Surgery, Tokyo, Japan, 5Kimitsu Chuo Hospital, Department of 
Gastroenterology, Chiba, Japan, 6Tokyo Metropolitan Tama Medical Center, 
Department of Surgery, Tokyo, Japan, 7Shonan Kamakura General Hospital, 
Gastroenterology Medicine Center, Kanagawa, Japan, 8Tokyo Metropolitan 
Cancer Infectious Disease Center Komagome Hospital, Department of 
Gastroenterology, Tokyo, Japan, 9Aichi Medical University School of 
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Cross Hospital, Department of Gastroenterology, Kyoto, Japan
contact e-Mail address: enomo430@gmail.com
Introduction: As colonic stent has been covered by Japanese medical insur-
ance, emergency operation and colonic stent have become a mainstream 
of treatment for the colorectal cancer obstruction instead of transanal de-
compression tube. But “Bridge to Surgery” by colonic stent is not recom-
mended in the European guidelines 2014.
aims & Methods: We evaluated retrospectively the treatment outcomes and 
long-term outcome of patients with obstructive colorectal cancer in Japan. 
This is a retrospective multi-center observational study under the Japan 
Colonic Stent Safe Procedure Research Group. The subjects were patients 
with histologically proven stage II/III left-sided colon or upper rectal can-
cer with obstruction, who underwent subsequent surgery with curative 
resection between 2010 and 2014. The patient age ranged from 20 to 80 
years. The definition of the obstruction was defined as the necessary of 
continual decompression or the difficulty of oral intake. There were 302 
patients from 27 institutions. Patients were divided into three groups; 
group E (emergency surgery, n=103), group S (stent placement, n=114), 
and group T (transanal decompression tube placement, n=85).
results: There were no significant differences in age, gender, site of prima-
ry tumor between the E group and the S group. The ratio of rectal cancer 
was significantly higher in the group T than the group E, and the ratio of 
Stage IIIb was significantly higher in the group S and in the group T than 
the group E. The 3-year Recurrence Free Survival (RFS) rate was 64.8 % 
in S group, 68.9 % in E group, 53.0 % in T group, respectively. There was 
no difference between S group and E group, and T group was significantly 
lower than E group (p=0.0170). Subgroup analysis showed that the 3-year 
RFS of patients with colon cancer did not differ among the three groups, 
while the 3-year RFS in patients with upper rectal cancer was lowest in the 
in the T-group (P< 0.05). Technical success rate was not different between 
group S: 99.1% and group T: 94.1%, but clinical success rate was higher 
in group S: 98.2% compared with group T: 85.9%. Complications of per-
foration and migration tended to be high in group T: 7.1% compared with 
group S: 1.8%. Complications after curative surgery are lower in S group 
and T group than in Group E. Temporary or permanent stoma rate was 
significantly lower in group S than in group E.
conclusion: There was no difference in 3-year relapse-free survival rate 
between emergency surgery and colon stent, and the transanal ileus tube 
was poor. This is possibly due to tumor locations and stages, as well as 
complications related procedure such as perforation and migration. Safe 
colonic stenting has good treatment outcomes and might have not poor 
prognosis compared with other procedure for the patients of obstructive 
colorectal cancer.
disclosure: Nothing to disclose 
groups; advanced adenomas; SPS 0%, Oligo-SPS 10 %, Large-SSP 16%, 
Low-risk SSP 11% and ≥1 non-serrated adenoma; SPS 25%, Oligo-SPS 
40%, large-SSP 44%, low-risk SSP 41%. SPS was recognised by endosco-
pists in 2/4 (50 %) cases.
conclusion: SSP patients, irrespective of risk, have a high synchronous 
polyp burden, including advanced adenomas. The sigmoid, excluded by 
two WHO SPS categories was the location for 1/4 of SSPs. Further studies to 
evaluate the need for SSP targeted surveillance and to consider broaden-
ing the WHO criteria are warranted.
disclosure: Nothing to disclose 
P0486 decIsIOn MakIng In The ManageMenT Of aduLTs 
WITh MaLIgnanT cOLOrecTaL POLyPs: an exPLOraTIOn Of The 
exPerIences Of PaTIenTs and cLInIcIans
Westwood C.1,2, Dhar A.3, Lee T.4, McSherry R.5,6, Bettany-Saltikov J.2, 
Stapley S.2
1County Durham and Darlington NHS Trust, Endoscopy, Bishop Auckland, 
United Kingdom, 2Teesside University, Middlesbrough, United Kingdom, 
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United Kingdom, 6Teesside University, Middlesborough, United Kingdom
contact e-Mail address: clarebarry72@hotmail.co.uk
Introduction: Ten percent of cancers diagnosed within the English Bowel 
Cancer Screening Programme are polyp cancers. The management of pol-
yp cancers usually involves a choice between surgery and surveillance. 
This choice is contentious and can be described as ‘preference sensitive’: 
a situation where one treatment option does not have superiority in terms 
of evidence. The best choice therefore depends on how individual patients 
value the risks and benefits of treatments. Difficulties in decision making 
for both clinicians and patients can arise because of the unexpected nature 
of a diagnosis of polyp cancer. This research focuses on the experiences of 
clinicians and patients of treatment decision making following a diagnosis 
of colorectal polyp cancer. To date, and to the author’s knowledge, there 
are no previous studies which investigate how patients make the decision 
between surgery or surveillance, even though each option could have a 
significant impact on the individual patient’s quality of life.
aims & Methods: This study was carried out across four NHS Trusts within 
the North East of England. A qualitative approach was taken, using Inter-
pretative Phenomenologial Analysis (IPA) as the approach to explore the 
experience and perspectives of both clinicians and patients following an 
unexpected diagnosis of polyp cancer. In depth semi-structured interviews 
with ten clinicians who were involved in the care of patients diagnosed 
with polyp cancer, and five patients who had experience of making a treat-
ment decision were carried out. The focus of the interviews was around the 
experiences of making the decision between surgery and surveillance. The 
phenomenological and interpretive nature of IPA allowed the researcher 
to use her experiences as a nurse consultant within the analysis to identify 
important themes and issues expressed by the participants.
results: Analysis of the interview transcripts showed that clinicians and 
patients were supportive of a shared approach to treatment decision mak-
ing. Several themes were identified which currently prevent this from tak-
ing place. Themes which were common to both groups include: complex-
ity of the risk information; lack of patient information resources; system 
(patient pathway) factors and time. Additional clinician related themes 
included lack of clinical data to support discussion, and influences from 
the multi-disciplinary team. Patient related themes included the influence 
of family and significant others. Many of the themes were directly related 
to the unexpected nature of the diagnosis of polyp cancer.
conclusion: This research study has evidenced several factors which are 
preventing patients being fully involved in important treatment decisions 
following a diagnosis of polyp cancer. Recommendations for improve-
ments in practice resulting from this study include: improving awareness 
of preference sensitive decisions amongst the population; improvements 
in patient pathways and improved access to information and resources 
relating to polyp cancer management for patients.
disclosure: Nothing to disclose 
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P0488 InITIaL TreaTMenT Of LefT sIded MaLIgnanT cOLOnIc 
OBsTrucTIOn WITh seLf-exPandIng MeTaL sTenTs In eLderLy 
PaTIenTs. a cOMMunITy hOsPITaL exPerIence
Garcia-Cano J.1, Taberna-Arana L.2, Godoy-López M.A.3
1Hospital Virgen de La Luz, Department of Digestive Diseases, Cuenca, Spain, 
2Health District, Family Practice, Cuenca, Spain, 3Hospital Virgen de La Luz, 
Radiology, Cuenca, Spain
contact e-Mail address: jegarca59@gmail.com
Introduction: The European Society of Gastrointestinal Endoscopy (ESGE) 
guideline1 suggests that, if available, self-expandable metal stent (SEMS) 
insertion should be considered in elderly (age > 70 years) or frail patients 
with malignant colorectal obtruction (MCRO). After initial obstruction relief 
SEMS can serve either as a definitive palliation or as a “bridge to elective 
surgery” (BTS). We aimed to evaluate the outcomes of this procedure in a 
Community Hospital.
aims & Methods: Retrospective analysis. MCRO was diagnosed using a 
combination of clinical symptoms, radiographic exams and colonoscopy. 
SEMS insertion was attempted from eight cm above the anal verge to the 
splenic flexure. Two methods were employed. For tumors located between 
eight to 20 cm, an ultrathin gastroscope with an outer diameter of 6 mm 
was employed to pass the stricture. A metal Savary guidewire (GW) was 
placed beyond the stenosis through the working channel. The ultrathin 
gastroscope was withdrawn leaving the GW in place. Afterwards an Ultraf-
lex Precision stent (Boston Scientific, Natick, Massachusetts ) was inserted 
over the wire (OTW) and deployed monitored with the ultrathin gastro-
scope placed side by side). No fluoroscopy was employed. For tumors be-
yond 20 cm, an endoscope with therapeutic channel was used to reach the 
stricture, which was subsequently negotiated, under fluoroscopic control, 
with a 0.035 in hydrophilic tip GW, loaded into an ERCP catheter. Once the 
GW traversed the stricture, a Wallflex colonic stent (Boston Scientific) was 
inserted through the scope (TTS) and deployed both under fluoroscopic 
and endoscopic guidance. All procedures were performed by an experi-
enced endoscopist.
results: In the last five years stenting was attempted in 31 patients (18 M 
and 13 F, mean age 81.46 years [SD 6.15] range 72-91). There were 20 OTW 
and 11 TTS procedures respectively. Tumor location was: rectum five cases, 
recto-sigmoid junction four, sigmoid colon 14, descending colon seven and 
splenic flexure in one case. Technical success was 29/31 (93.5%). There 
were two failures for inability to traverse the stricture (one in each group, 
OTW and TTS). MCRO symptoms did not improve in the tumor located in 
the splenic flexure. Therefore, clinical success was 28/31 (90 %). One pa-
tient died two days after the procedure for a not technique-related cause. 
Out of the 27 remaining patients SEMS served as a BTS in 10 (37%) and 17 
(63%) had the stent as a definitive palliation. Two patients presented mild 
tenesmus, and one had stent migration.
conclusion: Colorectal stenting using either the OTW or TTS technique ap-
pears to be safe and effective in this elderly population for the initial treat-
ment of MCRO.
references: 1van Hooft JE et al. Self-expandable metal stents for obstruct-
ing colonic and extracolonic cancer: ESGE Clinical Guideline. Endoscopy 
2014: 46:990
disclosure: Nothing to disclose 
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P0491 cheMOPrevenTIOn agaInsT cOLOn cancer By dIeTary 
InTake Of suLfOraPhane
Suzuki H.1, Mutoh M.2, Kamoshida T.3, Kakinoki N.3, Yoshida S.4, 
Ebihara T.5, Hirose M.6, Hyodo I.7, Yanaka A.8
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Introduction: Sulforaphane (SFN), a phytochemical compound, which be-
longs to isothiocyanates family found in abundance in broccoli sprouts, 
potently induces a variety of antioxidant enzymes via NF-E2-related factor 
2-Kelch-like ECH-associated protein 1-mediated pathway, thereby protects 
cells from injury induced by various kinds of oxidative stresses. We have 
previously shown that SFN protects gastric mucosa from oxidative injury 
induced by H. pylori infection. SFN also down-regulates histone deacety-
lase (HDAC) activity, thereby induces apoptosis and inhibits proliferation of 
tumor cells in variety of tissues. On the other hand, colon cancer has been 
increasing in Japan. Since numerous epidemiological studies have shown 
that colon cancer is inversely associated with intake of anti-oxidant veg-
etables, we examined if daily intake of SFN prevents colon tumorigenesis 
in mice, and in human subjects.
aims & Methods: 
1. Effects of SFN on Colonic tumorigenesis in Mice Treated with Chemi-
cal Carcinogen: Effects of SFN on colonic tumorigenesis were examined in 
the ICR male mice, pretreated with a chemical carcinogen, azoxymethane 
(AOM) (15 mg/kg). The mice treated with AOM for 3 or 6 times were fed 
for 8 or 24 weeks with or without sulforaphane glucosinolates (SGS: 2,200 
ppm/kg/day), which is a precursor of SFN. Effects of SGS treatment on for-
mation of the microscopic aberrant crypt foci (ACF), and the macroscopic 
tumors in colonic mucosa were evaluated.
2. Effects of SFN on formation of Colonic ACF in patients with colonic ad-
enoma: Effects of intake of raw broccoli sprouts (BS), 50 g/day, which con-
tains 220 mg SGS every other day, for 6 months on changes in the number 
of ACF in rectal mucosa was examined by colonoscopy in patients with 
colonic adenoma. This study was conducted by members of Tsukuba Can-
cer Clinical Trial Group. 
3. Effects of SFN on intestinal microbiota in human subjects: Effects of 
dietary intake of raw BS, 20 g/day, which contains 88 mg SGS every other 
day, for 2 weeks on intestinal microbiota in healthy volunteers was as-
sessed by measuring composition of stool bacteria, using a method of ter-
minal restriction fragment length polymorphism flora analysis. In human 
studies, alfalfa sprouts, which contains no SFN was used as a placebo 
control. The human studies 1 and 2 were approved by the ethical com-
mittee of each hospital, and were registered with the University Hospital 
Medical Information Network in Japan (Study 1: UMIN-000012022; Study2: 
UMIN-000032565).
results: 
1. Daily administration of SGS suppressed formation of microscopic ACF 
and macroscopic colonic tumors in the AOM-pretreated mice in vivo. 
2. Intake of BS for 6 months tended to decrease the number of colonic ACF 
in patients with colonic adenoma. 
3. Intake of BS for 2 weeks increased percentages of Bifidobacterium and 
Clostridium XVIa, which has been shown to enhance protection of colonic 
mucosa by increasing butyrate production in colonic lumen.
conclusion: 
1. Daily intake of SFN affords chemoprotection against colonic tumors in 
the mice treated with a chemical carcinogen. 
2. The present study further suggests that, in addition to previously re-
ported mechanisms, changes in the intestinal microbiota by SFN intake 
may also play a role in chemoprevention against colon cancer.
disclosure: The Human studies 1 and 2 were financially supported in part 
by a research grant from Murakami Noen. Co. Ltd. Akinori Yanaka is an en-
dowed chair of Hitachi Medical Education and Research Center in Tsukuba 
University Hospital, funded by Hitachi Co. Ltd. 
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P0494 PerfOrMance Of PrOPOsed aLgOrIThMs fOr 
esTaBLIshIng rIsk Of adverse OuTcOMe In T1 cOLOrecTaL 
carcInOMa
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8Bernhoven, Gastroenterology & Hepatology, Uden, Netherlands, 9Rijnstate 
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Utrecht, Gastroenterology & Hepatology, Utrecht, Netherlands, 12University 
Medical Center Utrecht, Pathology, Utrecht, Netherlands
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Introduction: Recently, two simplified prediction models have been pub-
lished to determine which patients should undergo adjuvant surgery after 
endoscopic resection of T1 colorectal cancer (CRC). In the Scottish screen-
detected T1 CRC based algorithm (Scottish model), the model identified 
low-risk cases based on completeness of resection (resection margin >0.1 
mm) and absence of lymphovascular invasion (LAI).1 The model of the 
French group identified low-risk cases based on a resection margin of ≥1 
mm (French model).2 Both models showed promising results but were 
never externally validated.
aims & Methods: In this study, we investigated two proposed algorithms 
and the Dutch guideline for prediction of adverse outcome in T1 CRC after 
endoscopic resection. Adverse outcome was defined as lymph node metas-
tasis (LNM) at baseline or any recurrence at follow-up. Cases were derived 
from a multicenter retrospective observational cohort of patients with an 
endoscopic resection of a T1 CRC diagnosed from 2014-2017 in 8 hospitals 
in the Netherlands. Recorded features included: screen-detection, polyp 
morphology and histological parameters (LAI, differentiation grade, and 
resection margins). Risk classification by the Dutch guideline algorithm 
(Dutch model) included absence of LAI, good/moderate differentiation and 
a resection margin of >1 mm as low-risk factors. The endpoints of the 
study were the percentage of low-risk cases identified, sensitivity, specific-
ity, positive predictive value (PPV), negative predictive value (NPV) and 
accuracy for each model.
results: In 754 endoscopically treated T1 CRCs (median follow-up 20 
months, IQR 13-28), 250 patients (33.1%) had secondary surgery. A total 
of 55 (7.3%) patients had an adverse outcome. LNM was present in 40 
(5.3%) and recurrence in 17 (2.3%) patients (2 patients with LNM also de-
veloped recurrence). The Dutch, Scottish and French models identified 256 
(35%), 394 (68%), and 347 (70%) patients as low-risk respectively. Sen-
sitivity, specificity and accuracy were 92.5%, 36.6%, and 40.6% for the 
Dutch model, 77.1%, 71.1%, and 71.5% for the Scottish model and 67.7%, 
72.4%, and 72.1% for the French model (see table 1 for PPV, NPV and cor-
responding 95%CIs). This corresponded with 4 (0.5%), 8 (1.4%), and 11 
(2.2%) missed cases with an adverse outcome in the total cohort for the 
Dutch, Scottish and French model respectively. Within the predicted high-
risk groups according to the Dutch, Scottish and French model, 49 (10%), 
27 (15%), and 23(15%) patients truly had an adverse outcome respectively. 
The models did not perform differently when stratified for polyp morphol-
ogy or screen-detection.
conclusion: For endoscopically treated T1 CRCs the analyzed models could 
adequately identify cases at low risk for adverse outcome in a large cohort 
(screen- and non-screen detected). These results show that a stringent 
model, such as the Dutch model, has the highest sensitivity, but leads 
to 59% of patients being referred for surgery without any benefit. Less 
stringent models such as the Scottish and French models may result in an 
absolute reduction of unnecessary surgery referrals of up to 33%, but at 
the cost of an increase in missed adverse outcomes. Considering these re-
sults there is room for improvement of the current Dutch model, provided 
that a cautious approach is taken.
P0492 WIThdraWn
P0493 rOLe Of LOW grade dysPLasIa sMaLL POLyPs durIng 
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Introduction: The role diminutive polyps and small polyps play in the de-
velopment of advanced neoplasia (AN) or cancer during follow-up (FU) 
continues to be debated. Recent studies have shown that the risk of AN 
development during FU is higher in patients with > 5 small polyps but 
similar in patients with 1-2 or 3-4 small polyps2,3.
aims & Methods: the current study aimed to evaluate if current European 
FU guidelines1 at first screening colonoscopy according to the number of 
low-grade dysplasia tubular adenoma < 1 cm (“micropolyps”, MP) are 
too strict. A longitudinal cohort study was carried out on a representative 
sample (50%) of patients who underwent a screening colonoscopy (clean 
colon) in 2010 showing at least 1 polyp. Patients with AN or cancers were 
excluded. Polyps > 1 cm or villous or high grade dysplasia/carcinoma in 
situ were considered AN. These patients made a FU colonscopy according 
to UE screening CCR guidelines. Patients were split up according to Euro-
pean guidelines in Low risk (1-2 MP), Intermediate risk (3-4 MP) and High 
risk (>5 MP). Data were analyzed by SPSS program.
results: Of 640 patients included in the sample 172 (27%) were included in 
the surveillance program (mean age 62,2± 5,7 yr, 50-70), 120 male (69,8%). 
During first colonoscopy (2010) 370 MP were detected (M±SD 2,1±1,5, range 
1-13 polyps for each patient). During FU (median 5.5 years), 315 colonos-
copies were performed (mean 1.8; range 1-5) and an AN was detected in 
23 patients (13.4%): 20/23 tubulovillous microadenoma, 1/23 high grade 
dysplasia, 2/23 tubular adenoma > 1 cm. The detection of AN among pa-
tients in treatment with ASA was non significantly lower than the others. 
AN detection was lower among Low risk patients (13/108; 10.7%) as com-
pared to Intermediate risk (7/33; 17.5%) and High risk (3/8; 27.3%) (P=ns). 
According to Kaplan-Meier analysis, the cumulative risk of AN among High 
risk was significantly increased (p=0.035) . No interval cancers were found 
during the follow-up.
conclusion: These findings suggest that EU guidelines for surveillance 
colonoscopies for > 3 small LGD polyps are excessively strict. We propose 
extending the time for a repeat colonscopy FU for these patients to 5 yrs
references: 1Segnan N. et al. European Guidelines for Quality Assurance in 
Colorectal Cancer Screening and Diagnosis - First Edition 2011 2Chang MM 
et al. Digest Liv Dis 2018; 50: 847-852 3Jung YK et al. Am J Gastroenterol 
2018: 113(12):1855-61.
disclosure: Nothing to disclose 
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  dutch model scottish model french model
Sensitivity,
(95% CI)
92.5% 
(81.8%-97.9%)
77.1% 
(59.9%-89.6%)
67.7% 
(49.5%-82.6%)
Specificity,
(95% CI)
36.6% 
(33.0%-40.3%)
71.1% 
(67.1%-74.9%)
72.4% 
(68.1%-76.4%)
Positive predictive 
value,(95% CI)
10.1% 
(9.25%-11.0%)
14.7% 
(12.1%-17.7%)
15.2% 
(12.0%-19.1%)
Negative predictive 
value,(95% CI)
98.4 % 
(96.1%-99.4%)
98.0% 
(96.3%-98.9%)
96.8% 
(94.9%-98.0%)
Accuracy,
(95% CI)
40.6% 
(37.0%-44.2%)
71.5% 
(67.6%-75.1%)
72.1% 
(67.9%-76.0%)
[Performance of proposed risk models for adverse outcome in T1 CRC]
references: 1. Richards CH, Ventham NT, Mansouri D, Wilson M, Ramsay 
G, Mackay CD, et al. An evidence-based treatment algorithm for colorec-
tal polyp cancers: results from the Scottish Screen-detected Polyp Cancer 
Study (SSPoCS). Gut. 2018;67(2):299-306.
2. Lopez A, Bouvier AM, Jooste V, Cottet V, Romain G, Faivre J, et al. Out-
comes following polypectomy for malignant colorectal polyps are similar 
to those following surgery in the general population. Gut. 2019;68(1):111-7.
disclosure: Nothing to disclose 
P0495 aBsence Of neO1 PredIcTs a POOr PrOgnOsIs and 
PrOMOTes TuMOr PrOgressIOn In cOLOrecTaL cancer
Zhang M., Zhou Z., Zhou Y., Li H., Liu L., Liu J., Zhao Q.
Zhongnan Hospital of Wuhan University, Gastroenterology, Wuhan, China
contact e-Mail address: zhangmeng81@whu.edu.cn
Introduction: Colorectal cancer (CRC) is one of the most common malig-
nancies worldwide, and its morbidity is increasing sharply in the young 
population. CRC progression and prognosis are associated with oncogene 
activation and tumor suppressor gene inactivation. Recently, many bioin-
formatics methods provided the platform to screen biomarkers with prog-
nostic and treatment implications of CRC. As a homologue of the Deleted 
in Colorectal Cancer (DCC) gene, NEO1 has been reported to be downregu-
lated in CRC and other several cancer types, but the specific role of NEO1 in 
CRC needs further exploration. The present study aimed to validate NEO1 
expression in CRC and explore the role and potential mechanism of NEO1.
aims & Methods: Firstly, several bioinformatics methods were utilized to 
examine NEO1 expression in CRC. Quantitative real-time PCR was further 
performed to validate NEO1 expression in CRC tissues. Next, ROC curve 
analysis and Survival analysis were used to test the relationship between 
NEO1 and prognosis of CRC. Subsequently, the effects of NEO1 were evalu-
ated through colony formation, cell proliferation, migration and invasion 
assays by transfection NEO1 plasmids or siRNAs. Finally, we took advan-
tage of Gene Ontology (GO) analysis and Gene Set Enrichment Analysis 
(GSEA) to explore potential function and mechanism of NEO1 in CRC.
results: In our study, results showed that NEO1 was downregulated in 
online CRC datasets, GSE41258 dataset and CRC tissues. Its low expres-
sion was associated with shortened survival of CRC patients. Moreover, 
overexpression of NEO1 promoted CRC cell proliferation, migration and 
invasion while silencing NEO1 inhibited CRC cell proliferation, migration 
and invasion. Finally, GO analysis revealed that NEO1 was associated with 
iron transport and response to wounding. GSEA indicated that NEO1 lower 
expressed samples were enriched in DNA repair.
conclusion: In conclusion, a tumor suppressor gene NEO1 was identified 
and demonstrated to be associated with the progression and prognosis of 
CRC, which might be a potential therapeutic target and prognostic bio-
marker for CRC patients.
disclosure: Nothing to disclose 
P0496 endOscOPIc InTerMuscuLar dIssecTIOn (eId) Of The 
M. PrOPrIa fOr deeP suBMucOsaL InvasIve cancer In The 
recTuM
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Lacle M.M.8, Didden P.1, Dutch T1 CRC Working Group
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5Ziekenhuis Gelderse Vallei, Mdl, Ede, Netherlands, 6Jeroen Bosch Hospital, 
‘s-Hertogenbosch, Netherlands, 7University Medical Center Utrecht, Surgery, 
Utrecht, Netherlands, 8University Medical Center Utrecht, Pathology, Utrecht, 
Netherlands, 9Zorg Groep Twente, Gastroenterology and Hepatology, 
Almelo, Netherlands, 10Elisabeth TweeSteden Hospital, Gastroenterology 
and Hepatology, Tilburg, Netherlands, 11Bernhoven, Gastroenterology and 
Hepatology, Uden, Netherlands
contact e-Mail address: l.m.g.moons@umcutrecht.nl
Introduction: Endoscopic submucosal dissection (ESD) offers a minimally 
invasive en-bloc resection technique for rectal lesions with superficial sub-
mucosal invasion (T1 CRCs). However, as ESD dissects through the submu-
cosa, it is often impossible to obtain a radical deep resection margin when 
deeper invasion in the submucosa (Sm2-3) is present. There is accumulat-
ing evidence that deep submucosal invasion is not an independent pre-
dictor of lymph node metastasis. Therefore, there is need for endoscopic 
techniques for resection of deep submucosal invasive T1 CRCs. Instead of 
dissecting through the submucosa, dissection between the circular and 
the longitudinal layers of the m. propria (intermuscular dissection), could 
provide the necessary radical deep margin, but without compromising the 
mesorectal fat plane allowing future completion surgery.
aims & Methods: In this prospective cohort, 15 rectal tumors with optical 
features of deeper invasion in the submucosa were treated with an in-
termuscular dissection (EID). Brief description of the technique: Standard 
submucosal dissection was performed until non-lifting developed. The in-
termuscular space was then lifted, followed by careful selective circumfer-
ential myotomy of the circular muscle layer, until the longitudinal muscle 
fibres were visualized. Then the intermuscular space was dissected. The 
EID area was not routinely clipped. Prophylactic antibiotics were admin-
istered intravenously. Patient-, polyp, procedural, and histological charac-
teristics were recorded. Primary endpoints were feasibility of performing 
EID, ability to obtain an R0 resection, and complication rate. Technical 
success was defined as achieving an en bloc resection. R0 resection was 
defined as free deep and lateral resection margins confirmed by histology.
results: Between December 2018 and April 2019, 15 patients (73% male, 
mean age 67 yrs, SD ± 11 yrs) with a lesion with suspicion of deeper sub-
mucosal invasion in the rectum were treated with EID (mean size 28 mm 
(range 16 to 50 mm)). The Paris classification was 0-Is in 66%, and 0-IIa 
in 33%. Surface morphology was non-granular in 80%, and a depression 
was present in 79%. Optical diagnosis with NBI showed a Hiroshima C1 
pattern in 1 (7%), C2 in 2 (13%) and C3 in 12 (80%) cases. Technical success 
was achieved in 13/15 (87%) of cases. In the 2 failed cases, it was impos-
sible to discriminate and lift the intermuscular space. An R0 resection was 
achieved in 11/13 (85%) technically successful cases. In 2 cases, a small 
area of fat was visualized which was closed with 2 hemoclips.Two cases 
had a positive deep resection margin. All these lesions were carcinomas 
microscopically. The depth of submucosal invasion was Sm1 in 1 (7%), Sm2 
in 3 (23%), Sm3 in 8 (61%), and T2 in 1 (7%) cases. Lymphovascular inva-
sion was observed in 7/13 (54%) cases, high-grade (Bd2-3) tumor budding 
in 4/12 (25%), and poor differentiation in 1/13 (7). One patient developed 
fever postoperatively without need for intervention. No other complica-
tions were observed. In total 6/13 (46%) cases had no histological risk 
factor other than deep invasion. A wait and see follow-up strategy was ap-
plied in 7/13 (54%) technically successful cases. No residual carcinoma was 
detected at the scar in the surgical specimen, and lymph node metastasis 
was detected in 1 case.
conclusion: Endoscopic intermuscular dissection (EID) seems a promising 
and safe new technique to remove deep submucosal invasive T1 carci-
nomas in the rectum, with a technical success rate of 87% and an R0-
resection rate of 85%.
disclosure: Consultant for Boston Scientific 
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conclusion: Perineal wound complications cause significant morbidity in-
creasing inpatient stay, IGAP flaps have fewer post-operative complica-
tions in our series. Strategies to optimise perineal wound care are needed.
disclosure: Nothing to disclose 
P0499 TaILOrIng Lynch syndrOMe surveILLance
Marques de Sá I., Castro R., Pita I., Dinis-Ribeiro M., Brandão C.
Portuguese Institute of Oncology, Gastroenterology, Porto, Portugal
contact e-Mail address: inesmarquesdesa@gmail.com
Introduction: Lynch syndrome (LS) is associated with increased risk of 
colorectal cancer (CRC) as well as extracolonic cancer. Identification and 
follow-up of individuals with LS is extremely important because they can 
benefit from surveillance programmes by reducing cancer-risk. There is an 
increased awareness that cancer risk varies with specific mismatch repair 
mutation. However, gene-specific surveillance as well as family-specific 
surveillance have not been systematically studied.
aims & Methods: Our aim was to assess the surveillance programme and 
tailoring strategies in a terciary centre. We conducted a retrospective co-
hort of all patients (n=241) under surveillance programme in our centre 
since their admission or treatment of the index cancer (median time of 
4 years). The main outcomes were cancer-related death and risk for new 
lesions.
results: Forty-eight percent had MSH2 mutation, 32% MLH1, 15% MSH6 
and 5% PMS2. 95% had family history of CRC, 37% of endometrial cancer, 
32% of gastric cancer and 12% of urinary tract cancer. From the 68 (28%) 
patients with CRC at admission, 4% developed metachronous cancer and 
3% died of CRC. Left-colectomy was related to higher risk of metachro-
nous lesions than right-colectomy (RR=12, p< 0,006). From the 173 pa-
tients without CRC on admission, 26% developed low-risk lesions, 23% 
high-risk lesions and 5% CRC. From the 237 patients without gastric cancer 
on admission, 3% developed dysplasia or adenocarcinoma. From the 108 
patients without endometrial cancer on admission, 7% developed endo-
metrial cancer and 53% underwent prophylactic hysterectomy (10% with 
atypia and 5% with cancer on the surgical specimen). The risk of endo-
metrial cancer was higher when family history was present (RR=2,38 p< 
0,007). From the 237 patients without urinary tract cancer on admission, 
7 develop this cancer (4 were asymptomatic and diagnosed by imaging). 
The risk of urinary tract cancer was higher with MSH2 mutation (RR=8, 
p< 0,001) or when family history was present (RR=11, p< 0,004). 3% of 
patients on follow-up died of extracolonic cancer (median time of 7 years).
conclusion: This cohort demonstrates the effectiveness of SL surveillance 
programme and suggests the possibility of tailoring strategies by gene and 
family history.
disclosure: Nothing to disclose 
P0500 PrevaLence Of OPIOId TheraPy In PaTIenTs WITh 
funcTIOnaL gasTrOInTesTInaL dIsOrders revIeWed aT a 
TerTIary cenTre
Mari A.1,2, Pesce M.3, Patel K.4, Legidis F.3, Emmanuel A.5, Zarate-Lopez N.6
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Introduction: The appropriateness of chronic opioid use in patients with 
non-cancer pain is increasingly challenged due to limited evidence of its 
efficacy and the risk of problematic use and dependence. The side effects 
of opioids on gut function suggest this therapy should be particularly 
avoided in patients with functional gastrointestinal (GI) disorders. Data 
on the prevalence of opioid use in patients with functional GI disorders is 
unknown. We aimed to evaluate the prevalence of opioid use in functional 
GI patients referred to a tertiary Neurogastroenterology clinic and to de-
termine the risk factors for their initiation.
aims & Methods: 100 consecutive outpatients (85 females, 37±15 years) 
with functional GI disorders referred for a specialist opinion at our tertiary 
referral centre were retrospectively reviewed. Two independent research-
P0497 LyMPhOvascuLar InfILTraTIOn Is a hIgh rIsk facTOr 
fOr LyMPh nOde MeTasTasIs IndePendenT Of dePTh Of 
InvasIOn In T1 cOLOrecTaL cancers
Thorlacius H.1, Rönnov C.-F.1, Arthursson V.1, Toth E.2, Krarup P.-M.3, 
Syk I.1
1Skåne University Hospital, Lund University, Surgery, Malmö, Sweden, 2Skåne 
University Hospital, Lund University, Gastroenterlogy, Malmö, Sweden, 
3Zealand University Hospital, Surgery, Roskilde, Denmark
contact e-Mail address: henrik.thorlacius@med.lu.se
Introduction: Depth of submucosal invasion is commonly used to predict 
risk for lymph node metastasis in T1 colorectal cancers although published 
data are conflicting on the risk of metastasis in relation to level of submu-
cosal growth.
aims & Methods: The aim of this study was to identify risk factors for 
lymph node metastasis in T1 colorectal cancers. Data on all patients with T1 
colorectal cancer undergoing surgical resection between 2009-2017 were 
collected from the Swedish Colorectal Cancer Registry. Potential risk fac-
tors for lymph node metastasis, including age, gender, tumour location, 
submucosal invasion (Sm1-3), grade of differentiation, lymphovascular in-
vasion, perineural invasion, tumour deposits and mucinous subtype were 
recorded. Patients lacking one of these factors were not included.
results: 991 patients (51% male) were included with median age of 72 
years. 110 patients (11%) had lymph node metastasis in the surgical speci-
mens. The overall incidence of lymph node metastasis was 8% (26/314) 
in Sm1, 12% (28/231) in Sm2 and 13% (56/446) in Sm3. In the absence of 
lymphovascular infiltration, the rate of lymph node metastasis was 6% in 
Sm1, 9% in Sm2 and 13% in Sm3. 
Notably, the incidence of lymph node metastasis markedly increased to 
40% (37/92) in cases with lymphovascular infiltration regardless of Sm 
classification. Presence of tumor deposits (14 cases) and perineural inva-
sion (15 cases) also increased the rate of metastasis but the numbers of 
these cases were too few for solid conclusions. Grade of differentiation 
and mucinous subtype had only a minor impact on the incidence of lymph 
node metastasis (16%).
conclusion: Thisis the largest study in the literature examining risk factors 
for lymph node metastasis in T1 colorectal cancers. Our results show that 
depth of submucosal invasion has limited influence and that lymphovas-
cular infiltration is the most important risk predictor for lymph node me-
tastasis in T1 colorectal cancers.
disclosure: Nothing to disclose 
P0498 PerIneaL fLaP recOnsTrucTIOn fOLLOWIng PeLvIc 
exenTeraTIOn
Gould L., Pring E., Fletcher J., Hadjikyriacou E., Antoniou A., 
Constantinides J., Jenkins J.T.
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contact e-Mail address: laura.e.gould@gmail.com
Introduction: Perineal wound complications following pelvic exenteration 
(PE) are a significant cause of morbidity. We assessed our long-term expe-
rience of using perineal flap reconstruction for patients undergoing PE at 
a tertiary referral unit.
aims & Methods: Retrospective review of all PE procedures from 2009-
2018 was performed. Demographics, neoadjuvant/adjuvant or historical 
chemoradiotherapy, perineal wound closure, flap type, inpatient stay and 
post-operative complications were recorded.
results: 209 PEs were performed, 120 (57%) patients had reconstruction 
with a perineal flap. 87% of these were for locally advanced or recurrent 
rectal cancer. 88% had prior pelvic radiotherapy. 75% of defects were 
closed using an inferior (IGAP) or superior (SGAP) gluteal artery perfora-
tor flap. Other flaps used were gracillis, vertical rectus abdominis and 
anterolateral thigh. 58% suffered wound complications, 14% were classi-
fied as a major complication (return to theatre within 90 days or readmis-
sion with a wound complication). Superficial dehiscence requiring vac-
uum dressing was the commonest complication (34%). Perineal wound 
complications increased median length of stay from 22 to 34 days (p= 
0.001). No significant association between BMI, neoadjuvant treatment, 
complexity of resection, post-operative nutrition and wound complica-
tions was observed. IGAP flap was associated with fewest complications 
OR 0.40 (0.18-0.87).
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ers (AM and FL) carried out a detailed chart evaluation of the presence and 
type of comorbidities and concomitant pharmacotherapy. Patients were 
also specifically asked about opioid use, the duration of therapy and the 
clinical indication for starting the opioids.
results: Twenty-one patients (20F, 38±12 years) were taking chronic opi-
oid therapy. The main reason for opioid initiation was chronic muscu-
loskeletal pain (12 patients, 57%), chronic abdominal pain (5 patients, 
24%) and chronic pelvic pain (1, 5%). The mean duration of the opioid 
treatment was 2.7±1 years. The risk factors associated with opioids use are 
depicted in table 1. In terms of management, patients under opioid were 
offered naloxegol (20%), psychology-based interventions (29%), and re-
ferral to pain specialists to rationalize opioid use (38%). The majority of 
the patients in the opioid group (80%) were referred for tertiary opinion 
from other areas of the UK, as compared to the 60% of patients without 
chronic opioid use.
conclusion: Female patients with chronic functional GI disorders with as-
sociated extra-intestinal functional pain syndromes and psychological co-
morbidity are prescribed opioid therapy more frequently. These patients 
are at increased risk of developing eating difficulties requiring advanced 
nutritional support, which is known to be more complicated in opioid us-
ers. Access to multidisciplinary coordinated therapy including pain man-
agement and psychological therapy is required early in these patients to 
avoid these adverse outcomes.
disclosure: Nothing to disclose 
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BreaTh TesTIng
Wilder-Smith C.H.1, Mohr Drewes A.2, Materna A.1, Olesen S.S.2
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Introduction: Patients with gastrointestinal (GI) symptoms but devoid of 
recognizable pathology are classified into various functional gastrointes-
tinal disorders (FGID) according to their GI symptoms. Sugar breath tests 
are used in patients with FGID to elucidate possible mechanisms, such 
as malabsorption and hypersensitivity. Due to the heterogenous nature of 
FGIDs, underlying mechanisms and the reactions during breath tests are 
likely to be divergent. 
Furthermore, the presence of prominent extra-GI symptoms may indicate 
a different pathogenesis than when GI symptoms related to intestinal fer-
mentation preponderate.
aims & Methods: The aim of this large study was to examine the symptom 
and gas responses during sugar breath tests in patients with FGID grouped 
according to their long-term GI and extra-GI symptoms by cluster analysis. 
Successive male and female patients over 18 years of age referred to our GI 
practice in the past 10 years for investigation of FGID and without evidence 
of organic disease were included in this study. Patients completed a stan-
dardized questionnaire rating their long-term GI and extra-GI symptoms. 
These data were subjected to latent class analysis to identify unobserved 
clustering in the patient population. Patients also performed standardised 
fructose and lactose breath tests (35g and 50g, respectively), and GI and 
extra-GI symptoms as well as H
2
 and CH
4
 breath concentrations were docu-
mented hourly for 5h during the breath test. The areas-under-the-curve 
(AUC) of aggregate GI and central nervous system (CNS) symptoms and of 
the breath gas concentrations were compared between the patient clus-
ters.
results: In total 2083 FGID patients (mean age 39.7 years, 70% females) 
were enrolled in the study and subjected to cluster analysis. The optimal 
number of clusters defined was 6, with good face validity. GI fermentation-
type symptoms were present across all 6 clusters and exclusively charac-
terized Cluster 1 (35% of patients). The further clusters were distinguished 
by additional reflux-like (cluster 2: 19%), allergy-like (cluster 3: 6%), cen-
tral nervous system (cluster 4: 17%), musculoskeletal (cluster 5: 10%), and 
generalized extra-GI (cluster 6: 14%) symptoms. Complete fructose and 
lactose breath tests were available in 1422 patients. The areas-under-the-
curve (AUCs) of hydrogen and methane breath concentrations were not 
significantly different across all the 6 clusters following fructose and lac-
tose (all p>0.05). 
However, the AUCs of both GI and CNS aggregate symptoms scores dif-
fered significantly across the 6 clusters during fructose and lactose breath 
tests (all p< 0.001). Maximum aggregate symptom scores were consistently 
greater in the clusters with most extra-GI symptoms.
conclusion: The chronic symptom clusters of patients with FGID, distin-
guished mainly by extra-GI symptoms, did not differ in their breath gas 
concentrations following fructose or lactose ingestion. The distinct symp-
tom patterns are consequently not explained by differences in the gaseous 
markers of malabsorption. The clusters were, however, distinguished by 
differences in the GI and CNS symptoms provoked following both sugars. 
Clearly, patients with a greater number of chronic extra-GI symptoms also 
show significantly more GI and CNS symptoms after fructose or lactose 
ingestion than those with mainly chronic GI symptoms. These results sug-
gest malabsorption does not explain the different phenotypical presenta-
tions of FGID. We hypothesize that hypersensitivity to the sugars or their 
metabolites underlies the differing symptoms, especially the multiorgan, 
extra-GI symptoms, in FGID.
disclosure: Nothing to disclose 
P0502 syMPTOMs assOcIaTed WITh MasT ceLL acTIvaTIOn 
syndrOMe are cOMMOn In PaTIenTs WITh funcTIOnaL 
gasTrOInTesTInaL dIsOrders
Wilder-Smith C.H.1, Mohr Drewes A.2, Materna A.1, Olesen S.S.2
1Brain-Gut Research Group, Gastroenterology Group Practice, Bern, 
Switzerland, 2Aalborg University Hospital, Dept. of Gastroenterology and 
Hepatology, Aalborg, Denmark
contact e-Mail address: info@ggp.ch
Introduction: Patients with functional gastrointestinal disorders (FGID) 
often have a wide range of gastrointestinal (GI) and extra-GI symptoms. 
Extra-GI symptoms are not included in the diagnostic criteria for FGID and 
are often attributed to separate functional or somatization syndromes. The 
mast cell activation syndrome (MCAS) encompasses a variety of disorders 
with either increased numbers or activation of mast cells leading to a wide 
range of both GI and extra-GI symptoms. Idiopathic MCAS is currently de-
fined by typical symptoms and the response to medications targeting mast 
cell activation, as there are no specific biochemical markers. The appar-
ent overlap in symptoms associated with MCAS and FGID, the increases 
in mast cell numbers and/or activation in FGID, and the abnormalities in 
histamine pathways shown in irritable bowel syndrome (IBS) suggest a 
potential functional association.
aims & Methods: The aim of this large single-centre study was to investi-
gate the overlap in GI and extra-GI symptoms most frequently associated 
with MCAS with the symptoms seen in patients with FGID. 
Successive male and female patients over 18 years of age referred to our GI 
practice for investigation of FGID and without evidence of organic disease 
were included. Patients completed a standardized, extensive GI and extra-
GI symptom questionnaire and FGID was classified as IBS and functional 
dyspepsia (FD) according to the Rome III criteria. The prevalence of at least 
7 of the symptoms most commonly used to define MCAS (abdominal pain, 
bloating, diarrhoea, nausea, gastro-oesophageal reflux, excessive tired-
ness, problems concentrating, headache, anxiety/depression states, skin 
rash, urticaria/pruritus, chronic sinusitis/rhinitis, irregular heartbeat, joint 
pain, myalgias) was determined for the overall patient cohort and for the 
Rome III subgroups.
results: We included 2083 patients with FGID in the study (mean age 39.7 
years, 70% females). IBS was diagnosed in 672 (32%), FD in 1839 (88%) 
and overlapping IBS and FD in 625 (30%) of patients. More than 7 of the 
defining symptoms of MCAS were reported in 748 (36%) of all 2083 pa-
tients, and in 281 (42%) of IBS patients, in 702 (38%) of FD patients and in 
266 (43%) of patients with overlapping IBS and FD. Of the 748 patients with 
more than 7 symptoms of MCAS, 281 (38%) had IBS, 702 (94%) had FD and 
266 (36%) had overlapping IBS and FD.
conclusion: Symptoms associated with mast cell activation syndrome are 
common in patients with functional gastrointestinal disorders. Conversely, 
functional gastrointestinal disorders are common in patients with symp-
toms of MCAS. Mast cells and associated biogenic amines, such as hista-
mine and serotonin, have been shown to be involved in the pathogenesis 
of both syndromes. The significance of the relationship between MCAS and 
FGID needs to be investigated further, as a better understanding of this 
overlap may open new treatment possibilities in FGID.
disclosure: Nothing to disclose 
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aims & Methods: aim. To evaluate prevalence of food and non-food al-
lergies in Fgid patients with and without extra-digestive manifestations.
Materials and Methods. In a single center setting, we prospectively inves-
tigated clinical features and allergies in outpatients referred for digestive 
symptoms. Each patient answered validated questionnaires on digestive 
and extra-digestive symptoms and underwent both serum and cutane-
ous allergological tests: IgE and skin prick testing to food and inhalant 
allergens; patch testing (SIDAPA 40 aptens). FGIDs were diagnosed ac-
cording the Rome III criteria. Extra-digestive syndromes included gen-
eral (tiredness, foggy mind, joint or muscle pain), neurologic (restless leg 
syndrome, migraine/headaches, dizziness, epilepsy, sensory symptoms), 
psychological (anxiety/panic disorders, depression, sleeping disorders, 
eating disorders), rheumatologic and immunologic (psoriasis, Raynaud’s, 
fibromyalgia, Sjogren, multiple sclerosis), urogenital (cystitis, vaginitis, 
prostatitis, vestibulitis, dyspareunia, dysmenorrhea, infertility), cutaneous 
(acne, alopecia) and other manifestations (tachyarrhythmias, presyncope, 
discopathies, endometriosis, multiple chemical sensitivity). The study was 
approved by the S. Orsola University Hospital Ethic Committee.
results: Between 2011 and 2014, 80 patients with organic diseases 
(F=51.3%, age 48.7±16.7 yrs, m±SD) and 970 FGID patients were enrolled 
(F=75.1%; 42.8±14.6 yrs). 827 FGID patients (85.3%; F=78.1%; 43.2±14.5 
yrs) complained of ≥1 extra-digestive disorders (ExtraD-FGIDs) vs 53 or-
ganic patients (71.6%; F=78.1%; 49.2±17.1 yrs; p=0.004). 718 FGID patients 
(74.0%; F=76.7%; 41.8±14.3 yrs) vs 42 patients with organic diseases 
(52.5%; F=52.4%; 43.7±14.9 yrs; p=0.001) had ≥1 positive allergic tests. 622 
patients (75.2%) with and 96 (67.1%) without extraD-FGIDs had ≥1 positive 
allergic tests (p=0.049). The difference was driven by a higher prevalence 
of chemical allergies (40.1% vs 28.5%; p=0.014), while no significant dif-
ference was found for food or inhalant allergies. Specifically, a significant 
higher frequency of chemical allergies was detected in patients with than 
in those without urogenital (47.2 % vs 33.2%, p=0.001), cutaneous (58.1% 
vs 37.7%, p=0.025), neurological (43.9% vs 36.1%, p=0.019), and psycho-
logical manifestations (41.4% vs 33.6%, p=0.013).
conclusion: Extra-digestive disorders are frequent in allergic patients with 
FGIDs. Non-food and specifically chemical allergies are significantly asso-
ciated to urogenital, cutaneous, neurological and psychological disorders 
in patients with FGIDs.
disclosure: Nothing to disclose 
P0505 are dIgesTIve syMPTOMs frequenT In PaTIenTs WITh 
chrOnIc adrenaL InsuffIcIency?
Quénéhervé L.1,2, Coron E.1,2, Drui D.3, Blin J.3, Masson D.2, Bach K.2
1University Hospital of Nantes, Digestive Disease Institute, Nantes, France, 
2Nantes University, Inserm U 1235 TENS, Nantes, France, 3University Hospital 
of Nantes, Endocrinology, Nantes, France
contact e-Mail address: lucille.queneherve@gmail.com
Introduction: Acute adrenal insufficiency is frequently associated with di-
gestive symptoms such as vomiting, diarrhea and abdominal pain. Howev-
er their prevalence in patients having a chronic adrenal insufficiency (CAI) 
is unknown. The hypothalamic-pituitary-adrenal axis plays also a role in 
the pathophysiology of irritable bowel syndrome (IBS).
aims & Methods: The aim of this study was to characterize and to quantify 
digestive symptoms in CAI patients using Rome IV questionnaire.
An online questionnaire was published on the website of a CAI patients 
association from June to October 2017. Information about demographics, 
adrenal insufficiency (age at diagnosis, etiology, type of medication) and 
quality of life was collected. Patients also answered to a French version of 
the Rome IV questionnaire and the Bristol scale.
results: We analyzed responses from 165 patients (Addison’s disease (AD) 
(n=74), congenital adrenal hyperplasia (CAH) (n=56), impairment of the 
hypothalamic-pituitary-adrenal axis (IHA) (n=35). Abdominal pain at least 
once a week during the 3 last months was reported by 38%, 31% and 54% 
of patients with AD, CAH and IHA respectively. Symptoms were consistent 
with the IBS criteria in 24%, 31% and 31% of patients with AD, CAH and 
IHA respectively.
Patients described their quality of life as bad in 34%, 21% and 54% of 
patients with AD, CAH and IHA respectively.
conclusion: Our study is the first to our knowledge to consider digestive 
symptoms in CAI beside acute adrenal insufficiency. Digestive symptoms 
are frequent and invalidating in CAI patients and are close to those of IBS 
patients in 50% of CAI patients.
disclosure: Nothing to disclose 
P0503 hIsTOMOrPhOLOgIcaL and MOLecuLar 
characTerIzaTIOn Of ParkInsOn’s dIsease PaTIenTs WITh 
chrOnIc cOnsTIPaTIOn: a PILOT sTudy
Bellini M.1, Fani B.1, Bertani L.1, Bellini G.2, Pancetti A.1, Fornai M.3, 
Ippolito C.4, Frosini D.2, Pellegrini C.3, Gambaccini D.1, Bernardini N.4, 
Ceravolo R.2, Marchi S.1, Blandizzi C.3
1University of Pisa, Translational Research and New Technologies 
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Introduction: Parkinson’s disease (PD) patients can report gastrointestinal 
symptoms even years before the onset of neurological symptoms. It has 
been suggested that the digestive pathways could be used by a pathogen 
to access the target neuronal populations inducing PD.
aims & Methods: The aim of this pilot study was to evaluate constipated 
PD patients for: 1) possible changes of inflammatory markers in blood and 
stool; 2) alterations of colonic mucosal factors involved in the maintenance 
of the intestinal barrier; 3) possible correlations of these parameters with 
the severity of motor and non-motor symptoms and impairment of quality 
of life.
Ten constipated PD patients and 10 constipated, sex and age matched, 
patients (Rome IV) were enrolled. All patients were requested to fill gas-
troenterological (Bristol Stool Chart, PAC-SYM, PAC-QoL, ODS score) and 
neurological (UPDSRS, PDQ-39, MMT, HAMD-17, SCOPA-AUT, NMSS) ques-
tionnaires. Blood (CBC, TSH, CRP, TNF, IL-1β, LBP) and stool (Hp antigen, 
fecal calprotectin, IL-1β, TNF) tests were carried out. All subjects under-
went a colonoscopy with biopsies (sigma and descending colon). Colonic 
samples were processed for morphological evaluations (haematoxylin/
eosin, sirius red/fast green, toluidine blue, confocal immunofluorescence) 
to evaluate respectively: eosinophilic density (inflammatory index) and 
collagen deposition (marker of remodelling due to chronic inflammation) 
in the lamina propria; acid mucin (changes in mucus producing cells) and 
claudin-1 (component of tight junctions) in intestinal epithelial barrier.
results: The onset of constipation anticipated that of PD onset in 7/10 
patients. Faecal IL-1β levels were higher in PD patients as compared to 
controls (18.2±9.7 pg/g vs 9.3±3.7 pg/g; p< 0.05). Faecal TNF and serum 
LBP levels were higher in PD, without reaching statistical significance 
(66.2±47.5 vs 56.3±34.6 pg/g and 33.6±14.8 vs 23.9±5.6 ng/ml, respective-
ly). Eosinophilic density was higher in controls than PD patients (56±16 vs 
13±4 / mm2; p< 0.05). Collagen levels and acid mucin were higher in PD 
patients (18.6±2.5 vs 13.1±1.3 PPP; p< 0.05, and 14.7±1.6 vs 10.3±1.5 PPP; p< 
0.05). Claudin-1 expression decreased along the epithelial surfaces in PD 
patients. A lack of correlation was found between these findings and the 
severity of digestive and neurological symptoms.
conclusion: PD constipated patients display higher levels of intestinal in-
flammation and tissue remodeling, as well as a higher degree of enteric 
barrier impairment than constipated patients without PD. These findings 
confirm an intestinal involvement in PD, and open the way for future 
pathophysiological studies.
disclosure: Nothing to disclose 
P0504 aLLergIes and exTra-dIgesTIve ManIfesTaTIOns In 
funcTIOnaL gasTrOInTesTInaL dIsOrders
Stanghellini V.1, Cogliandro R.1, Morselli Labate A.M.2, Del Vecchio S.1, 
Birtolo C.2, Bellacosa L.1, Cremon C.1, Barbara G.1
1University of Bologna Policlinico S.Orsola-Malpighi Internal Med. & 
Gastroenterology - Department of, Department of Digestive System, Bologna, 
Italy, 2University of Bologna, Bologna, Italy
contact e-Mail address: v.stanghellini@unibo.it
Introduction: Extra-digestive manifestations are frequently reported by 
patients with functional gastrointestinal disorders (FGIDs). Gut neuroin-
flammation and gut-brain axis are putative shared mechanisms. Gut bar-
rier damages associated with mast cells and/or eosinophils infiltration are 
common features of FGIDs, suggestive of a possible pathogenetic role of 
allergic reactions. An association between allergies and extra-digestive 
disorders in FGIDs has never been elucidated.
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P0506 eLevaTed exPressIOn Of urOkInase-TyPe 
PLasMInOgen acTIvaTOr Marks sTress-Induced vIsceraL 
hyPersensITIvITy In raTs
van Thiel I.A.M.1, Li Yim A.Y.F.2,3, van Hamersveld P.H.P.1, Welting O.1, 
Koomen M.P.M.1, Henneman P.2, de Jonge W.J.1, van den Wijngaard R.M.1
1Amsterdam University Medical Centers, Location AMC, Tytgat Institute 
for Liver and Intestinal Research, Amsterdam, Netherlands, 2Amsterdam 
University Medical Centers, Location AMC, Department of Clinical Genetics, 
Amsterdam, Netherlands, 3GlaxoSmithKline, Epigenetics Discovery 
Performance Unit, Stevenage, United Kingdom
contact e-Mail address: i.a.vanthiel@amc.uva.nl
Introduction: Visceral hypersensitivity, i.e. the increased response towards 
colonic stimuli, contributes to abdominal pain complaints observed in ir-
ritable bowel syndrome (IBS). In this study, we aimed to identify targets 
for stress-induced visceral hypersensitivity. To this end, we analyzed the 
transcriptome through RNA sequencing (RNAseq) of descending colon 
samples obtained from our rat model after which we confirmed our find-
ings in a separate cohort of rats, as well as in patient biopsies.
aims & Methods: In this study, we aimed to identify genes involved in the 
development of post-stress visceral hypersensitivity in rats. In the discov-
ery cohort, adult maternally-separated (MS) rats and non-handled (NH) 
rats were exposed to acute water avoidance (WA)-stress for one hour or 
left undisturbed (4 groups, n=3). Rats were sacrificed 4 hours after WA 
after which RNA was isolated for subsequent sequencing at GenomeScan 
(Leiden, The Netherlands; NextSeq 500, 10M reads). Statistical significance 
of differentially expressed genes was defined as genes with a Benjamini-
Hochberg adjusted p-value of less than 0.05. 
Subsequent validation of the gene of interest was done using quantitative 
real-time polymerase chain reaction (qRT-PCR) on distal colon samples 
obtained from an independent rat cohort. In this experiment, NH and MS 
animals were sacrificed 21 days after WA (n=8-9)[1]. 
Qualitative PCR analyses of the same gene of interest was performed in hu-
man biopsies obtained from colon descendens of normosensitive healthy 
volunteers and hypersensitive IBS patients (n=10 per group)[2]. Addition-
ally, immunohistochemical staining on paraffin-embedded tissues was 
performed to investigate whether possible changes in gene expression 
manifested at protein level; uPA positive cells were counted manually and 
quantified as positive cells per mm2.
results: RNAseq analysis of the four groups did not reveal differentially 
expressed genes. However, comparing MS without WA vs. MS after WA, 
revealed 1 differentially expressed gene: Plau (effect size =1.256 log2 fold 
change; p
adj
=0.0011), which encodes for the protein urokinase-type Plas-
minogen Activator (uPA). qPCR analysis on the independent rat cohort 
confirmed an increased expression of Plau in colonic tissue after maternal 
separation plus WA (NH after WA vs. MS after WA; Mann-Whitney test; p< 
0.005). Further investigation of the ortholog PLAU in human colon descen-
dens revealed no statistically significant differential expression (Mann-
Whitney test; p=0.0575). Nonetheless, subsequent immunohistochemistry 
revealed a non-significant increase in the number of uPA-positive cells in 
hypersensitive IBS colon (t-test; p=0.49).
conclusion: In this exploratory analysis we observed elevated expression 
of Plau associated with stress-induced visceral hypersensitivity in rat. En-
hanced expression of this gene transcript was confirmed in an indepen-
dent rat cohort that underwent MS and WA stress. However, we could not 
confirm these findings in hypersensitive IBS patients on neither mRNA nor 
protein expression. Based on literature, uPA may activate protease acti-
vated receptor-1 (PAR-1)[3]. PAR-1 antagonism was found to successfully 
reduce activity of sensory neurons in vitro upon exposure to supernatants 
of colonic IBS biopsies[4, 5]. To address the translational relevance of these 
findings, additional research should be performed on uPA protein levels 
and activity in human colon.
references: 1. Botschuijver, S., et al., Intestinal Fungal Dysbiosis Is Associ-
ated With Visceral Hypersensitivity in Patients With Irritable Bowel Syn-
drome and Rats. Gastroenterology, 2017. 153(4): p. 1026-1039. 2. Braak, B., 
et al., Mucosal immune cell numbers and visceral sensitivity in patients 
with irritable bowel syndrome: is there any relationship? Am J Gastroenter-
ol, 2012. 107(5): p. 715-26. 3. Kanno, Y., et al., uPA Attenuated LPS-induced 
Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca(2+)/
CaMKK/AMPK Axis. Int J Biol Sci, 2016. 12(1): p. 63-71. 4. Desormeaux, C., 
et al., Protease-activated receptor 1 is implicated in irritable bowel syn-
drome mediators-induced signaling to thoracic human sensory neurons. 
Pain, 2018. 159(7): p. 1257-1267. 5. Buhner, S., et al., Protease signaling 
through protease activated receptor 1 mediate nerve activation by mucosal 
supernatants from irritable bowel syndrome but not from ulcerative colitis 
patients. PLoS One, 2018. 13(3): p. e0193943.
disclosure: AFY Li Yim is an employee at GSK. 
P0507 PaTIenTs WITh IrrITaBLe BOWeL syndrOMe have LOW 
enzyMes acTIvITy Of The MeMBrane dIgesTIOn In The sMaLL 
InTesTIne
Dbar S.1, Parfenov A.1, Akhmadulina O.1, Sabelnikova E.2, Belostotsky N.1, 
Bykova S.1
1Moscow Clinical Scientific Center n.a. A. S. Loginov, Moscow, Russian 
Federation, 2Moscow Clinical Scientific Center n.a. A. S. Loginov, Science 
Department, Moscow, Russian Federation
contact e-Mail address: saradbar@yandex.ru
Introduction: The decrease in enzymes activity of the membrane digestion 
(EAMD) in the small intestine providing digestion of carbohydrates can 
cause clinical symptoms of irritable bowel syndrome (IBS).
aims & Methods: To estimate EAMD, namely glucoamylase (GA), maltase 
(M), sucrose (S) and lactase (L), in patients with IBS and the effect of their 
activity in long-term therapy with rebamipide. 102 patients with IBS, aged 
from 18 to 50 (41 men and 61 women) were examined. According to Rome 
IV criteria (2016), 68 patients had IBS with predominance of diarrhea, 20 
patients had IBS with predominant constipation and 14 patients showed 
mixed type of IBS. In all patients there was a more or less pronounced 
association of intestinal symptoms when consuming product containing 
milk (48.6%), potato starch (47.3%) and sugar (27.0%). The activity of GA, 
M, S and L were determined by Dahlquist-Trinder method in duodenal bi-
opsies obtained during esophagogastroduodenoscopy. The control group 
consisted of 20 healthy people aged 23-47. They showed following enzyme 
activity: L - 42 ±13 ng glucose/mg tissue x min, GA — 509 ±176, M — 1735 
±446, S - 136 ±35 ng glucose/mg tissue x min. These figures were taken 
as the norm.
results: 10,8% of the study group showed normal EAMD (11 out of 102 
patients), 32.3% had decreased activity of all studied enzymes and 58.8% 
had selective reduction of EAMD. Thirteen patients with reduced EAMD 
were recommended the FODMAP diet and ingest rebamipide 3 times a 
day x 200 mg for 3 months. Before the treatment the activity of GA of these 
patients averaged 83 ±78, M-417 ±221, S — 32 ±17, L-11 ±17 ng glucose/mg 
tissue x min. After the treatment 11 patients reported a decreased or no 
flatulence, abdominal pain, stool disorder; 2 people reported no change. 
The activity of GA increased to an average of 149 ±82 (by 78%, p = 0.016), M 
to 864 ±472 (by 131%, p = 0.0019), S - 63 ±35 (by 95%, p = 0.0041) and L — 
10 ±8 ng glucose/mg tissue x min.(the activity did not change significantly).
conclusion: In 89.2% of patients with IBS, there was a decrease of EAMD 
responsible hydrolysis of carbohydrates. The 3-month treatment with re-
bamipide helped reduce clinical symptoms and increase EAMD.
disclosure: Nothing to disclose 
P0508 effIcacy and safeTy Of saccharOMyces BOuLardII 
cncM I -745 In The TreaTMenT Of sMaLL InTesTInaL BacTerIaL 
OvergrOWTh In PaTIenTs sufferIng IrrITaBLe BOWeL 
syndrOMe WITh dIarrhea
Bustos Fernandez L.1, Man F.2, Dorribo C.1, Lasa J.S.1
1CMBF, Buenos Aires, Argentina, 2Gastro, Buenos Aires, Argentina
contact e-Mail address: luisbustosfernandez@gmail.com
Introduction: Irritable bowel syndrome (IBS) is a very common chronic 
gastrointestinal condition with abdominal pain, altered bowel habits and 
stool consistency. IBS-D is a sub-type with predominant diarrhea. Altered 
intestinal microbiota and the presence of small intestinal bacterial over-
growth (SIBO) have been documented in IBS. Saccharomyces boulardii 
CNCM I-745 (S boulardii) is a probiotic yeast with proven efficacy in antibi-
otic-associated diarrhea and acute gastroenteritis. However, there is scarce 
evidence regarding the impact of S boulardii on IBS-D patients.
aims & Methods: aim: To assess the efficacy and safety of S boulardii on 
SIBO-positive IBS-D patients.
Materials and methods: It was a randomized open label phase IV study on 
adult patients from two referral centers in Buenos Aires, Argentina with 
a diagnosis of IBS-D (Rome III criteria), with no systemic or severe diges-
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abundant in SIBO negative samples after Sb treatment. Five patients in 
each group reported at least one adverse event (AE). One patient reported 
1 serious AE (papillophlebitis) unrelated to the treatment.
conclusion: Sb CNCM I-745 reduced the bacterial overgrowth and im-
proved digestive symptoms in IBS-D patients. These effects were associ-
ated with intestinal microbiota modifications. The increased abundance 
of F. prausnitzii observed in S. boulardiipatients with symptom resolution 
merits further research.
disclosure: Dr. Luis Bustos Fernandez is member of the Latin America 
Board of Biocodex 
P0510 hOW addİng PrOBİOTİcs TO fOdMaP dİeT effecTs 
syMPTOMs Of IrrİTaBLe BOWeL syndrOMe: randOMİzed 
dOuBLe BLİnd PLaceBO-cOnTrOLLed sTudy
Bengi G.1, Turan B.2, Soytürk M.2, Cehreli R.2
1Dokuz Eylül Üniversity Tip Fak. Gastroenteroloji B.D Inciraltı, 
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Introduction: In the treatment of Irritable Bowel Syndrome (IBS), physi-
cian-patient relationship, diet and lifestyle changes should be considered 
in addition to medical treatment. Recent studies have shown that FODMAP 
(fermentable oligo- di- monosaccharides and polyols) restricted diet and 
probiotics may affect IBS symptoms.
aims & Methods: The aim of this study was to evaluate the combined ef-
fect of FODMAP-restricted diet and probiotic supplementary food products 
on IBS symptoms. In this study, out of all patients diagnosed with IBS 
according to Rome IV criteria, 51 of them are randomly placed in FODMAP 
+ probiotics group and the other 51 are randomly placed in FODMAP + 
placebo group. Before starting the study, all patients are asked to fill in 
questionnaires for Visual Pain Score, Bristol Stool Chart and IBSSS. Patients 
forwarded to a dietician to receive nutrition advice on low FODMAP diet. 
Low FODMAP diet applied as 9 gr/day. Patients, who are in low FODMAP 
diet + probiotics group, received food supplement containing 2 grams of 
probiotics once a day while the other group were receiving a placebo once 
a day in addition to their diet. Patients are assessed and scored via same 
tools in 1 month. A data analysis was made using abovementioned scales 
and scores about patients in FODMAP + probiotics group and FODMAP + 
placebo group before and after this program.
results: In both groups, placebo and probiotic fractures were significant-
ly improved in VAS and IBSS scores. The change in VAS score was 2.56 
(p=0.002) in the probiotic group and 2.77 (p=0.019 ) in the placebo group. 
When the IBS score was evaluated, the score of 307.46 in the probiotic 
group was 176.64; in the placebo group, it decreased from 310.26 to 183.87.
conclusion: A low FODMAP diet is a treatment option that has a positive 
effect on IBS symptoms. In our study, the low FODMAP diet showed sig-
nificant efficacy in correcting symptoms, but no additional contribution of 
probiotic was found.
disclosure: Nothing to disclose 
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Introduction: The low-FODMAP diet (LFD) in IBS patients is efficacious in 
the short term, however, its acceptability and long-term effects still need 
to be clarified. Moreover, it is not clear if what patients report during the 
clinical history about the “trigger” FODMAP foods is reliable.
aims & Methods: The aim of this ongoing study was to evaluate: 1) the 
efficacy and acceptability of a long-term FODMAP diet; 2) the patients’ reli-
tive signs nor intake of drugs known to alter microbiota. Patients were 
randomized to receive either S boulardii 250 mg b.i.d. plus dietary advice 
(Sb group) OR dietary advice only (Control group) for 15 days. SIBO was 
assessed by lactulose hydrogen breath test (LHBT). LHBT was done at in-
clusion (D0) and end of study (D15). Other criteria included IBS Symptom 
Severity Scale IBS-SSS (values 0 to 500), Bristol Stool Scale, Quality of Life 
(measured with the IBS-QoL questionnaire) and safety.
results: Fifty-four patients were included and treated, 6 were prematurely 
discontinued from the study and 48 (27 Sb, 21 Control) were included in 
the efficacy analysis. Mean age was 44-years old, BMI 25. At D15 the mean 
change from baseline of LHBT area under the curve (AUC) was greater in 
the Sb group (Table 1 part A). More patients in the Sb group had decreased 
LHBT AUC : 74% vs 57% (p=0.217). A post-hoc ANCOVA adjusted on base-
line AUC level showed that the inter-group difference of approximately 
1800 ppm was statistically significant (Table 1 part B & Fig2) and also that 
AUC at D0 had a strong impact on change under treatment. IBS-SSS de-
creased from 306 and 300 in the Sb and Control groups respectively to 180 
and 203 at D15. 
A trend to a higher proportion of patients with normal stool consistency 
was observed in Sb group (70.4% vs 47.6%, p=0.07). In each group, 5 
patients reported at least an adverse event (AE). One AE was serious (pap-
illophlebitis, Control) and another one (sinusitis, Sb) led to study discon-
tinuation, both unrelated to the treatment.
conclusion: This pilot study suggests that Sb in addition to dietary advice 
seems to positively affect SIBO in patients with IBS-D, although the differ-
ence between groups was statistically significant only in a post-hoc para-
metric analysis, without any safety issue. A confirmatory study is needed.
disclosure: Dr. Luis Bustos Fernandez is member of the Latin American 
Board of Biocodex 
P0509 IMPacT Of saccharOMyces BOuLardII cncM I-745 On 
MIcrOBIOTa & MycOBIOTa fOr The TreaTMenT Of BacTerIaL 
OvergrOWTh In IBs-d PaTIenTs
Lasa J.S.1, Man F.2, Dorribo C.1, Bustos Fernandez L.1
1CMBF, Buenos Aires, Argentina, 2Gastro, Buenos Aires, Argentina
contact e-Mail address: luisbustosfernandez@gmail.com
Introduction: Intestinal microbiota dysbiosis is thought to be associated 
with diarrhea-predominant Irritable Bowel Syndrome (IBS-D); therapeutic 
alternatives that could modify microbiota (e.g. diet, antibiotics and probi-
otics) have been proposed for the treatment of IBS-D. Probiotics such as S. 
boulardii CNCM I-745 (Sb) may be efficacious in IBS associated to dysbiosis 
or bacterial overgrowth.
aims & Methods: To compare the efficacy and safety of Sb plus dietary 
advice versus dietary advice only on small intestinal bacterial overgrowth 
(SIBO) in IBS-D patients and to describe their impact on intestinal micro-
biota composition and clinical improvement.
Adult patients from 2 referral centers in Buenos Aires with IBS-D (Rome III 
criteria) and SIBO were randomized (1:1) to receive either Sb plus dietary 
advice (Sb group) or dietary advice only (Control group) for 15 days. At the 
beginning and at the end of treatment, patients were asked to collect a 
fecal sample and underwent a lactulose breath test. Severity of symptoms 
was assessed with the IBS-SSS score and stool consistency was evaluated 
with the Bristol Stool Scale. Bacterial and fungal composition of fecal sam-
ples were analyzed based on 16S rDNA and ITS2 sequencing respectively. 
Additional qPCR analysis was performed to quantify the abundance of F. 
prausnitzii, M. smithii, B. thetaiotomicron and P. aeruginosa.
results: Fifty-four patients were included and 48 (27 Sb, 21 control) were 
evaluated for efficacy. Sb treatment led to a significant decrease of hy-
drogen excretion (difference between groups: -1800, IC95[-3595 ; -53], 
p=0.04). Microbiological analyses showed an adequate alpha and beta 
diversity, which enforced the good quality of samples. 
With regards to bacterial composition, c_Coriobacteriia (-67%), c_Delta-
proteobacteria (-77.6%) and g_Hungatella (-74.9%) were decreased. Inter-
estingly, F. prausnitziiwas more abundant in patients with marked clinical 
improvement with Sb: stool consistency normalization (+120%), negative 
SIBO with improved IBS-related symptoms (+400%), such as reduction of 
abdominal pain (+76.5%). 
Mycobiota analyses showed significant modifications in Saccharomyces 
and phylogenic related lineage (g_Saccharomyces (+27%), g_Debaryo-
myces (-88%)) and g_Filobasidium (>1000%) and upper related taxa. In 
addition g_Penicilium and upper related lineage were 100 times more 
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ability in detecting the real FODMAP foods able to provoke their symptoms.
Sixty-three IBS patients (Rome IV), consecutively recruited, started (T0) a 
LFD for 8 weeks (T1), and then followed a 8-12 week reintroduction period 
(T2). After that a personalized adapted LFD (aLFD) was issued to each pa-
tient. To assess long-term effects, patients were evaluated again at least 6 
months after T2 (T3). The following scales were used: IBS-SSS for assessing 
the severity of IBS symptoms, Likert scales to evaluate the degree of symp-
tom relief and the degree of satisfaction with the diet, and the FODMAP 
Adherence Report Scale (FARS) to evaluate dietary adherence. Patients’ 
opinions about FODMAP trigger foods at T0 were compared with data ob-
tained at the end of the reintroduction period. Dietary acceptability and 
food-related quality of life were evaluated using a 20-item questionnaire 
adapted from the nutrition-related QOL questionnaire.
results: At T3 (11.2±4.2 months) IBS-SSS improved compared to T0 
(218.9±105.8 vs 324.1±90.2; p< 0.002). Patients’ satisfaction with aLFD was 
7.5±2.4 on a 10-point Likert scale and degree of relief was 1.8±1.3 on a 
7-point Likert scale). Regarding dietary acceptability patients reported that 
they needed more time for cooking (P< 0.0001), it had higher costs (p< 
=0.00001) and they had problems eating out (P< 0.0001) during the LFD, 
but not during the aLFD. Adherence to the LFD was constantly high (T1: 
24.2 ± 0.9; T2: 24.2 ± 0.8; T3:24.0 ± 1.5 ns). Regarding patients’ perception 
of trigger foods, a moderate concordance was found only for lactose (k: 
0.54), a fair one for fructans, fructose and galactans (k: 0.38, 0.27 and 0.28, 
respectively) and a poor one for polyols (k: 0.12).
conclusion: IBS patients are satisfied with LFD because it improves symp-
toms. A LFD is well accepted and effective also in the long term. The pa-
tients’ perception regarding “trigger” foods reported during their clinical 
history is not reliable.
disclosure: Nothing to disclose 
P0512 fecaL TransPLanTaTIOn adMInIsTered vIa 
cOLOnOscOPy In IrrITaBILe BOWeL syndrOMe: resuLTs 
Of a randOMIzed PLaceBO-cOnTrOLLed sTudy
Lahtinen P.1, Jalanka J.2, Mattila E.3, Hillilä M.4, Punkkinen J.5, 
Koskenpato J.6, Anttila V.-J.7, Tillonen J.8, Satokari R.2, Arkkila P.7
1Päijät-Häme Central Hospital, Gastoenterology, Lahti, Finland, 2University of 
Helsinki, Helsinki, Finland, 3Helsinki University Central Hospital, Infectious 
Diseases, Helsinki, Finland, 4University of Helsinki, Gastroenterology, 
Helsinki, Finland, 5Pori Central Hospital, Gastroenterology, Pori, Finland, 
6Lääkärikeskus Aava, Helsinki, Finland, 7Helsinki University Central Hospital, 
Helsinki, Finland, 8Päijät-Häme Central Hospital, Lahti, Finland
contact e-Mail address: perttu.lahtinen@phsotey.fi
Introduction: Irritable bowel syndrome (IBS) is a common functional gut 
disorder with unknown etiology. Aberrant microbiota composition has 
been associated with IBS and is considered to play a role in the symptom 
development. Fecal microbiota transplantation (FMT) has been shown to 
be highly successful in treating patients with recurrent Clostridium difficile 
infection. We performed a randomized, double blind, placebo-controlled 
trial to evaluate the effect of a single FMT administered in colonoscopy on 
the symptom relief of IBS patients.
aims & Methods: We recruited 56 adult IBS patients with any level of symp-
tom severity and including all the IBS subtypes. The participants were ran-
domized 1:1 to receive either frozen and thawed FMT from a tested general 
donor or a placebo made from patients own fresh stool. The participants 
were asked to fill questionnaires at baseline and 4, 8, 12, 26 and 52 weeks 
after the FMT. Changes in symptom severity were recorded with IBS Symp-
tom Severity Score (IBS-SSS) scored 0-500. Additionally, quality of life was 
recorded with questionnaires IBS-QoL and 15-D, anxiety with Beck Anxiety 
Inventory (BAI) and depression with Beck Depression Inventory (BDI).
results: The primary endpoint of the study was a sustained reduction of 
IBS symptoms defined by a drop of IBS-SSS score of 50 points. This was 
achieved only at 12 weeks after the FMT in the treated group when com-
pared to the baseline (unpaired t-test p=0.03, 95%, CI 3.79 to 126.71). There 
was no statistical difference between the placebo and treated group at any 
time point. There were no other significant changes in the mental health 
status or quality of life measures between the treatment or placebo group 
or compared to the baseline.
conclusion: In this randomized placebo-controlled trial we did not find 
significant differences between FMT and placebo. The IBS symptom sever-
ity of the treatment group decreased significantly 12 weeks after FMT as 
compared to the baseline, but the change was transient. Adverse events 
were mild and indifferent between the two groups. The transient relief of 
IBS symptoms in the FMT treatment group indicate that microbiota is a 
potential therapeutic target in IBS. Larger placebo-controlled studies are 
needed with more homogenous study population and with different treat-
ment protocols. Currently, FMT cannot be recommended in treatment of 
IBS outside of study protocols.
disclosure: Nothing to disclose 
P0513 cOMPLIance TO PrOBIOTIc TheraPy In IrrITaBLe BOWeL 
syndrOMe In cLInIcaL PracTIce: a reaL-LIfe sTudy
Laterza L., Napoli M., Petito V., Scaldaferri F., Gaetani E., Gasbarrini A.
Fondazione Policlinico Universitario A. Gemelli IRCCS, Internal Medicine and 
Gastroenterology Unit, Rome, Italy
contact e-Mail address: marco.napoli.md@gmail.com
Introduction: Probiotics have been evaluated in multiple clinical trials on 
irritable bowel syndrome (IBS) showing efficacy on different IBS-related 
symptoms. Among them, the multistrain probiotic VSL#3 (manufactured 
by Nutrilinea Srl and distribuited by Ferring SPA) has been the object 
in clinical trials evaluating its administration for 4 to 8 weeks. However, 
whereas in clinical trials patients are closely monitored for compliance, in 
real-life setting long term compliance could be low. Furthermore, in many 
countries probiotics are fully paid by patients and the cost of therapy could 
further limit the compliance to probiotic therapy.
aims & Methods: This is a single-center, observational, prospective study 
to evaluate the compliance to prescription of probiotic therapy in real life 
and to identify factors able to influence adherence to therapy. Patients di-
agnosed with IBS according to Rome IV criteria and receiving a clinical 
prescription of VSL#3 for their IBS symptoms were evaluated for eligibility. 
Patients providing informed consent received a diary at the start of therapy 
to evaluate safety and effect of treatment for two months. After two months 
a final visit (at clinic or by telephone) was made to assess compliance and 
eventual reasons for discontinuation.
results: Fifty patients (mean age 41± SD 14.4 years, 26% males) have been 
enrolled and 49 completed the planned follow up. IBS subtypes are dis-
tributed as following: 44% diarrhea, 42% constipation and mixed in the 
remaining cases. Eighty-six percent of patients received a 4-week prescrip-
tion of one sachet per day. Sixty percent of patients resulted adherent in 
the FAS population. Among the 20 patients with reduced compliance, 5 
assumed less than 50%, 12 assumed 50% and 2 assumed more than 50 
but less than 80% of prescribed doses. Principal reasons of not adherence 
among the 20 patients are the price of the product (40%), mild adverse 
events (AEs) (30%) and poor appreciation of flavour (15%). Furthermore, 
one patient (5%) forgot to take the treatment, one (5%) stopped the treat-
ment for inefficacy and, for the patient who was lost at follow up (5%), 
the reason was not available. About AEs, 20% of patients experienced at 
least one (only one patient two AEs). All AEs were mild and they were: 
bloating (6/10 patients), constipation (2/10 patients) and flatulence (3/10 
patients). The AEs were considered related to treatment in 9/10 cases and 
they were a reason for discontinuation in 6/10 cases. All AEs completely 
resolved without sequelae. No serious adverse events have been reported. 
Sixty-two percent of patients who assumed the therapy reported overall 
satisfactory benefit on their IBS symptoms with the prescribed therapy.
conclusion: According to our results, despite a good safety profile, 60% 
of patients assumed all the prescribed probiotic therapy in real life set-
ting with reported overall satisfactory benefit. The main reasons for lack 
of compliance were price of the product, mild AEs (mainly bloating) and 
low palatability.
disclosure: L.L. consultant for Actial Farmaceutica. Lecturer for Janssen. 
M.N. nothing to disclose F.S. lecturer for Sanofi, Cadigroup and MSD E.G. 
nothing to disclose A.G. Speaker’s bureau for MSD, Abbvie, Gilead, Alfa-
sigma, Biocure, Actial Farmaceutica, Sanofi, Takeda, Dicofarm 
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with mild to moderate FI. The primary outcome was improvement in any 
of the 4 domains in the “Fecal Incontinence quality of life scale (FIQOLS)” 
using a 5 point Likert scale (higher score meaning better quality of life) 
. Secondary outcomes included improvement in severity and frequency 
of FI events according to the Wexner score and stool diaries, and safety. 
The first two weeks, served as the control period since no treatment was 
provided. During the third and fourth week, the tape was applied and 
served as the study period. Questionnaires were completed on days 0, 14 
and 28 of the study. At day 28 patients were asked to rate their general 
satisfaction and willingness to use the anal tape in the future using a 
visual analog scale.
results: Twenty patients were included, all females. The median age 
was 64 (Range 27-82). Four patients developed FI after an obstetric anal 
sphincter injury (OASIS) and one had FI secondary to peripheral neuropa-
thy; In 15 the FI was considered idiopathic, but seven of them had a remote 
history of OASIS. Significant improvement was observed in all domains 
of the FIQOLS from baseline to day 28 (Lifestyle: 2.8(0.69) to 3.3(0.68) 
p< 0.001; Coping/Behaivoir 1.9(0.64) to 2.5(0.73) p=0.0002; Depression/
Self-Perception 3.1(0.75) to 3.5 (0.74) p=0.006); Embarrassment 2.13(0.67) 
to 2.65 (0.76) p=0.002) but not between baseline and day 14 (Lifestyle: 
2.8(0.7) to 2.9 (0.7) p=0.6; Coping/Behaivoir 1.9(0.64) to 2.1(0.0.67) p=0.06; 
Depression/Self-Perception 3.1(0.75) to 3.2 (0.71) p=0.09; Embarrassment 
2.13(0.67) to 2.26 (0.89) p=0.4). Quality of life Improved significantly be-
tween day 14 and day 28 in all domains except Depression/Self-Perception 
(p=0.08, in all other comparisons p value was < 0.04). The mean Wexner 
score in days 0, 14 and 28 was 12.5(3.6), 11.9(3.5) and 10.3(4.8) (day0 vs. 
day14 p=0.13, day0 vs day28 p=0.054, day14 vs. day 28 p=0.18). Fifteen 
complete stool diaries were available for analysis. 
Absolute number of FI events between the control period and the treat-
ment period decreased by a mean of 52.3% in 11/15 patients, 2 patients re-
ported no change and 2 patients had a small (non-statistically significant) 
increased in the number of FI events. Fife patients (25% intention to treat) 
had 50% or more improvement in FI events. Out of 17 patients that com-
pleted the VAS scales, the median overall satisfaction with the device was 
80 (IQR 30-85) mm and the willingness to use the anal tape in the future 
was 90 (IQR50-90) mm. Other than mild difficulty to remove the anal tape, 
no adverse events were reported.
conclusion: The use of the anal tape was safe and effective. The primary 
outcome of significant improvement in quality of life was achived
disclosure: Nothing to disclose 
P0516 cOnservaTIve ManageMenT Of chrOnIc anaL fIssure: 
Is The BOTOx a gOOd rescue TheraPy?
Meixedo Arieira C.V.1,2,3, Dias de Castro F.1,2,3, Rosa B.J.F.1,2,3, 
Berkeley Cotter J.1,2,3
1Hospital da Senhora da Oliveira, Gastroenterology, Guimarães, Portugal, 
2Life and Health Sciences Research Institute (ICVS), School of Medicine, 
University of Minho, Braga/Guimarães, Portugal, 3ICVS/3B’s PT Government 
Associate Laboratory, Braga/Guimarães, Portugal
contact e-Mail address: catia_arieira@hotmail.com
Introduction: Chronic anal fissure (CAF) is one of the commonest proc-
tological diseases that presents with severe perianal pain and bleeding. 
Because of the disability associated with anal surgery, medical alternatives 
have been sought. Most recently, pharmacologic methods that relax the 
anal smooth muscle have been used to obtain fissure healing.
aims & Methods: 
aim: To investigate the effectiveness and the factors associated to CAF 
healing with conservative management. 
Methods: Retrospective study. Included consecutive patients referred for 
CAF to coloproctology consultation between March 2015 and June 2018. All 
the patients had a minimum follow up of 3 months.
results: Included 75 patients, 55 (73.3%) female with mean age of 47.0±16.1 
years. Nine patients (12.0%) had previous history of anal surgery and 6 
(8%) suffered from IBD. The CAF was anterior in 19 patients (25.3%), pos-
terior in 49 (65.3%) and 7 patients presented anterior and posterior CAF. 
All the patients were appropriately started on conservative dietary therapy 
and laxatives. Associated with this therapy all the patients performed topi-
cal medications (1 or 2 cycles): nitroglycerin in 85.6% of the patients and 
in 68% diltiazem. 43 patients (55.1%) were submitted sequentially to the 
2 topical treatments. CAF healing was achieved with topical treatment in 
33 (44%) patients.
P0514 TreaTMenT Of PerIanaL fIsTuLa In PrOcTOLOgy 
cOnsuLTaTIOn: assessMenT Of effIcacy and safeTy
Gamelas V.1, Simões G.2, Santos S.3, Pavão Borges V.3, Rocha M.3, 
Saraiva R.4, Vasconcelos Loureiro R.4, Carvalho D.4, Seves I.4, 
Costa Simões J.4, Ramos J.4, Bettencourt M.J.4
1Centro Hospitalar Universitário de Lisboa Central EPE, Gastroenterology, 
Lisboa, Portugal, 2Centro Hospitalar Universitário de Lisboa Central, 
Camarate, Portugal, 3Centro Hospitalar Universitário de Lisboa Central, 
Lisboa, Portugal, 4Centro Hospitalar Universitário de Lisboa Central EPE, 
Lisboa, Portugal
contact e-Mail address: veronicagamelas@gmail.com
Introduction: Perianal fistula significantly decrease quality of life and are 
traditionally treated by fistulotomy or fistulectomy. Efficacy and safety of 
fistula seton placement followed by superficial fistulotomy have been dis-
cussed in the past years.
aims & Methods: The aim of our study is to evaluate the efficacy and safety 
of this procedure on the treatment of perianal fistula.
This is a retrospective observational study of patients with cryptogenic 
perianal fistula aged 18 to 90 years old, who were followed in a central 
hospital proctology consultation between January 2006 and December 
2017. Clinical records of patients informatically coded as having anal fistula 
were analysed. Parks Classification was used to characterize anal fistula. 
We identified 263 patients, of whom 167 were excluded: 111 for incomplete 
information, 19 for submucosal fistula, 16 for coding error, 7 for complex 
fistula, 7 for HIV infection, 4 for inflammatory bowel disease, 2 for still 
having seton in situ at the time of data collection and 1 for age over 90.
Fistula were characterised by proctologic examination and imaging (ano-
rectal ultrasound and/or MRI). The treatment consisted of defining fistula 
anatomy by passing a probe through the fistula tract (cannulation). This 
was followed by seton placement which remained in situ for a variable 
time until fistula tract was exteriorized. Superficial fistulotomy was then 
performed with an electric cautery, under local anesthesia.
results: Ninety six patients with perianal fistula were included (66.67% 
males, mean age 56±15 [23-86] years old). Nineteen (19.89%) patients had 
previous history of anal fistula and 14 (14.58%) previous anorectal surgery.
Of the 96 patients, fistula cannulation was not possible in 2 (2.08%), for a 
partially closed fistula tract. Of the 94 patients submitted to fistula cannu-
lation, fistulotomy was possible in 74 (78.72%). Among the others, fistulot-
omy was not possible due to: loss of follow up - 16 patients (17.02%), loss 
of seton - 3 patients (3.19%) and therapeutic failure due to nonprogression 
of seton - 1 patient (1, 06%) - (ITT 80.2%, PP 98.7%).
We evaluated 74 patients submitted to cannulation and fistulotomy for 
perianal fistula treatment. The mean follow-up time was 59±45 [6,144] 
months. Of these patients, 47 (63.51%) had intersphincteric fistula (time 
with seton 15±31 weeks), 26 (35.14%) transsphincteric fistula (time with 
seton 32±47 weeks), 1 (1.35%) suprasphincteric fistula (time with seton 11 
weeks).
Adverse events were reported in 4 (5.4%) patients: 2 (2.7%) had transient 
pain after the procedure and 2 (2.7%) reported incontinence.
Two patients (2.7%) had recurrence after fistulotomy, in less than 8 weeks.
conclusion: Placement of seton followed by fistulotomy is a safe and effec-
tive method for perianal fistula treatment.
disclosure: Nothing to disclose 
P0515 “anaL TaPe” a genuIne exTernaL devIce fOr fecaL 
IncOnTInence
Livovsky D.M., Koslowsky B., Lysy J.
Shaare Zedek Medical Center, Digestive Diseases Institute, Jerusalem, Israel
contact e-Mail address: lysyj@szmc.org.il
Introduction: Fecal incontinence (FI) is a common underreported, de-
bilitating condition with devastating negative impact in quality of life. 
Its prevalence ranges from 7-18%. Management includes: Conservative / 
behavioral treatment, anal or vaginal plugs, and invasive methods. We 
developed an “anal tape” with an adjusting applicator to adapt the device 
to the skin surrounding the anus. We used an available elastic band with 
a special adhesive that is approved for use in the skin.
aims & Methods: The aim of this study was to determine the safety and 
efficacy of the “anal tape” device in patients with fecal incontinence. This 
is a four week prospective, self-controlled open label study of patients 
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The remaining patients who did not achieved CAF healing with topical 
therapy (56%) underwent botulinum toxin injection (Botox®). Fissure 
healing was observed in 54.7% (n=23) and partial healing in 3 patients 
(7.1%) with Botox®.
Two patients were re-injected with Botox®, one achieving complete fis-
sure healing. Sixteen (21.3%) were referred to anal surgery. Nevertheless, 
we observed that patients with higher age more frequently had fissure 
healing with medical therapy (49.4vs40.7 years; p=0.034).
conclusion: We observed that more than three quarters of the patients 
presented fissure healing with conservative management (topical+botox 
injection). Older patients may respond better to conservative manage-
ment. This highlights the benefit of early conservative and medical man-
agement of CAF, before attempting anal surgery.
disclosure: Nothing to disclose 
P0517 evOLuTIOn In The ManageMenT Of PresacraL 
TuMOurs
Gould L., Fletcher J., Pring E., Corr A., Burling D., Tozer P., 
Warusavitarne J., Antoniou A., Jenkins J.T.
St Mark’s Hospital, London, United Kingdom
contact e-Mail address: laura.e.gould@gmail.com
Introduction: Presacral tumours represent a small group of pathologies 
encountered by colorectal surgeons where specialist input is likely to be 
required. They represent a disparate number of pathological phenomena 
which are classified together through a shared anatomical association. 
These rare tumours can be either benign or malignant and arise de novo 
or from embryological remnants in the pelvis. With the increased use of 
radiological investigations there has been an increase in the identification 
of these lesions many of which are incidental. Understanding how the 
management of such tumours has evolved would be informative to the 
colorectal community.
aims & Methods: Retrospective database assessment of presacral tumours 
treated in a tertiary referral hospital from 1980s-2019. Patient demograph-
ics and related radiological and clinico-pathological data were assessed in 
relation to short and long term outcomes. From 2008, presacral tumours 
have been assess through a formal MDT process.
results: 132 presacral tumours were identified: 72% Female: 98 congeni-
tal benign; 10 congenital malignant; 8 benign neurogenic; 4 malignant 
neurogenic; 2 malignant osseous; 6 miscellaneous malignant; 4 miscel-
laneous benign. 102 [77%] underwent surgical excision; 30 [23%] deferred 
surgery or in surveillance. The total number cases seen has increased each 
decade from 13 in 1980s, 19 in 1990s, 23 in 2000s to 77 patients in 2010s. 
Surgical intervention occurred in nearly all early cases with 90% of pa-
tients in 2000s undergoing resection. There has been a shift towards sur-
veillance in the 2010s with 64% operated and 36% in surveillance. Stoma 
formation was required in 10%. Increasing proportions of patients were 
asymptomatic and noted incidentally on imaging.
conclusion: Presacral tumours are increasingly noted incidentally on im-
aging and significant proportions may be managed with radiological sur-
veillance. A formal specialist MDT process is required and referral to a 
specialist centre is recommended.
disclosure: Nothing to disclose 
P0518 hOW TO esTaBLIsh a dedIcaTed LOW anTerIOr 
resecTIOn syndrOMe (Lars) cLInIc
Metry M.1, Miah M.1, Kaur G.2
1Scunthorpe General Hospital, Scunthorpe, United Kingdom, 2Scunthorpe 
General Hospital, Surgery, Scunthorpe, United Kingdom
contact e-Mail address: mario.metry@nhs.net
Introduction: Sphincter saving resection with TME with/without preop-
erative radiotherapy are considered standard treatment for rectal cancer. 
This can result in bowel dysfunction of variable severity in these patients, 
including faecal urgency and frequency, incontinence, and difficult or in-
complete evacuation. An internationally validated patient-reported out-
come measure, Low Anterior Resection Syndrome (LARS) score, enables 
these symptoms to be measured. The Pre-Operative LARS score (POLARS) 
is a validated online tool developed by the Pelican Group, Basingstoke, 
which may be used to predict bowel dysfunction severity prior to anterior 
resection to help patients understand their risk of bowel dysfunction and 
also to highlight those patients who may require additional postoperative 
support.
aims & Methods: We aimed to assess the risk factors for and the predicted 
incidence of LARS in our anterior resection patient population to validate 
the need for a LARS clinic in our Lower GI physiology department.
All patients who had undergone curative surgery for rectal cancer in our 
district general hospital Jan 2016 - Dec 2018 were included in the study. 
Only those who had undergone restorative anterior resection were in-
cluded- the rest, including non-resection procedures (TEMS/ EMR etc) or 
AP resections with permanent colostomy, were excluded. Demographics, 
tumour height from the anal verge, preoperative treatment and details 
of the surgery were documented and the POLARS for each patient was 
calculated.
results: There were 53 male and 31 female patients in the study; the age 
ranged from 36 to 98 years, with 80.92% in the 51-80 year age group, 
58.33% in the 61-80 year group. The incidence of Major LARS was pre-
dicted as 8.33%, minor LARS was 78.57% and no LARS was only 13.1%.
Interestingly, the mean age in the Major LARS group was 53 as compared 
to 77 years in the no LARS group. The mean distance of the tumour from 
the anal verge was 10.14 cm in the Major LARS group as compared to 22.82 
cm in the no LARS group. No patient in the no LARS group had preopera-
tive radiotherapy as compared to 71.43 % in the major LARS group. There 
was only 1 female in the no LARS group whereas in the major LARS group 
71.43 % patients were female.
conclusion: Bowel dysfunction is well known following sphincter-preserv-
ing resection. We used the POLARS to help target the patients needing 
intensive support post treatment to prevent QOL issues. We found the risk 
of major LARS strongly correlated with female sex and younger age group 
patients as well as a shorter distance of the tumour from the anal verge; 
it was significantly higher in the group that had neoadjuvant therapy. We 
found our predicted incidence of minor/major LARS was 86.9% of our 
anterior resection population on POLARS. Therefore, we set up a LARS 
clinic in the lower GI physiology department, specifically for these patients 
following oncologic/surgical treatment of pelvic cancer- we have already 
received excellent feedback from the patients.
disclosure: Nothing to disclose 
P0519 fecaL IncOnTInence evaLuaTIOn and ITs 
cOnsequences On quaLITy Of LIfe - sTudy In a secOndary 
aTTenTIOn cLInIc
Grabin Granero G.1, Bonadio C.B.2, Brisotti J.L.2, Araújo M.N.F.2
1FACISB, Medicine, Barretos, Brazil, 2FACISB, Barretos, Brazil
contact e-Mail address: grabingui@gmail.com
Introduction: Anal incontinence (AI) is a involuntary loss of stool or gas 
and affects the individual quality of life in regards to physical, psychologi-
cal and social spheres. It is known that quality of life is usually under the 
influence of the grade of anal incontinence, but social facts can also affect 
the real quality of life, for exemple, older patients may be less disturbed 
by the symptoms.
aims & Methods: To evaluate the relation between the prevalence of anal 
incontinence and its grades of gravity in a population from a secondary 
care clinic and the real impact of symptoms in quality of life of those in-
dividuals, using quantitative and qualitative scores (of symptoms and of 
quality of life).
This is a transversal analytic stud with the application of questionnaires in 
patients from secondary care clinic. A personal and medical health survey 
were applied as well as two questionnaires, already validated in medical 
literature (Jorge-Wexner Anal Incontinence Scale and Fecal Incontinence 
Quality of Life - FIQL) were also applied in patients with FI symptoms (FI 
solid, liquid and gas; soiling, non-sensitive loss, urgency evacuation. FIQL 
scale already underwent both translation and cultural adaptation process-
es and consists of four different domains: lifestyle, behavior, depression 
and embarrassment. Jorge-Wexner scale is the most utilized to evaluate 
grades of AI. The patients were divided in 2 groups: mild AI (score 1-9) 
and moderate/serious AI (score 10-20) and according to age 18-59 and 
older than 60.
results: The reproducibility was tested through application of 1200 per-
sonal and medical questionnaires, being the population predominantly 
female (64.1%), with median age: 54 (iq 40-65). 162 patients (16%) pre-
sented AI symptoms. Among these patients, 153 that answered Jorge-
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P0521 recenT Trends In gasTrOenTerOLOgy and endOscOPy 
reLaTed MedIcaL PrOfessIOnaL LIaBILITy cLaIMs In The unITed 
sTaTes Of aMerIca
Jayaraj M.1, Ohning G.V.2, Parikh D.3, Krishnamoorthi R.4
1UNLV School of Medicine, Internal Medicine- Gastroenterology, Las Vegas, 
United States, 2UNLV School of Medicine, Gastroenterology, Las Vegas, 
United States, 3Medical Professional Liability Association, Rockville, United 
States, 4Virginia Mason Medical Center, Gastroenterology, Seattle, United 
States
contact e-Mail address: mahendran.jayaraj@unlv.edu
Introduction: In the recent years medical malpractice claims have contrib-
uted significantly to the rising cost of medical practice in all specialties 
in the United States by increasing the malpractice insurance premiums 
and costs associated with the practice of defensive medicine. Being a pro-
cedure oriented specialty, the trends in gastroenterology diagnoses and 
endoscopy related malpractice claims need to be studied to educate the 
gastroenterologists and allied health care professionals towards risk man-
agement and cost containment in this field.
aims & Methods: Retrospective analysis of Medical professional liability 
(MPL) claims data for the years 2006-2015 obtained from the MPL associa-
tion [formerly the Physician Insurers Association of America (PIAA) Data 
Sharing Project (DSP)] was done. Among the gastroenterology claims 
the presenting medical condition, operative procedure, outcomes of the 
claims and the costs associated with the closed claims were compared 
between 2006-2010 and 2011-2015 time periods to analyze the trend over 
the years.
results: From 2006-2015, there were 90,743 MPL closed claims and 
24,106 paid claims in all medical and surgical specialties. Out of all the 
claims, 2.07 %( 1879) of closed claims and 1.5% (367) of all paid claims 
were against gastroenterologists. In the claims against gastroenterolo-
gists, 71.0% of were dropped, withdrawn, or dismissed. Out of the claims 
that went to trial, 88.4% of claims that received a verdict were favorable 
toward the gastroenterologists. Within the GI, MPL claims involving di-
agnostic procedures of large intestine were the most common account-
ing for 26% of all closed claims leading to a payment of $18,392,668 in 
total and $301,519 as average indemnity. Average indemnity was highest 
for diagnostic procedures of gallbladder and biliary tract including ERCP 
procedures ($484,364).This was followed by procedures involving small 
intestine ($336,078), large intestine ($301,519) and esophagus ($267,577). 
In the time frame 2006-2015, the average indemnity increased by 8.2% 
from $341,563 in 2006-2010 to $369,508 in 2011-2015. Amount spent on 
legal defense also increased by 8.7% ($44,625 vs. $48,506) in gastroenter-
ology related claims for the respective time periods.
conclusion: Gastroenterology specialty has an increasing trend in spend-
ing on average indemnity and defense. Diagnostic procedures of the bili-
ary tract including ERCP have the highest average indemnity among the 
endoscopic procedures. Adequate endoscopic training, meticulous focus 
on procedural indication and well informed consent might help to reduce 
the costs associated with claims. Further studies are needed to investigate 
the variables associated with this trend in gastroenterology.
references: PIAA MPL specialty specific series -Gastroenterology 2006-
2015
disclosure: Nothing to disclose 
P0522 cOLOrecTaL BradyarrhyThMIa syndrOMe as 
PredIcTOr Of cOnsTIPaTIOn and cOLOrecTaL cancer
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Introduction: Constipation increases the risk of colorectal cancer [1-4]. 
Low frequency of defecation increases the risk of cardiovascular mortal-
Wexner scale, 116 (75.8%) demonstrated mild AI. 9 patients did not have 
symptoms that were nominated in the scale (soiling, non-sensitive loss 
and urgency evacuation). The media of aspects assessed at FIQL scale 
was, respectively, in mild and moderate/serious AI: lifestyle 3.36 (sd 0.95) 
vs 2.4 (sd 1.04), behavior 3.35 (sd 0.89) vs 2.09 (sd 0.88), depression 3.64 
(sd 0.82) vs 2.38 (1.0) and embarrassment 3.25 (sd 0.94) vs 2.15 (0.96); 
all comparisons were statistically significant (p< 0.05). Moreover, the pa-
tients were divided in two range of ages: patients from 18 until 59 years 
old and more than 60 years old. Comparing FIQL scale between those 
groups, there was no statistical diference regarding all aspects of the 
questionnaire: ( lifestyle p=0.74); behavior p=0.61; depression p=0.99 and 
embarrassment p=0.39).
conclusion: In the studied population, there was a direct association be-
tween the severity of AI, as stated by Jorge-Wexner scale and the quality 
of life, according to the classification of mild AI and moderate/serious AI. 
On the other side, there is no correlation between worse quality of life in 
patients younger than 60 years of age, despite the gravity of AI.
disclosure: Nothing to disclose 
P0520 assessIng The rIsk fOr gasTrOesOPhageaL refLux 
dIsease and ITs cOMPLIcaTIOns In PaTIenTs WITh cOnsTIPaTIOn
Asfari M.M.1, Sarmini M.T.2, Ellison S.B.1, Jackson C.S.3, Vega K.J.1
1Augusta University-Medical College of Georgia, Division of Gastroenterology 
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contact e-Mail address: kvega@augusta.edu
Introduction: Constipation is a common gastrointestinal disorder which 
can result in infrequent hard stools that are difficult and/or painful to pass. 
Constipation is also frequently associated with straining which is known to 
promote gastroesophageal reflux disease (GERD). Data on the presence of 
GERD in patients reporting constipation is limited. The aim of this study 
was to investigate if constipation increases the risk for GERD and its main 
complications including Barrett’s esophagus (BE), esophageal stricture 
(ES) as well as esophageal cancer (EC) using a large patient database.
aims & Methods: Using data from the National Inpatient Sample (NIS) 
database between 2004 and 2014, we identified patients who were diag-
nosed with constipation using appropriate ICD 9 coding. The control group 
were patients who did not have a diagnosis of constipation. Demographic 
information, tobacco use, hernia presence and GERD diagnosis along with 
its complications (esophageal stricture, Barrett’s esophagus as well as 
esophageal cancer), by ICD 9 coding, was then compared between the 2 
groups to determine if any association existed using univariate and multi-
variate logistic regression.
results: The total population studied in the NIS database comprised of 
53,237,367 patients, of which 1,751,039 (3.2%) were diagnosed with con-
stipation. Constipated patients were older (61 years old vs 49), more likely 
to be female (59.8% vs 57.8%) and African American (15.7% vs 14.6%) 
compared to the control group (P < 0.01 for all). Furthermore, patients 
with constipation were more obese (10.3% vs 9%), had increased tobacco 
use (11.8% vs 11%) and diaphragmatic hernias present (3% vs 1.6%) com-
pared to those without constipation (P< 0.01 for all). Of note, constipated 
patients had less alcohol abuse (3.1% vs 3.8%) and bariatric surgery (0.1% 
vs 0.4%) compared to the control group (P< 0.01 for both). History of para-
esophageal surgical repair was similar in both groups (0.1%). Using mul-
tivariate logistic regression, constipated patients had statistically signifi-
cant higher rates of GERD (OR 1.57, 95% CI 1.56-1.58), BE (OR 1.24, 95% CI 
1.21-1.27), ES (OR 1.21, 95% CI 1.18-1.24) and EC (OR 1.68, 95% CI 1.61-1.74) 
(P < 0.001 for all) compared to patients without constipation.
conclusion: Constipation is associated with a significant increase in risk for 
GERD and complications of GERD. The most significant association is for 
esophageal cancer. Screening for and treating GERD along with its com-
plications, if present, is essential for the optimal management of patients 
with constipation.
disclosure: Nothing to disclose 
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ity by 21-39% [5]. Constipation increases the risk of obesity [6]. However, 
the most initial risk factors for constipation and colorectal cancer remain 
poorly understood.
aims & Methods: Aim of this study was the description of the Colorectal 
Bradyarrhythmia Syndrome (CBS) as an early risk factor of constipation 
and colorectal cancer.
Using the method of “Chronoenterography” - weekly monitoring of enteral 
circadian rhythm [7, 8] surveyed 3 groups of volunteers. The first group was 
356 medical students (20-22 years, 71% of women). The second - was 100 
gastroenterologists (30-64 years, 41% of women). The third - 2501 doctors 
(24-75 years, 66% of women). 4 rhythms of defecation were revealed: nor-
mal (daily) - regular colorectal rhythm (RCR) - 7 times a week, CBS-I - 5-6 
times/wk., CBS-II - 3-4 times/wk., CBS-III - 1-2 times/wk., (constipation). 
The presence of physiologically optimal morning (06:00-12:00) acrophase 
of the circadian rhythm of defecation was determined. 3 levels of quality of 
life (QOL) were estimated: high - 80-100% of optimal; medium - 60-80%; 
low - 40-60%. The level of mood and laxative were revealed.
results: RCR was detected in 53% of medical students, CBS - in 47%. 
Morning phase of defecation was almost 3 times more common for stu-
dents with RCR than with CBS. CSC-I, CSC-II and CSC-III were detected in 
33%, 11% and 3% of students, respectively. The high level of QOL in stu-
dents with RCR was (in 36%) 1.5 times more often than with CBS (in 24%). 
The low level of QOL in students with CBS was (21%) 1.7 times more often 
than in students with RCR (12%).
Low mood level was found in 34% with CBS-I, but in 55% of students with 
CBS-III. 
Laxatives took 13%, 30% and 64% of students with CBS-I, CBS-II and CBS-
III, respectively. 
RCR was detected in 57% of gastroenterologists, and CBS - in 43%. Morn-
ing phase of bowel habits was almost 7 times more likely for gastroenter-
ologist with RCR than for persons with CBS. High QOL level was found for 
63% gastroenterologist with RCR but only for 49% with CBS. 
Regular colorectal rhythm was detected in 56% of doctors, and CBS - in 
44%. Morning phase of defecation was 4 times more common for doc-
tors with RCR than with CBS. CBS -I, CBS -II, CBS -III (constipation) was 
detected in 27%, 13% and 4% of doctors respectively. Doctors with RCR 
had predominantly the high level of QOL (80-100% of optimum), but doc-
tors with CBS - had predominantly average level of QOL (60-80% of the 
optimum). CBS was associated with a significant decrease in the level of 
mood in 30-55% of medical students. CBS is characterized by a progres-
sive increasing in using laxatives (from 13% in CBS-I to 64% in CBS-III).
conclusion: CBS occurs in all age groups, starting from the age of 20. CBS-
I was 7-10 times more common than CBS-III (constipation). CBS-I is the 
earliest predictor of constipation. The QOL of persons with CBS was lower 
than of persons with RCR. CBS is manifested by 3 main features: slowing 
the rhythm of defecation, the absence of the morning phase of defecation 
and the decreasing QOL level. Screening of the CBS is necessary for the 
earliest (at 20 years) detection of this syndrome as a functional predictor 
of constipation. CBS can be used for the functional primary prevention of 
colorectal cancer and to identify new risk groups for endoscopic screening 
of this type of cancer.
references: 1. Talley N.J., Lasch K.L, Baum C.L. A gap in our understanding: 
chronic constipation and its comorbid conditions.Clin Gastroenterol Hepa-
tol. 2009 Jan; 7(1):9-19. 2. Tashiro N, Budhathoki S, Ohnaka K. Constipation 
and Colorectal Cancer Risk: The Fukuoka Colorectal Cancer Study. Asian 
Pac. J. of Cancer Prevention, Vol 12, 2011, 2025-2030. 3. Guerin A, Mody R, 
Fok B et al. Risk of developing colorectal cancer and benign colorectal neo-
plasm in patients with chronic constipation. Alim. Pharm. Ther. 2014 Jul; 
40(1):83-92. 4. Shemerovskii KA. Constipation - a risk factor for colorectal 
cancer. Klin Med 2005, 83(12): 60-64. 5. Honkura K., Tomata Y., Sugiyama 
K. et al. Defecation frequency and cardiovascular disease mortality in Ja-
pan: The Ohsaki cohort study // Atherosclerosis. 2016. N246. P. 251-256. 6. 
Shemerovskii K.A, Ovsiannikov V. I, Mitreikin V. F. Irregular Bowel Habit 
Increases Risk of Obesity. UEG Journal, 2015, 3 (5S), A504, P1223. 7. Sh-
emerovskii K. A. Chronoenterography: monitoring of circadian rhythm of 
intestinal evacuatory function. Bull Exp Biol Med. 2002 May; 133(5):503-5. 
8. Shemerovskii K. A., V. I. Ovsiannikov, V. F. Mitreikin. Screening of Irregu-
lar Bowel Movement Frequency. 20th UEG Week 2012, Amsterdam, The 
Netherlands, 20-24 October 2012, Gut 2012; 61 (Suppl 3), A305-306, P0957.
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Introduction: Drivers of health care utilization in the irritable bowel syn-
drome (IBS) and inflammatory bowel disease (IBD) are unclear but symp-
toms and psychological distress may be important.
aims & Methods: This study aimed to explore the links between health 
care utilisation, type of bowel symptoms and severity of bowel symptoms 
in patients with IBS and IBD referred by GPs to a tertiary hospital. We ran-
domly selected 282 patients without evidence for structural causes for GI 
symptoms who had an outpatient appointment between 15 and 18 months 
ago. Symptoms were assessed with the validated SAGIS-instrument and 
patients categorised based upon the symptom pattern as (IBS-M (IBS with 
diarrhea and constipation symptoms), IBS-C (constipation) and IBS-D 
(diarrhea), and non-IBS symptoms. In addition, we selected 149 patients 
with IBD. Electronic medical records were reviewed and episodes of care, 
hospital admissions, gastroenterology and other specialists outpatient de-
partment (OPD) consultations, diagnostic procedures (MRI, CT, ultrasound) 
and the number of therapeutic day procedures for a period of 12 month 
before and 12 month after the index consultation determined. Costs for 
outpatients’ consultations and other procedures were quantitated based 
upon published data costs for the respective jurisdiction. Group differences 
were analysed using one-way analysis of variance and correlations were 
measured using Pearson correlation coefficients.
results: Out of 282 patients, 61 reported a mix of IBS diarrhea and consti-
pation (21.6% 95%CI 17.2-26.8), 106 (37.5% 95%CI 32.1-43.4) IBS diarrhea, 
17 (6.0%, 95% CI 3.8-9.4) IBS constipation only and 98 (34.8% 95%CI 29.4-
40.5) with other non-IBS symptoms. In total 149 patients had IBD but 83 
IBD patients did not report clinically relevant GI symptoms (total SAGIS 
score < 10). As shown in Table 1 patients with active IBD had higher health 
care utilisation, in particular gastroenterology outpatient consultations 
and imaging compared with patients with IBD in remission but were not 
different to those with IBS. 
Patient group hospital admissions OPd gI
OPd 
other MrI cT
ultra-
sound Procedures
IBD-remission 
(n=83)
1.16 (1.87)
4.35 
(1.80)*
2.28 
(4.32)
0.49 
(0.83)*
0.63 
(0.91)
0.32 
(0.63)
1.80 (2.78)
IBD-active (n=66) 1.88 (2.61)
5.30 
(2.92)
2.09 
(4.55)
1.27 
(2.01)
0.80 
(1.43)
0.50 
(0.93)
2.24 (1.61)
IBS-M (n=61) 2.48 (4.40)
4.15 
(2.48)
4.41 
(7.76)
1.38 
(2.49)
0.82 
(1.71)
0.39 
(0.86)
2.12 (1.53)
IBS-D (n=106) 1.68 (3.32)
4.10 
(2.46)
3.51 
(5.41)
0.70 
(1.07)
0.64 
(0.92)
0.41 
(0.76)
2.03 (3.09)
IBS-C (n=17) 1.23 (1.75)
3.65 
(2.85)
4.82 
(6.44)
0.29 
(0.49)
0.71 
(0.95)
0.43 
(0.53)
2.43 (1.40)
Other (n=98) 0.84 (1.68)
4.03 
(3.47)
2.42 
(5.79)
0.71 
(1.17)
0.71 
(1.02)
0.38 
(0.79)
1.76 (1.51)
*IBD remission versus active P< 0.05
[Table 1. Total health care utilisation among patient groups, all cell entries 
are mean (SD)]
Gastroenterology outpatient costs were significantly higher in patients 
with active IBD ($2,121) compared with IBD in remission ($1,739) (P=0.02) 
and similar to patients with IBS-M ($1659), IBS-D ($1,642), IBS-C ($1,459) 
and IBS-other ($1,612). Compared with non- IBS patients with symptoms, 
patients with IBS-D (P=0.03), IBS-C (P=0.03) and IBS-M (P=0.02) had high-
er other OPD costs. Other procedure costs were similar in patients with IBS 
and active IBD but higher than in non-IBS patients.
403Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
jor adverse event including perforation, severe delayed GI bleed or sepsis 
occurred after any endoscopic procedure discussed at the MDT.
conclusion: Based on our preliminary one-year experience of an ‘Ad-
vanced Endoscopy MDT’ is a useful platform for the safe, effective and 
efficient management of complex advanced endoscopic procedures. In our 
experience, it also appears to improve the quality of the service, clinical 
outcomes and facilitates optimal management. Studies are warranted to 
further assess the role of the MDT in endoscopy and patient satisfaction 
aspects.
disclosure: Dr Despott and Dr Murino receive research/ education support 
from Aquilant Medical, Fujifilm, Olympus and Pentax Medical. All other 
authors disclosed no financial relationships relevant to this publication. 
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Introduction: Overdiagnosis is the diagnosis of a disease that would not 
have developed to cause symptoms or death in the patient’s lifetime. While 
largely disregarded 10 years ago, overdiagnosis is now increasingly recog-
nized as a major harm of cancer screening.
aims & Methods: We used data from a randomized trial comparing screen-
ing with guaiac-based fecal occult blood testing (FOBT) every other year 
with no screening in Nottingham, UK, and estimated colorectal cancer 
overdiagnosis in FOBT screening [1,2]. 152,850 individuals aged 45-74 were 
randomized to screening (three to six screening rounds), or no screening. 
Attendance to at least one screening round was 59.9%, and 38.2% at-
tended all screening rounds. Since screening might prevent cancer also 
through adenoma removal, estimation of overdiagnosis requires knowl-
edge about the natural history of adenomas to colorectal cancer - which 
cannot be observed. We used the following microsimulation models to 
inform the natural growth of adenomas to colorectal cancer: 1. the Micro-
simulation Screening Analysis, MISCAN; 2. the Colorectal Cancer Simu-
lated Population model for Incidence and Natural history, CRC-SPIN; 3. the 
Simulation Model of Colorectal Cancer, SimCRC; and 4. a model derived by 
the German Cancer Research Center. 
We calculated annual transition rates for the progression from adenoma 
to cancer using the published median dwell time in the different models. 
For model 4, annual transition rates from non-advanced adenoma to ad-
vanced adenoma differed depending on age and sex, and we used the 
lowest (German, low) and the highest (German, high) reported rate in two 
independent analyses. 
We estimated overdiagnosed cancers as the difference between the num-
ber of cancers expected in the screening group (i.e. the total of observed 
cancers and cancers prevented by adenoma removal) and the number of 
cancers observed in the control group. The amount of overdiagnosis (per-
centage) is presented as the number of overdiagnosed cancers divided by 
cancers observed in the control group.
results: The observed colorectal cancer incidence was 3.0% in the screen-
ing group and 3.1% in the control group after a median of 19.5 years of fol-
low-up (hazard ratio 0.97; 95%CI 0.91-1.03). In the screening and control 
group, respectively, 2,139 (2.8%) and 1,484 (2.0%) individuals had at least 
one adenoma resected. The number of cancers prevented due to adenoma 
removal ranged from 45 to 296 in the screening group and from 37 to 179 
in the control group. The expected number of cancers in the screening 
group was between 2,324 and 2,575, which is 30 fewer to 221 more cancers 
than observed in the control group. Overall, the amount of overdiagnosed 
cancers is between -1.3% to 9.4%.
SAGIS intensity scores were correlated with the number of hospital ad-
missions r=0.23, P< 0.001, length of stay r=0.12, P=0.01, other outpatient 
consultations r=0.18, P< 0.001, CT scans r=0.115, P=0.02, other OPD costs 
r=0.18, P< 0.001, anxiety r=0.31, P< 0.001 and depression r=0.28, P< 0.001.
conclusion: Health care utilisation in patients with IBS is not different to 
patients with active inflammatory bowel disease and exceeds health care 
utilisation of patients with inactive inflammatory bowel disease. The in-
tensity of gastrointestinal symptoms is significantly associated with health 
care utilisation and health care costs.
disclosure: This study was sponsored by Allergan Pty Ltd. 
P0524 The rOLe Of an ‘advanced endOscOPy 
MuLTIdIscIPLInary TeaM MeeTIng’ fOr OPTIMaL ManageMenT 
Of PaTIenTs referred fOr cOMPLex endOscOPIc PrOcedures: 
One year exPerIence frOM a TerTIary referraL cenTre
Lazaridis N.1, Despott E.J.1, Telese A.1, Koukias N.1, Coppo C.1, Costa D.1, 
Varcada M.2, Wylie P.3, Raymond R.1, Bailey A.1, Luong T.4, Watkins J.4, 
Planche K.3, Hart C.2, Murino A.1
1The Royal Free Hospital and University College London (UCL) Institute for 
Liver and Digestive Health, Royal Free Unit for Endoscopy, London, United 
Kingdom, 2The Royal Free Hospital and University College London (UCL) 
Institute for Liver and Digestive Health, Department of Colorectal Surgery, 
London, United Kingdom, 3The Royal Free Hospital and University College 
London (UCL) Institute for Liver and Digestive Health, Department of 
Radiology, London, United Kingdom, 4The Royal Free Hospital and University 
College London (UCL) Institute for Liver and Digestive Health, Department of 
Cellular Pathology, London, United Kingdom
contact e-Mail address: nikolaos.lazaridis@nhs.net
Introduction: Optimisation of patient care though multidisciplinary team 
(MDT) meetings is now established as the standard of care in cancer path-
ways. Cases presented at MDTs are discussed by a panel of multidisci-
plinary experts in order to provide optimal management, tailored to the 
needs of individual patients, also considering co-morbidities and available 
expertise. Within the subspecialty of endoscopy, management of patho-
logical findings may vary significantly and could be approached through 
an array of different techniques/procedures. Similar to cancer pathways, 
an advanced endoscopy MDT platform, may help to achieve consensus on 
decision-making and management of complex cases, clinical outcomes 
and patient satisfaction.
aims & Methods: Over the last year, in our tertiary referral institution, we 
developed and adopted an ‘advanced endoscopy MDT’ to evaluate and 
manage complex cases referred to us for advanced endoscopic interven-
tion. An hourly bi-weekly meeting was established with the presence of 
at least two expert interventional endoscopists, a radiologist, a histopa-
thologist, a dedicated gastrointestinal (GI) surgeon and a nurse endos-
copist. Depending on the cases discussed, additional experts were also 
in attendance (e.g. hepato-pancreatico-biliary surgeons and neuroendo-
crine tumor specialists). Patients from our institution and other centres 
referred with lesions of the upper, lower and mid GI tract were presented 
and thoroughly discussed. Endoscopic images, radiological scans and his-
topathology reports were assessed in order to decide treatment options 
and surveillance intervals. We retrospectively reviewed all patients that 
were presented at our MDT over the last 12 months. Demographic, clinical, 
endoscopic findings and outcome data were analysed.
results: Over 12 months, 25 meetings were conducted; 312 cases were dis-
cussed for a total of 217 patients. Fifty-two patients (24%) were tertiary 
referrals from other centres. The main reasons for MDT referral were for 
consideration of double-balloon enteroscopy (DBE) (56 patients; 26%) and 
for appropriate endoscopic or surgical management of mucosal/submuco-
sal GI lesions. Through MDT discussion, 15 patients (7%) were referred for 
surgical management; 30 patients were treated with endoscopic submu-
cosal dissection (ESD) and 41 patients with endoscopic mucosal resection 
(EMR) (14% and 19% respectively). One ESD procedure was abandoned 
due to high suspicion of deep invasion and was referred for surgery. From 
the remaining 29 cases, R0 margins were reported for 28/29 patients. Five 
patients referred for DBE did not require endoscopic input and 17 cases 
were reviewed twice as additional radiological investigations or small 
bowel capsule endoscopy were deemed necessary. 
All patients were informed about the MDT’s outcome and 16 (7%) were of-
fered an additional clinic appointment to discuss management options; all 
patients were reviewed in clinic after any endoscopic intervention. No ma-
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conclusion: This is the first study to report overdiagnosis in colorectal can-
cer screening with FOBT. Our results indicate that the amount of overdi-
agnosis of colorectal cancer in FOBT screening is less than 10%, but the 
estimates are highly dependent on adenoma transition rates.
references: [1] Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hard-
castle JD. Nottingham trial of faecal occult blood testing for colorectal 
cancer: a 20-year follow-up. Gut. 2012;61(7):1036-40. [2] Hardcastle JD, 
Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Ran-
domised controlled trial of faecal-occult-blood screening for colorectal 
cancer. Lancet (London, England). 1996;348(9040):1472-7
disclosure: Nothing to disclose 
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P0526 Trends In heaLThcare resOurce uTILIzaTIOn 
and MedIcaTIOn use Of PedIaTrIc crOhn’s dIsease PaTIenTs 
In The unITed sTaTes, 2007-2017
Hunter T.1, Naegeli A.1, Choong C.2, Dong Y.2, Crandall W.2
1Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, 
Indianapolis, United States, 2Eli Lilly and Company, Indianapolis, United 
States
contact e-Mail address: hunter_theresa_marie@lilly.com
Introduction: This study aimed to analyze the healthcare resource utiliza-
tion (HCRU) and medication use of pediatric Crohn’s Disease (CD) patients 
in the United States (US) insured population from 2007 to 2017.
aims & Methods: Trends in HCRU (emergency department (ED) visits, in-
patient visits, any outpatient visits, and bowel surgery) and medication 
use were calculated for the 11-year period covering January 1, 2007 to De-
cember 31, 2017. Pediatric (0-17 years) patients with ≥1 CD diagnosis code 
(ICD-9: 555.x; ICD-10:K50.x) within the calendar year were included in this 
retrospective analysis of medical and pharmacy claims data from the IBM 
Marketscan Commercial, Medicaid, and Medicare-Supplemental Claims 
database. Patients with an Ulcerative Colitis diagnosis were excluded from 
this study.
results: The rate of biologic use among pediatric CD patients increased 
from 15.6% in 2007 to 52.9% in 2017. During this time, rates of cortico-
steroids (35.8% to 29.6%), immunomodulators (37.9% to 18.5%), opioids 
(26.0% to 25.0%), and 5-ASAs (49.9% to 24.8%) decreased. Rates of bow-
el surgery remained stable in the pediatric CD population between 2007 
and 2017. However, gastroenterologist visits and ED visits increased, while 
inpatient visits decreased (Table 1). The mean number of outpatient visits 
increased from 16.64 in 2007 to 21.63 in 2017.
  2007 n=2,506 2012 n=5,737 2017 n=4,507
Surgery; n (%) 63 (2.5%) 218 (3.8%) 134 (3.0%)
Gastroenterologist Visit; n (%) 1,309 (52.2%) 2,572 (44.8%) 2,709 (60.1%)
Emergency Department Visit; n (%) 791 (31.6%) 2,083 (36.3%) 1,762 (39.1%)
Inpatient Hospital Visit; n (%) 479 (19.1%) 1,092 (19.0%) 688 (15.3%)
Outpatient Visit; n (%) 2,503 (99.9%) 5,733 (99.9%) 4,506 (100.0%)
Number of Outpatient Visits; mean 
(SD)
16.64 (19.32) 19.06 (23.35) 21.63 (29.73)
[Table 1. Healthcare Resource Utilization among Pediatric Crohn’s Disease 
Patients]
conclusion: This study provides real-world evidence on the medication use 
and HCRU of pediatric patients with CD in the US. From 2007-2017, there 
was an increase in HCRU and over half of pediatric CD patients were pre-
scribed a biologic. Real-word data are needed to capture changes in HCRU 
patterns due to the evolving CD treatment landscape.
disclosure: Nothing to disclose 
P0527 Trends In MedIcaTIOn use and heaLThcare resOurce 
uTILIzaTIOn Of PedIaTrIc uLceraTIve cOLITIs PaTIenTs In The 
unITed sTaTes, 2007-2017
Hunter T.1, Naegeli A.1, Dong Y.2, Choong C.2, Crandall W.2
1Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, 
Indianapolis, United States, 2Eli Lilly and Company, Indianapolis, United 
States
contact e-Mail address: hunter_theresa_marie@lilly.com
Introduction: This study aimed to analyze the healthcare resource utiliza-
tion (HCRU) and medication use of pediatric Ulcerative Colitis (UC) patients 
in the United States (US) insured population from 2007 to 2017.
aims & Methods: Trends in HCRU (emergency department (ED) visits, in-
patient visits, any outpatient visits, and bowel surgery) and medication 
use were calculated for the 11-year period covering January 1, 2007 to De-
cember 31, 2017. Pediatric (0-17 years) patients with ≥1 UC diagnostic code 
(ICD-9: 556.x; ICD-10:K51.x) within the calendar year were included in this 
retrospective analysis of medical and pharmacy claims data from the IBM 
Marketscan Commercial, Medicaid, and Medicare-Supplemental Claims 
database. Patients with a Crohn’s Disease diagnosis were excluded from 
this study.
results: The rate of biologic use among pediatric UC patients increased 
from 3.2% in 2007 to 22.4% in 2017. Corticosteroids use increased from 
28.6% to 34.8%, while rates of immunomodulators (20.6% to 15.6%), 
opioids (24.8% to 22.5%), and 5-ASAs (62.7% to 60.0%) decreased. Rates 
of bowel surgery remained stable in the pediatric UC population between 
2007 and 2017. However, gastroenterologist visits and ED visits increased, 
while inpatient visits decreased (Table 1). The mean number of outpatient 
visits increased from 15.92 in 2007 to 20.89 in 2017.
  2007 n=1,327 2012 n=2,767 2017 n=2,296
Surgery; n (%) 24 (1.8%) 55 (2.0%) 43 (1.9%)
Gastroenterologist Visit; 
n (%)
655 (49.4%) 1,304 (47.1%) 1,357 (59.1%)
Emergency Department 
Visit; n (%)
422 (31.8%) 904 (32.7%) 905 (39.4%)
Inpatient Hospital Visit; 
n (%)
257 (19.4%) 488 (17.6%) 414 (18.0%)
Outpatient Visit; n (%) 1,327 (100%) 2,765 (99.9%) 2,295 (100%)
Number of Outpatient 
Visits; mean (SD)
15.92 (25.62) 17.80 (24.99) 20.89 (31.27)
[Table 1. Healthcare Resource Utilization among Pediatric Ulcerative Colitis 
Patients]
conclusion: This study provides real-world evidence on the medication use 
and HCRU of pediatric patients with UC in the US. From 2007-2017, there 
was an overall increase in the use of biologics and corticosteroids, as well 
as HCRU. Real-word data are needed to capture changes in HCRU patterns 
and cost due to the evolving UC treatment landscape.
disclosure: Nothing to disclose 
P0528 IMMunIzaTIOn sTaTus Of BuLgarIan PaedIaTrIc 
PaTIenTs WITh InfLaMMaTOry BOWeL dIsease
Shentova-Eneva R.1,2, Yankov I.3,4, Baycheva M.1,2, Kofinova D.1,2, 
Hadjiiski P.1,2, Grozeva D.3,4, Burnosuzov H.3,4, Tzvetanska A.2,5, 
Murdzheva M.6, Yaneva P.1,2
1Department of Gastroenterology and Haepatology, University Paediatric 
Hospital “Prof. Ivan Mitev”, Sofia, Bulgaria, 2Medical University of Sofia, 
Sofia, Bulgaria, 3Department of Paediatrics, University Hospital “Saint 
George”, Plovdiv, Bulgaria, 4Medical University of Plovdiv, Plovdiv, Bulgaria, 
5University Pediatric Hosptal - Sofia, Department of Virology, Sofia, Bulgaria, 
6Department of Microbiology and Immunology, Medical University, Plovdiv, 
Plovdiv, Bulgaria
contact e-Mail address: kofinova@abv.bg
Introduction: Paediatric inflammatory bowel diseases (PIBD), comprising 
Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel dis-
ease unclassified (IBDU) are immune-mediated disorders characterized 
by dysregulated immune responses leading to tissue damaging inflam-
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conclusion: Increased endoscopic activity correlated negatively with TI mo-
tility, consistent with observations in adults. The motility score was quick to 
calculate and represents a potential novel biomarker of disease activity in 
the paediatric population that now needs prospective validation.
disclosure: Nothing to disclose 
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P0532 auTOPhagy Is Increased and assOcIaTed WITh POOr 
PrOgnOsIs In esOPhageaL squaMOus ceLL carcInOMa
Iserhard R.1,2, Pilar E.S.2,3, Callegari-Jacques S.M.4, Ferst P.5, 
Filippi-Chiela E.C.2
1Hospital Ana Nery, Gastroenterology, Santa Cruz do Sul, Brazil, 
2Universidade Federal do Rio Grande do Sul (UFRGS), Graduate Program 
Science in Gastroenteroloy and Hepathology, Faculty of Medicine, Porto 
Alegre, Brazil, 3Clinicas Hospital of Porto Alegre, Unidade de Pesquisa 
Laboratorial- Patologia Experimental Serviço de Pesquisa Experimental, 
Porto Alegre, Brazil, 4Universidade Federal do Rio Grande do Sul (UFRGS), 
Department of Statistics, Institute of Mathematics and Statistics, Porto 
Alegre, Brazil, 5Universidade Federal do Rio Grande do Sul (UFRGS), Faculty 
of Medicine, Porto Alegre, Brazil
contact e-Mail address: riserhard@outlook.com
Introduction: The cellular and molecular carcinogenesis of the esophageal 
squamous cell carcinoma (ESCC) involves alterations in cell growth, death 
and metabolism. Advances in basic tumor biology and prognosis biomark-
ers may contribute to the clinical management and the development of 
new therapeutic strategies to these tumors. Autophagy is a self-catabolic 
physiological mechanism involved in the degradation of aged or mal-
functional organelles and proteins. Molecularly, autophagy is mediated 
by the Atg family of proteins, which mediates the formation of a double-
membrane structure called autophagosome. Key markers in this process 
are Beclin-1(Atg6), which forms a protein complex to initiate the formation 
of autophagosome, and MAP1LC3(Atg8), that mediates the closure of au-
tophagosome.9,10 Autophagosome englobes cellular components marked 
to degradation by adaptor proteins such as Sequestosome 1 (SQSTM1 or 
p62). The autophagosome fuses with lysosomes to form the autolysosome 
where cell components are degraded. The products of degradation are 
then released through lysosomal permeases back to the cytoplasmic en-
vironment. The role of autophagy depends on the step of carcinogenesis 
and the tumour type. In different cancers, its promotion and progression 
involves the reactivation of autophagy, allowing the tumor cells to adapt to 
the metabolic stress associated with tumor growth. Disturbs in autophagy 
have been associated with carcinogenesis.
aims & Methods: We compared the levels of three autophagy markers, 
SQSTM1, MAP1LC3B and BECN1 in ESCC and non-neoplastic biopsy samples. 
Then we evaluated the influence of autophagy gene expression in the sur-
vival and staging of ESCC in TCGA database. We also used a Nuclear Morpho-
metric Analysis (NMA) to correlated nuclear morphometry with autophagy.
results: The three markers were significantly increased in ESCC samples in 
comparison to control. We proposed an Autophagic Index (AutoIndex), by 
adding the individual levels of the three proteins and found this a stronger 
indication of the autophagic status. AutoIndex displayed an even higher 
difference, between ESCC and control, than single autophagy markers. 
ESCC samples showed a reduction in nuclear area, which correlated nega-
tively with the increase of autophagy. Using the TCGA database we discov-
ered that high levels of MAP1LC3 A/B, SQSTM1, Atg4A and Atg12 expression 
were associated with a poor prognosis and advanced staging, suggesting 
that autophagy contributes to ESCC aggressiveness.
conclusion: We found that an increase of autophagy may be involved in 
the progression of normal esophageal epithelia to ESCC. The combination 
of autophagy markers (AutoIndex), instead of its single values, has a great 
potential to be used as a prognostic tool in the strategy to diagnose and 
treat the ESCC.
disclosure: Nothing to disclose 
mation. The treatment regimens for patients with IBD often involve im-
munosuppressive therapy and increase susceptibility to infections, many 
of which can be prevented by vaccinations. The aim of our study was to 
analyze the immunization status of children diagnosed with IBD and iden-
tify factors affecting the immunization coverage.
aims & Methods: We retrospectively reviewed the medical records of 
paediatric IBD patients treated in the Department of Gastroenterology 
and Hepatology at the University Paediatric Hospital “Prof. Ivan Mitev”, 
Sofia and the Department of Paediatrics at the University Hospital “Saint 
George”, Plovdiv for the period September 2013-September 2018. The im-
munization status of the enrolled patients was assessed as per the na-
tional immunization programme.
results: A total of 90 children (39 girls and 51 boys) were included in the fi-
nal analysis. The median age of the study participants was 15 years (range 
2-17 years), 52.2% (47/90) were with UC, 45.5% (41/90) with CD and 2.3% 
(2/90) with IBDU.
The overall immunization coverage with traditional vaccines (hepati-
tis B, tuberculosis, poliomyelitis, diphtheria, tetanus and pertussis, 1st 
dose measles, mumps and rubella) was very good. 28.8% (26/90) of the 
study participants had incomplete immunization course against measles, 
mumps and rubella. 95.5% (86/90) of them were non-immunized against 
Haemophilus influenzae type b disease and pneumococcal disease (Both 
vaccines were included in the Bulgarian childhood immunization schedule 
in 2010 and the vaccination rates are still low). 
Despite having a full course of hepatitis B vaccination in the infancy, 25.5% 
(23/90) of our patients had undetectable antibodies against hepatitis B. 
Only three girls had a human papillomavirus (HPV) vaccination. Child’s age 
was the main factor affecting the immunization coverage.
conclusion: The assessment of the immunization status at IBD diagnosis is 
a critical step in the treatment planning process. It is important to admin-
ister all necessary vaccinations as soon as posible before the initiation of 
an immunosuppressive therapy.
disclosure: Nothing to disclose 
P0529 quanTIfIed TerMInaL ILeaL MOTILITy durIng Mr 
enTerOgraPhy as a BIOMarker Of crOhn’s dIsease acTIvITy 
a PedIaTrIc POPuLaTIOn: a reTrOsPecTIve sTudy
Cococcioni L.1, Menys A.2, Kumar S.3, Palm L.4, Rampling D.4, Taylor S.5, 
Kiparissi F.6, Watson T.A.4
1Great Ormond Street Hospital, Gastroenterology, London, United Kingdom, 
2UCL, Division of Medicine, London, United Kingdom, 3UCL, London, 
United Kingdom, 4Great Ormond Street Hospital, London, United Kingdom, 
5University College London - Centre for Medical Imaging, University College 
London, Centre for Medical Imaging, London, United Kingdom, 6Great 
Ormond Street Hospital NHS Foundation Trust, Gastroenterology, London, 
United Kingdom
contact e-Mail address: lucia.cococcioni@gmail.com
Introduction: A relationship between small bowel motility and inflamma-
tory activity in Crohn’s Disease is now well described in adults against 
endoscopic and histopathological measures of activity. This retrospective 
study explores this relationship between terminal ileal (TI) motility in chil-
dren against an endoscopic endpoint.
aims & Methods: A review of Great Ormond Street Hospital paediatric 
imaging database was performed to identify subjects with good quality 
MRE studies and an endoscopic review ±3 months to determine an endo-
scopic score for disease activity (SES-CD score). 38 subjects were identified 
(median age 11, range 5 to 18) with dynamic ‘cine’ imaging through the 
terminal ileum. 
The dynamic imaging was processed, blind to any clinical data, with a 
previously validated motility assessment algorithm (GIQuant®, Motilent, 
London, UK). A consultant radiologist delineated the TI on each subject 
within 5 cm of the ileocecal valve and the motility score derived. 
The TI was used as a reproducible reference to enable comparison be-
tween subjects. The TI motility score was correlated against the SES-CD 
and the population split into ‘active’ and in-active groups based on SES-CD 
<2 = remission
results: The median TI motility was 0.2 (range 0.05 to 0.6) and the median 
SES-CD score was 9.5 (range 0 to 32). The correlation between the two 
measures was R = -0.45, P = 0.005. The median SES-CD active motility was 
0.17 (range 0.05 - 0.47) and inactive was 0.37 (range 0.2 - 0.6) and mean 
difference was 0.16, P = 0.006.
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P0535 WhOLe genOMe sequencIng anaLysIs Of 
gasTrOParesIs IdenTIfIes nOveL rIsk LOcI
Smieszek S.1, Carlin J.2, Birznieks G.2, Polymeropoulos M.2
1Vanda Pharmaceuticals, Genetics, Washington D.C., United States, 2Vanda 
Pharmaceuticals, Washington D.C., United States
contact e-Mail address: sandra.smieszek@vandapharma.com
Introduction: Gastroparesis is a disorder characterized by delayed gastric 
emptying of solid food in the absence of a mechanical obstruction of the 
stomach, resulting in the cardinal symptoms of early satiety, postprandial 
fullness, nausea, vomiting, belching and bloating. To ascertain the genetic 
risk factors for gastroparesis we conducted the first to date whole genome 
sequencing (WGS) study of gastroparesis cohort.
aims & Methods: We investigated the frequency and effect of rare loss-of-
function (LOF) variants in patients with idiopathic and diabetic gastropa-
resis enrolled in a clinical study, VLY686-2301. The dataset consisted of 119 
WGS samples.
results: Among rare LOF variants, we report an increased frequency 
of a frameshift mutation within Motilin Receptor (MLNR) gene, vari-
ant rs562138828. Motilin is a 22 amino acid peptide hormone expressed 
throughout the gastrointestinal (GI) tract. The protein encoded by this gene 
is a motilin receptor which is a member of the G-protein coupled receptor 
1 family. We have shown an increased frequency of a frameshift mutation 
with MAF 0.01 as compared 0.0009 AF in GNOMAD (p-value = 0.01) with 
Odds Ratio of 21.9. We detect 4/119 gastroparesis patients carry the variant 
of interest that results in p.Leu202ArgfsTer105. 
Noteworthy is the fact that the 4 cases were equally split among idiopathic 
and diabetic, so this possible GP risk factor appears to be agnostic as to 
condition. The finding may be of direct relevance to treatment as individu-
als with the identified mutation may respond differently to gastroparesis 
treatments especially those targeting MLNR. 
Among other rare LOF, we identified a case of CHD7 discussed in literature 
in gastro-related context and a case of CFTR duodenal stenosis patho-
genic variant. The CFTR variant has been seen in pancreatitis and is likely 
causative of Cystic Fibrosis Gut which is characterized by increased mu-
cous viscosity and development of intestinal inflammation, dysbiosis and 
dysmotility.
conclusion: Whole genome sequencing of gastroparesis patient samples 
showed enrichment for rare variants in the MTLR in cases compared with 
controls. The identified LOF variants within the region can serve as risk 
factor for disease as well as inform treatments, especially given the knowl-
edge of different response to treatment.
disclosure: Nothing to disclose 
P0536 The exPressIOn and BIOLOgIcaL funcTIOn Of 
derMaTOPOnTIn In cOLOrecTaL cancer
Wang Z.1, Zhu X.1, Wang J.2, Chen W.2, Yang J.1
1West China Hospital of Sichuan University, Gastroenterology, Chengdu, 
China, 2West China Hospital of Sichuan University, Chengdu, China
contact e-Mail address: 15828307126@163.com
Introduction: Colorectal cancer (CRC) is a complex disease caused by 
the interaction of environmental and genetic factors. due to the insidi-
ous symptoms of colorectal cancer, about 50% of patients with colorectal 
cancer have reached the advanced stage at the time of diagnosis, hence, 
missed the optimal time for surgical treatment and had a poor prognosis. 
Therefore, we need to explore new biomarkers for colorectal cancer and 
find a convenient and effective screening method to achieve the purpose of 
early diagnosis and treatment. Tumor microenvironment has become one 
of the hotspots of research. 
More and more studies have confirmed that the development of tumor is 
closely related to the extracellular matrix (ECM). some researches have 
shown that DPT is involved in the occurrence and development of many 
types of tumors, but there are no studies on the expression and regulatory 
mechanism of DPT in colorectal cancer.
aims & Methods: In this study, we aimed to investigate the expression of 
DPT in colorectal cancer and its effect on the growth, proliferation, mi-
gration and invasion of human colorectal cancer cell lines. 126 pairs of 
colorectal cancer tissues and corresponding adjacent normal tissues were 
selected from the west China hospital of Sichuan university. The expression 
level of DPT gene in tissue samples was detected by real-time quantita-
tive PCR, and the correlation between the expression level of DPT and the 
clinical pathological characteristics and prognosis of patients was further 
analyzed. In addition, colorectal cancer cell lines with stable overexpres-
sion of DPT gene was constructed and verified by real-time fluorescence 
quantitative PCR. After that, cck-8 and Transwell cell migration and inva-
sion experiments were used to detect the influence of overexpression of 
DPT gene on the growth, proliferation, migration and invasion ability of 
human colorectal cancer cells.
results: qRT-PCR showed that the expression of DPT mRNA in colorectal 
cancer tissues was significantly lower than that in adjacent normal tis-
sues. Patients with low DPT expression level were more likely to have low 
grade differentiation (P=0.040), poor TNM stage (P=0.004) and lymph 
node metastasis (P=0.025) than those patients with high DPT expression 
level. Kaplan-meier survival analysis found that the cumulative survival 
rate of colorectal cancer patients with higher DPT expression level was 
significantly better than those with lower DPT expression level (P=0.0224). 
Further Cox multivariate analysis showed that the expression level of DPT 
was an independent risk factor for the prognosis of patients with colorectal 
cancer (P=0.035).By comparing the expression levels of DPT mRNA in such 
human colorectal cancer cell lines: RKO, HCT15, HCT116 and LS174T, we se-
lected HCT15 and HCT116 to construct DPT overexpression and blank control 
cell lines.CCK-8 assay showed that overexpression DPT could significantly 
inhibit the proliferation of HCT15 and HCT116 cells. Further transwell migra-
tion and invasion assay showed that overexpression DPT could significantly 
inhibited the migration and invasion ability of HCT15 and HCT116 cells.
conclusion: The abnormal expression of DPT is related to the occurrence of 
colorectal cancer. DPT can be used as a potential molecular biomarker to 
predict the prognosis of colorectal cancer patients.
disclosure: Nothing to disclose 
P0537 evOLuTIOn Of gasTrIc hIsTOPaThOLOgIc LesIOns 
In auTOIMMune aTrOPhIc gasTrITIs
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Introduction: Autoimmune atrophic gastritis (AAG) is an organ-specific 
disease characterised by a wide clinical spectrum. AAG affects individuals 
of any age, causing atrophy of the corpus-fundus mucosa of the stomach, 
with vitamin B12 and iron malabsorption. The aim of this study was to in-
vestigate AAG-related histopathological lesions and their evolution during 
a prolonged follow-up.
aims & Methods: Between January 2007 and July 2018 we enrolled and 
followed-up all patients diagnosed with AAG at our Gastroenterology out-
patient clinic. For each patient we collected and analysed data from gastric 
biopsy specimens and AAG-specific laboratory investigations (anti-parietal 
cell antibody, gastrin, and serum chromogranin A level).
results: 1059 gastric biopsy samples from 307 patients with AAG (mean 
age 59±15 years, F:M 2,3:1 ratio) were analysed. Typical histopathological 
features were present in 282/307 patients. Of these, 15% were classified 
as early stage, 19% as florid stage, and 67% as end stage. Only 4% had 
a complicated disease at diagnosis (8 patients presented dysplasia and 4 
NETs). Intestinal and pseudopyloric metaplasia are increasingly evident in 
end stages (in early stage 20/41 have intestinal metaplasia and 14/20 have 
pseudopyloric metaplasia, whereas in end stage 138/175 have intestinal 
and 150/175 pseudopyloric metaplasia); enterochromaffin-like cells hyper-
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conclusion: · Crush cytology is a cost-effective diagnostic tool with high 
diagnostic accuracy, specificity, and sensitivity, and it provides early diag-
nosis, which is helpful in planning further management of gastrointestinal 
carcinoma cases.
disclosure: Nothing to disclose 
P0539 cd24 fOr earLy deTecTIOn and surveILLance Of 
cancer usIng a unIversaL sIMPLe BLOOd TesT
Massarwi S.1, Shapira S.2, Kazanov D.3, Asido S.4, Hay-Levy M.4, 
Matatov G.4, Mdah F.1, Leshno A.5, Shaked M.5, Galzan L.5, Arber N.6
1Tel Aviv Sourasky Medical Center and Tel Aviv University, Tel Aviv, Israel, 
2Tel Aviv Sourasky Medical Center, Laboratory of Molecular Biology, The 
Integrated Cancer Prevention Center, Tel Aviv, Israel, 3Integrated Cancer 
Prevention Center, Tel Aviv Medical Center, Tel Aviv, Israel, 4Tel Aviv Medical 
Center, Tel Aviv, Israel, 5Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 6Tel 
Aviv Medical Center, Gastro, Tel Aviv, Israel
contact e-Mail address: shiranshapira@gmail.com
Introduction: In 2018, the global cancer burden has risen to 18.1 million 
new cases with 9.6 million deaths. The ultimate cancer therapy is preven-
tion or at least early detection. There are many attempts to develop a blood 
test for early detection, but none is in clinical use. CD24, a mucin-like 
cell surface protein, is overexpressed in numerous human cancers. We 
have shown that a simple non-invasive blood test evaluating CD24 levels 
had good sensitivity and specificity for detecting colorectal adenomas and 
cancer in patients undergoing screening colonoscopy at an urban medical 
center.
aims & Methods: To develop a universal improved simple blood test that 
could reliably identify individuals with common cancer types through as-
sessment of the levels of CD24 on PBLs.
Blood samples were obtained from consecutive patients and healthy vol-
unteers. 1x106 leukocytes were stained using anti-CD11b-PerCp-Cy5.5 and 
anti-CD24-FITC and analyzed by flow cytometry. Percentage of positive 
cells was determined by subtracting the percentage of CD24 and CD11b-
positive cells (dual stain) from CD24-positive cells (single stain). Healthy 
subjects underwent a thorough evaluation at the ICPC. All cancers were 
verified histologically.
results: The suggested screening assay distinguished normal from pa-
tient subjects especially with breast, pancreas, lung and colorectal cancers 
as well as early stage of adenoma (table 1). Interestingly, the levels of 
CD24 drop back to near normal level following successful surgery/che-
motherapy. Furthermore, CD24 score, in normal individuals with family 
history of cancer, was higher than those without family history (11.7±7.1 and 
19.3±8.9%, respectively).
  healthy
healthy 
with 
f.h
healthy 
without 
f.h
all 
cancers Bladder Pancreas crc
colon 
adenoma stomach
CD24 score 17 ±8 20 ±8 14 ±7 38.3±11 39 ±13 35 ± 8 39 ± 7 33 ± 11 40 ± 8.5
Sensitivity       94% 100% 89% 100% 87% 100%
Specificity 84% 74% 95%            
NPV Vs.H 
F.H No F.H
     
94% 
93% 
96%
100%
98%
98%
99%
100%
98% 
96% 
97%
100%
[Table 1]
conclusion: 
1. CD24 expression in PBLs may serve as a universal blood test for the early 
detection of numerous cancers.
2. The first ever blood test to detect adenomas.
3. CD24 may serve as a novel predictive marker in cancer therapy. 
4. The test can identify family members that are at an increased risk for 
cancer. 
5. Obviously, the test has to be validated in a prospective multi-center 
study.
disclosure: Nothing to disclose 
plasia is more commonly linear in early stage (21/41) and micronodular in 
end stage (141/175). A progressive increase in gastrin level through stages 
(326±435 vs 832±761; p< 0.05) was noticed, whereas chromogranin A level 
is similar in all stages (196±249 vs 178±180; p=ns). Anti-parietal cell anti-
bodies were detected in 80% of patients. Data indicated that 34% of early 
stage disease evolves unfavourably within 5 years. Dysplasia showed a 
prevalence of 8% in 5 years and 11% in 10 years, whilst NET G1 5% and 7% 
in 5 and 10 years, respectively. Among patients with no histopathological 
features of AAG, 17/25 demonstrated autoantibodies against parietal cells 
and have been defined as potential AAG. At 24 months follow-up, 50% 
developed overt AAG, of which 2 patients lately evolved in end stage and 1 
progressed in NET after 11 years.
conclusion: We herein showed that in AAG natural history, histological 
lesions progress from early to end stage within 10 years in most patients. 
Irrespective of the stage, patients must undergo a surveillance endoscopic 
program. The presence of antibodies directed against parietal cells could 
be an indicator of pre-atrophic autoimmune gastritis.
disclosure: Nothing to disclose 
P0538 dO We sTILL need Of BIOPsy fOr dIagnOsIs Of 
gasTrOInTesTInaL MaLIgnancy? uTILITy Of crush cyTOLOgy 
In fasT dIagnOsIs Of gI MaLIgnancy
Desai P.N.1, Kabrawala M.V.2, Patel C.1, Mehta R.2, Nandwani S.2, Kalra P.2, 
Prajapati R.2, Patel N.2, Arora P.3
1Surat Institute of Digestive Sciences, Endoscopy, Surat, India, 2Surat Institute 
of Digestive Sciences, Gastroenterolgy, Surat, India, 3Surat Institute of 
Digestive Sciences, Pathology, Surat, India
contact e-Mail address: drp_desai@hotmail.com
Introduction: 
· Gastrointestinal malignancies are commonly encountered in medical 
practice, and endoscopic examination and biopsy are extremely important 
first diagnostic modalities. 
· Crush cytology of gastrointestinal malignancy is a simple, cheap, and 
readily available technique that increases diagnostic yield and expedites 
diagnostic workup of such cases. 
· Compared with biopsy, crush preparations require a minute amount of 
tissues and provide rapid diagnosis.Hence, the study was designed to ac-
cess the diagnostic performance of crush cytology.
aims & Methods: To see the efficacy of crush cytology ( smears prepared 
from biopsy material ) in obtaining rapid diagnosis of GI cancers
Method: 
· All cases of gastrointestinal malignancy of the esophagus, stomach, and 
colo-rectum, which underwent endoscopic examination from August 2018 
to March 2019, in SIDS Hospital and Research Centre, Gujarat, India, were 
included in the study. 
· The diagnosis on crush cytology stained with H-E stain andhistopatholog-
ical diagnosis based on paraffin-embedded H&E sections was compared. 
Diagnostic accuracy, sensitivity,
results: 
· A total of 197 cases of gastrointestinal malignancy were evaluated with 
endoscopy and crush cytology during this period. 
· There were 187 cases of histologically confirmed carcinomas 
· Rest 10 cases of polyps (n = 7), ulcers (n = 2) and stenosis (n = 1). 
· Crush smear cytology positively diagnosed 161 cases of carcinomas
· Male/female ratio - 2.6:1 and 
· Mean age - 60.3 years. 
· Incidence of carcinomas was highest in the seventh decade of life, with 
36.6% cases. 
· The most common site of carcinoma was Colorectal (57.8%) followed 
by esophagus (24.1%), stomach (13.9%), and ampulla of vater with 4.3% 
cases each. 
· The most common histological types of gastric and colorectal malignancy 
were well-differentiated adenocarcinoma (83.8% & 69.2%) and poorly-
differentiated adenocarcinoma (2.7% & 30.8%), respectively. 
· Squamous cell carcinoma (52.9%) was the most common malignancy of 
the esophagus. Crush smears were unable to provide definite diagnosis in 
26 cases because of the morphological characteristics- well-differentiation 
(61.5%), low cellularity (23.1%) and carcinoma in-situ (15.4%). 
· The sensitivity of crush cytology was 79.5%, with a specificity of 100%, 
positive predictive value 90.3%, and negative predictive value of 19.8%. 
· The diagnostic accuracy of crush cytology was 82.5%.
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P0540 MOuse OrganOId cuLTures are The nOveL MOdeL TO 
sTudy The esOPhageaL IOn TransPOrT MechanIsMs
Korsos M.M., Venglovecz V.
University of Szeged, Department of Pharmacology and Pharmacotherapy, 
Szeged, Hungary
contact e-Mail address: margaretakorsos@gmail.com
Introduction: Esophageal epithelial cells (EECs) protect the lower layers 
during esophageal reflux. One of the major components of the epithelial 
defensive mechanisms is the ion transport processes, however their role 
under pyhisiological and pathophysiological conditions is not completely 
clear. One of the reason for this is the lack of good experimental models on 
which the functional changes of EECs can be investigated. Therefore, our 
aim in this study was to generate esophageal organoid cultures (EOC) from 
epithelial tissue of mice and to characterize the presence of ion transport-
ers on these EOCs.
aims & Methods: EECs were isolated from three different mice strains (CD1, 
C75/Bl6 and FVB/N). The esophagus was removed and digested with dis-
pase (2 U/ml) for 30 min. After the digestion the epithelia was peeled from 
the submucosa and incubated with trypsin in order to obtain individual 
cells. Cells were then suspended in Matrigel for 10-14 days and media 
was changed in every second days. Changes in intracellular pH (pH
i
) was 
measured using microfluorometry and the pH-sensitive dye, BCECF-AM. 
For determining the resting pH
i
, the high K+/nigericin technique was used.
results: EOCs were succesfully generated from all three mouse strains. 
In each cases, organoids have a three-dimensional, approximately sphe-
roidal structure, growing in the extracellular matrix. Their maximum size 
was about 200 µm at the end of the second week, although differences in 
morphology and size have been observed between the mice strains. Us-
ing EOCs, generated from CD1 mice, we have determined the resting pH
i, 
and the buffering capacity of the cells. Microfluorometric measurement 
showed the presence of functionally active Na+/H+ exchanger (NHE) and 
Cl- /HCO
3
- (CBE) transporters on the EOCs.
conclusion: We have successfully set up the culturing of mice esophageal 
organoids and our preliminary results showed that EOCs express both al-
kalizing (NHE) and acidifying (CBE) transporters. We strongly belive that 
EOCs are a suitable, in vitro experimental model to study esophageal epi-
thelial function and can also be used to investigate the pathomechanism 
of reflux-induced esophageal diseases. This study was supported by the 
National Research, Development and Innovation Office (FK123982) and the 
National Research, Development and Innovation Office, by the Ministry of 
Human Capacities (EFOP 3.6.2-16-2017-00006).
disclosure: Nothing to disclose 
P0541 rOLe Of LeukaeMIa InhIBITOry facTOr (LIf) On The 
TuMOrIgenIc PrOPerTIes Of cancer sTeM ceLLs In gasTrIc 
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1University of Bordeaux / INSERM / U1053 BaRITOn, Department of Biology 
and Medicine, Bordeaux, France, 2University of Costa Rica, INISA School of 
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contact e-Mail address: lornella.seeneevassen@u-bordeaux.fr
Introduction: Cancer stem cells (CSCs), a small cell subpopulation having 
intrinsic chemo resistance mechanisms and expressing CD44 cell surface 
glycoprotein, have been characterised in gastric adenocarcinoma. The link 
between the Hippo/YAP/TEAD pathway, key regulator of organ size and 
tissue homeostasis, and CSC properties has recently been suggested in 
gastric adenocarcinoma. Recent studies have defined Leukaemia Inhibi-
tory Factor Receptor (LIFR) and its ligand Leukaemia inhibitory Factor (LIF) 
as being upstream regulators of the Hippo pathway and LIF/LIFR signalling 
as having an anti-metastatic role in breast cancer cells.
aims & Methods: Consequently, this study aimed to determine the effect of 
LIF supplementation on the YAP/TEAD pathway and its impact on CSC phe-
notype and properties in gastric adenocarcinoma. AGS and MKN45 gastric 
cancer cell lines as well as patients’ derived gastric adenocarcinoma cells 
were used. The expression of Hippo/YAP/TEAD pathway related genes and 
of CSC markers was assessed by RTqPCR, western blot and immunofluores-
cence analysis. YAP/TEAD transcriptional activity was evaluated by TEAD-
luciferase reporter assay and proliferation assays as well as tumorsphere 
assays were carried out in vitro to evaluate CSC functional properties.
results: Results demonstrate that LIF supplementation represses the YAP/
TEAD pathway through a decreased YAP translocation to the nucleus and 
decreased expression of YAP/TEAD target genes. In addition, LIF decreases 
proliferation, tumorsphere initiation capacity and expression of gastric CSC 
markers in gastric adenocarcinoma cells.
conclusion: Our results indicate that LIF represses the YAP/TEAD pathway 
and presents anti-tumorigenic effects on gastric adenocarcinoma cells. 
Whether the effect of LIF on CSC properties passes through the YAP/TEAD 
pathway repression needs to be further investigated. This could in fine lead 
to the development of targeted strategies against CSCs to help decrease the 
number of relapse cases and bad prognosis in gastric cancer.
disclosure: Nothing to disclose 
P0542 WIThdraWn
P0543 eLafIn Is a MuLTIfaceTed PrOTeIn PrOTecTIng guT 
ePITheLIaL BarrIer frOM InfLaMMaTIOn
Jaeger M.-C.1, Guiraud L.1, Rolland-Fourcade C.1, Rolland C.1, Belot A.1, 
Sebbag M.1, Bermudez-Humaran L.2, Langella P.3, Vergnolle N.4,  
Deraison C.1
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Introduction: In the gastrointestinal tract, proteolytic activity is tightly reg-
ulated to prevent inappropriate and potentially harmful proteolysis. In IBD 
this regulation is broken and our recent work has demonstrated that elas-
tolytic activity is significantly increased in colonic epithelium from IBD pa-
tients. We have shown that (i) the expression of the only elastase released 
by epithelial cells ELA2 is up-regulated; and (ii) the selective elastase in-
hibitor ELAFIN is severely down regulated in colonic epithelium from IBD 
patients. We showed that oral treatments with ELAFIN-expressing L. Lactis 
bacteria restored proteolytic balance in the inflamed gut and was protec-
tive against acute and chronic colitis.
ELAFIN is a low-molecular weight molecule (10-kDa), which specifically 
inhibits elastases. At N-terminal terminus, a cationic helix showed anti-
microbial activities and could interact with phospholipids. Moreover ELA-
FIN is also able to inhibit NFkB and AP-1 activation but this domain is 
not localized on protein. Therefore, several mechanisms of action are thus 
possible to explain ELAFIN’s protective property, either from the extracel-
lular or the intracellular compartment.
aims & Methods: If ELAFIN-recombinant L. lactis has to be considered as 
a possible treatment for IBD in human, there is an absolute need to de-
fine the mechanisms by which ELAFIN delivery protects against intestinal 
inflammation. 
Because ELAFIN has demonstrated several biological properties, we gen-
erated and expressed in LAB ELAFIN’s mutants allowing investigation the 
biological properties of ELAFIN individually. To decipher the mechanisms 
by which ELAFIN is protective against intestinal inflammatory insult, dif-
ferent forms of ELAFIN-recombinant LAB were co-culture with thapsigar-
gin (10mg/ml) and ELAFIN (107 CFU/well). After 6H, cells were additionally 
exposed to gentamicin (100 mg/ml) to limit bacterial development. The 
barrier function was measured using FITC-dextran passage through the 
epithelial layer. The elastolytic activity and CXCL8 release were quantified 
from the culture media. Expression of inflammatory mediators was quanti-
fied by qPCR.
results: Addition of thapsigargin for 24H on Caco2 cells induced ER-stress 
and disruption of elastolytic balance. ELAFIN expression was decreased 
with up-regulation of ELA2, leading to increase of elastolytic activity in 
medium, disclosed in IBD patients. Concomitantly, barrier function was 
reduced, and expression of CXCL8, CXCL10 and hBD2 was increased. Co-
culture with ELAFIN expressing-LAB normalized all these parameters con-
firming anti-inflammatory properties of ELAFIN. 
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P0545 a PrOsPecTIve sTudy Of heMOsTasIs radIOTheraPy 
fOr InOPeraBLe gasTrIc cancer
Yasuda T.1, Tanaka O.2, Yasuda Y.1, Omatsu T.1, Nagata Y.3, Makita C.4, 
Matsuo M.5, Yagi N.1
1Asahi University Hospital, Gastroenterology, Gifu, Japan, 2Asahi University 
Hospital, Department of Radiation Oncology, Gifu, Japan, 3Hiroshima 
University Hospital, Department of Radiation Oncology, Hiroshima, Japan, 
4Gifu Prefectural General Medical Center, Department of Radiation Oncology, 
Gifu, Japan, 5Gifu University Hospital, Department of Radiology, Gifu, Japan
contact e-Mail address: everyday.enjoy29@gmail.com
Introduction: The first choice of treatment of gastric cancer is surgery, and 
adjuvant chemotherapy is performed in advanced stage. External beam 
radiotherapy (RT) alone is an effective and well tolerated modality in the 
local palliation of gastric cancer, with palliation lasting the majority of pa-
tients’ lives. Endoscopic hemostasis techniques for gastric cancer, the re-
bleeding hemostatic response rate is high. Treatment for the inoperable 
progressive stomach cancer includes hemostasis RT. Effectiveness of RT is 
well known. Tey et al. reported the review of palliative RT for gastric cancer 
of 7 researches. However, their analyses were all retrospective study, there 
were no prospective study of hemostasis RT in our best knowledge. From 
those results, we conducted prospective study.
aims & Methods: A total of 28 patients with gastric cancer with bleeding 
was enrolled. The initial dose was 20 Gy / 5 fractions for all stomach. The 
salvage dose was 15 Gy / 5 fractions for partial stomach. When hemoglobin 
level stabilized by blood test within 2 weeks after irradiation, we judged a 
hemostatic effect was achieved. When re-bleeding was found, the patients 
selected whether to take re-irradiation or not.
results: The response ratio of initial RT was 85% (22 / 26 patients). Six 
patients underwent re-irradiation, and all of them responded (100%). The 
median OS of all patients was 52 days. The median OS of non re-irradia-
tion (one-time) group and re-irradiation group were 54 days and 36 days 
without statistically significant. The adverse events were not occurred 3 or 
more in all patients.
conclusion: The salvage RT followed by initial RT is effective to reduce ad-
verse event. The OS was same between one-time irradiation and re-irra-
diation group. No grade 3 or more AEs was occurred. This RT is completed 
only 5 days and re-irradiation option is favorable to the patients. The range 
of effective hemostatic time was wide and no predictive factors was found 
in our prospective study. It might be necessary to determinate ideal dose 
and fraction number of initial irradiation, preferably less than 20 Gy.
references: Tey J, Soon YY, Koh WY, et al. Palliative radiotherapy for gastric 
cancer: a systematic review and meta-analysis. Oncotarget. 2017;8:25797-
25805
disclosure: Nothing to disclose 
P0546 Over-The-scOPe cLIP as fIrsT-LIne TheraPy In 
The ManageMenT Of hIgh-rIsk BLeedIng PePTIc uLcers: 
a case-MaTch cOnTrOL sTudy
Robles-Medranda C., Alcivar-Vasquez J., Oleas R., Baquerizo-Burgos J., 
Olmos J.I., Rubio-Cordova M., Puga-Tejada M., Pitanga-Lukashok H.
Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Gastroenterology 
and Endoscopy Division, Guayaquil, Ecuador
contact e-Mail address: robertoleas@gmail.com
Introduction: Nonvariceal upper gastrointestinal (GI) bleeding have an 
associated morbidity and mortality. Through-the-scope (TTS) hemostatic 
clips limitations are difficult of clip application during active bleeding, 
use in ulcers with a fibrotic base, or difficult-to-access because anatomic 
locations or large size. The over-the-scope clip (OTSC) is an atraumatic, 
large-size clipping device, with a high-pressure closure for larger a deeper 
ulcers.
aims & Methods: aim: to evaluate the efficacy and safety of OTSC as first-
line therapy in patients with high-risk (HR) bleeding ulcers compared to 
combined therapy (TTS clip and adrenaline injection). 
Methods: A retrospective analysis of a prospectively collected data in con-
secutive patients who presented with HR ulcer GI-bleeding between May-
2014 and September 2018. High risk upper GI bleeding were considered as 
those ulcers located in a major arterial territory, if the lesion had an endo-
scopically visible large-caliber artery (>2 mm), if there was a fibrotic ulcer 
with high-risk endoscopic stigmata (Forrest classification types I and II). 
The primary endpoint was the incidence of rebleeding or perforation with-
Neutralization of a-helix (mutant K44D/K50G) did not modify ELAFIN’s 
properties. However, disruption of protease inhibitory function (mutant 
A62G/M63G) was not able to modify permeability and inflammatory phe-
notype induced by exposure of intestinal epithelial cells to thapsigagin, 
showing that anti-inflammatory activity of ELAFIN was based on the con-
trol of elastase activity released by epithelial cells.
Surprisingly, ELAFIN immunostaining revealed the exogenous protein in 
the epithelial cells, in the nucleus. The ELAFIN’s transport was depen-
dent to its elastase inhibitory function. We showed that epithelial cells 
expressed LRP1 (LDL-related receptor 1) which is known to internalize com-
plexes of proteases and proteases inhibitors.
conclusion: This suggests that ELAFIN could act as anti-inflammatory 
molecule based on multifactorial mechanisms from outside to inside the 
epithelial cells.
disclosure: Nothing to disclose 
P0544 PrOPhyLacTIc TranscaTheTer angIOgraPhIc 
eMBOLIzaTIOn reduces The rIsk Of reBLeedIng In PaTIenTs 
WITh fOrresT IIa uLcer: a reTrOsPecTIve sTudy
Lan T., Tong H., Wu H., Tang C.
West China Hospital, Sichuan University, Department of Gastroenterology, 
Chengdu, China
contact e-Mail address: lthust@outlook.com
Introduction: About 20% of Forrest IIa ulcers rebleed even after endo-
scopic hemostasis. Prophylactic transcatheter angiographic embolization 
(p-TAE) might be a feasible way to reduce rebleeding, but its efficacy is 
controversial.
aims & Methods: This study aimed to evaluate the clinical efficacy of p-
TAE to prevent rebleeding and to assess the risk factors for rebleeding 
in the patients with Forrest IIa ulcers after endoscopic hemostasis. The 
patients with Forrest IIa ulcer underwent endoscopic hemostasis in West 
China Hospital during May 2009 and May 2018 were retrospectively re-
viewed. The patients were assigned to endoscopy (E) group and endoscopy 
plus p-TAE (E+p-TAE) group according to whether they received p-TAE after 
endoscopic hemostasis. Demography, data of laboratory tests, medication 
intake history, amount of fluid and red cell suspension infusion, time dura-
tion between admission and initial endoscopic hemostasis, morphologi-
cal characteristics of ulcers and non-bleeding visible vessels, Glasgow-
Blatchford score, modalities and sessions of endoscopy hemostasis, re-
bleeding rate after endoscopic hemostasis, rate of salvage hemostasis and 
intensive care unit transfer, hospital stay and mortality were collected for 
comparison of baseline characteristics, clinical efficacy and risk analysis 
of rebleeding.
results: Most of the baseline data in the two groups except for the protrud-
ed blood vessel and fluid infusion pre-procedure were comparable. The 
rebleeding occurrence of E+p-TAE group (n = 27) were significantly lower 
than that of E group (n = 86), 3.7% vs 25.6%, P =.014. Survival analysis 
also showed lower rebleeding risk of E+p-TAE group, P = .016. Protruded 
vessel in Forrest IIa ulcer (OR: 5.316, 95% CI: 1.538 - 18.374, P = .008) and 
no p-TAE intervention (OR: 20.932, 95% CI: 2.067 - 211.984, P = .010) were 
identified as independent risk factors for rebleeding of Forrest IIa ulcers. 
The rebleeding occurrence of protruded vessel within the first week after 
initial endoscopic hemostasis was significantly decreased by E+p-TAE in-
tervention (E vs E+p-TAE, 18.6% vs 0%, 
P = .011).
conclusion: No p-TAE after endoscopic hemostasis and protruded visible 
vessels were the independent risk factors for rebleeding of the patients 
with Forrest IIa ulcer. p-TAE following endoscopic hemostasis may effec-
tively prevent rebleeding for those patients partly through compensation 
for the inadequate endoscopic hemostasis due to the technical heteroge-
neity of endoscopists.
disclosure: Nothing to disclose 
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in 30 days of index endoscopy. Patients were excluded if they had bleed-
ing caused by varices, received OTSC for fistula or tissue defect closure or 
if the bleeding did not meet the criteria for HR ulcer bleeding. Baseline 
characteristics were confirmed through the corresponding hypothesis test. 
Analysis was performed on R v3.4.3.
results: 95 patients were included, 46 received an OTSC as primary therapy 
for HR bleeding ulcers and 49 matched cases received TTS hemostatic clips 
in combination with epinephrine injection (combined therapy). The mean 
age was 60.9 ± 19.1, 32.6% female. Most lesions were gastric ulcers (71.6%). 
The median number of OTSC used was 1 (1 - 3), whereas for combined thera-
py was 2 (1 - 8) TTS clips. Table 1 summarizes baseline characteristics. 
Six cases of rebleeding (6.3%) were observed: two in the OTSC group and 
four in the combined therapy group (p=0.444). Two cases of the OTSC 
group (4.3%) had rebleeding after 48 hours of the procedure; meanwhile, 
one case of rebleeding was observed in the combined therapy group at 
the same period and was treated with APC (p=0.520). Three cases in the 
combined therapy group had rebleeding in less than 48 hours after the 
procedure (p=0.088), two treated with an OTSC and one with APC. The 
median procedure time was 11 (10-15) mins for OTSC and 20 (15-40) for 
combined therapy (p< .001) (table 1).
  OTsc (n=46) combined therapy (n=49) p-value 
Age, mean ± SD 60.9 ± 19.1 62 ± 17.4 59.8 ± 20.6 <0.001
Female, n (%) 31/95 (32.6%) 16/46 (34.8%) 15/49 (30.6%) 0.664
No anticoagulation 
therapy, n (%)
72/95 (75.7%) 34/46 (73.9%) 36/49 (76.5%) 0.140
NSAID therapy, n (%) 6/95 (6.3%) 3/46 (6.5%) 3/49 (6.1%) 0.886
Previous transfusion, 
n (%)
15/95 (15.8%) 9/46 (19.5%) 6/49 (12.2%) 0.294
Lesion detected, gastric 
ulcer/duodenal ulcer
68/27 32/14 36/13 0.583
Forrest classification 
of Upper GI Bleeding, 
IA-B / IIA-C
15/80 11/35 4/45 0.009
[Table 1. Baseline characteristics of included patients.]
conclusion: The OTSC as first line single therapy is as safety and effective as 
combined therapy for the management of HR bleeding peptic ulcers; im-
proving the procedure time statistically significant. The OTSC could become 
in the future as a first line-therapy for HR bleeding peptic ulcers.
disclosure: Nothing to disclose 
P0547 The IncIdence Of MajOr BLeedIng evenT 
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Introduction: Endoscopic balloon dilation (EBD) has been established as 
an effective treatment for gastrointestinal stricture. However, bleeding and 
perforation are main complications associated with EBD, and EBD is clas-
sified as a high-risk endoscopic procedure in the guidelines concerning 
the endoscopy in patients on antithrombotics from European Society of 
Gastrointestinal Endoscopy. Although the incidence of these complications 
has been previously reported based on small studies, there are still few 
data to judge EBD as a high-risk procedure.
aims & Methods: The aim of this study was to investigate the incidence of 
bleeding and perforation after EBD and evaluate whether antithrombotic 
agents increases bleeding events through a large-scale study. This study 
was a retrospective multicenter study conducted in six hospitals across 
Japan. From April 2010 to March 2015, the patients who underwent EBD 
for upper gastrointestinal stricture were enrolled. Medical records and 
endoscopic findings were reviewed, and the primary endpoints were the 
incidence of major bleeding event and perforation after EBD.
results: 878 patients with upper gastrointestinal stricture were analyzed. 
The causes of stricture were as follows: surgery 417, endoscopic resection 
280, chemo-radiotherapy 130, tumor 18, and benign disease 33. A total of 
4884 procedures of EBD were performed in 878 patients and the mean 
number of EBD session per patient was 5.6 times. The incidence of major 
bleeding events which required urgent endoscopic hemostasis and hos-
pitalization was 0.18% per total EBD session (9/4884). Endoscopic hemo-
stasis was successfully achieved in all the bleeding events and 3 patients 
required blood transfusion. 670 EBD sessions were performed under an-
tithrombotic therapy. The major bleeding rate in the antithrombotic-users 
was higher than that in the non-users (0.75% vs 0.09%, P=0.004). On the 
other hand, there was no significant difference between the continued-use 
group and the cessation group (1.01% vs 0.71%, P=0.657, respectively). The 
incidence of perforation was 0.43% (21/4884). As for the management of 
perforation, 17 patients could recover by conservative treatment including 
endoscopic closure, and 4 patients received urgent surgery.
conclusion: This retrospective study with a large sample size demonstrated 
that EBD could safely be performed even under continued use of anti-
thrombotic agents.
disclosure: Nothing to disclose 
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Introduction: During the past decade, potential risk and prognostic factors 
for upper gastrointestinal bleeding (UGIB) have been evolved in developed 
countries in particular with an increased use of direct oral anticoagulants 
in thromboembolic diseases and a better management of UGIB by gas-
troenterologists with the use of new effective endoscopic haemostatic de-
vices. As few studies investigated prognostic factors associated with UGIB 
in this context, we conducted such a study to better understand the role of 
new determinants of UGIB on its outcomes.
aims & Methods: From November 2017 to October 2018, we carried out a 
prospective study in 46 public hospitals. We enrolled patients with symp-
toms of UGIB and subsequently confirmed UGIB by endoscopy (those who 
were admitted to the emergency medicine departments (EDs) with UGIB 
symptoms and those who were hospitalised for other reasons than UGIB). 
They were followed up at least for six weeks. Patients’ characteristics, en-
doscopic and follow-up data were collected and analysed. Univariable and 
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analyses, and propensity score matching for 19 baseline characteristics, 
which are known as ischemic or bleeding risks reported before.
results: ESDs are increasingly being performed without interrupting anti-
platelet drugs in our hospital; 13% in 2007, 64% in 2017. Bleeding event 
rate (3rd look endoscopy and blood transfusion) was significantly higher in 
the continued group than in the discontinued group (38.5% v.s 23.8% p = 
0.015 and 12.1% v.s 2.4% p = 0.004). 
However, there are no significant differences about ischemic event rate 
(urgent ECG and CAG) between two groups. Patients in the anti-platelets 
continued group were observed to have older age, higher prevalence of 
hypertension, dyslipidemia, diabetes, ischemic heart disease, heart fail-
ure, and cerebral infarction, lower serum albumin revel, and lower he-
moglobin revel.
Comparison of propensity score matched groups (n=91, each) also revealed 
that continuation of anti-platelets during ESD was associated with higher 
bleeding risk (38.5% v.s. 24.2% p = 0.055 and 12.1% v.s. 3.3% p = 0.048), 
but it was not associated with lower ischemic events.
  anti-platelets discontinued group (n=91)
anti-platelets 
continued group (n=91) p-value
3rd look(%) 22(24.2%) 35(38.5%) 0.055
blood transfusion(%) 3(3.3%) 11(12.1%) 0.048
urgent ECG(%) 6(6.6%) 7(7%) NS
urgent CAG(%) 1(1.1%) 0(0%) NS
[Bleeding and ischemic events: comparison of propensity score matched 
groups]
conclusion: This study reveals that continued use of anti-platelets during 
ESD does not decrease cardiac ischemic events, but may increases gastro-
intestinal bleeding events. Gastroenterologists and cardiologists need to 
discuss more carefully in judging the continuity of antiplatelet drugs in the 
ESD perioperative period, and continued use of anti-platelets may have to 
be limited to the patients with higher risk of ischemia in the future.
references: (1)Turk J Gastroenterol. 2017 Sep;28(5):329-336. (2)Ann Gastro-
enterol. 2018 May-Jun;31(3):344-349.
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Introduction: Endoscopic procedure is performed for active duodenal ulcer 
hemorrhage. But if endoscopic hemostasis fails, transarterial embolization 
(TAE) or operation is considered. The risk factors for difficulty of endo-
scopic hemostasis are poorly documented, whereas Glasgow Blatchford 
Score (GBS) has been attracting attention for predicting intervention for 
upper gastrointestinal hemorrhage and some studies have described the 
usefulness.
aims & Methods: We performed a retrospective analysis involving patients 
with hemorrhage of benign duodenal ulcer who had been admitted to our 
hospital and had endoscopic therapy from April 2005 to December 2017. 
We compared each GBS in the groups in which only endoscopic proce-
dure were performed (endoscopy group) and interventional radiology was 
additionally performed (TAE group), having made statistical analysis for 
items of GBS.
results: A total of 154 patients were included in this study. 141 patients 
(91.6%) of them were success in only endoscopic procedure, 12 patients 
(7.8%) were underwent TAE additionally, and 1 patient (0.6%) was under-
went operation. The mean GBS (±SD) in endoscopy group was 11.1±3.6, and 
the mean GBS in TAE group was 13.8±2.1. The GBS in TAE group was statis-
tically higher than in endoscopic group (p=0.0087), and the area under the 
receiver operating characteristic curve (AUROC) was 0.74 (95% confidence 
interval 0.63 to 0.86). A threshold GBS of 12 or more was best at predicting 
TAE, with sensitivity of 54.0%, specificity of 91.7%. Making an analysis of 
each item of GBS, haemoglobin was statistically lower (p=0.0076) in TAE 
multivariable analyses using logistic regression models were performed 
to identify predictors of rebleeding and those of in-hospital and six-week 
mortality.
results: Of the 2498 enrolled patients, 74.6% were diagnosed with UGIB 
after admission to EDs and 25.4% during hospitalisation. Median age of 
patients was 68.5 years +/- 16.3, 67.1% were men and 20.9% had a cirrho-
sis. Median Charlson score was 2 (IQR: 1-4), median Blatchford score was 
11 (IQR: 7-13), and median Rockall score was 5 (IQR: 3-6). Among included 
patients, 19% had an oral anticoagulant medication: 43.8% of them with 
direct oral anticoagulants. Endoscopy was performed within 24 hours in 
84.2% of patients and with general anaesthesia in 31%. An endoscopic 
assistant was present in most cases (91.5%). 
Main causes of bleeding were: 1) peptic ulcers and gastroduodenal ero-
sions (44.9%), 2) lesions related to portal hypertension (18.8%) and 3) 
oesophagitis (11.5%). Active bleeding was observed in 24.5% of patients, 
mainly associated with peptic ulcers and portal hypertensive lesions, and 
was endoscopically treated in 86.7% and 79.6% of the cases, respectively. 
During hospitalisation, 10.5% of patients experienced rebleeding and 
8.6% of them died. In-hospital mortality rate was lower among pa-
tients from EDs than those who were hospitalised (5.8% vs 16.8%, p< 
0.0001). Predictors associated with rebleeding were in-hospital bleeding 
(OR=1.36; 95%CI: 1.03-1.79), Blatchford score>11 (OR=1.45; 95%CI: 1.08-
1.94) and active bleeding (OR=1.94; 95%CI: 1.48-2.55). 
The six-week mortality rate was 12.0%. It was significantly lower in the 
EDs group than the in-hospital group (9.1% vs 22.2%; p< 0.0001). Predic-
tors associated with six week mortality were initial transfusion (OR=1.53; 
95%CI: 1.04-2.27), Charlson score>4 (OR=1.80; 95%CI: 1.31-2.48), Rock-
all score>5 (OR=1.97; 95%CI: 1.39-2.80), in-hospital bleeding (OR=2.44; 
95%CI: 1.75-3.40), and rebleeding (OR=2.59; 95%CI: 1.85-3.64).
conclusion: This study showed an improved management of UGIB com-
pared to previous studies. Despite this improvement, mortality rate re-
mained high at six-week follow-up in particular for patients who experi-
enced UGIB while they were hospitalised for other reasons than UGIB. This 
can be explained by the severity of underlying disease for which patients 
were initially hospitalised. Strong predictors of mortality were in-hospital 
bleeding and rebleeding without major role of the anticoagulation thera-
py. This study confirmed that previously known predictors were still valid in 
the recent advancement in the management of UGIB patients.
disclosure: Nothing to disclose 
P0549 cOnTInued use Of anTI-PLaTeLeTs durIng endOscOPIc 
suBMucOsaL dIssecTIOn (esd) dOes nOT decrease cardIac 
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evenTs
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Introduction: Anti-platelets drugs are one of the most important drugs in 
this aging society, widely utilizing for cardiovascular and cerebrovascular 
diseases. Over the past decades, it has been common to discontinue an-
tiplatelet drugs prior to gastrointestinal endoscopy, with emphasis on the 
prevention of bleeding. In recent years, non-interruption of anti-platelets 
peri-operatively is recommended in guidelines for endoscopic submucosal 
dissection (ESD) as a treatment for early gastric cancer (EGC). Although 
there have been several reports(1,2), the art of balancing between isch-
emia and bleeding during ESD remains unclear.
aims & Methods: In this study, we investigated the association between the 
aggressive continuation of anti-platelets in recent years and both cardiac 
ischemic and bleeding events after ESD in the real world clinical settings.
We conducted a retrospective cohort study comprising 1383 consecutive 
patients, who were hospitalized for ESD at the Department of Gastroenter-
ology in our hospital between January 2007 and July 2018. Among them, 
patients regularly taking anti-platelet drugs before hospitalizations (n = 
255) were extracted and divided into two groups: anti-platelets discontin-
ued group (n = 164) and continued group (n = 91). Primary outcomes were 
30-days cardiac ischemic and gastrointestinal bleeding events. We defined 
3rd look endoscopy and blood transfusion as the bleeding events, and ur-
gent electrocardiogram (ECG) and coronary angiography (CAG) as the isch-
emic events, respectively. We performed bivariate analysis, multivariate 
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group. The other items (blood urea, systolic blood pressure, pulse, me-
laena, syncope, hepatic disease, and cardiac failure) were no significant 
difference between two groups.
conclusion: The GBS is useful to predict need for TAE for active duodenal 
ulcer hemorrhage. This study may suggest that GBS≥12 is high risk of en-
doscopic hemostasis fails and TAE performed.
disclosure: Nothing to disclose 
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Introduction: Selective serotonin reuptake inhibitors (SSRIs) are currently 
recommended as the first line treatment for depression. Though many 
studies have evaluated the risk of upper gastrointestinal bleeding (UGIB) 
associated with SSRI use, the potential confounding effects of H. pylori (HP) 
and other medications have not been addressed.
aims & Methods: This was a propensity score matched cohort study to 
determine the risk of UGIB in HP infected patients who used SSRI after 
HP eradication therapy. HP-infected patients who had received a course 
of clarithromycin-containing triple therapy between 2003 and 2012 were 
identified from the territory-wide electronic health database. We excluded 
patients who failed HP eradication therapy and those who had used SSRI 
before the study start date. The follow-up period commenced from 60 days 
after the HP therapy until the occurrence of UGIB, death or the end of the 
study. The primary outcome was hospitalization for UGIB. To address for 
potential immortal time bias, time-dependent Cox regression model was 
used to compute the hazards ratios (HR) and 95% confidence intervals 
(CI) of UGIB risk, in which follow-up time was split into 1-month intervals. 
Covariates included baseline characteristics, medical conditions and con-
current medications. As SSRIs and other medication uses could change 
over time, drug usage was defined as at least one day use in each interval. 
To adjust for the baseline difference between SSRI users and non-users, 
propensity score (PS) matching analysis with a ratio of 1:2 was performed, 
in which concurrent medications uses in the first 1-month interval were 
used to calculate the propensity scores. Multivariate time-dependent Cox 
regression model was performed as sensitivity analysis.
results: 61,264 patients who had received HP eradication therapy were 
analyzed, including 3,358 SSRI users and 57,906 non-users. The median 
follow-up duration was 7.7 (interquartile range, 5.3-10.4) years. The overall 
crude incidence rate of hospitalization for UGIB was 3.98 (95% CI 3.80-
4.16) per 1000 person-year. In the time-dependent Cox model with 1:2 PS 
matching, SSRI was associated with higher risk of hospitalization for UGIB 
than non-users (HR1.95, 95% CI 1.41-2.70). This result was consistent in 
multivariate analysis (HR 1.81, 95% CI 1.34-2.45). After stratifying by age, 
the increased risk of SSRI was only significant among older patients (> 
50 years old). Apart from SSRIs, other independent risk factors of UGIB 
includes older age, male sex, history of UGIB or ulcer, presence of co-
morbid illnesses (hypertension, diabetes, cirrhosis and renal disease) and 
concomitant use of aspirin, other antiplatelet drugs, non-steroidal anti-
inflammatory drugs (NSAIDs), anticoagulants and corticosteroids (Table). 
In contrast, gastroprotective agents was associated with lower risk of UGIB 
(HR 0.54, 95% CI 0.47-0.63).
Variables HR (95% CI)
Age 1.06 (1.05-1.06)
Male sex 1.31 (1.19-1.44)
History of UGIB or ulcer 3.21 (2.91-3.55)
Gastroprotective agents 0.54 (0.47-0.63)
Aspirin 1.95 (1.67-2.28)
Other antiplatelets 2.04 (1.63-2.54)
NSAIDs 1.80 (1.46-2.22)
Anticoagulants 2.36 (1.76-3.16)
[Hazard ratios for UGIB]
conclusion: SSRI users have a higher risk of hospitalization for non-variceal 
UGIB than non-users even after treatment for Helicobacter pylori, particu-
larly among older patients, those with history of UGIB, comorbid illnesses 
and concurrent use of other medications that increased the bleeding risk.
disclosure: Nothing to disclose 
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Introduction: Antiplatelet and anticoagulant are widely used in various 
indications. Bleeding complications usually raise physicians’ concern; es-
pecially gastrointestinal bleeding (GIB). Proton-pump inhibitors (PPI) have 
been co-prescribed with the aforementioned drugs. However, there were 
evidence indicated that PPI might increase the risk of bleeding complica-
tions when they were co-administered with clopidrogrel or warfarin, as it 
synergist metabolisms of these drugs.
aims & Methods: To study bleeding events in patient receiving antiplatelet 
and/or anticoagulant, both GIB and extra-gastrointestinal bleeding (EGIB) 
compared between PPI status (with/without PPI).
Methods: This is a nested case-control study. We recruited subjected who 
developed bleeding as defined by new onset of anemia or any visible 
bleeding after taking antiplatelet/anticoagulant. Data were retrospectively 
collected from medical records of Siriraj Hospital from January 2013 to July 
2014. Demographic data, co-morbidities, bleeding outcomes were record-
ed. Events of both GIB and EGIB between 2 groups (with/without PPI) were 
compared. Descriptive data were presented in mean±SD and comparative 
data were analyzed using chi-square. Multivariate analysis was also con-
ducted when appropriate.
results: 1146 cases (mean age 71.89 ± 13.3 years) met the inclusion cri-
teria. PPI was prescribed in only 495 cases. Most of the patients (99.7%) 
had multiple comorbid diseases. Hypertension (83.7%), Diabetic Mellitus 
(51.6%) and Chronic Kidney Disease (42.84%) were the 3 most common. 
392 patients were receiving anticoagulant. Minor bleeding (the patient who 
developed new onset of anemia but no visualized bleeding) were found in 
681 cases (59.42%) while major bleeding (anemia with visualized bleed-
ing) 465 cases (40.6%). In major bleeders, 553 cases (48.25%) had UGIB, 
202 cases (17.6%) had LGIB and 100 cases (8.72%) developed EGIB (56 
patients had internal organ bleeding, 24 patients had skin and soft tissue 
bleeding and 20 patients had intracranial hemorrhage). In patients with 
GIB, PPI group had less UGIB [43.23% vs 52.38% OR = 0.692 (95%CI 0.547-
0.876) P= 0.002 in antiplatelet and/or anticoagulant takers, and 44.17% vs 
57.97% OR= 0.573 (95%CI 0.422-0.788) P < 0.001 in aspirin monotherapy 
taker]. However, there were no differences of overall bleeding between 
PPI/non-PPI group. Amongst EGIB; sites of bleeding between PPI/non-PPI 
groups were comparable. Patients who took warfarin containing regimen 
had a greater proportion of bleeding compared to aspirin monotherapy 
group; 34 patients (70.83%) with warfarin containing regimen tended 
to have more bleeding than 6 patients (12.5%) with aspirin alone in PPI 
group. These findings were similar to non-PPI group. Interestingly, aspirin 
combined with warfarin had more EGI bleeding in PPI group compared to 
non-PPI group, 31.25% vs 11.53%; OR 3.484 (95%CI 1.233-9.929), P = 0.019. 
The medians of overall INR level were 3.13 (1.33-4.40) and 3.07(1.88-4.40) 
in EGIB and GIB respectively with P = 0.309.
conclusion: As in general knowledge, our study demonstrated that PPI 
helped in alleviating UGIB in patients who took aspirin monotherapy re-
gardless of PPI status. Interestingly, EGIB was high in our study, most of 
the cases were contributed from warfarin containing regimen although 
all group were in therapeutic level. Warfarin combine with aspirin sig-
nificantly increased EGIB in PPI group in particular, this interaction need 
to be explored.
disclosure: Nothing to disclose 
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(83.1% vs 31.8%). There was a positive correlation between Glasgow 
Blatchford score (GBS) and cTn-I elevation (R+0.19, P-0.003). There was a 
high statistical significant difference between GI &II regarding GBS at cut 
off level (15 days)(p- 0.0001). In cTn-I positive cases, ROC curve for Tropo-
nin elevation was AUC 0.97,sensitivity and specificity were 97.4 & 100%, 
respectively. Odds ratio of smoking, viral hepatitis and LOS in cTn-I positive 
patients were 12.61, 14.49 & 2.76 times troponin negative patients, respec-
tively (P-0.0001).
conclusion: UGIB in cirrhotic patients may predispose to AMI especially in 
older ages, men, comorbid diseases than non-cirrhotic. Patients with cir-
rhosis when developing UGIB have increased LOS, more complications and 
higher mortality than non-cirrhotics. Also, bleeding severity is positively 
correlated with developing AMI in all groups. cTn-I level is not different 
statistically between the groups.
references: 1.Lingjie, H., Jianwei, Z.,1 and Shutian, Z., Risk factors of in-
hospital mortality among patients with upper gastrointestinal bleeding 
and acute myocardial infarction. Saudi J Gastroenterol. 2018; 24(3): 177-
182. 2.Chia-Jung, W., Hung-Jung, L., Shih-Feng, W., et al., Acute Myocar-
dial Infarction Risk in Patients with Coronary Artery Disease Doubled after 
Upper Gastrointestinal Tract Bleeding: A Nationwide Nested Case-Control 
Study. PLoS One. 2015; 10(11): e0142000.
disclosure: Nothing to disclose 
P0555 PaTIenTs PresenTIng WITh an acuTe uPPer gI 
BLeed can Be safeLy dIscharged TO reTurn fOr OuTPaTIenT 
endOscOPy When TheIr gLasgOW-BLaTchfOrd scOre Is ≤2
Richards B.1, MacDonald S.2, Creed E.2, Penman D.2, Priestley S.2, 
McClements D.2
1St Helens & Knowsley NHS Trust, Gastroenterology, Lancashire, United 
Kingdom, 2St Helens & Knowsley NHS Trust, Liverpool, United Kingdom
contact e-Mail address: beth.richards@doctors.org.uk
Introduction: Upper Gastrointestinal (GI) Bleeding is one of the most com-
mon presentations to hospitals worldwide with an estimated incidence of 
between 40-150/100,000 annually.1 In the UK this translates to approxi-
mately 1 presentation every 6 minutes and results in a significant financial 
burden for the National Health Service (NHS).2,3
Current guidelines in the UK and Europe suggest the use of the Glasgow 
Blatchford Score (GBS) to predict high and low risk patients.1,4,5The outpa-
tient management of patients who score as low risk is widely accepted as 
a way of reducing pressure on inpatient services and potentially offsetting 
some of the aforementioned financial burden. In the UK, the guidelines 
suggest this strategy only for those who score 0, in Europe this is extended 
to 0-1.1,4Recently, a number of research papers have hypothesised that this 
could safely be extended further.3,6
At St Helens and Knowsley NHS Trust, UK, the score threshold has already 
been extended to those with a GBS of 2 or less with the introduction of an 
Ambulatory GI Bleed Pathway in 2016. The aim of this audit was to evalu-
ate the safety of this pathway, which may subsequently influence future 
guidelines by revealing ambulatory care is safe for those with a higher GBS.
aims & Methods: Data was collected retrospectively from May 2016-De-
cember 2018. Scanned medical notes were accessed and data collected 
under a number of headings: basic demographics, documented GBS, pre-
senting date, date of endoscopy and findings at endoscopy. The 3 main 
end-points assessed were: 
1. The need for endoscopic intervention. 
2. Re-bleed rates within 30 days. 
3. Thirty day mortality rate.
results: A total of 224 patients were referred via the ambulatory GI bleed 
pathway with the majority presenting with fresh haematemesis, ‘coffee-
ground’ vomit or malaena. Patients were excluded from analysis for a 
number of reasons including those who were inappropriately referred. Of 
the remaining 196 patients, 54.59% (107) were male and 45.41% (89) were 
female. The average age of presentation was 39 years of age (range 18-79). 
The mean GBS was 0.57 (mode 0).
The average number of days from presentation to endoscopy was 2.35 
(range 0-19). We found 24 patients did not attend their appointment. 3 did 
not tolerate the procedure. 57 patients had an entirely normal endoscopy. 
Of the remaining 112, a number of diagnoses were seen at endoscopy. Of 
most significance, only 3 patients required endoscopic therapy, GBS scores 
for these patients were 0, 0 and 2. Just 2 suffered a re-bleed (GBS 0 and 0) 
within 30 days and 30-day mortality was 0%.
P0553 OPTIMaL endOscOPy TIMIng In PaTIenTs WITh acuTe 
varIceaL BLeedIng: a sysTeMaTIc revIeW and MeTa-anaLysIs
Huh C.W.1, Jung D.H.2
1Incheon St. Mary’s Hospital, The Catholic University of Korea, Department of 
Internal Medicine, Incheon, Korea (Republic of), 2Severance Hospital, Yonsei 
University College of Medicine, Internal Medicine, Seoul, Korea (Republic of)
contact e-Mail address: huhcw@catholic.ac.kr
Introduction: Although current guidelines recommend performing endos-
copy within 12 hours for acute variceal bleeding (AVB), the optimal timing 
of endoscopy for AVB remains controversial.
aims & Methods: To perform a systematic review and meta-analysis of all 
eligible studies to assess the effect of endoscopy timing on mortality and 
re-bleeding in AVB. 
PubMed, Cochran Library, and EMBASE through January 2019 were 
searched for relevant publications. Overall mortality rate, re-bleeding 
rate, and other clinical outcomes (successful hemostasis, need for salvage 
therapy, length of hospital stay, and number of blood transfusions) were 
determined. Methodological quality of included publications was evalu-
ated using the Risk of Bias Assessment tool for Non-randomized Studies. 
Mantel-Haenszel random effect model of RevMan software (Cochrane) was 
used to analyze binary endpoints and inverse variance method was used to 
analyze continuous outcomes.
results: This meta-analysis included five studies with 854 and 453 partici-
pants undergoing urgent endoscopy (≤ 12 hours) and non-urgent endosco-
py (> 12 hours), respectively. There was no significant difference in overall 
mortality rate between urgent and non-urgent groups (OR: 0.72, 95% CI: 
0.36 - 1.45, P = 0.36). Re-bleeding rate was similar between urgent and 
non-urgent groups (OR: 1.21, 95% CI: 0.76 - 1.93, P = 0.41). Other outcomes 
were also similar between the two groups.
conclusion: This study demonstrated that endoscopy timing did not affect 
mortality or re-bleeding rate of patients with AVB. Therefore, an appropri-
ate timing of endoscopy would be more important than an urgent endos-
copy depending on each patient’s condition.
disclosure: Nothing to disclose 
P0554 sTudy Of recenT MyOcardIaL IscheMIa In PaTIenTs 
PresenTed WITh uPPer gasTrOInTesTInaL BLeedIng WITh and 
WIThOuT POrTaL hyPerTensIOn
Abu El-Soud Ali A.1, Ahmed Sakr A.1, Gamal Shalaby A.2, 
Salah El-zaiat R.3, Yahya Abdelshafy D.4
1Faculty of Medicine-Menoufia University, Tropical Medicine, Shebeen El-
Kom, Egypt, 2Faculty of Medicine-Menoufia University, Cardiology, Shebeen 
El-Kom, Egypt, 3Faculty of Medicine-Menoufia University, Clinical Pathology, 
Shebeen El-Kom, Egypt, 4Shibin El-kom Teaching Hospital, Hepatology and 
Gastroenterology, Shebeen El-Kom, Egypt
contact e-Mail address: aymanahmedsakr@gmail.com
Introduction: Upper gastrointestinal bleeding(UGIB) and acute myocardial 
injury(AMI) are potentially life-threatening conditions that must be man-
aged urgently (1). UGIB can be complicated by hypovolemia, hypotension, 
and diminished oxygen-carrying capacity, which cause myocardial isch-
emia and necrosis (2). liver cirrhosis is known to cause bleeding tendency, 
but sometimes may cause ischemic manifestations. Both UGIB and liver 
cirrhosis have a higher mortality when developing AMI than either of them 
alone (1).
aims & Methods: To assess the relationship between UGIB in both portal 
hypertensive cirrhotic and non-cirrhotic groups and the development of 
AMI. A single-center prospective study done on 263 patients presented 
with UGIB, divided in to 4 groups; GI (no=118) cirrhotic patients with UGIB, 
GII: non-cirrhotic patients with UGIB (n=85), GIII: cirrhotic patients (30) 
with no history of UGIB and GIV: the healthy control group (30).
results: Age is higher in GI than GII(P-0.0001). Smoking, diabetes, history 
of previous MI and ICU admission were common associations in patients 
with UGIB and MI. Cardiac troponin I (cTn-I) level was not statistically sig-
nificant different between the groups (p-0.16), but cTn-I was positive for MI 
in 18/118 (15.3%) in GI and in 20/85 (23.5%)in GII (P-0.001). ECG ischemic 
signs were statistically significant different (P-0.01). OVs and PU were the 
most common causes of bleeding in GI&II (63.6%&90.6%), respectively 
(p-0.0001). Mortality rate was 11/118(9.3%)in GI and 4/85 (4.7%) in GII 
(P-0.0001). Length of hospital stay (LOS) was higher in GI than GII>5days 
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conclusion: Although more than half of patients had a diagnosis at en-
doscopy (57.14%), only a very small number of patients required inter-
vention (1.5%), even fewer (1%) suffered a re-bleed and no patients died 
within 30 days of being referred onto the ambulatory GI bleed pathway. 
Therefore, we conclude that ambulating patients presenting with Acute 
Upper GI Bleed who have a GBS of 2 or less is safe and that following 
more robust, multi-centre studies, perhaps this could be adopted into 
future guidance.
references: 1. Gralnek IM, Dumonceau JM, Kuipers EJ et al. Diagnosis and 
management of nonvariceal upper gastrointestinal hemorrhage: European 
Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2015; 
47: a1-a46 2. Siau, K., Chapman, W., Sharma, N., Tripathi, D., Iqbal, T. and 
Bhala, N. (2018). Management of acute upper gastrointestinal bleeding: 
an update for the general physician. Journal of the Royal College of Physi-
cians of Edinburgh, 47(3), pp.218-230. 3. Chatten, K., Purssell, H., Banerjee, 
A., Soteriadou, S. and Ang, Y. (2018). Glasgow Blatchford Score and risk 
stratifications in acute upper gastrointestinal bleed: can we extend this to 
2 for urgent outpatient management?. Clinical Medicine, 18(2), pp.118-122. 
4. National Institute for Health and Care Excellence. Acute upper gas- tro-
intestinal bleeding in over 16s - management. Clinical Guideline CG141. 
London: NICE, 2012. 5. Scottish Intercollegiate Guidelines Network. Man-
agement of acute upper and lower gastrointestinal bleeding. SIGN Clinical 
Guideline 105. Edinburgh: SIGN, 2008. 6. Stanley, A., Laine, L., Dalton, H., 
Ngu, J., Schultz, M., Abazi, R., Zakko, L., Thornton, S., Wilkinson, K., Khor, 
C., Murray, I. and Laursen, S. (2017). Comparison of risk scoring systems 
for patients presenting with upper gastrointestinal bleeding: international 
multicentre prospective study. BMJ, 2017 Jan 4;356:i6432. doi: 10.1136/bmj.
i6432
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P0556 endOscOPIc TreaTMenT On gasTrOesOPhageaL 
varIx afTer OxaLIPLaTIn-Based cheMOTheraPy
Huang X.1, Ni L.2, Fan X.3, Chen S.1
1Zhongshan Hospital, Fudan University, Endoscopy Center and Endoscopy 
Research Institute, Shanghai, China, 2Zhongshan Hospital, Fudan University, 
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Introduction: Oxaliplatin has been used as the first choice for colorectal 
cancer, which might induce sinusoidal endothelial injury and portal hy-
pertension. However, gastroesophageal varix formation after oxaliplatin-
based chemotherapy may sometimes be overlooked when these patients 
presented with melena or hematemesis.
aims & Methods: The aim of this study was to investigate the character-
istics of oxaliplatin-induced portal hypertension and the efficacy of en-
doscopic prophylaxis of re-bleeding. Between 2010 and 2017, patients 
with gastroesophageal varix after oxaliplatin-based chemotherapy were 
included. We excluded patients with hepatitis, alcoholic, and other known 
etiology of cirrhosis. In the same time period, cirrhotic patients with hepa-
titis B related variceal bleeding and received first endoscopic treatment for 
prophylaxis of rebleeding were included as controls.
results: A total of 31 patients with colorectal cancer and portal hyperten-
sion were identified, with an average of 6 cycles of oxaliplatin-based che-
motherapy. Among them, 28 (90.32%) patients had an episode of variceal 
bleeding. The mean period retrospect to the start time of chemotherapy 
and the diagnosis of gastroesophageal varix was 61.9 ± 6.63 months. Liver 
biopsy confirmed no evidence of liver fibrosis while the obstruction of he-
patic vessels. Two of them had liver arterio-portal fistula and eight pa-
tients had portal-systemic shunt. Endoscopic ligation and cyanoacrylate 
injection were performed in 22 patients with a history of variceal bleeding 
episode. The other 6 six patients had endoscopy evaluation for unsuit-
able for endoscopic treatment. Four patients received drugs (Carvedilol) 
and two received interventional procedures (transjugular intrahepatic 
portosystemic shunt (TIPS) and partial splenic embolization (PSE)). The 
comparison between oxaliplatin-based portal hypertension patients and 
cirrhotic patients with hepatitis B were showed in Table 1. Prothrombin 
time (PT), INR, alanine transaminase (ALT) and aspartate aminotransfer-
ase (AST) and MELD scores were much lower in chemotherapy patients (p< 
0.001). Kaplan-Meier analysis revealed that the 3-year re-bleeding rate 
for patients received oxaliplatin-based chemotherapy was higher than 
cirrhotic patients with hepatitis B (p=0.0018). Multivariate cox regression 
analysis included age, MELD score, portal vein thrombosis, PT, AST, AST 
and platelet count indicated that oxaliplatin-based chemotherapy were the 
independent factors for re-bleeding (95% CI 1.228-6.282, p=0.014).
 
oxalipaltin-
induced portal 
hypertension
cirrhosis with 
hepatitis B p value
age at first diagnosis of varix 61.82±1.96 50.45±1.00 <0.001
sex(male) 10(45.5%) 84(75%) p=0.007
hemoglobin (Hb) 88.24±5.25 89.98±2.13 0.748
platelets 81.48±9.6 62.80±2.62 0.077
prothrombin time 13.28±0.20 14.35±0.14 <0.001
INR 1.15±0.016 1.25±0.012 <0.001
ALT 17.22±1.29 34.00±3.30 <0.001
AST 23.84±1.86 40.03±3.07 <0.001
total bilirubin 14.31±1.68 16.08±0.77 0.361
albumin 36.21±0.93 34.08±0.51 0.088
creatinine 67.39±3.92 72.70±2.09 0.241
Child Pugh score 6.55±0.23 6.38±0.11 0.543
MELD score 7.95±0.27 9.10±0.032 <0.001
portal vein thrombosis (%) 5(22.7%) 25(22.3%) 0.580
[Baseline clinical and biochemical characteristics]
conclusion: Oxaliplatin-induced portal hypertension may lead to portal 
hypertension with mild liver injury. Endoscopic treatment can be used 
for preventing variceal bleeding, however, the rebleeding rate was much 
higher than other cirrhotic portal hypertension.
disclosure: Nothing to disclose 
P0557 IMPLeMenTaTIOn Of The uk acuTe uPPer gI BLeedIng 
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Donnelly M.1, Saffouri E.2, Pugmire J.3, Siau K.4, Basavaraju U.5, 
Stanley A.J.6, Morris A.J.7
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Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom, 3University 
of Glasgow, Social and Public Health Sciences Unit, Glasgow, United 
Kingdom, 4JAG Clinical Fellow, Royal College of Physicians, Wolverhampton, 
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Kingdom, 6Glasgow Royal Infirmary GI Unit, Department of Gastroenterology, 
Glasgow, United Kingdom, 7Glasgow Royal Infirmary, Gastroenterology, 
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contact e-Mail address: johnmorris99@yahoo.co.uk
Introduction: The 2015 UK National Confidential Enquiry into Patient Out-
come and Death (NCEPOD) report ‘Time to Get Control’ highlighted the 
need to improve the quality of care of patients with acute upper GI bleed-
ing (AUGIB)1. The British Society of Gastroenterology Endoscopy Quality 
Improvement Project created an evidence based care bundle for AUGIB 
targeting ward based management of patients within the first 24 hours 
(The UK AUGIB bundle). The impact of implementation of the UK AUGIB 
bundle has not been assessed in clinical practice.
aims & Methods: An audit of the impact of the UK AUGIB bundle was 
undertaken in 15 Scottish hospitals. Data were collected relating to demo-
graphics and management of patients with AUGIB within the first 24 hours 
of presentation, for a six-week period pre- and post-implementation of 
the UK AUGIB bundle. A period of bundle promotion was undertaken in 
all centres between data collection cycles. Outcomes measures included 
documentation of bundle implementation, risk scores and transfusion 
strategy. Caldicott approval was obtained in each site.
results: A total of 459 patients were included in the pre-bundle audit pe-
riod, and 434 patients in the post-bundle audit period. Following imple-
mentation, the AUGIB bundle was utilised in 41.2% of patients. The table 
demonstrates patient demographics and the impact of bundle implemen-
tation, highlighting improvements in recording of the Glasgow-Blatchford 
score and a re-bleeding plan, and improvements in transfusion strate-
gies. 
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medical, and physician associate backgrounds. Following completion of 
the scenario a structured debrief was conducted. Latent errors affecting 
patient safety at an individual, team or organisational level were iden-
tified and discussed. Following the scenarios, actions were put in place 
designed to address the identified errors in a timely fashion.
results: During the 18 unannounced sessions between February 2017 and 
April 2019 we identified the following latent errors:
· unavailability of Sengstaken-Blakemore tubes, Bair Huggers, electrocar-
diogram machines and a step for CPR on the ward
· lack of awareness as to how to activate the major haemorrhage protocol
· not checking allergy status before administering antibiotics
· junior doctors without working pagers
· deficiencies in resuscitation skills amongst non-training grade doctors
· members of the multiprofessional team forgetting each others’ names 
and parts of the ALS algorithm
· not knowing where the oral glucose gel is kept on the ward
Since the identification of these errors, corrective measures have includ-
ed: laminated ALS algorithms attached to the resuscitation trolleys and 
dedicated major haemorrhage protocol training at junior doctor induc-
tion. Equipment availability has been addressed by ward management. 
Dedicated training days for the non-training grade doctors has also been 
undertaken.
conclusion: In situ simulation is highly effective in identifying latent errors 
that could have potentially deleterious consequences on patient safety. 
This allows corrective measures to be undertaken in advance of real-life 
emergencies.
disclosure: Nothing to disclose 
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Introduction: Gastric slow waves regulate peristalsis, and gastric dysrhyth-
mias have been implicated in functional motility disorders. To accurately 
define slow wave patterns, it is currently necessary to collect recordings 
during open surgery, which is invasive and limit their application. We 
therefore developed a novel gastric slow wave mapping device for use 
during endoscopic procedures. We aimed to assess feasibility of the new 
device for acquisition of gastrointestinal slow wave.
aims & Methods: The device consists of a spreading catheter constructed 
of a flexible core coated with Pebax. Acquisition of gastric electrical signals 
was performed on healthy fasted weaner pigs under general anesthesia. 
Once deployed with endoscopic guidewire, catheter arrays is revealed with 
12 electrode at 5mm intervals. A multi-channel recorder (Acknowledge 
4.4, MP150; Biopac Systems, Santa Barbara, CA) was used to record gastric 
myoelectrical 
activity throughout the study. We compared gastric electrical signals from 
gastric mucosal according to various lesions.
results: Gastric slow wave activity was successfully recorded simultane-
ously via both the novel endoscopic probe and the serosal measurement. 
Recordings from the device and a reference array in pigs were identical in 
frequency, and activation patterns and velocities were consistent. Device 
and reference amplitudes were comparable.
conclusion: In conclusion, the novel endoscopic device achieves high-
quality mucosal slow wave recordings. It might be applied for endoscopic 
diagnostic studies to document slow wave patterns in patients with gastric 
motility disorders.
disclosure: Nothing to disclose 
variable Pre-bundle period
Post-bundle 
period p-value
Bundle not 
used
Bundle 
used p value
DEMOGRAPHIC 
VARIABLES
           
Number of 
patients
459 (51.4%) 434 (48.6%) N/A
205 
(53.4%)
179 
(46.6%)
N/A
Age (years)
64.7 
(63.0-66.4)
64.4 
(62.7-66.0)
0.772
65.8 
(63.4-68.1)
62.2 
(59.5-
64.8)
0.043
Male/ Female
264 (57.8%)/ 
193 (42.2%)
266 (61.4%)/ 
167 (38.6%)
0.530
123 (60.0%)/ 
82 (40.0%)
113 
(63.1%)/ 
66 
(36.9%)
0.395
Glasgow 
Blatchford score
6.3 (0-19)
7.4 
(0 - 20)
0.011
7.0 
(0 - 18)
8.0 (0 - 
20)
0.141
Varices 27 (7.3%) 51 (13.3%) 0.007 24 (13%) 24 (14%) 0.733
BUNDLE 
VARIABLES
           
Glasgow 
Blatchford Score 
recorded
163 (38.4%) 225 (57.3%) <0.001
86 
(42.2%)
122 
(74.0%)
<0.001
Target 
haemoglobin 
stated
53 
(35.3%)
78 (44.8%) 0.083
34 
(36.6%)
35 
(53.0%)
0.039
Transfusion 
threshold 
appropriate
58 
(13.3%)
83 
(19.6%)
0.012
40 
(19.6%)
36 
(20.2%)
0.880
Rebleeding plan 
documented
121 
(33.2%)
196 (50.7%) <0.001
83 
(44.9%)
95 
(56.55%)
0.028
[Patient demographic and bundle variables.]
No significant differences were observed in use of PPI in high risk bleeders, 
use of terlipressin/antibiotics in variceal haemorrhage or resumption plan 
for antithrombotics, with high pre-bundle performance in these domains.
conclusion: Implementation of the UK AUGIB bundle in Scottish hospitals 
resulted in significant improvements in quality standards including docu-
mentation of risk scoring, target haemoglobin, transfusion thresholds and 
re-bleed plan.
references: 1. Gastrointestinal haemorrhage: Time to Get Control? National 
Confidential Enquiry into Patient Outcome and Death. July 2015. Accessed 
April 2019 http://www.ncepod.org.uk/2-15gih.html
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P0558 MuLTIPrOfesssIOnaL In sITu sIMuLaTIOn Is an 
effecTIve MeThOd Of IdenTIfyIng LaTenT PaTIenT safeTy 
ThreaTs In gasTrOInTesTInaL eMergencIes
Jafar W.1, Suggitt D.2, Uttley E.3, Baxter D.3
1Stockport NHS Foundation Trust, Gastroenterology, Stockport, United 
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Introduction: Identifying errors in the ward environment, healthcare or-
ganisation or interaction between multiprofessional team members is 
crucial. Such identification may prevent serious mistakes that can occur in 
high pressure gastroenterology emergencies. Unannounced multiprofes-
sional in situ simulation can be an effective means of identifying latent 
patient safety threats before they occur. We set up a standardised in situ 
simulation programme centred around speciality specific emergency sce-
narios; not only to improve skills, team working and communication but 
also to identify and address latent errors. The in situ faculty consisted of a 
consultant gastroenterologist; skills tutor; education fellow and director of 
medical education.
aims & Methods: We identified key learning objectives for several different 
emergency scenarios including: massive upper gastrointestinal haemor-
rhage; septic shock; post-procedure complications and cardiac arrest. Us-
ing a wireless high fidelity simulation manikin we ran 18 unannounced 
sessions between February 2017 and April 2019. There was a minimum 
of three faculty in attendance in each of the sessions and an overall total 
of 79 participants representing the spectrum of different professions in-
cluding: doctors; nurses; health care assistants and students from nursing, 
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P0560 eLecTrOPhysIOLOgIcaL and PerMeaBILITy PrOPerTIes 
Of esOPhageaL ePITheLIuM In PaTIenTs WITh achaLasIa 
BefOre and afTer BaLOOn dILaTaTIOn
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1Ege University, Gastroenterology, Medical Biology, Izmir, Turkey, 2Ege 
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Ege University Fak., Bornova Izmir, Turkey, 4Ege University Dept. of 
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Introduction: Achalasia is a rare disorder with an incidence of approxi-
mately 1.6 cases per 100,000. The etiology of the disease especially chang-
es at the epithelial permeability is not known.
aims & Methods: The aim of this study was to investigate the electro-
physiological and permeability characteristics of esophageal epithelium 
in patients with a diagnosis of achalasia before and after baloon dilatation 
compared with healthy controls and gastroesophageal reflux phenotypes. 
27 patients (F: 17, M: 10, mean age 46 ± 15) diagnosed with upper gastro-
intestinal endoscopy with distal esophageal biopsies, timed barium swal-
low radiology, high resolution esophageal manometry (HRM) (according 
to Chicago 3.0v; 4 Type 1; 20 Type 2; 3 Type 3). 23 healthy volunteers and 60 
erosive gastroesophageal reflux patients (ERD A / B: 48, ERD C / D: 12) were 
also included. Upper gastrointestinal endoscopy, HRM, 24h pH-MII studies 
were performed in both healthy volunteers and ERD patients. Esophageal 
electrophysiology and permeability measurements were performed before 
the treatment of 27 achalasia patients. 14 patients were also evaluated 
2-3 months after the balloon dilatation. 3-4 esophageal biopsies were put 
into the mini-Ussing chambers to measure the transepithelial resistance 
(TEER), potential difference and tissue permeability via fluorescein diffu-
sion within 2 hours.
results: TEER and permeability of esophageal epithelium of Achalasia pa-
tients were not significantly different compared to the healthy volunteer 
group. However, when compared to the ERD group, the tissue resistance 
of achalasia patients were significantly higher and the permeability of the 
esophageal epithelium was significantly lower. Both tissue resistance and 
permeability of the esophageal epithelium after treatment were signifi-
cantly higher, epithelial permeability was significantly lower in Achalasia 
patients compared to healthy volunteer and ERD groups. When pre- and 
post-treatment were compared, an increase in tissue resistance and de-
crease in epithelial permeability were determined after treatment, but no 
significant difference was found (Table).
 
Teer (ohm) 
(mean±sd)
Permeability (pmol) 
(mean±sd)
Healthy volunteer 166,8 ± 47,2 §§§ 36,9±13,8 §§
Achalasia (pre-treatment) 188,3± 55,7 33,6±15
Achalasia (post- treatment) 216± 80 22,2±9,1
ERD A/B 133,2 ± 34,4 * §§ 49,6±28,4 ** §
ERD C/D 112,1 ± 38,6* § 60,1±40,5*** §§§
*p<0,001 vs Achalasia (pre- treatment), ** p<0,005 vs Achalasia (pre- treatment), 
*** p<0,05 vs Achalasia (pre- treatment), §p<0,001 vs Achalasia (post- treatment), 
§§p<0,005 vs Achalasia (post- treatment), §§§p<0,05 vs Achalasia (post- treatment)
[TEER and Permeability Results]
conclusion: Patients with achalasia have less gastric reflux however the 
mechanical trauma and long-term stasis of food inside the esophagus 
might have a noxious effect on the epithelium. Different than the expecta-
tions, pre-treatment findings of esophageal epithelial resistance and tis-
sue permeability were similar with HC. GERD is not uncommon in Acha-
lasia patients following treatments. In spite of that, no significant change 
was determined when the patients’ esophageal epithelial resistance and 
permeability were compared before and after treatment with balloon dila-
tation. Based on these results, we assume that, an adaptive cytoprotec-
tive mechanism might develop in the esophageal epithelium of achalasia 
patients.
disclosure: Nothing to disclose 
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hyPerPerMeaBILITy, duOdenaL eOsInOPhILIa and syMPTOMs 
In funcTIOnaL dysPePsIa PaTIenTs By acId-IndePendenT 
MechanIsMs
Wauters L.1,2, Frings D.3, Lambaerts M.3, Accarie A.3, Toth J.3, 
De Hertogh G.4, Farré R.3, Tack J.1,3, Vanuytsel T.1,3
1University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, 
Belgium, 2Katholieke Universiteit Leuven, Gastroenterology and Hepatology, 
Leuven, Belgium, 3Katholieke Universiteit Leuven, Translational Research 
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Introduction: The role of acid suppression with proton pump inhibitors 
(PPI) in relation to duodenal alterations and symptoms in functional 
dyspepsia (FD) patients is unknown. We studied duodenal permeability, 
eosinophil infiltration and symptoms in healthy volunteers (HV) and FD 
patients before and during PPI treatment.
aims & Methods: Duodenal biopsies and blood samples were collected 
in healthy volunteers (HV) and FD patients before and after treatment 
with pantoprazole 40mg OD for 4 weeks. Transepithelial electrical resis-
tance (TEER) and paracellular passage of a fluorescein-labeled dextran 
(4kDa) were measured in Ussing chambers and eosinophils counted on 
H&E-stained sections per high-power field (HPF; 0.24mm2). After each 
endoscopy, a naso-duodenal tube was positioned in the second part of 
the duodenum with aspiration of fasting and fed (Fortimel, 300kCal) flu-
ids with measurement of pH. Plasma high-sensitivity C-reactive protein 
(hs-CRP), the Patient Assessment of Gastrointestinal Disorders Symptom 
Severity Index (PAGI-SYM) and Perceived Stress Scale (PSS) were measured 
at both visits. Non-parametric and correlation analyses were performed 
within- and between-groups.
results: In total, 24 HV (15 female, median (IQR) age 26 (24-32) years) 
and 15 FD (13 female, 27.5 (22-34) years) were included. TEER was similar 
within- and between-groups. Dextran passage was higher in FD vs. HV off-
PPI (p< 0.01) and significantly decreased in FD patients on-PPI. Duodenal 
eosinophil counts were higher in FD vs. HV both off- (p< 0.0001) and on-
PPI (p=0.03) despite a significant reduction in eosinophilia in FD patients 
on-PPI. Duodenal fasting (p=0.02) and fed pH (p=0.03) were higher in FD 
vs. HV off-PPI with a trend for higher fed pH (p=0.08) in FD vs. HV on-PPI 
and an increase in both HV and FD on-PPI. Plasma hs-CRP was higher in 
FD vs. HV off-PPI (p=0.06) with a trend for decreased hs-CRP in FD on-PPI. 
PAGI-SYM decreased in FD on-PPI and was higher in FD vs. HV off- and 
on-PPI (both p< 0.0001). PSS was similar in FD on-PPI with higher scores 
in FD vs. HV both off- (p=0.04) and on-PPI (p< 0.01). Correlations were 
found between hs-CRP and passage (r=0.65, p=0.01) in FD off-PPI. Fed pH 
correlated positively with passage (r=0.58, p=0.03) in FD on-PPI. PAGI-SYM 
correlated with duodenal eosinophil counts (r=0.57, p=0.02) in FD off-PPI 
but not on-PPI. No correlations were found for HV. 
  hv (n= 24)   fd (n= 15)  
variable Off-PPI On-PPI p-value Off-PPI On-PPI p-value
TEER (Ω*cm2)
25.3 
(19.7-31.5)
23.1 
(19.8-26.4)
0.56
22.1 
(19.2-27)
26.6 
(20.7-28.5)
0.27
Paracellular 
passage (pmol)
19 
(10.1-23.2)
22.7 
(12.9-33.1)
0.07
25.6 
(20.2-31)
15.5 
(11.4 -29.3)
0.02
Eosinophils 
(per HPF)
3 (2-4) 1 (3-4) 0.72 12 (9-18) 4 (3-6) <0.001
Fasting pH
5.9 
(3.9-6.7)
7.2 
(6.7-7.3)
<0.001 7 (5-7.4)
7.2 
(6.6-7.5)
0.02
Fed pH
6.3 
(5.2-6.5)
6.6 
(6.4-6.8)
<0.01
6.4 
(6-6.9)
6.8 
(6.7-7.0)
0.03
hs-CRP (mg/L)
0.9 
(0.3-1.5)
0.7 
(0.2-1.6)
0.57
2 
(0.6-5.5)
0.9 
(0.2-1.6)
0.06
PAGI-SYM 0 (0-0.3)
0 
(0-0.4)
0.75 2.8 (2-3) 1.5 (1-2.3) <0.01
PSS
5 
(2.5-9.5)
5 (1-6) 0.12
13.5 
(8.8-18.3)
12.5 
(1.8-18)
0.40
[Table 1]
conclusion: In FD, elevated duodenal permeability, eosinophilia and 
symptoms but not stress are reduced by PPI and may be associated with 
systemic inflammation, which is associated with increased paracellular 
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P0563 endOgenOus gLucagOn-LIke PePTIde 2 PLays an 
IMPOrTanT PhysIOLOgIcaL rOLe In The adaPTIve resPOnse 
afTer sMaLL InTesTInaL Injury
Billeschou A.1, Hunt J.1,2, Agerlin Windeløv J.1,2, Juul Holst J.1,2, Kissow H.1,2
1University of Copenhagen, Department of Biomedical Sciences, Copenhagen, 
Denmark, 2Copenhagen University, NNF Center of Basic Metabolic Research, 
Copenhagen, Denmark
contact e-Mail address: anna.billeschou@sund.ku.dk
Introduction: Acute small intestinal injury such as chemotherapy-induced 
gastrointestinal mucositis often leads to extensive loss of mucosa, which 
can lead to malabsorption, abdominal pain and increased infection risks1,2. 
Intestinal adaptation is an important response and a natural compensa-
tory mechanism to the acute injury and is critical for recovery. Glucagon-
like peptide 2 (GLP-2) is secreted from enteroendocrine L-cells in response 
to food intake. GLP-2 has been demonstrated to enhance mucosal repair 
following intestinal damage4, however, whether the endogenous secre-
tion of GLP-2 is physiologically essential for mucosal repair and protection 
remains unresolved.
aims & Methods: This study aims to investigate whether deficiency of GLP-
2 receptor (GLP-2R) activity increases intestinal susceptibility and reduces 
the adaptive response to injury, using a model of chemotherapy-induced 
mucositis. 
Female GLP-2R knock out (KO) mice and their wild type (WT) littermates 
received an intraperitoneal injection of chemotherapy (5-fluorouracil 400 
mg/kg) inducing acute mucositis followed by regeneration. Additionally, 
GLP-2R KO and WT control received a saline injection. Bodyweight was 
monitored daily and recorded. 
Mice were sacrificed 3 or 6 days after induction of injury; the small intes-
tines were harvested, cleaned and the weight was recorded. Tissue from 
duodenum, jejunum, and ileum was analysed for myeloperoxidase (MPO) 
activity.
results: The body weight of GLP-2R KO mice and their WT littermates 
showed the same decrease in the acute phase of injury and the same 
increase in the adaptive phase. No difference in small intestinal weight 
between the KO and WT was found in the acute phase of injury. Six days 
after injury GLP-2R KO mice showed a significant decrease in small intes-
tinal weight compared to the WT mice (P< 0.0001). 
Only WT mice were able to show the additional adaptive regrowth nor-
mally seen after chemotherapy-induced injury in mice; with a small intes-
tinal weight significantly higher than healthy WT controls (P< 0.0001). In 
the acute state of injury, a significant increase in the inflammatory marker 
MPO was detected for the GLP-2R KO mice compared to their WT litter-
mates in the middle part of the small intestines (P< 0.05). 
Whereas no significant difference was found in the proximal and distal 
part of the small intestine. During the adaptive phase of injury, the MPO 
activity was back to baseline for both the GLP-2R KO and WT mice com-
pared to the healthy controls.
conclusion: This study shows that in the acute phase of injury GLP-2R ac-
tivation might be less in important for intestinal protection. However GLP-
2R activation seems to play an important physiological role in the adaptive 
response after intestinal injury.
references: 1 Elting, L. S. et al. The burdens of cancer therapy: clinical and 
economic outcomes of chemotherapy-induced mucositis. 98 (7), 1531-1539, 
(2003). 2 Kissow, H. J. C. o. i. s. & care, p. Glucagon-like peptides 1 and 
2: intestinal hormones implicated in the pathophysiology of mucositis. 9 
(2), 196-202, (2015). 3 Yusta, B. et al. GLP-1R Agonists Modulate Enteric 
Immune Responses Through the Intestinal Intraepithelial Lymphocyte 
GLP-1R. Diabetes. 64 (7), 2537-2549, (2015). 4 Hytting-Andreasen, R. et al. 
Endogenous glucagon-like peptide-1 and 2 are essential for regeneration 
after acute intestinal injury in mice. 13 (6), e0198046, (2018).
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P0564 WIThdraWn
passage in FD off-PPI. Increased duodenal pH on-PPI is associated with 
increased passage and hence is unlikely to explain the restored perme-
ability in FD patients observed during PPI, suggesting the involvement of 
other factors such as duodenal eosinophils, which may drive dyspeptic 
symptoms.
disclosure: Nothing to disclose 
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Introduction: Carbon monoxide (CO), similarly to hydrogen sulfide (H
2
S) is 
a gaseous mediator. CO is produced from heme via activity of heme oxy-
genase-1 (HO-1) and HO-2. CO and H
2
S exert anti-inflammatory and anti-
oxidant effects. However, possible preventive effect of CO released from its 
pharmacological donor, tricarbonyldichlororuthenium (II) dimer (CORM-2) 
against acute reflux esophagitis (RE)-induced esophageal damage has not 
been explained.
aims & Methods: The RE was induced in Wistar rats within 4 h by ligating 
pylorus and transitional region between the forestomach and glandular 
portion. Before induction of RE animals were pretreated with CORM-2 (0.5 
- 10 mg/kg i.g.), HO-1 inducing hemin (5 mg/kg i.g.) or HO-1 inhibiting zinc 
protoporphyrin IX (ZnPP, 10 mg/kg i.p.). CORM-2 was applied alone or in 
combination with indomethacin (5 mg/kg i.g.) to inhibit PG biosynthesis, 
L-NNA (15 mg/kg i.g.) to inhibit NO-synthase activity, capsazepine (5 mg/
kg i.g.) to block TRPV1 activity or capsaicin (125 mg/kg s.c.) to suppress the 
activity of sensory nerves. RuCl
3
(2.5 mg/kg i.g.) which is not a CO releaser, 
was administered as a negative control for CORM-2. The esophageal blood 
flow (EBF) was determined by laser flowmetry, esophageal lesions index 
(LI) and mucus production was assessed by macro- and microscopically 
by planimetry and histology (H&E, alcian blue/PAS staining), the muco-
sal expression of mRNA and/or protein for HO-1, HO-2, Annexin-1, Nrf-2, 
hypoxia inducible factor 1α (HIF-1α), IL-1β and TNF-α, COX-1 and COX-2, 
TRPV1 and endogenous H
2
S producing enzymes CTH, CBS and MPST were 
analyzed by real-time PCR, Western blot and/or immunohistochemistry. 
8-hydroxyguanosine (8-OHG) as DNA oxidation marker and PGE
2
concen-
tration in esophageal mucosa were determined by ELISA.
results: CORM-2 reduced LI, maintained mucus production and increased 
EBF with selected ED50 dose being 2.5 mg/kg i.g.Similar effects were ob-
served for hemin but not for RuCl3 or ZnPP. Capsazepine and capsaicin 
denervation but not L-NNA or indomethacin reduced esophagoprotective 
effects of CORM-2. CO donor increased HO-1/Nrf-2 or TRPV1 but did not 
affected CTH, CBS or MPST expression. CORM-2 downregulated COX-2, 
TNF-α, IL-1β and iNOS esophageal expression, decreased 8-OHG concen-
tration and maintained Annexin-1 and HIF-1α expression and PGE2 con-
centration increased by RE.
conclusion: We conclude that CO released from CORM-2 prevents esopha-
geal mucosa against the damage induced by RE via its hyperemic, anti-
inflammatory and anti-oxidative properties. These effects involved in 
CORM-2-mediated esophagoprotection are partly mediated by the ability 
of CO to maintain protective PGE
2
level and by the activity of Nrf2, Annexin-1 
and HIF-1α but the possible role of H
2
S biosynthesis enzymes remains un-
clear. [Funding source: National Science Centre, Poland (UMO-2016/23/D/
NZ4/01913)].
disclosure: Nothing to disclose 
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endOscOPIc MyOTOMy: a Large sIngLe cenTre sTudy
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2Asian Institute of Gastroenterology, Hyderabad, India
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Introduction: Per-oral endoscopic myotomy (POEM) has established its 
place in the management of achalasia. Gastroesophageal reflux is an im-
portant concern after POEM. However, there is limited data on the risk 
factors for GER after POEM.
aims & Methods: In this study, we aim to analyse the variables affecting 
the occurrence of GER after POEM. 
All patients who underwent POEM (December 2017 to January 2018) at a 
single tertiary centre were offered GER evaluation using 24-hour pH im-
pedance, esophagogastroduodenoscopy (EGD) and symptoms. Multivari-
ate analysis was performed to identify the variables affecting the incidence 
of GER after POEM.
results: A total of 260 patients with achalasia underwent POEM during 
the study period. 167 (64.2%) patients (mean age 41±14.42 years, 47.6% 
females, mean body mass index 22.2±3.89 kg/m2) underwent comprehen-
sive evaluation of GER. Majority (70.6%) of the patients were treatment 
naïve. High De-Meester score (>14.7) and reflux esophagitis was identi-
fied in 47.9% and 41.9% of patients, respectively. Symptomatic GER was 
found in 29.3% patients. On univariate analysis only sigmoid oesophagus 
was found to be associated with GER (OR 0.20; CI 0.04-0.99; p=0.04). On 
multivariable analysis type of achalasia, technique of POEM (anterior vs 
posterior), objective variables including pre or post POEM esophageal ma-
nometry and patient characteristics (age, sex, BMI, type of achalasia) were 
no associated with GER.
  Odds ratio
95% 
confidence 
interval
p value adjusted odds ratio
95% 
confidence 
interval
p value
Age (years) Male 
Gender Female 
Gender
1.31 1.00 
0.63
0.71-2.40 
Reference 
0.34-1.17
0.39 0.15
0.74 1.00 
0.67
0.35-1.55 
Reference 
0.42-1.49
0.43 0.72
Body mass Index 
(kg/m<2>
1.31 0.71-2.42 0.38 0.67 0.32-1.41 0.29
Previous therapy 
(yes/no)
1.09 0.56-2.14 0.78 1.21 0.53-2.76 0.64
Sigmoid 
oesophagus
0.20 0.04-0.99 0.04 6.35 0.55-72.98 0.14
Length of Myotomy 
(cm) Esophageal 
Gastric
1.31 2.32
0.71-2.46 
0.68-8.18
0.38 0.17 1.12 1.67
0.51-2.44 
0.52-5.37
0.77 0.39
Orientation of 
myotomy Anterior 
Posterior
0.89 0.47-1.66 0.71 1.14 0.51-2.44 0.74
Post POEM Eckardt 
score
1.21 0.65-2.22 0.38 1.35 0.64-2.86 0.426
Post POEM 
manometry IRP LES 
pressure
1.07 0.57-2.01 0.82 0.79 1.37
0.35-1.80 
0.60-3.12
0.59 0.44
Type of Achalasia 
Type I nad III
      0.66 0.32-1.42 0.31
[Logistic regression analysis of factors associated with gastroesophageal 
reflux after POEM]
conclusion: The incidence of post POEM GER is high and should be identi-
fied early to prevent complications. There are no procedural or patient 
related variables which appear to affect the incidence of GER.
disclosure: Nothing to disclose 
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Introduction: Gastric per-oral endoscopic myotomy (G-POEM) was first in-
troduced in 2013 for the management of refractory gastroparesis. Most of 
the studies included small sample size with short term follow up. Litera-
ture on the efficacy of G-POEM when considering the etiology of gastropa-
resis, prior therapies and total operative time is limited.
aims & Methods: We performed a systematic review and meta-analysis to 
evaluate the clinical efficacy of G-POEM in patients with refractory gastro-
paresis. We also evaluated if variation in total operative time, prior thera-
pies (botulinum toxin, gastric electrical stimulation) and etiology affected 
clinical success. We conducted a search of several databases to locate 
items pertaining to peroral endoscopic pyloromyotomy or gastric peroral 
endoscopic myotomy (G-POEM) in patients with refractory gastroparesis 
(Jan 2013 to Feb 2019). Random-effects model was used. Heterogeneity 
between study-specific estimates was calculated using Cochran Q test and 
I2 statistics. Publication bias was ascertained by funnel plot and Egger test. 
The outcome assessed was the pooled rate of clinical success with G-POEM 
as determined by total Gastroparesis Cardinal Symptom Index (t-GCSI) ≤2 
at follow up and improvement in the 4-hr Gastric Emptying Study (GES). 
Sub-group analysis was performed based on the total operative time. Me-
ta-regression analysis was used to evaluate the effect of prior treatments 
on clinical success.
results: Our initial search yielded 67 results. After excluding duplicates 
and non-english literature, 62 full length articles were screened and 16 
studies with 442 patients were included in the final analysis. Follow up t-
GCSI and 4-hr GES data was available for 373 and 258 patients respectively. 
The pooled rate of clinical success based on t-GCSI was 75.9% (95% CI 
69.7-81.2, I2=37.8) and based on improvement in 4-hr GES was 84% (95% 
CI 71.9-91.5, I2=66.2). Sub-group analysis was done to evaluate the clinical 
success of G-POEM as influenced by the total procedure time. Based on 
t-GCSI scores, for a procedure time of < 50 min (8 studies, 214 patients) 
the pooled rate of clinical success was 74.6% (95% CI 65.6-81.8, I2=3.3) 
whereas for >50 min (8 studies, 159 patients) it was 78.4% (95% CI 68.4-
85.9, I2=57.9). There was no statistical difference between the two (p=0.53). 
Similarly, based on 4-hr GES for a procedure time of < 50 min (6 studies, 
126 patients) the pooled rate of clinical success was 76.5% (95% CI 56.2-
89.2, I2=73.5) whereas for >50 min (8 studies, 132 patients) it was 88.7% 
(95% CI 75-95.4, I2=36.4). There was no statistical difference (p=0.20) be-
tween the two. The pooled rate of total adverse events was 13.4% (95% CI 
6.8-24.8, I2=63.7) and follow up time ranged from 2 months (shortest) to 
18 months (longest). Length of hospital stay ranged from 1 to 6 days. On 
meta-regression analysis, prior treatment with botulinum toxin injection 
(2-sided p-value =0.03) and gastric electrical stimulation (2-side p-val-
ue=0.03) seemed to significantly influence 4-hr GES success rate. Etiology 
(diabetes, idiopathic, post-surgical) and/ or prior treatments did not affect 
the outcome of G-POEM based on t-GCSI score.
conclusion: G-POEM is an effective and safe treatment modality for refrac-
tory gastroparesis. Our study shows that there is no difference in the suc-
cessful outcomes based on the etiology of gastroparesis or total operative 
time. However, prior treatment with botulinum toxin and gastric electri-
cal stimulation had a statistically significant influence on the success rate 
based on 4-hr gastric emptying.
disclosure: Nothing to disclose 
419Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
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Introduction: Esophageal achalasia is one of the primary esophageal 
motility disorders, and dysphagia and vomiting due to difficult passage 
at the lower part of the esophagus are main symptoms in patients with 
esophageal achalasia. Timed barium esophagogram (TBE) is a useful 
method to evaluate the clearance at the lower part of the esophagus in 
patients with esophageal achalasia, which we usually performed before 
and after surgery. Meanwhile, laparoscopic Heller-Dor operation (LHD) 
is a gold standard treatment of esophageal achalasia and is prevalent all 
over the world.
aims & Methods: The aim of this study is to analyze the effect of clear-
ance rate of the lower part of the esophagus for symptoms and surgi-
cal results in patients with esophageal achalasia. Between May 2002 and 
March 2019, 588 patients who underwent LHD at our institution were ex-
tracted from the database. Out of these, 433 patients met our inclusion 
criteria; such as the patients who underwent LHD as an initial operation 
with complete evaluation of preoperative esophageal clearance by TBE. 
These patients were divided into three groups based on the clearance rate 
of the lower part of the esophagus (Group A: clearance rate <10%, Group 
B: 10%≤clearance rate <50%, and Group C: 50%≤clearance rate). Patients’ 
background, pre- and post-operative symptom scores, surgical results and 
post-operative course were compared. Before and after surgery, a stan-
dardized questionnaire was used to assess the degree of frequency and 
severity of symptoms (dysphagia, vomiting, chest pain and heartburn). For 
each symptom, frequency and severity were separately assessed on a five-
point scale (range: 0-4), and a symptom score was calculated by multiply-
ing these points (range: 0-16). Moreover, satisfaction with operation was 
evaluated using the standardized questionnaire. Statistical analysis was 
performed by using Krasukal- Wallis test or chi-square test, and p-value 
less than 0.05 was defined as statistically different.
results: Their mean age was 44.6 years and 217 of them were male 
(50.1%). One hundred and eighty-six patients (43.0%) were in Group 
A, 163 (37.6%) in Group B, and 84 (19.4%) in Group C. The maximum 
width of the esophagus in Group C was smaller than that in other groups 
(p=0.0181). As to the pre-operative symptom score, dysphagia was signifi-
cantly lower in Group C (p=0.0442), whereas chest pain was significantly 
higher in Group C (p=0.0489). Surgical outcomes including the incidence 
of mucosal injury were not different among three groups. Moreover, the 
patient satisfaction with LHD was excellent regardless of preoperative 
esophageal clearance.
conclusion: Pre-operative clearance rate of the lower part of the esopha-
gus correlated with pre-operative dysphagia and chest pain, but did not 
affect the surgical outcomes of LHD, post-operative course or post-opera-
tive symptoms in patients with esophageal achalasia.
disclosure: Nothing to disclose 
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Janousek R.3, Martinek J.4
1Institute for Clinical and Experimental Medicine, Dept. of 
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Czech Republic
contact e-Mail address: zuzana.rabekova@ikem.cz
Introduction: Peroral endoscopic myotomy (POEM) is nowadays considered 
as a standard method for treatment of esophageal achalasia, however, the 
P0567 PredIcTOrs Of refLux esOPhagITIs afTer Per-OraL 
endOscOPIc MyOTOMy (POeM)
Masuda T., Yano F., Omura N., Tsuboi K., Hoshino M., Yamamoto S., 
Akimoto S., Kashiwagi H., Yanaga K.
The Jikei University School of Medicine, Surgery, Tokyo, Japan
contact e-Mail address: masudatakahiro730@gmail.com
Introduction: Per-oral endoscopic myotomy (POEM) is known as an ef-
fective therapeutic option for patients with achalasia and also for spas-
tic esophageal disorders including Jackhammer esophagus and defuse 
esophageal spasm. Gastroesophageal reflux disease (GERD) is common 
in patients who undergo POEM, with a reported prevalence of up to 40%, 
due to the lack of fundoplication. Subset of such patients clinically require 
an additional laparoscopic fundoplication due to a poor response to acid 
neutralization therapy. However, potential risks of GERD after POEM re-
mains unstudied.
aims & Methods: The aim of this study is to propose predictors of post-
POEM GERD. All patients who were diagnosed with achalasia and spastic 
esophageal disorders at our tertiary referral esophageal center are entered 
into a prospectively maintained institutional database. After Institutional 
Review Board approval, we queried this database to identify patients who 
underwent POEM procedure between January 2016 and March 2019 (n=42). 
Of these, patients with a history of prior endoscopic/laparoscopic myotomy 
(n=8) or whose post-operative upper endoscopic evaluation were unavail-
able (n=8) were excluded. Endoscopic surveillance was conducted at 3 
months, 1 year, and then yearly after POEM procedure. The patients were 
divided into two groups based on post-POEM endoscopic findings using 
the Los Angeles classification, ie, non-GERD group (grade N or M) and 
GERD group (grade A or more). Pre-operative evaluations based on timed 
barium esophagogram (TBE), high-resolution esophageal manometry 
(HRM), and Eckardt score were compared between the groups.
results: Twenty-six patients met the study criteria. Their median age was 
47 years, 16 patients were men, and the median BMI was 21.4 kg/m2. The 
median follow up period was 13 months. Eleven of 26 patients (42%) had 
an evidence of GERD based on post-POEM endoscopy. Age, sex, and BMI 
were comparable between the patients with and without GERD. Duration 
of disease was longer in patients with post-POEM GERD than those without 
GERD, although it did not reach statistical significance (120 vs. 36 months, 
p=0.069). Pre-operative Eckardt score was similar between the groups. 
According to Japan Esophageal Society classification of esophagogram in 
patients diagnosed with achalasia, there were no differences in morphol-
ogy type (straight esophageal type: sigmoid type: advanced sigmoid type, 
11:3:0 in non-GERD group and 8:2:1 in GERD group; p=0.793) and maximal 
esophageal transverse diameter (41.0 mm in non-GERD group vs. 44.0 
mm in GERD group, p=0.536) between the groups. Manometric diagno-
sis based on Chicago classification v3.0 was similar between the patients 
in non-GERD group and those in GERD group (achalasia type I: type II: 
type III: Jackhammer esophagus, 3:8:3:1 in non-GERD vs. 4:5:2:0 in GERD, 
p=0.922). No patient had a manometric hiatal hernia. The resting lower 
esophageal sphincter (LES) pressure and intraabdominal LES length were 
similar among the groups; however, the patients in the GERD group had 
significantly shorter overall LES length (OL) than those in the non-GERD 
group (2.9 vs. 3.5 cm, p=0.003). ROC curve analysis for OL revealed the 
cut-off value of 3.0 cm (AUC 0.885 [95%CI: 0.722-1.000], p=0.006) with the 
sensitivity of 100% and specificity of 71%. Prevalence of GERD was 100% 
in patients with OL < 3 cm and 13% in patients with OL ≥3 cm (p=0.001).
conclusion: Longer duration of disease may be a risk factor of esophagitis 
after POEM. Longer OL (≥3 cm) appears to prevent reflux esophagitis after 
POEM. Further study is warranted.
disclosure: Nothing to disclose 
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high risk of post-POEM reflux tempers the POEM enthusiasm. The aim of 
our case series was to assess the long-term clinical outcome of POEM and 
a thorough analysis of post-POEM reflux.
aims & Methods: A retrospective analysis of prospectively collected data 
of consecutive patients undergoing POEM at our tertiary center (December 
2012- March 2019). All patients were scheduled for follow up at 3and 12 
months after the procedure and every year thereafter. Upper GI endos-
copy, high-resolution manometry (HRM) and 24-hour pH monitoring were 
performed 3 months after POEM; endoscopy was then repeated between 
24-36 months. Main outcomes were treatment success defined as Eckardt 
score < 3, recurrence rate and parameters of post-POEM gastroesophageal 
reflux evaluated by 24h pH monitoring, presence of reflux esophagitis, re-
flux symptoms and use of proton pump inhibitors (PPIs).
results: A total of 292 patients with achalasia underwent 306 POEM pro-
cedures. Follow- up visits at 3, 12, 24, 36 and 48 months were completed 
in 250, 179, 131, 69 and 28 patients. At 3, 12, 24, 36 and 48M, treatment 
success was achieved in 98% (CI 96-100), 95% (92-98), 90% (85-95), 82% 
(73- 91) and 79% (67-91) of patients. A total of 25 patients experienced 
treatment failure (n=6) or recurrence (n=19). At 3 months, reflux esopha-
gitis was observed in 107/251 (42.6%, LA C/D in 12 patients). Abnormal 
acid exposure was detected in 93/215 (44.3%) patients. At 24-36 months, 
endoscopy was performed in 84 patients and reflux esophagitis was pres-
ent in 27 patients (32.1%). PPIs were administered to 37.2% and 42.7% of 
patients at 3 and 24 months, respectively.
conclusion: POEM is a highly effective endoscopic treatment for achalasia 
with still favorable treatment success of almost 80% at 4 years after the 
procedure. Higher rate of post-POEM reflux esophagitis seems to decrease 
over time.
disclosure: Nothing to disclose 
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Introduction: Esophageal junction outflow obstruction (EGJOO) is a new di-
agnosis recently introduced in Chicago Classification V3.0. It is a pathologi-
cal entity of unclear clinical significance and represents a heterogeneous 
range of conditions. It may be classified as structural (SO) when there is a 
mechanical cause for the obstruction such as the presence of hiatal hernia, 
esophageal rings and post-surgery or as functional (FO) when a potential 
obstructive cause is not identified.
aims & Methods: Aim: to evaluate the prevalence of EGJOO and to compare 
the clinical, manometric and phmonitoring characteristics of the patients 
according to the cause: SO versus FO.
Methods: Retrospective and single center study. All patients presented a 
High Resolution Manometry (HRM) with 36 channels of solid state. All the 
HRM between 01/2012 and 01/2019 were reviewed and were included pa-
tients with EGJOO diagnosis and then classified in SO and FO.
results: From 2357 HRM reviewed, 79 (3.4%) patients met criteria of EGJOO 
according to Chicago Classification v3.0, 57.0% females with mean age of 
59.8 (±13.8) years. Of them, 42 (53.2%) patients presented simultaneous 
esophageal pH monitoring. 
Forty patients (50.6%) were categorized as SO and 39 (49.4%) as FO. 
Fourteen patients presented previous history of Nissen fundoplication, 3 
presented bariatric surgery, 3 distal esophageal ring and 26 hiatal hernia. 
Patients with SO presented more frequently typical symptoms (52.5%vs 
20.5%; p=0.003) and atypical symptoms (22.5%vs5.1%; p=0.026) of GERD 
when compared to FO. 
Patients with FO presented higher intrabolus pressure (18.4 vs 15.5; 
p=0.039) when compared to SO and in multiple swallowing, FO presented 
higher distal contractile integral (DCI) (2818.3 vs 1670.9; p=0.003) compar-
ing to SO. 
No other differences were observed between the groups regarding other 
HRM parameters and pH monitoring.
conclusion: The frequency of EGJOO in our population was low and it rep-
resents a heterogeneous group of patients. The differences between SO 
and FO are scarce, however we found higher intrabolus pressure and DCI 
on multiple swallows in patients with FO.
disclosure: Nothing to disclose 
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Introduction: Some patients feel dysphagia as a stuck sensation in their 
throat, while the real obstruction site is in their lower oesophagus. Chest 
pain is also often reported by achalasia patients, but the mechanism of 
chest pain is still unknown. High-resolution manometry (HRM) enable us 
to categorize achalasia into three distinct subtypes by the status of the 
oesophageal body (Chicago classification :CC).
aims & Methods: The aim of this study was to clarify the symptoms of 
oesophageal achalasia patients using HRM. Seventy one newly diagnosed 
achalasia patients were enrolled. Symptoms, HRM and radiographic find-
ings were retrospectively reviewed. A structured self-reported question-
naire focused on dysphagia and chest pain were obtained from all the pa-
tients. The questionnaire consists of the main site of symptom (dysphagia 
and chest pain), timing, duration, food or behavior that cause symptoms, 
accompanying symptoms, and the preferable way to relieve symptoms. 
HRM was performed with ManoScan and assessed by CC v3.0. Oesophago-
grams were taken with 100ml of barium. Characteristics of the symptoms 
and the differences in symptom details among the manometric subtypes 
were investigated.
results: Of total 71 patients, 69 patients(97%) reported dysphagia and 
39patienpatiens(54%) reported chest pain. According to HRM findings, 
patients were classified into types I/II/III 25/37/9 patients (35/52/12%) by 
CC. The pressurization of oesophageal body after swallows was different 
among the subtypes (I/II/III 13.4/27.7/70.3mmHg, p< 0.05). Oesophago-
gram also showed the difference in the diameter of the oesophagus (I/II/
III 5.4/4.8/3.1cm, P< 0.05). Regarding dysphagia, Type II patients mostly 
felt dysphagia in the throat (54%), while type I and III patients mostly felt 
it in the epigastrium (52%, 55%). Type II patients often had dysphagia 
immediately after swallowing (41%), but that was only the case in 8.7% of 
type I and 33% of type III patients (p< 0.05). Drinking water was preferred 
to relieve dysphagia in type I and II patients (78% and 70%), but less so 
in type III (33%). About chest pain, patients with chest pain had higher 
pressurization in the oesophageal body than patients without pain (34.8 
vs. 21.5mmHg, p< 0.05). Type I patients rarely felt pain in the interdigestive 
period (14%), but more often while sleeping (43%) and in early morning 
(43%). Type III patients reported more pain in the interdigestive period 
(67%), but none while sleeping. The most reported answer for the dura-
tion was 5-10minutes for type I (36%), within 1 minute for type II (26%), 
and 1-5minutes for type III (67%). Type III patients reported more often 
than type I and II patients that solid food caused pain (I/II/III 0/10/33%, 
p=0.09).
conclusion: Detailed symptoms of achalasia, such as its site and timing, 
varied by subtypes. The status of the oesophageal body might induce those 
differences in symptoms.
disclosure: Nothing to disclose 
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S, et al. Peroral endoscopic myotomy in treatment-naive achalasia patients 
versus prior treatment failure cases. Endoscopy 2018;50:358-70. [4] Louie 
BE, Schneider AM, Schembre DB, Aye RW. Impact of prior interventions 
on outcomes during per oral endoscopic myotomy. Surgical endoscopy 
2017;31:1841-8.
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Introduction: G-POEM is an emerging method for treatment of severe gas-
troparesis (GP). Safe and reliable mucosal closure is necessary to avoid 
major adverse events.
aims & Methods: The aim of this prospective (ongoing) study was to com-
pare the effectivity of two closure methods: endoscopic clips (ResolutionTM® 
or InstinctTM®) and endoscopic suturing (ES, Apollo OverStitchTM®) in pa-
tients undergoing G-POEM for refractory GP. 
A single center, prospective study (NCT:03679104). All patients, who un-
derwent G-POEM in our centre and agreed to participate were enrolled. 
The closure method was assigned at the discretion of an endoscopist (one 
endoscopist performed all procedures) prior to the procedure. The main 
outcome was the proportion of subjects with successful closure. Unsuc-
cessful closure was defined as a need for a rescue method, or a need for 
an additional intervention (e.g. in case of leak). Secondary outcomes were 
easiness of closure [measured by means of a questionnaire on a VAS (vi-
sual analogue scale, 0 = impossible, 10 = very easy, scored by endoscopist as 
well as an endoscopy nurse)] and closure time.
results: A total of 15 patients [M:F/7:8; mean age 50.5 (29-74)] have been 
included so far; 8 patients received ES closure and 7 patients received a 
closure with endoclips [mean 6, range (5-19)]. All patients with ES had 
successful closure but 2 pts (29%) with clips needed a rescue method (n=1, 
KING closure with an endoloop) and an additional clipping because of leak 
on POD1 (n=1). The remaining patients (n=5, 71%) had a successful closure 
with clips. Closure with clips tended to be quicker [mean closure time 
and range 10.4 (8-13) vs 14.8 (9-20) min, p=0.189]. Endoscopist assessed 
closure with ES easier compared to clips [mean VAS, SD: 7.6 ±1.3 (ES) vs. 
5.4 ±1.7 (clips) p=0.02], nurses assessed easines of both closure methods 
as comparable (VAS 6.6 ±2.6 (ES) vs 7 ±1.2 (clips) p= 0.536].
conclusion: Endoscopic suturing system may be more reliable than clip-
ping for mucosal closure in patients undergoing G-POEM, even though is 
technically more demanding. Besides clips, centers performing G-POEM 
should have an alternative (rescue) closure method. (Supported from 
Czech Ministry of Health 17-28797A). Clin Trial: NCT03679104
disclosure: Nothing to disclose 
P0575 PerOraL endOscOPIc MyOTOMy (POeM): a cOMParaTIve 
sTudy BeTWeen chagasIc and IdIOPaThIc achaLasIa
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Introduction: Achalasia is a benign esophageal motor disorder that results 
from a progressive degeneration of ganglion cells in the myenteric plexus 
of the esophageal wall. It leads to failure of relaxation of the lower esoph-
ageal sphincter associated to the loss of the peristalsis in the distal esoph-
agus. The etiology of the primary or idiopathic achalasia is unknown. In 
Chagas disease, the esophageal infection with the protozoan parasite Try-
P0573 cOMParIsOn Of PerOraL endOscOPIc MyOTOMy 
BeTWeen de-nOvO achaLasIa and PrIOr TreaTMenT faILure 
achaLasIa
Yoo I.K.1, Yeniova A.O.2, Cho J.Y.1
1CHA Bundang Medical Center, CHA University, Division of Gastroenterology, 
Department of Internal Medicine, Seongnam, Korea (Republic of), 2Tokat 
Gaziosmanpaşa University Faculty of Medicine, Department of Internal 
Medicine Division of Gastroenterology, Tokat, Turkey
contact e-Mail address: ozgur.yeniova@gop.edu.tr
Introduction: Peroral endoscopic myotomy (POEM) has been recognized as 
an effective treatment for patients with achalasia (1). Prior treatment may 
affect the outcome of subsequent treatment (2). We aimed to compare the 
safety and efficacy of POEM in treatment-naive patients (TN) vs. those with 
prior treatment failure (PTF).
aims & Methods: We retrospectively analyzed the data of achalasia pa-
tients who underwent POEM from November 2011 to January 2018. A com-
parative analysis was performed between TN and PTF cases. Technical and 
clinical success, adverse events, operative time for POEM, hospital stay and 
length of myotomy were compared between the two groups.
results: Overall, 209 patients with achalasia underwent POEM during the 
studied period, including 113 patients (54%) in the TN group and 96 pa-
tients (45%) in the PTF group. The baseline characteristics of the TN and 
PTF groups were not significantly different except for duration of disease. 
The PTF group had longer disease duration than the TN group. (7.92 ± 9.28 
vs 4.45 ± 5.67 years respectively p=0.005). Both groups were technically 
successful. All of the POEM cases’ procedures were completed successfully. 
Operative time was longer in the PTF group than that in the de novo group, 
but the difference was not statistically significant. The occurrence rates of 
gas-related events and severe complications were similar in both groups. 
The operation time, hospital stay, length of myotomy were not significantly 
different between the two groups. 
Changes in the Eckardt score before and after POEM (5.11 ± 0.23 vs. 4.99 ± 
0.253; P=0.042 vs. P=0.001) were comparable in the TN and PTF cases. IRP 
and LES pressure decreased after POEM. The decreases in the IRP and LES 
pressure values were significantly different between TN group and the PTF 
group (Table 1). After 6 months, more patient suffered from reflux symp-
toms in the PTF group but DeMeester score and endoscopic evaluation 
were not significantly different between the two groups. 
 
Treatment naive 
group(n=113)
PTf group 
(n=96) P-value
Technical success, n (%) 113 (100%) 96 (100%) not applicable
Length of myotomy, cm (Esophagus) 7.22 ± 2.27 7.11 ± 1.97 0.630
Length of myotomy, cm (Stomach) 1.81 ± 0.59 1.82 ± 0.54 0.979
Operation time, minute 74.08 ± 31.93 76.52 ± 32.27 0.539
Duration of nill per oss, day 5.23 ± 1.51 5.28 ± 1.46 0.884
Hospital stay, day 7.23 ± 1.51 7.28 ± 1.46 0.884
Adverse event, n (%) 52 (46.0) 66 (68.7) 0.214
Clinical success (Eckardt score ≤3) 107 (94.6%) 91 (94.7%) 0.978
Difference of Lower esophageal 
sphincter pressure
22.88 ± 18.17 8.83 ± 18.10 0.001
Difference of Integrated Relaxation 
Pressure
18.02 ± 21.92 7.32 ± 14.21 0.004
Reflux symptoms after 6 months 
(Yes : No), n
41 : 71 47 : 46 0.045
[Table 1]
conclusion: Our results were comparable to other studies that compared 
TN and PTF in terms of the mean values of adverse effects, operation time 
and technical and clinical success of POEM (3,4). POEM is safe and equal-
ly effective for de-novo patients and for those in whom prior treatment 
failed. POEM should be considered as the treatment of choice in patients 
with history of failed prior treatment.
references: [1] Inoue H, Minami H, Kobayashi Y, Sato Y, Kaga M, Suzuki 
M, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. 
Endoscopy 2010;42:265-71. [2] Wu QN, Xu XY, Zhang XC, Xu MD, Zhang YQ, 
Chen WF, et al. Submucosal fibrosis in achalasia patients is a rare cause of 
aborted peroral endoscopic myotomy procedures. Endoscopy 2017;49:736-
44. [3] Nabi Z, Ramchandani M, Chavan R, Tandan M, Kalapala R, Darisetty 
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panosoma cruzimay result in the loss of the intramural ganglion cells. The 
peroral endoscopic myotomy (POEM) is an effective and safe treatment for 
achalasia. However, there is no study comparing outcomes of POEM ac-
cording to the etiology of the achalasia.
aims & Methods: We evaluated our prospectively collected database of 
POEM procedures performed at a single institution from November 2016 
to August 2017. Demographic data, clinical success, Eckardt score, low-
er esophageal sphincter (LES) pressure, body mass index (BMI), erosive 
esophagitis, adverse events, pneumoperitoneum requiring needle decom-
pression, operative time, and length of hospital stay were assessed. Clini-
cal success was defined as an Eckardt score ≤ 3 at 1 year. Student T-test and 
Logistic regression analyses were performed.
results: Fifty-one patients (52,9% F, mean age 50 ± 13.8) underwent POEM 
as a treatment for achalasia in this period, 20 patients with chagasic and 31 
with idiopathic etiology. All procedures were posterior full-thickness PO-
EMs. The overall clinical success rate was 92.2%. There was no statistical 
difference between groups regarding clinical success (90% in the chagasic 
group vs 93.6% in the idiopathic group, p= 0.640). Both groups presented 
significant reduction in Eckardt score compared to baseline (1.00 vs 7.50 in 
the chagasic group, p< 0.001; and 0.00 vs 8.00 in the idiopathic group, p< 
0.001), LES pressure (10.32 vs 21.76 in the chagasic group, p< 0.001; 10.70 vs 
25.21 in the idiopathic group, p< 0.001), and increase in BMI (27.11 vs 25.41 
in the chagasic group, p< 0.001; 25.99 vs 22.17 in the idiopathic group, 
p< 0.001) at 1 year follow-up. There was no statistical difference between 
groups regarding Eckardt score (p= 0.439), LES pressure (p= 0.507), and 
BMI (p= 0.254) at 12 months. There were no significant differences be-
tween groups concerning the rates of erosive esophagitis (35% vs 44%, p= 
0.432), adverse events (30% vs 12%, p= 0.311), pneumoperitoneum requir-
ing needle decompression (35% vs 35%, p= 0.81), operative time (101.3 
min vs 99.1 min, p= 0.840), and length of hospital stay (3.75 days vs 3.58 
days, p= 0.622).
conclusion: POEM is an effective and safe treatment in patients with acha-
lasia. There is no difference in outcomes comparing chagasic and idio-
pathic achalasia.
disclosure: Nothing to disclose 
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Introduction: Eosinophilic Esophagitis (EoE) is a chronic immune/antigen- 
mediated disorder, characterized by symptoms of esophageal dysfunction 
and esophageal eosinophilic-infiltration. EoE has been often associated 
with esophageal motility abnormalities, ranging from hypo- to hyper- con-
tractile motility disorders.
aims & Methods: The aim of this study is to evaluate the incidence and 
clinical characteristics of esophageal motility disorders in EoE.
97 consecutive patients (mean age 39, range 18-75yo, 20 F) with a diag-
nosis of EoE assessed in our unit between 2012 to 2018, were included. 
The diagnosis was posed according to international criteria. Among 97 pa-
tients, in 47 (48%) high resolution manometry (HRM) was not performed, 
so they were excluded from the study. Patients undergone HRM, were 
studied using the standardised international protocol and manometric 
diagnoses were made according to Chicago Classification 3.0. For the sta-
tistical analysis Fisher exact test was used.
results: Among 50 patients included (mean age 41, range 20-75 yo, 42M), 
26 (52%) showed normal manometric pattern. Between EoE patients with 
pathological pattern, 16 (67%) had hypocontractile disorders, and 8 (33%) 
had hypercontractile abnormalities. In particular, EoE patients with hy-
pocontractile patterns had frequent failed peristalses (N=4), ineffective 
esophageal motility (N=6), fragmented peristalsis (N=4), absent peristal-
sis (N=2). Among EoE patients with hypercontractile patterns, we found 
achalasia type III (N=2), achalasia type II (N=2), achalasia type I (N=1), 
EGJ outflow obstruction (N=1), Jackhammer esophagus (N=1), and 1 distal 
esophageal spasm (N=1). 
We then analysed both patients with normal and pathological manometric 
pattern in terms of age, sex and response to PPI.
Patients with normal motility n=26 (52%) showed:
Age (mean and median) 43,4yo; 40,5yo
Age at diagnosis (mean and median) 36,1yo; 33yo
Sex 22M (84,6%)
PPI response (9 of 17) 52,9%
Patients with motility disorders n=24 (48%) showed:
Age (mean and median) 37,9yo; 33,7yo
Age at diagnosis (mean and median) 29,2yo; 25yo
Sex 20M (83,3%)
PPI response (7 of 18) 38,9%
Among the group with abnormal motility, the same characterization was 
done.
Patients with hypercontractile disorders n=8 (33%)
Age (mean and median) 41,9yo;36,2yo
Age at diagnosis (mean and median) 27,2yo; 29,5yo
Sex 6M (75%)
PPI response (2 of 9) 22%
Patients with hypocontractile disorders n=16 (67%)
Age (mean and median) 36yo; 32yo
Age at diagnosis (mean and median) 30,4yo; 24yo
Sex 14M (87.5%)
PPI response (5 of 9) 55%
There was no difference in terms of prevalence of motility abnormalities 
(p=0.49) nor a predominance of hypo/hyper contractile pattern (p=0.14), 
between PPI responsive/non-responsive patients. Similarly, no difference 
in terms of motility abnormalities (p=1), nor a predominance of hypo/hyper 
contractile (p= 0.60) were found between females and males. Consider-
ing the mean age of the group (39yo), there was a different prevalence of 
motility abnormalities between younger and older patients, with greater 
frequency of pathological pattern in young patients (p= 0.045). However, 
there was no difference in terms of frequency of hypo- or hypercontractile 
disorders between young and old EoE patients (p= 0.49).
conclusion: This series shows that esophageal motility abnormalities are 
present in about half of EoE patients, especially in young subjects who 
showed a higher prevalence of hypocontractile disorders. A correlation 
with patient’s gender or response to PPI therapy was not observed.
references: Nurko S, Rosen R. Esophageal dysmotility in patients who have 
eosinophilic esophagitis. Gastrointest Endosc Clin N Am. 2008;18(1):73-ix. 
Lucendo AJ, Molina-Infante J, Arias Á, et al. Guidelines on eosinophilic 
esophagitis: evidence-based statements and recommendations for diag-
nosis and management in children and adults. United European Gastro-
enterol J. 2017;5(3):335-358.
disclosure: Nothing to disclose 
P0577 a PrOsPecTIve MuLTIcenTer sTudy On The PrevaLence 
Of eOsInOPhILIc OesOPhagITIs In The russIan federaTIOn 
aMOng aduLTs undergOIng uPPer endOscOPy
Kaibysheva V.1, Kashin S.V.2, Pirogov S.3, Galkova Z.4, Vidyaeva N.5, 
Fedorov E.D.6, Galeeva Z.7, Shapovaliantc S.1, Nikonov  E.8, Smirnov A.9, 
Ivanova E.10
1Pirogov Russian National Research Medical University, Moscow, Russian 
Federation, 2Yaroslavl Clinical Oncology Hosp., Department of Endoscopy, 
Yaroslavl, Russian Federation, 3P.A. Herzen Moscow Cancer Research Institute, 
Endoscopy, Moscow, Russian Federation, 4Russian National Research Medical 
University named by N.I. Pirogov, Endoscopy, Moscow, Russian Federation, 
5Yaroslavl Regional Cancer Hospital, Endoscopy, Yaroslavl, Russian 
Federation, 6Moscow University Hospital Nr. 31, Dept. of Endoscopy, Moscow, 
Russian Federation, 7Johnson Russia, Moscow, Russian Federation, 8Pirogov 
Russian National Research Medical University (RNRMU) , Moscow, Russian 
Federation, 9Pavlov First Saint Petersburg State Medical University, Saint 
Petersburg, Russian Federation, 10Moscow University Hospital No. 31, Dept. of 
Surgical Endoscopy, Moscow, Russian Federation
contact e-Mail address: valeryslove@mail.ru
Introduction: Eosinophilic oesophagitis (EoE) is a common cause of oe-
sophageal disease in Europe and the USA. Limited data have been re-
ported on its epidemiology in the Russian Federation. The aim of this study 
was to evaluate the prevalence of EoE in the Russian Federation among 
adult patients undergoing esophagogastroduodenoscopy (EGDS) due to 
upper gastrointestinal (UGI) symptoms.
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multiple taxonomic levels when comparing the two communities, which 
included significant decreases in Clostridia and Clostridiales in patients 
with EoE (q ≤ 0.1, permutation test with t-statistic).
conclusion: This finding is particularly important as previous studies show 
that members of Clostridia group are protective against the development 
of food allergies in a rodent model. Clostridia-containing microbiota is also 
associated with the expansion of intestinal regulatory T cells, and induc-
tion of IL-22 production by RORγt+ ILCs promoting an immune environment 
conducive for tolerance to dietary antigens. While our study is limited by 
the small sample size, the strengths of the study are a lack of confounders 
that have been associated with altered stool microbiome such as proton 
pump inhibitors, and other atopic illnesses in most patients. Our findings 
suggest defined microbial consortia containing Clostridia may be a poten-
tial therapeutic option in EoE.
disclosure: Advisory board uBiome and ad hoc Salix. 
P0579 OuTcOMes Of a saMe sessIOn OesOPhageaL dILaTIOn 
afTer reMOvaL Of IMPacTed fOOd BOLus: resuLTs Of a 
randOMIzed cOnTrOLLed sTudy
Ooi M.1,2, Duong T.1, Wong S.1,2, Rayner C.1, Nguyen N.1
1Royal Adelaide Hospital, Adelaide, Australia, 2Queen Elizabeth Hospital, 
Woodville South, Australia
contact e-Mail address: quocnam.nguyen@sa.gov.au
Introduction: Majority of food bolus obstruction (FBO) is caused by a be-
nign esophageal stricture for which endoscopic dilation is an effective 
treatment. However, it is unknown whether same-session endoscopic di-
lation (SSED) after removal of food bolus (FB) is clinically safe.
aims & Methods: : To evaluate the safety of performing SSED immediately 
after FB removal. Methods: A randomized controlled study was conducted 
between 2017-2019 on patients who had FBO due to oesophageal stricture 
were randomized into 2 groups: (i) SSED group - who had SSED using 
wire-guided Savary Gillard dilators vs (ii) non SSED group - deferred dila-
tion to another date. Primary outcome measures were technical success, 
procedural-related complication(s) and mortality.
results: 456 patients had endoscopic removal of food bolus, of which 236 
were excluded due to absence of an oesophageal stenosis (n=93), con-
current anticoagulation or antiplatelet (n=136), dilators were not avail-
able (n=7). 220 patients were randomized to group SSED (n=110) and non 
SSED group (n=110). Technical success of dilation and immediate clinical 
response were achieved in all patients. The median maximal dilation di-
ameter was 14mm (range 11-18mm). Apart from chest pain occurred in 9 
(8%) patients immediately after dilation that resolved with simple analge-
sia, there was no perforation, major bleeding requiring blood transfusion 
or death. Recurrent of FBO occurred in 41 (18.6%) at a mean time of 31 ± 
19 days, and was significantly higher in the non-SSED than SSED group (39 
vs. 2; P < 0.01).
conclusion: Same-session esophageal stricture dilation after FB removal 
is safe and significantly reduced the risk of recurrence, preventing repeat 
admission. Thus, our data support the use of routine use of SSED for pa-
tients who present with FBO.
references: 1. Longstreth G. F., Longstreth K. J., Yao J. F. Esophageal food 
impaction: epidemiology and therapy. A retrospective, observational 
study. Gastrointestinal Endoscopy. 2001;53(2):193-198. 2. Mahesh VN, 
Holloway RH, Nguyen NQ. Changing epidemiology of food bolus impac-
tion: is eosinophilic esophagitis to blame? J Gastroenterol Hepatol 2013 
Jun;28(6):963-6. 3. Vicari J. J., Johanson J. F., Frakes J. T. Outcomes of acute 
esophageal food impaction: success of the push technique. Gastrointes-
tinal Endoscopy. 2001;53(2):178-181. 4. Smith MT, Wong RKH. Esophageal 
foreign bodies: Types and techniques for removal. Curr Treat Options Gas-
troenterol. 2006;9:75-84. 5. ASGE Standards of Practice Committee. Iken-
berry SO, Jue TL, et al. Management of ingested foreign bodies and food 
impactions. Gastrointest Endosc. 2011;73:1085-1091.
disclosure: Nothing to disclose 
aims & Methods: This study was conducted in 11 endoscopy departments 
in the Russian Federation (4 in Moscow, 1 in Yaroslavl, 1 in Ivanovo, 1 in 
Kazan, 2 in Saint Petersburg, 1 in Ekaterinburg, 1 in Kemerovo) between 
October 2017 and March 2018. We enrolled 49240 patients aged 18 to 80 
years old who underwent an EGDS due to UGI symptoms (heartburn, dys-
phagia, food impaction, acid regurgitation, chest pain, epigastric pain, 
nausea, vomiting). Patients with endoscopic findings of EoE (oedema, 
rings, exudates, furrows, and strictures) were underwent oesophageal 
biopsy (at least 6 biopsies were obtained from the proximal and distal oe-
sophagus to quantify the maximum eosinophil count per high-power field 
(eos/hpf; hpf=0.24 mm). Patients were diagnosed with EoE if the number 
of eosinophils was ≥15.
results: EGDS revealed endoscopic features of EoE in 137 patients. Oesoph-
ageal biopsy confirmed eosinophilic oesophagitis in 62 cases. EoE patients 
had a mean age of 38.2 years (rank 20-67) years, 83.3% of patients were 
under 45 years of age, 79.1% patients were male. Individuals with EoE 
suffered predominantly from dysphagia (62.5%), heartburn (54.1%), food 
impaction (37.5%), and nausea (29.1%). 79.1% of EoE patients had a past 
history of gastroesophageal reflux disease, 25% suffered from allergic rhi-
nitis, 33.3% had atopic dermatitis, 8.3% -asthma. 1 patient had a family 
history of EoE (his sibling and mother also suffered from dysphagia due 
to EoE).
conclusion: The prevalence of EoE among adult patients undergoing up-
per endoscopy in the Russian Federation is 1 case for 794 UGI endoscopies 
(0.13%). The characteristic findings of EoE patients included male gender, 
age under 45 years and history of atopic diseases.
disclosure: Nothing to disclose 
P0578 a decreased aBundance Of cLOsTrIdIa characTerIzes 
The guT MIcrOBIOTa In eOsInOPhILIc esOPhagITIs
Kashyap P.1, Johnson S.2, Geno D.1, Lekatz H.1, Chen J.2, Katzka D.1
1Mayo Clinic, Gastroenterology and Hepatology, Rochester, United States, 
2Mayo Clinic, Biomedical Statistics and Informatics, Rochester, United States
contact e-Mail address: kashyap.purna@mayo.edu
Introduction: Eosinophilic esophagitis (EoE) is an allergic disorder char-
acterized by a Th2 mediated immune response, esophageal dysfunction 
and esophageal eosinophilic infiltration. While several genetic, and envi-
ronmental factors have been implicated in EoE, recent evidence supports 
a role for the gut microbiome. Abnormalities in the gut microbiome are 
associated with suppressed Th2 response and predisposition to atopic dis-
ease such as asthma and eczema.
aims & Methods: In this study we evaluated the gut microbiome repre-
sented in the stool from patients with EoE matched to healthy controls. 
All human studies were approved by the institutional IRB. Stool bacterial 
DNA was extracted using MoBio fecal DNA extraction kit, followed by 16S 
rRNA amplification using primers flanking the V4 hypervariable region 
(515F, 806R) and sequenced on Illumina MiSeq. Paired sequence reads 
were processed via the hybrid-denovo bioinformatics pipeline. A linear 
regression model (t-test) was used for testing the association with alpha-
diversity after rarefaction to 20,000 reads/sample. Taxa-level association 
analyses were performed at multiple taxonomic levels. Permutation-based 
false discovery rate (FDR) control was used to correct for multiple test-
ing on each taxonomic level, and FDR-adjusted p-values or q-values ≤ 0.1 
were considered significant. All statistical analyses were performed in R 
3.4.2.
results: Patients with EoE had a median age of 48 (34-64), body mass 
index (BMI) was 29.51 (22.40-36.49), 4 were male and all were Caucasian. 
Only one patient had asthma and one had atopic dermatitis. Six patients 
were on a regular diet. No patients were on PPIs. The healthy control pa-
tients had a median age 51 (33-61), BMI 24.75 (19.73-41.39), 3 were male 
and all were Caucasian. 
We compared the 16S rRNA-based microbial community composition 
in stool samples from the patients with EoE (n=12) and healthy control 
subjects (n=12). At the phylum level, we observed a marked decrease in 
Firmicutes and increase in Bacteroidetes in patients with EoE. The gut mi-
crobial communities from patients with EoE were characterized by a lower 
alpha diversity (species richness, p = 0.09; Shannon index, p = 0.01; linear 
regression). The beta-diversity was also significantly different between 
patients with EoE and healthy controls (p = 0.03, PERMANOVA based on 
weighted UniFrac; p = 0.04, omninbus test combining multiple beta diver-
sity measures). There were significant differences in relative abundance at 
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P0580 a nOveL BudesOnIde OrOdIsPersIBLe TaBLeT WITh 
a sPecIaL esOPhageaL-TargeTIng can Induce cOMPLeTe 
cLInIcaL, endOscOPIc and hIsTOLOgIc reMIssIOn In acTIve 
eOsInOPhILIc esOPhagITIs: resuLTs frOM a POsT-hOc anaLysIs 
Of The randOMIzed, dOuBLe-BLInd, PLaceBO-cOnTrOLLed 
eOs-1 TrIaL
Miehlke S.1, Schlag C.2, Straumann A.3,4, Vieth M.5, Müller R.6, 
Greinwald R.7, Lucendo A.J.8, on Behalf of the International EOS-1 Study 
Group
1Coopertion of Internal Medicine Center for Digestive Diseases, Hamburg, 
Germany, 2Technische Universität München, II. Medizinsiche Klinik, 
München, Germany, 3Swiss EoE Research Network, Gastroenterology FMH, 
Olten, Switzerland, 4University Hospital Zurich, Clinic for Gastroenterology 
and Hepatology, Zurich, Switzerland, 5Klinikum Bayreuth Abt. Pathology, Abt. 
Pathologie, Bayreuth, Germany, 6Dr. Falk Pharma GmbH, Clinical Research 
& Development, Freiburg, Germany, 7Dr. Falk Pharma GmbH, Research and 
Development, Freiburg, Germany, 8Hospital General de Tomelloso Dept. of 
Digestive Health, Dept. de Gastroenterologia, Tomelloso, Spain
contact e-Mail address: prof.miehlke@mdz-hamburg.de
Introduction: A 6-week treatment with a novel budesonide orodispers-
ible tablet twice daily (BOT 1mg BID), with a unique mode of delivery and 
esophageal targeting, was highly effective and safe in the EOS-1 study for 
induction of clinico-histological remission in adult patients with active 
eosinophilic esophagitis (EoE) according to standard criteria (1). Here we 
present in a post-hoc analysis the efficacy of BOT 1mg BID using new, most 
stringent criteria, e.g., as previously suggested by Greuter et al. (2).
aims & Methods: To assess the efficacy of BOT 1mg BID using most strin-
gent endpoints for the induction of complete normalization of esophageal 
biopsies, absence of endoscopic abnormalities and absence of clinical 
symptoms in adult patients with active EoE.
Adults with active EoE (n=88) randomly received 6-weeks double-blind 
treatment with either BOT 1mg BID (n=59) or placebo BID (n=29). 
A priori defined endpoints were: clinico-histological remission: < 16 eos/
mm2 hpf AND ≤2 points on daily numerical rating scales (0-10 points) each 
for dysphagia and odynophagia on each of the last 7 days
histological remission: peak < 16 eos/mm2 hpf
clinical remission: ≤2 points on numerical rating scales (0-10 points) each 
for dysphagia and odynophagia on each of the last 7 days.
Post-hoc stringently defined endpoints were: 
deep clinical remission (2): ‘0’ points on daily numerical rating scales (0-
10 points) each for dysphagia and odynophagia on each of the last 7 days.
deep endoscopic remission (2): modified EREFS subscores: fixed rings = 
‘Grade 0: none’ or ‘Grade 1: mild’, exudates = ‘Grade 0: none’, furrows = 
‘Grade 0: absent’, and edema = ‘Grade 0: absent’.
histological remission (2): peak < 15 eos/hpf
deep histological remission: ‘0’ eos/mm2 hpf in all biopsies.
deep disease remission (2): Being in deep clinical AND deep endoscopic 
AND histologic remission.
results: BOT 1mg BID was highly statistically superior to placebo in achiev-
ing all stringently defined clinical, endoscopic, and histological endpoints 
(see Table). 
 
number (%) of patients at week 
6 (LOcf)  
 
BOT 1mg BId 
(n=59)
Placebo BId 
(n=29)
p-value 
(2-sided)
A priori defined endpoints: Clinico-
histological remission
34 (58%) 0 (0%) < .0001
Histological remission 55 (93%) 0 (0%) < .0001
Clinical remission 35 (59%)   < .0001
Post-hoc defined most stringent 
endpoints: Deep clinical remission (2)
15 (25%) 0 (0%) = .0018
Deep endoscopic remission (2) 34 (58%) 0 (0%) < .0001
Histological remission (2) 56 (95%) 0 (0%) < .0001
Deep histological remission 53 (90%) 0 (0%) < .0001
Deep disease remission (2) 12 (20%) 0 (0%) = .0072
[Table: Standard & stringent efficacy endpoints]
conclusion: A 6-week treatment with BOT 1mg BID was highly effective for 
inducing deep histological, endoscopic and clinical remission as well as 
deep disease remission in adult EoE patients according to most stringent 
criteria.
references: (1) Lucendo AJ, et al. Gastroenterology 2019, DOI:https://doi.
org/10.1053/j. gastro.2019.03.025 (2) Greuter T, et al. Am J Gastroenterol. 
2017;112:1527-35.
disclosure: Mueller R & Greinwald R are employees of Dr. Falk Pharma 
GmbH 
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ManageMenT Of eOsInOPhILIc OesOPhagITIs aLOng TIMe In 
The EOE CONNECT regIsTry: The effecT Of cLInIcaL guIdeLInes 
TO IMPrOve cLInIcaL PracTIce
Ruiz Ponce M.1,2, Laserna-Mendieta E.J.1,2, Casabona-Francés S.2,3, 
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2Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain, 
3Hospital Universitario de La Princesa, Gastroenterologist, Madrid, Spain, 
4University of Padua, Department of Surgery, Oncology and Gastroenterology, 
Padua, Italy, 5University Hospital Vall de Hebron, Gastroenterology 
Department, Barcelona, Spain, 6Hospital de Viladecans, Barcelona, 
Spain, 7Hospital Central de Asturias, Gastroenterology, Oviedo, Spain, 8Rio 
Hortega University Hospital, Valladolid, Spain, 9Hospital Universitario 
de Fuenlabrada, Gastroenterology, Aranjuez (Madrid), Spain, 10Instituto 
de Investigación Sanitaria La Paz (IdIPaz), Madrid, Spain, 11Complejo 
Hospitalario Universitario de Albacete, Allergology, Albacete, Spain, 12Clínica 
Universidad de Navarra, Gastroenterology, Pamplona, Spain, 13Hospital 
Universitario de La Princesa, Hospital Universitario de la Princesa, Madrid, 
Spain, 14Hospital General de Tomelloso Dept. of Digestive Health, Dept. de 
Gastroenterologia, Tomelloso, Spain
contact e-Mail address: miriam.ruiz.ponce.93@gmail.com
Introduction: Eosinophilic oesophagitis (EoE) is a chronic inflammatory 
disease characterised by a dense eosinophilic infiltration of the oesopha-
gus and symptoms of oesophageal dysfunction. EoE is recognized as a par-
ticular form of non-IgE-mediated food allergy commonly associated with 
other IgE-mediated atopies. The novelty of the disease has contributed to a 
considerable diagnostic delay in many cases and to variable management 
of patients in clinical practice, who frequently underwent serum and skin 
allergy testing to find triggering antigens. Recent evidence discourages 
this practice due to its low yield.
aims & Methods: To investigate delay in EoE diagnosis, number of previ-
ous useless endoscopies performed in these patients and unneeded al-
lergy testing (laboratory, skin prick and atopy patch testing) once a EoE 
diagnosis is established, we searched within the EoE CONNECT database, 
a prospectively-maintained registry that resulted from the UEG Link Award 
program.
Patients’ data was extracted on 25th March 2019. For statistical compari-
sons, all variables were assessed depending on the date in which the dif-
ferent EoE clinical guidelines were published (2007, 2011, 2013 & 2017). 
Statistical analyses (Mann-Whitney test and Kruskal-Wallis test followed 
by Dunn post-hoc test) were performed using GraphPad software.
results: Data from 608 EoE patients recruited at 9 hospitals in Spain and 
1 more in Italy were retrieved from the EoE CONNECT registry. From those, 
dates for both symptoms onset and definitive EoE diagnosis were avail-
able for 434 patients. The diagnostic delay resulted in a mean ± standard 
deviation (SD) of 1778 ± 2411 days (approximately 4 years and 10 months). 
A significant decrease in diagnostic delay along time was noted, when 
patients were classified in five groups according to the publication dates 
of the different EoE guidelines (p< 0.001). Thus, for patients diagnosed up 
to 2007 the diagnostic delay was 4661 ± 3123 days, while it was only 164 ± 
142 days for patients diagnosed after the release of 2017 guidelines. Group 
comparisons displayed significant differences between most of the periods 
analysed. 
Twenty-eight patients had information on dates of upper endoscopies per-
formed prior to EoE diagnosis. Overall, 37 exams were performed before 
the one that provided an EoE diagnosis. The number of superfluous en-
doscopies were higher for patients diagnosed up to 2011 (n=13; 1.6 ± 1.0) 
compared to those diagnosed after 2011 (n=15, 1.1 ± 0.3) (p< 0.05). 
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EoE. The high frequency of this association seems to hypothesize a causal 
link between these two pathologies, whereas all this variability in mano-
metric pattern, epidemiological characteristic and response to therapy, 
suggests that the relationship is not univocal and that there may be dif-
ferent mechanisms that act independently to determine such association.
references: Spechler SJ, Konda V, Souza R. Can Eosinophilic Esophagitis 
Cause Achalasia and Other Esophageal Motility Disorders? Am J Gastroen-
terol. 2018 Nov;113(11):1594-1599
disclosure: Nothing to disclose 
P0583 eOsInOPhILIc esOPhagITIs quaLITy Of LIfe 
quesTIOnnaIre WeLL cOrreLaTes WITh dIsease acTIvITy and 
resPOnse TO TheraPy In acTIve eOsInOPhILIc esOPhagITIs 
PaTIenTs
Ghisa M.1, Inferrera M.1, Barberio B.1, Marinelli C.1, Gubbiotti A.2, 
della Coletta M.1, Lorenzon G.1, Tolone S.3, De Bortoli N.4, Zentilin P.5, 
Savarino V.5, Zingone F.1, Savarino E.1
1University of Padua, Department of Surgery, Oncology and Gastroenterology 
- DiSCOG Gastroenterology Unit, Padova, Italy, 2University of Padua, Padova, 
Italy, 3University of Campania ‘Luigi Vanvitelli’, Surgery, Naples, Italy, 
4University of Pisa, Department of Gastroenterology, Pisa, Italy, 5University of 
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contact e-Mail address: matteoghisa@yahoo.it
Introduction: Eosinophilic Esophagitis (EoE) is a chronic disease character-
ized by significant impairing of quality of life (QoL). The EoE-QoL-A (EQA) 
is a 5-scale, 30-item, self-reported, validated questionnaire for the assess-
ment of QoL in these patients. Data on the usefulness of this questionnaire 
in clinical practice are lacking.
aims & Methods: The aim of the study is to apply the EQA in a consecu-
tive population of EoE Italian patients, in order to evaluate whether the 
EQA changes on the basis of histological disease activity and therapeutic 
response to drug administration.
Thirty patients (7 Female, mean age 33-yo, range 18-75-yo) with a definite 
diagnosis of EoE, referred to our Unit, were included. The diagnosis was 
done according to the latest international criteria. Patients were enrolled 
at outpatient level, at first admission or follow-up, between January 2018 
to February 2019. Patients, were evaluated clinically and histologically 
before (baseline) and after medical therapy (proton pump inhibitors or 
topical steroid for 8weeks). At both time points, EoE patients completed 
the EQA. Histological activity was described as dichotomous parameter: 0 
for less than 15eos/hpf and 1 for more than 15 eos/hpf. Pearson correlation 
coefficient and paired t test were used for the analysis.
results: At baseline, all patients were histologically active, with a mean 
value of EQA of 45.07±SD32.69. After 8 weeks of medical treatment, EQA 
mean value was 37.63±SD28.37. A strong significant decrease of EQA score 
was therefore observed (p=0.021). After 8 weeks of medical treatment, 21 
patients (70%) achieved histological response. However, no difference in 
terms of EQA values between histological responders and non-responders, 
was shown (p=0.296). Moreover, no significant EQA changes occurred in 
non-responder patients, before and after treatment (p=0.878). In contrast, 
EQA significantly improved in histologically responder patients, before and 
after treatment (p=0.0113).
conclusion: EQA is a valid, reliable disease-specific tool for the measure-
ment of QoL in adult EoE Italian population. It can facilitate the assessment 
of therapeutic response and histological remission. Our data confirmed 
that therapy significantly improves QoL in EoE, mainly when histological 
remission is achieved. Developing multiple national-language versions of 
EQA is an important step in the standardization of research protocols and 
ambulatory management of this disease.
references: Taft TH, Kern E, Kwiatek MA, Hirano I, Gonsalves N, Keefer L. 
The adult eosinophilic oesophagitis quality of life questionnaire: a new 
measure of health-related quality of life. Aliment Pharmacol Ther. 2011 
Oct;34(7):790-8. Lucendo AJ, Sánchez-Cazalilla M, Molina-Infante J, Pérez-
Martínez I, Tenías JM, Barrio J, Nantes Ó, Ciriza-de-los-Ríos C, Perelló A, 
Arias Á. Transcultural adaptation and validation of the “Adult Eosinophilic 
Esophagitis Quality of Life Questionnaire” into Spanish. Rev Esp Enferm 
Dig. 2014 Jun;106(6):386-94.
disclosure: Nothing to disclose 
An assessment of allergy tests performed after a diagnosis of EoE as a 
part of the diagnostic or therapeutic management was performed in 173 
patients who had at least one laboratory, skin prick or atopy patch test 
after the date of diagnosis. The overall number of allergy tests was 348, 
with a mean ± SD of 2.0 ± 1.2 per patient. Three groups of patients were 
considered for statistical analysis: diagnosis in 2011 or before (n=50, 2.8 ± 
1.5), 2012-2013 (n=35, 1.8 ± 1.1), and after 2014 (n=88, 1.6 ± 0.7). Significant 
reductions in the performance of allergy tests were noted among periods 
(p< 0.001) and for two group comparisons, when diagnosis ≤2011 vs 2012-
2013 and diagnosis ≤2011 vs ≥2014 were compared (both p< 0.001).
conclusion: Our data demonstrate an increased awareness on EoE over 
time, with significant reductions in diagnostic delay and number of super-
fluous endoscopic exams as new clinical practice guidelines were released. 
The performance of allergy testing for the diagnostic and therapeutic man-
agement of EoE reduced significantly. A significant effect towards a proper 
management of EoE was found for the 2011 guidelines.
disclosure: Nothing to disclose 
P0582 achaLasIa Is a cOMMOn fIndIng In PaTIenTs WITh 
eOe undergOIng hIgh-resOLuTIOn ManOMeTry
Ghisa M.1, Marinelli C.1, Tolone S.2, De Bortoli N.3, Marabotto E.4, 
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Introduction: Eosinophilic Esophagitis (EoE) is a chronic immune/antigen-
mediated disorder, characterized by symptoms of esophageal dysfunction 
(dysphagia and/or food impaction) and, histologically, by eosinophilic-
infiltration. EoE has been associated with various esophageal motility dis-
orders, ranging from hypo- to hyper- contractile motility abnormalities, 
and more recently achalasia.
aims & Methods: The aim of this study was to assess the incidence of 
achalasia in patients with EoE, and to evaluate the disease course of EoE 
after achalasia treatment.
97 consecutive patients (mean age 39, range 18-75 yo, 20 F), with a diag-
nosis of EoE assessed in our Unit between 2012 to 2018, were included. 
The diagnosis was posed according to international criteria (presence of 
typical symptoms of esophageal dysfunction; at least 15 eosinophils per 
high-power field at mid/proximal oesophagus), excluding other causes 
of eosinophilia. Among 97 patients, in 47 (48%) conventional manometry 
(CM) or high resolution manometry (HRM) were not performed and were 
excluded from the study. Patients who accepted to undergo HRM, were 
studied by suing the standardised international protocol and manometric 
diagnoses were carried out according to Chicago Classification 3.0.
results: Among the 50 EoE patients (mean age 41, range 20-75 yo, 8 F), 26 
(52%) showed normal manometric pattern. Between patients with abnor-
mal manometric pattern, 16 (67%) had hypocontractile disorders, 8 (33%) 
hypercontractile abnormalities and 5 (21%) had a diagnosis of achalasia. 
Among them 1 type I achalasia, 2 type II achalasia and 3 type III acha-
lasia were present. 3 was male; 3 received EoE diagnosis in adolescent 
age, 2 after fifties, with a significant diagnostic delay. 3 had history of 
allergic disease. The main symptom was dysphagia (4patients), but also 
globus, odynophagia and regurgitation were present in some of them. 3 of 
them showed EREFS score=3, 1 showed value of 4 and 1 value of 5. At the 
esophagogram 4 of them had narrowed EGJ and 2 of them with dilation of 
the esophagus, 1 showed delayed esophageal empting. From a therapeutic 
point of view, only 2 patients responded to PPI. There was a response to 
topic steroid therapy in 2 cases, no response in 2 cases, no administra-
tion in 1. Considering therapy of achalasia, in 2 cases no treatment was 
required, in 1 case endoscopic dilation was performed, in 1 case surgery 
was accomplished and in 1 case endoscopic and then surgical therapy was 
necessary. Basing on this data, patients was characterized as follows: 2 
PPI-responder, 1 refractory EoE, 2 steroid responder EoE
conclusion: This retrospective study of consecutive patients showed that 
achalasia, is not uncommon in patients with EoE, affecting about 10% of 
patients of this cohort. No specific subtype of achalasia is associated with 
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P0584 usefuLness Of reaL-TIMe Measure Of gasTrIc Ph and 
sTandard cLInIcaL ParaMeTers TO PredIcT PersIsTenT acId 
refLux In a PaTIenT TreaTed WITh PrOTOn-PuMP InhIBITOrs 
fOr gasTrOesOPhageaL refLux dIsease
Januszewicz W.1,2, Hartley J.3, Waldock W.3, Roberts G.3, Alias B.3, 
Hobson A.4, Wernisch L.5, di Pietro M.6
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Cancer Unit, University of Cambridge, Cambridge, United Kingdom, 4The 
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Introduction: Gastroesophageal reflux disease (GERD) is the second com-
monest GI outpatient diagnosis in the US and has a prevalence reach-
ing up to 30% in many western countries. Proton-pump inhibitors (PPIs) 
are the mainstay of GERD treatment, however, up to one-third of patients 
have a poor symptomatic response. PH-impedance is the gold standard 
to assess whether this is due to persistent acid reflux, however, this test is 
inconvenient for patients and requires two hospital visits with significant 
indirect costs. PPIs suppress the acid production in the stomach, hence, 
gastric acidity might provide important information on pharmacological 
response to PPIs. EndoFaster is a novel endoscopic adjunct device that 
uses the gastric juice suctioned during endoscopy to provide a real-time 
measure of the gastric pH.
aims & Methods: We aimed to assess whether clinical parameters, includ-
ing real-time gastric pH measure with EndoFaster device, could be useful 
in predicting persistent acid reflux during PPI therapy and stratify patients 
for further testing. We prospectively recruited patients with GERD on PPIs 
that underwent gastroscopy as either initial investigation or surveillance 
for Barrett’s esophagus. All patients filled out a dedicated symptom ques-
tionnaire (RDQ) and received their clinically indicated endoscopy with 
gastric pH analysis by EndoFaster, immediately followed by ambulatory 
24-hour pH-impedance. We used a modified cut-off of 1.3% for patho-
logical esophageal acid exposure time (AET). Multiple linear regression 
models were used to analyze the correlation between AET and predictive 
variables. The accuracy of gastric pH in predicting persistent acid reflux 
was calculated.
results: We recruited 122 patients, of which 91 (74.6%) were included in 
the final analysis [46 male (50.5%), median age 53 years (IQR: 41-65)]. 
Forty-one patients (45.1%) had persistent acid reflux (AET≥1.3%) and were 
classified as PPI non-responders, and 50 had AET < 1.3% (PPI respond-
ers). Median AETs were 2.4 (IQR 1.2-4.9) and 0.1 (IQR 0.0-0.2), respectively 
(P<.001). 
There was no difference in age, gender, BMI, PPI-regimen, presence of 
hiatus hernia and BE, and severity of symptoms between groups. Gastric 
pH was significantly lower in non-responders as compared to respond-
ers [6.2 (±1.6) vs. 5.3 (±2.2), P=.037)] with a mean difference in pH of 0.9 
(95%CI 0.06 - 1.73). 
Single-point gastric pH significantly correlated with AET (P=.042; 
R2=11.0%). A pH cut-off of 5.05 had the best diagnostic accuracy in predict-
ing persistent acid reflux on PPIs with a sensitivity and specificity of 39.5% 
and 85.4%, respectively.
conclusion: Symptoms and clinical characteristics are not useful to predict 
persistent acid reflux in GERD patients on PPIs. One-point gastric pH is 
significantly lower in PPI non-responders as compared to responders, and 
correlates with 24-hour esophageal AET. Endofaster, in association with 
systematic symptoms assessment, could be used to triage patients for pH-
impedance test and should be evaluated in larger trials.
disclosure: Nothing to disclose 
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P0587 gasTrOesOPhageaL refLux dIsease and ParOxysMaL 
nOn-vaLvuLar aTrIaL fIBrILLaTIOn - a case-cOnTrOL sTudy
Barboi O.B.1, Floria M.2, Ciortescu I.1, Drug V.L.3
1Saint Spiridon Hospital Iasi, Gastroenterology, Iasi, Romania, 2Saint 
Spiridon Hospital Iasi, Internal Medicine, Iasi, Romania, 3University of 
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contact e-Mail address: oany_leo@yahoo.com
Introduction: There is still a controversy regarding the relationship be-
tween gastroesophageal reflux disease (GERD) and paroxysmal non-val-
vular atrial fibrillation (AF). Having the same predisposing factors as well 
as the adjacent anatomical positioning and nerve innervations between 
esophagus and atria can explain this relationship. The aim of this study 
was to evaluate the association between GERD and AF.
aims & Methods: A prospective case-control study was conducted at a ter-
tiary care centre from North-East of Romania over a period of 13 months 
(July 1, 2014 - July 31 2015). We included 135 patients divided in four groups: 
patients with GERD and paroxysmal non-valvular AF (GERD+AF group), 
patients with GERD and sinus rhythm (GERD+non-AF group), patients with 
AF and non-GERD (AF+non-GERD group) and patients without GERD and 
AF (non-GERD+non-AF group). All patients underwent upper endoscopy, 
echocardiography, 24-hour electrocardiographic Holter monitoring and 
lab tests.
results: The 135 patients were divided as follow: 36 GERD+AF patients, 25 
GERD+non-AF patients, 39 AF+non-GERD patients and 35 non-GERD+non-
AF patients. All groups were homogenous regarding sex distribution and 
age. Esophagitis increased the relative risk of the association of AF and 
GERD by 2.5 times (p< 0.005). Heart rate variability in terms of time-do-
main parameter (SDNN) was lower in GERD+AF group patients than the 
other three groups (69.60 vs 109.33 vs 123.56 vs 12.1, p< 0.005). Regard-
ing cardiac ultrasound parameters, median value of left atrial area in the 
group with GERD and AF patients was statistically higher comparatively 
with GERD+non-AF group (25.79±5.13 cm2 vs 23.88±5.10 cm2, p< 0.005). 
Hypertriglyceridemia was statistically significantly higher in GERD+AF 
group than in the other groups (p=0.005).
conclusion: These results suggest the association of GERD and AF, which 
is sustained by both the theory of inflammation and of the autonomic ner-
vous system imbalance.
disclosure: Nothing to disclose 
P0588 The rOLe Of esOPhageaL hIgh-resOLuTIOn 
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Santos A.L.1,2,3, Peixoto A.2,3,4, Silva J.2,3,5, Ramalho R.2,3,6, Macedo G.2,3,6
1Centro Hospitalar de São João, Gastroenterology, Porto, Portugal, 2WGO 
Oporto Training Center, Porto, Portugal, 3Porto Medical School, University 
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Introduction: Recent studies have demonstrated the important role of 
high-resolution manometry (HRM) in assessment of patients with gastro-
esophageal reflux disease (GERD) and it is now formally recommended by 
The Lyon Consensus.
aims & Methods: We intended to relate the findings in HRM with those of 
24h pHmetry in patients with GERD. 
Retrospective study, with inclusion of patients who were referred to per-
form 24h pHmetry and submitted to HRM, in a tertiary referral center, be-
tween March 2018 and July 2019. Chicago Classification v3.0 and The Lyon 
Consensus were used for the interpretation of data from the procedures.
results: A total of 49 patients were included, 53% females, with a mean 
age of 50±14 years.
In pHmetry assessment, 38% of patients had findings compatible with 
GERD and 9% with reflux hypersensivity. Among the referenced patients, 
71% presented changes in HRM: 38% esophagogastric junction obstruc-
tion (EGJ), 15% hypotonicity of the LES and 5% ineffective esophageal mo-
tility (IEM). The presence of IEM was associated with an abnormal pHmetry 
(p=0.040) as well as with the positive symptom association probability 
(SAP). The median acid exposure times (AET) was 0.7% (IQR 0.2-5.5%) 
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P0590 MnBI Is a BeTTer Marker Of OesOPhageaL dIsease 
severITy cOMPared TO usIng TOTaL acId refLux
Abdul-Razakq H., Raeburn A., Patel K., Emmanuel A., Zarate N., Sweis R.
University College London Hospital, Gastroenterology, London, United 
Kingdom
contact e-Mail address: rami.sweis@nhs.net
Introduction: The Lyon Consensus 2018 describes mean nocturnal baseline 
impedance (MNBI) as a possible measure of oesophageal mucosa perme-
ability, with lower values associated with damage; however MNBI has not 
yet entered routine clinical practice. This study aims to determine the re-
lationship of MNBI across three common presentations of reflux; Barrett’s 
oesophagus, NERD and functional heartburn (FH).
aims & Methods: Standard pH-Impedance measurements as well as 
symptom index (SI) were acquired for all patients. The impedance channel 
at 3cm was used to calculate MNBI by averaging 3 nocturnal 10 minute 
intervals 1hr apart. Consecutive tracings between 2014 and 2016 for 3 reflux 
subgroups were analysed; 22 Barrett’s Oesophagus (13 on proton pump 
inhibitors; PPI), 26 NERD and 26 FH. Results are presented as median (IQR; 
interquartile ratio). Comparisons were made using Kruskall-Wallace test 
and Mann-Whitney U test as appropriate. Correlations were performed 
using Spearman’s correlation coefficient.
results: There was no significant difference in total reflux (TR) be-
tween patients with Barrett’s (median TR 11.2%(2.5%,18.7%) and NERD 
(8.1%(5.5%,12.9%) (p=0.497). The difference with FH (TR 22%(12%,34%) 
is defined by the entry criteria (p< 0.0001). SI was significantly lower in 
Barrett’s (SI 4%(0%,25.6%) than NERD (30%(0%,45.2%) (p=0.48), but 
not FH (0%(0%,7.9%) (p=0.129).
There was no statistically significant difference in MNBI between Barrett’s 
while on or off PPIs (p=0.556). There was also no difference in MNBI be-
tween 9 patients with persistent Barrett’s who had attempts at ablation 
therapy compared to the 13 who had not (p=0.96). Using the Kruskall-
Wallace test, there was a significant difference observed in MNBI between 
all 3 categories of reflux (p< 0.0001). Specifically, there was a difference 
in patients with Barrett’s (median MNBI 429.5Ω(293Ω,950Ω) compared to 
NERD (1160Ω(964.5Ω,2764Ω) (p=0.003) and FH (3355Ω(2866.5Ω,3809.25Ω) 
(p< 0.0001). There was also a significant difference in patients with NERD 
compared to FH (p< 0.0001). 
There was a moderately inverse correlation between Barrett’s segment 
length (median 6cm(3cm,10cm) and MNBI (r = -0.436; p=0.038).
conclusion: In keeping with the published literature, this study shows 
that severity of reflux disease, as measured by ambulatory pH-impedance 
monitoring, was not dissimilar between Barrett’s oesophagus and NERD, 
while symptom burden was greater in NERD. On the other hand, MNBI 
can differentiate between the disease states despite the reduced symptom 
burden. Also, it correlates with the degree of mucosal damage associated 
with Barrett’s regardless of PPI use or previous therapy. MNBI may be a 
better marker of reflux disease severity than standard pH measurements.
disclosure: Nothing to disclose 
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1UMass Memorial Medical Center, Internal Medicine, Worcester, United 
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Introduction: Differentiating functional dyspepsia (FD) from gastroesopha-
geal reflux disease (GERD) by symptoms continues to remain a challenge. 
It has been thought that symptoms including upper abdominal pain, 
nausea, bloating correlates more with a diagnosis of functional dyspep-
sia whereas burning chest pain after eating and worse with lying down 
is thought to be more related to GERD. We analyzed the relationship of 
symptoms to 24 pH measurements to help better differentiate between FD 
and GERD based on symptoms.
aims & Methods: We performed a prospective study at one center involv-
ing 124 patients who have been experiencing various types of upper GI 
symptoms from 2015-2018. A survey was given to each patient to record 
and the median DeMeester score (DmS) was 3.8 (IQR 1.2-10). HRM was 
performed after a median time of 5 years (IQR 2-8) after the symptoms’ 
onset. The most prevalent symptom was the heartburn (67%) but regur-
gitation and chronic cough were those more often associated with reflux 
in the pHmetry (p=0.002 and p=0.014, respectively). In 75% of cases there 
was a previous therapeutic trial with proton pump inhibitor, mostly with-
out clinical improvement (57%); this fact was related with a LES hypotonic-
ity in HRM (p=0.018). In 71% of patients, the HRM’s findings had an impact 
in the subsequent patients’ therapeutical strategy.
conclusion: The routine performance of a manometric study in patients 
submitted to a pHmetry allows the identification of motor findings in ap-
proximately three-quarters of patients, facilitating the subsequent thera-
peutic approach.
disclosure: Nothing to disclose 
P0589 cLInIcaL aPPLIcaTIOn Of The gasTrOesOPhageaL 
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LaryngOPharyngeaL refLux syMPTOMs
Kim Y.D.1, Shin C.M.1, Jeong W.J.2, Kim N.1, Park Y.S.1, Lee D.H.1
1Seoul National University Bundang Hospital, Internal Medicine, 
Seongnam-si, Korea (Republic of), 2Seoul National University Bundang 
Hospital, Otorhinolaryngology, Seongnam-si, Korea (Republic of)
contact e-Mail address: nskyyd@naver.com
Introduction: Gastroesophageal reflux disease(GERD) is one of the most 
common esophageal diseases in Gastroenterology. Laryngopharyngeal 
reflux(LPR) is different clinical symptoms that occur simultaneously with 
GERD.
aims & Methods: To evaluate the usefulness of Gastroesophageal Reflux 
Disease Questionnaire (GerdQ) in patients with suspected laryngopharyn-
geal reflux (LPR) symptoms (globus, cough, hoarseness and throat pain)
A total of 111 patients with suspected LPR symptoms were incorporated 
from either
otorhinolaryngology or gastroenterology clinic. Patient’s laryngoscopic 
findings were graded by reflux finding score (RFS, n = 98), and RFS ≥ 7 was 
considered as positive LPR. Patient’s LPR symptoms were evaluated using 
reflux symptom index (RSI). Erosive esophagitis by endoscopy (n = 111) or 
abnormal results on 24-hr multichannel intraluminal impedance-pH (MII-
pH) testing (n = 111) were used as diagnostic references for gastroesopha-
geal reflux disease (GERD). Esophageal motor function
was evaluated using high resolution esophageal manometry (HREM, n = 
111); distal contractile integral (DCI) < 450mmHg∙cm∙s or fragmented peri-
stalsis (defect > 5cm) or absent peristalsis was considered as esophageal 
hypomotility.
results: Ninety-one of 98 (92.9 %) subjects were diagnosed as LPR but 
only 17 of 111 (15.3 %) had GERD. For GerdQ, the cutoff value of 9 showed 
the highest area under curve (AUC) by receiver operating curve (ROC) 
analysis (AUC = 0.616); the sensitivity, specificity, positive predictive value 
(PPV) and negative predictive value (NPV) were 52.9 %, 70.2 %, 24.3 % 
and 89.2 %, respectively. For RSI, the cutoff value of 13 showed the high-
est diagnostic yield (AUC = 0.654); the sensitivity, specificity, PPV and NPV 
were 75.3 %, 40.0 %, 95.9 % and 8.0 %, respectively. In patients with 
GERD (n = 17), both distal and proximal baseline impedance levels (3 cm 
and 15 cm above esophagogastric junction, respectively) were decreased 
(p < 0.05) and proximal extent of reflux were increased (p < 0.001). How-
ever, there was no difference in esophageal body motor function between 
patients with or without GERD (p >0.05).
conclusion: GERD is infrequent among patients with suspected LPR symp-
toms. In this population, the sensitivity of GerdQ is low thus GerdQ has a 
limited role in GERD diagnosis.
disclosure: Nothing to disclose 
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whether they had what was thought to be symptoms of GERD (burning, 
upward abdominal pain, ascending chest pain, awakened by symptoms) 
vs. symptoms of FD (intermittent, non-radiating upper abdominal pain, 
nausea, vomiting, bloating). Each patient then had a Bravo 24-hour pH 
study and De Meester scores were recorded to serve as the gold standard. 
Univariate analyses, including chi square and Fisher exact test, and multi-
variate logistic regression was done.
results: There was a total of 124 patients, 80 women and 44 men, with a 
mean age of 52.97 years were recruited. There were 113 Caucasians, 7 His-
panics, 3 Asian Americans, and 1 African American. Mean BMI was 30.73. 
Mean De Meester score was 31.71. Most symptoms were found to be not 
clinically significant for evaluation of GERD vs. FD, apart from radiating 
upward pain as a negative predictor of true GERD (p=0.006) and intermit-
tent nature of pain as a positive predictor of true GERD (p=0.001). From 
here, an equation was formulated incorporating this data: (Ascending 
pain * -1.51) + (Intermittent pain * 1.89) and a ROC curve was developed 
(graph 1) with ROC area of 0.76 with sensitivities and specificities listed 
in table 1.
cutpoints on 
rOc curve
sensitivity 
(%)
specificity 
(%)
correctly 
classified 
(%)
Positive 
Likelihood 
ratio
negative 
Likelihood 
ratio
≥-1.51 100 0 18.26 1  
≥0 85.71 32.98 42.61 1.2789 0.4322
≥.38 76.19 61.7 64.35 1.9894 0.3859
≥1.89 57.14 91.49 85.22 6.7143 0.4684
>1.89 0 100 81.74   1
[Table 1: Sensitivities and specificities of GERDYS equation]
conclusion: This study revealed that most “classic” symptoms of GERD 
and FD cannot truly differentiate between the two. Using our GERDYS 
equation as above can help support one diagnosis vs. the other with the 
understanding that overlap of these conditions occurs. This also demon-
strates the necessity of performing pH studies on any patient presenting 
with symptoms that could be concerning for either or concurrent disease 
processes. The importance of differentiating the two lies in the differing 
treatment of each disorder. Ultimately, this study acts as a stepping stone 
in better differentiating GERD from FD and in the future will help promote 
a decrease in the inappropriate use of proton pump inhibitors in the com-
munity and improve patient care as well as reduce costs.
disclosure: Nothing to disclose 
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Introduction: The novel metrics from pH-impedance monitoring, postreflux 
swallow-induced peristaltic wave (PSPW) index and the mean nocturnal 
baseline impedance (MNBI) appear particularly useful for the diagnosis of 
gastroesophageal reflux disease (GERD). The threshold values for PSPW 
index and MNBI are 61% and 2292 Ω respectively.
aims & Methods: We aimed to evaluate the power of PSPW index and 
MNBI to predict PPI response in patients with extra-esophageal syndrome.
We enrolled 44 consecutive patients (M/F 19/25, mean age 48.8±14.3 yrs, 
BMI 24.7±5.6). The predominant symptoms were hoarseness (76.1%), glo-
bus (73.9%) chronic cough (63%), sore throat (60.9%), throat discomfort 
(43.3%) and heartburn (38.6%). They underwent EGD according to Los 
Angeles classification. Off-medication pH-impedance was performed.
results: According with the pH-impedance results GERD was confirmed 
in 17 out of 44 pts (group GERD) and 27 subjects resulted negative for 
reflux (group No-GERD). Upper endoscopy showed erosive esophagitis 
in 7 out 44 pts (15.9%). Acid refluxes were significantly higher in group 
GERD (26.8±19) than in group No-GERD (10.4±8.3) (p=0.0003). Weakly acid 
refluxes didn’t differ between the two group (group GERD 14.4±12.8 vs. 
group No-GERD 9.6±6, p=0.099). PSPW index and MNBI had shown a sig-
nificantly lower value in group GERD (MNBI 1660.6±489 Ω; PSPW index 
36±16.8%) than in group No-GERD (3222±671.2 Ω; PSPW index 73.4±11.8%) 
(p < 0.0001). 
PPI response was higher in group GERD than in group No-GERD for both 
heartburn (10/17 group GERD vs 1/27 group No-GERD) and extra-esoph-
ageal symptoms (11/17 group GERD vs 1/27 group No-GERD) (p< 0.0001). 
Patients with a positive response to PPI, regardless of group which they 
belonged, had lower MNBI and PSPW index values (MNBI p=0.003; PSPW 
index p=0.003).
conclusion: The evaluation of PSPW index and MNBI showed statistically 
significant differences between GERD and No-GERD patients and between 
PPI responders and PPI non-responders. MNBI and PSPW index are the 
best parameters to identify patients with GERD and the response to PPI 
therapy, underlying the importance of evaluation in clinical setting of pa-
tients with GERD.
disclosure: Nothing to disclose 
P0593 vIrTuaL BIOPsy By IMPedancesPecTrOscOPy In 
BarreTT’s adenOcarcInOMa
Knabe M.1, Blößer S.1, Welsch L.1, Roeb E.2, May A.1
1Sana Clinic Offenbach, Medizinische Klinik II/IV / Gastro., 
Pneumol.,Hämatol.-Onkol., Offenbach, Germany, 2Universitätsklinikum 
Giessen, Gastroenterologie, Gießen, Germany
contact e-Mail address: lukas-welsch@web.de
Introduction: Early detection of adenocarcinoma in the esophagus is es-
sential for curative treatment. Targeted and random biopsies are the stan-
dard in diagnostic gastroscopy. This approach is time consuming and re-
sults are depending on endoscopists experience.
aims & Methods: The aim of the study was to investigate the diagnostic 
value of impedancespectroscopy in Barrett’s esophagus. We developed a 
pencil probe with eight golden electrodes for impedance measurement 
from 100 Hz to 1MHz. Immediately after endoscopic resection of esopha-
geal neoplasia in Barrett’s esophagus, the specimen was pinned on cork. 
Subsequently the tissue was measured in 10 different electrode combina-
tions and after that ink- marked for further pathological assessment.
results: From February 2017 to February 2018, 47 patients (45♂ ,2♀ ) with 
87 measurements were included. The mean age of patients was 66y (min 
48y to max 91y). Measurement from 58khz to 119kHz showed significant 
(p< 0.005) difference in impedance to distinguish between Barrett’s mu-
cosa and high-grade intraepithelial neoplasia / adenocarcinoma. A cut-off 
value of > 291 Ω (at a frequency of 58kHz) showed a sensitivity of 81% by 
ROC-analysis. However, the specificity remains low at 41%.
conclusion: Impedancespectroscopy has the potential as a screening tool 
for Barrett’s neoplasia. Further development for an in-vivo model are nec-
essary to proof this novel diagnostic tool.
disclosure: Nothing to disclose 
P0594 anaLysIs Of seLecTed BILe acIds In saLIva By 
hIgh-PerfOrMance LIquId chrOMaTOgraPhy-Mass 
sPecTrOMeTry as a POTenTIaL neW nOn-InvasIve dIagnOsTIc 
MeThOd fOr BarreTT’s esOPhagus
Konecny S.1,2, Kuban P.3, Durc P.3, Dolina J.1,2, Dosedelova V.3, 
Himmelsbach M.4, Buchberg W.4
1University Hospital Brno, Department of Internal Medicine and 
Gastroenterologyd, Brno, Czech Republic, 2Masaryk University, Faculty of 
Medicine, Brno, Czech Republic, 3CEITEC Masaryk University, Department 
of Bioanalytical Instrumentation, Brno, Czech Republic, 4Johannes-Keppler 
University, Department of Chemistry, Linz, Austria
contact e-Mail address: stefankonecny@gmail.com
Introduction: Barrett’s esophagus (BE) is defined as the replacement of 
squamous epithelium in the distal esophagus with metaplastic intesti-
nal columnar epithelium and develops because of chronic inflammation 
resulting from gastroesophageal reflux disease. BE is associated with an 
increased risk of developing esophageal adenocarcinoma (EAC). Experi-
mental, clinical and immunohistochemical studies show that one of the 
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population the presence of hiatal hernia and Hp infection. In 1428 cases 
the endoscopist described the presence at the distal esophagus of colum-
nar epithelium (suspected BE) and in this group the pathologist confirmed 
in 690 the presence of BE (defined histologically as replacement of the 
normal squamous epitelium of the distal esophagus by columnar epite-
lium containig intestinal metaplasma). The presence of short Barrett (< 
1cm) it was not considered in the analysis,because the risk of progression 
to high grade dysplasia or esophageal adenocarcinoma seem very low in 
this subset of patients.
results: The Database analysis shows that the prevalence of Barrett’s 
esophagus in our endoscopic population in the last twenty years was 
1,07% .The mean age of patients with Barrett’s esophagus at the diagno-
sis was 57 year (range 17-96 yr) and the male sex was prevalent (435 vs 
256). The extension of columnar epithelium,measured in accord to Prague 
Classification (M Prague score) (Pearson’s correlation coefficient for the 
relationship r=-0,0007) and the presence of hiatal hernia (r=0,013) weren’t 
independently associated with Barrett’s esophagus. The prevalence of Hp 
infection in patients with BE was 14,2%.
In all cases with progression to malignancy, the extension of metaplastic 
epithelium was >3 cm (long BE).
conclusion: In our population the overall prevalence of BE was 1,07 % 
with predominance of male sex,middle age and gastroesophageal reflux 
symptoms as suggested by the high prevalence of hiatal hernia. Our data 
confirmed also that the appearance of dysplasia or adenocarcinoma is re-
lated to BE extension,regarding only the cases of long Barrett. This sug-
gest that in the next years the surveillance programs,also in terms of cost-
effectiveness,will be to differentiate and ask in this direction.
disclosure: Nothing to disclose 
P0596 exPressIOn PrOfILe In BarreTT’s esOPhagus 
(Be) OBserved In huMans, surgIcaL anIMaL and In vITrO 
MOdeL InvOLvIng huMan-derIved esOPhageaL ceLL LInes. 
MOLecuLar Markers seLecTIOn characTerIsTIc fOr cLInIcaL 
Be and refLecTed In exPerIMenTaL MOdeLs fOr furTher 
TransLaTIOnaL PharMacOLOgIcaL sTudIes
Korbut E.1, Wójcik D.1, Wierdak M.1,2, Bakalarz D.1,3, Janmaat V.T.4, 
Brzozowski T.5, Magierowski M.1
1Jagiellonian University Medical College, Department of Physiology, Cracow, 
Poland, 2Jagiellonian University of Cracow, Department of Gastroenterology, 
Cracow, Poland, 3Institute of Forensic Research, Department of Forensic 
Toxicology, Cracow, Poland, 4Erasmus Medisch Centrum, Gastroenterology 
& Hepatology, Rotterdam, Netherlands, 5Jagiellonian University Collegium 
Medicum, Physiology, Krakow, Poland
contact e-Mail address: edyta.korbut@uj.edu.pl
Introduction: Barrett’s esophagus (BE) is a premalignant condition of 
esophageal epithelium caused by gastroesophageal reflux disease (GERD). 
Thus, several in vivo animal and in vitro models of GERD and BE were de-
veloped. However, clinical relevance of each of them implemented sepa-
rately was considered to be questionable.
aims & Methods: Therefore, we aimed to select appropriate translational 
molecular expression markers comparing particular genes expression pro-
file observed in clinical biopsies derived from BE patients, animal surgical 
model and in vitro model of GERD involving human derived esophageal 
cell lines, optimizing this in vitro model to reflect as much as possible 
these molecular alterations observed clinically.
Gene Expression Omnibus 2R (GEO2R) tool and GSE34619, GSE1420, 
GSE13083 database were used to select up/downregulated genes in hu-
man BE: KRT1, KRT4, KRT5, KRT7, KRT8, KRT14, KRT15, KRT18, KRT19, KRT20, 
MUC2, MUC5ac, MUC6, MUC3, TFF1, TFF2, TFF3, VILL1. 2. Male Wistar rats 
underwent microsurgical procedure to generate duodenoesophageal 
anastomosis leading to the development of metaplasia after 12 weeks in 
70% of animals. 
Esophageal biopsies were collected to assess mRNA expression for 
abovementioned genes using TaqMan probes and real-time PCR only in 
samples with confirmed microscopically metaplasia development. We 
also determined whether Barrett’s esophagus (BE) - specific mRNAs are 
regulated in squamous esophageal epithelial (HET-1A) and esophageal 
keratinocytes (EPC2-hTERT) human cell lines after exposure to hydro-
chloric acid and bile mixture (BA). EPC2-hTERT and HET-1A cells were 
exposed for 30 minutes to the medium adjusted to a pH of 7.0 or 5.0 using 
HCl together with BA or separately mixture at increasing concentrations 
factors in the pathogenesis of esophageal injury, BE and EAC is duodenal 
reflux and the associated synergistic damage to the esophagus by bile acid 
(BA) and gastric acid reflux. Oxidative stress secondary to bile acids (BAs) 
exposure has been associated with metaplastic degeneration of normal 
esophageal mucosa into BE cells and eventually EAC.
At the current time, a diagnosis of Barrett’s esophagus can only be made 
using endoscopy and detecting a change in the lining of the esophagus. 
The definitive diagnosis of Barrett’s esophagus requires biopsy confirma-
tion of the change in the lining of the esophagus.
The Prague classification system is universally accepted standardized en-
doscopic grading system for BE and uses the “C” value as the “circum-
ferential extent” and the “M” value as “maximal extent” of BE above the 
gastroesophageal junction in centimeters for endoscopic standardization 
of BE lengths.
aims & Methods: We studied the content of selected BAs in saliva samples 
in a cohort of 15 patients with endoscopically and histologically proven BE 
(Prague Classification C: 1-10, M: 2-13) and a control group consisting of 
10 subjects without known medical history or treatment for GERD or BE 
at least in the last 5 years. Concentration of major salivary BAs (glyco-
cholic acid, glycodeoxycholic acid, and glycochenodeoxycholic acid) in sa-
liva were analyzed using high-performance liquid chromatography-mass 
spectrometry (HPLC-MS) detection. 
Saliva samples were collected from healthy individuals and patients with 
BE during the day, but all subjects were asked not to eat, drink nor brush 
their teeth at least 3 hours before sampling. Afterwards were samples 
stored at -80 °C.
Before the measurement saliva samples were let to thaw at room temper-
ature. After that 900 µl of MeOH was added to 300 µl of saliva sample for 
protein precipitation. This mixture was vortexed, sonicated and centrifu-
gated and 1 mL of the supernatant was transferred to a new vial. Superna-
tant was dried under stream of nitrogen. Dried sample was re-dissolved 
in 300 µl of 80% MeOH, vortexed, sonicated and the supernatant was 
analyzed by HPLC-MS. The analysis was completed under 4 minutes.
results: We compared the concentrations of selected BAs in both groups of 
patients, and we found significantly increased concentrations of glycoche-
nodeoxycholic acid (p < 0.01) in the group of patients with BE. Significantly 
better statistical differentiation of samples was observed by using princi-
pal component analysis, especially in patients with high C and M values of 
BE length by Prague classification.
conclusion: Analysis of selected bile acids in saliva by HPLC-MS appears to 
be a potential new non-invasive diagnostic method for detection of Bar-
rett’s esophagus and for estimation of its severity. HPLC-MS is a highly sen-
sitive method to measure low amounts of bile acids in human saliva. The 
analysis is fast, but the sample preparation is more complicated. Further 
refinement of this new diagnostic method is needed.
disclosure: The authors acknowledge the financial support from the Minis-
try of Health of the Czech Republic (Grant No. 17-31945A). 
P0595 BarreTT’s esOPhagus and cOMPLIcaTIOns 
PrevaLence: TWenTy years OBservaTIOnaL reTrOsPecTIve 
sTudy In a generaL POPuLaTIOn
Caruso S., Mangano M., Saladino V., Villa F., Bosani M.A., Imbesi V., 
Ursini G., Putignano R., Terpin M.M., Baldacci M.P., Gambitta P.
Legnano Hospital, Gastroenterology Unit, Legnano, Italy
contact e-Mail address: maria.mangano@asst-ovestmi.it
Introduction: Barrett’s esophagus (BE) is defined as the presence of co-
lumnar metaplasia in the lining of the distal esophagus instead of squa-
mous epithelium. This condition represents a factor that predispose to 
esophageal adenocarcinoma,neoplasia significantly incremented in the 
last decade. BE, a know precursor,has a high prevalence but only few pa-
tients with this condition progress to malignancy. Surveillance and screen-
ing programs are controversial and lack proven efficacy.
aims & Methods: The aim of this retrospective analysis was to establish 
the prevalence of BE and related complications (dysplasia and adenocar-
cinoma appearance) by reviews the database of consecutives patients pre-
senting in our Endoscopy Unit from January 1997 to March 2019 for upper 
endoscopy.
We retrospectively assessed 148.000 the endoscopic reports of 63.994 
outpatients seen in our Endoscopy Unit from January 1997 to March 2019, 
evaluating the prevalence of BE and analyzed the demographic (sex,age) 
and endoscopic findings (BE extension).Collaterally we evaluate in BE 
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(0-600 µM). Concentration range was determined by cell viability MTT as-
say (50% inhibitory concentration (IC50) = 1250 µM for pH 7.0; IC50 = 65 
µM for pH 5.0). The BA mixture consisted of 25% deoxycholic acid, 45% 
glycocholic acid and 30% taurochenodeoxycholic acid. The treatment was 
implemented one time or repeated daily during one week. After the treat-
ment period, the cells were harvested and RNA was isolated and mRNA 
expression for abovementioned genes was determined by real-time PCR 
using TaqMan probes.
results: Changes in mRNA level were observed only for KRT genes in 
EPC2-hTERT cell line (up regulation of KRT7, KTR18 and KRT19; down-
regulation of KRT4, KRT5, KRT14 and KRT15) in acidic medium with the 
BA concentrations close to IC50. In HET-1A cell line BA treatment slightly 
up-regulated MUC2, KRT8, KRT19 and down-regulated KRT15. Alterations 
in gene expressions in both investigated cell lines are consistent with gene 
expression profiles in human BE. 
We conclude that in contrast with single treatment, one-week treatment 
with BA and HCl mixture in concentrations close to IC50 is able to induce 
BE specific factors in EPC2-hTERT cell line. In animal model of BE, KRT-
4, KRT-8, KRT-15, KRT-18, KRT-20, MUC-2, MUC-6, MUC-13, TFF-2, VILL-1 
mRNA expressions were modulated in the manner observed in human 
BE.
conclusion: We conclude that one week of daily treatment of EPC-2 or 
HET-1A cells with 100 uM of BA in pH= 5.0 reflects the most efficiently 
molecular profile of human BE. Moreover, we conclude that animal model 
of GERD (12 weeks) modulates expression profile reflecting in about 80% 
these alterations observed in human BE. We assume that combination of 
these two experimental BE models is relevant to be implemented in fur-
ther pharmacological studies testing possible novel therapeutic targets of 
this disorder.
disclosure: Funding source: National Science Centre, Poland (UMO-
2016/23/D/NZ4/01913) 
P0597 aLcOhOL and sMOkIng InfLuence IOnTransPOrTer 
MechanIsMs Of guInea PIg esOPhageaL ePITheLIaL ceLLs, cP-d 
dysPLasTIc BarreTT’s ceLL LIne and Oe-33 adenOcarcInOMa 
ceLL LIne
Becskeházi E., Gál E., Székács I., Rábóczki B., Venglovecz V.
University of Szeged, Department of Pharmacology and Pharmacotherapy, 
Szeged, Hungary
contact e-Mail address: eszter.becskehazi@gmail.com
Introduction: Several clinical studies indicate that alcohol and smoking 
predispose the consumers to esophageal inflammatory and malignant dis-
eases, but the cellular mechanism is not completely clear. Iontransporters 
play an important protective role in the esophageal epithelial cells (EECs), 
however the effect of ethanol (EtOH) and smoking on them is not known. 
Our aim in this study was to examine the effect of EtOH and smoking on 
the esophageal epithelial iontransport mechanisms.
aims & Methods: EECs were isolated from guinea pig after an enzymatic 
digestion. Changes in pH
i
 were measured using a fluorescent dye, BCECF-
AM. For the determination of the starting pH the high-K+/nigericin method 
was used. Total buffering capacity of EECs was measured by the NH
4
 pulse 
technique. The effect of EtOH (0.1, 1 and 10% vol) and cigarette smoke 
extract (CSE) (1, 10, 100 µg/ml) on Na+/H+ exchanger (NHE) activity was 
estimated by the NH
4
Cl pulse technique. CP-D and OE-33 cells were treated 
with various concentrations of EtOH and CSE for 6 and 24 hours. Total 
mRNA was isolated and transcripted to cDNA. mRNA expression of NHE1 
was detected using qPCR.
results: We have improved an EEC isolation technique which allows the 
functional characterization of these cells. The resting pH of the EEC prepa-
ration was 7.59±0.011. EtOH dose-dependently decreased the pH
i
 of both 
guinea pig EECs and OE33 cells and also the activity of NHE. 1-hour in-
cubation with CSE increased the NHE activity in EECs, but decreased it in 
CP-D cells. 6-hour incubation of OE33 cells with CSE and EtOH increased, 
whereas 24-hour incubation with these agents decreased the mRNA ex-
pression of NHE. Interestingly, combination of EtOH and CSE induced the 
most robust effect in the expression of NHE. In CP-D cells, alteration of 
NHE1 expression was not significant.
conclusion: We optimized an EEC isolation technique by which the ion-
transporter activity of EECs can be investigated. Our results have shown 
that alcohol induces acidosis and significantly impairs NHE function thus 
decreases the defensive mechanisms. As a result of CSE incubation, NHE 
activity rises, which can be a compensatory reaction for this toxic agent. 
In order to estimate the importance of these results in the pathology of 
inflammatory esophageal diseases further investigations are needed.
disclosure: This study was supported by the National Research, Development 
and Innovation Office (FK123982 to VV), the Economic Development and 
Innovation Operative Programme Grants (GINOP-2.3.2-15-2016-00015 
to PH, GINOP-2.3.2-15-2016-00020 to PH) and the National Research, 
Development and Innovation Office, by the Ministry of Human Capacities 
(EFOP 3.6.2-16-2017-00006 to ZR). 
P0598 L-TryPTOPhan, an essenTIaL aMInO acId and 
PrecursOr Of MeLaTOnIn, aTTenuaTes The esOPhageaL 
daMage In exPerIMenTaL raT MOdeL Of BarreTT’s esOPhagus. 
rOLe Of PIneaL gLand and esOPhageaL BLOOd fLOW
Majka J.1, Wierdak M.2, Ptak-Belowska A.3, Targosz A.1, Magierowski M.1, 
Strzalka M.1, Pajdo R.1, Sliwowski Z.1, Danielak A.1, Brzozowski T.1
1Jagiellonian University Medical College, Department of Physiology, Cracow, 
Poland, 2Jagiellonian University of Cracow, Department of Gastroenterology, 
Cracow, Poland, 3Jagiellonian University School of Medicine, Department of 
Physiology, Krakow, Poland
contact e-Mail address: mpbrzozo@cyf-kr.edu.pl
Introduction: Barrett’s esophagus may develop after an irritation in the 
lining of the esophagus caused by chronic gastrointestinal reflux into the 
esophagus. The long exposure to mixed reflux of the gastroduodenal con-
tents can predispose to chronic esophagitis and premalignant Barrett’s 
esophagus. Histamine H
2
-receptor antagonists and proton pump inhibi-
tors (PPI) are effective against esophageal reflux but efficacy of L-trypto-
phan, an essential amino acid considered as melatonin precursor from 
pineal gland in experimental rat model of Barrett’s esophagus has not 
been fully clarified.
aims & Methods: We determined whether the treatment with L-tryptophan 
which is considered as the precursor of melatonin, can reduce the mucosal 
damage induced by chronic reflux esophagitis progressing into Barrett’s 
esophagus in rat model which resembles human Barrett’s esophagus. 
Eighty rats prepared with esophagogastroduodenal anastomosis (EGDA) 
with or without pinealectomy (removal of pineal gland) resulting in 
chronic esophagitis were randomly divided into 4 groups treated i.g. daily 
either with: 1) vehicle 2) L-tryptophan (200 mg/kg-d i.g.) or melatonin (20 
mg/kg-d i.g.) applied alone or combined with luzindole, the antagonist of 
Mel1 receptor, 3) PPI pantoprazole (10 mg/kg-d) or H
2
-receptor antagonist, 
ranitidine (30 mg/kg-d). At 4 months, the macroscopic and microscopic 
lesion score, the esophageal blood flow (EBF) was determined by H
2
-gas 
clearance method, and plasma levels (ELISA) of TNF-α and IL-1β and , 
and mucosal expression of COX-2, EGF and EGFR mRNA was evaluated 
by RT-PCR.
results: Macroscopic and microscopic chronic esophagitis was developed 
in all EGDA animals followed by a decrease in the EBF and the significant 
rise in the plasma TNF-α and IL-1β levels. Extensive esophageal ulcer-
ations with development of columnar epithelium and formation of mucus 
glands in squamous epithelium, intestinal metaplasia distant to anasto-
mosis were observed. Pinealectomy, which blunted the plasma melato-
nin levels, aggravated the damage score and significantly decreased EBF 
compared with vehicle-control animals. Treatment with L-tryptophan or 
melatonin significantly reduced the LI by 45% and 39%, respectively, while 
causing a significant rise in the EBF. 
These beneficial effects of melatonin and L-tryptophan were significantly 
abrogated by co-treatment with luzindole. The expression of COX-2, EGF 
and EGFR mRNAs were absent in the esophageal mucosa of sham-control 
animals but strongly upregulated in metaplastic Barrett’s epithelium and 
this effect was significantly decreased by treatment with L-tryptophan, 
melatonin, or standard antisecretory agents pantoprazole or ranitidine.
Concurrent treatment with the COX-2 inhibitor celecoxib significantly re-
duced the L-tryptophan and melatonin-induced damage to esophageal 
mucosa in EGDA rats.
conclusion: The development of chronic reflux esophagitis in experimental 
rat model of esophageal injury resembling Barrett’s esophagus in humans 
is associated with severe morphology changes, an impairment of EBF due 
to excessive release of TNF-α, IL-1β and PGE
2
 overexpression of COX-2, EGF 
and its receptor, 2) treatment with L-tryptophan or melatonin acting on 
Mel2 receptors exert beneficial effect in Barrett’s esophagus via the sup-
pression of the release of TNF-α and IL-1β and attenuation of mRNA ex-
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can metabolisms compared with controls. When compared EAC and BEM 
samples, EAC-associated microbiota showed a significantly increased ami-
noacid and energy metabolism with a decreased apoptosis pathway com-
pared with BEM group.
conclusion: Overall, these data describe a specific microbial signature 
for both BE and EAC with a consequent functional impact on esophageal 
mucosa metabolism and open new horizons towards the identification of 
potential risk factors and innovative diagnostic/therapeutic tools.
disclosure: Nothing to disclose 
P0600 quanTIfIcaTIOn Of MIcrOvascuLar change fOr 
dIagnOsIng earLy dIgesTIve squaMOus ceLL carcInOMa By 
OPTIcaL cOherence TOMOgraPhy
Chen P.-H.1, Chen Y.-J.2, Kuo W.-C.2
1Taipei Veterans General Hospital, Endoscopic Center, Taipei, Taiwan, 
2National Yang-Ming University, Taipei, Taiwan
contact e-Mail address: u701117@gmail.com
Introduction: Early diagnosis of squamous cell carcinoma (SCC) in digestive 
tract including oral, pharynx to esophagus is difficult under current imag-
ing tool. Microvascular change, like intrapapillary capillary loop (IPCL) 
observed by magnifying endoscope with narrow band imaging (NBI), is 
the most important key to differentiate benign and early malignant lesion 
of these area. However, the operation of the scope is sometimes difficult 
and limited by anatomy, especially in oral cavity. The judgment of IPCL 
morphology is also subjective and needs learning curve. Optical coherence 
tomography (OCT) is a new optical imaging system with characteristics of 
non-contrast, non-contact, high resolution and 3D imaging. In our pub-
lished study, the morphology of IPCL presented by the OCT angiography 
is similar to endoscopic imaging and can be a diagnostic marker for early 
SCC. In addition to the IPCL, OCT angiography can further image deeper 
submucosal vessels and quantify these microvascular changes. The aim of 
this pilot study is to quantify the microvacular change to diagnose the early 
SCC in mice model.
aims & Methods: 12 weeks 4NQO induction was done to produce tongue 
SCC in mice model. The OCT imaging was performed every month after 
induction to observe different stage of carcinogenesis, including hyperpla-
sia, dysplasia, carcinoma in situ to early SCC. The mice was sacrificed after 
OCT imaging and the induced lesion was sent for histology. The histologi-
cal results were classified into three stages: normal (control mice), hyper-
plasia to low-grade dysplasia and high-grade dysplasia to early SCC. Three 
microvascular parameters of OCT angiography including density, diameter 
and tortuosity were analyzed and were compared between different stages
results: Total seventeen lesions were analyzed. Among them, three le-
sions were normal, nine lesions were hyperplasia to low-grade dysplasia 
and five lesions were high-grade dysplasia to early SCC. It is easy to iden-
tify the tumor area on en-face microvascular mapping because change 
of microvascular pattern. After quantification, significant increased micro-
vascular density (p< 0.05) and diameter (p< 0.01) is seen in high-grade 
dysplasia to early SCC than other stages. But the change of tortuosity is not 
significant between high grade-dysplasia to early SCC than hyperplasia to 
low-grade dysplasia.
conclusion: Like morphology of IPCL, the change of microvascular density, 
diameter and tortuosity can be a marker to diagnose early SCC. This is a 
first study to mapping this microvascular change en-face and quantify it 
in diagnosing SCC. These “quantified and objective markers” may be an 
automatic tool for diagnosing SCC in the future.
disclosure: Nothing to disclose 
pression of COX-2, EGF, and its receptor in esophageal mucosa, and 3) acid 
suppressive drugs such as pantoprazole, could be useful as the therapeutic 
option in the treatment of Barrett’s esophagus.
disclosure: Nothing to disclose 
P0599 MucOsaL sIgnaTure Of esOPhageaL MIcrOBIOTa 
In PaTIenTs WITh BarreTT’s esOPhagus and esOPhageaL 
adenOcarcInOMa
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Cuore, Microbiologia, Rome, Italy, 8Catholic University of Rome, Internal 
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Introduction: Improved diagnostic tools to dissect the risk factors that drive 
the transition from normal epithelium to Barrett’s Esophagus (BE) and 
Esophageal Adenocarcinoma (EAC) represent a clear need for new thera-
peutic alternatives. Gut microbiota exerts a crucial role in health, as well 
as in several gastrointestinal diseases and in various types of cancers.
aims & Methods: The aim of our study was to characterize esophageal 
microbiota composition and the microbiota-related functional predic-
tions in patients with BE and EAC. A total of 26 patients was enrolled on 
the base of specific including and excluding criteria: 10 without any en-
doscopic sign of pathological mucosa at the gastroscopy, as control group 
(1:1 ratio according to PPI use); 10 with a new diagnosis of BE (1:1 ratio 
according to PPI use); and 6 with a new diagnosis of distal esophageal/
esophagogastric junction cancer, confirmed histologically. Genomic DNA 
was extracted from distal esophagus biopsies obtained during gastros-
copy and V3-V4 regions of the 16S rRNA gene were sequenced by MiSeq 
Illumina platform. In patients with BE, biopsies were obtained from both 
the esophageal metaplastic lesion (BEM) and the normal esophageal mu-
cosa (BEU).
results: BE and EAC patients showed a higher level of biodiversity. BEU 
samples showed significant higher values of α-diversity when compared 
with control patients, while BEM shared similar values with EAC, being 
lower than BEU and higher than control patients. A substantial diver-
gence on the first axis was registered for unweighted Unifrac with con-
trol patients significantly separated from BEU and EAC. A lower level of 
Firmicutes and a significantly higher percentage of Bacteroidetes in BEU 
and EAC compared with control subjects was assessed. BEU and BEM 
exhibited a significantly higher presence of Fusobacteria compared with 
controls. Streptococcus relative abundance showed a progressive signifi-
cant reduction in the disease spectrum from controls to EAC. Veillonella 
exhibited a gradual abundance increase in this spectrum. Porphyromonas 
and Prevotella resulted consistently higher in BEU, and in both BEU and 
EAC, respectively, compared with controls. Actinobacillus was significantly 
higher in both BEU and BEM compared with controls and EAC. Fusobac-
terium and Leptotrichia levels were consistently increased in BEU and in 
both BEU and BEM, respectively, when compared with controls. Patients 
with EAC showed significantly upregulated microbial genes related to en-
ergy metabolism, metabolism of cofactors and vitamins, cellular processes 
and signaling, while immunologic system disease and apoptosis pathways 
were consistently down-regulated compared with controls. Microbiota 
associated to BEM was characterized by a high potential for replication 
and repair, genetic information processing, metabolism of cofactors and 
vitamins, energy metabolism, amino acids, nucleotides, lipids and gly-
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P0601 esd fOr esOPhageaL squaMOus ceLL carcInOMa: 
a eurOPean TerTIary cenTer PrOsPecTIveLy cOLLecTed 
exPerIence
Figueiredo Ferreira M.1, Bucalau A.-M.1, Huberty V.2, Verset L.3, Maris C.4, 
Van Laethem J.-L.1, El Nakadi I.5, Devière J.1, Lemmers A.1
1Erasme University Hospital, Gastroenterology, Brussels, Belgium, 2Hopital 
Erasme de Bruxelles Dept. de Gastroenterologie - Gastro-intestinal, Hopital 
Erasme de Bruxel, Gastro-intestinal, Brussels, Belgium, 3Institut Jules 
Bordet, Bruxelles, Belgium, 4Erasme University Hospital, Pathology, Brussels, 
Belgium, 5Erasme University Hospital, Digestive Surgery, Brussels, Belgium
contact e-Mail address: mariana.fig.ferreira@gmail.com
Introduction: Endoscopic submucosal dissection (ESD) is a widely recog-
nised treatment for superficial esophageal squamous cell carcinoma (SCC). 
However, reports from European centres on this endoscopic technique re-
main scarce and most of the available data still originates from Japanese 
series.
aims & Methods: The aim of our study is to present the results and evalu-
ate the efficacy and safety of ESD treatment for superficial oesophageal 
SCC in one European academic tertiary center.
We performed a single-center systematic prospectively collected registry, 
including all the patients with superficial oesophageal SCC treated by ESD 
from mars 2016 to november 2018. Our main outcomes were: R0 resection 
(defined as vertical and lateral margins clear from carcinoma or dyspla-
sia), curative resection (an en-bloc R0 resection with histology no more 
advanced than pT1a m2 SCC, with no lymphovascular invasion and no poor 
differentiation, as defined by the European Society of Gastrointestinal En-
doscopy), procedure-associated complications and locally or distant recur-
rence rate.
results: We included twenty ESD independent procedures performed on 
nineteen patients (mean age 65 [41-83] year old, 55% men). Most of the 
lesions were located in the medium and distal esophagus (45%, respec-
tively), with only 2 lesions (10%) located in the proximal region. The mean 
lesion size was 39 [15-100] mm and the mean procedure duration was 115 
[30-180] min. 65% occupied more than 50% of esophageal circumference.
En-bloc resection was achieved in 20 cases (100%) and R0 resection in 18 
cases (90%), with 2 patients presenting focal positive horizontal margins. 
A 6 months follow-up available in both cases showed no endoscopic or 
pathologic signs of SCC suggesting a coagulation artefact on the specimen.
Curative resection was accomplished in 9 cases (45%). The resection was 
non curative in 11 cases for the following reasons: 3 en-bloc R0 G1 pT1a m3 
SCC, 6 deep submucosal (sm2) SCC with free vertical margins, and 2 due to 
positive lymphovascular infiltration. 
One patient benefited from complementary radio-chemotherapy and one 
was submitted to complementary oesophagectomy (pT0N0). Other pa-
tients were followed endoscopically knowing their age or comorbidities, 
after multidisciplinary discussion. 
The endoscopic follow-up (median 15 [1-29] months) was available for 13 
of the 17 patients without adjuvant oncological therapy and disclosed that 
12 (92.3%) patients had no signs of recurrence.
The only case with lymphatic recurrence appeared in a patient with non 
curative ESD and past history of lymph node metastatic pharyngeal SCC.
In 80% of the cases, there were no complications needing any interven-
tion.
Despite steroid administration in 65% of cases for secondary strictures 
prevention (locally injected triamcinolone for >50% circumference resec-
tion or oral steroid for circumferential resections), 3 patients developed 
symptomatic strictures requiring endoscopic treatment.
One patient presented delayed post-ESD local hemorrhage, treated suc-
cessfully by endoscopic hemostasis.
conclusion: Our preliminary data confirm the safety and technical quality 
of esophageal ESD for SCC in a tertiary European center. The complexity 
to predict the oncological stage opens the room for staging ESD with the 
major limit being the risk of secondary stricture. Further work must be 
done by multicentric studies to better stratify the place of adjuvant onco-
logic treatment.
disclosure: Nothing to disclose 
P0602 MuLTIPLe PrIMary TuMOrs In PaTIenTs WITh 
esOPhageaL squaMOus ceLL carcInOMa
van de Ven S.1, Falger J.M.1, Verhoeven R.H.A.2, Bruno M.J.1, Koch A.D.1
1Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, 
Netherlands, 2Netherlands Comprehensive Cancer Organization, Department 
of Research & Development, Utrecht, Netherlands
contact e-Mail address: s.vandeven@erasmusmc.nl
Introduction: Patients with primary esophageal squamous cell carcinoma 
(P-ESCC) may develop multiple primary tumors (MPTs) in the upper aero 
digestive tract (UADT).[1] The MPT prevalence in these patients is reported 
to be high, up to 21.9%.[1-3] Most studies, however, are performed in Asia, 
where the ESCC prevalence is higher than in Western countries.[4]
aims & Methods: The aim of this study was to evaluate the prevalence of 
MPTs in the UADT in patients with P-ESCC in a Western population. We 
performed a nationwide, retrospective cohort study in collaboration with 
the Netherlands Comprehensive Cancer Registry (IKNL). All adult patients, 
diagnosed between 2000 and 2016 with ESCC as index tumor were in-
cluded in this study. 
Follow-up data were available until January 2018. No screening programs 
for MPTs were in place within this timeframe. Our primary endpoint was 
the prevalence of MPTs in the UADT in patients with P-ESCC. Secondary 
endpoints were; (1) MPT localization, (2) MPT histology, (3) the proportion 
of patients with synchronous (within 6 months before and after diagnosis 
of P-ESCC) or metachronous (> 6 months after diagnosis of P-ESCC) MPTs, 
and (4) risk factors associated with MPT development. We performed uni-
variate and multivariate analysis to analyze these risk factors.
results: A total of 9,058 patients were diagnosed with P-ESCC between 
2000 and 2016 (male: 57.3%). The median age was 67 years (IQR 60-75). 
Initial ESCC tumor stage was high (stage III/IV) in the majority of patients 
(59.9%). Most patients were treated with radiotherapy (n=2,163; 23.9%) 
or chemoradiotherapy (n=1,812; 20.0%). In 850 (9.4%) patients, ESCC was 
treated by primary surgery or endoscopic resection, and 1,288 (14.2%) pa-
tients received neoadjuvant therapy before surgery. 
A total of 545 MPTs were registered in 476 (5.3%) patients. Most MPTs 
were located in the head and neck region (47.9%), followed by the lungs 
(40.8%) and stomach (6.6%). Squamous cell carcinoma (61.8%) was the 
most common histology, followed by adenocarcinoma (14.5%). Of all 
MPTs, 329 (60.4%) were diagnosed synchronously and 216 (39.6%) meta-
chronously. 
Of all patients who were alive 6 months after P-ESCC diagnosis (n=5,938), 
191 patients (3.2%) developed a metachronous MPT. The median time be-
tween diagnosis of P-ESCC and the metachronous MPT was 3.0 years (IQR 
1.8-5.9). Of patients with metachronous MPT, MPT stage was high (stage 
III/IV) in 57.4%. These patients had a significantly worse 2-year survival 
than low stage MPT (stage I/II) (15.1% vs. 51.9%, p <0.01). 
The following factors were significantly correlated with MPT development: 
male sex (OR: 1.519; p <0.01), age ≤ 70 years (OR: 2.129; p <0.01), and lower 
tumor stage (stage I/II vs. III/IV) (OR: 2.053; p<0.01).There was no signifi-
cant difference in P-ESCC tumor stage between patients with synchronous 
and metachronous MPTs.
conclusion: Based on this nation-wide registry study a minimum of one 
out of twenty patients with P-ESCC develops an MPT. The majority of the 
registered MPTs were detected synchronously, screening from diagnosis of 
P-ESCC should therefore be recommended. Since patients with metachro-
nous MPTs had more often high-stage MPTs and a worse survival com-
pared to low-stage metachronous MPTs, we should screen for metachro-
nous MPTs to detect MPTs at an earlier, and lower tumor stage.
references: 1. Lee, G.D., et al., Esophageal Cancer Associated with Multiple 
Primary Cancers: Surgical Approaches and Long-term Survival. Ann Surg 
Oncol, 2013. 20(13): p. 4260-6. 2. Noguchi, T., et al., Necessity of screening 
for multiple primary cancers in patients with esophageal cancer. Ann Tho-
rac Cardiovasc Surg, 2002. 8(6): p. 336-42. 3. Kumagai, Y., et al., Multiple 
primary cancers associated with esophageal carcinoma. Surg Today, 2001. 
31(10): p. 872-6. 4. Arnold, M., et al., Global incidence of oesophageal can-
cer by histological subtype in 2012. Gut, 2015. 64(3): p. 381-7.
disclosure: Nothing to disclose 
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In this study, we evaluated the efficacy of PDT with Talaporfin for esopha-
geal cancer focusing on the vascular shutdown effect.
aims & Methods: Patients with histologically proven local failure limited 
within the muscularis propria after radiotherapy (RT) of 50 Gy or more for 
esophageal cancer were eligible.
The PDT procedure commenced with intravenous administration of a 40 
mg/m2-dose of talaporfin sodium, followed by laser irradiation at a 664-
nm wavelength 4 to 6 hours after administration. 
The local efficacy was classified based on endoscopic evaluation as lo-
cal complete response (L-CR). The L-CR rate per patients was the primary 
endpoint of this study. The secondary endpoints were confirmed local 
progression-free survival (L-PFS), and overall survival (OS).
Xenograft tumor mouse models were established with colon cancer cell 
lines (HCT116). After talaporfin intravenous injection, tumors were il-
luminated with the diode laser system (664nm). Tumor blood flow was 
measured by a laser speckle blood flow analyzing system; OMEGA ZONE2. 
Temporal changes of the flow were compared with the positive control; 
Combretastatin A-4 phosphate (CA4P).
results: Sixteen patients with a total of 19 lesions received additional laser 
irradiation. The median total laser exposure dose was 298 (range: 100-
800) J. Thirteen patients with a total of 16 lesions achieved L-CR after PDT 
(L-CR rate: 84.2%). The L-CR rate of T1 failure lesions was 92.8% (13/14), 
whereas the L-CR rate of T2 failure lesions was 60.0% (3/5).
PDT with Talaporfin decreased the blood flow in tumors but not in the 
neighboring healthy tissue.
conclusion: The possibility of esophageal perforation after PDT should be 
considered for longer than 1 month post-therapy. PDT with Talaporfin de-
creased the tumor blood flow significantly in vivo. The vascular shutdown 
effect of PDT with Talaporfin was suggested as an important part of its an-
titumor effects. PDT using talaporfin sodium and a diode laser is a curative 
salvage treatment for local failure after CRT for patients with esophageal 
cancer.
disclosure: Nothing to disclose 
P0605 rIsk facTOrs fOr sTrIcTure afTer esOPhageaL esd: 
can We PrevenT sTrIcTure WITh sTerOId InjecTIOn and Pga 
shIeLdIng?
Sakaguchi Y., Tsuji Y., Koike K.
University of Tokyo, Department of Gastroenterology, Graduate School of 
Medicine, Tokyo, Japan
contact e-Mail address: sakaguchi-tky@umin.ac.jp
Introduction: Endoscopic submucosal dissection (ESD) is currently the 
standard method of treatment for superficial esophageal carcinoma in 
many countries. However, resection of more than 3/4 the circumference 
of the esophagus has been reported to be a risk factor for postoperative 
stricture after ESD. A previous pilot study has shown that combining tri-
amcinolone injection and shielding with polyglycolic acid (PGA) sheets 
is effective in preventing postoperative stricture (Am J Gastro 2016). This 
analysis was performed to obtain more definitive evidence on the efficacy 
of this method, and determine factors which may induce stricture even 
after this method.
aims & Methods: We have performed a retrospective analysis of patients 
who have undergone esophageal ESD from Jan 2002 to Dec 2018 at the 
University of Tokyo Hospital. 136 consecutive patients who underwent 
esophageal ESD for superficial esophageal squamous cell carcinoma cov-
ering over 1/2 the circumference of the esophagus were extracted. Of these, 
after ethics committee approval in 2013, patients have undergone either 
“PGA shielding” or “steroid injection + PGA shielding” following ESD. Af-
ter exclusion of patients who did not undergo 12 week post-ESD follow-up, 
patients who underwent salvage surgery, and patients with regular oral 
steroid use, 111 patients (age 69.8±9.0 years) were analyzed. Multivariate 
logistic regression analysis was performed to evaluate risk factors associ-
ated with stricture, which was defined as the state where dilation was 
required for an upper gastrointestinal endoscope to pass.
results: 82.9% (92/111) of these high-risk patients required resection of 
over 3/4 the circumference of the esophagus. By multivariate logistic re-
gression analysis, location (p=0.037), resection circumference (p< 0.001), 
and method of prevention (p=0.020) were the only factors significantly as-
sociated with stricture. Further analyses demonstrated that stricture rates 
in the cervical esophagus (75.0%, p=0.040), and after total circumferential 
resection (83.3%, p< 0.001) were especially high.
P0603 The accuracy Of The PreOPeraTIve dIagnOsIs Of 
LyMPh nOde MeTasTasIs usIng cOMPuTed TOMOgraPhy fOr 
T1B esOPhageaL cancer PaTIenTs receIvIng esOPhagecTOMy 
afTer endOscOPIc TreaTMenT
Kawada K.1,2, Nakajima Y.1,2, Tokairin Y.1,2, Hoshino A.1,2, Okada T.1,2, 
Matsui T.1,2, Yamaguchi K.1,2, Kinugasa Y.2
1Tokyo Medical and Dental University, Esophageal Surgery, Tokyo, Japan, 
2Tokyo Medical and Dental University, Gastrointestinal Surgery, Tokyo, Japan
contact e-Mail address: kawada.srg1@tmd.ac.jp
Introduction: The standard treatment for T1b esophageal squamous cell 
carcinoma (tumor invasion to submucosa) is esophagectomy with lymph-
adenectomy in Japan. However, some cases are given endoscopic treat-
ment as the initial therapy. Based on the histopathological findings, the 
patients in whom the tumor has invaded to the submucosa are then rec-
ommended to undergo additional therapy. The accurate clinical evaluation 
of the lymph nodes is therefore crucial for selecting the optimum treat-
ment strategy for individual esophageal cancer patients.
aims & Methods: To investigate the accuracy of the preoperative diagno-
sis of lymph node metastasis for T1b esophageal cancer patients given 
esophagectomy after endoscopic treatment.Between January 2002 and 
December 2016, 139 cases of T1b esophageal cancer were treated with en-
doscopic treatment as the initial treatment. Thirty-six patients (25.9%) re-
ceived esophagectomy with lymphadenectomy. The concordance between 
the clinical and pathological nodes was then evaluated. The preoperative 
diagnosis was based on computed tomography (CT) findings.
results: The patient background characteristics were as follows: male/fe-
male, 30/6; median age, 64 years old (range 41-78); primary tumor site 
at cervical/upper/middle/lower/Barrett’s esophagus, 2/5/15/10/4; cN0/
cN1, 32/4. Lymph node metastasis was observed in 13 patients and 19 
lymph nodes (36.1%). The number of lymph node metastases was one 
in eight cases, two in one case, three in three cases and five in one case. 
The lymph node-positive sites were cervical/thoracic/abdominal in 11/5/3 
cases. Lymph node metastasis was most frequently observed in the right 
para-thoracic area. The sensitivity and specificity of clinical nodes for a di-
agnosis of pathological nodes were 30.8% and 100%, respectively, and the 
positive and negative predictive values were 100% and 71.9%, respectively. 
In 12 (63.1%) of the 19 sites, the size of the lymph nodes with metastasis 
was estimated to be < 3 mm on CT.
conclusion: The diagnosis of clinical nodes has low sensitivity and a low 
negative predictive value for the prediction of the pathological node cat-
egory in the preoperative diagnosis of lymph node metastasis for patients 
with T1b esophageal cancer treated endoscopically. We therefore need to 
carefully consider indications of endoscopic treatment for T1b esophageal 
cancer. Clinical staging techniques should be improved.
disclosure: Nothing to disclose 
P0604 The effIcacy Of PhOTOdynaMIc TheraPy WITh a 
neW PhOTOsensITIzer (TaLaPOrfIn sOdIuM) as a saLvage 
TreaTMenT fOr esOPhageaL cancer WITh a fOcus On The 
effecT Of vascuLar shuTdOWn
Tanaka M.1, Suzuki T.1, Nishie H.1, Kataoka H.2
1Nagoya City University Graduate School of Medical Sciences, Departments of 
Gastroenterology and Metabolism, Nagoya, Japan, 2Nagoya City University 
Gastroenterology and Metabolism, Nagoya, Japan
contact e-Mail address: mtanaka@med.nagoya-cu.ac.jp
Introduction: Esophageal cancer is one of the most common cancers 
worldwide. Chemoradiotherapy (CRT) is one of the curative treatments for 
esophageal cancer in patients with unresectable tumors or those who re-
fuse surgery. However, local failure after CRT is a problem. An alternate 
treatment in such patients is photodynamic therapy (PDT).
PDT consists of the intravenous administration of a photosensitizer, fol-
lowed by activation with a specific wavelength light. Activation of the 
photosensitizer causes the conversion of molecular oxygen into various 
reactive oxygen species that directly induce the death of the tumor cells or 
shut down the tumor-associated vasculature. However, the mechanism of 
the vascular shut down is not clear.
Talaporfin sodium, a second-generation photosensitizer, is rapidly cleared 
from the skin and requires a shorter sun-shade period. Furthermore, the 
depth of effect is expected to extend to deeper layers. 
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Comparison on the efficacy of “steroid injection + PGA shielding” vs “PGA 
shielding” vs “control” was performed. In the relatively low-risk subgroup 
excluding cervical esophageal cancer and complete circumferential resec-
tion, the postoperative stricture rate was 18.9% vs 41.4% vs 51.7% respec-
tively (p=0.014). The rate of patients requiring long-term dilation treat-
ment was 16.2% vs 31.0% vs 28.0% respectively (p=0.320), indicating that 
“steroid injection + PGA shielding” is the most effective method in both 
preventing and alleviating stricture. However “steroid injection and PGA 
shielding” showed only limited effects in extremely high-risk cases with 
either cervical esophageal cancer or complete circumferential resection.
conclusion: Combining steroid injection and PGA shielding is effective for 
preventing and alleviating postoperative stricture after esophageal ESD. 
There is a need for even more effective methods for cervical esophageal 
cancer and complete circumferential resection.
references: Triamcinolone Injection and Shielding with Polyglycolic Acid 
Sheets and Fibrin Glue for Postoperative Stricture Prevention after Esopha-
geal Endoscopic Resection: A Pilot Study. Sakaguchi Y, et al. Am J Gastro-
enterol. 2016 Apr;111(4):581-3. doi: 10.1038/ajg.2016.60
disclosure: Nothing to disclose 
P0606 WIThdraWn
P0607 Larger LesIOns and PrevIOus cheMOradIOTheraPy 
fOr esOPhageaL cancer Increased The rIsk Of faILure Of en 
BLOc resecTIOn Or PerfOraTIOn In esOPhageaL esd
Nagami Y.1, Ominami M.1, Sakai T.1, Fukunaga S.1, Yamagami H.1, 
Tanigawa T.1, Watanabe T.1, Fujiwara Y.2
1Osaka City University Graduate School of Medicine, Dept. of 
Gastroenterology, Osaka, Japan, 2Osaka City University, Dept. of 
Gastroenterology, Osaka, Japan
contact e-Mail address: yasuaki1975@hotmail.com
Introduction: Endoscopic submucosal dissection (ESD) is accepted as 
the standard treatment for early-stage esophageal neoplasia. However, 
esophageal perforation may occur, leading to mediastinitis and pneumo-
thorax, which sometimes require emergency surgery. In addition, failure 
of en bloc resection causes local recurrence. Until now, few studies have 
reported on predictors of failure of en bloc resection or perforation dur-
ing ESD.
aims & Methods: The aim of the present study is the risk factors of failure 
of en bloc resection or perforation in ESD for esophageal neoplasia.
This was a retrospective observational study conducted at a single institu-
tion. Between May 2004 and March 2016, 543 consecutive patients with 
927 esophageal lesions were treated with ESD. Patients with metachro-
nous esophageal neoplasia or missing data were excluded. The primary 
outcome was determining the predictors of failure of en bloc resection or 
perforation in patients who underwent esophageal ESD. Perforation was 
defined as a visible hole in the esophageal wall, exposing the mediastinal 
cavity.
results: A total of 543 patients with 736 lesions were evaluated. Failure 
of en bloc resection occurred in 6 patients (1.1%) with 6 lesions, and per-
foration occurred in 11 patients (2.0%) with 11 lesions (1.5%). Lesion di-
ameter [odds ratio (OR), 1.05; 95% confidence interval (CI): 1.02-1.07; p < 
0.001)], wider tumor circumference (OR, 9.80, 95% CI: 1.61-59.5; p=0.01), 
and previous chemoradiotherapy for esophageal cancer (OR, 3.87; 95% 
CI: 1.19-12.53; p=0.02) were associated with failure of en bloc resection 
or perforation according to crude logistic regression analysis. Multivariate 
logistic regression analysis showed that lesion diameter (OR, 1.04; 95% CI: 
1.02-1.06; p < 0.001) and previous chemoradiotherapy (OR, 5.24; 95% CI: 
1.52-18.06; p = 0.009) were independent predictive factors.
conclusion: Larger lesions and previous chemoradiotherapy for esopha-
geal cancer increased the risk of failure of en bloc resection or perforation 
in patients who underwent esophageal ESD.
disclosure: Nothing to disclose 
P0608 adenOcarcInOMa Of The esOPhagOgasTrIc juncTIOn 
In jaPan: a 10-year PrOsPecTIve MuLTIcenTer ePIdeMIOLOgIcaL 
sTudy In kurashIkI, jaPan
Matsueda K.1, Manabe N.2, Sato Y.3, Watanabe T.4, Mizuno M.1, Haruma K.5
1Kurashiki Central Hospital, Gastroenterology and Hepatology, Kurashiki, 
Japan, 2Kawasaki Medical School Endoscopy and Ultrasonography, Kurashiki, 
Japan, 3Sato Clinic Gastroenterology and Surgery, Kurashiki, Japan, 
4Watanabe Gastrointestinal Hospital, Kurashiki, Japan, 5Kawasaki Medical 
School, Kurashiki, Japan
contact e-Mail address: km5453@kchnet.or.jp
Introduction: Gastroesophageal reflux disease-related diseases, such as 
Barrett’s esophagus and adenocarcinoma of the esophagogastric junc-
tion (AEGJ), are believed to occur less frequently in Japan than in Western 
countries. The number of cases of these conditions reported in Japan 
has been gradually increasing in recent years; however, there is limited 
information on the epidemiology of AEGJ. Based on previously reported 
data (Matsueda K, et al. Dis Esophagus 2017; 30: 1-6), we decided to 
extend the observational period in order to conduct a long-term follow-
up study.
aims & Methods: The aim of this study was to investigate the clinicoepi-
demiological characteristics of AEGJ in Japan. We divided the investigation 
period into the following three parts: first period (2.5 years; January 1, 
2008-June 30, 2010), second period (4 years; July 1, 2010-June 30, 2014), 
and third period (3.5 years; July 1, 2014-December 31, 2017). During the first 
period, 88,199 consecutive cases (48,548 males and 39,651 females; mean 
age, 62 years) involving upper gastrointestinal endoscopy performed at 
12 hospitals in Kurashiki, Japan were recruited. The cases were prospec-
tively followed up for 7.5 to 10 years (mean, 8.7 years). Over a 10-year 
period from January 2008 to December 2017, we reviewed all endoscopy 
reports and associated medical records. AEGJ was defined as an adeno-
carcinoma of the distal esophagus (Siewert classification type I) and a true 
carcinoma of the cardia (Siewert type II). A new-onset patient was defined 
as a patient who had newly developed AEGJ, esophageal squamous cell 
carcinoma (SCC), and/or gastric cancer (GC) during the follow-up period. 
The new-onset rates of AEGJ, SCC, and GC, including Siewert type III, were 
calculated.
results: During the 10-year study period, 158 patients with AEGJ were 
identified (131 males and 27 females; mean age, 68 years), and of these 
patients, 16 had Siewert type I AEGJ and 142 had Siewert type II. The inci-
dence rate of AEGJ was 0.018%/year during the 10-years period and did 
not increase over the years. However, the proportion of patients with Siew-
ert type I AEGJ significantly increased during the follow-up period (Table 
1).
 
first period 
(n=47)
second period 
(n=55)
Third period 
(n=56) P value
type I/type I+II 1/47 (2%) 5/55 (9%) 10/56 (18%) < 0.05
[Table 1 The proportion of patients with Siewert type I AEGJ]
With regard to female patients, the number of cases increased from 5 (1.3 
cases/year) in the second period to 13 (3.7 cases/year) in the third period. 
The new-onset rate of AEGJ was very low compared with that of SCC or GC, 
but it gradually increased from 1.1/100,000 person-years (SCC, 3.4/100,000; 
GC, 42.3/100,000) in the second period to 3.2/100,000 person-years (SCC, 
8.8/100,000; GC, 37.7/100,000) in the third period.
conclusion: The incidence of AEGJ is still lower in Japan than in Western 
countries; however, the proportion of patients with Siewert type I AEGJ and 
the new-onset rate of AEGJ are gradually increasing.
disclosure: Nothing to disclose 
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aims & Methods: The aim of this study was to investigate the yield of en-
doscopic screening for HNSPTs in patients with primary ESCC. Secondary 
aims were to investigate whether screening should be performed synchro-
nously or metachronously, and to investigate whether there is enough evi-
dence to justify endoscopic screening in the Western world. We conducted 
a systematic literature search until February 2019 to retrieve studies from 
all available databases. Studies were included if ESCC patients were en-
doscopically screened for HNSPT. The primary outcome was the pooled 
prevalence of HNSPTs.
results: Twelve studies, all performed in Japan, were included in this sys-
tematic review with a total of 6483 patients (Table 1). The pooled preva-
lence of HNSPTs was 6.7% (95% CI: 4.9-8.4). The overall heterogeneity was 
high across the studies (I2 = 89.0%, p < 0.001). The proportion of synchro-
nous (48.2%) and metachronous (51.8%) HNSPTs was comparable. Most 
HNSPTs were low-stage (85.3%) and located in the hypopharynx (60.3%).
conclusion: Based on our results, HNSPT screening could be considered 
in patients with primary ESCC. The majority of HNSPTs were classified as 
low-stage, which can be treated curatively and have an excellent prog-
nosis. All studies were performed in Japan, it is therefore not clear if this 
consideration applies to the Western world.
author year design n Method quality score quality screening sites
          MINORS
Rele-
vance
Total    
Abiko 
et al.
2018
Pro-
spective
158 WL 18 3 21 High Larynx
Onochi 
et al.
2018
Retro-
spective
285 WL 10 3 13 Medium
Oro- 
hypopharynx
Morimoto 
et al.
2017
Retro-
spective
307
WL + 
NBI
18 5 23 High
Oro- 
hypopharynx, 
Larynx
Kaneko 
et al.
2013
Retro-
spective
348
WL + 
NBI
9 4 13 Medium
Oral cavity, 
pharynx
Katada 
et al.
2012
Pro-
spective
71
WL + 
NBI
16 5 21 High
Head and 
neck region
Muto 
et al.
2010
Pro-
spective
320
WL + 
NBI
23 4 27 High
Head and 
neck region
Nonaka 
et al.
2009
Pro-
spective
424
WL + 
NBI
19 5 24 High Pharynx
Lo et al. 2008
Pro-
spective
1675 WL 18 3 21 High
Head and 
Neck region
Watanabe 
et al.
2007
Pro-
spective
1118 Lugol 10 3 13 Medium
Head and 
neck region
Shimizu 
et al.
2003
Pro-
spective
99 Lugol 18 5 22 High
Hypopharynx, 
larynx
Kagei 
et al.
2002
Pro-
spective
1479 WL 10 2 12 Medium
Head and 
neck region
Motoyama 
et al.
2003
Pro-
spective
200 WL 13 4 17 High Larynx
[Table 1. Study characteristics and quality score of all 12 studies.  
WL = white light, NBI = Narrow Band Imaging]
references: 1. Chuang, S.C., et al., Risk of second primary cancer among 
esophageal cancer patients: A pooled analysis of 13 cancer registries. Can-
cer Epidemiol Biomarkers Prev, 2008. 17(6): p. 1543-1549. 2. Lo, O.S.H., et 
al., Esophageal cancers with synchronous or antecedent head and neck 
cancers: A more formidable challenge? Ann Surg Oncol, 2008. 15(6): p. 
1750-1756.
disclosure: Nothing to disclose 
P0609 usefuLness Of LInked cOLOr IMagIng In The earLy 
dIagnOsIs Of suPerfIcIaL esOPhageaL squaMOus ceLL 
carcInOMas
Nakamura K.1, Urabe Y.2, Oka S.3, Nagasaki N.3, Yorita N.3, Hata K.3, 
Kotachi T.1, Boda T.1, Tanaka S.4, Chayama K.3
1Hiroshima University Hospital, Departments of Endoscopy, Hiroshima, 
Japan, 2Hiroshima University, Regeneration and Medicine, Hiroshima, 
Japan, 3Hiroshima University Hospital, Gastroenterology and Metabolism, 
Hiroshima, Japan, 4Hiroshima University, Endoscopy and Medicine, 
Hiroshima, Japan
contact e-Mail address: kami_hi_koki@yahoo.co.jp
Introduction: Linked color imaging (LCI) installed in the FUJIFILM’s LASE-
REO endoscope system can highlight minor differences of color through 
image processing to expand the saturation and hue differences in the re-
gion of red color. 
This study investigated the usefulness of LCI in SESCC.
aims & Methods: We examined the visibility of lesions using LCI compared 
with that using white-light imaging (WLI) in 46 consecutive patients (29 
men and 17 women; average age: 68.1 ± 9.6 years; 40 heavy drinkers and 
36 smokers) with SESCC who underwent esophagogastroduodenoscopy 
using LCI in our department from April 2018 to November 18, 2018. The 
clinicopathological characteristics of the 46 cases were studied. 
The average tumor diameter was 21.4±17.6 mm (5-60 mm), and the tumor 
stage was 0-IIc in 40 cases and 0-IIa in 6; the tumor depth was limited to 
the epithelium or was invading the lamina propria (EP/LPM) in 30 cases, 
invading the muscularis mucosa or the upper third of the submucosal 
layer (MM/SM1) in 12, and invading the middle third of the submucosal 
layer (SM2) in 4. 
Changes in the visibility of the lesions were evaluated by 8 endoscopy spe-
cialists using the evaluation scale (+2: improved; +1: slightly improved; 0: 
equal; -1: slightly decreased; -2: decreased), and the overall score was 
defined as 8 or more in case of improved visibility, 7 to -7 in case of equal 
visibility, and -8 or less in case of decreased visibility. 
Furthermore, in each lesion, the color difference between the cancerous 
and noncancerous areas observed by LCI was compared to that by WLI. In 
addition, tumor diameter, macroscopic type, depth, smoking and drinking 
history, and multiple lugol-voiding lesions (multiple LVLs; 10 small LVLs of 
the surrounding mucous membrane) were examined.
results: The rate of change in the visibility of lesions by LCI was 41% (19/46) 
for improved visibility, 59% (27/46) for equal visibility, and 0% (0/46) for 
decreased visibility. The colors were significantly different between the 
cancerous and non-cancerous areas. The improved visibility was signifi-
cantly different between LCI and WLI (p<0.01; two sample t-tests), but no 
significant differences were observed for equal visibility. 
The improved visibility of the lesions by LCI had no correlations with the tu-
mor diameter, macroscopic type, color tone, depth, or smoking and drink-
ing history, but was significantly correlated with the presence of multiple 
LVLs (p<0.05; χ2 test). The kappa value of the interobserver agreement was 
0.45, which means that the observations were roughly consistent.
conclusion: LCI for SESCC does not reduce the visibility of the lesion com-
pared with WLI, and in particular, improves the visibility of the lesions with 
multiple LVLs.
disclosure: Nothing to disclose 
P0610 screenIng fOr head and neck secOnd PrIMary 
TuMOrs In PaTIenTs WITh esOPhageaL squaMOus ceLL cancer: 
a sysTeMaTIc revIeW and MeTa-anaLysIs
van de Ven S.1, Bugter O.2, Hardillo J.2, Bruno M.J.1, 
Baatenburg de Jong R.2, Koch A.D.1
1Erasmus MC - University Medical Center, Gastroenterology and Hepatology, 
Rotterdam, Netherlands, 2Erasmus MC - University Medical Center, 
Otorhinolaryngology and Head and Neck Surgery, Rotterdam, Netherlands
contact e-Mail address: s.vandeven@erasmusmc.nl
Introduction: Esophageal squamous cell carcinoma (ESCC) is often accom-
panied by head and neck second primary tumors (HNSPTs).[1] The prog-
nosis and survival of patients with an additional HNSPT is worse com-
pared to patients with only ESCC (5-year survival rate of 9.2% vs. 21.0%).
[2] Therefore, early detection of HNSPTs may improve the overall outcome 
of patients with ESCC.
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P0611 The PrevaLence Of gasTrIc MucOsaL InjurIes In 
LOW-dOse asPIrIn users By age
Shimada Y.1, Ikeda Y.1, Hayashida S.1, Takahashi S.1, Sato S.1, Amano N.1, 
Murata A.1, Tsuzura H.1, Sato S.1, Iijima K.1, Nagahara A.2, Genda T.1
1Juntendo University Shizuoka Hospital, Gastroenterology and Hepatology, 
Izunokuni-city, Japan, 2Juntendo University School of Medicine, 
Gastroenterology, Tokyo, Japan
contact e-Mail address: yshimada@juntendo.ac.jp
Introduction: Low-dose aspirin (LDA) use is increasing dramatically around 
the world. Particularly in Japan, the number of LDA users is expected to 
increase rapidly due to the country’s aging population. Therefore, it is an 
urgent issue for us to understand the features of gastric mucosal injury in 
patients taking LDA.
aims & Methods: The aim of this study is to explore the generation differ-
ence in prevalence of gastric mucosal injury in LDA users. This is a case-
controlled study conducted at our department. Data were extracted from 
the records of subjects who underwent upper gastrointestinal endoscopy 
at our department between April 2015 and February 2019. Of the 4,983 
subjects analyzed, we focused on the subjects who did not take potas-
sium-competitive acid blockers, proton pump inhibitors or histamine 2 
receptor antagonists. We analyzed data for subjects diagnosed endoscopi-
cally with gastric erosions and ulcers. These mucosal injuries are based on 
the definition of ulcer classification which was defined by Murakami and 
Suzuki in 1971. We compared the prevalence of gastric mucosal injuries 
between patients taking LDA (LDA users) and taking NO LDA (nonusers) by 
age. Statistical analyses were performed by Mann-Whitney U test.
results: This study included 147 subjects taking LDA (101 men, 26 women; 
mean age 72.5 years) and 3,362 subjects taking NO LDA (1,874 men, 1,488 
women; mean age 63.1 years). In LDA users, the prevalence of gastric mu-
cosal injury was 23.1% (3/13) (ages 39 and under), 25.0% (3/12) (ages 40-
49), 40.0% (2/5) (ages 50-59), 31.8% (7/22) (ages 60-69), 23.2% (10/38) 
(ages 70-79), 26.3% (10/38) (80 and over). In nonusers, the prevalence of 
gastric mucosal injury was 17.3% (125/722) (ages 39 and under), 19.30% 
(96/497) (ages 40-49), 21.9% (102/465) (ages 50-59), 21.4% (183/857) 
(ages 60-69), 20.5% (191/232) (ages 70-79), 20.5% (79/386) (80 and over) 
(p=0.0039). The prevalence of gastric mucosal injury was highest in the 
age group 50-59 in both LDA users and nonusers.
conclusion: We have demonstrated that the prevalence of gastric mucosal 
injury in LDA users was statistically significantly higher than in nonusers. 
In all age groups, the prevalence in LDA users was higher than in nonus-
ers.
disclosure: Nothing to disclose 
P0612 IncIdence and TreaTMenT OuTcOMes Of 
MeTachrOnOus gasTrIc cancer OccurrIng afTer 
curaTIve endOscOPIc suBMucOsaL dIssecTIOn Of 
undIfferenTIaTed-TyPe earLy gasTrIc cancer: 
jaPan cLInIcaL OncOLOgy grOuP sTudy: 
suPPLeMenTary anaLysIs Of jcOg1009/1010
Abe S.1, Takizawa K.2, Oda I.1, Ogawa G.3, Kadota T.4, Ono H.2, Hasuike N.5, 
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Takahashi A.11, Yoshikawa T.12, Terashima M.13, Muto M.14, 
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Department of Gastroenterology, Tokyo, Japan, 11Saku Central Hospital 
Gastroenterology, Advanced Care Center, Nagano, Japan, 12National Cancer 
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Introduction: Five-year cumulative incidence of metachronous gastric can-
cer (MGC) occurring after curative gastric endoscopic submucosal dissec-
tion (ESD) of several studies was reported in 10-16% 1). However, most 
subjects of previous studies were patients undergoing ESD of differenti-
ated-type (D-type) early gastric cancer (EGC), and little is known about 
long-term follow-up data of MGC occurring after gastric ESD of undiffer-
entiated-type (UD-type) EGC.
aims & Methods: The aim of this study was to evaluate incidence and 
treatment outcomes of MGC after curative gastric ESD of UD-type EGC. This 
study included patients who underwent curative ESD of initial solitary UD-
type EGC from JCOG1009/1010, which is a multicenter single-arm confirma-
tory trial in Japan and showed excellent long-term outcomes in patients 
undergoing curative ESD of UD-type EGC 2). Curative ESD of UD-type EGC 
was defined as histologically proven mucosal poorly differentiated adeno-
carcinoma or signet ring cell carcinoma of major histological type without 
ulceration nor lymphovascular invasion ≤ 20mm with free lateral and deep 
margin. Undifferentiated dominant-type (e.g., poorly to moderately dif-
ferentiated adenocarcinoma) was also included as UD-type EGC. Surveil-
lance endoscopy was performed biannually for the first three years and 
then annually. This study assessed the time to MGC occurrence after ESD, 
lesion characteristics, and treatment outcomes of MGC. MGC was defined 
as a gastric cancer that was located in a different position to the initial EGC 
occurring more than one year after the index ESD. Time to MGC occurrence 
was estimated by cumulative incidence function, regarding deaths and to-
tal gastrectomy as competing risks.
results: A total of 198 patients undergoing curative ESD of UD-type EGC 
were analyzed in this study. Male/female was 96/102, and the median age 
was 60 (range: 23-80). Gastric atrophy (none/mild/severe) was classified 
64/64/70, respectively. Eighty-five patients had Helicobacter pylori (H. py-
lori) infection, 59 did not have H. pylori infection, and 26 had successful H. 
pylori eradication at index gastric ESD (missing in 28 patients). Four pa-
tients post ESD of UD-type EGC developed MGC during a median follow up 
period of 5.8 years (range: 0.2-7.2). Five-year cumulative incidence func-
tion of MGC was 1.0% (95% CI: 0.2%-3.3%). The tumor location　(Upper/
Middle/Lower) were 1/1/2, respectively. The macroscopic type was 0-IIc in 
all four lesions. All MGCs were treated with ESD. Two MGCs were histologi-
cally D-type EGC, and the remaining two were UD-type EGC. The median 
tumor size of MGCs was 1.0 (range: 0.7-1.7) cm, and the depth of inva-
sion (M/SM1/SM2) was 2/1/1, respectively. Three out of the four patients 
achieved curative resection.
conclusion: MGC could occur less commonly after curative ESD of UD-type 
EGC compared with that of D-type EGC, and three out of four MGC were 
resected curatively with ESD.
references: 1) Abe S, et al. Metachronous Gastric Cancer Following Cu-
rative Endoscopic Resection of Early Gastric Cancer, Clin Endosc 2018 2) 
Takizawa K, et al. A non-Randomized Single-arm Confirmatory Trial of 
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procedure time and is associated with a high incidence of complications. 
Treatment should therefore be carefully performed, taking into account 
that such lesions are technically difficult to treat.
disclosure: Nothing to disclose 
P0615 The effecT Of anTIcOaguLanT TheraPy On POsT 
endOscOPIc suBMucOsaL dIssecTIOn BLeedIng fOr gasTrIc 
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Nakamura S.1, Eizuka M.3, Fujita Y.3, Uesugi N.3, Sugai T.3, Matsumoto T.1
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Introduction: Endoscopic submucosal dissection (ESD) has been accepted 
as a standard treatment for early gastric cancer (EGC). In the guideline 
published by the Japan Gastroenterological Endoscopy Society, it has been 
suggested that an anti-platelet medication should be continued throughout 
the peri-treatment period. However, the optimal management of anticoagu-
lant therapy for gastric ESD remains controversial. Moreover, little is known 
about the effect of anticoagulant therapy on post-ESD bleeding.
aims & Methods: In order to investigate the effect of anticoagulants for 
post-ESD bleeding for EGC, we retrospectively analyzed 2355 EGCs treated 
by ESD, including 137 lesions in patients under anticoagulants. Anticoagu-
lant therapy included warfarin and direct oral anti-coagulants (DOACs), 
such as dabigatran, rivaroxaban, edoxaban and apixaban. Using propen-
sity score matching analysis, clinicopathological findings were evaluated 
between lesions in patients with anticoagulant therapy and those in pa-
tients without. We used a one-to-one propensity score matching selected 
by age, gender, comorbidities (such as diabetes mellitus, renal failure 
and liver cirrhosis), tumor location, macroscopic appearance, histology, 
depth of tumor, ulcerative findings, procedure time, resected specimen 
size and perforation as parameters. Factors associated with post-ESD 
bleeding were analyzed with multivariable analyses with a logistic re-
gression method.
results: After propensity score matching, post-ESD bleeding was signifi-
cantly more frequent in lesions in patients with than without anticoagulant 
therapy (11.7% vs 1.5%, respectively; P = 0.001). Univariate analyses re-
vealed that anticoagulant therapy, heparin bridge therapy, undifferenti-
ated type, deep submucosal invasion and resected specimen size were 
associated with post-ESD bleeding. Multivariate analysis revealed anti-
coagulant therapy (OR 23.1, 95% CI 3.61-147.52) and resected specimen 
size (OR 1.03, 95% CI 1.00-1.06) to be independent factors associated with 
post-ESD bleeding.
conclusion: Anticoagulant therapy and resected specimen size were risk 
factors associated with post-ESD bleeding for EGC. Strategies for the pre-
vention of post-ESD bleeding should be seriously considered for patients 
under anticoagulant medication.
disclosure: Nothing to disclose 
P0616 facTOr assOcIaTed WITh MeTachrOnOus gasTrIc 
cancer In PaTIenTs undergOIng endOscOPIc suBMucOsaL 
dIssecTIOn Of earLy gasTrIc cancer
Kusumoto Y.1, Yamada T.2, Watsuji A.3, Adachi Y.3, Yamazaki H.3, 
Ashida M.3, Tanimoto T.3, Ohnishi K.3, Wakahara Y.3, Yamaguchi T.3, 
Hirao M.3, Hosui A.3, Hiramatsu N.3
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contact e-Mail address: yukizarulucky_3lib@yahoo.co.jp
Introduction: Risk factors for gastric cancer during continuous infection 
with Helicobacter pylori (H.pylori) have been well documented and H.pylori 
eradication is expected to suppress the occurrence of gastric cancer. How-
ever gastric cancer still remains one of the leading cancers in the world 
with a high mortality worldwide. In addition, the risk of developing a 
metachronous lesion following endoscopic resection of an early gastric 
cancer has been reported to between 1% and 4% per year. The gastric 
Endoscopic Submucosal Dissection to Expand its Indication for Early Gas-
tric Cancer of Undifferentiated Type: Japan Clinical Oncology Group study 
(JCOG1009/1010), DDW2019
disclosure: Nothing to disclose 
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P0614 MeTachrOnOus MuLTIPLe LesIOns deveLOPIng near 
scars afTer endOscOPIc suBMucOsaL dIssecTIOn fOr earLy 
gasTrIc cancer
Tanabe S.1, Kitahara G.2, Ishido K.2, Kubota Y.3, Watanabe A.4, Wada T.2, 
Azuma M.2, Katada C.2, Koizumi W.2
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Introduction: Along with the development of endoscopic submucosal dis-
section (ESD) for early gastric cancer(EGC), increasing numbers of patients 
have metachronous multiple lesions developing during follow-up after 
ESD. We often encounter patients in whom treatment is difficult to perform 
owing to the presence of metachronous multiple lesions developing near 
scars remaining after ESD.
aims & Methods: We compared the incidence of metachronous multiple 
lesions developing near scars after ESD with that of lesions developing at 
other sites to examine the clinicopathological characteristics of metachro-
nous multiple lesions developing near scars after ESD and the incidence of 
complications at the time of ESD. 
subjects & Methods: Among 2182 patients (2762 lesions) who underwent 
ESD for EGC in our hospital from September 2002 through August 2018, 
we studied 15 patients (20 lesions) with metachronous multiple lesions 
that developed near scars (group A) and 161 patients (304 lesions) with 
metachronous multiple lesions that developed in other regions (group B). 
The median follow-up period was 61 months (range, 13 to 186 months).
results: Group A comprised 9 men and 6 women with a median age of 
76 years, and group B comprised 129 men and 32 women with a median 
age of 73 years. In group A, 9 patients had elevated-type lesions, and 11 
patients had flat, depressed-type lesions. The median lesion diameter was 
10 mm. Differentiated-type lesions were found in 19 patients, and pre-
dominantly differentiated-type lesions in 1 patient. 
The curability was eCuraA in 15 patients, eCuraC-1 in 2 patients, and eCu-
raC-2 in 3 patients. In group B, 123 patients had elevated-type lesions, and 
181 patients had flat depressed-type lesions. The median lesion diameter 
was 13 mm. Differentiated-type lesions were found in 281 patients, differ-
entiated-predominant mixed type lesions in 18 patients, undifferentiated-
type lesions in 1 patient, and undifferentiated-predominant mixed type 
lesions in 4 patients. 
The curability was evaluated to be eCuraA in 247 patients, eCuraB in 19 
patients, eCuraC-1 in 17 patients, and eCuraC-2 in 21 patients. In group A, 
the site of gastric cancer was the upper part of the stomach in 1 patient, 
the middle part of the stomach in 13 patients, and the lower part of the 
stomach in 6 patients. In group B, the site of gastric cancer was the upper 
part of the stomach in 41 patients, the middle part of the stomach in 132 
patients, the lower part of the stomach in 118 patients, and other parts of 
the stomach in 13 patients. 
Three or more metachronous multiple lesions were found in 10 patients 
(67%) in group A and 50 patients (31%) in group B; this difference was 
significant (p< 0.01). The ESD procedure time was significantly longer in 
group A (110 minutes; range, 65 to 211) than in group B (78 minutes; range, 
24 to 332; p< 0.01). 
Complications comprised perforation in 3 patients (16.6%) and subsequent 
bleeding in 4 patients (22.2%) in group A and perforation in 12 patients 
(3.8%) and subsequent bleeding in 21 patients (5.0%) in group B. These 
differences were significant (both p< 0.01).
conclusion: Patients in whom many metachronous multiple lesions de-
velop during follow-up observation after ESD for EGC may have a higher 
risk of metachronous multiple lesions developing near scars. ESD for 
metachronous multiple lesions developing near scars requires a long 
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mucosal atrophy has been known as the risk factor range development of 
metachronous gastric cancer, however no reports of bile reflux has been 
reported.
aims & Methods: A retrospective study was conducted to clarify the risk 
factors associated with the development of metachronous gastric cancer 
(MGC) in patients whose early gastric cancers were treated by endoscopic 
submucosal dissection (ESD).
Three hundred thirty-eight patients who underwent ESD for the treatment 
of early gastric cancer between January 2013 and March 2018 at our hos-
pital were enrolled in this study. The mean age was 78 years, 251 patients 
were male, and 87 were female. MGC was defined as secondary gastric 
cancer discovered after one year of endoscopic therapy of early primary 
gastric cancer (PGC).
The factors considered were age, gender, BMI, current cigarette smoking, 
current alcohol drinking, the status of H.pylori infection, and gastric muco-
sal atrophy, bile reflux into the stomach, presence of xanthoma diagnosed 
by endoscopy.
results: MGC was found in 33 patients out of 338 patents (9.8%). Among 
them, 12 cases with MGC developed within 2 years, and 21 cases from 2 years 
to 5 years. Of the 33 cases of recurrence of gastric cancer, 22 cases (66.7%) 
were after H.pylori eradication. The ratio of presence of bile reflex into the 
stomach was significantly higher in MGC than in PGC (54.5% [18 of 33] vs 
36.7% [109 of 305], P=0.039). The ratio of presence of xanthoma was higher 
in MGC than in PGC (51.5% [17 of 33] vs 32.9% [100 of 305],  P=0.036).
Higher prevalence of current alcohol drinking (48.5% [16 of 33] vs 31.1% 
[95 of 305], P=0.052), and gastric mucosal severe atrophy (87.9% [29 of 33] 
vs 75.0% [229 of 305], P=0.055) was tended to find in MGC than in PGC. 
No significant differences were found in age, gender, BMI, the status of 
H.pylori infection, current cigarette smoking between two groups.
conclusion: In the present study, the presence of bile reflex into the stomach 
was shown to be a candidate factor which was associated with MGC. We 
should perform long follow-up endoscopy carefully even after H.pylori eradi-
cation, with special attentions in patients with xanthoma or biliary reflex.
disclosure: Nothing to disclose 
P0617 MeTfOrMIn use and rIsk Of gasTrIc adenOcarcInOMa 
In a sWedIsh POPuLaTIOn-Based cOhOrT sTudy
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Introduction: Whether the use of metformin decreases the risk of gastric 
non-cardia and cardia adenocarcinoma is unclear.
aims & Methods: This was a Swedish nationwide and population-based 
cohort study in 2005-2015. Firstly, associations between metformin use 
and gastric non-cardia and cardia adenocarcinomas were examined with-
in a cohort of diabetes patients using anti-diabetes medication (‘diabetes 
cohort’). Secondly, the same associations were analysed in another cohort 
including metformin users and 10 times as many non-users of metformin 
(‘matched cohort’). The non-users were frequency-matched with metfor-
min users for sex and age. Multivariable Cox proportional hazard regres-
sion analyses provided hazard ratios (HR) and 95% confidence intervals 
(CI). The HRs were adjusted for sex, age, calendar year, comorbidity, Heli-
cobacter pylori eradication treatment, use of non-steroidal anti-inflamma-
tory drugs or aspirin, and use of statins.
results: The diabetes cohort consisted of 544,130 individuals, including 
407,149 (74.8%) metformin users and 136,981 (25.2%) non-users of metfor-
min. During the follow-up, 892 (0.1%) individuals developed gastric ade-
nocarcinoma. Compared to non-users, metformin users had no decreased 
risk of gastric non-cardia adenocarcinoma (adjusted HR 0.93, 95% CI 0.78-
1.12) or cardia adenocarcinoma (adjusted HR 1.49, 95% CI 1.09-2.02). The 
matched cohort included 4,525,543 individuals, of whom 411,413 (9.1%) 
were metformin users and 4,114,130 (90.9%) were non-users. During the 
follow-up, 6,395 (0.1%) individuals developed gastric adenocarcinoma. 
Compared to non-users, metformin users had no decreased risk of gastric 
non-cardia adenocarcinoma (adjusted HR 1.30, 95% CI 1.18-1.42) or cardia 
adenocarcinoma (adjusted HR 1.58, 95% CI 1.38-1.81).
conclusion: Metformin use may not prevent gastric non-cardia or cardia 
adenocarcinoma.
disclosure: Nothing to disclose 
P0618 effecTs Of heLIcOBacTer PyLOrI On BIOLOgIcaL 
characTerIsTIcs In earLy gasTrIc cancer
Ni Z., Ye F., Zhang S.
The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 
China
contact e-Mail address: zhangshuotcm@126.com
Introduction: Early gastric cancer (EGC) is an early stage of gastric cancer, 
a curable malignant disease with a high cure rate. Finding the clinico-
pathological features of early gastric cancer is an important part of its early 
detection and timely diagnosis and reducing the mortality rate of gastric 
cancer.
aims & Methods: To elucidate the differences between the biological char-
acteristics of tumor cells in early gastric cancer and Helicobacter pylori(HP). 
Of the 111 patients with early gastric cancer were enrolled in this study, of 
whom were divided into 4 group: 23 HP- GC patients, 47 HP+ GC patients 
without a history of HP eradication(U-HP+ group), 12 HP+ GC patients with 
a history of HP eradication(E-HP+ group), 36 HP- GC patients without a 
history of HP infection(U-HP- group) and 28 HP- GC patients with a history 
of HP infection(I-HP- group) were enrolled in this study. We compared 
biological characteristics of tumor between the four group.
results: Compare with the U-HP- group, the I-HP- group was more fre-
quently in upper one third of stomach (P = 0.01). There was no significant 
difference in the expression of Ki67(P > 0.05). The expression of HER2 in 
U-HP+ group was higher (P = 0.049) than the E-HP+ group. In addition, 
there was a significant increase(P = 0.002) in the expression of HER2 of 
the HP+ group than that of the HP- group. In the HP+ group, there was a 
positively correlation in HP and the expression of HER2(P=0.014).
conclusion: HP- EGC patients without a history of HP infection more fre-
quently occurred in the upper part of the stomach. The proliferative capac-
ity of the cancer in different HP eradication and eradication were similar, 
while the neoplasm invasion in HP+ EGC were increase, especially in HP+ 
GC with a history of HP eradication.
disclosure: Nothing to disclose 
P0619 The rIsk fOr LyMPh nOde MeTasTasIs In ePsTeIn-Barr 
vIrus-assOcIaTed gasTrIc carcInOMa WITh suBMucOsaL 
InvasIOn
Tsuji Y.1, Ushiku T.2, Yamashita H.2, Seto Y.2, Fukayama M.2, 
Fujishiro M.2,3, Oda I.4, Katai H.4, Taniguchi H.4, Hasatani K.5, Kaizaki Y.5, 
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University, Yamaguchi, Japan, 7Yamaguchi University Graduate School of 
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contact e-Mail address: ping_01@me.com
Introduction: Epstein-Barr Virus (EBV)-associated gastric cancer (EBVGC) 
accounts for approximately 10% of gastric cancers. EBVGC is classified into 
one of the four molecular subtypes proposed by The Cancer Genome Atlas 
Research Network (Nature, 2014), and there have been reports which im-
ply the relatively low risk of lymph node metastasis (LNM) in EBVGC with 
submucosal invasion (pT1b-EBVGC). However, a large cohort study is still 
lacking.
aims & Methods: The present study aims to investigate the risk of LNM 
in pT1b-EBVGC through a multicenter study. This is a retrospective multi-
center study. 5 institutes, which have pathologists specializing in the di-
agnosis of EBVGC, participated in this study. We reviewed medical records 
and extracted all pT1b-EBVGC cases diagnosed between 2001 and 2016. 
Lesion characteristics, patients background factors and clinical outcomes 
were obtained. The diagnostic criteria for EBVGC were as follows: 1) gastric 
adenocarcinoma with lymphoid stroma; and 2) a positive result of in-situ 
hybridization for EBV encoded small RNA (EBER-ISH). For surgery cases, 
LNM was investigated based on the histopathological evaluation of resect-
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P0622 WIThdraWn
P0623 endOscOPIc uLTrasOund-guIded needLe-Based 
cOnfOcaL Laser endOMIcrOscOPy In gasTrOInTesTInaL 
suBePITheLIaL LesIOns: a feasIBILITy sTudy
Ohmiya N.1, Terada T.1, Tahara T.1, Hashimoto S.2, Horiguchi N.1, 
Funasaka K.1, Nagasaka M.1, Nakagawa Y.1, Shibata T.1, Yoshioka K.2
1Fujita Health University, Department of Gastroenterology, Toyoake, Japan, 
2Fujita Health University, Department of Liver, Biliary Tract and Pancreas 
Diseases, Toyoake, Japan
contact e-Mail address: nohmiya@med.nagoya-u.ac.jp
Introduction: Needle-based confocal laser endomicroscopy (nCLE) allows 
for real-time optical biopsies during endoscopic ultrasound-guided fine 
needle aspiration (EUS-FNA).
aims & Methods: Little is known about the nCLE imaging of gastrointestinal 
subepithelial lesions (GI-SELs); therefore, we determined its feasibility. We 
performed nCLE during EUS-FNA in 23 consecutive patients with GI-SELs 
between November 2015 and May 2018. We retrospectively compared nCLE 
findings with pathologic findings of EUS-FNA or surgical specimens.
results: The median number (range) of needle passes per EUS-FNA pro-
cedure was 2 (1-3). The adequate sample acquisition rate was 67.0% per 
needle pass and 95.7% per patient. EUS-FNA was diagnostic in 78.3% 
(18/23), suspicious in 4.3% (1/23), and nondiagnostic in 17.4% (4/23). The 
concordance rate of nCLE findings with final pathology was 95.7% (22/23), 
which was not significantly different from diagnostic and suspicious EUS-
FNA (P=.2482). nCLE could differentiate GI stromal tumors from leiomyo-
ma, in that GISTs were characterized by contrast-enhanced densely popu-
lated spindle cell tumors with unenhanced rod-shaped nuclei in 100% of 
12 patients, whereas leiomyomas were characterized by narrower spindle 
cell tumors with fewer and smaller unenhanced nuclei in 100% of 3 pa-
tients. A desmoid tumor appeared as spindle cell tumors both with unen-
hanced nuclei in some parts and with fewer and smaller nuclei in other 
parts. In rectal metastasis from lung adenocarcinoma, some pleomorphic 
dark nests were observed. There were no adverse events associated with 
nCLE and EUS-FNA.
conclusion: nCLE can be safe and useful for the on-site detection of ab-
normalities of GI-SELs.
disclosure: Nothing to disclose 
P0624 The rOLe Of InsuLIn-LIke grOWTh facTOr axIs In The 
PrOgressIOn and survIvaL In gasTrIc cancer
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Introduction: Overexpression of insulin-like growth factors and its binding 
proteins has been reported to be associated with the progression and sur-
vival of several cancers. However, their roles in the progression of gastric 
cancer remain poorly understood.
aims & Methods: We aimed to assess the impact of circulating levels of 
levels of insulin-like growth factors (IGF1, IGF2) and their binding proteins 
(IGFBP1, IGFBP2, IGFBP3) and the expression of IGFBP2 in gastric cancer 
issues on the progression and survival of gastric cancer. A total of 481 gas-
tric cancer patients were enrolled in this prospective hospital-based cohort 
study. Another 114 subjects without gastric cancer were recruited as con-
trol group. Plasma levels of IGF1, IGF2, IGFBP1, IGFBP2, and IGFBP3 were 
determined by commercially available enzyme-linked immunosorbent as-
say or radioimmunoassay kits. Expression of IGFBP2 was assessed by im-
munohistochemical stains. Their impacts on gastric cancer survival were 
analyzed by log-rank test and Cox proportional hazards regression models.
results: Plasma levels of IGFBP2 was significantly higher in patients with 
gastric cancer as compared to healthy controls (p< 0.001). Plasma levels 
of IGFBP2 was also significantly higher in patients with more advanced 
AJCC stages (p< 0.001). However, the plasma levels of IGF1, IGF2, IGFBP1, 
ed LNs. For endoscopic resection (ER) cases, no LNM was defined as the 
case where computed tomography scan did not identify any LNM during 
follow-up ≥ 3 years.
results: A total of 190 pT1b-EBVGC cases were enrolled. The number of 
ER and surgery cases were 30 and 160, respectively. Additional surgery 
was performed in 25 of 30 ER cases. LNM was identified in 9 cases (4.7%), 
which were all surgery cases. Table 1 shows the association between LNM 
and various factors.
  LnM - (181) LnM + (9) P value
Age 64.7 ± 10.1 69.8 ± 9.9 0.141
Sex (M/F) 149/32 8/1 1.000
Lesion size (mm) 29.5 ± 17.0 36.7 ± 22.3 0.230
Macroscopic appearance 
(depressed/protruded/others) 122/53/6 5/4/0 0.296
Location (U/M/L) 75/87/19 4/3/2 0.367
Depth (≥ SM500/< SM500) 159/22 9/0 0.602
Ly (0/1) 160/21 3/6 < 0.001
V (0/1) 153/28 7/2 0.635
[The association between LNM and clinical factors]
Lymphatic invasion (Ly) is the only significant risk factor for LNM (p< 0.001); 
neither lesion size nor submucosal invasion depth (≥ 500𝜇m/< 500𝜇m) 
were significantly correlated to LNM. The present study revealed that the 
risk for LNM in pT1b-EBVGC without Ly was 1.8% (3/163, 95%CI; 0.6-5.3%). 
Moreover, as for pT1b-EBVGC without Ly and ≤ 20mm, the rate of LNM was 
0% (0/62, 95%CI; 0-4.7%).
conclusion: The present study demonstrated the relatively low risk for LNM 
in pT1b-EBVGC, considering that the LNM risk of all pT1b-GC is approxi-
mately 20%. This result implies that pT1b-EBVGC is a good candidate for 
ER or local resection.
disclosure: Nothing to disclose 
P0620 WIThdraWn
P0621 hIsTOLOgIc vaLIdaTIOn Of argOn PLasMa 
cOaguLaTIOn versus MOnOPOLar cOaguLaTIOn fOr gasTrIc 
adenOMa WITh LOW grade dysPLasIa: a PrOsPecTIve 
randOMIzed cOnTrOLLed TrIaL
Huh C.W.1, Jung D.H.2, Kim B.-W.1
1Incheon St. Mary’s Hospital, The Catholic University of Korea, Department of 
Internal Medicine, Incheon, Korea (Republic of), 2Severance Hospital, Yonsei 
University College of Medicine, Internal Medicine, Seoul, Korea (Republic of)
contact e-Mail address: huhcw@catholic.ac.kr
Introduction: Endoscopic electrocoagulation such as argon plasma coagu-
lation (APC) or monopolar coagulation (MC) is a safe alternative treatment 
for gastric adenoma with low grade dysplasia (LGD). However, there was 
no study regarding the histologic validation of endoscopic electrocoagula-
tion for gastric LGD.
aims & Methods: The aim of this study was to validate the histologic com-
plete eradication of endoscopic electrocoagulation for gastric LGD.This was 
a prospective randomized controlled study involving patients who diag-
nosed gastric LGD and underwent endoscopic submucosal dissection (ESD) 
after endoscopic electrocoagulation from March 2014 to December 2018. 
Patients were randomly assigned to either APC or MC group. The main 
outcome was the complete histologic eradication rate.
results: In 68 patients, 34 patients were treated with ESD after APC and 34 
patients were treated with ESD after MC. The overall histologic complete 
eradication rate was 33.8% (23/68). The complete eradication rate was 
significantly higher in the APC group than those in the MC group (55.9% 
vs. 11.8%, P< 0.001). In multivariate analysis, APC was the only significant 
predictor of histologic complete eradication. (OR 7.66; 95% CI 2.139-27.448). 
There were no adverse events related to the procedure in both groups.
conclusion: Although APC is a more effective treatment option than MC 
in treating gastric LGD, both methods revealed disappointing results in 
histologic complete eradication. Therefore, endoscopic resection must be 
performed for curative treatment of gastric LGD.
disclosure: Nothing to disclose 
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and IGFBP3 were not significantly differed in gastric cancer patients and 
controls. Patients with the highest tertile of IGFBP-2 levels were associated 
with a worse overall survival compared to those with the lowest IGFBP2 
tertile levels (Hazard Ratio =1.51, 95% CI=1.19-1.92, p=0.001) after adjust-
ment for age, gender, location, histology type, depth of invasion, and 
nodal metastasis. Higher expression of IGFBP2 in gastric cancer tissues 
was also associated with a worse overall survival than those with lower 
expression of IGFBP2, after adjustment of the above variables. In contrast, 
the plasma levels of IGF1, IGF2, IGFBP1, and IGFBP3 were not correlated 
with the overall survival in gastric cancer patients.
conclusion: IGFBP2 plasma level, but not IGF1, IGF2, IGFBP1, or IGFBP3 
levels, was higher in patients with gastric cancer and correlated with stage 
and survival. Higher expression of IGFBP2 in gastric cancer tissues also 
correlated with a worse overall survival. The finding lends support that 
IGFBP2 is a potential therapeutic target for gastric cancer.
disclosure: Nothing to disclose 
P0625 OMenTaL faT TIssue PrOMOTes PerITOneaL 
dIsseMInaTIOn Of gasTrIc cancer
Natsume M., Shimura T., Iwasaki H., Okuda Y., Kataoka H.
Nagoya City University Graduate School of Medical Sciences, Department of 
Gastroenterology and Metabolism, Nagoya, Japan
contact e-Mail address: makoto04130510@gmail.com
Introduction: Gastric cancer (GC) has a clear predilection for peritoneal 
metastasis that cause poor prognosis. However, the exact mechanism why 
peritoneal metastasis frequently occurs in GC remains unknown. Omen-
tum is the major cite for peritoneal metastasis, which is consisted of a 
huge fat tissue. We hypothesize that omental adipocytes trigger GC cell 
toward malignant activity inducing peritoneal metastasis.
aims & Methods: We used 2 gastric cancer cell lines that were derived from 
primary GC tumor without metastasis. Omental adipocyte (OmAd) was used 
to assess interaction with GC cells. Endothelial cells (EC) were also used for 
in vitro angiogenesis assay including EC recruitment assay and tube forma-
tion assay. Cytokine protein array and PCR array were used for comprehen-
sive analysis to identify responsible factors, and western blot analysis and 
qPCR were used to determine expression level of each gene and protein.
results: Conditioned media (CM) derived from OmAd (OmAd-CM) sig-
nificantly promoted proliferation and migration of GC cells compared to 
control media. OmAd-CM also reinforced the ability of GC cells inducing 
EC recruitment and tube formation. The cytokine array identified that GRO 
was abundantly contained in OmAd-CM and CXCL2 is the most expressed 
among GRO family. Silencing CXCL2 from OmAd (siCXCL2-OmAd) inhibited 
OmAd-induced cell growth and migration in both GC cell lines, as well as 
angiogenesis. In addition, OmAd-CM induced HIF1α and VEGF-A produc-
tion of GC cells through AKT phosphorylation.
conclusion: Omental adipocytes triggers GC cells on aggressive pheno-
type through CXCL2 secretion, which induces angiogenesis followed by cell 
growth and peritoneal metastasis.
disclosure: Nothing to disclose 
P0626 hOxa11 gene IdenTIfIed By dna MeThyLaTIOn 
PrOfILIng as PrOgnOsTIc MOLecuLar Marker In huMan 
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Ignatavicius P.1, Dauksa A.1, Zilinskas J.1, Kazokaite M.2, Barauskas G.1
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contact e-Mail address: ignatavicius@gmail.com
Introduction: Gastric cancer is one of the most often diagnosed cancers 
worldwide with over 1,000,000 new cases annually. One of the most im-
portant epigenetic mechanism in the carcinogenesis is DNA methylation 
with 2 main processes of hypermethylation of tumor suppressor genes and 
hypomethylation of oncogenes. 
Multiple studies have shown the importance of these changes as possible 
biomarkers for the early diagnosis, treatment effectiveness and disease 
progression in various cancers.
aims & Methods: The aim of this study was to assess the DNA methylation 
status of selected genes in gastric cancer tissues samples and evaluate the 
prognostic importance of these genes. Patients (99) diagnosed with gas-
tric adenocarcinoma were included in the study. All patients underwent 
total or distal gastrectomy. Gastric cancer tissues and adjacent healthy 
gastric mucosa was taken from the surgical specimen. Genomic DNA was 
extracted from 25 to 40 mg of frozen tissues using”AllPrep DNA/RNA Kit” 
according to manufacturer’s recommendation. 
We selected a group of genes (RAD51B, GFRA3, AKR7A3, HOXA11, TUSC3, 
FLI1, SEZ6L, GLDC, NDRG) which are involved in cellular pathways such 
as signal transduction, apoptosis, cell to cell communication, cell cycles 
and cytokine signaling, are down-regulated in cancers and may be con-
sidered as potential tumor suppressor genes or oncogenes. Specific prim-
ers for methylated and unmethylated DNA sequence were designed using 
‘‘MethPrimer’‘. Methylation-specific polymerase chain reaction was per-
formed in 25 ml of total volume. The presence of a Polymerase chain reac-
tion product signal of the correct molecular weight indicates the presence 
of either unmethylated or methylated alleles.
results: Only methylation of the HOXA11gene (Candidate tumor suppressor) 
promoter was significantly more frequent in gastric cancer tumor tissue (P 
= 0.006) than in adjacent healthy gastric mucosa. Limited significance (P 
= 0.054) was observed in SEZ6Lgene (Tumor suppressor) promoter region 
comparing methylation frequency between gastric cancer tissue (50.5%) 
and healthy gastric mucosa (29.3%). The probability to survive longer was 
observed only with unmethylated HOXA11promoter in cancer tissues 71.2 
months (95% CI 57-85.3) comparing to methylated cases with survival of 
44.3 months (95% CI 34.8-53.9). Moreover, survival time was significantly 
shorter (28.5 months(95% CI 20.8-36.2) vs. 61.2 months (95% CI 50.9-71.4)) 
in gastric cancer patients, when methylation was observed in adjacent 
healthy gastric mucosa comparing to patients with methylation in one tis-
sue alone (healthy gastric mucosa or gastric cancer tissue). Multivariate 
Cox analysis revealed the HOXA11methylation as significantly associated 
with gastric cancer patients’ survival (HR=2.4, 95% CI 1.19-4.86).
conclusion: DNA methylation of HOXA11gene promoter is more frequent in 
gastric cancer tumor tissue (68.7%) than in healthy gastric mucosa (39.4%) 
and is associated with shorter postoperative survival in patients diagnosed 
with gastric adenocarcinoma. Our results suggest that HOXA11gene might 
be a prognostic molecular marker in patients with gastric adenocarcinoma.
disclosure: Nothing to disclose 
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Introduction: Repair of DNA damage is a complex and crucial process in-
volving multiple enzymes and pathways (base excision repair, mismatch 
repair, nucleotide excision repair, and double strand break repair). Defi-
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phisms of PG2 gene and miRNA, that are known to modulate PG2 expres-
sion (rs9471643 C/G; rs6458238 A/G; rs8111742 A/G; rs121224 C/G; rs1002765 
A/G; TATA-BOX length), was tested by real time PCR.
results: Out of the 141 ACAG pts (26 M, 115 F; mean age 54,5), 21 (15 %) 
(4M, 17F) presented GCs. A secondary autoimmune disorder was displayed 
by 98 pts (69,5%) and autoimmune tyroiditis was the most frequent 
(61,9%). A statistically significant difference in PG1/PG2 and G17 levels was 
found between ACAG pts with or without GCs (r=-0,3768 95% CI-0,5499 to 
-0,1726 p=0,0005).
Although it is known that PG2 levels correlate with Helicobacter Pylori (HP) 
infection in our series of ACAG and GCs and ACAG pts there wasn’t a statisti-
cal significant difference nor in number of HP positive (+) pts nor in IgG anti 
HP load (HP+ GCs pts 17,6%, HP+ ACAG pts 30,2%; GCs pts IgG anti HP mean 
19,42 SD: ±27,71, ACAG pts IgG anti HP mean 33,43 SD: ±41,43 p=ns). Among 
the 6 genetic polymorphisms, we found that rs8111742 A/G, rs121224 C/G 
were associated to a difference in serum PG2 levels and GCs (p=0,0016 and 
p=0,0051). No significant differences were found between pts with tyroiditis 
and GCs and pts without tyroiditis and with GCs (6,3 % and 8,5 % p=0,07).
conclusion: GCs are often diagnosed incidentally during endoscopy. We 
found a higher association between GCs type I and ACAG than data present 
in literature and of interest we found a statistically significant difference in 
PG1/PG2 and G17 levels between ACAG pts with or without GCs. The identi-
fication of a different level of PGs ratio and G17 in GCs-positive ACAG could 
be proposed as a potential indicative marker for a further endoscopic tar-
geted evaluation for GCs in ACAG pts.
disclosure: Nothing to disclose 
P0629 exPressIOn Of akT, MTOr, vegfr2, gsk3β In gasTrIc 
cancer, PrecancerOus LesIOns and cOndITIOns
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Introduction: Gastric cancer (GC) is one of the leading causes of cancer 
deaths worldwide[1]. Unfortunately GC is often found when it is not cur-
able [2]. GC development is a consecutive process which is called “Correa 
cascade”, that describes development of GC from H.pylori chronic gastritis 
through atrophic changes, metaplasia, dysplasia to gastric cancer [3,4,5]. 
Prevention of GC development and diagnostic of early GC is a very im-
portant direction in modern gastroenterology, endoscopy and anticancer 
programs. More and more attention is paid to the molecular processes of 
GC development, especially to grow factor receptor pathway. Research in 
this field could help to understand more about this process and to improve 
diagnostic systems and targeted therapy.
aims & Methods: Biopsy from 99 patients 22-93 years old admitted to Kras-
noyarsk Regional Hospital were collected during gastroscopy. After histo-
logical assessment patients were divided in 4 groups: 1st group - chronic 
nonatrophic pangastritis (n=27), 2nd - chronic atrophic pangastritis with in-
testinal metaplasia (n=31), 3rd - chronic atrophic pangastritis with dysplasia 
(n=11), 4th - GC (n=30) with signet ring cell carcinoma (n=15) and adenocar-
cinoma (n=15). Undirected imminohistochemical analysis with fluorescent 
marking was done in order to reveal the expression of AKT, mTOR, VEGFR2, 
GSK3β molecules, TUNEL method was used to asses apoptosis level.
results: Expression of AKT was significantly increased in patients with pre-
cancerous lesions and decrease in GC group (p1-3 = 0,0007, p2-3 = 0,006, 
p3-4 = 0,031). mTOR expression was decreased in GC group (p
1-4
 = 0,021, 
p
3-4
 = 0,05). Changes in VEGFR2, GSK3β expression was not statistically 
significant, but the tendency with maximal value in group with dysplasia 
and moderate decreasing in GC group was observed. There was no differ-
ence in expression in two types of cancer inside the GC group. The highest 
apoptosis level was observed in gastritis with metaplastic changes and 
lowest in GC group (p1-4 = 0,004, p2-4 = 0,021, p3-4 = 0,00002). These 
changes in molecules expression could mark the stages of tumor growth 
such as angiogenesis, decreasing of apoptosis and proliferation.
conclusion: Changes in AKT/mTOR/VEGFR/GSK3β pathway is an early 
event in gastric mucosa transformation, could happen even on stage of 
precancerous conditions, lesions and mark the stages of each step of Cor-
rea cascade. AKT is responsible for cell growth and proliferation and high 
ciencies in this system likely lead to genomic instability affecting cancer 
development and prognosis. Some specific polymorphisms in DNA repair 
genes have been reported to play a key role in the prognosis of gastric 
cancer (GC). However, results are inconsistent among studies.
aims & Methods: Since allele frequencies differ notably among ethnicities, 
we aimed to assess the prognostic value (overall survival) of DNA repair 
gene polymorphisms on GC in a Caucasian population in Spain. Six hun-
dred and three unrelated patients diagnosed with primary GC from Janu-
ary 2003 to December 2010 in a network of 16 general Spanish hospitals 
were included in the study. Genomic DNA from GC patients was typed for 
a panel of 120 single nucleotide polymorphisms (SNPs) located in 52 key 
DNA repair pathway genes by using the Illumina platform. Overal Survival 
(OS) among different genotype groups was estimated using the Kaplan-
Meier method and compared using the log rank test. Moreover, Cox pro-
portional hazards models were performed to evaluate the prognostic value 
of DNA repair gene polymorphisms on patient’s survival. Helicobacter py-
lori infection and CagA/VacA antibody status were determined in serum 
by western blot.
results: The median follow-up time for all GC patients in our study was 
12.5 months (range: 0.3-124). Four hundred and eighty five GC patients 
(80.4%) had died at the end of the follow-up period (December 2017) with 
a median OS of 10.07 months (CI 95%: 6.65-9.42). For censored patients, 
the median OS was 45.07 months (CI 95%: 36.21-53.38). Of the environ-
mental and clinicopathologic features evaluated in this study, Cox regres-
sion analysis identified tumor stages TNM III (HR:4.32, 95% CI:2.84-6.59) 
and IV (HR:9.27, 95%:6.2-13.85) as prognosis factors associated with sig-
nificantly reduced OS in GC patients, whereas surgical treatment (HR:0.45, 
95% CI:0.36-1.57), and chemotherapy (HR:0.52, 95%:0.39-0.68) were 
related to a better prognosis of the disease. Concerning gene polymor-
phisms, only the rs1799796A>G gene variant was associated with overall 
survival in GC patients after correction for multiple testing. This SNP is 
located in the XRCC3 gene which encodes a member of the Rad51-related 
protein family that participates in the double-strand break repair pathway. 
We found that GC patients carrying the XRCC3 rs1799796G variant showed 
a significantly higher OS than non-carriers (375 days vs.184 days; HR:0.7, 
95% CI:0.57-0.86). Further stratification of GC patients by age, gender, 
smoking habit, Helicobacter pylori status, tumor location, histological type, 
TNM stage, treatment and Charlson index, showed no effect of gene vari-
ants on patient’s survival.
conclusion: Our data show that the specific XRCC3 rs1799796G gene vari-
ant is relevant in determining the individual prognosis of gastric cancer in 
Caucasians.
disclosure: Nothing to disclose 
P0628 geneTIc POLyMOrPhIsMs Of Pg2 gene and Pg1/Pg2 
raTIO PredIcT The Presence Of gasTrIc carcInOIds 
In auTOIMMune aTrOPhIc gasTrITIs PaTIenTs
Magris R.1, Maiero S.1, Fornasarig M.1, Zanette G.2, Mazzon C.3, 
Visintin A.1, Steffan A.4, Canzonieri V.5, Guarnieri G.1, De Re V.6, 
Canton E.7, Cannizzaro R.1
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Italy, 4Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Clinical 
Pathology, Aviano, Italy, 5Centro di Riferimento Oncologico di Aviano (CRO) 
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7Centro Riferimento Oncologico, Aviano, Italy
contact e-Mail address: rcannizzaro@cro.it
Introduction: Autoimmune Chronic Atrophic Gastritis (ACAG) is epidemio-
logically and biologically linked to the development of gastric carcinoids 
type I (GCs) and gastric adenocarcinoma. 
ACAG is often associated to other autoimmune disorders. The aim of the 
study was to evaluate the incidence of GCs development and to discover 
potential diagnostic markers related to GCs in patients (pts) with ACAG.
aims & Methods: 141 pts with ACAG enrolled between years 2006-2017 and 
were evaluated by endoscopy for the presence of GCs. Pepsinogen I (PG1), 
Pepsinogen II (PG2) and Gastrin 17 (G17) serum levels were quantified us-
ing an enzyme-linked immune-sorbent assay kit. Serum levels of PGs and 
G17 were used to discriminate among pts with ACAG and pts affected by 
GCs in univariant and in multivariate analysis. A panel of genetic polymor-
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level of mTOR expression could explain metabolic changes, low apopto-
sis level and cell survival which are inherent characteristics of malignant 
tumor. Further research is needed to understand more about molecular 
processes in GC development.
references: 1. Jemal, A., et al., Global cancer statistics. CA Cancer J Clin, 
2011. 61(2): p. 69-90. 2. De Angelis, R., et al., Cancer survival in Europe 
1999-2007 by country and age: results of EUROCARE--5-a population-
based study. Lancet Oncol, 2014. 15(1): p. 23-34. 3. Li, S., et al., Endog-
enous molecular network reveals two mechanisms of heterogeneity within 
gastric cancer. Oncotarget, 2015. 6(15): p. 13607-27. 4. Correa, P. and M.B. 
Piazuelo, The gastric precancerous cascade. J Dig Dis, 2012. 13(1): p. 2-9. 
5. Dinis-Ribeiro, M., et al., Management of precancerous conditions and 
lesions in the stomach (MAPS): guideline from the European Society of 
Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group 
(EHSG), European Society of Pathology (ESP), and the Sociedade Portu-
guesa de Endoscopia Digestiva (SPED). Endoscopy, 2012. 44(1): p. 74-94.
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P0630 reLevance Of TOLL-LIke recePTOr gene 
POLyMOrPhIsMs TO gasTrIc cancer rIsk and PhenOTyPe
García-González M.A.1,2,3, Bujanda Fernández de Piérola L.4, 
Quintero Carrion E.5, Badía M.6, Strunk M.3,7, Sopeña F.3,8, Beniro R.3,9, 
Piazuelo E.3,7, Carrera-Lasfuentes P.3, Santolaria S.10, Thomson C.11, 
Pérez-Aísa Á.12, Nicolás-Pérez D.13, Arechavaleta S.3, Hijona E.14, 
Espinel Diez J.15, Campo Fernandez R.16, Moreira L.17, Manzano M.18, 
Geijo F.19, González-Huix F.20, Zaballa M.21, Espinós J.22, Titó L.23, 
Barranco L.E.24, Lanas A.2,3,25
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Santa Cruz De Tenerife, Spain, 6Hospital General de la Defensa., Zaragoza, 
Spain, 7Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain, 
8Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 9Faculty of 
Medicine, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 
10Hospital San Jorge, Huesca, Spain, 11Hospital Obispo Polanco, Teruel, Spain, 
12Hospital del Sol, Marbella, Spain, 13Hospital Universitario de Canarias, 
Tenerife, Spain, 14Hospital Donostia/Instituto Biodonostia, CIBERehd, 
Gastroenterology, San Sebastián, Spain, 15Complejo Asistencial Universitario 
de León, León, Spain, 16Hospital Parc Tauli, Sabadell, Spain, 17Hospital 
Clinic, Barcelona, Spain, 18Hospital 12 de Octubre, Madrid, Spain, 19Hospital 
Universitario de Salamanca, Salamanca, Spain, 20Hospital Josep Trueta, 
Girona, Spain, 21Hospital de Cruces, Barakaldo, Spain, 22Hospital Mutua 
Terrassa, Barcelona, Spain, 23Hospital de Mataró, Mataró, Spain, 24Hospital 
del Mar, Barcelona, Spain, 25University of Zaragoza University Hospital, 
Medicine-Gastroenterology, Zaragoza, Spain
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Introduction: The innate immune response constitutes the first line of de-
fense against infection by microbes such as Helicobacter pylori (H. pylori). 
This system senses, recognizes, and responds to bacterial components by 
activating a complex signaling cascade of pattern-recognition receptors 
(PRRs), which include the Toll-like receptors (TLRs). Several polymorphic 
variants in TLR genes have been shown to affect responsiveness to H. pylori 
infection leading to an aberrant activation of the NF-kB pathway and up-
regulation of pro-inflammatory molecule expression.
aims & Methods: Given the relevance of H. pylori infection and chronic in-
flammation in gastric carcinogenesis, we aimed to assess the role of spe-
cific TLR gene polymorphisms on gastric cancer (GC) risk and phenotype in 
a Caucasian population in Spain. Genomic DNA from 673 unrelated Span-
ish patients with primary GC and 673 sex- and aged- (± 5 years) matched 
cancer-free healthy controls was typed for 26 single nucleotide polymor-
phisms (SNPs) in the TRL1 (rs10004195, rs4833095, rs4833103, rs5743551), 
TLR2 (rs5743708, rs121917864, rs1898830, rs3804099, rs3804100), TLR4 
(rs4986790, rs4986791, rs11536889, rs10759932, rs16906079, rs2149356), 
TLR5 (rs5744168, rs5744174, rs2072493), TLR6 (rs5743810), TLR8 (rs1980499, 
rs3764880), TLR9 (rs5743836, rs352140, rs187084), and TLR10 (rs11466657, 
rs4129009) genes by using the Massarray (Sequenon) platform. Analysis of 
genotyping data was performed by the bioinformatic tool SNPassoc (R). H. 
pylori infection and CagA/VacA antibody status were determined in serum 
by western blot in patients and controls.
results: Logistic regression analysis identified H. pylori infection with CagA 
strains (OR: 2.13; 95% CI: 1.68-2.69), smoking habit (OR: 1.82; 95% CI: 
1.29-2.55) and positive family history of GC (OR: 2.83; 95% CI: 1.89-4.23) 
as independent risk factors for GC. Concerning gene polymorphisms, the 
most remarkable association was observed in the TLR2 gene with the G 
allele of rs1898830 being associated with a higher risk of GC (log-additive 
model OR: 1.21; 95% CI: 1.06-1.42). Moreover, the TLR1 rs10004195T>A poly-
morphism, previously reported to be related with H. pylori seroprevalence, 
was significantly associated with susceptibility to H. pylori infection in our 
control population (recessive model OR: 0.70; 95% CI: 0.51-0.97). No sig-
nificant differences in carriage, genotype, and allele frequencies of the TLR 
gene polymorphisms were found when GC patients were categorized ac-
cording to gender, age, smoking habit, H. pylori infection, CagA/VacA anti-
body status, family history of GC, tumor location, and histological subtype.
conclusion: Our data show that the TLR2 rs1898830A>G gene polymor-
phism is involved in defining the genetic basis of the risk to GC, and sup-
port the relevance of TLR1 rs10004195 gene variant on H. pylori-infection 
susceptibility.
references: 1. Meliț LE, Mărginean CO, Mărginean CD, Mărginean MO. 
(2019) The Relationship between Toll-like Receptors and Helicobacter 
pylori-Related Gastropathies: Still a Controversial Topic. J Immunol Res. 
8197048. eCollection 2019. 2. Castaño-Rodríguez N, Kaakoush NO, Mitch-
ell HM. (2014) Pattern-recognition receptors and gastric cancer. Front Im-
munol. 5:336. eCollection 2014. 3. Mayerle J, den Hoed CM, Schurmann 
C, Stolk L, Homuth G, Peters MJ et al. (2013) Identification of genetic loci 
associated with Helicobacter pylori serologic status. JAMA. 309:1912-20.
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P0631 PLasMa LOng nOncOdIng rnas Pandar, fOxd2-as1, 
and sMarcc2 as POTenTIaL nOveL dIagnOsTIc BIOMarkers fOr 
gasTrIc cancer
Shi Y.1, Ding S.2
1Peking University Third Hospital, Research Center of Clinical Epidemiology, 
Beijing, China, 2Gastroenterology, Beijing, China
contact e-Mail address: 0729xst@163.com
Introduction: Gastric cancer is still a common cancer worldwide. Investi-
gation of potential plasma biomarkers for gastric cancer diagnosis is es-
sential for prevention strategies and early intervention for gastric cancer-
control planning.
aims & Methods: 
Objectives: This study was aimed to explore the lncRNAs PANDAR, FOXD2-
AS1, and SMARCC2 as potential novel diagnostic biomarkers for gastric 
cancer.
Method: 109 gastric cancer patients and 106 healthy controls were involved 
in this study. Plasma lncRNAs PANDAR, FOXD2-AS1, and SMARCC2 were 
detected by real-time PCR. Student’s t-test, Mann-Whitney U test, and Chi-
square test were used to verify the differences of clinical variables be-
tween two groups. Receiver operating characteristic curve (ROC) was used 
to evaluate the diagnostic value of every biomarker. Multivariable analysis 
of risk factors for gastric cancer was performed using logistic regression 
analysis.
results: There were significant differences in age, gender, CEA, CA153 
between gastric cancer and healthy controls (P< 0.05). Comparing with 
healthy subjects, the levels of plasma lncRNAs PANDAR, FOXD2-AS1, and 
SMARCC2 were all significantly higher in gastric cancer patients (P< 0.05). 
These lncRNAs were significantly associated with clinicopathological pa-
rameters of gastric cancer, like pathological differentiation, TNM stage, 
and/or lymph nodes metastasis, and/or invasion depth (P< 0.05). The AUC 
for lncRNA PANDAR was 0.767, for FOXD2-AS1 was 0.700, for SMARCC2 
was 0.748, and the AUC of the combinative diagnostic value of these three 
lncRNAs was 0.839. Adjusted by other variables, these lncRNAs expression 
were significantly associated with gastric cancer.
conclusion: Plasma lncRNAs PANDAR, FOXD2-AS1, and SMARCC2 might be 
appropriate diagnostic biomarkers for gastric cancer.
disclosure: Nothing to disclose 
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P0634 sPOradIc duOdenaL BuLB neurOendOcrIne 
TuMOrs - gasTrIn(g)-ceLLs TuMOrs assOcIaTed TO 
heLIcOBacTer PyLOrI and MIcrOnOduLar g-ceLLs 
hyPerPLasIa
Costa D.1,2, Veiga J.2, Arruda J.3, Rodrigues A.3, Gonçalves R.1, 
Pardal F.3, Rolanda C.1,2
1Hospital de Braga, Gastroenterology, Braga, Portugal, 2Life and Health 
Sciences Research Institute (ICVS), School of Medicine, University of Minho, 
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contact e-Mail address: dc.dalilacosta@gmail.com
Introduction: Sporadic duodenal neuroendocrine tumors (NETs) are rela-
tively rare tumors of the gastrointestinal tract, but their incidence shows 
gradual increase in recent histopathological series. Gastrin-producing 
cells (G-Cells) NETs is the most frequent, though little is known about the 
features involved in its pathogenesis.
aims & Methods: Considering the role of atrophic gastritis and Helico-
bacter pylori (Hp) infection in antral G-cells hyperplastic changes, we 
aimed to investigate the relationship between these factors and the de-
velopment of sporadic bulb NETs. A prospective, case-control study was 
performed with 77 patients: 13 bulb NETs patients and 64 controls, ran-
domly selected (28 chronic atrophic gastritis, CAG; 21 chronic superficial 
gastritis; and 15 normal subjects). All participants underwent upper gas-
trointestinal endoscopy with biopsies (antrum, corpus and bulb). Gastritis 
pattern was accessed. Bulb samples were evaluated for D- and G-cells 
quantification and G-cells hyperplastic changes. Hp infection was deter-
mined in both locations. Baseline biodemographic variables were also 
analysed.
results: All NETs were G-cells tumors, small in size (median 7 mm), re-
stricted up to submucosa, resected by mucosectomy, with no evidence of 
dissemination at diagnosis or during follow-up. At multivariate analysis, 
gastric Hp infection (OR=8,2; p=0,022), duodenal Hp infection (OR=16; 
p=0,027) and bulbar G-cells linear/micronodular hyperplasia (OR=79; p=< 
0,001) were independent predictors of G-cells NETs development. Addi-
tionally, bulbar G-cells linear/micronodular hyperplasia had a significant 
association with chronic use of proton pump inhibitors (p=0.018). Both, 
NETs and G-cells hyperplasia, were not associated with body CAG.
conclusion: Data reinforced that sporadic G-cells NETs may originate from 
a proliferative phase sequence. Our data suggests that Hp and related 
inflammation, seems the most important factor in our population. Its 
involvement as cause or epiphenomena in bulb G-cells hyperplasia and 
tumor should be further studied.
disclosure: Nothing to disclose 
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P0635 PrevaLence Of heLIcOBacTer PyLOrI InfecTIOn 
In nOndIaBeTIc nafLd and IT assOcIaTIOn In severITy Of 
fIBrOsIs
Siricharoonwong W., Boonsirichan R.
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contact e-Mail address: kwangwarisara@gmail.com
Introduction: Nonalcoholic fatty liver disease (NAFLD) is one of the most 
common causes of cirrhosis worldwide. A considerable amount of patients 
without DM still has NASH and advanced fibrosis. Helicobacter pylori (H. 
pylori) infection contribute to the increase in levels of pro-inflammatory 
cytokines which have different metabolic effects and associated with in-
sulin resistance (IR). Therefore, H. Pylori may possibly have an effect on 
fibrosis progression in NAFLD in nondiabetic patients.
aims & Methods: Investigate the prevalence of H. pylori infection in non-
diabetic NAFLD patient and its association in advance fibrosis. 
Nondiabetic patients who were diagnosed NAFLD by abdominal ultraso-
nography and/or controlled attenuation parameter (CAP) from FibroScan® 
were recruited for H. pylori infection testing by a 14C-urea breath test. All 
participants were evaluated liver fibrosis with transient elastography. They 
were collected standard biochemical test (eg. FPG, LDL, liver function test) 
and interleukin-6 to evaluate the inflammatory response. To minimized 
the confounding effect, we excluded patients who had BMI > 28 kg/m2 or 
P0632 The OBesTaTIn/g-PrOTeIn cOuPLed recePTOr 39 
(gPr39) sysTeM Is InvOLved In The PrOLIferaTIOn Of gasTrIc 
cancer ceLL LInes
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Introduction: Obestatin is a 23-aminoacid peptide derived from pre-
proghrelin, was isolated from the stomach in 2005 and binds to the GPR39 
receptor. Our group has described the expression of the obestatin/GPR39 
system in healthy human stomach, as well as in gastric adenocarcinoma, 
where we have shown a role in both the pathogenicity and the prognosis 
of this tumor. The obestatin/GPR39 system regulates proliferation, epithe-
lial-mesenchymal transition, migration capacity, invasion and metastasis 
in the AGS cell line, which derives from a moderately differentiated adeno-
carcinoma. The GPR39 expression levels found in human gastric adenocar-
cinomas provide the basis for including GPR39 as a prognostic marker for 
these tumors.
aims & Methods: The objective of this study is to evaluate the involvement 
of this system in the proliferation of cell lines of human pancreatic cancer 
with different degrees of differentiation: the AGS cell line, a moderately 
differentiated adenocarcinoma; the KATO III cell line, a poorly differenti-
ated adenocarcinoma; and the NCI-N87 cell line, a liver metastasis of a 
well-differentiated adenocarcinoma.
The analysis of the obestatin/GPR39 system expression in the tumor the 
cell lines (AGS, KATO-III and NCI-N87) was performed by using immuno-
cytochemical techniques. In addition, cell proliferation assays were per-
formed after obestatin treatment (100 nM) by BrdU incorporation (AGS and 
NCI-N87) and manual counting (AGS and KATO-III). 10% FBS was used as 
positive control.
results: All the studied cell lines strongly expressed the obestatin/GPR39 
system. No immunostaining was shown in negative controls incubated 
without primary antibody. Obestatin (100 nM) exerted a mitogenic effect 
in the AGS line (46,2 8,66% over control; p< 0,01), the NCI-87 cells (60,82 
2,83% over control; p< 0,001) and in the KATO-III cell line (44,00 3,10% 
over control; p< 0,01).
conclusion: This study offers two main findings: 
1. The obestatin/GPR39 system is intensely expressed in tumor cell lines of 
the human stomach; 
2. The exogenous obestatin treatment increased the proliferation of these 
cell lines, with no differences between the different cell lines. The obtained 
results showed that the obestatin/GPR39 system is involved in the prolif-
erative processes in gastric cancer.
disclosure: Nothing to disclose 
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received steatogenic drugs. The outcome was the prevalence of H. pylori 
infection in NAFLD patients. We also investigated factors which indepen-
dently associated with advanced fibrosis.
results: A total of 117 NAFLD patients were enrolled. We found overall H. 
pylori infection in 54 patients (46%). In patients with advanced fibrosis (de-
fined as fibrosis stage > 3 from transient elastography), the prevalence of 
advanced hepatic fibrosis in NAFLD patients with H. pylori infection is high-
er (22/54, 40.7%) than in non-infected group (18/63, 28.6%). Obesity was 
the variable most associated with advanced fibrosis (OR 3.18 [1.25-8.09], 
p-value 0.02) in univariate analysis. H. pylori infection had a marginal ef-
fect to advanced fibrosis (OR 1.72 [0.8-3.71], p-value 0.17) but no statistically
significant in multivariate analysis. Other metabolic variables and inter-
leukin-6 were not significantly associated with advanced fibrosis.
conclusion: Prevalence of H. pylori infection in nondiabetic NAFLD patient 
similar to the general Thai population. Our results could not demonstrate 
the risk of H. pylori infection to advanced fibrosis. However, NAFLD pa-
tients with H. pylori infection tend to have a higher prevalence of advance 
hepatic fibrosis.
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Introduction: Gastric cancer is the third leading cause of cancer-related 
death worldwide and Helicobacter pylori is recognised as its main risk fac-
tor. We have reported that H. pylori infection leads, through an epithelial 
mesenchymal transition (EMT), to the emergence of CD44+ cells with can-
cer stem cell (CSC) properties. The Hippo tumour suppressor pathway and 
its oncogenic targets YAP/TAZ control cancer initiation and progression in 
many cancers. 
Their regulation in the context of H. pylori-mediated gastric carcinogenesis 
has not been described. We hypothesized that TAZ could be involved in 
the EMT process and CSC-like cells generation observed during H. pylori 
infection.
aims & Methods: The aim of this project was to investigate the role of TAZ 
during the EMT and the emergence of CSC induced by chronic infection 
with H. pylori and during gastric carcinogenesis.
The consequences of TAZ inhibition were studied on H. pylori-induced EMT 
and CSC signature and properties in gastric epithelial cell lines in vitro. 
The consequences of TAZ inhibition by a siRNA strategy were studied in 
MKN45 and NCI-N87 gastric epithelial cell lines infected or not with the 
carcinogenic H. pylori strains 7.13 and P12 as well as cagA and cagPAI iso-
genic mutants. The expression of Hippo/TAZ/TEAD pathway related genes 
and of EMT/CSC markers was assessed by RTqPCR, western blot and im-
munofluorescence. TAZ/TEAD transcriptional activity was evaluated by 
TEAD-luciferase reporter assay. EMT and CSC functional properties were 
evaluated by invasion and tumorsphere assays in vitro.
results: We showed that H. pylori infection transiently stimulates TAZ 
nuclear translocation and co-transcriptional activity in a CagA-dependent 
manner. TAZ inhibition reduced EMT markers expression, which correlated 
with a decrease of invasive properties induced upon H. pylori infection. 
Moreover, TAZ inhibition reduced spheroid formation which involves the 
CSC sub-population.
conclusion: The Hippo/TAZ pathway is activated upon H. pylori infection in 
gastric epithelial cells and TAZ activation participates to the regulation of 
H. pylori-induced EMT and CSC invasive and tumorigenic properties.
disclosure: Nothing to disclose 
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Introduction: The development and progression of chronic H.pylori gastri-
tis toward pre-neoplastic gastric lesions is a multifactorial process, which 
depends on interactions between environmental factors, H.pylori infection, 
gastric microbiota and host genetic factors. To date, there are no studies 
that would evaluate the role of shared genetic influences on susceptibil-
ity and phenotype of chronic H.pylori gastritis and premalignant gastric 
alterations in twins.
aims & Methods: To compare histological alterations of gastric mucosa 
according to Sydney classification, OLGA and OLGIM staging systems in 
monozygotic and dizygotic twins. This prospective study included 58 indi-
viduals with 13 pairs of monozygotic and 16 pairs (11 same- sex pairs and 
5 mixed- sex pairs) of dizygotic twins aged >18 years. Endoscopy for both 
twins was performed simultaneously on the same day. At endoscopy 5 bi-
opsy specimens were collected: 2 from the greater and lesser curvatures of 
antrum, 1 from incisura angularis, 2 from the anterior and posterior walls 
of the corpus. H. pylori gastritis was assessed by histology and graded by 
OLGA and OLGIM staging systems.
results: Mean age of monozygotic and dizygotic twins was 41.23 y and 
38.43 y, respectively. Total prevalence of H.pylori was 53.4%. Among 
monozygotic twins, six pairs were both positive, three pairs were both 
negative and four pairs were discordant for the presence of H.pylori. 
Among dizygotic twins, four pairs were both positive, five pairs were both 
negative and seven pairs were discordant for presence of H.pylori. Con-
cordance rate for chronic H.pylori gastritis in monozygotic twins was 69.2 
% (9/13 pairs) and in dizygotic twins 62.5% (10/16 pairs), p>0.05. Concor-
dance for antrum athrophy in monozygotic twins was 76.9 % and 75 % in 
dizygotic twins (p> 0.05). Concordance for corpus athrophy in monozygotic 
twins was 92.3% and in dizygotic twins 87.5% (p>0.05). Concordance for 
antrum IM in monozygotic twins was 84.6% and in dizygotic 75 % (p> 
0.05). Concordance for corpus IM in monozygotic twins was 84.6 % and 
in dizygotic 93.7 % (p> 0.05). There was no statistical difference in concor-
dance rates for OLGA and OLGIM stages both for monozygotic and dizygotic 
twins.
conclusion: Histological gastric mucosa alterations related to H.pylori gas-
tritis and premalignant lesions in monozygotic and dizygotic twins show 
high rates of concordance.
disclosure: Nothing to disclose 
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P0639 heLIcOBacTer PyLOrI-derIved MeMBrane vesIcLes 
MOdIfy gasTrIc ePITheLIaL ceLLs gene exPressIOn
Melo J.1,2,3, Cavadas B.1,2,3, Pinto V.D.1,2, Pereira L.1,2,4, Figueiredo C.1,2,4, 
Leite M.1,2,4
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University of Porto, Porto, Portugal, 2i3S - Instituto de Investigação e 
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Introduction: The stomach-colonizing Gram-negative bacterium Helico-
bacter pylori establishes a life-long infection in humans, infecting more 
than half of the world population. H. pylori is the main etiological factor of 
several gastroduodenal diseases, including chronic gastritis, peptic ulcers, 
gastric mucosa-associated lymphoid tissue lymphoma, gastric adenocarci-
noma, and more recently it has been associated with some extra-gastric 
diseases.
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manifested by increased level of α-SMA protein and its incorporation into 
stress fibers. The actin fibers dispersion characteristic for Hp (cagA+ vacA+) 
infection correlated with Snail mRNA upregulation.
conclusion: Gastric fibroblasts which are one of the main targets for Hp 
infection contribute to the paracrine interactions between Hp, gastric fi-
broblasts and epithelial cells. TGFβ secreted by Hp-activated gastric fi-
broblasts prompting their differentiation towards CAF-like phenotype 
promotes the EMT-related phenotypic shifts in normal gastric epithelial 
cell populations. This mechanism may serve as the prerequisite for gastric 
cancer development.
disclosure: Nothing to disclose 
P0641 TLR4 rs4986791 gene POLyMOrPhIsM and heLIcOBacTer 
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Iuliu Hateganu Cluj Napoca, Medical Informatics and Biostatistics, Cluj 
Napoca, Romania, 3University of Medicine, Pharmacy, Sciences and 
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Introduction: TLR4 is involved in the development of H. pylori induced gas-
tropathies, but also in gastric carcinogenesis.
aims & Methods: The aim of the study was to assess the clinical, endo-
scopic, and socioeconomic aspects, but also TLR4 rs4986791 gene polymor-
phism in children with H. pylori gastritis.
Methods. We performed a prospective study on 147 children admitted in 
a Pediatric Tertiary Gastroenterology Department from Romania, divided 
into 2 groups according the presence, or absence of H. pylori infection: 
group 1 - 50 children with H. pylori associated gastritis and group 2 - 97 
children with gastritis without H. pylori infection.
results: We observed that poor socioeconomic status was a significant 
risk factor for H .pylori infection (p=0.002, OR=4.03, 95% CI: [1.71; 9.50]). 
We found that the most frequent symptoms in patients with gastritis were 
epigastric pain, abdominal pain, heartburn, but without significant differ-
ences between the two groups. 
We identified significant correlations between the histopathological exam 
and rapid urease test (p< 0.001). The variant genotype of TLR4 rs4986791 
gene polymorphism was a protective factor against H. pylori infection, but 
without statistical significance.
conclusion: Socioeconomic status is a risk factor for H. pylori infection. 
The rapid urease test is a useful diagnostic tool for H. pylori infection. The 
variant genotype of the TLR4 rs4986791 gene polymorphisms might be a 
protective factor against H. pylori infection in children, but further studies 
are necessary in order to clearly identify its role.
references: 1. Castaño-Rodríguez N, Kaakoush NO, Goh K-L, Fock KM, 
Mitchell HM. The role of TLR2, TLR4 and CD14 genetic polymorphisms in 
gastric carcinogenesis: a case-control study and meta-analysis. PLoS ONE. 
2013;8(4):e60327. doi:10.1371/journal.pone.0060327 2. Meliț LE, Mărginean 
CO, Mărginean CD, Mărginean MO. The Relationship between Toll-like Re-
ceptors and Helicobacter pylori-Related Gastropathies: Still a Controver-
sial Topic. Journal of Immunology Research. doi:10.1155/2019/8197048 3. 
Khakzad MR, Saffari A, Mohamadpour N, et al. TLR4 and TLR2 expression 
in biopsy specimens from antral and corporal stomach zones in Helico-
bacter pylori infections. Rep Biochem Mol Biol. 2014;3(1):29-37.
disclosure: Nothing to disclose 
Gram-negative bacterial membrane vesicles are nanosized vesicles rang-
ing from 20 nm to 300 nm that are secreted by virtually all bacteria. They 
constitute a successful strategy used by bacteria to manipulate host cell 
functions important for their survival, colonization, and persistence in the 
host with implications in bacteria-mediated pathogenesis.
aims & Methods: The effect of bacterial membrane vesicles on host gene 
expression is poorly understood. Thus, the aim of this study was to in-
vestigate the impact of H. pylori-derived membrane vesicles uptake by 
gastric epithelial cells in the modulation of gene expression. Total RNA 
was isolated from the human gastric epithelial cell line MKN74 either 
unchallenged (N=3) or challenged (N=6) for 24 hours with membrane 
vesicles isolated from the H. pylori 26695 strain. A targeted RNA sequenc-
ing analysis covering 20,000 human genes was performed using the Ion 
Ampliseq Transcriptome kit. Differential expression analysis between un-
challenged and challenged MKN74 cells was performed using the DESeq 
R package. Overrepresentation of gene ontology terms was determined 
using topGO.
results: Our results show that ~1% (224/20,000) of the interrogated genes 
were differentially expressed between unchallenged and membrane ves-
icle-challenged MKN74 cells (adjusted P-value < 0.05), of which 99 genes 
were downregulated and 125 genes were upregulated. Enrichment analy-
sis of the top forty differentially expressed genes (20 up- and 20 down-
regulated) were clustered to gene ontology terms such as cytoskeleton and 
extracellular region for cellular components; growth factor and cytokines 
activity, protein binding, signalling receptor and protein kinase binding 
for molecular functions, and; regulation of phosphorylation, regulation of 
apoptotic process, signal transduction, and cell cycle regarding biological 
processes.
conclusion: In summary, our findings show that H. pylori-derived mem-
brane vesicles are able to modify gene expression of the gastric epithelial 
cell line MKN74, suggesting a role for these vesicles in the bacteria-medi-
ated pathogenesis.
disclosure: Nothing to disclose 
P0640 Helicobacter pylori-acTIvaTed gasTrIc fIBrOBLasTs 
Induce ePITheLIaL-MesenchyMaL TransITIOn Of 
gasTrIc ePITheLIaL ceLLs In a TransfOrMIng grOWTh 
facTOr BeTa-dePendenT Manner
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Introduction: Colonization of the gastric mucosa with Helicobacter pylori 
(Hp) leads to the cascade of pathologic events including local inflamma-
tion, gastric ulceration and adenocarcinoma formation. Paracrine loops 
between tissue cells and Hp have recently been implicated in the formation 
of gastric cancerous loci, however, the specific mechanisms underlying ex-
istence of these loops remain unknown. Here, we determined the pheno-
typic properties of gastric fibroblasts recently considered as the target for 
Hp (cagA+vacA+) infection and their influence on normal epithelial RGM-1 
cells.
aims & Methods: RGM-1 cells were cultured in the media conditioned 
with Hp-activated gastric fibroblasts. Their morphology and phenotypical 
changes associated with epithelial-mesenchymal transition (EMT) were 
assessed by Nomarski contrast microscopy, fluorescent microscopy and 
Western Blot analysis. Motility pattern of RGM-1 cells in infected and non-
infected fibroblast supernatant was examined by time-lapse videomicros-
copy, and by transwell migration assay. The content of TGFβ in Hp activated 
fibroblasts conditioned media was determined by ELISA.
results: The supernatant from Hp-activated gastric fibroblasts caused 
the EMT-like phenotypic diversification of RGM-1 cells. In particular, the 
formation of fibroblastoid cell sub-populations was observed along with 
disappearance of their collective migration. These cells were character-
ized by efficient movement, increased transmigration potential, thick actin 
stress fibers developement and decreased proliferation activity. Concomi-
tantly, we observed the downregulation of E-cadherin protein, upregula-
tion of N-cadherin protein and the increased TGFβ level in the secretome 
of Hp-activated gastric fibroblasts. The fibroblast-CAF like transition was 
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Introduction: Helicobacter pylori (H. pylori) is classified as a Class 1 carcino-
gen. Eradication of H. pylori is therefore imperative to prevent the natural 
progression of disease and help restore the gastric mucosa from peptic pa-
thologies. Apart from non-invasive testing using breath testing and stool 
sampling, the use of the rapid-urease test (RUT) during oesogastroduode-
noscopy (OGD) is widely practiced. Whilst previously pansensitive, there is 
mounting evidence showing increased resistance of H. pylori to standard 
antibiotic regimens, which has resulted in reduced eradication rates.
aims & Methods: To compare H. pylori detection through real-time poly-
merase chain reaction (RT-PCR) to the RUT done during OGD and deter-
mine the antibiotic sensitivity for quinolones and clarithromycin.
Method: Patients above 18 years of age, scheduled for an elective OGD 
were considered for recruitment. Exclusion criteria included: previous H. 
pylori treatment and antibiotic usage within the preceding three months. 
Two biopsies from the antrum and two from the corpus were collected. All 
four biopsies were combined and digested with tissue-lysing buffer and 
Proteinase K. Automated DNA extraction was performed followed by RT-
PCR for H. pylori DNA detection. Positive samples were tested for clarithro-
mycin and fluoroquinolones resistance using amplification and reverse hy-
bridization techniques. Data regarding the result of RUT performed during 
the OGD was also noted.
results: 200 patients (range 20-92 years) were recruited (females = 53.1%) 
Real-Time PCR detected H. pylori in 21% of patients compared to the 29.5% 
detection rate by the RUT. A positive RUT and a positive RT-PCR result was 
observed in 17.0% of patients while 12.5% of patients had a positive RUT 
result but a negative RT-PCR result. Furthermore, 4.0% of patients had 
a negative RUT but a positive RT-PCR result. Additionally, detection of H. 
pylori was also performed using reverse hybridization techniques with de-
termination of its antibiotic susceptibilities. H. pylori was detected in 19.5% 
of total patients using this secondary molecular technique.
Fluoroquinolone resistance was present in 21.4% of patients and 26.2% 
of patients exhibited clarithromycin resistance, while dual resistance to 
both clarithromycin and fluoroquinolones was detected in another 4.8% 
of patients.
conclusion: This data demonstrates similar H. pylori detection rates using 
RT-PCR and/or reverse hybridisation techniques but lower rates than the 
RUT. Moreover, our data also demonstrates a high resistance rate to both 
clarithromycin and fluoroquinolones. Such modern techniques should be 
considered to replace the RUT, to avoid unnecessary antibiotic prescrip-
tion due to false-positive results. This would therefore ensure the pre-
scription of adequate antibiotic regimens when H. pylori infection is in 
fact present.
disclosure: Nothing to disclose 
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frOM dIscrePanT cases TesTed By serOLOgy and hIsTOLOgy
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Introduction: In gastric mucosal atrophy H. pylori density may be decreas-
ing leading to false-negative histology results. Therefore, Maastricht V 
guidelines (Malfertheiner et al., 2016) accept the use of serogical tests for 
non-invasive H. pylori diagnosis.
aims & Methods: To evaluate the presence/absence of H. pylori by mo-
lecular methods in subjects with discrepant histology and serology result. 
Individuals with discrepant serology/histology result (group 1 - positive-
serology, but negative-histology, group 2 - negative-serology, but posi-
tive-histology) were selected from a GISTAR pilot-study database. Subjects 
having received H. pylori eradication therapy in life-time or reporting use 
of proton pump inhibitors, antibacterial medications, bismuth containing 
drug use one month prior upper endoscopy were excluded. 
Antibodies to H. pylori were assessed in plasma by enzyme-linked immu-
nosorbent assay (ELISA). H. pylori deoxyribonucleic acid (DNA) detection 
in frozen biopsy sample was performed using a real-time polymerase 
chain reaction (PCR) as a gold standard. Immunohistochemistry (IHC) 
was performed in subjects with postive-histology and negative-serology. 
Presence of inflammation was evaluated according to mucosal neutrophil 
infiltration, subjects with stage II or III in any of biopsies was considered 
as a group with inflammation, meanwhile 0 or I in all biopsies - as group 
without inflammation.
results: The final patient sample for analysis contained data from 97 indi-
viduals: serology-positive/histology-negative cases: 81, serology-negative/
histology-positive: 16. Among the first group there were approximately one 
fifth (21.0%) falsely positives by serology, while in the second group there 
were 6.3% false positives by histology. In the PCR positive group six of 15 
(or 40%) gastric mucosa showed no inflammation in all biopsies but the 
majority (14 subjects) had ICH positive results. 
The overall analysis of H. pylori tests’ discrepant cases are shown in the 
Table.
serology/
histology result Pcr result
number of cases 
n/total (%)
Inflammation 
present in any 
of biopsies n/
total (%)
Inflammation 
absent in all 
biopsies n/total 
(%)
Serology positive, 
histology negative 
cases
PCR positive 17/81 (21.0) 1/17 (5.9) 16/17 (94.1)
  PCR negative 64/81 (79.0) 1/64 (1.6) 63/64 (98.4)
Serology 
negative, 
histology positive 
cases
PCR positive 15/16 (93.8) 9/15 (60.0) 6/15 (40.0)
  PCR negative 1/16 (6.3) 0/1 1/1 (100)
[Table. Analysis for total patient sample in H. pylori tests’ discrepant cases.]
conclusion: Among this high H. pylori prevalence middle-aged popula-
tion, the majority of discrepant cases between serology and histology were 
rather due to false positive-serology than false-negative histology. This 
could be explained by possible loss of bacterium due to atrophic changes 
in mucosa.
disclosure: Nothing to disclose 
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aims & Methods: We performed a single-center retrospective study to ex-
amine the GC incidence rate in accordance with Hp infection status for 
examinees of screening endoscopy from April 2014 to March 2018. All 
examinees were screened for GC using ultrathin endoscopes mostly in-
serted transnasally, and Hp infection status was also diagnosed by Kyoto 
classification of endoscopic gastritis into three groups as Hp-infected, Hp-
past infected (mostly post Hp eradication), and Hp-uninfected. Clinical 
and pathological characteristics of GC cases and GC detection rate of each 
group were investigated.
results: During the study period, 28894 examinees (11622 females, 40.0%) 
were screened. Among them, 14402 (49.8%) were under the age of 50, 
and 476 (16.5%) were over the age of 70. Those who were examined annu-
ally for more than 2 years were 84.9% (24532 examinees). All the exam-
inees were diagnosed into three groups as Hp-infected (2843, 9.8%), Hp-
past infected (8239, 28.5%), and Hp-uninfected (17812, 61.6%), based upon 
Kyoto classification of endoscopic gastritis. Forty-eight GC cases (0.17%) 
were detected consisting of 16 cases of Hp-infected, 14 of Hp past-infected, 
and 18 of Hp-uninfected. All GC cases were treated endoscopically or sur-
gically, and 46 cases were early cancers. Accordingly, CG detection rate in 
accordance with Hp infection status was 0.56% for Hp-infected, 0.17% for 
past-Hp infected, and 0.10% for Hp-uninfected. Both the past-Hp infected 
and the Hp-uninfected groups showed significantly lower detection rates 
of GC (p< 0.001, chi-square tests) than the Hp-infected group.
conclusion: Our study elucidated that Hp eradication could decrease the 
incidence of GC drastically. However, unignorable numbers of early GC 
cases were also detected among the Hp-past infected and Hp-uninfected 
examinees, indicating that the screening intervals should be optimized in 
accordance with the Hp infection status. Our study has limitations because 
of the single-center study and of a large proportion of repeated examinees.
references: 1) Gastroenterology, Vol. 152, Issue 5, S260-S261
disclosure: Nothing to disclose 
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Introduction: Gastric mucosa-associated lymphoid tissue (MALT) lym-
phoma is considered to be closely related to Helicobacter pylori (H. pylori) 
infection. Although eradication of H. pylori is the mainstay of treatment 
for patients with gastric MALT lymphoma, 20% of them cannot be cured 
by eradication therapy. And treatment for patients with H. pylori-negative 
or eradication therapy-resistant gastric lymphoma has not yet been es-
tablished.
aims & Methods: The aim of this study is to assess the efficacy of low-
dose radiation therapy on H. pylori-negative or eradication therapy-resis-
tant MALT lymphoma. We enrolled patients with gastric MALT lymphoma 
from January 1994 through April 2018. The diagnosis was made based 
on morphological and immunophenotypic analysis of biopsies obtained 
from gastric lesions on esophagogastroduodenoscopy (EGD) in accordance 
with the current WHO classification. Patients with localized (stages I and 
II
1
) gastric MALT lymphoma according to the Lugano classification were 
eligible for enrollment. Patients were also examined to confirm H. pylori 
infection status. Those with H. pylori infection received eradication therapy. 
And patients who were not cured by eradication therapy were categorized 
into eradication therapy-resistant cases. Patients with H. pylori-negative or 
eradication therapy-resistant MALT lymphoma received low-dose radiation 
therapy. A total dose of 30 Gy was administered and the fraction size was 
1.5 Gy for 20 days. Response assessment was carried out every 3-6 months 
by EGD, various imaging techniques, and clinical examination. Patients 
with no endoscopic abnormality and no atypical lymphocytes detected by 
biopsy at endoscopic follow-up were considered to have achieved com-
plete remission (CR). Patients with atypical lymphocytes detected by biopsy 
were diagnosed as having partial remission (PR).
results: A total of 112 patients with gastric MALT lymphoma were enrolled. 
The median follow-up period was 76.4 months. 67 of them had H. pylori 
infection. 54 of those H. pylori-positive patients were successfully cured 
P0645 cLInIcaL asPecTs and The rOLe Of adIPOkInes In 
gaLLsTOne dIsease In PaTIenTs WITh nOn-aLcOhOLIc faTTy 
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Introduction: Close relationship between non-alcoholic fatty liver disease 
(NAFLD) and gallstone disease (GD) has been proved. Being aware of the 
specific features of the diseases the issue remains burning due to constant 
increase of patient number because of elevating the metabolic risk factors 
among the population, including obesity, overweight, diabetes mellitus 
type 2, dyslipidemia, etc.
aims & Methods: 
Objective: Update the comorbidity information about NAFLD and GD, 
evaluation of clinical and laboratory data, including insulin, leptin and 
adiponectin in patients with NAFLD in combination with GD.
Materials and methods: According to the design, the open comparative 
study with 215 patients with NAFLD was conducted. The following compar-
ison groups were formed: group 1 (n = 94) -patients with NAFLD without 
GD, group 2 (n = 63) - patients with NAFLD and GD and group 3 (n = 58) 
- patients with NAFLD, GD and previous cholecystectomy.
results: A high prevalence of coronary heart disease was detected in the 
group of patients with
GD and cholecystectomy (X2=6.198, p≤0.05); positive, statistically signifi-
cant correlation
relationships of cholelithiasis, cholecystectomy with ischemic heart dis-
ease (rs = 0.172, p≤0,05 and rs=0.241, p≤0.05, respectively). There was a 
statistically significant decrease in total bilirubin and total protein in pa-
tients in group 3 (H=7.376, p≤0.03 and H=6.345, p≤0.04). Insulin and leptin 
resistance were registered in patients with NAFLD and GD: insulin level 
14.5 (7.12-35.78) mkED/ml), HOMA-IR (5.23(2.35-11.45)), leptin (14.53(9.56-
28.67) ng/ml), its soluble receptors (8.03(3.98-9.45) ng/ml). There was a 
statistically significant increase in adiponectin (U=1106, p≤0.05) for pa-
tients with NAFLD and GD. The level of leptin was statistically significantly 
higher and positively interrelated with cholecystectomy (H=5.812, p≤0.05, 
rs=0.313, p≤0.05).
conclusion: Patients with NAFLD, GD and previous cholecystectomy have a 
high incidence of coronary heart disease; the phenomenon of insulin and 
leptin resistance, a high level of adiponectin were determined in patients 
with NAFLD and gallstone disease; hyperleptinemia was registered in pa-
tients with NAFLD and GD after cholecystectomy.
disclosure: Nothing to disclose 
P0646 gasTrIc cancer deTecTIOn raTes In accOrdance 
WITh The InfecTIOn sTaTus Of heLIcOBacTer PyLOrI uPOn 
kyOTO cLassIfIcaTIOn Of gasTrITIs By TransnasaL screenIng 
endOscOPy
Yoshimura R.1, Yoshimura D.2, Kitagawa Y.2, Fukuda S.2, Chaen T.2, 
Nakano K.2, Ochiai T.2, Ihara E.3
1Health Checkup Center Wellness, Fukuoka, Japan, 2Saiseikai Fukuoka 
General Hospital, Gastroenterology, Fukuoka, Japan, 3Kyushu University, 
Medicine and Bioregulatory Science, Fukuoka, Japan
contact e-Mail address: mdyoshimura@gmail.com
Introduction: Helicobacter pylori (Hp) infection is the principal pathogenic 
cause of gastric cancer (GC), and eradication of Hp has been expected 
to decrease the incidence of GC. The recent rapid decline of Hp infection 
rate and global standardization of eradication therapy may affect the ef-
ficiency of GC diagnosis for screening endoscopy. We previously reported 
the increasing numbers of GC cases without Hp infection1), however, the GC 
detection rate in accordance with Hp infection status on screening endos-
copy is not elucidated.
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by eradication therapy. 40 patients with H. pylori-negative or eradication 
therapy-resistant MALT lymphoma received radiation therapy. Of the 40, 
32 patients had H. pylori-negative gastric MALT lymphoma and 8 patients 
were eradication therapy-resistant. 36 of them achieved CR (90.0%). 29 
survived event-free. Two patients with CR were diagnosed with other dis-
eases; one was diagnosed with primary gastric cancer while the other with 
follicular lymphoma. Distant recurrence was detected in five patients with 
CR during follow-up. 2 of them died. One of the two died from primary 
lung cancer while the other died from metastases to the cervical lymph 
nodes and bone marrow from primary MALT lymphoma. One of the pa-
tients with distant recurrence in the rectum was diagnosed with primary 
gastric cancer. 4 patients only achieved partial remission. One of them 
died because of the transformation of the disease to diffuse large B-cell 
lymphoma while the remaining 3 sustained survival.
conclusion: Low-dose radiation therapy may be effective in treating H. py-
lori-negative or eradication therapy-resistant MALT lymphoma. However, 
careful systemic follow-up for distant involvement and second malignancy 
in the field of radiation is warranted. To monitor lymphoma and detect 
transformation at its earliest stages is crucial because transformation to 
diffuse large B-cell lymphoma is one of the leading causes of death in 
patients with gastric MALT lymphoma.
disclosure: Nothing to disclose 
P0648 cLOse assOcIaTIOn Of endOscOPIc scOres fOr 
gasTrIc cancer rIsk accOrdIng TO “kyOTO cLassIfIcaTIOn 
Of gasTrITIs” WITh seruM rIsk cLassIfIcaTIOn knOWn as 
“aBc MeThOd”
Hirai R.1, Shimodate Y.1, Ishikawa S.1, Minami M.1, Kanatani T.1, Hirai M.2, 
Doi A.1, Nishimura N.1, Mouri H.1, Matsueda K.1, Yamamoto H.1, Mizuno M.1
1Kurashiki Central Hospital, Gastroenterology And Hepatology, Kurashiki, 
Japan, 2Okayama University, Gastroenterology and Hepatology, Okayama, 
Japan
contact e-Mail address: me20070@s.okayama-u.ac.jp
Introduction: In Japan, endoscopic examination has been approved for a 
population-based gastric cancer screening program since 2016. Kyoto clas-
sification of gastritis provides the information of Helicobacter pylori infection, 
a major cause of gastric cancer, i.e., non-gastritis, no history of H. pylori 
infection; active gastritis, current infection with H. pylori; and inactive gas-
tritis, past infection. “ABC method”, a blood test examining serum H. pylori 
antibody and pepsinogen, has been also accepted as non-invasive and al-
ternative method to assess H. pylori infection status and gastric cancer risk.
aims & Methods: In this study, we aimed to clarify whether endoscopic 
evaluation of gastritis according to “Kyoto classification” helps to judge 
the risk of gastric cancer in the setting of population-based gastric cancer 
screening program. A prospective case registration study was conducted 
(UMIN000028629). Data were collected from 1784 participants who under-
went both of endoscopic screening for gastric cancer at Kurashiki Central 
Hospital Health Managing Center from September 2017 to June 2018. We 
compared the endoscopic score for gastric cancer risk according to “Kyoto 
classification of gastritis” with the results of “ABC method”, and evaluated 
the association between them by using Spearman’s correlation coefficient.
results: Endoscopically, non-gastritis was diagnosed in 1315 (73.7%) par-
ticipants, active or inactive gastritis was diagnosed in 446 (25%), and 
judgement was difficult in 23 (1.3%). In the ABC method, 1312 (73.5%) were 
classified into group A, and 472 into group B-D. The average endoscopic 
scores of each ABC group were as follows: group A, 0.11 ± 0.6; group B, 2.5 
± 2.1; group C, 4.7 ± 1.6; and group D, 4.4 ± 2.1. The endoscopic score based 
on the Kyoto classification correlated well with the risk classification of ABC 
method (correlation coefficient, 0.80). 
aBc method group a group B group c group d
H. pylori antibody (≧3U/mL) - + + -
Pepsinogen (PG Ⅰ≦70 and PG 
Ⅰ/Ⅱ≦3) - - + +
Gastric cancer risk Minimal Low High High
N (%) 1312 (73.5%) 335 (18.8) 121(6.8%) 16 (0.9%)
Endoscopic score 0.11± 0.56 2.5± 2.1 4.7± 1.6 4.4± 2.1
[Gastric cancer risk according to the ABC method and the endoscopic scores 
based on Kyoto classification of each group.]
conclusion: Endoscopic scores for gastric cancer risk according to “Kyoto 
classification of gastritis” were highly correlated with the known risk clas-
sification as “ABC method”. Our findings suggest that endoscopic evalua-
tion of gastritis according to “Kyoto classification of gastritis” is useful to 
judge the risk of gastric cancer in the setting of population-based gastric 
cancer screening program.
disclosure: Nothing to disclose 
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P0651 The rOLe Of hePaTOMa-derIved grOWTh facTOr 
(hdgf) In recruITMenT Of MesenchyMaL sTeM ceLLs and 
gasTrIc
Kuo C.-H.1,2, Liu C.-J.3, Wang Y.-K.2,3, Wu D.-C.2,3
1Kaohsiung Municipal Hsiao-Kang Hospital, Division of Gastroenterology, 
Department of Internal Medicine, Kaohsiung, Taiwan, 2Kaohsiung Medical 
University, Department of Medicine, College of Medicine, Kaohsiung, Taiwan, 
3Kaohsiung Medical University Hospital, Division of Gastroenterology, 
Department of Internal Medicine, Kaohsiung, Taiwan
contact e-Mail address: kjh88kmu@gmail.com
Introduction: Gastric carcinoma is one of the most prevalent cancers 
worldwide and is the secondary leading cause of cancer-related mortal-
ity because of the poor prognosis of patients. Hepatoma-derived growth 
factor (HDGF) is shown to contribute to cell proliferation, anti-apoptosis 
and VEGF expression, lymph node metastasis and poor prognosis in hu-
man gastric carcinoma. Carcinoma-associated fibroblasts (CAFs) possess 
abilities to promote primary tumor growth and progression by stimulating 
processes of neoangiogenesis, tumor cell proliferation, survival, migra-
tion, invasion and therapy resistance. Mesenchymal stem cells (MSCs) are 
reported to promote tumor malignance through differentiation of MSCs 
toward CAFs.
aims & Methods: HDGF is induced by co-culture experiments with Helico-
bacter Pylori strain ATCC 49503 and AGS cells. CAF markers are detected us-
ing reverse transcription and real-time PCR assays. The effect of HBMMSCs 
on invasive motility of gastric cancer cells is measured using transwell 
migration assay.
results: In the present study, H. pylori infection promotes HDGF expres-
sion in human gastric cancer cells. Human bone marrow mesenchymal 
stem cells (HBMMSCs) treated with HDGF assume properties of CAF-like 
myofibroblastic phenotypes through measuring myofibroblast markers 
[α-smooth muscle actin (α-SMA), procollagen α1, tropomyoson I, des-
min, fibroblast activation protein (FAP)], and fibroblast markers [ prolyl-
4-hydroxylase A1 (PHA1) and fibroblast specific protein-1 (FSP-1)/S100A4]. 
HDGF-recruited HBMMSCs enhances cell proliferation and invasive motility 
of human gastric cancer cells. Hepatoma-derived growth factor neutral-
izing antibody (HDGF-NAb) and serum significantly inhibit HDGF-induced 
recruitment and differentiation of HBMMSCs.
conclusion: These findings suggest that HDGF might play an important 
factor in gastric cancer progress through stimulation of HBMMSCs differ-
entiation to CAF-like myofibroblas cells.
disclosure: Nothing to disclose 
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daily for 10 days, each capsule containing 135 mg COLIMYCINE, 100 mg of 
GENTAMYCINE, AP-HP) was established. Four weeks after the treatment, a 
new lactulose breath test was performed.
results: Four weeks after treatment, an overall improvement in symptoms 
was observed in 92 patients (93%). There was also a significant decrease 
in expired H2 (P < 0.001) for all times. And a normalization of breath tests 
was registered in 42 patients (43%). 
Age, gender, BMI, IBS subtypes, duration of illness were not associated 
with breath test normalization after antibiotic therapy. Only a lower con-
centration of hydrogen expired at times 70 and between time 140 to 180 
min was predictive of a positive response to treatment (P0.001).
During treatment, an increase in diarrhea was observed in 13 patients and 
increased abdominal pain in 10 patients.
conclusion: In IBS patients, this study shows that COLIGENTA can be used 
for the treatment of SIBO. The reported clinical improvement (93%) was 
not systematically associated with standardization of respiratory tests 
(42%). These results prompt to perform a double-blind study with a pe-
riod longer evaluation.
disclosure: Nothing to disclose 
P0654 sPy gLass’s aPPLIcaTIOn In endOscOPIc 
reTrOgrade aPPendIcITIs TheraPy fOr The ManageMenT 
Of acuTe aPPendIcITIs
Liu B.-R., Ling-Jian K.
The First Affiliated Hospital of Zhengzhou University, Gastroenterology, 
Zhengzhou, China
contact e-Mail address: bingrongliu@qq.com
Introduction: To evaluate the feasibility of Spy Glass applied in endoscopic 
retrograde appendicitis therapy (ERAT) for the management of acute ap-
pendicitis.
aims & Methods: An electronic colonoscope (CFHQ290I, Olympus) with a 
cone-shape transparent cap was inserted into ileocecum to observe ap-
pendix orifice. After Inserting Spy Glass through the electronic colono-
scopic tunnel, the guide wire lead Spy Glass to the appendix cavity for 
observation. The appendiceal cavity was observed and treated accordingly 
(removal of fecal stones, flushing, biopsy if necessary) . This was done 
without X-ray or ultrasound guidance during the whole procedure.
results: Spy Glass could enter into appendix cavity and completed ERAT 
successfully.
conclusion: By using Spy glass ERAT can be successfully performed without 
guidence of X-ray or ultrasound, avoiding the hazard of radiation.
disclosure: Nothing to disclose 
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P0656 PredIcTIve facTOrs and cLInIcaL IMPacT Of “deeP 
reMIssIOn” In ceLIac dIsease
Peixoto A.1, Silva M.1, Santos A.L.1, Costa-Moreira P.2, Ferreira da Silva J.1, 
Dias E.2, Macedo G.1
1Centro Hospitalar De São João, Department of Gastroenterology, Porto, 
Portugal, 2Centro Hospitalar de São João, Department of Gastroenterology, 
Porto, Portugal
contact e-Mail address: armandoafp5@gmail.com
Introduction: Despite the usefulness of serology in the follow-up of pa-
tients with celiac disease, the ultimate indicator of adherence to the glu-
ten-free diet is the demonstration of mucosal healing, although this may 
not occur even in compliant patients. 
However, the need for duodenal reassessment biopsies is a controversial 
subject among “experts”.
aims & Methods: The aim of this study was to evaluate patients who un-
derwent histological reevaluation after starting a gluten-free diet, in order 
to identify those with histological improvement, including complete mu-
cosal healing and associated factors.
Starting from a dedicated consultation celiac disease consultation, pa-
tients with apparent clinical remission with normalization of antibody ti-
tres after at least twelve months of diet, were evaluated and who agreed 
to a proposed histological reassessment through upper endoscopy with bi-
small Intestinal I
10:30-17:00 / Poster Exhibition - Hall 7
P0652 a MOdeL TO sTudy IscheMIa-rePerfusIOn Injury 
In huMan InTesTInaL OrganOIds
Kip A.M., Olde Damink S.W.M., Lenaerts K.
Maastricht University Medical Centre, Department of Surgery, Maastricht, 
Netherlands
contact e-Mail address: m.kip@maastrichtuniversity.nl
Introduction: Intestinal ischemia-reperfusion (IR) is a phenomenon re-
lated to a variety of pathophysiological conditions (e.g. acute mesenteric 
ischemia, major surgery, shock). IR leads to damage of the intestinal epi-
thelium, which functions as a physical and immunological barrier and is 
therefore crucial in maintaining intestinal homeostasis. I
n order to investigate potential therapeutic targets to protect the epithe-
lium during intestinal IR and promote a regenerative response, we aim 
to validate a model to study IR in human intestinal organoids. Intestinal 
organoids have been shown to closely resemble self-renewal kinetics, 
3D architecture, and cell-type composition of the intestinal epithelium 
in vivo.
aims & Methods: A well-established human experimental model to study 
IR was used for temporal expression profiling of the in vivo intestinal 
response to IR. The top perturbed pathway was further validated using 
qPCR. Intestinal epithelial organoids were cultured from crypts isolated 
from surgical specimens of normal human small intestine. To simulate IR, 
organoids were subjected to 12 hours of hypoxia (1% O
2
) followed by 30 
and 120 minutes of reoxygenation. Activation of the UPR response was as-
sessed by qPCR for CHOP, GADD34, BiP and XBP1 splicing, and, in addition, 
signs of endoplasmic reticulum (ER) stress were evaluated using electron 
microscopy (EM).
results: The unfolded protein response (UPR) was the top perturbed path-
way during reperfusion of the ischemically injured human small intestine 
in vivo. 
Subjecting small intestinal organoids to 12 hours of hypoxia followed by 
30 minutes of reoxygenation significantly increased expression of UPR-
related genes CHOP and GADD34 and splicing of XBP1 mRNA compared 
to organoids not subjected to hypoxia. In addition, EM showed dilated ER 
after reoxygenation which is indicative of ER stress.
conclusion: In line with findings in the in vivo human IR model, reveal-
ing the response to unfolded protein as a highly regulated process during 
reperfusion, hypoxia-reoxygenation in intestinal organoids induces sig-
nificant activation of the UPR. Intestinal organoids can be used to improve 
insight in the pathophysiology of epithelial IR injury and regeneration, 
which could lead to new therapeutic targets.
disclosure: Nothing to disclose 
P0653 OPen sTudy Of The assOcIaTIOn 
cOLIMycIne / genTaMycIn In The TreaTMenT Of 
BacTerIaL OvergrOWTh Of The sMaLL InTesTIne 
In PaTIenTs WITh IrrITaBLe BOWeL syndrOMe
Bouchoucha M., Rompteaux P., Mary F., Airinei G., Sabate J.M.,  
Benamouzig R.
Hopital Avicenne, Gastroenterology, Bobigny, France
contact e-Mail address: michel.bouchoucha@avc.aphp.fr
Introduction: Small intestinal bacterial overgrowth (SIBO) is a disorder 
whose diagnosis can be made directly by quantitative cultures (jejunal 
suction fluid) or indirectly by respiratory tests. Different treatment are pro-
posed in this indication, but not available in all countries.
aims & Methods: The purpose of this study is to evaluate in patients with 
Rome III irritable bowel syndrome (IBS) and a SIBO, the effectiveness of 
antibiotic treatment COLIGENTA (COLIMYCINE / GENTAMYCINE) on digestive 
symptoms and SIBO diagnosed by lactulose breath test.
In 99 consecutive patients with Rome III IBS (16 IBS-Constipation, 45 of 
type IBS-Diarrhea, 12 Mixed IBS, and 26-non-specific IBS), a SIBO was 
diagnosed by lactulose breath test. After a 72 hours no-residue diet, the 
test consisted of a hydrogen breath test with samples every 10 minutes 
during 3 hours after ingestion of 10 g of LACTULOSE. The test was posi-
tive when the H2 production was greater than 20 ppm within the first 90 
minutes after ingestion of lactulose. Treatment with COLIGENTA (3 capsules 
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opsies were included. The data needed to perform this investigation were 
obtained from the electronic clinical records, later aggregated into a SPSS 
database, which was subsequently subjected to treatment and statistical 
analysis.
results: A total of 69 patients were included, 79.7% (n = 55) of the female 
sex, with a mean age of 22.5 years, in 36.2% of the cases diagnosed at 
pediatric age. In 68% of cases, the diagnosis was made in the context of 
“classic” clinical presentations, 17% in the context of “non-classical” pre-
sentations and 15% in latent phase. In most patients (79.2%) the diagnosis 
was initially suspected by serology. At endoscopy 11.8% of the patients 
did not present macroscopic features suggestive of celiac disease, and a 
histological grade of Marsh 3a-c was observed in 72.5% of all cases. A 
minority of patients (7%) had concomitant diagnosis of other autoimmune 
diseases. 
Four of the patients developed complications of the disease, including re-
fractory disease (n = 1), ulcerative jejunitis (n = 1), and osteoporosis (n = 
2). Eight patients (11.6%) underwent reassessment endoscopy within 24 
months of starting the diet, and the remainder after 24 months. The histo-
logical findings were normalized in 37.7% (n = 26), which was associated 
with the presence of lower Marsh score values at diagnosis  (p = 0.014) and 
the presence of other autoimmune conditions (p = 0.046). 
A histological improvement over baseline was observed in 55 patients 
(79.7%), of two or more grades in 37 cases, which was related to the initial 
transferrin saturation (p = 0.027), and with higher values  of the Marsh 
score at diagnosis (p = 0.005).
conclusion: Even under a gluten-free diet, normalization of the histologi-
cal findings of celiac disease is difficult to obtain and appears to be inde-
pendent of most clinical and serological findings at diagnosis. Patients 
with less severe histologic levels at diagnosis reach remission more easily, 
but only represent the minority of the population.
disclosure: Nothing to disclose 
P0657 hIsTOLOgIcaL, IMMunOhIsTOcheMIcaL and rna 
gene exPressIOn resPOnses In cOeLIac dIsease PaTIenTs 
chaLLenged WITh gLuTen
Taavela J.1,2, Viiri K.2, Popp A.2,3, Oittinen M.2, Dotsenko V.2, Peräaho M.1, 
Staff S.4,5, Sarin J.5,6, Leon F.7, Mäki M.2, Isola J.5,6
1Central Finland Central Hospital, Jyväskylä, Finland, 2Tampere Centre for 
Child Health Research, Tampere, Finland, 3University of Medicine and 
Pharmacy ”Carol Davila” and National Institute for Mother and Child Health 
”Alessandrescu-Rusescu”, Bucharest, Romania, 4Department of Gynaecology 
and Obstetrics, Tampere University Hospital, Tampere, Finland, 5Laboratory 
of Cancer Biology, Faculty of Medicine and Health Technology, Tampere, 
Finland, 6Jilab Inc, Tampere, Finland, 7Celimmune LLC, Bethesda, Maryland, 
United States
contact e-Mail address: juha.taavela@tuni.fi
Introduction: There is an unmet need for novel treatments, such as drugs 
or vaccines, adjunctive to or replacing a burdensome life-long gluten-free 
diet for coeliac disease. Hence, several phase 1 and 2 clinical trials are 
in progress to investigate whether novel treatment attenuates or prevents 
gluten-induced mucosal injury in coeliac disease. The gold standard for 
successful treatment is a healed small intestinal mucosa, and therefore, 
the outcome measures in proof-of-concept studies should be based on 
evaluation of small intestine biopsies.
aims & Methods: We evaluated quantitative morphometric (both archi-
tectural and inflammatory), immunohistochemical and mRNA gene ex-
pression in coeliac disease patients challenged with gluten using PAXgene 
fixed paraffin-embedded specimens.
Fifteen coeliac disease patients were challenged with 4 grams of gluten 
per day for 10 weeks and twenty-eight non-coeliac patients served as dis-
ease controls.
results: Digitally measured duodenal biopsies showed significant gluten-
induced morphological (villus height: crypt depth ratio) and inflammatory 
changes (intraepithelial CD3+ T-lymphocyte and lamina propria CD138+ 
plasma cell densities). Stainings for γδ T cells and IgA deposits, where 
previously frozen samples have been needed, were successful in PAXgene 
fixed paraffin-embedded samples. Molecular morphometry, using the 
mRNA expression ratio of villous epithelium-specific gene APOA4 to crypt 
proliferation gene Ki67, showed a similar significant distinction between 
paired baseline and post-gluten challenge biopsies as quantitative histo-
morphometry.
conclusion: Rigorous histologic and molecular markers suitable for gluten 
challenge studies can be obtained from a single paraffin-embedded bi-
opsy specimen. In addition, molecular morphometry seems to be a prom-
ising new tool to be further developed.
disclosure: Nothing to disclose 
P0658 cOeLIac dIsease - OLder PaTIenTs have The MOsT 
exTensIve sMaLL BOWeL InvOLveMenT On caPsuLe endOscOPy
Chetcuti Zammit S.1, Sanders D.S.2, Sidhu R.3
1Royal Hallamshire Hospital, Gastroenterology, Sheffield, United Kingdom, 
2Royal Hallamshire Hospital - NHS Trust, Royal Hallamshire Hospital; 
Sheffield/GB, NHS Trust, Sheffield, United Kingdom, 3Sheffield Teaching 
Hospitals, Sheffield, United Kingdom
contact e-Mail address: stf_che@yahoo.com
Introduction: The relationship between symptomatology, serology and find-
ings on small bowel capsule endoscopy (SBCE) in patients with coeliac dis-
ease (CD) remains unclear. Clarifying such associations will help determine 
if symptoms and serology can predict severity and extent of disease on SBCE.
aims & Methods: Patients with newly diagnosed CD (villous atrophy on 
duodenal histology and positive CD serology) were recruited. Patients un-
derwent a SBCE at the time of diagnosis. Information on SBCE was record-
ed. Signs and symptoms at presentation, serological markers, histological 
classification of disease in the duodenum were noted.
results: Sixty patients with newly diagnosed CD (mean age 44.9 years 
SD±17.4, 17 - 76) were included in this study. Older patients (p=0.025) and 
patients presenting with iron deficiency anaemia had more extensive small 
bowel (SB) involvement (p=0.026). Patients presenting with weight loss 
were more likely to have SB involvement beyond the duodenum (p=0.027). 
Patients presenting with iron deficiency anaemia (p=0.038) and weight 
loss (p=0.009) were significantly older at diagnosis. Serum albumin was 
lower in those patients diagnosed later on in life (p=0.007). 
There was no significant association between anti-tissue transglutaminase 
antibody (p=0.396) and extent of affected SB mucosa. 
Patients with more severe Marsh classification of disease on histology from 
the duodenal bulb had more extensive SB involvement (p=0.017).
conclusion: This is the largest study on newly diagnosed CD and SBCE. 
Older patients are likely to have more extensive disease on SBCE at di-
agnosis. Symptoms and serology had no impact on the findings on SBCE 
apart from weight loss and iron deficiency anaemia.
disclosure: Nothing to disclose 
P0659 caPsuLe endOscOPy In esTaBLIshed cOeLIac dIsease: 
cLInIcaL syMPTOMs, exTenT Of dIsease and sMaLL BOWeL 
TransIT
Chetcuti Zammit S.1, Kurien M.1, Sanders D.S.2, Sidhu R.3
1Royal Hallamshire Hospital, Gastroenterology, Sheffield, United Kingdom, 
2Royal Hallamshire Hospital - NHS Trust, Sheffield, United Kingdom, 
3Sheffield Teaching Hospitals, Sheffield, United Kingdom
contact e-Mail address: stf_che@yahoo.com
Introduction: Patients with established coeliac disease (CD) can present 
with recurrent symptoms requiring further investigations including small 
bowel capsule endoscopy (SBCE). There is paucity of data on the relation-
ship between the extent, severity of disease and small bowel transit (SBT) 
on capsule endoscopy in relation to histology, clinical and serological pa-
rameters.
aims & Methods: Hundred patients with CD and 200 controls were re-
cruited. All of these patients underwent a SBCE because of symptoms, ab-
normal serology or a suspicion of complications. Extent of disease SBCE 
and SBT were studied in relation to symptomatology, serology and severity 
of histology from the duodenum.
results: In patients with CD, 30 (30.0%) had a normal SBCE, 56 patients 
(56.0%) had proximal small bowel (SB) involvement, 7 patients (7.0%) 
had proximal and mid SB involvement and 7 patients (7.0%) had diffuse 
disease. SBT was shortest in controls (275.0; range 60.0 - 981.0 minutes), 
followed by those with established CD but a normal SBCE (260.0; range 
104.0 - 467.0 minutes) and those with established CD and macroscopic 
evidence of CD on SBCE (286.0; range 60.0 - 981.0 minutes) (p=0.0001). 
Age at time of SBCE (p=0.006), serum albumin (p=0.004) and haemo-
globin (p=0.0001), Marsh score of histology from the duodenal bulb (D1) 
451Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
P0661 assessIng gLuTen free dIeT adherence usIng cdaT 
and BIagI quesTIOnnaIres In PaTIenTs WITh cOeLIac dIsease
Baggus E., Rej A., Lau M., Zammit S., Mooney P., Marks L.J., Rees M., 
White W., Hadjivassiliou M., Sanders D.S.
University of Sheffield, Academic Unit of Gastroenterology, Sheffield, United 
Kingdom
contact e-Mail address: emrbaggus1@sheffield.ac.uk
Introduction: The gold standard currently for assessing adherence in indi-
viduals with coeliac disease (CD) is via duodenal biopsies, which is invasive 
and costly. There is currently no reliable non-invasive surrogate marker to 
detect gluten ingestion and persisting villous atrophy in CD patients.
aims & Methods: In view of this, our aim was to assess the utility of the 
CDAT and Biagi questionnaires for non-invasive assessment of gluten free 
adherence. Patients with an established diagnosis of coeliac disease, re-
ferred for further evaluation of dietary adherence and disease remission 
were assessed between January 2016 to December 2018. Patients were pro-
spectively recruited, and completed CDAT and Biagi questionnaires at their 
endoscopy appointment, with at least 4 duodenal biopsies taken from D2 
in addition to at least one biopsy from the duodenal bulb. The presence 
(Marsh 3a or above) or absence (Marsh 0-II) of villous atrophy was used 
to determine the sensitivities of the questionnaires in detecting persisting 
villous atrophy.
results: A total of 151 patients were recruited, 101 females (66.9%), median 
age 55.0 years, median duration of GFD of 72.0 months. The sensitivities of 
CDAT, Biagi, and combined CDAT & Biagi were 52.0% (95% CI 37.6-66.1), 
22.4% (12.2-37.0), 61.2% (46.2-74.8) respectively, compared to 30.6% (18.7-
45.6) and 34.3% (26.7-42.7) for IgA-TTG and EMA. Specificity of CDAT, Biagi 
and combined CDAT & Biagi were 69.8% (60.9-77.5), 93.1% (85.6-97.0), 
and 69.3% (60.5-77.2) respectively, compared to 91.6% (83.6-96.0) and 
92.5% (84.8-96.7) for IgA-TTG and EMA.
conclusion: The sensitivity of the CDAT questionnaire was not superior 
to IgA-TTG for predicting villous atrophy in patients with coeliac disease. 
However, the use of a combination of both Biagi and CDAT had a greater 
sensitivity than IgA-TTG and IgA-EMA (p< 0.05), but lower specificity (p< 
0.05). Duodenal biopsy remains the gold standard, although these scores 
remain useful tools in the assessment of dietary adherence.
disclosure: Nothing to disclose 
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Introduction: Several studies have shown that a substantial proportion of 
adult CD patients on a gluten-free diet (GFD) exhibit persistent villous atro-
phy (VA) on follow-up duodenal biopsy, suggesting that the most frequent 
cause was poor adherence to the GFD.
aims & Methods: To evaluate VA persistence after 2 years on a GFD in adult 
CD patients with strict control of diet adherence.
Symptomatic adult CD patients were prospectively included at diagnosis 
and started on a GFD. CD diagnosis was done according to established 
guidelines. A 2-year follow-up was carried out with clinical visits and di-
(p=0.0001) and the second part of the duodenum (p=0.0001), the presence 
of RCD features on histology correlated significantly with the percentage 
of affected mucosa on SBCE on univariate analysis. On multiple regres-
sion analysis, serum albumin level (p=0.036) and Marsh score of histology 
taken from the duodenal bulb (D1) (p=0.019), serum vitamin B12 (p=0.001) 
and folic acid levels (p=0.008) were statistically significant.
conclusion: Patients with CD have a persistently prolonged SB transit even 
if there is no evidence of disease on SBCE. This is the first study showing 
correlation between extent of disease and severity of duodenal histology 
according to the Marsh classification.
disclosure: Nothing to disclose 
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Introduction: Non-responsive coeliac disease (NRCD) is defined by persist-
ing symptoms or laboratory abnormalities in patients with coeliac disease 
(CD), and affects up to 30% of CD patients on a gluten-free diet (GFD). 
Causes of NRCD are heterogeneous, with refractory CD (RCD) being associ-
ated with poor prognosis.
aims & Methods: The aims of this study were to identify the aetiologies for 
persisting symptoms in patients with NRCD referred to a national UK centre 
for CD, and to assess and compare mortality in each group. Data on all CD 
patients, including those with persisting symptoms and tertiary referrals, 
was collected prospectively from 1998-2018. Patients were systematically 
investigated to establish the aetiology of their continued symptoms. They 
were also referred to a specialist coeliac dietitian to identify any lapses 
in GFD adherence or gluten cross-contamination. A repeat duodenal bi-
opsy was performed and compared to previous biopsies where possible 
to check for histological remission. Colonoscopy, lactose hydrogen breath 
test, glucose hydrogen breath test, SeHCAT scan, CLO testing, faecal elas-
tase, faecal calprotectin, stool culture, immunohistochemistry and γ-TCR 
clonality were performed where appropriate to establish a final diagnosis. 
Data on follow-up and outcomes was then collected for each group and 
survival analyses performed.
results: A total of 2,356 patients with suspected CD were seen in this time 
period (121 were tertiary referrals). Of these, 157 were excluded from analy-
sis due to unconfirmed diagnosis. Of the remaining 2,199 patients with 
confirmed CD, 2,123 had both villous atrophy and positive IgA-EMA/TTG, 
and 76 had seronegative CD. Of the 2,199 patients with confirmed CD (67% 
female, mean age at diagnosis 42.8 ± 18.5), 292 (13.3%) had persisting 
symptoms. The leading causes for persisting symptoms in patients without 
evidence of RCD (73% female, mean age at diagnosis 35.7 ± 19.2) were: 
gluten contamination (24%), functional/irritable bowel syndrome (20%), 
pancreatic exocrine insufficiency (7%), reflux dysmotility (5%), and micro-
scopic colitis (5%). Of a total of 74 patients who were identified with RCD 
(26% of all NRCD), 56 were diagnosed with RCD I (71% female, mean age 
at CD diagnosis 41.8 ± 19.0) and 18 RCD II (33% female, mean age at CD 
diagnosis 55.4 ± 13.3). Eighteen patients (6% of all NRCD) had developed 
further complications consisting of enteropathy associated T-cell lympho-
ma (EATL) (4), B cell lymphoma (4), ulcerative jejunitis (3), small bowel 
adenocarcinoma (3), oesophageal adenocarcinoma (2), cutaneous T cell 
lymphoma (1), and neuroendocrine carcinoma of small bowel (1). Higher 
age at diagnosis of CD was a predictor for having RCD in patients with 
persisting symptoms (p< 0.001). Patients diagnosed with RCD II were sig-
nificantly older at CD diagnosis (p=0.003), had a shorter delay between CD 
and RCD diagnosis (p=0.002) and were more likely to be male (p=0.006) 
compared to those diagnosed with RCD I. After a median follow up of 40.5 
months (IQR 21.8-73.3), mortality was 7% in the RCD I group, compared 
to 39% in the RCD II group (p=0.019), with a five-year survival of 68% in 
patients with RCD II.
conclusion: This is the largest UK study of NRCD and RCD. The contempo-
rary mortality data in RCD II remains poor. Management of this group is 
challenging, and more evidence is required. Patients with suspected RCD 
should be referred to the National Centre for consideration of novel thera-
pies such as IL-15 and Stem Cell Transplant.
disclosure: Nothing to disclose 
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etary surveillance at 6 weeks and after every 6 months. Dietary adherence 
was assessed using the validated CD adherence test questionnaire (Leffler 
2009). In each visit clinical status, serum anti-tTG2 and faecal gluten im-
munogenic peptides (f-GIP) were checked. For f-GIP, two faecal samples 
in different days of the week prior each visit were obtained and stored 
at -80ºC until processing. The concentration of GIP in stools was anal-
ysed by ELISA using the iVYLISA GIP stool (Biomedal S.L., Seville, Spain), 
considering positive values >80 ng GIP per g faeces. Duodenal follow-up 
biopsy was performed at 2 years. Biopsies were blindly evaluated by two 
expert pathologists, in case of disagreement, a consensus was achieved. 
Mucosal recovery was defined as the absence of VA. A sample size of 90 
patients was calculated to estimate a persistent VA rate of 40%, loss of 
follow-up of 15%, with an accuracy of 10%. We examined age, gender, 
educational attainment, marital status, employment situation, clinical 
and serological remission, and positive f-GIP to determine predictors of 
persistent VA.
results: 95 patients were included, three were excluded for not presenting 
VA and one for age < 16 years. Fifteen of 91 (16%) did not ended the follow-
up. Therefore, 76 patients finalized the study (36.5±1.6 years, 73% women). 
Follow-up duodenal biopsy showed persistent VA in 40 patients (53%, 95% 
CI, 41-63%) (Marsh 3a, 75% and Marsh 3b-c, 25%). Of the 40 patients, 
72.5% were asymptomatic and 75% had negative serology. There were no 
differences in the f-GIP+ rate among patients with persistent VA and those 
with recovery, which in general indicated weak gluten transgressions. On 
multivariate analysis only older age was an independent predictive risk fac-
tor of persistent VA (32% for 16-30 yrs; 60% for >30 yrs; p=0.016).
conclusion: Persistent VA rate after 2 years on a GFD was high in adult 
patients with CD, despite a strict control of diet adherence and that there 
were no differences in f-GIP values between persistent VA and recovery. 
There was an effect of increasing age on the frequency of persistent VA that 
was not related to dietary noncompliance and social differences.
disclosure: Nothing to disclose 
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Introduction: Seronegative villous atrophy (SNVA) on duodenal histology 
can be secondary to coeliac disease (CD) or other causes such as medica-
tions or infections. The introduction of small bowel capsule endoscopy (CE) 
has enabled us to study this condition further and to establish whether 
these patients develop complications.
aims & Methods: The CEs of patients (128) with SNVA on duodenal histol-
ogy were retrospectively analysed for features of CD (fissuring, scalloping, 
mosaic pattern, nodularity, villous atrophy, ulcers). Extent of affected SB 
mucosa was determined. 3 categories of patients were identified: group 
1: no identifiable cause for SNVA, group 2: histological response to gluten 
free diet (GFD), group 3: alternative cause for SNVA.
results: Overall, 49 (38%) patients had a positive CE. Patients with more 
severe histological pattern on duodenal biopsies were more likely to have 
a positive CE (partial villous atrophy (PVA) 21, 26%, subtotal villous atrophy 
(SVA) 12, 60% total villous atrophy (TVA) 13, 59%, p=0.001). More extensive 
SB disease corresponded to a more severe histological pattern (PVA 1%, 
SVA 15%, TVA 17%, p=0.001).
Patients with alternative causes for SNVA had the least extensive SB in-
volvement (group 1: 9.13 (+/-25.2), group 2: 9.77 (+/-23.5), group 3: 
0.025(+/-0.13)% p=0.038). Most patients had proximal SB disease (40, 
82%).
These patients were followed up for up for a median of 5 years (1 - 18 
years). 
Group 1: 43% (55) had no identifiable cause for SNVA. 40% (22) of these 
patients had a positive CE. 71% (39) had spontaneous resolution of SNVA 
without any intervention. The other patients received a trial of GFD to 
which none responded. Further treatment included steroids +/- immu-
nosuppressants in 10 patients. CE at diagnosis was positive in 8 (20.5%) 
of those with spontaneous resolution of SNVA, 14 (87.5%) patients with 
persistent SNVA (p=0.0001). 
Group 2: 27% (35) patients had a histological response to a GFD. 5 of these 
patients (14%) were IgA deficient. 49% (17) patients had a positive CE. 7 
patients eventually developed complications. All of them had a positive 
CE at the time of diagnosis (p=0.022). They also had more extensive SB 
disease than those patients who did not develop complications (50% vs 
1% p=0.002). 3 patients developed refractory coeliac disease (RCD) I, 2 
developed RCD 2. 2 patients developed RCD 2 and ulcerative jejunoileitis. 
Group 3: 37 patients (29%) had alternative causes for SNVA. 10 (27%) pa-
tients had positive CEs (2, 60% - NSAIDs, 2, 15% - H pylori positive, 4, 
67% - Giardia, 1, 33%) - angiotensin receptor blocker, 1 - Crohn’s disease, 
p=0.125).
conclusion: CE can be useful in patients with an unknown cause for SNVA 
as more extensive disease on CE at diagnosis can predict those with per-
sistent SNVA. In SNVA-CD, more extensive disease on CE at diagnosis can 
be a predictor of development of complications. These patients need to be 
monitored more closely.
disclosure: Nothing to disclose 
P0664 Is There a cOrreLaTIOn BeTWeen duOdenaL 
hIsTOLOgy and dIsease severITy On caPsuLe endOscOPy 
In PaTIenTs WITh vILLOus aTrOPhy?
Chetcuti Zammit S.1, McAlindon M.1, Sanders D.S.2, Sidhu R.3
1Royal Hallamshire Hospital, Gastroenterology, Sheffield, United Kingdom, 
2Royal Hallamshire Hospital - NHS Trust, Sheffield, United Kingdom, 
3Sheffield Teaching Hospitals, Gastroenterology, Sheffield, United Kingdom
contact e-Mail address: stf_che@yahoo.com
Introduction: There is a lack of uniformity of reporting on features of co-
eliac disease (CD) on small bowel capsule endoscopy (SBCE). This makes 
determining extent of disease and comparison of severity of disease be-
tween SBCEs challenging even for experts in the field.
aims & Methods: The de-identified SBCEs of 300 patients with CD (78; 
26%), antibody negative villous atrophy (18, 6%) and control patients 
(204; 68%) with normal duodenal histology were reviewed by 2 expert 
SBCE reviewers. All patients had duodenal histology taken 2 weeks from 
undertaking SBCE. The degree of agreement between identifying CD fea-
tures (fissuring, villous atrophy, scalloping, mosaicism, nodularity, ulcers) 
and determining extent of disease was then assessed. Multiple regression 
analysis was carried out to determine the correlation of CD features with 
extent of abnormal small bowel (SB). Ranks were then used to optimise 
the odds ratio obtained for each factor using an inbuilt function in SPSS. 
This resulted in the formulation of a score for each factor in each SB tertile.
results: The overall kappa co-efficient for all CD features for reviewers 1 
and 2 was 0.67. The intraclass correlation co-efficient for percentage extent 
of affected SB mucosa was 0.97 (p=0.0001). Percentage of extent of af-
fected SB mucosa correlated with overall severity of disease as classified 
by each reviewer (p=0.0001) and with histology from the second part of 
the duodenum (p=0.0001). The multivariate regression analysis resulted 
in statistically significant odds ratios of CD features correlating with extent 
of affected SB mucosa for both reviewers 1 and 2. These were then utilized 
to generate a score for features of CD in the SB. The overall scores for each 
patient correlated with extent of affected SB mucosa for reviewer 1 (Pear-
son correlation co-efficient 0.662, p=0.001) and 2 (Pearson correlation co-
efficient 0.838, p=0.001). The median overall scores of patients increased 
significantly according to the independent classification by reviewers: mild 
(34, 0-254), moderate (50, 27-133), severe (96, 69-128) (p=0.0001).
conclusion: The good correlation of CD scores between expert reviewers 
confirms the validity of CD features on SBCE. An objective score of CD fea-
tures in the SB might be useful in the follow up of patients with CD and 
serology negative villous atrophy.
disclosure: Nothing to disclose 
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Introduction: Breath tests are extremely popular in clinical practice to de-
termine carbohydrate malabsorption. Guidelines recommend assessment 
of symptoms which are more relevant for clinical management (1) to diag-
nose carbohydrate intolerance. We have recently developed a test-specific 
perception questionnaire for the assessment of carbohydrate induced gas-
trointestinal symptoms, the adult Carbohydrate Perception Questionnaire 
(aCPQ).
aims & Methods: Our aim was to validate the aCPQ for the assessment of 
carbohydrate related perception by internal-, cross- and external valida-
tion.
The aCPQ is a VAS-based questionnaire for the assessment of the presence 
and the severity of five complaints before and during the breath test: pain, 
nausea, meteorism, flatulence, diarrhoea. Criteria of internal validity were 
determined after the implementation of the questionnaire during lactose 
and fructose breath tests in 342 subjects (‘Vienna-original’ group). Cor-
relation between the questionnaire and a medical interview (n=338) was 
determined, interviews were performed by a physician who was blinded 
as to the results of the questionnaire. Cross validation was performed in 
a follow-up patient group in the same institution (‘Vienna-cross’ group, 
n=182), external validity was assessed in a group from another university 
center (‘Graz-external’ group, n=156). NS=not significant
results: The scale has good face validity as it is simple, easy to under-
stand and brief. The content validity ratio according to Lawshe equales 1. 
Intraclass correlation coefficients for test-retest reliability (n=159; 30 min-
utes interval) demonstrate good repeatability (p< 0.001), Cohen’s d as a 
measure of effect size is small (i.e. < 0.40; 0.19 or smaller for the five 
symptoms). Cronbach’s alpha is 0.85, indicating good internal consistency. 
Convergent validity and discriminant validity is supported according to the 
multitrait-multimethod-matrix method. Moreover, the results given by the 
questionnaire highly correlate with the result of the medical interview (p< 
0.001; Fisher exact test). Responsiveness to change has been verified dur-
ing breath tests with medium to large effect sizes (p< 0.05). 146 patients 
were diagnosed with malabsorption, 179 patients with intolerance, among 
them 97 patients having both malabsorption and intolerance. The ‘Vienna-
cross’ group included significantly more fructose tests (54%; p=0.02) and 
was significantly younger (43±1.3 years; p=0.05) than the ‘Vienna-original’ 
group. The percentage of patients who was diagnosed with intolerance 
AND malabsorption, only intolerance or only malabsorption was compa-
rable in both ‘Vienna’ groups before and after correcting for age, gender 
and carbohydrate tested (NS). The ‘Graz-external’ group was significantly 
younger (40±1.5 years; p< 0.001) than the ‘Vienna-original’ group. The 
percentage of patients who was diagnosed with intolerance AND malab-
sorption, only intolerance or only malabsorption was comparable in ‘Graz-
external’ and ‘Vienna-original’ before and after correcting for age, gender 
and carbohydrate tested (NS).
conclusion: The adult Carbohydrate Perception Questionnaire (aCPQ) is 
a simple, test-specific questionnaire. It is a valid instrument with excel-
lent psychometric properties and generalizability for the assessment of 
gastrointestinal symptoms after carbohydrate ingestion. The aCPQ should 
replace non-validated symptom assessment during carbohydrate breath 
tests, e.g. by interview, use of non-validated questionnaires or generic, 
non-test-specific instruments and allows a uniform diagnosis of carbohy-
drate intolerance.
references: Hammer et al. Dig Dis Sci 2018:1270
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Introduction: Fructose intolerance (FI), i.e. symptoms following ingestion 
of fructose, is common in patients with Functional Gastrointestinal Disor-
ders (FGID). Malabsorption of fructose resulting in intestinal distension 
and fermentation is generally assumed to be the underlying mechanism. 
Malabsorption can be indirectly characterized by measurement of intesti-
nal gases exhaled in breath (e.g. hydrogen, methane), or by quantifying 
the systemically absorbed fructose and its metabolites. We have previously 
shown that FI is not characterised by changes in expression of the main 
intestinal fructose transport proteins, GLUT5 and GLUT2 (1). Consequently, 
the cause of malabsorption in FI remains unclear.
aims & Methods: We aimed to investigate malabsorption as a cause for 
symptoms in FGID patients following ingestion of fructose. Plasma con-
centrations of fructose and fructose metabolites, short-chain fatty acids 
(SCFA), and the gaseous fermentation products hydrogen and methane 
were used as measures of fructose absorption. Thirty-one male or female 
patients with FGID (Rome III) ingested either 35g fructose or water in a 
randomised, blinded, crossover study in Switzerland (2). Plasma fructose 
and its metabolites (glucose, alanine, lactate, glycerate) and SCFAs (ac-
etate, propionate, butyrate, isobutyrate, valerate, isovalerate, and caproic 
acid) were quantified via liquid chromatography tandem mass spectrom-
etry from blood samples drawn at 0, 0.5, 1 and 2 hours post-dosing. Breath 
hydrogen and methane concentrations were measured and GI symptoms 
recorded at the same times. The aggregate GI symptom score, the sum 
of 8 GI symptoms graded by intensity as 0=none, 1=mild, 2=intense, was 
used to classify patients regarding FI (defined as increase of >2, maximum 
score of 16). Analyses were performed using areas‐under‐the‐curve of the 
variables for the first 2 hours post-dosing (AUC
0-2h
).
results: AUC
0-2h
 of fructose and metabolite plasma concentrations were 
similar in the 15 patients with and the 15 patients without FI (p>0.05), 
and did not correlate significantly with AUC
0-2h
 of aggregate GI symptom 
scores (r=-0.007). However, the AUC
0-2h
 of symptoms correlated positively 
with AUC
0-2h
 of hydrogen (r=0.73) and methane (r=0.62) concentrations. 
Patients with FI produced significantly more hydrogen and methane than 
fructose-tolerant patients (both p=0.04). The AUC
0-2h
 of the concentration 
of the SCFA valerate correlated positively with breath hydrogen (r=0.34) 
and methane (r=0.45), but negatively with plasma fructose (r=-0.41) con-
centrations.
auc of parameters fI n=15 non-fI n=15 p-values
Fructose (µM·h) 573 ± 134 547 ± 91 0.53
Hydrogen (ppm·h) 58.5 ± 49.2 26.6 ± 22.5 0.03
Methane (ppm·h) 20.1 ± 10.6 12.9 ± 6.9 0.04
Aggregate GI symptoms (score·h) 8.57 ± 4.88 0.45 ± 0.54 <0.0001
[Study parameters in fructose-intolerant (FI) and non-FI subjects 
(means±SD, independent t-test)]
conclusion: In patients with FGID, fructose intolerance is not correlated 
with decreased post-ingestion plasma fructose and its metabolites as in-
dicators of malabsorption, consistent with our findings on intestinal trans-
porter expression (1). Instead, FI appears to be associated with changes 
in the intestinal microbiome metabolism of fructose, arising from altered 
composition or activity of the intestinal microbiome in these patients.
references: 1. Wilder-Smith C et al. United European Gastroenter-
ol J. 2014;2:14-21 2. Wilder-Smith C et al. Neurogastroenterol Motil. 
2019;31:e13497
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Introduction: The morphological damages of intestinal Villi’s/ Crypt archi-
tecture by the intraepithelial lymphocytic infiltration (IEL) in non-coeliac 
gluten sensitivity (NCGS) have been much less quantified compared to co-
eliac disease (CD).
aims & Methods: 
aim: Morphological changes including IEL infiltration in intestinal villi’s 
and Crypt architecture were measured in gluten induced enteropathies 
aiming to differentiate between NCGS, CD and controls. 
Method: The study was designed at the International Meeting on Diges-
tive Pathology, Bucharest 2017. Investigators from 22 centres, 9 countries 
of 4 continents, recruited CD patients with Marsh 0-II histology (n=261), 
NCGS (n=175), and 262 controls and used one agreed protocol to analyse 
the small bowel mucosa in well-oriented duodenal biopsies. Demographic 
and serological data were also collected.
results: Participant countries consisted of Australia (20), Finland (20), 
India (25), Iran (37), Italy (239), Romania (10), Turkey (30), UK (166) and 
USA (151). The villus height was significantly shorter in NCGS compared to 
control (p< 0.001), the difference was significant even when the analysis 
limited to Marsh 0. Conversely, the villus height of NCGS was significantly 
longer than that in CD [600 (IQR: 400-705) vs 427 (IQR: 348-569), p< 0.001], 
the result was unchanged when analysis was limited to Marsh I-II [500 
(IQR:410-629) vs 423 (IQR:349-574, p=0.009). The median Crypt depth was 
significantly increased in NCGS group compared to controls [296 (IQR: 205 
-300) vs 222 (IQR: 158-294), p< 0.001) and it was similar to CD group [269 
(IQR: 182-322), p=0.822]. Interestingly NCGS with Marsh 0, still had signifi-
cantly increased crypts depth compared to controls (p< 0.001). The crypt 
depth value was similar in Marsh I-II for both NCGS and CD groups [273 
(IQR: 180-296) vs 269 (IQR: 180-324), p=0.822)]. In addition, the ratio of vil-
lus height to crypt depth was significantly lower in NCGS compared to con-
trols (p< 0.001), the difference was significant even when the analysis was 
limited to Marsh 0 (p< 0.001). In contrast, the ratio of villus height /Crypt 
Depth in NCGS was significantly higher than that in CD (p=0.009), the re-
sult was still significant when analysis was limited to Marsh I-II (p=0.046). 
The median IEL density was significantly higher 23/100EC in NCGS group 
compared to 14 in controls (p< 0.001) and lower than that in CD group 
40/100EC (p< 0.001). When comparison was restricted to Marsh 0, NCGS 
still had significantly higher IEL density than controls (p< 0.001). Compar-
ing IEL densities in Marsh I/II NGGS to Marsh I/II CD groups showed similar 
values (p=0.055). When the analyses were restricted to Marsh 0, the IEL 
density cut off scored 79% sensitivity and 55% specificity at 14/100EC for 
NCGS with 0.71 (95% CI: 0.64- 0.77, p< 0.001) area under curve. Similar 
analysis limited to Marsh I-II showed a cut-off of 25/100EC to diagnose CD 
and NCGS (together) from controls, with 95% sensitivity, 86% specificity 
and 0.94 (95% CI: 0.93-0.96, p< 0.001) area under the curve.
conclusion: Morphometric assessment of intestinal mucosa of NCGS pa-
tients showed a range of subtle abnormalities even when the histology is 
reported as Marsh 0 or normal. Comparing Marsh 0 of NCGS with controls, 
revealed the former have significantly higher IEL density, increased crypt 
depth, shorter villous height and decreased villous/crypt ratio. This global 
morphometric assessment brings novel insight into the Marsh 0 histol-
ogy spectrum that can improve the NCGS diagnostic yield as an additional 
biomarker.
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Introduction: Most of the cases of chronic diarrhoea after excluding organic 
disorders are labelled as functional diarrhoea or irritable bowel syndrome 
(IBS). Bile acid malabsorption (BAM) is a frequently underinvestigated 
cause of chronic diarrhoea in adult population. In Europe the diagnosis is 
commonly established by the Selenium homocholic acid taurine test scan 
(SeHCAT). BAM is defined as mild (10-15% retention), moderate (5-10%), 
or severe (< 5%).
aims & Methods: We aimed to evaluate and identify risk factors associated 
to MAB type 2. 
Methods: We retrospectively reviewed all patients who had SeHCAT scan 
performed between June 2014 and October 2018 in a University tertiary 
referral Hospital. We excluded all patients who had known risk factors 
for BAM. The diagnosis of BAM was established when SeHCAT retention 
was inferior to 15%. We collected the following variables: demographic 
characteristics, IBS-D Rome III criteria, duration of diarrhoea (months), 
stool culture, parasitic investigation on stool specimens, H. pylori infec-
tion, drugs use, and HLA-DQ2/DQ8 haplotype. Univariate and multivariate 
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aims & Methods: Consecutive patients who presented with overt OGIB at 
a tertiary centre over a 5 year period underwent either Capsocam SBCE 
or Pillcam SB3 SBCE. All had negative gastroscopies and colonoscopies / 
CT colonographies. SBCEs were reviewed by 2 experts. Findings in the 2 
groups were compared.
results: 94 patients (39.4% Capsocam; 60.6% Pillcam; 57.4% males; mean 
age 64.3±18.0 years) were included. Both groups were age (p=0.174) and 
gender (p=0.137) matched. Severity of anaemia (p=0.053) and duration of 
anaemia (p=0.264) were similar in both groups. 
There was no difference between groups in incomplete SBCEs (p=0.151). 
Diagnostic yield (DY) was comparable in both groups but Pillcam had a 
higher DY than Capsocam in the stomach (table 1).
Capsocam identified blood (2, 5.4%), erosions (1, 2.7%) and ulcers (1, 2.7%) 
in the stomach. Pillcam showed blood (4, 5.4%), erosions (11, 19.3%), ul-
cers (2, 3.5%), varices (1, 1.8%) and GAVE (1, 1.8%) in the stomach. 
Patients who underwent Capsocam examination had the following find-
ings in the SB: 1 (2.7%) ulcer, 7 (18.9%) angioectasia, 8 (21.6%) blood, 2 
(5.4%) erosions, 1 (2.7%) tumour, 1 (2.7%) diverticulum. Patients who un-
derwent Pillcam had these findings in the SB - 10 (17.5%) ulcers, 11 (19.2%) 
angioectasia, 7 (12.3%) blood, 19 (33.3%) erosions, 1 (1.75%) tumour, 2 
(3.51%) diverticulum, 2 (3.51%) phlebactesia, 4 (7.02%) polyps, 1 (1.75%) 
haemangioma, 1 (1.75%) intussusception. 
  capsocam n(%) Pillcam n(%) significance (p)
Gastric DY 3 (8.1) 15 (26.3) 0.033
Small bowel (SB) DY 17 (45.9) 25 (43.9) 0.842
Colon DY 2 (5.4) 3 (5.3) 0.976
[Table 1: DY of panoramic and axial SBCE for patients with overt OGIB;]
conclusion: SB DY was comparable between Capsocam and Pillcam groups 
in patients with overt OGIB but Pillcam offered a better gastric DY than 
Capsocam. This might be of relevance as a considerable number of lesions 
are missed in the upper GI tract in patients undergoing gastroscopy.
references: 1. Pioche M, Vanbiervliet G, Jacob P, Duburque C, Gincul R, 
Filoche B, Daudet J, Filippi J, Saurin JC, (SFED) FSoDE: Prospective ran-
domized comparison between axial- and lateral-viewing capsule endos-
copy systems in patients with obscure digestive bleeding. Endoscopy 2014, 
46:479-484. 2. Zwinger LL, Siegmund B, Stroux A, Adler A, Veltzke-Schliek-
er W, Wentrup R, Jürgensen C, Wiedenmann B, Wiedbrauck F, Hollerbach 
S, et al.: CapsoCam SV-1 Versus PillCam SB 3 in the Detection of Obscure 
Gastrointestinal Bleeding: Results of a Prospective Randomized Compara-
tive Multicenter Study. J Clin Gastroenterol 2018.
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Introduction: Capsule endoscopy has been widely accepted as a tool to 
investigate chronic occult blood loss from the gastrointestinal tract as a 
cause of anaemia.
aims & Methods: The aim of the study is to investigate the long term yield 
of capsule endoscopy (CE) for patients with occult gastrointestinal bleeding 
(OGIB) over 10 years in a tertiary referral hospital. 
A retrospective analysis of a prospectively collected database on patients 
with OGIB who underwent CE to investigate persistent anemia in a tertiary 
referral center during 2007-2017 was performed. Medical records were 
reviewed. CE findings were classified as significant, suspicious/equivocal 
and negative. Sites of pathology were categorized into proximal, mid, dis-
tal or diffuse.
results: A total of 644 [mean age 33.5 (range 18-88); n=432 (67%) female] 
had CE over this period. 174 patients (27%) with overt gastrointestinal 
bleeding were excluded from the study. A total of 470 patients (73%) who 
were suspected to have occult gastrointestinal bleeding were included into 
the study. Median time interval of CE after onset of anaemia was 296 days 
(range 1-745 days). Mean follow-up was 668.5days (range 81-1348 days). 
Capsules reached caecum in 459 cases (97.7%) and capsule retention was 
statistical analysis was performed with binary logistic regression model 
with analysis of successive steps forward to identify potential predictors 
of having a positive SeHCAT test. Variables with p < 0.1 in the univariate 
analysis were selected for the multivariate analysis.
results: 298 patients referred for chronic diarrhoea underwent SeHCAT 
testing (109M/189F). In the whole group, the median age was 46 yo (95% 
C.I 44.0-50.1), the median body mass index (BMI) was 24,8 kg/m2 (95% 
C.I 25,4-26,8). Out of all, 75.2% met IBS-D Rome III criteria, the median 
duration of diarrhoea was 36 months (95% C.I 42,5-54,8), 41.9% (70/167) 
exhibited a history of H. pylori infection, and 17.5%(17/131) showed parasitic 
stool infestation. The percentage of positive HLA-DQ2 and DQ8 haplotypes 
was 52.7% (109/207) and 17.4%(36/207), respectively. SeHCAT test was pos-
itive for BAM in 47.9% (143/298): 25.2% mild, 40.6% moderate, and 34.3% 
severe. Patients with positive SeHCAT test exhibited higher BMI and longer 
periods of diarrhoea (Table 1). 
 
Postive 
sehcaT
negative 
sehcaT
P
Gender (M;F) 68;78 41;111 <0.010
Age(yo) (median;95% IC)
43.0 
(41.3-46.1)
40.0 
(39.0-44.1)
0.036
BMI (Kg/m2:median;95%IC)
26.8 
(26.4-28.4)
23.9
(24.0-25.7)
<0.010
Duration of diarrhoea 
(months; median; 95% C.I)
36.0 
(44.7-65.5)
24.0 
(35.9-49.2)
0.073
IBS-D Rome III criteria (%) 105/146 119/152 0.228
Blastocystis Hominis (n) 8/124 20/122 0.016
Giardia Lamblia (n) 2/124 1/122 1.000
Dientamoeba fragilis (n) 8/124 2/122 0.085
Endolimax nanas (n) 1/124 6/122 0.065
Helicobacter pylori (n) 28/74 42/93 0.349
ISRS (n) 21/145 13/152 0.144
IBPs (n) 21/145 15/151 0.286
HLA-DQ2 Haplotype (n) 49/98 60/108 0.463
HLA-DQ8 Haplotype (n) 21/98 15/108 0.199
[Demographic Characteristics]
The following variables were selected for multivariate analysis: sex, age, 
BMI, duration of diarrhea, previous finding of parasites in stool speci-
mens and consumption of proton pump inhibitors. Female sex, absence of 
parasites in stools, and high BMI were identified as predictive factors for 
positive SeHCAT. The R-square of Cox and Snell, and of Nagelkerke of our 
model were of 11.4% and 15.2%, respectively.
conclusion: Although we identified female sex, a high BMI and the ab-
sence of parasites in stools as independent indicators of idiopathic BAM, 
these factors have a low capacity to predict a positive SeHCAT test. Addi-
tional studies are needed to identify better prognostic factors indicative of 
idiopathic bile acid malabsorption.
disclosure: Nothing to disclose 
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P0670 PanOraMIc versus axIaL sMaLL BOWeL caPsuLe 
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Introduction: Literature comparing axial small bowel capsule endoscopy 
(SBCE) (Pillcam, Given Imaging) and panoramic SBCE (Capsocam, Capsovi-
sion) in obscure gastrointestinal bleeding (OGIB) is limited and contradic-
tory (1,2).
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found in 4 cases (0.9%). Small bowel pathology identified in proximal, 
mid, distal and throughout (diffuse) small bowel based on small bowel 
transit time (SBTT) were 58.6%, 9.9%, 24.1%, 9.9% and 7.3% respec-
tively. Diagnostic yield of CE for significant pathology versus equivocal/
negative finding were 34.5% and 65.5%, respectively. Significant small 
bowel pathology was identified in 162 cases, of which 102 (63%) were an-
giodysplasia, 38 (23.5%) were inflammation or ulcers, 12(7.4%) were pol-
yps, 9(5.6%) were tumor, 1(0.5%) was blue rubber bleb syndrome. Small 
bowel ulcers were significantly associated with NSAID use (46%,p=0.023). 
A total of 191 patients underwent a single balloon enteroscopy (172 antero-
grade 19 retrograde approach) with an overall diagnostic yield 109 (57.1%). 
308 patients with negative CE were subsequently diagnosed with poor 
dietary intake of iron (n=167), heavy menstruation (n=54) hematologic 
disorders(n=26), colon cancer (n=2), colonic Dieulafoy’s (n=1), hemorrhoid 
(n=1) and hemosuccus pancreaticus (n=1). A total of 56 (18.2%) had no 
identifiable cause detected. Survival for positive CE vs equivocal/ negative 
CE were 63.7% vs. 99.4% (p< 0.01).
conclusion: Our study demonstrated that the yield of CE in persistent ane-
mia was 34.5% and prognosis of patients with equivocal or negative CE 
was excellent.
references: Van de Bruaene C et al. Small bowel capsule endoscopy: Where 
are we after almost 15 years of use? World J Gastrointest Endosc 2015;7(1):13-
36. Lopez et al. Iron deficiency anemia. Lancet 2016;387(10021):907-16. Mu-
hammad A et al. Role of small bowel capsule endoscopy in the diagnosis 
and management of iron deficieny anemia in elderly: A comprehensive 
review of the current literature. World J Gastroenterol 2014;20(26):8416-23 
Enns R. Capsule endoscopy in patients with iron deficiency. Gastroenterol 
Hepatol (N Y) 2012;8(12):847-9.
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Introduction: Gastrointestinal (GI) bleeding from the small bowel is rare 
(5-10% of all the GI bleedings)(1). Since 2001, videocapsule endoscopy 
(VCE) allowed the visualization of bleeding source in most (75%) of the 
previous obscure GI bleedings (OGIB)(1)
aims & Methods: In a prospective study, we aimed to assess the diagnostic 
yield of VCE in a cohort of consecutive patients (pts) with OGIB. Secondary 
endpoints was to assess the usefulness of VCE in the diagnostic work-up 
and management of pts with OGIB. From March 2016 to Feb. 2018, all 
pts with indication to perform VCE were considered. Inclusion criteria: 
1) diagnosis of OGIB/iron-deficient anemia (IDA);2) age>18-≤85 yrs; 3) 
non-diagnostic bidirectional endoscopy; 4)Follow up ≥5mos; 5)Informed 
consent. Exclusion criteria:1) swallowing disorders; 2) VCE contraindica-
tions; 3) Concomitant relevant GI diseases. 4) Pregnancy. All VCE images 
(PillCam,Covidien plc,Dublin,Ireland) were examined by 2 independent 
investigators. Data were expressed as mean [range].
results: During the study period, 50 out of the 84 pts (59.5%) referred for 
VCE, fulfilled the inclusion criteria (18 males [36%]; age 68 [27-83] yrs; 
haemoglobin 8 g/dL [4.5-12.9]). Indication for VCE: ongoing overt OGIB in 
11 (22%), previous overt OGIB in 14 (28%), occult-obscure bleeding (with 
IDA) in 25 (50%) pts. The time interval between OGIB (or diagnosis of 
IDA) and VCE was 30 [3-240] days. No VCE retentions occurred. Incom-
plete examinations were reported in 3 (6%) pts. All VCE were discharged 
in ≤7 days. Ongoing treatment: single antiplatelet therapy (aspirin, ADP 
receptor antagonist) in 15 (30%), dual antiplatelet therapy in 7 (14%), oral 
anticoagulant therapy in 7 (14%), nonsteroidal anti-inflammatory drugs 
in 13 (26%), SSRI-drugs in 3 (6%) pts. Lesions compatible with obscure GI 
bleeding (positive findings) were observed in 46 (92%) pts, including (%): 
small bowel (SB) angiodysplastic lesions in 24 (46%), SB erosions in 20 
(40%), red signs of recent bleeding in 10 (20%), blood or cloths in 8 (16%), 
venous ectasia in 8 (16%), mucosal or submucosal polyp/tumor mass in 5 
(10%), ulcers in 1 (2%) pt. Additional findings included (%): erosive gas-
troduodenitis in 17 (34%), gastric/duodenal angiodysplastic lesions in 4 
(8%), ulcers in 2 (4%) pts. VCE was negative in 4 (8%) pts: 1 (2%) pt with 
erosive gastroduodenitis (false negative), 2 (4%) pts with rectal bleeding 
due to rectal solitary ulcer and to hemorrhoids (true negative), respec-
tively. In 1 (2%) pt VCE was not diagnostic. Clinically significant lesions 
were observed more frequently in pts with occult OGIB (24/25 [96%] pts), 
followed by pts with ongoing overt OGIB (10/11 [91%]) and previous overt 
OGIB (12/14 [85.5%]). 
After VCE treatments were: medical in 30 (60%) pts; endoscopic in 7 (14%), 
surgical in 3 (6%), clinical observation with supportive treatments in 9 
(18%) pts. After VCE, 49/50 (98%) pts were followed up for ≥5 mos (17.8 
[5-28]). Bleeding resolution in these 49 pts was: complete in 31 (63.2%), 
partial in 9 (18.4%), absent in 9 (18.4%). Death occurred in 3 pts for non-
related OGIB conditions.
conclusion: In a prospective study, VCE use provided a high diagnostic 
yield in patients with OGIB, suggesting its use VCE as the first-line inves-
tigation in suspected mid-GIB. In this setting, VCE should be performed 
by dedicated gastroenterologists, in order to optimize the timing and the 
selection of patients.
references: 1) Gerson LB, Fidler JL, et al, ACG Clinical Guideline: Diagnosis 
and Management of Small bowel Bleeding. Am J of Gastroenterology 2015.
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Introduction: Patients having gastrointestinal bleeding (GIB) of unknown 
source usually presented with general clinical symptoms of blood loss and 
often this can only be reflected in a decrease level of hemoglobin.
aims & Methods: The aim of the study is to analyze, evaluate and compare 
clinical features and identified sources of bleeding in patients with intes-
tinal sources of bleeding.
From 14.02.2007 to 10.03.2019 there were 229 patients (m-117, f-112, mean 
age 52,3±18,3 years, range 17-89) who admitted to our clinics with GIB of 
unknown source. Obscure overt bleeding had 142 (62,0%) pts, obscure 
occult bleeding - 87 (38,0%) pts, that associated with severe anemia in 
86 (37,5%) pts, moderate anemia - in 87 (37,9%) pts and mild anemia - 
in 56 (24,4%) pts. Bleeding was associated with other complaints (incl. 
combination of complaints in 40 pts) in 98 (42,7%) pts: abdominal pain in 
50 (51,0%) pts, diarrhea in 26 (26,5%) pts, nausea/vomiting in 22 (22,4%) 
pts. Video capsule enteroscopy (VCE) was used for the small bowel exami-
nation in 179 (78,2%) pts. and balloon-assisted enteroscopy (BAE) - in 146 
(63,7%) pts. BAE was performed after VCE in 96 (53,6%) pts.
results: The source of GIB was found in 191 (83,4%) pts: in small bowel 
(SB) - in 170 (89,0%) pts; in the upper/lower GI tract - in 21 (11,0%) pts. 
No pathology was found in 38 (16,6%) pts. The sources of SB bleeding in-
cluded vessel malformations in 65 (35,7%) pts, tumors - in 54 (29,7%) pts, 
erosive/ulcerative enteropathy - in 42 (23,1%) pts, diverticula - in 9 (5,3%) 
pts (incl. Meckel’s diverticulum in 6 pts). Clinical features of the pts with 
SB sources of bleeding are presented in the table 1.
conclusion: The main indication for small bowel examination is GIB of 
unknown source, which can have a little bit different clinical manifesta-
tions depending on the source of bleeding. All the sources of SBB tend to 
be recurrent, and pts mostly have severe/moderate anemia. Vessel mal-
formations are more frequent sources of SBB in pts elder than 50 years old 
(p=0.008), more often presented with overt bleeding (p=0.007). Pts with 
tumors tend to have a long period of detection, more than 1 year; they 
usually have complaints of abdominal pain. Pts with enteropathy tend to 
have a shorter period of detection, less than 1 year, usually associated with 
diarrhea. All pts with SB diverticula have overt GIB, apparent with severe 
anemia, without any other complaints.
disclosure: Nothing to disclose 
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(III) Importantly, we observed a high variance in FS measurements (SD at 
baseline: 3.1 kPa, 1 months: 3.1 kPa, 3 months: 4 kPa, 6 months: 2.1 kPa, 12 
months: 2.4 kPa,) before weight loss.
conclusion: 
(I) Metabolic surgery significantly improves liver stiffness, metabolic sig-
natures and γ-GT. Patients with fibrosis stage < 2 responded significantly 
better.
(II) Fibroscan™ is a useful tool to detect patients with F≥2, demonstrating 
highly variable measures before weight loss (until 3 months). Hence, sug-
gesting critical evaluation during measurement and application of novel 
standards such as multiple region measurements to decrease sampling 
error and increase accuracy in morbidly obese patients.
Fibroscan™ is an important tool to preoperatively select patients for opti-
mal outcome and potential risk of metabolic surgery.
references: 1) Miñambres I et al. Obes Surg. 2018, doi: 10.1007/s11695-018-
3562-8 
2) Griffin C et al. AASLD 2018, oral Abstract #218, Hepatology 2018; 68 
(S1):43A
disclosure: Nothing to disclose 
P0675 vIsceraL OBesITy Measured By duaL x-ray 
aBsOrPTIOMeTry and BIOIMPedance as The PredIcTOr 
fOr IBs In OBese PaTIenTs
Hauser G.1, Klobucar Majanovic S.2, Belancic A.3, Pletikosic Toncic S.4, 
Krpina M.5, Tkalcic M.6
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Gastroenterology, University of Rijeka, FAculty of Medicine; Faculty of 
Health Studies, Rijeka, Croatia, 2University of Rijeka, Endocrinology, Rijeka, 
Croatia, 3University of Rijeka, Biology, Rijeka, Croatia, 4Universitty of Rijeka, 
Psychology, Rijeka, Croatia, 5Universitty of Rijeka, Rijeka, Croatia, 6University 
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Introduction: There are several studies considering obesity as the risk factor 
for various lower gastrointestinal symptoms. But the evidence regarding 
the relationship between visceral abdominal tissue (VAT) and the incidence 
of irritable bowel syndrome (IBS) are sparse. Moreover, the exact measure-
ment method for VAT is still debatable. Lee. GC et.al reported VAT measure-
ment by CT scan which is an invasive and expensive method and not appro-
priate in everyday usage. We aimed to measure VAT by Body composition 
measurements were obtained using the dual-energy X-ray absorptiometry 
(DXA) (Hologic Horizon W, Waltham, MA, USA) and multifrequency bioelec-
trical impedance analysis (BIA) (Seca mBA 515, Hamburg, Germany)and 
correlate the values with the presence of IBS symptoms.
aims & Methods: The primary outcome of this study was to investigate 
the association between VAT and the risk of IBS. The secondary outcome 
is to compare two different methods for VAT measurement. Totally we en-
rolled 94 obese patients (76.5% F; mean age M=47,99; SD=11,8 years). In 
this case-control study we compare the VAT, Fatty mass (FM), Free Fatty 
Mass (FFM), Waist circumference (WC) between subjects with obesity and 
IBS (IBS group N=29; 30.9%) and controls (obese patients without IBS, 
non-IBS group N=65; 69.1%), who underwent obesity programme at ter-
tiary care centre from January 2018. to January 2019. IBS was diagnosed 
by using Rome IV criteria questionnaire. The association between IBS and 
abdominal obesity was evaluated by measuring VAT, FFM, FM and waist 
nutrition I
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P0674 LIver fIBrOsIs sTage aT BaseLIne PredIcTs OuTcOMe 
Of MeTaBOLIc surgery
Kienbacher C.1,2, Wakolbinger (nee Luger) M.3,4,5, Traussnigg S.1, 
Kruschitz R.4,6, Wuerger T.7, Schindler K.4, Ferlitsch A.1,2, Prager G.8, 
Ludvik B.9, Trauner M.10
1Medical University of Vienna, Division of Gastroenterology and Hepatology, 
Department of Internal Medicine III, Vienna, Austria, 2Brothers of St. John 
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Department of Internal Medicine I, Vienna, Austria, 3Medical University 
of Vienna, Department of Social and Preventive Medicine, Center for 
Public Health, Vienna, Austria, 4Medical University of Vienna, Division 
of Endocrinology and Metabolism, Department of Internal Medicine III, 
Vienna, Austria, 5SIPCAN Save Your Life, Special Institute for Preventive 
Cardiology And Nutrition, Salzburg, Austria, 6General public hospital of the 
Order of Saint Elisabeth in Klagenfurt, Department of Internal Medicine, 
Klagenfurt, Austria, 7Medical University of Vienna, Department of Pathology, 
Vienna, Austria, 8Medical University of Vienna, Division of General 
Surgery, Department of Surgery, Vienna, Austria, 9Rudolfstiftung Hospital, 
Department of Medicine I and Karl Landsteiner Institute for Obesity and 
Metabolic Diseases, Vienna, Austria, 10Medical University of Vienna, Division 
of Gastroenterology and Hepatology, Department of Internal Medicine III, 
Wien, Austria
contact e-Mail address: kienbacher@gmx.at
Introduction: Non-alcoholic fatty liver disease (NAFLD) and vitamin D de-
ficiency (VDD) is highly prevalent in morbidly obese patients and can ad-
vance to non-alcoholic steatohepatitis (NASH), fibrosis, liver cirrhosis and 
liver cancer. Moreover, metabolic surgery might carry an increased risk for 
liver decompensation and mortality in cirrhotic patients. We examined the 
prevalence of liver fibrosis and response to metabolic surgery.
aims & Methods: In a randomized controlled trial, baseline intraoperative 
needle liver biopsy was performed in 46 patients with VDD who under-
went one-anastomosis gastric bypass (OAGB). Patients were followed for 
12 months for non-invasive Fibroscan™ (FS) measures (M and XL probe) 
for the non-invasive detection of the presence of histologically advanced 
fibrosis and response to metabolic surgery as well as metabolic signatures 
and laboratory improvements. Univariate and multivariable analysis were 
used to test the predictive relevance of data assessed.
results: 78% of subjects were female, mean age was 42 (SD 12) years with 
a BMI of 44 (4) kg/m , a waist circumference of 128 (11) cm, and a HOMA 
index of 6.96 (5.81). 26% suffered from diabetes, 50% from hypertension, 
and 26% from hyperlipidemia. 72% demonstrated NASH, 11% simple ste-
atosis, and 17% normal liver morphology. 30% showed significant fibrosis 
(F≥2), 9% advanced fibrosis (F3) and 4% cirrhosis (F4).
(I) Metabolic surgery significantly improved BMI, waist circumference, 
HOMA Index, liver tests, and liver stiffness. Importantly, patients with F< 2 
responded better. (adjusted for baseline value, age, sex, and diabetes mel-
litus). Of note, the groups (F< 2 vs. F>3) did not differ at baseline.
(II) FS correlated significantly (r=0.516; p< 0.001) with histological fibrosis 
readings and showed an AUC of 0.738 (p=0.009) to predict F≥2 and an 
even better AUC 0.815 (p=0.015) for F>3.
clinical features vessel malformations (n=65) Tumors (n=54) enteropathy (n=42) diverticula (n=9)
Sex: Male/ Female 31 (47,5%)/ 34 (52,5%) 24 (44,4%)/ 30 (55,6%) 27 (64,3%)/ 15 (35,7%) 6 (66,6%)/ 3 (33,4%)
Age: <50 years/ >50 years 24 (36,9%)/ 41 (63,1%) 26 (48,1%)/ 28 (51,9%) 23 (54,7%)/ 19 (45,3%) 5 (55,5%)/ 4 (44,5%)
Bleeding: Overt 
(Melena/ Haematochezia)/ Occult
44 (67,7%) (28 (63,6%)/ 
16 (36,4%))/ 21 (32,3%)
27 (50,0%) (17 (62,9%)/ 
10 (37,1%))/ 27 (50,0%)
18 (42,8%) (9 (50,0%)/ 
9 (50,0%))/ 24 (57,2%)
9 (100,0%) (3 (33,3%)/ 
6 (66,7%))/ 0 (0%)
Overt bleeding in anamnesis: 
For the first time/ Recurrent
8 (18,2%)/ 36 (81,8%) 9 (33,3%)/ 18 (66,7%) 4 (22,2%)/ 14 (77,8%) 5 (55,5%)/ 4 (44,5%)
Anemia: Severe/ Moderate/ Mild 23 (35,4%)/ 29 (44,6%)/ 13 (20,0%) 17 (31,5%)/ 20 (37,0%)/ 17 (31,5%) 11 (26,1%)/ 14 (33,3%)/ 17 (40,4%) 5 (55,5%)/ 3 (33,3%)/ 1 (11,2%)
Other complaints: Pain/ Diarrhea/ 
Nausea+vomiting
5 (7,7%)/ 4 (6,1%)/ 6 (9,2%) 18 (33,3%)/ 3 (5,5%)/ 7 (12,9%) 16 (38,1%)/ 19 (45,2%)/ 8 (19,0%) 0 (0%)/ 0 (0%)/ 0 (0%)
Duration of detection the source: 
<1 year/ >1 year
37 (56,9%)/ 28 (43,1%) 21 (38,8%)/ 33 (61,2%) 31 (73,8%)/ 11 (26,2%) 7 (77,7%)/ 2 (22,3%)
[P0673 Table. Clinical features and the sources of SB bleeding.]
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circumference (WC) Body composition measurements were obtained using 
the dual-energy X-ray absorptiometry (DXA) (Hologic Horizon W, Waltham, 
MA, USA) and multifrequency bioelectrical impedance analysis (BIA) (Seca 
mBA 515, Hamburg, Germany).
results: The prevalence of IBS in this sample was 30.8%, (OR 0.44; 95% 
(CI): 0.2645 to 0.7525, P= 0.0025) among all enrolled subjects. 
VAT(L) measured by bioimpedance is significant predictor for IBS in obese 
patients t = 2.51, df = 63.51, p< .05 (p=0.01468); Cohen’s d=0.51 (moderately 
high) IBS (M= 4.27; SD= 2.35), non-IBS (M= 6.09; SD= 3.94). 
Moreover, there is significant correlation between VAT measurement with 
bioimpedance and DEXA. FFM, FM and WC as well are not important pre-
dictors for IBS in obese patients. Younger obese patients are more prone 
to have IBS symptoms than older patients (OR 0.93; 95%(CI): 0.88 to 0.97; 
P=0.007).
conclusion: Visceral adiposity measured by simple and non-invasive 
method is associated with an increased risk of IBS. Bioimpedance and 
DEXA are reliable methods for VAT measurement. However, neither FFM, 
FM, BMI and WC are associated with an increased risk of IBS.
references: Lee CG. Visceral abdominal obesity is associated with 
an increased risk of irritable bowel syndrome.Am J Gastroenterol. 
2015;110(2):310-9.
disclosure: Nothing to disclose
P0676 endOscOPIc sLeeve gasTrOPLasTy vs 
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Introduction: Obesity is a worldwide epidemic that continues to be perva-
sive and associated with significant comorbidities that can result in poor 
quality of life along with reduced life expectancy. Despite progress in the 
understanding of the complex mechanisms in obesity, bariatric surgery 
remains the only current treatment of obesity that demonstrates long-term 
effectiveness. Endoscopic sleeve gastroplasty (ESG) is a novel minimally 
invasive technique that was first presented in 2008 and improved upon 
in 2013. Data is limited in terms of the efficacy and safety of ESG, and evi-
dence has not been synthesized in comparison to other options of bariatric 
surgery like laparoscopic sleeve gastrectomy (LSG).
aims & Methods: In this study, we aim to assess and compare the out-
comes of ESG with LSG by meta-analysis. We conducted a comprehensive 
search of several databases and conference proceedings (earliest inception 
to March 2019). Pooled rates of total weight loss (TWL%), excess weight 
loss (EWL%), and body mass index (BMI) with ESG were calculated at 1 
month, 6months, and 12 months. The outcomes at 12 months with ESG 
were compared to the outcomes at 12 months with LSG.
results: A total of 3713 patients were included in the analysis from 13 stud-
ies. Outcomes of ESG were analyzed from a total of 7 studies (1569 pa-
tients) and outcomes of LSG were analyzed from 6 studies (2144 patients). 
Baseline population characteristics were comparable between the ESG 
and LSG groups. The mean and/ or median age ranged from 30 years to 
48 years, with predominantly female population (75%). Mean range of 
BMI (kg/m2) was 33.3 to 38.9 in ESG cohort and 37.4 to 48 in LSG cohort. 
The pooled rates of TWL at 1m, 6m, and 12m were 8.5 (95% CI 7.7-9.3, 
I2=87.9), 15.4 (95% CI 13.8-16.9, I2=94.7), and 17.5 (95% CI 15.3-19.7, I2=94.6) 
respectively. The pooled rates of EWL at 1m, 6m, and 12m were 30.1 (95% 
CI 22.1-38.2, I2=96.6), 57.8 (95% CI 48.6-66.9, I2=93.5), and 64.1 (95% CI 
51.9-76.4, I2=92.7) respectively. The pooled rates of BMI at 1m, 6m, and 12m 
were 32.6 (95% CI 30.4-34.8, I2=97.5), 30.9 (95% CI 29.1-32.6, I2=96.7), and 
31.3 (28.2-34.3, I2=98) respectively. At 12 months, the pooled rates of TWL, 
EWL, and BMI with LSG was 46.3 (30.9-61.7, I2=99), 69.9 (95% CI 59.4-80.5, 
I2=99), and 27.9 (95% 25.2-30.6, I2=98.9) respectively. LSG demonstrated 
statistically superior TWL when compared to ESG with a statistical p-value 
of 0.02. EWL and BMI change with LSG and ESG were comparable with a 
statistical p-value of 0.5 and 0.13 respectively.
conclusion: ESG, as a minimally invasive treatment modality, demon-
strates successful clinical outcomes in patients with obesity, in terms of 
TWL% EWL%, and BMI. Outcomes at 12 months are similar to LSG, except 
for TWL that was statistically superior with LSG when compared to ESG. 
This study was limited by heterogeneity and indirect comparison. Well-
conducted large scale studies with adequate follow-up time are needed to 
establish the role of ESG in the treatment of obese patients.
disclosure: Nothing to disclose 
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Introduction: Perinatal period is characterized by phases of development 
with high sensitivity to the environmental factors. Among the risk fac-
tors, malnutrition or maternal obesity are now recognized to program 
children’s metabolism and promote the occurrence of obesity or type 2 
diabetes during postnatal life. This study aims to identify the effects of 
maternal perigestational exposure to an obesogenic diet in offsprings. 
This exposure might increase the occurrence of obesity, associated with 
metabolic disorders, inflammation and disturbances of digestive function 
in male offsprings.
aims & Methods: 8 female Wistar rats were fed a HFD, and 8 control fe-
male rats a standard diet (controls), supplemented or not with inulin. 
Female rats were exposed to these experimental conditions during a 
4-months pre-gestational period as well as during the gestation and lac-
tation periods. 
After weaning, 50 male pups were studied at young adulthood (D60), 
without any treatment during the experiment. Different segments of the 
digestive tract were studied for histological analysis, metabolic assays, in-
flammation and intestinal permeability.
results: Rats from mothers fed a HFD have a higher weight than con-
trol pups at weaning time (p< 0.001), and the inulin appears to limit this 
weight gain (HFD vs HFDi p< 0.05), phenomenon still present at d60 (C vs 
HFD p< 0.01; HFD vs HFDi p< 0.01). Lipid and glycemic assays did not show 
significant differences. FITC assays didn’t show any perturbation of the 
paracellular intestinal permeability. LPS and pro inflammatory cytokines 
assays (IL6, IL1β, TNFα) didn’t reveal any tissue inflammation.
conclusion: Our results indicate that pups from mothers fed an obesogenic 
diet are overweight at both weaning and young adulthood. Interestingly, 
inulin limits weight gain in these animals. 
The obesogenic diet of the mother promotes the occurrence of obesity in 
male offsprings and an inulin-based dietary supplement could help lim-
iting these deleterious effects. This hypothesis remains to be confirmed 
after analysis of the intestinal barrier tight junction proteins expression, 
other inflammatory markers and morphological alterations of the diges-
tive system.
disclosure: Nothing to disclose 
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or industrial fat-enriched diet; and further US monitoring using 5-20 MHz 
probes of diagnostic US machines in grey scale, Doppler, sonoelastogra-
phy, M-mode detecting tissue movement, US-guided interventions, injec-
tion US contrast agents: 
1) for precise diagnosis transabdominal US detecting signs of metabolic 
syndrome via detailed imaging of internal organs: liver size, echogenicity, 
stiffness, kidneys size, structure, Doppler measuring resistance index (RI) 
on segmental renal arteries, spleen size, muscle thickness at midfemoral 
level, assessment of visceral vessels, systemic hemodynamics, etc.; 
2) for screening all involved animals we measured the visceral fat thickness 
(threshold considered as 1.5 mm in mice) on sagittal probe position and 
collected records of panoramic abdominal scans (in sagittal and transverse 
probe positions) and measured the largest longitudinal liver size (via sub-
costal approach). Weight, body size, laboratory indices (cholesterol, uric 
acid, glucose, etc.), microbiome, genetic markers were also determined. 
After sacrificing we evaluated studied organs.
results: The model was successfully applied to study effects of new drugs: 
probiotic strains on high calorie-induced obesity model in BALB/c during 
21 days [2] and prebiotic effect on high-calorie diet-induced obesity in rats 
[3]. US detected development metabolic syndrome, endogenous intoxica-
tion syndrome, visceral obesity and liver and kidney dysfunction in mouse 
and rats. Ultrasound data showed visceral obesity, injury of the liver and 
organs in all experimental animals. We revealed nephropathy signs (thin-
ning, increasing echogenicity of kidney parenchyma, detecting increasing 
RI in renal arteries (over 0.7) was feasible in rats. Studies using the models 
demonstrated efficacy of studied strains, substances improving parameters 
during experiment. All observed changes were confirmed post mortem.
conclusion: The method of modeling is reliable, allows to monitor meta-
bolic syndrome signs with high translation potential reflecting develop-
ment disease in humans.
references: 1. Bubnov RV. The use of ultrasound equipment of general use 
for in vivo study of cerium dioxide nanoparticles introduction in mice. Ul-
trasound Med Biol. 2011, 37 (8): 1-S162. https://doi.org/10.1016/j.ultrasmed-
bio.2011.05.750 2. Bubnov RV, et al. Comparative study of probiotic effects 
of lactobacillus and bifidobacteria strains on cholesterol levels, liver mor-
phology and the gut microbiota in obese mice. EPMA J. 2017;8(4):357-76. 
https://doi.org/10.1007/s13167-017-0117-3. 3. Konopelniuk VV, et al. Efficacy 
of Fenugreek-based bionanocomposite on renal dysfunction and endog-
enous intoxication in high-calorie diet-induced obesity rat model—com-
parative study. EPMA J. 2017. https://doi.org/10.1007/s13167-017-0098-2
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Introduction: Metabolic syndrome (MeS) and inflammatory bowel dis-
ease (IBD) share common pathophysiological features including chronic 
inflammation in visceral adipose tissue, but the interplay still remains 
unrevealed. Great interest has been recently devoted to the association 
of FTO gene and obesity, although the biological function is still unclear. 
FTO is a member of a superfamily of Fe (II)-and 2-oxoglutarate-dependent 
dioxygenases and presents a nucleic acid demethylase. The proposed 
FTO pathophysiological mechanism includes alterations of methylation-
demethylation states of genes expression in metabolically active tissues.
aims & Methods: Newly diagnosed 94 Crohn’s disease (CD) and 98 ulcer-
ative colitis (UC) patients and 91 non-IBD controls with parameters of MeS 
were analyzed for FTO rs9939609 variant using PCR-ARMS (Polymerase 
Chain Reaction - Amplification Refractory Mutation System) method.
results: We analyzed distribution of genetic variant FTO rs9939609, previ-
ously associated with obesity, in our study population. The genotype dis-
tribution was in Hardy-Weinberg equilibrium in each and total analyzed 
group. Results showed that FTO AA genotype was more frequent in CD 
P0678 endOscOPIc sLeeve PLIcaTIOn (esP) fOr TreaTMenT 
Of OBesITy I-II. PreLIMInary resuLTs Of 2 sITes WITh The neW 
PaTTern fOr gasTrIc eMPTyIng deLay
Turro R.1, Espinós Pérez J.C.2, Lopez Nava G.3, Mata Bilbao A.4, 
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Introduction: Obesity is major disease in our society. Intragastric balloon 
is the endoscopic gold standard on short time weight loss. Endoscopic 
plicature can offer us better middle long term results than balloon for its 
durability.
aims & Methods: This is a multi-center, prospective pilot study intended to 
evaluate the safety and efficacy of the Gastric Endoscopic Sleeve Plication 
procedure (mid & distal body plications ) (GESP).
Study was Ethics approved at institutions. Written consent obtained. In-
dications have been obesity grade II. Use of the Incisionless Operating 
Platform (IOP) TM (USGI Medical, San Clemente, CA, USA) with a defined 
new pattern of disposition of the transmural plications with the g-cathTM 
EZ suture anchors in the greater curvature shortening and tubulizing the 
stomach to potentially delay gastric emptying and reduce gastric volume / 
accommodation for an enhanced physiological effect. 
Follow up data will be obtained prospectively every 2 weeks initially for 
the first 2 months and then monthly for the next 10 months on as part of 
our long term follow-up program that also emphasized changes in un-
healthy eating/lifestyle habits. 
Gastric emptying studies previously to the intervention, 2 months after and 
6 months after intervention are scheduled. Satiety test are also scheduled 
during the follow up, basal, 2 months and 6 months after the intervention.
Liver test with analytics and fibroscan are also done in those patients bas-
al, 2 months and 6 months.
results: 39 operations in 39 patients were successfully performed (M: 17 F: 
22). Mean BMI 36.9 (Range 31.2 - 40.3). Mean number of anchors placed 
was 18.3. All patients were discharged ≤ 24 hours. No serious adverse 
events (SAE). % Mean Total body weight loss at 5 months for the 34 pa-
tients was 13.93 ± 4.14 Kg.
conclusion: The GESP procedure seems to be a safe intervention without 
significant adverse effects to date. Initial results in weight loss are encour-
aging. However, long term follow-up and further study remains necessary 
to assess its value in treating the etiology of obesity.
disclosure: USGI Consultant Aspire Consultant Allurion Travel Grant 
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Introduction: Diagnostic ultrasound (US) using general US imaging devices 
can be effectively used for preclinical studies in small animals providing 
dynamic life-time control [1], furthermore, can enhance drug delivery and 
therapeutic effects with visual treatment monitoring (theranostic).
aims & Methods: The aim was to develop model of metabolic syndrome in 
small animals using general US machines for longitudinal in vivo observa-
tion and screening large numbers of cases for facilitating further transla-
tion.The modeling of metabolic syndrome performed in compliance with 
the ethical standards and includes conducting an experiment on labora-
tory animals (mice, rats, murine) with the introduction of high calorie diet 
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than UC and control group, 29.8%, 23.5% and 14.3%, respectively. It has 
been demonstrated that AA genotype was significant predictor of CD oc-
currence (p = 0.01), adjusted for age and gender in the logistic regression 
model. Compared to TT and TA carriers, carriers of AA genotype had 2.6 
higher odds for CD development (OR = 2.6 95% CI [1.2 - 5.4])
conclusion: The nutrigenetic approach in IBD could improve understand-
ing of obesity-associated complex diseases and contribute to better risk 
stratification, considering that genetic markers are not influenced by 
confounding factors such as education, physical activity, social-economic 
status and diet. Association of FTO variant with CD could direct further 
nutrigenomic studies in IBD research.
disclosure: Nothing to disclose 
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Lorenzon G.1, D’Incà R.1, Savarino E.V.1
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Introduction: Inflammatory bowel disease (IBD) is characterized by severe 
inflammation of the small bowel and/or the colon leading to recurrent di-
arrhea and abdominal pain. Butyrate represents one of the final product of 
saccharolytic fermentation of complex and nondigestible polysaccharides 
by anaerobic bacteria and has shown anti-inflammatory and regenera-
tive properties, providing symptomatic relief when orally supplemented 
in patients suffering from a various range of colonic diseases(1). Limited 
data are available on butyrate effectiveness in patients with IBD due to the 
difficultines of proving an adequate concentration of butyrate in the colon.
aims & Methods: We investigate the effect of a microencapsulated form 
of sodium Butyrate (MSB, ButyroseR, SILA, Noale, Italy) on the faecal mi-
crobiota of patients with IBD. In this prospective-randomized-placebo-
controlled study, 49 IBD patients, 19 CD and 30 UC with mild-to-moderate 
clinical activity were enrolled . Eighteen volunteers were recruited to 
provide a healthy microbiota model of the local people. Patients with ex-
tensive surgery were excluded. After stratification by clinical assessment, 
colonoscopy, and fecal calprotectin (FC) levels, the patients were random-
ized to oral administration of MSB (1800 mg/die) or placebo for 2 months, 
in addition to conventional therapy. Clinical activity was defined according 
to HBI in case of Crohn’s Disease (CD) and Mayo score in case of ulcerative 
colitis (UC). Before (T0) and after (T1) butyrate treatment, stool samples 
were collected for faecal microbiota assessment analysis by 16S ribosomal 
RNA Illumina MiSeq sequencing. Patients completed the quality of life 
questionnaire in IBD (IBDQ) on T=0 and T=1
results: We confirmed the evidence of a significant difference (p< 0.001) 
between the microbiota of healthy controls and IBD patients. MSB induced 
similar changes in the microbiota of IBD patients by increasing the bacte-
ria able to produce shortchain fatty acids (SFCA). However, an increased 
abundance of butyrogenic colonic bacteria (including genera Butyricicoc-
cus and Subdoligranulum) were observed in CD patients, whereas in UC 
patients we observed a major increase of Lachnospiraceae (sPLSDA analy-
sis). Clinically, when only patients with calprotectin levels above 250ug/g 
for CD and 150ug/g(2) for UC were considered, a 30% decrease of calpro-
tectin levels were observed in 67% of CD patients treated with MSB versus 
33.3% in those treated with placebo. Subjective improvement in QoL based 
on IBDQ was significantly observed either in the treatment (p=0.0046) 
and in placebo (p=0.039) group. However, a greater effect was observed 
among the UC patients.
conclusion: Microencapsulated sodium butyrate supplementation showed 
an increase of butyrogenic and SCFA bacteria stimulating growth with a 
mimicking prebiotic effect increasing the production of endogenous and 
physiological SCFAs with a marked improvement of QoL and reduction of 
the level of inflammatory markers.
references: [1] Duncan L.P., et al., (2004), Restricted distribution of the 
butyrate kinase pathway among butyrateproducing bacteria from the hu-
man colon., J Bacteriol , 2099-106 [2] Lin JF,et al., (2014), Metaanalysis: 
fecal calprotectin for assessment of inflammatory bowel disease activity, 
Inflamm Bowel Dis, 1407-15
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Introduction: Perinatal period is characterized by phases of development 
with high sensitivity to environmental factors. Among the risk factors, pes-
ticide exposure are now recognized to program children’s metabolism and 
promote the occurrence of obesity or type 2 diabetes. This study purposes 
the peri-gestational exposure of mothers (animal model: rat) to a low dose 
of pesticide (chlorpyrifos, CPF). This exposition might increase the occur-
rence of obesity, associated with metabolic disorders and disturbances of 
digestive function in male offsprings.
aims & Methods: 8 female Wistar rats were exposed to CPF, and 8 female 
rats to its vehicle (controls) , supplemented or not with inulin. Female rats 
were exposed to these experimental conditions during a pre-gestational 
period of 4 months as well as during the gestation and lactation periods. 
After weaning, 56 male pups were studied at young adulthood (D60), 
without any treatment during the experiment. Different segments of the 
digestive tract were studied for histological analysis, metabolic assays, in-
flammation and intestinal permeability.
results: Rats from mothers exposed to CPF have lower birth weights than 
control pups (p< 0.05), but this difference appears to decrease at young 
adult age (J60). Lipid and glycemic assays did not show significant differ-
ences. We noticed a decrease of IGF1 (p< 0.01) and leptin plasma levels 
but not significantly in animals from CPF-exposed mothers. FITC assays 
didn’t show any perturbation of the intestinal permeability. LPS and pro 
inflammatory cytokines assays (IL6, IL1β, TNFα) didn’t show any tissue in-
flammation.
conclusion: Preliminary results reveal that pups from mothers in contact 
with a pesticide during the peri-gestational period have developmental 
disabilities characterized by a lower birth weight, but also a decrease in 
plasma levels of factors involved in growth and metabolism (IGF1 and 
leptin). 
We suggest that the pesticide slows down fetal and postnatal develop-
ment. This hypothesis remains to be confirmed after analysis of tight junc-
tion proteins of the intestinal barrier, other inflammatory markers and 
morphological alterations of the digestive system.
disclosure: Nothing to disclose 
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aTTenuaTes crOhn’s dIsease syMPTOMs (rIse-uP sTudy)
von Martels J.Z.H.1, Bourgonje A.R.1, Klaassen M.A.Y.1, Alkhalifah H.A.A.1, 
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Introduction: Crohn’s disease (CD) is characterized by chronic intestinal 
inflammation and dysbiosis in the gut. Riboflavin (vitamin B
2
) has anti-
inflammatory, anti-oxidant and microbiome-modulatory properties. Here, 
we analyzed the therapeutic potential of riboflavin in CD and its effect on 
markers of inflammation, oxidative stress and the gut microbiome.
aims & Methods: In this prospective clinical intervention study, 70 CD pa-
tients were included and divided into one group with low and one group 
with high disease activity at baseline (defined by faecal calprotectin (FC) 
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P0685 dOes gasTrIc LePTIn PLay a key rOLe In cOnTrOLLIng 
fOOd InTake?
Ohta H.1,2
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Introduction: Patients with obesity maintain high levels of leptin (an-
orexigenic hormone) generate from amount of fat cells, which is called 
leptin resistance [1]. Recent research in mice suggested that gastric leptin 
secreted from chief cells into the stomach could control satiety during 
eating [2]. 
This study investigated whether the gastric leptin levels in human changed 
due to eating as mice and there were the differences between in normal 
body weight subjects and in obese subjects.
aims & Methods: Twelve patients with obesity and 5 volunteers of normal 
weight were enrolled in this study from February 2015 to October 2018. 
Visceral and subcutaneous fat volumes were evaluated by a CT scan before 
starting the bariatric therapy and at 6 months. The leptin levels in the 
serum were measured by radioimmunoassay before a meal and at 15 and/
or 30 minutes after beginning the meal. 
The co-relations between the leptin level, the volume of adipose tissue 
and the stimulation of gastric leptin secretion during eating were evalu-
ated statistically.
results: 
1) The co-relation coefficients between the sera leptin levels at hunger and 
subcutaneous fat volume was 0.83 and it is less co-related to visceral (0.21) 
or total (0.40) fat volume individually. 
2) The leptin levels were not co-related to data of insulin, liver function 
and cholesterol. 
3) The leptin levels were highly correlated with body weight loss by bar-
iatric therapy. 
4) Increases in leptin levels were observed in the normal subjects and 
in the patients with obesity only after eating more amount of food than 
threshold level. 
5) Dietary stimulation of gastric leptin secretion was available to regulate 
appetite in a short term only for people without hyperleptinemia.
conclusion: The leptin level was associated with the volume of adipose tis-
sue in the long term but it was not clear whether gastric leptin regulated 
appetite shortly after eating.
references: [1] Zhou Y “Leptin signaling and leptin resistance” Front Med. 
2013 June; 7(2) 201-22 [2] Cammisotto P “ A review on gastric leptin” Anat 
Cell Biol 2012;45:1-16
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Introduction: The omega-3 polyunsaturated fatty acids (O3PUFAs), eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA) display anti-
colorectal cancer (CRC) activity. Oral administration of mixed O3PUFAs in 
healthy volunteers is associated with changes in the intestinal microbiome 
in favour of short-chain fatty acid (SCFA) producing bacteria 1. 
However, it remains unclear whether this anti-CRC activity is mediated 
through direct exposure of O3PUFAs in the gut lumen and/ or via systemic 
bioavailability. We tested whether EPA and DHA levels increase in the dis-
tal small bowel after oral supplementation with mixed O3PUFAs.
aims & Methods: Patients with a temporary ileostomy following anterior 
resection for colorectal cancer were studied. Ileostomy fluid (IF) and red 
blood cell (rbc) membrane EPA and DHA levels were measured by liquid 
chromatography-tandem mass spectrometry before (V1), a few hours after 
the first dose (V2), and a few hours after the final dose (V3), following 28 
days of daily oral supplementation with 4g mixed EPA/DHA triglycerides 
cut-off value: 200 µg/g). Patients received 100 mg riboflavin (DSM, Nutri-
tional Products Ltd.) daily for 3 weeks. Clinical disease activity (Harvey-
Bradshaw Index: HBI), serum biomarkers of inflammation and redox sta-
tus (plasma free thiols), and gut microbiome taxonomical composition and 
functionality (fluorescent in-situ hybridization, FISH, and metagenomic 
shotgun sequencing, MGS), were analyzed before and after riboflavin in-
tervention.
results: Riboflavin supplementation significantly decreased serum lev-
els of inflammatory markers. In patients with low disease activity IL-2 
decreased, while in patients with high disease activity C-reactive protein 
(CRP) and tumor necrosis factor-α (TNF-α) were reduced, and free thiols 
significantly increased after supplementation. Moreover, HBI was signifi-
cantly decreased by riboflavin supplementation. Riboflavin supplementa-
tion led to decreased Enterobacteriaceae in patients with low FC levels as 
determined by FISH, however, MGS analysis showed no effects on diver-
sity, taxonomy or metabolic pathways of the gut microbiome.
conclusion: Three weeks of riboflavin supplementation suppresses sys-
temic inflammation and attenuates systemic oxidative stress in CD, con-
comitant with relief of clinical symptoms. FISH analysis showed decreased 
Enterobacteriaceae in quiescent CD, though this was not observed in MGS 
analysis. Our data demonstrates that riboflavin supplementation has ben-
eficial effects in CD.
disclosure: Nothing to disclose 
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Introduction: Zinc (Zn) is an essential micronutrient involved in processes 
of transcription and synthesis of nucleic acids and proteins. Zn deficiency 
may lead to modulation of the immune system, resulting in the decrease of 
cytokine levels, interleukins and IFN-γ. Patients with inflammatory bowel 
disease (IBD) may have micronutrient deficiency more common than as-
sumed. In previous studies Zn deficiency in IBD patients was in correlation 
with reduced food intake, enteric loss of nutrients and malabsorption.
aims & Methods: We aimed to assess Zn levels in IBD patients as well as 
healthy individuals, and to examine is there a correlation of Zn levels with 
disease activity.
Complete medical records of all patients with histologically diagnosed IBD 
were evaluated. As a control group we analyzed medical records of age 
and sex matched healthy volunteers, who had done their annual health 
check up. A case-control study was preformed among 45 newly diagnosed 
IBD patients and the same number age, sex matched healthy controls. All 
patients underwent a total colonoscopy with ileoscopy. Complete blood 
count was obtained in addition to inflammatory markers (CRP, erythrocyte 
sedimentation rate-ESR). Serum levels of Zn were measured spectropho-
tometrically. Mayo score, UCEIS and CDAI respectively were calculated for 
each patient.
results: Serum levels of Zn were significantly lower (P< 0.05) in IBD pa-
tients than controls. Moreover serum levels of Zn negatively correlated with 
younger age at the time of diagnosis, CRP, sedimentation levels and TIBC, 
whereas we found positive correlation of Zn and Iron levels. Additionally 
Zn levels negatively correlated with CDAI, UCEIS and Mayo score (P< 0.05)
conclusion: Our results suggest that Zn deficiency may be potential nonin-
vasive indicator of disease activity in IBD patients as well as the necessity 
of additional supplementation in these patients, which could potentially 
affect the disease course.
disclosure: Nothing to disclose 
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(1:1) as capsules with food. The primary end-point was the change in rela-
tive amount (% total fatty acid) and absolute concentration of EPA and 
DHA in IF and rbcs.
results: Eleven patients (8 male:3 female) with a median age of 63 years 
(range 42-81) completed the study. The ileostomy was present for a median 
9 months (range 2-18) prior to enrolment. Individual compliance with cap-
sules (pill counting) was 100% (range 50-107) over 28 days (range 1-33). 
Overall, the median relative amount of EPA (V2 0.53%; V3 0.36%) and 
DHA (V2 0.67%; V3 0.51%) in IF rose post-treatment compared to baseline 
values (V1; 0.19% and 0.23% for EPA and DHA, respectively). The median 
absolute concentration (µg/ml) in IF also increased for EPA (V2 1.53; V3 
1.13) and DHA (V2 2.62; V3 1.33) from baseline values (V1; 1.06 and 0.79 for 
EPA and DHA, respectively). Only four patients (36%) displayed a statisti-
cally significant increase (Mann Whitney U test, p=0.006) of O3PUFAs in IF 
after the first dose of capsules. At V2, this group displayed a higher rela-
tive amount of EPA (range 6.1 - 22.3%) and DHA (range 7.2 - 23.6%) in IF, 
compared with the other seven patients (range 0.1 - 1.07% and 0.3 - 1.21% 
for EPA and DHA, respectively). 
However, there was no significant inter-individual variation in levels of 
O3PUFAs in IF when measured at an equivalent amount of time (V2 me-
dian 2 hrs, V3 median 2 hrs) after the final dose of capsules (V3). There was 
no significant difference in the time interval between oral dosing and IF/
rbc sample collection, or frequency of stoma bag changes in the previous 
24 hours for V2 and V3. As expected, the relative amount of O3PUFAs in rbc 
increased after 28 days daily dosing compared to baseline values (EPA: V1 
1.19%, V2 1.08%, V3 2.76% and DHA: V1 4.61%, V2 4.50%, V3 6.88%), in 
keeping with previous studies.
conclusion: Intestinal lumen O3PUFA exposure is variable after oral con-
sumption. Reduction in luminal O3PUFA concentrations after 28 days 
dosing suggests intestinal adaptation in individuals who displayed high 
O3PUFA levels after the first dose of oral O3PUFA supplementation. Knowl-
edge of EPA and DHA concentrations in ileostomy fluid can be used to 
study changes in the microbiome and metabolome (SCFA) associated with 
O3PUFA treatment.
references: 1 - Watson H, Mitra S, Croden FC, Taylor M, Wood HM, Perry 
SL, et al. A randomised trial of the effect of omega-3 polyunsaturated fat-
ty acid supplements on the human intestinal microbiota. Gut. 2017 Sep 
26;gutjnl-2017-314968
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P0687 seLecTIve MIcrOBIOTa TransPLanTaTIOn Is effecTIve 
fOr cOnTrOLLIng TOureTTe’s syndrOMe
Ding X., Li Q., Xiang L., Li P., Zhang T., Zhang F.
Second Affiliated Hospital of Nanjing Medical University, Medical Center for 
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Introduction: Emerging scientific data support the significant role of mi-
crobiota in the modulation of the central nervous system. The reconsti-
tution of gut microbiota might be a potential option to treat Tourette’s 
syndrome (TS).
aims & Methods: This study aimed to evaluate the role of selective micro-
biota transplantation on TS. Patients aged 7 to 60 years old with TS and a 
Yale Global Tic Severity Scale (YGTSS) -total tic score ≥ 25 were enrolled 
in this open-label clinical trial. Participants received 200ml selective mi-
crobiota suspension (mixed species of cultured bacteria) daily through the 
nasojejunal transendoscopic enteral tubing (TET) tube for 3 days. Clini-
cal evaluations before, 1, 4 and 8 weeks after SMT were assessed with 
the YGTSS, the Adult Tic Questionnaire (ATQ)/the Parent Tic Questionnaire 
(PTQ), the Gilles de la Tourette Syndrome Quality-of-Life Scale (GTS-QoL) 
and the Clinical Global Impression (CGI)-Severity. 16S rRNA stool analy-
sis were performed to assess associated microbial changes. The urinary 
metabolic profiles of those patients were generated using nuclear mag-
netic resonance (NMR) spectroscopy. Safety was assessed in all patients 
after treatment.
results: Eleven males aged 19.2 ± 7.4 years old finished the study and were 
analyzed. SMT led to a significantly decrease on the YGTSS-total tic score 
from baseline to week 4 (46.2 ± 11.9 to 35.7 ± 17.9, p < 0.05). 45.5% (5/11), 
45.5% (5/11) and 36.4% (4/11) of patients achieved improvement (≥ 30% 
reduction in YGTSS -total tic score) at week 1, week 4 and week 8 after 
mini-FMT, respectively. The significant improvement in quality of life was 
demonstrated by a decreased GTS-QoL score from 42.1±19.5 to 25.5±19.6 at 
week 8 after treatment (p = 0.024). 
Patients with gastrointestinal symptoms (n = 5, such as diarrhea, consti-
pation or flatulence) seemed show better response to SMT than others, 
although there was no significant difference [80% (4/5) vs. 16.7% (1/6), 
p = 0.080]. 
Microbiota analysis showed that SMT altered the composition greatly. SMT 
induced significant alterations in urinary metabolic profiles. No severe 
adverse events related to SMT occurred during treatment and follow-up.
conclusion: SMT improves quality of life and symptoms of TS by altering 
microbiota and metabolic mechanism.
disclosure: Nothing to disclose 
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Introduction: Recurrent abdominal pain and dyspepsia are among the 
most common complaints in paediatric patients. They are often related to 
gastroduodenal disease (GDD), functional dyspepsia (FD) and other gas-
trointestinal disorders. 
Aim of the study was to analyze clinical, endoscopic and histological char-
acteristics of Armenian children with recurrent abdominal pain and dys-
peptic symptoms.
aims & Methods: 150 patients aged 2-18 years (70 males and 80 females, 
mean age 9.2±3.9 years) with recurrent abdominal pain and dyspepsia 
were involved in the study. All patients underwent EGDS with biopsies: 2 
from the antrum (1 for rapid urease test and histology, 1 for Hp culture), 
1 from the duodenal bulb and 1 from the distal esophagus. Histology was 
assessed according to the updated Sydney system. Gastric and duodenal 
biopsy specimens were stained by Giemsa modification for Hp infection. 
1antral biopsy was cultured in Hp selective media.
results: The patients were divided into 2 groups: 1st groupGDD- 70 (46.7%) 
(presence of erosions or ulcer in the stomach and/or duodenum, proven 
Hp infection by 2 invasive tests) and 2nd group FD -80 (53.3%) (no lesions 
in the stomach and duodenum, proven or excluded Hp infection by 2 in-
vasive tests). 
The most common complaints in both groups were recurrent epigastric 
pain, nausea and vomiting. Night time pain wasmore prevalent in patients 
with GDD in comparison to FD group (6.25% vs 17.1%)[Fisher 0.04, χ2-4.41 
(< 0.05)]. Heartburn was almost equally observed in both groups (10 pa-
tients, 14.3% vs 8 patients, 10%). By endoscopy in the 1st group 4 patients 
had nodular gastritis (5.7%), 55 aphtous erosions in the stomach and/or 
duodenum (78.6%) and 11 had PUD (15.7%). 74 (58.7%) FD patients were 
Hp positive.
By histological examination in the 1st group normal stomach mucosa was 
seen in 2 patients (2.8%), chronic active gastritis in 8 (11.4%), chronic 
non-active gastritis in 60 (85.7%), normal duodenal mucosa in 25 (35.7%), 
chronic active duodenitis in 4 (5.7%), chronic non-active duodenitis in 38 
(54.2%) and acute duodenitis in 3 (4.3%) patients.In the 2nd group distri-
bution of histological changes was: normal gastric mucosa in 28 (35%), 
chronic active gastritis in 2 (2.5%) and chronic non-active gastritis in 50 
(62.5%) patients, normal duodenal mucosa in 52 (65%), chronic active 
duodenitis in 4 (5%), acute duodenitis1 (1.25%), chronic non-active duo-
denitis in 23 (28.75%).In 36 (24%) patients esophagitis was diagnosed: 9 
by endoscopy (2 proven by histology) and 27 only by histological investiga-
tion: 20 (28.6%) in the GDD group and 16 (20%) in FD group.
A certain number of serious histologic lesions (22 patients, 14%) was 
noticed in patients with GDD and FD, respectively: gastric metaplasia in 
0 (0%) and 2 (2.5%), gastric dysplasia in 1 (0.7%) and 2 (2.5%), gastric 
atrophy in 4 (2.8%) and 1 (1.25%), gastric metaplasia in duodenum in 8 
(11.4%) and 3 (3.75%), duodenal glandular dysplasia in 1 (0.7%) and 0 
(0%).
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references: 1 Hernández. Castellet J, Narvaiza JL, Rincón JM, Ruiz I, Sán-
chez E, Sobradillo B, Zurimendi A. Curvas y Tablas de Crecimiento. Instituto 
de investigación sobre crecimiento y desarrollo. Fundación F. Orbegozo. 
Ediciones Garsi, Madrid, 1988.
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Introduction: Ways of transmission of Hр-infection cause the possibility 
of the existence of its family tanks and transmission to close relatives of 
the infected person. The risk of developing Hр-associated diseases of the 
upper digestive tract largely depends on the genetic structure of Hр. It 
is known that the most pronounced inflammation in the gastric mucosa 
is observed during colonization by its highly pathogenic strains of Hр. 
Chronic gastritis associated with low pathogenic strains of Hр is more of-
ten characterized by a superficial process of initial manifestation without 
signs of atrophy of the gastric mucosa. These facts are important to con-
sider when deciding on the appointment of therapy for Hр-infected family 
members of the patient.
aims & Methods: To determine the genetic structure of HP in close relatives 
of patients with HP-associated chronic gastritis.
Patients and methods. Among 120 children aged 8-15 years with verified 
chronic HP-associated gastritis, 16 patients with severe widespread inflam-
mation in the gastric mucosa were selected. All patients underwent gas-
troscopy with the morphological study of materials of gastrobiopsy. In them 
using the polymerase chain reaction has identified 16 factors of pathoge-
nicity of Hp: genes of the CagA, CagC, CagE, CagF, CagH, CagM, CagT, Va-
cAs1, VacAs2, IceA, BabA, hpaA, OipA, AlpB and genes encoding the urease 
subunit B (UreB) and I (UreI). Next, we conducted serologic screening with 
the definition of class G antibodies to HP antigens among close relatives 
(parents and sibs of DM). The two and a large excess of antibody titers 
above the reference values, all of them conducted a similar survey (n = 38).
results: All children and their relatives were diagnosed with moderate or 
severe chronic inflammation in the gastric mucosa. Morphological signs 
of its atrophy were revealed in 75 % of children and 90 % of their parents 
and sibs. Every fourth adult patient was diagnosed with intestinal meta-
plasia. Highly pathogenic HP strains were found in 81.3 % of children and 
90 % of their close relatives. Statistical analysis showed that the genetic 
structure of HP in most families (12 out of 16) is almost identical. The high-
est reproducibility in families is characteristic for such factors of HP patho-
genicity as, BabA, hpaA, VacA, Cag E, CagM, CagH, AlpB и UreB.
conclusion: The identity of the genetic structure of HP in children and 
their close relatives with chronic gastritis is established. Highly pathogen-
ic strains of HP cause a pronounced inflammatory process in the gastric 
mucosa. In endoscopic verification of this process, serological screening 
among close relatives of the patient is recommended. In patients with high 
titers of antibodies to HP antigens, an in-depth examination with an as-
sessment of their genetic structure of HP is necessary.
disclosure: Nothing to disclose 
P0691 The InfLuence Of The geneTIc sTrucTure Of 
heLIcOBacTer PyLOrI On The cLInIcaL and MOrPhOLOgIcaL 
ManIfesTaTIOns Of chrOnIc gasTrITIs In adOLescenTs
Eugeny S., E.M. Spivak, O.M. Manyakina, R.M. Levit, M.Yu. Kirillov, L.V. 
Ogneva, I.S. Akkuratova
Yaroslavl State Medical University, Paediatric, Yaroslavl, Russian Federation
contact e-Mail address: spivak58@mail.ru
Introduction: The genetic structure of Helicobacter pylori (Hp) is one of the 
most important factors determining the severity of chronic inflammation 
in the gastric mucosa. This makes it important to study the genome of Hp 
in diseases of the upper digestive tract.
aims & Methods: To establish the features of clinical manifestations and 
pathomorphology of gastric mucosa in Hp-associated chronic gastritis in 
adolescents, depending on the genetic characteristics of Hp.
conclusion: 
•	 Functional dyspepsia was diagnosed in 53.3%, and GDD in 46.7% of 
children with recurrent abdominal pain and dyspepsia.
•	Heartburn and nausea were equally observed in both groups of pa-
tients: 14.3% with GDD and 10% withFD.
•	A certain number (22 patients, 14%)of serious histologic lesions was 
noticed in both groups: 3.5% with GDD and 6.25% children with FD.
•	 EGDS with biopsies might be recommended inpatients with FD to ex-
clude serious histological changes even in case of macroscopically nor-
mal mucosa.
disclosure: Nothing to disclose 
P0689 MaLnuTrITIOn In PaedIaTrIc PaTIenTs WITh 
eOsInOPhILIc esOPhagITIs
Rodríguez Manchón S., Domínguez Ortega G., San Mauro Martin I., 
Velasco Rodríguez-Belvis M., Viada Bris J.F., Cañedo Villarroya E., Pedron 
Giner C., Bacelo Ruano I., Martinez Ibeas M.Á., Muñoz Codoceo R.A.
Hospital Infantil Universitario Niño Jesús, Section of Gastroenterology and 
Nutrition. Department of Paediatrics., Madrid, Spain
contact e-Mail address: silviarodman@gmail.com
Introduction: Patients with Eosinophilic Esophagitis (EoE) may be at nu-
tritional risk due to their own disease, to low dietary intake because of 
symptoms or to elimination diets. The aim of our study was to screen the 
presence of malnutrition in paediatric patients with EoE.
aims & Methods: We conducted a prospective observational study from 
November 2018 to February 2019 in a Paediatric tertiary referral centre. We 
included patients with EoE younger than 18 years. Patients with a previ-
ous diagnosis of other chronic disease were excluded. Demographic and 
anthropometric data, as well as medical history were recorded. The an-
thropometric assessment was made measuring weight (W), height (H) and 
obtaining Z-scores according to the WHO definitions for malnutrition in 
children ≤5 years and according to local growth charts (Hernandez et al 
19881) in those >5 years. Acute malnutrition was considered severe when 
W/H < -3 SD and mild when W/H < -2 SD; chronic malnutrition was consid-
ered severe if H/age < -3 SD, mild if H/age < -2 and acute superimposed on 
chronic if H/age < -2 SD and W/H< -2. Children ≤ 5 years were considered 
overweight if W/H> 2 SD and obese if W/H> 3 SD. Children>5 years were 
considered overweight if W/H> 1 SD and obese if W/H> 2 SD. SPSS 20 was 
used for statistical analysis.
results: We included 33 patients with a median age of 15 years (range 
10,7-17), 24 (72,7%) were male. 16 (48,5%) had asthma and 22 (66,7%) Ig 
E-mediated food allergies. Most patients (81,2%) were on an elimination 
diet: 15 because of their IgE-mediated food allergy, 4 as a dietary treat-
ment for their EoE and 7 secondary to both indications. The median diet 
duration was 4 years (1,6-9,8) and the median of group foods excluded 
per patient was 2 (1-4). In 16 (48,5%) patients, 2 or more group foods 
were excluded. The food groups most commonly excluded were: milk (12), 
nuts (14), fruits (8), egg (7), fish and shellfish (6), gluten (5) and legumes 
(4). 22 (41,5%) patients received medical treatment for their EoE: 11 swal-
lowed topical steroids (STS) and 11 proton pump inhibitors (PPI). Almost 
half of the patients (15, 45,5%), had active EoE in their last endoscopy and 
8 (15,1%) referred symptoms in the moment of the assessment.
Malnutrition was found in 9 (27, 2%) patients: acute mild malnutrition 
in 1 (3%), chronic mild malnutrition in 1 (3%), obesity in 4 (12, 1%) and 
isolated growth retardation in 3 (9,1%). Of those with malnutrition, 8 (88, 
9%) patients were on an elimination diet (p=0.4), with a median of 3 (1-
6) food groups excluded per patient and a median of diet duration of 4,8 
years (3,3-10,8). A third of those patients received previous nutritional sup-
plements with elemental formulas. No statistical differences were found 
between the presence of malnutrition and the number of food groups 
excluded (p=0.4), nor in relation to diet duration (p=0.2). Nevertheless, 
we found a trend towards statistical difference between the duration of 
the disease since diagnosis and the presence of malnutrition (p=0.08). No 
statistical differences were found in relation to existence of Ig-E related 
food allergies nor in relation to medical treatment: 2 of the patients with 
isolated growth retardation received treatment with PPI and 1 with STS; 3 
of the obese patients received medical treatment (2 PPI and 1 STS).
conclusion: Up to 27% of patients with EoE presented malnutrition. Most 
of them were on exclusion diets of prolonged duration and had multiple 
food groups excluded. Patients with a longer duration of their EoE tend to 
present malnutrition in a higher frequency.
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Patients and methods: 133 adolescents aged 15-18 years with Hp-associated 
chronic gastritis were examined. In material of gastrobiopsy, using the 
polymerase chain reaction has identified 16 factors of pathogenicity of Hp: 
genes of the CagA, CagC, CagE, CagF, CagH, CagM, CagT, VacAs1, VacAs2, 
IceA, BabA, hpaA, OipA, AlpB and genes encoding the urease subunit B 
(UreB) and I (UreI).
results: In Hp-associated chronic gastritis in adolescents in 60,9 % of cases 
there is a colonization of the gastric mucosa with highly pathogenic strains 
of Hp. Almost all these patients (98,5 %) there is a combination of several 
genes of the island of pathogenicity, including 60,2 % of cases simultane-
ously 10 and more. Most often identified factors, promote adhesion of Hp 
on the epithelial cells and the formation of biological films: hpaA - 76,7 %, 
OipA - 62,8 %, AlpB - 79,1 %. There were allocated 2 group of patients: 
the main group - teenagers, which identified highly pathogenic Hp strains 
(n = 81) and comparison group - patients associated with low pathogenic 
Hp strains (n = 52). Analysis of clinical syndromes of Hp-associated chronic 
gastritis in adolescents have not found the dependence of the symptoms of 
the disease from the structure of the genome of Hp. At the same time, the 
presence of highly pathogenic strains of Hp according to the morphological 
study is associated with high rates of contamination, increased inflamma-
tion, the appearance of signs of atrophy of the gastric mucosa.
conclusion: The genetic structure of Hp does not affect the clinical mani-
festations of chronic gastritis in adolescents, but determines the severity of 
the inflammatory process and athrophy in the gastric mucosa.
disclosure: Nothing to disclose 
P0692 The effecTIveness Of TheraPy Of heLIcOBacTer 
PyLOrI In chrOnIc gasTrITIs In adOLescenTs, dePendIng On 
The geneTIc sTrucTure Of heLIcOBacTer PyLOrI
Eugeny S., O.M. Manyakina, E.M. Spivak E.M., R.M. Levit, I.S. Akkuratova
Yaroslavl State Medical University, Paediatric, Yaroslavl, Russian Federation
contact e-Mail address: spivak58@mail.ru
Introduction: Features of the genetic structure of the Helicobacter pylori 
(Hp) can have a significant impact on the nature of changes in the gastric 
mucous of the upper digestive tract and on the development, course, prog-
nosis of gastroduodenal pathology, as well as the effectiveness of therapy.
aims & Methods: To establish the dynamics of pathomorphological chang-
es in the gastric mucosa in adolescents with chronic gastritis associated 
with high and low pathogenic strains of Hp, after a course of anti-Helico-
bacter pylori therapy.
Patients and methods. 40 adolescents aged 15-17 years with chronic Hp-
associated gastritis were examined. The polymerase chain reaction in ma-
terial of gastrobiopsy determined the Hp virulence factors: CagA, VacAs1, 
IceA, BabA and the gene encoding the urease subunit I (I Ure). All patients 
were examined twice: before and after 6 months a course of anti-Helico-
bacter therapy.
results: There were allocated 2 group of patients: the main group - teen-
agers, which identified highly pathogenic Hp strains (n = 27) and com-
parison group - patients associated with low pathogenic Hp strains (n = 
13). In repeated morphological study found that after a course of anti-
Helicobacter therapy expressed colonization of gastric mucosa Hp in the 
main group was found in 33,3 % of cases in the comparison group of only 
7,7 %, p < 0,05. In the main group, moderate and severe inflammation of 
the gastric mucosa of 92,6 % versus 31,8 %, p < 0,005. More than half of 
the patients of the main group in the morphological study retained signs 
of atrophy of gastric mucosa; significantly, more often revealed areas of 
hyperplasia and microerosis.
conclusion: Colonization of the gastric mucosa with highly pathogenic Hp 
strains is a factor preventing eradication of infection in chronic Hp-associ-
ated gastritis in adolescents. The majority of these patients 6 months after 
a course of anti-Helicobacter therapy remains moderate or severe degree 
of inflammation in the gastric mucosa.
disclosure: Nothing to disclose 
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Liver & Biliary II
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P0693 eaTIng BehavIOr cOrrecTIOn In PaTIenTs WITh 
nOn-aLcOhOLIc faTTy LIver dIsease dePendIng On 
POLyMOrPhIsMs Of The PParg2 and adrB2 genes
Nikiforova Y., Fadieienko G.
Government Institution L.T. Malaya Therapy National Institute of the 
National Academy of Medical S, Department of the Study of Diseases of the 
Digestive System and their Comorbidity with the Noncommunicable Diseases, 
Kharkov, Ukraine
contact e-Mail address: dr.jana@mail.ru
Introduction: According to the World Health Organization, the health of the 
population is 68-74% dependent on lifestyle and 18-20% on genetics. At 
the present stage in the treatment of patients with non-alcoholic fatty liver 
disease (NAFLD) not enough attention is paid to the study of the individual 
characteristics of eating behavior (EB) and nutrigenetiki. At the same time, 
EB violations are a modifiable risk factor, the correction of which can posi-
tively modulate nutrigenic features - a possible metabolic response to the 
use of certain nutrients. Personalized approach is a priority in improving 
the effectiveness of treatment of patients with NAFLD. The study of nutri-
genetics and its application in practice in the correction of nutrition is an 
important step towards personalized medicine.
aims & Methods: Fifty patients (26 men and 24 women) with NAFLD were 
examined. The control group consisted of 30 practically healthy patients 
reciprocating by sex and age. All patients studied the characteristics of EB 
(DEBQ questionnaire), anthropometric indicators, lipid and carbohydrate 
metabolism, the degree of liver steatosis, the area of visceral adipose tissue 
(CT scan), nutrigenetic features (definition of 5 polymorphisms: Pro12Ala 
of the PPARG2 gene (rs1801282), Gln27Glu of the ADRB2 gene (rs1042714), 
Arg16Gly of the ADRB2 gene (rs1042713), Trp64Arg of the ADRB3 gene 
(rs4994) and Thr54Ala of the FABP2 gene (rs1799883), associated with the 
risk of metabolic disorders. Patients were prescribed individual nutritional 
correction for 12 months, taking into account the identified polymorphisms 
associated with EB violation, namely: carriers of the Pro12Ala genotype of 
the polymorphism of the PPARG2 gene were prescribed a therapeutic diet 
with moderate fat intake of 1.1-1.2 g / kg / day and carbohydrate restriction 
of 2.5-3 g / kg / day, Pro12Pro genotype carriers - diet with restriction of 
fats up to 1.0 g / kg / day and moderate consumption of carbohydrates up 
to 3.5-4 g / kg / day.
results: After 12 months after individual correction, significant positive 
dynamics of the main anthropometric and laboratory-instrumental indica-
tors were observed: a decrease in body mass index and waist circumfer-
ence by a factor of 1.2 (p < 0.05), a decrease in the level of total cholesterol 
and low-density lipoproteins of 1.5 and 1.3 times, respectively (p < 0.001), 
the level of triglycerides, 2.1 times (p < 0.001) and the increase in high-
density lipoproteins by 1.4 times (p < 0.001)), a decrease in HOMA-IR in 
2.2 times (p < 0.001)), liver samples (reduction of alanine aminotr nsferase 
2.4 times and aspartate aminotransferase 2.5 times (p < 0.05)), CT scan 
- signs of steatosis (35% increase in liver x-ray density (p < 0.001)) and 
indicators of visceral obesity (a decrease of 2.1 times the area of visceral 
adipose tissue ((p < 0.001). In addition, during the control questionnaire, 
normalization of EB was observed in 86% of patients and a decrease in 
the degree of eating disorders in 14% of patients compared with baseline 
indicators (p < 0.001).
conclusion: Thus, the appointment of individual correction of EB taking 
into account nutritional features for at least 12 months contributes to a 
significant improvement in metabolic parameters associated with the risk 
of development and progression of NAFLD, the formation and stabilization 
of proper eating habits, which improves the effectiveness of treatment of 
patients with NAFLD.
disclosure: All authors have declared no conflicts of interest. 
P0694 a neW MeThOd Of TreaTMenT fOr decOMPensaTed 
LIver cIrrhOsIs: endOscOPIc uLTrasOund-guIded 
TransgasTrIc, TranshePaTIc InTraPOrTaL auTOLOgOus BOne 
MarrOW TransPLanTaTIOn
Wang F., Zheng S.
The Third Xiang-Ya Hospital, Central South University, Department of 
Gastroenteropathy, Changsha, China
contact e-Mail address: wfen-judy@csu.edu.cn
Introduction: Stem cell therapy recently has been explored extensively as a 
promising treatment for decompensated liver cirrhosis. However, the ge-
nomic instability of cultured stem cells and the low efficiency in obtaining 
them hindered the progress of stem cell transplantation. Moreover, it is 
pivotal to optimizing transplantation routes by which the stem cells can 
be delivered effectively. Here we report the novel Endoscopic ultrasound 
(EUS)-guided transgastric and transhepatic intraportal autologous bone 
marrow transplantation to achieve therapeutic goals in patients with de-
compensated liver cirrhosis.
aims & Methods: To investigate the effects of EUS-guided intraportal au-
tologous bone marrow transplantation in decompensated liver cirrhosis, 
five patients with decompensated liver cirrhosis were recruited. All pa-
tients were successfully performed autologous bone marrow transplanta-
tion through EUS-guided portal vein (PV) access using the transgastric and 
transhepatic approach. Regular revisiting was conducted every 1 month 
and now in 6 months follow-up.
results: Clinical symptoms of patients underwent portal vein transfusion of 
autologous bone marrow were improved obviously, while no side effects 
and complications were observed within 6 months follow-up. Specifically, 
albumin levels, ascites degree, and Child-Pugh score were significantly 
ameliorated in 1 month, and all follow-up data indicated the continuing 
improvement irrespective of postoperative time.
characteristic Baseline 1st month
P value 
(1st month 
vs Baseline)
6th month
P value 
(6th month 
vs Baseline) 
Albumin, g/L 27.58±4.91 35.76±5.87 0.044 38.68±8.98 0.041
Tbil, umol/L 22.08±10.99 24.48±11.92 0.749 22.58±13.40 0.951
PT, sec 16.02±1.73 14.48±1.11 0.132 14.36±1.60 0.153
No ascites 0% (0/5) 20% (1/5) - 60% (3/5) -
Mild ascites 40% (2/5) 40% (2/5) - 20% (1/5) -
Moderate and 
large ascites
60% (3/5) 40% (2/5) - 20% (1/5) -
Child-pugh 
class A
20% (1/5) 40% (2/5) - 80% (4/5) -
Child-Pugh 
class B
60% (3/5) 60% (3/5) - 20% (1/5) -
Child-Pugh 
class C
20% (1/5) 0% (0/5) - 0% (0/5) -
[Characteristics of patients]
conclusion: EUS-guided intraportal transplantation of autologous bone 
marrow improves both clinical symptoms and liver function for patients 
with decompensated liver cirrhosis. It may thus provide a safe, effective, 
non-radioactive, and minimally invasive treatment.
disclosure: Nothing to disclose 
P0695 geneTIcaLLy MOdIfIed hscs sTIMuLaTes LIver 
regeneraTIOn and cOuLd Be a neW PersPecTIve aPPrOach 
fOr deveLOPMenT LIver dIsease TreaTMenT
Zaikina E.I., Shafigullina A., Titova A., Garanina E., Mavlikeev M., 
Pevnev G., Gumerova A., Titova M., Rizvanov A., Kiyasov A.
Kazan Federal University, Institute of Fundamental Medicine and Biology, 
Kazan, Russian Federation
contact e-Mail address: elwish@mail.ru
Introduction: Mortality from chronic liver disease is rising exponentially. 
Nowadays a lot of effort is made to find new approaches to stimulate liver 
regeneration and to develop new methods for liver diseases treatment. 
Cell and gene therapy methods, which are based on using regional stem 
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results: According to immunohistochemistry results injection of mi-
crovesicles: 1) inhibits activation of HSC - there were 20% less desmin+ 
cells; 2) there were no transformation of HSC into α-SMA+ myofibroblasts 
and no risk of liver fibrosis; 3) inhibition of cellular proliferation. So, Ki-
67+ hepatocytes number (area of portal tract and central vein) decreased 
in compare to control group. Number of Ki-67+ nonparenchymal cells in 
portal tract area was 2 times less, than in control. 4) there were no differ-
ences in CK-19 expression in experimental and control groups. As far as 
the cellular proliferation and thus liver regeneration was inhibited, we`ve 
seen higher numbers of ALT levels in experimental group. Decreased re-
generation could be also visualized by lower triglycerides and cholesterol 
levels, there were less, than normal values. Blood urea nitrogen normal-
ized in control group on the 4th day, but in experimental - by the 7th day 
already.
conclusion: Injection of adMSC microvesicles inhibits general cellular re-
sponse to partial hepatectomy. Inhibition of hepatocytes activation and 
proliferation slows down liver regeneration, that is proved by biochemical 
tests. Inhibition of HSC activation means also lesser risk of their transfor-
mation into myofibroblasts and fibrosis development. Thus microvesicles 
transplantation is not for stimulation of liver regeneration. Probably these 
inhibitory effects could be applied for treatment of liver fibrosis, that needs 
to be studied.
references: Work supported by Program of Competitive Growth of KFU.
disclosure: All authors have declared no conflicts of interest. 
P0697 huMan duOdenaL suBMucOsaL gLands cOnTaIn sTeM 
ceLLs WITh POTenTIaL fOr LIver and PancreaTIc regeneraTIve 
MedIcIne
Cardinale V.1, Carpino G.2, Overi D.3, Safarikia S.4, Costantini D.5, 
Lu W.-Y.6, Riccioni O.3, Nevi L.5, Zhang W.7, Melandro F.8, Zizzari I.8, 
Moretti M.8, Chiappetta M.F.5, Nuti M.8, Maroder M.8, Berloco P.B.8, 
Forbes S.9, Reid L.7, Gaudio E.3, Alvaro D.10
1Sapienza University of Rome, Department of Medical-Surgical Sciences and 
Biothecnologies, Rome, Italy, 2University of Rome ‘Foro Italico’, Department 
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of Rome, Department of Anatomical, Histological, Forensic Medicine and 
Orthopedics Sciences, Rome, Italy, 4Sapienza University of Rome, Pharmacy 
and Medicine, Rome, Italy, 5Sapienza University of Rome, Department 
of Translational and Precision Medicine, Rome, Italy, 6University of 
Birmingham, Birmingham, United Kingdom, 7University of North Carolina 
School of Medicine, Chapell Hill, United States, 8Sapienza University of 
Rome, Rome, Italy, 9University of Edinburgh, Edinburgh, United Kingdom, 
10Sapienza University of Rome, Department of Medico-Surgical Sciences and 
Biotechnologies, Polo Pontino, Department of Translational and Precision 
Medicine, Rome, Italy
contact e-Mail address: vincenzo.cardinale@uniroma1.it
Introduction: Regenerative medicine of liver and pancreas has a para-
mount importance. Common precursors for liver, biliary tree and pancreas 
exist at early stage of development in the definitive ventral endoderm 
forming the foregut (1).
aims & Methods: Therefore, the aims of the present study were:
i) to evaluate whether adult human duodenal submucosal glands (SGs) 
contain cells expressing stem cell traits, 
ii) to establish a protocol for isolating these cells based on their anatomical 
and phenotypic traits, 
iii) to characterize self-renewal properties of duodenal SG cells and their 
potency to generate functional liver and β-pancreatic cells.
Human duodenum (N=15) were obtained from deceased adult organs 
and analyzed by immunohistochemistry and immunofluorescence (2). 
The entire duodenum was processed through a chemical dissolution of 
the mucosa layer that preserved the sub-mucosa, which was successively 
digested mechanically and enzymatically (2). Isolated cells were immune-
selected for the markers of pluripotent stem cells Tra-1-60+ SG cells and 
successively cultured in self-renewal or differentiation media (2). Parallel 
experiments were conducted in vivo through injection of Tra-1-60 + cells 
in the spleen of immunocompromised mice, or in streptozotocin-induced 
diabetic mice, or in Krt19CreTdTomatoLSL C57BL6/J mice (1, 2).
results: In human duodenum, SGs contain cells expressing stem cell mark-
ers and with a phenotype which differs from intestinal crypts. Uniquely, 
duodenal SGs contained Ck7+ and Tra-1-60+ cells which are not present in 
intestinal crypts. Lineage tracing study in mice demonstrates homeostatic 
cells seems to be perspective. Currently a particular interest is paid to he-
patic stellate cells (HSCs). Besides, it’s known that HSC is the only source 
of hepatocyte growth factor (HGF) and fibroblast growth factor 4 (FGF4) in 
the liver - growth factors, which play a key role in hepatocytes differentia-
tion during embryogenesis and liver regeneration. It is assumed that us-
ing genetically modified HSCs (gmHSCs) that express these growth factors 
could enhance their therapeutic potential.
aims & Methods: The aim of our work was to study gmHSCs properties 
in vitro and their influence on liver regeneration after transplantation into 
the rats after partial hepatectomy (PH). HSCs were isolated from Wistar 
rat’s liver, genetic modification was carried out by adenovirus Ad5-optH-
GF-optFGF4-RFP, which contained HGF, FGF4 and reporter gene of Red 
Fluorescent Protein (RFP). At first, we have studied gmHSCs phenotype 
in vitro, then we have injected gmHSCs into the rats’ portal vein dur-
ing PH operation (experimental group-EG). Control group (CG) of animals 
received HSCs, transdused by Ad5-RFP vector, which contains only RFP. 
The animals were sacrificed on 1, 2, 3, 5, 7, 10, 14 and 21 days after HSC 
transplantation. Paraffin slices were stained immunohistochemically with 
antibodies to RFP (reporter), α-FP (hepatoblasts) and α-SMA (myofibro-
blasts).
results: The results demonstrated that in vitro gmHSCs expressed hepa-
toblast marker α -FP earlier than native HSCs and the gene expression 
level (by RT-PCR) was also significantly higher in gmHSCs group than in 
native one. This means positive influence of HGF and FGF4 on gmHSCs 
differentiation in hepatocyte direction in vitro. In vivo transplanted HSCs 
saved their viability and migrated to liver parenchyma. A large number of 
RFP+hepatocyte-like cells were detected even on the 1st day after transplan-
tation (4,94±2,37 %) in the EG, then their number increased to 8,57±5,15 
% by the 2nd day. After that, RFP+ cells quantity gradually decreased to 
4,82±3,64 % by the 14th day. In the CG dynamics was the same, but the 
average number of cells was less. α-FP+ hepatocytes were also detected 
in both groups, but in the EG α-FP+ cells amount was significantly higher 
than in the CG. In all the groups α-SMA+ myofibroblasts, responsible for 
liver fibrosis, were not detected.
conclusion: gmHSCs transplantation had more intensive repopulating ef-
fect on hepatocytes during the transplantation. It proves the positive effect 
of the inserted HGF and FGF4 genes on the liver regeneration process. 
Thus, gmHSCs transplantation stimulates liver regeneration and contrib-
utes to hepatocytes repopulation without risk of liver fibrosis. 
Work supported by Program of Competitive Growth of KFU.
disclosure: All authors have declared no conflicts of interest. 
P0696 The effecT Of MesenchyMaL sTeM ceLLs derIved 
MIcrOvesIcLes TransPLanTaTIOn On LIver regeneraTIOn 
afTer ParTIaL hePaTecTOMy In raTs
Shafigullina A., Gomzikova M., Titova A., Mavlikeev M., Barkov A., 
Kundakchyan G., Usmonova G., Bilyalov A., Gumerova A., Rizvanov A., 
Kiyasov A.
Kazan (Volga Region) Federal University, Kazan, Russian Federation
contact e-Mail address: sh.aygul@gmail.com
Introduction: There are numerous studies of stimulation of liver regenera-
tion by transplantation of mesenchymal stem cells. Their effect is explained 
by direct intercellular interactions and paracrine communications. One of 
the alternative ways to influence on liver regeneration is injection of mi-
crovesicles. Microvesicles are extracellular vesicles that contain growth 
factors and cytokines and play a major role in intercellular paracrine com-
munications. It is said, that in compare to cells microvesicles transplanta-
tion is not accompanied by risk of metaplasia and mutations, because they 
do not contain any genetic information.
aims & Methods: To study the effect of transplantation of mesenchymal 
stem cells microvesicles derived from adipose fat tissue on liver regenera-
tion after partial hepatectomy in rats. 
Mesenchymal stem cells, isolated from visceral rat fatty tissue (adMSC), 
were treated by Cytochalasin B to derive microvesicles. These microvesicles 
were transplanted into portal vein of rats after partial hepatectomy. Control 
group of rats after partial hepatectomy received injection of PBS. On 2, 5, 
7 and 14 days after operation rats were sacrificed. Functional parameters 
of liver were analyzed by biochemical tests, morphological changes were 
studied by immunohistochemical staining of liver slices with antibodies to 
desmin (HSC marker), Ki-67 (proliferation marker), α-SMA (myofibroblasts 
marker), CK-19 (cholangiocytes marker).
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self-renewal of SGs, which is not supported by duodenal crypt cells. In 
vitro, SG cultures were composed of cells expressing Ck7, Sox9, EpCAM, 
Lgr5, and pluripotency markers (Sox2, Tra-1-60, Tra-1-81). SG cells have 
self-renewal properties, form organoids, and differentiate towards hepat-
ic and pancreatic lineages with distinctive functional properties. In vivo, 
transplanted cells engraft into livers of severe combined immunodeficient 
(SCID) mice and differentiate to mature liver cells; in experimentally in-
duced diabetes, insulin-positive cells appear within duodenal SGs.
conclusion: Actual candidate cell sources for regenerative medicine of liver 
and pancreas are mature cells (hepatocytes and islets) with poor success in 
literature or reprogrammed cells with the related limits of cell manipula-
tion and tumorigenic risk. Duodenal SGs could represent an easily avail-
able cell source for regenerative medicine of ventral endoderm organs 
with no need of reprogramming.
references: 1) Lanzoni G, Cardinale V, Carpino G. The hepatic, biliary, and 
pancreatic network of stem/progenitor cell niches in humans: A new refer-
ence frame for disease and regeneration. Hepatology. 2016 Jul;64(1):277-
86. 2) Carpino G, Cardinale V, Gentile R, Onori P, Semeraro R, Franchitto 
A, Wang Y, Bosco D, Iossa A, Napoletano C, Cantafora A, D’Argenio G, Nuti 
M, Caporaso N, Berloco P, Venere R, Oikawa T, Reid L, Alvaro D, Gaudio E. 
Evidence for multipotent endodermal stem/progenitor cell populations in 
human gallbladder. J Hepatol. 2014 Jun;60(6):1194-202.
disclosure: The authors declare no competing interests with exception of 
V.C., G.C., E.G., D.A., and L.R. who have submitted a provisional filling on 
isolation method for duodenal submucosal gland stem cells. 
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Introduction: Non-alcoholic fatty liver disease (NAFLD) is the most com-
mon cause of chronic liver disease worldwide. Transient elastography (TE, 
Fibroscan) with controlled attenuation parameter (CAP) has already been 
proven as an accurate measure for hepatic fibrosis and steatosis. However, 
its role in stratifying cardiovascular (CV) risk is unknown.
aims & Methods: Cohort, retrospective, single center study, including con-
secutive NAFLD patients that underwent Fibroscan. Patients were followed 
at least a year.
Co-variables were chosen bearing in mind clinical relevance and literature 
evidence.
The correlation towards the outcome variable (Cardiovascular event) was 
assessed with univariate and multivariate analysis, using SPSS - p value < 
0.05 was considered statistically significant
results: We assessed 96 patients with NAFLD, of whom 64 (66,7%) were 
female, with a mean age of 51,6 years old, all Caucasian. From our cohort, 
55.2 % of the patients met criteria for metabolic syndrome.
Several variables had statistical significance towards cardiovascular events 
incidence on the univariate analysis. (Cardiac failure; Hypertension; dys-
lipidemia, diabetes mellitus, metabolic syndrome, body mass index, CAP 
higher 290 db/m, Framigham score and some therapeutics, hypocoagula-
tion agents, antiplatelet agents, statins, antihypertension agents.)
We report 14 (14,4%) cardiovascular events during follow up, the CAP 
mean in this subgroup was 318,4 db/m.
For CAP values superior to 290 db/m (decibels per meter), the odd of in-
cidence of cardiovascular events were 4,2 times higher, for each unit of 
cap increase (Odds ratio crude 4,250; p value 0.05). Adjusting the regres-
sion multivariate model with previous significant variables, the association 
trend to statistically non-significance.
Framingham score was not correlated statistically with CAP values.
conclusion: We were able to stablish a correlation between CAP and in-
cidence of cardiovascular disease events. Meaning that, a CAP increase 
is associated with increase of incidence on CV events, mainly in high cap 
values, over 290 db/m. However, this correlation is diluted adjusting to 
another CV risk predictor covariables. Fibroscan is easy to apply, safe and 
a cost-effective method to evaluate NAFLD. CAP values are related to CV 
events, nevertheless, further studies are needed to identify properly the 
subpopulation that would most benefit from this feature.
disclosure: Nothing to disclose 
P0699 dIeTary InTake Of PhenOLIc acIds Is InverseLy 
assOcIaTed WITh LIver sTeaTOsIs and InsuLIn resIsTance 
In The generaL POPuLaTIOn
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Introduction: The inverse association between NAFLD and diet rich in fruit 
and vegetables has been demonstrated, but the specific compounds that 
may be responsible for this association need to be elucidated.
aims & Methods: The aim of this study was to test the association be-
tween phenolic acids (PA) consumption, liver steatosis, liver fibrosis, and 
insulin resistance (IR). This was a cross-sectional study among general 
population, included in a metabolic screening program. Liver steatosis 
was evaluated by ultrasonography to determine NAFLD and quantified by 
the HepatoRenal Index (HRI); fibrosis was assessed by FibroTest; IR by the 
sample upper quartile of HOMA score. Nutritional intake was measured 
by food frequency questionnaire (FFQ). Phenolic acids food content was 
calculated according to Phenol Explorer.
results: A total of 789 subjects were included (52.6% men, age 58.83±6.58 
years). Higher (above the upper median) phenolic acids intake was in-
versely associated with the presence of NAFLD, higher HRI and IR 
(OR=0.69, 95%CI 0.49-0.98, P=0.036; OR=0.64, 95%CI 0.45-0.91, P=0.013; 
OR=0.61, 95%CI 0.42-0.87, P=0.007, respectively), adjusting for age, gen-
der, BMI, dietary and lifestyle factors. Considering specific classes of PA, 
higher hydroxybenzoic acids intake was independently associated with 
lower odds of NAFLD, higher HRI and fibrosis (OR=0.72, 95%CI 0.51-0.99, 
P=0.049; OR=0.63, 95%CI 0.45-0.89, P=0.008; OR=0.28, 95%CI 0.12-0.64, 
P=0.003, respectively). Higher hydroxycinnamic acids consumption was 
independently associated with lower odds of IR (OR=0.63, 95%CI 0.44-
0.90, P=0.012).
conclusion: Phenolic acids may represent food compounds that are protec-
tive against insulin resistance and NAFLD-related liver damage.
disclosure: Nothing to disclose 
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P0701 rIsk Of MeTaBOLIc syndrOMe In suBjecTs 
WITh nOrMaL aLanIne aMInOTransferase LeveL: 
a POPuLaTIOn-Based naTIOnWIde sTudy
Sohn Y.W.1, Sohn W.2, Cho J.-Y.3
1Wonkwang University Sanbon Hospital, Gunpo, Korea (Republic of), 
2Wonkwang University Sanbon Hospital, Seoul, Korea (Republic of), 3Chosun 
University Hospital, Gwang-Ju, Korea (Republic of)
contact e-Mail address: giyoung@wonkwang.ac.kr
Introduction: This study aimed to investigate the risk of metabolic syn-
drome in subjects with normal ALT level for the general population.
aims & Methods: A cross-sectional study was conducted using nationally 
representative samples from the Korean National Health and Nutrition 
Examination Survey 2007-2015. A total of 43,402 adults (men: 17,535 and 
women: 25,867) with ALT ≤40 U/L and no history of hepatitis B, hepatitis 
C, liver cirrhosis, and liver cancer were analyzed. The risk of metabolic 
syndrome were evaluated according to ALT level (men: < 15 U/L, 15~30 U/L, 
and 30~40 U/L / women: < 10 U/L, 10~20 U/L, 20~40 U/L). Metabolic syn-
drome was defined by updated National Cholesterol Education Program 
Adult Treatment Panel III standards.
results: The prevalence of metabolic syndrome is significantly increased 
as ALT increases regardless of sex. The proportion of metabolic syndrome 
in men is 12.6%, 25.2%, and 39.7% in ALT < 15 U/L, 15~30 U/L, and 30~40 
U/L, respectively (p< 0.001) and that of metabolic syndrome in women is 
7.2%, 23.3%, and 44.7% in ALT < 10 U/L, 10~20 U/L, and 20~40 U/L, re-
spectively (p< 0.001). There is an ALT-dependent relationship in the risk of 
metabolic syndrome within normal ALT level adjusting age, alcohol intake, 
and body mass index. 
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ganj District) identified by manual census were interviewed by a door-
to-door survey using a structured questionnaire by trained field research 
assistants in this cross sectional study. Clinical examination and anthropo-
metric measurements were done by the investigators. Biochemical tests on 
blood were done after overnight fasting and ultrasonography were done 
by experienced radiologist on every subject. BMI was categorized by WHO 
standards and metabolic syndrome (MetS) was defined by Adult Treatment 
Panel III.
results: Of the total 1682, 1353 subjects responded (response rate 80.44%). 
In the final analysis1305 subjects (mean age 41.28 ± 15.10, female 908, 
69.6%) were included after exclusion of forty eight subjects for any 
amount alcohol consumption, HBsAg or Anti-HCV positivity. On ultraso-
nography, NAFLD was present among 242 (mean age 46.10 ± 12.30, male 
93, female 149) subjects with an overall prevalence of 18.5 % (male 23.40% 
vs female 16.4%, p=0. 003). Among subjects with underweight, normal 
weight, overweight and obesity, NAFLD was present in 0/161(0%), 57/643 
(8.9 %), 119/383 (31.1%) and 66/118(55.9%) respectively (p<0.001). NAFLD 
was more common among subjects aged 40 years or more [153/667, 24.4% 
vs 89/678, 13.1%; odds ratio (OR) 2.13, 95% confidence interval (CI):1.60-
2.85]; DM (82/168,48.8% vs 160/1137, 14.1%; OR=5.82; 95% CI:4.12-8.23, 
<p=0.001), abdominal obesity (134/365,36.7 % vs 108/940, 11.5 %; OR=4.45, 
95% CI:3.34-5.99, <p=0.001) and MetS (163/373, 43.7% vs 79/932 ,8.5 %; 
OR=8.38, 95% CI: 6.16-11.41). Table 1 compares the significant key param-
eters of MetS among subjects with and without NAFLD. 
Additionally, elevated ALT (>40U/L) was present among 53/242(22.0%) 
subjects with NAFLD. On binary logistic regression analysis, male sex, 
fasting hyperglycemia or pre-existing DM, higher SBP, abdominal obesity, 
BMI>25 kg/m2, presence of MetS and higher serum triglyceride were found 
to be risk factors for NAFLD.
characteristics subjects with nafLd (mean ±sd)
subjects without 
nafLd (mean ±sd) P value
SBP 126.84±19.76 113.82±17.65 <0.001
DBP 82.19±11.46 75.54±10.56 <0.001
Fasting blood glucose (mmol/L) 6.40±3.13 4.90±1.41 <0.001
S. Total cholesterol (mg/dl) 210±82.12 188.08 ±56.22 <0.001
S.LDL-C (mg/dl) 187.85±41.24 122.22±51.84 0.115
S.HDL-C (mg/dl) 37.62± 9.51 38.84±10.91 0.109
Fasting S. triglyceride (mg/dl) 226.84±140.12 142.48±93.01 <0.001
BMI (kg/m2) 27.93±4.04 22.87±4.06 <0.001
[Comparisons of metabolic syndrome parameters between subjects with and 
without NAFLD]
conclusion: NAFLD imposes a great burden of liver disease in the rural 
community of Bangladesh. Male sex, DM, higher SBP, abdominal obesity, 
BMI>25, presence of MetS and higher serum triglyceride are found to be 
risk factors for NAFLD.
disclosure: Nothing to disclose 
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Introduction: Epidemiologic data suggest that colonic adenomas have an 
increased tendency to occur in patients who are obese, or have a positive 
family history of colon cancer, or diabetes mellitus. Recent data suggest 
that impaired glucose tolerance, dyslipidemia, and metabolic syndrome 
are associated with a higher risk for colonic adenomas. Patients with non-
alcoholic fatty liver disease (NAFLD) often share several of the aforemen-
tioned risk factors for colonic adenomas. However, data are lacking about 
the relationship between NAFLD and colonic adenomas.
aims & Methods: The aim of this study was to systematically evaluate 
whether NAFLD is an independent risk factor for colonic adenomas.
The adjusted odds ratios (ORs) of metabolic syndrome in men are 1.55 
(95% confidence interval [CI]: 1.38-1.74), and 2.48 (95% CI: 2.16-2.85) in 
ALT 15~30 U/L, and 30~40 U/L, respectively (p< 0.001). And, the adjusted 
ORs of metabolic syndrome in women are 1.58 (95% CI: 1.35-1.86), and 
2.67 (95% CI: 2.26-3.15) in ALT 10~20 U/L, and 20~40 U/L, respectively 
(p<0.001).
conclusion: The risk of metabolic syndrome is increased as ALT increases 
within normal ALT level. Even if the ALT level is within normal range, it may 
be a useful marker to evaluate metabolic syndrome.
disclosure: Nothing to disclose 
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Introduction: Evidence is limited regarding to the association between di-
etary intake of antioxidants and non-alcoholic fatty liver disease (NAFLD) 
and steatohepatitis (NASH).
aims & Methods: The aim was to test the association between dietary vi-
tamins E and C intake and NAFLD, NASH and fibrosis markers. This was 
a cross-sectional study of general population. NAFLD was evaluated by 
ultrasonography and presumed steatosis, NASH and fibrosis by FibroMax. 
The level of steatosis was defined using SteatoTest, significant NASH de-
fined ≥2 and borderline-significant fibrosis ≥F1-F2. Nutritional intake was 
measured by food frequency questionnaire (FFQ).
results: Overall, 789 subjects were included (52.6% men, age 58.83±6.58 
years), 714 had reliable FibroMax. Adjusting for BMI, dietary and lifestyle 
factors, the upper tertile of vitamin E intake/1000 Kcal was associated with 
lower odds of NASH (OR= 0.64, 0.43-0.94, P= 0.024). There was an in-
verse association between reaching the recommended vitamin E intake 
and NASH (OR= 0.48, 0.30-0.77, P= 0.002). The upper tertile of vitamin C 
intake/1000 Kcal was associated with lower odds of NAFLD and NASH (OR 
= 0.68, 0.47-0.99, P= 0.045; OR= 0.57, 0.38-0.84, P= 0.004, respectively). 
Both vitamins were related with the level of steatosis according to Stea-
toTest.
conclusion: Vitamin E and C intake may be protective from NAFLD related 
liver damage.
disclosure: Nothing to disclose 
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Introduction: The prevalence and risk factors of nonalcoholic fatty liver dis-
ease (NAFLD) varies in different populations. Although nonalcoholic fatty 
liver disease (NAFLD) has been reported high from the Western and af-
fluent Asian countries, there is paucity of such data from less developed 
countries, particularly rural areas where most of the people live in Asia. 
Hence, we undertook a study on the epidemiology of NAFLD among the 
general population in a rural community of Bangladesh.
aims & Methods: All the adult persons (≥18 years) of a defined area of 
three villages (Charcharia and Churian, Dhaka District, Kharrah, Munshi-
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A prospective study. Setting University central hospital of army with case 
recruitment from the community and clinics. Patients Subjects aged 30-70 
years were recruited for colonoscopic screening from two study cohorts: 
(1) community subjects; and (2) consecutive patients with biopsy proven 
NAFLD. In the community cohort, hepatic fat was measured by fibroscan. 
Main outcome measures Prevalence of colorectal adenomas. Advanced 
colorectal neoplasm was defined as cancer or adenomas with villous ar-
chitecture or high grade dysplasia.
results: NAFLD patients (n=203) had a higher prevalence of colorectal ad-
enomas (34.7% vs 21.5%; p=0.043) and advanced neoplasms (18.6% vs 
5.5%; p=0.002) than healthy controls (N=201). Thirteen of 29 (45%) NAFLD 
patients with advanced neoplasms had isolated lesions in the right sided 
colon. Among patients with biopsy proven NAFLD, patients with non-alco-
holic steatohepatitis (N=49) had a higher prevalence of adenomas (51.0% 
vs 25.6%; p=0.005) and advanced neoplasms (34.7% vs 14.0%; p=0.011) 
than those with simple steatosis (N=86). After adjusting for demographic 
and metabolic factors, non-alcoholic steatohepatitis remained associated 
with adenomas (adjusted OR 4.89, 95% CI 2.04 to 11.70) and advanced 
neoplasms (OR 5.34, 95% CI 1.92 to 14.84). In contrast, the prevalence of 
adenomas and advanced neoplasms was similar between patients with 
simple steatosis and control subjects.
conclusion: Non-alcoholic steatohepatitis is associated with a high preva-
lence of colorectal adenomas. The adenomas are found more commonly 
in the right sided colon. Colorectal cancer screening is strongly indicated 
in this high risk group.
references: Nadege T. Touzin, Kelvin N.V. Bush. Prevalence of colonic ad-
enomas in patients with nonalcoholic fatty liver disease. Ther Adv Gastro-
enterol (2011) 4(3) 169176
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Introduction: Treatment of non-alcoholic fatty liver disease (NAFLD) is 
essentially based on life style modification:diet and physical activity and 
managing risk factors. Weight loss of at least 3-5% has proven to improve 
steatosis and 7-10% to improve fibrosis.
aims & Methods: To assess weight loss after 3 and 6 months of life style 
modification
Prospective study conducted over one year (December 2017 to December 
2018) including all patients followed for NAFLD. All patients have been 
educated about diet and physical activity , and have been informed about 
complications and risks of the metabolic syndrome.
results: We included 58 patients: 46 women and 12 men (sex-ratio =0.2) 
with an average age of 49.4 years [14-81 years]. Type 2 diabetes was found 
in 22 patients (37.9%), high blood pressure in 20 patients (34.5%) and dys-
lipidemia in 24 patients (41.4%). The average body mass index was 32.6 
Kg/m2 [20-55 kg/m2]. Seventeen patients (29.1%) were overweight and 35 
(60.6%) patients were obese. The average waist circumference was 104.24 
cm [67-138cm]. Android obesity was objective in 46 patients (79.3%) and 
hepatic cytolysis was found in 9 patients (15.5%). 
The average weight loss at 3 months was 1.26% [0.8-10%] and at 6 months 
was 2.33% [0.9-13.6%].
After 6 months of follow-up: 38 patients (65.5%) lost weight, 13 patients 
(22.4%) gained weight and 7 patients (12.1%) maintained a stable weight. 
Only 8 patients had a weight loss ≥5%.
Normalization of hepatic cytolysis was noted in 66.6% of patients who lost 
weight and had initial cytolysis.
Ischemic heart disease, gonalgia and advanced age were factors of non-
adherence in patients who had not lost weight.
conclusion: Life style modification allowed weight loss in 65.5% of patients 
and normalization of hepatic cytolysis in 65.5% of cases. Non-adherence 
to the treatment was related to the impossibility to perform regular physi-
cal activity.
disclosure: Nothing to disclose 
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Introduction: Nonalcoholic fatty liver diseases (NAFLD), from simple ste-
atosis to progressive nonalcoholic steatohepatitis (NASH), fibrosis and cir-
rhosis, are most common chronic liver diseases in the world. Somatostain 
(SST), a kind of neuroendocrine hormone, can suppress the release of 
gastrointestinal peptide, including cytokines. Octreotide, longer half-time 
somatosatin analog, is used as a replacement of somatostain due to simi-
lar effects.
aims & Methods: We aim to explore the relationship between endoplasmic 
reticulum and nonalcoholic steatohepatitis and octreotide effects. A total 
of 30 male C57BL/6J mice were assigned to normal chow (NC), high fat and 
high cholesterol diet (HFHC), HFHC + octreotide (HFHC+O) groups. After 
16-week feeding, mice received i.p. injection of either octreotide (60µg/
Kg/12h) or saline for 4 weeks. Body weight, food intake, liver weight, se-
rum and hepatic lipid levels, serum insulin, glucose tolerance test were 
measured, and serum and hepatic inflammatory cytokines were analyzed 
with ELISA. Hepatic histology was investigated with H&E staining, Oil red 
O staining, Sirius red staining and immunohistochemical (IHC) staining. 
Expression of endoplasmic reticulum function related molecules were 
measured with RT-PCR and western blot, respectively.
results: In contrast to NC group, Mice with HFHC showed significant in-
creased liver weight, ALT and AST levels, serum cholesterol and inflam-
matory cytokines, hepatic triglyceride and cholesterol levels, accompanied 
by aggregated fat deposition in hepatocytes and infiltrated inflammatory 
cells around hepatocytes, which were attenuated by octreotide treatment. 
Compared with NC mice, HFHC mice demonstrated increased F4/80 and 
α-SMA expression in IHC staining, and elevated expression of inositol re-
quiring enzyme 1 (IRE-1α), activating transcription factor 6 (ATF 6) and 
spliced X-box binding protein 1 (sXBP-1) with RT-PCR and western blot, 
while octreotide treatment reversed these changes.
conclusion: Octreotide can attenuate hepatic inflammation and lipid 
metabolism in a NASH mice model, probably by improving endoplasmic 
reticulum dysfunction. The further underlying mechanisms are under in-
vestigation.
disclosure: Nothing to disclose 
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Pimentel M.2, Triantafyllou K.1
1Attikon University Hospital, National and Kapodistrian University of Athens, 
Medical School, Hepatogastroenterology Unit, 2nd Department of Internal 
Medicine & Research Unit, Athens, Greece, 2Medically Associated Science 
and Technology (MAST) Program, Cedars-Sinai, Los Angeles, United States, 
3Department of Gastroenterology and Hepatology, Athens Medical Palaio 
Faliron General Hospital, Athens, Greece, 42nd Department of Pathology, 
National and Kapodistrian University of Athens, Medical School, Attikon 
University Hospital, Athens, Greece, 54th Department of Internal Medicine, 
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contact e-Mail address: gabriela.leite@cshs.org
Introduction: Non-alcoholic fatty liver disease (NAFLD) is a multifactorial 
disease. Among others, the interaction of gut microbiome with the host 
has been proposed as potential mechanism of NAFLD pathogenesis and 
progression. However, data about the composition of duodenal microbi-
ome of these patients is scarce.
aims & Methods: We aimed to characterize the duodenal microbiome (DM) 
of NAFLD patients and compare it to that of healthy controls. Patients with 
histological, biochemical or radiological diagnosis of NAFLD underwent 
upper gastrointestinal endoscopy and duodenal juice (2cc) was aspirated 
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of endoscopies by 12.1%. Additional parameters were examined, among 
which the quotient PLT / LogkPa exhibited the larger area under the curve. 
By setting a cut-off of ≤122000 µl-1 • kPa-1, this method maintained 100% 
sensitivity and NPV, managing at the same time to increase the percentage 
of endoscopies avoided to 20.6%. An additional cut-off of ≤ 92000 µl-1 • 
kPa-1 was examined due to its capability to further increase this percentage 
to 44.9%. However, this happened at the expense of an increased percent-
age of missed HRVs (6.3%).
conclusion: The Baveno VI criteria are validated in our study population. 
The new criteria developed in this study succeed in further decreasing the 
number of screening EGDs and appear as a legitimate alternative to the 
Baveno VI criteria. More studies are required, in order to verify their ef-
fectiveness.
references: De Franchis R, Abraldes JG, Bajaj J, Berzigotti A, Bosch J, Bur-
roughs AK, et al. Expanding consensus in portal hypertension Report of 
the Baveno VI Consensus Workshop: Stratifying risk and individualizing 
care for portal hypertension. J Hepatol. 2015;63:743-52. DOI:10.1016/j.
jhep.2015.07.001
disclosure: Nothing to disclose 
P0709 chrOnIc renaL dIsease afTer The fIrsT ePIsOde 
Of acuTe kIdney Injury In cIrrhOTIc PaTIenTs - a reaLITy 
We shOuLd keeP In MInd
Xavier S.1,2,3, Monteiro S.1,2,3, Magalhães J.1,2,3, Marinho C.1,2,3, Cotter J.1,2,3
1Hospital da Senhora da Oliveira, Guimarães, Gastroenterology, Guimarães, 
Portugal, 2University of Minho, School of Medicine, Braga, Portugal, 
3University of Minho, ICVS/3Bs PT Government Associate Laboratory, Braga/
Guimarães, Portugal
contact e-Mail address: smaxavier@gmail.com
Introduction: Acute kidney injury (AKI) is frequently identified in cirrhotic 
patients and associates with bad prognosis. Recent studies suggest that 
after the first event, a non-neglectable percentage of patients evolves to 
chronic kidney disease (CKD).
aims & Methods: We aimed to asses risk factors for progression to CKD and 
its’ impact on patients’ prognosis. 
Unicentric, retrospective study, including patients with cirrhosis admit-
ted for acute decompensation with AKI. Excluded patients with previous 
CKD (glomerular filtration rate (GFR) < 60mL/min/1.73m2 for >3 months), 
patients who died before 3 months of follow-up and patients without ad-
equate electronic records. Assessed GFR 3 months after the initial event 
and several outcomes.
results: Included 87 patients. Three months after de initial event, 34.5% of 
patients had CKD. Patients who developed CKD were more frequently un-
der proton pump inhibitors (66.7% vs 36.8%, p=0.008), had higher basal 
creatinine levels (1.1±1.1mg/dL vs 0.8±0.3mg/dL, p< 0.001) and reached 
higher maximum creatinine levels in the first AKI episode (1.8±1.1mg/dL vs 
1.4±0.7, p=0.004). On multivariate logistic regression, only basal creatinine 
level significantly associated with of progression to CKD (p=0.006, OR 28.7, 
IC 95% 2.6-315.8). 
Regarding outcomes, patients who devolved CKD showed higher rates 
of new AKI episodes (90.0% vs38.6%, p< 0.001) and had higher mortal-
ity rates at 6 months, 1 and 2 years (40.0% vs 10.5%, p=0.001; 53.3% vs 
15.8%, p< 0.001 and 56.7% vs 29.8%, p=0.015, respectively).
conclusion: After the first AKI episode over one third of patients evolve to 
CKD and these patients have not only higher rates of new episodes of AKI 
but also higher mortality rates at 6 months, 1 and 2 years. Basal creatinine 
level was the only independent predictor of progression to CKD.
disclosure: Nothing to disclose 
from the 3rd-4thpart of duodenum in sterile traps. Patients without liver 
disease, undergoing gastroscopy due to gastroesophageal reflux disease, 
comprised the control group. DNA was isolated using the MagAttract Pow-
erSoil DNA Kit. Microbiota was analyzed by 16S rRNA metagenomic se-
quencing in MiSeq platform (Illumina). Operational Taxonomic Units (OTU) 
clustering and taxonomic analysis were performed with CLC Microbial Ge-
nomics Module v. 2.5. A Negative Binomial GLM model was used to obtain 
maximum likelihood estimates for an OTU’s fold change between the two 
groups, and the Wald test was used to determine significance.
results: 19 subjects with NAFLD (7 females; age 57.1±11.2 yrs) and 12 con-
trols (7 females; age 45±17.6 yrs) had their DM fully mapped. Principal 
Coordinate Analysis (PCoA) of the UniFrac distance generated from taxon 
abundance (beta-diversity) revealed important differences in the DM pro-
file of subjects with NAFLD when compared to controls, resulting in two 
distinct clusters on PCoA plots.Intriguingly, the α-diversity indexes of sub-
jects with NAFLD were similar when compared to controls (Total number, 
P=0.2520; Simpson’s index, P=0.8320). The DM of control subjects was 
characterized by high relative abundance (RA) of the Firmicutes phylum 
(68%), followed by Bacteroidetes, Actinobacteria and Fusobacteria (14%, 
7%, and 5% respectively).Comparatively to controls, the DM of subjects 
with NAFLD was also characterized by high RA of the Firmicutes phylum 
(63%, P=0.346), but the RA of the Actinobacteria phylum was increased 
in these subjects (Fold change (FC)=1.60, P=0.02). Interestingly, the rela-
tive abundance of the TM7 phylum was also increased in subjects with 
NAFLD when compared to controls (FC=1.91, P=0.02). At order level, the RA 
of specific taxon from Actinobacteria and TM7 phyla were also increased 
in subjects with NAFLD when compared to controls, including the Bifi-
dobacteriales order (FC=6.96, P=0.03) and CW40 order (FC=4.86, P=0.02) 
respectively. Additionally, the Bacillales order from Firmicutes phylum and 
the Enterobacteriales order from Proteobacteria, were also increased in 
NAFLD subjects when compared to controls.
conclusion: The duodenal microbiome of NAFLD patients is different at 
phylum and order level compared to that of controls. A deeper assessment 
of the small bowel microbiome in this population may lead to clues to the 
development of NAFLD.
disclosure: Nothing to disclose 
P0708 nOn-InvasIve screenIng Of esOPhageaL varIces: 
a MuLTIcenTer sTudy evaLuaTIng The BavenO crITerIa and 
PrOPOsIng an aLTernaTIve aPPrOach
Protopapas A.1, Mylopoulou T.2, Papadopoulos V.2, Vogiatzi K.2, Goulis I.1, 
Mimidis K.2
1Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, 
Thessaloniki, Greece, 2Democritus University of Thrace, First Department of 
Internal Medicine, Alexandroupolis, Greece
contact e-Mail address: adoprot@hotmail.com
Introduction: Variceal bleeding is a common complication of patients with 
cirrhosis that can mark the transition from compensated advanced liver 
disease (cALD) to decompensated cirrhosis. Therefore, endoscopic screen-
ing for high-risk varices (HRVs) was initially proposed for all cirrhotics. In 
an effort to avoid unnecessary endoscopies, the Baveno VI workshop pro-
posed criteria that would identify cirrhotics with low risk of having HRVs. 
According to these criteria, in patients with cALD, platelet count > 150000/
µl and liver stiffness measurement (LSM) < 20 kPa, screening endoscopy 
could be avoided.
aims & Methods: Aim of this study is to validate the Baveno VI criteria and 
explore other possible parameters that can be used for the non-invasive 
screening of esophageal varices. Patients with advanced liver disease (de-
fined as LSM > 12 kPa) were prospectively enrolled. Patients with splanch-
nic vein thrombosis, use of beta-blockers and esophageal varices were 
excluded. The study participants were evaluated according to the Baveno 
criteria, undergoing LSM, laboratory tests and esophagogastroduodenos-
copy (EGD) which was conducted within six months of liver stiffness and 
laboratory measurements.
results: One-hundred and seven consecutive patients were enrolled in the 
study and underwent LSM and screening endoscopy. Fifty-one patients 
(47.7%) had portal gastropathy or normal endoscopic findings (F0), 34 
patients (31.8%) exhibited small varices without red spots (F1), and 22 pa-
tients (20.5%) had HRVs (F2/F3). Thirteen patients met the Baveno VI cri-
teria, none of which had HRVs. The Baveno VI criteria achieved 100% sen-
sitivity and negative predictive value (NPV) while decreasing the number 
471Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
P0710 esTIMaTIOn Of gLOMeruLar fILTraTIOn raTe (gfr) 
In cIrrhOTIcs: evaLuaTIOn Of equaTIOns currenTLy used In 
cLInIcaL PracTIce and vaLIdaTIOn Of rOyaL free hOsPITaL 
cIrrhOsIs gfr (gfr-rfh)
Protopapas A.1, Papagiouvanni I.1, Fragkou N.1, Agorastou P.1, Tzoumari T.1, 
Vettas C.1, Alevroudis E.2, Notopoulos A.2, Goulis I.1
1Aristotle University of Thessaloniki, Fourth Department of Internal Medicine, 
Thessaloniki, Greece, 2Hippokration General Hospital, Nuclear Medicine 
Laboratory, Thessaloniki, Greece
contact e-Mail address: adoprot@hotmail.com
Introduction: Many studies have stressed that the equations used currently 
for the estimation of GFR may overestimate renal function in cirrhotics. 
The GFR-RFH equation was developed in order to accurately estimate GFR 
in this population.
aims & Methods: Aim of this study was to evaluate the use of widely avail-
able equations (CKD-EPI, MDRD-4, MDRD-6) and the GFR-RFH equation 
to correctly estimate the measured GFR of patients with cirrhosis. We 
retrospectively analyzed data from cirrhotic patients that were evaluated 
for liver transplantation. These patients were submitted to somatometric 
tests, laboratory tests and measurement of GFR with the use of 51Cr-EDTA 
(GFR-M). The CKD-EPI, MDRD-4, MDRD-6 and GFR-RFH equations were 
calculated, while bias, precision and accuracy were estimated for each 
one of them and then compared with paired t-tests. Bias was defined as 
the mean difference between the GFR-M and the result of each equation; 
precision was defined as the standard deviation of the differences and ac-
curacy was defined as the square root of the mean squared error (mean 
of the squared differences). Higher values are associated with higher bias 
and smaller precision/accuracy.
results: One-hundred and thirty four cirrhotic patients were included (95 
male, 39 female). Twenty-one patients were Child-Pugh A, 66 Child-Pugh 
B and 47 Child-Pugh C. The patients displayed mean GFR-M: 72.36 ±23.52, 
CKD-EPI:78.28 ± 23.53, MDRD-4: 75.5 ± 25.7, MDRD-6: 71.45 ± 25 and RFH-
GFR: 54.3 ± 17.96. Bias was estimated for CKD-EPI, MDRD-4, MDRD-6 and 
GFR-RFH at -5.91, -3.13, 0.92 and 18.24 respectively. Statistically significant 
differences were observed between all equations separately ( p < 0.001 for 
all comparisons). Precision was estimated at 18.47, 20.81, 18.86 and 16.6, 
respectively. Only the comparison between MDRD-4 and GFR-RFH yielded 
a statistically significant result (p= 0.037). Finally, accuracy was estimated 
at 19.32, 20.97, 18.81 and 24.61, respectively. CKD-EPI and MDRD-6 exhib-
ited statistically better accuracy than GFR-RFH (p =0.006 and 0.001).
conclusion: GFR-RFH fails to provide a better estimation of renal function 
in cirrhotics in our sample, in comparison to the equations used in clini-
cal practice. Among equations that are widely used in a clinical setting, 
MDRD-6 seems to achieve the best overall result (smaller bias, equal pre-
cision, better accuracy) in patients with cirrhosis.
disclosure: Nothing to disclose 
P0711 sOLuBLe cd163 Is assOcIaTed WITh POrTaL 
hyPerTensIOn and PredIcTs survIvaL In PaTIeTs WITh 
hePaTITIs c and aLcOhOL-Induced LIver cIrrhOsIs
Gelman S.1, Salteniene V.2, Pranculis A.3, Kupcinskas L.4, Kupcinskas J.4
1Lithuanian University of Health Sciences, Department of Gastroenterology, 
Kaunas, Lithuania, 2Lithuanian University of Health Sciences Institute for 
Digestive Research, Kaunas, Lithuania, 3Lithuanian University of Health 
Sciences, Department of Radiology, Kaunas, Lithuania, 4Lithuanian 
University of Health Sciences Institute for Digestive Research, Department of 
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contact e-Mail address: j_kupcinskas@yahoo.com
Introduction: Clinically significant (CSPH) and severe portal hypertension 
(SPH) increase the risk for decompensation and life-threatening complica-
tions in liver cirrhosis. The search for non-invasive markers capable of pre-
dicting portal hypertension and patient survival is ongoing. Soluble CD163, 
a marker of Kupffer cell activation, has been associated with viral hepatitis, 
cirrhosis and portal hypertension. Additional data would aid in creating 
new non-invasive diagnostic and even treatment approaches in this field.
aims & Methods: In this study we aimed to evaluate plasma levels of solu-
ble CD163 in patients with liver cirrhosis, CSPH, SPH and biomarker poten-
tial to predict CSPH and SPH as well as patient survival. We prospectively 
investigated 100 patients with hepatitis C virus and alcohol-induced liver 
cirrhosis with characterized hepatic venous pressure gradient (HVPG) and 
30 healthy controls. Plasma levels of CD163 were determined by enzyme-
linked immunosorbent assay. Patients were observed for follow-up period 
of 24 months. Associations of CD163 with Child- Pugh score, HVPG, CSPH 
(HVPG ≥ 10 mHg), SPH (HVPG ≥ 12) and patient survival were assessed.
results: Plasma CD163 levels were significantly higher in cirrhotic patients 
than in healthy controls (p<0.0001) and increased with disease severity 
(Child-Pugh class A 1.3; Child-Pugh class B 1.5; Child-Pugh class C 1.8 mcg/
ml; p=0.004). There was a moderate correlation between CD163 and HVPG 
(r= 0.377; p<0.0001). Higher levels of CD163 predicted CSPH and SPH inde-
pendently from Child-Pugh class. AUC for the diagnosis of CSPH was 0.731 
(p< 0.0001) and for the diagnosis of SPH 0.7 (p=0.001). A total of 15 patients 
died during the follow-up period. Plasma levels of CD163 higher than 1.55 
mcg/ml were associated with increased mortality (24 month survival: 76% 
vs. 98%, p<0.0001). When stratifying patients according to this cut-off 
value, the OR for death in 24 months was 15.5 (p=0.01).
conclusion: Higher plasma levels of CD163 predicted CSPH, SPH and mor-
tality in patients with hepatitis C and alcohol-induced liver cirrhosis. Bio-
marker could be used as a surrogate marker for long-term survival in this 
patient population.
disclosure: Nothing to disclose 
P0712 endOgenOus MOTIOn Of The LIver cOrreLaTes WITh 
The severITy Of POrTaL hyPerTensIOn
Gelman S.1, Sakalauskas A.2, Jurkonis R.2, Lukosevicius A.2, Kupcinskas L.3, 
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Introduction: Portal hypertension (PH) causes life threatening complica-
tions in patients with liver cirrhosis, therefore timely diagnosis of clinically 
significant (CSPH) is of utmost importance. Hepatic venous pressure gradi-
ent (HVPG) measurement remains the gold standard to assess the sever-
ity of portal hypertension, however the procedure is invasive and is only 
performed in specialized centers. Non-invasive assessment using elastog-
raphy techniques has been successfully introduced, however these tech-
niques have certain limitations. The search for non-invasive, accurate and 
applicable methods for the evaluation of portal hypertension is ongoing.
aims & Methods: In this study we aimed to evaluate the performance of 
the radiofrequency ultrasound signal analysis algorithm based on endoge-
nous motion of the liver in predicting CSPH.The study included 36 patients 
with hepatitis C virus or alcohol- induced liver cirrhosis with characterized 
HVPG measurements. All patients underwent ultrasound examination us-
ing a research dedicated ultrasound scanner Ultrasonix SonixTouch. Raw 
B scans forming radiofrequency signals (record duration - 7.62 s) were 
acquired and stored for off-line analysis. The signal analysis algorithm 
was developed for the assessment of liver motion induced by cardiovascu-
lar activity. The statistical analysis of endogenous displacement and strain 
parameters was performed.
results: Three parameters showed statistically significant weak to moder-
ate correlation with HVPG measurement - d
retro 
(maximal amplitude of the 
displacements backward, µm; r=0.39; p=0.02 ); σ
ROI[0…10Hz, 2 × 2 cm]
 (standard 
deviation of strain [0…10 Hz, 2 × 2 cm] µm/cm; r=-0.41; p=0.01); µ
ROI[0…10Hz, 
1 × 1 cm]
 (average strain [0…10 Hz, 1 × 1 cm] µm/cm; r=-0.34; p=0.04). The 
median values of parameters were significantly higher in patients with 
CSPH (p=0.005, p< 0.05 and p< 0.01 respectively). AUC for the diagnosis of 
CSPH for d
retro 
was 0.84 (p< 0.0001); with a cut-off value of 0.72 µm provid-
ing 100%sensitivity and 73% specificity. AUC for the diagnosis of CSPH for 
σ
ROI[0…10Hz, 2 × 2 cm]
 was 0.71 (p=0.036); with a cut-off value of 0.48 µm/cm pro-
viding 76% sensitivity and 72% specificity. AUC for the diagnosis of CSPH 
for µ
ROI[0…10Hz, 1 × 1 cm]
 was 0.78 (p=0.0024); with a cut-off value of 0.57 µm/cm 
providing 76% sensitivity and 81% specificity.
conclusion: The new algorithm estimating endogenous strain of the liver 
provides reliable parameters which can predict the presence of CSPH.
disclosure: Nothing to disclose 
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We retrospectively investigated the long-term effect on hepatic residual 
function and the prognosis of the patients who had underwent B-RTO.
aims & Methods: We have performed B-RTO in 60 patients with GV since 
2005 at a single institute. Concomitant PSE underwent in 46 of those pa-
tients. We examined the parameters of hepatic functional reserve such as 
encephalopathy, ascites, total bilirubin, albumin, prothrombin time, and 
Child-Pugh score in the follow-up period 3, 6, 12, 24, and 36 months after 
B-RTO. We analyzed the survival curve using Kaplan-Meier method, and 
investigated the preoperative factor which affected a prognosis indepen-
dently with multivariate analyses. The study was approved by the Ethics 
Committee of Niigata City General Hospital. The study protocol conformed 
to the ethical guidelines of the Declaration of Helsinki.
results: GVs were well-embolized in 57 patients (95.0%), and GV disap-
peared in all patients successfully treated by B-RTO. The serum albumin 
levels were significantly elevated from 3.3 to 4.0 g/dL (p= 0.0076) and 
Child-Pugh scores decreased significantly from 7.0 to 5.7 (p= 0.4333) after 
B-RTO in three years. The median survival was of all cases was 2207 days, 
and the survival rate was 86.3 % at 1 year, 80.5 % at 3 years, 63.5 % at 
5 years. Multivariate analyses revealed that “with the cancer” and “pre-
operative Child-Pugh B-C grade” were the predictors of poor prognosis.
conclusion: B-RTO for GV has the long-term favorable effect on hepatic 
functional improvement. The addition of the PSE inhibits exacerbation of 
EV after B-RTO without increasing invasiveness.
disclosure: Nothing to disclose 
P0715 PLaTeLeT IndIces refLecT dynaMIc changes In 
exTraceLLuLar MaTrIx. The OBservaTIOn Of aLcOhOLIc LIver 
cIrrhOsIs and nOn-aLcOhOLIc faTTy LIver dIsease PaTIenTs
Michalak A.1, Guz M.2, Kozicka J.2, Cybulski M.2, Kasztelan-Szczerbinska B.1, 
Rycyk A.1, Cichoz-Lach H.1
1Medical University of Lublin, Department of Gastroenterology with 
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Biochemistry and Molecular Biology, Lublin, Poland
contact e-Mail address: lady.agatamichalak@gmail.com
Introduction: Platelet (PLT) indices have been proposed as potential mark-
ers in numerous pathologies for several years. Their role was also high-
lighted in the assessment of liver fibrosis and exacerbation of liver failure.
aims & Methods: The aim of our study was to verify PLT indices in the 
evaluation of liver fibrosis in the course of alcoholic liver cirrhosis (ALC) 
and non-alcoholic fatty liver disease (NAFLD) and to compare them with 
serological: indirect and direct markers of liver fibrosis. Another goal was 
to assess the relationship between PLT indices and clinical progression of 
liver failure in ALC (MELD score). Three hundred and two persons were 
enrolled to the study: 142 patients with ALC, 92 with NAFLD and 68 healthy 
volunteers in control group. Hematological indices were measured in 
each participant: mean platelet volume (MPV), platelet distribution width 
(PDW), plateletcrit (PCT). Indirect markers of liver fibrosis were also as-
sessed: AAR [aspartate aminotransferase (AST) to alanine aminotransfer-
ase (ALT) ratio], APRI (AST to PLT Ratio Index), FIB-4 (Fibrosis-4) and GPR 
(γ-glutamyl-transferase to PLT ratio). Among direct indices of liver fibrosis, 
procollagen I carboxyterminal propeptide (PICP), procollagen III aminoter-
minal propeptide (PIIINP), platelet-derived growth factor AB (PDGF-AB), 
transforming growth factor-α (TGF-α) and laminin were obtained. The as-
sessment of clinical progression of liver failure in ALC patients was done 
with MELD score. NAFLD fibrosis score and BARD score were calculated in 
NAFLD patients. Achieved results were compared to controls and between 
ALC and NAFLD groups. Then a correlation between evaluated indices was 
performed. Diagnostic value of each assessed parameter together with 
proposed cut-off in research group were measured with AUC (area under 
the curve).
results: PDW value in ALC group was significantly higher in comparison 
to controls (p< 0.0001), level of PCT was significantly lower (p< 0.0001) 
and MPV value did not differ significantly. PLT indices correlated positively 
with indirect indices of liver fibrosis: MPV with: APRI, FIB-4 and GPR (p< 
0.001), PDW with: APRI and FIB-4 (p< 0.0001). There were also negative 
relationships between PCT and both: APRI and FIB-4 (p< 0.0001). Strong 
positive correlations were noted between PCT and direct markers of liver 
fibrosis: PDGF-AB (p< 0.001) and TGF-α (p< 0.05). MELD score correlated 
with PLT indices; positively with: MPV and PDW (p< 0.001) and negatively 
with PCT (p< 0.05). MPV and PDW values in NAFLD group were signifi-
cantly higher (p< 0.0001 and p< 0,01, respectively) and PCT - lower (p< 
P0713 nOn-InvasIve screenIng Of esOPhageaL varIces - Is IT 
TIMe TO exPand The BavenO vI crITerIa?
Alexandrino G.1, Dias Domingues T.2, Figueiredo L.M.1, Rafael M.A.1, 
Costa M.N.3, Carvalho R.4, Folgado Alberto S.4, Martins A.4
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Introduction: The role of non-invasive methods for detecting liver fibrosis 
has been investigated in the identification of esophageal varices. The Bave-
no VI consensus states that in patients with compensated cirrhosis, liver 
stiffness by transient elastography (TE) < 20 kPa and platelets >150.000, 
screening endoscopy may be dispensed, given the very low probability of 
having high-risk varices with indication for prophylaxis or treatment (small 
varices with red wale marks and medium-large varices).
aims & Methods: We aimed to apply the Baveno VI criteria in a cohort of 
cirrhotic patients and see how they performed in real life clinical practice. 
Retrospective study of all patients evaluated between January 2017 and 
December 2018 with a liver stiffness by TE compatible with cirrhosis and 
platelet count and upper endoscopy performed up to 6 months after TE. 
Patients with history of esophageal varices or decompensated cirrhosis 
were excluded.
results: If the Baveno VI recommendations had been applied to this co-
hort, endoscopy would have been avoided in 47 (41.2%) patients, none 
of them with high-risk varices: specificity 100%, sensitivity 2.1%, positive 
predictive value 100%, and negative predictive value 47% for absence 
of varices requiring treatment (Table 1). Additionally, both platelet count 
(AUROC=0.894; p-value=0.0) and TE (AUROC=0.780; p-value=0.001) were 
individually effective in predicting absence of high-risk varices. However, 
considering all patients eligible for endoscopy, 53 (79.1%) did not have 
varices with therapeutic indication.
 
Patients who would avoid 
endoscopy (n=47)
Patients eligible for 
endoscopy (n=67)
no high-risk varices 47 (100.0%) 53 (79.1%)
high-risk varices 0 (0.0%) 14 (20.9%)
[Table 1]
conclusion: The Baveno VI criteria effectively identified a group of cirrhotic 
patients without varices requiring treatment in whom screening endoscopy 
could have been safely avoided. All patients with high-risk varices would 
be screened. The major drawback of the Baveno VI criteria seems to be the 
high number of futile screening endoscopies. With the greater availability 
of non-invasive methods of liver fibrosis, in the future we will probably be 
able to safely avoid endoscopy in a greater number of patients. Studies are 
needed to confirm this findings and explore cutoffs or other variables to 
safely dispense endoscopy in a larger number of patients.
references: Franchis R, et al. Expanding consensus in portal hyperten-
sion Report of the Baveno VI Consensus Workshop: Stratifying risk and 
individualizing care for portal hypertension. Journal of Hepatology 2015 
vol. 63, 743-752.
disclosure: Nothing to disclose 
P0714 LOng-TerM effecT On hePaTIc resIduaL funcTIOn 
afTer sIMuLTaneOusLy cOMBIned BaLLOOn-OccLuded 
reTrOgrade TransvenOus OBLITeraTIOn WITh ParTIaL 
sPLenIc eMBOLIzaTIOn fOr gasTrIc varIces
Waguri N., Osaki A., Yakubo S., Watanabe Y., Sato M.
Niigata City General Hospital, Gastroenterology & Hepatology, Niigata, Japan
contact e-Mail address: waguri@hosp.niigata.niigata.jp
Introduction: Balloon-occluded retrograde transvenous obliteration (B-
RTO) has been widely adopted for the management of gastric fundal vari-
ces (GV). There are only several reports that B-RTO leads to the improve-
ment of the hepatic residual function in the mid- and long-term. We have 
performed partial splenic embolization (PSE) simultaneously combined 
with B-RTO for the purpose of reduction of portal venous blood pressure. 
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0.01). PDW correlated positively with indirect markers of liver fibrosis (APRI 
and FIB-4; p<0.05) and PCT - negatively (APRI - p<0.01, FIB-4 - p<0.0001). 
There was a strong negative relationship between PCT and NAFLD fibrosis 
score (p<0.0001) and a weaker one between PCT and laminin (p< 0.05). 
MPV and PDW were significantly higher in ALC group compared to NAFLD 
patients (p<0.0001 and p<0.001, respectively); PCT level was significantly 
lower in ALC group (p<0.0001). AUC values and proposed cut-offs for MPV, 
PDW and PCT in ALC patients were: 0.458 (>11.1 fl), 0,764 (>59.3 %) and 
0,839 (<0.17 %), respectively. AUC values and proposed cut-offs for MPV, 
PDW and PCT in NAFLD patients were: 0,808 (< 7.9 fl), 0,643 (>52.8 %) and 
0,622 (<0.23 %), respectively.
conclusion: Hematological indices are closely related to serological mark-
ers of liver fibrosis. They reflect clinical progression of ALC. PCT in ALC and 
MPV in NAFLD were found to have the greatest clinical accuracy.
references: 1. Saremi Z, Rastgoo M, Mohammadifard M i wsp. Comparison 
of platelet number and function between nonalcoholic fatty liver disease 
and normal individuals. J Res Med Sci. 2017; 22: 75. 2. Coskun BD, Dizdar 
OS, Baspınar O i wsp. Usefulness of the neutrophil-to-lymphocyte ratio 
and platelet morphologic parameters in predicting hepatic fibrosis in 
chronic hepatitis C patients. Ann Clin Lab Sci. 2016; 46: 380-6. 3. Wang 
LR, Zhou YF, Zhou YJ i wsp. Elevation of plateletcrit increasing the risk 
of non-alcoholic fatty liver disease development in female adults: a large 
population-based study. Clin Chim Acta. 2017; 474: 28-33.
disclosure: Nothing to disclose 
P0716 red BLOOd ceLL dIsTrIBuTIOn WIdTh and ITs 
derIvaTIves as PredIcTOrs Of fIBrOsIs and cLInIcaL 
OuTcOMe In aLcOhOLIc LIver cIrrhOsIs and nOn-aLcOhOLIc 
faTTy LIver dIsease PaTIenTs
Michalak A.1, Guz M.2, Kozicka J.1, Cybulski M.2, Kasztelan-Szczerbinska B.1, 
Cichoz-Lach H.1
1Medical University of Lublin, Department of Gastroenterology with 
Endoscopy Unit, Lublin, Poland, 2Medical University of Lublin, Department of 
Biochemistry and Molecular Biology, Lublin, Poland
contact e-Mail address: lady.agatamichalak@gmail.com
Introduction: Higher values of red blood cell distribution width (RDW) and 
RDW to platelet ratio (RPR) have been proposed as predictors of poor sur-
vival in cirrhotic patients, recently. RDW to lymphocyte ratio (RLR) has been 
only proved to correlate positively with advanced liver fibrosis in primary 
biliary cholangitis patients and clinical manifestation of hepatitis E in the 
field of hepatology, so far.
aims & Methods: The aim of our survey was to assess the utility of RDW, 
RPR and RLR in the evaluation of liver fibrosis in alcoholic liver cirrho-
sis (ALC) and non-alcoholic fatty liver disease (NAFLD) patients. We also 
aimed to assess a relationship between above-mentioned parameters 
and clinical progression of ALC. 302 persons were included to the study: 
142 patients with ALC, 92 with NAFLD and 68 volunteers in control group. 
Hematological indices (RDW, RPR and RLR) were obtained from each par-
ticipant. Indirect markers of liver fibrosis were also measured: AAR [as-
partate aminotransferase (AST) to alanine aminotransferase (ALT) ratio], 
APRI (AST to PLT Ratio Index), FIB-4 (Fibrosis-4) and GPR (γ-glutamyl-
transferase to PLT ratio). Among direct indices of liver fibrosis, procollagen 
I carboxyterminal propeptide (PICP), procollagen III aminoterminal pro-
peptide (PIIINP), platelet-derived growth factor AB (PDGF-AB), transform-
ing growth factor-α (TGF-α) and laminin were obtained. The assessment 
of clinical progression of liver failure In ALC patients was done with MELD 
score. NAFLD fibrosis score and BARD score were calculated In NAFLD 
patients. Achieved results were compared to controls and between ALC 
and NAFLD groups. Then a correlation between evaluated indices was 
performed. Diagnostic value of each assessed haematological parameter 
together with proposed cut-off in research group were measured with AUC 
(area under the curve).
results: RDW, RPR and RLR values were significantly higher in ALC pa-
tients compared to controls (p< 0.0001). There were strong positive cor-
relations between RPR and indirect markers of liver fibrosis - FIB-4 and 
RPR (p< 0.0001). RDW and RPR correlated also negatively with PDGF-AB 
(p< 0,01 and p< 0.0001, respectively). Positive relationship was observed 
between RPR and MELD score (p< 0.01). RDW, RPR and RLR values were 
significantly higher in NAFLD patients compared to controls (p< 0.05, p< 
0.0001, p< 0.0001, respectively). RDW correlated positively with FIB-4 (p< 
0.05) and RPR - with APRI (p< 0.0001). There was also a strong rela-
tionship between RPR and NAFLD fibrosis score (p< 0.0001). RDW, RPR 
and RLR values were significantly higher in ALC patients compared to 
NAFLD group (p< 0.0001). AUC values and proposed cut-offs for RDW, RPR 
and RLR in ALC patients were: 0.912 (>14.2 %), 0,965 (>0.075) and 0.914 
(>8.684), respectively. AUC values and proposed cut-offs for RDW, RPR 
and RLR in NAFLD patients were: 0.606 (>12.8%), 0.724 (>0.047 %) and 
0,691 (>6.25 %), respectively.
conclusion: RDW and its derivatives seem to be powerful diagnostic mark-
ers of liver fibrosis especially in ALC patients. They might also reflect a 
decompensation of liver function in this group.
references: 1. Turcato G, Campagnaro T, Bonora A i wsp. Red blood cell 
distribution width independently predicts 1-month mortality in acute de-
compensation of cirrhotic patients admitted to emergency department. 
Eur J Gastroenterol Hepatol. 2018; 30: 33-38. 2. Fan X, Deng H, Wang X i 
wsp. Association of red blood cell distribution width with severity of hepa-
titis B virus-related liver diseases. Clin Chim Acta. 2018; 482: 155-60 3. Wu 
J, Zhang X, Liu H i wsp. RDW, NLR and RLR in predicting liver failure and 
prognosis in patients with hepatitis E virus infection. Clin Biochem. 2019; 
63: 24-31
disclosure: Nothing to disclose 
P0717 effIcacy and safeTy Of anTIcOaguLanT 
TreaTMenT In POrTaL veIn ThrOMBOsIs assOcIaTed WITh 
cIrrhOsIs: resuLTs Of a cOhOrT Of 43 PaTIenTs
Ouldgougam R.1, Zemmouchi S.1, Chikhi Y.1, Lounes F.1, Faraoune S.2, 
Cheraitia S.1, Kouihal W.1, Benmaouche F.1, Lahcene M.1
1Bologhine Hospital, Internal Medicine and Gastroenterology, Algiers, 
Algeria, 2CHU BAB EL Oued, Medical Imaging, Algiers, Algeria
contact e-Mail address: rogougam@yahoo.fr
Introduction: An increase risk of portal vein thrombosis (PVT) in cirrhotic 
patients is more reported, without the true impact of PVT being properly 
assessed. PVT in cirrhotic patients can lead to complications in both liver 
function and portal hypertension.
aims & Methods: The aim of the study was to evaluate efficacy and safety 
of anticoagulants in patients with cirrhosis and portal vein thrombosis 
without hepatocellular carcinoma. It was a prospective, single-center 
study including 43 patients with portal vein thrombosis recruited among 
580 cirrhotic patients between January 2009 and June 2017. Existence, 
extension and cruoric aspect of the thrombotic obstruction were estab-
lished in all cases by Doppler ultrasound and angio-CT scan. Anticoagulant 
treatment was initiated in case of symptomatic portal vein thrombosis or 
identification of a pro-thrombotic disease. 28 patients (65.1%) received 
anticoagulants (group G1) and 15 patients did not (group G2). The end-
points were: patency of the splanchnic venous system and evaluation of 
liver function based on the Child score: improvement was defined as a de-
crease of at least 2 points; deterioration by an increase of at least 2 points, 
liver function was unchanged if stability or decrease of less than 2 points.
results: The mean age was 47.4 years [37-81] and sex ratio 0.6. Diagnosis 
of cirrhosis was already known in 22 patients and clinical manifestations 
of portal vein thrombosis revealed in 21 (48.8%) patients. Thrombosis was 
revealed by: ultrasound in 14 (32.5%) patients, complications of portal hy-
pertension in 19 (44.2%) patients, acute abdominal pains in 7 patients and 
signs of intestinal ischemia in 3 patients. Seventeen patients presented at 
least one pro-thrombotic factor. Mean follow-up was 30.2 [21-62] months. 
Complete permeability of the venous portal system was achieved in 57.1% 
of treated patients (n=16) at the end of the study. Further, in G1 compared 
to G2, improvement of Child score and absence of hepatic insufficiency 
worsening were respectively recorded in 46.4% vs 0% and 21.4% vs 53.3% 
of cases, with p< 0.01. Moreover, no significant side effect of anticoagu-
lants was observed.
conclusion: Anticoagulation therapy for portal vein thrombosis in cirrhotic 
patients is a safe and effective treatment. It improves the hepatic function 
and the prognosis of patients.
disclosure: Nothing to disclose 
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P0719 LIver sTIffness Measured By shear Wave 
eLasTOgraPhy fOr PredIcTIng esOPhageaL varIces In 
PaTIenTs WITh hePaTITIs B vIrus reLaTed cIrrhOsIs
Yan Y., Xing X., Yang L., Yang J.
West China Hospital of Sichuan University, Department of Gastroenterology 
and Hepatology, Chengdu, China
contact e-Mail address: yuling.yan@scu.edu.cn
Introduction: Variceal bleeding is one of the most fatal complication in 
patients with liver cirrhosis. A screening esophagogastroduodenoscopy 
(EGD) is recommended in all patients with cirrhosis to detect those pa-
tients at risk of variceal bleeding. However, this technique is invasive, un-
comfortable and costly. Therefore, to find reliable noninvasive methods for 
predicting varices is crucial for clinic. 
Real-time shear wave elastography (SWE), which is a new method for 
measuring liver stiffness, has been developed. It has been confirmed that 
SWE has a higher technical success rate and a better diagnostic value for 
evaluating clinically significant portal hypertension than transient elastog-
raphy [1]. However, there was also no coincident cut-off value for predicting 
varices, and only several studies about SWE evaluating the varices risk in 
compensated liver cirrhosis, and with all etiology cirrhosis patients [2, 3]. 
Different etiology of cirrhosis would affect the LS values, especially, alco-
hol and cholestasis. Therefore, to evaluate LS values of different etiology’s 
cirrhosis respectively is valuable. Hepatitis B virus (HBV) related cirrhosis 
was the biggest part of cirrhosis patients in China. To our knowledge, no 
published study has examined the efficacy of SWE for predicting esopha-
geal varices in HBV related liver cirrhosis. The purpose of this retrospective 
study was to investigate the diagnostic performance of SWE for predicting 
the presence of esophageal varices and high-risk varices in patients with 
HBV related cirrhosis.
aims & Methods: To investigate liver stiffness of shear wave elastography 
(SWE) for predicting the presence of esophageal varices and high-risk vari-
ces in patients with hepatitis B virus (HBV) related cirrhosis. Clinical data 
from 135 patients with HBV virus related cirrhosis who underwent SWE and 
endoscopy were collected consecutively. Liver stiffness (LS) was measured 
by SWE. The time interval between SWE and endoscopy examination no 
more than 3 months. Comparisons of the accuracy of prediction between 
groups were made by areas under the receiver operating characteristic 
curves (AUROCs), and regression analyses were performed for the mul-
tiple variables related to the presence of esophageal varices and high-risk 
varices.
results: The optimal cutoff values for predicting the presence of esopha-
geal varices and high-risk varices were 12.95 and 13.05 kPa, respectively. 
AUROC of LS (0.883) was higher than platelet count (PLT) (0.805), APRI 
(0.809), FIB-4 (0.0.814), portal vein diameter (PVD) (0.739) and spleen 
vein diameter (SVD) (0.738) for predicting the presence of esophageal vari-
ces. AUROC of LS (0.901) was also higher than platelet count (0.755), APRI 
(0.767), FIB-4(0.767), PVD (0.742) and SVD (0.742) for predicting high risk 
varices. LS, albumin (ALB) and SVD were independent factors for predict-
ing the presence of esophageal varices and high-risk varices. AUROCs of 
patients without ascites for predicting presence of esophageal varices and 
high-risk varices were 0.863 and 0.879. LS combined ALB and SVD with 
AUROCs 0.934 and 0.966 for predicting the presence of esophageal varices 
and high-risk varices, respectively.
conclusion: LS of SWE, or LS combines albumin and SVD improves the 
diagnostic accuracy are reliable factors for predicting presence of esopha-
geal varices and high-risk varices in patients with HBV-related cirrhosis. 
In addition, SWE is a reliable noninvasive tool for predicting esophageal 
varices with ascites.
references: 1. Elkrief, L., et al., Prospective comparison of spleen and liver 
stiffness by using shear-wave and transient elastography for detection of 
portal hypertension in cirrhosis. Radiology, 2015. 275(2): p. 589-98. 2. Kim, 
T.Y., et al., Diagnostic Performance of Shear Wave Elastography for Pre-
dicting Esophageal Varices in Patients With Compensated Liver Cirrhosis. J 
Ultrasound Med, 2016. 35(7): p. 1373-81. 3. Petzold, G., et al., Evaluation of 
liver stiffness by 2D-SWE in combination with non-invasive parameters as 
predictors for esophageal varices in patients with advanced chronic liver 
disease. Scand J Gastroenterol, 2019: p. 1-8.
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P0718 an InsuffIcIenT POrTOsysTeMIc Pressure gradIenT 
reducTIOn afTer TransjuguLar InTrahePaTIc POrTOsysTeMIc 
shunT Is assOcIaTed WITh Increased rIsk Of varIceaL 
reBLeedIng
Wang X.1, Zhu Y.1, Yang J.1, Yan Y.2, Luo X.1, Yang L.1
1Sichuan University West China Hospital, Department of Gastroenterology 
and Hetatology, Chengdu, China, 2West China Hospital of Sichuan University, 
Department of Gastroenterology and Hepatology, Chengdu, China
contact e-Mail address: yuling.yan@scu.edu.cn
Introduction: Transjugular intrahepatic portosystemic shunt (TIPS) mark-
edly reduces portosystemic pressure gradient (PPG). A hepatic venous 
pressure gradient (HVPG) < 12 mm Hg is the most consistent threshold that 
is protective from having recurrent complications. However, PPG after TIPS 
may be incoordinate to predict variceal rebleeding due to the inescap-
able impact of artificial portosystemic shunt. This study aimed to evaluate 
the incidence, clinical outcomes and predicting factor of insufficient PPG 
reduction after TIPS.
aims & Methods: The present study retrospectively analyzed the data of 192 
patients in whom a TIPS was indicated by the prophylaxis of variceal re-
bleeding and control of acute bleeding between June 2015 and April 2018. 
and. The PPG was measured before and after TIPS placement. The patients 
with PPG ≥ 12 mm Hg were divided into group A, and the rest into group 
B. The primary endpoint was recurrent rate of variceal hemorrhage, and 
other clinical outcomes were also evaluated during the follow-up.
results: Forty-seven patients (24.5%) had an insufficient reduction of 
PPG (≥ 12 mm Hg ) after TIPS implantation. PPG significantly decreased 
from 26.5±4.4 mm Hg to 15.5±3.4 mm Hg (P < 0.001) in group A and from 
21.0±5.2 mm Hg to 7.6±2.5 mm Hg (P < 0.001) in group B. The median 
follow-up period was 422 days (range, 45-1082 days). During the follow-
up period, 8 patients (17.0%) in group A and 10 patients (6.9%) in group 
B had recurrent variceal bleeding (P = 0.039).But there was no significant 
difference of variceal rebleeding rates among patients in different PPG 
grades (P = 0.785). The 1-year and 2-year probability of remaining free 
of variceal bleeding rates were 83.6% and 73.6%, respectively. Mortality 
was higher in group A than group B (14.9% vs 4.1%, P = 0.011), while the 
overt hepatic encephalopathy rate (27.7% vs 32.4%, P = 0.541) between two 
groups showed no significant difference.
 
Overall 
(n=192)
group a 
(n=47)
group B 
(n=145) P value
PPG before TIPS, mm Hg 22.3±5.6 26.5±4.4 21.0±5.2 <0.001
PPG after TIPS, mm Hg 9.5±4.4 15.5±3.4 7.6±2.5 <0.001
12-15 mm Hg, n (%)   28 (60)    
16-19 mm Hg, n (%)   11 (23)    
≥20 mm Hg, n (%)   8 (17)    
Reduction in index pressure gradient, 
mm Hg (%)
12.8±5.5 11.0±5.0 13.4±5.5 0.039
Variceal rebleeding, n (%) 23 (12) 8 (17) 10 (7) 0.039
Overt hepatic encephalopathy, n (%) 60 (31) 13 (28) 47 (32) 0.541
Mortality, n (%) 13 (7) 7 (15) 6 (4) 0.011
[Comparison of clinical outcomes between two groups]
conclusion: PPG declines to < 12 mm Hg after TIPS creation is necessary 
to protects patients from variceal rebleeding. Stent-graft with adequate 
diameter should be chosen carefully to achieve sufficient reduction of PPG, 
otherwise endoscopic and (or) pharmacological therapy should be com-
bined.
references: 1. Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement 
guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). 
Cardiovasc Intervent Radiol, 2012;35:1295-1300. 2. Mollaiyan A , Bettinger D, 
Rossle M . The underdilation of nitinol stents at TIPS implantation: Solution 
or illusion? European Journal of Radiology, 2017;89(Complete):123-128.
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P0720 InfecTIOn as a PredIcTOr Of MOrTaLITy In PaTIenTs 
WITh decOMPensaTed LIver cIrrhOsIs: exPLOrIng The 
reLaTIOnshIP TO severITy Of LIver faILure
Bozin T.1, Madir A.1, Miletic M.1, Trkulja V.2, Grgurevic I.1,3
1University Hospital Dubrava, Department of Gastroenterology, Hepatology 
and Clinical Nutrition, Zagreb, Croatia, 2University of Zagreb School of 
Medicine, Department of Pharmacology, Zagreb, Croatia, 3University of 
Zagreb School of Medicine, Zagreb, Croatia
contact e-Mail address: tbozin@gmail.com
Introduction: To evaluate predictive value of infection on 30-day and over-
all medium-term mortality in patients with decompensated liver cirrhosis 
and to explore its relationship with severity of liver failure.
aims & Methods: We retrospectively reviewed medical records of patients 
with decompensated liver cirrhosis hospitalized at a single center between 
1st March 2014 and 31st December 2017. The primary outcome was 30-day 
mortality after the 1st hospitalization. Secondary outcome was overall 
medium-term mortality: patients were tracked (direct contact, medical 
records) until death, liver transplantation, loss of contact or 31st December 
2018 (censoring). Presence of infection was documented and classified as 
Healthcare associated (HCA) or community acquired (CA). Patients were 
evaluated for the Child-Pugh, MELD and CLiF OF score.
results: Of the 155 included patients (77% males, median age 62 years), 90 
had an infection (HCA n=42, CA n=48), mostly urinary tract infection, 53% 
G+ strains, with multidrug resistant bacteria in 23.8% of HCA and 4.2% 
CA infections. Thirty-day mortality was 10.8% in patients without infec-
tion, 22.9% in patients with CA and 31.0% in patients with HCA infection. 
With adjustment for Child-Pugh score, age, platelet count and hemoglobin 
levels, infection (HCA&CA combined) was independently associated with 
higher 30-day mortality (OR 2.73, 95%CI 1.07-6.94). The association disap-
peared after adjustment for the CLIF OF or the MELD score (higher scores 
associated with higher 30-day mortality). 
However, infection was also independently associated with higher CLiF OF 
(b=0.99, 95%CI 0.50-1.48) and higher MELD ((b=3.81, 1.92-5.70) scores. 
Mediation analysis revealed an indirect association between infection and 
30-day mortality that was mediated through its association with higher 
CLiF OF/MELD scores. 
Infection “added” to risk of 30-day mortality at each level of liver fail-
ure: adjusted estimated probabilities of 30-day mortality in models with 
infection*Child-Pugh class (or CLiF OR or MELD score) interactions, were 
(i) 7.1% with Child-Pugh class B, 13.3% with Child-Pugh class C, 9.3-10.6% 
with CLiF OF scores 6, 8 and 10, respectively, and 9.3%-10.7% with MELD 
scores increasing form 10 to 30 if no infection, and (ii) 12.2% and 32.1% 
(Child-Pugh B and C), 4.9%-44.4% (CliF OF 6-10) and 5.0% - 40.3% 
(MELD scores 10-30) in patients with infection. 
As for the overall medium-term mortality, HCA infection, but not CA infec-
tion, was independently associated with 2.0 to 2.8-times higher risk of 
death irrespective of whether CLiF OF or MELD scores were accounted for 
(HR=2.77, 1.67-4.62 if accounting for neither, HR=2.07, 1.21-3.59 if account-
ing for CLiF OF and HR=2.13, 1.24-3.65 if accounting for MELD).
conclusion: In patients with decompensated liver cirrhosis, infection is as-
sociated with higher 30-day mortality. It is also associated with worse liver 
function scores hence the association with mortality appears to be both 
direct and indirect via the level of liver failure.
disclosure: Nothing to disclose 
P0721 LIrer scOre - a neW PrOgnOsTIc TOOL In hePaTIc 
cIrrhOsIs decOMPensaTIOn
Freitas M.1,2,3, Xavier S.1,2,3, Magalhães R.1,2,3, Magalhães J.1,2,3, 
Marinho C.1,2,3, Cotter J.1,2,3
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Portugal, 2Life and Health Sciences Research Institute (ICVS), School of 
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Introduction: The liver-renal-risk (LIRER) score was developed to predict 
adverse outcomes in cirrhotic patients with Model for End-stage Liver 
Disease (MELD)< 18, helping the allocation to liver transplantation in this 
population.
aims & Methods: Aim: To assess the prognostic performance of LIRER com-
pared to other prognostic scores in patients with hepatic cirrhosis decom-
pensation, stratifying them in MELD< 18 e MELD≥18.
Methods: Retrospective, unicentric study that included patients admitted 
for initial decompensation of cirrhosis between January 2010 and February 
2017. The LIRER, Child-Pugh (CP), MELD and MELD-Na scores were calcu-
lated at admission.
results: 146 patients were included, 65.1% with MELD< 18. In the per-
formed analysis, LIRER was a predictor of in-hospital mortality (p=0.02), at 
30 days (p=0.04), 1 year (p=0.001), 2 years (p< 0.001) and overall mortality 
(p=0.007). The ROC curve analysis showed that LIRER (0.699, 0.719,0.689) 
was superior to CP (0.614; 0.642; 0.614), MELD (0.625; 0.639; 0.572) and 
MELD-Na (0.668; 0.670; 0.580) to predict 1 year, 2 years and overall mor-
tality, respectively. Stratifying patients in MELD< 18 and MELD≥18, LIRER 
was found to be an independent predictor of 1 year, 2 years and overall 
mortality only in patients with MELD< 18 (0.674; 0.702; 0.723). The LIRER 
score was superior to the other scores to predict 30-day hospitalar re-
admission (AUC 0.748), and the only significant in both groups (MELD< 
18: 0.728; MELD≥18: 0.736), with patients with LIRER>15.9 having a sig-
nificantly higher probabilityto be readmitted at 30 days (sensibility 69.6%, 
specificity 77.0%).
conclusion: The LIRER score is a better predictor of overall, at 1 and 2 years 
mortality than CP, MELD and MELD-Na scores, in the decompensation of 
cirrhosis in patients with MELD< 18. LIRER is therefore an important tool to 
predict medium-long-term outcomes in this population. Besides, it allows 
predicting the 30-day readmission probability in overall patients.
disclosure: Nothing to disclose 
P0722 surgIcaL rIsk assessMenT In cIrrhOsIs
Frias Gomes C., Morão B., Neto C., Barjas E., Ferreira A., Cravo M.
Hospital Beatriz Ângelo, Loures, Portugal
contact e-Mail address: catarinagomes27@gmail.com
Introduction: Patients with cirrhosis are living longer, with more advanced 
disease because of improved medical management. As a result, they are 
at an increase risk for other diseases and may require emergent or elec-
tive surgical procedures other than liver transplantation. Nevertheless, the 
adequate selection of these patients to surgery is still challenging due to 
previous reports of high mortality rate and postoperative complications.
aims & Methods: Our goal was to review the clinical performance of cir-
rhotic patients who underwent surgery in our hospital and to identify risk 
factors for mortality. A retrospective analysis of patients with cirrhosis who 
underwent abdominal or non-abdominal (orthopedics, vascular, ENT) 
surgery between 2016 and 2018 was performed. Primary outcomes were 
mortality, hospitalization length and need to hospital readmission.
results: A total of 49 patients were included (91.8% male, mean age 61.1 ± 
10.1 years, CHILD A 69.4% (34/49), CHILD B 30.6% (15/49), CHILD C 0). ASA 
classification was the following: 32.7% ASA II, 49% ASA III and 18.4% ASA 
IV. The majority of the patients was submitted to an abdominal surgery 
(63.3%) and 40.8% (29/49) underwent an urgent procedure. Mortality rate 
was 10.2%. Median time of hospitalization was 3 [1-70] days, with 10% 
of patients needing readmission. MELD Na (OR 1.33 IC 95% [1.02-1.49], 
p=0.03), ASA > III (OR 1.18 IC 95% [1.02-1.36], p=0,0049) and urgent sur-
gery (OR 1.33 IC 95% [1.03 - 1.72], p=0.004) were associated with a higher 
postoperative mortality. Hospital readmission was higher in patients with 
MELD Na > 13 (3/6 vs 2/38, p=0.04). Urgent procedures (1 vs 13 days, p < 
0.001), ASA > III (1 vs 5 days, p=0.004), albumin < 3.5 (1 vs 6 days, p=0.01) 
and MELD Na > 13 (2 vs 7 days, p=0.03) were associated with longer hos-
pital stay.
conclusion: In this cohort of CHILD A and B cirrhotic patients, the postop-
erative mortality rate was 10.2%. MELD Na, ASA > III and urgent procedure 
were independent associated with a higher mortality risk.
references: 1 - Northup PG, Friedman LS, Kamath PS. AGA Clinical Practice 
Update: Surgical Risk Assessement and Periperative Management in Cir-
rhosis: Expert Review. Clinical Gastroenterol Hepatol 2019 17(4):595-566 
2 - Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 
187 countries between 1980 and 2010: a systematic analysis. BMC Med 
2014;12:145.
disclosure: Nothing to disclose 
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conclusion: E-cadherin and its transcriptional regulators; snail and slug 
are potential indicators for assessing the stage of HCV-induced liver fibro-
sis and carcinogenesis but not for assessing the degree of hepatitis activ-
ity. Therefore, the snail family could be a promising target for designing 
effective preventive and therapeutic strategies for chronic HCV infection 
serious co-morbidities. 
references: 
1. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of 
HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 
2017; 14(2):122-132. 
2. Gloushankova NA, Rubtsova SN, Zhitnyak IY. Cadherin-mediated 
cell-cell interactions in normal and cancer cells. Tissue Barriers. 2017; 
5(3):e1356900. 
3. Sharma G, Raheja H, Das S. Hepatitis C virus: Enslavement of host fac-
tors. IUBMB Life. 2018; 7 0(1):41-49. 
4. Zhou JJ, Meng Z, He XY, Cheng D, Ye HL, Deng XG, et al. Hepatitis C virus 
core protein increases Snail expression and induces epithelial-mesenchy-
mal transition through the signal transducer and activator of transcription 
3 pathway in hepatoma cells. Hepatol Res. 2017; 47(6):574-583.
disclosure: 
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P0724 can sPLeen sTIffness MeasureMenT rePLace The 
uPPer endOscOPy TO PredIcT OesOPhageaL varIces In 
chrOnIc LIver dIsease B?
Mnif L.1, Hachicha S.1, Hela G.2, Boudabous M.1, Chtourou L.1, Amouri A.1, 
Tahri N.1
1Hedi Chaker Hospital, Gastroenterology, Sfax, Tunisia, 2Medecine University 
of Sfax, Gastroenterology, Sfax, Tunisia
contact e-Mail address: safa.hachicha@yahoo.fr
Introduction: The upper endoscopy is the gold standard method to search 
oesophageal varices, signes of portal hypertension. But, it is an invasive 
and non-risk-free examination. Few studies have investigated other non-
invasive tools that can replace the upper endoscopy in predicting portal 
hypertension.
aims & Methods: A total of 84 patients with viral Chronic B liver disease (28 
liver cirrhosis, 56 chronic hepatitis) were prospectively randomised; all pa-
tients underwent TE for measurement of LSM/SSM and upper endoscopic 
examination for the diagnosis of OV.
results: 53 men and 31 women were included, with a mean age of 49.04 
± 12.80 years. 42.86% of patients had no OV (V0); 14.27% had OV grade I 
(V1) and 28.57% had large oesophageal varices (OV grade II and III). Pa-
tients were divided into two groups, those with non varices and those with 
OV (42.86%). Spleen stiffness showed higher values in liver cirrhosis as 
compared with chronic hepatitis B patients (58.79KPa versus 26.93KPa; p< 
0.001) and in patients with OV as compared to those without OV (52.09KPa 
versus 26.64KPa; p< 0.001). The median value of SSM for patients with V1 
was 29.92 KPa (12.90 - 75KPa) , 61.27KPa (13.90 - 75KPa) for patient with V2 
(OV grade II) and 65.85 KPa (35.50-75KPa) for patients with V3 (OV grade 
III). A significant difference of SSM was observed between V1,V2 ,V3 sub-
groups (p=0.005) .But, there was no significant difference between Vo and 
V1. For a SSM higher than 33.1KPa, we managed to predict the presence of 
OV with an area under ROC (AUROC) at 0.795, a sensibility (ss) at 72.2% 
, a specificity (sp) at 77.1% and a negative predictive value (NPV) at 63%. 
For a SSM higher than 43KPa, we manage to predict the presence of large 
oesophageal varices with an AUROC at 0.906, a ss at 83.3%, a sp at 83.3% 
and NPV at 81%. The SSM was more interesting in predicting the pres-
ence of large OV than the presence of OV (AUROC 0.906 versus 0.795).To 
increase the performance of SSM, we calculate the arithmetic sum of SSM 
and LSM and we found that SSM+LSM was better than SSM to predict the 
presence of OV and large OV with AUROC at 0.824 and 0.937 respectively.
conclusion: The SSM seems to be an interesting non invasive tool to pre-
dict the presence of large OV requiring primary prophylaxis of varicose 
haemorrhage in order to reduce the number of screening endoscopy. The 
Association LSM+SSM may be considered as the first line non-invasive tool 
to predict the presence of OV in patients with viral chronic B liver disease.
disclosure: Nothing to disclose 
P0723 e-cadherIn and ITs TranscrIPTIOnaL 
reguLaTOrs In assessIng chrOnIc hePaTITIs c vIrus 
acTIvITy and cO-MOrBIdITIes
Hassan M.1, El-Ahwany E.1, Aboushousha T.2, Khalil H.2, Montasser A.2, 
Abu-Taleb H.3, Elzallat M.1, El-Talkawy M.4, Zoheiry M.1
1Theodor Bilharz Research Institute, Immunology Department, Giza, Egypt, 
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3Theodor Bilharz Research Institute, Environmental Research Department, 
Giza, Egypt, 4Theodor Bilharz Research Institute, Hepato-Gastroenterology 
Department, Giza, Egypt
contact e-Mail address: marwahassan_777@yahoo.com
Introduction: Hepatitis C virus (HCV) infection poses a great health prob-
lem to the world today, affecting hundreds of millions of people, and mil-
lions more are infected every year. Because HCV typically takes years, if not 
decades, to progress, the burden it places on healthcare systems will inev-
itably increase in the coming years despite the currently available therapy. 
Chronic HCV infection is one of the main causes of hepatic fibrosis, which 
if untreated for years, will cause distortion of hepatic architecture and pro-
gression to liver cirrhosis with its serious complications e.g. hepatocellular 
carcinoma (HCC). The mechanisms of HCV-induced liver fibrosis and hepa-
tocarcinogenesis are not yet well-recognized. E-cadherin is a cell surface 
glycoprotein that retains the stability of intercellular adhesion and cellular 
polarity, maintaining the epithelial barrier integrity. Its down-regulation, 
as a result of up-regulation of its transcriptional repressors including 
twist, snail (snail1), and slug (snail2), may induce epithelial-mesenchymal 
transition (EMT), a mechanism that is involved in HCC development and 
progression. The identification of molecular factors that promote EMT in 
HCV infection may provide valuable targets to prevent or to treat its fatal 
complications.
aims & Methods: This study was designed to determine the role of E-
cadherin and the transcription factors snail, slug, and twist2, which are 
the major regulators of EMT, in assessing chronic HCV activity and its as-
sociated fibrosis and carcinogenesis. Selected patients were subjected to 
thorough clinical examination and were assessed by: 
(a) laboratory investigations 
(b) abdominal U/S and triphasic CT. 
Fifty-nine liver biopsies were examined by histopathology and by immu-
nohistochemistry for E-cadherin, snail, slug, and twist2 expression. Grad-
ing of hepatitis activity (A) and staging of fibrosis (F) were evaluated using 
the METAVIR scoring system.
results: E-cadherin expression showed a significant progressive decline 
with increased stage of fibrosis and with hepatic carcinogenesis (p< 0.001). 
In contrast, snail and slug were positively associated with fibrosis staging 
and with HCC (p< 0.001). However, twist2 wasn’t affected by the degree of 
hepatitis activity, the stage of fibrosis, or by the development of HCC.
e-cadherin snail and slug Twist2
Low activity
(a1 and a2)
(n=24)
50.41±3.23 17.62±3.07 53.83±5.17
high activity
(a3)
(n=22)
51.13±4.24 20.13±4.74 63.63±6.13
Low fibrosis
(f1 and f2)
(n=36)
59.16±2.01 13.08±2.03 61.77±5.21
high fibrosis
(f3 and f4)
(n=10)
20.50±4.24b 39.50±9.95** 46.80±9.61
hepatocellular carcinoma
(n=13) 10.61±2.4
a, b 65.76±4.59*,** 59.61±3.82
Results are expressed as mean±SEM.
aSignificant decrease than low and high hepatitis activity and than high fibrosis 
(p<0.001).
bSignificant decrease than low fibrosis (p<0.001).
*Significant increase than low and high hepatitis activity and than high fibrosis 
(p<0.001).
**Significant increase than low fibrosis (p<0.001). 
[Table: E-cadherin, snail and slug, and twist2 expression patterns in 
hepatitis activity grades, liver fibrosis stages, and hepatocellular carcinoma]
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P0725 dIrecT acTIng anTIvIraL TreaTMenT decreases 
InhIBITOry TIM-3 IMMune checkPOInT recePTOr exPressIOn 
On nk ceLLs In PaTIenTs WITh chrOnIc hcv hePaTITIs
Par G.1, Szereday L.2, Meggyes M.2, Berki T.3, Miseta A.4, Farkas N.5, Par A.1
1University of Pecs, First Department of Medicine, Hepatology Unit, Pecs, 
Hungary, 2University of Pecs Medical School, Department of Medical 
Microbiology and Immunology, Pecs, Hungary, 3University of Pecs Medical 
School, Department of Biotechnology and Immunology, Pecs, Hungary, 
4University of Pecs Medical School, Department of Laboratory Medicine, 
Pecs, Hungary, 5University of Pecs, Medical School, Institute for Translational 
Medicine, Pecs, Hungary
contact e-Mail address: pargabriella@gmail.com
Introduction: In chronic HCV hepatitis immune cells have increased ex-
pression TIM-3 checkpoint inhibitor receptor that downregulates T cell ac-
tivation, resulting T cell exhaustion. In contrast to immune dysfunction of 
adaptive immune response high levels of TIM-3 expression on NK cells was 
associated with an activated phenotype towards cytotoxicity. Elimination of 
hepatitis C virus with direct-acting antiviral (DAA) treatment may modify 
host immune response via changing TIM-3 immune checkpoint molecule 
expression.
aims & Methods: In this prospective study we aimed to analyse changes 
in TIM-3 receptor expression by peripheral blood mononuclear cells in 
chronic HCV hepatitis patients during DAA treatment. Phenotype distri-
bution and expression of TIM-3 by peripheral blood CD3+, CD4+, CD8+ T 
cells, regulatory T cells, NK, NK dim, NK bright, NKT cells and monocytes 
were determined by multicolor flow cytometry in 14 patients with chronic 
hepatitis C pretreatment and after 12 weeks of dasabuvir, ombitasvir, pari-
taprevir/ritonavir combination treatment. Blood samples were collected 
baseline (BL), at the end of treatment (EOT) and at 12 weeks after EOT 
(SVR12) All patients achieved sustained virological response (SVR12).
results: While the percentage of NK bright cells significantly decreased 
during DAA therapy (BL: 3,1%, SVR12: 1,7%), the percentage of peripheral 
blood CD3+ T lymphocytes was significantly higher at SVR12 compared to 
baseline values (BL: 47 % vs SVR12: 56,3%). TIM-3 expression by NKT (BL: 
4,9% vs SVR12: 3,5%) and by NK bright cells (BL: 64% vs SVR12: 50,4%) 
decreased significantly after treatment.
conclusion: Sustained virological response was associated with increased 
percentage of peripheral cytotoxic T cells and also with decreased inhibi-
tory TIM-3 checkpoint inhibitor expression by NKT and NK bright cells. Our 
data suggest that DAA therapy via decreasing the expression of TIM-3 im-
mune checkpoint molecules on NK cell subpopulations may induce the 
modulation of NK cell cytotoxicity against T cells and contribute to the re-
covery of exhausted adaptive immune responses.
disclosure: Nothing to disclose 
P0726 MOLecuLar characTerIzaTIOn Of genOTyPIc PrOfILe 
Of hePaTITIs d vIrus In LIBya
Elzouki A.-N.1, Elzouki I.2, Elahmer O.3, Bashir S.4
1Hamad Medical Corporation, Medicine, Doha, Qatar, 2Department of 
Medicine, Tripoli Central Hospital, Tripoli, Libya, 3National Center for Disease 
Control, Tripoli, Libya, 4Center for Disease Control, Tripoli, Libya
contact e-Mail address: nelzouki_1999@yahoo.com
Introduction: Hepatitis D virus (HDV) is a hepatotropic virus that is de-
pendent on the hepatitis B virus (HBV) and supplies the viral envelope 
containing the surface antigen of hepatitis B. An estimated 15-20 million 
people are co-infected with HBV and HDV worldwide; with areas of high 
endemicity in the Middle East, and the Mediterranean region. Viral genetic 
diversity is related to the geographical origin of the isolates, and there are 
at least eight genotypes that are referred to as HDV-1 through HDV-8. Data 
on molecular characterization of HDV in Libya are lacking.
aims & Methods: This study aims to assess the HDV genotypic of patients 
infected with HDV in Libya. was genotyped by nested PCR-RFLP and se-
quencing from serum samples of 10 patients with HDV infection whom 
found to be positive in a cohort of 400 patients with hepatitis B infection. 
The genotypes were correlated with the clinical characteristics presented 
by patients with HBV/HDV infection.
All HDV strains belonged to genotype 1, with a wide distribution within 
the HDV-1 group. They all share the African amino acid marker, a serine at 
position 202 of the large hepatitis D virus protein.
results: All HDV strains belonged to genotype 1, with a wide distribution 
within the HDV-1 group. They all share the African amino acid marker, a 
serine at position 202 of the large hepatitis D virus protein.
conclusion: HDV genotype-1 is the only genotype found, with a high di-
versity within this group. Further studies are needed in order to better 
characterize and manage the HBV/HDV-infected patients according to the 
genetic variability of the viral strains.
disclosure: Nothing to disclose 
P0727 hePaTITIs c PaTIenTs WITh suBsTance MIsuse aTTend 
and engage BeTTer WITh a cOMMunITy-Based OuTreach 
cLInIc cOMPared TO a TradITIOnaL hOsPITaL-Based cLInIc
Phillips C., Yusuf A.
East Sussex Healthcare NHS Trust, Gastroenterology, Eastbourne, United 
Kingdom
contact e-Mail address: abdyus12@gmail.com
Introduction: In June 2017, a hepatitis C (HCV) clinic was established in the 
local substance misuse service (SMS) as an outreach clinic from the local 
hospital. The clinic initially operated once a month, but due to demand, 
fortnightly clinics were commenced in March 2018. The objective of the 
clinic was to provide HCV care (including work-up and treatment) to clients 
who, because of their substance misuse, might not attend hospital clinics.
aims & Methods: The aim of this study was to assess whether the outreach 
clinic improved attendance and engagement among these patients com-
pared to hospital-based clinics. The outreach clinic database was used to 
identify individuals who were offered an appointment between June 2017 
and December 2018. The hospital electronic booking system was then used 
to review historic appointments made for these patients in secondary care. 
Attendance and engagement with the hospital and outreach clinics were 
compared.
results: 51 individuals were referred to the SMS clinic between June 2017 
and December 2018. 31 of these (61%) had, at some point (dating as far 
back as the early 2000s), been referred to secondary care for assessment of 
their HCV. Among those referred, 12 (39%) never attended an appointment, 
18 (58%) attended at least once but were subsequently lost to follow-up 
and 1 (3%) was initiated on HCV treatment but was subsequently trans-
ferred to the SMS clinic once established on treatment. In comparison, of 
the 51 referred to the SMS clinic, 17 (33%) never attended an appointment, 
12 (24%) attended at least once but were then lost to follow-up while 22 
(43%) remained engaged with the outreach clinic.
conclusion: This study demonstrates that, compared to a hospital setting, 
an outreach clinic in the community substantially improves attendance 
and engagement among HCV patients with substance misuse. Contribu-
tory factors may include reduction in barriers with SMS oriented care, and 
ease of access as these patients regularly attend the SMS centre.
disclosure: Nothing to disclose 
P0728 hePaTITIs B vIrus InfecTIOn - Is MIgraTIOn sTaTus 
a rIsk facTOr?
Gauci J.1, Grima M.A.2, Zahra G.2, Galea K.2, Barbara C.2, Ellul P.2
1Mater Dei Hospital, Malta, Swieqi, Malta, 2Mater Dei Hospital, Msida, Malta
contact e-Mail address: jamesgauci111@gmail.com
Introduction: HBV infection is one of the most common infectious diseas-
es worldwide. Chronic infection may be complicated by cirrhosis and or 
liver cancer. Despite the introduction of a vaccine several decades ago, 
this disease is still widely prevalent. The prevalence of HBV infection var-
ies according to geographic location, with relatively low rates in Western 
Europe (< 1%). Overall trends in incidence in this region have improved, 
however, increasing immigration from countries with higher prevalence 
has impacted the problem.
aims & Methods: This epidemiological study was carried out to determine 
trends in incidence of chronic HBV infection in Malta, a country which has 
recently recorded the highest rate of immigration in the European Union. 
HBV infection was defined as the presence of positive hepatitis B surface 
antigen (HBsAg) and/or positive total antibody to hepatitis B core protein 
(anti-HbC). Patients infected with hepatitis B between 2008 and 2017 were 
identified through the Virology laboratory and Molecular Diagnostics (In-
fectious Diseases) which caters for all patients within the Maltese National 
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ficity, positive predictive value (PPV) and negative (NPV) and diagnostic 
accuracy expressed using the area under the receiver operating curve (AU-
ROC).
results: 405 patients, 68% men; mean age 53.17 ±9.10 (15-81). TE fibrosis 
stage: F0-F1 48%, F2 18.6%; F3 10.1%, F4 23.3%. The diagnostic accuracy, 
sensitivity and specificity of the BQS, as well as cut off, PPV and NPV are 
shown in Table 1.
conclusion: In the present real-life cohort, APRI and FIB-4 had diagnostic 
accuracy between 83.4 and 84.6% for cirrhosis, using TE as a reference, 
mainly because of its high NPV of 93% for APRI (cut off < 0.883), and for 
FIB-4 (cut off < 1.902). The BQS were less accurate than TE in the detection 
of intermediate stages of fibrosis.
  score aurOc sensivity specificity cut off PPv nPv
F0-F1 APRI 0.806 0.771 0.743 0.558 0.764 0.750
  FIB-4 0.789 0.686 0.773 1.539 0.766 0.694
F2-F3 APRI 0.582 0.759 0.489 0.506 0.374 0.834
  FIB-4 0.550 0.724 0.444 1.185 0.344 0.800
Cirrhosis APRI 0.834 0.808 0.809 0.883 0.562 0.933
  FIB-4 0.846 0.798 0.813 1.902 0.563 0.930
[Table 1]
references: 1- Ragazzo TG, Paranagua-Vezozzo D, Lima FR Accuracy of 
transient elastography-FibroScans, acoustic radiation force impulse (ARFI) 
imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index 
compared with liver biopsy in patients with chronic hepatitis C. Clinics (Sao 
Paulo). 2017 Oct;72(9):516-525. 2- Omar H, Said M, Eletreby R Longitudinal 
assessment of hepatic fibrosis in responders to direct-acting antivirals for 
recurrent hepatitis C after liver transplantation using noninvasive meth-
ods. Clin Transplant. 2018 Aug;32(8):e13334. 3- Zhao Y, Thurairajah PH, 
Kumar R, et al Novel non-invasive score to predict cirrhosis in the era of 
hepatitis C elimination: A population study of ex-substance users in Singa-
pore. Hepatobiliary Pancreat Dis Int. 2018 Dec 6. pii: S1499-3872(18)30268-
6. 4- Knop V, Hofmann WP, Buggisch P, et al Estimation of liver fibrosis by 
noncommercial serum markers in comparison with transient elastography 
in patients with chronic hepatitis C virus infection receiving direct-acting 
antiviral treatment. J Viral Hepat. 2019 Feb;26(2):224-230.
disclosure: Nothing to disclose 
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anTIvIraLs
Fernandez Alvarez P., Barrranco Castro D., Guerra Veloz M.F., 
Cordero Ruiz P., Bellido Muñoz F., Caunedo Alvarez A., Carmona Soria I.
Hospital Universitario Virgen Macarena, Gastroenterology and Endoscopy 
Unit, Sevilla, Spain
contact e-Mail address: paulafer7@gmail.com
Introduction: The new direct-acting antiviral (DAA) achieve rates of sus-
tained virological response (SVR) in patients with chronic hepatitis C that 
exceed 95%. Achieving SVR has been shown to prevent progression to liver 
disease final stages.
aims & Methods: The aim of this study is to evaluate changes in liver fi-
brosis by non-invasive serological methods after achieving SVR with new 
therapies in patients with chronic hepatitis C. 
A unicenter retrospective observational study of patients with chronic hep-
atitis C treated with DAA between 2014 and 2016 was carry out. Basal fibro-
sis assesment was performed by transitional elastography (TE). Advanced 
fibrosis was defined as > 9,5 KpA. Serological markers of fibrosis (FIB-4 / 
APRI) were determinated before treatment and 24 weeks post-treatment.
results: We found that among the sample 419 of 438 patients achieved SVR. 
Two hundred and seventy-eight patients (66,3%) were men with a median 
age of 55 years (48-64). One hundred and fifty-three patients (36,5%) were 
hypertensive and seventy-five (17,9%) were diabetic. Fifty-three percent of 
the patients presented genotype 1b and 10,7% showed genotype 3.
According to ET 285 patients (68%) had advanced fibrosis. The median 
fibrosis stage before treatment was 11,7 KpA (8,35; 19,3) by ET 2,23 (1,3; 
Health Service. Demographic and clinical data were recorded, including 
age, gender, ethnic and racial group, viral hepatitis markers, radiology 
as well as histology results. Statistics on the Maltese population were ob-
tained from the Eurostat database.
results: Four hundred and forty-one patients were noted to suffer from HBV 
infection. With an average population of 425,000 during the period stud-
ied, the calculated prevalence of known chronic HBV infection was 0.1%. 
The proportion of non-migrants suffering from HBV infection was 0.06% 
(n=245) of the average non-migrant population in Malta (n=398,604). The 
equivalent statistic for migrants was 0.6% (n=164) of the average migrant 
population (n=27,162). A third of HBV-infected patients were aged 34 years 
or less, 74% of these being migrants (see Table). The proportion of infect-
ed migrants was lower in older age groups where correspondingly lower 
rates of migrants prevail. The most prevalent race was Caucasian (78%, 
n=321) and the main ethnic group was non-Hispanic (97.5%, n=399). Cir-
rhosis was present in 20% of patients, while 6% (n=26) had hepatocellular 
carcinoma. None of the patients studied had documented Hepatitis C or 
HIV co-infection, while one (5%) had previous exposure to Hepatitis A.
conclusion: The prevalence demonstrated in our population is similar to 
that found in other countries in Western Europe. The risk of HBV infection 
was found to be 10-fold in the migrant population, hence emphasizing 
migrant status as a risk factor for infection. Rates of infection in individu-
als aged 34 years or less were much higher in the migrant population, 
most of which were presumably not protected by vaccination. Identifica-
tion of specific patient characteristics allows for appropriate planning of 
public health initiatives, hence contributing to the success of eradication 
programs. The results obtained in the course of this investigation suggest 
the need for screening and treatment of migrants, while ensuring that all 
children are vaccinated.
age % of Total Proportion of Migrants
< 34 33%(n=146) 74%
35-44 16.6%(n=73) 66%
45-54 13.9%(n=61) 25%
55-64 19.4%(n=86) 2%
65-74 6.2%(n=24) 1%
>75 2.1%(n=12) 0%
Unknown 11.1%(n=49) Unknown
[Percentage of hepatitis B virus infected patients stratified by age group]
references: European Commission. Eurostat Population Data (Demogra-
phy, Migration and Projections). Cited April 2019. Available from: https://
ec.europa.eu/eurostat/web/population-demography-migration-projec-
tions/data
disclosure: Nothing to disclose 
P0729 deTerMInaTIOn Of LIver fIBrOsIs By BIOcheMIcaL 
scOres In cOMParIsOn TO TransIenT eLasTOgraPhy In 
PaTIenTs WITh chrOnIc hePaTITIs c - a POrTuguese reaL LIfe 
cOhOrT
Figueiredo L.M.1, Dias Domingues T.2, Rafael M.A.1, Alexandrino G.1, 
Carvalho R.3, Costa M.N.4, Martins A.3
1Hospital Prof. Dr. Fernando Fonseca, Gastroenterology, Amadora, Portugal, 
2Centro de Estatística e Aplicações, Universidade de Lisboa, Lisboa, Portugal, 
3Hospital Prof. Dr. Fernando Fonseca, Amadora, Portugal, 4Hospital Prof. Dr. 
Fernando Fonseca, Gastroenterology, Lisboa, Portugal
contact e-Mail address: luisa_mmfigueiredo@hotmail.com
Introduction: Noninvasive methods for estimation of liver fibrosis may help 
to avoid liver biopsy in many contexts. In chronic hepatitis C (CHC), guide-
lines recommend transient hepatic elastography (TE) prior to initiation of 
treatment. The validation of biochemical scores (BQS), such as APRI and 
FIB-4, may contribute to the simplification of treatment.
aims & Methods: The aim of this study was to compare the diagnostic 
accuracy of TE in comparison to BQS in staging of fibrosis in CHC. Cross-
sectional study of patients with CHC followed at a Hepatology Unit, from 
February/2015 to February/2019, with baseline TE, determined with Fi-
broScan: F0-F1 < 7; 7£F2< 9.5; 9.5£F3< 12.5; F4≥12.5. APRI and FIB4 scores 
were calculated at the TE date and the respective cut-offs were calculated 
(Youden index) to define F0-F1, F2-F3 and F4, as well as sensitivity, speci-
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4,22) and 0,86 (0,49; 1,82) according to FIB-4 and APRI, respectively. This 
measurements 24 weeks after treatment were 1,35 (0,93; 2,16) and 0,30 
(0,21; 0,47) by FIB-4 and APRI, respectively (p < 0,001). 
serological markers Basal Week 24 p-valor
advanced eT: >9,5 kpa
FIB-4 2,87 (1,75; 5,31) 1,57 (1,1; 2,76) <0,001
APRI 1,21 (0,64; 2,39) 0,34 (0,24; 0,61) <0,001
no advanced Te: < 9,5 kpa
FIB-4 1,4 (0,94; 2,01) 0,99 (0,73; 1,28) <0,001
APRI 0,58 (0,36; 0,88) 0,22 (0,18; 0,30) <0,001
[Table 1]
conclusion: Patients with hepatitis C virus infection who achieved a SVR 
after received DAA showed a significant regression of the validated sero-
logical markers of fibrosis. This findings accomplish in patients with and 
without advanced fibrosis. 
It is probably that these changes allow us to select patients who do not 
beneficit themselves from a long-term follow-up. Nevertheless, to consoli-
date this, prospective studies with a larger patients number and follow-up 
time are needed.
disclosure: Nothing to disclose 
P0732 effecTs Of hcv eradIcaTIOn On cardIac funcTIOn 
In PaTIenTs WITh cIrrhOsIs: InITIaL resuLTs frOM a cOhOrT 
sTudy
Chiricuta A.1, Voiosu A.M.2, Daha I.3, Voiosu T.A.2, Bengus A.4, 
Mateescu B.R.5
1Colentina Clinical Hospital, Gastroenterology and Hepatology, Bucharest, 
Romania, 2Colentina Clinical Hospital, Gastroenterology, Bucharest, 
Romania, 3Colentina Clinical Hospital, Cardiology, Bucharest, Romania, 
4Spitalul Clinic Colentina, Gastroenterology, Bucharest, Romania, 5Spitalul 
Clinic Colentina Bucuresti, Gastroenterology, Bucharest, Romania
contact e-Mail address: radoiaurelia@yahoo.com
Introduction: Hepatitis C Virus (HCV) infection is one of the leading causes 
of cirrhosis worldwide and is associated with an increased risk of car-
diovascular events (stroke, acute coronary syndrome) [1]. Furthermore, 
these patients can develop cirrhotic cardiomyopathy (CCM) defined by a 
blunted adaptative response of the myocardium to stress. [2] Direct-acting 
antivirals (DAAs) are a new class of drugs with very high efficacy for the 
treatment of HCV. We aimed to assess the impact of HCV eradication on the 
cardiac profile of cirrhotic patients.
aims & Methods: This is an initial report from an ongoing prospective ob-
servational study. 17 consecutive patients with HCV cirrhosis were included 
before undergoing treatment with DAAs for a period of 3/ 6 months. Exclu-
sion criteria were pre-existent cardiovascular disease, obesity and chronic 
alcohol intake (above 80mg/day in the last 5 years). Routine blood tests, 
standard 12-lead electrocardiogram, N-terminal pro-brain natriuretic pep-
tide levels and contrast enhanced echocardiography examination with tis-
sue Doppler imaging were performed in all patients at baseline and after 1 
year of follow-up. CCM was diagnosed by echocardiography showing sys-
tolic dysfunction (SS, left ventricle ejection fraction < 55%) and/or diastolic 
dysfunction (DD, at least 2 out of 3 of the following: age-corrected E/A< 1, 
IVRT> 80ms and DT>200 ms) [3]. The main outcome was change in cardiac 
function after viral clearence assessed by echocardiography.
results: 17 patients were enrolled between july 2017-march 2018, of whom 
4 were lost to follow-up, 2 did not receive treatment and 1 was excluded 
due to presence of atrial fibrillation. 2 patients had decompensated cirrho-
sis based on Child-Pugh score. CCM was diagnosed in 8 out of 10 patients 
based on the presence of isolated DD in 6 and mixed systolic and diastolic 
dysfunction in 2. 
There was a significant statistical improvement in thrombocyte count, al-
bumin, INR and total bilirubin following treatment, but not for the Child or 
MELD score. There was a significant decrease in the lateral mitral annular 
systolic velocity (9.24 vs 8.52 cm/sec, p=0.05, Wilcoxon test), an increase 
in late velocity flow (A and VA waves) and a significant increase in mean 
arterial pressure (92 vs 106 mmHg, p=0.018). NT-proBNP, corrected QT and 
incidence of SD/DD did not significantly differ before and after viral eradi-
cation. 
There were 2 new cases of CCM based on DD and 1 case with normalisa-
tion of diastolic function. One patient developed exertional dyspnea during 
treatment with sofosbuvir/ledipasvir and the follow-up echocardiography 
showed a marked difference in pulmonary artery pressure before and after 
treatment (26 vs 53mmHg), with the exclusion of pulmonary or left cardiac 
diseases. Right heart catheterization ruled out severe arterial pulmonary 
hypertension.
conclusion: Eradication of HCV may influence cardiac function in patients 
with cirrhosis. Alterations in cardiac parameters in our cohort potentially 
due to viral clearence indicate that further study is warranted.
references: 1. Petta S. Hepatitis C virus and cardiovascular: A review. J 
Adv Res. 2016;8(2):161-168. doi:10.1016/j.jare.2016.06.001 2. EASL Clinical 
Practice Guidelines for the management of patients with decompensated 
cirrhosis. Angeli, Paolo et al. Journal of Hepatology 2018 , Volume 69, Is-
sue 2, 406 - 460 3. Moller S, Henriksen JH. Cardiovascular complications of 
cirrhosis. Gut 2008;57:268-278 4. Voiosu AM, Daha IC, Voiosu TA, Mateescu 
BR, Dan GA, Baicus CR, et al. Prevalence and impact on survival of hepato-
pulmonary syndrome and cirrhotic cardiomyopathy in a cohort of cirrhotic 
patients. Liver Int 2015;35:2547-2555.
disclosure: Nothing to disclose 
P0733 assessMenT Of cardIac funcTIOns BefOre and afTer 
TreaTMenT Of egyPTIan chrOnIc hePaTITIs c PaTIenTs usIng 
dIrecTLy acTIng anTIvIraLs
Talkhan M.1, Hamdy K.2, El Kilany H.2, Safwat E.2, Mohammed H.G.2, 
Dawod A.2
1Ain Shams University, Internal Medicine, Hepatogastroenterology and 
Endoscopy, Cairo, Egypt, 2Ain Shams University, Faculty of Medicine, Internal 
Medicine, Hepatogastroenterology and Endoscopy, Cairo, Egypt
contact e-Mail address: m.gamal.work@gmail.com
Introduction: Hepatitis C virus (HCV) infection is one of the main causes of 
chronic liver diseases worldwide. HCV infection has been associated with 
numerous extra-hepatic manifestations. Also, up to 50 percent of patients 
with advanced cirrhosis have features of cardiac dysfunction. Treatment for 
chronic HCV infection is evolving from interferon-based therapy to direct-
acting antiviral agents. Previous interferon-based anti-HCV therapies were 
mostly not tolerated by patients with advanced heart failure and had lim-
ited elimination efficacy. Those new highly anti-HCV-specific drugs lack 
the complex unspecific side effects upon cardiac. However, new regimens 
comprised of DAAs that target different steps in the HCV life cycle are in 
development and some have received breakthrough therapy status by the 
U.S. Food and Drug Administration. Also, recent retrospective studies, case 
reports and post marketing reports suggest that those drugs may cause a 
toxic cardiomyopathy.
aims & Methods: The aim of the study is to assess the effect of treatment 
of naïve Egyptians chronic hepatitis C patients on cardiac functions using 
direct acting antivirals. This study is a prospective cohort study that was 
conducted on 90 treatment-naïve adult patients with chronic hepatitis C 
infection. Patients were divided into 2 groups : 
group 1: 45 non cirrhotic patients received treatment with Sofosbuvir + 
Daclatasvir for 12 months.
group 2: 45 cirrhotic patients received treatment with Sofosbuvir + Dacla-
tasvir + ribavirin for 12 months. 
All patient achieved sustained virological response at week 12 (SVR12) 
All patients were assessed at week 0 ( start of treatment) and week 12 ( 
SVR 12) with laboratory studies including level of NT- Pro BNP, ultrasonog-
raphy, Echocardiography.
results: Assessment of LV systolic functions using EF % revealed no signif-
icant difference between the studied groups regarding EF before and after 
treatment ( P value 0.266 ,0.169 respectively) Change in EF was significant-
ly higher in non-cirrhotic group (P value 0.024) . EF significantly increased 
in non-cirrhotic group after treatment( P value 0.003 ). Assessment of dia-
stolic function using E/A ratio revealed no significant difference between 
the studied groups regarding E/A ratio before and after treatment(P value 
0.752, 0.881 respectively ) . E/A ratio was non-significantly changed in both 
groups(P value 0.202, 0.108 respectively ) . Assessment of mean pulmo-
nary artery pressure (MPAP) revealed No significant difference between 
the studied groups regarding MPAP before and after treatment (P value 
0.466, 0.923 respectively ) . MPAP was non-signifciantly changed in both 
groups(P value 0.693, 0.479 respectively) . Regarding serum level of NT-Pro 
BNP , it was significantly increased in both groups after treatment (P value 
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Patient characteristic (n=7)  
Age at last contact in years (median, IQR) 50 (43-58)
Male gender (n, %) 7 (100)
Years since last contact (median, range) 13 (4-20)
Treatment experienced (n, %) 4 (57)
RNA-positive at re-evalution (n, %) 3 (43)
LSM RNA-positive patients ≥9.5 kPa (n, %) 1 (33)
Treatment initiated (n, %) 3 (100)
Iqr: interquartile range, n: number, LTfu: lost to follow-up, LsM: Liver stiffness 
Measurement
[Table 1. Characteristics of patients linked to care]
references: 1. Koopsen et al. Chronic hepatitis B and C infections in the 
Netherlands: estimated prevalence in risk groups and the general popula-
tion. Epidemiol Infect. 2019 Jan;147:e147. 2. Beekmans et al. Re-evaluation of 
chronic hepatitis B and hepatitis C patients lost to follow-up: results of the 
Northern Holland hepatitis retrieval project. Hepatol Med Policy. 2018;3:5. 
3. Kracht et al. Retrieval And cure of Chronic Hepatitis C (REACH): Results 
of micro-elimination in the Utrecht province. Liver Int. 2019;39(3):455-62. 
4. Hofman et al. Mortality due to chronic viral hepatitis B and C infections 
in the Netherlands. Ned Tijdschr Geneeskd. 2016;160:D511. 5. World Health 
Organization. Combating hepatitis B and C to reach elimination by 2030. 
Geneva, 2016.
disclosure: CELINE is supported with funding from Gilead Sciences. MvD 
participated in advisory boards of Abbvie (all fees paid to institution). JA 
participated in advisory boards of Gilead, Janssen-Cilag, Bristol-Meyers 
Squibb (BMS), Abbvie, Merck Sharpe & Dohme (MSD) and ViiV and re-
ceived research grants from BMS, Abbvie and ViiV (all fees paid to institu-
tion). BvH participated in advisory boards of Janssen-Cilag, BMS, Abbvie, 
MSD and Norgine and received a research grant from Zambon Pharma. 
RdK has received honoraria for consulting/speaking from Gilead, Janssen-
Cilag, BMS, Abbvie, MSD, Roche and Norgine and received research grants 
from Gilead, Janssen-Cilag, BMS and Roche. MvdV has participated in ad-
visory boards (fees paid to institution) of Abbvie, Gilead, Johnson & John-
son, MSD and ViiV and has received independent research grants from 
Abbvie, Johnson& Johnson, Gilead and MSD. JD declares that the Radbou-
dumc, on behalf of JD, received honoraria or research grants from Novartis, 
Ipsen, Otsuka, Abbvie, and Gilead. JD has served as consultant for Gilead 
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P0735 recurrence Of hePaTOceLLuLar carcInOMa In 
chrOnIc hePaTITIs c PaTIenTs TreaTed WITh dIrecT acTIng 
anTIvIraL agenTs (daas): a sIngLe cenTer exPerIence
Kohla M.1, El-Azab G.2, Allam M.2, Assem M.2, Omar Y.3
1National Liver Institute, Hepatology and Gastroenterology, Cairo, 
Egypt, 2National Liver Institute - Menoufia University, Hepatology and 
Gastroenterology Department, Menoifia, Egypt, 3National Liver Institute - 
Menoufia University, Oncology Department, Menoifia, Egypt
contact e-Mail address: g.elazab@gmail.com
Introduction: Chronic HCV infection is a leading risk factor for HCC world-
wide. Some recent studies have shown an unexpected high rate and ag-
gressive pattern of tumor recurrence following successful therapy of HCV 
with DAAs. It has been suggested that disruption of immune surveillance 
may facilitate the emergence of metastatic clones.
aims & Methods: To assess recurrence of HCC after successful therapy in 
a cohort of Egyptian patients with chronic hepatitis C genotype 4 treated 
with Direct-Acting Antiviral agents (DAAs). Methods: This retrospective 
cohort study included 100 patients with HCV-induced cirrhosis who were 
treated with DAA therapy between December 2015 and December 2016. Pa-
tients were categorized into 2 groups: Group (I): included 50 patients with 
liver cirrhosis without any evidence of HCC. Group (II): included 50 patients 
with successfully treated HCC on top of HCV-induced liver cirrhosis. 
According to the guidelines of National committee for control of viral hepa-
titis (NCCVH) released in November 2015, these patients were included in 
the study only four weeks after successful intervention for HCC aiming at 
cure, with no evidence of activity by dynamic imaging. All patients were 
< 0.001 in both groups) with no significant difference between the studied 
groups before and after treatment (P value 0.058, 0.099 respectively). Also, 
there was no significant changes in ECG findings in both groups and there 
was also no significant difference between the studied groups.
conclusion: Treatment of chronic HCV infection using DAAs (Sofosbuvir, 
Daclatasvir, Ribavirin) has no clinicaly significant effect on cardiac func-
tions.However, some sort of sub-clinical myocardial affection can occur for 
further analytical studies.
disclosure: Nothing to disclose 
P0734 hePaTITIs c eLIMInaTIOn In The neTherLands (ceLIne): 
a naTIOnWIde sTudy reTrIevIng LOsT TO fOLLOW-uP chrOnIc 
hePaTITIs c PaTIenTs
Isfordink C.1,2, van Dijk M.3, Brakenhoff S.M.4, Arends J.E.5, 
van Hoek B.6, de Knegt R.J.4, van der Valk M.2, Drenth J.P.H.3, 
on Behalf of the HepNed Study Group
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Netherlands, 2Amsterdam UMC, Location AMC, Department of Infectious 
Diseases, Amsterdam, Netherlands, 3Radboud University Medical Centre, 
Department of Gastroenterology and Hepatology, Nijmegen, Netherlands, 
4Erasmus Medical Centre, Department of Gastroenterology and Hepatology, 
Rotterdam, Netherlands, 5UMC Utrecht, Department of Infectious Diseases, 
Utrecht, Netherlands, 6Leiden University Medical Centre, Department of 
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contact e-Mail address: c.j.isfordink-2@umcutrecht.nl
Introduction: Hepatitis C virus (HCV) infection prevalence in the Nether-
lands is estimated at 0.16%1. As of November 2014, direct-acting antiviral 
(DAA) therapy is reimbursed in the Netherlands for everyone with health 
insurance. Unfortunately, up to 30% of the diagnosed population has been 
lost to follow-up (LTFU) before receiving proper treatment2,3. Around 320 
patients in the Netherlands die annually as a result of HCV infection4.
The Hepatitis C Elimination in The Netherlands (CELINE) project is a na-
tionwide retrieval project that aims to retrieve and re-evaluate HCV pa-
tients who are LTFU, and link them to care. The ultimate goal is to elimi-
nate HCV in the Netherlands, in line with the WHO goals5.
aims & Methods: This multicentre cohort study aims to include patients 
from all 47 Dutch hepatitis treatment centres. Patients are identified based 
on laboratory records (HCV antibodies, immunoblot, RNA and genotype). 
Subsequently, patient records are reviewed to identify current HCV-positive 
but untreated patients. The Municipal Personal Records Database is used 
to obtain current addresses, which accords with privacy legislations. Pa-
tients are contacted for an assessment of current HCV status, liver disease 
severity and if needed DAA treatment. The primary endpoint of the study 
is the number of LTFU patients who have been successfully linked to care. 
Secondary endpoints are number of patients already cured, the total num-
ber of LTFU patients, reasons for being LTFU, transmission route and liver 
fibrosis severity of the LTFU population.
results: CELINE started mid-2018 and is scheduled to finish mid-2021. So 
far, four hepatitis treatment centres have finished the identification phase 
and initiated the retrieval phase. Of 3054 potential ever chronically in-
fected patients, 61% (n=1852) have already been cured and 10% (n=298) 
were LTFU and eligible for retrieval (alive and current address information 
available). 
Currently, 74 patients have been invited for outpatient clinic evaluation. Of 
these 74 patients, 24% (n=18) were already (being) treated, 7% (n=5) had 
too severe comorbidity or were deceased, 19% (n=14) refused to be re-
evaluated and in 41% (n=30) contact is not yet established. 
So far, seven patients (9%) have successfully been linked to care. The rea-
sons for being LTFU were: no indication or options for therapy (n=4), LTFU 
during therapy (n=2) and no consequence given to HCV test (n=1). Probable 
transmission routes were intravenous drug use (n=4) and blood transfu-
sion (n=3). For other patient characteristics see Table 1.
conclusion: These interim results show the first step in reaching HCV 
elimination in the Netherlands. As the retrieval phase is ongoing in four 
hospitals and soon to start in several other hospitals, we expect to increase 
the number of patients linked to care in the short term. 
Results are in line with those of the CELINE pilot project (REACH), which 
retrieved 16% of LTFU patients (n=47)3. CELINE can be used to serve as a 
blueprint for retrieval projects in other countries. 
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treated with Sofosbuvir, Daclatasvir with or without Ribavirin. Abdominal 
ultrasound (U/S) and abdominal (CT) were performed for groups I and II 
patients respectively at 12 weeks intervals during treatment and follow up 
period. Triphasic (CT) was ordered in group I patients if suspicious focal 
lesion was detected by U/S or raising in AFP values was observed.
results: Most patients in both groups were males (74% in group I and & 
78% in group II) with a mean age of 56.38±8.1& 57.9±6.2 years in groups I 
and II respectively. Treatment modality prior to DAA therapy was radiofre-
quency ablation (RFA) in 30 patients (60%), percutaneous ethanol injec-
tion (PEI) in 15 patients (30%) and liver resection in 5 patients (10%). For-
ty-one patients (82%) had undetectable HCV RNA at the end of treatment. 
Two patients in group I developed HCC during follow up period. Eleven 
patients (22%) in group II showed active nodules of HCC on repeated fol-
low up. Of these patients with HCC activity, five patients (45.5%) developed 
local recurrence of a previous focal lesions, while six patients (54.5%) de-
veloped de-novo focal lesions. Two patients (18.2%) had vascular invasion 
and one patient (9.1%) had bone metastasis.
conclusion: Treatment with a Sofosbuvir-based regimen was associated 
with a high recurrence of HCC in a cohort of Egyptian patients with HCC 
associated with chronic hepatitis C genotype 4. Patients with HCC should 
be properly evaluated prior to antiviral therapy with DAAs and followed up 
carefully during and after therapy.
disclosure: Nothing to disclose 
P0736 hcv MIcrOeLIMInaTIOn: InTervenTIOnaL sTudy 
In dIagnOsed PaTIenTs WIThOuT access TO The sysTeM 
(TWO Phase sTudy)
del Pino Bellido P., Guerra Veloz M.F., Cordero Ruiz P., Bellido Muñoz F., 
Caunedo Alvarez A., Carmona Soria I.
Hospital Universitario Virgen Macarena, Gastroenterology, Seville, Spain
contact e-Mail address: pilardelpino4@gmail.com
Introduction: According to national data, 117.453 patients with chronic Hep-
atitis C (CHC) have been treated in Spain until September 2018. However, 
there is an important group of patients that have not got access to the sys-
tem. The introduction of the one-step diagnostic process tries to improve 
referral in patients with detectable viral load, but, in our system, this is 
only applied to new diagnoses, so those previous positive serologies that 
have not fullfilled the diagnostic process may be excluded.
aims & Methods: The aim of this study is to confirm CHC infection in pa-
tients with positive HCV-antibodies who have never been referred to a gas-
troenterologist / hepatologist and to recover patients with CHC infection 
who have not completed treatment due to not attendance to medical visits/
loss of follow-up.
This was a retrospective (first phase) and interventional (second phase) 
single center study in which we included all positive HCV antibodies be-
tween January 2013 and May 2018 in Virgen Macarena’s health area (Se-
ville-Spain), prior to the implementation of the one-step diagnosis of HCV 
infection. 
In the first phase, we identified subjects who had never been referred and 
those who, after being referred, had lost follow-up. In a second phase, 
after contacting with primary care to establish a direct circuit for simpli-
fied referral, a specific Hepatitis C consultation was created. Later, patients 
were contacted by letter or phone call and blood tests, viral load and tran-
sient elastography (Fibroscan) were performed. Patients with confirmed 
viral load were summoned to a second visit where they were offered treat-
ment.
results: 1329 patients with positive HCV antibodies were included. 55,75% 
of them had a previous positive serology. 
PHASE I (Table 1)
Phase I retrospective
Global referral rate 1040/1329 = 78.3 %
Non-referral rate 289/ 1329 = 21.7%
HCV-antibodies diagnostic rate 914/1040 = 87,8%
Active infection rate 658/914 = 72%
Unnecessary referral rate 256/1040 = 24.6%
Treatment rate 451/658 = 68.5%
[Table 1. Phase I.]
Loss / non-attendance rate 231/1040 = 22.2%
PHASE II (PRELIMINARY DATA)
Lost / non-attendance clinical visits = 231:
We were able to contact 51.7% of them. The additional 17.1% did not an-
swer phone calls/ did not have a valid telephone number, and 3% refused 
to attend consultations. 
At the moment, viral load determination was requested in 87 patients. 
Active infection was confirmed in 82.8% of them. 57.1% of these patients 
were ex-ADVP; 14% were active drug users and 10% had a significant al-
cohol consumption, 37.9% presented advanced fibrosis (fibroscan> 9.5Kpa) 
and 4.6% had space-occupying lessions in ultrasound.
Never referred: 
Of those patients, we were able to contact 40.6%. Until now, viral load de-
termination was requested in 81 patients, 50% confirmed active infection, 
22.9% spontaneous resolution, 27.1% SVR of previous treatments. 63% of 
patients knew they had HCV. 55.1% of these patients were ex-ADVP; 11% 
were active drug users, 30% presented advanced fibrosis.
conclusion: 
•	One-step diagnosis of CHC infection avoids unnecessary referral of 
patients. However, there is an important group of patients who might 
get lost in the system.
•	 Simplied referral system with primary care allows high rates of diag-
nosis and treatment.
•	A high percentage of patients who were lost in the system have ad-
vanced liver fibrosis and need long-term follow-up.
disclosure: Nothing to disclose 
P0737 hBeag-negaTIve chrOnIc hBv InfecTIOn: Is hBsag 
quanTIfIcaTIOn hIgher Than 1000 Iu/ML InfLuenTIaL In The 
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Santos A.L.1,2,3, Cardoso H.2,3,4, Coelho R.1,2,3, Marques M.2,3,5, Macedo G.1,2,3
1Centro Hospitalar de São João, Gastroenterology, Porto, Portugal, 2WGO 
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João, Porto, Portugal
contact e-Mail address: anaasantos89@gmail.com
Introduction: Patients with HBeAg-negative chronic infection by hepatitis 
B virus (HBV) (previously inactive carriers) are expected to have a stable 
clinical course.
aims & Methods: The aim of this study was to compare the clinical evolu-
tion of these patients regarding to HBsAg levels. Retrospective and unicen-
tric study with assessment of patients with HBeAg-negative chronic HBV 
infection (EASL criteria), in a reference centre. Demographic characteriza-
tion and assessment prognostic determinant factors.
results: A total of 89 patients were included, 51% of female gender, with 
mean age of 53±16 years. Most of patients (83%) had mild or no fibrosis. 
The initial HBsAg quantification median was 949UI/mL (IQR 129-4208) and 
patients with HBsAg >1000IU/mL (48%) presented lower age (mean 49±15 
years; p=0.032). During a median follow-up of 8 years (IQR 4-9), HBsAg 
negativation was achieved in three cases, as well as a paired decrease 
in HBsAg levels [median 0.30log10IU/mL (IQR 0.02-0.62);p< 0.001]. A de-
crease HBsAg>1log10UI/mL was more frequent if initial HBsAg < 1000UI/
mL (p=0.029). Five patients needed to start antiviral therapy, after a me-
dian time of 6 years (IQR 3-8), one due to intrahepatic cholangiocarci-
noma; however, an association with HBsAg >1000UI/mL wasn’t verified 
(7vs 4%). The median initial HBV-DNA was 409IU/mL (IQR 49-1290) and 
the higher median viremia in follow-up was 1070IU/mL (IQR 158-3489). 
Initial HBsAg >1000 IU/ml was associated to higher viremia in follow-up 
(p< 0.001), including HBV-DNA >2000IU/mL (p< 0.001) e HBV-DNA>20.000 
IU/mL (p=0.023).
conclusion: Patients with HBsAg>1000IU/mL were associated to a lower 
age and higher viremia, which can be related with a shorter period of 
HBV infection. Generally, the prognosis was benign with significant HB-
sAg reduction during a long term follow-up; a decrease >1log10IU/mL was 
less frequent if HBsAg>1000 UI/mL. However, one hepatobiliar neoplasm 
was diagnosed and 4 patients presented progression to chronic hepatitis, 
which highlights the needed of surveillance.
disclosure: Nothing to disclose 
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P0738 scheduLed susPensIOn Of anTIvIraL TheraPy 
In seLecTed cases Of chrOnIc B hePaTITIs: hIgh susTaIned 
resPOnse and hBsag LeveLs reducTIOn
Santos A.L.1,2,3, Cardoso H.2,3,4, Macedo G.1,2,3
1Centro Hospitalar de São João, Gastroenterology, Porto, Portugal, 2WGO 
Oporto Training Center, Porto, Portugal, 3Porto Medical School, University 
of Porto, Porto, Portugal, 4Centro Hospitalar de São João, Gastroenterology, 
Baguim do Monte, Portugal
contact e-Mail address: anaasantos89@gmail.com
Introduction: EASL guidelines consider antiviral therapy suspension in 
selected cases of chronic B hepatitis, under rigorous monitoring. In this 
study, we intend to evaluate the clinical course of chronic B hepatitis pa-
tients after scheduled suspension of therapy.
aims & Methods: Retrospective, monocentric and longitudinal study, from 
a prospectively registered cohort. Adults patients with diagnosis of chronic 
B hepatitis, without advanced fibrosis, with at least 4 years of undetect-
able viremia were included. After informed consent antiviral therapy was 
suspended. The cases that didn’t presented criteria for retreatment (EASL 
guidelines) were considered as sustained response. Demographic char-
acterization of population, evaluation of sustained response and HBsAg 
levels.
results: A total of 26 patients were included (62% of woman, with mean 
age of 59±13 years). Antiviral drugs were tenofovir in 58% of cases, ente-
cavir in 35% and lamivudine in 8%.
The mean time of HBV undetectably until antivirals suspension was 
8.8±2.5 years.
A sustained response was observed in 54% of patients, during a mean 
follow-up of 24±9 months, after treatment suspension. It wasn’t possible 
to identify predictive response factors. Most retreatments (67%) were due 
to increasing viremia and ALT; two patients developed jaundice, with com-
plete reversion. The most used therapy was tenofovir (67%) and viral sup-
pression was observed with a mean time of 6±3 months. Although HBsAg 
levels were previously stable, a significant reduction in HBsAg after treat-
ment suspension was observed [0.6log10UI/mL (0.19-1.5)], independently 
of sustained response (p< 0.001).
conclusion: In this study, a high rate of sustained response was observed, 
which may be related to a long duration of viral suppression; however, two 
cases of jaundice were observed, highlighting the relevance of a rigorous 
surveillance. A significant decrease in HBsAg levels suggests that there may 
be a benefit, in therapeutic suspension, even in patients without sustained 
response; these facts should be assessed with a longer follow-up period.
disclosure: Nothing to disclose 
P0739 LOng-TerM IMPacT Of dIrecT-acTIng anTIvIraLs 
In PaTIenTs WITh hePaTITIs c and advanced fIBrOsIs
Barranco Castro D., Fernández Álvarez P., Guerra Veloz M.F., 
Cordero Ruiz P., Bellido Muñoz F., del Pino Bellido P., 
Lorenzo González L., Caunedo Álvarez Á., Carmona Soria M.I.
Hospital Universitario Virgen Macarena, UGC Aparato Digestivo, Seville, 
Spain
contact e-Mail address: daniel@barranco.ws
Introduction: The introduction of direct-acting antivirals (DAAs) have revo-
lutionized the treatment of Hepatitis C (HCV), achieving cure rates above 
95% (SVR). However, the long-term impact of treatment on clinical com-
plications and mortality in patients with advanced fibrosis is not currently 
known.
aims & Methods: The aim of our study is to describe long-term decompen-
sations in patients with advanced fibrosis treated with DAAs.
This is a retrospective observational study of patients with chronic HCV 
and advanced fibrosis (Fibroscan>9.5Kpa and/or APRI>1) treated with 
DAAs from 2014 to 2016 in the Virgen Macarena Hospital and followed 
up to December 2018. We collected demographic variables, pre-treatment 
decompensations, response to treatment, post-treatment decompensa-
tions (ascites, encephalopathy, variceal upper gastrointestinal bleeding, 
development of hepatocellular carcinoma HCC) and mortality (hepatic or 
non-hepatic cause).
results: A total of 298 patients were included, 67.8% (202) men, with a 
mean age of 57 (± 12) years, and a median follow-up of 37 months (range) 
(30; 43). 41.9% (125) had high blood pressure, 23.5% (70) were diabetic, 
and 15.1% (45) had pre-treatment alcohol consumption. The predominant 
genotype was 1b in 51.3% followed by genotype 3 in 13.8%. 96% (286) 
reached SVR. Table 1 shows the pre and post-treatment decompensation.
 
Pre-treatment % (n) Post-treatment % (n)
Ascites 8,7% (26) Ascites 2,3% (7)
Variceal gastrointestinal 
bleeding 3,7% (11)
Variceal gastrointestinal 
bleeding 2,7% (8)
Spontaneous bacterial 
peritonitis (no cases)
Spontaneous bacterial 
peritonitis 0.3% (1)
Hepatic encephalopathy 2,7% (8) Hepatic encephalopathy 1,7% (5)
[Table 1. Pre and post-treatment decompensation.]
During follow-up, 3.4% (10) of the patients developed HCC. The median 
time to development of HCC was 12.5 months (6.7; 21), and all cases oc-
curred in patients with fibroscan >12.5kPa (F4). Additionally, 3 cases oc-
curred in patients who did not reach SVR, and 4 cases had a previous 
diagnosis of HCC with a good response to local treatment (radiofrequency).
The post-treatment mortality was 6.4% during the follow-up: 5.4% (16) of 
hepatic cause and 1% (3) of non-hepatic cause.
conclusion: SVR after treatment with DAAs decreases the risks of decom-
pensation in patients with chronic HCV and advanced fibrosis, although 
they do not eliminate them. This fact, along with the presence of asso-
ciated comorbidities, implies a greater mortality risk and so means that 
long-term follow-up is necessary.
disclosure: Nothing to disclose 
P0740 hePaTITIs c screenIng In hOsPITaLIzed suBjecTs. 
a PrOsPecTIve sTudy In The veneTIan area (nOrTh-easT Of 
ITaLy)
Caroli A.1, Franceschet I.1, Forti A.2, Girardi L.1, Pozzan C.1, Cappuccio R.1, 
Checchin D.1, Lamboglia F.1, Scarparo C.3
1Ospedale dell’Angelo, AULSS 3 Serenissima, UOC Gastroenterologia 
ed Epatologia, Venezia-Mestre, Italy, 2Ospedale dell’Angelo, AULSS 3 
Serenissima, UOC Laboratorio Analisi, Venezia-Mestre, Italy, 3Ospedale 
dell’Angelo, AULSS 3 Serenissima, UOC Microbiologia, Venezia-Mestre, Italy
contact e-Mail address: alessandro.caroli@aulss3.veneto.it
Introduction: The World Health Organization (WHO) recommends the im-
plementation of strategies for the identification of HCV affected subjects 
for a “test-and-treat” approach in order to achieve HCV elimination in the 
next years. The best strategy to bring out the hidden chronic HCV infection 
remains uncertain. Current guidelines recommend screening in high risk 
populations. Hospitalized patients may represent an ideal population for 
HCV screening and for referral to treatment, but few data are available in 
this specific setting of subjects.
aims & Methods: 
aim: of this study was to determine the prevalence of HCV infection in 
hospitalized subjects in the Venetian area, North-east of Italy, in order to 
plan an extensive treatment strategy.
Methods: All patients consecutively admitted to the surgical depart-
ments of the “dell’Angelo” Hospital, Venezia-Mestre, from 01/01/2017 to 
31/12/2017, were tested for anti-HCV antibodies (CMA Abbott laboratories). 
In case of borderline values, a confirmatory RIBA test (INNOLIA HCV) was 
carried out. Positive patients were tested for HCV-RNA (RT-PCR Abbott 
laboratories) and HCV-genotype.
results: Overall, 6981 patients were tested at admission (2821 males, 
4160 females). 142 subjects resulted anti-HCV positive, with a prevalence 
of 2.0%. The prevalence was significantly higher in men (2.5%) than in 
women (1.7%) and increased with age (from 0.6% in 15-30 years patients 
to 2.7 % in 51-60 and over 70 years patients). The highest prevalence 
was observed in Vascular Surgery (3.6%), Traumatology (3.4%) and Neu-
rosurgery (2.6%), the lowest in Gynecology (1.0%) and Urology (1.6%). 
HCV-RNA was detectable in about two-thirds of patients and the most 
represented genotype was genotype 1 (80%). The large majority of sub-
jects (76%) was unaware of its status and is now recruiting for the treat-
ment.
conclusion: Our data show a significant prevalence of HCV infection in 
hospitalized subjects, two to three time higher than that expected in the 
general population of the Veneto region. Screening for HCV infection in 
483Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
this specific setting of subjects may thus represent an useful and simple 
strategy to identify hidden HCV-infection and to facility HCV treatment, in 
order to achieve HCV elimination.
disclosure: Nothing to disclose 
P0741 The reTreaTMenT effIcacy Of aLL-OraL dIrecT 
anTIvIraL TheraPy fOr PaTIenTs WITh hePaTITIs c vIrus 
InfecTIOn
Mawatari S., Kasai A., Taniyama O., Ijuin S., Sakae H., Tabu K., Oda K., 
Kumagai K., Ido A.
Kagoshima University Graduate School of Medical and Dental Sciences, 
Digestive and Lifestyle Diseases, Kagoshima, Japan
contact e-Mail address: mawatari@m2.kufm.kagoshima-u.ac.jp
Introduction: Direct-acting antiviral (DAA) therapy for hepatitis C virus 
(HCV) shows high sustained virologic response (SVR) rates. However, pa-
tients who have failed DAA therapy acquire resistance-associated substitu-
tions (RASs). Glecaprevir + Pibrentasvir (GLE/PIB) therapy is approved for 
DAA failure patients in Japan. We therefore evaluated the efficacy of DAA 
retreatment and the factors associated with retreatment failure.
aims & Methods: A total of 60 patients with HCV infection who had failed 
all-oral DAA therapy in the past were introduced to DAA retreatment. We 
evaluated the factors associated with retreatment failure. NS5A Q24, L28, 
R30, L31, P32, A92 and Y93 RASs at baseline and virologic failure were 
investigated by direct sequencing.
results: The patient age ranged from 54 to 87 years (mean, 71), 17 patients 
(28%) were male, 25 (42%) patients had cirrhosis, and 12 patients (20%) 
had a history of hepatocellular carcinoma therapy. 
Fifty-five patients had received Dacratasvir + Asunaprevir, three had re-
ceived Sofosbuvir + Ledipasvir (SOF/LDV), and one each had received Om-
bitasvir + Paritaprevir and Sofosbuvir + Ribavirin (SOF/RBV). 
Thirty-three patients were retreated with SOF/LDV, 2 were retreated with 
Elbasvir + Grazoprevir (EBR/GZR), and 25 were retreated with GLE/PIB. 
The SVR rates were 81.8% with SOF/LDV retreatment, 0% with EBR/GZR 
retreatment, and 87.0% with GLE/PIB retreatment. 
Eleven patients did not achieve an SVR. Six and two patients failed SOF/
LDV and EBR/GZR retreatment, respectively, and seven of these patients 
had coexisting NS5A Q24, L28, and/or R30 RASs, L31 RAS and Y93 RAS, 
while the other had P32L and A92K RASs at baseline. However, no marked 
change in the RASs between baseline and virologic failure were noted. 
Four patients who had initially failed DCV/ASV and SOF/LDV achieved an 
SVR on retreatment with GLE/PIB. 
However, one patient re-treated with EBR/GZR did not achieve an SVR. 
Of the three patients who failed GLE/PIB retreatment, two had Q24, L28, 
R30 and A92 RASs, and the other had P32 deletion RAS at baseline. In 
those who failed GLE/PIB retreatment, the R30Q or A92T RASs at baseline 
changed to R30E or A92K at virologic failure. Interestingly, 10 of 11 retreat-
ment failure patients had an interleukin 28b single nucleotide polymor-
phism (IL28b SNP) minor allele. 
The SVR rate of patients with an IL28b SNP minor allele was significantly 
lower than in those with a major allele (58.3% and 95.2%, respectively; 
p=0.004). Furthermore, the SVR rate of patients with ≥2 NS5A RASs was 
lower than those with ≤1 RAS (73.2% and 100%, respectively; p=0.014). 
In addition, all patients who had an NS5A Y93 RAS achieved an SVR with 
GLE/PIB retreatment, even if they had coexisting NS5A RASs, such as Q24, 
L28, R30 or L31.
conclusion: DAA retreatment with GLE/PIB resulted in a high SVR rate for 
patients with the NS5A Y93 RAS. However, viral factors, such as Q24, L28, 
R30 and A92 RASs, and host factors, such as the IL28b SNP, may influence 
the therapeutic effect of DAA retreatment.
disclosure: Nothing to disclose 
P0742 The gLOBe scOre In assessIng PrOgnOsIs Of PrIMary 
BILIary chOLangITIs WITh cOncOMITanT sjOgren’s syndrOMe
Ayari M., Ayadi S., Belhadjmabrouk E., Zaimi Y., Said Y., Mouelhi L., 
Debbeche R.
Charles Nicolle Hospital, Gastroenterology, Tunis, Tunisia
contact e-Mail address: ayari.myriam@hotmail.fr
Introduction: Sjögren’s syndrome (SS) is a systemic autoimmune chronic 
epithelitis that mainly affects the salivary and lacrymal glands. The coex-
istence of SS and primary biliary cholangitis (PBC) is not an uncommon 
condition, but remains poorly studied in the literature. In fact the influence 
of SS on the clinical outcomes of PBC patients remains unclear.
aims & Methods: The aim of the study was to determine the prevalence 
and the prognostic value of SS during PBC. A retrospective study was con-
ducted including all patients followed for PBC at our department between 
2000 and 2018. SS was systematically sought.The diagnosis was done 
when at least 4 of the following criteria was met: dry eye for >3 months, 
dry mouth for >3 months, positive Schirmer test, abnormal salivary gland 
scintigraphy findings, diagnostic minor salivary gland biopsy, and positive 
anti-Ro (SS-A) or anti-La (SS-B) antibodies. 
In subgroup analysis, PBC patients were classified into 2 groups: with con-
comitant SS or without SS. The response to UDCA therapy was evaluated 
according to Paris-2 criteria at 1 year of the treatment. The Globe score, a 
prognostic tool predicting survival without transplantation, was calculated 
for the 2 groups.
results: Overall, 53 patients were included with mean age of 55 years 
(range 19-78 years). There was naturally a female predominance with a 
sex ratio F/M = 5.6 .The median follow-up was 6 years. SS was diagnosed 
in 14 patients. The prevalence of SS in PBC patients was 26%. There were 
no significant differences in age, sex, and levels of albumin, international 
normalized ratio, creatinine, alanine aminotransferase, alkaline phos-
phatase, gamma-glutamyl transferase, total bilirubin or platelet count 
between the 2 groups. In the PBC-SS subgroup, the mean age was 50 
years. The circumstances of discovery of PBC were: cholestasis with pruri-
tus (61%), jaundice (30%), asthenia assessment (6%) and exploration of 
celiac lymph nodes (3%). 
At one year of UDCA therapy, a biochemical remission according to Paris 
II criteria was noted in 38% of PBC-SS patients and 36% in PBC-only pa-
tients (p>0.05). The mean value of the Globe score in PBC-SS patients was 
1.4 versus 1.6 in PBC patients without SS (p> 0.05). The presence of SS 
was not significantly correlated with a poor therapeutic response, nor the 
prognosis of PBC.
conclusion: To our knowledge, this is the first study to investigate the prog-
nostic value of SS in patients with PBC using the globe score. Although 
their association does not appear to affect the course of PBC, screening 
should be systematic to improve the quality of life of the patients. Further 
validation of these findings in prospective studies with a larger population 
of patients is needed.
disclosure: Nothing to disclose 
P0743 add-On sTaTIns IMPrOve resPOnse TO 
ursOdeOxychOLIc acId In PaTIenTs WITh PrIMary BILIary 
chOLangITIs
Higuera-de la Tijera F.1, Díaz-Castro M.A.1, Servin-Caamaño A.2
1Hospital General de México, Gastroenterology and Hepatology, Mexico City, 
Mexico, 2Hospital General de México, Internal Medicine, Mexico City, Mexico
contact e-Mail address: fatimahiguera@yahoo.com.mx
Introduction: Ursodeoxycholic acid (UDCA) is the standard therapy for pri-
mary biliary cholangitis (PBC); however, the proportion of non-responders 
to UDCA is as high as 40-50%. Non-response to UDCA is related to pro-
gression of the disease and bad prognosis.
aims & Methods: To identify risk factors related to treatment failure with 
UDCA in patients with PBC.
A case-control study nested in a cohort, which included patients with PBC 
in whom the response to treatment with UDCA was evaluated according to 
Barcelona criteria. We compared characteristics between responders and 
non-responders to UDCA, and to evaluate risk factors related to treatment 
failure we performed univariate and multivariate logistic regression analy-
ses. A P< 0.01 value was considered significant. Patients with self-reported 
non-adherence to UDCA were excluded (n=15).
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results: 119 patients with PBC, 98.3% women, the mean age was 49.9±11.4 
years-old. All received UDCA (dose= 13-15 mg/kg/day), all reported ad-
herence to therapy; nevertheless, according to Barcelona criteria, 49 
(41.2%) were classified as non-responders. In the univariate analysis, 
albumin (mg/dL) and platelets count (cell/109/L) (U/L) were lower in non-
responders than in responders: 3.5(range=2.0-4.8) vs. 4.0(range=2.6-4.8), 
P< 0.0001; 118 (range=52-518) vs. 200 (78-436), P< 0.0001, respectively. 
Bilirubin (mg/dL) and alkaline phosphatase (U/L) were higher in non-
responders: 1.9 (range=1.0-6.4) vs. 1.6 (range=1.0-3.0), P< 0.0001; and 666 
(range=143-1445) vs. 480 (range=170-1556), P=0.01, respectively. 
Non-responders had a higher proportion of advanced fibrosis/cirrhosis 
(83.7% vs. 25.7%; P< 0.0001; OR=14.8, 95%CI=5.8-37.4); obesity (81.6% 
vs.31.4%; P< 0.0001; OR=9.7, 95%CI=4.0-23.4); overlap with autoimmune 
hepatitis (AIH) (42.9% vs. 7.1%; P< 0.0001; OR=9.8, 95%CI=3.3-28.5); 
and longer course of the disease: 5-10 years (44.9% vs. 38.6%; P=0.004; 
OR=4.3, 95%CI=1.6-11.5), and >10 years (40.8% vs. 8.6%; P< 0.0001; 
OR=17.6, 95%CI=5.2-59.6). The add-on of statins enhanced the response 
to UDCA (60% vs. 16.3%; P< 0.0001; OR=0.1, 95%CI=0.05-0.3). Fibrates did 
not have any effect (47.1 vs. 46.9%; P=0.98; OR=1.0, 95%CI=0.5-2.1). Age, 
AST, ALT, GGT, cholesterol and INR were not different between groups. The 
results obtained in the multivariate analysis are shown in Table 1.
variable Or (95% cI) P
Bilirubin (> 2.0mg/dL) 4.4 (1.1 - 17.0) 0.03
Fibrosis F3 or F4 7.1 (1.9 - 26.6) 0.004
Obesity 4.9 (1.4 - 17.9) 0.015
AIH overlap 20.8 (3.1 - 137.6) 0.002
Add-on statin * 0.08 (0.02 - 0.4) * 0.002
Time of evolution (5-10 years) 1.2 (0.3 - 5.4) 0.78
Time of evolution (>10 years) 6.1 (1.0 - 38.3) 0.05
AIH autoimmune hepatitis; CI confidence interval; F3 advanced fibrosis; F4 cirrhosis; OR 
odds ratio; PBC primary biliary cholangitis; UDCA ursodeoxycholic acid. * = protective 
factor. Multivariate analysis: Binary logistic regression.
[Multivariate analysis contrasting factors related to treatment failure to UDCA 
in patients with PBC according with Barcelona criteria]
conclusion: Statins improved the response to UDCA. The overlap with AIH, 
the presence of advanced fibrosis/cirrhosis, bilirubin >2.0mg/dL, and obe-
sity are factors related to treatment failure with UDCA according to Barce-
lona criteria.
disclosure: Nothing to disclose 
P0744 PhenOTyPIc and geneTIc sPecTruM Of aBcB4 gene 
defIcIency In aduLT PaTIenTs: a case serIes
Falcão D., Pedroto I., Moreira T.
Centro Hospitalar Universitário do Porto, Gastroenterology, Porto, Portugal
contact e-Mail address: danielateixeirafalcao@gmail.com
Introduction: Mutations in the ABCB4 gene initially described as respon-
sible for Progressive Familial Intrahepatic Cholestasis Type 3 (PFIC3), pre-
senting in childhood, are increasingly associated to a wide and heteroge-
neous spectrum of cholestatic liver diseases in adults, such as Intrahepatic 
Cholestasis of Pregnancy (ICP), Low Phospholipid Associated Cholelithiasis 
syndrome (LPAC), Hormone-induced Cholestasis, Drug-induced liver in-
jury and sporadic cases of cryptogenic biliary cirrhosis.
aims & Methods: Characterization of the phenotypic and genetic features 
of patients with ABCB4 mutations diagnosed between 2015 and 2019 in 
a Hepatology outpatient clinic. Data from 14 patients was retrospectively 
collected and analysed.
results: Fourteen patients from seven families were included (11 female, 
mean age of 41.3 years, 17-69 years). Nine patients presented with re-
current elevated serum liver tests, of which three had a gama-glutamil 
transferase (GGT) 10 times the upper limit of normal, five had a previous 
diagnosis of ICP and six with cholelithiasis and cholecystectomy at a young 
age (mean age of 27 years), two patients with intra-hepatic stones, and 
one case of drug-induced liver injury. ABCB4 gene screening identified six 
different mutations. Two patients with mutation in a homozygous state, 
c.504C>T(p.N168N) and 12 with heterozygous mutations. Two patients are 
compound heterozygotes with missense mutations, c.959C>T (p.S320F) 
and c.1529A>G (p.N510S). Heterozygous missense variants were found in 
seven patients, c.959C>T (p.S320F) in five cases, c.3082A>G (p.Met1028Val) 
in one case and c1529A>G (p.Asn510Ser) in another case. Three patients 
have nonsense mutations detected, C.874A>T (p.Lys292) in two cases and 
nonsense deletion c.1181delT (p.L394fs*18) in another case. Liver biopsy 
was performed in three patients and revealed mild macrovesicular ste-
atosis in two of these and portal fibrosis, ductopenia and mild necroin-
flammatory activity was found in one of the patients with heterozygous 
compound mutation.
conclusion: Although, phenotype-genotype relationships have not been 
clear defined, an early diagnosis of genetic variants, namely heterozygous 
compound states, may have an important role in management decisions 
and patient outcomes. To our knowledge, we describe a not previously re-
ported deletion (c.1181delT) in ABCB4 gene. The c.504T>C polymorphism, 
although a silent mutation at the protein level has been previously de-
scribed as associated with predisposition to ICP.
disclosure: Nothing to disclose 
P0745 quanTITaTIve seruM and BILIary PrOTeOMIcs 
as Markers fOr screenIng and dIagnOsIs Of PrIMary 
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Färkkila M.A.1, Saraswat M.2, Tohmola T.2, Joenväärä S.2, Tenca A.3, 
Arola J.4, Renkonen R.5
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Introduction: Primary sclerosing cholangitis [PSC] is a chronic inflamma-
tory disease of biliary epithelium leading to strictures of intra- and ex-
trahepatic bile ducts causing cholestasis and biliary cirrhosis (1). PSC is 
associated with markedly increased risk of cholangiocarcinoma [CCA] (2), 
SIR ranging from 161 to 973 (2-3), with the lifetime risk around 10% (4-5). 
CCA is the most common reason for death among patients with PSC (6,7). 
Most of the CCA’s are diagnosed within first year after diagnosis of PSC 
warranting diagnosis of PSC in much earlier state. For the moment, no 
good screening tests are available for PSC, except elevated P-ALP. Bile pro-
teomic analysis has previously been demonstrated to discriminate benign 
conditions from CCA in patients with PSC (8,9).
aims & Methods: aims: To evaluate the proteomic profiles in serum and 
bile samples in controls and PSC patients to find new noninvasive markers 
for screening and diagnosing PSC.
Patients and methods: In total, 79 patients with confirmed PSC referred 
for ERC for diagnosis and surveillance of the disease were included (48 
females). During ERC bile sample was aspirated using balloon catheter 
and then stored in -80oC. Brush cytology (BC) was collected both from 
extra- and intrahepatic bile ducts for Papanicolaou staining for grading 
dysplasia. Cholangiographic findings are scored according to modified 
Amsterdam score (Helsinki score). Serum samples are collected at the time 
of ERC. 18 serum and 6 bile samples from healthy controls were included
Label -free quantitative proteomics from serum and bile from the same 
individuals was performed UDMSE mode in Synapts G2-Si, nUPLC-TRIZAIC 
C18 tile as previously described.
results: Quantitative serum proteomics from 79 patients with PSC, but not 
dysplasia or CCA were compared to 18 serum from healthy controls. 112 
significantly (Mann-Whitney) differentially expressed proteins were found 
with a maximal fold change of 2.8. The Ingenuity network analyses showed 
enriched expression on Protein synthesis, Cell morphology and Tissue de-
velopment functions. Concomitantly the bile proteomics from same set of 
patients expressed 64 differentially expressed proteins, but here the fold 
changes were much higher, up to 128. The Ingenuity network analyses 
showed enriched expression on Cell morphology, Free radical scavenging 
and Infections diseases.
conclusion: We show in a large set of clinical serum and bile specimens 
that PSC alters significantly the proteomic profiles and further analyses 
could identify putative novel biomarkers for screening and detection of 
PSC in its early, asymptomatic phase.
references: 1. Dyson JK et al Lancet. 2018. dx.doi.org/10.1016/S0140-
6736(18)30300-3. 2. Bergquist A, et al. J Hepatol. 2002;36:321-7. 3. Mannin-
en P, et al. Scand J Gastroenterol. 2015;50:423-8. 4. Boberg KM, et al. Scand 
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J Gastroenterol 2002; 37: 1205-11. 5. Claessen MM. J Hepatol. 2009;50:158-
64. 6. de Valle et al. Liver Int. 2012;32:441-8. 7. Lewis JT, et al. Am J Surg 
Pathol. 2010;34:27-34. 8. Lankisch T, et al. Hepatology 2011;53:875-84. 9. 
Navaneethan U et al. Gastroenterology Report 2015;3:136-43
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P0746 IsOLaTed eLevaTIOn Of anTIMITOchOndrIaL 
anTIBOdIes (aMa): PersOnaLIzed fOLLOW-uP accOrdIng 
TO The rIsk Of PrOgressIOn
Jardim Carvao J.I.1, Magno Pereira V.1, Abreu N.1, Abreu I.2, 
Sousa Andrade C.1, Jasmins L.1
1Hospital Central do Funchal, Gastroenterology, Funchal, Portugal, 2Hospital 
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contact e-Mail address: joanacarvao@hotmail.com
Introduction: The presence of AMA in patients with elevation of alkaline 
phosphatase (ALP) allows the diagnosis of primary biliary cholangitis 
(PBC). Without cholestasis however is insufficient for the diagnosis. The 
European Association for the Study of the Liver (EASL) recommends an-
nual follow-up for these patients in order to detect liver disease, with a 
low evidence level.
aims & Methods: Characterize the population with isolated AMA elevation 
and further identification of group risks for the progression of CBP. 
Observational study of a prospectively maintained database of AMA posi-
tive patients between January 2010 and December 2018. A positive AMA 
was considered by indirect immunofluorescence reactivity testing (≥1: 40). 
Exclusion criteria: previous diagnosis of PBC, cirrhosis, any upper limit of 
normal (ULN) of the reference level for ALP (120 U/L). Baseline levels were 
defined with simultaneous collection of AMA. When applicable, liver blood 
tests were collected annually. Statistical analysis was performed with SPSS 
(v.23). Significance level was set at < 0.05.
results: 49 patients were included in this study of which 93,9% were fe-
male and the median age was 51 years (40,5 - 62,5). 36,7% had a diag-
nosis of systemic autoimmune disease. Baseline median values of ALP, 
gamma-glutamyl transferase (GGT) and total bilirubin (TBil) were 76 U/L 
(59 - 86,5), 29,7 U/L(18,7 - 58,3) and 0,5 mg/dl (0,4 -0,7), respectively. Only 
28,6% of patients were submitted to annual biochemical follow-up. 5 
patients fulfilled PBC EASL criteria in the follow-up. These patients had 
higher baseline cholestasis levels than those who did not develop PBC 
(median ALP U/L 88 vs. 70, p=0.007; GGT U/L 118 vs. 27 p=0.002; TBil mg/
dl 1,3 vs. 0,45, p=0.002, respectively). ALP, GGT and TBil had an area under 
the curve (AUC) for predicting PBC of 0.854, 0.958 and 0.933, respectively 
(p< 0.05). An ALP value of > 86,5 U/L had a 75% sensibility and 80% speci-
ficity in predicting the development of PBC.
conclusion: Patients with higher baseline cholestasis levels, in the normal 
range (86-120 U/L) may have a higher risk for developing PBC. The further 
categorization of a risk group suggests a personalized rather than a gen-
eralized follow-up.
references: Invernizzi P, Marzioni M, Corpechot C, et al. EASL Clinical Prac-
tice Guidelines: The diagnosis and management of patients with primary 
biliary cholangitis. J Hepatol 2017;67(1):145-72.
disclosure: Nothing to disclose 
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exPerIences frOM a dIsTrIcT generaL hOsPITaL
Leow K., Agbna M., Yusuf A., Alfred S., Neal D., Jeevagan A., Mayhead P.
Eastbourne District General Hospital, Gastroenterology, Eastbourne, United 
Kingdom
contact e-Mail address: khai.leow@doctors.org.uk
Introduction: 
•	 Primary biliary cholangitis (PBC) is an uncommon but important 
cause of chronic liver disease which undiagnosed will often lead to 
cirrhosis and its associated complications. 
•	 Lifelong Ursodeoxycholic acid (UDCA) therapy at a dose of 13-15 mg/
kg/day remains the mainstay of treatment, with biochemical response 
indices at one year invaluable in predicting long term outcomes (1). 
•	HCC surveillance should be undertaken in patients with overt cirrhosis 
identified on baseline ultrasonography as part of risk stratification for 
PBC (1). 
aims & Methods: Aims: 
•	 To assess if the optimum dose of UDCA is utilized in our PBC cohort.
•	 To assess if HCC surveillance is being carried out in PBC patients with 
cirrhosis.
Methods:
•	 318 Anti-mitochondrial antibody (AMA) positive patients over a 10 year 
period (January 2008 - December 2017) were identified via a labora-
tory search.
•	 Those with a clinical diagnosis of PBC, defined by AMA positivity ac-
companied by unexplained cholestatic liver enzymes were included 
in this study. 
results: 
•	 The sample size (n=74) consisted of 68 female patients (91.9%), with a 
median age of 65 years at diagnosis in this cohort.
•	 16 subjects (21.6%) were on the recommended UDCA dosage of 13-
15mg/kg/day with 4 patients (25%) having their biochemical response 
assessed after 12 months of therapy.
•	Overt cirrhosis was diagnosed in 20 patients (27%) via ultrasonog-
raphy, from which 15 (75%) were assimilated into the HCC screening 
programme. 
•	Among the non-cirrhotic cohort, 42 subjects (77.8%) remained on 
surveillance.
conclusion: 
•	 This audit emphasises the importance of raising awareness regarding 
the correct dosing of UDCA in the treatment of PBC in order to maxi-
mise therapeutic response.
•	Disease staging should be driven by the use of transient elastogra-
phy over ultrasonography in light of its diagnostic accuracy, which will 
minimize the need for unnecessary surveillance in patients without 
advanced disease. 
references: 1. Hirschfield GM, et al. Gut 2018;0:1-27. doi:10.1136/
gutjnl-2017-31525
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P0749 dOnOr-recIPIenT gender and age MaTchIng IMPacT 
In de nOvO neOPLasMs afTer LIver TransPLanTaTIOn
Shalaby S.1, Taborelli M.2, D’Arcangelo F.1, Zanetto A.1, Ferrarese A.1, 
Becchetti C.1, Sciarrone S.1, Pellone M.1, Gambato M.1, Germani G.1, 
Senzolo M.1, Russo F.P.1, Boccagni P.3, Zanus G.3, Cillo U.3, Piselli P.4, 
Serraino D.2, Burra P.1, Gruppo di Studio Immunosoppressione 
e Tumori - Italian Transplant and Cancer Cohort Study
1Multivisceral Transplant Unit, Department of Surgery, Oncology and 
Gastroenterology, Padua University Hospital, Padua, Italy, 2Cancer 
Epidemiology Unit, CRO National Cancer Institute, IRCCS, Aviano, Italy, 
3Hepatobiliary Surgery and Liver Transplantation Unit, Department of 
Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, 
Italy, 4Department of Epidemiology, National Institute for Infectious Diseases 
L. Spallanzani, Rome, Italy
contact e-Mail address: sarahshalaby18@gmail.com
Introduction: De novo neoplasms (DNN) after liver transplantation (LT) 
have been reported as one of the major causes of mortality in liver recipi-
ents, being the most common cause of death after the second decade after 
LT. Current post-LT surveillance strategies are based largely on data col-
lected on general population, but should be customized in the light of risk 
factors specific to LT recipients. The influence of donor-recipient sex and 
age matching on long-term survival after liver transplant is controversial, 
and data on the possible effect on DNN risk are lacking
aims & Methods: A cohort study was conducted using data collected in 9 
Italian centres between 1985 and 2014. Patients were excluded if: ≤18 years 
old, follow-up shorter than 90 days after LT, cancer diagnosis done within 
90 days after LT. Person-years (PYs) at risk for DNN were computed from 
90 days post-LT to the date of death, date of cancer diagnosis or end of 
follow-up, whichever came first. 
A competing risk approach was applied to estimate 5-year cumulative 
cancer incidence by time since LT. Hazard ratios for DNN and the corre-
sponding 95% confidence intervals (CIs) were obtained using Cox models 
adjusted for recipient gender, age at transplant, calendar year at trans-
plant, and aetiology of liver disease
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results: A total of 1927 patients (75.5% males, median age at LT 53 years-
old) were transplanted during the study period (85% after year 2000) 
receiving an organ from a deceased donor in 95.5% of cases. Distribu-
tion of LT recipients according to recipient/donor gender and donor age 
is shown in Table 1. Cumulative cancer incidence at 5 years after LT for 
all recipients was 5.4%, with no differences when the results were strati-
fied by donor gender (male 5.8 vs females 4.6%, p=0,45). Considering 
both donor gender and age, among male patients receiving a graft from a 
male donor, the 5-year cumulative incidence was higher when donor was 
≥60 years-old (p=0.03) (Figure 1). In the multivariate analysis, donor age 
or gender were not associated with DNN risk. However, considering their 
joint effect, at elevated donor age (≥60 years), the risk of DNN increased 
for patients receiving an organ from male donors (HR=2.00, 95% CI: 1.02-
2.50). Conversely, among patients receiving an organ from female donors, 
the risk did not vary according to donor age. When the associations were 
examined in strata of recipient gender, a similar pattern of risk emerged 
among male only (HR=2.26; 95% CI: 1.05-4.87 for those receiving an organ 
from male donors ≥60 years vs < 35 years)
conclusion: In our cohort the risk of DNN occurrence was increased in 
male patients receiving a liver graft from older male donors, irrespectively 
from patients’ age at transplant. Gender and age differences in liver donor 
could influence DNN risk due to both patients’ and donors’ biologic and 
lifestyle factors. These results, if confirmed in other studies with differ-
ent cohorts’ characteristics, could be useful to further guide post-LT DNN 
screening-personalization and risk stratification
disclosure: Nothing to disclose 
P0750 angIOTensIn II recePTOr BLOckers MIghT Be 
PrOTecTIve agaInsT nOn-aLcOhOLIc faTTy LIver dIsease 
afTer LIver TransPLanTaTIOn
Eshraghian A.1, Nikeghbalian S.2, Malek-Hosseini S.A.2
1Avicenna Center for Medicine and Organ Transplant, Gastroenterology and 
Hepatology, Shiraz, Iran (Islamic Republic of), 2Avicenna Center for Medicine 
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contact e-Mail address: eshraghiana@yahoo.com
Introduction: Renin-angiotensin system (RAS) has been proposed to be in-
volved in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Some 
evidences suggest that angiotensin II receptor blockers (ARBs) are effec-
tive for treatment of NAFLD. This study aimed to investigate association of 
treatment with angiotensin II receptor blockers (ARBs) after liver trans-
plantation and occurrence of NAFLD in liver transplant recipients.
aims & Methods: Study population were recruited from Shiraz Liver Trans-
plant Registry (SLTR). All liver transplant recipients between March 2014 
and March 2017 who were treated with ARBs for hypertension were includ-
ed. These patients were matched to a group of liver transplant recipients 
on age, sex, diabetes and hypertension not treating with ARBs. NAFLD was 
defined as presence of hepatic steatosis diagnosed by ultrasound and ex-
clusion of secondary causes of hepatic steatosis. Data were analyzed using 
Student’s t-test and by Chi-square test. Independent variables associated 
with NAFLD were analyzed by logistic regression method.
results: Totally, 81 patients were included. 26 patients treated with ARBs 
were compared to 55 patients not treated with these medications. No ad-
verse effects were reported with ARBs treatment. 
univariate Multivariate analysis
  NAFLD (+) NAFLD (-) P-Value OR 95 % CI P-value
Age (years) 51.7 ± 8.27 53.8 ± 11.28 0.330      
PTDM (yes/no) 32/14 17/13 0.251 1.68 0.58-4.90 0.336
Weight (kg) 81.18 ±15.39 75.78 ± 15.42 0.127 1.017 0.98-1.05 0.335
ARBs 20 % 50 % 0.005 3.62 0.096-0.793 0.017
Hyperlipidemia 
(yes/no)
31/18 18/14 0.528      
NODAT 
(yes/no)
18/29 9/19 0.591      
Triglyceride 
(mg/dL)
236.7 ±150.2 178.7± 89.05 0.05 1.003 0.998-1.008 0.188
[Clinical characteristics of patients with and without NAFLD after liver 
transplantation]
Age, sex, hypertension and diabetes were not statistically different be-
tween two groups (P>0.05). NAFLD was diagnosed in 10 patients (38.4 
%) among those who were treated with ARBs versus in 39 patients (70.9 
%) among those who were not treated with ARBs (OR: 3.9; 95 % CI: 0.96-
0.684; P-value= 0.005). 
In univariate analysis, higher serum triglyceride level was associated with 
NAFLD after liver transplantation (P=0.05). In regression analysis patients 
treating with ARBs were less likely to develop NAFLD after liver transplan-
tation (OR: 3.62; 95 % CI: 0.096-0.793; P-value= 0.017).
conclusion: NAFLD is less likely to be diagnosed in liver transplant recipi-
ents treating with ARBs after liver transplantation. ARBs can be considered 
for treatment of hypertension after liver transplantation especially in those 
who are at risk for development of hepatic steatosis.
references: 1. Musso G, Saba F, Cassader M, et al. Angiotensin II Type 1 
Receptor rs5186 Gene Variant Predicts Incident NAFLD and Associated Hy-
pertension: Role of Dietary Fat-Induced Pro-Inflammatory Cell Activation. 
Am J Gastroenterol. 2019 Apr;114(4):607-619.
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P0751 The effecT Of BasILIxIMaB InducTIOn WITh reduced 
TacrOLIMus exPOsure On Measured gfr afTer LIver 
TransPLanTaTIOn: a reaL-LIfe exPerIence
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Introduction: Chronic kidney disease (CKD) is a frequent complication after 
liver transplantation that leads to increased mortality and decreased qual-
ity of life. CKD has a multifactorial etiology, and is in part related to calci-
neurin inhibitor exposure (e.g. tacrolimus). The immunosuppression pro-
tocol at Sahlgrenska University Hospital was revised in 2010 to comprise 
basiliximab induction with reduced and delayed tacrolimus exposure; the 
effects of this revised protocol on kidney function has not been studied.
aims & Methods: We aimed to retrospectively evaluate the effect of re-
duced and delayed (R&D treatment) tacrolimus exposure on kidney func-
tion after liver transplantation in a real-life setting. 624 liver transplan-
tation recipients received immunosuppression with either conventional 
dose tacrolimus (target trough level M0-2: 10-15 µg/L, 5-10 µg/L there-
after) + corticosteroids (conventional treatment, n=201) or basiliximab 
induction with reduced-dose (target trough level M0-3: 5-8 µg/L, 3-5 
µg/L thereafter) tacrolimus delayed until post-operative day 3 and myco-
phenolate mofetil (MMF) (R&D treatment, n=342). The primary end-point 
was measured glomerular filtration rate (mGFR, Chrome-EDTA or iohexol) 
12 months after transplantation. Secondary endpoints included 3-month 
mGFR, graft and patient survival. A subgroup analysis was performed by 
baseline mGFR (< 60 ml/min/1.73m²). Statistical analyses were performed 
using the Student’s t-test, linear regression and Kaplan-Meier survival 
analysis.
results: Baseline characteristics were comparable between the conven-
tional and R&D treatment groups. Through univariate linear regression 
age, sex, malignancy or alcohol as primary indication, baseline mGFR, 
intraoperative blood loss, ischemia time, bilirubin at waitlist, creatinine at 
waitlist, INR at waitlist, hemodialysis on transplantation day and waiting 
list time were relevant confounders that were adjusted for. Mean mGFR at 
12 months after transplantation was significantly higher in the R&D treat-
ment group after adjusting for relevant confounders (adjusted mean 69.7 
vs 58.6 ml/min/1.73m²; P< 0.001). Mean mGFR 3 months after transplanta-
tion was also significantly higher in the R&D treatment group (adjusted 
mean 64.2 vs 56.4; P=0.003). 
Five-year graft survival was higher in the R&D treatment group (85% vs 
75%, P=0.013) and five-year patient survival rates were comparable be-
tween the groups (88% vs 84%, P=0.125). A subgroup analysis in patients 
with baseline mGFR < 60 ml/min showed significantly higher 12-month 
mGFR in the R&D treatment group(unadjusted mean 53.9 vs 45.5 ml/
min; P=0.046) and higher 3-month mGFR (unadjusted mean 48.7 vs 41.5; 
P=0.034).
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conclusion: In a real-life setting, induction with basiliximab and reduced 
and delayed tacrolimus exposure and MMF is associated with less peri-
operative kidney damage and similar survival compared to conventional 
tacrolimus exposure in liver transplantation recipients.
disclosure: Nothing to disclose 
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Introduction: de novo metabolic syndrome (MS) is an emerging complica-
tion after liver transplantation (LT), resulting in an increased cardiovas-
cular morbidity and mortality. This prospective study aimed to assess the 
incidence of MS post-LT and its possible associated risk factors.
aims & Methods: LT patients between April 2013 and October 2016 were 
prospectively included. Patients with pre-LT MS were excluded. Gener-
al and metabolic variables were collected at LT and at 6 months, 1 and 
2-years post-LT as well as donor variables. Post-LT MS was evaluated ac-
cording to the modified NCEP-ATP III criteria.
results: 42 liver transplanted patients were included. The most common 
indications to LT were HCV (38%) and alcoholic liver disease (ALD) (36%). 
Six-month, 1- and 2-year incidence of de novo MS was 43%, 57% and 71% 
respectively. The incidence of post-LT MS at 6 months, 1 and 2 years post-
LT was significantly higher in patients transplanted for ALD compared to 
patients transplanted for other causes (80%, 86.7% and 93.3% vs. 22.2%, 
40.7% and 59.3% respectively; p<0.001). 
Considering the individual metabolic variables, patients transplanted for 
ALD presented a significantly higher incidence of obesity (33.3%, 46.7% 
and 53.3% vs. 0.3%, 14.8% and 18.5%; p=0.012), hypertension (66.7%, 
73.3% and 73.3% vs. 18.5%, 25.9% and 33.3%; p=0.006) and hypercholes-
terolemia (40%, 60% and 66.7% vs. 18.5%, 29.6% and 33.3%; p=0.034) 
compared to non-ALD liver transplanted patients, whereas no differences 
were found in the incidence of diabetes or hypertriglyceridemia. 
No differences were found in terms of anthropometric and metabolic 
variables pre-LT between these two groups. At multivariate analysis ALD 
remained a risk factor significantly associated with de novo MS (HR 2.35, 
95%CI 1.06-5.19; p=0.035).
conclusion: de novo MS is a frequent complication post-LT showing a 
progressive increase overtime. A strict metabolic follow-up is mandatory 
starting early after LT, particularly for patients transplanted for ALD.
disclosure: Nothing to disclose 
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Introduction: The approach to patients with suspected choledocholithiasis 
requires careful consideration. Missed common bile duct stones (CBDS) 
pose a risk of recurrent symptoms, pancreatitis, and cholangitis. However, 
the morbidity and cost from indiscriminant and/or invasive biliary evalu-
ation should also be minimized. Utilizing resources for CBDS identifica-
tion in efficient way is of utmost importance. MRCP is the recommended 
investigation for patients with intermediate likelihood of common bile 
duct stones (CBDS) following first line investigations -ultrasound scan 
(USS) and liver function tests (LFTs). In accordance with American Society 
of Gastrointestinal Endoscopy (ASGE) and British Society of Gastroenterol-
ogy (BSG) Guidelines MRCP prior to scheduled endoscopic or surgical duct 
clearance is not mandated in strong likelihood of CBDS.
aims & Methods: The clinical audit was set up to evaluate current practice 
of CBDS stone diagnosis prior to endoscopic biliary duct clearance proce-
dures against recommendations of the ASGE and BSG Guidelines in the 
UK’s general district hospital. Data was collected retrospectively. All MRCPs 
requests during the period of 01/07/2017 - 01/07/2018 in UK’s district gen-
eral hospital were reviewed. Cases of MRCP requests for suspected CBDS 
were identified. 
Electronic records were reviewed for clinical indications and rational to 
suspect CBDS. Identified patients were stratified into low, intermediate 
and high risk of CBDS as per ASGE guidelines. Cases with incomplete data, 
paediatric patients, MRCP requested after bile ducts draining procedure 
were excluded.
results: In 28.9% of performed MRCPs there was no justification for re-
questing MRCP for suspected CBDS. The most common reasons for unjus-
tifiable MRCP requests were: strong likelihood of CBDS (hence should have 
gone directly to bile ducts clearance procedure), low likelihood of CBDS 
and/or suboptimal clinical details for MRCP, failure to perform first line 
investigations prior to requesting MRCPs.
conclusion: MRCPs to diagnose CBDS are frequently made without ratio-
nal, and hence do not result in change in management. Results of the 
singe centre audit are likely to represent situation on a larger scale. This 
may be partly because there is no agreed pan-European guidelines for 
the management of moderate and high risk of CBDS and/or agreed set 
threshold for determining likelihood of CBDS. 
Establishment of pan-European registry or international snap shot audit 
on diagnostic strategies and further management in moderate and high 
likelihood of CBDS will enable to identify degree of variability in prac-
tises across different sites as well as gives opportunity to derive trends 
in clinical outcome depending on different approaches in diagnosis and 
management. Large scale pan-European audit will aid in developing pan-
European guidelines on the role of MRCP in management of CBDS.
disclosure: This abstract is submitted for abstract/oral presentation to the 
Annual Conference of the Royal College of Radiologists (UK) 
P0754 MeasureMenT Of LIver sTIffness WITh 2d-shear 
Wave eLasTOgraPhy (2d-sWe) In BarIaTrIc surgery 
candIdaTes reveaLs accePTaBLe dIagnOsTIc yIeLd cOMPared 
TO LIver BIOPsy
Goshayeshi L.1, Rajabzadeh F.2, Jamialahmadi T.3, Nematy M.3, Jangjoo A.4
1Mashhad University of Medical Sciences, Department of Gastroenterology, 
Mashhad, Iran (Islamic Republic of), 2Azad University of Medical Sciences, 
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University of Medical Sciences, Surgery, Mashhad, Iran (Islamic Republic of)
contact e-Mail address: ladangosh@yahoo.com
Introduction: Non-alcoholic fatty liver disease (NAFLD) is common among 
severely obese patients. Two-dimensional shear wave elastography (2D-
SWE) has been validated as a noninvasive diagnostic tool for liver stiff-
ness measurement. However, the technical feasibility and accuracy of this 
method in severely obese patients are still under debate.
aims & Methods: We aimed to assess the diagnostic accuracy of 2D-SWE 
in bariatric surgery candidates in comparison with the gold standard liver 
biopsy.
Methods: 90 severely obese candidates for bariatric surgery were includ-
ed. Liver stiffness was measured using 2D-SWE fourteen days before liver 
biopsy. Liver biopsy was taken on the day of surgery. The area under the 
receiver operating curve (AUROC) was calculated for the staging of liver 
fibrosis.
results: 2D-SWE was performed in 97.3% of patients successfully. Histo-
logic stages of fibrosis (F0-F4), were detected in 34.2%, 36%, 6.3%, 3.6%, 
and 0.9% of patients, respectively. The AUROC for 2D-SWE was 0.77 for 
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F1, 0.72 for F2, 0.77 for F3, and 0.70 for F4. In univariate analysis, 2D-SWE 
values were correlated with BMI, waist circumference, NAFLD activity score 
(NAS) and steatosis, whereas these components did not affect liver stiff-
ness in multivariate analysis.
conclusion: Two-dimensional shear wave elastography of the liver can be 
feasible and has good accuracy in severely obese candidates for bariatric 
surgery. Therefore, 2D-SWE may be a good option for assessing liver fi-
brosis, especially in the early stages of fibrosis to lessen complications of 
surgery in this population. However, this method should be applied on a 
larger scale for late stage of fibrosis.
disclosure: Nothing to disclose 
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Introduction: Choline is a quaternary ammonium base serving as an es-
sential nutrient in all mammalian cell membranes, including hepatocytes. 
Its metabolism is cell- and tissue-specific [1,2]. Choline plays a role in 
hepatic mitochondrial impairment, oxidative stress and DNA methylation 
levels of genes involved in lipid metabolism [3].
aims & Methods: 
aim: The aim of this study was to compare findings between patients with 
liver cirrhosis and subjects with a normal liver on a [¹¹C]choline PET/CT. 
Methods: This prospective pilot study was conducted between the years 
2012-2016. The cohort included 14 patients with prostate cancer (reference 
group) and 11 patients with cirrhosis attending a tertiary medical center. 
Demographic, clinical and laboratory data were obtained from the medical 
files. All participants underwent a dynamic [11C]choline PET/CT (Discovery 
ST, GE Medical Systems, Milwaukee WI). We compared the maximal stan-
dard uptake values (SUVmax) and the area under the curve (AUC) at 1110 
seconds in both groups.
results: The mean age of the cirrhosis group (63.4% men) was 68.4±10.7 
and the control group, 69.7±7.3 years. The mean SUVmax was significantly 
higher in the cirrhosis group than in the controls (right lobe, 10.06±12 vs. 
6.3±1.6, p=0.011; left lobe, 8.6±11.6 vs. 5.4±0.9, P=0.024; spleen 17.99±27.8 
vs. 13.4±2.6, P=0.027; kidney, 35.9±59.5 vs. 19.3±4.8, P=0.025). The cor-
responding AUC values at 1110 seconds was significantly distinguished 
between the groups (right lobe, 13538±20020 vs. 8427.3±1557.9, p=0.026; 
left lobe 12304±18871 vs. 6878.9±1294.3, p=0.024; spleen, 12875±17930 vs. 
8263.9±1279.2, p=0.023; kidney, 24623±36025 vs. 13667±3873.9, P=0.032). 
No correlations were found between the clinical characteristics and the 
imaging-derived parameters in the patients with cirrhosis.
conclusion: Our findings suggest a role for [¹¹C]choline PET/CT as a non-
invasive biomarker of cirrhosis. Further larger-scale studies are needed to 
confirm these observations
references: 1. Li Z, Agellon LB (2005) Phosphatidylcholine homeostasis 
and liver failure. J Biol Chem 280: 37798-37802. 2. Zeisel SH (2006) Choline: 
critical role during fetal development and dietary requirements in adults. 
Annu Rev Nutr 26: 229-250. 3. Zhu J, Wu Y, Tang Q, Leng Y, Cai W (2014) 
The effects of choline on hepatic lipid metabolism, mitochondrial function 
and antioxidative status in human hepatic C3A cells exposed to excessive 
energy substrates. Nutrients 6: 2552-2571.
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Introduction: Chronic liver diseases are a major health problem. The de-
tection of initial stages of liver fibrosis allows an adequate handling oh 
these patiens. This could change the natural evolution, delaying descom-
pensation in advanced stages. 
Recently, the comparability between non-invasive methods and liver bi-
opsy for assessment of fibrosis has been demostrated.
aims & Methods: The aim of this study was to correlate the values of fi-
brosis determinated by non-invasive methods, serological markers (APRI 
and FIB-4) and ultrasound shear wave elastography (SWE) in patients with 
chronic liver disease.A unicenter retrospective study was carry out. All liver 
disease patients who underwent SWE (ITACHI US) for any indication in the 
University Hospital Virgen Macarena between June 2017 and November 
2018 were selected. 
Serological fibrosis markers were calculated for all etiologies with close 
analytics (< 3 months) to the performance of the test. To classify the stage 
of fibrosis we used the accepted cut points of advanced fibrosis: APRI> 1 
and FIB-4> 2.67.
results: Two hundred thirty nine cases were included. Thirty patient pre-
sented advanced fibrosis according to serological markers. The area un-
der the curve for advanced fibrosis by SWE was 0,803 (CI 95%). The best 
cut-off point to determine advanced fibrosis was ≥ 7.55 with a sensitivity 
of 83.3% and a specificity of 66.8%. A negative predictive value (NPV) of 
96.5% was obtained.
Table 1 shows the diagnostic capacity of advanced fibrosis according to SW 
and serological markers by etiology. 
  advanced fibrosis (aPrI/fIB4) advanced fibrosis (sWe)
  Yes No   Yes No  
  n (%) n (%) p-valor n (%) n (%) p-valor
Viral 11 (36,7) 116 (55,%) 0,028 43 (45,7%) 84 (57,9%) <0,001
Enolism 7 (23,3%) 21 (10,1%) 0,028 23 (24,5%) 5 (3,4%) < 0,001
NASH 7 (23,3%) 57 (27,4%) 0,028 18 (19,1%) 47 (32,4%) < 0,001
Autoim-
mune
5 (16,7%) 14 (6,7%) 0,028 10 (10,6%) 9 (6,2%) < 0,001
[Table 1]
conclusion: SWE had an adequated diagnostic ability for determinating 
advanced fibrosis in patients with chronic liver desease compared with 
serological markers.
A cut-off point SWE lower than 7.55 predicts with high probability the ab-
sence of advanced fibrosis.
Prospective studies are needed to support our results and compare them 
with other types of elastrography-based imaging techniques or transient 
elastography.
disclosure: Nothing to disclose 
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P0757 fIBrOsIs screenIng In PaTIenTs WITh nafLd usIng 
a sIMPLe POInT shear Wave eLasTOgraPhy TechnIque
Bâldea V., Mare R., Șirli R., Popescu A., Sporea I.
‘‘Victor Babeș’ University of Medicine and Pharmacy, Gastroenterology and 
Hepatology, Timisoara, Romania
contact e-Mail address: ruxi2323@yahoo.com
Introduction: Nonalcoholic Fatty Liver Disease(NAFLD) has recently been 
recognized as the most prevalent liver disease worldwide, fibrosis stage 
being the strongest predictor for disease-specific mortality. Non-invasive 
assessment of liver fibrosis has been increasingly used instead of liver bi-
opsy. ElastPQ is a point Shear Wave Elastography(pSWE) technique that 
has good accuracy for staging liver fibrosis(1).
aims & Methods: The aim of this study was to assess the value of ElastPQ 
as a screening tool for liver fibrosis in NAFLD patients. The study group in-
cluded 420 consecutive patients with NAFLD evaluated in daily outpatient 
practice over a period of 18 months. The diagnosis of NAFLD was made 
by the presence of hepatic steatosis on ultrasound(“bright liver” with 
posterior attenuation and increased hepato-renal index), after excluding 
significant alcohol consumption. Liver fibrosis was assessed by means of 
pSWE(ElastPQ; Affinity 70, Phillips). Valid liver stiffness values were de-
fined as the median of 10 liver “non-zero” measurements in a homoge-
nous area of liver parenchyma. Reliable liver stiffness measurements were 
defined as the median value of 10 measurements with an IQR/M < 30%. To 
discriminate between ElastPQ fibrosis stages we used the following cut-off 
values: F≥ 2: 6.9 kPa; F≥ 3: 8.4 kPa and for F=4: 12.4 kPa(2).
results: NAFLD consisted of 42.4% (420/990) of cases evaluated by liver 
elastography in daily outpatient practice. We enrolled 414 consecutive pa-
tients with NAFLD with reliable liver stiffness measurements, mean age 
48.6±12.6 years, 70% male, 30% female. After applying the cut-off values 
proposed, we found out that 86.4% (358/414) of patients where below the 
cut-off value of significant < F2 fibrosis, while advanced fibrosis F≥ 3 was 
found in 6% (25/414) of patients.
conclusion: NAFLD was the most frequent indication for performing ElastPQ 
in daily outpatient practice. ElastPQ is a good and reliable point of care tool 
for fibrosis screening that could rule out significant fibrosis in the major-
ity of patients and help identify patients with advanced fibrosis related to 
NAFLD and prioritize them for referral and treatment of their liver disease.
references: 1. Lee J et al. Non-invasive Assessment of Liver Fibrosis with 
ElastPQ: Comparison with Transient Elastography and Serologic Fibrosis 
Marker Tests, and Correlation with Liver Pathology Results. Ultrasound 
Med Biol. 2017;43(11):2515-2521. 2. Roccarina Davide et al. SAT-322-Com-
parison of point shear wave elastography (ElastPQ-pSWE) and FibroScan 
Transient Elastography (F-TE) for liver fibrosis staging in patients with 
NAFLD, Journal of Hepatology, Volume 70 , Issue 1 , e780.
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Introduction: The aim of this paper was to evaluate the inter-and intraob-
server reproducibility of the new time-harmonic elastography diagnostic 
system (THED) (1) and the impact of ultrasound (US) experience in acquir-
ing reliable measurements, since no official recommendations are avail-
able for this system.
aims & Methods: Elastographic measurements (EM) were obtained in 27 
consecutive subjects using THED. Three examiners with different levels of 
experience in US and US-based elastography, performed 10 valid EM on 
each subject. 
We defined their experience as follows: E1- no experience in elastography 
and less than 50 ultrasound (US) examinations, E2: more than one year 
elastographic experience and more than 500 US examinations and E3: 
more than 1000 US examinations, without any experience in elastography. 
We used the intraclass correlation coefficient (ICC), inter-rater agreement 
(Kappa coefficient) and concordance correlation coefficient to assess the 
inter- and intraobserver reproducibility
results: We did not find significant differences between the means of EM 
obtained by the examiners overall and across study group [1.66 (E1) vs 
1.66 (E2) vs 1.65 (E3), p=0.76]. The overall agreement between examiners 
was excellent: 0.94 (95% CI: 0.89-0.97). There was at least a good agree-
ment between examiners (E1 vs. E3: k=0.80, 95% CI:0.67-0.94; E1 vs. E2: 
k=0.81, 95% CI:0.69-0.94), and good to excellent in E2 vs. E3: k=0.89, 95% 
CI:0.82-0.96. The intraobserver reproducibility for each of the examiners 
was excellent, however the ICCs were higher in more experienced examin-
ers in US: E1- 0.92, (95% CI:0.82-0.96) vs. E3-0.94 (95% CI:0.87-0.97) vs. 
E2-0.97 (95% CI:0.95-0.99). The concordance correlation coefficients were 
similar: E1 vs. E3-0.84, E1 vs. E2-0.89 and E3 vs. E2-0.89.
conclusion: The good ICCs and Kappa coefficients for the mean values 
show that THED is a reproducible method. Ultrasound experience did not 
significantly influence the results.
references: (1) Tzschätzsch H, Nguyen Trong M, Scheuermann T, Ipek-
Ugay S, Fischer T, Schultz M, Braun J, Sack I. Two-Dimensional Time-Har-
monic Elastography of the Human Liver and Spleen. Ultrasound Med Biol 
2016;42(11):2562-2571.
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Introduction: In chronic liver disease fibrosis is the key prognostic factor. 
Liver biopsy, the reference standard for hepatic fibrosis assessment, is an 
invasive procedure with a small but significant risk of life-threatening 
complications. Many non-invasive tests have been evaluated as alterna-
tives. Liver surface nodularity (LSN) is the highest-accuracy ultrasono-
graphic sign to detect advanced liver fibrosis (F3-F4) [1‒3]. 
Pocket-size Ultrasound Devices — with their small size, low cost and ease 
of use — have been assessed in several clinical settings, but never in CLD.
aims & Methods: Our cross-sectional study evaluated PUD feasibility, re-
producibility and accuracy in identifying LSN.
Between September 2017 and January 2019 we enrolled all consecutive 
consenting adults referred for liver parenchymal biopsy.,.
LSN was evaluated by 2 independent operators using PUD (Vscan® Dual 
Probe GE Healthcare, UK), and by an operator using standard GIUS. Tran-
sient elastography (TE) and liver biopsy were performed on all patients.
PUD reproducibility was evaluated by κ coefficient. PUD, GIUS and TE re-
sults were compared with histology (METAVIR). The estimated pre-test 
probability of severe fibrosis was 35%. Sensitivity, specificity, positive/
negative likelihood ratios, and post-test probability were calculated.
results: For 72 patients (31 M, age 47±28 years, NAFLD/NASH 35%, AIH 
25%, PBC/PSC 14%, HBV/HCV 12%,, other 14%) PUD reproducibility (κ 
0.82, 95% CI 0.68‒0.96) and concordance between PUD and GIUS (κ 0.78, 
95% CI 0.64‒0.94) were excellent. In diagnosing F≥3 PUD achieved: 87% 
sensitivity, 91% specificity, LR+ 9.7, LR- 0.14, PPV 84%, NPV 93% against 
GIUS (95% sensitivity, 93% specificity, LR+ 13.5, LR- 0.05, PPV 88%, NPV 
97%) and TE (67% sensitivity, 96% specificity, LR+ 16, LR- 0.35, PPV 89%, 
NPV 86%).
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conclusion: PUD proved feasible, with excellent reproducibility. PUD per-
formed very well in diagnosing advanced compensated CLD, and compa-
rably to GIUS and TE. PUD is deployable as first-line screening to select 
patients for more invasive techniques, thus shortening clinical decision 
times.
references: References 1) Colli et al. Radiology 2003, 2) Paggi J Hepatol 
2008, 3) Lee et al. Korean J Hepatol. 2010
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Introduction: To date no study has ever explored the potential role of a 
new 2-dimensional Shear Wave Elastography (2D-SWE) technique that has 
been recently implemented on Esaote MyLab Nine devices. The aim of our 
study was to evaluate the agreement between 2D-SWE with Esaote MyLab 
Nine (QElaXto) and 2D-SWE with Aixplorer Supersonic Imagine (SSI) as the 
reference standard.
aims & Methods: Data was collected prospectively from November 2018 to 
February 2019 on patients who were scheduled to undergo liver elastog-
raphy as requested by our Hepatology Unit. Exclusion criteria were HCC/
malignant liver nodules, severe extra-hepatic comorbidities and liver stiff-
ness (LS) >50kPa. LS was sampled from the same intercostal space with 
both QElaXto and SSI when possible. Values were tested with correlation 
coefficient analysis and Bland-Altman analysis (B&A); agreement between 
the two elastography techniques was assessed with Spearman correlation.
results: The study included 130 patients (42[32%] HCV and 26[20%] 
NAFLD; 96% Child-Pugh A). Failure of LS measurements occurred in only 
one patient for both elastography techniques (BMI >40) and another pa-
tient was excluded from the analysis because of LS>50 kPa. Correlation 
coefficient was very good at 0.951; B&A analysis showed a mean of 1.4 kPa, 
with limits of agreement at -1.5 and 4.3 kPa. Spearman’s rho correlation of 
SSI versus QElaXto was 0.885. The relationship became less strong in the 
higher range of LS (≥14 kPa), corresponding to patients with liver cirrhosis.
conclusion: There is an overall excellent degree of concordance of QElaXto 
as compared to the “reference standard” SSI, with the first method show-
ing lower LS results as compared to the latter. Further studies are warrant-
ed in order to validate this new technique in comparison or in combination 
with other non-invasive methodologies and liver biopsy.
disclosure: Nothing to disclose 
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Introduction: The prevalence of cardiomyopathy in cirrhotics remains un-
known because of its latent nature, characterized by blunted contractile 
responsiveness to stress, altered diastolic relaxation, and electrophysi-
ological abnormalities.
aims & Methods: Our aim was to detect early myocardial dysfunction using 
new echocardiography technologies in cirrhotic patients and correlating 
them to liver stiffness (LS) and severity of liver disease.
Consecutive patients with liver cirrhosis without structural heart disease, 
portal vein thrombosis, hepatocellular carcinoma outside Milan criteria, 
transjugular intrahepatic portosystemic shunt (TIPS) and with optimal 
acoustic echocardiography window in order to assess the myocardial strain 
were included. Conventional and speckle-tracking echocardiography (Ven-
dor GE, EchoPAC PC software) were performed by a single investigator 
(EACVI TTE certified). Subclinical myocardial dysfunction of left ventricle 
was defined as average global longitudinal strain (GLS) < -18 % (Lang RM, 
et al. J Am Soc Echocardiogr 2015;28:1-39).
LS was assessed by transient elastography (TE, Fibroscan®, Echosens) and 
share wave elastography (SWE) from Hitachi (Arietta V70). Reliable results 
were defined as median value of 10 valid measurements with an IQR/Med 
< 30 % and expressed in kPa. The presence of ascites, esophageal varices, 
splenomegaly and/or thrombocytopenia were considered as sign of portal 
hypertension.
results: We evaluated 60 patients, but 10 did not fulfilled the inclusion 
criteria (1 portal vein thrombosis, 2 coronary artery disease, 1 cor pulmo-
nale, 4 patients with valvular dysfunction and 2 with suboptimal acoustic 
echocardiography window). The final analysis included 50 patients, with 
mean age of 58.3 ± 10.5 years (66% males).
Compensated cirrhosis (Child-Pugh A) was present in 60% of patients, 
24% were classified as Child-Pugh B and 16% as Child-Pugh C. 
LS could be evaluated in 76 % of cases by TE and in all patients by Hitachi 
SWE.
Slightly reduced left ventricular ejection fraction (EF) was observed in 4% 
of patients. Subclinical systolic dysfunction as assessed by GLS was present 
in 16 % of cases. The presence of systolic dysfunction seems to correlate 
with LS assessed by Hitachi SWE (Table).
Parameter gLs < -18% or reduced ef (n=10) 
gLs ≥ -18% and 
normal ef (n=40) p value 
LS by TE (kPa) 43.1±26.2 33.2±20.5 0.16
LS by SWE (Hitachi)(kPa) 10.8±3.8 14.2±5.7 0.002 
MELD 9.9±3.8 11.3±4.5 0.36
Child-Pugh: compensated (A), 
decompensated (B+C)
A:7(70%), 
B+C:3(30%)
A:24(60%), 
B+C:16(40%)
A: 0.82, 
B+C: 0.82
Portal vein velocity (cm/s) 17.1±3.9 15.3±3.2 0.15
Signs of portal hypertension 6 (60%) 31 (77.5%) 0.46
Etiology: alcoholic (A), other 
etiologies (B)
A:5 (50%), 
B:5 (50%)
A:27(67.5%), 
B:13(32.5%)
A:0.50, 
B:0.50
Age (years) 61.5±12.2 57.2±10.1 0.29
Gender: male (A), female (B)
A:5(50%), 
B:5(50%)
A:28(56%), 
B:12(44%)
A: 0.98, 
B: 0.98
CO-Cardiac output (ml/min) 5.9±1.3 5.6±1.7 0.55
[Table Correlation between myocardial dysfunktion and liver stiffness and 
severity of liver disease]
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conclusion: Clinical or subclinical left ventricular dysfunction was identi-
fied in 20% of cirrhotic patients and this seems to correlate with LS as-
sessed by Hitachi SWE, but not with the severity of liver cirrhosis.
disclosure: Nothing to disclose 
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Introduction: Cirrhosis is a major cause of morbidity and mortality world-
wide. 
The rapid progress of medicine has transformed the representation of the 
hepatitis C virus infection, in no more than three decades, from an un-
known disease to a safe and simple to treat one, with virologic cure in 
most patients. 
Advances in understanding of HCV molecular biology have created the op-
portunity to develop designed drugs that target specific steps in the infec-
tion and replication of HCV. This breakthrough has led to the development 
of direct-acting antivirals (DAAs) and, from this, to the rapid approval of 
HCV treatment and the possibility for disease elimination. 
For a long period of time, cirrhosis was considered an irreversible end 
stage of liver disease, mostly due to lack of treatment possibilities. Today, 
this irreversibility is no longer a “dogma”. There are some research studies 
showing the potential for liver remodeling, at least at microscopic level, 
with regression of fibrosis after the removal of causative agents in both 
patient and experimental fibrosis models.
The main question is what happens next with liver, remaining in a frozen 
status with some degree of microscopical changes or improvements are 
visible at the macro level, detectable by sectional imaging tools such as CT.
Our hypothesis is based on improvements in the features of cirrhosis seen 
on CT scan that can suggest the reversibility of liver fibrosis/cirrhosis after 
the achievement of sustained virologic response (SVR) in HCV related cir-
rhotic patients.
aims & Methods: The purpose of this study is to evaluate the capabil-
ity of CT examination to identify changes in hepatic morphology, able to 
demonstrate the liver remodeling after obtained SVR in patients with HCV 
related cirrhosis. 
CT examinations of 45 patients with HCV related cirrhosis were performed 
before and after the administration of a direct-acting antivirals (DAAs) 
treatment. The liver changes were assessed by measuring volume, caudate 
right hepatic ratio, hepatic vessel diameters, periportal widening space 
and right posterior notch. There have been measured the portal vein trunk, 
splenic and superior mesenteric veins and the volume of the spleen as 
part of portal hypertension assessment.
results: The significant variations were detected in the right hepatic vein 
showing a statistically significant widening after the treatment (Mdn=8.12), 
compared to the diameters recorded before treatment (Mdn=6.35), z=-
3.894, p< 0.001, r=-0.20. The liver volume of the patients prior to the treat-
ment was significantly higher (Mdn=1786.77) than the estimated volume 
subsequent to the treatment (Mdn=1716.44), z=-1.970, p=0.049, r=-0.20. The 
volume of the spleen before (Mdn=564.79) the treatment was significantly 
higher than the volume determined after the treatment (Mdn=474.44), z=-
2.500, p=0.012, r=-0.269. The other parameters showed no improvement.
conclusion: The sectional imaging techniques such as CT can be used to 
demonstrate the improvement of hepatic status after treatment. The most 
sensitive parameters are the right hepatic vein diameter and the splenic 
volume reduction, followed by liver volume reduction.
disclosure: Nothing to disclose 
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Introduction: Hepatic portal venous gas (HPVG) is generally recognized to 
indicate poor prognoses in patients with serious intestinal damage. Al-
though surgical removal of the damaged portion is only considered an 
effective therapy, some of the patients can recover with non-surgical con-
servative treatments.
aims & Methods: To establish diagnostic algorithm for determining an 
optimal treatment, we reviewed our experienced cases of HPVG and at-
tempted to clarify their clinical features. Thirty-five cases of HPVG [34 pa-
tients (19 women and 15 men); ages 34-99 yr (median, 85 yr)] diagnosed 
at Takatsuki General Hospital from April 2012 to February 2019, were in-
cluded in the present retrospective study. Their most common complaint 
was abdominal pain (28 cases). Necessity for surgical treatment had been 
determined mainly by computed tomography (CT) findings, namely, ab-
dominal free-air, lack of contrast enhancement of the intestinal wall, and 
intestinal emphysema. The patients’ data including clinical backgrounds, 
physical examination findings, blood test results, CT images, and treat-
ment outcomes were analyzed separately of surgical patients and non-
surgical patients. Fisher`s exact test and Mann-Whitney U-test were used 
for statistical analysis, and p< 0.05 was considered to be significant.
results: 1) Eight cases were surgically treated. Seven (87.5%) of them sur-
vived and one (12.5%) died. Intestinal necrosis was confirmed in all cases 
during surgery, and the necrotic portions were removed. Final diagnoses 
were non-occlusive mesenteric ischemia (n=4), clostridium difficile enteri-
tis (n=1), strangulation ileus (n=1), superior mesenteric artery thrombosis 
(n=1) and gastric perforation (n=1; a fatal case).
2) Twenty-seven cases were treated conservatively (non-surgical patients). 
Thirteen of them had needed surgical operations to be cured but opera-
tions were abandoned because of their poor general conditions, such as 
extremely low performance status (ECOG PS 4; n=9). However, three (23%) 
of these 13 patients survived. The remaining 14 of 27 patients were diag-
nosed as being able to be sufficiently cured by conservative treatments. Of 
these 14 patients, only one patient (7%) died.
3) To identify potential prognostic factors in the non-surgical patients, 
comparative analyses were performed between the fatal (n=11) and the 
surviving (n=16) cases. Ascites (82% vs 31%), signs of peritoneal irritation 
(80% vs 6%), and shock (55% vs 0%) were significantly frequent in the 
fatal cases. Compared with the surviving cases, base excess was lower 
(median -5.5 vs 1.8 mEq/L) in the fatal cases. Percentage of patients fulfill-
ing SIRS criteria (80% vs 37.5%) and plasma levels of CRP (median 10.22 vs 
2.09 mg/dL) and lactic acid (median 39 vs 26 mg/dL) tended to be higher 
in the fatal cases, but the differences were not significant.
conclusion: HPVG has a high mortality rate, that of our hospital was 34%. 
If intestinal necrosis is suspected, surgical removal of the necrotic portion 
should be considered. In non-surgical patients, ascites, signs of peritoneal 
irritation, shock, and low base excess were closely associated with poor 
prognoses. Conversely, absence or fewness of these findings may predict 
recovery from the life-threatening condition with conservative treatments.
disclosure: Nothing to disclose 
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P0765 Budd-chIarI syndrOMe: WhIch ePIdeMIOLOgIc 
PrOfILe? a MOrOccan exPerIence
Bouhnoun Z.1, Hakima A.2, Lahmidani N.3, El yousfi M.4, Dafrallah B.5, 
El Abkari M.6, Ibrahim A.1, Nourdin A.7
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Morocco, 5UH Hassan II, fes, Morocco, 6CHU Hassan II, Gastroenterology 
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contact e-Mail address: zahra.bouhnoun@gmail.com
Introduction: The Budd-Chiari syndrome (BCS) is an uncommon illness 
of the liver whose incidence is estimated at 0.9 /million/ year and results 
from the obstruction of the hepatic venous drainage whatever is the site 
of the obstacle, from the hepatic venules until the final part of the lower 
vena cava. The goal of our work was to trace the epidemiologic profile of 
this syndrome.
aims & Methods: It is a descriptive retrospective study including all the 
patients presenting a BCS over a 14-year period (from January 2001 to 
December 2015). We studied the epidemiologic, clinical, biological, radio-
logical, etiologic and evolutionary data of the patients.
results: During the 14-year period, we collected 1323 portal hypertension 
cases (PHT), of which 3.9% (N=52) patient presented a Budd-Chiari syn-
drome. The median age of the patients was 35 years [15-75 years], with a 
slight female prevalence (52% of the cases). The ascites was the most re-
vealing symptom in 48% of the cases. Radiological exploration had shown 
a primitive origin of the SBC on thrombosis of the hepatic veins known 
in 71%, thrombosis of the retro-hepatic lower vena cava in 10% and the 
association of both in 15% of the cases. The thrombosis of the portal vein 
was associated with 15% of the cases. The secondary origin of the BCS was 
found in two cases (4%): the first case was secondary to a compression by 
a hepatic mass and the second by a cyst hydatic.
The fiberscope has materialised Esophageal varices in 59.6% of the cases. 
The etiology of the Budd-Chiari was related to a deficit in antithrombin 
III in 9.6% of the cases, and a deficit out of protein S and C in 11.5% of 
the cases, a myélofibrose in 0.5% of the cases and two cases (4%) for 
each following etiology: a agenesis of the IVC, a secondary compression, a 
cœliaque disease and a disease of Behcet. The anticoagulants were man-
aged in 90% of the cases. The evolution was marked by the development 
of a carcinoma hépatocellulaire in 4% of the cases, the hemorrhagic de-
compensation in 10%, the refractory ascites in 19% and hepatic encepha-
lopathy in 12%. Intrahospital mortality was of 11.5%.
conclusion: In our series the Budd-Chiari accounted for 3.9% of the PHT, 
it interested primarily the young subject of the female sex. The hepatic 
thrombosis of the veins known accounted for 71% of the patient with an as-
sessment of thrombophilia disturbed in 21% of the cases and intrahospital 
mortality rather important of 11.5% of the cases
disclosure: Nothing to disclose 
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Introduction: The current paradigm (CP) of chronic hepatitis C (CHC) treat-
ment in Portugal is characterized by a lengthy process between diagnosis 
and treatment. The number of patients lost to follow-up (LTFU) within that 
period is a barrier to hepatitis C virus (HCV) elimination by 2030.
aims & Methods: The objective of this analysis was to quantify the efficien-
cy gains that could be obtained by changing to a new paradigm (NP) that 
minimizes time between diagnosis and treatment considering the popula-
tion to be treated in the next 5 years in Portugal. A Microsoft Excel® model 
was developed to simulate patients’ pathway from diagnosis to end of 
treatment, quantifying time elapsed, LTFU, disease progression and costs 
(excluding HCV treatment costs) from the societal perspective. Four groups 
of patients were considered: people who inject drugs (PWID), incarcerated 
(INC), men who have sex with men (MSM) and general population (GP). 
Model inputs, specific to each subgroup, were obtained from the literature 
complemented by an expert panel. All patients were assumed to be treat-
ed for 12 weeks. The CP was compared to two scenarios: a simplification 
of complementary diagnosis tests at the specialist level (NP1) and NP1+a 
streamlined path to the specialist after a positive rapid HCV test.
results: A total of 3,500 patients were estimated to be treated per year 
in the next 5 years. The majority were PWID (58.5%) followed by 23.5% 
from GP, 11.0% from MSM and 7.0% being incarcerated individuals. The CP 
comprised of 17 steps, 15 of which require the patient to physically attend 
a health care facility. LTFU in the CP was highest among PWID (40%) fol-
lowed by INC (33%). The simplification of the CP would reduce the number 
of patient visits to 9 (NP1) or 6 (NP2). Out of 1,104 patients who would be 
LTFU per year under the CP, 7% would be retained in the NP1 1 and 71% in 
the NP2. Summary results comparing CP to NP1 and NP2 in terms of health 
outcomes and cost reductions, are detailed in Table.
endpoint current Paradigm [cP]
new Paradigm 1 
[nP1]
new Paradigm 2 
[nP2]
Total process time from 
diagnosis to end of treatment
67 weeks 58 weeks 45 weeks
Proportion LTFU 32% 29% 7%
Patient time used (3,500 
patients per year, 5 years)
23 years 15 years (-34%) 11 years (-55%)
Cirrhosis cases over 5 years 94 86 (-9%) 32 (-66%)
Total costs over 5 years 20.4 million €
15.8 million € 
(-23%)
14.6 million € 
(-29%)
[Results of simplifying the process from diagnosis to treatment]
conclusion: Simplification of the current CHC treatment paradigm results 
in efficiency gains in terms of LTFU, reduction of advanced liver disease 
cases, reduction in medical costs and productivity gains.
disclosure: This analysis received financial support from Gilead Sciences, 
Portugal. 
P0767 esTIMaTIng PrOPOrTIOn Of cIrrhOsIs and 
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(POrTugaL) - resuLTs frOM a eurOPean PILOT
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Introduction: WHO set target to reduce mortality attributable to hepatitis B 
(HBV) and hepatitis C (HCV) by 65% by 2030. While national mortality data 
from cirrhosis (CIR) and hepatocellular carcinoma (HCC) exist, proportion 
of cases due to HBV and/or HCV are unknown. A study protocol was devel-
oped to calculate the attributable fraction of HBV, HCV and other risk fac-
tors for CIR and HCC in a standardised way and piloted in Sofia (Bulgaria) 
and Lisbon (Portugal).
aims & Methods: All patients presenting with CIR and/or HCC at the na-
tional reference centre in Sofia during 2016-2017 and the first 100 sequen-
tial patients with CIR and 100 with HCC presenting at national reference 
centre in Lisbon during 2015-2016 were included. Cases with CIR and HCC 
were identified based on ICD-10 codes in Sofia and on clinical criteria in 
Lisbon. Patients diagnosed with both CIR and HCC were classified as HCC. 
HBsAg and anti-HCV positivity were considered markers for chronic HBV 
and HCV, respectively. When markers for both HBV and HCV were present, 
HCV-RNA existence defined the case as being attributable to HCV. When 
viral markers were absent, excessive alcohol consumption (>30 grs/day) or 
non-alcoholic-fatty liver disease (NAFLD) were considered main risk fac-
tors for CIR or HCC.
results: Data for 518 CIR, 84 HCC cases were collected in Sofia and 100 
CIR and 100 HCC in Lisbon. 70% of CIR and 80% of HCC cases in Sofia 
and 78% of CIR and 82% of HCC in Lisbon were males. 38% of CIR, 68% 
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of HCC in Sofia and 53% of CIR and 71% of CIR in Lisbon were ≥60 years. 
In both sites, distribution of CIR and HCC cases did not differ by gender (p 
Sofia =0.07, p Lisbon =0.48) but patients with HCC were significantly older 
(p Sofia =0.00, p Lisbon =0.03). In Sofia the main risk factors for CIR were: 
alcohol 46%, HBV 18%, HCV 16% and NAFLD 4% and for HCC: HBV 37%, 
HCV 25%, alcohol 8%, NAFLD 8%. In Lisbon main risk factors for CIR were: 
alcohol 56%, HCV 25%, HBV 6%, NAFLD 6% and for HCC: alcohol 46%, 
HCV 37%, HBV 9%, NAFLD 3%. Considerable overlap between risk factors 
was observed.
conclusion: Viral hepatitis B and C were important risk factors for liver 
morbidity in both centres. The pilot demonstrated the feasibility of col-
lecting data on viral hepatitis prevalence that can be used to estimate 
mortality attributable to HBV and HCV for monitoring elimination. Further 
consideration should be given to representativeness of samples collected 
from reference centres, assessment of cases with overlapping risk factors, 
data collection simplification.
disclosure: Nothing to disclose 
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Introduction: Nonalcoholic Fatty Liver Disease (NAFLD) is a common cause 
for increased values in liver blood tests and abdominal ultrasound find-
ings, in the primary care (PC) setting. Advanced fibrosis is a significant 
predictor of long-term complications and mortality. Accordingly, a major 
focus of clinical care for patients with NAFLD should be the determination 
of those at highest risk for the complications of advanced liver disease, 
pointing out the PC critical role for identification, risk stratification and 
adequate referral.
aims & Methods: The purpose of this paper is to assess the referral letters 
for Hepatology appointments of NAFLD patients in a tertiary hospital. In 
Portugal, referral letters are in the form of an electronic free text paper.
Retrospective assessment of referral letters (RL) for first Hepatology ap-
pointments between January 2016 and December 2018.
results: A total of 975 patients were referred to Hepatology appointments, 
with 121 NAFLD diagnosed (12.4%), a growing number in the three years 
of this study.
Within NAFLD patients, 52.9% are men, with an average age of 56. The 
main reasons for NAFLD patients referrals were: altered liver blood tests 
and steatosis on abdominal ultrasound (31.4%); altered liver blood test 
(23.9%); steatosis in abdominal ultrasound (12.4%). Only 5 RL (4%) made 
reference to the calculation of the NAFLD Fibrosis Score (NFS) and none 
mentioned the Fibrosis-4 (FIB4). Immunologic and virologic studies were 
mentioned on 12.4% RL.
Upon first observation in the Hepatology appointment, 63.3% of patients 
had a NFS predicting absence of significant fibrosis, 26.5% an undeter-
mined NFS and 10.2% with an NFS predicting advanced fibrosis. Liver bi-
opsy was performed in 27 patients, with findings of fibrosis score F3-F4 in 
12 of them (10% of the population).
Currently, 61.4% maintain follow-up in Hepatology appointments and 33% 
were discharged to the PC setting. From the ones discharged, 24.2% had a 
normalization of the blood tests after risk factor management. The average 
number of appointments was 2.69 and 4% were discharged on the first 
appointment.
conclusion: In a population of NAFLD patients referred to Hepatology ap-
pointments in a tertiary hospital, most had a NFS predicting low risk fibro-
sis. Only a small percentage of RL mentioned this, which may translate an 
overuse of speciality appointments.
As the growing prevalence of NALFD, an effective hospital response for 
clinical management of NAFLD implies a communication within the medi-
cal community for the development of significant transformations. Using 
stratification methods such as NFS was shown cost-effective and as such it 
should be increasingly used in the PC setting. Creating referral protocols is 
an efficient way of promoting the use of such tools.
disclosure: Nothing to disclose 
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Introduction: The farnesoid X receptor (FXR) is expressed in the liver and 
intestine at high levels. Among its actions, it is important in regulating 
multiple steps in the enterohepatic circulation of bile acids which are im-
portant for cholestatic diseases and in bile acid diarrhoea. It has previously 
been demonstrated that transcription of fibroblast growth factor 19 (FGF19) 
is one of the most potently stimulated effects regulated by FXR. Ileal FGF19 
is important for the regulation of hepatic bile acid synthesis. EYP001 is a 
selective, synthetic, non-bile acid FXR agonist, which is being developed 
for several liver and intestinal diseases. EYP001 has been shown to be 
safe and well-tolerated and to stimulate serum FGF19 levels, together with 
inhibition of markers of hepatic bile acid synthesis and bile acid levels.
aims & Methods: The aim of this study was to determine the FXR-de-
pendent effects of EYP001 in human ileum. Normal human ileal muco-
sal biopsies were obtained at routine ileo-colonoscopy. Incubations were 
performed for 6h with EYP001 or with negative or positive (chenodeoxy-
cholic acid, CDCA) controls. RNA was extracted and transcript expression 
measured by QRT-PCR. FGF19 protein was measured in the culture fluid 
by ELISA.
results: FGF19 transcripts were potently stimulated by EYP0011 (50 µmol/L) 
with a median 1400-fold increase (p=0.012, n=8). This was 1.2x more po-
tent than CDCA (50 µmol/L). EYP001 at 10 µmol/L was about 25% as ac-
tive; 100 µmol/L was not more potent. Expression of other FXR-responsive 
genes SHP, OSTα and FABP6 was increased about 4-fold by EYP001, much 
less than the 1000-fold changes found with FGF19. ASBT was not signifi-
cantly affected. FGF19 protein was also stimulated significantly by EYP001.
conclusion: These studies have shown that EYP001 is a potent FXR agonist 
in human ileal mucosal explant culture, stimulating FGF19 transcript levels 
and protein production. These findings justify further studies of EYP001 in 
human diseases where a response to FXR agonists is predicted such as in 
bile acid diarrhoea.
disclosure: PRR, RD, PS, EM, JV are employed by Enyo. FS and JW have 
received grant funding from Enyo 
P0770 The InfLuences Of esT and anTIBIOTIc TreaTMenT On 
The BILIary MIcrOBIOTa Of chOLedOchOLIThIasIs PaTIenTs
Shen H.1, Ye F.2, Zhang X.1
1Affiliated Hangzhou First People’s Hospital, Zhejiang University School of 
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Introduction: The number of samples involved in previous studies of the 
bile duct microbiota in choledocholithiasis patients is relatively small, thus 
a comprehensive understanding of the biliary microbiota is still lacking. 
In addition, the influences of endoscopic sphincterotomy (EST) and pre-
operative use of antibiotics on the biliary bacterial community still remain 
unclear.
aims & Methods: Bile samples (obtained by ERCP from the common bile 
duct) and clinical data of 121 patients were collected. The samples were 
divided into 4 groups (NN: with no antibiotic use and no history of EST, 
n = 31; NE: with no antibiotic use but with a EST history, n = 20; AN: with 
antibiotic use but no EST history, n = 55; AE: with antibiotic use and EST 
history, n = 15). Based on 16S rDNA sequencing method, the putative im-
pacts of EST and antibiotics on the biliary microbiota were investigated.
results: The NN samples had a distinguished bacterial profile from those 
of the NE group, with 20 genera having differential relative abundances 
among the two groups, which thus might be related with relapse of the 
common bile duct stones. 
Moreover, the history of EST could affect the beta-diversity rather than 
alpha-diversity of the biliary microbiota of patients without antibiotic 
treatment. The predicted KEGG pathways were also altered in NN and NE 
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samples, of which the majority were related with metabolic pathways. 
Antibiotic treatment had diverse effects on the composition of the bili-
ary microbiota, which were characterized by different or fluctuant variance 
patterns of some specific genera. Regardless of the antibiotic type and 
treatment course, a panel of bacterial taxa, including Escherichia/Shigella, 
Fusobacterium, Neisseria, Haemophilus, Aeromonas and Porphyromonas, 
were always observed to have differential relative abundances in the 
samples receiving antibiotics relative to those without preoperative treat-
ment. Notably, after antibiotic treatment, the alpha-diversity indexes were 
significantly increased in treated samples than the rest ones, which was 
different from the results obtained from the gut microbiota. Meanwhile, 
the potential interactions among biliary bacteria as well as the predicted 
profiles of KEGG orthologies were also affected by the introduction of an-
tibiotics.
conclusion: The compositions of the biliary bacterial community could be 
impacted by both routine EST operation and the use of antibiotics, which 
suggested the possibility of optimizing the therapy methods. And further 
in-depth exploration of the pathogenic mechanism of the biliary bacterial 
flora in choledocholithiasis should benefit the treatment of patients.
disclosure: Nothing to disclose 
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Introduction: Cholestasis can present with jaundice and intense pruritus, 
the pathophysiology of which is unclear. Data from the relevant studies 
indicated that hepatic mast cells have potential roles in progression of 
cholestasis and cholestasis induced itch such as elevated total blood his-
tamine concentration in bile duct ligation (BDL) models of cholestasis, 
activation of mast cells by bile acids, increased skin mast cell accumula-
tion in jaundiced animals and decreased biliary hyperplasia in cholestatic 
rodents after mast cell stabilizer; cromolyn sodium administration. In this 
study, we aimed to compare the effects of cromolyn sodium and other 
various therapeutic agents on serum biochemistry, serum histamine, total 
bile acids, autotaxin levels, liver histopathology and mast cell distribution 
in the liver, skin and peritoneum in experimental cholestasis induced by 
BDL in rats. We also aimed to investigate its efficacy on cholestatic pruritus 
and to compare the effectiveness with a group of therapeutic agents used 
in this area.
aims & Methods: Sixty-nine male rats of Spraque Dawley, weighing be-
tween 193-296 grams, were randomly divided into 8 groups. We weighed 
the rats preoperatively and applied the determined treatment every day 
consecutively for 10 days after the surgery. The BDL was not performed 
during the laparotomy and no medical treatment was given to the sham 
group (n =9). The control group (n=12) underwent BDL and intraperitoneal 
(ip) saline was given as the treatment. BDL was applied to the other 6 
groups. Group 1 (n=9) received ip cromolyn sodium, group 2 (n=8) re-
ceived ip chlorpheniramine maleate, group 3 (n=8) received oral sertra-
line, group 4 (n=8) received ip ondansetron, group 5 (n=7) received oral 
ursodeoxycholic acid and lastly group 6 (n=8) received ip naloxone. On 
the fifth and tenth days of the experiment, subjects were observed for 5 
minutes in terms of itching behavior. After 10 days, the rats were weighed 
and blood samples were taken under general anesthesia. Lastly, tissue 
(skin-subcutaneous, peritoneal membrane, liver) samples were taken for 
histopathological studies with sacrification.
results: Other than groups 2 to 6, the significant decreases in all param-
eters including serum histamine and autotaxin levels, plasma total bile 
acids, total and direct bilirubin concentrations, alkaline phosphatase and 
gamma-glutamyl transpeptidase measures were observed only in group 
1 compared to the control group (p<0.05). When liver specimens were 
evaluated histopathologically; portal inflammation, lobular inflammation, 
bile duct proliferation, necrosis and fibrosis were significantly improved in 
group 1 and 3 (p< 0.05). We identified increased mast cell accumulation in 
the liver, the skin and the peritoneum in the control group. Only in group 
1, liver and peritoneal mast cells were significantly decreased compared to 
the control group (p=0.003, p=0.004, respectively), whereas the decrease 
in skin mast cells was not significant (p=0.09). On the fifth and tenth days 
of the experiment, the mean duration of the rat’s itching was significantly 
lower in all groups compared to the control group (p<0.05). Duration of 
the itching was observed to increase in the control group from day 5 to 10 
and the itching period was detected to decrease in Group 1, 2, 4 and 5.
conclusion: Our study has shown that cromolyn sodium has promising 
anti-pruritic efficacy and has provided biochemical and histopathological 
recovery in the relevant parameters of cholestasis in the animal model.
disclosure: Nothing to disclose 
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Introduction: SeHCAT scan, is an essential diagnostic modality for bile acid 
malabsorption (BAM). The British Society of Gastroenterology (BSG) rec-
ommends use of this test for identifying BAM in diarrhoea-predominant 
irritable bowel syndrome (IBS-D) and people with Crohn’s disease (CD) 
without ileal resection.1 However, its use for evaluation of chronic diar-
rhoea and its cost-effectiveness to the National Health Service (NHS) is 
subject to further evidence. We aim to demonstrate the utility of this inves-
tigation in patients with chronic diarrhoea classifying them into different 
associated gastrointestinal (GI) conditions.
aims & Methods: We retrospectively analysed SeHCAT scans done over a 
period of 1 year. This data was further classified based on their association 
with diarrhoea predominant irritable bowel syndrome (IBS-D), Crohn’s 
disease (CD), ulcerative colitis (UC), post-cholecystectomy, celiac disease 
and chronic pancreatitis (CP). The patients with CD were further sub-cat-
egorised and analysed.
results: Total patients included were 122 with 72.1% (n=88) females, aver-
age age 49.6 years (range 81 -17). BAM was present in 50% (n=61) of those 
evaluated. Positive cases were classified as mild (21.3%, n=13), moder-
ate (23%, n=14) and severe (55.7%, n=34). On analysis of prevalence of 
BAM based on associated GI conditions it was found 70.3% of 37 pa-
tients with CD had the condition. Similarly the prevalence of BAM noted in 
other groups were 42.3% of 26 IBS-D, 55.5% of 27 Post-cholecystectomy, 
33.33% of 6 UC, 60% of 5 CP. We had only one patient with celiac disease 
and was found to have BAM. There were 16 patients who did not have 
a GI diagnosis but were evaluated for chronic diarrhoea with a SeHCAT 
scan. Three of these were diagnosed to have BAM. Of the 37 CD patients 
18 had CD without ileal disease, 72.2% (n=13) having BAM. Nine had ileal 
involvement (Montreal L1 or L3) and 66.7% (n=9) with BAM. Seven of the 
CD patient had previous ileal resection and 71.4%(n=5) were positive for 
BAM. Similarly 3 CD patients had other colonic surgery and BAM was 
noted in 66.7% (n=2).
conclusion: We noted that SeHCAT scan is a useful test for evaluation of 
chronic diarrhoea in conditions with high pre-test probability. If done ear-
lier in suspected cases it saves the cost of undergoing more investigations 
for chronic diarrhoea. Our analysis also indicated that in inflammatory 
bowel disease (IBD), especially CD, regardless of the location phenotype 
and surgical history, BAM was noted with equal prevalence. Further stud-
ies with larger dataset are needed to identify the utility and cost-effective-
ness of SeHCAT scan in diagnostic algorithm for chronic diarrhoea.
references: 1. Arasaradnam, R.P, et al., 2018. Guidelines for the investigation 
of chronic diarrhoea in adults: British Society of Gastroenterology. Gut, 
pp.gutjnl-2017.
disclosure: Nothing to disclose 
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P0773 The IMPOrTance Of 24 BILe acIds In LIver BILe Of 
BenIgn and MaLIgnanT BILIary sTenOsIs
Rejchrt S.1, Hroch M.2, Repak R.1, Fejfar T.1, Douda T.1, Peterova E.1,2, 
Bures J.1
1Charles University Faculty of Medicine and University Hospital, 2nd 
Department of Internal Medicine - Gastroenterology, Hradec Kralove, Czech 
Republic, 2Charles University Faculty of Medicine, Department of Medical 
Biochemistry, Hradec Kralove, Czech Republic
contact e-Mail address: rejchrt@lfhk.cuni.cz
Introduction: Differential diagnosis of benign and malignant biliary ste-
nosis might be difficult. Histology of bioptic specimens is often indetermi-
nate. Laboratory markers (serum bilirubin > 75 µmol/L, CA 19-9 > 400 U/
mL) and the length of stenosis (> 15 mm) can be helpful but not specific 
enough (ref. 1). Only one study of altered bile composition has been pub-
lished so far. Bile salts, phospholipids and cholesterol were significantly 
lower in 14 patients who developed non-anastomotic biliary strictures af-
ter liver transplantation (ref. 2).
aims & Methods: The aim of our prospective study was to investigate 24 
different bile acids in liver bile of patients with benign and malignant bili-
ary stenosis and controls without stenosis. 
A total of 73 patients entered the study: 7 subjects with benign biliary ste-
nosis (6 men, 1 woman; 68±13 years old), 21 with malignant biliary stenosis 
(15 men, 6 women; 72±14 years old) and 45 patients without biliary ste-
nosis (22 men, 23 women; 70±13 years old), out of those 25 subjects with 
and 20 without choledocholithiasis. Serum total bilirubin and C-reactive 
protein were investigated before ERCP. Samples of hepatic bile were col-
lected from the common hepatic duct endoscopically (prior to contrast me-
dia use) and immediately frozen at -80 ºC until the analysis. Twenty-four 
different bile acids were investigated by high-performance liquid chroma-
tography / mass spectrometry: lithocholic, ursodeoxycholic, hyodeoxycho-
lic, chenodeoxycholic (CDCA), deoxycholic, alfa- and beta-muricholic, hyo-
cholic, obeticholic, glycolithocholic (GLCA), glycoursodeoxycholic (GUDCA), 
glycohyodeoxycholic, glycochenodeoxycholic (GCDCA), glycodeoxycholic 
(GDCA), glycocholic (GCA), glyohyocholic, taurolithocholic (TLCA), tau-
roursodeoxycholic (TUDCA), taurohyodeoxycholic, taurochenodeoxycholic, 
taurodeoxycholic (TDCA), tauromuricholic (TMCA), trihydroxycholestanoic 
(THCA), taurocholic (TCA) and cholic (CA) acid.
results: Serum total bilirubin was significantly higher in patients with ma-
lignant biliary stenosis compared with non-stenotic controls (p = 0.005). 
Significant relationship (r > 0.7) was found between several pairs of bile 
acids (GLCA-GDCA; GLCA-TLCA; GCDCA-GDCA; GCDCA-GCA; CDCA-CA; 
GUDCA-TUDCA; GDCA-TDCA; TCDCA-TCA; TMCA-THCA). Significantly lower 
bile acids concentrations in malignant biliary stenosis compared with con-
trols without stenosis were found for GLCA (median 12.4, IQR 0 - 44.7 vs 
32.1, 4.1 - 260.1 µmol/L; p = 0.032), GUDCA (median 123.7, IQR 2.6 - 319.9 vs 
259.2, 38.0 - 1247.0 µmol/L; p = 0.032), GCDCA (median 4995.0, IQR 2404.9 
- 9474.5 vs 2642.0, 308.7 - 5746.8 µmol/L; p = 0.006), GDCA (median 381.0, 
IQR 8.9 - 1497.8 vs 1110.5, 135.9 - 4421.3 µmol/L; p = 0.031), GHCA (median 
8.0, IQR 2.7 - 14.6 vs 16.4, 10.3 - 33.8 µmol/L; p = 0.005), TUDCA (median 
19.2, IQR 0 - 58.8 vs 58.9, 9.5 - 152.8 µmol/L; p = 0.044) and TDCA (median 
118.3, IQR 7.1 - 321.6 vs 377.5, 79.8 - 930.7 µmol/L; p = 0.036). Significant dif-
ference between benign and malignant stenosis was found for CA (median 
97.8, IQR 5.8 - 465.9 vs 0, 0 - 20.4 µmol/L; p = 0.022). Other results did not 
reach statistical significance.
conclusion: Analysis of bile acids might be helpful in the differential di-
agnosis of malignant and benign biliary stenosis. However, more patients 
must be enrolled in the study in order to be able to evaluate the real diag-
nostic yield of bile acids monitoring. 
The study was supported by the Research Project MH CZ - DRO (UHHK, 
00179906).
references: 1. Can J Gastroenterol 2000; 14(5): 397-402. 2. J Hepatol 2009; 
50(1): 69-79.
disclosure: Nothing to disclose 
P0774 reaL-TIMe deeP IMagIng Of BILIary excreTIOn TO The 
InTesTInaL TracT By usIng near-Infrared PhOsPhOrs
Umezawa M.1, Yoshida M.1, Kamimura M.1,2, Soga K.1,2
1Tokyo University of Science, Department of Materials Science and 
Technology, Faculty of Industrial Science and Technology, Tokyo, Japan, 
2Tokyo University of Science, Imaging Frontier Centre (IFC), Research Institute 
for Science and Technology (RIST), Organization for Research Advancement, 
Noda, Japan
contact e-Mail address: masa-ume@rs.noda.tus.ac.jp
Introduction: Biliary excretion from the liver to the intestinal tract, an ex-
cretion route in addition to the renal clearance via glomerular filtration, 
is an important biomedical phenomenon related to health and diseases 
such as jaundice, gallstone formation, and excretion of therapeutic drugs. 
We hypothesized that an emerging fluorescence imaging system in the 
wavelength range of over-thousand-nanometre (OTN) near-infrared (NIR), 
which allows deep bioimaging with high spatial resolution due to its less 
scattering by biological tissues [1-4], may be available to monitor the dy-
namic change of the biliary excretion.
aims & Methods: The aim of the present study was to investigate the pos-
sibility of real-time monitoring of the biliary excretion using the in vivo 
deep OTN-NIR fluorescence imaging system in a non-clinical experimental 
(mouse) model. An OTN-NIR fluorescence dye IR-1061 (Sigma-Aldrich) was 
loaded into micelle nanoparticles (MNPs) composed of an amphiphilic 
polymer N-(carbonyl-methoxypolyethyleneglycol 2000)-1,2-distearoyl-sn-
glycero-3-phosphoethanol-amine (DSPE-PEG
2k
) by a simple ‘one-pot’ pro-
cedure as described previously [5] with minor modifications. 
The particle size of the prepared OTN-NIR fluorescence MNPs (OTN-MNPs) 
was 9 nm. The OTN-MNPs emit OTN-NIR fluorescence peaked at 1100 nm 
under 980-nm excitation. 
After intravenous injection of the OTN-MNPs into 6-week-old mice under 
anesthesia, OTN-NIR fluorescence images of mice were observed by a por-
table NIR fluorescence in vivo imaging system SAI-1000 (Shimadzu). All 
animal care and experiments were carried out according to the guidelines 
on care and use of laboratory animals as stated by Tokyo University of 
Science.
results: Following intravenous injection of the OTN-MNPs into mice, 
whole-body blood vessels were visualized using the proposed system. 
The OTN-MNPs were trapped by the reticuloendothelial system and mostly 
distributed to the liver within 60 min post-injection. The mice were fed a 
high-fat diet to enhance bile secretion, and after 90−180 min, OTN-NIR 
fluorophores are excreted from the liver with bile to the duodenum. We 
successfully imaged time-dependent dynamic change of distribution of the 
fluorophores encapsulated by the MNPs in the hepatobiliary route of live 
mice.
conclusion: The OTN-MNP is useful for in vivo real-time imaging of hepa-
tobiliary excretion with the OTN-NIR fluorescence imaging technique. This 
technique is useful for screening hepatobiliary excretion of administered 
substances and for monitoring of the bile excretion from the liver through 
the intestinal tract.
references: [1] Smith A.M. et al., Nat. Nanotechnol., 4 (2009) 710-711. [2] 
Soga K. et al., J. Photopolym, Sci. Technol., 25 (2012) 57-62. [3] Hemmer E. 
et al., Nanoscale, 5 (2013) 11339-11361. [4] Jaque D. et al., Adv. Opt. Photon., 
8 (2016) 1-103. [5] Kamimura M. et al., Polym. J., 49 (2017) 799-803.
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P0775 The BILe acId agOnIsT Tgr5 Induces InTesTInaL 
grOWTh In a gLP-2 dePendenT Manner and aMeLIOraTes 
InTesTInaL Injury In MIce
Hunt J.1, Billeschou A.1, Ullmer C.2, Hartmann B.1, Holst J.J.1,3, Kissow H.1
1University of Copenhagen, Biomedical Sciences, Copenhagen, Denmark, 
2F. Hoffmann-La Roche Ltd, Roche Pharmaceutical Research and Early 
Development, Basel, Switzerland, 3University of Copenhagen, NNF Center for 
Basic Metabolic Research, Copenhagen, Denmark
contact e-Mail address: jenna.hunt@sund.ku.dk
Introduction: Enteroendocrine L cells express the bile acid receptor Take-
da-G-protein-receptor-5 (TGR5). Activation of TGR5 triggers the release 
of glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2). 
Treatment with GLP-2 analogues, and to a lesser extent GLP-1, results in 
intestinotrophic effects and ameliorates intestinal injury in rodents.
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aims & Methods: In this study, we aim to investigate the contributions of 
the TGR5 receptor to glucagon-like peptide secretion and the impact on 
the intestinal architecture and healing response. 
Female mice (n=8) were treated with the orally bioavailable TGR5 agonist 
RO5527239 (30 mg/kg) or vehicle twice daily for ten days and the intestinal 
parameters explored; including intestinal weight, morphometry and gut 
hormone analysis. In a subsequent study, GLP-2r KO mice (n=12) and their 
wild type littermates were either treated with RO5527239 (30 mg/kg) or 
vehicle twice daily for ten days and small intestinal weight was recorded. 
Finally, female mice (n= 8) received a single injection of the chemother-
apy 5-fluorouracil (5-FU) (400 mg/kg) or saline and were treated with 
RO5527239 (30 mg/kg) or vehicle twice daily until sacrifice 72 h after 5-FU. 
Body weight and intestinal parameters were explored.
results: Agonist treatment resulted in a significant increase in relative 
small intestinal weight (p< 0.0001). Morphological changes were primar-
ily located proximally leading to an increase in mucosa cross-sectional 
area and villus height in the duodenum (p< 0.01). The large intestine was 
structurally unaffected but the concentration of intact GLP-1 and GLP-2 was 
increased in colonic tissue (p< 0.01). 
Agonist treatment resulted in an increase in relative small intestinal weight 
(p< 0.01) in the wild type mice, which was not present in the GLP-2r KO 
mice. Agonist treatment of 5-FU treated mice resulted in an increase in 
villus height (p< 0.05), crypt depth and a decrease in histological severity 
score.
conclusion: This study shows that activation of the TGR5 resulted in small 
intestinal growth and the increased secretion of GLP-1 and GLP-2 from 
the colon. Additionally, TGR5 activation produced a growth response in 
the small intestine in a GLP-2 dependent manner and ameliorated 5-FU 
mucositis in mice. Taken together, this work suggests TGR5 as a potential 
target for alleviating intestinal injury through the stimulation of GLP-2 se-
cretion.
disclosure: Nothing to disclose 
P0776 cOMParIsOn Of The cLInIcaL OuTcOMes Of 
suPraPaPILLary and TransPaPILLary sTenT InserTIOn 
In unresecTaBLe chOLangIOcarcInOMa WITh BILIary 
OBsTrucTIOn
Shin J.1, Park J.-S.2, Jeong S.3, Lee D.-H.4
1Inha University Hospital, Gastroenterology, Incheon, Korea (Republic of), 
2Inha University School of Medicine, Gastroenterology, Incheon, Korea 
(Republic of), 3Inha University Hospital, Dept. of Internal Medicine, Incheon, 
Korea (Republic of), 4Inha University Hospital, Incheon, Korea (Republic of)
contact e-Mail address: shinjongv@naver.com
Introduction: To prevent stent migration, transpapillary stent placement 
has been recommended for the endoscopic treatment of malignant hilar 
biliary stricture. However, placement above the papilla is currently favored 
because it is believed to prevent reflux of duodenal contents and prolong 
stent patency.
aims & Methods: The aim of the current study was to compare the effica-
cies and safety aspects of transpapillary and suprapapillary stent place-
ment. In addition, success rates of stent revision were evaluated with re-
spect to stent location.
The medical records of 73 hilar cholangiocarcinoma patients that under-
went endoscopic metal stent insertion between January 2005 and Decem-
ber 2015, were retrospectively reviewed. Patients were allocated by stent 
location to a suprapapillary group (S group; N=44) or a transpapillary 
group (T group; N=29). Clinical outcomes, durations of stent patencies, 
adverse events related to stent placement, and revision success rates in the 
two study groups were compared.
results: Suprapapillary stent placement was performed in 44 patients 
and transpapillary placement was performed in 29. Patency periods were 
similar in the two groups (group S, 140 days; group T, 157 days; P =0.476). 
Rates of stent obstruction in the S and T groups were 38.4% and 21.9%, 
respectively (P=0.470). An adverse event related to stent insertion occurred 
in 15 (20.5%) of the 73 study subjects with no significant intergroup dif-
ference. The success rate of endoscopic revision was significantly higher 
in the T group (P = 0.01), and the time required for revision tended to be 
shorter in the T group.
conclusion: The effectivenesses and safeties of suprapapillary and trans-
papillary stent insertion were found to be similar, but the success rate of 
endoscopic revision was significantly higher for transpapillary stent inser-
tion. Therefore, we recommend transpapillary stent placement be consid-
ered for patients with hilar cholangiocarcinoma and biliary obstruction.
disclosure: Nothing to disclose 
P0777 a POsITIve LyMPh nOde raTIO-Based nOMOgraM 
sTagIng sysTeM TO PredIcT cancer-sPecIfIc survIvaL fOr 
PaTIenTs WITh resecTed gaLLBLadder cancer
Yan Y., Mao K., He C., Zhang J., Wang J., Xiao Z.
Sun Yat-Sen University, Hepatobiliary Surgery of Sun Yat-Sen Memorial 
Hospital, Guangzhou, China
contact e-Mail address: yanyc@mail2.sysu.edu.cn
Introduction: Gallbladder cancer (GBC) is one of the most aggressive ma-
lignant tumors with a poor long-term prognosis worldwide, and there is 
no effective and convenient method for predicting cancer-specific survival 
(CSS). Positive lymph node ratio (pLNR), but not the location or number of 
invaded nodes, independently predicts the surgical outcomes of patients 
who have undergone curative resection. We aim to analyze the signifi-
cance of pLNR in GBC patients and develop a novel staging system based 
on a formulated nomogram for CSS.
aims & Methods: A total of 1,356 patients with resected GBC were divided 
into a training set (n=904) in an earlier period and a validation set (n=452) 
thereafter. We used a univariate Cox regression analysis to screen for risk 
clinicopathological factors for CSS in the SEER discovery set. We further 
performed stepwise multivariate Cox regression analysis to screen for im-
portant independent factors for CSS. A competing risk model based on 
risk factors was evaluated by Cox multivariate analysis to ensure that they 
were related to CSS. A novel nomogram based on the pLNR for predicting 
CSS at 1 and 3 years was formulated with the other identified independent 
important factors. The SEER internal testing set was used to evaluate the 
predictive reliability and accuracy of the nomogram. The concordance in-
dex and calibration plots were used to evaluate model discrimination. The 
predictive accuracy and clinical value of the nomograms were measured 
by decision curve analysis (DCA). The CSS nomogram was further validated 
in an internal validation set.
results: The 1-, 2- and 3-year CSS rates were 54.94%, 29.65%, and 15.12%, 
respectively, in the entire SEER cohort. The optimal cutoff value for pLNR 
determined by the maximum Youden index of the ROC curve was 0.08. 
According to the survival analysis, patients in the pLNR≤8% group had a 
poorer CSS than those in the pLNR>8% group in the discovery set. pLNR 
was associated with histologic type, histologic grade, tumor size, tumor 
extension, N classification, M classification, TNM staging system, and dis-
tant organ metastasis (including bone, brain, liver and lung) by statisti-
cal significance. The pLNR was an independent prognostic factor for CSS 
based on Cox regression analyses. A prognostic nomogram that combined 
T classification, pLNR, M classification, histologic grade, live metastasis 
and tumor size was formulated with a c-index of 0.763 (95% CI, 0.728-
0.798), while the c-indexes for the staging system of AJCC 8th, the AJCC 7th, 
and the AJCC 6th for CSS prediction were 0.718, 0.718, and 0.717, respec-
tively. The calibration curves showed perfect agreement. The DCA showed 
that the nomogram provided substantial clinical value. The nomogram 
(the AUCs of time-dependent ROC curve analysis for one, three, and five 
years were 0.693, 0.716, and 0.726, respectively) showed high prognostic 
accuracy.
conclusion: Based on the clinical risk factors identified in a large popula-
tion-based cohort, especially the pLNR, a robust prognostic predictor of 
CSS for resected GBC patients, we established the first practical formu-
lated nomogram staging system that includes the T classification, pLNR, N 
classification, tumor size, histologic grade and liver metastasis. Moreover, 
the internal cohort validation results demonstrated that these nomograms 
performed very well and showed excellent discrimination compared with 
the AJCC 7th and 8th edition staging systems. Our nomograms were dem-
onstrated to be clinically useful in a DCA, and they should therefore help 
clinicians generate better risk stratifications and formulate individual 
treatments.
disclosure: Nothing to disclose 
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P0778 suffIcIenT TIssue acquIsITIOn raTe Of PerOraL 
chOLangIOscOPy-guIded fOrcePs BIOPsy
Onoyama T., Takeda Y., Yamashita T., Hamamoto W., Sakamoto Y., 
Koda H., Kurumi H., Matsumoto K., Isomoto H.
Tottori University, Division of Medicine and Clinical Science, Department of 
Multidisciplinary Internal Medicine, Faculty of Medicine, Yonago, Japan
contact e-Mail address: golf4to@yahoo.co.jp
Introduction: Peroral cholangioscopy (POCS)-guided forceps biopsy (FB) is 
a commonly used method for diagnosing indeterminate biliary lesions and 
for the preoperative identification of the exact perihilar and distal margins 
of biliary tract cancer (BTC). However, POCS-FB may result in the acquisi-
tion of an insufficient amount of specimen at times. Therefore, we evalu-
ated the sufficient tissue acquisition rate (TAR) and the factor affecting the 
sufficient TAR of POCS-FB for the biliary tract.
aims & Methods: Patients who underwent POCS-FB for biliary disease be-
tween September 2016 and October 2018 at our hospital were enrolled 
retrospectively. We evaluated the sufficient TAR of POCS-FB for biliary 
lesion and that for non-stenotic bile duct. Sufficient tissue was defined 
as a specimen that allowed the evaluation of the histological finding of 
the biliary epithelium. A specimen that contained only interstitial tissue 
was deemed insufficient. Moreover, the factors affecting sufficient TAR of 
POCS-FB were evaluated. Subgroup analyses of age, sex, malignant biliary 
disease, the location of the biliary lesion, length of biliary stricture, mac-
roscopic types of BTC, presence of acute cholangitis, level of serum total 
bilirubin, level of CEA, level of CA19-9, procedure time, EST, biopsy site, 
and previous biliary stenting before POCS were assessed to determine the 
sufficient TAR of POCS-FB. We carried out univariate analyses to assess the 
sufficient TAR, and factors with P < 0.1 were included in the multivariate 
logistic regression analyses. The pathological diagnostic ability for BTC and 
the adverse event of the POCS-FB were also evaluated.
results: We enrolled 47 patients with biliary disease and performed POCS-
FB for biliary lesion and POCS-FB for non-stenotic bile duct in 40 and 
36 patients, respectively. The malignant group included 12 patients with 
perihilar cholangiocarcinoma (CCA), 14 patients with distal CCA, one with 
intrahepatic CCA and one with cystic ductal carcinoma. The benign group 
included 9 patients with benign biliary strictures, 3 patients with immu-
noglobulin G subclass 4-associated sclerosing cholangitis, 3 patients with 
primary sclerosing cholangitis, 2 patients with drug-induced cholangitis, 
one with intraductal papillary neoplasm of the bile duct, and one with a 
peribiliary cyst. The sufficient TAR of POCS-FB for biliary lesions and that 
for non-stenotic bile duct were 86.4%, and 68.9%, respectively.
In the multivariate logistic regression analyses, age < 65 years old (odds 
ratio 0.170, 95% Confidence interval [CI] 0.044-0.649, P = 0.004) and previ-
ous biliary stenting before POCS (odds ratio 0.199, 95% CI 0.053-0.756, P 
= 0.017) were the significant factors affecting the sufficient TAR of POCS-FB 
for biliary lesion. For non-stenotic bile duct, the biliary lesion in the distal 
bile duct (odds ratio 0.322, 95% CI 0.139-0.744, P = 0.008), procedure time 
in 75 minutes or less (odds ratio 3.012, 95% CI 1.092-8.312, P = 0.033), and 
EST (odds ratio 7.041, 95% CI 2.117-23.421, P = 0.002) were the significant 
factors affecting the sufficient TAR of POCS-FB. Sensitivity, specificity, and 
accuracy of POCS-FB for BTC were 76.2%, 94.7%, and 85.0%, respectively. 
The adverse event rate of POCS-FB was 17.0%, including acute pancreatitis 
(8.5%), infection (cholangitis, 6.4%), and hemorrhage (2.1%).
conclusion: The previous biliary stenting was a factor affecting low TAR of 
POCS-FB for biliary lesion. In the POCS-FB for non-stenotic bile duct, the 
presence of the lesion in the distal bile duct, the POCS-FB without EST, and 
the long procedure time of POCS were factors affecting low TAR.
disclosure: Nothing to disclose 
P0779 effecTs Of sarcOPenIa and BackgrOund facTOrs On 
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Introduction: Recently, as the number of elderly biliary tract cancer pa-
tients has increased, the opportunities for administering chemotherapy 
to these patients has also increased. On the other hand, sarcopenia is an 
important prognostic factors in various types of carcinoma, and it is pos-
sible that it may influence the treatment effectiveness. However, clinical 
trials of chemotherapy for biliary tract cancer often target patients up to 
the age of 75 years, but too few studies have been done on chemotherapy 
for the elderly with sarcopenia.
aims & Methods: The aim of this study was to investigate the effects of 
sarcopenia and other background factors on treatment and prognosis in 
elderly biliary cancer patients who received chemotherapy. A retrospective 
analysis was performed on 46 patients aged 65 years or older who un-
derwent chemotherapy for unresectable biliary tract cancer at two related 
institutions between November 2012 and April 2018. Sarcopenia was as-
sessed by measurement of the psoas muscle index (PMI). PMI at the third 
lumbar spine level was calculated from prechemotherapeutic computed 
tomography images. Treatment-related factors included age, sex, medical 
history (hypertension, diabetes, dyslipidemia, cholelithiasis), Eastern Co-
operative Oncology Group performance status (ECOG PS), tumor site, met-
astatic site, postoperative recurrence, chemotherapy regimen, body mass 
index, body fat composition, laboratory data (white blood cell, albumin, 
hepatobiliary enzymes, lactate dehydrogenase, C-reactive protein (CRP), 
serum tumor markers (CA19-9, CEA)). We also used the modified Glasgow 
Prognostic Score (mGPS), Platelet-Lymphocyte Ratio (PLR), and the CRP/
Albumin Ratio (CAR) as an indicator of nutritional status. The associa-
tions between these clinical factors and overall survival (OS) and time to 
treatment failure (TTF) were determined using univariate and multivariate 
analysis.Furthermore, stratification was performed based on the presence 
or absence of sarcopenia, and the influence of sarcopenia on OS and TTF 
was similarly examined.
results: The mean age of the patients was 75.9±5.5 years at the start of 
chemotherapy.
The univariate analysis showed that the significant factors affecting OS 
included sarcopenia, PS, lung metastasis, liver metastasis, CA 19-9, PLR, 
and CAR (p< 0.05). 
Next, a multivariate analysis using Cox proportional hazards regression 
showed that independent significant results were obtained for sarcopenia 
(HR 5.55 : 95%CI 1.96~15.94 : P=0.0013) and CAR (HR 3.04 : 95%CI 1.23~7.50 
: P=0.016). Similarly, in TTF, the significant factors included sarcopenia, PS, 
CA 19-9, PLR, and CAR in univariate analysis, and independent significant 
results were obtained for sarcopenia (HR 2.85 : 95%CI 1.20~6.80 : P=0.018) 
in multivariate analysis. Finally, as a result of stratification according to the 
presence or absence of sarcopenia, significant differences from univariate 
analysis were seen in PS, lung metastasis, CRP, CA19-9, mGPS and CAR in 
OS, and PS, CRP, CA 19-9, mGPS and CAR in TTF.
conclusion: In chemotherapy of elderly biliary tract cancer patients, the 
presence or absence of sarcopenia and the nutritional status are related 
to the treatment effect, and should be considered as potential markers to 
predict the outcome of chemotherapy. We suggest that maintenance of 
muscle mass and improvement of nutritional status may affect the effect 
of chemotherapy.
references: [1] Arai H, Akishita M, Kuzuya M, et al. Clinical Guidelines for 
Sarcopenia. Geriatrics & Gerontology Int 2018;18:1-44. [2] Kurita Y, Ko-
bayashi N, Tokuhisa M, et al. Sarcopenia is a reliable prognostic factor in 
patients with advanced pancreatic cancer receiving FOLFIRINOX chemo-
therapy. Pancreatology 2019;19:127-135.
disclosure: Nothing to disclose 
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P0780 deveLOPMenT Of a BILIary MuLTI-hOLe seLf-
exPandaBLe MeTaLLIc sTenT fOr BILe TracT dIseases
Kobayashi M.
Yokkaichi Municipal Hospital, Gastroenterology, Yokkaichi, Japan
contact e-Mail address: makoto-kobayashi@outlook.com
Introduction: Uncovered stents used for malignant obstructions in the 
biliary tree, especially in the hilar area, are prone to obstruction by tu-
mor ingrowths. In comparison, however, covered stents may block bile 
duct branches and are at risk of migration. We have developed a Multi-
Hole Self-Expandable Metallic Stent (MHSEMS), with a hole in each cell, to 
prevent the obstruction of bile duct branches. In addition, the holes may 
prevent migration due to small ingrowths by reducing the tension of the 
membrane.
aims & Methods: A MHSEMS has a hole in each stent cell on its cover-
ing membrane. When the stent is positioned in a junction connected by 
side branches, bile flows inside the stent through the holes in its covering 
membrane. Tumors may grow through these holes but may become sup-
pressed due to the size of the ingrowth. As a result of low membrane ten-
sion caused by the holes, the placed stent becomes fixed to surrounding 
tissues and is prevented from migrating. Presently, the MHSEMS is avail-
able with two types of hole sizes: small and large. 
In addition, a lasso attached to the distal end of the MHSEMS is helpful 
for stent removal. Even if an obstruction by a tumor ingrowth does occur, 
the silicone cover will protect the surrounding tissue and enhance any 
ablation effect, such as during endobiliary radiofrequency ablation (RFA), 
allowing the patient to be a candidate for such treatment. Using MHSEMS, 
we treated six patients with malignant biliary obstruction and one case 
with uncontrolled post-endoscopic sphincterotomy bleeding.
results: We had a 100% success rate for stent deployment. Stent patency 
was also 100% successful. In addition, jaundice improved in all patients 
with a malignant stricture, while complications such as pancreatitis, 
bleeding and cholangitis did not occur. The mean patency duration was 
found to be 274 days. None of the six cases showed any stent migration. 
For post-endoscopic sphincterotomy bleeding, complete hemostasis was 
achieved and the stent was successfully removed after 2 weeks.
conclusion: MHSEMS may be considered a hybrid-type stent, with char-
acteristics that fall between those of UCSEMS and CSEMS. Thus, MHSEMS 
may be regarded as a promising new treatment option for benign and 
malignant bile duct strictures.
disclosure: Makoto Kobayashi has a patent on the Multi-Hole Self-Expand-
able Metallic Stent (MHSEMS) with royalties paid by M.I.Tech Co., Ltd. 
P0781 PerOraL sIngLe OPeraTOr chOLangIOscOPy fOr 
IndeTerMInaTe BILIary sTrIcTures In cLInIcaL PracTIce 
Of a TerTIary referraL cenTer: InsuffIcIenT dIagnOsTIc 
accuracy and a LIMITed cLInIcaL IMPacT
de Vries B.1, van der Heide F.1, ter Steege R.2, Koornstra J.J.3, 
Buddingh K.T.4, Gouw A.5, Weersma R.K.1
1University Medical Center Groningen, Gastroenterology & Hepatology, 
Groningen, Netherlands, 2Martini Ziekenhuis Groningen, Gastroenterology, 
Groningen, Netherlands, 3University Medical Center Groningen, 
Gastroenterology, Groningen, Netherlands, 4LUMC, Urology, Leiden, 
Netherlands, 5University of Groningen, Pathology, Groningen, Netherlands
contact e-Mail address: abdevries.boudewijn@gmail.com
Introduction: Peroral single operator cholangioscopy (pSOC) is considered 
to be a valuable diagnostic modality for indeterminate biliary strictures 1. 
Nevertheless, the chosen measures of diagnostic accuracy for pSOC vary 
and the impact on patient management is scarcely reported. The aim of 
this study was to estimate diagnostic accuracy of pSOC visual assessment 
and targeted biopsies for indeterminate biliary strictures. Additional aims 
were to compare diagnostic accuracy pSOC with sequentially taken brush 
cytology and to assess the clinical impact of pSOC outcome on patient 
management.
aims & Methods: A retrospective single center open label cohort study was 
performed for patients of 18 years and older who underwent pSOC for in-
determinate biliary strictures between November 2007 and May 2017 with 
the Spyglass® or Spyglass DS® system. Indeterminate biliary strictures 
were defined as strictures of the intra- or extrahepatic bile duct without 
a mass detectable on abdominal imaging, in which conventional workup 
was non-diagnostic and a clear explanation from the clinical context was 
lacking (e.g. no recent trauma or biliary surgery)2,3. Endoscopy and pathol-
ogy reports were reviewed for results of brush cytology and pSOC visual 
impression and targeted biopsies. Diagnostic accuracy of pSOC was de-
fined as sensitivity, specificity, positive predictive value (PPV) and nega-
tive predictive value (NPV) and compared to same parameters of brush 
cytology. Clinical impact was assessed by review of medical records and 
was classified in three categories; change, confirmation or no influence in 
patient management.
results: A total of 76 patients were included, with primary sclerosing chol-
angitis being present in 40%. In 87% of patients prior ERCP was per-
formed, combined with brush cytology in 59%. In 55% of patients a bili-
ary stent was in situ and removed prior to pSOC procedure. A malignant 
stricture was diagnosed in 22 patients (30%), including 17 cholangiocarci-
noma. The sensitivity, specificity, PPV and NPV for pSOC visual impression 
was 64%, 61%, 42% and 83%. For pSOC targeted biopsies, the sensitivity, 
specificity, PPV and NPV was 15%, 63%, 75% and 67%. In contrast, se-
quential brush cytology yielded a sensitivity, specificity, PPV and NPV of 
47%, 92%, 73% and 81%. The clinical impact of pSOC outcome on patient 
management was limited, as it had no influence on management in 33% 
of patients and only resulted in change of management in 13% of patients.
conclusion: In a population with a high prevalence of primary sclerosing 
cholangitis and prior biliary stents in situ, the diagnostic accuracy of pSOC 
for indeterminate biliary strictures was found to be inferior to brush cytol-
ogy and had low impact on patient management.
references: 1. Chen YK, Parsi MA, Binmoeller KF, et al. Single-operator 
cholangioscopy in patients requiring evaluation of bile duct disease or 
therapy of biliary stones (with videos). Gastrointest Endosc. 2011;74(4):805-
814. doi:10.1016/j.gie.2011.04.016 2. Levy MJ, Baron TH, Clayton AC, et al. 
Prospective evaluation of advanced molecular markers and imaging tech-
niques in patients with indeterminate bile duct strictures. Am J Gastroen-
terol. 2008;103(5):1263-1273. doi:10.1111/j.1572-0241.2007.01776.x 3. Bowlus 
CL, Olson KA, Gershwin ME. Evaluation of indeterminate biliary strictures. 
doi:10.1038/nrgastro.2015.182
disclosure: Nothing to disclose 
P0782 rOLe Of PerOraL chOLangIOscOPy fOr dIagnOsIs 
and sTagIng Of BILIary TuMOrs
Morais R.1, Santos S.2, Gaspar R.1, Rodrigues-Pinto E.1, Vilas-Boas F.1, 
Pereira P.1, Macedo G.1
1Centro Hospitalar São João, Gastroenterology, Porto, Portugal, 2University of 
Porto and Centro Hospitalar São João, Porto, Portugal
contact e-Mail address: ruimorais20@gmail.com
Introduction: In the approach to biliary strictures it is important to estab-
lish a histopathological diagnosis. On the other hand, in the preoperative 
evaluation of malignant biliary lesions, intraductal extension may condi-
tion therapeutic approach. Peroral cholangioscopy (POC) has shown to be 
a useful diagnostic procedure in the evaluation of biliary strictures, how-
ever its role on preoperative staging has not been established.
aims & Methods: The aim of our study was to evaluate POC role in the di-
agnosis and preoperative intraductal staging of extrahepatic biliary cancer.
Retrospective cohort study that included all patients who underwent POC 
with SpyGlass TM Direct Visualization System (Boston Scientific) for diagnosis 
of biliary strictures or preoperative evaluation of extrahepatic biliary tu-
mors, between January 2015 and January 2019, in a single tertiary center. 
The primary endpoint was to assess the accuracy, sensitivity and speci-
ficity of SpyGlass visual findings and SpyGlass-guided biopsy findings in 
the diagnosis of patients with biliary strictures. A final diagnosis of ma-
lignancy was made based on positive histopathology of SpyGlass-guided 
biopsy/other tissue sampling procedures or evidence of disease progres-
sion consistent with malignancy during at least a 6 months follow-up. The 
secondary endpoint was to evaluate the ability of POC to detect mucosal 
cancerous extension preoperatively in possibly resectable peri-hilar chol-
angiocarcinoma (CCA) and the changes on surgical approach based on 
findings. In all malignant cases, we compared previous imagiologic ana-
tomic classification with that accessed with POC. Anatomic classification 
was based on Bismuth-Corlette Classification (BCC).
results: Forty-three patients were included, 63% male with a median age 
of 62 years (IQR 53-72). Thirty-eight (88.3%) underwent POC due to in-
determinate biliary strictures, 3 (7%) due to bile duct filling defect and 
2 (4.7%) for intraductal staging of perihilar CCA. In the follow-up, a final 
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diagnosis of malignancy was established in 56%. Visual impression accu-
racy with SpyGlass was 95% (100% sensitivity and 90% specificity). SpyBite 
biopsies accuracy was 81% (67% sensitivity and 100% specificity). 
In the 19 patients with a final perihilar CCA diagnosis, intraductal evalua-
tion with SpyGlass altered anatomic classification (BBC) defined by previ-
ous imagiologic findings in 8 (42.1%) patients (BCC 3a to 4, n=3; BCC 2 to 
4, n=3; BCC 2 to 3a, n=2). In 2 cases, a resectable BCC type 2 was a type 
3a based on SpyGlass examination, which modified the surgical approach 
from a bile duct resection (BDR) to a BDR with right hepatic lobectomy. 
In 3 cases, a previous BCC type 2 lesion was reclassified as BCC type 4 on 
SpyGlass approach and in two of these cases the lesions were considered 
irresectable. 
The remaining 3 patients were previous classified as a BCC type 3a based 
on imagiologic findings and were actually a BCC type 4 on SpyGlass exami-
nation. One patient previously considered candidate for surgical resection 
was deemed irresectable. 
Although, TNM data was missing in another, was considered irresectable 
and was referred for palliative biliary stent. The remaining case was ir-
resectable, so there was no change on therapeutic approach after POC.
conclusion: POC was useful in the diagnostic evaluation of biliary stenosis. 
Its use in potentially resectable cases of CCA was important to stablish best 
therapeutic approach. In the future, preoperative staging of perihilar CCA 
with POC combined with imagiologic evaluation of vascular extension of 
the lesions may optimize surgery results.
disclosure: Nothing to disclose 
P0783 dIgITaL chOLangIOscOPIc InTerPreTaTIOn: 
When nOrTh MeeTs The sOuTh
Kahaleh M.1, Gaidhane M.2, Raijman I.3, Tyberg A.4, Sethi A.5, Slivka A.6, 
Adler D.G.7, Sejpal D.V.8, Shahid H.1, Sarkar A.1, Martins F.9, Bertani H.10, 
Tarnasky P.11, Gress F.12, Gan I.13, Ardengh J.C.14, Kedia P.11, Arnelo U.15, 
Jamidar P.16, Shah R.J.17, Robles-Medranda C.18
1Robert Wood Johnson Medical School Rutgers University, Gastroenterology, 
New Brunswick, United States, 2Weill Cornell Medical Center, 
Gastroenterology, New Brunswick, United States, 3Greater Houston 
Gastroenterology, Gastroenterology, Houston, United States, 4Rutgers 
Robert Wood Johnson, New Brunswick, United States, 5Columbia University 
Medical Center, New York, United States, 6University of Pittsburgh Medical 
Center, Gastroenterology, Pittsburgh, United States, 7University of Utah 
Health, Gastroenterology, Salt Lake City, United States, 8Baylor College 
of Medicine Houston, Long Island, United States, 9Hospital Israelita 
Albert Einstein, São Paulo, Brazil, 10Nuovo Ospedale Civile S. Agostino 
Endoscopy Unit, Baggiovara, Italy, 11Digestive Health Associates of Texas, 
Dallas, United States, 12Columbia University, Division of Digestive and 
Liver Diseases, New York, United States, 13Vancouver General Hospital, 
GI, Vancouver, Canada, 14HCFMRP-USP, Surgery and Anatomy, São Paulo, 
Brazil, 15Karolinska Institutet, CLINTEC, Division of Surgery, Department 
of Upper Gastrointestinal Diseases, Stockholm, Sweden, 16Yale University, 
Gastroenterology/Medicine, Guilford, United States, 17University of Colorado, 
Gastroenterology, Aurora, United States, 18Instituto Ecuatoriano de 
Enfermedades Digestivas (IECED) - University Hospital Omni, Espiritu Santo 
University, Guayaquil, Ecuador
contact e-Mail address: amy.tyberg@gmail.com
Introduction: Digital single-operator cholangioscopy (DSOC) (SpyGlass 
DSTM, Boston Scientific, MA, USA) allows for high-definition imaging of the 
biliary tree. The superior visualization has led to the development of two 
different sets of criteria to evaluate and classify indeterminate biliary stric-
tures: the Monaco criteria and the criteria in Carlos Robles-Medranda’s 
publication (CRM). Our objective was to assess the interrater agreement 
(IA) of DSOC interpretation for indeterminate biliary strictures using the 
two newly published criteria.
aims & Methods: 40 de-identified DSOC video clips were sent to 15 in-
terventional endoscopists with experience in cholangioscopy. They were 
asked to score the videos based on the presence of Monaco Classifica-
tion criteria: stricture, lesion, mucosal changes, papillary projections, ul-
ceration, white linear bands or rings, and vessels. Next they scored the 
videos using CRM criteria: villous pattern, polypoid pattern, inflammatory 
pattern, flat pattern, ulcerate pattern and honeycomb pattern. The endos-
copists then diagnosed the clips as neoplastic or non-neoplastic based 
on the criteria. Intraclass correlation (ICC) analysis was done to evaluate 
interrater agreement for both criteria sets and final diagnosis.
results: Clips of 26 malignant lesions and 14 benign lesions were scored. 
The IA using both the Monaco criteria and CRM criteria ranged from poor 
to excellent (range 0.1 to 0.76) and (range 0.1 to 0.62) respectively.; Within 
the Monaco criteria, IA was excellent for lesion (0.75) and fingerlike papil-
lary projections (0.74); good for tortuous vessels (0.7), mucosal features 
(0.62), uniform papillary projections (0.53), and ulceration (0.58); and fair 
for white linear bands (0.4). Within the CRM criteria, the IA was good for 
villous pattern (0.62), flat pattern (0.62), and honeycomb pattern; fair for 
ulcerated pattern (0.56), polypoid pattern (0.52) and inflammatory pattern 
(0.54). The diagnostic IA using Monaco criteria was good (0.65), while the 
diagnostic IA using CRM was fair (0.58). The overall diagnostic accuracy 
using the Monaco classification was 61% and CRM criteria was 57%.
conclusion: The IOA and accuracy rate of DSOC using visual criteria from 
both Monaco Criteria and CRM are similar. However, some criteria from 
both sets suffer from poor IA, thus affecting the overall diagnostic accura-
cy. More formal training and refinements in visual criteria with additional 
validation are needed to improve diagnostic accuracy.
disclosure: Drs. Michel Kahaleh, Amy Tyberg, Amrita Sethi, Prashant Kedia, 
Paul Tarnasky, Divyesh Sejpal, Douglas G. Adler and Raj Shah are consul-
tants for Boston Scientific. Drs. Isaac Raijman, Paul Tarnasky are speakers 
for Boston Scientific. 
P0784 TreaTMenT OuTcOMe Of endOscOPIc PaPILLecTOMy 
On aMPuLLary TuMOrs WITh hIgh-grade adenOMa Or earLy 
adenOcarcInOMa
Kim M.K.1, Chung K.H.2, Paik W.H.1
1Seoul National University Hospital, Internal Medicine, Seoul, Korea 
(Republic of), 2Eulji Hospital, Eulji University School of Medicine, Internal 
Medicine, Seoul, Korea (Republic of)
contact e-Mail address: mink131376@gmail.com
Introduction: Endoscopic papillectomy is widely used for the curative treat-
ment of ampulla of Vater tumors replacing surgical resection. However, 
there are scarce data on the treatment outcome in tumors with high-grade 
adenoma or early adenocarcinoma. The aim of this study was to evaluate 
the outcome after endoscopic papillectomy of ampullary tumor with high-
grade adenoma or early adenocarcinoma.
aims & Methods: From January 2005 to December 2018, all the patients 
underwent endoscopic papillectomy as an initial curative treatment for 
ampullary high-grade adenoma or early adenocarcinoma at Seoul Na-
tional University Hospital were retrospectively reviewed. The patients who 
were confirmed with high-grade adenoma or early adenocarcinoma were 
recommended to undergo subsequent surgical resection. Patients who re-
fused to undergo surgery were followed up at 1 month with endoscopy. If 
residual tumor was identified at follow up endoscopy, it was considered 
as incomplete resection, and progression free survival of patients without 
incomplete resection was evaluated.
results: A total of 230 endoscopic papillectomy were performed during 
study period. Among them, 80 were high-grade adenoma or adenocarci-
noma (46 high-grade adenoma and 34 adenocarcinoma). One patient with 
adenocarcinoma was died after the procedure related complication (mas-
sive hemorrhage). Within 1 month after the procedure, 13 patients received 
subsequent surgical resection and presence of residual tumor on surgical 
specimen was 9 of 13 (69.2%). 21 patients had residual tumor on follow 
up endoscopy (incomplete resection rate of 35%) and 6 patients were lost 
to follow up. Total recurrence was 13 cases during the follow up period. 
Median progression free survival of patients without incomplete resection 
(n = 39) were 963 days (95% confidence interval, 525 - N/A).
conclusion: Incomplete resection rate and probability of remaining tumor 
in surgical specimen were remarkably high after the endoscopic papil-
lectomy of ampullary high-grade adenoma or early adenocarcinoma. In 
addition, tumors recurred frequently in long-term follow-up even after the 
complete resection. Endoscopic papillectomy should be cautiously applied 
in ampullary tumor with high-grade adenoma or early adenocarcinoma.
disclosure: Nothing to disclose 
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P0785 9-(n-MeThyL-L-IsOLeucIne)-cycLOsPOrIn a (nIM811) 
reduce The severITy Of acuTe PancreaTITIs vIa InhIBITIOn 
Of The MITOchOndrIaL TransITIOn POre
Tóth E.1,2, Maléth J.1,3, Závogyán N.1, Erdős R.1, Bálint E.R.4, Rakonczay Z.J.4, 
Venglovecz V.5, Hegyi P.2,6
1University of Szeged, First Department of Medicine, Szeged, Hungary, 
2Hungarian Academy of Sciences and University of Szeged, Momentum 
Translational Gastroenterology Research Group, Szeged, Hungary, 
3University of Szeged, Momentum GI Research Group, Szeged, Hungary, 
4University of Szeged, Department of Pathophysiology, Szeged, Hungary, 
5University of Szeged, Department of Pharmacology and Pharmacotherapy, 
Szeged, Hungary, 6University of Pecs, Centre for Translational Medicine, Pecs, 
Hungary
contact e-Mail address: tothemesem@gmail.com
Introduction: Mitochondrial dysfunction has crucial role in the develop-
ment of acute pancreatitis (AP), however the accurate molecular mecha-
nism is not known yet.
aims & Methods: In this study we investigated a possible molecular target 
- the genetic and pharmacological inhibition of mitochondrial transition 
pore (mPTP, which has a regulator unit; the Cyclophilin D (Cyp D) ) in the 
aspect of AP. Pancreatic ducts (PD) and acinar cells were isolated by enzy-
matic digestion from Bl/6 wild type or Cyp D knock out (Cyp D KO) mice. In 
vitro measurements were performed by confocal and microfluorometry. AP 
was induced by cerulein (10x50µg/kg) or taurocholic acid (2ml/kg,4%). As 
a non immunsupressant pharmacological inhibitor of Cyp D : NIM811 were 
used (in vitro -2µM, in vivo - 5mg/kg or 10 mg/kg NIM811).
results: Genetic and pharmacologic inhibition (NIM811, cyclosporinA) of 
Cyp D significantly reduced the loss of Δψ (in PD and acinar cells) and 
protected PDs HCO
3
 - secretion during the administration of 500µM cheno-
deoxycholic acid (CDC) or 100 mM ethanol (EtOH) and 200µM palnitoleic 
acid (PA) treatment (p< 0.05). Immunfluorescence meaurements revealed 
a significant difference in the amount of the mitochondrial protein TOM20 
levels between the CDC and the EtOH+PA treated WT and mPTP inhibited 
(Cyp D KO or CYA/NIM811) groups (PD and acini). We detected significantly 
reduced apoptosis, necrosis levels in Cyp D KO and NIM811 treated groups 
compared to WT controls (PD and acinar cells). 
Significantly reduced oedema, necrosis, leukocyte infiltration, serum amy-
lase and in vivo ductal fluid secretion levels were detected in samples 
from Cyp D KO animals or NIM811 treated animals (p< 0.05)compared to 
WT controls in vivo.
conclusion: Our data highlights a potencial new pharmacon; the NIM811 
which reduced the severity of AP in mice. Our results also revealed that 
protecting mitochondrial homeostasis have a central role in the function 
of pancreatic ductal epithelial cells presumably by providing ATP for fluid 
and ion secretion. These data suggests that NIM811 could open up new 
perspectives in the treatment of AP.
disclosure: Nothing to disclose 
P0786 nOcIcePTIn recePTOrs as a nOveL TargeT fOr The 
TreaTMenT In acuTe PancreaTITIs
Tarasiuk A., Fichna J.
Medical University of Lodz, Department of Biochemistry, Lodz, Poland
contact e-Mail address: jakub.fichna@umed.lodz.pl
Introduction: The pathophysiology of experimental acute pancreatitis (AP) 
consists of the activation of pancreatic enzymes within acinar cells, the 
release of the activated enzymes in the interstitium, the autodigestion of 
the pancreas, and the release of activated pancreatic enzymes and oth-
er factors into the circulation that result in the development of multiple 
organ dysfunction. Current treatment options are limited, and predomi-
nantly aimed at supportive therapy. Better understanding of the underly-
ing pathophysiology of AP may lead to more targeted therapeutic options, 
potentially leading to improved survival. In general, the effects mediated 
by the nociceptin receptors (NOP) on gastrointestinal functions resemble 
those of classic analgesic opioid agonists and nociceptin, the endogenous 
NOP agonist, has been reported to play an important role in the regulation 
of pancreatic exocrine secretion.
aims & Methods: The primary aim was to examine the potential role of 
NOP in AP.
The AP mouse model was induced by the intraperitoneal (i.p.) administra-
tion of the L-arginine solution followed by second i.p. injection after 1h 
(dose 400mg/100g body weight (BW)). After 12h from the first L-arginine 
i.p. injection, mice were divided into 3 experimental groups: AP mice 
treated with a potent and selective NOP agonist (SCH 21510, i.p. injection 
every 12h; 1 mg/kg BW), AP mice treated with a potent and selective NOP 
antagonist ((±)-J 113397, i.p. injection every 12h; 12 mg/kg BW), and non-
treated AP mice (injected with equivalent volume of 0.9% NaCl every 12h). 
Control mice were injected with equivalent volume of 0.9% NaCl. Mice 
were kept under observation, allowed free access to feed and water, and 
sacrificed at 72h. Pancreatic and lung tissues were collected for histology 
in 10% buffered formalin or snap frozen in liquid nitrogen for myeloper-
oxidase (MPO) analysis.
results: Treatment of mice with SCH 21510 did not influence histopatholog-
ical changes or the MPO activity in pancreas and lungs while (±)-J 113397 
reduced pancreatic injury and MPO activity, as well as inhibited pancreati-
tis-associated lung injury.
conclusion: The results of the present study showed that the modulation of 
NOP through selective NOP antagonist (±)-J 113397 significantly decreased 
AP symptoms and for that reason the receptor may be considered as a 
novel treatment target in AP.
disclosure: Nothing to disclose 
P0787 The funcTIOn Of cfTr cL- channeL In The 
exOcrIne/endOcrIne Pancreas under PaThOLOgIcaL 
cOndITIOns
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Szeged, Hungary, 2University of Szeged, First Department of Medicine, 
Szeged, Hungary, 3Ulster University, Northern Ireland Centre for Stratified 
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Introduction: The exocrine and endocrine pancreas work in close interac-
tion with each other in which the CFTR Cl- channel plays an essential role 
by regulating ductal secretory processes and, as shown by some studies, 
β-cell insulin secretion. The role of the channel under certain pathologi-
cal conditions is not completely known, therefore our aim in this study 
was to investigate the exocrine and endocrine functions in diabetes- or 
pancreatitis-induced wild-type (WT) and CFTR knock out (KO) mice.
aims & Methods: Intra-interlobular pancreatic ductal fragments were iso-
lated from WT and CFTR KO mice by enzymatic digestion. Pancreatic ductal 
fluid and HCO
3
- secretion was measured by in vivo fluid secretion mea-
surements and fluorescence microscopy. Islet functions during i.p. glucose 
tolerance test were investigated by serum insulin and glucagon measure-
ments. Pancreas tissue sections were prepared and immunhistologically 
stained against insulin, glucagon and CFTR to observe islet and ductal 
morphology. Pancreatitis was induced by i.p. injection of cerulein and 
disease severity was assessed by evaluation of histological sections and 
serum amylase measurements. Diabetes was induced by i.p. administra-
tion of streptozotocin and disease development was confirmed by glucose 
tolerance test.
results: Pancreatic ductal fluid and HCO
3
- secretion significantly increased 
in diabetic and decreased in pancreatitis induced mice. Serum levels of 
insulin decreased in diabetic animals, whereas the serum levels of gluca-
gon were elevated. The absence of CFTR decreased ductal fluid and HCO
3
- 
secretion and resulted in lower serum insulin and higher glucagon levels. 
Immunhistological staining of insulin and glucagon in pancreas tissue 
sections revealed a morphological change in CFTR KO islets with higher 
content of α-cells that localized towards the center. Diabetic animals did 
not show difference in CFTR expression compared to the control group, 
whereas mice with pancreatitis showed less staining of intercalated and 
intralobular ducts.
conclusion: Our results suggest that CFTR Cl- channel plays a key role in 
ductal HCO
3
- secretion and has a direct or indirect role in islet function 
and structure.
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Introduction: Numerous case-reports and observational studies suggest 
that several medications, such as azathioprine (AZA) and 5-aminosalycilic 
acid (5-ASA), can induce acute pancreatitis. The important role of pancre-
atic ducts in the pathomechanism of acute pancreatitis has been highlight-
ed recently. Pancreatic ductal functions are essential for the homeostasis 
and integrity of the pancreas. Toxic factors, such as alcohol or bile acids, 
can impair the ductal HCO
3
- secretion which can ultimately lead to pan-
creatic injury. Our knowledge about pancreatic ductal functions in drug 
induced pancreatitis is, however, limited. Since medications can also act 
as toxic factors, we wanted to investigate what effects do AZA and 5-ASA 
have on pancreatic ductal functions and HCO
3
- secretion.
aims & Methods: For investigation of in vivo effect of drugs C57BL6 mice 
were fed daily with 15 and 150 mg/kg AZA, as well as 50 and 500 mg/kg 
5-ASA by gastric feeding needle for one and four weeks. Control mice re-
ceived 10 ml/kg 0.9% NaCl solution. Mice were euthanized and pancreatic 
ductal segments were isolated with microdissection technique. Changes in 
intracellular pH was estimated using a fluorescent dye, BCECF-AM. Cells 
were incubated with 2 µM BCECF-AM in standard Hepes solution for 30 
min at room temperature. To determine HCO
3
- secretion rates and activity 
of basolateral transporters (NHE and NBC), we used the ammonium pulse 
method. Pancreatic ducts from non-treated animals were also isolated and 
HCO
3
- secretion was assessed under normal conditions and under acute 
perfusion with solutions containing different concentrations of AZA and 
5-ASA.
results: In the presence of either 1 or 10 µg/ml AZA or 5-ASA the regen-
eration from alkalosis was significantly lower compared to control ducts, 
which means that either AZA or 5-ASA in 1 and 10 µg/ml concentrations 
can inhibit HCO
3
- -secretion across the apical membrane of the ductal cells. 
We found similar results in case of regeneration from acidosis with the ex-
ception of 1 µg/ml AZA. Administration of 10 µg/ml AZA or 5-ASA and 1 µg/
ml 5-ASA significantly decreased the regeneration of acidosis in pancreatic 
ducts, which suggests that 10 µg/ml AZA or 5-ASA and 1 µg/ml 5-ASA can 
inhibit HCO
3
--influx across the basolateral membrane. However, 1 µg/ml 
AZA caused no significant changes in regeneration from acidosis in isolat-
ed pancreatic ducts. Per os treatment of mice both with AZA and 5-ASA for 
one week caused no changes in HCO
3
--secretion in either concentration. 
Treatment with AZA caused significantly lower basolateral transporter ac-
tivity compared to control animals in a dose dependent manner, while 
treatment with 5-ASA showed no effect. After four weeks of treatment both 
drugs impaired the ductal HCO
3
--secretion rates. No correlation to 5-ASA 
doses was to be observed, while treatment with 150 mg/kg AZA proved 
to be lethal after 12-14 days. Basolateral transporter activity was only im-
paired after treatment with 15 mg/kg AZA.
conclusion: Both azathioprine and 5-aminosalycilic acid can impair ductal 
HCO
3
--secretion under acute exposure. Per os treatment for a longer time-
period with both drugs can also reduce the ductal functions. This effect 
might explain the relatively high number of acute pancreatitis cases in 
patients treated with these medications. In order to understand the exact 
molecular mechanisms further investigations are highly needed. 
This study was supported by OTKA, MTA and ÚNKP
disclosure: Nothing to disclose 
P0789 vx-770 and vx-809 resTOre The aLcOhOL-Induced 
cfTr exPressIOn defecT In PancreaTIc ducTaL ceLLs
Grassalkovich A.1,2, Maléth J.3, Tóth E.1, Madácsy T.3, Rakonczay Jr. Z.4, 
Venglovecz V.2, Hegyi P.1,5
1University of Szeged, First Department of Medicine, Szeged, Hungary, 
2University of Szeged, Department of Pharmacology and Pharmacotherapy, 
Szeged, Hungary, 3University of Szeged, Momentum GI Research Group, 
Szeged, Hungary, 4University of Szeged, Department of Pathophysiology, 
Szeged, Hungary, 5University of Pecs, Centre for Translational Medicine, Pecs, 
Hungary
contact e-Mail address: g.annaa97@gmail.com
Introduction: Our research group previously showed that ethanol (EtOH) 
increases the severity of acute alcohol-induced pancreatitis by disrupt-
ing level and function of the cystic fibrosis transmembrane conductance 
regulator (CFTR). It is well known that Ivacaftor (VX-770) and Lumacaftor 
(VX-809) can correct the impaired CFTR function and expression in cystic 
fibrosis (CF) patients.
aims & Methods: The main aim of the study is to test the effect of these 
compounds on the CFTR expression during EtOH exposure.
Intact guinea pig pancreatic ducts (PDs) and Capan-1 cells were treated 
with different concentration of EtOH (30, 50 and 100 mM) alone and in 
combination with VX-770 (10 µM) and/or VX-809 (10 µM) for 12 hours. CFTR 
expression was evaluated by immunofluorescent staining and our images 
were captured by confocal microscopy.
results: Exposure of Capan-1 cells and guinea pig PDs to EtOH dose-de-
pendently decreased the plasma membrane expression of CFTR. 10 µM 
VX-770 and VX-809 alone had no significant effect on the channel’s ex-
pression, however, both of the compounds dose-dependently prevented 
the EtOH-induced CFTR damage that could be observed even after 2 hours 
of treatments. Co-administration of VX-770 and VX-809 also prevented the 
EtOH-induced (30 and 50 mM) decrease in CFTR expression, however was 
not able to prevent the effect of 100 mM EtOH. In addition, combination of 
the two drugs did not potentiate each other’s effect.
conclusion: Our findings suggest that VX-809 and VX-770 can restore the 
CFTR expression defect caused by alcohol. These data suggest that cor-
recting CFTR function or expression could have therapeutic benefits in 
pancreatitis.
references: This study was supported by the Economic Development and 
Innovation Operative Programme Grants (GINOP-2.3.2-15-2016-00015), the 
National Research, Development and Innovation Office, by the Ministry of 
Human Capacities (EFOP 3.6.2-16-2017-00006), the HAS-USZ Momentum 
Grant (LP2014-10/2017-PÉTER LENDÜLET) and UNKP-18-4 New National 
Excellence Program Of The Ministry Of Human Capacities.
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Hoffmeister A.
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Introduction: AR42J are immortalized pancreatic adenocarcinoma cells 
that share similarities with pancreatic acinar cells. AR42J are often used 
as a cell-culture model of cerulein (CN)-induced acute pancreatitis (AP). 
Nevertheless, it is controversial how to treat AR42J for reliable induction of 
AP. Also, gene knockout or overexpression often remains challenging. In 
this study, we provide evidence for optimized CN-induced AP in AR42J and 
high transfection efficacy using glyoxalase-I (Glo-I) as target of interest.
aims & Methods: Effect of dexamethasone (dexa) and CN on cell morphol-
ogy and amylase secretion was analyzed via ELISA of supernatant. Effect 
of CN on IL-6 and TNF-alpha and NF-κB-p65 was measured via qRT-PCR, 
ELISA and Westernblot (WB). Transfection efficacy was measured by WB, 
qRT-PCR and immune fluorescence of pEGFP-N1-Glo-I-Vector and Glo-I-
siRNA
results: Treatment of AR42J with 100nm dexamethasone is mandatory for 
differentiation to an acinar cell like phenotype and amylase production. 
CN resulted in secretion of amylase but does not influence amylase pro-
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duction. High levels of amylase secretion were detected between 3 and 
24 hours of incubation. Treatment with LPS alone or in combination with 
CN did not influence amylase secretion. CN led neither to increased secre-
tion nor production of TNF-alpha. No CN-induced elevation of IL-6 was 
observed. CN-induced stimulation of NF-κB was found to be highest on 
protein level after 6h of incubation. Only cells up to a passage of 35 should 
be used for experiments. DNA-amount of 2.5µg was sufficient to induce 
Glo-I overexpression on protein and mRNA levels with highest effect after 
12 to 24 hours. Knockdown was achieved by using 30pM of Glo-I-siRNA 
leading to effective reduction of protein levels after 72 hours. AR42J cell 
passages of 35 or more should not be used for CN-induced AP.
conclusion: CN-induced AP in AR42J cells is a reliable in-vitro model of AP 
but specific conditions are mandatory to obtain reproducible data.
disclosure: Nothing to disclose 
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Introduction: Inflammation caused by oxidative stress (ROS) is an essential 
mechanism for initiation and deterioration of acute pancreatitis (AP). An 
important source for ROS comprises the reactive compound methylglyoxal 
(MGO) itself and the MGO-derived formation of advanced glycation end-
products (AGEs). AGEs bind to RAGE and activate NF-κB leading to pro-
duction of proinflammatory cytokines. MGO is detoxified by glyoxalase-I 
(Glo-I). The importance of Glo-I has been shown in different models of 
inflammation and carcinogenesis. Nevertheless, the role of Glo-I and MGO 
in AP has not been evaluated so far. This study analyzed Glo-I in cerulein 
(CN)-induced AP and determined the effects of Glo-I knockdown, -overex-
pression and pharmacological modulation.
aims & Methods: AP was induced in C57BL/J6 mice by 10 i.p. injections of 
50 µg/kg b.w. CN. Glo-I was analyzed in explanted pancreata by Western-
blot (WB), qRT-PCR and immunohistochemistry. AR42J cells were differ-
entiated by dexamethasone and an AP was induced in-vitro by 100nM CN. 
Cells were co-treated with ethyl pyruvate (EP) and BrBzGSHCp2, two Glo-I 
modulators. Knockdown and overexpression of Glo-I was achieved by tran-
sient transfection with Glo-I siRNA and pEGFP-N1-Glo-I-Vector. Amylase 
secretion, TNF-α production (ELISA), Expression of Glo-I, RAGE and NF-κB 
(WB) were measured.
results: Glo-I was significantly upregulated on protein and mRNA levels 
in CN treated mice. In AR42J cells, treatment with EP and BrBzGSHCp2 
resulted in significant reduction of CN-induced amylase secretion. CN-in-
duced NF-κB expression was attenuated by BrBzGSHCp2 but not EP. Over-
expression of Glo-I resulted in significant reduction of CN-induced amy-
lase levels. Glo-I knockdown was accompanied by consecutive increase of 
amylase-secretion. Interestingly, Glo-I knockdown but not overexpression 
reduced NF-κB expression via decrease of RAGE.
conclusion: Glo-I is overexpressed in a model of CN-induced AP. Pharma-
cologic modulation and overexpression of Glo-I reduced amylase secretion 
in AP in vitro. Targeting Glo-I in AP could be an innovative therapeutic 
approach for future in vivo studies.
disclosure: Nothing to disclose 
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Introduction: Severe hypertriglyceridemia is an important, well-known 
cause of acute pancreatitis (AP). Existing data on clinical characteristics of 
hypertriglyceridemia-induced acute pancreatitis(HTG-AP) are very limited.
aims & Methods: The aim of this project was examine prevalence, pa-
tient characteristics and clinical outcomes of HTG-AP patients compared to 
other etiologies from a large, international cohort study.
Acute Pancreatitis Patient Registry to Examine Novel Therapies In Clinical 
Experience (APPRENTICE) is a global, multicenter, cohort study. AP pa-
tients were prospectively enrolled in 22 international centers. Data were 
collected via standardized questionnaires and registered in REDCap (Re-
search Electronic Data Capture). Revised Atlanta Classification definitions 
were used to determine severity. Primary HTG-AP was confirmed when 
common etiologies were excluded and serum triglycerides were>500mg/
dl. Pearson’s chi-squared test and t-test were used to compare categori-
cal and continuous variables, respectively. Multivariable logistic regression 
model was used with severe/moderate condition as the outcome.
results: 1478 patients were prospectively enrolled, of whom 69 diagnosed 
with HTG-AP (prevalence=4.6%). Compared to the other etiologies, HTG-
AP patients were younger (40.4 vs 50 years; p< 0.0001) had higher BMI 
(30.4 vs 27.5kg/m2; p=0.0002) and more frequent alcohol use (70.6% vs 
48.9%;p< 0.0001), were more likely diabetics (59.4% vs 15.3%; p< 0.0001), 
and had more frequently recurrent AP (RAP) (40.6% vs 24%; p=0.002). 
Median TG level for HTG-AP patients was 1675 mg/dl and 133 mg/dl for the 
others. In terms of clinical outcomes, ICU admission was more frequent in 
HTG-AP patients (26.1% vs 16.4; p=0.036), but no significant difference was 
found in terms of rate of moderate/severe AP, length of hospital stay, or 
mortality. At the multivariable logistic regression, male sex and increasing 
BMI were associated with risk of moderate/severe AP while HTG-AP was 
not. Within the HTG-AP population, no differences were found in terms of 
patient and hospitalization features based on magnitude of HTG levels.
conclusion: HTG-AP accounts for 4.6% of AP cases, affects younger, over-
weight and diabetic patients, and those who use alcohol, require ICU and 
have RAP more often compared to other etiologies. This suggests that HTG-
AP has a higher cost compared to other etiologies. However, no difference 
was found in terms of severity, length of stay or mortality. Also, basal HTG 
levels do not seem to affect the clinical outcome of these patients.
disclosure: Nothing to disclose 
P0793 a BedsIde scOre PredIcTIng cOMMOn BILe ducT sTOne 
In PaTIenTs WITh acuTe BILIary PancreaTITIs
Khoury T.1, Kadah A.2, Mari A.3, Mahamid M.4, Sbeit W.5
1Galilee Medical Center, Department of Gastroenterology, Naharia, Israel, 
2Galilee Medical Center, Gastroenterology, Nahariya, Israel, 3Nazareth EMMS 
Hospital, Gastroenterology, Qalansawa, Israel, 4Sharee Zedek Medical Center 
and the Nazareth Hospital EMMS, Gastroenterology and Liver Disaeses, 
Jerusalem, Israel, 5Galilee Medical Center, Nahariya, Israel
contact e-Mail address: tawfik.khoury.83@gmail.com
Introduction: Gallstones are considered the most common cause of acute 
pancreatitis. Despite that most of the stones are expelled spontaneously 
through the papilla due to their small size; about 20% to 30% of pa-
tients with acute biliary pancreatitis (ABP) will have persistent CBD stones. 
Therefore, the identification of retained common bile duct stone after an 
acute episode of biliary pancreatitis is of paramount importance since 
stone extraction is mandatory.
aims & Methods: We aimed to generate a simple non-invasive scor-
ing model to predict the presence of CBD stones in patients with biliary 
pancreatitis. We performed a retrospective study at Galilee Medical Cen-
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ter including patients with an established diagnosis of pancreatitis with 
suspected CBD stone. One hundred and fifty-four patients were included, 
among them thirty-three patients (21.5%) were diagnosed with CBD stone 
by endoscopic ultrasound (US).
results: In univariate analysis, age (OR 1.048, P=0.0004), aspartate trans-
aminase (OR 1.002, P=0.0015), alkaline phosphatase (OR 1.005, P=0.0005), 
gamma-glutamyl transferase (GGT) (OR 1.003, P=0.0002) and CBD width 
by US (OR 1.187, P=0.0445) were significantly associated with CBD stone. 
In multivariate regression analysis, three parameters were identified to 
significantly predict CBD stone; age (OR 1.062, P=0.0005), GGT level (OR 
1.003, P=0.0003) and dilated CBD (OR 3.685, P=0.027), with area under 
the curve of 0.8433. We developed a diagnostic score that included the 3 
parameters that were significant on multivariate analysis, with assignment 
of weights for each variable according to the co-efficient estimate. A score 
that ranges from 51.28 to 73.7 has a very high specificity (90% - 100%) for 
CBD stones, while a low score that ranges from 9.16 to 41.04 has a high 
sensitivity (82% - 100%). By performing internal validation, the NPV of the 
low score group was 93%
conclusion: We recommend incorporating this score as an aid for stratify-
ing into patients with acute biliary pancreatitis with low or high probabil-
ity for the presence of CBD stone
disclosure: Nothing to disclose 
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Introduction: Recent guidelines advocate the step-up approach for the 
management of infected pancreatic necrosis (IPN). Nearly half of patients 
will require secondary necrosectomy after drainage. A previous study (1) 
identified 4 risk factors of catheter drainage failure: male gender, multiple 
organ failure, percentage of necrosis and heterogeneous collection, lead-
ing to propose a nomogram with an area under receiver operating char-
acteristic (ROC) curve of 0.76. Our primary objective was to validate this 
novel nomogram. Our secondary goals were to explore others potential 
predictors of failure of catheter drainage.
aims & Methods: We retrospectively studied 72 consecutive patients admit-
ted in 3 university hospitals for suspected IPN requiring interventions by 
catheter drainage first between 2012 and 2016 . All computed tomography 
(CT) examinations performed prior to the first drainage procedure were 
reviewed by a single blinded radiologist. Drainage success or failure rates 
were assessed. Success was defined by survival without any additional 
necrosectomy, while failure was defined by death and/or additional ne-
crosectomy after the drainage procedure because of lack of improvement. 
ROC curve of predictors of drainage failure according to Hollemans nomo-
gram and area under the curve (AUC) were also calculated.
results: Catheter drainage alone achieved success in 44.4% of patients. 
Nomogram predicted catheter drainage failure with an area under the ROC 
curve of 0.71. Scores ≤ 8 (low) or 40 (maximum) resulted in 100% success 
or failure rates of primary catheter drainage, respectively. In multivari-
ate analysis, catheter drainage failure was independently associated with 
body mass index (BMI) (OR: 1.14; 95% CI: 1.01-1.29; P: 0.02), heterogeneous 
collection (OR: 18.84; 95% CI: 2.02-175.86; P: 0.01) and respiratory failure 
24 hours prior catheter drainage (OR: 16.76; 95% CI: 1.94-144.4; P: 0.01).
conclusion: More than half of patients required necrosectomy because of 
failure of radiological catheter drainage. However, Hollemans nomogram 
can be useful to predict catheter drainage failure, especially for extreme 
values. Heterogeneous collection on CT and respiratory failure 24h prior 
to drainage were strongly associated with catheter drainage failure. Early 
identification of patients at risk of drainage failure alone might help im-
proving their management and reducing antibiotics duration.
references: Hollemans RA, Bollen TL, van Brunschot S, Bakker OJ, Ahmed 
Ali U, van Goor H, et al. Predicting Success of Catheter Drainage in Infected 
Necrotizing Pancreatitis. Ann Surg. avr 2016;263(4):787-92.
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Introduction: Recent guidelines ruled out prophylactic antibiotics to pre-
vent IPN and advocate the step-up approach for the management of IPN. 
Emerging drug resistant bacteria is a rising problem among SAP and ICU 
patients. However, there is no recommendation regarding antimicro-
bial therapy management for IPN (molecules and duration). In real life, 
many patients will have culture levied under broad spectrum antimicro-
bial therapy. Our primary objective was to determine the impact of prior 
antibiotherapy on samples cultures collected during interventions for a 
suspected infected pancreatic necrosis (IPN) among patients admitted for 
severe acute pancreatitis (SAP) and to determine if prior antibiotic therapy 
negatively affects the results of the culture. Description of microbiological 
species and their patterns of resistance were our secondary goals.
aims & Methods: We retrospectively studied 62 consecutive patients ad-
mitted in ICU for suspected IPN requiring interventions. We collected data 
about microbiological samples, as well as antimicrobial therapy type and 
duration before and after intervention for suspected IPN. We classified 
species according to the definitions proposed by Magiorakos et al.
results: IPN was confirmed for 48 patients, with 137 samples collected 
during interventions. 57% of positive cultures were levied under efficient 
antibiotherapy, previous antibiotherapy did not influence cultures results 
(p=0.84). 1/3 of samples were polymicrobial. Half of the patients developed 
multi and extensively drug resistant bacteria. Prolonged antibiotics did not 
sterilized collections or necrotic tissues for extensively drug resistant bac-
teria that were founded into necrotic collection even after several weeks 
of adapted antibiotics.
conclusion: Previous antibiotherapy did not influence microbiological cul-
ture results and prolonged adapted broad-spectrum antibiotics did not 
allow sterilizing necrotic tissue or fluid collections. Our results showed a 
50% prevalence of drug resistant bacteria. Negative cultures among pa-
tients under antibiotics should question the diagnosis of IPN and antibi-
otics discontinuation. Strategies to reduce antimicrobial therapy use and 
exposure in the course of SAP are needed. Futures prospective studies 
should determine the optimal antimicrobial therapy duration.
references: Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas 
ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and 
pandrug-resistant bacteria: an international expert proposal for interim 
standard definitions for acquired resistance. Clin Microbiol Infect Off Publ 
Eur Soc Clin Microbiol Infect Dis. mars 2012;18(3):268-81.
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P0796 The PrOgnOsTIc rOLe Of faTTy LIver dIsease In acuTe 
PancreaTITIs: a MeTa-anaLysIs
Váncsa S.1, Szakács Z.1, Hegyi P.1, Erőss B.1, Németh D.1, Pàr G.2, 
on Behalf of the Hungarian Pancreatic Study Group
1Institute for Translational Medicine, Medical School, University of Pécs, 
Pécs, Hungary, 2Division of Gastroenterology, First Department of Medicine, 
Medical School, University of Pécs, Pécs, Hungary
contact e-Mail address: vancsasz@yahoo.com
Introduction: Acute pancreatitis (AP) is a life-threatening condition with 
an average mortality of 2-5%, which can rise up to 30% in severe cases. 
Tremendous efforts were made to identify factors that can predict diseases 
course. A potential predictor may be pre-existing fatty liver disease (FLD).
aims & Methods: The aim of this study was to perform a meta-analysis on 
the prognostic role of FLD in AP. 
We performed a systematic search in seven medical databases for cohort 
studies reporting on adult AP cases with and without FLD of any origin 
proven by cross-sectional imaging and/or histology. The primary out-
come was in-hospital mortality, secondary outcomes included AP severity, 
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length of hospital stay (LOH), necrotizing AP and systemic inflammatory 
response syndrome (SIRS). We calculated risk ratio (RR) for categorical 
variables (i.e., mortality, AP severity, and necrosis) and weighted mean 
difference (WMD) for LOH with 95% confidence intervals (CIs) with the 
random effect model. Heterogeneity was tested with I2-statistics.
results: Twelve studies containing data on 6233 patients were eligible for 
meta-analysis. Patients with FLD were more likely to die (RR=3.24, CI: 1.65-
6.34, p=0.001; I2=41.6%), to develop severe (RR=2.27, CI: 1.9-2.7, p< 0.001; 
I2=0.0%), and necrotizing AP (RR=2.37, CI: 1.92-2.92, p< 0.001; I2=30.4%) 
compared to those not having pre-existing FLD. The presence of systemic 
complications affecting at least one organ (RR=2.03, CI: 1.54-2.67, p< 0.001; 
I2=68.1%) and SIRS (RR=1.94, CI: 1.64-2.29, p< 0.001; I2=34.4%) was signifi-
cantly higher in the FLD group. There was a tendency for longer LOH with 
FLD (WMD=2.08 days, CI: 1.09-3.07, p< 0.001; I2=0.0%).
conclusion: Our results showed that fatty liver disease is a risk factor of 
mortality, severe disease course, necrosis, systemic complications and lon-
ger length of hospitalization in AP; therefore, we suggest the incorporation 
of FLD into the prognostic tools in AP.
disclosure: Nothing to disclose 
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Introduction: IPN is associated with a high morbimortality. Current treat-
ment of IPN is based on minimally invasive methods, mainly endoscopic 
or percutaneous drainage and necrosectomy. We designed a step-up 
protocol for the treatment of IPN based on local administration of anti-
biotics with drainage previous endoscopic necrosectomy (Pancreatology 
2016;16:719-25).
aims & Methods: Aim of our study was to analyse the proportion of pa-
tients requiring necrosectomy in our step-up protocol for IPN. Methods: 
Retrospective, observational and descriptive study of patients with acute 
pancreatitis (AP) admitted to our department between January 2015 and 
December 2018. Cases with pancreatic necrosis (PN) and IPN (defined as 
positive culture of the necrosis) were evaluated. The number of patients 
who responded to each of the three steps of our protocol were analysed: 
Step 1, systemic antibiotics; step 2, endoscopic transmural drainage + local 
administration of antibiotics; step 3, endoscopic necrosectomy. Transmural 
drainage was performed by endoscopic ultrasound, by using plastics and/
or metal stents. During the same procedure, a nasocystic catheter was 
placed deep in the necrotic cavity through metal stents or in parallel to 
plastic stents. Endoscopic necrosectomy was performed when previous 
steps failed. Data are shown as percentage.
results: 1158 patients with AP were included. 110 patients (8.4%) suffered 
from necrotising pancreatitis, and 48 of them (42.6% of necrotising pan-
creatitis) had IPN and were treated with systemic antibiotics. Nineteen 
patients (39.6% of IPN) responded to systemic antibiotics. Six patients with 
IPN on systemic antibiotics died within the first 4 weeks of disease before 
a second therapeutic step could be applied. Three patients underwent ur-
gent surgical necrosectomy within the first 4 weeks of disease with a 100% 
mortality. The remaining 20 patients underwent endoscopic transmural 
drainage and local antibiotic administration through nasocystic catheter. 
Nine of them (47.4%) did well and 9 needed endoscopic necrosectomy 
(45% of all IPN). Two patients died before necrosectomy could be per-
formed. Overall mortality of the total cohort of AP was 2.53%.
conclusion: Addition of local infusion of antibiotics through a nasocystic 
catheter to endoscopic transmural drainage avoids the need of necrosec-
tomy in half of patients with IPN, who did not respond to systemic anti-
biotics. These data justify a randomized controlled trial to evaluate this 
approach.
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Introduction: Both alcohol consumption and smoking have been reported 
to be harmful to the pancreas and these addictions often go together.
aims & Methods: Our aim is to epidemiologically characterize smoking 
and alcohol consumption habits and evaluate their independent and joint 
clinical effects in acute pancreatitis (AP). 
A total of 1435 adult patient with the diagnosis of AP from 28 healthcare 
centers were enrolled between 2012 and 2017 by the Hungarian Pancreatic 
Study Group. Four groups of patients were retrospectively formed: non-
smoker-non-drinker (NS-ND), smoker-non-drinker (S-ND), non-smoker-
drinker (NS-D) and smoker-drinker (S-D).
results: 693 (48.7%) of the patients were ND-NS, 119 (8.4%) S-ND, 334 
(23.5%) NS-D and 278 (19.5%) were S-D. The average age of onset of AP 
was significantly lower in the S-ND, NS-D and S-D groups as compared to 
the NS-ND group (51.7±15.1, 54.9±16.0 and 46.3±11.9 years respectively vs. 
61.1±17.6, p< 0.001). The male/female ratio was 0.6 in the ND-NS group, 
0.9 in the S-ND, 3.2 in the NS-D and 6.0 in the S-D groups. Drinking alone 
had no effect on the BMI (NS-ND: 28.3±5.9, NS-D: 28.2±5.1), but smoking 
in addition to drinking was associated with lower BMI (S-ND: 27.5±6.5 and 
S-D: 25.7±5.3, p< 0.001). 
There are fewer mild cases and more moderately severe cases in the NS-D 
and S-D groups as compared to the NS-ND group of patients. To reason 
this change, we can observe an increase in the rate of local complica-
tions (ND-NS: 34.4%, NS-D: 37.5%, S-D: 44.1%) including fluid collection 
(28.3%, 31.3%, 35.5%), pseudocyst (9.0%, 9.2%, 13.3%) and necrosis 
(8.8%, 11.0%, 11.5%). 
Drinking and smoking together also elevate the risk for recurrent AP (RAP). 
18.9% of the patients had RAP in the NS-ND, while 23.5% in the NS-D and 
31.9% in the S-D groups.
Concerning on admission serum blood parameters, smoking together with 
drinking has a significant synergic moderating effect on amylase and li-
pase levels. The amylase in the S-D group was significantly lower than in 
the NS-ND group (710 vs. 1309, p< 0.05). Smoking and alcohol consump-
tion together are associated with higher levels of C-reactive protein (CRP) 
but has no effect on white blood cell count.
conclusion: Drinking and smoking together result in the onset of pancre-
atitis 15 years earlier, in addition, it elevates the risk of recurrent disease. 
Drinking and smoking synergize with each other and increase the rate of 
local complications and moderately severe cases.
disclosure: Nothing to disclose 
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Introduction: Although endoscopy is a cornerstone in the treatment of 
walled-off pancreatic necrosis (WON), long term outcomes are unclear.
aims & Methods: We performed a retrospective cohort study of patients 
with WON who have been treated with transgastric drainage and necro-
sectomy (ETDN) in a tertiary referral center. Primary outcomes were devel-
opment of exocrine- or endocrine insufficiency, use of analgesics, number 
of WON- and non-WON related re-admissions, and need for endoscopic 
intervention during follow-up due to main pancreatic duct (MPD) abnor-
malities. From Jan. 2010 to Dec. 2018, 215 patients with WON underwent 
ETDN in our center. We excluded patients who underwent ETDN more than 
90 days from the onset of acute pancreatitis (n=35), patients with known 
chronic pancreatitis (n=4), patients who died during admission (n=29) and 
during follow-up (n=18), and patient with missing data (n=7). We regis-
tered patient characteristics including the development of exocrine (need 
for pancreatic enzyme replacement therapy) and endocrine insufficiency 
(need for peroral antidiabetics or insulin), number of WON-related re-
admissions, use of analgesics, and need for endoscopic therapy on MPD 
during follow-up.
results: We included 122 patients (68 males, median age 57 years). Gall-
stones were the main etiology (52%). Median time from onset to index 
intervention was 33 days (range 11-88). ETDN was performed primarily due 
to infection (81%). Median computer tomography severity index (CTSI) and 
modified CTSI scores were 7 and 9, respectively. Median follow-up time 
was 52 months (range 11-112 months). 
During follow-up, 21 (17%) patients developed exocrine insufficiency and 
33 (27%) developed endocrine insufficiency, ten patients (8%) needed po-
tent opioids and ten patients needed mild opioids. The median number 
on WON-related readmissions was 0 (range 0-16) and 18 (15%) patients 
needed endoscopic therapy on MPD during follow-up. 
Presence of diabetes at index endoscopy (OR 7.57; 95% CI, 2.54-22.55; p< 
0.001) and endoscopic therapy on MPD during follow-up (OR 7.67; 95% 
CI, 2.55-23.09; p< 0.001) both predicted development of exocrine insuffi-
ciency in univariate regression analyses. In multivariate analysis, only en-
doscopic therapy on MPD predicted development of exocrine insufficiency 
(OR 7.98; 95% CI, 2.37-26.83; p< 0.001). CTSI (OR 1.55; 95% CI, 1.23-1.97; p< 
0.001) and modified CTSI (OR 1.71; 95% CI, 1.25-2.34; p< 0.001) predicted 
development of endocrine insufficiency both in univariate and multivari-
ate analysis.
conclusion: This study reports long-term data on patients with WON treat-
ed with ETDN. The proportion with endocrine and exocrine insufficiency 
was relatively small as was the proportion with opioid requiring pain. 
WON-related readmissions were rare. 
This suggests that the treatment has beneficial long-term outcomes. The 
risk of developing exocrine and endocrine insufficiency is correlated to 
main pancreatic duct abnormalities and imaging severity index, respec-
tively.
disclosure: Nothing to disclose 
P0801 PrOgnOsIs Of acuTe PancreaTITIs assOcIaTed WITh 
hIgh seruM TrIgLycerIdes Managed In a TerTIary cenTer Of 
gasTrOenTerOLOgy
Bunduc S.1,2, Covasa L.1, Iacob R.A.1,2, Gheorghe C.1,2
1I. C. Fundeni, Gastroenterology and Hepatology, Bucharest, Romania, 2Carol 
Davila University of Medicine and Pharmacy, Bucharest, Romania
contact e-Mail address: stfnbndc@gmail.com
Introduction: After alcohol and gallstones, hypertriglyceridemia (HTG) is 
the third most common cause of acute pancreatitis (AP). Data in the litera-
ture regarding correlation between level of serum tryglicerides (TG) and 
disease severity is at variance.
aims & Methods: The objective in our study was to analyze the prognosis 
of AP in patients who associated high level of serum TG. Data was col-
lected in a retrospective manner and included all cases of AP admitted in 
our clinic between 1st of January 2014 and 31st of December 2018. Revised 
Atlanta Classification was used to define severity. Levels of TG were mea-
sured at admission and 48 hours afterwards - the first value obtained 
during day 3 to 7 of hospitalization was considered. They were recorded 
according to the definition of the National Cholesterol Education Program/ 
Adult Treatment Panel III (NCEP/ATPIII) as high - 200-499 mg/dL and very 
high - > 499 mg/dL respectively.
results: There were 123 cases of AP admitted in our center during the 
5-year study period. We found no correlation between abnormal TG levels 
and severity, mortality rate, admission duration and local complications 
rate, defined as mentioned. High TG at admission and persistent high TG 
during hospitalization were significantly associated with occurrence of 
systemic complications, at a similar rate ( 27 .8%, p = 0.03 and 27.3%, p = 
0.04 respectively). Acute kidney injury was more prevalent in those with 
high TG at admission ( 16.7 %, p = 0.02), while sepsis occurred more often 
in those with persistently high TG ( 13.6 %, p = 0.01). Only persistently high 
TG levels correlated with necessity (27%, p = 0.05 ) and a longer duration 
(p = 0.03) of Intensive Care Unit (ICU) admission. Presence of very high 
TG level at admission correlated with length of ICU stay. No correlations 
were found between persistence of very high TG during hospitalization (8, 
6.5%), and other registered variables.
conclusion: In our study HTG was significantly associated with an in-
creased incidence of systemic complications in AP. Nevertheless need for 
ICU admission and length of stay were only correlated with persistent HTG 
longer than 48 hours after admission. Mortality and severity of AP were 
not impacted by presence of HTG in our group.
disclosure: Nothing to disclose 
P0802 LefT venTrIcuLar assIsT devIce (Lvad) use Is 
assOcIaTed WITh acuTe PancreaTITIs: a MuLTIcenTer 
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Corral J.E.1, Yarlagadda B.2, Vemireddy L.P.2, Kroner P.T.3, Goswami R.M.2, 
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Introduction: Case series suggest that left ventricular assist devices (LVAD) 
increase the risk of acute pancreatitis. Hemolysis and ischemia have been 
proposed as putative mechanisms. Cardiac transplant recipients also have 
perioperative ischemia and medications that can potentially cause pancre-
atic inflammation.
aims & Methods: We aim to compare the incidence of acute pancreatitis 
in patients receiving advanced heart failure therapies. Our secondary goal 
is to identify potential risk factors associated with acute pancreatitis in the 
same population. 
A retrospective cohort of patients with advanced heart failure (NYHA class 
III and IV) was followed from 2012 to 2018 in three referral hospitals. Three 
groups were compared: LVAD recipients (final destination), transplant re-
cipients (with LVAD as a bridge for transplant, or direct transplant recipi-
ents) and controls that refused or did not qualified for advanced therapies. 
Patients were enrolled the day they had an AICD placed (or the day they 
presented to our heart failure clinic).
Demographics, body mass index (BMI), tobacco and alcohol use, baseline 
ejection fraction, history of gallstone disease and development of hemo-
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lysis were recorded. Log-rank test and adjusted hazard ratios compared 
pancreatitis incidence between groups. Kaplan Meier curves were elabo-
rated.
results: 1,344 patients were included in the cohort: 407 with LVAD as final 
destination, 589 with transplant (233 with LVAD bridge and 356 transplant-
ed directly) and 348 controls. 987 (73.4%) patients were male, mean age 
was 60.9 ±14.3 years, average BMI was 28.4 ±5.9Kg/m2. 701 (55.3%) pa-
tients had previous alcohol use, and 263 (21.5%) had history of gallstones. 
Mean follow-up was 85.7 ±61.2 months. 423 (31.5%) patients died during 
cohort follow-up. 
A total of 39 cases of acute pancreatitis were reported. Annual incidence 
was 6.7 cases per 1000 LVAD patients, 2.3 per 1000 transplant recipients, 
4.1 per 1000 patients on bridge therapy (after receiving a heart transplant) 
and 3.2 per 1000 controls (log-rank test for equality p=0.03). Combined, 
the annual incidence of acute pancreatitis was 5.6 cases per 1000 LVAD 
users and 2.7 cases in 1000 nonusers (p=0.009). 
Unadjusted hazard ratio for acute pancreatitis in LVAD was 2.4 (95%CI 1.2-
4.6) and 2.0 (95%CI 0.7-5.5) after adjusting for gender, age, BMI, ejection 
fraction, alcohol use, smoking, history of gallstones disease and hemoly-
sis. History of gallstone disease had the highest effect on developing acute 
pancreatitis (adjusted hazard ratio 4.0, 95%CI 1.6-9.9).
Among the patients who developed pancreatitis, 4 (10.5%) had history of 
significant alcohol use and 19 (48.7%) moderate use; 17 (46.9%) had his-
tory of smoking, 21 (55.3%) had history of gallstone disease and 14 (36.8%) 
hemolysis.
Prevalence of gallstone disease was similar in patients with or without 
LVAD (21.0% vs. 22.0% p=0.6). History of hemolysis was significantly high-
er in patients with LVAD (6.0% vs. 35.0%, p< 0.001). 
Abdominal imaging showed a spectrum of disease including a normal 
pancreas (17.9%), edematous pancreatitis (44.7%), small fluid collections 
(17.9%) and hemorrhagic/necrotic pancreatitis (5.3%).
conclusion: Patients with LVAD have twice the risk of developing acute 
pancreatitis compared to heart transplant recipients and heart failure con-
trols. The effect of LVAD seems to dissipate once patients undergo cardiac 
transplantation and gallstone disease likely plays an important effect in 
pathogenesis. Studies that elucidate the mechanisms behind pancreatic 
injury in advanced heart failure and interventions to prevent them are 
strongly suggested.
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Introduction: Hypertriglyceridaemia (HTG) is the third most common cause 
of acute pancreatitis (AP) and opposite to the other etiologies, most often 
moderate or severe AP develop. Unfortunately, only small amount of data 
are available concerning its dose-dependency.
aims & Methods: Our aim was to investigate the dose-dependent effects of 
serum triglyceride levels on AP. Data of 716 patients were retrospectively an-
alyzed from the prospectively collected, international, multicenter AP regis-
try operated by the Hungarian Pancreatic Study Group (HPSG). AP patients 
over 18-year-old, who underwent triglyceride measurement within the first 
three days were included from 31 centers and 12 countries. Six groups were 
created based on the highest triglyceride level of the initiating three days 
(< 1.7 mmol/l, 1.7-2.19 mmol/l, 2.2-5.59 mmol/l, 5.6-11.19 mmol/l, 11.2-22.39 
mmol/l, >22.4 mmol/l). HTG was indicated above 1.7 mmol/l.
results: The total data quality was 81%. 30.6% (n=219) of the patients 
presented with HTG. The ratio of male gender in the whole cohort was 
59% (n=421) and was significantly elevated in the HTG group, compared to 
patients with normal triglyceride level (p< 0.001). BMI and diabetes in the 
personal history correlated with the hypertriglyceride level (p=0.001, p< 
0.001). Triglyceride dose-dependently and above 22.4 mmol/l significantly 
(p=0.003) elevated the risk for severe pancreatitis. HTG above 11.2 mmol/l 
was significantly related to a higher risk for local complications (p< 0.001), 
local fluid collection (p=0.004), pancreas necrosis (p=0.02) and HTG above 
5.6 mmol/l was significantly related to a higher incidence of diabetes as 
complication (p=0.008). Risk for systemic organ failure was significantly 
elevated above 22.4 mmol/l triglyceride (p=0.002).
conclusion: Serum triglyceride has a dose-dependent effect on the risk for 
local and systemic complications and severity of AP.
disclosure: Nothing to disclose 
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Introduction: Chymotrypsinogen C (CTRC) plays a significant role in regu-
lating trypsinogen activation. Early activation of trypsinogen inside the 
pancreas is a key molecular mechanism in the pathogenesis of pancreatitis 
that results in self-digestion and local inflammation of the organ. Loss-of-
function mutations in the CTRC gene encoding Chymotrypsinogen C impair 
either the catalytic activity or the expression of the enzyme. Impaired ex-
pression of CTRC might be caused by variants in the 5’ upstream region, 
however, this region of the gene was not investigated yet.
aims & Methods: Our aim was to sequence the 5’ upstream region of the 
CTRC gene in patients and controls in order to identify variants that may 
predispose to chronic pancreatitis. We selected 117 patients with non-alco-
holic (NACP), 147 patients with alcoholic chronic pancreatitis (ACP) and 263 
controls recruited by the Hungarian Pancreatic Study Group (HPSG - www.
pancreas.hu). Mutations within the ~1.4 kb CTRC 5’ upstream region were 
analyzed by Sanger sequencing.
results: We found 2 common polymorphisms (c.-913A>G and c.-811G>A) 
and 4 further variants (c.-993G>T, c.-314AAAT[5], c.-92C>T and c.-59C>T) in 
the ~1.4 kb long 5’ upstream region of the CTRC gene. However, we found 
that the variant c.-913A>G slightly accumulated in patients compared to 
controls, genotype and allelic distribution of the identified variants were 
generally comparable between each group of patients and controls.
conclusion: Based on our preliminary results, the identified mutations in 
the 1.4 kb long 5’ upstream region of the CTRC gene are not associated with 
chronic pancreatitis.
references: Hegyi E, Sahin-Tóth M. Genetic Risk in Chronic Pancreatitis: 
The Trypsin-Dependent Pathway. Dig Dis Sci. 2017;62(7):1692-1701.
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Introduction: Smoking represents an independent risk factor for the devel-
opment of chronic pancreatitis (CP). It is well documented that secretion 
of pancreatic ductal alkaline fluid (which is regulated mostly by the anion 
exchanger and cystic fibrosis conductancia regulator- CFTR) is diminished 
in CP. Earlier we demonstrated that cigarette smoking significantly dimin-
ishes fluid and HCO
3
- secretion, and CFTR activity in guinea pig pancreas, 
however, the underlying mechanisms are unknown. The aim of this study 
was to understand the pathomechanism of smoke-induced pancreatic 
ductal cell damage.
aims & Methods: CFTR function was measured in non-smoker and smoker 
patients with, or without chronic pancreatitis based on Cl- concentrations in 
sweat. The effect of smoking on CFTR expression was analysed by RT-qPCR, 
immunofluorescence staining. Pancreatic ducts were isolated from guinea 
pig pancreas. Cigarette smoke extract (CSE) was prepared by smoking of 
15 cigarettes into 10 ml distilled water. Intracellular pH, Ca2+ concentration 
and ATP levels were evaluated by fluorescence microscopy. Mitochondrial 
membrane potential was measured by using confocal microscopy.
results: Cl- concentrations increased in sweat samples from patients from 
CP and further elevation was detected in a smoker group. Smoking sig-
nificantly decreased the membrane expression of CFTR in human tissue 
samples. CSE incubation decrease CFTR mRNA and protein expression on 
Capan 1 cells. Smoking CSE incubation also decreases HCO
3
- secretion in 
guinea pig pancreatic ducts via inhibition of the Cl-/HCO
3
- exchanger, Na+/
H+ exchanger and Na+/HCO
3
- cotransporter. CSE pretreatment decreased the 
amplitude of carbachole-induced Ca2+ signal in pancreatic ducts, suggest-
ing that cigarette smoking alters Ca2+ signaling pathways in some way. CSE 
incubation was reduced mitochondrial membrane potential in guinea pig 
pancreatic ducts.
conclusion: The inhibition of CFTR and other ion transporters by CSE could 
play a crucial role in the development of ductal insuffiency and chronic 
pancreatitis. This study was supported by OTKA, MTA, SZTA and ÚNKP.
disclosure: Nothing to disclose 
P0806 The guT MIcrOBIOTa can cOMPensaTe enzyMaTIc 
acTIvITy In PaTIenTs WITh PancreaTIc exOcrIne InsuffIcIency
Oliver L.1, Fort E.2, Ramió-Pujol S.1, Bahí A.3, Puig C.3, Llirós M.3, 
Serra-Pagès M.1, Garcia-Gil J.1,4, Aldeguer X.1,2,3
1GoodGut S.L., Girona, Spain, 2Hospital Universitari Dr. Josep Trueta, 
Gastroenterology, Girona, Spain, 3Institut d’Investigació Biomèdica de Girona 
- IdIBGi, Girona, Spain, 4Universitat de Girona, Biology, Girona, Spain
contact e-Mail address: lia.oliver@goodgut.eu
Introduction: Pancreatic exocrine insufficiency (PEI) is an inflammatory 
condition of the pancreas in which the fibrosis development and loss of 
pancreatic parenchyma lead to an alteration of the endocrine and exocrine 
function. Genetic predisposition is one of the main common causes of PEI 
development, although malformations, autoimmunity, alcohol and nicotine 
are other predisposing factors, especially the interaction among several of 
them. The possible involvement of certain microbial groups in scenarios 
where the disease and inflammation have control needs to be elucidated.
aims & Methods: The objective of this work was to explore the state of the 
intestinal microbiota in search of some indicative bacteria that allow us to 
differentiate healthy individuals from an PEI population.
Two cohorts were included in this study at Hospital Dr. Josep Trueta (Gi-
rona, Spain): 11 patients with PEI and 6 low risk, healthy (i,e.,non-smokers 
and non-drinkers) subjects. Patients with PEI had fecal elastase values < 
15 µg/g or between 15 and 200 µg/g and values below 29% of C13-triglyc-
erides in the breath test. Patients brought a sample of feces from which 
17 bacterial markers representing the main physiological and ecological 
phyla were analyzed. Two different indexes were defined according to the 
different functional groups of microorganisms based on the enzymatic 
activities of amylase, lipase and protease. In addition, 1 index indicative 
of eubiosis was also defined. The indexes were calculated by adding the 
relative abundance of the bacterial markers. The relative abundance was 
calculated according to the total bacterial load (Eubacteria). Therefore, the 
lower the value of the index the greater the abundance of the markers that 
constitutes it.
results: When analyzed separately, the different bacterial markers did 
not present significant differences between the patients with PEI and the 
healthy subjects. However, significant differences were observed when 
comparing PEI and healthy subjects when the all bacterial indexes were 
combined. The 2 indexes based on enzymatic activity were significantly 
higher in healthy controls than in PEI patients (p-value=0.044, p-val-
ue=0.032, respectively). In contrast, the eubiosis index was significantly 
higher in PEI patients than in healthy controls (p-value=0.039).
conclusion: Patients suffering from PEI have lower (log)-ratios indexes de-
fined according to amylase, proteolytic, and lipase bacterial activities and 
an increase in the eubiosis. Since no clinical/physiological implications 
were derived from these enzymatic activity differences, the results sug-
gest a possible involvement of the bacteria present in the digestive tract to 
compensate the lack of enzymatic activity characteristic of PEI.
disclosure: Prof. Garcia-Gil, Dr. Aldeguer, Dr. Serra-Pagès, Dr. Ramió-Pu-
jol, Ms. Oliver are employees from GoodGut, company who has received 
private and public funding. Prof. Garcia-Gil, Dr. Aldeguer, Dr. Serra-Pagès, 
Dr. Ramió-Pujol, Ms. Oliver report grants from MINECO and from CDTI, 
during the conduct of the study. Prof. Garcia-Gil, Dr. Aldeguer and Dr. Ser-
ra-Pagès are also GoodGut shareholders, outside the submitted work. The 
rest of the authors have nothing to disclose. 
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P0808 rOLe Of cOMMOn CASR varIanTs In chrOnIc 
PancreaTITIs
Takáts A.1, Szentesi A.1,2, Farkas Jr G.3, Izbéki F.4, Erőss B.1, Czakó L.2, 
Vincze A.5, Hegyi P.1,2,6, Sahin-Tóth M.7, Hegyi E.1, Hungarian Pancreatic 
Study Group
1University of Pécs Medical School, Institute for Translational Medicine, 
Pécs, Hungary, 2University of Szeged, First Department of Medicine, Szeged, 
Hungary, 3University of Szeged, Department of Surgery, Szeged, Hungary, 
4Szent György University Teaching Hospital of Fejér County, Székesfehérvár, 
Hungary, 5University of Pécs, First Department of Medicine, Pécs, Hungary, 
6Hungarian Academy of Sciences-University of Szeged, Momentum 
Gastroenterology Multidisciplinary Research Group, Szeged, Hungary, 
7Boston University Henry M. Goldman School of Dental Medicine, Center 
for Exocrine Disorders, Department of Molecular and Cell Biology, Boston, 
United States
contact e-Mail address: amanda.takats@gmail.com
Introduction: The calcium sensing receptor (CASR) plays an essential role 
in maintaining mineral ion homeostasis and is also expressed in human 
pancreatic acinar and ductal cells. Over the past years, the possible involve-
ment of common CASR variants in chronic pancreatitis (CP) has emerged, 
however, their role in the pathogenesis of CP remains controversial due to 
the lack of large case-control studies.
aims & Methods: Our aim was to analyze the clinically frequent CASR vari-
ants in an ethnically homogenous group of Hungarian CP patients and 
healthy controls. 257 CP patients (cases) and 183 controls with no pancre-
atic disease from the Hungarian National Pancreas Registry were enrolled. 
As the most common CASR variants are located in exon 7, we PCR amplified 
and sequenced this exon with its flanking intronic regions.
results: We identified three common exon 7 variants in our cohort: 
c.2956G>T (p.A986S), c.2968A>G (p.R990G) and c.3031C>G (p.Q1011E). 
No significant differences were found in allele frequencies of these vari-
ants in cases compared to the control group: p.A986S (19.26% vs 18.58%, 
OR=1.05, p=0.8), p.R990G (7.8% vs 6.3%, OR=1.26, p=0.4) and p.Q1011E 
(3.7% vs 4.1%, OR=0.9, p=0.8). However, genotype distribution analysis re-
vealed, that the p.A986S variant in homozygous state was overrepresented 
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in patients relative to controls (3.5% vs 1.1%, OR=3.3, p=0.13). Although 
this difference was not statistically significant, there is a clear trend which 
warrants extension of the studies to a larger cohort in the future.
conclusion: The homozygous c.2956G>T (p.A986S) variant is overrepre-
sented in the Hungarian cohort of chronic pancreatitis patients relative to 
the control group. Our results strengthen the previous findings in a French 
cohort (Masson E, 2015) and support the possible pathogenic role of the 
homozygous p.A986S variant in chronic pancreatitis.
disclosure: Nothing to disclose 
P0809 assOcIaTIOn BeTWeen endOscOPIc uLTrasOnOgraPhy 
fIndIngs and PaThOLOgy/BLOOd BIOcheMIcaL fIndIngs In 
chrOnIc PancreaTITIs
Itoh T., Akao J., Kinoshita F., Otsuka N., Nagao K., Tahara J., Takayama Y., 
Shimizu K., Tokushige K.
Tokyo Women’s Medical University, Gastroenterology, Shinjuku-Ku, Japan
contact e-Mail address: ito.taito@twmu.ac.jp
Introduction: Endoscopic ultrasonography (EUS) diagnostic categories for 
changes indicating early chronic pancreatitis were formulated as the Rose-
mont classification. Japan was the first in the world to introduce diagnostic 
criteria for “early-stage chronic pancreatitis,” centered on EUS imaging 
diagnostics, in the Japanese Clinical Diagnostic Criteria for Chronic Pan-
creatitis 2009. However, EUS findings and diagnostic factors for chronic 
pancreatitis are often inconsistent. This study aimed to investigate the 
usefulness of EUS by conducting a statistical analysis of EUS findings in 
patients with chronic pancreatitis diagnosed on the basis of EUS findings 
and the volume of alcohol consumption, presence of diabetes, history of 
acute pancreatitis, and blood biochemical findings, and by comparing EUS 
and pathological findings.
aims & Methods: Between February 2014 to December 2017, 54 patients 
with repeat episodes of upper abdominal pain or abnormalities in pan-
creatic blood enzymes who had been diagnosed with early-stage chronic 
pancreatitis or chronic pancreatitis on the basis of EUS testing at our hos-
pital were categorized into confirmed, probable, and early-stage chronic 
pancreatitis cases in accordance with the Japanese Clinical Diagnostic Cri-
teria for Chronic Pancreatitis 2009. Statistical analysis was conducted for 
each group on the association with the volume of alcohol consumption, 
presence of diabetes, history of acute pancreatitis, blood biochemical find-
ings, and Rosemont classification.
results: The 54 study participants were comprised of 37 men and 17 wom-
en, with a mean age of 58.0 years. Of the cases, 24, 5, and 25 were con-
firmed, probable, and early-stage chronic pancreatitis, respectively. The 
mean alcohol consumption (pure alcohol by grams per day) tended to be 
higher in the confirmed cases (89 g/day) than in the probable (27.5 g/day) 
or early-stage chronic pancreatitis cases (30.1 g/day; p=0.08). No signifi-
cant differences were observed among the groups for the presence of dia-
betes, history of acute pancreatitis and blood biochemical findings. When 
the EUS and pathological findings were compared, the imaging results 
were consistent with the EUS fibrosis findings and irregular pancreatic 
duct images.
conclusion: Our study showed no association between the clinical diag-
nosis of chronic pancreatitis based on EUS findings and the presence of 
diabetes, history of acute pancreatitis, or blood biochemical findings. One 
previous report suggested a tendency of anomalous EUS findings to in-
crease in patients aged ≥60 years. Thus, at present, whether EUS find-
ings of chronic pancreatitis, considered to be representative of histological 
fibrosis, are changes due to aging is difficult to determine, which makes 
careful diagnosis vital to avoid overdiagnosis of the condition.
references: Raimondi S et al. Best Practice & Research Clinical Gastroen-
terology 2010;24:349-58. Gibo J et al. a Journal of Technical Methods and 
Pathology 2005
 Rajan E et al. Gastrointest Endosc 2005
disclosure: Nothing to disclose 
P0810 WhaT Is The OPTIMaL ManageMenT Of ParaduOdenaL 
PancreaTITIs? surgery Is assOcIaTed WITh hIgher IncIdence 
Of dIaBeTes BuT sIMILar quaLITy Of LIfe and PaIn cOnTrOL
Balduzzi A.1, Marchegiani G.2, Andrianello S.2, Romeo F.3, Amodio A.4, 
de Pretis N.5, Malleo G.6, Frulloni L.7, Salvia R.2, Bassi C.4
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Borgo Roma Hospital, Surgical and Gastroenterological Dep., Verona, Italy, 
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Introduction: Paraduodenal pancreatitis (PP) is a focal form of chronic 
pancreatitis that affects the groove area between duodenum and the head 
of the pancreas. Consensus regarding surgical or non-surgical manage-
ment as the best treatment option still is lacking.
aims & Methods: We retrospectively evaluated all patients managed for 
PP at The Pancreas Institute of the University of Verona Hospital. The 
outcomes of surgical vs. medical treatment with regards to pain control, 
quality of life (QoL) and pancreatic insufficiency were evaluated through 
specific questionnaires.
results: The final study population consisted of 75 patients: 62.6% un-
derwent surgery and 37.4% were managed without surgery. All surgical 
procedures consisted of pancreaticoduodenectomy. The median follow-
up from the diagnosis of PP was 60 (12 - 240) months. Patients who un-
derwent surgery experienced a similar incidence of steatorrhea (44.7 vs. 
52.6%; p= 0.4) but a significant higher incidence of diabetes (59.6 vs. 
10.7%; p< 0.01) when compared to those managed without surgery. There 
was no difference in terms of reported chronic pain (Graded chronic pain 
scale, median 0 vs. 1; p= 0.1) and QoL (Pancreatitis QoL Instrument, median 
82 vs. 79; p=0.2). However, surgical patients reported a worse level of self-
care activities associated with glycemic control (Diabetes self-management 
questionnaire, median 20 vs. 28, p=0.02).
conclusion: In patients affected by PP, surgery and medical therapy seem 
to obtain similar results in terms of QoL and pain control. However, surgery 
is associated with an increased prevalence of postoperative diabetes with 
consequent relevant issues in the self-care management.
disclosure: Nothing to disclose 
P0811 WIThdraWn
P0812 chrOnIc PancreaTITIs Is assOcIaTed WITh Increased 
cardIOvascuLar MOrTaLITy: a POPuLaTIOn-Based anaLysIs
Syed A.1,2, Thakkar S.3, Sandhu D.4, Dhawan M.1, Mitre M.1, Kulkarni A.1, 
Farah K.1, Morrissey S.1, Dulai P.5, Kochhar G.6
1Allegheny Health Network, Gastroenterology, Pittsburgh, United States, 
2Case Western Reserve University - School of Medicine, Internal Medicine, 
Cleveland, United States, 3Allegheny Health Network, Gastroenterology, 
Sewickley, United States, 4Case Western Reserve University/MetroHealth 
Medical Center, Internal Medicine/Gastroenterology, Cleveland, United 
States, 5University of California San Diego, Gastroenterology, San Diego, 
United States, 6Allegheny Health Network, Gastroenterology & Hepatology, 
Pittsburgh, United States
contact e-Mail address: aslam.syed@ahn.org
Introduction: Chronic pancreatitis (CP) is associated with high morbidity 
and mortality. Chronic inflammatory changes leading to systemic athero-
sclerosis can cause ischemic heart disease (IHD). Studies observing this 
relationship are limited, particularly describing associated epidemiologi-
cal relationships, mortality rates, and the role of statin therapy. This study 
aims to analyze variables that pose a risk of IHD development in patients 
with chronic pancreatitis, and report the role of statin use.
aims & Methods: A population-based study was conducted using a cloud-
based, HIPPA-enabled web platform called Explorys (IBM, New York) to 
collect aggregated de-identified electronic health records. At the time of 
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the study, Explorys had access to over 62 million unique records. Data was 
obtained using ICD-9 code criteria for chronic pancreatitis, ischemic heart 
disease, and HMG-CoA reductase inhibitors (statins). Patient characteris-
tics and all-cause mortality rates were compared with patients of IHD after 
a diagnosis of CP as a first time event using relative risk (RR) with 95% 
confidence interval (CI) in a random-effect model.
results: Chronic pancreatitis was found in 81,820 patients, of which 14,500 
(17.7%) had subsequent development of IHD. The RR of IHD was signifi-
cantly higher in patients with prior CP vs. the control population in our 
registry [RR 7.50 (95% CI: 7.37-7.63), P< 0.0001]. Family history of cardiac 
disease, tobacco use, obesity, and aspirin use were higher in the CP with 
IHD population. Patients that were elderly (> 65), male, and African-Amer-
ican were at higher risk of IHD with prior CP. Also, there was a higher rate 
of all-cause mortality in patients with CP and IHD vs. patients with CP 
alone. The younger population (18 - 65) and African-Americans with CP on 
statins had a beneficial effect in the prevention of IHD. Statins did not affect 
all-cause mortality in patients with CP and IHD vs. patients on statins with 
CP with subsequent IHD (P=0.3338).
characteristic
chronic 
Pancreatitis 
[n=81,820]
chronic 
Pancreatitis 
with 
subsequent 
Ihd 
[n=14,500]
relative risk 
[95% cI] P
Age, n [%]        
18-65 53,640 [66] 6,870 [47] 0.47 [0.46, 0.49] < 0.0001
>65 27,740 [34] 7,590 [52] 2.14 [2.08, 2.20] < 0.0001
Male, n [%] 42,390 [52] 8,290 [57] 1.24 [1.21, 1.28] < 0.0001
Ethnicity, n [%]        
Caucasian 58,240 [71] 10,340 [71] 1.01 [0.97, 1.04] 0.7039
African-American 16,670 [20] 3,500 [24] 1.24 [1.20, 1.29] < 0.0001
Hispanic 4,390 [5] 740 [5] 0.95 [0.89, 1.01] 0.1246
Cormorbidities, n [%]        
FH of Cardiac Disease 11,620 [14] 2,410 [17] 1.20 [1.16, 1.25] < 0.0001
History of tobacco use 31,770 [39] 6,450 [44] 1.26 [1.23, 1.30] < 0.0001
BMI > 30 47,300 [58] 11,210 [77] 2.48 [2.40, 2.58] < 0.0001
Aspirin use, n [%] 32,600 [40] 10,710 [74] 4.26 [4.12, 4.42] < 0.0001
All-cause Mortality, n [%] 10,670 [13] 3,160 [22] 1.86 [1.80, 1.92] < 0.0001
[Baseline characteristics]
conclusion: Patients at higher risk of IHD post CP diagnosis include being 
elderly, male, and African-American. Mortality is significantly increased 
in patients with CP and IHD vs. CP alone. Statins had a beneficial effect in 
decreasing the rates of IHD in patients that were less than 65 and African-
Americans.
disclosure: Nothing to disclose 
P0813 quaLITy Of LIfe assessMenT In PaTIenTs WITh 
PancreaTIc dIsOrders and exOcrIne InsuffIcIency receIvIng 
enzyMe rePLaceMenT TheraPy
Kovacheva-Slavova M., Genov J., Golemanov B., Vladimirov B.
University Hospital Tsaritsa Ioanna-ISUL, Gastroenterology, Sofia, Bulgaria
contact e-Mail address: kovacheva_mila@abv.bg
Introduction: With disease progression and complications appearance pa-
tients with pancreatic disorders complain of impaired overall quality of life 
(QoL). Nowadays the QoL assessment is adopted as part of the monitoring 
strategy of the treatment and the patients’ outcome.
aims & Methods: The aim of this study was to investigate QoL in patients 
with pancreatic disorders, receiving pancreatic enzyme replacement thera-
py due to pancreatic exocrine insufficiency. Study enrolled 142 patients (88 
males, mean age 52years): 82 patients had chronic pancreatitis (CP), 30- 
acute pancreatitis (AP), 30- pancreatic cancer/pancreatic resection (PC/
PR). QoL was evaluated by the European Organization for Research and 
Treatment of Cancer QoL questionnaire (QLQ-C30), containing 30 ques-
tions. The QLQ-C30 is composed of both multi-item scales and single-item 
measures. These include five functional scales, three symptom scales, a 
global health status / QoL scale, and six single items. Each of the multi-
item scales includes a different set of items - no item occurs in more than 
one scale. Severity of CP was assessed by M-ANNHEIM classification. We 
evaluated nutritional status (prealbumin and retinol binding protein (RBP) 
by immunonephelometry, fat-soluble vitamins A, D, E by HPLC and LC-MS/
MS. Statistical analysis was performed via SPSSv22.
results: Patients with pancreatic cancer had shown worst QoL, including 
all functional scales, symptomatic scales (fatigue, nausea, pain), dyspnoea, 
loss of appetite and diarrhoea. Mean levels of scale scores of physical 
functioning (p=0.013), role functioning (p=0.06) and dyspnoea (p=0.032) 
were significantly lowest in patients with PC/PR. We demonstrated signifi-
cant worsening of mean levels of scale scores according to global health 
status and almost all functional scales and symptomatic scales/items (ex-
cept of cognitive functioning, dyspnoea, insomnia, constipation, and diar-
rhoea) with progression of CP with significant lowest QoL in patients with 
advanced CP. Patients with AP without walled-off necrosis had significant 
overall better QoL scale scores compared to those with walled-off necrosis. 
In all groups of patients (CP, AP, PC/PR) we observed a tendency to better 
QoL assessment with nutritional status normalization. Significant differ-
ences were found mainly in the protein markers prealbumin and RBP in 
patients with CP and PC/PR.
conclusion: An effort should be point at multidisciplinary approach for 
up-to-date strategy for patients with pancreatic disorders, focusing not 
only on the improvement of symptoms and nutritional status, but also on 
social well-being. Questionnaires on quality of life are useful clinical tools 
that would identify patients at risk who to be provided with therapeutic 
education and physical rehabilitation, behavioral support and medication.
disclosure: Nothing to disclose 
P0814 aTTaInIng MOre Than 90% PancreaTIc sTOne 
dIsInTegraTIOn raTe By usIng a neW ThIrd-generaTIOn 
shOckWave LIThOTrIPTer WITh addITIOnaL endOscOPIc 
LIThOTOMy
Ito K.1, Okano N.2, Kishimoto Y.1, Takuma K.2, Hara S.2, Iwasaki S.3, 
Yoshimoto K.2, Yamada Y.2, Watanabe K.2, Kimura Y.2, Igarashi Y.3
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contact e-Mail address: ken.itou@med.toho-u.ac.jp
Introduction: Multiple case reports and case series describe the successful 
management of pancreatic duct stones with mechanical lithotripsy (ML), 
electrohydraulic lithotripsy (EHL), and extracorporeal shock wave lithotrip-
sy (ESWL). Combining ESWL with ERCP may increase the rate of complete 
main pancreatic duct (MPD) clearance. However, no randomized studies 
have compared the efficacy of ESWL with other lithotripsy modalities for 
MPD clearance.
aims & Methods: To evaluate the adequate methods of pancreatic stone 
treatments and compare the abilities of lithotripters to fragment pancreatic 
stones, we retrospectively evaluated 161 cases from June 2012 to Decem-
ber 2018 that were performed by 8 well-trained pancreaticobiliary physi-
cians. For the preparation management of ESWL, endoscopic pancreatic 
sphincterotomy (EPST) was routinely performed with ERCP. Cases compli-
cated by abdominal complaints (exacerbation of pancreatitis, pseudocysts, 
and fistula), endoscopic nasal pancreatic drainage (ENPD) or endoscopic 
pancreatic stent (EPS) placement were initially possible. Pancreatic stones 
treated with endoscopic monotherapy were excluded in this study. ESWL 
was continued until the stone disintegration was observed. If sufficient 
effect was not achieved, endoscopic electrohydraulic lithotripsy (EHL) or 
endoscopic lithotomy using basket or grasping forceps was additionally 
performed. For ESWL, we used a third-generation electromagnetic shock 
wave lithotripter (Lithoskop, Siemens, Erlagen, Germany; group 1) from 
2008 to 2016 and Modulith SLX-F2 (Storz Medical AG, Tagerwilen, Swit-
zerland; group 2) from 2017 to 2018. ESWL disintegration and additional 
endoscopic lithotomy rates were evaluated and compared between the 
two lithotripters.
results: In this study, 161 patients (169 stones; Lithoskop, 129 cases and 
Modulith, 40 cases) were evaluated. The ENPD/EPS placement success 
rates were 43.9% and 45.7% in groups 1 and 2, respectively, showing no 
significant difference between the ESWL preparations. No significant dif-
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ferences were also found between the stone characteristics (stone size, 
computed tomography value, and number and location of stones). For the 
144 stones in the MPD head, the success rates of the initial ESWL procedure 
were 68.1% in group 1 and 78.6% in group 2, showing no significant differ-
ence between the two lithotripters. The overall success rate with additional 
endoscopic lithotomy was decreased to 66.7% in group 1 and increased to 
92.9% in group 2, showing a higher stone lithotomy rate using Modulith 
SLX-F2 and additional endoscopic treatments (p < 0.05). For the 25 stones 
in the MPD body, the success rate after the initial ESWL procedure was 
53.9% in group 1 and 83.3% in group 2, respectively, showing no signifi-
cant difference between the two lithotripters. The overall success rate with 
additional endoscopic lithotomy was increased to 61.5% in group 1 and 
91.7% in group 2, showing no significant difference between the two treat-
ment methods (p = 0.07). MPD head stricture was significantly associated 
with factors of unsuccessful additional stone lithotripsy and was the only 
factor of unsuccessful stone lithotripsy.
conclusion: No significant differences were found in the disintegration 
rates between the two lithotripters. However, pancreatic stone disintegra-
tion rate attained more than 90% by using a Modulith SLX-F2 lithotripter 
with additional endoscopic lithotomy.
disclosure: Nothing to disclose 
P0815 uTILITy Of a 21-gauge MenghInI TyPe BIOPsy needLe 
fOr an endOscOPIc uLTrasOund-guIded fIne needLe BIOPsy 
fOr The hIsTOPaThOLOgIcaL dIagnOsIs Of auTOIMMune 
PancreaTITIs
Tsutsumi K.1, Ueki T.1, Kawahara S.1, Oda T.1, Noma Y.2
1Fukuyama City Hospital, Department of Internal Medicine, Fukuyama, Japan, 
2National Hospital Organization Fukuyama Medical Center, Department of 
Gastroenterological Medicine, Fukuyama, Japan
contact e-Mail address: tsutsumi@cc.okayama-u.ac.jp
Introduction: The pancreatic histology is a cardinal factor influencing a 
diagnosis of autoimmune pancreatitis (AIP), but the International Consen-
sus Diagnostic Criteria (ICDC) state that it should be assessed only using 
surgical or core biopsy specimens. We evaluated the utility of pancreatic 
tissue collection using a 21-gauge Menghini type biopsy needle with an 
endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) for the di-
agnosis of AIP.
aims & Methods: From January 2015 to December 2018, 14 patients at our 
institution who had been diagnosed with definitive type 1 AIP (n=13) or 
not-definitive type 1 AIP (n=1) based on pancreatic imaging, serum IgG4 
levels, and other organ involvement according to the ICDC underwent an 
EUS-FNB using a 21-gauge biopsy needle (EUS Sonopsy CY®; HAKKO, Na-
gano, Japan) originally made for a liver biopsy. No patients had type 2 AIP. 
After the enlarged lesion in the pancreas had been punctured, the needle 
was pushed forward quickly with aspiration under 10 mL of negative pres-
sure, and then the handle of the needle was turned until the tip of the 
needle was confirmed to be rotated in the lesion. To reduce the contami-
nation of blood, this procedure was repeated only three times. The male-
to-female ratio of patients was 11:3, and the median age was 71 (range: 
50-79) years old. Diffuse enlargement and segmental or focal enlargement 
of the pancreas was present in 10 (71%) and 4 (29%) patients, respectively.
results: Adequate specimens were obtained in all patients, with a median 
of 4.5 (range: 2-6) punctures. Regarding the histopathological findings 
based on the ICDC, lymphoplasmacytic infiltration, IgG4-postive plasma-
cyte infiltration (>10/high-power field), storiform fibrosis, and obliterative 
phlebitis were detected in 9 (63%), 9 (63%), 4 (29%), and 0 patients, 
respectively. Consequently, 9 patients (63%) were histopathologically di-
agnosed with AIP (level 1 and level 2 criteria of lymphoplasmacytic scleros-
ing  pancreatitis met by 4 [29%] and 5 [36%] patients, respectively). This 
histological finding contributed to a diagnosis of definitive type 1 AIP in a 
patient who had had not definitive type 1 AIP. Two patients (14%) who had 
undergone endoscopic pancreatography on the same day had procedure-
related pancreatitis.
conclusion: The 21-gauge Menghini type biopsy needle may be useful for 
the histopathological diagnosis of AIP because of its high recovery rate of 
pancreatic tissue with relatively little blood contamination.
disclosure: Nothing to disclose 
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Introduction: Autoimmune pancreatitis (AIP) type 1 is part of a larger sys-
temic disease defined by fibrosclerotic processes and elevated IgG4 and 
hence called IgG4-related disease (IgG4-RD). Primary sclerosing cholangi-
tis (PSC) is a chronic cholestatic liver disease characterized by progressive 
destruction of the bile ducts and eventually development of biliary cirrho-
sis. IgG4 associated cholangiopathy (IAC) may be present at the time of AIP 
type 1 diagnosis or occurs later in the disease course. IgG4 is considered 
reliable but not ideal marker for diagnosis of AIP type 1 with reported 
sensitivity between 71 to 81%. It is essential to differentiate sclerosing chol-
angitis with AIP from primary sclerosing cholangitis (PSC) as the treatment 
and prognosis of the two diseases are totally different.
aims & Methods: Based on circumstantial evidence on other IgG subclass-
es found elevated in autoimmune rheumatologic diseases the aim of this 
study was to test all IgG subclasses to assess their usefulness to differenti-
ate AIP with IAC from PSC as the other chronic and autoimmune disease of 
the bile ducts. We performed retrospective analysis of patients with AIP at 
our outpatient clinic. Patients from the PSC registry were taken as a control 
group. Blood samples for the measurement of all IgG subclasses were 
analyzed at the time of diagnosis before the patients received corticoste-
roid/immunosuppressive therapy.
results: From our patient registries, we included 142 patients where all 
IgG subclasses were measured, 69 with AIP type 1and 73 with PSC. Pa-
tients with AIP and IAC had higher values in IgG2 when compared to AIP 
alone or PSC with a high specificity (97%) and high positive predicted 
value (PPV=91%). In patients with normal or low IgG2 or IgG4, a high IgG1 
indicated PSC.
conclusion: IgG1 and IgG2 can distinguish patients with AIP-related chol-
angitis (IAC) from those with PSC. High serum IgG2 in those who are IgG/
IgG4 positive and elevated IgG1 in those who have low or normal IgG2 and 
IgG4 indicating PSC in this context can be considered an additional aid in 
establishing the one condition and/or excluding the other.
disclosure: Nothing to disclose 
P0817 Lung InvOLveMenT In PaTIenTs WITh auTOIMMune 
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Vujasinovic M.1, Panic N.1, Valente R.1, Haas S.L.2, Löhr J.-M.3
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Introduction: Immunoglobulin G4-related disease (IgG4-RD) is a systemic 
immune-mediated disease characterized pathologically by the infiltration 
of IgG4-bearing plasma cells into involved organs. Autoimmune pancreati-
tis (AIP) is a form of chronic pancreatitis with a heavy lymphocytic infiltra-
tion and two distinct histopathological subtypes: lymphoplasmacytic scle-
rosing pancreatitis (AIP type 1) and idiopathic duct-centric pancreatitis (AIP 
type 2). Pulmonary involvement (including lung, pleura and mediastinum) 
has been reported in 12% of patients with systemic IgG4-RD presentations. 
Most of the epidemiological data is coming from Japan and there is a lack 
of information from Europe, especially from Scandinavian countries. We 
are presenting first results on lung involvement in patients with AIP in 
European population.
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aims & Methods: We performed a single-center retrospective study on a 
prospectively collected cohort of patients diagnosed with AIP at the outpa-
tient clinic of the Department for Digestive Diseases at Karolinska Univer-
sity Hospital in Stockholm, Sweden from 2004 to 2018. Demographic and 
clinical data were collected from the medical charts.
results: Eighty-seven patients with AIP were included in the study; 56.3% 
male and 43.7% female, average age of 50.3±19.2 years. Patients were fol-
lowed for 51.7±40.6 months after the diagnosis of AIP. Majority were never 
smokers (60.7%). Lung involvement was diagnosed in 17 (19.5%) patients: 
13 patients with asthma, 5 patients with nodular lesions, 2 patients with 
granulomatosis with polyangiitis and 2 patients with mediastinal lymph-
adenopathy (in 4 patients combination of mentioned clinical conditions 
were presented).
conclusion: Lung involvement was diagnosed in 17 (19.5%) patients in AIP. 
Compare with other studies, our patients were younger, presentation of 
OOI was more often and the proportion of female was higher. There was 
no connection with environmental factors such as occupation of patients.
disclosure: Nothing to disclose 
P0818 IL1r1 gene POLyMOrPhIsMs In Igg4-reLaTed 
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PerIaOrTITIs/PerIarTerITIs
Ashihara N., Ota M.
Shinshu University School of Medicine, Second Department of Internal 
Medicine, Asahi, Japan
contact e-Mail address: kenta55226@gmail.com
Introduction: Immunoglobulin G4-related disease (IgG4-RD) is a systemic 
condition characterized by high serum immunoglobulin G4 (IgG4) concen-
tration and IgG4-bearing plasma cell infiltration in affected organs. Re-
cently, IgG4-RD has been recognized to affect the cardiovascular system as 
the IgG4-related periaortitis/periarteritis,which includes the inflammatory 
aneurysms, lymphoplasmacytic aortitis, and aortic dissection. IgG4-relat-
ed periaortitis/periarteritis show adoventia and/or tunica media thickness 
by IgG4-postitive plasma cells. Nearly half of the inflammatory abdominal 
aortic aneurysms leading to surgical treatment might be classified into 
IgG4-related. Therefore, it is important to predict the onset of vascular le-
sions at the time of diagnosis of IgG4-RD. However, the factors of onset of 
IgG4-related periaortitis/periarteritis are unclear.
aims & Methods: In this study, we performed GWAS screening analysis 
for 124 cases of IgG4-related disease. And the association analysis was 
performed between in the groups with vasculitis (41) and without vascu-
litis (83). The vasculitis was detected by imaging findings using contrast-
enhanced CT.
results: Some SNPs in candidate genes (CAMK2A, VPS13B, IL1R1) showed a 
statistically significant correlation to the onset of vasculitis. Among them, 
we focused in investigation of IL1R1 gene involved in various immune re-
sponses. We performed fine mapping of additional 8 SNPs (rs3917225, 
rs2287049, rs3917273, rs2160227, rs951192, rs3917318, rs7582198) with Taq-
Man assays. 3minor alleles of rs951192, rs3917318 and rs7582198 showed 
significant correlation (p< 0.0009, OR>4) with the vasculitis group as the 
additive model.
conclusion: These results suggest that IL1R1 gene polymorphisms are re-
lated with the onset of IgG4-related periaortitis/periarteritis.
disclosure: Nothing to disclose 
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Introduction: Previously we reported pancreatic atrophy after the begin-
ning of steroid therapy was associated with diabetes control worsening 
and incidence of new onset of diabetes in patients with autoimmune pan-
creatitis (AIP). However, the predictor for pancreatic atrophy and the exac-
erbation of diabetes after steroid therapy remains unknown.
aims & Methods: To evaluate the role of equilibrium computed tomographic 
(CT) imaging for the prediction of pancreatic atrophy after steroid therapy.
Forty-six steroid treated AIP patients, who underwent CE-CT examinations 
before and after steroid therapy, were included in this study during De-
cember 2005 to December 2017. CT attenuation (Hounsfield units [HU]) 
values in noncontrast (NC) and equilibrium phase (EP) images were mea-
sured by placing three regions of interest (ROIs) from the pancreas swell-
ing at the diagnosis of AIP. The incidence of the pancreatic atrophy and 
diabetes exacerbation after steroid therapy was estimated by the following 
three parameters in CE-CT before steroid therapy: 
1) HU values in NC images; 
2) HU values in EP images; and 
3) subtracted HU values between NC and EP images. 
Pancreatic atrophy after steroid therapy was defined to be present when 
the width of the pancreatic body was less than 10 mm. Pancreatic vol-
ume of whole pancreas was measured in CE-CT before and after steroid 
therapy, and volume reduction rate was also calculated.
results: Pancreatic atrophy was observed in 14 patients and not in 32 
patients after the steroid therapy. The volume of the whole pancreas af-
ter steroid therapy correlated with the diameter of the pancreatic body 
(r=0.59, P<0.0001). Volume reduction rate of whole pancreas was also 
correlated with pancreatic body diameter (r=-0.49, P=0.001). Pancreatic 
atrophy was associated with the thickness of pancreatic body on HU values 
in EP and subtracted images (114.5±12.8 vs 99.5±11.1; P=0.0002, 70.9±14.72 
vs 57.2±13.1: P=0.003) before steroid therapy, but not with HU values in NC 
images (P=0.42). HU values in EP and subtracted images were correlated 
with exacerbation of diabetes (P=0.0085, P=0.04). In addition, pancreatic 
body diameter, pancreas volume, and volume reduction rate after steroid 
therapy were associated with the exacerbation of diabetes (P=0.0003, 
P=0.002, P=0.0006).
conclusion: Equilibrium contrast and subtracted CT imaging at the diag-
nosis of AIP would be a potential predictor for pancreatic atrophy and the 
exacerbation of diabetes after steroid therapy.
disclosure: Nothing to disclose 
P0820 rITuxIMaB fOr The TreaTMenT Of 15 PaTIenTs WITh 
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Introduction: Autoimmune pancreatitis (AIP) is an immune mediated fibro-
inflammatory disease of the pancreas. It frequently shows an incomplete 
response to glucocorticoids and immunosuppressants. B cell depletion is 
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an effective treatment for type 1 AIP. Rituximab (RTX) seems to be an ap-
pealing alternative to conventional therapies for non responder or relapser 
patients.
aims & Methods: The aim of this study was to assess the efficacy of RTX 
in type 1 AIP in a prospective panel study.15 patients with relapsing type 1 
AIP after conventional steroid therapy and not responding or intolerant to 
Azatioprine, were treated with 4 doses of RTX (1000 mg each) from Febru-
ary 2013 to December 2017. Diagnosis of type 1 AIP was achieved with ICDC 
criteria. 14 of them had extrapancreatic involvement. Disease response was 
measured by IgG4 Related Disease Responder Index (IgG4 RD RI) and by 
serum IgG4 levels.
results: Disease remission was achieved by 14 of the subjects (93%). The 
baseline IgG4 RD RI declines from a mean of 13.4 (range 7 21) to 1.5 (range 
1 10) 6 months after the treatment (p< 0.001). Serum IgG4 levels decreased 
from 492 mg/dl (range 118 1260) to 92.5 mg/dl (range 37 180) (p< 0.001). 
The 36% of patients relapsed (5/15) after 28 months of follow up (range 
15 39). The follow up was significantly lower in patients in complete remis-
sion (10, range 3 20) compared with those who relapsed (36, range 17 46) 
(p=0.005). Two mild adverse infuse reactions associate with the use of RTX 
were reported (13%).
conclusion: RTX seems to be effective in type 1 AIP. Overall, RTX treatment 
was well tolerated with minimal side effects. We need more trials to evalu-
ate the long term safety profile.
disclosure: Nothing to disclose 
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Introduction: Autoimmune pancreatitis (AIP) is an inflammation of the 
pancreas which was first described in 1961 but received its current name 
in 1995. Since it was detected there have been several different diagnostic 
criteria for AIP, the most recent being the International Consensus Diag-
nostic Criteria (ICDC) for AIP which were proposed in 2011. The first-line 
treatment for AIP typically consists of a steroid treatment; a response to 
steroid treatment also forms part of the diagnostic criteria for AIP. Pancre-
atic atrophy has been observed in several patients with AIP and it has been 
discussed whether the development of atrophy is aggravated by the treat-
ment with steroids. Another disease which has been associated with AIP is 
diabetes mellitus (DM), the prevalence ranging from 12%-83.3%. Although 
AIP can be seen as a type of chronic pancreatitis (CP) and patients with AIP 
also can develop signs of CP, there have only been very few studies that 
have compared the course of the two diseases with each other.
aims & Methods: Aim of our study was to compare these two groups with 
each other in regard to the rate at which these patients developed pancre-
atic atrophy and DM. For this study we collected the data of 105 patients 
who had come to the Gastrocentrum of the Karolinska University Hospital 
for AIP and CP and who in the course of time had developed an atrophy of 
the pancreas. Two patients were excluded because they lacked follow-up. 
The imaging which best coincided with the patients time of diagnosis was 
determined as month zero and all follow-up imaging evaluated to deter-
mine when the patient developed an atrophy, classified as first or second 
degree. Furthermore we determined if and when the patient had devel-
oped DM and looked at the measures of fecal elastase 1(FE-1) as parameter 
for the exocrine function.
results: The study showed that patients with AIP developed pancreatic at-
rophy significantly faster than patients with CP. Furthermore, the patients 
with AIP who had received steroid treatment had a significantly quicker 
development of atrophy 2nd degree compared to patients with AIP who did 
not receive steroid treatment. We also found that the time to development 
of DM was significantly shorter in the group of patients with AIP when com-
pared with CP. Furthermore, at the time of diagnosis, patients with AIP had 
significantly lower values of fecal elastasis-1 than patients with CP.
conclusion: Patients with AIP develop pancreatic atrophy and DM signifi-
cantly quicker than patients with CP of other etiology. Steroid treatment 
may aggravate the development of pancreatic atrophy in patients with AIP.
disclosure: Nothing to disclose 
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Introduction: Surgical resection with chemotherapy remains the preferred 
treatment for pancreatic ductal adenocarcinoma (PDA). Data remains lim-
ited regarding survival rates for resectable PDA with adjuvant chemother-
apy treatment when managed by a multidisciplinary team. The objective 
of this study is to assess survival rates and outcomes of adjuvant chemo-
therapy for resectable PDA following presentation at a multidisciplinary 
pancreas conference (MDPC).
aims & Methods: All patients presented at a tertiary care center from April 
2013 to August 2016 with PDA were discussed at the MDPC and were fol-
lowed prospectively until November 2018. Patients were included in the 
study if the MDPC determined they had resectable PDA. Resectable PDA 
was defined as no involvement or abutment of regional vascular structures 
and no extra-pancreatic disease as determined by radiologic imaging. Pa-
tients underwent attempted upfront surgery and were followed until the 
end of the study timepoint.
results: A total of 278 patients were presented at the MDPC during the 
study period. The MDPC determined that 91 patients met criteria for re-
sectable disease and 70 were fit for surgery. A total of 64 patients under-
went successful surgery, as 6 patients had metastatic disease upon lapa-
rotomy (91.4% resection rate). Of the 64 patients that underwent surgery, 
37 (58%) started adjuvant chemotherapy with only 16 (25%) completing 
treatment. Patients who completed their adjuvant chemotherapy had a 
significantly prolonged survival time versus those who did not complete 
all cycles (36.9 months vs. 18.8 months, P = 0.014) (Figure 1). Reasons for 
patients who did not receive adjuvant chemotherapy included debilitation 
and post-operative complications (Table 1). Patients receiving any adjuvant 
chemotherapy had a median overall survival of 34.8 months versus a me-
dian overall survival of 17.1 months for those that did not (P = 0.43). Each 
additional cycle of chemotherapy conferred a relative survival advantage 
of 13.7% (P = 0.016).
reasons for not starting chemotherapy number of Occurrences
Post-Op Complications 7
Debilitation/Not Tolerating 5
ICU Admission 3
Metastatic Disease 3
Loss of follow-up 2
Prolonged Recovery 1
Surgically Curative 1
Unknown 5
Reasons for Not Completing Chemotherapy Number of Occurrences
Side effects 8
Metastatic Disease 4
Debilitation 3
Not Tolerable 1
Unknown 5
[Failed Chemotherapy]
conclusion: Our data suggest that successful completion of adjuvant che-
motherapy has better survival outcomes, specifically for those who com-
pleted 4-6 cycles versus those that completed 1-3 cycles. Each successive 
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cycle following resection provides a significant survival advantage of near-
ly 14%. Given that only 25% of patients in this study completed adjuvant 
chemotherapy due to debilitation, operative complications, family issues, 
etc., consideration should be given for optimizing fitness or providing pre-
operative neoadjuvant therapy in resectable PDA. Further studies are war-
ranted.
disclosure: Nothing to disclose 
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Introduction: Although application of MR diffusion-weighted imag-
ing (DWI) for pancreatic cancer diagnosis has spread in recent years, its 
sensitivity and specificity for pancreatic tumors has not been elucidated. 
Furthermore, results of its use in combination with magnetic resonance 
cholangiopancreatography (MRCP) remain unclear.
aims & Methods: We attempted to clarify sensitivity and specificity, as well 
as positive and negative predictive values of DWI for pancreatic tumors. In 
addition, each of those 4 factors were examined with MRCP, and combined 
use of DWI and MRCP. Of 671 cases that underwent DWI and MRCP exami-
nations from June 2017 to March 2019 at our hospital, 203 also evaluated by 
a pathological examination or contrast-enhanced endoscopic ultrasound 
sonography were retrospectively reviewed. Those included a case with a 
solid pancreatic mass in which both endoscopic ultrasound fine-needle 
aspiration biopsy (EUS-FNA) and surgery were rejected. Therefore,202 pa-
tients were eligible for this study. Cases positive for a pancreatic tumor 
were defined based on pathological diagnosis following surgical excision, 
or EUS-FNA or pancreatic fluid cytology findings. On the other hand, those 
negative for a pancreatic tumor were defined when no solid tumor was 
detected by contrast-enhanced EUS, or cases with a solid mass detected by 
contrast-enhanced EUS ultimately denied based on EUS-FNA or pancreatic 
juice cytology findings. DWI was performed with a b-value of 800 and 
cases with high signal were defined as DWI-positive. MRCP-positive was 
determined when localized main pancreatic duct stenosis accompanied by 
caudal pancreatic duct dilation were detected by MRCP.
results: Among the 202 cases, 15 had pancreatic tumors (invasive ductal 
carcinoma, 11; PanIN-3, 1, intraductal papillary mucinous neoplasia high 
grade (IPMN HGD), 3; neuroendocrine tumor (NET) G1, 1). DWI showed a 
sensitivity of 93.3%, specificity of 94.1%, positive predictive value of 56.0%, 
and negative predictive value of 99.4%, while those values for MRCP alone 
were 86.7%, 98.9%, 86.7%, and 98.9%, respectively, and for the combina-
tion of DWI and MRCP were 100%, 94.1%, 57.7%, and 100%, respectively. 
Of the 15 cases with a pancreatic tumor, all but 1 (PanIN-3) were revealed 
by DWI, including a 5-mm NETG1 tumor. The PanIN-3 case not seen in DWI 
findings was visualized by MRCP as localized main pancreatic duct stenosis 
with dilation of the caudal main pancreatic duct.
conclusion: For pancreatic tumor diagnosis, DWI was found to be more 
sensitive than MRCP, while those in combination resulted in increased 
sensitivity. DWI was able to reveal lesions at the edge of the pancreas not 
shown by MRCP. Based on our findings, we consider that the combination 
of DWI and MRCP is a rational protocol. However, the positive predictive 
value of DWI is low and false positive findings are often noted, thus addi-
tional imaging methods such as EUS and contrast-enhanced CT are neces-
sary for qualitative diagnosis.
disclosure: Nothing to disclose 
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Introduction: Pancreatic ductal adenocarcinoma (PDAC) has a suboptimal 
response to systemic treatments with an impact on survival due to its pow-
er to evade host immune surveillance (1). The binding of Programmed-cell 
Death 1 (PD-1) to its ligand Programmed-cell Death Ligand 1 (PD-L1) gives 
rise to a major immune tolerance mechanism (2). Thus, PD-L1 hyper-ex-
pression induced by tumor cells generates T cell apoptosis, escaping the 
tumor from immune surveillance. In addition, evaluation of MMR-D status 
is equally important, considering FDA approval of PD-1 inhibitor, pembro-
lizumab, for the treatment of unresectable or metastatic, microsatellite 
instability-high (MSI-H) or MMR-D PDAC that have progressed following 
prior treatment (3).
aims & Methods: Considering that PDAC PD-L1 expression quantification is 
limited to surgical resection due to the current IHC test requirement for a 
histologic rather than a cytologic evaluation, (4) the objectives of the proj-
ect include the assessment of tumor PD-L1/MMR-D expression in patients 
with PDAC using Endoscopic Ultrasound-Fine Needle Biopsy (EUS-FNB) 
samples.
results: At this moment, in this prospective, non-randomized, single-arm, 
interventional study we
enrolled 20 patients with suspicion of pancreatic masses who performed 
EUS-FNB for
confirmation of diagnosis. All patients have had a confirmed diagnosis of 
PDAC and
subsequently IHC was made for PD-L1/MMR-D testing. Through EUS-FNB, 
PD-L1/MMR-D
status was determined in all cases. PD-L1 positive rate measured by im-
munohistochemistry was 20% while MMR-D mutation was absent in all 
cases. In addition, PD-L1 status was positive in 2 patients with a PDAC T4 
stage.
conclusion: EUS-FNB can successfully determine primary pancreas ma-
lignancy PD-L1/MMR-D status. PD-L1 expression levels represent a poor 
prognosis factor in PDAC patients
references: 1.Delitto D, Perez C, Han S, et al. Downstream mediators of 
the intratumoral interferon response suppress antitumor immunity, induce 
gemcitabine resistance and associate with poor survival in human pancre-
atic cancer. Cancer Immunol Immunother 2015;64(12):1553-1563. 2. Sloot S, 
Chen YA, Zhao X, et al. Improved survival of patients with melanoma brain 
metastases in the era of targeted BRAF and immune checkpoint therapies. 
Cancer 2018;124:297-305. 3. Yamaki S, Yanagimoto H, Tsuta K, et al. PD-
L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic 
factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly 
sensitive detection using phosphor-integrated dot staining. Int J Clin On-
col 2017;22:726-733. 4. Tessier-Cloutier B, Kalloger SE, Al-Kandari M, et al. 
Programmed cell death ligand 1 cut-point is associated with reduced dis-
ease specific survival in resected pancreatic ductal adenocarcinoma. BMC 
Cancer 2017;17:618.
disclosure: Nothing to disclose 
P0825 PancreaTIc cancer In LIver TransPLanT recIPIenTs
Macinga P., Gogova D., Chmelova K., Bajer L., Frankova S., Sperl J., 
Spicak J., Hucl T.
Institute for Clinical and Experimental Medicine, Department of 
Gastroenterology and Hepatology, Prague, Czech Republic
contact e-Mail address: peter.macinga@ikem.cz
Introduction: The chronic use of immunosuppressive agents in liver trans-
plant recipients increases the long-term risk of malignancy (including gas-
trointestinal cancers), compared with that of general population.
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aims & Methods: The purpose of our study was to investigate incidence 
and characteristic of pancreatic cancer in liver transplant recipients. We 
performed a retrospective analysis of medical records of all adult patients 
who underwent liver transplantation in our center between years 1996 and 
2017. All patients were treated by combination of calcineurin inhibitors and 
mycophenolate mofetil with or without concomitant corticosteroids.
results: In examined period, one thousand, three hundred fifty-two 
adult patients underwent liver transplantation in our center; the median 
follow-up was 60 (1-276) months. Adenocarcinoma of the pancreas was 
diagnosed in five patients (0.4%, SIR 1.76), four men and one woman. 
Average age of patients diagnosed with pancreatic cancer was 61 (56-67) 
years, the mean period between liver transplantation and occurrence of 
malignancy was 54 (26-136) months. Indications for liver transplantation 
were alcoholic liver cirrhosis (2x), overlap syndrome of primary sclerosing 
cholangitis and autoimmune hepatitis, liver cirrhosis due to chronic HCV 
infection and secondary sclerosing cholangitis. Four of five patients were 
non-smokers; the only smoker had tumor duplicity (lung cancer). Two pa-
tients were diabetics; one of them was diagnosed with new-onset DM six 
months prior to finding of cancer. One patient had chronic pancreatitis. 
One patient was diagnosed with stage IB cancer, all the others with stage 
IIB. Three patients underwent surgical treatment. Median overall survival 
was 3 (1-30) months, in resected group it was 12 (1-30) months.
conclusion: In our study, liver transplant recipients had higher incidence 
of pancreatic cancer compared to that of general population. They were 
diagnosed in younger age and with earlier stage of the disease. Despite 
that, the prognosis was unfavorable.
disclosure: Nothing to disclose 
P0826 sIgnIfIcance Of In vITrO PhOTOdynaMIc 
cyTOdIagnOsIs usIng 5-aMInOLevuLInIc acId In sOLId 
PancreaTIc TuMOrs exTracTed By endOscOPIc 
uLTrasOund-guIded fIne-needLe asPIraTIOn
Hirao M.1, Housui A.1, Ashida M.1, Wakahara Y.1, Tanimoto T.1, Onishi K.1, 
Kusumoto Y.2, Yamaguchi T.1, Yamada T.3, Hiramatsu N.1
1Osaka Rosai Hospital, Gastroenterology, Osaka, Japan, 2Osaka Rosai 
hospital, gastroenterology, Sakai, Japan, 3Osaka Rosai Hospital, 
Gastroenterology & Hepatology, Sakai, Japan
contact e-Mail address: snowmotty1@yahoo.co.jp
Introduction: Recently photodynamic diagnosis using 5-aminolevulinic 
acid (5-ALA) has been gaining attention in diagnosing neoplastic diseases 
in the field of urology. 
In the present study, in vitro method of photodynamic cytodiagnosis 
(PDCD) using the reagent 5-ALA in the cytodiagnosis of solid pancreatic 
tumors was attempted to develop and the accuracy of PDCD for malignancy 
was assessed.
aims & Methods: EUS-FNA was performed for patients with solid pan-
creatic tumors at Osaka Rosai Hospital from September 2015 to March 
2018. Samples were diagnosd independently by conventional cytology and 
PDCD. The definitive diagnosis of benign or malignant diseases was evalu-
ated with the histopathological examinations on surgical specimens. In 
patients who did not undergo surgery, the final diagnosis was evaluated 
with the clinical, radiological, and serological evaluation during follow-
up over 6 month as well as the histopathological examinations on cell 
blocks. ALA is the natural precursor in the heme biosynthetic pathway that 
induces the intracellular accumulation of endogenous protoporphyrin IX 
(PPIX) when provided exogenously in large excess. It is metabolized into 
PPIX in the mitochondria and is characterized by excessive intracellular ac-
cumulation in cancer cells. Because PPIX is overproduced in cancer cells, 
when stimulated by blue light, ALA-induced PPIX can be applied as a red 
fluorescence detection marker for photodynamic diagnosis (PDD).
results: A total of 53 patients with solid pancreatic tumors (35 males and 
18 females, average age: 70.2 years old [range, 38-89 years old]) were 
enrolled. The definitive diagnosis were 7 benign lesions (2 with chronic 
pancreatitis and 5 with autoimmune pancreatitis) and 46 malignant le-
sions (41 with pancreatic ductal carcinoma, 4 with pancreatic acinar cell 
carcinoma, and 1 with neuroendocrine tumor). With regard for malignant 
patients with class 4 and 5 disease, the diagnoses of conventional cytology 
had a sensitivity of 93.5% (43/46), a specificity of 85.7% (6/7), a positive 
predictive value of 97.7% (43/44). By in vitro PDCD method, the reddish 
fluorescence was detected in the cell samples, which was judged as cancer 
cells. PDCD showed a sensitivity of 91.3% (42/46) and specificity of 100% 
(7/7), while conventional cytology showed a sensitivity of 93.5% (43/46) 
and specificity of 85.7% (6/7). Two patients are successfully diagnosed as 
malignancy by only PDCD method, while four patients were false-nega-
tive, two of which had pancreas cancer with formy gland pattern. In formy 
gland cells, PPIX is poorly produced since there are no mitochondria in 
these cells.
conclusion: In vitro PDCD performed using the 5-ALA method can effec-
tively and safely identify a diagnosis of pancreatic cancer without requiring 
an expert pathologist. The sensitivity of this technique could be increased 
in the diagnosis of pancreatic malignancy by combining it with the con-
ventional method.
disclosure: Nothing to disclose 
P0827 dePressIOn and PancreaTIc cancer, heLP Is On ITs 
Way!
Syed A.1,2, Kochhar G.3, Farah K.1, Morrissey S.1, Mitre M.1, Dhawan M.1, 
Kulkarni A.1, Thakkar S.4
1Allegheny Health Network, Gastroenterology, Pittsburgh, United States, 
2Case Western Reserve University School of Medicine, Internal Medicine, 
Cleveland, United States, 3Allegheny Health Network, Gastroenterology 
& Hepatology, Pittsburgh, United States, 4Allegheny Health Network, 
Gastroenterology, Sewickley, United States
contact e-Mail address: aslam.syed@ahn.org
Introduction: Pancreatic cancer (PaC) is the third leading cause of all can-
cer related deaths with a high mortality rate and poor prognosis. Identi-
fying risk factors and symptoms help improve the clinical management 
and outcomes of PaC. Depression often occurs in patients diagnosed with 
cancer, and is prevalent in up to 50-78% of patients with PaC. This study 
aims to evaluate demographical trends and mortality rates in patients di-
agnosed with PaC with preceding and subsequent depressive disorder. Ad-
ditionally, the role of mental health professionals and its effect on survival 
is observed.
aims & Methods: A longitudinal population-based study, using an IBM 
platform called Explorys was used to collect de-identified data. Over 60 
million patients, spanning nationally in over 40 healthcare systems’ elec-
tronic medical records are in this cloud-based, HIPPA-enabled platform. 
Data was obtained using SNOMED and ICD-9 code criteria with search 
terms “malignant tumor of the pancreas” and “depressive disorder.” A tem-
poral relationship was established to delineate relationship of depression 
diagnosis with PaC. Demographical data, mortality rates, depressive dis-
order symptoms and the role of mental health professionals (psychiatrist, 
psychologist, and behavioral professional) was observed and reported.
  depression and Pac [n = 11,730]
control 
[n = 5,290,190]
Odds ratio 
[95% cI] P
Male, n [%] 4,890 [41.7] 1,707,420 [32.3] 1.50 [1.45, 1.56] < 0.0001
Race, n [%]        
Caucasian 9,440 [80.5] 4,187,610 [79.2] 1.09 [1.04, 1.14] 0.0004
African-American 1,420 [12.1] 548,350 [10.4] 1.19 [1.13, 1.26] < 0.0001
Hispanic 90 [0.8] 50,910 [1] 0.80 [0.65, 0.98] 0.0310
Age, n [%]        
18-65 4,030 [34.4] 3,674,020 [69.4] 0.23 [0.22, 0.24] < 0.0001
> 65 7,650 [65.2] 1,523,850 [28.8] 4.63 [4.46, 4.81] < 0.0001
Findings, n [%]        
Anxiety 5,080 [43.3] 2,200,320 [41.6] 1.07 [1.03, 1.11] 0.0002
Sleep Disorder 4,470 [38.1] 1,613,450 [30.5] 1.40 [1.35, 1.46] < 0.0001
Agitation 170 [1.4] 40,270 [0.8] 1.92 [1.85, 1.99] < 0.0001
Suicidal Thoughts 380 [3.2] 388,670 [7.3] 0.42 [0.41, 0.44] < 0.0001
Weight Loss 3,580 [30.5] 353,210 [6.7] 6.14 [5.92, 6.37] < 0.0001
Fatigue 5,470 [46.6] 1,463,100 [27.7] 2.29 [2.20, 2.37] < 0.0001
[Depression Preceding Pancreatic Cancer]
results: A total of 58,140 patients were found to have diagnosis of PaC, of 
which 11,730 (20.2%) had prior diagnosis of depression, and 11,690 (20.1%) 
had subsequent diagnosis of depression. Incidence was higher in females, 
Caucasians, African-Americans, and younger patients (18 - 65). All-cause 
mortality was higher in patients with depressive disorder and PaC vs. PaC 
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patients without depression (P < 0.001). Patients with PaC and depressive 
disorder that were referred to a mental health professional had a lower 
rate of all-cause mortality when compared to patients without a referral (P 
= 0.009). Additionally, 83.1% of patients had a diagnosis of PaC within 6 
months of their depressive disorder diagnosis. Over 90% had diagnosis of 
PaC within 3 years. Preceding symptoms of anxiety, sleep disorder, agita-
tion, and weight loss were strongly associated with higher rates of PaC.
conclusion: Identifying and treating symptoms of PaC potentially helps 
improve outcomes and survival. This study shows that depressive disor-
der is under diagnosed in PaC and leads to higher mortality. Identifying 
clinical signs and symptoms of depression may help diagnose PaC earlier, 
and treatment improves survival. High vigilance is encouraged within the 
first 3 years of depressive disorder diagnosis for those at risk of pancreatic 
cancer. Referral to mental health care professionals improves survival in 
patients with PaC, therefore referrals or screenings should be considered 
as part of a multidisciplinary team management in pancreas cancer. 
disclosure: Nothing to disclose 
P0828 TreaTMenT and survIvaL Of PancreaTIc cancer 
recurrence In The neTherLands - PreLIMInary resuLTs 
Of a naTIOnWIde anaLysIs
Daamen L.1, Groot V.P.1, Besselink M.G.H.2, Busch O.R.C.3, Van Dam R.M.4, 
Festen S.5, Groot Koerkamp B.6, Haj Mohammad N.7, de Hingh I.8, 
Intven M.9, Kazemier G.10, Los M.11, Meijer G.9, Raicu M.11, 
Schreinemakers J.12, Stommel M.13, Verkooijen H.9, Molenaar I.Q.9, 
van Santvoort H.C.1, Dutch Pancreatic Cancer Group
1University Medical Center Utrecht, Surgery, Utrecht, Netherlands, 
2Amsterdam UMC, Surgery, Amsterdam, Netherlands, 3Academic Medical 
Center Amsterdam, Gastro-Intestinal Surgery, Amsterdam, Netherlands, 
4Maastricht University Medical Center +, Maastricht, Netherlands, 5OLVG, 
Amsterdam, Netherlands, 6Erasmus MC University Medical Center, Surgery, 
Rotterdam, Netherlands, 7University Medical Center Utrecht, Cancer Center, 
Utrecht, Netherlands, 8Catherina Hospital, Eindhoven, Netherlands, 
9University Medical Center Utrecht, Utrecht, Netherlands, 10VU University 
Medical Center, Surgery, Amsterdam, Netherlands, 11St. Antonius Ziekenhuis, 
Nieuwegein, Netherlands, 12Amphia Ziekenhuis, Breda, Netherlands, 
13Radboud University Medical Center, Nijmegen, Netherlands
contact e-Mail address: l.a.daamen-3@umcutrecht.nl
Introduction: Despite the high rate of recurrence after resection of pancre-
atic ductal adenocarcinoma (PDAC), Dutch and European guidelines for 
standardized follow-up are lacking. This has led to different surveillance 
strategies in daily clinical practice. In this context, data on the exact inci-
dence, symptomatology, treatment and survival following PDAC recurrence 
in the Netherlands are lacking.
aims & Methods: A multicenter retrospective observational cohort study 
was performed in 17 Dutch pancreatic cancer centers. Data from the first 10 
centers were used for preliminary analyses. All patients registered in the 
prospective Dutch Pancreatic Clinical Audit who underwent PDAC resection 
(2014-2016) were included. Additional data on follow-up and treatment 
of PDAC recurrence were collected. Mean survival was evaluated using 
Kaplan-Meier curves. Multivariable Cox regression was performed to com-
pare survival rates between patients who underwent treatment for recur-
rence and patients who received best supportive care. Survival analyses 
were stratified for symptomatic and asymptomatic patients.
results: 401 resected patients with a median follow-up of 15 months (IQR 
9-25 months) were analyzed. A total of 305 patients (76%) developed PDAC 
recurrence at a median follow-up of 9 months (IQR 6-15 months). Median 
overall survival in these patients was 13 months (IQR 9-21 months). In total, 
91 patients (30%) underwent treatment for PDAC recurrence. Treatment 
was independently associated with longer survival, in both symptomatic 
patients (HR0.16 (95%CI 0.09-0.30); P< 0.001) and asymptomatic patients 
(HR0.16 (95%CI 0.04-0.63); P=0.01). Of 57 patients with asymptomatic re-
currence, 25 patients (44%) received palliative treatment, as compared 
with 63 (29%) of 214 symptomatic patients (P=0.04).
conclusion: Treatment of both asymptomatic and symptomatic PDAC re-
currence seems independently associated with improved survival. As 
these results are subjected to confounding by indication, lead-time bias 
and guarantee-time bias, prospective studies are needed to determine the 
true value of standardized follow-up and treatment of PDAC recurrence, 
accounting for psychosocial and economic aspects.
disclosure: Nothing to disclose 
P0829 reducTIOn Of rOck2 gene exPressIOn cOrreLaTes 
WITh LIver MeTasTasIs as an Index Of MeTasTasIs fOr 
InvasIve ducTaL carcInOMa Of The Pancreas
Hamada Y.1, Kato D.2, Ishiguro M.1
1University of Fukuoda, Dept. of Pathology, Fukuoka, Japan, 2University of 
Fukuoda, Dept. of Surgery, Fukuoka, Japan
contact e-Mail address: yoshihiro42@me.com
Introduction: Although resections for invasive ductal carcinoma of the pan-
creas (IDCP) are expected to leave no residual carcinoma (R0), the 5-year 
survival rate is only 37.4% [1]. The cause of the poor prognosis after surgi-
cal resection of IDCP is recurrent carcinoma. Recurrent sites after pancre-
atic resection of IDCP are usually found in the liver and local site. Notably, 
survival of patients with liver metastasis (LM) is significantly shorter than 
that of patients with local site recurrences [2]. Effective diagnosis and treat-
ment of LM are primary steps to improve IDCP prognoses. We found that 
the median numbers of invaded veins and percentage of invaded veins/
total number of veins in the IDCP area were significantly higher in the LM 
group (UEGW 2016, [3]). However, there remains the need to identify gene 
mutations related to liver metastasisfor possible gene therapies. Various 
studies have shown that RNA microarray analysis improves the diagnosis 
and risk stratification of many cancers, but few studies have investigated 
the potential for liver metastasis of IDCP. In this study, we analyzed poten-
tial gene mutations involved in liver metastasis of IDCP by RNA microar-
ray. Furthermore,immunohistochemistry wasperformed using diagnosed 
sections.
aims & Methods: Of 402 patients who were diagnosed with IDCP, 21 (5.2%) 
had tumors with pTS1. The follow-up period of the 21 patients was 6 
monthsto 25 years. All patients underwent anR0 resection. Handling of the 
surgical specimensand assessment of vascular permeation by the carcino-
ma were performed as described previously [4]. Clinicopathological factors 
were assessed according to the Classification of Pancreatic Carcinoma(4th 
English edition)by the Japan Pancreas Society. Messenger RNA was ob-
tained from formalin fixed, paraffin-embedded pancreatic sections. RNA 
harvested from resected pancreatic cancers was hybridized to RNA micro-
arrays. Immunohistochemical staining was also performed. The antibody 
clone and dilution were ROCK2 (Gene Tex, USA) and 1:500, respectively.
results: The small tumour group (n=21) included 12 malesand ninefemale-
saged 51-80years. Five patients died because ofliver metastasis (LM group, 
n=5), and 12 patients survivedwithout recurrence. The other patients died 
of non-pancreatic desease. We searched for gene mutation groups cor-
related to liver metastasis of IDCP, such as the vascular smooth muscle 
contract group, pathway in cancer group, Wnt signal group,and focal ad-
hesion group. Significant reduction of ROCK2 gene expressionwas a com-
mon occurrence inthe four groups (p=0.013). Moreover, reductionof ROCK2 
expression indiagnosed sectionswas foundin all cases of LM, but not in 
non-LM patients (p=0.009).
conclusion: IDCP patients with reductionof ROCK2 gene expression have 
thepotential for liver metastasis regardless of R0 resectioning of IDCP.
references: [1]Pancreatic cancer registry report 2007. Japan Pancreas So-
ciety http://doi.org/10.2958/suizo.22.e239-e247 [2]Westerdahl J, Andrén-
Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer-local or he-
patic? Hepatogastroenterology 1993; 40: 384-7 [3] Hamada Y, Nakayama Y. 
Aggressive venous invasion in the area of carcinoma correlates with liver 
metastasis as an index of metastasis for invasive ductal carcinoma of the 
pancreas. Pancreatology 17; 951-955: 2017 [3] Nakayama Y, Inoue H, Hama-
da Y, et al. Intraductal tubular adenoma of the pancreas, pyloric gland 
type: a clinicopathologic and immunohistochemical study of 6 cases. Am J 
Surg Pathol. 29 ;607-616: 2005
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P0830 InITIaTIOn Of OraL feedIng earLy POsTOPeraTIveLy 
dOes nOT Increase The IncIdence Of cOMPLIcaTIOns afTer 
PancreaTOduOdenecTOMy fOr PancreaTIc cancer
Bezmarevic M.1, Panisic-Sekeljic M.2, Soldatovic I.3, Mirkovic D.1
1Clinic for General Surgery, Military Medical Academy, University of Defense, 
Department of Hepatobiliary and Pancreatic Surgery, Belgrade, Serbia, 
2Military Medical Academy, University of Defense, Unit for Perioperative 
Nutrition, Clinic for General Surgery, Belgrade, Serbia, 3Faculty of Medicine, 
University of Belgrade, Institute of Statistic and Informatics, Belgrade, Serbia
contact e-Mail address: bezmarevicm@gmail.com
Introduction: Pancreatoduodenectomy (PD) is associated with significant 
incidence of morbidity, including postoperative pancreatic and biliary fis-
tula (POPF and POBF), delayed gastric emptying (DGE), and other major 
and minor postoperative complications. These affecting the need and mo-
dality of nutritional support and prolongs hospital stay.1,2 The reluctance 
to initiate early oral feeding arises from the fear of an increased risk for 
postoperative complications.3,4
aims & Methods: Aim of this study was to evaluate the influence of early 
per oral food intake on development of postoperative complication after 
PD. This prospective observational study included 72 patients underwent 
PD due to pancreatic cancer. Patients were divided into 2 groups regarding 
time of initiation of solid per oral food intake (group 1 from 3-5 and group 
2 >5 postoperative day). The groups were compared in relation to the oc-
currence of POPF, POBF, DGE and the Clavien-Dindo (CD) grade.
results: The group 1 included 24(33%), and the group 2 48(67%) patients. 
There were no difference in age (p=1), gender (p=0.99), ASA score (p=1) 
and intraoperative blood loss (p=0.74) between groups. Duration of sur-
gery was shorter in the group 2 (p=0.02), where 39(81%) patients under-
went pylorus preserving PD versus 9(37%) patients with standard Whipple 
procedure in group 1 (p=0.001). POPF (grade A to C) occurred in 15(20%) 
patients, and clinical relevant POPF (grade B and C) occurred in 7(9.7%) 
patients. POBF occurred in 6(8%) patients and DGE was present in 16(22%) 
patients, respectively. POPF (grade A to C) developed in 5(21%) patients 
in group 1 and 10(21%) patients in group 2, (p=1). POPF (grade B and C) 
developed in 3(12.5%) patients in group 1 and 4(8.3%) patients in group 
2, (p=0.62). POBF occured in 0 patients in group 1 and 6(12%) patients 
in group 2, (p=0.17). One (4%) patient in group 1 experienced DGE and 
15(31%) patients in group 2, (p=0.001). CD grade ≥3 had 4(17%) patients 
in group 1 and 21(44%) patients in group 2, (p=0.001). The presence of 
CD grade ≥3 was associate with delayed initiation of per oral food intake 
(p=0.009). Significant correlation between CD grade and time of initiation 
of per oral food intake was found (p< 0.001).
conclusion: Early initiation of oral feeding in patients underwent PD had 
no impact on POPF and POBP occurrence. Delayed initiation of per oral 
food intake was associated with the presence of DGE and CD grade ≥3.
  Total n=72 group 1 (n=24) group 2 (n=48) P
POPf n(%) 15 (20) 5 (21) 10 (21) 1.000
POBf n(%) 6 (8) 0 6 (12) 0.169
dge n(%) 16 (22) 1 (4) 15 (31) <0.001
cd grade n(%)  
0 27 (38) 16 (66) 11 (23) <0.001
1 14 (19) 3 (13) 11 (23) 0.002
2 6 (8) 1 (4) 5 (10) 0.017
≥3 25 (35) 4 (17) 21 (44) <0.001
[Table 1. Difference in postoperative complications between groups]
references: 1. Gerritsen A, Wennink RA, Besselink MG, van Santvoort HC, 
Tseng DS, Steenhagen E, Borel Rinkes IH, Molenaar IQ. Early oral feed-
ing after pancreatoduodenectomy enhances recovery without increasing 
morbidity. HPB (Oxford). 2014 Jul;16(7):656-64 2. Braga M, Pecorelli N, 
Ariotti R, Capretti G, Greco M, Balzano G, Castoldi R, Beretta L. Enhanced 
recovery after surgery pathway in patients undergoing pancreaticoduode-
nectomy. World J Surg. 2014 Nov;38(11):2960-6 3. Lassen K, Coolsen MM, 
Slim K, Carli F, de Aguilar-Nascimento JE, Schäfer M, Parks RW, Fearon 
KC, Lobo DN, Demartines N, Braga M, Ljungqvist O, Dejong CH; ERAS® 
Society; European Society for Clinical Nutrition and Metabolism; Interna-
tional Association for Surgical Metabolism and Nutrition. Guidelines for 
perioperative care for pancreaticoduodenectomy: Enhanced Recovery After 
Surgery (ERAS®) Society recommendations. Clin Nutr. 2012 Dec;31(6):817-
30 4. Wu W, Hong X, Fu L, Liu S, You L, Zhou L, et al. The Effect of Pylorus 
Removal on Delayed Gastric Emptying after Pancreaticoduodenectomy: A 
Meta-Analysis of 2,599 Patients. PLoS ONE 2014;9(10): e108380.
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P0831 safeTy and effIcacy Of The ThuLIuM and erBIuM 
Laser sysTeM On BLeedIng vascuLar LesIOns Of The gI TracT: 
resuLTs frOM The fIrsT reaL-LIfe MuLTIcenTre sTudy
Tontini G.E.1, Dioscoridi L.2, Rimondi A.1, Cavallaro F.3, Cantù P.1, Elli L.1, 
Pastorelli L.3, Pugliese F.2, Mutignani M.2, Vecchi M.1
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Gastroenterology and Endoscopy, Milan, Italy, 2Ospedale Niguarda Ca’ 
Granda, Endoscopy Unit, Milan, Italy, 3IRCCS Policlinico San Donato, 
Endoscopy Unit, San Donato Milanese, Italy
contact e-Mail address: gianeugeniotontini@libero.it
Introduction: Recent pilot studies assessed the feasibility of the Thulium 
and Erbium laser system (TELS) for endoscopic haemostasis, ablation and 
resection. Herein, we investigated for the first time ever, the safety and 
efficacy of endoscopic treatment with TELS in patients with gastrointestinal 
bleeding due to vascular lesions.
aims & Methods: Consecutive patients treated with TELS for chronic gas-
trointestinal bleeding with moderate/severe anaemia due to vascular le-
sions were enrolled in two Italian centres between March 2016 and Octo-
ber 2018.
Technical success and safety as established by the ASGE Lexicon, were de-
fined as primary endpoints.
As secondary endpoints, we assessed the biological success comparing the 
lowest haemoglobin values ±1 month prior to and after treatment, along 
with the need of packed red blood cells (PRB) transfusions ±6 month prior 
to and after treatment. For gastric antral vascular ectasia (GAVE), a new 
scoring system was proposed to evaluate pre/post-treatment endoscopic 
severity by assessing both mucosal involvement (< 30%=+1, 30-50%=+2, 
>50%=+3), and presence of bleeding (traces of blood=+3, active=+5). For 
each procedure, image/video documentations and TELS technical param-
eters (i.e., lasing time, power output, energy employed) were digitally re-
corded. Student paired t-test was performed.
results: Twenty-six patients (20 men; range 48-91 years) underwent 32 
endoscopic TELS sessions for the treatment of angioectasias (14/26), GAVE 
(9/26), and RP (3/26). All procedures resulted in a complication-free tech-
nical success, thereby reaching the primary study endpoints. Haemoglo-
bin values showed a significant rise along with a decreased need of PRB 
transfusions. The median value of GAVE endoscopic severity remarkably 
improved within a six-month follow-up.
TELS endoscopic treatments (for each vascular 
lesion type)
32 (13 for GAVE; 14 for Angioectasia; 
5 for RP)
Complication-free (any degree of adverse event) 
technical success
32/32
Δ Lowest Hb ± 1month (30/32 procedures*)
+1.58 g/dl (95%CI = 0.93−2.23, 
p-value <0.001)
Δ PRB ± 6months (30/32 procedures*)
-1.8 units (95CI% = -2.8−-0.8; 
p-value <0.001)
GAVE endoscopic severity (9/14 procedures*) 5 to 2
[Results - Ongoing follow-up data*]
conclusion: This multicentre study conducted in real-life setting suggests 
that TELS is a safe and effective tool for the endoscopic treatment of pa-
tients with gastrointestinal bleeding caused by various types of superficial 
vascular lesions.
disclosure: Nothing to disclose 
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P0832 PercuTaneOus TransesOPhageaL gasTrOTuBIng 
(PTeg) -Three Ways Of PrOcedure
Murakami M.1,2, Nishino K.1, Okamoto T.1, Murakami S.1, Mori K.1, 
Murakami B.1, Azuma M.2, Tanabe S.3, Kida M.4, Koizumi W.2
1Murakami Memorial Hospital, Internal Medicine, Saijo, Japan, 2Kitasato 
University School of Medicine, Endoscopy and Gastroenterology, 
Sagamihara, Japan, 3Kitasato University School of Medicine, Advanced 
Medicine Research and Development Center for New Medical Frontiers, 
Sagamihara, Japan, 4Kitasato University, Endoscopy and Gastroenterology, 
Sagamihara, Japan
contact e-Mail address: masato@murakami-kinen.or.jp
Introduction: Percutaneous transesophageal gastrotubing (PTEG) was es-
tablished as an alternative route to access the gastrointestinal tract for the 
patients that Percutaneous Endoscopic Gastrostomy was contraindicated. 
PTEG will be an ideal method for tube feeding and decompression. There 
are three ways of procedure, and a similar effect is expected.
aims & Methods: The aim of this study is to evaluate the clinical usefulness 
of PTEG for the patients who need tube feeding or decompression from 
gastrointestinal tract. A rupture-free balloon (RFB) catheter is inserted into 
the upper esophagus. Percutaneous balloon puncture with a specialized 
needle is then performed from the left side of patient’s neck under ultra-
sonographic control. A guide wire is inserted through the needle into the 
RFB, followed by a dilator and sheath. A placement tube is then inserted 
through the sheath, and the sheath is removed. Conventional procedure 
supported by fluoroscopy was classified in group A, Group B was support-
ed by endoscopy. Double Balloons equipped Over tube type RFB were used 
instead of primary RFB under endoscopic support was classified in group 
C that the puncture needle is punctured into the over tube trough the bal-
loon. We perform PTEG in a total of 185 patients (115men and 70women, 
mean age 71.3 years) in whom PEG was not feasible. PTEG was performed 
for nutrition in 104 patients and for decompression in 81.
results: The number of patients was 30 in group A, 117 in group B, and 
38 in group C respectively. Satisfactory results were achieved in all 185 
patients. Median follow-up was 327.0 days in those who received nutri-
tion and 66.0 days in patients who received decompression. Nine of the 
30 patients who were started in the fluoroscopically assisted (Group A) 
needed endoscopic assistance to complete the procedure. Two of the 117 
patients in the endoscopic assistance(Group B) required fluoroscopy be-
cause of the tube insertion into the jejunum. All patients could free from 
nasal tube prior insertion. Six of 104 patients for nutrition were able to 
free from tube feeding due to PTEG tube feeding support. Oral ingestion 
could be achieved in 44.0% and home care could achieved in 66.0% of 
decompression group patients. Major complications were bleeding in two 
patients required blood transfusion and one patient had tracheal penetra-
tion, which was managed conservatively. Other complications were minor 
oozing bleeding in thirteen patients that did not require blood transfusion, 
subcutaneous emphysema in two patients, which were managed conser-
vatively. Complication rate　of each group was 16.7%,11.1%,15.7%,respec-
tivery. No patient required surgical treatment or died after PTEG.
conclusion: PTEG is safe and useful for long-term nutrition and/or decom-
pression for the patient who is contraindicated to PEG. PTEG is a suitable 
procedure of the patients having an eating disorder and/or the malignant 
disease as tubal feeding and palliative care. Same result is achieved in any 
way of procedure.
disclosure: Nothing to disclose 
P0833 feasIBILITy and effecTIveness Of IrrevIrsIBLe 
eLecTrOPOraTIOn aPPLIed By endOscOPIc caTheTers On 
gasTrOInTesTInaL TracT: an exPerIMenTaL anIMaL sTudy
Han Jo J., Choi H.S., Lee K.W., Kim S.H., Kim S.H., Jang S.H., Choi S.J., 
Kim S.H., Lee J.M., Kim E.S., Keum B., Jeen Y.T., Lee H.S., Chun H.J., 
Kim C.D.
Korea University College of Medicine, Department of Internal Medicine, 
Division of Gastroenterology and Hepatology, Seoul, Korea (Republic of)
contact e-Mail address: roadstar82@naver.com
Introduction: Irreversible Electroporation (IRE) is an ablation technique 
that induces apoptosis by applying an electric field. IRE has several advan-
tages over other ablation techniques. Recently, ablation therapy studies 
have been performed on Barrett’s esophagus and gastrointestinal tumors, 
and they are becoming popular as next ablation therapy in various can-
cers. The purpose of this study was to investigate the possibility of apply-
ing IRE therapy to gastrointestinal tract using newly designed endoscopic 
ablative catheters.
aims & Methods: After a pig was anesthetized, the esophagogastroduo-
denoscope was approached into the stomach of the pig. We inserted the 
IRE catheters into the channel of the endoscope. Then the DC generator 
was connected to the IRE catheter and applied electrical stimulation to the 
target of duodenum, stomach, and esophagus. The conditions of electrical 
stimulation are as follows; amplitude ranged from 500V to 2000V, pulse 
number ranged from 20 to 60, pulse duration was 100us, pulse length was 
100ms. Pigs were sacrificed after 24 hours later and ablated tissues were 
analyzed by H & E staining and TUNEL assay.
results: Result from H & E staining, there was no damage at 500 V in all 
the organs. On the contrary, erosion and necrosis occurred in mucosa at 
1000V, and inflammation occurred in submucosa at 1500V in both stomach 
and duodenum. At 2000V, extensive hemorrhage and inflammation oc-
curred in the submucosa. However, submucosal inflammation was also 
developed in pulse number 80. In the esophagus, epithelial seperation oc-
curred at 1000V and epithelial erosion occurred at 1500V. It was the 2000V 
that inflammation of submucosa occurred. Secondly, TUNEL assay was 
used to confirm apoptosis, and as the voltage and pulse became larger, 
the area in which apoptosis was induced was wider.
conclusion: Tissue apoptosis was successfully induced by using the IRE 
catheter. Our newly designed IRE catheters showed feasibility and effec-
tivenss on GI tract.
disclosure: Nothing to disclose 
P0834 LOng TerM survIvaL Of earLy gasTrIc cancer WITh 
suBMucOsaL InvasIOn afTer esd
Takagi Y.1, Yamamoto K.1, Michida T.2, Sato Y.1, Tokuda Y.1, Hiyama S.1, 
Tatsumi N.1, Ito T.1
1Japan Community Healthcare Organization Osaka Hospital, Department of 
Gastroenterology, Osaka, Japan, 2Saitama Medical College, Gastroenterology 
and Hepatology, Kawagoe, Japan
contact e-Mail address: risv4k2b@yahoo.co.jp
Introduction: Clinical outcome of early gastric cancer (EGC) with submuco-
sal (SM) invasion after endoscopic submucosal dissection (ESD) is not fully 
elucidated. Additional surgery may decrease the mortality by lymph node 
metastasis, but can be an overtreatment for some patients with SM inva-
sion gastric cancer. We investigated the clinical outcome for SM invasion 
gastric cancer after ESD.
aims & Methods: We investigated the clinical outcomes for EGC with SM 
invasion after ESD and validity of Japanese guideline
Methods: ESD was performed for 1196 patients (1637 lesions) of EGC at our 
hospital between July 2006 and December 2018. 148 patients (153 lesions) 
were histopathologically diagnosed as tubular adenocarcinoma with SM 
invasion. Based on the Japanese guideline, we recommended the patients 
to undergo radical surgery or be followed up without additional treat-
ment after ESD. Concretely, the patients whose histopathological findings 
revealed SM invasion depth were shallower than 500µm, lymphatic and 
venous invasion were negative, horizontal and vertical margin, ulcerative 
findings were negative, and tumor size were 3cm or smaller, pathological 
findings were undifferentiated type were followed up without additional 
treatment. Other patients were recommended to undergo radical surgery. 
Patients were divided into radical surgery group (n=78) and no additional 
treatment group (n=70). We retrospectively analyzed the disease-specific 
survival (DSS) and disease-free survival (DFS) in both groups, and risk fac-
tors of lymph node metastasis in surgical specimen or recurrence after 
ESD.
results: 3 year and 5 year DSS are 98 % and 98 % in radical surgery group, 
and 98 % and 98 % in no additional treatment group. 3 year and 5 year 
DFS were 97 % and 97% in radical surgery group, and 96 % and 93 % in 
no additional treatment group, respectively. There are no statistically sig-
nificant differences between the radical surgery group and no additional 
treatment group in DSS and DFS. In radical surgery group, six patients had 
lymph node metastasis in surgical specimen. Two patients who had not 
have lymph node metastasis recurred afterwards. On the other hand, three 
patients who were recommended to undergo radical surgery but didn’t 
do it had a local recurrence in no additional treatment group. The rate of 
lymph node metastasis in surgical specimen or recurrence were 13.4% 
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(11/82) in the subgroup of histopathologic findings with deep submuco-
sal invasion (SM deeper than 500µm), 40% (6/15) with venous invasion, 
20.6% (7/34) with lymphatic invasion, 21.2% (7/33) with ulcerative find-
ings, 15% (6/40) with large tumor size (>30mm) , 10%(2/20) with vertical 
margin positive or unclear and 14.3% (2/14) with undifferentiated histo-
logical type , respectively. Multivariate analysis revealed that venous inva-
sion and ulcerative finding were independent risk factors of lymph node 
metastasis in surgical specimen or recurrence (odds ratio: 3.9, 3.7 95% 
confidence interval 1.13 to 14.4, 1.10-14.4; p=0.03,p=0.03 , respectively).
conclusion: This study demonstrates that the patients of gastric cancer with 
SM invasion after ESD revealed long term survival. Venous invasion, and 
ulcerative finding seemed to be significant risk factors of lymph node me-
tastasis in surgical specimen or recurrence.
references: Japanese gastric cancer treatment guideline 2018(ver. 5)
disclosure: Nothing to disclose 
P0835 cLInIcaL OuTcOMes Of endOscOPIc suBMucOsaL 
dIssecTIOn fOr gasTrIc heTerOTOPIc Pancreas WITh 
recurrenT PancreaTITIs
Noh J.H., Kim D.H., Yoon J.Y.
University of Ulsan College of Medicine, Asan Medical Center, 
Gastroenterology, Seoul, Korea (Republic of)
contact e-Mail address: mdjh1432@gmail.com
Introduction: Gastric heterotopic pancreas (GHP) is generally asymptom-
atic and rarely has complications such as pancreatitis, pseudocysts, gastric 
outlet obstruction, upper gastrointestinal bleeding, obstructive jaundice, 
or intussusception. We investigated clinical outcomes to determine the 
feasibility and effectiveness of ESD for GHP with recurrent pancreatitis.
aims & Methods: Subjects who underwent ESD for GHP with recurrent 
pancreatitis at Asan Medical Center between 2003 and 2017 were eligible. 
The clinical features of patients and tumors, image finding, histopatholog-
ic characteristics, adverse events, results of ESD, and long-term outcome 
were investigated. We diagnosed with acute gastric heterotopic pancreati-
tis when the patient with GHP has recurrent severe abdominal pain and 
meets more than one of the following criteria. (1) increased size of GHP 
on endoscopic ultrasonography (EUS) or CT during the pain; (2) increase 
of serum pancreatic enzyme with normal pancreas on image; (3) no more 
abdominal pain after ESD.
results: A total of 5 patients had undergone ESD for acute gastric hetero-
topic pancreatitis after conservative management. The median age was 
32 years (interquartile range [IQR]: 28-37 years), and 2 was male. All le-
sions were located on greater curvature of antrum and 3 out of the lesions 
had a typical central indentation. On EUS, all lesions involved muscularis 
mucosa, submucosa and muscularis propria. The median tumor size was 
20 mm (IQR: 18-35 mm), and the median procedure time was 26 minutes 
(IQR: 17-27 minutes). There were no procedure-related complications such 
as delayed bleeding or stricture. The 4 patients had increased in size of 
GHP on EUS or CT during the pain, one of them accompanied by elevation 
of serum pancreatic enzymes and had a complication of pseudocyst forma-
tion. In 1 patient, there was no increase in size of GHP but continued severe 
abdominal pain and had elevation of amylase. He resolved the recurrent 
abdominal pain after ESD. All patients had no recurrent abdominal pain 
during the follow-up period after ESD (mean follow-up period: 24.8±12.3 
months).
conclusion: ESD appears to be a feasible and effective alternative option to 
surgery for the treatment of GHP with recurrent pancreatitis, based on the 
favorable clinical outcomes.
disclosure: Nothing to disclose 
P0836 cLInIcaL OuTcOMes Of endOscOPIc suBMucOsaL 
dIssecTIOn fOr gasTrIc LesIOns usIng a nOveL dIaTherMy 
knIfe WITh sucTIOn funcTIOn fOr BLeedIng cOnTrOL 
assIsTance
Matsui H.1, Ohya T.R.2, Furuhashi H.2, Horiuchi H.2, Kamba S.1, 
Dobashi A.2, Tamai N.2, Sumiyama K.2
1Jikei University, Endoscopy, Tokyo, Japan, 2Jikei University School of 
Medicine, Endoscopy, Tokyo, Japan
contact e-Mail address: hiro24tht80@yahoo.co.jp
Introduction: The Endosaber (Sumitomo Bakelite, Tokyo, Japan) is a newly 
developed, inexpensive multi-functional, needle-type knife with four tiny 
channels at the tip of the sheath capable of both suctioning and inject-
ing. The equipped feature distinct from conventional endoscopic devices 
is the suction function, which enables clear visibility of the bleeding point 
during hemostasis. The tip of the sheath can come directly in contact with 
the bleeder, and with suction, clear the field at the same time. The aim of 
this study was to evaluate the clinical outcomes and safety of ESD using 
Endosaber for gastric lesions.
aims & Methods: We included patients who underwent ESD for gastric 
lesions between June 2018 and August 2018 in this retrospective study. 
Lesions treated with ESD using a novel diathermy knife with suction 
capability,Endosaber (ESD-E) and conventional ESD (ESD-C) were com-
pared. The endpoints were the treatment outcomes of ESD (en bloc resec-
tion rate, total procedure time, the procedure speed of specimen, the rate 
and procedures of using hemostatic therapies, the adverse events and the 
cost-effectiveness.
results: Thirty-six gastric lesions in 33 consecutive patients (25 male, 8 
female) were analyzed. ESD-E group consisted of 12 gastric lesions and 
ESD-C group consisted of 24 gastric lesions. The mean age was 68.2±10.6 
years. There were no significant differences between the two groups with 
age, gender, location of lesions, morphology, and operator level. There 
were no significant differences in the average size of lesions between the 
two groups (17.2±10.7mm in ESD-E vs.12.8±10.1 mmin ESD-C (p=0.24).
Treatment outcomes of ESD showed an en bloc resection rate of 100% 
in both groups in gastric ESD; complete resection rate of 100% in ESD-
E group vs. 97.0% in ESD-C group (p=1). With respect to adverse events, 
there was one micro-perforation observed in ESD-C group. There were no 
significant differences in the average time of ESD between the two groups 
(34.8±19.9 min in ESD-E vs. 37.8±22.5 minin ESD-C (p=0.70)). In the pro-
cedure speed of ESD specimens there were no significant differences be-
tween the two groups ( 30.0 mm2/min in ESD-E group vs. 19.3 mm2/min 
in ESD-C group(p< 0.20)). However multivariate regression analysis with 
operator level that was variables potentially affecting clinical outcomes 
identified using Endosaber as significantly correlated with gastric ESD.In 
rate of using hemostatic therapies there were no significant differences-
between the two groups (44.4% in ESD-E group vs. 47.1% in ESD-C group 
(p=1)). Fewer hemostatic procedures using the hemostatic forceps were 
performed in ESD-E group than in ESD-C, although the difference was not 
significant (0.9±1.7 in ESD-E group vs. 1.9±2.6 in the ESD-C group (p=0.3)). 
Then the cost of devices in ESD was significantly different between the two 
groups (338.6±155.9 EURin ESD-E group vs. 414.5±0 EUR in ESD-C group 
(p< 0.05)).
conclusion: ESD using Endosaber was safe and comparable to conven-
tional ESD in gastric ESD. Using Endosaber appears to be faster than ESD-C 
significantly. Moreover, using Endosaber significantly lowered the ESD cost 
compared to conventional ESD. Further prospective studies are needed, 
but the sufficient utilization of the suction function might reduce the use 
of hemostatic forceps.
disclosure: Nothing to disclose 
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P0837 endOscOPIc suBMucOsaL dIssecTIOn Of esOPhageaL, 
gasTrIc and cOLOrecTaL TuMOrs: exPerIence Of caMPInas 
sTaTe unIversITy/gasTrOcenTrO - BrazIL, BeTWeen The years 
2008 TO 2018
Meirelles dos Santos J.O., Nogueira Rodrigues da Cunha V., 
Rubira Correa B., Miranda Fernandes de Lima L., Patriota Sampaio D., 
Miyajima N., Saddy Rodrigues Coy C., Garcia Montes C., 
Gardere Camargo M., Luis Ferreira G., Luiza Aluizio C.
University of Campinas, Endoscopy, Campinas, Brazil
contact e-Mail address: myxn@ig.com.br
Introduction: Endoscopic resection has become a therapeutic option for 
the treatment of gastrointestinal(GI) tumors with or without superficial 
submucosal invasion. Endoscopic Submucosal Dissection(ESD) is a tech-
nique developed for en bloc resection of GI tumors that has been con-
solidated as safe, effective and with few complications, allowing adequate 
tumoral staging and improving rates of curative resections.
aims & Methods: To describe the experience of a tertiary center for en-
doscopic treatment of esophageal, gastric and colorectal tumors by the 
ESD. A retrospective study evaluate patients with esophageal, gastric and 
colorectal tumors submitted to ESD from 2008 to 2018. Indication criteria 
for ESD were based on Guidelines of the Japanese Society and European 
Society. All resection products were sent for histopathological analysis.
results: Ninety-two patients underwent ESD: 10 esophageal, 40 gas-
tric and 42 colonic. In relation to esophageal tumors, mean age was 
58(45-71)years, 90% male, being 9 squamous cell carcinomas(SCC) and 
1 adenocarcinoma(ACA). Average size of tumors: 30.5 (20-40)mm and 
mean procedure time: 114(60-160)min. Complication rate: 20%, with 2 
cases of perforation successfully treated endoscopically. Resection en bloc 
was possible in 9 patients. Histopathological analysis: 7 SCC intramuco-
sal (m1=3;m2=1;m3=2)and 3 submucosal tumors (Sm1=1;Sm2 = 2). Nine 
cases had free deep resection margin; 2 had lateral margin invasion and 1 
case the margins evaluation was not possible (peacemeal resection). Cure 
rate: 40%. About gastric tumors, mean age was 58(53-88)years, 57.5% 
male, with 25 ACA and 15 adenomas. Mean size: 30.4(15-60)mm and 
mean procedure time: 124(60-240)min. Complication rate: 8.5%, with 1 
perforation and 2 late bleeding(1 of them elderly, with liver disease and 
blood dyscrasia that evolved to death). Resection en bloc was possible 
in 33 patients. Histopathological study showed: 15 cases pre-diagnosed 
as adenomas, 8 were ACA. Twenty five pre-diagnosed as ACA, 22 con-
firmed ACA and 3 showed adenomas with high-grade dysplasia(HGD). 
Among the ACA, 20 were intramucosal(m1=5;m2= 6;m3 = 9)and 10 with 
submucosal invasion(Sm1=8;Sm2=2). All cases had free deep resection 
margins, 2 with lateral focal involvement and 3 with vascular invasion. 
In 1 case, there was recurrence 3 months after ESD and the patient un-
derwent gastrectomy. Cure rate: 90%. Regarding colorectal tumors, the 
mean age was 61(34-85)years, 57.1% female. Twenty six(62%) classified as 
granular laterally-spreading tumor(LST-G) and 16(38%) as non-granular 
LST(LST-NG), according to Kyoto Classification. The mean lesion size was 
29.7(20-100)mm, with 20 located in the rectum, 3 sigmoid, 6 ascending, 6 
transverse, 6 descending and 4 in the cecum. Mean duration of the proce-
dure: 150 min(60-420 min). Histological diagnosis evidencied 28 adeno-
mas: 19 with HGD, 8 with low grade dysplasia(LGD), 3 serreted with LGD. 
Twelve ACA: 11 mucosal invasion(m1=4;m2=4;m3=3)and one with submu-
cosal invasion(Sm2). Among the LST-G (26), 7 had histological diagnosis of 
ACA, 12 adenomas with HGD and 7 with LGD. In relation to the LST-NG(16), 
5 had diagnosis of ACA, 5 adenomas with HGD and 6 adenomas with LGD. 
Deep margins were all free of lesion, and in 3 cases(7.1%) lateral margin 
was compromised. There were 6 complications(14.3%): 2 minor bleedings 
without hemodynamic instability and 4 perforations, treated with conser-
vative measures(clinical support and placement of endoscopic clips), all 
with good evolution. Cure rate: 98%.
conclusion: ESD was safe, effective method, curative in gastric and colorec-
tal tumors with few complications.
disclosure: Nothing to disclose 
P0838 dIagnOsTIc accuracy Of endOfasTer 
cOMPared TO hIsTOLOgy fOr chrOnIc aTrOPhIc 
gasTrITIs In hyPO-achLOrhydrIc PaTIenTs usIng 
narrOW Band IMagIng TargeTed BIOPsIes: 
a reaL-TIMe PrOsPecTIve sTudy
Cazzato M.1, Esposito G.1, Galli G.1, Conti L.1, Lahner E.2, Corleto V.D.1, 
Zullo A.3, Di Giulio E.1, Annibale B.1,4
1Sant’Andrea Hospital, Sapienza University, Department of Medical-Surgical 
Sciences and Translational Medicine, Rome, Italy, 2Sapienza University, 
Department of Medical-Surgical Sciences and Translational Medicine, Rome, 
Italy, 3Nuovo Regina Margherita Hospital, Gastroenterology and Digestive 
Endoscopy, Rome, Italy, 4Ospedale S. Andrea, Medical and Surgical Sciences, 
Rome, Italy
contact e-Mail address: gle.esposito@gmail.com
Introduction: NISO Biomed EndoFaster is a medical device which auto-
matically analyzes gastric juice in real time through its aspiration during 
upper gastrointestinal endoscopy. The operating principle of the device 
is based on determining the pH of gastric juice allowing the detection of 
hypo-achlorhydric conditions.
aims & Methods: The aim of this study was to compare the diagnostic ac-
curacy of EndoFaster with histological examination as gold standard for 
chronic atrophic gastritis through narrow band imaging (NBI) targeted 
biopsies.
Prospective study on consecutive adult patients undergoing to gastroscopy 
for the suspect of chronic atrophic gastritis (anemia, dyspepsia), in a sin-
gle unit of Digestive Endoscopy (University Hospital Sant’Andrea, Rome) in 
the period between April and November 2018 were included. Patients in 
therapy with proton pump inhibitor in the previous 4 weeks, gastric sur-
gery and/or known gastric neoplasia were excluded. At the beginning of 
the endoscopic examination, a sample of gastric juice (2 ml) was aspirated 
and analyzed by EndoFaster in real time (15 seconds). Endoscopists were 
blinded for the report of the device. Evaluation of gastric mucosa in high 
resolution white light (HR-WL) was firstly performed, then with narrow 
band imaging (HR-NBI) allowing to perform targeted biopsies where the 
suspicion of intestinal metaplasia was present. In case of normal gastric 
mucosa with NBI, biopsies were performed randomly using the Sydney 
System protocol.
results: Overall, 124 patients were included (64% F; 56 (18-80) years). 
Chronic atrophic gastritis was present in 42% of patients. Endofaster 
showed an accuracy for atrophic gastritis of 87.1% and a sensitivity, speci-
ficity, PPV and NPV of 77.4%, 94.4%, 91.1% and 84.9%, respectively. The 
pH value measured by Endofaster showed a positive correlation with the 
grade of atrophy (r = 0.67, 95% CI 0,73 to 0,81, p < 0.0001). NBI showed an 
accuracy of 90% and a sensitivity, specificity, PPV and NPV of 90%, 89.7%, 
83.7% and 93.8%, respectively, for the diagnosis of intestinal metaplasia. 
Endofaster allowed to diagnose atrophic gastritis in 3.0% of patients nega-
tive to NBI (atrophic gastritis without intestinal metaplasia).
conclusion: Endofaster seems a promising tool to diagnose chronic atro-
phic gastritis. The evaluation of hypo-achlorhydria during gastroscopy can 
also address bioptic sampling in chronic atrophic gastritis patients without 
metaplasia.
disclosure: Nothing to disclose 
P0839 fInaL resuLTs Of a PrOsPecTIve sTudy cOMParIng 
cOnfOcaL Laser endOMIcrOscOPy WITh sTandard BIOPsIes 
In The assessMenT Of PersIsTenT Or recurrenT InTesTInaL 
MeTaPLasIa/neOPLasIa afTer endOscOPIc TreaTMenT Of 
BarreTT’s esOPhagus reLaTed neOPLasIa
Krajciova J.1, Kollar M.2, Maluskova J.2, Vackova Z.1, Spicak J.1, Martinek J.1
1Institute for Clinical and Experimental Medicine, Dept. of 
Hepatogastroenterology, Prague, Czech Republic, 2Institute for Clinical and 
Experimental Medicine, Dept. of Clinical and Transplant Pathology, Prague, 
Czech Republic
contact e-Mail address: kraj@ikem.cz
Introduction: Patients after endoscopic treatment of Barrett’s esophagus 
(BE) related neoplasia (BORN) should undergo regular endoscopic surveil-
lance with biopsies to detect persistent or recurrent intestinal metaplasia 
(IM) or neoplasia (N). Probe-based confocal laser endomicroscopy (pCLE) 
offers detailed examination of cellular structures and may examine larger 
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areas compared to standard biopsy. The role of pCLE in the surveillance of 
patients after endoscopic treatment of BORN has not been systematically 
assessed.
aims & Methods: The aim of this prospective study was to evaluate the 
efficacy of pCLE (vs. standard biopsies) in detection of persistent/recurrent 
IM/neoplasia in patients after endoscopic treatment of BORN.
This is a single center, prospective, controlled and pathologist-blinded 
study in patients undergoing surveillance endoscopy after endoscopic 
treatment of BORN. pCLE images were obtained from the neo-Z-line (in 
few cases including macroscopically visible tongues), the cardia and the 
esophagus. Thereafter, standard biopsies were taken and sent for histo-
pathological analysis (minimally 4 biopsies from macroscopically normal 
neo-Z-line, 2 biopsies from the cardia and the esophagus and targeted 
biopsies from visible abnormalities, if present). 
Intestinal metaplasia (IM) on pCLE was defined by the presence of regular 
capillaries in upper and deeper parts of the mucosal layer along with iden-
tification of dark (“non-refractile”) mucin in goblet cells in columnar-lined 
mucosa. The dysplastic BE was characterized by black cells with irregular 
borders and shapes, and irregular leaking capillaries in the mucosa.
results: We examined 52 patients, from these 22 patients (42%) had the 
initial diagnosis of low-grade intraepithelial neoplasia (LGIN), 10 patients 
(19%) had high-grade intraepithelial neoplasia (HGIN) and 20 patients 
(39%) had an early adenocarcinoma (EAC). Eight patients (15%) under-
went endoscopic resection (ER) only, 25 patients (48%) underwent ER or 
ESD of all visible lesions followed by radiofrequency ablation (RFA), and 19 
patients (37%) had RFA as a single treatment modality.
Persistent/recurrent IM was detected only at the level of neo-Z-line in 12 
patients (23%, 12/52 pts) by both standard biopsies and pCLE.pCLE but not 
biopsies detected persistent/recurrent IM in 4 patients (8%, 4/52), another 
2 patients had IM present in biopsies but not in pCLE (4%, 2/52).
pCLE (but not biopsies) diagnosed one patient with recurrent LGIN in a 
macroscopic visible tongue arising from neo-Z-line, no other recurrences 
of BORN occurred.
Sensitivity and specificity of pCLE in detection of persistent/recurrent IM 
was 87.5% (95% CI 61.7 - 98.5) and 90.5% (95% CI 77.4 - 97.3), respectively, 
with a positive predictive value of 77.8% (95% CI 57.5 - 90.1) and a negative 
predictive value of 95.0% (95% CI 83.8 - 98.6). Agreement of pCLE and 
histopathological findings was 90%.
conclusion: pCLE is comparable to standard biopsies in detection of persis-
tent/recurrent IM after endoscopic treatment of BORN.
Supported by a grant from Ministry of Health of the Czech Republic, No. 16-
27648A.
ClinTrial registration: NCT02922049
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P0840 deveLOPMenT Of near-Infrared hyPersPecTraL 
IMagIng endOscOPy
Satou D.1, Hosokawa N.2, Maeda K.3, Takamatsu T.1,4, Kadota T.1, 
Okubo K.2,5, Umezawa M.2, Kamimura M.2,6, Takemura H.3, Yokota H.7, 
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Kashiwa, Japan, 2Tokyo University of Science, Materials Science and 
Technology, Tokyo, Japan, 3Tokyo University of Science, Mechanical 
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Imaging Frontier Center, Chiba, Japan, 6Tokyo University of Science, Reseach 
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Introduction: In recent years, Near-Infrared Hyperspectral Imaging (NIR-
HSI) has been attracting attention. HSI data includes spectral information 
in each pixel that is handled as images of any wavelength band1. The spec-
tral signature of each pixel in the images enables the HSI to identify vari-
ous pathological conditions. The HSI system can cover NIR spectral ranges 
(700-2,500 nm) which can penetrate biological tissues more efficiently 
than visible light because the tissues scatter and absorb less light at longer 
wavelengths2. On the other hand, to analyze big data of NIR-HSI, machine 
learning is useful for recognizing and extracting the feature of NIR-HSI3. 
Therefore, NIR-HSI with machine learning provides great advantages for 
supplying diagnostic support information to detect tumor beneath a nor-
mal mucosa such as gastrointestinal stromal tumor (GIST).
aims & Methods: The aim of this study was to establish the method of 
diagnosis of GIST covered by normal mucosa by using NIR-HSI machine 
learning. The subjects were surgically resected gastric GIST specimens at 
our hospital from April 2016 to March 2018. Before fixation, NIR-HSI im-
ages of specimens were captured from the mucosal surface side with an 
NIR hyperspectral camera, Compovision (Sumitomo Electric Industries, 
Ltd., CV-N800HS). On the obtained NIR-HSI images, the area of GIST re-
gions was defined by a pathologist to prepare training data for GIST and 
normal regions. The GIST specimens for analysis were selected using the 
following criteria: (i) GIST was covered with normal mucosa, (ii) normal 
mucosa existed around GIST in surgical resected specimen, (iii) GIST with 
a certain size capable of spectral extraction. For each selected specimen, 
the spectra were extracted from the pixels which were labelled as normal 
and GIST regions to prepare training data. The number of extracted spectra 
from the normal and GIST regions was the same to prevent the occurrence 
of bias in the training data. Then, one of the machine learning systems, 
support vector machine (SVM), was employed to predict normal and GIST 
regions from spectral data of each pixel in the NIR-HSI and the prediction 
accuracy was analyzed by leave-one-out cross-validation.
results: Images of 14 specimens were captured with Compovision and four 
specimens that met the criteria mentioned above were selected to use for 
the analysis. For each specimen, the number of extracted spectra from 
the normal and GIST regions as training data was 1700 to 3000 pixels, 
respectively. At wavelength between 1000 and 1600 nm, average accuracy, 
sensitivity and specificity were 86.9% (95% CI, 81.5-92.2%), 91.7% (95% 
CI, 81.6-101.8%) and 80.2% (95% CI, 70.5-89.9%), respectively.
conclusion: GIST diagnostic system with NIR-HSI and machine learning 
could identify GIST regions covered by normal mucosa with high accuracy. 
Applying this system to a flexible scope that can be inserted into the for-
ceps channel can enable us to use it in clinical setting.
references: 1. Kumashiro R, et al. Integrated Endoscopic System Based 
on Optical Imaging and Hyperspectral Data Analysis for Colorectal Cancer 
Detection. Anticancer Res. 2016; 8: 3925-32. 2. Smith, A. M., et al. Bioimag-
ing: second window for in vivo imaging. Nat Nanotechnol, 2009; 11: 710-1. 
3. Melgani F, et al. Classification of Hyperspectral Remote Sensing Images 
with Support Vector Machines. IEEE Trans Geosci Remote Sens. 2004; 42: 
1778-90.
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P0841 cLInIcaL OuTcOMe and PredIcTIng facTOrs Of severe 
nOn-heMOrrhagIc esOPhageaL endOscOPIc urgencIes: The 
exPerIence Of a TerTIary referraL cenTer
Brozzi L.1, Mascarenhas M.2, di Stefano S.3, Perini C.3, Macedo G.2
1Gastroenterology and Digestive Endoscopy Unit, Pancreas Institute, G.B. 
Rossi University Hospita, Department of Medicine, Verona, Italy, 2Centro 
Hospitalar S. João and Medical School University, Gastroenterology and 
Hepatology Department, Porto, Portugal, 3Gastroenterology and Digestive 
Endoscopy Unit, Pancreas Institute, G.B. Rossi University Hospital, 
Department of Medicine, Verona, Italy
contact e-Mail address: lorenzo.brozzi89@gmail.com
Introduction: Caustic and foreign body ingestion represent a significant 
part of endoscopic urgencies. They can lead to critical conditions and se-
vere complications that may need a multidisciplinary approach. A correct 
use and interpretation of diagnostic findings at admission is mandatory for 
risk stratification and subsequent clinical decision.
aims & Methods: Aim of this retrospective single center study was to eval-
uate predicting factors of clinical outcome of inpatients with esophageal 
non-hemorrhagic urgencies, especially Foreign body ingestion (FBI) and 
caustic ingestion (CAI). All consecutive cases of esophageal non-hemor-
rhagic urgencies admitted as inpatients in the tertiary Referral Univer-
sity Hospital São João in Porto were collected, in a period between 2000 
and 2019. Type of urgencies and clinical history were evaluated together 
with clinical records regarding preliminary exams (blood tests, EGDS, TC), 
length of hospitalization, complications and outcome.
results: Sixty-seven patients were included (M/F: 1.79, mean age 54.3±13.3 
years): 44 cases of FBI (most frequently animal bones), 22 cases of CAI 
(most commonly Sodium Hypochlorite) and 1 case of other substances in-
gestion (polyurethane). The Charlson Comorbidity score index had a mean 
value of 3, with no significant difference between FBI and CAI groups. 
Twenty-seven patients (40%) were affected by psychiatric disease, in par-
ticular alcoholism and depression. Psychiatric disease was strongly associ-
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ated with CAI and intentional ingestion (p < 0.0001). Among all patients, 
66 had a mean length of hospitalization (LoH) of 15 days (CAI Vs FBI, 24.9 
Vs 11.3 days, p 0.05) while only 1 patient died after 5 days from caustic 
ingestion. Blood tests at first day showed a mean value of C-reactive pro-
tein (CRP) of 68.9 mg/L in FBI group and 27.2mg/L in CAI group with a 
significant difference (p=0.036) and significantly associated with LoH in the 
FBI group (p>0.001), but not in CAI group. WBC had a mean value of 10,3 
x10^9/L in FBI and 11.3x10^9/L with no significant differences between FBI 
and CAI (p 0.28) and no significant association with LoH (p 0.37). EGDS was 
performed in the majority of cases within the first 24h. In the CAI group, 
esophageal involvement was complete in the 65% of the cases. Zargar 
classification showed a significant association with LoH in CAI group (p 
0.042). In the FBI group, lacerations were recognized in 41.5% of the cas-
es, while perforation was present in 29.3%, with no significant association 
with outcome.
Among the findings of CT scan, edema of the esophageal wall was the 
most common finding in CAI group (p 0.02) and perforation in FBI group 
(p 0.006). In the CAI group, CT scan Severity Index was significantly as-
sociated with LoH (p 0.01), while the presence of perforation was the most 
significant factor in the FBI group (p 0.06).
conclusion: EGDS with Zargar Classification is useful for risk stratification 
in patients with caustic ingestion. CT scan Severity Index for caustics and 
the presence of perforation for foreign body ingestion are associated with 
severity of the condition.
CRP at admission is an excellent and inexpensive predictor of clinical out-
come in foreign ingestion cases. However, in caustic ingestion patients, it 
may underestimate the severity of the clinical picture.
 
egds - 
zargar 
classifica-
tion
egds - 
presence of 
perforation
cT scan- 
caustic inge-
stion severity 
index
cT scan - 
presence of 
perforation
c-reactive 
protein at 
admission
White 
blood count 
at admis-
sion
Caustic Inge-
stion group- 
Length of 
hospitalization
p= 0.042 p= 0.38 p= 0.01 p= 0.38 p= 0.36 p= 0.2
Foreign object 
group- Length 
of hospitali-
zation
na p= 0.37 na p= 0.006 p= 0.0001 p= 0.8
[Table 1: risk factors and clinical outcome]
references: - Faz, Athena Alipour, et al. “Epidemiologic features and out-
comes of caustic ingestions; a 10-year cross-sectional study.” Emergency 
5.1 (2017). - Zhong, Qian, et al. “Esophageal foreign body ingestion in 
adults on weekdays and holidays: a retrospective study of 1058 patients.” 
Medicine 96.43 (2017).
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P0842 dIagnOsTIc yIeLd Of endOscOPy fOr PredIcTIOn 
Of acuTe grafT versus hOsT dIsease In The uPPer 
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Schulze L.1, Kreft A.2, Galle P.R.3, Neumann H.4
1University Medical Center of the Johannes Gutenberg University Mainz, 
Mainz, Germany, 2University Medical Center Mainz, Pathology, Mainz, 
Germany, 3Medizin. Universität Mainz, I. Medizinische Klinik & Poliklinik, 
Mainz, Germany, 4University Medical Center Mainz, Interventional Endoscopy 
Center, I. Medizinische Klinik und Poliklinik, Mainz, Germany
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Introduction: Intestinal graft-versus-host disease (GvHD) is a frequent 
complication after hematopoietic progenitor cell transplantation (HSCT) 
and biopsies are recommended for diagnosis. However, the best biopsy 
sites have yet not been clearly established and final histology results are 
often delayed as specific staining is required.
aims & Methods: aim: We aimed to assess the diagnostic yield of endos-
copy for prediction of GvHD of the upper gastrointestinal tract. In addition, 
we aimed to determine the best sites for obtaining biopsies for diagnosis 
of GvHD. 
Material and methods: A large scaled retrospective cohort study was con-
ducted. Patients diagnosed with acute GvHD in the upper gastrointestinal 
tract were included. Details included symptoms at time of referral for en-
doscopy, type of procedure performed, macroscopic findings on endos-
copy, and histologic findings of biopsies obtained. Biopsies were graded 
with the Lerner score. Sensitivity, specificity, positive predictive value 
(PPV), and negative predictive values (NPV) were calculated.
results: : A total of 101 patients (mean age 50.24, 44%female) underwent 
upper endoscopy and were diagnosed with intestinal GvHD. Mean Lerner-
score was 2.0, 1.5, 1.5, and 1.8 for the esophagus, antrum, corpus and 
duodenum, respectively. 
Sensitivity, specificity, PPV and NPV for endoscopic prediction of GvHD 
were inconclusive and not significantly (P>0.05) different between the 
esophagus (Sensitivity=54%, Specificity=62%, PPV=45%, NPV=70%), an-
trum (Sensitivity=53%, Specificity=66%, PPV=42%, NPV=75%), corpus 
(Sensitivity=50%, Specificity=54%, PPV=40%, NPV=64%) and duodenum 
(Sensitivity=58%, Specificity=83%, PPV=83%, NPV=58%).
conclusion: The diagnostic yield of endoscopy for prediction of acute GvHD 
in the upper gastrointestinal tract is considerable low and cannot replace 
histopathological evaluation. No specific biopsy side showed superior pre-
diction of GvHD. Therefore, we recommend a stepwise biopsy-protocol for 
patients undergoing upper endoscopy for diagnosis of GvHD.
disclosure: Nothing to disclose 
P0843 evaLuaTIOn Of endOscOPIc resecTIOn cOMBIned WITh 
cryOBaLLOOn aBLaTIOn sysTeM fOr esOPhagus In POrcIne 
MOdeLs
Sunakawa H.1, Yoda Y.1, Takeshita N.2, Hori K.1, Shinmura K.1, Ikematsu H.1, 
Fujii S.3, Yano T.1
1National Cancer Center Hospital East, Gastroenterology and Endoscopy, 
Kashiwa, Japan, 2National Cancer Center Hospital East, Medical Device 
Innovation Center, Kashiwa, Japan, 3National Cancer Center, Exploratory 
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Introduction: Endoscopic resection (ER) is a standard treatment for super-
ficial esophageal squamous cell carcinoma (SESCC). Metachronous devel-
opment of SESCC due to field cancerization is a major issue to be solved 
even with a high en bloc resection rate of endoscopic submucosal dissec-
tion (ESD). Furthermore, ER for lesions on the post ER scar is difficult in 
technique, and new therapeutic options are necessary to develop. 
The Cryoballoon Ablation system (CBAS), (HOYA Pentax Medical), is a new 
endoscopic ablation therapy. Operation using CBAS is simple and fast, and 
high efficacy and safety for patients with dysplastic Barrett’s esophagus or 
SESCC are reported. While CBAS might be a good candidate for additional 
treatment after ER or salvage treatment for lesions on post ER scar.
aims & Methods: The study objective was to evaluate the technical fea-
sibility and tissue damage of combination treatment of ER and CBAS in 
porcine models.
In this study, feasibility of combination therapy were evaluated in three 
pigs (pigA,B,C). All ER procedure were performed by EMR using Cap 
method(EMR-C). The detail of combination therapy for each pigs were as 
follows; 
a) Simultaneous EMR-C and CBAS( CBAS was performed for post EMR-C 
mucosal defect ; ER+CBAS) for pig A, EMR-C+CBAS were performed at two 
sites on the first day, and at other two sites on the 28 days later., 
b) CBAS for post EMR-C scar for pig B, EMR-C was performed at two sites 
on the first day, and CBAS was performed for two sites of EMR-C scars 
and two sites of normal mucosa at 28 days after EMR-C. c) EMR-C for post 
CBAS scar for pig C, CBAS was performed in two sites on the first day, and 
28 days later EMR-C was performed at two sites on post CBAS scar and 
two normal sites. 
All pigs were euthanized at 32 days after initial procedure and evaluated 
tissue damage. EMR-C specimens were evaluated pathologically. The out-
come parameters, the occurrence of any bleeding or perforation, weight 
loss were evaluated in all pigs.
results: All endoscopic procedures were as schedule. In pig B, CBAS was 
performed for EMR-C scars without any technical difficulty. In Pig C, only a 
mild scar was observed with endoscopy at the site after CBAS at 28 days. 
And, lifting with submucosal injection was smooth and resection was 
technically easy in EMR-C for CBAS scars. All pigs did not experience an-
orexia, rapid weight loss, bleeding and perforation during the observation 
period and was euthanized at 32 days after initial endoscopic procedure. 
Pathological evaluation of EMR-C specimens showed only mild fibrosis in 
the lamina propria mucosae after CBAS compared to EMR-C specimens in 
normal areas. Tissue damage of treatment against pig A B were as shown 
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in table1. There was no significant difference between CBAS alone and 
combination with ER. While the tissue damage of CBAS or EMR-C+CBAS 
spread throughout the entire esophageal wall at 4 days after treatment, 
only mild fibrosis was observed in the lamina propria mucosa at 28 days 
after treatment.
animal 
number treatment
ablation 
duration 
(seconds)
Time to 
euthanasia from 
treatment (days)
Maximum depth of 
ablation damage 
(wall layers)
pigA EMR+CBAS 8 4 adventitia
pigA EMR+CBAS 8 4 muscularis propria
pigB CBAS for EMR sca 8 4 muscularis propria
pigB CBAS for EMR sca 8 4 submucosa
pigB CBAS 8 4 adventitia
pigB CBAS 8 4 submucosa
[Histological damage of treatment against pig A, B]
conclusion: Combination treatment of endoscopic resection and CBAS can 
be technically feasible, and there was no significant difference of tissue 
damage comparing with CBAS alone.
disclosure: Nothing to disclose 
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Introduction: Histologic assessment of atrophy or intestinal metaplasia, or 
serum pepsinogen are reportedly useful for risk stratification of gastric 
cancer. However histologic assessment requires biopsy, and pepsinogen 
levels are affected by Helicobacter pylori eradication therapy. Endoscopic 
atrophy gradually proceed from the distal part of the stomach to proximal, 
and the degree of endoscopic atrophy using Kimura-Takemoto classifica-
tion is reported useful even after eradication, but Kimura-Takemoto clas-
sification is unfamiliar outside Japan.
aims & Methods: In this study, we constructedconvolutional neural net-
work (CNN), and evaluated its ability to classify the degree of the endo-
scopic atrophy. We performed standard esophagogastroduodenoscopy 
(EGD) and captured esophagogastroduodenal mucosal images. Clinical 
diagnosis ofthe degree of endoscopic atrophy using Kimura-Takemoto 
classification as reference standard was established by board certified en-
doscopists of Japanese gastroenterological endoscopy society. Endoscopic 
images were classified into four categories according to the location of 
the stomach, “antrum”, “body (antegrade view)”, “body (retroflex view)”, 
and “cardia or fundus”. A deep CNN was pre-trained and fine-tuned on 
a dataset of 11497 images (4373 with atrophy and 7124 without atrophy; 
4294 are body (downward view), 4003 body (retroflex view), and 3200 
“antrum”) obtained from 2016 to 2018. Images of cardia or fundus were 
excluded from the training data set. A separate test data set (3124 images 
from 92 patients (34 no atrophy, 14 mild (C1, C2), 26 moderate (C3, O1) and 
18 severe atrophy (O2, O3)) obtained from January to February 2019 was 
evaluated by the CNN.
results: The trained CNN output a continuous number between 0 and 1as 
the probability index for the presence or the absence of atrophy, and lo-
cation of the stomach per image. If the number of images diagnosed as 
atrophy are equal or larger than no atrophy in each location classified by 
the CNN, the location was judged as atrophic. Either the body (antegrade 
view) or the body (retroflex view) is judged as atrophic, it is classified as 
moderate to severe atrophy. On the other hand, both of the body (ante-
grade view) and the body (retroflex view) are judged as non-atrophic, it is 
classified as none to mild atrophy. Among 48 none to mild atrophy diag-
nosed by endoscopists, the CNN “correctly” diagnosed as none to mild in 
41 cases (85%). And among moderate to severe atrophy diagnosed by en-
doscopists, the CNN “correctly” diagnosed in 33 case (75%). Time needed 
to diagnose 3124 images was 84 seconds.
conclusion: The degree of endoscopic atrophy could be diagnosed based 
on endoscopic images using CNN in a considerably short time. It was sug-
gested that the CNN can be introduced to risk stratification of gastric cancer 
based on endoscopic images.
disclosure: Nothing to disclose 
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P0846 cLInIcaL OuTcOMes Of Per-OraL endOscOPIc TuMOr 
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gasTrIc cardIa
Onimaru M.1, Inoue H.1, Bechara R.1,2, Tanabe M.1, Abad M.R.A.1, 
Shimamura Y.1, Ueno A.1, Sumi K.1, Ikeda H.1, Ito H.1
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Japan, 2Queen’s University Division of Gastroenterology Kingston General 
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contact e-Mail address: mnbonmr0827@gmail.com
Introduction: The clinical success of per-oral endoscopic myotomy (POEM) 
has led to the development of a new field of ‘submucosal endoscopy’. This 
study aimed to evaluate the safety, efficacy, and limitations of per-oral 
endoscopic tumor resection (POET) in the management of submucosal tu-
mors (SMTs) in the esophagus and the gastric cardia.
aims & Methods: POET was performed in 47 patients from January 
2011-December 2017. Indication for POET was SMT< 30mm in size in minor 
axis. Patient and tumor characteristics (age, gender, tumor location, size, 
and histology), operative and clinical results of POET (procedure time, pro-
cedure completion rate, en bloc resection rate, length of hospitalization, 
adverse events, recurrences) were collected prospectively and analyzed 
retrospectively.
results: POET was successfully completed in 43 patients (91.5%) without 
any major adverse events (Clavian-Dindo IIIb-IV). Four patients required 
conversion to an open surgical procedure due to suboptimal visualization 
during POET. Two patients had a piecemeal resection of their SMTs. Me-
dian follow-up was 44 months (10-96 months), during which time there 
were no incidences of recurrence. Tumors in which the minor axis was 
>30mm or if the product of the major and minor axes, termed tumor mass 
index (TMI) was greater than 1000, had a high likelihood of being con-
verted to surgical resection.
conclusion: POET is a safe and effective treatment for SMTs. However, in 
patients where the minor axis is greater than 30mm or the TMI>1000, sur-
gical excision should be considered. Furthermore, application of POET for 
SMTs with malignant potential should be carefully considered to ensure 
optical oncologic outcomes.
disclosure: Inoue H is an advisor of Olympus Corporation and Top Corpo-
ration. He has also received educational grants from Olympus Corp., and 
Takeda Pharmaceutical Co. Bechara R is a consultant of Olympus Corpora-
tion. Onimaru M, Tanabe M, Abad MRA, Shimamura Y, Ueno A, Sumi K, 
Ikeda H, Ito H have no conflict of interests to declare. 
P0847 MeasureMenT Of MucOsaL MITOchOndrIaL Oxygen 
durIng uPPer endOscOPy as a POTenTIaL nOveL TesT fOr The 
dIagnOsIs Of MesenTerIc IscheMIa
van Dijk L.1,2, Ubbink R.3, Terlouw L.1,2, van Noord D.4, Mik E.G.3, 
Bruno M.J.1
1Erasmus MC - University Medical Center, Gastroenterology and Hepatology, 
Rotterdam, Netherlands, 2Erasmus MC - University Medical Center, 
Radiology, Rotterdam, Netherlands, 3Erasmus MC - University Medical 
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Rotterdam, Netherlands, 4Franciscus Gasthuis & Vlietland, Gastroenterology 
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Introduction: Chronic mesenteric ischemia (CMI) is a grave and debilitat-
ing condition. Variability of symptoms and abundant collateral circula-
tion, makes diagnosing CMI challenging, especially in single vessel dis-
ease. Functional tests such as tonometry and visible light spectroscopy 
are used to detect mucosal ischemia, but both have their limitations(1). 
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An easy-to-use and accurate functional test to diagnose CMI is highly 
desired. Protoporphyrin IX-triplet state lifetime technique (PpIX-TSLT) is a 
novel method used to measure oxygen in mitochondria(2). After admin-
istration of aminolevulinicacid (ALA) mitochondrial PpIX increases. Green 
light is used to excite PpIX, causing light emission by delayed fluores-
cence. After collision with oxygen molecules PpIX returns to its ground 
state, halting light emission. The duration of light emission is measured. 
When few mitochondrial oxygen is present, collisions are less likely to oc-
cur resulting in a longer duration of light emission. In vivo measurements 
of mitochondrial oxygen have been performed in skin and liver, but this 
technique has never been applied to perform in vivo endoscopic mucosal 
oxygen measurements(3,4).
aims & Methods: Aim of the current study was to verify the feasibility of 
measuring mucosal mitochondrial oxygen during upper endoscopy. Mito-
chondrial oxygen measurements were performed in six healthy volunteers 
during 10 upper endoscopies, 4 hours after oral administration of ALA. 
The ALA dose administered was 0, 1, 5 or 20mg/kg. Measurements were 
conducted at 3 mucosal spots in the antrum, duodenal bulb and descend-
ing duodenum. Measurements were performed with the catheter close to 
the mucosa and while applying pressure in order to induce local ischemia 
by compromising capillary circulation. Measurements are reported as 1 di-
vided by duration of light emission in microseconds, whereby high values 
represent high oxygen content.
results: Measurements proved easy to perform and were successful in all 
volunteers. ALA dose of 5 mg/kg showed adequate signal-to-noise ra-
tio values of >20 in duodenal bulb and descending duodenum, without 
occurrence of side effects. Median and interquartile ranges (IQR) of the 
measurements without application of pressure were 0.092 (0.061-0.132) 
in antrum, 0.041 (0.032-0.049) in duodenal bulb and 0.016 (0.011-0.026) 
in descending duodenum. Values decreased significantly (p< 0.001) at all 
locations when pressure was applied. Median (IQR) during pressure in the 
antrum was 0.052 (0.032-0.069), in the duodenal bulb 0.013 (0.010-0.022) 
and in the descending duodenum, 0.009 (0.008-0.011).
conclusion: Endoscopic measurement of mucosal mitochondrial oxygen 
is technically feasible and demonstrated to be oxygen dependent, with an 
optimal ALA dose of 5mg/kg. In vivo endoscopic mucosal mitochondrial 
oxygen measurements are a possible novel functional test for the diag-
nosis of CMI.
references: 1. van Noord D, Kolkman JJ. Functional testing in the diag-
nosis of chronic mesenteric ischemia. Best Pract Res Clin Gastroenterol. 
2017;31(1):59-68. 2. Mik EG. Special article: measuring mitochondrial 
oxygen tension: from basic principles to application in humans. Anesth 
Analg. 2013;117(4):834-46. 3. Mik EG, Johannes T, Zuurbier CJ, Heinen A, 
Houben-Weerts JH, Balestra GM, et al. In vivo mitochondrial oxygen ten-
sion measured by a delayed fluorescence lifetime technique. Biophys J. 
2008;95(8):3977-90. 4. Romers LH, Bakker C, Dollee N, Hoeks SE, Lima A, 
Raat NJ, et al. Cutaneous Mitochondrial PO2, but Not Tissue Oxygen Satu-
ration, Is an Early Indicator of the Physiologic Limit of Hemodilution in the 
Pig. Anesthesiology. 2016;125(1):124-32.
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Introduction: Endoscopic submucosal dissection (ESD) has been developed 
as an option for treatment of esophageal, gastric and colorectal lesions. 
Recently, in Japan, endoscopic submucosal dissection (ESD) for the duo-
denal tumors has come to be treated. Meta-analysis for superficial non-
ampullary duodenal epithelial tumors (SNADETs) reported that ESD might 
achieve higher en bloc and complete resections at the expense of a greater 
perforation rate compared to endoscopic mucosal resection. However, the 
high incidence rate of complications involving bleeding, perforations, and 
postoperative leakages require mainly high invasive surgery. Some studies 
were reported that prophylactic defect closure using Over-The-Scope Clips 
(OTSCs) was useful for preventing postoperative complications. Therefore, 
ESD for the duodenal tumors is increasing gradually.
In such a situation, we have recently detected the lesions near ampulla of 
Vater. Those lesions make it the most technically difficult to perform en-
doscopic submucosal dissection and also perform combined laparoscopic 
and endoscopic surgery due to the location. In this study, we investigated 
the clinical outcomes for SNADETs located within 10 mm from the ampulla 
of Vater which were defined as para-ampullary tumors (PA) compared to 
non-ampullary tumors (NA).
aims & Methods: We enrolled the patients with duodenal tumors that re-
ceived ESD in June 2016 to October 2018. 3 patients as PA and 35 patients 
as NA were included in this study. All SNADETs were performed ESD using 
the pocket-creation method. The post-ESD mucosal defect was closed us-
ing OTSC or conventional clip. We examined the clinical outcomes of PA 
compared to NA.
results: Clinical characteristics were male / female (PA/NA 3:0/23:12), 
mean age (PA/NA 64.3/61.7 years), mean tumor diameter (PA/NA 30.0/16.9 
mm), tumor morphology (PA/NA I:IIa:IIb:IIc 1:1:0:1/3:22:0:10). All of the 
SNADETs were completely removed by ESD with all the scissors forceps. 
We performed prophylactic defect closure using OTSCs and clip by clip-
ping. Endoscopic retrograde biliary drainage was also placed in all PA, 
because the ampulla of Vater was included in the resected area. The mean 
procedure time and closure time were 97 and 45minutes in PA and 70 and 
22 minutes in NA respectively. The complete defect closure was achieved 
in 100 % in PA and 97.1% in NA respectively. R0 resection rate and en 
bloc resection rate were 100 and 100% in PA and 94.3 and 100% in NA, 
respectively. There was no complication in PA and there were 2 cases in 
NA. 1 case was delayed bleeding and other was postoperative perfora-
tion. Perforation occurred in only one patient who did not have successful 
closure of the defect. Delayed bleeding was detected in one patient who 
occurred the bleeding from the mucosal surface sutured in OTSC. Lesions 
consisted of 1 adenocarcinoma and 2 adenomas in PA and 30 adenocarci-
nomas, 1 adenoma and others in NA. Although the tumor size was signifi-
cantly larger in the PA group (30 vs 16mm, respectively p = 0.02) and the 
treatment time and the closure time were longer due to ERBD placement, 
(97+45min vs 62+22min, respectively), complete closure was possible and 
there was no significant difference in the treatment results.
conclusion: ESD with prophylactic defect closure using OTSC and conven-
tional clip for para-ampullary tumors was as efficient and safe as that for 
non-ampullary tumors regardless of technical difficulties.
disclosure: Nothing to disclose 
P0849 The use Of sPrayaBLe WOund dressIng cOMPrIsIng 
MuLTIfuncTIOnaL hydrOPhOBIzed MIcrOParTIcLes durIng 
gasTrIc uLcer heaLIng fOLLOWIng endOscOPIc suBMucOsaL 
dIssecTIOn: a MInIaTure sWIne MOdeL
Kabayama M.1, Sasaki F.1, Maeda H.1, Hiraishi N.1, Morinaga Y.1, 
Arima S.1, Nasu Y.1, Tanoue S.1, Hashimoto S.1, Kanmura S.1, 
Nishiguchi A.2, Taguchi T.2, Ido A.1
1Kagoshima University Graduate School of Medical and Dental Sciences, 
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Introduction: Methods for preventing complications following endoscopic 
submucosal dissection (ESD) have recently been investigated; however, 
currently, there is no available method to efficiently prevent scar contrac-
ture after ESD. We have reported that usage of high-adhesion gelatin po-
rous films reduce inflammation and tissue contraction during gastric ulcer 
healing following ESD in a swine model. 
However, the sheet had a complication that the lesion to stick was limited 
and the operability was poor. We changed the dosage form from sheet 
type to spray type.
Sprayable wound dressing comprises multi-functional hydrophobized mi-
croparticles (hMPs) that possess the abilities for tissue adhesiveness in wet 
environments, acceleration of blood coagulation, enhancement of epithe-
lialization, and enhancement of angiogenesis.
aims & Methods: In the present study, we aimed to determine the effects 
of hMPs on the healing of gastric ulcers following ESD in miniature swine 
model. The gastric ulcers were generated by performing ESD. Following 
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ESD (Day 0), the artificial ulcers were either sprayed with hMPs (hMPs 
group, n = 4) or left unsprayed (control group, n = 4). Macroscopic and 
microscopic examinations were performed on Day 14 following ESD.
results: Infiltration of inflammatory cells in the submucosal layers were 
significantly reduced (p = 0.034). Expressions of alpha-SMA-positive cells 
and Type I collagen were significantly suppressed (p = 0.002 and p = 0.019, 
respectively), indicating that hMPs suppressed fibrosis after ESD. The num-
bers of VEGF-positive cells and microvessels were not significantly differ-
ent between the groups, whereas the number of cells positive for vWF 
were significantly increased (p = 0.016). Furthermore, there was a signifi-
cant reduction in the atrophy and fibrosis score (p = 0.024), which reflects 
the degree of atrophy or fibrosis of the muscularis propria.
conclusion: The use of hMPs reduced the degree of inflammation, fibrosis, 
and tissue contraction during the gastric ulcer healing process following 
ESD. hMPs can be easily delivered using clinically-available air pump de-
vices and can be tightly localized. Therefore, hMPs would contribute to 
reduce the burden on operators and patients by reducing operation times 
and ensuring an accurate procedure. Specifically, hMPs may offer success-
ful treatment of wounds without stricture after ESD procedures and also 
provide a novel therapeutic modality for wound treatment after ESD.
disclosure: Nothing to disclose 
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Introduction: According to a recent meta-analysis the rate of missed gas-
tric cancer during upper endoscopy is approximately 10% (1). While risk 
factors for missed upper gastrointestinal cancer have been identified in 
retrospective studies, the effect of missed upper gastrointestinal cancer on 
long-term survival is not clearly documented.
aims & Methods: We aimed to identify risk factors associated with missed 
upper gastrointestinal cancer and to compare survival between missed 
and non-missed upper gastrointestinal cancer. This is a single centre, 
retrospective cohort study. All upper endoscopies performed at our de-
partment between January 2007 and December 2015 were included in the 
study. The endoscopy database was cross-referenced with the Slovenian 
Cancer Registry Database. Missed cancers were defined as those diag-
nosed within 36 months since the last upper endoscopy. We excluded pa-
tients with a history of previous upper gastrointestinal cancer and those 
who were in surveillance program due to high risk conditions for the can-
cer development (Barrett’s oesophagus, intestinal metaplasia with OLGIM 
stage ≥ 3). The association of demographic and endoscopic characteristics 
was analysed with multivariable logistic regression, categorical data were 
compared using the chi-squared test. Survival analysis was performed 
with the Kaplan-Meier method.
results: During the study period 29,617 upper endoscopies were performed 
and 663 upper gastrointestinal cancers were diagnosed; 164 (24.7%) pa-
tients were excluded because of previous upper gastrointestinal cancer, 
further 10 (1.5%) were excluded because their cancer was diagnosed dur-
ing surveillance for precancerous conditions. In the final cohort of 489 
upper gastrointestinal cancers, 37 were missed (7.6 %; esophagus: 3.8%; 
gastric: 8.0%; duodenum: 23%) (Table 1). 
  diagnosed cancer (n=443) Missed cancer (n=37) P value
Age, mean (SD) 69 (12) 69 (12) 0.92
Female, n (%) 138 (31.2) 12 (32.4) 0.87
Alarm symptoms at index endoscopy 379 (85.5) 20 (54.1) <0.0001
Stage at diagnosis, n (%)     0.714
limited to organ 74 (16.7) 5 (13.5)  
locally advanced 199 (44.9) 16 (43.2)  
metastatic 126 (28.4) 10 (27.0)  
incomplete data 44 (9.9) 6 (16.2)  
Treatment with curative intent 210 (47.4) 13 (35.1) 0.278
[Characteristics of missed and non-missed upper gastrointestinal cancers in 
the study cohort.]
conclusion: Median survival of patients with missed upper gastrointestinal 
cancer during upper endoscopy was shorter compared to non-missed up-
per gastrointestinal cancer.
references: Pimenta-Melo AR, Monteiro-Soares M, Libânio D, Dinis-
Ribeiro M. Missing rate for gastric cancer during upper gastrointestinal 
endoscopy: a systematic review and meta-analysis. Eur J Gastroenterol 
Hepatol. 2016 Sep;28(9):1041-9.
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Introduction: Superficial duodenal epithelial tumors (SDETs) are rare, and 
there is no report of detailed endoscopic diagnosis of many SDET cases.
aims & Methods: We investigated the relationship between endoscopic 
findings and final histopathological diagnosis of a large number of SDETs. 
Four hundred fifty-six SDETs in 434 patients who underwent endoscopic 
resection was retrospectively reviewed in this study, including 195 pro-
spectively registered SDETs in 186 patients who underwent magnified 
endoscopic examination with image-enhanced endoscopy (IEE-ME). We 
investigated the location, size, macroscopic type, and color of SDETs and 
confirmed IEE-ME findings including surface structures (closed- or open-
loop structure) and presence of white opaque substance (WOS) in these 
SDETs. We performed histopathological diagnosis based on the Vienna 
classification (VCL) and divided the lesions into category 3 (C3) and beyond 
category 4.1 (C4/5).
results: The proportion of VCL C4/5 cases decreased from 30% for le-
sions of lesions in the duodenal bulb to 12.4% for lesions in the horizon-
tal portion (P=0.0087) and increased with lesion size (P < 0.0001). Based 
on IEE-ME findings, lesions with closed-loop structure and negative WOS 
were significantly more frequently diagnosed as VCL C4/5 (P=0.0222, and 
0.0038, respectively). In multivariate analysis, tumor size (odds ratio (OR), 
20.39; 95% confidence interval (CI), 2.23-186.40; P < 0.0093) and negative 
WOS (OR, 5.81; 95% CI, 1.24-27.18; P < 0.0268) were significant predictors 
of VCL C4/5 of SDETs.
factor Odds ratio 95% cI P value
size (per cm) 20.39 2.17-198.68 0.0093
WOs (negative) 5.81 1.23-28.35 0.0268
[Multivariate analysis of predictors of duodenal cancer]
conclusion: We found that negative WOS by IEE-ME and lesion size were 
independent predictors of VCL C4/5 in SDETs. These factors may help us 
select more appropriate therapeutic strategies for SDETs.
disclosure: Nothing to disclose 
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P0852 OuTcOMes Of a nOveL BarIaTrIc sTenT In The 
ManageMenT Of sLeeve gasTrecTOMy Leaks: a MuLTIcenTer 
sTudy
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Introduction: The management of laparoscopic sleeve gastrectomy (LSG) 
leaks remains a challenge. This can be treated with placement of self-
expandable metal stents, which are most effective in the acute and early 
settings. However, migration is a frequent adverse event (AE). Novel fully 
covered stents with a larger proximal flare to limit migration designed 
specifically to treat post-sleeve leaks were recently introduced.
aims & Methods: The aim of this study is to evaluate the safety and efficacy 
of a novel stent specifically designed for post-sleeve leaks treatment.
This is a multicenter retrospective study, including patients with acute and 
early post-LSG leaks, treated with a large bariatric stent. The outcomes in-
clude technical success, clinical success, and safety profile.A multivariable 
regression was performed to assess predictors of success.
results: Thirty-seven patients were included (10 acute and 27 early leaks), 
with 30 stents in the post pyloric (POST) and 7 in the pre-pyloric (PRE) 
position. Technical success was 100%. Mean stent dwell time was 29.08 
days. Clinical success was achieved in 78.37%. Leak duration, leak size and 
stent dwell time did not correlate with clinical success. During follow-up, 
8 patients had stent migration (21,62%) and all were in a POST position. 
AE post stent removal were also evaluated (PRE:57.14% vs POST:33.3%, 
p=0.45). There was no difference between PRE and POST position in the 
severe AE analysis.
conclusion: This novel large-caliber fully-covered stent specifically de-
signed for sleeve leaks appears to be effective at treating acute and early 
leaks. 
However, the large flanges and long stent length do not appear to reduce 
migration rate, and may be associated with higher overall adverse event 
rates. Additionally, avoiding placement in the post-pyloric position may 
help mitigate migration risk.
disclosure: Author 2: consultant (with non-financial support) for Boston 
Scientific and Olympus. Author 6: reports grants and personal fees from 
Fractyl Labs, GI dynamics, GI windows, Appolo Endosurgery, Olympus, 
Medtronic, and M.I. Tech. Author 22: reports grant and personal fees from 
Appolo Endosurgery and Olympus; and personal fees from Medtronic and 
Boston Scientific. All other authors have no conflict of interest. 
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Introduction: Recently, synchronous multiple early gastric cancers are be-
ing increasingly reported due to the aging society and development of 
endoscopy techniques.
aims & Methods: We usually perform reexamination of esophagogastro-
duodenoscopy (re-EGD) for the patients who have a gastric adenoma or 
adenocarcinoma before ESD, and sometimes detect the another lesion. We 
evaluated the clinicopathological findings of those lesions.
Between January 2014 and December 2018, we performed re-EGD for 1299 
patients in our hospital. The lesions which were detected anew in re-EGD 
were extracted, then we investigated their clinicopathological characteris-
tics retrospectively.
results: 76 patients with 83 lesions were detected in re-EGD. The location 
is cardia/ gastric body/ angle/ pylorus: 7/ 30/ 36/ 20, and les/ ant/ gre/ pos: 
29/ 15/ 19/ 20. The average diameter was 9.1mm(2-40mm). The pathologi-
cal diagnosis were 18 adenoma, 46 differentiated adenocarcinoma, and 1 
undifferentiated adenocarcinoma. The invasion depth was all intramuco-
sal cancer. Their H.pylori infection status was 29 were positive, 46 were 
after eradication, and 1 was negative. The degree of atrophy was 1 was 
mild(C-1, 2), 19 were moderate (C-3, O-1), and 56 were severe(O-2, 3). On 
the other hand, with respect to the 83 lesions which were detected from 
the beginning, the average diameter was 14.8mm, and pathological diag-
nosis were 5 adenoma, 76 differentiated adenocarcinoma, and 2 undif-
ferentiated adenocarcinoma. The lesions which were detected in re-EGD 
were significantly smaller than those were detected from the beginning 
(p< 0.01), and ratio of adenocarcinoma is lower than those (p< 0.01). With 
respect to the location, 64/83 (77%) of the lesion were located in the same 
area of the lesions which were detected previously.
conclusion: The patients with a gastric cancer often have the another le-
sion synchronously. The lesions which were detected newly tend to be 
smaller than the lesions which were already detected, and located in same 
area of those frequently.
disclosure: Nothing to disclose 
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Introduction: Buried bumper syndrome (BBS) is an uncommon complica-
tion of percutaneous endoscopic gastrostomy (PEG) placement; its inci-
dence is 1%. Several techniques for endoscopic management of BBS have 
been described, given the absence of a dedicated device to date.
aims & Methods: This was a retrospective, international multicentre, co-
hort study involving 15 Endoscopy Units across Europe between December 
2016 and February 2019. Patients with BBS treated endoscopically with a 
novel, sphincterotome-like, dedicated device were included. A total of 55 
cases were retrospectively analysed. The primary endpoint was success 
rate of buried bumper endoscopic removal with the dedicated device. A 
median follow-up of 96 days was performed in 38 patients and complica-
tions rate were registered.
results: The study group included 42 men (76%) and 13 women (24%) 
with a median age of 66 years (range 17-94). Diagnosis of BBS was sus-
pected through clinical assessment and confirmed through endoscopic 
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examination. Radiological examinations were performed in only 7 cases 
(12.7%). Patients underwent PEG placement 859.5 days (range 49-4380) 
before the removal of the buried bumper, due to cerebrovascular disease 
(16 patients, 29%), cerebral palsy (9 patients, 16.4%), head and neck can-
cer (9 patients, 16.4%), Parkinson’s disease (4 patients, 7.3%), neurological 
diseases and psychomotor retardation (4 patients, 7.3%), amyotrophic lat-
eral sclerosis (4 patients, 7.3%), multiple sclerosis (2 patients, 3.6%), can-
cer (2 patients, 3.6%), cerebral tumor (1 patient, 1.8%), head injury (1 pa-
tient, 1.8%), oesophageal cancer (1 patient, 1.8%), poly-trauma (1 patient, 
1.8%), miscellaneous (1 patient, 1.8%). Nine patients had a clinical history 
of previous BBSs (16%), treated with a different therapeutic approach. The 
buried bumper was located in the gastric body in 46 patients (83.6%) and 
in the gastric antrum in 9 patients (16.3%). The use of additional devices 
was applied in 40 procedures (72.7%). In this regard, a wire was used in 
14 patients (25.4%), a snare in 14 patients (25.4%), a forceps in 8 patients 
(14.5%), a knife in 2 patients (3.6%) and a balloon in two patients (3.6%). 
The median time for the endoscopic removal of the buried bumper, re-
corded in 42 patients, was 22 minutes (range 5-60). The buried bumper 
was successfully removed in 53 cases (96.4%). Peri-procedural endoscopic 
complications occurred in 7 procedures (12.7%). Significant bleeding, in 
particular, occurred in 4 patients (7.3%), a small perforation in 2 patients 
(3.6%) and in one patient (1.8%) a slight laceration of the gastro-oesoph-
ageal junction occurred during the PEG extraction. Two patients (3.4%) 
developed a post-procedure sepsis that was successfully treated with an-
tibiotics. In 44 patients (80%) a new PEG was placed during the same 
procedure of removal of the buried bumper, through the same site of the 
gastric wall in 35 patients (80%), while a new gastrostomy was required in 
9 patients (20%). In 5 patients (9.1%) a second PEG was placed after a me-
dian time of 4.5 days (range 2-14), all the times through a new site of the 
gastric wall. A median follow up of 96 days (range 1-593) was performed 
in 38 patients (69.1%), during which no significant complications occurred 
and one patient died of unrelated condition (encephalitis).
conclusion: To the best of our knowledge this is the first international mul-
ticentre study regarding the endoscopic management of BBS with a dedi-
cated device. Based on our preliminary data it appears to be user-friendly, 
safe, quick and effective for minimally invasive, endoscopic management 
of BBS.
disclosure: Dr Despott and Dr Murino receive research/ education sup-
port from Aquilant Medical, Fujifilm, Olympus, Pentax Medical, Boston 
scientific and GI supply. All others authors have no conflicts of interest to 
disclosure. 
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Introduction: Endoscopic submucosal dissection (ESD) has recently be-
come widely acceptedas the ideal minimally invasive curative treatment 
for early stage gastrointestinal cancer. However, the safety and success of 
ESD depends on doctors’ skill levels. There are no established training 
systems to overcome this difficulty, with the level of proficiency still being 
dependent on the skill of the individual doctor.
aims & Methods: The aim of this study was to use an eye tracking device to 
measure endoscopic skill, assess the differences between experienced and 
novice endoscopists, isolate commonalities between experienced endos-
copists, and identify elements required for ESD. Three endoscopists who 
were experienced in ESD (Group E) and threewho were novices (Group N) 
each performed ESD on an ex vivo porcine stomach model while wearing 
eye-tracking glasses. Eye tracking is technically to measure the point of 
gaze or measurement of eyes activity. We measured the area of distribu-
tion of gazeand compared between two groups.
results: The area of distribution of gazewas significantly smallerfor Group 
Ethan for Group N (P=0.021). We divided into three phases; prediction, 
incision and dissection phase. In terms of prediction and dissection phase, 
there was significantly smaller for Group E than for Group N.
conclusion: The experienced endoscopists in this study were able to pre-
dict their next step in advance and their movements were consistent. This 
showed that not only endoscopic skills but also the knowledge required 
to predict the next movement is important in ESD. The development of a 
training system based on this analysis could make ESD a safer and more 
efficient procedure.
disclosure: Nothing to disclose 
P0856 endOscOPIc hand suTurIng cOnTrIBuTes TO fasTer 
heaLIng Of The MucOsaL defecTs afTer gasTrIc endOscOPIc 
suBMucOsaL dIssecTIOn: a hIsTOLOgIcaL anaLysIs In In vIvO 
POrcIne MOdeLs
Akimoto T.1, Goto O.2, Sasaki M.1, Mizutani M.1, Tsutsumi K.1, Kiguchi Y.1, 
Takatori Y.1, Nakayama A.1, Kato M.1, Fujimoto A.3, Ochiai Y.1, Maehata T.1, 
Yahagi N.1
1Keio University, School of Medicine, Division of Research and Development 
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Introduction: Endoscopic hand suturing (EHS) is one of closure techniques 
for mucosal defects after endoscopic submucosal dissection (ESD) using 
a curved needle with absorbable suture and a trough-the-scope needle 
holder1. However, it is unclear whether EHS can keep post-ESD mucosal 
defects closed and promote healing. Furthermore, the histologic healing 
process of the sutured defects is also unknown.
aims & Methods: To evaluate how EHS contributes to the mucosal healing, 
we investigated histological analyses of the sutured defect after ESD in in 
vivo porcine models. 
We conducted this study using two live pigs. Under general anesthesia, the 
first pig underwent gastric ESDto create two 2 cm-mucosal defects (one 
on the anterior wall (AW) and another on the posterior wall (PW), respec-
tively). The defect on PW was closed by EHS (a sutured group), and that on 
AW was left open as a control group. On postoperative week (POW) 1 and 
2, the previously-created sites were observed endoscopically, and subse-
quently the same procedure as mentioned above was conducted to create 
new lesions (one for ESD plus EHS, another for ESD only), respectively. In 
the second pig, the control groups were set on PW and the sutured groups 
were set on AW. On POW 3, the pigs were killed for histology after endo-
scopic observation. In each session, the size of the mucosal defects was 
endoscopically estimated and recorded. 
When the mucosal defects were replaced with scar tissue or remained 
closed by EHS without dehiscence, they were recorded as zero. For his-
tological assessment, the width of absent epithelium in hematoxylin and 
eosin stain and the width of absent muscularis mucosae in alpha-smooth 
muscle actin (αSMA) stain were measured in each treated sites. In addi-
tion, fibroblast, which contributes to the healing process of ulcers, was 
defined as the area of positive αSMA in submucosa of the treated areas. 
It was measured in 3 fields (×400 magnification) for each slice using soft-
ware ImageJ with the IHC profiler plugin. The endoscopically-estimated 
size of the mucosal defects and the histologically-measured the widths 
and the area were compared between the two groups. Furthermore, his-
tological morphology of the mucosal layer in the sutured group was as-
sessed.
results: The endoscopic average size of the mucosal defects (mm) (n = 6 
on POW 1, 4 on POW 2, 2 on POW 3) were 15 ± 2.6, 6.3 ± 2.8, 2.0 ± 2.0 in 
the control group and 0, 0, 0 in the sutured group (p = 0.001, 0.004, 0.21), 
respectively. The histologic average width of absent epithelium (mm) (n = 
2 on POW 1, 2 on POW 2, 2 on POW 3) were 10.7 ± 2.2, 4.2 ± 3.5, 1.1 ± 1.1 in 
the control group and 0.88 ± 0.30, 0, 0 in the sutured group (p = 0.023, 
0.18, 0.21), respectively. The histologic average width of absent muscularis 
mucosae (mm) (n = 2 on POW 1, 2 on POW 2, 2 on POW 3) were 13.2 ± 2.6, 
8.2 ± 2.9, 7.5 ± 1.0 in the control group and 2.8 ± 0.7, 0, 0 in the sutured 
group (p = 0.030, 0.054, 0.009), respectively. 
The area of fibroblast (µm2) (n = 2 on POW 1, 2 on POW 2, 2 on POW 3) 
were 7079, 16963, 19656 in the control group and 9728, 6577, 4908 in the 
sutured group (p = 0.21, 0.0001, 0.0003), respectively. In the histological 
assessment of the sutured sites on POW 2 and 3, the muscularis mucosae 
fused to each other, and the connected epithelium covered on it in line 
without inversion.
conclusion: EHS may contribute to faster healing of the post-ESD mucosal 
defects without dehiscence in the porcine models. Histologically, layer-to-
layer healing seems to be obtained in the sutured mucosa by EHS as with 
a natural healing process of the mucosal defect after ESD.
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references: 1. Goto O, Sasaki M, Akimoto T, et al. Endoscopic hand-sutur-
ing for defect closure after gastric endoscopic submucosal dissection: a 
pilot study in animals and in humans. Endoscopy 2017; 49: 792-7
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Introduction: Upper gastrointestinal (UGI) anastomotic leaks have a high 
risk of morbidity and mortality. A variety of endoscopic techniques are cur-
rently available; however, no definite consensus exists on the most appro-
priate therapeutic approach. Knowledge of current practices is important 
for the design of prospective studies.
aims & Methods: To explore the current practices on the management of 
UGI anastomotic leaks. A survey questionnaire consisting of 35 opinion-
probing questions and 4 short clinical cases was distributed among inter-
national expert therapeutic endoscopists regarding management of UGI 
anastomotic leaks.
results: A total of 44% of 163 surveys were returned. Majority (69%) were 
gastroenterologists and 56% had >10 years of experience. A third of re-
spondents treat between 10-19 patients annually. Stent placement is the 
technique most frequently used (average ranking [AR]: 6.3), followed by 
endoscopic internal drainage (EID) (AR: 4.7), OTSC (AR: 4.6) and endoscop-
ic vacuum therapy (EVT) (AR: 4.1). Regarding stents, 56% use FC-SEMS 
as their usual first option. The vast majority (80%) utilize techniques to 
minimize migration (suture: 33%); 4 weeks was the most common (49%) 
reported stent dwell time. The majority of respondents perform epithelial 
ablation prior to OTSC placement (62%) and suturing (61%). Regarding 
EVT, 75% change the sponge every 3-5 days and 56% perform balloon 
dilation and intracavitary EVT in patients with large cavities but small leak 
defects. Regarding endoscopic septotomy, 56% consider a minimal inter-
val of 4 weeks from surgery and 90% consider the need to perform further 
septotomy sessions, with a median of 11 days between treatments. Regard-
ing EID, 82% prefer to place two plastic stents and 62% shorter stents (Ta-
ble 1). Persistent inflammation with clinical sepsis was the definition most 
commonly (55%) reported for endoscopic failure. Regarding clinical cases, 
EVT and stent placement, with or without percutaneous/surgical drainage, 
were the therapeutic options most often chosen by respondents in patients 
with previous oncologic surgery; EVT and EID were the therapeutic options 
most often chosen in patients with previous bariatric surgery.
conclusion: There is a wide variation in the management of patients with 
UGI anastomotic leaks, even among experts. Future prospective studies 
are needed to move from an expert- to an evidence- and personalised-
based care.
disclosure: None of the authors acted as Reviewer or Editor of this article. 
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P0858 hyBrId argOn-PLasMa-cOaguLaTIOn versus 
radIOfrequency aBLaTIOn In BarreTT’s esOPhagus afTer 
endOscOPIc resecTIOn Of neOPLasTIc LesIOns: a randOMIzed 
TrIaL aT a TerTIary cenTer
Knabe M., Wetzka J., Kronsbein H., Richl J., May A.
Sana Clinic Offenbach, Medizinische Klinik II/IV / Gastro., 
Pneumol.,Hämatol.-Onkol., Offenbach, Germany
contact e-Mail address: mate.knabe@googlemail.com
Introduction: Neoplastic Barrett esophagus (BE) is usually treated by a 
combination of endoscopic resection for (visible) neoplasia followed by 
ablation of the remaining Barrett’s mucosa with the aim to eradicate the 
entire BE. Different ablation techniques have been established in clini-
cal routine for this therapy approach. Radiofrequency ablation (RFA) and 
argon-plasma -coagulation (APC) are most frequently used. There is some 
evidence that prior injection to APC (Hybrid-APC) lowers stricture rates in 
these patients. There is only very rare data comparing APC and RFA in a 
randomised trial setting and no study comparing H-APC with RFA so far.
aims & Methods: The Aim of this study is to compare the two major abla-
tion techniques in a large group of patients. The study was planned as a 
non-inferior trial. All patients who have been treated for neoplastic lesions 
in Barrett’s esophagus and were planned for subsequent ablation were 
randomized to RFA or H-APC. Time of deviation, complications and pos-
tinterventional pain ( 1-10 on scale, duration) were measured. All patients 
are planned for follow-up gastroscopy after 3,6,12 and 24 months with 
chromoendoscopy and biopsies at the Z-line.
results: 64 patients (60 males, 4 females, mean age 64,9 years) have been 
included to the study with N=28 randomized to RFA and N=38 to H-APC 
group. N=28 patients have completed ablation and short-term follow-up 
(3 or 6 months). 114 ablative interventions have been performed so far. 
In mean 1,8 ablations (min 1 max 5) were needed for successful Barrett’s 
  Ideal patient characteristics
  stent OTsc evT suture septotomy eId
Time of leak Acute Chronic 
No experience No information
93.8% (n=60) 17.2% 
(n=11) n=2 n=5
96.8% (n=61) 19% (n=12) 
n=6 n=2
48.7% (n=19) 71.8% 
(n=28) n=27 n=5
89.5% (n=34) 31.6% 
(n=12) n=32 n=1
3.2% (n=1) 100% (n=31) 
n=38 n=2
54.3% (n=25) 65.2% 
(n=30) n=22 n=3
Leak size 0 - 1cm 1 - 2cm 
2 - 3cm >3cm No experience 
No information
54.1% (n=33) 63.9% 
(n=39) 55.7% (n=34) 
42.6% (n=26) n=2 n=8
77% (n=47) 47.5% (n=29) 
9.8% (n=6) - n=6 n=4
25% (n=10) 40% (n=16) 
67.5% (n=27) 77.5% 
(n=31) n=27 n=4
64.7% (n=22) 50% (n=17) 
47.1% (n=16) 35.3% 
(n=12) n=32 n=5
51.9% (n=14) 63% (n=17) 
51.9% (n=14) 63% (n=17) 
n=38 n=6
63.6% (n=28) 65.9% 
(n=29) 45.5% (n=20) 
38.6% (n=17) n=22 n=5
Leak location Intra-thoracic 
Intra-abdominal No experience 
No information
93.2% (n=55) 45.8% 
(n=27) n=2 n=10
64% (n=32) 92% (n=46) 
n=6 n=15
92.5% (n=37) 60% (n=24) 
n=27 n=4
58.6% (n=17) 96.6% 
(n=28) n=32 n=10
25% (n=7) 92.9% (n=26) 
n=38 n=5
66% (n=31) 83% (n=39) 
n=22 n=2
Associated collection Yes No 
No experience No information
11.3% (n=7) 88.7% (n=55) 
n=2 n=7
7% (n=4) 93% (n=53) 
n=6 n=8
95.2% (n=40) 4.8% (n=2) 
n=27 n=2
11.1% (n=4) 88.9% (n=32) 
n=32 n=3
90% (n=27) 10% (n=3) 
n=38 n=3
97.9% (n=46) 2.1% (n=1) 
n=22 n=2
Previous surgery Bariatric 
Oncologic No experience 
No information
78.6% (n=44) 75% (n=42) 
n=2 n=13
87.8% (n=43) 71.4% 
(n=35) n=7 n=15
81.6% (n=31) 84.2% 
(n=32) n=27 n=6
96.6% (n=28) 72.4% 
(n=21) n=32 n=10
100% (n=27) 25.9% (n=7) 
n=38 n=6
95.5% (n=42) 59.1% 
(n=26) n=22 n=5
[P0857 Table. Ideal patient characteristics for each endoscopic technique]
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eradication. There was no significant difference in Barrett’s length be-
tween the two groups. The mean length of BE before ablation was 3,7cm 
(H-APC) and 4.9cm (RFA).
Barrett’s eradication rate after 6 months follow-up was 90% in the RFA 
group and 78 % in the hybrid- APC group. Except of non-healers (10.1 %) 
all Barrett remnants were localized at the neo-Zline. However, the post 
interventional pain was significantly higher in the RFA group: mean 3.7 
/10 and duration of 7.3 days, whereas patients in H-APC group complained 
about pain for 3.3 days in mean and severity of 1.9/10.
conclusion: Bothe ablation techniques have good results in eradication 
rate with slightly better outcome for the RFA group. The pain severity and 
duration therefore were significantly higher in the RFA group. Combina-
tion of H-APC in the tubular esophagus und RFA at the Z-Line might lead to 
a better outcome for Barrett’s eradication and patients discomfort.
disclosure: Nothing to disclose 
P0859 endOscOPIc fuLL ThIckness resecTIOn fOr 
TreaTMenT Of gasTrIc suBePITheLIaL TuMOrs
Chiu P.W.Y., Yip H.C., Chan S., Teoh A., Wong S., Ng E.
Chinese University of Hong Kong, Department of Surgery, Hong Kong, Hong 
Kong, China (SAR)
contact e-Mail address: philipchiu@surgery.cuhk.edu.hk
Introduction: Submucosal tunnel endoscopic resections (STER) had been 
increasingly performed for treatment of gastric subepithelial tumors. One 
of the limitations for STER is the risk of incomplete tumor resection due to 
close dissection and bridging of tumor capsule. Endoscopic full thickness 
resection (EFTR) allowed complete resection of the tumor with margins to 
prevent recurrence. This study aimed to review the techniques and out-
comes of EFTR for treatment of gastric subepithelial tumors.
aims & Methods: Patients who received endoscopic resection for gastric 
subepithelial tumors were recruited. The gastric subepithelial tumors 
were considered eligible for endoscopic resection with size < 40mm. All 
patients received preoperative assessments including EUS and CT scan to 
define the extend of tumors and the proportion of extra and intralumenal 
components. All the procedures were performed under general anesthesia 
with CO2 insufflation. EFTR started after injection with mucosal incision 
up to 50% of tumor circumference, followed by submucosal dissection to 
identify tumor margin. Further dissection was performed using ESD de-
vices. After adequate exposure of lateral margins, incision into muscularis 
propria was performed to achieve full thickness resection. Luminal defects 
were closed by either clips, clip-loop crown method or Overstitch suturing.
results: From 2012 to 2019, 18 patients received EFTR for gastric subepithe-
lial tumors. The mean age was 60.6 years, and 6 were male. The GIST were 
located at greater curvature (4), cardia (6), lesser curve (4) and antrum (2). 
The mean size was 21.9mm (10 - 50 mm). Half of the EFTR were performed 
in operation theatre while half were done at endoscopy. The mean hospital 
stay was 4.2 days, and mean operative time was 92 minutes (34-180 mins). 
There was one conversion to laparoscopic resection. Closure of luminal 
defect were performed with clips (7), Overstitch endoscopic suturing (7) 
and clip and loop crown closure (3). Most patients resumed full diet on 
day 3, and all the pathologies confirmed GIST tumors with clear resection 
margins.
conclusion: Endoscopic Full Thickness Resection is technically feasible and 
safe procedure for treatment of gastric GIST. Future research should focus 
on refining the techniques of EFTR and closure of the defect.
disclosure: Nothing to disclose 
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Introduction: Laparoscopic sleeve gastrectomy (LSG) is one of the most 
commonly performed bariatric procedures for treatment of morbid obesity. 
Despite its popularity, it is not without risks, the most serious of which is 
the staple line leak. Staple line leaks are difficult to manage and require 
significant resources in the form of surgical, radiological and endoscopic 
interventions, resulting in long hospital and intensive care stays and sig-
nificant morbidity.
aims & Methods: The objective of this report is to describe our single-
institution experience in managing SG staple-line leaks with fully-covered 
self-expanding metal stents (SEMS) across the leak sites. 
Data for all patients who underwent endoscopic stent placement for an SG 
leak between 12/2016 and 02/2019 at a single academic institution were 
retrospectively reviewed. Patient medical history, perioperative informa-
tion, stent placement details, outcomes, and subsequent interventions 
were recorded.
results: Twenty-six patients with SG staple-line leaks treated with fully-
covered endoscopic stents were identified. Leaks were detected at a medi-
an of 11.5 days post-procedure (range, 1-31 d). Stents remained in place for 
an average of 44.8 ±10.8 days. Complete migration occurred in three (12%) 
and partial migration (1 - 4 cm) in five (20%) of the stent placements. 
One patient was lost to follow-up, and 22 of the remaining 25 patients 
(88%) healed after stent placement. Two patients (8%) ultimately required 
operative revision with partial gastrectomy and Roux-en-Y oesophagojeju-
nostomy for management of persistent leakage.
conclusion: Endoscopic management using fully-covered SEMS for sta-
ple-line leaks after SG is effective in the majority of patients. However, 
migration is the limiting factor for optimal management. Algorithms are 
needed for the management of chronic staple-line leaks, which are less 
likely to heal after stent placement. Our data indicate that earlier use of 
SEMS seems to reduce the time until closure and the length of the total 
hospital stay.
disclosure: Nothing to disclose 
P0861 The rOLe Of endOscOPIc heMOsTaTIc POWder In nOn-
varIceaL gasTrOInTesTInaL BLeedIng: a sysTeMaTIc revIeW 
and MeTa-anaLysIs WITh IMPLIcaTIOn On cLInIcaL PracTIce
Bukhari M.1, Sabbagh W.1, Alkhattabi A.1, Aljehani M.1, Qatomah A.1, 
El Zein M.2, Haito Y.3, Alkandari A.4, Al omar H.5, Ibrahim M.6, Khashab M.7
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Introduction: Acute non-variceal upper gastrointestinal bleeding (NVUGIB) 
is a common medical problem that results in high morbidity and mortality. 
Endoscopic hemostasis has been widely accepted as first-line manage-
ment for patients with NVUGIB. Hemostatic nanopowder is a novel therapy 
used to treat patients with upper gastrointestinal bleeding. Hemostasis is 
achieved by adhering of the powder to the bleeding site, which leads to a 
mechanical barrier. The powder has been shown to enhance clot forma-
tion and shortens coagulation time. It is delivered through a catheter and 
sprayed onto the bleeding site under direct endoscopic guidance, without 
direct tissue contact. The reported success rate of homeostatic nanopow-
der in patients with NVUGIB ranges between 75 to 100%, with the re-
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bleeding rate of 10-49%. This systematic review and meta-analysis aimed 
to assess the effectiveness of hemostatic powder in achieving initial hemo-
stasis, either as primary monotherapy, or as a part of salvage therapy in 
treating patients with NVUGIB.
aims & Methods: We performed a comprehensive literature search of 
PubMed, EMBASE, Web of Science, and Cochrane Library through Novem-
ber 2018. Studies with more than ten patients were selected according 
to predefined criteria and analyzed to generate pooled data. Weighted 
pooled rate (WPR) for initial hemostasis, rebleeding rate for primary 
monotherapy or salvage therapy, and post-procedure complications were 
calculated for overall studies. Heterogeneity was quantified using the I-
squared measure. Meta-analysis with Fixed effects model was performed 
to calculate data for initial hemostasis, rebleeding rate, and complications.
results: Out of 1379 studies obtained from the initial database search, 16 
studies with a total of 688 patients met the inclusion criteria and were 
included in the meta-analysis. Most of the patients were treated for pep-
tic ulcer bleeding (62.5%). Hemostatic powder was used in 473 (68.8%) 
patients as primary monotherapy and in 215 (31.2%) patients as a salvage 
therapy. The weight pooled rate (WPR) for initial hemostasis as primary 
monotherapy was 93% (95% CI: 0.93-0.90) and 95% (95% CI: 0.91-0.97) 
as a salvage therapy. The rate of rebleeding after initial hemostasis in 
monotherapy was 19% (95% CI: 0.16-0.23) and salvage therapy was 31% 
(95% CI: 0.25-0.13) respectively. The WPR for post-procedure complica-
tions was 4% (95% CI: 0.02-0.07).
conclusion: Hemostatic nanopowder appears to be a safe and effective 
therapeutic option for the management of acute non-variceal upper gas-
trointestinal bleeding. This study represents the first meta-analysis that 
demonstrates the success of the hemostatic nanopowder in those patients. 
Further trials should clarify the ideal setting for the use of hemostatic pow-
der.
references: 1. Yau AH, Ou G, Galorport C, et al. Safety and efficacy of 
Hemospray(R) in upper gastrointestinal bleeding. Can J Gastroenterol 
Hepatol 2014;28:72-6. 2. Sulz MC, Frei R, Meyenberger C, et al. Routine 
use of Hemospray for gastrointestinal bleeding: prospective two-center 
experience in Switzerland. Endoscopy 2014;46:619-24. 3. Masci E, Arena M, 
Morandi E, et al. Upper gastrointestinal active bleeding ulcers: review of 
literature on the results of endoscopic techniques and our experience with 
Hemospray. Scand J Gastroenterol 2014;49:1290-5. 4. Sung JJ, Luo D, Wu 
JC, et al. Early clinical experience of the safety and effectiveness of Hemo-
spray in achieving hemostasis in patients with acute peptic ulcer bleeding. 
Endoscopy 2011;43:291-5. 5. Changela K, Papafragkakis H, Ofori E, et al. 
Hemostatic powder spray: a new method for managing gastrointestinal 
bleeding. Therap Adv Gastroenterol 2015;8:125-35.
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Ikeda H., Onimaru M., Inoue H.
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contact e-Mail address: yutoshimamura1219@gmail.com
Introduction: Fourth-generation endocytoscopy (EC; GIF-H290EC; GIF-
Y0074 [prototype], Olympus., Tokyo, Japan) was newly developed to pro-
vide high-definition images with ultrahigh magnification (×520 fold) al-
lowing in-vivo histologic assessment of gastrointestinal lesions by visual-
izing the cellular nuclei and cytoplasm.
aims & Methods: This study aimed to evaluate the diagnostic accuracy 
of EC in the diagnosis of superficial esophageal squamous cell cancer 
between non-expert endoscopists. A single-center, retrospective study 
of prospectively collected data of all squamous esophageal EC examina-
tions was conducted. The double staining method using crystal violet and 
methylene blue was applied to all lesions. Two endoscopists with exper-
tise in EC collected images of 57 esophageal lesions, whose histology was 
established between June 2015 and April 2018. The image quality was as-
sessed by these experts and poor quality images were discarded. Two non-
experts endoscopists with no experience in EC and blinded to white-light 
and narrow-band imaging findings as well as histopathologic diagnosis, 
independently reviewed and diagnosed all endocytoscopic images after 
one hour lecture of EC. EC diagnosis was made based on the new sim-
plified criteria that we modified from a previously reported classification 
(Inoue H, et al. Gastrointest Endosc Clin N Am. 2004). The classification is 
based on the density and size of the nucleus, the shape of the cells, and 
the frontline of cellular border: EC 1a: normal; EC 1b: inflammation; EC 2: 
intraepithelial neoplasia (IN); and EC 3: squamous cell carcinoma (SCC). 
The diagnostic performance of fourth-generation EC was assessed while 
using the gold standard histopathology as a reference and the interob-
server agreement by using the κ value.
results: EC images of 47 lesions (82.4%) were were selected for image 
review. The histopathology of the 47 lesions were as follows: normal 2; 
inflammation 14; intraepithelial neoplasia 4; and SCC 27. The sensitivity, 
specificity, and overall accuracy of EC for esophageal cancer diagnosis 
(EC1+2 vs EC3) were 82.1% (95%CI:64.4-92.1), 78.9% (95%CI:56.7-91.5), 
and 80.9% (95%CI:67.5-89.6) by endoscopist A; and 100.0% (95%CI:87.9-
100.0), 68.4% (95%CI:46.0-84.6), and 87.2% (95%CI:74.8-94.0) by endos-
copist B. The inter-observer agreement, Kappa statistic= 0.68 (95%CI:0.47-
0.89), was good.
conclusion: Fourth generation endocytoscopy using a new simplified clas-
sification yielded optimal diagnostic accuracy for the diagnosis of super-
ficial SCC in endoscopists without previous expertise in EC. EC aids in the 
diagnosis of early esophageal cancer and can be applied in clinical set-
tings after minimal training.
disclosure: Nothing to disclose 
P0863 MuscuLOskeLeTaL Injury aMOng endOscOPy 
PhysIcIans, nurses and TechnIcIans
Shah S.1, Abid S.2, Khan A.1,3
1Aga Khan University Hospital, Gastroenterology, Karachi, Pakistan, 2Aga 
Khan University and Karolinska Institute, Karachi, Pakistan, 3Aga Khan 
University Hospital, Medicine, Karachi, Pakistan
contact e-Mail address: samana.shah@aku.edu
Introduction: Ergonomics is the study of physical and cognitive demand of 
a task in accordance with an individual’s capacity, to minimize injury and 
maximize efficiency. Studies have suggested a high prevalence of muscu-
loskeletal injuries among endoscopists and ancillary staff. Survey-based 
studies estimate a 37% to 89% prevalence of musculoskeletal pain among 
gastroenterologists. 
There is paucity of data especially of endoscopists from eastern popula-
tions.
aims & Methods: Assess the frequency and severity of musculoskeletal 
injury among endoscopy staff who are involved in endoscopic procedures
To assess the effect of musculoskeletal injury on quality of work in en-
doscopy
A questionnaire was developed based upon the recommendation of the 
present guidelines. The data will be collected by the self-administered 
questionnaire, focusing on eleven components, covering demographics, 
musculoskeletal injury and working hours and duration.
results: A total of 47 participants, 30 (63.8%) male, 39 (83%) had right 
hand dominance and 8 (12.8%) had left hand dominance. There were en-
doscopists, trainees and ancilliary staff, 13 (27.7%), 9 (19.1%) and 29(53.2%) 
respectively. Assessing level of activity, 18(38.3%) had no regular exercise, 
11 ( 23.4%) exercised less than 150 minutes per day, 13 (27%) more than 
150 minutes.
23 (48.9%) of the participants had been doing endoscopies for upto 5 
years, 24 (51%) had been involved in endoscopy for more than 5 years. 
37 (78.7%) reported experiencing pain or numbness, of these 16 (42.6%) 
had neck pain, 13 (34%) lower back pain, 9(25%) shoulder pain, 7 (19.1%) 
hand pain, 6 (14.9%) thumb pain, 4(10.6%) elbow pain and 3(8.5%) re-
ported carpal tunnel syndrome. 10 (27%) of those having pain attributed it 
to endoscopy 21 (56%) were not certain, 6 (16%) said that symptoms were 
not caused by endoscopy.
16(44.4%), said pain was evident during endoscopy in 12 (34.3%) were 
quite bothered by their symptoms. The duration of symptoms was more 
than 6 months in 14 (37%), in 28 (77%) symptoms were static. 11 (29.7%) 
had to take time off from work, 23.4% of total group. 17 (45.9%) took medi-
cations for resolution of pain.
The responders were asked if they use some modifications to prevent these 
injury and 11(23.4) endoscopic monitor at eye level, 3 (7%) cardiac monitor 
at headside, 5 (10.6) stopped to move patients 7 (14.9%) sit while perform-
ing colonoscopy, 12 (25%) use height adjustable beds.
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conclusion: There is high prevalence of musculoskeletal injury in person-
nel involved in endoscopy, much of which has been attributed to endo-
scopic practice by responders in this study. Strategies to improve the er-
gonomics are vital.
Raising awareness and enhancing ergonomics in endoscopy may prevent 
endoscopic-related injury.
Neck pain 16 (42.6%)
back pain 13 (34%)
Shoulder pain 9 (25%)
hand pain 7 (19.1%)
Thumb pain 6 (10.6%)
Elbow pain 4(8.5%)
Carpal tunnel 3 (8.5%)
[Musculoskeletal injury frequency]
references: Training the Endo-Athlete: An Update in Ergonomics in En-
doscopy Singla, Manish et al. Clinical Gastroenterology and Hepatology, 
Volume 16, Issue 7, 1003 - 1006
disclosure: Nothing to disclose 
P0864 endOscOPIc ManagMenT Of PLuMMer-vInsOn 
syndrOMe
Ben Mohamed A., Medhioub M., Mahmoudi M., Khsiba A., Hamzaoui L., 
Azzouz M.M.
Faculty of Medicine of Tunis, Tunis, Tunisia
contact e-Mail address: asmabenmed2014@gmail.com
Introduction: Plummer Vinson Syndrome (PVS) also called Kelly Patterson 
is a rare clinical condition. It is characterized by dysphagia associated with 
iron deficiency anemia and upper esophageal webs in the post-cricoid re-
gion. Endoscopic esophageal dilatation is sometimes necessary. The pur-
pose of our study was to evaluate the clinical, morphological, therapeutic 
features of this syndrome.
aims & Methods: Twenty patients with PVS, diagnosed from January 2007 
to December 2016, were collected. Treatment was based on endoscopic di-
lation associated with iron supplementation. The dilation was performed 
as an outpatient by Savary-Gilliard esophageal bougies with an increasing 
caliber from 7 to 14 mm. A new dilatation session was performed in case 
of recurrence of dysphagia and / or esophageal stricture.
results: There were 20 patients ( 18 women (90%) and 2 men (10%)). The 
average age was 52 years (35-73). All patients suffered from dysphagia 
and anemic syndrome with an average duration of 22 months. All patients 
had iron deficiency anemia with an average hemoglobin level of 9.7g / dL 
(5.9-11) and a mean ferritin level of 11 µg / L (4-20). Twenty-three dilatation 
sessions were performed, on average 1.25 sessions per patient (1 to 3 ses-
sions). One patient had 2 webs, the rest of our patients had a single web.
The associated diseases were celiac disease in one case (5%), Biermer 
anemia in 4 cases (20%) and chronic gastritis Helicobacter Pylori negative 
in 3 patients (15%). No post-dilation complications occurred. The evolution 
was favorable marked by a disappearance of the dysphagia and a correc-
tion of the anemia in all the cases. No case of malignancy was observed 
during the patient follow-up with a mean follow-up of 30 months (8-60).
conclusion: Plummer Vinson syndrome is a rare condition that affects the 
quality of life of patients. Its treatment is based on endoscopic dilatation 
and iron supplementation. Due to the progressive risk of malignancy regu-
lar monitoring is required.
disclosure: Nothing to disclose 
P0865 vaLIdaTIOn Of a scOrIng sysTeM fOr The quaLITy 
Of vIeW aT uPPer gI endOscOPy
King D.1, Harvey P.1, Rees J.2, Cheung D.1, Khan F.3, Cole A.3, Trudgill N.1
1Sandwell and West Birmingham NHS Trust / University of Birmingham, 
Gastroenterology, West Bromwich, United Kingdom, 2Sandwell and West 
Birmingham NHS Trust / University of Birmingham, Gastroenterology, 
Birmingham, United Kingdom, 3Derby Digestive Diseases Centre, Royal Derby 
Hospital, Gastroenterology, Derby, United Kingdom
contact e-Mail address: dominic.king@nhs.net
Introduction: Despite Oesophagogastroduodenoscopy (OGD) being the gold 
standard for visualising the upper gastrointestinal (GI) tract, there are few 
criteria for a successful procedure compared to e.g. colonoscopy. Post OGD 
upper GI cancer - failing to diagnose upper GI cancer at endoscopy up to 3 
years before diagnosis - occurs in 10% of upper GI cancers. Our aim was to 
validate an OGD visualisation score through evaluating its reproducibility.
aims & Methods: Subjects undergoing diagnostic OGD were prospectively 
recruited. The OGD was recorded, and video footage anonymised. Eight 
experienced endoscopists rated 16 pre-selected video recordings provid-
ing two scores for six areas (upper and lower oesophagus, upper and 
lower stomach, first and second part of duodenum). The first score is an 
adapted luminal contents score.1,2 The second view score is based on bowel 
preparation quality scales. Each area was scored between 1 and 4 with 1 
being excellent and 4 being poor; the best score a video could receive was 
6 and the poorest was 24 (example contents and view scores - Table 1). 
The Intra-Class Correlation (ICC) estimate (two-way random effects model 
for absolute agreement of raters) was used to measure the correlation of 
the average ratings for both the median scores and the poorest scores for 
each scoring system.3
results: 16 patients were included in the validation study (50% male, me-
dian age 55 (40.5-67.5) years. The median contents score was 11 (range 
6-21). The highest contents score recorded by area was: 1 - 5%; 2 - 38%; 
3 - 41%; 4 - 16%. The highest view score recorded by area was: 1 - 13%; 
2 - 26%; 3 - 45%; 4 - 16%. The median view score was 10 (range 6-19). 
Both the contents and the view scores demonstrated respectable correla-
tion between mean observer scores.3 The contents ICC for the median score 
was moderate, at 0.74 (95% CI 0.48-0.89) and for the highest score, good, 
at 0.90 (0.81-0.96). The view score also demonstrated good ICC values for 
the median rating at 0.90 (0.59-0.92) and for the highest score, at 0.85 
(0.70-0.93).
conclusion: The quality of OGD visualisation scoring showed good correla-
tion between observers and appears to be a valid tool for the assessment 
of OGD quality. Having validated this scoring system, a cohort study will 
examine the association between visualisation scores and patient and en-
doscopist specific factors and allow assessment of interventions to improve 
OGD quality.
contents score description grade view score description grade
No foam, mucus, bubbles, 
debris, food or blood
1
Full distension, allowing clear view of 
all 4 quadrants on withdrawal
1
Minimal foam, mucus, bubbles, 
food or blood that does not 
obscure view
2
Full distension not completely achieved 
resulting in some limitation of view
2
Moderate foam, mucus, 
bubbles, debris, food or blood 
obscuring view to some extent
3
Reduced distension resulting in limited 
mucosal views
3
Abundant foam, mucus, 
bubbles, debris, food or blood 
significantly obscuring view
4
A collapsed oesophagus that does 
not distend, making the mucosa 
very difficult to assess or impassable 
stricture preventing full examination or 
failed intubation
4
[Table 1: example scores]
references: 1: Kuo CH, Sheu BS, Kao AW, et al. A defoaming agent should 
be used with pronase premedication to improve visibility in upper gastro-
intestinal endoscopy. Endoscopy 2002;34:531-4. doi:10.1055/s-2002-33220 
2: Chang C-C, Chen S-H, Lin C-P, et al. Premedication with pronase or 
N-acetylcysteine improves visibility during gastroendoscopy: an endos-
copist-blinded, prospective, randomized study. World J Gastroenterol 
2007;13:444-7. 3: Koo TK, Li MY. A Guideline of Selecting and Reporting 
Intraclass Correlation Coefficients for Reliability Research. J Chiropr Med 
2016;15:155-63. doi:10.1016/j.jcm.2016.02.012
disclosure: Nothing to disclose 
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P0866 an audIT Of POsT Ogd uPPer gasTrOInTesTInaL 
cancers (POugIc): 41% are POTenTIaLLy PrevenTaBLe
Flais A.1, Maruf S.1, Dhanji A.1, Mahmood M.1, Dhanji M.1, King D.2, 
Trudgill N.2
1Sandwell and West Birmingham NHS Trust, Gastroenterology, West 
Bromwich, United Kingdom, 2Sandwell and West Birmingham NHS Trust 
/ University of Birmingham, Gastroenterology, West Bromwich, United 
Kingdom
contact e-Mail address: dominic.king@nhs.net
Introduction: Upper gastrointestinal (GI) cancer has a poor prognosis, with 
most diagnosed at a late stage and only 1 in 5 surviving beyond 5 years. 
Failure to diagnose a cancer during an oesophagogastroduodenoscopy 
(OGD) may postpone effective treatment. This study examined post OGD 
upper GI Cancers within two hospitals to estimate how many were poten-
tially preventable.
aims & Methods: Between 2016-18 all cases of upper GI cancer were 
identified through coding records. Electronic case files were reviewed for 
evidence of an OGD between 6 months and 3 years before the cancer di-
agnosis. An OGD that failed to diagnose upper GI cancer within this time 
frame was considered a post OGD upper GI cancer (POUGIC). An algorithm 
was developed to categorise POUGIC cases based on previous work on post 
colonoscopy colorectal cancer, the presence or absence of a pre-malignant 
or cancer associated lesion and whether the OGD procedure was adequate 
or not (Table 1).
results: 324 upper GI cancer cases were identified during the study pe-
riod. 66% were male and median age was 72 (IQR 64-80) years. 17 (5%) 
were considered POUGIC cases - 47% male and median age 71 (64-78) 
years. 24% were Barrett’s surveillance OGDs. Sedation was used in 38% 
of cancer cases (35% of POUGIC) and 81% of cancer cases were recorded 
as being well tolerated (71% of POUGIC).
Applying the POUGIC algorithm to the 17 cases identified, adequate OGDs 
and sampling or follow up were found in: type 1a - 11.8%; 2a - 11.8%; 
3a - 35%. For those cases with inadequate OGDs or sampling or follow 
up: type 1b - 11.8% (pre-malignant lesion - inadequate sampling or follow 
up); 2b - 17.6% (cancer associated lesion - inadequate sampling or follow 
up); 3b - 11.8% (possible missed lesion prior exam inadequate). In total 
41% of cases were type “b” cases and potentially preventable, examples 
of which included Barrett’s surveillance period being longer than current 
guidance (Type 1b), inadequate follow up of an oesophageal ulcer (Type 
2b) and alternative and inferior investigations arranged when endoscopies 
were abandoned due to poor patient tolerance of the procedure (Type 3b).
Type 1 Premalignant lesion (Barrett’s oesophagus, adenoma, hyperplastic polyp, gastric Intestinal Metaplasia or atrophy) in the same segment as cancer.
a biopsy and surveillance adequate
b biopsy and surveillance inadequate
Type 2 Lesion associated cancer same segment as cancer (oesophageal ulcer or stricture, grade c or d reflux oesophagitis, gastric ulcer)
a Cancer associated lesion noted and biopsy sampling and follow up adequate
b Cancer associated lesion noted but biopsy sampling and follow up 
inadequate
Type 3 no pre-malignant lesion/lesion associated cancer same segment as cancer
a Possible missed lesion, prior exam adequate
b Possible missed lesion, prior exam inadequate
[Table 1. POUGIC Algorithm]
conclusion: 5% of upper GI cancer cases identified in this audit were 
POUGIC, which is lower than previously reported. The POUGIC algorithm 
used in this audit allows for the categorisation of cases into those which 
are potentially avoidable and unavoidable - 41 % were potentially avoid-
able. A focus on quality improvement of Type “b” cases is important to di-
agnose upper GI cancer earlier and improve outcomes in upper GI cancer. 
disclosure: Nothing to disclose 
P0867 advanTages Of caP-assIsTed devIce In The 
endOscOPIc ManageMenT Of fOOd BOLus OBsTrucTIOn In The 
esOPhagus: a MuLTIcenTer randOMIzed, cOnTrOLLed TrIaL
Ooi M.1,2, Wong S.1,2, Duong T.1, Appleyard M.3, Rayner C.1, Grimpen F.3, 
Nguyen N.1
1Royal Adelaide Hospital, Adelaide, Australia, 2Queen Elizabeth Hospital, 
Woodville South, Australia, 3Royal Brisbane and Women’s Hospital, Herston, 
Australia
contact e-Mail address: quocnam.nguyen@sa.gov.au
Introduction: Food bolus (FB) is a common presentation to emergency de-
partment. Endoscopic removal of FB can be challenging. Data on the use 
of a cap in FB is limited. This study compares the safety and advantages 
of cap-assisted device in removal of FB compared to conventional devices.
aims & Methods: A randomized, prospective multicenter trial at 3 high-vol-
ume tertiary-care referral endoscopic centers in Australia was performed. 
Consecutive patients who underwent an endoscopy for acute food bolus 
were randomized into this multicenter study. Patients were randomized to 
use either (i) transparent cap-assisted device or (ii) conventional device/s. 
Food bolus retrieval time, rate of en-bloc removal, total procedure time, 
procedure adverse events, type, size and location of FB were studied.
results: A total of 342 patients were enrolled into the study. The cap-as-
sisted group had a shorter food bolus retrieval time (FBRT) (4.6+3.1min 
vs. 22.3+11.3mins, P< 0.01) procedure time (22.9+6.1min vs. 47.7+17.1min, 
P=< 0.01), a higher success rate of FB removal (99.4% vs 93.6%, P= 0.01) 
a higher rate of en-bloc removal (93.0% vs. 28.1%, P< 0.01), a lower rate 
of major adverse events (9/171 vs. 13/171, P< 0.01) and a larger measured 
mean FB size (FB length: 17.6+2.9mm vs. 8.3+9.2mm, P< 0.01 and FB 
width: 52.3+20.7mm vs. 26.6+27.5mm, P< 0.01) compared to conventional 
group. The type and location of FB were comparable between the two 
groups, with no significant differences (p>0.05).
conclusion: The use of a transparent cap was found to be safe and effec-
tive in removal of oesophageal FB. This technique was associated with a 
shorter procedure time, a higher rate of en bloc removal of FB, a lower 
rate of adverse events and a larger mean FB size retrieved compared to 
conventional technique.
disclosure: Nothing to disclose 
P0868 MucOsaL TransPLanTaTIOn fOr The ManageMenT 
Of sTrIcTure afTer endOscOPIc suBMucOsaL dIssecTIOn
Saif U., Zhou Y., Liu B.-R.
The First Affiliated Hospital of Zhengzhou University, Gastroenterology, 
Zhengzhou, China
contact e-Mail address: karypton@hotmail.com
Introduction: Endoscopic submucosal dissection (ESD) of high grade dys-
plasia and early esophageal cancer has gained acceptance in the last de-
cade as an effective therapeutic option. Although the short term results of 
ESD are promising, a high risk of procedure related complications, includ-
ing post- procedural stricture remains unresolved.
aims & Methods: The aim of this study were to assess the effectiveness 
and safety of mucosal transplantation into esophagus from the stomach 
in preventing stricture formation after ESD in early esophageal cancer. Six 
patients who underwent circumferential ESD for early esophageal cancer 
were enrolled. After the patients underwent ESD, the mucosal patches 
taken from the posterior wall of the middle part of the gastric body by the 
ESD were placed to the ulcer site of esophagus. The guide wire was then 
inserted into the gastric cavity via flexible endoscopic channel to fix the 
patches with the stent at the ulcer site. The stent was removed after the 
performance with media of 7.83 days (range 7-9). All of the patients were 
followed up with endoscope.
results: The graft survival rate was 83.3% with strictures occurred at a 
mean of 33.67 days (range 20-56) after the procedure. The median number 
of endoscopic balloon dilatation sessions was 5.67 (range 4-7).
conclusion: Gastro-esophageal mucosal transplantation for stricture pre-
vention after circumferential submucosal dissection for early esophageal 
cancer and or high grade dysplasia seems feasible with excellent outcome. 
This study opens new perspective in this field.
disclosure: Nothing to disclose 
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P0869 safeTy PrOfILe Of PerOraL endOscOPIc MyOTOMy 
(POeM)
Drazilova D.1, Vackova Z.1, Hucl T.2, Štirand P.1, Kieslichova E.3, 
Janousek R.4, Ryska O.5, Spicak J.1, Martinek J.1
1Institute for Clinical and Experimental Medicine, Hepatogastroenterology, 
Prague, Czech Republic, 2Institute for Clinical and Experimental Medicine, 
Gastroenterology and Hepatology, Prague, Czech Republic, 3Institute for 
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Prague, Czech Republic, 4Institute for Clinical and Experimental Medicine, 
Radiodiagnostic and Interventional Radiology, Prague, Czech Republic, 
5Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS 
Foundation Trust, Surgery, Lancaster, United Kingdom
contact e-Mail address: drazilovad@gmail.com
Introduction: Peroral endoscopic myotomy (POEM) is endoscopic method 
of esophageal myotomy with high clinical efficacy and safety and repre-
sents a desirable therapeutic alternative to laparoscopy as a less invasive 
approach. Nevertheless, POEM remains an invasive intervention carrying 
risk of potential complications.
aims & Methods: The aim of our analysis was to assess the periopera-
tive and early postoperative adverse events (AEs) in patients undergoing 
POEM. 
We retrospectively evaluated the prospectively collected data from all con-
secutive patients who underwent POEM at our institution between Decem-
ber 2012 and May 2018 and searched for periprocedural complications.
results: A total of 231 patients have undergone 243 POEM procedures (12x 
re-POEM) from which 50 procedures (20.6%) passed uneventfully while 
in 193 procedures (79.4%), some AE occurred. Perioperative AEs included 
subcutaneus emphysema (79/243; 32.5%; no treatment needed), capno-
peritoneum requiring puncture (141; 58%), allergic reaction to antibiot-
ics (2; 0.8%), anaesthesia-related complications (14; 5.8%). Postoperative 
AEs included pain requiring analgesics (158; 65%), fever (20; 8.2%) and 
pneumonia (3; 1.2%). One patient (0.4%) lost taste and smell irrevers-
ibly. A total of 10 serious adverse events occurred in 8 patients (3.3%): 
post-POEM leak from mucosal incision requiring endoscopic clipping in 
5, pneumothorax in 2 (1 required drainage), pleural effusion requiring 
drainage in 1 and scrotum emphysema in 1 case. One patient died during 
the procedure due to cardiac arrest (the autopsy revealed unrecognized 
pulmonary hypertension and severe ischemic heart disease). The mean 
length of stay was 2.5 (±0.5) days, prolonged (≥4 days) hospitalization was 
required in 25 (10,8%) patients. 
ASA score was available in 170 patients: I- 44/170 (25.9%), II- 90 (52.9%) 
and III- 36 (21.2%). In patients with ASA I, II, III no adverse events occurred 
in 18.2%, 17.8% and 16.7% respectively. Serious complications were diag-
nosed in patients with ASA I, II, III in 2.3%, 4.4% and 5.6% respectively. 
The correlation between severe complications and ASA score was not sta-
tistically significant (p=0.754).
conclusion: POEM-related adverse events are rather common; however, 
most of them are mild. Although being quite rare, severe complications, 
and even fatal, may still occur. ASA score does not seem to be a significant 
predictor of major complications.
disclosure: Nothing to disclose 
P0870 fITTIng The quaLITy IndIcaTOrs In fecaL 
IMMunOhIsTOcheMIcaL TesT (fIT) POsITIve cOLOnOscOPy
Lim K.-W.1, Asokkumar R.1,2, Chin Y.K.1,3, Khor C.J.L.1, Siew Ching D.K.1, 
Salazar E.1, Hang Hock S.1, Chan W.1, Ying H.4
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contact e-Mail address: kimwei.lim2@mohh.com.sg
Introduction: Adenoma detection rate (ADR) is an important quality mea-
sure to assess the colonoscopy examination and high ADR is shown to 
protect against CRC. The ADR varies widely amongst endoscopist. Recently, 
adenoma per colonoscopy (APC) has been proposed as an additional qual-
ity measure to overcome the limitations with ADR. It was suggested that 
high ADR with low APC rate may reflect less thorough “remove one ad-
enoma and done” type colonic evaluation. 
We hypothesized that this may not be true and ADR consistently correlates 
with APC during colonoscopy. We studied the relationship of ADR and APC 
in FIT positive patients where adenoma prevalence is higher and com-
pared their efficacy based on correlation with advanced adenoma detec-
tion rate (AADR).
aims & Methods: We retrospectively studied the FIT positive database from 
November 2016 to October 2018 at Singapore General Hospital. Four gas-
troenterologist and 13 surgeons performed the colonoscopy. We excluded 
endoscopist who performed less than 10 cases from analysis. We defined 
advanced adenoma as adenoma ≥10mm in size or with villous histology 
or high-grade dysplasia. We included them in the ADR and APC calcula-
tion. We used descriptive and Student-t test statistics for comparison. We 
used Pearson’s correlation and Fisher r-to-z transformation to compare the 
relationship between ADR and APC, ADR and AADR, and APC and AADR. 
We performed multivariate analysis to identify factors that predicted high 
ADR.Our institutional review board approved this audit.
results: We analyzed 476 FIT positive patients who underwent colonos-
copy: 118 evaluated by gastroenterologist and 358 by surgeons. The mean 
± SD age was 64± 8 years and majority were females (53%). Each endosco-
pist performed 28 ± 14 colonoscopies. The mean Boston bowel preparation 
score was 6.3 ± 1.6. The caecal intubation rate was 100% and the mean 
withdrawal time was 11.6 ± 1.7 minutes. The overall ADR, APC and AADR 
was 51%, 1.06 and 16%, respectively. We found the ADR, APC and AADR 
was significantly higher for gastroenterologist than surgeons (45% vs. 
70%, 0.8 vs. 1.8, 14 vs 22, p=0.0001). We found the overall ADR correlated 
strongly with APC (R=0.89, p=0.0001) and moderately with AADR (R=0.71, 
p=0.001). Similarly, the APC correlated significantly to AADR (R=0.61, 
p=0.009). We did not observe any difference in the correlation coefficient 
between ADR-AADR and APC-AADR (0.71 vs. 0.61, p=0.63). Age and with-
drawal significantly predicted high ADR (p< 0.001) in multivariate analysis. 
The cancer detection rate in this entire cohort was 5%.
conclusion: ADR was significantly higher in FIT positive patients and cor-
related significantly with APC and AADR. In quality assessment of colonos-
copy, ADR should be used as the indicator than APC. We did not observe 
“remove one adenoma and done” behavior.
disclosure: Nothing to disclose 
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Introduction: Classical endoscopic mucosa resection (EMR) creates a sub-
mucosal cushion of fluid to avoid muscle layer damage at the time of snare 
resection. Sometimes the submucosal injection may narrow the working 
space in the colon, or increase the tension of the lesion and sometimes 
make it harder to snare (specially nongranular lesions). Underwater en-
doscopic resection (UEMR), first described by Dr. Binmoeller
1
, avoids the 
need for submucosal injection, and it may be helpful in challenging situa-
tions such as non-lifting lesions, or difficult locations.
aims & Methods: The aims of the study were to assess the safety, utility 
and technical success rate of the underwater technique for the treatment 
of challenging colonic lesions.
Clinical, endoscopic and histological data were collected from cases of 
UEMR performed in 4 centers between January 2016 and July 2018. Inclu-
sion criteria was lesions with no-lifting sign (in previous endoscopic injec-
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tion) that were poor candidates for classic EMR, difficult location (ileocecal 
valve, diverticulum or appendix) or lesions with a previous failed attempt 
for EMR in an expert center. SMSA polyp score was not applied because 
previous attempt of EMR is not addressed by this scoring system.
results: 60 UEMR in challenging situations were performed, of which 57 
completed follow-up (mean 186 days) to date. The mean age of the pa-
tients was 66.14, being 68% men.
There were 37 (61.67%) non-lifting lesions (including recurrent/residual 
lesions in ICV and appendix, and non-treated lesions), 17 (28.3%) appen-
dicular or ileocecal valve lesions not previously treated, 1 (1.6%) intradi-
verticular lesion, 2 (3.3%) lesions in complex sigma and 3 (5%) residual 
lesion including ileocecal valve.
The mean size (diameter) of the lesions was 19 mm, and the mean size 
(largest diameter) of the resection specimen was 15.3 mm (95% CI 13.68 - 
16.99 mm) being the largest specimen of 30 mm in diameter, with En bloc 
resection in 34 cases (56,67%), and piecemeal resection in 2-3 fragments 
in 19 cases (31,67%). The histology showed pT1 in 4 cases (one low risk 
pT1a), HGD and intramucosal cancer in 8 cases, and no advanced histology 
(LGD, SSP/A withoud displasia) in the others. There was one postprocedur-
al bleeding requiring endoscopic treatment and no major complications 
(no perforations). The success (complete macroscopic resection) of the 
technique was 98% with 3 recurrences, that were succesfully re-treated 
endoscopically and 4 patients underwent surgery, 3 cases due to high risk 
features at histology (pT1b) and 1 case of deep intraapendicular lesion.
conclusion: Underwater endoscopic resection in the colon is a safe and 
useful technique for challenging colorectal lesions such as non-lifting le-
sions, appendiceal, ileocecal valve, diverticular, and difficult sigmoid loca-
tions.
residual/recurrent lesion non-lifting 27 (45%) -includes aO &  Icv
Non-lifting  untreated lesion 10 (16,67%)
AO untreated lesion 12 (20%)
ICV untreated lesion 5 (8,3%)
Intradiverticular untreated lesion 1 (1,6%)
Failed EMR attempt at sigmoid lesion 2 (3,3%)
Incomplete resection (re-schedule) 3 (5%) -one case ICV
[Location of the lesions]
references: 1. Binmoeller K, Weilert F, Shah J, Bhat Y, Kane S. Gastrointest 
Endosc. 2012 May;75(5):1086-91. doi: 10.1016/j.gie.2011.12.022.
disclosure: This abstract was accepted as oral presentation at ESGE Days 
2019 
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Introduction: Endoscopic full-thickness resection (EFTR) using a modi-
fied over-the-scope clip (FTRD kit) in the colorectum is a technique that 
allows en-bloc full-thickness resection of lesions for selected cases (e.g. 
non-lifting lesions suspicious of flat malignant polyps), especially for le-
sions < 20mm
1
.
aims & Methods: To study the safety and feasibility of the endoscopic full-
thickness resection (EFTR) in colorectal lesions using an over-the-scope-
clip.
The clinical, endoscopic and histological data were collected prospectively 
in all cases of EFTR performed in 10 centers of Spain using the FTRD kit 
(Ovesco Endoscopy, Tübingen, Germany) during the period from June 2015 
to July 2018.
results: 71 EFTR were scheduled.
In 3 patients EFTR was not possible due to impossibility to pass the sig-
moid with the kit. In the other 68 patients the technical success was 85.2% 
with en-bloc resection in 83,8%.
The mean age of the patients was 67 years (range 40-86), being men 
64,79%.
Indications were: non-lifting sign recurrent lesions (46.47%), non-lifting 
sign untreated lesions (23.94%), incomplete resection of non-lifting sign 
lesions (11,26%), appendicular lesions (2.8%), suspected T1 lesion (7%), 
EFTR of suspicious scar (4,2%), subepithelial lesions (4.2%).
The mean diameter of the resected specimen was 21.53mm (95% CI 19.87-
23,2).
Final histology: LGD adenoma (40%), HGD adenoma (23%), intramucosal 
adenocarcinoma (4.47%), SSP (5.87%), T1sm1 (2.9%), advanced adenocar-
cinoma >sm2 (13%), scar tissue (6%) and others (2.8%).
In one case the OTSC was not deployed, with intraprocedural perforation. 
There were 2 cases of delayed perforation and 1 case of delayed bleeding.
10 patients underwent surgery: 3 perforation, 1 intraapendicular lesion, 
and 6 for advanced adenocarcinoma.
During the follow-up, 3 recurrences / residual tissues were treated endo-
scopically (benign histology).
conclusion: EFTR using a modified OTSC (FTRD system) for selected cases 
(such as failure of other endoscopic treatments in lesions < 20-25mm ) is a 
safe and feasible technique.
Evaluation of the insertion with a long cap (e.g. “prOVE” cap) and traction 
of the lesion prior to EFTR is highly recommended. Special care must be 
taken to avoid performing the resection if the OTSC is not deployed.
references: 1. Schmidt A ,Bayna T, Schumacher B, et al. Gut 2017 . doi: 
10.1136/gutjnl-2016-313677
disclosure: Nothing to disclose 
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Introduction: Endoscopic full-thickness resection (EFTR) using a modified 
over-the-scope clip (FTRD kit) in the colorectum is feasible for selected 
cases (e.g. suspicious of flat malignant polyps) , allowing en-bloc resection 
of lesions up to 20-25mm. But in some cases there is a risk of technical 
failure due to poor traction, rupture of the snare or loosing of the resection 
plane, and part of the lesion or the whole of it might get trapped inside the 
over-the-scope clip (OTSC).
aims & Methods: Our aim was to study the outcomes of the patients with 
the lesion trapped in the OTSC due to technical failure.
Clinical, endoscopic and histological data were collected prospectively 
in all cases of EFTR performed in 10 centers of Spain using the FTRD kit 
(Ovesco Endoscopy, Tübingen, Germany) during the period from June 2015 
to July 2018.
Cases of technical failure with part or the entire lesion trapped inside the 
OTSC were analyzed.
results: 68 cases of EFTR were evaluated.
In 10 cases, the lesion was trapped in the OTSC and could not be resected 
properly.
The mean age of the patients was 71 years, being men 80%.
Indications were: non-lifting sign recurrent lesions (6 cases), non-lifting 
sign untreated lesions (1), incomplete resection with non-lifting sign (2), 
appendicular lesions (1).
Location were appendix (1 case), stump (1), right colon (1), transverse colon 
(2), left colon (2), sigma (2), rectosigmoid junction (1).
The mean diameter of the lesion was 19mm.
In 8 cases there was a partial resection of the lesion (mean diameter of the 
lesion 18mm), and in 2 cases only biopsies were taken.
Final histology: LGD (4 cases), HGD (2), intramucosal adenocarcinoma (1), 
SSP (2), advanced adenocarcinoma >sm2 (2).
In the follow-up, three lesiones underwent surgery (appendicular lesion 
and advanced adenocarcinoma), 3 residual lesions were treated endo-
scopically and in 4 cases the scar showed no residual tissue.
conclusion: In some cases of intended EFTR , residual tissue trapped inside 
the OTSC might be easily treated endoscopically and sometimes might be 
treated by the OTSC itself, if the residual lesion is small.
disclosure: Nothing to disclose 
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resecTIOn fOr 5-9 MM cOLOrecTaL POLyPs
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Introduction: Cold snare polypectomy (CSP) is becoming a common method 
for removal small or diminutive polyps without submucosal injections or 
electrocautery. The aim of this study was to assess long-term efficacy and 
safety of cold snare polypectomy versus conventional endoscopic mucosal 
resection for 5-9 mm colorectal polyps with well-matched patient groups.
aims & Methods: In this retrospective analysis, 328 colorectal polyps from 
187 patients were removed with CSP or endoscopic mucosal resection 
(EMR) in Seoul St. Mary’s Hospital between March 2014 and June 2014. 
Resected polyps were divided into CSP group and EMR group. A 1:2 pro-
pensity case-matches analysis was used with covariates of baseline char-
acteristics, including sex, age, polyp size, follow-up duration, and proce-
dure-performed endoscopists. Finally, 5-9 mm sized polyps were included 
in this study. The recurrence rate and complication rate were compared 
between the matched two groups.
results: Two groups were well balanced by propensity score matching, 
and 151 polyps were matched. Fifty eight polyps from 35 patients were 
treated by CSP and 93 polyps from 71 patients treated by EMR. In CSP group 
and EMR group, mean age (years, mean ± SD) was 64.8±7.6 and 64.1±9.5 
(p=0.638), polyp size 5.9±0.8 cm and 6.0±0.9 cm (p=0.397), and follow-up 
duration 33.1±9.2 months and 32.2±10.0 months (p=0.584), respectively. 
While 6 of 58 polyps (10.3%) in CSP group recurred during follow-up pe-
riod, 1 of 93 polyps (1.1%) recurred in EMR group (p=0.008). Serious ad-
verse events such as delayed bleeding and perforation did not occur in 
either group.
conclusion: CSP group had significantly higher recurrence rate than EMR 
group after resection of 5-9 mm colorectal polyps. Both methods were 
safe without serious adverse events. Further prospective study including a 
large number of patients is required.
disclosure: Nothing to disclose 
P0875 TIP-In endOscOPIc MucOsaL resecTIOn fOr Large 
cOLOrecTaL sessILe POLyPs
Sato Y., Ozawa S.-I., Yasuda H., Kato M., Kiyokawa H., Yamashita M., 
Matsuo Y., Yamamoto H., Itoh F.
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Introduction: Tip-in endoscopic mucosal resection (EMR) is a modified 
EMR technique using which en bloc resection of large colorectal sessile 
polyps can be performed; however, its usefulness for colorectal sessile 
polyps of >20 mm has not been reported. This study examined treatment 
outcomes of tip-in and conventional EMR for large colorectal sessile polyps 
of ≥20 mm.　
aims & Methods: This was a retrospective case-control study conducted 
at a single tertiary center in Japan. Subjects included those with large 
colorectal sessile polyps of ≥20 mm, excluding pedunculated-type polyps, 
who underwent endoscopic resection between January 2010 and January 
2019. For tip-in EMR, 15-mm snare master or 20-mm spiral snare (Olym-
pus Co., LTD, Tokyo, Japan) was used. After a sufficient local injection, the 
snare tip was projected by 2 mm and a mucosal incision was created on 
the oral side of the lesion. After this, while fixing the snare tip to the sub-
mucosal layer, the snare was expanded while gradually pulling the scope. 
Once the lateral margin of the lesion was completely secured, the snare 
was closed while de-airing, and resection was then performed. The pri-
mary outcome was endoscopic treatment outcomes when using tip-in and 
conventional EMR, and the secondary outcome was the local recurrence 
rate after endoscopic treatment.
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results: During the study period, 126 patients 126lesions (72 men and 54 
women, mean age: 69.9±12 years, mean tumor size: 23.6±4.1mm) were 
resected using tip-in or conventional EMR. Forty-three colorectal lesions 
were treated using tip-in EMR and 83 using conventional EMR. Tip-in EMR 
had a significantly higher en bloc resection rate (90.7% vs. 50.7%, P = 
0.008), and significantly shorter treatment duration (6.64 ± 0.64 min vs. 
10.47 ± 0.81 min, P = 0.005) than conventional EMR. Perforation rates with 
tip-in and conventional EMR were 4.6% and 3.6%, respectively, indicat-
ing no significant difference (P = 0.556). All cases with perforation were 
successfully sutured using hemoclips, and additional surgical intervention 
was not required. Local recurrence was examined in 80 cases who were 
followed up for >6 months after endoscopic resection. The mean follow-up 
period was 25.7 ± 15.5 months. Recurrence rate was 0% and 7.0% in tip-in 
and conventional EMR cases, respectively, without significance difference 
(P = 0.495.)
conclusion: Tip-in EMR showed high en-block resection rate and no resid-
ual tumor was found. This technique is a potential endoscopic treatment 
alternative for large colorectal sessile polyps of ≥20 mm.
references: Chien H, Imai K, Hotta K, Ito S, Yamaguchi Y, Kawata N, Tanaka 
M, Takizawa K, Kakushima N, Matsubayashi H, Ono H (2016) Tip-in EMR 
for R0 resection for a large flat colonic tumor. Gastrointest Endosc 84:743.
disclosure: Nothing to disclose 
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Introduction: The development of the procedure questionnaire, by the Eu-
ropean Colonoscopy Quality Investigation (ECQI) Group, has been previ-
ously described in posters presented at United European Gastroenterology 
Week, 2015 and 2016.
aims & Methods: To assess the factors associated with sedation use in 
diagnostic and screening patients ≥50 years of age using questionnaire 
responses from across Europe. Data collection is an ongoing process: we 
analysed data collected between 2/6/16 and 30/4/18 (n=6445). 
All screening and diagnostic colonoscopies in patients aged ≥50 years 
were identified in our dataset (n=3365). Stepwise multivariable logistic re-
gression analysis was conducted to determine the main factors associated 
with sedation use. Analysis was performed on the following variables: age 
in 10-year categories; body mass index (BMI) categories; gender; inpatient 
status; reason for procedure; time of day colonoscopy performed; previous 
total colonoscopy in last 5 years; Boston Bowel Preparation Score (BBPS) 
≥6; retraction time categories; chromoendoscopy used; high-definition 
equipment used; assistive technology used; intended endpoint; and in-
tended endpoint reached.
results: There were 1394 procedures where the results of all selected vari-
ables were known provided by 59 practitioners from 38 institutions: 71.0% 
of procedures used sedation. In order, the most associated variables were:
1. Use of high-definition equipment (76.3% vs. 55.5%, p< 0.0001).
2. Use of assistive technology (59.0% vs. 72.8%, p< 0.0001).
3. Female gender (78.8% vs. 62.2% male, p< 0.0001).
4. Longer retraction time (83.9% > 10 minutes vs. 65.1% 6 - 10 minutes 
and 66.7% < 6 minutes, p< 0.0001).
5. Use of chromoendoscopy (76.3% vs. 69.5%, p=0.0051).
6. Younger patient age (78.0% 50 - 59 years vs. 67.6% 60 - 69, 68.1% 
70 - 79, 69.4% ≥80, p< 0.0001).
7. Inpatient status (84.0% vs. 68.7% outpatient, p< 0.0001).
conclusion: The use of sedation appears to be more associated with fac-
tors related to the equipment/techniques used during colonoscopy than 
patient characteristics.
disclosure: Toth E, Agrawal A, Amaro A, Hünger M, Petruzziello L, Jover 
R, Ono A: Consultant & advisory board participant to Norgine. Spada C: 
Consultant fee from Norgine. Brink L: Consultancy & Advisory Board par-
ticipant to Norgine, AMBU. Fischbach W: Consultancy & Advisory Board 
participant to Norgine; Speaking - Abbott, Bio Merieux, Falk; Advisory 
speaking - Aptalis, Fresenius Biotech, Pfizer; Advisory - Boehringer Ingel-
heim, med update. Kinnunen U: Consultant & advisory board participant 
to Norgine and Olympus (European NBI Expert Training Group). Riemann 
JF: In terms of ECQI, consultant to Norgine, otherwise no conflict of inter-
est. Amlani B: Employee of Norgine. Koulaouzidis A: No relevant conflict 
of interest. Patai A: No conflict of interest. Pecere S: No conflict of interest. 
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Introduction: Underwater endoscopic mucosal resection (UEMR) is sim-
ple and effective technique, and recently widespread for the treatment of 
colorectal polyps. Although UEMR has lots of benefits compared to con-
ventional EMR, UEMR has some problems to be solved. Especially, in un-
derwater condition, diagnosis of the extent of the superficial colorectal 
lesions is sometimes difficult compared to that in conventional air fulfilled 
condition because chromoendoscopy is not available. Image enhanced en-
doscopy (IEE) such as blue laser imaging (BLI) or narrow band imaging 
was reportedly useful to diagnosis the lesion extent, but these IEE are 
not good at poor bowel preparation. On the other hand, linked color im-
aging (LCI) which enhances color contrast seemed theoretically useful to 
diagnose the lesion extent even in underwater. Thus, we evaluated which 
observation mode (white light imaging [WLI], BLI, or LCI) was the most 
effective to diagnose the lesion extent of superficial colorectal polyps in 
underwater condition.
aims & Methods: Between April 2018 and December 2018, consecutive 
superficial colorectal polyps observed by three mode (WLI, BLI, and LCI) 
in underwater condition before UEMR were prospectively registered into 
database of our endoscopy unit, and the images were retrospectively ana-
lyzed. Observation in underwater and UEMR was conducted by using a 
LASEREO system (FUJIFILM, Tokyo, Japan) with an EC-L600ZP endoscope. 
Color values of the lesion and surrounding non-neoplastic mucosa were 
calculated using Photoshop (CIE L*a*b* color space). Then, color differ-
ence between the lesion and surrounding non-neoplastic mucosa (ΔE) 
was examined in each mode. The extent of the lesion was confirmed his-
tologically after UEMR. The visibility score of images in each mode was 
also evaluated by four evaluators (2 experts and 2 non-experts, who were 
blinded to background and histology). The visibility score was categorized 
from 4 (excellent visibility) to 1 (poor visibility).
results: In total, 73 colorectal polyps (50 adenomatous polyps [Ad] and 23 
sessile serrated adenoma/polyps [SSA/P]) observed by each mode were 
analyzed. Median lesion size (range) was 7 (5-25) mm. Among them, 61 
polyps (44 Ad and 17 SSA/P) were observed in transparent underwater 
condition, and 12 polyps (6 Ad and 6 SSA/P) were observed in crowdy un-
derwater condition due to poor bowel preparation. In transparent condi-
tion, color difference between the lesion and surrounding non-neoplastic 
mucosa (ΔE) of 61 lesions with BLI (8.2) and LCI (7.4) was significantly 
higher than with WLI (5.2) (P< .001). The mean visibility score of BLI (3.5) 
and LCI (3.4) was significantly higher than that of WLI (3.4) (P< .001). 
There was no significant difference between BLI and LCI regarding color 
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difference and visibility score. The color difference and visibility score of 
44 Ad was similar to 61 polyps as mentioned above. But, the color dif-
ference of 17 SSA/P with BLI was significantly higher than that of WLI, 
and there was no significant difference between LCI and WLI. In crowdy 
underwater condition, the mean visibility score of WLI (2.5) and LCI (2.8) 
was significantly higher than that of BLI (2.1) (P=002, P< .001, respec-
tively). The mean visibility score of LCI was tend to be higher than that of 
WLI (P=008). Accurate measurement of color difference was impossible 
in crowdy condition.
conclusion: BLI and LCI was useful to evaluate the extent of colorectal pol-
yps in transparent underwater condition. BLI seemed to be suitable to 
evaluate the extent of SSA/P. In crowdy underwater condition, LCI was bet-
ter to evaluate the colorectal polyps.
references: 1. Yamashina T, uedo N, et al. Comparison of Underwater vs 
Conventional Endoscopic Mucosal Resection of Intermediate-size Colorec-
tal Polyps. Gastroenterology 2019 Apr 11. pii: S0016-5085(19)35685-9. 2. 
Binmoeller KF, Weilert F, et al. “Underwater” EMR without submucosal in-
jection for large sessile colorectal polyps (with video). Gastrointest Endosc. 
2012 May;75(5):1086-91.
disclosure: Nothing to disclose 
P0878 revIeW Of effecTIveness Of PaTIenT InfOrMaTIOn 
LeafLeT (PIL) In PaTIenTs undergOIng gasTrOInTesTInaL 
endOscOPy
Ho S.1, Koo S.1, Butt F.2
1South Tyneside and Sunderland NHS Foundation Trust, Gastroenterology, 
South Shields, United Kingdom, 2South Tyneside NHS Foundation Trust, 
Gastroenterology, South Shields, United Kingdom
contact e-Mail address: sophie.koo@gmail.com
Introduction: In the United Kingdom, endoscopy services are overbur-
dened and waiting times are long due to limited resources. To improve 
this, there is a national drive for increasing Straight to Test (STT) patients. 
An effective Patient Information Leaflet (PIL) is paramount to facilitate this.
PILs are an effective patient education tool to support patients in making 
informed choices for their health care. Multiple factors influence the ef-
fectiveness with readability being the most important factor that directly 
affects patient’s ability to access the information provided.(1) Effective pro-
vision of information can improve patient satisfaction, greater compliance 
to treatment and follow up, thereby improving patient care. 
Research shows patients retain only 20% of verbal discussion with health 
care providers, but this improves to 50% with additional written or visual 
information. (2)
As per our endoscopy unit policy, all patients are provided with a paper PIL 
pre-procedure (updated every 3 years).
aims & Methods: Primary aims: 
1. To assess patient use and effectiveness of PIL 
2. To assess effectiveness of PIL in STT patients at South Tyneside District 
Hospital.
Secondary aims: 
1. To assess preferred formats of PIL 
Methods: All consecutive patients attending the endoscopy day ward over 
a 10 week period were asked to fill in a questionnaire and return it prior 
to discharge.
results: 206 patients returned the PIL (M=97, F=105, Prefer not to say=4). 
Patients underwent gastroscopy (n=79), colonoscopy (n=70), flexible sig-
moidoscopy (n=12), capsule endoscopy (n=14). Majority of patients (52.7%) 
were aged 55-74 years. 
Only 76.2% of patients read the PIL in full with women more likely than 
men. There is interest in electronic format and audio-visual aids despite 
a majority (88.1%) of patients still preferring printed PIL. 1 in 5 of patients 
who did not read the PIL thought an electronic PIL would be useful.
1 in 6 patients did not find the PIL useful. Issues reported were that the PIL 
was too long/difficult to understand/too complicated (n=8). Others felt the 
PIL had incorrect information or caused anxiety (n=5). Patients who did not 
find the PIL useful were >45 years. 
Patients who had a prior discussion with their clinician or had an endosco-
py pre-assessment found the PILs very or extremely useful (n=151, 85.6%). 
STT patients account for 10% of all patients (these patients neither had 
a discussion with a clinician nor a pre-assessment). Only 62% of these 
patients read the PIL in full and 23.5% of them did not find the PIL useful, 
suggesting poor understanding of the procedure.
conclusion: Almost a quarter of patients did not read the PIL and 18% of 
patients found the PIL somewhat useful or not useful. This implies poor 
understanding of the procedure which may have legal consequences. 
Although our numbers are low, our results still show a significant propor-
tion of STT patient did not find the PIL useful. In view of increasing use of 
STT pathway, there is a need to reinforce the use of pre-assessment clin-
ics and to introduce newer innovations such as audio-visual aids. Use of 
audio-visual aids in an ophthalmology pre-operative setting has shown to 
meet patient information needs, improve patient satisfaction and reduce 
patient anxiety.(3)
Our results show a demand for electronic platforms to access patient infor-
mation and healthcare providers need to adapt to this. 
We aim to re-audit patient satisfaction after introduction of audio-visual 
aids.
references: 1. Protheroe J, Estacio EV, Saidy-Khan S. Patient information 
materials in general practices and promotion of health literacy: an obser-
vational study of their effectiveness. Br J Gen Pract. 2015;65(632):e192-7. 
2. Gauld VA. Written advice: compliance and recall. J R Coll Gen Pract. 
1981;31(230):553-6. 3. Ahmed KJ, Pilling JD, Ahmed K, Buchan J. Effect of 
a patient-information video on the preoperative anxiety levels of cataract 
surgery patients. J Cataract Refract Surg. 2019;45(4):475-479.
disclosure: Nothing to disclose 
P0879 endOscOPIc suBMucOsaL dIssecTIOn fOr cOLOrecTaL 
LesIOns: OuTcOMes frOM a unITed sTaTes exPerIence
Gupta N.R.1, Rodriguez Ruiz G.2, Donboli K.1, Siddiqui U.D.1, 
Chapman C.G.1, Waxman I.1
1University of Chicago, Center for Endoscopic Research and Therapeutics, 
Chicago, United States, 2Hospital Central Norte Petroleos Mexicanos, Mexico 
City, Mexico
contact e-Mail address: nina.gupta@uchospitals.edu
Introduction: Endoscopic submucosal dissection (ESD) is an endoscopic re-
section technique used for removal of large non-pedunculated colorectal 
polyps and early (T1) colorectal cancers. This innovative modality provides 
an alternative to surgical resection. It allows for en bloc resection regard-
less of lesions size, which facilitates specimen orientation and accurate 
pathologic staging. The technique is also often curative as previously 
demonstrated by experiences showing a high R0 resection rate with low 
recurrence rate. While ESD is a well established technique in Asia for man-
agement of early gastrointestinal (GI) neoplasia, adoption in the western 
world has been limited.
aims & Methods: \We aim to describe outcomes from a colorectal ESD 
program at a United States (US) academic tertiary medical center and 
compare this to published non-Asian and Asian experiences.
Retrospective review was performed of colonic lesions referred to the Uni-
versity of Chicago Medical Center for ESD from 2012 to 2019. Data collected 
included lesion characteristics, procedural outcomes, histology findings, 
and patient follow up.
results: The study included 73 patients with a median age of 63 years 
(range 30-83) of which 34 were male (46.6%) and 39 were female (53.4%). 
The rectum was the most common location (n=47, 64.4%). Mean lesion 
size was 30.1 mm (SD± 18.0 mm) and most frequent Paris classification 
was IIa (n=21, 28.8%). 
Complete ESD was achieved in 72 cases (98.6%) with 61 patients (83.6%) 
confirmed to have an R0 resection on histology. ESD was performed en 
bloc in 50 cases (68.5%). The en bloc resection rate improved from 54.1% 
to 83.3% from the first half of the cases to second half (p=0.007). Adeno-
carcinoma was present in 14 of the resected lesions (19.2%). The mean 
procedure time was 116.3 min (SD± 54.4). Complications occurred in 9 cas-
es (12.3%) with 4 cases of delayed bleeding (5.5%), 4 cases of perforation 
(5.5%) and 1 case of perforation with delayed bleeding (1.4%). 
Most complications (n=6, 66.7%) were successfully treated endoscopically. 
Surgery was needed in three cases of perforation. Follow up procedures 
were performed in 32 patients (43.8%) while the remaining 41 patients 
(56.2%) followed up elsewhere or are not due yet. Mean follow up interval 
was 7.4 months (SD± 4.1). 
Follow up endoscopy showed inflamed or regenerative mucosa in almost 
all cases (n=31, 96.9%) with only 1 case of recurrent adenoma (3.1%). Table 
1 compares these US outcomes to a recent meta-analysis1 of pooled ESD 
outcomes in non-Asian and Asian countries. 
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  united states center
non-asian 
countries
asian 
countries
En Bloc Resection 68.5% 81.2% 93.0%
R0 Resection 83.6% 71.3% 85.6%
Recurrence 3.1% 5.2% 1.1%
Delayed Bleeding 6.8% 4.2% 2.4%
Perforation 6.8% 8.6% 4.5%
Need for Surgery Post ESD Complication 4.1% 3.1% 0.8%
[Colorectal ESD Outcomes at a United States Single Center Compared to 
Pooled Outcomes from Non-Asian and Asian Countries]
conclusion: This study shows successful outcomes of colorectal ESD at a 
US tertiary center. While the en bloc resection rate was lower than in other 
published cohorts, there was a learning curve with significant improve-
ment over time. Additionally, both the R0 resection rate and lesion recur-
rence rate were more favorable than in other Western experiences, and 
approach the rates seen in Asian countries. Complications were slightly 
higher in this study, but most were managed endoscopically. Overall, 
colorectal ESD is an important endoscopic advancement and effective non-
surgical treatment for early neoplasia. ESD training in the United States 
should be increased to optimize utilization and achieve outcomes com-
parable to Asia.
references: 1. Fuccio L, Hassan C, Ponchon T et al. Clinical outcomes after 
endoscopic submucosal dissection for colorectal neoplasia: a systematic 
review and meta-analysis Gastrointest Endosc 2017;8674-86.e17
disclosure: Nothing to disclose 
P0880 feasIBILITy Of The endOscOPIc cLassIfIcaTIOn Of 
fIBrOsIs In endOscOPIc suBMucOsaL dIssecTIOn (esd) fOr 
cOLOrecTaL neOPLasMs
Tamegai Y.1, Takeda S.2, Takarabe S.3
1Cancer Institute Hospital, Dept. of Endoscopy, Tokyo, Japan, 2Matsudo 
City Medical Center, Department of Gastroenterology, Matsudo City, Chiba, 
Japan, 3Ichikawa General Hospital, Tokyo Dental College, Department of 
Gastroenterology, Ichikawa City, Chiba, Japan
contact e-Mail address: yoshiro.tamegai@jfcr.or.jp
Introduction: The possibility of complete curative en bloc resection is 
sometimes related to the presence and degree of fibrosis in the submuco-
sal layer (SM), rather than tumor size and location. In this study, we ana-
lyzed the clinical outcomes of ESD for colorectal neoplasms accompanied 
by fibrosis. The aim of this study was thus to establish a safe and curative 
ESD procedure for colorectal neoplasms showing fibrosis in the SM layer.
aims & Methods: ESD was performed for 1,659 epithelial neoplasms in 
1,620 patients (male 906, female 714, average 66.7 years old) from January 
2003 to October 2018, and was completed for 1,643 lesions. Of these cases, 
359 showed SM fibrosis. These cases were divided into three groups: ab-
sence of fibrosis (A), fibrosis due to benign causes (B), and fibrosis due to 
cancer invasion (C). Furthermore, cases were classified as mild (grade 1), 
moderate (grade 2), or severe (grade 3). Clinical outcomes and pathologi-
cal findings of the above-mentioned ESD cases were analyzed according to 
these endoscopic classifications to facilitate the safe achievement of ESD. 
In addition, histological validation of endoscopic diagnosis was examined 
for the 240 of the 359 cases with fibrosis, to clarify for differential diagnosis 
between Type B and C.
results: Of the 359 cases with fibrosis, 226 cases involved benign causes 
(Type B), and 133 cases were considered related to cancer invasion (Type 
C). As the results of the validation study (n=240) for differential diagnosis 
between Types B and C as follows; sensitivity: 88.7%, specificity: 90.5%, 
accuracy: 89.2%, PPV: 96.3%, NPV: 74.0%. En bloc resection rates (n=359) 
were as follows: A, 97.7%; B-1: 97.1%; B-2: 88.8%; B-3: 63.3%; Type C-1: 
100%; C-2: 91.4%; C-3: 61.5%. The en bloc resection rates for Types B-3 
and C-3 were significantly lower (P < 0.05) than that for Type A. Similarly, 
R0 rates for Type B (82.8%) and C (82.9%) were significantly lower than 
that for Type A (93.5%). There were 12 cases (0.7%) of perforation, 5 of 
which (Type B) required emergency surgery. From these results, tumors 
accompanied by mild to moderate fibrosis become the standard indication 
for ESD. The tumors accompanied by severe fibrosis should be indicated 
as relative indications for ESD and required high quality of ESD technique 
to avoid perforation.
conclusion: Accurate diagnosis of fibrosis based on the perioperative en-
doscopic findings appears feasible and contributes to completing the ESD 
procedure safely and curatively.
disclosure: Nothing to disclose 
P0881 OnLy LInked cOLOr IMagIng Increases cOLOr 
cOnTrasT BeTWeen cOLOn POLyPs and surrOundIng MucOsa
Weigt J.1, Arciniegas Sanmartin I.D.2, Obst W.3, Canbay A.E.1
1Otto-von-Guericke University Magdeburg, Gastroenterology, Hepatology 
& Infectious Diseases, Magdeburg, Germany, 2Hospital Santa Casa de 
Misericordia de Porto Alegre, Gastroenterologia, Porto Alegre, Brazil, 3Otto-
von-Guericke University Hospital Magdeburg, Gastroenterology, Hepatology 
& Infectious Diseases, Magdeburg, Germany
contact e-Mail address: jochen.weigt@med.ovgu.de
Introduction: HD-white light endoscopy (WLE) is the gold standard in the 
detection of colon adenoma. Virtual chromoendoscopy cannot improve 
adenoma detection. Recently linked color imaging (LCI) was developed 
which is combining special light and a post processing in one imaging 
modality. First study results show a better visibility and a higher adenoma 
detection rate using LCI.
aims & Methods: Evaluation of color difference between colon adenoma 
and surrounding mucosa as a potential explanation of higher detection 
rate.
results: Prospective acquisition of images from adenoma in the three light 
modes WLE, Blue Light Imaging (BLI) and LCI.
Transformation of the images into L*a*b* color space. Measurement of 
color at areas of 31 x 31 pixels, two inside the polyp and 2 in the surround-
ing mucosa each. Calculation of the color difference according to the Delta 
E (Lab) Method.
We used paired t-test for statistical analysis.
results: In total 90 polyps were evaluated. Delta-E in WLE was lowest 
(12.34 ± 6.73). The highest Delta-E value was calculated for LCI (16.83 ± 
10.85). The Delta-E using BLI was 14.38 ± 11.42. The difference between LIC 
vs BLI and BLI vs. WLE was not significant. He difference between WLE and 
LCI was highly significant (p=0.002)
conclusion: Only linked color imaging leads to a significant increase of 
the color contrast of colon adenoma. This is a useful explanation for the 
reported increased adenoma detection rate using LCI.
disclosure: JW honor. of Fujifilm 
P0882 feasIBILITy and accuracy Of InnOvaTIve 3 
dIMenTIOnaL cOLOnOscOPe IMage usIng fIBer Brag 
graTIng sensOr
Han Jo J.1, Keum B.1, Kim S.H.1, Lee K.W.1, Jang S.H.1, Kim S.H.1, Choi S.J.1, 
Kim S.H.1, Lee J.M.1, Choi H.S.1, Kim E.S.1, Jeen Y.T.1, Lee H.S.1, Chun H.J.1, 
Kim C.D.1, Kang K.M.2, Kim J.S.2, Jang M.S.2, Kim J.S.2
1Korea University College of Medicine, Department of Internal Medicine, 
Division of Gastroenterology and Hepatology, Seoul, Korea (Republic of), 
2Center for Bionics, Korea Institute of Science and Technology, Seoul, Korea 
(Republic of)
contact e-Mail address: roadstar82@naver.com
Introduction: Colonoscopy is difficult procedure, largely due to unpredict-
able looping during insertion. If the endoscopist is able to see the colo-
noscope on the image display, fewer attempts are needed to straighten 
the shaft of the scope. A prototype Fiber Brag Grating(FBG) scope guided 
endoscopy provides a facility for continuous viewing on a monitor of the 
position of the colonoscope during examination. The aim of this study was 
to evaluate the accuracy and feasibility of the innovative 3D Colonoscope 
image using FBG sensor.
aims & Methods: In the first part of the study, the FBG sensor was inserted 
into the working channel of a general colonoscope in the first 100 cm from 
the tip of the scope. Then, the scope was placed in front of the monitor 
to confirm movement of the scope in all three dimensions. We evaluated 
loop formation such as N loop, alpha loop, reverse alpha loop, with the 
3D imaging monitor. In the second part of the study, 5 patients underwent 
colonoscopy with a FBG sensor, the colonoscope can be displayed in an-
teroposterior or lateral view, or in both positions together. The fluoroscopy 
was used in all investigations for comparison.
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results: In the first part of the study, the results showed that the shape 
sensor was reliable at a maximum bending curvature of 80mm-1. The av-
erage tip position error was 1.22 ± 0.82 mm, which corresponds to 0.82 ± 
0.7% of the total length of the sensor. Colonoscope movement and loops 
were detected correctly through the monitor. The prototype FBG in the 
second part of the study showed a high correlation and little discrepancy 
with the comparative findings on fluoroscopy. During the colonoscopy, we 
could confirm the shape of the loop made in the body.
conclusion: Image of colonoscopy reconstructed by FBG sensor can be suc-
cessfully applied to display colonoscope configuration. This flexible, thin 
and almost weightless shape sensor would be a novel technique for iden-
tification of colonoscope shape.
disclosure: Nothing to disclose 
P0883 effecTIveness Of sucTIOn vaLve BuTTOn reMOvaL 
fOr POLyP fragMenTaTIOn and PaThOLOgIcaL dIagnOsIs 
In exTracTIng resecTed cOLOn POLyPs On The BasIs Of 
PrOPensITy scOre MaTchIng anaLysIs
Kishida Y., Hotta K., Imai K., Ito S., Yabuuchi Y., Yoshida M., Kawata N., 
Kakushima N., Takizawa K., Ishiwatari H., Matsubayashi H., Ono H.
Shizuoka Cancer Center, Division of Endoscopy, Shizuoka, Japan
contact e-Mail address: y.kishida@scchr.jp
Introduction: When colorectal polyps were endoscopically resected, they 
were usually extracted by suctioning and sent for pathological examina-
tion. However, the fragmentation of polyp during extraction is one of the 
limitations for appropriate pathological diagnosis. Suction valve button is 
one of the intricating parts in construction of endoscope which may have 
implicit fragmentation risk.
aims & Methods: In this study, we retrospectively evaluated the effect of 
removing the suction valve button during extracting polyp for fragmenta-
tion and pathological cut-end diagnosis. 
We reviewed the reports of endoscopically removed polyps between Sep-
tember 2018 and February 2019. Cases included in this study were clinically 
diagnosed as neoplasm using magnifying endoscopy, collectively resected 
by cold snare polypectomy (CSP) or EMR, and extracted by suctioning. En-
doscopic and pathologic findings listed as following were collected; pa-
tient age, sex, colonoscope (HQ-290ZI: device channel 3.7 mm, PCF-290ZI: 
device channel 3.2 mm, Olympus), lesion location, lesion size, resection 
method (CSP or EMR), removal of suction valve button during polyp ex-
traction, and for the outcomes, polyp fragmentation rate, pathological his-
tology, and pathological cut-end among neoplastic lesions (“negative” or 
“positive/imponderable”). Polyp extraction with suction valve button was 
the conventional method of pressing the button and retrieving the polyp 
into a polyp trap affixed to the suction connector of the colonoscope. For 
the polyp extraction without suction valve button, we removed the button 
from the colonoscope before suctioning the polyp and sealed the suction 
valve cylinder by finger to apply suction. 
Fragmentation was defined as the macroscopic presence of multiple 
pieces of extracted polyp in the trap, all of which was double-checked by 
doctor and nurse, and all of the pieces were put into the formalin bottle 
for fixation. We used one-to-one propensity score matching method to 
adjust for the difference between the groups of with and without suction 
valve button.
results: We selected 322 pairs of cases for analysis on the basis of pro-
pensity score matching. After matching, the difference of the variables 
between each group were closely balanced. The fragmentation rate was 
significantly different between the extraction with and without suction 
valve button (36,7% vs. 22.4%, P < .001). For histological diagnosis in each 
group, the rate of normal colon mucosa was 8.4% and 9.9%, whereas that 
of neoplastic lesion was 90.0% and 88.6%, which were not significantly 
different. Among the neoplastic lesions, the rate of cut-end negative was 
higher in button-removed group (82.8% vs 90.8%, P = .010). On the other 
hand, when we concern pathological histology of normal colon mucosa as 
cut-end “imponderable”, the cut-end negative rate was 76.7% vs 81.8% 
(P = .113). In the multivariate analysis, suction valve button removal was 
the only independently associated factor for fragmentation (Odd ratio [OR] 
0.496, P < .001) and for negative cut-end in neoplastic lesions (OR 0.505, 
P = .009). Additionally, the rate of pathological diagnosis as normal co-
lon mucosa was independently associated with the resection method (CSP 
10.4%, EMR 2.1%, OR 0.342, P = .003), but not with button removal (OR 
1.23, P = .453).
conclusion: Suction valve button removal during extracting polyps was an 
effective way to improve the rates of fragmentation and pathological cut-
end diagnosis of neoplastic lesions.
disclosure: Nothing to disclose 
P0884 fLexIBLe sIgMOIdOscOPy fOr evaLuaTIOn Of 
anasTOMOTIc InTegrITy PrIOr TO The reversaL Of a LOOP 
ILeOsTOMy
Oh S.Y.
Ajou University School of Medicine, Department of Surgery, Suwon, Korea 
(Republic of)
contact e-Mail address: kgsosy@gmail.com
Introduction: Preoperative evaluation for anastomotic status has been rou-
tinely done with contrast enema (CE) before ileostomy closure. However, 
there are few data supporting the routine practice of examining CE prior to 
ileostomy closure. Actually, CE gives limited information to surgeon com-
pared to endoscopic evaluation and even can cause colon perforation and 
contrast peritonitis.
aims & Methods: The aim of this study is to evaluate the feasibility and 
usefulness of preoperative flexible sigmoidoscopic examination instead of 
contrast enema (CE) prior to ileostomy closure in rectal cancer patients 
who underwent anterior resection with a loop ileostomy.
We reviewed prospectively collected data of patients with rectal cancer 
who underwent anterior resection with a loop ileostomy from October 
2008 to November 2016. We compared postoperative outcomes between 
patients who underwent flexible sigmoidoscopy (FS) and underwent CE 
study.
results: Ninety-eight patients underwent CE examination, and 49 pa-
tients underwent FS prior to the reversal of a loop ileostomy. There was 
no significant difference in gender, body mass index, anastomotic type and 
anastomotic level between two groups except for age and time to ileos-
tomy closure. Two patients in CE group developed anorectal suppuration 
after the reversal of an ileostomy. They showed intact anastomotic site on 
preoperative examination. Patients in FS group developed no anorectal 
suppuration after the reversal of an ileostomy.
conclusion: Preoperative findings on CE could not predict postoperative 
anorectal problem. FS can evaluate the status of anastomotic site without 
increasing the postoperative anorectal problem. We suggest that CE can be 
replaced by FS in assessment of anastomotic integrity prior to the reversal 
of a loop ileostomy.
disclosure: Nothing to disclose 
P0885 anaLysIs Of an OPen-ended cOaxIaL MeThOd 
fOr deTecTIOn cOLOrecTaL cancer OBTaIned ThrOugh 
cOLOnOscOPy BIOPsIes: PreLIMInary resuLTs
Nevárez A.1, Fornés-Leal A.2, Parra-Escrig A.2, García-Pardo C.2, 
Frasson M.3, Cardona N.2, Pons Beltrán V.1
1Hospital Universitari i Politècnica La Fe, Digestive Endoscopy Unit, Valencia, 
Spain, 2Universidad Politécnica de Valencia, iTEAM Research Institute, 
Valencia, Spain, 3Research Institute La Fe, University Hospital La Fe, Surgery, 
Valencia, Spain
contact e-Mail address: nevarezja78@gmail.com
Introduction: Many technological advances have been made to optimize 
the detection of colorectal cancer lesions. Research has shown that the 
electromagnetic properties of healthy and cancerous tissues differ in many 
biological tissues.
aims & Methods: We aim at analyzing electromagnetic properties of 
healthy and pathological colon tissue and their differences with biopsies 
gathered from colonoscopy procedures. The dielectric constant and the 
conductivity of healthy and pathological colorectal samples of 70 patients 
were analyzed using the open-ended coaxial technique and were later 
correlated with their pathology results. Since these properties depend on 
multiple factors like tissue’s temperature, system calibration and the pa-
tient itself, polyps were analyzed by computing the difference between the 
healthy and the pathological samples within each patient. Measurements 
were performed on adenocarcinomas (CRC), adenomas without dysplasia, 
adenomas with low-grade dysplasia, adenomas with high-grade dyspla-
sia, hyperplastic and hamartomatous polyps.
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results: The differences obtained in dielectric constant between CRC and 
healthy pairs are higher than in the rest of pathologies. Within the fre-
quency region where larger differences appear, the median of this differ-
ence is 4.8 units. Differences in conductivity are lower, having a median 
of 2 units. By selecting a threshold in the difference of dielectric constant 
that maximizes the diagnostic capability of CRC, the system showed a sen-
sitivity of 75% and a specificity of 89% for detecting this disease (table 1).
conclusion: Results have shown that measurements of electromagnetic 
properties of tissue could aid in the detection of colorectal pathologies. 
The variability of the results is quite large, and hence the system should be 
improved prior to a potential implementation.
disclosure: Nothing to disclose 
P0886 cOneccT cLassIfIcaTIOn: a neW cLassIfIcaTIOn TO 
BesT chOOse The TreaTMenT In case Of Large suPerfIcIaL 
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Introduction: Several classifications has been developed to predict the risk 
of submucosal invasion in case of superficial colorectal lesion. We devel-
oped the CONECCT (COlorectal NEoplasia Classifiation to Choose the Treat-
ment) classification that merged all existing classification (Paris, SANO, 
KUDO, WASP, LST, NICE) in one table to simplify endoscopic characteriza-
tion. The originality of this classification is the combination of macroscopic 
features with mucosal pattern and vascular pattern abnormalities without 
using magnification.
We performed a prospective study to evaluate the performance of the 
CONECCT classification to differentiate adenoma (CONECCT IIA) and high 
risk adenoma or superficial carcinoma (CONECCT IIC: SANO IIIA or Mac-
ronodule bigger than 1 cm or ulceration or non-granular type).
aims & Methods: Bicenter prospective study of all characterization data re-
corded before ESD for large superficial colorectal lesions in two European 
expert’s centers. Sensibility (Se) Specificity (Spe) Positive predictive value 
(PPV) Negative predictive value (NPV) of presence of macronodule bigger 
than 1 cm, SANO IIIA, Paris 0-IIC (presence of ulceration) and CONECCT IIC 
were calculated.
Lesions were evaluated thanks to last generations endoscope: FUJIFILM 
series 760 or OLYMPUS series 190 without magnification or dual focus just 
before the ESD procedure.
results: 515 colorectal ESDs were performed between 01/2016 and 04/2019 
at 2 European expert’s centers. 
Results of ESD: En bloc Resection = 95,7%, R0 resection = 81%, Curative 
resection = 80%
466 lesions with a mean size of 57 mm that had all characterization data 
(Paris, SANO, KUDO, WASP, LST, NICE, CONECCT) were included. 64% of le-
sions were LST-G, 21% LST-NG and 15% protruded lesions. 80% of lesions 
were CONECCT IIc, 42% SANO IIIA, 14% had an ulceration (Paris O-IIc) and 
51% had a macronodule.
Histological analysis: LGD : 147 (32%) ; HGD (Vienne 4.2 and 4.3) : 174 
(37%) ; IM carcinoma: 101 (22%) ; Sm < 1000 : 22 (5%), sm > 1000:17 (4%) 
T2: 4 (1%)
Sensibility and specificity:
· LST with macro-nodule bigger than 1 cm:
- Submucosal cancer: Sen=74% / Spe=51% / PPV=13.6% / NPV=95,1%
· Paris IIC
- Submucosal cancer: Sen=24.4% / Spe=86.8% / PPV=15.4% / NPV=92%
· Sano IIIA
- Submucosal cancer: Sen=69.8% / Spe=60.4% / PPV=15.4% / NPV=95.1%
· CONECCT IIC
- Submucosal cancer: Sen=100% / Spe=21.1% / PPV=11.6% / NPV=100%
No difference was observed using FUJIFILM or OLYMPUS Scope (p=0,95):
FUJIFILM:
· Sano IIIA
- Submucosal cancer: Sen=66.7% / Spe=59,2%% / PPV=13.5% / NPV=94.9%
· CONECCT IIC
- Submucosal cancer: Sen=100% / Spe=23.6% / PPV=10.4% / NPV=100%
OLYMPUS:
Sano IIIA
- Submucosal cancer: Sen=78.9% / Spe=57.1% / PPV=14.6% / NPV=96.7%
CONECCT IIC
- Submucosal cancer: Sen=100% / Spe=20% / PPV=10.4% / NPV=100%
conclusion: The CONECCT classification allows to predict with a 100% sen-
sibility and a 100% NPV the risk of submucosal invasion with high defini-
tion scope without magnification.
PPV is always very small (around 15%) indicated that we are not able to 
clearly identify the submucosal cancer. However NPV of CONECCT classifi-
cation is perfect (100%) indicated that we are able to exclude submucosal 
carcinoma using the CONECCT classification (CONECCT IIA). CONECCT IIA 
lesions never presented submucosal adenocarcinoma and are best target 
for a piece-meal resection, however en-bloc resection by ESD should be 
the treatment of choice for CONECCT IIC lesions.
disclosure: Nothing to disclose 
P0887 an InTernaTIOnaL POLyPecTOMy PracTIce survey
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Introduction: Polypectomy plays a key role in colorectal cancer (CRC) pre-
vention. In recent years new polypectomy techniques, like cold snare re-
section, have been introduced. Ablative techniques, such as hot forceps 
resection and argon plasma coagulation (APC), have been associated with 
more complications and seemed to be losing popularity. We conducted an 
international survey to better understand changes in polypectomy practice 
patterns during recent years, uptake of cold snare polypectomy and adher-
ence to guideline recommendations.
aims & Methods: Colonoscopy practitioners were contacted through Gas-
troenterology, Colorectal Surgery and Endoscopy societies around the 
world and asked to participate in a Google Form online survey. The pri-
mary aim was to evaluate the uptake of cold snare polypectomy in the last 
5 years and to evaluate the current predominant polypectomy approaches 
for colorectal polyps between 1-20mm. Secondary aims were to evalu-
ate perceived benefits and concerns related to each specific polypectomy 
techniques and to evaluate adherence to recent guideline recommenda-
tions.
results: The survey was distributed by 9 societies and completed by 808 
colonoscopy practitioners around the world. Survey participants reported 
an 87.5 % (95% CI 85.2%-89.8%)) increase in use of cold snare during the 
last 5 years, with 55.3% (95% CI 51.9%- 58.7%) of survey participants re-
porting more than a 50% increase in its use. Cold snare was reported to be 
the predominant polypectomy technique for 4-5 mm polyps (67.0% (95% 
CI (63.7%-70.2%) and also for 6-10mm polyps (55.2% (95% CI 51.7%-
58.6%). For polyps 1-3 mm, cold forceps remains the predominant utilized 
polypectomy technique (78.4% (95% CI (75.6%-81.3%), while hot snare 
polypectomy remains the predominant utilized polypectomy technique for 
polyps 10-20 mm (92.5% (95% CI (90.7%-94.3%)) (table 1). 54.8 % (95% 
CI (51.4%-58.3%) of survey participants reported having no concerns for 
using cold snare, which was more than for other techniques: cold for-
ceps (29.7%), hot snare (27.0%), APC (13.1%) and hot forceps (9.5%). Cold 
forceps most reported concern was incomplete resection (60.6% (95% CI 
(57.3%-64.0%)). Hot snare most reported concerns were delayed bleeding 
(54.8%; 95% CI (51.4%-58.3%) and perforation (48.1%; 95% CI (44.7%-
51.6%)). 66.6% (95% CI (63.3%- 69.8%) of survey participants reported 
never using APC and 61.5% (95% CI (58.2%-64.9%)) never using hot for-
ceps for standard polypectomy.
conclusion: This survey found a substantial increase in utilizing cold snare 
polypectomy during recent years. Cold snare polypectomy has meanwhile 
become the predominant polypectomy approach for 4-10mm colorectal 
polyps among endoscopists. For smaller (1-3mm) polyps cold forceps and 
for larger (10-20 mm) polyps hot snare polypectomy currently remains the 
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predominant polypectomy approach. Ablative techniques (hot forceps and 
APC) are not used anymore by the majority of endoscopist for standard 
1-20 mm polypectomy. Current clinical practice patterns are well aligned 
with recently issued guideline recommendations.
disclosure: Nothing to disclose 
Polyp size aPc cold forceps hot forceps cold snare hot snare
1 - 3 mm 3 (0.4%) 626 (78.4%) 25 (3.1%) 140 (17.5%) 4 (0.5%)
4 - 5 mm 3 (0.4%) 188 (23.4%) 28 (3.5%) 537 (67.0%) 46 (5.7%)
6 - 10 mm 2 (0.2%) 22 (2.7%) 15 (1.9%) 442 (55.2%) 320 (40.0%)
11 - 20 mm 10 (1.2%) 3 (0.4%) 10 (1.2%) 37 (4.6%) 742 (92.5%)
[Physicians preferred resection strategy for various polyp sizes]
P0888 The OPTIMaL IMagIng WIndOW fOr MOLecuLar 
fLuOrescence endOscOPy usIng a c-MeT TargeTed 
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cOLOrecTaL POLyPs
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Introduction: White-light colonoscopy is the gold standard for colorectal 
polyp detection and colorectal cancer (CRC) prevention. However, there is 
still a polyp detection miss-rate of up to 22%.1 Fluorescence molecular en-
doscopy (FME) using EMI-137, a c-Met targeted fluorescent peptide, has the 
potential to guide the endoscopist and improve polyp detection rates.2 The 
aim of this study was to determine the optimal dose-to-imaging interval 
for FME and to further evaluate the safety and tolerability of EMI-137 in a 
population at high-risk for CRC.
aims & Methods: FME was performed in 15 patients with a colorectal ad-
enoma containing at least low-grade dysplasia. EMI-137 was administered 
intravenously (0.13 mg/kg) to three patients at either 1, 2 or 3 hours prior to 
colonoscopy. The two cohorts with the most optimal target-to-background 
ratio (TBR), or the 1- and 2-hour cohort in case of similar TBRs, were 
expanded to six patients. Fluorescence was visualized and quantified in 
vivo using multi-diameter single-fiber reflectance, single-fiber fluores-
cence (MDSFR/SFF) spectroscopy. Fluorescence was correlated to standard 
histology and c-Met expression on 4mm tissue sections ex vivo. EMI-137 
localization was assessed using fluorescence microscopy and confirmed by 
in vitro c-Met binding experiments.
results: FME using EMI-137 appeared to be safe and well tolerated. The 
dose-to-imaging interval for the 1-, 2- and 3-hour cohort was 0:54 - 1:28 
hour (n=6), 1:50 - 2:33 hours (n=6) and 2:41 - 3:20 hours (n=3). In vivo visu-
alization and quantification of fluorescence showed significantly increased 
fluorescence in dysplastic versus normal tissue for the 1-, 2- and 3-hour 
cohorts (median intrinsic fluorescence Qmf
a,x
= 3.46·10-4 vs. 2.15·10-4 mm-1, 
P < 0.0001; 3.28·10-4 vs. 2.04·10-4 mm-1, P < 0.0001 and 3.22·10-4 vs. 1.94·10-
4 mm-1, P < 0.0001 respectively). Ex vivo, an overall median TBR of 1.62 
was observed based on histological delineation of 41 tissue sections, with 
significant c-Met membrane overexpression in dysplasia. Fluorescence mi-
croscopy showed increased fluorescence in the proximity of the dysplastic 
crypts compared to normal tissue. A dose-dependent specific binding of 
EMI-137 was observed in vitro.
conclusion: We demonstrate that FME using EMI-137 appeared to be safe 
and feasible within a one-to-three hour timeframe. No significant differ-
ences have been observed between the time-cohorts, although a dose-
to-imaging interval of one hour was considered preferable from a clinical 
perspective. Future pivotal studies will study the use of EMI-137 for im-
proved detection of colorectal polyps in screening colonoscopies of pa-
tients at average risk of developing colorectal cancer.
references: 1. van Rijn JC, Reitsma JB, Stoker J, et al. Polyp Miss Rate Deter-
mined by Tandem Colonoscopy: A Systematic Review. The American Jour-
nal of Gastroenterology. 2006 Feb;101(2):343-50. 2. Burggraaf J, Kamerling 
IMC, Gordon PB, et al. Detection of colorectal polyps in humans using an 
intravenously administered fluorescent peptide targeted against c-Met. 
Nature Medicine; 2015 Jul 13;21(8):955-61.
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P0889 use Of The BOsTOn BOWeL PreParaTIOn scaLe In The 
reaL WOrd: WhaT affecTs IT?
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Introduction: The adequacy of bowel cleansing is one of the quality mea-
sures for lower intestinal endoscopy, affecting both the security and the 
diagnostic accuracy of the procedure. The aim of this study was to evaluate 
the quality of bowel preparation in a series of consecutive exams and to 
determine its predictive factors.
aims & Methods: Retrospective study assessing patients that underwent 
colonoscopy in a tertiary hospital between 01/2016 and 06/2018. For the 
morning procedures, the preparation was given on the day before colo-
noscopy and for the afternoon procedures, a split-dose bowel cleansing 
regimen was adopted. The Boston Bowel Preparation Scale (BBPS) was 
used to evaluate the quality of the bowel preparation - total BBPS score ≥6 
was considered as adequate.
results: A total of 4872 colonoscopies in 3839 patients [men - 51.4%, mean 
age - 61.2±13.9 years] were performed, by 11 endoscopists. The main in-
dications were: surveillance for neoplastic polyps/colorectal cancer (CRC) 
(52.0%); family history of CRC (21.9%). In this last case, patients were edu-
cated regarding bowel preparation by the Family Risk Clinic nurses. 
Cecal intubation rate was 96.2%. Inadequate bowel preparation (BBPS< 
6) was observed in 32.3% of the colonoscopies, with BBPS being ≤1 in the 
right colon in 26.8% of cases in the right colon; 16.4% in the transverse 
colon, and 17.9% in the left colon.
The quality of bowel preparation was significantly associated, in univari-
ate analyses, with gender (BBPS< 6: 37.5% men vs 26.8% women), day 
of the week, hour of the exam, morning/afternoon procedure (BBPS< 6: 
35.0% morning vs 22.5% afternoon), endoscopist and family history of CRC 
(BBPS< 6: 21.8% of the exams performed because of family history of CRC 
vs 35.5% of the exams performed for other reasons).
On multivariate logistic regression analysis, predictive factors for quality 
of bowel preparation were gender (p< 0.001), day of the week (p=0.016), 
morning/afternoon procedure (p< 0.001) and colonoscopies performed 
because for family history of CRC (p< 0.001).
conclusion: In the real world, we confirmed gender, educational interven-
tions and split dose regimens (adopted for the afternoon procedures) as 
factors influencing quality of bowel preparation.
disclosure: Nothing to disclose 
P0890 effIcacy and securITy Of The dOuBLe cLIP 
cOunTerTracTIOn MeThOd fOr resIduaL Or LOcaLLy 
recurrenT LesIOns In cOLOnIc endOscOPIc suBMucOsaL 
dIssecTIOn
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contact e-Mail address: faller.julien@gmail.com
Introduction: Endoscopic submucosal dissection (ESD) for the resection of 
scarred colonic lesions is a feasible but challenging technique because of 
submucosal fibrosis. We previously reported an internal traction meth-
od using two clips and a rubber band and making ESD easier.This study 
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aimed to evaluate the efficacy and security of ESD using this countertrac-
tion technique (DCT-ESD) in case of residual or locally recurrent colonic 
lesions.
aims & Methods: We retrospectively analyzed all residual or locally recur-
rent colonic lesions, DSM treated, in two french expert center, between 
august 2017 and february 2019. The countertraction technique has been 
systematically used.
The primary endpoint was the En bloc R0 resection rate. Secondary end-
points were en bloc resection rate, degrees of fibrosis, tumor diameter, 
procedure time, resection speed, secondary surgical treatment, and com-
plication rate.
results: Among the 44 patients included, there were 29 (66%) locally 
recurrent colonic lesions and 15 (34%) residual lesions after a primary 
endoscopic resection. Severe submucosal fibrosis was observed in 39 
patients (88.6%) and intermediate fibrosis in 5 patients (11.4%). Mean 
resected specimen diameter, procedure time and resection speed were 
40mm [20-65mm], 50min [6-230min], and 27mm2/min [6-95mm2/min], 
respectively. The en bloc resection rate was 90.9% (4 piecemeal mucosal 
resections conversions at the beginning of the study). This rate increases 
to 100% from the 11th resection due to the learning curve. Only 72.7% 
of all patients had negative margins (En bloc R0) often due to a hole 
inside the lesion. At all, 4 patients (9.1%) had needed secondary surgi-
cal treatment, three for incomplete resection and one for none curative 
resection criteria. Complication included three (6.8%) small intraopera-
tive perforations endoscopic treated. There was no secondary perforation 
but one case of delayed bleeding. No surgery was necessary following a 
complication.
conclusion: In cases with scarred colonic lesions, thanks to the double clip 
and rubber band countertraction method, ESD allows curative resection 
with low complication risk. This technique is an alternative to Full thick-
ness resection (FTRD) particularly for large lesions over 3 cm.
references: - Lacopini F,et al. Colorectal endoscopic submucosal dissec-
tion: predictors and neoplasm-related gradients of difficulty. Endosc Int 
Open. sept 2017; - Matsumoto A, et al. Outcome of endoscopic submu-
cosal dissection for colorectal tumors accompanied by fibrosis. Scand J 
Gastroenterol. nov 2010; - Oyama T. Counter Traction Makes Endoscopic 
Submucosal Dissection Easier. Clin Endosc. nov 2012 ; - Jacques J et al. 
Double-clip counter-traction using a rubber band is a useful and adaptive 
tool for colonic endoscopic submucosal dissection. Endoscopy. févr 2018;
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P0891 The rOLe Of The educaTIOnaL PrOjecT «quacOL - 
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Introduction: Suboptimal quality of colonoscopy is associated with in-
creased risk of interval colorectal cancer. It is uncertain how quality in 
colonoscopy might be improved. We assessed the effect of the educational 
project «QuaCol» on colonoscopy quality. It was performed in Russia be-
tween trials «QuaCol 1» and «QuaCol 2». We compared results of «QuaCol 
1» versus «QuaCol 2».
aims & Methods: We examined colonoscopies performed at the Endos-
copy Department of Yaroslavl Regional Cancer Hospital (YRCH) within trial 
«QuaCol 1» between September and December 2014 and trial «QuaCol 2» 
between November 2018 and February 2019. The main quality indicators 
such as polyp detection rate (PDR), adenoma detection rate (ADR), caecal 
intubation rate (CIR) and colonoscopy withdrawal time (CWT), bowel prep-
aration were assessed. We assessed also using of split-regimen laxative. 
The colonoscopies were performed by the same 9 colonoscopists during 
«QuaCol 1» and «QuaCol 2». 
Our study divided colonoscopists into 2 groups, depending on their re-
spective ADRs within «QuaCol 1»: low-detectors (ADR ≤ 20 %) and high-
detectors (ADR > 20%). Then we assessed their ADRs in «QuaCol 2» and 
compared results.
results: 987 patients (F 65,9%, M 34,1%; mean age 53) were included in 
the trial «QuaCol 1» and 1366 patients (F 71%, M 29%; mean age 55) were 
included in the trial «QuaCol 2». The main quality indicators were ADR 
(21,2 vs 29 %, p < 0,0001), CIR (92, 3 vs 96 %, p < 0,0001), PDR (40 vs 49 
%, p < 0,0001), CWT > 6 min (34 vs 41,4%, p < 0,0001), adequate bowel 
preparation (92 vs 94 %, p < 0,05). Split-regimen was used (83 vs 94,8 %). 
The ADR of low-detectors increased significantly higher (16,7 vs 24,5%, p < 
0.0001) than of high-detectors (31 vs 35,4 %, p < 0,01) after performing of 
the educational project «QuaCol».
conclusion: The quality of colonoscopy in YRCH within «QuaCol 1» was 
recognized as suboptimal to according recommendation ESGE. Then was 
performed the educational project «QuaCol - Quality in Colonoscopy». 
The educational project included some lectures about colonoscopy quality 
indicators, about importance of adequate bowel preparation and factors 
affecting on patients complains - low-volume laxative, split-regimen, low-
fiber diet. Hand-on-trainings were organized for improving of the tech-
nique and skills of endoscopists. Then «QuaCol 2» was performed. Accord-
ing to our study, the quality of colonoscopy in YRCH Obecame is optimal 
after performing of the educational project «QuaCol». Our data demon-
strated that ADR is increased (it was statistically valid). CIR is increased (it 
was statistically valid). PDR is increased (it was statistically valid). CWT > 
6 min is increased (it was statistically valid). Adequate bowel preparation 
is slightly increased (it was not statistically valid). Our study showed the 
medical educational may be a key factor of improving in colonoscopy qual-
ity. The improvement of colonoscopy quality is associated with increase 
prevention role of colonoscopy against colorectal cancer.
references: 1. Kaminski Michal F. et al. Performance measures for lower 
gastrointestinal endoscopy: a European Society of Gastrointestinal Endos-
copy (ESGE) Quality Improvement Initiative. Endoscopy 2017;49. 2. B. Rem-
backen, C. Hassan, J. F. Riemann, A. Chilton, M. Rutter, J.-M. Dumonceau, 
M. Omar, T. Ponchon. Quality in screening colonoscopy: position statement 
of the European Society of Gastrointestinal Endoscopy (ESGE). Endoscopy 
2012; 44: 957-968. 3. M. Antipova, M. Burdyukov, M. Bykov, L. Domarev, E. 
Fedorov, S. Gabriel, K. Glebov, S. Kashin, M. Knyazev, A. Korotkevich, A. 
Kotovsky, I. Kruglova, V. Krushelnitsky, E. Mayat, M. Merzlyakov, D. Mtvral-
ashvili, A. Pyrkh, O. Sannikov, E. Shitikov, A. Subbotin, A. Taran, V. Veselov, 
D. Zavyalov , C. Hassan, F. Radaelli, L. Ridola, A. Repici and M. Korolev. 
Quality of colonoscopy in an emerging country: A prospective, multicentre 
study in Russia. Gastroenterology 2015; 148 , 4: 209-210.
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P0892 OuTcOMes Of cOLOnOscOPIc surveILLance and 
MOLecuLar PhenOTyPIng In PaTIenTs aT heredITary rIsk 
Of cOLOrecTaL cancer
Norton B.1, Coultas J.2, Nicholas V.2, Wright T.2, Brown R.2, Monahan K.2,3
1Imperial College London, Department of Genomic Medicine, London, 
United Kingdom, 2West Middlesex University Hospital, Department of 
Gastroenterology, London, United Kingdom, 3St Mark’s Hospital, Family 
Cancer Clinic, London, United Kingdom
contact e-Mail address: benjamin.norton@nhs.net
Introduction: An estimated 35% of cases of colorectal cancer (CRC) are due 
to heritable factors, and approximately 30% of the UK population has a 
family history of CRC. Those at hereditary risk should be effectively man-
aged through registration, phenotypic and genotypic characterisation, and 
risk-stratified colonoscopic surveillance. We assessed the impact of sur-
veillance in patients at hereditary risk of CRC managed through the Family 
History of Bowel Cancer Registry at West Middlesex University Hospital 
(WMUH). Through analysis of this registry data, we assessed the diagnos-
tic yield of colonoscopic surveillance and assessed the role of molecular 
testing.
aims & Methods: We analysed prospectively collected colonoscopic sur-
veillance data at WMUH between 2010-2018. Patients were divided into 
five family history risk populations as defined by current British Society of 
Gastroenterology (BSG) guidelines. Patient demographics including age, 
gender and family history were collated, alongside colonoscopy findings, 
and molecular data including mismatch repair (MMR) status and germline 
testing. Impact of these variables on the prevalence of non-advanced ad-
enomas (NAAs) and advanced adenomas (AAs) were assessed by logistic 
regression using SPSS software. Time to NAA or AA was determined by 
survival analysis and findings were compared between index and surveil-
lance colonoscopy.
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results: In total, 752 colonoscopies were performed in 454 patients with 
1081 years of colonoscopic follow-up. Five CRCs, 56 AAs and 204 NAAs 
were identified with an adenoma detection rate (ADR) of 20.01%. Time to 
both NAA and AA occurred at significantly earlier age in patients with LS. 
The prevalence of CRC, AA and NAAs in patients without Lynch syndrome 
(LS) was 0.46%, 7.85% and 25.04%, respectively, with no significant dif-
ferences between non-LS family history populations. Although the number 
of affected offspring did associate with AA detection on univariate analysis 
(P = 0.038), only age was significantly associated with both NAA and AA 
detection on multivariable analysis (P < 0.001). A normal index colonos-
copy was strongly associated with normal findings during surveillance 
(p < 0.001). A family history of MMR proficient CRC was associated with 
an ADR equivalent to the non-LS population (22.67%). Molecular testing 
significantly altered surveillance strategy in 27.6% of patients through re-
categorisation of familial risk.
conclusion: This data emphasises the strong association of colorectal neo-
plasia with MMR status and the need to exclude LS in patients at famil-
ial risk. Age is independently associated with colorectal neoplasia risk in 
this analysis, however patients often undergo colonoscopic surveillance 
inappropriately early. A normal index colonoscopy is associated with a low 
diagnostic yield in subsequent colonoscopies in this population, and this 
relatively low yield may influence future guideline strategies. Finally, we 
believe that molecular phenotyping to risk stratify patients helps to facili-
tate effective colorectal cancer prevention.
disclosure: Nothing to disclose 
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Introduction: Colorectal cancer (CRC) accounts for over 40,000 new cases/
year in the UK, and in 35% of cases CRC develops due to inherited sus-
ceptibility. Patients at hereditary risk undergo colonoscopic surveillance to 
reduce CRC incidence and mortality. High quality colonoscopy, measured 
by key performance indicators (KPIs) including adenoma detection rate 
(ADR), caecal intubation rate (CIR), and polyp recovery rate (PRR) may 
enhance surveillance outcomes. 
This is particularly important for high risk patients where colonoscopy 
may be a one-off intervention, or where there is significant risk of inter-
val cancers. Consequently, we assessed colonoscopy quality in a cohort 
at hereditary risk of CRC managed at West Middlesex University Hospital 
(WMUH), and determined their relationship to colonoscopist KPIs in non-
surveillance cohorts.
aims & Methods: We analysed prospective colonoscopic surveillance data 
through the Family History of Bowel Cancer Registry at WMUH between 
2010-2019. A cohort of 454 patients at hereditary risk were divided into five 
risk groups based on current British Society of Gastroenterology guide-
lines. Patient demographics including age, gender and family history were 
collated alongside colonoscopist data, colonoscopy findings, and KPIs. Us-
ing linear regression on SPSS software, we compared findings to the ADR, 
CIR and PRR of colonoscopists in non-surveillance patients.
results: During surveillance, 752 colonoscopies were performed by 12 
clinicians. The adequacy of bowel preparation and CIR across all colo-
noscopists was 89.2% and 98.0%, respectively. The collective ADR during 
index, 1st, 2ndand 3rdsurveillance colonoscopies was 19.6%, 15.9%, 29.3% 
and 25.8%, respectively. T
here was no difference in ADRs at Index, 1stand 2ndsurveillance colonoscopy 
between familial risk groups. The average ADR for colonoscopists across 
all surveillance colonoscopies was 22.8% (8.6-38.1%). In the non-surveil-
lance cohort ADR was 29.5% (13.3-40.7%), CIR 93.5% (78.8-95.7%) and 
PRR 95.2% (86.9-98.2%). Colonoscopist ADRs during surveillance corre-
lated with both ADRs (R20.738, P < 0.01) and PRRs (R20.695, P < 0.01) in the 
non-surveillance cohort but not CIR.
conclusion: ADR is the main indicator of efficacy during colonoscopy and 
a consistent independent risk factor for interval CRCs in screening colo-
noscopies. Colonoscopists ADRs in patients undergoing surveillance cor-
related with their ADRs and PRRs during colonoscopies in a non-surveil-
lance cohort. Therefore, we suggest that all surveillance colonoscopies are 
performed by endoscopists consistently achieving BSG colonoscopy KPI 
minimum standards.
disclosure: Nothing to disclose 
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Introduction: Colonoscopy is the best exploration for detection of colorectal 
cancer (CRC) and polyps. An adequate bowel preparation, usually defined 
with BBPS score ≥2-2-2, is a marker of quality that should be fulfilled in 
at least 85% of colonoscopies. With this aim, a low-residue diet is usu-
ally recommended for outpatient colonoscopies. Compliance with bowel 
preparation protocol is mandatory. In this context, a free diet without re-
strictions may improve tolerance and adherence to the bowel cleansing 
protocol, especially in outpatient setting, the main scenario of colorectal 
cancer screening programs.
aims & Methods: Our aim was to compare the quality of colonoscopy with 
two different diets: low-residue diet and a free diet without restrictions. 
A prospective, randomized, single blind clinical trial was designed to 
evaluate the impact of low-residue diet and free diet without restrictions 
the day before colonoscopy for bowel cleansing. The BBPS scale was used, 
with a value of ≥2-2-2 defining an adequate preparation. Patients between 
18 and 75 years old, scheduled for outpatient colonoscopy were included. 
Patients with previous colonoscopies, colorectal surgery, obesity grade 
II o more (BMI≥35) or severe constipation without response to conven-
tional treatment were excluded. Participants were randomised to group 
A (low-residue diet the day before colonoscopy) or B (free diet, including 
breakfast on the day of colonoscopy). Endoscopists were blinded for diet. 
Sodium picosulfate/magnesium citrate was used in all patients, giving the 
first dose 8 hours and the second dose 4 hours before colonoscopy. Sex, 
age, indication for colonoscopy, BMI, diabetes, diverticula, tolerance to 
preparation, exploration and recuperation, time of exploration and polyp 
detection rate (PDR) were evaluated. Results are shown as means and per-
centages, and analysed by chi-square and T-student test as appropriate.
results: Based on previous sample size calculation, 201 patients were 
included (52.2% women, median age 51 years, range 23-75). Main in-
dications for colonoscopy were CCR family history (60.1%), rectal bleed-
ing (15.9%) and abdominal pain (6.9%). Diabetes was present in 6.5% 
of patients. The median BMI was 26.7±3.88. Diverticula were reported in 
20.8% of cases. The median procedure time was 14.5 minutes (875±360 
seconds). PDR was 37.8%. 108 patients (53.7%) were included in group 
A and 93 (46.3%) in B. An adequate bowel preparation was observed in 
96.2% in group A and 87.1% in group B (p=0.03). Only 2 procedures had 
to be interrupted due to poor bowel preparation, both in group A. There 
were no differences in age (p 0.99), sex (p 0.19), BMI (p 0.91), tolerance 
to preparation (p 0.20), exploration (p 0.32) or recuperation (0.93), explo-
ration time (0.54) or PDR (0.80). No differences were observed between 
patients with adequate or poor bowel preparation in sex (p=0.21), age 
(p=0.22), BMI (p=0.17), diverticula (p=0.46), diabetes (p=0.57), amount of 
liquids (p=0.86).
conclusion: In outpatient colonoscopy without risk factors for poor bowel 
preparation, a free diet without restrictions for bowel cleansing is associ-
ated with an adequate bowel preparation in more than 85% of patients. 
The impact of a low-residue diet in this setting is statistically significant, 
although clinically less relevant than expected.
disclosure: Nothing to disclose 
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P0895 effIcacy and safeTy Of suck-and-snare eMr 
fOr TreaTMenT Of nOn-LIfTIng cOLOrecTaL POLyPs
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Introduction: Endoscopic mucosal resection (EMR) is a well-established 
technique for removal of benign colorectal polyps. Submucosal fibrosis 
can cause non-lifting or insufficient submucosal lifting and is frequently 
encountered during EMR for recurrent or residual adenoma. It increases 
complexity of the procedure, because it is often difficult or even impossible 
to grasp non-lifting tissue in the snare. Suck-and-snare (SAS) is a modi-
fied adjunctive EMR technique using suction to grasp and snare the target 
area. Our aim was to describe the efficacy and safety of the SAS technique 
for non-lifting colorectal polyps.
aims & Methods: We prospectively registered all consecutive patients in 
whom the SAS technique was used in the endoscopic treatment of pre-
sumed benign non-lifting colorectal polyps. With the SAS technique, the 
target area is suctioned into a cap (soft straight 4mm) mounted on the 
scope. A prepositioned snare strangulates and resects the lesion after 
maximum aspiration. Clinical and endoscopic data on target area, techni-
cal success, adverse events and follow-up were collected.
results: From May 2016 until March 2019, 70 patients (mean age 69 yrs 
(SD ±8.8), male 66%) were included. Non-lifting was caused by fibrosis 
due to recurrent or residual adenoma (n=51, including 3 also known with 
IBD), IBD (n=5) and other reasons (n=14). The target areas were remaining 
island(s) (n=35) or the entire lesion (n=35), with a median size of 15 mm 
(range 3-42 mm). Technical success with complete removal of polyp tissue 
with SAS alone was achieved in 47 patients (67%). In 20 patients (28%) at 
least 75% of the target area could be resected, followed by adjunctive cold 
avulsion and/or ablative therapy. In 3 cases ≤15% of the target area could 
be removed with SAS. Reason for incomplete removal was inadequate 
grasp with the snare, together with insufficient suction into the cap in 2 
cases. No polyp- or procedural factors were associated with recurrence at 
follow-up. Benign histology was reported in 67 cases (96%). Unexpectedly, 
invasive cancer was found in 3 patients, of whom 2 were referred for sur-
gery and 1 preferred surveillance. Recurrence rate after SAS for benign le-
sions was 26% (16/61) after median follow-up time 7 months (range 2-20). 
Follow-up data is pending in 6 cases. Muscle layer injury related to SAS 
occurred in 6 patients (11%), including 3 transmural perforations, success-
fully treated with clips. Delayed bleeding in 5 cases (7.5%), all could be 
managed endoscopically or were self-limiting.
conclusion: Suck-and-snare EMR is a promising adjunctive technique with 
an acceptable safety profile, and seems attractive in finishing endoscopic 
resection for benign non-lifting fibrotic colorectal polyps.
disclosure: Nothing to disclose 
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Introduction: Adenoma detection rate (ADR) is the most important qual-
ity measure in screening colonoscopies because it is inversely related to 
the development of interval cancer and mortality. Minimum standard ADR 
recommended according to different ESGE Guidelines is ≥25%; however, 
this recommendation is based in studies that evaluated the prevalence 
of adenomas in asymptomatic patients undergoing a primary screening 
colonoscopies. However, it remains unknown whether this cut-off must be 
the same for other colonoscopy indications.
aims & Methods: The aim of this study was to describe the ADR based 
on procedure indication and to predict the ADR recommended cut-off for 
other indications.
An observational, multicenter and cross-sectional study was conducted 
between February 2016 and December 2017 in 14 Spanish centers. Four 
colonoscopy indications have been considered: primary screening colo-
noscopies (reference category), positive fecal immunochemical test (+FIT) 
(OC-SensorTM; cut-off level 20µg/g), post-polypectomy surveillance and 
gastrointestinal symptoms. The ADR was calculated by age, sex, body mass 
index, comorbidities and aspirin use. The ESGE Guideline published in 
2017 has been considered as the reference for ADR recommendations. Lo-
gistic regression analysis was used to assessed the relationship between 
ADR and indications, and population proportions and its confidence in-
tervals (95%CI) were calculated using the exact Clopper-Pearson method.
results: A total of 14867 patients were included and the global ADR was 
38%. According to procedure indications and adjusted by factors men-
tioned previously, statistically significant differences between ADRs were 
found (p-value< 0.001). The ADR in gastrointestinal symptoms was 28.1% 
(OR 0.67, 95%CI 0.58-0.79); 46.4% (OR 2.01, 95%CI 1.71-2.35) in FIT-based 
procedures; 48.2% (OR 1.41, 95%CI 1.20-1.67) in surveillance compared 
to 30.8% in primary screening colonoscopies. Trend lines for the ADR in 
each indication were calculated based on endoscopists that performed 
procedures in all indications and no correlation between the quality of en-
doscopists and the ADR was found. 95%CI calculated for ADR population 
proportions was 27-29.3% in symptoms, 45.1-47.7% in +FIT endoscopies, 
46.1-50.3% in post-polypectomy surveillance and 28.2-33.5% in colonos-
copy screening group. Finally, based in our results, we propose a formula 
for calculating the minimal ADR adjusted to the clinical practice of each 
endoscopist.
conclusion: ADR significantly differs between colonoscopy indications. 
Policies addressing performance measures beyond colonoscopy screening 
procedures may be developed. According to population proportions re-
sults, two different cut-offs could be suggested as new minimum standard 
ADR recommendations: ≥25% in gastrointestinal symptoms and primary 
screening colonoscopies and ≥45% in FIT-based screening and endoscopic 
surveillance.
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references: Kaminski MF, Thomas-Gibson S, Bugajski M, et al. Perfor-
mance measures for lower gastrointestinal endoscopy: a European Society 
of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. En-
doscopy 2017;49(4):378-97.
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Introduction: Colorectal cancer (CRC) is the third neoplastic lesion diag-
nosed in males and the second one in females. The mortality for this neo-
plasia has decreased since the widespread of the colonoscopy as a tool in 
the screening. The ESGE (European Society of Gastrointestinal Endoscopy) 
guidelines establish the quality indicators in screening colonoscopy for the 
detection and differentiation of colonic neoplasia.
aims & Methods: In this study, we have evaluated the experience of a 
single Italian centre (ASST Spedali Civili - University of Brescia) in colo-
noscopy. We analysed the adenoma detection rate (ADR), polyp detection 
rate (PDR), serrated detection rate (SDR) in the right and left colon in our 
Endoscopy Unit in 2017. Moreover, we evaluated the influence of bowel 
preparation and endoscopist’s experience in the detection and treatment 
of colonic lesions. We divided 3077 patients who met the inclusion criteria 
(full colonoscopies and no colonic resections) in 4 groups: I. age ≥ 50 years 
with fecal occult blood test (FOBT) positive (n=282); II. age ≥ 50 years with 
a different indication (n=1291); III. surveillance colonoscopy for familiarity 
for CRC or previous history of neoplastic colonic lesions, any age (n=1100); 
IV. age < 50 years, any indications (n=404). The bowel preparation was 
scored with Boston Bowel Preparation Scale (BBPS) and a score ≥ 6 was 
considered sufficient. Statistical analysis were performed with SPSS and 
chi-square test has been calculate.
results: The bowel preparation was found sufficient in 259 (91,8%) pa-
tients in group I, in 1097 (84,9%) in group II, in 1013 (92,1%) in group III 
and 367 (90,8%) in group IV. The PDR was higher in the group I (52,1%) 
and group III (49,8%) compared to group II (37,4%) and group IV (18,3%). 
A similar pattern was observed for the ADR: higher in the group I (40,7%) 
and group III (34,6%) and lower in the group II (28,7%) and group IV 
(10,9%). However, the SDR was 5,7%, 5,4% and 5,7% in group I, II, and III, 
respectively; while, it was 2,0% in group IV. A sufficient bowel prepara-
tion does not improve either PDR, ADR or SDR. Regarding the differences 
between right and left colon, the PDR was superior in the left colon in all 
groups (41,1% vs 24,5%, 24,7% vs 21,6%, 31,3% vs 30,4% and 12,2% vs 
8,1% in group I, II, III and IV respectively). The ADR was higher in the left 
colon in the group I (31,2% vs 18,1%), group II (16,2% vs 13,3%) and group 
IV (5,8% vs 5,3%), while in the group III it was superior in the right colon 
(24,2% vs 15,4%). On the other hand, the SDR was higher in the right 
colon compare to the left colon in all groups (3,2% vs 2,5%, 4,2% vs 1,5%, 
4,4% vs 1,8% and 1,7% vs 0.,7%). Between endoscopists, the PDR was 
from 24,9% to 51,5%; the ADR from 17,1% to 40,0% and the SDR from 1,0% 
to 9,4%; without any correlations with bowel preparation.
conclusion: In our experience, the ADR, PDR and SDR were higher in pa-
tients with risk factors for having CRC (group I and III), compared to the 
general population (group IV). The bowel preparation does not influence 
these considered parameters and it is possible that they are not enough 
and new parameters, such as cancer interval, could be considered in a 
quality colonoscopy definition. ADR and PDR were superior in the left co-
lon; while, the SDR was better in the right colon; probably, because hyper-
plastic polyps are more frequent in this side.
disclosure: Nothing to disclose 
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Introduction: Fecal immunochemistry test (FIT) and colonoscopy are the 
first-tier colorectal cancer (CRC) screening tests recommended for average 
risk adults aged 50 years and above in the United States.
aims & Methods: To compare the predictors of adenoma detection rate 
(ADR) of Positive FIT with screening colonoscopy (SC).
Individuals ≥ 50 years, at average risk of CRC who underwent quantitative 
FIT or SC as part of their routine CRC screening between 09/01/2017 and 
08/30/2018 were reviewed. The quality of bowel preparation was assessed 
by Aronchick scale and fair/ good/excellent was considered adequate. The 
colonoscopy findings of the individuals following a positive FIT (FITC) were 
compared to those who underwent SC. 
Advanced adenoma was defined as polyp ≥ 10 mm in size, with villous 
histology or high - grade dysplasia. Lesions were categorized into proxi-
mal - cecum to splenic flexure and distal - descending colon to rectum. 
Demographic variables, ADR, AADR, mean size of the largest polyp, ad-
enoma per colonoscopy (APC) were compared between the two groups 
using chi-square test and student’s T test. p < 0.05 was determined sta-
tistically significant.
results: 351 individuals were identified in FITC group (follow up rate was 
60.16% after a positive FIT) and 1841 in SC group. The ADR was 66% in 
FITC and 34% in SC (odds ratio OR 3.78, CI 2.97-4.82, p< 0.0001). AADR 
was 35.89% in FITC and 8.64% in SC (OR 5.92, CI 4.51-7.77, p < 0.0001). 
The mean size of the largest polyp for FITC was significantly higher than SC 
(FITSC 12.09 ± 1.15 mm, SC 8.06 ± 0.56 mm, p < 0.0001) for proximal (FITC 
10.03 ± 1.11, SC 7.37 ± 0.58, p < 0.0001) as well as distal lesions (FITC 12.10 
± 1.49, SC 8.89 ± 0.92, p= p.0002). APC was also significantly higher in FITC 
(3.31 ± 0.50) compared to SC (1.90 ± 0.13), p < 0.0001. Individuals who had 
a true positive FIT (adenoma detected) were more likely men and had a 
history of smoking whereas individuals who had a positive SC (adenoma 
variables fITc -Positive (adr) (n= 232)
fITc - negative 
(n= 119)
fITc - adr Odds 
ratio (cI)
fITc - adr 
P value
sc Positive 
(adr) (n= 430)
sc negative 
(n= 1411)
sc - adr Odds 
ratio (cI)
sc - adr 
P value
fITc - adr vs sc - 
adr Odds ratio (cI) P value
Mean Age 62.2 (61.2 - 63.2) 62.7 (61.2 - 64.1) - 0.637 61.5 (60.7 - 62.2) 60.4 (60.0 - 60.8) - 0.156 p =0.178
Male 51.7% (120) 38.7% (46) 1.70 (1.08 - 2.67) 0.021 40.5% (174) 43.4% (612) 0.89 (0.72 - 1.10) 0.285 1.58 (1.14 - 2.17) p= 0.005
Non- Hispanic 
Black
59.9% (139) 49.6% (59) 1.52 (0.97 - 2.37) 0.065 45.1% (194) 45.4% (641) 0.99 (0.80 - 1.23) 0.909 1.81 (1.31 - 2.51) p= 0.0003
Obesity 61.2% (142) 51.2% (61) 1.50 (0.96 - 2.34) 0.075 51.6% (222) 50.2% (708) 1.06 (0.85 - 1.32) 0.599 1.48 (1.07 - 2.05) p= 0.018
Smoking history 66.4% (154) 53.8% (64) 1.70 (1.08 - 2.67) 0.022 56.3% (242) 48.2% (680) 1.38 (1.14 - 1.72) 0.003 1.53 (1.10 - 2.14) p= 0.012
Diabetes mellitus 2 31.5% (73) 26.9% (32) 1.24 (0.76 - 2.04) 0.376 28.6% (123) 23.0% (324) 1.34 (1.05 - 1.73) 0.017 1.15 (0.81 - 1.62) p= 0.442
Essential 
hypertension
74.1% (172) 72.3% (86) 1.10 (0.67 - 1.81) 0.707 68.1% (293) 57.7% (814) 1.57 (1.25 - 1.97) 0.0001 1.34 (0.94 - 1.92) p= 0.108
Hyperlipidemia 64.2% (149) 69.8% (83) 0.78 (0.48 - 1.25) 0.301 60.7% (261) 56.1% (792) 1.21 (0.97 - 1.50) 0.094 1.16 (0.83 - 1.61) p= 0.373
[P0898 Predictors of Adenoma Detection Rate (ADR) in Positive FIT colonoscopy (FITC) and Screening colonoscopy (SC)]
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detected) were more likely to have a history of smoking, diabetes mellitus 
type 2, hypertension and hyperlipidemia. 
When individuals with true positive FIT were compared with positive SC, 
FIT true positives were more likely to be Non-Hispanic blacks, had a his-
tory of smoking and obesity.
conclusion: As expected, the odds of detecting adenomas and advanced 
adenomas were more common in the FITC compared to the SC group. FIT 
requires larger size to detect adenomas compared to screening colonosco-
py and the difference was more pronounced for distal lesions. Risk factors 
of CRC influenced FIT and screening colonoscopy ADRs differently except 
for smoking (increased odds of positive FITC and SC). Understanding the 
demographic predictors for a positive CRC screening test will help provid-
ers and patients select the most suitable screening method.
disclosure: Nothing to disclose 
P0899 dIssecTIOn-enaBLed scaffOLd assIsTed resecTIOn 
(descar): safeTy, feasIBILITy, and effIcacy fOr resecTIOn Of 
resIduaL and nOn-LIfTIng cOLOnIc neOPLasIas
Villa E.1, Stier M.W.2, Donboli K.1, Chapman C.G.1, Siddiqui U.D.1, 
Waxman I.1
1University of Chicago, Center for Endoscopic Research and Therapeutics, 
Chicago, United States, 2University of Chicago, Gastroenterology, Chicago, 
United States
contact e-Mail address: eespee88@gmail.com
Introduction: Colonic lesions referred for endoscopic mucosal resection 
(EMR) may not be amenable to conventional snare resection due to previ-
ous manipulation or submucosal invasion or because of flat areas of visible 
tissue that cannot be snared. Current methods for treating residual tissue 
may lead to incomplete resection or not allow complete tissue sampling 
for histologic evaluation. In 2018, our group initially described Dissection-
enabled Scaffold Assisted Resection (DeSCAR)—a technique combining 
circumferential endoscopic submucosal dissection (ESD) with EMR—to be 
a safe technique for the endoscopic resection for removal of superficial, 
non-lifting or residual lesional “islands” with suspected submucosal in-
volvement or fibrosis1. 
Our aim is to describe our expanded experience and follow up of patients 
undergoing DeSCAR and assess the efficacy, safety, and feasibility of this 
technique for endoscopic resection of non-lifting or residual colonic le-
sions.
aims & Methods: Lesions referred for EMR were retrospectively reviewed. 
In addition to our initial cohort of 29 patients from 2015-2017, 28 additional 
patients from 2018-2019 were identified where lifting and/or snaring of co-
lonic lesions was incomplete, and the DeSCAR technique was undertaken. 
Cases were reviewed for location, prior manipulation, rates of successful 
hybrid resection, adverse events, and endoscopic follow up to assess for 
residual lesions.
results: 57 lesions underwent DeSCAR due to non-lifting or residual “is-
lands” of tissue. Patients were 51% female and 49% male with an average 
age 69 (SD +/- 9.6 yrs). Lesions were located in the cecum (n=16), right 
colon (n=22), transverse colon (n=5), left colon (n=7), rectum (n=4), or in 
other locations defined by distance from the anus (n=4). Average lesion 
size was 27.7 mm (SD +/- 16.6 mm). Previous manipulation occurred in 54 
of 57 cases (68% biopsy, 47% resection attempt, 18% intralesional tattoo 
injection). The technical success rate for resection of non-lifting lesions 
was 100%. There were two delayed bleeding episode (one requiring en-
doscopic intervention) and one small perforation (managed by success-
ful endoscopic hemoclip closure at the time of perforation), but no other 
adverse events were observed. Endoscopic follow up was available in 25 
patients (44%) with no residual adenoma noted in 23 patients (92% of 
those with surveillance).
conclusion: Our expanded experience with DeSCAR continues to demon-
strate a high safety, feasibility, and effectiveness profile as an alternative 
to argon plasma coagulation and avulsion for the endoscopic management 
of non-lifting or residual colonic lesions, providing en-bloc resection of 
tissue for histologic review. Further studies are needed to demonstrate 
long-term eradication and direct comparison with other currently avail-
able endoscopic techniques.
references: 1. Stier M, Chapman C, Kreitman A, Hart J, Xiao S et al. Dissec-
tion-enabled scaffold-assisted resection (DeSCAR): A novel technique for 
resection of residual or non-lifting GI neoplasia of the colon (with video). 
Gastrointest Endosc. 2018; 87(3): 843-851.
disclosure: 1. Christopher G. Chapman, MD: Apollo Endosurgery, Inc. 2. 
Uzma D. Siddiqui, MD: Boston Scientific Corp., Medtronic, Olympus Corp. 3. 
Irving Waxman, MD: Boston Scientific Corp., Cook Medical Inc., Medtronic, 
Neurotronics Inc., Olympus Corp. 
P0900 endOscOPIc feaTure Of dePressed TyPe cOLOrecTaL 
neOPLasMs In MagnIfyIng endOscOPy and endOcyTOscOPy
Kudo S.1, Mochizuki K.1, Matsudaira S.1, Kouyama Y.1, Kataoka S.2, 
Ishigaki T.3, Ichimasa K.1, Takeda K.1, Nakamura H.1, Toyoshima N.1, 
Misawa M.1, Mori Y.4, Ogata N.1, Kudo T.1, Hisayuki T.1, Hayashi T.1, 
Wakamura K.1, Sawada N.1, Baba T.1, Ishida F.1
1Showa University Northern Yokohama Hospital, Digestive Disease Center, 
Yokohama, Japan, 2Showa University Northern Yokohama Hospital, 
Colorectal Endoscopic Resection Standardization Implementation Working 
Group of Japanese Society, Yokohama, Japan, 3Showa University Northern 
Yokohama Hospital, Yokohama, Japan, 4Showa University Northern 
Yokohama Hospital, Digestive Disease Center, Tokyo, Japan
contact e-Mail address: kudos@med.showa-u.ac.jp
Introduction: Colorectal cancers are generally recognized to develop from 
“polyps”. This “adenoma-carcinoma sequence” theory has been in the 
mainstream of development of colorectal cancers. However, recently the 
existence of many depressed-type cancers has been revealed, which are 
considered to emerge directly from normal epithelium, not through the 
adenomatous stage. This theory is called “de novo” pathway. 
Now, it is possible to presume the histology of colorectal lesions using 
magnifying endoscopy (pit pattern classification) and endocytoscopy (EC 
classification). We can observe not only the structural atypia but also the 
cellular atypia in vivo.
aims & Methods: The aim is to clarify the endoscopic characteristics of 
depressed-type colorectal neoplasms, demonstrating the validity of pit 
pattern and EC classification.
A total of 32025 colorectal neoplasms excluding advanced cancers were 
resected endoscopically or surgically in our unit from April 2001 to Febru-
ary 2018. 
Of these, 24704 lesions were low-grade dysplasia, 6058 were high-grade 
dysplasia and 1263 were submucosally invasive (T1) carcinomas. According 
to the developmental morphology classification, they were divided into 3 
types: depressed, flat and protruded-type. We investigated the rate of T1 
carcinomas and the characteristics of depressed-type neoplasms concern-
ing pit pattern and EC classification.
results: The rate of T1 carcinomas in depressed-type lesions reached to 
62.7%, meanwhile that in flat-type and protruded-type lesions was 3.2% 
and 2.8%, respectively. Within less than 5mm in diameter, that was 10.1%, 
0% and 0%, respectively. Most of the flat-type (92.3%) and protruded-
type (94.5%) lesions showed type III
L 
or IV pit pattern corresponding to 
adenomas, whereas 91.7% of the depressed-type lesions were character-
ized by type III
S
, V
I 
or V
N 
pit patterns corresponding to carcinomas. As for 
endocytoscopy, most of the flat-and protruded-type lesions showed EC2 
corresponding to adenomas. In contrast, the depressed-type lesions were 
observed as EC3a (37.0%) and EC3b (55.6%) corresponding to invasive 
carcinomas.
conclusion: This study revealed the diagnostic characteristics of depressed-
type lesions. They show typically type III
S
, V
I 
or V
N 
pit patterns in magnifying 
endoscopy and type EC3a or EC3b in endocytoscopy. These lesions tend to 
invade the submucosal layer even when they are small. It is important to 
diagnose colorectal neoplasms according to their morphology.
disclosure: Nothing to disclose 
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P0901 InTerMedIaTe rIsk Of aPPendIcITIs fOLLOWIng 
fuLL-ThIckness resecTIOn Of adenOMas arIsIng frOM The 
aPPendIceaL OrIfIce- a reTrOsPecTIve anaLysIs
Walter B.1, Wannhoff A.2, Schmidbaur S.1, Meier B.2, Meining A.1,3, Caca K.2
1Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany, 
2Klinikum Ludwigsburg, Abt. für Innere Medizin, Ludwigsburg, Germany, 
3Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, 
Würzburg, Germany
contact e-Mail address: benjamin.walter@uniklinik-ulm.de
Introduction: Conventional endoscopic resection techniques of adenomas 
near the appendiceal orifice have certain limitations e.g. an increased 
risk for perforation. Endoscopic full-thickness resection (eFTR) is a novel 
technique for adenoma resection up to 20mm in diameter. As full thick-
ness resection near the appendiceal orifice is associated with a subtotal 
appendectomy it remained unclear whether the risk for development of 
an appendicitis or mucocele is increased. We present the results of a ret-
rospective analysis of 38 patients with adenomas involving the appendi-
ceal orifice treated with the FTRD system (Ovesco Endoscopy, Tuebingen, 
Germany).
aims & Methods: Retrospective analysis of patients treated with eFTR for 
adenoma near the appendiceal orifice between 2014 and 2018. 38 patients 
from 2 centres (Ludwigsburg, Ulm) were included, median age 68.0 (47-
85) yrs., follow up-time median 11 (6-32) months. The objective was the 
evaluation of post treatment complications in acute and long term follow 
up (appendicitis, mucocele). Patients with prior appendectomy were ex-
cluded from the study.
results: All patients received prophylactic antibiotic treatment for on aver-
age 3.7 days in a row started perintenventionally. No acute severe adverse 
events were reported for the eFTR procedure. Symptoms of appendicitis 
occurred in 9 patients (23.7%) within follow-up. In 3 cases conservative 
treatment was sufficient, 5 patients were transferred to appendectomy. No 
development of a mucocele was reported in long time follow up.
conclusion: Based on this retrospective analysis eFTR of adenomas involv-
ing the appendiceal orifice is associated with an intermediate risk for de-
veloping appendicitis and consecutive risk for appendectomy. Therefore 
we conclude patients must be thoroughly informed about the risks. The 
reason why some patients develop appendicitis should be further eluci-
dated.
disclosure: Alexander Meining, Karel Caca: Consultancies for OVESCO, Ger-
many 
P0902 effIcacy and feasIBILITy Of fuLL ThIckness 
defecT cLOsure usIng MOdIfIed endOLOOPs: ex vIvO sTudy 
In a POrcIne cOLOn MOdeL
Dobashi A.1,2, Rajan E.1
1Mayo Clinic, Developmental Endoscopy Unit, Division of Gastroenterology 
and Hepatology, Rochester, United States, 2The Jikei University School of 
Medicine, Department of Endoscopy, Tokyo, Japan
contact e-Mail address: akira.dobashi@nifty.com
Introduction: To ensure a safer endoscopic full-thickness resection (EFTR), 
a reliable defect closure system is essential. The commercially available 
endoloop was modified for the purposes of a more secure closure. The 
aim of this study was to evaluate the efficacy and feasibility of modified 
endoloops for defect closure.
aims & Methods: Two prototype endoloops (Olympus, Tokyo) were stud-
ied. One was an endoloop with a double-cinch and the other an endoloop 
with a 3mm needle at the base of the loop. Phase 1: Full-thickness colon 
resections measuring 2 cm in diameter were created free-hand. The clos-
ing force for each device was compared to the gold standard of a hand-
sewn defect closure using leak testing. Five different closure methods were 
studied: 1. conventional endoloop, 2. endoloop with a double-cinch, 3. en-
doloop with a needle, 4. over-the-scope clip (Padlock clip; US Endoscopy, 
OH), 5. free-hand suturing. Phase 2: EFTR was performed to compare the 
closing forces of the optimal modified endoloop identified from Phase 1 to 
the conventional endoloop. Using endoloops, a pseudopolyp containing 
the entire colonic wall was created and then resected using a hot snare.
results: Phase 1: A total of 17 sites were resected using the free-hand mod-
el. The median maximum pressure for leak testing in hand-sewn closure 
was 22 mmHg compared to conventional endoloop (21 mmHg; p=0.56), 
double-cinch endoloop (47 mmHg; p=0.077), endoloop with a needle (22 
mmHg; p=0.86), and over-the-scope clip (40 mmHg; p=0.13). In Phase 2: 
EFTRs were successfully completed in 16 colonic sites (conventional en-
doloop, 8 sites; double-cinch endoloop, 8 sites). The median lesion size 
in conventional and double-cinch endoloops were 17mm (range: 14-20) 
and 19 mm (range: 15-22), respectively (p=0.13). The median maximum 
pressure for leak testing in the conventional and double-cinch endoloops 
were 29 mmHg (range, 20-45) and 42mmHg (range, 34-55), respectively 
(p< 0.01).
conclusion: A double-cinch endoloop demonstrated a significantly higher 
closing force compared to conventional endoloops. The median maximum 
pressure for leak testing was higher with the double-cinch endoloop com-
pared to hand-sewn closure, but did not reach significance. This simple 
modification to a currently available and familiar device could enhance 
defect closure following EFTR.
disclosure: Nothing to disclose 
P0903 enOugh Is enOugh: an In-vITrO dOse-fIndIng sTudy 
Of anTIfOaMIng effecTs Of sIMeThIcOne
Kutyla M.1, Shah A.2, Meeusen V.1, Elson J.1, Oconnor S.1, Hourigan L.F.1, 
Holtmann G.J.1,3
1Princess Alexandra Hospital, Gastroenterology & Hepatology, Brisbane, 
Australia, 2Princess Alexandra Hospital, Queensland Health, Department 
of Gastroenterology & Hepatology, Brisbane, Australia, 3University of 
Queensland, School of Medicine, Brisbane, Australia
contact e-Mail address: g.holtmann@uq.edu.au
Introduction: Simethicone is an antifoaming agent frequently added to 
endoscopic rinse solutions but has recently been implicated as a possible 
risk factor for endoscopy transmitted infections due to a potential simethi-
cone build-up in the working channels [1-3]. However, we have previously 
shown that discontinuation of simethicone use has a detrimental effect 
on the polyp and adenoma detection rates [4, 5]. However, the build-up 
of a deposit in the working channels of the endoscope is likely related 
to the simethicone concentration in the rinse solution. Unfortunately, no 
data are available on the minimal effective dose of simethicone that has 
antifoaming effects. We therefore aimed to determine the lowest effective 
concentration of simethicone that retains antifoaming properties.
aims & Methods: We developed an ‘in vitro bubble model’. For this pur-
pose six 100 mL test tubes filled with water for irrigation were prepared 
with a standard kitchen detergent (Fairy®, 1% v/v). One test tube served as 
control, while different doses of simethicone ((Infacol®, 0.02, 0.2, 2.0, 20 
and 200 mg) were added to the other 5 test tubes. Oxygen was streamed 
for 30 seconds into the test tube at a rate of 2 L/min. After 10 seconds, 
digital photos were taken and the foam or bubbles that were visible on 
the photos rated semi-quantitatively rated (0 = no air bubbles, 1 = isolated 
air bubbles not impairing the visibility, 2 = air bubbles partly covering the 
surface, 3 = air bubbles fully covering the surface, 4 = multi-layered air 
bubbles) by five independent assessors blinded for the dosing of simethi-
cone. Sufficient suppression of air bubbles was assumed when all asses-
sors reported a score of 1 or less.
After determining the minimal effective dose of simethicone, we imple-
mented this into routine clinical practice and compared polyp detection 
rates before and after introduction of the low-dose simethicone. To con-
trol for differences in the performance of endoscopists, we compared data 
from the same clinicians pre and post the dose change.
results: Simethicone at doses as low as 20 mg/100 mL resulted in a com-
plete or near complete prevention of bubble formation. Thus, doses as 
low as 20 mg/100 mL appear to be the appropriate minimal doses of si-
methicone to suppress bubble formation during endoscopic procedures. 
We compared polyp detection rates in 1,340 patients undergoing routine 
colonoscopy (606 female, age 59.6±14.9 [mean ± SD]), with 1,475 patients 
undergoing routine colonoscopies (655 female, age 58.3±15.2 [mean ± SD]) 
after implementation of the low dose simethicone protocol. In the high 
dose, the polyp detection rate was 56.5% (53.8-59.1% [95% CI]) and in the 
low dose it was 56.7% (54.2-59.3% [95% CI]).
conclusion: While in most endoscopy units simethicone is added ad libitum 
to rinse solutions (e.g. 200 mg/100 mL), our data suggest that doses as low 
as 20 mg/100 mL are sufficient to abolish or prevent the formation of air 
bubbles or foam. Most importantly, this low dose of simethicone resulted 
in no change to our polyp detection rates, indicating that it is a clinically 
appropriate dose.
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references: 1. Ofstead, C.L., et al., Simethicone residue remains inside gas-
trointestinal endoscopes despite reprocessing. Am J Infect Control, 2016. 
44(11): p. 1237-1240. 2. van Stiphout, S.H., et al., Crystallization in the wa-
terjet channel in colonoscopes due to simethicone. Endoscopy, 2016. 48(S 
01): p. E394-e395. 3. Kovaleva, J., et al., Transmission of infection by flexi-
ble gastrointestinal endoscopy and bronchoscopy. Clin Microbiol Rev, 2013. 
26(2): p. 231-54. 4. Bai, Y., et al., Impact of preprocedure simethicone on 
adenoma detection rate during colonoscopy: a multicenter, endoscopist-
blinded randomized controlled trial. Endoscopy, 2018. 50(02): p. 128-136. 
5. Kutyla, M., et al., Influence of Simethicone Added to the Rinse Water 
during Colonoscopies on Polyp Detection Rates: Results of an Unintended 
Cohort Study. Digestion, 2018. 98(4): p. 217-221.
disclosure: Nothing to disclose 
P0904 endOscOPIc suBMucOsaL dIssecTIOn (esd) Of 
earLy recTaL neOPLasIa usIng The TIssue reTracTOr 
sysTeM (Trs), a neW endOscOPIc PLaTfOrM fOr endOLuMInaL 
en BLOc TIssue resecTIOn In The gasTrOInTesTInaL TracT 
- fIrsT reTrOsPecTIve case serIes aT a gerMan reference 
cenTer
Kandler J., Wessel J., Neuhaus H., Beyna T.
Evangelisches Krankenhaus Düsseldorf, Department of Internal Medicine, 
Düsseldorf, Germany
contact e-Mail address: torsten.beyna@evk-duesseldorf.de
Introduction: Endoscopic resection (ER) is the curatively intended first-
line therapy for early rectal neoplasia (ERN)1. Prerequisite is successful 
R0 resection, which cannot always be achieved with lesions >20mm by 
endoscopic mucosal resection (EMR). In these cases, ESD is the preferred 
method2. Advantages of ESD are higher en bloc resection and lower re-
currence rates, while EMR is faster to perform and shows lower perfora-
tion rates3-5. 
For safer and faster ER, stable device position and good view into the sub-
mucosal space are needed. Tissue Retractor System (TRS) was developed 
to enable this with help of mechanisms established in laparoscopic sur-
gery with a conventional endoscope6. TRS is a novel system, consisting 
of flexible overtube with expandable working chamber with 2 indepen-
dent instrumentation catheters. With forceps via catheters, tissue can be 
stretched and held in position for ER.
aims & Methods: Primary objective: Technical success of TRS-ESD (com-
plete resection of target lesion using TRS). Secondary objectives: En bloc, 
R0 and curative resections, adverse events (AEs).
Retrospective analysis of all TRS-ESD cases of ERN between June 2018 and 
February 2019 at a tertiary referral center in Germany.
results: 8 patients treated with ESD using TRS were included (3 women, 
5 men, mean age 67 years, range 53-82). Target lesions were therapeutic 
naive, located in rectum (7 distal, 1 proximal), slightly-elevated with ses-
sile parts (laterally spreading tumors nodular mixed type) and classified 
as type 2a or 2b according to JNET (Japan NBI expert team) classification7. 
Mean diameter 45.6mm (20-80mm). Technical success (complete resec-
tion using TRS) was achieved in 87.5% (7/8). In 12.5% (1/8) positioning of 
TRS (distal rectum) was not successful for anatomical reasons. 
However, all lesions were resected completely (100%). The single lesion, 
non suspicious of malignancy, where TRS positioning was not successful, 
was resected by EMR (piece-meal technique, PM-EMR); all other lesions 
(87.5%, 7/8) were resected by ESD en bloc using TRS. Histologically, ade-
nomas were found in 62.5% (5/8: 2 low grade dysplasia, LGD, 3 high grade 
dysplasia, HGD) and adenocarcinomas (AC) in 37.5% (3/8). 
Overall, R0 resection was achieved in 75% (6/8). All (3/3) carcinomas were 
resected en bloc, R0 and curatively. 2 of 5 adenomas were not resected R0 
(1 PM-EMR of LGD-adenoma due to failed TRS-positioning, 1 en bloc resec-
tion with focal adenoma in horizontal margin). All HGD-adenomas were 
curatively resected. No intraprocedural or delayed AEs occurred.
conclusion: ESD using TRS seems to be feasible and safe in the rectum. 
En bloc and R0 resection rates were comparable to those of conventional 
ESD. The rate of curative ESDs in cases of AC was high with 100%, which is 
less explained by the use of TRS than by adequate pretherapeutic selection 
of lesions. Whether use of TRS could finally be helpful reducing disadvan-
tages of ESD cannot be answered with this work. 
Although perforation rate of 0% was lower than that of conventional ESD, 
data is limited by the small number of cases and the retrospective analysis. 
Duration of intervention could not be analyzed in the current retrospective 
dataset, but appeared not to be shorter. A reason could be longer learning 
curve for this complex procedure. For final appraisal now data from large 
scale prospective trial is needed.
references: 1. Schmiegel W, Buchberger B, Follmann M, et al. S3-Leitlinie 
- Kolorektales Karzinom. Z Gastroenterol 2017;55:1344-1498. 2. Pimentel-
Nunes P, Dinis-Ribeiro M, Ponchon T, et al. Endoscopic submucosal dis-
section: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. 
Endoscopy 2015;47:829-54. 3. Probst A, Ebigbo A, Markl B, et al. Endoscopic 
submucosal dissection for early rectal neoplasia: experience from a Euro-
pean center. Endoscopy 2017;49:222-232. 4. Probst A, Golger D, Anthuber M, 
et al. Endoscopic submucosal dissection in large sessile lesions of the recto-
sigmoid: learning curve in a European center. Endoscopy 2012;44:660-7. 5. 
Saito Y, Fukuzawa M, Matsuda T, et al. Clinical outcome of endoscopic sub-
mucosal dissection versus endoscopic mucosal resection of large colorectal 
tumors as determined by curative resection. Surg Endosc 2010;24:343-52. 6. 
Kantsevoy SV, Bitner M, Piskun G. New endoscopic platform for endolumi-
nal en bloc tissue resection in the gastrointestinal tract (with videos). Surg 
Endosc 2016;30:3145-51. 7. Sano Y, Tanaka S, Kudo SE, et al. Narrow-band 
imaging (NBI) magnifying endoscopic classification of colorectal tumors 
proposed by the Japan NBI Expert Team. Dig Endosc 2016;28:526-33.
disclosure: TB and HN disclose lecture fees and consultancy honoraria 
from Boston Scientific. JK and JW disclose no conflicts of interests. 
P0905 a 3-day versus 1-day LOW resIdue dIeT TO IMPrOve 
cOLOnOscOPy PreParaTIOn resuLT and PaTIenT TOLeraBILITy, 
a randOMIzed, sIngLe-BLInded, cOnTrOLLed TrIaL
Taveira F., Areia M., Elvas L., Alves S., Brito D., Saraiva S., Cadime A.T.
Portuguese Oncology Institute of Coimbra, Gastroenterology, Coimbra, Portugal
contact e-Mail address: fctav@hotmail.com
Introduction: The European Society of Gastrointestinal Endoscopy (ESGE) 
recommends a low-fibre diet on the day preceding the colonoscopy, al-
though some endoscopistas suggest a 3-day diet before colonoscopy. We 
intended to study the influence of a 3-day (3D) versus 1-day (1D) low resi-
due diet in bowel preparation results and the effect on patient tolerability 
and adherence.
aims & Methods: Randomized controlled trial, single-centre, endoscopist 
single-blinded, consecutive outpatients scheduled for total colonoscopy. 
Bowel preparation was 4L split-dose of polyethylene glycol. Randomiza-
tion in 2 groups (n = 206), D3 vs. D1. The primary outcome was the bow-
el cleansing quality assessment by the Boston Bowel Preparation Scale 
(BBPS) (adequate cleansing ≥ 2 points per segment) to achieve a reduction 
from 15 to 5% of inadequate preparation result with a 3-day regimen. 
Statistical analysis in intention to treat (ITT) and per protocol (PP) with de-
scriptive analysis, χ2 and logistic regression with 95% confidence intervals 
(CI). Clinical Trial register NCT02955901.
results: 412 patients were included, and groups were homogeneous in 
relation to gender, age, colonoscopy indication and risk factors for inad-
equate preparation.
The inadequate bowel preparation rate (primary outcome), assessed by 
the BBPS, was not significantly different between groups: ITT analysis 
(n=412) D3 8.3% vs. D1 5.3%, p=0.24 and PP analysis (N=400) D3 6,5% vs. 
D1 3,5%, p=0.16. 
Secondary outcomes, on ITT analysis, were similar between groups (D3 vs. 
D1): cecal intubation rate (95.1% vs. 98.1%, p=0.1), polyp detection (52.9% 
vs. 52.4%, p=0.92) and advanced adenomas detection (34.9% vs. 39.8 %, 
p=0.45). No differences were also found between groups (D3 vs. D1) re-
garding adverse effects / patients complaints (55.8% vs. 60.2%, p=0.37), 
ease in acquiring the proposed diet (5.3% vs. 6.8%, p=0.54) and willing-
ness to repeat the regimen (77.2% vs. 80.6%, p=0.4) but difficulty in fol-
lowing the prescribed diet was significantly higher in D3 group: 11.7% vs. 
4.4% p=0.008, OR 2.7, 95%CI 1.3-5.8.
Non-compliance with split dose (OR 30, 95%CI 7.7-120), chronic constipa-
tion (OR 3.3, 95%CI 1.3-8.8), consumption of tricyclic antidepressants (OR 
3.2; 95%CI 1.1-8.8) and diabetes (OR 3.1, 95%CI 1.2-7.9) were statistically 
significant factors for inadequate preparation.
conclusion: The increase for 3 days of a low residue diet prior to colonos-
copy did not reduced the rate of inadequate bowel preparation; similar 
bowel preparation quality results are obtained with only 1 day of low resi-
due diet within the ESGE threshold and with better adhesion and toler-
ability by the patient, under a split-dose preparation
disclosure: Nothing to disclose 
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P0906 cOMParIsOn Of The effecTIveness Of fOur BOWeL 
cLeansIng PreParaTIOns BefOre cOLOnOscOPy - randOMIzed, 
sIngLe - BLInd sTudy
Kmochova K.1, Suchanek S.1, Ngo O.2, Majek O.2, Zavoral M.1
11st Faculty of Medicine, Charles University, Department of Internal Medicine, 
Military University Hospital, Prague, Czech Republic, 2Faculty of Medicine, 
Masaryk University, Institute of Biostatistics and Analyses, Brno, Czech 
Republic
contact e-Mail address: klara.kmochova@uvn.cz
Introduction: The effectiveness of bowel preparation is an essential re-
quirement of successful colonoscopy. Polyethylenglycol is a gold standard 
in bowel preparation. It’s main disadvantage is high volume. Oral sulfate 
solution (OSS), low volume PEG + ascorbic acid (2L-PEG/Asc) and sodium 
picosulfate + magnesium citric-acid solution (SP/MC) are low-volume 
preparations that might be appropriate substitution of PEG.
aims & Methods: Comparison of the effectiveness of four bowel cleansing 
preparations.
Randomized, single-blind study. Patients with colonoscopy from all indi-
cations (except planned therapeutic procedure) were recruited. Instruc-
tions were provided in both verbal and written version and split-dose 
regimen was recommended. The bowel cleansing quality was evaluated 
by the experienced endoscopists blinded about the type of a bowel prepa-
ration. The effectiveness was assessed by the degree of bowel cleansing 
according to Boston Bowel Preparation Scale (BBPS) and polyp detection 
rate (PDR).
results: In the period from 09/2017 to 03/2019 there were 439 individu-
als included in the study of which 6 patients eventually did not undergo 
colonoscopy from different reasons and 13 patients did not have total colo-
noscopy. The final analyzed number of patients was 420. The numbers of 
individuals with each preparation were as follows: 109 PEG; 108 OSS; 103 
2L-PEG/Asc and 100 SP/MC. Representation of men was 51 % and average 
age was 58 years for whole group. Split-dose regimen was respected by 
82% of patients. Adequate bowel cleansing (BBPS total score ≥ 6 and sub 
score ≥ 2 in each colonic segment) was comparable for all groups (95.4% 
PEG vs. 94.4% OSS vs. 98.1% 2L-PEG/Asc vs. 96.0% SP/MC; p = 0.600). 
Excellent bowel cleansing (BBPS total score ≥ 8 and sub score ≥ 2 in each 
colonic segment) was observed often in PEG and OSS group however the 
difference was not significant (86.2% PEG vs. 84.3% OSS vs. 80.6% 2L-
PEG/Asc vs. 80.0% SP/MC; p = 0.580). Average value of total BBPS and av-
erage sub score for each colonic segment and preparations shows table 1. 
Polyp detection rate was comparable for all groups (49.5% PEG vs. 50.0% 
OSS vs. 36.9% 2L-PEG/Asc vs. 42.0% in SP/MC; p = 0.166). There was also 
no difference in detection of advanced colorectal neoplasia (≥ 10 mm, high 
grade dysplasia or cancer): 11.0% PEG vs. 10.2% OSS vs. 9.7% in 2L-PEG/
Asc vs. 15.0% in SP/MC; p = 0.654. Average size of detected polyp was 5 
mm and average number of detected polyp for each person was 2.
conclusion: All tested low volume solutions provide comparable effective-
ness of bowel preparation as polyethylenglycol and they could be consid-
ered as it’s alternative. 
Supported by the projects MO1012 and Progres Q28/LF1. The study is regis-
tered on ClinicalTrials.gov.(NCT03242369).
  Peg Oss 2L-Peg/asc sP/Mc
Total number; 
p - value
Number of patient 109 108 103 100 420
Excellent preparation 86.2% 84.3% 80.6% 80.0% 0.580
Adequate preparation 95.4% 94.4% 98.1% 96.0% 0.600
Average value of total 
BBPS (SD)
8.4 (1.1) 8.4 (1.3) 8.4 (1.0) 8.3 (1.0)  
Sub score: RC 2.6 (0.6) 2.7 (0.6) 2.7 (0.5) 2.6 (0.6)  
TC 2.9 (0.4) 2.8 (0.5) 2.8 (0.4) 2.8 (0.4)  
LC 2.9 (0.4) 2.9 (0.4) 2.9 (0.3) 2.9 (0.3)  
[Table 1.]
Excellent bowel preparation: BBPS total score ≥ 8 and sub score ≥ 2 in 
each colonic segment; Adequate bowel preparation: BBPS total score ≥ 6 
and sub score ≥ 2 in each colonic segment; RC: right colon; TC: transverse 
colon; LC: left colon; SD: standard deviation.
disclosure: Nothing to disclose 
P0907 adherence TO surveILLance guIdeLInes afTer 
reMOvaL Of cOLOrecTaL POLyPs: a MuLTI-naTIOnaL, MuLTI-
cenTer, PrOsPecTIve survey
Oh C.K.1, Aniwan S.2, Piyachaturawat P.3, Wong Z.4, Soe T.5, 
Luvsandagva B.6, Tran Q.T.7, Achmad Fuad Bakry F.8, Cho Y.-S.9
1Seoul St. Mary’s Hospital, Division of Gastroenterology, Department of 
Medicine, Seoul, Korea (Republic of), 2Chulalongkorn University, Internal 
Medicine, Bangkok, Thailand, 3Chulalongkorn University and King 
Chulalongkorn Memorial Hospital, Bangkok, Thailand, 4National University 
of Malaysia, Selangor, Malaysia, 5University of Medicine, Yangon, Myanmar, 
6Ulaanbaator Songdo Hospital, Ulaanbaator, Mongolia, 7Hue University 
Hospital, GI Endoscopy and Internal Medicine, Hue, Viet Nam, 8RSMH 
General Hospital, Palembang, Indonesia, 9Seoul St. Mary’s Hospital, The 
Catholic University of Korea, Gastroenterology, Seoul, Korea (Republic of)
contact e-Mail address: ckdryekd@gmail.com
Introduction: The rate of polyp detection and removal from the screening 
colonoscopy have grown tremendously in many Asian countries. However, 
there is a great concern for demand of surveillance colonoscopy. Despite 
a continuing effort to lengthen intervals for surveillance colonoscopy, a 
number of surveys have indicated that most doctors still recommend more 
frequent surveillance colonoscopy than guideline suggest. The aim of this 
study is to investigate the surveillance recommendations of Asian gastro-
enterologists after polypectomy and compare them with recommendations 
from international guidelines.
aims & Methods: A survey study was performed among seven Asian coun-
tries from July 2018 and October 2018. An email invitation which a link 
provided was send to gastroenterologists, general internal medicine and 
surgeons. Participants were asked to complete a survey of eight clinical 
scenarios designed to evaluate their potential course of action in response 
to screening or follow-up colonoscopy results. The US Multi-Society Task 
Force on Colorectal Cancer 2012 was determined as a standard guideline. 
We stratified participants according to their number of colonoscopy as 1) 
performed ≥ 20 colonoscopies per month [high-volume (HV)] and 2) < 20 
colonosopies per month [low-volume (LV)].
results: One hundred thirty-seven doctors were invited. A total of valid 
response were obtained from 123 doctors (89.8%). Respondents included 
40 Korean gastroenterologists and 83 physicians from other Asian coun-
tries. Majority of participants (73%) practiced in a tertiary hospital and 
87% were gastroenterologists. Approximately, half of participants adhered 
to the guideline regardless of adenomas except a combination between 
adenoma ≥10 mm with tubulovillous and high grade dysplasia, in which 
35% of participants adhered to the guideline. Only 12% of participants 
adhered to the guideline of 10 years interval for no polyp in a patients with 
a prior high-risk adenoma. According to the stratification by colonoscopy 
number, 78 (64%) participants were in HV group, and 45 (36%) were in LV 
group. The HV group more adhered to the guideline recommendation after 
removal of adenoma than LV group. The reasons for non-adherence to the 
guideline were concern of missed polyp (59%), low cost for colonoscopy 
(26%), incomplete resection (25%), and medical liability (15%).
conclusion: This study shows a remaining discrepancy between physician’s 
recommendation and current guideline for post-polypectomy surveillance. 
Physicians in LV group frequently do not adhere to the guideline, suggest-
ing a need for appropriate control and continuing education. Concern for 
quality of colonoscopy and incomplete polyp resection were mainly related 
to non-adherence.
disclosure: Nothing to disclose 
P0908 In PaTIenTs WITh an OveraLL cLeansIng success The 
1L POLyeThyLene gLycOL ner1006 achIeves MOre hIgh-quaLITy 
cLeansed segMenTs Per PaTIenT Than Three sTandard BOWeL 
PreParaTIOns
Bisschops R.1, Manning J.2, Halonen J.3, Álvarez-González M.A.4
1Katholieke Universiteit Leuven, Gastroenterology, Leuven, Belgium, 2Borders 
General Hospital, NHS Borders, Melrose, United Kingdom, 3Norgine, Medical 
Affairs, Harefield, United Kingdom, 4Hospital del Mar, Barcelona, Spain
contact e-Mail address: raf.bisschops@uzleuven.be
Introduction: Detection of all adenomas during colonoscopy is important 
for patient protection against colorectal cancer. At a minimum, this re-
quires successful pre-colonoscopy colon cleansing which is usually based 
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on the least clean colon segment. High-quality cleansing has however 
been shown to improve adenoma detection. The prospective phase 3 de-
velopment programme for 1L polyethylene glycol (PEG) NER1006 (studies 
DAYB, MORA and NOCT) is the largest to date on colon cleansing quality [1-
3]. The primary analysis revealed a higher or at least as effective adequate 
level cleansing efficacy of NER1006 versus sodium picosulfate/magnesium 
citrate (SPMC), 2L PEG + ascorbate (2LPEG), and oral sulfate solution (OSS). 
An improved high-quality cleansing efficacy has already been shown for 
NER1006 at the treatment group level, but the patient level benefits remain 
unclear.
aims & Methods: This post hoc analysis of 1749 patients in three randomised 
phase 3 trials examined if the number of high-quality cleansed colon seg-
ments per patient could improve with NER1006 versus SPMC, 2LPEG or 
OSS. All patients with documented segmental cleansing scores and neo-
plasia counts were included. Treatment-blinded central readers assessed 
the segmental cleansing quality using the validated Harefield Cleansing 
Scale (HCS) scores 0-4 based on colonoscopy videos by site colonoscopists. 
Patients with an overall cleansing success (HCS Grades A-B) were stratified 
per trial and allocated bowel preparation. The mean number of attained 
high-quality colon segments (HCS scores 3-4) per patient was calculated. 
One-sided t-tests compared the mean number of high-quality colon seg-
ments per patient using NER1006 versus the comparator in each trial.
results: A total of 1471/1749 patients (84%) achieved overall cleansing suc-
cess (Table). With comparable split dosing regimens, overall cleansing 
success rates reflected the primary published results [1-3]. The mean num-
ber of high-quality colon segments per patient was greater for patients 
using NER1006 than any of the comparators in each respective trial. Day 
before split dosing with NER1006 was more effective than with SPMC: 1.13 
vs 0.76; P=0.005. Overnight or morning only split dosing with NER1006 
was more effective than with 2LPEG: 2.52 and 2.65 vs 1.65; P< 0.001 for 
both. Similarly, overnight split dosing with NER1006 was more effective 
than with OSS: 2.61 vs 2.30; P=0.032. The additional effect size for NER1006 
versus its comparators ranged from 0.31-1.00 high-quality segments per 
patient.
conclusion: These results demonstrate that despite comparable or higher 
adequate cleansing success, this does not prevent NER1006 from being 
clearly more effective than SPMC, 2LPEG or OSS in delivering more high-
quality cleansed segments per patient.
  dayB MOra nOcT
  ner1006 sPMc ner1006 ner1006 2LPeg ner1006 Oss
split dosing 
regimen
Day 
before
Day 
before
Overnight
Morning 
only
Over-
night
Over-
night
Over-
night
Patients with 
overall cleansing 
success (hcs grade 
a-B), n/n (%)
151/229 
(65.9)
133/239 
(55.6)
248/256 
(96.9)
242/266 
(91.0)
230/250 
(92.0)
231/251 
(92.0)
236/258 
(91.5)
high-quality 
segments (hcs 
score 3-4) per 
patient with overall 
cleansing success, 
mean (sd)
1.13 
(1.29)
0.76 
(1.07)
2.52 (1.76) 2.65 (1.81)
1.65 
(1.71)
2.61 
(1.80)
2.30 
(1.81)
effect size 0.37 - 0.88 1.00 - 0.31 -
P-value vs 
comparator 0.005 - <0.001 <0.001 - 0.032 -
[Table. High-quality segments (HCS score 3-4) per patient with overall 
cleansing success assessed by treatment-blinded central readers]
references: 1. Bisschops R et al. Endoscopy 2019; 51(1):60-72 2. DeMicco MP 
et al. Gastrointestinal Endoscopy 2018; 87(3):677-687 3. Schreiber S et al. 
Endoscopy 2019; 51(1):73-84
disclosure: Raf Bisschops: Investigator in the MORA study. Has received 
honoraria from Norgine for speaking and Advisory Board attendance. Jon-
athan Manning: Investigator in the MORA study. Has received honoraria 
from Norgine for speaking and for Investigator Advisory Board attendance. 
Juha Halonen: Employee of Norgine. Marco Antonio Álvarez-González: In-
vestigator in the MORA study. Has received honoraria from Norgine for 
Advisory Board attendance and from Casen-Recordati for speaking and 
teaching. 
P0909 adenOMa Per cOLOnOscOPy (aPc) and adenOMa Per 
POsITIve ParTIcIPanT (aPP) as quaLITy MeTrIcs In screenIng 
cOLOnOscOPy
Mathou N.1, Papastergiou V.1, Giannakopoulos A.1, Evgenidi A.1, 
Schoretsanitis E.1, Lenas M.2, Apessou D.2, Paraskeva K.D.1
1General Hospital of Nea Ionia ‘Konstantopoulio-Patision’, Gastroenterology, 
Athens, Greece, 2General Hospital of Nea Ionia ‘Konstantopoulio-Patision’, 
Pathology, Athens, Greece
contact e-Mail address: konparaskeva@gmail.com
Introduction: Adenoma detection rate (ADR; proportion of colonoscopies 
with at least 1 adenoma) is the most validated metric in colonoscopy qual-
ity. However, ADR is not free of limitations. These include the “one and 
done” phenomenon, in which endoscopists may be less vigilant after hav-
ing detected their first adenoma. Alternative quality indicators considering 
the total number of adenomas have been proposed, although supported 
by scant evidence.
aims & Methods: We evaluated APC (total number of adenomas divided by 
the total number of colonoscopies) and APP (total number of adenomas 
divided by the number of colonoscopies with at least 1 adenoma) as quality 
markers for screening colonoscopy, based on the correlation of each with 
the ADR and the advanced ADR (AADR; proportion of colonoscopies with 
an advanced neoplasm). For this purpose, consecutive screening colonos-
copies conducted in a single endoscopy unit in Greece (Jan 2015-June 2018) 
were retrospectively reviewed. Pearson’s correlation was used to evaluate 
the relationship between APC-ADR, APC-AADR, APP-ADR and APP-AADR.
results: A total of 1505 colonoscopies performed by 6 endoscopists were 
analyzed. The ADRs ranged from 13.0% to 28.7% (mean, 22.7%), AADRs 
from 3.9% to 8.8% (mean, 6.6%), APCs from 0.18 to 0.45 (mean, 0.30) and 
APPs from 1.29 to 1.50 (mean, 1.38). APC showed a strong correlation with 
ADR (r=0.91, p=0.01) and AADR (r=0.89, p=0.02). Contrarily, no association 
could be identified between APP and both these parameters (ADR: p=0.91; 
AADR: p=0.37).
conclusion: In our setting, APC, but not APP, demonstrated significant cor-
relation with both ADR and AADR and may considered as alternative qual-
ity indicator of screening colonoscopy.
disclosure: Nothing to disclose 
P0910 scar assessMenT afTer PIeceMeaL endOscOPIc 
MucOsaL resecTIOn - InTerOBserver agreeMenT In 
hIsTOLOgIcaL recurrence PredIcTIOn
Silva J.C., Fernades C., Silva A.P., Proença L., Freitas T., Pinho R., 
Fernades S., Leite S., Ponte A., Sousa M., Gomes A.C., Afeto E., 
Carvalho J.
Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de 
Gaia, Portugal
contact e-Mail address: catarina.rib.gomes@gmail.com
Introduction: It is unclear whether scar assessment after piecemeal endo-
scopic mucosal resection (pEMR) has to include scar biopsy in the absence 
suspected recurrence. Histological recurrence (HR) is an important limita-
tion of pEMR and occurs in ≤20%. Currently HR assessment is routinely 
performed through endoscopic evaluation and scar biopsy. Advanced im-
aging methods such as Narrow-Band Imaging (NBI) may predict HR with 
high acuity.
aims & Methods: This study aims to evaluate agreement between gastro-
enterologists with different endoscopic experience, in the prediction of HR 
based on the endoscopic scar assessment.
Patients undergoing colonoscopy 3-6 months after a pEMR of 20mm or 
larger non-invasive colorectal lesions were included. Scar biopsy was per-
formed and in case of suspected endoscopic recurrence residual lesion 
was resected.
Thirty-eight high definition images with white light (WL) or NBI were se-
lected, of which 18 with HR and 20 without HR. 12 participants with differ-
ent degrees of experience in therapeutic endoscopy performed an offline 
assessment of pEMR scars. The images were randomized. Participants 
were blinded for the randomization and histology. Each gastroenterologist 
classified the images as HR or without HR, and the interobserver agree-
ment coefficient (k) was calculated.
results: Mean age was 66±12 years, with 60.5% male (n = 23). The mean 
lesion size was 35±15 mm, with 60.5% 0-Is-IIa (n=23).
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Endoscopic prediction of recurrence had high sensitivity (55.6%-88.9%) 
and specificity (85.0-95.0%). Negative predictive value (70.4%-94.1%) 
and positive predictive value (82.4-93.8%) were also calculated.
Coefficient of agreement (k) between the different participants was 0.806 
(p< 0.001). In patients with recurrence k-coefficient was 0.881 (p < 0.001). 
In patients without recurrence k-coefficient was 0.925 (p < 0.001). There 
were no significant differences between NBI (k-0.769; p < 0.001) and WL 
(k-0.837; p < 0.001).
conclusion: Endoscopic prediction of recurrence based on offline scar as-
sessment under WL and NBI showed high interobserver agreement among 
gastroenterologists with different degrees of experience in therapeutic en-
doscopy.
disclosure: Nothing to disclose 
P0911 reTrOgrade InsPecTIOn Of The cOLOn WITh a 
dedIcaTed reTrOgrade vIeWIng endOscOPe Increases 
adenOMa deTecTIOn raTe
Rath T.1, Vitali F.2, Klenske E.2, Siebler J.1, Zopf S.3, Neurath M.F.1
1University Hospital Erlangen, Ludwig Demling Endoscopy Center of 
Excellence, Erlangen, Germany, 2University Hospital Erlangen, Department 
of Medicine 1, Erlangen, Germany, 3Klinikum Fürth, Department of 
Gastroenterology, Fürth, Germany
contact e-Mail address: timo.rath@uk-erlangen.de
Introduction: Adenoma detection rate (ADR) is inversely related to the in-
cidence of interval colorectal cancers and therefore serves as a benchmark 
criterion for quality assessment during screening or surveillance colonos-
copies. Within this study, we evaluated whether additional retrograde in-
spection of the colon can increase ADR and the number of adenomas per 
patient.
aims & Methods: Patients undergoing screening or surveillance colonos-
copies were prospectively enrolled. During colonoscopy, each segment of 
the colon (Cecum and ascending colon, transverse colon, descending and 
sigmoid colon) were inspected first with HD standard forward view (SFV) 
followed by inspection of the same segment in retroflected view (RFV) us-
ing a dedicated endoscope with a 210° retroflex angulation (Pentax Retro-
View). Number of adenomas in each segment detected with SFV and RFV 
as well as withdrawal times with SFV and RFV were recorded.
results: At the time of abstract submission, 56 patients (mean age 59.4 
years, 38 male) were prospectively included. Inspection of the whole co-
lon in retroflexion was possible in all patients. Polyp detection rate (PDR) 
with SFV was 36% and increased to 46% when additional RFV was per-
formed in each segment. Likewise, ADR increased by 9% when RFV was 
performed (ADR SFV: 32%, ADR RFV: 41%). Adenoma per patient rate was 
1.7 with SFV and increased to 2.3 with additional RV. Size of the additional 
adenomas found with RFV ranged from 3 to 10 mm. Withdrawal times 
were not significantly different between SFV and RV.
conclusion: Additional retroflection of the colon using a dedicated endo-
scope can significantly increase ADR and the number of adenomas found 
per patients. This approach should be considered during standard colo-
noscopy to increase ADR and to improve the quality of colonoscopy.
disclosure: Nothing to disclose 
P0912 cLInIcaL and PaThOLOgIcaL feaTures Of 
dePressed-TyPe cOLOrecTaL carcInOMas
Kudo S.1, Takishima K.1, Kouyama Y.1, Matsudaira S.1, Ishigaki T.2, 
Ichimasa K.1, Takeda K.1, Nakamura H.1, Toyoshima N.1, Misawa M.1, 
Mori Y.3, Ogata N.1, Kudo T.1, Hisayuki T.1, Hayashi T.1, Wakamura K.1, 
Sawada N.1, Baba T.2, Ishida F.1
1Showa University Northern Yokohama Hospital, Digestive Disease Center, 
Yokohama, Japan, 2Showa University Northern Yokohama Hospital, 
Yokohama, Japan, 3Showa University Northern Yokohama Hospital, Digestive 
Disease Center, Tokyo, Japan
contact e-Mail address: kudos@med.showa-u.ac.jp
Introduction: Colorectal cancers have two development theories. One is 
“adenoma-carcinoma sequence”.The other is “de novo” pathway, con-
sidered to emerge directly from normal epithelium, not through the ad-
enomatous stage. We investigated clinicopathological characteristics of 
depressed-type colorectal carcinomas considered as”de novo”pathway.
aims & Methods: A total of 34,276 colorectal neoplasms excluding ad-
vanced cancers were resected endoscopically or surgically in our center 
from April 2001 to December 2018. Of these, 1,203 lesions were T1 carcino-
mas. According to the morphological development classification (modified 
Paris classification), they were divided into 3 types: 265 lesions (22%) were 
depressed-type, 428 lesions (36%) were flat-type and 510 lesions (42%) 
were protruded-type. We investigated the clinicopathological differences 
of these types.
results: Among T1 carcinomas, the rate of vessel invasion was 47% in de-
pressed-type, 22% in flat-type and 21% in protruded-type, that of poorly 
differentiated or mucinous adenocarcinoma was 16%, 10% and 14%, that 
of massively submucosal invasion was 94%, 70% and 78%, and that of 
tumor budding was 48%, 26% and 30%, respectively. The rates of these 
pathological factors were significantly higher in depressed-type lesions 
than other types. The rate of adenomatous component was 5%, 55% and 
52%, and the rate of polypoid growth was 14%, 56% and 96% respec-
tively. It was significantly lower in depressed-type lesions than other types. 
The mean size of tumor of each type was 15mm, 30mm, and 19mm, and 
that of depressed-type was significantly smaller than other types. The rate 
of lymph node metastasis was 9%, 6% and 12%, respectively. The rate of 
distant metastasis or recurrence was 1% (10/1,203). Among these 10 cases, 
5 cases were depressed-type lesions among which one showed a para-
aortic lymph node metastasis and four showed lung metastases.
conclusion: Depressed-type colorectal carcinomas had significantly lower 
adenomatous components and smaller size than flat- or protruded-types, 
suggesting that they follow a growth “de novo” pathway different from the 
“adenoma-carcinoma sequence”. Depressed-type colorectal carcinomas 
contained worth pathological features than other types. Giving a care-
ful attention to the morphological features is important to diagnosis the 
colorectal carcinomas.
disclosure: Nothing to disclose 
P0913 effIcacy and LOng-TerM OuTcOMes Of recTaL 
neurOendOcrIne TuMOrs afTer endOscOPIc suBMucOsaL 
resecTIOn WITh a LIgaTIOn devIce
Takita M., Ohata K., Matsuhashi N.
NTT Medical Center Tokyo, Gastroenterology, Tokyo, Japan
contact e-Mail address: myc0p1asm@mail.goo.ne.jp
Introduction: The therapeutic strategies for the rectal neuroendocrine tu-
mor (NET) still have not been standardized. We often use endoscopic sub-
mucosal resection with a ligation device (ESMR-L) for treatment of rectal 
NET. We conducted this study to evaluate the clinical outcomes of rectal 
NET treated by ESMR-L.
aims & Methods: Between May 2002 and March 2018, 199 patients with 
200 rectal NETs underwent ESMR-L in our hospital. Firstly, we investigated 
association between clinicopathological characteristics including endo-
scopic findings and therapeutic outcomes. Curative resection was defined 
as margin negative without lymphovascular invasion. Subsequently, the 
long-term outcomes after a 48-months follow-up period were also evalu-
ated.
results: The majority were male (74.5%) and the average age was 52.4 
years. Most of the lesions were located at Rb (82.5%), and the average 
size was 4.6mm. Of the 200 lesions, 199 achieved margin negative and 125 
achieved curative resection, respectively. Multivariate logistic regression 
analyses revealed that the tumor size ≧5mm (OR: 2.30, 95% CI; 1.24-4.26, 
P=0.008) and presence of central depression (OR: 3.72, 95% CI; 1.06-13.1, 
P=0.04) are significantly associated with non-curative resection. 13 (17.3%) 
of the non-curative resection underwent additional surgery, among 
which 2 cases (15.4%) had histological lymph node metastasis. Both of 
them could not detect the metastasis in preoperative period. Regarding to 
long-term outcomes, no case had local or distant metastases during the 
follow-up period. With respect to complications, 13 (6.5%) cases had de-
layed bleeding and one (0.5%) had perforation, but they were successfully 
managed conservatively.
conclusion: ESMR-L is a feasible procedure as an endoscopic resection for 
rectal NET. Since there were few patients with non-curative resection who 
underwent additional surgery, we cannot exclude the possible presence of 
clinically undetectable metastatic lesions. However, considering that there 
was no recurrence in those cases, observation without additional surgery 
in a subset of cases with non-curative resection might be allowed.
disclosure: Nothing to disclose 
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P0914 endOscOPIc fuLL ThIckness resecTIOn Of cOLOrecTaL 
LesIOns WITh The fuLL ThIckness resecTIOn devIce: The fIrsT 
greek exPerIence
Velegraki M.1, Trikola A.2, Vasiliadis K.2, Fragaki M.1, Mpitouli A.1, 
Dimas I.1, Voudoukis E.1, Giannikaki E.3, Kapranou A.4, Kordelas A.4, 
Stefanidis G.2, Paspatis G.A.1
1Venizeleion General Hospital of Heraklion, Gastroenterology Department, 
Heraklion, Greece, 2Athens Naval Hospital, Gastroenterology Department, 
Athens, Greece, 3Venizeleion General Hospital of Heraklion, Histopathology 
Department, Heraklion, Greece, 4Athens Naval Hospital, Histopathology 
Department, Athens, Greece
contact e-Mail address: magdalini_ve@hotmail.com
Introduction: Endoscopic full thickness resection (EFTR) by the Full Thick-
ness Resection Device (FTRD®) is an invasive treatment for colorectal le-
sions not resectable by conventional endoscopic techniques. This study 
presents the first Greek experience on FTRD® procedure, assessing EFTR 
efficacy and safety.
aims & Methods: We conducted a retrospective analysis of 21 patients con-
secutively treated with FTRD® at two referral centers from October 2015 
through April 2019. The indications included difficult adenomas (non-lift-
ing and/or at difficult locations), early adenocarcinomas and subepithelial 
tumors. 
Primary endpoints were technical success (resection in one piece and 
macroscopically complete) and R0 resection (negative lateral and deep 
margins based on histological examination).
results: Technical success and R0 resection occurred in 17 of 21 proce-
dures (80.9%). In 11 patients with difficult adenomas, they were achieved 
in 81.8%. In the subgroup with carcinomas (n=3), technical success and R0 
resection rate was 66.6% while in the subgroup with subepithelial tumors 
(n=7) the rate was 85.7%. In general, technical success and R0 resection 
were decreased significantly for lesions >20mm versus ≤20mm (p=0.005). 
In 21 patients a total of four adverse events occurred (19%) and one of the 
patients underwent laparoscopic appendectomy due to EFTR around the 
appendix.
conclusion: Our study showed favorable results concerning EFTR feasibil-
ity, efficacy and safety, especially for lesions ≤20 mm, non-lifting adeno-
mas, subepithelial tumors and adenomas involving the appendix. Techni-
cal success, R0 resection and adverse events rates are comparable with 
data reported in literature. Larger randomized studies comparing avail-
able surgical techniques with EFTR are needed to better define the clinical 
benefit and long-term outcomes of EFTR in selected patients.
disclosure: Nothing to disclose 
P0915 vIsuaL esTIMaTIOn Of cOLOrecTaL POLyP sIze In a 
cOLOn MOdeL
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Introduction: Correct estimation of colorectal polyp size is important for 
surveillance policy, to estimate malignant potential and to plan the meth-
od of removal1. In relation to smaller polyps, size estimation is of major 
importance in the ‘resect-and-discard’ strategy2. Currently, the gold stan-
dard of polyp size determination is the pathological measured diameter, 
but often is relied on visual (endoscopic) rating of polyp size. Literature 
shows that this visual estimation is frequently inaccurate when compared 
to the pathological report3,4. We aimed to assess factors which could hypo-
thetically influence the accuracy of visual polyp size and volume estimation 
in a colon model.
aims & Methods: We created a colon model with artificial polyps of differ-
ent size, shape and volume, which were photographed using an Olympus 
video colonoscope (Olympus EVIS EXERA III, CF-HQ190L) at fixed distances 
of 1, 3, and 5cm. The pictures were presented to 15 endoscopists of three 
different centers, who were asked to estimate polyp diameter and vol-
ume. Polyp diameters were categorized into ≤5mm, 6-9mm and ≥10mm, 
as these were considered clinical relevant categories1,2. Level of agreement 
between the visually estimated diameter category and the true (measured) 
diameter category was assessed using the Kappa test. Agreement in vol-
ume estimation was assessed using intraclass correlation.
results: The Kappa for agreement of the correct category of polyp diameter 
was 0.41 (95% confidence interval (CI) 0.33-0.48), which equals a fair to 
moderate agreement5. Agreement did not substantially improve with ex-
perience, with a Kappa of 0.42 (95% CI 0.33-0.51) in the experienced group 
(>48 months of endoscopic experience) versus 0.39 (95% CI 0.26-0.51) in 
the less experienced group. Moderate agreement was observed between 
estimated and true polyp volume (intraclass correlation 0.69, CI 0.63-0.74). 
Subanalysis showed that the best distance to estimate polyp diameter was 
at 3cm (Kappa of 0.45, versus 0.37 at 1cm and 0.40 at 5cm). Polyps pho-
tographed at 1cm were consequently estimated larger than those photo-
graphed at 3 and 5cm, for diameter as well as volume.
conclusion: In this study using a colon model with artificial polyps we 
found fairly disappointing results in estimation of polyp size (both diam-
eter and volume). Our data suggests that endoscopists tend to overesti-
mate polyp size at short endoscopic distance and underestimate polyp size 
at larger distance. Three centimeters seems to be the ideal endoscopic 
distance for optimal polyp size estimation.
Novel techniques are needed to more accurately assess polyp size during 
endoscopy.
references: 1. Van Heijningen EM et al. Features of adenoma and colo-
noscopy associated with recurrent colorectal neoplasia on a large com-
munity-based study. Gastroenterology. 2013 Jun;144(7):1410-8. 2. Kandel 
P, Wallace MB. Should we resect and discard low risk diminutive colon 
polyps. Clin Endosc. 2019 Jan;Epub ahead of print. 3. Anderson BW et al. 
Endoscopic over-estimation of colorectal polyp size. Gastrointest Endosc. 
2016 Jan;83(1):201-8. 4. Eichenseer PJ, Dhanekula R, Jakate S, Mobarhan S 
and Melson JE. Endoscopic mis-sizing of polyps changes colorectal cancer 
surveillance recommendations. Dis Colon Rectum. 2013 Mar;56(3):315-21. 
5. Landis JR, Koch GG. The measurement of observer agreement for cat-
egorical data. Biometrics. 1977;33(1):159-74.
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P0916 deLayed BLeedIng afTer cOLOnOscOPIc TreaTMenT 
In PaTIenTs TakIng anTIcOaguLanTs
Tomida H.1, Yoshio T.2, Uragami N.3
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Introduction: Delayed bleeding after endoscopic treatment in antithrom-
botic therapy is still a serious complication. Japanese guidelines for gas-
troenterological endoscopy have recommended continued warfarin treat-
ment in patients where the INR within therapeutic range and withdrawal 
of direct anticoagulants (DOACs) only on the day of treatment. However 
these guidelines have suggested the management of anticoagulants, the 
differences of the influence on delayed bleeding between warfarin and 
DOACs, and among each DOACs haven’t been clarified yet.
aims & Methods: The aim of this study is to clarify the effect of anticoagu-
lants on bleeding after colonoscopic treatment. This study was three insti-
tutions retrospective cohort study based on clinical records. We assessed 
265 consecutive patients with anticoagulants who underwent colonoscopic 
treatment from January 2013 to December 2017. 122 patients were taking 
warfarin and 143 patients taking DOACs, including 33 patients on dabiga-
tran, 58 patients on dabigatran, 39 patients on apixaban and 13 patients 
on edoxaban. Delayed bleeding has been defined as an event requiring 
emergency endoscopic hemostasis or a >2g/dL decrease in hemoglobin 
level after colonoscopic treatment.
results: The overall delayed bleeding rate was 4.5% (12/265), and the 
bleeding rate was significantly higher in the DOACs group with 7.0% 
(10/143) than in the Warfarin group with 1.6% (2/122) (p=0.041). In DOACs, 
the delayed bleeding rate of each agents were 3% in dabigatran (1/33), 
8.6% in rivaroxaban (5/58), 7.7% in apixaban (3/39), 8.3% (1/13) in edoxa-
ban. Dabigatran, as direct thrombin inhibitor, had lower delayed bleed-
ing rates than factor Xa inhibitors, but there was no significant difference. 
Heparin bridge therapy (HBT) after procedure was performed more fre-
quently in warfarin group (19%) than in DOACs group (2.8%) (p< 0.001), 
however, there was no association between delayed bleeding and HBT. 
Antiplatelet agents were combined in 45 cases (17%) and were signifi-
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cantly higher in warfarin group (34% vs 9.7%, p<0.001), but combined use 
of antiplatelet agents was not related to delayed bleeding. There was no 
significant differences in tumor diameter, tumor location and procedure 
(ESD or Polypectomy/EMR) between the two groups. The hospitalization 
period was significantly shorter in DOACs group (7days vs 2days, p< 0.001). 
Perioperative thromboembolism occurred in 1 case of DOACs group, and 
the patient was improved with only slight paralysis.
conclusion: In colonoscopic treatment, delayed bleeding was more fre-
quent in patient with DOACs, and the DOACs effects differed in each agent. 
In DOACs, the possibility of rapid onset of anticoagulant effect after oral 
administration was considered. We have previously reported that there 
was less delayed bleeding rate after gastric ESD in patients taking dabi-
gatran. A shift from factor Xa inhibitors to dabigatran could be the option 
to reduce the delayed bleeding in gastrointestinal endoscopic treatment.
disclosure: Nothing to disclose 
P0917 cOLOnIc endOscOPIc suBMucOsaL dIssecTIOn usIng 
endOMasTer ease rOBOTIc sysTeM: a PrecLInIcaL sTudy
Chiu P.W.Y.1, Phee L.2, Ho K.Y.3
1Chinese University of Hong Kong, Department of Surgery, Hong Kong, 
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Introduction: One of the difficulties in performing endoscopic submucosal 
dissection (ESD) is the lack of retraction during submucosal dissection. The 
development of master and slave transluminal endoscopic robot (MAS-
TER), EndoMaster EASE System, aims to enhance safety and efficacy of 
ESD through two flexible robotic arms for tissue retraction and dissection. 
This is a preclinical animal study to evaluate performance of colorectal ESD 
using the latest version of the EndoMaster EASE System.
aims & Methods: The latest version of the EndoMaster EASE System con-
sisted of an independently designed flexible robotic platform with build-in 
endoscopic imaging system with working channels for the passage of 2 
robotic arms and accessories. In this animal study, the outcomes measured 
included operating time (from starting incision to finishing dissection), 
completeness of resection, procedure-related complications as well as 
limitation of arms manipulation in narrow working space as assessed by 
counting the frequency of blind cutting.
results: A total of 5 colorectal ESD procedures were performed in a 66.7kg 
porcine model under general anesthesia [Figure 1]. The mean operative 
time was 73.8 minutes, and the mean size of specimen resected was 1340 
mm2. There was no perforation, while profuse bleeding was encountered 
during one of the ESD procedures [Table 1]. Hemostasis was achieved after 
adequate exposure of bleeding arteriole by retracting the mucosal with 
robotic arm. The en-bloc resection rate was 100%
conclusion: This study confirmed the feasibility and safety in performing 
ESD using the EndoMaster EASE System in porcine colon. This provides an 
important preclinical experience for the next clinical trial.
no Weight (kg) Location
OT 
time
disssec-
tion Time 
(mins)
speci-
men size 
(mm2)
dissection 
speed 
(mm2/
min)
difficulty in 
manipula-
tion
compli-
cation
1 66.7
Sigmoid 
(36cm)
68 46 35x35 26.63 nil nil
2 66.7
Rectum 
(5cm)
46 26 50x45 86.53 nil nil
3 66.2
Sigmoid 
(28cm)
30 18 25x25 34.72 nil nil
4 58
Sigmoid 
(36cm)
158 100 40x50 20.00 yes
intra-
operative 
bleeding
5 58
Sigmoid 
(24cm)
79 67 20x30 8.95 nil nil
[Outcomes of Colorectal ESD using the EndoMaster EASE System in porcine 
model]
disclosure: Philip Chiu serve on scientific advisory board of EndoMASTER 
Pte Louis Phee and Lawrence Ho are co-founder of EndoMASTER Pte 
P0918 PrevaLence and characTerIsTIcs Of cOLOnIc POLyPs 
aMOng PaTIenTs referred fOr fasT Track cOLOnOscOPy fOr 
IrOn defIcIency anaeMIa
Dru R.C.1, Court E.L.2, Getachew A.E.2, El Falaha S.2, Curtis N.J.2, 
Francis N.K.2
1Yeovil District Hospital NHS Foundation Trust, General Surgery, Yeovil, 
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Introduction: Iron deficiency anaemia (IDA) is a common indication for 
fast track referral for suspected colorectal cancer. The vast majority of 
these patients undergo upper and lower gastrointestinal (GI) endoscopy. 
Most research focuses on the incidence of colorectal cancer, but there 
is a paucity of published data concerning colonic polyps in this patient 
population.
aims & Methods: The aim of this study was to investigate the prevalence 
and characterisation of polyps, the histological subtype, and to identify any 
relationship between these and the degree of anaemia in patients referred 
for colonoscopy via the fast track pathway.
A dedicated, prospectively populated database of fast track referrals for 
endoscopy was utilised. Patient demographics, polyps and/or tumour 
characteristics, and haematological results at the time of referral were 
captured. These included haemoglobin level (Hb), mean cell volume 
(MCV), and markers of iron metabolism (iron, transferrin, transferrin satu-
ration, and ferritin levels). Anaemia was defined as Hb level of < 120g/L 
for women and < 135g/L for men. Descriptive details of patient age, sex, 
referral route (if not fast track), and polyp characterisation were recorded. 
Data was analysed using the IBM SPSS® statistical tool.
results: 846 patients underwent colonoscopy for anaemia at our centre 
over a period of 5 years (31st March 2014 to 7th April 2019). 355 patients 
in the cohort were found to have polyps (42.0%) and 58 had colorectal 
cancer (6.9%). 
In cancer patients, low Hb and MCV were statistically significant (p 0.014 
and 0.008 respectively). Hb had a negative predictive value of 0.92 for 
malignancy, being just 0.38 for polyps. 
After exclusion of patients with cancer and those who did not have full 
haematinics data, further subgroup analysis was carried out on a total 
of 217 patients. Median polyp number and size were 1 (range 1-8) and 
5mm (range 1-40mm) respectively. 66.4% of those patients with IDA had 
a pathologically confirmed adenoma, but there was no difference in mea-
sured blood results between adenoma and non-adenoma patients (p val-
ue range 0.249 - 0.935). In addition, neither polyp size nor site correlated 
with any of the blood tests analysed (all rs< ±0.15, p>0.3).
conclusion: Colorectal polyps are common but incidental findings among 
patients who undergo colonoscopy for iron deficiency anaemia. The level 
of anaemia does not appear to correlate with incidence, site, or size of 
polyps. Further research is required to validate these findings and to inves-
tigate novel markers for patients with anaemia, as colonoscopy does not 
appear to identify the cause of anaemia in the majority of cases.
disclosure: Nothing to disclose 
P0919 LOW-dOse recTaL dIcLOfenac fOr The PrevenTIOn 
Of POsT-ercP PancreaTITIs In eLderLy PaTIenTs
Maeda N.1, Higashimori A.1, Nakatani M.1, Mizuno Y.1, Nakamura Y.1, 
Ikeda D.1, Hashimoto A.1, Morimoto K.1, Fukuda T.1, Fujiwara Y.2
1Minami Osaka Hospital, Gastroenterology, Osaka, Japan, 2Osaka City 
University Graduate School of Medicine, Gastroenterology, Osaka, Japan
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Introduction: According to the guidelines of the European Society of Gas-
trointestinal Endoscopy and Japan Gastroenterological Endoscopy Society, 
50-100 mg rectal dose of nonsteroidal anti-inflammatory drugs (NSAIDs; 
diclofenac or indomethacin) is recommended for prophylaxis of post-en-
doscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). 
However, little is known about the appropriate dose of NSAIDs to prevent 
PEP in elderly patients. 
Moreover, the recommended dose is higher than the 25 mg dose that is 
commonly administered to Japanese patients, especially frail elderly pa-
tients with a low body weight or decreased renal function, who are more 
prone to adverse reactions.
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aims & Methods: The aim of this study was to evaluate the efficacy and 
safety of 25 mg rectal dose of diclofenac to prevent PEP in elderly patients 
aged over 75 years.
This was a retrospective observational study in a single institution. Be-
tween April 2013 and March 2019, 636 patients underwent 1200 ERCP pro-
cedures. Patients aged over 75 years with normal upper intestinal anatomy 
including Billroth I reconstruction were enrolled in this study. The exclu-
sion criteria were as follows: 1) acute pancreatitis, 2) peptic ulcer disease, 
3) contraindication to NSAIDs, 4) aspirin-induced asthma, and 5) severe 
kidney dysfunction with serum creatinine over 120 µmol/L. Consequently, 
303 patients with 626 procedures were included in this study. They were 
administered with or without the rectal administration of 25 mg diclofenac 
30 min before the procedure. The primary outcome was overall occur-
rence of PEP. Generalized estimating equations (GEE) were used to ana-
lyze repeated-measures data. The propensity score approach with inverse 
probability of treatment weighting (IPTW) was used to adjust for covariate 
imbalance between diclofenac and non-diclofenac groups.
results: Patients were assigned to either administration of 25 mg diclof-
enac group (59 patients with 132 procedures) or non-diclofenac group (244 
patients with 504 procedures). Their average age, body-mass index, and 
creatinine clearance (Ccr) were 83.5±5.5 years old, 21.2±4.2 kg/m², and 
43.5±16.8 mL/min/1.73m2, respectively. Patients with decreased renal func-
tion less than Ccr 60 mL/min/1.73 m2 accounted for 86% (260/303). Thirty-
four patients developed PEP and the incidence rate of PEP in diclofenac 
group (3.4%, 2/59) was significantly lower than in non-diclofenac group 
(13.1%, 32/244, p=0.037). The multivariate analysis using GEE revealed that 
prophylactic administration of low-dose diclofenac reduced the incidence 
of PEP (OR, 0.226; 95% CI, 0.052-0.975; p=0.046). Multivariate analysis 
using IPTW also showed that low-dose diclofenac was effective to prevent 
PEP (OR, 0.158; 95%CI, 0.029-0.872; p=0.034). After ERCP, there were no 
adverse events related to diclofenac such as gastrointestinal hemorrhage/
ulceration and acute renal failure.
conclusion: A 25 mg rectal dose of diclofenac was considered to be ef-
fective and safe in preventing PEP in elderly patients aged over 75 years.
disclosure: Nothing to disclose 
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Introduction: Complications associated with endoscopic retrograde chol-
angiopancreatography (ERCP) includepost-endoscopic sphincterotomy 
(EST) bleeding, perforation and sedation problems, in addition to post-
ERCP pancreatitis. ERCP is frequently necessaryin cases of obstructive pan-
creatitis caused by choledocholithiasis orpancreatic cancer. However, once 
pancreatitis develops,complications are believedto arise owing to papil-
lary oedema or deterioration of general condition.
In the present prospective multicentre study, we investigated whether 
pancreatitis beforeERCP was performed increasedthe risk of complications 
associated with ERCP.
aims & Methods: We prospectively followed 3920 patients examined by 
performing ERCP in five high-volume centresbetween April 2015 and 
May 2017. The outcomemeasures were as follows: presence or absence of 
pancreatitis prior to the examination, patients’ backgrounds, procedures, 
serum amylase level after the examination and complications associated 
with ERCP.
results: In total, 127 (3.2%)patients hadacute pancreatitis before ERCPwas 
performed. Nosignificant difference was observed between the pancre-
atitis and non-pancreatitis groups in terms of age, sex and mean exami-
nation time. The ASA physical status classification scoreand frequency of 
obstructive jaundice and untreated papilla were significantly higher in the 
pancreatitis group (p < 0.001). We observed that the pancreatitis group 
had a higher frequency of cannulation, incidence of endoscopic sphincter-
otomy (EST), placement of biliary and pancreatic stents, pancreatography 
and insertion of guidewire than non-pancreatitis group (p = 0.003, p = 
0.001, p < 0.001, p = 0.002 and p < 0.001, respectively). Nosignificant dif-
ference was observed in the incidence of cholangitis, cholecystitis, bleed-
ing after EST, perforation, biliary tract injury and sedation complications.
Theincidences of pancreatic duct injury were higher in the pancreatitis 
group than in non-pancreatitis group (p < 0.001). The frequency of post-
ERCP pancreatitis was 7% (266/3650).
conclusion: ERCP performed for patients with acute pancreatitis had an 
acceptable level of safety. We also found that the biliary cannulation rate 
was higher in patients with pancreatitis. However, care should be taken 
when inserting a guidewire to the pancreatic duct owing to an increased 
risk of pancreatic ductal injury.
disclosure: Nothing to disclose 
P0921 cLInIcaL usefuLness Of a cOnvenTIOnaL gasTrOscOPe 
fOr endOscOPIc reTrOgrade chOLangIOPancreaTOgraPhy 
In PaTIenTs WITh surgIcaLLy aLTered gasTrOInTesTInaL 
anaTOMy
Nakatani M.1, Higashimori A.1, Maeda N.1, Nakamura Y.1, Hashimoto A.1, 
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) in 
patients with surgical altered gastrointestinal anatomy (SAGA) is techni-
cally challenging. Some studies reported that ERCP using balloon-assisted 
enteroscope (BAE) yield better results than previous attempts of ERCP us-
ing conventional endoscopes. However, requirement for the specific endo-
scopic system limits the numbers of hospitals equipped with BAE. Consid-
ering the distance from the mouth to the blind end in patients with SAGA, 
it would be possible to perform ERCP using a conventional gastroscope 
instead of BAE.
aims & Methods: The aim of this study was to assess the efficacy and safety 
of ERCP using gastroscope in patients with SAGA. Additionally, we identi-
fied the risk factors of failure of ERCP using gastroscope.
This was a retrospective observational study in a single institution. Be-
tween April 2013 and September 2018, ERCP procedures using the gas-
troscope, Q260J (Olympus, Japan, working length of 1040 mm, working 
channel of 3.2 mm) were performed in patients with SAGA such as post-
gastrectomy with Billroth-II (B-II) and Roux-en-Y (R-Y) and post-pancreat-
icoduodenectomy with modified Child method (PD). Success rates of deep 
insertion, cholangiogram and treatment were evaluated. We estimated 
the predictive factors of failure of ERCP using gastroscope. Generalized 
estimating equations (GEE) were used to analyze repeated-measures data.
results: Total 29 patients with 47 procedures were included, comprising 
B-II (10 patients with 17 procedures), R-Y (13 patients with 18 procedures) 
and PD (6 patients with 12 procedures). Deep insertion was successful 
in 41/47 procedures (87%), average insertion time was 7.7±6.4 min. Suc-
cessful cholangiogram and treatments were obtained in 38/41 (93%) and 
36/41 (88%) procedures, respectively. Overall average procedure time was 
35.3±15.5 min. Although there was no significant difference in the success 
rate of deep insertion among three groups, the rate in patients with R-Y 
tended to be low, the rate in patients with B-II, R-Y and PD being 86% 
(15/17), 75% (14/18) and 100% (12/12), respectively. Complications occurred 
in 4/47 procedures (8.5%), and all complications were managed conser-
vatively. There were no independent predictive factors of failure associated 
with our endoscopic procedures. In a separate analysis focusing on pa-
tients with R-Y, laparotomic gastrectomy was the only independent predic-
tive factor of failure of deep insertion by multivariate logistic regression 
with GEE (odds ratio, 5.06; 95% confidence interval, 1.00-25.47).
conclusion: Since ERCP using the conventional gastroscope was safe and 
effective in patients with SAGA, gastroscope could be used in place of BAE. 
However, because the success rate of deep insertion in patients with lapa-
rotomic gastrectomy with R-Y was relatively low, such patients should re-
ceive ERCP using BAE.
disclosure: Nothing to disclose 
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P0922 ercP Is MOre chaLLengIng In cases Of acuTe BILIary 
PancreaTITIs Than In acuTe chOLangITIs - an anaLysIs Of The 
hungarIan ercP regIsTry daTa
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) 
is necessary in acute biliary pancreatitis (ABP) when cholangitis or com-
mon bile duct stone is present. However, the inflammation of the pancreas 
and the surrounding tissues might make it more difficult. This topic is not 
widely studied, therefore we intended to quantify this challenge for the 
endoscopist by analyzing 5 tertiary centers’ data from the prospectively 
collected data of Hungarian ERCP registry.
aims & Methods: 150 ABP cases and 243 acute cholangitis (AC) cases 
without ABP were included. Previous papillotomy, altered gastroduodenal 
anatomy and biliary stricture cases were excluded. The rate of biliary ac-
cess, advanced cannulation method, adverse event rates, cannulation and 
fluoroscopy time, as well as subjective difficulty were evaluated.
results: Needle-knife precut use was significantly higher in the ABP than in 
AC group (33% vs. 21%; p=0.013), however, no difference was found between 
biliary cannulation rates of the two groups (93% vs. 91%). Significantly more 
pancreatic guidewire manipulation (30% vs. 16%; p=0.01) and prophylactic 
pancreatic stent use (22% vs. 9%; p< 0.001) was seen in the ABP than in AC 
group. Moreover, longer cannulation time in the ABP patients (300 vs. 200 
s; p=0.008) but similar fluoroscopy times (90 vs. 87 s) were measured in 
the two groups. There was no difference between the adverse events rate of 
ABP vs. AC cases (immediate bleeding: 11% vs. 9%, only one case required 
transfusion in the AC group, all other cases were controlled endoscopically; 
hypoxia: 5% vs. 7%). No significant difference was found in the subjective 
difficulty, however, there was a trend towards easier examinations (< 3 on a 
10-point scale) in the AC group (40% vs. 51%; p=0.073).
conclusion: ERCP in ABP cases is more challenging than in AC but does 
not affect the outcomes in our registry data. The increased need for pre-
cutting, longer cannulation time and higher rate of pancreatic guidewire 
manipulations show more frequent difficult biliary cannulation in the ABP 
patients without worsening the biliary cannulation success rate. The level 
of subjective difficulty also correlates with these data. Adverse events rates 
were similar in the groups.
disclosure: Nothing to disclose 
P0923 PerfOraTIOn Of The LaTeraL duOdenaL WaLL 
caused By PLasTIc BILIary sTenT dIsPLaceMenT TreaTed WITh 
Over-The-scOPe-cLIP: a PrOsPecTIveLy cOLLecTed cOhOrT
Bureau M.-A., Gkolfakis P., Blero D., Devière J., Lemmers A.
Erasme Hospital, Université Libre de Bruxelles (ULB), Department of 
Gastroenterology, Hepatopancreatology and Digestive Oncology, Brussels, 
Belgium
contact e-Mail address: pgkolfakis@med.uoa.gr
Introduction: Duodenal perforation is a complication of ERCP in less than 
1% of procedures and can sometimes be caused by the impaction of a 
distally migrated stent into the lateral duodenal wall. Treatment options 
when this occurs may include endoscopic treatment with either through-
the-scope clips or over-the-scope clips (OTSC) and surgical repair.
aims & Methods: The goal was to determine the incidence of duodenal 
perforation caused by plastic biliary stents displacement in our center 
and identify possible predisposing factors. We also wanted to evaluate 
the efficacy and safety of endoscopic closure with OTSC. To obtain data, 
we went over the database including all ERCPs performed and screened 
for duodenal perforation secondary to biliary plastic stents displacement 
from January 1st 2014 to March 31st 2019. We then collected individual data 
of the screened cases.
results: Six cases of ERCP done for lateral duodenal wall perforation 
caused by plastic biliary stent displacement were identified during that pe-
riod (0.8% of the 696 ERCPs with plastic stent placement performed over 
the same period). In most cases the diagnosis of perforation was done less 
than five days after the stent placement (4/6) and the time between stent 
insertion and perforation diagnosis ranged from 2 to 91 days. In the major-
ity of these patients (5/6) biliary stenting was done with multiple double 
flaps straight plastic stents, in all cases the longest stent was the culprit 
and in most of them (5/6) the culprit stent was in the left intra-hepatic bile 
ducts. The length of the perforating stents ranged from 12 to 18 cm. Two 
patients had a history of previous stenting achieving a higher total stents 
diameter than what was applied at the last examination (patient 3 had a 
maximum total stents diameter of 18.5 Fr while the total diameter of stents 
in his last ERCP was of 10 Fr and patient 4 had a maximum total stents 
diameter of 27 Fr while the total diameter of stents in his last ERCP was 
of 25.5 Fr). Each patient was treated with a 12mm OTSC which permitted 
successful closure of all perforations (6/6; 100%) confirmed by subsequent 
imaging modalities. In five patients no further interventions were needed 
and outcome at 28 days was excellent for four of them. One patient died at 
day 17 after perforation closure but his death was not related to the com-
plication. Further intervention after successful treatment was needed for 
another patient. This patient developed peritonitis requiring laparotomy 
and peritoneal lavage. The laparotomy did not show any residual leak at 
the perforation site but the patient eventually died of this complication at 
day 5 post perforation.
Patients 
characteri-
stics (gen-
der, age)
stenting 
indication
days between 
stent 
placement and 
perforation 
diagnosis
culprit stent 
informations
Immediate 
outcome
28 days out-
come
1. M 75
Biliary leak 
post hepatec-
tomy
21
Double flaps 
18 cm 8,5 Fr 
(1/2 migrated)
Success at 
closure
No further 
interventions or 
complications
2. M 61
Bilioma post 
liver transplan-
tation
2
BSLC 17 cm 
8,5 Fr
Success at 
closure
No further in-
terventions but 
death 17 days 
later (biliary 
sepsis)
3. F 31
Choledocholi-
thiasis and bile 
duct stenosis
4
Double flaps 
15 cm 7 Fr (1/2 
migrated)
Success at 
closure
No further 
interventions or 
complications
4. M 52
Ischemic 
cholangitis
91
Double 
flaps 12 cm 
8,5 Fr (2/3 
migrated)
Success at 
closure
No further 
interventions or 
complications
5. M 72
Bile duct com-
pression after 
hepatic artery 
embolization
2
Double flaps 
13 cm 8,5 Fr 
(1/2 migrated)
Success at 
closure
Peritonitis 
needing laparo-
tomy and death 
3 days later
6. F 46
Anastomotic 
stenosis post 
liver transplan-
tation
2
Double flaps 
12 cm 8,5 Fr 
(1/2 migrated)
Success at 
closure
No further 
interventions or 
complications
[Table 1: Cases Summary]
conclusion: Perforation of the lateral duodenal wall by a biliary stent is a 
rare complication of ERCP in a tertiary referral center. In this study, most 
cases were related to multiple straight plastic stents with double flaps. A 
history of maximal total stents diameter achieved before the last ERCP, use 
of longer stents (>12 cm) and placement of stent into the left intra-hepatic 
bile ducts could be potential risk factors. OTSC appears as an effective 
treatment with a closure success rate of 100% in our cohort. 
disclosure: Nothing to disclose 
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P0924 WhO shOuLd adMInIsTer sedaTIOn durIng 
ercP - anesThesIOLOgIsT, InTensIvIsT Or endOscOPIsT? 
a cOMParaTIve PrOsPecTIve sTudy
Alburquerque Miranda M.A.1, Vargas García A.L.2, Zaragoza Velasco N.3, 
Pechkova M.2, Planella De Rubinat M.4, Ballester R.4, Figa M.5, 
González-Huix Lladó F.6, SEED Working Group on ERCP
1Clínica Girona - Hospital de Palamós, Gastroenterology, Gerona, Spain, 
2Clínica Girona, Girona, Spain, 3HUAV, Gastroeneterology and Hepatology, 
Monzon, Spain, 4Hospital Arnau de Vilanova, Lleida, Spain, 5Hospital 
Dr. Josep Trueta, Gastroenterology, Girona, Spain, 6Clinica Girona, 
Gastroenterology, Girona, Spain
contact e-Mail address: nictalope7@gmail.com
Introduction: The proper training in sedation and who should administer 
it during ERCP still unknown.
aims & Methods: To compare safety and effectiveness of sedation during 
ERCP (sERCP) regarding which medical doctor directs it. 
A comparative prospective non-randomized study done in daily practice. 
Consecutive patients who underwent to ERCP were collected at two cen-
ters. January 2017 - May 2018. Sedation was directed either by an endosco-
pist (endoscopist-directed propofol: EDP), on Monday or by an intensivist 
(intensivist-administered propofol: IAP), on Wednesday or by an anesthe-
siologist (monitored anesthesia care: MAC), on Thursday. The safety was 
measured by the appearance of serious adverse events (SAE) and the ef-
fectiveness, by the cancelled ERCP rate, sedation time and patient position 
that determined ease of ERCP and quality of radiologic images.
results: 454 patients (Age: 72.7 ±15.7y; women: 54.63%): 147 into EDP 
group, 137, IAP group and 170, MAC group. The endoscopist had the largest 
experience in sERCP (>100 procedures): 98%, p=0.000 and he adminis-
tered only propofol in 81.9%, the intensivist administered propofol plus 
midazolam in 78.7% and anesthesiologist, propofol plus other agents (i.e. 
opioids, ketamine) in 86.2%, p=0.000. The sedation was deepest in MAC, 
Observers’s Assessment of Alertness-Sedation score (OAAS): 5.19 ±0.6, 
p=0.000. The SAE rate was 8.6%, lowest in EDP: 4.8%, p=0.042. The SpO
2
 
< 70% was the most frequent SAE: 4.5%, highest in MAC: 6.1%, p=0.085 
and it had required more respiratory resuscitation measures (chin-lift ma-
neuver, increasing of FIO
2
 or Guedel airway insertion) in MAC and IAP than 
EDP, p=0.003. The tracheal intubation was most frequent in MAC: 1.8%, 
p=0.074. Concerning effectiveness, the highest cancelled ERCP rate was 
observed in MAC: 2.9%, p=0.015. Similarly, in this group the lateral decu-
bitus position was most frequent (31.6%, p=0.000), which determined the 
worst radiologic image (17.8%, p=0.000). The sedation time was shortest 
in IAP: 44.4 ±1.8 min, p=0.023. In a multivariate analysis, the shorter train-
ing on sERCP: OR =6.56 (3.18-13.54 CI95%), Obstructive sleep apnea: OR 
=4.34 (2.07-9.11 CI95%) and age ≥75years: OR =2.18 (1.03-4.63 CI95%) were 
associated to appearance of complications.
conclusion: Our data suggest that sERCP is safer and more effective when 
is administered by an expert nursing team directed by an endoscopist.
disclosure: Nothing to disclose 
P0925 endOscOPIc uLTrasOund (eus)-
dIrecTed TransgasTrIc endOscOPIc reTrOgrade 
chOLangIOPancreaTOgraPhy (ercP): a sIngLe cenTer 
exPerIence Of an evOLvIng PrOcedure
Mohy-ud-din N.1, Carleton N.2, Syed A.3, Antoury C.2, Farah K.2, 
Kulkarni A.4, Dhawan M.2, Thakkar S.5, Kochhar G.2
1Allegheny Health Network, Medicine Institute, Pittsburgh, United States, 
2Allegheny Health Network, Gastroenterology & Hepatology, Pittsburgh, 
United States, 3Allegheny Health Network, Gastroenterology, Pittsburgh, 
United States, 4Allegheny Health Network, Pittsburgh, United States, 
5Allegheny Health Network, Gastroenterology, Sewickley, United States
contact e-Mail address: drkochhar@gmail.com
Introduction: EUS-directed transgastric ERCP is an emerging technique 
for pancreaticobiliary intervention in patients with a history of Roux-en-Y 
gastric bypass (RYGB). It can allow ERCP to be performed in a minimally 
invasive fashion and with a high technical success rate.
aims & Methods: The aim of this study was to analyze the safety and effica-
cy of EDGE procedures performed at a single tertiary care center. Patients 
with a history of RYGB who underwent an EDGE procedure between Janu-
ary 2018 and April 2019 were included in the study. Patient demographics, 
procedure time, technical success and complications (bleeding, infection, 
perforation and pancreatitis) were recorded. Total time to complete pro-
cedure and hospital length of stay was calculated by addition of the time 
for EUS and ERCP. Statistical analysis was performed using SPSS 23 (IBM, 
Armonk, NY).
results: Eighteen patients were included in the study. Mean age was 61 +/- 
11 years and 78% (n=14) were females. EDGE was performed after a failed 
ERCP in 22% (n=4). EDGE was performed as a same-day procedure in 33% 
(n=6) and access route was transgastric for 89% (n=16) vs transjujenal for 
11% (n=2). Technical success was 100% (n=18). LAMS was removed during 
the initial ERCP for 44% (n=8), follow-up EGD for 17% (n=3), elective sur-
gery (Whipples procedure) for 3% (n=17%), follow up ERCP for 11% (n=2), 
follow-up EUS for 6% (n=1) and left in place for 6% (n=1). 72% (n=13) un-
derwent spontaneous closure of the fistula, 17% (n=3) underwent closure 
intraoperatively, 6% (n=1) underwent closure with endoscopic mucosal 
clips. Post-procedural bleeding occurred in 6% (n=1). LAMS dislodgement 
during the procedure with successful replacement of the LAMS occurred in 
6% (n=1). The mean hospital length of stay was 1.09 +/- 0.76 days.
conclusion: EDGE is a safe and efficacious procedure that has a 100% tech-
nical success rate and short length of stay with minimal complications.
disclosure: Nothing to disclose 
P0926 sPygLassds guIded LIThOTrIPsy fOr PancreaTIc ducT 
sTOnes In syMPTOMaTIc, TreaTMenT refracTOry chrOnIc 
PancreaTITIs- 12 MOnThs fOLLOW uP On cLInIcaL, TechnIcaL 
success and quaLITy Of LIfe
Gerges C.1, Pullmann D.1, Weber P.1, Siersema P.D.2, Neuhaus H.1, 
Van Geenen E.J.M.3, Beyna T.1
1Evangelisches Krankenhaus Düsseldorf, Dpt. of Internal Medicine, 
Düsseldorf, Germany, 2Radboud University Medical Center - Gastroenterology 
& Hepatology, Radboud University Medical Center, Gastroenterology 
& Hepatology, Nijmegen, Netherlands, 3UMC St Radboud, Nijmegen, 
Netherlands
contact e-Mail address: gerges.christian@gmail.com
Introduction: Pancreatic duct (PD) stones are a common complication in 
chronic calcifying pancreatitis (CCP) and contribute to pain onset and pain 
exacerbation. (Digital) single-operator pancreaticoscopy (d-SOP) guided 
lithotripsy was shown to be a promising option of therapy regarding tech-
nical success (95% ductal clearance) and short-term pain relieve. How-
ever, there is only little evidence of mid-and long-term clinical success and 
impact on quality of life.
aims & Methods: Analysis of clinical success and impact on quality of life 
after d-SOP guided lithotripsy in CCP in ongoing follow up. A single-center, 
retrospective analysis of all d-SOP guided lithotripsies (n=23) of PD stones 
in 20 CCP patients after introduction of next generation d-SOP (SpyGlass 
DS) in 2015. Clinical success was determined by a systematic questionnaire 
regarding pain intensity and incidence as well as quality of life after 3,6 
and 12 months in an ongoing follow up.
results: After d-SOP guided lithotripsy technical success (PD decompres-
sion) was achieved in a total of 19/20 cases. Clinical success (pain reduc-
tion >50 % in numerical rating scale (NRS) pain score) was achieved in 
19/20 cases. In early follow-ups 95% of the patients reported major im-
provement in symptoms und quality of life. In the latest (12 months) follow 
up 2 patients were referred to a surgeon for partial pancreatectomy, one 
patient was lost to follow-up. Of the 17 remaining patients clinical success 
- as defined above - was persistent in 11 cases and 12 patients described 
major improvements in symptoms and disability in daily life. There was no 
need of further interventional therapy except subsequent stentingin case 
of persistent PD strictures.
conclusion: d-SOP guided lithotripsy was found to be safe and effective 
regarding technical success and clinical outcome. Beneficial effects on 
symptom control and quality of life seem to last in the majority of CCP 
patients after a 12 months follow-up.
disclosure: Nothing to disclose 
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P0927 a nOveL, sMaLL j-TIPPed guIdeWIre reduce The rIsk 
Of POsT-endOscOPIc reTrOgrade chOLangIPancreaTOgraPhy 
PancreaTITIs In PaTIenTs WITh dIffIcuLT BILIary cannuLaTIOn
Fukasawa M.1, Hirose S.1, Takano S.1, Kadokura M.1, Shindo H.1, 
Takahashi E.1, Kawakami S.1, Fukasawa Y.1, Hayakawa H.2, Sato T.1, 
Enomoto N.1
1University of Yamanashi, First Department of Internal Medicine, Faculty 
of Medicine, Chuo, Yamanashi, Japan, 2University of Yamanashi, First 
Department of Internal Medicine, Chuo, Japan
contact e-Mail address: fmitsu@yamanashi.ac.jp
Introduction: ESGE guideline recommends using pancreatic guidewire 
(PGW)-assisted biliary cannulation in patients where biliary cannulation 
is difficult and repeated unintentional access to the main pancreatic duct 
occurs. However, insertion of the GW into the pancreatic duct has a risk of 
post-endoscopic retrograde cholangiopancreatography (ERCP) pancreati-
tis. Recently, J-tipped GW designed for improving luminal passage have 
been developed and reported to be beneficial in selective biliary cannula-
tions. Although J-tipped GW was not applicable to pancreatic duct due to 
its large tip radius, the newly developed small J-tipped GW with a smaller 
loop has enabled pancreatic duct interventions.
aims & Methods: The aims of this study were to evaluate the safety and 
efficacy of newly developed small J-tipped guidewire for PGW-assisted 
biliary cannulation. PGW-assisted biliary cannulation for difficult biliary 
cannulation with naïve papilla were performed in a total of 277 cases. 
We used angle-tipped GWs from January 2011 to February 2014 and small 
J-tipped GWs from March 2014 to September 2016. The patients were di-
vided into two groups chronologically, according to the time period dur-
ing which guidewires were used for PGW-assisted biliary cannulation: the 
angle-tipped GW group (from January 2011 to February 2014) and the small 
J-tipped GW group (from March 2014 to September 2016). Pancreatic stent 
was inserted after PGW-assisted biliary cannulation. The success rates and 
complications were evaluated.
results: Success rates of PGW-assisted biliary cannulation were 81% in 
the small J-tipped GW group and 70% in the angle-tipped GW group, 
respectively. There was no statistical difference between the two groups 
(p = 0.052). The rate of post-ERCP pancreatitis was significantly lower in 
the small J-tipped GW group compared with that in the angle-tipped GW 
group (6.3% vs 19.0%, P = 0.01). Moreover, localized pancreatitis or pan-
creatic ductal leakage caused by injury of pancreatic duct were signifi-
cantly less in the small J-tipped GW group compared to the angle-tipped 
GW group. Multivariate analysis showed that the use of the small J-tipped 
GW was the only factor reducing the risk of post-ERCP pancreatitis (OR 
0.32, 95% CI 0.12-0.87, P = 0.026).
conclusion: Newly developed small J-tipped GW reduce a risk of develop-
ing post-ERCP pancreatitis in patients with difficult biliary cannulation.
disclosure: Nothing to disclose 
P0928 nOn-aLcOhOLIc faTTy LIver dIsease as 
a rIsk facTOr fOr POsT endOscOPIc reTrOgrade 
chOLangIOPancreaTOgraPhy PancreaTITIs
Sbeit W.1, Khoury T.1, Wengrower D.2, Livovsky D.M.2, Mari A.3, Kadah A.1, 
Goldin E.4, Mahamid M.5
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contact e-Mail address: tawfik.khoury.83@gmail.com
Introduction: The prevalence of post endoscopic retrograde cholangiopan-
creatography pancreatitis (PEP) is variable and ranges from 5-25%. Fatty 
liver disease has been increasingly encountered in the last decade and 
it is already reported as a risk factor for several extra-hepatic diseases, 
however, it has not been reported as a risk factor for PEP.
aims & Methods: We aimed to assess whether NAFLD is a risk factor for 
the development of PEP. We performed a retrospective multicenter study. 
All patients who underwent ERCP during 2014-2016 who had a diagnosis 
of NAFLD by abdominal imaging were eligible for inclusion. Four hundred 
and one patients were included, among them, thirty-eight (9.5%) were di-
agnosed with PEP according to clinical, laboratory and radiological criteria.
results: The mean age in groups A (patients without PEP) and group B 
(patients with PEP) were 61.2 ± 20.9 and 67.6 ±19.3, respectively. Forty-five 
percent in group A and 44% in group B were males. The most common 
indication for ERCP in the two groups was confirmed CBD stones, cholan-
gitis and obstructive jaundice. One-hundred twenty-four patients (34%) in 
group A had fatty liver as diagnosed by pre-endoscopic ultrasound (US) 
compared to 21 patients (55.3%) in group B, P=0.01. 
In univariate analysis, several predictors of PEP were identified. Fatty liver 
(OR 2.363, 95% CI 1.211-4.614, P=0.01), AST (OR 1.008, 95% CI 1.000-1.016, 
P=0.04), ALT (OR 0.979, 95% CI 0.968-0.991, P=0.0007), ALP (OR 1.008, 
95% CI 1.001-1.015, P=0.01), GGT (OR 1.014, 95% CI 1.006-1.021, P=0.0005) 
and total bilirubin (OR 1.141, 95% CI 1.039-1.253, P=0.005) were statis-
tically significant in predicting PEP. In multivariate regression analysis, 
only fatty liver showed statistically significant correlation with PEP (OR 
3.224, 95% CI 1.548-6.713, P=0.001), while the other parameters showed 
very weak association with PEP, with ROC area under the curve (AUC) of 
0.8156. Notably, no patients with dilated CBD of more than 10 mm had 
developed PEP.
conclusion: NAFLD was shown to be a risk factor for PEP. Therefore, we 
suggest to consider prophylactic pancreatic stenting and/or NSAID’s sup-
positories among these patients.
disclosure: Nothing to disclose 
P0929 Is vascuLarITy enOugh TO PredIcT neOPLasIa In 
BILe ducT LesIOns durIng PerOraL chOLangIOscOPy?
Robles-Medranda C., Oleas R., Olmos J., Alcivar-Vasquez J., 
Puga-Tejada M., Baquerizo-Burgos J., Pitanga-Lukashok H.
Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Gastroenterology 
and Endoscopy Division, Guayaquil, Ecuador
contact e-Mail address: robertoleas@gmail.com
Introduction: The direct visualization of the intraductal biliary system via 
peroral cholangioscopy (POCS) changes the clinical management in pa-
tients with bile duct lesions. Macroscopic features have been used to de-
termine neoplasia in bile duct lesions during POCS such as the presence 
of masses or irregular surfaces; however, the presence of bleeding, oozing 
or tortuous vessels as signs of neovasculature might be most the accurate 
findings for neoplasia.
aims & Methods: To evaluate the role of neovasculature in bile duct lesions 
for the prediction of neoplasia during peroral cholangioscopy. 
A cohort study with prospectively collected endoscopic data of patients 
with bile duct lesions evaluated via POCS who was aged ≥18 years. Patients 
with lesions but with no subsequent histological confirmation, with less 
than six months of follow-up, or concomitant choledocholithiasis during 
POCS were excluded for analysis. POCS were performed using a digital, 
single-operator cholangioscopy system (Spyglass®, Boston Scientific, 
Marlborough, MA, USA). Neovasculature was defined as the presence of 
irregular or spider vascularity on bile duct lesions. The neovasculature 
overall diagnostic accuracy was estimated considering a six months fol-
low-up as a gold standard. Inter-observer agreement analysis was per-
formed between two endoscopists (JO & JAV). A p-value< 0.05 was consid-
ered statistically significant. Data were analyzed in R-3.4.2 (R Foundation 
for Statistical Computing; Vienna, Austria).
 
Total 
(n=95)
neoplastic 
(n=52)
non-neopastic 
(n=43)
p-value
age (years), median (range) 66 (20-93) 71.2 (37-93) 61 (20-87) <0.001
gender (female), n (%) 51 (53.7) 26 (50.0) 25 (58.1) 0.428
Main POcs indication 
(Tumor suspicion/
indeterminate stenosis), n/n
50/45 42/10 8/35 <0.001
Previous ercP, n (%) 40 (42.1) 15 (28.8) 25 (58.1) 0.039
Bile common duct 
localization, n (%) 61 (64.2) 30 (57.7) 31 (72.1) 0.028
Presence of neovascularity, 
n (%)
65 (68.4) 49 (94.2) 16 (37.2) <0.001
neoplastic histology, n (%) 48 (50.0) 48 (92.3) 0 <0.001
[Table 1. Baseline characteristics between neoplastic vs. non-neoplastic 
groups according to follow-up.]
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results: Ninety-five patients were enrolled, median age 65.6 (16 - 93) 
years old, 56 (55%) were female. Neovasculature signs were appreciated 
in 65/95 (68%) of cases. The biopsies sample were adequate in 90/95 
(95%) cases. Histology confirmed neoplasia in 45/61 (74%) cases; while, 
follow-up in 49/65 (75%). 
Table 1 summarized baseline characteristics between neoplastic vs. non-
neoplastic groups according to follow-up. The vascularity for predicting 
neoplastic lesions reached sensitivity, specificity, positive and negative 
predictive value (PPV & NPV), positive & negative likelihood ratio, observed 
and inter-rater agreement of 94%, 63%, 75%, 90%, 2.53 (95% IC 1.71 - 
3.76), 0.09 (95% IC 0.03 - 0.28), 80% and 57% (p< 0.001), respectively. 
The interobserver agreement analysis exhibited an excellent agreement 
(Κ>80%; p< 0.001).
conclusion: Irregular or spider vascularity on bile duct lesions during POCS 
evaluation predict properly biliary neoplastic lesions.
disclosure: Nothing to disclose 
P0930 anaLysIs Of POsT-ercP PancreaTITIs raTe In 
The TIMe TO successfuL BILIary deeP cannuLaTIOn and 
OPeraTOr change frOM TraInee TO exPerT
Kawamoto H., Tanikawa T., Ishii K., Urata N., Nakamura J., Suehiro M., 
Sasai T., Nishino K., Kawanaka M., Haruma K.
Kawasaki Medical School General Medical Center, Internal Medicine, 
Okayama, Japan
contact e-Mail address: hirofumi.kawamoto@gmail.com
Introduction: Selective biliary deep cannulation is a first step of biliary 
endoscopic treatment and one of the most important procedures to mas-
ter for trainees. When this procedure is time-consuming, the complication 
risk may increase. We retrospectively analyzed the relation between biliary 
cannulation time and post-ERCP pancreatitis (PEP) and assumed the time 
to change an operator from a trainee to an expert.
aims & Methods: Between April, 2011 and March, 2019, there are 996 pa-
tients with intact papilla [536 male, median of age 75 year old (IQR: 66-
83)] in whom the selective biliary deep cannulation was mandatory for 
the endoscopic treatment. The diseases of the patients were benign in 765 
cases (76.8%). ERC was usually commenced with conventional cannula-
tion technique. Wire-guided cannulation, pancreatic guide wire method, 
or needle knife precut were allowed. The expert (EX) was H.K. who expe-
rienced more than 3000 ERCP cases and the other operators were defined 
as trainees (TR). 
Although the operator change from TR to EX was within EX discretion, 
the time of operator change was principally within 15 minutes. The PEP 
was defined as sever epigastric pain and more than twice value of upper 
serum AMY level which were occurred in the patients within 24 hours 
after treatment. The degree of PEP severity was classified according to 
Cotton criteria. The rate of PEP was analyzed according to the first opera-
tor and time.
results: The success rate of biliary cannulation was 98.9% (985/996). 
The median time of cannulation was 5 minutes (IQR: 2-15). PEP rate was 
6.0% (60/996). The moderate PEP was noted in 5.0% (3/60) and the rest 
mild. The number of EX-first cases was 310 (31.1%) and that of TR-first 
cases 686 (68.9%). The rate of operator change from TR to EX was 31.6% 
(217/686). The success rate of cannulation in EX-first cases was 99.7% 
(309/310) and that in TR-first cases was 98.5% (676/686);(p=0.11). The me-
dian cannulation time was 3 minutes (IQR: 1-8.8) in EX-first cases and that 
in TR-first cases was 5.5 minutes (IQR: 2-14.8); (p< 0.001). The PEP rate 
in EX-first cases was 4.2% (13/310) and that in TR-first cases was 6.9% 
(47/686);(p=0.10). In TR-first cases, median successful cannulation time by 
TR alone was 6 minutes (IQR: 2-15) and median time of operator change 
was 10 minutes (IQR: 7-15). Comparing the PEP rate according to success-
ful cannulation time: within 10 minutes (short time: ST) and more than 10 
minutes (long time: LT), the PEP rate was 4.4% (31/700) in ST and 9.8% 
(29/296) in LT; (p< 0.01). 
Compared between the first operators in ST cases, the PEP rate in EX-
first cases was 3.6% (9/247) and that in TR-first cases was 4.9%(22/453); 
NS (p=0.46). In LT cases, that in EX-first cases was 6.3% (4/63) and that 
in TR-first cases 10.7% (25/233); NS (p=0.30). Compared in intra-operator 
time, in EX first cases, there was no significant difference (3.6% vs 6.3%: 
p=0.34) in PEP rate between ST and LT. However, compared in TR-first 
cases, significant increase in PEP rate was noted (4.9% vs 10.7%: p< 0.01). 
In operator-changed cases, total PEP rate was 6.9% (15/217). PEP rate in 
ST was 4.3% (5/116) and that in LT was 9.9% (10/101); NS (p=0.10). In cases 
that successful cannulation was achieved by TR alone, total PEP rate was 
6.8% (32/468). However, PEP rate significantly increased (p< 0.001) from 
5.1% (ST: 21/412) to 19.6% (LT: 11/56).
conclusion: In case of time-consuming, the more PEP rate increases, es-
pecially in TR-first cases. These data suggests that operator change may 
be considered in case that TR consumes more than 10 minutes to achieve 
successful deep biliary cannulation.
disclosure: Consultant: Piolax Medical Devices Gadelius Medical 
P0931 ergOnOMIc InjurIes In endOscOPIsTs and TheIr rIsk 
facTOrs
Kalwar H.A., Kamani L.
Liaquat National Hospital, Gastroenterology, Karachi, Pakistan
contact e-Mail address: hamidgulk@yahoo.com
Introduction: Endoscopists often experience musculoskeletal pain and in-
jury (most often in the back, neck, shoulders, hands, wrists, and thumbs) 
that are associated with the minute and repetitive strain that is placed 
on these areas during endoscopic procedures. The aim of this study is to 
assess the musculoskeletal injuries in endoscopists and their risk factors.
aims & Methods: Objective: To assess frequency of ergonomic injuries in 
endoscopists and their risk factors, at a tertiary care hospital, Karachi.
subject & methods: This cross sectional study was conducted at the De-
partment of Gastroenterology, Liaquat National Hospital after informed 
written consent on endoscopy practitioners doing endoscopies throughout 
the Pakistan. Endoscopists were asked to fill-up the Performa. Chi square 
test was used for analysis. P-value < 0.05 was considered as significant.
results: Out of 61 endoscopists 58 (95.1%) were male and 3 (4.9%) were 
female with the mean age of 44.02+7.873 years. The most common er-
gonomic injury noted was back pain in 25 patients (41%), leg pain in 14 
(23%) and hand pain in 12 (19.7%). Ergonomic injuries were common in 
endoscopists with higher BMI (p< 0.004), were seen more in enodscopists 
performing high number of procedures (p< 0.001), more commonly noted 
in endoscopists with higher cumulative duration of GI practice (p< 0.001) 
and common in endoscposists not doing regular exercise (p< 0.030). But 
ergonomic injuries were not associated with mini-rests between proce-
dures (p< 0.133), glove size of the enodoscopists (p< 0.102) and hand domi-
nancy (right handed & left handed) (p< 0.182).
conclusion: Among endoscopists there is a increased prevalence of inju-
ries definitely or potentially related to endoscopy. Higher procedure vol-
ume, cumulative years performing endoscopy, BMI and lack of regular 
exercise are associated with more work-related injuries.
disclosure: Nothing to disclose 
P0932 PancreaTIc ParenchyMa aTrOPhy and dILaTed MaIn 
PancreaTIc ducT can Be negaTIve PredIcTOrs Of PancreaTITIs 
reLaTed TO BILIary seMs InserTIOn
Yamada T., Umemura M., Asai Y.
Iwata City Hospital, Gastroenterology, Iwata, Japan
contact e-Mail address: masahiro58398@docomo.ne.jp
Introduction: Obstructive jaundice is crucial for the patients with pancrea-
tobiliary malignancy. Insertion of self-expansive metallic stent (SEMS) into 
biliary duct is known useful to improve obstructive jaundice and quality 
of life (QOL) of these patients. However, post ERCP pancreatitis (PEP) after 
SEMS insertion across the papilla of Vater is one of the most important 
adverse events affect patients’ QOL.
aims & Methods: Ninety patients received biliary SEMS insertion for biliary 
obstruction due to malignancy in Iwata City Hospital form 2010 to 2018 
were reviewed. We evaluated the relationship between incidence of PEP 
after biliary SEMS insertion and clinical factors, including age, sex, se-
rum amylase level, tumor location, cause of obstruction, with/without EST, 
with/without pancreatography, diameter of main pancreatic duct (MPD), 
and thickness of pancreatic parenchyma.
results: Mild and severe PEP were diagnosed in 11 (12.2%) and 1 (1.1%) pa-
tients, respectively. Only the thickness of pancreatic parenchyma (p< 0.001) 
and diameter of MPD (p< 0.001) showed significant difference between 
PEP and non-PEP groups. However, other factors did not show significant 
difference in the incidence of PEP. The incidence of PEP among patients 
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whose thickness of pancreatic parenchyma at the left side of corpus verte-
brare were less than 10mm (1.7%) in computed tomography was quite low-
er than patients whose thickness were 10mm or more (32.2%) (p< 0.001). 
Similarly, the wider (5mm or more) diameter of MPD (1.6%) reduced the 
incidence of PEP compared to narrower ones (30.0%) (p< 0.001).
conclusion: These results imply that pancreatic parenchyma atrophy and 
dilated MPD are negative predictive factor of pancreatitis related to biliary 
SEMS insertion.
disclosure: Nothing to disclose 
P0933 ParTIaLLy cOvered seLf-exPandaBLe MeTaL sTenTs 
rePLace PLasTIc sTenTs fOr MaLIgnanT exTrahePaTIc BILIary 
OBsTrucTIOn: resuLTs Of a MedIcaL cenTer
Huang W.-H., Yu C.-J., Ting C.-F., Yang C.-Y., Chuang S.-C., Peng C.-Y.
China Medical University Hospital, Internal Medicine, Taichung, Taiwan
contact e-Mail address: u97766.huang@msa.hinet.net
Introduction: Endoscopic biliary stenting has been well established as 
standard treatment of malignant biliary obstruction. Comparing with plas-
tic stent, self-expandable metal stent (SEMS) has longer stent patency. 
However, few reports are published to compare primary SEMS placement 
and reintervention of SEMS to replace plastic stent.
aims & Methods: The aim of this study was to assess the differences in 
stent patency and complications between patients with primary metal 
stent placement and reintervention to replace previous plastic stent. 
From Jan., 2010 to Dec., 2016, patients with malignant obstruction below 
the common hepatic duct (CHD) confluence undergoing biliary stenting 
with partially covered self-expandable metal stents (PCSEMS) were retro-
spectively analyzed. Malignancy was diagnosed based on clinical, labora-
tory, imaging , and pathologic studies.
results: A total of 81 patients (43 female and 38 male; mean age 72.5±13.1 
years) with PCSEMS for malignant obstruction below the CHD confluence 
were included. Malignancy included pancreatic cancer (n=58, 71.6%), 
cholangiocarcinoma (n=12, 14.8%), ampullary cancer (n=8, 9.9%), meta-
static cancer (n=2, 2.5%), and gallbladder cancer (n=1, 1.2%). Strictures 
were located at upper (n=3, 3.7%), middle (n=12, 14.8%), and distal extra-
hepatic duct (n=66, 81.5%), respectively. Average length of stricture was 
21.2±9.0 mm. All patients underwent endoscopic sphincterotomy before 
metal stent placement. The length of PCSEMS was 40 mm (n=11, 13.6%), 
60 mm (n=58, 71.6%), and 80 mm (n=12, 14.8%). The lumen diameter of 
PCSMS was all the same (10 mm). Twenty of 81 (24.7%) patients received 
chemotherapy and/or radiotherapy. PCSEMS was placed as a primary in-
tervention in 21 (26 %) patients, and PCSEMS replacing plastic stent was 
performed in 60 (74%) patients. Overall stent patency was 210±112 days. 
During the period of follow-up (190.2±190.5 days), stent complications oc-
curred in 25 of 81 (31%) patients and included cholangitis (n=10), stent mi-
gration (n=6), cholecystitis (n=2), pancreatitis (n=2), stent occlusion (n=2), 
perforation (n=1), liver abscess (n=1), and hemorrhage (n=1), Although 
stent patency, and stent complications were lesser in reintevention (26.7%) 
than in primary intervention (42.9%), the differences were not statistically 
significant (P > 0.05).
conclusion: For patients with malignant obstruction below the CHD con-
fluence, primary metal stent placement and reintervention with PCSEMS 
showed comparable stent patency and complications.
disclosure: Nothing to disclose 
P0934 dIcLOfenac dOes nOT reduce The rIsk Of acuTe POsT 
endOscOPIc reTrOgrade chOLangIOgraPhy PancreaTITIs In 
PaTIenTs WITh PrIMary scLerOsIng chOLangITIs
Koskensalo V.1,2, Jokelainen K.2,3, Udd M.1,2, Lindström O.1,2, Rainio M.1,2, 
Tenca A.2,3, Kylänpää L.1,2, Färkkilä M.2,3
1Helsinki University Central Hospital, Abdominal Center, Helsinki, Finland, 
2University of Helsinki, Helsinki, Finland, 3Helsinki University Central 
Hospital, Department of Gastroenterology, Helsinki, Finland
contact e-Mail address: vilja.koskensalo@helsinki.fi
Introduction: European society of gastrointestinal endoscopy (ESGE) rec-
ommends (1) rectal indomethacin or diclofenac prior to endoscopic ret-
rograde cholangiopancreatography (ERCP) as a prophylaxis for post-ERCP 
pancreatitis (PEP). Primary sclerosing cholangitis (PSC) is a chronic chole-
static liver disease characterized by intrahepatic or extrahepatic stricturing 
and markedly increased risk for biliary neoplasia (2). ESGE/EASL suggest 
(3) that ERCP can be done in PSC if MRC plus liver biopsy is equivocal or 
contraindicated in patients with persisting clinical suspicion of PSC and in 
addition ERCP is done for ductal sampling (brush cytology) and dilatation 
of significant strictures. The risk for PEP is approximately 7 % in PSC (4).
aims & Methods: Our aim was to evaluate the role of rectal diclofenac as 
a prevention of PEP or other ERCP-related complications in PSC patients. 
Since November 2013 all ERCP patients without contraindications in Hel-
sinki University Hospital (HUH) Endoscopy unit in Meilahti have received 
rectal diclofenac before ERCP procedure. This survey was a retrospective 
patient-control study, where we collected the clinical data from patient re-
cords from 1000 consecutive ERCP procedures made for patients with PSC 
or suspected PSC at HUH Endoscopy unit and with administration of rectal 
diclofenac (procedures after November 2013). Control procedures (n=1000) 
were with the same indication but without administration of rectal diclof-
enac (ERCP procedures before November 2013). Totally 2000 ERCPs were 
made for 925 patients between January 2009 and January 2018. Acute PEP 
and other ERCP-related complications were evaluated.
results: PEP developed in 49 patients (4.9%) in diclofenac group and 62 
patients (6.2%) in control group (p=0.241). There was no statistically sig-
nificant difference between the groups in severity of PEP or in other acute 
complications. Risk of PEP was slightly more elevated in patients with na-
tive papilla: 11.4% in diclofenac group and 8.7% in control group, p=0.294. 
  diclofenac group (n=1000)
control group 
(n=1000) p-value
Age* at ERCP 40 (16-73) 39 (16-79) 0.568
Female 370 (48.0) 401 (52.0) 0.168
BMI* (kg/m²) 25.0 (13.7-45.0) 24.5 (12.1-48.0) 0.222
Native papilla 193 (19.3) 358 (35.8) 0.000
Diverticulum 24 (2.4) 34 (3.4) 0.230
Duration of ERCP* (minutes) 26 (5-94) 26 (5-123) 0.953
Biliary papillotomy 214 (21.4) 409 (40.9) 0.000
Pancreatic papillotomy 41 (4.1) 80 (8.0) 0.000
Inflammatory bowel disease 743/975 (76.2) 478/944 (50.6) 0.000
Post-ERCP pancreatitis (PEP) 49 (4.9) 62 (6.2) 0.241
Severity of PEP     0.130
mild 34/49 (69.4) 36/62 (58.1)  
moderate 10/49 (20.4) 22/62 (35.5)  
severe 5/49 (10.2) 4/62 (6.5)  
Cholangitis 15/1000 (1.5) 28/1000 (2.8) 0.063
Bleeding 7/1000 (0.7) 2/1000 (0.2) 0.179
Perforation 6/1000 (0.6) 5/1000 (0.5) 1.000
Other 0/1000 (0.0) 1/1000 (0.1) 1.000
PEP in native papilla patients 22/193 (11.4) 31/358 (8.7) 0.294
[Table 1. Patient characteristics and ERCP complications. Numerical data are 
presented as median (range)* or number of patients (%).**Cotton et al. (6)]
conclusion: In low-risk unit, diclofenac does not reduce the risk of PEP or 
other ERCP-related complications in patients with PSC. In addition, there 
is no significant difference in PEP rate in patients with native papilla com-
pared to those with biliary papillotomy. The results of the present study are 
in line with our previous report in non-PSC-patients (5).
references: 1. Dumonceau JM et al. Prophylaxis of post-ERCP pancreatitis: 
European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endos-
copy 2014;46:799-815. 2. Dyson JK et al. Primary sclerosing cholangitis. 
Lancet 2018;391:2547-2559. 3. Aabakken L et al. Role of endoscopy in pri-
mary sclerosing cholangitis: European Society of Gastrointestinal Endos-
copy (ESGE) and European Association for the Study of the Liver (EASL) 
Clinical Guideline. Endoscopy 2017;49:588-608. 4. Ismail S et al. Risk fac-
tors for complications of ERCP in primary sclerosing cholangitis. Endos-
copy 2012;44:1133-8. 5. Rainio M, et al. Diclofenac does not reduce the 
risk of post-endoscopic retrograde cholangiopancreatography pancreatitis 
in low-risk units. J Gastrointest Surg. 2017;21:1270-1277. 6. Cotton PB et al. 
Risk factors for complications after ERCP: a multivariate analysis of 11,497 
procedures over 12 years. Gastrointest Endosc 2009;70:80-88.
disclosure: Nothing to disclose 
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P0935 TransPancreaTIc sPhIncTerOTOMy: a vaLuaBLe 
TechnIque TO gaIn BILIary access
Gódi S.1, Pécsi D.2, Czakó L.3, Altorjay I.F.4, Gyökeres T.5, Hegyi P.6, Patai Á.7, 
Szepes Z.3, Vincze A.1, Hungarian Endoscopy Study Group
1University of Pécs, First Department of Medicine, Pécs, Hungary, 2University 
of Pécs, Institute for Translational Medicine, Pécs, Hungary, 3University 
of Szeged, First Department of Medicine, Szeged, Hungary, 4University of 
Debrecen, II. Intern. MED, Debrecen, Hungary, 5Medical Centre Hungarian 
Defence Forces, Gastroenterology, Budapest, Hungary, 6University of Pecs, 
Centre for Translational Medicine, Pecs, Hungary, 7Markusovszky University 
Teaching Hospital, Gastroenterology, Szombathely, Hungary
contact e-Mail address: godi.szilard@gmail.com
Introduction: In cases of inadvertent pancreatic guidewire cannulation, 
transpancreatic sphincterotomy (TPS) is a feasible alternative to achieve 
biliary access. We intended to compare several aspects of TPS with the 
standard needle-knife precut papillotomy (NKPP) using data from the 
Hungarian ERCP Registry
aims & Methods: 76 TPS and 240 NKPP cases could be analyzed from the 
database. Biliary cannulation success rate, postERCP pancreatitis (PEP) 
rate, use of prophylactic measures, cannulation time and subjective dif-
ficulty were compared.
results: Biliary cannulation achieved more frequently after TPS (70/76, 
92.1%) compared to NKPP (200/240, 83.3%, p=0.058). PEP developed at 
a similar rate after TPS (3/76, 3.9%) and NKPP (8/240, 3.3%). Prophylactic 
pancreatic stent (PPS) was inserted in 44 of 76 (57.9%) cases in the TPS 
group, while only in 15 of 240 (6.3%) cases in the NKPP group. Multiple 
pancreatic guidewire passages occurred in 26 patients in the NKPP group, 
but PPS was placed only in 6 (23.1%) of them. Indomethacin suppository 
was used in 52.6% of TPS and 49.2% of NKPP cases. Additional needle-
knife precut was needed after TPS in 7 cases, 1 PEP developed in these 
cases. We found no statistically significant difference in the subjective dif-
ficulty on a 10- point scale between the two techniques (TPS: 5.8 vs. NKPP: 
6.7) and there was also no difference in the mean cannulation time (TPS: 
9.0 min vs. NKPP: 7.4 min).
conclusion: TPS is an effective and safe technique in cases of difficult bili-
ary access and also allows the use of preventive methods (e.g. PPS) easily. 
However, the Hungarian practice shows a serious deviation from interna-
tional recommendations in this regard. One of the long-term goals of the 
registry is to improve the use of PEP prevention techniques in Hungary.
disclosure: Nothing to disclose 
P0936 anaLysIs Of BILIary cannuLaTIOn aLgOrIThM 
In hIgh-vOLuMe hungarIan ercP cenTers Based On 
PrOsPecTIveLy cOLLecTed regIsTry daTa
Pécsi D.1, Gódi S.2, Hegyi P.3, Altorjay I.F.4, Czakó L.5, Kovács G.4, 
Orbán-Szilágyi Á.6, Pakodi F.2, Szepes Z.5, Gyökeres T.6, Bakucz T.6, 
Vincze A.2, Hungarian Endoscopy Study Group
1University of Pécs, Institute for Translational Medicine, Pécs, Hungary, 
2University of Pécs, First Department of Medicine, Pécs, Hungary, 3University 
of Pécs, Centre for Translational Medicine, Pecs, Hungary, 4University of 
Debrecen, II. Intern. MED, Debrecen, Hungary, 5University of Szeged, First 
Department of Medicine, Szeged, Hungary, 6Medical Centre Hungarian 
Defence Forces, Gastroenterology, Budapest, Hungary
contact e-Mail address: vincze.aron@pte.hu
Introduction: Selective biliary duct cannulation (BDC) was analysed in our 
current practice based on the data from five tertiary centers according to 
the recent evidence-based ESGE algorithm of biliary access.
aims & Methods: The prospectively collected ERCP Registry contained 1011 
cases of intact papilla with biliary indications. The rate of difficult bili-
ary access and the usage of advanced biliary cannulation methods were 
analysed.
results: Simple cannulation (659 cases, 65.2%): Deep BDC was achieved 
with guidewire in 305 cases (30.2%), with papillotome in 312 cases 
(30.9%), but failed in 39 cases (3.9%) due to anatomical obstacles. In 3 
(0.3%) cases the BDC was not successful. The average cannulation time 
was 125 s, only 6.1% of the patient had longer than 300 s cannulation time. 
Twelve (1.9%) post-ERCP pancreatitis (PEP) occurred. Pancreatic guidewire 
(PGW) assisted cannulation (134 cases, 13.3%): BDC was achieved with 
double guidewire in 27, with papillotome in 3, while after prophylactic 
pancreas stent (PPS) insertion in 12 cases. Pre-cutting was used after PGW 
or PPS insertion in 12 and 33 cases, TPS was performed in 47 cases. The 
average cannulation time was 481 s. Biliary access failed in 18 patients 
(13.4%), while PEP rate was 2.2%. Needle-knife precut (NKP) (160 pa-
tients, 15.8%): BDC failed in 28 (17.5%), while PEP developed in 7 cases 
(4.4%). The average cannulation time was 514 s. Needle-knife fistulotomy 
(NKF) (58 patients, 5.7%): BDC failed in 4 (6.9%), PEP developed in 2 cases 
(3.4%). The average cannulation time was 466 s. The overall failure rate 
of BDC in our cohort was 5.2% (53/1011) excluding anatomical reasons. 42 
out of 44 initially failed procedures were successfully completed later on.
conclusion: Advanced biliary cannulation methods were used in our ter-
tiary centers in more than one third of the cases. NKF had the highest 
BDC rate and required the shortest cannulation time. The PEP rates were 
similar in the different groups.
disclosure: Nothing to disclose 
P0937 recTaL versus InTraMuscuLar dIcLOfenac In The 
PrevenTIOn Of POsT ercP PancreaTITIs. The exPerIence Of 
a greek TerTIary referraL cenTer
Kalantzis I.1, Poulou A.1, Papatheodorou A.2, Gkoumas K.1
1Hellenic Red Cross Hospital, Gastroenterology, Athens, Greece, 2Hellenic Red 
Cross Hospital, Radiology, Athens, Greece
contact e-Mail address: johnkalantzis@hotmail.com
Introduction: Acute pancreatitis is a potentially serious complication of 
Endoscopic Retrograde Cholangiopancreatography (ERCP). Independent 
patient-related and procedure-related factors increase the risk of post-
ERCP pancreatitis (PEP). Non-steroidal anti-inflammatory drugs (NSAIDs) 
administered mainly rectally before or immediately after endoscopy, have 
demonstrated an efficacy in reducing the incidence of PEP.
aims & Methods: Investigating the difference in the incidence of PEP 
among intramuscular (IM) or rectal (PR) administration of diclofenac 
before ERCP, taking into account patient-related and procedure-related 
factors associated with PEP, as well as the intraprocedural hemorrhage 
during the endoscopy. The retrospective study of our department’s records 
revealed rectal administration of diclofenac for two years 2014-15 (N = 233) 
and intramuscular for the consecutive two years 2016-17 (N = 283). Data 
analysis was performed with the SPSS statistical package.
results: 516 patients (294 men, 222 women) were included in the study 
(mean age: 72 years). The indication was either choledocholithiasis (N=351, 
68%) or benign/malignant biliary/pancreatic stenosis (N=165, 32%). The 
diagnosis of PEP was defined by the criteria of the Atlanta Classification. 
The total incidence of PEP was 4.5% (N=23), with no significant differences 
between rectal (N = 12, 5.2%) and intramuscular (N=11, 3.9%) route of ad-
ministration (p=0.633). The factor that appeared to be of significance was 
pre-cut sphincterotomy, since patients who had pre-cut sphincterotomy 
had a 2.67 fold higher probability of PEP (p=0.050). Marginal significance 
was also revealed for the passage of the guidewire in the pancreatic duct 
more than once (10.8% vs 4%) (p=0.074), as well as with the duration of 
cannulation attempts over 10 minutes (7.4% vs 3.3%) (p=0.069). Younger 
age, female gender, history of pancreatitis or PEP, non-dilated extrahepat-
ic bile ducts, normal serum bilirubin, pancreatic injection, biliary balloon 
sphincter dilation and failure to clear bile duct stones did not show sta-
tistically significant results. Intraprocedural bleeding during ERCP (N=11, 
2.1%) was almost twice higher in the rectal (N=7, 3%) compared to in-
tramuscular group (N=4, 1.4%) (p=0.236). Although pancreatic stent was 
not placed in 21 of the 23 patients who developed PEP, it did not appear 
statistically significant in the prevention of PEP either alone (p=0.703) or in 
combination with diclofenac administration (p=0.517). The mean amylase 
value in PEP incidents did not show significant difference between the two 
NSAIDs subgroups (p=0.639), as it did not in the mean amylase value in 
patients who had hyperamylasemia after ERCP (p=0.172). In the multivari-
ate analysis the only significant and independent factor for PEP was precut 
sphincterotomy (p=0.029), with these patients displaying 2.7 times greater 
probability of PEP manifestation.
conclusion: The results of our study did not reveal any statistically signifi-
cant difference between rectal or intramuscular administration of diclof-
enac in the prevention of PEP, despite the opposite results of the majority 
of the so far published studies and meta-analysis. Some of the risk factors 
associated with increased risk of PEP were also confirmed
references: 1. Cotton P, Garrow DA, Gallagher J, Romaqnuolo J. Risk factors 
for complications after ERCP: a multivariate analysis of 11497 procedures 
over 12 years. Gastrointest Endosc. 2009;70:80-88 2. Jean-Marc Dumon-
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ceau, Angelo Andriulli, B. Joseph Elmunzer, Alberto Mariani, Tobias Meis-
ter, Jacques Deviere, Tomasz Marek, Todd H. Baron, Cesare Hassan, Pier A. 
Testoni, Christine Kapral. Prophylaxis of post-ERCP pancreatitis: European 
Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2014; 
46: 799-815
disclosure: Nothing to disclose 
P0938 The cLassIfIcaTIOn Of BILIary sTrIcTures In 
PaTIenTs WITh rIghT LOBe LIver TransPLanT recIPIenTs 
and ITs reLaTIOn WITh endOscOPIc TreaTMenT success
Parlak E.1, Simsek C.1, Koksal A.S.2, Eminler A.T.2, Unal E.3, Ciftci T.T.3, 
Akinci D.3, Yilmaz S.4
1Hacettepe University Faculty of Medicine, Gastroenterology and Hepatology, 
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Introduction: Traversing the stricture with a guidewire is a prerequisite 
for endoscopic treatment of biliary strictures developed after living donor 
liver transplantation (LDLT). Percutaneous, combined (magnetic compres-
sion anastomosis) or surgical methods can be used in cases of failure. As 
the biliary anastomosis is performed in patients with anatomic variations, 
there is great diversity in the biliary strictures. In this study, we aimed to 
evaluate the effect of biliary anastomosis and biliary strictures on the suc-
cess of endoscopic treatment and suggest a radiologic classification.
aims & Methods: The cholangiographic findings of 125 biliary strictures 
developed among 104 patients (77 male, mean age:51 years) with right 
lobe LDLT and choledocho-choledochostomy, who underwent ERCP at two 
reference centers of Turkey between 2013 and 2019, were retrospectively 
reviewed. Patients with biliary leak (n=14), referred for stent exchange 
(n=76), with no biliary strictures (n=7), left lobe (n=13) or cadaveric trans-
plantation (n=54), strictures traversed by percutaneous route previously 
(n=12) and those with missing data (n=9) were excluded. The effect of nine 
different types of anastomosis classified according to the number (1,2 or 
>2) and location (common bile duct, hepatic bile ducts or cystic duct) of 
anastomosis and crossing of anterior and posterior ducts, the angle be-
tween the proximal and distal sites of the anastomosis (0-30°, 30-60°, 
60-90°, >90°), the contrast enhancement pattern of the stricture (passage 
of contrast and visualization of the anastomosis), and the anatomy of the 
proximal site of the choledochus (round, triangular, intermediate form, 
end to site anastomosis) on the success of traversing the anastomosis with 
a guidewire were evaluated.
results: Out of 125 biliary strictures, 86 (68,8%) could be passed via en-
doscopic route. After excluding 6 patients in whom the strictures were tra-
versed via percutaneous route at outside centers, the remaining 33 stric-
tures were managed by either percutaneously (n=13; 39,4%) or magnetic 
compression anastomosis (n=20; 60,6%). Compared to round appearance, 
triangular (OR:6,5) or intermediate form (OR:17,7) of the proximal site of 
the choledochus and end to side anastomosis (OR:5,1) were associated 
with an increased chance of traversing the stricture (p< 0,001). The success 
of endoscopic treatment was higher in patients with passage of contrast 
through the stricture associated with (92%) or without (81%) visualization 
of the anastomosis, compared to those with no passage of contrast (20%) 
(p< 0,001). The success was increased as the angle between the proximal 
and distal sites of the anastomosis approximated to zero (0-30°:74%, 30-
60°=69%, 60-90°=63%, >90°=41%). The types of anastomosis and stric-
ture (anastomotic or non-anastomotic) and the duration passed between 
the transplantation and ERCP had no effect on the success of treatment.
conclusion: The types of biliary anastomosis and stricture affect the suc-
cess of endoscopic treatment in patients with biliary strictures after right 
lobe LDLT. These data may play role in making decision about the type of 
anastomosis during the surgery in suitable patients.
disclosure: Nothing to disclose 
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Introduction: Pseudoaneurysms usually occur after vascular injuries or 
erosions such as in trauma or inflammation like pancreatitis, and are as-
sociated with high morbidity and mortality. Digital subtraction angiog-
raphy with coil embolization is the established treatment for aneurysm. 
There are limited data in literature on endoscopic ultrasound (EUS) guided 
thrombin injection for pseudoaneurysm.
aims & Methods: Aim of the study is to assess the efficacy and safety of 
EUS guided thrombin injection in pseudoaneurysm. Prospective study was 
done at SMS Hospital, Jaipur from January 2018 to December 2018. All 
patients with symptomatic visceral artery pseudoaneurysm were enrolled 
consecutively. Data related to demography, laboratory parameters, radio-
logical imaging, pseudoaneurysm and endotherapy were analyzed.
results: Eight patients with median age 34(27-58) years, all males were 
studied. Etiology of pseudoaneurysm was chronic pancreatitis in 6(75%) 
and idiopathic in 2(25%) patients. Vessel was splenic artery in 5(62.5%), 
left hepatic artery 2(25%) and gastroduodenal artery in 1(12.5%) patients. 
Size of pseudoaneurysm was 2.9 cm x 2.6 cm (1.8x1.9- 4x5 cm). All patients 
were presented with history of gastrointestinal bleeding and two patients 
had hemobilia. Hemoglobin was 5.2 gm/dl (4.1-12.2 gm/dl) and require-
ment of packed red cell transfusion was 3(0-5) units. Thrombin require-
ment was 400 IU (200-500IU) for loss of doppler flow signals. Computed 
tomography and EUS after 3 months showed obliterated pseudoaneu-
rysms in 7(87.5%) patients, while recurrence was seen in 1(12.5%) patient 
after 6 weeks of thrombin injection.
conclusion: EUS-guided thrombin injection is a new option for manage-
ment of pseudoaneurysm.
disclosure: Nothing to disclose 
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1Centro Hospitalar Lisboa Ocidental, Gastrenterology, Lisbon, Portugal, 
2Fundaçao Champalimaud, Gastrenterology, Lisbon, Portugal, 3Centro 
Hospitalar Lisboa Ocidental, Pathology, Lisbon, Portugal
contact e-Mail address: sfelixcatarina@gmail.com
Introduction: Endoscopic ultrasonography (EUS) is the most widely used 
method for characterization of subepithelial lesions (SELs) arising from the 
gastrointestinal (GI) tract. 
However, the diagnostic accuracy of fine needle aspiration (EUS-FNA) 
ranges widely from 46% to 93% in the evaluation of GI stromal tumors1. 
Recent studies have showed superior diagnostic accuracy of fine needle 
biopsy needles (EUS-FNB), comparing to the standard EUS-FNA needles. 
Nevertheless there have been little head-to-head comparative data be-
tween FNB needles.
aims & Methods: The aim of this study was to compare the diagnostic yield 
of the side-type needles with the end-type needles in the diagnosis of SELs 
of the GI tract. 
A retrospective cohort study was conducted, including consecutive patients 
with SELs of the GI tract undergoing EUS-FNB between January 2016 and 
November 2018. Macroscopic on-site evaluation was used to evaluate 
core quality and set the number of needle passages necessary to obtain 
a macroscopic visible core. All samples were reviewed by one experient 
pathologist, who was blinded to the type of needle used, and classified 
as diagnostic (if biopsy specimens were adequate for making a diagnosis, 
including immunohistochemical staining whenever necessary), suggestive 
(if a suggestive primary diagnosis was assigned, but a definitive final di-
agnosis was not achieved) and non diagnostic (if samples were primarily 
insufficient for diagnosis)2. Primary outcome was defined as the ability to 
provide a suitable sample allowing histological interpretation (diagnostic 
yield). Secondary outcome was defined as the number of needle passages 
required to obtain a proper macroscopic sample.
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results: A total of 21 lesions were included (stomach n=16, duodenum n=2, 
rectum n=2, oesophagus n=1; median of lesion size on EUS 24 mm (10-
134)) from 21 patients (9 females/12 males; median age 67 years (50-79)). 
The procedure was technically feasible in all patients. Side-type needles 
were used in 10 lesions and end-type needles in 11 lesions (fork-tip needle 
n=3, Freensen needle n=8). Diagnostic yield was 80% (8/10) in side-type 
needle group and 81.8% (9/11) in the end-type needle group (pvalue 1). 
Median needle passages to obtain a macroscopic visible sample was 3 
(IQR 1) in the side-type needle group and 3 (IQR 2) in the end-type needle 
group (p value 0.821). There were no intra-procedure EUS-FNB related 
adverse events.
conclusion: In our study there were no significant difference in diagnostic 
yield between side-type and end-type needles. Number of passages to ob-
tain a macroscopic visible sample were similar between EUS-FNB needles. 
The procedure was feasible and safe in all lesions.
references: 1- Faulx A, Kothari S, Acosta R et al. The role of endoscopy 
in subepithelial lesions of the GI tract. Gastrointestinal Endoscopy 2017. 
85:1117-1132 2- Lee M, Min BH, Lee H, et al. Feasibility and Diagnostic Yield 
of Endoscopic Ultrasonography-Guided Fine Needle Biopsy With a New 
Core Biopsy Needle Device in Patients With Gastric Subepithelial Tumors. 
Medicine 2015. 94
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Introduction: Endoscopic ultrasonography-guided fine-needle aspiration 
(EUS-FNA) has become a indispensable examination in the clinical fields. 
Furthermore, therapeutic EUS such as pseudocyst drainage, EUS-biliary 
drainage, and EUS-pancreatic duct drainage, etc. have become popular 
year by year. Generally, it has been believed that the learning of EUS-FNA 
takes long time and certain number of case experiences are essential, in 
order to become a good endosonographer. And it is difficult to learn EUS/
EUS-FNA without instructors. 
Futhermore, clinical cases are not enough for training young endosonog-
rapher and hands-on training with models are able to reduce the number 
of performing clinical EUS-FNA on training program. Therefore, we have 
developed newly designed model for training therapeutic EUS-FNA proce-
dure such as EUS-HGS and PFC drainage, and investigated its usefulness 
and limitations.
aims & Methods: We have collaborated with Olympus Co. and made model 
for EUS-HGS by special plastic material (Century medical Co., Tokyo) and 
pseudocyst model by non-rupture-balloon (Sumitomo Bakelight Co., To-
kyo) which is 8cm in diameter. This balloon is filled by lubricant, and these 
models are put into water tank. We have tried this model at Kitasato Inter-
ventional hands-on training workshop with 40 attendees. We have inves-
tigated whether all attendees can complete EUS-FNA of the pancreas and 
pseudocyst drainage or not? And how long does it take to complete the 
procedure? Furthermore, we have checked their impression of this model. 
We have employed UCT-260 (Olympus Co., Tokyo) ,19G EUS-FNA needles 
and 7Fr plastic stent as a drainage tube.
results: Concerning about EUS-HGS, all attendee have to identify B2 
and B3 branch, secondly puncture B3 with 19G needle, thirdly put in a 
0.035inch guidewire, and finally deploy 7Fr stent. 96% (43/45) of attend-
ees have completed EUS-HGS model with 7 minutes in average. Concern-
ing about pseudocyst model, attendees have to firstly look for the good 
position for pseudocyst drainage, secondly attendee puncture the balloon 
with 19G needle, thirdly put in a 0.035 inch guidewire, push a dilator into 
the model, and finally put a 7 Fr drainage tube in the pseudocyst model. 
89% (40/45) of attendees have completed pseudocyst drainage with 8.5 
minutes in average. All balloons have not ruptured during these proce-
dures and kept the balloon size, in spite of some leakage. According to 
their impression, resistance of puncture and putting in a stent is less, com-
pared with clinical cases, however it is very useful to understand EUS-HGS 
and EUS-guided pseudocyst drainage.
conclusion: We concluded that newly designed EUS-HGS and pseudocyst 
model is useful to train the beginner, in order to understand the proce-
dure. Furthermore, using these models, we can do hands-on training ev-
erywhere and there is no necessity of animal laboratory because of dry 
model.
disclosure: Nothing to disclose 
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Introduction: Abdominal pain is a common problem in patients with pan-
creatic cancer, present in as many as 70% to 80% of patients at the time 
of diagnosis. It can be difficult to treat and patients may suffer from drug-
related side effects. In these patients, celiac plexus neurolysis (CPN) may 
be indicated.
aims & Methods: To assess efficacy and safety of endoscopic ultrasound 
guided celiac ganglia versus bilateral plexus neurolysis using absolute 
alcohol for managing abdominal pain associated with pancreatic cancer. 
A prospective randomized study were conducted on 35 patients with ab-
dominal pain due to inoperable cancer pancreas. They were randomly as-
signed into two groups of EUS-CPN (celiac ganglia or Bilateral technique). 
Then patients were followed up at 2 weeks, 6 weeks and 6 months after 
procedure.
results: In Group A (23 patients; 65.7%) celiac ganglia neurolysis was done 
and group B (12 patients; 34.3%) bilateral technique was done. Group A & B 
were matched regarding age, gender, site, type of pancreatic pathology and 
type of analgesics used before the procedure. Both techniques achieved 
similar rates of successful pain relief (83.3% of patients in Group A and 
82.6% in Group B) without significant difference in Visual Analogue Scale 
of pain at 2 weeks and 2 months post-procedure. They were also similar 
regarding onset on pain relief and time of pain recurrence. There were no 
major complications or moralities related to the procedure, however minor 
complications occurred in 10 patients (28.6%) as transient hypotension and 
self-limiting diarrhea. The rate of complication was similar in both groups.
conclusion: EUS-guided celiac ganglia neurolysis is an easy technique 
more feasible and comparable with bilateral plexus neurolysis in terms 
of overall pain relief and reduction in dose and/or frequency of analgesics 
needed without increase in rate of procedure-related complications.
disclosure: Nothing to disclose 
P0944 reLaTIOnshIP BeTWeen fIrsT-vIsIT PaTIenTs WITh 
dIaBeTes MeLLITus and endOscOPIc uLTrasOund IMages Of 
earLy chrOnIc PancreaTITIs
Kubo H., Tashiro N., Ogami Y., Yasuda M., Okajima T.
Nakabaru Hospital, Internal Medicine, Fukuoka, Japan
contact e-Mail address: canoa@dune.ocn.ne.jp
Introduction: Early chronic pancreatic is a new clinical entity. Endoscopic 
ultrasound (EUS) is an essential modality to diagnose patients with early 
chronic pancreatitis. 
However, diabetes mellitus (DM) derives from a disorder of the pancreatic 
function, and the relationship between early chronic pancreatitis and DM 
is still not clear.
aims & Methods: This prospective study was conducted for 21 patients with 
DM. EUS was performed before medical treatment. Diabetologist were 
in charge of treatment and were blind to the EUS findings. We analyzed 
gender, age, BMI, smoking, alcohol, family history, past history, hyperten-
sion, hyperlipidemia, HbA1c, anti-GAD antibodies, insulin secretion func-
tion, complications and therapeutic discipline. In addition, we evaluated 
whether the EUS findings contributed to the decision on which therapeutic 
method to use.
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results: 12 out of 21 cases meet the criteria for EUS findings for early chron-
ic pancreatitis, while the others did not. Initial treatment went well for all 
the patients with DM. 
In the univariate analysis, age, HbA1c, and therapeutic method were sig-
nificant variables to differentiate between the presence or absence of EUS 
findings for early chronic pancreatitis. Patients without EUS findings for 
early chronic pancreatitis tended to be younger (p = 0.030), with a higher 
HbA1c (p = 0.032) and higher insulin usage (p = 0.021) than patients with 
early chronic pancreatitis. In the multivariate analysis, absence of EUS 
findings for early chronic pancreatitis was an important factor in the use of 
insulin for treatment (p = 0.016).
conclusion: EUS is a valuable modality to differentiate between the pres-
ence or absence of early chronic pancreatitis in patients with DM. It seems 
likely that an EUS can contribute to the decision on which treatment meth-
od to use for patients with DM.
disclosure: Nothing to disclose 
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Introduction: EUS-guided biliary drainage procedures (EUS-BD) have been 
demonstrated to be effective but technically challenging and require a 
substantial learning curve. Both phantoms and “ex vivo” biliary dilatation 
models, have been described to enhance learning in this field, but they 
provide a limited level of realism [1,2].
Swine model is the most realistic tool for training in EUS and biliary dilata-
tion swine models have been described. However, they provide an erratic 
biliary dilatation, and can also be technically cumbersome [3-6]
aims & Methods: The aims of our study were to develop a swine bili-
ary dilatation model using temperature-controlled Endobiliary Radiofre-
quency Ablation (EB-RFA) and to investigate feasibility of EUS-BD in this 
kind of model.
Seven fourteen-month-old mini pigs underwent ERCP and a dedicated 
biliary radiofrequency catheter with a distal temperature sensor (ELRA RF 
catheter, STARmend, Goyang, Korea) was used to deliver energy into the 
common bile duct.
With the end-point to obtain a biliary stricture EB-RFA energy was then 
delivered at 7 or 10W with a target temperature of 75 or 80°C for one or 
two rounds (ranging from 60 to 120 seconds each). 
Two weeks after EB-RFA, EUS examination confirmed massive biliary dil-
atation and EUS-guided biliary drainage procedure (EUS-BD) was then 
attempted by performing a hepaticogastrostomy (HGS) or a cholecysto-
gastrostomy (CG).
results: EB-RFA was successfully performed in all 7 pigs into the distal or 
proximal CBD (distal CBD, n = 6; proximal CBD, n =1). There were no im-
mediate post-procedural adverse events.
After two weeks all pigs were jaundiced without clinical evidence of acute 
cholangitis. EUS examination revealed massive intrahepatic and extrahe-
patic biliary dilation in all pigs and EUS-BD was attempted in the same 
session. HGS was performed in 6 pigs. Technical success was achieved in 
five of 6 pigs. Technical failure of HGS occurred during stent deployment. 
CG was successfully performed in one pig with both distended gallbladder 
and intrahepatic and extrahepatic biliary dilatation.
On the macroscopic evaluation, fibrotic tissue has been found around the 
CBD stricture without any sign of damage.
conclusion: Our study demonstrates that EB-RFA is an effective minimally 
invasive method for creating a critical biliary stricture with associated up-
stream biliary dilation.
Furthermore, EUS-BD was technically feasible in this model which pro-
vides excellent level of realism in comparison to procedures undertaken 
in humans.
references: 1) Dhir V, Itoi T, Fockens P et al. Novel ex vivo model for hands-
on teaching of and training in EUS-guided biliary drainage: creation 
of”Mumbai EUS” stereolithography/3D printing bile duct prototype. Gas-
trointest Endosc 2015; 81: 440- 446 2) Dhir V, Itoi T, Pausawasdi N et al. 
Evaluation of a novel, hybrid model (Mumbai EUS II) for stepwise teach-
ing and training in EUS-guided biliary drainage and rendezvous proce-
dures. Endoscopy International Open 2017; 05: E1087-E1095 3)Rumalla A, 
Petersen BT, Baron TH, et al. Development of a swine model for benign 
stenosis of the bile duct by endoscopic application of intraluminal thermal 
injury. Gastrointest Endosc 2003; 57:73-7 4) Alcaide N, Lorenzo-Pelayo N, 
Ruiz-Zorrilla R, et al. Endoscopic Porcine Model of Biliary Obstruction Us-
ing Over-the-Scope Clips: Feasibility and Applicability to Training in EUS-
Guided Drainage Procedures. Gastroint Endosc 2013; 77, (5S) 5) Lee TH, 
Choi JH, Lee SS, et al. A pilot proof-of-concept study of a modified device 
for one-step endoscopic ultrasound-guided biliary drainage in a new ex-
perimental biliary dilatation animal model. World J Gastroenterol 2014; 
20: 5859-5866 6) Park JS, Kwon CI, Jeong S et al. Development of a swine 
bile duct dilation model using endoclips or a detachable snare under cap-
assisted endoscopy.
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Introduction: Endoscopic ultrasound (EUS) is consider as the technique 
of choice for the evaluation of gastrointestinal and extraintestinal lesions, 
mainly for pancreatico-biliary diseases. Standard linear EUS scopes have 
been usually thick and stiff in the tip.
aims & Methods: 
Aim of our study was to compare the maneuverability and image quality 
of a recently develop slim linear echoendoscope to the current standard 
scopes in the evaluation of pancreaticobiliary diseases.
Material and methods: Retrospective analysis of a prospectively collect-
ed endoscopy database from a referral academic center over 4 months. 
Patients undergoing diagnostic EUS with the slim linear echoendoscope 
(with a rounded and shorter distal part, together with a shorter bending 
section), attached to the ultrasound system HITACHI ARIETTA-V70 (Hitachi, 
Tokyo, Japan) were included in the study. All procedures were performed 
under conscious sedation. EUS-guided tissue acquisition was performed 
if indicated. The maneuverability and image quality were evaluated. A de-
scriptive analysis was performed, showing results as mean ± SD or 95% 
confidence interval.
results: Out of 537 EUS procedures performed in the study period, 128 
(23.8%) were done with the new linear slim echoendoscope for examina-
tion of the pancreas and bile ducts, and were included in the study. Mean 
age was 63 years (range 22-91, 72 females). Compared with the examina-
tions performed with the standard EUS scope, the new slim echoendo-
scope performed better in terms of maneuverability during esophageal 
intubation, pylorus traversing and accessing from duodenal bulb to the 
second portion. Image quality at the standard stations (esophagus, stom-
ach, and duodenum) was also considered better with the new scope. A 
complete pancreatico-biliary exploration was achieved in all cases (100%). 
Final diagnosis was stone disease in 40 cases, chronic pancreatitis in 34, 
acute pancreatitis in 5, solid pancreatic tumors in 10, 9 cases with peptic 
ulcer disease, 1 case of retroperitoneal lymph nodes, 1 case of liver me-
tastasis, and 17 cases presented a normal exploration. EUS-guided tissue 
acquisition was performed in 9 cases (7 pancreatic tumors, liver metasta-
sis and lymph nodes), being feasible in all cases. No complications were 
reported.
conclusion: The new slim echoendoscope showed improved maneuver-
ability and image quality. A complete biliopancreatic exploration can be 
performed safely and effectively, including EUS guided tissue acquisition.
disclosure: Nothing to disclose 
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Introduction: EUS guided biliary drainage is indicated in case of impos-
sibility or failure of classic biliary drainage by ERCP. Recently we reported 
a good efficiency of EUS guided choledocoduodenostomy using the HOT-
AXIOS device (Electrocautery enhanced lumen apposing metal stent) in a 
retrospective multicentric study. However in this study, technical success 
was 88.5%. Utilization of the recommended technique (direct punction 
of the common bile duct with the HOT AXIOS + using a 6 mm Stent + 
fistulotomy with a pure section current) was the only predicting factor of 
clinical success.
We decide to reevaluate this procedure one year after in the same centers.
aims & Methods: French retrospective multicentric study of a prospective 
database including all cases of EUS guided CDS with HOT AXIOS device in 
the 7 centers that participate to the first study.
Primary ENDPOINT: technical success rate defined as the ability to correctly 
deploy the Hot Axios stent between the common bile duct and the duode-
nal bulb with visualization of bile flow.
Secondary endpoints: Clinical success rate (decrease in bilirubin of at least 
50% at day 7 or normalization at day 30), per-procedural complication 
rate, short-term complications (all complications occurring between the 
procedure and discharge from the hospital), Recurrence of biliary obstruc-
tion during follow-up.
results: 70 consecutive patients were included in this study between 
01/09/2017 and 22/09/2018 by 11 operators in 9 centers. 
Pancreatic adenocarcinoma was the etiology of biliary obstruction in 77% 
of cases. Failure of primary ERCP was due to duodenal stenosis in 44% 
of cases, tumoral infiltration of the papilla in 22% of cases, and failure of 
deep cannulation in 4% of cases.
95% of patient had 1 or 0 ERCP procedure before EUS-CDS.
The mean duration of the procedure was 5 min (+/- 3). The recommended 
technique (direct fistulotomy with HOT-AXIOS using e pure cut current + 
using a stent of 6 or 8 mm) was used in 98.5% of cases.
Primary Endpoint: Technical success rate was 98.5% with only one failure.
Secondary Endpoints: Clinical success rate: 98.4%.
Per procedural complication: 1.6%: one bleeding during the fistulotomy 
stopped by the expansion of the stent itself.
Short term complications: 0%.
Recurrence of biliary obstruction: 7 cases (11.5%) (median follow up: 151 
days).
conclusion: EUS-CDS with the HOT AXIOS is efficacious and safe in distal 
malignant obstruction of the common bile duct in cases of ERCP failure 
with impressive results once the expertise is acquired and the recom-
mended technic is followed. 
It should be the technique of choice in case of distal tumoral obstruction 
and failure or impossibility of ERCP. Moreover it could chanllenge ERCP 
in the future as a primary option for biliary drainage on case of distal 
malignant obstruction.
disclosure: Jeremie JACQUES, Fabien FUMEX, Jocelyn Privat, Bertrand NA-
POLEON, Romain LEGROS: Consultants for Boston Scientific 
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20g needLe fOr PancreaTIc sOLId TuMOr
Watanabe S., Toki M., Kitada S., Goto T., Yoshida T., Ota H., Ochiai K., 
Koichi G., Hisamatsu T.
Kyorin University School of Medicine, Third Department, Tokyo, Japan
contact e-Mail address: shunshun.www@gmail.com
Introduction: EUS-FNAB is widely used for pathological diagnosis of pan-
creatic solid tumor. EchoTip ProCore 20G needle (PC20) is a puncture nee-
dle useful for histopathology because it has a large diameter and forward 
bevel type of core trap. In this study, we examined the tissue diagnostic 
efficacy of PC20 in pancreatic solid mass.
aims & Methods: We conducted a retrospective study of EUS-FNAB for 
pancreatic solid tumor that was using PC20 from the first pass performed 
between October 2016 and December 2018 at Kyorin University hospital.
The main outcome was to evaluate the accuracy of histological diagno-
sis and the positive effect that added cytology. Secondary outcome was 
to examine the accuracy of histological diagnosis by number of passes. 
In EUS-FNAB, we firstly collected specimens by suction method. In cases 
with bleeding, cases in that specimens were small amount to exam, and 
cases when the needle was broken, we added more passes, or changed to 
slow-pull method, or other needles. Group4,5 in histology and Class IV, V 
in cytology were diagnosed as malignant tumor.
results: A total of 90 patients were enrolled this study. The final diagnosis 
were pancreatic ductal carcinoma in 81, metastasis pancreatic carcinoma 
in 3, neuroendocrine tumor in 3, autoimmune pancreatitis in 1, and the 
others in 2. The cytological accuracy in PC20 was 85.6% (77/90). The his-
tological accuracy in PC20 was 95.6% (86/90), other four patients were 
diagnosed by the changing to other needle, the accuracy by combining 
histological and cytological yield was 98.9% (89/90). By adding cytology 
to histology, the total accuracy was risen 3.3%, but it was no significant 
difference in comparison to only histological yield (p=0.36).
In number of passes using PC20, the histological accuracy was 86.6% 
(78/90) in once, 94.4% (85/90) in twice, and 95.6% (86/90) in 3 or more 
times. There was significant difference between once and twice (p=0.05), 
but no difference between twice and 3 or more times.
conclusion: EUS-FNAB with PC20 for pancreatic masses showed sufficient 
accuracy in histological diagnosis. Additional effect of passes more than 
twice was not proven in accuracy of histological diagnosis.
disclosure: Nothing to disclose 
P0949 sLOW-PuLL cOMPared TO sucTIOn TechnIque 
fOr eus-guIded saMPLIng Of PancreaTIc sOLId LesIOns: 
a MeTa-anaLysIs Of randOMIzed cOnTrOLLed TrIaLs
Capurso G.1, Archibugi L.2, Petrone M.C.3, Arcidiacono P.G.4
1San Raffaele Scientific Institute Irccs, Pancreas Translational & Clinical 
Research Center, Rome, Italy, 2Hospital San Raffaele, Pancreato-biliary 
Endoscopy and Endosonography Division, Milan, Italy, 3Vita-Salute San 
Raffaele University, Pancreato-Biliary Endoscopy and Endosonography 
Division, Milano, Italy, 4Ospedale San Raffaele, PancreatoBiliary Endoscopy 
and Endosonography Division, Pancreas Translational and Clinical Research 
Center, Milan, Italy
contact e-Mail address: livia.archibugi@hotmail.it
Introduction: The European Society of Gastrointestinal Endoscopy (ESGE) 
guidelines suggest to employ the suction (SU) technique for endoscopic 
ultrasound (EUS)-guided fine needle aspiration (FNA) of pancreatic solid 
lesions. However, recently some randomized controlled trials have report-
ed that the slow-pull (SP) technique has a similar diagnostic accuracy with 
possibly less blood contamination. However, these results are heteroge-
neous and often limited to small cohorts.
aims & Methods: The aim of the study was to perform a meta-analysis to 
compare sensitivity, specificity, accuracy and adequacy of the SU and SP 
techniques for FNA of solid pancreatic lesions.
A computerized bibliographic search was restricted to randomized con-
trolled trials only. Pooled effects were calculated using a random-effects 
model and expressed in terms of pooled sensitivity and specificity and OR 
(95% CI) for accuracy and adequacy.
results: Overall, 7 RCTs were included (2 conducted in the US, 2 in Korea, 1 
in India, 1 in Brasil, 1 in Italy); 4 were full text publications, 3 abstracts; the 
RCTs investigated 646 patients (216 sampled with SP, 211 with SU, and 119 
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with both). The SP technique showed a slightly higher pooled sensitivity 
compared to SU (83.1% vs 77.2%), while specificity was similar (96.2% vs 
96.4%). A non-significant superiority of SP in terms of pooled accuracy 
(OR 0.59; 95% CI 0.3-1.1; p=0.1) was recorded, while adequacy was similar 
(OR 1.17; 95% CI 0.5-2.5; p=0.6). Two studies reported data on significant 
blood contamination with a pooled rate of 10.8% for SP and 25.6% for SU.
conclusion: The present meta-analysis reveals non-superiority of SU over 
SP, with some trend toward better performance of SP with reduced blood 
contamination; the current recommendations regarding preferential use of 
suction might need to be revised in light of these findings.
disclosure: Nothing to disclose 
P0950 exPerIence WITh eus-guIded BIOPsy usIng The 
PuncTure BIOPsy fOrcePs
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1Radboudumc, Radiology and Nuclear Medicine, Nijmegen, Netherlands, 
2NMC Specialty Hospital, Gastroenterology, Abu Dhabi, United Arab 
Emirates, 3Evangelisches Krankenhaus Düsseldorf, Gastroenterologie, 
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contact e-Mail address: g.litjens@radboudumc.nl
Introduction: Endoscopic Ultrasound (EUS) guided fine needle aspiration 
(FNA) can be used to obtain cytology of solid organs, lymph nodes and 
submucosal tumors of the gastrointestinal tract. However, there is a rising 
demand for histology sampling for the evaluation of tissue architecture 
and to perform additional diagnostics. Available needles for fine needle 
biopsy (FNB) can provide histology in roughly 57-89% of the cases [1-3]. 
Considering the poor performance of FNB and the rising demand for his-
tology sampling, new techniques are needed to increase the diagnostic 
tissue histology yield [4]. Recently, a new promising device was developed 
to increase histology yield in EUS-guided puncturing [5], with an updated 
design: a Nitinol 19-gauge puncture biopsy forceps (PBF; MTW Endoskopie 
Manufaktur, Wesel, Germany).
aims & Methods: We conducted a retrospective multicenter feasibility 
study in 2018 with one University Hospital (Radboudumc (RU), Nijmegen, 
The Netherlands), one general hospital (Evangelisches Krankenhaus (EVK), 
Düsseldorf, Germany) and two private hospitals (New Medical Centre Spe-
cialty Hospital (NH), Abu Dhabi and Thumbay Hospital (TH), Dubai, United 
Arab Emirates). Data were derived from pathology and doctors’ reports. 
Primary outcome was diagnostic yield. Secondary outcomes were safety 
(bleeding, perforation) and technical performance.
results: Nineteen patients were included: 4 from RU, 3 from EVK, 10 from 
NH and 2 from TH. The majority of patients was male (12/19, 63%), the 
age ranged from 34-76 years of age. The BPF was used for biopsy of the 
pancreas in 9, GE junction lesion in 3, lymph nodes in 2, submucosal le-
sion in 3 (1 duodenal bulb and 2 gastric wall) and during rectal EUS in 2 
patients (perirectal lesion and thickened small bowel wall). 1-5 passes per 
case were performed with the PBF. In 17 patients FNA or FNB with another 
needle was also performed.
Primary outcome: In 68% (13/19) diagnostic histology was obtained with the 
PBF. In 3 cases no diagnosis could be made with either histology or cytolo-
gy. In 3 cases diagnosis was made on the cytology only and in 4 on histology 
from the PBF only. In 9 cases both histology and cytology were diagnostic. 
Secondary outcomes: No adverse events occurred in these 19 patients. The 
PBF was very sharp resulting in easy penetration. The forceps mechanism 
in the tip works well even after multiple biopsies in the same patient. The 
Nitinol tip facilitates good bridging possibilities. A lock mechanism on the 
handle prevents the PBF from opening during introduction. However, in 
one patient the PBF was accidently opened in the shaft. In two patients the 
spring mechanism failed after the first pass making it unable to continue 
with the same needle.
conclusion: The PBF is a promising device that can be used for a wide 
range of indications. However, technical improvement of the needle is 
needed to prevent technical failure. The PBF can potentially be useful in 
cases where cytology alone is not adequate for diagnosis or when histol-
ogy is desired for additional stains, genotyping or molecular analysis. To 
determine the value of the PBF and its position in the diagnostic field a 
prospective study is needed in which the PBF is compared to other rou-
tinely used device(s).
references: 1. Attili, F., et al., Performance of a new histology needle for 
EUS-guided fine needle biopsy: A retrospective multicenter study. Dig Liver 
Dis, 2018. 50(5): p. 469-474. 2. DeWitt, J., et al., Comparison of EUS-guid-
ed tissue acquisition using two different 19-gauge core biopsy needles: 
a multicenter, prospective, randomized, and blinded study. Endosc Int 
Open, 2015. 3(5): p. E471-8. 3. Bang, J.Y., R. Hawes, and S. Varadarajulu, 
A meta-analysis comparing ProCore and standard fine-needle aspiration 
needles for endoscopic ultrasound-guided tissue acquisition. Endoscopy, 
2016. 48(4): p. 339-49. 4. Hebert-Magee, S., Is there a role for endoscopic 
ultrasound-guided fine-needle biopsy in pancreatic cancer? Endoscopy, 
2015. 47(4): p. 291-2. 5. Litjens, G., et al., First experience of obtaining pan-
creatic tissue with a puncture biopsy forceps versus fine needle aspiration. 
Endoscopy, 2015. 47 Suppl 1: p. E609-10.
disclosure: Dr. ir. E.J.M. van Geenen is advisor of MTW Endoskopie Manu-
faktur, Wesel, Germany. A proportion of the needles used for this study 
where provided free of charge by MTW Endoskopie Manufaktur, Wesel, 
Germany. 
P0951 endOscOPIc uLTrasOund-guIded 
chOLedOchOduOdenOsTOMy fOLLOWed By duOdenaL 
sTenTIng In PaTIenTs WITh MaLIgnanT unresecTaBLe 
BILIOduOdenaL OBsTrucTIOn
Kumar A., Rai P.
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Gastroenterology, 
Lucknow, India
contact e-Mail address: ashok110@gmail.com
Introduction: In patients with advanced pancreaticobiliary malignancy, 
along with biliary obstruction, gastric outlet obstruction is a frequent oc-
currence. Endoscopic retrograde cholangiopancreatography (ERCP), a first 
line modality for palliation of obstructive jaundice is often unsuccessful 
in patients with combined bilioduodenal obstruction, due to inability to 
reach the duodenal papilla and early dysfunction of biliary self-expanding 
metal stent (SEMS) due to the duodenobiliary reflux enhanced by duode-
nal stenosis.
As an alternative, Endoscopic ultrasound (EUS)-guided choledochoduo-
denostomy (EUS-CDS) and duodenal stent placement has been recently 
described with high rates of technical and clinical success, but with limited 
number of studies and unclear sequence of stenting (i.e. whether biliary 
or duodenal stenting first).
aims & Methods: We evaluated the technical success, clinical success and 
safety of endoscopic ultrasound-guided choledochoduodenostomy fol-
lowed by duodenal SEMS placement in patients with malignant bilioduo-
denal obstruction.
Medical records of consecutive patients with unresectable malignant dis-
tal biliary obstruction and gastric outlet obstruction (GOO), who required 
biliary drainage by EUS-CDS (because of failure of attempt at ERCP) and 
antroduodenal stenting were reviewed. EUS-CDS was done using 6-cm, 
PCSEMS (Wallflex, Boston Scientific). Technical success, clinical success 
[biliary stent- more than 50% reduction in total bilirubin at 2 weeks post-
procedure; antroduodenal stent- improvement in Gastric Outlet Obstruc-
tion Scoring system (GOOSS)], stent patency rate and adverse events (AEs) 
were assessed.
results: Between January 2015 and January 2019, 11 patients underwent 
combined EUS-CDS and antroduodenal stent placement. Both EUS-
CDS and antroduodenal stent placement were technically and clinically 
successful in all patients. Median total serum bilirubin decreased from 
15.8mg/dL to 5.9mg/dL at 2 weeks post procedure. Recurrence of jaundice 
was not seen until 2 months post double stent placement or death. 
Median GOOSS improved from 0.56 to 2.3 at 4 weeks post-procedure. All 
patients were able to maintain weight above 90% of baseline at 4 weeks 
and 72.7% of patients had weight above 80% of baseline at 8 weeks post 
duodenal stent deployment. 
GOO did not recur in patients who were alive at 2 months. In 8 (72.7%) 
of the 11 patients, the biliary and antroduodenal stents were patent and 
functioning normally at 2 months post-procedure. 
Only one patient had bile leak, which resolved with therapeutic paracen-
tesis. There were no procedure-related deaths. Most of the patients (9/11) 
died of advanced cancer cachexia.
conclusion: EUS guided choledochoduodenostomy followed by duodenal 
stenting is safe and has high technical and clinical success for palliation of 
malignant bilioduodenal obstruction.
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references: 1. Nakai Y, Hamada T, Isayama H, et al. Endoscopic manage-
ment of combined malignant biliary and gastric outlet obstruction. Dig 
Endosc. 2017;29:16-25. 2. Hamada T, Isayama H, Nakai Y, et al. Duodenal 
invasion is a risk factor for the early dysfunction of biliary metal stents in 
unresectable pancreatic cancer. Gastrointest Endosc. 2011;74:548-555. 3. 
Ogura T, Chiba Y, Masuda D, et al. Comparison of the clinical impact of en-
doscopic ultrasound-guided choledochoduodenostomy and hepaticogas-
trostomy for bile duct obstruction with duodenal obstruction. Endoscopy. 
2016;48:156-163. 4. Moon JH, Choi HJ. Endoscopic double-metallic stenting 
for malignant biliary and duodenal obstructions. J Hepatobiliary Pancreat 
Sci 2011;18:658-63 5. Kawakubo K, Isayama H, Nakai Y et al. Simultane-
ous duodenal metal stent placement and EUS-guided choledochoduode-
nostomy for unresectable pancreatic cancer. Gut Liver 2012; 6: 399-402. 6. 
Hamada T, Nakai Y, Lau JY, et al. International study of endoscopic man-
agement of distal malignant biliary obstruction combined with duodenal 
obstruction. Scand J Gastroenterol 2018;53:46-55.
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Introduction: Endoscopic ultrasound (EUS) guided tissue acquisition (TA) 
is the method of choice to establish a pathological diagnosis of solid pan-
creatic lesions. EUS guided TA is a complex multistep procedure involving 
efforts of both endosonographers and cytopathologists. 
Reported outcomes on the quality and yield of EUS guided TA are skewed 
towards high-volume academic institutions. For community hospitals, in 
which the majority of these procedures are performed, these data are un-
known. Rate of adequate sample(RAS) (the proportion of tissue samples 
sufficient for cytopathological evaluation) is the only quality indicator 
solely reflecting the work of the endosonography team.
aims & Methods: The aims of this study are 1. to determine and improve 
the RAS of EUS guided TA in a group of community hospitals and 2. to 
identify determinants of RAS. From January 2015 until October 2018 five 
community hospitals in the Rotterdam region in the Netherlands, prospec-
tively included procedures. The primary outcome variable was RAS. Uni-
variate and multivariate analyses were performed to identify determinants 
of yield such as type and size of needle used, application of suction, pres-
ence of rapid on site cytopathological evaluation (ROSE) and the number 
of procedures performed by the endosonographers.
results: Seventeen endosonographers, with individual EUS experience 
ranging from 1-14 years, performed 372 consecutive procedures over a pe-
riod of 46 consecutive months. Overall RAS was 93% (ASGE ref standard: 
>85%)(ref 1). In a multivariate analysis the use of suction and number 
of procedures performed by endosonographers were statistically signifi-
cantly and positively associated with RAS (p=0.01) and (p=0.04) respec-
tively. No significant interaction was found between number of proce-
dures and use of suction. No significant association was found between 
RAS and needle type, needle size, ROSE and number of passes. Seven 
endosonographers performed less than 20 procedures (median 9 (3-
18)) accounting for 70 procedures in total. Within this subgroup RAS was 
87%. The remaining seven endosonographers performed 302 procedures 
(median 56 (21-63)) yielding a RAS of 95%. Differences in RAS between 
“low-volume” and “high-volume” endosonographers were statistically 
significant p=0.01.
conclusion: Both use of suction and higher number of procedures per-
formed by endosonographers are associated with better outcome (RAS) 
of EUS guided TA in this prospective cohort in community hospitals. The 
quality of EUS guided TA in a community hospital may be partly influenced 
by the number of procedures done. However, the quality of an individual 
endosonographer depends on more factors than its volume alone and re-
quires further research.
references: 1. Wani, S., et al. (2015). “Quality indicators for EUS.” Am J 
Gastroenterol 110(1): 102-113.
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Introduction: EUS-guided biopsy is a safe and accurate method for the his-
tological diagnosis of solid liver lesions. However, few data are available 
on liver parenchymal diseases.
aims & Methods: Aim of our study was to evaluate in an ex-vivo model 
the ability of different EUS needles to obtain histological samples of liver 
tissue.
Material y Methods: 7 different types of EUS biopsy needles in an ex-vi-
vo pig liver were tested: A1: 22G Franseen type needle; L1-L3: standard 
cytology needles of 25G, 22G and 19G respectively; SC1-SC3: SharckCore 
type needles of 25G, 22G and 19G respectively. Biopsies were performed 
without suction and without stylet. Two passes were performed with each 
needle type. Samples were collected in formalin. Samples were consid-
ered satisfactory if they were at least 1cm in length and if they included at 
least 10 porta spaces. Fragmentation was evaluated as well.
results: Table shows results obtained with each of the needles used.
case n.º cILInders
fragMen-
TaTIOn
Measure 
(cm)
POrTaL 
sPaces quaLITy
A1 8 High 0,1-0,4 2 Non-satisfactory
L1 8 High 0,1 0 Non-satisfactory
L2 4 Medium 0,1 0 Non-satisfactory
L3 9 High 0,1-0,4 0 Non-satisfactory
SC1 9 High 70,1-0,8 7 Non-satisfactory
SC2 11 High 0,1-1 11 Satisfactory
SC3 11 High 0,1-1,4 10 Satisfactory
[Table 1]
conclusion: SharkCore needles (22G and 19G) allow obtaining a core liver 
biopsy in an ex-vivo model, suitable for histological evaluation. These re-
sults should be confirmed in vivo.
disclosure: Nothing to disclose 
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P0955 eus-guIded PLaceMenT Of neW gOLd fIducIaL 
Markers fOr sTereOTacTIc BOdy radIaTIOn TheraPy In 
LOcaLLy advanced PancreaTIc cancer: PreLIMInary resuLTs 
Of feasIBILITy and safeTy
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Rozzano, Italy, 7Humanitas University/Humanitas Research Hospital, 
Gastroenterology, Rozzano, Italy, 8Humanitas Research Hospital, Digestive 
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Introduction: Radiation therapy has an emerging role in the multi-modal 
treatment of locally advanced pancreatic cancer (LAPC). Stereotactic body 
radiation therapy (SBRT) is an innovative radiation technique characterized 
by a high prescription dose delivered in only a few fractions thus increasing 
the local control rate. Endoscopic ultrasound (EUS)-guided fiducial place-
ment allows for accurate tracking of target motionduring SBRT delivery.
aims & Methods: The aim of this study is to present preliminary results 
on the feasibility and safety of EUS-guided fiducial placement using 
a new preloaded needle in patients with LAPCIn a prospective phase II 
study(NCT03158779), patients with LAPC treated with induction chemother-
apy according to FOLFIRINOX or gemcitabine + nab-paclitaxel schedules 
were then treated with an ablative dose of SBRT (54Gy in 6 daily fractions).
Gold markers were implanted under EUS-guidance into the tumor at op-
posite edges. A new dedicated EUS delivery device was used: a 22G needle 
preloaded with 4 gold fiducials (0.43mm width x 5mm length).Fluoroscopy 
was used to confirm correct fiducial deployment. Prior to fiducial place-
ment, patients received IV antibiotic prophylaxis and rectal indomethacin. 
Technical aspects of the EUS procedure and fiducial visualization were 
scored on a predetermined 5-point Likert scale (1 = best, 5 = worst).
results: From May 2017 to March 2019, 10 patients (mean age 65.7 years) 
were enrolled. Before fiducial placement, all patients received induction 
chemotherapy with gemcitabine + nab-paclitaxel (6 patients) or FOLFIRO-
NOX (4 patients) for a median duration of 4.6 months (range 2-7 months). 
At restaging, all patients still had locally advanced tumors with no re-
gression to resectable disease. The mean tumor size was 28.5 mm. Other 
characteristics are listed in Table 1.
PaTIenT age gender LOcaTIOn Of neOPLasIa
dIaMeTer Of 
neOPLasIa
TechnIcaL 
dIffIcuLTIes
nuMBer 
fIducIaLs
adjusT-
MenT
1 72 F HEAD 36
MILD 
(HARDNESS 
OF TISSUE)
3
YES (< 3 
MM)
2 57 M UNCINATE 42
MILD 
(HARDNESS 
OF TISSUE)
3 NO
3 54 M BODY 42 NO 2 NO
4 71 F BODY 31
COLLATERAL 
VESSELS 
AROUND 
LESION
2 NO
5 70 F BODY 36 NO 4 NO
6 53 F HEAD 30
RELEASE 
OF TWO 
FIDUCIALS IN 
ONE SHOT
4 NO
7 75 F UNCINATE 18 NO 2 NO
8 80 M NECK 12
COLLATERAL 
VESSELS 
AROUND 
LESION
1 NO
9 72 F UNCINATE 16 NO 2 NO
10 53 F BODY 22 NO 3 NO
[Table 1]
A total of 26 fiducials were implanted, with a mean number of 2.6 fiducials 
placed per patient (range 1-4). All the fiducials were successfully deployed 
inside the target lesion with a technical success of 100%. In 5 of 10 pa-
tients, the procedure had no technical difficulties. In the other 5 patients, 
fiducial placement was characterized by minor technical difficulties due 
to increased hardness of lesion, interposing vessels or poor control with 
the first marker release. EUS, fluoroscopic and CT visualization of the fidu-
cials was rated as excellent. Patients started the SBRT protocol 10.2 days 
(range 6-19) after simulation CT-scan. At the beginning of the SBRT deliv-
ery, minimal movement of one fiducial (<3 mm) occurred in one patient. 
No severe adverse events occurred and all procedures were performed in 
an outpatient setting.
conclusion: These preliminary results demonstrate the feasibility and safe-
ty of the EUS-guided fiducial placement using a new preloaded needle in 
patients with LAPC. Only minor technical difficulties (mainly due to tumor 
hardness or collateral vessels) were encountered that did not affect the 
correct placement of the fiducials.
disclosure: Nothing to disclose 
P0956 safeTy and effIcacy Of endOscOPIc uLTrasOund 
guIded BIOPsy usIng a TransvascuLar aPPrOach
Bojórquez Gutiérrez A.E.1, Zubiaga Fernández L.2, Betés Ibañez M.1, 
Hidalgo F.3, Peralta Herce S.1, Gómez Villagrá M.1, Mora Moriana L.1, 
Muñoz Navas M.1, Súbtil Íñigo J.C.1
1Clínica Universidad de Navarra, Gastroenterology, Pamplona, Spain, 
2Universidad de Navarra, School of Medicine, Pamplona, Spain, 3Clínica 
Universidad de Navarra, Anesthesiology, Pamplona, Spain
contact e-Mail address: abojorquez@unav.es
Introduction: Traditionally, when performing endoscopic ultrasound (EUS) 
guided biopsy, target lesions beyond vascular structures were avoided 
due to concerns of major bleeding complications, leaving surgery as the 
only option for tissue sampling. There are few case reports and series 
published, underlining one small case series of transaortic sampling with 
favorable results. Furthermore, based on previous feasibility studies, the 
American Society of Gastrointestinal Endoscopy (ASGE) published a review 
on potential applications of EUS-guided portal vein interventions which 
seem safe and effective.
aims & Methods: Due to the limited data available, we reviewed our expe-
rience in EUS-guided biopsy using a transvascular approach to assess its 
safety and diagnostic performance.
A retrospective analysis was done of 15 patients who underwent, for can-
cer staging, an EUS-guided biopsy with a transvascular approach from July 
2007 to March 2019.
case sex/age Punctured structure needle
nº 
Lesions nº Passes complications
1 M/59 Aortic Arch 25 G 1 3 No
2 F/42 Vena Cava 25 G 2 1 and 2 No
3 F/42 Portal Vein 25 G 1 5 No
4 F/59 Aortic Arch 25 G 1 2 No
5 F/55 Aortic Arch 25 G 1 3 No
6 M/53 Aorta 25 G 1 2 No
7 F/35 Aortic Arch 25 G 1 4 No
8 F/63 Aortic Arch 25 G 1 3 No
9 F/48 Aorta 25 G 1 1 No
10 M/60 Aortic Arch 25 G 1 1 No
11 F/51 Aortic Arch 25 G 1 1 No
12 F/60
Pulmonary 
Artery and 
Aorta
22 and 25 G 
(respectively) 2 1 and 1
Minor, self-limiting 
hemorrhage.
13 M/61 Aorta 25 G 1 3 No
14 F/66
Left 
pulmonary 
artery
22 G 1 1
Bronchial 
hemorrhage, 
intubation and 
endoscopic treatment.
15 M/55 Aortic Arch 25 G 1 3 Self-limiting periaortic hematoma.
[Table 1. Cases of EUS-guided biopsy using a transvascular approach.]
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results: The sample has a median age of 59.93 years (Table 1). With re-
spect to medication, 26.67% were under non-steroidal anti-inflammatory 
drugs, 20% aspirin and 6.67% low-molecular weight heparin. The medi-
cation was temporarily interrupted if it was necessary. Eighty percent of 
the patients underwent general anesthesia and 20% deep sedation with 
intermittent bolus of propofol.
The punctured vascular structure was arterial in 86.67% of the cases, be-
ing the aorta (80%) the most punctured. The needle used in all the cases 
was a 25G, except in the biopsies through the pulmonary artery in which a 
22G was used, with a median of 2.27 passes for lesion. (IC 95: 1.56 - 2.75). 
An on-site pathologist was present in all cases. The cytology report was 
positive for malignancy in 86.67% of the cases and negative for malig-
nancy in 6.67% of the cases.
In 93.33% of the cases, the procedure was performed in an ambulatory 
fashion. Three patients had mild bleeding; one was a self-limiting peri-
aortic hematoma, another one stopped bleeding with echoendoscope 
compression and another one required hospital admission for observation 
and did not need any other intervention.
conclusion: This is one the largest case series published to date. Taking 
into consideration the diagnostic performance and the low complication 
rate, we consider the EUS-guided biopsy with a transvascular approach a 
feasible procedure and reasonably safe in cases in which there is no other 
ultrasonographic window.
disclosure: Nothing to disclose 
P0957 cuMuLaTIve suM anaLyses guIdIng IMPrOveMenT Of 
TeaM PerfOrMance In eus guIded TIssue acquIsITIOn Of sOLId 
PancreaTIc LesIOns In cOMMunITy hOsPITaLs
Schutz H.M.1, Quispel R.1, Leeuwenburgh I.2, Hol L.3, Honkoop P.4, 
Schot I.5, Veldt B.J.1, Van Driel L.M.J.W.6, Bruno M.J.6, On Behalf of QUEST 
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4Albert Schweitzer Hospital, Gastroenterology, Dordrecht, Netherlands, 
5Ijsselland Hospital, Gastroenterology, Capelle aan den IJssel, Netherlands, 
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contact e-Mail address: h.schutz@rdgg.nl
Introduction: Endoscopic ultrasound (EUS) guided tissue acquisition (TA) 
is a complex multistep procedure involving efforts of both endosonogra-
phers and cytopathologists. Published outcomes on the quality and yield 
of EUS guided TA are skewed towards high-volume academic institutions. 
For community hospitals, in which the majority of these procedures are 
performed, these data are unknown. Rate of adequate sample (RAS) (the 
proportion of tissue samples sufficient for cytopathological evaluation) is 
the only quality indicator solely reflecting the work of the endosonography 
team. The ASGE guideline described a performance target of 85% for RAS 
(Ref 1). Cumulative SUM (CUSUM) analysis is a method that can be used for 
quality control (Ref 2). For EUS CUSUM has been used to evaluate learning 
curves of trainees (Ref 3).
aims & Methods: The aim of this study is to investigate whether CUSUM 
might be a good method to visualize and evaluate the quality of daily prac-
tice EUS guided TA of solid pancreatic lesions in community hospitals.
In Rotterdam region, The Netherlands, a group of five community hospitals 
formed an EUS interest group (QUEST). With three annual meetings and a 
regional symposium the goal of QUEST is to improve the quality of EUS in 
community hospitals. For this particular study, in each hospital retrospec-
tive data was collected of EUS-FNA/FNB procedures performed in the year 
2014. In January 2015, a prospective registration of all consecutive EUS 
procedures with FNA/FNB started. CUSUM was used to identify changes 
in quality. With CUSUM each adequate sample contributes to an upwards 
slope of the CUSUM curve, each inadequate sample will contribute to a 
downwards slope of the CUSUM curve. Two decision limits are calculated. 
When a curve crosses the upper limit, the quality is good, according to 
literature. When a curve crosses the lower limit an intervention is needed 
to improve the quality. When a curve stays between the decision limits 
the observations should be continued until the curve will cross one of the 
decision limits.
results: A total of 103 retrospective procedures and 372 consecutive pro-
spective procedures were included. Values of RAS are shown in table 1. 
 
ras 
hospital a
ras 
hospital B
ras 
hospital c
ras 
hospital d
ras 
hospital e
ras Total 
cohort
Retrospective 
series
70% 95% 100% 55% 78% 80%
Prospective 
series
88% 89% 98% 99% 91% 93%
95% CI 0.2 - 41 -13 - 16 -13 - 9 23 - 64 -4 - 34 6 - 22
p-value 0.047 0.4 0.4 <0.01 0,1 <0,01
[Table 1. Adequate sample rates and differences between retrospective and 
prospective series.]
With CUSUM analysis the learning curve shows a downwards slope in 
2014 (retrospective series) and crosses the lower decision limit during 
that year. The formation of QUEST (January 2015) marked a turning point 
with the curve showing an upwards slope crossing the upper decision 
limit in December 2017. CUSUM learning curves also revealed differences 
in quality between the five hospitals in QUEST showing relevant positive 
improvements after team formation, especially for those hospitals initially 
underperforming.
conclusion: CUSUM showed to be a valid method to measure quality of 
EUS guided TA of solid pancreatic lesions. It provides continuous feedback 
on the development (or maintenance) of TA quality and can also be used 
to compare hospitals. We conclude that after the formation of the QUEST 
group, RAS of the participating community hospitals is comparable to the 
ASGE guideline.
references: 1. Wani S, Wallace MB, Cohen J, Pike IM, Adler DG, Kochman 
ML, et al. Quality indicators for EUS. Am J Gastroenterol. 2015;110(1):102-
13. 2. Williams SM, Parry BR, Schlup MM. Quality control: an application 
of the cusum. BMJ. 1992;304(6838):1359-61. 3. Wani S, Cote GA, Keswani 
R, Mullady D, Azar R, Murad F, et al. Learning curves for EUS by using 
cumulative sum analysis: implications for American Society for Gastro-
intestinal Endoscopy recommendations for training. Gastrointest Endosc. 
2013;77(4):558-65.
disclosure: Nothing to disclose 
P0958 fIve fna sPecIMens In One Pass: a dIsruPTIve neW 
needLe cOncePT
Lachter J.1, Gross S.A.2
1Rambam Health Care Campus, Technion - Israel Institute of Technology and 
Meuhedet Health Service, Gastro, Haifa, Israel, 2NYU Medical School, New 
York, United States
contact e-Mail address: jesse.lachter@gmail.com
Introduction: EUS-guided FNA and FNB have established their place for 
tissue acquisition. However, the procedure has been stagnating in re-
cent years at a level of accuracy which falls short of patient and physician 
hopes. In recent years, needles have been redesigned to allow for core 
sampling, (FNB), to allow for immune-staining of specimens. 
However, false negative results for malignancy range from 4% (experts 
centers) to 30%. Multiple needle passes are often needed, but often slide 
along the same tract as the first pass, limiting diagnostic yield. An FNA ap-
proach usually requires 3-5 passes, with fewer passes for the FNB needles. 
Furthermore, rapid on-site cytology can lower number of passes, but the 
majority of centers find this to be logistically and/or financially prohibi-
tive. Needles after repeated passes bend out of shape leading to use of a 
second needle, which has cost implications. Tumor composition can be a 
mosaic of desmoplasia, necrosis, cystic areas, and malignant cells. If the 
needle is in the wrong plane and the endoscopist is unable to do fanning 
an inconclusive diagnosis can occur. We introduce a new needle concept 
to improve diagnostic yield and lower false negatives, with use of a device 
which has five needles.
aims & Methods: A multi-pass needle has been designed which ensures 
five specimens will be from various sites, because the five needles are all 
penetrating at the same time in different planes of the lesion. This needle 
apparatus uses the same sheath as a standard 19 gauge needle, but within 
the sheath it houses a five-lumen plastic tube, which separates between 
the central 22g needle and the four peripheral 25g needles. The ergonom-
ically-designed handle has a two-phase mechanism which allows the en-
doscopist to first place the 22g needle within the target lesion, which is the 
same as the process done today, and to then extrude the four 25g needles, 
which are pre-bent so as to spread out to a diameter of about one cm, 
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at a distance of about 3cm from the scope. These additional needles will 
each, without fanning, obtain specimens near to the central needle, and 
therefore a greater representation of tumor tissue will be obtained, while 
completing the procedure in one pass, with better accuracy due to less 
false negatives. The two channels for suction can be attached to either the 
single central needle and/or to all four peripheral needles with stopcocks 
facilitating the maintaining of suction when so desired. Each needle has 
its own stylet, these may be removed at any time desired.
results: We present in the accompanying figure the InstaFan, a disrup-
tive technological advance, for the delivery of better EUS biopsies. Ex vivo 
studies found that the 5 needles did not cause leakage from the gut or 
perforation of the gut wall, and that the 5 needles delivered resulted in five 
distinct specimens each of which was an adequate specimen for patho-
logical diagnostic purposes using the cell block method and paraffin slices 
allowing immune-staining.
conclusion: Future directions of the InstaFan will be animal in vivo animal 
safety study followed by first trials in humans. The goal of the InstaFan 
will be to reduce false negatives, thus increasing optimization of tumor 
diagnosis.
disclosure: Both authors disclose financial association with the developers 
of this new needle 
P0959 hIgh dIagnOsTIc yIeLd Of MuTaTIOnaL anaLysIs 
On eus-guIded BIOPsIes usIng a neW franseen needLe In 
PaTIenTs WITh LOcaLLy advanced PancreaTIc cancer (LaPc)
Carrara S.1, Di Leo M.2, Laghi L.3, Sandrucci G.4, Poliani L.2, 
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Introduction: Genomic analyses of pancreatic cancer display a complex 
mutational background with few known oncogenic events in well know 
cancer-related genes, and many other low prevalence mutated genes.
In order to conduct a genetic study of locally advanced pancreatic cancer 
(LAPC), bioptic samples of the primitive tumor are necessary. Endoscopic 
ultrasound-fine needle aspiration with cytology has led to some prelimi-
nary results, however, the quantity of cellsobtained may be insufficient to 
perform a genetic analysis.
New histology needles have been developed to obtain more material and 
a better preservation of the tissues for ancillary analysis such as somatic 
mutations analysis and immunohistochemistry.
aims & Methods: 33 patients with naïve LAPC underwent EUS- fine needle 
biopsy (FNB)with the new 22GFranseen needle. Bioptic samples were sent 
topathological evaluation and to genetic analysis. DNA extraction was per-
formed, and Next Generation Sequencing provided mutational profiles of 
the extracted DNA samples. NGS was performed with a 161 genes panel; 
18 of the most prevalent genes were selected to undergo computational 
analysis.
results: EUS- FNB allowed for a macroscopic core in 31 patients (94%), 
and pathological diagnosis was obtained in 100% of patients. Good quality 
DNA was extracted from 32 samples (97%), and NGS analysis confirmed 
the diagnosis in 30 patients (93.75%). The diagnostic yield of NGS analysis 
improved when combined with serum CA19.9 levels (97%). Results on DNA 
extraction and NGS analysis are depicted in table 1.
Genetic profiling obtained from NGS sequencing revealed pathogenic 
mutations in KRAS, TP53, GNAS, SMAD4 and CDKN2A, as well as a large 
number of mutations of uncertain significance. Preliminary data analysis 
revealed that the mutational burden of known oncogenes may be under-
estimated.
conclusion: The tissue obtained with the new 22G Franseen FNB needle 
demonstrated a high diagnostic yield for the histological diagnosis of pan-
creatic adenocarcinoma and gave material of good quality of NGS analysis.
The ability to identify distinct mutation subsets via EUS-TA could greatly 
aid patient stratification and would represent a crucial step in the field of 
personalized medicine.
disclosure: Nothing to disclose
  resuLTs nOTes
DNA EXTRACTION 
FOR NGS ANALYSIS
32/33 PATIENTS (97%) 1/33 NECROTIC SAMPLE
KRAS 29/32 PATIENTS (91%) MISSENSE MUTATION
TP53 13/32 PATIENTS (41%)
9 MISSENSE MUTATION 4 TRUNCATIVE 
MUTATION
GNAS 3/32 PATIENTS (9%) MISSENSE MUTATION
SMAD4 2/32 PATIENTS (6%)
1 MISSENSE MUTATION 1 TRUNCATIVE 
MUTATION
CDKN2A 1/32 PATIENTS (3%) MISSENSE MUTATION
[Table 1]
P0960 WIThdraWn
P0961 The rOLe Of suBMucOsaL TaTTOOs durIng devIce 
assIsTed enTerOscOPy On suBsequenT PaTIenT ManageMenT
Chetcuti Zammit S.1, Sanders D.S.2, Sidhu R.3
1Royal Hallamshire Hospital, Gastroenterology, Sheffield, United Kingdom, 
2Royal Hallamshire Hospital - NHS Trust, Sheffield, United Kingdom, 
3Sheffield Teaching Hospitals, Sheffield, United Kingdom
contact e-Mail address: stf_che@yahoo.com
Introduction: ESGE recommends placing a submucosal tattoo to mark an 
identified lesion and/or the deepest point of insertion during device as-
sisted enteroscopy (1).
aims & Methods: Patients who underwent a double balloon enteroscopy 
(DBE) during which a tattoo was placed were included. Information on 
repeat DBEs, second look small bowel capsule endoscopies (SBCEs) and 
subsequent surgeries was gathered.
results: 283 patients (mean 57 years +/-15.5; 52.7% males) had a tattoo 
placed during DBE. Most underwent antegrade DBE (218; 77.0%). The most 
common indication was iron deficiency anaemia (IDA) (Table 1).
Indication frequency Percentage
Iron deficiency anaemia 72 25.4
Ulcers 48 17.0
GI bleed 63 22.3
Polyp 27 9.5
Angioectasias 21 7.4
? Tumour 19 6.7
? Crohn’s disease 18 6.4
? Stricture 18 6.4
Abnormal radiology 10 3.5
? Coeliac complication 8 2.8
Diarrhoea, weight loss, malabsorption 6 2.1
White tipped villi 2 0.7
Retained SBCE 2 0.7
[Table 1: Indications for DBE;]
Pathology was reached in 158 (55.8%) patients. Other patients (111; 39.2%) 
had a normal DBE with subsequent investigations ruling out any pathol-
ogy. In 14 patients (4.9%), the pathology was not reached. 
A repeat DBE was carried out in 47 patients. Tattoo from previous DBE was 
detected in 18 (38.3%) patients. 28 of these patients underwent a DBE 
using a different route. A tattoo was detected in only 6 (21.4%) of these 
patients and in 12 (63.2%) patients who underwent a DBE via the same 
route (p=0.006).
36 patients (12.7%) were diagnosed with a tumour, meckel’s diverticulum 
or a stricture. 26 (72.2%) underwent surgery and 20 (76.9%) of these pa-
tients had the lesion tattooed facilitating surgery.
80 patients underwent a second SBCE after DBE to ensure pathology was 
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not missed. Of these, 53 (66.3%) had a tattoo identified. 21 of these pa-
tients (26.3%) had pathology detected beyond the tattoo requiring alterna-
tive procedures.
In those patients (14) where pathology was not reached, 5 underwent sur-
gery, 4 patients were not for surgery due to the multiple carcinoid tumours 
identified and 5 patients were treated conservatively as the pathology was 
deemed to be benign on subsequent investigations.
conclusion: Placing a tattoo can be helpful where the suspicion of pathol-
ogy is high despite a negative DBE as this will help the detection of the 
pathology in relation to the tattoo on subsequent SBCEs. A tattoo can help 
pathology be localised during surgery and facilitate resection.
references: 1 Rondonotti E, Spada C, Adler Set al. . Small-bowel capsule 
endoscopy and device-assisted enteroscopy for diagnosis and treatment 
of small-bowel disorders: European Society of Gastrointestinal Endoscopy 
(ESGE) Technical Review Endoscopy. 2018;50:423-446.
disclosure: Nothing to disclose 
P0962 caPsuLe endOscOPy, enTerOscOPy and radIOLOgy - 
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2Royal Hallamshire Hospital - NHS Trust, Royal Hallamshire Hospital; 
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Introduction: Capsule endoscopy (CE) has a useful role in patients with 
established coeliac disease (CD) with new symptoms or where a complica-
tion is suspected. Similarly double balloon enteroscopy (DBE) is helpful 
for histological diagnosis of pathology reported on CE in conjunction with 
radiology.
aims & Methods: Patients with established CD who underwent DBE +/- 
CE +/- radiological investigations were included. Information on findings, 
histological results and final diagnosis were gathered.
results: Twenty-four patients with established CD (median age 63 years, 
54.2% males) underwent antegrade (83.3%) or retrograde DBE (16.7%). 
Patients underwent small bowel (SB) investigations because of persistent 
symptoms or anaemia (11, 45.8%) or to rule out complications of refractory 
coeliac disease (RCD) (13, 54.2%). Patients underwent a CE (23, 95.7%) 
and radiological investigations (13, 54.2%) prior to DBE. Findings on CE 
included: mass lesion (5, 20.8%), stricture (1, 4.2%), evidence of gluten 
enteropathy (9, 37.5%), ulcers (7, 28.3%). Findings on radiological imaging 
were: abdominal lymphadenopathy (3, 23.1%), thickened SB (6, 46.2%), 
mesenteric mass (1, 7.7%), strictures (1, 7.7%), lymphoma (1, 7.7%). Twenty-
two patients (91.7%) had positive findings on DBE. In 3 of these, findings 
related to CD were present. However, the suggested mass / stricture on CE 
or radiological imaging was not seen. Histological findings were: raised 
intraepithelial lymphocytes (5, 20.8%), partial (5, 20.8%), subtotal (4, 
16.7%) and total villous atrophy (6, 25.0%), adenocarcinoma (2, 8.3%), 
changes consistent with RCD 2 (1, 4.2%), enteropathy associated T cell lym-
phoma (EATL) (1, 4.2%). There was a good concordance between CE and 
DBE (K=0.646, p=0.001) and between radiological investigations and DBE 
(K=0.755, p=0.005). The concordance between CE and radiological stud-
ies was lower (k=0.429, p=0.070). DBE revealed more severe histological 
changes in the SB in 7 (n=10, 70.0%) patients compared to duodenal biop-
sies taken during gastroscopy (p=0.036).
CE revealed ulcers in 29.0% (7) of patients. However only 2 (28.6%) pa-
tients had the diagnosis of ulcerative jejunoileitis confirmed on DBE. One 
patient with adenocarcinoma had positive findings on all 3 modalities. An-
other patient with adenocarcinoma had positive findings on CE and DBE. 
The patient diagnosed with EATL had a positive MRI. DBE was confirmative 
of the diagnosis. CE only showed scalloping and villous blunting in the 
proximal SB. In another patient diagnosed with neuroendocrine tumour, 
both CE and CT were diagnostic. 
However, the lesion was not reached during DBE.
conclusion: CE has a high diagnostic yield as an initial investigation 
compared to radiological studies. DBE has a useful role in establishing 
a confirmative diagnosis of pre-malignant and malignant conditions. In 
patients with active disease on CE, DBE can be useful in obtaining histo-
logical specimens that can provide additional information to that obtained 
from duodenal biopsies.
disclosure: Nothing to disclose 
P0963 18f- fLuOrO deOxy gLucOse-LaBeLLed auTOLOgOus 
LeukOcyTe POsITrOn eMIssIOn TOMOgraPhy/cOMPuTed 
TOMOgraPhy vs neWer MrI TechnIques: OPenIng neWer 
hOrIzOns In deTecTIng InfecTIOn In fLuId cOLLecTIOns Of 
acuTe PancreaTITIs
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Introduction: Acute pancreatitis (AP) is a significant medical and surgical 
problem with variable clinical course and outcomes. Severe acute pan-
creatitis (SAP) is one of the most dangerous Illnesses, with a significant 
mortality as high as 8%-39%. Infection of the pancreatic necrosis is a 
dreaded complication during the late course and the resulting sepsis &/
or multiple-organ dysfunction syndrome (MODS) are the main causes of 
death. Superimposed infection in setting of pancreatitis remains both di-
agnostic and therapeutic challenge and may be potentially life threatening 
if the diagnosis is delayed. Therefore prompt non-invasive diagnosis of 
infection is crucial because it has pivotal influence on decision making and 
management. The clinical presentation, and laboratory parameters are 
often equivocal and the definitive proof of infection is generally obtained 
by performing an image guided aspiration of the collection followed by 
Gram’s staining and culture for bacteria and/or fungal organisms. 
With significant advancements in imaging techniques , we intended to 
explore the utility of novel imaging techniques for early non-invasive 
detection of infection in this clinical setting . We performed a study to 
evaluate the role of two newer imaging modalities i.e 18F-FDG-Labelled 
Autologous leukocyte PET/CT and MRI (including advanced techniques like 
diffusion weighted imaging (DWI), spectroscopy (MRS)) in this scenario.
aims & Methods: To evaluate the utility of novel imaging techniques i.e 
18F-FDG-Labelled Autologous Leukocyte PET/CT and MRI (including DW-
MRI, MRS) in early non- invasive detection of infection in setting of acute 
pancreatitis.
We performed a prospective analytical study which approved by our in-
stitutional review committee in which patients of AP and suspected infec-
tion were radiologically evaluated by both 18F-FDG-Labelled Autologous 
Leukocyte PET/CT and advanced MRI within a span of 24-36 hrs .Targeted 
image guided sampling and aspiration was then performed from the sus-
pected collection,followed by microbiological assessment.
results: After evaluation of 32 patients of acute pancreatitis with clinical 
suspicion of infection in the fluid collections, positive microbiological evi-
dence of infection were found in 14 patients and all these patients showed 
restricted diffusion on MRI and increased uptake on 18F-FDG-Labelled 
Autologous Leukocyte PET/CT. 18 patients who did not have microbiologi-
cally proven infection showed no restricted diffusion on DWI or increased 
uptake on PET/CT.
conclusion: Advanced imaging techniques like 18F-FDG-Labelled Autolo-
gous Leukocyte PET/CT and DW MRI are showing encouraging results with 
high sensitivity for early detection of infection in setting of acute pancreati-
tis. Addition of these modalities to the imaging protocols may help in early 
diagnosis of superimposed infection thereby improving clinical outcomes. 
Also both these modalities have shown comparable accuracies in our study.
disclosure: Nothing to disclose 
P0964 uLTrasOnOgraPhIc assessMenT In InfLaMMaTOry 
BOWeL dIsease PaTIenTs and fecaL caLPrOTecTIn LeveLs: 
eMergIng TOOLs In MOnITOrIng dIsease acTIvITy
Anda L.1, Costache R.2, Gheorghe L.S.1, Gheorghe C.1
1Fundeni Clinical Institute, Gastroenterology, Bucharest, Romania, 2Fundeni 
Clinical Institute, Bucharest, Romania
contact e-Mail address: anda_les@yahoo.com
Introduction: Current guidelines recommend bowel ultrasound (BUS) be-
sides gold standard endoscopic assessment in the management of inflam-
matory bowel disease (IBD) patients [1]. Sonographic measurements su-
perpose with endoscopic findings and other imagistic methods (MRI) [2]. 
Faecal calprotectin level correlates significantly with endoscopic disease 
activity in IBD [3] and the test is useful in clinical practice for assessment of 
endoscopic activity and remission.
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aims & Methods: 42 IBD patients were included in the study (3 diagnosed 
with ulcerative colitis, 39 with Crohn’s disease). Diagnosis was established 
endoscopically and histologically and both patients with active and inac-
tive disease were included. Exclusion criteria referred to patients with 
superimposed infection (viral and Clostridium Difficile) and patients that 
had solely rectal involvement of the disease. Patients were prospectively 
evaluated sonographically using a 4-8 MHz micro-convex transducer and 
the examiner was blinded to biological data. No special preparation was 
needed before BUS. Data collection was performed noting 3 sonographic 
measurements of bowel wall thickness in each patient and the assessment 
of intestinal wall structure. The sonographic measurements were noted in 
the corresponding regions according to endoscopic observations. Mean 
value of BWT was calculated. Faecal calprotectin levels were obtained for 
each patient and the test had a cut-off value of 50 mg/kg.
results: Strong correlations were observed for the three measurements 
of the bowel wall thickness ( Spearman’s equation, r= 0.754, r=0.787 and 
r=0.793, p< 0.001) and values of faecal calprotectin. A mean calculated 
value of the 3 measurements of BWT was highly correlated with the level 
of calprotectin too (r=0.802, p< 0.001). The observation that the higher 
the value of the faecal calprotectin the greater the disturbance of the wall 
stratification ( CI 95% [-710.6-359.7], p< 0.001) suggested a relationship 
between the presence of a stratified wall appearance and calprotectin lev-
els.
conclusion: Sonographic findings (BWT and bowel wall structure) and fae-
cal calprotectin levels could be used in clinical practice to evaluate disease 
activity in IBD patients.
references: 1. 1. Maaser C et al., ECCO-ESGAR Guideline for Diagnostic 
Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, 
detection of complications, Journal of Crohn’s and Colitis, 2018, 1-32. 
doi:10.1093/ecco-jcc/jjy113 2. Allocca A et al., Comparative Accuracy of 
Bowel Ultrasound Versus Magnetic Resonance Enterography in Combina-
tion With Colonoscopy in Assessing Crohn’s Disease and Guiding Clinical 
Decision-making, Journal of Crohn’s and Colitis, 2018, 1-8. doi:10.1093/
ecco-jcc/jjy093 3. N’Haens G et al, Fecal Calprotectin is a Surrogate Mark-
er for Endoscopic Lesions in Inflammatory Bowel Disease, Inflammatory 
Bowel Diseases, 2012,12: 2218-2224, https://doi.org/10.1002/ibd.22917
disclosure: Nothing to disclose 
P0965 cOLITIs On cT - dOes ThIs Mean InfLaMMaTOry 
BOWeL dIsease?
Patel R.N., Ramakrishnan S., Veglio-Taylor E.-P., Tariq Z., King J., 
Besherdas K.
Royal Free London NHS Trust, Gastroenterology, London, United Kingdom
contact e-Mail address: rajan.patel@nhs.net
Introduction: Cross sectional imaging is commonly used to assess the ab-
domen for a variety of symptoms. Colitis reported on CT has become a 
frequent indication for lower gastrointestinal endoscopy. The outcomes of 
performing colonoscopy for radiology reported colitis is not clearly known.
aims & Methods: A retrospective, single centre study of patients referred 
for a colonoscopy with the indication of ‘abnormal imaging’. Data was col-
lected using the endoscopy software audit tool over a 12-month period 
(September 2017 to August 2018). Patients who had undergone an imaging 
modality other than CT and those with an overt colonic polyp or mass on 
CT were excluded from the analysis. Analyses were performed using chi-
square and student t-test.
results: 249 patients (183 CT (73.5%), 66 CTVC (26.5%)) underwent a 
colonoscopy for CT evidence of mural thickening (218 (87.6%)), fat strand-
ing (88 (35.3%)), inflammation (104 (41.8%)) or local lymph nodes (37 
(14.9%)); median age 68 (IQR 53 - 79); median time from CT to endoscopy 
33 days (IQR 12.5 - 56.5). Initial indication for CT examination: Abdomi-
nal pain 112 (45.0%), Change in bowel habit 39 (15.7%), ?Malignancy 32 
(12.9%), PR bleeding 13 (5.2%), Weight loss 9 (3.6%) and Other 44 (17.7%). 
53 (21.3%) patients had completely normal lower GI endoscopy. 111 
(44.6%) had uncomplicated diverticulosis, 11 (4.4%) diverticulitis, 20 
(8.0%) haemorrhoids and 37 (14.9%) colorectal polyps. 
20 patients (8.0%) had endoscopic evidence of colitis; 14 (6%) histological 
evidence of colitis. 10 (4%) confirmed IBD at 6 months follow up (4 UC, 6 
CD).
 
normal 
(n=53)
colitis 
(n=20)
Malignancy 
(n=21) *p value
age, mean 63.6 54.4 69.5 <0.02
Time to endoscopy (days), mean 45.3 24.5 24.9 <0.04
Mural thickening (%) 48 (90.1) 19 (95) 20 (95.2) ns
fat stranding (%) 14 (26.4) 12 (60) 9 (42.9) <0.03
Inflammation (%) 16 (30.2) 12 (60) 9 (42.9) 0.06
Lymph nodes (%) 4 (5.7) 8 (40) 11 (52.4) <0.00006
haemoglobin (g/L), mean 128.0 123.8 112.2 0.005
crP (mg/L), mean 29.8 55.5 68.1 0.10, <0.05
[Table 1. Comparison of endoscopic diagnoses according to CT features and 
blood results.]
conclusion: Colitis reported on CT correlates with endoscopic colitis in 
only 8% of patients in this study. Less than 5% are diagnosed with IBD 
at 6months follow up. The correlation improves in younger patients and 
with shorter interval between CT and endoscopy. One in five patients had 
completely normal endoscopy and over 90% had a benign diagnosis. Ra-
diological reporting of fat stranding was an independent risk factor for 
endoscopic colitis. Anaemia and raised CRP helps identify those at higher 
risk of malignancy whilst raised CRP alone shows a trend towards identify-
ing true colitis. We conclude that the findings of ‘colitis’ on CT does not 
imply IBD in the majority.
disclosure: Nothing to disclose 
P0966 usefuLness Of sLIM fuLLy-cOvered seLf-exPandaBLe 
MeTaL sTenT fOr unresecTaBLe hILar MaLIgnanT BILIary 
OBsTrucTIOn
Fujisawa T.1, Ushio M.1, Takahashi S.1, Yamagata W.1, Takasaki Y.1, 
Suzuki A.1, Ito K.1, Ochiai K.1, Okawa Y.1, Tomishima K.2, Ishii S.3, 
Saito H.1, Isayama H.3
1Juntendo University Gaduate School of Medicine, Department of 
Gastroenterology, Tokyo, Japan, 2Juntendo University, Department of 
Gastroenterology, Tokyo, Japan, 3Juntendo University, Gastroenterology, 
Tokyo, Japan
contact e-Mail address: tossshy@yahoo.co.jp
Introduction: Endoscopic treatment for unresectable hilar malignant bili-
ary obstruction is still difficult because intrahepatic biliary branches were 
independent of each other, and a standard treatment has not been estab-
lished yet. We have been using slim fully-covered self-expandable metal 
stent (SFCSEMS) side-by-side placement method, and examined the use-
fulness of this method.
aims & Methods: A retrospective study was conducted on unresectable 
hilar malignant biliary obstruction in which SFCSEMS (6mm in a diam-
eter) were placed between December 2016 and April 2019 in our hospital. 
Recurrent biliary obstruction (RBO), prognosis, and adverse events were 
analyzed according to Tokyo criteria 2014.
results: The subjects were 31 cases with first metal stent placement (19 
men, average age 69.4 years), primary diseases were 10 cases of chol-
angiocarcinoma, 8 cases of gallbladder cancer, 2 cases of hepatocellular 
carcinoma, 11 cases of metastatic tumor. The subjects include many cases 
in advanced status of the cancer, 37% of cases with performance status 
(PS) 3 or higher, and 70% of cases with Bismuth classification 3 or higher. 
Single SFCSEMS was placed in 2 cases, two SCSEMS in 24 cases and three 
in 4 cases with 100% of technical success rate. The clinical success rate was 
90% (27/30), and all three failure cases were PS 3 or more and Bismuth 4, 
all of which were considered to be in liver failure. Stent removal was at-
tempted in all 12 cases in which RBO was occurred during the course, and 
all of them could be removed without any adverse events. After removal, 
the SFCSEMS was reinserted in 6 of 12 cases and changed into plastic stents 
in 5 cases, and EUS-guided hepaticogastrostomy in 1 case. Median time to 
RBO was 128 days, and survival was 114 days. adverse events related with 
the deployment procedure was only 2 cases (6.7%) in 1 case of mild pan-
creatitis and 1 case of cholangitis. Pancreatitis was conservatively treated 
and cholangitis was improved by adding another metal stent to the cause 
biliary branch which was obstructed by SFCSEMS.
conclusion: The slim fully-covered SEMS with 6mm diameter is considered 
to be an effective method because it is easy to remove, and patency is 
equal to or more than that of other methods, and there are few incidents.
disclosure: Nothing to disclose 
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P0967 BILaTeraL MeTaL versus PLasTIc sTenTIng fOr 
PaLLIaTIOn Of jaundIce In PaTIenTs WITh unresecTaBLe 
carcInOMa gaLLBLadder
Kumar A., Rai P.
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Gastroenterology, 
Lucknow, India
contact e-Mail address: ashok110@gmail.com
Introduction: Gall Bladder Cancer (GBC) is one of the most common bili-
ary malignancy and frequently presents as locally advanced disease with 
jaundice. Most of these patients cannot undergo curative surgical resection 
and need palliative biliary stenting for biliary decompression. Endoscopic 
biliary drainage is well established modality for palliation of malignant 
lower end biliary obstruction, but it is technically challenging for hilar bili-
ary strictures. Plastic stents (PSs) have been widely used, but Self Expand-
ing Metal Stents (SEMSs) are becoming increasingly popular. However, 
the previously published studies have been heterogenous with regard to 
underlying disease pathology (GBC, cholangiocarcinoma and others), level 
of malignant block (varying from I-IV Bismuth classification) and type of 
biliary system drainage (unilateral or bilateral).
aims & Methods: This study aimed to determine the safety and efficacy of 
plastic or metal stent deployment in a homogenous population of patients 
with type II (Bismuth classification) malignant hilar block due to unresect-
able gall bladder cancer.
Records of all patients with Gall Bladder cancer with hilar block who un-
derwent endoscopic biliary drainage at our tertiary-care center between 
January 2013 and December 2018 were analyzed for the following outcome 
parameters: technical success (TS), functional success (FS), early and late 
complications, stent patency and survival. Patients were followed from 
stent insertion until death or stent occlusion.
results: A total of 71 patients were evaluated, of whom 60 [mean age of 
54.2 years (range: 34-79) years; men 26, women 34] underwent bilateral 
stent placement. Twenty seven patients had SEMS placed and 33 patients 
had plastic stents (PS) placed. TS was achieved in 33(100%) patients 
treated with PS and in 25(92.6%) patients palliated with SEMS. SEMS 
provided significantly higher success of biliary drainage as compared to 
plastic stents, on both intention to treat (81.4% vs 57.6%, p=0.019) and 
per protocol analysis (88.0% vs 57.6%, p=0.019) with a lower number of 
ERCP procedures (1 vs 1.58) and lower complication rates (22.2% vs 39.4%) 
compared with PS. SEMS remained patent for a significantly longer dura-
tion than PS [122.6 days (range 25-219) vs. 25(0-94) days, respectively, p= 
0.000]. Thirty days mortality was higher (but statistically insignificant) in 
the PS group as compared to SEMS group [18.2% vs.7.4% days, respec-
tively, p= 0.222]. Use of metal stents was associated with a significantly 
longer median survival time [126.0 days (3-266)] than in patients treated 
with PS [87.9 days (9-291), p= 0.000].
conclusion: SEMS should be preferred over plastic stents for palliation of 
jaundice in malignant hilar block due to unresectable gall bladder cancer 
because of better adequacy of biliary drainage, higher stent patency and 
patient survival with lower complication rates and reduced number of total 
ERCP procedures with SEMS.
references: 1. Liberato MJ, Canena JM. Endoscopic stenting for hilar chol-
angiocarcinoma: efficacy of unilateral and bilateral placement of plastic 
and metal stents in a retrospective review of 480 patients. BMC Gastroen-
terol 2012; 12:103. 2. Perdue DG, Freeman ML, Lee JG, et al. Plastic versus 
self-expanding metallic stents for malignant hilar biliary obstruction: a 
prospective multicenter observational cohort study. J Clin Gastroenterol 
2008; 42:1040-1046. 3. Raju RP, Jaganmohan SR, Ross WA, Davila ML, Raju 
GS, et al. Optimum palliation of inoperable hilar cholangiocarcinoma: 
comparative assessment of the efficacy of plastic and self-expanding metal 
stents. Dig Dis Sci 2011; 56:1557-1564. 4. Mukai T, Yasuda I, Nakashima M, 
Doi S, Iwashita T, Iwata K, et al. Metallic stents are more efficacious than 
plastic stents in unresectable malignant hilar biliary strictures: a random-
ized controlled trial. J Hepatobiliary Pancreat Sci 2013; 20:214-222. 5. Wag-
ner HJ, Knyrim K, Vakil N, Klose KJ. Plastic endoprostheses versus metal 
stents in the palliative treatment of malignant hilar biliary obstruction. A 
prospective and randomized trial. Endoscopy 1993; 25:213-218. 6. Sangchan 
A, Kongkasame W, Pugkhem A, Mairiang P. Efficacy of metal and plastic 
stents in unresectable complex hilar cholangiocarcinoma: a randomized 
controlled trial. GastrointestEndosc 2012; 76:93-99.
disclosure: Nothing to disclose 
P0968 feasIBILITy Of endOscOPIc uLTrasOund-guIded 
BILIary draInage rePLaceMenT Of PercuTaneOus 
TranshePaTIc BILIary draInage
Morita S.1, Hoshi T.1, Abe S.1, Yagi K.1, Suda T.1, Terai S.2
1Uonuma Institute of Community Medicine Niigata University Hospital, 
Gastroenterology and Hepatology, Minamiuonuma City, Niigata, Japan, 
2Graduate School of Medical and Dental Sciences, Niigata University, 
Gastroenterology and Hepatology, Niigata, Japan
contact e-Mail address: m0riz0u@extra.ocn.ne.jp
Introduction: Percutaneous transhepatic biliary drainage (PTBD) for ma-
lignant biliary obstruction is a useful alternative treatment for patients in 
whom endoscopic transpapillary drainage is difficult to perform. We ex-
amined the feasibility of endoscopic ultrasound-guided biliary drainage 
(EUS-BD) replacement of PTBD for internalization of biliary drainage.
aims & Methods: This single-center retrospective study reviewed records 
of patients who had undergone EUS-BD replacement of PTBD between 
March 2017 to April 2019. We evaluated technical success; procedure time; 
clinical success, defined as subsequent removal of percutaneous catheter; 
adverse events; time to recurrent biliary obstruction; and reintervention.
results: EUS-BD (EUS-hepaticogastrostomy in 9 and EUS-choledochodu-
odenostomy in 2) was performed in 11 patients (9 males, mean age 82 
years) to replace PTBD. The median period from PTBD placement to EUS-
BD was 8 (range, 3-34) days. Technical success was achieved in all cases. 
The mean procedure time was 44.0 ± 17.1 min. There were two early ad-
verse events, bile peritonitis in one and acute cholangitis in one. Both con-
ditions were improved with only antibiotic administration. Clinical success 
was achieved in all cases with PTBD catheter removal after a median of 7 
(range, 1-52) days. Median time to recurrent biliary obstruction was 100 
(26-357) days. Reintervention was performed in 6 patients. Five patients 
were exchanged for the new stent endoscopically, and one was required 
reinsertion PTBD.
conclusion: EUS-BD replacement of PTBD for internalization of biliary 
drainage is a feasible, effective and safe techniquefor patients in whom 
endoscopic transpapillary drainage is difficult. At the time of reinterven-
tion, reinsertion PTBD is not required in most cases and an endoscopic 
approach is possible.
disclosure: Nothing to disclose 
P0969 The usefuLness Of nOn-fLared shOrT fuLLy 
cOvered MeTaLLIc sTenT fOr refracTOry BenIgn PancreaTIc 
sTrIcTures In advanced chrOnIc PancreaTITIs
Lee Y.N.1, Moon J.H.1, Park J.K.1, Cho S.1, Lee T.H.2, Cha S.-W.3, Cho Y.D.3, 
Park S.H.2
1Digestive Disease Center and Research Institute, Department of Internal 
Medicine, SoonChunHyang University School of Medicine, Bucheon, Korea 
(Republic of), 2Digestive Disease Center and Research Institute, Department 
of Internal Medicine, SoonChunHyang University School of Medicine, 
Cheonan, Korea (Republic of), 3Digestive Disease Center and Research 
Institute, Department of Internal Medicine, SoonChunHyang University 
School of Medicine, Seoul, Korea (Republic of)
contact e-Mail address: yunnah@schmc.ac.kr
Introduction: Fully covered self-expandable metallic stent (FCSEMS) have 
been used recently to treat refractory benign pancreatic stricture in ad-
vanced chronic pancreatitis. However, stent migration and stent-induced 
ductal change are main limitations. The aim of this study was to evaluate 
the usefulness of non-flared short FCSEMS that was designed to minimize 
ductal injury and migration for refractory pancreatic stricture in advanced 
chronic pancreatitis.
aims & Methods: Total 25 consecutive patients with symptomatic benign 
pancreatic duct strictures that was unresolved with plastic stents were pro-
spectively enrolled between August 2012 and July 2018. A short (3 or 5 cm) 
FCSEMS having long lasso (7 cm) used in this study has non-flared convex 
ends to minimize tissue hyperplasia and smaller center portion to prevent 
migration. The FCSEMS placement (intraductal or transpapillary) was per-
formed across the stricture and removal was performed after 3 months.
results: The technical and clinical success rates of FCSEMS placement (14 
intraductal and 11 transpapillary stenting) were 100% (25/25), respectively. 
Stent migration was observed in 1 patients (4.0%) but improved stricture 
and not needed for additional intervention. Intended stent removal was 
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successful in 24 patients (100%) (median duration of stenting, 109 days; 
interquartile range, 91‒126). Follow-up ERCP showed resolution of duct 
strictures in all patients. Stent-induced ductal change was not observed in 
all patients. Stricture recurrence was observed in 8.0% (2/25) during 665 
days of median duration of follow-up (interquartile range, 437‒1244).
conclusion: Non-flared short FCSEMS may be potentially effective option 
for refractory pancreatic stricture in advanced chronic pancreatitis with 
minimizing stent-induced ductal injury and stent migration.
disclosure: Nothing to disclose 
P0970 InTraducTaL PLaceMenT Of nOn-fLared fuLLy 
cOvered MeTaLLIc sTenT fOr refracTOry anasTOMOTIc BILIary 
sTrIcTures afTer LIvIng dOnOr LIver TransPLanTaTIOn: 
LOng-TerM resuLTs Of PrOsPecTIve MuLTIcenTer TrIaL
Moon J.H.1, Lee Y.N.1, Yoo J.-J.1, Park J.K.1, Cho S.1, Lee J.-K.2, Lee K.T.2, 
Lee K.H.2, Lee W.J.3, Woo S.M.3, Lee T.H.4, Park S.-H.5
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(Republic of), 2Samsung Medical Center, Sungkyunkwan University School 
of Medicine, Department of Internal Medicine, Seoul, Korea (Republic 
of), 3Pancreatobiliary Cancer Clinic, National Cancer Center, Ilsan, 
Korea (Republic of), 4Digestive Disease Center and Research Institute, 
Soonchunhyang University School of Medicine, Department of Internal 
Medicine, Cheonan, Korea (Republic of), 5Digestive Disease Center and 
Research Institute, Soonchunhyang University School of Medicine, Cheonan, 
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Introduction: Fully covered self-expandable metallic stent (FCSEMS) may 
be an effective modality for managing anastomotic biliary stricture (ABS) 
after liver transplantation. However, stent migration and stent-induced 
ductal injury are main limitations. The objective of this study was to evalu-
ate the usefulness of an unflared, intraductal FCSEMS that was designed to 
minimize migration and ductal injury for refractory ABS after living donor 
liver transplantation (LDLT).
aims & Methods: A total of 32 consecutive patients with symptomatic ABS 
after LDLT unresolved by plastic stents with or without balloon dilation at 
four tertiary medical centers were prospectively enrolled in this study. A 
short (3 or 5 cm) FCSEMS having long lasso (10 cm) used in this study had 
unflared convex ends to minimize tissue hyperplasia and smaller center 
portion to prevent migration. The FCSEMS was placed above the papilla in 
all patients and removed at 3-4 months after stenting.
results: Technical and clinical success rates of intraductal placement with 
FCSEMS were 100% (32/32) and 81.2% (26/32), respectively. Early stent 
migration was observed in 5 (15.6%) patients. However, 3 patients with 
early stent migration had stricture resolution without needing additional 
intervention. Intended stent removal was successful in 27 (100%) patients 
(median, 101 days; range, 23‒118 days). No stent-induced ductal change 
was observed in all patients. Stricture recurrence was observed in 11.5% 
(3/26) of patients during 639 days of median duration of follow-up (range, 
366‒2079 days).
conclusion: Intraductal placement of an unflared short FCSEMS may be a 
promising option for refractory ABS after LDLT with minimal stent-induced 
ductal injury and stent migration.
disclosure: Nothing to disclose 
P0971 InTraducTaL PLasTIc sTenT PLaceMenT Is an 
effecTIve TheraPy fOr unresecTaBLe MaLIgnanT BILIary 
OBsTrucTIOn
Yamaguchi A., Wada K., Moriuchi R., Tao K., Konishi H., Miura R., 
Tamaru Y., Kusunoki R., Kuwai T., Kouno H., Kouno H.
Kure Medical Center and Chugoku Cancer Center, Gastroenterology and 
Hepatology, Kure, Japan
contact e-Mail address: yamaguchia@kure-nh.go.jp
Introduction: Recent reports have described the efficacy of plastic stent 
(PS) placement inside the bile duct for malignant biliary strictures. How-
ever, the superiority of intraductal PS placement (IS) over PS placement 
across the sphincter (conventional PS placement [CS]) and uncovered me-
tallic stent placement above the sphincter of Oddi (MS) is unclear.
aims & Methods: The aim of this study was to evaluate the efficacy of IS, 
and compare its efficacy with the efficacies of CS and MS for malignant 
biliary strictures. This retrospective study included 40 patients (43 proce-
dures) with an unresectable malignant hilar or middle bile duct obstruc-
tion, who underwent IS between January 2008 and December 2018 at our 
institution. The indication for IS was a distance of at least 3 cm between the 
lower end of the stricture and the sphincter. We compared the efficacy of IS 
with the efficacies of CS (34 patients [46 procedures]) and MS (21 patients 
[21 procedures]). Among the 40 patients who underwent IS, the origins 
of the malignant biliary stricture were gallbladder cancers in 10 patients, 
intrahepatic cholangiocarcinomas in 11patients, bile duct cancers in 6 pa-
tients, pancreatic cancers in 3 patients, and others in 10 patiets. We evalu-
ated complications associated with stent placement, the Time to recurrent 
Biliary Obstruction (TRBO), and stent removability at occlusion. We modi-
fied a 7-Fr Flexima biliary stent (Boston Scientific Co., Boston, MA) and 
attached a nylon thread (size 2/0) to the distal end for removal. If insertion 
was difficult due to winding or narrowing of the intrahepatic bile duct (ex. 
B3 and B6), we placed a Flexima nasobiliary drainage tube(7.5Fr), cut to 
the appropriate length, as an internal stent. Most stent placements were 
performed after preoperative nasobiliary drainage.
results: The overall technical success rates in the IS, CS, and MS groups 
were all 100%. The TRBO was greater in the IS group than in the CS group 
(117 days vs. 45 days, P < 0.001, log-rank test); however, the TRBO was not 
significantly different between the IS and MS groups (117 days vs. 139days, 
P = 0.57). The predictive factors of longer TRBO in plastic stents were IS 
(vs CS), usage of anti-cancer drugs, and multiple stents replacement in 
univariate analysis and was IS in multivariate analysis (P< 0.001, Cox’s 
propotional hazards model). 
In the IS group, there were no early complications associated with stent 
placement; however, delayed complications were observed in 4 patients 
from this group (3 had cholecystitis and 1 had stent migration to the he-
patic side). Additionally, in the IS group, 19 patients developed stent dys-
function. The causes of dysfunction were sludge or food deposition in 14 
patients, reflux cholangitis in 1 patient, bending of the stent in 1 patient, tu-
mor overgrowth in 1 patient, dislocation to the duodenal side in 1 patient, 
and migration to the hepatic side in 1 patient. In 14 patients from the IS 
group, stent replacement was attempted and was performed successfully. 
There were no complications associated with stent removal.
conclusion: The TRBO is longer with IS than with CS for malignant bili-
ary obstruction. Additionally, the TRBO tends to be shorter with IS than 
with MS; however, the difference might not be significant. Additionally, 
complications are relatively minor with IS, and the stent can be removed 
if dysfunction occurs. Therefore, IS is an effective option for unresectable 
malignant hilar and middle bile duct obstructions, and it is as effective 
as MS.
disclosure: Nothing to disclose 
P0972 InnOvaTIOn Of eus-guIded TransMuraL draInage 
usIng a nOveL seLf-exPendIng MeTaL sTenT
Chun J.W.1, Choi J.H.2, Huh G.3, Lee S.H.3, Paik W.-H.4, Ryu J.-K.3, Kim Y.-T.5, 
Jeong S.6, Lee D.-H.7, Kim G.H.8, Kang S.-G.9
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Korea (Republic of), 6Inha University Hospital, Internal Medicine, Incheon, 
Korea (Republic of), 7Inha University Hospital, Incheon, Korea (Republic of), 
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Introduction: Endoscopic ultrasonography (EUS)-guided transmural drain-
age has been accepted as a modality of choice for pancreatic fluid collec-
tions and gallbladder (GB) drainage. Double pigtail plastic stents, conven-
tional tubular-shaped self-expanding metal stents (SEMS), and recently 
introduced lumen apposing metal stents (LAMS) are commonly used for 
this procedure. 
However, each type of stent has its own disadvantages; plastic stent is 
prone to occlusion due to its small diameter, fully covered SEMS has a 
higher risk of migration, and LAMS has been reported to cause serious 
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adverse events such as bleeding and buried LAMS syndrome. There are 
still unmet needs in dedicated stents for transluminal drainage despite the 
ongoing developments.
aims & Methods: This animal study aims to evaluate a newly designed 
fully covered metal stent with dual coiled ends for the transluminal drain-
age. We performed the EUS-guided GB drainage with a newly developed 
metal stent in 8 mini pigs with surgically induced GB distension. This stent 
is a SEMS with coiled ends, which is made of nitinol wire and fully covered 
with silicone. The diameter of the stent is 8mm and the length is 6cm. Both 
pigtail ends are coiled 360 degrees in order to minimize the risk of bidi-
rectional migrations. EUS-guided GB drainage was performed as follows; 
First, GB was punctured with a 19-gauge needle under direct sonographic 
visualization from the stomach. A guidewire was inserted through the ac-
cess needle and coiled inside the GB. Further puncture with a cystotome 
and tract dilatation with a balloon catheter was done, followed by the 
deployment of the stent with an 8Fr delivering catheter under the guid-
ance of fluoroscopy, EUS and endoscopy. After the EUS-guided cholecysto-
gastrostomy was completed, pigs were raised and monitored for certain 
periods before the removal of a stent; 28 days in 2 pigs, 35 days in 2 pigs, 
42 days in 2 pigs, and 49 days in 2 pigs. The primary outcome was techni-
cal success rate and the secondary outcomes were adverse events, stent 
dysfunction, stent removability, and the successful fistula formation.
results: The stent was placed successfully between the gallbladder and the 
stomach without any adverse event in all cases. Neither stent migration 
nor dysfunction was observed during the study period and all the stents 
were removed easily as scheduled. Successful cholecysto-gastric fistula 
formation was confirmed at endoscopic and histologic level in all cases.
conclusion: EUS-guided transmural drainage and fistula formation using 
a new fully covered metal stent with dual coiled ends was technically fea-
sible without any adverse event in this animal study. We expect this newly 
developed stent to be useful in EUS-guided transluminal drainage. Further 
clinical studies on the application of this stent in real practice are needed 
to evaluate the efficacy and safety.
disclosure: Dr. Lee is the inventor of the newly developed metal stent used 
for the study. The stents were provided free of charge and financial support 
was provided for the study by S&G Biotech Inc. 
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a MuLTIcenTrIc sTudy (WITh vIdeO)
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1Humanitas - Mater Domini, Gastrointestinal Endoscopy, Castellanza (VA), 
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contact e-Mail address: b_mangiavillano@hotmail.com
Introduction: Esophageal cancer is the sixth most common cancer world-
wide and in presence of non-surgical candidate presenting dysphagia, the 
placement of a self-expandable metal stent (SEMS) uncovered, partially 
covered (PCSEMS) or fully-covered (FCSEMS) nowadays represent a safe 
and effective palliative treatment for the relief of dysphagia. Esophageal 
stent are placed over-the-wire (OTW), under X-ray control, with or without 
endoscopic assistance during the stent release. Actually, there are no data 
in literature about the use of the new through-the-scope (TTS) esophageal 
stent placed for malignant dysphagia.
aims & Methods: The aim of our study is to evaluate the clinical efficacy 
of the new TTS esophageal stent in this group of patients.35 patients (10F 
and 25M - mean age: 76±9.1ys) with malignant dysphagia unfit for surgery 
undergone TTS esophageal stent placement (Taewoong Medical Co.) were 
retrospectively evaluated. 27 patients presented adenocarcinoma, 6 were 
squamous neoplasia, 1 neuroendocrine tumor and 1 ab-extrinsic compres-
sion by breast cancer limphoadenopathy. Length of stenosis was of 5.6±2.8 
cm. 28 stenosis were located at the III distal esophagus, 6 in the middle 
and 1 in the proximal. 13 stent were of 18mm diameter, 18 of 20mm diam-
eter and 4 of 22 mm. We replaced 10 SEMS, 11 PCSEMS and 14 FCSEMS. All 
of the stents were placed for palliation.
results: All of the 35 of the patients had completely relief od dysphagia, 
starting liquid and solid oral intake 24h after the procedure. No adverse 
events were observed during the stent placement. In one case (2.8%) the 
guide-wire was not used. In 12 patients a submucosal marking of the distal 
part of the stenosis was used (34.2%). 5 distal migration were observed 
(14.7%): 1 PCSEMS after three months of chemotherapy (CT) and 4 FCSEMS 
(28.5% of all FCSEMS), of which 1 after 45 days of CT and 3 at 1, 2 and 5 
days after placement. No technical difficulties were encountered by the 
endoscopists during the stent placement.
conclusion: The efficacy of the new TTS esophageal stent, in the relief of 
malignant dysphagia, is comparable to the standard OTW esophageal stent 
but adverse events seems to be reduced. Migration rate was higher for the 
FCSEMS. TTS esophageal stent allows to reduce procedure’s time and the 
technique seems more simple if compared to the OTW. An antimigration 
system may diminish the migration rate of the FCSEMS.
disclosure: Nothing to disclose 
P0974 equIvaLence In LOng-TerM OncOLOgIcaL OuTcOMes Of 
cOLOnIc sTenTIng as BrIdge TO surgery In cOMParIsOn WITh 
surgery aLOne In sTage II and III LefT-sIded OBsTrucTIve 
cOLOrecTaL cancer
Ishibashi R.1, Yoshida S.1,2, Kondo R.1, Hata M.1, Hakuta R.1, Nakada A.1, 
Takahara N.1, Yamada A.1, Nakai Y.1,2, Koike K.1
1University of Tokyo, Graduate School of Medicine, Department of 
Gastroenterology, Tokyo, Japan, 2University of Tokyo, Endoscopy and 
Endoscopic Surgery, Tokyo, Japan
contact e-Mail address: rei1484@gmail.com
Introduction: Endoscopic stenting with self-expanding metallic stent is 
considered as one of an effective treatment for intestinal decompression in 
obstructive colorectal cancer. However, many physicians remain hesitant 
to perform colonic stenting as bridge to surgery (BTS) in a curative setting, 
since it has been suggested to adversely affect oncological outcomes of 
colorectal cancer patients. The aim of this study is to verify the equivalence 
of colonic stenting to surgery alone for stage II and III left-sided obstructive 
colorectal cancer in long-term oncological outcomes.
aims & Methods: This study was conducted as a retrospective chart review 
at a single institute in Japan. The data of patients who had operable left 
side obstructive colorectal cancer at first diagnosis were collected retro-
spectively from the clinical records of the University of Tokyo Hospital be-
tween 2007 and 2017. We defined obstructive colorectal cancer as the ma-
lignant stricture caused by colorectal adenocarcinoma that a colonoscope 
cannot pass and requires fasting or food restriction allowing only liquid 
food. We compared the patients who received colonic stenting before sur-
gery (Stent group) and who received surgery alone without decompres-
sion treatment (Surgery alone group). Patient characteristics, pathological 
findings, duration of fasting, and duration of recurrent-free survival and 
overall survival were obtained from electric medical record.
results: We identified 364 obstructive colorectal cancer patients during 
this period, of which 114 patients were classified as stage II or III. Among 
them, 23 patients received stent placement for decompression and 91 pa-
tients were received surgery alone. There was no difference between the 2 
groups regarding gender, age and location of primary tumor. There were 
more cases of stage II in the Stent group than in the Surgery alone group 
(65.2 % vs 41.8%, P = 0.04). In pathological findings, although there was 
no statistical difference in the depth of tumor, the Surgery alone group had 
more patients with local lymph node metastasis (49.5 vs 34.8 %, P = 0.04) 
and neural invasion (72.7 vs 42.9 %, P = 0.04). Stent placement was clini-
cally successful in all cases except one, and no perforation were observed. 
Duration of fasting was shorter in stent group (23.6 vs 28.8 days P = 0.03). 
Regarding the long-term oncological outcomes, no statistically significant 
difference was observed in recurrent-free survival or overall survival. In 
multivariate analysis of recurrence, local lymph node metastasis and neu-
ral invasion were risk factors, but stent placement was not identified as a 
risk factor.
conclusion: Stent placement without perforation as a bridge to surgery for 
obstructive colorectal cancer patients does not adversely affect long-term 
oncological outcomes.
disclosure: Nothing to disclose 
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P0975 rIghT-sIded cOLOnIc sTenTIng In PaLLIaTIve cOLOn 
cancer: MOre chaLLengIng BuT LOWer LaTe cOMPLIcaTIOn 
raTe and aT LeasT equIvaLenT survIvaL
Dewar D.H.1, Walker G.1, Engledow A.H.2
1University Hospital Lewisham, Gastroenterology, London, United Kingdom, 
2University Hospital Lewisham, Colorectal Surgery, London, United Kingdom
contact e-Mail address: daviddewar@nhs.net
Introduction: Stent insertion for malignant colonic obstruction is estab-
lished as a palliative measure as well as a bridge to surgery. UK guidelines 
on colorectal cancer (NICE CG131) specifically does not recommend place-
ment of a stent in right-sided malignant large bowel obstruction.
aims & Methods: Patients referred for colonic stenting in our centre over 
a 10-year period up until 2019 were included. Technical and clinical out-
comes, and subsequent progress, including late complications, surgery, 
re-stenting, oncological therapies, and death were recorded. To assess 
the durability of stent benefit, we measured time to re-intervention (re-
stenting, surgery, or death without re-intervention), surgery-free survival 
(to surgery, or death without surgery), and overall survival (to death, ir-
respective of any intervention).
results: 135 stent procedures were undertaken for malignant large bowel 
obstruction - of these 105 cases were index procedures with palliative 
intent, comprising 80 left-sided tumours and 25 right-sided obstructing 
tumours proximal to the splenic flexure. The median age was 74 years 
(range 27-94), and 56% were male. Technical and clinical success rates 
were respectively 90% / 86% for left-sided stents, and 72% / 68% for 
right-sided stent procedures (p=0.04 / p=0.07). There was evidence of 
improving outcomes with time with technical success in 2009-2014 and 
2014-2019 being 81% and 96% for left-sided, and similarly improving from 
60% to 79% for right-sided stents (p>0.05). Reasons for clinical failure 
in left and right-sided stents were inadequate bowel preparation (0% v 
12%), inability to cross stricture with wire (7.5% v 16%), and failure to 
relieve obstruction after satisfactory luminal deployment of stent (5% v 
4%). There were no complications during the stent procedures, but later 
complications requiring surgical intervention were 3 perforations in left-
sided stent cases (day 1, day 27, day 101); 1 patient with an extrinsic cancer 
had early stent migration on day 4; 1 patient developed an abdominal wall 
abscess on day 47; 1 stent occlusion was operated on day 90. Stent migra-
tion was identified in a further 6 left-sided stent patients (day 27 palliated, 
day 123 and day 274 both re-stented; a further 3 patients, all undergoing 
chemotherapy and >6 months post stent, were noted on follow-up CT to 
have incidental stent migration, but no intervention was required). Stent 
occlusion in a further 7 cases required re-stenting at a median of 228 days 
(177 to 498 days). One right-sided patient re-obstructed on day 536 and 
had surgery but no other interventions occurred in this group. Comparing 
left and right-sided stents, overall complication rates in the 12 months after 
stenting were 25% / v 0% (p=0.02), duration of stent benefit was 177 v 320 
days (p=0.07), surgery-free survival 223 v 320 days (p=0.12) and overall 
survival 306 v 320 days (p=0.29). Patients who had a failed palliative stent 
procedure had a median survival of only 75 days (p=0.002), which was not 
related to any complications.
conclusion: Outcome and survival after right-sided colonic stenting ap-
pears at least comparable to left-sided stenting - although technical suc-
cess was statistically lower, there was a lower complication rate in the 12 
months after stent insertion with no re-interventions, compared to 1 in 5 in 
the left-sided group. The survival of right-sided stent patients was not infe-
rior to left-sided stent patients. We believe right-sided stenting should be 
a management option for patients presenting with proximal large bowel 
obstruction and palliative cancer.
references: nice.org.uk/guidance/cg131
disclosure: Nothing to disclose 
P0976 facTOr assOcIaTed TechnIcaL and cLInIcaL faILure 
Of seLf exPandaBLe MeTaL sTenT In MaLIgnanT cOLOrecTaL 
OBsTrucTIOn
Myung D.-S., Kim K.-H., Hong J.-Y., Choi J.-H., Jung M.-W., Joo Y.-E.
Chonnam National University Medical School, Department of Internal 
Medicine, Division of Gastroenterology and Hepatology, Gwangu, Korea 
(Republic of)
contact e-Mail address: myungdaeseong@daum.net
Introduction: Self-expanding metal stents (SEMSs) can be used as a pal-
liative treatment or to decompress colon prior to definitive surgery. The 
purpose of this study was to investigate the factor associated clinical and 
technical Failure of SEMS used as palliation and bridge to surgery for ma-
lignant large bowel obstruction.
aims & Methods: We retrospectively reviewed the records of patients with 
malignant colorectal obstruction who tried SEMS insertion in our hospi-
tal between January 2008 and December 2017. We analyzed demographic, 
clinical characteristics. Technical failure was defined as failure to deploy 
the stent across the colon stenosis site. Clinical failure was defined as the 
absence of resolution of obstructive symptoms and passage of gas and 
stool within 7 days despite achievement of technical success.
results: SEMS were tried in total 466 patients. The indication of SEMS was 
as a bridge to surgery in 225 (48.3%) patients and as palliation in 241 
(51.7%) patients. 83 (17.8%) patients were seen in right colon obstruction. 
383 (82.2%) patients were seen in left colon obstruction. Technical failures 
were found in 50 patients (10.7%). After SEMS insertion, clinical failure 
was found in 23 of 416 patients (5.5%). 
On univariate analysis, the rate of technical failure was high in patients with 
peritoneal carcinomatosis, abdominal pain (Visual Analogue Scale(VAS) 
≥5), abdominal tenderness, C-reactive protein (>4.4mg/dl), fever, pallia-
tive treatment, metastasis. Multivariate analysis revealed that peritoneal 
carcinomatosis(odds ratio: 2.43, 95% CI: 1.22-4.83, p=0.012), abdominal 
pain (Visual Analogue Scale >5) (odds ratio: 3.40, 95% CI: 1.08-10.549, 
p=0.036) were a significant risk factor for technical failure. 
On univariate analysis, the rate of clinical failure was high in patients 
with peritoneal carcinomatosis and elevated White Blood Cell(WBC) 
count(>10800/㎕). Multivariate analysis revealed that peritoneal carcino-
matosis (odds ratio: 3.14, 95% CI: 1.30-7.61, p=0.011) and elevated WBC 
count (odds ratio: 2.55, 95% CI: 1.03-6.33, p=0.043) were a significant risk 
factor for clinical failure.
stent complication (58/466, 12.4%) Treatment for stent complication
Perforation (15/58, 25.9%) operation :13
  supportive care due to poor general condition: 1
  Operation refuse: 1
Migration (26/58, 44.8%) 2nd stent insertion: 11
  operation :13
  observation: 2
Re-stenosis (17/58, 29.3%) operation: 13
  2nd stent insertion: 3
  Treatment refuse: 1
[Stent complication and treatment of complication]
conclusion: Before trying SEMS insertion for malignant colorectal obstruc-
tion, endoscopist must consider patient condition. Patient with peritoneal 
carcinomatosis, abdominal pain (VAS≥5), elevated WBC count is negatively 
impacted outcomes of SEMS placement.
disclosure: Nothing to disclose 
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P0977 anaLysIs Of The rIsk facTOrs cOLOnIc PerfOraTIOns 
In PaTIenTs afTer sTenTIng fOr MaLIgnanT cOLOrecTaL 
OBsTrucTIOn
Vodoleev A.1,2, Duvanskiy V.3, Pirogov S.4, Karpova E.S.5, Perfil’ev I.1, 
Kryazhev D.2, Veselov V.1, Sukhin D.1, Yarotskov I.6
1National Medical Research Center of Radiology, Moscow, Russian 
Federation, 2Eramishantsev Clinical Hospital, Moscow, Russian Federation, 
3RUDN-University, Department of Endoscopy, Endoscopic and Laser Surgery, 
Moscow, Russian Federation, 4P.A. Herzen Moscow Cancer Research Institute, 
Endoscopy, Moscow, Russian Federation, 5Moscow Herzen Research 
Oncological Institute, Moscow, Russian Federation, 6RUDN-University, 
Surgery, Moscow, Russian Federation
contact e-Mail address: asvodoleev@list.ru
Introduction: SEMS implantation is an effective method of decompression 
for patients with malignant colorectal obstruction. However, the use of 
colonic stenting is limited due to relatively high rate of complications. The 
most serious complication is perforation, requiring emergency surgery 
and associated with high mortality and risk of cancer cell dissemination. 
According to publications, rate of perforations is 2-10%, but we have very 
limited and unsystematic data about risk factor of perforations.
aims & Methods: The aim of our research work was to analyze the factors 
influencing the occurrence of various types of perforation after colorec-
tal stenting. We retrospectively carefully studied cases of 197 patients with 
malignant colorectal obstruction who received endoscopic SEMS insertion 
from December 2012 to April 2019. We divided perforations into 2 types: 1) 
perforation of the tumor and / or colonic wall with a stent and perforation 
of the proximal colon segments due to dilatation or ischemic lesion.
results: The technical and clinical success rates were 98.0% and 92.3%. 
After successful procedure, in 11 (5.6%) patients perforation was recog-
nized on 1-20 days. One patient has silent perforation (intraoperative find-
ing), in 1 case - autopsy finding. Severe obstructive symptoms (11-15 points 
on the Colon Obstruction Score (odd ratio 7.2432; 95% confidence interval, 
1.040-28.787) and 0-1 on the CROSS scale odd ratio, (odd ratio 4.439; 95% 
confidence interval, 0.48-0.59) were perforation-related factors for the 
entire sample of cases. Additionally, stage T4b was risk factor of perfora-
tion in first subgroup odd ratio (odd ratio 7.87; 95% confidence interval, 
2.040-12.508), and cecum dilatation on X ray more 10 cm was significantly 
associated with occurrence of perforation in second subgroup (odd ratio 
2.602; 95% confidence interval, 1.279 - 5.634).
conclusion: Severity of obstructive symptoms was significantly associated 
with occurrence of perforation. In order to reduce perforation rate, clini-
cians should pay more attention when performing SEMS placement and 
monitoring patients with these risk factors.
disclosure: Nothing to disclose 
P0978 addITIOnaL surgery afTer cheMOTheraPy fOLLOWIng 
endOscOPIc cOLOnIc sTenTIng In The ManageMenT Of 
OBsTrucTIve cOLOrecTaL cancer WITh dIsTanT MeTasTasIs
Hanabata N.1, Sasaki Y.2, Araki Y.1, Igarashi S.3, Shimaya K.1, Numao H.1, 
Munakata M.1, Fukuda S.4
1Aomori Prefectural Central Hospital, Gastroenterology, Aomori, Japan, 
2Hirosaki University Hospital, Medical Informatics, Hirosaki, Japan, 3Hirosaki 
University, Gastroenterology and Hematology, Hirosaki, Japan, 4Hirosaki 
University,Graduate School of Medicine, Gastroenterology and Hematology, 
Hirosaki, Japan
contact e-Mail address: ohana@pastel.ocn.ne.jp
Introduction: Endoscopic stenting with a self-expandable metallic stent 
(SEMS) in patients with acute large-bowel obstruction due to CRC has been 
established as a palliative therapy or a bridge to surgery with more favor-
able rates of permanent stoma, primary anastomosis, and overall compli-
cations. In the previous study, we demonstrated that when technical and 
clinical successes are achieved by careful SEMS placement, chemotherapy 
under long-term SEMS is a feasible therapeutic option for patients with 
obstructive CRC. However, the outcome of additional surgery after che-
motherapy under long-term SEMS placement has not been investigated.
aims & Methods: The aim of this study was to evaluate outcome of ad-
ditional surgery after chemotherapy following endoscopic colonic stenting 
by comparing that of chemotherapy following stenting without additional 
surgery and that of chemotherapy following surgery.
In total, 68 patients with stage IV CRC who visited the Aomori Prefectur-
al Central Hospital for obstructive symptoms between January 2012 and 
March 2018 were evaluated. In this retrospective study, the patients were 
classified into an SC (stenting before chemotherapy) group (n = 36), com-
prising those who underwent chemotherapy following endoscopic colonic 
stent placement, and an OC (operation before chemotherapy) group (n = 
32), comprising those who underwent chemotherapy following surgery. 
In the SC group, for comparison, the patients were further classified into 
those who did (n = 20) and did not (n = 16) undergo additional surgery. Pa-
tients’ characteristics including age, gender, tumor location, performance 
status, obstructive symptom and prognostic nutritional index (PNI), ad-
verse events and overall survival were evaluated.
results: Patients characteristics in the SC and OC groups
There were no significant between-group differences in age, tumor loca-
tion, performance status, obstructive symptom and PNI. Male to female 
ratio was significantly lower in the OC group (16/16) than in the SC group 
(28/8, p=0.017). 
Patient characteristics in the SC group for those who did and did not undergo 
additional surgery
There were no significant between-group differences in male to female 
ratio, performance status, frequency of tumor locations, and response 
grades to chemotherapy. Patient age was significantly lower in patients 
who underwent additional surgery (62.9) than in those who did not (70.6, 
p< 0.01).
Adverse effects in the SC group
The frequency of procedure-related adverse events occurring after 30 
post-stenting days included perforation (3.1%) at 149 days post-stenting, 
dislodgement and migration (21.9%) at 84 days post-stenting, and re-ob-
struction (12.5%) at 98 days post-stenting.
Overall survival
There was no significant difference in overall survival between the SC and 
OC groups (p = 0.371). In the SC group, patients who underwent additional 
surgery had an improved survival compared with those who did not (p < 
0.001) and those in the OC group (p = 0.027). Furthermore, in the SC group 
receiving additional surgery, 8 patients with PNI increase before and after 
stenting had an improved survival compared with 12 patients without PNI 
increase (p < 0.001).
conclusion: In the SC group, additional surgery was found to significantly 
improve overall survival which can be predicted by PNI evaluated before 
and after stenting. We conclude that chemotherapy under long-term SEMS 
with additional surgery is a feasible therapeutic option for patients with 
obstructive CRC.
disclosure: Nothing to disclose 
P0979 The rOLe Of eus-guIded gasTrOenTerOsTOMy In The 
TreaTMenT Of MaLIgnanT gasTrIc OuTLeT OBsTrucTIOn
Kastelijn J.1, Moons L.M.G.1, Garcia-Alonso F.J.2, Pérez-Miranda M.3, 
Masaryk V.4, Will U.4, Tarantino I.5, van Dullemen H.6, Bijlsma R.7, 
Poley J.W.8, Vleggaar F.P.9
1University Medical Center Utrecht, Gastroenterology and Hepatology, 
Utrecht, Netherlands, 2Hospital Universitario Río Hortega, Valladolid, Spain, 
3Hospital Universitario Rio Hortega, Gastroenterology, Valladolid, Spain, 
4SRH Wald-Klinikum, Gastroenterology and General Internal Medicine, 
Gera, Germany, 5ISMETT, Gastroenterology, Palermo, Italy, 6University 
Medical Centre Groningen, Gastroenterology and hepatology, Groningen, 
Netherlands, 7Martini Ziekenhuis Groningen, Groningen, Netherlands, 
8Erasmus University Medical Center, Rotterdam, Netherlands, 9Univ. 
Medisch Centrum Utrecht, Gastroenterology and Hepatology, Utrecht, 
Netherlands
contact e-Mail address: j.b.kastelijn@umcutrecht.nl
Introduction: In patients with malignant gastric outlet obstruction (mGOO) 
and an expected survival of at least six weeks, surgical gastrojejunostomy 
(sGJJ) seems favoured over duodenal stenting. (SUSTENT-study; Jeurnink 
et al, 2010). There is accumulating evidence that EUS-guided gastroenter-
ostomy (EUS-GE) could be an effective and safe alternative treatment of 
mGOO. It is minimally invasive with fast relief of complaints, like duode-
nal stenting, but it also has the potential of low reintervention rates and 
long-lasting patency, like sGJJ. However, the exact role of EUS-GE in the 
management of mGOO remains unclear and evidence about its long-term 
durability is limited. We therefore aimed to evaluate the long-term patency 
of EUS-GE.
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aims & Methods: We performed an international, multicentre retrospective 
analysis of EUS-GE cases that were performed between 2015 and 2019 in 
six centres from four European countries. All cases concerned EUS-guided 
placements of a Hot AXIOS Stent (Hot AXIOS™ Stent and Electrocautery-
Enhanced Delivery System, Boston Scientific Corporation, USA), as pallia-
tive treatment for mGOO, regardless of the cancer etiology. Data on patient 
and procedural characteristics were recorded. Endpoints were: 
1. Technical success (defined as a successful placement of the Hot AXIOS 
stent between the stomach and an intestinal or duodenal loop), 
2. Clinical success (defined as the ability to tolerate a liquid diet without 
vomiting after a technical successful placement of the Hot AXIOS stent), 
3. Long-term patency (defined as the time to recurrence after a technical 
and clinical successful treatment), and 4) adverse events.
results: In total 41 patients (51% female, mean age 69.5 years (range 40-
90)) were included in this study. Most patients were unable to tolerate oral 
intake, with 21/41 (51.2%) having a GOOSS-score of 0. Etiology of mGOO 
included pancreatic cancer (39%), gastric cancer (15%), duodenal cancer 
(7%), periampullary cancer (7%), gallbladder cancer (5%), biliary tract 
cancer (7%), and extrinsic compression by metastases (17%). Ascites was 
present in 14/41 (37%) and peritoneal carcinomatosis in 13/41 (36.1%) pa-
tients. 
The Hot AXIOS stent was placed using the direct technique in 32/41 (78%) 
patients. Balloon assistance was used in the remaining 22%. A 15 mm 
diameter stent was placed in 28/41 (70%) and 20 mm in the remaining 
30%. Additional balloon dilation of the stent was performed in 9 (26.5%) 
patients. 
Technical success was achieved in 35/41 (85%) patients. Stent maldeploy-
ment/misplacement was the sole reason for technical failure (n=6). Clini-
cal success was achieved in 30/35 (86%) of the technical successful cases. 
In 2/30 clinical successful cases, recurrent obstructive symptoms occurred 
after 33 and 283 days of follow-up. Procedural adverse events occurred in 
8 (19.5%) patients which concerned misplacement in seven (four resulting 
in a perforation), and one punction of the colon. Postprocedural adverse 
events occurred in 14 (35%) patients, of which 5 were fatal.
conclusion: The long-term patency of EUS-GE seems good once it is per-
formed successfully and relief of symptoms has been achieved, with re-
current symptoms in only 6.7% of cases. This long-term durability makes 
EUS-GE a possible treatment option for mGOO. The high number of fatal 
complications due to misplacement of the Hot AXIOS stent might be a 
concern.
references: Jeurnink SM, Steyerberg EW, van Hooft JE, van Eijck CH, 
Schwartz MP, Vleggaar FP, Kuipers EJ, Siersema PD; Dutch SUSTENT Study 
Group. Surgical gastrojejunostomy or endoscopic stent placement for the 
palliation of malignant gastric outlet obstruction (SUSTENT study): a mul-
ticenter randomized trial. Gastrointest Endosc. 2010;71(3):490-9
disclosure: Moons: Consultant for Boston Scientific; Perez-Miranda: Con-
sultant & speaker for Boston Scientific, MITech, speaker for Olympus & 
Taewoong; Poley: Consultant for Boston Scientific, Cook and Pentax; Will: 
Consultant for Boston Scientific; Masaryk: Consultant for Boston Scientific; 
Vleggaar: Consultant for Boston Scientific 
P0980 kIssIng suTurIng effecTIve MeThOd fOr Large 
gasTrOInTesTInaL WaLL defecT cLOsure
Liu B.-R., Ahmed M.R., Yang H.
The First Affiliated Hospital of Zhengzhou University, Gastroenterology, 
Zhengzhou, China
contact e-Mail address: bingrongliu@qq.com
Introduction: Endoscopic full-thickness resection (EFTR) has been estab-
lished as a minimally invasive surgical method for en bloc resection. How-
ever, it remains a challenge to safely and efficiently close large defects 
left after the procedure1. Successful closure of the wall defect is the key 
procedure for EFTR technique.
aims & Methods: Our aim was to demonstrate an easy, safe and feasible 
technique which uses a combination of clips and nylon loops to close large 
defects using a single-channel endoscope, called the “Kissing Suturing” 
method. 
We retrospectively studied 35 patients (defect size up to 2 cm in diameter) 
were treated at our hospital with the ‘Kissing Suturing’ method for large 
defect closure resulting from EFTR procedure. After EFTR procedure, a ny-
lon loop of a detachable snare was fixed in the tip of the transparent cap. 
Then, placed the loop in the defect area and used two clips to anchor it 
to the two edges of the defect. Tightening the loop produce two smaller 
defects which could then be closed with clips or following placing ad-
ditional loops.
results: A total of 35 patients (20 male, 15 female) with an average of 57.8 
years old (range, 27-82) were treated with ‘Kissing Suturing’ method for 
large defect closure resulting from EFTR. The mean tumor size was 3.56 
cm (range, 2-7 cm). A successful complete resection rate by EFTR was ac-
complished in 35/35 (100%). The mean defect size was 3.56 cm (range, 
2-7 cm). Complete closure of all post-EFTR defects was succeeded in all 
patients (success rate 100%) with the mean time was 77.62 minute (range, 
13-211 minute). There was no major complication such as peritonitis, de-
layed bleeding or perforation in all patients.
conclusion: This study provides evidence that the use of clips and nylon 
loops with single-channel endoscope namely ‘‘Kissing Suturing’‘ method 
for large defect closure seems to be safe, easy and feasible.
references: 1. Shi D, Li R, Chen W, et al. Application of novel endoloops 
to close the defects resulted from endoscopic full-thickness resection 
with single-channel gastroscope: a multicenter study. Surg Endosc. 2017; 
31:837-842.
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P0981 cOLOnIc sTenT PLaceMenT fOr MaLIgnanT 
OBsTrucTIOn: a sIngLe cenTre uk exPerIence
Ahmed J.1, Sivananthan A.2, Mahmoud-Ahmed S.1, Arshad A.1, David L.1, 
Cope E.1, Lean S.1, Siaw Y.H.1, Oke S.1, Rameshshanker R.1, Postgate A.3
1The Hillingdon Hospitals NHS Trust, Gastroenterology, Uxbridge, United 
Kingdom, 2Imperial College London, Gastroenterology, London, United 
Kingdom, 3St Marks Hospital and Academic Institute, Gastroenterology, 
Uxbridge, United Kingdom
contact e-Mail address: jabedahmed88@hotmail.co.uk
Introduction: Colorectal cancer is the 4th most common cancer in the UK 
with an incidence of 41700 new cases every year. 
Colonic Stenting for malignant obstruction has been used for palliation 
and as a bridge to elective surgery. The 2014 ESGE guidelines cautioned 
use in the latter group due to the risk of upstaging disease. More recent 
ACPGBI position statements suggest lower morbidity in the stent group 
compared with primary resection and survival equivalence.
aims & Methods: To review the use of colonic stenting in malignant ob-
struction at a busy district general hospital against current clinical guide-
lines.
A 5 year retrospective review of patients in whom colonic stenting for ma-
lignant obstruction was attempted (Jan2014-Jan2019). Data were retrieved 
from endoscopy database, radiology reports and discharge summaries.
results: A total of 36 patients (M:F 1:1) were identified. Mean age was 69 
(SD 16, Range 32-97).
The 36 patients can be separated into 25% (9/36) with known colorectal 
cancer who eventually required a stent due to obstructive symptoms and 
75% (27/36) who presented acutely with obstruction with a previously un-
diagnosed colorectal cancer.
47% (17/36) of patients were stented with a view to subsequent surgery. 
53% (19/36) were stented for palliative treatment only.
Known cancer patients average diagnosis to stent time and admission to 
stent times were 243 and 2 days respectively.
Acute first presentation average diagnosis to stent time and admission to 
stent times were 6.23 and 2.53 days respectively.
Stents were placed in the sigmoid colon in 44% (16/36), descending colon 
in 17% (6/36) and splenic flexure in 17% (6/36).
All stents were performed by one of three experienced consultant endos-
copists, in a symptomatic cohort. 
They all had a contrast CT scans confirming the diagnosis and level of 
obstruction prior to the procedure.
No stricture dilatations were performed.
Uncovered Cook Evolution stents were used in all cases, from 6-10cm in 
length.
No patient in the cohort had extra colonic obstruction.
83% of patients had a phosphate enema, 6 patients who had no prep, with 
most reporting a good or satisfactory preparation on endoscopy report.
Only 9 of the 17 patients who were stented with a view to surgery pro-
ceeded to surgery. In the remaining 8 out of 17 a decision was made not 
to have surgery or no information was available. None of the proximal 
lesions which were stented had a subsequent resection.
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Repeat CT imaging was performed on average 97.8 days after stent inser-
tion.
The average time to elective surgery from stent insertion was 27.33 days 
(13-39 days).
35/36 stents attempted were successful on first attempt with remaining 
case succeeded on second attempt.
Stent complications were: 1 stent related perforation which occurred 4 
days post insertion for a palliative indication and a partial stent obstruc-
tion managed conservatively. 
47% (17/36) of patients died with an average stent to death time of 209 
days. 11 of these had been stented with palliative intent whilst 6 had been 
stented with a view to subsequent surgery.
conclusion: 1. Colonic Stenting for malignant obstruction has a high suc-
cess rate, and a low morbidity and mortality rate. 
2. It can provide long-term relief of obstruction in palliative patients, or 
provide a bridge to elective surgery.
3. The use of stenting as a bridge to surgery in potentially curable patients 
remains controversial but appears to be a reasonable and safe option in 
experienced hands.
disclosure: Nothing to disclose 
P0982 LaMs In afferenT LIMB syndrOMe ManagMenT
El Bacha H.1, Leblanc S.2, Doat H.3, Savier H.3, Dousset H.4, Soubrane O.5, 
Prat H.6
1Hopital Ibn Sina / Université Mohamed V / Faculté de Medecine, 
Gastroenterologie et Hepatologie, Rabat, Morocco, 2CHU COCHIN Dept. of 
Gastroenterology, Paris, France, 3Hopital Pitie Salpetriere, Paris, France, 
4Hopital Cochin, Paris, France, 5Hopital Beaujon, Paris, France, 6Hôpital 
Cochin Dept. of Gastroenterology, Paris, France
contact e-Mail address: elbachahicham@hotmail.fr
Introduction: Afferent limb syndrome (ALS) or Afferent loop syndrome is a 
late postoperative complication of duodenopancreatectomy defined as the 
dilatation of the afferent limb with accumulation of biliopancreatic fluid 
due to the mechanical obstruction of the afferent limb usually by cancer 
recurrence . ALS can cause abdominal pain pancreatitis and reflux cholan-
gitis. Standard treatment is surgery , but in patient in bad shape surgery is 
an invasive treatment carrying its own morbidity and mortality.
We present here an endoscopic technic for ALS managment.
aims & Methods: We present here five cases of ALS treated by endoscopic 
entero-anastomosis by Lumen apposing metal stents (LAMS).The aim 
of the technique was to obtain an internal drainage of the afferent limb 
through the stomach or jejunum by creating an endoscopic anastomosis. 
The gastroenterostomy or enteroenterostomy was created under endo-
scopic ultrasound (EUS) and fluoroscopic guidance.
results: All procedures were successful with no related complications, two 
patients had a complete regression of their symptoms, one experienced 
cholangitis recurrence after 3months, two patients died after some weeks 
due to their malignancies.
conclusion: EUS-guided entero-enterostomy by LAMS offers a convenient 
and safe palliative solution for patients presenting ALS due to progressive 
malignancy after duodenopancreatectomy.
disclosure: Nothing to disclose 
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P0983 LaParOscOPIc surgery fOr achaLasIa: OuTcOMes 
Of 572 cOnsecuTIve cases In jaPan
Fukushima N.1, Yano F.1, Omura N.2, Tsuboi K.1, Hoshino M.2, 
Yamamoto S.2, Akimoto S.2, Masuda T.1, Mitsumori N.2, Kashiwagi H.2, 
Yanaga K.2
1Jikei University School of Medicine, Surgery, Tokyo, Japan, 2Jikei University 
School of Medicine, Tokyo, Japan
contact e-Mail address: naoko9037@gmail.com
Introduction: Laparoscopic Heller-myotomy with Dor-fundoplication (LHD) 
is the most common surgical treatment for achalasia. Recent development 
of surgical equipment allows less invasive procedures such as reduced 
port surgery (RPS) and needlescopic surgery (NS), providing a better cos-
metic results. All these techniques are available in our tertiary referral 
hospital in Japan. The aim of this study is to explore the outcomes of LHD 
including RPS and NS based on a large cohort of 572 patients diagnosed 
with achalasia.
aims & Methods: All patients diagnosed with achalasia are entered into a 
prospectively maintained institutional database. After Institutional Review 
Board approval, we queried this database to identify patients who under-
went LDH between August 1994 and May 2018. Of these, 572 patients who 
were followed at our clinic at least 3 months after surgery were included. 
The mean age was 45.6 years and 279 patients were women. The follow-
ing characteristics were explored in this study: surgical procedure, opera-
tive time, blood loss, number of intraoperative complications, length of 
postoperative hospital stay, prevalence of postoperative reflux esophagitis, 
prevalence of esophageal stenosis requiring endoscopic balloon dilation, 
and degree of patients’ satisfaction for LHD scored from 1 (disappointed) to 
5 (excellent) based on postoperative interview.
results: Based on Japan Esophageal Society classification of esophago-
gram, 453 patients had straight esophageal type, 76 patients had sigmoid 
type, 26 had advanced sigmoid type, and data unavailable in 17 patients. 
The average maximum esophageal transverse diameter was 5.1±1.6 
(range, 10 to 12.5) cm grade I in 74, grade II in 327, grade III in 149, and 
data unavailable in 22 of them. 50 patients (9%) underwent RPS, and 
NS was performed in 42 (7%) patients. The average operative time was 
174.8 ± 46.2 (range, 67-447) min and median blood loss was 0 ml. Intraop-
erative complications were observed in 98 patients (17%), which included 
mucosal injury on the esophagus and/or stomach in 84, the vagus nerve 
injury in six, piriform fossa injury in two, small intestine injury in one, and 
splenic injury in one patient, respectively. None but one patient (0.1%) 
with splenic injury required open conversion. Duration of postoperative 
hospital stay was 5.3 ± 3.0 (range, 3-35) days, postoperative reflux esopha-
gitis was noted in 70 patients (12%), and endoscopic esophageal dilation 
was required in 7 patients (1%) due to outflow obstruction. Four patients 
(0.7%) underwent reoperation at 7 to 63 (mean 30 month) months after 
the primary surgery for postoperative stenosis, dislocation of the wrap, 
and delayed perforation of the small intestine. Satisfaction score for symp-
tomatic relief was 4.7±0.6.
conclusion: The rate of intraoperative complications of LHD for esophageal 
achalasia was relatively high, though most of them did not require open 
conversion. LHD had reasonable perioperative outcomes with excellent 
symptomatic relief.
disclosure: Nothing to disclose 
P0984 LOng-TerM quaLITy Of LIfe afTer TOTaL gasTrecTOMy 
versus IvOr LeWIs esOPhagecTOMy
Jezerskyte E.1, Saadeh L.M.2, Hagens E.R.C.1, Sprangers M.A.G.3, 
Noteboom L.1, van Laarhoven H.W.M.4, Eshuis W.J.1, 
van Berge Henegouwen M.I.1, Gisbertz S.S.1
1Amsterdam UMC (Location AMC), Department of Surgery, Amsterdam, 
Netherlands, 2Veneto Institute of Oncology, Oncological Surgery Unit, 
Padova, Italy, 3Amsterdam UMC (Location AMC), Department of Medical 
Psychology, Amsterdam, Netherlands, 4Amsterdam UMC (Location AMC), 
Department of Medical Oncology, Amsterdam, Netherlands
contact e-Mail address: e.r.hagens@amsterdamumc.nl
Introduction: Surgical treatment for gastroesophageal junction (GEJ) can-
cers is challenging since both a total gastrectomy and an esophagectomy 
can be performed. The preferred treatment is unknown given the scarce 
evidence regarding their effects on surgical morbidity, pathology, long-
term survival and health-related quality of life (HR-QoL). The aim of this 
study was to investigate the difference in long-term health-related quality 
of life in patients undergoing total gastrectomy versus Ivor Lewis esopha-
gectomy in a tertiary referral center.
aims & Methods: From 2014 to 2018, patients with a follow-up of at least 
one year after either a total gastrectomy or an Ivor Lewis esophagectomy 
for GEJ or cardia carcinoma completed the EORTC QLQ-C30 and EORTC 
QLQ-OG25 questionnaires. Problems with eating, reflux and nausea and 
vomiting were chosen as the primary HR-QoL endpoints. The secondary 
endpoints were the remaining HR-QoL domains, postoperative complica-
tions and pathology results.
results: 101 patients with a mean age of 63 years were included, 30 af-
ter gastrectomy and 71 after Ivor Lewis esophagectomy. The response rate 
was 80.2%. Median follow-up was two years (range 12-84 months). Pa-
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tients after total gastrectomy reported significantly more problems with 
eating (p=0.028, 95% CI 0.595-10.137). Reflux and nausea and vomiting 
were not significantly different between the two groups. Of the remaining 
HR-QoL domains odynophagia was significantly worse in the total gastrec-
tomy group (p=0.014, 95% CI 1.010-8.611). After Ivor Lewis esophagectomy 
patients reported significantly more insomnia, choking when swallowing 
and coughing (p=0.021, 95% CI -11.922 - -0.981; p=0.001, 95% CI -9.437 
- -2.466; p=0.000, 95% CI -18.525 - -7.643). No significant difference was 
found in postoperative complications or Clavien-Dindo grade between the 
two groups. Significantly more lymph nodes were resected in esophagec-
tomy group (p=0.008), however, no significant difference in number of 
positive lymph nodes or radicality of surgery was found.
conclusion: In light of the scarce evidence about the difference in long-
term HR-QoL in patients with GEJ or cardia carcinoma undergoing gas-
trectomy or esophagectomy, the results of our study contribute to the pro-
motion of knowledge on this topic. After a follow-up of more than one 
year problems with eating and odynophagia were more common in the 
gastrectomy group and insomnia, choking when swallowing and cough-
ing in the esophagectomy group. No significant difference was found in 
reflux, nausea and vomiting, postoperative complications or radicality of 
surgery. Based on this study it is difficult to determine which procedure for 
GEJ cancer is preferred.
disclosure: Nothing to disclose 
P0985 c-reacTIve PrOTeIn as a PredIcTOr fOr anasTOMOTIc 
Leakage afTer esOPhageaL surgery
Hagens E.R.C., Lam W.C., Eshuis W.J., van Berge Henegouwen M.I., 
Gisbertz S.S.
Amsterdam UMC, Location AMC, University of Amsterdam, Cancer Center, 
Surgery, Amsterdam, Netherlands
contact e-Mail address: e.r.hagens@amsterdamumc.nl
Introduction: Anastomotic leakage following an esophageal resection for 
esophageal cancer is a severe complication, leading to more post-opera-
tive morbidity or even death. CRP is commonly used by surgeons to raise 
suspicion of anastomotic leakage and other infectious complications, but 
optimal cut-off values and diagnostic accuracy are undetermined.
aims & Methods: The aim of this prospective observational cohort study 
was to determine the accuracy and optimal cut-off values of CRP to predict 
anastomotic leakage, and to determine if there is an association between 
the level of CRP and the severity of anastomotic leakage. Consecutive pa-
tients with an esophageal carcinoma scheduled for an esophagectomy 
with gastric tube reconstruction between April 2016 and October 2018 in 
the Amsterdam UMC, location AMC, The Netherlands were included. CRP 
was measured routinely on post-operative day (POD) 3, 5 and 7. Anasto-
motic leakage was assessed and severity was scored according to the ECCG 
classification. Anastomotic leakage was confirmed if a defect or leakage of 
oral contrast was seen on a CT-scan or by endoscopy or if saliva was drain-
ing form the neck incision. The diagnostic accuracy of CRP was assessed 
by receiver operator curve (ROC) analysis. Youden’s index was adopted to 
determine the cut-off value in ROC analysis with highest sensitivity and 
specificity for predicting anastomotic leakage.
results: 200 patients were included in this study. A cervical anastomo-
sis was created in 25 patients, of which 7 (28.0%) developed anastomotic 
leakage. An intrathoracic anastomosis was created in 175 patients of which 
17 (9.7%) patients developed anastomotic leakage. Median CRP levels in 
patients with and without anastomotic leakage were 99 and 188 mg/L on 
day 3, 62 and 154 mg/L on day 5, and 45 and 163 mg/L on day 7, respectively 
(p< 0.001 for all days). POD 5 showed the highest area under the ROC to 
predict anastomotic leakage with a cut-off value of 119.5 mg/L. Severity of 
anastomotic leakage and level of CRP did not significantly correlate with 
each other on postoperative day 3, 5 and 7 (p=0.204, p=0.092 and p=0.161 
respectively). The optimal cut-off value for CRP to predict anastomotic 
leakage or any complication is shown per day in table 1 with the corre-
sponding area under the ROC, sensitivity, specificity, positive predicting 
value and negative prediction value.
conclusion: CRP on POD 5 has the highest diagnostic accuracy to predict 
anastomotic leakage, using a cut-off value of 119.5 mg/L, resulting in a 
negative predicting value of 96% and specificity of 92%. CRP is therefore 
a feasible marker to predict anastomotic leakage. However, larger stud-
ies should be conducted to confirm this finding, also taking other post-
operative days into account.
 
cut-off value 
crP (mg/L)a aucrOc P-value
1 sensitivity 
(%)
specitificy 
(%)
PPv 
(%)
nPv 
(%)
Diagnostic values for prediction of any postoperative complication
CRP POD-3 99.65 0.657 0.000 75 53 72 56
CRP POD-5 119.50 0.688 0.000 34 93 88 48
CRP POD-7 71.90 0.719 0.000 62 73 81 51
Diagnostic values for prediction of anastomotic leakage
CRP POD-3 141.40 0.695 0.004 71 61 19 94
CRP POD-5 119.50 0.801 0.000 71 82 30 96
CRP POD-7 127.85 0.756 0.001 69 79 30 95
a Youden-index, p1 Comparison between AUCROC and reference line, CRP = C-reactive 
protein, POD = postoperative day, NVW = negative predicting value, PVW = positive 
predicting value
[Table 1. Diagnostic values for CRP to detect postoperative complications]
disclosure: Nothing to disclose 
P0986 facTOrs assOcIaTed WITh deLayed gasTrIc eMPTyIng 
In PaTIenTs underWenT dIsTaL gasTrecTOMy fOr gasTrIc 
cancer: are There any PredIsPOsIng gasTrIc MucOsaL 
facTOrs?
Park H.-W.1, Lee S.2, Lee E.J.3
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contact e-Mail address: soluchan@naver.com
Introduction: Postoperative delayed gastric emptying is one of the most 
common problem in the early postoperative period after distal gastrectomy 
and may have effects on the early recovery after surgery.
aims & Methods: We evaluated several clinicopathological features associ-
ated with delayed gastric emptying and the primary aim of this study was 
to investigate whether the preoperative endoscopic findings could be as-
sociated with postoperative delayed gastric emptying. 
A total of 39 patients underwent distal gastrectomy for gastric cancer at 
Seoul Medical Center between August 2016 and December 2018 were col-
lected and reviewed retrospectively. All patients underwent an esopha-
gogastroduodenoscopy for preoperative evaluation and the results were 
reviewed by a single qualified gastroenterologist. The patients underwent 
either open or laparoscopic distal gastrectomy along with D2 lymphad-
enectomy by a single surgeon performed all surgical procedures. And the 
reconstructive procedure was selected based on the tumor location and 
surgeon’s preference among four types of reconstruction methods. And all 
patients also underwent a gastric emptying SPECT/CT in the early postop-
erative period for evaluation of early alimentary limb leakage and remnant 
gastric motility. The relationship between delayed gastric emptying and 
clinicopathological factors was statistically analyzed.
results: Among 39 patients, 26 (66.7%) patients showed delayed gastric 
emptying. An average T1/2 emptying time was 244min. Reflux esophagitis 
was endoscopically detected in 36 patients (92.3%). 35 patients (89.7%) 
had an atrophic gastritis and 13 patients (33.3%) infected with Helicobacter 
pylori. And Helicobacter pylori infection was associated with delayed gas-
tric emptying (p=0.013). Reconstructive procedure was also associated with 
delayed gastric emptying (p=0.011). Billroth I reconstruction showed no 
stasis in comparison to the other reconstruction methods.
conclusion: Helicobacter pylori infection and the type of reconstruction 
following distal gastrectomy seem to be associated with delayed gastric 
emptying after distal gastrectomy.
disclosure: Nothing to disclose 
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P0987 The IncIdence and rIsk facTOrs Of PancreaTITIs 
afTer duOdenecTOMy In faMILIaL adenOMaTOus POLyPOsIs
Mehta N.1, Yoon J.2, Shah R.2, Laguardia L.1, O’Malley M.1, Augustin T.3, 
Mankaney G.1, Church J.4, Kalady M.4, Walsh M.3, Bhatt A.1, Burke C.1
1Cleveland Clinic, Gastroenterology and Hepatology, Cleveland, United States, 
2Cleveland Clinic, Internal Medicine, Cleveland, United States, 3Cleveland 
Clinic, General Surgery, Cleveland, United States, 4Cleveland Clinic, Colorectal 
Surgery, Cleveland, United States
contact e-Mail address: mehtan5@ccf.org
Introduction: Duodenectomy is recommended in patients with Familial 
Adenomatous Polyposis (FAP) with Spigelman stage IV duodenal polypo-
sis to prevent cancer. Pancreticoduodenectomy (PD) (both pylorus-sparing 
and classic), pancreas-sparing duodenectomy (PSD) and segmental duo-
denal resections are all surgical options. PD consists of removal of the 
head of the pancreas, common bile duct, and gallbladder along with the 
duodenum. The anastomosis in PD includes a hepaticojejunostomy and 
pancreaticojejunostomy. A PSD preserves the pancreas and includes anas-
tomoses of the jejunum to the biliary-and-pancreatic-duct complex.
aims & Methods: We aim to evaluate the incidence and risk factors for 
new onset pancreatitis in FAP patients after foregut surgery. We identi-
fied consecutive FAP patients following duodenal resection (PD, PSD, seg-
mental duodenectomy) at Cleveland Clinic, between 05/1992 and 01/2018 
from the David G. Jagelman Inherited Colon Cancer Registries. A history of 
pancreatitis preceding the surgery or those without follow-up data were 
excluded. Medical records were used to determine demographics and risk 
factors for pancreatitis. Pancreatitis was defined as 2 out of 3: i) typical 
symptoms ii) lipase three times the upper limit of normal or iii) radiogra-
phy consistent with pancreatitis.
results: 77 FAP patients (51.9% male) with duodenal resection were iden-
tified. 24 underwent PD, 10 segmental duodenectomy, and 43 PSD [Table 
1]. 10/77 patients (13%) developed new onset, post-surgical pancreatitis. 
7/10 who developed post-surgical pancreatitis had undergone PSD and the 
remainder PD [Table 2]. 2/10 developed pancreatitis perioperatively within 
30 days and 8 developed pancreatitis >30 days after surgery (range: 2-19 
years after surgery). 9/10 required hospitalization for pancreatitis (median 
BISAP score 0, indicating likelihood of mortality at < 1%). 1 death from 
pancreatitis occurred perioperatively (BISAP score 3). Of the 8 with non-
perioperative pancreatitis, 5 developed acute recurrent pancreatitis (4 of 
whom underwent PSD) prior to endoscopic intervention. 6/8 required en-
doscopic retrograde cholangiopancreatography (ERCP) with balloon dila-
tion for stenosis at the pancreaticojejunal (PJ) anastomosis (range: 1-2 ER-
CPs for successful treatment). ERCP was successful at dilating the stenosis 
in 5 of 6 cases. No patients had family history of pancreatitis or significant 
alcohol intake (>2 drinks/day males, >1 drink/day females). 4/10 had his-
tory of cholecystectomy, 1 remotely for gallstones and 3 during PD.
conclusion: FAP patients may develop pancreatitis after duodenectomy. It 
usually occurs years after surgery and commonly due to stenosis at the PJ 
anastomosis which can lead to acute recurrent pancreatitis. Evaluation of 
the PJ anastomosis should be considered for patients that develop pancre-
atitis after duodenectomy to evaluate for stenosis.
disclosure: Nothing to disclose 
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Introduction: Obesity is a worldwide epidemic affecting over 600 million 
individuals. There are several medical treatments for obesity, however, 
their efficacy are limited and most patients regain weight after losing 
it. Still standard bariatric surgery is the most effective method for sus-
tained weight loss with a potential for resolution of over-weight associ-
ated comorbidities. Gastrointestinal symptoms are common in the early 
post-bariatric surgical period making gastroscopy is the main investiga-
tive tool.
aims & Methods: The aim of our study was to assess the yield, effective-
ness and safety of gastroscopy within 3-months post-bariatric surgery 
performed for investigating gastrointestinal symptoms. We performed a 
single retrospective study in EMMS Nazareth Hospital from 2010 to 2018. 
All patients who underwent gastric-bypass (either Roux-en-Y(R-en-Y) or 
Mini-gastric bypass (MGB)) and who had early gastrointestinal symptoms 
were included in the study.
results: Four-hundred and twenty-eight (428) patients were included in 
the study. Among them, 154 patients (36%) underwent R-en-Y surgery 
and 274 patients (64%) underwent Mini-gastric bypass (MGB). Baseline 
characteristics were similar in the two groups. The mean age (years), 
male gender and the BMI were among the R-en-Y group compared to the 
MGB group were 42.3±10.8 vs. 42.8±11.2, 54.3% vs. 53.8% and 41.7±4.7 vs. 
42.3±3.7, respectively (P=NS).
Overall, 39 (9.1%) patients from the all study cohort underwent gastrosco-
py due to upper gastrointestinal tract complaints during the first 3 months 
after surgery. Eighteen (11.6%) patients in the R-en-Y group, and 21 (7.6%) 
patients among the MGB group, P< 0.005. 
The endoscopic findings showed normal surgical anatomy in 14 (35.8%) 
subjects; five patients (27.8%) in the R-en-Y group as compared to 9 patients 
(42.8%) among the MGB (P < 0.005). Erosive esophagitis with suspected 
bile reflux was documented in only one patient (5.5%) among the R-en-Y 
group as compared to 3 patients (14.2%) in the MGB group (P< 0.005). No-
tably, the upper gastrointestinal tract symptoms related gastroesophageal 
reflux disease (GERD) improved only in one patient (the only patient after R-
en-Y), and persisted among all three patients after MGB, despite high dose 
proton pump inhibitors (PPI) for at least 6 months of follow-up. 
Anastomotic stricture, marginal ulcer, functional obstruction due to non-
absorbable sutures and gastro-gastric fistula were observed in 2,3,1,0 pa-
tients (11.1%, 16.7%, 5.5%, 0% respectively) among the R-en-Y patients 
and 2,2,1,1 patient (9.5%,9.5%,4.7%, 4.7% respectively) among the MGB 
group.
A single session of balloon dilation of the anastomotic stricture was suc-
cessfully performed in all 4 patients (2 in each group) with symptomatic 
and endoscopic improvement; moreover, removal of surgical suture was 
successfully performed using endoscopic scissors in 2 patients (one in each 
group) also with complete resolution of patient’s symptoms. 
There were no procedural or sedation related complications reported dur-
ing or after the gastroscopy among all patients who underwent gastros-
copy.
conclusion: Gastrointestinal symptoms in the early post-bariatric surgery 
are common with most endoscopic examination revealing normal surgical 
anatomy. Although gastroscopy is mostly normal in this setting in most 
patients, it is safe and potentially effective in treating these uncommon 
complications.
disclosure: Nothing to disclose 
P0989 endOscOPIc “sucTIOn chaMBer” TO TreaT cOMPLex 
duOdenaL Leaks afTer uPPer gasTrO-InTesTInaL surgery: 
a sIngLe cenTer exPerIence
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Introduction: Leaks from duodenal stump after upper gastrointestinal sur-
gery are difficult to manage and usually require re-do surgery, since con-
servative treatments often fail. 
Vacuum-assisted drainage has been already used in the endoscopic man-
agementof colorectal, esophageal anastomotic leaks and duodenal perfo-
rations [1]. However, it has never been reported to treat leaks from duo-
denal stump.
The use of negative pressure decreases the intraluminal pressure involved 
in the leak formation, induce the collapse of the fistula wall associated 
with granulation tissue formation and draw fluids and secretions away, 
decreasing bacterial load.
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aims & Methods: Here we report our single-center experience on the en-
dotherapy of duodenal stump leaks after upper gastrointestinal surgery 
using an innovative approach. Between January 2016 and December 2018, 
5 consecutive patients (M:F 3:2, mean age: 43 y.o.) were referred to our 
unit for complex dehiscence of the duodenal stump. Previous upper-
gastrointestinal surgery included 3 subtotal gastrectomy with Roux-en-Y 
reconstruction(two for gastric cancer, one for stab wounds); 1 subtotal gas-
trectomy with Braun reconstruction (gastric cancer after liver transplanta-
tion); 1 gastric bypass (for severe obesity). 
All these patients underwent a re-do surgery that failed to repair the in-
testinal leak.
On the basis of our expertise in the treatment of post-surgical adverse 
events [2-3], the rationale to treat these patients was to create a “suction 
chamber” to the enteral lumen: a fully-covered self-expandable enteral 
metal stentwas inserted with the distal crown into the peritoneum through 
the duodenal leak. 
Subsequently, the common bile duct and the main pancreatic duct were 
endoscopically drained inserting a biliary and a pancreatic stent through 
the meshes of the enteral stent. An aspirative large naso-duodenal tube, 
with the tip about 1-2 cm out of the enteral stent’s distal crown was placed 
(creating the so called “suction chamber”). If present, the surgical drain-
age was pulled out about 3 cm away from the leak to favorite the peritone-
al-enteral pressure gradient than the peritoneal-atmospheric one.
results: Technical and clinical success rate were achieved in all the pa-
tients (5/5, 100%).
The mean duration of aspirative patency was 36 (23-103) days with a 
mean duration of hospital stay of 92 (47-273) days. An abdominal CT scan 
check was generally performed 2 days after the procedure (to verify the 
reduction of the intraperitoneal fluid collections) and 30 days after the 
procedure to decide to stop the aspiration through the naso-peritoneal 
tube. Abdominal drains were removed 15 (4-26) days after the proce-
dure, after an additional CT scan check. Stent removal was scheduled 
at 6 months in all the patients. Mean follow-up was 26 (13-35) months: 
no mortality neither long-term adverse events related to the endoscopic 
procedures were reported.
conclusion: Endotherapy of duodenal stump leak is feasible and effective 
in tertiary referral endoscopy centers with expertise in the management 
of post-surgical adverse events. Our “suction chamber” method offers 
the possibility to treat complex dehiscence especially if re-do surgery 
failed.
references: 1. Kuehn F, Loske G, Schiffmann L, Gock M, Klar E. Endoscopic 
vacuum therapy for various defects of the upper gastrointestinal tract. Surg 
Endosc. 2017; 31: 3449-3458. 2. Mutignani M, Dioscoridi L, Dokas S, Aseni 
P, Carnevali P, Forti E, Manta R, Sica M, Tringali A, Pugliese F. Endoscopic 
multiple metal stenting for the treatment of enteral leaks near the biliary 
orifice: a novel effective rescue procedure. World J Gastrointest Endosc. 
2016; 8: 533-540. 3. Mutignani M, Dioscoridi L, Forti E, Pugliese F, Fontana 
P, Tringali A. “Yo-yo” stents to treat pancreatic leaks and fistulas after duo-
denopancreatectomy: a new effective endoscopic therapy. Dig Liver Dis. 
2017; 62: 2648-2657.
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Introduction: Since re-do surgery and interventional radiology are con-
sidered the first-line treatment for bilio-digestive anastomotic stricture, 
endoscopic treatment has been utilized as a minimally invasive alternative 
for management of these adverse event, with two critical issues: 
1. Ability to reach the biliary anastomosis; 
2. Perform an effective therapeutic procedure. Duodenoscope, gastroscope 
and pediatric colonoscope have all been used, with poor rate of biliary 
anastomosis achievement. 
Enteroscopes (short, long, single- or double-balloon) [1] have also been 
utilized, with an overall technical success rate of about 76%. Finally, high 
success rate (around 90%) have also been described for the EUS-guided 
approach, which has a high morbidity (18%-50%) and mortality (1.5%) [2].
aims & Methods: We proposed a totally endoscopic approach to improve 
the endotherapy of bilio-digestive anastomotic stricture.
From January 2014 to April 2019, 33 consecutive patients (mean age: 60 
y.o.; M/F 20/13) affected by bilio-digestive anastomotic stricture treated 
by endoscopic enteral-enteral bypass (EEEB) and subsequent endoscopic 
retrograde cholangiography (ERC) were included in the present study. To 
reach the anastomotic site, an EEEB between the duodenal or gastric wall 
and the biliary jejunal loop using luminal apposing or biflanged metal 
stents under both fluoroscopic and endoscopic ultrasound’s guidance was 
performed. This allowed the establishment of a short-way for therapeutic 
ERC procedures using large operative channel’s endoscopes.
results: EEEB was successful in 31 patients and therapeutical ERC was per-
formed in all the 31 cases using multiple or single large-bore fully-covered 
self-expandable metal stenting (SEMS). We registered a 100% clinical suc-
cess with a mean number of ERC sessions of 3. During a mean follow-up of 
23 months (range: 1,5 - 59 months), two anastomotic stricture recurrences 
(6,4%) occurred, successfully re-treated through the EEEB. One case of 
post-ERC bleeding due to portal hypertension occurred and was treated 
conservatively. No long-term adverse events were observed.
If we briefly compare EEEB-guided ERC with other techniques, the radio-
logical/percutaneous approach allows placement of SEMSs but not their 
removal, while enteroscopy does not permit use of large-bore SEMSs. In 
addition, selective cannulation of the bile duct with cholangiography is of 
paramount importance to characterized complex stenosis(es) and to drive 
subsequent endoscopic management. This can be only obtained by using 
the EEEB-guided ERC. Moreover, the EEEB allowed us to perform repeated 
treatments in patients with complex clinical situation or re-treat those with 
recurrence.
conclusion: EEEB is safe, feasible, and allows a successful long-term treat-
ment of different biliary adverse events in a tertiary referral centers with 
high-level experience in both ERCP and EUS.
In the setting of bilio-digestive anastomotic strictures, EEEB-guided 
ERC permits to use endoscopes with large operative channel to treat the 
stenosis(es) with large-bore SEMS, to manage case of complex strictures 
and multiple-ducts biliary anastomosis, to guarantee a long-lasting grad-
ual dilation and to re-treat the patients in case of recurrence.
references: 1. Itokawa F, Itoi T, Ishii K, et al. Single- and double-ballon 
enteroscopy-assisted endoscopic retrograde cholangiopancreatography in 
patients with Roux-en-Y plus hepaticojejunostomy anastomosis and Whip-
ple resection. Dig Endosc 2014; 26: 136-143. 2. Giovannini M, Bories E, Na-
poleon B, et al. 855 multicentric randomized phase II study: percutaneous 
biliary drainage vs EUS guided biliary drainage: results of the intermediate 
analysis. Gastrointest Endosc 2015; 81: AB174.
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P0991 PLavac - reTrOsPecTIve sTudy On The evaLuaTIOn 
Of a “PLaTzBauch” (acuTe fasIcaL dehIscence) and v.a.c. 
TheraPy
Burkert N.1, Sargut M.1, Ceyhan G.O.2
1Technische Universität Klinikum rechts der Isar München, Surgery, Munich, 
Germany, 2Technische Universität München, Chirurgische Klinik und 
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Introduction: Acute fascial dehiscence (FD) is a feared complication after 
laparotomy. The incidence of FD is about 3.5%, 14 - 67 % of Patients (Pat) 
with FD died. Known causes for FD include: wound infection, premature 
mobilization, increased intraabdominal pressure. However, all studies in 
this field are outdated. Also, we do not know the context between Vakuum 
Assisted Closure (VAC)-Therapy and FD. In this paper, we aim to update 
the database about FD and to investigate a possible therapeutic effect of 
VAC Therapy on FD.
aims & Methods: We analyzed all patients who were diagnosed with FD 
within the first 30 days after a laparotomy between July 2007 and August 
2016, retrospectively. We analyzed 180 patients with a FD. We excluded 67 
patients with a laparotomy previously within one year.
results: 113 patient (73,5% male) occurred a FD on the 10th [2;30]day after 
laparotomy. The main reason for FD was a wound infection (38,9%) or a 
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high intraabdominal pressure because of an intestinal paralysis, ileus or 
ascites (20,3%). A lot of pat with a FD were operated in the primary op-
eration with an emergency indication (38,9%). They got mostly a median 
laparotomy (77,9%) and were closed by continuous fascia suturing (61,1%). 
The Pat stayed extended 33 [9;120] days at hospital. 18 patients (15,9%) 
died during hospitalization. 20 patients (17,7%) had a second FD. We saw 
that Pat with a VAC-Therapy after first FD had a significant higher risk to 
get a second FD (p=0,041).
conclusion: FD is serious complication and we show that VAC-Therapy has 
a negative influence to get a second FD, but it is to discus whether the 
VAC-Therapy is the problem or the associated wound infections. It hasto be 
investigated in future prospectiv studies.
disclosure: Nothing to disclose 
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Introduction: Anastomotic leak after low anterior resection represents 
dreaded complication, which is associated with a significant mortality and 
affects both oncological and functional outcomes. OverStitchTM (Apollo En-
dosurgery) is an endoscopic suturing system now widely available for a 
variety of endoscopic procedures allowing to place full thickness sutures.
aims & Methods: The aim of our study was to assess the feasibility of 
endoscopic repair of anastomotic leak on animal model. Secondary aim 
was to evaluate whether this technique prevents intraabdominal sepsis.
Model of low colorectal anastomotic leak was introduced in 28 male pigs. 
Laparoscopic low anterior resection was performed and the anastomosis 
created with 28 mm circular stapler after removing half of the staples.
Fourteen pigs had an endoscopic anastomotic repair with OverStitchTM 2 
days later. A double-channel endoscope was introduced and defect closed 
with 2/0 prolene and secured with original knotless fixation. Three-grade 
scale (I - closed completely, II - closed with visible gaps, III - closure not 
possible) was used to assess the completion of closure. The signs of in-
traabdominal septic complications - IASC and anastomotic healing includ-
ing burst test were assessed after animals being sacrificed on 9th postop-
erative day. Fourteen animals with no treatment were included in control 
group. Chi square test was used to compare both groups. 
The protocol was approved by local ethical committee in accordance with 
the European Convention on Animal Protection. The study was supported 
by AZV 16-31806A, MO 1012.
results: Endoscopic closure was technically possible in all 14 cases (gr. 
I - 11, gr. II - 3 and gr. III - 0) with mean procedure time of 31 (19-70) min. 
Two animals from suture group died due to peritonitis on 8th and 9th post-
operative day. Overall IASC rate was however significantly lower compared 
to the control - 5/14 vs. 11/14 (p= 0,022). The autopsy confirmed healed 
anastomosis with no visible defect in 10/14 cases after endoscopic suturing 
and in 2/14 within control group (p=0,0023). The burst test performed in 10 
healed OverStitch cases confirmed sufficient closure with mean pressure 
of 200 (80-300) mmHg.
conclusion: OverStitchTM endoscopic suturing is technically feasible for re-
pair of low colorectal anastomotic leak. This technique reduced the rate of 
intraabdominal septic complications.
disclosure: Nothing to disclose 
P0993 LOng TerM PersIsTence Of anOrecTaL dysfuncTIOn 
fOLLOWIng sPhIncTer PreservIng surgery fOr recTaL 
cancer: cOrreLaTIOn WITh BaseLIne PhysIOLOgy TesTIng and 
BIOfeedBack TheraPy
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Introduction: Rectal cancer is commonly treated by chemotherapy and 
radiation therapy, followed by anal sphincter-preserving surgery where 
possible, with a temporary protecting ileostomy. Low anterior resection 
syndrome (LARS) is a constellation of symptoms, commonly developing 
following stoma reversal, which includes faecal urgency, incontinence and 
difficulty emptying, severely affecting quality of life of cancer survivors. 
Scant data exists on the natural history of LARS, and specifically on the 
role of anorectal physiology testing and sphincter-strengthening oriented 
biofeedback therapy (BF) in predicting long term symptoms.
aims & Methods: To evaluate long term outcomes of sphincter-preserving 
surgery and it’s correlation to baseline anorectal physiology testing and BF. 
75 consecutive patients (49 males, age 61 +-12 yrs) undergoing sphincter-
preserving surgery were studied. 43 (57%) patients participated in long 
term follow up (median 4 years, range 1-11). Severity indexes and quality 
of life measures at long term follow up were recorded and analyzed in cor-
relation to baseline clinical characteristics, anorectal physiological studies 
and BF treatment.
results: : Baseline characteristics of the cohort are described in Table 1. 
On long term follow up, mean LARS score was 34 (SD 11), with 33 patients 
(86%) displaying severe LARS (scores>30). Mean faecal incontinence se-
verity index was 30 (SD 19) and mean bowel frequency/day was 7 (SD 4). 
Mean FI-QOL was 2.2 (SD 0.9) and SF-36 total mean was 51 (SD 22).
Sixty-six (88%) patients underwent anorectal manometry (ARM), 30% 
of them before stoma closure. Anal resting and squeeze pressures were 
low in 67% and 23% of patients, respectively. Balloon expulsion time was 
abnormal in 42% of patients. 23 (30%) patients underwent BF treatment 
(mean of 4 meetings, range 1-16), 32% of them before stoma closure. 
Lower resting pressure showed a trend towards predicting higher LARS 
scores at follow up (p=0.055). BF therapy before or after stoma closure and 
absence of post-surgical complications were associated with higher (less) 
bodily pain scores on follow up SF36 (77 vs 48, respectively, p=0.006), but 
did not predict symptom severity scores.
Tumor distance from anal verge - mean, cm (sd) 6 (3)
Tumor Stage (T)  
0 or 1 n(%) 23(33%)
2- n(%) 25(33%)
3- n(%) 24(32%)
4- n(%) 1(1%)
Type of surgery  
Low anterior resection- n(%) 42(56%)
Colo-anal anastomosis- n(%) 33(44%)
Post-surgery complication (including pelvic abscess, anorectal 
fistula and strictures)- n(%)
22(32%)
Anorectal manometry (n=66)  
Anal resting pressure- mmHg; mean(SD) 57(34)
Anal squeezing pressure - mmHg; mean(SD) 152(72)
Anal relaxation on push maneuver - %- mean(SD) 16(23)
Recto-anal inhibitory reflex - absent- n(%) 32(51%)
First rectal sensation thresholds- mean, ml (SD) 42(23)
Defaecation urge sensation thresholds- mean, ml (SD) 62(29)
Maximal tolerated volume- mean, ml (SD) 83(32)
[Table 1. Baseline characteristics of patients undergoing sphincter-sparing 
surgery (n=75).]
conclusion: Severe symptoms and impaired quality of life persist at a me-
dian of 4 years following sphincter preserving surgery. ARM might help 
predict symptom severity, and BF might slightly mitigate symptoms’ impact 
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on quality of life. Nevertheless, improvement of current treatment options, 
including utilization of a more comprehensive anorectal BF protocol and/
or sacral neuromodulation, is critically needed in this group of patients.
disclosure: Nothing to disclose 
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Introduction: Treatment options for Zenker’s diverticulum (ZD) include 
open surgery, rigid endoscopy and flexible endoscopy. Clinical success is 
achieved in 80-90% of cases after endoscopic septotomy, however, ad-
verse events (AEs) occur in 14% and, importantly, symptom recurrence in 
up to a third of patients. Recurrence is thought to be due to incomplete 
septotomy. A new technique using POEM for direct visualization/complete 
dissection of the septum has been described; however, outcomes of POEM 
for ZD (Z-POEM) are not known.
aims & Methods: To study the technical feasibility, safety, and efficacy of Z-
POEM in the management of ZD. This is a retrospective international study 
involving 10 centers (2 Asia, 2 Europe, 1 Mexico, 5 USA). Consecutive pa-
tients who underwent Z-POEM for ZD were included. Technical success is 
defined as successful completion of the Z-POEM. Clinical success is defined 
as complete/near complete resolution of dysphagia (Dakkak/Bennett score 
of 0 or 1) without the need for repeat endoscopic/surgical interventions. 
AEs were categorized/ rated per the ASGE lexicon.
results: A total of 75 patients (73yr, F 33) were included with an average 
Charleson Comorbidity Index of 4. Eleven patients had prior treatment for 
ZD, which included open surgery in 5, dilation in 1, and flexible endoscopy 
in 5. The mean size of ZD was 31.29±1.63mm (10-89mm). Most common 
indications for Z-POEM were dysphagia (46%) and regurgitation (29%). 
General anesthesia was used for all cases. The technical success rate was 
97.3% (73/75). Types of septotomy device used: hybrid knife (n=44), Tri-
angle tip knife (n=12), standard Stag-beetle knife (n=7), IT-2 knife (n=7), 
Hook knife (n=2), IT-nano (n=1), both hybrid and Stag-beetle knife (n=2). 
The 2 technical failures were due to inability to locate the septum and 
failed tunnel creation (Table. 1). 
AEs occurred in 6.7% (5/75): 1 bleed (mild) conservatively managed and 
4 perforations (1 severe, 3 moderate). One severe perforation was a small 
contained perforation requiring ICU monitoring which subsequently self-
resolved. Of the 3 moderate perforations, 2 were treated using cyanoac-
rylate glue and 1 was closed using clips. The mean procedure time was 
52.4±2.9 min and mean length of hospital stay was 1.8±0.2d. Clinical 
success was achieved in 92% (69/75) with a decrease in mean dysphagia 
score from 1.87 to 0.25 (p< 0.0001). The median length of follow-up was 
291.5 days (IQR=103.5-436). At 12-month follow-up, 1 patients reported 
symptom recurrence.
conclusion: Endoscopic management of ZD using the POEM technique is 
novel and feasible with promising efficacy and safety results. Long-term 
follow-up is needed to ensure durability of response. In addition, com-
parative studies with other treatment modalities are warranted. 
disclosure: Nothing to disclose
  N=75
Clinical Success %(n) 92% (69)
Technical Success %(n) 97.3% (73)
Mean POEM procedure time (min) (mean, SD) 52.4, 2.9
Repeat Intervention  
Surgical intervention (n) 0
Endoscopic intervention (n) 1
Post-procedure F/U (median, IQR) 291.5 (IQR 103.5-436)
Days of hospitalization (mean, SD) 1.8, 0.2
Pre-procedure dysphagia score (mean, SD) 1.96, 0.68
Post-procedure dysphagia score (mean, SD) 0.25, 0.52
[Technical and clinical outcomes of Z-POEM]
P0995 WIThdraWn
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Introduction: Endoscopic suturing is an alternative to surgical treatment 
for a broad spectrum of care, ranging from closure of mucosal or full 
thickness gastrointestinal tract defects to stent fixation to primary sleeve 
gastroplasty. A growing number of academic referral centers and commu-
nity hospitals worldwide are performing endoscopic suturing procedures 
using the OverStitch Endoscopic Suturing System (Apollo Endosurgery Inc. 
Austin, Texas).
aims & Methods: The aim of this registry is to collect demographic, proce-
dural characteristics and follow-up outcomes of endoscopic suturing from 
multiple participating centers.
A retrospective analysis of a prospectively collected series of any patient 
who underwent an endoscopic suturing procedure using the OverStitch 
device for a gastrointestinal application from 6 European centers from 
January 2018 to April 2019 was performed.
This registry includes five main groups:
1. Closure of full thickness defects (post-operative leaks/anastomosis de-
hiscence, fistula closure, perforation)
2. Closure of mucosal defects (mucosal excision defects (EMR, ESD), enter-
otomies (e.g. EFTR), POEM/STER mucosal entry sites, ulcers)
3. Fixation of endoprosthetics
4. Gastrointestinal Bleeding
5. Other (GERD Cardioplasty, revision bariatric procedure, any other ap-
plication of the endoscopic suturing device not listed above)
The data have been entered into a secure database by an identifier known 
only to the physician or his/her designee(s). All information in the data-
base is de-identified prior to entry.
results: To date, 67 patients (all Caucasian, male: 37; median age: 60.8 
years) have been entered into the registry. Six European centers contrib-
uted to this first collection with a varying number of procedures from each 
center (max: 29; min: 1). The distribution of cases for each group is shown 
in Table 1.
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Regardless of the procedure type, there were no cases of failure to intro-
duce the device and advance it to the target area. Furthemore, suturing 
was technically achieved as intended in all 67 cases. In the group of closure 
of mucosal defects, follow-up has been reported for 7 patients (range: 90 
days-1 year) with a 100% success rate. A mean of 1.9 running sutures were 
used. Patients who underwent fistula closure had a follow-up range of 
30 to >90 days with a success rate of 77.8% (2 patients required repeat-
ed suturing; 2 patients have no follow-up data). All cases of perforation 
were successfully closed initially with a continued success rate of 92.9% 
in follow-up (range 30-90 days). Closure of post-op leaks performed in 
7 patients, with a continued success rate of 80% in those with reported 
follow-up of 90 days or more (in 1 patient with a follow-up of 30 days the 
leak wasn’t resolved; 2 patients have no follow-up data). Thirteen stents 
(located in the esophagus, stomach and duodenum) were fixed by sutur-
ing with success in 84.6% (11 of 13) cases (follow-up range 30 to 90 days; 
no follow-up data for 6 patients).
conclusion: This data demonstrates safety and feasibility of endoscopic 
suturing for several GI indications. In our opinion, this European registry 
is a valuable tool to pool outcomes of endoscopic suturing cases and to 
address future research directions.
disclosure: Nothing to disclose 
grOuPs PaTIenTs
Closure Mucosal Defect 11 (16,4%)
GI Full Thickness Fistula 11 (16,4%)
GI Full Thickness Perforation 17 (25,3%)
GI Full Thickness Post-op Leak 7 (10,4%)
Fixation of Endoprosthetics 19 (28,3%)
Gastrointestinal Bleeding 0
Other 2 (3%)
[Table 1]
P0997 TreaTMenT Of refracTOry hePaTIc encePhaLOPaThy 
due TO sPLenOrenaL shunT In LIver cIrrhOsIs: OccLusIOn Or 
dIversIOn?
Wei B.1, Deng K.2, Huang Z.3, Wu H.2, Tang C.2
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Introduction: Hepatic encephalopathy (HE) encompasses a spectrum of 
neuropsychiatric abnormalities observed in patients with liver dysfunc-
tion, after the exclusion of other brain diseases. Significant portal-systemic 
shunts are closely linked to the development of portosystemic encepha-
lopathy. An effective approach for treating this type HE is the occlusion of 
the large shunts. However, the shunts that exist in cirrhosis patients are a 
physiologic phenomenon that has evolved to compensate for the presence 
of portal hypertension. 
As a result, occluding the shunt is likely to increase portal pressure and 
the risk of hemorrhage. It is therefore important to consider whether oc-
clusion is the optimal treatment for portosystemic encephalopathy in cir-
rhosis patients.
aims & Methods: To compare the efficacy of two methods of interventional 
therapy for the treatment of refractory hepatic encephalopathy (HE) due to 
a splenorenal shunt. Fifteen cirrhotic patients with refractory hepatic en-
cephalopathy due to splenorenal shunt were studied. Either occlusion or 
diversion of the splenorenal shunt was undertaken to treat HE. The shunt 
was occluded by coils and tissue glue in the occlusion group. Selected 
embolization of the spleen vein was performed between the shunt and 
superior mesenteric vein in the diversion group.
results: Occlusion was performed in 8 patients(occlusion group) and 
splenic vein embolization in 7 patients(diversion). Complete resolution of 
HE occurred in all 15 patients without recurrences during the follow-up. 
Improvement of Child-Pugh score was found in both methods. A weak 
trend toward a smaller increase in portal pressure change was observed 
in the diversion method.
conclusion: Hepatic encephalopathy can be effectively treated with both 
diversion and occlusion interventional methods. The splenorenal shunt 
was reserved to relieve the portal pressure change by the diversion meth-
od, comparing to the occlusion method.
references: 1.Naeshiro, N., et al., Percutaneous transvenous emboliza-
tion for portosystemic shunts associated with encephalopathy: Long-term 
outcomes in 14 patients. Hepatol Res, 2014. 44(7): p. 740-9. 2.Franzoni, 
L.C., et al., Embolization of splenorenal shunt associated to portal vein 
thrombosis and hepatic encephalopathy. World J. Gastroenterol., 2014. 
20(42): p. 15910-5. 3.Inoue, M., et al., Splenic Vein Embolization Using Coil 
Anchors and Prophylactic Occlusion of a Hepatofugal Collateral for Hepatic 
Encephalopathy due to Splenorenal Shunt: Technical Note and Literature 
Review. Case Rep Radiol, 2013. 2013: p. 160653. 4.Zamora, C., et al., Por-
tosplenic blood flow separation in a patient with portosystemic encepha-
lopathy and a spontaneous splenorenal shunt. J Vasc Interv Radiol, 2004. 
15(8): p. 875-9.
disclosure: Nothing to disclose 
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Introduction: Endoscopic submucosal dissection (ESD) is the therapeutic 
endoscopic method that allows en-bloc and radical (R0) resection of early 
gastrointestinal neoplasia. ESD is still a technically demanding method, 
which needs special training and has some risk of complications.
aims & Methods: The main aim is to evaluate effectiveness of ESD and 
hybrid technique ESD / EMR (endoscopic mucosal resection) in the treat-
ment of early gastrointestinal neoplasia in one tertiary endoscopic centre. 
Data from a retrospective registry of patients who underwent ESD and hy-
brid ESD/EMR from February 2015 to March 2019 were evaluated. Thera-
peutic results and performance related complications were analysed.
results: A total of 43 ESD and ESD/EMR were analysed in 40 patients (mean 
age 64.5 years, 27 males). The lesion distribution was as follows: rectum (n 
= 30), sigmoid colon (n = 2), transverse colon (n = 1), oesophagus (n = 4) 
and stomach (n = 6). The mean lesion size was 30.9 mm (range 5-70 mm). 
En-bloc resection was achieved in 39 of 43 lesions (90.7%) and R0 resec-
tion was achieved in 35 of 39 en bloc resection (89.7%). 20 lesions (46.5%) 
were assessed as sessile polyps (type 0-Is according to Paris classification). 
The classic ESD technique was used in 32 lesions (74.4%; R0 resection in 
28 lesions), hybrid technique (ESD/EMR) in 11 lesions (25.6%; R0 resection 
in 7 lesions). Perforation was observed in 16 cases (37.2%). However, all 
perforations were closed with an endoscopic method using hemoclips, in 
one case OVESCO clip was successfully applied. Only one delayed bleed-
ing after ESD was observed, successfully resolved endoscopically. Surgical 
treatment was not necessary in any of these complications. The average 
inpatient time was 4.7 days (2-11 days). 24 patients (55.8%) were treated 
with antibiotics (Cephalosporins). Histological findings were as follows: 
6 cancers (14.0%) with invasion to the upper third of submucosa (sm1), 
4 intramucosal carcinomas (9.3%), 1 neuroendocrine tumours (2.3%), 1 
gastrointestinal stromal tumour (2.3%), 12 adenomas with high grade dys-
plasia (27.9 %) and 13 adenomas with low grade dysplasia (30.2%). One 
patient underwent surgical resection for invasive T2 carcinoma. Follow up 
endoscopy was performed in 29 of 43 lesions (67.4%), all with negative 
findings.
conclusion: Our analyses demonstrate that ESD and hybrid technique ESD/
EMR are effective and safe therapeutic methods for radical resection (R0) 
of early gastrointestinal neoplasia. Periprocedural complications can be 
treated conservatively. 
funding: The works were supported by grants AZV ČR reg. 17-31909A and 
NV18-08-00246.
disclosure: Nothing to disclose 
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P0999 PerOraL endOscOPIc MyOTOMy afTer OPeraTIve 
InTervenTIOns On The gasTrOesOPhageaL juncTIOn
Shumkina L., Pavlov I., Nedoluzhko I., Shishin K.
A.S. Loginov Moscow Clinical Science Center, Operative Endoscopy, Moscow, 
Russian Federation
contact e-Mail address: ivannedoluzhko@gmail.com
Introduction: Peroral endoscopic myotomy (POEM) may be a challenge in 
patients with previous interventions on the esophageal-gastric junction. 
The degree of fibrosis in submucosal space plays a key role in the feasibil-
ity and safety of tunnel technique.
aims & Methods: To evaluate the safety of peroral endoscopic myotomy in 
patients previously operated on the esophageal-gastric junction.
Between July 2014 and May 2018, 123 patients underwent POEM in the 
Moscow Clinical Scientific Center, including 46 (37%) patients previously 
operated on the esophageal-gastric junction. The group of operated 
patients involved 41 (89%) patients after pneumatic balloon dilation, 3 
(6.5%) patients after Heller myotomy, 1 (2%) patient after previous esoph-
agogastroplication, 1 (2%) after POEM.
results: The POEM procedure was successfully completed all patients. The 
mean operative was comparable in both groups: 106 min (55-195 min) in 
previously operated patients and 103 min (45-180 min) in naïve patients. 
F0 degree was detected in 14 (30%) cases, F1 in 29 (63%), maximal fibrosis 
(F2) in 3 (6.5%) patients who had previously undergone pneumatic balloon 
dilation. In patients after Heller’s myotomy and esophagogastroplication, 
the degree of fibrosis reached F1, despite the expected more pronounced 
fibrosis. In the group of primary patients F0, the degree was detected in 
27 (35%) observations, F1 - 46 (60%), severe fibrosis (F2) was detected in 
4 (5%). There were no intraoperative complications affecting the tactics of 
surgical intervention in one observation. There were no major bleeding 
episodes requiring blood transfusion in either group. In one case in the 
group of previously operated patients, a mucosal defect was detected after 
the formation of the tunnel. The lesion was clipped.
The technical success of the surgical intervention was up to 100%. There 
were no intraoperative complications. X-ray examination on the 1st day af-
ter intervention with a water-soluble contrast showed appropriate evacu-
ation and no leakage. Patients were discharged the 2nd day after surgery.
conclusion: The history of failed previous surgical interventions is not a 
contraindication to the POEM procedure and does not significantly affect 
the course of surgical intervention.
disclosure: Nothing to disclose 
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P1000 heLIcOBacTer PyLOrI  InfecTIOn PrOTecTs agaInsT 
chrOnIc cOLITIs By reguLaTIng cOLOnIc ePITheLIaL BarrIer 
funcTIOns
Zhang H.1, Dai Y.2, Shen H.1, Yang J.1, Zhang X.1, Wang W.2
1Hangzhou First People’s Hospital, Gastroenterology, Hangzhou, China, 
2Peking University First Hospital, Gastroenterology Department, Beijing, 
China
contact e-Mail address: hongchen_zhang@126.com
Introduction: Large epidemiological studies and meta-analyses have dem-
onstrated an inverse association between Helicobacter pylori (H.pylori) 
infection and the risk of developing inflammatory bowel diseases (IBD). 
However, the mechanisms by which H.pylori infection protects against IBD 
are still unclear. Our previous published study has found that H.pylori infec-
tion can affect the Th17/Treg balance in colon. Here, we explored the pos-
sible protective effects and mechanisms of gastric H. pylori colonization on 
a chronic colitis model, with focus on whether H. pylori exerted its effects 
through regulating the barrier function of the colonic epithelial cells (CECs).
aims & Methods: The aims of our study is to confirm that H.pylori infec-
tion exerts its protective effect on chronic colitis in mice by regulating the 
colonic epithelial barrier function. Chronic colitis model was induced by 
DSS treatment. To evaluate the severity of colitis, the body weight, rectal 
bleeding and stool consistency were observed to generate a disease activ-
ity index score (DAI). All mice were sacrificed at 45 days. H&E staining was 
performed for pathological scoring of both colitis. The colonic permeability 
of mice was measured by fluorescein-isothiocyanate-dextran (FITC-Dex-
tran) method. Immunohistochemical staining for BrdU was performed to 
evaluate the proliferative activity of colonic epithelial cells. The expression 
of apoptosis associated proteins (Cleaved-caspase-3, Bcl-2 and Bax) and 
necroptosis associated proteins (p-MLKL, RIPK1 and RIPK3) were deter-
mined by western blotting. Western blotting was also used to detect the 
expression of tight junction proteins (Occludin and Claudin3).
results: H.pylori+DSS group exhibited significantly less weight loss and 
DAI score, and increased survival rate during the experiment when com-
pared with DSS group (P<0.05). In accordance with the clinical data, 
the colon length in H.pylori+DSS group was longer than the DSS group 
(6.98±0.73cm vs. 8.09±0.45cm, P<0.05). H.pylori+DSS group had a sig-
nificant decreased microscopic histological score compared to DSS group 
(7.17±0.75 vs. 4.5±0.97, P<0.05), suggesting that H.pylori infection might 
ameliorate the severity of chronic colitis in mouse model.
The intestinal permeability improved in H.pylori infected group compared 
with DSS-induced mice (1141±55.57 pg/ml vs 913.9±32.44 pg/ml, P<0.05). 
CECs proliferation determined by BrdU staining demonstrated that the 
proliferative activity was increased in H.pylori infected group (38.00±7.975 
vs 135.3±13.56, P<0.05). The expressions of tight junction protein ( Occlu-
din and Claudin3) were enhanced in H.pylori infected group (0.15±0.08 
vs 0.85±0.49, P<0.05 and 0.11±0.06 vs 0.67±0.13, P< 0.05). The expres-
sion of cleaved-caspase 3 and the ratio of Bcl-2/Bax decreased signifi-
cantly in H.pylori+DSS group (0.60±0.42 vs 0.38±0.28, P<0.05; 0.09±0.08 
vs 1.43±0.65, P<0.05), suggesting that H.pylori infection might ameliorate 
the apoptosis of CECs. 
Notably, Compared with DSS group, H.pylori infection inhibited the 
necroptosis associated proteins including RIPK1(0.76±0.12 vs 0.16±0.04, 
P<0.05), RIPK3 (0.94±0.19 vs 0.24±0.08, P< 0.05) and p-MLKL (0.90±0.19 
vs 0.06±0.02, P< 0.05), suggesting that necroptosis inhibition might be 
involved in the protective effects against colonic inflammation.
conclusion: H.pylori infection can attenuate the intestinal inflammation 
in DSS-induced mice, which may be due to improving intestinal mucosal 
barrier function by enhancing the expression of tight junction protein and 
inhibiting the apoptosis and necroptosis of colonic epithelial cells.
disclosure: All authors have declared no conflicts of interest. 
P1001 cOMMensaL fungI and TheIr ceLL-WaLL β-gLucans 
dIrecT dIfferenTIaL resPOnses In huMan InTesTInaL 
ePITheLIaL ceLLs, suggesTIng a MechanIsM fOr MucOsaL 
TOLerance
Cohen-Kedar S.1,2, Schwartz S.1,2, Sadot E.3, Wolff-Bar M.4, Shaltiel T.3, 
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Introduction: Intestinal epithelial cells (IECs) are the first to encounter lu-
minal antigens and play an active role in intestinal immune responses. 
Antibodies directed against fungal cell-wall glycans are associated with 
Crohn’s disease (CD) and may represent loss of tolerance towards intestinal 
microorganisms. We previously reported that the receptor Dectin-1 and its 
major signaling mediator Syk are expressed in normal ileal and colonic 
IECs. Furthermore, the fungal cell-wall glycans β-glucans induced IL-8 and 
CCL2 secretion by IEC lines in a Dectin-1 and Syk dependent manner.
aims & Methods: To address the mechanism of IECs response to fungi and 
fungal glycans. 
Mucosal samples were obtained from healthy individuals and fungal rec-
ognizing C-type lectin receptors (CLRs) expression was assessed by im-
munofluorescence (IF). Mucosal explants and IEC lines (HT-29 and SW480) 
were stimulated with Candida albicans and Saccharomyces cerevisiae and 
the β-glucans zymosan and curdlan. Signaling was assessed by Western 
blot and IF. Chemokine secretion was assessed by ELISA.
results: The CLRs Dectin-1, Dectin-2, DC-SIGN and Mincle were identified 
in ileal and colonic human mucosal samples as well as in IEC lines. Stimu-
lation of mucosal explants and IEC lines with commensal fungal particles 
of live, heat-killed (HK)- or UV-inactivated wild-type C. albicans, as well as 
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HK- S. cerevisiae and β-glucans resulted in Syk phosphorylation. However, 
in IEC lines, β-glucans, but not fungal particles, induced phosphorylation 
of the MAP kinases JNK and p38 and the transcription factors c-JUN and 
NFκB p65. 
Furthermore, only β-glucan stimulation induced the secretion of the pro-
inflammatory chemokines Gro-α, GM-CSF, IL-8 and CCL2 (e.g. 13.5±0.4 
vs. 0.35±0.005 ng/ml GRO-α in zymosan-treated vs. control HT-29 cells, 
respectively, p≤ 0.0001). β-glucan induced chemokine secretion was sen-
sitive to Syk (R406) and JNK (SP600125) inhibitors (e.g. 79% and 57% in-
hibition of zymosan induced IL-8 secretion in SW480 cells, respectively) as 
well as to NFκB-p65 inhibition by BAY 11-7082 (e.g. up to 90% inhibition, 
p≤ 0.01, of curdlan induced IL-8 and Gro-α secretion from SW480 cells). 
Notably, β-glucan induced NFκB p65 phosphorylation was insensitive to 
Syk inhibition. 
Finally, co-stimulation of IEC lines with β-glucans and HK C. albicans yield-
ed a decrease in all tested chemokine secretion compared to stimulation 
with β-glucans alone (e.g. 27% inhibition, p≤0.01, of zymosan induced 
GRO-α secretion in HT-29 cells and 30% and 32% inhibition, p≤ 0.01, of 
curdlan and zymosan induced IL-8 and GRO-α secretion respectively, in 
SW480 cells).
conclusion: CLRs expressed by IECs allow recognition of luminal fungi and 
their cell-wall glycans such as β-glucans. Epithelial response to β-glucans 
includes Syk-dependent activation of JNK, p38 and c-JUN, as well as a 
Syk-independent activation of NFκB p65. While Syk is activated, the lack of 
JNK, p38, c-JUN and NFκB p65 activation and chemokine secretion upon 
epithelial recognition of commensal fungi may reflect regulatory signals, 
resulting from CLRs response to other glycans expressed by intact fungi 
that contribute to mucosal tolerance. This is supported by the inhibitory 
effect of C. albicans on β-glucan-induced chemokine secretion. Skewed 
epithelial response to commensal fungi may impair homeostasis, lead to 
loss of tolerance and contribute to the pathogenesis of CD.
disclosure: Nothing to disclose 
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Introduction: Proteolytic activity in the intestine is detected both in the 
lumen and in tissues in physiological conditions. It is increased in both 
compartments in pathological situations such as Inflammatory Bowel Dis-
ease (IBD) and Irritable Bowel Syndrome (IBS). The increased activity can 
be due to an overexpression of proteases, to a decreased expression of 
natural endogenous protease inhibitors, or both.
aims & Methods: Our objective was to identify the disease-associated pro-
teases and their inhibitors that are present in the intestine. We therefore 
developed a number of tools for that aim. First, we developed fluorescent 
enzymatic assays and a range of substrates to detect proteolytic activity 
in human tissues and feces. Next, we revealed localization of enzymatic 
activity by in situ zymography from frozen tissue sections. We used serine 
protease-targeted activity-based probes (ABP) coupled with mass spec-
trometry analysis to identify active forms of proteases present within the 
gut tissues of healthy individuals, patients with gastrointestinal disorders 
as well as in naïve mice or in mouse models of gut inflammation. Ex-
pression levels of proteases and their related inhibitors were analysed by 
qPCR, immunostaining and western-blots using mouse and patient’s tis-
sues as well as 3D organoids cultures.
results: We have identified different proteases such as a previously un-
covered form of epithelial elastase, chymotrypsin as well as PRSS-1, 2 and 
3 in gut tissues. Importantly, in situ zymography revealed that most of the 
proteolytic activity localised in the intestine originated from the epithe-
lium. Some proteases and inhibitors had differential expression in IBD and 
IBS. Expression of proteases and inhibitors in epithelium were confirmed 
in patients’ organoids culture.
conclusion: Epithelial proteases and protease inhibitors appear as major 
actors of mucosal homeostasis. Their functional study highlights new pos-
sible therapeutic intervention for intestinal pathologies.
disclosure: Nothing to disclose 
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cOLITIs: resuLTs frOM The unIfI InducTIOn and MaInTenance 
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Introduction: Serum concentrations of monoclonal antibody-based bio-
logics have been shown to correlate with their efficacy. PK, exposure-
response (ER), and immunogenicity of ustekinumab (UST) were evaluated 
in UNIFI induction and maintenance studies in UC. Induction results were 
presented previously1.
aims & Methods: PK, immunogenicity, efficacy & safety data were obtained 
from two Phase 3, double-blind, PBO-controlled trials in adult patients 
(pts) with moderate-severe UC. These included 1 induction study which 
enrolled 961 pts (UNIFI). Patients enrolled in the induction study received 
a single IV infusion at Week 0 of PBO, UST 130 mg, or weight-range-based 
doses approximating 6 mg/kg UST (~ 6 mg/kg: 260 mg for pts ≤55 kg, 390 
mg for pts >55 kg & ≤85 kg, & 520 mg for pts >85 kg). Responders to a 
single IV infusion of UST comprised the primary study population for the 
maintenance study (n=523) & were randomly assigned to receive SC UST 90 
mg q12w, UST 90 mg q8w, or PBO. Blood samples were collected to mea-
sure serum UST concentration and antibodies to ustekinumab. Key efficacy 
outcomes were based on the Mayo score and inflammatory biomarkers (C-
reactive protein [CRP] and fecal calprotectin [fCal]). Relationships between 
serum UST concentrations & efficacy, and the incidence of selected safety 
events of infections, serious infection & serious adverse events (SAE) were 
evaluated.
results: Serum UST concentrations over time were dose proportional, un-
affected by concomitant immunosuppressants, & similar between pts who 
were biologic failures & non-failures. Median peak serum UST concentra-
tions in the induction study were 43.2 µg/mL & 127.0 µg/mL for the 130 mg 
& ~6 mg/kg dose groups, respectively. At induction week 8, median UST 
concentrations were 2.51 µg/mL & 8.59 µg/mL, respectively. Steady-state 
was reached by the start of the second SC maintenance dose (16 or 20 
weeks from the IV induction dose for the q8w and q12w regimen respec-
tively). Median steady-state trough serum UST concentrations over time 
in the UST q8w group (2.69 to 3.09 µg/mL) were 3-fold higher than in the 
q12w group (0.92 to 1.19 µg/mL). During induction & maintenance, serum 
UST concentrations were positively associated with the proportions of pts 
achieving response & remission, respectively (Table), and there was an 
inverse association between serum UST concentrations and CRP and fCal 
levels. No relationship was observed between serum UST concentrations 
& the incidence of infections, serious infections or SAEs during induction 
or maintenance treatment with UST. The incidence of antibodies to UST 
through 1 year using a drug-tolerant assay was 3.4% among those receiv-
ing UST maintenance vs. 9.1% in the PBO group; no impact of antibodies 
on efficacy was observed.
conclusion: Serum UST concentrations were approximately dose-propor-
tional. A positive E-R of serum UST with clinical efficacy measures and 
an inverse relationship with inflammatory markers was observed during 
UST IV induction & SC maintenance treatment. Adverse events including 
infections did not increase with increased serum UST concentrations at the 
doses evaluated in induction and maintenance. These findings are consis-
tent with those in UST for Crohn’s disease.
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serum ustekinumab concentration (µg/mL)*/Proportion of 
Patients (%)
Efficacy Outcome 1st Quartile 2nd Quartile 3rd Quartile 4th Quartile
Clinical Response at 
Induction Week 8
<2.2/41.2 2.2 to <3.9/47.7 3.9 to <8.8/61.1 ≥8.8/74.2
Clinical Remission at 
Maintenance Week 44
<0.9/29.9 0.9 to <1.9/46.2 1.9 to <3.2/46.8 ≥3.2/61.5
*Serum concentration quartiles based on ustekinumab concentration at Week 8 for the 
induction analysis, and average steady-state trough concentration for the maintenance 
analysis
[Table. Proportions of Patients Achieving Efficacy Endpoints by Serum 
Ustekinumab Concentration]
references: 1.Adedokun OJ, Xu Z, Marano C, O’Brien C, Szapary P, Zhang H, 
Johanns J, Leong R, Hisamatsu T, van Assche G, Danese S, Abreu MT, Sands 
BE, Sandborn WJ. Pharmacokinetics and Exposure-response Relationships 
of Intravenously Administered Ustekinumab during Induction Treatment 
in Patients with Ulcerative Colitis: Results from the UNIFI Induction Study. 
Poster presentation at: ECCO 2019; Copenhagen, Denmark.
disclosure: Drs. , Leong, Hisamatsu, van Assche, Danese, Abreu, Sands, 
Sandborn are all investigators for Janssen Research & Development, LLC 
Drs. Adedokun, Xu, Marano, O’Brien, Szapary, Zhang, Johanns are all em-
ployees of Janssen Research & Development, LLC 
P1004 cOLOnIc InfLaMMaTIOn In crOhn’s dIsease Induces 
changes In gLucOse MeTaBOLIsM ThrOugh MOduLaTIOn Of 
endOgenOus IncreTIn sysTeM
Zatorski H.1,2, Salaga M.1, Zielińska M.1, Mokrowiecka A.2, 
Cygankiewicz A.3, Krajewska W.M.3, Małecka-Panas E.2, Fichna J.1
1Medical University of Lodz, Department of Biochemistry, Lodz, Poland, 
2Medical University of Lodz, Department of Digestive Tract Diseases, Lodz, 
Poland, 3University of Lodz, Department of Cytobiochemistry, Lodz, Poland
contact e-Mail address: zatorski.h@gmail.com
Introduction: The role of incretin hormone, glucagon-like peptide (GLP-
1), in Crohn’s disease (CD) is still poorly understood. GLP-1 is secreted by 
intestinal L cells and decreases blood glucose levels. GLP-1 is rapidly de-
graded by dipeptidyl peptidase IV (DPP-IV), with a half-life of less than 
2 minutes. CD patients may be at a greater risk of glucose metabolism 
disturbances due to overproduction of proinflammatory cytokines and ex-
cessive administration of diabetogenic drugs. We hypothesize that a pos-
sible mechanism of disturbances in glucose metabolism may be related to 
changes in the levels of incretin hormones due to inflammation.
aims & Methods: The primary aim of this study was to investigate whether 
colitis is associated with changes in glucose metabolism. The secondary 
goal was to investigate potential involvement of incretin system as an un-
derlaying factor. 
To develop a chronic colonic inflammation mimicking CD in humans, 
mouse model of colitis induced by intracolonic administration of 
2,4,6-trinitrobenzenesulfonic acid (TNBS) at dose 150 mg/kg at day 0 was 
used. On day 7 mice were sacrificed and macroscopic score as well as 
ulcer score were recorded. In all mouse experiments the expression of 
inflammation markers: tumor necrosis factor-α (TNF-α), IL-6 and IL-17 
was determined. 
The effect of colitis on glucose metabolism was studied by measurement 
of fasting glucose levels, as well as the GLP-1, DPP-IV, prohormone con-
vertase 1/3 (PC 1/3) and GLP-1 receptor (GLP-1R) expression. Moreover, to 
translate results obtained in mice, we measured the level of GLP-1, DPP-
IV and expression of PC 1/3 mRNA in serum (n=11-15) and colon samples 
(n=5-6) from healthy controls and CD patients.
results: There were significant differences in macroscopic score, ulcer 
score in mice with colitis compared to control mice. TNF-α was signifi-
cantly higher when compared to control mice, whereas IL-17 expression 
was decreased. No difference in expression of IL-6 was observed between 
groups. 
Glucose levels in mice treated with TNBS were significantly higher in com-
parison to control group, what was associated with non-significantly lower 
level of GLP-1 and significantly higher level of DPP-IV in mouse serum. In 
mouse colon samples, GLP-1 levels were significantly lower whereas PC 
1/3 expression, an enzyme involved in processing proglucagon into GLP-
1 were significantly higher in mice with colitis compared to controls. No 
change in DPP-IV was observed. Furthermore GLP-1R expression was non-
significantly higher in mice treated with TNBS when compared to controls. 
In humans, GLP-1 and DPP-IV levels were significantly decreased in the 
serum of CD patients in comparison to healthy control subjects. Surpris-
ingly, GLP-1 level was significantly increased in colon samples of the same 
cohort of CD sufferers, when compared to control samples. Furthermore, 
there was no significant reduction of PC 1/3 mRNA expression in CD group 
when compared to control group.
conclusion: Changes in incretin hormone levels in response to colonic 
inflammation contributes to the impaired glucose metabolism. Our data 
suggest that targeting incretin system by GLP-1R agonists or DPP-IV inhibi-
tors may become a novel therapeutic option in the treatment of CD with 
both anti-inflammatory and anti-diabetic effect.
disclosure: Nothing to disclose 
P1005 a sysTeMaTIc revIeW and nOveL cLassIfIcaTIOn 
sysTeM TO defIne deeP reMIssIOn
Gulati A.1, Alipour O.1, Shao L.1, Zhang B.2
1University of Southern California, Gastroenterology and Liver Diseases, 
Los Angeles, United States, 2University of California San Francisco, 
Gastroenterology, San Francisco, United States
contact e-Mail address: gulatialakh@gmail.com
Introduction: Current therapeutic goals for inflammatory bowel disease 
(IBD) focus on symptomatic response, but many patients experience dis-
ease progression. There has been a movement towards tighter control of 
IBD, defined as deep remission. Achieving deep remission could lead to 
lower rates of complications, surgical interventions, and hospital visits. No 
consensus definition currently exists for deep remission, although clini-
cal, endoscopic, and biochemical remissions are all components that have 
been proposed in the definition. We systematically reviewed the different 
variations of deep remission and created a classification system to provide 
uniformity when discussing deep remission among clinicians.
aims & Methods: We performed a systematic review using the search 
terms (“inflammatory bowel disease” OR “IBD” OR “crohn*” OR “CD” OR 
“ulcerative colitis” OR “UC” OR “colitis”) AND (“mucosal healing” OR “deep 
remission” OR “complete remission” OR “full remission” OR “endoscopic 
remission”) in Pubmed and EMBASE on October 1, 2018. 7,514 articles and 
abstracts were identified. Two authors independently reviewed the pub-
lications which defined deep remission. Publications which included pe-
diatric patients or were published in foreign language were excluded. A 
total of 37 peer-reviewed publications that defined deep remission were 
included. A classification system for deep remission was created based on 
the variety of definitions.
results: There were 9 different definitions of deep remission in the 37 
publications, involving combinations of the following remission variables: 
clinical, endoscopic, biochemical, histologic, radiographic, or immunolog-
ic. The majority of definitions, 21/37 (56.7%), only included clinical and en-
doscopic remissions as part of deep remission. The remaining definitions 
for deep remission were as follows: 4/37 (10.8%) with clinical, endoscopic, 
and biochemical remissions; 4/37 (10.8%) with endoscopic and histologi-
cal remissions; 3/37 (8.1%) with clinical, endoscopic and histologic remis-
sions; 1/37 (2.7%) with clinical, endoscopic, histologic, and biochemical re-
missions; 1/37 (2.7%) with clinical and radiographic remissions; 1/37 (2.7%) 
with histological remission, 1/37 (2.7%) with endoscopic and biochemical 
remissions, and 1/37 (27%) with immunologic and histologic remissions.
conclusion: Given there is no consensus definition for deep remission, we 
propose a classification system to simplify the combinations of remission 
variables recognized as definitions of deep remission. Our system recog-
nizes the most common definition of deep remission, clinical and endo-
scopic remission, as DR-A. However, the system allows for the flexibility 
of alternate definitions encompassing other remission variables. This is 
important as clinical treatment goals transition to tighter disease control, 
and physicians focus on different indicators of remission such as histologic 
or radiographic evidence. Future studies will likely assess greater num-
bers of remission variables to ensure complete dormancy of underlying 
inflammation in IBD patients. That transition is best represented in our 
classification system by DR-E. Our classification system is a stepping stone 
towards providing clarity amongst clinicians in discussions involving deep 
remission.
disclosure: Nothing to disclose 
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Type of deep remission definition
Deep Remission A (DR-A) Clinical Remission + Endoscopic Remission
Deep Remission B (DR-B)
Clinical Remission + Other Remission Variable 
(but not Endoscopic Remission)
Deep Remission C (DR-C)
Endoscopic Remission + Other Remission Variable 
(but not Clinical Remission)
Deep Remission D (DR-D)
2 Remission Variables 
(but not Clinical nor Endoscopic Remission)
Deep Remission E (DR-E)
>2 Remission Variables 
(any combination)
Remission Variables
Clinical, Endoscopic, Biochemical, Histological, 
Radiographic, Immunologic, or other remission types
[Deep Remission Classification System]
P1006 c86/cd16 POsITIve ceLLs accuMuLaTe In The MucOsa 
Of B3-PaTIenTs and cOuLd MedIaTe eMT In crOhn’s dIsease
Coll S.1, Cosin-Roger J.2, Navarro-Vicente F.3, Alos R.4, Calatayud S.5, 
Barrachina M.D.5, Ortiz-Masia D.6
1Universidad de Valencia, Pharmacology, Valencia, Spain, 2Unidad Mixta 
Facultad de Medicina-Hospital Dr Peset, FISABIO, Pharmacology, Valencia, 
Spain, 3Hospital de Manises, Manises, Spain, 4Hospital de Sagunto, Sagunto, 
Spain, 5Univ. de Valencia-CIBERehd, Pharmacology, Valencia, Spain, 
6CIBERehd-Univ. de Valencia, Dept. de Medicina, Valencia, Spain
contact e-Mail address: sandra.coll@uv.es
Introduction: Macrophages contribute to fibrosis through the release of 
different mediators and the pattern of secretion may vary according to 
their phenotype.
aims & Methods: The aim of the present study is to analyze the pattern 
of expression of macrophages, the expression of EMT related genes and 
cytokines in surgical resections from Crohn’s disease (CD, n=43) patients 
which were categorized according to Montreal classification (B2 or B3); 
unaffected mucosa of patients with colorectal cancer was used as control 
(n=20). mRNA was isolated from intestinal samples and the expression of 
macrophage and EMT markers and cytokines were analyzed by RT-PCR. 
PBMCS were isolated from healthy donors and treated during 5 days with 
secretomes, from control, B2 or B3 surgical resections; the mRNA expres-
sion of macrophage markers were determined by RT-PCR. Results are ex-
pressed as mean±SEM (n≥5). Statistical analysis was performed by ANOVA 
+ Newman-Keuls test. Correlations between data were analysed using 
Pearson’s correlation coefficient (*p < 0.05).
results: The expression of CD16 and CD86 was significantly higher in intes-
tinal samples from B3 CD patients (7,2 ±1,1 and 7,7±1,3, respectively) than 
in controls (1,4±0,2 and 2,5±0,4, respectively) or B2 CD patients (4,8±0,9 
and 4,5±0,6, respectively). The mRNA expression of CD16 and CD86 were 
significantly higher in PBMCS treated with B3-secretomes than in those 
treated with B2- or control secretomes. The expression of CD16 and CD86 
significantly correlated with FSP1 (r=0.74, P=0.002* and r=0.66, P=0.003*, 
respectively), VIMENTIN (r=0.60, P=0.02* and r=0.82, P=0.001*, respec-
tively), SNAIL1 (r=0.61, P< 0.01* r=0.52, P=0.04*, respectively), IL4 (r=0.63, 
P=0.01* and r=0.60, P=0.02*, respectively) and IFNγ (r=0.56, P=0.001* 
and r=0.58, P=0.01*, respectively) in intestinal tissue from the fistulizing 
CD group.
conclusion: A macrophage phenotype expressing CD86/CD16 may act as a 
source of EMT mediators in intestinal tissue from CD patients with a pen-
etrating (B3) behavior. IL4 and IFNγ could be responsible for the increase 
in the number of CD86/CD16 macrophages in the B3 behavior.
disclosure: Nothing to disclose 
P1007 cOrreLaTIOn Of The BIOLOgIcaL acTIvITy reLaTed 
TO sTerOId-refracTOrIness In uLceraTIve cOLITIs BeTWeen 
cOLOnIc TIssue and PLasMa
Clos Parals A.1, Loren V.2,3, Garcia-Jaraquemada A.4, Naves J.E.2, 
Cabré Gelada E.5, Segú C.6, Coma M.7, Manyé J.3,8, Domènech E.3,9
1Hospital Germans Trias I Pujol, Ap Digestivo, Badalona, Spain, 2Institut 
de Recerca Germans Trias i Pujol (IGTP), Badalona, Spain, 3CIBER de 
Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain, 4Inst 
Germans Trias I Pujol, IBD Unit, Barcelona, Spain, 5Hospital Germans Trias 
i Pujol, Gastroenterology Unit, Badalona, Spain, 6Anaxomics Biotech SL., 
Barcelona., Spain, 7Anaxomics Biotech SL., Barcelona, Spain, 8Germans 
Trias i Pujol Research Institute, Gastroenterology, Badalona, Spain, 9Hospital 
Germans Trias i Pujol, Gastroenterology Unit, Badalona, Barcelona, Spain
contact e-Mail address: ariadna.closparals@gmail.com
Introduction: The steroid-refractoriness is a common complication of ul-
cerative colitis (UC), which appears unpredictably. Several mechanism of 
action (MoA) has been implicated in corticosteroid (CS) failure, however, 
there are no conclusive studies on the molecular functions involved in it. 
Therefore, ourgroup used rectal biopsies from patients with active UC and 
different response to CS treatment to generate a predictive computational 
strategy based on Biology of Systems. Combining mRNA and miRNAs in-
testinal expression profiles with updated molecular information related 
to UC and CS, we were able to identify a MoA associated with steroid-
refractoriness in UC1.
aims & Methods: In order to transfer these results to clinical practice, we 
tried to explore the reflection of the biological activity of the intestinal 
mucosa into the plasma of these patients. 
RNA-seq (Illumina, USA)-assessed plasmatic miRNAs (pmiRNAs) were 
statistical compared between responders and non-responders CS patients. 
Differential pmiRNAs between both groups of patients and their target pro-
teins were identified. The resulting molecular data were compared with 
our previous intestinal mucosal results, following statistical approaches: 
a) pmiRNAs vsbiopsy differential miRNAs (bmiRNAs); 
b) Target proteins of pmiRNAs vs. those of the bmiRNAs; 
c) Target proteins of pmiRNAs vs.proteins encoded by mucosal mRNA dif-
ferentials; and 
d) Target proteins of pmiRNAs vs. key proteins linked to steroid-refracto-
riness MoA.
results: Four of the pmiRNA differentially expressed (miR-194-5p, miR-
145-5p, miR-216a-5p and miR-224-5p) were related to biopsies findings, 
either sharing the same protein target with the differential bmiRNA or 
linked to MoA key proteins. Interestingly, the miR-145-5p targeted directly 
VEGF-alpha (a down-regulated MoA-protein in responder’s patients1) and 
CDK4, an over-expressed protein at mRNA level in non-responder’s pa-
tients; while miR-224-5p targeted CXCR4 (over-expressed mRNA in non-
responder group) and NCOA6 (glucocorticoid receptor co-activator). Final-
ly, another one pmiRNA (hsa-miR-487a-3p) showed differences between 
patients in both tissues (intestinal mucosa and plasma), over-expressed in 
intestinal biopsies and suppressed in plasma of non-responder’s patients
conclusion: In conclusion, there is a biological steroid-refractoriness-MoA 
reflection from the intestinal mucosa to the plasma in patients with UC, 
which making up interesting molecules (miRNAs and proteins) as possible 
biomarkers or therapeutic targets to improve CS response
references: 1. Lorén V., et al. ANP32E, a Protein Involved in Steroid-Re-
fractoriness in Ulcerative Colitis, Identified by a Systems Biology Approach. 
Journal of Crohn’s and Colitis, 2019.
disclosure: Nothing to disclose 
588 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
P1008 effecTs Of usTekInuMaB MaInTenance TheraPy On 
endOscOPIc IMPrOveMenT and hIsTOLOgIc IMPrOveMenT In 
The unIfI Phase 3 sTudy In uLceraTIve cOLITIs
Li K.1, Friedman J.R.1, Marano C.1, Zhang H.1, Yang F.1, Sandborn W.J.2, 
Sands B.E.3, Feagan B.G.4, Peyrin-Biroulet L.5, Hertogh G.D.6
1Janssen Research & Development, LLC, Spring House, United States, 
2University of California, San Diego, United States, 3Icahn School of Medicine 
at Mount Sinai, Division Of Gastroenterology, New York, United States, 
4Robarts Clinical Trials Inc., Gastroenterology, London, Canada, 5Nancy 
University Hospital Inserm U 954, Hepato-Gastroenterology, Vandoeuvre les 
Nancy, France, 6KU Leuven, Pathology, Leuven, Belgium
contact e-Mail address: kli@its.jnj.com
Introduction: Ustekinumab is an effective therapy for moderate-to-severe 
ulcerative colitis (UC),1,2 but its effects on mucosal healing (endoscopic im-
provement + histologic improvement) during maintenance treatment are 
unknown.
aims & Methods: We evaluated the effects of maintenance ustekinumab on 
histologic and endoscopic activity in the UNIFI Phase 3 study of ustekinum-
ab in moderate-to-severe UC (n=961). Subjects in response 8 weeks after 
receiving intravenous ustekinumab were randomized to receive mainte-
nance treatment with subcutaneous (SC) placebo or ustekinumab 90 mg 
every 8 (q8w) or 12 weeks (q12w). Two colonic biopsies were collected 
from the distal colon at screening and Weeks 0 and 44 of maintenance. En-
doscopic improvement (EI) was defined as a Mayo endoscopy subscore < 1; 
histologic improvement (HI) comprised the following Geboes score-based 
criteria: absence of erosions or ulcerations, absence of crypt destruction, 
and < 5% of crypts with neutrophil infiltration. To encompass both macro- 
and microscopic scales, histo-endoscopic mucosal healing (MH) was de-
fined as achieving both EI and HI.
results: At maintenance Week 44, EI was achieved in 28.6%, 43.6%, and 
51.1% of subjects treated with placebo, ustekinumab q12w (p=0.002 vs 
placebo), and ustekinumab q8w (p< 0.001), respectively. HI was achieved 
at Week 44 in 32.9%, 54.0%, and 59.3% of subjects treated with pla-
cebo, ustekinumab q12w, and ustekinumab q8w, respectively (p< 0.001 
for both q12w and q8w). MH was achieved at Week 44 in 24.1%, 38.8%, 
and 45.9% of subjects treated with placebo, ustekinumab q12w (p=0.002), 
and ustekinumab q8w (p,0.001), respectively. HI at Week 44 (irrespective 
of maintenance treatment) was significantly associated with EI and MH 
(p< 0.001) and with both lower absolute levels and larger post-treatment 
changes in total Mayo score, partial Mayo score, and Mayo symptom sub-
scores for stool frequency and rectal bleeding at Week 44. Both EI and HI 
following 8 weeks of ustekinumab treatment were associated with clini-
cal remission and steroid-free clinical remission at Week 44 (p< 0.05), as 
well as remission through Week 44 (i.e. at both Week 8 and Week 44). 
For example, 26% of subjects with induction HI were in clinical remission 
through Week 44, versus 4% of subjects without induction HI. Induction 
MH was similarly associated with positive outcomes at maintenance Week 
44.
conclusion: Among subjects with moderately-to-severely active UC, those 
receiving SC ustekinumab maintenance had higher rates of EI, HI, and MH 
than those receiving placebo. Both EI and HI are associated with subse-
quent clinical remission and steroid-free clinical remission.
clinical Outcomes histologic Improvementa
Without histologic 
Improvementa p-value
b
Week 44 N=140 N=124  
Endoscopic Improvement 62% 47% <0.02
Mucosal Healing 59% 43% <0.02
Clinical Remission 54% 40% <0.02
Steroid-free Clinical Remission 52% 39% <0.04
Week 8 AND Week 44      
Endoscopic Improvement 31% 6% <0.0001
Mucosal Healing 40% 0% <0.0001
Clinical Remission 26% 4% <0.0001
a: Values are reported as mean ± SD.
b: P-values based on t-test.
[Proportions of Pts with or without Histologic Improvement at Wk8 Who 
Achieved Positive Clinical Outcomes at Wk44 in UNIFI Phase 3 Maintenance 
Study]
references: 1.BE Sands, et al. Safety and Efficacy of Ustekinumab Induc-
tion Therapy in Patients with Moderate to Severe Ulcerative Colitis: Results 
from the Phase 3 UNIFI Study. Presented at ACG 2018, October 9, 2018, 
Philadelphia, PA
2.WJ Sandborn, et al. Efficacy and Safety of Ustekinumab as Maintenance 
Therapy in Ulcerative Colitis: Week 44 Results from UNIFI. Presented at 
ECCO 2019, March 9, 2019, Copenhagen, Denmark..
disclosure: Drs. Li, Friedman, Marano, Zhang, and Yang are all employees 
of Janssen Research & Development, LLC Drs. Sandborn, Sands, Feagan, 
Peyrin-Biroulet,and De Hertogh are all investigators for Janssen Research 
& Development, LLC 
P1009 In vITrO InhIBITIOn Of endOPLasMIc reTIcuLuM 
sTress In PaTIenTs WITh crOhn’s dIsease
Rodrigues B.L.1, Pascoal L.B.1, Coope A.1, Ayrizono M.L.S.1, Camargo M.G.1, 
Velloso L.A.2, Fagundes J.J.1, Leal R.F.1
1University of Campinas, Department of Surgery, Colorectal Surgery Unit, IBD 
Research Laboratory, Campinas, Brazil, 2University of Campinas, Laboratory 
of Cell Signaling, School of Medical Sciences, Campinas, Brazil
contact e-Mail address: brunnu.lima@gmail.com
Introduction: Endoplasmic reticulum (ER) is responsible for the synthesis 
and processing of secretory and membrane proteins. The stress state of the 
endoplasmic reticulum (ERS) occurs due to the inability of certain proteins 
to adopt the appropriate conformation stage, thus leaving them unfolfed 
within the ER. The accumulation of unfolded proteins is detrimental to 
the cell, which may respond by driving the proteins to degradation, paus-
ing the transcription process or even initiating apoptosis(1). Gene associa-
tion and meta-analysis studies show that ERS possibly correlates with the 
pathogenesis of Crohn’s disease (CD)(2).
aims & Methods: Our aim was to investigate the occurrence of ERS in 
the intestinal mucosa of patients with CD, and to evaluate the effect of a 
chemical inhibitor on its activation and modulation of pro-inflammatory 
cytokines. Biopsies of intestinal mucosa were collected by colonoscopy 
from patients with CD (CD group) and patients who did not present inflam-
matory bowel diseases (control group). 
Cell culture was performed to evaluate the ERS and its potential resolution 
with chemical inhibitor. Non-parametric tests were performed for statisti-
cal analysis, with p < 0.05. The study was approved by the Research Ethics 
Committee.
results: Samples were collected from 10 patients with active CD (CDEIS≥5) 
and 6 control patients. After cell culture, a significant difference was 
observed in the activation of the main ERS pathways in the CD group. 
A modulation in the expression of pro-inflammatory cytokines was also 
observed after the treatment. Treatment with a chemical inhibitor also led 
to a significant decrease in the expression of the genes responsible for the 
activation of ERS pathways and to a decrease in the main inflammatory 
cytokines present in CD.
conclusion: The activation of the main ERS pathways suggests a role in 
the maintenance of the inflammatory process in CD. The use of a chemical 
inhibitor has been shown to be effective in significantly decreasing the 
activation of ERS and to modulate the inflammation in CD.
references: 1) Hotamisligil G.S. (2010) Endoplasmic reticulum stress and 
the inflammatory basis of metabolic disease. Cell 140, 900-917 2) Hoefkens 
E, Nys K, John JM et al., Autophagy. 2013 Dec;9(12):2046-55.
disclosure: Nothing to disclose 
P1010 Presence Of anxIeTy and dePressIOn In PaTIenTs 
WITh InfLaMMaTOry BOWeL dIsease In aLBanIa
Kocollari A.1, Sina M.1, Prifti S.1, Kristo A.2, Horanlli D.1, Pengili E.1
1University Hospital Center Mother Teresa, University Clinic of 
Gastrohepatology, Tirana, Albania, 2University Hospital Center Mother 
Teresa, Faculty of Medicine, Tirana, Albania
contact e-Mail address: adeak89@hotmail.com
Introduction: The presence of anxiety and depression is higher in patients 
with chronic diseases compared to the general population. A long term 
medical illness may become a risk factor for depression. There is important 
evidence that inflammatory bowel disease (IBD), which includes Crohn’s 
disease (CD) and ulcerative colitis (UC), is associated with higher rates of 
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anxiety and depression compared to the general population¹. Despite this 
knowledge, IBD patients are not routinely screened for depression and 
anxiety.
aims & Methods: The aim of our study was to show the prevalence of 
anxiety and depression in IBD patients in Albania and also to evaluate 
its correlation with the disease severity.This is a prospective study of IBD 
patients, followed-up in a 2 year period, at the University Hospital Mother 
Theresa, in Tirana, which represents the largest in and outpatient facility in 
Albania. The presence of anxiety and/or depression was determined using 
the Hospital Anxiety and Depression Scale², compiled under the explana-
tions and supervision of medical staff. Patients with known mental ill-
ness followed by Psychiatry were excluded. Patient demographics, disease 
characteristics and medication information were collected. Multivariable 
analysis was used to determine associations between patient character-
istics and depression and/or anxiety. Statistical analysis was made with 
Chi-square (p-value, significance level: 0.05).
results: We have followed 46 IBD patients (26 F : 20 M), on treatment with 
anti-TNF since July 2016. Of these, there were 9 patients (19%) with Crohn’s 
disease and 37 patients (81%) with Ulcerative Colitis. 16 patients (34%) 
were under treatment with Adalimumab and 30 patients (66%) were un-
der treatment with Infliximab.Among these 46 IBD patients, there were 
18.7% with depression and 34.3% with anxiety, wih a rate of 40.6% of pa-
tients suffering from depression and/or anxiety. Females were more likely 
to have anxiety with a significantly rate of 63% compared to males: 27%. 
Ulcerative colitis patients were also more likely to have depression and/
or anxiety (84.6%) than Crohn’s disease patients (15.4%). Disease activity 
calculated by Mayo score (for UC) and CDAI score (for CD), was found to be 
significantly associated with depression and/or anxiety. Correlation coef-
ficient (r) between depression and disease activity was: - 0.314, while for 
anxiety, it was calculated: -0.298 (p values respecitively: 0.03 and 0.04).
conclusion: A significant number of patients with IBD, suffer from depres-
sion and/or anxiety and this has an important impact on their quality of 
life. Patients with a severe disease activity are at a higher risk for anxi-
ety and depression and this may suggest that it can be important to start 
screeningall the IBD patients with this questionnaire in order to evaluate 
them and eventually refer them to the psychiatrists.
references: 1. Graff L. A., Walker J. R., Bernstein C. N. Depression and 
anxiety in iflammatory bowel disease: a review of comorbidity and 
management. Inflammatory Bowel Diseases. 2009;15(7):1105-1118. 2. 
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta 
Psychiatr Scand 1983;67:361-370.
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sPOndyLOarThrITIs assOcIaTed WITh IBd
Selvarajah U.1,2, Miguens Blanco J.1, Martinez-Gili L.1, Pechlivanis A.1, 
Radhakrishnan S.1,2, Keat A.3, Williams H.R.T.1,2, Marchesi J.1, Machado P.3, 
Orchard T.1,2
1Imperial College London, Department of Surgery & Cancer, London, United 
Kingdom, 2Imperial College Healthcare NHS Trust, London, United Kingdom, 
3London North West Healthcare, Harrow, United Kingdom
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Introduction: Prevalence of axial spondyloarthritis in inflammatory bowel 
disease (axSpA-IBD) is up to 25 times higher than in the normal pop-
ulation, and there is some evidence to suggest that different forms run 
different courses. In addition, the very strong association with HLA-B*27 
seen in axial spondyloarthritis not associated with IBD (axSpA-not IBD) 
is much weaker in axSpA-IBD. This difference leads us to conclude that 
environmental factors, particularly the milieu (microbiome, metabonome 
and inflammatory status) in the gut lumen may be important in defin-
ing the course of disease. Establishing axSpA- IBD from axSpA-not IBD is 
important for both management and prognostic reasons. Here we present 
initial analysis from proton high-resolution nuclear magnetic resonance 
(1H-NMR) spectroscopy, profiling human serum, urine and stool to test the 
hypothesis that metabolites differ between ax-SpA-IBD, ax-SpA-not IBD, 
psoriatic peripheral arthritis (PsA) and control cohorts (HC). We have used 
multivariate statistics analysis to find distinct metabolic signatures across 
the cohorts.
aims & Methods: 1H-NMR spectra were acquired from serum, urine and 
stool samples of 71 patients (23 ax-SpA- not IBD, 15 ax-SpA-IBD, 16 PsA and 
17 HC) in a Bruker 600 MHz NMR spectrometer, following Bruker SOP pro-
tocols. Multivariate analysis of all NMR features involved principal com-
ponents analysis (PCA) and orthogonal partial least squares discriminant 
analysis (OPLS-DA). NMR resonances for assigned metabolites influenced 
by gut microbiota were compared using Mann-Whitney U test.
results: PCA revealed clustering of the groups; OPLS-DA modeling in stool 
metabolites was able to distinguish between ax-SpA- not IBD and ax-SpA-
IBD cohorts (Q2Y 0.468, p-values for 1,000 random permutations: pR2Y= 
0.102 and pQ2Y= 0.002). In this initial analysis, there was no differentiation 
between cohorts in urine and serum.
conclusion: (1)H NMR-based metabolic profiling is able to distinguish 
between ax-SpA- IBD and ax-SpA- not IBD in stool. Further modeling of 
urine and serum metabolic profiles will be undertaken to examine wheth-
er the differences in stool are reflected in other biofluids as well as deeper 
analysis specific metabolites.
references: Asquith, M et al. The role of the gut and microbes in the 
pathogenesis of spondyloarthritis. Best Pract Res Clin Rheumatol. 2014 
Oct;28(5):687-702. Orchard, TR et al. The prevalence, clinical features and 
association of HLA-B27 in sacroiliitis associated with established Crohn’s 
disease. Aliment Pharmacol Ther. 2009 Jan;29(2):193-7. Williams HR et al. 
Characterization of inflammatory bowel disease with urinary metabolic 
profiling. Am J Gastroenterol. 2009 Jun;104(6):1435-44. Hicks LC et al. 
Metabonomics and diagnostics. Methods Mol Biol. 2015;1277:233-44.
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P1012 The jak InhIBITOr-TOfacITInIB InhIBITs sIgnaLIng 
PaThWays EX-VIVO and has funcTIOnaL IMPLIcaTIOns In huMan 
InTesTInaL MucOsa
Kaboub K.1,2, Cohen-Kedar S.1,3, Wasserberg N.4, Hayman-Manzur L.5, 
Berger Y.4, Levy-Barda A.6, Yanai H.2,3, Dotan I.2,3, Rabinowitz K.M.1,3
1Rabin Medical Center and Tel Aviv University, The Felsenstein Medical 
Research Center, Petah Tikva, Israel, 2Tel Aviv University, Sackler 
Faculty of Medicine, Tel Aviv, Israel, 3Rabin Medical Center, Division of 
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Campus, Surgery, Petah Tikva, Israel, 5Rabin Medical Center, Beilinson 
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contact e-Mail address: kawsarkaboub@gmail.com
Introduction: Tofacitinib, an orally administered pan-Janus kinase (JAK) 
inhibitor modulating the JAK-STAT (signal transducers and activators of 
transcription) signaling pathway, is used for the treatment of patients with 
ulcerative colitis (UC). Tofacitinib effects in the intestinal mucosa are still 
elusive.
aims & Methods: To identify tofacitinib effects in human intestinal mucosa 
and to decipher whether discordant responses occur in the normal or in-
flamed mucosa of patients with UC or Crohn’s disease (CD).
Human mucosal explants were obtained from patients with inflamma-
tory bowel disease (IBD) and normal controls. Phosphorylated STAT (p-
STAT) levels were assessed using Western blot and Immunofluorescence. 
Lamina propria lymphocytes were isolated from explants and stimulated 
with anti-CD3/CD28 beads in the presence or absence of tofacitinib for 3 
days. Cytokine production by CD3+ T cells and cell viability were assessed 
by flow cytometry. T
84
 intestinal epithelial cell (IEC) lines were cultured 
on transwells for 12-14 days to generate epithelial barrier, measured as 
transepithelial electrical resistance (TEER), and stimulated with IL-13 baso-
laterally in the presence or absence of tofacitinib for 24h. Permeability was 
assessed by TEER measurements and Claudin-2 (CLDN2) gene expression, 
assessed using RT-PCR.
results: Mucosal explants were obtained from 11 subjects (7 controls, 4 
CD). p-STAT1 and p-STAT3 expression was located mainly in the lamina 
propria and was higher in explants with active inflammation compared 
to normal controls. A dose-dependent decrease in p-STAT1 and p-STAT3 
expression in response to tofacitinib was observed compared to non-treat-
ed (NT) mucosa. Normal controls and explants obtained from areas with 
active inflammation responded similarly. Interestingly, significantly more 
potent inhibitory effect on STAT1 compared to STAT3 phosphorylation was 
observed (100nM tofacitinib compared to NT, p< 0.0023). 
Moreover, upon tofacitinib treatment, CD3+ IL4+ and CD3+ IFN-γ+ cells, iso-
lated from normal and explants with active inflammation, were decreased 
in a dose-dependent manner (35.5% and 37.5% without tofacitinib; 20.1% 
and 25% with 10nM; 11.6% and14.5% with 100nM tofacitinib, respectively). 
No significant effect on IL-17 production by T cells or on T cells mortality 
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was observed. In T
84
 cells, tofacitinib prevented IL-13-induced decrease in 
TEER and increase CLDN2 expression in a dose dependent-manner (p< 
0.001 and p< 0.0054, respectively; n=3).
conclusion: Tofacitinib was a more potent inhibitor of specific p-STAT in 
the intestinal mucosa of both normal controls and patients with IBD. In-
flamed mucosal explants from patients with CD responded to tofacitinib 
by inhibiting JAK-STAT signaling pathway and cytokine secretion by intes-
tinal lymphocytes. Furthermore, tofacitinib ameliorated epithelial barrier 
disruption induced by IL-13. Thus, beneficial effects are expected in CD. 
Ex-vivo examination of drug effects in the intestinal mucosa may be used 
as a tool for evaluation of treatment effects.
disclosure: The study is an investigator-initiated research funded by Pfizer 
P1013 seLf-asseMBLIng PePTIde hydrOgeL enhances 
InTesTInaL BarrIer funcTIOn In TOPIcaL TnBs MOdeL In raTs
Araki T.1, Yamauchi R.1, Yamasaki H.1, Morita M.1, Yoshimura T.1, Mori A.1, 
Fukunaga S.1, Kuwaki K.1, Yoshioka S.1, Mitsuyama K.1,2, Torimura T.1
1Kurume University School of Medicine, Department of Medicine, Kurume, 
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Introduction: Inflammatory bowel disease (IBD) often forms intractable 
ulcers. Self-assembling peptide hydrogel (SAPH, PuraMatrixTM, 3D Matrix 
Co., Ltd., Tokyo) is composed of only amino acids present in the living 
organisms; its forms nanofibers with a diameter of 10 nm and forms a gel 
when it comes in contact with blood or bodily fluids or under physiological 
conditions. In recent years, SAPH has also been reported to promote re-
generation of damaged sites in various organs. However, the tissue repair 
effect of SAPH in ulcers of IBD is not reported yet. In this study, we evalu-
ated the effect of SAPH on repairing ulcers using the rat model topical 
trinitrobenzene sulfonic acid (TNBS) -induced colitis.
aims & Methods: Seven-week-old male SD rats were laparotomized un-
der anesthesia. The proximal colon was clamped with ringed forceps. An 
ethanol solution (35%; 0.2 ml) containing 0.15 M TNBS was injected into 
the proximal colon lumen via a needle to prepare a localized ulcer model. 
On the second and fourth day, SAPH (n = 6) or saline (n = 5) was applied 
to the ulcerated area under colonoscopy. On the second, fourth and sev-
enth days, the ulcer size was measured with an endoscope. The rats were 
sacrificed on the 7th day, and the ulcer area of the colon, colonic weight 
(g /3 cm), and histologic findings were evaluated. The tissue levels of pro-
inflammatory cytokines (interleukin [IL]-1α, IL-6, IL-22 and tumor necrosis 
factor [TNF]-α) and tight junctions (cloudin [Cldn]-1, Cldn-2, occludin, cad-
herin-1, Zo-1, Zo-3)) in tissue were determined using real time-PCR.
results: 
(i) Endoscopic evaluation: SAPH group showed reduction in ulcer size as 
compared with that in the control group (P = 0.015). 
(ii) Macroscopic finding evaluation: Ulcer area was significantly reduced 
in the SAPH group than in the control group (P = 0.024). Colonic weight 
also tended to decrease in the SAPH group compared to the control group. 
(iii) Real time-PCR analysis: In the SAPH group, expression of several pro-
inflammatory cytokines (IL-1α and IL-6) decreased and expression of cldn-1 
increased (p < 0.05).
conclusion: SAPH effectively suppresses colonic injury through the down-
regulation of pro-inflammatory cytokines and the up-regulation of cldn-1. 
Use of SAPH has been suggested to be a potential therapeutic strategy for 
refractory ulcers of the intestinal tract in IBD.
disclosure: Nothing to disclose 
P1014 gLucOcOrTIcOId augMenTs ePITheLIaL PerMeaBILITy 
In cd PaTIenT-derIved InTesTInaL OrganOIds
Xu P.1, Pierik M.J.2, Becker H.3, Masclee A.A.2, Jonkers D.M.4
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Introduction: Intestinal barrier dysfunction has emerged as a key patho-
genic factor contributing to the onset and exacerbation of Crohn’s Disease 
(CD). Exogenous glucocorticoid (GC) is a first-line therapeutic for the treat-
ment of moderate to severe CD. Recently, GC therapy was shown to restore 
intestinal permeability in CD patients. However, the underlying mecha-
nisms remain largely unknown.
aims & Methods: The main aim of the study was to investigate the effect of 
glucocorticoid prednisolone on intestinal barrier integrity and to elucidate 
the underlying molecular mechanisms using CD patient-derived intestinal 
organoids. Hollow 3D intestinal organoids were generated from stem-cell 
containing crypts isolated from proximal colon biopsies of remissive CD 
patients (SES-CD< 3, n=6, ethical approval NL31636.068.10). To mimic the 
inflammatory microenvironment, a mixture of cytokines containing TNF-α, 
IFN-Ƴ and IL-1β (20 ng/mL each) were added to the culture medium for 
24 hours, with or without prednisolone (500 ng/mL) for 12 hours. Epithe-
lial permeability of the organoids was assessed by the flux of fluorescein 
isothothiocyanate-labelled dextran 4 kDa (FITC-D4) from the basal to the 
luminal compartment using confocal microscopy. Gene expression and 
localization of barrier junctions were analyzed by qRT-PCR and immuno-
fluorescent staining. Cell signaling activities were analyzed using west-
ern blot. Data are expressed as means ± SEM. Statistical significance was 
evaluated using one-way ANOVA and Tukey’s post-hoc test.
results: Exposure of the cytokine mixture significantly disrupted epi-
thelial barrier function of the intestinal organoids, as evidenced by in-
creased luminal/basal FITC-D4 ratio as compared to the control treatment 
(5.051+0.376 vs 1.000+0.098, p< 0.001). This effect was partially rescued 
upon prednisolone supplementation (1.857+0.214 vs 5.051+0.376, p< 
0.001). Compared to the control treatment group, exposure of cytokine 
mixture resulted in a significant reduction of E-Cadherin and an increase 
of Claudin-2 on both mRNA and protein levels, and led to an increased 
phosphorylation of MLCK. Supplementation of prednisolone ameliorated 
the junctional alterations and barrier dysfunction induced by the cytokine 
mixture (p< 0.05).
conclusion: Using CD patient-derived intestinal organoid model, we dem-
onstrated that glucocorticoid prednisolone has a protective effect against 
the cytokine-induced epithelial barrier dysfunction. Prednisolone pro-
motes epithelial integrity through enhancing the expression of E-Cadherin 
and reducing the expression of Claudin-2, and inhibiting the cytokine-in-
duced MLCK phosphorylation. Our findings provide a novel mechanism for 
the beneficial effect of prednisolone in the treatment of IBD.
disclosure: Nothing to disclose 
P1015 dIfferences In IMMune ceLL POPuLaTIOn suBseTs 
In InfLaMMaTOry BOWeL dIsease PaTIenTs under anTI-Tnf 
TreaTMenT and heaLThy cOnTrOLs
Barreiro-De Acosta M.1,2, Notarariego S.3, Viñuela-Roldan J.E.4, 
Romero P.2, Quiroga-Castiñeira A.1,2, Dominguez-Muñoz J.E.1,2
1University Hospital of Santiago de Compostela, Gastroenterology, Santiago 
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Santiago de Compostela, Spain, 3Health Research Institute of Santiago de 
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Hospital of Santiago de Compostela, Immunology, Santiago de Compostela, 
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contact e-Mail address: manubarreiro@hotmail.com
Introduction: Inflammatory bowel disease (IBD) is a chronic inflamma-
tion that affect gastrointestinal tract, especially small and large bowel. The 
pathogenesis seems to be related to environmental factors and genetic 
susceptibility that put together lead to the failure of functions in several 
immune system process like: loss of tolerance in Treg cells, detriment of 
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apoptosis in Th1/Th17 cells and exacerbate of proinflammatory cytokines 
production of TNF-α, IFN-γ and IL-17. B cells are gaining interest in this 
inflammatory process considering that their depletion is not favourable 
for the disease course. Anti TNF-α treatment usually re-establish a fair B 
cell level and the monitoring of the transitional B gather the condition of a 
good market to follow the disease development.
aims & Methods: The aim of this study is to reveal the existence of a spe-
cific immune system cell pattern; to discover T cell ability of cytokines pro-
duction and transcription factor activation; among IBD patients in remis-
sion under infliximab (IFX) therapy.
A pilot case-control study was performed. Inclusion criteria were IBD 
patients in clinical remission under maintenance IFX treatment. After in-
formed consent, blood samples were obtained in IBD patients just before 
IFX infusions and in healthy controls. Participants were classified in dif-
ferent groups: Healthy control (HC), Crohn’s disease (CD) and ulcerative 
colitis (UC). Remission was defined as a Partial Mayo < 2 in UC and a 
Harvey-Bradshaw < 4 in CD. Blood samples were used to determine the 
immune cell status of patients and negative controls. To investigate the 
immune system cell distribution, peripheral mononuclear blood cells were 
isolated from fresh blood in order to characterize: monocyte, dendritic 
cells (DC), Th1, Th17, Treg and B cell. Cells were then incubated with a spe-
cific fluorescent antibodies’ cocktails, then identified with flow cytometry. 
T cells ability to produce TNF-alpha, IL-17 and INF-gamma was tested by 
performing intra cellular staining, while T-bet, Fox-P3 and Ror-gamma t 
expression thought intra nuclear staining, data were collected with flow 
cytometry. Results are shown in percentages and analyzed with Prism 5.0, 
for parametric data.
results: Thirty participants were consecutively included, 10 CD, 10 UC, 
mean age of 45, all in remission under IFX maintenance therapy and 10 
HC. The surface staining demonstrated differences between the group’s 
cell subtype. CD and UC patients showed a decrease of CD25Hi CD127- Treg 
subset, vs negative control, pointing out that UC patients decrease 2%, 
while CD only 1%. Decrease of transitional B cell subset CD38Hi CD24Hi 
CD19+ was observed in CD and UC patients. The cytokine production in 
T cell, showed a significant increase of TNF-alpha (50-60% vs 20-30% 
HC), especially in IL-17(5% vs 1-2% HC), while no significant different was 
observed in IFN-gamma production. Regarding the transcription factor ex-
pression T-bet and FoxP3 increased significantly in CD and CU vs HC, with 
a clear tendency of CD patients to express more FoxP3 than UC patients, 
while Ror-γt was more specifically expressed in UC than CD.
conclusion: The immune system cell subset is highly modified by the IBD 
disease type (CD, UC) despite being in remission under anti-TNF therapy, 
indeed the T cell ability to cytokine production demonstrate their deregu-
lation towards the Th1 phenotype. Transcription factors expression showed 
as well this unbalance leading to Ror-γt and FoxP3.
disclosure: Nothing to disclose 
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Introduction: Local extracellular acidification occurs at sites of inflamma-
tion and ischemia. Protons present in an acidic microenvironment may 
lead to activation of pH-sensing G protein-coupled receptor GPR68, also 
known as ovarian cancer G protein-coupled receptor 1 (OGR1). Recent 
studies suggest a link between IBD and this pH-sensing receptor. We pre-
viously reported that GPR68 is regulated by tumor necrosis factor (TNF) via 
a NF-κB dependent pathway. 
Further, we demonstrated that GPR68 regulates barrier function and epi-
thelial restoration, and that GPR68 expression is enhanced in intestinal 
inflammation in IBD patients. We have also shown that the genetic abla-
tion of GPR68 ameliorates colitis in different murine models. In the current 
study, we investigated the effects of a novel GPR68 antagonist in a murine 
colitis model.
aims & Methods: Acute colitis was induced in wild type (C57BL/6) mice 
by the addition of 1.5% dextran sulfate sodium salt (DSS) in the drink-
ing water for 7 consecutive days. The small molecule GPR68 inhibitor was 
administered by oral gavage in a vehicle solution (methylcellulose 0.5%), 
twice daily (interval of 12 h). Doses used were per kilogram bodyweight 
per day: 25 mg, 50 mg, 100 mg (n=10 mice per group). Water or DSS con-
trol groups were gavaged with vehicle solution without inhibitor (n=10 
mice per group). On day 8, mice were sacrificed and inflammatory param-
eters were evaluated.
results: An amelioration of murine DSS-induced colitis in the GPR68 -in-
hibitor treated group compared to DSS-treated control animals was ob-
served. Endoscopy revealed that GPR68 -inhibitor treated mice showed 
a lower MEICS score, indicating reduced inflammation compared to DSS 
control animals. 
Macroscopically, the colon tissue of the inhibitor treated mice showed no 
thickening, vascularity was similar to water control mice and no fibrin was 
detected. However, inhibitor treated mice showed an elevated score in 
stool consistency. Further colon shortening was significantly reduced in 
treated mice, indicating an attenuation of colon inflammation. 
Microscopically, H&E staining revealed that inhibitor treated mice exhib-
ited markedly less infiltration and epithelial damage compared to DSS 
control mice. Immunohistochemistry (IHC) staining for the cellular pro-
liferation markers Ki67 showed slightly enhanced proliferation in inhibitor 
treated mice compared to DSS control mice. 
Moreover, decreased infiltration of T-cells was observed in treated mice 
compared to the DSS control group. However, a difference in body weight 
or health score could not be demonstrated among the groups treated with 
the inhibitor compared to controls, and MPO activity and neutrophil infil-
tration did not differ between groups.
conclusion: .The inhibition of GPR68 has an ameliorating effect on the 
extent of DSS-induced colitis in wild type mice. Our data suggests that 
targeting proton-sensing GPR68 by a specific small molecule antagonist 
may be a novel therapeutic approach for the treatment of IBD.
disclosure: Nothing to disclose 
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Introduction: Transient receptor potential (TRP) channels have been iden-
tified as cellular sensors of exogenous and endogenous environments, 
agents and mediators. Previous studies have focused on the expressions of 
these TRP channel members in colonic tissue of patients with inflamma-
tory bowel disease (IBD), whereas no data exists regarding the expressions 
of these channels in peripheral blood mononuclear cells (PBMCs). We ex-
amined, for the first time, the comprehensive expression profile of TRP 
channels belonging to the TRPV (vanilloid) and TRPM (melastatin) channel 
superfamilies in PBMCs from patients with IBD.
aims & Methods: PBMCs were obtained from 44 patients with ulcerative 
colitis (UC), 35 patients with Crohn’s disease (CD), and 45 normal subjects. 
The mRNA levels of TRP channels and pro- and anti-inflammatory cyto-
kines, TNF-alpha, IL-1 beta, IL-6 and IL-10, in the PBMCs were measured 
using a quantitative real-time-polymerase chain reaction, and the disease 
activities were compared according to laboratory parameters.
results: Overall, the mRNAs of each of the TRP channel members were 
expressed at different levels in the PBMCs from patients with IBD. Com-
pared with the levels in the PBMCs from normal controls, the expression of 
TRPV2 mRNA was significantly lower and that of TRPM2 mRNA was higher 
in PBMCs from both patients with UC and those with CD. 
The expressions of TRPV3 and TRPM5 mRNAs were lower and that of 
TRPV4 mRNA was higher only in PBMCs from patients with CD. Comparing 
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the two diseases, the expressions of TRPV1 and TRPV3 mRNAs were lower 
and that of TRPV4 mRNA was higher in the PBMCs from patients with CD 
than in those from patients with UC. The expression of TRPV2 mRNA was 
negatively correlated with disease activity in the UC and CD groups, while 
the expression of TRPM4 mRNA was negatively correlated with disease 
activity only in the UC group. 
Significant correlations between the expressions of individual TRP channel 
members were observed in both the UC and CD group. The expression of 
IL-6 mRNA, TNF-alpha and IL-1 beta mRNA, was correlated with that of 
TRPV1 and TRPV3 mRNA in UC and TRPM5 mRNA in both UC and CD. The 
expression of IL-10 mRNA was negatively correlated with that of TRPV2 and 
TRPM2 mRNA in UC.
conclusion: The present results indicate, for the first time, that PBMCs from 
patients with IBD exhibit varying mRNA expression levels of TRP channel 
members, which may play an important role in the progression of IBD. In 
addition, the expression levels of these TRP channel members in PBMCs 
are promising markers for IBD. Further studies are needed to determine 
the clinical and pathogenic role of TRP channels in IBD.
disclosure: Nothing to disclose 
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Introduction: Many patients with Inflammatory Bowel Disease (IBD) ex-
hibit extra-intestinal disease symptoms and anemia is the most common 
hematological manifestation affecting up to two thirds of the patients. IBD-
associated anemia is considered to be the result of a combination of iron 
deficiency anemia (IDA) and anemia of chronic disease (ACD). In case of 
IDA, patients often require intravenous iron supplementation, as this is 
known to increase patients’ disease outcome and quality of life. 
However, in clinical practice, it is difficult to determine the responsiveness 
of patients to iron treatment. Iron homeostasis is intimately associated 
with oxygen metabolism in the intestinal mucosa, which is regulated by 
the hypoxia-inducible factor-1alpha (HIF-1α) pathway. Here, iron (Fe2+) is a 
critical cofactor to the hydroxylase reaction that targets the HIF-1α protein 
to degradation in the presence of oxygen. 
Therefore, an interplay between Fe2+ levels and the HIF-1α pathway regu-
lates oxygen sensing in human epithelial cells and may be a crucial mech-
anism underlying IDA in IBD patients. In this study, we aimed to determine 
the association between serum iron status and activation of the HIF-1α 
pathway in mucosal biopsies of IBD patients.
aims & Methods: Biopsies were collected from both ileum and colon and 
evaluated for their inflammatory status. In addition, serum laboratory pa-
rameters of iron metabolism close to biopsy dates (hemoglobin, MCV, free 
iron, ferritin, TYBC, transferrin, transferrin saturation) were documented. 
Based on serum iron status and inflammation, patients were categorized 
into either a group having ‘normal’ iron status (n=81) or a group having 
systemic IDA (n=29). RNA sequencing data (n=167 entries) from intestinal 
biopsies of 110 IBD patients were retrospectively analyzed for 18 HIF-1α 
pathway genes, including HIF1A, HIF2A, HIF-hydroxylases (EGLN1, EGLN2) 
and HIF-1α target genes (EGLN3, CA9, PDK1, SLC2A1, MUC3, TFF3, A2BAR, 
SLC29A1, ADK, HAMP, SLC11A2, HMOX1, TFRC and TF), some of which are 
involved in iron metabolism, and analyzed for differential expression with 
iron status.
results: The HIF-1α pathway was activated in inflamed ileal and colonic 
tissue compared to adjacent non-inflamed tissue. Moreover, IBD patients 
with systemic IDA showed increased expression of HIF-1/2α target genes in 
inflamed tissue, with significantly elevated mucosal levels of ileal SLC11A2 
(P< 0.05) and PDK1 (P< 0.05) and colonic TFRC (P< 0.05) levels. mRNA 
levels of HIF1A, HIF2A and the HIF-hydroxylases EGLN1 and EGLN2 were not 
different between patients with or without IDA.
conclusion: IBD patients with systemic iron deficiency show differential 
expression of HIF-1α target genes SLC11A2, PDK1, SLC2A1 and TFRC as com-
pared to patients with a normal iron status. These preliminary data sug-
gest an association of systemic iron status in IBD and activation of the HIF-
1α pathway in the intestinal mucosa. These data reveal a possible disease 
mechanism involved in IBD-associated anemia that can be modulated by 
treatment.
disclosure: Nothing to disclose 
P1019 nexT-generaTIOn sequencIng-Based evIdence 
fOr a decrease Of guT MIcrOBIOTa BuTyraTe PrOducTIOn 
caPaBILITy In crOhn’s dIsease
Markelova M.1, Danilova N.1, Boulygina E.1, Grigoryeva T.V.1, Odintsova A.2, 
Abdulkhakov R.3, Ardatskaya M.4, Lo Sasso G.5, Battey J.5, Sierro N.5, 
Poussin C.5, Ivanov N.5, Peitsch M.5, Hoeng J.5, Abdulkhakov S.1,3
1Kazan Federal University, Institute of Fundamental Medicine and Biology, 
Kazan, Russian Federation, 2Republican Clinical Hospital of Tatarstan 
Republic, Kazan, Russian Federation, 3Kazan State Medical University, 
Kazan, Russian Federation, 4Central State Medical Academy of Administrative 
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Introduction: Butyrate is an essential metabolite in the human gut, as it 
is the preferred source of energy for colon epitheliocytes and is known for 
its anti-inflammatory properties. The main source of butyrate is bacterial 
fermentation of fiber. It is known that the microbiota of Crohn’s disease 
(CD) patients is characterized by reduced abundance of butyrate-produc-
ing bacteria. The four major pathways involved in butyrate synthesis are 
acetyl-CoA, lysine, 4-aminobutyrate, and glutarate pathways.
aims & Methods: The aim of the study was to reveal the differentially 
abundant genes encoding enzymes involved in butyrate synthesis path-
ways in the gut microbiota of CD patients compared to the control group. 
The study included 40 CD patients and 42 healthy controls. Total DNA was 
extracted from stool samples and sequenced using the NextSeq 500 plat-
form (Illumina). Reads were mapped to the ChocoPhlAn database using 
the HUMAnN2 algorithm to assess the representation of microbial meta-
bolic pathways. Relative abundances of genes were calculated as “cpm” 
- a number of reads mapped to a gene divided by the total number of 
mapped reads; p< 0.05 was considered as statistically significant. Butyr-
ate levels were measured in stool samples by gas-liquid chromatography.
results: Butyrate levels were significantly decreased in the stool samples 
of CD patients (1.14±1.1 µg/g) compared to the control group (1.82±1.55 
µg/g). All of the pathways mentioned above include conversion of cro-
tonyl-CoA to butyryl-CoA catalyzed by butyryl-CoA dehydrogenase (Bcd). 
Abundance of the Bcd gene was not significantly different between the 
CD and control groups. The final stage of butyrate synthesis is transfor-
mation of butyryl-CoA catalyzed by butyryl-CoA:acetate CoA-transferase 
(But), or alternatively by butyrate kinase (Buk); this stage is catalyzed 
by butyryl-CoA:acetoacetate CoA-transferase (Ato) in the lysine pathway. 
Abundance of the But gene also did not differ between the groups. How-
ever, abundances of phosphotransbutyrylase (Ptb) and Buk genes coding 
enzymes that catalyze butyryl-CoA transformation to butyrate through bu-
tyryl-phosphate were reduced in CD patients (1.9±3.2 cpm and 45.9±30.5 
cpm) compared to controls (2.4±1.9 cpm and 63.3±21.1 cpm, respectively). 
Most butyrate-producing bacteria have only one type of enzyme - But or 
Ptb+Buk - for the last stage of butyrate synthesis. Thus, the microbiota of 
CD patients is supposed to be depleted in bacteria carrying Ptb+Buk genes.
The acetyl-CoA pathway is present in the majority of butyrate producers. 
Relative abundance of this pathway was decreased in CD patients due 
to a reduced number of the hydroxybutyryl-CoA dehydrogenase gene 
(19.1±15.2 cpm) and the 3-hydroxybutyryl-CoA dehydratase gene (20.1±15.6 
cpm) compared to the control group, where these genes were detected 
by 26.9±10.1 cpm and 27.6±11.1 cpm, respectively. Stool samples from CD 
patients were characterized by a reduced abundance of 4-aminobutyrate 
pathway, in particular, by depletion of 4-hydroxybutyrate dehydrogenase 
gene (0.1±0.2 cpm) compared to controls (0.3±0.2 cpm). Ato as a part of 
the lysine pathway was decreased in CD patients (2.2±1.8 cpm) in com-
parison to the control group (2.3±4.2 cpm). The glutarate pathway was not 
significantly different between the cohorts.
conclusion: Stool samples of CD patients were characterized by reduced 
levels of butyrate caused by a decreased number of genes coding enzymes 
involved in three out of four main butyrate synthesis pathways (acetyl-CoA, 
4-aminobutyrate, and lysine).
disclosure: The research described in this abstract was financially sup-
ported by Philip Morris International. 
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P1020 Increased exPressIOn Of ePITheLIaL-derIved 
gasderMIn-B (gsdMB), a nOveL MOLecuLe ThaT PrOMOTes 
ePITheLIaL resTITuTIOn and rePaIr, In PaTIenTs WITh IBd
Rana N.1, Pizarro T.T.2
1Case Western Reserve University School of Medicine, Pathology, Cleveland, 
United States, 2Case Western Reserve University School of Medicine, 
Pathology and Medicine, Cleveland, United States
contact e-Mail address: nxr186@case.edu
Introduction: The resolution of inflammation at mucosal surfaces is a ba-
sic physiological process that promotes restitution of the epithelial barrier 
and appropriate tissue repair, in an attempt to restore normal organ func-
tion and homeostatic conditions with the interfacing microenvironment. 
This process is critical for patients with IBD, wherein efficient resolution of 
inflammation and mucosal healing is one of the most important goals to 
attain in order to maintain long-term remission. Gasdermin-B (GSDMB), 
a novel molecule belonging to the Gasdermin family of proteins, has re-
cently gained intense interest for its potential role in the pathogenesis and 
progression of chronic inflammatory disorders, particularly those that af-
fect mucosal surfaces, including asthma and IBD. Importantly, GWAS have 
revealed SNPs within the gene encoding GSDMB as being reportedly asso-
ciated to both an increased susceptibility of acquiring IBD and an increase 
in GSDMB expression.
aims & Methods: The aim of the present study was to examine the ex-
pression pattern and functional relevance of GSDMB in the pathogenesis 
of IBD. Primary intestinal biopsy and isolated intestinal epithelial speci-
mens, as well as formalin-fixed intestinal tissues, from both IBD patients 
and non-inflamed controls were evaluated for mRNA and protein levels 
by qRT-PCR and Western blots, respectively, and cellular localization was 
examined by IHC/confocal microscopy. Using the human colonic epithe-
lial cell line, HT-29, CRISPR-cas9 knockout (KO) cells lacking GSDMB were 
generated, and used for in vitro XTT and cell migration functional assays. 
Finally, subcellular localization of GSDMB was investigated after in vitro 
stimulation with LPS and nigericin (NG) by fluorescent imaging and sub-
cellular fractionation/Western blot analysis.
results: We report for the first time a dramatic increase in epithelial-
specific GSDMB expression in IBD patients (both UC and CD) compared to 
healthy controls. HT-29 epithelial cells stimulated with LPS and NG sug-
gests regulation that is NLRP3-dependent, with a functional decrease in 
in vitro proliferative activity and wound repair in epithelial cells lacking 
GSDMB. 
Additionally, we report unique subcellular localization of GSDMB primarily 
within the cytosolic compartment, with indication of migration towards a 
membrane/organelle compartment after stimulation with LPS and NG in 
human epithelial cells.
conclusion: Taken together, our data suggests that increased epithelial-
derived GSDMB during IBD is protective in function and promotes epithe-
lial-specific proliferation. To our knowledge, this is the first report of GS-
DMB’s functional role in IBD, and provides the rationale for the potential 
therapeutic use of GSDMB to obtain optimal gut mucosal wound healing 
towards promotion of resolution of inflammation.
disclosure: Nothing to disclose 
P1021 PrecLInIcaL InvesTIgaTIOns Of IMu-838, an OraLLy 
avaILaBLe sMaLL MOLecuLe InhIBITOr Of dIhydrOOrOTaTe 
dehydrOgenase fOr The TreaTMenT Of InfLaMMaTOry BOWeL 
dIsease
Kohlhof H.1, Mühler A.2, Gröppel M.3, Vitt D.3
1Immunic AG, Management / PCD, Planegg-Martinsried, Germany, 2Immunic 
AG, Clinical Development, Planegg-Martinsried, Germany, 3Immunic AG, 
Development, Planegg-Martinsried, Germany
contact e-Mail address: hella.kohlhof@immunic.de
Introduction: IMU-838 is a small molecule inhibitor of DHODH (Dihydrooro-
tate Dehydrogenase) and currently in clinical phase 2 testing for ulcerative 
colitis and multiple sclerosis. Inhibition of DHODH in highly activated im-
mune cells, such as in T cells in inflammatory bowel disease, leads to 
induction of metabolic stress signals with immediate onset of inhibition of 
cytokine release of IL-17 and IFNgamma (IFNg) and later on to induction 
of apoptosis in those cells driving inflammation in the bowel wall. We 
performed in-vitro and in-vivo experiments to further explore the impact 
of IMU-838 on other aspects of the immune network important in inflam-
matory bowel disease with particular focus on regulatory macrophages 
and TNFalpha (TNFa).
aims & Methods: Efficacy of IMU-838 was tested in a 2.8% DSS induced 
C57BL/6 colitis mouse model in a therapeutic setting with four days of 
colitis induction prior to treatment start with IMU-838. The impact of IMU-
838 on cytokine regulation was testes in PHA stimulated human periph-
eral blood mononuclear cells (PBMCs) and in a mixed lymphocyte reac-
tion (MLR). Cytokine regulation was tested via gene expression analysis 
and protein secretion via ELISA technique. In the MLR assay, the impact 
of IMU-838 on regulatory macrophages and the synergistic effects with 
anti-TNFa Infliximab treatment were tested via FACS analysis. Therefore, 
isolated PBMCs from two healthy donors were pre-incubated for 48h and 
then incubated for another four days with IMU-838 in four different con-
centrations (30, 10, 3, 1µM) with and without anti-TNFa antibody Infliximab 
(10µg/ml).
results: In a DSS induced colitis model, IMU-838 was administered in 
monotherapy with an oral low dose of 20mg/kg in a therapeutic setting. 
IMU-838 demonstrated improvement of the diarrhea score, the histology 
score and TNFa secretion as markers for improvement of the disease. Even 
though IMU-838 had no impact on TNFa secretion in PHA stimulated hu-
man PBMCs, a significant reduction of TNFa secretion in a mixed lympho-
cyte reaction assay (MLR) was found. Administration of IMU-838 to the 
MLR assay slightly enhanced the percentage of regulatory macrophages 
(which are known to be important for improvement in IBD under anti-TNF 
therapy). In MLR experiments combining IMU-838 and anti-TNF Infliximab 
a strong increase in regulatory macrophages and decrease in TNFa secre-
tion was shown, thereby confirming a substantial synergism of the effects 
for the combining the two molecules.
conclusion: Preclinical experiments support that IMU-838 and its mech-
anism of DHODH inhibition testing of IMU-838 in clinical trials for IBD 
patients. Beside the already known inhibition of IL-17 and IFNg cytokine 
secretion as well as apoptosis induction of highly activated T cells, these 
recent investigations of IMU838 also indicate a beneficial impact on regu-
latory macrophages and inhibition of. In addition, combining IMU-838 
with an anti-TNFa antibody has shown a strong synergism of effects on 
regulatory macrophages and TNFa secretion, which seems to indicate that 
a combination trial in IBD patients suffering from insufficient or reduced 
efficacy of anti-TNFa antibodies such as infliximab should be considered.
disclosure: All authors are employees of Immunic AG 
P1022 anTI-Tnfα TheraPy Induces T cd8+ effecTOr MeMOry 
PrOfILe and reduces LeveLs Of acTIvaTIOn In PaTIenTs WITh 
crOhn’s dIsease
Garcia L.D., Carvalho A.E.Z., Mangueira C.L.P., Miranda S.M., Gil J.Z., 
Neto A.S., Rizzo L.V., Carvalho K.I.
Hospital Israelita Albert Einstein, São Paulo, Brazil
contact e-Mail address: dargeniole@gmail.com
Introduction: The dysregulation of immune system mediated by T lympho-
cyte seems to be the most important factor for progression of Crohn’s Dis-
ease (CD) (Marsal & Agace, 2012). CD8+ T cells (TCD8+) are a subset of cyto-
toxic lymphocytes that can differentiate into both central (T
cm
) and effector 
(T
em
) memory cells. Two animal models suggested that the destruction of 
intestinal epithelial cells by TCD8+ is the event that lead to the disease ac-
tivity proposing a role for this cells in CD pathogenesis (Westendorf et al., 
2006; Nancey et al., 2006). In patients with CD that experienced relapsing 
or chronically active disease, an increase in T cell activation genes and a 
difference in TCD8+ activation status was demonstrated prior to commenc-
ing treatment (Lee et al., 2011) but there is no data about the effects of 
Anti-TNFα therapy in TCD8+ subpopulations. 
We hypothesized that Anti-TNFα therapy decreased the activation levels 
and modulate the memory phenotype of TCD8+ to better control the in-
flammatory process.
aims & Methods: We aimed to characterize the subpopulations of TCD8+ 
in blood and in tissue of patients with CD. The blood was collected and 
cells were acquired by multiparametric flow cytometry. the analysis was 
performed by FlowJo software. For co-expression analysis, Pestle and 
Spice was used. We also collected five tissue samples from patients who 
underwent surgery and TCD8+ was quantify using confocal microscopy. 
Statistical analysis was performed using Prism5 [GraphPad software] and 
Mann-Whitney tests.
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results: We enrolled 44 CD patients, which 27 patients were under Anti-
TNFα therapy and 17 patients was under conventional therapy. Among the 
patients, there was no difference between age, gender and several labo-
ratories parameters (like Calprotectin and CRP) that was used to better 
define this cohort. 
We first observed that patients receiving Anti-TNFα therapy had an in-
crease in the percentage of circulating TCD8+ when compared to patients 
that are under conventional therapy (p = 0.0429). When we analyzed the 
tissue lesion and healthy area from surgery material, TCD8+ shows no sta-
tistical difference between the two regions. 
When we analyzed the expression of CD38, HLA-DR, CD73 and CD39 in 
TCD8+ in peripheral blood, we observed lower expression of CD38 (p = 
0.0033), HLA-DR (p = 0.0002) and CD73 (p = 0.0021) in patients with Anti-
TNFα therapy when compared to patients receiving conventional therapy, 
but no statically differences was observed in the expression of CD39 be-
tween the groups.
Next, we analyzed the expression of memory subsets. Anti-TNFα therapy 
decrease the pool of T
cm
 cells (p = 0.0007) and T
cm
 with coexpression of 
CD38 (p < 0.0001) and HLA-DR (p = 0.0457). On the other hand, T
em
 cells (p 
= 0.0004) and T
emra
 cells (p < 0.0001) shows an increase in patients under 
Anti-TNFα therapy when compared to conventional therapy. The multivari-
ate analysis of the markers CCR7, CD45RA, CD38 and HLA-DR demonstrated 
that the majority of TCD8+ in patients receiving Anti-TNFα therapy lacked 
the expression of all markers (p = 0, 0002). Already in patients that are un-
der conventional therapy, we observed the co-expression of CD38, HLA-DR 
and CCR7 in the same population (p = 0, 0002). In the functional analysis 
CD8 T cells do not demonstrated any difference in cytokine production be-
tween groups.
conclusion: We conclude that Anti-TNFα therapy induces a profile of TCD8+ 
effector memory cells and reduces the activation levels of this cells in pa-
tients of Crohn’s Disease, demonstrated the capacity for induce better im-
mune response.
references: Marsal J, Agace WW. Targeting T-cell migration in inflam-
matory bowel disease. J Intern Med. 2012 Nov; 272(5):411-29. Westen-
dorf AM, Fleissner D, Deppenmeier S, Gruber AD, Bruder D, Hansen W, 
Liblau R, Buer J. Autoimmune-mediated intestinal inflammation-impact 
and regulation of antigen-specific CD8+ T cells. Gastroenterology. 2006 
Aug; 131(2):510-24. Nancey S, Holvöet S, Graber I, Joubert G, Philippe D, 
Martin S, Nicolas JF, Desreumaux P, Flourié B, Kaiserlian D. CD8+ cyto-
toxic T cells induce relapsing colitis in normal mice. Gastroenterology. 
2006 Aug; 131(2):485-96. Lee JC, Lyons PA, McKinney EF, Sowerby JM, Carr 
EJ, Bredin F, Rickman HM, Ratlamwala H, Hatton A, Rayner TF, Parkes M, 
Smith KG. Gene expression profiling of CD8+ T cells predicts prognosis in 
patients with Crohn disease and ulcerative colitis. J Clin Invest. 2011 Oct; 
121(10):4170-9.
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P1023 vITaMIn d defIcIency In crOhn’s dIsease: 
a sIngLe-cenTer PrOsPecTIve sTudy
Ayadi S., Ayari M., Belhadjmabrouk E., Zaimi Y., Said Y., Mouelhi L., 
Debbeche R.
Charles Nicolle Hospital, Gastroenterology, Tunis, Tunisia
contact e-Mail address: ayari.myriam@hotmail.fr
Introduction: Crohn’s disease (CD) is a chronic inflammatory bowel disease 
(IBD), involving dysbiosis of intestinal microbiota, a dysfunction of the in-
testinal barrier and a dysregulation of innate and adaptive immunity on a 
genetically predisposed ground. In recent years, the immunomodulating 
effects of vitamin D have gained a huge interest in its possible pathogenic 
influence on the pathophysiology of IBD. However, it remains unclear if 
this association is a result of inflammatory process, or a cause. Therefore 
Interest in links between vitamin D deficiency and CD has grown substan-
tially.
aims & Methods: The aim of the study was to assess the vitamin D status in 
patients with CD and in healthy controls and to determine related factors 
associated with vitamin D deficiency in patients with CD. We conducted a 
prospective study over 18 months, including patients followed for a CD and 
age-, sex-, and socio-economic status-matched healthy controls. Serum 
25-hydroxyvitamin D (25 (OH) D) concentration was measured with radio-
immunoassay. Vitamin D deficiency was defined by levels < 30 ng/ml and 
subdivided into: vitamin insufficiency: 10 ng/ml < 25 (OH) D < 30 ng/ml and 
vitamin deficiency: 25 (OH) D < 10 ng/ml. 
Crohn’s disease activity was evaluated by a combination of clinical, bio-
chemical, and endoscopic assessment. Crohn’s disease activity index 
(CDAI) was calculated for each patient.
results: We included 77 subjects (52 patients with MC and 25 controls). The 
mean age was of 38 years ± 11 [20 - 64]. The average level of 25 (OH) D was 
comparable in both groups (8.83 + 8.89 ng/ml in patients and 10.06 + 7.42 
ng/ml in controls; p= 0,554), also in patients with active disease and remis-
sion (7.47 ng/ml ± 10.72 and 10.2 ng/ml ± 6.52 respectively; p=0.273). Most 
patients and controls had suboptimal levels of vitamin D (98% and 96% re-
spectively) including (75% and 67% respectively) with vitamin D deficiency, 
(25% and 33% respectively) with vitamin D insufficiency. Deficiency rates 
were higher in patients than controls but this difference was not statistically 
significant. In univariate analysis, lower serum 25(OH) D was associated 
with anemia (p=0.002), hypo-albuminemia (p=0.002), elevated C-reactive 
protein (CRP) (p=0.003), CDAI (p< 0.001), ileal location (p=0.04) and im-
munosuppressive therapy (p=0.01). In multivariate analysis, only CDAI was 
significantly associated (p=0.003) with vitamin D deficiency (OR=9.33).
conclusion: Vitamin D deficiency is common during CD and was associated 
with disease activity and higher CDAI. Vitamin D status should be used as 
a biomarker in assessing disease activity among CD patients in addition 
to CDAI and CRP. Supplementation could be proposed as a therapeutic to 
improve outcomes of the disease.
disclosure: Nothing to disclose 
P1024 InnaTe IMMunITy PrOfILe frOM The “nOrMaL” 
MucOsa Of uLceraTIve cOLITIs PaTIenTs
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Introduction: Innate immunity modulates the integrity of the epithelial 
barrier, microbial detection and autophagy which occurs during the in-
flammatory process presented in ulcerative colitis (UC). UC is associated 
with polymorphisms in the TLR2 (R753Q) and TLR4 (Asp299Gly) genes, 
increasing expression of TLR4 and TLR2 in the mucosa and enhances the 
release of proinflammatory cytokines and the activation of NFκB. However, 
the role of innate immunity associated with macroscopically normal mu-
cosa in UC is not well known.
aims & Methods: Objetive: To establish the profile of gene expression re-
lated to the innate immunity of normal macroscopic (non-inflamed) mu-
cosa in patients with UC.
Methods:Consecutive patients of UC who underwent a colonoscopy by 
clinical practice in a tertiary hospital were included. The total (TMS) and 
partial (PMS) scores were recorded according to the Mayo index at the time 
of the colonoscopy. The histological activity based on the Geboes scoring 
system was previously determined to the PCR study to stratify the samples 
according to the degree of colitis (inactive colitis Geboes < 3). Colon bi-
opsies of the inflamed (iUC) and non-inflamed (safe) (sUC) mucosa were 
obtained in patients with active UC, stratified as mild colitis (LsUC, TMS 
1-4 / Geboes < 3) and moderate / severe colitis (MsUC, TMS 5- 12 / Geboes 
< 3); n = 47). Likewise, patients with quiescent UC (QUC, defined as TMS 
= 0 / pMS = 0 / Geboes, n = 46) and a control group (non-IBD) (C; n = 13) 
were included. Gene expression of innate immunity was quantified using 
Taqman Human Immune Assay-microfluidic cards in colonic mucosa, con-
sidering the degree of UC and the location of the samples.
results: Biopsies from mucosa with quiescent colitis (qCU), as well as 
those from mucosa do not affect by inflammation, both in patients with 
mild colitis (LsUC) and moderate / severe colitis (MsUC), demonstrated an 
expression of genes related to innate immunity different from the control 
group without UC. 36, 55 and 3 genes were overexpressed and 7, 14 and 
7 underexpressed genes were under-expressed in QUC, LsUC and MsUC, 
respectively, compared to non-IBD controls ( p< 0.05) (Table 1). 
conclusion: The normal mucosa, by endoscopic and histologic criteria, in 
patients with UC presents a differential pattern of innate immunity from 
that observed in non-IBD subjects, suggesting the existence of a panco-
lonic inflammatory predisposition that can condition the clinical evolution 
of the disease.
disclosure: Nothing to disclose
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P<0,0001 fold changesΔ    
Genes QUC vs C LsUC vs C MsUC vs C
IL-12A 0.47 0.24  
IL-10 0.48 0.33 *1.54
IL-15 0.61 0.34  
IL-2 0.46 0.25  
IL-18     *2.05
IL-8     *4.05
CCR4 0.64 0.39  
Bc12L1 0.72 0.48  
[Table 1. Changes in the expression of selected genes assesed by real-time 
RT-PCR (Taqman Human Immune Assay). *over expressed]
P1025 BenefIT Of MIneraLOcOrTIcOId recePTOr anTagOnIsM 
In InTesTInaL InfLaMMaTIOn and fIBrOsIs
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Rouen, France, 5Rouen University Hospital, Department of Gastroenterology, 
Rouen, France
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Introduction: Mineralocorticoid receptor (MR) is involved in inflammation 
and fibrosis process from extra-intestinal organs and may thus constitutes 
a therapeutic target in inflammatory bowel diseases (IBD). MR is highly 
expressed in the colon and all components of renin-angiotensin system 
(RAS) are expressed within the gastrointestinal tract. RAS components 
are increased in IBD and Ramipril, a RAS antagonist decreased matrix 
metalloprotease (MMP) activities in tissues from Crohn’s disease fistula. 
Lipocalin-2 is a MR-modulated in the pro-inflammatory and pro-fibrotic 
processes induced by mineralocorticoids. We aimed to investigate whether 
MR participates to IBD-induced inflammation and fibrosis.
aims & Methods: 
In vitro study: Human colon fibroblasts CCD-18Co were incubated with 10 
ng/mL of TGF-ß for 24 hours to obtain an in vitro model of intestinal fibro-
sis. Cells were also induced with primary ligand of the MR (aldosterone at 
10−8 mol/L) or MR antagonist (spironolactone at 10−6 mol/L) or Lipocalin-2 
(5 to 50ng/mL) for 24 hours (n=4 independents experiments). Fibrosis 
markers such as a- SMA, CTGF, COL1A1, COL3A1 and MMP-9 expression 
were analyzed by Western Blot and RT-qPCR.
In vivo study: To induce colitis, mice received 2% dextran sulfate sodium 
(DSS) in drinking water ad libitum for 7 days followed by 3 days of normal 
water. Pharmacological MR (spironolactone, 30mg/kg, n=10) or RAS an-
tagonists (Ramipril, 10mg/kg, n=10) were investigated in DSS colitis (DSS, 
n=10). Cell specific deletion of MR in smooth muscle (SM) were studied 
in DSS-induced SM22-MR deleted mice (n=5) and their littermate (n=3). 
Body weight was daily recorded. Gene expression of IL-6, MCP-1 and TNFα 
were evaluated by RT-qPCR. Fecal calprotectin and colon myeloperoxidase 
activity (MPO) were recorded.
results: In vitro, TGF-ß significantly increased α-SMA, CTGF, COL1A1 and 
COL3A1 mRNA levels in CCD-18 Co (p<0.01). Spironolactone inhibited 
α-SMA (p<0.01) while aldosterone significantly increased it in TGFb-in-
duced intestinal myofibroblasts (p<0.01). 
In vivo, DSS-induced colitis led to a significative body weight loss (p<0.001) 
and increased inflammatory markers such as a decreased colon length 
(p<0.01), a higher colon MPO activity (p< 0.01) and a higher fecal calpro-
tectin (p< 0.01). Ramipril significantly decreased body weight loss vs DSS 
or spironolactone groups (p< 0.05). 
Ramipril increased colon length (p<0.05) while it decreased colon 
MPO activity (p<0.01) and fecal calprotectin (p<0.01). Ramipril signifi-
cantly decreased IL-6, TNFα, MCP-1 mRNA levels compared to DSS or 
DSS+spironolactone treated mice (p< 0.01). SM22 specific MR deletion 
protected mice from DSS colitis compared to littermate mice. SM22 MR 
deleted mice had a lower colonic IL-6 mRNA levels (P<0.05) and a lower 
colon MPO activity (P=0.056).
conclusion: MR antagonism decreased fibrosis markers in vitro. Smooth 
cell specific MR deletion prevented colitis. Ramipril treatment inhibited 
DSS-induced colitis. MR and RAS may represent novel therapeutic targets 
in intestinal fibrosis.
disclosure: Nothing to disclose 
P1026 cOLOnIc MucOsaL eOsInOPhIL hyPerPLasIa and 
acTIvaTIOn feaTures cOLLagenOus cOLITIs and LyMPhOcyTIc 
cOLITIs
Cuende-Estévez M.1, Tristán E.2, González-Castro A.M.1, Expósito E.1, 
Batista L.2, Lobo B.3,4, Carrasco A.2, Zucchiatti A.5, Landolfi S.5,6, 
Robles V.4, Pigrau M.7, Benages A.7, Dot J.7, Santos J.4,8,9, 
Fernández-Bañares F.2,9, Esteve M.2,10, Vicario M.1,9, Guagnozzi D.1,4,9
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4Hospital Universitari Vall d’Hebron & Facultat de Medicina, Universitat 
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Spain, 8Vall d’Hebron Institut de Recerca, Laboratory of Neuro-Immuno-
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9Centro de Investigación Biomédica en Red de Enfermedades Hepáticas 
y Digestivas (CIBEREHD), Barcelona, Spain, 10Centro De Investigación 
Biomédica En Red De Enfermedades Hepáticas Y Digestivas (CIBEREHD), 
Barcelona, Spain
contact e-Mail address: mariacuende95@gmail.com
Introduction: Collagenous colitis (CC) and lymphocytic colitis (LC), the two 
main subtypes of Microscopic Colitis (MC), are chronic inflammatory dis-
eases of the colon, characterized by watery diarrhoea, normal (or near 
normal) endoscopy with characteristic histopathological features, which 
define its diagnosis. CC is mainly characterized by the presence of a subep-
ithelial collagen band (>10 micrometers) and LC mainly by the presence of 
≥20 intraepithelial lymphocytes per 100 epithelial cells. The inflammatory 
infiltrate in the lamina propria has been described as increased numbers 
of mononuclear cells in both entities. In few studies, eosinophil infiltration 
has been described only in CC. However, whether eosinophils character-
ize one or both entities and its role in the pathophysiology of MC remains 
unknown.
aims & Methods: Our aim is to quantify mucosal eosinophilic infiltration 
and describe its activation in CC and LC. Colonic mucosal biopsies (sigma 
region) were obtained from newly diagnosed patients with active CC (n=8) 
and LC (n=15), and from healthy volunteers (HV; n=8), as the control group. 
Lamina propria and intraepithelial eosinophils were counted per high-
powered field (hpf) after eosinophil-specific major basic protein (MBP) 
immunohistochemical (IHC) staining. The ultrastructure of eosinophils was 
assessed by transmission electron microscopy.
results: In HV samples, scattered mucosal eosinophils were found across 
the colonic tissue and identified by weak MBP signal, while in MC, eosino-
phils were identified in patchy areas and displayed a large cytoplasm and 
high MBP signal intensity. The number of eosinophils in the lamina propria 
was significantly higher in patients (CC: 20.1±5.50; LC: 19.9±3.30 cells/hpf) 
as compared with controls (HV: 1.5±0.5 cells/hpf; P< 0.05). 
The number of intraepithelial eosinophils was also higher in samples from 
MC patients (CC: 0.43 [0.0-1.88]; LC: 0.13 [0.0-4.78] cells/hpf) than from 
controls (HV: 0.0 [0.0-0.17]; P< 0.05). Interestingly, IHC analysis revealed 
extracellular staining of MBP in lamina propria eosinophils from MC pa-
tients (CC: 7.7±2.1; LC: 7.6±1.3 eosinophils/hpf) while few eosinophils dis-
played signs of protein release in control tissues (HV: 0.6±0.2 eosinophils/
hpf; P< 0.05). The analysis of mucosal ultrastructure confirmed eosino-
philic activation only in samples from patients. While the control group 
showed intact eosinophils, CC and LC samples displayed both piecemeal 
degranulation and eosinophil cytolysis with associated clusters of free eo-
sinophilic granules in the lamina propria.
conclusion: Despite the histological characteristics that differentiate CC 
and LC, mucosal eosinophilic increase and activation are observed in both, 
CC and LC. Further studies are needed to identify whether eosinophils play 
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a specific role in the pathophysiology of MC subtypes or if its contribution 
to mucosal inflammation is secondary to the aetiology of these diseases.
disclosure: Nothing to disclose 
P1027 facTOrs assOcIaTed WITh The quaLITy Of care 
PerceIved By PaTIenTs In IBd unITs frOM sPaIn. anaLysIs 
frOM The IqcarO PrOjecT
Calvet Calvo X.1, Carpio Lopez D.2, Vera Mendoza M.I.3, Saldaña R.4, 
Marin L.5, Mínguez M.6, Juliá De Páramo B.7, Cea-Calvo L.7, 
Casellas Jorda F.8
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3Hosp. Univ. Puerta de Hierro, Madrid, Spain, 4Confederación Española de 
Asociaciones de Pacientes con Enfermedad de Crohn y Colitis Ulcerosa, 
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Unit, Badalona, Spain, 6Hospital Clínico de Valencia, Universidad de 
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contact e-Mail address: berta_julia@merck.com
Introduction: Measuring patient’s perceived quality of care (QoC) in 
Inflammatory Bowel Disease (IBD) units is becoming increasingly 
important. The aim of the current analysis from the IQCARO project was 
to assess the factors associated with the QoC in IBD units from Spain, by 
measuring the completion of a validated predefined decalogue of QoC 
indicators1.
aims & Methods: A survey including a Decalogue of QoC indicators, 
previously developed by patients, IBD gastroenterologist and IBD 
nurses, was distributed through the webpage of the Confederation of 
Spanish Associations of Patients with Crohn’s disease and Ulcerative 
Colitis (ACCU). The survey also included patient’s sociodemographic and 
clinical characteristics. Patients could answer yes/no to every item of the 
decalogue, scoring 1/0 respectively. The final QoC index was obtained by 
calculating the mean of the total score of each indicator (higher score 
represents better QoC). Qualitative variables were presented as absolute 
frequencies and percentages and quantitative variables as mean and 
standard deviation or median and interquartilic range depending on the 
distribution of the data. In the multivariate analysis the QoC index was 
dichotomized (high quality/low quality) with a cut-off point of 9.5 to be 
used as a dependent variable in a binary logistic regression model in order 
to determine the factors that can influence the evaluation of QoC as high.
results: Online-completed surveys from 605 patients were considered 
valid for the analysis. 451 patients (74,5%) were attended by IBD specialists, 
138 (22,8%) by general gastroenterologists (GG) and 16 (2,7%) by other 
professionals. The population included patients from the 17 Spanish 
autonomous communities, and 183 sites. The mean age of the patients was 
42.3 years, with a mean disease duration of 13 years. 66% were women 
and 60.7% had Crohn’s disease. The mean QoC index was 7.8/10 being 
significantly higher (meaning better QoC) in patients attended by IBD 
specialists vs GG: 8.2 vs 6.7 respectively, p< 0.001. We found no significant 
differences in disease activity, number of flares, hospitalizations, emergency 
room visits in the last year or patients’ perception of controlled disease in 
the last two weeks, when comparing patients attended by IBD specialist or 
GG. When we analyzed the QoC index score as a dichotomized variable, we 
found that older patients, longer disease duration, routine follow-up by 
an IBD specialist, and a better perception of a controlled disease were all 
associated with high QoC while, active disease, unscheduled visits in the 
last year, higher number of flares, and unemployement were correlated 
with low QoC. The multivariate analysis showed that employment, 
controlled disease, low number of unscheduled visits and being attended 
by an IBD specialist were all associated with a high QoC. Table 1.
  coef Or Ic95 p
IBD specialist 1.11 3.05 (1.88;4.95) <0.001
Employed 1.09 2.97 (1.51;5.85) 0.002
Controlled disease 1.08 2.69 (1.90;4.63) <0.001
Number of unscheduled visits -0.20 0.81 (0.72;0.93) 0.003
ed visits Constant -2.89     <0.001
[Binary logistic regression analysis]
conclusion: The perception of the QoC received by IBD patients in Spain is 
good particularly when they are followed-up by IBD specialists rather than 
GGs. Personal and disease related aspects may influence the perception of 
the QoC received. 
references: X. Calvet et al. Journal of Crohn’s and Colitis, Volume 12, Is-
sue supplement_1, February 2018, Pages S217-S218. https://doi.org/10.1093/
ecco-jcc/jjx180.359
disclosure: This project was endorsed by Spanish working group of 
Crohn’s Disease and Ulcerative Colitis (GETECCU), Confederation of Span-
ish associations of patients with Crohn’s Disease and Ulcerative Colitis 
(ACCU), Spanish nurses’ group of inflammatory bowel diseases (GETEII) 
and funded by MSD Spain. 
P1028 The sOcIOecOnOMIc IMPacT Of LIvIng WITh uLceraTIve 
cOLITIs, a Burden Of ILLness sTudy
Lobo A.1, Rose A.2, Finnegan A.3, Hayee B.4, Peyrin-Biroulet L.5, 
Sturm A.6, Fiorino G.7, Burish J.8, Terry H.9, Avedano L.10, Tucknott S.11, 
Noone D.2, Evans J.2
1Sheffield Teaching Hospitals, Sheffield, United Kingdom, 2HCD Economics, 
Health Economics, Daresbury, United Kingdom, 3University of Chester, 
Chester, United Kingdom, 4Kings College Hospital, Gastroenterology, 
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Nancy, France, 6DRK Kliniken Berlin I Westend, Gastroenterology, Berlin, 
Germany, 7IRCCS Humanitas, IBD Center, Rozzano, Italy, 8North Zealand 
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Kingdom, 10European Federation of Crohn’s & Ulcerative Colitis Association 
EFCCA, EFCCA CEO, Brussels, Belgium, 11IBDrelief, Shoreham-by-Sea, United 
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contact e-Mail address: jonathan.evans@hcdeconomics.com
Introduction: Ulcerative Colitis (UC) is a chronic inflammatory disorder af-
fecting the mucosal surface of the rectum and colon characterised by peri-
ods of relapse and remission. The increasing incidence and prevalence of 
UC, morbidity associated with its chronic, relapsing and remitting nature 
and the increasing earlier use of biological therapies, has important impli-
cations to the health economy. The lack of current data on direct and indi-
rect medical cost of treatment and societal cost justified the urgent need to 
conduct a study to quantify the current economic landscape related to UC. 
The living with Ulcerative Colitis, identifying the socioeconomic burden in 
Europe (LUCID) study was a descriptive, retrospective, cross-sectional, Eu-
ropean (France, Germany, Italy, Spain, United Kingdom, Denmark, Norway, 
Poland, Romania and Turkey), multi-site, bottom-up, prevalence-based 
Burden of Illness research study carried out by HCD Economics and the 
University of Chester in partnership with Crohn’s and Colitis UK.
aims & Methods: The primary objective of the LUCID study was to quan-
tify the existing UC-related costs for each country and by disease severity. 
The study population was recruited through gastroenterologists (surveyed 
between Aug 2018- February 2019) and included adult patients diagnosed 
with UC by endoscopy and histology, at least 24 months prior the index 
date (date of clinical consultation). The study cohort population consisted 
of two arms; Arm 1: Patients with moderate or severe UC status at initia-
tion of documentation period (12 months prior the index date) and, Arm 
2: Patients with moderate or severe UC that achieved mild UC or remission 
at initiation of documentation period. Physician completed questionnaires 
(CRF) captured clinical information, direct medical costs and some direct 
non-medical costs. Each patient was invited to complete a corresponding 
public patient involvement and engagement (PPIE) form which captured 
further direct non-medical costs and indirect costs. Due to the descrip-
tive nature of this study a formal calculation of sample size and statistical 
power was not applicable. Per-patient costs were calculated by multiply-
ing the quantities of the resource use collected with the national unit price 
and then extrapolated to population level to calculate the total societal 
economic burden. Total costs were only calculated for patients with com-
pleted PPIE forms due to the need to add non-direct medical and indirect 
costs to the direct medical costs.
results: Completed physician-reported forms (CRF) and PPIE forms were 
assessed for 1,658 patients. Of these, 1001 (60.7%) and 648 (29.3%) patients 
were in arm 1 and arm 2 respectively, with 9 patients unable to be assigned 
to either arm. Total average EU cost per patient in the last 12 months was 
€8,833.94 in arm 1 and €6,512.74 in patients in arm 2 with direct medical 
costs per patient amounting to €4381.70 in arm 1 and €3078.48 in arm 2. 
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Direct non-medical costs per patient were €1353.93 for arm 1 and €1128.37 
for arm 2. Societal costs per patient amounted to €3098.31 of the total cost 
for arm 1 and €2305.89 for arm 2.
conclusion: These preliminary results suggest that non-medical costs and 
indirect costs make up substantial proportions of the overall cost implying 
that the cost of treatment constitutes only a part of the overall burden of 
UC. Further analysis is planned to identify the drivers of costs in each arm 
in order to make comparisons between them.
disclosure: The LUCID study was funded internationally by Pfizer and Eli 
Lilly and in the UK by Celgene. The study was governed by an expert refer-
ence group consisting of the authors. 
P1029 IncIdence Of cOLLagenOus cOLITIs and LyMPhOcyTIc 
cOLITIs In Terrassa, sPaIn, 2015-2018: a cOnTInuOus 
ePIdeMIOLOgIc sTudy
Batista L.1, Ferrer C.2, Esteve M.3, Fernández-Bañares F.4
1Hospital Universitari Mutua de Terrassa, Terrassa, Spain, 2Hopital 
Universitari Mutua Terrassa, Pathology, Terrassa, Spain, 3Gastroenterology, 
Hospital Universitari Mutua Terrassa, Terrassa, Spain, 4Hospital Universitari 
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contact e-Mail address: ffbanares@mutuaterrassa.es
Introduction: The incidence of microscopic colitis (MC) has increased in 
several geographical areas but long-term epidemiologic data are scarce.
aims & Methods: We report an incidence study of collagenous colitis (CC) 
and lymphocytic colitis (LC) during 2015-2018, as a follow-up of our previ-
ous studies 1993-2008.
Population-based study of residents of the catchment area of the hospi-
tal, with a new diagnosis of MC between 2015 and 2018. All patients with 
non-bloody watery chronic diarrhea referred for a diagnostic colonoscopy 
were included. Multiple biopsy specimen samples were obtained when 
the macroscopic appearance of the colonic mucosa was normal to rule out 
MC. Diagnosis of both CC and LC was based on accepted standard criteria. 
Patients were identified by diagnosis register of the Department of Pathol-
ogy. Age- and gender-specific crude incidence rates based on the year of 
diagnosis were calculated. An exact rate ratio test was used to compare the 
incidence rates for the two time periods.
results: Collagenous colitis was diagnosed in 20 patients (16 females) and 
LC in 27 patients (22 females). The mean annual incidence (per 100,000 
inhabitants) was MC 9 (95% confidence interval: 6.6-12), CC 3.85 (2.2-5.5), 
and LC 5.2 (3.2-7.2). Age-specific incidence showed a peak in females older 
than 60 years. Female:male ratio was 14:1 in subjects < 60 years, and 3:1 
in those ≥60 years. A comparison of current study period with 1993-2008 
showed unchanged mean incidence of CC, but a significant increase in 
women with LC (Rate ratio=2.7; 95% CI, 1.5-5; p=0.001).
conclusion: After a rise during early 2000s, annual incidence of CC has 
been stable during the last 10 years around 4/100,000 inhabitants. How-
ever, the incidence of LC, which was stable in the period 1993-2008, has 
significantly increased in women during the last decade.
disclosure: Nothing to disclose 
P1030 anxIeTy and dePressIOn In InfLaMMaTOry BOWeL 
dIsease PaTIenTs - aPPLIcaTIOn Of hOsPITaL anxIeTy and 
dePressIOn scaLe
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Moreira M.J.1,2,3, Cotter J.1,2,3
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contact e-Mail address: smaxavier@gmail.com
Introduction: Inflammatory bowel diseases (IBD) are chronic and debili-
tating conditions, that can contribute to the development of anxiety and 
depression symptoms.
aims & Methods: We aimed to assess the prevalence of these symptoms in 
a population of IBD patients, using Hospital Anxiety and Depression Scale 
(HADS), and identify predictors of these symptoms. 
Unicentric, transversal cohort study, including adult outpatients with IBD. 
Excluded patients with psychiatric disease, severe comorbidity or malig-
nancy and those who refused to participate in the study. Assessed several 
clinical and analytical parameters and determined the anxiety (HADS-A) 
and depression (HADS-D) sub scores, which were considered positive if 
≥8points.
results: Included 99 patients, 65.7% with Crohn’s Disease (CD). HADS-A≥8 
in 64.6% and HADS-D≥8 in 96.0%. 
HADS-A score ≥8 associated with female gender (64.1% vs 40.0%,p=0.021), 
presence of extraintestinal manifestations (EIMs) (91.3% vs 8.7%,p=0.002) 
and longer disease duration (8.2±6.7 years vs 5.2±4.1 years, p=0.017). 
When assessing only CD patients, HADS-A score ≥8 associated with higher 
consumption of benzodiazepines (29.3% vs 8.3%,p=0.048), EIMs (88.9% 
vs 11.1%,p=0.008) and longer disease duration (8.9±6.4 years vs 4.4±4.3 
years, p=0.001). 
HADS-D score ≥8 associated with intravenous biologic therapy (100.0% 
vs 0.0%, p=0.001), EIMs (86.9% vs 13.0%, p=0.038) and ferritin and C 
Reactive Protein levels (113±137 vs 44±34 ng/mL, p=0.007 and 5.6±5.6 vs 
2.9±0.0mg/dL, p< 0.001). In patients with CD, HADS-D ≥8 associated in-
travenous biologic therapy (100.0% vs 0.0%, p=0.019), EIMs (88.9% vs 
11.1%,p=0.019) and calprotectin levels (366±337 vs 93±16ug/g, p< 0.001). In 
patients with ulcerative colitis no predictors of HADS-A or HADS-D scores 
≥8 were found.
conclusion: In patients with IBD, anxiety symptoms are present in nearly 
2/3 of patients and depression symptoms in over 90%. Anxiety symptoms 
are more frequent in women and patients with long standing disease, 
while depressive symptoms associate with disease inflammatory activity. 
Presence of EIMs associated with both types of symptoms.
disclosure: Nothing to disclose 
P1031 Less InPaTIenT cOMPLIcaTIOns and ecOnOMIc Burden 
In feMaLe PaTIenTs adMITTed WITh uLceraTIve cOLITIs
Kroner P.T.1, Kesler A.M.2, Corral J.E.3, Cangemi J.R.3
1Mayo Clinic, Gastroenterology, Jacksonville, United States, 2Mayo Clinic, 
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Introduction: Gender in ulcerative colitis (UC) is a well-studied topic with 
contradicting results with a slight male predominance seen in large popu-
lation based studies in Olmsted County, Minnesota, while other studies 
have shown a slight female predominance. Yet, the relationship between 
UC and gender is not well-understood. Hence, it is unclear what is respon-
sible for differences in gender.
aims & Methods: The aim of this study is to assess the inpatient prevalence 
and inpatients outcomes of UC by gender. 
Case-control study using the NIS 2016, the largest public inpatient data-
base in the US. All patients with ICD9-10CM codes for UC were included. 
None were excluded. Female patients were identified within the database 
using the female gender indicator. 
The primary outcome was determining the odds of UC in female patients 
compared to males. Secondary outcomes included determining inpatient 
morbidity, mortality, resource utilization, colectomy rates, hospital length 
of stay (LOS), and inflation-adjusted total hospital costs and charges. 
Propensity score matching was used to create a matching population for 
Charlson Comorbidity Index and age. Multivariate regression analyses 
were used to adjust for income in patient zip code, hospital region, loca-
tion, size and teaching status.
results: A total of 38, 950 patients with UC were identified and propen-
sity matched for selected covariates. The mean patient age was 45, and 
47.2% were female. For the primary outcome, females had decreased ad-
justed odds (aOR: 0.92, p< 0.01) of being admitted for UC. For secondary 
outcomes, female patients displayed lower adjusted odds of multi-organ 
failure, being placed on TPN, and undergoing colectomy. Females also had 
lower adjusted mean hospital costs, charges, and length of stay (LOS). All 
adjusted odds and means are displayed in Table 1.
conclusion: Females have lower inpatient prevalence of UC, complications, 
and economic burden compared to males. This reinforces the slight male 
predominance that was seen in the older Olmstead County population-
based studies. One can speculate that the difference in complications, 
costs, charges, and LOS indicate that females have less severe disease 
course at hospital admission. Numerous studies have examined the asso-
ciation of gender with disease severity and outcomes, and there continues 
to be conflicting data. 
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Thus, future studies are needed to determine what contributes to the 
variation in disease prevalence and course by gender, and possibly better 
tailor treatment regimens by gender.
disclosure: Nothing to disclose 
variable adjusted Or 95%cI p-value
Ulcerative Colitis 0.92 0.86 - 0.98 0.01
Mortality 1.03 0.48 - 2.23 0.94
Shock 0.86 0.54 - 1.37 0.53
ICU 0.78 0.48 - 1.26 0.30
TPN 0.69 0.51 - 0.93 0.01
Multi-organ failure 0.66 0.55 - 0.80 <0.01
Colectomy 0.74 0.56 - 0.99 0.04
Variable Adjusted Means 95%CI p-value
Additional Adjusted Costs -$1,677 -2508,846 <0.01
Additional Adjusted Charges -$5,615 -9300,1929 <0.01
Additional Adjusted Length of 
Stay (days)
-0.5 -0.80,0.21 <0.01
[Adjusted odds ratios and means for selected variables in female patients 
with UC compared to males.]
P1032 use Of TargeTed BacTerIOPhage cOckTaIL fOr The 
TreaTMenT Of InfLaMMaTOry BOWeL dIsease
Matiuhin Y.1, Weinstock E.1, Pollock S.1, Khabra E.1, David H.1, 
Silberberg Y.1, Reichman H.1, Golembo M.1, Puttagunta S.2, Zak N.1
1Biomx, Ness Ziona, Israel, 2Biomx, Killingworth, United States
contact e-Mail address: yuliam@biomx.com
Introduction: An abnormal intestinal microbiota (dysbiosis) is associated 
with the inflammatory bowel disease (IBD) phenotype and is considered to 
be a causal or synergistic factor, together with genetic and environmental 
elements, in perpetuating chronic inflammation. Recent studies demon-
strated that a specific Klebsiella pneumoniae strain (KP2H7) isolated from 
the oral cavity of IBD patients causes strong TH1 immune stimulation in 
germ free wild type mice and colitis in germ free mono-colonized colitis-
prone mice [Atarashi et al. Science, 2017]. The present study aims to vali-
date the KP2H7 bacteria as a disease-associated target in IBD patients and 
to initiate development of a bacteriophage-based therapy that targets this 
specific bacterial strain by demonstrating ability of a rationally designed 
phage cocktail to significantly reduce the KP2H7 load in colonized animals.
aims & Methods: 300 stool samples from patients including IBD patients 
from France and Israel were assessed for the presence of KP2H7 strains by 
applying metagenomic analyses and KP2H7 isolation methods combined 
with strain specific qPCR, respectively. To examine the prevalence of KP2H7 
in the IBD population in the United States (US), the metagenomic data 
released by the Human Microbiome Project group (HMP Part 2) were re-
analyzed to determine its association with IBD. 
In parallel, “phage hunting” techniques were applied to isolate tens 
of natural phage that target the KP2H7 strains from environmental and 
clinical samples. By combining phage with complementary characteristics 
(such as differences in their bacterial hosts and recognition of different 
bacterial surface receptors), phage cocktails were designed and tested for 
their ability to significantly reduce KP2H7 bacterial burden in mice that 
were colonized with this bacteria by oral gavage.
results: A KP2H7 prevalence of about 30% was consistently observed in 
IBD patients across three different geographical locations (Table 1). In the 
subset of patients for whom deep metadata was also available, a trend in 
KP2H7 abundance was observed in correlation with disease severity (flare 
vs remission). 
The phage cocktail targeting KP2H7 strains demonstrated significant reduc-
tion of bacterial burden in the stool and intestinal mucosa (5 log reduction 
after 3 administrations of a 5 phage cocktail) when orally administered to 
mice that were previously colonized with these bacteria.
conclusion: The KP2H7 prevalence data collected from IBD patients offer 
support for the potential association of KP2H7 and similar strains with IBD, 
and have demonstrated the existence of a significant target population for 
phage therapy targeting these bacteria. The efficient eradication of KP2H7 
strains by a specifically tailored phage cocktail administered orally to colo-
nized mice suggests that IBD patients carrying these strains may benefit 
from phage therapy. Since this new treatment modality addresses poten-
tial microbiome drivers of IBD and not just disease symptoms, it should be 
further evaluated as a potential disease-modifying therapy. 
country ulcerative colitis n/n (%) crohn‘s disease n/n (%) IBd n/n(%)
Israel 19/52 (37) 17/57 (30) 36/109 (33)
United States 9/30 (30) 23/50 (46) 31/80 (39)
France 11/46 (24) 15/43 (35) 26/89 (29)
[Prevalence of KP2H7 strains in patients with IBD]
references: Atarashi K, Suda W, Luo C, et al. Ectopic colonization of oral 
bacteria in the intestine drives TH1 cell induction and inflammation. Sci-
ence 2017 358; (6361): 359-365
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Introduction: Inflammatory bowel disease (IBD) encompasses two main 
life-long chronic immune-mediated disorders, namely Crohn’s disease 
(CD) and ulcerative colitis (UC). Symptoms range from abdominal pain and 
diarrhoea, to fever, weight loss, and malnutrition requiring hospitalisa-
tion. IBD has a negative impact on quality of life, including private and 
social life. IBD is also susceptible to stigmatisation, mainly because of its 
symptoms, the old assumption of being a psychosomatic disorder, and 
because it may deeply affect sexual function. Patients affected by chronic 
disorders may have an impaired resilience, that is defined as the capacity 
of thrive in face of adversity, adapting body, mind and spirits to life cir-
cumstances, including health issues. No study has ever assessed resilience 
in IBD patients.
aims & Methods: Aim of this study was to investigate resilience and per-
ceived stigmatisation in an Italian adult cohort of IBD patients. Starting 
January 2019, consecutive IBD patients were prospectively enrolled, and 
were regularly followed up at the IBD tertiary medical centre in Pavia. A 
definite diagnosis of CD and UC was established for a duration of at least 
three months prior to enrolment. Over, the same period, a cohort of blood 
donors from the same geographic area was enrolled as healthy controls 
(HC) to evaluate the average level of resilience in the Italian population. 
Demographic and relevant clinical data were recorded at the time of the 
physician evaluation, and every patient was asked to fill in the perceived 
stigma scale (PSS) and the 25-item Connor-Davidson resilience scale 
(CD-RISC25). PSS included sub-scores for significant others (friends, fam-
ily members, spouse or partner) and for health care providers. Disease 
activity was assessed through Harvey-Bradshaw Index (HBI) for CD and 
partial Mayo Score for UC. The study is still ongoing and patients are being 
recruited.
results: A total of 101 IBD patients were enrolled (mean age 46.37±16.5 yrs, 
F:M=0.8:1), including 46 CD and 55 UC. 249 HC were enrolled (mean age 
42.16±12.28 yrs, F:M=1:1.5) as controls for resilience only. The mean PSS 
score for significant others was 0.62±0.48, and no difference was seen 
between CD and UC patients. Patients with an active disease had a mean 
PSS of 1.27 compared to those with inactive disease (0.8, p=0.05). No dif-
ference was seen between males and females (1.02 vs 0.82; p=0.22). Mean 
CD-RISC25 was significantly lower in IBD patients compared to HC (62.93 
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vs 69.45; p=0.0003). Also, females IBD patients had a lower mean CD-
RISCS25 compared to males (59.43 vs 65.63, p=0.06). Mean CD-RISC25 was 
also lower in patients with active disease compared to inactive disease 
(48.5 vs 67.52; p=0.02).
conclusion: This is the first study showing a low resilience in IBD patients, 
especially in those in the active phase. Also, patients with active IBD are 
more likely to suffer from social stigmatisation that may negatively impact 
on quality of life. These results should not be overinterpreted, as the study 
is still underway. More studies are needed in order to evaluate possible 
targeted interventions for this population.
references: 1. Di Sabatino A, Lenti MV, Giuffrida P, Vanoli A, Corazza GR. 
New insights into immune mechanisms underlying autoimmune diseases 
of the gastrointestinal tract. Autoimmun Rev 2015;14:1161-9. 2. Aaa Kaplan 
GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol 
Hepatol 2015;12:720-7. 3. Taft TH, Keefer L, Leonhard C, Nealon-Woods M. 
Impact of perceived stigma on inflammatory bowel disease patient out-
comes. Inflamm Bowel Dis 2009;15:1224-32. 4. Looper KJ, Kirmayer LJ. 
Perceived stigma in functional somatic syndromes and comparable medi-
cal conditions. J Psychosom Res 2004;57:373-8. 5. Fife BL, Wright ER. The 
dimensionality of stigma: a comparison of its impact on the self of persons 
with HIV/AIDS and cancer. J Health Soc Behav 2000;41:50-67. 6. Taft TH, 
Keefer L. A systematic review of disease-related stigmatization in patients 
living with inflammatory bowel disease. Clin Exp Gastroenterol 2016;9:49-
58. 7. Connor KM, Davidson JR. Development of a new resilience scale: the 
Connor-Davidson Resilience Scale (CD-RISC). Depress Anxiety 2003;18:76-
82.
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Introduction: The exact etiology of ulcerative colitis (UC) is unknown, how-
ever, according to the present view, the disease is the result of a chronic 
inflammatory reaction resulting from abnormal immune response of nor-
mal gut flora in genetically susceptible individuals.
aims & Methods: The aim of our study was to determine the composition 
of the intestinal microbiome in UC patients after restorative proctocolec-
tomy with ileal pouch-anal anastomosis, compared with UC patients with 
varying extention, FAP (familial adenomatous polyposis) patients after 
colectomy and IPAA surgery and healthy controls.Active and inactive UC 
patients who underwent on restorative proctocolectomy and IPAA forma-
tion were enrolled in the study. 
To compare, active and inactive UC patients with different extent were en-
rolled, as well. The same number of healthy subjects was aimed to enroll 
as control group. Clinical data of patients, blood and fecal samples were 
collected. Fecal microbiota structure was determined by sequencing the 
V4 hypervariable region of the 16S rRNA gene. Fecal community structure 
was determined at genus level.
results: Overall, 63 patients were enrolled: 25 UC patients with pouch, 
17 UC patients, 8 FAP patients with pouch and 13 healthy control. Only 6 
of UC patients with pouch received maintenance therapy (5-ASA, cortico-
steroids), on the contrary, only one UC patient was without medication. 
Significant bacterial abundance differences were observed among the ex-
amined groups. 
Compared to the control, both UC groups had higher Streptococcaceae, 
Pasteurellaceae, and lower Desulfovibrionaceae abundance. Higher bacte-
rial abundance of Bacteroidaceae, Erysipelotrichaceae, Clostridiaceae, Pep-
tostreptococcaceae, and lower Ruminococcaceae, Rikenellaceae, Porphyro-
monadaceae were found in the UC patients with pouch group compared 
to UC patients and controls. There was a significant difference between 
the groups regarding to the abundance of Prevotellaceae and Enterobacte-
riaceae. Fecal microbiome determination of FAP patients are in progress.
conclusion: Changes in bacterial abundance had been observed in UC 
patients with and without pouch compared to healthy controls. These 
changes may be a part of the pathomechanism , but the consequence of 
intestinal inflammation in UC, as well.
disclosure: Nothing to disclose 
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Introduction: Despite advances in Ulcerative Colitis (UC) therapies, many 
patients suffer refractory defaecatory symptoms in the absence of active 
inflammation. For this group, treatment remains challenging, with a pau-
city of research and limited therapeutic options. In this prospective, ongo-
ing study, we aim to determine the prevalence of faecal incontinence (FI) 
in patients with quiescent UC.
aims & Methods: In a cross-sectional study, consecutive patients with UC 
attending Inflammatory Bowel Disease (IBD) clinics were invited to par-
ticipate. Patients completed a series of validated questionnaires; including 
an IBD-specific FI questionnaire (ICIQ-IBD questionnaire), Hospital Anxi-
ety and Depression Scale (HADS), the Rome IV diagnostic questionnaire, 
and the IBD-control questionnaire. Participants were requested to return 
a Faecal Calprotectin (FCP) within 2 weeks of completing questionnaires. 
Quiescent UC was defined as IBD-control 8 score ≥13 and IBD-control-VAS 
≥85, and/or FCP levels ≤250 (where available, FCP data were used in pref-
erence to IBD-control to classify UC activity). Data were compared between 
active and quiescent groups using chi-square and non-parametric tests.
results: Overall, n=97 UC patients (n=50 males, mean age 48 (range 18-
82) participated. ICIQ-IBD data revealed that most patients experience 
FI (84/97 (87%) during ‘relapses’. Interestingly, 58/97 (60%) reported FI 
when in ‘remission’, and this group had higher median HADS depres-
sion (P=0.0002), poorer QoL scores (P< 0.0001), and trend towards higher 
HADS anxiety (P=0.09) scores, compared to those without FI. Disease ac-
tivity data (IBD-control and/or FCP) were available for all patients, and 
based on these 61/97 (63%) had quiescent UC. The prevalence of FI based 
on ICIQ-IBD did not differ between those with active (22/36, 61%) and qui-
escent UC (36/61, 59%), P=NS. In those with FI on ICIQ-IBD, median IBD-FI 
symptom scores, IBD-FI QoL scores and HADS (anxiety: P=0.47, depression: 
P=0.18) did not differ between disease activity groups. However, within 
the quiescent group, patients that met the more stringent Rome IV crite-
ria for FI (n=13) had higher median IBD-FI symptom scores (P=0.007) and 
HADS-depression scores (P=0.05),a trend to worse IBD-FI QoL (P=0.07), 
but similar HADS-anxiety (P=0.68).
conclusion: This study is one of the first to identify that regardless of dis-
ease activity, FI affects most patients with UC, detrimentally impacting pa-
tients’ psychological wellbeing, impairing their QoL, and should therefore 
routinely be screened for in clinics. There is an urgent need for further 
research in the often neglected area of FI and quiescent disease.
disclosure: Nothing to disclose 
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Introduction: Inflammatory Bowel Disease (IBD), consisting of Crohn’s dis-
ease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of 
the gastro-intestinal tract. The etiology of IBD is complex with an interplay 
between genomic susceptibility, diet, microbiome and environmental fac-
tors. Once disease develops, its course remains highly variable and unpre-
dictable due to yet unknown disease modifiers. The role of environmen-
tal factors in etiology and disease course remain inconclusive, while the 
identification of modifiable risk factors is crucial for potential personalized 
preventative and disease modifying strategies. We executed a large popu-
lation-based study evaluating known and possibly involved environmental 
factors in the etiology of and disease course in IBD.
aims & Methods: All IBD patients of the 1000IBD cohort at the University 
Medical Center Groningen (UMCG), the Netherlands, were asked to fill the 
validated Groningen IBD Environmental Questionnaire (GIEQ). Overall, 848 
environmental factors were, grouped in 15 categories. 
To study etiology, patients were group-matched, based on age at diagnosis 
and sex, in a 1:2 ratio to participants of the population-based LifeLines 
cohort study, who completed a comparable questionnaire. To study dis-
ease course, data collected by the GIEQ was linked corresponding clinical 
data from the 1000IBD cohort. Disease complications were defined as the 
need for biological therapy or surgery. Logistic regression was applied to 
estimate the multivariable-adjusted effect of lifestyle factors on IBD (odds 
ratio; OR) and 95% confidence intervals. Case-control comparisons were 
corrected for their differences in age, sex and history of smoking for etiol-
ogy, as well as disease duration for disease course. A p< 0.05 was consid-
ered as nominal and Bonferroni adjusted p-value as statistically signifi-
cant. A large number of environmental factors were examined, the interim 
results are reported.
results: 728 patients of the 1000IBD cohort completed the GIEQ. There 
were no differences in baseline characteristics between participants and 
the remaining cohort (P>0.2). Several environmental factors were associ-
ated with statistically significant increased risk of IBD, such as the pres-
ence of more than three stressful life-events prior to diagnosis CD (OR 2.9, 
95%CI 1.9-4.5) and UC (2.6,1.7-4.0); and prenatal smoke exposure for CD 
(1.9,1.4-2.6) and UC (1.6,1.2-2.2), but showed no effect on disease course. 
While living environment for the first 5 years of life showed a nominal risk 
increasing trend for CD and UC, an urban living environment was associ-
ated with higher odds of surgery later on (2.3,1.2-4.7). Having pets during 
the first year of life showed a striking protective effect for both disease 
(CD and UC; cat 0.4,0.4-0.5, dog 0.4,0.4-0.6), while having a pet during 
disease was associated with increased risk of both the need for biologicals 
as well as surgery in UC (2.6,1.1-6.1;4.2,1.9-9.2, respectively).
conclusion: Stress and prenatal smoke exposure were associated with sig-
nificantly higher odds of developing IBD. Childhood pets were associated 
with less odds of IBD, whereas current pets might negatively influence dis-
ease course in established UC. Larger studies are needed to validate these 
findings and further evaluate the role of modifiable environmental factors 
and their interactions in preventive strategies and personalized treatment.
disclosure: RKW: unrestricted research grants from Takeda and Ferring 
Pharmaceutical Company GD: unrestricted research grants from Abbvie, 
Takeda and Ferring Pharmaceuticals. Advisory boards for Mundipharma 
and Pharmacosmos. Received speakers fees from Takeda and Janssen 
Pharmaceuticals Other authors have nothing to disclose. 
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Introduction: The role of Mycobacterium Avium subspecies Paratuberculosis 
(MAP) in Crohn’s disease (CD) is controversial. Due to many similarities 
between CD and Johne’s disease, a chronic enteritis in dairy cattle caused 
by MAP, its role in CD etiology has been studied repeatedly. CD patients 
seem more prone to MAP infection compared to healthy controls. However, 
whether MAP acts as a causative agent of CD, an inflammatory trigger or 
as a secondary invader remains elusive. Over 200 genetic risk loci have 
been identified in inflammatory bowel diseases, but genetic determinants 
of MAP infection are poorly studied. Moreover, whether MAP exposure af-
fects CD disease course remains elusive. In this study, we explore genetic 
determinants of MAP infection and the association of MAP infection with 
the course of IBD.
aims & Methods: Detailed clinical characteristics, serum and DNA were 
obtained from in total 847 patients with IBD included in the prospective 
1000IBD cohort. In addition, serum samples from 53 healthy controls were 
collected. MAP serology was determined in all available serum samples. 
Two conjugates (Protein A-HRP: detects IgA, IgE, IgG1,2,4 and IgM, and 
Protein G-HRP: detects IgG1-4) were used to measure antibody response to 
four different MAP antigens (Protoplasmic MAP antigen and three recom-
binant MAP antigens). Cut-off values according to Bernstein et al. were 
used to determine seropositivity with a 95% specificity. Logistic regres-
sion models, adjusted for age, sex, disease duration, history of smoking 
and batch effects, were used to explore the association between MAP 
and IBD disease course. All patients were genotyped with the Illumina 
Global Screening Array, and genetic data were imputed to the Haplotype 
Reference Consortium reference panel. A genome-wide association study 
(GWAS) for presence of MAP seropositivity was performed.
results: Patients with IBD had similar rates of MAP seropositivity as com-
pared to controls (P>0.2) and baseline characteristics were comparable 
between seropositive and seronegative patients. Disease location, behav-
ior and extent, classified using the Montreal classification, were not as-
sociated with MAP seropositivity (P>0.1). Multivariate analyses identified 
MAP seropositivity for conjugate A as risk factor of a more complicated 
disease course in patients with CD (biological use [OR 2.19; (95% CI 1.01-
4.75]) and in patients with UC (surgery [OR 2.01 95% CI 1.01-3.99]). Using 
GWAS, a total of 50 genetic loci were associated with MAP seropositivity at 
a suggestive genome-wide significance threshold (P< 5x10-5). One of these 
loci (rs7901290 [P=8E-7; OR=1.86) harbors the CAMK1D gene, which is in-
volved the regulation of granulocytes. Another associated locus (rs1001792 
[P=4E-7; OR=1.92]) harbors the TNFRSF10B gene, which has been associ-
ated with and apoptosis induction.
conclusion: Patients with IBD had similar rates of MAP seropositivity com-
pared to healthy controls. MAP seropositivity showed no association with 
IBD disease location, specifically not with ileal Crohn’s disease. However, 
seropositivity for MAP conjugate A, representative for mucosal and acute 
phase immunoglobulins, was identified as a risk factor of a more compli-
cated disease course in both CD and UC. GWAS analyses show suggestive 
associations between MAP seropositivity and immunomodulating genes. 
Future studies in independent cohorts using Ig isotype specific tests are 
needed to validate these findings and to explore the interaction between 
genetic susceptibility, MAP exposure and IBD.
disclosure: RKW: unrestricted research grants from Takeda and Ferring 
Pharmaceutical Company GD: unrestricted research grants from Abbvie, 
Takeda and Ferring Pharmaceuticals. Advisory boards for Mundipharma 
and Pharmacosmos. Received speakers fees from Takeda and Janssen 
Pharmaceuticals Other authors have no disclosures. 
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Introduction: Inflammatory bowel disease (IBD) prevalence is estimated to 
be rising but no detailed, recent United Kingdom (UK) data are available. 
The last reported prevalence rate in the UK was 0.40% in 2003.1
aims & Methods: We aimed to establish the current and projected future 
prevalence in Lothian, Scotland.
We conducted an extensive all-age multiparameter search strategy us-
ing inpatient IBD international classification of disease (ICD-10) coding 
(K50/51)(1997-2018), IBD pathology coding (1990-2018), primary and sec-
ondary care prescribing data (2009-18) and a paediatric registry (1997-
2018) to identify “possible” IBD cases to 31/08/18. 
A team of IBD physicians manually confirmed all diagnoses through elec-
tronic health record (EHR) review as per Lennard-Jones/Porto criteria. 
Prevalence and incidence calculations were performed using mid-year 
population estimates or projections from National Records Scotland.2 
Trends in incidence, prevalence and mortality over time were reported as 
annual percentage change, calculated by exponentiating the beta-coeffi-
cient of Poisson regression and subtracting 1. Poisson modelling was also 
used to calculate significance in these trends over time. Autoregressive 
integrated moving average (ARIMA) regression was applied to forecast 
prevalence to from 31/08/18 to 01/08/28.
results: In total, 24,601 possible IBD cases were identified and then manu-
ally reviewed, revealing 10,499 true positives. The optimum search strategy 
was pathology plus mesalazine prescription and ICD-10 K50/51 coding that 
identified 95% true positives with 6% false negatives. 
The point prevalence for all IBD in Lothian on 31/08/18 was 784/100,000 
(ulcerative colitis (UC) 432/100,000, Crohn’s disease (CD) 284/100,000, and 
IBD unclassified (IBDU) 68/100,000) (Table 1). 
year
Population 
of Lothian 
healthboard
uc 
(prevalence/
100,000)
cd 
(prevalence/
100,000)
IBdu 
(prevalence/
100,000)
all 
(prevalence/
100,000)
2008 808,940 315 216 36 567
2009 816,510 334 224 38 596
2010 825,520 349 232 41 621
2011 836,610 359 242 43 644
2012 843,740 375 249 47 671
2013 849,720 386 258 51 694
2014 858,120 398 265 56 719
2015 867,800 411 270 59 739
2016 880,000 418 274 62 753
2017 889,450 427 278 66 772
2018 897,210 432 284 68 784
[Standardised prevalence per 100,000 population for Lothian on 31st August 
between 2008-18]
There was no significant change in incidence between 2008-2018 (annual 
percentage change 14.4%; 95% CI -0.9, +32.1%, P= 0.66), nor IBD preva-
lent cohort mortality (annual average percentage change 10.5%, 95% CI 
-18.8, +50.0, P= 0.52).
However prevalence increased by 4.3% per year over the same period 
(95% CI +3.7, +4.9%, P< 0.0001) (Table 1). ARIMA modelling projected a 
point prevalence on 01/08/28 of 1.02% (95% CI 0.97-1.07%) that will affect 
an estimated 1.53% (95% CI 1.37-1.69%) of those over 80 years of age. 
conclusion: We report a rigorously validated IBD cohort with all-age point 
prevalence on 31/08/18 of 1 in 125, one of the highest worldwide. Incidence 
has consistently exceeded mortality in our cohort for the past 10 years, 
exemplifying the effects of compound prevalence.
We project prevalence will rise to 1 in 98 by mid 2028, with the majority 
of IBD patients over 50years of age. This has significant current and future 
implications for IBD service delivery.
references: 1. Stone MA, Mayberry JF, Baker R. Prevalence and manage-
ment of inflammatory bowel disease: a cross-sectional study from central 
England. European Journal of Gastroenterology & Hepatology 2003;15:1275-
80. 2. www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-
theme/population/population-estimates/mid-year-population-estimates
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P1039 hIv POsITIve PaTIenTs are aT a greaTer rIsk fOr 
deveLOPMenT Of InfLaMMaTOry BOWeL dIsease
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Mohy-ud-Din N.4, Thakkar S.3, Jairath V.5, Dulai P.6
1Allegheny Health Network, Gastroenterology & Hepatology, Pittsburgh, 
United States, 2Allegheny Health Network, Gastroenterology, Pittsburgh, 
United States, 3Allegheny Health Network, Pittsburgh, United States, 
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Introduction: Overlap and intersection exists between inflammatory bowel 
disease (IBD) and HIV with regards to mucosal barrier and immune cells. 
HIV is felt to potentially attenuate inflammation in IBD, however, very lim-
ited data exists on the development of IBD in HIV+ patients. This is of im-
portance as treatments for IBD are being studied for HIV and treatments 
for HIV therapies are being studied for IBD.
aims & Methods: Using Explorys (1999-2019), a HIPAA-enabled web plat-
form that includes clinical and lab data from over 63 million unique indi-
viduals, we aimed to quantify the risk for new-onset IBD among patients 
who had a diagnosis of HIV versus the general population. IBD was diag-
nosed based on a combination of ICD-9 codes and at least one prescription 
for an IBD specific medication (5-ASA, immunomodulator, biologic). Rela-
tive risks (RR) with 95% Confidence Intervals (CI) are reported.
results: A total of 357,950 patients tested positive for HIV, of which 10,570 
developed new-onset IBD after their HIV diagnosis (3,043/100,000 per-
sons). The risk of developing IBD among HIV positive patients was 5-fold 
higher than the general population (RR 5.26, 95% CI 4.81, 5.74, p< 0.001). 
The majority of patients developing new-onset IBD were not on anti-ret-
roviral therapy for their HIV (89% vs. 11%, p< 0.001) and a higher pro-
portion of new-onset IBD cases in the HIV positive patients were Crohn’s 
disease as compared to the new-onset IBD cases in the general popula-
tion (65% vs. 42%, p< 0.001).
  de-novo IBd in hIv+
IBd group 
without hIv+ P
Subtypes, n [%]      
Crohn‘s Disease 6,840 [65] 152,580 [42] < 0.0001
Ulcerative Colitis 3,000 [28] 128,560 [35] < 0.0001
Indeterminate Colitis 730 [7] 85,480 [23] < 0.0001
IBD-Associated Outcomes, n [%]      
Colectomy 1,180 [11] 44,720 [12] 0.0018
Proctolectomy 30 [0] 3,840 [1] < 0.0001
Ileostomy 3,490 [33] 18,780 [5] < 0.0001
Fistulectomy 50 [0] 2,220 [1] < 0.0001
All-Cause Mortality, n [%] 570 [5] 21,040 [6] < 0.0001
[HIV+ Patients and De-Novo IBD]
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conclusion: We observed that HIV positive patients are at a greater risk for 
development of IBD as compared to the general population. The majority 
of new IBD diagnoses among HIV positive patients are Crohn’s disease and 
are often not receiving anti-retroviral therapy. Further research is needed 
to confirm these observations and to understand how antiretroviral thera-
py influences the risk for development of IBD.
disclosure: Nothing to disclose 
P1040 The IMPacT Of eaTIng haBITs On The Occurrence 
Of uLceraTIve cOLITIs
Bikbavova G., M.A. Livzan, V.I. Sovalkin, D.V. Turchaninov, T.V. Tretyakova
Omsk Medical State University, Hospital Therapy, Endocrinology, Omsk, 
Russian Federation
contact e-Mail address: galiya1976@mail.ru
Introduction: Ulcerative colitis is a chronic state, and its etiology is not 
currently evident. Inflammatory bowel diseases originate at the interface 
of inherited predisposition, impact of certain environment factors and in-
testinal microflora changes. Impact of nutrition factors on emergence of 
risk of ulcerative colitis has been discussed for many years, which was 
confirmed by the increased incidence of inflammatory bowel diseases in 
developed countries compared to developing countries. Changes in gen-
eral nutrition approaches in the last years have caused the prevalence of 
bowel diseases to increase. It should be noted that there is an increased 
incidence of inflammatory bowel diseases in the countries with previously 
lower incidence, which is associated with the changes in the lifestyle of 
modern society.
aims & Methods: Aim of this study was: to estimate the impact of nutrition 
factors on the risk of development of ulcerative colitis based on the analy-
sis of food consumed; to evaluate the significance of consumption of cer-
tain nutrients in development of ulcerative colitis among Western Siberian 
population. We conducted a survey of 81 patients suffering from ulcerative 
colitis and 39 healthy respondents. We studied the profile of eating habits 
of patients with ulcerative colitis (prior to being diagnosed) compared to 
habits of healthy respondents. The study of nutritional patterns of patients 
with ulcerative colitis and healthy respondents was conducted using the 
standardized WHO CINDI questionnaire. The survey includes 12 questions 
regarding the frequency and amount of consumption of certain foods. Par-
ticular attention was paid to the consumption of milk and dairy products, 
meat, fruits, vegetables, carbohydrate foods and sugar. Respondents were 
offered to choose out of possible options.
results: The diet of patients with ulcerative colitis is characterized by rare 
consumption and small portions of fresh and cooked vegetables and fruits 
prior to the first symptoms of the disease (U=1094,5; Z=-2,7; p=0,01). Pa-
tients with ulcerative colitis consumed more sugar with tea and/or coffee 
compared to healthy respondents prior to the first symptoms of the disease 
(U=1214,0; Z=-2,0; p=0,04). Patients with ulcerative colitis poorly tolerated 
milk and dairy products prior to the first symptoms of the disease (2I=9,72, 
p< 0,01). There were no statistically significant differences detected be-
tween patients with ulcerative colitis and healthy respondents and their 
consumption of meat (U=1330,0; Z=-1,4; p=0,16), spicy, fried, salty smoked 
food (U=1530,0; Z=0,3; p=0,78), and frequency of visits to fast food outlets 
(U=040; Z=-1,0; p=0,33).
conclusion: Our study confirms the possible effect of a lack of dietary fiber 
and excessive sugar intake on the emergence of ulcerative colitis.
disclosure: Nothing to disclose 
P1041 funcTIOnaL rare varIanTs InfLuence The cLInIcaL 
resPOnse TO anTI-Tnf TheraPy In crOhn’s dIsease
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Introduction: Loss-of-function (LoF) variants are one of the most interest-
ing forms of rare functional genetic variations as they impair the function 
of a gene and are more likely to lead to extreme phenotypes
aims & Methods: Our aim was to know the impact of functional rare vari-
ants in clinical response to anti-TNF therapy in Crohn’s disease (CD). 
CD anti-TNF naïve patients starting anti-TNF treatment due to active disease 
(CDAI>150) were included. The whole genome was sequenced using the Il-
lumina Hiseq4000 platform. Clinical response was defined as a CDAI score 
< 150 at week 14 of anti-TNF treatment. Low-frequency variants were anno-
tated and classified according to their damaging potential. The whole ge-
nome of CD patients was screened to identify homozygous LoF variants. The 
TNF signaling pathway was tested for overabundance of damaging variants 
using the SKAT-O method. Functional implication of the associated rare 
variation was evaluated using cell-type epigenetic enrichment analyses
results: A total of 41 CD patients were included. From them, 54% were 
male, 75% had ileal or ileocolonic involvement, 12% had structuring and 
26.8% fistulising behavior, 20% had perianal disease, 41.5% had previ-
ous surgery, 80% of them were under concomitant immunomodulators; 
61% were treated with infliximab and 39% with adalimumab. At week 14, 
61 % had remission and 24% were primary non-responders. A total of 
3,250 functional rare variants (2,682 damaging and 568 LoF variants) as-
sociated with response to anti-TNF therapy were identified. The strongest 
damaging impact was detected in 10 LoF SNPs (table 1). Two homozygous 
LoF mutations were found in HLA-B and HLA-DRB1 genes associated with 
lack of response and remission, respectively. Genome-wide LoF variants 
were enriched in epigenetic marks specific for the gastrointestinal tissue 
(colon, P=4.11e-4; duodenum, P=0.011). The burden of damaging variation 
in the TNF signaling pathway was associated with response to anti-TNF 
drugs (P=0.018); damaging variants were enriched in epigenetic marks 
from CD8+ (P=6.01e-4) and CD4+ (P=0.032) T cells
conclusion: Functional rare variants are involved in the response to anti-
TNF therapy in CD. Cell-type enrichment analysis suggests that the gut 
mucosa and CD8+ T cells are the main mediators of this response. These 
findings provide new insights into the underlying heterogeneity of CD, re-
vealing the basis of TNF-dependent biological mechanisms
603Vol. 7 | October 2019
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Men (%) 22 (53.7)
Location (%)
Ileal
Colonic
Ileocolonic
14 (34)
6 (14.6)
17 (41.5)
Behavior (%)
Inflammatory
Stricturing
Fistulizing
21 (51.2)
5 (12)
11 (26.8)
Perianal disease (%) 8 (19.5)
Extraintestinal manifestations (%) 14 (34)
Previous surgery (%) 17 (41.5)
Smoking habit (%) 16 (39)
Steroids 7 (17)
Immunomodulators (%)
Thiopurines
Methotrexate
30 (73)
3 (7.3)
Anti-TNF type (%)
Adalimumab
Infliximab
16 (39)
25 (61)
[Table 1. Characteristics of the study population]
disclosure: M. Chaparro has served as a speaker, or has received research 
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Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma. JP Gis-
bert has served as a speaker, a consultant and advisory member for or has 
received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, 
Biogen, Takeda, Janssen, Roche, Celgene, Ferring, Faes Farma, Shire Phar-
maceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro 
Pharma, Otsuka Pharmaceutical, Vifor Pharma. 
P1042 use Of TPMT genOTyPIng fOr evaLuaTIOn Of 
ThIOPurInes TOxIcITy rIsk In LaTe-OnseT IBd PaTIenTs
Zalizko P.1,2, Stefanovics J.1, Rovite V.3, Klovins J.3, Pukitis A.1,2
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Introduction: Thiopurines are the most widely used immunosuppressants 
in inflammatory bowel disease (IBD), but in elderly IBD patients they are 
associated with an increased risk of adverse effects (AE) [Calafat M. et 
al, 2018]. Elderly patients with IBD are more vulnerable due to a higher 
rate of comorbidities, polypharmacy and changes in pharmacokinetics, 
and therefore have an increased risk for treatment related complication 
[Broekman M., 2017]. Starting thiopurines over 60 years of age should be 
followed by a closer monitoring. Thiopurine S-methyltransferase(TPMT) 
deficiency leads to an accumulation of higher levels of cytotoxic thiopu-
rine nucleotides in patients carrying defective TPMTalleles and can pro-
spectively identify patients at higher risk for thiopurines toxicity [Robert 
D. Nerenz, 2018].
aims & Methods: To evaluate a role of TPMT genotyping in late-onset IBD 
patients as part oftherapeutic drug monitoring. DNA samples of 127 IBD 
patients over 40 years old (median age 53 years; Q1-Q3=47,0-62,0) were 
obtained from the Genome Database of the Latvian Population. TPMTgeno-
typing with a real-time polymerase chain reaction (PCR) (TaqMan Drug 
Metabolism Genotyping Assays) was performed for detection of rs1800462, 
rs1800460, and rs1142345 single nucleotide polymorphisms (SNPs). The 
three common non-functional TPMTalleles (TPMT*2, *3B, and *3C) were 
determined in 57,5% women and 42,5% men. Data were collected about 
demographics, medication intolerance, allergies and comorbidities. Data 
were analysed in SPSS®23.
results: Our study includes 77% (n=98) of patients with ulcerative coli-
tis, mean age 55±11 years and 23% (n=29) of patients with Crohn’s dis-
ease, mean age 57±13 years, p=0,4. 92,1% were wild-type homozygous 
TPMT*1/*1 genotype, 7,9 % (n=10) were heterozygous. In total four patients 
had history of azathioprine (AZA) adverse events: gastrointestinal intoler-
ance (n=2), hepatotoxicity (n=1), myalgia (n=1). In total 20,5% (n=26) of pa-
tients marked allergies on different medication groups as antibiotics, an-
algesics, etc.The most frequent polymorphism was TPMT*1/*3A genotype 
in 6,3%. No patients were homozygous for any mutation. 7,9% (n=10) of 
patients with TPMT*1/*1 genotype takes AZA in standard dosage 2-2,5 mg/
kg without any adverse drug effects. In total 75,6% (n=96) of patients had 
comorbidities as cardiovascular diseases (arterial hypertension, steno-
cardia, chronic heart failure) and endocrine diseases (diabetes mellitus, 
thyroid disorders, adiposity).
conclusion: We have identified TPMT*1/3Aas the most prevalent polymor-
phisms in late-onset IBD patients. TPMT genotyping is an effective method 
of thiopurines toxicity risk evaluation in late-onset IBD patients. Our data 
shows that AZA still remains effective treatment in late-onset IBD patients, 
however detection of TPMT status should be used as a part of therapeutic 
drug monitoring.
disclosure: Nothing to disclose 
P1043 PredIcTed effIcacy Of a PharMacOgeneTIc PassPOrT 
fOr InfLaMMaTOry BOWeL dIsease
Bangma A.1,2, Voskuil M.D.1,2, Uniken Venema W.T.C.1,2, Brugge H.2, 
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Introduction: The therapeutic armamentarium for Inflammatory Bowel Dis-
ease (IBD) is rapidly expanding, but inter-individual variability in response 
remains high, partly driven by genetic variation. Several gene-drug inter-
actions predictive of therapeutic outcomes or adverse drug responses have 
been identified: genetic variants in thiopurine-S methyltransferase (TPMT) 
and nudix hydrolase 15 (NUDT15) are predictive of thiopurine-induced my-
elosuppression (TIM), the HLA-DQA1-HLA-DRB1 haplotype is predictive of 
thiopurine-induced pancreatitis (TIP), and recently the HLA-DQA1*05 hap-
lotype has been identified as a genetic determinant of immunogenicity of 
TNFα-antagonists. Pre-treatment pharmacogenetic testing allows person-
alised therapies and optimisation of therapeutic outcomes, but its uptake 
into clinical practice and guidelines has been slow. The aim of this study 
was to explore the predicted clinical effectivity of an IBD specific pharma-
cogenetic passport, including multiple pharmacogenetic predictors.
aims & Methods: Detailed clinical characteristics were obtained from 
patients treated with azathioprine and/ or a TNFα-antagonist in an IBD 
specialised tertiary hospital. The presence of thiopurine toxicity and/or 
immunogenicity of TNFα-antagonists was retrospectively evaluated us-
ing stringent criteria (1,2). All patients were genotyped with the Illumina 
Global Screening Array. Genetic data underwent stringent quality control 
and were imputed to the Haplotype Reference Consortium panel. An in-
house developed computational pipeline translated genetic data into an 
IBD pharmacogenetic passport with predicted risks for thiopurine toxicity 
and TNFα-antagonist immunogenicity for each patient. Using proposed 
pharmacogenetic-guided treatment guidelines, clinical effectivity esti-
mates were calculated to show the predicted implications of pharmacoge-
netic pre-treatment testing in the context of IBD management.
results: Among 817 IBD patients that were exposed to thiopurines and/or 
TNF-α antagonists, 165 adverse drug responses were identified. An IBD 
pharmacogenetic passport would have predicted 59 (36%) of these adverse 
drug responses. For every 50 patients genotyped for NUDT15 and TPMT 
variants prior to start of thiopurine therapy, one case of TIM would have 
been prevented. When including genotyping of the HLA-DQA1-HLA-DRB1 
haplotype to predict TIP, only 41 patients need to be genotyped to prevent 
one case of either TIM or TIP. For every 26 patients with an IBD pharmaco-
genetic passport, predicting all three gene-drug interactions, 10 patients 
would receive a positive test result. If these 10 patients subsequently re-
ceive pharmacogenetic-guided alternative treatment strategies, one case 
of either thiopurine toxicity or immunogenicity of TNFα-antagonists will be 
prevented, which results in a number needed to genotype of 26.
conclusion: This is the first study that assesses the predicted clinical ef-
fectivity of pre-treatment pharmacogenetic testing for multiple gene-drug 
interactions in a large IBD cohort. Based on our findings, an IBD pharma-
cogenetic passport will lead to a significant reduction in potentially life-
threatening thiopurine toxicity and increased TNFα-antagonist therapy 
response rates, and should be implemented into clinical guidelines for 
IBD treatment.
references: 1. Walker GJ, Harrison JW, Heap GA, Voskuil MD, Andersen V, 
Anderson CA, et al. Association of Genetic Variants in NUDT15 With Thiopu-
rine-Induced Myelosuppression in Patients With Inflammatory Bowel Dis-
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ease. JAMA. 2019 Feb 26;321(8):773-85. 2. Heap GA, Weedon MN, Bewshea 
CM, Singh A, Chen M, Satchwell JB, et al. HLA-DQA1-HLA-DRB1 variants 
confer susceptibility to pancreatitis induced by thiopurine immunosup-
pressants. Nat Genet. 2014 Oct;46(10):1131-4.
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Introduction: Colonic localization of inflammatory bowel diseases (IBD), 
ulcerative colitis (UC) and Crohn’s disease (CD), represents an impor-
tant risk factor in the development of colorectal cancer (CRC). The risk of 
CRC increases 8-10 years after the diagnosis of IBD and strong evidences 
suggest that CRC occurs in the inflamed epithelium, according to the se-
quence dysplasia-carcinoma. To date, more than 200 genetic loci have 
been associated to IBD although none to the development of IBD related 
cancer.
aims & Methods: The aim of this study is to clarify the role of some on-
cogenes and protoncogenes in the molecular mechanism that leads IBD 
patients to CRC. On the basis of available literature we profiled a panel of 
40 genes (39 geness potentially involved in cancer predisposition and the 
most important gene associated to IBD, NOD2). A germline variant iden-
tification analysis pipeline was performed on the DNA of individuals with 
CRC diagnosis and IBD history. 
Data about patients’ features, disease history, disease pattern, family his-
tory, and drugs were recorded. We ranked all identified germline muta-
tions by pathogenicity and summarized the allelic frequencies of patho-
genic or likely pathogenic variants.
results: We identified 25 IBD patients all consecutively enrolled in a single 
referral center. The mean age at diagnosis of IBD was of 43 yrs (range 
20-72), and a mean age at diagnosis of cancer of 54 yrs (range 36-76). 
Independently to the disease phenotype status, 8 pts (32%) resulted car-
riers of at least one major NOD2 susceptibility variants. Multigene panel 
testing identified 23 mutations in 18 IBD patients (72%): 4 in APC, 3 in 
MLH1, BRCA1 and CHEK2, 2 in MYH and PDGFRA, 1 in MSH2, MSH3, EPCAM, 
POLD1, POLE, CDKN2A. Only in two cases (8%) the family history suggested 
a Lynch syndrome.
conclusion: This study demonstrates that a high rate of pathogenic varints 
in CRC/IBD patients, above all in APC and mismatch repair genes. The 
identification of this variantsmove attention from duration of disease to 
genetic predisposition as risk factor to develop a CRC. Identification of car-
riers should make possible stratify patients who need an intensive surveil-
lance regimen or an early indication to prophylactic colectomy.
disclosure: Nothing to disclose 
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Introduction: We believe that multi-generation IBD families have a 
monogenetic mechanism of inheritance.
aims & Methods: To identify gene variance associated with IBD inheritance 
we performed whole exome sequencing (WES) in all our IBD families 
receiving care at Johns Hopkins IBD Center. We included 37 (35) families 
with IBD in our study, 17 of which were families of Ashkenazi Jewish 
ancestry. One hundred fifteen members were sequenced. Affected 
individuals diagnosed with either Crohn’s disease or Ulcerative colitis 
underwent deep exome sequencing (1-4 individuals/family) performed by 
our department in collaboration with the genetic department and pediatric 
gastroenterology. Using PhenoDB analysis we performed individual and 
merge analysis to identified candidate gene for autosomal dominant or 
recessive inheritance.
results: After we have filtered out all the non-frameshift variants and 
those variants with allele frequency incidence of more than 1% we de-
tected: 0-66 variants per family with autosomal recessive compound het-
erozygous inheritance potential, 0-39 variants per family with autosomal 
recessive homozygous potential and 6-454 variants per family with auto-
somal dominant potential. We then performed merged analysis of all the 
families included in the study and we identified 35 autosomal dominant 
variants but none autosomal recessive variants. These 35 gene variants 
were selected if they met the following criteria: present in 3 or more IBD 
families, express loss of function, present in GWAS studies, have a high 
genetic score, have an OMIM phenotype.
Out of the 35 gene selected PCGL2 gene variant was noted in seven fami-
lies: three families from IBD adult cohort, four families from very early 
onset IBD. All three adult families exhibit genetic anticipation.
conclusion: PLCG2 have been found in other autoimmune diseases char-
acterized by antibody deficiency, in immune dysregulation syndrome and 
familial cold autoinflammatory syndrome 3. Understanding the PLCGL2 
role in IBD inheritance associated with genetic anticipation has implica-
tions for genetic counseling for children and grandchildren of IBD patients 
developing novel therapy.
disclosure: Nothing to disclose 
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Introduction: It has been seen that 30-40% of patients treated with Inflix-
imab (IFX) who achieve an initial response to induction therapy lose this 
response over time with maintenance treatment. Therapeutic drug moni-
toring (TDM) could be used to optimize management in such situations. 
However, IFX serum levels are not well defined. The aim of the study was 
to find our cut-off range of Infliximab serum levels in Crohn’s disease (CD) 
patients in remission in clinical practice.
aims & Methods: An observational retrospective study was developed from 
1st February, 2016, to 30th November, 2017, in our hospital. Patients with 
established CD who had been on maintenance dosing schedule of IFX 
were included. 
IFX and antibody to IFX levels were measured before each infusion at 
least twice and after 6 months of treatment in all patients. All the tests 
were performed using enzyme linked immunosorbent assay (ELISA) with 
Progenika kits (PROMONITOR®). Clinical remission was defined using 
Harvey Bradshaw Index (HBI≤4). The interpretation of data was by cluster 
analysis (Silhouette measure of cohesion and separation: cluster quality 
>0.5**).
results: 105 CD patients were included in the study, 57.1% men, with a 
mean age of 39 (DE±12.9). The median (range) time of the disease was 11 
years (7-15). The median (range) time of follow-up was 32 months (22-38).
Montreal phenotypes were: 76% A2, 35.2% L2 and 53.3% B1. Perianal 
disease was present in 51.4%. 265 IFX levels were measured during the 
follow-up.
Patients who achieved remission had IFX serum levels between 4.26 - 8.26 
ug/ml versus 0.06 - 1.43 ug/ml in patients who did not achieve remission 
(silhouette 0,72) the first time; and 2.84 - 7.75 ug/ml versus 0.05 - 2.69 ug/
ml in patients who achieved remission versus those who did not achieve 
remission respectively the second time (silhouette 0,78) (Fig 1-2). 4,26- 7,75 
ug/ml were the best cut-off range for remission (Table 1).
Time 1 Time 2 Most restrictive interval  
0.06-1.43 0.05-2-69 0.06-1.43 No Remission
1.43-4.26 2.69-2.84 1.43-4.26 Uncertainly zone
4.26-8.26 2.84-7.75 4.26-7.75 Remission
[Crohn’s Disease]
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We found that perianal disease does not have any influence on IFX serum 
levels for achieved remission.
conclusion: In our practice the best value to predict remission status in 
patients undergoing IFX TDM was 4 - 8 ug/ml, which was higher than in 
other studies.
references: **Kaufman, L., Rousseeuw, P. J. (1990). Finding groups in 
data. An introduction to cluster analysis. New York: John Wiley & Sons. 
doi: https://doi.org/10.1002/9780470316801.
disclosure: Nothing to disclose 
P1047 earLy MOnITOrIng Of resPOnse (MOre) TO gOLIMuMaB 
TheraPy Based On fecaL caLPrOTecTIn and TrOugh seruM 
LeveLs In PaTIenTs WITh uLceraTIve cOLITIs: a MuLTIcenTer 
PrOsPecTIve OBservaTIOnaL sTudy
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Introduction: Study objective: In order to evaluate early prediction mark-
ers for the therapy response of golimumab (GLM) in ulcerative colitis, we 
aimed to assess the association of an detectable GLM trough serum level 
together with a reduction in fecal calprotectin level in week 6 (W6) with 
a clinical response in week 26 (W26) in patients with moderate-severe 
ulcerative colitis.
aims & Methods: The study was designed as a prospective, single-arm, 
multicenter, observational study with no interim analyses in Germany be-
tween October 2014 and December 2017. Patients aged ≥ 18 years, with 
diagnosed moderate-severe active ulcerative colitis and starting GLMtreat-
ment were offered participation in this ethics approved study at ten reg-
istered IBD centers. These sites were recruited by the IBD study platform 
“German Inflammatory Bowel Disease Study Group” (GISG). After screen-
ing, for each eligible patient enrolled, the study duration was 26 weeks 
with six visits at weeks 0 (baseline), 2, 6, 14, 22 and 26. 
The primary outcome was clinical response measured by Partial Mayo 
Scoring Index (PMS). Clinical response was defined by a Partial Mayo Score 
≤ 1 or a reduction in the PMS by two points. Calprotectin level for response 
in was defined as reduction of ≥50 % in comparison to baseline. Detect-
able GLM trough level was defined as ≥2.5 µg/ml. 
The sample size was calculated for 61 patients (including 3 % drop-outs). 
Analysis of the primary outcome was done according to the Intention-To-
Treat (ITT) method. Missing (outcome) data were imputed as follows: be-
tween W0 - W6 classified as therapy failure; between W6 - W26 as Last 
Observation Carry Forward (LOCF) Effect estimates were reported as rela-
tive risks with corresponding 95 % confidence intervals (CI).
results: 61 patients were enrolled, two patients were excluded due to 
screening failures. During the course of the study 28 patients discontinued 
their participation (47,5%) due to 1. withdrawal of GLM therapy (n = 21; 
35,6%), 2. withdrawal of consent (n=7; 11,9% ). 
In the ITT cohort, gender distribution was almost equal (female 52.5%; 
male 47.5%), the median age was 40.1 (Interquartile Range: 22.1), the 
mean duration of ulcerative colitis was 8.7 years (95% CI, 6.5 - 10.9). Pa-
tients had moderate disease according to PMS with a mean scoring point 
of 5.6 (95% CI, 5.2 - 6.1). 54.2 % of the enrolled patients were anti-TNF 
naïve, 8.5 % had experienced a primary and 37.3 % a secondary loss of 
TNF-alpha therapy prior to the start of GLM therapy. 
We showed that patients with an early detectable positive GLM trough 
level in W6 and a change in calprotectin at the same time had a 1.54 fold 
increase chance (RR: 0.65, 95% Cl: 0.44-0.95; n=45) to achieve a clinical 
remission at w26 in comparison to patients who had no early detectable 
positive GLM trough level and no change in calprotectin in w6. On the 
other hand we analyzed that patients without early detectable GLM trough 
level and no change in calprotectin in w6 had a 3.46 fold higher risk (RR 
3.46; 95%: Cl 0.56-22.45; p=0.1; n=45) for not achieving response in w26.
conclusion: In this prospective multicenter study we were able to show 
the impact of fecal calprotectin and serum golimumab level at week 6 to 
predict the therapeutic response at week 26. Further studies are needed to 
confirm the statistical significance our primary result.
disclosure: UH:Lecture and consulting fees: AbbVie, MSD, Ferring, Falk 
Foundation, Takeda, Mundipharma, Hospira, Vifor Pharma 
P1048 InfLIxIMaB LeveLs & anTIBOdIes In IBd- reLaTed 
PerIPheraL arThraLgIa
Levartovsky A.1, Ungar B.2, Yavzori M.3, Picard O.3, Fudim E.4, Eliakim A.5, 
Paul S.6, Roblin X.7, Ben-Horin S.8, Kopylov U.9
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Institute, Ramat Gan, Israel, 3Sheba Medical Center, Ramat Gan, Israel, 4Tel 
Hashomer Hospital, Gastroenterology Lab, Herzliya, Israel, 5Sheba Medical 
Center, Dept. of Gastroenterology, Ramat Gan, Israel, 6CHU Saint Etienne, 
Service d’Immunologie, Saint-Priest En Jarez, France, 7University of St. 
Etienne Dept. de Gastroenterologie, Saint Etienne, France, 8University of Tel 
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Introduction: Extra-intestinal manifestations (EIM) are common in inflam-
matory bowel diseases (IBD) and may affect up to 50% of the patients 
during the course of the disease. Peripheral arthralgia (PA) is by far the 
most common EIM. To date, TNF-alpha inhibitors are the most established 
treatment for EIMs in IBD. Infliximab (IFX) trough levels (TL) and anti-IFX 
antibodies (ATI) are correlated with multiple outcomes in IBD such as clini-
cal response and remission, mucosal healing, fistular healing and more. 
To date, a correlation between IFX TL\ATI and PA has not been evaluated.
aims & Methods: This retrospective study included IBD patients followed 
by gastroenterology departments of Sheba Medical Center and Saint Eti-
enne Medical Center. Patients with active peripheral arthralgia at onset of 
IFX treatment were included. IFX TL and ATI were evaluated at week 6, 14 
and 26 and correlated with PA persistence.
results: Forty nine patients (42 CD, 7 UC) with IBD associated arthralgia 
were included. The overall prevalence of arthralgia was 59.2% (29/49), 
44.9% (22/49) and 53.1% (26/49) after 6, 14 and 26 weeks respectively. 
At 14 and 26 weeks of treatment, arthralgia was less prevalent in clinical 
responsive patients than in patients who didn’t respond to IFX (8.8% vs 
66.7%, p=0.004 and 35% vs 70.6%, p=0.031, respectively). IFX TL were 
not associated with PA at week 14 (median, 4.5 vs 3.15 ug/ml, p=0.26) and 
at week 26 (median, 3.9 vs 3.6 ug/ml, mean, p=0.84) however detectable 
ATI were significantly more prevalent in patients with PA than in patients 
without PA at week 26 (46.2% vs 13.6%, p=0.015).
conclusion: In patients with IBD-related PA, IFX ATI are associated with 
an increased risk of persistence of arthralgia. No direct correlation was 
demonstrated between IFX TL and persistence of arthralgia.
disclosure: Bella Ungar received consultation fees from Janssen and Ab-
bvie.Shomron Ben-Horin received consulting and advisory board feesand/
or research support from AbbVie, MSD, Janssen, Takeda andCellTrion. Uri 
Kopylov received speaker and advisory fees fromAbbvie, Jannsen, MSD, 
Takeda and Medtronic, and research sup-port from Jannsen, Medtronic 
and Takeda. Rami Eliakim receivedconsultant and speaker fees from Jans-
sen, Abbvie, Takeda andMedtronic. None of the other authors have any 
conflicts to declare 
P1049 dOes fIBrOBLasT grOWTh facTOr 19 (fgf19) LeveL 
cOrreLaTe WITh InfLaMMaTOry BOWeL dIsease acTIvITy?
Panek-Jeziorna M., Mulak A.
Wroclaw Medical University, Department of Gastroenterology and 
Hepatology, Wroclaw, Poland
contact e-Mail address: agata.mulak@wp.pl
Introduction: Fibroblast growth factor 19 (FGF19) is the ileal hormone pro-
viding feedback inhibition of bile acid (BA) synthesis in the liver which may 
serve as a surrogate marker to assess BA malabsorption. FGF19 is a key 
target of the farnesoid X receptor (FXR). The FXR activation inhibits intes-
tinal inflammation. While disturbances in BA metabolism and enterohe-
patic circulation have been well documented in Crohn’s disease (CD), still 
little is known about the role of these mechanisms in the pathogenesis of 
ulcerative colitis (UC).
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aims & Methods: To evaluate serum FGF19 level and its correlation with 
inflammatory bowel disease (IBD) activity in patients with UC and CD. Fast-
ing serum FGF19 level was measured using ELISA test in 62 IBD patients 
(33 M, 29 F, mean age 40.0 ± 15.8) and 19 healthy control subjects (8 M, 11 
F, mean age: 39.9 ± 13.0). The IBD patients were divided into 4 subgroups 
according to the disease form and activity: non active UC (n=15), active 
UC (n=16), non-active CD (n=15) and active CD (n=16). The clinical disease 
activity in UC patients was assessed by Rachmilewitz index, and in CD by 
CDAI. The endoscopic disease activity was evaluated using the Mayo Endo-
scopic Score in UC and SES-CD in CD. Moreover, abdominal pain intensity 
using visual analog scale (VAS), as well as serum CRP and fecal calprotec-
tin levels were measured. Non-parametric statistics were used and results 
are expressed as median and the lower and upper quartiles [25Q-75Q].
results: Median serum FGF19 level was lower in active UC (114.3 pg/ml) 
than in non-active UC (175.3 pg/ml) (p=0.093). Median FGF19 level in the 
healthy controls amounted to 151.6 pg/ml, but there were no statistically 
significant differences between the patients with active and non-active UC 
compared to the controls. Despite the fluctuations of FGF19 level depen-
dent on the disease activity, in the majority of UC patients it was still within 
the normal range. In patients with active CD, serum FGF19 level was sig-
nificantly lower than that in the controls (56.5 vs 151.6 pg/ml, p=0.043). The 
lower serum FGF19 level was found in 38% of patients with active CD, and 
13% of patients with non-active CD. An inverse correlation was observed 
between serum FGF19 and number of stools per 24 hours and Bristol Stool 
Form Scale score, as well as clinical disease activity in CD. No correlation 
between FGF19 level and endoscopic disease activity was revealed in either 
form of IBD. In patients with UC the inverse correlations between FGF19 
level and abdominal pain intensity (R= -0.48, p=0.007), as well as inflam-
matory markers including fecal calprotectin level (R= -0.38, p=0.036) and 
serum CRP level (R= -0.36, p=0.045) were found.
conclusion: The ELISA test for FGF19 constitutes a useful tool to evaluate BA 
malabsorption in the course of IBD. Serum FGF19 level, although remain-
ing within the normal range in the majority of IBD patients, shows fluc-
tuation dependent on the disease activity, which indicates the association 
between the regulatory mechanisms of BA enterohepatic circulation and 
IBD activity. The inverse correlations between FGF19 level and abdominal 
pain and inflammatory markers may imply its potential analgesic and anti-
inflammatory effects - direct or due to the FXR-FGF19 axis activation. The 
dynamic of FGF19 level fluctuation dependent on the IBD phase suggests 
new therapeutic aims associated with FXR activation, which constitutes a 
key element of the gut-liver axis.
disclosure: Nothing to disclose 
P1050 OuTcOMe Of IMMedIaTe InfLIxIMaB OPTIMIsaTIOn 
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Introduction: Recent studies have demonstrated that proactive therapeutic 
drug monitoring (TDM) with drug titration to a target trough concentration 
is associated with better clinical outcomes. Moreover, dose intensification 
strategy based on the parallel assessment of clinical symptoms, serum and 
fecal biomarkers and serum infliximab (IFX) concentration may further in-
crease therapeutic response.
aims & Methods: The aim of this study is to evaluate the outcome of IFX 
optimisation based on proactive drug monitoring in combination with the 
assessment of clinical activity and biomarkers using rapid assays. 
This is a prospective study of consecutive Crohn’s disease (CD) and ulcer-
ative colitis (UC) patients on IFX maintenance therapy. Blood and fecal 
samples were obtained from the patients at the day when subsequent 
IFX infusion was scheduled. C-reactive protein (CRP) and hematocrit levels 
were measured. Serum IFX and fecal calprotectin (FC) concentrations were 
benchmarked with rapid, lateral flow-based assays. Clinical activity indi-
ces were calculated. On the basis of all data, patients were assigned to 4 
groups: no intervention (NI), dose increased (DI), stopping (ST) or switch. 
After optimisation, patients are followed for 6 months with determining all 
the above mentioned parameters retrospectively at every 2 months.
results: Twenty-six CD and 21 UC patients were enrolled. On the basis 
of the rapid tests, DI was performed in 14 CD and 11 UC patients, NI in 8 
CD and 7 UC patients, and ST in 4 CD and 2 UC patients. One UC patients 
was switched from IFX to adalimumab. In DI CD group, serum level of IFX 
increased, CDAI decreased significantly compared to the baseline. Level 
of CRP and FC did not change significantly at month 2, but CRP decreased 
significantly at month 4. 
Twelve CD patients stayed in remission in the DI group; two relapses were 
observed, one patient was switched to ustekinumab and one patient re-
ceived corticosteroid. In DI UC group IFX level increased significantly, CRP, 
pMayo and FC decreased compared to baseline. 
Seven patients in NI CD group and 3 patients in the NI UC group remained 
in remission till the end of the follow up. None of the examined param-
eters, except for serum IFX level at month 4 changed significantly. 
One patient in the ST group required reintroduction of therapy with adali-
mumab at month 2. Serum IFX concentration and FC level measured with 
the rapid, lateral flow-based assay and ELISA kits are correlated (r=0.69, 
p=0.0012).
conclusion: Change in therapy was performed in 32 cases on the bases of 
benchmarked concentrations of serum IFX and FC levels. Our results sug-
gest benefit of using rapid tests in daily practice. Results of rapid, lateral 
flow-based assays and ELISA kits are correlated.
disclosure: Nothing to disclose 
P1051 IndIvIduaL PaTIenT-LeveL auTOMaTIc deTecTIOn Of 
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Introduction: Capsule endoscopy (CE) is a well- established modality for 
diagnosis and monitoring of Crohn’s disease (CD) .Some of the drawbacks 
of CE technology include interobserver variability and prolonged reading 
time. Deep learning technology is being extensively explored in several 
fields of medicine and has a potential to provide efficient and automated 
image processing.
The aim of our study was to evaluate a the patient level performance of 
deep learning model for detection of small bowel ulcers on capsule en-
doscopy images.
aims & Methods: We retrospectively collected capsule endoscopy images 
of patients with established Crohn’s disease and normal subjects. Each im-
age was labeled by an expert gastroenterologist as either normal mucosa 
or containing mucosal ulcers. A Convolutional Neural Network (Xception) 
was trained to classify images into either normal mucosa or with mucosal 
ulcers.
We compared the results of the networks for randomly split images and 
for individual patients.
First we trained the network on five-folds randomly split images (each fold 
with 80% training images and 20% images testing). Than we conducted 
three experiments in which images from n-1 patients were used to train a 
network and images from a different individual patient were used to test 
the network. Areas under the curves (AUC) and accuracies were computed 
for each individual network.
results: Overall, the dataset included 4,255 capsule endoscopy images 
from 15 patients (11 with and 4 without CD, respectively); 2,272 images 
contained ulcerated mucosa and 1,983 normal images.
For randomly split images the performance of CNN was excellent with 
AUC ranging between 0.97 and 0.99 and accuracies ranging from 96.7% 
to 97.8%.
For individual patient-level (patients 1,2 and 3) experiments, the AUCs were 
also excellent (0.97, 0.99 and 0.99, respectively). Variability was seen in the 
accuracies for different patients (73.2%, 88.2% and 95.6%, respectively).
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conclusion: Deep learning technology provides accurate automated detec-
tion of mucosal ulcers on capsule endoscopy images for both pooled and 
individual patient images. To simulate real life results, individual patient-
level experiments must be conducted. This technology may be applicable 
for real-life processing of CE imaging in suspected and established Crohn’s 
disease.
disclosure: Shomron Ben-Horin received consulting and advisory board 
feesand/or research support from AbbVie, MSD, Janssen, Takeda and-
CellTrion. Uri Kopylov received speaker and advisory fees fromAbbvie, 
Jannsen, MSD, Takeda and Medtronic, and research sup-port from Jannsen, 
Medtronic and Takeda. Rami Eliakim receivedconsultant and speaker fees 
from Janssen, Abbvie, Takeda andMedtronic. None of the other authors 
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Introduction: Pulmonary dysfunction is frequently underestimated in in-
flammatory bowel disease (IBD) patients. The aim of this study was to 
investigate pulmonary function in IBD patients and identify possible risk 
factors for pulmonary dysfunction.
aims & Methods: Consecutive informed and consented IBD patients < 60 
years old followed up in our centre underwent pulmonary function tests 
(PFTs) during their regular follow up visit. Measurements conducted were 
forced vital capacity (FVC), forced expiratory volume in one sec (FEV1) and 
maximal mid-expiratory flow (MMEF 75/25). Exclusion criteria were an 
acute or chronic respiratory disease as well as the presence of an estab-
lished pulmonary extra-intestinal manifestation.
results: 135 IBD patients have been enrolled so far (males: 55.6%, Crohn’s 
disease: 63.7%, mean age at IBD diagnosis: 34.2 years [SD±11.9], median 
[IQR] duration of IBD: 7.5 months [0.1-34.3], extraintestinal manifestations: 
36.3%). Thirty-eight patients (28.1%) had never smoked with the rest 
being either active (36.3%) or ex- (33.3%) smokers. Thirty-four patients 
(25.2%), including 7/38 (35.3%) non-smokers, revealed abnormal PFTs 
(males: 22/34, Crohn’s disease: 25/34); 12 (35.3 %) exhibited a restrictive 
pattern, 12 (35.3 %) an obstructive pattern and 10 (29.4%) small airway 
disease. Interestingly, appendectomy was more commonly reported in 
non-smokers with abnormal PFTs compared to those without (p=0.002). 
IBD was active at baseline in 4/34 and extraintestinal manifestations were 
present in 15/34 patients. Anti-TNFalpha agents were administered in 17/34 
(50%) patients. Six patients were under combination therapy with an IMS. 
There was no association of abnormal PFTs with gender, disease sort or 
location or behavior or activity, tonsillectomy, IBD therapy either as mono-
therapy or as combination therapy and the presence of anemia.
conclusion: More than one fourth of our IBD patients in total and of non-
smokers in particular demonstrate abnormal PFTs measured in a random 
outpatient visit without any symptoms, signs or history of respiratory dis-
ease. Appendectomy was associated with LFTs abnormality in non-smok-
ers perhaps revealing an immunologic defect influencing the development 
of obscure primary or secondary pulmonopathy on the background of IBD. 
These results should of course be interpreted with caution for the time be-
ing, while awaiting those of a larger cohort.
disclosure: Nothing to disclose. 
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Introduction: This study aims to investigate the performance of Lactoferrin 
and Calprotectin compared to the Riley Score and especially to the Nany 
index assessing the histological inflammatory activity in a cohort of pa-
tients with ulcerative colitis (UC).
aims & Methods: Secondary analysis of clinical data from UC patients who 
were treated in the Department of Internal and Integrative Medicine at 
the Kliniken Essen-Mitte, Germany. Patients were included in the pres-
ent study, if colonoscopy-results, biopsies and data of the fecal biomark-
ers Lactoferrin and Calprotectin were available. A total of 3 biopsies were 
taken each in the sigma and rectum and the Riley Score and Nancy index 
were calculated by an experienced pathologist blinded to the results of the 
fecal biomarkers. The histologic scores were correlated to Lactoferrin (LF) 
and Calprotectin (Cal) levels in stool harvested within 7 days before the 
endoscopic intervention. Comparisons were done for differences between 
biomarker levels and the grades of the Nancy index. Sensitivity, specificity, 
negative predictive value and positive predictive value as well as optimized 
cut-offs were calculated. Remission was defined as Nancy Index ≤ 1.
results: 228 patients (60.1 % female, mean age 45.26 years) with diag-
nosed UC were included in the analysis. The Riley score and Nancy index 
correlated significantly with LF (r
s
 (228) = 0.43; p < .001/ r
s
 (228) = 0.43; p 
< .001) and Cal (r
s
 (228) = 0.40; p < .001/ r
s
 (228) = 0.38; p < .001). Median 
levels of LF and Cal differed significantly between the grades 0-4 of the 
Nancy index (both p < .001). Subsequent post-hoc tests showed that LF dif-
fered between the grades 0 and 3 (z = -6.15, p < .001), 0 and 4 (z = -4.82, p 
< .001), 1 and 3 (z = -3.31, p = .009), 1 and 4 (z = -2.83, p = .046), 2 and 3 (z = 
-3.66, p = .003) and 2 and 4 (z = -2.88, p = .040) and Calprotectin between 
the grades 0 and 2 (z = -3.90, p = .001), 0 and 3 (z = -5.69, p < .001), 0 and 
4 (z = -4.46, p < .001), 1 and 3 (z = -3.77, p = .002) and 1 and 4 (z = -3.27, 
p = .011). Moreover the median levels of LF and Cal differed significantly 
between patients in remission (Nancy Index ≤ 1) and patients with disease 
activity (Nancy Index ≥ 2), both p < .001. Optimized cut-off-values and the 
diagnostic accuracy of LF and Cal for the differentiation between active and 
inactive disease using the Nancy Index as reference standard are < 5.85 for 
LF and < 34.28 for Cal resulting in a diagnostic accuracy of .73 for LF and .76 
for Cal with a sensitivity of 76.4 for LF, 64.6 for Cal and a specitifity of 64.3 
for LF and 78.6 for Cal. Table 1 shows the sensitivity, specificity, positive 
predictive value and negative predictive value of LF and CAL.
conclusion: The fecal biomarkers Lactoferrin and Calprotectin correlated 
significantly with the Riley and Nancy index. LF and CalP differed signifi-
cantly between the grades of the Nancy index. The results support the 
utility of fecal biomarkers for detecting active histologic inflammation in 
patients with ulcerative colitis. 
  cut off se (%) sP (%) PPv (%) nPv (%)
Lactoferrin ≤ 7.25 µg/g 103/144 (71.5) 55/84 (65.5) 103/132 (78.0) 55/96 (57.3)
Calprotectin < 50 µg/g 82/144 (56.9) 68/84 (81.0) 82/98 (83.7) 86/130 (52.3)
[Table 1. Sensitivity, Specificity, positive predictive value and negative 
predictive value of Lactoferrin and Calprotectin using manufactures’ cut-offs]
disclosure: Research grant: Steigerwald Arzneimittelwerke GmbH, Falk 
Foundation; TechLab, Dr. Willmar Schwabe; Repha GmbH biologische Ar-
zneimittel Lectures: Falk Foundation; MSD Sharp&Dohme GmbH; Repha 
GmbH biologische Arzneimittel; Ardeypharm GmbH; Celgene GmbH; Dr. 
Willmar Schwabe Advisory board: Medizinverlage Stuttgart; Steigerwald 
Arzneimittelwerke GmbH; Repha GmbH; Ferring Arzneimittel GmbH; 
Sanofi 
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P1054 red BLOOd ceLL dIsTrIBuTIOn WIdTh and ITs 
derIvaTIves as POTenTIaL Markers In The cOurse Of 
uLceraTIve cOLITIs - an OBservaTIOn Of PaTIenTs TreaTed 
WITh InfLIxIMaB
Michalak A., Radwan P., Kasztelan-Szczerbinska B., Laskowska K., 
Cichoz-Lach H.
Medical University of Lublin, Department of Gastroenterology with Endoscopy 
Unit, Lublin, Poland
contact e-Mail address: lady.agatamichalak@gmail.com
Introduction: Red blood cell distribution width (RDW) is associated with 
various medical conditions. Its elevated level was found to be the predic-
tor of poor outcome in cancer, liver cirrhosis and cardiovascular diseases. 
RDW was also suggested as a marker of inflammation in the course of 
inflammatory bowel disease (IBD). 
Nevertheless, it seems that a potential role of its derivatives (red blood cell 
distribution width-to-platelet ratio (RPR) and red blood cell distribution 
width-to-lymphocyte ratio (RLR)) in this field of gastroenterology has not 
been explored so far.
aims & Methods: The aim of our study was to find out if there are devia-
tions in RDW and its derivatives levels - RPR and RLR - in the course of 
infliximab (IFX) induction regimen in ulcerative colitis (UC) patients. We 
also looked for relationship between mentioned parameters, platelet in-
dices and C-reactive protein (CRP). One hundred and twelve participants 
were qualified to the survey: 56 patients with active UC and 56 persons 
in control group. UC patients were treated with IFX (3 doses of standard 
induction therapy). RDW, RPR and RLR values were obtained in the blood 
of UC patients at 0, 2, and 6 weeks of induction regimen and in follow-up 
six weeks later. Results were compared with control group.
results: RDW value in UC patients prior to the first dose of IFX was above 
normal range; it was also higher in comparison to control group (p< 0.001) 
and normalized in follow-up (p<0.01). Baseline RLR level in study group 
compared to controls was higher (p<0.001) and decreased after finished 
IFX induction regimen (p>0.05); Baseline RPR value did not differ sig-
nificantly; in follow up its level increased (p<0.001). We noticed several 
correlations in UC patients. 
Prior to the treatment with IFX, RPR correlated positively with mean plate-
let volume (MPV) (p<0.01) and platelet distribution width (PDW) (p<0.001); 
negative correlation was observed between RPR and plateletcrit (PCT) 
(p<0.001). In follow up RPR correlated negatively with PCT (p<0.001) and 
CRP (p<0.001); positive correlation was noticed between RPR and PDW 
(p=0.001).
conclusion: Performed study revealed that RDW, RPR and RLR values are 
affected by IFX therapy in UC patients ad should be considered as potential 
laboratory markers in the course of IBD.
references: 1. Öztürk ZA, Dag MS, Kuyumcu ME, et al. Could platelet in-
dices be new biomarkers for inflammatory bowel diseases? Eur Rev Med 
Pharmacol Sci. 2013; 17: 334-41. 2. Goyal H, Hu ZD. Prognostic value of red 
blood cell distribution width in hepatocellular carcinoma. Ann Transl Med. 
2017; 5: 271.
disclosure: Nothing to disclose 
P1055 heMaTOLOgIcaL Markers In The evaLuaTIOn Of 
InfLaMMaTIOn In crOhn’s dIsease PaTIenTs
Michalak A., Radwan P., Kasztelan-Szczerbinska B., Laskowska K., 
Cichoz-Lach H.
Medical University of Lublin, Department of Gastroenterology with Endoscopy 
Unit, Lublin, Poland
contact e-Mail address: lady.agatamichalak@gmail.com
Introduction: Recently, neutrophil-to-platelet ratio (NLR), platelet-to-
lymphocyte ratio (PLR) and mean platelet volume-to platelet ratio (MPR) 
have been proposed as potential markers in various medical disorders, 
e. g. cancer, cardiovascular diseases, liver cirrhosis. However, the above-
mentioned indices have not been explored in inflammatory bowel disease 
patients so far.
aims & Methods: Our goal in this survey was to assess NLR, PLR, MPR and 
their relationships with platelet indices and C-reactive protein (CRP) in 
Crohn’s disease (CD) patients treated with infliximab (IFX). We included 
80 participants to the study: 40 patients with active CD and 40 persons in 
control group. CD patients were treated with IFX (five doses of standard 
therapy). NLR, PLR, MPR and their relatioships with CRP, mean platelet 
volume (MPV), plateletcrit (PCT) and platelet distribution width (PDW) 
were assessed in blood of CD patients at 0, 2, 6, 14 and 22 weeks. Results 
were compared with controls.
results: Baseline values of NLR and PLR among CD patients were higher 
in comparison to controls (p< 0.001); MPR level was lower (p< 0.01). In CD 
group, after five doses of IFX, a decrease in NLR (p< 0.001) and PLR values 
(p=0.001) together with increase of MPR level (p< 0,001) were noticed. We 
also observed significant correlations in CD patients, present simultane-
ously prior to the biological treatment and after five doses of IFX. NLR 
correlated positively with PLR and CRP (p< 0.01). There was a negative 
correlation between PLR and MPR (p< 0.01), together with positive asso-
ciation between PLR and PCT (p< 0.001). Finally, MPR correlated positively 
with MPV (p< 0.01) and negatively with PCT (p=0.001). In addition, CRP 
correlated negatively with MPR at baseline (p< 0.001) and positively with 
CRP (p=0.004) after five doses of IFX.
conclusion: CD, IFX therapy, NLR, PLR and MPR are closely related to each 
other. Analyzed hematological indices might be potential tools in the mon-
itoring of CD patients.
references: 1. Iida H, Kaibori M, Matsui K i wsp. Ratio of mean platelet 
volume to platelet count is a potential surrogate marker predicting liver 
cirrhosis. World J Hepatol. 2018; 10: 82-7. 2. Zhao Z, Liu J, Wang J i wsp. 
Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio 
(NLR) are associated with chronic hepatitis B virus (HBV) infection. Int Im-
munopharmacol. 2017; 51: 1-8. 3. Voudoukis E, Karmiris K, Koutroubakis 
IE. Multipotent role of platelets in inflammatory bowel diseases: a clinical 
approach. World J Gastroenterol. 2014; 20: 3180-90.
disclosure: Nothing to disclose 
P1056 neuTrOPhIL-TO-PLaTeLeT raTIO, PLaTeLeT-TO-
LyMPhOcyTe raTIO and Mean PLaTeLeT vOLuMe-TO PLaTeLeT 
raTIO as POTenTIaL heMaTOLOgIcaL IndIces In The evaLuaTIOn 
Of InfLaMMaTIOn In uLceraTIve cOLITIs PaTIenTs
Michalak A., Radwan P., Kasztelan-Szczerbinska B., Laskowska K., 
Cichoz-Lach H.
Medical University of Lublin, Department of Gastroenterology with Endoscopy 
Unit, Lublin, Poland
contact e-Mail address: lady.agatamichalak@gmail.com
Introduction: There is a growing body of evidence that new routinely ob-
tained noninvasive blood indices could become markers of inflammation 
in inflammatory bowel disease patients. Nevertheless, the number of ob-
servations devoted to this field of gastroenterology is still very small.
aims & Methods: We aimed in our survey to look for relationships between 
hematological parameters in ulcerative colitis (UC) patients treated with 
infliximab (IFX). One hundred and twelve participants were enrolled to 
the study: 56 patients with active UC and 56 persons in control group. UC 
patients were treated with IFX (3 doses of standard induction therapy). 
Neutrophil-to-platelet ratio (NLR), platelet-to-lymphocyte ratio (PLR), 
mean platelet volume-to platelet ratio (MPR) and their correlations with 
red blood cell and platelet indices were measured in the blood of UC pa-
tients at 0, 2, and 6 weeks of induction regimen and in follow-up six weeks 
later. Results were compared with control group.
results: NLR and PLR levels in UC patients prior to the first dose of IFX were 
higher in comparison to controls; MPR value was lower (p< 0.001). NLR 
value decreased after finished IFX induction therapy (p< 0.001). PLR level 
became lower too, however not significantly. MPR value became higher 
(p< 0.001). Several correlations were noticed in UC patients. PLR corre-
lated positively with mean platelet volume (MPV) and red blood cell dis-
tribution width (RDW) before the introduction of IFX (p< 0.01); there were 
also positive correlations between MPR and both - platelet distribution 
width (PDW) and plateletcrit (PCT) (p< 0.001). In follow-up after finished 
induction regimen PLR correlated positively with NLR and PCT (p< 0.001); 
negative correlations were noticed between PLR and both MPR and PDW 
(p< 0.01).
conclusion: Deviations in white blood cell, red blood cell and platelet in-
dices seem to be closely related to each other in UC patients and affected 
by IFX therapy. NLR, PLR and MPR are potential diagnostic tools in the 
monitoring of UC patients.
references: 1. Ghoshal K, Bhattacharyya M. Overview of platelet physiolo-
gy: its hemostatic and nonhemostatic role in disease pathogenesis. Scien-
tific World Journal. 2014; 2014: 781857. 2. Iida H, Kaibori M, Matsui K i wsp. 
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Ratio of mean platelet volume to platelet count is a potential surrogate 
marker predicting liver cirrhosis. World J Hepatol. 2018; 10: 82-7. 3. Zhao Z, 
Liu J, Wang J i wsp. Platelet-to-lymphocyte ratio (PLR) and neutrophil-to-
lymphocyte ratio (NLR) are associated with chronic hepatitis B virus (HBV) 
infection. Int Immunopharmacol. 2017; 51: 1-8.
disclosure: Nothing to disclose 
P1057 The rOLe Of OncOsTaTIn M In dIagnOsIs, PrOgnOsIs 
and TheraPy resPOnse Of IBd
Verstockt S.1,2, Verstockt B.2,3, Machiels K.4, Vancamelbeke M.5, 
Ferrante M.2,3, Cleynen I.6, Vermeire S.2,3, KU Leuven
1KU Leuven, Human Genetics, Leuven, Belgium, 2KU Leuven, Department 
of Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, 
Belgium, 3University Hospitals Leuven, Department of Gastroenterology and 
Hepatology, Leuven, Belgium, 4Katholieke Universiteit Leuven, Department of 
Gastroenterology, Department of Chronic Diseases, Metabolism and Ageing 
(CHROMETA), Leuven, Belgium, 5KU Leuven, Clinical and Experimental 
Medicine, Leuven, Belgium, 6KU Leuven, Human Genetics, Heverlee, Belgium
contact e-Mail address: sare.verstockt@kuleuven.be
Introduction: Oncostatin M (OSM) has been implicated in the pathogen-
esis of inflammatory bowel disease (IBD), wherein its increased mucosal 
expression drives intestinal stromal cell inflammation and predicts non-
responsiveness to anti-TNF therapy1. In this study we aimed to further un-
ravel the potential of OSM as a diagnostic, prognostic and/or therapeutic 
biomarker.
aims & Methods: We collected serum and mucosal biopsies from Crohn’s 
disease (CD) and ulcerative colitis (UC) patients: (1) treatment-naive newly 
diagnosed patients; (2) patients initiating anti-TNF or (3) vedolizumab 
therapy; (4) post-operative CD patients six months after ileocolonic resec-
tion with ileocolonic anastomosis; (5) multiple-affected IBD families in-
cluding unaffected first-degree relatives (FDRs). For each group, matched 
samples from non-IBD controls were included as comparison. Serum OSM 
protein levels were measured using the Proseek Multiplex Inflammation 
panel (OLINK), and mucosal OSM expression using RNA-sequencing or 
microarray technology. An overview of the studied samples and the cor-
responding applied definitions and technologies can be found in Table 
1. Wilcoxon tests (R 3.5.1) were applied to assess statistical significance, 
defined as a p value < 0.05.
results: In newly diagnosed CD and UC patients, we observed increased 
colonic OSM expression (fold change (FC)=60.2, p=3.7E-09) and serologi-
cal protein levels (FC=4.9, p=1.3E-11) compared to non-IBD controls, with 
the strongest upregulation in extensive UC and fistulizing CD. Moreover, 
elevated mucosal OSM (but not serum OSM) at diagnosis was associated 
with the need for biological therapy within one year after diagnosis (poor- 
vs. good-prognosis: FC=5.0, p=1.5E-03). Prior to both anti-TNF and ve-
dolizumab therapy, colonic OSM was upregulated in future non-remitters 
(FC=2.5, p=5.0E-02; FC=2.3, p=1.0E-02 respectively). In contrast, baseline 
serum OSM could not identify future anti-TNF or vedolizumab non-remit-
ters (FC=1.0, p=3.0E-01; FC=0.9, p=4.1E-01 respectively). In CD patients with 
post-operative recurrence (POR) higher serum OSM levels were found at 
month 6, as compared to patients without POR and to controls (FC=2.6, 
p=1.9E-02; FC=2.9, p=4.5E-03). Furthermore, mucosal OSM in POR CD pa-
tients did not differ from CD patients without POR (FC=1.2, 1.4E-01), but 
was significantly upregulated as compared to controls (FC=1.5, p=5.0E-03). 
In multiple-affected IBD families increased serum levels were observed in 
FDRs as compared to matched control families (FC=1.7, p=4.0E-04), and 
levels were similar to those of IBD patients.
conclusion: Colonic OSM levels are increased in CD and UC patients at the 
time of diagnosis, and higher levels correlate with poor prognosis. In ad-
dition, upregulation of colonic OSM is associated with future anti-TNF/
vedolizumab non-remitters. Therefore, OSM at the mucosal site is a sur-
rogate marker of biological treatment-refractoriness in IBD.
references: 1. West NR et al. Nat Med. 2017
disclosure: B Verstockt received financial support for research from Pfizer; 
lecture fees from Abbvie, Ferring Pharmaceuticals, Janssen, R-biopharm 
and Takeda; consultancy fees from Janssen. S Vermeire received financial 
support for research from MSD, Abbvie, Janssen, Takeda and Pfizer; lecture 
fees from Abbott, Abbvie, Merck Sharpe & Dohme, Ferring Pharmaceuti-
cals, Pfizer, Takeda, Galapagos/Gilead and UCB Pharma; consultancy fees 
from Pfizer, Ferring Pharmaceuticals, Shire Pharmaceuticals Group, Merck 
Sharpe & Dohme, Abbvie, Takeda, Prodigest, Celgene, Galapagos, Gilead, 
Arena Pharmaceuticals, Genentech/Roche, Abivax, and AstraZeneca Phar-
maceuticals. M Ferrante reports financial support for research: Janssen, 
Pfizer, Takeda, Consultancy: Abbvie, Boehringer-Ingelheim, Celltrion, Fer-
ring, Janssen, Lilly, Mitsubishi Tanabe, MSD, Pfizer, Takeda; Speakers fee: 
Abbvie, Amgen, Biogen, Boehringer-Ingelheim, Chiesi, Falk, Ferring, Jans-
sen, Lamepro, Mitsubishi Tanabe, MSD, Pfizer, Takeda, Tramedico, Tillotts, 
Zeria. 
cOhOrT suBgrOuPs PrOTeOMIcs saMPLes TranscrIPTOMIcs saMPLes 
(RNAseq*/microarray**)
1.Treatment-naïve newly diagnosed IBd patients 
(= within 6 months after diagnosis, naïve for biologicals/
immunosuppressives, no IBD related surgery)
Crohn’s disease (CD) 
Ulcerative colitis (UC) 
Non-IBD controls
30 
16 
40
16 colonic samples* 
11 colonic samples*
29 colonic samples*
1.Treatment-naïve newly diagnosed IBd patients 
(= within 6 months after diagnosis, naïve for biologicals/
immunosuppressives, no IBD related surgery)
Poor-prognosis 
(=the need for biological therapy within one 
year after diagnosis) 
Good-prognosis
28 
18
15 colonic samples* 
12 colonic samples*
2. anti-Tnf cohort Remission 
(=the complete absence of ulcerations (CD) or 
a Mayo endoscopic sub-score 0 - 1 (UC)) 
No remission
91 
95
12 colonic samples* 
21 colonic samples*
3. vedolizumab cohort Remission 
(=the complete absence of ulcerations (CD) or 
a Mayo endoscopic sub-score 0 - 1 (UC)) 
No remission
105 
82
24 colonic samples* 
25 colonic samples*
4. Post-operative cd patients undergoing ileocecal resection 
with ileocolonic anastomosis
No post-operative recurrence 
(=Rutgeerts i0/i1 at month 6) 
Post-operative recurrence 
(=Rutgeerts ≥ i2b at month 6) 
Non-IBD controls
36 
17 
40
8 ileal samples** 
24 ileal samples** 
12 ileal samples**
5. Multiple-affected IBd families 
(=min. 3 first-degree relatives with IBD)
IBD 
Unaffected first-degree relatives (FDRs) 
Non-IBD control families
47 
33
39
/
[P1057 Table 1: Overview of the studied samples and corresponding applied definitions and technologies]
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P1058 PrOsPecTIve, randOMIzed cLInIcaL TrIaL cOMParIng 
The effIcacy Of TWO vaccInes agaInsT hePaTITIs B vIrus (hBv) 
In InfLaMMaTOry BOWeL dIsease (IBd) PaTIenTs
Chaparro M.1, Gordillo J.2, Domènech E.3, Esteve M.4, 
Barreiro-de Acosta M.5, Villoria A.6, Iglesias-Flores E.7, Blasi M.2, 
Naves J.E.3, Benítez O.4, Nieto L.5, Calvet X.6, García-Sánchez V.7, 
Villagrasa J.R.8, Marín A.C.1, Donday M.G.1, Gisbert J.P.1
1Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology 
Unit, Madrid, Spain, 2Hospital Santa Creu i Sant Pau, Gastroenterology 
Unit, Barcelona, Spain, 3Hospital Universitario Germans Trias i Pujol and 
CIBERehd, Gastroenterology Unit, Badalona, Spain, 4Hospital Universitari 
Mutua Terrassa and CIBERehd, Gastroenterology Unit, Tarrasa, Spain, 
5Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, 
Santiago de Compostela, Spain, 6Hospital de Sabadell and CIBERehd, 
Gastroenterology Unit, Sabadell, Spain, 7Hospital Universitario Reina 
Sofía, Gastroenterology Unit, Córdoba, Spain, 8Hospital Universitario de La 
Princesa and Instituto de Investigación Sanitaria Princesa (IIS-IP), Preventive 
Medicine, Madrid, Spain
contact e-Mail address: mariachs2005@gmail.com
Introduction: 
aims & Methods: To compare the success rate between two HBV vaccines 
in IBD patients: the traditional (Engerix®) and a new vaccine with an ad-
juvant (Fendrix®). Secondary aim was to identify predictor factors of re-
sponse to the vaccine.
IBD patients with negative HBV serology and without previous vaccination 
were included in this multicenter study (EUDRA-CT number: 2010-023947-
14), and randomized 1:1 to receive double doses of Engerix® or Fendrix® or 
at months 0, 1, 2 and 6. Anti-HBs concentration was measured 2 months 
after the 3rd and 4th doses. Response to vaccination was defined as anti-
HBs ≥100 UI/L.
results: 173 from 180 included patients were randomized and received the 
first vaccine dose. 98% received the first 3 doses of vaccine and 97% com-
pleted the vaccination schedule. During vaccination, 24% of patients were 
under immunomodulators (IMM), 15% under anti-TNF and 24% under 
combo therapy (IMM and anti-TNF). 54% of patients received Engerix® 
and 46% Fendrix®; the main characteristics of patients (age, gender, type 
of IBD, treatment and proportion of drop-outs) were similar between the 
2 groups. 
variables Odds ratio 95% confidence interval
Age (>60 years vs. £60 years of age) 0.17 0.06-0.49
Fendrix (single dose) over Engerix (double dose) 1.8 0.8-4.1
IBD treatments    
Steroids vs. no treatment 0.03 0.004-0.3
Immunomodulators in monotherapy vs. no treatment 0.1 0.02-0.58
Anti-TNF in monotherapy vs. no treatment 0.05 0.01-0.3
Combo therapy vs. no treatment 0.02 0.004-0.1
[Table 1. Multivariate analysis of predictive factors associated with response 
(anti-HBs≥100 IU/L after 4 doses) to hepatitis B virus vaccine in infl]
Overall, in the per-protocol (PP) analysis, 45% of patients had response 
(pre-defined as anti-HBs³100 IU/L) after the first 3 doses (168 patients re-
ceived 3 doses), and 71% after the completion of the vaccination schedule 
(159 completed the vaccination). 47% of patients that did not respond after 
the 3th dose, responded to the 4th vaccine administration (p<0.0001). In the 
PP analysis, the response rate after the 4th dose was 75% (95%CI, 57-78%) 
with Fendrix® vs. 68% (64-85%) with Engerix® (p=0.3); however, consider-
ing anti-HBs≥10 IU/L (the standard threshold to define response), there 
was a trend towards higher success rate with Fendrix® than with Engerix® 
(88% vs. 77%, p=0.07). The response rate after 4 doses was significantly 
lower in patients under IMM, anti-TNF agents and combo therapy com-
pared with no treatment: 77%, 63%, 45% and 96%, respectively (p<0.01 
for each comparison). 
In the multivariate analysis, older age, the treatment with steroids alone, 
IMM, anti-TNF agents and combo therapy were associated with lower 
probability of response to the vaccination. The type of vaccine -Engerix® or 
Fendrix®- was not associated with the response to the vaccination (table 1). 
The proportion of adverse events probably related to the vaccine was sig-
nificantly higher in patients receiving Fendrix® vs. Engerix® (17% vs. 4%), 
being local pain the most frequent one; all of them were mild.
conclusion: We could not demonstrate a statistically significant higher re-
sponse rate of Fendrix® (single dose) over Engerix® (double dose) in IBD 
patients. A 4-dose vaccine schedule significantly increases (over 40%) the 
response compared with a 3-dose regimen. Older age and IMM and anti-
TNF treatment impaired the success rate of the vaccine. Both vaccines are 
safe in IBD patients.
disclosure: M. Chaparro has served as a speaker, or has received research 
or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, 
Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma. JP Gis-
bert has served as a speaker, a consultant and advisory member for or has 
received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, 
Biogen, Takeda, Janssen, Roche, Celgene, Ferring, Faes Farma, Shire Phar-
maceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro 
Pharma, Otsuka Pharmaceutical, Vifor Pharma. 
P1059 cOMPLIance WITh InTernaTIOnaL guIdeLInes On 
vaccInaTIOn and MaLIgnancy PrevenTIOn aMOng PaTIenTs 
WITh InfLaMMaTOry BOWeL dIsease
Mellos A., Michalopoulos G., Makris K., Kapizioni C., Kourkoulis P., 
Koutoufaris G., Milioni K., Giannelis P., Vrakas S., Xourgias V.
Tzaneio General Hospital, Department of Gastroenterology, Piraeus, Greece
contact e-Mail address: gmicha78@hotmail.com
Introduction: IBD patients receiving immunosuppressive therapy are at 
increased risk of developing opportunistic infections and certain types of 
malignancy, often associated with the type of immunosuppressive therapy. 
International guidelines have been published, involving vaccination pro-
tocols and malignancy screening with cervical smear, mammography and 
skin examination, yet adherence from patients remains low.
aims & Methods: To determine self-reported compliance with influenza 
virus and pneumococcal vaccination guidelines, as well as malignancy 
screening with cervical smear, mammography and skin examination, 
among Greek patients with inflammatory bowel disease.
Method: In collaboration with the Hellenic Society of Crohn’s Disease’s and 
Ulcerative Colitis’ Patients, a questionnaire was posted on the Society’s 
website, inviting IBD patients only on immunosuppressive therapy to fill it 
in. The questionnaire included demographic data, disease characteristics 
as well as influenza and pneumococcal vaccination queries, skin exami-
nation (all patients), cervical smear and mammography screening rates 
(female patients).
results: A total of 176 patients completed the questionnaire [CD=134 
(76.14%) UC=42 (23.86%), male=57 (32.38%) female=119 (67.6%)]. Among 
them, 51(28.9%) patients were treated with one immunomodulator (MTX-
AZA), 73 (41.4%) with anti-TNF, 19 (10.7%) with Vedolizumab, 3 (1.7%) with 
Ustekinumab whereas 30 (17%) patients were treated with combination 
therapy. According to the results, 97 patients (55.1%) received the influ-
enza virus vaccine, 81 patients (46%) received the 13-strain PPV, whereas 14 
patients (8%) weren’t sure if they received the vaccine or not. Fifty nine pa-
tients (33.5%) received the 23-strain PPV and 25 patients (14.2%) weren’t 
sure if they received the vaccine or not. Thirty nine patients (22.2%) under-
went skin examination whereas 26 patients (14.8%) weren’t aware of it. 
Twenty four patients (18.9%) had never undergone cervical smear testing 
and 57 (46.7%) had never performed a mammography. There was no sta-
tistically significant difference between vaccination and screening compli-
ance rates of patients receiving monotherapy and combination therapy.
conclusion: There appears to be a significant proportion of patients re-
ceiving immunosuppression therapy (>50%) that does not comply with 
the international guidelines on vaccination and malignancy prevention (it 
cannot be clarified whether this is a problem of lack of education or sim-
ply non-compliance), putting themselves at risk . Even high-risk patients 
(combination immunotherapy) do not seem to have better compliance 
rates.
disclosure: Nothing to disclose 
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P1060 The hIsTOLOgIcaL heaLIng In uLceraTIve cOLITIs 
PaTIenTs can Be BesT PredIcTed By The cOMBInaTIOn Of 
faecaL caLPrOTecTIn and endOscOPIc heaLIng assessed 
By advanced OPTIcaL enhanceMenT TechnIques
Cannatelli R.1,2, Shivaji U.N.1,3, Smith S.1,3, Zardo D.4, Bazarova A.1, 
Gkoutos G.1, Nardone O.M.1, Ghosh S.1,3, Iacucci M.1,3,5
1University of Birmingham, Institute of Translational Medicine, Birmingham, 
United Kingdom, 2University of Milan, Gastroenterology, Milan, Italy, 
3University of Birmingham, NIHR Biomedical Research Centre, Birmingham, 
United Kingdom, 4University Hospitals Birmingham NHS Foundation Trust, 
Department of Histopathology, Birmingham, United Kingdom, 5University of 
Calgary, Ibd Clinic, Division Of Gastroenterology, Calgary, United Kingdom
contact e-Mail address: cannatellirosanna@gmail.com
Introduction: Endoscopic mucosal healing (MH) is an important target of 
therapy and prognostic factor in Ulcerative Colitis (UC) patients. Consider-
able interest has been generated by reports that 18-24% of patients with 
endoscopic healing at white light endoscopy (WLE) are found to still have 
active inflammation from the histological results. Faecal Calprotectin (FC) 
is a widely used surrogate marker of MH. Recently, we have published and 
validated endoscopic MH using high definition (HD) electronic chromoen-
doscopy which provides fine details of mucosal and vascular patterns.1,2
aims & Methods: In this study, we aim to investigate MH using Fecal Cal-
protectin (FCP) multiple endoscopic and histological scoring systems as-
sessed with advanced endoscopic platforms widely available, We prospec-
tively obtained clinical data, endoscopic scores {Mayo Endoscopic Score 
(MES), Ulcerative Colitis Endoscopic Index of Severity (UCEIS) PICaSSO 
score (Paddington International virtual ChromoendoScopy ScOre)}1 FCP for 
51 UC patients (mean age 45y, 51% male) undergoing colonoscopy for coli-
tis assessment or surveillance using high definition iscan optical enhance-
ment (iscan-OE) Pentax, NBI near focus (NBI-NF) Olympus or Blue Light 
Imaging (BLI) Fujinon . Histologic activity was scored by Robarts Histologi-
cal Index (RHI) and Nancy Index (NI). Receiver Operating Characteristics 
(ROC) curves were plotted to determine operating characteristics of FCP 
alone or in combination with endoscopic scores to predict histologic heal-
ing using modelling algorithms.
results: 24 (47.1%) patients had endoscopic remission defined as MES= 0 
or UCEIS (≤1) using HD-WLE. The mean (SD) of FCP was 505.5 (741.0) µg/g 
and 23 (45.1%) patients had FCP≤100 µg/g. 24 (47.1%) were in histologic 
remission, defined as RHI ≤ 6; and 21 (41.2%) patients were in histologic 
remission defined as NI ≤1. 
ROC curves showed that the optimum cut-off of FC alone to predict histo-
logical healing with RHI was 163 µg/g with an accuracy of 82.4% (95%CI 
69.-91.6) and Area Under ROC curve (AUROC) of 83.6% (95%CI 71.8-95.5). 
Using NI, the best threshold was 112 µg/g with accuracy of 82.4% (95%CI 
69.1-91.6) and AUROC of 85.7% (95%CI 75.4-96.0).
When FC (≤100 µg/g) and PICaSSO were combined to predict histological 
healing, measured with RHI, the optimum cut-off was PICaSSO=3 with ac-
curacy of 90.2% (95%CI 78.6-96.7) and AUROC of 95.5% (95%CI 90.4-100). 
Combining FC with PICaSSO with the formula “FC+1.5*Picasso” the ac-
curacy and AUROC to predict histological healing with NI at the threshold 
of PICaSSO=5 were 92.1% (95%CI 81.1-97.8) and 96.5% (95%CI 91.8-100), 
respectively.
The accuracy of predicting histological healing with RHI for the combina-
tion of UCEIS & FC (≤100µg/g) was 90.2% (95%CI 78.6-96.7) and AUROC 
94.4% (95%CI 88.1-100) at the cut-off of PICaSSO=4. However, with NI, the 
best cut-off was PICaSSO=3, with accuracy of 92.9% (95%CI 77.5-98.0) and 
AUROC 92.2% (95%CI 84.7-99.7).
PICaSSO alone was able to predict histological healing at the cut-off of 
PICaSSO=3, with accuracy of 92.2% (95%CI 81.1-97.8) and AUROC of 95.1% 
(95%CI 89.1-100) with RHI. However, with NI accuracy was 90.2% (95%CI 
78.6-96.7) and AUROC was 95.5% (95%CI 90.1-100) at the same cut-off.
conclusion: The combination of advanced optical enhancement endoscop-
ic scores such as PICaSSO with FC could help to identify UC patients with 
histologic healing (RHI or NI) with higher accuracy than FC alone. Using 
new advanced endoscopic technologies now widely available, endoscopic 
scoring and histologic scoring no longer have large discrepancies as re-
ported before.1,2
references: 1. Iacucci M, Daperno M, Lazarev M, et al. Development and 
reliability of the new endoscopic virtual chromoendoscopy score: the PI-
CaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ul-
cerative colitis. Gastrointest Endosc 2017; 86(6): 1118-27.e5. 2. Trivedi PJ, 
Kiesslich R, Hodson J, et al. The Paddington International Virtual Chro-
moendoscopy Score in ulcerative colitis exhibits very good inter-rater 
agreement after computerized module training: a multicenter study across 
academic and community practice (with video). Gastrointest Endosc 2018; 
88(1): 95-106.e2.
disclosure: Nothing to disclose 
P1061 MeTaBOLIc BOne assessMenT In PaTIenTs WITh 
crOhn’s dIsease
Ben Mohamed A.1, Ghanem M.2, Ben Slimene B.1, Ben Abdallah H.1, 
Bouali R.1, Ebdelli M.N.1
1Faculty of Medecine of Tunisia, Tunis, Tunisia, 2Hopital Militaire Tunis, Tunis, 
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contact e-Mail address: asmabenmed2014@gmail.com
Introduction: Osteoporosis and osteopenia are frequently reported in 
Crohn’s disease, and their prevalence varies between 15 and 30%.The aim 
of our study was to evaluate the prevalence of bone loss in patients with 
Crohn’s disease and to determine its predictive factors.
aims & Methods: We conducted a retrospective study including patients 
with Crohn’s disease followed from 2010 to 2016. The measurement of 
bone mineral density (BMD) was realized by dual energy x ray absorpti-
ometry (DXA) .BMD was evaluated by calculating bone mass expressed in 
g / cm2 and T-score expressed as standard deviation scores (SDS).
results: Sixty patients were colllected.The average age was 35.7 years ( 19 
t-70) . The sex ratio M / F was 1.41 (35 men and 25 women). Twenty two 
patients were smokers (36.6%), the average number of pack years was 
13.3 PY. The average body mass index (BMI) was 22.7 Kg / m² (12.3 kg / 
m² - 30.84 kg / m². Denutrition (BMI < 18,5 kg / m²) was present in 13.33% 
of patients. The mean number of relapses was 2.57 (1-8). According to 
the Montreal classification 33.33% (20/60) were ranked L1, 13.3% (8/60) 
ranked L2, 50% (30/60) ranked L3, and 3.33% (2/60) classified L4. Corti-
cotherapy was noted in 73.3% of patients, the average number of courses 
was 1.44 (1-5) and the average cumulative dose was 3.75 g. The average 
duration of the evaluation of the disease was 84 months. Twenty four pa-
tients (40%) underwent intestinal resection. Biologically, 53% of patients 
had an inflammatory syndrome.
BMD was normal in 24 patients (40%) and low in 36 patients (60%). Os-
teopenia was reported in 28 cases (46.66%) and osteoporosis in 8 cases 
(13.33%).
The risk factors for bone loss were an age greater than 45 years (p = 0.04), 
a number of corticosteroid courses > 3 (p = 0.02) and a duration of disease 
progression> 4 years (p = 0.045).
However, the bone loss was not related to the gender, the location of the 
Crohn’s disease, or the history of intestinal resection.
conclusion: Bone loss is common in people with Crohn’s disease, hence 
the need for early detection to initiate specific treatment especially when 
Corticosteroid therapy is used.
disclosure: Nothing to disclose 
P1062 WhaT are The PredIcTOrs Of an adequaTe BOWeL 
PreParaTIOn In InfLaMMaTOry BOWeL dIsease?
Ribeiro Gomes A.C.1, Pinho R.T.2, Fernandes C.3, Fernandes S.S.4, 
Sousa M.5, Silva J.C.5, Afecto E.6, Carvalho J.7
1Centro Hospitalar Vila Nova de Gaia, Gastroenterology, Porto, Portugal, 
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de Gaia, Portugal, 4Centro Hospitalar Vila Nova de Gaia, Gastroenterology, 
Valongo, Portugal, 5Centro Hospitalar Vila Nova de Gaia/Espinho, 
Gastroenterology, Vila Nova de Gaia, Portugal, 6Centro Hospitalar Vila Nova 
de Gaia/Espinho, Serviço de Gastrenterologia, Vila Nova de Gaia, Portugal, 
7Centro Hospitalar Vila Nova de Gaia, Vila Nova de Gaia, Portugal
contact e-Mail address: catarina.rib.gomes@gmail.com
Introduction: The effectiveness of colonoscopy is dependent on the quality 
of bowel preparation. There are multiple modifiable and nonmodifiable 
factors that affect the quality of bowel preparation. One recent systematic 
review and meta-analysis was conducted and showed that age, male sex, 
inpatient status, diabetes mellitus, hypertension, cirrhosis, opioid use, 
constipation, stroke, and tricyclic antidepressant (TCA) use were associ-
ated with inadequate bowel preparation. 
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However, information regarding risk factors for inadequate bowel prepa-
ration in inflammatory bowel disease (IBD) is scarce. In this population an 
adequate bowel preparation is particularly important for the evaluation 
of the endoscopic activity and for the screening of pre-malignant lesions 
through chromoendoscopy.
aims & Methods: The aim of this study was to assess the quality of bowel 
preparation and the predictive factors for an inadequate bowel prepara-
tion in patients with IBD. A retrospective single-center analysis of patients 
with IBD who underwent colonoscopy between July 2017 and December 
2018 was performed. Incomplete colonoscopy or colonoscopies performed 
in an emergency setting were excluded. Clinical and endoscopic activity in 
Crohn’s Disease was assessed using the Harvey-Bradshow Index (HBI) and 
the Simplified Endoscopic Score- Crohn’s Disease and Rutgeerts, respec-
tively. Clinical and endoscopic activity in Ulcerative Colitis was assessed 
using the Mayo score.
results: 255 patients were evaluated, 51.4% male (n=131), with a mean age 
of 46 ± 15.1 years-old. The median American Society of Anesthesiologists 
(ASA) score was 1 (IQR: 1-2) and the median duration of IBD was 9.1 ± 7.7 
years. Crohn’s Disease was more prevalent 58% (n=148), and most of the 
patients were in clinical remission 68.2% (n=174) or under some medica-
tion 86.2% (n=220). Polyethylene glycol (PEG) was the main bowel prepa-
ration 40.8% (n=104) and 85.9% (n=219) had a previous nurse consulta-
tion. Bowel preparation was inadequate in 13.3% (n=34) of patients. In the 
univariate analysis, patients with poor bowel preparation had a higher 
proportion of a previous stroke (8.8% vs. 0.9%, p=0.002), higher opioid 
use (8.8% vs. 0%, p < 0.01), and had less frequently a nurse consultation 
(73.5% vs. 87.8%, p=0.03). The bowel preparation was not associated with 
age, male sex, body mass index, active smoking, abdominal surgical his-
tory, diabetes mellitus, ASA score, disease duration, IBD type, IBD treat-
ment, clinical and endoscopic activity, and type of bowel preparation. In 
the multivariate analysis, only a previous nurse consultation showed to be 
associated with an adequate bowel preparation (p=0.02).
conclusion: The quality measure of bowel preparation (≥ 90%) was not 
reached in this study. In this study, only a previous nurse consultation was 
shown to be associated with an adequate bowel preparation.
disclosure: Nothing to disclose 
P1063 LOng-TerM heaLTh sTaTe Of chILdren BOrn frOM IBd 
MOThers exPOsed TO anTI-Tnf TreaTMenT durIng Pregnancy
Mantzaris G., Viazis N., Tsoukali E., Pontas C., Tziortziotis Y., 
Hatzievangelinou C., Gkeros F., Filippidis G., Karampekos G., 
Vraka M., Christidou A., Archavlis E.
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contact e-Mail address: gjmantzaris@gmail.com
Introduction: Infliximab (IFX), adalimumab (ADL) and golimumab (GLM) 
are anti-TNF inhibitors of IgG1 class which do not cross the placenta until 
the 3nd trimester of the pregnancy; therefore, they are considered a safe 
treatment for the foetus during the 1st and 2nd trimester of the pregnancy. 
Infants born from IBD mothers exposed to anti-TNFs during this period of 
pregnancy did not exhibit higher rates of congenital abnormalities, early 
life infections, or any adverse events to early vaccinations. However, at 
usual dosing regimens blood levels of IFX are higher in pregnant com-
pared to non-pregnant IBD female patients. Furthermore, IFX levels may 
be detected in the newborn’s circulation despite cessation of IFX sched-
uled treatment in the mother before the 22nd week.
aims & Methods: We aimed to assess the short and long-term effects of 
IFX, ADL and GLM on the maturation of the immune system, response 
to vaccinations and development of serious illnesses in offsprings of IBD 
females exposed to these anti-TNFs until the 26th week of pregnancy. Pro-
spective, single center study. Data on somatic and mental development, 
serious illnesses, adverse events to vaccinations and general health state 
of children were recorded. The source of information was information 
from mothers, the child’s health-book (a full record of child’s somatic and 
mental development, vaccinations and any illness necessitating a visit to 
the family paediatrician or a hospital) and direct or phone contacts to the 
family paediatricians.
results: Data were collected for 19 children (11 female) born from 14 moth-
ers [7 with CD (3 after right hemicolectomy), 7 with UC (4 extensive, 3 
left-sided disease)] on monotherapy with IFX (10), ADL (3), GLM (1) at con-
ventional doses from the beginning of the pregnancy until between the 19th 
and 26th gestational week. Three women had conceived by in vitro fertiliza-
tion, and 4 women had >1 pregnancy. Two women reported a prior spon-
taneous abortion. All infants were born full-term with normal somatomet-
ric data. At birth, low levels of IFX were measured in 3 children (1, 1.5 and 
2 µg/ml, respectively), whose mothers had stopped treatment at 24th, 26th 
and 19th gestational week, respectively. Levels of ADL and BLM were unde-
tectable. All mothers resumed anti-TNF treatment after 1-3 months post-
partum. 18/20 children received regular vaccinations uneventfully but 2/20 
have not yet completed all vaccinations. 4/20 children were not breast-fed 
but only 1/4 for fear of anti-TNF treatment. 11/20 children are aged 3-10 
years. None of these has developed any serious autoimmune, allergic, or 
malignant disease, and have responded satisfactorily to vaccinations and 
have normal rates of somatometric development.
conclusion: In this small, single-centre, prospective study, treatment with 
IgG1-anti-TNF agents until the 26th gestational week does not seem to be 
related with later development, response to vaccinations, or any later ad-
verse life events.
disclosure: Nothing to disclose 
P1064 assOcIaTIOn BeTWeen seruM and TIssue PrOTeIn 
PrOfILes In PaTIenTs WITh InfLaMMaTOry BOWeL dIsease: 
The ascerTaIn sTudy
Stevens T.W.1, Koželj M.2, Novak G.2, Gecse K.B.1, Duijvestein M.1, 
Löwenberg M.1, Wildenberg M.E.1,3, Drobne D.2, D’Haens G.R.1
1Amsterdam UMC, University of Amsterdam, Department of Gastroenterology 
and Hepatology, Amsterdam, Netherlands, 2University Medical Center 
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Introduction: Molecular markers to facilitate personalized treatment of in-
flammatory bowel disease (IBD) are needed. Intestinal tissue might be the 
optimal matrix for biomarker discovery as the affected intestine contains 
high concentrations of inflammatory proteins. However, the use of tissue 
is limited due to the invasive nature of biopsy procurement. Therefore, 
matched validation of candidate markers in serum is an attractive ap-
proach.
aims & Methods: The objectives of this study were to (i) investigate the 
correlation between the proteomic profile of intestinal biopsies and serum 
of patients with active IBD and (ii) to identify proteins that discriminate IBD 
from non-IBD and Crohn’s disease (CD) from ulcerative colitis (UC). In this 
prospective multicentre cross-sectional study, consecutive IBD patients and 
controls were included between April 2017 and May 2018. Patients with IBD 
had active endoscopic disease defined by the presence of ≥1 ulcer (≥0.5 cm 
in size) in CD or an endoscopic Mayo score ≥1 in UC. Non-IBD controls were 
matched in age and had a normal colonoscopy. In all patients, five biopsies 
were procured. In CD patients, biopsies were taken from the edge of the 
most prominent ulcer. In UC, biopsies were taken from inflamed mucosa 
between 20-25 cm from the anal verge or the nearest inflamed region. In 
non-IBD controls, biopsies were taken between 20-25 cm from the anal 
verge. A predefined set of 92 inflammatory proteins was measured in both 
intestinal biopsies and serum using a proximity extension assay (OLINK, 
Uppsala, Sweden). Adjustments for multiplicity were performed using the 
Benjamini-Hochberg approach. Statistical significance was set at an ad-
justed P value < 0.05.
results: In total, 41 patients with CD, 39 with UC and 10 controls were 
included. Forty-three (47.8%) patients were male and the mean (SD) age 
was 39.6 years (13.3). Median [IQR] CRP and faecal calprotectin values in 
IBD patients were 8.1 [4.2 - 22.3] (mg/L) and 452.5 [303.4 - 736.5] (µg/g), 
respectively. Median SES-CD score [IQR] was 8 [5 - 13] in CD. In the UC 
group, 20 (51.3%), 16 (41%) and 3 (7.7%) patients had an endoscopic Mayo 
score of 3, 2 and 1, respectively. A significant positive correlation was ob-
served between tissue and serum in IBD patients for IL17A (r = 0.44), TGF-
alpha (r = 0.42) and IL6 (r = 0.39). In serum, 29 proteins could discriminate 
IBD from controls (adjusted P < 0.05) of which IL17A was most discrimina-
tive. No differences in protein abundance were observed between UC and 
CD in serum. In tissue, none of the proteins differed between IBD and 
controls after adjustment for multiple testing. 
When comparing intestinal tissue between UC and CD, significantly higher 
concentrations of five distinct proteins were observed in UC (IL-17A, IL13, 
CCL4, LIF and CCL3) while the CCL25 level was higher in CD than in UC 
(adjusted P < 0.05).
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conclusion: Of 92 inflammatory proteins, only IL17A, TGF-alpha and IL6 
showed moderate positive correlation between tissue and serum. Twenty-
nine serum proteins could discriminate between IBD and non-IBD. Six tis-
sue proteins differentiated CD from UC. The most consistently implicated 
protein was IL17A. Overall, a poor correlation between tissue and serum 
proteomic profiles in IBD was found. Ongoing research will focus at the 
intestinal tissue transcriptome compared to circulating proteins.
disclosure: TS, MK and MD: no conflicts of interest. GN: has served as 
speaker and/or advisor for Takeda, Abbvie, MSD, Janssen, Octal pharma, 
Amgen, Pfizer, Ferring, Falk Pharma. KG: served as speaker and/or advi-
sor for Amgen, AbbVie, Biogen, Boehringer Ingelheim, Ferring, Hospira, 
Immunic AG, Janssen, MSD, Pfizer, Samsung Bioepis, Sandoz, Takeda, Ti-
genix and Tillotts. ML: Speaker and/or principal investigator for Abbvie, 
Celgene, Covidien, Dr. Falk, Ferring Pharmaceuticals, Gilead, GlaxoSmith-
Kline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer, Protagonist therapeu-
tics, Receptos, Takeda, Tillotts, Tramedico. Research grants from AbbVie, 
Merck Sharp & Dohme, Achmea healthcare and ZonMW. MEW: Speaker 
fees from Takeda, Tillotts, research grants from Glaxo Smith Kline. DD: re-
ports speaker and consultant fees from MSD, Abbvie, Takeda, Pfizer, Jans-
sen, Krka, Dr. Falk Pharma, Ferring. GRD: has served as advisor for Abbvie, 
Ablynx, Allergan, Amakem, Amgen, AM Pharma, Avaxia, Biogen, Bristol 
Meiers Squibb, Boerhinger Ingelheim, Celgene/Receptos, Celltrion, Cos-
mo, Covidien/Medtronics, Ferring, DrFALK Pharma, Eli Lilly, Engene, Gala-
pagos, Genentech/Roche, Gilead, Glaxo Smith Kline, Immunic, Johnson 
and Johnson, Lycera, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, 
Merck Sharp Dome, Mundipharma, Nextbiotics, Novonordisk, Otsuka, Pfiz-
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Trials, Salix, Samsung Bioepis, Sandoz, Setpoint, Shire, Teva, Tigenix, Til-
lotts, Topivert, Versant and Vifor. Received speaker fees from Abbvie, Bio-
gen, Ferring, Johnson and Johnson, Merck Sharp Dome, Mundipharma, 
Norgine, Pfizer, Samsung Bioepis, Shire, Millenium/Takeda, Tillotts and 
Vifor. Received research grants from Abbvie, Johnson and Johnson, MSD, 
Medtronics, DrFALK Pharma, Glaxo Smith Kline, Takeda, Samsung, Pfizer, 
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PrOsPecTIve MOnOcenTrIc sTudy
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Introduction: The possible role of histological activity in clinical manage-
ment of Ulcerative Colitis (UC) is undefined.
aims & Methods: In a prospective study, we aimed to assess the role of 
histological activity as a predictive marker of clinical relapse in a cohort of 
UC patients (pts) undergoing colonoscopy and followed up for 1 year (yr). 
Secondary aim was to assess in the same cohort of UC pts, the correlation 
between clinical, endoscopic and histological scores of activity.From Feb. 
2016 to Feb. 2017, consecutive UC pts with clinical indication for colonos-
copy were prospectively enrolled. Inclusion criteria: 
1) Diagnosis of UC; 
2) Age>18 and ≤80yrs; 
3) Regular follow up; 
4) Indication for colonoscopy; 
5) Compliance to clinical follow up at 1 yr. 
During colonoscopy ≥2 biopsies were taken from≥1 macroscopically in-
volved area and possibly, from ≥1 uninvolved area. All colonoscopies were 
performed by the same IBD-dedicated gastroenterologist. The day of 
colonoscopy clinical activity was assessed by the Mayo partial score (ac-
tivity≥3)(1), endoscopic activity by the Mayo endoscopic score (activity≥2)
(1). Histological activity was assessed by the same IBD-dedicated patholo-
gist using the Geboes Simplified Score (GSS) for UC (activity≥3.1)(2). Scores 
were blindly assessed by the 3 investigators. Data were expressed as mean 
[range].Spearman’s correlation coefficients were used to investigate the 
association between different scores of activity. Cox proportional hazards 
regression model was used for both univariate and multivariate analyses to 
identify the predictors of clinical relapse at 1 year (Odds Ratio, OR [95% CI]).
results: The study cohort included 77 UC pts with clinical, endoscopic and 
histological assessment at baseline, clinically followed up for 1 year. Clini-
cal characteristics of the 77 UC pts: 43 M (55.8%); age 51 [24-80] yrs; UC 
duration 14.7 [1-48 yrs]. UC extent included (%): pancolitis in 33 (42.8%), 
left sided in 24 (31.2%), proctitis in 20 (26%) pts. The day of colonoscopy 
UC was clinically active in 15 (19.4%), inactive in 62 (80.6%) pts. Endoscop-
ic activity was observed in 39 (50.6%) pts and histological activity (GSS≥ 
3.1) in 37 (48%) pts; 5 of these 37 pts were in endoscopic remission. Mod-
erate correlations were observed between clinical and endoscopic scores 
(r=0.439; p< 0.0001), clinical and histological scores (r=0.32; p=0.0045), 
endoscopic and histological scores (r=0.653; p< 0.0001). During the clini-
cal follow at 1 yr, clinical relapse of UC occurred in 24 (31%) pts while 53 
(69%) pts maintained clinical remission. At baseline 11 out of 24 (46%) 
UC pts were clinically active, 15 out of 24 (63%) pts showed endoscopic 
activity, and 16 out of 24 (67%) pts histological activity. Among the 5 pts 
showing endoscopic remission and histological activity at baseline, 1 pt 
developed clinical relapse within 1 yr. Univariate analysis identified clinical 
activity (OR 4.82 [2.15-10.82]; p< 0.001) and histological activity (OR 2.599 
[1.11-6.08]; p< 0.027) as predictive factors for clinical relapse at 1 yr. The 
multivariate model retained only histological activity as predictive marker 
of clinical relapse (OR 2.44 [1.04-5.75]; p< 0.041). We estimated that, after 
controlling for age and gender, pts with histological activity (GSS≥3.1) have 
2.44 fold risk of clinical relapse at 1 yr compared to pts with histological 
remission (GSS< 3.1).
conclusion: Histological activity provided independent information for 
clinical relapse in a cohort of UC patients prospectively followed up for 1 
year. Histological activity had a moderate correlation with the endoscopic 
and clinical activities.
references: 1.Schroeder KW. NEJM 1987;317:1625 2.Jauregui-Amezaga A. 
JCC 2017;11:305
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P1066 duraBILITy Of The anTI-hBs TITers afTer 
vaccInaTIOn agaInsT hePaTITIs B vIrus (hBv) In PaTIenTs 
WITh InfLaMMaTOry BOWeL dIsease (IBd)
Chaparro M.1, Gordillo J.2, Domènech E.3, Esteve M.4, 
Barreiro-de Acosta M.5, Villoria A.6, Iglesias-Flores E.7, Blasi M.2, 
Naves J.E.3, Benítez O.4, Nieto L.5, Calvet X.6, García-Sánchez V.7, 
Villagrasa J.R.8, Marín A.C.1, Donday M.G.1, Gisbert J.P.1
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Santiago de Compostela, Spain, 6Hospital de Sabadell and CIBERehd, 
Gastroenterology Unit, Sabadell, Spain, 7Hospital Universitario Reina Sofía 
and IMIBIC, Gastroenterology Unit, Córdoba, Spain, 8Hospital Universitario 
de La Princesa and Instituto de Investigación Sanitaria Princesa (IIS-IP), 
Preventive Medicine, Madrid, Spain
contact e-Mail address: mariachs2005@gmail.com
Introduction: Among immunocompromised patients who respond to the 
HBV vaccine, clinically significant HBV infection has been documented in 
those who do not maintain anti-HBs concentrations > 10 IU/l.
aims & Methods: 
1) To understand the kinetics of the anti-HBs titers over time in IBD patients 
who have initially responded to the vaccination. 
2) To identify predictive factors of negativization of anti-HBs titers over 
time.
This multicenter study included IBD patients vaccinated in the COMVI-B 
trial (EUDRA-CT number: 2010-023947-14), where patients with negative 
HBV serology and without previous vaccination against HBV were random-
ized 1:1 to receive Fendrix® or double doses of Engerix® at months 0, 1, 2 
and 6. Patients with anti-HBs > 10 IU/L 2 months after the 4th dose were 
followed-up. Anti-HBs titers were then measured at 6 and 12 months. 
When anti-HBs titers were < 10 IU/L during the follow-up, they were con-
sidered negatives. Long-term maintenance of positive anti-HBs titers was 
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estimated using Kaplan-Meier curves. Cox-regression analysis was per-
formed to identify potential predictive factors for losing anti-HBs protective 
titers during follow-up.
results: A total of 131 patients had anti-HBs ≥10 UI/L after completing vac-
cination; from them, 117 patients (90%) accepted to be included in the 
follow-up study. From those, 55% were male, 54% had ulcerative colitis 
and 90% had anti-HBs ≥100 IU/L after vaccination. With respect to IBD 
treatments, 2.6% received solely steroids during follow-up, 29% immu-
nomodulators in monotherapy, 15.4 anti-TNF in monotherapy and 19% 
combo therapy (immunomodulators plus anti-TNF agents). Fifty percent of 
patients received each of the vaccines (Engerix® or Fendrix®). There were 
no differences in the main characteristics (age, anti-HBs concentration 
after complete vaccination or IBD treatment) between the study groups 
(Engerix® or Fendrix®) but the proportion of patients exposed to anti-TNF 
was superior among patients vaccinated with Fendrix® (43 vs. 25%, p< 
0.04). The cumulative incidence of negativization of the anti-HBs titers 
was 13% after 6 months and 20% after 12 months of follow-up. In the 
multivariate analysis, to have had anti-HBs ≥100 IU/L (vs. < 100 UI/L) af-
ter the vaccination was the only factor that was associated with a higher 
probability of maintaining anti-HBs titers during the follow-up (HR=9.8, 
95%CI=4-23, p< 0.0001). The type of vaccine administered, patient’s age or 
immunosuppressive treatment during follow-up were not associated with 
the risk of negativization of anti-HBs titers.
conclusion: A high proportion of IBD patients with protective anti-HBs ti-
ters after vaccination loose them over time (20% of patients after 1 year). 
The risk of loosing protective anti-HBs titers is dramatically increased in 
patients achieving anti-HBs below 100 IU/L after the vaccination. Thus, 
anti-HBs >100 IU/L should be the threshold to consider HBV vaccination 
success in IBD patients. Once the patient has responded to the vaccine, 
patient’s age or immunosuppressive treatment during follow-up seems to 
have no impact on the maintenance of anti-HBs titers.
disclosure: M. Chaparro has served as a speaker, or has received research 
or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, 
Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma. JP Gis-
bert has served as a speaker, a consultant and advisory member for or has 
received research funding from MSD, Abbvie, Hospira, Pfizer, Kern Pharma, 
Biogen, Takeda, Janssen, Roche, Celgene, Ferring, Faes Farma, Shire Phar-
maceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, Casen Fleet, Gebro 
Pharma, Otsuka Pharmaceutical, Vifor Pharma 
P1067 PaTIenT-rePOrTed OuTcOMes Measured WITh IBd dIsk 
In InfLaMMaTOry BOWeL dIsease
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1University of Pecs Medical School, First Department of Internal Medicine, 
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Introduction: Inflammatory bowel disease (IBD) is a chronic destructive 
disorder deteriorating the functional status of the affected patients.
aims & Methods: The aim of our study was to test a new tool for measur-
ing patient-reported outcomes, the IBD Disk invented to assess disability in 
patients with IBD under biological treatment. Patients attending the out-
patient clinic were administered the self-completion 10-item visual scale 
of IBD Disk. Features of interest included abdominal pain, body image, 
education and work, emotions, energy, interpersonal interactions, joint 
pain, regulating defecation, sexual functions, and sleeping. Disease activ-
ity scores (CDAI or Mayo) were assessed by the treating physician.
results: In total, 90 patients with IBD were evaluated (75 and 15 cases of 
Crohn’s disease [CD] and ulcerative colitis [UC], respectively). The IBD Disk 
total score in CD was higher for active disease (score of 49.5 ± 27.7 com-
pared to 25.5 ± 19.5 for inactive disease, p = 0.013) and for female gender 
(32.6 ± 23.8 vs 24.0 ± 19.9 for men; p = 0.08). There was a significant, 
positive correlation of moderate strength between IBD Disk total score and 
disease activity (rho = 0.521; p = 0.023), while the score showed no as-
sociation with age, disease duration, concomitant disease and previous 
surgeries. Interestingly, patients with inactive disease (n = 54) had severe 
(>50) or marked (31-50) disability (13% and 9.3%, respectively). The high-
est scores were achieved in the subgroups evaluating energy, body image, 
and emotions (4.5±2.8, 3.6±3.1 and 3.3±3.0, respectively).
conclusion: IBD Disk was easy to administer in everyday practice while the 
application of the score allowed the rapid and representative assessment 
of patients’ health-related quality of life.
disclosure: Nothing to disclose 
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Introduction: Even though it is known that fecal calprotectin levels cor-
relate with inflammatory activity in inflammatory bowel disease (IBD) pa-
tients, some limitations were described, including fecal collection, sample 
delivery and processing (Meuwis 2013), high within-day variability (Lassan 
2014) and the subsequent uncertainties on the optimal time for sampling 
(Calafat 2015). Recently, some authors proposed that serum calprotectin 
may be useful in disease activity evaluation in rheumatologic patients 
(Hammer 2010). Accordingly, we measured serum calprotectin levels in 
IBD patients in comparison with both patients with irritable bowel syn-
drome (IBS) and healthy volunteers, in order to test whether this blood 
biomarker could separate organic from functional disorders.
aims & Methods: We enrolled 21 Crohn’s disease (CD), 14 ulcerative colitis 
(UC) and 22 IBS patients as well as 20 healthy volunteers, comparable for 
age and gender (30 Females, age 35±6 yrs). We selected 18 patients in 
remission (10 CD and 8 UC), 7 mildly active (4 CD and 3 UC), 9 moderately 
active (7 CD and 2 UC) and 1 severely active (UC), according to Harvey-
Bradshaw index for CD and partial Mayo score for RCU. Serum calprotectin 
was determined for each patient, after an overnight fast (Calprest, Euros-
pital, Italy). Fecal calprotectin was also measured, by means of ELISA test.
results: As expected, after a logarithmic transformation, in IBD patients 
serum calprotectin levels were significantly higher than in IBS patients 
(1,37 mg/ml; 95% confidence interval (IC) 0,86-2,1 mg/ml in IBS vs 4,54 
mg/ml 95%IC 2,09-7,1 mg/ml in IBD; p< 0,001) and healthy volunteers (1,15 
mg/ml; 95% IC 0,87-1,5 mg/ml in healthy volunteers vs 4,54 mg/ml 95%IC 
2,09-7,1 mg/ml in IBD; p< 0,001). Building a ROC curve, we could identify 
2,42 mg/ml as the threshold level to distinguish IBS from IBD (area un-
der the ROC curve 0,8; P< 0,001) with 67% sensitivity and 88% specificity. 
There was no correlation between fecal and serum calprotectin nor in the 
whole sample, nor in the different groups. We found no significant differ-
ence between serum calprotectin level among UC and CD patients.
conclusion: The results of our study suggest that serum calprotectin could 
be a promising biomarker providing an accurate separation between IBD 
patients and IBS or healthy patients. The lack of correlation between fecal 
and serum calprotectin levels suggests that in the future this new bio-
marker could improve the accuracy of IBD diagnosis: in patients with ab-
dominal symptoms of unknown origin, the combination of fecal and serum 
calprotectin could be helpful in identify those patients who need invasive 
procedures. 
Moreover, in IBD serum calprotectin seems not to be influenced by the 
site of the disease involvement, suggesting its potential role in monitoring 
IBD patients.
disclosure: Nothing to disclose 
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P1069 faecaL caLPrOTecTIn LeveLs In LyMPhOcyTIc and 
cOLLagenOus cOLITIs
Cooney J., Naughton T., Hanna M.
University Hospital Lewisham, Gastroenterology, London, United Kingdom
contact e-Mail address: josephcooney@doctors.org.uk
Introduction: Microscopic colitis (MC) is comprised of lymphocytic (LC) 
and collagenous (CC) subtypes, and its diagnosis is dependent on clinical 
symptoms of chronic watery diarrhea in addition to well-defined histo-
logical criteria [1]. Faecal calprotectin (FC) is known to be a useful non-
invasive biomarker in the investigation of inflammatory bowel disease [2] 
but there are few published data describing FC in MC. 
Previous small studies have shown that FC is elevated in 73% MC [1] and 
that in active CC the median FC is 48-80 µg/g [3, 2], but to the best of our 
knowledge no previous studies have assessed FC in LC and CC compara-
tively.
aims & Methods: The two main objectives of our study were to establish 
whether faecal calprotectin levels are elevated in microscopic colitis and if 
there is a difference between faecal calprotectin levels in microscopic and 
lymphocytic colitis. 
Electronic patient records were reviewed from our hospital to obtain FC 
levels measured at the time of diagnosis, for all patients with a histologi-
cal diagnosis of MC between 01/01/2014 and 06/10/2017. Median and range 
FC levels were calculated for CC and LC as well as MC overall. The Mann-
Whitney U-test was used to ascertain whether there was a difference be-
tween FC level in CC and LC, with a p< 0.05 considered to be statistically 
significant. FC level of > 16 µg/g was considered to be elevated.
results: 70 patients had a histological diagnosis of MC between 01/01/2014 
and 06/10/2017; 25/70 (36%) had FC checked at diagnosis. The average age 
was 60 years for LC (range 29-88 years, 4 male: 11 female), and 75 years for 
CC (range 50-89 years, 1 male : 9 female). 20 of these 25 patients with MC 
(80%) had an elevated FC, while 5 (20%) patients had a faecal calprotectin 
level of < 16. Table 1 shows median and range FC in LC and CC indepen-
dently, and also in LC and CC combined (microscopic colitis overall). 
  Lc cc Microscopic colitis overall (Lc and cc combined)
number of patients 40 30 70
number of patients 
with fc tested 15 10 25
Median fc (µg/g) 63 324 148
range fc (µg/g) <16 to 476 86 to >1800 <16 to >1800
[Table 1]
The Median FC in Microscopic colitis overall was elevated at 148 µg/g. 
The Median FC was 324 µg/g for CC and 63 µg/g for LC, which showed 
statistical significance using Mann-Whitney U-test (p= 0.01078)
conclusion: This has been the first study to compare faecal calprotectin 
values in Collagenous and Lymphocytic colitis. This showed a statistically 
significant difference towards higher levels of FC in collagenous colitis. 
The main reasons for the higher calprotectin level in CC are unclear, but 
as faecal calprotectin is a predominantly a marker of neutrophils [4] and 
as damage to the surface epithelium has been shown to be more common 
and pronounced in collagenous colitis compared to lymphocytes [5], this 
could be a possible explanation. 
In addition, FC was elevated in 80% of patients with MC suggesting a 
correlation between calprotectin levels and microscopic colitis. However, 
it is noteworthy that the 20% of patients in our cohort had undetectable 
calprotectin indicating that faecal calprotectin alone is insufficient to 
exclude microscopic colitis and should be used in conjunction with lower 
GI endoscopy and colonic biopsies, in particular in cases with a high index 
of clinical suspicion of microscopic colitis.
references: [1] Stoicescu A, Becheanu G, et al, Microscopic Colitis - A Missed 
Diagnosis in Diarrhea-Predominant Irritable Bowel Syndrome, Maedica 
Buchar,2012;Jan;7(1):3-9 [2]Von Arnim U, Wex T, et al, Fecal calprotectin: 
a marker for clinical differentiation of microscopic colitis and irritable 
bowel syndrome, Clin Exp Gastroenterol;2016;9:97-103 [3] Wildt S, Nor-
dgaard-Lassen, et al, Metabolic and inflammatory faecal markers in col-
lagenous colitis, European Journal of Gastroenterology & Hepatology;July 
2007;19;7;567-574 [4]Alibrahim B, Aljasser M, et al, Fecal Calprotectin Use 
in Inflammatory Bowel Disease and Beyond: A Mini-Review, Canadian 
Journal of Gastroenterology and Hepatology;2015;29;3;157-163 [5] Miehlke 
S, Verhaegh B, et al, Microscopic colitis:pathophysiology and clincal man-
agement, Lancet Gastroenterol Hepatol;2019;4305-14
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Introduction: The UK Bowel Cancer Screening Programme (BCSP) was 
launched in 2006 to cover the population of England and Wales. It screens 
individuals aged 60-69 years with a Faecal Occult Blood test (FOBt) fol-
lowed by a screening colonoscopy if FOBt positive. We report 7-year follow 
up of our cohort of patients with an incidental (“asymptomatic”) diagnosis 
of IBD first reported in 2011.
aims & Methods: We report 7-year follow up of our cohort of patients with 
an incidental (“asymptomatic”) diagnosis of IBD first reported in 2011. A 
retrospective review of BCSP outcomes was conducted at our centre from 
its launch in 2008 until 2011. Screening data included the number of pa-
tients invited, number screened (FOBt outcome “normal” or “abnormal”) 
and number of colonoscopies performed. Of 136,811 patients invited, 67,485 
were screened (uptake of 49. 33% ; FOBt positivity 2. 02%). Colonoscopy 
was performed in 1401 patients (female 523), polyps detected in 630 (41. 
37%), cancer in 134 (8. 80%) and 469 (30. 79%) had a normal exam. Of 
16 patients diagnosed with IBD and confirmed at histology, clinical data 
including demographics, disease characteristics, treatment and outcomes 
were recorded and follow-up data is presented until 31 May 2018.
results: Of 16 patients, 2 died from metastatic prostate cancer and post-
operative complications following colectomy. One patient was lost to fol-
low up. 
11/13 patients had UC (E1=3, E2=5, E3=3) and 3 patients had Crohn’s 
disease(A3L2B1). 
At last follow up, 2 patients with E1 UC progressed to E2 and E3 disease 
respectively. CD phenotype did not change. 
9 of 11 patients with UC were in clinical remission and 2 patients had ac-
tive disease (pMayo 3 and 4 respectively) and received anti-TNF therapy. 
All 3 patients with CD remained in clinical remission. Of 11 UC patients, 
8 continued 5 ASA therapy , 1 received Vedolizumab (following antibody 
mediated loss of response to anti-TNF), 1 patient received anti-TNF with 
Methotrexate and another is on no treatment and in clinical remission. In 
the CD cohort (n=3), 2 patients were on Adalimumab monotherapy, and 1 
on 6-Mercaptopurine.
conclusion: An incidental diagnosis of IBD is not an uncommon. With the 
advent of endoscopic bowel cancer screening this number is set to in-
crease. Incidental IBD appears to follow an indolent course over age 60 
with a stable disease phenotype This subset of patients may present an 
important model for study of early disease providing novel insights into 
disease pathogenesis and evolving treatment paradigms.
disclosure: Nothing to disclose 
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P1071 a reTrOsPecTIve reaL WOrLd anaLysIs Of 
6-ThIOguanIne nucLeOTIde (6-Tgn) MOnITOrIng fOr 
azaThIOPrIne dOsIng In InfLaMMaTOry BOWeL dIsease
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Introduction: Thiopurines (TPs) are frequently used as monotherapy to 
maintain remission in patients with inflammatory bowel disease (IBD). 
The red-cell 6-Thioguanine Nucleotide (6-TGN) biomarker is commonly 
measured to guide dosing. While there is scanty prospective data to sup-
port 6-TGN-directed therapy, efficacy is inferred from observed rates of 
remission in patients with higher levels, but the link between TP dose and 
TGN level is not clear [1,2].
aims & Methods: The aim of our study was to determine the value of 
6-TGN measurements in predicting treatment escalation in patients with 
IBD on azathioprine monotherapy at 12 months post treatment initiation, 
in whom the dose was not modified during the aforementioned period.
We carried out a retrospective review of all IBD patients initiated on aza-
thioprine monotherapy between December 2010 and July 2018, at a single 
specialist centre in the UK. Electronic patient records were used to collect: 
sampling date, Sex, Age, 6-TGN result (between 2-6 months post treat-
ment initiation), MMP, MMP:TGN Ratio, Azathioprine dose (Mg), Weight 
(Kg), Azathioprine dose per kilo (Mg/Kg), disease, previous medications, 
adverse events, and treatment escalation. Treatment escalation was de-
fined as the addition of a steroid, 5-ASA, biologic, or surgery within 12 
months of azathioprine treatment initiation.
A series of hierarchical regression experiments was carried out based on 
a probabilistic prediction framework, described in detail elsewhere [3,4]. 
In effect, variables were added in sequence to determine whether they 
improve the out-of-sample probabilistic prediction error (i.e. brier score) 
of a linear regression model with a logit-link function. 95% confidence 
intervals for each of the aforementioned performance metrics were calcu-
lated using a Jackknife estimator of variance algorithm. Statistical signifi-
cance assessed using the Wilcoxon signed-rank test, with the significance 
threshold set at 5%. All predictive modelling was performed using the R (v 
3·2·0) statistical software suite and the mlr (v 2·7) machine learning library.
results: 298 individuals were identified that met the inclusion criteria 
(139F; mean age 36.1±14.0y; 152 UC; 146 CD). Median azathioprine dose 
was 125mg (Range: 25 - 250), and median weight-adjusted dose was 
1.83 mg/kg (Range: 0.3 - 3.2). Median TGN response was 313.5 (Range: 
5 - 1,705). Using demographic data (i.e. sex, age, weight, diagnosis, and 
previous medications) as a baseline model, the resulting Brier score was 
0.183 (S.E. 0.039).
conclusion: This study is one of the largest retrospective studies [1] exam-
ining the efficacy of TGN monitoring in azathioprine monotherapy. The 
results suggest that metabolite data, including both TGN and MMP, does 
not appear to contain any additional information about the probability of 
requiring treatment escalation at 12 months above that of demographic 
information. Given the contradictory evidence in the literature, definitively 
recommending a 6-TGN-based dose-optimisation strategy would require 
prospective study.
references: [1] Moreau, AC, et al. Inflammatory bowel diseases 2014, 20(3), 
464-471. [2] Chapdelaine Aet al. Clinical rheumatology, 36(6), 1341-1348. 
[3] Mateen BA, et al. Clinical rehabilitation. 2018 Oct;32(10):1396-405. [4] 
Gressmann F, et al. Probabilistic supervised learning. arXiv preprint arX-
iv:1801.00753. 2018 Jan 2.
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Introduction: Iron deficiency and iron deficiency anemia are the most com-
mon extra-intestinal manifestations of chronic inflammatory bowel dis-
ease (IBD), significantly impairing patient’s quality of life. Since the diag-
nostic value of ferritin as an acute phase protein (aPP) in IBD is therefore 
limited1, the simultaneous determination of the C-reactive protein (CRP) is 
recommended for interpretation in the context of inflammation2. Since the 
CRP and ferritin have distinctly different half-lives, the WHO recommends 
α
1
-acid glycoprotein (AGP) as a second biomarker3.
aims & Methods: The aim of our study was therefore for the first time to 
interpret the inflammatory increase of ferritin in IBD patients by CRP and 
AGP, individually and in combination.
By 03/2019, 118 IBD patients (45.48 ± 15.25 years, 47.46% f.) (38 with 
Crohn’s disease, 47 with ulcerative colitis, 33 controls) were enrolled. In 
addition to the Hb value, ferritin (cut-off 30 µg/mL), CRP (cut-off 5 mg/L) 
and AGP (cut-off> 0.65 g/L) were determined in all patients.
results: When CRP alone was used, 29.76% (25/84) had an inflammatory 
increase in ferritin, and 82.14% (69/84; p < 0.05) when using AGP or both. 
Increased AGP levels were more common in patients with ulcerative colitis 
(60 vs. 11.11%) than in patients with Crohn’s disease (57.63 vs. 32.20%) 
compared to elevated CRP levels. Serum ferritin levels correlate with CRP 
(0.420 p = 0.002), but not with (0.022, p = 0.876). 
There was no specific correlation between CRP and AGP (0.098, p = 0.487). 
The assumption that most patients with high CRP levels also have high 
AGP concentrations and vice versa was confirmed by our data only in 55% 
of cases.
There were 11 patients with complete iron deficiency when CRP alone was 
used, 18 patients with functional iron deficiency, one with chronic anemia 
(ACI) and one with mixed-type anemia. Functional iron deficiency was 
found in 28 patients using CRP and/or AGP (+ 55%, p < 0.05) and 5 pa-
tients had ACI (according to (4)).
conclusion: Our data underline the problem of determining ferritin also 
with the aid of CRP in the diagnosis of iron deficiency in IBD. We were able 
to demonstrate that the determination of CRP and/or AGP significantly 
improves the diagnostic accuracy of serum ferritin levels in IBD patients.
references: (1) Dignass A et al. Int J Chronic Dis 2018 (2) Dignass A et al. J 
Crohns Colitis 2015 (3) Thurnham D et al. Am J Clin Nutr 2010 (4) Weiss G, 
Goodnough L New Engl J Med 2005
disclosure: Consultancy fees: Immundiagnostik AG 
P1073 redefInIng and vaLIdaTIng endOscOPIc and 
hIsTOLOgIcaL heaLIng By usIng vIrTuaL eLecTrOnIc 
chrOMOendOscOPy In uLceraTIve cOLITIs
Iacucci M.1,2,3, Cannatelli R.2,4, Gui S.X.5, Lethebe B.C.6, Bazarova A.2, 
Gkoutos G.2, Kaplan G.3, Panaccione R.3, Kiesslich R.7, Ghosh S.1,2
1University of Birmingham, NIHR Biomedical Research Centre, Birmingham, 
United Kingdom, 2University of Birmingham, Institute of Translational 
Medicine, Birmingham, United Kingdom, 3University of Calgary, Ibd Clinic, 
Division of Gastroenterology, Calgary, United Kingdom, 4University of 
Milan, Gastroenterology, Milan, Italy, 5University of Calgary, Department of 
Pathology, Calgary, Canada, 6University of Calgary, Research Unit, Calgary, 
Canada, 7HSK Hospital, Division of Gastroenterology, Wiesbaden, Germany
contact e-Mail address: m.iacucci@bham.ac.uk
Introduction: Ulcerative colitis patients with endoscopic mucosal healing 
by white light endoscopy may still have histologic inflammation. Electronic 
chromoendoscopy (PICaSSO-Paddington International Virtual Chromoen-
doScopy ScOre)1 may better predict mucosal healing. We investigated the 
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relationship between mucosal healing (MH) defined by PICaSSO, and his-
tological index (RHI). We specifically explored the magnitude of difference 
between endoscopy and histology defined mucosal healing using refined 
endoscopic assessments.
aims & Methods: A prospective study enrolling 82 UC patients (M 66%) 
was conducted. Mayo subscore (MES), PICaSSO mucosal and vascular en-
doscopic score were recorded. High definition electronic virtual chromo-
endoscopy was used in all patients. Histological score (Robarts histopa-
thology index-RHI) was used to score histological inflammation. Receiver 
operating characteristic (ROC) curves were plotted to determine the best 
cut-off threshold for PICaSSO scores that predicted histological healing ac-
cording to the RHI. We then validated the PICaSSO score against histology 
(RHI) in an independent cohort of 70 UC patients (M 52%); and sensitivity, 
specificity, and accuracy were calculated.
results: A PICaSSO of ≤4 predicted histological healing at RHI ≤6, with 
accuracy of 92.8% (95% CI: 84.8, 97.3). The accuracy of MES in predicting 
histological healing with RHI was inferior at 84.2% (95% CI: 74.4, 91.2). 
The corresponding AUROCs were 98.9% (95% CI: 97.6, 100) and 92.0% 
(95% CI: 85.9, 98.6) respectively. 
In the validation cohort, PICaSSO £ 4 predicted histological healing at RHI 
£6 with sensitivity 96.6% (95%CI 82.2-99.9), specificity 68.3% (95%CI 
51.9-81.9) and accuracy 80.0% (95%CI 68.7-88.6). PICaSSO £3 predicted 
histological healing by RHI with sensitivity 96.6% (95%CI 82.2-99.9), spec-
ificity 92.7% (95%CI 80.1-98.5) and accuracy 94.3%.
conclusion: The histological healing by RHI is accurately predicted by PI-
CaSSO at threshold values of ≤3 in a validation cohort of UC patients. Ad-
vanced electronic endoscopic techniques are able to predict histologically 
proven MH with high accuracy. Large prospective studies are necessary 
to ascertain whether, with new endoscopic technologies such as readily 
available VCE, histology can still provide additional information about 
course of UC.
references: 1. Iacucci M, Daperno M, Lazarev M, et al. Development and 
reliability of the new endoscopic virtual chromoendoscopy score: the PI-
CaSSO (Paddington International Virtual ChromoendoScopy ScOre) in ul-
cerative colitis. Gastrointest Endosc 2017;86:1118-1127.e5.
disclosure: Nothing to disclose 
P1074 The reaL WOrLd use Of fecaL caLPrOTecTIn hOMe 
TesTIng In PaTIenTs WITh InfLaMMaTOry BOWeL dIsease 
under MaInTenance TreaTMenT WITh adaLIMuMaB
Orfanoudaki E., Theodoraki E., Foteinogiannopoulou K., Mantaka A., 
Koutroubakis I.
University Hospital of Heraklion, Gastroenterology, Heraklion, Greece
contact e-Mail address: elina_or@yahoo.gr
Introduction: Fecal calprotectin (FC) has been suggested as an important 
biomarker for the management of patients with inflammatory bowel dis-
ease (IBD). It is an indirect index of disease activity and plays a crucial role 
in the treat-to-target strategy. Consecutive measurements of FC in patients 
in clinical remission can predict a disease relapse and lead to an early 
treatment optimization. We aimed to present our real world experience 
using the FC home testing in the management of IBD patients under main-
tenance treatment with adalimumab.
aims & Methods: Consecutive IBD patients under maintenance treatment 
with adalimumab were studied retrospectively based on prospectively re-
corded data in a registry. The study period was from 10/2016 until 3/2019. 
Inclusion criteria was at least one available FC measurement (ELISA, Büh-
lmann fCAL Home test). During this period patients’ compliance in the 
FC home test as well as all the treatment modifications including adali-
mumab intensification, change of biologic agent or IBD related surgical 
intervention were assessed.
results: From a total of 72 IBD patients under maintenance treatment with 
adalimumab, 63 (87.5%) who had good compliance performing the home 
FC test [median number of measurements 3 (1-10)] and complete follow-
up data were included in the study. Patient characteristics are presented 
in Table 1. In 21 of them (33.3%) treatment modification (10 adalimumab 
intensification, 1 de-escalation , 8 change to other biologic agent, 2 sur-
geries) has become necessary during the study period based on the evalu-
ation of consecutive values of FC (mean FC value 718 µg/g ±314, 45% of pts 
had values>1000 µg/g), mostly after endoscopic confirmation of disease 
flare (18/21). The rest 42 patients who remained on stable treatment had 
mean FC levels 272 µg/g ±236, (57.1% of them had values< 250 µg/g) sig-
nificantly lower than the first group p< 0.0001. Twenty three out of these 
42 patients underwent a colonoscopy and mucosal healing was confirmed 
in 7/23 (30.4%) while FC was< 50 µg/g in 9/23 (39.1%).
conclusion: The IBD patients’ compliance rate of performing the FC home 
test is high (87.5%). Moreover, our results confirm the important role of 
consecutive FC measurements at home, in combination with the endo-
scopic evaluation for the optimization of treatment in IBD patients receiv-
ing maintenance treatment with adalimumab. 
disclosure: Nothing to disclose 
Mean age (years ± SD) 42.3± 14.9
Men (%) 37 (59%)
Disease duration (years, mean ± SD) 13.4 ± 9.5
Diagnosis  
Crohn’s disease (%) 56 (89%)
Ulcerative colitis (%) 7 (11%)
Current smokers 21 (33%)
Disease location  
Ileum (L1) 24
Colon (L3) 7
Ileum+colon (L3) 25
Perianal disease (p) 14
Proctitis (E1) 0
Left sided colitis (E2) 4
Extensive colitis (E3) 3
Extraintestinal manifestations 32 (51%)
Median duration of adalimumab use in months (IQR) 32 (20-62)
Combination treatment with immunomodulators 13 (21%)
Experienced in biologic agents 28 (44%)
IBD related surgery 16 (25%)
[Table1 Demographic and clinical characteristics of the IBD patients (N=63)]
P1075 PredIcTIve endOscOPIc facTOrs Of cLInIcaL 
severITy In uLceraTIve cOLITIs (uc) usIng uLceraTIve cOLITIs 
endOscOPIc Index scOre (uceIs)
Cherkaoui Malki M.1, El Bacha H.2, Benzzoubeir N.3, Chahed Ouazzani L.4, 
Errabih I.5
1University Hospital Ibn Sina, Gastroenteroly B, Rabat, Morocco, 2Hopital Ibn 
Sina / Universite Mohamed V / Faculte de Medecine, Gastroenterologie et 
Hepatologie, Rabat, Morocco, 3Hepato-gastro-Enterology Unit. Medical Clinic 
« B » - Universitary Hospital Ibn Sina of Rabat, Rabat, Morocco, 4The Sina 
University Hospital, Rabat, Morocco, 5Ibn Sina University Hospital, Dept. de 
Médecine B, Rabat, Morocco
contact e-Mail address: cherkaoui.manal23@gmail.com
Introduction: Digestive Endoscopy, besides the diagnosis and surveillance 
of ulcerative colitis (UC), is also interesting to establish the severity of the 
disease by using the UCEIS score which assess vascular pattern, bleeding, 
and ulcers.
aims & Methods: The purpose of our work is to demonstrate the items of 
the score that are most associated to the severity of the flare-ups. This is a 
retrospective study conducted from January2013 to January2018 including 
480 patients with UC. The endoscopic severity was assessed by UCEIS score 
and the clinical activity by the Modified Truelove & Witts score.The statisti-
cal study was performed using SPSS20.0. A logistic regression analysis 
was performed as multivariate analysis. The binary dependent variable 
is the severe flare-up and the independent variables were the 3 items of 
UCEIS score. Statistical significance was established at p values of less than 
0.05
results: The clinical assessment revealed that the flare-ups were mild 
in 22.08%, moderate in 48.05% and severe in 28.57%. The study of the 
3 items of UCEIS score revealed a patchy obliteration vascular pattern in 
66.23%, obliterated in 27.27%, and normal in 6.49%, bleeding was absent 
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in 46.8%, mucosal in 42.9%, luminal mild in 37.7% and luminal severe 
in 1.3%, ulcers were absent in 18.2%, < 5mm in 37.7%, > 5mm in 19.5% 
and deep in 24.7%. Thus, the UCEIS score was as followed 6.5% were in 
remission, 33.8% were in mild, 49.4% were moderate, 3.9% were severe. 
The multivariate logistic regression analysis revealed that vascular pattern 
and the presence of ulcers were significantly associated and predictive of 
severe flare-ups (p=0,038, 0,049 respectively).
conclusion: By studying and analyzing the UCEIS score, vascular pattern 
and the presence of erosions/ulcers are the items associated and predict-
ing the clinical severity of the flare-ups.
disclosure: Nothing to disclose 
P1076 evaLuaTIOn Of PaIred and seParaTed endOscOPIc 
reads aT BaseLIne and Week 14 In The exPLOraTOry BergaMOT 
InducTIOn cOhOrT
Mishkin D.S.1, Schreiber S.2, Daperno M.3, Oh Y.S.4, Hussain F.5, 
Hassanali A.4, Lacey S.6, Li R.7, Reinisch W.2,8
1Atrius Health, Boston, United States, 2Christian-Albrechts-University, Kiel, 
Germany, 3AO OrdineMauriziano di Torino, Turin, Italy, 4Genentech, Inc., 
South San Francisco, United States, 5IQVIA, Immunology and Internal 
Medicine, Medical Strategy & Science, Rockville, United States, 6Roche 
Products Limited, Welwyn Garden City, United Kingdom, 7Roche Products 
Limited, Mississauga, Canada, 8Medical University of Vienna, Vienna, Austria
contact e-Mail address: oh.young@gene.com
Introduction: Treatment guidelines recommend that Crohn’s disease eval-
uation and treatment decisions should include endoscopic evaluation in 
conjunction with clinical and laboratory assessment (1,2). Previous work 
found that an adjudicated central read model (CRM) for evaluating Sim-
ple Endoscopic Score for Crohn’s Disease (SES-CD) that included a local 
reader and at least 1 central reader reduced placebo rates, variability and 
increased treatment response rates versus single reader models (3). This 
study explored the impact on scoring by blinded reading of paired endo-
scopic reads versus unpaired reads scored by the CRM model.
aims & Methods: To compare the total SES-CD as evaluated by paired 
readings of the week 0 and week 14 endoscopies (i.e. simultaneous as-
sessment of pre- and post-induction treatment endoscopic videos) by the 
same central reader versus scores based on unpaired readings by the CRM. 
Patients in this analysis (n = 63) were a random subset from the explor-
atory BERGAMOT induction cohort, who were randomised 2:2:1 to receive 
subcutaneous etrolizumab 105 mg every 4 weeks (with placebo at week 2; 
n = 24); etrolizumab 210 mg at weeks 0, 2, 4, 8, and 12 (n = 24); or placebo 
(n = 15). Three central readers performed the paired endoscopy readings. 
The unpaired reads were evaluated using the CRM and included a pre-
defined sliding threshold to trigger adjudication of discordant scores by 
a second central reader as reported previously. All readers were blinded 
to treatment arm, timing of the endoscopy, and the other reader’s assess-
ments.
results: In the overall population, 48% had ileo-colonic disease, 30% had 
colonic disease and 22% had disease restricted to the ileum. Prior treat-
ment for Crohn’s disease included anti-TNFs (73%), oral corticosteroids 
(49%), or non-biologic immunosuppressants (27%). In general, the mean 
baseline and week 14 SES-CD evaluated by the paired read model were 
higher than those assigned by the CRM. Differences between models in 
assigning categorical thresholds were more varied (Table). The placebo 
rates of ≥50% SES-CD decrease from baseline, SES-CD ≤ 4, and SES-CD 
≤ 2 were similarly low (0%-6.7%) with either the unpaired CRM or the 
paired endoscopy model. More patients achieved ≥50% SES-CD decrease 
from baseline with etrolizumab treatment using the CRM compared to the 
paired read model (21% vs 13%, respectively). 
  Placebo n = 15
etrolizumab 
105 mg
n = 24
etrolizumab 
210 mg
n = 24
etrolizumab 
105 mg and 210 mg
n = 48
  Paired CRM Paired CRM Paired CRM Paired CRM
≥50% 
decrease 
from baseline 
at week 14
0 0 3 (13%) 5 (21%) 3 (13%) 5 (21%) 6 (13%) 10 (21%)
[Table. SES-CD ≥ 50% decrease from baseline at week 14 by paired and 
unpaired (CRM) endoscopic read models.]
conclusion: Based on data generated by experienced central readers in a 
small subset of patients, both paired and unpaired central reading of CD 
endoscopic videos resulted in very low placebo response rates. However, 
unpaired central reading resulted in increased treatment response rates 
compared to a paired read paradigm.
references: 1. Van Assche G, et al. J Crohns Colitis 2010;4(1):7-27. 2. Lichten-
stein GR, et al.Am J Gastroenterol 2018;113(4):481-517. 3. Reinisch W et al. 
Presented at 13th Congress of ECCO; Feb 14-17, 2018; Vienna, Austria. P132.
disclosure: DM is central reviewer and consultant for Quintiles GI Review-
ers, LLC. SS is consultant for Genentech/Roche and Takeda and speaker for 
Takeda. MD has received grants from Abbvie, MSD, Takeda, Janssen, and 
Roche, personal fees from Bioclinica and Pfizer, and nonfinancial support 
from Abbvie, Takeda, Janssen, Pfizer, and Roche. YSO and AH are employ-
ees of and hold stock in Genentech/Roche. FH has nothing to declare. AH is 
employee of Genentech. SL is employee of Roche. WR has received hono-
raria as speaker, consultant, or advisor from Abbott Laboratories, Abbvie, 
Aesca, Amgen, AM Pharma, Aptalis, Astellas, Astra Zeneca, Avaxia, Roland 
Berger GmBH, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-
Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Co-
vance, Danone Austria, Elan, Ernest & Young, Falk Pharma GmbH, Ferring, 
Galapagos, Genentech, Gilead, Grünenthal, ICON, Immundiagnostik, Index 
Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, 
Lipid Therapeutics, LivaNova, Mallinckrodt, MedImmune, Millenium, Mit-
subishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, 
Parexel, PDL, Pharmacosmos, Philip Morris Institute, Pfizer, PLS Education, 
Procter & Gamble, Prometheus, Provention, Robarts Clinical Trial, Sandoz, 
Schering-Plough, Second Genome, Seres Therapeutics, Setpointmedical, 
Shire, Sigmoid, Takeda, Therakos, Tigenix, UCB, Vifor, Yakult, Zealand, 
Zyngenia, and 4SC. 
P1077 sTaTus Of seruM vITaMIn B12 In PaTIenTs WITh crOhn’s 
dIsease
Ben Mohamed A., Mouelhi L., Ayadi S., Zaimi Y., Jery K., Said Y., 
Kheher S., Salem M., Debbeche R.
Faculty of Medecine, Tunis, Tunisia
contact e-Mail address: asmabenmed2014@gmail.com
Introduction: Vitamin B12 is an essential vitamin for hematopoiesis. Its ab-
sorption mainly occurs at the terminal ileum.Crohn’s disease (CD) primar-
ily involves the intestinal tract and can affect vitamin absorption. This study 
was designed to assess the prevalence of vitamin B
12
 deficiency in patients 
with CD, and to identify the risk factors associated with abnormal serum 
vitamin B
12
 levels.
aims & Methods: Aim of the work: Evaluate plasma vitamin B12 level in pa-
tients with Crohn’s and identify risk factors for any vitamin B12 deficiency. 
It was a descriptive and cross-sectional study successively enrolling over 
a period of 3 months (from May 2015 to November 2015) all patients with 
Crohn’s disease. Standard blood tests together with determination of se-
rum vitamin B12 concentration were performed at baseline.
results: In multivariate analysis, a terminal ileum resection segment 
length >50 cm and both penetrating and stricturing behavior were the 
independent predictive factor for vitamin B12 deficiency in these patients.
Eighty-eight patients were included with a median age of 42.45 ± 13.81 
years and a sex ratio of 0.87. Crohn’s disease was located at the ileum 
in 30% of patients, the ileum and right colon in 40% of cases. CD was 
inflammatory in 41% of cases,stenosing in 35% of casees, penetrating in 
6% of cases and both stenosing and penetrating in 18% of cases.Fourty 
nine percent of patients were treated by azathiopurin, 7% by anti TNF α 
and 13% by combotherapy. 
The rate of intestinal resection was 42%. Ileal resection was noted in 37% 
of cases with an average resection length of 35.73 ±20.79 cm [4-115 cm]. 
Nine patients had an extended resection (>50 cm). Vitamin B12 levels were 
normal (≥ 200 ng/L) in 69 patients (78%) and decreased (< 200 ng/l) in 19 
patients (22%). Clinically, no patient with vitamin B12 deficiency showed 
clinical signs of vitamin B12 deficiency.
In univariate analysis, a resection segment length >50 cm (p=0.012 ; 
HR=9.06 ;95% CI [1.62-50.60]) and both penetrating and stricturig be-
havior (p=0.002 , HR= 7.59 ; 95% CI [2.15-26.79]) were significantly as-
sociated with vitamin B12 deficiency. However, vitamin B12 deficiency was 
inversely associated with the inflammatory behavior (p=0.002, HR=0.12, 
95% CI [0.026-0.056] ) and the history of corticosteroid therapy (p=0.004 , 
HR=0.32 ;95% CI [0,10-1,00]).
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conclusion: Vitamin B12 deficiency in Crohn’s disease patients is quite 
common (22%). Only a terminal ileum resection segment length over 50 
cm and both penetrating and stricturing behavior predispose to vitamin 
B12 deficiency. Annual monitoring of serum vitamin B12 or preferably ho-
lotranscobalamin II in these patients will detect deficient patients, which 
should be supplemented with vitamin B12.
disclosure: Nothing to disclose 
P1078 The rOLe Of sMaLL BOWeL caPsuLe endOscOPy In 
dIagnOsIs and MOnITOrIng Of crOhn’s dIseases versus 
radIOLOgIcaL InvesTIgaTIOns: a dIsTrIcT hOsPITaL exPerIence
Mir N.1, Anjum M.R.1, Rafique H.2, Shah A.1, Perry I.3
1The Royal Wolverhampton NHS Trust, Gastroenterology, Wolverhampton, 
United Kingdom, 2The Royal Wolverhampton NHS Trust, Wolverhampton, 
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contact e-Mail address: nmir887@gmail.com
Introduction: A single gold standard for the diagnosis of CD is not avail-
able. In clinical practice, It is diagnosed by clinical evaluation and a com-
bination of endoscopic, histological, radiological and biochemical investi-
gations. Studies have explored the role of small bowel capsule endoscopy 
(SBCE) in diagnosing Crohn’s disease, . We collected the data retrospec-
tively of patients at Royal Wolverhampton NHS Trust to analyze local data 
of Crohn’s patients and the sensitivity of SBCE versus radiology to diagnose 
small bowel Crohn’s.
aims & Methods: We carried this study retrospectively based on data over 3 
years period (2014-2017) of patients enrolled at The Royal Wolverhampton 
NHS Trust. Retrospective data was collected from SBCE data base, which 
included 90 cases. Cases were identified further who had been diagnosed 
with small bowel Crohn’s disease either based on the results, or who had 
capsule for prognostic values/monitoring of established Crohn’s disease. 
Further stratification gave us cohort of 90 patients who had both SBCE and 
some form of radiological investigation done for same symptoms, namely: 
Computed tomography (CT) Scan, CT Enterography (CTE), CT Colonography 
(CTC), Magnetic Resonance Enterography (MRE). Data was tabulated, and 
analysis was done using SPSS v20.
results: Total 59 patients were included in the study. 38 (64.4%) were 
female and 21 (35.6%) were males. Age range was from 18 to 79 years with 
a median age of 45 years. 36 (61%) were diagnosed as new diagnosis of 
Crohn’s disease while 23 (39%) had established diagnosis but underwent 
investigations based of ongoing symptoms. Except for 4 patients, rest had 
colonoscopy as initial investigations. Out of these 4, two were diagnosed 
many years ago and report couldn’t be chased, while other two had new 
diagnosis of Crohn’s, but refused colonoscopy. Frequency of radiologi-
cal investigations done was follows; CT 15 (25.4%), CTC 5 (8.5%), CTE 2 
(3.4%), MRE 37 (62.7%). Decision about different investigations was dic-
tated by urgency of situation. CTC was done as initial test in patients who 
described mainly large bowel symptoms. Out of 59 patients, 17 (28.8%) 
had evidence of small bowel inflammation on both SBCE and radiology. 
In 2 (3.4%), diagnosis of Crohn’s was made on radiology while SBCE was 
non-diagnostic (1 established Crohn’s patient, 1 new diagnosis of Crohn’s). 
In 40 (67.8%) patients, SBCE was diagnostic while radiology was non-di-
agnostic. SBCE had sensitivity of 96.61% while radiology had sensitivity of 
32.20% in our study population.
conclusion: SBCE and radiology are complementary methods for diagnos-
ing small bowel Crohn’s disease. In our study, SBCE has shown better 
sensitivity in diagnosing small bowel Crohn’s disease as compared to ra-
diology.
references: 1. Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lind-
say JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F. 3rd 
European evidence-based consensus on the diagnosis and management of 
Crohn’s disease 2016: part 1: diagnosis and medical management. Journal of 
Crohn’s and Colitis. 2016 Sep 22;11(1):3-25. 2. Albert JG, Martiny F, Krummen-
erl A, Stock K, Lesske J, Göbel CM, Lotterer E, Nietsch HH, Behrmann C, Fleig 
WE. Diagnosis of small bowel Crohn’s disease: a prospective comparison 
of capsule endoscopy with magnetic resonance imaging and fluoroscopic 
enteroclysis. Gut. 2005 Dec 1;54(12):1721-7. 3. Dionisio PM, Gurudu SR, Leigh-
ton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield 
in patients with suspected and established small-bowel Crohn’s disease: a 
meta-analysis. Am J Gastroenterol 2010;105:1240-8; quiz 1249.
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P1079 sPecIaLIsT PharMacIsT Led IMMunOMOduLaTOr 
servIce revIeW - 1 year OuTcOMe In a uk dIsTrIcT hOsPITaL
Richards A., Daughney R., Henshall A., Saeed S., Kong C.
Stockport NHS Foundation Trust, Gastroenterology, Manchester, United 
Kingdom
contact e-Mail address: anneliese.richards@nhs.net
Introduction: Immunomodulators are widely used to achieve and maintain 
remission for Inflammatory bowel disease (IBD) patients 1 however these 
medications require regular close monitoring in order to optimise patient 
care. With a constant stretch on NHS resources it can be challenging to 
have a robust system in place to facilitate this. The introduction of an IBD 
specialist pharmacist clinic has the potential to improve patient outcome 
and disease stability. This study aims to review the impact this clinic has 
had on a district general hospital following its initiation in 2017.
aims & Methods: Data was retrieved from the pharmacy patient record for 
the immunomodulator clinic for 2017, exclusion criteria were those with 
autoimmune hepatitis. General demographics including age and gender, 
number of referrals, cause of referrals, wait time, drug treatment, number 
of phone calls and patient outcomes at one year were all recorded. The 1 
year outcomes were divided into four categories: stable/shared care with 
the general practitioner, escalation of therapy, de-escalation or discon-
tinuation (this category comprised of adverse medications side-effects, 
patient movement out of area and dis-engagement from NHS services).
results: For the year 2017, 68 referrals were made to the immunomodula-
tor clinic. 40 (59%) had Crohns disease, 22 (32%) had Ulcerative Colitis 
(UC) and 6 (9%) had IBD-unspecified. Mean waiting time from point of 
referral was 26.1 days. Patients who needed escalated therapy had as-
sociated longer mean wait time of 30.29 days. Those with stable or de-
escalated disease at one year had a mean wait time of 21.9 days. 
The most common drug was azathioprine 48 patients (70.5%) of which 4 
were also receiving combination therapy with allopurinol; Methotrexate 13 
patients (19.2%) and mercaptopurine 7 (10.3%) of which 1 patient was also 
being treated with allopurinol. 
At one year 30 patients achieved stabilisation of disease (35%), 9 needed 
escalation of treatment (13%), 6 had their treatment de-escalated (9%) 
and the remaining 23 were discontinued from the clinic (35%). Discontinu-
ation was mainly due to side-effects (15/23 patients) or disengagement 
from NHS services (4 patients). All patients on combined therapy with al-
lopurinol (5 patients) had stable disease at one year. The drug treatment 
with the lowest proportion of patients needing escalation of therapy was 
methotrexate with 7.7%, mercaptopurine required 14.2% to be escalated 
and azathioprine required 14.6%
On average 7.1 calls were made to patients in one year, ranging from 0-20 
calls. Those who required escalation of therapy were called on average 3 
times prior to escalation, de-escalated patients were called 5 times a year 
and those who had stable disease at one year needed on average 9.5 calls 
a year to achieve this. The small number of calls for escalation of therapy 
is felt to be due to the rapid escalation of management compared to the 
traditional clinic model.
conclusion: The pharmacy immunomodulator clinic provides a robust and 
essential service to manage IBD patients who may otherwise deteriorate 
as well as providing a database for means of auditing. Being seen sooner 
in the clinic is associated with better outcomes in this study - illustrated 
by a higher rate of de-escalated and stabilised patients, however was not 
statistically significant (p value 0.55). Stability of patients is also associated 
with more phone calls per year to fine tune management, again reflecting 
the impact of a dedicated immunomodulator service on patient outcomes.
Larger studies and multi-centre sites would help in sharing experiences.
references: 1 National Institute for Health and Care Excellence, Crohn’s 
disease: management,CG152 London: National Institute for Health and 
Clinical Excellence;2012
disclosure: Nothing to disclose 
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P1080 BenefITs Of IMPLeMenTIng a raPId access cLInIc 
In a hIgh vOLuMe InfLaMMaTOry BOWeL dIsease cenTer: 
access, resOurce uTILIzaTIOn and OuTcOMes
Nene S.1, Gonczi L.2, Verdon C.1, Reinglas J.1, Kohen R.1, Bessissow T.1, 
Afif W.1, Wild G.1, Seidman E.1, Bitton A.1, Lakatos P.L.1,2
1McGill University Health Center, Division of Gastroenterology, Montreal, 
Canada, 2Semmelweis University, First Department of Internal Medicine, 
Budapest, Hungary
contact e-Mail address: kislakpet99@gmail.com
Introduction: Emergency situations in inflammatory bowel diseases (IBD) 
put significant burden on both the patient and healthcare system. Emer-
gency department (ED) attendance is high among IBD patients.
aims & Methods: We aimed to prospectively measure indicators of Qual-
ity-of-Care after the implementation of a new ‘rapid access clinic’ service 
(RAC) at the McGill University Health Centre (MUHC) tertiary care IBD cen-
ter. Furthermore, to compare the resource utilization, outcomes and costs, 
in patients presenting via the RAC to that of the MUHC Emergency Depart-
ment IBD related visits. The RAC provides patients opportunity to receive 
urgent evaluation by an IBD specialists, thus potentially avoiding the ED 
visit. The RAC service was structured by providing an emergency contactin-
formation to the patients, with a specific document explaining the perti-
nent symptoms that merit utilization of this access avenue. Each email/
telephone contact was reviewed by a specialized IBD nurse or physician. 
Patient access, diagnostic procedures, resource utilization and outcome 
parameters were collected consecutive patients who contacted the RAC 
service between July 2017 and March 2019. For the comparative analysis 
data was retrieved from ED visits by patients not having access to RAC 
services between January 2018 and January 2019.
results: 488 patients (41.3% men, mean age: 39 years, CD: 68.4% / UC: 
31.6%) with valid medical reason for contacting the RAC clinic and 135 pa-
tients (60.7% men, mean age: 45 years, CD: 71.1% / UC: 28.9%) accessing 
the ED were included. 85.8% of the requests were deemed appropriate for 
a rapid appointment at the IBD clinic. The reason for RAC appointment was 
potential disease flare in 71.6% of patients. The median time to RAC visit 
with MD was 2 days (IQR: 0-6 days) following the first contact. Patients had 
a fast-track evaluation with objective laboratory (CRP (90.9%) and fecal 
calprotectin (73%)) and clinical assessment. Endoscopy and imaging was 
only performed in 17.9%, 6.7% (colonoscopy and flexible sigmoidoscopy) 
and 6%, 2.1% (CT and MRI). Clostridium difficile stool test and stool cul-
ture test were performed in 43.1% and 41.9. Medical therapy was changed 
in 54.4% of patients. ED visits within 30 days following RAC occurred in 
8.8% of all patients (unplanned ED visit rate: 5.9%). Diagnostic procedures 
and overall resource utilization at ED visit was substantially different from 
the RAC visits: abdominal CT was performed in 65.7%, multiple specialists 
consults (gastroenterology, surgery, internal medicine). Average medical 
cost estimates per patient was 403.3 CAD vs 1885.5 CAD, with 64.4% of 
patients at ED requiring at least one day hospital admission.
conclusion: Implementation of an IBD RAC improved patient care by fa-
cilitating easier access to IBD specific medical care as well as by avoiding 
unnecessary ED visits. Patients underwent fast-track evaluation with opti-
mized utilization of diagnostic tests and lower costs compared to ED visits.
disclosure: Nothing to disclose 
P1081 are randOM BIOPsIes sTILL requIred durIng IBd 
surveILLance: a sysTeMaTIc revIeW and MeTa-anaLysIs
Lord R.1, Khan A.2, Burr N.3, Subramanian V.3
1Leeds Teaching Hospitals NHS Foundation Trust, Leeds, United Kingdom, 
2Leeds Teaching Hospitals, Leeds, United Kingdom, 3University of Leeds, 
Leeds, United Kingdom
contact e-Mail address: asif.khan12@nhs.net
Introduction: Patients with colonic IBD have an increased risk for devel-
oping colorectal cancer and surveillance is recommended. There is still 
debate on the role of random biopsies. Studies using newer generation 
endoscopes and dye based chromoendoscopy have suggested that most 
dysplasia is endoscopically visible. A recent retrospective study found that 
1 in 8 patients with dysplasia were detected by random biopsies alone(1) 
and a meta-analysis has shown an increased risk for developing advanced 
neoplasia in patients with endoscopically invisible dysplasia (2). Random 
biopsies however are felt to be laborious, time consuming with poor yield 
and targeted biopsies alone has been advocated. The aim for this system-
atic review/meta-analysis was to determine what proportion of patients 
with dysplasia are identified by random biopsy alone and to identify if 
specific advanced endoscopic technologies used or the cohort’s risk has 
an effect on this rate.
aims & Methods: Following PRISMA guidelines, we conducted a literature 
search using the electronic databases MEDLINE/EMBASE. Two indepen-
dent reviewers screened citations and extracted data. Data analysis was 
performed with STATA13. Random-effects model was used to calculate 
pooled proportions with 95%CI. The primary outcome was the overall 
pooled proportion of patients with dysplasia who were identified by ran-
dom biopsy only. A subgroup analysis was performed with studies pooled 
according to the different endoscopic technologies used (standard defi-
nition white-light (SDWL), standard definition chromoendoscopy (SDCE), 
high definition white-light (HDWL), high definition chromoendoscopy 
(HDCE), virtual chromoendoscopy (VCE), autoflourescence and full-spec-
trum endoscopy) and according to the risk of cancer in the populations 
enrolled in the studies (high-risk defined as having either included only 
patients with extensive colitis, or >9% of the cohort having PSC or >20% 
of the cohort previously having colonic dysplasia). Heterogeneity was as-
sessed using I2statstic.
results: 36 studies met our inclusion criteria. 14 RCTs, 14 prospective and 
8 retrospective studies. 13.05% (95%CI 7.28-19.87%) of patients with dys-
plasia were identified by random biopsies alone; I2=81.2% (p< 0.001). 
Subgroup analysis showed HDCE having one of the smallest proportion 
of patients with random biopsy only dysplasia at 4.94% (95%CI 0.00-
16.10%) (I255.9% (p=0.03)) whilst SDWL had the highest pooled propor-
tion for patients with random biopsy alone dysplasia, 20.39% (95%CI 
10.70-31.79%) (I2 =80% (p< 0.001)). The pooled proportion of patients with 
dysplasia identified by random biopsy alone within the high-risk group 
was more than double, 14.19% (95%CI 7.43-22.29%) (I2=81% (p=< 0.001)), 
when compared with that of the low-risk group, 6.42 (95%CI 0.04-18.45%) 
(I2=79% (p=< 0.001)).
conclusion: This is the first meta-analysis looking at factors associated 
with the rate of detecting endoscopically invisible dysplasia. There was 
marked heterogeneity and overlapping confidence intervals reflecting the 
varied nature of included studies and risk groups enrolled. HDCE was as-
sociated with the least rates of endoscopically invisible dysplasia among 
all subgroups with at least 2 or more studies included. Random biopsies 
may still be required when surveillance is performed in high-risk popula-
tions. We propose that future prospective studies should undertake tar-
geted and random biopsies along with capturing established risk factors 
for each individual. This will provide more robust evidence when attempt-
ing to define a subpopulation more likely to be harbouring endoscopically 
invisible dysplasia.
references: ) Moussata D, Allez M, Cazals-Hatem D, Treton X, Laharie D, 
Reimund JM, et al. Are random biopsies still useful for the detection of 
neoplasia in patients with IBD undergoing surveillance colonoscopy with 
chromoendoscopy? Gut. 2018;67(4):616-24. 2) Fumery M, Dulai PS, Gupta 
S, Prokop LJ, Ramamoorthy S, Sandborn WJ, et al. Incidence, Risk Factors, 
and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With 
Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clin Gastro-
enterol Hepatol. 2017;15(5):665-74 e5.
disclosure: Nothing to disclose 
P1082 fecaL caLPrOTecTIn (fcaL) In IBd: an usefuL 
and nOn InvasIve PredIcTOr Of MucOsaL heaLIng and 
cLInIcaL reLaPse
Sambuelli A.1, Gil A.1, Negreira S.1, Tirado P.1, Huernos S.1, Goncalves S.1, 
Chavero P.1, Goldberg G.1, Litwin N.2
1Hospital Bonorino Uadondo, IBD, Buenos Aires, Argentina, 2Laboratorio 
de Investigación en Gastroenterologia, Buenos Aires, Argentina
contact e-Mail address: alicia.sambuelli@gmail.com
Introduction: FCal emerged as useful tool for IBD management, but dif-
ferent assay methods, cut-offs, scenarios, patient phenotypes and popula-
tions may influence the clinical usefulness.
aims & Methods: Two substudies were designed for for the IBD population 
from a Latin-American center:
1) To investigate the value of FCal in mucosal healing (MH) prediction (op-
timal cut-off, specificity, sensitivity, VPP, VPN) and thresholds for clinical 
activity and phenotypes, 
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2) To evaluate the ability of FCal monitoring in IBD in remission to predict 
relapse. 
FCal was determined with Bühlmann fCAL®ELISA. 
Substudy-1 (MH prediction and activity/pattern of IBD): Included 100 IBD 
pts: (44 UC 56 CD), who underwent routine colonoscopy (VCC) with catego-
rization by IBSEN score (Frøslie KF, Gastroenterol 2007) “MH”(scores 0-1) 
and “non-MH”, colleting FCal samples within previous week. Optimal FCal 
cut-off for “MH”prediction (opt-MH cut-off) was calculated (ROC analysis). 
Substudy-2 (Prediction of relapse): included 50 UC and 50 CD in clinical 
remission (≥3 monts), FCal: basal, ≥biannual, VCC basal/final. Analysis: 
Kaplan Meier survival analysis for FCal levels above and below opt-MH 
cut-off. Mean follow-up 23.0±11.8 monts. Global definitions of clinical ac-
tivity: Partial Mayo (UC), HBI (CD), Location/Extent (Montreal).
results: 
Substudy-1: FCal levels (Mean±SD) in pts. with “MH” (25 UC, 30 CD) were 
significant lower vs. “Non-MH”: UC (191.3±174.6 vs. 621.1±368.3, p=0.0001) 
and CD (237.0±196.9 vs. 618.5±319,3 p< 0.0001) Kruskal-Wallis. Opt-MH 
cut-off was 242µg/g, AUC 0.84 (95% CI 0.753-0.906)p=0.0001, sensitiv-
ity: 76.4%, specificity: 84.5%, PPV: 85.7%, NPV: 74.5%. By clinical crite-
ria FCal was lower (p< 0.0001) in remission vs activity in UC (165.7±14.1 
vs. 630.3±349.6) and CD (276.4±250.1 vs. 662.1±289.9), but FCal cut-off 
was higher (284 µg/g) than opt-MH cut-off. In endoscopically active CD 
pts, FCal levels in colonic CD were higher 851.9±232.0 vs. other locations 
544.4±313.3 (p=0.04). 
Substudy-2: Cumulative probabilities of clinical relapse at 6, 12, 18, 24 
monts of pts. with FCal>242 µg/g (n 34) were 20.6%, 38.2%, 44.7%, 
51.6%, and with FCal≥cut-off (n 66) rates were 1.5%, 3.1%, 5.1% and 7.9% 
respectively, HR: 14.22 (95% CI 6.18 to 32.72), p< 0.0001, sensitivity: 85%, 
specificity 82.7%, VPP: 67.7%, VPN: 93.9%. Globally, relapsed 15 (30%) of 
UC and 12 (24%) of CD (NS). Clinical relapses with FCal>242 were 67.7% vs. 
6.1% (≤ than cut-off), endoscopic relapses (available in 91 pts.) with FCal 
>242: 75% vs. 6.8% (≤ than cut-off), both p< 0.00001
conclusion: 
1) Fcal was a good predictor of MH in UC and CD according opt-MH cut-off 
(242 µg/g), Sensitivity: 76.4%, Specificity: 84.5%, PPV: 85.7%, PNV: 74.5%. 
2) FCal values were significantly lower in remission vs. activity, in UC and 
CD, but in endoscopically active colonic CD, FCal was higher vs. other loca-
tions, 
3) FCal showed to be an effective tool to predict relapse for levels above 
opt-MH cut-off.
disclosure: Nothing to disclose 
P1083 anxIOus, dePressed, PhysIcIan-crITIcaL BuT LOTs Of 
cOMPLaInTs - PersOnaLITy characTerIsTIcs Of caM users In 
PaTIenTs WITh IBd
Klaus J.G., Rauschek L., Schulte L., Kretschmer M., Berthold J., Sularz M.
Universitätsklinikum Ulm, Ulm, Germany
contact e-Mail address: jochen.klaus@uniklinik-ulm.de
Introduction: Many patients ask to combine complementary and alterna-
tive medicine (CAM) with guideline-based state of the art therapy in in-
flammatory bowel disease (IBD). In line with this, the new German S3 
Guideline for the treatment of Ulcerative Colitis (UC) published in 2018 
gives an update of how to use or not to use CAM in UC. In our study, we 
investigated the use of CAM in a cohort of IBD patients and various person-
ality characteristics of patients to describe differences between CAM-users 
and non-users.
aims & Methods: 291 German IBD patients filled in an anonymous ques-
tionnaire including 88 questions on the underlying IBD itself, on disease 
activity (HBI in CD and pMS in UC), QoL (SIBDQ), on CAM and CAMs used. 
Psychological tests (Hospital Anxiety and Depression Scale (HADS), State-
Trait-Anxiety Inventory (STAI), Social Support Questionnaire (F-SozU), 
Complaints-list (BL-R’), NEO-Five-Factor Inventory (NEO-FFI)) were used 
to record differences in personal attributes between CAM-users and non-
users.
results: 138 (47.2%) male and 151 (52.8%) female patients, 183 (62.9%) 
with Crohn’s Disease (CD) and 108 (37.1%) with UC completed the ques-
tionnaires. HBI in CD was 5.4 (± 4.6) and pMS was 2.29 (±2.4) in UC. 127 
(43.6%) patients admitted intended use of CAM in the past or the present. 
Phytotherapies (117(92.1%)) were most frequently used, followed by pro-
biotics (82(68.3%)), relaxation techniques (76(64.4%)) and homeopathy 
(59(52.2%)). We were able to identify significant differences between CAM 
users and non-users with regard to depression and anxiety levels, number 
of complaints, patient type and personality. CAM users have significantly 
higher values on the depression scale (HADS, p=0.027), more disease com-
plaints (p=0.040) and more often very severe anxiety symptoms (p=0.009). 
CAM users personality is characterized by higher values in openness to ex-
periences (p=0.011), tolerance (p=0.037) and conscientiousness (p=0.038) 
according to NEO-FFI. In addition, CAM users reported significantly higher 
rates of a physician-critical patient type (p< 0.001). We could not detect any 
significant differences between CAM users and CAM non-users in quality 
of life, values of STAI anxiety scales, social support, and personality traits 
extraversion and neuroticism according to NEO-FFI.
conclusion: German IBD patients widely use CAM. CAM is mainly used by 
patients who have higher levels of depression, more disease complaints 
and very severe anxiety symptoms. Since CAM users are primarily physi-
cian-critical patient types, attending IBD physicians should identify and 
approach such patients as early as possible, ask them about the use of 
CAM, and provide them with their best advice on CAM. By incorporating 
evidence-based CAM into conventional therapies, physicians could proba-
bly benefit from a better collaboration with physician-critical patient types.
disclosure: Nothing to disclose 
P1084 WhIch uLTrasOund change Occurs MOsT quIckLy 
In resPOnse TO TreaTMenT In crOhn’s dIsease: reducTIOn 
In BOWeL WaLL ThIckness Or MuraL PerfusIOn?
Wilkens R.1,2, Lu C.1, Novak K.L.3, Iacucci M.4,5, Heatherington J.4, 
Ghosh S.3,5, Panaccione R.3, Wilson S.R.1
1University of Calgary, Division of Gastroenterology, Department of Medicine, 
Calgary, Canada, 2Hvidovre Hospital, Unit of Gastroenterology, Department 
of Medicine, Hvidovre, Denmark, 3University of Calgary, Medicine, Calgary, 
Canada, 4University of Calgary, Ibd Clinic. Division of Gastroenterology, 
Calgary, Canada, 5Institute of Translational Medicine, Birmingham, United 
Kingdom
contact e-Mail address: runetw@gmail.com
Introduction: Objective markers of disease activity are of paramount im-
portance for evaluation of treatment response in Crohn’s disease. Intesti-
nal Ultrasonography (IUS) is long acknowledged for this indication, with 
recognized limitations, and Contrast Enhanced IUS (CEUS) shows promis-
ing results in showing blood flow response. However, the optimal timing 
for reduction in mural perfusion is as yet unknown.
aims & Methods: We aim to investigate reduction in wall thickness and 
mural perfusion in inflamed bowel treated with Corticosteroids, Biolog-
ics or a combination of both. This observational study includes patients 
with known CD experiencing a flare with the need of medical treatment 
escalation or initiation. Patients were examined with CEUS if greyscale IUS 
showed bowel wall thickness (BWT) > 3 mm, as part of standard of care. 
Follow-up varied with treatment choice: at week (W) 1 and W4 for steroids, 
W4 and W12 for biologics and W1, W4 and W12 for combination, using 
W1 as baseline for start of biologics. CEUS was performed using the mi-
crobubble contrast agent, perflutren lipid microspheres, 0.3 ml followed 
by saline flush. The US machine and all parameters were constant dur-
ing and between scans. Time intensity curve analysis was performed and 
Peak enhancement (PE), area under the curve (AUC) and Wash-in Slope 
(WiS) were analyzed. Blood samples and fecal calprotectin were collected 
at baseline, W4 and W12 for the steroid group, and baseline and W12 for 
the biologic group. As part of standard of care, most patients underwent 
endoscopy at baseline and at follow-up after W12. W12 Response to treat-
ment was evaluated with combination endoscopy (SES-CD < 3 OR reduc-
tion from baseline > 50 % OR Rutgeerts i0-i1) and laboratory markers (CRP 
< 8 AND Calpro < 250).
results: 46 treatment patients include steroids n=14, biologics n=25, and 
combination n=7. Mean age 35.1 years [range 19.7-77.1], 45.7 % females, 
BMI 25.1 [16.9-51.3]. No difference between groups although a trend to 
larger BWT with increasing treatment intensification 7.3 mm [3.5-11.0], 8.3 
mm [4.0-13.5] and 9.8 mm [7.0-12.0] respectively, p = 0.14. Responders 
experienced a greater reduction in BWT after 4W of any treatment -2.2 mm 
(95% CI -3.1 to -1.4) vs. non-responders -0.9 mm (-1.8 to 0.1) respectively, 
p=0.049. Moreover 6 patients (13 %) achieved transmural healing (BWT 
≤ 3 mm) within W4. Also patients responding to biologics alone reduced 
BWT by -2.2 mm (-3.2 to -1.3) vs. non-responders -0.3 mm (-2.1 to 1.4) at 
W12, p=0.037. CEUS analyzes showed a trend towards response at W4 for 
steroid responders, however only for diminishment of WiS -7.00 dB/s (-11.5 
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to -2.5) vs. -4.00 dB/s (-4.5 to -3.5), p=0.09. Same trend towards response 
was found in the biological group at W4 -3.3 dB/s (-5.3 to -1.4) vs. 0.4 dB/s 
(-5.5 to 6.3) for non-responders, p=0.09. At W12 all three parameters were 
significantly different for responders vs non-responders, WiS p=0.011, PE 
p=0.026, AUC p=0.029.
conclusion: At 4 weeks, IUS can already show reduction in bowel wall 
thickness, and for some even transmural healing, predicting week 12 
responders to steroid and/or biological therapy. CEUS shows significant 
perfusion reduction at 3 months confirming endoscopic and/or biochemi-
cal response in those with successful biologic therapy. Our study did not 
achieve enough power to show reduction in perfusion already after 4 
weeks.
disclosure: Lantheus Medical Imaging: contrast agent support 
P1085 InTrInsIc BraIn aBnOrMaLITIes In uc PaTIenTs and 
effecT Of anxIeTy and dePressIOn
Liu C.1, Wang F.2, Zhang L.2, Qi R.2
1Jinglin Hospital, Nanjing University, Gastroenterology and Hepatology, 
Nanjing, China, 2Jinglin Hospital, Nanjing University, Nanjing, China
contact e-Mail address: liuchang_gi@163.com
Introduction: We have discovered that patients who suffered from ulcer-
ative colitis (UC) may also accompany with anxiety and depression, which 
affect the quality life. According to previous researches, anxiety and de-
pression are usually along with brain functional changes. In order to 
observe the relationship between brain functional changes and anxiety, 
depression especially in UC patients, a functional magnetic resonance im-
aging (f-MRI) technology was applied to conduct the study. The purpose of 
this study was to investigate the spontaneous brain activities and influence 
factors in UC patients compared with healthy people.
aims & Methods: 27 patients diagnosed as UC were recruited from jinling 
hospital, 17 of them and 17 matched healthy controls with similar gander, 
age and years of education were underwent a functional magnetic reso-
nance imaging (f-MRI) 3.0T scan. Regional homogeneity (ReHo) was used 
to measure the synchronism of regional brain activities. T test, Chi-square 
test, pearson correlation were used to analyse the data.
results: On one hand, a significant decreased ReHo values in Parietal_Inf_L 
(except supramarginal gyrus and angular convolution) and Parietal_Sup_L 
were found in UC patients compared with healthy controls. Moreover, 
there were significant negative correlations between ReHo values and SAS 
scores (Pearson correlation, p=0.019, < 0.05, r=-0.3997), however no statis-
tical significance was found between ReHo values and SDS scores (Pearson 
correlation, p=0.086, >0.05). On the other hand, there is statistical signifi-
cance in SAS (42.72±12.543) and SDS (38.75 (33.75-53.13)) scores between 
UC patients and healthy controls. 
Moreover, years of education revealed statistical significance in SAS scores 
(c2=9.047, p=0.009< 0.05) between UC patients and healthy controls. No 
statistical significance was found in SDS scores between several factors in 
UC patients and healthy people.
conclusion: Abnormal brain functional changes exist in UC patients and 
they are more likely to be anxious and depressed than healthy people. 
These findings provide evidence that the disorder in brain-gut axis (BGA) 
may exist in UC patients.
disclosure: Nothing to disclose 
P1086 The cOrreLaTIOn BeTWeen chesT x-ray and chesT 
cT fOr The deTecTIOn Of LaTenT TuBercuLOsIs durIng 
InfLaMMaTOry BOWeL dIsease
Naji S.1, Boubker S.1, Khannoussi W.1, Ismaili Z.2, Kharrasse G.3
1Mohammed VI University Hospital, Hepato-Gastro-Enterology, Oujda, 
Morocco, 2Medical School, Hepato-Gastro-Enterology, Oujda, Morocco, 
3Faculty of Medicine Oujda, Avicenne, Oujda, Morocco
contact e-Mail address: sihamnaji@hotmail.com
Introduction: Over the last decade, Anti-Tumor Necrosis Factor (anti-TNF) 
agents have shown great effectiveness in the treatment of inflammatory 
bowel disease (IBD). Nevertheless, their use exposes the patient to an in-
creased risk of opportunistic infections, particularly tuberculosis. For this 
reason, the pre-therapeutic check-up is important in order to detect latent 
tuberculosis.
aims & Methods: The aim of our study was to evaluate the correlation 
between chest X-ray and chest CT for detection infection.
This is a descriptive retrospective study done in the Hepato-Gastroenterol-
ogy unit of our university hospital, over a period of 4 years from September 
2015 to December 2018 and collected all patients with IBD requiring an 
anti-TNF treatment. All patients had chest x-rays and chest CT scans.
results: Sixty-seven patients were included in our study. The average age 
of our patients was 35.37 years. There were 22 women (32.85%) and 45 
men (67.15%) with a sex ratio M/F: 2. 86. 56% of patients were followed for 
Crohn’s disease, 11.9% for Ulcerative Colitis and 1.49% for indeterminate 
colitis. Respiratory symptoms were found in only 3 patients (4.47%). Chest 
X-ray revealed lesions in favour of latent tuberculosis in 2.9% of cases 
(n=2), including interstitial syndrome. Thoracic CT scan revealed lesions in 
favour of tuberculosis in 13.43% of cases (n=9), including micronodules in 
55.55% of cases and a focal of alveolar condensation in 44.44% of cases. 
The Quantiferon assay was also performed in patients with positive CT; it 
was positive in 88.88% of cases (n=8). The diagnosis of pulmonary tuber-
culosis was confirmed in 9 patients. The correlation between chest CT and 
chest radiography was calculated using the Pearson score which showed 
a low correlation (r=0.048). In addition, the correlation between thoracic 
CT and Quantiferon, calculated using the Pearson score, was higher with a 
statistically significant p (p< 0.001).
conclusion: In our series of sixty-seven patients candidate for an anti-TNF 
treatment, the correlation between chest X-ray and chest CT for the detec-
tion of latent tuberculosis during inflammatory bowel disease was very 
low ( r=0.048 ). CT Scan should be concurred reference diagnostic tool to 
detect attaint tuberculosis. However, the correlation between chest CT and 
Quantiferon must be well studied with a larger sample.
disclosure: Nothing to disclose 
P1087 usIng MagneTIc resOnance enTerOgraPhy gLOBaL 
scOres (Megs) TO assess resPOnse TO usTekInuMaB In 
crOhn’s dIsease
Honap S.1, Griffin N.2, Nicolescu A.2, Irving P.M.1
1IBD Centre, St. Thomas’ Hospital, London, United Kingdom, 2Department of 
Radiology, St. Thomas’ Hospital, London, United Kingdom
contact e-Mail address: honap@hotmail.co.uk
Introduction: Magnetic resonance enterography (MRE) is a key modality 
in diagnosing and monitoring Crohn’s disease (CD). MEGS, a quantitative 
MRI index of inflammatory burden in CD, has been previously validated 
against Harvey Bradshaw Index (HBI), C-reactive protein (CRP) and faecal 
calprotectin (FC)1. It has also been shown to reflect clinical response to 
anti-TNF therapy and clinical classification of disease activity2.
aims & Methods: To evaluate the utility of MEGS in assessing radiological 
response to ustekinumab, a monoclonal antibody targeting IL12/23. Pa-
tients established on ustekinumab, with a baseline and follow up MRE 
(at least three months after ustekinumab induction), were retrospectively 
reviewed. Clinical data, including HBI, CRP and FC, were collected to es-
tablish disease activity at baseline and at the first follow up MRE. Two 
consultant gastrointestinal radiologists, without clinical data, analysed im-
ages to calculate MEGS. Statistical analysis was performed using Graph-
Pad Prism version 8.0.
results: Sixteen patients (median age 37, 50% male) with moderate to 
severe CD at baseline, according to a Physician Global Assessment (PGA), 
were identified. Median time to first follow up MRE was 10 months (range 
5-18). 3/16 were responders according to PGA, and although MEGS de-
creased in each case (44, 16.3 and 8.5 to 38, 15.5 and 5.5 respectively), 
this did not reach statistical significance. 13/16 were non-responders and 
pre-induction median MEGS increased (21 (range 2-79.5) vs. 26 (5.5-85.5), 
p< 0.002), reflecting increasing symptom burden and biochemical pa-
rameters despite therapy. The overall interobserver agreement between 
reporting radiologists was good with a mean difference between the two 
observers’ MEGS of -3.95 (Bland Altman Limit of Detection (-16.48 to 8.57)).
conclusion: Quantitative MRI scores for Crohn’s disease activity are in-
creasingly being used in clinical practice, and our study demonstrates 
good interobserver agreement. Whilst our data is suggestive of a correla-
tion between change in MEGS and PGA in this complex, prior biologic 
refractory patient population, larger protocolised studies are needed.
references: 1. Makanyanga JC, Pendsé D, Dikaios N, Bloom S, McCartney 
S, Helbren E, et al. Evaluation of Crohn’s disease activity: initial validation 
of a magnetic resonance enterography global score (MEGS) against faecal 
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calprotectin. Eur Radiol. 2014 Feb;24(2):277-87. 2. Prezzi D, Bhatnagar G, 
Vega R, Makanyanga J, Halligan S, Taylor SA. Monitoring Crohn’s disease 
during anti-TNF-α therapy: validation of the magnetic resonance enterog-
raphy global score (MEGS) against a combined clinical reference standard. 
Eur Radiol. 2016 Jul;26(7):2107-17.
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Hepato-Gastroenterologie, Paris, France, 26GHI Le Raincy-Montfermeil, 
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Introduction: Endoscopic remission has become a major goal of treatment 
in patients with ulcerative colitis. Few endoscopic data are available in 
patients with steroid-refractory acute severe ulcerative colitis (ASUC) re-
quiring a second-line medical therapy. The aim of the present study was 
to describe the evolution of endoscopic lesions in patients with ASUC re-
sponding to infliximab (IFX) or cyclosporine (Cys).
aims & Methods: All patients enrolled into the CYSIF trial (1), that was an 
open-label comparison between IFX and Cys in patients admitted for a 
steroid-refractory ASUC, were eligible for inclusion in the present endo-
scopic sub-study. Only patients who achieved clinical remission at day 98 
were included in this sub-study. Flexible sigmoidoscopies were planned 
during the study at baseline, day 7, 42 and 98. They were locally read 
and the presence of pre-specified endoscopic lesions was recorded per 
segment. Mayo endoscopic subscore (MES) was reported; UCEIS and its 
components, vascular pattern (VP), bleeding (B) and ulceration/ erosion 
(U), were post-hoc calculated from endoscopic reports. Endoscopic remis-
sion (ER) was defined as MES or UCEIS at 0. Remission for each UCEIS 
component was defined by VP, B or U at 0. Remission rates were compared 
between VP, B and U components in the whole cohort at each time-point 
through paired chi-square test. Using the same method, ER rates and re-
mission of each UCEIS component were compared between rectum and 
sigmoid segments. ER rates and remission rates of each UCEIS component 
were compared between patients treated with IFX and those receiving Cys 
through chi-square test or Fisher exact test when necessary. According to 
the numerous tests performed, significance was achieved for a p-value 
less than 0.01.
results: From the 115 patients included in the trial, 63 have been includ-
ed in the present endoscopic sub-study (32 IFX and 31 Cys). Mean±SD of 
UCEIS and MES was respectively 7.0±1.2 and 3.0±0.2 at baseline, 5.3±1.7 
and 2.9±0.5 at day 7, 2.3±2.1 and 1.6±1.2 at day 42 (n=62), 1.1±1.3 (n=58) 
and 0.9±1.0 (n-59) at day 98. When comparing to ER rates on VP at day 7 
(3%), at day 42 (29%), at day 98 (50%) in the whole cohort, ER rates on 
B and on U were higher at day 7 (21% and 8%, p=0.001 and p=0.38), at 
day 42 (63%, p< 0.001 for both) and at day 98 (76% and 83%, p< 0.001 for 
both). There was no observed difference in ER rates between sigmoid and 
rectum whatever the assessment used. ER rate at day 98 was significantly 
higher in patients treated with IFX than in those treated with Cys (66% vs. 
24%; p=0.002), whereas no difference was observed at baseline, day 7 or 
day 42. This observed difference at day 98 was related mainly to the VP 
component.
conclusion: In this prospective cohort of steroid-refractory ASUC patients 
who achieved clinical remission at day 98, UCEIS endoscopic remission 
started with absence bleeding, followed by ulceration/erosion and then 
by restoration of the vascular pattern. Endoscopic remission was similar in 
rectum and sigmoid. IFX provided a significantly higher rate of endoscopic 
remission than Cys at day 98.
references: 1. Laharie D et al. Ciclosporin versus infliximab in patients with 
severe ulcerative colitis refractory to intravenous steroids: a parallel, open-
label randomised controlled trial. Lancet 2012; 380:1909-15.
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Introduction: The UNIFI induction study evaluated the efficacy and safety of 
ustekinumab (UST) in patients with moderately to severely active ulcerative 
colitis (UC) after a single intravenous infusion. In this analysis, we evalu-
ated the rapidity of the onset of the treatment effect.
aims & Methods: Eligible patients were randomly assigned to placebo 
(PBO) or UST 130 mg or ~6 mg/kg. Patients recorded stool frequency and 
categorized rectal bleeding daily for the 7 days before each visit. Partial 
Mayo scores were calculated at baseline and Week 2 using the average 
of the stool frequency and rectal bleeding scores from the most recent 
consecutive 3-day period before the visit and the physician’s global as-
sessment score recorded at the visit. C-reactive protein (CRP) and fecal 
biomarkers were measured at baseline and Day 14.
results: At baseline, the mean 3-day average daily stool frequency was 7.0 
in the PBO group, 6.9 in the UST 130-mg group, and 7.0 in the UST ~6-mg/
kg group. Patients receiving UST showed greater reductions in the daily 
number of stools compared with PBO as soon as the first assessment time 
point at Day 7. Mean changes from baseline in daily stool frequency were 
-0.7 for PBO, -1.0 for UST 130-mg (p=0.098), and -1.2 for UST ~6-mg/kg 
group (p=0.018) by Day 7, respectively, and -0.9, -1.6 (p< 0.001), and -1.9 
(p< 0.001) by Day 13, respectively. The percentage of patients with no blood 
in their stool at baseline and Day 14 were 13.5% and 26.0%, respectively, 
in the PBO group, 10.9% and 32.5% in the UST 130-mg group, and 12.1% 
and 37.3% in the UST ~6-mg/kg group. Patients receiving UST showed 
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significantly greater improvement from baseline to Day 14 in partial Mayo 
score and CRP (Table, p<0.001 for all comparisons of UST vs PBO). Differ-
ences between the UST and PBO treatment groups in mean changes from 
baseline to Day 14 in fecal calprotectin did not reach significance (PBO 
-33.96 mg/kg, UST 130 mg 79.12 mg/kg [p=0.875], UST ~6 mg/kg -412.68 
mg/kg [p=0.152]). However, patients receiving UST showed significantly 
greater improvement in fecal calprotectin at Week 4 (mean changes from 
baseline: PBO -226.78 mg/kg, UST 130 mg -881.22 mg/kg [p=0.013], UST ~6 
mg/kg -802.75 mg/kg [p< 0.001]). Similar results were observed for fecal 
lactoferrin.
conclusion: The effect of UST began rapidly after induction, with symptom-
atic improvement and reduction of systemic inflammation seen as early as 
the first assessments at Days 7 and 14, respectively.
  PBO Iv usT Iv 130 mg usT Iv ~6 mg/kg
Primary efficacy analysis set 319 320 322
Partial Mayo score, mean (SD)    
Baseline 6.2 (1.46) 6.2 (1.42) 6.2 (1.33)
Change from baseline to Week 2 -1.0 (1.63) -1.5 (1.74) -1.6 (1.69)
Nominal p-value   <0.001 <0.001
C-reactive protein, mean (SD) mg/L    
Baseline 9.8 (16.65) 9.6 (17.07) 12.1 (19.34)
Change from baseline to Week 2 -0.7 (16.20) -4.1 (13.41) -4.2 (12.53)
Nominal p-value   <0.001 <0.001
[Table: Partial Mayo scores and C-reactive protein levels at baseline and 
changes from baseline to Week 2]
disclosure: Drs. Sands, Abreu, Rowbotham, Leong, Danese are all inves-
tigators for Janssen Research & Development, LLC Drs. Marano, Baker, 
O’Brien, Zhang, and Johanns are employees of Janssen Research & De-
velopment, LLC 
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BOWeL dIsease PaTIenTs: a 19-year exPerIence Of a TerTIary 
cenTre
Guedes T.1, Pinto C.2, Garrido M.1, Salgueiro P.3, Torres T.4, Pedroto I.1, 
Lago P.1
1Centro Hospitalar Universitário do Porto, Gastroenterology, Porto, Portugal, 
2Instituto Português de Oncologia do Porto, Gastroenterology, Porto, 
Portugal, 3Centro Hospitalar Universitário do Porto, Porto, Portugal, 4Centro 
Hospitalar Universitário do Porto, Dermatology, Porto, Portugal
contact e-Mail address: tiagoapguedes@gmail.com
Introduction: Inflammatory bowel disease (IBD) and Psoriasis are chronic 
inflammatory conditions with an organotropic preference, where the influ-
ence of innate and adaptative immunity seems to play a crucial role. This 
shared pathologic process explains the use of similar therapeutic strate-
gies like corticosteroids, immunomodulators and monoclonal antibodies. 
Psoriasis can be associated to IBD as an independent entity, as an extrain-
testinal manifestation of IBD, or even as a paradoxical event of anti-tumor 
necrosis factor (TNF) therapy. Their co-occurrence adds complexity to the 
challenge of patient management.
aims & Methods: Our main goal was to review our experience of patients 
treated with TNFa inhibitors regarding the occurrence of dermatological 
lesions, namely, psoriasis. We retrospectively analyzed data regarding a 
cohort of patients with the diagnosis of IBD and submitted to anti-TNF 
therapy, from January 2000 until the end of January 2019. We included pa-
tients observed by the dermatology department due to suspicious lesions 
during treatment with anti-TNF therapy. Data was retrieved from clinical 
registries.
results: 422 patients were analyzed. Suspicious dermatological lesions 
were found in 111 patients (24%) and a diagnosis of psoriasis was made 
in 34 (8%). The prevalence was higher in the females (26 vs 8). Among 
patients with Psoriasis, the predominant IBD type was CD (only 1 patient 
with UC). The majority of the former presented ileocolonic disease(46%), 
a non-stricturing non-penetrating behavior(49%) and were diagnosed 
between 16-40 years old(79%). Psoriatic lesions were found mainly in 
scalp(n=13), trunk(n=10) and palmoplantar regions(n=7). 35% of the pa-
tients were diagnosed while being treated with combined therapy with 
immunosuppressive drugs (4 with methotrexate and 8 with azathioprine). 
41% of patients were treated with two or more biologic drugs. The diag-
nosis of psoriasis preceded the use of anti-TNF therapy in 7 patients. 27 
patients were on treatment with TNFa inhibitors at the time of psoriasis 
diagnosis. The mean time from anti-TNF exposure until development of 
psoriasis was 28 months with a mean follow up time of 7 years. Psoriatic 
lesions were controlled in 4 patients by switching infliximab to adalim-
umab. The discontinuation of anti-TNF therapy due to psoriasis occurred 
in 12% (n=4/34) of patients. 50% swapped to ustekinumab or vedolizumab 
with good skin disease control.
conclusion: In our cohort there was an incidence of psoriasis in IBD pa-
tients treated with anti-TNF of 8%, resulting in alterations in the man-
agement of IBD therapy. The majority of our patients improved their skin 
condition with anti-TNF switch, despite lack of studies regarding this.
The incidence of this lesions on IBD patients treated anti-TNF thera-
py(6-11%) is consistent with that found in other diseases like rheumatoid 
arthritis. Psoriatic lesions were more frequently identified in patients with 
CD than in UC patients, with gender being identified as a risk factor. The 
paradoxically occurrence of psoriatic skin lesions, is an emergent issue in 
the context of anti-TNF drugs use. Effective drugs on psoriasis and IBD, 
targeting different pathways than anti-TNF, are changing the reality al-
lowing further control over both diseases. Nowadays a good control of 
intestinal and skin inflammation can be achieved without compromising 
the outcomes expected for each. A multidisciplinary approach is of utmost 
importance in managing IBD treatment and potential complications.
disclosure: Nothing to disclose 
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Introduction: Real-world data is needed to understand outcomes in pa-
tients with ulcerative colitis (UC) or Crohn’s disease (CD) who discontinue 
first-line (1L; biologic-naive) vedolizumab (VDZ) treatment (Tx) and go on 
to receive subsequent anti-tumour necrosis factors (anti-TNF) Tx.
aims & Methods: The objective was to compare the clinical effectiveness 
of second-line (2L) anti-TNF Tx post 1L VDZ and 1L anti-TNF use in patients 
with UC or CD. This was a real-world, multi-country, retrospective chart re-
view study in adult (≥18 years old) UC and CD patients treated with 1L anti-
TNF or 2L anti-TNF after discontinuation of 1L VDZ for any reason (received 
May 2014 to March 2018). Patients were included from sites across Canada, 
Greece and the United States. Anti-TNF therapies included: adalimumab, 
infliximab, golimumab and certolizumab pegol. The index date was de-
fined as date of 1L Tx initiation. Clinical effectiveness data were collected 
from 1L or 2L Tx initiation to earliest of death, chart abstraction date or 6 
months post-1L Tx discontinuation (Canada only). Cumulative rates of Tx 
persistence, clinical response, and clinical remission were estimated using 
the Kaplan-Meier method for UC and CD (separately and combined) over 6 
months. Cumulative rates of clinical response and clinical remission were 
assessed using pre-defined hierarchical algorithms of standard disease 
measures as reported in the medical records. P-values were generated 
using the log-rank test.
results: This analysis included 579 anti-TNF patients (1L: 497 [UC: 224; 
CD: 273]; 2L: 82 [UC: 58; CD: 24]) from 36 sites. The proportion of pa-
tients in each cohort were: adalimumab (1L: 41.4%; 2L:19.5%), infliximab 
(1L: 52.7%; 2L: 79.3%), golimumab (1L: 4.8%; 2L: 1.2%) and certolizumab 
pegol (1L: 0.8%; 2L: 0.0%). Mean (SD) age at index date: 1L, 39.6 (15.2); 
2L, 49.4 (18.6) years, male: 1L, 49.9%; 2L, 61.0%, median (range: min-
max) disease duration: 1L, 2.0 (< 0.1 - 49.0); 2L, 3.7 (0.1 - 54.0) years. At 6 
months, cumulative rates of Tx persistence (1L: 83.9%; 2L: 83.6%), clinical 
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response (1L: 49.5%; 2L: 65.6%) and clinical remission (1L: 29.5%; 2L: 
31.4%), were similar between 1L and 2L patients (Table 1). Results were 
similar when data were stratified by UC and CD, albeit sample sizes were 
small (Table 1).
conclusion: Cumulative rates of Tx persistence, clinical response and 
clinical remission observed in the first 6 months of Tx were comparable 
between 1L anti-TNF patients and those who switched to a 2L anti-TNF 
following the discontinuation of 1L VDZ. This suggests that 1L VDZ may not 
impact the effectiveness of subsequent anti-TNF Tx in real-world clinical 
practice. As 2L sample size was limited, these hypothesis-generating data 
warrant further study. 
  Overall ulcerative colitis crohn‘s disease
Outcomes
first-
Line 
n=497
second-
Line 
n=82
first-
Line 
n=224
second-
Line 
n=58
first-
Line 
n=273
second-
Line 
n=24
Treatment Persistence: 3 
months, % [n at risk] 91.7 [451]
95.1 [64] 
P=0.45
87.4 
[195]
94.3 [47] 
P=0.18
95.2 
[256]
96.4 [17] 
P=0.81
Treatment Persistence: 6 
months, % [n at risk] 83.9 [411]
83.6 [36] 
P=0.87
76.6 
[170]
79.5 [26] 
P=0.50
90.0 
[241]
92.2 [10] 
P=0.82
clinical response: 3 
months, % [n at risk]
33.9 
[269]
43.6 [23] 
P=0.25
38.4 
[109]
44.8 [16] 
P=0.54
30.1 
[160]
41.3 [7] 
P=0.52
clinical response: 6 
months, % [n at risk]
49.5 
[186]
65.6 [9] 
P=0.09
57.1 [61]
61.1 [6] 
P=0.58
43.5 
[125]
74.8 [3] 
P=0.13
clinical remission: 3 
months, % [n at risk] 17.5 [310]
22.6 [30] 
P=0.44
9.7 [136]
11.0 [24] 
P=0.92
22.9 
[174]
49.2 [6]* 
P=0.02
clinical remission: 6 
months, % [n at risk]
29.5 
[240]
31.4 [13] 
P=0.56
19.6 
[104]
14.7 [12] 
P=0.69
36.2 
[136]
74.6 [1]* 
P<0.01
Cumulative data were generated from Kaplan-Meier analyses and p-values are from 
the log-rank test. *Significant difference (P<0.05) between first and second-line. N at 
risk: Number of patients still on treatment at timepoint and clinical outcome can still 
be assessed. Rates of clinical response and clinical remission were assessed using 
pre-defined hierarchical algorithms of: CD: Crohn’s disease activity index → Harvey 
Bradshaw index→ medical record documentation of complete or partial response → 
Physician global assessment. UC: Mayo Overall Score → Mayo Partial score → medical 
record documentation of complete or partial response → Physician global assessment.
[Clinical Effectiveness of First-Line Anti-TNF and Second-Line Anti-TNF (Post-
Vedolizumab) Therapies in Ulcerative Colitis and Crohn’s Disease Patients]
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Introduction: The regulatory approval of ustekinumab (targeting IL-12/IL-
23 in Crohn’s Disease) and clinical data for several anti-IL-23 monoclonal 
antibodies support targeting the IL-23 pathway for treatment of inflam-
matory bowel disease (IBD). PTG-200 (also known as JNJ-67864238) is an 
oral peptide, that acts locally in intestinal tissues to block IL-23 signaling 
by selectively binding the IL-23 receptor (IL-23R). In vitro studies confirmed 
PTG-200 is a potent, selective, and competitive IL-23R inhibitor. The GI-
restricted nature of PTG-200 is demonstrated by marked drug concentra-
tions in GI tissues and feces, and limited systemic blood exposure in ani-
mal models. PTG-200 therapeutic potential was established in a rat model 
of TNBS-induced colitis, where the threshold concentration of PTG-200 in 
colonic tissue and luminal feces for efficacy and pharmacodynamics was 
determined.
aims & Methods: The objectives of this first-in-human (FIH) Phase 1 study 
were to assess safety, tolerability, and pharmacokinetics (PK) including 
food effect and fecal exposure of orally administered PTG-200. This FIH 
Phase 1 study was a single-center, randomized, double-blind, placebo-
controlled trial comprising single ascending and 14-day multiple ascend-
ing dose (SAD and MAD) oral administration in 82 male normal human 
volunteers. Doses ranged from 150 mg to 900 mg once daily (QD, fasted or 
fed) or twice daily (BID, fed). Subjects were monitored for safety and toler-
ability. PK in plasma, urine and feces was evaluated, including plasma PK 
profile following a high-fat meal.
results: Oral administration of PTG-200 was well-tolerated. There were 
no serious adverse events, dose-limiting toxicities, or clinically significant 
adverse events. PTG-200 plasma exposure was low (Table 1), below that 
expected to result in systemic biological activity. Following single-dose 
oral administration under fasted conditions, peak plasma concentration 
(Cmax) exhibited a dose-related increase with a median Tmax at 2.0 h. 
Administration of a high-fat meal prolonged the median Tmax to 4.0 h 
and had a modest effect on Cmax and estimated overall exposure. Repeat 
dosing led to dose-related increase in plasma exposure. Consistent with 
a terminal half-life of ~1.5 h in plasma, PTG-200 showed no evidence of 
accumulation except in the 900 mg BID group (2.75-fold). PTG-200 was de-
tected in urine only at 900 mg BID. Fecal concentrations in several cohorts 
met or exceeded the targeted preclinical threshold concentration which 
was established using the rat TNBS-induced colitis model.
cohort dose and frequency
feeding 
status day cmax (ng/mL) auc0-last (ng*hr/mL) 
4 150 mg, QD Fed Day 1 0.33 ± 0.26 0.89 ± 0.81
4 150 mg, QD Fed Day 14 0.39 ± 0.12 0.97 ± 0.57
5a 300 mg, QD Fed Day 1 0.61 ± 0.60 1.79 ± 1.23
5a 300 mg, QD Fed Day 14 0.56 ± 0.26 1.69 ± 0.81
5b 150 mg, BID Fed Day 1 0.23 ± 0.08 0.80 ± 0.30
5b 150 mg, BID Fed Day 14 0.23 ± 0.07 0.62 ± 0.25
6 900 mg, QD Fed Day 1 1.16 ±0.85 3.92 ± 3.00
6 900 mg, QD Fed Day 14 1.11 ±0.72 3.11 ± 1.59
7 900 mg, BID Fed Day 1 0.48 ±0.25 2.52 ± 1.92
7 900 mg, BID Fed Day 14 1.06 ±0.70 5.15 ± 3.09
[Table 1. Plasma PK (Cmax and AUC0-last) of PTG-200 in MAD. Cmax and 
AUC0-last are presented as mean ± standard deviation. ]
conclusion: Orally administered PTG-200 was well-tolerated in this FIH 
study. PK was consistent with the GI-restricted design of PTG-200. These 
safety and PK characteristics, combined with fulfillment of preclinical fe-
cal drug threshold concentrations, support further clinical development of 
PTG-200 for the treatment of IBD. A Phase 2 study in patients with moder-
ate-to-severe Crohn’s disease has been planned.
disclosure: Nothing to disclose 
P1093 The effecTs Of cannaBIs exTracTs On InfLaMMaTOry 
BOWeL dIsease (IBd) exPLanT BIOPsIes
Pery S.1, Abu Jabal N.1,2, Ringel Y.3, Konikoff F.1,2, Naftali T.1,2, 
Tartakover Matalon S.4,5
1Meir Medical Center, Kfar Saba, Israel, 2Tel Aviv University, Tel-Aviv, Israel, 
3Meir Medical Center, Gastroenterology and Hepatology, Kfar Saba, Israel, 
4Meir Medical Center, Gastroenterology and Hepatology Laboratory, Kfar 
Saba, Israel, 5Tel-Aviv University, The Sackler Faculty of Medicine, Tel-Aviv, 
Israel
contact e-Mail address: shaul.pery@clalit.org.il
Introduction: Cannabis treatment improves chemical induced Colitis in 
mice as well as clinical disease burden in human measured by the Lich-
tiger score. The mechanism by which cannabis affected Disease score is 
unknown. In IBD the inflamed microenvironment damages the epithelial 
barrier. Following damage, a process of barrier restitution begins, which 
depends on epithelial cell proliferation.
aims & Methods: 
Aim: To analyze the effect of cannabis on cultured colon biopsies from IBD 
patients and on human colon epithelial cell line exposed to soluble IBD 
microenvironment. 
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Methods: Biopsies (3-5,~10mg/biopsy) were collected during endoscopy 
from inflamed and uninflamed colon areas of IBD patients, cultured for 
5-6hr with medium, cannabis-extract (C2F,50/100µg/ml) or methanol 
(C2F-solvent) and analyzed using immunohistochemistry and manually 
cell count or QuPath digital software for: 
1) Epithelial and stromal cell proliferation and apoptosis (Ki67 and cleaved-
caspase-3 expression, respectively) 2) Epithelial-cell-number/crypt-diam-
eter. The secretomes of the cultured biopsies were analyzed for MMP9/2 
activity (impair epithelial permeability, by Zymogram test) or added to co-
lon epithelial cells (CC841) for 48hr. Following culture CCD841 cells were 
analyzed for viability (by Alamar-blue), cell-number and death (automatic 
cell-counter and trypan blue) and PCNA expression (proliferation marker, 
western-blot).
results: Cannabis extract increased epithelial cell proliferation in all biop-
sies (p< 0.05, 12-31%), seen in both digital and manual cell-count. In cor-
respondence with this, cannabis (100µg/ml) increased the number of epi-
thelial cells in crypt circumference in all biopsies (~ 32%, p< 0.05). Simi-
larly, secretomes collected from C2F treated inflamed biopsies increased 
CCD841 proliferation (45%↑ cell-number and 41-380%↑ PCNA expres-
sion) compared to inflamed secretomes. Whereas, secretomes collected 
from untreated inflamed biopsies reduced CCD841 cell number (22%) and 
viability (16%) compared to secretomes of uninflamed areas (p< 0.05). Ex-
posure of CCD841 directly to C2F (100µg/ml) reduced their viability (80%↓, 
p< 0.05). Cannabis extract also increased Ki-67 expression in the stromal 
cells of the inflammatory tissue (in 5/6 experiments), yet, had no effect 
on epithelial and stromal cell-apoptosis. While as the cannabis (50µg/ml) 
reduced MMP9/2 activity in the uninflamed secretomes in 4/5 patients, it 
increased the MMP9 level in the inflamed secretomes (5/6 patients).
conclusion: Cannabis facilitates colon epithelial proliferation in ex-vivo 
and in-vitro human models and thus may facilitate mucosal healing. How-
ever, it had a complex and area dependent effect on the MMPs activity, 
reflecting the complexity of cannabis anti-inflammatory effect.
disclosure: Nothing to disclose 
P1094 assessMenT Of BudesOnIde MMx® effecTIveness fOr 
acTIve, MILd-TO-MOderaTe uLceraTIve cOLITIs In The POLIsh 
suB-grOuP Of The PrOsPecTIve MuLTI-cenTer OBservaTIOnaL 
sTudy cOre PracTIce
Rydzewska G.1,2, Paridaens K.3, Danese S.4, Jesionowski M.5
1Central Clinical Hospital of the Ministry of Interior and Administration, 
Gastroenterology with IBD Subdivision, Warsaw, Poland, 2Jan Kochanowski 
University, The Faculty of Medicine and Health Science, Kielce, Poland, 
3Ferring Pharmaceuticals Centre S.A., Global Medical Affairs, Saint-Prex, 
Switzerland, 4Humanitas Clinical and Research Center, IRCCS, IBD Center, 
Rozzano, Italy, 5Ferring Pharmaceuticals Poland, Medical Department, 
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Introduction: Budesonide MMX® is approved for induction of remission 
in mild-to-moderate active ulcerative colitis (UC) in adults, where 5-ASA 
is not sufficient. There is lack of data on its effectiveness and safety in 
clinical reality.
aims & Methods: This was the Polish sub-group of multi-center prospec-
tive observational study CORE Practice. The proportion of patients with 
clinical benefit, clinical remission, symptoms resolution, endoscopic 
healing, endoscopic remission, fecal calprotectin normalization, change 
in quality of life, treatment satisfaction, change in economic parameters 
as well as tolerability, treated with Budesonide MMX® for mild-to-mod-
erate UC in a real-life setting were evaluated. Patients were prescribed 
Budesonide MMX® 9mg in accordance with the terms of the SmPC, within 
a 5 days’ time window before the enrolment. The primary endpoint was 
the clinical improvement of Budesonide MMX® defined as the percentage 
of patients achieving ≥3-point decrease in the UCDAI score at the end of 
induction treatment.
results: The data from the Polish sub-group cohort of 181 patients with 
mild-to-moderate UC were analyzed. Clinical improvement ≥ 3-point in 
UCDAI at the end of treatment induction was achieved in 72,2% patients. 
Clinical remission defined as UCDAI clinical subscore ≤ 1-point was ob-
served in 61,4% of patients at the end of induction treatment. Symptoms 
resolution at the end of treatment, defined as rectal bleeding = 0 and stool 
frequency ≤1 was observed in 72.2% patients. Full symptoms resolution 
(rectal bleeding = 0 and stool frequency = 0) at the end of the Budesonide 
MMX® treatment was achieved in 52,3% of patients. The significant im-
provement of quality of life was observed according to the SIBD-Q (p 
<0.001), compared with baseline, achieving increase in mean SIBD-Q total 
score from 40 to 56 points. The highest treatment satisfaction level (VAS 
score 10) was observed in 40.2% of patients. One patient discontinued 
Budesonide MMX® due to an adverse event that was related to the study 
drug, what counts for less than 1% of patients.
conclusion: The data from the Polish sub-group of the real-life study CORE 
Practice confirms the clinical efficacy of Budesonide MMX® 9 mg in the 
majority of patients with active mild to moderate UC. Budesonide MMX® 
was safe, well tolerated and showed benefitable effect on patient’s quality 
of live.
disclosure: G.Rydzewska has declared paid and unpaid consultancies and 
honoraria for lectures during last few years from Ferring; K. Paridaens - 
nothing to disclose, S.Danese - has served as a speaker, consultant and 
advisory board member for Schering-Plough, Abbott (AbbVie) Laborato-
ries, Merck and Co, UCB Pharma, Ferring, Cellerix, Millenium Takeda, Ny-
comed, Pharmacosmos, Actelion, α Wasserman, Genentech, Grunenthal, 
Pfizer, Astra Zeneca, Novo Nordisk, Cosmo Pharmaceuticals, Vifor, and 
Johnson and Johnson.M. Jesionowski - nothing to disclose, 
P1095 Perfuse: a french PrOsPecTIve/reTrOsPecTIve 
nOn-InTervenTIOnaL cOhOrT sTudy Of InfLIxIMaB-naIve and 
TransITIOned PaTIenTs receIvIng InfLIxIMaB BIOsIMILar sB2; 
1sT InTerIM anaLysIs
Bouhnik Y.1, Fautrel B.2,3, Desjeux G.4, Freudensprung U.5, Addison J.5, 
Brigui A.6
1Beaujon Hospital, AP-HP, Paris Diderot University, Department of 
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Department of Rheumatology, Paris, France, 3UPMC University Paris 06, 
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(EEMOIS), Sorbonne Universités, Paris, France, 4E-health Services Sanoïa, 
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Introduction: SB2 is approved in the EU as an infliximab (IFX) biosimi-
lar, having demonstrated bioequivalence and similar efficacy, safety and 
immunogenicity as the reference. There is limited real-world evidence 
published on persistence or immunogenicity of SB2, either in IFX-naive 
patients or in those transitioning from originator or another IFX biosimilar. 
PERFUSE is an ongoing non-interventional study intending to enrol over 
1,000 patients receiving SB2 as routine therapy.
aims & Methods: To describe clinical characteristics, immunogenicity and 
treatment persistence over 12 months in patients initiating SB2 in routine 
clinical practice at 8 specialist gastroenterology sites across France.
Eligible adult patients have a diagnosis of Crohn’s Disease (CD) or Ulcer-
ative colitis (UC) and initiated SB2 in routine clinical practice after Septem-
ber 2017, either as their first IFX or transitioning from treatment with IFX 
originator or another IFX biosimilar. Data are captured prospectively and/
or retrospectively from patient records obtained during routine clinic visits 
for up to 12 months (M12) following initiation. Outcome measures include 
persistence on SB2, clinical characteristics at baseline (time of initiation of 
SB2), disease scores (Harvey-Bradshaw Index (HBI), Simple Clinical Colitis 
Activity Index (SCCAI)), trough levels (TL) and anti-infliximab antibodies 
(ADA).
results: This interim analysis (IA) includes 575 IBD patients (446 with CD, 
129 with UC); 273 patients with CD and 78 with UC reached M12 by data 
extraction date, with persistence on SB2 being 95.6% (95% CI 92.4, 97.7) 
and 93.6% (95% CI 85.7, 97.9) in CD and UC respectively. In the 522 pa-
tients with prior IFX, no clinically relevant difference in disease score from 
baseline to M12 was observed; mean individual change was -0.34 (95% 
CI -0.72, 0.04) and -0.22 (95% CI -0.89, 0.44) in CD and UC respectively. 
Baseline ADA assay was performed on 241 (50.6%) patients, showing 
mean total ADA concentration below 1µg/mL, with no increase over the 
observation period. 
conclusion: This IA indicates that patients with IBD can be successfully 
transitioned from originator or biosimilar IFX to SB2, with no loss of dis-
ease control and without immunogenicity concerns. Over 90% of patients 
initiated de novo or transitioned from originator or another IFX biosimilar 
continued SB2 treatment at M12 post-initiation.
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cd uc
age, years
Women n (%)
duration of disease, 
years 
n 
446
Mean (sd) 
38.32 (12.95)
173 (38.8)
13.8 (9.2)
q1, q3 
28 - 46.75
-
6 - 19
n 
129
Mean (sd) 
39.32 (12.69)
58 (45)
9.5 (7.7)
q1, q3 
29-49
-
4 - 14
Prior Ifx 
treatment
naiive (n) 
(%)
Originator 
(n) (%)
Biosimilar 
(n) (%)
446
37 (8.3)
316 (70.9)
93 (20.9)
-
-
-
129
16 (12.4)
79 (61.2)
34 (26.4)
-
-
-
Mean sB2 
dose (mg/
kg)
at initiation
at M12
369
273
7.2 (2.5)
7.7 (2.5)
5-10
5-10
107
78
7.1 (2.4)
7.6 (2.5)
5-10
5-10
Patients remaining on 
sB2 at M12 (n) (%) 273 261 (95.6) 92.4- 97.7* 78 73 (93.6) 85.7-97.9*
Patients with prior Ifx originator/ biosimilar exposure only:
Ifx TL (µg/
mL)
Baseline
M12
199
45
5.7 (4.5)
5.9 (4.7)
2.4-8.2
2.5-8.7
63
9
6.6 (5)
8.6 (6.6)
2.4 - 10.4
1.6-15.5
Total ada 
(µg/mL)
Baseline
M6
M12
179
94
47
0.8 (4.5)
0.55 (4.2)
0.001 (0.001)
0.0-8.23
0.0-0.01
0.0-0.01
62
26
1
0.8 (5.2)
0.01 (0.02)
0
0.01-0.01
0.0-0.01
0.0-0.0
hBI
Baseline
M12
Individual 
change: 
M12-
baseline
n 
272
222
187
Mean (sd) 
2.3 (3)
2.2 (2.4)
-0.34 (2.7)
95% cI 
2.0, 2.7
1.9, 2.5
-0.72, 0.04
n Mean (sd) 
-
-
-
95% cI 
-
-
-
sccaI
Baseline
M12
Individual 
change: 
M12-
baseline
 
-
-
-
-
-
-
81
60
58
1.4 (2.0)
1.03 (1.9)
-0.22 (2.5)
0.9, 1.8
0.54, 1.53
-0.89, 0.44
[Table 1: Baseline characteristics, SB2 persistence, TDM and disease scores 
Data extract date: 19 March 2019; *95% confidence interval]
disclosure: Biogen International GmbH funded and sponsored this study. 
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P1096 TuBercuLOsIs InfecTIOn under anTI-Tnf - shOuLd We 
Be LOOkIng fOr IT?
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Introduction: Anti-tumor necrosis factor (TNF) therapy revolutionized the 
treatment of inflammatory bowel disease. However, a major concern is the 
increased risk of developing tuberculosis (TB), which requires diagnosis 
and treatment of latent TB infection (LTBI) before initiation of anti-TNF 
agents. Currently, no recommendations exist regarding the need to regu-
larly re-test patients for latent TB during treatment.
aims & Methods: We aimed to assess the incidence and to identify risk fac-
tors for newly acquired TB infection in patients under anti-TNF. 
Adult patients under anti-TNF for over 12 months were retrospectively as-
sessed. Patients with a negative pre-treatment interferon-gamma releas-
ing assay (IGRA) that repeated IGRA during anti-TNF treatment were re-
viewed. Patients with a pre-treatment positive IGRA were excluded.
results: Out of 244 patients under anti-TNF (124 infliximab, 120 adalim-
umab), 87 patients were included. Patients had a mean age of 40±14 years, 
64.4% were females, 93.1% were under infliximab and 64.4% had Crohn’s 
disease. Positive repeat IGRA was identified in 9 patients (10.3% of our 
sample, 3.7% of all patients under anti-TNF in our center), of which 3 had 
active tuberculosis and 6 had LTBI. 
When comparing patients with and without positive repeat IGRA, no dif-
ferences were found regarding age (39.6 years vs 36.7 years, p=0.991) or 
gender (10.7% females vs 9.7% males, p=0.999). Patients with repeat posi-
tive IGRA more frequently had close contact with patients with TB (22.2% 
vs 0.0%, p= 0.010), however no differences were found regarding travels 
to TB-endemic areas (11.1% vs 7.7%, p=0.548), professional risk for TB in-
fection (11.1% vs 9.0%, p=0.999), concomitant treatment with immuno-
suppressants (77.7% vs 71.8%, p=0.999), use of systemic steroids during 
anti-TNF treatment (33.3% vs 35,9%, p=0,999), diabetes mellitus (11.1% 
vs 5.1%, p=0.429) or active smoking (22.2% vs 20.5%, p=0.999). Also, no 
differences were found regarding the duration of treatment at the time of 
repeat IGRA (30.2±26.7 months vs 42.5±30.1 months, p=0.640).
conclusion: In patients under anti-TNF, at least 3.7% of patients have a 
positive repeat IGRA after starting treatment. In our sample, only close 
contact with patients with TB was associated with a positive repeat IGRA. 
Therefore, considering that infection during treatment is present in a non-
negligible percentage of patients, and most of the classical risk factors can 
not be used to identify at-risk patients, physicians may consider routine 
repeat IGRA in patients under anti-TNF.
disclosure: Nothing to disclose 
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Introduction: Ustekinumab (UST), an IL12/23 blocker approved for Crohn’s 
disease, was effective in Phase 3 induction and maintenance studies of pa-
tients with moderate-severe ulcerative colitis (UC). Since discontinuation 
of corticosteroids (CS) is an important goal of therapy in UC, this analysis 
aims to further describe the CS sparing effects of ustekinumab treatment 
through Week 44 of the UNIFI trial.
aims & Methods: Responders to UST IV induction entered maintenance 
and were randomized to UST 90mg SC (q12wks or q8wks), or PBO. Dur-
ing the induction and maintenance studies, oral CS were not to be initi-
ated or increased beyond baseline. At Week 0 of the maintenance study, 
a scheduled taper was recommended for all patients receiving CS. CS-free 
Clinical Response (CSR) and remission (CSRem) rates (at Week 44, and 
for >90 days prior to Week 44) were calculated for the overall population 
and for the subset of patients on CS at maintenance baseline. Among the 
subset of patients on CS at maintenance baseline, the mean prednisone-
equivalent (P.Eq) CS dose (mg/day) through Week 44 were calculated as 
were the rates of subjects who were CS-free at Week 44 and for >90 days 
prior to Week 44
results: Overall 50.6% (265/523) of patients in the primary analysis popu-
lation were receiving CS at maintenance baseline. The proportions of pa-
tients who were receiving concomitant CS at maintenance baseline were 
52.3%, 47.7%, and 52.3% in the UST q8w, UST q12w and PBO groups, re-
spectively. As detailed in Table 1, in the overall population, CSR and CSRem 
rates were significantly higher for patients who continued on UST therapy 
during maintenance compared with placebo. Among the patients who 
achieved CSR or CSRem at Week 44, the majority achieved these endpoints 
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and eliminated CS use at or up to 90 days prior to Week 44. Similar results 
were observed in the subset of patients on concomitant CS at maintenance 
BL. In this group, the mean daily P.Eq CS dose at maintenance BL was ap-
proximately 15.0 mg/day for all treatment groups. Mean decrease in aver-
age daily P.Eq dose at Wk 44 was more pronounced and the proportion 
of patients who were CS-free was greater in the UST maintenance arms.
conclusion: UST maintenance therapy, with both q8w and q12w dosing 
regimens, is effective in reducing and eliminating the use of CS in patients 
with UC; the majority of patients (>90%) who achieved clinical response or 
clinical remission were able to eliminate corticosteroids.
Overall Population PBO Maintenance usT q12w usT q8w
Number of patients n=175 n=172 n=176
CRa at wk 44 (n,%) 84 (48.0%) 123 (71.5%)* 135 (76.7%)*
CSR at wk 44 (n, %) 80, 45.7% 120, 69.8%* 132, 75%*
CRem b at wk 44 (n,%) 43, 24.6% 68, 39.5%** 75, 42.6%*
CSRem at wk 44 (n, %) 41, 23.4% 65, 37.8%** 74, 42%*
CSRem >90 days prior to wk 44 (n, %) 39, 22.3% 64, 37.2%** 74, 42% **
Patients on CS at maintenance BL      
Number of patients n=91 n=82 n=92
CR a at wk 44 (n, %) 38, 41.8% 56, 68.3% ** 63,68.5% **
CSR at wk 44 (n, %) 34, 37.4% 53,64.6% ** 60,65.2% **
CRem b at wk 44 (n, %) 19, 20.9% 28, 34.1%* 37, 40.2% **
CSRem at wk 44 (n, %) 17, 18.7% 25, 30.5%** 36, 39.1% *
CSRem >90 days prior to wk 44 (n, %) 16, 17.6% 24, 29.3%** 36, 39.1% **
Mean decrease in the average daily P.Eq 
CS dose (mg/day)
-6.7 -11 -11.5
CS-free at wk 44 43, 47.3% 56, 68.3%* 73, 79.3%**
CS-free >90 days prior to wk 44 (n, %) 40, 44% 55, 67.1%* 71, 77.2%**
a. decrease from induction baseline in the Mayo score ≥ 30% & ≥ 3 points with either a 
decrease in rectal bleeding subscore (RBS) ≥ 1 or a RBS of 0 or 1
b. global definition: MAYO score ≤ 2 points with no individual subscore >1
*p<0.05
**p<0.001
CR: clinical response; CRem: clinical Remission; CSR: CS-free Response; CSRem: CS-free 
remission
[Table 1]
disclosure: Drs. Danese, Sands, Peyrin-Biroulet, Rowbotham, Leong, 
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employee of Janssen Biologics BV 
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Introduction: One of the new promising methods of treatment of patients 
with ulcerative colitis (UC) is biological therapy using bone marrow mes-
enchymal stromal cells (MSC). In some cases, simultaneously with MSC, 
patients receive concomitant anticytokine therapy. Currently, a new strategy 
for UC therapy is to achieve a deep remission of the disease. To compare 
the level of immunobiological and histological markers of inflammation—C-
reactive protein (CRP), the Geboes Score (GS) and faecal calprotectin (FCP) 
— in patients with UC receiving cell therapy MSC, anti-integrin therapy with 
vedolizumab (VDB), and combined therapy of bone marrow MSC and VDB.
aims & Methods: To compare the effectiveness of combined therapy of 
mesenchymal stromal cells and vedolizumab with monotherapy MSC and 
VDB. 45 patients with total ulcerative colitis of moderate severity were di-
vided into groups depending on the therapy. The first group of patients 
with UC aged from 19 to 51 years (Me-29) (n=15) received anti-inflammato-
ry therapy with the use of the culture of 2 million MSC/kg according to the 
scheme the second group of patients with UC (n=15) aged 23 to 50 years 
(Me-38) received VDB in accordance with the recommended scheme, the 
third group of patients with UC (n=15) aged 24 to 56 years (Me-31) received 
the MSC+VDB. The level of CRP, PCF and is was assessed 26 weeks after 
initiation of therapy. The baseline CRP was 24.6±1.8; 25.5±2.0 and 24.8±2.1 
mg/l, respectively. Baseline GS in the groups of patients was 4.6±0.4; 
4.35±0.25 and 4.5±0.3 points, respectively. The initial level of the FCP made 
1090±88.8; 1000±83.9 and 1010±120.5 µg/g, respectively.
results: After 26 weeks from the start of therapy in the first group of pa-
tients, the level of CPP was 7.8±2.1 mg/l, in the second group 7.4±1.3 mg/l, 
in the third group 7.5±1.0 mg/l (p>0.05). After 26 weeks from the start of 
therapy in the first group of patients, the level of FCP was 98.8±9.3 µg/g, 
in the second group 90.6±7.5 µg/g, in the third group 82.8±6.3 µg/g (p 
<0.05 compared with the 1-st and 3-d groups). After 26 weeks from the 
start of therapy in the first group of patients with GS was 0.7±0.1 points, in 
the second group 0.65±0.1 points, in the third-0.35±0.06 points (p<0.001 
compared with the 1-st and 3-d groups).
conclusion: Combined mesenchymal stromal cells and anti-integrin ther-
apy with vedolizumab contributes to a more pronounced reduction in the 
degree of inflammation of the intestinal mucosa.
disclosure: Nothing to disclose 
P1099 hIgh IncIdence Of hyPergLycaeMIa In sTerOId 
TreaTed hOsPITaLIsed InfLaMMaTOry BOWeL dIsease (IBd) 
PaTIenTs and ITs rIsk facTOrs IdenTIfIed By MachIne 
LearnIng MeThOds
Harris R.1, McDonnell M.1, Mills T.1, Dharmasiri D.2, Downey L.1, 
Felwick R.1, Phan H.3, Borca F.3, Cummings F.1, Gwiggner M.1
1University Hospital Southampton, Gastroenterology, Southampton, United 
Kingdom, 2Royal Bournemouth Hospital, Gastroenterology, Bournemouth, 
United Kingdom, 3University of Southampton, CIRU, Southampton, United 
Kingdom
contact e-Mail address: richard.harris3@uhs.nhs.uk
Introduction: Glucocorticoids (GC) have been first line treatment for hos-
pitalised inflammatory bowel disease (IBD) patients for over 60 years, 
despite the introduction of biologic therapy. The use of steroids in IBD 
inpatients is common and remains prominent in international guide-
lines. IBD patients often have systemic inflammation complicated by 
malnutrition leading to metabolic stress. The frequency and specific risk 
factors for hyperglycaemia in hospitalised IBD patients receiving GC are 
unknown
aims & Methods: 100 consecutive IBD inpatients receiving intravenous 
hydrocortisone (IVH) for acute flares had capillary blood glucose (CBG) 
monitoring automatically triggered by the electronic prescription. CBG, 
biomarkers, IBD severity scores (Harvey Bradshaw, partial Mayo) and 
weight loss were prospectively recorded. Undiagnosed Diabetes Mellitus 
(DM) was defined as baseline HbA1c >48 mmol/mol. Machine learning 
(random forest regressor, RFR) was applied to the data to evaluate risk 
factors of hyperglycaemia.
results: 55% of hospitalised IVH treated IBD patients had a CBG meet-
ing the WHO criteria of DM (>11mmol/L), while 21% and 7% had a CBG 
>14mmol/l and >20mmol/l, respectively. Only 7 patients had pre-existing 
DM, which was confirmed by admission HbA1c. RFR indicated disease se-
verity score, duration of IVH, HbA1c and electrolyte imbalances (which af-
fected 64%) were best predictors of hyperglycaemia. 
50% were started on or switched biological therapy during hospitalisa-
tion. 59% were discharged on prednisolone, 14% on budesonide and 28% 
on no GC. 47 patients had HbA1c checked at 3 month follow-up of which 
4 were in the diabetic range. 1 had known DM with elevated CBG during 
admission treated with insulin titration, 2 had elevated CBG as inpatients 
with no prior DM and were discharged on anti-diabetic medications (1 gli-
clazide, 1 insulin) and 1 was on long-term steroids for asthma who did not 
have CBG >11.0mmol/L as an inpatient. 4 patients discharged on gliclazide 
for steroid induced DM had documented repeat HbA1c recorded, which 
were all in the normal range. 
conclusion: Our data demonstrates that hyperglycaemia is common in IVH 
treated inpatients, therefore CBG monitoring should be routine practice. 
Predictive modelling (RFR) identifies more severe disease activity, duration 
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of IVH treatment and HbA1c as risk factors for hyperglycaemia. The im-
portance of IVH duration suggests hyperglycaemia risk may be physician-
modifiable. 
Alternative treatment strategies such as earlier introduction of biologics 
(which were used in half of the cohort), rapid steroid taper and nutritional 
therapies could be used to minimise medication associated metabolic 
instability in high risk patients. Limited follow-up HbA1c data suggests 
oral hypoglycaemic medication may be effective to mitigate further 
hyperglycaemia.
disclosure: Nothing to disclose
  crohn‘s ulcerative colitis IBd-u combined
Total 56 39 7 100
female (%) 27 (48%) 20 (54%) 4 (57%) 51 (51%)
age (range) 41 (18-80) 45 (16-80) 47 (25-75) 43 (16-80)
disease duration 7 (0-52) 5 (0-18) 2 (0-11) 6 (0-52)
BMI 24 (15-36) 25 (16-40) 23 (16-28) 24 (15-40)
hBI / p.Mayo 15 (6-37) 8 (5-12) 5 (2-9) n/a
admission crP 64 (0-303) 84 (0-440) 166 (24-300) 78 (0-440)
calprotectin 2619 (7-7049) 3345 (628-7091) 2815 (218-6000) 2897 (7-7091)
Pre-existing dM 6 (11%) 1 (3%) 0 7 (7%)
Max cBg >11.0 28 (49%) 22 (59%) 5 (71%) 55 (55%)
Max cBg >14.0 14 (25%) 5 (14%) 2 (29%) 21 (21%)
Max cBg >20 6 (11%) 1 (3%) 0 (0%) 7 (7%)
[Cohort Characteristics and Frequency of Hyperglycaemia]
P1100 IMPacT Of MIrIkIzuMaB TreaTMenT On InfLaMMaTOry 
BOWeL dIsease quesTIOnnaIre scOres In PaTIenTs WITh 
MOderaTe TO severeLy acTIve crOhn’s dIsease
Sands B.1, Sandborn W.2, Peyrin-Biroulet L.3, Higgins P.4, Hirai F.5, 
Jairath V.6, Belin R.7, Dong Y.7, Gomez Valderas E.7, Miller D.7, 
Morgan-Cox M.7, Naegeli A.7, Pollack P.7, Tuttle J.7, Hibi T.8
1Icahn School of Medicine at Mount Sinai, New York, United States, 
2University California San Diego, La Jolla, United States, 3University Hospital 
of Nancy, Nancy, France, 4University of Michigan, Ann Arbor, United States, 
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Lilly and Company, Indianapolis, United States, 8Kitasato Institute Hospital 
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contact e-Mail address: miller_debra_l@lilly.com
Introduction: Mirikizumab (miri; LY3074828) is a humanized monoclonal 
antibody directed against the p19 subunit of IL-23, with efficacy demon-
strated in psoriasis, ulcerative colitis, and Crohn’s disease (CD). The ef-
fect of miri on health-related quality of life (HRQoL) as measured by the 
Inflammatory Bowel Disease Questionnaire (IBDQ) was examined as part 
of a Phase 2, multicenter, randomized, parallel-arm, double-blind placebo 
(PBO)-controlled trial (NCT02891226) in patients with moderate to severely 
active CD.
aims & Methods: At baseline, subjects (N =191) were randomized in a 
2:1:1:2 ratio across 4 treatment arms (PBO, 200, 600, and 1000 mg miri 
administered intravenously [IV] at Weeks 0, 4, and 8). The IBDQ, a 32-
item patient-completed questionnaire that measures 4 domains (bowel 
and systemic symptoms, emotional and social function), was analyzed at 
Weeks 0, 4, and 12, with higher scores indicating a better quality of life. 
IBDQ score change from baseline (BL), IBDQ response, and IBDQ remission 
were assessed. Treatment comparisons were made using mixed effects for 
repeated measures analysis for continuous endpoints and logistic regres-
sion with nonresponder imputation for categorical endpoints
results: Patients who received 600 or 1000 mg miri had greater change 
from BL in IBDQ scores at 4 weeks compared to PBO (PBO: 15.18±3.30; miri 
200 mg: 24.16±4.83; 600 mg: 27.08±4.77; 1000 mg: 25.52±3.36; 600 and 
1000 mg miri p< 0.05 vs PBO). At 12 weeks, all miri groups had greater 
change from BL in IBDQ scores compared to PBO (PBO: 16.23±3.65; 200 
mg: 41.14±5.18; 600 mg: 45.50±5.22; 1000 mg: 41.22±3.64; all p< 0.001 vs 
PBO). Similarly, at Week 12 IBDQ response was achieved in 58.1%, 68.8%, 
and 68.8% of patients in miri 200, 600, and 1000 mg groups, compared 
to 45.3% in the PBO group (600 mg p< 0.1, 1000 mg p< 0.01), and IBDQ 
remission was achieved in 35.5%, 53.1%, and 42.2% of patients in the miri 
200, 600, and 1000 mg groups, respectively, compared to 15.6% in the PBO 
group (200 mg p< 0.1, 600 and 1000 mg p< 0.001).
conclusion: Miri treatment produced statistically significant and clinically 
meaningful improvements in HRQoL as measured by IBDQ after 12 weeks 
in patients with CD, with clinically relevant changes noted as early as 4 
weeks.
disclosure: This study was funded by Eli Lilly and Company. 
  Treatment groups
  Placebo Mirikizumab
Mean (sd) unless otherwise 
specified (n=64)
200 mg
(n=31)
600 mg
(n=32)
1000 mg
(n=64)
Week 0
age, years 39.0
(13.0)
38.1
(11.8)
40.4
(13.3)
37.7
(13.1)
Male, n (%) 28
(43.8)
17
(54.8)
14
(43.8)
34
(53.1)
corticosteroid use, n (%) 21
(32.8%)
14
(45.2%)
7
(21.9%)
15
(23.4%)
disease duration, years 10.2
(9.8)
8.9
(7.4)
10.8
(9.7)
8.6
(6.7)
Previous biologic use, n (%) 43
(67.2)
19
(61.3)
19
(59.4)
39
(60.9)
disease location, n (%)
Ileal 11
(17.2)
6
(19.4)
5
(15.6)
11
(17.2)
colonic 25
(39.1)
14
(45.2)
10
(31.3)
26
(40.6)
Ilealcolonic 28
(43.8)
11
(35.5)
17
(53.1)
27
(42.2)
IBdq 113.88
(37.07)
104.77
(34.31)
127.03
(35.47)
120.31
(32.40)
Week 4
IBdq change from BL, LsM (se) 15.18
(3.30)
24.16
(4.83)
27.08
(4.77)*
25.52
(3.36)*
Week 12
IBdq change from BL, LsM (se) 16.23
(3.65)
41.14
(5.18)***
45.50
(5.22)***
41.22
(3.64)***
IBdq responsea, n (%) 29
(45.3)
18
(58.1)
22
(68.8)
44
(68.8)
% difference vs PBO (95%cI) --- 12.8
(-8.5, 34.0)
23.4*
(3.3, 43.6)
23.4**
(6.8, 40.10)
IBdq remissionb, n (%) 10
(15.6)
11
(35.5)
17
(53.1)
27
(42.2)
% difference vs PBO (95%cI) --- 19.9*
(0.8, 38.9)
37.5***
(18.1, 56.9)
26.6***
(11.5, 41.6)
aIBDQ response: ≥16-point improvement in IBDQ score.
bIBDQ remission: total IBDQ score ≥170. 
BL=baseline; BMI=body mass index; CI=confidence interval; IBDQ=Inflammatory Bowel 
Disease Questionnaire; LSM=least squares mean; PBO=placebo; SD=standard deviation; 
SE=standard error; vs=versus; *p<0.1 **p<0.01 ***p<0.001 vs PBO. 
[Table 1.]
P1101 TuBercuLOsIs InfecTIOn In InfLaMMaTOry BOWeL 
dIsease PaTIenTs WhO receIved BIOLOgIc agenTs: a sIngLe 
cenTer exPerIence Of 20 years
Dashdamirova S.1, Hatemi A.I.2, Erzin Y.Z.2, Tuncer M.2, Celik A.F.2
1Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Internal 
Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Cerrahpasa 
School of Medicine, Gastroenterology, Istanbul, Turkey
contact e-Mail address: ihatemi@yahoo.com
Introduction: TNF-alpha blockers increase the risk of tuberculosis (TB) 
infection. This risk is especially important in countries which have a high 
rate of TB infection. The incidence of TB infection in Turkey was reported as 
15.2 / 100.000 in 2017 which shows that in our country we should be alert 
about the risk of TB infection in inflammatory bowel disease (IBD) patients 
who receive immunosuppressive treatment.
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aims & Methods: The aim of this retrospective study is to determine the 
rate of latent and active tuberculosis infection in IBD who received bio-
logic treatment in our center.: 349 IBD patients who received TNF-alpha 
antagonist treatment from 1998 to 2018 were included in the study. Infor-
mation about the demographic data, IBD type, previous and current treat-
ment, latent TB screening results, duration of isoniazid (INH) prophylaxis 
treatment, lung imaging results, and diagnosis of active TB infection was 
obtained from patients’ files and electronic data system of our hospital.
results: A total of 349 patients (56.4 % male, mean age 42 ± 14 years) were 
included in the study, the mean disease duration was 10 ± 6 years, 76.5% 
had Crohn’s disease. Taking into account that some of the patients had 
received more than one type of anti-TNF alpha agent; 77% of the patients 
(n = 269) received infliximab, where 48.1% (n = 168) received adalimumab, 
5.7% (n = 20) received certolizumab, 5.4% (n = 19) received vedolizumab, 
and 1.1% (n = 4) received golimumab. Latent tuberculosis infection screen-
ing was positive in 171 (48.9%) patients (157 tuberculin test > 5 mm and 14 
positive Quantiferon test), 96.4% (n = 165) of these patients had received 
INH treatment for latent TB. Incidence of active TB development was 1.7% 
(n = 6). Two of them had received INH treatment. In two latent tuberculosis 
screening was negative. The remaining two patients were inadequately 
screened: one of them had a negative tuberculin test but Quantiferon test 
was not obtained, the other patient had a borderline positivity of Quan-
tiferon test. In three patients with active TB infection, pulmonary TB was 
accompanied by extra-pulmonary infection (Table). Two patients had TB 
infection after 4 years of TNF-alpha antagonist treatment, which can be 
the result of a new TB exposure. In 2 patients anti-TNF treatment was 
initiated again after then tuberculosis treatment was completed. None of 
these 2 patients developed tuberculosis reactivation. No association was 
found between the risk of developing TB and gender, age, disease type, 
type of TNF-alpha antagonist agent used and concomitant immunosup-
pressive therapy. 
Treatment 
at the 
diagnosis 
of TB
Inh 
treatment 
for latent 
TB infection 
(months)
PPd 
(mm)
quantiferon 
test
duration of Tnf-
alpha antagonist 
treatment before 
the diagnosis of 
TB (months)
Location of TB 
infection
AZA CS 
5-ASA ADA
- 0 Negative 7
Lung +spleen 
+peritoneum
AZA ADA 9 6 Negative 48 Lung
5-ASA IFX - 0 Negative 44 Lung
AZA IFX - NA undetermined 2 Lung
AZA IFX - 0 NA 7
Lung+lymph 
nodes
AZA ADA 6 9 NA 3 Lung+spleen
[Patients who had TB infection]
Abbreviations for the table : AZA: azathioprine ADA: Adalimumab CS: Cor-
ticosteroids IFX: Infliximab INH: Izoniazide NA:Not available TB: Tubercu-
losis
conclusion: Active TB infection was detected in 1.7% (n = 6) of the 349 IBD 
patients who had biologic treatment during a period of 20 years. Two of 
these 6 patients have had isoniazid treatment for latent TB, in 2 of them 
screening for latent TB was negative. As a result although latent tuberculo-
sis screening and treatment are recommended by guidelines, this modality 
may not be sufficient to eliminate the risk of TB infection in patients who 
receive biologics agents in countries with high incidence of TB infection.
disclosure: Nothing to disclose 
P1102 effIcacy and IMPrOved heaLTh-reLaTed quaLITy Of 
LIfe afTer 52-Weeks Of MIrIkIzuMaB TreaTMenT In PaTIenTs 
WITh uLceraTIve cOLITIs: an uPdaTe frOM a randOMIsed, 
dOuBLe-BLInd, cOnTrOLLed, Phase 2 sTudy
Ferrante M.1, Sandborn W.2, Bandhari B.R.3, D’Haens G.4, Feagan B.5,6, 
Durante M.7, Arora V.7, Tuttle J.7, Naegeli A.7
1Universitair Ziekenhuizen Leuven, Leuven, Belgium, 2University California 
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contact e-Mail address: naegeli_april_n@lilly.com
Introduction: The efficacy and safety of mirikizumab (miri), an IL-23p19 
antibody, has previously shown efficacy and health-related quality-of-life 
(HRQoL) improvement in patients with moderate-to-severe ulcerative coli-
tis (UC) at 12 weeks in a phase 2, randomized, double-blind, placebo-
controlled trial (AMAC, NCT02589665).
aims & Methods: This analysis evaluated the effects of maintenance treat-
ment with miri on clinical response, clinical remission, endoscopic healing, 
and HRQoL improvement in UC patients. Patients with moderate-to-severe 
UC (Mayo score 6-12; Endoscopic subscore ≥2) treated with miri during the 
induction period and who achieved clinical response or better at week 12 
were re-randomized to miri 200 mg administered subcutaneously every 
4 weeks (Q4W) (N=47) or every 12 weeks (Q12W) (N=46) through week 52. 
HRQoL was measured by the Inflammatory Bowel Disease Questionnaire 
(IBDQ) and evaluated using a mixed-model repeated-measures analysis. 
The percentage of patients at week 52 with clinical response,1 clinical re-
mission,2 endoscopic healing,3 IBDQ total score ≥170, and IBDQ improve-
ment ≥16 were also assessed.
results: At week 52, IBDQ scores significantly improved from baseline 
in both miri treatment groups (Table). In each treatment group, at week 
52, ≥80% of patients had an improvement in IBDQ total score ≥16 points 
from baseline and ≥67% achieved IBDQ total score ≥170. Similarly, ≥76% 
of patients demonstrated a clinical response, ≥37% demonstrated clinical 
remission, and ≥48% demonstrated endoscopic healing at week 52.
conclusion: Maintenance treatment with miri resulted in HRQoL improve-
ment as well as clinical response, clinical remission, and endoscopic heal-
ing at week 52 in patients with moderate-to-severe UC. These are the first 
data in UC to demonstrate the longer-term effects of an IL-23p19 antibody 
on the HRQoL of patients with UC.
disclosure: Study was funded by Eli Lilly and Company. 
 
Mirikizumab q4W
(n=47)
Mirikizumab q12W
(n=46)
Baseline IBdq total score, Ls mean (se) 
observed
n=46
121 (4)a
n=46
127 (4)a
IBdq total score change from baseline at 
Week 12, Ls mean (se)
n’=46
54 (4)b
n’=46
47 (4)b
IBdq total score change from baseline at 
Week 52, Ls mean (se)
n’=42
58 (4)b
n’=43
51 (4)b
IBdq total score improvement ≥16 at Week 
52, n (%) nrI
n‘=46
39 (85) 37 (80)
IBdq total score ≥170 at Week 52, n (%) nrI n’=46
31 (67) 31 (67)
clinical response1</sup at Week 52, n (%) nrI 38 (81) 35 (76)
clinical remission2 at Week 52, n (%) nrI 22 (47) 17 (37)
endoscopic healing3 at Week 52, n (%) nrI 27 (57) 22 (48)
aAnalysis of variance model for baseline measures with treatment as the variable. 
bp<0.001 vs baseline (Week 0), based on the MMRM model for post-baseline measures 
with baseline, geographical region, prior biologic therapy, treatment, time, and 
treatment*time as variables. 
1Clinical response: 9-point Mayo score (comprising the subscores of rectal bleeding, 
stool frequency, and the endoscopic findings) decrease ≥2 points and ≥35% change from 
baseline, with rectal bleeding=0,1 or decrease ≥1. 
2Clinical remission: rectal bleeding=0, stool frequency=0,1 with ≥1 point decrease from 
baseline, endoscopy=0,1. 
3Endoscopic healing: Mayo endoscopic subscore=0,1.
LS=least squares; NRI=nonresponder imputation, used for missing values; n‘= number 
of subjects in the population with baseline and post-baseline value at the specified time 
point; SE=standard error.
[Table 1.]
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P1103 sILver nanOParTIcLes Based On BLackcurranT 
exTracT aLLevIaTe dss-Induced cOLITIs In MIce
Krajewska J.B.1, Dlugosz O.2, Banach M.2, Fichna J.1
1Medical University of Lodz, Department of Biochemistry, Lodz, Poland, 
2Cracow University of Technology, Faculty of Chemical Engineering and 
Technology, Cracow, Poland
contact e-Mail address: krajewska.julia@gmail.com
Introduction: Inflammatory Bowel Disease (IBD) is a chronic, severely de-
bilitating disease which cannot be pharmacologically controlled due to 
ineffective activity or serious side effects of current therapies. In the search 
for new treatment options, we examined the anti-inflammatory potential 
of two preparations of silver particles in vitro in lipopolysaccharide (LPS)-
stimulated RAW264.7 cells and in vivo in murine dextran sulphate sodium 
(DSS)-induced colitis model.
aims & Methods: The nanoparticles were obtained with the use of black-
currant extract exploiting the reducing and stabilizing potential of poly-
phenols, ascorbic acid and anthocyanins. The concentration of polyphenol 
compounds equaled 75 mg/dm3 and the extract showed high capacity for 
free radicals binding, as evidenced by1,1-Diphenyl-2-picrylhydrazyl (DPPH) 
radical reduction assay. Based on UV-VIS analysis, the obtained, round 
nanoparticles show homogenous distribution and are well-dispersed 
within suspension. Two formulations were prepared, with final silver 
nanoparticle concentration equal to 100 and 500 mg/dm3 and the mean 
particle diameters of 95 nm (Ag95) and 213 nm (Ag213), respectively. High-
er silver concentration was associated with larger particles.
results: In vitro, Ag95 and Ag213 did not show any significant cytotoxicity 
in RAW264.7 cells up to 1 and 2.5 ppm, respectively, as evidenced in Neu-
tral Red Uptake test. Opposite to the model drug, 10 uM budesonide, the 
preparations did not increase viability of LPS-stimulated cells. However, 
Ag95 at 1 ppm and Ag213 at 2.5 ppm were more effective in NO production 
inhibition, as evaluated by Griess test.
In vivo, both suspensions of silver particles showed anti-inflammatory 
properties in DSS-induced murine model of colitis. The studied prepa-
rations inhibited weight loss, decreased macroscopic score and colon 
shortening. Additionally, Ag95 and Ag213 reduced neutrophil infiltration 
assessed by myeloperoxidase activity assay. When tested at the same dose 
(0,4mg/kg, once daily, i.c.), Ag213 was more effective than Ag95. Higher 
dose (2 mg/kg) further improved Ag213 performance.
conclusion: The anti-inflammatory action of silver preparations may be 
useful in IBD treatment. The objective is to maintain high anti-inflammato-
ry potential, simultaneously minimizing the risk of side effects. The tested 
formulations Ag95 and Ag213, showing good bioavailability and activity, 
meet these requirements, which warrants further characterization.
disclosure: Nothing to disclose 
P1104 IncIdence and IndIcaTOrs Of suBOPTIMaL resPOnse 
TO TuMOr necrOsIs facTOr anTagOnIsT TheraPy In 
InfLaMMaTOry BOWeL dIsease In neWLy IndusTrIaLIzed 
cOunTrIes: resuLTs frOM The exPLOre sTudy
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Introduction: Inflammatory bowel disease (IBD) patients in Western coun-
tries frequently experience suboptimal response to anti-tumor necrosis 
factor (TNF) therapy. The EXPLORE study aimed to assess the incidence 
and indicators of suboptimal response to first-line anti-TNF agents in IBD 
patients in real-world practice in newly industrialized countries, where 
data are currently limited.
aims & Methods: A retrospective chart review study was conducted in 
Asia-Pacific (APAC; South Korea, China, Taiwan, Singapore), Latin America 
(LatAm; Argentina, Colombia, Mexico) and Russia-Middle East (RME; Rus-
sia, Saudi Arabia, Turkey) in adult patients diagnosed with ulcerative coli-
tis (UC) or Crohn’s disease (CD), who initiated anti-TNF treatment between 
March 2010 and March 2015. The cumulative incidence (CI) of suboptimal 
response (Kaplan-Meier method) was assessed over the first 24 months of 
treatment, as the occurrence of a first indicator of: IBD-related hospitaliza-
tion, dose escalation (increase in frequency and/or dose), discontinuation 
including switch to another anti-TNF, non-biologic therapy augmentation, 
or IBD-related surgery. Primary non-response (PNR) and secondary loss 
of response (SLOR) were defined as any suboptimal response indicator 
at < 4 and ≥4 months after anti-TNF initiation (excluding PNR patients), 
respectively.
  Overall aPac Latam rMe
  uc (n=570) cd (n=1104) uc (n=173) cd (n=497) uc (n=99) cd (n=86) uc (n=298) cd (n=521)
Overall frequency of suboptimal response, n (%) 188 (33.0) 454 (41.1) 81 (46.8) 253 (50.9) 36 (36.4) 40 (46.5) 71 (23.8) 161 (30.9)
cumulative incidence of suboptimal response, %                
12 months 24.4 30.0 34.4 40.4 25.9 30.7 18.2 19.9
24 months 32.9 41.2 45.1 54.1 38.2 42.5 23.8 29.5
cumulative incidence of Pnra, % 13.6 16.9 20.2 26.5 11.4 10.8 10.5 8.6
cumulative incidence of sLOrb, %                
12 months 12.6 15.8 17.8 18.9 16.4 22.4 8.5 12.4
24months 22.3 29.2 31.2 37.5 30.2 35.6 14.8 22.9
first indicator of suboptimal responsec, n (%) uc (n=188) cd (n=454) uc (n=81) cd (n=253) uc (n=36) cd (n=40) uc (n=71) cd (n=161)
Anti-TNF dose escalation 23 (12.2) 65 (14.3) 3 (3.7) 34 (13.4) 12 (33.3) 9 (22.5) 8 (11.3) 22 (13.7)
Non-biological therapy augmentation 57 (30.3) 108 (23.8) 25 (30.9) 68 (26.9) 15 (41.7) 14 (35.0) 17 (23.9) 26 (16.1)
Anti-TNF discontinuation including switch 45 (23.9) 42 (9.3) 31 (38.3) 18 (7.1) 5 (13.9) 4 (10.0) 9 (12.7) 20 (12.4)
IBD-related surgery 7 (3.7) 79 (17.4) 2 (2.5) 35 (13.8) 2 (5.6) 8 (20.0) 3 (4.2) 36 (22.4)
IBD-related hospitalizations 62 (33.0) 164 (36.1) 20 (24.7) 99 (39.1) 6 (16.7) 5 (14.6) 36 (50.7) 60 (37.3)
APAC: Asia-Pacific; CD: Crohn’s Disease; IBD: Inflammatory Bowel Disease; LatAm: Latin America; RME: Russia-Middle East; TNF: tumor necrosis factor; UC: Ulcerative colitis. aCumulative 
incidence at 4 months. bSLOR among patients who did not experience PNR and who are still on anti-TNF at 4 months. c6 UC and 4 CD patients had more than one suboptimal response 
indicator on the same day.
[P1104 Table 1. Cumulative Incidence and Indicators of Suboptimal Response to First-Line Anti-TNF Therapy in IBD Patients in Newly Industrialized Countries]
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results: Overall, 1674 first-line anti-TNF treated patients (570 UC; 1104 
CD) were included: male, UC 56.1%, CD 61.2%; median (min-max) age 
(years), UC 39.0 (18-82), CD 31.0 (19-83); median (min-max) disease dura-
tion (years), UC 3.0 (0-34), CD 1.0 (0-33); median (min-max) follow-up 
(months), UC 45.9 (24-60), CD 46.5 (14-60). At 24 months, the CI of subopti-
mal response to first anti-TNF treatment was 32.9% in UC and 41.2% in CD 
patients (unadjusted log-rank: p< 0.01); the APAC region had the highest CI 
(UC 45.1%; CD 54.1%) (Table 1). The CI of PNR was 13.6% and 16.9% in UC 
and CD patients, respectively. The CI of SLOR was 22.3% in UC and 29.2% 
in CD patients at 24 months. The most frequent first suboptimal response 
indicator was ‘IBD-related hospitalization’ (UC 33.0%; CD 36.1%) followed 
by ‘non-biologic augmentation’ (UC 30.3%; CD 23.8%) (Table 1).
conclusion: Suboptimal response to first-line anti-TNF agents is common 
in IBD patients in newly industrialized countries and is more frequently 
experienced in CD than in UC. Observed regional differences in the rates of 
suboptimal response, PNR and SLOR, may reflect local practice variations 
and restrictions in the management of anti-TNF treated patients.
disclosure: The study was funded by Takeda Pharmaceuticals Company Ltd. 
P1105 vedOLIzuMaB Induces deeP reMIssIOn and IMPrOves 
quaLITy Of LIfe In PaTIenTs WITh InfLaMMaTOry BOWeL 
dIseases: The ancOna exPerIence
Quatraccioni C., Annulli G., Daretti L.M., Antuono S., Calzolari M., 
Guardati P., Benedetti A., Di Sario A.
Ospedali Riuniti di Ancona, Clinica di Gastroenterologia, Epatologia ed 
Endoscopia Digestiva d’Urgenza, Ancona, Italy
contact e-Mail address: cla.quatraccioni@gmail.com
Introduction: Vedolizumab (VDZ) is an α4β7 integrin antagonist approved 
for the treatment of adult patients (pts) with moderate to severe ulcerative 
colitis (UC) and Crohn’s disease (CD).
aims & Methods: The primary outcome of the study was to evaluate the 
effect of VDZ on clinical response in pts with UC and CD at the 14th week. 
Secondary outcomes were to evaluate clinical remission, mucosal healing, 
deep remission, steroid-free remission and quality of life at different time 
points (14th week, 6, 12 and 24 months).
We retrospectively evaluated 39 pts who referred to our Inflammatory 
Bowel Disease Unit and received VDZ for moderate-severe UC (26 pts) 
and moderate-severe CD (13 pts). As concerns the UC and CD outcomes, 
clinical response was defined by a reduction in Mayo score ≥3 points and 
in Harvey-Bradsaw index (HBI) ≥3 points, clinical remission by a Mayo 
score ≤2 and by a HBI < 5 and endoscopic remission by endoscopic Mayo 
subscore ≤1 and by endoscopic SES-CD score ≤2, respectively. Steroid free-
remission was evaluated in UC pts only. Deep remission was defined, in 
both diseases, as clinical, endoscopic and biochemical remission. Serum 
C-reactive protein (CRP) and faecal calprotectin (FC) were evaluated in pts 
at all time points. Quality of life (QoL) was evaluated by the 32-item version 
of Inflammatory Bowel Disease Questionnaire (IBDQ-32).
results: UC pts: 12 out of 26 UC pts had previously failed anti-TNF therapy; 
clinical response at the 14th week was observed in 77% of the pts and no 
significant differences were found between naive and anti-TNF treated 
pts. Non-responder pts showed a more severe Mayo endoscopic subscore 
(2.8 vs 2.2; P< 0.02). Clinical remission occurred in 60%, 64%, 67% and 
75% of pts at the 14th week, 6, 12 and 24 months, respectively. Steroid-free 
remission was 85% (17/20) at the 14th week and 75% at 24 months. Mu-
cosal healing was above 70% at all time points. In pts who had a clinical 
response, FC levels decreased from 529.15 mg/kg at baseline to 103.7 mg/
kg at the 14th week and was always less than 50 mg/kg after 6, 12 and 24 
months. Similarly, CRP levels decreased from 1.85 mg/dl at baseline to 
0.9 mg/dl at the 14th week, and were within the normal range (< 0.50 mg/
dl) after 12 and 24 months. Deep remission was 35% at the 14th week and 
75% at 24 months. QoL in responder pts was 131±34 at baseline, signifi-
cantly increased after 14 weeks (171,9±29; P< 0.001) and remained stable 
over time. 
CD pts: 12 out of 13 pts had previously failed anti-TNF therapy; clinical re-
sponse at the 14th week was observed in 46% of the pts, whereas clinical 
remission rates were 100%, 80%, 100% and 100% at the 14th week, 6, 12 
and 24 months, respectively. Mucosal healing was observed in 25% of pts 
at 12 months and in 100% of pts at 24 months, whereas deep-remission 
was achieved in 25% and 50% of pts at the same time points. In responder 
pts, FC, CRP and QoL showed a significant improvement starting from the 
6th month. 
Advers events were observed in 5/39 pts: psoriasis (2 pts), joint symptoms 
(1 pt), arterial hypertension (1 pt) and mild urticaria (1 pt); however only 1 
pt with psoriasis had to discontinue the treatment.
conclusion: VDZ was effective and safe for induction and maintenance of 
deep remission and of steroid-free remission in pts with UC, and signifi-
cantly improved their QoL; serum CRP and FC levels correlated with clinical 
response. Even if data in CD pts are limited, VDZ appeared effective for 
induction and maintenance of clinical and endoscopic remission also in 
these pts, although the improvement in biochemical indices and in the QoL 
required at least 6 months.
disclosure: Nothing to disclose 
P1106 PerIPheraL BLOOd MeThyLaTIOn PrOfILes are sTrOng 
PredIcTOrs Of resPOnse and nOn-resPOnse TO InfLIxIMaB 
and vedOLIzuMaB In crOhn’s dIsease
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Introduction: Crohn’s disease (CD) remains an incurable condition de-
spite expanding therapeutic options. Treatment are randomly initiated 
and switched in case of insufficient response. Biomarkers that allow pre-
diction of response offering guidance for treatment selection are lacking, 
leading to poor disease control and complications. Epigenetics, mainly 
DNA methylation patterns, have been shown to predict CD behavior and 
recurrence. We investigated the predictive power of peripheral blood (PB) 
methylation profiles in CD patients treated with infliximab (IFX) or vedoli-
zumab (VDZ).
aims & Methods: We identified CD patients who were distinct responders 
(R) and non-responders (NR) to IFX and VDZ based on clinical and endo-
scopic criteria who were prospectively sampled in the biobank Future-IBD 
at Amsterdam UMC. DNA was isolated from PB at baseline and 8 weeks 
into treatment. Methylation screening was performed using the Infinium® 
Methylation EPIC Bead Chip (850K) by Illumina (San Diego, CA). Response 
assessment was performed after 12-16 weeks.
results: In this pilot study we analyzed 12 CD patients treated with IFX (6 R 
and 6 NR) and 12 with VDZ (5 R and 7 NR). Analysis of differentially methyl-
ated positions (DMPs) between R and NR both before and after induction 
treatment yielded 38 DMPs for IFX and 9 DMPs for VDZ, both at a Benja-
min-Hochberg adjusted α of 0.05. For IFX, all DMPs showed a complete 
separation of responders and non-responders and a striking mean meth-
ylation difference of at least 10% between responders and nonresponders. 
Similar results, but for distinct loci, were obtained in the VDZ cohort. The 
largest effect size with complete separation of R and NR to VDZ showed a 
methylation difference of >30%.
conclusion: DMPs associated with response/nonresponse to IFX and VDZ 
were mutually exclusive indicating that both marker sets are specific for 
each treatment. We observed large methylation differences between R and 
NR which is exceptional in complex diseases like CD. These observations 
open the road to personalized treatment selection in CD. Further validation 
of these markers is ongoing.
disclosure: Nothing to disclose 
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P1107 cOMParIng The desIgn Of TWO recenT MesaLazIne 
TrIaLs WITh resPecT TO eMa guIdeLIne On The deveLOPMenT 
Of neW MedIcInaL PrOducTs fOr The TreaTMenT Of 
uLceraTIve cOLITIs
Laoun R.1, Hofmann R.2
1Tillotts Pharma AG, Medical Affairs, Rheinfelden, Switzerland, 2Tillotts 
Pharma AG, Medical Affairs Director, Rheinfelden, Switzerland
contact e-Mail address: raphael.laoun@tillotts.com
Introduction: Developing a new drug for treating ulcerative colitis (UC) is 
challenging. More challenging is the clinical trial design.
aims & Methods: We highlight the phase 3 trial design of a new 5ASA drug 
(TP0503) and compare it to the latest EMA “guideline on the development 
of new medicinal products for the treatment of Ulcerative Colitis” from 
2018. We also compare TP0503 to another recent mesalazine trial (SAT25). 
We also compare TP0503 to another recent mesalazine trial (SAT25).
Each item in the EMA guideline was compared to TP0503 protocol (Mesala-
zine 1600 mg vs. Mesalazine 400 mg; NCT01903252) and SAT25 (Mesalazine 
1000 mg vs. Mesalazine 500 mg; NCT01745770). This comparison covers the 
patient selection (section 4 of EMA guideline), efficacy assessment (section 
5) and study design (section 6). Safety aspects (section 7) and the risk man-
agement plan (section 8) were well-respected by both trials.
results: As per EMA guideline, patient selection in TP0503 and SAT25 was 
based on symptoms, endoscopic and histologic findings. Patients with 
malignancy and Clostridium D. infection were excluded from TP0503. Pa-
tients with malignancy were not clearly excluded from SAT25. While both 
trial designs relied on endoscopic score to include or exclude patients, 
SAT25 used Rachmilewitz Endoscopic score (EI) which is less widely used 
than the Mayo Endoscopic Score (MES). SAT25 included patients with EI≥4 
(mild to severe) without relying on central reading. All TP0503 patients 
had higher endoscopic score with MES≥2 (moderate to severe). MES was 
assessed by one central reader. TP0503 is one of the first trials that used 
central reading for inclusion and efficacy assessments.
For the efficacy assessment, TP0503 respected each item of the guideline 
looking at the symptomatic and endoscopic remission as a treatment goal 
for induction and maintenance of remission in UC. In TP0503, the primary 
endpoint (PEP) was a co-primary endpoint at week 8 of clinical remission 
and endoscopic remission as defined by MAYO≤2 without any subscore>1. 
SAT25 PEP, was less stringent and used clinical remission as the only PEP. 
SAT25 did not report a combined PEP of clinical and endoscopic remission, 
diverging from the EMA guideline.
For the study design, TP0503 respected each item of the guideline except 
for two. For ethical reasons, it was not possible to randomize UC patients 
to a placebo arm therefore TP0503 trial was a non-inferiority trial. Nor 
were they stratified according to prior treatment. While the SAT25 study 
group didn’t include any placebo arm or stratify to prior treatment, they 
also, didn’t perform any long term trial to evaluate the efficacy of the Me-
salazine 1000 mg in maintenance.
With regards to missing data, TP0503 considered all missing data as fail-
ures, unlike the SAT25 trial where the LOCF was used to manage some 
missing data. Patients on topical co-medication were excluded from both 
trials. Looking at safety aspects, beside the exclusion of acute severe colitis 
and patients with pouchitis, which are not part of the mesalazine indica-
tions, TP0503 and SAT25 respected all other criteria.
conclusion: TP0503 had more uptodate design than SAT25 with more 
stringent criteria. It mostly adhered to the 2018 EMA guideline even though 
it was designed 5 years prior.
  eMa guidelines (2018) TP0503 (2017) saT25 (2018)
 
Maximum score per 
guidelines scoring (%) scoring (%)
Patient selection 7 6.5 92.9% 6 85.7%
assessment of efficacy 21 17 81.0% 12 57.1%
study design 25 14.5 58.0% 10 40.0%
safety aspects 7 6 82.7% 6 82.7%
Total 60 44 73.3% 34 56.7%
[Comparison between TP0503, SAT25 and EMA Guideline]
disclosure: Employee of Tillotts Pharma AG 
P1108 anTI-Tnf TreaTMenT effecTIveLy reduced raTe Of 
hOsPITaLIzaTIOn In PaTIenTs WITh InfLaMMaTOry BOWeL 
dIsease WITh Or WIThOuT exTraInTesTInaL ManIfesTaTIOns: 
reaL WOrLd daTa In gerMany
Bettenworth D.1, Lee W.-J.2, Clark R.2, Rath S.3, Yang M.4, Cook E.E.4, 
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1University Hospital Münster, Department of Medicine B, Münster, Germany, 
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Introduction: Extraintestinal manifestations (EIMs) are prevalent among 
patients with inflammatory bowel diseases (IBD), including Crohn’s dis-
ease (CD) and ulcerative colitis (UC). However, the impact of EIMs on 
healthcare resource utilization is not well understood. Tumor necrosis fac-
tor inhibitors (TNFi) have shown to be effective in reducing risk of hospi-
talization and reducing EIMs in IBD patients.
aims & Methods: This study assessed the prevalence of hospitalization 
in patients with IBD stratified by the presence of concomitant EIM(s) and 
evaluated the effect of TNFi on hospitalization in the real world. This study 
used the InGef database (2011-2017), containing anonymous claims from 
statutory health insurance in Germany. Adults with ≥2 CD or UC claims, 
≥2 TNFi claims, and continuous enrollment for at least 12 months before 
(baseline) and 15 months after the first TNFi prescription (index date) were 
included. The rate of all-cause and IBD-related hospitalizations during 
baseline were compared to the 12-month period starting 3 months after 
the index date (follow-up). The first 3 months were excluded to allow time 
for the treatment to take effect.
results: A total of 1,658 IBD patients who received a TNFi were identified 
(CD: 1,108; UC: 550). Over 50% (845/1658) had ≥1 all-cause hospitaliza-
tion at baseline, and 90% (765/845) of the events were IBD-related. Dur-
ing baseline, over one-third of patients (35%) had at least one EIM (CD: 
34%; UC: 38%). More patients with EIM(s) had at least 1 hospitalization 
compared to those without an EIM (all-cause: 56% vs. 48%, p< 0.01; IBD-
related: 50% vs. 44%, p< 0.05), and the majority resulted from an emer-
gency room (ER) visit (all cause: 34% vs. 28%, p< 0.01; IBD-related: 30% 
vs. 25%, p< 0.05). Patients with EIM(s) also had a greater mean number 
of hospitalizations than patients without an EIM (all-cause: 1.2 vs. 0.9, p< 
0.001; IBD-related: 1.0 vs. 0.7, p< 0.01). During the TNFi therapy follow-up 
period, the proportion of patients with ≥1 all-cause hospitalization de-
creased by ≥17% in both groups, and almost all were IBD-related (EIM: 
Δ=17%; no EIM: Δ=18%, both p< 0.001, Table). 
    With eIMa (n=581) Without eIMa (n=1077)
    Pre-Index Post-Index P-value Pre-Index
Post-
Index P-value
all-
cause
% with ≥1 
hospitalization, 
n (%)
324 
(55.8%)
224 
(38.6%) <0.0001
521 
(48.4%)
335 
(31.1%) <0.0001
 
% with ≥1 
hospitalization 
resulting from ER, 
n (%)
199 
(34.3%)
118 
(20.3%) <0.0001
301 
(27.9%)
181 
(16.8%) <0.0001
  # hospitalizations, mean ± SD
1.2 
± 1.5
0.8 
± 1.4 <0.0001
0.85 ± 
1.18
0.55 ± 
1.04 <0.0001
  Length of stay, days, mean ± SD
11.7 
± 22.7
7.6 
± 19.6 <0.0001
7.6 
± 16.1
5.9 
± 19.7 <0.0001
IBd-
related
% with ≥1 
hospitalization, 
n (%)
288 
(49.6%)
187 
(32.2%) <0.0001
477 
(44.3%)
282 
(26.2%) <0.0001
 
% with ≥1 
hospitalization 
resulting from ER, 
n (%)
176 
(30.3%)
99 
(17.0%) <0.0001
272 
(25.3%)
147 
(13.6%) <0.0001
 
# of 
hospitalizations, 
mean ± SD
1.0 
± 1.4
0.6 
± 1.2 <0.0001
0.7 
± 1.1
0.5 
± 0.9 <0.0001
EIM, extraintestinal manifestation; IBD, inflammatory bowel disease; ER, emergency room; SD, 
standard deviation.
aEIMs included bone manifestation, bronchopulmonary disease, hepatobiliary disease, 
mucocutaneous disease, musculoskeletal disease, ocular disease, oral disease, pancreatic 
disease, renal disease, or cardiovascular events.
[Hospitalization before and after initiating a TNFi therapy among patients 
with IBD by EIM status]
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Hospitalizations resulting from an ER visit decreased during follow-up 
(EIM: Δ=14%; no EIM: Δ=11%, both p< 0.001), and almost all of the reduc-
tion was IBD-related (EIM: Δ=13%; no EIM: Δ=12%, both p< 0.001). The 
mean number of all-cause hospitalizations (EIM: Δ=0.4; no EIM: Δ=0.3, 
both p<0.001) and length of stay (EIM: Δ=4.1 days; no EIM: Δ=1.7 days, both 
p<0.001) was also reduced after TNFi use.
conclusion: Hospitalization is highly prevalent among patients with IBD, 
especially among those with concomitant EIM(s) who had higher rates of 
hospitalization and ER visits than those without an EIM. TNFi treatment is 
effective in reducing all-cause and IBD-related hospitalizations, and this 
effect appeared to be comparable in both patients with or without a prior 
EIM.
disclosure: Acknowledgements and Funding Statement: Design, study 
conduct, and financial support for the study were provided by AbbVie; Ab-
bVie participated in the interpretation of data, review, and approval of the 
abstract; all authors contributed to the development of the publication and 
maintained control over the final content. Conflict of Interest Disclosures: 
D Bettenworth: has served as consultant for AbbVie, Amgen, Janssen, 
Pharmacosmos, Takeda, and Tillotts and has received speaker fees from 
AbbVie, Falk, Ferring, MSD, Pfizer, Roche, Takeda, and Vifor. S Vavricka: 
has served as consultant for/received speaker fees from AbbVie, Celgene, 
Celltrion, Ferring, Gilead, Janssen, MSD, Pfizer, Shire, Takeda, Tillotts, UCB, 
and Vifor. M Yang and E Cook are employed by Analysis Group, Inc., which 
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P1109 cOMBIned endOscOPIc and hIsTOLOgIcaL heaLIng WITh 
vedOLIzuMaB In TheraPy-refracTOry crOhn’s dIsease, daTa 
frOM The LOve-cd TrIaL
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Introduction: Efficacy of vedolizumab (VDZ) has been confirmed in Crohn’s 
disease (CD), but there is limited data on mucosal healing, a combination 
of endoscopic and histological remission. In the LOVE-CD (LOw countries 
VEdolizumab in CD) trial we explored this novel endpoint in patients with 
active CD receiving VDZ for 52 weeks.
aims & Methods: The aim of this exploratory analysis was to assess mu-
cosal healing, the combination of endoscopic and histological healing, 
through week 26 in CD patients treated with VDZ. We included patients 
who had centrally read endoscopy at week 0 and 26 and paired biopsies 
at the same time points. Only patients with active histological inflam-
mation at baseline (Robarts Histopathology Index (RHI) score > 7) were 
studied. 
All patients had active CD (Crohn’s Disease Activity Index (CDAI) > 220 and 
presence of mucosal ulcerations at baseline endoscopy) and were treated 
with VDZ 300 mg infusions at week 0, 2, 6 and every 8 weeks thereafter 
to week 52, with an additional infusion at week 10 in the absence of clini-
cal response. Mucosal biopsies were collected from the edge of the most 
prominent ulcer in the terminal ileum and 4 colonic segments (ascending, 
transverse, descending colon and sigmoid and rectum), or from the most 
severely affected area if no ulcers were present. 
If a segment was completely normal, two biopsies were taken at random 
per segment. Histopathology was assessed blindly using the RHI, which 
represents a reproducible and responsive index that incorporates four 
histologic descriptors (i.e. severity of chronic inflammatory infiltrate, the 
number of neutrophils in the lamina propria, the number of neutrophils 
in the epithelium and the severity of erosions or ulceration), each of which 
is graded from 0 to 3 (Mosli M et al. Gut. 2017;66(1):50-58). In case more 
than one biopsy was available per segment, the biopsy sample with the 
maximum RHI score was used for further analysis.
results: Paired biopsies from the same segment were available in 65 pa-
tients, 40 of which (62%) had active histological inflammation (RHI score > 
7) at baseline. Out of these patients, 35/40 (88%) failed on prior anti-TNF 
therapy and median disease duration was 8 (4-18) years. Fourteen out of 
these 40 patients (35%; 95% CI (0.21, 0.52)) achieved mucosal healing at 
week 26 (SES-CD < 4 and RHI ≤ 6). Endoscopic remission at week 26 was 
observed in 17/40 (43%) and histologic remission in 23/40 (58%).
conclusion: Mucosal healing was achieved in 35% of CD patients with ac-
tive histological inflammation at baseline after 26 weeks treatment with 
VDZ. These outcomes show that VDZ is able to induce both endoscopic and 
histological healing in therapy-refractory CD.
references: Mosli M et al. Gut. 2017;66(1):50-58
disclosure: Nothing to disclose 
P1110 cOMPrehensIve LIfesTyLe-MOdIfIcaTIOn IncLudIng 
MuLTI-MOdaL sTress ManageMenT TechnIques In PaTIenTs 
WITh uLceraTIve cOLITIs - resuLTs Of a randOMIzed-
cOnTrOLLed TrIaL and The TrIer sOcIaL sTress TesT
Langhorst J.1, Schoels M.2, Haller H.2, Anheyer D.2, Cinar Z.2, 
Eilert R.2, Kofink K.2, Engler H.3, Elsenbruch S.3, Cramer H.4, 
Dobos G.J.5, Koch A.K.6
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Germany, 6Kliniken Essen- Mitte, Faculty of Medicine Essen, University of 
Duisburg-Essen, Department of Internal and Integrative Medicine, Essen, 
Germany
contact e-Mail address: j.langhorst@kliniken-essen-mitte.de
Introduction: Psychosocial stress can have a negative impact on the course 
of disease in ulcerative colitis. A comprehensive lifestyle-modification pro-
gram that includes stress management techniques addresses this unmet 
need.
aims & Methods: In this randomized controlled trial, 97 patients with 
ulcerative colitis in remission and reduced quality of life were randomly 
assigned to a 10-week LSM program or a one day work-shop as control 
(Table 1). Perceived stress, anxiety, depression, and flourishing were mea-
sured before and after the intervention and after 24 and 48 weeks.
In an exploratory sub-study, 16 female patients (8 intervention and 8 con-
trols) additionally underwent an acute psychosocial stress paradigm, the 
Trier Social Stress Test (TSST) which is a validated laboratory procedure 
to induce stress in human participants. Here, cardiovascular responses, 
blood parameters, and state anxiety were captured at baseline, stress, re-
covery 1 (+20min), and recovery 2 (+55min).
results: Comprehensive lifestyle-modification significantly decreased 
patients’ perceived stress compared to control (p< .001) at time point 
post intervention. Flourishing was significantly increased at 48 weeks 
(p=.006). No effects on anxiety (p = .075) or depression (p = .146) were evi-
dent (all p<0.05). TSST induced a rise of stress parameters in both groups. 
Significant differences were evident for pulse (Δ=6.99bpm; p=.015), 
adrenaline (Δ=-19.07pg/ml; p=.037) and on a ten percent level for state-
anxiety (Δ=9.026; p=.066) at stress and for systolic blood pressure (Δ=-
10.24mmHg; p=.05) and on a ten-percent-level for adrenocorticotropic 
hormone at (Δ=2.53ng/ml; p=.067) at recovery 2. Cortisol, noradrena-
line, leukocytes, thrombocytes, lymphocytes, monocytes or neutrophiles 
showed no differences.
conclusion: A Comprehensive lifestyle-modification program significantly 
decreased patients’ perceived stress and increased flourishing in patients 
with UC. Those changes in stress perception were supported by results of 
the TSST under laboratory experimental conditions.
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Lifestyle-
modification 
(n = 47)
Lifestyle-
modification 
TssT (n = 8)
control 
(n = 50)
control TssT 
(n = 8)
Age years
50.28 ± 11.90 
(18 - 74)
44.6 ± 14.3 (18 
- 57)
45.54 ± 12.49 
(19-71)
49.25 ± 4.30 
(43 - 57)
Female n (%) 34 (72.3) 8 (100) 35 (70) 8 (100)
Weight
72.79 ± 14.90 
(52-100)
71.13 ± 12.87 
(62-97)
70.24 ± 16.86 
(49.6 - 150)
61.19 ± 9.72 
(51-79)
Height
171.19 ± 9.05 
(152 - 196)
173.88 ± 6.11 
(167-183)
173.76 ± 9.94 
(156 - 197)
169.00 ± 4.00 
(164-176)
Anamnestic pattern 
n (%)
       
Proctitis 14 (29.8) 1 (12.5) 15 (30) 3 (37.5)
Left-sided colitis 17 (36.2) 4 (50) 15 (30) 2 (25)
Pancolitis 13 (27.7) 3 (37.5) 17 (34) 3 (37.5)
Missing 3 (6.4) 0 (0) 3 (6) 0 (0)
Time since diagnosis 
years
18.04 ± 12.00 
(2 - 46)
10.50 ± 7.95 
(2-24)
14.76 ± 10.99 
(1 - 43)
12.63 ± 4.03 
(5-17)
Smokers n (%) 2 (4.3) 1 (12.5) 3 (6) 1 (12.5)
Medication intake 
n (%)
       
Steroids 2 (4.3) 0 (0) 0 (0) 0 (0)
Azathioprine 4 (8.5) 2 (25) 3 (6) 0 (0)
Other 
immunosuppressant
0 (0) 0 (0) 1 (2) 0 (0)
Mesalazine 33 (70.2) 7 (87.5) 34 (68) 7 (87.5)
Herbal medicine 7 (14.9) 0 (0) 15 (30) 1 (12.5)
Biologicals 3 (6.4) 2 (25) 3 (6) 1 (12.5)
Other 8 (17) 0 (0) 12 (24) 2 (25)
[Table 1. Sociodemographic and clinical characteristics]
disclosure: Research grant: Steigerwald Arzneimittelwerke GmbH, Falk 
Foundation; TechLab, Dr. Willmar Schwabe; Repha GmbH biologische 
Arzneimittel Lecture: Falk Foundation; MSD Sharp&Dohme GmbH; Repha 
GmbH biologische Arzneimittel; Ardeypharm GmbH; Celgene GmbH; Dr. 
Willmar Schwabe Advisory board: Medizinverlage Stuttgart; Steigerwald 
Arzneimittelwerke GmbH; Repha GmbH; Ferring Arzneimittel GmbH; 
Sanofi 
P1111 acuTe severe cOLITIs: shOrT and LOng TerM IMPacT 
Of InfLIxIMaB
Ghribi M.1, Mohamed G.2, Benslimen B.2, Sondes D.B.2, Ben Abdallah H.2, 
Abdelli M.N.2, Bouali R.3
1Tunisian University of Medecine, Gastroenterology, Tunis, Tunisia, 2Military 
Hospital Tunis, Gastroenterology, Tunis, Tunisia, 3Hopital Militaire Public, 
Hépato-gastroentérologie, Tunis, Tunisia
contact e-Mail address: marwa_ghribi1@yahoo.com
Introduction: Acute severe colitis is a serious complication of inflammatory 
bowel disease. It can lead to colectomy and death. Its medical treatment 
has been step forward within the last decades, based on infliximab or 
cyclosporine as second medical therapy.
aims & Methods: The aim of this study is to precise the impact of infliximab 
on the short and long term prognosis of acute severe colitis not respond-
ing to corticosteroids. 
All patients admitted for acute severe colitis have been retrospectively 
enrolled, between the years 1994 and 2018. Standard therapy based on 
intravenous corticosteroids was initially led in all patients. We particularly 
interested in patients failed to steroids and hence treated with infliximab 
as second line medication, and we studied the rate of avoiding colectomy 
in the short and in the long term as well as the rate of clinical and endo-
scopic remission.
results: 69 patients with acute severe colitis were reviewed ( median 
age:34y. (15-64y.); 38 females and 31 males). There were 61% with ulcer-
ative colitis, 33% with Crohn’s disease and 6% with indeterminate colitis. 
32,9% of patients (n=22) failed to corticosteroids. Among them, 9 patients 
have been treated with Infliximab infusions (5mg/Kg) . 88,8% of them 
avoided urgent colectomy and where discharged within 4 weeks. All pa-
tients experienced clinical remission within a median follow up of 64,96 
mo [6 -234]. 4 patients have undergone a colonoscopy during follow up. 
Endoscopic remission was noticed in 3 patients and a mucosal healing 
without complete remission was reported in one patient. Nine other pa-
tients have been subsequently treated with Infliximab for active chronic 
disease. No adverse event was reported during follow up. Colectomy-free 
survival rates were better in the group of patient treated with infliximab 
but not significatevily (p=0.695)
conclusion: Infliximab is an efficient treatement for corticoresistant acute 
severe colitis as a second line treatment and as a remission promoting 
factor. It diminished the urgent and distant colectomy without serious ad-
verse effects.
disclosure: Nothing to disclose 
P1112 Peak usTekInuMaB cOncenTraTIOn afTer 
InTravenOus LOadIng dOse PredIcTs faecaL caLPrOTecTIn 
nOrMaLIsaTIOn In crOhn’s dIsease: POTenTIaL rOLe fOr 
TheraPeuTIc drug MOnITOrIng?
Drobne D.1, Zdovc J.2, Kurent T.1, Hanzel J.1, Sever N.1, Javornik K.1, 
Tuta K.1, Koželj M.1, Smrekar N.1, Novak G.1, Ferkolj I.1, Stabuc B.1, 
Vovk T.2, Grabnar I.2
1University Medical Centre Ljubljana Slovenia, Department of 
Gastroenterology and Hepatology, Ljubljana, Slovenia, 2Faculty of Pharmacy 
Ljubljana, Ljubljana, Slovenia
contact e-Mail address: david.drobne@gmail.com
Introduction: Up to one third of patients with Crohn’s disease do not re-
spond or respond partially to the intravenous loading dose of ustekinum-
ab. This was partially explained by low ustekinumab concentrations during 
maintenance phase (1). However, exposure-response relationship during 
induction, particularly during the first 4 weeks following intravenous load-
ing, has not been sufficiently studied in the real-life setting yet.
aims & Methods: We prospectively investigated the association of 
ustekinumab induction drug levels to calprotectin normalisation (defined 
as levels < 100 mg/kg) after intravenous induction in Crohn’s disease in a 
real-life setting.
Ustekinumab drug levels (ELISA assay) at 4 prespecified time points during 
induction (one hour post-infusion (peak level), week 2, week 4 and week 
8) were correlated to faecal calprotectin (Calprest assay) levels at weeks 8, 
16 and 24 of starting ustekinumab. We recruited 52 consecutive patients 
who started ustekinumab due to active Crohn’s disease at a tertiary refer-
ral university centre. All patients received an intravenous loading dose of 
ustekinumab (approximately 6 mg/kg as per label, infused over 60 min) 
followed by 90 mg q 8 weeks maintenance. Median disease duration at 
start of treatment was 15 years (IQR: 8-23), most patients (35/52 (67%)) had 
failed previous biological treatment (25 anti-TNF, 9 vedolizumab, 1 both). 
At inclusion 8/52 (15%) were on systemic steroids. Mann-Whitney U-test 
and ROC analysis were used to test for differences and identify optimal 
cut-offs of ustekinumab drug levels to predict calprotectin normalisation.
results: Median calprotectin decreased from 134 (IQR:72-235) to 80 (IQR: 
26-173) by week 8, to 65 (IQR:32-188) by week 16 and 66 (IQR: 35-203) by 
week 24 of start of ustekinumab. Faecal calprotectin was normal in 27/47 
(57%), 23/42 (55%), 26/41 (63%) of patients at week 8, 16 and 24, respec-
tively. Median ustekinumab drug levels were higher at all assessed time 
points in patients with normal calprotectin at weeks 8, 16 and 24 compared 
to those with increased calprotectin levels (Table 1). Ustekinumab levels 
of >94 (sensitivity 85%, specificity 65%, PPV 74%) 1-hour post-infusion, 
>25 (sensitivity 90%, specificity 56%, PPV 69%) at week 2, >20 (sensitiv-
ity 60%, specificity 100%, PPV 100%) at week 4, and >7 (sensitivity 60%, 
specificity 95%, PPV 94%) at week 8 were identified as optimum cut-offs 
for calprotectin normalisation at week 8, with similar values for weeks 16 
and 24. Importantly, these cut-offs had a high negative predictive values 
(at 1h post-infusion: 71% and at week 2: 70%) for calprotectin normalisa-
tion at 6 months.
conclusion: Our data indicate that induction concentrations of ustekinum-
ab after an intravenous loading dose, as early as 1 hour after infusion, 
predict faecal calprotectin normalization during the first 6 months in 
Crohn’s disease. These data indicate that therapeutic drug monitoring 
of ustekinumab during induction could potentially improve outcomes by 
identifying patients in need of early proactive dose optimisation.
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ustekinumab 
concentration [µg/mL], 
median (Iqr)
faecal calprotectin 
at week 8 P value
area under the 
rOc curve (95% 
confidence interval)
  <100 mg/kg ≥100 mg/kg    
Peak (1 h after infusion) 111 (98-124) 92 (83-116) 0.033 0.73 (0.56-0.91)
Week 2 32 (28-36) 25 (21-30) 0.005 0.77 (0.61-0.92)
Week 4 20 (16-24) 12 (7-17) <0.0001 0.82 (0.68-0.96)
Week 8 7 (4-11) 3 (2-5) <0.0001 0.84 (0.71-0.97)
[Table 1]
references: 1. Verstockt B, Dreesen E, Noman M, Outtier A, van den Ber-
ghe N, Aerden I, et al. Ustekinumab exposure-outcome analysis in Crohn’s 
disease only partly explains limited endoscopic remission rates. J Crohns 
Colitis 2019: 10.1093/ecco-jcc/jjz008. [published ahead of print]
disclosure: DD reports speaker and consultant fees from MSD, Abbvie, 
Takeda, Pfizer, Janssen, Krka, Dr. Falk Pharma, Ferring; all outside the sub-
mitted work. JH reports lecture fees from Biogen and Takeda outside the 
submitted work. BŠ reports lecture and consultant fees from Krka, Bayer, 
Takeda and grants from Krka outside the submitted work. NSm reports 
lecture fees from Takeda outside the submitted work. GN reports lecture 
and consultant fees from Takeda, MSD, Abbvie, Biogen, and Janssen out-
side the submitted work. MK reports lecture fees from Takeda outside the 
submitted work. All other authors have nothing to disclose. 
P1114 effecTIveness and evOLuTIOn In The use 
Of usTekInuMaB In reaL-LIfe cLInIcaL PracTIce: 
a sIngLe cenTer exPerIence WITh InTravenOus InducTIOn 
TheraPy In refracTOry crOhn’s dIsease PaTIenTs
Calvo Moya M.1, Vera Mendoza M.I.1, Vasquez Ruíz H.2, 
Matallana Royo V.1, Menchen Viso B.3, Manso Manrique M.3, 
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Introduction: Ustekinumab(UST) is a fully human monoclonal antibody 
against IL-12/23. It has shown efficacy in inducing and maintaining clinical 
remission in patients with Crohn’s disease (CD). To date UST is approved 
in Spain only in refractory to AntiTNF CD patients, but information about 
clinical benefit of UST in patients previously exposed to several biologics in 
real-life practice is limited.
aims & Methods: Retrospective cohort study in a tertiary hospital in which 
73 CD patients received UST from April 2010 to April 2019 were evaluated. 
Those who received intravenous dose due to active disease (Harvey-Brad-
shaw index score [HBI] >4) were considered for the analysis. The main-
tenance schedule every 8 or 12 weeks was at physicians’ discretion. The 
clinical benefit was defined by the HBI score and evaluated at week 8, 24 
and 48.
results: 68 patients included; median follow up was 5 months (IQR: 1-12). 
Characteristics of the study population are summarized in Table. All pa-
tients were exposed at least one biological treatment (98% anti-TNFα 
agent and 16% vedolizumab), and 69% more than two.
At week 8, 33% and 45% experienced clinical response and clinical re-
mission, respectively. 41 patients reached 6 months of follow up: 24% 
and 71% achieved clinical response and clinical remission, respectively. 
22 patients reached 12 months of follow up, 18% and 82% experienced 
clinical response and clinical remission, respectively. During follow-up, 8 
patients (15%) required intensification at 90mg sc every 4 weeks (median: 
12 months; IQR: 11-13). Of these, 4 had clinical benefit (50% response and 
13% remission). Clinical evaluation still pending in 3 cases.
Patients who received UST after failure of only one biologic agent obtained 
better outcomes than those who received UST after 2 or 3 biologics, al-
though it did not achieved statistical significance (p=0.09).
Withdrawal of UST occurred in 6 (9%) patients along the follow up, due to 
lack of efficacy in all cases. No adverse event recorded. 
Clinical use of UST increased through time: among all patients included 
18 (26%) received UST in 2017, 29 (42%) in 2018, and 21 (31%) in the first 
trimester of 2019. Moreover, 5 (29%) of patients included in 2017 had previ-
ously failed 3 or 4 biologic agent, 7 (24%) in 2018 and 3 (14%) in the first 
trimester of 2019.
conclusion: Our real-life clinical experience confirms favorable data of 
clinical efficacy and safety of UST in refractory CD patients and showed a 
trend towards an increasing and earlier use of UST.
disclosure: Nothing to disclose 
Median age (IQR) (years) 49 (40-54)
Median duration of the disease until beginning treatment 
with ustekinumab (IQR) (months)
146 (70-265)
Female gender (%) 31 (46)
Smoking status (%) 18 (26)
Extraintestinal manifestations (%) 57 (84)
Comorbidity (%) 17 (25)
Age at diagnosis: A1, A2 and A3 (%) 7, 53, 7 (10, 80, 10)
Ileal, colonic, ileocolonic, Upper gastrointestinal tract 
involvement (%)
20, 12, 31, 5 (29, 18, 46, 7)
Inflammatory, stenosing and fistulizing pattern (%) 40, 16, 12 (59, 23, 18)
Perianal disease (%) 30 (44)
Previous bowel surgeries (%) 40 (59)
Previous immunosuppresants (%) 61 (90)
Previous biological treatment (%) 68 (100)
1, 2, 3 or 4 previous biologics (%) 26, 27, 13, 2 (38, 40, 19, 3)
Median number of previous biological treatment (IQR) 2 (1-3)
Concomitant immunosuppresants (%) 15 (22)
Steroids during induction (%) 12 (18)
[Characteristics of the study population]
P1115 usTekInuMaB IMPrOved WOrk PrOducTIvITy In 
PaTIenTs WITh MOderaTe TO severe uLceraTIve cOLITIs: 
resuLTs frOM The Phase 3 unIfI InducTIOn and MaInTenance 
sTudIes
Naessens D.1, Han C.2, Zhang H.3, Johanns J.3, Marano C.3, Sands B.E.4
1Janssen Pharmaceutica, NV, Beerse, Belgium, 2Janssen Global Services, 
LLC, Malvern, United States, 3Janssen Research & Development, LLC, Spring 
House, United States, 4Icahn School of Medicine at Mount Sinai, Division of 
Gastroenterology, New York, United States
contact e-Mail address: dnaessen@its.jnj.com
Introduction: We evaluated the effect of ustekinumab (UST) on work pro-
ductivity and daily activity in patients with moderate-severe active ulcer-
ative colitis (UC) in the UNIFI induction and maintenance studies.
aims & Methods: In the induction study, patients were randomized to a 
single intravenous (IV) dose of placebo (PBO, n=319), UST 130 mg (n=320), 
or UST ~6 mg/kg (n=322). Patients who were in clinical response 8 wks af-
ter receiving UST IV induction were eligible for the maintenance study and 
randomized to subcutaneous (SC) PBO (n=175), UST 90 mg q12w (n=172), 
or UST 90 mg q8w (n=176). Work productivity was assessed using the Work 
Productivity and Activity Impairment Questionnaire (WPAI), a validated 
tool that assesses work time missed (absenteeism), reduced job effective-
ness (presenteeism), overall work impairment, and daily activity impair-
ment due to health over the previous week. The impact of UC on overall 
daily productivity at home, school, and work was assessed using a visual 
analog scale (VAS, 0 to 10, 0=no impact at all, 10=impacts very much).
results: At induction baseline, patients had a mean percent work time 
missed ranging from 17.7% to 19.3%, impairment while working from 
39.1% to 45.3%, overall work impairment from 43.7% to 49.1%, and activ-
ity impairment from 51.8% to 52.8%. At Wk8, patients who received UST 
IV had significantly greater improvement in WPAI domains and daily pro-
ductivity VAS compared with PBO (Table). 
In the maintenance study, UST-treated patients generally maintained or 
numerically improved WPAI scores, while scores for patients in the PBO 
group worsened. The mean changes from baseline to Wk44 in work time 
missed was 4.7% in the SC PBO group, -2.0% (p=0.133) in the SC UST 
90-mg-q12w group, and 2.1% (p=0.172) in the SC UST 90-mg-q8w group, 
impairment while working was 7.4%, -1.6 (p=0.017), and -6.4% (p< 0.001), 
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respectively; overall work impairment was 7.7%, -2.2% (p=0.013), and 
-6.1% (p<0.001), respectively; and activity impairment was 9.3%, 0.8% 
(p=0.002), and -4.2% (p< 0.001), respectively. Mean changes from base-
line to Wk44 in daily productivity VAS scores were 1.0, -0.2 (p<0.001), and 
-0.5 (p<0.001), respectively.
domain PBO Iv usT Iv 130mg usT Iv ~6mg/kg
WPAI % work time missed 
due to health
-3.7% (30.41%) -5.9%* (31.39%) -9.1%** (23.84%)
WPAI % impairment while 
working due to health
-6.9% (21.89%) -15.1%* (29.17%) -20.4%† (24.11%)
WPAI % overall work 
impairment due to health
-8.0% (24.83%) -17.2%** (30.36%) -21.8† (26.26%)
WPAI % activity 
impairment due to health
-10.9% (28.66%) -17.7%** (29.45%) -20.8%† (26.27%)
Impact on daily productivity 
at home, school and work 
VAS (0-10)
-1.3 (2.95) -2.3† (3.03) -2.3† (2.84)
*p<0.05, **p<0.01, †p<0.001
[Mean (standard deviation) changes from baseline to Wk8 in WPAI and daily 
productivity VAS results during the induction study]
conclusion: Patients who received UST IV induction reported significantly 
greater improvement in work productivity and daily activity compared with 
PBO. In patients who responded to UST IV induction, those who received 
UST SC maintenance through Wk44 sustained or improved the levels of 
work productivity and activity that were achieved during induction.
disclosure: Drs. Naessens is an employee of Janssen Pharmaceutica, NV. 
Dr. Han is an employee of Janssen Global Services, LLC. Drs. Zhang, Jo-
hanns, and Marano are all employees of Janssen Research & Development. 
LLC. Dr. Sands is an investigator for Janssen Research & Development, LLC 
P1116 ManageMenT and OuTcOMes Of anTI-drug anTIBOdIes 
TO InfLIxIMaB, a LOng-TerM OBservaTIOnaL sTudy
McGettigan N.1, Harkin G.2, Moran C.1, Harewood G.1, Patchett S.1, 
Cheriyan D.2, Boland K.1, O’Toole A.2
1Beaumont Hospital, Gastroenterology, Dublin, Ireland, 2Beaumont Hospital, 
Dublin, Ireland
contact e-Mail address: neasamcgettigan@hotmail.com
Introduction: Secondary loss of response (LOR) to Infliximab (IFX) occurs 
in up to 40% of IBD patients. One of the causes of LOR is the development 
of anti-drug antibodies (ADAs) which neutralize IFX. At present, evidence 
regarding the optimal management of ADAs is lacking.
aims & Methods: This is a long-term retrospective observational study of 
adult patients receiving IFX who developed ADAs >8mg/L over a study pe-
riod of 3 years. This study reviewed the optimisation of Infliximab therapy 
and subsequent outcomes in patients who developed ADAs. The primary 
aim of this study is to identify the best practice of management of ADAs 
to IFX to avoid discontinuation of therapy/LOR and to identify predictors of 
development of ADAs. Secondary aims include review of adverse outcomes 
following development of ADAs.
results: 132 patients with IBD and 1 patient with collagenous colitis are in-
cluded in the study. Baseline characteristics include 54% male, mean age 
of 39.4, mean IFX drug trough level 4.7 mg/L, mean ADA level 103 mg/L, 
25% were on a previous biologic and 26% were on combination therapy 
prior to the development of ADAs. 
52% of patients discontinued IFX- 72% due to LOR, 16% due to clinical 
remission, 12% due to infusion reaction. 
Both an increase in IFX and adjustments to combination therapy (increase 
in IFX + addition/increase in immunomodulator) were associated with 
lower rates of discontinuation of treatment vs no intervention (P-Value < 
0.001, P-Value < 0.001 respectively). No difference was seen with adjust-
ment of immunomodulator therapy alone (P-Value= 0.62). An increase in 
IFX resulted in a significant difference in ADAs and IFX trough levels pre 
and post intervention (P-Value < 0.001, P-Value = 0.032).
There was a significant reduction in ADAs overtime for the entire cohort 
(Mean of 103 mg/L vs mean of 55 mg/L on follow-up, P-Value= 0.008) 
and a correlation was noted with ADAs and low drug trough levels (P-
Value= 0.056). No significant correlation was found between the presence 
of ADAs and CRP, fecal calprotectin or serum albumin. 15% were admitted 
to hospital, 11% underwent surgery, 19% required steroids. 32% switched 
to another biologic- 63% of patients were switched to Adalimumab.
conclusion: A high percentage of patients who develop ADAs to IFX ex-
perience LOR. A reduction in ADA levels was seen due to proactive drug 
monitoring. Both escalation of IFX alone and combination therapy resulted 
in lower rates of LOR. Our most common practice post LOR due to ADAs 
was to switch within drug class.
disclosure: Nothing to disclose 
P1117 ThIOPurIne WIThdraWaL durIng susTaIned cLInIcaL 
reMIssIOn In crOhn’s dIsease
Sanchez-Aldehuelo R., Sanchez Rodriguez E., Rodriguez de Santiago E., 
Mesonero Gismero F., Fernandez C., Albillos A., Lopez-Sanroman. A.
Hospital Universitario Ramón y Cajal, Servicio de Gastroenterología y 
Hepatología, Madrid, Spain
contact e-Mail address: ruben.sanchez.aldehuelo@gmail.com
Introduction: Cessation of thiopurines (TP) in patients with Crohn’s disease 
(CD) in clinical remission (CR) is controversial.
aims & Methods: To describe the evolution of CD patients who discon-
tinued TP and to detect predictors of reactivation after withdrawal. An 
observational unicentric retrospective study was conducted including CD 
patients in clinical remission who discontinued TP.
results: We included 39 patients with CD in remission (51.3% females; 26 
inflammatory, 8 stricturing and 5 penetrating behaviour; 9 with terminal 
ileum involvement, 4 colonic, 26 ileocolonic, and 11 with perianal disease). 
TP were indicated to maintain remission after steroids in 27 (69.2%), to 
prevent postoperative recurrence in 8 (20.5%), and to induce remission as 
part of a combination therapy in 4 (10.3%). 
Median azathioprine dose was 150 mg/day. Median duration of TP treat-
ment was 5.3 years (p25-p75: 3.3-7.2) and of steroid-free remission 60.9 
months (p25-p75: 32.4-76.6). Reasons for TP withdrawal were patient’s 
choice/request in 10 (25.6%), physician proposal in 27 (69.2%) and drug-
related adverse events in 2 (5.15%). By the time of TP discontinuation, 
median C reactive protein (CRP) was 2.5 mg/L (p25-p75: 1-3.8), faecal cal-
protectin (FC) 37 µg/g (p25-p75: 16-80) and mean Harvey-Bradshaw Index 
(HBI) 0.2. 
Relapse was observed in 17 patients (43.6%), after a median follow-up of 
47 (p25-p75: 26.2 - 81.5) months. Median time until relapse was 17 (p25-
p75: 7-33.2) months. At relapse, median CRP was 6.6 (3-18) mg/L, FC 429 
(340.5-479.5) µg/g and mean HBI 5.5. After relapse, 4 (21.1%) patients re-
started TP; 4 (21.1%) were prescribed one single course of CE without fur-
ther therapy; 2 (10.5%) one course of CE and TP reintroduction; 2 (10.5%) 
CE and a biological agent; 1 (5.3%) CE, a biological agent and mesalazine, 
1 (5.3%) methotrexate; 1 (5.3%) low dose TP with allopurinol and CE and 1 
(5.3%) underwent surgery. 
During follow-up, 3 (17.6%) patients received another single course of CE, 1 
(5.9%) needed surgery and 2 (11.8%) both. Mean follow-up of non-relaps-
ing patients was 30.4 (13.9-49.2) months.TP treatment duration of shorter 
than 5 years before discontinuation, was associated to a higher risk for 
relapse (HR 3.69 p< 0.01).
conclusion: TP withdrawal is possible in patients with CD in sustained 
clinical remission; however, almost half of them can relapse.
disclosure: Nothing to disclose 
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P1118 Is The sWITch TO a secOnd ThIOPurIne a safe sTraTegy 
In eLderLy PaTIenTs WITh InfLaMMaTOry BOWeL dIsease? 
a MuLTIcenTre cOhOrT sTudy Of The eneIda regIsTry
Calafat Sard M.1, Mañosa M.2,3, Ricart E.3,4, Marin Pedrosa S.5, Calvo M.6, 
Rodriguez-Moranta F.7, Taxonera Samso C.8, Nos Mateu P.3,9, 
Mesonero F.10, Martin-Arranz M.11, Mínguez M.12, P. Gisbert J.3,13, 
García-López S.14, De Francisco Garcia R.15, Gomollon Garcia F.3,16, 
Calvet X.3,17, García-Planella E.18, Rivero M.19, Martínez-Cadilla J.20, 
Argüelles F.21, Arias L.22, Cimavilla M.23, Zabana Y.3,24, Cañete F.2,3, 
Domènech E.2,3
1Hospital Universitari Germans Trias i Pujol, Gastroenterology, Barcelona, 
Spain, 2Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 
3CIBER de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain, 
4Hospital Clinic, Barcelona, Spain, 5Hospital Universitario Reina Sofía, 
Córdoba, Spain, 6Hospital Universitario Puerta de Hierro Majadahonda, 
Majadahonda, Spain, 7University Hospital of Bellvitge (HUB-IDIBELL), 
Barcelona, Spain, 8Hospital Clinico, Madrid, Spain, 9Hospital La Fe, Chair, 
Valencia, Spain, 10Hospital Ramon y Cajal, Madrid, Spain, 11Hospital La Paz, 
Madrid, Spain, 12Hospital Clínico de Valencia, Valencia, Spain, 13Hospital 
Universitario La Princesa, Madrid, Spain, 14Hospital Universitario Miguel 
Servet, Zaragoza, Spain, 15Hospital Universitario Central de Asturias, Madrid, 
Spain, 16Hospital Clínico Universitario Lozano Blesa, Servicio de Aparato 
Digestivo, Zaragoza, Spain, 17Hospital Universitari Parc Tauli, Sabadell, 
Spain, 18Hospital Santa Creu i Sant Pau, Barcelona, Spain, 19Marqués de 
Valdecilla Universitary Hospital, Gastroenterology, Santander, Spain, 
20Complexo Hospitalario Universitario de Ourense, Instituto de Investigación 
Sanitaria Galicia Sur, CIBERehd, Vigo, Spain, 21Hospital Universitario Virgen 
Macarena, Madrid, Spain, 22Hospital Universitario de Burgos, Burgos, Spain, 
23Hospital Universitario Rio Hortega, Valladolid, Spain, 24Hospital Universitari 
Mutua de Terrassa, Terrassa, Spain
contact e-Mail address: margalidasard.calafat@gmail.com
Introduction: Thiopurines are the most commonly used immunosuppres-
sants in inflammatory bowel disease (IBD), but their main limitation is the 
high rate of drug-related adverse events (AE) and treatment discontinua-
tion. Switching to a second thiopurine may be an alternative in these cas-
es, but series published up to now, include a limited number of patients. 
In a previous study, we demonstrated that starting thiopurines in elderly 
age is associated with a higher incidence of AE.
aims & Methods: Our aim was to evaluate the tolerance of switch to a 
second thiopurine as well as the persistence of treatment and the factors 
associated with it. Based on the ENEIDA registry (a large, prospectively 
maintained database of the Spanish Working Group in IBD -GETECCU), 
adult IBD patients that switch to a second thiopurine due to AE were iden-
tified. Two cohorts were selected regarding the age at the beginning of 
thiopurine treatment: between 18-50 years, and over 60 years. The rate 
and concordance of AE that occurred with the second thiopurine, treat-
ment discontinuation due to AE and the overall persistence of the second 
thiopurine were evaluated.
results: Of the 17,371 patients who started a first thiopurine in these two 
cohorts, 3,903 patients discontinued thiopurine treatment due to AE. In 
1,278 of them (32%) a switch to a second thiopurine was performed (93% 
to mercaptopurine, 7% to azathioprine), 1,105 patients below 50 years of 
age and 173 over 60 years. The AE of the first thiopurine were: digestive 
intolerance 60%, hepatotoxicity 13%, myelotoxicity 6%, acute pancreatitis 
2%, other 19%. The rate of post-switch AEs was 58%, leading to the dis-
continuation due to AE of the second-thiopurine in 46% of cases. In those 
patients who presented post-switch AE, the most likely AE was the same 
that occurred with the first thiopurine, particularly digestive intolerance 
(61%). The cumulative probability of post-switch treatment discontinua-
tion due to AE was 40%, 43%, 47% and 50% at 6 months, 1-3-5 years, 
respectively. The persistence of post-switch treatment was 44%, 40% and 
34% at 1-3-5 years, respectively. The multivariate analysis showed that 
the only independent risk factors of treatment discontinuation due to AE 
were the switch over 60 years (53% vs. 45%, OR 1.5: 95% CI 1.1-2.1), 
having developed digestive intolerance (48% vs. 41%, OR 1.4: 95% CI 1.1-
1.8) or pancreatitis (83% vs. 45%, OR 6.8: 95% CI 2.6-18.2) with the first 
thiopurine.
conclusion: In the largest series reported to date, we observed that switch 
to a second thiopurine is a valid strategy except in the case of pancreatitis. 
Close monitoring is advisable among elderly IBD patients switching to a 
second thiopurines because of AEs.
disclosure: Nothing to disclose 
P1119 LOng-TerM OuTcOMe Of acuTe severe 
uLceraTIve cOLITIs resPOndIng TO InTravenOus sTerOIds: 
a MuLTIcenTre cOhOrT sTudy
Salameh R.1, Kirchgesner J.2, Allez M.3, Collins M.4, Carbonnel F.4, 
Gornet J.M.5, Beaugerie L.6, Amiot A.1
1Henri Mondor Hospital, APHP, Gastroenterology, Creteil, France, 2Hôpital 
Saint-Antoine, AP-HP, Gastroenterology, Paris, France, 3Hopital Saint-Louis, 
APHP, Université Denis Diderot Paris 7, Gastroenterology, Paris, France, 4CHU 
Bicetre, Hepato-Gastroenterology, Le Kremlin Bicetre, France, 5Hôpital Saint-
Louis, Gastroenterology, Paris Cedex 10, France, 6Saint-Antoine Hospital, 
AHPD and Paris 6 University, Gastroenterology, Paris, France
contact e-Mail address: robert.salameh@yahoo.com
Introduction: Acute severe ulcerative colitis (ASUC) is a life-threatening 
condition that occurs in up to 25% of patients with UC. Intravenous steroids 
(IVS) are effective in nearly two-thirds of patients. Few data are available 
on long-term outcomes of patients responding to IVS. ECCO guidelines rec-
ommended maintenance therapy with thiopurine in thiopurine-naïve pa-
tients and a biological agent in patients with previous thiopurine-failure.
aims & Methods: We performed a retrospective observational study of con-
secutive patients with UC, hospitalized for ASUC (as defined by Truelve and 
Witts’ criteria), among four tertiary centres in Paris area, between January 
2006 and December 2017. Patients included responded to IVS. Relapse was 
defined as partial Mayo Clinic score ≥ 3 and/or any subscore >1 and the 
initiation of second line therapy. Patients with Crohn’s disease or inflam-
matory bowel disease unclassified, and those in whom biologics were ini-
tiated before response to IVS could be assessed were not included. Disease 
activity was assessed using the Lichtiger index and the partial Mayo Clinic 
score. Endoscopic activity was assessed using partial Mayo Clinic endo-
scopic subscore and UCEIS. Relapse-free and Colectomy survival was stud-
ied with Kaplan-Meier method, log-rank test and Cox regression model.
results: 142 patients (70 (49.3%) male; median age: 33.9 [IQR 25.5-48.1] 
years; UC duration 1.4 [0.1-4.3] yrs; 79 (55.6%) patients with pancolitis; 
100 (70.4%) with no history of immunomodulator and biological agent 
use) were included in this study. At inclusion, patients had a mean total 
Mayo Clinic score of 10.0 ± 1.0, a mean Lichtiger index of 13.1 ± 2.2, a CRP 
serum level of 91.9 ± 75.4 mg/L and a mean UCEIS of 4.8 ± 1.2. Deep ulcer-
ations were observed in 24.3% of the cases. Median hospital stay was of 8 
(6-10) days. Maintenance therapy included 5-ASA in 59 (41.5%) patients, 
immunomodulators in 54 (38.0%), anti-TNF agents in 18 (12.7%) and ve-
dolizumab in 5 (3.5%). More patients were treated with 5-ASA in the naïve 
group (54.0% vs. 11.9%, p< 0.001) and with biological agents in the failure 
group (47.6% vs. 3.0%, p< 0.001) whereas no difference was noted for im-
munomodulators (40.5% vs. 43.0%, p = 0.85). After a median follow-up of 
4.8 (2.6-7.3) years, 90 (63.4%) of the 142 patients relapsed and 12 (8.5%) 
required colectomy. The probabilities of relapse-free survival were 58.1%, 
47.8%, 45.5%, 41.9% and 39.8% % at 1, 2, 3, 4 and 5 years, respectively. 
The multivariate analysis demonstrated that patients treated with 5-ASA 
(HR=1.59, 95%CI[1.01-2.49], p=0.04) were more likely to experience failure 
whereas patients with < 6 stools/day at day 3 (HR=0.40, 95%CI[0.21-0.77], 
p=0.006) and partial Mayo Clinic score < 2 at day 5 (HR=0.48, 95%CI[0.30-
0.77], p=0.003) were less likely to experience failure. There was no dif-
ference in failure-free survival between the naïve and failure group. The 
probabilities of colectomy-free survival were 95.8%, 95.0%, 93.2% and 
92.1% at 90.9% at 1, 2, 3, 4 and 5 years, respectively. The multivariate 
analysis demonstrated that patients with Lichtiger index > 12 (HR=10.1, 
95%CI[1.30-78.55], p=0.03) were more likely to experience colectomy.
conclusion: In patients with ASUC responding to IVS, there was a high 
failure rate of the initial maintenance therapy with only 40% of patients 
still in clinical remission at 5 years. Conversely, the colectomy rate was 
less than 10% at 5 years. Improvement in maintenance therapy after ASUC 
responding to IVS is needed.
disclosure: Aurelien Amiot received consulting fees from Abbvie, Hospira, 
Takeda, Gilead and Biocodex as well as lecture fees and travel accom-
modations from Abbvie, Janssen, Biocodex, Hospira, Ferring, Takeda and 
MSD. This author has also received advisory board fees from Gilead, Take-
da and Abbvie. 
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P1120 TransLaTIOnaL sTudIes In nOnhuMan PrIMaTes 
and huMan vOLunTeers suPPOrT The Phase 2 PrOgraM fOr 
ravagaLIMaB In MOderaTeLy TO severeLy acTIve uLceraTIve 
cOLITIs
Schreiber S.1, Clarke S.H.2, McRae B.L.2, Caldwell R.G.3, Nader A.3, 
Alperovich G.4, Lazar A.5
1Universität Kiel UKSH, Medizinische Abt. I, Kiel, Germany, 2AbbVie 
Bioresearch Center, Worcester, United States, 3AbbVie Inc., North Chicago, 
United States, 4Abbvie, Medical, Madrid, Spain, 5AbbVie Deutschland GmbH 
& Co KG Abt. Immunologie, Ludwigshafen, Germany
contact e-Mail address: s.schreiber@mucosa.de
Introduction: Inhibition of cellular activation of lymphocytes, macro-
phages, and dendritic cells via interference between cluster of differen-
tiation 40 (CD40) and its ligand (CD40L) represents an attractive target 
in inflammatory bowel disease (IBD). In chronic inflammatory conditions, 
non-hematopoietic, tissue-resident cells, such as epithelial and endothe-
lial cells, can also express CD40, and its stimulation contributes to tissue 
damage. Preclinical studies with anti-mouse CD40 antagonist and agonist 
monoclonal antibodies (mAbs) have demonstrated that CD40 signaling is 
required to induce and maintain intestinal inflammation in mouse models 
of IBD. We developed a humanized anti-CD40 mAb antagonist, ravagalim-
ab, as a potential therapeutic in IBD.
aims & Methods: To test the ability of ravagalimab to block the develop-
ment of T cell-dependent responses, we immunized cynomolgus monkeys 
with keyhole limpet hemocyanin (KLH) and assessed suppression of anti-
KLH immunoglobulins M and G (IgM and IgG). In addition, healthy volun-
teers received single or multiple doses of ravagalimab and the functional 
effect of CD40 receptor blockade on CD40L-mediated induction of p38 
phosphorylation was analyzed ex vivo in B cells.
results: Ravagalimab exhibited exclusive antagonist activity in vitro. It 
exhibited immunosuppressive pharmacology when evaluated for T-cell-
dependent antibody response in cynomolgus monkeys, completely inhibit-
ing formation of KLH-specific IgM and IgG when compared with vehicle-
treated animals. CD40 receptor occupancy on B cells from healthy subjects 
increased rapidly following intravenous administration of ravagalimab, 
reaching maximum occupancy of >90% within 1 to 3 days. This maxi-
mum receptor occupancy was maintained for up to 4 weeks (in a dose-
dependent manner) after the last dose of ravagalimab. During maximum 
receptor occupancy, ravagalimab was able to fully inhibit CD40L-mediated 
induction of p38 phosphorylation in B cells from healthy subjects. Impor-
tantly, when full receptor occupancy was lost, CD40L-mediated induction 
of p38 phosphorylation was completely restored, indicating that the inhi-
bition is reversible. Based on these translational studies, a clinical study to 
evaluate efficacy, safety, and pharmacokinetics of ravagalimab as a treat-
ment for patients with moderately to severely active ulcerative colitis (UC) 
is presently conducted as a multicenter proof-of-concept study (clinicaltri-
als.gov, NCT03695185). The primary endpoint is the proportion of patients 
with endoscopic improvement (Mayo endoscopic subscore of 0 or 1) at 
week 8 as assessed by central endoscopy reading.
conclusion: Translational evidence from an animal model and human cell 
assays strongly supports testing of the anti-CD40 antagonist mAb ravag-
alimab in a phase 2a study in patients with UC.
disclosure: Stefan Schreiber has received consulting fees and/or lectured 
for AbbVie, Amgen, Biogen, Bristol-Myers Squibb, Boehringer, Celltrion, 
Janssen, Merck, Pfizer, Roche, and Takeda. Stephen H. Clarke, Bradford L. 
McRae, Robert G. Caldwell, Ahmed Nader, Gabriela Alperovich, and An-
dreas Lazar are full-time employees of AbbVie and may own stock or stock 
options. 
P1121 IMPacT Of BIOLOgIc TreaTMenT Of crOhn’s dIsease 
On heaLThcare resOurce uTILIzaTIOn In us PaTIenTs
Hunter T.1, Naegeli A.1, Choong C.2, Dong Y.2, Crandall W.2
1Eli Lilly and Company, Global Patient Outcomes and Real World Evidence, 
Indianapolis, United States, 2Eli Lilly and Company, Indianapolis, United 
States
contact e-Mail address: hunter_theresa_marie@lilly.com
Introduction: This study compared healthcare resource utilization (HCRU) 
among Crohn’s Disease (CD) patients currently prescribed biologics and CD 
patients not currently prescribed biologics.
aims & Methods: Adult (18+ years) patients with ≥1 CD diagnosis code (ICD-
9: 555.x; ICD-10:K50.x) from January 1, 2017 to December 31, 2017 were 
included in this retrospective analysis of medical and pharmacy claims 
data from the IBM Marketscan Commercial, Medicaid, and Medicare-Sup-
plemental Claims database. Patients with an Ulcerative Colitis diagnosis 
were excluded from this study. Subgroups analyses were conducted to 
compare CD patients prescribed biologics and CD patients not prescribed 
biologics during 2017. A two-sample t-test was conducted to compare con-
tinuous variables and chi-squared tests were used to compare categorical 
variables.
results: A total of 49,292 CD were included in this analysis; 16,613 (33.7%) 
were prescribed a biologic and 32,679 (66.3%) were not prescribed a 
biologic. Biologic users were more likely to be male (46.7% vs. 41.0%; 
p<0.001) and younger (mean age: 40.51 vs. 46.79 years; p<0.001) when 
compared to patients not prescribed a biologic. Biologic users were more 
likely to be prescribed immunomodulators (21.9% vs/ 13.3%; p<0.001) and 
corticosteroids (40.8% vs. 34.3%; p<0.001), while patients not receiving 
biologics were more likely to be prescribed 5-ASAs (29.9% vs. 16.5%; 
p<0.001). Biologic users were also more likely to have gastroenterologist 
visits (75.1% vs. 52.2%; p<0.001). Patients not prescribed biologics were 
more likely to have ER visits (38.8% vs. 32.0%; p<0.001) and inpatient 
hospital visits (20.6% vs. 17.3%; p<0.001).
conclusion: Medication use was higher among CD biologic users, however 
CD patients not prescribed biologics had higher HCRU.
disclosure: Nothing to disclose 
P1122 OLaMkIcePT (sgP130fc) deMOnsTraTes TargeT 
engageMenT and InTerLeukIn-6 PaThWay InhIBITIOn 
assOcIaTed WITh cLInIcaL effecTIveness In an OPen LaBeL 
TrIaL (fuTure) In acTIve IBd
Schreiber S.1, Aden K.2, Conrad C.3, Bernardes J.4, Bethge J.5, Tran F.6, 
Hoeper H.4, Nikolaus S.7, Röcken C.8, Cottingham I.9, Rasmussen B.10, 
Petri N.10, Waetzig G.H.11, Chen M.12, Rosenstiel P.13
1Universität Kiel UKSH Medizinische Abt. I - UKSH, Universität Kiel UKSH 
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Kiel, Germany, 8UKSH Kiel, UKSH Kiel, Kiel, Germany, 9Ferring, R&D, St. Prex, 
Switzerland, 10Ferring Pharmaceuticals Centre S.A., Kopenhagen, Denmark, 
11Conaris Research Institute, Kiel, Germany, 12Sun Yat-Sen University, 
Gastroenterology & Hepatology, Guangzhou, China, 13Kiel University, 
University Hospital Schleswig-Holstein, Institute of Clinical Molecular 
Biology (IKMB), Kiel, Germany
contact e-Mail address: k.aden@ikmb.uni-kiel.de
Introduction: Interleukin-6 (IL-6) is a master regulator of inflammatory 
responses. Immediate IL-6-mediated effects are attributed to classic sig-
nalling, following binding of IL-6 to a membrane bound IL-6 receptor com-
plex. In contrast, chronic inflammation is mediated by trans-signalling, in 
which a complex of circulating soluble IL-6R isoforms (sIL-6R) together 
with IL-6 can engage virtually every body cell by binding to the ubiquitous 
gp130 co-receptor. The fusion protein olamkicept (sgp130Fc, FE 999301, 
TJ301, ola) is a cytokine trap that selectively neutralises IL-6/sIL-6R com-
plexes and hence intercepts trans-signalling(1). In clinical Phase I, ola 
showed target engagement and excellent tolerability without systemic im-
mune suppression in >50 healthy and patient volunteers. Here, we report 
the first administration of ola to patients with active IBD in an open label 
study (FUTURE).
aims & Methods: FUTURE was a Phase 2a open label study, in which 20 
adult patients with active IBD were included (baseline endoscopies) and 
16 patients (UC=9, CD=7) were dosed with ola (600 mg iv q 2 weeks for 
up to 12 weeks plus 42-day safety follow-up). Patients had moderately to 
severely active UC (Mayo score max. 11 and endoscopic sub-score ≥2) or 
ileocolonic CD (CDAI 220-500, SES-CD>7), immunologically active inflam-
mation (CRP >5 mg/L), had failed conventional therapies, and had received 
no more than 2 prior biologics (limited to anti-TNFs and/or vedolizumab). 
Primary endpoint was the proportion of patients with reduced mucosal 
expression of a predefined 6-gene score measured by RNA sequencing. 
Objective assessments included centrally read endoscopies, histology and 
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various explorative molecular parameters and inflammatory biomarkers. 
The trial was sponsored and conducted by the University Medical Center 
Schleswig Holstein under prior approval of the medical faculty’s ethics 
committee and the Paul-Ehrlich Institute (EUDRA-CT 2016-000205-36). Ola 
was provided by Ferring Pharmaceuticals A/S.
results: Ola was well tolerated. AEs were unspecific in nature and showed 
no signs of immune suppression. There were no life-threatening or poten-
tially ola-related SAEs. Activity scores were in the moderate-severe range 
(Mayo 10, CDAI 330) with high inflammation markers [median CRP/FCP 
29.6/1,795) (UC) and 16.4/2,098 (CD)] and with median disease duration of 
5.3 (UC) and 6.9 (CD) years. Pharmacokinetic studies showed stable and 
sustained exposure in plasma concentrations. Target engagement of ol-
amkicept was confirmed by whole-blood STAT3 phosphorylation assays in 
all patients. Overall, 55% of patients with UC responded (5/9) and 22% 
(2/9) reached remission (Mayo), and 28% (2/7) CD patients responded 
with 14% (1/7) reaching remission. All patients in clinical remission also 
showed endoscopic healing. The primary endpoint was achieved in 12,5% 
(n=2/16) patients and was highly predictive of later clinical endoscopic and 
histologic remission. Blood transcriptome analysis showed early molecu-
lar anti-inflammatory signature (as early as 4 h after treatment) in all pa-
tients, irrespective of treatment outcome.
conclusion: TThe first human efficacy data with ola indicate anti-inflam-
matory efficacy of IL-6 trans-signalling inhibition in patients with IBD. This 
preliminary signal appears to be stronger in UC than in CD. A larger, place-
bo-controlled, multinational Phase II study examining olamkicept (TJ301) 
in moderately to severely active UC is currently conducted in China and 
other East Asian countries (NCT03235752).
references: Jostock T, Müllberg J, Özbek S, Atreya R, Blinn G, Voltz N, 
Fischer M, et al. Soluble gp130 is the natural inhibitor of soluble interleu-
kin-6 receptor transsignaling responses. European Journal of Biochemistry 
2001;268:160-167.
disclosure: This trial was conducted under non-commercial sponsorship 
by University Medical Center Schleswig Holstein, Campus Kiel, with full 
source data verification and regulatory support by the Kiel Center for Clini-
cal Studies (ZKS). Grant support and the IMP were received from Ferring 
Pharmaceuticals A/S. 
P1123 effIcacy, safeTy and cOsT-effIcIency Of adaLIMuMaB 
80 Mg every OTher Week In PrevIOusLy InTensIfIed PaTIenTs 
On adaLIMuMaB 40 Mg every Week
Barreiro-De Acosta M.1,2, Ferreiro Iglesias R.1,2, Jardi-Cuadrado A.1,2, 
Quiroga-Castiñeira A.1,2, Baston-Rey I.1,2, González J.3, Sousa A.3, Zarra I.3, 
Dominguez-Muñoz J.E.4
1University Hospital of Santiago de Compostela, Gastroenterology, Santiago 
de Compostela, Spain, 2Health Research Institute of Santiago de Compostela, 
Santiago de Compostela, Spain, 3University Hospital of Santiago de 
Compostela, Pharmacy, Santiago de Compostela, Spain, 4University Hospital 
of Santiago de Compostela. Health Research Institute of Santiago de 
Compostela, Gastroenterology, Santiago de Compostela, Spain
contact e-Mail address: manubarreiro@hotmail.com
Introduction: Dose escalation is often recommended for loss of response in 
patients with inflammatory bowel disease (IBD) under maintenance treat-
ment with anti-TNF, but this strategy considerably increases the costs. A 
new presentation of adalimumab (ADA) 80 mg has been approved with 
a similar price per unit in our hospital as the ADA 40 mg presentation.
aims & Methods: The aim of this study was to evaluate the efficacy, safety 
and cost-efficiency of ADA 80 mg every other week (eow) in IBD patients 
under intensified treatment with ADA 40 mg every week.
Material and methods: A prospective and observational study was per-
formed. Inclusion criteria were all IBD patients under intensified main-
tenance therapy with ADA 40 mg every week. Patients were informed 
about the reasons (cost and convenience) for switching to ADA 80 mg eow 
and asked for their consent. Follow-up time was 6 months. The Harvey 
Bradshaw index (HBI ≤4) and the Mayo partial index (Mayo partial index 
≤2) were used to evaluate clinical remission in Crohn’s disease (CD) and 
ulcerative colitis (UC) patients, respectively. Adverse events were moni-
tored. Faecal calprotectin (FC) and C reactive protein (CRP) were evalu-
ated at baseline (week 0, before first dose of subcutaneous injection of 
ADA 80mg) and at months 1, 2 and 6. Biological remission was defined as 
clinical remission, together with FC < 250 µg/g and CRP < 5 mg/dL. Trough 
drug concentrations and drug antibodies were measured at baseline and 
at months 1, 2 and 6 by ELISA (Promonitor). Trough levels < 5 mg/L were 
considered as infratherapeutic. A descriptive analysis was performed and 
data are shown as percentage, median and range. Cost-efficacy analysis 
was also performed.
results: Sixteen patients were included (15 CD and one extensive UC, 
median age 40 years, 56.3% male, 37.5% non-smokers and 31.3% ex-
smokers). In CD, 46.7% had ileal disease, 13.3% colonic disease and 40% 
ileocolonic disease. 46.7% CD patients presented fistulising behaviour. At 
baseline, 86.7% of patients were in clinical remission and 92.3% were in 
clinical remission after 1 month. Median FC concentration and CRP concen-
tration from baseline to month 6 are shown in Table 1. 
  at month 0 at month 1 at month 2 at month 6
Median fecal 
calprotectin (µg /g) 
(range)
317 
(6-1900)
223 
(10-3754)
92 
(32-4527)
82 
(7-3772)
Median c reactive 
protein (mg/dL) 
(range)
0.14 
(0-19)
0.44 
(0.01-2.94)
0.41 
(0.01-6.95)
0.16 
(0.01-1.08)
[Median faecal calprotectin and C reactive protein in IBD patients under 
maintenance treatment con adalimumab 80 mg every other week]
60%, 53,3% and 68,8% of patients were in biological remission at month 
0, 1 and 2, respectively. No adverse events were registered. No significant 
differences in trough levels concentrations were observed from baseline 
to month 2, but 7% of patients had trough levels < 5 mg/L. At month 6, 
three patients withdrew ADA 80mg treatment because of relapse, none 
of them were in biological remission at inclusion. The remaining patients 
maintained clinical remission; 61.5% of them were in biological remis-
sion. After six months, including only patients in remission that completed 
the treatment, a total of 114,000 € were saved with the new schedule of 
treatment.
conclusion: Changing to a single dose ADA 80 mg eow is an effective, 
safe and efficient strategy in IBD patients under intensified maintenance 
therapy with ADA 40 mg every week.
disclosure: Nothing to disclose 
P1124 sPerMIdIne TreaTMenT aMeLIOraTes exPerIMenTaL 
cOLITIs in vivo
Niechcial A.1, Katkeviciute E.1, Hering L.1, Wawrzyniak M.1, 
Schwarzfischer M.1, Baebler K.1, Atrott K.1, Scharl M.1,2, Spalinger M.R.1
1University Hospital Zurich, Department of Gastroenterology and Hepatology, 
Zürich, Switzerland, 2Zürich Center for Integrative Human Physiology, 
University of Zürich, Zürich, Switzerland
contact e-Mail address: anna.niechcial@usz.ch
Introduction: Genetic variants within the gene locus encoding protein ty-
rosine phosphatase non-receptor type 2 (PTPN2) are associated with an 
increased risk for inflammatory bowel disease (IBD). In the intestine of 
IBD patients, cellular levels of the natural polyamine spermidine are re-
duced. We have already demonstrated, that spermidine activates PTPN2 
and thereby supresses pro-inflammatory effects in vitro and in vivo. These 
effects are even further enhanced in immune cells derived from PTPN2 
variant IBD patients, however the molecular mechanisms underlying the 
anti-inflammatory properties of spermidine remain poorly defined.
aims & Methods: The aim of this study was to investigate the effect and 
molecular mechanisms of spermidine treatment in a T-cell mediated 
mouse colitis. 
To induce intestinal inflammation, Rag2-/- immunodeficient mice were 
injected intraperitoneally with wild-type (WT) or PTPN2-deficient (KO) 
naïve T-cells. Spermidine (3mM) was administered in the drinking water 
throughout the experiment. Colitis severity was evaluated by using mouse 
endoscopy, histological analysis of the colon, and myeloperoxidase activ-
ity. To assess T-cell subsets, flow cytometry was performed on lamina pro-
pria lymphocytes (LPL).
results: Spermidine treatment significantly ameliorated colitis symptoms, 
as observed by decreased weight loss (p< 0.001), reduction of endoscopic 
colitis scores (p< 0.001), absence of colon shortening (p< 0.01) and lower 
signs of inflammation in histological assessment of the terminal colon (p< 
0.001) in mice receiving WT T-cells and KO T-cells. In addition, myeloper-
oxidase activity, a measurement of infiltrating myeloid cells was signifi-
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cantly reduced (p< 0.001) in mice receiving spermidine when compared 
to untreated mice. Furthermore, administration of spermidine resulted in 
a significant reduction of CD4+ T-cell numbers (p< 0.01) in LPL of mice re-
ceiving WT T-cells, but not in mice receiving KO T-cells. Interestingly upon 
spermidine treatment, relative abundance of neither IFN-γ+ T helper (Th) 1 
cells, IL-17+ Th17 cells nor IL-17+IFN-γ+ Th1/17 was affected in mice receiving 
WT T-cells or KO T-cells.
conclusion: Our results demonstrate that spermidine treatment signifi-
cantly ameliorates T-cell induced colitis. Interestingly, the mode of action 
of spermidine is not dependent on presence of PTPN2 in T-cells, which 
implicates that spermidine treatment might have a local effect on the mu-
cosa and or other stromal cells. Nevertheless, our findings indicate that 
spermidine administration might be a promising novel therapeutic strat-
egy for IBD treatment.
disclosure: Nothing to disclose 
P1125 IdenTIfIcaTIOn Of BIOMarkers and MechanIsTIc 
InsIghT fOr uPadacITInIB In crOhn’s dIsease: seruM 
InfLaMMaTOry MedIaTOr anaLysIs frOM The Phase 2B ceLesT 
sTudy
Vermeire S.1, Guay H.M.2, Verstockt B.3, Hong F.2, Lee W.-J.4, Cataldi F.4, 
Lacerda A.4, Danese S.5
1University Hospital Leuven, Gastroenterology, Leuven, Belgium, 2AbbVie 
Inc., Worcester, United States, 3KU Leuven, Leuven, Belgium, 4AbbVie Inc., 
Chicago, United States, 5Istituto Clinico Humanitas, Milan, Italy
contact e-Mail address: severine.vermeire@uz.kuleuven.ac.be
Introduction: The CELEST study (NCT02365649) evaluated the selective Ja-
nus kinase-1 (JAK-1) inhibitor upadacitinib (UPA) in patients with moder-
ately to severely active Crohn’s disease (CD). Improvements in clinical and 
endoscopic outcomes and a safety profile consistent with that reported 
in rheumatoid arthritis trials were observed.1,2 Here we report pharma-
codynamic profiling of serum inflammatory mediators in CELEST patients 
with the aim of understanding UPA mechanism of action in CD and link-
ing biomarkers to intestinal inflammation, abdominal pain (AP), and stool 
frequency (SF).
aims & Methods: CELEST was a Phase 2, multicenter, randomized, double-
blind, placebo (PBO)-controlled study designed to evaluate the efficacy 
and safety of multiple dosing regimens of UPA versus PBO in adult patients 
with an inadequate response or intolerance to immunomodulators and/or 
TNF inhibitors.1,2 Serum samples from the baseline (BL) visit and the end 
of the induction period (Wk 16) were analyzed by the OLINK® inflamma-
tion panel (92 proteins) and by Singulex immunoassay for interleukin-17A 
(IL-17A), IL-17C, IL-17F, IL-22, and IL-23p19. Protein level changes (BL-Wk 
16) were analyzed by an ANCOVA model where the BL protein level was 
adjusted as a covariate and the treatment effect was considered signifi-
cant when a false discovery rate < 0.10 was observed after multiplicity 
adjustment on F-test p-values. Spearman rank correlation coefficients (r
s
) 
were used to determine relationships between BL levels or BL-Wk 16 level 
changes of serum biomarkers (also including serum C-reactive protein and 
fecal calprotectin) and improvements in Simple Endoscopic Score for CD 
(SES-CD), AP, and SF.
results: Paired BL and Wk 16 serum samples were available from 104 pa-
tients (UPA 3 mg twice daily [BID], n=18; 6 mg BID, n=19; 12 mg BID, n=13; 
24 mg BID, n=18; 24 mg once daily, n=18; and PBO, n=18). UPA treatment 
significantly reduced expression of serum pro-inflammatory mediators 
(Table) that are associated with immune cell migration, type I/II interfer-
on (IFN) responses, T cell activation, T helper cell-1 (Th1) responses, and 
CD8+ T cell responses. Additionally, numerical changes for modulation of 
mediators of macrophage and dendritic cell activity, hematopoiesis, and 
neuroprotection were observed. UPA treatment did not significantly modu-
late expression of IL-23/Th17-related serum cytokines in CD. Correlations 
were observed for BL-Wk 16 changes in serum proteins and SES-CD, AP, or 
SF. Importantly, oncostatin-M reductions correlated with SES-CD (r
s
=0.35, 
p=0.02) and with SF improvement (r
s
=0.33, p=0.04), suggesting similar 
drivers of these aspects of disease. AP improvement correlated with reduc-
tions in CSF-1 (r
s
=0.37, p=0.01), TNFRSF9 (r
s
=0.34, p=0.03), IL-12B (r
s
=0.31, 
p=0.07), CXCL9 (r
s
=0.31, p=0.07), and CD8A (r
s
=0.31, p=0.09), which are all 
associated with the Th1/CD8/IFN-γ pathway.
conclusion: This analysis of inflammatory mediators in serum of CD pa-
tients from CELEST identifies potential pharmacodynamic biomarkers and 
mechanistic insights for the JAK-1 inhibitor, UPA. These data suggest that 
UPA has a differentiated mechanism from therapies targeting IL-12/23 p40 
and IL-23 p19. Correlations between biomarker changes and changes in 
signs, symptoms, and intestinal inflammation of CD suggest that UPA may 
drive improvement of these aspects of CD through distinct mechanisms.
Biomarker p-value
TNFRSF9
CXCL10
CCL19
PD-L1
CXCL9
CXCL11
TNFB
CD5
IL-18
CCL23
SLAMF1
0.01
0.01
0.01
0.03
0.03
0.03
0.04
0.08
0.08
0.08
0.09
[Biomarkers displaying BL-Wk 16 changes (all reductions) meeting the 
statistical cut-off with calculated FDR adjusted p-values]
references: 1. Sandborn WJ et al. DDW 2017 [Abstract #874h]. 2. Panés J et 
al. ECCO 2018 [Abstract #P273]. 3. Olink proteomics website, https://www.
olink.com/products/inflammation-2/, accessed Mar 28, 2019.
disclosure: Bram Verstockt: Financial support for research from Pfizer; lec-
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Takeda; consultancy fees from Janssen. Silvio Danese: Served as speaker, 
consultant, and advisory board member for AbbVie, Allergan, Biogen, 
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UCB Pharma, and Vifor Pharma. Séverine Vermeire: Received grant sup-
port from AbbVie, MSD, Pfizer, and Takeda; lecture fees from AbbVie, Fer-
ring Pharmaceuticals, Hospira, MSD, and Takeda; consultancy fees from 
AbbVie, Celgene Ferring Pharmaceuticals, Galapagos, Genentech/Roche, 
Hospira, MSD, Mundipharma, Pfizer, Shire Pharmaceuticals Group, and 
Takeda. Heath M. Guay, Feng Hong, Wan-Ju Lee, Fabio Cataldi, and Ana 
Lacerda: AbbVie employees, and may own AbbVie stock and/or options. 
The study was funded by AbbVie. AbbVie participated in the study design, 
data acquisition and interpretation, and in the writing, review, and ap-
proval of this abstract. Medical writing assistance was provided by Kevin 
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P1126 Pregnancy OuTcOMes In WOMen exPOsed TO 
gOLIMuMaB - uPdaTe
Esslinger S.1, Gabriel S.2, Otero-Lobato M.1, Clark M.2, Sheridan P.2, 
Geldhof A.1
1Janssen Biologics B.V., Medical Affairs, Leiden, Netherlands, 2Janssen 
Research & Development, LLC, Horsham, United States
contact e-Mail address: sesslin1@its.jnj.com
Introduction: Rheumatologic disorders and inflammatory bowel disease 
(IBD) can affect women of childbearing potential. Golimumab (GLM) is ap-
proved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing 
spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axial SpA), 
polyarticular juvenile idiopathic arthritis (pJIA) and ulcerative colitis (UC). 
To characterize pregnancy outcomes in patients treated with GLM, data 
obtained from maternal exposure to GLM are presented.
aims & Methods: This dataset includes individual patient cases reported to 
the manufacturer through 06 April 2018. Cases retrieved included prospec-
tively reported (ie, pregnancy outcome not known when first reported) 
and retrospectively reported (ie, pregnancy outcome known when first re-
ported) maternal exposures to GLM during pregnancy or within 2 months 
prior to conception, and a reported pregnancy outcome. Cases originated 
from various sources, including spontaneous reporting, clinical studies, 
and registries.
results: Two hundred nine pregnancy cases with reported outcomes (113 
rheumatological, 37 UC, and 59 others) were identified. Of these 209 cas-
es, 128 were prospective and 81 were retrospective. Overall, 9 congenital 
anomalies were reported (1 in UC). A total of 50 spontaneous abortions 
were noted (23.9%). Of these, 22.0% (11/50) received GLM in combination 
with MTX. Detailed outcomes are provided in Table 1.
conclusion: The rates of congenital malformations and spontaneous abor-
tions were consistent with published background rates for the general 
population. Limitations of this analysis included the lack of a direct com-
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parison group, the variable amount of data available in the reports, and 
the possible bias towards reporting more negative outcomes in retrospec-
tive cases.
Pregnancy 
Outcome            
  count (%) rheum uc Other congenital anomaly MTx(a)
Prospective cases  
Live birth(b) 90 (70.3) 45 (66.2) 17 (73.9) 28 (75.7) 1 (25) 10 (45.4)
Spontaneous 
abortion
23 (18.0) 16 (23.5) 3 (13.0) 4 (10.8) 0 8 (36.4)
Elective/Induced 
abortion(c)
13 (10.2) 6 (8.8) 2 (8.7) 5 (13.5) 3 (75) 3 (13.6)
Ectopic pregnancy 2 (1.6) 1 (1.5) 1 (4.3) 0 0 1 (4.5)
Total 128 68 23 37 4 22
retrospective 
cases  
Live birth(d,e) 49 (60.5) 26 (57.8) 8 (57.1) 15 (68.2) 5 (100) 3 (37.5)
Spontaneous 
abortion
27 (33.3) 16 (35.6) 5 (35.7) 6 (27.3) 0 3 (37.5)
Elective/Induced 
abortion
4 (4.9) 2 (4.4) 1 (7.1) 1 (4.5) 0 1 (12.5)
Ruptured ectopic 1 (1.2) 1 (2.2) 0 0 0 1 (12.5)
Total 81 45 14 22 5 8
grand total 209 113 37 59 9 30
Rheum=RA, AS, PsA (a) Patient received MTX at the time of conception/during 
pregnancy. (b) The count includes 6 cases with pregnancy outcome live birth with AEs: 
Low birth weight baby (3), Premature baby (2); Feeding disorder neonatal, Jaundice and 
Respiratory distress (reported once each) and 1 case with congenital anomaly Foetal 
macrosomia. (c) The count includes 3 cases with congenital anomalies: Anencephaly, 
Down syndrome and Turner‘s syndrome. (d) The count includes 6 cases with 
pregnancy outcome live birth with AEs: Premature baby (2); Bradycardia foetal, Colitis 
ulcerative, Fungal infection, Gastric disorder, Low birth weight baby, Milk allergy, Rash 
generalised and Sepsis. (e) The count includes 5 cases with congenital anomalies: Atrial 
septal defect, Cataract congenital, Congenital anomaly, Ellis-van Creveld syndrome, 
Galactosaemia and Heart disease congenital.
[Table 1: Summary of Pregnancy Outcomes in Patients Treated With GLM]
disclosure: Authors are employees of Janssen Research & Development or 
Janssen Biologics BV 
P1127 TreaTMenT OuTcOMes fOLLOWIng adMInIsTraTIOn 
Of vedOLIzuMaB In PaTIenTs WITh MOderaTe TO severe 
uLceraTIve cOLITIs
Bamias G.1, Xourafas V.1, Tsoukali E.2, Viazis N.2, Mantzaris G.J.2, 
Gizis M.1, Zacharopoulou E.3, Tzouvala M.3, Leonidakis G.4, Zampeli E.4, 
Michopoulos S.4, Makris K.5, Michalopoulos G.5, Papatheodoridis G.6, 
Greek Vedolizumab Study Group
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Hospital of Nikea and Pireaus Ag Panteleimon, Gastrenterology, Nikea, 
Greece, 4Alexandra Hospital, Dept. of Gastroenterology, Athens, Greece, 
5Tzaneio Hospital Piraeus, Gastroenterology, Pireaus, Greece, 6National 
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Introduction: The anti-integrin monoclonal antibody vedolizumab (VDZ) 
has been approved for the treatment of moderate to severe ulcerative 
colitis (UC). There is a need for evaluating the clinical efficacy of VDZ in 
real-world clinical settings. In addition, the effect of VDZ on the endo-
scopic activity of UC and its ability to induce mucosal healing are still being 
explored.
aims & Methods: We aimed to report the clinical and endoscopic response 
to VDZ in a large cohort of Greek patients with UC who were refractory 
to previous therapies. Patients were recruited from 11 tertiary Greek IBD 
centers. VDZ was administered according to standard induction and main-
tenance protocols. Short-term response was evaluated at week 12 and de-
fined according to the Gemini 1 criteria (reduction in the Mayo Clinic score 
of at least 3 points and a decrease of at least 30% from baseline, with a 
decrease of at least 1 point on the rectal bleeding subscale or an absolute 
rectal bleeding score of 0 or 1). Long-term efficacy was evaluated at week 
54. Persistence of treatment at week 54 was considered as an indicator of 
clinical efficacy. The Gemini 1 Criteria for remission at 54 weeks (full Mayo 
score of 2 or lower and no subscore higher than 1) were also independent-
ly applied. Mucosal healing was defined as endoscopy Mayo score of 0.
results: In total, 97 patients with UC [males=57, mean age: 45, (range: 
17-79 years)] have been included in the study. Three patients had proctitis 
(E1), 37 left-sided colitis (E2), and 57 extensive disease (E3). Twenty-three 
patients (23.7%) had at least one active extraintestinal manifestation at 
VDZ commencement. There were 53 anti-TNF naive patients. We present 
herein data from the 78 patients who have completed at least one-year 
from initiation of VDZ treatment. 
Short-term response data: At wks 12-14, 17/78 patients (21.8%) exhibited 
no response, while 61/78 (78.2%) fulfilled criteria for clinical response. 
Twenty-two patients (28.2%) were on concomitant treatment with corti-
costeroids and 13 (16.7%) with azathioprine/6-mercaptopurine. A colo-
noscopy at 12-14 wks was performed in 48 patients; 27% had complete 
mucosal healing (endo Mayo score=0), whereas an additional 48% had 
partial endoscopic response (decrease in endoscopic Mayo Score). We ob-
served statistically significant improvement in patient-reported outcomes 
(PRO) from week 0 to week 12 of treatment with VDZ. In particular, PRO-
UC1/rectal bleeding decreased from 1.22 ± 0.98 to 0.32 ± 0.65, (P< 0.0001) 
and PRO-UC2/number of bowel movements from 2.69 ±1.12 to 1.51 ± 0.78, 
(P< 0.0001), whereas SIBDQ score increased from 43 ± 13 to 55 ± 10, (P< 
0.0001). 
Long-term response data: At week 54, 52/78 patients were still on VDZ 
therapy (drug persistence: 68%). Less than 10% of patients were receiv-
ing concomitant steroids and 15% azathioprine/6-mercaptopurine. Of the 
patients who had a colonoscopy at week 52 (n=30), 30% demonstrated 
complete mucosal healing and another 43% had a partial endoscopic re-
sponse. At wk 54, PRO-UC1/rectal bleeding decreased from 1.34 ± 1.03 to 
0.31 ± 0.6, (P<0.0001) and PRO-UC2/number of bowel movements from 
1.82 ± 1.12 to 0.67 ± 0.88, (P<0.0001), whereas SIBDQ score increased from 
41 ± 16 to 50 ± 13, p=056).
conclusion: In this national multicenter study, VDZ demonstrated high re-
sponse rates both in the short- and long-term evaluations. Satisfactory 
outcomes were obtained at the clinical and endoscopic measurements 
combined with improved quality of life. Our study adds to other published 
data on real-world evidence and supports the notion that VDZ is a reliable 
therapeutic option for patients with UC.
disclosure: This study has been funded by an IISR from Takeda to G.B. 
and G.P. 
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P1130 LOng-TerM safeTy and effIcacy Of rIsankIzuMaB 
TreaTMenT In PaTIenTs WITh crOhn’s dIsease: 3-year InTerIM 
resuLTs frOM The OngOIng Phase 2 OPen-LaBeL exTensIOn 
sTudy
Ferrante M.1, Feagan B.G.2, Panés J.3, Baert F.4, Louis E.5, Dewit O.6, 
Kaser A.7, Duan W.R.8, Gustafson D.8, Liao X.8, Wallace K.8, Kalabic J.9, 
D’Haens G.R.10
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contact e-Mail address: jasmina.kalabic@abbvie.com
Introduction: Efficacy and safety of the IL-23 inhibitor risankizumab (RZB) 
have been previously assessed in pts with moderate-to-severe Crohn’s 
disease (CD) following induction and maintenance treatments.1,2 Pts who 
643Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
responded to RZB in the Phase 2 induction and maintenance study2,3 could 
enroll in an open-label extension (OLE).4 Interim safety and efficacy of RZB 
maintenance treatment, up to 3 yrs, are reported from this ongoing OLE.
aims & Methods: Pts who achieved clinical response (decrease from BL in 
CD Activity Index [CDAI] ≥100) without remission (CDAI < 150) after Period 2 
(Wk 26) or clinical response and/or remission after Period 3 (Wk 52) of the 
preceding study1 were enrolled to receive open-label 180 mg s.c. RZB every 
8 wks for up to 206 wks.4 Pts who lost clinical response or remission after 
completing the preceding study were re-induced with open-label 600 mg 
i.v. RZB at Wks 0, 4, 8. Pts receiving re-induction treatment could only re-
ceive subsequent 180 mg s.c. RZB every 8 wks if they regained response or 
remission following re-induction treatment. Ileocolonoscopy with central 
reading was performed yearly. Treatment-emergent adverse events (AEs) 
were collected throughout the study up to 20 wks after the last dose of 
study drug or the data cut-off date of Feb 04, 2019. Efficacy data (clini-
cal remission [CR] and endoscopic remission [ER] [CD Endoscopic Index 
of Severity (CDEIS) ≤4 or CDEIS ≤2 for pts with isolated ileitis at baseline]) 
are reported to Wk 104 in the OLE, when all pts enrolled in the OLE had 
the opportunity to reach the visit date before the interim cut-off date. Non-
responder imputation (NRI) was used for binary endpoints.
results: A total of 65 adults with CD were enrolled, including four pts who 
were re-induced. Median age was 34 yrs (range 19-67 yrs) and median 
disease duration was 10 yrs (range 2-38 yrs). Sixty pts (92.3%) were previ-
ously exposed to TNF antagonists; 13 pts (20%) and 21 pts (32.3%) were 
receiving corticosteroids only and immunomodulators only, respectively, 
and 9 (11.8%) pts were receiving both, prior to BL of the preceding study. 
At the data cut-off date, mean (SD) exposure to RZB was 866.8 (316.6) 
days, and 18 (27.7%) pts had prematurely discontinued from the study. At 
Wk 0 of the current study, 47/65 (72.3%) pts were in CR and 27/63 (42.9%) 
pts had ER based on the observed data. Both CR and ER were sustained 
up to Wk 104 (Table). After a median follow-up of 31 months, AEs were 
reported for 58/65 (89.2%) pts; 22 (33.8%) experienced serious AEs. The 
most common AEs were nasopharyngitis (29.2%), gastroenteritis (20.0%), 
fatigue, abdominal pain, and worsening CD (18.5% each), and arthralgia 
(15.4%). Serious infections were reported in six pts: anal or subcutaneous 
abscess (1 pt each), Campylobacter infection (1 pt), viral gastroenteritis (2 
pts), and peritonitis (2 pts). No events of tuberculosis were reported, and 
no malignancies or deaths occurred.
conclusion: In this 3-yr interim analysis, both clinical and endoscopic re-
missions were sustained in pts with CD receiving long-term open-label 
RZB treatment. The safety profile of RZB remains consistent with previous 
results.2 No new safety signals were identified.
 
clinical remission 
n/n (%)
endoscopic remissiona 
n/n (%)
Week 0b 47/65 (72.3) 27/65 (41.5)
Week 8 48/65 (73.9) —
Week 16 46/65 (70.8) —
Week 48 46/65 (70.8) 35/65 (53.9)
Week 104 41/65 (63.1) 28/65 (43.1)
All patients in the OLE had the opportunity to reach the Week 104 visit before the cut-off 
date. aData are from central reading. bVisits in OLE.
[Clinical remission and endoscopic remission by visit in patients receiving 
open-label 180 mg s.c. RZB maintenance treatment (NRI analysis)]
references: 1. Feagan BG et al. Lancet 2017;389:1699-1709. 2. Feagan BG 
et al. Gastroenterology 2017;152:S1310. 3. Feagan BG et al. Lancet Gastro-
enterol Hepatol 2018;3:671-680. 4. Ferrante M et al. 2018, UEG Journal 
2018;6(Supplement 1) [OP307].
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P1131 suPerIOr OuTcOMe WITh earLy BIOLOgIc-cOMBInaTIOn 
TreaTMenT In crOhn’s dIsease: daTa frOM an InTernaTIOnaL 
IncePTIOn cOhOrT
Matheeuwsen M.1, Vermeijden N.K.1, Bossuyt P.2, Pouillon L.2, 
Bemelman W.A.3, D’Haens G.R.1, Gecse K.B.1
1Amsterdam UMC, Gastroenterology and Hepatology, Amsterdam, 
Netherlands, 2Imelda GI Clinical Research Center, Gastroenterology, 
Bonheiden, Belgium, 3Academisch Medisch Centrum, Surgery, Amsterdam, 
Netherlands
contact e-Mail address: matheeuwsen_1@hotmail.com
Introduction: Crohn’s disease (CD) is a complex disorder characterized by 
intestinal inflammation leading to progressive bowel damage. Treatment 
goals have evolved over preceding years from clinical remission to preven-
tion of structural bowel damage. It is unknown which treatment options/
sequences lead to the most optimal outcome in patients with newly diag-
nosed CD.
aims & Methods: The aim of this study was to compare different treatment 
strategies and associated outcomes in early CD. We performed a retro-
spective study including adult patients with newly diagnosed CD at the 
Academic Medical Center of Amsterdam (The Netherlands) (September 
2013-September 2018) or at the Imelda hospital in Bonheiden, Belgium 
(January 2009-January 2019). Based on first-line treatment choice, pa-
tients were assigned to one of the five pre-defined management groups. 
Primary outcome was time to treatment failure, defined as a switch to 
another treatment, escalating CD treatment, need for endoscopic balloon 
dilation or surgery, CD-associated hospitalization or a new perianal fistula. 
Kaplan-Meier survival analysis was used to estimate the median treatment 
survival per group.
results: One hundred and forty-nine patients were included: treatment 
with corticosteroids only as first treatment (group 1) was started in 24 
patients, immunomodulators (azathioprine, 6-mercaptopurine or metho-
trexate; group 2) in 70 patients, biological therapy (infliximab, adalim-
umab or vedolizumab; group 3) in 22 patients, biological therapy in combi-
nation with an immunomodulator (group 4) in 21 patients and 12 patients 
underwent early surgery (group 5). 
Baseline characteristics (CRP, CD Endoscopic Index of Severity, Simple En-
doscopic Score for CD, smoking status) were similar between treatment 
groups. Group 5 had significantly more patients with stricturing (Montreal 
B2) and penetrating (Montreal B3) disease subtypes (Table 1). 
Log-rank test revealed significantly longer median treatment survivals in 
group 5 (215 days; 95% CI 25, 405), group 4 (863 days) and group 3 (321 
days; 95% CI 184, 457) compared to median treatment survival in group 2 
(119 days; 95% confidence interval (CI) 85, 152) (p≤0.01). 
Median treatment survival in group 4 (863 days) was significantly longer 
compared to group 1 (195 days; 95% CI 139, 251) (p< 0.01) (Table 1). 
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  group 1. (n=24)
group 2. 
(n=70)
group 3. 
(n=22)
group 4. 
(n=21)
group 5. 
(n=12) significance
Baseline (at diagnosis)
age (years, 
mean, [sd])
39 
[19]
35 
[16]
28 
[12]
37 
[16]
39 
[16] p=0.15
active smoker 
(%)*
35 
(n=20)
47 
(n=53)
47 
(n=15)
36 
(n=14)
27 
(n=11) p=0.85
crP (mg/L, 
mean, [sd])*
22 [28] 
(n=15)
29 [33] 
(n=38)
21 [21] 
(n=12)
23 [16] 
(n=10)
65 [79] 
(n=7) p=0.51
cdeIs (mean, 
[sd])*
17 [5] 
(n=2)
9 [4] 
(n=14)
13 [4] 
(n=6)
10 [5] 
(n=5) 8 [5] (n=6) p=0.06
ses-cd (mean, 
[sd])*
18 [14] 
(n=3)
13 [5] 
(n=16)
18 [6] 
(n=6)
13 [8] 
(n=6)
10 [6] 
(n=6) p=0.27
Montreal L1 (%) 38 51 41 43 33 p=0.63
Montreal L2 (%) 16 6 18 24 0 p=0.07
Montreal L3 (%) 46 43 41 33 67 p=0.46
Montreal B1 (%) 54 61 68 71 8 p<0.01
Montreal B2 (%) 8 14 9 24 67 p<0.01
Montreal B3 (%) 8 9 5 5 50 p<0.01
Outcome
Treatment 
survival 
(days, median, 
[95% cI])
195 
[139, 251]
119 
[85, 152]
321 
[184, 457]
863 days 
**
215 
[25, 405] p<0.01
[Table 1. *% based on available data indicated by n=(x) **Median survival 
not reached after median follow-up 751 days; hence 95%-CI cannot be 
calculate]
conclusion: These real-world data show superiority of biological treat-
ment, combination therapy and early surgery in newly diagnosed CD pa-
tients.
disclosure: Nothing to disclose
P1132 uTILITy Of vedOLIzuMaB drug LeveL MOnITOrIng In IBd 
PaTIenTs - reaL LIfe exPerIence: PILOT sTudy
Belvis Jiménez M.1, Guerra Veloz M.F.2, Argüelles-Arias F.3, Sáez A.4, 
Maldonado Perez B.4, Castro Laria L.4, Benítez Roldán A.4, 
Caunedo Álvarez Á.4
1HUV Macarena, Gastroenterology, Sevilla, Spain, 2HUV Macarena, 
Gastroenterology and Endoscopy Unit, Sevilla, Spain, 3HUV Macarena, UGC 
DIGESTIVO, Sevilla, Spain, 4HUV Macarena, Sevilla, Spain
contact e-Mail address: mariabelvisjimenez@gmail.com
Introduction: Therapeutic drug monitoring has become an accepted tool 
in the therapy management in Inflammatory Bowel Disease (IBD). The as-
sessment of trough levels and neutralising anti-drug antibodies are wide-
ly used to optimise the therapeutic management, and its usefulness has 
been more studied in anti-TNF therapies especially in situations of treat-
ment failure. However, there is not enough data published on the useful-
ness of the measurement of vedolizumab (VDZ) levels in IBD patients, with 
no established cut-off points. The objective of our study was to evaluate 
the correlation between VDZ level at induction and maintenance treatment 
with the clinical response in patients with IBD.
aims & Methods: This is a retrospective observational, single center study. 
We included adult patients with UC and EC treated with VDZ between Jan-
uary and December 2018, VDZ serum levels were prospectively collected 
before induction at 6, 14 and 24 weeks. Clinical and biochemical response 
was collected at 14 and 24 weeks. Data was analyzed by classification tree 
model to establish variables related with remission.
results: 12 patients were included, 58.3% with UC and 41.7% with CD. 
69.2% were women with a mean age of 41 ± 12 and a mean disease dura-
tion of 11.5 ± 8.15 years. 91.7% were treated with anti-TNF therapy previ-
ously. The median VDZ level was 33.4 mg/ml (26,7 -39,1), 10,3 mg/ml (7,26-
12,8), 11,2ug/ml (8,47-14,45) at baseline, week 14 and week 24 respectively. 
Clinical remission was achieved in 33.3% (4/12) at week 14, and 41.6% 
(5/12) at week 24. 33.3% (4/12) in patients who had VDZ level at week 6 
between 35 - 47,4 ug/ml. 
The only variable that was correlated with the remission at weeks 14 and 
24 in the tree model CRT was the VDZ level at week 6 (induction therapy) 
(Table 1).
clinical remission Week 14 
and 24
vdz level week 6 
(ug/ml)
Prediction 
certainty (%)
Yes 35 - 47.4 100
No <35 // >47,4 100
[Table 1]
conclusion: In our cohort, the only variable that was correlated with the 
remission at weeks 14 and 24 was the VDZ level at week 6. VDZ level at 
week 14 and 24 were not correlated with clinical remission.
disclosure: Nothing to disclose 
P1133 reTrOsPecTIve sTudy Of The effecTIveness and 
safeTy Of usTekInuMaB In refracTOry crOhn’s dIsease
Truyens M.1,2, Goossens M.3, Glorieus E.3, Geldof J.3, Hindryckx P.3, 
Lobaton Ortega T.3
1IBD Research Unit UZ Ghent, Gastroenterology, Ghent, Belgium, 2VIB Center 
for Inflammation Research, Ghent, Belgium, 3University Hospital Ghent, 
Gastroenterology, Ghent, Belgium
contact e-Mail address: marie.truyens@ugent.be
Introduction: Ustekinumab (UST) is in Belgium increasingly used in mod-
erate to severe Crohn’s disease (CD). The goal of the current study was to 
describe the real-life experience with UST in our tertiary center.
aims & Methods: A retrospective monocentric study was performed in 
patients with CD who were started on UST between December 2017 and 
December 2018. All patients received an initial intravenous dose of 6 mg/
kg followed by subcutaneous UST (90 mg, q8). The clinical, biological, 
endoscopic and radiological response were assessed after the induction 
(week 4-8) and during the maintenance phase. The clinical, endoscopic 
and radiological response was based on the physicians’ assessment. A 
biological response was defined as a decrease of ≥50% in C-reactive pro-
tein (CRP) and/or fecal calprotectin (FC), remission as a normalization of 
the parameters.
results: A total of 51 patients were included, of which the majority was 
refractory to TNF inhibitors and/or vedolizumab (table 1). The median du-
ration of follow-up was 45 weeks (IQR 24-69). UST was discontinued in 
11 patients (21.6%) after a median of 26 weeks (IQR 10-34). Reasons for 
discontinuation were a loss of response, including 2 patients who were in 
need of surgery (n=5), primary non response (n=4), malignancy (n=1) and 
patient’s wish (n=1). 
The clinical response at short term (4-8 weeks after the initial IV induc-
tion), could be assessed in 43 patients: 27/43 patients (62.8%) had a re-
sponse and 4 patients (9.3%) were in clinical remission. In 12 patients 
(27.9%) no response was seen. During the maintenance phase patients 
were assessed at a median of 26 weeks (IQR 23-39). A clinical response 
in the maintenance period was seen in 25/51 patients (49%) and an ad-
ditional 12 patients (23.5%) reached remission. 
A biological response was achieved in 8/37 patients (21.6%) and biologi-
cal remission in 16/37 (43.2%), the remaining patients (35.1%) showed 
no response. Endoscopy was performed in 20 patients and an endoscopic 
response was confirmed in 10/20 patients (50%), remission in 2 patients 
(10%). The other 8 patients (40%) had no endoscopic response. Radio-
logical evaluation was performed in 21 patients of which 12 showed no 
response (57.1%), 7/21 (33.3%) had a response and 2 (9.5%) were in ra-
diological remission.
Ten patients (19.6%) were hospitalized for IBD-related complications, 
most of them for surgery (9/10). Other AEs occurred in 11 patients, most 
often arthralgia. One patient developed a flare of an underlying spon-
dyloarthropathy and UST was discontinued. A paradoxical worsening of 
psoriasis was observed in one patient.
conclusion: In this population of refractory CD patients, UST was effica-
cious to induce and maintain clinical remission. Endoscopic and radiologi-
cal response in these preliminary analyses were modest.
disclosure: Nothing to disclose 
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Age (years), median [IQR] 41.7 [32.4-53]
Gender (female/male), n [%] 29 [56.9]/22 [43.1]
Age at diagnosis (years), median [IQR] 24.5 [18-34.8]
Duration of disease (years), median [IQR] 12 [8-21]
History of resection, n [%] 29 [58]
Extra-intestinal manifestations, n [%] 19 [37.3]
Immunosuppressant at baseline, n [%] 11 [19.6]
Azathioprine 5 [9.8]
Methotrexate 4 [7.8]
Purinethol 1 [2]
Corticosteroids at baseline, n [%] 24 [47.1]
Previous biologicals, n [%]  
0 3 [5.9]
1 14 [27.5]
2 17 [33.3]
≥ 3 17 [33.3]
[Patient characteristics]
P1134 effIcacy Of usTekInuMaB InTensIfIcaTIOn and 
re-InducTIOn In crOhn’s dIsease PaTIenTs WITh InsuffIcIenT 
Or LOss Of resPOnse
Truyens M.1,2, Goossens M.3, Glorieus E.3, Geldof J.3, Hindryckx P.3, 
Lobaton Ortega T.3
1IBD Research Unit UZ Ghent, Gastroenterology, Ghent, Belgium, 2VIB Center 
for Inflammation Research, Ghent, Belgium, 3University Hospital Ghent, 
Gastroenterology, Ghent, Belgium
contact e-Mail address: marie.truyens@ugent.be
Introduction: Ustekinumab (UST) has proven to be an efficient maintenance 
therapy for moderate to severe Crohn’s disease (CD). However, a significant 
percentage of patients treated with subcutaneous maintenance UST experi-
ence a secondary loss of response (LOR) or partial response. We evaluated 
the clinical, biological and endoscopic response to UST optimization includ-
ing IV re-induction (intravenous UST at a dose of 6 mg/kg) and/or shorten-
ing of the dosage interval (mainly every 4 weeks) in this context.
aims & Methods: A retrospective, single-center study was performed in-
cluding patients with CD who were treated with maintenance UST and 
received either IV re-induction and/or shortening of the dosage interval 
for a partial response or LOR. The clinical and endoscopic response was 
based on the physician’s assessment. A biological response was defined 
as a decrease of ≥50% in C-reactive protein (CRP) and/or fecal calprotectin 
(FC); remission as a normalization of these parameters.
results: Eighteen out of the 51 (35.3%) UST-treated CD patients needed 
optimization of UST: 2 patients only received IV re-induction, 9 patients 
only shortening of the dosage interval and 7 patients received both IV re-
induction and intensification. 
The median time to optimization was 34.5 weeks (IQR 20.3-42.3). Re-
sponse to dose optimization was assessed at a median of 15.5 weeks (IQR 
6.8-19.3). 
One of the 2 patients who underwent re-induction alone experienced a 
good clinical and endoscopic response; the other patient had no clinical, 
biological nor endoscopic response and UST was discontinued. 
A combined re-induction and shortening of the dosage interval was per-
formed in 7 patients. Of these, 6 experienced a clinical response and 1 pa-
tient had no response. Biological remission was confirmed in 3/6 patients, 
whereas the other 3/6 had no biological response. Endoscopic response 
was observed in 1/3 patients. Despite optimization, UST was ended in one 
patient due to a persistent LOR. 
Nine patients underwent intensification alone, which was successful in 
inducing a clinical response in 3/9 (33.3%) and a clinical remission in 
4/9 (44.4%). Two patients (22.2%) had no clinical response. Biological 
remission was observed in 4/7 patients (57.1%) and 3/7 patients had no 
biological response (42.9%). Endoscopic evaluation in 4 patients showed 
a response in 2/4 and no response in the other 2. In 2/9 patients (22.2%) 
UST was stopped; one due to LOR and the other patient due to an adverse 
event (flare of underlying spondyloarthropathy).
Other adverse events (AEs) were seen in 2 patients: 1 patient had arthral-
gia and 1 patient developed a rash, both AEs were mild and UST could be 
continued.
conclusion: About a third of patients treated with maintenance UST un-
derwent optimization. Of these 18 patients, 10 (55.6%) regained a good 
clinical response and 4 (22.2%) were in clinical remission. UST could be 
continued in the majority of patients.
disclosure: Nothing to disclose 
P1135 TheraPeuTIc drug MOnITOrIng suPPOrTs cLInIcaL 
decIsIOn MakIng When eMPLOyed BefOre and afTer 
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Haggarty R.1,2, Waddell K.1, Veryan J.1, Nowell E.1, Seenan J.P.1,2, 
Macdonald J.1,2
1Queen Elizabeth University Hospital, Department of Gastroenterology, 
Glasgow, United Kingdom, 2University of Glasgow, College of Medical, 
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contact e-Mail address: jonathanmacdonald@nhs.net
Introduction: Therapeutic drug and anti-drug antibody monitoring (TDM) 
of infliximab (IFX) is used with increasing regularity as a tool to optimize 
outcomes in inflammatory bowel disease (IBD). Trough levels (TL) of 2-8 
mcg/ml are recommended during maintenance IFX treatment. The intro-
duction of biosimilar infliximab (BI) in 2015 lead to widespread switching 
of patients from originator infliximab (OI) to BI. The value of TDM when 
switching to BI has not been defined. This study aimed to assess the im-
pact of TDM testing before and after a managed switch to BI.
aims & Methods: Individuals with IBD treated with OI and demonstrating 
a satisfactory response to treatment, were entered in to BI switch pro-
gramme in Dec 2016. Pre-switch information was provided to patients, vir-
tual or face to face clinical assessment was undertaken and it was recom-
mended that all patients had pre-switch TDM performed. After switching 
patients returned to routine clinical care. Further TDM was performed at 
clinician discretion with recommendation to follow published TDM testing 
guidance (1). Virtual review of all patients was undertaken 2 years post-
switch. Demographics, pre and post switch TDM data, OI and BI dosing 
regimens and other IBD related medications were recorded along with 
clinical outcome data. Comparative analysis of pre-switch and most con-
temporary TDM results was performed.
results: 76 individuals considered to be clinically responding to OI were 
entered in to the BI switch programme. 70/76 (92%) had TDM at < 3 
months pre-switch. OI was discontinued prior to switch in 2 patients. 74 
people were switched from OI to BI. 52/74 (70%) were on 5mg/kg 8 weekly 
OI pre-switch, 38 (51%) were on immunomodulators.
Of 69/74 with pre-switch TDM, 32/69 (46%) had subtherapeutic TLs (< 
2mcg/ml). Median pre-switch TL was 2.2 mcg/ml (IQR 1.1-3.4 mcg/ml). 
Pre-switch TL review lead to 37/74 (50%) receiving an increased dose of BI 
at switch. In total 47/74 had ≥1 dose escalation at the time of or subsequent 
to switch.
58/74 (78%) had TDM testing in the 2 years after switch (median no. tests 
2; range 1 - 5) at which point 54/74 (73%) remained on BI with sustained 
clinical response. 49 out of 54 still on BI had both pre and post switch TDM 
with results demonstrating a statistically significant increase in mean TLs 
(2.1 vs 6.3 mcg/ml; p< 0.001); only 6% had persisting sub-therapeutic TLs.
conclusion: High rates of sustained clinical response were observed to oc-
cur following a BI switch supported by the use of pre and post switch TDM. 
TDM dose escalation resulted in a statistically significant increase in TLs, 
this may account for the rates of continued clinical response.
references: 1. Papamichael K. Frontline Gastroenterol. 2016 Oct;7(4):289-
300
disclosure: Nothing to disclose 
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P1136 cOrreLaTIOn Of vedOLIzuMaB TrOugh LeveLs WITh 
cLInIcaL and BIOcheMIcaL Markers In InfLaMMaTOry BOWeL 
dIsease
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Introduction: The clinical utility of vedolizumab (VDZ) trough levels (VTLs) 
is not well established.
aims & Methods: The aim of this study was to determine if there is a cor-
relation between VTLs and clinical and biochemical outcomes. We per-
formed a prospective, cross-sectional study to examine the association 
between VTLs and clinical and biochemical outcomes. VTLs immediately 
prior to VDZ infusion were collected simultaneously with CRP and Har-
vey Bradshaw index (HBI)/Simple Clinical Colitis Activity index (SCCAI) (for 
Crohn’s disease, CD, and ulcerative colitis, UC, respectively). Biochemical 
remission was defined as CRP ≤ 5 mg/L and clinical remission was defined 
as HBI ≤ 4 or SCCAI ≤ 2. Combined remission was defined as those meet-
ing criteria for both clinical and biochemical remission. Fishers exact and 
Mann-Whitney U tests were used to compare groups and ROC analysis to 
identify a therapeutic threshold.
results: 45 samples with matched clinical and biochemical data were col-
lected for 43 patients (24 UC, 15 CD and 4 inflammatory bowel disease- 
unclassified). Approximately equal numbers of patients had 4-weekly VDZ 
infusions (n=21) compared to 8-weekly (n=22). 25 out of 43 patients (58%) 
were on concomitant immunomodulation. The median trough level was 
18.3 µg/mL (range < 2 - 44.7 µg/mL) and anti-VDZ antibodies were not de-
tected in any patient. No significant difference could be detected between 
median VTLs for active disease vs combined remission (24.1 µg/mL vs 16.4 
µg/mL, p=0.84). 
In the UC subgroup, there was a difference in median VTLs between those 
in biochemical remission compared to those with active disease (24.5 µg/
mL vs 7.3 µg/mL, p=0.088). ROC analysis did not identify an optimal thera-
peutic threshold to achieve combined remission [AUC (95% CI) 0.52 (0.32-
0.72)]. However, in the UC cohort a potential therapeutic threshold was 
identified [AUC (95% CI) 0.76 (0.41-1.0)]. A VTL of 10.7 µg/mL differentiated 
those with a normal CRP from those with a raised CRP. A comparison (us-
ing Fisher’s exact test) of the highest vs lowest VTL quartiles did not show 
a significant difference in the proportion of patients who were in remission 
vs active disease.
conclusion: A correlation between VTLs and clinical and biochemical 
markers of disease activity was not shown. However, in the UC cohort a 
level of 10.7 µg/mL differentiated those in biochemical remission from 
those with active disease. This is a preliminary, small sample size study 
and analysis of VTLs for our entire VDZ cohort is being conducted.
disclosure: Nothing to disclose 
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Introduction: Vedolizumab (VDZ) is an approved biological treatment for 
moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). Pa-
tients who lose response on VDZ 300 mg every 8 weeks (Q8W) during 
maintenance therapy may benefit from dose intensification to VDZ 300 mg 
every 4 weeks (Q4W). Our aim was to assess the effect of VDZ dose intensi-
fication on serum trough levels (TL) and regain of response.
aims & Methods: We performed a multicenter prospective study from June 
2017 through December 2018 including patients with loss of response to 
VDZ Q8W during maintenance therapy, defined as a total Mayo score >6 
for UC, and a HBI score >4 with evidence of inflammation (C-reactive pro-
tein (CRP) > 5mg/L, faecal calprotectin >250 mg/kg or confirmation on 
endoscopic or radiological imaging) for CD. Blood samples (TL and CRP) 
and clinical variables (partial Mayo and HBI score) were collected at T0 
(last infusion of Q8W interval and start of Q4W dosing), T1 (week 4 after 
dose escalation) and T2 (week 8 after dose escalation). Biological response 
(CRP ≤5mg/L or decrease of >50% in patients with a CRP >5 mg/L at base-
line) and clinical response (decrease of partial Mayo ≥2 points for UC or 
decrease of HBI ≥3 points for CD) were assessed at T1 and T2. VDZ TL were 
measured using the vedolizumab ELISA from apDia. Non-parametric and 
correlation analyses were performed comparing T0, T1 and T2.
results: A total of 62 patients (34 UC and 28 CD) were included with 28% 
on concomitant corticosteroids, 11% on azathioprine or 6-MP and 2% on 
methotrexate. After dose escalation, median (IQR) TL increased from 8.8 
(5.1-13.5) µg/ml (T0) to 19 (11.9-22.9) µg/ml (T1) and 23.1 (15.5-28.4) µg/ml 
(T2) (all p< .0001) with a similar evolution in UC and CD (Table). 
uc (n=34) T0 T1 T2 
Median (IQR) TL (µg/ml) 8.1 (4.8-11.6) 17.4 (10.8-21.6) 21.3 (14.3-25)
Median (IQR) CRP (mg/l) 5.8 (1.4-9) 5.7 (1.7-15.4) 3.9 (1.9-11)
Median (IQR) partial Mayo 5 (5-6) 3 (3-5) 3 (1-5)
cd (n=28) T0 T1 T2 
Median (IQR) TL (µg/ml) 9.1 (5.2-16.6) 21.2 (12.4-28.1) 23.6 (19.7-31.7)
Median (IQR) CRP (mg/l) 7.2 (2.8-14.2) 6.4 (2.9-15.1) 4.9 (2.7-9.4)
Median (IQR) HBI 8 (5-13) 4 (1-6) 3 (1-4)
[Table]
In UC patients, partial Mayo score significantly decreased from T0 to T1 
(p=0.002) with a trend for further decrease from T1 to T2 (p=0.08). In CD 
patients, HBI score significantly decreased from T0 to T1 (p=0.002) with 
a trend for further decrease from T1 to T2 (p=0.07). The decrease in CRP 
from 6.4 (1.9-12.6) mg/L at T0 to 5.8 (2.1-15.2) mg/L at T1 and 4.4 (2.7-
10) mg/L at T2 was not significant (all p>.05) and similar in UC and CD 
(Table). Also for patients with a CRP at baseline of >5 mg/L, the decrease 
in CRP from 11.6 (7.2-18.9) mg/L at T0 to 10.1 (5.2-16.7) mg/L at T1 and 8.8 
(4.1 - 15.3) mg/L at T2 was not significant (all p>.05) and similar in UC and 
CD. Biological and clinical response was achieved in 30% and 51% at T1 
and 44% and 59% at T2, respectively. The median increase in TL between 
T0 and T2 was similar between biological responders and non-respond-
ers (12.3 (8.3-14.8) vs. 12.4 (7.6-16.1), p=0.78) and clinical responders and 
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non-responders (14 (10.3-17.4) vs. 12.2 (6.9-14.6), p=0.12). No correlation 
was found between increase in TL between T0 and T2 and change in CRP, 
partial Mayo or HBI scores.
conclusion: Dose escalation of VDZ 300 mg from Q8W to Q4W in UC and 
CD patients with loss of response results in higher TL at 4 and 8 weeks. 
Regain of biological and clinical response was observed in 44% and 59% 
of patients respectively but was not associated with an increase in TL.
disclosure: Takeda research grant 
Other Lower gI disorders II
09:00-17:00 / Poster Exhibition - Hall 7
P1138 eLecTrIcaL cOnducTIvITy In BIfIdOBacTerIuM anIMaLIs 
suBsPecIes LacTIs BB-12
Bozkurt H.S.
Maltepe University Medicine Faculty Internal Medicine, Gastroenterology, 
Istanbul, Turkey
contact e-Mail address: sancarb79@gmail.com
Introduction: BB-12 is technologically well suited, expressing fermentation 
activity, high aerotolerance, good stability and a high acid and bile toler-
ance[1,2]. Because of high redox potential in the colon flora ecosystem, BB-
12 is highly resistant bacteria in distress condition. The BB-12 cell envelope 
is an electrical and physical barrier that can be overcome by pathways that 
consist of redox proteins.Bacterial cellular electron transfer systems (CET) 
are defined microbial bioelectrochemical processes in which electrons are 
transferred from the cytosol to the membrane of the cell[3].Although the 
strength of BB-12 in the event of stress has been shown previously[2], CET 
features of BB-12 are not completely identified. Here we first describe that 
the probiotic bacteria Bifidobacterium animalis subsp. Lactis BB-12 strain 
features of CET under the various atmosphere.
aims & Methods: Mean gut bifidobacterial count of 5 billions (5x109) cfu of 
Bifidobacterium animalis subsp. Lactis-BB12 (Chr Hansen) were used for 
the experiment in Yildiz Technical University, Davutpaşa Campus, Science 
and Arts Faculty, Physics Department. This Bifidobacterium dissolved in 5 
millilitres of distilled water and prepared sample
results: Charge transport behavior and the effect of the RH level on it in 
the BB-12 film have been investigated by means of I-V measurements. 
Within water moisture environment, electrical conductivity of the BB-12 
increased more than six decades while under N
2
 environment conductivity 
returns to the initial current value(Figure-1). This behaviour in conductivity 
modulation was reversible at least in the three cycles
conclusion: This experimental findings showed us that there was no struc-
tural transformation under relative humidity. On the other side, increase 
in the conductivity was interpreted by the increase in the population of 
charge carries, supplied by the interaction BB-12 with the water moisture, 
monitored by amine and carboxyl group through FTIR and Zeta potential 
measurements.The type of surface charge of Bifidobacterium animalis sub-
sp. lactis BB-12 was found to be negative by zeta potential measurements, 
claiming that electrons were the charge carriers. Overall, obtained result 
in this study indicated that Bifidobacterium animalis subsp. lactis BB-12 has 
a great potential for humidity sensing device at room temperature
references: 1. Bozkurt, H.S., E. MM Quigley, B. Kara. Bifidobacterium 
animalis subspecies lactis engineered to produce mycosporin-like amino 
acids in colorectal cancer prevention. SOM 2019; Vol. 7: 1-5. 2. Ruiz, L., P. 
R. Madiedo, M. Gueimonde, C. G. de los Reyes-Gavilán.How do bifido-
bacteria counteract environmental challenges? Mechanisms involved and 
physiological consequences. Genes Nutr. 2011; 6: 307-318. 3. Light, S. H., 
L. Su, R. Rivera-Lugo, J. A. Cornejo, A. Louie. A flavin-based extracellular 
electron transfer mechanism in diverse Gram-positive bacteria. 2018 Na-
ture;562:140-144
disclosure: Nothing to disclose 
P1139 heaT-TreaTed LacTOBacILLI IMPacT MurIne MIcrOBIOTa 
cOMPOsITIOn and PrevenT PaThOgen-Induced InfLaMaTIOn
Warda A.1, Bettio P.1, Hueston C.1, di Benedetto G.1, Clooney A.1, Hill C.1,2
1APC Microbiome Ireland, University College Cork, Cork, Ireland, 2University 
College Cork, School of Microbiology, Cork, Ireland
contact e-Mail address: alicja.warda@ucc.ie
Introduction: Probiotics are live microorganisms that, when administered 
in adequate amounts, confer a health benefit on the host. These benefits 
can include impacts on digestive health, the host immune system, and the 
gut-brain axis. Increasing evidence supports a relationship between the 
gut microbiota, inflammation, host response and health [1-3]. More re-
cently, a number of studies have investigated the potential of heat-treated 
microorganisms to confer a benefit on humans or animals; these have 
often been referred to as ‘pharmabiotics’ [2,4,5].
The therapeutic application of heat-treated microorganisms could be con-
sidered to have a number of advantages over living organisms, such as 
longer shelf life, no cold chain requirements, ease of storage and trans-
port and therefore also potential applications in less developed regions, 
no risk of infection in vulnerable individuals, no translocation of bacterial-
virulence or antibiotic-resistance cassettes if the genetic material has been 
destroyed by the inactivation step, and no loss of activity when used in 
conjunction with antibiotics or anti-fungal agents [4-6].
aims & Methods: We have demonstrated that supplementing the diet with 
heat-treated Lactobacillus LB is capable of subtly modifying both the mi-
crobiota and behavior in healthy male mice [6]. In this study we set out 
to elucidate the role of heat-treated Lactobacillus LB in female mice, par-
ticularly focusing on the impact on the development of colitis following 
Citrobacter infection. Female mice [N=48] were divided into two groups, 
one fed standard chow, and one fed chow with a Lactobacillus LB prepa-
ration (5%). The Lactobacillus LB preparation consists of a heat-treated 
fermentate generated by two Lactobacillus strains, L. fermentum and L. 
delbrueckii. After four weeks we implemented a Citrobacter rodentium in-
fection strategy that is used as a model for several important human in-
testinal disorders, including Crohn’s Disease, Ulcerative Colitis and colon 
tumorigenesis [7]. Infection with C. rodentium results in the colonisation of 
the large intestine and subsequent mild inflammation that is maintained 
after the pathogen has been cleared [8]. This allows us to study the effect 
of the Lactobacillus LB preparation on both infection and inflammation. 
Throughout the experiment samples were collected for 16S rRNA analysis 
of microbiota, virome analysis, SCFA, and inflammation markers.
results: Diet supplementation with the Lactobacillus LB preparation caused 
subtle but significant changes in the murine microbiota, with less abun-
dant taxa being most affected. Prolonged consumption had no adverse 
effect on murine health. The Lactobacillus LB preparation did not provide 
protection against Citrobacter infection. However, a reduction of the length 
of small intestine which occurred in the control-fed Citrobacter infected 
animals was prevented by the supplemented diet. An increase of colon 
crypt length in control-fed Citrobacter infected animals was also prevented. 
Overall, our results suggest that the Lactobacillus LB preparation diet has 
a reproducible effect on microbiota composition and diversity, as well as 
limiting the effect of Citrobacter induced inflammation in animals.
conclusion: This study provides evidence for the effect of heat-treated 
bacteria (and their metabolites) on the murine microbiota, on infection-
induced inflammation and on the behaviour of healthy mice. Prepara-
tions containing heat-treated microorganisms, or pharmabiotics, can be 
safe and effective interventions to impact on the microbiome and on host 
health.
references: [1] Dinan TG & Cryan JF. The Microbiome-Gut-Brain Axis in 
Health and Disease. Gastroenterol Clin North Am 2017;46(1):77-89. [2] Gi-
ron F & Quigley EMM. Pharmabiotic Manipulation of the Microbiota in Gas-
trointestinal Disorders: A Clinical Perspective. J Neurogastroenterol Motil 
2018;24(3):355-366 [3] Pedersen HK, et al. Human gut microbes impact host 
serum metabolome and insulin sensitivity. Nature 2016;535(7612):376-81. 
[4] Taverniti V & Guglielmetti S. The immunomodulatory properties of pro-
biotic microorganisms beyond their viability (ghost probiotics: proposal of 
paraprobiotic concept). Genes Nutr 2011;6(3):261-74. [5] de Almada CN, et 
al. Paraprobiotics: Evidences on their ability to modify biological respons-
es, inactivation methods and perspectives on their application in foods. 
Trends Food Sci Technol 2016;58:96-114. [6] Warda AK, et al. Heat-killed 
lactobacilli alter both microbiota composition and behaviour. Behav Brain 
Res 2018;362:213-23. [7] Collins JW, et al. Citrobacter rodentium: infection, 
inflammation and the microbiota. Nat Rev Microbiol 2014;12(9):612-23. [8] 
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Wiles S, et al. Organ specificity, colonization and clearance dynamics in 
vivo following oral challenges with the murine pathogen Citrobacter ro-
dentium. Cell Microbiol 2004;6(10):963-72.
disclosure: This study was funded by Adare Pharmaceuticals, who pro-
duced the Lactobacillus LB preparation. Adare had no part in the conduct 
of the experiments or in the interpretation of the data. 
P1140 characTerIzaTIOn Of The MucOsaL MIcrOBIOMe 
In faMILIaL adenOMaTOus POLyPOsIs PaTIenTs WITh InTacT 
cOLOn Or suBjecTed TO POuch surgery
Prossomariti A.1,2, Biagi E.3, Turroni S.3, Brigidi P.3, Piazzi G.1,2, Colussi D.1, 
Miccoli S.4,5, Turchetti D.4,5, Alquati C.1,2, Bazzoli F.1, Ricciardiello L.1,2,5
1University of Bologna, Dept. of Medical and Surgical Sciences, Bologna, 
Italy, 2University of Bologna, Center for Applied Biomedical Research (CRBA), 
Bologna, Italy, 3University of Bologna, Dept. of Pharmacy and Biotechnology; 
Unit of Microbial Ecology of Health, Bologna, Italy, 4University of Bologna/S.
Orsola-Malpighi Hospital, Medical Genetic Unit, Bologna, Italy, 5University 
of Bologna, Dept. of Medical and Surgical Sciences/Center for the Study of 
Hereditary Cancers, Bologna, Italy
contact e-Mail address: anna.prossomariti2@unibo.it
Introduction: Surgical treatment represents the gold standard for Familial 
Adenomatous Polyposis (FAP) patients with profuse disease. Most FAP pa-
tients undergo proctocolectomy with j-pouch, and pouchitis is emerging 
as a recurrent post-surgical complication. Alterations in the intestinal mi-
crobial community play a pivotal role in intestinal inflammation and have 
been found in UC patients with pouchitis. However, the impact of intestinal 
dysbiosis on pouchitis onset in FAP patients remains poorly characterized.
aims & Methods: In this pilot study, we aimed to characterize the mucosal 
microbiome structure in FAP patients and to establish whether intestinal 
dysbiosis may contribute to the development of pouchitis in these patients. 
Sixteen patients with a clinical and genetic diagnosis of FAP (age > 18 
years) were enrolled. Microbiome analysis was performed by 16S rRNA 
gene sequencing using an Illumina platform on DNA samples extracted 
from intestinal biopsies.Microbiome characterization was available for 
fifteen out of sixteen FAP patients. Active pouchitis was defined as a Pou-
chitis Disease Activity Index (PDAI) ≥ 7. We first analyzed differences in 
taxon relative abundance among patients with intact colon (n=6) or those 
who underwent hemicolectomy with ileocolic anastomosis (n=1) (Group 
1; n=7) and patients who underwent proctocolectomy with ileal-pouch-
anal-anastomosis (IPAA) (n=6) or those who underwent colectomy with 
ileo-rectal-anastomosis (IRA) (n=2) (Group 2; n=8). Moreover, among pa-
tients belonging to the Group 2 we analyzed differences between patients 
with healthy pouch (Group 2A; n=5) and patients with pouchitis (Group 
2B; n=3).
results: According to the PDAI score 3 out of 8 patients within the Group 
2 received a diagnosis of chronic and active pouchitis. Microbiome se-
quencing demonstrated a reduction in the relative abundance of Actino-
bacteria (4.39% vs. 0.52%) and Bacteroidetes (28.95% vs. 10.11%) phyla 
(Families: Coriobacteriaceae and Bacteroidaceae, respectively) associated 
with increased levels of Proteobacteria (34.05% vs. 59.32%) phylum (Fam-
ily: Pseudomonadaceae) in patients within the Group 2 compared with 
Group 1. Among patients belonging to the Group 2, patients with pou-
chitis (Group 2B) showed decreased abundance of Bacteroidetes (15.95% 
vs. 0.36%) and Firmicutes (31.58% vs. 8.83%) phyla and had a micro-
biota almost entirely represented by Proteobacteria (46.08% vs. 81.39%) 
(mainly Oxalobacteriaceae and Pseudomonadaceae families) compared 
with healthy pouch patients (Group 2A).
conclusion: Our findings suggest that alterations in the mucosal micro-
biota could be involved in the development of pouchitis in FAP patients 
subjected to proctocolectomy with j-pouch and that gut microbiota char-
acterization in these patients may help clinicians determining the efficacy 
of antibiotic therapies. Further studies are warranted on larger series to 
confirm these data.
disclosure: Nothing to disclose 
P1141 The sTudy On The changes and rOLes Of InTesTInaL 
BacTerIa MIcrOBIOTa In cOrOnary hearT dIsease 
cOMPLIcaTed WITh nOnaLcOhOLIc faTTy LIver dIsease
Zhang Y.1,2, Xu J.1,2,3, Wang X.1,2, Liu Y.1,2
1Peking University People’s Hospital, Department of Gastroenterology, 
Beijing, China, 2Peking University People’s Hospital, Clinical Center of 
Immune-Mediated Digestive Diseases, Beijing, China, 3Peking University 
People’s Hospital, Institute of Clinical Molecular Biology & Central 
Laboratory, Beijing, China
contact e-Mail address: yi.wen.zhang@foxmail.com
Introduction: Previous study reported that patients who suffered coronary 
heart disease (CHD) complicated with non-alcoholic fatty liver disease 
(NAFLD) had worse cardiac function and clinical outcomes than patients 
with CHD only. Notably, the mechanism was still unclear. Previous study 
focused on the role of metabolism in CHD patients complicated with 
NAFLD (CHD-NAFLD) and evidence showed that the microbiota was an im-
portant factor in metabolism. Therefore, this study aimed to investigate the 
characteristics and effects of intestinal bacteria microbiota in CHD-NAFLD 
patients.
aims & Methods: People were recruited and divided into three groups, 
including CHD patients (without NAFLD), CHD-NAFLD patients and healthy 
controls (HCs). Each group contained 24 people. Fecal samples and clini-
cal information from three groups were carefully collected. The Illumina 
sequencing of 16S rRNA gene V3-4 region amplicons sequencing was 
applied to profile the overall structure of the fecal bacterial microbiota. 
Based on the Operational Taxonomic Units (OTUs), the characteristics of 
the bacterial microbiota of the sample and the correlation with clinical 
indexes were analyzed.
results: In analysis of clinical information, CHD patients showed an in-
crease in uric acid and triglycerides compared with HCs. The CHD-NAFLD 
patients showed a further increase in BMI, uric acid and triglyceride. In in-
vestigation of bacterial profile, we firstly compared the overall CHD patients 
(including CHD-NAFLD patients and CHD patients) with HCs. As a result, 
there was a significant reduction in the abundance of Parabacteroides and 
Collinsella. We further analyzed the difference of bacterial composition in 
between CHD-NAFLD and CHD patients. The intestinal bacterial microbiota 
in CHD-NAFLD patients showed an increase in the abundance of Copococ-
cus and Veillonella, and a reduction in the abundance of Parabacteroides, 
Bacteroides_fragilis, Bifidobacterium_longum_subsp_infantis, Ruminococcus_
gnavus and Bacteroides_dorei. Among them, the abundance of Ruminococ-
cus_gnavus and Bacteroides_dorei was significantly lower than that in CHD 
patients. Additionally, spearman’s correlation was performed to clarify the 
correlation between bacterial microbiota and clinical indexes. BMI was 
positively correlated with the abundance of Copococcus and negatively cor-
related with the abundance of Bifidobacterium_longum_subsp_infantis. The 
abundance of Veillonella was positively correlated with LDL-C and AST. The 
abundance of Bacteroides_dorei was negatively correlated with ALT, AST 
and LDL-C. These data indicated that the abundance of intestinal bacterial 
microbiota was closely related to the changes in clinical indexes.
conclusion: Changes of intestinal bacterial microbiota in CHD-NAFLD pa-
tients may be important factors affecting the degree of metabolic disorder, 
which may be one of the important reasons for the worse clinical outcome 
and disease progression in CHD-NAFLD patients than in CHD patients.
disclosure: Nothing to disclose 
P1142 The sTudy On The changes and rOLes Of InTesTInaL 
fungaL MIcrOBIOTa In cOrOnary hearT dIsease cOMPLIcaTed 
WITh nOnaLcOhOLIc faTTy LIver dIsease
Xu J.1,2,3, Zhang Y.1,2, Wang X.1,2, Liu Y.1,2
1Peking University People’s Hospital, Department of Gastroenterology, 
Beijing, China, 2Peking University People’s Hospital, Clinical Center of 
Immune-Mediated Digestive Diseases, Beijing, China, 3Peking University 
People’s Hospital, Institute of Clinical Molecular Biology & Central 
Laboratory, Beijing, China
contact e-Mail address: yi.wen.zhang@foxmail.com
Introduction: Patients who suffered coronary heart disease (CHD) compli-
cated with non-alcoholic fatty liver disease (NAFLD) were reported to have 
worse cardiac function and clinical outcomes than patients with CHD only. 
However, it was not clear about the mechanism. Previous study focused 
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on the role of metabolism in CHD patients complicated with NAFLD (CHD-
NAFLD). Lots of evidence showed that the metabolism could be regulated 
by the microbiota. The research on gut microbiota mainly focused on bac-
teria, and there were few studies related to fungi. Therefore, this study 
aimed to investigate the characteristics and effects of intestinal fungal mi-
crobiota in CHD-NAFLD patients.
aims & Methods: People were recruited and divided into three groups, 
including CHD patients (without NAFLD), CHD-NAFLD patients, and healthy 
controls (HCs). Each group contained 24 people. Fecal samples and clinical 
information were carefully collected. The microbial genome DNA was ex-
tracted and the internal transcribed spacer (ITS) 3-4 rDNA was amplified. 
Illumina sequencing platform was used for high-throughput sequencing 
analysis. Based on the Operational Taxonomic Units (OTUs), the charac-
teristics of the fungal microbiota of the sample and the correlation with 
clinical indexes were analyzed.
results: In analysis of clinical information in recruited subjects, CHD pa-
tients showed an increase in uric acid and triglycerides compared with 
HCs. The CHD-NAFLD patients showed a further increase in BMI, uric acid 
and triglyceride. In investigation of fungal profile, we firstly compared the 
overall CHD patients (including CHD-NAFLD patients and CHD patients) 
with HCs and found the significant reduction in the abundance of Exophia-
la_attenuata and Malassezia_restricta. We further analyzed the difference of 
fungal composition in between CHD-NAFLD and CHD patients. The intes-
tinal fungal microbiota in CHD-NAFLD patients showed an increase in the 
abundance of Preussia, Xylodon and Cladorrhinum, and a reduction in the 
abundance of Candida_glabrata and Ganoderma. Among them, the abun-
dance of Ganoderma was significantly lower than that in CHD patients. 
Additionally, we used spearman’s correlation to clarify the correlation be-
tween fungal microbiota and clinical indexes. The ejection fraction was 
negatively correlated to the abundance of Xylodon. Uric acid was positively 
correlated with the abundance of Cladorrhin um and Preussia. These data 
indicated that the abundance of intestinal fungal microbiota was closely 
related to the changes in clinical indexes.
conclusion: Therefore, these changes of intestinal fungal microbiota in 
CHD-NAFLD patients may be important factors affecting the degree of 
metabolic disorder. But there are few reports on these fungi. More studies 
are needed to confirm the effects of these fungi on human.
disclosure: Nothing to disclose 
P1143 The effecT Of BILe acIds as a MajOr reguLaTOr 
Of InTesTInaL MIcrOBIOTa, esPecIaLLy On dIfferenT ParTs 
Of The MIce cOLOn
Ryu K.1, Han S.2, Jeong J.2, Choi Y.1, Im C.1, Kang Y.1, Huh K.1, Lee T.1, 
Kim S.1, Song K.1, Koo H.1, Lee M.2, Moon J.2, Kang M.3
1Konyang University College of Medicine, Gastroenterology, Daejeon, Korea 
(Republic of), 2Konyang University College of Medicine, Anatomy & Histology, 
Daejeon, Korea (Republic of), 3Dankook University Hospital, Internal 
Medicine, Cheonan-si, Korea (Republic of)
contact e-Mail address: young56@kyuh.ac.kr
Introduction: Bile acids are the end products of hepatic cholesterol me-
tabolism, assembled in the liver and they are the major regulators of 
intestinal microbiota. Human bile acids are mainly occupied by cholic 
acid(CA), chenodeoxycholic acid(CDCA), deoxycholic acid(DCA) and litho-
cholic acid(LCA). Since most of the bile acids secreted into the intestine are 
reused through the enterohepatic circulation, continuous oral administra-
tion of certain bile acids result in an increased composition ratio in the bile 
acid pool.1 Each of bile acids have a varying degree of hydrophobicity and 
pH, so the influence on microbiotas also varies.2,3 Rodent cecum is largely 
developed and there is a large amout of mictobiotas in it, so food is known 
to be kneaded and digested here. That is why many animal experimental 
studies use and analyze the strain of rodent cecum as an alternative of 
human. However, since cecum is not developed in humans, it is necessary 
to confirm that the same results are obtained in the cecum and the rest of 
colon of rodents.
aims & Methods: We examined the effect of each bile acids on various 
microbiotas in vitro and tried to find out whether similar changes occurred 
in the intestines by artificially increasing the fraction of specific bile acids, 
especially on different parts of colon.
1. We analyzed the effects of each bile acids on the various microbiotas 
using the disk diffusion method commonly used for microbial susceptibil-
ity test.
2. The 6 weeks-old-male C57BL/6 mices were treated with five bile 
acids(CA, CDCA, DCA, LCA, UDCA (ursodeoxycholic acid) and vehicle). In 
six groups each bile acids were delivered at a dose of 15 mg/kg/day via the 
transgastric rout. Fecal samples were collected every week and also the 
feces directly from the colon were collected on the day of the sacrifice and 
were separated from the cecal feces. The bacterial population was ana-
lyzed by real-time PCR and general population of bactreias were measured 
by universal bacterial primer.
results: As a result of the test for susceptibility to bile acids, the inhibitory 
effect on the micrbiotas of each bile acid was various, and the microbiotas 
found in the bile or intestinal tract were less inhibited overall than the 
strains found in other organs. Most of the repressed strains were inhibited 
by DCA and CDCA, but were also affected by other bile acids and were not 
consistent.
When the remainder of the rest of colon and the cecum were analyzed 
separately, it was reported that the total number of strains were increased 
in the CA and LCA administration groups in the colon except the cecum, but 
it was reported to be reversed in the cecum. In rest of colon, Firmicutes, a 
phylum known to be associated with obesity, were found to be lower than 
Phylum Bacterioidetes, but higher in cecum.
The results of the microbial susceptibility test for a major strains of mice 
were somewhat in agreement with the number of microbiotas in rest of 
colon, but not in the cecum.
conclusion: Bile acids have a remarkable inhibitory effect on intestinal 
micrbiotas, which varies according to the type of strain and bile acid. The 
effect of bile acids on microbiotas in the intestinal tract is similar to that 
of microbial susceptibility tests and this result was significant in the colon 
except the cecum. The artificial control of bile acid composition can read 
to change the environment of bowel microbiotas. Examinations of animal 
models to replace human beings may be more meaningful in colon except 
cecum.
references: 1. Qi Y, Jiang C et al. Bile acid signaling in lipid metabo-
lism: metabolomic and lipidomic analysis of lipid and bile acid markers 
linked to anti-obesity and anti-diabetes in mice. Biochim Biophys Acta 
2015;1851:19. 2. Sandhya Bansal et. al. Bile Acid Amphiphiles with Tun-
able Head Groups as Highly Selective Antitubercular Agents. Med. Chem. 
Commun., 2014;5:1761 3. Begley M et. al. Gahan CG, Hill C. The interaction 
between bacteria and bile. FEMS Microbiol Rev 2005;29:625.
disclosure: Nothing to disclose 
P1144 dIfferenT InTesTInaL BacTerIOcIn PrOducTIOn 
In cOLOrecTaL neOPLasIa In MaLes and feMaLes
Kohoutova D.1,2, Forstlova M.3, Moravkova P.4, Smajs D.5, Bures J.6
1Faculty of Medicine in Hradec Kralove, 2nd Department of Internal Medicine 
- Gastroenterology, Hradec Kralove, Czech Republic, 2Royal Marsden 
Hospitals NHS Trust, London, United Kingdom, 3Faculty of Medicine in 
Hradec Kralove, Department of Clinical Microbiology, Hradec Kralove, 
Czech Republic, 4Faculty of Medicine in Hradec Kralove, Department of 
Internal Medicine - Gastroenterology, Hradec Kralove, Czech Republic, 
5Masaryk University, Faculty of Medicine, Brno, Czech Republic, 6Charles 
University Faculty of Medicine, 2nd Department of Internal Medicine - 
Gastroenterology, Hradec Kralove, Czech Republic
contact e-Mail address: darina.kohoutova@seznam.cz
Introduction: Colorectal carcinoma (CRC) is the third most frequently diag-
nosed malignancy in males and the second most common malignancy in 
females. There were 1,006.000 new CRC diagnoses in males and 794.900 
in females in 2018 worldwide. Bacteriocins are small proteins, which are 
produced by the Enterobacteriaceae bacteria, especially by Escherichia coli. 
Bacteriocins are divided into more groups, colicins and microcins are the 
most important ones. Colicins and microcins do possess not only anti-
bacterial, proapoptotic and probiotic properties, but some of them have 
shown significant biological activity against different cancer cells in vitro 
and in vivo conditions. In general, colorectal neoplasia are more frequent 
in males.
aims & Methods: The aim of this prospective study was to evaluate natu-
ral colicin and microcin production by large intestinal mucosal bacteria at 
each stage of colorectal neoplasia in males and females.
A total of 63 patients with colorectal neoplasia and 20 controls were en-
rolled into the study. Three groups of patients with colorectal neopla-
sia were included: individuals with non-advanced colorectal adenoma, 
non-a-A (11 men, 10 women, mean age 63±10), patients with advanced 
650 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
colorectal adenoma, a-A (13 men, 7 women, mean age 65±9) and sub-
jects with CRC (12 men, 10 women, mean age 70±10). Advanced colorectal 
adenoma fulfilled the following criteria: an adenoma with low grade dys-
plasia larger than 10 mm and/or containing high grade dysplasia being 
of any size and/or adenoma of any size with villous component. Control 
group consisted from 7 men and 13 women (mean age 57±14) with normal 
findings on screening colonoscopy and with negative history of colorectal 
neoplasia. We used the original methodology reported by our group. After 
appropriate microbiological culture bacteriocin production by each strain 
was investigated by PCR methods.
results: A total of 239 mucosal biopsies were taken (52 controls, 63 non-
a-A, 60 a-A, 64 CRC) and samples were further investigated. A total of 
522 Escherichia coli and related strains were investigated for bacteriocin 
production.
There was a significantly higher colicin production in each group of 
colorectal neoplasia compared to controls, p< 0.01.
There was a significantly higher microcin production in each group of 
colorectal neoplasia compared to controls, p< 0.05.
Colicin production in men increased dramatically at the stage of CRC and 
differed significantly compared to production of colicins in females at the 
stage of CRC, p< 0.001.
There was a later onset of increased production of microcins observed 
during the adenoma-carcinoma sequence in men compared to women: 
statistically higher production of microcins was observed in females com-
pared to males at the stage of a-A, p=0.001. Subsequently, microcin pro-
duction decreased in females and increased in males at the stage of CRC, 
when males produced microcins significantly more frequently compared 
to females, p=0.023.
conclusion: Strains isolated from the large bowel mucosa in patients with 
colorectal neoplasia produce bacteriocins more frequently compared to 
those with normal findings on colonoscopy. 
Fundamental differences in colicin and microcin production have been 
confirmed between males and females.
references: Kohoutova et al. Escherichia coli strains of phylogenetic 
group B2 and D and bacteriocin production are associated with advanced 
colorectal neoplasia. BMC Infect Dis 2014; 14: 733. Kohoutova et al. Bacte-
riocin Production by Mucosal Bacteria in Current and Previous Colorectal 
Neoplasia. Gastroenterology 2018; 154(6), Supplement 1: Page S-413.
disclosure: Nothing to disclose 
P1145 grOWTh InhIBITIOn Of cLOsTrIdIuM dIffIcILe By The 
InTesTInaL IsOLaTes frOM huMan feces: InvesTIgaTIOn Of key 
MIcrOBIOTa In fMT (fecaL MIcrOBIOTa TransPLanTaTIOn)
Lee D.H.1, Seol M.J.2, Ma S.Y.2, Park Y.S.1, Yoon H.1, Shin C.M.1, Kim N.1, 
Cho J.H.1
1Seoul National University Bundang Hospital, Internal Medicine, Seongnam, 
Korea (Republic of), 2BioBankHealing, R&D Center, Seongnam, Korea 
(Republic of)
contact e-Mail address: dhljohn@snubh.org
Introduction: Clostridium difficile is gram-positive, anaerobic, and a spore 
forming, a common bacterium of the human intestine. Over the past 
decades, the incidence and severity of C. difficile infection (CDI) have in-
creased. 
Despite the clinical trial, treatment of patients with refractory CDI and 
those with multiple CDI recurrences is limited, and there is an ongoing for 
continued research to improve the outcomes these patients 
Fecal Microbiota Transplantation (FMT) as an alternative treatment has 
been shown to be an effective treatment for recurrent and refractory CDI. 
However, its mechanism and a key bacteria were still unknown. In this 
study, we investigated the intestinal isolates to inhibit the growth of C. 
difficile.
aims & Methods: Intestinal bacteria strains were isolated from fecal 
sample and identified by the 16S rRNA gene analysis. Each isolate and C. 
difficile was sub-cultivated in the broth media at 37 °C under anaerobic 
conditions. C. difficile culture was spreading on the agar plates and steril-
ized disc laid on the plate. Then, impregnated on the disc with the culture 
supernatant which removed bacteria. The plate was observed after 48hr 
incubation in anaerobic environment.
results: More than forty genera including Enterococcus, Clostridium, Bacil-
lus, Lactobacillus, Bifidobacterium, Eubacterium were isolated from human 
fecal sample. Among them, 5 strains of Lactobacillus and 4 strains of Bifi-
dobacterium were shown to suppress C. difficile growth. These belonged to 
B. longum, B. pseudocatenulatum, B. adolescentis, B. dentium, L. ruminis, L. 
rhamnosus, L. sakei, L. salivarius, and L. gasseri. Also, we confirmed Copro-
coccus and Ruminococcus species can inhibit C. difficile growth.
conclusion: We found some of Bifidobacterium species and Lactobacil-
lus species from human feces could partially suppress against C. difficile 
colonization. These results suggested a potential that some of Bifidobacte-
rium species and Lactobacillus species could be helpful in preventing CDI. 
Therefore, these bacteria will be anticipated to play a crucial role in FMT 
for CDI treatment in the future.
disclosure: Nothing to disclose 
P1146 InTernaLLy aPPLIed uLTravIOLeT LIghT as a 
nOveL aPPrOach fOr effecTIve and safe anTI-MIcrOBIaL 
TreaTMenT
Rezaie A.1, Leite G.2, Park J.3, Kim S.1, Weisman S.3, Melmed G.3, 
Barlow G.3, Morales W.3, Celly S.3, Parodi G.3, Sakhaie S.4, Melmed Z.3, 
Ybarra E.1, Mathur R.3, Pimentel M.3
1Cedars-Sinai Medical Center, Gastroenterology, Los Angeles, United States, 
2Cedars-Sinai Medical Center, MAST, Los Angeles, United States, 3Cedars-
Sinai Medical Center, Los Angeles, United States, 4Australian Clinical Labs, 
Melbourne, Australia
contact e-Mail address: ali.rezaie@yahoo.com
Introduction: With emergence of microbial resistance and superbugs, 
there is a crucial need for safe, highly effective antimicrobial treatments 
with broad applicability to invasive pathogenic bacteria and fungi. Ultra-
violet-C light (200-280 nm) is germicidal but associated with neoplastic 
transformation in humans. Ultraviolet-A (UVA, 320-400 nm) phototherapy 
reduces (epi)dermal inflammation without significant adverse effects but 
has not been evaluated in internal viscera. We aimed to assess the in-vitro 
bactericidal efficacy and in-vivo safety of intracolonic UVA using a novel 
light delivery system.
aims & Methods: Customized optical rods (D=4mm, L=40mm) were de-
signed to homogenously side-emit UVA. A mercury vapor lamp served as 
light source (Asahi Max-303), and UV bandwidth/irradiance peaks were 
assessed (Ocean Optics; Extech). UVA intensities used in this study were 
less than natural sunlight. (Table 1) In-vitro tests were performed using 
microbial liquid cultures of various enteric pathogens. Cultures exposed 
to UVA at 20-min intervals were compared to unexposed control cultures 
and transferred to solid medium plates for CFU counts. In-vivo testing of 
UVA effects on normal colon were performed using BALB/cJ mice (n=10, 
male=5). Under anesthesia, 5 mice underwent colonic UVA exposure 
(2,000 µW/cm2) for 30 minutes via an optic rod introduced anally up to 
the splenic flexure as compared to 5 mice treated with the same technique 
with an unlit optic rod. Rigid endoscopy (Olympus A37027A) was used to 
evaluate the mucosa before and serially after UVA exposure. Endoscopic 
videos were blindly interpreted by two gastroenterologists with expertise 
in animal model endoscopies. Full thickness microscopic assessments 
were performed by a blinded pathologist on Swiss-roll preparations of 
the whole colon.
results: Exposure to UVA was associated with a significant reduction in 
concentrations of various microbes, including Clostridioides difficile and 
Candida albicans (Table 1). The germicidal effects increased with greater 
time of exposure. Proteus mirabilis and Pseudomonas aeruginosa did not 
reveal any growth after 20 and 40 minutes of exposure, respectively. Dur-
ing in-vivo tests no perforation or fatalities were seen after light exposure. 
No evidence of erythema, mucosal friability or bleeding was observed 
during endoscopies. No chronic inflammation or dysplasia was seen on 
examined full-thickness colonic specimens exposed to UVA.
conclusion: UVA light exposure exhibits significant in-vitro bactericidal ef-
fects in array of clinically important bacteria, including C. difficile. UVA is 
also effective against C. albicans which may prevent fungal bloom following 
antibacterial treatment. In this first study of intracolonic UVA application, 
UVA exposure is not associated with endoscopic or histologic injury. UVA 
therapy can potentially provide an effective and safe novel antimicrobial 
approach to the treatment of enteric infections and inflammation. Future 
studies are required to assess the antimicrobial and anti-inflammatory ef-
fects of UVA phototherapy on internal organs.
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Microorga-
nism
uva 
Intensity 
(µW/cm2)
group
Baseline 
cfux107
/mL
20 min 
cfux107/
mL
P 
value
40 min 
cfux107
/mL
P value
60 min 
cfux107
/mL
P 
value
Clostri-
dioides 
difficile
2,000
Exposed 
Control
0.1
0.1
0.08
0.13
0.01
0.01 
0.17
0.003
0.0031
0.39
0.01
Candida 
albicans
1,700
Exposed 
Control
0.14
0.14
0.09 
0.17
0.007
0.03 
0.2
0.001
0.0032 
0.16
0.001
Pseudo-
monas 
aeruginosa
3,500
Exposed 
Control
0.81
0.81
0.07
0.61
<0.001
No 
growth 
0.93
<0.001
No 
growth
0.85
<0.001
Klebsiella 
pneumo-
niae
1,300
Exposed 
Control
5.9
5.9
6.34 
7.49
0.17
3.34 
10.5
<0.001
1.53 
13.81
<0.001
Escherichia 
coli
1,300
Exposed 
Control
1.25
1.25
0.41 
3.31
<0.001
0.21 
4.2
0.001
0.03
5.52
<0.001
Enterococ-
cus faecalis
2,400
Exposed 
Control
9.21
9.21
2.99
10.6
0.1
0.61 
14.72
0.01
0.08 
17.74
0.01
Strepto-
coccus 
pyogenes
1,800
Exposed 
Control
1.17
1.17
0.68 
0.83
0.64
0.64 
1.68
0.001
0.17 
1.31
0.004
Proteus 
mirabilis
2,400
Exposed 
Control
0.62
0.62
No 
growth 
0.59
<0.001
No 
growth 
0.49
<0.001
No 
growth
0.54
<0.001
Staphy-
lococcus 
epider-
midis
2,150
Exposed 
Control
0.57
0.57
0.43 
0.59
0.01
0.03 
0.69
<0.001
0.0001
0.7
<0.001
[Concentration of microbes in the liquid suspension before and after UVA 
therapy as compared to unexposed controls.]
references: Financial support partly by The Kenneth Rainin Foundation
disclosure: AR, MP and GM have intellectual property in regards to Inter-
nal UV therapy. 
P1147 cOLOrecTaL cancer screenIng and chOIce Of The 
POsITIve cuT-Off LeveL. are french decIsIOn MakIng 
crITerIa OPTIMaL In reLaTIOn TO a PersOn’s equaL access TO 
cOLOnOscOPy In regards TO advanced neOPLasIa rIsk?
Kaufmanis A., Koivogui A., Vincelet C., Deyra J., Ait Hadad H., Delattre H., 
Brixi Z., Bercier S., Le Trung T.
CRCDC-IDF, Paris, France
contact e-Mail address: a.kaufmanis@adc77.org
Introduction: Many European countries use fecal immunochemical test 
(FIT) as a test for colorectal cancer (CRC) screening using different Cut-off 
levels ranging from 15-80 µHb/g [Réf-1, 2]. In France the selected level 
is 30µgHg/g. These levels are generally adjusted to existing capacity to 
provide colonoscopies for the persons with positive tests. The Netherlands 
and England provide colonoscopy for positive test within a fixed number of 
days by a gastroenterologist dedicated to the screening program. In these 
countries the screening capacity pool is separated from the general colo-
noscopy pool. In France any gastroenterologist performs a colonoscopy for 
a person with a positive test. There is no system of prioritization in place. 
In France organised CRC screening program and access to screening by FIT 
is advised for persons with “average CRC risk”. Individuals with identified 
two fold risk (first degree family history, adenoma history) are excluded 
from screening and directly prescribed a colonoscopy. [Réf-3].
aims & Methods: Our aim was to compare, within the French screening 
programme, the risk to detect advanced-adenoma (AA)/CRC in persons 
with different Hb cut-off levels in the previous campaign and who were 
currently considered negative and the AA/CRC general risk. If the risk 
within certain cut-off levels is twice that of general population should they 
not have direct access to colonoscopy as do others with comparable risk? 
Study included a reference group of 602 731 “average risk” inhabitants of 
Parisian region aged 50-74 years who did their FIT test in 2015-2016 (1st FIT 
campaign: R1). Two years later (R2) we examined the probability to detect 
cancer by a FIT test for those who were negative within this R1. Different 
subgroups of Relative-Risk (RR) analysis were formed, based on the hae-
moglobin cut-off during the R1 campaign. We compared these subgroups 
with a reference group.
results: A total of 602 731 people (55.02% women, average age: 61.3 years 
for women and 60.9 for men) participated in the R1. Of them 4.6 % had 
a positive test. In this group AA and CRC detection rate was 13.0 ‰ and 
2.9 ‰ respectively. Among those who had a negative test in R1, 330,469 
(57.5%) (55.7% women, average age: 63.2 years for women and 63.0 years 
for men) performed a second test during R2. Among them 3.3% were 
positive, with an increased risk of positivity (2.9 % -16.2 %) correlating to 
Hb level in in R1. Compared with individuals of reference group R1 4644 
individuals with R1 [20-30[ µgHb/g level were 3.0 times more likely to have 
a positive R2 test, 2.6 (CI, 2.3-3.1) times more likely to have AA and 2.6 (CI, 
1.9-3.7) times more likely to have CRC. At the moment of study colonoscopy 
results were known for 52.4% of those who tested positive in R2. The avail-
able data show an increased risk of AA and CRC correlating with the results 
of the faecal haemoglobin cut-off in R1.
conclusion: The probability of detecting colorectal cancer within the sec-
ond round of FIT based screening program for those who were negatives 
but above 20µgHb/g level, is more than two fold if we compare with the 
reference group who represents the average risk population of the Parisian 
region. This increase of risk could not be explained just by aging of 2 years. 
This strongly suggests that this Hb concentration level during the first test 
may be an equal or more important risk factor than for instance the first 
degree family history. Additional studies (early second test or colonoscopy 
based) should be conducted to confirm this hypothesis. If this hypothesis is 
confirmed, the French program should lower the cut off level.
references: 1.https://ec.europa.eu/health/sites/health/files/major_chron-
ic_diseases/docs/2017_cancerscreening_2ndreportimplementation_en.pdf 
2.http://www.healthscotland.scot/media/1619/bowel-screeening-inserts_
nov17_english.pdf
3.https://www.edp-biologie.fr/images/stories/news/2018/Mars/
joe_20180322_0068_0013.pdf If accepted for presentation the results will be 
updated in september 2019
disclosure: Nothing to disclose 
P1148 PrevaLence Of cOLOrecTaL cancer In cryPTOgenIc 
PyOgenIc LIver aBscess PaTIenTs, dO They need rOuTIne 
screenIng cOLOnOscOPy? a sysTeMaTIc revIeW and 
MeTa-anaLysIs
Mohan B.1, Aravamudan V.2, Khan S.3, Chandan S.4, Ponnada S.5, 
Asokkumar R.6, Navaneethan U.7, Adler D.8
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3University of Arizona/Banner University Medical Center, Tucson, United 
States, 4University of Nebraska Medical Center, Gastroenterology and 
Hepatology, Omaha, United States, 5Carilion Roanoke Medical Center, 
Roanoke, United States, 6Singapore General Hospital, Gastroenterology, 
Singapore, Singapore, 7Florida Hospital, Center for Interventional 
Endoscopy, Orlando, United States, 8University of Utah School of Medicine, 
Gastroenterology and Hepatology, Salt Lake City, United States
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Introduction: Patients with cryptogenic pyogenic liver abscess (PLA) do not 
have a definite source of infection and it could be a manifestation of com-
promised colonic mucosal barrier due to colorectal cancer (CRC). Associa-
tion of PLA and CRC is unclear. Evidence is weak and limited to small sized 
studies. As a result, the need for colonoscopy in PLA patients is debatable.
aims & Methods: We conducted a comprehensive search of multiple elec-
tronic databases and conference proceedings (from inception through 
January 2019) to identify studies that reported on the prevalence of CRC in 
PLA patients. Our goals were to evaluate the pooled rate of CRC in patients 
with cryptogenic PLA.
results: 12 studies were included in the analysis. Majority of them were 
from East Asian countries. 18,607 patients were diagnosed with PLA in 
the study group and 60,130 patients were in the control group. 63% were 
males in the age range of 56 to 94 years. 90.5% of the lesions were left 
sided and 93.1% were positive for Klebsiella pneumoniae. A total of 18,607 
PLA patients were reported, of which 17,906 patients underwent screening 
for CRC. A total of 713 colorectal lesions were found, of which 648 were 
diagnosed with CRC. 60,130 patients were used as control group, of which 
509 patients were diagnosed with CRC. The pooled rate of prevalence of 
CRC was 7.9% (95% CI 5-12.1, I2=92.4, relative risk=6.6) in patients with 
PLA, as compared to 1.2% (95% CI 0.3-5.7, I2=93.4) in control, with statisti-
cal significance (p=0.001). Relative risk = 6.6.
conclusion: Although limited by heterogeneity, our study demonstrates 
that patients with cryptogenic PLA are at a 7-fold risk of having CRC when 
compared to patients without PLA. Based on our results a screening colo-
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noscopy should be considered in East Asian population with cryptogenic 
PLA, especially when positive for Klebsiella pneumoniae.
disclosure: Nothing to disclose 
P1149 a naTIOnWIde anaLysIs Of readMIssIOn raTes afTer 
cOLOrecTaL cancer surgery In The us
Kim J.W.1, Mannalithara A.2, Singh G.3, Ladabaum U.2
1Inje University Ilsan Paik Hospital, Internal Medicine, Goyang, 
Korea (Republic of), 2Stanford University Medical Center, Division of 
Gastroenterology and Hepatology, Redwood City, United States, 3Institute of 
Clinical Outcomes Research and Education, Woodside, United States
contact e-Mail address: jongman12@gmail.com
Introduction: Hospital readmission after surgery constitutes a serious bur-
den for patients as well as health systems and payers. Data on readmis-
sion rates after colorectal cancer (CRC) surgery are scarce. We analyzed 
US national rates of, and factors associated with, 30-day readmission after 
CRC surgery.
aims & Methods: We queried the National Readmissions Database (NRD) 
from 2010 to 2015 to calculate national estimates of 30-day readmission 
rates after CRC surgery, and the causes for readmission. Patients included 
had non-subepithelial CRC, were aged 18 years or more, and survived the 
index admission. Patients with appendiceal or anal cancer were excluded. 
In order to allow follow-up of 30 days, patients who were discharged in 
December were excluded, because patients are not tracked across years. 
We also analyzed potential factors associated with readmission, first using 
non-adjusted and ultimately multivariable-adjusted logistic regression. All 
results were weighted for national estimates. Joinpoint analysis was per-
formed to test for changes in temporal trends.
results: The US national estimate for the number of overall index cases of 
CRC surgery during the study period was 616,348. Among these patients, 
90,555 (14.7%) were readmitted within 30 days of discharge. During our 
study period, the readmission rate showed a decreasing trend from 15.5% 
in 2010 to 13.5% in 2015 (p-trend < 0.001, Table 1). Joinpoint analysis did 
not show any significant change in this trend over time. The most fre-
quent diagnoses for readmission were gastrointestinal (54.8%), infectious 
(10.6%), and cardio-/cerebrovascular (6.3%). 
The three most common gastrointestinal diagnosis codes for readmission 
were postoperative, post-traumatic, other device infections (11.9%); mal-
function, reaction & complication of GI device or procedure (8.7%); and in-
testinal obstruction (5.9%). After adjusting for covariates, rectal resection 
(odds ratio [OR], 1.372 [95% confidence interval {CI}, 1.324-1.422]), longer 
length of stay (OR with log-increase in 1, 1.395 [95% CI, 1.358-1.432)), met-
ropolitan teaching hospital (OR vs metropolitan nonteaching, 1.109 [95% 
CI, 1.072-1.147), non-routine discharge including transfer to a short term 
hospitals (vs routine, OR, 1.617 [95% CI, 1.336-1.957]), elective admission 
(OR, 1.072 [95% CI, 1.034-1.111]), open laparotomy (OR, 1.172 [95% CI, 1.134-
1.212), and higher Elixhauser comorbidity score (OR for increase in 1, 1.009 
[95% CI, 1.008-1.010]) were potential risk factors for subsequent readmis-
sion. 
Advanced cancer (OR, 0.304 [95% CI, 0.288-0.321]), and older age (OR 
for >84 y vs 18-44 y, 0.790 [95% CI, 0.727-0.858]) and female gender (OR, 
0.941 [95% CI, 0.916-0.966) were associated with decreased odds for re-
admission.
year 2010 (n, %)
2011 
(n, %)
2012 
(n, %)
2013 
(n, %)
2014 
(n, %)
2015 
(n, %)
Overall 
(n, %)
Not 
readmitted
89,882 
(84.5%)
88,371 
(84.5%)
87,968 
(85.2%)
86,557 
(85.8%)
86,444 
(85.8%)
86,571 
(86.5%)
525,793 
(85.3%)
Readmitted
16,480 
(15.5%)
16,274 
(15.5%)
15,331 
(14.8%)
14,708 
(14.5%)
14,275 
(14.2%)
13,486 
(13.5%)
90,555 
(14.7%)
Total
106,362 
(100%)
104,645 
(100%)
103,299 
(100%)
101,265 
(100%)
100,719 
(100%)
100,057 
(100%)
616,348 
(100%)
[Table 1. 30-Day readmission rate by year, US national estimates]
conclusion: In a US national analysis, we found that the 30-day readmis-
sion rate after CRC surgery was 14.7% in the period from 2010 to 2015, with 
a decreasing trend from 15.5% in 2010 to 13.5% in 2015. Some associations 
appear as expected, such as increased odds of readmission with rectal 
resection, and some appear surprising and require further study, includ-
ing the decreased odds of readmission with advanced cancer and in older 
patients. It remains to be determined whether any of the predictors of 
readmission can point to modifiable factors that can decrease readmission 
rates after CRC surgery.
disclosure: Nothing to disclose 
P1150 fIT POsITIve cOLOnOscOPy PerfOrMance aT a Large 
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Care Services, Health Care Division, Tel Aviv, Israel, 3Tel Aviv Sourasky 
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Introduction: Annual FIT at 50-75Y is currently the national screening pro-
gram for CRC in Israel. FIT is considered to be effective for CRC early diag-
nosis but not a CRC preventive measure compared to colonoscopy. Positive 
FIT indicates the need for prompt colonoscopy due to a relatively high rate 
of advanced neoplastic lesions in the colon, while time to colonoscopy up 
to 6 months has been shown as effective in advanced cancer prevention.
aims & Methods: To review colonoscopy performance among FIT positive 
cases and its timing after FIT. To identify factors for lack of colonoscopy 
performance in FIT positive cases and to study the profile of neoplastic 
findings in FIT positive colonoscopies performed in a large HMO in Israel.
Maccabi Health care services (MHS) is an Israeli HMO with 2 million mem-
bers. All MHS members aged 50-75 during 2018 were included in the 
analysis. MHS database was searched for FIT and colonoscopy associated 
parameters. CRC registry was crossed with FIT positive cases. Time be-
tween FIT performance and colonoscopy was calculated. Colonoscopy and 
pathology reports were individually studied for specific endoscopic lesions 
and corresponding histological findings, respectively.
results: During 2018, 523,530 members were at the age group of 50-75y. 
among them- 134,542 performed FIT with 6,925 having positive results. 
For those, colonoscopy was performed after 3, 3-6, 6-9 months from FIT 
testing in 4035(58%), 337(5%), 49(0.7%), respectively. A survey in a sub-
sample of 430 cases who did not perform colonoscopy up to 9 months 
post FIT showed that 74% did perform a colonoscopy in a private setting, 
7% were still in workup, 4% refused and 8% agreed and performed colo-
noscopy through the survey. In another subsample of 536 colonoscopies, 
polyps were reported in 164/536(31%) cases and cancer in 20/536(4%). 
The records of cases with polyps were searched for endoscopic and histo-
logic findings. Cases with adenomas- 95/536(18%) with 27 non-advanced 
and 68 advanced (5% and 13% of total sample; 28% and 72% of adenoma 
cases, respectively). Advanced polyp by histology (villous of HGD) was 
found in 23/68 and advanced size or number in 45/68. The rate of hyper-
plastic polyps was 3.5%.
conclusion: Colonoscopy performance after FIT positive test is satisfac-
tory and mostly performed within 3 months of FIT testing according to the 
quality parameters of MHS. The rate of advanced adenomas is higher in 
about 2 folds than in average Israeli risk population (1), thus making FIT a 
CRC preventive measure. Rate of cancer is 3.5 folds of the rate at average 
risk screening colonoscopy.
references: Strul H, Kariv R, et al. J Gastroenterol. 2006 Feb;101(2):255-62. 
The prevalence rate and anatomic location of colorectal adenoma and can-
cer detected by colonoscopy in average-risk individuals aged 40-80 years.
disclosure: Nothing to disclose 
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P1151 POsT-cOLOnOscOPy cOLOrecTaL cancer versus 
deTecTed cOLOrecTaL cancer: dOes TuMOur MOrPhOLOgy 
and faMILy hIsTOry dIffer?
Forsberg A.1, Kärenen A.2, Ghazi S.2, Lindblom A.3
1Karolinska Institutet, Institution of Medicine Solna, Stockholm, Sweden, 
2Karolinska Institutet, Department of Laboratory Medicine, Stockholm, 
Sweden, 3Karolinska Institutet, Department of Molecular Medicine and 
Surgery, Stockholm, Sweden
contact e-Mail address: anna.forsberg@ki.se
Introduction: Colonoscopy is the golden standard for detecting colorec-
tal cancer (CRC). The prevalence of post-colonoscopy CRC (PCCRC), a CRC 
detected within 6-36 months after a negative colonoscopy examination, 
has been recognized as a quality measure. Mechanisms for PCCRC either 
might be missed or incompletely excised lesions or CRC developed de novo 
since the initial colonoscopy. Little is known about histopathological fea-
tures and low-risk family history for CRC in PCCRC compared to detected 
CRC (dCRC).
aims & Methods: The aim of the study was to compare PCCRC and dCRC 
regarding different tumour morphology parameters and family history for 
CRC. From The Swedish low-risk CRC study 1,535 individuals operated for 
CRC during the years 2004-06 were included. All had data on family his-
tory for CRC (defined as at least one first degree relative with CRC) and the 
tumours were thoroughly histologically reviewed. Data from the Swedish 
patient inward and outward as well as causes of death registers were col-
lected. Those who had performed a colonoscopy within 0-36 months be-
fore the cancer diagnosis were included for analysis. Cancers were divided 
into PCCRC and dCRC, with CRC diagnosis within 6-36 and 0-6 months 
after the colonoscopy, respectively. Statistical analysis included Chi-2 test, 
Students’ T-test and logistic regression.
results: There were 476 CRCs included in the analysis. Of these, there were 
29 PCCRCs and 447 dCRCs. The mean age was 66.1 years in the PCCRC 
group and 69.2 years in the dCRC group (p=0.07). When controlling for sex 
and age, there was no significant difference between the two groups in 
five-year mortality, 34% in PCCRC and 28% in dCRC (p=0.334). The results 
of the logistic regression analysis are summarized in the table.
conclusion: In this small Swedish cohort study, low-risk family history for 
CRC was not a significant risk factor for PCCRC. Crohn-like peritumoral 
lymphocytic reaction was less frequently seen in PCCRC compared to dCRC. 
This might be an indication of different prognosis for PCCRCs compared 
to dCRCs.
covariate Or p-value 95% cI
Sex (female vs male) 0.91 0.845 0.37-2.25
Age (continuous) 1.00 0.854 0.95-1.04
Localisation (right vs left) 0.77 0.565 0.31-1.89
T-stage (T3/T4 vs T1/T2) 4.11 0.067 0.91-18.66
N-stage (1, 2 or 3 vs 0) 1.58 0.311 0.65-3.85
Peritumoral lymphocytic reaction (yes 
vs no)
0.40 0.030 0.18-0.91
Vascular growth (yes vs no) 0.19 0.110 0.02-1.46
Medullary type (yes vs no) 2.21 0.357 0.41-11.95
Family history CRC (yes vs no) 1.20 0.755 0.38-3.75
[Multivariate logistic regression for post-colonoscopy colorectal cancer 
(PCCRC) versus detected colorectal cancer (dCRC)]
references: Ghazi S, Lindforss U, Lindberg G, Berg E, Lindblom A, Papado-
giannakis N; Low-Risk Colorectal Cancer Study Group. Analysis of colorec-
tal cancer morphology in relation to sex, age, location, and family history. J 
Gastroenterol. 2012 Jun;47(6):619-34. doi: 10.1007/s00535-011-0520-9.
disclosure: Nothing to disclose 
P1152 nOn-PeduncuLaTed, screen-deTecTed T1 cOLOrecTaL 
carcInOMas have an Increased rIsk fOr LyMPh nOde 
MeTasTasIs as cOMPared TO nOn-screen-deTecTed T1 
cOLOrecTaL carcInOMas
van der Schee L.1,2, Haasnoot K.J.C.1, Elias S.G.3, Backes Y.1, 
van Berkel A.-M.4, Boersma F.5, ter Borg F.6, Gijsbers K.M.7, Kessels K.8, 
Schrauwen R.9, Spanier B.W.M.10, Terhaar sive Droste J.11, 
De Vos Tot Nederveen Cappel W.2, Vleggaar F.P.12, Laclé M.M.13, 
Moons L.M.G.1, Dutch T1 CRC Working Group
1University Medical Center Utrecht, Gastroenterology & Hepatology, 
Utrecht, Netherlands, 2Isala Clinics, Zwolle, Netherlands, 3University 
Medical Center Utrecht, Julius Center for Health Sciences and Primary 
Care, Utrecht, Netherlands, 4Noordwest Hospital Group, Gastroenterology 
& Hepatology, Alkmaar, Netherlands, 5Gelre Hospital, Apeldoorn, 
Netherlands, 6Deventer Hospital, Deventer, Netherlands, 7Deventer 
Hospital, Gastroenterology & Hepatology, Deventer, Netherlands, 8Sint 
Antonius Hospital, Gastroenterology & Hepatology, Utrecht, Netherlands, 
9Bernhoven, Gastroenterology & Hepatology, Uden, Netherlands, 10Rijnstate 
Hospital, Gastroenterology, Arnhem, Netherlands, 11JBZ, Gastroenterology & 
Hepatology, ‘s-Hertogenbosch, Netherlands, 12University Medisch Centrum 
Utrecht, Gastroenterology & Hepatology, Utrecht, Netherlands, 13University 
Medical Center Utrecht, Pathology, Utrecht, Netherlands
contact e-Mail address: lisavdschee@gmail.com
Introduction: Implementation of the FIT-based colorectal cancer (CRC) 
screening program in 2014 has led to an increased detection of T1 CRCs in 
the Netherlands. Current risk stratification is based on non-screen-detect-
ed T1 CRCs. However, it is unknown whether screen- and non-screen-de-
tected T1 CRCs have a comparable risk of adverse outcomes such as lymph 
node metastasis (LNM) and recurrence.
aims & Methods: In this study we compared screen-detected and non-
screen-detected T1 CRCs. A multicenter retrospective observational cohort-
study was performed, identifying all consecutive T1 CRCs diagnosed be-
tween 2014 and 2017 in 8 hospitals in the Netherlands. Data on whether a 
T1 CRC were screen-detected or non-screen-detected, together with polyp 
characteristics, histological risk factors, treatment approach and clinical 
variables such as age, gender and co-morbidities were collected. Differ-
ences in LNM were evaluated by using multivariate logistic regression 
analysis, adjusting for clinical variables, polyp characteristics and histo-
logical risk factors.
results: A total of 1101 T1 CRCs (median follow-up 21.7 months (IQR 19-
30)) were included in the study, of which 693 (62.9%; 34.2% female) 
were screen-detected and 408 (37.1%; 42.4% female) were non-screen-
detected. Screen-detected T1 CRCs were smaller (mean size of 20.0 mm 
(SD 11.5) vs. 22.5 mm (SD 13.2), p=0.005), more frequently located in the 
left-sided colon (61% vs. 54%, p=0.02), and patients were younger (67.2 
(IQR 63-71) vs. 69.3 (IQR 62-78) years, p< 0.001) compared to non-screen-
detected patients with T1 CRC. Within the group of patients referred for 
surgery, screen-detected T1 CRC was associated with a higher risk of LNM 
than non-screen-detected T1 CRC (16.4% vs. 10.4%; adjusted OR 1.78,95% 
CI 0.93-3.34; p=0.08). This difference was mainly attributable to a higher 
LNM risk in non-pedunculated screen-detected T1 CRCs (18.8% vs. 10.5%, 
p=0.03), as there was no significant difference in LNM risk in peduncu-
lated T1 CRCs (9.1% vs 8.3%). Within the group of non-pedunculated T1 
CRCs (n=669 (65% of total), of which screen-detected n=427(64%)) there 
was no difference between screen- and non-screen-detected T1 CRCs re-
garding histological features such as lymphovascular invasion (14.8% vs 
11.1%, p=0.35) and poor differentiation (6.3% vs. 5.3%, p=0.49). However, 
positive (R1) or inconclusive (Rx) resection margins were more frequently 
present in screen-detected patients (46.9% vs. 34.7%, p=0.002), although 
this feature was not independently associated with LNM in this cohort 
(p=0.094). While non-screen-detected patients were referred for prima-
ry oncologic surgery more often than screen-detected patients (65% vs 
53%, p=0.003), there was no difference in overall surgical referral rate 
(56.2% vs. 62.8% p=0.10). 
Interestingly, the major difference in LNM in non-pedunculated T1 CRCs 
was found within the primary surgery group (screen-detected 17.6% vs. 
non-screen-detected 6.2%, p=0.008), and not in the secondary surgery 
group (screen-detected 20.2% vs. non-screen-detected 21.4%, p=0.871).
conclusion: Non-pedunculated T1 CRCs detected within the FIT-based 
screening program have a higher risk for synchronous lymph node me-
tastasis compared to non-screen detected T1 CRCs. This difference is most 
pronounced in patients referred for primary surgery, suggesting that these 
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polyps may have alarming malignant features with optical diagnosis. This 
increased risk should be kept in mind, now that local minimally invasive 
treatments such as full thickness resections are becoming more widely 
available.
disclosure: Nothing to disclose 
P1153 OuTcOMes Of cOLOrecTaL cancer screenIng sTarTIng 
aT The age Of 45 In average-rIsk, asyMPTOMaTIc PaTIenTs
Chalifoux S., Tsai F., Strum W.
Scripps Clinic, Gastroenterology and Hepatology, La Jolla, United States
contact e-Mail address: sarachalifoux@gmail.com
Introduction: Colorectal cancer (CRC) is the fourth most common cancer 
diagnosed among adults in the United States and most guidelines recom-
mend colorectal cancer screening for average-risk individuals starting at 
age 50. Since 1994, there has been a 51% increase in CRC among indi-
viduals younger than 55. Updated guidelines from the American Cancer 
Society (ACS) in May 2018 recommend starting colorectal cancer screen-
ing for all individuals at age 45. T
hese recommendations are based on modeling studies and there are lim-
ited data on the effectiveness and outcomes of colorectal cancer screen-
ing in average risk individuals younger than 50.
aims & Methods: The aim of this study was to compare the rates of adeno-
mas and advanced adenomas detected in average risk patients undergoing 
screening colonoscopies between the ages of 45-49 versus 50-54. In this 
retrospective study, a total of 3,760 patients undergoing colorectal cancer 
screening from June 2018 to December 2018 were reviewed, with 1,447 
patients excluded based on active digestive symptoms, anemia or personal 
history of CRC. The rates of adenomatous lesions and advanced adeno-
matous lesions in each cohort were compared. Advanced adenomas were 
defined as any adenoma ≥10 mm in size, high-grade dysplasia, villous or 
tubulovillous histology, and adenocarcinoma. The locations of advanced 
adenomas were also compared.
results: In the 45-49 cohort, there were a total of 190 patients who under-
went screening colonoscopy, of which 47.7% were women. In this cohort, 
73 (38%) patients had non-advanced adenomas (adenoma size < 5 mm in 
27, and 5-9 mm in 46). A total of 10 (5%) patients had advanced adenomas 
based on advanced histology (polyp size 5-9 mm in 3, and ≥10 mm in 1) 
and size (adenomas ≥10 mm in 6). One 49 year old patient had an adeno-
carcinoma found on screening colonoscopy. 
In the 50-54 cohort, there were a total of 2,123 patients who underwent 
screening colonoscopy, of which 52.4% were women. In this cohort, 870 
(41%) patients had non-advanced adenomas (adenoma size < 5 mm in 
443, and 5-9 mm in 427). A total of 119 (5.6%) patients had advanced 
adenomas based on histology (polyp size < 5 mm in 2, 5-9 mm in 13, and 
≥10 mm in 17) and size (adenomas ≥10 mm in 87). No patients had adeno-
carcinoma found on screening colonoscopy in this cohort. 
The adenoma detection rate was 44.2% in the 45-49 cohort and 46.6% 
in the 50-54 cohort (p=0.53). The advanced adenoma detection rate was 
5.8% in the 45-49 cohort and 5.6% in the 50-54 cohort (p=0.91). Advanced 
adenomatous lesions were most frequently found in the ascending colon 
for both cohorts (Table 1). 
45-49 cohort 50-54 cohort
Location number Location number
Cecum 1 Cecum 20
Ascending 7 Ascending 30
Transverse 1 Transverse 20
Sigmoid 0 Sigmoid 18
Rectosigmoid 0 Rectosigmoid 6
Rectum 2 Rectum 18
[Table 1: advanced adenoma locations]
conclusion: This study provides preliminary data on the outcomes of CRC 
screening starting at the age of 45 in a Southwestern population since the 
updated ACS screening guidelines were released in May 2018. Our results 
show that asymptomatic patients between the ages of 45-49 who undergo 
screening colonoscopy have adenomas and advanced adenomas detected 
at rates similar to patients screened between the ages of 50-54. Addi-
tionally, one adenocarcinoma was discovered on screening colonoscopy 
in a patient before the age of 50. These findings support consideration of 
colorectal cancer screening at age 45.
disclosure: Nothing to disclose 
P1154 POsT-cOLOnOscOPy cOLOrecTaL cancer raTe Is sLOWLy 
decreasIng: a reTrOsPecTIve POPuLaTIOn Based cOhOrT 
sTudy Of The aduLT sWedIsh POPuLaTIOn
Forsberg A.1, Widman L.2, Ekbom A.3, Hultcrantz R.4
1Karolinska Institutet, Institution of Medicine Solna, Stockholm, Sweden, 
2Karolinska Institutet, Department of Biostatistics, Institute of Environmental 
Medicine, Stockholm, Sweden, 3Clinical Epidemiology Unit, Karolinska 
Hospital M9:01, Department of Medical Epidemology, Stockholm, Sweden, 
4Karolinska Institutet, Medicine, Stockholm, Sweden
contact e-Mail address: anna.forsberg@ki.se
Introduction: The rate of post-colonoscopy colorectal cancer, PCCRC, 
a cancer detected 6-36 months after a colonoscopy in which no cancer 
was found, has been recognised as a key quality indicator of colonoscopy. 
Mechanisms for PCCRC might be either missed or incompletely excised le-
sions or de novo cancer developed after the index colonoscopy.
aims & Methods: The aim was to evaluate the PCCRC rates and associ-
ated risk factors for PCCRC during a 10-year period. Data was collected 
from the Swedish patient registries on individuals > 18 of age. All unique 
individuals who had undergone at least one colonoscopy during the years 
2003-15 were identified. Those with a CRC diagnosis prior to inclusion in 
the study were excluded. The rest was individually linked to the Swed-
ish Cancer Registry and the Swedish Cause of Death Register. CRCs within 
0-6 months of a colonoscopy examination were considered as detected 
cancers and CRCs diagnosed within 6-36 months as PCCRCs. Colonosco-
pies performed 2003-12 were included in the analysis. The PCCRC rate was 
analysed with colonoscopies as the denominator (1). Statistical analyses 
employed Poisson regression analysis with cluster-robust standard errors. 
Covariates included were age, sex, comorbidities, procedure, location of 
the CRC, T-stage, time-period and the geographical location of the diag-
nosing hospital.
results: There were 461,031 colonoscopies performed on 349,129 (56% 
on women) individuals included in the study. The mean age at the first 
examination was 59.4 years. Of these, there were 19,178 individuals with 
a CRC diagnosis 0-36 months after a colonoscopy. There were 1,329 PC-
CRCs, which is equal to the number of colonoscopies that failed to detect 
a CRC. The number of colonoscopies that detected a CRC was 18,480. The 
PCCRC rate for the ten-year period was 6.7%. The rate was 8.1% in 2003 
and 5.9% in 2012. Gender, younger age, right-sided CRC, comorbidities, 
previous history of colorectal polyps as well as polypectomy during the 
procedure and the first time-period were associated with a significantly 
increased risk of PCCRC.
Main group covariate rr p-value 95% cI
Sex Male vs female 0.87 0.007 0.79-0.96
Age group Age 18-30 years 1.40 0.128 0.91-2.18
  Age 30-40 years 1.35 0.052 1.00-1.83
  Age 40-50 years 1.31 0.028 1.03-1.66
  Age 50-60 years 1.06 0.529 0.88-1.29
  Age 60-70 years 1.12 0.134 0.97-1.29
  Age 70-80 years 1.06 0.419 0.92-1.21
  Age > 80 years (ref) 1.00    
Comorbidity Ulcerative colitis Yes/No (No=ref) 5.12 <0.001 4.48-5.85
  Crohns disease Yes/No 3.85 <0.001 3.01-4.92
  Prior polyp diagnosis Yes/No 1.84 <0.001 1.50-2.26
Procedure Polypectomy Yes/No 2.01 <0.001 1.68-2.41
Location CRC Left- vs right-sided CRC 0.56 <0.001 0.49-0.64
  Undefined vs right-sided CRC 0.62 0.014 0.42-0.91
T-stage CRC T1/T2 vs T3/T4 1.27 <0.001 1.15-1.41
  Undefined vs T3/T4 0.66 <0.001 0.55-0.80
Time period 2008-12 vs 2003-07 0.87 0.008 0.79-0.96
[Table. Multivariate Poisson regression analysis for post-colonoscopy versus 
detected colorectal cancer with colonoscopy as the denominator]
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In the table, the multivariate analysis for the risks of PCCRC is shown. The 
covariates Diabetes, Diverticulosis, Ischemic Heart Disease, COPD, Heart 
Failure and Geography were controlled for but results not shown.
conclusion: The PCCRC rate is slowly decreasing in Sweden. The strongest 
risk factors for PCCRC were UC and Crohns’ disease. Increased effort for 
detecting CRCs in risk groups is of concern. 
references: 1. Morris EJ, Rutter MD, Finan PJ, et al. Post-colonoscopy 
colorectal cancer (PCCRC) rates vary considerably depending on the meth-
od used to calculate them: a retrospective observational population-based 
study of PCCRC in the English National Health Service. Gut 2015;64(8):1248-
56. doi: 10.1136/gutjnl-2014-308362
disclosure: Nothing to disclose 
P1155 PaTIenTs referred WITh anaeMIa shOuLd Be 
InvesTIgaTed fOr cancer regardLess Of IrOn sTaTus
Oldroyd C., Vithayathil M., Osman A., Corbett G.
Cambridge University Hospital, Gastroenterology, Cambridge, United 
Kingdom
contact e-Mail address: christopher.oldroyd@nhs.net
Introduction: Patients referred under the 2-week wait (2WW) pathway for 
gastrointestinal cancer with iron deficiency anaemia (IDA) are investigated 
in our centre with colonoscopy, upper GI endoscopy and CT scanning. It is 
necessary to justify these investigations given the burden they place upon 
radiology and endoscopy services.
aims & Methods: Our aim was to examine the predictive role of ferritin in 
such referrals and to assess whether this might be used to better stream-
line investigations. 
Referrals to the upper and lower GI cancer pathway over a period of one 
year were screened for referrals made exclusively for IDA. Data was col-
lected on ferritin level, age, gender, cancer detection and modality of can-
cer detection. Low ferritin was defined as < 15µg/L. Categorical variables 
were compared using a chi-squared test.
results: 3669 referrals to the upper and lower GI cancer pathway between 
May 2017 and May 2018 were screened for inclusion. 377 patients were 
referred for IDA of which 52 (13.8%) were found to have a malignancy. 
This compares to a national cancer detection rate of 7.6% for all referrals 
to 2WW pathways.
191 patients (52.0%) had a low ferritin. There was no statistically signifi-
cant difference between rate of cancer detection in the low and normal 
ferritin groups (10.4% vs 20.8% p=0.06). Males were more likely to have 
a cancer detected than females (21.8% vs 6.9%, p= 0.00003). The cancers 
detected included several non-GI malignancies in both low ferritin and 
normal ferritin groups (5/20 vs 10/30, p=0.53) (See table). 
CT scanning missed the malignancy in 7 cases of colorectal cancer subse-
quently detected on colonoscopy. 6 cancers were detected using upper GI 
endoscopy and all of these had been visible on CT scanning.In addition, all 
of the upper GI malignancies had normal ferritin levels.
  Low ferritin normal ferritin
Colon 14 11
Pancreas 1 2
Renal 1 1
Prostate 1 2
Other Breast (1) Adrenal (1) Bladder (1)
Lung(4) Stomach (2) Oesophagus (2) 
GOJ (2) Lymphoma (1) No primary (1) 
Cholangiocarcinoma
[Cancer detection]
conclusion: This study demonstrated a high rate of cancer detection for 
anaemia referrals but there was no statistically significant correlation be-
tween ferritin level and detection of cancer. Ferritin may not be a helpful 
marker in screening anaemia referrals. These results challenge the use of 
upper GI endoscopy in the investigation of anaemia on the cancer pathway 
since all cancers were seen on CT.
disclosure: Nothing to disclose 
P1156 The PrevaLence Of sessILe serraTed 
adenOMa/POLyP In cOLOrecTuM and ITs reLaTIOnshIP 
TO synchrOnOus cOLOrecTaL advanced neOPLasIa: 
a sysTeMIc revIeW and MeTa-anaLysIs
Shiu S.-I.1,2,3, Kashida H.4, Ho H.-C.1,3
1Taichung Veterans General Hospital, Department of Internal Medicine, 
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Introduction: Colorectal cancer (CRC) is the third most common tumor in 
men and the second in women, resulting in the fourth most common can-
cer-related cause of death in the world. In 2010 WHO classification system 
divided serrated lesions in colorectum into three types: hyperplastic polyp, 
traditional serrated polyp, and sessile serrated adenoma/polyp (SSA/P). 
Among them SSA/P is an important premalignant precursor of CRC. How-
ever, the true prevalence of SSA/P and its relationship to CRC are still un-
known due to unaccepted bowel preparation, detection difficulty, and poor 
discrimination within endoscopists and pathologists.
aims & Methods: The aim of this systemic review and meta-analysis is to 
evaluate the true prevalence of SSA/P and its relationship to synchronous 
colorectal advanced neoplasia.
A comprehensive, computerized research was performed on PubMed pub-
lished from 1 January 2010 to 6 July 2018 to search relevant articles without 
language limitation. Clinical trials were included in narrative systemic re-
view if they matched the following inclusion criteria: 
(1) published as case-controlled study, cohort study or cross-sectional 
study; 
(2) defined objectively for diagnosis of SSA/P within studies; 
(3) addressed the prevalence and characteristics of SSA/P. 
Within these trials if they met additional criteria involving reported out-
come of risk of advanced neoplasia in relation to SSA/P they were enrolled 
into meta-analysis.
results: The prevalence of all SSA/Ps in this review ranged from 0.038 to 
20.23% and pooled prevalence was 2.7% (95%CI, 1.9-3.9%). In subgroup 
analysis the overall prevalence of SSA/P between period of 2010-2014 and 
period of 2015-2018 showed 2.7% (95%CI, 1.2-6.0%) and 2.8% (95%CI, 
1.9-4.1%) respectively. 
We calculated the pooled data on the risk of SSA/P and synchronous ad-
vanced neoplasia in patient with SSA/Ps available from 8 trials resulting 
in pooled OR of 3.53 (95%CI, 2.39-5.20, I2=4%) without detection in het-
erogeneity test.
conclusion: In this systemic review the prevalence of SSA/P was 2.7% 
(95%CI 1.9-3.9%) and was no difference between the period of 2010-2014 
and 2015-2018. Besides SSA/P is associated with increasing risk of synchro-
nous advanced neoplasia in colorectum.
disclosure: Nothing to disclose 
P1157 hIgh MeaT InTake and LOW srage are assOcIaTed 
WITh cOLOnIc POLyPs MaInLy In sMOkers In a case cOnTrOL 
sTudy
Ivancovsky-Wajcman D.1, Zelber-Sagi S.1,2, Fliss-Isakov N.2, Webb M.2,3, 
Zemel M.4, Shibolet O.2,3, Kariv R.2,3
1University of Haifa, School of Public Health, Haifa, Israel, 2Tel Aviv Medical 
Center, Gastroenterology, Tel Aviv, Israel, 3Tel Aviv University, Tel Aviv, Israel, 
4Tel Aviv Medical Center, Department of Surgery, Tel Aviv, Israel
contact e-Mail address: danaivanc@gmail.com
Introduction: Colonic polyps, both adenomatous and hyperplastic (HP), 
have been shown to be associated with red and processed meat consump-
tion and with smoking habits. Recently, we have shown that red and/or 
processed meat consumption and pack years are inversely associated with 
RAGE soluble receptor (sRAGE) for advanced glycation end products. In 
addition, sRAGE levels have been shown to be associated with the risk for 
colorectal cancer (CRC) in male smokers and in post-menopausal women. 
However, further evidence is lacking as for the modifying effect of smoking 
on the association between red and/or processed meat or sRAGE levels 
with different types of colonic polyps.
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aims & Methods: The aims of this study were to assess the association 
between red and/or processed meat or sRAGE levels and different types 
of colonic polyps and to test the possible effect modification of smoking 
habits. This was a case-control study, among consecutive subjects aged 
40-70 years, undergoing colonoscopy during 2010-2015. 
Cases with colorectal polyps were compared to controls with no past or 
present polyps. Detailed information was gathered regarding polyp histol-
ogy, anatomic location and lifestyle habits including smoking. Smoking 
was defined as ordinal variable with three levels; never smokers, light 
smokers (pack years under the median of the total sample corresponding 
to 19.75) and heavy smokers (≥19.75). 
Serum sRAGE levels were measured and red and/or processed meat con-
sumption was calculated by food frequency questionnaire (FFQ). High red 
and/or processed meat consumption was defined as consumption above 
the sample median (>0.33 portions/week) and low sRAGE defined as levels 
under the sample first tertile (< 1013.42 pg/ml).
results: A total of 789 participants were included (cases with colorectal 
polyps n=403, controls n=386), 743 subjects had sRAGE measurements. 
Among the entire sample, high red and/or processed meat consump-
tion was significantly associated with higher odds for adenomatous pol-
yps throughout the colon and with distal HP (OR=1.41, 95% CI 1.00-1.97, 
P=0.048; OR=2.04, 1.02-4.05, P=0.043, respectively), but the associa-
tion with total polyps was not significant (OR= 1.36, 95%CI 0.99-1.88, 
P=0.057). 
However, stratification by pack years, revealed a significant association of 
red and/or processed meat consumption with total polyps among heavy 
smokers (OR=1.96, 95% CI 1.01-3.80, P=0.048). Moreover, low sRAGE 
levels were significantly associated with higher odds for HP, specifically 
with proximal HP (OR=2.03, 95% CI 1.06-3.89, P=0.032; OR=2.96, 1.20-7.33, 
P=0.019, respectively).
conclusion: High red and/or processed meat consumption is associated 
with adenomatous polyps throughout the colon, with distal HP and among 
smokers also with total polyps. Low serum sRAGE is associated with HP, 
especially proximal. These results may aid in designing prevention recom-
mendations for colonic neoplasia as well as open a new frontier in under-
standing CRC pathogenesis.
disclosure: Nothing to disclose 
P1158 faecaL dna TesT In cOMBInaTIOn WITh faecaL 
IMMunOcheMIcaL TesT fOr haeMOgLOBIn Is usefuL fOr 
deTecTIOn Of cOLOrecTaL advanced adenOMa
Suehiro Y., Yamasaki T.
Yamaguchi University Graduate School of Medicine, Oncology & Laboratory 
Medicine, Ube, Japan
contact e-Mail address: ysuehiro@yamaguchi-u.ac.jp
Introduction: The main approach to colorectal cancer screening world-
wide is the faecal immunochemical test for haemoglobin (FIT). Although 
the sensitivity of the FIT for the diagnosis of colorectal neoplasia is about 
90% for colorectal cancer, it falls to about 30% for the detection of ad-
vanced adenoma. To avoid this disadvantage, more sensitive methods are 
required.
aims & Methods: As TWIST1 methylation is specific to colorectal neoplasia, 
detection of TWIST1 methylation from faeces samples might be useful for 
colorectal neoplasia screening. However, because the content of human 
DNA in faeces is very small, it is very difficult to detect TWIST1 methylation 
by conventional bisulphite-based methylation assays. Therefore, we de-
veloped a new methylation assay without bisulphite treatment and evalu-
ated its sensitivity and specificity in combination with and without FIT for 
detection of colorectal neoplasia from faeces samples. DNA was treated 
with three methylation-sensitive restriction enzymes and an exonuclease, 
followed by measurement of TWIST1 methylation level by droplet digital 
PCR. The FIT and faecal DNA test were performed on 71 control individuals 
and 372 patients with colorectal neoplasia including 40 with non-advanced 
adenoma, 127 with advanced adenoma, and 205 with colorectal cancer.
results: Sensitivity of the FIT was 7.5% for non-advanced adenoma, 32.3% 
for advanced adenoma, and 93.7% for colorectal cancer, and specificity 
was 87.3%. Sensitivity of the faecal DNA test was 27.5% for non-advanced 
adenoma, 47.2% for advanced adenoma, and 44.3% for colorectal can-
cer, and specificity was 91.5%. Sensitivity of the FIT and faecal DNA test 
combined was 35.0% for non-advanced adenoma, 68.5% for advanced 
adenoma, and 95.6% for colorectal cancer, and specificity was 80.3%.
conclusion: Combination of the faecal DNA test with FIT may provide an 
alternative screening strategy for colorectal neoplasia, especially for po-
tentially precancerous lesions.
disclosure: Yutaka Suehiro receives research funding from Eiken Chemical 
Co., Ltd. 
P1159 geneTIc rIsk scOre TO IdenTIfy IndIvIduaLs WITh 
an Increased rIsk Of cOLOrecTaL adenOMas
Gargallo Puyuelo C.J.1, Lanas A.2, Carrera Lasfuentes P.3, 
Ferrandez A.4, Quintero Carrion E.5, Carrillo Palau M.6, Alonso Abreu I.6, 
García-González M.A.7
1Hospital Lozano Blesa, Zaragoza, Spain, 2University of Zaragoza University 
Hospital, Dept. Medicine & Gastroenterology, Zaragoza, Spain, 3CIBER 
de Enfermedades Hepáticas y Digestivas (CIBERehd), Zaragoza, Spain, 
4AMB San Jose Digestive Dept., Zaragoza, Spain, 5Hospital Universitario 
de Canarias, Gastroenterology, Santa Cruz de Tenerife, Spain, 6Hospital 
Universitario de Canarias, Tenerife, Spain, 7Instituto Aragonés de Ciencias 
de la Salud, Centro de Investigación Biomédica de Aragón (CIBA), Zaragoza, 
Spain
contact e-Mail address: asgarcia@unizar.es
Introduction: Common low-penetrance genetic variants (SNPs) has been 
consistently associated with colorectal cancer (CRC) risk, but the risk con-
ferred by each of these variants is usually modest. The relevance of these 
SNPs in the development of colorectal adenomas has been scarcely evalu-
ated.
aims & Methods: To evaluate the potential of a genetic risk score (GRS) to 
identify individuals with an increased risk of colorectal adenomas.
Patients were selected from the Spanish colorectal cancer screening reg-
istries in Aragon and The Canary Islands. Patients with hereditary non-
polyposis CRC, familial adenomatous polyposis, history of CRC or inflam-
matory bowel disease were excluded. We included 858 patients with no 
precancerous colorectal lesions and 642 with adenomas. Genomic DNA 
from participants was genotyped by the MassArray™(Sequenom) platform 
for a panel of 99 SNPs previously associated with CRC risk. We derived a 
GRS based on the 11 SNPs significantly associated with adenoma develop-
ment in our study. The number of risk alleles was coded as 0, 1 or 2 for 
each SNP assuming a log-additive genetic effect. To test the relevance of 
our score, we estimated the impact of having each additional risk allele by 
computing the odds ratio (OR) and the associated 95% confidence interval 
(95%CI). In addition, the predictive value for colorectal adenoma risk was 
calculated as the area under the ROC curve (AUC). PredictABEL R package 
was used to compute the genetic risk score.
results: Five SNPs were identified using a multivariate logistic model that 
included the 11 SNPs that were associated with colorectal adenomas in 
our study: rs10505477, rs11255841, rs13181, rs4779584 and rs8180040. We 
observed that the risk of developing adenomas increased with the number 
of risk alleles (per-allele OR=1.209, 95%CI 1.122 to 1.302 p< 0.001). Five risk 
alleles were considered as reference since it was the median number in 
patients without adenomas. See Table 1. 
nº of risk 
alleles
Patients n 
(%)
Without 
lesions n 
(%)
With 
adenomas 
n (%)
Or (95% cI) p-value
≤2 30 (2.1) 19 (2.3) 11 (1.8) 0.894 (0.401-1.993) 0.783
3 112 (7.8) 73 (8.8) 39 (6.4) 0.844 (0.536-1.331) 0.466
4 225 (15.6) 142 (17.1) 83 (13.5) 0.968 (0.679-1.380) 0.858
5 366 (25.4) 229 (27.6) 137 (223) 1 (reference)  
6 364 (25.8) 199 (24.0) 165 (26.9) 1.431(1.054-1.941) 0.021
7 228 (15.8) 118 (14.2) 110 (17.9) 1.621 (1.147-2.292) 0.006
≥8 117 (8.1) 49 (5.9) 68 (11.1) 2.500(1.616-3.869) 0.000
Total 1442 (100.0) 829 (100.0) 613 (100.0)
1.209 (1.122-1.302) 
per allele
p trend 
<0.001
[Risk of colorectal adenomas associated with increasing number of risk 
alleles in five selected SNPs in study population]
Individuals with ≥8 risk alleles had a 2.5-fold increase in adenoma risk 
compared with those with 5 risk alleles. The GRS adjusted by sex and 
age showed a discriminating power of 66% (AUC = 0.657, 95%CI 0.628 
to 0.685).
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conclusion: An increased GRS based on CRC-associated SNPs was associ-
ated with increased prevalence of colorectal adenomas. 
These findings may help to identify better a subgroup of patients with 
increased risk of adenomas who would benefit from stricter cancer screen-
ing programs.
disclosure: Nothing to disclose 
P1160 rOLe Of InTerLeukIn 10 geneTIc POLyMOrPhIsMs 
In MexIcan PaTIenTs WITh recTaL cancer
de-León-Rendón J.L.1, Villanueva Herrero J.A.1, López Pérez R.Y.2, 
Recalde Rivera M.A.1, Vargas Velásquez D.A.1, Jiménez Bobadilla B.1, 
Gracida Mancilla N.I.3, Ángeles Martínez J.4
1Hospital General de Mexico, Colon and Rectal Surgery, Mexico City, Mexico, 
2Hospital General de Mexico, Gastroenterology, Mexico City, Mexico, 3Hospital 
General de Mexico, General Surgery, Mexico City, Mexico, 4Hospital de 
Especialidades ‘Dr. Antonio Fraga Mouret’ Centro Médico Nacional ‘La Raza’, 
Epidemiology, Mexico City, Mexico
contact e-Mail address: dr.jorgedeleon@hotmail.com
Introduction: Chronic inflammation is a well-established risk factor for 
colorectal cancer. Interleukin-10 (IL-10) is a cytokine whose main biologi-
cal function is to limit inflammatory responses and is crucial to maintain 
immune homeostasis of the gastrointestinal tract. Some single nucleotide 
polymorphisms (SNPs) of IL-10 have been associated with cancer risk.
aims & Methods: To evaluate the role of SNPs rs1800896, rs1800872 and 
rs1800871 of IL-10 in Mexican mestizo patients with rectal cancer. 
A prospective study was conducted in which 53 patients with rectal cancer 
and 52 healthy controls were included. Information was collected focused 
on the demographic, clinical, biochemical characteristics; CT, MRI and his-
topathological reports of each patient, by reviewing the clinical files. SNPs 
rs1800896, rs1800872 and rs1800871 of IL-10 were genotyped by RT-PCR 
with Ab3130 kit.
results: We identified that the AA genotype of rs1800872 behaved as a pro-
tective factor for invasion of regional nodes [OR0.14 (IC95% 0.02-0.80) p=< 
0.04], presence of distant metastasis [OR0.30 (IC95% 0.10-0.83) p=< 0.01] 
and for the development of a late stage of the disease (CS III-IV) [OR0.14 
(IC95% 0.02-0.79) p =< 0.04]. The CC genotype of rs1800871 was a protec-
tive factor for the presence of distant metastasis [OR0.33 (IC95% 0.12-0.94) 
p=< 0.03], whereas its CT heterozygous form was at risk for greater local 
infiltration (T3-T4) [OR1.11 (IC95% 1.01-1.22) p=< 0.001]. 
The genotypic GG frequency of rs1800896 was a risk factor for non-response 
to neoadjuvant therapy [OR4.0 (IC95% 2.82-5.65) p=0.005], whereas the 
AG genotype represented a protective factor for non-response to neoadju-
vant therapy [OR0.25 (IC95% 0.17-0.35) p=< 0.005]. The allelic frequency A 
[OR0.22 (IC95% 0.08-0.58) p=0.001] and the AA genotype [OR0.20 (IC95% 
0.06-0.64) p=0.003] of rs1800872 were protective factors for non-response 
to therapy neoadjuvant, while the allelic frequency C [OR4.42 (IC95% 1.70-
11.44) p=0.001] and the CC genotype [OR6.77 (IC95% 2.86-17.90) p=< 0.001] 
of the same polymorphic site were found as risk for the no response to 
neoadjuvance. As for the rs1800871, the allelic frequency C [OR0.27 (IC95% 
0.11-0.69) p=0.004] and the CC genotype [OR0.20 (IC95% 0.06-0.60) 
p=0.004], were protective for the non-response to neoadjuvant, whereas 
the allelic frequency T [OR3.6 (IC95% 1.44-8.99) p=0.004] and TT genotype 
[OR6.0 (IC95% 2.10-17.12) p=< 0.001] resulted in risk for non-response to 
neoadjuvant therapy. 
Of the patients included who underwent surgical procedures, we found a 
protective factor for post-surgical complications at the allelic frequency A 
[OR0.34 (IC95% 0.12-0.97) p=< 0.04] and the AA genotype [OR0.18 (IC95% 
0.04-0.75) p=0.01] of the rs1800872, while its allelic frequency C [OR2.86 
(IC95% 1.02-8.04) p=0.04] behaved as a risk for postoperative compli-
cations. rs1800871 is also involved in post-surgical complications, its al-
lelic frequency C [OR0.30 (IC95% 0.10-0.86) p=0.02] and homozygous 
CC genotype [OR0.18 (IC95% 0.04-0.75) p=0.01] were protective factors 
for the development of post-surgical complications, however, its allelic 
frequency T [OR3.26 (IC95% 1.15-9.18) p=0.02] and TT genotype [OR6.0 
(IC95% 2.10-17.12) p=< 0.001] represented a risk factor for postoperative 
complications.
conclusion: IL-10 SNPs could impact in different aspects in evolution of 
rectal cancer, particularly in tumor infiltration, progression, treatment re-
sponse and post-surgical outcomes. This is the first study worldwide that 
associate IL-10 SNPs with neoadjuvant response and post-surgical out-
comes exclusively in rectal cancer patients.
references: Oncol Lett. 2019; 17(2):2365-2369. J Cancer Res Ther. 2017; 
13(2):252-256. Cancer Lett. 2015; 367(2):103-7.
disclosure: Nothing to disclose 
P1161 anaLysIs Of The dIsTrIBuTIOn and PhenOTyPe 
Of MacrOPhages InfILTraTIng InTO TuMOr TIssues In 
earLy-sTage cOLOrecTaL neOPLasIa
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Ninomiya Y.3, Oka S.3, Tanaka S.3, Chayama K.1
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Hiroshima, Japan, 2Prefectural University of Hiroshima, Health Science, 
Hiroshima, Japan, 3Hiroshima University Hospital, Endoscopy, Hiroshima, 
Japan
contact e-Mail address: ikatsuaki1222@yahoo.co.jp
Introduction: Inflammatory cells such as neutrophils and macrophages are 
infiltrated in the tumor microenvironment (TME). The macrophages found 
in the TME are often referred to as tumor-associated macrophages (TAMs), 
which are classified into two types: M1 and M2. M1 macrophages exhibit 
high bactericidal and tumoricidal capacity. In contrast, M2 macrophages 
promote tissue repair, regulate immune function, and are involved in tu-
mor progression. It has been reported that TAMs often have a M2 pheno-
type form and are associated with a poor prognosis in some cancers, such 
as melanoma. In contrast, some reports show a positive correlation of high 
number of macrophages with better prognosis in colorectal cancer (CRC) 
patients. The role of TAMs in progression of CRC is still controversial. Al-
though most studies report an association between TAMs and an advanced 
CRC, there is no report on the detail about association between TAMs and 
early-stage colorectal neoplasia. The aim of this study is to elucidate the 
distribution and function of TAMs in early-stage colorectal neoplasia.
aims & Methods: The subjects were 40 patients of early-stage colorectal 
neoplasia (20 submucosal invasive cancer and 20 dysplasia, including 10 
low and 10 high-grade dysplasia) treated at our hospital from 2011 to 2018. 
The phenotype and distribution of macrophages were assessed by double 
immunofluorescent staining of CD68 as a marker for total macrophages 
and CD163 as a marker for M2 macrophages. M1 macrophages were de-
fined as CD68 positive and CD163 negative. The number and phenotype of 
macrophages were evaluated as the most representative area at each part, 
including center, lateral periphery, and deepest part of the tumor (invasive 
edge), in addition to the non-neoplastic mucosa adjacent to the tumor. 
Five representative high-power fields (1 HPF = 0.0988 mm2) for each part 
were chosen and analyzed.
results: When comparing dysplasia and submucosal invasive cancer, the 
number of total macrophages in submucosal invasive cancer was signifi-
cantly higher than that in dysplasia at each part, and the number of total 
macrophages at the deepest part of the tumor was higher as compared to 
that at the other parts in both dysplasia and submucosal invasive cancer. 
With regard to the phenotype of macrophages, in dysplasia, most macro-
phages were of M1 type with only a few of M2 type at each part and the 
number of M1 macrophages at the deepest part of the tumor was signifi-
cantly higher as compared to that at the other parts. In contrast, in sub-
mucosal invasive cancer, the number of both M1 and M2 macrophages at 
the deepest part of the tumor was significantly higher as compared to that 
at the other parts. Additionally, the number of M1 and M2 macrophages at 
the deepest part of tumor in submucosal invasive cancer was significantly 
higher as compared to that in dysplasia. Especially, the difference in the 
number of M2 macrophages between dysplasia and submucosal invasive 
cancer was remarkable at the deepest part of the tumor.
conclusion: In submucosal invasive CRC, the number of macrophages, es-
pecially M2 macrophages was significantly higher at the deepest part of 
tumor. These findings suggested that macrophages differentiate into M2 
macrophages by interaction with tumor cells and hence promote the pro-
gression of CRC.
disclosure: Nothing to disclose 
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P1162 a PrOsPecTIve cOhOrT sTudy On The BenefIT Of 
PreOPeraTIve uLTraThIn cOLOnOscOPy fOr cOLOrecTaL 
cancer PaTIenTs WITh sTenOsIs
Ito S., Hotta K., Imai K., Kishida Y., Kakushima N., Takizawa K., Kawata N., 
Yoshida M., Yabuuchi Y., Ishiwatari H., Matsubayashi H., Ono H.
Shizuoka Cancer Center, Division of Endoscopy, Shizuoka, Japan
contact e-Mail address: sa.ito@scchr.jp
Introduction: Preoperative colonoscopy for colorectal cancer (CRC) with 
stenosis is often insufficient because of poor preparation or incomplete 
colonoscopy. There is no large cohort study to clarify the usefulness of 
ultrathin colonoscopy for CRC with stenosis, although data after colon stent 
placement using a small diameter scope have been reported.1
aims & Methods: This prospective cohort study aimed to evaluate the 
ability of an ultrathin colonoscope (UTC) to pass through stenosis and to 
detect synchronous neoplasms proximal to the stenosis. If the passage of 
a standard colonoscope (PCF-H290ZI: outer diameter 11.7 mm) was not 
feasible because of the stenosis, UTC (PCF-PQ260L: outer diameter 9.2 
mm) was used. A total of 100 patients in whom UTC was used were pro-
spectively registered from September 2017 at the Shizuoka Cancer Center 
(UMIN000028505). Patients with stent placement, who had undergone 
neoadjuvant chemotherapy, and who needed right hemicolectomy were 
excluded. 
After colonoscopy, data on the tumor location, possibility of cecal inser-
tion, grade of bowel preparation (according to the Boston Bowel Prepara-
tion Scale), presence of synchronous neoplasms, and day of surgery were 
recorded. Primary endpoints were the pass-through and cecal insertion 
rates. The detected synchronous neoplasms (adenomas and cancers) and 
their pathological findings after resection were also examined.
results: Of 650 patients with advanced stage CRC who underwent preop-
erative colonoscopy during the recruitment period, 193 could not undergo 
complete colonoscopy using a standard colonoscope. After the exclusion 
of 93 patients, including 15 with stent placement, 21 who had undergone 
neoadjuvant chemotherapy, 21 indicated for right-hemicolectomy, and 40 
others, a total of 100 patients who underwent ultrathin colonoscopy were 
enrolled in this study until February 2019 and analyzed. 
The mean age of the 100 patients was 65.6 ± 10.8 years, and 59% of 
the patients were male. The pass-through and cecal insertion rates were 
67% (67/100) and 58% (58/100), respectively. Synchronous lesions located 
proximal to the stenosis were detected in 65.5% (38/58) of the complete 
colonoscopies, with a total of 76 lesions, including 18 advanced neo-
plasms with three advanced stage CRCs. The bowel preparation score in 
the complete colonoscopy was 6.4 ± 2.6. The number of median waiting 
days for surgery was significantly longer in the pass-through of the UTC 
group (14 days vs. 10 days, P = 0.022). Two patients (6.1%) in the non-
pass-through group required abdominal decompression by transanal il-
eus tube insertion before surgery.
conclusion: Ultrathin colonoscopy for CRC with stenosis improved insert-
ability compared to that in standard colonoscopy. Moreover, preoperative 
ultrathin colonoscopy for patients with stenosis has the potential to change 
the treatment strategy by predicting the risk of intestinal obstruction and 
detecting synchronous neoplasms.
references: 1. Kim JS, Lee KM, Kim SW, et al. Preoperative colonoscopy 
through the colonic stent in patients with colorectal cancer obstruction. 
World J Gastroenterol. 2014; 20: 10570-6.
disclosure: Nothing to disclose 
P1163 quaLITy Of OnLIne MedIcaL InfOrMaTIOn On 
cOLOrecTaL cancer screenIng
Ong Y.L.1, Namasivayam V.2
1National University of Singapore, Yong Loo Lin School of Medicine, 
Singapore, Singapore, 2Singapore General Hospital, Gastroenterology & 
Hepatology, Singapore, Singapore
contact e-Mail address: ongyanlings@gmail.com
Introduction: Colorectal cancer (CRC) screening improves CRC mortality. 
The uptake of CRC screening is influenced by patient motivation which in 
turn is influenced by online health information. The Internet is a widely-
used resource by patients to support healthcare decisions. 
However, online content is not subjected to peer review and may be of 
variable quality.
aims & Methods: The aim of the study is to determine whether the quality 
of online information on CRC screening varies according to the source of 
information. As many patients will not search beyond the first page of 10 
hits[1], we also assessed whether higher quality hits are found in the first 
page of searches.
Google search was performed to identify English websites providing on-
line information on CRC screening. The following keywords were searched: 
“colorectal cancer screening”, “colon cancer screening”, “rectal cancer 
screening”, “colonoscopy”, “FIT/FOBT”, “CT colonography”, “stool DNA”, 
“colon polyp screening”, “flat polyp screening”, “nonpolypoid colorectal 
neoplasm screening”. The first 2 pages for each keyword search were com-
piled. Scientific papers, advertisements, newspaper articles, publicly mod-
ifiable pages, videos, sites requiring subscription and duplicate websites 
were excluded. Websites were classified as professional society, hospital, 
government agency or patient advocate group. The quality of online infor-
mation was assessed by the primary author using the DISCERN instrument, 
a validated 16-point questionnaire (total score 16-80) that evaluates the 
quality of written information[2]. DISCERN scores were graded as excellent 
(68-80), good (55-67), fair (42-54), poor (29-41) or very poor (16-28). The 
proportion of websites with excellent or good grading in each category 
was compared. Standard tests of statistical significance were used.
results: The search identified 191 websites of which 40 were eligible for in-
clusion. Sixteen (40.0%) were written by professional societies, 15 (37.5%) 
by hospitals, 4 (10.0%) by government agencies and 5 (12.5%) by patient 
advocate groups. The overall median DISCERN score was 44.5 [23.0-67.0]). 
The median DISCERN scores were 51.5 [30.0-67.0] vs 36.0 [23.0-67.0] vs 
44.5 [41.0-52.0] vs 42.0 [40.0-45.0] respectively. None of the websites had 
an excellent DISCERN score. The proportion of websites with at least excel-
lent or good grading was significantly higher in websites from professional 
societies compared to hospitals, government agencies and patient advo-
cate groups (25.0% vs 13.3% vs 0.0% vs 0.0%, p=0.005) (Table 1). 
Twenty five websites appeared on the first page of search results and 15 
appeared on the second page. The median DISCERN scores were 46.0 
[28.0-67.0] vs 43.0 [23.0-55.0] respectively. There was no significant differ-
ence in the quality of online information between websites appearing on 
the first and second page of search (20.0% vs 6.7%, p=0.515).
conclusion: The quality of online information on CRC screening is highly 
variable. Professional societies provide higher quality of information than 
other sources but their websites might not be found in the first page of 
searches. While patients should be directed to online sources that provide 
high quality information, there remains an unmet need to improve the 
quality of online information on CRC screening. 
grading based on 
dIscern score
Professional 
societies (n=16)
hospitals 
(n=15)
government 
agencies (n=4)
Patient advocate 
groups (n=5)
Excellent or good 4 (25.0%) 2 (13.3%) 0 (0.0%) 0 (0.0%)
Fair, poor or very 
poor
12 (75.0%) 13 (86.7%) 100 (100.0%) 100 (100.0%)
[Table 1. Sources of online medical information and quality of information]
references: [1] Van Deursen AJ, Van Dijk JA. Using the Internet: Skill related 
problems in users’ online behavior. Interacting with computers. 2009 Jun 
30;21(5-6):393-402. [2] Batchelor JM, Ohya Y. Use of the DISCERN instru-
ment by patients and health professionals to assess information resources 
on treatments for asthma and atopic dermatitis. Allergology International. 
2009;58(1):141-5.
disclosure: Nothing to disclose 
P1164 cLInIcOPaThOLOgIcaL feaTures and TheraPeuTIc 
sTraTegy fOr LefT-sIded sessILe serraTed adenOMa/POLyPs
Takeuchi Y.1, Shigita K.2, Nagata S.1, Asayama N.1, Aoyama T.1, 
Fukumoto A.2, Mukai S.1
1Hiroshima City Asa Citizens Hospital, Department of Gastroenterology, 
Hiroshima, Japan, 2Hiroshima City Asa Citizens Hospital, Department of 
Endoscopy, Hiroshima, Japan
contact e-Mail address: yukari-ogawa@nms.ac.jp
Introduction: Although sessile serrated adenoma/polyps (SSA/Ps) are con-
sidered premalignant lesions and their clinicopathological features have 
been previously reported, the differences based on lesion location (left- 
and right-sided) have not been clarified.
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aims & Methods: This study aimed to investigate the clinicopathologi-
cal features and therapeutic strategy for left-sided SSA/P. In this study, 
666 consecutive patients with lesions diagnosed as SSA/P by experienced 
endoscopists after endoscopic examinations (white light, narrow-band 
imaging, and pit pattern) and resected endoscopically in Hiroshima Asa 
Citizens Hospital between August 2010 and March 2017 were enrolled. The 
pathological diagnosis of each SSA/P was evaluated by two pathologists 
on the basis of the following Japanese Society for Cancer of the Colon and 
Rectum criteria: (1) crypt dilation, (2) irregularly branching crypts, and (3) 
horizontally arranged basal crypts (inverted T- and/or L-shaped crypts). 
When at least two of the three criteria were met in ≥10% of the lesion area, 
the serrated lesion was diagnosed as SSA/P. Resected lesions were classi-
fied into four groups (left-sided SSA/P: 173, left-sided HP: 94, right-sided 
SSA/P: 340, and right sided HP: 59). Evaluated endoscopic and pathologi-
cal findings of left-sided SSA/P were compared with those of left-sided HP 
and right-sided SSA/P. SSA/P with cytological dysplasia (SSA/P-CD) was 
defined as a SSA/P with conventional adenoma-like dysplasia, and ser-
rated dysplasia (SSA/P-SD) was defined as a SSA/P showing proliferation 
of atypical cells that are more cuboidal in shape and have eosinophilic cy-
toplasm, enlarged round nuclei with open vesicular prominent chromatin, 
and prominent nucleoli in addition to increased mitoses.
results: The proportion of lesions with size ≥10 mm, mucus cap, varicose 
microvascular vessel, and type II open pit was significantly higher in the 
left-sided SSA/P group than in the left-sided HP group (35% vs 6%, 35% 
vs 10%, 48% vs 22%, and 53% vs 18%, respectively; p< 0.01). The propor-
tion of females and lesions with size ≥10 mm, flat morphology (0-IIa), 
mucus cap, and type II open pit was significantly lower in the left-sided 
SSA/P group than in the right-sided SSA/P group (23% vs 39%, 35% vs 
53%, 25% vs 50%, 35% vs 70%, and 53% vs 77%, respectively; p< 0.01). 
Although there was no significant difference in crypt dilation and irregu-
larly branching crypts in the left- and right-sided SSA/Ps, the proportion 
of horizontallyarranged basal crypts was significantly lower in the left-
sided SSA/P group than in the right-sided SSA/P group (62% vs 84%; p< 
0.01). Twenty-seven cases (5%) of SSA/P-CD and 43 cases (8%) of SSA/P-
SD were included in this study. The independent endoscopic finding of 
SSA/P-CD was an adenomatous pit pattern accompanied by type II/open 
II pit pattern in the multivariate analysis. No significant endoscopic find-
ings of SSA/P-SD, except for lesion size, were found in either the left- or 
right-sided SSA/Ps. The proportion of right-sided SSA/P-SD increased with 
larger lesion size (< 5 mm: 0%, 5-9 mm: 8%, ≥10 mm: 15%), while that of 
left-sided SSA/P-SD was low, regardless of lesion size (< 5 mm: 6%, 5-9 
mm: 4%, and ≥10 mm: 3%).
conclusion: The endoscopic and pathological features of left-sided SSA/P 
are different from those of right-sided SSA/P. Lesions with an adenoma-
tous pit pattern accompanied by type II/open II pit pattern should be treat-
ed, but the lesion size of left-sided SSA/P is not an important indication of 
resection unlike that of right-sided SSA/P.
disclosure: Nothing to disclose 
P1165 The cLInIcaL IMPacT Of MrI fOr deTecTIng 
exTra-PerITOneaL fIndIngs In cOLOrecTaL cancer PaTIenTs 
cOnsIdered fOr crs/hIPec
Engbersen M.1, van ‘t Sant-jansen I.1, Aalbers A.2, Lambregts D.M.J.1, 
Kok N.2, Lahaye M.J.1
1The Netherlands Cancer Institute, Radiology, Amsterdam, Netherlands, 2The 
Netherlands Cancer Institute, Surgery, Amsterdam, Netherlands
contact e-Mail address: mj.lahaye@gmail.com
Introduction: Part of the clinical value of MRI is not only to describe the 
peritoneal disease load but could also be to detect extra-peritoneal metas-
tases that contraindicate cytoreductive surgery and hyperthermic chemo-
therapy. The purpose of this study is to evaluate whether an preoperative 
wholebody MRI for assessing peritoneal disease also has led to additional 
extra-peritoneal findings not described with earlier imaging.
aims & Methods: Between February 2016 and October 2017, patients with 
colorectal peritoneal metastases considered for CRS/HIPEC who under-
went a dedicated peritoneal MRI for preoperative staging were included. 
The MRI was performed additionally to standard diagnostic work-up of a 
preoperative CT chest/abdomen. The MRI protocol consisted of diffusion 
weighted, T2 weighted and contrast enhanced imaging of the chest, abdo-
men, and pelvis. The peritoneal MRI images were evaluated by one of two 
radiologists with experience with diffusion-weighted imaging and whole-
body MRI and all extra-peritoneal findings were scored. The reference 
standard was histology. The results of the MRI were compared with all 
other, already available, clinical and imaging data to determine whether 
findings of the MRI were new.
results: Of the 86 candidates with a peritoneal MRI, CRS/HIPEC was at-
tempted for 55 patients and was successfully in 52. All patients had under-
gone CT chest/abdomen imaging prior to the MRI scan and 9 patients a 
PET/CT was performed. The mean days between CT and MRI imaging was 
28.5 (standard deviation: ±30.9). Five patients had liver metastases and 
four patients had lung metastases detected with regular diagnostic work 
up (CT/CTPET). MRI detected in 3/86 patients new liver metastases and in 
2/86 patients new lung metastases. Of the 5 (5.8%) patients with one or 
more additional extra-peritoneal findings, 4 were deemed ineligible for 
CRS/HIPEC at an MDT meeting and 1 at surgical exploration (laparotomy) 
for histology.
conclusion: For patients considered for CRS/HIPEC, additional peritoneal 
MRI including diffusion-weighted body imaging can detect additional ma-
lignant extra-peritoneal lesions such as liver and lung metastases. Per-
operative imaging with peritoneal MRI can not only contribute to staging 
of the peritoneal disease load but can also detect contra-indications that 
were not seen on prior imaging and thereby prevent a potentially futile 
CRS/HIPEC effort.
disclosure: Nothing to disclose 
P1166 Mr IMagIng TO PredIcT cOMPLeTe cyTOreducTIOn and 
survIvaL In cOLOrecTaL PerITOneaL MeTasTases In PaTIenTs 
cOnsIdered fOr crs/hIPec
Engbersen M.1, van ‘t Sant-jansen I.1, van Eden H.2, Lambregts D.M.J.1, 
Aalbers A.3, Velzing J.1, Kok N.3, Lahaye M.J.1
1The Netherlands Cancer Institute, Radiology, Amsterdam, Netherlands, 
2The Netherlands Cancer Institute, Surgery, Amsterdam, Netherlands, 3The 
Netherlands Cancer Institute, Amsterdam, Netherlands
contact e-Mail address: mj.lahaye@gmail.com
Introduction: Selecting colorectal cancer patients with peritoneal metas-
tases for CRS-HIPEC remains a big diagnostic problem. In order to prevent 
under or overtreatment an invasive surgical staging system, the Peritoneal 
Cancer Index (PCI), was introduced. In order to avoid these invasive staging 
surgeries this study assesses the performance of the PCI determined with 
preoperative peritoneal MRI (MRI PCI) to predict successful cytoreductive 
surgery (CRS), disease free survival and overall survival in HIPEC candi-
dates. Can MRI replace surgical staging?
aims & Methods: Between February 2016 and October 2017, 86 patients 
with colorectal peritoneal metastases considered for CRS/HIPEC who un-
derwent a dedicated peritoneal MRI for preoperative staging were includ-
ed. The MRI protocol consisted of diffusion weighted, T2 weighted and 
contrast enhanced imaging of the thorax, abdomen, and pelvis. Peritoneal 
MR images were evaluated by two readers, independently and retrospec-
tively, to determine the Peritoneal Cancer Index (MRI-PCI). Relevant pa-
tient characteristics were obtained from patient files. Receiver characteris-
tic operator (ROC) analysis was used to determine the performance of the 
MRI-PCI to predict successful CRS/HIPEC and Cox regression analysis to 
determine to prognostic value of MRI for disease free survival and overall 
survival.
results: CRS/HIPEC was attempted for 55 patients and was successfully 
in 52. The median follow-up from MRI was 18.30 months (1st-3rd Quartile: 
12.73-24.33). The mean (standard deviation) MRI-PCI of reader 1 and 2 was 
11.8 (8.46) and 10.5 (8.59), respectively. An area under the curve was found 
of 0.83 (95% confidence interval: 0.74-0.93) for reader 1 and 0.86 (95% 
confidence interval: 0.77-0.94) for reader 2 to predict a complete resection. 
For the patients who received successful CRS/HIPEC and complete resec-
tion, the MRI-PCI showed prognostic value for disease free survival for 
both readers (p< 0.05). The MRI-PCI of reader 1 showed a prognostic value 
for overall survival (p=0.01), independently of whether complete resection 
was achieved, while reader 2 was borderline significant (p=0.05) in this 
patient cohort.
conclusion: MRI can predict whether successful CRS/HIPEC can be 
achieved and shows prognostic value for disease free and overall survival. 
This means that MRI is an accurate tool for selecting CRC patients which 
may benefit from CRS-HIPEC. Surgical staging should be reserved for bor-
derline cases after MR imaging.
disclosure: Nothing to disclose 
660 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
P1167 rIsk Of MeTachrOnOus neOPLasIa On surveILLance 
cOLOnOscOPy In yOung and OLd age grOuPs afTer 
POLyPecTOMy
Laish I.
Sheba Medical Center, Ramat Gan, Israel
contact e-Mail address: ido.laish@gmail.com
Introduction: Few reports exist that address the appropriate colonoscopy 
surveillance interval for individuals < 50 years old. We compared the risk 
of metachronous neoplasia among young (< 50 years), adult (50-74 years) 
and old (≥ 75y) age groups.
aims & Methods: This is a single center retrospective cohort study. Subjects 
were eligible if they underwent their first colonoscopy with polypectomy 
between 2005 and 2014 and had at least one surveillance colonoscopy 
after 3-5 years. Exclusion criteria included known genetic syndromes, in-
flammatory bowel disease, previous colectomy, incomplete procedures 
and the occurrence of cancer or multiple polyps at baseline. Patients were 
stratified at baseline according to adenoma characteristics into low-risk 
adenoma (LRA) and advanced adenoma groups. The primary outcomes 
were the occurrence of overall and high-risk neoplasia at surveillance 
colonoscopy in each age-group.
results: At baseline (N=495), young patients were more likely to have 
smoking exposure and to report a family history of CRC whereas aspirin 
use and diabetes were more frequent in the adult and old age-groups. 
In the baseline LRA- group (N= 201), the 5-year risk of metachronous 
high-risk neoplasia was 12.5%, 15.2% and 22.5% (P= 0.426) in the young, 
adult and old age-groups, respectively. In the baseline advanced adenoma 
group (N= 294), the 3-year risk of metachronous high-risk neoplasia was 
13.3%, 14.8% and 25.3% (P = 0.041), respectively. All interval cancer in 
this group - 3 cases, developed in the old age-group (3.8%, P = 0.027). 
In multivariate analysis, after adjusting for baseline risk factors, the only 
risk factor for metachronous high-risk neoplasia was old age-group (old 
vs. young age groups: OR 2.191, CI 1.099-4.373; P= 0.026; old vs. adult age 
groups: OR 1.876, CI 1.087-3.238; P= 0.024).
conclusion: Considering the comparable risk of metachronous high-risk 
neoplasia in young and adult patients, surveillance recommendations af-
ter polypectomy should not differ. Since this risk is higher in the old age-
group, a more frequent surveillance is warranted and should be counter-
balanced with the higher complication risk and comorbidities.
disclosure: Nothing to disclose 
P1168 Is The adenOMa deTecTIOn raTe an IMPOrTanT 
IndIcaTOr In The deTecTIOn Of OTher nOn-neOPLasTIc 
fIndIngs?
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1Centro Hospitalar Vila Nova de Gaia, Gastroenterology, Porto, Portugal, 
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Introduction: Colonoscopy enables screening and prevention of colorectal 
cancer (CRC) by removing adenomatous polyps. Adenoma detection rate 
(ADR) is the proportion of screening colonoscopy patients who are found 
to have at least one adenoma. ADR should be used as a measure of ad-
equate inspection at screening or diagnostic colonoscopy in patients aged 
50 years or more. ADR has been inversely associated with the risk of CRC 
and death. However little is known about the correlation of the adenoma 
detection rate and the detection of other non-neoplasic findings.
aims & Methods: The aim of this study was to evaluate if ADR is associ-
ated with a higher detection of non-neoplasic findings. We retrospectively 
analyzed patients undergoing colonoscopy by three endoscopists at our 
center (A, B, C). Patients with an incomplete colonoscopy were excluded 
as well as colonoscopies performed in the setting of overt gastrointestinal 
bleeding, inflammatory bowel disease or polypectomy/mucosectomy. An-
giodysplasia, diverticula, nonspecific inflammation, erosions or ulcers or 
subepithelial lesions were considered non-neoplastic findings.
results: A total of 229 colonoscopies were analyzed. The mean age was 64 
± 13.1 years-old. 54.6% were male (n=125). The median ASA score was 2 
(IQR: 1 - 3). The mean indication was post-polypectomy surveillance 25.8% 
(n=59), followed by CRC surveillance 27.1% (n=62) and screening for CRC 
20.5% (n=47). The indication for colonoscopy was significantly different 
between groups (p=0.04): CRC surveillance was higher in endoscopist B 
(31.9%, n=23) and C (36.5%, n=23), and post-polypectomy surveillance 
was higher in endoscopist A (35.1%, n=33). An excellent bowel cleansing 
was higher in colonoscopies performed by endoscopist A (A. 59.6% vs. B: 
48.6% vs. C: 19%, p< 0.01). The global ADR was 36.2% (n=83) and was not 
significantly different between endoscopists (A: 42.6% vs. B: 36.1% vs. C: 
27%, p=0.14). The ADR was not associated with higher detection rate of 
non-neoplasic findings (31.3% vs 30.1%, p=0.88), even when concerning 
each endoscopist (A: 27.5% vs 33.3%, p=0.65; B: 38.5% vs 23.9%, p=0.28 e 
C: 29.4% vs 32.6%, p=0.81).
conclusion: In our study, ADR was not associated with a better detection 
of other non-neoplastic findings in the total sample and by endoscopist.
disclosure: Nothing to disclose 
P1169 faecaL BacTerIaL sIgnaTure TesTIng fOr cOLOrecTaL 
cancer screenIng In POsITIve faecaL IMMunOcheMIcaL TesT 
POPuLaTIOn
Malagón M.1,2,3, Ramió-Pujol S.2, Serrano M.2, Amoedo J.2,3, Oliver L.2, 
Bahí A.1, Miquel-Cusachs J.O.4,5, Gilabert P.6, Saló J.4, Guardiola J.6, 
Piñol V.3,5, Serra-Pagès M.2, Castells A.7,8, Aldeguer X.1,2,5, Garcia-Gil J.2,3
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Microbiota, Salt, Spain, 2GoodGut SL, Girona, Spain, 3Universitat de 
Girona, Girona, Spain, 4Consorci Hospitalari de Vic, Vic, Spain, 5Hospital 
Universitari Doctor Josep Trueta, Girona, Spain, 6Hospital Universitari 
de Bellvitge - IDIBELL, l’Hospitalet de Llobregat, Spain, 7Hospital Clínic - 
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Introduction: Colorectal cancer (CRC) is the third most common cancer in 
men and the second in women worldwide, and a leading cause of mor-
tality. Guidelines recommend routine screening for CRC in asymptomatic 
adults starting at age 50. The most extensively used non-invasive test for 
CRC screening is the faecal immunochemical test (FIT). Although its over-
all sensitivity for CRC is around 61-91% and for advanced adenomas (AA) 
between 27-67%, these figures still imply a high false-positive rate and a 
low positive predictive value (PPV).
aims & Methods: The aim of this work was to develop a new non-invasive 
CRC screening tool based on faecal bacterial markers capable of decreas-
ing FIT false-positive rate in FIT-positive population. Analysis of the rela-
tive abundance of eight CRC-associated bacterial markers (B10, B46, B48, 
G. morbillorum, P. stomatis, B. fragilis, B. thetaiotaomicron, R. intestinalis) 
and four associated to IBD (F. prausnitzii, F. prausnitzii phylogroups I and II, 
E. coli) was performed.
The bacterial signature (RAID-CRC Screen) was defined in a proof-of-con-
cept with 172 individuals and the obtained results were validated in an ex-
ternal cohort of 327 subjects. All study participants had joined the national 
CRC-screening program.
results: In the proof-of-concept study, regardless of the colonoscopy re-
sult, the most prevalent bacteria were butyrate producers (B10, B46, B48, 
F. prausnitzii, and R. intestinalis), with abundance values of 19%, 16%, 
18%, 16%, and 12%, respectively. P. stomatis and B. fragilis were signifi-
cantly more abundant in CRC than in individuals with normal colonoscopy 
(p=0.002 and p=0.017, respectively).
The development of RAID-CRC Screen algorithm was focused on the reduc-
tion of false positive results for Advanced Neoplasia (AN; CRC+AA) among 
the FIT-positive subjects, while maintaining 100% sensitivity for CRC. The 
combination of F. prausnitzii, B46, B48, G. morbillorum, B. fragilis, and the 
total bacterial load led to the achievement of an algorithm with sensitivity 
of 95%, specificity of 26%, PPV of 50%, and a negative predictive value 
of 86%, for AN. These results lead to a decrease in the false positive rate 
up to 30%.
In the clinical validation of RAID-CRC Screen a sensitivity of 84% and speci-
ficity of 16% were obtained for the detection of AN. While with FIT 20 µg/g 
there were 184 false-positive results, RAID-CRC Screen reduced this value 
to 154, implying a reduction of the false-positive rate of 16%, which con-
firms the robustness of the defined bacterial signature.
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conclusion: RAID-CRC Screen test would allow reducing up to 20% of the 
colonoscopies that are performed unnecessarily in FIT-positive partici-
pants of CRC-screening programs. Thus, it becomes a good complement 
to be implemented in a CRC screening scenario.
  characteristics crc advanced adenoma
non-advanced 
adenoma
normal 
colonoscopy
Proof-of-
concept n (%) 11 (6.3) 67 (39.0) 38 (22.1) 56 (32.6)
 
Age (mean, 
range)
61 (50-69) 61 (50-69) 60 (50-69) 59 (49-69)
 
Sex, female 
(%)
6 (54.5) 19 (28.3) 15 (39.5) 37 (66.1)
clinical 
validation n (%) 19 (5.8) 124 (37.9) 85 (26.0) 99 (30.3)
 
Age (mean, 
range)
61 (54-69) 61 (50-73) 61 (50-70) 58 (49-69)
 
Sex, female 
(%)
6 (31.6) 52 (41.9) 42 (49.4) 53 (53.5)
[Table 1. Characteristics of patients included in the proof-of-concept and 
clinical validation studies, classified according to their diagnosis.]
disclosure: Prof. Garcia-Gil, Dr. Aldeguer, Dr. Serra-Pagès, Dr. Serrano, Dr. 
Ramió-Pujol, Mr. Amoedo, Ms. Oliver are employees from GoodGut, com-
pany who has received private and public funding. Prof. Garcia-Gil, Dr. 
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Oliver and Ms. Malagón report grants from MINECO and from CDTI, dur-
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Pagès are also GoodGut shareholders, outside the submitted work; and 
all of them have two licensed patents to GoodGut: EP14382074.4 and PCT/
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P1170 faBP4 PrOMOTes InvasIOn and MeTasTasIs Of cOLOn 
cancer By reguLaTIng faTTy acId TransPOrT
Xia M., Tian W., Zhang W., Zhan Q., An F.
Wuxi People’s Hospital Affiliated to Nanjing Medical University, 
Gastroenterology, Wuxi, China
contact e-Mail address: xmzb1013@163.com
Introduction: Colon cancer is a common malignant tumor and it is estimat-
ed that about 1,200,000 new cases are reported every year. Recent studies 
have shown that FABP4 can participate in tumor invasion and metastasis.
aims & Methods: In order to explore the effects and mechanism of Fatty 
acid-binding protein 4 (FABP4) on proliferation, migration, invasion and 
energy metabolism of colon cancer cells.We measured the distribution of 
fat, the content of triglyceride and the level of FABP4 mRNA in colon cancer 
and adjacent normal tissues. At the meantime, the adipose tissue extract 
was co-cultured with human colon cancer cell line HCT-8 and the cells 
were divided into three groups: Control, Co-culture, Co-culture + inhibitor 
group. And we detected the proliferation, migration and invasion of HCT-8 
cells. Then we analyzed the content of ATP, LDH, glycerol and fatty acid by 
specific kits. In addition, we used FABP4 overexpressed adenovirus to in-
fect HCT-8 cells, and then detect cell proliferation, migration and invasion. 
Meanwhile, we measured the levels of intracellular metastasis related 
protein MMP-2, MMP-9 and energy-related protein p-Akt.
results: The content of fat in colon cancer tissues was significantly higher 
than that in adjacent normal tissues and the level of FABP4 mRNA in co-
lon cancer tissues was significantly higher than that in adjacent normal 
tissues. Besides, the adipose tissue could promote the migration and in-
vasion of human colon cancer cells in vitro. Moreover, the content of in-
tracellular ATP and LDH, glycerol and fatty acid in culture supernate were 
decreased significantly after co-culture and FABP4 overexpression could 
promote migration and invasion of cancer cells and the levels of intracel-
lular MMP-2, MMP-9, p-Akt were increased.
conclusion: FABP4 may promote the transfer of fat from adjacent normal 
tissues to cancer tissue and co-culture with adipose tissue promoted the 
migration and invasion of colon cancer cells and cellular energy metabo-
lism. Overexpression of FABP4 could promote migration and invasion and 
increased the levels of MMP-2, MMP-9 and p-Akt protein. This may pro-
vide a new idea for the diagnosis and treatment of colon cancer.
disclosure: Nothing to disclose 
P1171 a PaTIenT seLf-Made One sTeP quIck faecaL TesT 
reduces unnecessary cOLOnOscOPIes and PrIOrITIzes hIgh 
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Introduction: Gastrointestinal symptoms are a common reason for patients 
to consult primary care physicians. Most of these patients have no relevant 
pathology, but in an effort not to miss colorectal cancer (CRC), precancer-
ous lesions or inflammatory bowel disease (IBD) many of them undergo 
colonoscopy. Faecal biomarkers have been proposed as useful diagnostic 
tools in this setting. Quick faecal tests, which can be performed by patients 
and give immediate results, may be a useful strategy to determine which 
patients need rapid investigation and also the ones who have low risk of 
significant pathology.
aims & Methods: To evaluate the diagnostic accuracy of a one-step combo 
card test for the simultaneous semi-qualitative detection of human hae-
moglobin (hHb), human transferrin (hTf), human calprotectin (hCp) and 
human lactoferrin (hLf) in stool samples of symptomatic patients. 
Methods: Symptomatic patients referred for colonoscopy, who returned 
stool samples and completed colonic examinations, were prospectively 
recruited. Certest FOB+Transferrin+Calprotectin+Lactoferrrin® (Certest 
Biotec S.L, Zaragoza, Spain), a coloured chromatographic inmmunoassay 
for the simultaneous semi-qualitative detection of hHb, hTf, hCp and hLf, 
was performed. Cut-off values of the test are 5.1 µg/gr for hHb, 0.4 µg/gr 
for hTf, 50 µg/gr for hCp and 10 µg/gr for hLf. 
CRC, advanced adenoma (>10mm, >3 adenomas, villous component, high 
grade dysplasia), IBD, angiodisplasia and microscopic colitis were consid-
ered as relevant pathology.
Positive and negative predictive values (PPV, NPV), sensitivity and specific-
ity for each marker and for the different combinations were calculated.
results: 482 patients (251 - 52.1% female, median age 63 years, IQR: 
51.5-74.5) were included. The most frequent indications for colonoscopy 
were recent history of rectal bleeding (128/482, 26.6%), chronic diarrhea 
(99/482 -20.5%), abdominal pain (85/482 - 17.6%), and anemia/iron defi-
ciency (79/482 - 16.4%). Colonoscopies were mainly requested by primary 
care level (315/482 - 65.4%), and by Gastroenterology outpatient’s clinics 
(117/482 - 24.3%). 
Relevant pathology was found in 115/482 (23.9%) patients. CRC was diag-
nosed in 24/482 (5%) patients. IBD was detected in 14/482 (2.9%) patients. 
Diagnostic accuracy of hHb, hTf, hCp and hLf for relevant colonic pathology 
are summarized in Table 1.
162/482 (33.6%) patients had negative results of all 4 biomarkers. 151/162 
colonoscopies of this group have no relevant pathology (NPV 93.2%). This 
11 patients with pathology were 9 advanced adenomas and two micro-
scopic colitis, so no case of CRC or IBD would have been potentially missed 
(NPV 100%). 29/482 (6%) patients had all 4 biomarkers positive, 13/29 
(44.8%) were diagnosed with CRC and 7/29 (24.1%) with IBD (PPV 68.9% 
for CRC + IBD).
Test negative test Positive test PPv nPv sensitivity specificity
hHb 362 120 57.5% 87.3% 60% 86.1%
hCp 183 299 33.1% 91.2% 86.1% 45.5%
hTf 380 102 47% 82.4% 41.7% 85.3%
hLf 417 65 53.8% 80.8% 30% 91.8%
[Table 1.]
conclusion: This semi-quantitative rapid self-made faecal combo test may 
be a useful and quick diagnostic tool to avoid unnecessary colonoscopies 
and to prioritize high risk symptomatic patients.
disclosure: Nothing to disclose 
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P1172 ManageMenT Of recTaL neOPLasTIc LesIOns By 
endOscOPIc suBMucOsaL dIssecTIOn and TransanaL 
endOscOPIc MIcrOsurgery In The naTIOnaL cancer InsTITuTe 
In sLOvakIa
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Gastroenterologické Oddelenie, Bratislava, Slovakia
contact e-Mail address: borispekarek@yahoo.com
Introduction: Colorectal carcinoma is the most common type of cancer in 
Slovakia. Recognition and successful removal of the early forms of colorec-
tal carcinoma reduces morbidity and mortality caused by this disease. 
When removing early neoplastic lesions in the rectum “en bloc”, we have 
a choice between endoscopic submucosal dissection (ESD) and transanal 
endoscopic microsurgery (TEM).
aims & Methods: The aim of this study was to compare the outcomes of 
endoscopic submucosal dissection (ESD) and transanal endoscopic micro-
surgery (TEM) in a cohort of patients with neoplastic rectal lesions in our 
hospital (National Cancer Institute in Slovakia).We retrospectively analyzed 
the cohort of 100 patients consecutively treated for neoplastic colorectal 
lesion by ESD (60 patients) or TEM (40 patients) in the National Oncology 
Institute in Slovakia. 
We collected clinical, endoscopic and histological data including the di-
ameter of removed lesions, duration of the procedures, histopathological 
types of lesions, the rates of “en bloc” and R0 resections, the rates of 
acute and late complications, the length of hospital stay and the rate of 
recurrence.
results: The average diameter of lesions removed by ESD were signifi-
cantly greater when compared to TEM (45,6 mm vs. 34,9 mm; p< 0,01). 
We observed higher rates of “en bloc” resections (95 % vs. 75%; p< 0,01) 
and R0 resections 93,3 % vs. 67,5%; p< 0,001) in the ESD group. The aver-
age length of hospital stay was significantly shorter in ESD group. (5,6 vs. 
8,8 days; p< 0,0001). The average duration of procedure was significantly 
shorter in the TEM group (151,1 vs. 77,7 min; p< 0,001).
conclusion: ESD and TEM have both proven to be effective and safe for 
treating neoplastic lesions of rectum. In our hospital, ESD was more effec-
tive in achieving “en bloc” resection, R0 resection and was also associated 
with shorter hospital stay. However, in our conditions, the average dura-
tion of ESD was longer than TEM.
disclosure: Nothing to disclose 
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Introduction: Endoscopic mucosal resection (EMR) is established as a safe, 
effective, efficient and definitive first line therapy for the management of 
large (>20mm) laterally spreading colonic lesions (LSL). 4 % of referred 
LSL contain covert submucosal invasive carcinoma (SMIC), which is only 
detected after EMR. Although enbloc resection is ideal, when this has not 
occurred, at present, there are no established guidelines on the optimal 
management for these patients. Surgery is usually advised but such pa-
tients are often elderly with multiple co-morbidities and surgery is more 
expensive, resource intensive and morbid.
aims & Methods: To determine outcomes in patients with covert SMIC 
within a large prospective multicentre cohort.
Patients within the Australian colonic endoscopic resection (ACE) cohort 
were prospectively followed, and cases with SMIC were identified. Overt 
SMIC cases, where EMR was not attempted due to clear malignancy, were 
excluded, and only those in whom EMR was completed and cancer was 
subsequently diagnosed (covert) were included. Surgical and histologic 
outcomes were recorded and presence of residual local malignancy (de-
fined as either lymph node involvement or residual carcinoma in the re-
section specimen) was determined.
results: From a prospective cohort of 3372 cases of LSL, 225 cases of SMIC 
were identified. 74 overt SMIC cases were excluded. Of 151 covert SMIC 
cases, complete outcomes were available in 124. 95 patients proceeded 
to surgical resection (77%), while 29 were managed conservatively (23%). 
Patients managed conservatively were older (p=0.001) and had higher ASA 
scores (p=0.001). Based on the EMR histology, 57 (46%) had Kikuchi SM1 
disease and 67 (54%) had Kikuchi SM2 or 3 disease. Overall, residual local 
malignancy was detected in 32 of 95 cases (34%). Of 56 with SM1 disease, 
37 (66%) proceeded to surgical resection. Within this group residual lu-
minal cancer was detected in 6 cases (16%) and nodal disease in 2 (5%), 
in both cases the tumour was poorly differentiated. Of 19 SM1 cases man-
aged conservatively (due to advanced age in 3, co-morbidities in 7 and 
patient preference in 9), follow up colonoscopy was performed in 14 (74%). 
Recurrence was detected in 1 case, who subsequently underwent success-
ful surgical resection. Over a median follow-up of 36 months (range 5-95 
months) 1 death occurred due to cardiac disease, and the other 18 remain 
alive and disease free. On multivariate analysis with stepwise backward 
regression, independent risk factors associated with subsequent residual 
surgical disease., were presence of SM2 or 3 invasion (odds ratio 3.4 (95% 
CI 1.3-9.3), p=0.015), and presence of submucosal fibrosis (SMF) (odds ra-
tio 2.5 (95% CI 1.1-6.1), p=0.041).
conclusion: The majority of patients with covert SMIC proceeding to sur-
gical resection have no residual local disease. This risk is increased with 
deeper submucosal invasion at initial EMR histology (SM2 or SM3) and 
presence of submucosal fibrosis. In patients with disease confined to 
SM1 where no SMF is present, the need for surgery needs to be balanced 
against the patient’s age and co-morbidities. Further data are needed to 
more precisely inform this decision process.
disclosure: Nothing to disclose 
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Introduction: Surveillance colonoscopy is strongly recommended after sur-
gical resection (SR) of colorectal cancer (CRC) or endoscopic resection (ER) 
of adenoma because of their risk of metachronous colorectal neoplasia. 
However, there is little evidence about metachronous lesions following re-
section of submucosal invasive CRC (SM-CRC), for which both surgical and 
endoscopic resection can be chosen.
aims & Methods: The aim of the present study was to clarify the incidence 
of metachronous advanced neoplasia (AN) after SM-CRC resection. This 
retrospective observational study reviewed consecutive patients who un-
derwent surgical or endoscopic resection of SM-CRC at the National Cancer 
Center Hospital East, Kashiwa, Japan, between January 2005 and Decem-
ber 2013. We included patients who underwent: 
(i) histopathologically-proven complete resection of SM-CRC by SR or ER 
as the first-line treatment; 
(ii) resection of all other colorectal neoplasia; and, 
(iii) one or more surveillance total colonoscopies after resection of SM-
CRC. 
The overall and cumulative incidence of metachronous AN detected at sur-
veillance colonoscopies were calculated using the Kaplan-Meier method 
and compared by the log-rank test. The Cox proportional hazards model 
was used to analyze risk factors of incidence of metachronous AN.
results: A total of 343 patients were eligible for inclusion. The median 
age was 65 years (range, 33-87), and 219 (63.9%) were male. The loca-
tion of SM-CRC was right-sided colon in 100 (29.2%), left-sided colon in 
131 (38.2%), and rectum in 112 (32.7%). 93 (27.1%) underwent only ER 
(ER group), and 250 (72.9%) underwent ER followed by SR or only SR 
for SM-CRC (SR group). The median follow-up period was 61.7 months 
(range, 12.6-151.6), and the median number of surveillance colonoscopies 
was 3 (range, 1-12). The median follow-up period of the SR group was 
61.9 months, whereas that of the ER group was 60.5 months. The median 
number of surveillance colonoscopies of the SR group was 2, whereas 
that of the ER group was 4.
The overall incidence rate of metachronous AN was 8.5% (29/343 pa-
tients; 95% confidence interval [CI], 5.7-11.9). The overall cumulative in-
cidence rates at 3 and 5 years were 4.8% and 6.0%, respectively. The 
cumulative incidence rate was significantly higher in the ER group than 
in the SR group (P < .001); in the colon group than in the rectal group (P 
= .021); and in the group with synchronous AN than in the group without 
synchronous AN (P < .001). The multivariate analysis identified ER (hazard 
ratio [HR], 2.90; 95% CI, 1.26-6.68) and synchronous AN (HR, 4.37; 95% 
CI, 1.96-9.73) as significant risk factors for metachronous AN.
conclusion: ER and Synchronous AN were significantly associated with 
incidence of metachronous AN after SM-CRC resection. Intensive surveil-
lance colonoscopy should be considered after ER of SM-CRC and patients 
with synchronous AN.
disclosure: Nothing to disclose 
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Introduction: In the last decade ESD has shown very promising results, 
but the technique is still burdened by complications, depending mostly 
on endoscopist experience. Organizational options such as preventive hos-
pitalization seem to play a role too, but no clear guidelines are available 
on this issue. In Eastern Countries, an endocopist is considered an expert 
with more than 80 ESD performed in the stomach (in general, gastric le-
sions are easier to remove with this technique). In Western Countries, a 
low incidence of gastric lesions makes ESD very difficult to be learned by 
professionals, and, actually, the learning curve of this procedure is longer 
and performed mostly in the colon-rectum tract.
aims & Methods: Aims are: 1.to estimate the number of ESD procedures to 
be performed by a single operator to learn proficiently the technique in a 
Western country; 2.to establish if the patient has to be hospitalized when 
performing ESD compared to other resection techniques and which are 
main complications. From 2012 to 2019 in a urban hospital, all mucosec-
tomies >2 cm of a single operator were collected to draw the ESD learn-
ing curve. The cumulative summation analysis (CUSOM) was calculated to 
establish ESD learning curve for en bloc resection parameter.
Information was collected on preventive hospitalization, complications 
(perforation; acute and delayed bleeding), hospital length of stay, neo-
plasm relapse at follow-up. The results were compared with EMR and 
EFTR (performed using the Full Thickness Resection Device (FTRD®). Sta-
tistical analyses: chi squared and t Student tests were performed for com-
parison, setting statistical significance p < 0.05.
results: 311 procedures were collected (128 ESD, 152 EMR and 31 EFTR). 
81.6% were hospitalized with a mean length of stay of 2.7±2.04 days (range 
1-13). 54.8% were females (M:F=171/311) with a mean age 66.4±11 yrs. 160 
patients made a regular follow-up (mean follow-up 18.6±15.6 months). 
The CUSOM curve for en bloc parameter after 128 ESD showed a decrement 
of the curve without reaching the inferior limit (-1.23), we estimated that 
further 10 consecutive ESD procedures are needed to complete the curve 
(138 in all). ESD sites: rectum (59), colon sx (31), colon dx (22), stomach/
esophagus/duodenum (16). EMR sites: rectum (17), colon sx (25), colon dx 
(90), stomach/esophagus/duodenum (20). EFTR sites: rectum (4), colon sx 
(7), colon dx (16), stomach/esophagus/duodenum (4). No significant differ-
ences were found in hospital length of stay (EMR 2.74-ESD 2.85-EFTR 2.23 
p=ns). Perforation was significantly higher in ESD technique (ESD 26/128 
20.3% vs EMR 5/152 3.2% vs EFTR 0/31 0%, p< 0.05). The mean recovery 
stay was longer in patients with perforation 3.5 days±2.9 Vs no perfora-
tion 2.5±1.8 (p=ns), no perforation underwent surgery. No differences were 
observed for acute or delayed bleeding according to the endoscopic tech-
nique (acute: ESD 3/128 2.3%; EMR 4/152 2.6%; EFTR 2/31 6.4%, p=ns; 
delayed: ESD 8/128 7.8%; EMR 7/152 4.9%; EFTR 1/31 3.4%, p=ns). All the 
delayed bleedings happened after patients discharge. During the follow-
up were observed 20 neoplasms relapse (20/160 pts in regular follow up 
-12.5%): 12 (15.6%) in EMR; 8 (10.4%) in ESD, 0(0%) in EFTR. Relapses 
were associated with margins R1+ in en bloc resections in 23.1% of cases 
(p< 0.05). Margins R0 showed 2.8 % relapses.
conclusion: In our experience, to become expert in ESD in the colon nearly 
140 procedures need to be performed. Patients need to be hospitalized 
only if a perforation occurs during the procedure. Delayed bleeding is rare 
and in our casuistry it happened always after discharge.
disclosure: Nothing to disclose 
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Introduction: The difficulty in insertion of colonoscope, the poor maneu-
verability, or the abundant fat tissue in submucosal layer sometimes occur 
during colorectal endoscopic submucosal dissection (ESD) in patients with 
obesity. However, association between obesity and colorectal endoscopic 
submucosal dissection (ESD) has not been investigated. In this study, we 
evaluated the clinical impact of obesity in patient who underwent colorec-
tal ESD.
aims & Methods: We retrospectively reviewed 543 patients who under-
went colorectal ESD at Omori Red Cross Hospital from April 2012 to Febru-
ary 2019. Patients that we could not confirmed BMI records, we discon-
tinued the ESD, or had recurrent lesions were excluded. The remaining 
536 patients (599 lesions) were divided two groups based upon body 
mass index (BMI, kg/m2): obesity group (BMI≧25) and non-obesity group 
(BMI<25).
results: 120 patients (132 lesions) were in obesity group and 416 patients 
(467 lesions) were in non-obesity group. There is no significant difference 
between both groups in mean age (67.8±9.9 vs. 68.5±12.4), lesion diameter 
(27.1±14.5mm vs. 26.4±13.1mm), location (C/A/T/D/S/R= 18/34/31/12/18/19 
vs. 66/108/101/36/68/88) and macroscopic type (I/IIa/IIc/combined/SMT= 
.21/107/0/3/1 vs. 78/371/5/7/6). In short term clinical outcomes, there is no 
significant difference in procedure time (47.2±43.7min vs. 42.0±34.7min), 
en bloc resection rate, curable resection rate, and pathological diagno-
sis. While the amount of sedative (flunitrazepam) per body weight was 
significantly lower in obesity group (1.62×10-2±0.85×10-2mg/kg vs. 1.92×10-
2±0.95×10-2mg/kg), cases in which reduction of percutaneous arterial oxy-
gen saturation occurred were significantly more in obesity group (46.7% 
vs. 29.8%). The procedure time by trainee (less than 100 cases of colorectal 
ESD experience) was significantly longer in obesity group (58.8±48.1min 
vs. 48.1±31.3min).
conclusion: This study showed colorectal ESD could be performed safely 
and effectively in obese patients. However, ESD in patients with obesity 
requires attention to changes especially in respiratory condition.
disclosure: Nothing to disclose 
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Introduction: Lymph node risk assessment has become a major issue to 
recommended additional surgery with lymph node dissection after endo-
scopic resection (ER) of a superficial colorectal cancer. This risk is based on 
histological criteria (depth invasion, differenciation, lymphovascular inva-
sion, budding, positive margins) and their presence is an indication for 
additional surgery at this time. The challenge is to determine if there are 
any subgroups for which surgery could be avoided.
aims & Methods: 
aims: Evaluate the relapse-free survival rate in all patients and in specific 
subgroups, measure the lymph node and/or metastatic risk of colorectal 
adenocarcinoma pT1sm2 and evaluate the morbidity rate of endoscopic 
resections for tumor pT1sm2.
Methods: Patients with endoscopic or surgical resection of colorectal ad-
enocarcinoma pT1sm2 between 2012 and 2018 at Institut Paoli Calmettes 
(Marseille, France) and Edouard Herriot hospital (Lyon, France) were ret-
rospectively included. We evaluated two predefinied groups of patients 
. First group was “supposedly good prognosis” patients (SGP) including 
ER alone with no pejorative histological criteria, patients with ER and ad-
ditional surgery with favorable histology (pT0N0) or primary surgery with 
adenocarcinoma pT1sm2 and no pejorative criteria. The second group was 
“supposedly effective endoscopic resection”(SEER) including ER alone with 
no pejorative criteria, ER with additional surgery, histologically pT0N0 and 
negative deep margins. At last we studied patients treated by ER alone. 
For each group, free-recurrence survival rate (FRS) at 12 and 24 month 
and complete remission (CR) rate (defined as absence of local or meta-
static recurrence in the first 12 months, excluded local recurrence treated 
by endoscopy) were assessed. The rate of histological lymph node inva-
sion, adverse events of endoscopic and surgical treatment were recorded.
results: 74 patients were included (38 women and 36 men) with a median 
age of 68 years (51-88). The mean hospitalization lenght was 2 days (1-7) 
and the median follow-up was 16 months (0-81). 33 tumors were located 
in the descending colon, 18 in the ascending colon, 4 in the transverse 
colon and 18 in the rectum. All tumors were well differentiated, 49 % had 
budding , 2,7% vascular invasion, 5,6% lymphatic invasion and 40% had 
positive deep margins. 68 patients had ER : 22 patients alone and 46 had 
additional surgical treatment with lymph node staging. 6 patients were 
operated without previous endoscopic resection. During the follow-up, 4 
patients died. No deaths were related to cancer. There were 4 local recur-
rences and 3 were treated by a new ER and 1 by endocavitary radiation 
therapy. In the general population, the FRS rate was 98% at 12 months and 
97% at 24 months. CR rate at 12 months was 98%. In the “SGP” group, the 
FRS rate was 100% and 97% at 12 and 24 months respectively. The CR rate 
at 12 months was 100%. In the SEER group, the FRS rate at 12 months was 
100% and 94% at 2 years and the CR rate 100%. In the “endoscopic resec-
tion alone” group alone: 8 patients had no pejorative criteria, 14 had at 
least 1 and the FRS rate was 100% and 90% respectively. The lymph node 
invasion rate was 6.4% with a mean number of lymph nodes examined 
of 15 (7-30). The complication rate for endoscopic resections was 11% (all 
treated by endoscopy) and 9,5% for surgical complications.
conclusion: Endoscopic resection of pT1sm2 adenocarcinoma without his-
tological pejorative criteria might be a good candidate to avoid additional 
surgery. Howeveralonger follow-up and more patients are needed to con-
firm this approach.
disclosure: Nothing to disclose 
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Introduction: Lynch syndrome (LS) is one of the most frequent causes of 
hereditary colorectal cancer (CRC). However, there is a group of patients 
who develop CRC or tumors of the LS domain in which microsatellite in-
stability and / or loss of expression of DNA repair genes are observed in 
the tumor, but without evidence of pathogenic mutation. This group of pa-
tients is known as Lynch-like syndrome (LLS) and they represent approxi-
mately 30% of all patients with unstable tumors. There is no consensus 
about follow-up and management of relatives of LLS patients.
aims & Methods: Our aim is to compare risk of cancer in first-degree rela-
tives (FDR) in a large cohort of LLS and LS patients. Patients who met crite-
ria for LLS diagnosed with CRC were included, when their tumors showed 
immunochemical loss of MSH2, MSH6, PMS2, or loss of MLH1 with BRAF-
wild type and/or no MLH1 methylation and absence of pathogenic muta-
tion in these genes, and was compared with those with confirmed LS and 
CRC. Neoplasms were followed in patients diagnosed with LS and LLS and 
among their relatives. Based on this information, we calculated the stan-
dardized incidence ratios (SIRs) for CRC and other neoplasms associated 
with LS, among FDR of patients diagnosed with LLS and compared it with 
SIRs among FDR of patients with LS.
results: A total of 205 families with LS and 126 families with LLS had com-
plete pedigrees, including the ages of relatives without cancer. A total of 
1896 FDRs were included: 1198 from families with LS and 698 from families 
with LLS. FDR of patients with LLS have a high incidence of CRC (SIR 2.11; 
95% CI, 1.59-2.75), that was significantly lower than in FDR of confirmed 
cases of LS (SIR 4.28; 95% CI, 3.69-4.93; p< 0.001). The risk of develop-
ment neoplasms associated with LS (other than CRC) was also observed in-
creased among relatives of patients with LLS (SIR 2.04; 95% CI, 1.44-2.80), 
but lower than the risk presented among family members of patients with 
LS (SIR 5.10, IC95%: 4.35-5.94; p< 0.001).
conclusion: Relatives of patients with LLS have a high risk of developing 
CRC, although this risk is lower than that of families with Lynch syndrome. 
FDR of patients with LLS should be managed taking into account this in-
creased risk of CRC.
disclosure: Nothing to disclose 
P1181 Was “Leave-In-sITu sTraTegy” fOr dIMInuTIve 
adenOMas WeLL TOLeraTed?
Kurata T.1, Kudo S.2, Maeda Y.2, Mori Y.3, Misawa M.2, Ogawa Y.4, 
Sakurai T.2, Okumura T.5, Minegishi Y.6, Mochizuki K.2, Wakamura K.2, 
Hayashi T.2, Ishida F.2
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Introduction: Colonoscopy with polypectomy of adenomas reduces the in-
cidence and mortality of colorectal cancers (1). With recent increment of 
the number of screening colonoscopies, it is reported that eradication of 
adenomas during colonoscopy can be a big burden for endoscopists (2). 
On the other hand, some studies suggest the safety of following diminu-
tive polyps up without removal might be sufficient (3,4). According to the 
Japanese Society of Gastroenterology guidelines (5), diminutive adenomas 
which has no evidence of carcinoma in their appearance are allowed to 
be left in situ, provided strict surveillance colonoscopies within 3 years 
(=”leave-in-situ strategy”) are conducted, which is different initiative from 
the European or American guidelines(6,7). However, the tolerability of the 
“leave-in-situ strategy” of diminutive adenomas are unknown.
aims & Methods: The aim was to consider tolerability of the “leave-in-situ 
strategy” of diminutive adenomas by retrospectively assessing it’s safety 
and compliance. Patients whose diminutive adenomas were not resected 
at the initial colonoscopies between April 2001 and November 2015 at a 
referral center were chosen as the subjects. All the subjects were asked 
to receive surveillance colonoscopies within 3 years. The primary outcome 
measure is the incidence rate of index lesions (ILs) at the surveillance colo-
noscopy within 3 years. The ILs were defined as follows: adenomas ≧10 
mm , high grade dysplasias, villous adenomas, and invasive cancers. The 
secondary outcome measures included the rate of patients who received 
the 3-year surveillance colonoscopies and the number of the diminutive 
polyps which were detected at both the initial and surveillance colonos-
copies.
results: A total of 4816 patients were left untreated of diminutive adeno-
mas (n=2502) at the initial colonoscopies. The incidence rate of index le-
sions at the surveillance colonoscopies was 2.3%(36/1543; 12 adenomas 
≧10 mm, 22 high grade dysplasias, and 2 invasive cancers). The rate of 
patients who underwent 3-year surveillance colonoscopies was 32.0% 
(1543/4816).
conclusion: “Leave-in-situ strategy” of diminutive adenomas can be ac-
ceptable whose rate of ILs in the surveillance colonoscopies is limited to 
2.3% which is similar to those in the National Polyp Study (8). However, 
strict instruction to the patients is indispensable considering the low re-
ceiving rate of surveillance colonoscopies.
references: 1. Zauber AG, et al. N Engl J Med. 2012, 366: 687 696. 2. Jasper 
L.A., et al. Gastrointest Endosc. 2017,85(6):1169-1176. 3. Maeda Y , Kudo SE , 
et al. ONCOLOGY LETTERS. 2017,14:2735-2742 4. Ninomiya Y , et al. Digestive 
Endoscopy 2017, 29(7):773-781 5. Tanaka S, et al. J Gastroenterol 2015, 50: 
252-260. 6. Cesare Hassan, et al. Endoscopy 201,45: 842-851 7. Davila RE, 
et al: Gastrointest Endosc 2006, 63: 546 557 8. Winawer SJ, et al. N Engl J 
Med. 1993, 328 ; 901-906
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P1182 hIghLy varIaBLe fOLLOW-uP In PaTIenTs WhO refraIn 
frOM addITIOnaL surgery afTer endOscOPIc resecTIOn Of a 
hIgh-rIsk T1 cOLOrecTaL carcInOMa In The neTherLands
Gijsbers K.M.1,2, de Graaf W.3, Moons L.M.G.2, ter Borg F.1, 
on Behalf of the Dutch T1 CRC Working Group
1Deventer Hospital, Gastroenterology & Hepatology, Deventer, Netherlands, 
2University Medical Center Utrecht, Gastroenterology & Hepatology, Utrecht, 
Netherlands, 3Erasmus MC, Gastroenterology, Rotterdam, Netherlands
contact e-Mail address: kimgijsbers1992@gmail.com
Introduction: The incidence of submucosal invasive (T1) colorectal cancers 
(CRCs) has increased with the implementation of the national screening 
program. In case of endoscopic resection of a T1 CRC with histological risk 
factors for an adverse outcome, the guidelines advise adjuvant surgical 
segmental resection. For various reasons (comorbidity, perceived low risk 
of residual cancer, risk of surgery), an additional resection may not be car-
ried out and patients wish to have regular follow-up. A standard protocol 
for surveillance of these patients is unavailable.
aims & Methods: In this national survey, an inventory has been made of 
the surveillance strategy for patients after endoscopic resection of a high-
risk T1 CRC who refrain from additional surgery. Dutch gastroenterologists 
and surgeons participating in the Dutch T1 CRC Working group were asked 
to participate in an online survey. They were questioned on demographics, 
baseline staging after detection of a T1 CRC and surveillance protocols.
results: In total, 69/130 (53%) physicians (87% gastroenterologist) partici-
pated in the survey. In case of an unexpected malignancy after polypectomy, 
36/69 (52%) performed full oncological staging, the remainder only in case 
of high-risk features in the endoscopically removed specimen. Pathology 
criteria used to determine high risk status were; lymphovascular invasion 
(100%), resection margin not free/indeterminable (93%), poor differentia-
tion (90%), malignancy ≤ 1 mm from resection margin (78%), tumor bud-
ding grade 2/3 (57%), and submucosal invasion depth >1000 µm (47%). 
A local protocol was available in 30% of participating centers only. We 
recorded 61 different surveillance strategies in 63 participants, using 19 dif-
ferent combinations of diagnostic tests. Most common used combinations 
were endoscopy only (n=9); endoscopy and rectal MRI (n=8); endoscopy, 
rectal MRI, liver ultrasound, chest X-ray and CEA (n=7) and endoscopy, 
rectal MRI, abdominal CT and CEA (n=6). Endoscopy was used in all sched-
ules, in 50 of 63 strategies (79%) at least twice in the first year. 48/63 (76%) 
used MRI in case of a rectal T1 CRC. 30/63 (48%) used abdominal CT and 
22/63 (35%) abdominal ultrasound for surveillance, of which 6 physicians 
used a combination of both. 23 of 63 physicians performed chest imaging, 
60% used serum CEA. Mean follow-up time was 36 months (95% CI 31.5-
40.5) for endoscopy, 26 months (95% CI 20.0-31.6) for rectal MRI and 30 
months (95% CI 21.7-37.7) for abdominal CT (all varying 3 - 60 months). The 
interval between surveillance investigations differed from 3-monthly in the 
first year to >1 year. Peaks were seen at 3, 6, 12, 24, 36 and 48 months for 
each modality. Most physicians experienced none (27/69), or 1-3 (28/69) 
recurrences.
conclusion: There is a high inter-practitioner variety in the follow-up of 
patients with an endoscopically resected high-risk T1 CRC who refrain from 
adjuvant surgery. A prospective study to evaluate the efficacy and safety of 
strict surveillance is needed.
disclosure: Nothing to disclose 
P1183 cLInIcaL and OncOLOgIcaL OuTcOMes Of LaTeraL 
LyMPh nOde dIssecTIOn usIng BOTh TransaBdOMInaL and 
exTraPerITOneaL aPPrOach
Kinoshita T.1, Komori K.2, Oshiro T.2, Natsume S.1, Shimizu Y.2
1Aichi Cancer Center, Gastroenterological Surgery, Nagoya, Japan, 2Aichi 
Cancer Center, Nagoya, Japan
contact e-Mail address: t-kinoshita@aichi-cc.jp
Introduction: Total mesorectal excision (TME) with lateral pelvic lymph 
node dissection (LLND) is a standard procedure for lower rectal cancer in 
Japan. However, ME alone is the international standard surgical procedure 
for rectal cancer and complete LLND is difficult because of the narrow vi-
sual field in the pelvic cavity and the complicated anatomical structure.
aims & Methods: Our LLND using a transabdominal and extraperitoneal 
approach provides a wider visual field through the paravesical space and 
enables us to perform complete lymph node dissection of these regions. 
Herein we introduce our LLND procedure and report the clinical and on-
cological outcomes.
After ME, bilateral hypogastric nerves were separated to be preserved. 
Firstly, common iliac nodes were dissected; aortic bifurcation nodes and 
median sacral nodes were also dissected by exposing the aortic bifurcation 
and the pelvic surface of the sacrum through a transabdominal approach. 
Secondly, after external iliac nodes dissection was performed to the pe-
ripheral side by the abdominal approach as possible. Proximal internal 
iliac nodes were removed and superior vesical artery was separated. 
Subsequently, the paravesical space was opened widely via an extraperito-
neal approach, the external iliac artery was exposed and the external iliac 
nodes were completely removed from inguinal ligament. Obturator nodes 
were completely dissected while preserving the obturator nerve, resect-
ing the obturator artery and vein, and confirming lateral pelvic wall and 
sciatic nerve. Finally, distal internal iliac nodes from the coccygeal muscle 
(Alcock’s canal) were completely dissected while preserving the superior 
vesical artery and the pelvic plexus, and transecting several inferior vesical 
arteries.
results: Between 2008 and 2018, we performed ME with LLND for 239 
patients with cStageI-III lower rectal cancer. The median operative time 
was 380 min, and the median blood loss was 620 ml. Postoperative com-
plications developed in 124 (51.9%) patients, and the most frequent one 
was pelvic cavity infection (including lymphocele ) in 51 (21.3%) patients. 
Temporary urination disorder developed in only 19 (7.9%) patients, and 
persistent urination disorder required intermittent urethral catheteriza-
tion developed in only one woman. Lateral Lymph node metastasis was 
pathologically found in 57(23.8%) patients after LLND. The 5-year local-
recurrence-free survival was 84.3% and the numbers of patients with lo-
cal recurrence were 14 (5.9%), respectively. Overall 5-year survival rate 
excluding cStageIV patients was 89.1%.
conclusion: Our LLND provides a wider visual field in the pelvic cavity by 
using both transabdominal and extraperitoneal approach, and results in 
favorable clinical and oncological outcomes.
We introduce our procedure of LLND. However LLND is invasive procedure 
which needs longer operative time and greater blood loss. So we show 
laparoscopic LLND as our new procedure securing equivalent range of 
lymph node dissection.
disclosure: Nothing to disclose 
P1184 facTOrs InfLuencIng InTerruPTIOn Of cOLOrecTaL 
endOscOPIc suBMucOsaL dIssecTIOn fOr deTerMInIng 
TheraPeuTIc sTraTegIes
Fukuchi T.1, Hirasawa K.2, Maeda S.3
1Yokohama City University Medical Center, Gastroenterological Center, 
Division of Endoscopy, Yokohama, Kanagawa, Japan, 2Yokohama City 
Medical Center, Endoscopy, Yokohama, Japan, 3Yokohama City University, 
Yokohama, Kanagawa, Japan
contact e-Mail address: take3232@gmail.com
Introduction: Although the colorectal endoscopic submucosal dissection 
(ESD) procedure is standardized worldwide, the difficulty of the procedure 
is well known. However, there have been no studies on the causes of treat-
ment interruption.
aims & Methods: The present study aimed to evaluate the factors involved 
in interruption of colorectal ESD. We retrospectively analyzed 1116 consecu-
tive superficial colorectal neoplasms of 1012 patients who were treated 
with ESD between August 2008 and September 2018. The clinical and 
pathological characteristics and treatment outcomes were analyzed.
results: Interrupted ESD was reported for 16 lesions (1.4%) of the total 
study population. Univariate analysis of clinical characteristics indicated 
that age, 0-I macroscopic-type tumor, and tumor location on the left side 
colon were risk factors for interruption. Multivariate analysis revealed that 
0-I macroscopic-type tumor was the sole preoperative independent risk 
factor for interruption. Univariate analysis revealed that the presence of 
muscle-retracting sign (MRS), deep submucosal tumor invasion, and in-
termediate invasive growth pattern represented the etiology of interrup-
tion. 
Multivariate analysis indicated MRS to be the sole independent cause of 
interruption. Additionally, the resectability and curability of 0-I type tu-
mors were significantly inferior to those of predominantly lateral spread-
ing tumors. Observations of 0-I macroscopic-type tumors, MRS, and sub-
mucosal deep invasion were significantly more frequent in interrupted 
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cases. Conventional endoscopic images without magnification endoscopy 
were more associated with interruption than irregular surface or Vi pit 
pattern in cases with 0-I type tumors.
conclusion: Endoscopic submucosal dissection of 0-I type tumors is highly 
disruptive, and undiagnosable submucosal infiltration can reduce the cur-
ability.
disclosure: Nothing to disclose 
P1185 arTIfIcIaL InTeLLIgence PredIcTs The LyMPh nOde 
MeTasTasIs Of T2 cOLOrecTaL cancer - PrOPOsaL Of a nOveL 
IndIcaTIOn fOr fuLL-ThIckness endOscOPIc resecTIOn
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1Showa University Northern Yokohama Hospital, Digestive Disease Center, 
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Introduction: Although all T2 colorectal cancers (CRCs) undergo surgical 
colectomy with lymph node dissection, they actually show approximately 
30% of lymph node metastasis (LNM)-positivity. Thus, the remaining 70% 
patients have an option of receiving local resection such as full-thickness 
endoscopic resection. However, accurate pre-operative prediction of LNM 
of T2 CRCs has been considered impossible. The aim is to investigate 
whether artificial intelligence (AI) can predict LNM-positivity of T2 CRCs.
aims & Methods: A total of 511 consecutive patients with T2 CRCs that were 
surgically resected in 2001-2016 were retrospectively analysed. We divided 
patients at a ratio of 3:1: data from 383 patients were used for machine 
learning for the AI model, and the remaining 128 patients were included 
for model validation. The AI model analyzed 37 clinicopathological factors 
and then predicted LNM-positivity or LNM-negativity on support vector 
machine which is a representative machine learning method. Operative 
specimens were used as the gold standard for the presence of LNM. The AI 
model was validated by calculating the sensitivity, specificity, and accuracy 
for predicting LNM.
results: The rate of LNM-positivity in validation dataset was 28% (36/128). 
The AI model showed a sensitivity of 100% (95% CI, 86%-100%), specific-
ity of 20% (12%-29%) and accuracy of 42% (34%-51%), respectively.
conclusion: The AI model accurately predicts 20% of the LNM-negative T2 
CRCs. Such patients can be good candidates for the local resection without 
lymph node dissection such as full-thickness endoscopic resection.
disclosure: Nothing to disclose 
P1186 auTOnOMIc resPOnse TO dIsTIncT MenTaL and 
PhysIcaL sTressOrs Is IMPaIred In PaTIenTs WITh IrrITaBLe 
BOWeL syndrOMe
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Introduction: Irritable bowel syndrome is the most common functional 
gastrointestinal disorder (FGID). The pathophysiological mechanisms of 
FGID are complex. Accumulating evidence indicates that autonomic dys-
regulation contributes to FGID. The symptoms of IBS are often triggered 
by stress, however, the mechanisms of autonomic dysregulation in IBS, 
especially in response to stress are incompletely understood.
aims & Methods: The aim of this study was to assess potential changes 
of vagal and sympathetic regulation in patients suffering from IBS in re-
sponse to distinct types of stressors (active mental stress vs. passive physi-
cal stress). 
Methods: Studied population included 12 patients diagnosed with IBS and 
12 sex- and age-matched healthy controls. All patients were diagnosed ac-
cording to ROME IV criteria for functional gastrointestinal disorders. Blood 
pressure (BP) and heart rate were continuously recorded using Finometer 
MIDI (FMS, Netherlands) at rest and during two distinct stressors - mental 
arithmetic test and cold pressor test (cooling of forearm in 1-3oC water bath 
for 5 min). Evaluated parameters: 
1. baroreflex sensitivity (BRS, calculated from spontaneous heart rate vari-
ability and BP variability) reflecting reflex of vagally-mediated heart rate 
regulation in response to changes of BP, 
2. spectral power in low-frequency band of systolic BP variability (LF-SBP) 
reflecting sympathetic alpha-adrenergic stimulation of vascular smooth 
muscles, 
3. systolic and diastolic BP, and; 
4. mean heart rate.
results: BRS (reflecting vagal reflex function) in patients with IBS was sub-
stantially reduced compared to controls at rest and in response to both 
mental arithmetic test and to cold pressor test (p<0.01 for all comparisons). 
In contrast, LF-SBP (reflecting sympathetic function) was normal at base-
line, but significantly increased in IBS compared to controls during cold 
pressor test (p<0.05). No differences were found in systolic and diastolic 
BP and heart rate.
conclusion: Our data show impaired dynamic sympatho-vagal balance in 
patients with irritable bowel syndrome at rest and in response to differ-
ent types of stressors. The vagal function was reduced both at baseline 
and during stress, while exaggerated sympathetic response is evoked 
predominantly by stress. These findings support the hypothesis of altered 
autonomic regulation during stress as a potential mechanism worsening 
the symptoms of IBS. 
We suggest that comprehensive evaluation of stress response using non-
invasive analysis of distinct autonomic effectors could help to better un-
derstand the role of autonomic dysregulation in functional gastrointestinal 
disorders.
Support: Slovak Scientific Grant Agency [VEGA 1/0044/18]; project Bio-
medical Center Martin [ITMS 26220220187] co-financed from EU sources.
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P1187 exPressIOn Of TOLL-LIke recePTOrs In IrrITaBLe 
BOWeL syndrOMe
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Axiaris G.2, Nakos A.3, Voumvouraki A.2, Germanidis G.2
1The Royal Free Hospital and University College London (UCL) Institute 
for Liver and Digestive Health, Royal Free Unit for Endoscopy, London, 
United Kingdom, 2Medical School, Aristotle University of Thessaloniki, 
AHEPA Hospital, Division of Gastroenterology, First Department of Internal 
Medicine, Thessaloniki, Greece, 3424 General Military Hospital, Division of 
Gastroenterology, Thessaloniki, Greece
contact e-Mail address: nikolaos.lazaridis@nhs.net
Introduction: Our aim was to investigate the underlying etiological mecha-
nisms in the development of irritable bowel syndrome (IBS). Recent stud-
ies implicate the involvement of innate immune system dysfunction and 
low-grade inflammation in the pathogenesis of IBS. Toll-like receptors 
(TLRs) are a family of transmembrane innate immune receptors that rec-
ognize various bacterial and viral cell components and regulate immune 
response. TLR-signaling alterations have been suggested as an underlin-
ing factor in the manifestation of the syndrome.
aims & Methods: A total of 44 IBS patients and 25 healthy controls were 
included in the study population. All participants underwent colonoscopy 
and right-sided colonic biopsies were obtained from 31 patients. TLR ex-
pression was measured with real-time quantitative Reverse Transcription 
PCR (RT-qPCR). 
Total RNA was isolated and was reversed transcribed to cDNA and quanti-
fication of TLR2 and TLR4 mRNA levels was achieved by RQ-PCR. Quality of 
life questionnaires, Rome III criteria and stool pattern questionnaires were 
completed by all participants.
results: There were no significant differences between healthy controls 
(HC) and IBS patients regarding age, body mass index and gender. IBS pa-
tients were subdivided in constipation group (23%), diarrhoea (57%) and 
mixed type (13%). TLR2 and TLR4 mRNA expression were increased in IBS 
patients compared to controls though there was no statistical significance. 
IBS-D patients had elevated TLR4 expression (p=0.008) compared to HC 
and IBS-C patients had decreased TLR4 (p=0.027). Furthermore, IBS-D 
patients presented with increased TLR2 and TLR4 mRNA expression com-
pared to IBS-C patients (p=0.018 and p=0.005).
668 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
conclusion: Expression of TLR2 and TLR4 was investigated in IBS patients 
and HC. Increased levels of TLRs were documented in the IBS group al-
though there was no significant difference to the HC group. TLR4 was over-
expressed in IBS-D patients and on the contrary IBS-C patients presented 
with decreased expression of TLR4. TLR2 and TLR4 were increased signifi-
cantly in IBS-D patients compared with IBS-C subgroup.
disclosure: Nothing to disclose 
P1188 cOLOnIc eOsInOPhILIa Is assOcIaTed WITh currenT 
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Introduction: There are multiple reports of persons with depression have 
displayed elevated levels of pro-inflammatory cytokines compared to 
healthy controls, but the origin of the inflammation is not determined. 
Eosinophils are normal in the GI tract (except in the esophagus). We have 
found subtle increased duodenal eosinophilia is linked to mood changes 
in dyspepsia, and have identified increased colonic eosinophils in a subset 
with IBS diarrhea.
aims & Methods: Given the abundance of mucosal associated lymphoid 
tissue present in the gut and evidence of gut-brain axis communication, 
we hypothesised that there may be a direct association between colonic 
eosinophilia and depression. The random population based colonoscopy 
study (PopCol) was performed 2002-2006 and included colonoscopies with 
biopsies on 745 individuals from the general population (Kjellström et al 
Eur J Gastro Hep 2014). Eosinophils (per 5 high power fields) have been 
counted in 161 out of the 745 individuals. Current depressive symptoms 
were reported on HADS at a baseline visit before the colonoscopy, 6 in-
dividuals (4 %) had a HADs depression score of 11 and above. Incident 
depression was defined as a Stockholm County registry recording of health 
care visit with an ICD-10 code F32 or F33 during 2006-2015 in individuals 
with HADS score below 11 at the baseline investigation. The cross sectional 
association between eosinophil counts and depressive symptoms were 
calculated using linear regression bootstrapped with 2000 replications. 
The association between baseline eosinophil counts and incident depres-
sion (17 cases, 138) was calculated using logistic regression.
results: There was an association between eosinophil counts in transverse 
(beta: 0.23, p=0.028) and sigmoid colon (beta: 0.28, p=0.001), but not ter-
minal ileum (beta: -0.08, p=.44), caecum (beta: 0.06, p=0.49) and rectum 
(beta: 0.16, p=0.27), and HADs depression scores, independent of smoking, 
age and gender. No association was found between eosinophil counts and 
incident depression (p’s>0.13). Adjusting for IBS status (32.9 % had IBS) 
did not change the results.
conclusion: The present result supports a direct association between co-
lonic eosinophilia and depressive symptom severity in a general popula-
tion. Future studies are needed to elucidate if this is a causal association.
disclosure: Nothing to disclose 
P1189 PhenOTyPIcaL changes In enTerIc gLIaL ceLLs and 
TheIr assOcIaTIOns WITh The neurOnaL PrOcess eLOngaTIOn 
sTIMuLaTed By neurOMOduLaTOrs fOr enTerIc nervOus 
sysTeM
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Introduction: Enteric glial cells (EGCs) present at the submucosal plexus 
and myenteric plexus change own phenotype by themselves and bring by-
directional and functional roles with adjacent neurons. Such phenomena 
occur under the stress circumstances in accordance with chemical media-
tors closely related to the pathogenesis of irritable bowel syndrome. How-
ever, direct mechanism(s) of these glial changes remains to be elucidated 
especially for effects of neuromodulators. Although some reports suggest 
the significance of neuronal process elongation in visceral hypersensitivity, 
effects by above neuromodulators and associations between the neuronal 
process elongation and glial efficacy are also unknown.
aims & Methods: For screening of phenotypical changes in EGCs and neu-
rons, we investigated the cellular proliferation and morphology of EGCs 
and neurons such as cytoplasmic shape, process elongation, and connec-
tions after stimulation with chemical mediators including expressions of 
nerve growth factor (NGF), and GAP43 in EGCs. We also evaluated pheno-
typical changes in neurons after stimulation with the conditioned medium 
of EGCs. EGC (CRL-2690 purchased from ATCC) and PC12 (CRL-1721.1) were 
used for the consequent experiments after reaching to sub-confluent con-
dition. Morphological changes of these cells were evaluated by immuno-
fluorescence with F-actin (a cytoskeletal marker) and S100β (a marker of 
glial cell) or PGP9.5 (a marker of neuron) antibody after stimulation with 
each mediator (NGF: 50 ng/ml, corticosterone: 1 µM, 5-HT: 1 µM, ATP: 1 µM, 
and tryptase: 1 µM) for 24 hours. We evaluated expressions of NGF in the 
EGCs after stimulation with tryptase. To evaluate interaction between EGC 
and neuron, we collected the condition medium of EGCs after stimulation 
with tryptase for 6 hours, and evaluated morphological changes of PC12 by 
immunofluorescence with F-actin or GAP43 and PGP9.5 after incubation 
with the condition medium for 24 hours. We measured cell number for 
cellular proliferative evaluation.
results: In a screening of each mediator affecting phenotypical change of 
EGCs, NGF (2-fold) and tryptase (1.8-fold) significantly induced cell pro-
liferation of EGCs. In glial morphology, NGF did not affect cell body of 
EGC from the basal culture condition (a star-shaped form). However, NGF 
markedly induced irregularly branched processes with dense connecting 
with adjacent EGCs. On the contrary, corticosterone and 5-HT significantly 
changed cell body of EGC from star-shaped form to fibrous or spindle form 
(thin cytoplasm) with long-branched processes with freely connecting with 
other EGCs. Tryptase slightly extended cytoplasm of EGCs, and ATP induced 
long-branched processes with dense and free connecting with adjacent 
EGCs as well as corticosterone and 5-HT. On the other hand, NGF and 
corticosterone increased neuronal proliferation. In neuronal morphology, 
these mediators extended cytoplasm of neurons and increased intracel-
lular F-actin and extracellular spicule formation in parallel with process 
elongation. However, 5-HT, ATP, and tryptase did not affect neurons in-
cluding proliferation and morphology. Expression of NGF was increased in 
EGCs stimulated with tryptase but not corticosterone. Conditioned medium 
of EGCs stimulated with tryptase caused neuronal process elongation simi-
lar to the effect of NGF stimulation, and increased GAP43 proteins.
conclusion: These neuromodulators induced phenotypical changes in 
EGCs more prominently than neurons. Phenotypical changes in EGCs may 
result in neuronal process elongation mediated by NGF.
disclosure: Nothing to disclose 
P1190 IMPacT Of MucOsaL gLIaL ceLLs and suBMucOsaL 
gLIaL ceLLs On enhanceMenT Of neurOnaL neTWOrk 
MedIaTed By nerve grOWTh facTOr In a raT MOdeL Of 
vIsceraL hyPersensITIvITy
Fujikawa Y., Tominaga K.
Wakakusa-Daiichi Hospital, Higashiosaka, Japan
contact e-Mail address: yoshi_zb@yahoo.co.jp
Introduction: Neuronal elongation toward the epiderm is caused by an 
imbalance of nerve attractive factors such as nerve growth factor (NGF) 
and nerve repulsive factors such as semaphorin 3A (Sema3A). The phe-
nomenon is partly responsible for itch sensitization (so called somatic hy-
persensitivity) in patients with atopic dermatitis. Previously, we reported 
that hyperplasia of myenteric glial cells contribute to hypercontraction in 
an irritable bowel syndrome (IBS) model. In addition, abnormalities of 
enteric neuron and glial cells observed in the colonic mucosa are reported 
to contribute to the pathogenesis of IBS. However, it is unknown how glial 
cells and nerve elongation factors change and associate with the neuronal 
network formation both in the mucosa and submucosa layer of IBS.
aims & Methods: We evaluated the changes in the neuronal network sepa-
rately in the mucosa and submucosa and the dynamics of glial cells and 
neuronal elongation factors in an IBS model. We used Wistar Kyoto rats 
(WKY) which are genetically instable to anxiety, and prepared an IBS mod-
els after intracolonic injections of acetic acid (2 mL, 0.6%) to these rats. 
Distal colonic segments were obtained from control (Wistar rats), WKY, and 
IBS models, and each layer (mucosa, submucosa, and muscle) were sepa-
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rately striped from the whole colonic tissues. Between the mucosal and 
submucosal layers, we compared mRNA expression of NGF and Sema3A 
by real-time RT-PCR. To evaluate the morphological changes of glial cells 
and neuronal network formation, whole mount submucosal plexus tissues 
were prepared for immunohistochemistry with glial fibrillary acid protein 
and PGP9.5 (pan-neuronal marker) antibodies. To evaluate the neuronal 
outgrowth in the mucosa, frozen colonic tissues were prepared for immu-
nohistochemistry with GAP43 antibody. We also evaluated the localization 
of NGF and Sema3A in the mucosa and submucosa layer.
results: mRNA expressions of NGF (2.3-fold) and Sema3A (3.1-fold) were 
significantly increased in the submucosal layer in the WKY group com-
pared to the control, while there were no change in the mucosa between 
both groups. In the IBS group, mRNA expression of NGF initially begun 
to increase in the submucosal layer, and its increase was subsequently 
observed in the mucosa. Sema3A mRNA expression was increased in the 
submucosal layer, but decreased in the mucosal layer. Submucosal glia ex-
hibited hyperplasia of their processes that apparently overlapped with the 
neurons and changes in bulbous swelling of terminals in the IBS group. 
Neuronal network was dramatically enhanced in the submucosal layer of 
the IBS group, whose change gradually appeared from the outer submu-
cosal plexus toward the inner submucosal plexus. As well as submucosal 
plexus, nerve fiber outgrowth (GAP43 positive neuron) was increased in 
the mucosal layer. NGF was localized in the both submucosal and mucosal 
glial cells but not mast cells in this model.
conclusion: Enteric glial cells are associated with enhanced neuronal net-
work both in the mucosa and submucosa mediated by the coordination 
of NGF and Sema3A in the IBS model. These findings may underlie in the 
pathogenesis of visceral hypersensitivity in IBS.
disclosure: Nothing to disclose 
P1191 gasTrOInTesTInaL syMPTOMs In a POPuLaTIOn 
affecTed By InTersTITIaL cysTITIs/BLadder PaIn syndrOMe 
(Ic/BPs): frOM IrrITaBLe BOWeL syndrOMe (IBs) TO narcOTIc 
BOWeL syndrOMe (nBs) and TheraPeuTIc reLevance Of BOdy 
Mass Index (BMI) cOnTrOL
Lopalco F.1, Cervigni M.2, Marturano M.2, Gasbarrini A.1, Gaetani E.1
1IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Università 
Cattolica del Sacro Cuore, Department of Internal Medicine and 
Gastroenterology, Rome, Italy, 2Catholic University of Rome, Female Pelvic 
Medicine & Reconstructive Surgery Center, Rome, Italy
contact e-Mail address: fabianalopalco93@yahoo.it
Introduction: Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) is a debili-
tating chronic, inflammatory disorder of the bladder characterized by vari-
able degree of pain, frequency and urinary urgency, with a negative impact 
on the Quality of Life (QoL). BPS patients are often affected by gastrointes-
tinal symptoms such as abdominal pain, dyspeptic symptoms, constipa-
tion and diarrhea, often consistent with a diagnosis of IBS. Severe chronic 
abdominal pain is sometimes treated with opioids. Furthermore, patients 
introduce many dietetic restrictions in order to improve their symptoms.
aims & Methods: This study aimed to evaluate the effects of chronic opioid 
treatment on abdominal pain, gastrointestinal symptoms and QoL. It also 
aimed to better understand how a weight control strategy can influence 
IBS/BPS patients’ psychological state. A two-year study was conducted in 
the Multicentric Interstitial Cystitis Referral Center of the Catholic Univer-
sity in Rome, in a population of 44 female, aged 25-78, affected by IC/
BPS according to the “European Society for the Study of Interstitial Cystitis 
(ESSIC)” criteria. Patients were categorized into groups according to opioid 
use and BMI: 17 “opioid users (at least 1 month)” and 27 “non-opioid us-
ers (in the last month)”; normal BMI group (BMI: 19-24.9) including 20 
patients, underweight group (BMI < 18.9) including 8 patients and over-
weight group (BMI >25) including 16 patients. All subjects were asked to 
fill our Psycho-Gastroenterological Questionnaire (PGQ), which includes 
Visual Analogue Scale (EQ-VAS), Bristol Stool Chart (BSC), Gastrointestinal 
Symptoms Rating Scale (GSRS), State-Trait Anxiety Inventory (STAI Y-1, STAI 
Y-2), Psychological General Well-Being Index (PGWBI), Hospital Anxiety 
and Depression Scale (HADS), General Self-Efficacy Scale (GSE), Connor-
Davidson Resilience Scale (CD-RISC). Differences between groups were 
evaluated by Student’s t test and considered significant for p< 0.05.
results: Compared to opioid users, non-opioid users had a higher EQ-
VAS score (46.7±14.9 vs 29.7±21.6, p=0,004), a lower grade of stypsis on 
BSC (3.4±1.7 vs 1.6±0.9, p=0,0002), and a lower GSRS score (14.2±6.5 vs 
19.9±6.1, p=0,006). Within the GSRS, “abdominal pain” (1.1±0.8 vs 1.9±0.8, 
p=0,002), “heartburn” (0.9±0.7 vs 1.7±1.0, p=0,003), “acid regurgitation” 
(0.7±0.7 vs 1.2±1.0, p=0,05), “nausea and vomiting” (0.7±0.9 vs 1.4±0.9, 
p=0,01), “hard stools” (1.2±1.0 vs 1.8±0.9, p=0,05), and “feeling of incom-
plete evacuation” (0.7±0.8 vs 1.8±1.1, p=0,0004) were significantly lower 
among non-opioid users. On the other hand, there were no differences 
between groups in the other scores. Compared to pathologic BMI group 
(underweight plus overweight patients), normal BMI group has a higher 
EQ-VAS score (44.3±21.0 vs 36.7±18.3) and a lower GSRS score (15.9±7.0 vs 
16.8±6.9), but these differences were not statistically significant. On the 
other hand, all psychometric scores are significantly better among normal 
BMI group: STAI Y-1 (48.6±11.5 vs 55.6±12.5, p=0.06), STAI Y-2 (42.1±11.3 
vs 51.7±10.3, p=0.005), PGWBI (61.0±20.5 vs 47.3±17.2, p=0.02), HADS-A 
(7.1±4.4 vs 11.0±5.1, p=0.01), HADS-D (5.8±3.6 vs 9.4±3.3, p=0.001), CD-RISC 
(70.2±16.9 vs 56.6±12.3, p=0.003).
conclusion: Our study demonstrates that chronic opioid treatment in-
creases abdominal pain and worsens gastrointestinal symptoms and QoL 
in subjects with IC/BPS+IBS, configuring a condition of NBS. On the other 
hand, weight control can strongly improve patients’ QoL. Further stud-
ies in larger samples are required to establish the influence of potential 
confounders.
references: Gillenwater J, Wein AJ. Summary of National Institute of Ar-
thritis, Diabetes, Digestive and Kidney Diseases workshop on Interstitial 
Cystitis. J Urol 1998; 140: 203-6.
disclosure: Nothing to disclose 
P1192 MeTaBOLOMIcs reveaLs PerTurBaTIOn Of 
TryPTOPhan-kynurenIne axIs In PaTIenTs WITh funcTIOnaL 
gasTrOInTesTInaL dIsOrders afTer a sIngLe OraL dOse Of 
frucTOse
Wilder-Smith C.H.1, Lee S.H.2, Low R.W.-T.2, Miao J.2, Kioh D.Y.Q.2, 
Chan E.C.Y.2,3
1Brain-Gut Research Group, Gastroenterology Group Practice, Bern, 
Switzerland, 2National University of Singapore, Pharmacy, Singapore, 
Singapore, 3Singapore Institute of Clinical Sciences, Agency for Science, 
Technology and Research, Singapore, Singapore
contact e-Mail address: info@ggp.ch
Introduction: Fructose intolerance is common in patients with Functional 
Gastrointestinal Disorders (FGID) and is typically attributed to intestinal 
malabsorption. However, fructose is also known to invoke systemic meta-
bolic changes, including modulation of the tryptophan (TRP)-kynurenine 
(KYN) pathways. This modulation has been associated with low-grade in-
flammation and cognitive changes, both of which are reported to be com-
mon in FGID and may be effected by either host or microbiome pathways 
(1-3).
aims & Methods: Plasma TRP, KYN and further systemic metabolites were 
quantified in FGID patients after fructose ingestion and related to mea-
sures of fructose intolerance and malabsorption.Thirty-one male and fe-
male FGID patients, defined by Rome III criteria, were prospectively en-
rolled into a double-blind, randomised, crossover study (4). Blood, breath 
samples and symptom ratings were collected at 0, 0.5, 1 and 2h post-
ingestion of 35g fructose or the blinded nocebos, 3.9mL cyclamate/sac-
charine sweetener or water. Plasma TRP and KYN were quantified via liq-
uid chromatography mass spectrometry, while other systemic metabolites 
were profiled via gas chromatography time-of-flight mass spectrometry.
results: The KYN/TRP ratio (KTR) increased from 0h to 2h after fructose 
ingestion (p< 0.001) in all FGID patients, and the change in KTR was sig-
nificantly higher following fructose than water (p< 0.01) and cyclamate/
saccharine (p< 0.01). Twelve other metabolites were significantly differ-
ent (Variable importance in projection>1, p< 0.005) between fructose and 
water interventions, including long-chain fatty acids (myristic acid, oleic 
acid, palmitic acid, palmitoleic acid, stearic acid) and pro-inflammatory 
mediators (linoleic acid, arachidonic acid). Breath hydrogen and meth-
ane concentrations and symptoms did not correlate significantly with the 
changes in KTR.
conclusion: Ingestion of fructose resulted in acute changes in the trypto-
phan-kynurenine axis and in fatty acid metabolism in patients with FGID. 
These changes do not appear to be specifically associated with malabsorp-
tion or intolerance of fructose and may rather be related to tryptophan 
metabolism and the recently highlighted link to the aryl hydrocarbon re-
ceptor and downstream effects on microbiome and host neuroimmune 
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function (5). Fructose stimulation may consequently be useful for further 
mechanistic assessment of the known immune activation and neural sen-
sitization in FGID.
references: 1. Berstad A. et al. Scand J Gastro 2014;49:1493-1498. 2. 
Ledochowski M. et al. Scandi JJ Gastro 2001;36:367-371. 3. Enko D. et al. 
Psych Res 2018;62:595-599. 4. Wilder-Smith CH et al. Neurogastro Mot 
2019;31:e13497. 5. Neavin DR et al. Int J Mol Sci 2018;19. pii: E3851. doi: 
10.3390/ijms19123851.
disclosure: Nothing to disclose 
P1193 an evaLuaTIOn Of PredIcTIve facTOrs fOr BOWeL 
PreParaTIOn BefOre cOLOnOscOPy usIng The BOsTOn BOWeL 
PreParaTIOn scaLe
Tsunashima H.1, Onda T.1, Sekine K.1, Mabuchi M.1, Doi S.1, Kikuchi K.2, 
Sato K.2
1Teikyo University Mizonokuchi Hospital, Gastroenterology, Kanagawa, 
Japan, 2Teikyo University Mizonokuchi, Gastroenterology, kanagawa, Japan
contact e-Mail address: dragonkaranomail@yahoo.co.jp
Introduction: Before colonoscopy, adequate bowel preparation is manda-
tory to achieve high-quality observation for entire mucosa. Several pre-
vious studies have reported factors associated with inadequate bowel 
preparation, including an older age, obesity, and diabetes mellitus. We 
investigated the predictive factors for bowel preparation.
aims & Methods: We evaluated 800 colonoscopies performed from March 
2016 to Jun 2019 to analyze the degree of bowel preparation using the 
Boston Bowel Preparation Scale (BBPS) and assessed the predictive factors 
for inadequate bowel preparation. All patients received low-volume (2 L) 
polyethylene glycol solution with ascorbate (MoviPrep®) before colonos-
copy. The potential predictive factors for inadequate bowel cleansing were 
older age (≥ 75), male gender, obesity (BMI ≥ 25), constipation, laxative 
use, a history of abdominal surgery, single- or split-dose intake prepara-
tion, diverticulosis and diabetes mellitus. Inadequate bowel preparation 
was defined as a BBPS ≤ 5. We excluded patients with a diagnosis or his-
tory of colonic stricture, inflammatory bowel disease or prior colectomy.
results: The median (range) patient age was 68 (27-84), and 43% were 
women. The median (range) number of bowel movements per week was 
5.7 (1-11). The median (range) BBPS score was 8 (3-9), and the rate of ad-
equate bowel preparation (BBPS ≥ 6) was 94.3%. A univariate analysis of 
the factors associated with inadequate bowel preparation were obesity (P 
= 0.007), diabetes mellitus (P = 0.005) and constipation (P = 0.0428). A 
multivariate logistic regression analysis showed that obesity (OR 2.76 [95% 
CI 1.07-7.23], p=0.035) and diabetes mellitus (OR 3.65 [95% CI 1.32-9.64], 
p=0.0133) were independent factors related to inadequate bowel cleansing.
conclusion: Using the BBPS score to evaluate colon cleansing, the predic-
tive factors associated with inadequate bowel preparation were obesity 
(BMI ≥ 25) and diabetes mellitus.
disclosure: Nothing to disclose 
P1194 a nOveL MeThOd fOr characTerIsIng POsTPrandIaL 
InTesTInaL cOnTracTIOns, effecTs Of gLucagOn and recTaL 
dIsTenTIOn In dOgs
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Introduction: Motility disturbances are frequently implicated in functional 
gastrointestinal disorders. Current options for assessing intestinal motility 
provide limited information on the propagation pattern of the intestines.
aims & Methods: This study aimed to investigate the validity of a new 
method for examining and quantifying intestinal motility. Seven healthy 
female dogs were operated on to have a cannula placed in their duode-
num. The canine intestinal motility was studied under three sets of ex-
periments (postprandial; glucagon injection and rectal distention, RD). A 
solid-state 4.2 mm manometric catheter with 10 sensors spaced at 1-cm 
intervals was inserted into the intestinal lumen via the cannula. The lumi-
nal contractile signals were converted into electrical signals by the pres-
sure transducer and saved for further analysis. A special software was de-
veloped to analyse the data collected. The intestinal motility was evaluated 
by frequencies of antegrade, retrograde and simultaneous contractions, 
motility index (MI), propagation pattern (percentages of antegrade, retro-
grade and simultaneous contractions), propagation distance and velocity 
of antegrade and retrograde contractions.
results: 
1. Feeding did not induce changes in the frequencies of different contrac-
tions. The frequencies of postprandial contractions (numbers per min, 
npm) were 8.1±1.4 npm for antegrade contractions; 3.5±1.0 npm for ret-
rograde contractions; and 8.9±0.7 npm for simultaneous contractions. MI 
also remained unchanged (11.8±0.5 vs. 11.4±0.2, p = 0.19). Postprandially, 
the dominant propagation pattern was antegrade (45.0±8.1%), followed 
by simultaneous (34.5±5.2%) and retrograde (20.5±2.0%). The average 
distance propagated was 4.8±0.8 cm with the antegrade contractions, 
4.4±0.3 cm with the simultaneous contractions and 2.3±0.2 cm with retro-
grade contractions. The propagation velocity of the antegrade contractions 
was 12.1±0.4 cm/min and 10.7±0.5 cm/min for retrograde contractions.
2. Post glucagon injection, the frequencies of antegrade contractions de-
creased from 7.6±1.0 to 4.3±0.6 npm (p = 0.001), the frequencies of other 
contractions did not change significantly. MI was reduced slightly (11.5±0.4 
vs. 10.6±0.2, p = 0.013). The dominant propagation pattern became simul-
taneous (42.0±2.9%), followed by antegrade (34.6±2.8%) and retrograde 
(23.1±3.7%). The average distance propagated by antegade contractions 
decreased to 3.6±0.5 cm/min (p = 0.0287). The propagation velocity was 
not altered by glucagon injection. 
3. RD did not significantly disrupt the intestinal contractile and propaga-
tion patterns.
conclusion: Our method was able to differentiate between antegrade, 
retrograde and simultaneous contractile and propagation patterns. Clini-
cally it can be used to quantify the dynamic intestinal propagation process 
and pinpoint whether the motility issue is due to antegrade, retrograde or 
simultaneous contraction. This could greatly enhance the clinical use of 
manometry in investigating the cause of intestinal dysmotility.
disclosure: This work was partially supported by a grant from the NIH 
SPARC program (U18TR001920) 
P1195 affecTIve deTerMInanTs Of syMPTOM severITy In IBs 
PaTIenTs
Sanda P.1, Tkalcic M.2, Troskot Peric R.3, Blazic F.4, Hauser G.5
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Croatia, 2University of Rijeka, Department of Psychology, Rijeka, Croatia, 
3Clinical Hospital Sveti Duh, Zagreb, Croatia, 4Clinical Hospital Centre, Rijeka, 
Croatia, Gastroenterology, Rijeka, Croatia, 5Clinical Hospital Centre, Rijeka, 
Croatia, Department of Internal Medicine, Division of Gastroenterology, 
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contact e-Mail address: goran.hauser@medri.uniri.hr
Introduction: Irritable Bowel Syndrome (IBS) is one of the most common 
and challenging disorder confronting gastroenterologist. Symptoms in-
clude abdominal pain associated with altered bowel habits. The disorder 
is characterized by heightened anxiety and depression. Even IBS patients 
with no comorbidities have higher, although still subclinical levels of anxi-
ety and depression. There are many aspects of anxiety that can possibly 
contribute to IBS symptom perpetuation, but perhaps the most illness spe-
cific one is visceral anxiety.
aims & Methods: The aim of this study was to test the predictive value 
of trait anxiety, depression and visceral anxiety in the prediction of IBS 
symptom severity.
A total of 39 Rome IV-diagnosed IBS outpatients at tertiary care centre 
(79.4% F, M age = 49.4 years) were recruited. They completed a set of 
questionnaires, including State-Trait Anxiety Inventory (STAI-T), Beck De-
pression Inventory (BDI-II) and Visceral Anxiety Inventory (VSI). They also 
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kept a diary for 14 days which, among other aspects, involved completing 
a short symptom intensity scale. The total symptom intensity was cal-
culated for each day and a final average of 14 days was used for each 
participant.
results: Symptom severity was positively correlated with trait anxiety 
(r=.37*), depression (r=.35*) and visceral anxiety (r=.58**). Hierarchical 
regression analysis showed that in the final model only visceral anxiety 
was a significant predictor (β=.51**) of symptom severity and the model 
explained a total of 35.8% of symptom severity variance. Considering that 
trait anxiety significantly predicts symptom severity (β=.37*) when entered 
in the model alone and that adding depression (β=.17) in the second step 
reduces that effect to non-significant (β=.24), and finally adding visceral 
anxiety in the third step completely nullifies that effect (β=.08) there are 
indications that depression partially and visceral anxiety fully mediates the 
trait anxiety - symptom severity relationship.
conclusion: The obtained results indicate that trait anxiety and depression 
might be related to symptom severity via visceral anxiety, which empha-
sizes the importance of using this simple, yet very informative measure of 
illness-specific anxiety in IBS patients.
disclosure: Nothing to disclose 
P1196 Is There a LInk BeTWeen IBs and sTuTTerIng? 
PreLIMInary resuLTs
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Introduction: Theories of stuttering have described the role of anxiety in 
several ways, from treating it as the main cause of the disorder to a mere 
by-product of stuttering. Most studies have detected a positive correlation 
between anxiety and stuttering severity, with higher levels of anxiety in 
the stuttering population compared to healthy persons. Irritable Bowel 
Syndrome (IBS) is one of the most common and challenging disorder con-
fronting gastroenterologist. Symptoms include abdominal pain associated 
with altered bowel habits. The disorder is characterized by heightened 
anxiety and depression.
aims & Methods: The aim of this study was to examine the prevalence 
of IBS in a sample of people who stutter and to explore the relationship 
between several anxiety measures and IBS symptom frequency among 
people who stutter.A total of 57 people who stutter (73.6% M, M age = 
32.4 years) and were treated for stuttering at VaLMod rehabilitation cen-
tre were recruited. During their regular holistic multidimensional logo-
paedic treatment they completed the Rome IV diagnostic questionnaire, 
a short questionnaire on the frequency of 6 IBS symptoms, State-Trait 
Anxiety Inventory (STAI-T), Visceral Anxiety Inventory (VSI) and Anxiety 
Sensitivity Index ASI.
results: Only 8 participants (4F, 4M) fit the IBS criteria (Rome IV), which is 
a somewhat lower prevalence rate compared to the general population. It 
needs to be pointed out that the sample consisted of almost three times 
as many men than women. If we look at women alone, the prevalence 
rate is around 26% which is close to prevalence in the general popula-
tion. People who stutter, but do not fit the IBS criteria, have higher STAI 
scores (M=44.53; SD=9.34) than a normative age group of healthy persons 
(M=35.55; SD=9.76), which is in line with previous studies (Ezrati-Vinac-
our & Levin, 2004; M=46.00; SD=8.80). People who stutter and fit the IBS 
criteria have even higher (t=2.59; df=9.62; p< .05) STAI scores (M=53.99; 
SD=9.41). Their STAI score seems to be higher than the score obtained 
for the regular, non-stuttering IBS population, previously published in our 
other studies (M=46.30; SD=9.63).
People who stutter and fit the IBS criteria have higher scores in VSI scores 
(t=2.26; df=8.34; p< .05), ASI scores (t=2.76; df=8.34; p< .05) and the fre-
quency of IBS symptoms (t=4.67; df=8.18; p< .01) than those who don’t fit 
the IBS criteria. In the total sample of people who stutter, IBS symptom 
frequency is correlated with all three anxiety measures (STAI r=.42**; VSI 
r=.52**; ASI r=.67**), with VSI explaining 27.4% of symptom frequency 
variance.
conclusion: It seems IBS is not more frequent in people who stutter. How-
ever, it seems that stuttering aggravates anxiety in IBS. Patients who stutter 
and have IBS seem to have more pronounced anxiety than people who 
stutter but don’t have IBS and people who have IBS but don’t stutter.
disclosure: Nothing to disclose 
P1197 The assOcIaTIOn BeTWeen jOInT hyPerMOBILITy 
syndrOMe and rOMe Iv funcTIOnaL gasTrOInTesTInaL 
dIsOrders: a case-cOnTrOL sTudy Of PrevaLence, quaLITy 
Of LIfe IMPaIrMenT, heaLThcare uTILIsaTIOn and nOn-gI 
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Introduction: Individuals with joint hypermobility syndrome (JHS) are in-
creasingly encountered within gastroenterology services and pose complex 
clinical challenges. Limited data suggests a high prevalence of functional 
gastrointestinal disorders (FGIDs) in JHS, with non-GI somatic symptoms 
a potentially relevant confounder. However, no study has addressed the 
prevalence and associations for FGIDs in subjects with JHS against age and 
sex-matched general population-based controls.
aims & Methods: An Internet based cross-sectional general health survey 
was completed by 642 subjects with JHS - recruited with the help of the 
charity organization Ehlers-Danlos Support UK - and 642 age/sex-matched 
population controls from the UK. The mean age was 39 years (SD 13) and 
96% were female. The survey enquired for FGIDs using the Rome IV di-
agnostic questionnaire, non-GI somatic symptoms, quality of life, and 
healthcare utilisation. FGID prevalence data was compared between the 
groups, with subsequent logistic regression models (adjusting for the 
number of non-GI somatic symptoms) used to determine the associations 
for FGIDs and healthcare utilisation in subjects with JHS compared to the 
general population.
results: Nearly all subjects (98%) with JHS fulfilled symptom-based crite-
ria for any Rome IV FGID compared with 46% of the general population. 
The parts of the digestive tract most commonly affected by FGIDs in JHS 
and control subjects were the bowel (90% vs. 39%, respectively), gastro-
duodenal (70% vs. 13%) and anorectal (54% vs. 10%) regions. Moreover, 
those with JHS were more likely than the general population to have FGIDs 
in ≥ 2 regions (84% vs. 16%). Subjects with JHS reported a higher number 
of non-GI somatic symptoms (9 vs. 4.4), poorer mental and physical qual-
ity of life scores, and greater healthcare utilisation such as physician con-
sultations, abdominal surgeries, use of opiates (84% vs. 28%) and neu-
romodulators (43% vs. 20%). Following adjustments for non-GI somatic 
symptoms, the association of FGIDs and healthcare utilisation in subjects 
with JHS was reduced by up to fourfold and in some instances eliminated.
conclusion: This large case-control study shows that individuals with 
JHS report a very high prevalence of Rome IV FGIDs and incur consid-
erable health impairment and health care utilisation. These associations 
are drastically reduced when controlling for non-GI somatic symptoms. 
Hence, reducing non-GI somatic symptoms should be considered as an 
early therapeutic target in JHS.
disclosure: Nothing to disclose 
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P1198 dIfference Of The defecaTIOn desIre BeTWeen 
cOnsTIPaTed PaTIenTs and nOn-cOnsTIPaTed PaTIenTs: 
a Large-scaLe InTerneT survey
Ohkubo H.1, Takatsu T.1, Misawa N.1, Yoshihara T.1, Ashikari K.1, Fuyuki A.1, 
Matsuura T.1, Higurashi T.1, Yamamoto K.2, Nakajima A.1
1Yokohama City University Hosp., Dept. of Gastroenterology, Yokohama, 
Japan, 2Yokohama City University, Biostatistics, Yokohama, Japan
contact e-Mail address: ohkuboh@yokohama-cu.ac.jp
Introduction: Chronic constipation (CC) is a functional bowel disorder with 
a high prevalence worldwide. However, treatment satisfaction and qual-
ity of life (QOL) is low, and several clinical problems remain unresolved 
today. Loss of defecation desire (LODD) is presumed to be one cause of 
impaired QOL; however, it is still unknown whether LODD is more common 
in patients with CC than those without. Understanding the difference of 
the defecation desire between constipated patients and non-constipated 
controls is important to help solve the clinical problems.
aims & Methods: To compare the rate of LODD between patients who had 
self-recognition of constipation and actually met the Rome-IV criteria (CC 
arm) and age-sex-matched controls who have no symptoms of constipa-
tion and do not meet the Rome-IV criteria (non-CC arm), we performed 
a nationwide internet questionnaire survey in March 2019 targeting the 
Japanese adults (aged 20-79 years old) registered in the large-scale panel 
on the website owned by Rakuten Insight, Inc. 
We used an original online questionnaire which collected information 
about sex, age, presence or absence of defecation desire, stool form, con-
stipation score, and whether meeting the Rome-IV constipation criteria or 
not. Degree of defecation desire is stratified into the following four scales; 
‘never’, ‘rarely’, ‘usually’, and ‘always’, then ‘never’ and ‘rarely’ are defined 
as LODD.
results: A total of 20990 subjects, 9669 with self-recognition of constipa-
tion and 11321 without any symptoms of constipation, were included dur-
ing the 10 days investigation period. Of the 9669, 26.8% (n=2591) met the 
Rome-IV criteria and were selected as CC arm. Rate of LODD in CC arm and 
non-CC arm was 57.4% and 8.0%, respectively (p< 0.001, OR;15.4 [13.1-
18.1]). LODD was observed evenly from young to old people in CC arm.
conclusion: This study confirmed that patients with CC are much more 
likely to decrease or lose defecation desire than non-constipated controls 
regardless of age. To improve the problematic clinical situations in this 
filed, physicians should pay more attention to ‘defecation desire’ as an 
indicator of treatment effect in daily clinical practice.
disclosure: This study was supported by Mochida Pharmaceutical Co, Ltd. 
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Introduction: Functional bowel disorders (FBDs) are defined based on dif-
ferent combinations of abdominal pain, bloating/distension, and abnor-
mal bowel habits, i.e. diarrhea or constipation. Which of these symptoms 
patients consider most bothersome varies between individuals.
aims & Methods: We aimed to examine how the most bothersome bowel 
symptom differs between different FBDs and how this relates to health 
care utilization, quality of life, non-GI symptoms and demographic fac-
tors in the general population. A community sample of 6,300 adults 18 
years and older in the US, United Kingdom (UK) and Canada (2,100 in each 
country) completed a secure online survey. Quota-based sampling was 
used to ensure equal proportion of sex and age groups across countries, 
and to control education distributions. The survey included the Rome IV 
diagnostic questionnaire for adults, the Short Form - 8 (SF-8) quality of life 
questionnaire, the Patient Health Questionnaire - 12 (PHQ-12) for non-GI 
somatic symptoms, questions on health care utilization, abdominal sur-
gery, use of medications, and question about the most bothersome of the 
four symptoms defining FBD in the past three months.
results: Data from 5,931 individuals were retained for analysis (49.2% fe-
male; mean age 47.4 (range 18-92) years) after 369 inconsistent respond-
ers were eliminated. Rome IV criteria for FBDs were fulfilled by 27.8% of 
subjects. The symptoms most commonly reported to be most bothersome 
by FBD subjects were “watery or mushy stools, or having many bowel 
movements in a day” (29%), and “hard stools or going several days with-
out having a bowel movement” (25%), followed by abdominal bloating or 
distension (21%) and abdominal pain (17%). The most commonly reported 
most bothersome symptom among individuals with IBS was abdominal 
pain (40%), in functional constipation and in opioid-induced constipa-
tion it was hard and infrequent stools (44% and 61%), and in functional 
diarrhea and functional abdominal bloating/distension all patients report-
ed that the symptom defining each disorder (loose stools and bloating/
distension, respectively) was the most bothersome. For men with FBDs, 
loose, frequent stools were the most common most bothersome symp-
tom (36%), whereas this was hard, infrequent stools for females (27%). 
FBD individuals with different most bothersome symptoms also differed 
regarding healthcare utilization, quality of life, and overall somatic symp-
tom severity (Table 1): Those with abdominal pain as their most bother-
some symptoms had the poorest quality of life and highest non-GI somatic 
symptom burden, and had the highest proportion of frequent health care 
users (doctor visits ≥ once a month). The abdominal pain group also had 
the highest proportion of subjects regularly taking medications for nausea, 
acid reduction, and pain (OTC), whereas regular use of constipation and 
diarrhea medications, respectively, was most common among individuals 
with those symptoms as their most bothersome bowel symptoms.
conclusion: The most bothersome bowel symptom differs among individu-
als meeting Rome IV FBD criteria, and this influences health care utiliza-
tion, medication preference, quality of life and overall somatic symptom 
severity. Targeting the most bothersome symptom when treating FBDs 
seems relevant to improve health care outcomes.
 
abdominal 
pain 
(n=285)
Loose, 
frequent 
stools 
(n=483)
hard, 
infrequent 
stools 
(n=412)
abdominal 
bloating / 
distension 
(n=343)
p-value
Mental QOL (SF-8) 42±12 44±12 45±12 42±13 0.004
Physical QOL (SF-8) 44±10 46±11 45±12 47±10 0.001
Non-GI Somatic 
symptoms (PHQ-12)
7.9±4.4 6.2±3.5 6.5±3.3 6.3±3.5 <0.0001
Doctor visits 1+ times 
a month (%)
19% 12% 14% 12% 0.03
Abdominal surgeries 
(%)
31% 29% 28% 29% 0.86
[Table 1. Different Most Bothersome Symptoms and Associated Factors]
disclosure: Magnus Simren and Ami Sperber are members of the Board 
of Directors, and William Whitehead former board member, of the Rome 
Foundation, which sponsored the study. Olafur Palsson received research 
support from the Rome Foundation to carry out the study. 
P1200 The InTesTInaL gas quesTIOnnaIre (Igq): 
PsychOMeTrIc vaLIdaTIOn Of a neW InsTruMenT fOr 
MeasurIng gas reLaTed syMPTOMs and TheIr IMPacT 
On daILy LIfe aMOng generaL POPuLaTIOn and IBs
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contact e-Mail address: duracinsky.m@gmail.com
Introduction: Gas-related symptoms (GRS) are common among the gen-
eral population and patients with functional gastrointestinal disorders. 
There is no patient-reported outcome covering these symptoms and their 
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impact on daily life. We first performed interviews in 3 countries among 
IBS patients and general population (GP) (1). This resulted in a 43-item 
pilot questionnaire (17 symptom items with 24h recall period and 26 im-
pact items with 7-day recall). 
A psychometric validation study is reported here.
aims & Methods: One hundred subjects (60 IBS, 40 GP) complaining of 
GRS had to be included in each of the 3 countries (UK, Spain, France) to 
ensure reliable item statistics. IBS patients fulfilled ROME IV criteria with 
IBS-SSS scores between 150-300. Subjects completed the IGQ, The func-
tional Digestive Disorders Quality of Life (FDDQL) score (0-100, higher = 
better quality of life) and the generic EQ-5D. Among the 100 subjects, 30 
were asked to repeat the IGQ after a 7-day interval on paper or electroni-
cally. After item analysis and reduction, convergent/divergent (IGQ vs FD-
DQL and EQ-5D) and known-group validity (IGQ vs IBS-SSS) and test-retest 
reliability (intraclass correlation, ICC) were checked.
results: 305 subjects were included (UK: 105; Spain: 100; France: 100), 
with 186 IBS (IBS-C: 68; IBS-D: 61; IBS-M: 57), and 119 GP. Mean age was 
42±14 yrs, 69% were female. Mean IBS-SSS was 252±41 among IBS. FDDQL 
total score was 45±13 (IBS) vs 59±19 (GP). Factorial analysis (n=304) re-
sulted in a 6-factor structure, bloating symptom items loading on the first 
factor. The structure was similar among IBS and GP. Twenty-six items (10 
symptom and 16 impact items) were deleted (high floor effect or inter-item 
correlation, cross-loading or no clear loading). 
The confirmatory factorial analysis on the remaining 17 items (7 symptom 
and 10 impact items) among 302 subjects, with no missing data, yielded a 
6-factor structure explaining 67% of the variance with respectively bloating 
(6 items), flatulence (3), belching (2), bad breath (2), stomach rumbling (2) 
and difficult gas evacuation (2). Scores from 0 to 100 (worse) were com-
puted: for each of the 6 symptoms, a total score and a score gathering the 
5 other symptoms except bloating. 
Scores were worse among IBS vs GP, e.g. 75±19 vs 66±22 for total score 
(p< 0.001). IGQ total and bloating scores were correlated with the FDDQL 
global, Discomfort and Diet dimension scores (r between 0.42-0.68). Log-
ically there was no correlation between IGQ and EQ-5D. IGQ total score 
got worse in parallel with IBS-SSS (r=0.24, p=0.0006): 59±34. ICC of IGQ 
scores was between 0.47-0.84, except for flatulence (0.27) among the 67 
subjects who were considered stable at the 2nd visit after an interval of 
7.3±0.9 days. 
Similarly, the correlation between the completion of IGQ in paper vs elec-
tronic among these 67 stable subjects was high (ICC: 0.77 for global score).
conclusion: The IGQ is a robust instrument for capturing and measuring 
gas related symptoms. The final 17-item questionnaire has good psycho-
metric properties and is available in paper and electronic versions in 3 
languages.
references: (1) Chassany O, Tugaut B, Marrel A, Guyonnet D, Arbuckle R, 
Duracinsky M, Whorwell PJ, Azpiroz F. The Intestinal Gas Questionnaire: de-
velopment of a new instrument for measuring gas-related symptoms and 
their impact on daily life. Neurogastroenterol Motil. 2015 Jun;27(6):885-98.
disclosure: The study was funded by Danone. 
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Universitario Elche, Department of General Surgery, Elche, Spain, 5Hospital 
Universitari MútuaTerrassa, Universitat de Barcelona, Department of General 
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Introduction: Chronic idiopathic constipation has a favorable response 
with conservative measures in most cases, but in a small proportion of 
patients surgical strategies may be necessary, having inconsistent results. 
Sacral nerve stimulation (SNS) is a potential alternative, and as a tem-
porary device is used previous to a definite implantation, other possible 
treatments are not excluded if the result is not as expected. Results in cur-
rent published data vary, probably due to the design of the studies, small 
number of patients and the inclusion of different types of constipation.
aims & Methods: The main objective was to evaluate the short and long-
term efficacy of sacral neuromodulation (SNS) in patients with chronic 
slow transit constipation (CSTC). Secondary outcomes were to evaluate 
adverse effects of implantation of the device and to correlate the efficacy 
with transit time and anorectal manometry (AM) data. 
Methods: a multicenter, controlled, crossover randomized, double-blind 
trial was designed. Patients with CSTC(< 2 bowel movements (BM)/week; 
refractory to maximum conservative available treatment) were included 
for 4 weeks of peripheral nerve evaluation (PNE), the ones with response 
in BM(>3times/week), decreased intake of laxatives (reduction >50 % of 
laxatives or enemas/week) and subjective improvement (VAS), were im-
planted with SNS. Patients were randomly included in a 6-week ON and 
OFF stimulation period separated by a 2-week washout phase. After the 
randomization all stimulators were left in ON. A stool diary (4 weeks), 
visual analog scale (VAS), Cleveland Clinic Constipation Score (CCCS), Short 
Form Health Survey (SF-36) and a local validated survey for constipation 
(CVE-20) were evaluated at 6 and 14 weeks, every 3 months during the first 
year and then once a year. CTT and AM were performed after 6 months and 
subsequently every year.
results: 19 out of 26 patients met inclusion criteria (18 women, median 
age 52.74 years). 13 (68%) responded to PNE and underwent permanent 
SNS implantation, mean follow-up of 25.98 ± 12.65 months. When analyz-
ing ON and OFF periods, significant improvement in successful BM (21.64 
vs 15.18) p< 0,01). During the follow-up and at the end of it, 9 out of 15 
variables of the stool diary improved significantly compared to baseline, 
as well as CCCS (27,66 vs 10,99, p < 0.001) and VAS (92,79 vs 47,71 p< 0.001). 
Quality of life evaluated by SF-36 improved except in social impairment 
and with CVE-20, specific for constipation, it improved in most aspects 
except in emotional aspects. 
Anal pressures did not change, whereas rectal sensitivity for urgency de-
creased significantly. Changes in CTT (Fig 2) were also significant (171 +/-9 
vs 116 +/- 23, p< 0.004). No severe adverse events were registered, only 
mild sacral/anal pain or in the implantation site.
conclusion: In a selected group of patients with CSTC, SNS implantation 
can be an effective treatment and is associated with an improvement in 
CTT.
references: 1. Dinning PG et al. Treatment efficacy of sacral nerve stimula-
tion in slow transit constipation: a two-phase, double-blind randomized 
controlled crossover study. Am J Gastroenterol 2015; 110: 733-40. 31 12.- 
Patton V et al. Sacral nerve stimulation fails to offer longterm benefit in 
patients with slow-transit constipation. Dis Colon Rectum 2016; 59: 878-85. 
32 2. Zerbib F et al. Randomized clinical trial of sacral nerve stimulation for 
refractory constipation. Br J Surg 2017; 104: 205-13. 3. Mowatt G, Glazener 
C, Jarrett M. Sacral nerve stimulation for faecal incontinence and constipa-
tion in adults. Cochrane Database Syst Rev 2007; (3):CD004464. 4. Ganio 
E, Masin A, Ratto C, Altomare DF, Ripetti V, Clerico G, Lise M, Doglietto GB, 
Memeo V, Landolfi V, Del Genio A, Arullani A, Giardiello G, de Seta F (2001) 
Short-term sacral nerve stimulation for functional anorectal and urinary 
disturbances: results in 40 patients: evaluation of a new option for anorec-
tal functional disorders. Dis Colon Rectum 44(9):1261-1267
disclosure: Nothing to disclose 
P1202 MeTagenOMIc anaLysIs Of InTesTInaL MIcrOBIOTa 
and MycOBIOTa aMOng dIarrhea-PredOMInanT IrrITaBLe 
BOWeL syndrOMe PaTIenTs frOM argenTIna
Bustos Fernandez L.1, Man F.2, Dorribo C.1, Lasa J.S.1
1CMBF, Buenos Aires, Argentina, 2Gastro, Buenos Aires, Argentina
contact e-Mail address: luisbustosfernandez@gmail.com
Introduction: It has been suggested intestinal microbiota is associated with 
the development of diarrhea-predominant Irritable Bowel Syndrome (IBS-
D). There is scarce evidence regarding this aspect among IBS-D patients 
from a South American population. Additionally, intestinal mycobiota has 
not been exhaustively studied on this patients
aims & Methods: To describe bacterial and fungal composition of intestinal 
microbiota among Argentinean patients with IBS-D.
Adult patients with IBS-D (Rome III criteria) from Buenos Aires, Argentina 
were consecutively enrolled. One fecal sample per patient was collected 
for microbiota and mycobiota analyses. Patients completed the IBS Symp-
tom Severity Scale (IBS-SSS). Demographic features were assessed as well 
as stool consistency via the Bristol Stool Scale. After genomic DNA extrac-
tion and purification, bacterial and fungal composition of fecal samples 
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were analyzed based on 16S rDNA and ITS2 sequencing respectively. Cor-
relation between microbial and fungal abundance and the clinical features 
was assessed by Pearson correlation test.
results: 71 patients fulfilling inclusion criteria were enrolled. Firmicutes 
was the predominant phyla (73.61%), followed by Bacteroidetes (13%). A 
relatively elevated proportion of Proteobacteria (8%) was identified. Alis-
tipes was the most represented genus. When analyzing correlations be-
tween microbiota composition and different clinical features, we found 
a negative correlation (r= -0.5, p 0.003) between stool consistency score 
and butyrate-producing microorganisms, such as Butyricicoccus and Lach-
nospiraceae UCG010 genera. Symptom severity assessed by IBS-SSS was 
positively correlated with the abundance of Victivallaceae uncultured or-
ganisms, Synergistes and Ruminococcus gnavus groups genera (r= 0.42, 
0.33 and 0.32 respectively, p 0.05). ITS2 DNA sequences analysis showed 
that the predominant fungal phyla was Ascomycota (89.12%), followed by 
Basidiomycota (2.78%); Saccharomyces, Debaryomyces and Candida were 
the dominant genera. No significant correlation between mycobiota com-
ponents and clinical features was found.
conclusion: We describe the bacterial and fungal composition of intestinal 
microbiota in IBS-D patients from Argentina. Although certain significant 
correlations were identified between microbiota composition and clinical 
features such as symptom severity, the clinical implications of such find-
ings deserve further research.
disclosure: Dr. Luis Bustos Fernandez is member of the Latin American 
Board of Biocodex 
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Introduction: Little is known about changes in symptoms compatible with 
Functional GI Disorders (FGID) with increasing age at the population level, 
since most published studies have used clinical samples, and mostly focus 
on younger individuals.
aims & Methods: A community sample of 6,300 individuals age 18 and 
older in the US, UK and Canada (2,100 in each country) completed a secure 
online survey. Quota-based sampling was used to ensure equal propor-
tion of sex and age groups (40% aged 18-39, 40% aged 40-64, 20% aged 
65+) across countries, and to control education distributions. The survey 
included the Rome IV Diagnostic Questionnaire, demographic questions, 
questionnaires measuring overall somatic symptom severity and quality 
of life, and questions on health care utilization, medications and surgical 
history.
results: 6,300 individuals completed the survey. 374 were excluded due to 
inconsistent responses, leaving 5,926 (49.2% female; mean age 47.4 ±17.1 
years) for our analyses; of these 4,700 were 18-64 years and 1,226 aged 
65+. Symptoms compatible with at least one FGID were less prevalent in 
65+ (32.9%) than in subjects aged 18-64 years (41.3%) (p<0.0001). This 
difference was significant in females (38.1% vs. 49.7%; p<0.0001), but not 
in males (29.0% vs. 32.6%; p=0.08), and in the US (31.0 vs. 42.2%; p< 
0.0001) and the UK (29.4% vs. 39.3%; p<0.0001), but not in Canada (38.1% 
vs. 42.4%; p=0.12). For symptoms compatible with upper FGID (esopha-
geal and gastroduodenal), lower prevalence for most disorders was noted 
in the 65+ group (see Table). 
For lower FGID (bowel and anorectal) a different pattern was seen, with 
lower prevalence for irritable bowel syndrome (IBS), functional abdominal 
bloating/distension and proctalgia fugax in 65+, no differences in preva-
lence for the functional bowel disorders defined by abnormal bowel hab-
its, i.e. functional constipation, functional diarrhea and opioid-induced 
constipation, whereas fecal incontinence was the only FGID that was more 
common in 65+ (Table). Regarding other factors, subjects aged 65+ re-
ported less severe overall somatic symptoms, better mental, but worse 
physical quality of life, had undergone abdominal surgery more frequent-
ly, consumed more acid-reducing and pain medications, but less psycho-
tropic medications, and used health care more frequently than younger 
adults (p< 0.0001 for all).
conclusion: In general, symptoms compatible with FGID decrease in older 
adults at the population level, with the exception of fecal incontinence 
which increases, and bowel habit disturbances, which remain unchanged 
in prevalence. This pattern needs to be taken into account when planning 
GI health care for a growing population of older adults.
upper gI 
disorders:
18-64 
years
65+ 
years p-value
Lower gI 
disorders:
18-64 
years
65+ 
years p-value
Functional Chest 
Pain
1.7% 1.2% 0.25 IBS 6.5% 2.8% <0.0001
Functional 
Heartburn
2.2% 0.2% <0.0001 Functional 
Constipation
6.5% 5.7% 0.36
Reflux 
Hypersensitivity
1.7% 0.5% <0.0001 Functional 
Diarrhea
5.6% 5.0% 0.44
Globus 1.1% 0.9% 0.75
Functional 
Abd. 
Bloating/
Distent.
3.7% 2.4% 0.03
Functional 
Dysphagia
4.8% 3.4% 0.04
Unspecified 
Functional 
Bowel 
Disorder
10.3% 8.9% 0.16
Functional 
Dyspepsia
10.3% 5.4% <0.0001
Opioid-
induced 
Constipation
1.5% 1.3% 0.69
Belching 
disorders
1.0% 0.2% 0.008 Fecal 
Incontinence
2.9% 4.8% 0.002
Rumination 
Syndrome
3.7% 2.2% 0.008 Levator Ani 
Syndrome
1.9% 1.1% 0.06
Chronic Nausea 
and Vomiting 
Syndrome
1.6% 0.3% <0.0001 Proctalgia 
Fugax
5.8% 3.7% 0.003
Cyclic Vomiting 
Syndrome
1.4% 0.2% <0.0001        
Cannabinoid 
Hyperemesis 
Syndrome
0.2% 0.1% 0.70        
[Prevalence of symptoms compatible with FGID.]
disclosure: Magnus Simren and Ami Sperber are members of the Board 
of Directors, and William Whitehead former board member, of the Rome 
Foundation, which sponsored the study. Olafur Palsson received research 
support from the Rome Foundation to carry out the study. 
P1204 IncIdence Of POsT-InfecTIOus IrrITaBLe BOWeL 
syndrOMe and funcTIOnaL dysPePsIa afTer a nOsOcOMIaL 
nOrOvIrus gasTrOenTerITIs OuTBreak
Serra K., Surís G., Arajol C., Orobitg J., Camps Aler B., Gilabert P., 
Ibáñez-Sanz G., Ruiz-Cerulla A., Rodríguez-Alonso L., 
Rodríguez-Moranta F., Guardiola J.
Bellvitge University Hospital, Gastroenterology, Barcelona, Spain
contact e-Mail address: katja.serra@bellvitgehospital.cat
Introduction: Bacterial and parasitic intestinal infections are well-known 
risk factors for development of post-infectious irritable bowel syndrome 
(PI-IBS), but the natural history of viral gastrointestinal infections is poorly 
understood. In May 2017, an outbreak of Norovirus gastroenteritis (GE) was 
reported at Hospital de Bellvitge, with 250 affected workers. In order to 
determine the incidence and risk factors of functional gastrointestinal dis-
orders (FGID) after a Norovirus GE, we conducted this prospective cohort 
study with control group.
aims & Methods: By e-mail, during the 4 weeks after the GE outbreak, 
we invited all hospital workers to participate, both the affected cases and 
those who not (controls). Questionnaires evaluating digestive symptoms 
using the Rome IV criteria for IBS and functional dyspepsia (FD) were sent 
at baseline and at 6 and 12 months. The severity of the GE episode was also 
assessed using the Vesikari scale.
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results: 71 cases and 84 controls answered the questionnaires. Baseline 
characteristics of cases and controls were similar. Prior to the infectious 
episode, the prevalence of IBS and FD was identical in both groups (IBS: 
6% and 6% respectively; FD: 17% and 17% respectively, p = 0.9).
Excluding individuals with previous FGID, after 6 months of the GE the 
proportion of individuals who developed IBS or FD was higher in the case 
group than in the control group (IBS: 14% and 5% respectively, p=0.06; 
FD: 18% and 3% respectively, p=0.006). After 12 months, there were no 
differences in prevalence of IBS and FD between cases and controls (IBS: 
5% and 4% respectively, p=0.7, FD: 9% and 6% respectively, p=0.5). In-
dependent predictors of FGID were the GE severity assessed by Vesikari 
scale (OR 1.32 IC95% (1.05-1.65), p=0.017) and smoking (OR 3.9 IC95% 
(1.01-14.9), p=0.048).
conclusion: Functional gastrointestinal disorders are common after Noro-
virus gastroenteritis but they are often transient. The risk is determined by 
the severity of the infectious episode.
disclosure: Nothing to disclose 
P1205 PrevaLence and IMPacT Of seLf-rePOrTed 
cOnsTIPaTIOn In The generaL POPuLaTIOn
Pannemans J.1,2, Van den Houte K.1, Fischler B.3, Piessevaux H.4, 
Carbone F.1, Vanuytsel T.1,2, Tack J.1,2
1KU Leuven, Translational Research Center for Gastrointestinal Disorders, 
Leuven, Belgium, 2UZ Leuven, Gastroenterology, Leuven, Belgium, 3Hôpital 
Saint Pierre, Liaison Psychiatrie, Brussels, Belgium, 4Cliniques Universitaires 
Saint-Luc, Dept of Hepato-gastroenterology, Brussels, Belgium
contact e-Mail address: jasper.pannemans@kuleuven.be
Introduction: Chronic constipation, as defined by the Rome IV criteria, is 
a highly prevalent functional bowel disorder. However, as the criteria im-
pose strict diagnostic thresholds, the prevalence of self-reported constipa-
tion is considerably higher, and there is major overlap with other bowel 
disorders, especially irritable bowel syndrome. We therefore conducted a 
pooled-analysis to evaluate the presence of self-reported constipation in 
the general population, its association with other bowel symptoms and its 
health-economic impact.
aims & Methods: We used an internet survey (Medistrat internet panel, 
representative of the national adult population) to collect information on 
bowel symptoms’ prevalence and their impact. In this analysis, we fo-
cused on patients who reported constipation symptoms over the last 12 
months. First, we compared participants who experienced constipation to 
those who reported other bowel symptoms. Second, subjects reporting 
constipation were subdivided in painful constipation (PC), and those who 
did not experience abdominal pain (NPC).
results: 1012 subjects (mean age 45.2±0.5 years, 62% females), of whom 
217 (21%) reported constipation, completed the survey. Subjects report-
ing constipation experienced more other bowel symptoms than those 
without constipation [3(2-6) vs. 2(1-4), p< 0.0001]. The constipation group 
reported higher prevalence’s of abdominal pain, altered stool frequency, 
alternating bowel habits and bloating (all p< 0.05). Further, constipated 
subjects reported higher symptom occurrence ≥3 days per month (65.9% 
vs. 52.9%; p< 0.01). 
Furthermore, the days of symptom occurrence significantly differed be-
tween the constipated participants and those with other bowel move-
ments. Those with constipation had symptoms 1-2 days/week (28.6% vs. 
22.7%), while those with other bowel movements experienced symptoms 
>2 days/month more often (35.7% vs. 24.9%); (p=0.036). Finally, in total 
44% of participants with constipation reported taking laxatives for their 
complaints, compared to just 8% of those whom reported other bowel 
symptoms (p< 0.001). 
Of those with constipation, 134 patients reported NPC compared to 83 pa-
tients with PC (43±14.29 and 41±14.46 years, respectively). Women were 
significantly more represented in the group reporting constipation com-
pared to those reporting other bowel symptoms (81.57% vs. 56.60%, p< 
0.0001). Thirty-eight out of 83 PC patients (45.24%) fulfilled the Rome IV 
IBS criteria. 
More patients with NPC compared to PC marked constipation as their most 
bothersome symptom (75% vs. 44%, p = 0.014). In addition, excessive gas 
was experienced more frequently in the NPC compared to the PC group 
(64% vs. 39%, p = 0.044). PC patients also reported more consultations 
with a medical doctor (40.24% vs. 14.29%, p< 0.0001), and more visits to 
specialists (50% vs. 10%, 95% CI 1.8-44.9), but not to general practitioners 
or other doctors in the past 12 months. Concerning medication, the use of 
anti-spasmodics was significantly higher in the PC-group compared to the 
NPC-group (38.24% vs. 12%, p=0.025).
conclusion: Self-reported constipation, often associated with other bowel 
symptoms, is a highly prevalent condition in the general population. Es-
pecially when abdominal pain is present, this generates major healthcare 
costs.
disclosure: Nothing to disclose 
P1206 exTra-gasTrOInTesTInaL syMPTOMs characTerIze 
cLusTers Of funcTIOnaL gasTrOInTesTInaL dIsOrders ThaT 
are nOT readILy dIsTInguIshed By rOMe III crITerIa
Wilder-Smith C.H.1, Mohr Drewes A.2, Olesen S.S.2, Materna A.1
1Brain-Gut Research Group, Gastroenterology Group Practice, Bern, 
Switzerland, 2Aalborg University Hospital, Dept. of Gastroenterology 
and Hepatology, Aalborg, Denmark
contact e-Mail address: info@ggp.ch
Introduction: Functional gastrointestinal disorders (FGID) are defined ac-
cording to the Rome criteria by the grouping of non-specific GI symptoms 
without demonstrable underlying organic pathology. These definitions do 
not consider extra-GI symptoms or extra-GI pathology. The non-specific GI 
symptoms accompany a wide range of pathologies, including some with-
out primary GI origin.
aims & Methods: The aim of this large single-centre study was to char-
acterize subgroups of FGID patients based on GI and extra-GI chronic 
symptom profiles using cluster analysis. Furthermore, the relationships 
between retrieved clusters and different Rome III groups of FGID were as-
sessed. Successive male and female patients over 18 years of age referred 
to our GI practice for investigation of FGID and without evidence of organic 
disease were included. Patients completed a standardized, extensive GI 
and extra-GI symptom questionnaire focusing on their long-term symptom 
profiles and FGID was classified according to the Rome III criteria. The 
long-term symptom profile data were subjected to latent class analysis to 
identify unobserved clustering in the patient population and to find mean-
ingful groups that were similar in their clinical assessment parameters. 
For each patient cluster, the prevalence of irritable bowel syndrome (IBS), 
functional dyspepsia (FD), functional bloating (FB), functional diarrhoea 
(FDa) and functional constipation (FCo) was determined.
results: In 2083 patients with FGID (mean age 39.7 years, 70% females), 
the optimal number of clusters was 6. Face validity was apparent, with 
some distinctions seen between clusters in distributions of GI symptoms, 
but more apparent differences seen for distributions of extra-GI symptoms. 
GI fermentation-type symptoms were present across all 6 clusters and ex-
clusively characterized Cluster 1 (35% of patients). The further clusters 
were distinguished by additional reflux-like (cluster 2: 19%), allergy-like 
(cluster 3: 6%), central nervous system (cluster 4: 17%), musculoskeletal 
(cluster 5: 10%), and generalized extra-GI (cluster 6: 14%) symptoms. Us-
 
cluster 1 
gI fermentation-like 
(n=736)
cluster 2 
fermentation + 
reflux-like 
(n=117)
cluster 3 
fermentation + 
allergy-like 
(n=391)
cluster 4 
fermentation + central 
nervous system 
(n=348)
cluster 5
fermentation + 
musculoskeletal 
(n=208)
cluster 6 
fermentation + 
generalized extra-gI 
(n=283)
p-values
Irritable bowel syndrome 195 (26) 35 (39) 138 (35) 126 (36) 68 (33) 110 (39) 0.001
Functional dyspepsia 605 (82) 91 (78) 373 (95) 319 (92) 182 (88) 269 (95) <0.001
Functional bloating 67 (9) 12 (10) 7 (2) 8 (2) 9 (4) 5 (2) <0.001
Functional diarrhoea 248 (34) 35 (30) 149 (38) 118 (34) 69 (33) 107 (38) 0.42
Functional constipation 89 (12) 16 (14) 67 (17) 75 (22) 34 (16) 63 (22) <0.001
[P1206 Patients numbers (%) defined by Rome III subgroups in symptom clusters. There is considerable overlap between Rome groups.]
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ing Rome III criteria, the prevalence of the FGID subtypes differed signifi-
cantly between the 6 symptom clusters (see Table): 
IBS (26-39%; p=0.001), FD (78-95%; p<0.001), FB (2-9%; p<0.001), FDa 
(30-38%; p=0.42) and FCo (12-22%; p<0.001). The differences in preva-
lence of FGID subtypes across the symptom clusters were statistically sig-
nificant, but mostly not clinically relevant (see Table).
conclusion: Patients with FGID fall into distinct subgroups based mainly 
on their extra-GI long-term symptoms. The Rome III definitions did not 
readily distinguish between subgroups of FGID across the clusters. Inclu-
sion of extra-GI symptoms in the classification of FGIDs may be helpful 
in identifying subgroups with distinct underlying pathologies and thereby 
therapeutic possibilities.
disclosure: Nothing to disclose 
P1207 dOes InTesTInaL MIcrOBIOTa cOMPOsITIOn dIffer 
BeTWeen dIarrhea-PredOMInanT IrrITaBLe BOWeL syndrOMe 
PaTIenTs WITh Or WIThOuT an aLTered LacTuLOse BreaTh 
TesT?
Bustos Fernandez L.1, Man F.2, Dorribo C.1, Lasa J.S.1
1CMBF, Buenos Aires, Argentina, 2Gastro, Buenos Aires, Argentina
contact e-Mail address: luisbustosfernandez@gmail.com
Introduction: Background: It has been suggested that the intestinal micro-
biota is associated with the development of diarrhea-predominant Irrita-
ble Bowel Syndrome (IBS-D). A significant proportion of such patients ex-
hibit abnormal hydrogen excretion on lactulose breath tests, which could 
be associated with small intestinal bacterial overgrowth (SIBO). Patients 
with IBS-D and an abnormal lactulose breath test may show a different 
intestinal microbiota profile, which could be associated with such altera-
tions in gas excretion.
aims & Methods: To compare the bacterial and fungal composition of in-
testinal microbiota of IBS-D Argentinean patients with or without SIBO.
Adult patients with IBS-D (Rome III criteria) were consecutively enrolled. 
One fecal sample per patient was collected for microbiota and mycobiota 
analyses. Furthermore, patients undertook a lactulose breath test (LHBT). 
An increase of at least 20 ppm in hydrogen excretion before 100 minutes 
was considered to be a criterion for SIBO. After genomic DNA extraction 
and purification, bacterial and fungal composition of fecal samples were 
analyzed based on 16S rDNA and ITS2 sequencing respectively.
results: 71 patients were enrolled; mean age was 43.5±14.5 years and 
62% were female. 76% were SIBO positive. No significant differences 
were found in terms of demographic features between SIBO-positive 
and SIBO-negative patients. 16S rDNA alpha and beta diversity analyses 
showed comparable microbiota composition between SIBO positive and 
SIBO negative. However, Akkermansia genus and upper-related taxa were 
significantly more abundant (+672%, p=0.009) in SIBO negative patients. 
Furthermore, Turicibacter genus and upper-related taxa were also more 
abundant (+535%, p=0.04) in SIBO negative patients. Cloacibacillus ge-
nus was greatly increased in SIBO negative patients (+8463%, p=0.0006). 
On the other hand, Ruminococcaceae UCG 003 and Ruminoclostridium 
9 genera were decreased in SIBO negative patients (-70% and -46.6%, 
p=0.003 and 0.0007, respectively). Mycobiota analyses showed no major 
difference.
conclusion: Differences in terms of bacterial and fungal composition of in-
testinal microbiota were found between SIBO-positive and SIBO-negative 
IBS-D patients. Clinical implications of these findings require further in-
vestigation.
disclosure: Dr Bustos Fernandez is memeber of thge Latin American Board 
of Biocodex 
P1208 The InTra-IndIvIduaL varIaBILITy Of fecaL 
caLPrOTecTIn In heaLThy IndIvIduaLs
Netzer S.1, Netzer P.1,2
1GastroZentrum Netzer AG, Bern, Switzerland, 2Lindenhofspital, Bern, 
Switzerland
contact e-Mail address: serainanetzer@rocketmail.com
Introduction: Fecal Calprotectin (FC) is a marker for intestinal inflamma-
tion, which allows the clinician to distinguish between functional and or-
ganic intestinal illnesses, as well as to evaluate the activeness of disease 
in chronic inflammatory bowel disease (IBD). There are singular studies 
that report day-to-day variability in FC concentration measured in patients 
with IBD. If such a variation also exists in healthy individuals has not been 
evaluated as of yet.
aims & Methods: Our aim was to determine the intra-individual day-to-
day variability of FC in the intestinally healthy. The results could influence 
the further management of patients with intestinal discomfort. To achieve 
this, 163 healthy volunteers without gastrointestinal symptoms, colitis re-
lated manifestations or intake of NSAID gave three stool samples of the 
morning bowel movement on three consecutive days. The samples were 
sent via mail. The FC-analysis was made by enzyme-linked immunosor-
bent essay (ELISA) method after Bühlmann (Rothen Medizinische Labora-
torien AG Basel). 
Material was financed by Netzer AG, analysis by MCL Laboratorien Nieder-
wangen. The threshold to pathological FC- values was 50µg/g, as recom-
mended in Switzerland. Volunteers with elevated values were investigated 
further, only those remained in the study who had no signs of organic 
gastrointestinal disease.
results: 163 volunteers (aged 17-66y, mean 37y, median 32y, f=100), showed 
a range of FC-values of 3 - 2142 µg/g. The first measurement showed a 
range of 3 - 587 µg/g, mean value 44.5, median 20, standard deviation 
(sd) 75.1. The second measurement showed a range of 6 - 2142 µg/g, mean 
value 60.3, median 22, sd 183.4. The third measurement showed a range 
of 9 - 699 µg/g, mean value 41, median 18, sd 73.7. Every one of the three 
measurement series showed only two values >400 µg/g. Of all 163 vol-
unteers, 114 (69.9%) showed FC- values of 50µg/g and lower in all three 
samples, thus having inconspicuous results throughout. 49 volunteers 
(30.1%) showed at least one value deemed pathologic. Of these 49, 40 
(24.5%) showed both normal and elevated (>50µg/g) values and 9 (5.5%) 
showed elevated values throughout. By applying a cut-off of 100µg/g, 26 
volunteers (15.9%) showed at least one elevated measurement and only 4 
(2.5%) had values consistently over 100µg/g.
conclusion: The presented data show a high variability of FC in a short 
amount of time in a third of the healthy volunteers. This suggests several 
measurements of FC to be adequate to reach a decision if further inves-
tigation (e.g. endoscopy) is necessary. The mean value of three measure-
ments could show a higher correlation to actual intestinal inflammation 
and could help reduce unneeded interventions. Further investigations in 
a non-healthy population are recommended. The data also support the 
question, if raising the cut-off to 100µg/g would be appropriate to keep 
the rate of false positive results low without missing relevant disease, as 
several investigators have recommended already.
disclosure: Nothing to disclose 
P1209 IrrITaBLe BOWeL syndrOMe and gLuTen chaLLenge: 
resuLTs Of a randOMIzed sIngLe-BLInd cOnTrOLLed TrIaL
Rostami-Nejad M.1, Mohaghegh H.2, Saadati S.2, Sadeghi A.2, Rostami K.3, 
Asadzadeh-Aghdaei H.2, Zali M.R.4
1Gastroenterology and Liver Disease Research Institute, Celiac Disease, 
Tehran, Iran (Islamic Republic of), 2Gastroenterology and Liver Diseases 
Research Center, Research Institute for Gastroenterology and Liver Diseases, 
Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic 
Republic of), 3Palmerston Hospital, Departments of Gastroenterology, Mid 
Central DHB, Palmerston North, New Zealand, 4Shaheed Beheshti University 
of Medical Sciences, Tehran, Iran (Islamic Republic of)
contact e-Mail address: m.rostamii@gmail.com
Introduction: The major dilemma in medical practice is the gluten toler-
ance assess in IBS patients and evaluation of symptoms in different dosage 
of gluten challenge. For this purpose, we designed a single-blind free diet 
controlled gluten challenge to report a true NCGS prevalence among IBS 
patients
aims & Methods: In this trial, 40 participants were asked to follow low 
FODMAP+ strict gluten free diet for 6 weeks. Then, all patients were ran-
domly allocated to one of the following groups: 
Group A: patients received special bread containing of 8 g/ gluten for 2 
weeks. Those who had tolerance to prescribed dose received 16 g/d for 
more 2 weeks. Then tolerated patients took 32 g/d for further 2 weeks; 
Group B: continued gluten free diet for more 6 weeks; 
Group C: received regular gluten containing diet for 6 weeks. 
At the end, participants were asked to fill VASs scale to evaluate the im-
provement of symptoms, SF-36 and Zung questionnaire.
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results: After 6 weeks of following gluten free and low FODMAP diet, all 
IBS symptoms, except for defecation frequency, were significantly im-
proved. In group A: 25% tolerated up to 8 g 20% to 16 g, and 55% to 32 g 
gluten. At the end of the study, no significant difference was found between 
groups in terms of pain, bloating, satiety, impact on community function, 
defecation and total score. In regard to SF-36 questionnaire, significantly 
lowest bodily pain was found in group C (A: 3.93±1.44, B: 4.71±2.33 and C: 
3.29±0.95) (p=0.02). Borderline significant difference was detected for so-
cial functioning score (p=0.049). There was significant reduction regarding 
nervous and anxiety score (p=0.021), calmness (p=0.047), dry and warm 
hands (p=0.02) and easily asleep (p=0.01) in group B compared other 
groups.
conclusion: Most patients with irritable bowel syndrome have tolerance 
to gluten. But following gluten free diet would decrease anxiety in IBS 
patients.
disclosure: Nothing to disclose 
P1210 OsTeOPOnTIn has nO rOLe as a dIagnOsTIc 
BIO-Marker In IrrITaBLe BOWeL syndrOMe (IBs)
Mostafa H.1, Zaghloul M.2, Khalil G.I.3, Dwidar F.I.4
1Alexandria University, Medical Research Institute, Internal Medicine, 
Alexandria, Egypt, 2Kafrelsheikh University, Faculty of Medicine, Hepatology, 
Gastroentrology and Infectious Diseases, Alexandria, Egypt, 3Alexandria 
University, Medical Research Institute, Chemical Pathology, Alexandria, 
Egypt, 4Alexandria University, Medical Research Institute, Alexandria, Egypt
contact e-Mail address: mariam_zaghloul@med.kfs.edu.eg
Introduction: Osteopontin (also known as early T lymphocyte activation 
Eta-1), a cytokine which promotes Th1 immune responses. Several recent 
reports have suggested an important role for osteopontin in the patho-
gensis of inflammatory bowel diseases as well as its possible use as a 
bio-marker. It has been proposed that inflammation may play a role in IBS, 
based on several lines of evidence.
aims & Methods: The aim of this work was to find out the diagnostic po-
tential of osteopontin as bio-marker in irritable bowel syndrome. 40 pa-
tients, who were fulfilling Rome IV criteria for IBS, were investigated. As 
well as 20 healthy subjects were enrolled as controls.All subjects were 
subjected to:medical history taking,thorough physical examination and 
laboratory investigations which included:-Routine laboratory tests ,fecal 
calprotectin assessment and serum osteopontin assessment.Colonoscopy 
and histopathological examination of biopsies from the colon were done 
for patients only after informed consent.
  IBs cases (n = 40) control (n = 20) t p
ESR at 1st hrs (mm/hr)        
Mean ± SD 12.13 ± 2.05 11.80 ± 2.38 0.548 0.586
Median 13.0 13.0    
ESR at 2nd hrs (mm/hr)        
Mean ± SD 24.55 ± 3.17 23.25 ± 4.38 1.315 0.194
Median 25.0 23    
CRP (mg/l)        
Mean ± SD 4.44 ± 1.53 4.13 ± 1.10 0.791 0.432
Median 4 4    
Calprotectin (mg/kg)        
Mean ± SD 28.60 ± 19.24 21.75 ± 9.08 1.872 0.066
Median 19 20    
Osteopontin (ng/mL)        
Mean ± SD 2.92 ± 0.91 2.50 ± 0.78 1.748 0.086
Median 2.80 2.25    
[Comparison between the two studied groups according to the markers of 
inflammation]
results: Out of 40 patients (group I); 20 were IBS-D (diarrhea predomi-
nant), 14 IBS-C (constipation predominant) and 6 IBS-A (alternating diar-
rhea and constipation). Both group I and group II were matched as regard 
age and sex. There were no statistical significant difference between the 
two studied group in routine laboratory investigations. Stool analysis was 
normal in all subjects. No statistical significant difference between the two 
groups as regard the mean erythrocytes sedimentation rate (ESR) at the 
first and second hour [p = 0.586& 0.194 respectively]. Also no statistical 
significant difference between the two groups as regard the mean C-reac-
tive protein (CRP), the mean fecal calprotectin level and the mean serum 
osteopontin level [p = 0.432, 0.066 &0.086 respectively]. As regard colono-
scopic findings in IBS patients: Hyperemia was found in 4 patients, polyps 
were found in 2 patients, diverticulae, ulcers and mass were not found 
in any patients. Regarding histopathological findings of colonoscopic bi-
opsies in IBS patients: Non specific colitis was found in 30 patients and 
10 patients were normal. Lymphocytic colitis was not found in any of the 
patients group. 
conclusion: Osteopontin has no role as a diagnostic bio-marker in IBS. 
Further work on a larger patients sample will be required to study the 
probability of the use of osteopontin as non invasive bio-marker in the 
differentiation between functional and inflammatory gastrointestinal dis-
orders.
references: 1. Sperber AD, Drossman DA. Review article: the functional 
abdominal pain syndrome.Aliment PharmacolTher 2011; 33: 514-24. 2. No-
baek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal 
microflora is associated with reduction in abdominal bloating and pain in 
patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-
8. 3. Ortiz-Lucas M, Saz-Peiró P, Sebastián-Domingo JJ.Irritable bowel syn-
drome immune hypothesis. Part one: the role of lymphocytes and mast 
cells.Rev Esp Enferm Dig 2010;102:637-47. 4. Grover M, Herfarth H, Dross-
man DA. The functional-organic dichotomy: postinfectious irritable bowel 
syndrome and inflammatory bowel disease irritable bowel syndrome.Clin-
GastroenterolHepatol 2009; 7:48-53.
disclosure: Nothing to disclose 
P1211 BOTh OBjecTIve exPerIMenTaL and naTuraLIsTIc 
resPOnses dIfferenTIaTe gasTrOInTesTInaL syMPTOMaTIc 
frOM asyMPTOMaTIc IndIvIduaLs
Jones M.P.1, Beath A.P.2, Talley N.J.3, Holtmann G.J.4, Koloski N.A.5, 
Walker M.M.6, Ejova A.7
1Macquarie University, Dept. of Psychology, North Ryde, Australia, 
2Macquarie University, Dept. of Psychology, Sydney, Australia, 3University 
of Newcastle, Faculty of Health & Medicine, Callaghan, Australia, 4Princess 
Alexandra Hospital, Gastroenterology & Hepatology, Brisbane, Australia, 
5University of Newcastle, Callaghan, Australia, 6University of Newcastle, 
Dept. of Anatomical Pathology, Newcastle, Australia, 7University of Auckland, 
School of Psychology, Auckland, New Zealand
contact e-Mail address: mike.jones@mq.edu.au
Introduction: An objective method of differentiating functional gastroin-
testinal disease (FGID) from health remains an elusive goal although there 
has been some promising work using biomarkers1. Another potential av-
enue comes from work showing that FGID individuals have altered central 
(brain and central nervous system) processing of visceral stimuli relative 
to healthy controls2. Further, FGID individuals appear to have selective at-
tention to gastrointestinal words3 suggesting an attentional bias towards 
GI-relevant terms. Individuals meeting criteria for FGIDs have also been 
shown to exhibit exaggerated threat perception4. Previous work has taken 
either an experimental approach, eg fMRI studies of acute, regional brain 
activation in response to noxious stimuli, or an epidemiological approach 
based on measuring symptom experiences by questionnaires or daily di-
ary record. How well gastrointestinal disease might be differentiated from 
health based on a combination of these distinct objective and subjective 
profiles is lacking in the literature.
aims & Methods: This study aimed to determine whether a combination 
of objective responses to experimental stimuli (EEG, below) and subjective 
but prospectively recorded, naturalistic responses to daily events (EMA, 
below) can differentiate symptomatic and asymptomatic individuals. 28 
GI symptomatic and 27 asymptomatic individuals were recruited from the 
community. Organic pathology and current mood disorders were ruled out 
by self-report. All subjects viewed 20 GI-illness-related words, 20 nega-
tively-valenced words, and 20 neutral words from a validated word bank 
six times in a randomised order. Attention was measured through ERP 
peak amplitude in the Occipital region measured via an electroencepha-
lograph (EEG) in the P100 period (75-125 milliseconds after word stimulus 
presentation), as this clearly corresponds to pre-attentional processing. Av-
erage level and variability in gastrointestinal and non-gastrointestinal pain 
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as well as mood were recorded prospectively using ecological momentary 
assessment5 (EMA) via a smartphone app over a 14-day period. Total GI 
symptom burden was measured through the gastrointestinal symptom rat-
ing scale6 (GSRS). Discrimination between symptomatic and asymptomatic 
subjects was evaluated through the area under the ROC curve (AUC).
results: GI symptomatic subjects yielded a higher average P100 response 
to all stimulus categories than asymptomatic subjects (b=1.28, 95% con-
fidence interval 0.74, 1.82, p< .001), consistent with enhanced threat per-
ception but not limited to GI concepts. A combination of increased P100 
response amplitude, higher average level and greater variance in current 
mood and higher average level and greater variance in GI pain and higher 
average level and greater variance in non-GI pain yielded strong dis-
crimination between symptomatic and asymptomatic subjects (AUC=0.90) 
which increased to AUC=0.93 if total GI symptom burden is included.
conclusion: In contrast to a large body of past work which has used an 
individual’s recall of past symptom experience to classify individuals as 
diseased or healthy, this study demonstrated prospectively that FGID in-
dividuals have a distinct day-to-day experience of both GI and extra-GI 
pain and respond to experimentally-induced stimuli differently to asymp-
tomatic individuals. The combination of these responses provide good dif-
ferentiation of symptomatic individuals from healthy controls. The use of 
non-invasive, inexpensive stimuli offers a promising avenue of investiga-
tion for objective diagnostic testing.
references: 1. Jones MP, Chey WD, Singh S, et al. A biomarker panel and 
psychological morbidity differentiates the irritable bowel syndrome from 
health and provides novel pathophysiological leads. Alimentary phar-
macology & therapeutics. 2014;39(4):426-437. 2. Rubio A, Pellissier S, 
Van Oudenhove L, et al. Brain responses to uncertainty about upcom-
ing rectal discomfort in quiescent Crohn’s disease - a fMRI study. Neu-
rogastroenterology & Motility. 2016:n/a-n/a. 3. Gibbs-Gallagher N, Pals-
son OS, Levy RL, Meyer K, Drossman DA, Whitehead WE. Selective recall 
of gastrointestinal-sensation words: evidence for a cognitive-behavioral 
contribution to irritable bowel syndrome. The American journal of gas-
troenterology. 2001;96(4):1133-1138. 4. Crane C, Martin M. Risk Perception 
in Individuals With Irritable Bowel Syndrome: Perceived Susceptibility to 
Health and Non-Health Threats. Journal of Social and Clinical Psychology. 
2004;23(2):216-239. 5. Mujagic Z, Leue C, Vork L, et al. The Experience Sam-
pling Method--a new digital tool for momentary symptom assessment in 
IBS: an exploratory study. Neurogastroenterology and motility : the official 
journal of the European Gastrointestinal Motility Society. 2015;27(9):1295-
1302. 6. Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for 
gastrointestinal symptoms in patients with irritable bowel syndrome and 
peptic ulcer disease. Digestive diseases and sciences. 1988;33(2):129-134
disclosure: Nothing to disclose 
P1212 The severITy Of gasTrOInTesTInaL syMPTOMs 
as a PredIcTOr Of TreaTMenT effecT In a 12- Week 
MuLTIdIscIPLInary InTegraTed TreaTMenT aPPrOach fOr 
funcTIOnaL gasTrOInTesTInaL dIsOrders (fgIds)
Bray N.1, Koloski N.A.1,2,3, Jones M.P.4, Chao C.-Y.3, Billin A.3, Bettens G.3, 
McAllister S.3, Arthur L.3, Campos J.3, Talley N.J.2,5, Holtmann G.J.1,3
1University of Queensland, School of Medicine, Brisbane, Australia, 
2University of Newcastle, Faculty of Health & Medicine, Callaghan, Australia, 
3Princess Alexandra Hospital, Gastroenterology & Hepatology, Brisbane, 
Australia, 4Macquarie University Psychology, Psychology, North Ryde, 
Australia, 5Australian Gastrointestinal Research Alliance (AGIRA), Newcastle, 
Australia
contact e-Mail address: g.holtmann@uq.edu.au
Introduction: Current treatment for FGIDs categorise patients based on 
symptoms and attempt to target potential biological disease mechanisms, 
yet extensive literature suggests FGIDs result from interactions between 
biological, psychological and social factors. Therefore, a biopsychosocial 
framework for treatment for FGIDs should be considered. We have previ-
ously demonstrated that an Integrated Care Clinic (ICC) approach incor-
porating a multidisciplinary integrated treatment program in the setting 
of a gastroenterology outpatient department (OPD) significantly reduces 
overall gastrointestinal (GI) symptom burden in FGID patients. This study 
aimed to identify whether the effect of the intervention is moderated by 
the severity of GI symptom burden at baseline, to help identify predictors 
that may characterise a patient’s response to a multidisciplinary integrated 
treatment program.
aims & Methods: This study explored total GI symptom burden at baseline 
as a predictor of reduction in total GI symptom burden post intervention. 
51 consecutive gastroenterology outpatients recruited to the ICC were in-
cluded. These patients received a team-based integrated care approach 
including individualised assessment and treatment sessions with a gas-
troenterologist, general practitioner, psychologist, dietician and exercise 
physiologist, as deemed necessary by the team to meet the patient’s 
needs. 
Patients were grouped into total GI symptom burden-stratified subgroups 
according to baseline gastrointestinal symptoms severity as measured 
using the validated Structured Assessment of Gastrointestinal Symptoms 
scale (SAGIS) which measures the intensity of 22 upper and lower gas-
trointestinal symptoms, 0 = no problem to 4 = very severe problem for 
a maximum score 88 points. Stratification groups were based on mean 
baseline score (M = 27): low for total SAGIS score below 27 and high for 
total SAGIS score above 27. Within-subject changes were compared using 
a paired sample t-test and change scores between GI symptom severity 
strata were compared using an unpaired t-test.
results: Mean age was 41.7 (SD-14.90) years with 84% females. In total, 
53% of patients had irritable bowel syndrome, 10% had functional dys-
pepsia, and 37% had overlap of both. The mean baseline score was 27 and 
the overall mean change in total GI symptom burden post intervention was 
9 units; by total GI symptom burden strata the mean was 4 units for the GI 
symptom burden low group and 14 units for the GI symptom burden high 
group. Total GI symptom burden significantly decreased from baseline (p < 
0.015 by paired t-tests within both groups). 
However, the decrease was higher in the GI symptom burden high group 
than the GI symptom burden low group (p = 0.002 comparing the change 
scores between the two groups using an unpaired t-test). Clinically sig-
nificant reductions in total SAGIS score were present in 70% of the total 
GI symptom burden high group compared to 33% of the total GI symptom 
burden low group.
conclusion: These results indicate that total GI symptom burden indepen-
dent of varying GI total symptom burden is reduced by a multidisciplinary 
integrated treatment approach in FGID patients However, the reductions 
were substantially greater in patients with more severe manifestations of 
FGID, and this will need to be considered in future studies on the cost-
benefit analysis of multidisciplinary treatment approaches.
disclosure: Nothing to disclose 
P1213 recruITMenT In funcTIOnaL BOWeL dIsOrder sTudIes: 
Why Is IT sO chaLLengIng?
Howell C.1, Kemppinen A.2, Markaryan E.3, Allgar V.4, Pandya P.5, 
McLaughlin J.6, Whorwell P.7, Dodd M.8, Gregson J.8, Knowles C.H.9, 
Yiannakou Y.10
1Enteromed Ltd, Research, London, United Kingdom, 2Clever Cookie Ltd, 
Cambridge, United Kingdom, 3Enteromed Ltd, London, United Kingdom, 
4University of York, Department of Health Sciences, York, United Kingdom, 
5Thornton Medical Centre, Thornton-Cleveleys, United Kingdom, 6University 
of Manchester, Diabetes, Endocrinology and Gastroenterology in the Faculty 
of Biology, Manchester, United Kingdom, 7University Hospital of South 
Manchester, South Manchester Neurogastroenterology Service, Manchester, 
United Kingdom, 8London School of Hygiene & Tropical Medicine, 
Department of Medical Statistics, London, United Kingdom, 9Queen Mary 
University of London School of Medicine NCBRSI, NBRC, London, United 
Kingdom, 10University Hospital of North Durham, County Durham and 
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contact e-Mail address: yan.yiannakou@nhs.net
Introduction: Recruitment can be a major challenge to randomized clinical 
trials, and failure to achieve recruitment goals can endanger the overall 
quality of the study and lead to costly delays and non-completion [1]. In 
functional bowel disorder (FBD) studies, recruitment rates are particularly 
low and many studies fail to recruit patients on time and within bud-
get [2]. Several factors attribute to this failure. Although FBD is relatively 
common, patients are often discharged quickly and have limited chance 
to build a rapport with the research team. Conversely patients who are 
not discharged often have severe refractory symptoms, rendering them 
far from ideal for most trials. Patients are often reluctant to come off laxa-
tives/anti-diarrhoeals, thus are not keen to risk being on placebo, and are 
less willing to undertake the trial burden compared to studies of higher 
mortality conditions.
679Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
aims & Methods: Our aim was to design a study for irritable bowel syn-
drome with diarrhoea (IBS-D) that was both deliverable and would maxi-
mise recruitment potential. The trial RELIEVE IBS-D, is currently recruiting 
430 patients in 27 sites in the UK studying the effectiveness of the intestinal 
adsorbent Enterosgel for the treatment of IBS-D. We developed a study 
that was suitable for primary and secondary care recruitment, and that 
included pragmatic (real life) inclusion / exclusion criteria with low screen 
thresholds. Patient involvement (PPI) was used in both study design and 
all patient-facing documentation. An open label phase was included so 
that all patients received the intervention, as it is known that obtaining a 
form of personal gain through participation is a primary factor influencing 
participation in clinical trials.
Rescue therapy was only restricted for baseline and a re-screening phase 
was introduced to compensate for the variable nature of the condition [3]. 
Patient burden was restricted with a reduced visit number, low question-
naire number and an online daily diary with text-based reminders and 
limited number of questions. Following the guidelines, participants were 
encouraged to adjust their daily dosage during both phases based on their 
symptoms to better imitate “real world conditions” [4].
Several recruitment strategies are being employed. We use primary care 
patient identification centres for hospital sites to reduce attrition rates [5] 
and we contact eligible patients through the new ContactME IBS registry 
that enrols patients who have expressed an interest in research participa-
tion. A number of sites are also leveraging Clinithink Inc software that 
allows extensive mining of hospital records for eligible patients. We have 
used various forms of advertising through social media to gain a good rep-
resentation of the clinical profile of IBS patients in the general population.
results: The study began in October 2018 with recruitment starting in No-
vember, as of end of March 2019, 94 patients have been consented and 41 
randomised. These rates are expected to increase as the main recruitment 
strategies will be employed in April to coincide with IBS awareness month.
conclusion: Although recruitment is still a challenge, careful consideration 
during study design and employment of a comprehensive range of recruit-
ment strategies can go some way to mitigate any potential issues from 
failure to recruit.
references: 1. Anderson, DL. A Guide To Patient Recruitment. CenterWatch/
Thomson Healthcare; Boston, Massachusetts, USA: 2001. 2. Walters SJ, Bo-
nacho dos Anjos Henriques-Cadby I, Bortolami O, et al. Recruitment and 
retention of participants in randomised controlled trials: a review of trials 
funded and published by the United Kingdom Health Technology Assess-
ment Programme. BMJ Open 2017;7:e015276. 3. Kahan, BC. Using re-ran-
domization to increase the recruitment rate in clinical trials - an assess-
ment of three clinical areas. Trials. 2016;17:595-604 4. European Medicines 
Agency. Guideline on the evaluation of medicinal products for the treat-
ment of irritable bowel syndrome 25 September 2014 CPMP/EWP/785/97 
Rev. 1 5. Dal-Ré R, Luque A, Guardiola L, Rodríguez F. Irritable bowel syn-
drome: attrition rates of patients identified at primary care centers during 
a 50-week period versus those identified in hospitals in a phase II clinical 
trial. Int J Clin Pharmacol Res. 2001;21(3-4):127-36.
disclosure: CAH and EM are employees of Enteromed Ltd the sponsor of 
the RELIEVE IBS-D study. AK, PP, JM, PW, MD, JG, CK, and YY have no con-
flicts of interest to declare. 
P1214 assOcIaTIOn BeTWeen dIeTary InTake and syMPTOMs 
In PaTIenTs WITh IrrITaBLe BOWeL syndrOMe
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Törnblom H.2, Tack J.1, Simrén M.2
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Belgium, 2Sahlgrenska Academy and University Hospital, Clinical Nutrition 
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Introduction: Irritable bowel syndrome (IBS) is one of the most common 
functional gastrointestinal (GI) disorders with a prevalence of 5-10%. Pre-
vious evidence shows that GI symptoms can be triggered by dietary in-
take, resulting in patients avoiding certain foods in order to relieve these 
symptoms.
aims & Methods: We aimed to enhance our understanding of food intake 
as trigger for symptom generation by correlating habitual dietary intake 
and symptom outcomes. Two IBS cohorts were included, using the first 
cohort for exploratory (hypothesis-generating) and the second for confir-
matory (hypothesis-testing) purposes. Patients kept 4-day food diaries of 
their habitual food intake and simultaneously filled out symptom ques-
tionnaires, including information about bowel habits (Bristol stool form 
scale), quality of life (IBS-QOL), and IBS symptom severity (IBS-SSS and 
GSRS-IBS). Nutrient intake was calculated using dedicated software, and 
additionally FODMAP intake in the exploratory cohort, and health-con-
sciousness of the diet in the second cohort were determined. We tested 
linear correlations between dietary variables and symptom variables and 
conducted a principal component analysis (PCA) with two principal com-
ponents of the dietary intake data of both cohorts. Moreover, we tested 
mediation in the association between total calorie intake and IBS symptom 
severity.
results: The exploratory cohort (N=112, 75% female, aged 33.5±11.3 years, 
body mass index (BMI) 23.1±3.8 kg/m2, IBS-SSS 310.5±83.7, 23% IBS-con-
stipation (IBS-C), 44% IBS-diarrhea (IBS-D), 7% IBS-mixed (IBS-M), 26% 
IBS-unsubtyped (IBS-U)) and confirmatory cohort (N=76, 81% female, 
aged 42.2±16.4 years, BMI 24.3±3.8 kg/m2, IBS-SSS 308.1±66.1, 39/16/3/42% 
IBS-C/D/M/U patients) demonstrated various statistically significant food-
symptom correlations. Total caloric intake correlated with overall GI symp-
tom severity (GSRS-IBS) (exploratory (e): R=-0.213 , p=0.026; confirmatory 
(c): R=-0.274, p=0.018), fiber intake with hard (R
e
=-0.217, p
e
=0.027) and 
loose bowel movements (BM) (R
c
=0.247, p
c
=0.037), and legume intake with 
quality of life (R
e
=-0.296, p
e
=0.002; R
c
=-0.269, p
c
=0.029). In the PCA, PC 
2 was negatively correlated with the IBS-SSS score (R=-0.27, p< 0.001). 
PC 2 was characterized by a higher intake of calories (loading: 0.54) and 
legumes (loading: 0.38), but a lower intake of diet drinks (loading: -0.40), 
and less nighttime consumption (loading: -0.40). No significant correla-
tions were found between FODMAP intake and IBS symptom severity, nor 
between the heath-consciousness of the diet and IBS symptom severity or 
quality of life. The negative association between total calorie intake and 
IBS symptom severity was mediated by not eating and not being hungry 
due to symptoms.
conclusion: Based on this analysis of two IBS cohorts, we were able to 
demonstrate associations between dietary intake and GI symptoms as well 
as disease-specific quality of life. Patients with severe IBS may have re-
duced energy intake because of GI symptoms. Further characterization of 
food-symptom associations can lead to the development of personalized 
dietary advice in the management of IBS.
disclosure: Nothing to disclose 
P1215 effecT Of a MucOPrOTecTanT (xyLOgLucan + Pea 
PrOTeIn and TannIns + xyLO-OLIgOsaccharIde) On InTesTInaL 
PerMeaBILITy and MucOsaL MIcrOInfLaMMaTIOn In The 
jejunuM Of IrrITaBLe BOWeL syndrOMe WITh dIarrhea
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contact e-Mail address: santosjav@gmail.com
Introduction: Irritable Bowel Syndrome (IBS) is a disorder of brain-gut 
interaction characterised by chronic and recurrent abdominal pain, altered 
defecation and sensitivity to stress. One of the important advances in the 
knowledge of the origin of IBS is the common finding of a dysfunction of 
the intestinal barrier (permeable barrier) associated with structural and 
molecular alterations in the intercellular junctions and the presence of im-
mune activation and low-grade mucosal inflammation, particularly in IBS-
diarrhea (IBS-D). Mucoprotectans such as the combination of xyloglucan + 
pea protein and tannins + xylo-oligosaccharide (XPPTX) may be useful to 
control permeability changes induced by life stress.
aims & Methods: Our hypothesis is that XPPTX, through the establishment 
of a mucus-associated biofilm, exerts a direct local protective effect capa-
ble of preventing the increase of intestinal permeability and the immuno-
inflammatory response triggered by acute experimental stress in patients 
with IBS-D. Therefore, we aimed to:
680 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
•	 To determine the effect of the administration of XPPTX on intestinal per-
meability induced by acute stress in the jejunum of patients with IBS-D, 
and to
•	 Evaluate the effect of the administration of XPPTX on changes in tight 
junctions and intestinal microinflammation induced by acute stress in 
the jejunum of patients with IBS-D.
Methods: We designed a randomised, double-blinded, placebo-controlled 
pilot study in patients with IBS-D. In a first step, 28 healthy subjects (15 
F) were included to determine control baseline small bowel permeability 
(SBP) using the lactulose/mannitol test for 2 h. In a second step, we evalu-
ated SBP in 104 patients with IBS-D (70 F). Out of these, thirty three IBS-D 
showed values of baseline SBP over percentile 75 of healthy (188,4 mg/L of 
mannitol). Twenty-two were randomised to receive 7 days of oral (b.i.d.) 
XPPTX (n=10, 6 F) or placebo (cornstrach)(n=12, 8 F), followed by a deter-
mination of SBP after 15 min of acute experimental stress (cold pressor 
test) and a jejunal biopsy using Watson’s capsule. Biopsies were processed 
for histology (H&E staining), mast cell (CD117), intraepithelial lymphocytes 
(CD3) & eosinophil counts (H&E), mucus evaluation (PAS-Alcian blue), and 
transmission electron microscopy (TEM). In addition, background stress 
levels (tests of Holmes-Rahe & Cohen), depression (Beck’s inventory) and 
severity of IBS (IBS-SSS) were also evaluated.
results: There were no differences in baseline demographics, background 
stress, psychological characteristics and IBS-SSS between XPPTX and 
placebo groups. We did not identify any difference in mucus evaluation, 
mast cell, lymphocytes and eosinophil counts between groups. Compared 
to baseline, both placebo (26.8±39.6%) and XPPTX (31.1±21.2%) reduced 
significantly SBP (P< 0.0001) after cold stress but without differences be-
tween them (P=0.79). Response to XPPTX was much more consistent and 
homogeneous than placebo. Mean (Placebo=23.1±3.3 nm; XPPTX=23.5±1.6 
nm) and maximum (Placebo=28.3±5.7 nm; XPPTX=28.4±1.9 nm) intercel-
lular space at the level of apical tight junctions was similar in both groups, 
though again response to XPPTX was much more consistent and homo-
geneous than placebo. No correlations were found between permeability 
and clinical and psychological parameters.
conclusion: The mucoprotectant XPPTS significantly reduces post-stress 
intestinal permeability in IBS-D but is not superior to placebo in this small 
pilot study. Future studies with higher number of patients are needed to 
determine the efficacy of XPPTX in controlling SBP in IBS-D and its poten-
tial clinical benefit.
disclosure: This study has been funded by Noventure S.L. 
P1216 The effecT Of LacTOBacILLus PLanTaruM On 
syMPTOMs and The MIcrOBIOMe In suBjecTs WITh IrrITaBLe 
BOWeL syndrOMe
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Introduction: Irritable bowel syndrome (IBS) is a complex condition with 
variable symptomatology involving a broad range of both physiologic and 
psychological symptoms, such as mucosal integrity and function, gut func-
tion, visceral perception and brain-gut dysregulation. Intake of a probiotic 
bacteria is one alternative to improve IBS.
aims & Methods: The aim of the study was to investigate if Lactobacillus 
plantarum DSM 9843 (LP) could improve symptoms and affect the faecal 
microbiome in subjects with IBS. 
After a 2-week run-in period, subjects with IBS according to Rome III crite-
ria, were randomized to receive either LP or placebo capsules for 4 weeks. 
A total of 197 male and female patients with IBS were included at two sites 
in the Netherlands (PreCare Trial & Recruitment). An irritable bowel sever-
ity scoring system (IBS-SSS) form was filled in at each visit (Day -14, Day 
1 and Day 28). Abdominal pain, frequency of bowel movements and stool 
consistency were reported daily. Faecal samples were collected before and 
after the intervention and the microbiome analysed with 16S rRNA gene 
profiling (NIZO).
results: There was no significant difference in abdominal pain, IBS-SSS, 
bloating, frequency of bowel movements and stool form when comparing 
subjects that consumed LP or a placebo product. However, a subgroup 
analysis on the subjects that had IBS with predominant constipation (IBS-
C, 25% of the subjects), showed that IBS-SSS was reduced significantly 
in the LP group compared with the placebo group (Table 1). The IBS-SSS 
form is validated and includes five questions: abdominal pain (severity, 
frequency), abdominal distension, satisfaction with bowel habits and how 
IBS affects and interferes with the life in general (Francis et al. 1997). The 
maximum score is 500 (100 scores/question) and a reduction with 50 
scores indicates an improvement.
 
LP (n=20) 
Mean (se)
Placebo (n=27) 
Mean (se)
P-value between 
treatments, t-test
Before treatment 249 (10) 260 (8)  
After 4 weeks treatment 183 (19) 251 (17)  
Change - 66 (20) - 9 (16) 0.027
[Table 1. Change in IBS-SSS after intake of Lactobacillus plantarum DSM 
9843 or placebo. Subgroup with IBS-C.]
Analysis of the faecal microbiome showed that the family Lactobacillaceae 
was more abundant in the group that consumed LP than in the placebo 
group, reflecting the presence of the given Lactobacillus plantarum strain 
in the faeces. Furthermore, the genus Oscillospira was significantly higher 
in the LP group compared to the placebo group. A lower abundance of 
this genus has earlier been found in infants suffering from Crohn’s disease 
(Kaakoush et al. 2012) and in patients with flatulence (Manichanh et al. 
2014).
conclusion: A beneficial statistically significant effect of treatment with LP 
as compared with placebo on symptoms associated with IBS could not be 
demonstrated. Subgroup analysis of subjects with IBS-C showed a ben-
eficial effect on the total IBS-SSS score after consumption of LP. Minor 
changes in the microbiome were found except an increase of the given 
bacteria and of Oscillospira after intake of LP. Further studies are suggested 
to investigate the mechanism behind the beneficial effect on IBS symptoms 
shown after consumption of LP in subjects with IBS-C.
references: Francis CY, Morris J, Whorwell PJ, The irritable bowel severity 
scoring system: a simple method of monitoring irritable bowel syndrome 
and its progress. Alimentary Pharmacology& Therapeutics 1997;11:395-402. 
Kaakoush NO, Day AS, Huinao KD, Leach ST, Lemberg DA, Dowd SE, Mitch-
ell HM. Microbial dysbiosis in pediatric patients with Crohn’s disease. J Clin 
Microbiol. 2012 Oct;50(10):3258-66. Manichanh C, Eck A, Varela E, Roca 
J, Clemente JC, González A, Knights D, Knight R, Estrella S, Hernandez C, 
Guyonnet D, Accarino A, Santos J, Malagelada JR, Guarner F, Azpiroz F. 
Anal gas evacuation and colonic microbiota in patients with flatulence: 
effect of diet. Gut. 2014 Mar;63(3):401-8.
disclosure: G Önning, N Larsson and A-K Robertson are affiliated to Probi 
AB, that owns the bacterial strain investigated in the study. 
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Singapore, Singapore, 9Singapore General Hospital, Department of 
Haematology, Singapore, Singapore
contact e-Mail address: shuwen.tay@mohh.com.sg
Introduction: Irritable bowel syndrome (IBS) is a prevalent condition which 
negatively impacts quality of life and places a large burden on health-
care globally. Current pharmacological treatment has variable efficacy 
and often has unsatisfactory results. Traditional Chinese Medicine (TCM) 
is widely accepted in Asia and many seek it as alternative therapy. To date, 
attempts to characterize TCM efficacy universally suffer from poor scientific 
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method or they do not faithfully replicate authentic TCM best practice. We 
sought to address these deficiencies combining the best of TCM practice 
with western medicine in this study.
aims & Methods: This was a randomised, double blind, placebo controlled 
parallel group study carried out in a single centre in Singapore. Patients 
who fulfilled ROME III criteria for IBS-Constipation predominant subtype 
(IBS-C), and the TCM syndrome of Liver Qi stagnation (LCS) were recruited. 
To reflect typical TCM practice, LCS diagnosis can be further “modified” into 
3 subtypes based on a standardised TCM diagnostic criteria. TCM treatment 
consist of a standardized core herbal formula specific for treatment of LCS 
or a modified formula based on the LCS subtype. After a 2-week run in, 
subjects were randomised (1:1) to receive the prescribed TCM treatment 
or placebo with 10% of active core ingredients for 8-weeks. The primary 
endpoint was change of IBS-Symptom Severity Score (IBS-SSS) at end of 
treatment compared to baseline. Secondary outcomes include change in 
individual gastrointestinal symptoms, Bristol stool scale, bowel move-
ment, psychological scale, quality of life and adverse events. Analysis was 
performed based on Intention to treat using 2-sided T test and chi-squared 
as appropriate. Ethics Board review was obtained. The trial was registered 
on Singapore and international (ClinicalTrials.gov) trial registries prior to 
recruitment.
results: 59 patients were screened, 40 were randomized and 39 patients 
with valid data were analysed. Patient characteristics and primary outcome 
is shown in table 1. Patient characteristics were similar in both arms. There 
was a non-significant benefit in IBS-SSS in the TCM group vs the control 
group with adjusted difference by baseline of -28.0 (95% CI = -84.9, 28.95; 
p=0.325). TCM was well tolerated, there was no serious adverse events in 
both arms, only 2 patients from the placebo arm withdrew from the study. 
One due to body ache which resolved after cessation of treatment, another 
due to hair loss. There was no significant difference in the other secondary 
outcomes.
  TcM control p-value
Female 
(%)
90 74 0.19
Mean Age 
(years)
43.3 42.7 0.90
Race      
Chinese 
(%)
95 84 0.24
  Baseline
End of 
Treatment 
Response
Change Baseline
End of 
Treatment 
Response
Change  
IBS-SSS 
mean (SD)
256.2 
(101.0)
205.4 
(103.8)
-50.8 
(49.83)
227.3 
(102.6)
215.6 
(118.9)
-11.7 
(106.99)
0.32
[Patient Characteristics and Primary Outcome]
conclusion: A TCM treatment regime which allowed for subtype modifica-
tion reflecting typical TCM practice showed a non-significant benefit in 
patients with constipation predominant irritable bowel syndrome in a 
randomised, double blind, placebo-controlled study design. The treatment 
was well tolerated with minimal side effects. Larger RCTs should be con-
ducted to further validate this.
disclosure: Nothing to disclose 
P1218 TheraPy Of IrrITaBLe BOWeL syndrOMe and OTher 
funcTIOnaL gasTrOInTesTInaL dIseases WITh sTW 5 In a seLf 
MedIcaTIOn seTTIng
Vinson B.R.1, Skeib S.2, Kelber O.2, Möller J.2, Raskopf E.3,4, Nieber K.5, 
Fink C.6
1Bayer Vital GmbH, Phytomedicines Supply and Development Center, 
Steigerwald Arzneimittelwerk GmbH, Medical Affairs Consumer Health, 
Darmstadt, Germany, 2Bayer Consumer Health, Phytomedicines Supply 
and Development Center, Steigerwald Arzneimittelwerk GmbH, Research 
and Development, Darmstadt, Germany, 3ClinNovis GmbH, Köln, Germany, 
4Institut für Medizinische Statistik und Bioinformatik, Universitätsklinikum 
Köln, Köln, Germany, 5Institute for Pharmacy, University of Leipzig, Leipzig, 
Germany, 6Steigerwald GmbH, Medical Affairs, Darmstadt, Germany
contact e-Mail address: careen.fink@bayer.com
Introduction: Surveys on everyday life therapeutic use and patient satisfac-
tion are important tools to gain real life evidence and understanding of 
patients’ needs for medicinal products [1]. 
The herbal combination preparation STW 5 has been available in the Ger-
man market for more than 58 years [2]. Its scientific evidence for treatment 
of functional gastrointestinal diseases like irritable bowel syndrome and 
functional dyspepsia includes a multitude of clinical, pharmacological and 
toxicological studies [3].
aims & Methods: Up to now, few data on self-assessed usage behavior, 
perception of effectiveness and tolerability for STW 5 are available. There-
fore, pharmacy customers with product desire or recommendation for STW 
5 were asked whether they would participate in a survey on the product. 
Patients received a questionnaire regarding demographic data, gastro-
intestinal complaints, effectiveness, tolerability and satisfaction with the 
product. They were asked to answer it during the next few days and send 
it back to a contract research institute within a week.
results: Data from 843 patients were evaluated. 29.4 % were male and 
70.6 % female. The majority was in the 30-49 age range. In 384 patients, 
complaints were related to the upper, in 139 to the lower abdomen, in 
311 patients to both regions. In 7.3 % of the 384 patients a functional 
dyspepsia had been diagnosed, in 16.9 % of the 139 patients an irritable 
bowel syndrome. Up to 64% of the patients specified a good or very good 
improvement of the respectively predominant symptom with treatment 
of STW 5. Symptom relief was perceived as fast and covered the com-
prehensive spectrum of complaints. Tolerability was rated good to very 
good in 97.4 % of all patients and did not differ between patient groups. 
Correspondingly 93.2 % of the users were “very satisfied” or “satisfied”. 
91 % of the customers would recommend STW 5 to others for treating 
their complaints.
conclusion: Overall, it can be concluded that this patient survey gives a re-
liable picture of the behavior of users of STW 5 in a self medication setting, 
with high satisfaction values as well in irritable stomach as in irritable 
bowel syndrome and single symptoms. The favorable tolerability ratings 
confirm the ratings from the clinical studies on the product.
references: 1. Nieber K. and Lehmacher W. Med. Wochenschr. f. Phar-
mazeuten 2009 (8): 301-306 2. Storr M. et al. Pharmakon 2016, 4(4):356-
364 3. Abdel-Aziz H. et al., Planta Med. 2017, 83(14/15):1130-1140
disclosure: BV, SS and OK are employees at Steigerwald Arzneimittelwerk 
GmbH. JM is intern at Steigerwald Arzneimittelwerk GmbH. 
P1219 neTWOrk MeTa-anaLysIs Of The effIcacy and safeTy 
Of PharMacOLOgIcaL TheraPIes fOr IBs-d and IBs-M
Black C.J.1,2, Burr N.E.1,2, Camilleri M.3, Earnest D.L.4, Quigley E.M.5, 
Moayyedi P.6, Houghton L.A.2, Ford A.C.1,2
1St James’s University Hospital, Gastroenterology, Leeds, United Kingdom, 
2University of Leeds, Leeds Institute of Medical Research at St James’s, Leeds, 
United Kingdom, 3Mayo Clinic, Gastroenterology, Rochester, United States, 
4University of Arizona College of Medicine, Division of Gastroenterology, 
Tucson, United States, 5Houston Methodist Hospital, Division of 
Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center 
for Digestive Disorders, Houston, United States, 6McMaster University, 
Medicine and Gastroenterology, Hamilton, Canada
contact e-Mail address: chrisjamesblack4@gmail.com
Introduction: Over half of patients with irritable bowel syndrome have ei-
ther diarrhoea (IBS-D) or a mixed stool pattern (IBS-M). The relative ef-
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ficacy of pharmacological therapies in IBS-D and IBS-M is unclear in the 
absence of head-to-head trials. We conducted a network meta-analysis to 
resolve this uncertainty.
aims & Methods: We searched MEDLINE, EMBASE, EMBASE Classic, the 
Cochrane central register of controlled trials, and clinicaltrials.gov through 
January 2019 to identify randomised controlled trials (RCTs) assessing the 
efficacy of pharmacological therapies in adults with IBS-D or IBS-M. Tri-
als included in the analysis reported a dichotomous assessment of overall 
response to therapy at 8 to 12 weeks of follow-up, and data were pooled 
using a random effects model. Efficacy and safety of all pharmacological 
therapies were reported as a pooled relative risk of remaining symptom-
atic with 95% confidence intervals (CIs) to summarise the effect of each 
comparison tested. Treatments were ranked according to their P-score.
results: We identified 21 eligible RCTs (7 alosetron, 5 ramosetron, 2 cilan-
setron, 1 ondansetron, 2 rifaximin, 4 eluxadoline), containing 10654 pa-
tients. With the exception of ondansetron, all drugs were superior to pla-
cebo, according to the Food and Drug Administration (FDA)-recommended 
endpoint of improvement in both abdominal pain and stool consistency 
for trials in IBS. Alosetron 1mg twice-daily ranked first for efficacy, based 
on this composite endpoint (RR = 0.69; 95% CI 0.60 to 0.80, P-score = 
0.95), as well as for effect on global symptoms of IBS (RR = 0.62; 95% CI 
0.52 to 0.75, P-score = 0.95). With respect to effect on stool consistency all 
drugs, including ondansetron 12mg once-daily, were superior to placebo, 
but alosetron 1mg twice-daily was again ranked first (RR = 0.70; 95% CI 
0.60 to 0.81, P-score = 0.85). Ramosetron 2.5mcg once-daily was ranked 
first for effect on abdominal pain (RR = 0.74; 95% CI 0.65 to 0.85, P-score 
= 0.89). Total numbers of adverse events were significantly greater with 
alosetron 1mg twice-daily, compared with placebo. Rifaximin 550mg three 
times daily ranked first for safety, with ondansetron 12mg od ranked sec-
ond (P-scores 0.74 and 0.68, respectively). Constipation was significantly 
more common with all drugs, except rifaximin 550mg three times daily 
and ondansetron 12mg once-daily.
conclusion: In a network meta-analysis of randomised controlled trials of 
pharmacological therapies for IBS-D and IBS-M, we found all drugs to 
be superior to placebo, but the 5HT
3
-receptor antagonists alosetron and 
ramosetron appeared to be the most effective. Unfortunately, these drugs 
are unavailable in the UK and Europe. Ondansetron, which is available al-
though unlicensed, ranked well across all analyses, but was only superior 
to placebo for its effect on stool consistency, based on the inclusion of a 
single small trial. Overall, improving access to 5HT
3
 receptor antagonists 
may be helpful for the management of IBS-D and IBS-M, and the result of 
further trials of ondansetron will be informative.
disclosure: MC has received research funding from Allergan. DLE has acted 
as a consultant for Prometheus Laboratories. EMQ has acted as a con-
sultant to Almirall, Synergy and Salix. PM has received honoraria from 
Allergan and Salix, and research funding from Allergan. LAH has acted as 
a consultant for, and received research funding from Takeda, USA, and has 
acted as a consultant for Pfizer, USA. ACF has acted as a consultant for and 
received researching funding from Almirall 
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P1220 cOsT-effecTIveness Of The use Of hLa-dqa1-hLa-
drB1 POLyMOrPhIsM TO IdenTIfy PedIaTrIc PaTIenTs WITh 
InfLaMMaTOry BOWeL dIsease aT rIsk fOr azaThIOPrIne-
Induced acuTe PancreaTITIs
Velasco M.1, Viada Bris J.F.2, Palomino Pérez L.2, Asensio Antón J.3, 
Muñoz Codoceo R.A.2
1Hospital Infantil Universitario Niño Jesús, Gastroenterology, Madrid, Spain, 
2Hospital Infantil Universitario Niño Jesús, Gastroenterology and Nutrition, 
Madrid, Spain, 3Hospital Infantil Universitario Niño Jesús, Clinical Analysis 
Department, Madrid, Spain
contact e-Mail address: martavrb@gmail.com
Introduction: Thiopurines may be effective for maintaining remission in 
pediatric inflammatory bowel disease (IBD), but due to their low safety 
profile, the most recent evidence-based guidelines recommend they 
should be reserved as second-line therapy after 5-ASA has failed (1). One 
idiosyncratic adverse effect of thiopurines is acute pancreatitis and affects 
2-7% of patients treated with azathioprine (AZA) (2,4). Its development 
is unpredictable and usually leads to drug withdrawal. An association 
within the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype has been previ-
ously identified (3). The risk of pancreatitis during AZA-therapy was highly 
predictable and genotype-dependent: 0.5% for wild-type (A/A), 4.3% for 
heterozygous (A/C), and 14.6% for homozygous patients (C/C). Some au-
thors even propose a new AZA treatment algorithm that could help to 
select those patients with higher risk of pancreatitis (4).
aims & Methods: The aim of our study was to conduct a cost-effectiveness 
analysis of the use of HLA-DQA1-HLA-DRB1 polymorphism to identify pe-
diatric patients with inflammatory bowel disease at risk for azathioprine-
induced acute pancreatitis (A-IAP).
We perfromed a theoretical analysis of costs and benefits resulting from 
routinely studying the HLA-DQA1*02:01-HLA-DRB1*07:01 haplotype in 
those pediatric patients with IBD that are candidates for the use of aza-
thioprine as maintenance therapy, in order to avoid using this treatment in 
those at risk of A-IAP. We calculated the number needed to screen (NNS), 
defined as the number of patients that need to be screened to prevent 
one adverse event, based on the available data. This was computed as the 
inverse of the Absolute Risk Reduction (ARR), defined as the difference in 
percentage outcomes between the related and un-related haplotype.
The costs of the HLA typing were based on the INNO-LiPA® test (FUJIRE-
BIO, Spain).
The costs of acute pancreatitis cases were based on the diagnosis-related 
group (DRG) weights applied by the Spanish Ministry of Health. These 
relative weights represent the expected cost of a particular kind of patient 
compared to the average cost of all the acute hospitalized patients.
results: The cost of the screening for the HLA-DQA1*02:01-HLA-DRB1*07:01 
haplotype was approximately 90€ per patient. Considering the previously 
reported incidence of A-IAP of 0.5% in the A/A, 4.3% in the A/C and 14.6% 
in the C/C genotype; NNS was 5.4. NNS was rounded up to 6 patients, so 
the expected cost for avoiding one case of A-IAP was 540€.
The A-IAP diagnose in the DRG 32ndversion (DRG 282.3) has a mean weight 
of 1.15. The total cost of a case of A-IAP was about 20.109 € per patient. 
This leads to saving up to 19.569€ for every 6 patients screened before 
starting the AZA treatment.
conclusion: Based on our results, routinely performing HLA-DQA1-HLA-
DRB genotyping prior to initiation of AZA could be cost-effective in order 
to avoid A-IAP. Furthermore, the caregivers’ absenteeism costs derived 
from a child hospitalization were not included in this analysis and would 
reinforce our conclusions. However, the costs derived from the therapeutic 
alternative that would be considered for those who could not receive AZA 
should be considered. But, most importantly, and beyond the economic 
rationale, preventing this potentially severe adverse effect could improve 
the clinical outcomes of our patients and allow an individualized manage-
ment. This patient-tailored approach should be the goal of clinicians, not 
only to optimize the use of Public Health Funds, but also to maximize our 
patients’ quality of life.
references: 1. Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, 
Martin de Carpi J, Bronsky J, et al. Management of paediatric ulcerative 
colitis, Part 1: ambulatory care- an evidence-based guideline from ECCO 
and ESPGHAN. 2018; 2. Ledder OD, Lemberg DA, Ooi CY, Day AS. Are thio-
purines always contraindicated after thiopurine-induced pancreatitis in 
inflammatory bowel disease? J Pediatr Gastroenterol Nutr. 2013;57(5):583-
6. 3. Heap GA, Weedon MN, Bewshea CM, Singh A, Chen M, Satchwell 
JB, et al. HLA-DQA1-HLA-DRB1 variants confer susceptibility to pancreatitis 
induced by thiopurine immunosuppressants. Nat Genet. 2014;46(10):1131-
4. 4. Wilson A, Jansen LE, Rose R V., Gregor JC, Ponich T, Chande N, et al. 
HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-
induced pancreatitis in patients with inflammatory bowel disease. Aliment 
Pharmacol Ther. 2018;47(5):615-20. 5. Dan Mayer. Essential Evidence-
Based Medicine, Volumen 2. Cambridge University Press, 2004: 272-274.
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P1221 safeTy and effecTIveness Of granuLOcyTe and 
MOnOcyTe adsOrPTIve aPheresIs In PaedIaTrIc PaTIenTs WITh 
InfLaMMaTOry BOWeL dIsease: a MuLTIcenTre cOhOrT sTudy
Toita N.1, Tanaka H.2, Arai K.3, Shimizu H.3, Abukawa D.4, Kobayashi T.5, 
Yoshimura N.6, Tanida S.7, Hosoi E.8
1Sapporo Kosei General Hospital, Department of Pediatrics, Sapporo, Japan, 
2Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan, 3National 
Center for Child Health and Development, Division of Gastroenterology, 
Setagaya, Japan, 4Miyagi Children’s Hospital, Department of General 
Pediatrics, Sendai, Japan, 5Hakodate Goryoukaku Hospital, Department 
of Gastroenterology, Hakodate, Japan, 6Tokyo Yamate Medical Center, of 
Internal Medicine, Division of IBD, Shinjuku, Japan, 7Nagoya City University, 
Graduate School of Medical Sciences, Department of Gastroenterology and 
Metabolism, Nagoya, Japan, 8JIMRO Co., Ltd., Tokyo, Japan
contact e-Mail address: hirokit@mtc.biglobe.ne.jp
Introduction: The usefulness of granulocyte and monocyte adsorptive 
apheresis (GMA) in paediatric patients with inflammatory bowel disease 
(IBD) has not been evaluated in detail. We investigated the safety and ef-
fectiveness of GMA in paediatric patients with IBD who participated in the 
“Post-marketing surveillance study on the safety and response of GMA 
treatment in patients with Crohn’s disease or ulcerative colitis with at least 
one special situation who received Adacolumn (PARTICULAR)”.
aims & Methods: The aim of this study is to investigate the safety and ef-
fectiveness of GMA in paediatric patients with IBD who participated in the 
PARTICULAR study. This retrospective, multicentre cohort study included 
patients with ulcerative colitis (UC) or Crohn’s disease (CD) who had at 
least one special situation feature and who had received GMA therapy in 
medical institutions of Japan between November 2013 and March 2017. 
Patients with at least one special situation, including elderly patients, pa-
tients with anaemia and patients on multiple immunosuppressants were 
enrolled. Patients >18 years were excluded from this study. GMA was per-
formed using Adacolumn (JIMRO, Takasaki, Japan). Each patients received 
up to a maximum of 11 sessions. All adverse events (AEs) were recorded 
during the observation time interval. In addition, feasibility problems (FPs) 
during the operation of the GMA column were recorded. Any AE for which 
the causality of GMA could not be ruled out was classified as adverse de-
vice effect (ADE). The safety of GMA was assessed in all patients. The ef-
fectiveness of GMA was assessed in patients with UC with a partial Mayo 
(pMayo) score of ≥3. Remission was defined as a pMayo score of ≤2, while 
response was defined as a decrease in the pMayo score by ≥2 points and 
by ≥30% decrease relative to that at baseline plus all 3 sub-scores ≤1. 
Patients receiving concomitant treatment with infliximab, adalimumab or 
calcineurin inhibitors were excluded from the effectiveness assessment.
results: A total of 53 paediatric patients (40 UC, 13 CD; 30.2% female) from 
27 institutions, with a median age of 16.0 years [range 6-12 (9 patients), 13-
15 (14 patients) and 16-18 (30 patients)]; median body weight 49.6 Kg and 
median duration of disease 0.7 years. The incidence of AEs, ADEs and FPs 
were 18.9%, 5.7% and 20.8%, respectively. The ADEs included abdominal 
discomfort in 2 patients (3.8%) and one patient each with fever, nausea/
vomiting and headache (1.9% each). The FPs included blood access failure 
in 10 patients (18.9%), venous pressure elevation in 4 patients (7.5%), clot 
formation in the apheresis lines in 2 patients (3.8%) and venous access 
difficulty in 1 patient (1.9%). GMA therapy was discontinued in 17 patients 
(32.1%) ahead of their planned treatment schedule. Among these patients, 
the GMA therapy was discontinued for the following reasons: (1) decision 
by the physician (n = 12), (2) withdrawal due to AE (n = 4) and (3) with-
drawal by own will (n = 1). No patients discontinued GMA therapy due to 
ADE and FP. The effectiveness of GMA was assessed in 29 patients with UC. 
The remission and response rate of the paediatric patients with UC were 
55.2% and 65.5%, respectively.
conclusion: There were AEs and FPs in approximately 20% of paediatric 
patients with IBD who were treated with GMA. However, none of these 
discontinued GMA treatment owing to ADE or FP. Remission and response 
were achieved by GMA in 55% and 66% of paediatric patients with UC, 
respectively. These data suggest that GMA is a well-tolerated treatment 
alternative for paediatric patients with IBD.
disclosure: Hiroki Tanaka has received lecture fees from JIMRO Co. Ltd., 
AbbVie GK, EA Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., Kyo-
rin Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation. 
Katsuhiro Arai has received lecture fees from Takeda Pharmaceutical Co. 
Ltd, AbbVie GK, Nippon Kayaku Co. Ltd, EA Pharma Co. Ltd and Kyorin 
Pharmaceutical Co. Ltd.; and has received research grants from Nippon 
Kayaku Co. Ltd. Naoki Yoshimuara has received lecture fees from JIMRO Co. 
Ltd., AbbVie GK, Mochida Pharmaceutical Co. Ltd. and Mitsubishi Tanabe 
Pharma Corporation. Satoshi Tanida has received research grant from EA 
Pharma Co. Ltd. Eiji Hosoi is employee of JIMRO Co. Ltd. All other authors 
have nothing to disclose. 
P1222 excLusIve enTeraL nuTrITIOn fOr InducTIOn Of 
reMIssIOn In PaedIaTrIc crOhn’s dIsease: cOMParIsOn 
BeTWeen a dIsease-sPecIfIc fOrMuLa and sTandard 
POLyMerIc fOrMuLas
Martínez Ibeas M.A., Rodríguez Manchón S., Bacelo Ruano I., 
Viada Bris J.F., Velasco Rodríguez-Belvís M., Cañedo Villarroya E., 
Pedrón Giner C., Muñoz Codoceo R.A.
Hospital Infantil Universitario Niño Jesús, Paediatric Gastroenterology and 
Nutrition Department, Madrid, Spain
contact e-Mail address: martavrb@gmail.com
Introduction: Exclusive enteral nutrition (EEN) is effective and currently 
recommended as the first line of treatment to induce remission in children 
and adolescents with acute active Crohn’s disease (CD). Standard enteral 
nutrition (polymeric, normocaloric with moderate fat content) can be used 
for primary and supportive nutritional therapy in active CD.
aims & Methods: The main aim was to demonstrate the non-inferiority 
of an age-appropriate normocaloric polymeric formula (F0) versus an in-
flammatory bowel disease (IBD) specific normocaloric polymeric formula 
(F1) to induce remission in paediatric patients newly diagnosed of CD. Sec-
ondary objectives were to evaluate the nutritional status and analyze the 
percentage of withdrawal before 8 weeks, their causes and the need of 
other treatments. This observational, descriptive and retrospective study 
included patients under 18 diagnosed with CD from September 2008 to 
December 2018 in the paediatric IBD Unit of a tertiary care hospital in 
whom EEN was indicated to induce remission at diagnosis. Patients were 
divided into two groups (EEN with F0 or EEN with F1), comparing clinical, 
analytical and anthropometric data at diagnosis, and after 2 and 8 weeks 
of EEN. Clinical remission was defined as a Paediatric Crohn Disease Activ-
ity Index (PCDAI) ≤10.
results: We included 29 patients, 9 (31%) women and 20 (69%) men with 
a mean age of 9.9 years (2.1-17.5) at diagnosis. Eleven patients (37.9%) 
received F0 and 18 (62.1%) F1. The mean duration of EEN was 56.3 days 
(18-78). One patient (3.5%) refused the treatment and required tube feed-
ing and 6 (20.7%) dropped out from EEN before 8 weeks (33.3% F0 and 
66.7% F1). Among 6 withdrawals, 5 (83.3%) developed a fistulizing peri-
anal disease (40% F0 and 60% F1) and required biological therapy, and 
1 (16.7%) did not respond to EEN with F1, requering corticosteroids. The 
PCDAI mean value was 36.4 (20-52.5) at diagnosis in the group with F0 
and 31.47 (12.5-57.5) with F1. After 2 weeks, 62.5% of patients with F0 and 
56.3% with F1 reached clinical remission. After 8 weeks, 90.9% of patients 
with F0 and 77.8% with F1 maintained clinical remission. There were no 
statistically significant differences between the 2 groups at both endpoints. 
The C-reactive protein (CRP) mean value at diagnosis, and after 2 and 8 
weeks was 7.7 mg/dl (0.2-27.3), 1.7 y 1.1 mg/dl respectively in the F0 group, 
and 5.6 mg/dl (0.2-12.8), 1.2 y 0.9 mg/dl in the F1 group, without statisti-
cally significant differences (p=0.7; 0.93; 0.34 respectively). After 8 weeks, 
median CRP decreased significantly in F0 group (p=0.01) and F1 group (p< 
0.0005). The mean erythrocyte sedimentation rate (ESR) at diagnosis, at 
2 and 8 weeks was 39.1 mm (11-69), 26 and 17 mm respectively in the F0 
group, and 42.4 mm (11-78), 23.2 and 14.6 mm in the F1 group, without sta-
tistically significant differences (p=0.65; 0.64; 0.43). Median ESR decreased 
significantly at week 2 with F1 (p=0.001) but not with F0 (p=0.17). However, 
there was a significative reduction in both of them at week 8 (p< 0.05). 
Weight and body mass index (BMI) improved with F0 and F1, but only the 
F1 group reached statistical significance (p=0.007 for weight and p=0.003 
for BMI), and not the F0 group (p=0.24 and 0.37)
conclusion: The use of F0 was not inferior to F1, without any statistically 
significant differences in the percentage of patients in clinical remission 
after 2 and 8 weeks with EEN, nor in the decrease of CRP and ESR after 
8 weeks. Faster ESR reduction was found in patients treated with F1 and 
only these ones presented a statistically significant improvement in their 
nutritional status.
disclosure: Nothing to disclose 
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P1223 LOngTerM cLInIcaL OuTcOMe afTer ThIOPurIne 
dIscOnTInuaTIOn In eLderLy IBd PaTIenTs
Jorissen C.1, Verstockt B.2, Schils N.3, Ferrante M.4, Vermeire S.3
1University Hospital Leuven, Leuven, Belgium, 2Translational Research 
in Gastrointestinal Disorders - IBD, Department of Chronic Diseases, 
Metabolism and Aging|KU Leuven, Leuven, Belgium, 3University Hospital 
Leuven, Dept. of Gastroenterology, Leuven, Belgium, 4University Hospitals 
Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
contact e-Mail address: celinejorissen@hotmail.com
Introduction: Thiopurines - although still used frequently in treatment of 
inflammatory bowel diseases (IBD) - carry a significant malignancy risk, 
particularly with prolonged use and in patients over the age of 60. Mainly 
the risk of lymphoma, but also non-melanoma skin cancer and nodular re-
generative hyperplasia of the liver are well reported. These concerns ques-
tion the continuation of thiopurines in IBD patients above 60. Stopping 
therapy however may trigger relapses and therefore needs to be balanced 
against the safety risk. We assessed the longterm outcome of elderly IBD 
patients after discontinuation of thiopurines (TP) while in clinical remis-
sion with emphasis on relapse rates and the management thereof in these 
patients.
aims & Methods: The electronic medical records from all IBD patients 
above the age of 60 followed at our referral center who ever received 
treatment with TP were reviewed. Patients who stopped TP after 60 years 
of age while in clinical (symptom control) and endoscopic remission (mu-
cosal healing) were the target population. Longterm outcomes of inter-
est included duration of thiopurine-free clinical remission, time to clinical 
relapse and therapies given in case of relapse. The risk for malignancies 
was also recorded.
results: From the 674 identified patients who ever received TP therapy, 532 
patients stopped therapy < 60 years of age (regardless of reason for with-
drawal). A total of 142 patients >60 years of age on TP were identified. Of 
those, 91 patients (55 Crohn’s disease (CD) and 36 ulcerative colitis (UC)), 
stopped TP at >60 years while in clinical and/or endoscopic remission and 
51 stopped while not in remission. After a median follow up of 31.4 months 
after TP discontinuation, 63 (69.2%) patients remained in clinical and en-
doscopic remission and 28 (30.8%) relapsed. Remission rates and median 
time to relapse were similar between CD patients (40/55 or 72%; median 
22 months) and UC patients (23/36 or 64%; median 20 months). However, 
the median duration of TP therapy in the patients with relapse was sig-
nificantly shorter than in the patients who remained in remission (median 
duration of TP 45 months versus 102.5 months respectively; p=0.005). Of 
the patients who relapsed, 17 were initiated on a biological (61%) and 7 
patients received a short course of steroids (25%). However, surgery was 
eventually needed in 36% of patients (10/28), including total colectomy 
with ileostomy in 2 UC patients. In the total group of 142 IBD patients on TP 
at>60 years, 26 malignancies (18%) developed: non-melanoma skin can-
cers (8), colon adenocarcinoma (5), hematologic malignancies (3), lung 
(2), breast (2), brain (1), endometrium (1), prostate (1), glottis (1), bladder 
(1) and melanoma (1). For 7 patients, the development of a malignancy was 
the direct reason for stopping TP.
conclusion: In this single center retrospective cohort of elderly IBD pa-
tients in remission and on TP, discontinuation of TP resulted in sustained 
clinical remission in 69% of patients after a median of 20 months. Patients 
who flared after discontinuation of TP were mostly rescued with biological 
therapies although more than one third of patients necessitated surgery. 
A significant proportion of patients developed malignancies under TP but 
also after TP discontinuation, indicating that these patients necessitate a 
continued close follow up. Decision making in this vulnerable subgroup of 
patients remains difficult with a careful balance between adverse events 
when continuing TP and risk for major surgery when stopping TP.
disclosure: Nothing to disclose 
P1224 TOxIn PrOducIng kLeBsIeLLa OxyTOca In InfanTs: 
cOMMensaL Or PaThOBIOnT?
Greimel T.1, Stampfer L.1, Leitner E.2, Zechner E.L.3, Unterhauser K.4, 
Hauer A.1, Gorkiewicz G.5, Krause R.6, Högenauer C.7, Hoffmann K.M.1,8
1Medical University Graz, Department of Pediatrics and Adolescent Medicine, 
Graz, Austria, 2Medical University Graz, Institute of Hygiene, Graz, Austria, 
3Medical University Graz, Institute of Molecular Biosciences, Graz, Austria, 
4Karl-Franzens University Graz, Institute of Molecular Biosciences, Graz, 
Austria, 5Medical University Graz, Institute of Pathology, Graz, Austria, 
6Medical University Graz, Section of Infectious Diseases and Tropical 
Medicine, Department of Internal Medicine, Graz, Austria, 7Univ.-Klinik Graz, 
Gastroenterology/Hepatologie, Graz, Austria, 8Kinderärzte Zentrum Graz-
Raaba, Raaba-Grambach, Austria
contact e-Mail address: hoffmaka@mac.com
Introduction: Klebsiella (K.) oxytoca is a gastrointestinal pathobiont that 
has the potential to produce the cytotoxin tilivalline, which causes anti-
biotic-associated haemorrhagic colitis. K. oxytoca colonizes healthy adults 
in up to 9%, however, there is no data on the natural occurrence and its 
potential to produce tilivalline in healthy children.
aims & Methods: We investigated K. oxytoca colonization and its ability for 
toxin production in healthy infants.We collected stool samples of healthy 
infants at 3 different time points (week 0, 4 and 8). K. oxytoca colonization 
was determined using conventional stool culture and PCR analysis. Toxicity 
of isolated K. oxytoca strains was analysed by cell culture MTT toxin assay 
and K. oxytoca toxin PCR.
results: Of 61 infants (25 male, 36 female, age 1 - 28 weeks) 30 (49%) test-
ed positive for K. oxytoca in conventional stool culture and 44 (72%) tested 
positive in K. oxytoca PCR. Colonization increased with time: 21% / 62% 
(culture / PCR) at week 0, 26% / 67% at week 4, 31% / 69% at week 8. One 
patient tested negative for PCR but positive for conventional stool culture. 
48% of K. oxytoca positive infants were exclusively breastfed at the time of 
study inclusion, compared to 82% of K. oxytoca negative patients (p=0.02, 
Fisher’s exact). There were no statistical differences between positive and 
negative infants in regard to age, weight or sex, C-section, use of probiot-
ics, previous antibiotic therapy or previous diseases. The cell culture MTT 
toxin assay confirmed toxicity of culture positive K. oxytoca isolates in 49%. 
K. oxytoca toxin PCR was positive in 75% of PCR isolates. Conformity of cell 
culture toxin assay and toxin PCR was noted in only 71% of the analyses, 
whereas the negative predictive value of the toxin PCR was 100%.
conclusion: In contrast to adults, more than 70% of healthy infants were 
colonized with K. oxytoca, the majority of which possessed the ability to 
produce the cytotoxin tilivalline. Exclusive breastfeeding might decrease 
the probability of K. oxytoca colonization. PCR shows a higher detection 
rate of K. oxytoca compared to conventional stool culture but lacks infor-
mation about the clinical significance (e.g. relative abundance) of K. oxy-
toca colonization. K. oxytoca toxin PCR alone can not be used to confirm 
actual toxin production, but with a negative predictive value of 100% can 
be used to rule out the potential of toxin production of the isolated strain. 
Pediatricians have to be aware of the high prevalence of toxin producing 
K. oxytoca in infants, especially when confronted with haemorrhagic colitis 
during antibiotic therapy in this age group.
disclosure: Nothing to disclose 
P1225 shOuLd hyPnOTheraPy Be The fIrsT LIne TreaTMenT 
OPTIOn fOr schOOL chILdren and adOLOescenTs WITh 
IrrITaBLe BOWeL syndrOMe?
Vasant D.1,2, Hasan D.S.S.3, Cruickshanks P.3, Whorwell P.1,4
1Manchester University Foundation Trust, Neurogastroenterology, Manchester, 
United Kingdom, 2University of Manchester, Manchester, United Kingdom, 
3Manchester University NHS Foundation Trust, Neurogastroenterology/
Hypnotherapy, Manchester, United Kingdom, 4University of Manchester 
Wythenshawe Hospital, Medicine, Manchester, United Kingdom
contact e-Mail address: dipeshvasant@hotmail.com
Introduction: Irritable Bowel Syndrome (IBS) symptoms in school children 
and adolescents are relatively common, often causing considerable em-
barrassment, social withdrawal, disruption to education and psychological 
distress. Pharmacological options in this group are limited due to safety 
concerns concerning antidepressants, making behavioural therapies such 
as gut-focused hypnotherapy an attractive treatment option.
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aims & Methods: Here, we evaluated outcomes from gut-focused hypno-
therapy in patients with IBS ≤ 18 years of age. Consecutive young patients 
(≤18 years of age) with severe IBS symptoms referred to our tertiary neuro-
gastroenterology unit received 12 sessions of gut-focused hypnotherapy at 
weekly intervals using the Manchester Protocol. All patients completed the 
Tellgen Absorption Scale before treatment and all completed the following 
measures before and after hypnotherapy; IBS symptom severity score (IBS-
SSS), Hospital Anxiety and Depression scale (HADS), Non Colonic Symptom 
score and quality-of-life (QoL) score. Interference with education and the 
impact of hypnotherapy was also recorded. The primary outcome measure 
was response to hypnotherapy defined by a 50 point reduction in IBS-SSS. 
Data, expressed as mean ± standard error, were compared statistically be-
fore and after treatment using paired t-tests.
results: 26 young patients fulfilling Rome III diagnostic criteria for IBS 
(median age 16 (range 8-18) years, n=17 (65%) female, mean duration of 
IBS 5.3 ± 0.9 years, IBS-D n=11, IBS-C n=6 and IBS-mixed n=9), completed 
the hypnotherapy programme. Mean baseline IBS-SSS was 321.5 ± 16.0. Af-
ter hypnotherapy, n=23/26 (88%) responded, with an overall mean reduc-
tion in IBS-SSS of -160.9 ± 15.4 (P< 0.0001), and n=19/26 (73%) achieved 
the FDA recommended outcome of ≥30% reduction in abdominal pain 
scores. Hypnotherapy also improved; mean non-colonic symptom score 
by 102.1 ± 15.0 (P< 0.0001), mean HADS-anxiety by -3.0 ± 0.8 (P=0.0007), 
mean HADS-depression by -2.1± 0.6 (P=0.002), and improved mean QoL 
score by +89.7 ± 13.1 (P< 0.0001).
conclusion: These data, which form one of the largest reported series of 
gut-focused hypnotherapy in children and adolescents with severe IBS, 
suggest that this treatment is even more effective in this group of pa-
tients than in adults. Hypnotherapy in severe childhood IBS patients may 
therefore have a role in preventing further suffering in adult life, reducing 
healthcare utilisation and related costs with wider socio-economic ben-
efits. Furthermore, it allows many of them to return to full time education. 
These results, taken with previous clinical trial data, raise the possibility 
that early intervention with hypnotherapy for childhood IBS might reduce 
the subsequent burden of this problem in adults.
disclosure: Nothing to disclose 
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P1226 IL-7 recePTOr InfLuences anTI-Tnf resPOnsIveness 
and T ceLL guT hOMIng In InfLaMMaTOry BOWeL dIsease
Belarif L.1, Danger R.2, Kermarrec L.3, Naveilhan P.3, Vanhove B.1, 
Poirier N.1
1Ose Immunotherapeutics, Nantes, France, 2Centre de Recherche en 
Transplantation et Immunologie (CRTI), UMR 1064, Inserm, Université de 
Nantes, Nantes, France, 3Institut des Maladies de l’Appareil Digestif (IMAD), 
The Enteric Nervous System in Gut and Brain Disorders, Université de 
Nantes, INSERM, Nantes, France
contact e-Mail address: nicolas.poirier@ose-immuno.com
Introduction: It remains unknown what causes inflammatory bowel dis-
ease (IBD), including signaling networks perpetuating chronic gastroin-
testinal inflammation in Crohn’s disease (CD) and ulcerative colitis (UC), 
in humans.
aims & Methods: According to an analysis of up to 500 patients with IBD 
and 100 controls, we report that key transcripts of the IL-7 receptor (IL-7R) 
pathway are accumulated in inflamed colon tissues of severe CD and UC 
patients not responding to either immunosuppressive/corticosteroid, anti-
TNF, or anti-α4β7 therapies.
results: High expression of both IL7R and IL-7R signaling signature in the 
colon before treatment is strongly associated with nonresponsiveness to 
anti-TNF therapy. While in mice IL-7 is known to play a role in systemic 
inflammation, we found that in humans IL-7 also controlled α4β7 integrin 
expression and imprinted gut-homing specificity on T cells. IL-7R blockade 
reduced human T cell homing to the gut and colonic inflammation in vivo 
in humanized mouse models, and altered effector T cells in colon explants 
from UC patients grown ex vivo. Our findings show that failure of current 
treatments for CD and UC is strongly associated with an overexpressed 
IL-7R signaling pathway. In addition, we observed a significant increase of 
IL-7 concentration in the serum of UC and CD patients compared to various 
autoimmune diseases such as multiple sclerosis or autoimmune hepatitis.
conclusion: Thoses results point to IL-7R as a relevant therapeutic target 
and potential biomarker to fill an unmet need in clinical IBD detection and 
treatment.
disclosure: BV and NP are shareholders of OSE Immunotherapeutics, a 
company owning IL-7 receptor antagonists. 
P1227 an IMMunOsuPPressIve Pd-L1 POsITIve TuMOur 
MIcrOenvIrOnMenT Marks OesOPhageaL adenOcarcInOMas 
refracTOry TO neO-adjuvanT cheMOradIOTheraPy
Koemans W.1, van Dieren J.2, van den Berg J.3, Chalabi M.2, Voncken F.4, 
Meijer G.3, van Sandick J.1, Kodach L.3
1The Netherlands Cancer Institute, Surgical Oncology, Amsterdam, 
Netherlands, 2The Netherlands Cancer Institute, Gastrointestinal Oncology, 
Amsterdam, Netherlands, 3The Netherlands Cancer Institute, Pathology, 
Amsterdam, Netherlands, 4The Netherlands Cancer Institute, Radiotherapy, 
Amsterdam, Netherlands
contact e-Mail address: w.koemans@nki.nl
Introduction: Oesophageal adenocarcinoma is an aggressive cancer with a 
poor overall prognosis. For patients with a locally advanced resectable tu-
mour and no distant metastases neo-adjuvant chemoradiotherapy (nCRT) 
followed by oesophageal resection is associated with better survival than 
surgery alone. However, a large proportion of patients still develop disease 
recurrence. The mechanism of poor response to nCRT is not yet under-
stood. An effective antitumour immune response is critical for a successful 
tumour elimination. Therefore, an immunosuppressive tumour microen-
vironment may play an important role in failure of standard therapies.
aims & Methods: The aim of this study was to characterize tumour mi-
croenvironment and immune infiltrate in oesophageal adenocarcinoma 
patients in relation to pathological treatment response to nCRT.
Methods: Surgical resection specimens were used from 65 patients with 
oesophageal adenocarcinoma treated with nCRT: 40 responders (Mandard 
tumour regression grade 2) and 25 non-responders (Mandard tumour re-
gression grade 4 or 5). Tumour sections were stained with pSTAT1, CD3, 
CD8, FOXP3 and PD-L1 antibodies. Immunostained slides were scanned at 
high resolution and digital image analysis was performed using Halo soft-
ware (version 2, Indica Labs, Corrales). Group differences were analysed 
using the chi-square test or the Mann-Whitney U test.
    Total responders non-responders p-value
Patients   65   64   25    
Median age in years (range) 63 (44-82) 64 (44-82) 63 (46-78)  
Gender Male 51 (79%) 31 (78%) 20 (80%) 0.811^
  Female 14 (21%) 9 (22%) 5 (20%)  
pT stage pT1 13 (20%) 11 (27%) 2 (8%) 0.012^
  pT2 10 (15%) 9 (23%) 1 (4%)  
  pT3 40 (62%) 20 (50%) 20 (80%)  
  pT4 2 (3%) 0 (0%) 2 (8%)  
pN stage pN0 38 (58%) 27 (68%) 11 (44%) 0.203^
  pN+ 27 (42%) 13 (32%) 14 (56%)  
PDL1 expression* Positive 18 (28%) 6 (15%) 12 (48%) 0.006^
  Negative 42 (65%) 30 (75%) 12 (48%)  
  Unknown 5 (7%) 4 (10%) 1 (4%)  
Mean CD3 density/mm2 1693   1295   2332   0.002º
Mean CD3 density/mm2 654   486   924   0.014º
Mean FOXP3 density/mm2 218   215   224   0.182º
pT stage = pathological T stage; pN stage = pathological N stage (TNM 7th edition) 
*Oesophageal tumours were designated as PD-L1 positive if at least 10% of stroma cells 
demonstrated membranous staining 
^chi-square test; ºMann-Whitney U test
[Table 1]
results: Both responders and non-responders displayed active interferon 
gamma signaling in the tumour cells as judged by positive pSTAT1 staining, 
suggesting that tumour antigen presentation on MHC class I and tumour-
specific stimulation of the immune system were common in both groups. 
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Surprisingly, a significantly higher amount of CD3+ (p=0.002) and CD8+ 
(p=0.014) tumour infiltrating lymphocytes was seen in non-responders as 
compared to responders. Thus, differences cannot solely be explained by 
induction of T-cell infiltration in responders compared to non-responders. 
Also, the amount of FOXP3+ regulatory T-cells was similar in both groups. 
Significantly more non-responders were found to have PDL-1 expression in 
the tumour stroma than responders (48% versus 15%, p=0.006).
conclusion: In tissue samples of oesophageal adenocarcinoma patients 
treated with neo-adjuvant chemoradiotherapy, the presence of an im-
munosuppressive tumour microenvironment was associated with absence 
of treatment response, suggesting that cancer immunotherapy may be a 
valuable alternative treatment option for this group of patients.
disclosure: Nothing to disclose 
P1228 auTOanTIBOdIes TOWards aTP4a and aTP4B suBunITs 
Of gasTrIc PrOTOn PuMP h+,k+-aTPase are reLIaBLe 
serOLOgIcaL Pre-endOscOPIc Markers Of cOrPus aTrOPhIc 
gasTrITIs
Lahner E.1, Lampasona V.2, Brigatti C.3, Piemonti L.3, Dottori L.1, Conti L.4, 
Esposito G.1, Davidson H.W.5, Wenzlau J.M.5, Annibale B.1
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Introduction: Corpus atrophic gastritis (CAG) is a risk factor for gastric 
cancer and carcinoids. Histology is the gold standard for diagnosis, non-
invasive serological tests include gastrin, pepsinogens and parietal cells 
autoantibodies (PCA)(1,2). Autoantibodies targeting the H+/K+-ATPase are 
considered diagnostic markers of autoimmune atrophic gastritis, whose 
diagnostic utility remains to be defined(3). A high diagnostic performance 
of a luminescent immunoprecipitation system (LIPS) assay detecting au-
toantibodies to H+/K+-ATPase alpha (ATP4A) or beta (ATP4B) subunits in 
patients with known diagnosis of CAG has been shown(4).
aims & Methods: To validate the diagnostic performance of ATP4A and 
ATP4B LIPS assays as pre-endoscopic diagnostic tools for detecting CAG in 
patients at clinical suspicion for this condition as compared to histology of 
gastric biopsies as reference test. 
Prospective study on 211 consecutive patients (age 65, range 18-90 years, 
female 61.6%) with clinical suspicion of CAG collected between May 
2017-April 2018. Inclusion criteria were: anemia (iron or cobalamin de-
ficiency), autoimmune diseases, family history for CAG, history of long-
standing non-investigated dyspepsia, chronic proton pump inhibitors. 
Exclusion criteria were: age< 18 years, previous diagnosis of CAG. Included 
patients underwent gastroscopy with standard biopsies for histopathol-
ogy (updated Sydney). A serum sample for each patient was preserved at 
-20°C for the LIPS ATP4A and ATP4B assays, pepsinogen I, and EIA parietal 
cell antibodies (PCA). Serological results were compared with histology to 
assess the diagnostic performance of LIPS assays. For ATP4A and ATP4B 
LIPS assays, recombinant antigens fused to a luciferase reporter were in-
cubated with test sera and immune complexes recovered using protein 
A-sepharose; after addition of the luciferase substrate light output was 
measured in a luminometer and converted to arbitrary units using results 
from a positive serum as reference (5). Pepsinogen I and EIA PCA were 
assessed by commercial kits.
results: Histopathology of gastric biopsies proved presence of CAG in 
115(54.5%) and absence in 96(45.5%) patients. ATP4A LIPS yielded a 
76.5% sensitivity and a 86.4% specificity, ATP4B LIPS a 77.4% sensitivity 
and a 87.5% specificity. EIA PCA showed a 65.1% sensitivity and a 91.7% 
specificity, and Pepsinogen I a 71.3% sensitivity and a 92.7% specificity. 
The areas under the ROC curve of ATP4A (0.822) and ATP4B (0.836) were 
similar to that of EIA PCA (0.820, p>0.05), while that of pepsinogen I was 
higher (0.907, p< 0.01). Considering both LIPS assays or EIA PCA and pep-
sinogen I together, sensitivity increased to 83.5% or 83.3% at cost of speci-
ficity, 82.3% or 88.3%, respectively. 
Regarding ATP4A LIPS, in false negative patients (23.5%) severe corpus 
atrophy (p< 0.001), intestinal metaplasia (p=0.001), and age< 65 years 
were less frequent (p=0.043) than in true positives. Regarding ATP4B LIPS, 
in false negative patients (22.6%) severe corpus atrophy (p< 0.001), and 
intestinal metaplasia (p=0.05) were less frequent than in true positives, 
but age was similar.
conclusion: The LIPS assays detecting autoantibodies against ATP4A and 
ATP4B subunits showed a good pre-endoscopic diagnostic performance in 
patients with clinical suspicion of CAG, with higher specificity but lower 
sensitivity than traditional EIA PCA. Sensitivity of LIPS assays and EIA PCA 
was increased by combining pepsinogen I. These autoantibodies seem 
promising serological biomarkers of CAG suggesting a close relationship 
between their expression and advanced oxyntic mucosa damage.
references: 1) Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune 
atrophic gastritis--pathogenesis, pathology and management. Nat Rev 
Gastroenterol Hepatol 2013; 10: 529-41 2) Lahner E, Norman GL, Severi C, 
et al. Reassessment of Intrinsic Factor and Parietal Cell Autoantibodies in 
Atrophic Gastritis With Respect to Cobalamin Deficiency. Am J Gastroen-
terol 2009; 104: 2071-9. 3) Rusak e, Chobot A, Krzywicka et al. Anti-parietal 
cell antibodies - diagnostic significance. Advances in Medical Sciences 
2016; 61(2):175-179. 4) Lahner E, Brigatti C, Marzinotto I, Carabotti M, Sca-
lese G, Davidson HW, Wenzlau JM, Bosi E, Piemonti L, Annibale B, Lam-
pasona V. Luminescent Immunoprecipitation System (LIPS) for Detection 
of Autoantibodies Against ATP4A and ATP4B Subunits of Gastric Proton 
Pump H+,K+-ATPase in Atrophic Body Gastritis Patients. Clin Transl Gas-
troenterol 2017; 8: e215. doi: 10.1038/ctg.2016.71. 5) Lahner E, Marzinotto I, 
Brigatti C, Davidson H, Wenzlau J, Piemonti L, Annibale B, Lampasona V. 
Measurement of Autoantibodies to Gastric H+,K+-ATPase (ATP4A/B) Using 
a Luciferase Immunoprecipitation System (LIPS). Methods Mol Biol 2019; 
1901:113-131.
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P1229 nLrP3 InfLaMMasOMe-derIved InTerLeukIn-1β 
aTTenuaTes sTress-Induced gasTrIc Injury vIa The cOx-2/Pge2 
axIs
Higashimori A., Watanabe T., Nadatani Y., Nakata A., Otani K., Taira K., 
Hosomi S., Tanaka F., Nagami Y., Tanigawa T., Fujiwara Y.
Osaka City University Graduate School of Medicine, Gastroenterology, Osaka, 
Japan
contact e-Mail address: higamo@med.osaka-cu.ac.jp
Introduction: Activation of inflammasomes, a multiprotein complex con-
sisting of one of NOD-like receptors (NLRs), ASC, and pro-caspase-1, re-
sulted in cleavage of pro-caspase-1, leading to processing of pro-IL-1β 
into its mature form. Water immersion restraint stress (WIRS) can induce 
inflammatory responses and severe mucosal injury in the stomach. We re-
cently reported that inflammasomes were activated to protect the damage 
during the development of WIRS-induced gastric injury (Gastroenterology 
2018: S-207, 2018).
aims & Methods: 
aims: We investigated the mechanisms by which the inflammasome pro-
tected WIRS-induced gastric damage. We also determined which inflam-
masome was involved in the protection of the injury. 
Methods: After fasting for 24 h, male wild-type, caspase-1-knockout (KO) 
and NLPR3 KO mice were placed in a restraint cage and immersed in the 
water bath. Mice were sacrificed after WIRS, and mucosal lesions were 
subjected to measurements of ulcer size and assay of mRNA levels by 
real-time RT-PCR. Protein levels of mature IL-1β and cleaved caspase-1 
in stomach were measured by Western blotting. Prostaglandin E
2
 (PGE
2
) 
production by gastric tissue was assessed by enzyme immunoassay. Some 
animals were given rabeprazole, a proton pump inhibitor, before admin-
istration of the stress to examine the involvement of gastric acid in the 
inflammasome activation.
results: Macroscopic gastric injury developed 3 h after WIRS, while signifi-
cant increases in mRNA expression of IL-1β and protein levels of mature 
caspase-1 and IL-1β were observed on 30 min. NLRP3 mRNA expression 
increased by WIRS, whereas that of other NLRs did not change during ex-
perimental period. NLRP3 KO as well as caspase-1 KO mice exhibited high 
sensitivity to the stress induced injury with reduced expression of mature 
IL-1β protein. Administration of recombinant IL-1β (rIL-1β) abolished such 
aggravation of the injury in these KO mice without affecting gastric muco-
sal pH. In wild-type mice, the levels of cyclooxygenase (COX)-2 mRNA and 
PGE
2
 production by gastric tissue significantly increased on 30 min after 
WIRS. Supplementation of rIL-1β further increased COX-2 expression and 
PGE
2
 production and inhibited the injury. Immunoneutralization of IL-1β 
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exerted opposite effects on the injury and COX-2/PGE
2
 axis. Rabeprazole 
attenuated the stress-induced injury with the increase of gastric mucosal 
pH, but failed to prevent inflammasome activation.
conclusion: These results suggest that NLRP3 inflammasome-mediated IL-
1β plays a protective role in stress-induced gastric injury via activation of 
the COX-2/PGE
2
 axis. Gastric acid may not be involved in the activation of 
the NLRP3 inflammasome in stress-induced gastric injury.
disclosure: Nothing to disclose 
P1230 reaL WOrLd daTa On eMOTIOnaL sTress, dIsaBILITy 
and sOcIaL care fOr ced PaTIenTs
Kubesch A.1, Hausmann J.1, Boulahrout P.2, Filmann N.3, Blumenstein I.1
1University-Hospital Frankfurt, Department of Internal Medicine 1, Frankfurt 
am Main, Germany, 2Frankfurt University of Applied Sciences, Department 4 
Social Work and Health, Frankfurt am Main, Germany, 3University-Hospital 
Frankfurt, Institute of Biostatistics and Mathematical Models, Frankfurt am 
Main, Germany
contact e-Mail address: irina.blumenstein@kgu.de
Introduction: Inflammatory bowel disease (IBD) often manifests itself at a 
young age before or in the middle of working life. There has been insuf-
ficient research into the emotional stress levels of IBD patients, how often 
they suffer from a recognised
aims & Methods: The aim of this study was to assess the level of emotional 
stress and the degree of recognised disability in IBD patients. The aim was 
also to evaluate whether there was any contact with the social system. 
Furthermore, it was examined whether predictive parameters regarding 
recognised disability can be identified in IBD patients. Between 15 Novem-
ber and 21 December 2018, patients with IBD and non-IBD volunteers were 
invited to participate in an online survey developed specifically for this 
study (accessible via www.soscisurvey.de).
results: 505 patients with IBD (441 women, 87.3%) and 166 non-IBD pa-
tients (control group; 109 women, 65.7%) participated in the online survey. 
Patients with IBD reported significantly increased levels of everyday and 
work-related stress within the last six months and five years (p=0.0001), 
respectively. IBD patients were more likely to have a recognised disability 
(p=0.0001). A low academic status was the strongest indicator (p=0.006). 
Interestingly, only 153 IBD patients (30.3%) reported that they had been 
in contact with social workers or other forms of social support due to 
their illness. A recognised disability was the strongest indicator for this 
(p=0.0001).
conclusion: Our study provides real-world data on emotional stress and 
the disability in a large German IBDcohort. It could be shown that patients 
with IBD suffer more often from emotional stress and more often have a 
recognised disability than non-IBD patients. There were differences be-
tween Crohn’s disease and Ulcerative colitis. In addition, it was found that 
only about 1/3 of the patients had come into contact with the social system 
and the corresponding support and that this patient group is therefore ap-
parently undersupplied in this area.
disclosure: Nothing to disclose 
P1231 On-TreaTMenT IMPrOveMenT Of an eMergIng 
PsychOsOMaTIc dePressIve dIsOrder aMOng saLMOneLLa 
carrIers: a MuLTIcenTer exPerIence frOM egyPT
Saied Bakeer M.1, Youssef M.I.1, M. Elshazly H.2, A.El-Gendy A.-E.A.3, 
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Introduction: Based on our observations, as physicians in a referral hospi-
tal, we have been noticing the association between history of enteric fever 
and somatic disorders associated with low mood. At 2 hospitals: Al-Hus-
sein university hospital, Cairo; National Liver Institute hospital, Menoufia; 
we are receiving patients from all over Egypt, including rural areas where 
enteric fever is endemic.
aims & Methods: 
aim: Here we report this series for 60 Egyptian patients referred to us for 
evaluation of different somatic disorders. 
Methods: After extensive evaluations, the patients’ symptoms were proved 
to be functional, their typhoid carrier states were documented, they were 
evaluated for depression using Hamilton-D questionnaire and the severity 
of depression was recorded. All patients were treated by ceftriaxone, 2 gm, 
IV, daily for 15 days. Clinical evaluation and Hamilton score were reas-
sessed at the end of treatment and 6 weeks thereafter. The patients did not 
receive any anti-depressant nor anti-anxiety treatment during their course. 
Typhoid carrier was defined by documenting the history of typhoid fever 
that was diagnosed by culturing the salmonella species not by serology, 
plus at least one occasion of salmonella isolates from stool culture while 
a febrile, plus absence of fever in the past 3 weeks. The Widal test wasn’t 
accepted as a criterion for enrollment.
results: Typhoid carrier status was diagnosed in 60 patients, 32 males 
(53%) and 28 females (47%), the median age was 47 and the age range 
was 19-63 years. All patients were Egyptians and were referred to us from 
rural/villages area. 40 patients (66%) weren’t complaining of any chronic 
diseases while 12 (20%) had diabetes mellitus, 16 (26%) had hypertension 
and 4 (6%) were suffering from bronchial asthma. As regarding smok-
ing, 24 patients were smoker (40%) while 60 % weren’t smoking before. 
Patients showed clinically significant improvement in term of the present-
ing somatic complaints as well as their Hamilton-D score immediately 
post-treatment and consolidate for 6 weeks post-treatment completion. 
The changes in the presenting somatic complaints were highly statistically 
significant P value< 0.01. It shows that fatigue and myalgia were present 
in 60 (100%) patient, anorexia in 48 (80%), chronic abdominal pain in 44 
(73%), change in bowel habits in 52 (86%), vomiting in 24 (40%), myalgia 
in 28 (46%), atypical chest pain in 16 (26%), palpitations in 36 (60%), 
dyspnea in 32 (53%),urinary frequency in 24 (40%), erectile dysfunction in 
18 out of 32 males (50%), while menstrual disturbance was present in 12 
out of 28 females (42%). At the 6th week point the figures and percentages 
were 4 (6%), 12 (20%), 16 (26%), 28 (46%), 24 (40%), 0 (0%), 0 (0%), 4 
(6%), 8 (13%), 4 (6%), 12 (20%), 4 (6%) and un-applicable, respectively.
conclusion: Typhoid carrier, in our study, was associated with psychoso-
matic depression that improved on antibiotic therapy.
disclosure: Nothing to disclose 
P1232 WIThdraWn
688 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
P1233 PercuTaneOus TreaTMenT Of cOMPLIcaTed hydaTId 
LIver cysTs: aBOuT 49
Chabib F.-Z., Benelbarhdadi I., Ajana F.-Z.
Ibn Sina University Hospital, Medical Unit C, Rabat, Morocco
contact e-Mail address: dr.chabib.fatimazahra@gmail.com
Introduction: The of the liver hydatid cyst (LHC) is a parasitic disease due 
to the development of the larval form of the taenia of the dog echinococ-
cus granulosus. This pathology remains frequent and constitutes a public 
health problem. Infectious, biliary and thoracic complications are pres-
ent in 40% of cases. Topographic diagnosis has become easy thanks to 
advances in medical imaging. Percutaneous treatment was validated by 
the WHO in 1997 for uncomplicated cysts, and its place in the treatment of 
complicated forms remains controversial.
aims & Methods: The aim of this work is to evaluate, the place of percuta-
neous treatment in complicated liver hydatid cysts (LHC) essentially those 
are infected or with biliary fistula.
this is a retrospective and descriptive study included all patients with 
complicated(HLC), confirmation of biliary fistula (BF) was done by bilious 
aspect of the aspirated liquid, or on the determination of bilirubin level 
with a rate higher than 5 mg / l, the diagnosis of infected (HCL) was made 
on the purulent aspect of the liquid and the bacteriological exam . All our 
patients had percutaneous treatment either by suction aspiration drainage 
or by PAIR (puncture, aspiration, injection, reaspiration), and received al-
bendazole. The evaluation of the efficacy was made on ultrasound criteria.
results: Forty-nine patients followed for (HLC) complicated with biliary 
fistula and / or infection had received percutaneous treatment in our de-
partment, their average age was 33 years [5- 75], with no predominance 
of sex: 25 F and 24 H, 47% had history of (HLC) surgery, and most of them 
had a recurrence, and only two (4%) patients had previous PAIR . For the 
(HLC) treated , the average size was 9.4 cm [3.3-20]; 60% of (HLC) were 
type I, 38% type II and only 2% type III according to the GHARBI classifica-
tion. Twenty-five patients presented with biliary fistula (51%), five had an 
infected (HLC) (10%), both complications were present in nineteen patients 
(38.7%) and the success rate in our series was of 73% :100% in infected 
cysts, 76% in case of biliary fistula, 68% in case of combination of the two 
complications.
conclusion: Percutaneous treatment is an effective and safe method to 
treat complicated (HLC). Further studies are needed to confirm these re-
sults. But the best treatment of liver hydatid cyst remains the prevention.
disclosure: Nothing to disclose 
P1234 reLaTIOnshIP BeTWeen PaTIenT BackgrOund and The 
causaTIve BacTerIa Of chOLangITIs and drug sensITIvITy
Itoh T.1, Tanaka M.2, Naritomi T.3, Fukuya Y.3, Nagahara H.3
1Tokyo Women’s Medical University, Gastroenterology, Shinjuku, Japan, 
2Tokyo Women’s Medical University, Institute of Gastroenterology, Shinjuku, 
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contact e-Mail address: ito.taito@twmu.ac.jp
Introduction: Cholangitis increases the internal pressure of the biliary duct, 
resulting in bacteria in the bile flowing out from the hepatic vein into the 
systemic circulation, which is said to cause bacteremia. This study aimed 
to identify the effective initial pharmacotherapy that is suitable for individ-
ual patients by investigating the relationship between patient background 
and the causative bacteria of cholangitis and drug sensitivity.
aims & Methods: The study conducted a statistical analysis on the relation-
ship between the primary disease of cholangitis, details of biliary drainage 
treatment, causative bacteria, and drug sensitivity of the bacteria in 107 
patients with cholangitis who were admitted to the hospital between April 
2014 and October 2018, where the causative bacteria could be identified 
using endoscopic retrograde cholangiopancreatography in blood and bile 
cultures.
results: The 107 patients were comprised of 46 men and 51 women, with 
a mean age of 77 years. A total of 308 strains of causative bacteria were 
identified from blood cultures, and 333 strains were identified from bile 
cultures. The primary disease was cancer such as pancreatic cancer in 
80 patients and non-cancerous conditions such as choledocholithiasis 
in 27 patients. The biliary drainage treatment in the patients with cancer 
consisted of self-expandable metal (n = 49) and plastic stents (n = 31), 
with significantly more self-expandable metal stents used in the cancer 
patients (p < 0.001). The culture results indicated that the patients with 
cancer tended to have a significantly higher number of strains resistant to 
third-generation cephalosporin antibiotics such as cefotaxime and fourth-
generation cephalosporin antibiotics such as cefepime. In particular, while 
ESBL-producing Escherichia coli was not isolated from the patients without 
cancer, it was detected 22 times in the patients with cancer. A significantly 
higher number of resistant strains were found in the plastic stent group in 
the subgroup analysis of the patients with cancer.
conclusion: This study found a significantly higher number of resistant 
strains in the patients with cancer and cholangitis, which was particularly 
high in the patients where drainage was performed with a plastic stent. 
Possible causes include the following: patients with cancer have repeated 
occlusion of the bile duct as the cancer progresses, the plastic stent is more 
prone to occlusion than the self-expandable metal stent, and the patients 
have a greater exposure to antibiotics due to their immunocompromised 
state. Broad-spectrum antibiotics, excluding cephalosporin antibiotics, 
are preferable as initial treatment for cholangitis caused by cancer.
disclosure: Nothing to disclose 
P1235 varIaTIOn In PneuMOnIa raTes By endOscOPIc 
PrOcedure and sedaTIOn PerfOrMed In OuTPaTIenT seTTIngs
Hutfless S.1, Chu D.2, Liu S.2, Kalloo A.3
1Johns Hopkins University, Department of Medicine, Baltimore, United States, 
2Johns Hopkins University, Baltimore, United States, 3Johns Hopkins Medical 
Institution, Baltimore, United States
contact e-Mail address: shutfle1@jhmi.edu
Introduction: Aspiration pneumonia following endoscopic procedures is 
associated with anesthesia assistance. We aimed to examine the type of 
sedation and rates of hospitalization for pneumonia following endoscopic 
procedures performed in the outpatient hospital setting.
aims & Methods: The January 2015-December 2018 United States Medicare 
fee-for-service claims of individuals 65 and older were queried. This age 
groups represents about 30% of the United States population. Bronchos-
copy, colonoscopy (diagnostic and screening), cystoscopy, EGD and ERCP 
were included. Monitored anesthesia care (MAC) and moderation sedation 
were identified by Healthcare Common Procedure Coding System (HCPCS) 
and associated modifiers. Simultaneous anesthesia care for 2-3 and 4 or 
more procedures was examined. Aspiration pneumonia within 7 days was 
identified by a hospitalization with ICD codes 5070, 5078, J690 or J698 and 
infectious pneumonia was identified by codes 480-486 and J12-J18. Only 
pneumonia recorded as present on admission was considered an event 
to increase specificity that the patient was admitted with this condition. 
Logistic regressions for pneumonia included the sedation variables, type 
of procedure, age, sex, race, year, comorbidities, screening vs diagnostic 
procedure, and procedure discontinuation.
results: There were 9,023,288 eligible procedures (4,096,589 colonoscopy 
[26% screening], 3,853,942 EGD, 178,350 ERCP, 633,864 cystoscopy, and 
351,527 bronchoscopy). MAC was documented for 58% of procedures (56% 
colonoscopy, 62% EGD, 81% ERCP, 69% cystoscopy and 43% bronchosco-
py). Aspiration pneumonia was recorded in only 19 patients; older age and 
male sex were associated with an increased risk of aspiration pneumonia. 
There were only 40 admissions for infectious pneumonia; no factor was 
associated with infectious pneumonia.
conclusion: In the outpatient hospital setting in the United States, pneu-
monia after endoscopy procedures that the hospital considered as present 
on admission was rare.
disclosure: Nothing to disclose 
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P1236 endOscOPIc fIndIngs In severe yeLLOW fever 
PaTIenTs PresenTIng WITh acuTe uPPer gasTrOInTesTInaL 
BLeedIng: a reTrOsPecTIve case serIes sTudy
Galetti F.1, Ogawa Matsubayashi C.1, Farias Ferreira G.1, Coronel M.1, 
Rocha R.1, Martins K. R.1, de Moura D.2, Baba E.1, de Moura E.1
1Clinics Hospital of the University of Sao Paulo Medical School, Digestive 
Endoscopy Department, São Paulo, Brazil, 2Brigham and Women’s Hospital, 
Harvard Medical School, Division of Gastroenterology, Hepatology and 
Endoscopy, Boston, Massachusetts, United States
contact e-Mail address: carol.ogawa.m@gmail.com
Introduction: The incidence of yellow fever in Brazil has been low during 
the last decades, but since December 2016, an epidemic yellow fever has 
resurged in this country. In the severe form (15%-60%), gastrointestinal 
hemorrhage can be present, with a high mortality rate (20-50%). This is 
one of the first studies reporting the causes of gastrointestinal bleeding in 
patients with severe yellow fever. We aimed to describe the main endo-
scopic findings in patients with severe yellow fever in whom an emergency 
upper gastrointestinal endoscopy (UGE) was performed.
aims & Methods: This is a retrospective case series study that included 
a total of 26 patients referred to a tertiary care center in Brazil for sus-
pected severe form yellow fever diagnosis (between December 2017 and 
April 2018), undergoing UGE for acute upper gastrointestinal bleeding. The 
principal reasons of hospitalization of theses patients in our hospital were 
acute liver failure (88%).
results: The mean age was 36 years (range 16 yo - 63 yo), and 84,61% 
were men.
The table 1 summarizes main endoscopic findings and treatments
In the esophagus, four cases of Mallory-Weiss syndrome (three with active 
bleeding treated endoscopically with adrenaline injection in two cases and 
band ligation in one case); two cases of active variceal bleeding treated 
with band ligation and one case of esophageal perforation (Boerhaave’s 
syndrome) that evolved into a bilateral esophago-mediastinal fistula treat-
ed with endoscopic placement of two plastic pigtail stents and bilateral 
pleural drainage.
In the stomach, eight cases presented with of severe hemorrhagic pan-
gastritis (four with diffuse oozing bleeding that did not allow adequate 
endoscopic hemostasis and four without active bleeding); one case with 
focal oozing hemorrhage of the gastric mucosa, which resolved after a sec-
ond UGE with hemoclip placement; four cases with gastric ulcers (two with 
active bleeding treated with hemoclip); one case with a vascular Dieulafoy 
lesion treated with hemoclip. 
In the duodenum, one case presented with hemorrhagic duodenitis with 
diffuse oozing bleeding that did not allow adequate endoscopic hemo-
stasis; one case with an active duodenal ulcer treated with hemoclip; one 
case with bulbar telangiectasias without bleeding. In two cases the spe-
cific cause of bleeding was not determined, due to the presence of large 
amounts of non-aspirable blood clots in the stomach and duodenum.
conclusion: This is one of the first series describing the endoscopic find-
ings and experience in this subset of patients. Liver acute failure due to 
yellow fever is an uncommon condition for endoscopists worldwide. 88% 
of the patients included in this study were hospitalized due to acute liver 
failure.
Severe vomiting episodes before gastrointestinal bleeding explained Mal-
lory-Weiss and Boerhaave’s syndrome cases. Most cases presented diffuse 
hemorrhagic gastritis probably due to the severe coagulopathy that lim-
ited endoscopic therapeutic options. UEG in severe yellow fever patients 
is challenging and required endoscopic treatment in 32 % in this case 
series study.
disclosure: Nothing to disclose 
P1237 ePIdeMIOLOgy and TIMe Trends Of uPPer 
gasTrOInTesTInaL BLeedIng - a POPuLaTIOn Based cOhOrT 
sTudy Over MOre Than 30 years
Vora P.1,2, Pietilä A.3, Brobert G.4, Salomaa V.3
1Bayer AG, Epidemiology, Berlin, Germany, 2Ludwig-Maximilians-University, 
IBE, Munich, Germany, 3National Institute for Health and Welfare (THL), 
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Introduction: Gastrointestinal bleedings (GIBs) are acute events which are 
potentially severe but not always life threatening and often can be safely 
treated. There have been numerous studies reporting on the rates of GIBs 
associated with use of drugs but very few studies have examined the rates 
of upper GIBs (uGIBs) in the general population and trends over time
aims & Methods: The aim of this study was to evaluate the incidence rates 
of uGIBs and the trends over time in the general population of Finland. 
Data from participants of prospectively conducted population-based FIN-
RISK health examination surveys was utilized for this study. FINRISK en-
rolled persons aged 25-74 years, recruited by random sampling from the 
population register, stratified by 10-year age group, sex and study area. 
The total number of participants in each survey was approximately 6000-
8000. The participation rate in 1972 survey was >90% with a gradually 
declining trend to 57% in men and 67% in women in 2012. The follow-
up took place using record linkage to the country-wide electronic health 
registers which included hospital discharge register and causes of death 
register. With the help of these national registers, the coverage of the 
follow-up was 100% for persons living in Finland. The follow-up period 
was from the enrollment up to the onset of an uGIB leading to hospitaliza-
tion, death due to any cause, or end of the follow-up period which was 
December 31st, 2016. Participants with a history of GIBs before the baseline 
were excluded from the analyses. Incidence rates, recurrence rates (events 
recorded were >30 days apart), cause-specific mortality rates and 28-day 
case-fatality rates for uGIBs were calculated with 95% confidence intervals 
(CIs). The time-trends in event rates were calculated using a log-linear 
poison regression model adjusting for baseline age, gender, region, and 
the year of enrollment. Age standardization was conducted using weights 
from the European standard population
results: A total of 71,068 participants were included in the study and they 
experienced 1643 incident uGIBs. The median age of participants experi-
encing uGIBs was 48.6 years, among the ones without GIBs it was 45.4 
years. The age standardized incidence rates for uGIBs in males and fe-
males were 1.59 and 0.95 per 1000 py, respectively. Among men, the inci-
dence rates declined approximately by half by the end of the study period 
compared to late 1980’s (ref. period), and among women a consistent de-
cline was seen, so that at the end of the study period the rates were less 
than 20% of those in the late 1980’s. Among incident uGIBs, the recurrence 
rates of uGIBs in males and females were 20.3 and 13.3 per 1000 py, re-
spectively. There was a substantial random variation but the general trend 
in proportion of recurrent uGIBs was increasing. Cause-specific mortality 
rates from uGIBs in males and females were 0.14 and 0.07 per 1000 py, re-
spectively. Compared to the late 1980’s, mortality due to uGIBs decreased 
sharply in the early 1990s by 40-60% and remained stable since the late 
1990s, approximately at 20% of the level in the late 1980’s. The 28 day 
case-fatality rates in males and females were 8.2% and 6.6%, respectively. 
The case-fatality rate for overall uGIBs for males and females calculated for 
5-year periods since 1987 showed a declining trend up to the period 2002-
06. However, no further decline was seen in the last decade.
conclusion: Overall, the age-standardized incidence rates of uGIBs are 
higher in males than in females. The rates of uGIBs and deaths due to 
uGIBs have significantly decreased since the late 1980’s over the years.
disclosure: Pareen Vora is an employee at Bayer AG, Berlin Germany; Gun-
nar Brobert is an employee at Bayer AB, Solna, Sweden; Veikko Salomaa 
has participated in a conference trip sponsored by Novo Nordisk and re-
ceived a honorarium for participating in an advisory board meeting (unre-
lated to the present study). Veikko Salomaa and Arto Pietilä has ongoing 
research collaboration with Bayer AG. 
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P1238 effIcacy Of PurasTaT In uPPer and LOWer 
acuTe gasTrOInTesTInaL BLeedIng: a duaL case serIes 
exPerIence
De Nucci G.1, Reati R.2, Dinelli M.3, Redaelli D.2, Mandelli E.D.4, 
Omazzi B.2, Morganti D.2, Manes G.5
1ASST Rhodense, Gastroenterology and Endoscopy Unit, Milano, Italy, 
2ASST Rhodense, Gastroenterology and Endoscopy Unit, Milan, Italy, 
3AO SanGerardo, Endoscopy Unit, Monza, Italy, 4Ospedale Guido Salvini, 
Gastroenterology and Endoscopy Unit, Milan, Italy, 5ASST Rhodense, 
Gastroenterology, Garbagnate, Italy
contact e-Mail address: gimanes@tin.it
Introduction: Gastrointestinal (GI) bleeding is a common cause for hospi-
talization, resulting in significant mortality and morbidity. Innovative topi-
cal hemostatic modalities have been developed for endoscopic use. Our 
aim is to demostrate the efficacy, feasibility and safety of Purastat to con-
trol GI bleedings. Puramatrix is a synthetic, bioresorbable material used 
to produce Purastat, created to control venous/arteriolar bleedings, It’s 
easy, quick and trasparent allowing to continue the procedure/to use other 
haemostatic therapies.
aims & Methods: We report a case series of 33 patients (23 males, 10 wom-
en, median age 74 years) recovered to two endoscopy units (Garbagnate 
Milanese and Monza) for acute GI bleeding after failure of other hemo-
static strategies (injection/clipping/thermal coagulation). 14/25 patients 
presented a lower GI haemorrhage from an oozing site after mucosectomy 
for non polypoid colon adenomas in different sites of the colon (8 pts from 
the right colon) 5 patients showed melena for duodenal bleeding from 
bulbar kissing ulcers, 4 patients with melena and anemization after duo-
denal mucosectomy for a laterally spreading tumor of the second part of 
the duodenum, 4 patients had emathemesis after Vater papilla’s sphinc-
terotomy, 1 patient showed progressive anemization for bleeding inside 
a pseudocyst after endoscopy ultrasound guided drainage, 1 patient pre-
sented with a massive rectal bleeding after a prostatic biopsy, 3 patients 
from neoplastic gastric ulcer localized in the body and in the fungus and 
1 patient with a massive bleeding after gastric random sampling due to 
obscure underlying arteriovenous in-wall malformation.
results: In all these patients, we tried to achieve a successfull hemostasis 
first of all using an adrenaline injection and subsequently with clipping 
and/or argon plasma coagulator application without success. Finally we 
used a strate of Purastat applying 3 ml of gel, with a successfull, stable he-
mostasis and a complete patients recovery in few days after the procedure, 
no pain and haemodinamical stability. No need to surgery or radiological 
haemostatic procedures
conclusion: Purastat is a new, safe and feasible hemostatic device capable 
to control different types of GI haemorrhages even if the arteriolar mas-
sive ones.
disclosure: Nothing to disclose 
P1239 are There any ePIdeMIOLOgIc Or ManageMenT 
dIfferences BeTWeen uPPer gasTrOInTesTInaL BLeedIng 
nOT assOcIaTed and assOcIaTed TO POrTaL hyPerTensIOn? 
cOMParaTIve anaLysIs In a sOuThern sPanIsh area
Díaz Jiménez J.A.1,2, Leal Téllez J.2, Calle Gómez A.R.2
1Hospital de La Línea de la Concepción, Unidad Aparato Digestivo, La Línea 
de la Concepción, Spain, 2Hospital Universitario Puerta del Mar, UGC Aparato 
Digestivo, Cádiz, Spain
contact e-Mail address: adiazjime@gmail.com
Introduction: The aim is to evaluate comparatively different epidemiologic 
and management aspects of Upper Gastrointestinal Bleeding not associ-
ated (UGBNPH) and associated (UGBPH) to Portal Hypertension, in Puerta 
del Mar Hospital, Cádiz, Andalucía, Spain.
aims & Methods: Retrospective research including every patient admitted 
to Gastroenterology Department of Puerta del Mar Hospital (Cádiz), be-
tween January 2016 and December 2016, because of Upper Gastrointestinal 
Bleeding (UGB).
We analysed different variables: relation to Portal Hypertension, age, 
cardiovascular risk factors such Arterial Hypertension (AHT), Diabetes 
Mellitus (DM) and Dyslipidemia (DLP); concomitant treatment with Pro-
ton Pump Inhibitors (PPIs), Antiplatelets, Antithrombotics, Nonsteroideal 
Anti-Inflammatory Drugs (NSAIDs) and Antidepressants; clinical and en-
doscopic findings; red blood cells and iron requirement. We also analysed 
short and medium term survival rates and recurrence rate in one-year 
period.
results: We included 105 patients admitted because of Upper Gastrointes-
tinal Bleeding (71,4% not associated to Portal Hypertension; 28,6% associ-
ated to Portal Hypertension), with an average age older in the first group 
(UGBNPH 69,7 years old; UGBPH 59,8 years old). 
We did not find significant differences by etiology when analyzing DM 
(29,5%). However, it was more usual the AHT (53,3% vs 36,7%) and DLP 
(34,7% vs 16,7%) in not associated to Portal Hypertension group.
We did not find significant differences when analyzing use of PPIs (37,1%) 
and Antidepressants (17,1%). Nevertheless, it did exist a higher frecuence 
of Antiplatelets (29,3% vs 6,7%), Antithrombotics (29,3% vs 3,3%) and 
NSAIDs (20% vs 0%) in patients with UGBNPH).
Clinical debut as Melena (66,7%) and Hematemesis (61,9%) was similar, 
with no differences depending on etiology of bleeding. 
Regarding Endoscopic findings, we found more frecuently Gastric Ulcer in 
UGBNPH (37,3%) and Esophageal Variceal bleeding among UGBPH (70%).
We did not find significant differences by etiology regarding amount of pa-
tients that required red blood cells transfusion during admission (62,9%), 
the number of packed blood cells used (4 as average) and iron treatment 
beginning (21,9%).
Short and medium-term survival rates were slightly higher in not associ-
ated to Portal Hypertension group: short-term (94,7% vs 90%) and me-
dium-term (one year after admission) (84% vs 80%). Finally, recurrence 
rate in one-year period was fairly higher in associated to Portal Hyperten-
sion group (40,7% vs 14,1%), especially in women and Portal Hypertension 
Gastropathy bleeding.
conclusion: Upper Gastrointestinal Bleeding not asocciated to Portal Hy-
pertension is more frecuent that the associated one in our environment. 
Cardiovascular risk factors such as Arterial Hypertension, Dyslipidemia or 
concomitant treatments as Antiplatelets, Antithrombotics and NSAIDs are 
more often related to UGBNPH. The amount of patients with red blood 
cells transfusion requirement was similar by different etiologies. Survival 
rates are slightly higher in UGBNPH, while bleeding recurrence is quite 
more frecuent in UGBPH.
disclosure: Nothing to disclose 
P1240 nOveL heMOsTaTIc POWder sTOPs BLeedIng In a LIve 
POrcIne MOdeL Of uPPer gI BLeedIng
Donnellan F.1, Ali-Mohamad N.2, Baylis J.R.2, Cau M.2, McFadden A.1, 
Kastrup C.J.2
1Vancouver General Hospital, Vancouver, Canada, 2University of British 
Columbia, Vancouver, Canada
contact e-Mail address: fdonnellan77@hotmail.com
Introduction: Hemostatic powders are an attractive option in upper GI 
bleeding. However, currently available powders are not effective in For-
est Ia bleeds and are associated with unacceptably high rebleeding rates. 
These limitations are related to their mechanism of action which is based 
on provision of a mechanical bandage on, rather than delivery of any ther-
apeutic agents to, the site of injury.
CounterFlow is a novel hemostatic powder which based on self -propel-
ling technology can deliver thrombin against blood flow and into the site 
of injury.
aims & Methods: To determine efficacy of CounerFlow hemostatic powder 
in stopping bleeding in a live porcine model of acute severe upper GI 
bleeding. 
Bleeding model includes anesthetised pig, surgical laparotomy and 1cm 
gastrotomy, placement of gastroepliploic vascular bundle into gastric lu-
men, incision of artery with ERCP needle knife to create an actively spurt-
ing bleed, and delivery of powder by upper endoscopy and a 7Fr catheter 
using a CO2 powered hand held delivery system.
results: A total of 8 bleeds were created in 4 different pigs. Successful he-
mostasis was achieved in 100% of bleeds. Average time to achieve hemo-
stasis was 4.31 mins (range 1 -11 mins). Average mass of powder required 
to achieve hemostasis was 2.4g (range 1.1 - 6.7g).
conclusion: A novel self propelling hemostatic powder has shown early 
promise in stopping bleeding in a live porcine model of acute severe up-
per GI bleeding.
references: Self-propelled particles that transport cargo through flowing 
blood and halt hemorrhage. Baylis JR et al. Sci Adv. 2015 Oct 2;1(9):e1500379
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disclosure: Drs. Kastrup and Baylis have filed patent applications regard-
ing CounterFlow, and are co-founders of a start-up company, CoMotion 
Drug Delivery Systems, Inc. (“CoMotion”), whose focus is commercializing 
CounterFlow. Dr. Donnellan is also a shareholder in CoMotion. 
P1241 effIcacy Of heMOsTaTIc POWders In The TreaTMenT 
Of gasTrOInTesTInaL BLeedIng reLaTed TO neOPLasTIc Or 
nOn-neOPLasTIc LesIOns
Cardamone C.1, Paoluzi O.A.1, Aucello A.2, Grasso E.1, Giannelli M.1, 
Baiocchi L.3, Fantini M.C.1, Monteleone G.1, Del Vecchio Blanco G.1
1University Tor Vergata, Department of Systems Medicine - Gastroenterology 
Unit, Rome, Italy, 2MG Vannini Hospital, Digestive Endoscopy Unit, Rome, 
Italy, 3Policlinico Tor Vergata, Department of Experimental Medicine and 
Surgery - Liver Unit, Rome, Italy
contact e-Mail address: car.cardamone@gmail.com
Introduction: EndoClot System (Endoclot Plus Inc., Santa Clara, CA, 
USA) and Hemospray (Cook Medical, Winston-Salem, NC, USA) are two 
sprayable powders for induction of immediate bleeding stop recently in-
troduced in gastrointestinal endoscopy.
aims & Methods: Aim of the study was to evaluate the efficacy and safety 
of the two kinds of hemostatic powder (HP) in the management of gastro-
intestinal bleeding (GIB). From September 2017 to March 2019, all patients 
with endoscopically confirmed GIB were considered eligible for the study. 
Inclusion criteria were active bleeding at the time of the endoscopy and 
the failure (complete or partial ineffectiveness) or inapplicability of stan-
dard procedures of hemostasis (local adrenaline infiltration, argon plasma 
coagulation or electrohemostasis, mechanical with clips). Once identified 
the source of GIB, Endoclot System or Hemospray was sprayed over the 
lesion and the short-term efficacy was evaluated observing the bleed-
ing lesion for several minutes. The choice of which kind of HP to be used 
was arbitrary or related to the availability of the product in the endoscopy 
room. The efficacy of HP was evaluated according to the hemostasis which 
was defined as follows: immediate =no bleeding after application up to 
end of the procedure; stable=no bleeding recurrence in the 72 hours after 
the procedure; definitive =no more episodes of bleeding till the discharge. 
We also evaluated any adverse event possibly related to the use of HPs.
results: A total of 29 patients (19 males; median age: 72 years, range: 
32-89) were included. All patients had symptoms of upper GIB but two 
with rectal bleeding (one following an endoscopic submucosal dissection 
and one due to colorectal cancer). Of 29 patients, 20 were at first episode 
of GIB while 9 had already been submitted to an endoscopic hemostatic 
procedure for GIB. All patients were found to have an active GIB due to: 
chemotherapy-related mucosal damage or graft versus host disease (two 
patients, both with extensive mucosal denudation in the esophagus); ul-
cer in the stomach (3 patients), in the duodenum (4 patients), and in the 
gastric anastomosis (4 patients); inoperable malignancy infiltrating the 
wall of the stomach (8 patients), duodenum (4 patients), or colon (one 
patient); post-endoscopy procedures (sphincterotomy in two patients and 
endoscopic submucosal dissection in the rectum in one patient). The use of 
HP achieved immediate hemostasis in 28 out of 29 patients (97%), stable 
hemostasis in 23 patients (79%) and definitive hemostasis in 22 patients 
(76%). No adverse events occurred.
conclusion: The HPs are effective for stopping GIB related to different kinds 
of neoplastic and not neoplastic lesions, not responding or not amenable 
to be treated with standard hemostatic techniques.
disclosure: Nothing to disclose 
P1242 OuTcOMe Of uPPer gI haeMOrrhage In PaTIenTs WITh 
acuTe Or chrOnIc renaL faILure and InfLuence Of renaL 
faILure On rIsk sTraTIfIcaTIOn scOrIng
Murray I.A.1, Haddock R.2, Fuchtbauer D.3, Menzies A.4, Michell N.4, 
Laursen S.B.3, Stanley A.J.5
1Musgrove Park Hospital, Gastroenterology, Taunton, United Kingdom, 2NHS 
Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom, 
3Odense University Hospital, Medical Gastroenterology, Odense, Denmark, 
4Royal Cornwall Hospital, Truro, Gastroenterology, Truro, United Kingdom, 
5Glasgow Royal Infirmary GI Unit, Gastroenterology, Glasgow, United 
Kingdom
contact e-Mail address: rosiehaddock1@doctors.org.uk
Introduction: Renal failure is associated with poorer outcome following 
upper gastrointestinal haemorrhage (UGIH) and is a parameter in some 
pre-endoscopy risk stratification scores which are used to identify low-
risk patients who may be safely managed as outpatients. We studied the 
outcome of patients admitted with UGIH in relation to their renal function 
and risk stratification scores.
aims & Methods: Prospectively collected data from a 1-year international 
multi-centre study of consecutive patients presenting with UGIH. Demo-
graphics, endoscopic findings, treatment and outcomes were recorded. 
eGFR was determined retrospectively from admission creatinine. If eGFR 
was < 60ml/minute, it was recorded whether this was acute kidney injury 
(AKI) or chronic kidney disease (CKD) by review of electronic patient notes. 
Glasgow Blatchford (GBS), admission Rockall (aRS), AIMS65 and PNED 
scores were determined. Need for endoscopic therapy, transfusion, sur-
gery, rebleeding within 7days and 30-day mortality rates were recorded.
results: The main findings are shown in table 1 and are median or per-
centage except where indicated. 
  normal renal function akI ckd p value
number 1208 165 250  
age 52 75 82 <0.0001
female 39.7% 42% 50% <0.05
endoscopy findings        
normal 12.0% 11.5% 12.4%  
Benign ulcer 17.9% 24.2% 19.2%  
varices 5.2% 6.7% 4.4%  
cancer 2.2% 0% 2.4%  
not scoped 27.6% 24.2% 18.4% NS
endoscopic therapy 18.6% 25.9% 27.6% <0.001
surgery 0.6% 0% 1.2% NS
rebleed <7days 4.6% 8.4% 6.8% 0.06
30-day mortality:        
Bleed related 1.2% 7.2% 4%  
non bleed related 3.1% 10.8% 13.2% <0.0001
Transfusion 27.7% 41.6% 49.6% <0.0001
Transfusion (average units) 3.7 4.7 4.4 <0.05
need for treatment or died 37.5% 57.8% 63.2% <0.0001
Length of stay (average in days) 3.96 8.11 6.58 <0.0001
[Table 1. Results summary]
In determining low risk patients who did not require endoscopic therapy, 
transfusion, surgery, radiological embolisation and did not die within 30d, 
GBS < 1 gave highest sensitivity for those patients with normal renal func-
tion, AKI or CKD (94.8-100%). Specificity was 51.6-64.8%, although GBS 
< 1 only identified “low risk” patients in 1.9% and 2.0% of AKI and CKD 
patients compared to 30% of those with normal renal function.
In comparison, AIMS65=0 had sensitivity 70.4-80%, specificity 54.1-94.3% 
identifying more patients as low risk (44.2%, 22.7%, 6.4% respectively). 
Admission Rockall = 0 identified a similar percentage to GBS as low risk 
with poorer sensitivity (75-100%). PNED < 1 identified the highest num-
ber of low risk patients (52.8%,18.9% and 12.4%) but had low sensitivity 
(53.6-80.5%).
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conclusion: Patients admitted with UGIH and renal impairment are old-
er and more likely to be female, than those with normal renal function. 
Transfusion requirements, need for endoscopic therapy, rebleed rate and 
mortality (bleed and non-bleed related) and are all increased in this 
group. GBS identifies low risk patients with AKI or CKD with high sensitiv-
ity, although few low risk patients are in this group. No other commonly 
used pre-endoscopy risk score is accurate in identifying low-risk patients 
with renal impairment.
disclosure: Nothing to disclose 
P1243 evOLuTIOn Of adMITTed PaTIenTs WITh 
gasTrOInTesTInaL BLeedIng and anTIPLaTeLeT-anTIcOaguLanT 
TheraPy fOr cardIOvascuLar dIsease
Murcia Pomares O.1, Baile Maxía S.2, Martínez-Moreno M.3, Romero A.4, 
Núñez L.3, Hortelano I.4, Bellot P.4, Vicente N.3
1Hospital General Universitario, Unidad de Gastroenterología, Alicante, 
Spain, 2Hospital General Universitario, Unidad de Gastroenterología, 
Alicante, Spain, 3Hospital General de Elche, Elche, Spain, 4Hospital General 
de Alicante, Alicante, Spain
contact e-Mail address: omp_89@hotmail.com
Introduction: The evolution of admitted patients due to gastrointestinal 
bleeding (GB) and previously treated with new oral anticoagulants (NOAC) 
has not completely characterized and compared to admitted patients with 
GB and previous treatment with other antiplatelet (AP) or anticoagulant 
(AC) therapy.
aims & Methods: Our aim was to compare re-bleeding and mortality rates 
between both groups. A prospective multicenter cohort study was design 
and patients with AP-AC treatment for cardiovascular disease and acute 
GB were consecutively included between January 2017 and march 2018 in 
Alicante, Spain. Demographic, physical, endoscopic, blood parameters, 
previous treatment and evolution outcomes were recorded. Descriptive 
and analytic analysis were performed, comparing outcomes between pa-
tients with NOACs vs patients with other AP-AC therapy. Chi-square and 
t-Student test were used in univariate analysis for comparative analysis, 
while mean +/- standard deviation (SD) or frequencies and percentages 
showed descriptive results. P< 0.05 was considered significant.
results: 170 patients were included with a mean length of admission of 
11.0 days (SD 9.8). 59% of patients were men and the mean age was 76.3. 
50 (29.4%) had suffered a previous GB. NOACs were part of therapy in 61 
(35.9%) patients, whereas the rest were being treated with other AP-AC 
therapy. During their stay at the hospital, a total of 24 patients rebled, 
5 patients had ischemic complications and 6 patients died. Comparisons 
show that NOAC group had lower systolic pressure (118 vs 127; p=0.05) 
and a trend to higher cardiac frequency (87 vs 80 bpm; p=0.06). A lower 
but non-significant cypher of hemoglobin was also detected (8.9 vs 9.8 g; 
p=0.39). 
No differences were seen in the number of transfusions and Blatchford 
score. The length of admission was also similar between them (mean 
11.3 vs 11.0 days, p=0.87). Rebleeding (p=0.23), ischemic complications 
(p=0.46) and mortality (p=0.47) rates did not differ between both groups. 
Comparing different NOACs, no significant differences were seen in the 
same rates either.
conclusion: In our prospective cohort study, no differences were detected 
during the admission of patients with acute bleeding concerning related 
complications and mortality in patients with NOACs vs patients with other 
AP-AC therapy.
disclosure: Nothing to disclose 
P1244 PredIcTOrs Of endOscOPIc InTervenTIOn In uPPer 
gasTrOInTesTInaL BLeedIng durIng hOsPITaLIzaTIOn In 
MedIcaL Wards InPaTIenTs adMITTed fOr OTher causes
Khoury T.1, Kadah A.1, Mahamid M.2, Mari A.3, Daher S.4, Sbeit W.1
1Galilee Medical Center, Gastroenterology, Nahariya, Israel, 2Sharee Zedek 
Medical Center and the Nazareth Hospital EMMS, Gastroenterology and Liver 
Disaeses, Jerusalem, Israel, 3Nazareth EMMS Hospital, Qalansawa, Israel, 
4Hadassah Medical Center, Gastroenterology, Jerusalem, Israel
contact e-Mail address: tawfik.khoury.83@gmail.com
Introduction: Upper gastrointestinal bleeding is a complication often en-
countered in inpatients hospitalized for another reason. Often these pa-
tients are unstable and the decision to perform upper endoscopy in these 
patients is not easy.
aims & Methods: To characterize variables that may predict endoscopic 
intervention in inpatients admitted for non-gastrointestinal bleeding (GIB) 
causes who later developed inpatient upper GIB. A retrospective analysis 
of patients who underwent inpatient gastroscopy from 5.2014 to 12.2017 
at two academic medical centers were performed. Clinical and laboratory 
data were collected.
results: One-hundred and seven patients were included. Nineteen pa-
tients (17.8%) underwent endoscopic intervention (group A) and 88 pa-
tients underwent endoscopy without intervention (group B). Average age 
in groups A and B was 66.7±18.4 and 71.1±14.6 years (P=0.13), respectively. 
Predictors of endoscopic intervention were cirrhosis (31.5% vs. 3.4%, P< 
0.0001), lower blood pressure (109.8/60.8 mmHg vs. 126.8/68.3 mmHg, 
P< 0.03) and higher heart rate before gastroscopy (97.7 vs. 87.7, P=0.03), 
mechanical ventilation during admission (41.7% vs. 18.7%, P=0.04), num-
ber of blood units administered (4.3 vs. 2.6 units, P=0.001), lower he-
moglobin level at time of gastroscopy (8.3 mg/dl vs. 9.3 mg/dl, P=0.04), 
increase in urea level delta (7.1 vs. 2.55, P=0.05) and higher Glasgow 
Blatchford (13.9 vs. 11.2, P=0.0004), AIMS-65 (2.3 vs. 1.5, P=0.001) and 
Rockall (6.4 vs. 4.3, P<0.0001) scores, respectively. 
Recent antiplatelets, anticoagulation use and infectious etiology didn’t 
predict endoscopic intervention (P>0.1 and P=0.6, respectively). Proton 
pump inhibitors at admission and prior to endoscopy didn’t decrease the 
need of endoscopic intervention (P=0.3). Mortality rate was similar be-
tween groups A and B (36.8% vs. 39.7%, P=0.4).
conclusion: Several clinical and laboratory parameters were found to pre-
dict endoscopic intervention in inpatients with DE NOVO upper GIB. Fur-
ther prospective studies are needed to validate our findings
disclosure: Nothing to disclose 
P1245 Over-The-scOPe cLIP as a rescue TheraPy fOr 
fIBrOTIc BLeedIng esOPhageaL varIces: a sIngLe-cenTer 
exPerIence
Oleas R., Alcivar-Vasquez J., Alvarado-Escobar H., Puga-Tejada M., 
Robles-Medranda C.
Instituto Ecuatoriano de Enfermedades Digestivas (IECED), Gastroenterology 
and Endoscopy Division, Guayaquil, Ecuador
contact e-Mail address: robertoleas@gmail.com
Introduction: Repetitive endoscopic band ligations (EBL) are associated 
with fibrosis of the esophageal wall. Fibrosis of the esophageal wall im-
paired the band ligation of esophageal varices during endoscopy. 
Sclerotherapy is the standard rescue therapy for the management of fi-
brotic esophageal varices; however, feasibility and safety are a concern for 
sclerotherapy.
aims & Methods: aim: We aimed to evaluate the safety and efficacy of 
Over-The-Scope clip in the management of actively bleeding fibrotic 
esophageal varices. 
Methods: This was a historic cohort study. Data from patients with upper 
gastrointestinal bleeding from a single tertiary center were retrospectively 
recorded and prospectively analyzed. Patients in whom endoscopic band 
ligation failed to adhere to fibrotic esophageal varices were treated with 
the deployment of over-the-scope clips.
results: Ninety-six patients with actively bleeding esophageal varices were 
included from September 2016 to January 2019. Five patients had fibrosis 
within the esophageal wall and active bleeding esophageal varices. Thus, 
the over-the-scope clip was deployed over the bleeding fibrotic varix as 
rescue therapy. The median age was 65 years old (range: 52 - 83); three 
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patients were female. The cirrhosis etiology was alcohol in one patient, 
and NASH in four patients. Two patients had two previous EBLs, two pa-
tients had three previous EBLs before the index bleed and one patient a 
single previous EBL. Four patients have a Child-Pugh B and one patient 
a Child-Pugh C. During follow-up esophagogastroduodenoscopy, two pa-
tients were submitted to further EBL for variceal eradication after the index 
over-the-scope clip therapy. Neither re-bleeding nor mortality during the 
index bleeding was documented. Table 1 summarizes patients data per 
each case.
Patient 
no.
age 
(years) etiology
child 
score
Previous 
eBL
further 
eBL Mortality
1 69 Alcohol B 2 2 No
2 60 NASH B 3 0 No
3 65 NASH B 3 0 No
4 52 NASH C 1 2 No
5 83 NASH B 2 0 No
[Table 1. Characteristics of patients with fibrotic esophageal varices treated 
with Over-The-Scope Clip (OTSC).]
conclusion: The over-the-scope clip is a safe and effective alternative in 
the management of fibrotic esophageal varices. The over-the-scope clip 
might be considered as an alternative to sclerotherapy in the management 
of fibrotic esophageal varices. Randomized controlled trials are required 
to validate these data.
disclosure: Nothing to disclose 
P1246 OuTcOMes On The use Of heMOsPray In uPPer 
gasTrOInTesTInaL BLeeds secOndary TO PePTIc uLcers: 
PrOsPecTIve MuLTIcenTre InTernaTIOnaL heMOsPray 
regIsTry
Hussein M.1,2, Alzoubaidi D.2, Graham D.1, Weaver M.3, Mullady D.3, 
Early D.3, Fernández-Sordo’ J.4, Ragunath K.4, Dunn J.5, Rey J.W.6, 
Hayee B.7, Moreea S.8, Anderson J.9, Bovineau G.10, Ochieng A.11, Boger P.11, 
Mainie I.12, Murino A.13, Despott E.13, Goetz M.14, Bhandari P.15, Lovat L.2, 
Coron E.10, Keisslich R.6, Haidry R.1,2
1University College London Hospital, Gastroenterology, London, United 
Kingdom, 2University College London, London, United Kingdom, 3Washington 
University School Of Medicine, St Louis, Mo, Washington, United States, 
4Nottingham University Hospital, Nottingham, United Kingdom, 5Guys and 
St Thomas Hospitals, London, United Kingdom, 6Horst Schmidt Kliniken, 
Wiesbaden, Germany, 7Kings College Hospital, Gastroenterology, London, 
United Kingdom, 8Bradford Hospitals Foundation Trust, Bradford, United 
Kingdom, 9Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire, 
United Kingdom, 10University of Nantes, Institute of Digestive Disease, 
Nantes, France, 11University Hospital Southampton, Southampton, United 
Kingdom, 12Belfast City Hospital, Belfast, United Kingdom, 13Royal Free 
Hospital, London, United Kingdom, 14Universitätsklinikum Tübingen, 
Interdisziplinäre Endoskopie, Tübingen, Germany, 15Portsmouth University 
Hospital, Dept. of Gastroenterology, Portsmouth, United Kingdom
contact e-Mail address: mohamed.hussein3@nhs.net
Introduction: Peptic ulcers are the commonest cause of upper Gastrointes-
tinal (GI) bleeding (UGIB), accounting for 44% of all UGIBs. The mortality 
from GI bleeding remains high at 7%. Hemospray (Cook Medical, North 
Carolina, USA) is a novel haemostatic powder aimed to treat GI bleeding. 
The aim of this study is to look at outcomes in patients with GI bleeds 
secondary to peptic ulcers treated with hemospray in 14 centres, and ex-
amine outcomes based on baseline ulcer morphology based on the Forrest 
classification.
aims & Methods: Data was prospectively collected on hemospray use in 
UGIBs in the UK, France, Germany and the USA (Jan’16-March’19). He-
mospray was used during emergency endoscopy for UGIBs secondary to 
peptic ulcers (oesophageal, gastric or duodenal) at the discretion of the 
endoscopist as a monotherapy, dual-therapy with standard haemostatic 
techniques or rescue therapy once standard methods have failed. Haemo-
stasis was defined as cessation of bleeding within 5 minutes of hemospray 
application. Rebleeding was defined as a sustained drop in Hb (>2g/l), 
haematemesis or melaena with haemodynamic instability following index 
endoscopy.
results: 202 patients with UGIBs secondary to peptic ulcers were recruited 
(136M, 66 F, 125/202 (62%) duodenal, 47/202 (23%) gastric, 30/202 (15%) 
oesophageal). Immediate haemostasis was achieved in 178/202 (88%) pa-
tients. The median Blatchford score was 12 at baseline (IQR, 10-14), median 
rockall score was 7 (IQR, 6-8). 
Immediate haeomastasis was achieved in 34/39 (87%) patients with For-
rest 1a ulcers, 99/117 (85%) with forrest 1b, 25/25 (100%) with forrest 2a, 
20/21 (95%) with Forrest 2b. There was 7/29 (24%) rebleeds with forrest 1a 
ulcers, 13/84 (15%) with forrest 1b. In the 24/196 (12%) patients who did not 
achieve haemostasis 18/24 (75%) were Forrest 1b ulcers. 
In the total PUD cohort treated with hemospray, 26/154 (17%) had a re-
bleed, the median rockall score in this group was 7 (IQR,6-8). The number 
of rebleeds in oesophageal ulcers was 2/23 (9%), 6/38 (16%) in gastric 
ulcers, 18/93 (19%) in doudenal ulcers. 
  forrest 1a (n=39)
forrest 1b 
(n=117)
forrest 2a 
(n=25)
forrest 2b 
(n=21)
Haemostasis 34/39 (87%) 99/117 (85%) 25/25 (100%) 20/21 (95%)
Median Blatchford 
score
13 IQR: 11-14 12 IQR:10-15 12 IQR: 11-14 13 IQR: 11-14
Median Rockall 
score
7 IQR: 6-8 7 IQR:6-8 7 IQR: 6-8 7 IQR: 6-8
Rockall score 7 predicted re-bleeding rate: 25-40%
Re-bleeding 7/29 (24%) 13/84 (15%) 2/23 (9%) 4/18 (22%)
Rockall score 7 predicted mortality: 20-30%
7-day mortality 7/34 (21%) 11/99 (11%) 1/23 (4%) 3/19 (16%)
30-day mortality 9/34 (26%) 21/99 (21%) 3/23 (13%) 5/19 (26%)
[Outcomes in different Forrest classification groups]
conclusion: Hemospray is effective in achieving immediate haemostasis 
in UGIBs secondary to peptic ulcers. The baseline Blatchford score and 
rockall scores in our cohort are high with patients recruited from tertiary 
centres with a complex mix of potentially high-risk cases compared to 
community centres. The rebleeding and mortality rates are in keeping/
below the predicted rate based on the scores. 
The best outcome with hemospray was seen in patients with forrest 2a ul-
cers, with 100% haemostasis, lowest number of re-bleeds and lowest over-
all 30-day mortality. The majority that did not achieve haemostasis were 
forrest 1b ulcers. Highest rebleeding rate was in doudenal ulcers. The he-
mospray registry will continue the expand with the recruitment of US sites.
disclosure: Nothing to disclose 
P1247 cOMParIsOn Of endOscOPIc heMOsTasIs and 
TransarTerIaL eMBOLIzaTIOn (Tae) Of heMOrrhagIc gasTrIc 
uLcer aT Our hOsPITaL
Sugiyama Y., Fukami Y., Ishii R., Hara H., Machida T., Yonemoto Y., 
Ikemiyagi H., Yoshino K., Sakita S.
Yokohama City Minato Red Cross Hospital, Gastroenterology, Yokohama city, 
Japan
contact e-Mail address: yuta1360@gmail.com
Introduction: Endoscopic hemostasis is the first choice of treatment for 
hemorrhagic gastric ulcers; however, if endoscopic hemostasis fails, 
switch to transarterial embolization (TAE) and surgery should always be 
considered. It may be possible to provide prompt treatment by examining 
predictive factors of switch from endoscopic hemostasis to TAE. This time 
we retrospectively compared endoscopic hemostasis with TAE for the treat-
ment of hemorrhagic gastric ulcer at our hospital.
aims & Methods: This study was aimed to assess predictive factors for 
requirement of switch from endoscopic hemostasis to TAE. Patients 
with benign hemorrhagic gastric ulcer requiring endoscopic hemosta-
sis (clip method, coagulation method, and injection of hypertonic saline 
epinephrine(HSE)) who visited the hospital between December 2009 and 
December 2018 (n= 393) were enrolled. They were classified into two 
groups; one group underwent only endoscopic hemostasis, while the oth-
er received endoscopic treatment and TAE. Age, medical history, medica-
tion, Glasgow-Blatchford score (GBS), number of endoscopic hemostasis, 
total blood transfusion volume, and blood test of hemoglobin (Hb), serum 
albumin (Alb), blood urea nitrogen (BUN) and PT-INR were retrospectively 
reviewed and statistically considered.
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results: Of the 393 patients with hemorrhagic gastric ulcer underwent 
endoscopic hemostasis, hemostasis was achieved with endoscopy alone 
in 382 cases (97.2%) and 11 cases (2.8%) were switched to the TAE. The 
overall mean age was 68.7 years, and there was no significant difference 
between the 2 groups in terms of the medical and oral history (antithrom-
botic drugs, gastric acid inhibitors, and NSAIDs). Eight patients (72.7%) of 
TAE were able to achieve complete hemostasis; however, 2 did not achieve 
hemostasis with TAE, and surgery was performed. One patient was unable 
to identify point of bleeding; however, natural hemostasis was achieved. 
In one case, a splenic abscess was formed after the TAE, and splenec-
tomy was performed, suggesting a complication due to TAE. There was 
no intestinal necrosis or perforation after TAE. The mean GBS at the first 
examination was 10.0±3.3 in endoscopic hemostasis group and 12.2±3.5 in 
TAE group, which was significantly higher in TAE group (p=0.0382); fur-
ther, number of endoscopic hemostasis was 1.1±0.3 and 2.5±1.1 (p=0.0008), 
and total blood transfusion volume was 3.8±3.8 units and 20.8±11.3 units 
(p=0.0007) respectively, which were also statistically higher in TAE group. 
Hb and Alb at the first visit were significantly lower in TAE group (Hb; 
p=0.0241, Alb; p=0.0230).
conclusion: As predictive factors of cases switching from endoscopic he-
mostasis to TAE, it is suggested that GBS at the first examination, number 
of endoscopic hemostasis, total blood transfusion volume, blood param-
eters of Hb and Alb at the first examination could be useful indices.
disclosure: Nothing to disclose 
P1248 assesMenT OuTcOMes Of neW ThreshOLds Of The 
gLasgOW BLaTchfOrd scOre In ManagIng PaTIenTs WITh 
uPPer gasTrOInTesTInaL BLeedIng. The exPerIence Of a 
TerTIary cenTer
Jiménez-Rosales R.1, Vadillo-Calles F.1, Ortega-Suazo E.J.1, 
Martínez-Cara J.1, Redondo-Cerezo E.2
1Hospital Universitario Virgen de Las Nieves, Gastroenterology, Granada, 
Spain, 2Hospital Virgen de las Nieves, Digestive Diseases, Granada, Spain
contact e-Mail address: ritajimenezrosales@gmail.com
Introduction: Upper gastrointestinal bleeding(UGIB) remains a significant 
cause of hospital admission. In order to stratify patients according to the 
risk of complications and to predict the need of clinical intervention, sev-
eral risk scores(RS) have been proposed and their in the early patients 
assesment is repeatedly recommended by international guidelines to 
distinguish high-risks patients, who may need clinical intervention and 
hospitalization, from low risk patients with a lower chance of developing 
complications (1). Many RS have been developed, being pre-endoscopy 
scores more appropriate because it seems more important to predict risk 
as soon as possible after the UGIB onset to help direct management, es-
pecially when the endoscopist is on-call (2). The most well established 
pre-endoscopic score is the Glasgow-Blatchford score(GBS). Patients with 
a GBS=0 have less than 1% likelihood of requiring endoscopic interven-
tion and may safely be discharged before undergoing endoscopy, however, 
90% of patients have a GBS>0 and would require inpatient management. 
A more recent study used a cutoff of ≤ 1 and show a 99.2% sensitivity 
when identifying low-risk patients, which identification would decrease 
the number of admitted patients admitted by half(3).
aims & Methods: The aim of our study is to assess outcomes in patients 
with UGIB and GBS ≤ 1.
This was a prospective study on consecutive UGIB patients (variceal and 
non variceal) treated in “Virgen de las Nieves” University Hospital from 
2013 to 2018. All patients underwent upper endoscopy. Information regard-
ing clinical and biochemical data and procedures was collected. Docu-
mented clinical outcomes were in-hospital and delayed (6-months) mor-
tality, rebleeding and delayed 6-months hemorrhagic and cardiovascular 
events. Descriptive and inferential statistical analysis was carried out.
results: 632 UGIB patients were included,613 GBS>1 and 19 GBS≤1. GBS≤1 
patients differed from GBS>1 in comorbidities (26.3%vs.75.4%; p<0.001), 
antithrombotic use (10.5%vs.38.2%; p=0.014), smoking habit (0%vs.20.8%, 
p=0.026), alcohol intake (5.26vs.18.99; p=0.001), melena at presentation 
(31.6%vs.70.1%; p< 0.001), loss of consciousness (0%vs.12.2%; p=0.027), 
pulse (80.26vs.90.32; p=0.003), urea (31.68vs.86.11; p<0.001), creatinine 
(0.79vs.1.21; p<0.001), hemoglobin (13.8vs.9.4 ;p<0.001), INR (1.01vs.1.56; 
p<0.001), endoscopic treatment ( 10.5%vs.43.9%; p=0.004), rebleeding 
(0%vs.17.8%; p=0.043), red cell units transfusions (0vs2.78; p<0.001), days 
of admission(1.37vs.8.89; p<0.001), in-hospital mortality (0%vs.10.1%; 
p=0.047), delayed mortality (0%vs.11.1%; p=0.036), delayed hemorrhagic 
events (0%vs.19.2%; p=0.035), delayed cardiovascular events (0%vs9.5%; 
p=0.045). No differences were found in terms of sex, age, hematemesis, 
blood pressure, albumin, platelets and need for surgery or interventional 
radiology (0%vs4.1%; p=0.360).
conclusion: This study showed patients with GBS≤1 are less complex and 
have great outcomes. This finding is similar to what has been previously 
described(3).
Being a referral center, our hospital takes care of a high number of pa-
tients with a special dedication to GI bleeding. This fact, as well as a 
24/365 on-duty gastroenterologist determines a low threshold to perform 
urgent GI endoscopy. 
In light of these findings we support what has been published previously, 
that is the safe outpatient management of patients with a GBS≤1. Delay-
ing endoscopy in these cases would not have changed the results, with 
healthcare savings.
In conclusion, as international guidelines recommend, we should use a 
risk score to guide our performance.
references: 1. Monteiro S, Gonçalves TC, Magalhães J, et al. Upper gas-
trointestinal bleeding risk scores: Who, when and why? World Journal of 
Gastrointestinal Pathophysiology 2016;7:86-96 2. Stanley AJ, Laine L. Man-
agement of acute upper gastrointestinal bleeding. BMJ. 2019;25; 364:l536. 
3. Laursen SB, Dalton HR, Murray IA, et al. Performance of new thresholds 
of the Glasgow Blatchford score in managing patients with upper gastro-
intestinal bleeding. Clin Gastroenterol Hepatol 2015;13:115-121.
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P1249 The IMPacT Of On-caLL vs. On-duTy endOscOPIsT In 
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gasTrOInTesTInaL BLeedIng: a PrOsPecTIve sTudy 
In a TerTIary cenTer
Jiménez-Rosales R.1, Vadillo-Calles F.1, Ortega-Suazo E.J.1, 
Martínez-Cara J.1, Redondo-Cerezo E.2
1Hospital Universitario Virgen de Las Nieves, Gastroenterology, Granada, 
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Introduction: Upper gastrointestinal bleeding (UGIB) is a true emergency, 
associated with significant morbidity, mortality and healthcare costs. Sev-
eral factors have been found to influence UGIB outcomes including the 
experience of the endoscopist, off-hours hospital admission, hospital vol-
ume and time to endoscopy(1). A recent meta-analysis shows that patients 
with UGIB who were admitted during off-hours had a significantly higher 
mortality and were less likely to receive endoscopy within 24 hours of ad-
mission. Indeed, there seems to be a strong correlation between timely 
endoscopic management and staff coverage in the hospital, particularly 
the availability of on-call endoscopists during off-hours(2).
aims & Methods: The aim of our study was to compare whether there are 
differences in UGIB outcomes between two periods in our hospital, one 
with on-call endoscopist (OCE) and another with on-duty endoscopist(ODE).
This was a prospective study on consecutive UGIB patients (variceal and 
non variceal) treated in “Virgen de las Nieves” University Hospital from 
2013 to 2018 (OCE until July 2016, ODE afterwards, always a resident on-du-
ty). Every patient underwent upper endoscopy in the first 24h. Information 
regarding clinical and biochemical data and procedures was collected. 
Documented clinical outcomes were in-hospital and delayed (6-months) 
mortality, rebleeding and delayed (6-months) hemorrhagic and cardiovas-
cular events. Descriptive and inferential statistical analysis was carried out.
results: 638 patients with a diagnosis of UGIB were included, 505 OCE 
and 133 ODE. Not differences were found between OCE and ODE in terms 
of in-hospital complications (15.8%vs.16.5%,p=0.845), number of red 
blood cell units transfusions (2.84vs.2.28;p=0.441),days of hospital stay 
(8.98vs.8.61;p=0.463), rebleeding(16.9%vs.18.9%;p=575), need for sur-
gery or interventional radiology (4.4%vs.3%;p=0.484), acute mortality 
(9.7%vs.9.5%,p=0.960), delayed mortality (11.6vs.7.3%;p=0.177), delayed 
hemorrhagic events(18.5%vs.17.4%,p=0.855) or delayed cardiovascular 
events (9.1%vs.8.7%;p=0.922). Patients managed by ODE presented higher 
rate of mayor bleeding stigmata (64.2%vs.48.8%,p=0.005) and need for 
endoscopic treatment (50.4%vs.41.2%,p=0.045).
conclusion: Our hospital is a tertiary and referal center, with an 24/365 
on-duty endoscopist. In this study, we observed no differences in the main 
UGIB outcomes between patients management by OCE vs. ODE, compen-
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sated probably by optimal timing and performance of endoscopy within 24 
hours by an experienced endoscopist in the first period. This finding is in 
accordance with previous result from Xian Feng Xia et al. showing that in 
hospitals providing endoscopy outside normal hours, off-hours admission 
was not associated with an increased risk of mortality(2).
However, we found a higher rate of bleeding stigmata and need for en-
doscopy in ODE. This finding may be explained by the shortened lapse 
between admission and endoscopy. Longer delays might allow the physi-
ological healing process to downstage endoscopic lesions, reducing endo-
scopic therapy requirements. 
In conclusion, endoscopic attention during off-hours is important for the 
quality of care for patients with UGIB to warrant endoscopic performance 
within 24 hours(3) with no relevant differences between an on-call vs. on-
duty endoscopist schedule.
references: 1. O’Byrne M, Smith-Windsor E, Kenyon CR, et al. Regional 
differences in outcomes of nonvariceal upper gastrointestinal bleeding in 
Saskatchewan. Can J Gastroenterol Hepatol. 2014; 28:135-9. 2. Xian Feng 
Xia, Philip Wai Yan Chiu, Kelvin Kam Fai Tsoi, et al. The effect of off-hours 
hospital admission on mortality and clinical outcomes for patients with 
upper gastrointestinal hemorrhage: A systematic review and meta-anal-
ysis of 20 cohorts. United European Gastroenterol J. 2018; 6: 367-381. 3. 
Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. 
BMJ. 2019;25; 364:l536.
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1Hospital Universitario Virgen de Las Nieves, Gastroenterology, Granada, 
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Introduction: Upper gastrointestinal bleeding (UGIB) is one of the main 
causes of hospital admission and urgent endoscopy in Gastroenterology 
departments and represents a true emergency, associated with significant 
morbidity, mortality and healthcare costs.
Bleeding from upper GI neoplasms (UGIN) has been reported to be re-
sponsible for 1-5% of all acute UGIB (1). Although surgical treatment has 
been shown to control the bleeding episode and improve survival, most 
patients present with advanced-stage unresectable cancer (2). 
Endoscopy therapy has proven to be effective in these cases and hemosta-
sis has been achieved in 67-100% of patients (3). 
However, treatment outcomes for UGIB caused by neoplasms have been 
scarcely reported.
aims & Methods: The aim of our study was to compare the outcomes of 
patients with UGIB secondary to neoplasms with those with UGIB second-
ary to other causes. 
This was a prospective study on consecutive patients with UGIB (variceal 
and non variceal) treated in “Virgen de las Nieves” University Hospital 
from 2013 to 2017.
All patients underwent upper endoscopy, and information regarding clini-
cal and biochemical data, procedures, and outcomes for 6 months after 
admission were collected. The clinical outcomes documented were in-
hospital mortality and rebleeding. Descriptive analysis, bivariate analysis 
and multivariate logistic regression models were carried out.
results: 638 patients with a diagnosis of UGIB were included, in 28 sec-
ondary to neoplasms. We included gastric neoplasm (12 patients), gastric 
polyps (8 patients), gastrointestinal stromal tumors (GIST)(4 patients), 
gastric lynphoma (3 patients) and a duodenal tumor invasion (1 patient). 
These patients differed from the rest in age, previous neoplasms history, 
heart failure, haemoglobin and platelets levels at admission, anticoagu-
lant drugs intake and mortality within 6 months (table 1). They did not 
differ in comorbidities, interventions, complications, acute and rebleed-
ing. 
There were 5 patients (17,9%) who died in hospital, only one associated 
with the hemorrhage. Within the first 6 months, 6 patients died (21%), all 
of them due to disseminated cancer, not to GI bleeding. 
Age (OR 1,04; 95% CI 1,01-1,07. p0,01) and previous neoplasm history (OR 
20,78; 95% CI 1,63-265,44. p0,02) were independent risk factors for de-
layed-6months mortality.
conclusion: In this study, we observed that UGIB due to neoplasms has 
a similar clinical curse in the acute episode than bleeding secondary to 
other causes with regards to in-hospital mortality, complications, need 
for interventions or rebleeding. We observed some differences in the long 
term outcomes such as mortality within 6 months after discharge. As ex-
pected, a previous neoplasm history is a clear predictor of mortality for 
these patients.
  neoplasm Others p
Age 73,4 64,3 0,001
Previous neoplasm history 28,6% 12,3% 0,012
Heart failure 21,42% 9,67% 0,04
Haemoglobin 8,38 9,56 0,022
Platelets 269821 207542 0,006
Anticoagulant 32,1% 16,1% 0,026
Comorbidities (ASA>2) 64,3% 68,05% 0,67
Hospital stay (days) 12,29 8,92 0,12
Blood unit transfusion 3,29 2,69 0,38
Blood pressure 110,7 112,7 0,66
Endoscopic treatment 25% 39,7% 0,12
Rebleeding 3.7% 7,7% 0,71
Acute complications 14,28% 16,06% 0,53
Acute mortality 19,23% 9,24% 0,09
Mortality 6months 21% 10% 0,027
[Table 1]
references: 1. Schatz RA, Rochey DC. Gastrointestinal bleeding due to 
gastrointestinal tract malignancy: natural history, management and out-
comes. Dig Dis Sci (2017) 62:491-501. 2. Kim Y, Choi J, Cho SJ et al. Outcome 
of endoscopic therapy for cancer bleeding in patients with unresectable 
gastric cancer. Journal of Gastroenterology and Hepatology (2013) 1489-
1495. 3. Savides TJ, Jensen DM, Cohen J et al. Severe upper gastrointestinal 
tumor bleeding: endoscopic findings, treatment, and outcome. Endoscopy 
1996; 28: 244-8. 
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P1251 uPPer gasTrOInTesTInaL BLeedIng In scOTLand: 
Trends In deMOgraPhIcs and OuTcOMes 2000-2015
Chaudhary S.1, Mackay D.2, Pell J.P.2, Morris A.J.1, Church N.3, Fraser A.4,5, 
Stanley A.J.1
1Glasgow Royal Infirmary, Gastroenterology, Glasgow, United Kingdom, 
2University of Glasgow, Institute of Health and Wellbeing, Glasgow, United 
Kingdom, 3Royal Infirmary of Edinburgh, Gastroenterology, Edinburgh, 
United Kingdom, 4Queen Elizabeth University Hospital, Gastroenterology, 
Glasgow, United Kingdom, 5Aberdeen Royal Infirmary, Gastroenterology, 
Aberdeen, United Kingdom
contact e-Mail address: sardar.chaudhary@nhs.net
Introduction: Upper gastrointestinal bleeding (UGIB) remains a common 
cause of presentation and admission to hospital in the UK, with the inci-
dence in Scotland one of the highest in the world. Over the past 15 years 
there have been several developments to improve management of patients 
with UGIB. Our aim was to investigate the number of patients presenting 
to Scottish hospitals with UGIB between 2000-2015 and assess the differ-
ence in demographics, aetiology of bleeding and clinical outcomes, in-
cluding those for weekends and weekday presentations.
aims & Methods: Data were collected from SMR01 hospital admissions 
records and GRO death certificates for the period 1st January 2000 to 31st 
December 2015 and analysed in the national safe haven. All outputs were 
disclosure-checked for confidentiality purposes. Admission and death 
rates were computed for each year with trends over the study period esti-
mated using Poisson regression. Standard errors were adjusted to account 
for any serial dependence.
results: A total of 129,404 patients presented to Scottish hospitals with 
UGIB between January 2000 and December 2015. Mean age at admission 
increased over this period from 59.2 years to 61.4 years (P=0.049). There 
was no difference in the annual number of patients over the 15-year pe-
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riod. The incidence of UGIB was highest in the more deprived quintiles, 
although there was a reduction in incidence in the three most deprived 
quintiles over the study period (SIMD1; P< 0.001: SIMD2; P =0.002: SIMD3; 
P=0.001). There was a significant decrease in 30-day case-fatality from 
10.1% in 2000 to 7.9% in 2015 (p< 0.001), which was significant across 
all the deprivation quintiles (P< 0.001). This reduction was seen for both 
variceal and non-variceal bleeding (IRR 0.967; P< 0.001 and IRR 0.980; 
P< 0.001 respectively) with deaths as a proportion of admissions declin-
ing fastest in the variceal compared to the non-variceal group (24.4% to 
14.5%, and 9.8% to 7.8% respectively). The mean length of stay also fell 
from 3.9 days to 2.1 days, an average decline of 0.14 days per year (95% CI 
.15612 - .11723; P< 0.001). There was no difference in 30-day case-fatality 
between patients presenting at weekdays or weekends.
conclusion: The number of patients presenting with UGIB to Scottish hos-
pitals annually has remained similar over the 15-year study period. How-
ever case-fatality and length of hospital stay has fallen, despite a rise in 
the mean age of patients.
disclosure: Nothing to disclose 
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IncIdence and OuTcOMe BeTWeen 2007 and 2017
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and Hepatology, Zagreb, Croatia, 4University Hospital Center ‘ Sestre 
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contact e-Mail address: mrivkovi@gmail.com
Introduction: The aim of this study was to demonstrate differences in epi-
demiological, clinical, endoscopic characteristics and outcome of peptic 
ulcer bleeding (PUB) between 2007 i and 2017.
aims & Methods: From January 2007 to December 2007 a total of 137 pa-
tients referred to our emergency department due to PUB, and from Janu-
ary 2017 to December 2017 a total of 128 patients referred to our emergency 
department due to PUB. They were screened and enrolled in this study.
results: There was no statistically significant difference in PUB incidence 
between 2007 and 2017(38.8/100000 vs 36.3/100000). In 2017 74% patients 
with PUB was older than 65 years (p< 0.001). Men were the majority in 
both groups of patients (over 60%) and most of the patients were bleed-
ing from stomach ulcers(more than 55%). In the year 2017 more patients 
were bleeding from high risk peptic ulcers(Forrest 1a, 1b, 2a i 2b)( 63.3 vs 
48.9%, p < 0.001). In 2017 most patients had moderately severe to severe 
comorbidities(50.3 vs 34.3%, p< 0.001). Initial hemostasis was performed 
more in 2017 than 2007(61.7 vs 40.9%, p < 0.001). There was no differ-
ence in the recurrence of bleeding(8.6 vs 6.7%), in required for surgical 
intervention(4.7 vs. 6.6%), 30-day mortality(7 vs. 4.4%) and need for red 
blood cell transfusion(55.5 vs 50.4%) between year 2017 and 2007. In 2017 
significantly more patients received fresh frozen plasma transfusion(12% 
vs 4.4%, p < 0.05) and patients were longer hospitalized(7 vs. 6 days, 
p < 0.01). In the year 2017 and 2007 the majority of patients with PUB 
were taking agents that attenuate cytoprotective function of stomach and 
duodenal mucosa( 51.1 vs 52.4%). In 2017 higher number of patients was 
taking anticoagulant and antiplatelet therapy compared to 2007(32.8 vs 
13.3%, p < 0.01).
conclusion: PUB predominantly occurs in older age groups with signifi-
cant comorbidities, and it is associated with taking agents that attenuate 
cytoprotective function of stomach and duodenal mucosa, especially with 
antiplatelet and anticoagulant therapy.
references: 1. Holster IL, Kuipers EJ. Management of acute nonvariceal 
upper gastrointestinal bleeding: current policies and future perspectives.
World J Gastroenterol. 2012 ;18:1202-7. 2. van Leerdam ME. Epidemiology 
of acute upper gastrointestinal bleeding.Best Pract Res Clin Gastroenter-
ol. 2008;22:209-24. 3. Nagashima K, Tominaga K, Fukushi K, Kanamori 
A, Sasai T, Hiraishi H.Recent trends in the occurrence of bleeding gastric 
and duodenal ulcers under the Japanese evidence-based clinical practice 
guideline for peptic ulcer disease. JGH Open. 2018;2:255-261.
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P1253 rIkkunshITO Increased aPPeTITe ThrOugh The 
acTIvaTIOn Of vTa, reWard cenTer In BraIn
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Japan, 4Teikyo University Chiba Medical Center, Chiba, Japan, 5Saitama 
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Introduction: reviously we reported that Rikkunshito (RKT), Japanese 
herbal medicine improved urocortin1-induced appetite loss through an 
increase in ghrelin< span> < /span>secretion in rats [Am J Physiol Endo-
crinol Metab 2011; 301: E72-82, Psychoneuroendo-crinology, 2014;50:300-
10]. Recently RKT was also elucidated to improve symptoms of functional 
dyspepsia (FD) [Neurogastroenterol Motil 2018; 30]. In the present study, 
we undertook to elucidate a mechanism for orexigenic effects of RKT in the 
central nervous system using in-vivo experiment with rats. To study effects 
of RKT on the function of< span> < /span>brain, we evaluated expression 
of c-Fos as an indicator of activation of neurons in the nuclei of appetite 
control system and reward system in the brain. Then the activation of do-
pamine neuron was also evaluated using immunohistochemical staining 
of tyrosine hydroxylase (TH) which is the rate-limiting enzyme in the syn-
thesis of dopamine and norepinephrine.
aims & Methods: Study on appetite: As anorexic models, rats with cho-
lecystokinin-8 (CCK) administration and restraint stress (RS) were used, 
because these factors were known to induce anorexia and were supposed 
to be involved in the pathophysiology of FD. Effects of CCK or/and restraint 
stress on food intake were examined with or without RKT. To elucidate 
the involvement of brain in the actions of RKT, RKT was given to rats 2 hrs 
before treatments with CCK and RS. The brains were fixed with transcar-
dial perfusion with paraformaldehyde and glutaraldehyde, and the brains 
were removed and continuously fixed and cut into serial transverse sec-
tions. The sections were incubated with anti-c-Fos polyclonal antibody so-
lution followed by incubation with anti-TH antibody and the immunohisto-
chemical staining was performed. Numbers of c-Fos-immunoreactive (ir) 
neurons or TH-immunoreactive (ir) neurons were counted under bright 
field microscope.
results: 1. RKT significantly (p< 0.05) restored food intake inhibited by the 
combination of CCK and RS. RKT increased c-Fos-ir neurons not only in the 
neuclei on hypothalamus but also in ventral tegmental area (VTA) [RKT(-): 
RKT (+) 298±34 : 631.3±30, p< 0.01] and nucleus accumbens (Nac) [RKT(-): 
RKT (+) 111.0±19 : 232±35, p< 0.05] in CCK and RS-treated rats. Number 
of neurons double-stained with anti-c-Fos antibody and anti-TH antibody 
was markedly increased by RKT in VTA [RKT(-): RKT (+) 13±1.7 : 74±17, p< 
0.05]. GHSR1A (ghrelin receptor) antagonist, D-Lys3-GHRP-6 suppressed 
RKT-induced increase in food intake and c-Fos expression in the neurons 
of VTA in CCK and RS-treated rats.
conclusion: The result suggests that RKT restores appetite through the 
ghrelin-dependent activation of the neurons in reward system such as VTA 
and Nac. The results may explain the mechanism for the effects of RKT to 
improve appetite in patients with anorexia due to FD and other causes.
disclosure: Nothing to disclose 
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P1254 ex vIvO IMagIng Of neurOnaL acTIvaTIOn By usIng 
gcaMP6s Is suITaBLe fOr PharMacOLOgIcaL sTudIes Of IOn 
channeLs MedIaTIng acTIOn POTenTIaL cOnducTIOn In The 
axOns Of vIsceraL nOcIcePTOrs
Lipták P.1, Patil M.J.2, Pavelková N.3, Kollárik M.3
1Jessenius Faculty of Medicine, Clinic of Gastroenterological Internal 
Medicine, Martin, Slovakia, 2Johns Hopkins University School of Medicine, 
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Introduction: The information about noxious and inflammatory stimuli in 
the visceral organs is transmitted to the central nervous system by the ac-
tion potentials conducted in the axons of visceral pain-mediating afferent 
nerves (nociceptors). Although it is well established that the voltage-gated 
sodium channels (NaV1) are essential for the action potential conduction, 
it is unknown which of 9 known NaV1 subunits (NaV1.1 thorough NaV1.9) 
mediate the action potential conduction in the axons of visceral nocicep-
tors. Selective inhibition of the NaV1s mediating action potential conduc-
tion in nociceptors could aid the treatment of visceral pain. Unfortunately, 
the electrophysiological single fiber recording is extremely time consum-
ing for this type of studies.
aims & Methods: To evaluate the hypothesis that ex vivo imaging of neu-
ronal activation by the calcium indicator GCaMP6s expressed in sensory 
neurons is suitable for pharmacological studies of NaV1 channels medi-
ating the action potential conduction in the axons of visceral nociceptive 
(capsaicin-sensitive) neurons.
Methods: The vagus nerve with the sensory jugular/nodose ganglion (JNG) 
was isolated from the Pirt-Cre;R26-GCaMP6s mice in which virtually all 
JNG neurons express GCaMP6s. The distal end of the vagus nerve was 
electrically stimulated by the concentric electrode and the resulting activa-
tion of JNG neurons was detected by imaging GCaMP6s with multiphotone 
microscopy (excitation wavelength 920nm,6-10 optical sections separated 
by 20µm, frame rate 0.17Hz). NaV1 inhibitors were selectively superfused 
(37oC) over the desheathed segment of the vagus nerve between the stimu-
lation electrode and JNG. The putative nociceptive subset of vagal neurons 
was identified by the GCaMP6s response to capsaicin (1µM) applied to JNG.
results: Vagal electrical stimulation with increasing frequency 0.5-10Hz 
(pulse 1ms, 100V) for 20s evoked increasing intensity of the GCaMP6s 
signal in JNG neurons. When normalized to the signal at 5Hz, the sig-
nal evoked by 0.5, 1, 3, 5 and 10Hz was 6±1%, 16±1%, 67±2%, 100±0% 
and 134±5%, respectively (N=160 capsaicin-sensitive neurons). Therefore, 
the stimulation with 5Hz was used. The NaV1 inhibitor tetrodotoxin (TTX, 
0.1µM) applied to the vagus nerve completely abolished activation evoked 
by 5Hz electrical stimulation of the vagus nerve in 88% of capsaicin-sen-
sitive neurons (N=93). This is consistent with the previous findings that 
TTX-sensitive NaV1s are required for action potential conduction in the 
vast majority of axons in the vagus nerve. The selective NaV1.7 inhibitor 
PF-05089771 (3µM) applied to the vagus nerve completely abolished ac-
tivation evoked by 5Hz electrical stimulation of the vagus nerve in 57% of 
capsaicin-sensitive neurons (N=282).
conclusion: Our data show that the activation of vagal neurons evoked by 
electrical stimulation of the vagus nerve and detected by calcium reporter 
GCaMP6s expressed in vagal neurons can be abolished in the predictable 
all-or-none fashion by NaV1 inhibitors applied to the vagus nerve. We 
conclude that ex vivo imaging of neuronal activation by the GCaMP6s ex-
pressed in sensory neurons is suitable for the pharmacological studies of 
the NaV1 channels mediating the action potential conduction in the axons 
of visceral nociceptive neurons.
Supported by U01 DK116311 and VEGA 1/0304/19
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Introduction: Glutamate (Glu) is the major excitatory neurotransmitters of 
a brain, but an excess of Glu, results in hyperactivation and subsequent 
death of neurons. The tripeptide Pro-Gly-Pro (PGP) is a fragment of various 
regulatory oligopeptides. PGP effectively protects the gastric mucosa from 
stress-induced ulcers and damage caused by prolonged administration of 
monosodium glutamate (food supplement).
aims & Methods: We studied the effects of PGP (10 uM), its N-acetylated 
and N-phosphorylated derivative (AcPGP and P-PGP) on the intracellular 
Ca2+ concentration ([Ca2+]
i
), mitochondrial potential (ΔΨm) and cell sur-
vival of primary neuroglial cultures subjected to glutamate excitotoxicity. 
Primary cultures were prepared from the cortex 1-2-day old Wistar rats. 
Single cell [Ca2+]
i
 and ΔΨm fluorescence microscopy measurements were 
performed employing Fura-FF and Rh123, respectively. The survival of 
neuroglial cultures was studied using vital fluorescent dyes Syto-13 and 
EthD-1. Peptides were synthesized at the IMG RAS. The experiments with 
animals were carried out in accordance with the declaration on the hu-
man behavior towards animals and in accordance with the Order of the 
Ministry of Healthcare and Social Development of Russia “On Approval of 
Laboratory Practices”.
results: PGP and AcPGP by itself were not neurotoxic. In contrast to them 
P-PGP revealed a weak neurotoxicity reducing cell survival by ~20%. Glu 
reduced the ratio of live/dead cells by ~45%. Addition of PGP ~30min prior 
to Glu application increased the proportion of live cells by ~27%. It is has 
been shown earlier that the acetylation of PGP makes it more resistant to 
prolyl peptidases preventing its hydrolysis. However PGP but not AcPGP 
delayed the development of the Glu-induced delayed calcium deregulation 
(DCD) and synchronous with DCD profound drop of ΔΨm.
conclusion: Uncovered earlier gastroprotective effect of the peptide PGP 
against monosodium Glu-induced ulcer could be, at least partially, related 
to neuroprotection of gut innervation. We have shown that PGP (10 µM) 
diminish the excitotoxic effect of Glu 33 µM and promote recovery of [Ca2+]
i
 
and mitochondrial potential after Glu removal from the cell culture. Acety-
lation or phosphorylation of the N-terminus of PGP prevented its neuro-
protective effect. In our early studies it has been shown that dipeptide GP 
has a pronounced gastroprotective effect on the stressor model of ulcer 
formation. Probably the gastro-neuroprotective effect of PGP is partially 
mediated by its dipeptide moiety GP.
disclosure: Nothing to disclose 
P1256 evaLuaTIOn Of gasTrOInTesTInaL MOTILITy In PaTIenTs 
WITh MIOneurOgasTrOInTesTInaL encePhaLOPaThy (MngIe)
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Introduction: Myoneurogastrointestinal encephalopathy (MNGIE) is a rare 
mitochondrial disease caused by mutations in the thymidine-phosphory-
lase enzyme gene. Clinically it is characterized by severe gastrointestinal 
dysmotility associated with cachexia and a demyelinating sensory-motor 
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polyneuropathy. Given the low incidence (1-9 per million), most patients 
are mistakenly diagnosed of other digestive diseases. Despite the fact that 
gastrointestinal symptoms are progressive and invariably lead to death, 
there are so far no studies evaluating gastrointestinal function in these 
patients.
aims & Methods: We retrospectively studied patients with biochemically 
and genetically confirmed MNGIE who had been referred for evaluation 
of gastrointestinal function to our Motility Unit between August 2008 and 
January 2019.
results: In this period, 8 patients ultimately diagnosed of MNGIE (age 
range 16-41 years, 5 men and 3 women) were evaluated. At the time of 
referral, 5 of the 8 patients were misdiagnosed as Crohn’s disease (n = 
2), celiac disease (n = 1) and superior mesenteric artery syndrome (n = 
2). All patients were severely underweight (BMI range 9 - 15.4 kg/m2) 
and complained of chronic digestive symptoms including abdominal pain, 
vomiting and diarrhea; six of them required total parenteral nutrition. All 
patients except one, showed radiological signs suggestive of intestinal 
pseudo-obstruction: air-fluid levels by plain abdominal x-ray and intesti-
nal dilatation by CT scan in the absence of mechanical obstruction. Specific 
motility tests were performed depending on clinical symptoms and the 
patient’s tolerance. Gastric emptying evaluation by scintigraphy was per-
formed in 5 patients and detected gastroparesis in 4. Esophageal manom-
etry was performed in 5 patients, all of which exhibited ineffective motility 
and a hypotensive lower esophageal sphincter. Small bowel manometry 
was performed in 4 patients and all showed a rare giant non-propagating 
contraction pattern. In 3 of them this manometric pattern helped to estab-
lish the diagnosis of MNGIE within the clinical context. Six of the 8 patients 
died (1 to 60 months after diagnosis, median 2 mo) due to gastrointestinal 
complications of the disease.
conclusion: In patients with MNGIE severe digestive symptoms due to gas-
trointestinal dysmotility often lead to misdiagnosis. We have detected a 
specific intestinal dysmotility pattern which may help to identify patients 
with MNGIE.
disclosure: Nothing to disclose 
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Introduction: Outcomes of laparoscopic Heller’s myotomy (LHM) in obese 
patients with achalasia are sub-optimal along with increased risk of gas-
troesophageal reflux disease (GERD). The impact of obesity on treatment 
success and GERD after POEM are not well known. Hence our study aims 
were to compare the clinical outcomes and rates of GERD after POEM in 
non-obese versus obese patients with achalasia.
aims & Methods: Chart review of all achalasia patients who underwent 
POEM at our institution between April 2014 and June 2018 was performed. 
Patients with timed barium oesophagram (TBE) and high-resolution oe-
sophageal manometry (HREM) prior to POEM along with post-POEM TBE, 
HREM and oesophageal pH study were included. Patients were categorized 
into two groups, non-obese (body mass index, BMI< 30 kg/m2) and obese 
(BMI≥30 kg/m2). Patient demographics, TBE, HREM, pH study findings and 
Eckardt scores were compared between the two groups.
results: A total of 89 patients (46 non-obese; 43 obese) met the study cri-
teria. There were no significant differences in age, gender, achalasia sub-
type, operative time, length of stay (LOS) and complication rates between 
the two groups. Treatment success (Eckardt score <3) was similar in both 
groups (97.7% non-obese vs 92.7% obese, p=0.35). Abnormal DeMeester 
scores on pH study (>14.72) were similar in non-obese and obese patients 
(58.7% versus 46.5%, p=0.25). Symptomatic GERD was also similar in both 
groups (17.8% in non-obese vs. 20% in obese, p=0.79).
conclusion: POEM is an equally safe and effective treatment option for both 
non-obese and obese patients with achalasia in the short term. Interest-
ingly, POEM does not lead to higher rates of GERD in obese compared to 
non-obese patients.
disclosure: Nothing to disclose 
factor
non-obese (n=46) 
(mean BMI: 25.1 ± 2.4 
kg/m2) 
Obese (n=43) 
(mean BMI: 36.2 
± 5 kg/m2) 
p-value
age at POeM (years) 58.1±16.4 56.6±13.9 0.64
Operative time (minutes) 102.5[84.0,120.0] 98.0[79.0,118.0] 0.51
rate of complications 2.2% 4.7% 0.61
Pre-POeM eckardt score 7.0[5.0,8.0] 6.0[5.0,8.0] 0.46
Pre-POeM eckardt score 0.00[0.00,1.00] 1.00[0.00,2.0] 0.16
POeM success rate 97.7% 92.7% 0.35
POeM failure rate 2.3% 7.3% 0.35
rate of symptomatic gerd 17.8% 20% 0.79
abnormal deMeester score on 
24-hr oesophageal ph study 58.7% 46.5% 0.25
[Patient demographics, procedural details and outcomes]
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In InTracTaBLe nausea and vOMITIng aT 10 years: 
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Introduction: Gastric electrical simulation has been shown to relieve vom-
iting and nausea in medically refractory patients. Efficacy of gastric electri-
cal stimulation has been reported mostly in short term studies, however 
no studies have evaluated its efficacy beyond 10 years after implantation.
aims & Methods: Patients implanted at our center for medically refractory 
severe and chronic nausea and/or vomiting were evaluated at baseline 
and over 10 years after implantation using symptomatic scale and quality 
of life score (GIQLI score). Improvement was defined a s a reduction of 
more than 50% of the vomiting frequency.
results: 50 patients were implanted from January 1998 to December 2009. 
The mean follow-up was 10.5 (+/- 3.7) years. Among the 50 patients, 7 
were explanted due to a lack of efficacy, 2 patients died and 4 were lost to 
follow-up. Out of the 37 patients evaluated, 27 (73%) showed a reduction 
of of the frequency of vomiting episode by at least 50%. In intention to 
treeat analysis, 27/50 (54%) of patients reported an improvement. Beyond 
10 years, an score improvement of early satiety (3.05 vs 1.76 , < 0.001), 
bloating (2.51 vs 1.70, p = 0.012), nausea (2.46 vs 1.35 , p=0.001), and vomit-
ing (3.35 vs 1.49 p < 0.001) was observed. Quality of life was improved over 
10 years (GIQLI score: 69.7 vs. 86.4, p = 0.005) as well as body mass index 
(BMI: 23.4 vs. 26.2 p = 0.048).
conclusion: Gastric electrical simulation is safe and effective in the long 
term in patients with medically refractory nausea and vomiting, with an 
efficacy of 54% at 10 years on an intention to treat analysis.
disclosure: Chloe Melchior has interests with MSD, Kyowa Kirin, Mayoly 
Spindler; Guillaume Gourcerol has interests with Allergan, Kyowa Kirin, 
Biocodex, Sanofi, Mayoly Spindler, Laborie. All other authors have no con-
flicts of interest of financial ties to disclose. 
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P1259 Per-OraL endOscOPIc MyOTOMy (POeM) Is a safe and 
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Gabbard S.1, Murthy S.3, Raja S.3, Sanaka M.R.1
1Cleveland Clinic Foundation, Gastroenterology and Hepatology, Cleveland, 
United States, 2Cleveland Clinic Foundation, Bio-Statictics, Cleveland, United 
States, 3Cleveland Clinic Foundation, Thoracic and Cardiovascular Surgery, 
Cleveland, United States
contact e-Mail address: chadalp@ccf.org
Introduction: With global epidemic of obesity, it is not uncommon to en-
counter morbidly obese patients with achalasia. The management of mor-
bidly obese or class III obesity patients (BMI
≥40 kg/m2 ) with achalasia is complex and the existing literature is sparse. 
We conducted a study to assess the outcomes of per-oral endoscopic my-
otomy (POEM) in morbidly obese patients with achalasia.
aims & Methods: Medical records of all the achalasia patients who under-
went POEM between April 2014 and June 2018 at our institution were re-
viewed. Morbidly obese patients (BMI ≥40) who underwent timed barium 
oesophagram (TBE) and high-resolution oesophageal manometry (HREM) 
prior to POEM along with 2-month post-POEM oesophageal pH study, TBE 
and HREM were included. Demographics, type of achalasia, prior inter-
ventions, TBE, HREM, Eckardt scores and pH study findings were analyzed. 
Eckhardt score of ≤3 was considered as successful palliation of symptoms. 
Wilcoxon singed rank tests were used to assess changes in HREM and TBE 
findings (pre-POEM vs. 2 month post-POEM) and a p-value < 0.05 was 
considered statistically significant.
results: A total of 13 patients met the study criteria. Average age at POEM 
was 56.1±1 years, with majority of the patients being females (69%; n=9) 
and Caucasians (58.3%; n=7). Mean duration of achalasia symptoms was 
6 years [1.0, 8.0] and type-II achalasia was most prevalent. 23% (n=3) 
and 30% (n=4) patients had undergone prior treatment with botulinum 
toxin and pneumatic dilation respectively. Median operative time was 80 
minutes [63.0,100.0] and average total myotomy length was 8.8±0.80 cm. 
There were no complications except for post-operative pneumonia in 1 
patient. POEM was successful in 92% (12/13) of the patients. Significant 
improvement was noted in post-procedure Eckhardt’s scores, basal mean 
pressure and integrated relaxation pressure on two month follow up. In 
addition, there was significant improvement in the width of barium col-
umn at 1 minute and height at 5 minutes. A trend of improvement was 
noted in height of barium column at 1 minute and width at 5 minutes, 
but it did not reach statistical significance. In the post-POEM pH study, 
DeMeester scores were abnormal in 70% (7/10) of patients, however only 
10% (1/10) of patients complained of gastro-oesophageal reflux (GOR) 
symptoms.
conclusion: POEM is a safe and effective treatment option for morbidly 
obese patients with achalasia. POEM leads to significant improvement in 
Eckardt scores, HREM and TBE parameters at short-term follow up. Al-
though symptomatic reflux was low, a significantly higher rate of abnor-
mal oesophageal acid exposure was noted on objective testing.
disclosure: Nothing to disclose 
factor class III obese patients (n=13)
Age at POEM (years) 56.1±13.5
Operative time (minutes) 80.0 [63.0,100.0]
Complications 7.6% (n=1) post-operative pneumonia
Pre-POEM Eckardt score 6.0[6.0,8.0]
Post-POEM Eckardt score 0.00[0.00,1.5]
POEM success rate 91.7%
POEM failure rate 8.3%
Rate of symptomatic GERD 10% (n=1)
Abnormal DeMeester score on 24-hr 
oesophageal pH study
70% (n=7)
[Patient demographics, procedural details and outcomes]
P1260 endOscOPIc PyLOrOMyOTOMy (g-POeM), effIcacy 
evaLuaTIOn afTer One year, In refracTOry gasTrOParesIs: 
french MuLTIcenTrIc sTudy
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Introduction: Long term results of G-POEM for refractory gastroparesis are 
lacking. Here we report the results of the largest multicenter study with 
long term follow up about G-POEM for refractory gastroparesis.
aims & Methods: Retrospective, multicentric study of all G-POEM cases, 
performed in seven French expert centers, for refractory gastroparesis, 
within at least one year of follow up
Primary Endpoint: One year clinical success defined by improvement of 
GCSI by at least one point. 
Secondary Endpoints: complications rate, identification of predictors of 
clinical success, clinical success at two years.
Our inclusion criteria were, at least one year follow up, and available GCSI 
score prior GPOEM and 12 months after.
Exclusion criteria were missing GCSI score, technical failure, normal gas-
tric emptying scintigraphy and loss of follow up.
results: 
Description of the population: 133 patients were analysed in 7 French ex-
pert centers and 10 diferent operators. Among them we included 92 pa-
tients for the efficacy analysis, 61% were women, the median age was 
55 years old. About aetiologies : 35% diabetes, 26% post-surgery, and 
33% idiopathic. The median evolution duration of the symptoms was 40 
months. Twenty seven percents had already a prior interventional treat-
ment. The median 4h% remaining in stomach before G-POEM, was 45%. 
The mean GCSI average before G-POEM was 3,6. 
Technical success was achieved in 99,2%. 
Primary Endpoint:Clinical success was achieved in 65,2% at one year , with 
a mean GCSI amelioration of 41%. The GCSI score decrease significantly 
one year after the GPOEM (p=0,0001)
Secondary Endpoints: In univarieted analysis, we identified predictives 
factors of success, wich are a high Satiety subscore in GCSI score (2,12 [ 
1,31-3,44], p=0,002 ), an elevated pre-operative GCSI score (1,85 [ 1,07-
3,20], p=0,027 ) and an advanced age (1,03 [ 1,00-1,06], p = 0,04). We also 
identified predictives factors of failure, which are a BMI >20kg/m2 (0.62 [ 
0.39-1.00], p=0,048) and an elevated gatric retention rate on pre-operative 
gastric emptying scintigraphy (0,98 [ 0,961,00], p=0,048).
We noticed any immediate complication, and only 6% of later complica-
tions.
At two years clinical success was maintained at 73,2% (n=41).
conclusion: This large and multicentric study confirms the efficiency and 
safety of G-POEM in the treatment of refractory gastroparesis The clinical 
success after one year is achieved for 65% of the patients. We identified 
interesting predictives factors of succes. G-POEM should be the first treat-
ment in case of refractory gastroparesis.
disclosure: Nothing to disclose 
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P1261 endOLuMInaL funcTIOnaL LuMen IMagIng PrOBe 
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Introduction: Gastroparesis is a complex and a disabling gastrointestinal 
motility disorder characterized by delayed gastric emptying without physi-
cal stomach obstruction and its management is challenging due to the 
limited relief that traditional treatment options provide Gastric peroral en-
doscopic myotomy (GPOEM) has emerged as a promising novel endoscopic 
technique for the management of refractory gastroparesis. Despite the 
promising outcomes, the main challenge remains in identifying the subset 
of patients with pylorospasm that will potentially benefit the most from 
the procedure. Endoluminal Functional Lumen Imaging Probe (EndoFLIP) 
is a novel device that evaluates sphincter physiologic parameters including 
distensibility; however, the role of EndoFLIP in G-POEM is still unknown.
aims & Methods: Aim is to determine the association of EndoFLIP mea-
surements with symptoms improvement following GPOEM in patients with 
refractor gastroparesis. In this prospective multicenter study, EndoFLIP 
evaluation was performed on patients who underwent G-POEM procedure 
for management of gastroparesis. EndoFLIP measurements, including pre- 
and post-G-POEM pylorus diameter (D) (mm), cross-sectional area (CSA) 
(mm2), pressure (P) (mmHg), compliance (C) (mm2/mmHg), and distensi-
bility index (DI) (mm2/mmHg), were recorded at 40 ml bag volume. Delta 
(d) of each measurement was defined as the change of value from prior to 
after G-POEM. Clinical success was defined by at least one score decrease 
in the total Gastroparesis Cardinal Symptom Index (GCSI) scoring system 
with more than a 25% decrease in at least 2 of its sub-scales.
results: A total of 36 patients (23 [63.9%] female, median age 55yr [IQR: 
43.3-62.0]) at 4 tertiary centers (3 US, 1 Europe) underwent G-POEM with 
EndoFLIP evaluation and were followed for 6 months. Clinical success was 
achieved in 19 (52.8%) patients at 6 months. Comparing mean Endoflip 
measurements between patients with and without clinical success, pre G-
POEM P was significantly lower (14.22 ± 4.54 vs 19.04 ± 7.81, p=0.35), while 
post G-POEM D (14.59 ± 2.54 vs 10.91 ± 4.62, p=0.007) and post G-POEM 
CSA (171.97 ± 56.88 vs 108.92 ± 82.53, p=0.016) were significantly higher in 
patients who achieved clinical success (Table. 1).
 
Pre-gPOeM 
measurements P-value
Post-gPOeM 
measurements P-value
 
Patients wit-
hout symptom 
improvement
Patients with 
symptoms 
improvement
 
Patients wit-
hout symptom 
improvement
Patients with 
symptoms 
improvement
 
Diameter
12.08 
(SD 3.81)
11.99 
(SD 3.17)
0.938
10.91 
(SD 4.62)
14.59 
(SD 2.54)
0.007
CSA
125.22 
(SD 77.38)
120.33 
(SD 51.27)
0.831
108.92 
(SD 82.53)
171.97 
(SD 56.88)
0.016
Pressure
19.04 
(SD 7.81)
14.22 
(SD 4.54)
0.035
17.44 
(SD 7.56)
17.44 
(SD 5.22)
0.942
DI
6.57
(SD 3.63)
9.94 
(SD 6.14)
0.086
7.58 
(SD 8.24)
7.58 
(SD 8.24)
0.362
Comp-
liance
131.48 
(SD 72.37)
198.09 
(SD 121.45)
0.087
151.65 
(SD 164.45)
151.65 
(SD 164.45)
0.265
[Comparison of EndoFLIP measurements in patients with vs without 
symptoms improvement]
Logistic regression model identified pre G-POEM C (OR = 1.023, 95% CI 
1.001-1.045), dD (OR = 2.156, 95% CI 1.106-4.204), and dP (OR = 1.311, 95% 
CI 1.001-1.716) to be independent predictors of clinical success at 6 months 
after G-POEM. Receiver operating characteristic (ROC) analysis revealed 
that dD, with an area under the curve (AUC) of 0.785 (95% CI 0.625-0.946), 
had the highest accuracy for prediction of clinical success, providing speci-
ficity of 77% and sensitivity of 63% at a cut-off point of 2.3 mm. On the 
other hand, dP with AUC of 0.737 (95% CI 0.564-0.909), and pre G-POEM C 
with AUC of 0.664 (95% CI 0.470-0.858) had lower predicting accuracies.
conclusion: Increase of at least 2.3 mm in pylorus diameter post-GPOEM 
procedure is useful for predicting clinical success in patients with gastro-
paresis. EndoFLIP may have a potential role in identifying G-POEM candi-
dates among patients with refractory gastroparesis, thus allowing better.
disclosure: Dr. Mouen Khashab is a consultant for Medtronics, Dr. Vivek 
Kumbhari is a consultant for Medtronics. 
P1262 cOMParIsOn Of Per-OraL endOscOPIc MyOTOMy 
(POeM) OuTcOMes BeTWeen PaTIenTs WITh recurrenT 
syMPTOMs afTer PrIOr PneuMaTIc dILaTaTIOn (Pd) and PrIOr 
LaParOscOPIc heLLer’s MyOTOMy (LhM)
Parikh M.P.1, Chadalavada P.1, Gupta N.M.1, Thota P.N.1, Lopez R.2, 
Wadhwa N.1, Ray M.1, Gabbard S.1, Murthy S.3, Raja S.3, Sanaka M.R.1
1Cleveland Clinic Foundation, Gastroenterology and Hepatology, Cleveland, 
United States, 2Cleveland Clinic Foundation, Bio-Statictics, Cleveland, United 
States, 3Cleveland Clinic Foundation, Thoracic and Cardiovascular Surgery, 
Cleveland, United States
contact e-Mail address: chadalp@ccf.org
Introduction: Pneumatic dilation (PD) and laparoscopic Heller’s myotomy 
(LHM) are established treatment options for achalasia. However, recur-
rence of symptoms requiring re-interventions is not uncommon during 
long-term follow-up. Per-oral endoscopic myotomy (POEM) is emerging as 
an effective treatment modality for palliation of symptoms in such patients. 
In this study, we compared the outcomes of POEM between patients with 
recurrent symptoms after prior PD and LHM
aims & Methods: Medical records of all the achalasia patients who un-
derwent POEM between April 2014 and June 2018 were reviewed. Patients 
who underwent timed barium oesophagram (TBE) and high-resolution 
oesophageal manometry (HROM) prior to POEM along with 2-month post-
POEM oesophageal pH study, TBE and HROM were included. Patients were 
categorized into two groups as: failed PD (no exposure to LHM) and failed 
LHM (no exposure to PD). Patients in either groups might have had prior 
Botox injections. Patient details, TBE, HROM, pH study findings and Eck-
ardt scores were compared between the two groups. 
Analysis of covariance was performed to assess the association between 
prior treatment groups and 2-month outcomes while adjusting for possible 
confounders and a p-value < 0.05 was considered statistically significant.
results: A total of 49 patients (failed PD=28; failed LHM=21) met the study 
criteria. There were no significant differences in demographics, myotomy 
length or complication rates between the two groups. However, patients 
with failed PD were more likely to be obese, with higher ASA classification 
and required shorter operative time. There was a significant improvement 
in Eckardt scores, HROM and TBE parameters at 5 minutes in both groups. 
POEM success rate was similar at 96.3% and 90% in failed PD and failed 
LHM groups respectively (p=0.57). 
Patients in failed LHM group did not have a significant change in 1-minute 
TBE measures. On univariate analysis, patients in failed PD group had sig-
nificantly higher pre-POEM LES basal pressure and lower width of barium 
column at 1 and 5 minutes. In addition, patients in failed PD group had 
significantly lower post-POEM barium height and width at 1 and 5 min-
utes. On adjusted analysis, change in height of barium column at 1-minute 
was significantly higher in patients in failed PD group. There were no dif-
ferences in the pH study findings such as DeMeester scores and/or total 
acid exposure times between the two groups.
conclusion: POEM is safe and equally effective treatment modality for suc-
cessful palliation of symptoms in patients with recurrent symptoms after 
both PD and LHM. Operative time is shorter and there was greater im-
provement in TBE parameters in prior PD group. Post POEM GERD rates 
were similar in both groups. Long-term efficacy studies of POEM are need-
ed in these patients.
disclosure: Nothing to disclose 
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factor
failed pneumatic 
dilatation (Pd); 
(n=28)
failed laparoscopic 
heller myotomy;
(n=21)
p-value
Operative time (minutes)
80.5 
[70.0,101.0]
110.0 
[87.0,130.0]
0.008
Rate of complications 0 (0%) 1 (4.8%) 0.43
Pre-POEM Eckardt score 6.0[5.0,9.0] 6.0[5.0,8.0] 0.66
Post-POEM Eckardt score 1.00[0.00,2.0] 0.00[0.00,2.0] 0.77
POEM success rate 96.3% 90% 0.57
POEM failure rate 3.7% 10% 0.57
Rate of symptomatic GERD 18.5% 11.1% 0.68
Abnormal DeMeester score 
on 24-hr oesophageal pH 
study
53.8% 47.1% 0.66
[Patient demographics, procedural details and outcomes]
P1263 hIgh resOLuTIOn ManOMeTry TradITIOnaL 
ParaMeTers are nOT usefuL TO PredIcT resPOnse TO 
endOscOPIc TreaTMenT In PaTIenTs WITh 
esOPhagO-gasTrIc juncTIOn OuTfLOW OBsTrucTIOn
Della Coletta M.1, Ghisa M.2, Frazzoni M.3, Frazzoni L.4, Gubbiotti A.5, 
Tolone S.6, De Bortoli N.7, Zingone F.5, Savarino V.8, Savarino E.V.5
1University of Padua, Division of Gastroenterology, Department of Surgery, 
Oncology and Gastroenterology, Padua, Italy, 2Azienda Ospedaliera di 
Padova, DISCOG - UOC Gastroenterologia, Vedelago, Italy, 3Baggiovara 
Hospital, Digestive Pathophysiology Unit, Modena, Italy, 4S.Orsola-Malpighi 
Hospital, Department of Medical and Surgical Sciences, Bologna, Italy, 
5University of Padua, Department of Surgery, Oncology and Gastroenterology, 
Padua, Italy, 6University of Campania ‘Luigi Vanvitelli’, Surgery, Naples, Italy, 
7University of Pisa, Department of Gastroenterology, Pisa, Italy, 8Universita di 
Genova, Department of Internal Medecine, Genova, Italy
contact e-Mail address: marcodellacoletta@gmail.com
Introduction: According to Chicago Classification vers. 3.0, Esophago-Gas-
tric Junction Outflow Obstruction (EGJ-OO), is a major oesophageal motor 
disorder characterized by an elevated IRP (i.e. higher than 15 mmHg*s*cm 
with Medtronic device) and preserved peristalsis. Pathogenesis and treat-
ment of this high-resolution manometry (HRM) diagnosis is unknown, 
although the majority of the experts agree on using endoscopic dilation 
or botox injection, particularly in patients reporting dysphagia and weight 
loss. To date, limited data are available to support the hypothesis that 
HRM may be of clinical value in identifying patients who will respond to 
endoscopic therapy.
aims & Methods: We aimed to investigate whether HRM features could 
be useful to predict the therapeutic outcome in EGJ-OOpatients undergo-
ing endoscopic therapy.Patients with symptoms of esophageal dysfunction 
(e.g. dysphagia, chest pain, and regurgitation) underwent upper endosco-
py to rule out organic disease, and thereafter HRM. Symptom severity was 
assessed by a Likert type scale with four items, from 0 (absent symptom) to 
3 (severe symptom), for each symptom. A manometric diagnosis of EGJ-OO 
was made according to CC ver. 3.0. and in case of drugs-unresponsive (i.e. 
calcium channel blockers or phosphodiesterase 5 inhibitors) symptoms 
after six months, an endoscopic treatment (pneumatic dilation or botox 
injection) was proposed to the patients. We opted for using botulinum 
toxin injection in elderly subjects (> 75 years) or in case of relevant co-
morbidities. Clinical response was defined by a symptom score of 0 or 1 
for the main symptom (i.e. the leading one requiring outpatient visit and 
further investigations). Only patients with a follow-up of at least 6 months 
were considered.
results: Thirteen [8M, mean age 64 (50-83)] patients with EGJ-OO under-
went endoscopic treatment (11 pneumatic dilation and 2 botulinum toxin 
injection). In the group treated by pneumatic dilation, 9/11 (82%) had a 
good response and 2 failed thetreatment. Among the two patients who un-
derwent botox injection, 2/2 (100%) had a good response. The difference 
in efficacy of the two treatments was found to be not statistically significant 
by Fisher’s test (p=ns) analysis. By using uni- and multivariate regression 
analysis, a monometric parameter predictive of response to treatment was 
not observed (p=ns).
conclusion: Traditional HRM parameters are not useful to predict the re-
sponse of EGJ-OO patients to endoscopic treatment. Further metrics should 
be developed in order to understand which patients may benefit of endo-
scopic treatment in case of EGJ-OO diagnosis
disclosure: Nothing to disclose 
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Introduction: According to Chicago Classification vers. 3.0, Esophago-Gas-
tric Junction Outflow Obstruction (EGJ-OO), is a major oesophageal motor 
disorder characterized by an elevated IRP (i.e. higher than 15 mmHg*s*cm 
with Medtronic device) and preserved peristalsis. In case of EGJ-OO, an 
evaluation by using Computer tomography (CT) or ultrasound endoscopy 
(EUS) has been suggested in order to rule out presence of organic disease. 
Indeed, at least 50% of EGJ-OO is associated with anatomical abnormali-
ties, including hiatal hernia, peptic stricture, previous foregut surgery or 
EGJ cancer.
aims & Methods: We aimed to evaluate whether additional high-resolu-
tion manometry (HRM) tests such as multiple rapid swallow (MRS) and 
rapid drinking challenge (RDC) can discriminate between functional and 
anatomical EGJ-OO in order to further select which patients should un-
dergo radiology or EUS. Consecutive patients referred to Digestive Physio-
pathology Unit of the Gastroenterology Unit of Padua University and com-
plaining of oesophageal symptoms were enrolled. Each patient underwent 
to upper endoscopy and esophagogram with barium and thereafter an 
oesophageal HRM was performed. In case of IRP>15 mmHg*s*cm without 
a pattern of achalasia, a diagnosis of EGJ-OO was established. Anatomi-
cal EGJ-OO was defined by the presence of: hiatal hernia, abnormalities 
induced by previous foregut surgery, peptic strictures, mucosal or submu-
cosal lesions, and eosinophilic esophagitis. Only in absence of any of these 
diagnoses, a functional EGJ-OO was defined. Patients assuming opioid 
drugs chronically were excluded from the analysis.
results: Forty-nine patients with EGJ-OO were enrolled [24 Male, mean 
age 49 (10-83)]. Fourteen (29%) presented an anatomical abnormality, 
whereas thirty-five (71%) were has a functional EGJ-OO. Multiple Rapid 
Swallow test was available in thirty-seven patients and was abnormal in 
8/9 of anatomical EGJ-OO and in 13/28 of functional EGJ-OO. Using Fish-
er’s test, the difference in percentage of abnormal MRS test in the two 
group was statistically significant (p< 0.05). Mean DEA and peak-DCI were 
higher in the functional EGJ-OO as compared to the anatomical EGJ-OO 
(68±28 vs 108±49 and 2409±1702 vs 4763±3701, respectively). In contrast, 
the mean DCI was higher in functional EGJ-OOcompared to anatomical 
EGJ-OO(1379±1050 vs 2752±2535), but this difference was not statistically 
significant (p=0.07). RDC was not different between the two groups (p=ns).
conclusion: Abnormal MRS test in patients with EGJ-OO could be a useful 
tool to segregate anatomical from functional EGJ-OO patients. Among the 
functional EGJ-OO patients, a major contractile force seems to be present, 
suggesting that this could be correlated with inadequate adaptation of the 
esophageal body motility to the appearance of a recent flow obstruction.
disclosure: Nothing to disclose 
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P1265 IMPaIred esOPhagOgasTrIc juncTIOn eLevaTIOn as an 
IndIcaTOr Of a fuLL-ThIckness Per-OraL endOscOPIc MyOTOMy
Manolakis A.1,2, Abad M.R.A.3, Ikeda H.4, Sumi K.5, Onimaru M.2, 
Sharma A.2, Rodriguez de Santiago E.2, Fukuda H.6, Shimamura Y.6, 
Inoue H.7
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Diseases Center, Cavite, Philippines, 4Showa University Northern Yokohama 
Hospital, Digestive Diseases Center, Tokyo, Japan, 5Showa University Koto 
Toyosu Hospital, Digestive Disease Center, Tokyo, Japan, 6Showa University 
Koto Toyosu Hospital, Tokyo, Japan, 7Showa University Northern Yokohama 
Hospital, Digestive Disease Center, Yokohama, Japan
contact e-Mail address: amanwl@yahoo.com
Introduction: Per-oral endoscopic myotomy (POEM), a highly-effective 
treatment for Achalasia cardia has also been associated with increased risk 
for post-procedure gastroesophageal reflux (GER). One of the risk factors 
for post-POEM GER seems to be the dissection of both circular and longitu-
dinal muscle fibers (full-thickness myotomy-FTM). Irrespective of whether 
it is intentional or accidental, selective and full-thickness dissection may 
coexist, making it difficult to determine whether e.g. a partial FTM has a 
functional consequence.
aims & Methods: To investigate whether the disturbance of post-swallow 
transient proximal, “elevation” of the esophagogastric junction (EGJ), me-
diated by contraction of the longitudinal muscle fibers, could serve as a 
reliable objective indicator of a POEM with FTM. Forty-four patients with 
achalasia -mean age (standard deviation): 53 (15), male:female ratio 1.1:1- 
that underwent posterior POEM at Showa University Koto Toyosu Hospital 
were included. POEM reports, videos, pre- and post-POEM High Resolu-
tion Manometry (HRM-Star Medical Inc, Tokyo, Japan) images were ex-
amined and compared to determine the presence/absence of esophageal 
shortening/EGJ vertical elevation as well as absent, segmental or full-
length FTM. 
The Chicago Classification 3.0 was utilized to distinguish achalasia sub-
types: type I (N=14), type II (N=23), type III (N=3) and early onset achalasia 
(N=4). HRM assessment was performed in a blinded fashion for presence/
absence of FTM.
results: Selective myotomy/absent FTM was documented in 27 patients 
(61%), segmental in 11 (25%) and full-length FTM in 6 (14%). Pre-POEM 
HRM was consistent with absent/minimal EGJ elevation in 13 cases (30%), 
all diagnosed as type I achalasia. Post-POEM HRM revealed 7 additional 
cases (20 in total, 45%, P=0.19), with absent/minimal EGJ elevation that 
received either full-length (N=5) or long-segment (N=2) FTM. The sensitiv-
ity and specificity of absent EGJ elevation for the detection of FTM post-
POEM, was 87.5% and 64%, respectively. A limitation of the present study 
is that comparison could not be performed in the case of type I achalasia, 
as HRM-documented EGJ elevation was predominantly absent both pre- 
and post-POEM.
conclusion: Utilizing HRM and the “elimination” of EGJ elevation as a 
marker, the occurence of significant FTM during POEM can be reliably 
documented in patients with all achalasia subtypes except type I.
disclosure: A. Manolakis received grant from the Hellenic Society of Gas-
troenterology H. Inoue is an advisor for Top Corp and Olympus Corp 
P1266 duOdenaL hyPerPerMeaBILITy and sysTeMIc Markers 
Of LOW-grade InfLaMMaTIOn are LInked WITh gasTrIc 
eMPTyIng and syMPTOMs In funcTIOnaL dysPePsIa PaTIenTs 
WITh POsTPrandIaL dIsTress
Wauters L.1,2, Lambaerts M.2, Frings D.2, Accarie A.2, Toth J.2, Farré R.2, 
Tack J.1,2, Vanuytsel T.1,2
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contact e-Mail address: lucas.wauters@kuleuven.be
Introduction: We previously demonstrated increased duodenal mucosal 
permeability and low-grade inflammation with eosinophils in functional 
dyspepsia (FD) patients (1). However, the role of duodenal alterations in 
relation to gastric emptying and symptoms in functional dyspepsia (FD) 
patients is still unclear.
aims & Methods: FD patients with symptoms of postprandial distress (PDS) 
according to Rome IV criteria were recruited. Gastric emptying for liquids 
and solids was determined using the calculated half emptying time of the 
13C-glycin (significantly delayed > 75 min) and 14C-octanoic acid (signifi-
cantly delayed > 110 min) breath tests, respectively. Duodenal biopsies 
were collected to measure the transepithelial electrical resistance (TEER) 
and paracellular passage of a fluorescein-labeled dextran (4kDa) in Ussing 
chambers. After the endoscopy, a naso-duodenal tube was positioned in 
the second part of the duodenum with aspiration of fluids before and af-
ter a liquid meal (Fortimel, 300kCal) with measurement of pH. Plasma 
samples were collected to measure high-sensitivity C-reactive protein 
(hs-CRP) and patients filled out the Patient Assessment of Gastrointestinal 
Disorders Symptom Severity Index (PAGI-SYM). Descriptive and correlation 
analyses were performed to determine markers of gastric emptying and 
FD symptoms.
results: In total, 17 FD patients (15 females, median (IQR) age 28 (22-34) 
years) with 15 (88%) belonging to the pure PDS group and 2 (12%) the 
overlap group with epigastric pain syndrome (EPS). The median gastric 
half emptying time was 68 (41-76) min for liquids and 66 (57-80) min for 
solids. Significantly delayed gastric emptying was present in 4 patients 
(24%) for liquids and only in 1 patient (6%) for solids. Median TEER was 
22.1 (19.2-27) Ω*cm2 and paracellular passage 25.2 (20-30.3) pmol. Fasting 
and fed pH were similar (7 (5.2-7.3) vs. 6.5 (6.2-6.8), p=0.72) and median 
hs-CRP was 2 (0.6-5.5) mg/L. Fasting duodenal pH correlated positively 
with gastric emptying for liquids (r= 0.59, p=0.02). Gastric emptying for 
solids was positively correlated with both duodenal paracellular passage 
(r=0.62, p=0.03) and plasma hs-CRP (r=0.57, p=0.03). In addition, gastric 
emptying for solids was negatively correlated with the intensity of bloating 
(r=-0.53, p=0.04).
conclusion: Although delayed gastric emptying for solids is uncommon, 
duodenal alterations with increased permeability and low-grade systemic 
inflammation are linked with gastric emptying in FD patients with PDS-
symptoms. These data provide further substance for the potential central 
role of the duodenum in symptom generation and gastric motor abnor-
malities.
references: (1) Vanheel et al., Gut 2017
disclosure: Nothing to disclose 
P1267 evaLuaTIOn Of a PrOTOcOL fOr MeasureMenT Of 
dIsTensIBILITy Of The LOWer esOPhageaL sPhIncTer In The 
cLInIcaL fOLLOW uP Of PaTIenTs WITh achaLasIa
Medhus A.W.1, Evensen H.1,2, Kristensen V.1, Larssen L.1, Hauge T.1,2, 
Sandstad O.1
1Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 
2University of Oslo, Institute of Clinical Medicine, Oslo, Norway
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Introduction: The Endoflip™ (Crospon Ltd, Ireland) impedance planimetry 
system is now commonly applied to assess the distensibility of the lower 
esophageal sphincter (LES), which is of particular relevance in the diagno-
sis, treatment and follow up of patients with achalasia. A suggested proce-
dure protocol is available (1), and a graded filling approach of the balloon 
up to maximum fill volume of 50 ml is recommended. The 40 ml volume 
is most reliable to determine the distensibility of LES (1). Limited data are 
available on the use and feasibility of assessment of LES distensibility in 
clinical follow up of patients with achalasia.
aims & Methods: The aim of the present study was to evaluate the feasibil-
ity and the recommended protocol for LES distensibility measurements by 
applying the Endoflip™ system in the clinical follow up of patients with 
achalasia one year after per oral endoscopic myotomy (POEM).
At our department, achalasia patients are routinely having a clinical follow 
up one year after POEM. After acquiring the Endoflip™ system, distensibility 
measurement of LES with the probe EF-325 was included in this follow up 
and performed directly after an upper endoscopy with the patient in the su-
pine position. The recommended protocol with graded filling of the balloon 
at 30, 40 and 50 ml fill volume was applied. After reaching the maximum 
fill volume of 50 ml, a repeated measurement at 40 ml was performed. To 
compare the two measurements at 40 ml fill volume, Wilcoxon signed rank 
test was applied. Summary values are given as median (range).
results: During the first four months with distensibility measurements, the 
Endoflip™ system was applied without complications in eleven consecu-
tive POEM controls (four females) with a median age of 54 years (26-73). 
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The two distensibility measurements at 40 ml performed prior to and after 
50 ml fill volume differed significantly (Table).
conclusion: Performing LES distensibility measurement is feasible in clini-
cal follow up of patients treated for achalasia by POEM. However, LES dis-
tensibility at the recommended 40 ml balloon fill volume is significantly 
higher when measured after maximum fill volume. The protocol for mea-
surements should thus be standardized with respect to whether results 
have been acquired prior to or after maximum balloon fill volumes to en-
sure reliability and validity of the results.
Balloon fill volume 30 ml 40 ml 50 ml 40 ml p-value*
Luminal diameter 
(mm)
8.7 
(6.1-13.0)
13.1 
(10.3-19.9)
16.9 (13.8-
23.8)
15.3 
(12.1-20.1)
0.05
Intra balloon 
pressure (mm Hg)
34.4 
(15.9-78.0)
31.8 
(24.5-92.0)
42.4 
(19.9-109.0)
30.3 
(22.5-88.0)
0.11
Distensibility 
(mm2/mm Hg)
2.7 
(0.8-7.3)
3.8 
(1.5-7.9)
6.2 
(2.1-12.2)
5.6 
(2.1-8.9)
<0.01
[Endoflip™ measurements with different balloon fill volumes (*comparison 
of the two measurements with 40 ml fill volume)]
references: 1. Endoflip™ impedance planimetry system. Protocol and in-
terpretation. Pandolfino J, Clarke J, Vela M, et al. Medtronic review 2018.
disclosure: Nothing to disclose 
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Introduction: By-pass surgery is currently one of the most effective treat-
ments available for obesity and type II diabetes. Some limited data reports 
increased gastric belching after sleeve gastrectomy. However, there is no 
data about bariatric by-pass surgery and belching.
aims & Methods: We aimed to evaluate belching after bariatric by-pass 
surgery. Seventeen morbid obese patients and 12 healthy volunteers were 
enrolled in the study. Twelve patients had Roux-en-Y gastric bypass (RYGB) 
and the other 5 pts had gastric mini-bypass surgery, median 24 months 
(18-54 months) ago. All patients were questioned about the presence of 
symptoms for belching, gastroesophageal reflux disease, and dyspepsia. 
24-hour pH-impedance were performed in all patients and healthy vol-
unteers. Each of the patients underwent gastroscopy before 24-hour pH-
impedance.
results: Female dominance was observed in patients group [%76.5 (n=13) 
vs %41.7 (n=5)]. However, ages and gender were not statistically different 
in both groups (P > 0.05). The mean DeMeester score was significantly 
higher in patients (9.11 ± 19.40 vs 6.04 ± 5.60, P = 0.048). However, patho-
logic acid reflux (DeMeester score >14) rate were similar in both groups 
(11.8% vs %8.3). Symptom association probability positivity was detected 
in 11.8% of patients in the impedance study. The rate of alkaline reflux rate 
was higher in patients (6% vs 0%). The belching rate was 50% in patients 
according to questionnaire. Esophagitis was detected in 25% of patients in 
gastroscopy. The number of gas reflux (123.24 ± 80 vs 37.2 ± 21.5, P = 0.001) 
and Supragastric/Gastric belches was significantly higher in patients (182 ± 
64/228 ± 66.69 vs 25.08 ± 15.20/12.17 ± 17.65, P = 0.001). Although number 
of supragastric belching is higher in controls. Gastric belching was higher 
than supragastric belching in patients.
conclusion: Belching is increasing afterthe bariatric by-pass surgeryin the 
long term period. Gastric belching frequency is higher than supragastric 
belching in these patients.
disclosure: Nothing to disclose 
P1269 heLIcOBacTer PyLOrI eradIcaTIOn TheraPy May 
cOnTrIBuTe TO easy deTecTIOn Of auTOIMMune gasTrITIs 
WITh H. pylori InfecTIOn
Yamazato T.1, Iriguchi Y.1, Oda J.1, Mizutani M.1, Tomino Y.1, Yorimitsu N.1, 
Sonoda T.1, Ooshima N.1, Yamamura A.2
1Tokyo Metropolitan Cancer Detection Center, Gastroenterology, Futyu, Japan, 
2Tokyo Metropolitan Cancer Detection Center, Inspection, Futyu, Japan
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Introduction: Endoscopic features of autoimmune gastritis (AIG) include 
severe atrophy of the gastric body and lesser atrophy of the gastric antrum. 
Strict criteria for diagnosing AIG are important because this condition can 
cause anemia, gastric neoplasms, and autoimmune polyendocrine syn-
drome. However, diagnostic criteria for AIG have not yet been determined.
aims & Methods: We investigated AIG at our center from 2007 to 2018. 
This retrospective cohort study evaluated patients’ gender, medical history, 
history of Helicobacter pylori eradication, laboratory data [serum gastrin, 
parietal cell antibody (PCA), intrinsic factor antibody (IFA), anti-H. pylori 
antibody, and pepsinogen (PG) I and II levels], and histological diagnosis 
of AIG. We defined complete AIG as severe atrophy of a gastric body, as 
evidenced on endoscopy, predominantly of the gastric body rather than the 
gastric antrum, hyper serum gastrin(>200pg/ml), positive PCA or IFA, and 
histological diagnosis of AIG. We defined suspected AIG as patients who 
did not meet the criteria for complete AIG.
results: Twenty-eight of the 87951 patients who underwent endoscopy 
were enrolled in this study. There were 16 cases of complete AIG and 12 
cases of suspected AIG. The mean patient age was 69.1 (range, 41-87) years 
for complete AIG and 71.5 (range, 52-86) years for suspected AIG. Males 
constituted only 4 (25.0%) of all complete AIG cases. Furthermore, 4 (25%) 
of all complete AIG cases had history of cancer (stomach, breast, and co-
lon). All patients exhibited severe endoscopic atrophy, predominantly of 
the gastric body. Mean serum gastrin levels were 2939 (range, 225-9590) 
in patients with complete AIG and 1026 (range, 180-2270) in patients with 
suspected AIG. Two (12.5%) cases were negative for PCA and positive for 
IFA in the complete AIG group. In the suspected AIG group, six cases were 
negative for both PCA and IFA; however, they still exhibited severe atro-
phy of the gastric body on endoscopy and elevated gastrin levels (range, 
490-5410). Two cases in the complete AIG group were H. pylori-antibody 
positive (2/16); in contrast, there were five positive cases in the suspected 
AIG group (5/12). PG I level (range, 3.8-19.9) was low among all patients 
in the complete AIG group and in 4 patients with suspected AIG. In one 
patient with suspected AIG, we could not calculate PCA because of the 
anti-mitochondrial antibody and IFA negativity; however, this patient ex-
hibited severe atrophy of the gastric body on endoscopy and was histologi-
cally diagnosed with AIG. Two cases had histories of H. pylori eradication 
and exhibited more severe atrophy of the gastric body on endoscopy after 
(rather than before) H. pylori eradication.
conclusion: Diagnostic criteria for AIG are warranted, and further study 
is needed. H. pylori eradication therapy may contribute to easy detection 
of AIG with H. pylori infection, because this therapy reduces the influence 
of H. pylori in patients with autoimmune gastritis with H. pylori infection.
disclosure: Nothing to disclose 
P1270 gasTrOParesIs: OuTcOMe Of fOcus grOuPs fOr The 
deveLOPMenT Of a quesTIOnnaIre fOr syMPTOM assessMenT 
In PaTIenTs sufferIng frOM IdIOPhaTIc and dIaBeTes 
gasTrOParesIs
Carbone F.1, De Buysscher R.2, Van den Houte K.3, Holvoet L.1, 
Vandenberghe A.4, Tack J.5
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Introduction: Gastroparesis (GP) is defined as “a combination of symptoms 
and documented delay in gastric emptying (GE) in the absence of mechan-
ical obstruction”. The main causes of GP are Idiopathic gastroparesis (IGP) 
and Diabetes gastroparesis (DGP). To date, no validated patient reported 
outcomes (PRO) for evaluation of treatment efficacy in these conditions 
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are available. According to FDA guideline, PRO instrument item genera-
tion and selection should be derived from patient focus groups (FGs) and 
cognitive interviews (CIs).
aims & Methods: Our aim was to perform FGs and cognitive interviews for 
the development of a new questionnaire for the assessment of symptom 
pattern and severity in both IGP and DGP. Patients with IGP, a negative 
endoscopy and a strongly delayed GE rate (T1/2 >109min, GE breath test) 
were invited to participate. During the FGs, symptom spectrum of gastro-
paresis was discussed to determine type of symptoms, triggering by meals 
or factors, duration, bothersomeness, predictability and impact. A verbal 
descriptor for each symptom was proposed to the patients after discussion 
of the symptom. Threshold for selection of symptoms was 50%. From the 
list of emerged relevant symptoms, Subsequently, FGs for DGP patients 
were organized using the same framework.
results: 14 IgP (11 Females, 43.6±3.3 years, T1/2:155.2±16.2) patients partic-
ipated. All (100%) confirmed experiencing symptoms that were triggered 
or aggravated by ingestion of a meal. Main symptoms corresponded to 
postprandial fullness (PPF:100%), epigastric pain (EP:100%), early satia-
tion (ES:100%), nausea (N:100%), retching (RT:71%) and vomiting (V:57%). 
. Other relevant symptoms were bloating (B:86%), abdominal distention 
(AD:71%), heartburn (H:79%) and regurgitation (RG:64%). In diabetic gas-
troparesis (n=10, 7 Females, 45.5±3.7 years, t1/2:156.9±17.0 min) symptoms 
were also meal related (100%) and comprised PPF (100%), EP (100%), ES 
(70%) N (100%), V (70%), RT (70%), RG (50%), B (90%), AD (70%), belch-
ing (70%) and H (80%). Following this, pilot instruments were developed 
and customized through CIs for qualitative and cognitive debriefing to es-
tablish content validity.
conclusion: This study confirm that symptoms corresponding to postpran-
dial fullness, epigastric pain, early satiation, nausea, vomiting, retching 
regurgitation, bloating and heartburn are the key items for developing a 
PRO for both idiopathic and diabetic gastroparesis.
disclosure: Nothing to disclose 
P1271 dOes MeasureMenT Of syMPTOMs durIng a gasTrIc 
eMPTyIng TesT IMPrOve cOrreLaTIOn BeTWeen syMPTOMs and 
eMPTyIng raTe?
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Introduction: Functional dyspepsia (FD) and idiopathic gastroparesis (IGP) 
are characterised by upper gastrointestinal symptoms and a negative en-
doscopy, and severely delayed emptying in case of gastroparesis. It is ar-
gued whether distinguishing these entities is necessary as previous stud-
ies showed a poor correlation between delayed gastric emptying (GE) and 
symptom severity.
aims & Methods: We aim to evaluate the relationship between symptom 
severity and GE when simultaneously assessed. During a GE test (breath 
test with 13C-octanoic acid labelled 250 Kcal meal), severity (0-4) of 6 symp-
toms (postprandial fullness (PPF), epigastric pain (EP) and burning (EB), 
bloating (BL), nausea (N) and belching (B)) was assessed before and every 
15 min for 4hs postprandially. The sum of individual symptom scores gen-
erates the meal-related symptoms score; the sum of all symptoms gener-
ates overall global meal-related symptom severity. Data were compared 
in patients with normal and delayed GE (cut-off T
1/2
³ 109 min) using non-
parametric statistical tests, Mann-Whitney test, 2-Way-Anova with Bonfer-
roni posthoc-test correction and spearman correlation.
results: Of 504 FD patients (70% females (F), 43.6±0.7 years, 23.3±0.2 kg/
m2), 382 patients (67% F, 43.8±0.8 years, 23.3±0.2 kg/m²) had normal and 
122 patients (77% F, 42.7±1.5 years, 23.2±0.6 kg/m²) had delayed GE. Global 
symptom severity tended to be higher in patients with delayed GE (81.9±3.4 
vs. 99.5±7.1, p=0.06). Only nausea was significantly increased in patients 
with delayed GE (10.7±0.8 vs. 15.9±1.6, p=0.01). However, no correlations 
were observed between GE rate and any of the symptoms (global symptom 
score: r=0.06, p=0.2; nausea: r=0.08, p=0.09). In all analysis, 2-Way-Anova 
showed significant interactions for increasing symptoms over time, but no 
significant differences were observed between normal and delayed GE. 
Only nausea showed partially significant increase in delayed GE 90 min 
after the meal (p< 0.01) compared to normal GE.
conclusion: IGP patients tend to display higher dyspeptic symptoms se-
verity, but only meal-related nausea scores were significantly higher. The 
severity of symptoms, even when assessed during the meal, was not as-
sociated to the GE rate. These findings have important implications for the 
value of routinely applying GE testing in clinical practice.
disclosure: Nothing to disclose 
P1272 hIgh PrevaLence Of sMaLL InTesTInaL BacTerIaL 
OvergrOWTh aMOng funcTIOnaL dysPePsIa PaTIenTs
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Introduction: Functional dyspepsia (FD) is a multifactorial disorder as its 
development may be based on several different pathophysiological mech-
anisms. Small intestinal bacterial overgrowth (SIBO) is characterized by 
either increased numbers or presence of colonic type bacteria in the upper 
gastrointestinal tract. FD could be related to SIBO since impaired motility 
of the gastrointestinal tract is one of the main etiologic factors involved in 
both diseases pathogenesis.
aims & Methods: Consecutive outpatients fulfilling Rome IV criteria for 
FD underwent upper gastrointestinal endoscopy. Severity of FD symptoms 
was graded by the patient assessment of upper gastrointestinal symptom 
severity index (PAGI-SYM) questionnaire. 2cc of duodenal juice (3rd - 4th 
part) was aspirated in special sterile traps. SIBO was defined as ≥103 CFU/
ml of duodenal aspirate and/or presence of colonic type bacteria. Patients 
with Irritable Bowel Syndrome (IBS) and healthy controls (HC) - under-
going gastroscopy due to gastroesophageal reflux disease (GERD) - com-
prised positive and negative controls, respectively. Concentrations (pg/ml) 
of tumor necrosis factor-alpha (TNFα), interleukin (IL)-1β and IL-6 were 
measured in the duodenal fluid. We aimed to compare the SIBO preva-
lence between FD patients, IBS patients and healthy controls.
results: We enrolled 347 subjects (FD 227/90 IBS/30 HC) aged 
53.7±14.6years. Among FD patients, 144 (63.4%) had Postprandial Distress 
syndrome (PDS), 64 (28.2%) Epigastric pain Syndrome (EPS) and 19 (8.4%) 
mixed type. SIBO was diagnosed in 44/227 FD patients, with Gram (-) bac-
teria being the predominant species (24/44, 54.5%). SIBO prevalence 
among FD subtypes was: PDS 30/114 (26.3%); EPS 8/64 (12.5%); mixed 6/19 
(31.6%). Overall, SIBO prevalence was significantly higher in FD compared 
to HC [44/227(19.3%) vs. 1/30(3.3%), p=0.037] and it was similar to IBS 
[44/227(19.3%) vs. 15/90(16.7%), p=0.63]. SIBO prevalence was lower in the 
EPS group as compared to the PDS and mixed symptoms groups (12.5% 
vs. 27.1%, p=0.11). SIBO presence correlated neither with total nor with 
any subscale score of the PAGI-SYM questionnaire. Mean concentration 
of IL-1β was similar between FD and HC subjects (5.13±17.9 vs. 6.3±14.3, 
p=0.65) but it was significantly lower than that of IBS individuals (402±89.6 
vs. 5.13±17.9, p< 0.001 and 401.9±89.6 vs. 6.3±14.3, p< 0.001 respectively). 
TNFα and IL-6 concentrations did not differ between the three groups.
conclusion: In a cohort of Greek FD patients, SIBO prevalence is similar to 
that of IBS subjects and higher compared to that of healthy controls.
disclosure: Nothing to disclose 
P1273 gasTrIc eMPTyIng scans: POOr adherence TO 
naTIOnaL guIdeLInes
Lacy B., Wise J., Vazquez-Roque M.
Mayo Clinic, Gastroenterology, Jacksonville, United States
contact e-Mail address: lacy.brian@mayo.edu
Introduction: Gastric-emptying scintigraphy (GES) is considered the gold 
standard for measuring gastric emptying. Performing the test correctly 
is critical as it ensures an accurate diagnosis which directly influences 
patient care from both a diagnostic and therapeutic perspective. While 
published protocol guidelines for GES exist, national compliance with 
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these guidelines has not been thoroughly studied. This study aimed to 
determine whether facilities that perform GES adhere to well-established 
national guidelines published 10 years ago.
aims & Methods: To assess compliance with GES protocol guidelines, we 
developed a questionnaire that evaluated a total of 51 measures addressing 
the relevant procedure subcategories of the published Procedure Guide-
line for Adult Solid-Meal Gastric Emptying Study 3.0. Questions focused 
on patient preparation (16), pertinent medical history (15), precautions/
contraindications (2), radiopharmaceuticals (5), image acquisition (4), 
processing (2), interpretation criteria (5) and reporting (2). Demographic 
data was also collected. The anonymous questionnaire was distributed 
electronically. Responses were entered into an excel table and analyzed 
using standard statistical methods.
results: 109 medical institutions (MI) responded; of these, 45 (41.3%) were 
academic/teaching medical centers. The mean number of annual GES pro-
cedures was 165.9 (range, 12 to 450 GES/year). The validated egg meal is 
utilized in 58.4% of the MI and 60.0% of MI conduct a 4 hour GES. 89.2% 
ask if the patient has an egg allergy prior to GES, although 92.8% do not 
stop the test if the patient reports an egg allergy. Blood glucose levels of 
diabetic patients are tested in 17.5% of the MI prior to GES. Discontinuation 
of opioids is required in 65.0% of MI prior to GES and 50% of these MI 
require at least two days of discontinuation of opioids. 36.4% of MI record 
dose and frequency of pain medications. 29.5% of MI ask if the patient 
uses tobacco products. 69.5% of MI report GES results at 1, 2, and 4 hours. 
Metoclopramide or erythromycin is administered during the test in 2.3% 
of the MI. Academic/teaching medical centers had the lowest compliance 
rate on twelve (23.5%) of the 51 adherence measures.
conclusion: Our results suggest that adherence to national guidelines for 
performing GES is low, even at academic medical centers. This suggests 
that a barrier exists between established clinical guidelines and institu-
tional implementation that has a direct impact on patient care.
disclosure: Nothing to disclose 
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Introduction: In the recent EOS-1 trial, a 6-week therapy with a novel 
budesonide orodispersible tablet (BOT), with a unique mode of delivery 
and esophageal targeting, given twice daily (1mg BID) led to a significant 
improvement in the validated disease specific overall Adult Eosinophilic 
Esophagitis Quality of Life (EoE-QoL-A) questionnaire and all of its sub-
scores (1).
aims & Methods: This maintenance study also assessed the Health related 
Quality of life (HRQoL) and its change from baseline over 48 weeks of treat-
ment. In total, 204 patients being in clinico-histological remission were 
randomized (1:1:1) to a 48-weeks treatment with BOT 1 mg BID, BOT 0.5 
mg BID or placebo.
The overall EoE-QoL-A 30 items score was assessed with a weighted aver-
age score between 0 to 4 at baseline and end of treatment (EOT) - higher 
scores denoted better HRQoL.
results: For the overall EoE-QoL-A 30 items score a statistically significant 
increase (i.e., improvement in QoL) from Baseline to EOT was observed 
in both budesonide groups. In contrast, the overall EoE-QoL-A 30 items 
score showed a statistically significant decrease (i.e., deterioration in QoL) 
from Baseline to EOT in the Placebo group. The differences in the absolute 
changes from baseline between the budesonide groups and placebo were 
also clinically relevant and statistically significant (see Table). 
 
BOT 1mg BId 
(n=68)
BOT 0.5mg BId 
(n=68)
Placebo BId 
(n=68)
Baseline, Mean (sd) 3.2 (0.59) n=64 3.2 (0.56) n=64 3.0 (0.70) n=64
eOT, Mean (sd) 3.5 (0.48) n=67 3.3 (0.46) n=66 2.8 (0.75) n=65
absolute change from 
dB Baseline to eOT, 
Mean [95% cI]
0.3 [0.14; 0.39] 
n=63
0.2 [0.12; 0.34] 
n=62
-0.2 [ 0.39; 0.08] 
n=61
difference between 
absolute changes from 
Baseline to eOT (BuL vs. 
Placebo)* [95% cI]*
0.50 [0.30; 0.70] 
p<0.0001 (2-sided)
0.46 [0.27; 0.66] 
p<0.0001 (2-sided)
 
*for intergroup differences (BOT 0.5mg BId or BOT 1mg BId vs Placebo) between 
absolute changes from Baseline to eOT a two-sided t-test was used for exploratory 
testing.
[Disease specific overall Adult Eosinophilic Esophagitis Quality of Life (EoE-
QoL-A) 30 item questionnaire ]
conclusion: Both, BOT 1mg BID and BOT 0.5mg BID were able to maintain 
and even further improve patient’s HRQoL compared to placebo over 48 
weeks.
references: (1) Lucendo AJ, et al. Gastroenterology 2019, DOI:https://doi.
org/10.1053/j. gastro.2019.03.025
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P1275 eOsInOPhILIc esOPhagITIs - vIsuaL scOre: a nOveL 
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Introduction: Eosinophilic Esophagitis (EoE) is a chronic disease charac-
terised by significant impairing of quality of life (QoL). Current methods 
for measure QoL are almost tricky and not easy to use routinely. Starting 
from the validated EoE-QoL-A questionnaire (EQA), we elaborated the EoE 
Visual Score (EVS), an easy and quick, self-administered questionnaire for 
daily clinical practice.
aims & Methods: The aim of this pilot study was to evaluate EVS and its 
correlation with clinical response to therapy, histological disease activity 
and EQA.
Thirty patients (7 Female, mean age 33-yo, range 18-75-yo) with a definite 
diagnosis of EoE, referred to our Unit, were included. The diagnosis was 
done according to the latest international criteria. Patients were enrolled 
at outpatient level, at first admission or follow-up, between January 2018 
to February 2019. The EVS is a 10-scale, 11-item pictogram, depicting the 
different areas involved in the assessment of QoL in EoE patients (eat-
ing/diet impact, social impact, emotional impact, disease anxiety, chok-
ing anxiety). Patients, were clinically and histologically evaluated, before 
(baseline) and after medical therapy (proton pump inhibitors or topical 
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steroid for 8weeks). At both time points, all patients completed the EQA 
and EVS. Histologic activity was described as dichotomous parameter: 0 
for less than 15eos/hpf and 1 for more than 15 eos/hpf. Pearson correlation 
coefficient and paired t test were used for the analysis.
results: At baseline, patients were all histologically active, with a mean 
value of EQA and EVS of 45.07±SD32.69 and 26.37±SD20.43, respectively. 
After 8 weeks of medical treatment, mean value of EQA and EVS were 
37.63±SD28.37 and 21.43±SD20.92, respectively. A strong significant corre-
lation between EQA and EVS at both time points (r=0.784 p< 0.001 and 
r=0.816 p< 0.001, respectively) was observed. EVS had a significant mean 
value difference before and after treatment (p=0.032). After 8 weeks of 
medical treatment, 21patients (70%) achieved histological response, but 
no difference in EVS mean values was found between histological re-
sponders and. non-responders (p=0.222). Moreover, no significant differ-
ence for EVS mean values was observed before and after treatment in both 
histological non-responder (p=0.064) and responders (p=0.105).
conclusion: The EVS is an effective and quick tool for daily clinical practice, 
able to depict patients QoL and to facilitate the assessment of therapeutic 
response. It well correlates with the already validated EQA. Nevertheless, 
further larger studies are required to evaluate the usefulness of EVS in 
clinical practice.
references: Taft TH, Kern E, Kwiatek MA, Hirano I, Gonsalves N, Keefer L. 
The adult eosinophilic oesophagitis quality of life questionnaire: a new 
measure of health-related quality of life. Aliment Pharmacol Ther. 2011 
Oct;34(7):790-8. Lucendo AJ, Sánchez-Cazalilla M, Molina-Infante J, Pérez-
Martínez I, Tenías JM, Barrio J, Nantes Ó, Ciriza-de-los-Ríos C, Perelló A, 
Arias Á. Transcultural adaptation and validation of the “Adult Eosinophilic 
Esophagitis Quality of Life Questionnaire” into Spanish. Rev Esp Enferm 
Dig. 2014 Jun;106(6):386-94.
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Marker Of dIsease acTIvITy In PaTIenTs WITh eOsInOPhILIc 
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of Pisa, Dept. of Gastroenterology, Pisa, Italy, 5University of Genoa, Dept. 
of Internal Medicine, Genova, Italy, 6Universita di Genova, Dept Internal 
Medecine, Genova, Italy
contact e-Mail address: matteoghisa@yahoo.it
Introduction: Eosinophilic Esophagitis (EoE) is a chronic disorder, charac-
terized by symptoms of esophageal dysfunction and, histologically, by eo-
sinophilic-infiltration. Endoscopic and histological examination is required 
both at diagnosis and follow-up, since a reliable non-invasive marker has 
not been identified yet. Eosinophil cationic protein (ECP) is released dur-
ing eosinophils degranulation and it can be assessed in human faeces.
aims & Methods: The aim of the study is to evaluate the potential use of 
ECP in EoE patients’ faeces (F-ECP) as a potential marker of disease activ-
ity.
29 consecutive EoE-patients assessed at our Unit between January 2018 to 
January 2019 for endoscopic follow-up, were included. Faecal and histo-
logical specimen were collected on the same day. Histological activity was 
staged considering the number of eosinophils for high-power field (Eos/
HPF). A control-group of 71 patients (mean age 52-yo, range 35-64, 38 
Male), in whom EoE had been ruled out according to International criteria, 
was included. F-ECP was evaluated with a fluorescence-enzyme-immuno-
assay (PHADIA, Thermo Fisher Scientific). Spearman’s rank correlation was 
applied for statistical analysis and F-ECP predictive positive and negative 
values (PPV, NPV) were calculated.
results: EoE-study-population consisted of 29 patients affected by EoE 
(mean age 32-yo, range 18-62 yo, 24 M), showing F-ECP values ranging 
from 0 to 172 ug/L (mean value 17,3 ug/L), compared to values ranging from 
0 to 32 ug/L (mean value 8,1 ug/L) in the control-group. A statistically sig-
nificant relationship between F-ECP and Eos/HPF was observed (p 2-tailed 
= 0.02438). PPV and NPV of F-ECP were evaluated using two cut-off values, 
F-ECP < 2 ug/L (as negative) and F-ECP < 8,1 ug/L (as mean value in the 
control group). Among the study group, 21 patients (72%) showed histo-
logical remission, but only 8 (38%) had F-ECP negative values. Setting a 
cut-off value of 8,1 ug/L, F-ECP NPV and PPV for histological remission 
were 86% and 40%, respectively, while they were 100% and 38% with 
cut-off value of 2 ug/L.
conclusion: Our preliminary data show a good correlation of F-ECP values 
with histology activity and a clear difference in terms of levels between EoE 
patients and controls. However, the wide variability of ECP levels evaluated 
in our series requires further cases and more histologically-active patients, 
in order to assess its usefulness in clinical practice.
disclosure: Nothing to disclose 
P1277 PrevaLence and cLInIcaL feaTures Of endOscOPy 
negaTIve eOsInOPhILIc esOPhagITIs
Kaneko T.1, Matsumura T.1, Okimoto K.2, Akizue N.3, Ota Y.1, Saito K.1, 
Maruoka D.4, Nakagawa T.5, Arai M.6, Kato N.1
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Introduction: Some patients with eosinophilic esophagitis (EoE) do not 
have typical endoscopic findings. Therefore, multiple esophagus biopsies 
are recommended regardless of endoscopic findings in patients with dys-
phagia. This study aimed to investigate the prevalence and clinical features 
of endoscopy negative EoE.
aims & Methods: We conducted two retrospective studies. In the first study, 
forty-seven patients with dysphagia were included. All patients underwent 
endoscopy and esophageal high resolution manometry (HRM) test. Mul-
tiple esophageal biopsies were taken from the middle and lower esopha-
gus. The prevalence of EoE and the presence or absence of endoscopic 
findings were examined. In the second study, thirty-five patients diag-
nosed with EoE in the same period were included. Patients were divided 
into those with typical endoscopic findings and those without, differences 
of clinical features were examined.
results: 
Study 1: Of the 47 patients, 12 patients (26 %) were diagnosed with acha-
lasia, 3 (6 %) with ineffective esophageal motility, 5 (11%) with esophago-
gastric junction (EGJ) outflow obstruction, 4 (9%) with Jackhammer esoph-
agus, 5 (11%) with absent contractility, and 2 (4%) with distal esophageal 
spasm (DES). The remaining 16 patients’ (34%) results were normal. As a 
result of biopsies, 6 patients (13%) were diagnosed with EoE (HRM results: 
normal in 4, DES in 1, and EGJ outflow obstruction in 1). 
Study 2: Of 35 patients with EoE, 21 (60%) had white plaques, 22 (63%) 
had longitudinal furrows, and 11 (31%) had esophageal rings. Eight pa-
tients (23%) did not have typical endoscopic findings. We examined dif-
ferences between patients with endoscopic findings and those without. 
Symptom severity (Frequency Scale for Symptoms of GERD: FSSG score) 
was 10.18 for endoscopic findings and 18.43 for negative cases, and there 
was a significant difference (p = 0.021 < 0.05) between the two groups. 
There were no significant differences without FSSG score (gender, age, 
height, weight, BMI, presence or absence of allergic disease, esophagus 
eosinophil count, proton pomp inhibitor and steroid history, blood eosino-
phil count, and IgE levels).
conclusion: Thirteen percent of the patients with dysphagia were diag-
nosed with EoE, and 23 % of EoE patients do not have typical endoscopic 
findings. Patients with negative endoscopic findings had more severe 
symptoms than those with positive findings.
disclosure: Nothing to disclose 
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P1278 aPPLIcaTIOn Of cOnvOLuTIOnaL neuraL neTWOrks fOr 
dIagnOsIs Of eOsInOPhILIc esOPhagITIs Based On endOscOPIc 
IMages
Okimoto E.1, Ishimura N.1, Aoyama K.2, Tada T.3, Adachi K.4, 
Kinoshita Y.1,5
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Introduction: Eosinophilic esophagitis (EoE) is a clinicopathological dis-
ease diagnosed by symptoms related to esophageal dysfunction accompa-
nied by esophageal eosinophilia, and its prevalence has been rapidly in-
creasing in Western and Asian countries. Subjective symptoms associated 
with EoE such as dysphagia are not specific, thus endoscopic identification 
of suggestive EoE findings is quite important for facilitating endoscopic 
biopsy sampling, leading to histopathological identification of esophageal 
eosinophilia. However, poor inter-observer agreement regarding diagno-
sis among endoscopists has become an issue, especially with inexperi-
enced practitioners. On the other hand, image recognition performed with 
artificial intelligence (AI) with deep learning through convolutional neural 
network (CNN) has dramatically improved and is increasingly applied for 
diagnostic imaging in a variety of medical fields, though its effectiveness 
for endoscopic diagnosis of EoE has not been evaluated.
aims & Methods: We evaluated the diagnostic utility of AI for EoE with 
endoscopic imaging. A total of 1484 training images of 165 patients histo-
logically proven to be in an active phase of EoE (≥15 eosinophils per high 
power field), including 1182 obtained with white light imaging (WLI) and 
302 with narrow band imaging (NBI), as well as 2318 normal esopha-
gus images, including 1292 obtained with WLI and 1026 with NBI, were 
examined retrospectively. All images were obtained from the records of 
Shimane University Hospital and related facilities, and used to develop 
deep learning through CNN to diagnose EoE. Additionally, we prepared 
a second set of 1156 test images from 40 patients with EoE and 96 sub-
jects with a normal esophagus, including 336 with EoE and 820 with a 
normal esophagus, and used those to evaluate the diagnostic accuracy 
of the CNN for each image and case. When more than half of the images 
were diagnosed as EoE or normal, that was used as the final diagnosis 
for each case.
results: The CNN required 31 seconds to analyze 1156 test images from 
136 cases, and correctly diagnosed EoE in 79.8% using comprehensive di-
agnosis of WLI and NBI per image analysis, with an overall sensitivity of 
78.6% and specificity of 80.2%. Diagnosis using only WLI tended to have 
a higher level of sensitivity than that with both WLI and NBI (92.8% vs. 
78.6%), while accuracy and specificity were not significantly different be-
tween them. For each case, the CNN correctly diagnosed 36 of 40 EoE cases 
using comprehensive diagnosis of WLI and NBI, with overall sensitivity and 
specificity of 90.0% and 90.6%, respectively. Likewise, diagnosis with only 
WLI tended to have a higher sensitivity than that with both WLI and NBI 
(94.9% vs. 90.0%).
conclusion: We developed a new CNN system for detecting EoE using en-
doscopic images, which provided accurate diagnosis based on WLI within 
a very short time period. Our findings indicate the usefulness of CNN when 
diagnosing EoE, especially for aiding inexperienced endoscopists.
disclosure: Nothing to disclose 
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Introduction: Eosinophilic esophagitis (EoE) is an immune-mediated con-
dition associated with chronic allergy. Endoscopic findings in EoE may 
include linear furrowing of the mucosa, white plaques or exudates, con-
centric rings, friable and diffuse luminal narrowing or strictures, but can 
often be normal. Biopsies are taken randomly and are often negative. The 
aim of the study was to evaluate whether chromoendoscopy with Iodine/
Potassium iodine solution (IPIS) is useful for identification of EoE during 
endoscopy, target and reduce the numbers of needed biopsies.
aims & Methods: We included 10 patients with known EoE and 10 patients 
with dyspepsia. All underwent gastroscopy with IPIS staining 0.5-1% of the 
whole esophagus. Selective biopsies were taken from the areas without 
uptake and areas with uptake of IPIS stain for histopathological compari-
son and diagnosis.
results: Normal squamous esophageal epithelium took up IPIS and col-
ored it dark brown, while pathologic epithelium become light yellowish 
due to reduced iodine uptake. In all 10 patients with EoE we observed 
diminished uptake of IPIS in whole length of the esophagus. 4 patients 
with EoE had leopard skin pattern after installation IPIS. In these patients, 
all biopsies from areas with low uptake, showed histologically confirmed 
EoE (mean 88 eosinophils per high power field (HPF)), whereas areas with 
more normal uptake showed significantly lower number of eosinophils 
(mean 18 eosinophils/HPF). In the group with dyspepsia, the uptake of 
IPIS was found to be normal, with even dark brown colorization of the 
esophageal mucosa.
conclusion: IPIS seems be useful for identification of patients with EoE 
during endoscopy. Areas with uptake deficit in otherwise normal looking 
squamous epithelium should be biopsied. The technique allows targeted 
biopsies for improved identification of EoE and reduce sampling errors. 
Further studies in an unselected patient population must be performed to 
further explore this finding.
disclosure: Nothing to disclose 
P1280 eOsInOPhILIc OesOPhagITIs: The rIsIng IncIdence 
and Burden Of dIsease In a Large nhs TrusT
Tierney M., Fricker J., Gordon J.N.
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Introduction: Eosinophilic oesophagitis (EoE) is an immune-mediated 
inflammatory condition of the oesophagus that, despite an increasing 
awareness and incidence of the disease in the last few years, remains 
poorly characterised and poorly understood. The diagnosis is relatively 
easily made on biopsy by the presence of an eosinophilic infiltrate (>15 
eos/HPF) in patients presenting with symptoms of oesophageal dysfunc-
tion and/or suggestive endoscopic features. 
Despite this in many cases opportunities for diagnosis are missed and the 
diagnosis delayed which a potential impact on disease severity and pro-
gression. The spectrum of disease is wide and is putting an increasing 
burden and economic cost on specialist services managing the disease.
aims & Methods: The aim of our study was to quantity the scale of the 
problem, the spectrum of disease, and the disease burden in a large NHS 
Trust covering a population of 600,000. We performed a retrospective 
search was performed of the histopathology database using the term 
‘eosinophilic oesophagitis’ to identify positive oesophageal biopsies, 
cross-referencing with the endoscopic database. Demographic data was 
collected including indication for endoscopy, endoscopist, relevant en-
doscopic findings, and treatment. Patients for whom full endoscopy re-
cords were unavailable were excluded as were those with reflux related 
eosinophilia.
results: 136 cases of definite EoE were identified over a four year period 
with a year-on-year increase in cases. 96 (70.6%) cases were male with a 
mean age at diagnosis 44.6 years. The vast majority of cases were iden-
tified by either nurse endoscopists (45%) or medical gastroenterologists 
(41%) with the nurse endoscopists with the highest proportion of biop-
sies taken in patients presenting with dysphagia in a normal oesophagus. 
The main indications for endoscopy were dysphagia (63.7%), food bolus 
obstruction (16.4%), known eosinophilic oesophagitis (6.6%), stricture/
dilatation (5.5%) and reflux (5.5%). 
The endoscopic appearance was recorded as normal in 51% of cases. In 
the remaining patients the most common findings were concentric rings 
(24%), fibrotic stricture (12%), narrowed impassable lumen (9%) and re-
flux oesophagitis (4%). 
These findings support a spectrum of disease. Approximately 50% of pa-
tients responded to acid suppression with the rest treated with oral topical 
steroid and dietary manipulation. A small number of patients (11%) had 
strictures that required endoscopic dilatation.
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conclusion: The incidence of EoE in our population was high considering 
it is a relatively rare condition. There was male predominance in keeping 
with the known literature. Dysphagia was the most frequent indication for 
endoscopy and there were a few known cases of eosinophilic oesophagitis 
undergoing reassessment after treatment. Nurse endoscopists appeared 
particularly effective at appropriately biopsying and diagnosing the dis-
order which may represents a greater awareness of the condition and a 
greater adherence to current guidelines regarding biopsy. However in a 
significant minority of cases opportunities for diagnosis were missed and 
the diagnosis delayed. In 51% of cases the oesophagus looked normal 
which has important implication regarding biopsy. The severity of dis-
ease appears to vary widely from asymptomatic non-progressive disease 
to severe fibrosis and stricturing. This study has provided an insight into 
an increasingly important condition and provides a basis to improve case 
finding and prompt earlier diagnosis.
disclosure: Nothing to disclose 
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sTudy
Fabisiak A.1,2, Bartoszek A.1, Binienda A.1, Krajewska J.B.1, Mosińska P.1, 
Niewinna K.1, Tarasiuk A.1, Mokrowiecka A.2, Fabisiak N.3, Salaga M.1, 
Małecka-Panas E.2, Fichna J.1
1Medical University of Lodz, Department of Biochemistry, Lodz, Poland, 
2Medical University of Lodz, Department of Digestive Tract Diseases, Lodz, 
Poland, 3Medical University of Lodz, Department of Gastroenterology, Lodz, 
Poland
contact e-Mail address: adfabisiak@gmail.com
Introduction: Gastroesophageal reflux disease (GERD) is one of the most 
common upper gastrointestinal disease with prevalence reaching 25.9% 
in Europe. Current therapy of GERD aims primarily at decreasing the acid 
secretion in the stomach and the most effective drugs are proton pump 
inhibitors which are the first-line treatment. Noteworthy, the Barrett’s 
esophagus (BE) and thus esophageal adenocarcinoma (EA) may develop 
on a basis of GERD. The marker of such transformation is still sought af-
ter to lower the cost of potential surveillance of patients. Free fatty acid 
receptors (FFARs) are G protein-coupled receptors playing a role in im-
mune responses and tumorigenesis, the two processes involved in the 
GERD-BE-EA transformation. The role of FFARs in GERD has not been yet 
investigated.
aims & Methods: The primary aim was to compare the expression of FFARs 
1-4 in esophageal mucosa between the patients with GERD and healthy 
controls (HC). FFAR expression was quantified using quantitative RT PCR 
in esophageal samples obtained from patients with GERD and healthy 
controls. Moreover, patients were asked to fill GERD-Health Related Qual-
ity of Life (GERD-HRQL) questionnaire. Student’s t-test was chosen when 
comparing two means; one-way ANOVA followed by the Newman-Keuls 
post-hoc test was used for analyses of multiple treatment means. Pearson 
correlation was used to assess the correlation between the FFARs expres-
sion and GERD-HRQL results.
results: A total of 35 patients with GERD (27 with non-erosive reflux disease 
(NERD) and 8 erosive reflux disease (ERD)) and 8 HC were recruited to the 
study. Overall, the relative expression of FFARs 1-4 were non-significantly 
higher in esophageal biopsies taken from patients with GERD than in HC. 
FFAR1 appeared to be the most profoundly expressed FFAR in esophageal 
mucosa of either GERD patients or HC and presented a non-significantly 
higher relative expression compared to three other FFARs (2938.00±726.90 
for FFAR1 vs 1802.00±454.30 for FFAR2 vs 2136.00±703.00 for FFAR3 vs 
64.17±9.07 for FFAR4 for GERD patients and 1846.00±707.00 for FFAR1 vs 
1145.00±447.00 for FFAR2 vs 640.00±219.00 for FFAR3 vs 34.59±6.18 for 
FFAR4 for HC). Expression of FFAR4 was the lowest of all FFARs in all 
biopsies. When classifying patients with regard to endoscopic findings, all 
FFARs exhibited higher expression in NERD vs. ERD patients and HC. The 
expression of FFAR2 was non-significantly lower in patients with ERD vs 
HC. All other FFARs demonstrated similar expression when comparing ERD 
to HC. Lastly, we performed Pearson correlation test to analyze possible 
association between the relative expression of FFARs to GERD-HRQL score. 
All correlations were negative and only FFAR3 expression significantly, 
negatively correlated with GERD-HRQL score (r=-0.4305, p=0.025).
conclusion: We observed an increase in relative expression of FFARs in 
esophageal biopsies from GERD patients compared to HC, especially in 
case of NERD. This trend was most profoundly visible for FFAR1 and least 
for FFAR4. Noteworthy, FFARs expression negatively correlated with pa-
tients’ quality of life, meaning that the higher expression of these receptors 
may be associated with lower intensity of symptoms perceived by patients 
with GERD. Taken together, our results show that FFARs indeed may play a 
role in GERD pathophysiology.
disclosure: Nothing to disclose 
P1282 TransePITheLIaL TIssue PerMeaBILITy In esOPhageaL 
ePITheLIuM decreases In PaTIenTs WITh gasTrOesOPhageaL 
refLux dIsease fOLLOWIng anTI-refLux surgery
Ergun P.1, Kipcak S.2, Bor S.3, Ege Reflux Study Group
1Ege University, Gastroenterology / Medical Biochemistry, Izmir, Turkey, 2Ege 
University, Gastroenterology / Medical Biology, Izmir, Turkey, 3Ege University, 
Ege Reflux Study Group, School of Medicine, Gastroenterology, Izmir, Turkey
contact e-Mail address: pelinergun@yahoo.com
Introduction: Gastroesophageal reflux disease (GERD) is a chronic disor-
der and typical symptoms recur six months after the discontinuation of 
medical therapy in 75-80% of patients. Anti-reflux surgery is a successful 
alternative in some cases and success rate is high. It is also a good model 
to evaluate the recovery of the epithelium with decreasing the contact time 
of noxious gastric refluxate including acid, pepsin, bile acids and pancre-
atic juice.
aims & Methods: We aimed to evaluate the electrophysiological recovery 
in esophageal epithelium of the cases before and after laparoscopic anti-
reflux surgery and compare with healthy controls. Esophageal biopsies 
from 15 patients with GERD and predominantly typical symptoms included 
(10 men; 43,7 ± 12,6 years). All patients were evaluated with GERD and 
quality of life questionnaires, high resolution esophageal manometry, 24 
h impedance-pH monitoring, upper gastrointestinal endoscopy with dis-
tal esophageal biopsies. 3-4 months after laparoscopic anti-reflux surgery 
upper gastrointestinal endoscopy repeated in asymptomatic patients and 
esophageal biopsies were taken. 23 healthy controls (7 men; 41,9 ± 10,8 
years) were also included. The transepithelial resistance (TEER) and tissue 
permeability via fluorescein diffusion within 2 hours were recorded.
results: TEER of esophageal epithelium was significantly higher after the 
surgery (p=0.0002) and healthy controls (HC) (p=0.0009). There was no 
difference between pre-operative patients and HC in TEER. Mucosal per-
meability measured with fluorescein diffusion of post-operative measure-
ments was significantly decreased than pre-op patients (p=0.038). There 
was no significant difference neither pre-operative nor post-operative 
measurements than HC (Table).
conclusion: The TEER and permeability results implicate that laparoscopic 
anti-reflux surgery showed an efficient recovery within esophageal epi-
thelium in patients with GERD. One possible explanation of the higher 
tissue resistance following the surgery than HC might be explained with 
the continue “silent” reflux in HC.
disclosure: Nothing to disclose 
  Teer (Ohms) flourescein permeability (pmols)
Healthy controls 166.8 ± 46.2 36.9 ± 13.5
Pre-op patients 151.0 ± 51.6 48.6 ± 27.8
Post-op patients 214.8 ± 61.0* 29.5 ± 17.3**
(*; p< 0.001 vs. pre-op patients and vs. healthy controls, **; p< 0.05 vs. pre-op patients)
[Transepithelial resistance and flourescein permeability results of the groups]
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Introduction: Stretta is an option for patients with gastroesophageal re-
flux disease (GERD), offering an alternative to invasive surgery, endoscopic 
therapies or continue PPI therapy.
aims & Methods: We aim to investigate the electrophysiological differ-
ences and diffusion characteristics as a reflection of tissue integrity within 
esophageal mucosa before and after stretta. Patients with predominantly 
typical symptoms and true nonerosive reflux disease or LA-esophagitis A 
were included. GERD and quality of life questionnaires, high resolution 
esophageal manometry, 24 h impedance-pH monitoring, upper gastro-
intestinal endoscopy with distal esophageal biopsies were performed in 
nine patients before stretta (4 men, 44.5±10.4 years). 3-4 biopsies were 
put into the chambers to measure the transepithelial resistance (TEER), 
potential difference (PD) and tissue permeability via fluorescein diffusion 
within 2 hours as well as evaluation of dilated intercellular spaces with 
light microscopy. The Stretta procedure performed under sedation with 
regular protocol without any complication. Three weeks of PPI therapy was 
given to all patients following the procedure than stopped. All patients 
were symptom free or have less than 50% of typical symptoms at the end 
of the 8 weeks of follow up. Approximately two months after stretta, up-
per GI endoscopy repeated, esophageal biopsies were taken. All results 
were compared with 23 healthy controls (7 men; 41,9 ± 10,8 years). 24 h 
impedance-pH monitoring was performed in eleven out of 23 HC.
results: TEER of pre-stretta group was significantly lower than healthy 
controls (HC) (p=0.037). But no significance was found between pre-stret-
ta and post stretta group (p=0.17) even though there was a great mar-
gin (124.6 ± 55.7 vs 157.2 ± 61.3). No difference was shown in post stretta 
group compared to HC (166.8 ± 46.2) (p=0.59). Mucosal permeability in 
pre-stretta group was significantly lower than post-stretta group (p=0.006) 
and HC (p=0.015) while there was no significance between post stretta and 
HC (Table).
  Teer (Ohms) flourescein permeability (pmols)
Pre-stretta 124.6 ± 55.7* 67.2 ± 31.5*
Post-stretta 157.2 ± 61.3 28.5 ± 18.2**
Healthy controls 166.8 ± 46.2 36.9 ± 13.5
(*; p<0.05 pre-stretta vs HC, **; p<0.05 pre-stretta vs post-stretta)
[Transepithelial resistance and flourescein permeability results of the groups]
conclusion: Electrophysiological results indicate that epithelial permeability 
and possibly mucosal damage has recovered after stretta treatment within 
esophageal epithelium. Those changes might be explained with less reflux 
load at the distal esophagus. A direct effect of the procedure inside the 
tissue is a low possibility since application effects only a small area. 
disclosure: Nothing to disclose 
P1284 Par2, P2x2 and P2y2 Mrna exPressIOn In PaTIenTs 
WITh gasTrOesOPhageaL refLux dIsease and TheIr 
reLaTIOnshIP TO refLux syMPTOMs: a PILOT sTudy
Mokrowiecka A.1, Bartoszek A.2, Fabisiak A.1,2, Fichna J.2, 
Malecka-Panas E.1
1Medical University of Lodz, Dept of Digestive Tract Diseases, Lodz, Poland, 
2Medical University of Lodz, Dept of Biochemistry, Lodz, Poland
contact e-Mail address: annazlo@wp.pl
Introduction: Current treatment of gastroesophageal reflux disease (GERD) 
aims primarily at decreasing the acid secretion, however there is still a 
group of patients not responding to conventional therapy. According to 
recent model of GERD pathogenesis, reflux esophagitis is an immune cell-
mediated damage, rather than a caustic chemical injury. Acid exposure 
can increase expression of several receptors on esophageal epithelial cells. 
The proteinase-activated receptor-2 (PAR2) is a member of the G protein-
coupled receptor family and has been involved in inflammation, visceral 
hyperalgesia, and in transepithelial resistance. Purinergic receptors are a 
family of membrane-bound receptors using ATP as transmitter. P2X and 
P2Y receptors play important roles in signaling visceral pain and esopha-
geal hypersensitivity. Thus these receptors represent a potential target for 
future pharmacological treatment of GERD.
aims & Methods: The aim was to assess the expression of PAR2, P2X2 and 
P2Y2 mRNA in esophageal mucosa in different groups of GERD patients as 
well as to compare with reflux symptoms and HRQL.
PAR2, P2X2 and P2Y2 mRNA expression was quantified using quantita-
tive RT-PCR in esophageal samples obtained from patients with GERD and 
healthy controls. Moreover, patients completed the GERD-Health Related 
Quality of Life (GERD-HRQL) questionnaire. Student’s t-test was chosen 
when comparing two means; one-way ANOVA followed by the Newman-
Keuls post-hoc test was used for analyses of multiple treatment means. 
Using Pearson correlation test we analyzed relationship between the rela-
tive expression of receptors and GERD-HRQL score.
results: A total of 53 patients with GERD (37 with non-erosive reflux dis-
ease (NERD) and 16 erosive reflux disease (ERD)) and 9 healthy controls 
were recruited to the study. Overall, the relative expression of PAR2, P2X2 
and P2Y2 were non-significantly higher in esophageal biopsies taken 
from patients with GERD than in controls (77.60±28.50 vs 284.60±67.72; 
26.81±10.27 vs 274.40±77.46; 3476.0±508.2 vs 7215.0±1338.0, accordingly).
When classifying patients to non-erosive and erosive reflux disease PAR2 
receptor expression was non-significantly higher in ERD compared to 
NERD and controls (326.10±112.30 vs 266.90±84.76 vs 77.60±28.50). 
P2X2 exhibited the highest expression in NERD compared to ERD and con-
trols (302.20±82.94 vs 40.18±17.78 vs 26.81±10.27), similarly to P2Y2 which 
expression was higher in NERD than in ERD and controls (7321.00±1651.00 
vs 5306.0±1738.00 vs 3476.00±508.0).
GERD-HRQL scores revealed significant positive correlation to PAR2 ex-
pression (r=.03883), as well as to P2Y2 expression (NS), however were 
negatively correlated with P2X2 expression (r=-0.2991).
conclusion: Higher PAR2 expression was found in erosive reflux disease 
and may be associated with higher intensity of symptoms perceived by 
patients with GERD. Relative expression of P2X2 and P2Y2 were increased 
particularly in NERD, where they could mediate sensitization of esopha-
gus. Our results show that PAR2, P2X2 and P2Y2 may play a role in GERD 
inflammation and could be in future a therapeutic targets for reflux symp-
toms.
disclosure: Nothing to disclose 
P1285 The effecT Of dIfferenT Ph refLuxaTe On The TyPe 
Of IMMune resPOnse In gerd PaTIenTs
Paraskevova A.1, Trukhmanov A.1, Lyamina S.2, Kalish S.2, Storonova O.1, 
Pirogov S.3, Ponomarev A.4, Rumyantseva D.1, Sokolov K.4, Malyshev I.2, 
Maev I.2, Ivashkin V.1
1Sechenov University, Vasilenko Clinic of Internal Diseases Propedeutics, 
Gastroenterology and Hepatology, Moscow, Russian Federation, 2Moscow 
State University of Medicine & Dentistry, Moscow, Russian Federation, 
3Moscow Herzen Research Institute of Oncology, Moscow, Russian 
Federation, 4Sechenov University, Moscow, Russian Federation
contact e-Mail address: paraskevova.anna@mail.ru
Introduction: Assessment of 24-hour pH-monitoring can provide confir-
matory evidence of gastroesophageal reflux disease (GERD). The primary 
outcome of 24-hour pH-monitoring is the distal oesophageal acid expo-
sure time (AET) < 6%. Currently, discusses the possible impact of immune 
response (Th1 or Th2) in the development of the inflammatory response in 
the esophagus.
aims & Methods: The aim of the study was to investigate interleukin 
(IL)-8 and IL-10 expression after exposure to different human reflux-
ates (pH< 5, pH 5-7, pH>7) to peritoneal macrophages of C57/BL6 mice 
(n=68) with the following macrophage culturing in standard conditions 
(10% FBS, RPMI1640) for 36 hours. According to data of endoscopy and 
24-hour pH-monitoring (normative value of AET< 6%*) we divided 68 pa-
tients with GERD to 28 (14 men, 45.74±2.23 yr) non-erosive reflux disease 
(NERD), 22 (15 men, 45.0±3.24 yr) erosive reflux disease ERD and 18 (13 
men, 47.22±2.95 yr) Barrett’s esophagus (BE). We performed 24-hour pH-
monitoring on the Ohmega - Ambulatory Impedance-pH Recorder (Medi-
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cal Measurements Systems (MMS), Netherlands). Macrophage culturing 
(RPMI1640 medium, 10% FBS) in standard conditions (37oC, 5% CO2) for 
36 hours flow cytometry (Beckman Coulter, FC500). Assessment of secre-
tory activity of peritoneal macrophages (proinflammatory cytokine IL-8 
and anti-inflammatory cytokine IL-10). The statistical analysis was done 
using SPSS Statistics 17.0.
results: In NERD patients median pH of refluxates was 6.18 [4.2; 7.4], in 
ERD - 6.71 [5.7; 8.1], in BE - 6.24 [4.6; 7.3]. Median value of the level of 
IL-8 after exposure refluxates with pH< 5 was 69.0 [42.1; 125.3] pg/mL, 
with pH 5-7 was 60.3 [15.4; 120.0] pg/mL, with pH>7 - 37.6 [8.7; 73.4] pg/
mL. Median value of the level of IL-10 after exposure refluxates with pH< 5 
was 4.1 [1.5; 10.2] pg/mL, with pH 5-7 was 7.8 [1.3; 33.8] pg/mL, with pH>7 
- 16.8 [5.7; 61.3] ph/mL. Exposure to acid refluxates causes an increased 
production of Th1 proinflammatory cytokine IL-8 (r= -0.352, p= 0.026), but 
exposure to non acid refluxates causes an increased production of Th2 
anti-inflammatory cytokine IL-10 (r= 0,697, p= 0,001). The results of 24-
hour pH-monitoring demonstrated that in NERD patients median AET was 
4.7 [0.3; 18.0] %, in ERD - 9.3 [0.2; 57.8] %, in BE - 14.5 [1.3; 49.9] %.
conclusion: Exposure to acid refluxates causes an increased of Th1 immune 
response with increased production of Th1 cytokine (IL-8). Exposure to 
non acid refluxates causes an increased of Th2 immune response with 
increased production of Th2 cytokine (IL-10). Th1 and Th2 cytokines 
production demonstrates statistically significant different with acid and 
non acid refluxates. We observed that AET was higher in ERD and BE 
patients than in NERD patients. It suggests that high level AET may lead to 
Th1 immune response.
disclosure: Nothing to disclose 
P1286 esOPhageaL InfusIOn Of MenThOL dOes nOT affecT 
esOPhageaL MOTILITy BuT evOkes hearTBurn In PaTIenTs 
WITh gasTrOesOPhageaL refLux dIsease (gerd)
Banovcin P.1, Duricek M.1, Liptak P.1, Nosakova L.1, Hyrdel R.1, Kollarik M.2,3
1Jessenius Faculty of Medicine, Comenius University, Department of 
Gastroenterology, Martin, Slovakia, 2The Johns Hopkins University School of 
Medicine, Baltimore, United States, 3Morsani College of Medicine, University 
of South Florida, Department of Molecular Pharmacology and Physiology, 
Tampa, United States
contact e-Mail address: pbanovcin@gmail.com
Introduction: A common food additive menthol is thought to trigger the 
symptoms of GERD by influencing esophageal peristalsis and the lower 
esophageal sphincter (LES) function. However, recent studies reported the 
expression of TRPM8 receptor for menthol and cold in esophageal sensory 
C-fiber nerves.
aims & Methods: We evaluated the effect of esophageal infusion of men-
thol on esophageal motility and the sensations evoked from the esopha-
gus. High resolution manometry (HRM) catheter with attached thin tube 
for menthol infusion (opening 5 cm above LES) was placed transnasally. 
HRM protocol which included baseline recording and 10 water (5ml) 
swallows was performed in supine position before and after esophageal 
infusion of menthol (3mM, 20 min, 8ml/min). The sensations evoked by 
menthol infusion were evaluated for quality and for intensity of painful 
component by visual analogue scale (VAS, range 1-10). In additional sub-
jects menthol infusion was performed without HRM and only the sensa-
tions were evaluated.
results: Menthol did not appreciably affect HRM measurements character-
izing LES function and esophageal peristalsis in healthy subjects (N=12) or 
GERD patients (N=10). For example, in healthy subjects esophageal infu-
sion of menthol did not change the magnitude of the inspiratory aug-
mentation of LES (10.6+1.8 mmHg before vs. 9.1+1.6 mmHg after menthol, 
P=0.3), distal contractile integral (DCI, 742±137 vs. 840±124, P=0.5) nor the 
percentage of ineffective swallows (40±10% vs. 23±8%, P=0.13). Similarly, 
in GERD patients menthol did not change the inspiratory augmentation 
of LES (9.5+1.2 mmHg vs. 9.1+1.2 mmHg, P=0.6), DCI (287±86 vs. 314±102, 
P=0.7) nor ineffective swallows (75±10% vs. 71±13%, P=0.6). 
In contrast, menthol had a striking effect on esophageal sensations in pa-
tients with GERD. While the esophageal infusion of menthol evoked only a 
cold sensation in 11 of 12 healthy subjects, it evoked heartburn in 10 of 10 
patients with GERD (P< 0.01). 
In healthy subjects the cold sensation was perceived only as a minor 
discomfort (VAS score 1.9±0.3) but in patients with GERD the menthol-
induced heartburn was perceived as painful (VAS score 5.6±0.5, P< 0.01). 
The intensity of menthol-induced heartburn was comparable to the inten-
sity of heartburn evoked by a brief infusion of acid (pH=1.0, 10min) in a 
separate group of patients (VAS score 7.1± 0.7, N=12).
conclusion: We conclude that esophageal infusion of menthol does not 
affect esophageal motility. However, the sensations evoked by menthol 
change dramatically from a relatively non-painful cold sensation in healthy 
subjects to painful heartburn in patients with GERD. Our results suggest 
that menthol triggers the symptoms of GERD directly by influencing esoph-
ageal nerves rather than indirectly by affecting esophageal motility. Sup-
ported by VEGA 1/0304/19.
disclosure: Nothing to disclose 
P1287 effIcacy and safeTy Of TransOraL IncIsIOnLess 
fundOPLIcaTIOn (TIf) In refracTOry gasTrOesOPhageaL 
refLux dIsease: a sysTeMaTIc revIeW and MeTa-anaLysIs
Gopalakrishnan Ravikumar N.P.1, Sannapaneni S.2, Thota P.3, Sanaka M.4
1University at Buffalo, Internal Medicine, Buffalo, United States, 2Texas 
Health Presbyterian Hospital, Dallas, United States, 3Cleveland Clinic 
Foundation Digestive Disease Institute, Cleveland, United States, 4Cleveland 
Clinic Foundation Digestive Disease Institute, Gastroenterology, Cleveland, 
United States
contact e-Mail address: ravikumar.naveen1@gmail.com
Introduction: Refractory gastroesophageal reflux disease (GERD) is com-
mon and can affect up to 40% of patients who are on proton pump in-
hibitor therapy. Surgical fundoplication (Nissen fundoplication) has proven 
to be an effective treatment option for these patients but it remains an 
invasive procedure in this era of minimally invasive surgery. Several endo-
luminal approaches to GERD management have been developed as a po-
tential bridge between medical management and surgical fundoplication. 
Transoral incisioness fundoplication (TIF) is a novel endoscopic technique 
which has shown some promise in early studies; however, its safety profile 
and efficacy remain uncertain.
aims & Methods: We aimed to assess the efficacy and safety of TIF in refrac-
tory GERD through a systematic review and meta-analysis.We performed 
a thorough literature search using PubMed, EMBASE, Cochrane library, 
Medline, Google Scholar and Science citation index between January 2010 
to January 2018. Search terms included MeSH and non-MeSH terms relat-
ing to gastroesophageal reflux disease, refractory gastroesophageal reflux 
disease, endoscopic techniques in gastroesophageal reflux disease and 
transoral incisionless fundoplication. Additional case-reports, case series, 
and abstracts were retrieved by searching from references of relevant stud-
ies. Primary outcomes measured were cumulative technical success rate 
and adverse events. Secondary outcomes measured were the improve-
ment in Gastroesophageal Reflux Symptom Score (GERSS), DeMeester 
score and Reflux symptom index (RSI).
results: Based on our search criteria, 41 studies were identified and 6 
were excluded after careful review. 35 studies which included 1586 pa-
tients (49.4% males) were analyzed. The overall technical success rate of 
TIF was 98.4% (95% confidence interval [CI] 96 to 99, p < 0.001) and had 
an adverse event rate of 3.2% (95% CI 1 to 4, p < 0.001). Post TIF, there was 
a significant improvement in GERSS score (mean difference 17.29, 95% CI 
17.26 to 18.28,p < 0.001),RSI (mean difference 14.37, 95% CI 13.39 to 15.19,p 
< 0.001) and DeMeester score (mean difference 9.78, 95 % CI 8.12 to 11.89, 
p < 0.001).
conclusion: TIF is a technically feasible and effective endoscopic therapeu-
tic option for refractory GERD with good clinical responses. However, more 
controlled trials are required in future to compare the efficacy and safety 
between TIF and Nissen fundoplication.
disclosure: Nothing to disclose 
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P1288 cOMParIsOn Of The effIcIency Of TWO dIfferenT 
PPI fOrMuLa In TreaTMenT Of aTyPIcaL gerd PaTIenTs, a 
randOMIzed sTudy
Ting P.H., Luo J.C.
Taipei Veterans General Hospital, Department of Internal Medicine, Taipei, 
Taiwan
contact e-Mail address: seohyun1130@gmail.com
Introduction: Patients with atypical gastro-esophageal reflux disease 
(GERD), including cough, globus, and hoarseness usually require more 
aggressive or double dose proton pump inhibitor (PPI) therapy than pa-
tients with typical GERD. The prospective, open-label, randomized study 
aims to compare the efficacy of lansoprazole, a fast orally-disintegrating 
PPI and dexlansoprazole, a dual delayed release PPI in patients with atypi-
cal GERD symptoms.
aims & Methods: Patients with atypical GERD symptoms and a total Reflux 
Symptom Index (RSI) score ≥11 were eligible for enrollment. From Jan. 2017 
to Dec. 2018, 232 subjects were randomly assigned (1:1 ratio) to receive oral 
lansoprazole 30 mg, once daily before breakfast or oral dexlansoprazole 60 
mg, once daily before breakfast for 8 weeks. The primary endpoint is to com-
pare the response rate after 8-week PPI therapy between the two groups.
results: There were 101 (43.5%) with cough, 144 (62.1%) with globus, and 
41 (17.7%) with hoarseness among these 232 study subjects. After 8-week 
PPI therapy, dexlansoprazole treated group had a significantly higher 
symptoms response rate than lansoprazole treated group in cough (76.5 
% vs. 38.0 %) and globus (69.7 % vs. 30.8 %)(p all< 0.05 by intention to 
treat). Multivariate logistic regression analysis showed that use of dex-
lansoprazole, presence of dyslipidemia and typical GERD symptoms (acid 
reflux and heart burn) and absence of globus symptom were predictors for 
symptom response for cough; use of dexlansoprazole, no cough symptom, 
and presence of erosive esophagitis were predictors for symptom response 
for globus (p all < 0.05). No predictor for therapy response to hoarseness 
was noted.
conclusion: There is a higher response rate for cough and globus symp-
toms in atypical GERD patients after a 8-week PPI therapy with dexlanso-
prazole rather than lansoprazole.
disclosure: Nothing to disclose 
P1289 effIcacy Of da-5204 (sTILLen 2x®) fOr PaTIenTs WITh 
gasTrOesOPhageaL refLux dIsease: a randOMIzed, dOuBLe-
BLInd, PLaceBO-cOnTrOLLed PILOT sTudy
Shim H.I., Cho J.H., Shin C.M., Yoon H., Park Y.S., Kim N., Lee D.H.
Seoul National University Bundang Hospital, Internal Medicine, Seongnam, 
Korea (Republic of)
contact e-Mail address: sharpsim1222@naver.com
Introduction: Proton pump inhibitor (PPI) alone is not satisfactory for the 
treatment of gastroesophageal reflux disease (GERD). Therefore, we inves-
tigated the efficacy of DA-5204 (Stillen 2X®, 90mg of Artemisia asiatica 
95% ethanol extract per tablet) and PPI combination therapy on GERD in 
comparison to PPI alone.
aims & Methods: This randomized, double-blind, placebo-controlled study 
randomly assigned 70 patients with endoscopically proven esophageal mu-
cosal injury (Los Angeles classification A or B) into 2 groups: pantoprazole 
40mg once daily with DA-5204 twice daily (DA-5204 group) or pantopro-
zole 40mg once daily with placebo twice daily (placebo group) for 4 weeks. 
The primary endpoints were endoscopically effective (normal mucosa or 
minimal change) or complete healing (normal mucosa) rates, and second-
ary endpoint was sufficient relief (≥ 50% reduction) of reflux symptoms us-
ing Gastroesophageal Reflux Disease Questionnaire (GerdQ) questionnaire.
results: Final analyses included 29 patients with the DA-5204 group and 
30 patients with the placebo group. At weeks 4, there was a significantly 
difference of the endoscopically effective healing rate between the two 
groups (DA-5204 group vs. placebo group; 93.1% vs. 56.7%; p = 0.001) 
as well as the complete healing rate (DA-5204 group vs. placebo group; 
82.8% vs. 33.3%; p < 0.000). The rates of sufficient relief for reflux symp-
toms according to GerdQ tended to be higher in the DA-5204 group than 
in the placebo group, with no significant difference.
conclusion: Our findings suggest that combined therapy with PPI and DA-
5204 is more effective in treating GERD than PPI alone.
disclosure: Nothing to disclose 
P1290 On-deMand versus cOnTInuOus PrOTOn 
PuMP InhIBITOr TheraPy as fIrsT-LIne TreaTMenT fOr 
gasTrOesOPhageaL refLux dIsease: a sIngLe-cenTer 
PrOsPecTIve sTudy
Yoon J.Y., Kim D.H.
University of Ulsan College of Medicine, Asan Medical Center, 
Gastroenterology, Seoul, Korea (Republic of)
contact e-Mail address: fatei@hanmail.net
Introduction: The recommended schedule of proton pump inhibitor as 
first-line treatment for gastroesophageal reflux disease (GERD) is 4-8 
weeks of continuous medication; however, patients often do not take all 
prescribed medication and spontaneously resort to on-demand schedule. 
We compared the efficacy of esomeprazole as first-line treatment accord-
ing to the pattern of medication adherence (on-demand vs. continuous).
aims & Methods: Patients who diagnosed with GERD by GERD question-
naire (Gerd-Q) between December 2017 and May 2018 were enrolled. The 
patients were prescribed with daily esomeprazole 20 mg for 4 weeks. After 
regularly taking the medicine for at least 1 week, the patients were al-
lowed to choose between continuous and on-demand therapy during the 
remaining 3 weeks depending on the degree of the subjective measure of 
symptoms. The number of remaining pills in the on-demand group was 
calculated, and Gerd-Q scores of the two groups were compared at base-
line and after the 4-week study period.
results: Out of a total of 94 patients, 62 enrolled in the on-demand group 
and 32 in the continuous group. In the on-demand group, the median 
number of remaining pills was 7.50 (range, 1-21). In the on-demand group 
and the continuous group, the mean Gerd-Q scores were 9.42 and 9.47 at 
baseline (p=0.850) and 7.21 and 6.91 at 4 weeks (p=0.149), respectively. 
Total and individual item scores of the Gerd-Q were significantly decreased 
in both groups at the end of the study period (p< 0.001). There were no 
significant differences between the two groups in terms of mean changes 
in the Gerd-Q score (on-demand vs. continuous groups: -2.21 vs. -2.56, 
p=0.537).
conclusion: On-demand therapy with esomeprazole 20 mg showed com-
parable efficacy to continuous therapy in terms of subjective symptom 
management in patients with GERD.
disclosure: Nothing to disclose 
P1291 adMInIsTraTIOn Of a BITTer TasTanT has nO 
InfLuence On The nuMBer Of TransIenT LOWer OesOPhageaL 
sPhIncTer reLaxaTIOns In heaLTh
Geysen H.1, Geeraerts A.1, Vanuytsel T.2, Tack J.3, Pauwels A.4
1KU Leuven, TARGID, Leuven, Belgium, 2KU Leuven, Department of 
Gastroenterology, Leuven, Belgium, 3University of Leuven, University Hospital 
Gasthuisberg, Gastroenterology, Leuven, Belgium, 4Katholieke Universiteit 
Leuven, TARGID, Leuven, Belgium
contact e-Mail address: hannelore.geysen@kuleuven.be
Introduction: Dietary measures such as avoiding high fat meals, sweets, 
coffee, alcoholic and carbonated beverages are often advised to patients 
with gastro-oesophageal reflux disease (GORD) due to their ‘reflux induc-
ing’ characteristics. However, the evidence for these advices is weak due 
to conflicting findings and the small number of patients included in the 
currently available clinical studies. Our group previously showed that ad-
ministration of a bitter compound can alter the intragastric pressure (IGP) 
after a meal (1). Additionally, we demonstrated the existence of a negative 
correlation between IGP and the number of transient lower oesophageal 
sphincter relaxations (TLOSRs) (2). However, the effect of a bitter com-
pound on TLOSRs and subsequent reflux episodes has never been inves-
tigated and it is unclear whether bitter food items should be avoided in 
GORD. We hypothesise that bitter administration in healthy volunteers (HV) 
will lead to an increase in the number of TLOSRs.
aims & Methods: After an overnight fast, 19 female HV (36 y [21-63]) un-
derwent a high-resolution impedance manometry (HRiM) measurement. 
After placement of the HRiM probe (Unisensor, Attikon, Switzerland), 10 
µmol/kg (0.1 mL/kg) of a 100 mM denatonium benzoate solution or an 
identical volume of placebo (water) was administered directly into the 
stomach. The number of TLOSRs and reflux episodes were quantified 30 
minutes before and two hours after consumption of a high caloric meal 
(mashed potatoes, apple sauce and meatloaf; 1000 kcal), using the dedi-
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cated software (Solar GI, Laborie, Canada). The HV were asked to complete 
a questionnaire concerning the presence and intensity of different upper 
gastro-intestinal (GI) symptoms every 15 minutes. The study was organised 
in a double-blind, randomized, cross-over design with at least one week 
washout between both administrations. Results were analysed using a 
paired t-test or Wilcoxon signed rank test when appropriate.
results: There was no significant difference in the number of TLOSRs nor 
the number of reflux episodes between the bitter and placebo condition 
(Table 1). 
  Bitter Placebo p-value
TLOSRs 17 ± 5.5 15 ± 4.4 0.14
Reflux episodes 10 ± 6.0 10 ± 4.7 0.73
[Table 1: The number of TLOSRs and reflux episodes in the two different 
conditions (mean ± SD).]
Additionally, no differences were observed in the nature (gas or liquid) 
and extent of reflux events between the different conditions. LOS pres-
sures dropped significantly in the first postprandial hour to start recover-
ing slowly back to baseline values during the second postprandial hour (p< 
0.0001), without any difference between both conditions. No difference in 
GI symptom occurrence was noted.
conclusion: Administration of the bitter tastant denatonium benzoate, had 
no influence on the number of TLOSRs nor on the number of reflux epi-
sodes compared to placebo. Therefore, we speculate that the consumption 
of bitter food will not have an influence on the number of reflux episodes 
nor on the occurrence of GORD-related symptoms in GORD patients.
references: 1. Andrews CN, Verschueren S, Janssen P, Maes A, Deloose E, 
Depoortere I, et al. Su2072 The Bitter Taste Receptor Agonist Denatonium 
Benzoate Alters Intragastric Pressure Profiles During Nutrient Drink Test 
in Healthy Volunteers. Gastroenterology. 2013;144(5):S549. 2. Pauwels A, 
Altan E, Tack J. The gastric accommodation response to meal intake deter-
mines the occurrence of transient lower esophageal sphincter relaxations 
and reflux events in patients with gastro-esophageal reflux disease. Neu-
rogastroenterol Motil. 2014;26(4):581-8.
disclosure: Nothing to disclose 
P1292 IW-3718, a nOveL gasTrIc-reTenTIve BILe acId 
sequesTranT, IMPrOves gerd syMPTOMs In PaTIenTs WITh 
PersIsTenT gerd desPITe OngOIng PPI TreaTMenT - Phase 
2B sTudy resuLTs
Fass R.1, Vaezi M.F.2, Vakil N.3, Hanlon J.4, Mittleman R.S.5, Hall M.5, 
Shao J.Z.5, Chen Y.4, Lane L.4, Gates A.M.4, Borgstein N.4, Currie M.G.5
1MetroHealth Medical Center and Case Western Reserve University, Cleveland, 
United States, 2Vanderbilt University Medical Center, Nashville, United States, 
3University of Wisconsin School of Medicine and Public Health, Madison, 
United States, 4Ironwood Pharmaceuticals, Incorporated, Cambridge, United 
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United States
contact e-Mail address: ronnie.fass@gmail.com
Introduction: Proton pump inhibitors (PPIs) are the standard therapy for 
gastroesophageal reflux disease (GERD). However, it is estimated that ap-
proximately 30% of patients with GERD have persistent symptoms despite 
taking label-dose PPIs. GERD and persistent GERD are characterized by 
reflux of stomach contents into the esophagus resulting in heartburn (HB) 
and regurgitation (RG), esophageal injury, and complications. IW-3718 is 
a novel gastric-retentive bile acid sequestrant in clinical development for 
persistent GERD. The positive impact of IW-3718 was previously reported 
for HB and RG, based on derived endpoints. The aim of this study was to 
determine the impact of IW-3718, added to label-dose PPIs, on individual 
GERD symptoms measured by the modified Reflux Symptom Question-
naire-electronic Diary (mRESQ-eD), a patient-reported, evidence-based 
clinical outcomes assessment.
aims & Methods: This double-blind, placebo-controlled study included 
a screening, a 2-week pretreatment, and an 8-week treatment period. 
Enrolled patients were taking label-dose PPIs; had GERD, evidenced by 
erosive esophagitis (EE) on esophagogastroduodenoscopy (EGD) and/or 
abnormal acid exposure while taking PPIs (pH < 4 for ≥4.2% of a 24-hour 
interval; “Bravo-positive”); and had HB or RG symptoms ≥4 days per week 
for 8 weeks despite ongoing use of label-dose PPIs. Patients were strati-
fied by baseline (BL) EE status and randomized (1:1:1:1) to placebo (PBO) 
or IW-3718 (500, 1000, or 1500 mg) twice daily (BID) in addition to once-
daily (QD) PPI. During the pretreatment and treatment periods patients 
self-reported the severity (6-point scale [0=did not have, 5=severe]) or fre-
quency (5-point scale [0=never, 4=very often]) of 10 symptoms associated 
with GERD on the mRESQ-eD daily. The symptoms assessed for “severity” 
were HB, burning feeling behind breastbone or center of upper stomach, 
pain behind breastbone or center of upper stomach, difficulty swallowing, 
hoarseness, and cough. The symptoms assessed for “frequency” were RG 
(liquid or food) moving upward toward throat or mouth, acid or bitter 
taste, coughing, and burping. For each of the 10 symptoms, change from 
BL to Week 8 in the weekly average was analyzed using an analysis of co-
variance model with treatment group and EE status as factors and BL score 
as a covariate. No adjustment was made for multiplicity.
results: The modified intent-to-treat population included 280 patients (68-
71/arm). At BL, 52% had EE and 73% were Bravo-positive. Demographics 
were similar across groups. Changes from BL to Week 8 for each of the 10 
mRESQ-eD symptom items are presented in Table 1. Greater improvements 
were seen for all symptom items in the 1500-mg IW-3718 group compared 
with PBO (P≤0.05), except burping frequency (P=0.17).
conclusion: In addition to improving HB and RG, IW-3718 (1500 mg BID) 
improved other GERD-related symptoms in patients with persistent GERD 
who continued receiving PPIs QD.
endpoint statistic: Mean 
change from Baseline
PBO
(PPI alone)
BId
n=69
IW-3718
500 mg
BId
n=71
IW-3718
1000 mg
BId
n=71
IW-3718
1500 mg
BId
n=68
P value
IW-3718
1500 mg
vs
PBO
Heartburn severity -1.4 -1.5 -1.7 -1.8 0.03
Burning feeling behind 
breastbone or center of 
upper stomach severity
-1.3 -1.4 -1.6 -1.8 0.01
Pain behind breastbone 
or center of upper 
stomach severity
-1.3 -1.3 -1.5 -1.7 0.03
Difficulty swallowing 
severity
-0.9 -0.8 -1.0 -1.2 0.03
Hoarseness severity -0.6 -0.7 -1.0 -1.1 <0.01
Cough severity -0.6 -0.7 -1.0 -1.2 <0.01
Regurgitation (liquid or 
food) moving upward 
toward throat or mouth 
frequency
-0.8 -1.0 -1.0 -1.2 <0.01
Acid or Bitter Taste 
Frequency
-0.9 -0.9 -1.1 -1.2 0.05
Coughing frequency -0.6 -0.6 -0.7 -1.0 <0.01
Burping frequency -0.8 -1.0 -0.9 -1.0 0.17
[Table 1. mRESQ-eD Symptom Items: Change From Baseline to Week 8 in 
Weekly Average (mITT Population)]
disclosure: J. Hanlon, R.S. Mittleman, M. Hall, J.Z. Shao, Y. Chen, L. Lane, 
A.M. Gates, N. Borgstein, and M.G. Currie are current or former Ironwood 
employees and may own stock or stock options in Ironwood Pharmaceuti-
cals, Inc. M.F. Vaezi, R. Fass, and N. Vakil have served on medical advisory 
boards as paid consultants for Ironwood Pharmaceuticals, Inc. 
P1293 dIagnOsIng dysPLasIa In BarreTT’s OesOPhagus - The 
seaTTLe PrOTOcOL reMaIns The dOMInanT sTraTegy In nOn 
exPerT cenTres
Keyte G.1, Iqbal M.1, Viswanath Y.1, Khan A.2, Wells C.2, Vasani J.2, 
Beintaris I.2, Dhar A.1
1Darlington Memorial & Bishop Auckland Hospitals, Gastroenterology, 
Co. Durham, United Kingdom, 2University Hospital of North Tees, 
Gastroenterology, Stockton-on-Tees, United Kingdom
contact e-Mail address: muhammad.iqbal16@nhs.net
Introduction: Detection of dysplasia at Barrett’s surveillance depends on 
a number of factors including: the endoscopist’s skill, use of advanced 
imaging (NBI, Acetic acid), adherence to Seattle protocol, and high-risk 
patient factors like male sex, smoking, length of Barrett’s segment and 
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family history of oesophageal adenocarcinoma. Whether the high rates 
of visible dysplasia diagnosis reported from expert tertiary centres needs 
further study.
aims & Methods: The aim of this pre-EQuIP study was to analyse routes 
to dysplasia diagnosis in a dedicated Barrett’s surveillance programme, 
specifically looking at the grade of the endoscopist, use of image enhance-
ment (IE), diagnosis by Seattle biopsy protocol vs. random biopsy, and the 
nature of dysplasia (Low grade, LGD vs. high grade, HGD). An electronic 
database search of over 600 Barrett’s surveillance histology was carried 
out for the period 2015-2018 in two NHS Trusts, extracting all reported dys-
plasia. The endoscopy database was then interrogated for the following: 
patient demographics, grade of endoscopist (medical consultant gastro-
enterologist, non-medical endoscopist and surgical consultant), sedated 
vs. unsedated procedure, visible dysplasia, HD-white light vs. IE, length of 
Barrett’s segment and Prague classification, Paris classification of any vis-
ible lesions, targeted vs. Seattle Protocol biopsies, and grade of dysplasia. 
All endoscopies were done with high-resolution scopes; where a visible 
lesion was identified, a targeted biopsy was taken.
results: 148 patients with dysplasia were analysed, M:F ratio 4.5:1, mean 
age 68yrs. Barrett’s length ranged from 1-14cm, with 50% endoscopists 
reporting the Prague classification. Surveillance was done by: consultant 
gastroenterologists (70pts), nurse endoscopists (55pts), consultant sur-
geons (15pts) and registrars (8pts). At Site A only 3.2% of endoscopists 
explicitly mentioned a Seattle biopsy protocol in their report. Across both 
sites histology showed that protocol had been followed in 56.7% of en-
doscopies, with 54.2% gastroenterologists, 52.6% nurse endoscopists and 
73.7% surgeons taking multi-level biopsies (Seattle equivalent protocol). 
The distribution of dysplasia LGD:HGD:carcinoma in the Seattle group was 
1:1.48:1.32 vs. random biopsy of 2.54:2.47:1. In Site A, there was a statisti-
cally significant difference between the two groups, showing that more 
carcinomas were picked up in the Seattle group, chi-square statistic 12.65, 
DF=3 p=0.0018.
conclusion: In this real-world NHS study, we found that after 4 years of 
the BSG guidelines, visible dysplasia is extremely difficult to detect. The 
Seattle biopsy protocol was followed in only 56.7% of endoscopies and is 
the dominant route, indicating a need for quality improvement & training 
amongst medical and non-medical endoscopists, including IE surveillance 
and chromoendoscopy.
disclosure: Nothing to disclose 
P1294 reLaTIOnshIP BeTWeen BarreTT’s esOPhagus and 
cOLOnIc dIseases: reference TO endOscOPIc surveILLance
Nakahara R.1, Yuki T.2, Ujihara T.3, Murakami D.3, Iwaki T.3, 
Sagami R.3, Suehiro S.1, Katsuyama Y.3, Hayasaka K.1, Harada H.3, 
Miyaoka Y.4, Fujishiro H.5, Amano Y.6
1New Tokyo Hospital, Gastroenterology, Matsudo, Chiba, Japan, 2Matsue Red 
Cross Hospital, Division of Gastroenterology, Matsue, Japan, 3New Tokyo 
Hospital, Gastroenterology, Matsudo, Japan, 4Shimane Prefectural Central 
Hospital, Department of Endoscopy, Izumo, Japan, 5Shimane Prefectural 
Central Hospital, Department of Gastroenterology, Izumo, Japan, 6New Tokyo 
Hospital, Endoscopy, Matsudo, Japan
contact e-Mail address: pppryoutarou@yahoo.co.jp
Introduction: Given that the risk factor of Barrett’s carcinogenesis is pre-
dictable, an appropriate management and surveillance of Barrett’s esoph-
agus (BE) may be provided. There are many reports regarding positive 
relationship between BE and colorectal neoplasm (CNs) in Western coun-
tries, this has been suggested BE and esophageal adenocarcinoma (EAC) 
are related with some colonic disease. However, it is still conflicting and 
little is known in Asian countries whose EAC has been also increasing. The 
purpose of this retrospective study was to investigate the relationship be-
tween BE or EAC, and colonic diseases including CNs, colon diverticulosis 
and inflammatory bowel diseases (IBD).
aims & Methods: We retrospectively reviewed the medical records of 5606 
patients (male gender: 56.9%, and median age: 68.2, range 16-98 years 
old) received both of colonoscopy and esophagogastroduodenoscopy be-
tween January 2016 and December 2017 in 3 core hospitals, and investi-
gated their endoscopic findings and clinical covariables were age, gender, 
BMI, smoking, alcohol intake drug use (aspirin/NSAIDs, anti-coagulants, 
proton pump inhibitors, statins, anti-diabetics). BE was defined when 
Barrett’s mucosa with more than 1.0cm of M-extent according to the 
Prague C and M criteria.
results: BE with more than 1cm in length were found in 728 out of 5606 
(12.9%) patients. The Predictors for BE were male gender (63.4%, P< 
0.001), age (mean 69.3 +/- 11.8 years old, P< 0.001), PPI administration 
(35.2% vs. 29.0%, P< 0.001), anti-diabetics administration (12.3% vs. 
9.8%, P=0.041), reflux esophagitis (15.6% vs. 7.9%, P< 0.001), hiatal her-
nia (59.0% vs. 34.5%, P< 0.001), presence of CNs (74.0% vs. 54.0%, P< 
0.001), colon diverticulosis (34.0% vs. 29.3%, P=0.011) and IBD (0.6% vs. 
1.8%, P=0.020). Related CNs were adenoma and adenocarcinoma, but not 
hyperplastic polyp, especially located in the proximal colon. Multivariate 
analysis showed that colon neoplasms (t = 8.54, P< 0.001), reflux esopha-
gitis (t = 5.27, P< 0.001), and hiatal hernia (t = 11.73, P< 0.001) were posi-
tively correlated with presence of BE.
conclusion: Presence of CNs was strongly associated with patients with BE. 
Colon diverticulosis and IBD may be a positive and negative predictor for 
BE. Information provided from colonoscopy appear useful to establish the 
strategy for the surveillance of BE.
disclosure: Nothing to disclose 
P1295 The asIan BarreTT’s cOnsOrTIuM (aBc) 
MuLTInaTIOnaL survey On The Preferred dIagnOsIs and 
ManageMenT aPPrOach Of BarreTT’s OesOPhagus (BO) 
In The asIa-PacIfIc
Soh A.1, Lee Y.Y.2, Zhang Y.3, Siah K.T.H.4, Tong D.5, Law S.6, 
Ruszkiewicz A.7, Tseng P.-H.8, Trong Duc Q.9, Lee Y.C.10, Singh R.11, Wu J.12, 
Gotoda T.13, Sharma P.14, Ho K.Y.4, Asian Barrett’s Consortium (ABC)
1National University Hospital, Gastroenterology and Hepatology, Singapore, 
Singapore, 2Universiti Sains Malaysia, Penang, Malaysia, 3Shandong 
University, Shandong, China, 4National University Health System, Singapore, 
Singapore, 5University of Hong Kong, Surgery, Hong Kong, Hong Kong, 
China (SAR), 6The University of Hong Kong, Hong Kong, China, 7Lyell McEwin 
Hospital, Adelaide, Australia, 8National Taiwan University Hospital, Dept. of 
Internal Medicine, Taipei, Taiwan, 9University of Medicine and Pharmacy, Ho 
Chi Minh City, Viet Nam, 10National Taiwan University, Taipei, Taiwan, 11Lyell 
McEwin Hospital, Department of Medicine, Adelaide, Australia, 12Chinese 
University of Hong Kong, Medicine & Therapeutics, Hong Kong, Hong Kong, 
China (SAR), 13Tokyo Medical University, Tokyo, Japan, 14University of Kansas 
School of Medicine, Dept. of Gastroenterology, Leawood, United States
contact e-Mail address: alex_ys_soh@nuhs.edu.sg
Introduction: The ABC is an Asia-Pacific workgroup on BO, affiliated to the 
National Cancer Institute in the United States. At present, guidelines from 
major societies worldwide provide differing definitions and viewpoints, 
making the standardization of the diagnosis of BO challenging. As a re-
sult of studies using different methodologies, endoscopic practices and 
histopathological criteria used in the diagnosis of BO, there is substantial 
variability in the published prevalence of BO in Asia.
aims & Methods: We aim to better understand current practices and per-
ceptions of Asian endoscopists regarding BO. We designed an online sur-
vey of 11 key questions to understand the preferred diagnosis and manage-
ment practices of Asian Endoscopists on BO.
results: Of 985 invited respondents, 593 completed the survey (response 
rate of 60.2%) with 60.5% from Japan vs. 39.5% outside Japan. 90.6% 
were physicians, and 77.4% of respondents spend at least 20% of time per-
forming endoscopy. Results are shown in Table 1. The preferred Iandmark 
of the oesophagogastric junction in Japan was the distal margin of pali-
sade vessels in 59.3% of Japanese but outside Japan, the squamocolumnar 
junction was preferred in 59.8% (P< 0.001). Any length of columnar-lined 
epithelium was the preferred definition of BE in 63.5% of Japanese vs. 
71% outside Japan that preferred a minimum length of 1cm (P< 0.001). 
46% respondents from Japan did not use the Prague C&M criteria, whereas 
outside Japan, 82.5% of respondents did so to varying extents (P< 0.001). 
The Seattle protocol for biopsies was not a routine among 73% of Japanese 
respondents, whereas outside Japan there was increased adherence al-
though only 12% routinely do so (P< 0.001). Regarding histology, in Japan, 
a third (32.9%) felt that no histological confirmation was required but an-
other third (35.4%) required only columnar tissue, but outside Japan, 38% 
preferred only columnar tissue while 36.3% required specialized intestinal 
metaplasia to diagnose BO (P< 0.001). Two-yearly surveillance endoscopy 
for long segment BO without dysplasia was performed in 81.3% within 
Japan vs. 59.4% outside Japan (P< 0.001). For treatment of BO without 
dysplasia with Proton Pump Inhibitors (PPI) only for oesophagitis or when 
symptomatic, it was preferred by 80.8% in Japan vs. 69.7% outside Japan 
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(P=0.002). For biopsies indefinite for dysplasia, a third (33.1%) of Japa-
nese would confirm with a second pathologist and another third (36.5%) 
would rescope 6 monthly but outside Japan, 58.5% of respondents would 
perform the former (P< 0.001). For low grade dysplasia without a lesion, 
6 monthly surveillance was preferred in 61.3% within Japan vs 48.3% out-
side Japan (P< 0.001). For high grade dysplasia without lesion, endoscopic 
submucosal dissection was the preferred option for 82.5% of Japanese vs. 
54.7% outside Japan (P< 0.001).
conclusion: In conclusion, diagnosis and management approach of BO 
appear to vary widely within Asia, with stark contrast between Japanese 
and non-Japanese endoscopists. Lack of standardization, education and 
research are possible causes for the observed differences.
disclosure: Nothing to disclose 
Q1. What is your 
preferred endoscopic 
landmark of the 
esophagogastric 
junction?
Squamo-columnar 
Junction (Z-line): 27.9% 
(Japan) vs 59.8% 
(Outside Japan)
Proximal margin of 
gastric folds: 11.7% 
(Japan) vs 26.9% 
(Outside Japan)
Distal margin of 
palisade vessels: 
59.3% (Japan) vs 10.7% 
(Outside Japan)
Diaphragmatic pinch: 
1.1% (Japan) vs 2.6% 
(Outside Japan)
    p<0.001
Q2. What is your 
preferred endoscopic 
definition of Barrett’s 
esophagus?
Length of columnar 
lined epithelium ≥2 cm: 
23.4% (Japan) vs 38.9% 
(Outside Japan)
Length of columnar 
lined epithelium ≥1 cm: 
13.1% (Japan) vs 32.1% 
(Outside Japan)
Any length of columnar 
lined epithelium in 
the esophagus : 63.5% 
(Japan) vs 29.1% 
(Outside Japan)
      p<0.001
Q3. How often do 
you use the Prague C 
& M criteria in your 
assessment of Barrett’s 
esophagus?
All the time: 12% 
(Japan) vs 22.2% 
(Outside Japan)
>70% of the time: 5.3% 
(Japan) vs 15% (Outside 
Japan)
30-70% of the time: 
8.6% (Japan) vs 13.7% 
(Outside Japan)
<30% of the time: 
28.1% (Japan) vs 31.6% 
(Outside Japan)
Never: 46% (Japan) vs 
17.5% (Outside Japan)
  p<0.001
Q4. What is your 
preferred histologic 
definition of Barrett’s 
esophagus?
Any columnar tissue: 
35.4% (Japan) vs 38% 
(Outside Japan)
Specialized Intestinal 
Metaplasia: 17% (Japan) 
vs 36.3% (Outside 
Japan)
Gastric Metaplasia: 
14.8% (Japan) vs 20.1% 
(Outside Japan)
No histological 
confirmation required: 
32.9% (Japan) vs 5.6% 
(Outside Japan)
    p<0.001
Q5. In your practice, 
how regular do you 
survey your long-
segment Barrett’s 
esophagus without 
dysplasia?
Every 2 years: 81.3% 
(Japan) vs 59.4% 
(Outside Japan)
Every 3 years: 5% 
(Japan) vs 18.8% 
(Outside Japan)
Every 5 years: 1.4% 
(Japan) vs 4.7% (Outside 
Japan)
None at all: 12.3% 
(Japan) vs 17.1% (Outside 
Japan)
    p<0.001
Q6. How often do you 
follow the Seattle 
protocol (i.e. four-
quadrant biopsies every 
2 cm) in your biopsies 
of Barrett’s esophagus 
during surveillance 
endoscopy?
All the time: 2.5% 
(Japan) vs 12% (Outside 
Japan)
>70% of the time: 3.6% 
(Japan) vs 8.5% (Outside 
Japan)
30-70% of the time: 
3.6% (Japan) vs 16.2% 
(Outside Japan)
<30% of the time: 
17.3% (Japan) vs 44.4% 
(Outside Japan)
Never: 73% (Japan) vs 
18.8% (Outside Japan)
  p<0.001
Q7. What is your 
preferred treatment of 
Barrett’s esophagus 
without dysplasia?
Lifelong Proton Pump 
Inhibitor (PPI) : 17% 
(Japan) vs 22.6% 
(Outside Japan)
PPI only when patient 
has symptoms of 
gastroesophageal 
reflux or evidence of 
esophagitis : 80.8% 
(Japan) vs 69.7% 
(Outside Japan)
Radiofrequency 
Ablation: 0.8% (Japan) 
vs 4.3% (Outside Japan)
Anti-reflux procedure 
(e.g. fundoplication): 
1.4% (Japan) vs 3.4% 
(Outside Japan)
    p=0.002
Q8. For Barrett’s 
esophagus patients 
whose biopsies showed 
indefinite for dysplasia, 
your preferred approach 
is:
Confirm with second 
pathologist and repeat 
endoscopy after a course 
of PPI: 33.1% (Japan) vs 
58.5% (Outside Japan)
Surveillance 6 monthly: 
36.5% (Japan) vs 20.5% 
(Outside Japan)
Surveillance yearly: 
29.8% (Japan) vs 19.7% 
(Outside Japan)
Surveillance 3-5 yearly: 
0.6%% (Japan) vs 1.3% 
(Outside Japan)
    p<0.001
Q9. For Barrett’s 
esophagus patients 
without a lesion but 
whose biopsies showed 
low grade dysplasia, 
your preferred approach 
is:
Surveillance 6 monthly: 
61.3% (Japan) vs 48.3% 
(Outside Japan)
Surveillance yearly: 
22.3% (Japan) vs 20.9% 
(Outside Japan)
Surveillance 3-5 yearly: 
1.1% (Japan) vs 3% 
(Outside Japan)
Ablative therapy, 
e.g., radiofrequency, 
cryotherapy, argon 
plasma coagulation : 
1.1% (Japan) vs 17.9% 
(Outside Japan)
Endoscopic mucosal 
resection: 2.2% (Japan) 
vs 6.8% (Outside Japan)
Endoscopic submucosal 
dissection: 12% (Japan) 
vs 3% (Outside Japan)
p<0.001
Q10. For Barrett’s 
esophagus patients 
without a lesion but 
whose biopsies showed 
high grade dysplasia, 
your preferred treatment 
is:
Endoscopic mucosal 
resection: 14.2% (Japan) 
vs 22.6% (Outside 
Japan)
Endoscopic submucosal 
dissection: 82.5% 
(Japan) vs 54.7% 
(Outside Japan)
Ablative therapy, 
e.g., radiofrequency, 
cryotherapy, argon 
plasma coagulation: 
2.2% (Japan) vs 17.9% 
(Outside Japan)
Surgery, e.g., 
esophagectomy: 1.1% 
(Japan) vs 4.7% (Outside 
Japan)
    p<0.001
[P1295 Table 1]
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P1296 cOMParaTIve anaLysIs Of The effIcacy and 
safeTy Of sTandard versus sIMPLIfIed radIOfrequency 
aBLaTIOn PrOTOcOL fOr dysPLasTIc BarreTT’s esOPhagus: 
a duaL-InsTITuTIOn sTudy
Tan W.K.1,2, Ragunath K.3,4, White J.3,4, Santiago Garcia J.3,5, 
Ortiz-Fernández-Sordo J.3,6, Mirela P.3,7, Alias B.1, Hadjinicolaou A.V.1,8, 
Sujendran V.9, di Pietro M.1
1MRC Cancer Unit, University of Cambridge, Cambridge, United Kingdom, 
2Addenbrooke’s Hospital, University of Cambridge, Department of 
Gastroenterology, Cambridge, United Kingdom, 3NIHR Nottingham 
Biomedical Research Centre, Nottingham University Hospital NHS Trust 
and the University of Nottingham, Nottingham, United Kingdom, 4Queens 
Medical Centre Campus Nottingham University Hospitals, Nottingham 
Digestive Diseases Centre, Nottingham, United Kingdom, 5Nottingham 
University Hospitals, Endoscopy, Nottingham, United Kingdom, 6Nottingham 
University Hospitals Dept. of Gastroenterology, Digestive Dis. Biomedical 
Research, Nottingham, United Kingdom, 7Emergency Universitar Hospital 
Elias, Gastroenterology, Bucharest, Romania, 8Addenbrooke’s Hospital, 
University of Cambridge, Department of Gastroenterology, Cambridge, United 
Kingdom, 9Addenbrooke’s Hospital, University of Cambridge, Department of 
General Surgery, Cambridge, United Kingdom
contact e-Mail address: weikeithtan@gmail.com
Introduction: Radiofrequency ablation (RFA) has been validated as a safe 
and effective treatment modality for dysplastic Barrett’s esophagus (BE). 
The standard protocol of RFA includes an intermediary cleaning phase be-
tween two ablation session. A simplified protocol which omits this clean-
ing phase is less labour intensive and has shown to be as efficacious in 
studies based on single ablation procedures.
aims & Methods: The aim of this study was to compare the efficacy and 
safety of the standard and simplified RFA protocols used for the whole 
treatment pathway and including both circumferential and focal devices. 
We performed a retrospective analysis of prospectively collected data on 
patients who received RFA between 2007-2017 at two institutions within 
the UK. Outcomes assessed were: 1) complete remission of dysplasia (CR-
D) and intestinal metaplasia (CR-IM) at 18 months, and 2) rate of esopha-
geal stricture. Patients that received a combination of both treatment pro-
tocols were excluded.
results: 145 patients were included in the analysis of which 73 patients 
received the standard protocol and 72 patients received the simplified 
protocol. CR-D was achieved in 94.5% and 95.8% of patients receiving 
either the standard or simplified protocol, respectively (p=0.71). CR-IM was 
achieved in 84.9% and 77.8% of patients in the standard and simplified 
protocol groups, respectively (p=0.27). Complications were observed in 
11.4% of patients, including 13 cases oesophageal strictures, and 1 case of 
mild esophageal tear during sizing of RFA balloon. Esophageal strictures 
were significantly more common among patients who received the simpli-
fied protocol (12.5%) compared to the standard protocol (1.4%, p=0.008). 
The median number of esophageal dilatation required was 1 (range 1-7).
variable standard protocol simplified protocol all patients P value
Number of patients 73 72 145 -
Age, mean (SD) 66.3 (9.0) 67.0 (9.7) 66.6 (9.3) 0.66
Gender (% males) 86.3 86.2 86.2 0.97
BE length, M value 
(median, IQR)
5.0 (5.0) 4.0 (4.0) 4.0 (4.0) 0.35
Prior-EMR, n (%) 47 (64.4) 42 (58.3) 89 (61.4) 0.45
Extent of prior-EMR 
(median, IQR)
2 (2) 3 (3) 3 (2) 0.12
Number of RFA 
(median, IQR)
3 (1) 2 (1) 2 (1) 0.17
Dysplasia Grade, 
n (%) - LGD - HGD 
- IMC
- 7 (9.6) 
27 (37.0) 
39 (53.4)
- 13 (18.1) 
33 (45.8) 
26 (36.1)
- 20 (13.8) 
60 (41.4) 
65 (44.8)
0.082
CR-D, % (95% CI) 94.5 (89.2-99.9) 95.8 (91.1-100) 95.2 (91.6-98.7) 0.71
CR-IM, % (95% CI) 84.9 (76.5-93.3) 77.8 (67.9-87.6) 81.4 (75.0-87.8) 0.27
Rescue EMR, 
% (95% CI)
9.6 (2.7-16.5) 6.9 (0.9-13.0) 8.3 (3.7-12.8) 0.56
Strictures, 
% (95% CI)
1.4 (0-4.1) 12.5 (4.7-20.3) 6.9 (2.7-11.1) 0.008
[Table 1. Patient baseline characteristics and comparative outcomes stratified 
by different RFA protocols]
conclusion: The simplified RFA protocol is equally effective compared to 
the standard protocol in terms of eradication of dysplasia and IM. When 
deciding treatment options for patients, the advantages of the simplified 
protocol which includes shorter procedural time and reduced discomfort 
for patients will need to be balanced against the significantly higher risk 
of strictures. 
disclosure: Nothing to disclose 
P1297 narrOW Band IMagIng endOscOPy WITh TargeTed 
BIOPsIes versus sTandard endOscOPy WITh randOM BIOPsIes 
In PaTIenTs WITh BarreTT’s OesOPhagus: a MeTa-anaLysIs
Hajelssedig O.1,2, Zorrón Cheng Tao Pu L.3, Thampson J.4, Abdulazeem H.5, 
Mayer C.6, Shaukat Ali F.7, Lord A.8, El Sayed I.9, Singh R.10, O.Khier A.11,12, 
John D.13
1Nelson Marlborogh District Health Board, Medicine, Nelson, New Zealand, 
2Harvard T. H.Chan School of Public Health, Executive and Continuing 
Professional Education, Boston, United States, 3University of Adelaide, 
Adelaide, Australia, 4University of Oxford, Department of Orthopaedics 
Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom, 
5QIMR Berghofer Medical Research Institute, Berlin, Germany, 6Oklahoma 
State University, College of Health Sciences, Tulsa, United States, 7Presence 
Saint Joseph Hospital, Chicago, United States, 8QIMR Berghofer Medical 
Research Institute, Brisbane, Australia, 9Medical Research Institute, 
Alexandra University, Alexandra, Egypt, 10Lyell McEwin Hospital, Department 
of Medicine, Adelaide, Australia, 11Digestive Disease Institute, Cleveland 
Clinic, Gastroenterology, Abu Dhabi, United Arab Emirates, 12University of 
Queensland, Gastroenterology, Brisbane, Australia, 13Campbell collaboration, 
Delhi, India
contact e-Mail address: jylimed21@gmail.com
Introduction: Barrett’s oesophagus (BO) is the only identifiable premalig-
nant condition for oesophageal adenocarcinoma (OAC) which represents 
the eighth most common cancer and the sixth cause of cancer-related 
deaths worldwide1. Surveillance in BO aims to detect and subsequently 
eradicate dysplasia and early OAC. The present guidelines2 recommend 
surveillance endoscopy in BO to be performed with random biopsies (Se-
attle protocol) every 2-3 years. 
However, this method has high sample errors, laborious and correctly 
implemented only by half of endoscopists. Image enhancing technologies 
such as narrow band imaging (NBI) could provide an alternative to ran-
dom biopsies. NBI has the ability to enhance the features of oesophageal 
mucosa and submucosa potentially allowing the endoscopist to take only 
targeted biopsy from areas that show an abnormal mucosal pattern that 
could be harporing dysplasia. Although NBI-targeted biopsy has been 
shown to perform equally or better in several studies, random biopsies 
remains up-to-date the standard of care.
aims & Methods: This metanalysis intends to critically evaluate all avail-
able literature in this field and determine based on a comparative meta-
nalysis if NBI targeted biopsies equally performs or outperforms random 
biopsies method for surveillance of BO.
This metanalysis was conducted according to the Preferred Reporting Items 
of Systematic reviews and Meta-Analyses (PRISMA) recommendations. It 
has been registered in advance in PROSPERO under ID: CRD42017073281.
A comprehensive search for studies utilising NBI for BO was conducted by 
two researchers in the Cochrane Register, MEDLINE/Pubmed, EMBASE and 
grey literature. Human studies that compared NBI targeted biopsies with 
random biopsies for BO were retrieved. Methodological quality of included 
studies was assessed by the Quality Assessment of Diagnostic Accuracy 
Studies-2 (QUADAS-2). Data from included studies were extracted, entered 
and analysed using the RevMan version 5 software. Analysis was per-
formed with random effects method and the results reported per-patient 
rather than per-lesion.
results: 14 studies were initially selected for the systematic review but 
only 6 studies with totoal 493 patients have fulfilled our inclusion criteria 
for metanalysis. The overall sensitivity (Sn), specificity (Sp), negative pre-
dictive value (NPV), and positive predictive value (PPV) for NBI-targeted 
biopsy detecting all dysplasia is 76%(95% CI 0.61-0.91), 99%(95% CI 0.99-
1.00), 97%(95% CI 0.96-0.99), and 84% (95% CI 0.69-0.99), respectively. 
For high-grade dysplasia, the results respectively are 83%(95% CI 0.73-
0.93), 99%(95% CI 0.99-1.00), 97%(95% CI 0.93-1.00), and 92%(95% CI 
0.84-1.00). For detection of intestinal metaplasia, the same parameters 
respectively are: 0.83 (95% CI 0.63-1.00) 0.89 (95% CI 0.81-0.97).
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conclusion: NBI-guided targeted endoscopic biopsy has high diagnostic 
accuracy and can replace the current standard of care of random method 
in expert tertiary centres. For wider adoption of this NBI method more 
studies with better methodology are needed in the future.
references: 1\ J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. 
Mathers, M. Rebelo,D.M. Parkin, D. Forman, F. Bray Lyon FIA for R on C. 
Cancer Incidence and Mortality Worldwide [Protocol]. Cochrane Database 
of Systematic Reviews 2014, Issue IARC CancerBase No. 11. 2\ Nicholas J. 
Shaheen , MD, MPH, FACG 1 , Gary W. Falk , MD, MS, FACG 2 , Prasad G. 
Iyer , MD, MSc, FACG 3 and Lauren Gerson , MD, MSc, FACG. ACG Clinical 
Guideline: Diagnosis and Management ofBarrett’s Esophagus [Protocol]. 
Cochrane Database of Systematic Reviews 2015, Issue The American Jour-
nal of GASTROENTEROLOGY. [Other:]
disclosure: Nothing to disclose 
P1298 effIcacy, TOLerance and safeTy Of hyBrId argOn 
PLasMa cOaguLaTIOn fOr The TreaTMenT Of BarreTT’s 
esOPhagus: a us PILOT sTudy
El Hage Chehade N.1, Shimizu T.1, Chang K.2, Samarasena J.1
1University of California Irvine, Gastroenterology, Orange, United States, 
2University of California Irvine, Orange, United States
contact e-Mail address: nelhagec@uci.edu
Introduction: Hybrid APC is a novel technique that has been recently devel-
oped for the ablation of Barrett’s Esophagus. It is based on the combina-
tion of APC and submucosal saline injection to overcome some of the dis-
advantages of standard APC ablation. The current literature on this method 
is however limited.
aims & Methods: The aims of this US pilot study were to evaluate the ef-
ficacy, tolerance and safety of Hybrid-APC for the treatment of BE.
Patients with biopsy proven BE were eligible with both treatment-naïve 
and patients previously treated included. Procedures were performed by 
two expert endoscopists using a standardized technique. Efficacy of abla-
tion was measured on by demonstrating either a reduction of visible BE 
or biopsies proving complete resolution of intestinal metaplasia (CRIM). 
To evaluate tolerance and safety, patients were called on post-procedure 
days 1 and 7.
results: 22 patients with BE (4.5% Intramucosal CA, 31.8% High Grade 
Dysplasia, 18.1% LGD, 36.3% non-dysplastic, 9.1% indefinite for dysplasia) 
underwent 40 treatments with Hybrid APC. Average age was 67.5 years, 
86% male. Mean initial Prague score was C0.73, M1.99. 50% of patients 
had undergone prior RFA, 22.7% prior EMR, 13.6% prior cryotherapy, and 
36.3% were treatment naive. The average index treatment time was 23.9 
minutes. With regards to efficacy, 17 out of 22 (73%) patients achieved 
CRIM. All patients had endoscopic improvement of BE disease with an 
average length of BE at follow-up of C0.21, M0.63. Average pain scores 
(0-10 scale) on follow up were 2.65 and 0.62 at day 1 and 7 respectively. 
There were two treatment-related strictures (9%) which required a single 
balloon dilation. There were no other early or late complications.
conclusion: Based on this US pilot study, Hybrid APC appears to be promis-
ing in the treatment of Barrett’s Esophagus. The ablation protocol used in 
this study demonstrated efficacy, tolerability and a safety profile similar 
to radiofrequency ablation. Given the significant price difference of Hy-
brid APC with other modalities for Barrett’s ablation, this modality may be 
more cost effective.
disclosure: None 
P1299 reduced sTrIcTure raTes WITh a nOveL haLO 360 
radIOfrequency regIMe fOr BarreTT’s dysPLasIa
Saffouri E.1, Haddock R.1, Berriman T.J.1, Pugmire J.2, Fullarton G.1, 
Morris A.J.1
1Glasgow Royal Infirmary/NHS Greater Glasgow and Clyde, Gastroenterology 
and Upper GI Surgery, Glasgow, United Kingdom, 2University of Glasgow, 
Glasgow, United Kingdom
contact e-Mail address: rosemaryhaddock@nhs.net
Introduction: In the UK, radiofrequency ablation (RFA) is established as 
treatment of choice for flat oesophageal neoplasia or after removal of fo-
cal lesions by endoscopic mucosal resection (EMR) to eradicate Barrett’s 
mucosa1. A specific complication of RFA is oesophageal stricture develop-
ment. The UK national RFA registry has quoted a 11-17% rate of strictures 
requiring dilatation, with higher rates in patients treated with 12J rather 
than 10J paired ablations using the HALO 360 Express RFA catheter (p< 
0.01). Two 10J ablations, separated by a cleaning step requiring removal of 
the catheter, is now standard of care. The cleaning step is time-consuming 
and can be poorly tolerated.
aims & Methods: In December 2017 we adapted our practice to include ir-
rigation with 30cc normal saline between 10J ablations as a cooling phase 
during the HALO RFA procedure and removed the cleaning phase between 
ablations. We have audited patient and disease demographics and out-
comes data, especially oesophageal stricture rate, for all patients who had 
first HALO 360 express for 12 months before and after technique modifica-
tion (1/12/16-1/12/18) in our hospital. Statistical analysis of variables was 
calculated using fisher’s exact test, Wilcoxon ranksum, and logistic regres-
sion analysis.
results: In the capture period, 36 patients had standard treatment and 
48 patients underwent the modified technique. In the latter group, a sig-
nificantly longer mean Barrett’s segment was observed (6.1cm vs 8.2cm; 
p=0.01). We observed a stricture rate of 22.2% (8/36) in the standard treat-
ment group, and 4.2% (2/48) in the modified group (p=0.014).
Stricture rate was significantly higher (p=0.026) with increasing Prague 
circumferential and maximum Barrett’s length (p=0.023). There was no 
statistical difference in stricture rate when prior EMR or degree of dyspla-
sia was considered.
The modified treatment was the only variable independently associated 
with stricture formation. A logistic regression model showed 85% reduced 
odds of stricture using the modified treatment (p=0.036) after adjusting 
for age, procedure type, grade of dysplasia, prior EMR, and Prague mea-
surements.
conclusion: These findings suggest a benefit of our novel adaptation of 
HALO 360 RFA treatment in Barrett’s neoplasia with the novel treat-cool-
treat technique resulting in significantly lower rate of stricture development.
references: 1. https://www.bsg.org.uk/resource/bsg-guidelines-on-the-
diagnosis-and-management-of-barrett-s-oesophagus.html
disclosure: E Saffouri has received educational support or hospitality from 
Gilead, Ferring, Cook, and Dr Falk. 
P1300 LyMPh nOde MeTasTasIs rIsk Of sIeWerT TyPe II 
adenOcarcInOMa: cOMParIsOn Of BarreTT’s esOPhageaL 
adenOcarcInOMa and gasTrIc cardIa adenOcarcInOMa 
resecTed By endOscOPIc suBMucOsaL dIssecTIOn and 
surgery
Akazawa N.1, Fujisaki J.2
1Cancer Institute Hospital of JFCR, Gastroenterology, Tokyo, Japan, 2Japanese 
Found. for Cancer Research, Cancer Institute Hospital, Tokyo, Japan
contact e-Mail address: naoki-a@jt6.so-net.ne.jp
Introduction: Esophagogastric junction adenocarcinoma includes Barrett’s 
esophageal adenocarcinoma and gastric cardia adenocarcinoma. Curative 
criteria for endoscopic submucosal dissection in esophagogastric junction 
adenocarcinoma patients are controversial. Therefore, we elucidated the 
clinicopathological differences between Barrett’s esophageal adenocar-
cinoma and gastric cardia adenocarcinoma and estimated risk factors of 
lymph node metastasis.
aims & Methods: Patients who underwent surgical resection or endoscopic 
submucosal dissection for superficial esophagogastric junction adenocar-
cinoma of Siewert type II were included.
results: Sixty-nine patients (44.2%) had Barrett’s esophageal adenocar-
cinoma, and 87 (55.8%) had gastric cardia adenocarcinoma. Barrett’s 
esophageal adenocarcinoma patients were significantly younger (62 vs 70 
years, p< 0.01) and had a high frequency of poorly differentiated adenocar-
cinoma components (30% vs 15%, p=0.02) and lymphatic invasion (28% vs 
12%, p=0.01). There was lymphovascular invasion in the deep muscularis 
mucosa in 31.6% of patients with Barrett’s esophageal adenocarcinoma. 
Ten cases of lymph node metastasis were identified. Lymph node metas-
tasis was not identified in patients with standard submucosal invasion < 
500 µm without risk factors [tumor size >30 mm, lymphovascular invasion, 
poorly differentiated components]. Frequency of tumor size >30 mm (60% 
vs 17.1% p< 0.01), undifferentiated adenocarcinoma (40% vs 2.7% p< 0.01), 
poorly differentiated component (80% vs 17.8% p< 0.01), and lymphovas-
cular invasion (90% vs 20.5% p< 0.01) was significantly higher in Barrett’s 
esophageal adenocarcinoma patients.
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conclusion: Standard submucosal invasion < 500 µm without lymphovas-
cular invasion, poorly differentiated components, and tumor size >30 mm 
were considered candidates for curative endoscopic resection for esopha-
gogastric junction adenocarcinoma. Furthermore, histopathological sur-
veillance for lymphovascular invasion is important for deep muscularis 
mucosa invasion of Barrett’s esophageal adenocarcinoma.
disclosure: Nothing to disclose 
P1301 PuBLIc Preferences and PredIcTed uPTake 
fOr esOPhageaL cancer screenIng sTraTegIes: 
a dIscreTe chOIce exPerIMenT
Peters Y., van Grinsven E., van de Haterd M., van Lankveld D., Verbakel J., 
Siersema P.D.
Radboud University Medical Center, Gastroenterology and Hepatology, 
Nijmegen, Netherlands
contact e-Mail address: y.peters@radboudumc.nl
Introduction: The majority of patients with esophageal adenocarcinoma 
(EAC) present with advanced disease, resulting in poor survival rates. 
Screening for EAC and its precursor Barrett’s esophagus could possibly 
reverse the increasing incidence of EAC. In order to realize screening, it is 
important to understand the factors that influence population preferences 
for different EAC screening strategies and using them to achieve high at-
tendance rates for a screening program for EAC.
aims & Methods: We aimed to determine individuals’ preferences for EAC 
screening and to assess to what extent procedural characteristics of EAC 
screening tests predict willingness for screening participation. 
A discrete choice experiment questionnaire was sent by postal mail to 1000 
individuals aged 50 to 75 years who were randomly selected from the mu-
nicipal registry. Each subject answered 12 discrete choice questions of two 
hypothetical screening tests that comprised five attributes: EAC-related 
mortality risk reduction, procedure-related pain and discomfort, screen-
ing location, test specificity, and costs. A multinomial logit model was used 
to estimate patient preferences for each attribute level and to calculate 
relative importance scores of each attribute and expected rates of uptake. 
Regression analyses was performed to determine if socio-demographic 
characteristics predicted how respondents made decisions.
results: In total, 375 patients (37.5%) completed the questionnaire. Test 
specificity had the highest impact on respondents’ preferences, accounting 
for 27.2%, followed by pain and discomfort (26.8%), and mortality reduc-
tion (24.6%). Women were twice as much likely than men to value pain 
and discomfort as the most important attribute category (OR 2.08; 95%CI 
1.28 - 3.33; P=0.003). In contrast, men were more likely to report mortality 
reduction as the primary determinant (OR 1.83; 95%CI 1.08-3.11). Individu-
als who worry about their own risk of developing cancer consider pain and 
discomfort to be important (OR 2.17; 95%CI 1.25-3.75) and worry less about 
test specificity (OR 0.45; 95%CI 0.25-0.82). Respondents preferred a test 
causing no or moderate pain and they were willing to give up 29 avoided 
EAC-related deaths per 10,000 screened individuals if the test causes only 
moderate instead of heavy pain.
The average expected uptake of EAC screening was 62.8% (95%CI 61.1-
64.5). However, with the most preferred screening test, the probability of 
screening participation increased to 88.9% (95%CI 87.1%-90.4%). Heavy 
pain and discomfort had the largest impact on screening uptake (-22.8%; 
95%CI -26.8- -18.7). Male gender (β 2.81; P< 0.001), cancer worries (β 1.96; 
P=0.01), upper endoscopy (β 1.46; P=0.05) or population-based screening 
(β 2.47; P=0.05)experience, and upper gastrointestinal symptoms (β 1.50; 
P=0.05) were significantly associated with screening participation.
attributes Impact of attribute levels on probability of screening participation (%) (* indicates p<0.05)
Mortality reduction 
(per 1000 screened 
individuals)
2 per 1000 
reference
3 per 1000 
+5.8%*
4 per 1000 
+14.0%*
5 per 1000 
+17.8%*
Pain and discomfort No pain reference
Mild pain 
-1.5%
Moderate pain 
-2.0%
Heavy pain 
-22.8%*
Out-of-pocket costs 
(€)
Costs: €0 
reference
Costs: €25 
-6.2%*
Costs: €50 
-10.3%*
Costs: €75 
-16.7%*
specificity (%) Specificity: 50% reference
Specificity: 70% 
-3.2%
Specificity: 90% 
+12.7%*
Specificity: 100% 
+17.1%*
[Effects of changing the screening program characteristics on the probability 
of participation in esophageal cancer screening.]
conclusion: This study suggests a substantial interest in EAC screening in 
the general population. Based on our results, an optimal screening test 
should have high specificity, cause no or mild to moderate pain or dis-
comfort and result in a decrease in EAC-related mortality. Understanding 
individuals’ preferences for EAC screening tests helps to further design the 
optimal screening modality by selecting the attributes that maximize at-
tendance and further reduce morbidity and mortality from EAC.
disclosure: Nothing to disclose 
P1302 BarreTT’s esOPhagus screenIng: accuracy Of 
exhaLed BreaTh anaLysIs usIng an eLecTrOnIc nOse devIce
Peters Y.1, Schrauwen R.W.M.2, Tan A.C.3, Bogers S.K.2, De Jong B.1, 
Siersema P.D.1
1Radboud University Medical Center, Gastroenterology and Hepatology, 
Nijmegen, Netherlands, 2Bernhoven, Gastroenterology and Hepatology, 
Uden, Netherlands, 3Canisius Wilhelmina Hospital, Hepatogastroenterology, 
Nijmegen, Netherlands
contact e-Mail address: y.peters@radboudumc.nl
Introduction: The majority of patients with esophageal adenocarcinoma 
(EAC) present with advanced disease, resulting in poor survival rates. 
Timely detection of EAC and its precursor Barrett’s esophagus (BE) could 
decrease both cancer mortality and incidence. Currently, an accurate, 
minimally-invasive screening method for BE for widespread use is not 
available.
aims & Methods: We aimed to assess the accuracy with which an elec-
tronic nose for breath analysis could discriminate patients with BE from 
controls without BE.
In this multicenter, cross-sectional, proof-of-principle study, patients un-
dergoing a clinically indicated upper endoscopy between August 2017 and 
March 2019 were invited to provide a 5-minute breath sample using an 
electronic nose immediately prior a scheduled endoscopy. Patients were 
subdivided in three subgroups: BE (defined as ≥1 cm of columnar mucosa 
with histopathologic confirmation of intestinal metaplasia without dyspla-
sia), gastroesophageal reflux disease (GERD) (defined as GerdQ-score ≥8 
or the endoscopic presence of reflux esophagitis), and controls without 
BE or GERD.
The Aeonose™ is an olfactory system that analyses volatile organic com-
pounds (VOC). Three metal-oxide sensors interact with VOCs in the breath 
sample to create a digital breath print specific to the VOCs. Data is ana-
lyzed by an artificial neural network to identify data classifiers to extract 
breath-print differences between patients with BE, GERD and controls, 
respectively. Optimal models were cross-validated using a leave-10%-out 
approach. Main outcomes were sensitivity and specificity for detecting BE 
compared with upper endoscopy as the reference standard.
results: Breath samples were obtained from 212 individuals. Recruitment 
rates were 95%. Mean age of participants was 59.6 years and 56% were 
male. Seventy-three patients had a diagnosis of BE with a median (IQR) 
length of the BE segment of 4 (3-7) cm, 68 patients were diagnosed with 
GERD (32.4% reflux esophagitis), and 71 control patients did not have any 
esophageal abnormalities except for hiatal hernia. Diagnostic accuracy 
was high for discrimination of BE from both GERD and controls (area un-
der the curve [AUC] 0.80, sensitivity 85% [95%CI: 74% - 92%], specificity 
66% [95%CI: 58% - 74%]). Similarly, breath prints of BE patients could be 
differentiated from GERD patients (AUC 0.78, sensitivity 82% [95%CI: 71% 
- 90%], specificity 68% [95%CI: 55% - 78%]).
In a sub-analysis of patients using proton pump inhibitors for at least 1 
month prior to study enrolment (n = 157; 68 BE, 46 GERD and 43 con-
trols), a similar diagnostic accuracy for discriminating BE from both GERD 
and controls was observed: BE versus both GERD and controls AUC 0.81, 
sensitivity 71% and specificity 80%; BE versus GERD AUC 0.86, sensitivity 
93% and specificity 70%; BE versus controls AUC 0.87, sensitivity 74% and 
specificity 88%.
conclusion: This portable electronic nose is able to detect the presence or 
absence of BE in patients with and without GERD with good diagnostic ac-
curacy. Given the high tolerability, high acceptability and low costs, breath 
testing may be a promising approach to be used for non-invasive screen-
ing for BE in a primary care setting.
disclosure: The eNose company supplied the electronic noses used in this 
study for free. 
718 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
P1303 sTudIes TO deTerMIne rIsk facTOrs fOr BarreTT’s 
neOPLasIa In WOMen shOuLd fOcus On a faMILy hIsTOry 
Of esOPhageaL carcInOMa, OngOIng gerd syMPTOMs and 
OBesITy
Iwaya Y.1,2, Shimamura Y.2,3, Mosko J.2, Teshima C.2, Kandel G.2, Kortan P.2, 
May G.2, Marcon N.2
1Shinshu University, School of Medicine, Gastroenterology, Matsumoto, 
Japan, 2St. Michael’s Hospital, University of Toronto, Gastroenterology, 
Toronto, Canada, 3Showa University Koto Toyosu Hospital, Gastroenterology, 
Tokyo, Japan
contact e-Mail address: yiwaya@shinshu-u.ac.jp
Introduction: Current guidelines do not recommend endoscopic screening 
for Barrett’s esophagus (BE) in females, except in patients who have mul-
tiple risk factors for BE and esophageal adenocarcinoma (EAC). However, it 
is unclear which factors most predict BE neoplasia risk in females. There-
fore, identifying how females with EAC and high-grade dysplasia (HGD) 
differ from males may be useful to develop screening recommendations 
for women.
aims & Methods: We conducted a retrospective analysis of a prospectively 
maintained database comprising consecutive patients with early stage EAC 
(T1a and T1b) and HGD at a single, tertiary-referral center from March 2001 
to July 2017. Information regarding baseline clinical characteristics, drug 
and risk factor exposures, clinicopathological staging of EAC/HGD and fol-
low-up status including treatment outcome such as complete remission of 
dysplasia (CR-D) and complete remission of intestinal metaplasia (CR-IM) 
were determined. Univariate and multivariate analyses were performed 
to identify factors that differed significantly between female and male pa-
tients with EAC/HGD.
results: We identified 511 patients with T1 EAC and HGD (383 and 128, 
respectively); 88 (17%) patients were female. Compared to male patients, 
female patients were more likely to have ongoing GERD symptoms and a 
family history of esophageal carcinoma (51% vs. 39%, p=0.045; 8.3% vs. 
2.8%, p=0.033, respectively) and less likely to have ever been smokers or 
drinkers of alcohol (65% vs. 76%, p=0.030; 58% vs. 81%, p< 0.001, re-
spectively) on univariate analysis. On multivariate analysis, ongoing GERD 
symptoms, family history of esophageal carcinoma and obesity (BMI>30) 
were significant independent factors. Although the maximum length of 
BE in females was significantly shorter than in males (4.1 cm vs. 5.0 cm, 
p=0.024), there were no significant differences in terms of pathological 
findings such as tumor depth of invasion, differentiation, lymphovascular 
invasion or deep margin positivity. Furthermore, there were no significant 
differences between the groups regarding outcomes of endoscopic thera-
pies with CR-D, CR-IM and recurrence of dysplasia and intestinal metapla-
sia with a mean follow-up period of 44.3 ± 30.2 months.
conclusion: Female patients with T1 EAC or HGD were more likely to have 
a family history of esophageal carcinoma, ongoing GERD symptoms and 
obesity compared to male patients despite similar clinical outcomes with 
endoscopic therapies. While guidelines recommend BE screening in male 
patients, female patients should be considered for screening endoscopy if 
they possess these risk factors.
disclosure: Nothing to disclose 
P1304 The IMPacT Of IMage enhanced endOscOPy screenIng 
fOr synchrOnOus esOPhageaL neOPLasM On survIvaLs Of 
head and neck cancer PaTIenTs
Chung C.-S.1,2, Chen K.-C.3, Hsieh C.-H.4, Lin S.-C.5, Lin C.-K.3, Liao L.-J.6
1Far Eastern Memorial Hospital, Division of Gastroenterology and 
Hepatology, Department of Internal Medicine, New Taipei City, Taiwan, 
2College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan, 3Far 
Eastern Memorial Hospital, Department of Gastroenterology and Hepatology, 
New Taipei City, Taiwan, 4Far Eastern Memorial Hospital, Department of 
Radiation Oncology, New Taipei City, Taiwan, 5Far Eastern Memorial Hospital, 
Department of Medical Oncology, New Taipei City, Taiwan, 6Far Eastern 
Memorial Hospital, Department of Otolaryngology, New Taipei City, Taiwan
contact e-Mail address: chungchenshuan_3@yahoo.com.tw
Introduction: The incidence of esophageal second primary tumor (SPT) in 
head and neck cancer (HNC) patients is not low. The impact of routine 
image-enhanced endoscopy (IEE) screening for SPT of esophagus on the 
prognosis of HNC patients is not elucidated.
aims & Methods: Patients with registered malignancies of head and neck 
region and esophagus were recruited from a hospital-based cancer reg-
istry between July 2000 and December 2016. Magnifying endoscopy with 
narrow-band imaging and chromoendoscopy with Lugol’s solution was 
performed for IEE screening. The biopsied specimen reported with revised 
Vienna classification category 1 and 2 was defined as group I and category 
3 to 5 as group II. The outcome assessment was connected to national 
death registry database and Kaplan-Meier estimate and Cox regression 
model were used for survival analysis.
results: Finally, 1,577 HNC and 501 esophageal cancer patients were en-
rolled for analysis. The 5-year overall survival (OS) rate of stage I/II HNC, 
stage III/IV HNC and esophageal cancer patients were 58%, 29%, and 
8%, respectively (p< 0.01). The 5-year OS rate of HNC patients with nega-
tive IEE results were higher than HNC patients without IEE screening, fol-
lowed by IEE screening group I and II, and esophageal cancer patients 
(44% vs. 39% vs. 35% vs. 11% vs. 8%, p for trend < 0.01). 
Among advanced HNC patients, those who received IEE screening of 
esophagus had a trend of better prognosis than those without (5-year OS 
rate of 31% vs. 28%, p=0.17). 
In multivariate analysis of OS, age [hazard ratio (HR) 1.01, p< 0.01] and 
cancer of oropharynx (HR 1.43, p=0.01) were associated with poor surviv-
al. Compared with stage I/II HNC who received IEE screening of esopha-
gus, stage III/IV patients with IEE (HR 2.33, p< 0.01) and without IEE (HR 
2.77, p< 0.01) screening had worse survival.
conclusion: The application of IEE screening for esophageal SPTs is helpful 
in risk stratification and prognosis prediction for HNC patients. Routine IEE 
screening is recommended in newly-diagnosed HNC patients.
disclosure: Nothing to disclose 
P1305 sIgMOId TyPe and agIng as POTenTIaL rIsk facTOrs 
fOr deveLOPIng esOPhageaL squaMOus ceLL carcInOMa In 
achaLasIa PaTIenTs: a reTrOsPecTIve sTudy
Abad M.R.A., Iwaya Y., Nishikawa Y., Fujiyoshi Y., Quarta Colosso B.M., 
Ueno A., Shimamura Y., Tanabe M., Sumi K., Tomida H., Ikeda H., 
Onimaru M., Inoue H.
Showa University Koto Toyosu Hospital, Digestive Diseases Center, Tokyo, 
Japan
contact e-Mail address: yiwaya@shinshu-u.ac.jp
Introduction: Incidence of esophageal cancer has been reported to be in-
creasing recently. Achalasia has been considered as one of the risk fac-
tors for developing esophageal squamous cell carcinoma (ESCC). Although 
patients with achalasia were reported to have a higher risk of developing 
ESCC compared to the general population, details and characteristics of 
achalasia patients who develop ESCC are still not clearly defined.
aims & Methods: This study aims to evaluate the characteristics of patients 
with achalasia associated with developing ESCC. A retrospective analysis 
study between January 2010 and November 2018 has been conducted at 
Showa University Koto Toyosu Hospital, Tokyo, Japan. Database of patients 
who underwent Per-oral Endoscopic Myotomy (POEM) has been reviewed. 
Patients who were diagnosed with esophageal achalasia based on the 
Modified Chicago Classification were included in the study.
results: A total of 19 patients (1.5%) were identified to have ESCC from 
1256 achalasia patients. Eleven (57.9%) were males and 8 (42.1%) were 
females. Median age was 64 (IQR= 55.5-75). Based on the Modified Chi-
cago Classification, the type of achalasia seen were as follows: Type I/II/III= 
9/7/3. In terms of histopathological findings, 17 patients (89.47%) exhib-
ited mucosal ESCC, and 2 patients (10.53%) showed SCC extending to the 
submucosal layer. The occurrence of ESCC in achalasia patients was noted 
to be more likely in the older population (median: 68 vs 46, p= <0.001) 
compared to achalasia patients without ESCC. 
Furthermore, a higher prevalence of sigmoid type (56% vs 12%, p= < 
0.001) was observed in achalasia patients with ESCC in comparison with 
those non-ESCC achalasia patients. There were no significant differences 
between the two groups in terms of gender, types of Chicago classification, 
and Eckardt Score. All patients underwent successful endoscopic resection 
without any complications.
conclusion: Achalasia has been deemed to be a risk factor for develop-
ing ESCC which involves various mechanisms. Patients with achalasia who 
belong in the older population and presenting with a sigmoid type were 
recognized to be at a higher risk for developing ESCC and should be moni-
tored more closely during follow-up.
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P1306 endOcyTOscOPIc OBservaTIOn and deeP LearnIng 
arTIfIcIaL InTeLLIgence fOr esOPhageaL LesIOns
Kumagai Y.1, Kawada K.2, Takubo K.3, Tada T.4, Ozawa T.5, Mochiki E.1, 
Ishida H.1
1Saitama Medical Center, Saitama Medical University, Digestive Tract and 
General Surgery, Saitama, Japan, 2Tokyo Medical and Dental University, 
Esophageal Surgery, Tokyo, Japan, 3Tokyo Metropolitan Institute of 
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contact e-Mail address: kuma7srg1@gmail.com
Introduction: Endocytoscopy (ECS) is a novel endoscopic technique that 
allows detailed diagnostic examination of the gastrointestinal tract at the 
cellular level. ECS was first developed and applied for clinical use in 2003 
in our own study.
aims & Methods: In the present study, we used the ECS to observe various 
esophageal lesions, and evaluated the diagnostic accuracy in distinguish-
ing neoplastic from non-neoplastic lesions using both endoscopist’s and 
pathologist’s opinion. Further, we applied deep-learning artificial intel-
ligence (AI) to analyse ECS images of the esophagus to determine whether 
AI can support endoscopists for the replacement of biopsy-based histology.
We examined the morphology of surface cells using vital staining with 
toluidine blue and compared the histological features of 272 cases, in-
cluding 129 cases of esophageal squamous cell carcinoma (ESCC) and 143 
non-neoplastic esophageal lesions (65 cases of radiation esophagitis, 54 
case of gastro esophageal reflux disease (GERD), and 13 cases of other 
esophagitis, 3 cases of benign tumor and 8 cases of normal squamous 
epithelium). One endoscopist classified the lesions using the type clas-
sification (Type 1; surface epithelial cells have a low N/C ratio and cell 
density but without evident nuclear abnormality. Type 2; surface epithelial 
cells have a high nuclear density but no evident nuclear abnormality and 
clear borders between cells. Type 3; surface epithelial cells have evidently 
increased nuclear density and nuclear abnormality, such as irregular nu-
clear size and shape.). Further, we consulted one pathologist for judge-
ment in each case as “neoplastic”, “borderline”, or “non-neoplastic” from 
the ECS cell images. 
Using 4,715 ECS images (1141 malignant and 3574 non-malignant images) 
from 240 cases, a deep learning AI was trained. To evaluate the diagnostic 
accuracy of the AI, test set of 1520 ECS images, collected from 55 patients 
(27 ESCCs and 28 benign esophageal lesions) were examined.
results: On the basis of in vivo ECS observation, the endoscopist classified 
82 cases as type1, 57cases as type2, and 133 cases as type3. The sensitiv-
ity, specificity and overall accuracy of ECS for malignant lesions by the 
endoscopist were 96.1%, 93.0% and 94.5%, respectively, if Type 3 was 
considered to be malignant. The pathologist classified 130 cases as non-
neoplastic, 17 cases as borderline, and 125 cases as neoplastic. With re-
gard to the pathologist’s interpretation of the ECS images, the sensitivity, 
specificity and overall accuracy of ECS for malignant lesions were 96.1%, 
94.4% and 95.2%, respectively if borderline category is considered to be 
correctly diagnosed. On the basis of ECS images, neither the endoscopist 
nor the pathologist was able to clearly distinguish regenerative squamous 
epithelium and pseudo-malignant erosion in gastroesophageal reflux dis-
ease and esophagitis after radiotherapy from esophageal cancer. In such 
cases, biopsy histology would be necessary in addition to ECS diagnosis. 
The AI correctly diagnosed 25 of the 27 ESCC cases, with an overall sensitiv-
ity of 92.6%. 25 of the 28 non-cancerous lesions were diagnosed as non-
malignant, with a specificity of 89.3% and an overall accuracy of 90.9%. 
Although this result was inferior but close to the result obtained by the 
endoscopist.
conclusion: ECS diagnosis for the esophagus realize the concept of optical 
biopsy, and enables us to omit biopsy histology. AI may support endosco-
pists in diagnosing ESCC based on ECS images in the future.
disclosure: Nothing to disclose 
P1307 usefuLness Of endOscOPIc LaryngOPharyngeaL 
surgery fOr suPerfIcIaL PharyngeaL squaMOus ceLL 
carcInOMa
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Introduction: Endoscopic laryngopharyngeal surgery (ELPS) for superfi-
cial pharyngeal squamous cell carcinoma (SPSCC) has been reported as 
a minimally invasive treatment. However, the usefulness of ELPS for SP-
SCC was not investigated well because a small number of patients was 
involved in previous studies and an indication of ELPS for SPSCC invading 
up to subepithelial layer was still controversial. This study aimed to reveal 
the effectiveness of ELPS for pharyngeal squamous cell carcinoma (SCC) 
invading up to epithelial and subepithelial layer with short- and mid-term 
outcomes.
aims & Methods: The patients who underwent ELPS for SPSCC between 
April 2015 and March 2019 were included. We retrospectively analyzed a 
clinical course, adverse events, en bloc/R0 resection rate, recurrence, and 
prognosis. Tumor thickness was evaluated from the tumor surface to the 
base of the malignant tissue in the thickest tumor section based on gen-
eral rules for clinical studies on Head and Neck Cancer 2018. After ELPS, 
surveillance was performed with physical examination and laryngoscope 
observation every three months, computed tomography at intervals of ev-
ery 6 months and endoscopic observation under narrow band imaging 
(NBI) every year.
results: Forty-three patients with 56 SPSCCs were included this study. 
Table shows outcomes of ELPS for SPSCC. The median hospitalization 
was 11 days (range, 7-38). Dysphagia was found in 5 cases and 3 of them 
required hospitalization for more than 30 days. In those 5 cases all le-
sions were located in the hypopharynx and the resected lesion size was 
35 mm or more. There were statistically significant differences in removed 
lesion size between patients with dysphagia (n=5) and without dysphagia 
(n=46) (median; 40mm vs. 25mm, p< 0.001). No patients received addi-
tional treatment even though lymphovascular invasion was found. During 
the follow-up (median=24 months; range, 1-43) no local recurrence was 
observed but pharyngeal lymph node metastasis was found in a case who 
had SCC located in the hypopharynx invaded up to subepithelial layer (tu-
mor diameter: 17mm, tumor thickness: 3500µm, ly[+], v[+]) after 16 months 
from ELPS. This patient received chemoradiotherapy and survived for 24 
months without recurrence. Metachronous H&N and oesophageal SCC 
were found in three cases (7%) and six cases (14%), respectively during 
follow-up period. All lesions were found under endoscopic observation 
with NBI and those were completely removed by additional ELPS. Two pa-
tients died of oesophageal cancer recurrence.
Patient (n=43)  
Male 41 (95%)
Age; median (range) 70 (59-85)
Synchronous or metachronous squamous cell carcinoma; head 
and neck / oesophagus
15 (35%) / 36 (84%)
   
Lesions (n=56)  
Location; oropharynx / hypopharynx 5 / 51
Tumor diameter; median (range), mm 17 (3-40)
En bloc resection rate / R0 resection rate 98% / 71%
Invasion depth (epithelial / subepithelial) 16 / 40
Adverse event; post-operative bleeding / perforation / dysphagia 0 / 0 / 5
[Outcomes of ELPS for SPSCC]
conclusion: ELPS was effective for SPSCC including tumors invaded into the 
subepithelium. Resection of larger lesion was a risk factor for dysphagia, 
which affected the prolonged hospital stay. After ELPS, surveillance with 
NBI endoscopy should be performed considering the high cumulative inci-
dence of metachronous pharyngeal and oesophageal carcinoma.
disclosure: Nothing to disclose 
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P1308 TreaTMenT sTraTegy fOr cervIcaL esOPhageaL cancer
Mori N.1, Tanaka T.2, Matono S.3, Saisho K.1, Akagi Y.1
1Kurume University School of Medicine, Surgery, Kurume, Japan, 2Kurume 
University, Dept. of Surgery, Kurume, Japan, 3Kurume University, School of 
Medicine, Kurume, Japan
contact e-Mail address: mori1118@med.kurume-u.ac.jp
Introduction: Treatment for cervical esophageal cancer (CEC) is mainly sur-
gery and definitive chemo-radiotherapy (dCRT). However, treatment strat-
egy for CEC recently has been changed in condideration of quality of life 
after treatment. We have been performing neoadjuvant chemotherapy for 
CEC using FP (5FU/CDDP) from 2003 and using DCF (Docetaxel/CDDP/5FU) 
from 2009, and have decided to perform whether operation or dCRT by 
response of NAC.
aims & Methods: 59 esophageal cancer patients who underwent operation 
or dCRT between 2003 and 2017 were analyzed as to treatment outcome, 
retrospectively.
results: There were 43 men and 16 women, with a median age 64years. 
The average of duration of follow-up periods were 1367±1587 days. Tu-
mors were located at CePh in 17 patients, Ce in 26, and CeUt in 16. Clinical 
T stage was 1b in 2 patients, 2 in 4, 3 in 21, and 4a in 32. Clinical N stage 
was 0 in 20 patients, 1 in 16, 2 in 18, and 4 in 4. Clinical Stage was I in 
1 patient, II in 13, III in 20, and IVa in 25. 30 patients underwent FP, and 
29underwent DCF as NAC. After NAC, no patients were obtained com-
plete response (CR), 19 exhibited a partial response (PR), 31 had a stable 
disease (SD), and 1 presented with progressive disease (PD). 40 patients 
underwent surgery, and 19 received dCRT. Of 40 patients, 35 underwent 
pharyngo-laryngo-esophagectomy (PLE), and 5 cervical esophagectomy. 
36 patients obtained a pathologically complete response (pCR) by surgery. 
Of 19 patients who received dCRT, 12 patients obtained a clinical CR. Post-
operative complications were developed in 10 patients and detail as fol-
lows: 4 had recurrent nerve palsy, 3 necrosis or ulcer of trachea, 2 necro-
sis of free jejunum, 1 osteomylitis, and 5 others. 24 patients were received 
adjuvant therapy. Of 24, 11 received radiotherapy, 9 chemoradiotherapy, 
and 4 chemotherapy. 21 patients had recurrences after surgery. Of 21, 17 
had distant metastasis, 11 lymph node metastasis, and 3 local recurrence. 
Of 12 patients who had obtained CR by dCRT, 8 had no recurrence. The 4 
remained patients and 2 patients who obtained non-CR by dCRT under-
went salvage surgery (PLE). The overall survival rates at 5 years (OS) were 
47%, and those of patients who underwent surgery and dCRT were 39% 
and 74 %, respectively (p=0.07).
conclusion: It suggests that dCRT could become alternative therapy of sur-
gery for cervical esophageal cancer. Surgery for non-responder for NAC 
and salvage surgery for patients with recurrence after clinical CR by dCRT 
would play an important role. It is necessary for improvement of treatment 
outcome to find a new treatment for recurrence after surgery, because of 
high incidences of recurrence.
disclosure: Nothing to disclose 
P1309 cLInIcaL effecTIveness and safeTy Of 
seLf-exPandIng MeTaL sTenT PLaceMenT fOLLOWIng 
PaLLIaTIve cheMOTheraPy In PaTIenTs WITh advanced 
esOPhageaL cancer
Bakheet N.1,2
1Cairo University Hospital (Kasr Al Ainy), Hepato-Gastroenterology and 
Endemic Department, Cairo, Egypt, 2Asan Medical Center, University of Ulsan 
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Introduction: To investigate the effect of prior chemotherapy on self-ex-
panding metal stent (SEMS)-related complications in patients with locally 
advanced primary esophageal cancer.
aims & Methods: Data from patients with locally advanced primary esoph-
ageal cancer who received SEMS placement with or without prior chemo-
therapy were retrospectively reviewed. Patients were grouped according to 
prior palliative therapy: group A had received SEMS only, and group B had 
received palliative chemotherapy prior to SEMS placement. Patient age, 
stricture length, location, and dysphagia score prior to SEMS placement 
were evaluated. Outcomes after SEMS placement, including technical and 
clinical success rates, the occurrence of complications and survival, were 
compared.
results: The study included 105 patients (group A, n = 41; group B, n = 
64). There were no significant differences between the two groups prior 
to SEMS placement. SEMS placement was technically successful in all pa-
tients, with no procedure-related complications reported. Clinical success 
was achieved in 95.1% of patients in group A and 96.8% of patients in 
group B. The duration of stent patency was significantly shorter in group 
B (162 days; 95% CI, 126.6-198.4 versus group A (339 days; 95% CI, 258.8-
419.3), p = 0.001. No significant differences were seen between the two 
groups regarding dysphagia score improvement (p = 0.66), complications
(p = 0.094), or survival (p = 0.592).
conclusion: Prior chemotherapy did not increase the risk of complications 
following SEMS placement in patients with locally advanced esophageal 
cancer.
disclosure: Nothing to disclose 
P1310 vaLIdaTIOn Of MagnIfyIng endOscOPIc 
cLassIfIcaTIOn Of The jaPan esOPhageaL sOcIeTy fOr 
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Fukumoto Y., Furutachi S., Mannami T.
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Introduction: Predicting the invasion depth of superficial esophageal 
squamous cell carcinoma (SESCC) is crucial for determining the precise 
indication for endoscopic submucosal dissection (ESD), because the rate 
of lymph node metastasis increases in proportion to the invasion depth of 
SESCC. Recently, the Japan Esophageal Society (JES) developed a simplified 
classification for SESCC based on the degree of microvascular irregular-
ity observed on magnifying endoscopy (ME). The JES classification defines 
severely irregular microvessels as type B vessels, which corresponds to 
cancerous lesions. The type B vessels are subclassified into type B1, B2, 
and B3 vessels that are correlated to histological invasion depth of T1a-EP 
or T1a-LPM, T1a-MM or T1b-SM1, and T1b-SM2, respectively. According to 
previous studies, the diagnostic accuracy of type B2 vessel is about 60%-
70%, which is considered to be relatively low and unsatisfactory.
aims & Methods: Predicting the invasion depth of superficial esophageal 
squamous cell carcinoma (SESCC) is crucial for determining the precise 
indication for endoscopic submucosal dissection (ESD), because the rate 
of lymph node metastasis increases in proportion to the invasion depth of 
SESCC. Recently, the Japan Esophageal Society (JES) developed a simplified 
classification for SESCC based on the degree of microvascular irregularity 
observed on magnifying endoscopy (ME). Type B vessels are subclassi-
fied into type B1, B2, and B3 vessels that are correlated to histological 
invasion depth of T1a-EP or T1a-LPM, T1a-MM or T1b-SM1, and T1b-SM2, 
respectively. According to previous studies, the diagnostic accuracy of type 
B2 vessel is about 60%-70%, which is considered to be relatively low and 
unsatisfactory.
results: Of the 50 target areas, the number of the areas showing type B1, 
B2, and B3 vessels were 39, 9, and 2, respectively. The number of SESCC 
with tumor depths T1a-EP or T1a-LPM, T1a-MM or T1b-SM1, and T1b-SM2 
were 44, 4, and 2, respectively. The sensitivity/specificity/positive predic-
tive value (PPV)/negative predictive value (NPV) of the B1, B2, and B3 
vessels were 86.4%/83.3%/97.4%/45.5%; 75%/87%/33.3%/97.6%; and 
100%/100%/100%/100%, respectively. The accuracy of the B1, B2, and B3 
vessels were 86%, 86%, and 100%, respectively. The PPV of B2 vessels 
was relatively low.
We noted 3 and 6 cases in the B2-narrow and B2-broad groups, respec-
tively. The sensitivity/specificity/PPV/NPV of the B2-narrow and B2-broad 
groups were 0%/16.7%/0%/50% and 100%/50%/50%/100%, respective-
ly. The accuracy of the B2-narrow and B2-broad groups were 33.3% and 
66.7%, respectively. We noted 4 and 5 cases in the B2-only and B2-mixed 
groups, respectively. The sensitivity/specificity/PPV/NPV of the B2-only and 
B2-mixed groups were 100%/83.3%/75%/100% and 0%/16.7%/0%/25%, 
respectively. The accuracy of the B2-only and B2-mixed groups were 
88.9% and 11.1%, respectively.
conclusion: The accuracy of type B2 vessel was 86% whereas its PPV was 
as low as 33.3%. Contrastingly, the accuracy of the B2-only group, a pro-
posed subcategorization of type B2 vessels, was 86%. The B2-only group 
was considered to be a useful predictor of T1a-MM or T1b-SM1.
disclosure: Nothing to disclose 
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P1311 uTILITy Of sTenT dOuBLe PaLLIaTIOn fOr esOPhageaL 
cancer WITh aIrWay InvOLveMenT - The exTreMIs Of care
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Introduction: Primary esophageal cancer (EC) frequently presents as an 
advanced disease with airway involvement. Placement of combined 
esophageal (eS) and airway stents (aS) have been reported in small series 
to be effective palliation strategies.
aims & Methods: Our aim is to present the largest cohort of EC patients 
who underwent double stent palliation, and to evaluate the safety and 
efficacy of this approach. Methods - Longitudinal cohort study of patients 
with primary EC undergoing 2-stage esophageal and airway stent place-
ment at an oncology referral institute (Jan2000-Jan2019). Assessments: 
baseline demographics and clinical variables; baseline and week 2 dys-
phagia, dyspnea and performance status [PS] scores; baseline and week 8 
BMI; overall survival. Statistics: Paired t-Test; Kaplan-Meier method.
results: Seventy patients (89% men, mean age 60.20 ± 8.41) underwent 
double stenting. eS was placed for esophageal stenosis and dysphagia 
(n=41; placement of a second eS due to recurrence in 9 cases) or ERF 
(n=29); aS was required for ERF sealing (n=29+7 new ERF after eS) and 
to ensure airway patency due to malignant stenosis (n=29; placement of a 
second aS due to recurrence in 13 cases) or compression (n=5). 
There were 13, endoscopically managed, major complications after eS 
(hemorrage [n=1] migration [n=5], new fistulas [n=7]. As for aS, 4 major 
complications were recorded (hemorrage [n=1] and 3 deaths due to re-
spiratory infection and ultimately respiratory failure 3 to 7 days after the 
procedure). 
Overall, patients showed significant improvement in dysphagia and dys-
pnea symptoms (3,21vs.1,31 e 15,56vs.10,87; p=0,00). Along with symptom 
outcomes, there was a PS improvement for 89,2% (n=58) of the patients. 
BMI at week 8 was comparable to baseline records. 
Mean survival was 137.83 ± 24.14 days (95% CI: 90.51-185.15). Survival was 
longer for lower performance status (PS1, 249.95 days; PS2, 83.74 days; 
PS3, 22.43 days; PS4, 30.00 days)
conclusion: This is the largest comprehensive assessment of double stent 
palliation in advanced incurable EC. For both esophageal or airway steno-
sis and fistula, placement of combined eS and aS was a feasible, effective, 
fast-acting and safe modality for symptom palliation and BMI mainte-
nance. Patient autonomy followed symptom improvement. 
Since it is impossible to provide treatment for cure in most of these cases, 
this endoscopic strategy, performed in differentiated units with the re-
quired technical capacity, may guarantee treatment for the relief of pali-
ative EC.
disclosure: Nothing to disclose 
P1312 Is BIPOLar knIfe safe Than MOnOPOLar knIfe 
In endOscOPIc suBMucOsaL dIssecTIOn fOr esOPhageaL 
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Introduction: Endoscopic submucosal dissection (ESD) is a standard treat-
ment for early stage esophageal neoplasia. It was reported that the bipolar 
knife required significantly less energy and resulted in less tissue damage, 
and can decrease the incidence of perforation in animal model. On the 
other hand, all cases had submucosal fibrosis and it was not decreased 
esophageal stricture under esophageal ESD using bipolar knife compared 
with monopolar knife in porcine model. However, little is known the ef-
ficacy and safety of bipolar knife for esophageal ESD in clinical.
aims & Methods: In the absence of prior reports, we evaluated the efficacy 
and safety of bipolar knife for esophageal ESD.
This was a retrospective observational study in a single institution. Be-
tween May 2012 and July 2018, 543 consecutive patients with 918 esopha-
geal lesions were treated with ESD. Cases using multiple device and cases 
for esophageal SMT were excluded. The largest lesion was the target in 
patients with multiple lesions. Bipolar knife were used in anterior half and 
monopolar knife were used in posterior half. The primary outcomes were 
resectability and adverse events of esophageal neoplasia such as perfora-
tion, delayed bleeding, stricture, subcuteneous emphysema, pneumotho-
rax, and mediastinal emphysema. We compared these outcomes of cases 
using bipolar needle knife with monopolar needle knife. Perforation was 
defined as a visible hole in the esophageal wall, exposing the mediastinal 
space. Generalized estimating equation were used for statistical analy-
sis, and inverse probability of treatment weighting (IPTW) with propensity 
scores was used to reduce selection bias between the groups.
results: A total of 531 cases with 633 lesions were evaluated. Monopolar 
and bipolar group were 368 case with 440 lesions and 163 cases with 193 
lesions. 
No significant difference was observed between the groups, such as age, 
gender, comorbidities, antithrombotic use, history of previous chemora-
diotherapy, CO2 use, location, macroscopic appearance, lesion size, lesion 
circumference, clinical invasion depth, hemostatic forceps use, prophy-
lactic steroid use and traction method use. En bloc and complete (R0) 
resection rates in the monopolar and bipolar group were high and similar, 
(99.5% vs 100.0%, and 97.0% vs 96.9%). Perforations and postoperative 
bleeding also occurred similar rate (2.7% vs. 2.1%, p=0.79, and 1.4% vs 
1.0%, p=1.00). The incidence of subcuteneous emphysema and pneumo-
thorax also similar, (1.1% vs 0.5%, p=0.67, 0.0% vs 0.5%, p=0.13). However, 
mediastinal emphysema were observed more frequently in the bipolar 
group than monopolar group (19.2% vs 11.4% vs, p= 0.01). All cases could 
be treated with endoscopic and conservative management. The incidence 
of stricture was similar between the groups (8.6% vs 5.2%, p=0.15). IPTW 
methods showed similar results and mediastinal emphysema occurred 
more frequently in bipolar group (OR=6.32, 95% CI: 1.79-22.38, p=0.004). 
Limitations of this study were retrospective single center analysis and all 
cases were not evaluated mediastinal emphysema by computed tomogra-
phy after ESD.
conclusion: ESD for esophageal neoplasia using bipolar needle knife was 
safe and effective as well as that using monopolar knife. Mediastinal em-
physema might increase than monopolar knife.
disclosure: Nothing to disclose 
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P1313 endOscOPIc TheraPy Is as effecTIve as surgIcaL 
resecTIOn fOr earLy OesOPhageaL cancer: a TerTIary 
referraL exPerIence Of 251 cOnsecuTIve cases
Reyhani Calvo A.1,2, Davies A.1,2, Zylstra J.3, Santaolalla A.2, Gimson E.2, 
Baker C.1, Kelly M.1, Van Hemelrijck M.2, Gossage J.1, Zeki S.S.4, Dunn J.3
1Guy’s and St Thomas Hospital, Upper Gastrointestinal Surgery, London, 
United Kingdom, 2Kings College London, London, United Kingdom, 3Guy’s 
and St Thomas Hospital, London, United Kingdom, 4St Thomas’ Hospital, 
Gastroenterology, London, United Kingdom
contact e-Mail address: arasteh.reyhani@nhs.net
Introduction: Endoscopic eradication therapy (EET) is considered first 
line for the management of early oesophageal adenocarcinoma, but the 
transition from surgical management with primary oesophagectomy, the 
historical treatment of choice for high grade dysplasia and early cancer, 
has been challenging. Recent National audit data from the UK (NOGCA) 
demonstrated access to EET was variable according to geographic region, 
and only 65% were offered EET as first line. This study therefore aimed to 
compare the short and long term outcomes of consecutive patients with 
early oesophageal cancer treated during a transition period from oesopha-
gectomy to EET in a single tertiary referral centre.
aims & Methods: A single centre contemporaneously maintained database 
of consecutive patients treated for High grade dysplasia (HGD) and early 
oesophageal adenocarcinoma at a tertiary referral centre between 2000-
2018. All patients were discussed at MDT and histology confirmed by cen-
tral pathology review by 2 expert GI pathologists. EET was adopted as first 
choice treatment in 2012. All patients underwent EMR using Duette MBM 
kit by 2 experienced operators (JD,SZ). Follow up was either with RFA or 
APC according to standard protocols. Oesophagectomy was not preceded 
by neoadjuvant chemotherapy although some patients underwent resec-
tion following an initial attempt at EMR. Primary outcomes were overall 
and disease specific survival. Secondary outcomes included hospital stay, 
complications and cancer recurrence.
results: 251 patients were identified; 113 patients underwent oesophagec-
tomy and 138 patients were treated with EMR +/- further EET (59% + RFA/
APC, 25% + RFA, 9% + APC, 7% stepwise EMR). The mean age for oesoph-
agectomy was 64.6 years vs. EET 71.6 years (p=< .0001). The mean follow 
up time for oesophagectomy patients was 5.6 years vs 2.4 years after EET. 
The proportion of T1b cancers was higher in the oesophagectomy group 
(HGD 25% vs 39%, T1a 17% vs 34%, T1b 43% vs 16%, p< 0.001). Poor differ-
entiation (23% vs 5%, p< 0.001) and lymphovascular invasion (19% vs 4%, 
p< 0.001) were also significantly higher in the surgical group. Inpatient 
hospital stay was significantly higher in the oesophagectomy group (me-
dian 14 days vs 1.5 days EMR; p=< .0001). In-hospital and 30 day mortality 
was 0% in both groups. The surgical group was associated with more 
significant complications (Clavien dindo ≥ 3) 26% vs. EMR 1%, p=< .0001. 
Cancer recurrence occurred in 18% of patients after oesophagectomy (local 
4%, systemic 9%, mixed 5%) vs. 5% following EET (all local). The time to 
recurrence in both groups was not statistically significant. There was no 
difference in overall survival between both groups (HR 0.83 95%CI 0.45-
1.54). Stage matched survival in the HGD, T1a and T1b sub-groups did not 
significantly differ between the groups.
conclusion: In this large consecutive series of early oesophageal adenocar-
cinoma patients treated during a transition period from oesophagectomy 
to EET, there was no difference in overall disease free survival between 
both modalities. Post procedure mortality was zero in both groups. Im-
portantly EMR/EET was safe, with no patients requiring surgery or ICU 
admission. Oesophagectomy was associated with prolonged recovery and 
significant post-operative morbidity - complications were more common 
and severe. These data add weight to the argument that EET should be 
available for all patients with early OAC as the gold standard of care. Af-
ter EMR, patients with adverse prognostic features may still benefit from 
oesophagectomy.
disclosure: Nothing to disclose 
P1314 aPPLIcaTIOn Of cOnvOLuTIOnaL neuraL neTWOrks 
TO evaLuaTIng The InvasIOn dePTh Of earLy gasTrIc cancer 
Based On endOscOPIc IMages
Hamada K.1, Kawahara Y.2, Aida T.3, Okada H.4
1Okayama University Hospital, Department of Endoscopy, Okayama, 
Japan, 2Okayama University Medical School, Department of Practical 
Gastrointestinal Endoscopy, Okayama, Japan, 3Okayama University Graduate 
School of Interdisciplinary Science and Engineering in Health Systems, 
Okayama, Japan, 4Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Department of Gastroenterology and 
Hepatology, Okayama, Japan
contact e-Mail address: paosishou@yahoo.co.jp
Introduction: Endoscopic diagnostic accuracy of the invasion depth of early 
gastric cancer is reported to range from 71% to 95% [1]. Recently, artificial 
intelligence (AI) has been applied to endoscopic examination and is ex-
pected to improve endoscopic diagnosis [2, 3].
aims & Methods: The aim of this study was to evaluate the feasibility of 
convolutional neural networks (CNN), a type of AI, for evaluating the in-
vasion depth of early gastric cancer based on endoscopic images. From 
patients who underwent treatment for early gastric cancers in our hos-
pital between January 2012 and December 2016, we selected 100 patients 
with mucosal cancers that were treated with endoscopic resection (ER) (M 
group), 50 patients with cancers invading the submucosa that were ini-
tially treated with ER (SM-ER group), and 50 patients with cancers invad-
ing the submucosa that were treated surgically (SM-OPE group). A total of 
3508 non-magnifying endoscopic images of early gastric cancers, includ-
ing white-light imaging, linked color imaging, blue laser imaging-bright, 
and choromoendoscopic images with indigo-carmine, were included in 
this study. The following images were excluded: narrow-band imaging, 
blue laser imaging, magnifying endoscopic images, poor images because 
of bleeding or edema caused by scope contact, and poor images because 
of halation or tarnishing of the lens. Three-fold cross-validation was con-
ducted, and the results are presented as the mean value of three tests. The 
patients of each group were divided into three subgroups each. A deep 
CNN was pre-trained and fine-tuned on a dataset of endoscopic images 
from two-thirds of patients in the M and SM-OPE groups, and a dataset of 
endoscopic images from the other one-third of patients in all three groups 
was evaluated by the CNN. Invasion depth was evaluated for each image 
and patient. Majority decision was applied to the patient evaluation and 
a lesion was diagnosed as a mucosal cancer when the number of images 
diagnosed as mucosal cancers and as cancers invading the submucosa 
was the same.
results: Regarding the image evaluation, the sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) for diagnosing 
mucosal cancer were 82.7%, 63.0%, 69.1%, and 78.4%, respectively. Re-
garding the patient evaluation, the sensitivity, specificity, PPV, and NPV for 
diagnosing mucosal cancer were 82.0%, 71.0%, 73.9%, and 79.8%, re-
spectively. The diagnostic accuracy for early gastric cancer, including both 
mucosal cancer and cancer invading the submucosa was 72.8% and 76.5% 
for the image and patient evaluations, respectively.
conclusion: The application of CNN to evaluating the invasion depth of 
early gastric cancer based on endoscopic images is feasible, although 
some devices are required to improve diagnostic accuracy.
references: 1. Matsuura N, Iishi H, Uedo N et al. Diagnosis of invasion 
depth of early gastric cancer by normal endoscope [in Japanese with Eng-
lish abstract]. Stomach and Intestine. 2015; 50: 603-615. 2. Hirasawa T, 
Aoyama K, Tanimoto T et al. Application of artificial intelligence using a 
convolutional neural network for detecting gastric cancer in endoscopic 
images. Gastric Cancer. 2018; 21: 653-660. 3. Kanesaka T, Lee TC, Uedo N et 
al. Computer-aided diagnosis for identifying and delineating early gastric 
cancers in magnifying narrow-band imaging. Gastrointest Endosc. 2018; 
87: 1339-1344.
disclosure: Nothing to disclose 
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P1315 The OuTcOMes Of underWaTer eMr and cOnvenTIOnaL 
eMr fOr suPerfIcIaL nOn-aMPuLLary duOdenaL ePITheLIaL 
TuMOr; a PrOsPecTIve sTudy WITh a cOMParIsOn TO 
hIsTOrIcaL cOnTrOLs
Kiguchi Y.1, Kato M.1,2, Nakayama A.1, Sasaki M.1, Mizutani M.1,2, 
Tsutsumi K.1, Akimoto T.1, Takatori Y.1, Mutaguchi M.3, Takabayashi K.3, 
Ochiai Y.1, Maehata T.1, Kanai T.2, Yahagi N.1
1Keio University School of Medicine, Division of Research and Development 
for Minimally Invasive Treatment, Cancer Center, Tokyo, Japan, 2Keio 
University School of Medicine, Department of Internal Medicine, Division of 
Gastroenterology and Hepatology, Tokyo, Japan, 3Keio University School of 
Medicine, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan
contact e-Mail address: kiguchiyoshiyuki@gmail.com
Introduction: Underwater EMR (UEMR) has been reported as an alterna-
tive to EMR for superficial non-ampullary duodenal epithelial tumor (SNA-
DET). However, the detailed outcomes are still unclear.
aims & Methods: This study aimed to compare the clinical outcomes of 
UEMR and EMR for SNADETs smaller than 20 mm.This was a prospective 
observational study with a comparison to historical controls. From Novem-
ber 2017 to December 2018, 104 consecutive cases with SNADETs smaller 
than 20 mm were prospectively included (UMIN000025442). A total of 240 
cases of attempted EMR were chosen as historical controls. We compared 
the adverse event rates, rates of conversion to ESD, en bloc resection rate 
and R0 resection rate. Next, multivariate analysis was constructed to iden-
tify predictors for conversion to ESD, piecemeal resection, and RX or R1 
(RX/R1) resection.
results: Concerning adverse events, there were no significant differences 
between the two groups (delayed bleeding: 2% for UEMR and 1% for EMR; 
perforation: 0% in both groups). The conversion rate to ESD in the UEMR 
group was significantly lower than that of the EMR group (13% vs 30%, 
p< 0.01). Conversely, the en bloc resection rate and R0 resection rate of 
the UEMR group were significantly lower than those of the EMR group (en 
bloc resection: 87% vs 96%, p< 0.01, R0 resection: 67% vs 80%, p=0.05). 
In multivariate analyses, attempted EMR, lesion size and depressed type 
were independent predictors of conversion to ESD. Attempted UEMR was 
an independent predictor of piecemeal resection and RX/R1 resection.
conclusion: The present study revealed that UEMR was equivalent to EMR 
in terms of safety. UEMR reduced the number of cases requiring conversion 
to ESD. However, it increased the risk of piecemeal and RX/R1 resection.
disclosure: Nothing to disclose 
P1316 WhaT kInd Of earLy gasTrIc cancer afTer h. PyLOrI 
eradIcaTIOn Is dIffIcuLT TO dIagnOse?
Wakatsuki T., Sakaki T., Nagahara H., Sudou K., Sakabayashi Y., 
Fukumoto Y., Furutachi S.-I., Mannami T.
Okayama Medical Center, Department of Gastroenterology & Hepatology, 
Okayama, Japan
contact e-Mail address: t_wakatsuki0530@yahoo.co.jp
Introduction: Early gastric cancer (EGC) occurring after successful Helico-
bacter pylori eradication is difficult to diagnose, due to non-neoplastic epi-
thelia covering the periphery of the surface of cancerous areas. This might 
lead to unclear demarcation of the cancer when observed using narrow 
band imaging with magnifying endoscopy (NBI-ME).
aims & Methods: This retrospective control study aimed to clarify the his-
topathological characteristics of EGC that has cancerous areas covered 
with non-neoplastic epithelia. There were 383 cases of EGC that under-
went endoscopic submucosal dissection (ESD) between November 2011 
and January 2019 at Okayama Medical Center. Sixty two lesions from 55 
patients who had received H. pylori eradication before ESD were included. 
The specimens resected by ESD were cut by a width of 2 mm. For each le-
sion, every section was evaluated histopathologically, and the percentage 
of sections that had non-neoplastic epithelia covering the carcinoma was 
calculated. Based on the percentages calculated, the lesions were clas-
sified into two groups: covered group (27 lesions, 143 sections) (50% or 
more) and non-covered group (35 lesions, 139 sections) (less than 50%).
Baseline characteristics, endoscopic features, and histological findings 
were evaluated. For endoscopic features, the following were evaluated: 
irregular microvascular/micro-surface pattern, light blue crest, green epi-
thelium, intraepithelial microinvasion, over flow, and demarcation line. 
The lengths of non-neoplastic epithelia covering the carcinoma, percent-
age of sections in which non-neoplastic tubules exist among cancer tu-
bules, and background mucosa (fundic or pyloric glands/intestinal meta-
plasia) were evaluated in the histopathological evaluation.
results: No significant differences were observed for the baseline char-
acteristics. For the endoscopic features, only the demarcation line dem-
onstrated a significant difference; the lesions classified as covered group 
had a higher proportion of unclear demarcation lines (p=0.0006). For the 
histopathological evaluation, the average length of non-neoplastic epithe-
lia covering the carcinoma was 1.11 mm in the covered group, which was 
significantly longer than 0.57 mm in the non-covered group (p=0.001). The 
proportion of sections in which non-neoplastic tubules exist among cancer 
tubules was 77.8% in the covered group; this was significantly higher than 
the 48.6% observed in the non-covered group (p=0.001). The proportion 
of background mucosa which were fundic or pyloric glands was 62.7% in 
the covered group; this was significantly higher than the 49% observed in 
the non-covered group (p=0.02).
conclusion: EGC occurring in the area where background mucosa is a 
fundic or pyloric gland tends to be covered with non-neoplastic epithelia 
peripherally. More careful observation is required in the fundic or pyloric 
gland area than in the intestinal metaplasia area.
disclosure: Nothing to disclose 
P1317 yIeLd Of InvesTIgaTIng IsOLaTed hyPOferrITInaeMIa 
referred frOM PrIMary care
Mothey M.1, Shirazi-Nejad A.1, Hebden J.2
1Sheffield Teaching Hospital, Gastroenterology, Sheffield, United Kingdom, 
2Sheffield Teaching Hospital, Sheffield, United Kingdom
contact e-Mail address: priyankajale@ymail.com
Introduction: The value of investigating isolated hypoferritinaemia is un-
clear. The BSG guidelines on iron deficiency anaemia (IDA) suggest con-
sideration of endoscopic investigation in those aged >50 after discussing 
the risk and potential benefit
aims & Methods: We prospectively evaluated consecutive patients seen by 
a consultant gastroenterologist who had been referred from primary care 
with isolated hypoferritinaemia. All patients were offered investigation as 
per IDA guidelines following clinic consultation. Data was collected from 
the initial consultant consultation letter and from Infoflex (endoscopy) 
and Sunquest ICE system (blood results, radiology and histology). Lesions 
judged to be sources of significant blood loss were as defined by Rockey 
et al1 (carcinomas, adenomatous polyps >15mm, vascular ectasia ≥5 or 
>8mm, duodenal / gastric / colonic ulcers >1cm, oesophagitis [LA grade D], 
erosive gastritis and active colitis).
results: Eighty-two patients (median age 67.5 {42-93}; 58 females) were 
seen over a 5-year period (2014-2019). Thirty patients (36%) were asymp-
tomatic (no symptoms or lethargy only). Fifty-eight patients (71%) had 
bidirectional endoscopies, 15 (18%) a combination of endoscopic and ra-
diological imaging, and 6 (7%) having imaging alone. Two patients were 
excluded (1 died before investigations and 1 investigated as part of BCSP). 
Colonic carcinoma was discovered in 1 patient (1.3%). No gastric carcino-
mas were found (although a gastric carcinoma was discovered 12 months 
following a normal examination in a patient with a partial gastrectomy for 
previous gastric carcinoma). Other significant findings were: colonic polyps 
in 2 (2.5%); coeliac disease (serology negative, Marsh 3a) in 1 (1.3%); com-
plex renal cyst resulting in nephrectomy in 1 (1.3%); hyperplastic/regen-
erative gastric polyps in 2 (2.5%); and an oozing gastric polyp in 1 (1.3%). 
There were no significant gastric or duodenal ulcers or angiodysplasias. 
Investigations were normal or non-significant in 74 (93%) patients: normal 
25 (31%), gastritis 24 (30%), gastric polyps 10 (13%), colonic adenomas 8 
(10%), oesophagitis LA grade A-B 4 (5%), haemorrhoids 4 (5%), duode-
nitis 2 (2.5%), Barrett’s 1 (1.3%), duodenal adenoma 1 (1.3%), gastric ulcer 
1 (1.3%), oesophageal erosions 1 (1.3%). Lung carcinoma was discovered 
in 1 patient who had a CT for associated weight loss; and a hepatocellular 
carcinoma in 1 patient, identified on renal tract ultrasound.
conclusion: Gastrointestinal malignancy is rarely found in investigation of 
isolated hypoferritinaemia.
references: 1. Rockey DC and Cello JP. Evaluation of the gastrointestinal 
tract in patients with iron deficiency anaemia. N Engl J Med 1993; 329: 
1691-5
disclosure: Nothing to disclose 
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P1318 screenIng endOscOPy In PaTIenTs WITh advanced 
chrOnIc LIver dIsease BeyOnd POrTaL hyPerTensIOn: 
hIgher PrevaLence Of gasTrIc neOPLasIa In cOMParIsOn 
TO a heaLThy screenIng POPuLaTIOn
Morais R.1, Marques M.1, Gaspar R.1, Alves R.2, Dias E.1, Silva J.1, 
Santos-Antunes J.1, Pereira P.1, Lopes S.1, Cardoso H.1, Liberal R.1, 
Macedo G.1
1Centro Hospitalar São João, Gastroenterology, Porto, Portugal, 2Hospital 
Garcia de Orta, Medicina Interna, Lisboa, Portugal
contact e-Mail address: ruimorais20@gmail.com
Introduction: The Baveno VI and the expanded Baveno VI criteria were 
proposed to help identify patients who could safely avoid screening esoph-
agogastroduodenoscopy (EGD) for clinically significant varices among 
patients with compensated advanced chronic liver disease (cACLD). Al-
though several studies have meanwhile validated those criteria, all fail 
to acknowledge the possible role of the avoided EGD for the same time 
screening of gastric neoplasia in cACLD population. Liver diseases are as-
sociated with an increased risk of extra-hepatic malignancies. Previous 
epidemiological studies have suggested that patients with cirrhosis have 
an increased risk for gastric cancer.
aims & Methods: We aimed to evaluate the prevalence of gastric neoplasia 
in patients with cACLD who underwent screening EGD in a country with 
intermediate gastric cancer risk and high Helicobacter pylori prevalence.
This retrospective cohort study enrolled all asymptomatic cACLD patients 
who underwent EGD for varices screening from January 2008 to June 2018. 
Cases were matched with asymptomatic healthy individuals who under-
went EGD for gastric cancer screening at the same time as colonoscopy 
performed for colorectal cancer screening. Patients with prior history of 
organ transplantation and/or GI bleeding were excluded.
results: We included 1974 subjects (610 patients, 1364 controls) 46.3% 
male, with a median age of 58 (50-66) years. Besides a male predomi-
nance in cases (69.0% vs. 45.6%, p< 0.001), no other demographic char-
acteristic differed between cases and controls. The leading aetiology of 
cACLD was alcoholic liver disease (53.3%), followed by chronic hepatitis C 
(16.2%). Of the 610 patients with cirrhosis, 13 (2.1%) had gastric neoplasia 
[gastric cancer, n=10; high-grade dysplasia (HGD), n=2; low-grade dyspla-
sia (LGD), n=1]. Most of the lesions (61.5%) were located in the gastric 
body, with a median size of 18 mm (15-24). Eight patients underwent sur-
gical resection (R0 resection rate of 100%). Complications were observed 
in three of these patients (anastomotic leak n=2; nosocomial pneumonia 
n=1), with associated decompensated liver disease, leading to death in two 
of them. Three patients underwent endoscopic resection [n=2 endoscopic 
submucosal dissection (ESD), n=1 endoscopic mucosal resection (EMR)], 
with an en bloc resection rate, R0 resection rate and curative resection 
rate of 100%, without complications. Two patients were referred for pal-
liative care due to decompensated liver disease. Compared to controls, 
cirrhotic patients had a higher prevalence of gastric neoplasia (2.1% vs. 
1%, p=0.044; gastric cancer 1.6% vs. 0.8%, p=0.08). The prevalence of 
Helicobacter pylori infection was lower in patients compared to controls 
(36.2% vs. 47.2%, p=0.004). In the 13 cACLD patients in whom were de-
tected neoplastic gastric lesions, 8 were diagnosed on the initial screening 
endoscopy. Four of these patients would have an avoidable EGD according 
to the Baveno VI criteria.
conclusion: The prevalence of gastric neoplasia is significantly increased in 
cACLD patients compared to healthy screening population. Despite grow-
ing evidence supporting the role of non-invasive methods to rule out vari-
ces, EGD should still be considered in these patients, at least in those from 
countries with intermediate gastric cancer risk. Detection at an early stage 
may allow adequate treatment with less invasive techniques such as ESD, 
avoiding the considerable morbidity and mortality associated with surgical 
intervention in these patients.
references: De Franchis R, Baveno VI. Faculty. Expanding consensus in 
portal hypertension. Report of the Baveno VI Consensus Workshop: Strati-
fying risk and individualizing care for portal hypertension. J Hepatol Zullo 
A, Romiti A, Tomao S, et al. Gastric cancer prevalence in patients with liver 
cirrhosis. Eur J Cancer Prev. 2003; 12( 3): 179-82.
disclosure: Nothing to disclose 
P1319 nOn-cardIa earLy gasTrIc cancer In cenTraL 
vIeTnaM: uncOMMOn BackgrOund MucOsa and PreLIMInary 
resuLTs Of esd TreaTMenT afTer 5 years
Tran Q.T.1,2, Nguyen T.H.T.1, Shimizu S.3, Aghdassi A.A.4, Lerch M.M.5, 
Miyahara R.6, Goto H.7, Tran V.H.1
1Hue University Hospital, GI Endoscopy and Internal Medicine, Hue City, 
Viet Nam, 2University Medicine Greifswald, Internal Medicine A, Greifswald, 
Germany, 3Kyushu University Hospital, Kyushu, Japan, 4Medizin. Universität 
Greifswald, Inst. für Medizin A, Greifswald, Germany, 5University Medicine 
Greifswald - Medicine A, University Medicine Greifswald; Greifswald/DE, 
Medicine A, Greifswald, Germany, 6Nagoya University, Nagoya, Japan, 
7Nagoya University Graduate School of Medicine, Nagoya, Japan
contact e-Mail address: quangtrungdr@huemed-univ.edu.vn
Introduction: Gastric cancer (GC) is the second leading causes of malig-
nancy-related death in Vietnam, with increasing incidence of non-cardia 
early gastric cancer (EGC). Data on accurate diagnosis of EGC and treat-
ment of this disease by endoscopic submucosal dissection (ESD) in Viet-
nam is still very limited.
aims & Methods: To describe the characteristics of non-cardia EGC and 
evaluate the effectiveness and the safety of ESD in the context of Central 
Vietnam.
We prospectively enrolled patients with EGC detected by magnified chro-
moendoscopy from December, 2013 to December, 2018 at Hue University 
Hospital, Vietnam. Selected cases of non-cardia EGC received standardized 
ESD technique and have been following up carefully as in protocol.
results: Among 606 cases of GC, 46 cases were non-cardia EGC and 
underwent ESD. The depth of invasion was T1a in 33 (71.7%), T1b1 in 10 
(21.7%), and T1b2 in 3 (6.6%) cases. Mild- moderate chronic atrophic gas-
tritis background, most being C2, and the gastritis-like with little malig-
nant appearance EGC was the predominant type (63%). Severe chronic 
atrophic gastritis was found in only 2.2% of cases. ESD was performed of 
which 97.8 % received en-bloc resection; the mean procedure time was 
76 ± 22 minutes (24-155), and mean sample size was 28 ± 7 mm (16.5-60). 
Complications consisted of two patients with severe bleeding and one case 
with minor perforation, all was successfully managed endoscopically. The 
longest follow-up time was 5 years with no recurrence. However, there 
were 2 cases who developed new high-grade dysplasia lesions and both 
of them underwent ESD second time successfully.
conclusion: In Central Vietnam, a significant proportion with non-cardia 
EGC have a background mucosa of mild chronic atrophic gastritis and the 
gastritis-like with little malignant appearance. ESD treatment has demon-
strate early promising results in that it appears effective and relatively safe.
 
Italy 
[1]
france 
[2]
south east asia 
[3]
vietnam 
(our data) p
study period 2005-2011 2010-2013 2009-2015 2013-2018  
study method Retrospective Prospective Retrospective Prospective  
cases’ number 20 319 35 46  
esd size (mm) Median 29 39 ± 23 Median 20 (5-60) 28±7 (16.5-60) 0.001*
esd time 
(minutes) Median 119.1 108.2 ± 62
Median 105 
(15-480)
76 ±22 
(24-155)
0.006*
esd knives IT knife, Hook 
knife
Dual knife, 
Flush knife
IT knife, Hybrid 
knife
IT2 knife, Flush 
knife
 
en-bloc 
resection rate NA 91.5% 91.4% 97.8% 0.134*
r0 rate 90% 71.2% 77.1% 95.7% 0.01**
severe bleeding 0 15 (4.7%) 1 (2.9%) 2 (4.3%) 0.72**
Perforation 3/20 (15%) 26 (8.1%) 0 1 (2.2%) 0.15*
[Comparison with the ESD data of some other areas]
references: 1.Catalano, F., et al., Endoscopic submucosal dissection in the 
treatment of gastric submucosal tumors: results from a retrospective co-
hort study. Gastric Cancer, 2013. 16(4): p. 563-70. 2. Barret, M., et al., The 
expansion of endoscopic submucosal dissection in France: A prospective 
nationwide survey. United European Gastroenterol J, 2017. 5(1): p. 45-53. 
3. Najib Azmi, A., et al., Endoscopic Submucosal Dissection Outcomes for 
Gastroesophageal Tumors in Low Volume Units: A Multicenter Survey. Di-
agn Ther Endosc, 2016. 2016: p. 5670564.
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P1320 effecT Of POTassIuM-cOMPeTITIve acId BLOcker TO 
heaLIng Of arTIfIcIaL uLcer afTer endOscOPIc suBMucOsaL 
dIssecTIOn: PrOsPecTIve randOMIzed TrIaL
Ban H.1, Otsuka T.2, Sugimoto M.2, Andoh A.3
1Kusatsu General Hospital, Gastroenterology, Kusatsu, Japan, 2Shiga 
University of Medical Science Hospital, Division of Digestive Endoscopy, Otsu, 
Japan, 3Shiga University of Medical Science, Gastroenterology, Otsu, Japan
contact e-Mail address: hban@kusatsu-gh.or.jp
Introduction: Recently, endoscopic submucosal dissection (ESD) is com-
monly carried out to treat early-stage gastric cancer. Patient age, lesion 
size, location, and histology of tumor are related to the incident rate of 
complications and the healing speed of artificial ulcers after ESD. Vono-
prazan (VPZ) is a novel potassium-competitive acid blocker (P-CAB), which 
exerts faster, more potent, sustained gastric acid inhibition than proton 
pump inhibitors (PPIs). However, it remains unclear whether the P-CAB 
effectively plays for the healing of artificial ulcer after ESD.
aims & Methods: We compared healing process of artificial ulcer after ESD 
between treatment of P-CAB and PPI, as a prospective study at a single 
center. In addition, we evaluated influence of Helicobacter pylori (H. pylori) 
infection status in healing speed of artificial ulcer. One hundred nineteen 
six patients with gastric cancers or gastric adenomas treated by ESD at 
Shiga University of Medical Science from September 2015 to August 2018. 
By the minimization method using location of tumor (upper, middle or 
lower of the stomach) and tumor size (less than 20 mm or more), we ran-
domly divided kinds of acid inhibitory drugs (VPZ 20mg for 8 weeks or lan-
soprazole (LPZ) 30mg for 8 weeks). Artificial ulcer size was endoscopically 
measured at the 1st, 2nd, 4th and 8th weeks after ESD. In addition, based on 
H. pylori status, we finally classified into 4 groups: V+ subgroup: H. pylori-
positive and VPZ, V- subgroup: H. pylori-negative and VPZ, L+ subgroup: 
H. pylori-positive and LPZ, and L- subgroup: H. pylori-negative and LPZ.
results: There were no significant differences in patient characteristics, 
location, depth and size of tumor among 2 groups. Reduction rates of ar-
tificial ulcer of VPZ were 37.8±32.8% at the 1st week, 73.8±19.4% at the 2nd 
week, 94.0±6.2% at the 4th week, and 99.8±0.1% at the 8th week, respec-
tively. Reduction rates of LPZ were 30.2±34.0% at the 1st week, 69.4±24.7% 
at the 2nd week, 93.4±8.1% at the 4th week, and 99.9±0.1% at the 8th week, 
respectively. There was no significant difference between the 2 groups.In H. 
pylori-negative status, reduction rates were similar for V- and L- subgroup. 
In H. pylori-positive status, reduction rates of V+ subgroup was relatively 
higher than L+ subgroup at 2nd week (75.3±16.2%, 67.5±15.8%, P=0.06).
conclusion: P-CAB has advantage to healing of artificial ulcer after ESD 
due to faster, more potent, sustained gastric acid inhibition than PPIs, 
especially in early phase within 2 weeks after ESD. These observations 
suggested that VPZ has high potential to prevent adverse events including 
bleeding, irrespective with H. pylori-infection status.
disclosure: Nothing to disclose 
P1321 gasTrIc cancer PaTIenTs WhO underWenT 
gasTrecTOMy are hIgh rIsk fOr cOLOrecTaL neOPLasIa: 
a case cOnTrOL sTudy
Lee J.S., Gweon T.G.
Incheon St. Mary’s Hospital, The Catholic University of Korea, Incheon, Korea 
(Republic of)
contact e-Mail address: leejaesin@daum.net
Introduction: Several studies suggested that colorectal neoplasia could 
be prevalent in gastric cancer patients. However, most of studies included 
gastric cancer patients before gastrectomy. The aim of this study was to 
investigated whether colorectal neoplasia was more prevalent in gastric 
cancer patients after gastrectomy than normal population.
aims & Methods: We reviewed medical records of consecutive gastric can-
cer patients who underwent screening colonoscopy in 2017. Colonoscopy 
was done after at least 1 year of gastrectomy. Healthy individuals who re-
ceived colonoscopy during the same period were matched to gastric cancer 
group by age and sex, at a 2:1 manner. We compared the frequency of 
colorectal neoplasia, advanced neoplasia, and cancer among gastric can-
cer patients with that of the control group.
results: A total of 354 (118, gastric cancer; 236, control group) were includ-
ed in this study. The rate of colorectal neoplasia and advanced neoplasia 
were higher in the gastric cancer patients than the control group (colorec-
tal neoplasia, 49.2% vs 33.5%, p < 0.01; advanced neoplasia, 21.2% vs 
11.0%, p < 0.01). The rate of colorectal cancer didn’t differ between the two 
groups (3.4% vs 0.8%, p = 0.10). Age ≥ 50, male gender, and gastrectomy 
for gastric cancer were significant risk factors for colorectal neoplasia in 
multivariate analysis.
  gastric cancer group (total 118)
control group 
(total 236) P-value
Colorectal neoplasm 58 (49.2%) 79 (33.5%) < 0.01
Advanced colorectal neoplasm 25 (21.2%) 26 (11.0%) < 0.01
Colorectal cancer 4 (3.4%) 2 (0.8%) 0.10
[Rate of colorectal neoplasm in gastric cancer patients who underwent 
gastrectomy]
conclusion: Colorectal neoplasia and advanced neoplasia were significant-
ly more prevalent in patients with gastric cancer who underwent gastrec-
tomy than the control group. Gastric cancer was independent risk factor for 
colorectal adenoma. We recommend regular colonoscopy in gastric cancer 
patients after gastrectomy.
disclosure: Nothing to disclose 
P1323 fLaT eLevaTed LesIOns WhIch have Been dIagnOsed 
WITh adenOMa jusT By cOnvenTIOnaL endOscOPy can Be 
dIscrIMInaTed BeTWeen earLy gasTrIc cancer and adenOMa 
By MagnIfIed endOscOPy WITh nBI
Iwasaki T., Uchita K., Kojima K., Iwamura S.
Kochi Red Cross Hospital, Dept. of Gastroenterology, Kochi, Japan
contact e-Mail address: space-rendez-vous@sings.jp
Introduction: A white and flat elevated lesion is a typical endoscopic find-
ing of gastric adenoma with an intestinal phenotype. However, histopatho-
logical studies have recently revealed that some of these lesions which 
have a gastric phenotype just in part are consequently diagnosed as gastric 
cancers, because disease progression are faster than adenoma. Thus it is 
crucial to distinguish between these two phenotypes.
aims & Methods: Magnified endoscopic findings were compared between 
lesions with a gastric phenotype (gastric cancers) and those with an in-
testinal phenotype (adenomas), all of which were detected as white and 
flat elevated lesions by conventional endoscopy. A total of 211 gastric neo-
plasias were treated by endoscopic submucosal dissection (ESD) at Kochi 
Red Cross Hospital between October 2010 and November 2018. In these 
lesions, 51 lesions which showed white and flat elevated were included 
this study. All lesions were examined by ME-NBI before ESD and resected 
en an block. The central region of the lesions was immunostained by MU-
C5AC, MUC6, MUC2, and CD10. These lesions were divided into 2 groups, 
Group A and Group B, according to the result of immunostaining. Group 
A was the lesions which had gastric phenotype, positive for MUC5AC and 
/ or MUC6, diagnosed of gastric cancers. Group B was the lesions which 
had only intestinal phenotype, positive for only MUC2 and/or CD10, diag-
nosed of typical gastric adenoma. Mucin expression in ≥10% and < 10% 
of cells was defined as positive and negative, respectively, in accordance 
with previous reports 
1). The magnified endoscopic findings were retrospectively examined and 
compared between the groups: microstructure of the surface, microvas-
cular pattern, deposition of white opaque substances (WOS), and the 
presence of a crypt opening (CO). Microstructure pattern was classified as 
having an intralobular loop (ILL) pattern, which was defined as having a 
papillary or granular structure containing looped vessels; a fine network 
pattern (FNP), which was defined as having a regular crypt opening with 
regular polygonal microvessels; and a mixed pattern 
2). Microvascular pattern was classified according to the VS classification 
system reported by Yao et al.
results: There were 21 lesions in Group A and 30 lesions in Group B. The 
ILL pattern was dominant in Group A (81.0%, 17/21), and the FNP was 
dominant in Group B (60.0%, 18/30). Only one case had vessels exhibiting 
an epithelial circular (VEC) pattern. The microvascular pattern was irregu-
lar in 47.6% (10/21) of cases in Group A and in only 3.3% (1/30) of cases 
in Group B. The proportion of lesions with WOS deposition was slightly 
higher in Group B (50.0%, 15/30) than in Group A (42.9%, 9/21), and the 
proportion of lesions with the presence of a CO was higher in Group B 
(86.7%, 26/30) than in Group A (19.0%, 4/21).
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conclusion: Among white and flat elevated lesions that are diagnosed with 
adenomas by standard endoscopic observation, those with a gastric phe-
notype, which are diagnosed with cancers, have characteristic magnified 
endoscopic findings, including an ILL pattern and an irregular microvascu-
lar pattern. These findings will be important for　distinguishing between 
adenomas and adenocarcinomas.
references: 1) Kanemitsu T, Yao K, et al. Magnifying Endoscopic Diagnosis 
of Extremely Well-differentiated Pure Adenocarcinoma of the Gastric Type. 
Stomach and intestines 53 (1) ,43-59, 2018 2) Yokoyama.A, Inoue H, Mina-
mi H, et al. Novel narrow band imaging magnifying endoscopic classifica-
tion for early gastric cancer. Digestive and liver disease 42, 704-708, 2010
disclosure: Nothing to disclose 
P1324 rasPBerry shaPed gasTrIc LesIOns In heLIcOBacTer 
PyLOrI-negaTIve PaTIenTs
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Asaoka D.1, Hojo M.1, Yao T.2, Nagahara A.1
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Introduction: A reddish semipedunculated polyp with a morphological 
raspberry-like appearance in Helicobacter pylori (Hp)-negative patients has 
been recognized to be hyperplastic polyp (HP) conventionally. However, 
part of this poly is reported as gastric adenocarcinoma of foveolar-type 
(GAFV) which has recently proposed as a new rare variant of gastric ad-
enocarcinoma and has garnered much attention as one of Hp-negative 
gastric cancer [1]. In this way, this type of polyp which is newly categorized 
as a raspberry shaped gastric lesion (RSGL) includes various lesions. How-
ever, clinicopathological and endoscopic features and differential diagno-
sis of RSGLs in Hp-negative patients have not been elucidated.
aims & Methods: This study aimed to clarify the clinicopathological and 
endoscopic features of RSGLs in Hp-negative patients. We collected RSGLs 
from endoscopic database in our hospital between April 2014 and Febru-
ary 2019 including 556 EGCs which underwent endoscopic resection. We 
classified RSGLs histopathologically, and analyzed their clinicopathological 
and endoscopical features.
results: A total of 17 RSGLs (10 males, 7 females) in Hp-negative patients 
were collected (Table), and classified into 6 histological types as follows; 
  gafv gafg gafgM hP
fgP like 
lesion with 
atypical 
foveolar hy-
perplasia
hyperplasia 
of foveolar 
epithelium 
and parietal 
cell
Number of cases 7 2 2 4 1 1
Age 52.5 65.5 41.5 69 70 65
Gender 
(male/ female)
5/2 0/2 1/1 2/2 1/0 1/0
Location (U/M/L) 4/3/0 2/0/0 2/0/0 3/0/1 1/0/0 0/1/0
Location (Greter 
curvature/ Lesser 
curvature)
7/0 2/0 2/0 1/3 1/0 0/1
Tumor size(mm) 5(3-8) 8.5(5-12) 4.5(4-5) 5.5(3-9) 12 6
Macroscopic 
type (elevated /
depressed)
7/0 2/0 2/0 4/0 1/0 1/0
Depth of invasion 
(M/SM)
7/0 0/2 1/1      
[Clinicopathological findings of raspberry shaped gastric lesion in 
Helicobacter pylori-negative patients]
1. GAFV (7cases), 2. gastric adenocarcinoma of fundic gland type (GAFG, 
2cases), 3. gastric adenocarcinoma of fundic gland mucosal type (GAFGM, 
2cases), 4. HP (4cases), 5. fundic gland polyp (FGP) like lesion with atypi-
cal foveolar hyperplasia (1cases), 6. Hyperplasia of foveolar epithelium and 
parietal cell (1cases). “FGP like lesion with atypical foveolar hyperplasia” 
and “hyperplasia of foveolar epithelium and parietal cell” showed pari-
etal cell protrusions histopathologically, which considered to be associ-
ated with long-term use of proton pump inhibitors. Clinicopathologically, 
RSGLs were frequently found in the greater curvature of upper gastric body 
except for HP. All RSGLs showed strongly reddish protruded lesions mac-
roscopically. In white-light endoscopic images, GAFV were observed as 
entirely reddish lesions, however, other lesions partially accompanied with 
whitish areas. Magnifying endoscopy with narrow-band imaging was per-
formed in 9 cases (GAFV/ GAFG/ GAFGM/ HP/ FGP like lesion with atypi-
cal foveolar hyperplasia / hyperplasia of foveolar epithelium and parietal 
cell=3/2/2/1/1). Only 2 case of GAFGM was diagnosed as cancer with MES-
DA-G [2], however, GAFV and GAFG were diagnosed as non-cancer. There 
were no endoscopic findings that were useful to distinguish each lesion.
conclusion: RSGLs in Hp-negative patients could be classified into vari-
ous types histopathologically and should be suspected as gastric cancer. 
Though RSGLs are characterized by the location, RSGLs may be difficult 
to diagnose endoscopically. Therefore, RSGLs should be diagnosed histo-
pathologically, and further examination will be needed for precise endo-
scopic diagnosis of RSGLs.
references: 1. Isono Y, Baba Y, Mukai K, et al. Gastric adenocarcinoma co-
existing with a reddish semipedunculated polyp arising from Helicobacter 
pylori-negative normal gastric mucosa: a report of two cases. Clinical jour-
nal of gastroenterology 2018; 11, 481-486. 2. Muto M, Yao K, Kaise M, et al. 
Magnifying endoscopy simple diagnostic algorithm for early gastric cancer 
(MESDA-G). Digestive endoscopy : official journal of the Japan Gastroen-
terological Endoscopy Society 2016; 28, 379-393.
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P1325 sarcOPenIa Is a rIsk facTOr fOr asPIraTIOn 
PneuMOnIa assOcIaTed WITh esOPhageaL and gasTrIc 
endOscOPIc suBMucOsaL dIssecTIOn (esd) In eLderLy PaTIenTs
Arao M.1, Araki H.2, Ibuka T.3, Shimizu M.1
1Gifu University Hospital, Dept. of Internal Medicine, Gifu, Japan, 2Gifu 
University Hospital, Dept. of Gastroenterology, Gifu, Japan, 3Gifu University 
School of Medicine, Dept. of Gastroenterology, Gifu, Japan
contact e-Mail address: aryao_poor_boy@yahoo.co.jp
Introduction: Endoscopic submucosal dissection (ESD) is a safe and ef-
fective treatment for gastric and esophageal neoplasms even in elderly 
patients. However, this approach involves adverse events, including per-
foration, bleeding, and aspiration pneumonia. Although aging is an in-
dependent risk factor to develop aspiration pneumonia, other risk factors 
for aspiration pneumonia among elderly patients are unclear. Here, we 
aimed to investigate risk factors for aspiration pneumonia among elderly 
patients.
aims & Methods: This was a retrospective observational study conducted 
at a single center, which included 170 patients ≥80 years of age who had 
undergone esophageal or gastric ESD. We compared patients with sarco-
penia (sarcopenia group) with patients without sarcopenia (non-sarcope-
nia group). The presence of sarcopenia and aspiration pneumonia were 
confirmed by computed tomography.
results: The overall incidence of sarcopenia was 42.9%. In the sarcope-
nia group, the incidence of aspiration pneumonia was 21.9% whereas it 
was 9.3% in the non-sarcopenia group (p=0.0212). Body mass index was 
significantly lower in the sarcopenia group than in the non-sarcopenia 
group (20.6±2.9 vs 23.6±3.1, p< 0.001). Procedure time did not significantly 
differ between the two groups (72±54 minutes vs 62±44 minutes, p=0.201) 
nor did the proportion of abnormal respiratory function tests was not 
significantly different between two groups (62.1% vs 63.5%, p=0.87). On 
multivariate analysis, sarcopenia was an independent risk factor for the 
development of aspiration pneumonia (odds ratio=2.61, 95% confidence 
interval 1.07 to 6.37, p=0.0347).
conclusion: Sarcopenia was a risk factor for aspiration pneumonia after 
esophageal or gastric ESD.
disclosure: Nothing to disclose 
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P1326 rOLe Of MuLTIdIscIPLInary TeaM In The ManageMenT 
Of neurOendOcrIne neOPLasIa: a reaL-WOrLd exPerIence
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ENETS Center of Excellence, Pathology, Rome, Italy, 4Sant’Andrea University 
Hospital, ENETS Center of Excellence, Nuclear Medicine, Rome, Italy, 
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Introduction: Neuroendocrine Neolpasia (NENs) are rare and heterog-
enous diseases, in terms of both pathological and clinical features. Their 
prognosis is affected by including primary tumor site, staging, and grad-
ing.Due to the complexity of NENs management, a multidisciplinary ap-
proach is widely advised for an effective care of patients with this un-
common kind of cancer. Multidisciplinary care is strongly encouraged by 
both Neuroendocrine Tumor Society (ENETS and NANETS). Since data on 
multidisciplinary management of patients with NENs in specialized centers 
with dedicated MDT are scanty.
aims & Methods: Aimed to analyze modality of presentation and clinical 
outcome in patients with NENs managed in a center of excellence with 
dedicated MDT. Prospective observational study including all consecutive 
newly patients visited at the Sant’Andrea Hospital site of the Rome EN-
ETS - Center of Excellence between January 2014 and June 2018. All the 
major clinical and pathological data were collected in an electronical ano-
nymized database. All patients were discussed in a NEN multidisciplinary 
team which included clinicians involved in patients’ management
results: A total of 318 patients were evaluated. Of these, 122 patients were 
excluded because referred to the center for a second opinion; since these 
patients no data on their follow-up were available. Thus, the final analysis 
was performed on 196 patients, including with a median age of 59 yr (IQR 
50.5 - 70.5 yr). Of these, 164 patients had GEP NENs (83.7%), and 19 pa-
tients had lung primary NEN (9.7%).At time of initial visit at the center, Ki67 
value was available in 178 patients (90.8%), median value being 3% (IQR 
2 - 9). Overall, 159 patients (81.1%) already had NEN diagnosis at time of 
referral; in these patients, median interval between initial NEN diagnosis 
and time of referral to the center was 4 months (IQR 2 - 12 months). The 
remaining 37 patients (19.9%) were newly diagnosed at the center. A total 
of 64 patients (32.7%) got in touch with the center by using the center’s 
website form, whereas 132 patients (67.3%) booked the first visit by public 
health regional system tools. Overall, 74 patients (37.8%) were referred to 
the center by other hospitals. Median waiting time to obtain the first visit 
in the NEN-dedicated ambulatory was 7 days (IQR 7 - 10 days). After first 
visit, all patients were discussed at the MDT meeting. Additional cross-
sectional radiological examinations or nuclear medicine diagnostic pro-
cedures were requested in 164 patients (83.7%). After these procedures, 
a change in disease staging was performed in 50/164 patients (30.5%). 
After MDT meeting discussion, pathological revision of available histologi-
cal slides was advised in 53 patients (27%), whereas new bioptic sampling 
was advised in 30 patients (15.3%). Overall, a change in clinical manage-
ment was observed in 98 patients (50%) after MDT discussion. Of these, 67 
patients (68.4%) received medical treatment ( somatostatin analogs 37 pts 
37.8%; everolimus 15 pts , 15.3%, systemic chemotherapy 6 pts, 6.1%, pep-
tide receptor radionuclide therapy 4 pts 4%), 9 patients (9.2%) underwent 
surgery, and 19 pts (19.4%) were followed up without medical or surgical 
intervention. The remaining 3 patients were treated by endoscopic resec-
tion (n=2) or liver radiofrequency (n=1).
conclusion: This study reports the features of NEN pts admitted to an Ital-
ian center of Excellence, which mostly had non-functioning tumors, ad-
vanced disease and low Ki67. In those pts referred by other hospital, the 
median interval between initial diagnosis and taking care by the center 
was 4 months.
disclosure: Nothing to disclose 
P1327 endOscOPIc uLTrasOund-guIded angIOTheraPy Of 
gasTrIc varIces WITh cOMBIned cOILs and gLue InjecTIOn: 
an eurOPean sTudy
Privat J.1, Donatelli G.2, Demmak H.1, Keita A.1
1Hopital de Vichy, Endoscopy, Vichy, France, 2Hôpital Privé des Peupliers, 
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France
contact e-Mail address: jocelyn.privat@ch-vichy.fr
Introduction: Gastric varices (GV) represent 20% of patients with portal 
hypertension.
Endoscopic cyanoacrylate injection is recommended in bleeding gastric 
varices.
Nevertheless, it is associated with more than 25% of re-bleeding and se-
rious adverse events, mainly glue embolization. Endoscopic ultrasound 
(EUS)-guided and combined coil and glue injection provide a new alter-
native treatment for bleeding varices.
aims & Methods: This is a retrospective analysis of EUS-guided coil and 
glue injection for gastric varices bleeding from 10/2013 to 03/2019. We 
used linear therapeutic ultrasound endoscopes without fluoroscopic con-
trol. The procedures were performed on general anesthesia and antibio-
prophylaxia. We injected cyanoacrylate combined with Lipiodol after the 
application of one or many coils (5 x 50 mm). A control EUS was done at 
4 weeks. 
The primary outcomes were varices obliteration and the need of reinter-
vention.
results: 33 patients were treated by EUS-guided coil and glue injection, 
26 (78%) for recent bleeding varices and 7 (22%) for primary prophylaxis.
There was 60% of males and the mean age is 61 years (28-84). Technical 
success was achieved in all patients (100%). The mean number of coil 
was 1.2 (1-3 coils) and the mean volume of glue injected was 1.5 mL (0.5-
3 mL). Complete obliteration was confirmed for the 33 patients (100%), 
30 after one session (91%), 2 after 2 sessions and one after 4 sessions. 
Post-procedure pain occured in 3 patients (9%) during 1 to 7 days. No 
symptomatic embolization was observed with a mean follow-up of 436 
days (21-1818).
conclusion: EUS-guided combined coil and glue injection for gastric and 
ectopic varices appears to be a feasible and highly effective technique with 
less re-bleeding and complication than the classic endoscopic glue-only 
injection.
references: EUS-guided treatment of gastric fundal varices with combined 
injection of coils and cyanoacrylate glue. Bhat YM, Weilert F, Fredrick Rt, 
Kane SD, Shah JN, Hamerski CM, Binmoeller KF. Gastronintest Endosc. 2016 
Jun;83(6):1164-72.
disclosure: Nothing to disclose 
P1328 shared angIOgenIc drIvers Of InTesTInaL vascuLar 
dIsOrders
Douglas A.R.1, Smith S.1, Ryan B.2, Breslin N.3, Murphy G.3, Ismail M.S.3, 
Holleran G.2, O’Connor A.4, McNamara D.1,5
1Trinity College Dublin, Clinical Medicine, Dublin, Ireland, 2Adelaide and 
Meath Hospital, Gastroenterology, Dublin, Ireland, 3Tallaght University 
Hospital, Gastroenterology, Dublin, Ireland, 4Tallaght Hospital/Trinity 
College Dublin, Gastroenterology, Dublin, Ireland, 5Tallaght Hospital, 
Gastroenterology, Dublin, Ireland
contact e-Mail address: douglaar@tcd.ie
Introduction: Neovascularisation is common to a variety of GI disorders 
with differing etiologies and presentations. Shared angiogenic factors 
modulated by disease specific elements could be a common denominator 
and represent novel diagnostic and therapeutic targets. As yet, assessment 
of angiogenic factors across common GI vascular disorders has not been 
reported.
aims & Methods: To assess serum levels of angiogenic factors in intestinal 
vascular disorders.
Following ethical approval and informed consent, serum from patients 
with small bowel angiodysplasia (SBA), portal hypertensive gastropathy 
(PHG), gastric antral vascular ectasia (GAVE) and non-bleeding, non-
anaemic controls were collected. Using ELISA, concentrations (ng/ml) of 
Angiopoietin 1 (Ang-1), Angiopoietin 2 (Ang-2) and Vascular Endothelial 
Growth Factor (VEGF) were measured. Results were expressed as a mean 
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and compared between groups using a T-test, p-value of < 0.05 was con-
sidered significant. The relative expression of Ang-1 and Ang-2 was calcu-
lated between groups.
results: To date 44 samples were tested: 10 SBA, 11PHG, 8 GAVE and 15 
Controls. Mean age 60 (range 20-86) years and 20 (45%) were males. 
Controls were significantly younger (49 vs 66yrs) p =0.0005. There was 
no difference in VEGF levels between the groups, 443 ng/ml, 316 ng/ml, 
435 ng/ml V’s 421 ng/ml (p=0.59). SBA, PHG and GAVE Ang-1 levels were 
similar and were significantly lower than controls: 35696 ng/ml, 23111 ng/
ml, 30753 ng/ml, V’s 53115 ng/ml, (p=0.0002, 95%CI 241 to 701). Ang-2 
levels were higher in PHG and GAVE cases: 4298 ng/ml, 4232 ng/ml, V’s 
1899 ng/ml in controls (p=0.01, 95%CI 77.8 to 668) but were similar for SBA 
2803 ng/ml (p=0.4). 
As a result, the ratio of Ang-1/Ang-2 was found to be significantly lower in 
PHG 10 (p=0.002, 95%CI 8.65 to 35.50) and GAVE 10 (p=0.004, 95%CI 7.82 
to 35.28) groups compared to Controls 32 respectively. While SBA Ang-1/2 
ratios were similar to controls 32.
The ratio of Ang-1/Ang-2 did not differ within the control group by age, < 
65 years Ang1/2 ratio 33 V’s >65 years Ang-1/2 ratio 22 (p=0.4). The mean 
age within disease groups was similar SBA 69 (range 53-86); PHG 60 
(range 38-81); GAVE 68 (range 58-85). Age is therefore unlikely to explain 
the discrepancy in Ang-2 levels and resultant Ang-1/Ang-2 ratios between 
the SBA and the other disease groups.
conclusion: Our novel study of intestinal vascular disorders suggests a 
common alteration in Ang-1 levels, a vascular factor associated with vessel 
stabilization and maturation, across a variety of GI vascular disorders. Dif-
ferences in Ang-2 profiles and resultant Ang-1/Ang-2 ratios among vascu-
lar disorders suggest disease-specific modulation and reflects the known 
variability in Ang-2 roles. VEGF appears not to play a significant role in the 
vascular conditions investigated.
disclosure: Nothing to disclose 
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Camarate, Portugal, 2Centro Hospitalar Universitário de Lisboa Central EPE, 
Gastroenterology, Lisboa, Portugal, 3Centro Hospitalar Universitário de 
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Universitário de Lisboa Central EPE, Gastroenterology, Leiria, Portugal, 
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contact e-Mail address: ritaosaraiva@gmail.com
Introduction: Acute necrotizing esophagitis (ANE), also known as “black 
oesophagus”, is a rare condition characterized by circumferential necrosis 
of varying lengths in the oesophagus. 
The aim of this study was to determine the incidence of ANE, its clini-
cal presentation and endoscopic appearance, risk factors and associated 
conditions, related complications, management, short and long-term out-
comes.
aims & Methods: The aim of this study was to determine the incidence 
of ANE, its clinical presentation and endoscopic appearance, risk factors 
and associated conditions, related complications, management, short and 
long-term outcomes.
Retrospective analysis of all upper endoscopies performed over an eight-
year period (2011-2018) in a tertiary care hospital. We considered acute 
necrotizing esophagitis the endoscopic appearance of diffuse or spotty 
dark pigmentation oesophageal mucosa with abrupt transition to normal-
appearing mucosa at gastroesophageal junction in a patient without any 
other cause to explain it and with no previous history of relevant oesopha-
geal disease.
results: Over an eight-year period, there were performed 37 403 upper 
endoscopies and 7103 were done in an urgent setting. Acute necrotizing 
esophagitis was observed in 13 patients and all underwent urgent upper 
endoscopy. Therefore, overall prevalence was 0.03% and in urgent setting 
it was 0.18%. The median age was 67 years-old (±12) and 77% (10/13) were 
male. The main clinical manifestation of AEN was upper gastrointestinal 
bleeding, which occour in 77% (10/13) of the patients. At the time of clinical 
manifestation 85% (11/13) of the patients had severe comorbid conditions 
and it was possible to identify previous hemodynamic instability in 62% 
(8/13). 
In all cases the endoscopy was done within 12 hours of clinical manifes-
tation. Endoscopically besides the black-appearing oesophageal mucosa, 
71% (10/14) had other abnormal endoscopic findings, the most common 
finding was peptic ulcer disease. All patients underwent CT that ruled out 
AEN complications, except for one patient that had mediastinitis, which 
was successfully treated conservatively.
Regarding the treatment, cases were managed with supportive therapy 
and endovenous proton pump inhibitor. Most of the patient were also on 
broad-spectrum antibiotics (77%). 
23% (5/13) of the patients died during the hospital stay and 40% (2/5) of 
them died in the first 24h after clinical manifestation of AEN. None of the 
deaths were related with AEN or its complications. All causes of death 
were related to underlying clinical condition, the most common cause of 
death was sepsis. All the discharged patients had no complications related 
with AEN and were alive in the 2 years follow-up. In all the endoscopically 
re-evaluated patients the condition had completly resolved.
conclusion: AEN is an important cause of upper gastrointestinal bleeding 
in critically ill patients with severe co-morbidities. ANE is an important 
marker of severe disease and increased overall mortality. Even though AEN 
it is not a serious clinical condition per se, its association with high mortal-
ity will largely depend on the underlying critical illness.
disclosure: Nothing to disclose 
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P1330 IndIvIduaL characTerIsTIcs assOcIaTed WITh 
heLIcOBacTer PyLOrI InfecTIOn In The gIsTar sTudy 
POPuLaTIOn In LaTvIa
Razuka-Ebela D.1, Polaka I.2, Parshutin S.2, Santare D.2, Ebela I.1, 
Murillo R.3, Herrero R.3, Tzivian L.1, Park J.Y.3, Leja M.2
1University of Latvia, Faculty of Medicine, Riga, Latvia, 2University of Latvia, 
Institute of Clinical and Preventive Medicine, Riga, Latvia, 3International 
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contact e-Mail address: d.razuka.ebela@gmail.com
Introduction: Prevalence of H. pylori (HP) infection is higher in developing 
countries comparing with developed ones and is linked to lower socio-
economic status. Studies covering the association between HP and indi-
vidual level characteristics other than socioeconomic factors are lacking 
in Europe [1]. To our knowledge, no such studies have been published for 
Northern and Eastern European populations, where several countries have 
a high prevalence of HP infection.
aims & Methods: The aim of the current study was to identify individual 
characteristics associated with HP infection in a high income country with 
high HP prevalence (79%) and gastric cancer incidence (27/100,000) [2,3]. 
1855 participants aged 40-64 years from the “Helicobacter pylori eradica-
tion and pepsinogen testing for prevention of gastric cancer mortality (GI-
STAR) study” in Latvia were included in the analysis [2]. All participants 
were tested for H. pylori IgG antibodies (Eiken Chemical, Japan). Data on 
sociodemographic characteristics (gender, age, income, education, em-
ployment status), diet (consumption of ≥ 400g of fruit/vegetables, ≥ 200g 
dairy, portions of red and white meat daily, frequency of consumption of 
meat products, pickled, smoked, salted, and spicy products, coffee, tea 
(days per week), very hot food/drinks weekly, adding salt to already salted 
food), exercise, smoking (current, former), alcohol consumption, binge-
drinking, and medical history (self-reported history of disease, surgery, 
drug use) were obtained by survey and compared for participants positive 
(HP+) and negative for HP (HP-). A multiple logistic regression model was 
built adjusting for potential confounders (income, age and gender [1]). 
Individual characteristics with p < 0.10 in univariate analysis investigating 
their association with HP+ were included in the final model as follows: 
level of education, smoking, binge-drinking, consumption of ≥200g dairy, 
≥400g of vegetables/fruit daily, very hot food/drinks, pickled products, 
adding salt to food, self-reported history of HP eradication, peptic ulcer, 
thyroid and cardiovascular disease.
results: 1044 (56.3%) participants were HP+. In fully adjusted multiple 
logistic regression HP+ was positively significantly associated with con-
sumption of dairy (OR 1.36; 95% CI 1.10, 1.67), very hot food/drinks weekly 
(OR 1.33; CI 1.04, 1.69), and addition of extra salt to already salted food 
(OR 1.29; CI 1.04, 1.60), current smoking (OR 1.43, CI 1.07, 1.91) and binge-
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drinking (OR 1.34, CI 1.02, 1.75). In addition, HP+ was inversely associated 
with consumption of fruit/vegetables (OR 0.77; CI 0.61, 0.97), self-reported 
history of HP eradication (OR 0.56; CI 0.38, 0.82), peptic ulcer (OR 0.56; CI 
0.38, 0.80), and cardiovascular disease (OR 0.78; CI 0.61, 0.98).
conclusion: We found HP+ to be associated with lifestyle factors, rather 
than socioeconomic indicators. Lifestyle intervention and possibly H. pylori 
eradication may be especially beneficial in this subset of the population 
because those HP+ were also more likely to have other and multiple risk 
factors for the development of gastric cancer (smoking, increased salt, but 
decreased fruit/vegetable intake, history of peptic ulcer disease).
references: 1. Eusebi LH, Zagari R.M, Bazzoli F. Epidemiology of Helico-
bacter pylori Infection. Helicobacter, 2014:19:1-5. 2. Leja M, Park JY, Murillo 
R et al. Multicentric randomised study of Helicobacter pylori eradication 
and pepsinogen testing for prevention of gastric cancer mortality: the GI-
STAR study. BMJ Open. 2017;7(8):e016999. 3. Statistics on Oncology. The 
Centre for Disease Prevention and Control of Latvia. 16.08.2018. Accessed: 
10.04.2019. https://www.spkc.gov.lv/lv/statistika-un-petijumi/statistika/
veselibas-aprupes-statistika1
disclosure: The study was supported by project nr. lzp-2018/1-0135 “Re-
search on implementation of a set of measures for prevention of gastric 
cancer mortality by eradication of H. pylori and timely recognition of pre-
cancerous lesions” of the Latvian Council of Science. 
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P1332 sPanIsh sPecIaLysT care survey On The ManageMenT 
Of h. PyLOrI InfecTIOn: Preferences and decIsIOns
Martín de Argila C.1, Giralt Martínez E.2, Delgado Juárez R.3
1Hospital Universitario Ramón y Cajal, Gastroenterology Department, Madrid, 
Spain, 2Grupo Saned, Research Department, Barcelona, Spain, 3Casen 
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contact e-Mail address: carlosmartindeargila@gmail.com
Introduction: H. pylori (HP) is the most common bacterial infection in the 
world. The increase in bacterial resistance to the antibiotics most used 
against this microorganism significantly conditions the treatment of this 
infection. Recently, the new recommendations of the International and Na-
tional Consensus have proposed different therapeutic strategies to improve 
the eradication.
aims & Methods: To evaluate the preferences and current therapeutic deci-
sions of the Spanish Gastroenterology Specialists in the management of HP 
infection. An online survey was designed to register 21 variables regarding 
demographics, type of practice, continuous education received and prefer-
ences on management. Responses were anonymously codified. Responses 
were weighted by age, years of experience, training received in HP treat-
ment and type of center (public, private) where work.
results: A total of 369 gastroenterologist participated in the study giving 
response to the survey. The study was performed between March and May 
2018. 54% were women and the average age was 39 years (±10.2). 92% of 
responses came from public practices and 44% from private sector, mean-
ing that many participants worked in both. 17.6% worked in populations 
of more than 500,000 inhabitants, 62.1% in populations from 100,001 to 
500,000 inhabitants and 20.3% in populations of less than 100,000 inhab-
itants. 53% have received continuous education program on HP infection 
in the last 12 months. 16% have participated in some research program 
about infection. 75% of the surveyed doctors said that the management 
of the infection is a decision of each doctor, there was no protocol in their 
workplace for the management of the infection. The most common first-
line therapy of choice was non-bismuth quadruple concomitant therapy 
[57%, with clarithromycin, metronidazole, amoxicillin and a proton pump 
inhibitor (PPI)] followed by bismuth quadruple single capsule therapy 
(36%, with a PPI, tetracycline, metronidazole and bismuth), triple therapy 
(5%, with a PPI, clarithromycin and amoxicillin) and other (2%). Triple 
therapy was more used in private practice and by gastroenterologists with 
more than 20 years of professional experience. The factors that most in-
fluenced the decision of the choice of first-line treatment were therapeutic 
efficacy (53%), over prescription limitations in their sanitary environment 
(29%), economic burden (5%), safety (4%), lower risk of side effects (4%), 
patient characteristics (2.4%), possible interactions with other medica-
tions (1.6%) and treatment characteristics that may favor adherence to 
treatment (1.6%).
conclusion: This survey shows how Spanish gastroenterologists have 
adapted rapidly to current HP consensus recommendations, using qua-
druple therapeutic strategies in first line to ensure greater efficacy of treat-
ment against increased bacterial resistance. It draws attention to how the 
management of HP infection is a decision of each doctor, without following 
an established protocol in their workplace.
disclosure: Doctor Martín de Argila states that he has received an eco-
nomic compensation for his collaboration in this article from Laboratorios 
Casen Recordati. The corresponding author, Delgado Juárez, works as a 
medical advisor at Laboratorios Casen-Recordati. The authors state that 
neither the affiliation nor the economic compensation affect the objectivity 
of the study results. This study was funded by Laboratorios CasenRecordati. 
P1333 MOdIfIed 7-day versus sTandard 10-day 
cOncOMITanT TheraPy fOr heLIcOBacTer PyLOrI 
eradIcaTIOn: a randOMIzed cOnTrOLLed TrIaL
Rojsanga W., Chanpiwat K., Bunchorntavakul C.
Rajavithi Hospital, Gastroenterology, Bangkok, Thailand
contact e-Mail address: dr.chalermrat@gmail.com
Introduction: Eradication rates for H. pylori with a standard triple therapy 
have declined globally. A 10-day standard concomitant therapy (SCT) is as-
sociated with slightly higher eradication rates, but with more side effects, 
when compared to that of the triple therapy. More aggressive acid sup-
pression may allow shortening treatment duration without compromising 
eradication rates.
aims & Methods: This study aimed to compare the H. pylori eradication 
rates between a 7-day modified concomitant therapy (MCT) and a 10-day 
SCT.
This open-label, randomized study was conducted at Rajvithi Hospital, 
Bangkok, Thailand during November 2016-2017. Patients with active H. 
pylori infection were included (n=240) and randomized (1:1) into either 
7-day MCT (omeprazole 40 mg BID, amoxicillin 1000 mg BID, clarithromy-
cin 500 mg BID and metronidazole 400 mg TID for 7 days) or 10-day SCT 
(omeprazole 20 mg BID, amoxicillin 1000 mg BID, clarithromycin 500 mg 
BID, and metronidazole 400 mg TID for 10 days). H. pylori eradication was 
evaluated by 14C-urea breath test at 4-6 weeks after the completion of treat-
ment. Eradication rates were analyzed by per-protocol (PP) and intention-
to-treat (ITT) analysis. Side effects and patient compliance were recorded.
results: A total of 120 patients were randomized into each treatment 
group. There was no significant difference in baseline patient characteris-
tics between groups. In ITT analysis, H. pylori eradication rates were 88.3% 
(106/120) and 88.3% (106/120) in the 7-day MCT and 10-day SCT groups, re-
spectively (p>0.99). In PP analysis, H. pylori eradication rates were 94.6% 
(106/112) and 95.5% (106/111) in the 7-day MCT and 10-day SCT groups, 
respectively (p=0.77). Bitter taste was the most common treatment-related 
side effect in both groups (72.3% in the 7-day MCT vs. 66.7% in the 10-
day SCT, p=0.36). Headache (9.8% vs 18.9%, p=0.05) and diarrhea (17% vs 
27.9%, p=0.05) were less commonly reported in the 7-day MCT than in the 
10-day SCT group, respectively.
conclusion: The 7-day MCT was safe and able to achieve similar eradica-
tion rate, as compared with a 10-day SCT. Due to its better tolerability, 
7-day MCT may be a practical alternative first-line treatment option for H. 
pylori eradication.
disclosure: Nothing to disclose 
P1334 cOMParaTIve sTudy Of sequenTIaL versus 
cOncOMITanT nOn-BIsMuTh quadruPLe TheraPy as fIrsT-LIne 
eradIcaTIOn fOr heLIcOBacTer PyLOrI
Pereira F., Azevedo R., Linhares M., Ramos D., Pinto J., Caldeira A., 
Tristan J., Pereira E., Sousa R., Banhudo A.
Hospital Amato Lusitano, Gastroenterology, Castelo Branco, Portugal
contact e-Mail address: pereiraflavio14@gmail.com
Introduction: Helicobacter pylori (Hp) is a major cause of peptic ulcer dis-
ease and gastric malignancies. Hp eradication rate has reduced, in part 
because of increased antibiotic therapy resistance. Recent international 
guidelines have shown preference towards Concomitant non-bismuth 
quadruple therapy as first-line empirical option, instead of sequential 
treatment, when choosing a non-bismuth regimen.
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aims & Methods: We aim to compare the efficacy of the sequential and 
concomitant non-bismuth quadruple therapy as first line empirical antibi-
otic regimens in terms of Hp eradication rate. We conducted a retrospec-
tive study between January/2015 and March/2019 including patients with 
Hp infection. Patients were treated as first-line eradication therapy with 
the Sequential quadruple treatment (comprising 5 days of proton-pump 
inhibitor and amoxicillin, followed by 5 days of proton-pump inhibitor, 
clarithromycin and metronidazole) or the Concomitant non-bismuth qua-
druple therapy (comprising 14 days of proton-pump inhibitor, amoxicillin, 
metronidazole and clarithromycin). Eradication of Hp was confirmed after 
treatment. Eradication rate was calculated for each treatment regimen.
results: 101 patients were included (52,5% female, mean age of 55,4±13,4 
years). Main indications for Hp testing were dyspepsia (33%), peptic ul-
cer disease (31%) and erosive gastritis/bulbitis (27%). The tests more fre-
quently used for diagnosis of Hp infection were histology (56%) and rapid 
urease test (35%). 55 (54,5%) and 46 (45,5%) patients were treated with 
Sequential and Concomitant therapies, respectively. Hp eradication was 
mainly confirmed by stool antigen test (53%), histology (20%) and urea 
breath test (18%). Global eradication rate was 88%. Hp eradication rate 
achieved 89% with Sequential therapy and 87% with Concomitant treat-
ment, with no statistical difference (p>0,05).
conclusion: Global erradication rate with non-bismuth quadruple regi-
mens was good (88%), with no statistical difference between Sequential 
and Concomitant treatments. Therefore, we suggest that both the protocols 
may be used in current clinical practice as first line empirical eradication 
treatment.
disclosure: Nothing to disclose 
P1335 The effIcacy and safeTy Of secOnd-LIne regIMens 
fOr heLIcOBacTer PyLOrI eradIcaTIOn TreaTMenT: a sysTeMIc 
revIeW and neTWOrk MeTa-anaLysIs
Chang Y.-L.1, Tung Y.-C.1, Liou W.-S.1, Su Y.-H.2, Shiu S.-I.3
1Taichung Veterans General Hospital, Pharmacy, Taichung, Taiwan, 
2Taichung Veterans General Hospital, Medical Library, Taichung, Taiwan, 
3Taichung Veterans General Hospital, Department of Internal Medicine, 
Taichung, Taiwan
contact e-Mail address: b9002007@hotmail.com
Introduction: The prevalence of antibiotic resistance varies greatly among 
countries and increases gradually in recent years. Declined first-line Heli-
cobacter pylori (H. pylori) eradication rate becomes a significant healthcare 
burden and challenge for prescribing adequate second-line eradication 
therapy. Secondary antibiotic resistance to clarithromycin, metronidazole, 
and levofloxacin were more than 15% after first-line treatment failure. 
Optimal second-line eradication regimen to achieve best eradication rate 
remain elusive. 
Therefore, we conducted a network meta-analysis to compare the relative 
efficacy of second-line H. pylori eradication among 15 regimens since 2000 
to find the favorable regimens in treatment-experienced patients.
aims & Methods: We reviewed three major bibliographic databases, in-
cluding PubMed, Embase, and Cochrane Central Register of Controlled 
Trials, and enrolled relevant randomized trials and cohort studiesthat 
evaluated second-line H. pylori eradication rate between January 2000 and 
September 2018.We performed network meta-analysis by WinBUGS and 
STATA software and assessed the quality of enrolled articles withRoB 2.0 
tool for randomized trials and ROBINS-I tool for non-randomized studies 
of interventions.
The odds ratio (OR)was calculated for the comparative treatment effects 
between second-line therapieswhen compared to 7-days clarithromycin-
based triple therapy as well as in subgroup analysis.
results: In our study 66 trials with 10582 treatment-experienced partici-
pants were recruited in the network meta-analysis. Among all regimens, 
add-on therapy of probioticsafter and/or duringsecond-line antibiotic 
therapy(OR4.39, 95% CrI1.46-12.80), quinolone-based sequential therapy 
for 10-14 days (OR 3.38, 95% CrI1.29-8.65), quinolone-based quadruple 
therapy for 10-14 days (OR 3.32, 95% CrI1.28-8.47), add-on therapy of pro-
biotics before and/or during second-line antibiotic therapy(OR 3.12, 95% 
CrI 1.01-9.32), and add-on therapy of probiotics during second-line anti-
biotic therapy(OR 3.03, 95% CrI 1.09 - 8.22)had greater efficacy with sta-
tistical significance. Besides regimens with longer duration tend to show 
higher efficacy of eradication compared with regimens with shorter dura-
tion.
conclusion: In our meta-analysis we found add-on therapy of probiotic-
sbefore/during/after second-line antibiotic therapy, quinolone-based se-
quentialtherapy for 10-14 days, and quinolone-based quadrupletherapy for 
10-14 days are superior to the rest of regimens in treatment-experienced 
patients.In addition, extending the duration of regimens achieved higher 
efficacy of eradication rate than those with shorter duration.
disclosure: Nothing to disclose 
P1336 a reaL-LIfe sTudy On BIsMuTh quadruPLe and 
nOn-BIsMuTh quadruPLe TheraPy (10 and 14 days) In The 
eradIcaTIOn Of h. PyLOrI InfecTIOn In PaTIenTs naïve TO 
TreaTMenT
Gravina A.G.1, Zagari R.M.2, Nardone G.3, Federico A.1, Dallio M.1, 
Martorano M.4, Mucherino C.5, Romiti A.2, Avallone L.1, Granata L.1, 
Colacino L.1, Tuccillo C.1, Sgambato D.1, Miranda A.1, Romano L.6, 
Loguercio C.1, Romano M.1
1Division of Hepatogastroenterology, University of Campania ‘Luigi Vanvitelli’, 
Department of Precision Medicine, Naples, Italy, 2University of Bologna, 
Department of Medical and Surgical Sciences, Bologna, Italy, 3’Federico II’ 
University, Division of Gastroenterology, Naples, Italy, 4Immacolata Hospital, 
Gastroenterology and Endoscopy Unit, Sapri, Italy, 5S. Anna-S. Sebastiano 
Hospital, Gastroenterology and Endoscopy Unit, Caserta, Italy, 6Federico II 
University, Surgical Digestive Endoscopy, Department of Clinical Medicine 
and Surgery, Naples, Italy
contact e-Mail address: marco.romano@unicampania.it
Introduction: International guidelines suggest bismuth quadruple (BQ) or 
non bismuth quadruple (i.e. concomitant) (CT) therapy as first line regi-
mens to eradicate H. pylori infection. Choice should be based on knowl-
edge of prevalence of antimicrobial resistance in a particular area, previ-
ous antimicrobial exposure, drug allergy. In areas of high clarithromycin 
(CLA) or dual (i.e. CLA + metronidazole) resistance BQ should be preferred 
because of its higher efficacy compared to CT. We hypothesized that previ-
ous exposure to CLA might be more likely associated to infection with a 
CLA resistant strain.
aims & Methods: In this real life study, therefore, we evaluated the efficacy 
of BQ vs CLA-containing CT (10 or 14 days) in H. pylori infected subjects 
naïve to treatment. Patients who had previously been exposed to CLA were 
given BQ whereas those who had not were given CT. In Italy BQ is only 
possible through the 3-in-1pill formulation for 10 days. Two hundred and 
1 patients (pts) (125F and 76M, mean age 47.3yrs) were treated with BQ 
(esomeprazole (ESO) 40 mg bid, 3-in-1pill formulation 3 tablets qid), 203 
patients received CT (ESO 40 mg bid + CLA 500mg bid + amoxicillin 1gbid 
+ tinidazole 500mg bid) of these 100 pts for 10 days (CT10d) (54F and 46M, 
mean age 46.4 yrs) and 103 (55F and 48M, mean age 48.3 yrs) pts for 14 
days (CT14d). All pts received probiotics during therapy. Diagnosis of H. 
pylori infection was through 13UBT or histology in those pts who underwent 
esophagogastroduodenoscopy. Assessment of eradication was through 
13CUBT at least 1 month after the end of therapy. Incidence of treatment-
related adverse events (TRAEs) was evaluated by a questionnaire at the 
end of therapy. Compliance was considered to be good if at least 80% of 
medications had been taken. Intention-to-treat (ITT) and Per Protocol (PP) 
analysis was performed, 95% confidence intervals (CI) were calculated 
and significance of differences was assessed by Chi square test.
results: Ten pts in BQ group, 6 pts in CT10d group and 3 pts in CT14d 
discontinued therapy because of side effects; 2) ITT and PP eradication 
rates in BQ were 184/201 (91.5%, 95%CI 86.8-95) and 183/191 (95.8%; 85% 
CI 91.9-98.2), respectively; 3) ITT and PP eradication rates in CT10d were 
80/100 (80%; 95% CI 70.8-87.3) and 80/94 (85.1%; 95% CI 76.3-91.6), re-
spectively; ITT and PP eradication rates in CT14d were 99/103 (96.1%; 95% 
CI 90.3-98.9) and 97/100 (97%; 95% CI 91.5-99.4), respectively; 4) BQ vs 
CT10d: p< 0.004 and p< 0.001 (ITT and PP, respectively); BQ vs CT14d: p:ns 
(ITT and PP); CT14d vs CT10d: p< 0.001 and p=0.003 (ITT and PP, respec-
tively); 5)Prevalence of TRAEs was 26.9%, 26%, and 22.3% in BQ, CT10d 
and CT14 d, respectively (p:ns); 6) Treatment discontinuation due to TRAEs 
was 5.5%, 6%, and 2.9% in BQ, CT10d and CT14d, respectively (p:ns).
conclusion: 
1) In an area of high prevalence of CLA and dual resistance BQ and CT14d 
are highly and equally effective in the treatment of H. pylori infection in pts 
naïve to treatment and significantly superior to CT10d; 
2) No significant differences as to compliance or incidence of TRAEs be-
tween treatment was detected; 
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3) Prescribing therapy based on knowledge of previous exposure to CLA 
may represent a winning strategy.
disclosure: Nothing to disclose 
P1337 hIgh IncIdence Ofh. PyLOrI resIsTance In an IrIsh 
cenTre WhIch negaTIveLy IMPacTs TreaTMenT
Douglas A.R.1, Fitzpatrick H.1, Mohd Faudzi F.1, Brennan D.2, 
Omorogbe J.A.3, Smith S.2, Ryan B.4, O Connor A.5, McNamara D.1,6
1Trinity College Dublin, Trinity Academic Gastroenterology Group, Dept of 
Clinical Medicine, Dublin, Ireland, 2Trinity College Dublin, Dept of Clinical 
Medicine, Dublin, Ireland, 3Tallaght University Hospital, Gastroenterology, 
Dublin, Ireland, 4Adelaide and Meath Hospital, Department of 
Gastroenterology, Dublin 24, Ireland, 5AMNCH, Dublin, Ireland, 6Tallaght 
Hospital, Gastroenterology, Dublin, Ireland
contact e-Mail address: douglaar@tcd.ie
Introduction: Helicobacter pylori is a gram-negative bacterium responsible 
for many gastric conditions. Due to increasing antimicrobial resistance, 
eradication rates employing currently available treatment options, have 
significantly declined. Local antimicrobial surveillance is needed to guide 
therapies and improve outcomes.
aims & Methods: To evaluate the prevalence of H. pylori primary, secondary 
and multidrug resistance and the impact on treatment outcome. Following 
ethical approval and informed consent, antral and corpus biopsies were 
prospectively obtained from patients undergoing routine endoscopy who 
required H. pylori testing at Tallaght University Hospital during 2018-2019. 
Culture samples were processed if subjects were CLO positive. Antimi-
crobial susceptibility to seven antibiotics: Metronidazole, Clarithromycin, 
Amoxicillin, Levofloxacin, Rifampicin, Tetracycline, Moxifloxacin was tested 
as standard by Etest strips. The minimum inhibitory concentration (MIC) 
was evaluated and susceptibilities were assigned according to the EUCAST 
clinical breakpoints. Patients were treated with standard eradication re-
gimes and success was determined by C13UBT with a Delta value of < 4.0.
results: 66 patients were recruited, mean age 51 (31-81) years, 19 (56%) 
females. Culture was successful in 33 (50%). 61% (20/32) with no prior 
treatment (PR= primary resistance) and 39% (13/33) (SR= secondary resis-
tance) having failed prior treatment. PR and SR groups were demographi-
cally similar. 
Few individuals were sensitive to all antibiotics; 4/20 (20%) PR vs 1/13 
(8%) SR. 
Primary resistance rates were high; Metronidazole 12/20 (60%), Clarithro-
mycin 9/20 (45%), Amoxicillin 7/20 (35%), Levofloxacin 6/20 (30%), Ri-
fampicin 9/20 (45%), Tetracycline 5/20 (25%), Moxifloxacin 2/20 (10%). 
Unexpectedly, secondary resistance rates were similar; Metronidazole 
11/13 (85%) p=0.1, Clarithromycin 9/13 (69%) p=0.2, Amoxicillin 6/13 (46%) 
p=0.4, Levofloxacin and Tetracycline 4/13 (31%) p=0.6 and p=0.5, Rifampi-
cin 2/13 (15%) p=0.08, Moxifloxacin 3/13 (23%) p=0.3.
Dual resistance to Metronidazole and Clarithromycin was common 52% 
(17/33) and similar in PR and SR groups (9/20 45% and 8/13 62%) p=0.3. 
The multidrug (>3 antibiotics) resistance rate was 48% (16/33) and was 
also similar in PR and SR groups, 45% and 54% respectively.
Overall our eradication rate was disappointing 39% (13/33) and did not 
differ between PR and SR groups; 45% (9/20) and 31% (4/13) (p=0.48). 
Successfully eradicated patients had similar resistance rates to Clarithro-
mycin, Metronidazole and Amoxicillin (46%, 54%, 31%) compared to non-
eradicated patients (60%, 80%, 45%).
conclusion: Primary, secondary, dual and multidrug H. pylori resistance is 
very high in our cohort and has increased significantly from previous pub-
lished Irish data. Unsurprisingly, our high resistance rates were reflected 
in poor overall, first line and second line eradication rates. The very high 
levels of primary resistance account for the lack of difference in the eradi-
cated vs non-eradicated groups. Based on this data novel approaches to 
eradication in Ireland are warranted.
disclosure: Nothing to disclose 
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Introduction: Recently, the eradication rate of Helicobacter pylori (H. pylori) 
infection has been decreasing. We investigated the efficacy of bismuth-
containing quintet therapy compared with moxifloxacin-based sequential 
therapy as a first-line eradication treatment.
aims & Methods: We enrolled 164 patients with H. pylori infection from 
October 2015 to October 2016, and randomly assigned into 2 groups: 
bismuth-containing quintet therapy (BCQT group; rabeprazole 20mg bid, 
amoxicilline 1g bid, metronidazole 500mg bid, moxifloxacin 400mg qd, 
and tripotassium dicitrato bismuth 600mg bid for 7 days) or moxifloxacin-
based sequential therapy (MBST group; rabeprazole 20mg bid and amoxi-
cillin 1g bid for 7 days, followed by rabeprazole 20mg bid, metronidazole 
500mg bid, and moxifloxacin 400mg qd for 7 days). Successful eradication 
was defined as negative for 13C-urea breath test after 4 weeks of treatment.
results: The eradication rates by intention-to-treat analysis were 76/82 
(92.7%, 95% confidence interval [CI] 89.8-95.6%) in the BCQT group and 
70/82 (85.4%, 95% CI 81.5-89.3%) in the MBST group (p = 0.066). The 
eradication rates by per-protocol analysis were 76/79 (96.2%, 95% CI 
94.0-98.4%) in the BCQT group and 70/80 (87.5%, 95% CI 83.8-91.2%) in 
the MBST group (p = 0.043). Compliance was good (100%) in both groups. 
The adverse event rates were lower in the BCQT group (9/79, 11.3%) than 
in the MBST group (12/80, 15.0%) (p = 0.048).
conclusion: The bismuth-containing quintet therapy was more effective 
and safe compared to the moxifloxacin-based sequential therapy as a first-
line eradication treatment of H. pylori infection.
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In a LeBanese naïve POPuLaTIOn
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Introduction: Concomitant therapy and bismuth quadruple therapy are 
both recommended as 1st line treatment regimens for the empiric treat-
ment of Helicobacter pylori, especially after the increased resistance to 
clarithromycin. Our goal is to compare both of the treatment regimens 
among a representative sample of the Lebanese population to eventually 
conclude whether or not one of these therapies has a higher efficacy as a 
1st line treatment regimen. This study also aims to compare the efficacy of 
these regimens when given as 2nd line therapy after crossover.
aims & Methods: It is a randomized, prospective and crossover study, 
started from March 2016 to December 2018. Participants were randomly 
chosen and diagnosed with active Helicobacter pylori through histology. 
None of them had a prior eradication therapy or had a recent exposure to 
antibiotics. Patient were randomized into two equal groups: patients in the 
first group received 10 days of concomitant therapy (Esomeprazole 40mg 
twice a day, Amoxicillin 1g twice a day, Clarithromycin 500mg twice a day 
and Metronidazole 500mg twice a day), while patients in the second group 
received 10 days of bismuth quadruple therapy (Esomeprazole 40mg twice 
daily, and a capsule containing all three components: Bismuth, Tetracy-
cline and Metronidazole) 3 capsules were taken four times a day. Eradica-
tion was evaluated by the 14C urea breath test done 6 weeks after the end 
of antibiotic use. Esomeprazole was also stopped for at least two weeks 
prior to testing. A negative breath test indicated a successful eradication. 
All patients with a positive breath test were switched to the other treat-
ment regimen for 10 days and then re-evaluated for eradication according 
to the same protocol.
732 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
results: The eradication rate was 91.43% in the concomitant group and 
94.25% in the Bismuth group (NS). 14 out the 15 patients who failed eradi-
cation after concomitant treatment as first line, achieved eradication after 
crossover. All 10 patients who failed Bismuth based first line treatment and 
received concomitant second line regimen, had a negative breath test at 
the end of the study.
conclusion: Bismuth quadruple therapy and concomitant therapy are 
equally effective as 1st line treatment regimens for Helicobacter pylori erad-
ication in a naïve Lebanese population. They are also highly and equally 
effective when used as 2nd line after crossover.
disclosure: Nothing to disclose 
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Introduction: After a failed eradication attempt, H. pylori treatment’s ef-
ficacy is compromised due to the selection of resistant strains.
aims & Methods: To evaluate the efficacy by intention-to-treat (ITT) and 
per-protocol (PP) of second-line treatments in Europe. 
A systematic prospective registry of the clinical practice of European gas-
troenterologists regarding H. pylori infection and treatment (27 countries 
and 300 recruiting investigators). An e-CRF was created on AEG-REDCap 
to systematically register all adult patients infected with H. pylori. Variables 
included: Patient’s demographics, previous eradication attempts, pre-
scribed eradication treatment, adverse events (AEs), and outcomes (cure 
rates, compliance, follow up, etc.). Data extraction: All cases with treatment 
failure after just one eradication attempt. Analysis: Cases with an empiric 
treatment were evaluated separately from those with a tailored therapy.
results: Overall, 4,388 second-line patients were included. Culture was 
performed in 9% of the total of cases. Resistance rates (when available) 
were: 63% to clarithromycin, 52% to metronidazole, and 40% to both. In 
total 4,019 were treated empirically: mean age was of 50 years, 64% were 
women and 5% had penicillin allergy. 58% of indications were dyspepsia 
and 17% gastroduodenal ulcer. 13C-UBT was used in 49% of the cases to 
diagnose the infection. Mean efficacy was 77% (by ITT) and 83.5% (by PP). 
7 and 10-days regimens did not reach optimal efficacy except for single-
capsule bismuth quadruple therapy (>90% PP). 14-days regimens with 
double doses esomeprazole reported better results (>90% PP) when qui-
nolones were used in triple regimens and bismuth quadruple therapies. 
After non-bismuth quadruple failure, efficacy was reported higher when 
the triple therapy with moxifloxacin or the bismuth quadruple therapy with 
levofloxacin were used. Over 97% of patients were compliant. AEs were 
reported in 29% of the cases and tolerance was similar among therapies. 
Most frequent second-line use and efficacy per antibiotic combination is 
shown in the table.
Treatment n % use n (ITT) ITT (%) (95% cI) n (PP) PP (%) (95% cI)
Triple-A+L 1,449 36.1 1,349 77 (75-79) 1,271 81 (79-83)
Pylera 510 12.7 466 87 (84-90) 442 91 (88-94)
Quadruple-A+L+B 459 11.4 446 88 (85-91) 421 90 (87-93)
Triple-C+A 414 10.3 358 51 (46-56) 221 79 (74-84)
Quadruple-
M+Tc+B
179 4.5 167 81 (75-87) 158 84 (78-90)
Quadruple-
C+A+M
145 3.6 133 83.5 (77-90) 131 84 (78-90)
Triple-A+Mx 140 3.5 138 88 (83-93) 134 91 (86-96)
Triple-A+M 85 2.1 79 56 (45-67) 73 59 (48-70)
Total 3,966 98.7 3,689 77 (76-78) 3,346 83 (82-8)
ITT - intention to treat, PP - per-protocol, 95%CI - 95% confidence interval, PPI - proton 
pump inhibitor, C - clarithromycin, M - metronidazole, T - tinidazole, A - amoxicillin, L - 
levofloxacin, B - bismuth salts, Tc - tetracycline, Mx - moxifloxacin, N - Total of patients 
receiving an empiric treatment
[Most frequent second-line use and efficacy per antibiotic combination]
conclusion: Second-line triple therapies generally provide low eradication 
rates except when prescribing moxifloxacin for 14 days. Bismuth-contain-
ing quadruple therapies seem to provide higher efficacy, especially the 
combination of bismuth with a PPI, levofloxacin and amoxicillin or single 
capsule bismuth quadruple therapy.
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Introduction: Helicobacter pylori (HP) infection is significantly more fre-
quently diagnosed in patients with diabetes. Patients with type 2 diabetes 
infected with HP showed higher values of estimated Homa insulin resis-
tance factor (HOMA-IR) than those without coexisting infection. Insulin 
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resistance in patients with type 1 diabetes (DMT1) is associated with thick-
ening of the intima media complex thickness complex (IMT), accumulation 
of advanced glycation end products (AGEs) in the skin and progression of 
chronic complications.
aims & Methods: The aim of this study is to assess the relationship be-
tween the incidence of H. pylori infection and the accumulation of AGEs in 
the skin in patients with type 1 diabetes. 
The study included 103 patients with DMT1 meeting the criteria for inclu-
sion. Inclusion criteria were: age > 18 years, caucasian, duration of DMt1 >5 
years. Exclusion criteria: treatment with proton pump inhibitors, H2 block-
ers and bismuth preparations, steroids, non-steroidal anti-inflammatory 
drugs and antibiotics within one month prior to the start of the study, 
pregnancy, and other chronic gastrointestinal diseases. A fast, qualitative, 
one-step test was performed to detect the HP antigen in faecal samples 
(Helicobacter Antigen Test by Hedrex). The content of AGEs in the skin was 
estimated using an AGE Reader device (DiagnOptics). The AF score was 
calculated automatically (the amount of light emitted by the skin to the 
amount of light emitted by the device). 
Anthropometric parameters (height, body weight, BMI, waist and hip 
circumference, WHR index) were analysed. Basic laboratory parameters: 
glycated haemoglobin value (HbA1c), lipid profile, inflammatory marker 
(C-reactive protein) ALT, AST, creatinine and eGFR (MDRD) were also evalu-
ated.
results: HP positive (n=72) and HP negative (n=31) groups did not differ 
in age, sex, duration of diabetes, metabolic control and inflammatory re-
sponse markers. The studied groups differed in the amount of AGEs in 
the skin. This relationship between H Pylori infection and increased AGEs 
content in the skin was confirmed in a multifactor regression model taking 
into account age, sex, DM duration, HbA1c, BMI, LDL cholesterol and the 
presence of hypertension and tobacco use.
conclusion: Increased accumulation of AGEs in the skin in patients with 
DMT1 with coexisting H. pylori infection, may be an indication to pay spe-
cial attention to eradication treatment in this group of patients.
references: -
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Introduction: Helicobacter pylori (HP) infection is well known to contribute 
to the development of gastric cancer (GC). Eradication after endoscopic 
treatment of early GC is recommended to prevent metachronous cancer 
in the remnant stomach. In addition, HP eradication therapy after surgical 
treatment of GC can improve the survival rate of GC patients. In this study, 
we aimed to investigate the rate of HP diagnosis and eradication treatment 
after GC surgery in a tertiary institute in Korea.
aims & Methods: Patients who received surgical treatment after diagnosis 
of GC at Seoul National University Bundang Hospital from 2003 to 2017 
were retrospectively analyzed using Electronic Medical Recording and 
Clinical Data Warehouse (CDW). HP examinations (histology CLO test, and 
urea breath test) before and after surgery, prescription for eradication, and 
follow-up examination results are reviewed in detail.
results: Total 3,734 patients were diagnosed with GC and received surgical 
treatment. 2,272 patients (60.8%) were tested (1,372 patients preopera-
tively; 905 patients after surgery) (Fig.). 1,283 patients (56.5%) were posi-
tive for HP infection. Among HP+ GC patients 354 patients (27.6%) received 
eradication treatment and 89 patients were followed-up loss. 237 of 265 
patients (89.4%) were finally successfully eradicated, but 28 patients were 
failed to eradicate. Among 929 HP+ GC patients who did not receive HP 
treatment 345 showed spontaneous negative conversion during follow-
up tests. 71 patients showed fluctuation of test results without eradication 
(dynamic changes for HP), and 989 patients were persistently negative for 
HP (Fig.).
conclusion: Both diagnostic test and eradication treatment rates in pa-
tients received GC surgery were significantly low, about one-third patients 
were not tested even once, and only about 20% of HP-positive patients 
were successfully eradicated. Considering the high prevalence of GC in Ko-
rea and potential benefits of eradication therapy in GC patients, these low 
rates are disappointing. More attentions and interests of clinicians for GC 
patients with surgery are needed in terms of HP eradication.
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Introduction: Early gastric cancer patients have a good prognosis after 
radical resection. However, there is risk of metachronous gastric neoplasm 
(MGN) if the patients have a gastric remnant after the surgery. The aim of 
this study was to clarify the risk factors for MGN after partial gastrectomy 
for gastric cancer.
aims & Methods: Data of 680 patients who received surgical treatment 
after diagnosis of gastric cancer (GC) at Seoul National University Bundang 
Hospital from 2003 to 2017 were retrospectively analyzed using Electronic 
Medical Recording and Clinical Data Warehouse (CDW). A univariate Cox 
proportional hazards model was used to identify possible covariates as 
significant risk factors for MGN. Then, the variables with p< 0.2 were sub-
jected to multivariate Cox proportional hazards model to identify inde-
pendent contribution. In addition, the variables which were considered to 
be possible risk factors for MGN based on the previous studies were also 
analyzed in multivariate model.
results: Total 680 patients were diagnosed with GC and received surgi-
cal treatment, and 524 patients who received subtotal, proximal, or distal 
gastrectomy for curative purposes were enrolled. Baseline characteristics 
of the patients were shown in Table 1. Among these patients, 11 patients 
(1.6%) were diagnosed as having MGN in the gastric remnant. Clinicopath-
ologic characteristics of MGNs were summarized in Table 2. 6 of 11 (55%) 
were treated by endoscopic resection, and 4 of 11 (36%) were received sur-
gery. Statistical analysis showed that male sex was the only independent 
risk factor (Table). 
variable Patients with Mgn (%) (n=11)
Patients without 
Mgn (%) (n=513) P value
Sex: Female
Male
0 (0%)
11 (100%)
198 (39%)
315 (61%)
*0.01
Family history of GC: No
Yes
6 (55%)
5 (45%)
107 (21%)
406 (79%)
0.06
Smoking status: No
Yes
2 (18%)
9 (82%)
205 (40%)
308 (60%)
0.21
Alcohol drinking: No
Yes
3 (27%)
8 (73%)
168 (33%)
345 (67%)
1.00
Gastric Atrophy:
Absent or mild
Moderate or severe
11 (100%)
0 (0%)
458 (89%)
55 (11%)
0.62
Intestinal Metaplasia: Absent or mild
Moderate or severe
7 (64%)
4 (36%)
412 (80%)
101 (20%)
0.24
HP status: Never
Past
Current
6 (55%)
3 (27%)
2 (18%)
170 (33%)
138 (27%)
205 (40%)
0.25
Type of initial GC: EGC
AGC
8 (73%)
3 (27%)
322 (63%)
191 (37%)
0.75
MGN, metachronous gastric neoplasm; H. pylori, Helicobacter pylori; IM, intestinal 
metaplasia.
*Results were considered statistically significant when p-values were less than 0.05
[Table 1. Clinicopathological characteristics of patients with and without 
MGN.]
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There is a possibility that family history of GC might be also a risk factor for 
MGN, but the probability value was not statistically meaningful (p=0.06) 
mainly because the recurrence number was low.
conclusion: Our data suggested that more intensive surveillance includ-
ing follow-up endoscopy is needed for the remnant stomach in patients 
with these risk factors to detect MGN at its early stage. Further analysis 
in undergoing.
disclosure: Nothing to disclose 
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Introduction: Helicobacter pylori (Hp) infection is widely known as a main 
cause of gastric cancer. In the past, most gastric cancer cases were in-
fected with Hp. Therefore, Hp-negative gastric cancer (HPNGC) cases 
were uncommon, most of which were undifferentiated adenocarcinoma 
(UDA=diffuse-type adenocarcinoma in Lauren classification). Nowadays, 
the rate of Hp infection is decreasing with passing generations in Japan. 
HPNGCs, which were considered rare, are now being reported more often 
including specific histological types of cancers like gastric adenocarcinoma 
of fundic gland type (GAFG) and UDA [1,2]. However, the histological clas-
sification, and the endoscopic and clinicopathological features of HPNGC 
have not been fully described.
aims & Methods: HPNGCs were extracted from 849 lesions of early gas-
tric cancers resected endoscopically from April 2009 to January 2019. The 
samples were classified histologically, and their endoscopic and clinico-
pathological features were analyzed retrospectively.
results: We found 51 cases (55 lesions) of HPNGC (6.5%) which were 
classified into: GAFG, gastric adenocarcinoma of fundic gland mucosal 
type (GAFGM), gastric-phenotype differentiated adenocarcinoma (G-DA), 
gastrointestinal-phenotype differentiated adenocarcinoma (GI-DA), and 
UDA=25/4/6/11/9 lesions, respectively (differentiated adenocarcinoma 
= intestinal-type adenocarcinoma in Lauren classification). GAFG was 
found in 13 males and 12 females with a mean age of 66.6 years (loca-
tion: U/M/L=21/3/1, tumor size:7.4mm, color: white(W)/red(R)=22/12, mac-
roscopic type: elevated/flat or depressed=17/8; invasion depth: mucosa(M)/
submucosa(SM)=7/18). GAFGM was found in 3 males and 1 female with a 
mean age of 51.7 years (location: U/M/L=4/0/0, tumor size: 8.7mm, col-
or: W/R=1/3, macroscopic type: elevated/flat or depressed=4/0, invasion 
depth: M/SM=1/3). G-DA was found in 4 males and 2 females with a mean 
age of 57.8 years (location: U/M/L=3/3/0, tumor size: 6.9mm, color and 
macroscopic type: 5 reddish protruded lesions like a raspberry and 1 whit-
ish flat-elevated lesion). A total of 4 out of 5 raspberry-shaped lesions 
were disappeared by biopsy and their invasion depth could not be mea-
sured. The invasion depth was M in the other 2 cases. GI-DA was found in 6 
males and 5 females with a mean age of 56.8 years (location: U/M/L=3/1/7, 
tumor size: 9.2mm, color: W/R=2/9, macroscopic type: elevated/flat or de-
pressed=6/5, invasion depth: M/SM=11/0). UDA was found in 6 males and 3 
females with a mean age of 54.9 years (location: U/M/L=0/6/3, tumor size: 
7.9mm, color: W/R=8/1, macroscopic type: elevated/flat or depressed=0/9, 
invasion depth: M/SM=9/0). All of UDA were signet-ring cell carcinoma. No 
vascular invasion and relapse-free survival was confirmed in patients with 
cancer of all histological types. Magnifying endoscopy with narrow-band 
imaging (M-NBI) was performed in 51 out of the 55 lesions at maximum 
magnification. Of these, 33 lesions were diagnosed as non-cancer by M-
NBI (33/51; 64.7 %).
conclusion: This study clarified the characteristics of HPNGCs, such as lo-
cation, color, and macroscopic findings differed by their histological type 
as follows: (1) GAFG, GAFGM, and G-DA tended to occur in U/M as red or 
white elevated lesions; (2) UDA tended to occur in M/L as white flat or 
depressed lesions; and (3) GI-DA tended to occur in U/M/L as red elevated 
or depressed lesions. There were many lesions difficult to diagnose as 
cancer by M-NBI. We conclude that understanding the endoscopic and 
clinicopathological features of each histological type may provide more 
precise endoscopic diagnosis of HPNGC.
references: 1. Ueyama H, Yao T, Nakashima Y, et al. Gastric adenocarcinoma 
of fundic gland type (chief cell predominant type): proposal for a new 
entity of gastric adenocarcinoma. Am J Surg Pathol 34: 609 -619, 2010 2. 
Yoshimura D, Yoshimura R, Mizutani T, et al. Clinical and pathological 
characteristics of gastric cancer without Helicobacter pylori infection and 
its background gastric mucosa. Gastroenterology 152: S260-261, 2017
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Noh G.1, Kim N.1,2, Choi Y.1, Kim H.J.3, Yoon H.1, Shin C.M.1, Park Y.S.1, Lee 
D.H.1
1Seoul National University Bundang Hospital, Department of Internal 
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Introduction: Recently we have shown reversibility of atrophic gastritis and 
intestinal metaplasia after Helicobacter pylori eradication up to 10-year fol-
low-up study. Only a few studies have evaluated pepsinogen (PG) change 
after eradication of H. pylori but there was no study regarding this issue in 
patients with gastric cancer (GC) and dysplasia.
aims & Methods: The aim of this study is to evaluate the effect of H. pylori 
eradication on PG in GC and dysplasia patients in comparison to control 
group with a long-term follow-up. From March 2003 to February 2019, we 
prospectively enrolled 368 subjects with GC and dysplasia and 610 subjects 
with non-GC and non-dysplasia as control group. All of GC and dysplasia 
patients were treated by enodoscopic mucosal resection or submucosal 
dissection. H. pylori tests (Giemsa stain, CLOtest and culture) were per-
formed to evaluate HP status. Serum PG levels were measured using a 
Latex-enhanced Turbidimetric Immunoassay (Shima Laboratories, Tokyo, 
Japan) before and after eradication, compared by using linear mixed mod-
el and student’s t-test. The follow-up points were classified as 1-11 months, 
12-23 months, 24-35 months and more than 36 months.
results: Among 368 GC/dysplasia patients, 102 (27.7%) were H. pylori-neg-
ative, 179 (48.6%) were H. pylori-eradicated, and 87 (23.7%) were H. pylori 
non-eradicated/eradication failure. Among 610 control group patients, 373 
(61.1%) were H. pylori-negative, 168 (27.6%) were H. pylori-eradicated, and 
69 (11.3%) were H. pylori non-eradicated/eradication failure. In GC/dyspla-
sia there were not significantly different in PG values in H. pylori-negative 
and H. pylori non-eradicated/eradication failure group at all follow-up 
points compared to those at baseline (Table). 
  Before 1-11 months
p- 
values
12-23 
months
p- 
values
24-35 
months
p- 
values
≥36 
months
p- 
values
control 168 98   65   22   19  
Pg I 75.6 
(3.18)
64.0 
(3.73)
0.006
55.2 
(4.59)
<0.001
44.4 
(7.70)
0.001
49.2 
(8.67)
0.037
Pg II 23.5 
(1.07)
11.7 
(1.34)
<0.001
10.4 
(1.67)
<0.001
8.93 
(2.86)
<0.001
10.8 
(3.12)
0.001
Pg I/II 
ratio
3.94 
(0.16)
5.99 
(0.20)
<0.001
5.38 
(0.25)
<0.001
5.09 
(0.42)
0.106
4.65 
(0.47)
1.000
gc/
dysplasia 179 76   89   51   57  
Pg I 55.7 
(2.65)
41.0 
(3.68)
<0.001
40.3 
(3.56)
0.002
36.8 
(4.55)
0.003
40.8 
(4.53)
0.043
Pg II 20.7 
(0.70)
10.6 
(1.05)
<0.001
9.12 
(0.98)
<0.001
8.75 
(1.29)
<0.001
10.4 
(1.23)
<0.001
Pg I/II 
ratio
2.80 
(0.12)
4.04 
(0.16)
<0.001
4.38 
(0.15)
<0.001
4.59 
(0.19)
<0.001
4.19 
(0.20)
<0.001
[Table. Comparison of gastric cancer and dysplasia with control in 
pepsinogen levels before and after eradication of H. pylori]
In contrast H. pylori-eradicated group of GC/dysplasia mean serum PG I 
(55.7 vs. 41.0, p< 0.001) became significantly lower and mean PG I/II ratio 
(2.80 vs. 4.04, p< 0.001) became higher at 1-11 months after eradication 
compared to those at baseline (Table). This improvement of PG values af-
ter eradication maintained during all follow-up points with no significant 
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differences between H. pylori-eradicated and H. pylori-negative group. 
However, mean serum PG II did not show any change in both of control 
or GC/dysplasia group. Control group showed similar tendency to the GC/
dysplasia (Table). 
Between the control and GC/dysplasia groups significant difference in mean 
serum PG I and mean PG I/II ratio were observed at 1-11 months (PG I: 41.0 
vs. 64.0, p<0.001, PG I/II ratio: 4.04 vs. 5.99, p<0.001) and 12-23 months (PG 
I: 40.3 vs. 55.2, p = 0.01, PG I/II ratio: 4.38 vs. 5.38, p = 0.001) after eradica-
tion. These differences disappeared from ≥ 24 months of follow-up
conclusion: Considering the PG I and PG I/II ratio of GC/dysplasia group 
become similar to those of control group at the long-term follow-up after 
eradication, H. pylori eradication plays an important role in the prevention 
of metachronous cancer/dysplasia development.
disclosure: Nothing to disclose 
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P1346 The PrevaLence Of sMaLL InTesTInaL BacTerIaL 
OvergrOWTh In PaTIenTs WITh hyPerLIPIdeMIa
Kvit K.1, Kharchenko N.2, Chornenka O.3, Dorofeeva U.3
1Danylo Halytsky Lviv National Medical University, Therapy №1 and 
Medical Diagnostics, Lviv, Ukraine, 2Shupyk National Medical Academia of 
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Ukraine, 3Medicover Ukraine, Lviv, Ukraine
contact e-Mail address: akskris@ukr.net
Introduction: Microorganisms which colonize the intestine are capable to 
impact on cholesterol metabolism by affecting the key stages of its syn-
thesis. Excessive microbial growth of anaerobes in the jejunum, which is 
typical for syndrome of bacterial overgrowth (SIBO), leads to its damage, 
with the development of system inflammation, that causes early decon-
jugation of bile acids with the formation of their toxic salts and impaired 
enterohepatic circulation. In this case, induction of hypercholesterolemia 
is possible, especially in individuals with hereditary predisposition.
aims & Methods: The aim of this study was to determine the prevalence 
SIBO in a series of patients with hyperlipidemia and in controls. 30 pa-
tients with hyperlipidemia (14 men and 16 women) average age 33,69±1.73 
years with average BMI 24,4±1.54 were examined in “Medicover Ukraine” 
(Lviv, Ukraine). The diagnostic criteria were: BMI not more that 25, waist 
circumference < 94 cm for male,< 80 cm for female, no significant alco-
hol consumption. 20 control subjects (8 men and 12 omen), an average 
29,9±0.68 years, BMI 24,2±1.21 were matched with main group patients. 
All controls had normal lipid range. Both groups of patients underwent 
biochemical evaluation - lipid profile, C-reactive protein, ALT, AST, GGTP, 
bilirubin, apoB. Ultrasound examination was proved to all patients of both 
groups. with aim to exclude the patients with fatty liver disease as one 
of the reasons of increased lipids level. All subjects were examined by a 
lactulose breath test.
results: The prevalence of SIBO in hyperlipidemia group was 78.9%. Small 
intestinal transit time amounted 100 minutes. Meanwhile, the SIBO occur-
rence in controls was 40% with average time of small intestine transit 140 
minutes. The measurement of SIBO by lactulose test showed the equal re-
sult of the basal dose of hydrogen in both groups. In contrast, the maximal 
dose was particularly higher in patients with hyperlipidemia in compari-
son with control group (94,7±13,69 vs. 36,13±5,4) . There was remarkable 
positive connection between LDL, TG, VLDL and the dose of exhaled hydro-
gen on 120 minute (r=0.6, r= 0.62, r=0.7 respectively) and strong negative 
correlation between HDL and 120 minutes dose (r=-0.74) in main group. 
Surprisingly, CRP did not interrelate with bacterial overgrowth in both 
groups. In contrast, there was strong correlation relationship between AST 
and AST/ALT ratio and SIBO existence.
conclusion: The prevalence of SIBO in patients with hyperlipidemia is pre-
dominantly higher than in patients without lipid metabolism disturbance. 
The hydrogen level is significantly higher in patients with hyperlipidemia 
in comparison with controls. There is an axis between high LDL, VLDL and 
TG level and hydrogen rate in patients with hyperlipidemia.
references: 
1. Adkins c., Rezaie A. Small intestinal bacterial overgrowth and coronary 
artery disease: what is in the cards? Digestive diseases and sciences, 2018, 
63(2) : 271-272 
2. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and 
bile acid receptors in metabolic regulation. Physiol rev., 2009; 89 : 147-191. 
3. Dukowicz A., Lacy B., Levine G. Small intestinal bacterial overgrowth. A 
comprehensive review. Gastroenterol hepatol., 2007, 3(2) : 112-122.
4. Rhodes Jm, Middleton P, Jewell Dp. The lactulose hydrogen breath 
test as a diagnostic test for small-bowel bacterial overgrowth. Scand j 
gastroenterol., 1979; 14 : 333-336.
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Introduction: Although aspirin (ASA) is widely used all over the world to 
prevent cardiovascular diseases, ASA is well known to cause peptic ulcer. 
Proton pump inhibitor (PPI) is also used to prevent ASA induced peptic 
ulcer. However, with the recent development of enteroscopy, it has been 
reported that not only ASA causes small intestinal injury, but also PPI de-
teriorates the injury in human. Establishing the animal model of ASA in-
duced small intestinal injury has been difficult since administration of ASA 
cannot stably induce mucosal injuries in mice. The animal model should 
be established to reveal the mechanisms underlying the deterioration due 
to PPI in order to establish possible treatment.
aims & Methods: Our aims are to establish the mouse model of ASA in-
duced small intestinal injury, to investigate the effect of PPI on gut micro-
biota, and to find the possible treatment using probiotics.
Male C57BL/6JJcl mice were fed with 60% fructose diet for 9 weeks, and 
administered 200mg/kg of ASA 3 hours before sacrifice. To investigate the 
effect of PPI on ASA induced small intestinal injury, 20mg/kg of omepra-
zole was administered intraperitoneally once a day. Bifidobacterium bifi-
dum G9-1 was administered orally (1×109 CFU / head) from 1 week before 
sacrifice until the end. The degree of small intestinal injury was assessed 
using histological score. Akkermansia muciniphila was administered (1×109 
CFU / head) orally for 9 weeks instead of PPI.
results: By feeding high fructose diet, ASA induced small intestinal injury 
was successfully created. On the other hand, no damage was found in the 
mice fed with basal diet. These intestinal damages were exacerbated with 
PPI, whose histological score was higher than that of ASA without PPI 
group. As PPI has been reported to cause gut dysbiosis, we investigated 
gut microbiota in small intestine. Bifidobacterium was decreased by PPI 
administration, and was decreased when mice were fed with high fructose 
diet compared to the mice fed with basal diet. The relative abundance 
of Akkermansia in jejunum dramatically increased from 0.08% to 2.5% 
after the administration of ASA and PPI (p < 0.05), but was significantly 
suppressed from 2.5% to 0.3% after the administration of Bifidobacterium 
bifidum G9-1 with ASA and PPI (p < 0.05). 
Furthermore, when administered ASA and PPI, the thinning of mucus 
layer in jejunum was significantly induced. It was also observed in the 
mice that received an oral administration of Akkermansia muciniphila in-
stead of the administration of PPI. On the other hand, when administered 
Bifidobacterium bifidum G9-1, thinning of mucus layer was ameliorated. 
While the number of goblet cells in jejunum were significantly lower in 
ASA + PPI group than that of vehicle group (p < 0.05), reduction of goblet 
cells was significantly improved with the administration of Bifidobacterium 
bifidum G9-1 (p < 0.05). 
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  vehicle asa asa+PPI asa+PPI+g9-1 akkermansia
Injury - + ++ -  
Thinning of mucin layer -   + - +
[Small intestinal injury and thinnning of mucin layer]
conclusion: These results suggest that gut dysbiosis caused by PPI such 
as increase of Akkermansia and reduction of Bifidobacterium, leads to the 
thinning of mucus layer through the reduction of goblet cells in small in-
testine. That may cause dysfunction of intestinal barrier, which results in 
the susceptibility to ASA induced small intestinal injury.
disclosure: This study was funded by Biofermin Pharmaceutical Co., Ltd. 
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Introduction: Genome wide association studies identified a plethora of risk 
genes for the development of Crohn’s disease (CD) one of which is gluta-
thione peroxidase 4 (GPX4) (1). Its main function is to maintain cellular 
homeostasis by reducing lipid peroxides (LPO) in cellular membranes (2) 
and to prevent cell death. The prime substrate for LPO are polyunsaturated 
fatty acids (PUFA) in cellular membranes. The increasing consumption of 
specific PUFAs, such as AA and DHA, due to an increasing consumption 
of a western style diet was paralleled by a rising incidence of IBD during 
the last decades. However, the impact of increased PUFA uptake on the 
development of CD remains elusive.
aims & Methods: The aim of the study was to analyse the influence of di-
etary lipids in a genetically susceptible host. We crossed Gpx4flox/flox (3) mice 
with Villin-Cre+/- mice to obtain Gpx4flox/wt;Villin-Cre+/- (Gpx4+/-IEC) mice, that 
specifically delete one allele of Gpx4 in the intestinal epithelium. WT and 
Gpx4+/-IEC littermates were fed a western style diet (WD) or a PUFA enriched 
western style diet (PUFA WD) for 3 months. Inflammation was assessed on 
H&E tissue sections. Staining for neutrophils was done with MPO and GR1. 
Microbiota was analysed in fecal samples by 16s amplicon sequencing.
results: Gpx4+/-IEC mice on a PUFA enriched western style diet developed 
small intestinal inflammation while WT littermates were unaffected. The 
inflammation mainly occurred in the jejunum while other parts of the 
small intestine and as well as the colon were not affected. Inflammation 
was characterised by infiltrating neutrophils and mononuclear cells as 
well as the formation of granuloma like lesions. Additionally, increased 
levels of the IL-8 homologue CXCL-1 were found in epithelial cell scrap-
ings of Gpx4+/-IEC mice. The fecal microbiota analysis revealed a decreased 
a-diversity in PUFA WD fed mice as well as a distinct ß diversity when 
compared to WD fed mice. However, we found no differences between WT 
and Gpx4+/-IEC mice.
conclusion: Here we show that PUFAs in a western style diet evoke small 
intestinal inflammation in GPX4 deficient hosts, independent from micro-
biota alterations. We identified these PUFAs as a non toxic dietary compo-
nent that evokes CD like inflammation in the small intestine.
references: 1 L. Jostins et al., Host-microbe interactions have shaped the 
genetic architecture of inflammatory bowel disease. Nature 491, 119-124 
(2012). 2 Dixon et al., Ferroptosis: An Iron-Dependent Form of Nonapop-
totic Cell Death. Cell 149, 1060-1072, (2012) 3 S. E. Yoo et al., Gpx4 ablation 
in adult mice results in a lethal phenotype accompanied by neuronal loss 
in brain. Free radical biology & medicine 52, 1820-1827 (2012).
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Introduction: Genetic variation of Glutathione peroxidase 4 (GPX4) is as-
sociated with the development of Crohn’s disease (CD) (1). GPX4 is an anti-
oxidative acting enzyme particularly reducing lipid peroxides (LPO) within 
biomembranes, and particularly polyunsaturated fatty acids (PUFAs) which 
are prone to oxidation due to their carbon-carbon double bond backbone 
(2). 
PUFAs are essential fatty acids and enriched in a common western style 
diet rich in red meat, eggs and oils. Dietary enrichment of arachidonic 
acid, an ω-6 PUFA, paralleled a rising incidence of inflammatory bowel 
disease (3). How dietary PUFAs affect the development of CD remains cur-
rently unknown.
aims & Methods: In MODE-K cells, a small intestinal epithelial cell line 
(IECs), Gpx4 siRNA silencing was established. Silenced cells were stimu-
lated with palmitic acid, a saturated fatty acid, oleic acid and palmitoleic 
acid, two monounsaturated fatty acids as well as a range of ω-3 and ω-6 
PUFAs (stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, 
arachidonic acid, docosahexaenoic acid), respectively. LPO was measured 
with BODIPY 581/591 C11 by flow cytometry and cytokine production was 
assessed and confirmed by a multiplex ELISA in the supernatant.
results: Gpx4 silencing led to increased levels of LPO, which was further 
aggravated by the stimulation with ω-6 PUFA arachidonic acid and a 
range of ω-3 PUFAs. Stimulation with the same PUFAs led to an increased 
release of IL-6, CXL-1 as well as other pro-inflammatory cytokines and che-
moattractants only in GPX4-deficient IECs. The addition of α-tocopherol, a 
lipophilic reactive-oxygen species scavenger, prevented the formation of 
LPO and the release of cytokines. Interestingly saturated and monounsatu-
rated fatty acids neither induced cytokine production nor aggravated LPO 
in Gpx4-silenced IECs.
conclusion: Our data provides evidence that specific non-toxic dietary lip-
ids, which are enriched in a western-style diet, induce cytokine production 
in GPX4-deficient IECs which is accompanied by increased levels of LPO 
which could be reversed by LPO scavenging.
references: 1. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui 
KY, et al. Host-microbe interactions have shaped the genetic architecture 
of inflammatory bowel disease. Nature. 2012;491(7422):119-24. 2. Ayala A, 
Munoz MF, Arguelles S. Lipid peroxidation: production, metabolism, and 
signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. 
Oxid Med Cell Longev. 2014;2014:360438. 3. Patterson E, Wall R, Fitzgerald 
GF, Ross RP, Stanton C. Health implications of high dietary omega-6 poly-
unsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
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Introduction: Potential probiotic strains protect the intestinal barrier in 
animal models, but human data are lacking. We aimed to study the effect 
of Lactobacillus rhamnosus CNCM I-3690 on intestinal hyperpermeability, 
occurring during public speech (1), and the relation with stress-related 
symptoms and fecal microbiota diversity.
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aims & Methods: Healthy students were randomized to the L. rhamnosus 
fermented milk or placebo (acidified milk) consumed daily (2 x 125g) for 
4 weeks prior to public speech (exam) and 2 more weeks until NSAID-
administration (indomethacine 125mg; positive control). Small intestinal 
permeability was quantified by a 2h lactulose-mannitol ratio (LMR), frac-
tional excretion of mannitol (FEM) and lactulose (FEL) at baseline and after 
the exam. Salivary cortisol was measured with ELISA and the State-Trait 
Anxiety Inventory (STAI) and Perceived Stress Scale (PSS) were completed 
at both visits. Stool samples were collected for 16S sequencing in a subset 
of subjects (n= 76) at both visits. Primary outcome was the change during 
stress vs. baseline of LMR between treatment groups. Mixed models with 
contrasts between groups were applied with correction for multiple test-
ing for secondary endpoints only. Within-group changes were compared 
to nominal alpha 5%.
results: In total, 92 students (55 female, mean age 23±1.9 years) were 
included (46 per group). No differences between groups were found for 
change in LMR (delta=-0.003, 95%CI [-0.01;0.005], p=0.51), FEL or FEM. 
Within-group analyses showed similar LMR and FEL but an increase of 
FEM during exam vs. baseline for placebo but not L. rhamnosus (Table 1). 
LMR and FEL increased in both groups after NSAIDs (all p< 0.001) with a 
trend for an increase in FEM in the placebo (p=0.07) but not L. rhamnosus 
group (p=0.39). Salivary cortisol increased during exam vs. baseline in the 
placebo and L. rhamnosus group with no difference between groups. The 
increase in STAI before the exam vs. baseline was significant in the pla-
cebo and L. rhamnosus groups with a lower increase in L. rhamnosus vs. 
placebo (delta=-4.73, 95%CI [-8.84;-0.62], p=0.02). The increase in PSS 
before the exam vs. baseline was significant in the placebo and not L. 
rhamnosus group with a trend for a lower increase in L. rhamnosus vs. 
placebo (delta=-2, 95%CI [-4.24;0.32], p=0.09). Preliminary analyses of 
the fecal microbiota suggested an increase of the alpha-diversity in the 
L. rhamnosus group vs. placebo group after the exam. No serious adverse 
events occurred.
conclusion: Despite the primary endpoint was not reached, L. rhamno-
sus CNCM I-3690 seems to prevent stress-induced hyperpermeability to 
mannitol, a pathway that differs from NSAID-induced hyperpermeability to 
lactulose. Subjective but not objective stress-markers were reduced sug-
gesting gut-brain mediated effects via the microbiota, for which prelimi-
nary analyses suggested an increase of the alpha-diversity upon consump-
tion of the L. rhamnosus vs placebo.
  Placebo (n= 46)   L. rhamnosus (n= 46)  
variable baseline exam p-value baseline exam p-value
LMR 0.03±0.01 0.03±0.01 0.78 0.03±0.02 0.03±0.01 0.54
FEL (%) 0.10±0.05 0.12±0.07 0.28 0.12±0.05 0.12±0.05 0.76
FEM (%) 9.3±2.5 10.6±3.7 0.02 9.5±3.9 10±4 0.23
Cortisol (ng/ml) 5.8±5.4 13.9±7.1 <0.0001 4.9±3 12.6±6.2 <0.0001
STAI 28.7±6.4 45.2±1.4 <0.0001 29.8±5.7 41.8±1.7 <0.0001
PSS 7.8±4.9 10.3±5.1 0.002 7.9±4.7 8.4±5.4 0.58
[Table 1]
references: (1) Vanuytsel et al., Gut 2014
disclosure: The study was supported by an unrestricted research grant 
from Danone. 
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dysfuncTIOn In dIarrhOea-PrOne IrrITaBLe BOWeL syndrOMe
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1Vall d’Hebron Institut de Recerca, Laboratory of Translational Mucosal 
Immunology, Digestive Diseases Research Unit, Barcelona, Spain, 
2Vall d’Hebron Institut de Recerca, Laboratory of Neuro-Immuno-
Gastroenterology, Digestive Diseases Research Unit, Barcelona, Spain, 
3IRB Lleida, Vascular and Renal Translational Research Group, Lleida, 
Spain, 4Hospital Universitari Vall d’Hebron & Facultat de Medicina, 
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Spain, 5Centro de Investigación Biomédica en Red de Salud Mental 
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Introduction: Irritable bowel syndrome (IBS) is a chronic gastrointestinal 
disorder characterized by recurrent abdominal pain associated with al-
tered bowel motility and high frequency of mental comorbidities such as 
psychological stress, anxiety and depression. IBS remains a chronic debili-
tating disorder with undefined pathophysiological mechanisms for which 
specific biomarkers are lacking. Enhanced humoral immunity has been 
identified in the intestinal mucosa; however, the role of plasma cells has 
not been addressed.
aims & Methods: Our aim is to characterize the antibody-mediated re-
sponse and its association with IBS pathophysiology. Mucosal jejunal bi-
opsies and stool samples were obtained from diarrhoea-IBS (IBS-D; n = 
18) patients meeting Rome III criteria and age-matched healthy volunteers 
(H; n = 18) as the control group. Bowel movements, stool consistency and 
abdominal pain were monitored (10 days prior to biopsy). Psychological 
stress and depression were assessed by validated questionnaires. The 
number and the activation of mucosal plasma cells were determined by 
transmission electron microscopy. Luminal immunoglobulins (Ig) were 
determined in faecal content by ELISA.
results: Mucosal plasma cells were found in the subepithelial area and 
located in proximity to nerve endings. This distance was significantly low-
er in samples from IBS-D compared to H (IBS-D: 1.26 (0.21-4.25); H: 2.13 
(0.26-7.06) micrometers; P< 0.05). Plasma cells showed morphological 
signs of activation such as enlarged cytoplasm and expanded endoplasmic 
reticulum cisterna, features mainly observed in IBS-D. Moreover, while in-
dividual plasma cells were observed scattered in control group, clusters of 
long-lived plasma cells featured the jejunal mucosa of IBS-D. The number 
of plasma cells was higher in IBS-D respect to H (IBS-D: 1,407±257; H: 
336 ± 83.9 plasma cells/mm2, P< 0.05) as previously reported (Gut, 2015) 
and significantly correlated with proximity to nerve endings (r2=-0.63, P< 
0.01). The quantification of Ig in faeces revealed no differences in sIgA, IgM 
and IgE concentration between groups, while IBS-D showed significantly 
higher concentration of total IgG (IBS-D: 11.38 (1.5-45.82); H: 3.68 (0.61-
35.34) ng/mg protein; P< 0.05), IgG2 (IBS-D: 0.71± 0.53; H: 0.40 ± 0.29 ng/
mg protein; P< 0.05) and IgG3 respect to H, the later not reaching statisti-
cal significance (IBS-D: 1.05 (0.28-3.65); H: 0.91 (0.19-1.83) ng/mg protein; 
P=0.08). Both, H and IBS-D groups had equivalent concentration of IgG1 
and IgG4. Notably, luminal IgG positively correlated with abdominal pain 
(r2=0.50; P< 0.05) and distance of plasma cells to nerves negatively cor-
related with psychological stress (r2=-0.55; P< 0.05) and depression (r2=-
0.46; P< 0.05).
conclusion: Mucosal humoral immunity and its interaction with nerves are 
identified as potential factors associated with brain-gut axis dysfunction in 
IBS-D. Studies aimed at determining the underlying mechanisms warrant 
further investigation.
references: Vicario M, González-Castro AM, et al. Increased humoral 
immunity in the jejunum of diarrhoea-predominant irritable bowel syn-
drome associated with clinical manifestations.Gut. 2015 Sep;64(9):1379-88. 
doi: 10.1136/gutjnl-2013-306236. Epub 2014 Sep 10.
disclosure: Nothing to disclose 
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P1352 exPLOrIng IMMune ceLL heTerOgeneITy In POsT 
OPeraTIve ILeus usIng scrna seq reveaLed a PrO resOLvIng 
rOLe fOr MyeLOId ceLLs exPressIng argInase-1
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van Baarle L.1, Pirottin D.2, Marichal T.2, Matteoli G.1
1KU Leuven, Translational Research Center for Gastrointestinal Disorders 
(TARGID), Leuven, Belgium, 2University of Liège, GIGA-Research and 
Department of Functional Sciences, Liège, Belgium
contact e-Mail address: gianluca.matteoli@kuleuven.be
Introduction: Patients undergoing open abdominal surgery often suffer 
from a transient episode of intestinal dysmotility referred to as postop-
erative ileus (POI). Intestinal manipulation (IM) during the surgery evokes 
tissue damage and consequently an inflammatory response leading to 
impaired gastrointestinal (GI) motility. Recently our lab revealed a critical 
role for monocyte-derived macrophages (MΦs) in supporting neuromus-
cular function and restoring intestinal homeostasis after surgical trauma. 
Blocking monocytes recruitment to the muscularis externa (ME) after IM 
increased neutrophil-mediated immunopathology and prolong the clinical 
outcome of POI.
aims & Methods: Despite significant advances in our understanding of Mφ 
regulation and function during intestinal inflammation, the factors and the 
effector molecules responsible for the pro-resolving Mφ-effect remain not 
well defined. To answer these questions, we have employed state of the 
art single cell RNA sequencing (sc-RNA seq) of different subset of intes-
tinal Mφs at the steady state and during the acute and resolution phase 
of POI. 
Wild-type female mice (WT; C57BL/6JOlaHsd) and Csf1rCreERT2/+ Arg1fl/
fl were subjected to IM to induce POI. The severity of POI was evaluated 
by assessing GI transit, and ME inflammation via flow cytometric analysis 
of recruited immune cells. Immune cells infiltrating the muscularis ex-
terna of naïve mice and of mice 1 day and 3 days after IM were analysed 
by sc-RNA seq. Sc-RNA seq was performed on the Chromium Single Cell 
Gene Expression Solution (10x Genomics). Seurat R package was used for 
graph-based clustering and visualizations.’SingleR’ package was used for 
immune cell type annotations. Trajectory analysis was performed with 
Monocle2. Gene set enrichment analysis (GSEA) was done on the average 
expression of the cell clusters using java GSEA Desktop Application.
results: Sc-RNAseq of immune cells from the naive, inflamed and resolv-
ing muscularis revealed a complex immune cell landscape during differ-
ent phases of POI. Resident immune cell populations including muscula-
ris Mφs were seen in naive ME as expected. At day 1 post IM, myeloid cell 
infiltration was apparent including mainly monocytes and neutrophils. At 
day3 post IM, most of the infiltrated myeloid cells seemed to be cleared 
as the inflammation resolves. The heterogeneity between the myeloid 
cell types seen on Day1/Day3 go beyond the current understanding by 
using conventional cell surface marker-based flow cytometry. Trajectory 
analysis revealed possible differentiation trajectory of classical mono-
cytes to give rise to mature Mφs via multiple intermediate phenotypes. 
GSEA analysis showed that PPAR-γ targets are differentially upregulated 
between the cells at the beginning and end of the trajectory hinting at 
a possible role for PPAR-γ in driving the differentiation of monocytes 
towards mature Mφs. During this differentiation, the monocyte derived 
Ly6C low and MHCII low Mφs express the major pro- resolving Mφ fac-
tor Arginase 1. Mice lacking Arginase 1 in myeloid cells failed to recover 
gastrointestinal transit after IM. Hence, the Arg1 expressing myeloid cells 
could be directly responsible for supporting the recovery of gastrointesti-
nal motility after damage.
conclusion: Our study reveals a critical role for monocyte-derived Mφs in 
restoring intestinal homeostasis after surgical trauma. The specific func-
tions of each of these myeloid sub populations has to be further analysed 
to deepen our understanding of the intestinal inflammatory cascade and 
the process of resolution of inflammation which could be key in developing 
novel therapy.
disclosure: Nothing to disclose 
P1353 dIagnOsTIc yIeLd and accuracy Of sMaLL BOWeL 
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1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University 
of Milan, Gastroenterology, Milano, Italy, 2Fondazione IRCCS Ca’ Granda, 
Gastroenterologia ed Endoscopia, Milano, Italy, 3Fondazione IRCCS Ca’ 
Granda Ospedale Maggiore Policlinico di Milano, Gastroenterologia ed 
Endoscopia, Invorio, Italy, 4Fondazione IRCCS Ca’ Granda Ospedale Maggiore 
Policlinico, Gastroenterologia ed Endoscopia, Milano, Italy, 5Fondazione 
IRCCS Ca’ Granda, Center for Prevention and Diagnosis of Celiac Disease, 
Milano, Italy
contact e-Mail address: andreascostantino@gmail.com
Introduction: Video capsule enteroscopy (VCE) is considered the reference 
standard for the assessment of small bowel disorders since it has the high-
est diagnostic yield for the detection of luminal and mucosal alterations. 
There are no studies comparing VCE with small bowel ultrasonography 
(B-US). The aim of this study is to compare the diagnostic yield of VCE and 
B-US in the diagnosis of small bowel disorders.
aims & Methods: The aim of this study is to compare the diagnostic yield of 
VCE and B-US in the diagnosis of small bowel disorders.
We retrospectively enrolled 159 patients undergoing VCE and B-US for 
the following indications: obscure gastrointestinal bleedings, suspect or 
follow-up of known complicated celiac disease, chronic diarrhea or mal-
absorption syndromes. The interval between the two exams had to be infe-
rior to one year. We evaluated the diagnostic yields of the two techniques. 
The accuracy of small bowel ultrasonography was determined using VCE 
as the reference standard.
results: The diagnostic yields calculated in the whole sample were 55% 
for VCE and 33% for B-US (p< 0,05). The subgroups analysis showed that 
VCE ability to detect pathological signs is higher; there was a statistical 
significant difference between the diagnostic performances of the two 
techniques in patients with OGIB (62% vs 14%, p< 0,05) and suspect or 
known complicated celiac diseases (55% vs 35%, p< 0,05), while the dif-
ference was not statistical significative among patients with chronic diar-
rhea and malabsorption syndromes (51% vs 46%, p=0,8).
conclusion: Compared to B-US, VCE is more accurate to detect lesions in 
patients with OGIB and suspect or known complicated celiac disease. B-US 
could have a role in the screening of celiac disease complications, since 
it was able to detect patients with severe complications (RCD II, EATL, ad-
enocarcinoma). 
In patients with chronic diarrhea and malabsorption syndromes, B-US was 
able to detect signs suggestive for enteropathies, especially in patients 
with Chron’s disease.
disclosure: Nothing to disclose 
P1354 cOuLd neuTrOPhIL-TO-LyMPhOcyTe raTIO PredIcT 
uLceraTIve cOLITIs fLare durIng Pregnancy?
El-Sadek H.
Faculty of Medicine, Zagazig University, Gastroenterology & Hepatology Unit, 
Internal Medicine Department, Zagazig, Egypt
contact e-Mail address: hanyelsadek75@yahoo.com
Introduction: Women with ulcerative colitis (UC) in remission, frequently 
suffer from flaring of disease activity during pregnancy. Predicting such 
problem early in pregnancy, would arouse not to decrease the dose or 
number of medications used to maintain remission, and hence UC relapse 
could be avoided. Serum neutrophil-to-lymphocyte ratio (NLR) is a prom-
ising simple marker of systemic inflammation.
aims & Methods: The aim of this study was to assess the value of neutro-
phil to lymphocyte ratio (NLR) in predicting UC flare during pregnancy. In 
this study, clinical and laboratory data of 27 female patients with UC who 
got pregnant while in remission were retrospectively analyzed. Baseline 
serum measurements (early at first trimester) of NLR and other inflam-
matory markers were recorded. Disease activity during pregnancy was as-
sessed using Truelove and Witts criteria.
results: Flare up of UC throughout pregnancy was noticed in ten patients 
(10/27, 37.0%), and was significantly associated with increased mean 
baseline values of platelets count, ESR, CRP and NLR (P=0.035, P=0.014, 
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P=0.006 and P< 0.001, respectively). Using logistic regression analysis, 
baseline NLR was the only independent predictor of UC flare (P=0.002). 
Spearman’s correlation analysis showed significant positive correlation 
between NLR and each of CRP (r =0.418, P=0.030) and ESR (r =0.522, 
P=0.005). The sensitivity and specificity of NLR (90.0% and 88.2%, respec-
tively), at a cut-off level ≥2.85, for prediction of UC flare (area under the 
curve [AUC]=0.915, P< 0.001), are much higher than that of CRP and ESR.
conclusion: The NLR is an effective, simple and readily available biomarker 
for prediction of UC flare during pregnancy.
disclosure: Nothing to disclose 
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Introduction: Current data suggests that the intestinal microbiota is in-
volved in the cardiovascular disease occurrence with the host-microbe in-
teraction regulating metabolic pathways. Microorganisms which colonize 
the intestine are capable to impact on cholesterol metabolism by affecting 
the key stages of its synthesis. Excessive microbial growth of anaerobes in 
the jejunum, which is typical for syndrome of bacterial overgrowth (SIBO), 
leads to its damage, with the development of system inflammation, that 
causes early deconjugation of bile acids with the formation of their toxic 
salts and impaired enterohepatic circulation. In this case, induction of hy-
percholesterolemia is possible, especially in individuals with hereditary 
predisposition.
aims & Methods: The aim to evaluate the SIBO prevalence in patients with 
hyperlipidemia. One more idea was to examine the prevalence of SIBO in 
such patients. 96 patients with hyperlipidemia (average age 43.03±2.67 
and BMI 26.15±0.67) were examined in “Medicover Ukraine”. 47 control 
subjects, an average age 48.25±2.47 and average BMI 24,2±1.21 were 
matched with main group by metabolic characteristics. All control subjects 
had normal lipid range and no history of coronary disease. The average 
waist circumference in main group was 98.6±1.09 cm (in men), 86.3±0.65 
cm (in women), in controls - 91.2±2.1 cm in men, 82.7±1.8 in women. .Both 
groups of patients underwent biochemical evaluation of serum that in-
cluded blood cell count, lipid profile, C-reactive protein, ALT, AST, GGTP, 
bilirubin, apo B, apo A. Determination of microbial composition at the 
level of major microbial phyla was carried out by identification of total 
bacterial DNA, and DNA of Bacteroidetes, Firmicutes and Actinobacteria 
was performed with quantitative real-time PCR (qRT-PCR), using gene-
targeted primers. All subjects were examined by a lactulose breath test 
what is one of the most diagnostically valuable methods for determining 
excessive bacterial growth.
results: The prevalence of SIBO in hyperlipidemia group was 78.9%. 
Meanwhile, the SIBO occurrence in controls was 40%. The composition of 
microbiota was not significantly different between main group and control 
- Bacteroidetes, Firmicutes, Actinobacteria, Firmicutes/Bacteroidetes ratio 
was equal in both groups (p³0,05). Strong negative correlation between 
Bacteroidetes and Firmicutes (r=-0.74), and Bacteroidetes and Firmicutes/
Bacteroidetes index (r=-0.69) was marked in patients of main group. 
Moreover, there was strong positive correlation among Firmicutes and 
CRP (r=0.6) and apo B (r=0.8). Meanwhile, Actinobacteria in patients with 
hyperlipidemia had the negative correlation within total, direct, indirect 
bilirubin (r=-0.52, r=-0.75, r=-0.52 respectively), CRP (r=-0.86) and apo B 
(r=-0.52). BMI strongly correlated with different phyla of bacteria - there 
was negative correlational relationship between BMI and Bacteroidetes 
and Actinobacteria (r=-0.98), and positive association between BMI and 
Firmicutes (r=0.98).
conclusion: The prevalence of SIBO in patients with hyperlipidemia is pre-
dominantly higher than in patients without lipid metabolism disturbance. 
The decreasing of Bacteroidetes leads to Firmicutes increasing on the 
background of hyperlipidemia. The growth of Firmicutes level influences 
on the CRP and apo B level increasing in patients with hyperlipidemia. The 
increasing of Actinobacteria leads to the bilirubin, CRP and apo B level 
decreasing in patients with hyperlipidemia. BMI in patients with hyperlip-
idemia interrelates with gut bacteria.
disclosure: Nothing to disclose 
P1356 cOndITIOned MedIuM derIved frOM BOne MarrOW 
MesenchyMaL sTeM ceLLs WITh InfLaMMaTOry acTIvaTIOn 
reguLaTes InfLaMMaTOry resPOnse TO acuTe radIaTIOn-
Induced InTesTInaL Injury
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Introduction: Bone marrow mesenchymal stem cells (MSCs) have powerful 
anti-inflammatory and imm) could improve the structural and functional 
repair of the small intestine afterunomodulatory properties. Our previous 
experiments have demonstrated that conditioned medium from bone mar-
row MSCs with inflammatory activation (MSC-CMIEC-6(IR) acute radiation-
induced intestinal injury, but its effects on the inflammatory response to 
acute radiation-induced intestinal injury have not been defined.
aims & Methods: To investigate the effects of MSC-CM on the inflamma-
tory response to acute radiation-induced intestinal injury.Eighty Sprague-
Dawley rats (provided by the experimental center of the North Campus of 
Sun Yat-Sen University in China) were randomly divided into four groups 
(n=20/group): control group, irradiation (IR) group, irradiation+MSC-CMIEC-
6(NOR) group (IR+MSC-CMIEC-6(NOR) group) and irradiation+MSC-CMIEC-6(IR) 
group (IR+MSC-CMIEC-6(IR) group), followed by continuous administra-
tion via the tail vein and abdominal cavity. Intestinal tissue and serum 
samples were collected 1, 3, 5, 7 days after radiation for hematoxylin-eosin 
staining and analysis of the concentrations of inflammatory factors via 
ELISA. Mesenteric lymph nodes were collected 3 days after radiation for 
analysis of the percentage of CD4+Foxp3+Treg cells via flow cytometry.
results: Compared with the IR group and IR+MSC-CMIEC-6(NOR) group, the 
intestinal structure (small intestine epithelial villi and crypt) was signifi-
cantly improved and the pro-inflammatory factors such as interleukin-1β, 
interleukin-6 and tumor necrosis factor-α in the small intestine were sig-
nificantly decreased in the IR+MSC-CMIEC-6(IR) group, whereas the level of 
anti-inflammatory factor interleukin-10 was significantly increased. Simi-
larly, the levels of pro-inflammatory factors such as Activin A, interleukin-
1β, interleukin-6 and tumor necrosis factor-α in the serum samples were 
significantly decreased and the level of anti-inflammatory factor IL-10 
was significantly increased. The changes in the levels of inflammatory 
factors were most significant at 3 days after irradiation. The number of 
CD4+Foxp3+ Treg cells in mesenteric lymph nodes in the IR+MSC-CMIEC-
6(IR) group was significantly higher than that in control group and IR+MSC-
CMIEC-6(NOR) group.
conclusion: These results suggest that MSC-CMIEC-6(IR) can regulate the 
balance of pro-inflammatory factors and anti-inflammatory factors, and 
increase the number of CD4+Foxp3+ Treg cells in mesenteric lymph nodes, 
thus inhibiting the inflammatory response at systemic and mucosal levels 
in acute radiation-induced intestinal injury and promoting the repair of 
small intestinal mucosal injury.
disclosure: Nothing to disclose 
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P1357 effecT Of PrOBIOTIc suPPLeMenT In syMPTOMaTIc 
ceLIac dIsease PaTIenTs On LOng-TerM gLuTen-free dIeT; 
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Introduction: A strict gluten-free diet (GFD) is currently the only recom-
mended treatment for celiac disease (CD). Despite apparent compliance 
with the diet, 30-50% of treated patients have gastrointestinal (GI) symp-
toms. We explore the effect of a three-month course probiotic supplement 
on persistent symptoms in patients with CD following a long-term GFD.
aims & Methods: We conducted a prospective, randomized, double-blind, 
placebo-controlled trial. Adult patients were enrolled if they were on a 
GFD for at least two years and were symptomatic at screening according to 
the GI symptom rate score (GSRS). 31 patients were randomized to receive 
probiotic (n=16) or placebo (n=15) for 12 weeks. Patients who answered 
“considerably relieved” or “completely relieved” over the 12 weeks of in-
tervention were defined as responders.
results: Thirty one patients including 16 in probiotic group (with mean 
age= 31±15, 50% female) and 15 in placebo group (with mean age= 
39.5±20, 53.3% female) were enrolled. At the baseline analysis, there 
were no significant differences in the total score and subscales compar-
ing probiotics vs. placebo. After 12 weeks trial, there was statistically 
significant relief in symptoms for diarrhea (46.7% vs. 12.5%, p=0.04) 
and fatigue (40% vs. 6.2, p= 0.03); But there were no significant differ-
ences for abdominal cramp (93.3% Vs. 93.75%, p=0.38), bloating (86.7% 
Vs. 87.5%, p=0.25), fatty diarrhea (93.3% Vs. 87.5%, p=013), gas feel-
ing (93.3% Vs. 81.25%, p=0.38), weight loss (80% Vs. 81.25%, p=0.38), 
heartburn (93.3% Vs. 81.25%, p=0.82), muscle pain (73.3% Vs. 81.25%, 
p=0.96), nausea/vomiting (33.3% vs. 31.2%, p=0.90), and bloody diar-
rhea (6.7% vs. 6.2%, p=0.97), anemia (46.7% Vs. 37.5 %, p=0.72), depres-
sion mood (13.3% Vs 50.0%, p=0.09) and stress (53.3% Vs 81.2%, p=0.12) 
between two groups.
conclusion: This experimental study suggests that probiotic supplement 
may improve specific CD symptoms in a subgroup of treated patients with 
higher symptomatic burden despite adherence to the diet. Further studies 
are require to confirm these findings.
disclosure: no conflict of interest 
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Introduction: Patients with coeliac disease (CD) frequently have mineral 
bone density (MBD) alterations. Implications of this alterations and the 
best way to monitor them are yet to be defined. Our objective was to evalu-
ate the prevalence of MBD alterations at the diagnosis of CD and the as-
sociated risk factors.
aims & Methods: A retrospective study of 96 patients (median age 25 years 
old; 79,6% women) with MBD evaluation at the diagnosis of CD was per-
formed. Patients were divided into three groups: normal MBD (t score > 
-1.0), osteopenia (t score -1.0 to -2.5) and osteoporosis (t score < -2.5). 
Different clinical, serologic and histopathologic data were analyzed. Logis-
tic regression of the variable with statistical significance was performed. 
In patients with MBD alterations and subsequent follow-up, associations 
with MBD normalization were also searched.
results: Osteopenia was present in 53,1% of the patients and osteopo-
rosis in 7,3%. Osteopenia group presented more frequently Marsh score 
>2 when compared with normal MBD group. The osteoporosis group was 
older (p=0,011) and had more frequently Marsh score > 2 in histopatho-
logic analysis (p=0.019) and vitamin D deficiency (p=0.039), when com-
pared with normal MBD group. In logistic regression, Marsh score >2 (OR 
1.4, p=0.005) was statistically significant in the osteopenia group. Age >45 
years old (OR 3,19; p=0,036), male gender (OR 3,51; p=0,027) and Marsh >2 
(OR 2,17; p=0,001) were statistically significant in the osteoporosis group. 
MBD normalization occurred in 25% in subsequent follow-up. Anti-trans-
glutaminase antibody normalization was associated with MBD normaliza-
tion (OR 2,5; p=0.012).
conclusion: MBD is frequently decreased at the time of CD diagnosis. Os-
teoporosis had an association with older age, male gender and marsh 
score >2. Osteopenia presented an association with Marsh >2. In face of 
this evidence, MBD should be performed at the diagnosis of CD, especially 
if the patient presents a Marsh score >2. Normalization of anti-transgluta-
minase antibody is associated with MBD normalization.
disclosure: Nothing to disclose 
P1359 screenIng fOr cOeLIac dIsease In eLderLy PaTIenTs 
PresenTIng WITh IrOn defIcIency anaeMIa
Ayeboa-Sallah B., Adam I., Yusuf A.
East Sussex Healthcare NHS Trust, Gastroenterology, Eastbourne, United 
Kingdom
contact e-Mail address: ben.ayeboa-sallah@nhs.net
Introduction: Iron deficiency anaemia (IDA) is a common indication for 
referral to gastroenterology. Gastrointestinal blood loss from colonic or 
gastric cancers as well as malabsorption in coeliac disease are the main 
causes of IDA in developed countries. Screening for coeliac disease in all 
patients with IDA is recommend by national guidelines1.
aims & Methods: The aim of our study was to assess whether screening 
for coeliac disease is routinely performed for elderly patients with IDA. We 
retrospectively reviewed the electronic health records of all patients ≥65 
years with IDA who underwent colonoscopy at our hospital between 01 
October 2018 and to 31 March 2019. We collected data on demographics, 
cancer findings and tests for coeliac disease, either serology or histology 
of duodenal biopsies.
results: A total of 291 patients with an average age of 74.7 years (range 65 
to 93) were included in our study. There were 19 (6.5%) cases of cancer in 
this cohort. 225 patients (77.3%) had a duodenal biopsy or coeliac serol-
ogy as part of investigation for IDA. Of those screened, five patients (2.2%) 
were tested positive for coeliac disease. There were no cases of cancer and 
coeliac disease in the same patient in this cohort.
conclusion: Coeliac disease remains an important cause of IDA, even in 
the elderly patients. However, we found that over twenty percent of elderly 
patients who presented with IDA at our hospital were not screened for 
coeliac disease, which might potentially lead to unnecessary further inves-
tigations for their IDA.
references: 1. Gut 2011;60:1309e1316
disclosure: Nothing to disclose 
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P1360 cOeLIac dIsease, BuT nOT nOn-cOeLIac WheaT 
sensITIvITy Is sTrOngLy assOcIaTed WITh PsOrIasIs: 
a POPuLaTIOn-Based sTudy Of 3542 randOMLy seLecTed 
suBjecTs
Walker M.M.1, Potter M.2, Talley N.J.3, Koloski N.4, Jones M.P.5, 
Holtmann G.J.6, Keely S.7, Taylor O.8
1University of Newcastle Dept. of Anatomical Pathology, Dept. of Anatomical 
Pathology, Newcastle, Australia, 2Hunter Medical Research Institute, 
University of Newcastle, School of Medicine and Public Health, New Lambton 
Heights, Australia, 3University of Newcastle, Faculty of Health & Medicine, 
Callaghan, Australia, 4University of Newcastle, Newcastle, Australia, 
5Macquarie University Psychology, Psychology, North Ryde, Australia, 
6Princess Alexandra Hospital, Gastroenterology & Hepatology, Brisbane, 
Australia, 7University of Newcastle, New Lambton Heights, Australia, 
8Imperial College London St Mary’s Hospital, London, United Kingdom
contact e-Mail address: marjorie.walker@newcastle.edu.au
Introduction: Patients with psoriasis are at approximately 3-fold increased 
risk of coeliac disease (CD) (1). Psoriasis has also been linked with non-
coeliac gluten or wheat sensitivity (2). Anti-gliadin antibodies (AGA) have 
been shown to correlate with psoriasis severity and those with psoriasis 
and AGA antibodies experience improved symptoms on a gluten free diet 
(3). Our aim was to determine the link between coeliac disease, self-re-
ported non-coeliac wheat sensitivity and psoriasis in a population study.
aims & Methods: A total of 3542 people randomly selected from the Aus-
tralian population returned a survey (the Digestive Health and Wellbeing 
Survey, response rate = 43%) which contained questions on GI symptoms, 
such as heartburn, epigastric burning, pain, swelling and bloating in the 
last 3 months and included a self-reported physician diagnosis of coeliac 
disease and/or psoriasis. Wheat sensitivity was defined as those with GI 
symptoms on wheat ingestion without a formal diagnosis of CD. There was 
minimal response bias. Associations between categorical variables were 
evaluated using Pearson chi-squared test. A total of 3542 people randomly 
selected from the Australian population returned a survey (the Digestive 
Health and Wellbeing Survey, response rate = 43%) which contained ques-
tions on GI symptoms, such as heartburn, epigastric burning, pain, swell-
ing and bloating in the last 3 months and included a self-reported physi-
cian diagnosis of coeliac disease and/or psoriasis. Wheat sensitivity was 
defined as those with GI symptoms on wheat ingestion without a formal 
diagnosis of CD. There was minimal response bias. Associations between 
categorical variables were evaluated using Pearson chi-squared test.
results: The prevalence of psoriasis by self-report was 4.5%. Of those 
with psoriasis 22.5% reported coeliac disease compared to only 4.2% 
who did not have CD (unaffected cohort) (OR 6.5, 95% CI 2.95-13.4). There 
was a significant association between psoriasis, CD and frequent bloating 
(p=0.027). In those with CD and psoriasis, 36% reported bloating on more 
than one day per week compared to only 13% in those with CD only. There 
was no significant association with other GI symptoms. There was no sig-
nificant association between non-coeliac wheat sensitivity and psoriasis 
with 16.0% of patients with wheat sensitivity reporting psoriasis compared 
to 13.4% reporting no psoriasis (p=0.349). There was a significant associa-
tion between having CD, psoriasis and other autoimmune disorders. These 
included rheumatoid arthritis (p=0.004), asthma (p=0.0001) and sclero-
derma (p=0.0001). The prevalence of self-reported wheat sensitivity in this 
cohort was 14.9% (95% CI 13.7-16.2) and CD, 1.2% (95%CI 0.8-1.6) (4).
conclusion: In this cohort, coeliac disease, but not self-reported non-coe-
liac wheat sensitivity, is strongly associated with psoriasis. Those with co-
eliac disease who report bloating are more likely to report psoriasis. Those 
with other autoimmune diseases and psoriasis are more likely to have 
coeliac disease. It may be worthwhile screening such patients by serology 
and asking whether ingesting wheat worsens their symptoms to improve 
diagnosis of coeliac disease in this population.
references: 1. Ungprasert P et al Indian J Dermatol. 2017 62:41-46. 2. Car-
roccio A et al. Gastroenterology. 2015 149:596-603 3. Michaelsson G et al. 
Br J Dermatol. 2000;142:44-51. 4. Potter MDE, et al Am J Gastroenterol. 
2018;113:1036-1044
disclosure: Nothing to disclose 
P1361 duOdenaL BIOPsIes are unnecessary fOr The 
excLusIOn Of cOeLIac dIsease In PaTIenTs WITh a negaTIve 
TransgLuTaMInase (TTg)
Stonelake S.1, Wilkinson J.2, Gulmez S.2, Leung E.1
1Hereford County Hospital, Hereford, United Kingdom, 2Hereford County 
Hospital, General Surgery, Hereford, United Kingdom
contact e-Mail address: jessica.wilkinson6@nhs.net
Introduction: The British society of Gastroenterology guidelines (BSG) rec-
ommend that if coeliac serology (tissue transglutaminase (tTG) antibody 
27 or endomysial antibody) is negative, small-bowel biopsies need not 
be performed unless there are other features which make a diagnosis of 
coeliac disease more likely.
aims & Methods: Patients undergoing oesophagogastroduodenal (OGD) 
endoscopy between November 2018 and March 2019 for iron deficiency 
anaemia were identified. Demographics and investigations for anaemia 
and coeliac disease (Hb, MCV, ferritin, tTG antibodies, endomysial anti-
body, IgA levels) were collected. Electronic clinic letters were opened to 
identify patients who had diarrhoea, making a diagnosis of coeliac disease 
more likely. The OGD report, number of duodenal biopsies and histopa-
thology results were collected. Sensitivity and specificity of tTG levels for 
coeliac disease were calculated.
results: There were 120 patients identified. Mean age was 68 years, male 
to female ratio of 30:90. Mean haemoglobin, MCV and ferritin was 105 
g/l, 81 fl/red cell, and 27 ng/ml respectively. Ninety (75%) patients had tTG 
levels tested. Endomysial antibody and IgA levels were measured in 7 (6%) 
and 71 (59%) patients respectively. The tTG levels and endomysial antibod-
ies were positive in 3 patients. There were no patients with IgA deficiency. 
All 120 patients had duodenal biopsies regardless of the tTG or endomysial 
antibody result. Eighty-seven (97%) of the patients undergoing tTG levels 
had a negative result. Of these, 12 patients had diarrhoea necessitating 
biopsy. No patients with a negative tTG was found to have coeliac disease 
from duodenal biopsy histology. Of the 3 positive tTG and endomysial an-
tibody tests for coeliac disease (3%), two were confirmed with duodenal 
biopsy as coeliac disease and one patient had suboptimal biopsy which 
showed likely coeliac disease. There was a mean of 3 duodenal biopsies 
per patient (range 1-7). In this series tTGA was 100% sensitive and specific 
for coeliac disease. Seventy-five patients (63%) had an inappropriate bi-
opsy according to the BSG guidelines.
conclusion: Small bowel biopsy is not necessary to confirm a negative tTGA 
result in patients with iron deficiency anaemia. There was no increased 
yield of coeliac disease detection in the context of diarrhoea. These results 
support the BSG guidance stating biopsies should be reserved to confirm a 
positive tTG result or where tTG levels have not been performed.
disclosure: Nothing to disclose 
P1362 OccasIOnaL IngesTIOns Of gLuTen are TOLeraTed 
In a grOuP Of PaTIenTs WITh ceLIac dIsease
Elli L.1, Di Lernia L.1, Bascuñán K.2, Orlando S.1, Ferretti F.1, Branchi F.1, 
Lombardo V.3, Scricciolo A.4, Vecchi M.5, Roncoroni L.6, Fabiano S.7, 
Barigelletti G.7, Segato S.5, Bardella M.T.3
1Fondazione IRCCS Ca Granda, Center for Prevention and Diagnosis of Celiac 
Disease, Milano, Italy, 2University of Chile, Department of Nutrition, Faculty 
of Medicine, Santiago, Chile, 3Center for Prevention and Diagnosis of Celiac 
Disease, Milano, Italy, 4Center for the Diagnosis and Prevention of Celiac 
Disease, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Cà Granda 
Ospedale Maggiore Policlinico, Milano, Italy, 5Fondazione IRCCS Ca’ Granda, 
Gastroenterology, Milano, Italy, 6IRCCS Cà Granda Ospedale Policlinico, 
Center Prevention and Diagnosis of Celiac Disease, Milano, Italy, 7Fondazione 
IRCCS Istituto Nazionale dei Tumori, Cancer Registry Unit, Milano, Italy
contact e-Mail address: lucelli@yahoo.com
Introduction: Gluten free diet (GFD) decreases the quality of life of patients 
with celiac disease (CD) who frequently ask to occasionally ingest gluten 
containg food.
aims & Methods: We evaluated CD patients reporting voluntary and oc-
casional transgressions to the GFD. CD patients undergoing annual follow-
up were enrolled and divided in two groups:
i) patients reporting an occasional and voluntary gluten ingestions (GFD-
transgression) and;
ii) patients following a strict GFD (GFD-adherent). 
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Patients underwent clinical examination, blood tests, duodenal biopsy. In 
the GFD-transgression group a capsule enteroscopy, a validated food-fre-
quency questionnaire (FFQ) assessing the frequency and quantity of gluten 
intake and mortality were assessed.
results: 197 patients were included into the study (age 45 ± 16 years, age 
at diagnosis 30 range 6-49 years, 38 females). In patients not adhering to 
the GFD (n=48), mean gluten intake was 185.2 ± 336.9 g/year, duration of 
GFD transgression was 8.6 ± 6.9 years. Most of the patients reported an 
ingestion of gluten per week or per months. Among uncompliant patients, 
23(47%) did not present any histological alteration; Marsh score profile 
was not different among the two groups. 75% of patients did not report 
any gastrointestinal symptoms after gluten ingestion. 23% of patients in 
the GFD-transgression group presented positvie tTG-IgA vs none in the 
GFD-adherent group (n=149). No association was found between gluten 
intake, clinical symptoms and biomarkers. Mortality was not different be-
tween groups and general population.
conclusion: Our results showed that a group of CD patients with a long-
term gluten intake does not show significant clinical symptoms or his-
tological abnormalities, suggesting that a degree of tolerance towards 
gluten consumption can be reached. Although a strict GFD remains the 
only treatment available for CD patients, its tolerance should be accurately 
monitored over time.
disclosure: Nothing to disclose 
P1363 OuTcOMes Of PaTIenTs adMITTed WITh ceLIac dIsease 
dIagnOsed WITh Clostridioides Difficile
Kroner P.T.1, Kesler A.M.2, Corral J.E.3, Lacy B.E.3
1Mayo Clinic, Gastroenterology, Jacksonville, United States, 2Mayo Clinic, 
Jacksonville, United States, 3Mayo Clinic, Gastroenterology and Hepatology, 
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Introduction: Patients with Celiac disease (CD) are at increased risk of in-
fections, as evidenced by increased prevalence of tuberculosis, influenza, 
and sepsis. Alterations in immunity and microbiota can contribute to this 
predisposition. Although the prevalence of Clostridioides difficile (C.Diff) 
continues to increase in the US, there is little data on the association and 
outcomes in patients with CD.
aims & Methods: Therefore, the aim of this study was to assess inpatient 
prevalence, outcomes and resource utilization of patients with CD and 
C.Diff infection in the US in the past decade. 
This was an observational retrospective cohort study using the NIS 2007 
to 2016, the largest publically available inpatient database in the US. All 
patients with CD were included using ICD9-10CM codes. The cohort was 
stratified according to the coexistence of CDiff infection. No patients were 
excluded. The primary outcome was determining the association of CD 
with C.Diff infection. Secondary outcomes were determining the CDiff in-
patient prevalence trend in the CD patients, as well as mortality, morbid-
ity, length of hospital stay (LOS), total hospital charges and costs, which 
were adjusted for inflation using the Consumer Price Index. Multivariate 
regression was used to adjust for age, gender, income in patient zip code, 
Charlson Comorbidity Index, hospital region, location, size and teaching 
status.
results: A total of 337,201 patients with CD were identified, of which 
5,500 had associated C.Diff. Mean age was 55 years and 71% were fe-
male. The inpatient prevalence of C.Diff in patients with CD increased from 
0.9/100,000 admissions in 2007 to 1.65/100,000 admissions in 2016. After 
adjusting for confounders, patients with CD displayed increased adjusted 
odds (aOR:1.56, p< 0.01) of having coexisting C.Diff compared to patients 
without CD. In addition, patients with CD had lower odds of mortality, ICU, 
shock, multiorgan failure, but increased odds of requiring TPN. Patients 
with CD also had lower adjusted mean hospital costs, charges, and LOS 
than the general admitted population with C.Diff. All outcomes are dis-
played in tables 1 and 2.
conclusion: Patients with Celiac Disease had higher odds of C.Diff com-
pared to non-CD patients, which could be attributed to CD-related gut mu-
cosal integrity, immunological or microbiome alterations. The inpatient 
prevalence of C.Diff in patients with CD increased from 2007 to 2016. This 
may be a reflection of the general increase of C.Diff cases in the inpatient 
population coupled with improved CD diagnostic modalities. Overall, pa-
tients with CD and C.Diff infection did show decreased morbidity/mortality 
and resource utilization, suggesting that the clinical course is less severe. 
Further studies should continue to assess the gut immunological and mi-
crobiome changes in CD to further clarify potential factors associated with 
increased C.Diff infections.
disclosure: Nothing to disclose 
variable adjusted Odds ratios / adjusted Means 95% cI p-value
C.Diff 1.56 1.46-1.67 <0.01
Mortality 0.44 0.30-0.65 <0.01
ICU 0.47 0.35-0.62 <0.01
Shock 0.65 0.49-0.85 <0.01
Multiorgan failure 0.83 0.71-0.97 0.02
TPN 1.69 1.32-2.18 <0.01
Additional Hospital Costs -$6,261 -8632,-3890 <0.01
Additional Hospital Charges -$24,995 -32572,-17417 <0.01
Additional Length of Stay -2.0 -2.8,-1.2 <0.01
[Adjusted means and odds ratio for the evaluated parameters comparing 
patients with CD compared to patients without CD. a=adjusted.]
P1364 The MILanO quesTIOnnaIre: a neW dIeTary 
scOre fOr evaLuaTIOn Of cOMPLIance TO gLuTen free 
dIeT In PaTIenTs WITh ceLIac dIsease
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Granda, Center for Prevention and Diagnosis of Celiac Disease, Milan, Italy, 
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Introduction: Gluten free diet is the only recognized treatment for patients 
with celiac disease. Follow up for these patients is not standardized and 
the adherence to gluten free diet is not always easy to monitor.
aims & Methods: We aimed to develop a novel questionnaire to monitor 
adherence to gluten free diet
in celiac disease. 
The ‘Milano’ questionnaire is composed of 9 items: 6 questions are based 
on a visual analogue scale (VAS, obtaining continuous variables) and 3 of 
them are yes/no questions. Questions have been expressly formulated in 
order to investigate factors strictly connected with adherence to gluten free 
diet (GFD). In particular: voluntary gluten assumption, accidental gluten 
assumption (i.e. possibility of contaminations) and attention paid on the 
control of nutritional labels of GF products.
Two questions evaluate the presence and severity of symptoms experi-
enced in case of accidental or voluntary gluten assumption. The question-
naire was compared to tTGA titres and duodenal histology.
results: The Milano questionnaire was administered to 285 patients (209 
females and 76 males). We observed a significant correlation between the 
score obtained and serological status of the patients. In particular lower 
scores obtained were associated with higher probability of positivity to 
tTGA, suggesting a score of 30 as a cut off value. In particular, among 
the questionnaire items, 3 of them resulted significantly different between 
the groups based on tTGA positivity: question number 1 about general at-
tention to GFD, question number 2 concerning the frequency of voluntary 
assumption of gluten and question number 7 about the eventual check 
of nutritional labels of products. We also observed a positive correlation 
between a score minor than 30 and the grade of villous atrophy at biopsy 
obtained during GFD.
conclusion: This study shows that a new dietary questionnaire, the Milano 
questionnaire, is an useful tool to evaluate compliance to the GFD of celiac 
patients during clinical follow up.
disclosure: Nothing to disclose 
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P1365 WIThdraWn
P1366 ceLIac hePaTITIs: Is There a reLaTIOnshIP WITh ceLIac 
dIsease nuTrITIOnaL defIcIencIes?
Costa-Moreira P.1, Peixoto A.2, Santos A.L.2, Dias E.3, Silva J.4, 
Macedo G.4
1Centro Hospitalar e Universitário São João, Gastroenterology, Porto, 
Portugal, 2Centro Hospitalar de São João, Department of Gastroenterology, 
Porto, Portugal, 3Centro Hospitalar e Universitário São João, Porto, Portugal, 
4Centro Hospitalar e Universitário São João, Gastroenterology, Porto, Portugal
contact e-Mail address: pedromoreira.med@gmail.com
Introduction: Celiac hepatitis characterized by gluten-responsive mild el-
evation of transaminases is the more common liver manifestation of celiac 
disease (CD). It has been assumed that celiac hepatitis is related with the 
disruption of the “gut-liver axis”. In the same way, a nutritional deficiency 
in CD is an indirect marker of intestinal absorptive function damage, as 
well as a possible precipitant of the systemic inflammatory cascade.
aims & Methods: We aimed to study the relationship between nutritional 
deficiencies and the presence of abnormal liver function tests at the time 
of CD diagnosis. 
A retrospective analysis of a CD cohort followed in a specialized outpatient 
clinic was performed. For each case, clinical and laboratory data at the 
time of diagnosis was collected. Within laboratory values, ferritin, folic 
acid, calcium, magnesium, phosphorus and vitamins A, B12, D and E were 
recorded. The correlation between continuous variables was established 
by Spearman’s correlation; statistical differences between medians was 
assessed with the Mann-Whitney U test.
results: We included 161 cases (mean age 35.5 ± 13.9 years old, 78.3% 
female) with an average follow-up of 10.6 ± 9.7 years. At diagnosis, 14.9% 
(n=24) of the patients had abnormal liver tests compatible with celiac 
hepatitis [median ALT 54 (IQR 41-62) IU/L; median AST 43 (IQR 39-53) IU/L; 
median GGT 15 (IQR 10-26) IU / L; median FA 99 (72-127) IU/L; median total 
bilirubin 0.55 (IQR 0.42-1.73) mg/dL]. 
At the time of CD diagnosis, the value of ALT showed a significant correla-
tion with the value of anti-transglutaminase immunoglobulin A (TTG-IgA) 
(k=0.23; p=0.02). 
Using regression analysis, the presence of abnormal liver tests was as-
sociated with iron-deficiency anemia (OR 3.12; CI95% 1.31-8.24, p=0.04). 
The median value of ALT was significantly higher in the presence of folic 
acid deficiency (median 34 (IQR 20-39) vs.18 (IQR 14-29), p=0.02] and vita-
min D deficiency [median 21 (IQR 16-37) vs.16 (IQR 14-25), p=0.02]
conclusion: We found a statistically significant relationship between the 
presence of celiac hepatitis and iron deficiency anemia. Also, the serum 
value of ALT was significantly increased in folic acid and vitamin D defi-
ciency. Gut dysfunction leading to an increased intestinal permeability and 
consequent liver tissue exposure to endotoxins may explain the previously 
mentionted relationship
disclosure: Nothing to disclose 
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P1367 PrOgnOsTIc facTOrs On BOdy WeIghT LOss By an 
InTragasTrIc BaLLOOn TheraPy
Ohta H.
Sapporo Orthopedics and Cardiovascular Hospital, Gastroenterology, 
Sapporo, Japan
contact e-Mail address: hideohta@true.ocn.ne.jp
Introduction: Intra-gastric balloon therapy (IGBT) is a non-invasive modal-
ity of the bariatric therapy and can reduce 10 to 14 % of total body weight 
(TBW) before the therapy [1]. FDA recommends that doctors should indwell 
the balloon during only 6 months in stomach and then excrete it after 
therapy. If we can estimate the effect of bariatric balloon therapy before 
the therapy, it is clinically very useful.
aims & Methods: Our aim is to clarify the key factors which can maximize 
the body weight loss by IGBT. We analyzed the correlation between TBWL 
(TBW loss) and BMI, visceral and subcutaneous fat amount, leptin, insu-
lin in sera, liver dysfunction, metabolic complications and its drugs, gut 
microbiomes before therapy in our clinical trial [UMIN 0008675] which 
enrolled 25 patients with obesity. On analyzing, we took some biases (sex, 
age) into account. In multivariable logistic regression analysis, TBWL (1: 
≥10%, 0:< 10%) was assigned for independent variables and afore-men-
tioned factors were assigned for dependent variables.
results: 
1) Visceral fat amount was closely correlated with TBWL (correlation coef-
ficient: 0.76). On the other hand, subcutaneous obesity group and high 
BMI>40 group could not reduce TBW over 5%. 
2) Obese patients complicated with diabetes realized nearly 14~18% TBWL 
after 6 months therapy if their primary diabetes were regulated very well. 
3) The patients with hyperleptinemia could reduce only 4.3% of TBW be-
fore therapy. 
4) Patients with NAFLD could reduce 13.2% of TBW and improve the liver 
function adequately by IGBT. 
5) HR was higher in visceral fat, complication and drug, anti-obesity mi-
crobiota.
conclusion: Visceral fat amount and metabolic complication have possibil-
ity of becoming better prognostic factors in bariatric balloon therapy.
references: [1] Abu Dayyeh et al. “Endoscopic bariatric therapies” Gastro-
intest. Endosc. 2015, No.5, 1073-86
disclosure: Nothing to disclose 
P1368 hePaTIc sTeaTOsIs and LIver fIBrOsIs effecTs afTer 
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Introduction: Obesity and hepatic steatosis are major diseases with high 
morbidity. Treatment for patients (px) with hepatic steatosis (HS) with or 
without liver fibrosis is weight loss. Intragastric balloon is the endoscopic 
gold standard on short time weight loss. Endoscopic plicature can offer 
better middle long-term results than balloon for its durability. Liver stiff-
ness (LS) and hepatic steatosis (HS) can be estimated with transient elas-
tography (TE) and controlled attenuation parameter (CAP).
aims & Methods: Multi-center, prospective pilot study intended to evaluate 
the safety and efficacy of the Gastric Endoscopic Sleeve Plication procedure 
(mid & distal body plications) (GESP) and its effect on hepatic fibrosis and 
steatosis.
Study was approved by ethic committee at both institutions. Px signed a 
written consent. Px with grade I-II obesity were included for the proce-
dure. Use of the Incisionless Operating Platform (IOP)TM (USGI Medical, 
San Clemente, CA, USA) with a defined new pattern of disposition of the 
transmural plications with the g-cathTM EZ suture anchors in the greater 
curvature shortening and tubulizing the stomach to potentially delay gas-
tric emptying and reduce gastric volume/accommodation for an enhanced 
physiological effect. 
LS and CAP was measured with Fibroscan® device provided with M or XL 
probe (Echosens, France) by experienced personnel. Quality criteria for LS 
by TE were: 10 measurements obtained with a success rate ≥ 60% and a 
IQR≤30% of the median. Blood test was evaluated at baseline (BL) and 6 
months post-GESP.
results: 39 px were included in these multicenter-trial. 17 pxs (44%) from 
Centro Medico Teknon (CMT) were analyzed. 17 GESP in 17 pxs were suc-
cessfully performed in CMT (59% females) without serious adverse events. 
LS+CAP was successful in all px (82% with XL probe). 
Preliminary data on LS+CAP was obtained in 16 px (94%) at 2 months and 
in 7 px (42%) at 6 months. Body weight loss at 2 (n=14) and 6 months (n=8) 
was 14±4% (13.1±4.2 kg) and 19±11% (15.8±7.2 kg). 
At BL, 11 px had absent/mild fibrosis (F0-F1), 4 px had significative fibrosis 
(F2), 1 px had severe fibrosis (F3) and 1 px cirrhosis (F4), with a mean LS of 
4.1±0.9, 8.2±0.4, 9 and 12.3 kPa, respectively; HS S0, S1, S2, S3 was present 
in 4, 2, 3 and 8 px, with a mean CAP of 205±19, 248±5, 285±8 and 342±21, 
respectively.
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At 2 months, 3 px (19%) with BL F2 (mean LS 8±0.4 kPa) had a statistically 
significant improvement of LS (mean LS 6.6±0.2, p=0.007). In regard to 
HS, 50% (n=8) of px had a reduction of HS in 2 stages and 19% (n=3) in 1 
stage; 4 S0 at BL and 1 (6%) S3 at BL had no variation. A total of 5 px (31%) 
with BL HS (3 S2 and 2 S1) achieved S0. The only px with BL cirrhosis had 
a mild improvement of LS (12.3 vs 11.3 kPa) with an associated reduction in 
2 stages of HS (S3 to S1); unfortunately, we still not have data on 6 months 
evaluation of this patient.
At 6 months, all 7 px had BL FO-F1 and showed a significant reduction in 
HS (303±47 vs 221±24, p=0.001) along with lower ALT levels (34±20 vs 17±4 
IU/L, p=0.46) and elevation of HDL cholesterol (53±15 vs 60±19, p=0.036). 
LS, hemoglobin, platelets, creatine, total and LDL cholesterol, triglycerides, 
AST and total bilirubin were no significant different.
conclusion: Preliminary results with reduction of weight loss with GESP 
procedure are promising for treatment of hepatic fibrosis and steatosis in 
patients with grade I-II obesity. Long term follow-up its necessary to assess 
its value for treatment of HS and LS.
disclosure: Nothing to disclose 
P1369 BrazILIan MuLTIcenTer sTudy Of endOscOPIc sLeeve 
gasTrOPLasTy WITh OversTITch use - InITIaL resuLTs
Sander B.1, Santos Paiva D.1, Sander M.1, Scarparo J.2, Matz F.3, Ramos F.3, 
Alberti L.4
1Sander Medical Center, Bariatric Endoscopy, Belo Horizonte, Brazil, 
2Scarparo Scopia, Bariatric Endoscopy, São Paulo, Brazil, 3EndoDiagnostic, 
Bariatric Endoscopy, Rio de Janeiro, Brazil, 4Universidade Federal de Minas 
Gerais, Surgery, Belo Horizonte, Brazil
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Introduction: With the current picture of obesity pandemic, the Endoscopic 
Sleeve Gastroplasty technique (ESG) has become an important tool as an 
option for treatment¹. The therapeutic success rates described in literature 
vary from 50% to 100%, with little or no complication during or after the 
procedure, without cases of mortality, as well. This study was developed to 
analyze the results obtained by the respective technique in different treat-
ment centers for obesity.
aims & Methods: Three treatment centers for obesity from the main capi-
tals of Brazil participated in this study. All patients were instructed on the 
ethical aspects of the research, and were followed for eighteen months 
after the procedure by a multidisciplinary team. Since July 2017, a total 
of 126 patients (109 submitted to full-thickness U-shaped sutures = SU; 17 
submitted to full-thickness U-shaped sutures + Reinforcement = SUR) were 
randomly assigned to the study. Among the seventeen patients in the SUR 
group, only eight reached six months of follow-up.
results: The sample profile consists of young adults with a mean age of 
41.3 ± 10.5 years, being most of them women (63.5%). Initially, the patients 
presented mean weight: 97.4 ± 20.6 kg and mean BMI: 34.3 ± 4.9 kg / m. 
There was a significant* mean decrease of weight (6 months: 10.3± 5.1 
kg, 12 months: 17.5± 8.6 kg, 18 months: 23.1± 8.2 kg) and BMI (6 months: 
3.6±1.6 kg / m, 12 months: 6.5±2.6 kg / m; 18 months: 7.9±2.4 kg / m). 
The results observed for the TBWL % (Total Body Weight Loss percentage) 
parameters were: 6 months = 10.3 ± 3.9; 12 months = 16.6 ± 6.2; 18 months 
= 21.3 ± 5.1. And the mean EWL % (Excessive Weight Loss percentage) 
was 41.8 ± 21.2, 64.1 ± 29.3 and 73.3 ± 27.6 at 6 months, 12 months and 18 
months respectively. 
Patients submitted to SUR presented superior results in EWL % (when 
compared to patients submitted to SU in 6 months of follow-up: SU = 38.1 
± 19.6, SS = 43.9 ± 15.9. A mean of 62.5 ± 6.1 and 89.2 ± 4.9 bites per suture 
was observed, with a mean of 4.6 ± 0.5 and 7.2 ± 0.5 threads respectively 
for SU and SUR suture. There was no case of complication during or after 
the procedure. 
* Parametric t test; p < 0.05
conclusion: The results described in this sample confirm the data pointed 
out in the literature¹, ², ESG is a safe procedure and with high rates of 
therapeutic success. The results also showed that SUR procedures clinically 
imply double the rates of long-term therapeutic success. In this sample, 
100% of patients submitted to SUR at 06 months had lost almost 45% 
of excess weight and no weight regain was observed in this group. We 
believe that these findings may be due to the mechanical response of SUR, 
as it promotes an even greater reduction of the lumen of the gastric tube, 
inducing with more intensity and for a longer time the delay of the gastric 
emptying and increasing the satiety. 
It is important to emphasize that the high success rates described in this 
study are a direct consequence of a precise and adjusted interaction of the 
multidisciplinary support team. The data presented in this study are part 
of a larger ongoing study.
references: 1. Jain D et al. Endoscopic Sleeve Gastroplasty - A New Tool 
to Manage Obesity. Clin Endosc. 2017 Nov; 50(6): 552-561. 2. Bazerbachi 
F, Vargas Valls EJ, Abu Dayyeh BK. Recent clinical results of endoscopic 
bariatric therapies as an obesity intervention. Clin Endosc 2017;50:42-50. 
3. Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a 
potential endoscopic alternative to surgical sleeve gastrectomy for treat-
ment of obesity. Gastrointest Endosc 2013;78:530-5.
disclosure: Nothing to disclose 
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anasTOMOsIs decrease - InITIaL resuLTs - BrazILIan 
MuLTIcenTer sTudy
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Alberti L.4
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Introduction: Weight regain has been a constant concern, as reports in 
literature indicate that rates can reach up to 50%, especially in patients 
who have undergone bariatric surgery. However, it is not yet clear how 
weight regain occurs because it is a variable that undergoes various intrin-
sic and extrinsic interferences of the individual. The technique to reduce 
the anastomotic size has been successfully developed around the world. 
Thus, this paper aims to describe the initial results of a long-term clinical 
study in Brazil.
aims & Methods: Three treatment centers for obesity from the main Brazil-
ian capitals participated in this study. All patients were instructed on the 
ethical aspects of the research, and were followed for eighteen months 
after the procedure by a multidisciplinary team. Thirty-one patients (twen-
ty-one submitted to full-thickness Z-shaped sutures and ten submitted 
to full-thickness Z-shaped sutures + Reinforcement) participated in this 
study, since July 2017, and were followed up for eighteen months.
results: Thirty-one patients with a mean age of 42.9 ± 8.7 years partici-
pated in this study, most of them women (84.4%). Pre-intervention data: 
Weight: 103.7 ± 17.9 kg and BMI: 36.2 ± 6.1 kg / m. A mean of 28.9 ± 9.3 bites 
per suture and 2.1 ± 0.7 threads were used in the procedure. There was a 
significant* mean reduction of 11.9 ± 5.3 kg, 15.2 ± 6.1 kg and 19.3 ± 8.9 kg 
at 6 months, 12 months and 18 months respectively. A mean reduction of 
4.1 ± 1.5, 5.5 ± 2.1 and 6.7 ± 2.5 points in the BMI parameter was observed 
for follow-up times of 6 months, 12 months and 18 months, respectively. 
There was progressively an increase of TBWL % (Total Body Weight Loss 
percentage) = 11.3 ± 3.6, 14.6 ± 3.8 and 17.7 ± 4.5 for 6, 12 and 18 months 
respectively. The Excessive Weight Loss was significant at 6 months (EWL % 
= 40.4 ± 13.5), at 12 months (50.3 ± 17.7) and 18 months at follow-up (56.3 ± 
8.6). No complications were observed during or after the procedure.
conclusion: The data so far have shown very significant results in relation 
to the main outcome (EWL %), as this study presented an approximate 
loss of 50% of the excess weight in the first 12 months. There was a slight 
increase in this parameter in later follow-up. There should be pointed out 
that between one year and a year and a half, the weight loss was kept go-
ing on. In this initial cut of the study, no complications were observed dur-
ing or after the procedure. These results are due in large part to the mul-
tidisciplinary work employed throughout the follow-up of these patients.
references: ¹ Jain D et al. Endoscopic Sleeve Gastroplasty - A New Tool 
to Manage Obesity. Clin Endosc. 2017 Nov; 50(6): 552-561. ² Bazerbachi 
F, Vargas Valls EJ, Abu Dayyeh BK. Recent clinical results of endoscopic 
bariatric therapies as an obesity intervention. Clin Endosc 2017;50:42-50. ³ 
Abu Dayyeh BK, Rajan E, Gostout CJ. Endoscopic sleeve gastroplasty: a po-
tential endoscopic alternative to surgical sleeve gastrectomy for treatment 
of obesity. Gastrointest Endosc 2013;78:530-5.
disclosure: Nothing to disclose 
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P1371 endOscOPIc gasTrIc MucOsaL resecTIOn fOr WeIghT 
LOss and suPPressIng sysTeMIc ghreLIn LeveLs In vIvO MOdeL
Liu B.-R.1, Liu D.1, Zhao L.2, Kong L.1, Li D.1, Yang H.1, Ahmed M.R.1
1The First Affiliated Hospital of Zhengzhou University, Gastroenterology, 
Zhengzhou, China, 2The First Affiliated Hospital of Zhengzhou University, 
Zhengzhou, China
contact e-Mail address: bingrongliu@qq.com
Introduction: Obesity is a chronic metabolic disorder that is challenging to 
control. Ghrelin may be involved in the occurrence of obesity and associ-
ated with weight-loss resistance 1. Endoscopic gastric mucosal resection 
(EGMR) is performed by the combination of endoscopic submucosal dis-
section (ESD) and endoscopic mucosal resection (EMR).
aims & Methods: The aim of this study was to analyzed the impact of 
EGMR on body weight and ghrelin levels to explore its potential as a novel 
weight-loss technology. EGMR procedure was carried out to resect the 
mucosal layer of the fundus and body of the stomach in five healthy pigs, 
while another five were untreated as controls. Weight was monitored con-
tinuously for 12 weeks and fasting plasma ghrelin levels were analyzed by 
enzyme-linked immunosorbent assay (ELISA) within 1 and 2 months after 
the EGMR procedure.
results: Compared with the control group, pigs in the experimental 
group exhibited reduced gastric volume and weight-loss with time after 
the EGMR procedure. The average weight in the experimental group was 
51.6±17.27 kg at 12 weeks after the EGMR procedure and 64.00 kg±11.86 
kg in the control group (P = 0.0001). There were significant differences 
in ghrelin levels. Compared with baseline, ghrelin levels decreased to 
250.72±15.57 pg/ml at 1 month after the EGMR procedure, and continued to 
decrease to 169.15±17.93 pg/ml at 2 months after the EGMR procedure. In 
contrast, there were no obvious changes in the ghrelin levels between the 
experimental and control groups (F = 90.11, P = 0.0007).
conclusion: EGMR procedure can effectively reduce stomach volume per-
manently and suppress ghrelin, indicating the potential of this approach 
as a novel weight-loss technology.
references: 1. Pereira JADS, da Silva FC, de Moraes-Vieira PMM. The Impact 
of Ghrelin in Metabolic Diseases: An Immune Perspective. J Diabetes Res. 
2017; 2017:4527980.
disclosure: Nothing to disclose 
P1372 LargesT MucOsaL resecTIOn In The WOrLd fOr WeIghT 
LOss
Liu B.-R., Ahmed M.R., Fang M.
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Zhengzhou, China
contact e-Mail address: bingrongliu@qq.com
Introduction: Obesity is one of the most ubiquitous chronic diseases1. In-
spired by the complication of esophageal stenosis after endoscopic sub-
mucosal dissection (ESD)2, we hypothesized that resection of a sufficiently 
large area of the gastric mucosa should result in contracture and a reduc-
tion in gastric volume and provide a new strategy for medical treatment 
of obesity.
aims & Methods: The aim of this study was to evaluate large gastric muco-
sal resection using combination methods of ESD and endoscopic mucosal 
resection (EMR) procedures for weight loss. A cap-based single-channel 
endoscope was used to resect 80% of the circumference of the anterior, 
posterior, greater curvature mucosal layer of the stomach. Small portions 
of mucosa (mucosal islands) were left to promote wound healing and re-
generation of the gastric mucosa after the procedure. Finally, coagulation 
forceps were used to coagulate the bleeding or potential bleeding sites in 
the submucosal and muscular layer to prevent recurrent bleeding.
results: From December 2015 to March 2019 a total of eight patients (n=8) 
underwent gastric mucosal resection procedure for weight loss and two 
patients (n=2) were associated with type 2 diabetics. The mean initial body 
weight was 108.56 kg (range, 75-135kg). One week after the procedure, 
gastroscopy showed a large area of ulceration on the greater curvature 
of the stomach covered by yellow plaque. One month after the procedure, 
the area of the ulcer was noticeably smaller, the mucosal islands were 
wider, and the plaque was white and clean. The mean BMI was decreased 
to 32.24 kg/m2 from 37.13 kg/m2. Eighteen months after the procedure, 
gastroscopy confirmed ulcer healing completely with a normal appear-
ing mucosa. CT scan confirmed that the gastric volume was reduced. The 
mean follow-up time was 12.66 months (range, 3-30 months). All patients 
experience early satiety after eating and lost most of the excess weight. 
Following the procedure, the mean BMI reduction was 29.73 kg/m2, 28.05 
kg/m2, 27.59 kg/m2, 27.15 kg/m2, and 27.19 kg/m2 at three months (n=8), six 
months (n=8), twelve months (n=6), twenty-four months (n=2), and thirty 
months (n=2), respectively. One patient (n=1) had recurrent vomiting and 
could not take food one month after the procedure, and received stent 
implantation in our hospital. There were no others major adverse effect 
intra-procedure or during 30 months follow-up period. The blood glucose 
level was decreased to normal and no therapy was needed.
conclusion: This new procedure appears to be an effective, safe, and less 
invasive restrictive-type bariatric procedure with low technical complexity 
and complications.
references: 1. Hruby A, Hu FB. The Epidemiology of Obesity: A Big Picture. 
Pharmacoeconomics. 2015; 33: 673-689 2. Kakushima N, Kawata N, Tanaka 
M et al. Complications of endoscopic dilation for esophageal stenosis after 
endoscopic submucosal dissection of superficial esophageal cancer. Surg 
Endosc 2015; 29:2953
disclosure: Nothing to disclose 
P1373 MuLTI-sTraIn PrOBIOTIc Increases The guT 
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frOM a randOMIzed, dOuBLe-BLInd PLaceBO-cOnTrOLLed 
sTudy
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Pediatrics, Copenhagen, Denmark, 3Copenhagen University Hospital 
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Introduction: Maternal obesity is associated with adverse pregnancy out-
comes with both maternal and neonatal complications. Probiotic supple-
mentation during pregnancy may have positive effects on maternal blood 
glucose, gestational weight gain (GWG), and the risk of gestational diabe-
tes mellitus (GDM).
aims & Methods: The primary aim of this study was to determine the fea-
sibility of probiotic intervention in obese pregnant women from the early 
second trimester until delivery. The secondary aim was to investigate the 
effect of daily probiotic supplementation on GWG, maternal glucose ho-
meostasis, infant birthweight, and maternal gut microbiota.
We carried out a randomized double-blinded placebo-controlled study 
in 50 obese pregnant women with pre-pregnancy body mass indices be-
tween 30 and 35 kg/m2. Participants were randomly allocated to two treat-
ment groups, Vivomixx (n=25) or placebo (n=25) at 14-20 weeks of ges-
tation (baseline) and followed with two pre-delivery visits at gestational 
week 27-30 and 36-37 and with one post-delivery visit 2-3 days after birth. 
All visits included blood and fecal sampling. An oral glucose tolerance test 
was performed at baseline and gestational week 27-30.
results: Forty-nine participants completed the study, Vivomixx (n=25), 
placebo (n=24). Thirty-eight participants took more than 80% of the cap-
sules, Vivomixx (n=21), placebo (n=17). There was no significant difference 
in HbA1c levels and the occurrence of GDM between groups. There was, 
however, a trend towards lower GWG and lower infant birthweight in the 
probiotic group. Fecal microbiota analyses showed an overall increase in 
α-diversity over time only in the Vivomixx group (p=0.016).
conclusion: Administration of probiotics is feasible, and a multi-strain 
probiotic were able to increase α-diversity during pregnancy in obese 
women. A larger study population is needed to uncover whether the 
trends found regarding probiotic effects on GWG and lower infant birth-
weight become significant.
disclosure: Both the probiotic and placebo capsules as well as half a year’s 
salary to the study have been donated to Copenhagen University Hospital 
Hvidovre by Next Gen Pharma India Pvt. Ltd., H. No. 331, 1st Floor, Sec-
tor 15A, Noida 201301, National Capital Region, India. The funding source 
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had no role in the study design, data collection, interpretation of analysis, 
writing of the manuscript, or decision to submit the publication. Anders 
Elm Pedersen is affiliated with Merck A/S, Denmark. The present work is 
not related to this affiliation. The study was financed by grants from the 
following private foundations; Jeppe Juhls og hustru Ovita Juhls Mindel-
egat, Else og Mogens Wedell-Wedellborgs Fond, Aase og Ejnar Danielsens 
Fond, Knud og Edith Eriksens Mindefond, Toyota-Fonden Denmark, and 
Next Gen Pharma India Pvt. Ltd. The study was co-financed by the Fac-
ulty of Health and Medical Sciences, University of Copenhagen. All funding 
sources had no role in the study design, data collection, interpretation of 
analyses, writing of the manuscript, or decision to submit the publication. 
P1374 Phase angLe as Marker Of nuTrITIOnaL sTaTus In 
PaTIenTs WITh crOhn’s dIsease: a crOss secTIOnaL sTudy
Cioffi I.1, Imperatore N.2, Marra M.1, Pagano M.C.1, Santarpia L.1, Alfonsi L.1, 
Testa A.3, Contaldo F.1, Pasanisi F.1, Castiglione F.4
1Nutrition, Department of Clinical Medicine and Surgery, Federico 
II University Hospital, Naples, Italy, 2University of Naples Dept. of 
Gastroenterology, Gastroenterology, Department of Clinical Medicine and 
Surgery, Naples, Italy, 3Gastroenterology, Department of Clinical Medicine 
and Surgery, School of Medicine ‘Federico II’ of N, Dept. Clinical Medicine 
and Surgery, Naples, Italy, 4Federico II University, Naples, Italy
contact e-Mail address: iolanda.cioffi@unina.it
Introduction: The assessment of body composition (BC) can offer a practi-
cal approach to identify malnutrition, frequently observed in patients with 
Crohn’s disease (CD). Bioelectrical phase angle (PhA) provides crucial in-
formation on cell mass quality and hydration status.
aims & Methods: The aim of this study was to assess BC, PhA and muscle 
strength in CD patients as indicators of both nutritional and functional sta-
tus.
Consecutive adult CD patients aged between 18-65 years were recruited for 
this cross-sectional study. Disease activity was clinically defined by Crohn’s 
Disease Activity Index (CDAI) in active (>150) and quiescent (< 150) phase. 
All participants underwent anthropometry, BC and handgrip-strength 
(HGS) measures; additionally, biomarkers involved in the nutritional status 
were assessed. Data from CD patients were also compared with a group of 
healthy subjects age-, sex- and BMI- matched.
results: A total of 140 CD patients with a mean age of 38.8 ±13.9 years 
and an average body weight of 64.9±12 kg were recruited and compared 
to controls. Findings showed that all nutritional parameters, especially 
PhA (CD: 6.35±0.94° vs. Controls:6.81±0.79°; p=0.000), were lower in CD 
patients, especially in the active group, compared to controls. Active-CD 
patients had also a lower body weight and fat mass compared both to the 
quiescent and control groups. PhA was also negatively correlated with age 
(r=-0.362; p=0.000) and CDAI (r=-0.315; p=0.000), whereas was positively 
associated with FFM (r=0.443; p=0.000) and HGS (r=0.539; p=0.000). Simi-
larly, serum protein markers are lower for active-CD patients compared to 
the quiescent group (p< 0.05); while, CRP meaningfully increased.
conclusion: Overall, nutritional indicators tend to be lower in CD patients 
compared to controls. Specifically, PhA-values impaired with increasing 
of disease activity, being a sensitive marker of nutritional status. There-
fore, the assessment of BC should be recommended in clinical practice for 
screening and monitoring nutritional status of CD patients.
disclosure: Nothing to disclose 
P1375 a PrOsPecTIve MuLTI-cenTer sTudy On The 
PrevaLence Of frucTOse MaLaBsOrPTIOn In PaTIenTs 
WIThchrOnIc InfLaMMaTOry BOWeL dIsease
Helwig U.1,2, Koch A.K.3, Reichel C.4, Jessen P.5, Zietz B.6, Büning J.7, 
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1Private Praxis, Oldenburg, Germany, 2University of Kiel, Kiel, Germany, 3KEM 
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Germany, 5Private Praxis, Altenholz, Germany, 6Reha Klinik Mölln, Mölln, 
Germany, 7Private Practice, Lübeck, Germany, 8Universität Kiel UKSH, 
Medizinische Abt. I, Kiel, Germany, 9Klinikum Bamberg, Bamberg, Germany
contact e-Mail address: helwig@internisten-ol.de
Introduction: Patients with chronic inflammatory bowel disease (IBD) 
might have a greater likelihood of also being fructose malabsorbers as 
compared to healthy controls. The aim of this study was to determine the 
prevalence and symptom severity of fructose malabsorption in patientswith 
active and inactive IBD compared to healthy controls.
aims & Methods: The present study was a multi-center non-interventional 
diagnostic pilot trial approved by the Ethics Committee of the Christian-
Albrechts-University Kiel, Germany. Fifty-seven patients with active IBD, 
93 patients with IBD in remission, and 101 healthy controls admitted to 
twelve different out-patient clinics for Internal Medicine in Germany were 
included prospectively. Fructose malabsorption was diagnosed by hydro-
gen breath testing after the ingestion of 50g fructose diluted in 300ml 
water and defined as an increase in H
2
levels by at least 20 parts per million 
compared to baseline. Patients diagnosed with bacterial over-population 
as diagnosed by the glucose breath test and non-H2 producers as diag-
nosed by the lactulose breath test that were tested negatively on fruc-
tose as well as lactose were excluded from the analyses.Gastrointestinal 
symptoms during the breath tests were evaluated using four-point items 
to determine subjective severity of bloating, abdominal pain and diarrhea.
results: 251 participants were included in the study (table 1). 205 patients 
(45 with active IBD, mean age 39.20 ± 13.48 years, 55.6% female; 80 with 
IBD in remission, mean age 43.03 ± 11.79 years, 58.8% female; 81 healthy 
controls, mean age 28.92 ± 8.81 years, 61.7 % female) remained after di-
agnosing for bacterial over-population and non-H2 producers. The num-
ber of patients diagnosed with fructose malabsorption - 35/44 (79.6%) in 
patients with active IBD, 59/80 (73.8%) in patients with inactive IBD, and 
66/81 (81.5%) in healthy controls - did not differ between the three groups 
(χ2(2, N= 205) = 1.48, p= .48). Abdominal pain was more frequent in pa-
tients with active IBD than in patients with IBD in remission (z = -2.936, p= 
.010) and diarrhea was more frequent in patients with active IBD than in 
healthy controls (z = 2.489, p= .038).
conclusion: Within the present study, fructose malabsorption is not more 
common in patients with IBD than in healthy subjects. However, the stron-
ger symptoms of the patients with IBD may have pathological and thera-
peutic relevance.
disclosure: Lecture and consulting fees: AbbVie, MSD, Ferring, Falk Foun-
dation, Takeda, Mundipharma, Hospira, Vifor Pharma 
P1376 LacTOse sensITIvITy and LacTOse MaLaBsOrPTIOn. 
The TWO faces Of LacTOse InTOLerance In PaTIenTs WITh 
funcTIOnaL BOWeL dIsOrders
Bouchoucha M.1, Rompteaux P.1, Steuer N.2, Raynaud J.-J.1, Sabate J.M.1, 
Benamouzig R.3
1Hopital Avicenne, Gastroenterology, Bobigny, France, 2Hopital Avicenne 
Service de Gastroenterologie, Gastroenterology, Bobigny, France, 3Hopital 
Avicenne, Service de Gastroenterologie, Bobigny, France
contact e-Mail address: michel.bouchoucha@avc.aphp.fr
Introduction: In France, 30 to 50% of adults have incomplete digestion 
of lactose. The importance of the symptoms is a function of the residual 
lactase activity and the amount of lactose ingested. These symptoms are 
more frequent in postprandial period, 30 minutes to 2 hours after inges-
tion of food containing lactose. They are not specific, evocating bowel 
disorders,(gas, bloating, abdominal cramps, diarrhea, nausea, vomiting) 
or general disorders. They are frequently confused with irritable bowel 
syndrome, that may delay the prescription of an adapted regime.
aims & Methods: The purpose of this study is to evaluate the frequency of 
lactose malabsorption and the frequency of lactose sensitivity in patients 
with functional bowel disorders, with symptoms revealed or increased af-
ter lactose ingestion.
We included 142 consecutive patients (104 women, 73%) with functional 
bowel disorders. In all patients, the search for a small intestine bacte-
rial overgrowth by glucose breath test was negative. These patients have 
completed a Rome III questionnaire and performed the lactose absorption 
test that measures the blood glucose before and 15, 30, 45 and 60 minutes 
after ingestion of 50 g of lactose. A malabsorption was diagnosed when 
the peak blood glucose level was below 0.20 g / l and a lactose sensitivity 
was registered if digestive signs appeared during the test.
results: Lactose sensitivity without malabsorption was present in 58 pa-
tients (group I, 41%), a malabsorption without lactose sensitivity was found 
in 14 patients (group II, 10%) and 23 patients (group III, 16%) exhibited at 
the same time lactose malabsorption and lactose sensitivity. 47 patients 
(Group IV, 33%) showed neither malabsorption nor sensitivity to lactose
Compared with group IV patients, patients in group I were younger (38.8 
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± 1.5 vs 44.4 ± 2.7 years, P = 0.039) and complained of greater incidence 
of chest pain (29% vs. 26%, P = 0.042). Other demographic parameters, 
frequency of other symptoms (esophageal, gastroduodenal, intestinal and 
anorectal according to Rome III) were similar in the four groups of pa-
tients.
conclusion: The joint study of lactose absorption and lactose sensitivity is 
useful to eliminate the pathogenesis of this sugar in patients with disor-
ders intestinal function and justify the establishment of a lactose-free diet.
In symptomatic patients after ingestion of lactose, we suggest distinguish 
patients suffering from malabsorption of lactose by decreased Intestinal 
lactase activity from patients with lactose sensitivity characterized by the 
appearance of symptoms without decrease of lactose absorption.
disclosure: Nothing to disclose 
P1377 PaTTerns Of fIBer InTake aMOng BrazILIan aduLTs: 
a naTIOnWIde WeB-Based survey
Passos M.C.F.1, Guedes L.S.2, Takemoto M.L.S.3
1Federal University of Minas Gerais, Alfa Institute of Gastroenterology, Belo 
Horizonte, Brazil, 2Takeda Pharmaceuticals, São Paulo, Brazil, 3ANOVA 
Consultoria em Saúde, São Paulo, Brazil
contact e-Mail address: mcpassos@medicina.ufmg.br
Introduction: Adequate fiber intake has been directly linked to physiologi-
cal gut balance and is recognized as essential for human health. The World 
Health Organization (WHO) recommends for adults a daily fiber consump-
tion of ≥25 g, but previous studies observed a fiber intake in Brazil lower 
than recommended.
aims & Methods: We aimed to describe fiber intake among adults in Brazil, 
through a nationwide web-based survey. Data was collected in September 
2018 using an online platform with closed-ended questions. A representa-
tive sample of Brazilian internet users stratified by sex, age, socioeconomic 
status and geographic region was adopted. Sample size was calculated 
using a 2% error margin and 95% confidence interval (n=2,000). Data 
was descriptively analyzed using measures of frequency, central tendency 
and dispersion.
results: Sample included 2,000 individuals who were well-balanced in 
terms of sex (51% female), with mean age of 36 years (most represented 
age group was 35-54 years, 40%) and from all country geographic regions 
(49% from Southeast). Most subjects (64%) were classified as having low 
socioeconomic status/income, consistent with Brazilian general popula-
tion. 70% of them consider their usual diet as healthy and 78% reported 
consuming fibers regularly. Fibers from natural sources are consumed at 
least once a day by 69% of the sample, while daily fiber supplements were 
reported by 30%. Absence of regular fiber intake was reported by 22% of 
respondents and the most common reason was “lack of knowledge about 
fiber sources” (39%), followed by “daily inclusion of fibers would be ex-
pensive” (30%) and “lack of time” (22%). Fibers sources with higher fre-
quency of daily intake in the sample were: beans and pulses (67%), whole 
grains (57%), and vegetables (56%). Nuts were the least frequent group 
with only 13% of daily intake (18% never consume). 74% of the sample 
informed that they knew about the role of fibers in improving intestinal 
function, but only 30% knew the difference among soluble and insoluble 
fibers. When informed about the food sources of each type of fiber (soluble 
and insoluble) and asked about the regular intake of each type, only 2% 
answered that they do not consume any of them regularly (as opposed 
to 22% before receiving information about specific fiber sources). 87% of 
the individuals who reported taking regular fiber supplements classified 
their intestinal function as normal. Men reported having better intestinal 
function than women.
conclusion: Our findings indicate that fiber intake in Brazil is probably 
insufficient with a high proportion of individuals reporting irregular or 
absent ingestion of fiber sources in their daily lives. Lack of knowledge 
about fiber sources and fiber types seems to play a role in this inadequate 
intake, highlighting the need for nutritional education to achieve healthy 
dietary patterns in the country.
disclosure: Maria do Carmo F. Passos is a global member’s advisory board 
for Takeda Pharmaceuticals, Mantecorp, EMS and Speaker for Aché, Nestlé, 
Danone, Hypera, EMS, Janssen. Luciana S Guedes is Sr Medical Manager 
at Takeda Pharmaceuticals 
P1378 IrreguLar dIeTary haBITs WITh a hIgh InTake Of 
cereaLs and sWeeTs are assOcIaTed WITh MOre severe 
gasTrOInTesTInaL syMPTOMs In IBs PaTIenTs
Nilholm C.1, Larsson E.1, Roth B.1, J Gustafsson R.2, Ohlsson B.3
1Skane University Hospital, Department of Clinical Sciences, Malmö, Malmö, 
Sweden, 2Skåne University Hospital Malmö, Department of Gastroenterology, 
Malmö, Sweden, 3Skanes Universitetssjukhus, Department of Clinical 
Sciences, Malmö, Malmö, Sweden
contact e-Mail address: clara.nilholm@med.lu.se
Introduction: Dietary advice constitutes one of the first choices of treatment 
for irritable bowel syndrome (IBS). However, almost 50% of the IBS popu-
lation do not improve their symptoms following accepted recommenda-
tions such as the NICE guidelines or a low FODMAP diet. The sucrase-iso-
maltase (SI) genes are responsible for the enzymatic breakdown of starch 
and sucrose in the small intestine. Recently, we have recognized that an 
increased prevalence of functional SI gene variants can be seen in patients 
with IBS, resulting in enzymatic defects and possible difficulty digesting 
starches and sucrose [1].
aims & Methods: The primary aim was to examine participants’ dietary 
habits at baseline, and to correlate the dietary habits with gastrointesti-
nal (GI) symptoms and blood levels of minerals and vitamins. Secondly, 
we wanted to examine the effect of a starch- and sucrose-reduced diet 
(SSRD) on GI symptoms. IBS patients, without any organic GI disease, and 
total IBS-SSS score >175, were randomized to either the dietary interven-
tion group (n=80); following a SSRD for 2 weeks or to the control group 
(n=25) who continued with their ordinary eating habits. The main dietary 
advise was to decrease the intake of cereals, sweets/soft drinks, and to 
avoid vegetables and fruits with high content of starch (2). All subjects had 
blood samples drawn and completed questionnaires regarding GI symp-
toms (visual analog scale for irritable bowel syndrome (VAS-IBS), irritable 
bowel syndrome symptom severity scale (IBS-SSS) and Rome IV), and two 
4-day food diaries, at baseline and after 2 weeks. The food intake was cat-
egorized into regular (3-6 meals/day) or irregular food habits, the intake 
frequency of fast food and soda was counted, and an on-going current diet 
was registered. Food items were categorized into meat, fish, vegetables, 
fruits, dairy products, cereals, and sweets/soft drinks.
results: Patients with regular dietary habits exhibit less pronounced GI 
symptoms, measured as total IBS-SSS score, than patients with irregular 
habits (p=0.029). Intake frequency of sugar-rich soda correlated with total 
IBS-SSS score, vomiting and nausea and intestinal symptoms’ influence on 
daily life. Women with an on-going diet had lower levels of ferritin than 
women without diet (p< 0.029, adjusted for age). A majority of the patients 
had serum levels of 25-OH vitamin D below reference values. IBS patients 
randomized to the intervention group showed significant improvement of 
several symptoms after the 2-week dietary intervention, in contrast to con-
trols, with 31.1% of subjects in the intervention group being responders 
(>50% decrease in total IBS-SSS score). The change in GI symptoms be-
tween 2 weeks and baseline, delta values, differed between the interven-
tion and control group regarding total IBS-SSS score (p< 0.001, abdominal 
pain (p=0.001), diarrhea (p=0.002), bloating and flatulence (p=0.005), 
psychological well-being (p=0.048), intestinal symptoms’ influence on 
daily life (p< 0.001). The decreased intake of cereals and sweets/soft drinks 
correlated with decreased scores of total IBS-SSS, abdominal pain, diar-
rhea and bloating and flatulence. The dietary advice was easy to adhere to.
conclusion: Dietary habits affect the experience of GI symptoms and blood 
levels of minerals and vitamins in patients with IBS. A starch-and sucrose-
reduced reduced diet with reduced intake of cereals and sweets/soft drinks 
has marked effect on reducing GI symptoms in this cohort. The pathologic 
mechanisms behind this improvement need to be further researched in 
future studies.
references: 1. Garcia-Etxebarria, K.; Zheng, T.; Bonfiglio, F.; Bujanda, L.; 
Dlugosz, A.; Lindberg, G.; Schmidt, P.T.; Karling, P.; Ohlsson, B.; Simren, 
M.; Walter, S.; Nardone, G.; Cuomo, R.; Usai-Satta, P.; Galeazzi, F.; Neri, 
M.; Portincasa, P.; Bellini, M.; Barbara, G.; Jonkers, D.; Eswaran, S.; Chey, 
W.D.; Kashyap, P.; Chang, L.; Mayer, E.A.; Wouters, M.M.; Boeckxstaens, 
G.; Camilleri, M.; Franke, A.; D’Amato, M. Increased Prevalence of Rare 
Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Pa-
tients. Clin Gastroenterol Hepatol 2018;16:1673-1676. 2.Sucrose Intolerance. 
Genetic Sucrase-Isomaltase Deficiency [cited 2018-07-10]. Available from: 
https://www.sucroseintolerance.com/choosing-your-foods
disclosure: Nothing to disclose 
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P1379 cOMParIsOn Of nuTrIenT InTakes BeTWeen PaTIenTs 
WITh dIfferenT PancreaTIc dIseases
Grigoreva I.1, Romanova T.2, Verevkin E.3, Suvorova T.4, Tov N.4
1Research Institute of Internal and Preventive Medicine - Branch of the 
Institute of Cytology and Genetics, Gastroenterology, Novosibirsk, Russian 
Federation, 2Research Institute of Internal and Preventive Medicine - Branch 
of the Institute of Cytology and Genetics, Laboratory of Gastroenterology, 
Novosibirsk, Russian Federation, 3Research Institute of Internal and 
Preventive Medicine - Branch of the Institute of Cytology and Genetics, SB of 
RAS, Novosibirsk, Russian Federation, 4Novosibirsk State Medical University, 
Novosibirsk, Russian Federation
contact e-Mail address: igrigorieva@ngs.ru
Introduction: The last decade has seen a steady increase in the number of 
persons with pancreatic pathology, which is becoming an important social 
and economic problem. Both acute and chronic pathology of the pancreas 
can lead to the development of endocrine and exocrine pancreatic insuf-
ficiency, disrupting the processes of digestion, absorption.
aims & Methods: Compare nutrient intake for patients with pancreatic can-
cer (PC) , acute pancreatitis (AP) and chronic pancreatitis (CP).
166 patients were examined in the clinical study. Of these, 43 patients with 
pancreatic cancer (62.8 ± 4.7 years) and 123 patients with acute pancre-
atitis (AP) and chronic pancreatitis (CP), the average age of patients with 
pancreatitis is 50.4 ± 2, 2 years. Of these, 42 patients with acute pancre-
atitis and 81 patients with chronic pancreatitis. All patients underwent an 
ultrasound examination of the pancreas, liver and biliary tract, patients 
with PC were performed computed tomography of the pancreas. A survey 
of patients with AP was conducted in the first 5-10 days from the day of 
hospitalization, patients with CP - during the exacerbation. The actual nu-
trition was assessed using a questionnaire, including 142 product names 
indicating the portions of this product and the frequency of consumption 
over the past 3 months. Indicators of consumption of basic nutrients were 
calculated in grams and as a fraction of the daily caloric value they provide. 
The nutrient set was compared with the “Norms of physiological needs for 
energy and nutrients” (V. Tutelyan, 2009).
results: The total caloric content of the daily diet of patients with various 
pathologies of the pancreas did not differ. The energy of the diet was: in 
patients with PC - 2593.7 ± 309.1 kcal / day, in patients with CP - 2553 ± 
586.7 and in patients with AP - 2438 ± 224.2 kcal / day.
The diet of patients with pancreatic pathology was unbalanced by the fat 
and carbohydrate components. The high proportion of total fat intake (PC - 
48.5% of kcal / day, CP - 46.2%, AP - 47.8%) and insufficient consumption 
of carbohydrates (35.3% of kcal / day, 39.1% and 38.0%, respectively). In 
individuals with pancreatic cancer, the diet included 135.2 ± 18.1 g / day of 
total fat and 235.3 ± 27.2 g / day of total carbohydrates.
The proportion of protein in the diet of patients with PC was 102.3 ± 12.2 g 
/ day, which is higher than the recommended physiological intake rate - 
16.2% of kcal / day, as well as in patients with CP and AP - 14.7% and 14 , 
2%. The content of vitamins B1, B2, PP in the diet of patients with various 
pathologies of the pancreas is within the recommended standards, but 
there is a significant excess of the norms of consumption of vitamins A and 
C in the diet of patients with prostate cancer (1787.8 ± 558.4 mkg ret. Equiv. 
and 335.5 ± 84.1 mg, respectively, p < 0.05), and in patients with AP, the 
content of beta-carotene in the diet is reduced (3.6 ± 0.9 mg / day).
conclusion: The levels of nutrient intake in individuals with different pa-
thologies of the pancreas were significantly different, the daily diet was 
unbalanced. The consumption of proteins, fats, vitamins A and C exceeds 
the recommended consumption rates. The share of total carbohydrate in-
take reduced in patients with cancer of the pancreas and in patients with 
acute and chronic pancreatitis. Probably, this can be regarded as an indi-
rect sign of low adherence of patients with pancreatic diseases to compli-
ance with medical recommendations, including dietary recommendations.
disclosure: Nothing to disclose 
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P1380 currenT chaLLenges facIng jaPanese feMaLe 
dOcTOr In The fIeLd Of gasTrOenTerOLOgy: hOW dO We 
MOve fOrWard?
Sugimura M.1, Katakura K.2, Ohira H.3, Iwabuchi M.1, Ukai K.1, Iijima K.4, 
Ueno Y.5, Masamune A.6, Shimosegawa T.7
1NHO Sendai Medical Center, Gastroenterology, Sendai, Japan, 2Fukushima 
Medical University, Department of Gastroenterology, Fukushima, Japan, 
3Fukushima Medical University School of Medicine, Fukushima, Japan, 
4Akita University Graduate School of Medicine, Gastroenterology, Akita, 
Japan, 5Yamagata University Graduate School of Medicine, Yamagata, 
Japan, 6Tohoku University Graduate School of Medicine, gastroenterology, 
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contact e-Mail address: sugimura.mikako.fp@mail.hosp.go.jp
Introduction: The number of women entering medical school increased re-
markably over the past several decades and nearly a third of the graduates 
are female in Japan. However, the percentage of female gastroenterology 
fellows has remained stable at approximately 10%. Therefore, the Japa-
nese society of Gastroenterology (JSGE) organized the Supporting Women 
in Gastroenterology group at each 10 regional bureau nationwide in 2016 
and started to discuss this issue. 
Purpose: The purpose of this study was to clarify the current situation and 
how to get more females in the field of gastroenterology area in Japan.
aims & Methods: We conducted a survey by questionnaire for female 
member of JSGE Tohoku branch from October to December in 2016. That 
includes ; age distribution, marital status, specialized field, working hours, 
working condition during pregnancy and child care or elderly care, evalu-
ation of current working environment, and desired support measures for 
continuous service.
results: Of 233 female doctors in gastroenterology, 120 (53.8%) returned 
the questionnaire. The results are as follows ; age distribution (-29 years 
old ; 8.3%, 30-39; 41.7%, 40-49; 29.2%, 50-59; 15.0 %, 60-; 5.8 %), mari-
tal status (married; 68.3%, unmarried; 31.7%), specialized field (gastro-
enterology; 78.3%, surgeon ; 4.2%, others; 17.5%), working hours (8-10 
hours per day ; 30.8%, 10-12 ; 17.5%, more than 12; 19.2%), approximately 
90% of them came back to work soon after short maternity leave and 91% 
of those who were entitled to didn’t take elderly-care leave. Many working 
mothers feel that they aren’t fully understood by their colleagues. On the 
contrary, some unmarried female doctors complained of heavier workload 
due to other person’s maternity leave and/or exemption from their duties. 
Most of the respondents thought that the understandings and supports 
from their boss and colleagues, working flexibly and/or sharing their work 
are essential for continuing their work.
conclusion: Current working environment of women in gastroenterology 
field in Japan are tough. To get more female to this area and enable them 
to work with less burden, improvement of long working hours and change 
in awareness of their boss and colleagues are very important.
disclosure: Nothing to disclose 
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P1381 TreaTIng funcTIOnaL gasTrOInTesTInaL dIseases 
In The PaedIaTrIc POPuLaTIOn: are herBaLs an OPTIOn? 
a sysTeMaTIc revIeW
Möller J.1, Raskopf E.2,3, Kelber O.1, Nieber K.4, Fink C.5
1Bayer Consumer Health, Phytomedicines Supply and Development Center, 
Steigerwald Arzneimittelwerk GmbH, Research and Development, Darmstadt, 
Germany, 2ClinNovis GmbH, Köln, Germany, 3Institut für Medizinische 
Statistik und Bioinformatik, Universitätsklinikum Köln, Köln, Germany, 
4Institute for Pharmacy, University of Leipzig, Leipzig, Germany, 5Steigerwald 
GmbH, Medical Affairs, Darmstadt, Germany
contact e-Mail address: careen.fink@bayer.com
Introduction: Functional gastrointestinal diseases describe a spectrum of 
gastrointestinal dysfunctions, mainly functional dyspepsia (FD) and irri-
table bowel syndrome (IBS). Symptoms include abdominal pain, nausea, 
fullness and stool irregularities, leading to a severely impaired quality of 
life (1).
aims & Methods: Given the high medical need in these indications espe-
cially in children (2), there is a requirement for effective and well-tolerated 
treatment options in this age group. 
A PubMed-Medline search for clinical studies and reviews regarding FD 
and IBS in children in compliance with the PRISMA statement was con-
ducted and complemented by hand searching and cross-referencing.
results: The search gained 79 hits for FD in children, thereof 13 on pharma-
cological treatment options, 2 of which were herbals. For IBS, it gained 321 
hits, including 23 on pharmacological treatments, thereof 5 herbals. These 
were Psyllium, Peppermint oil and STW 5 as well as Turmeric, Cannabis, 
Aloe vera and Ginger, with clinical studies in children mentioned only for 
Psyllium, STW 5 and Peppermint oil (1-5). For FD, Hippophae rhamnoides 
and STW 5 were identified, both with clinical evidence (1, 6). Only STW 5 
was mentioned for both diseases. 
A closer look into the evidence for this preparation showed a number of 
studies supporting the therapeutic usefulness in children of all ages, ret-
rospectively (7, 8) as well as prospectively (9-14). These included 44.488 
children, showing an excellent safety profile with only few mild side ef-
fects in this age group, and a convincing rating of the therapeutic useful-
ness.
conclusion: Functional GI diseases are an important indication especially 
in children, where herbal preparations provide effective treatment options 
with a low risk profile and therefore play a prominent role in their man-
agement. Grades of evidence are different and most convincing for STW 5 
likewise in FD and IBS, while Psyllium and Peppermint oil as well as Hip-
pophae rhamnoides show evidence only for IBS or FD, respectively.
references: 1. Malfertheiner, Dig Dis. 2017, 35 Suppl 1: 25-29; 2. Shulman et 
al., Clin Gastroenterol Hepatol. 2017, 15: 712-719; 3. Charrois et al., Pediatr 
Rev. 2006, 27: 49-51; 4. Grigoleit and Grigoleit, Phytomedicine 2005, 12: 
601-6; 5. Fifi et al., Nutrients 2018, 10:E1715; 6. Xiao et al., Hell J Nucl Med. 
2013, 16: 38-43; 7. Kelber Z Phytother, 2010, 31: 40-47; 8. Gundermann and 
Hänicke, Päd. 2004, 10: 408; 9. Vinson and Radke, Gatroenterol. 2011, 140: 
102; 10. Nazarenko et al., Med. novosti 2008, 10: 79-83; 11. Aryaev and 
Kozhevin, Modern Pediatrics, 2009, 5: 151-154; 12. Shadrin et al., Modern 
Pediatrics, 2012, 6: 161-165; 13. Bovbel and Maljugin, Med. novosti, 2009, 
4: 51-54; 14. Ermakova et al., Med. novosti, 2009, 8: 72-78
disclosure: OK is employee at Steigerwald Arzneimittelwerk GmbH. JM is 
intern at Steigerwald Arzneimittelwerk GmbH. 
P1382 dIagnOsIs Of ruMInaTIOn syndrOMe In chILdren 
WITh aMBuLaTOry IMPedance-Ph MOnITOrIng
Nikaki K.1, Rybak A.2, Nakagawa K.1, Rawat D.3, Woodland P.1, Borrelli O.2, 
Sifrim D.1
1Wingate Institute for Neurogastroenterology, QMUL, London, United 
Kingdom, 2Great Ormond Street Hospital, Gastroenterology Department, 
London, United Kingdom, 3Royal London Hospital, Paediatric 
Gastroenterology, London, United Kingdom
contact e-Mail address: kornilia_nikaki@hotmail.com
Introduction: According to the Rome IV criteria the diagnosis of rumination 
in children is based on typical symptoms during clinical evaluation. High 
resolution manometry/impedance (HRM/Z) can be used to confirm the 
clinical suspicion of rumination but is rather poorly tolerated in children 
and only records one postprandial period.
aims & Methods: The aim of our study was to identify a specific diagnostic 
pattern of rumination during ambulatory Impedance-pHmetry (MII-pH). 
We retrospectively assessed MII-pH tracings from children with clinical di-
agnosis of rumination syndrome confirmed by HRM/Z (minimal 2 typical 
rumination episodes in postprandial evaluation). We then compared the 
MII-pH parameters of these patients with those from children with GERD 
and “non-GERD” children (investigated for possible GERD but with normal 
MII-pH). We established cut-off levels for significant MII-pH parameters 
and developed a rumination-specific scoring system. We then validated 
the scoring system on another group of patients who underwent both 
HRM/Z and MII-pH (traces scored blindly).
results: We identified 12 children with confirmed diagnosis of rumina-
tion based on HRM/Z findings (median age: 13.9 years, 6M:6F). Another 18 
children were identified with GERD (median age: 8.1 years, 8M:10F) and 
12 children with non-GERD (median age: 12.4 years, 6M:6F). Children with 
rumination had significantly higher number of total reflux events (RE)/24 
hrs, total number of proximal RE/24 hrs (p< 0.0001) and postprandial 
non-acid RE/hr (p=0.0072) compared to GERD and non-GERD groups. The 
SAP for regurgitation/reflux/vomiting was significantly higher in the ru-
mination group (p=0.0009). The scoring system includes: 1)Total proximal 
RE/24hrs >57.5, 2)Postprandial non-acid RE/hr >2, 3)SAP for regurgitation/
reflux/vomiting >97.5. Each parameter scores 1 and rumination is diag-
nosed if the score is < 2. We validated the scoring system in a group of 
18 children who underwent both a HRM/Z and MII-pH (8 diagnosed with 
rumination - 3M:5F, median age: 13 years - and 10 with a negative HRM/Z 
- 4M:6F, median age:8.5 years). The sensitivity and specificity of the score 
is 75% and 80% respectively.
conclusion: Children with rumination have many more symptomatic reflux 
episodes (SI/SAP positive) with high proximal extent, particularly during 
postprandial periods compared to GERD and controls. Our scoring system 
allows for early identification of children with rumination syndrome.
disclosure: Nothing to disclose 
P1383 aduLT aBdOMInaL PaIn can Be PredIcTed frOM earLy 
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Introduction: Early childhood factors have been implicated in the develop-
ment of chronic functional gastrointestinal (GI) symptoms in adulthood, 
including the irritable bowel syndrome. A number of specific factors have 
been suggested, including early GI symptoms1, early life events2 exposure 
to immune-activating events3 and the child’s psychosocial environment4. 
However most of these studies are based on recall of childhood events 
after the individual has reached adulthood and hence may be subject to 
recall bias. In a prospective birth cohort our group recently demonstrated 
that mode of delivery and early psychosocial factors influenced the devel-
opment of abdominal pain to 12 years of age5 but were unable to confirm 
other factors such as early immune-activation by exposure to environmen-
tal factors such as pets in the household.
aims & Methods: We now report on additional data collected on the birth 
cohort at average age 20 years, aiming to identify early childhood fac-
tors that are associated with the prevalence of abdominal pain. 5478 in-
dividuals (response rate 32%) were able to be contacted and agreed to 
participate in a follow-up. Factors recorded during early childhood and 
previously identified as associated with adult FGIDs were evaluated using 
logistic regression.
results: 55% of the sample was female. Overall the prevalence of GI pain 
was 20% (95% confidence interval 19-21%). Increased abdominal pain in 
adulthood could be predicted from GI pain reported by parents as early as 
two years of age although the predictive ability improved when measured 
later in childhood (Table 1). In addition, poor appetite reported by parents 
at age five was also associated with increased prevalence of GI pain in 
adulthood (Table 1). The occurrence of serious life events in the child’s 
year of birth and parental concerns for the child as early as two years of 
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age were all associated with increased prevalence of GI pain in adulthood, 
in addition to female gender (Table 1). In contrast, neither number of pets 
in the household at age 1 (OR=1.04, p=0.4) nor age 5 (OR=0.98, p=0.7) 
were associated with adult abdominal pain. We also considered early (< 5 
years) allergy to milk, eczema and asthma, social support, marital status 
of parents, mental health conditions, temperament, antibiotic use, mode 
of delivery at birth and duration of breast feeding but none of these were 
associated with adult abdominal pain.
factor gI pain + gI pain - Odds ratio 95% cI p-value
Female gender (%) 71 51 2.42 2.10, 2.80 <.001
GI pain at 2 years (%) 8 5 1.74 1.24, 1.44 .001
GI pain at 5 years (%) 12 9 1.42 1.05, 1.93 .02
GI pain at 8 years (%) 17 9 2.15 1.53, 3.02 <.001
GI pain at 12 years (%) 21 10 2.36 1.74, 3.20 <.001
Life events (%) 6 4 1.49 1.04, 2.15 .03
Parent worries at 2 years 
(mean/SD)
2.57 (1.21) 2.45 (1.14) 1.10 1.02, 1.18 .02
Parent worries at 8 years 
(mean/SD)
2.39 (1.00) 2.22 (0.98) 1.18 1.05, 1.32 .006
[Table 1. Early childhood factors univariately associated with adult 
abdominal pain prevalence]
Female gender (OR=2.39, 95% confidence interval 2.07, 2.76, p< .001) and 
GI pain at eight years (OR=1.35, 95% confidence interval 1.09, 1.67, p=.006) 
were statistically independent predictors of adult GI pain.
conclusion: GI pain experienced in adulthood appears to result from a 
process that starts early in a child’s development and is influenced by its 
psychosocial environment. Greater attention to signs evident as early as 
infancy may have long-lasting benefits to patients. In contrast to previous 
findings, the child’s physical environment appears to be less relevant, in 
including the presence of immune-stimulating factors.
references: 1. Lowman BC, Drossman DA, Cramer EM, McKee DC. Rec-
ollection of childhood events in adults with irritable bowel syndrome. 
Journal of clinical gastroenterology. 1987;9(3):324-330. 2. Bradford K, 
Shih W, Videlock EJ, et al. Association between early adverse life events 
and irritable bowel syndrome. Clinical gastroenterology and hepatology 
: the official clinical practice journal of the American Gastroenterological 
Association. 2012;10(4):385-390 e381-383. 3. Koloski NA, Jones M, Welt-
man M, et al. Identification of early environmental risk factors for irri-
table bowel syndrome and dyspepsia. Neurogastroenterology & Motility. 
2015;27(9):1317-1325. 4. Tanaka Y, Kanazawa M, Fukudo S, Drossman DA. 
Biopsychosocial model of irritable bowel syndrome. J Neurogastroenterol 
Motil. 2011;17(2):131-139. doi:10.5056/jnm.2011.17.2.131 5. Jones MP, Faresjö 
Å, Beath A, Faresjö T, Ludvigsson J. Abdominal Pain in Children Devel-
ops With Age and Increases With Psychosocial Factors. Clin Gastroenterol 
Hepatol in press https://doi.org/10.1016/j.cgh.2019.04.036
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P1384 cLInIcaL and PrOgnOsTIc vaLue Of The fecaL zOnuLIn 
In exTreMeLy PreMaTure BaBIes
Khasanova S.1, Kamilova A.2
1Republican Perinatal Center, Neonatology, Tashkent, Uzbekistan, 
2Republican Specialized Scientific and Practical Medical Center of Pediatrics, 
Gastroenterology and Nutriciology, Tashkent, Uzbekistan
contact e-Mail address: okamilova@mail.ru
Introduction: The state of integrity of the intestinal barrier is significant 
in the development of conditions associated with digestive disorders of 
varying severity, especially in premature babies. Increased zonulin in the 
tissues of the intestine leads to the expansion of intercellular contacts and 
an increase in intestinal permeability. [1-6]
aims & Methods: The aim of the study is to evaluate the clinical and prog-
nostic significance of fecal zonulin in extremely premature babies up to 
32 weeks.
Material and methods: We examined 108 premature babies with gesta-
tional age at birth from 22 to 32 weeks and 27 full-term newborns who 
constituted the control group. Studies of fecal zonulin were carried out in 
dynamics on the 3rd, 7th and 14th days of life. The content of zonulin in fe-
ces was determined using Immunodiagnostik (Germany) reagents (ELISA) 
by enzyme-linked immunosorbent assay.
results: We found an increase in the level of fecal zonulin (FZ) in 17 times 
on the third day of life, 8 times on the 7th day of life and almost 5 times on 
the 14th day of life compared to the control group, whose values  were -28.5 
± 3 on the 3rd day, 6 ng / ml, on day 7 - 61.1 ± 5.1 ng / ml and 14 days of 
life - 89.8 ± 5.8 ng / ml. To identify parallels between the values  of the FZ 
and other clinical and laboratory parameters, we divided all children into 
clusters with certain limits of fluctuations of the values  of the FZ. Cluster 
A consisted of patients with fecal zonulin values  up to 500 ng / ml (n = 
52), cluster B - children with values  from 500 to 1000 ng / ml (n = 40) and 
cluster C - 16 children with fecal zonulin values  (more than 1000 ng / ml).
In cluster B, on the 7th day of life, along with higher rates of fecal zonulin, 
the marker of the inflammatory process — C-reactive protein (respectively, 
cluster A-9.6 ± 1.0 and B-18.0 ± 2.7 , t-2.94, p < 0.001). The hemoglobin 
values  determined on the first day of life in newborns in cluster B had 
significantly lower values  than in cluster A. (175.1 ± 2.7 g / l and 152.5 ± 4.2 
g / l, t-2.31, p < 0.001).
On day 14 of life in cluster A, the mother’s prothrombin index was signifi-
cantly lower than in cluster B (cluster A-82.0 ± 1.4%, cluster B-96.0 ± 1.9%; 
t-5.89, p < 0,001).
To study the relationship between the values  of fecal zonulin and the prog-
nosis of necrotizing enterocolitis, we divided all patients into 2 groups. The 
first group consisted of 10 children who developed necrotizing enterocolitis 
by 10.2 ± 4.5 days of life and 81 children entered the 2nd group without 
necrotizing enterocolitis.
In the group of children with NEC on the 7th day of life, we observed an 
almost twofold, significantly significant increase in zonulin values  com-
pared with the compared group without NEC (343.5 ± 76.7 and 618.4 ± 89.9 
with p < 0.05).
conclusion: The dynamics of fecal zonulin in premature babies revealed a 
multiple increase in its values  within 14 days of life compared with healthy 
full-term babies. The level of faecal zonulin on day 7 of life is a predictor of 
the development of NEC in very premature babies.
references: 1. Fasano A, Not T, Wang W, Uzzau S, Berti I, Tommasini A, Gold-
blum SE.Zonulin, a newly discovered modulator of intestinal permeability, 
and its expression in coeliac disease. Lancet 2000 Apr 29;355(9214):1518-9. 
DOI: 10.1016/S0140-6736(00)02169-3 2. Drago S1, El Asmar R, Di Pierro M, 
Grazia Clemente M, Tripathi A, Sapone A, Thakar M, Iacono G, Carroc-
cio A, D’Agate C, Not T, Zampini L, Catassi C, Fasano AGliadin, zonulin 
and gut permeability: Effects on celiac and non-celiac intestinal mucosa 
and intestinal cell lines Scand J Gastroenterol. 2006 Apr;41(4):408-19. 
DOI: 10.1080/00365520500235334 3. El Asmar R1, Panigrahi P, Bamford 
P, Berti I, Not T, Coppa GV, Catassi C, Fasano A, Host-dependent zonu-
lin secretion causes the impairment of the small intestine barrier func-
tion after bacterial exposure. Gastroenterology. 2002Nov;123(5):1607-15.
doi: 10.1053/gast.2002.36578 4. Anna Tarko,1 Anna Suchojad,1 Marta 
Michalec,1 Małgorzata Majcherczyk,1 Aniceta Brzozowska,2 and Iwona 
Maruniak-Chudek1 Zonulin: A Potential Marker of Intestine Injury in New-
borns Disease Markers Volume 2017, Article ID 2413437, 6 pages https://doi.
org/10.1155/2017/2413437
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P1385 The usefuLness Of PrOBIOTIc adMInIsTraTIOn In 
OBese chILdren WITh nOnaLcOhOLIc faTTy LIver dIsease
Belei O., Olariu L., Marcovici T., Marginean O.
University of Medicine and Pharmacy Victor Babes, First Pediatric Clinic, 
Timisoara, Romania
contact e-Mail address: belei.oana@gmail.com
Introduction: The increasing rate of pediatric obesity imposed nonalco-
holic fatty liver disease (NAFLD) as the most frequent cause of chronic liver 
conditions in children. It includes simple liver steatosis and may progress 
to non-alcoholic steato-hepatitis and cirrhosis. Recent studies suggested 
that intestinal dysbiosis and gut-derived endotoxins may be important in 
this progression, therefore probiotics may have a positive role in improv-
ing liver parameters.
aims & Methods: The aim of this paper was to evaluate the usefulness 
of probiotics administration to obese children with NAFLD to optimize 
metabolic parameters and to reduce intestinal dysbiosis. Methods: 102 
obese children aged 10-18 years were enrolled in this double-blind, 
751Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
placebo-controlled study. NAFLD was assessed in all children using ab-
dominal imaging and laboratory findings. All children underwent clinical 
and anthropometric evaluation, liver and renal function tests, glycemia, 
insulinemia and lipid metabolism assessment. Glucose hydrogen breath 
test was performed for small intestinal bacterial overgrowth (SIBO) as-
sessment at baseline and after 12 weeks of probiotic intervention. NAFLD 
subjects were equally randomized to receive either probiotic Lactobacillus 
reuteri (108 CFU/day) or placebo for 12 weeks add on hypo-caloric diet and 
increased physical activity.
results: 36/102 (35%) of obese children presented NAFLD. Children who 
received probiotic supplementation had a significant higher reduction 
of body mass index after 12 weeks compared to placebo group (P< 0.01). 
There was a significantly higher reduction of intestinal dysbiosis, amino-
transferases level and serum triglycerides levels after the intervention pe-
riod in the probiotic group compared to placebo (P< 0.05).
conclusion: In this study, decreasing in body mass index was higher in 
the group receiving probiotics compared to placebo. Lactobacillus reuteri 
added to proper diet had a beneficial effect on lipid profile and trans-
aminases level and significantly decreased the intestinal dysbiosis in obese 
children with NAFLD.
disclosure: Nothing to disclose 
P1386 IMPOrTance Of MeTaBOLIc cOMPLIcaTIOns In 
severe OBesITy cOMPared TO OBesITy In The regIOn Where 
The OBesITy ePIdeMIc shOWed MOderaTe Increase
Kim T.H.1, Sohn M.J.1, Woo M.H.1, Hwang J.H.2, Park S.-W.2, Ko J.S.1, 
Moon J.S.1
1Seoul National University College of Medicine, Pediatrics, Seoul, Korea 
(Republic of), 2Catholic University of Daegu School of Medicine, Preventive 
Medicine, Daegu, Korea (Republic of)
contact e-Mail address: doctscales90@gmail.com
Introduction: The prevalence of obesity is increasing worldwide among 
children and adolescents. Although obesity in children has a relatively low 
risk of metabolic complications, those with more severe types of obesity 
may be at higher risk in adults. In many countries with moderate increase 
of the obesity epidemic, the association between severe obesity and meta-
bolic complications has been rarely reported in pediatric populations.
aims & Methods: The purpose of this study is to assess the prevalence of 
severe and extremely severe obesity and each metabolic complication us-
ing a nationally representative data in Korea and to identify proper moni-
toring tools for assessing the current obesity epidemic.
A total of 790,653 student (380,580 female) aged 5-19 years were recruited 
from the Korean student health examination, 2011-2018. Obesity was de-
fined by age- and sex-specific BMI reference according to the WHO Growth 
reference data (2007). Obesity was defined by using the skinner’s new 
classification: Class I obesity (BMI ≥ 100% of 95th percentile), Class II (se-
vere obesity, BMI ≥ 120% of 95th percentile), and Class III (extremely severe 
obesity, BMI ≥ 140% of 95th percentile). Metabolic complications included 
hypertension, hyperglycemia, hypercholesterolemia, and elevated amino-
transferase. All analyses were performed using SAS software (Version 9.4).
results: Comparing 2011 and 2018, the overall prevalence of Class II (se-
vere) obesity have increased by 63% (from 3.0% to 4.9%) (p< 0.0001) 
and Class III (extremely severe) obesity increased by 100% (from 0.4% 
to 0.8%) (p< 0.0001), whereas Class I (conventional) obesity increased by 
28.7% (from 15.7% to 20.2%) (p< 0.0001). In logistic regression analysis, 
the adjusted odds ratios (ORs) for Class III obesity were calculated accord-
ing to each metabolic complications; hypertension was 10.3 times higher 
than non-obese group (p< 0.001), hyperglycemia was 2.6 times higher (p< 
0.001), hypercholesterolemia was 2.1 times higher (p < 0.001), and elevat-
ed aminotransferase was 12.7 times higher (p < 0.001). The mean numbers 
of metabolic complications in each obesity group was 1.14 in Class III obe-
sity, 0.76 in Class II, 0.5 in Class I, and 0.29 in non-obese group. (Table 1) 
Obesity 
group
The number of metabolic 
complications (%)
mean 
(95% cI)
mean 
difference1 
(95% cI) 
p-value
  0 1 2 3 4      
Non-obese 75.7 20.3 3.7 0.3 0.1
0.29 
(0.27, 0.31)
   
Class I 
Obesity
60.1 30.8 8 1 0.02
0.5 
(0.49, 0.51)
0.21 
(0.19, 0.24)
<.0001
Class II 
Obesity
43.7 39.5 14.3 2.3 0.16
0.76 
(0.73, 0.78)
0.47 
(0.44, 0.5)
<.0001
Class III 
Obesity
22.8 47.9 22.8 5.6 0.9
1.14 
(1.08, 1.2)
0.85 
(0.79, 0.92)
<.0001
[Table 1. The mean numbers of metabolic complications in each obesity 
group, 2011-2018]
conclusion: We found that the prevalence of Class II and III obesity (severe 
and extremely severe) is highly increasing and the risk of metabolic com-
plication is sharply increasing according to severity of obesity in childhood. 
Close monitoring of metabolic complications is important to track severe 
obesity. Further longitudinal studies are needed to verify childhood obe-
sity at the highest metabolic risk.
disclosure: Nothing to disclose 
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P1387 Is adIPOnuTrIn sTILL a facTOr In hcv? PnPLa3, 
sTeaTOsIs and fIBrOsIs PrOgressIOn In chrOnIc hePaTITIs c
Crisan D.1, Grigorescu M.2, Crisan N.3, Craciun R.C.4, Lupsor M.5, 
Radu C.-I.6, Grigorescu M.D.7, Suciu A.4, Epure F.8, Avram L.9, Leach N.10
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Introduction: There is an established correlation between the PNPLA3 
rs738409 C>G single nucleotide polymorphism (SNP) and hepatic steatosis 
and fibrosis in HCV infected patients. However not all data is convergent 
regarding the exact impact of this SNP on the pattern of disease progres-
sion in different clinical settings. 
In this study, we aimed to further bridge the knowledge gap on this topic 
by investigating the role of the G allele in promoting steatosis, fibrosis 
and disease progression in relation to other metabolic and anthropometric 
host factors.
aims & Methods: Two hundred and fifty consecutive patients, previously 
diagnosed with chronic hepatitis C (CHC) underwent liver biopsy. Histol-
ogy was assessed using the Metavir scoring system. Transient elastography 
was used for follow-up. Ninety-eight patients were genotyped for PNPLA3 
rs738409 and followed up for fibrosis progression.
results: PNPLA3 rs738409[G] allele was significantly correlated with severe 
steatosis (p = 0.04), severe fibrosis at the time of enrollment (p = 0.0005) 
and fibrosis progression with an OR of 10.31 (95% CI 1.06-99.59, p=0.04), 
after a mean follow-up time of 62.85 (95%CI: 52.21-76.15) months. Severe 
steatosis at the time of enrollment had an OR of 11.02 (95% CI 1.48-82.09, 
p=0.01) for the association with fibrosis progression. The HOMA-IR index 
was also positively correlated with severe fibrosis (p=0.03) and fibrosis 
progression on univariate analysis (p=0.02).
conclusion: PNPLA3 rs738409[G] allele is a reliable predictor for steatosis 
and fibrosis in CHC. The presence of G allele, along with severe steatosis 
and insulin resistance are significant predictors for fibrosis progression.
disclosure: Nothing to disclose 
P1388 nOn-InvasIve Markers Of LIver fIBrOsIs and 
TransIenT eLasTOgraPhy In PaTIenTs WITh nOn-aLcOhOLIc 
sTeaTOhePaTITIs: WhIch fOrMuLa shOuLd We use TO MOnITOr 
fIBrOsIs?
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Introduction: Transient hepatic elastography is widely used in staging 
and monitoring of fibrosis in patients with non-alcoholic steatohepati-
tis (NASH). According to the European Association for the Study of Liver 
(EASL) recommendations, the evaluation of transient elastography should 
be complemented with non-invasive markers to improve its accuracy.
aims & Methods: We aimed to evaluate the correlation between the varia-
tion of the transient elastography (TE) and noninvasive fibrosis markers in 
a historical cohort of biopsy-proven NASH patients. 
For this, we performed an observational and retrospective study in a ran-
dom sample of NASH patients in whom diagnosis was established by liver 
histology. For each case, TE and NAFLD activity score, fibrosis-4 index for 
liver fibrosis (FIB-4), AST to platelet ratio (APRI) and AST/ALT ratio data 
were documented at the time of the diagnosis and at the date of the last 
clinical contact. The difference between the final and initial values was cal-
culated for each variable (Δ, “delta”). The statistical relationship between 
the ΔTE and variation in noninvasive fibrosis markers was established in a 
linear regression model.
results: We evaluated 62 cases (mean age at diagnosis 49.9 ± 12.9 years, 
56.5% of the male gender) with an average follow-up time of 3.54 ± 1.54 
years. Liver disease was diagnosed in the cirrhotic stage in 16.1%. 
During follow-up, we observed the presence of an acute cardiovascular 
event in 5 patients; one case developed hepatocellular carcinoma. The 
therapeutic goals of weight reduction and regular physical activity were 
reached in 30.6% and 27.4% of the patients, respectively. 
The mean ΔTransient Elastography value was -0.38 ± 7.6 kPa. Bivariate 
correlation test showed a statistically significant correlation between the 
ΔTransient Elastography and ΔNAFLD activity score (k = 0.48, p < 0.01), 
ΔFIB-4 (k = 0.65, p < 0.01) and ΔAST/ALT ratio (k=0,37, p=0.2). After adjust-
ment of the Δ values for the follow up time in a linear regression multi-
variate model, this significant relationship was maintained (NAFLD activity 
score: β3.01, p < 0.01; FIB-4: β3.36, p < 0.01; AST/ALT ratio: β=8.38, p = 
0.2).
conclusion: In this sample of NASH patients, the variation of the NAFLD 
activity score, FIB-4 and AST/ALT ratios was correlated with the variation of 
EHT values. Among the formulas, the variation in FIB-4 values presented a 
better correlation with the transient elastography values.
disclosure: Nothing to disclose 
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TOOLs In The assessMenT Of LIver fIBrOsIs In aLcOhOLIc 
LIver cIrrhOsIs and nOn-aLcOhOLIc faTTy LIver dIsease 
PaTIenTs - a sIngLe-cenTer exPerIence
Michalak A.1, Guz M.2, Kozicka J.1, Cybulski M.2, Kasztelan-Szczerbinska B.1, 
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Introduction: Advanced liver fibrosis was proved to correlate positively 
with mean platelet (PLT) volume (MPV) to PLT ratio (MPR) and neutrophil 
to LYM ratio (NLR) and negatively with PLT to LYM ratio (PLR). However, 
the number of available analyses in this field of hepatology is still lim-
ited.
aims & Methods: The aim of our investigation was to evaluate the diag-
nostic accuracy of MPR, NLR and PLR in the assessment of liver fibrosis in 
alcoholic liver cirrhosis (ALC) and non-alcoholic fatty liver disease (NAFLD) 
patients and to compare it with serological: indirect and direct markers 
of liver fibrosis. Another goal was to assess relationships between above-
mentioned hematological indices and clinical progression of ALC. Three 
hundred and two participants were recruited to the study: 142 patients 
with ALC, 92 with NAFLD and 68 healthy volunteers in control group. He-
matological indices (MPR, NLR and RLR) were measured in each person. 
Indirect markers of liver fibrosis were also obtained: AAR [aspartate ami-
notransferase (AST) to alanine aminotransferase (ALT) ratio], APRI (AST 
to PLT Ratio Index), FIB-4 (Fibrosis-4) and GPR (γ-glutamyl-transferase 
to PLT ratio). Among direct indices of liver fibrosis, procollagen I car-
boxyterminal propeptide (PICP), procollagen III aminoterminal propep-
tide (PIIINP), platelet-derived growth factor AB (PDGF-AB), transforming 
growth factor-α (TGF-α) and laminin were assessed. The assessment of 
clinical progression of liver failure in ALC patients was done with MELD 
score. NAFLD fibrosis score and BARD score were calculated in NAFLD pa-
tients. Achieved results were compared to controls and between ALC and 
NAFLD groups. Then a correlation between evaluated indices was done. 
Diagnostic value of each assessed haematological parameter together with 
proposed cut-off in research group were measured with AUC (area under 
the curve).
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results: MPR and NLR values in ALC patients were significantly higher 
in comparison to controls (p<0.0001); PLR level was significantly lower 
(p<0.0001). MPR and PLR correlated positively with indirect markers of 
liver cirrhosis (APRI, FIB-4; p<0.001). Positive (but weaker) relationships 
were found between NLR and both: AAR and GPR (p<0.05). MPR corre-
lated negatively with PDGF-AB (p<0.0001); positive relationship was ob-
served between PLR and PDGF-AB (p<0.01). 
Additionally, NLR correlated negatively with PIIINP (p<0.05). MELD score 
correlated positively with NLR (p< 0.0001) and negatively - with PLR 
(p<0.001). NLR level in NAFLD patients was significantly higher in com-
parison to controls (p<0.0001). MPR and PLR valued did not differ sig-
nificantly. MPR correlated positively with indirect markers of liver fibrosis 
- APRI (p<0.0001), FIB-4 (p<0.0001) and GPR (p<0.01). 
A strong positive relationship between MPR and NAFLD fibrosis scale was 
noted, too (p<0.0001). MPR and NLR values were significantly higher in 
ALC patients compared to NAFLD group (p<0.0001); PLR level was signifi-
cantly lower (p<0.0001). AUC values and proposed cut-offs for MPR, NLR 
and PLR in ALC patients were: 0,929 (>0.048), 0.821 (>2.227) and 0.675 
(<70.445), respectively. AUC values and proposed cut-offs for MPR, NLR 
and PLR in NAFLD patients were: 0.547 (>0.038), 0.725 (>2.034 %) and 
0.528 (>97.101 %), respectively.
conclusion: PLR and NLR turned out to be the most powerful markers of 
liver fibrosis in ALC patients. Moreover, they also correlated with clinical 
progression of the disease. Diagnostic accuracy of MPR, NLR and PLR was 
found to be weaker in examined NAFLD patients.
references: 1. Kalra A, Wedd JP, Bambha KM i wsp. Neutrophil-to-lym-
phocyte ratio correlates with proinflammatory neutrophils and predicts 
death in low model for end-stage liver disease patients with cirrhosis. 
Liver Transpl. 2017; 23: 155-65 2. Lai Q, Melandro F, Larghi Laureiro Z i 
wsp. Platelet-to-lymphocyte ratio in the setting of liver transplantation 
for hepatocellular cancer: a systematic review and meta-analysis. World J 
Gastroenterol. 2018; 24: 1658-65 3. Iida H, Kaibori M, Matsui K i wsp. Ratio 
of mean platelet volume to platelet count is a potential surrogate marker 
predicting liver cirrhosis. World J Hepatol. 2018; 10: 82-7
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P1390 LIver MIcrOrna-34a Is acTIvaTed In MuLTIPLe 
anIMaL MOdeLs Of nafLd and cOrreLaTes WITh key dIsease 
haLLMarks In huMan PaTIenTs
Simão A.L.1, Rodrigues P.M.2, Afonso M.B.1, Santos-Laso Á.2, 
Jimenez-Agüero R.2, Eizaguirre E.2, Bujanda L.2, Pareja M.J.3, 
Bañales J.M.2, Rodrigues C.M.P.1, Castro R.E.1
1Research Institute for Medicines (iMed.ULisboa) - Faculty of Pharmacy, 
Universidade de Lisboa, Lisbon, Portugal, 2Biodonostia Research Institute, 
Donostia University Hospital, University of the Basque Country (UPV/EHU), 
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Introduction: Non-alcoholic fatty liver disease (NAFLD) comprises a spec-
trum of stages from simple steatosis to non-alcoholic steatohepatitis 
(NASH). Recent evidence supports a functional role for microRNAs (miR-
NA/miRs) in regulating NAFLD progression. In particular, pro-apoptotic 
miR-34a expression has been reported to sequentially increase during 
disease progression in both experimental and human NAFLD.
aims & Methods: We now aimed to elucidate whether modulation of miR-
34a in NAFLD constitutes a key, primary event and which disease hall-
marks correlate with its expression, hinting at its multiple roles in disease 
pathogenesis. 
C57BL6 mice were fed five different NAFLD-inducing diets, namely a me-
thionine and choline-deficient diet for 2 and 8 weeks; a high-fat choline-
deficient diet for 14 weeks; a high fat, 2% cholesterol diet with high fruc-
tose for 25 weeks; a high-fat/calorie diet with high fructose/glucose in 
drinking water for 16 weeks; and a choline-deficient amino acid-defined 
diet for 32 weeks. Liver biopsies were obtained from a cohort of 166 NAFLD 
patients, histologically and metabolically characterized (NAS 0 to 4: n=89; 
NAS > 4: n=77). Human liver total RNA was used for analysis of miR-34a by 
Taqman Advanced Real-Time RT-PCR.
results: Mice fed with any of the five diets developed different degrees 
of NASH, paralleling liver triglyceride deposition, steatosis, inflammation 
and weigh gain. Mild-to-severe fibrosis was observed in all animals, ex-
cept for mice fed the high fat, 2% cholesterol diet, where fibrosis was ab-
sent. Nonetheless, miR-34a expression levels were significantly increased 
in the livers of all these mice (at least p< 0.05), comparing with control 
diets-fed animals.
NAFLD patients exhibited different degrees of steatosis and NASH, with 
or without the presence of fibrosis and concomitant diseases, including 
diabetes, arterial hypertension and cholelithiasis. Liver miR-34a expres-
sion was found to progressively and significantly increase with the raise 
of steatosis, lobular inflammation and NAS score (at least p< 0.05). Fur-
thermore, miR-34a expression levels were also significantly higher in pa-
tients with bridging fibrosis and cirrhosis (at least p< 0.05), as well as in 
those with concomitant diabetes, arterial hypertension and cholelithiasis 
(at least p< 0.05). Finally, liver miR-34a expression levels positively cor-
related with histological analysis (steatosis, lobular inflammation, fibrosis 
and NAS score), serum hepatic enzymes (AST and ALT), hepatic triglyceride 
content and age (at least p< 0.05).
conclusion: In conclusion, liver miR-34a appears to be a key player in 
NAFLD pathogenesis and progression, correlating with several well-char-
acterized disease hallmarks. A better understating of the overlapping roles 
of miR-34a in NAFLD development may help in establishing novel and 
appealing therapeutic targeting options (Gilead Sciences International - 
Research Scholars Program in Liver Diseases; PTDC/MED-PAT/31882/2017 
and SFRH/BD/104160/2014, FCT, Portugal).
disclosure: Nothing to disclose 
P1391 esTaBLIshMenT Of a nOveL dIeTary-Induced MOuse 
MOdeL shOWIng sTeaTOhePaTITIs WITh severe fIBrOsIs
Ichimura M., Ogawa H., Matsumoto M., Tsuneyama K.
Tokushima University, Pathology and Laboratory Medicine, Tokushima, 
Japan
contact e-Mail address: ichimura.mayuko@tokushima-u.ac.jp
Introduction: Experimental induction of liver fibrosis is still difficult in ro-
dents. Carbon tetrachloride-induced fibrosis is secondary to hepatocellular 
necrosis that is similar to human viral hepatitis, while nonalcoholic steato-
hepatitis (NASH) is characterized by perivenular-pericellular fibrosis with 
elongation of delicate fiber rather than remarkable necrosis.
aims & Methods: We previously made a model of NASH-related cirrhosis 
mimicking human fibrotic pattern of NASH using a rat fed with a high-fat 
and cholesterol (HFC) diet; thus, the aim of this study was to establish a 
mouse model of liver fibrosis. Six-week-old male Tsumura-Suzuki obese 
diabetes (TSOD) mice, a model of spontaneous metabolic syndrome and 
NASH, and Tsumura-Suzuki non obese (TSNO) mice that are control of 
TSOD mice were fed with a HFC diet and normal diet for 12 months. Blood 
and liver were collected at 20, 32, 44 and 56 weeks of age.
results: TSOD mice fed the HFC diet showed obesity, diabetes and ste-
atohepatitis with slight fibrosis. On the other hand, TSNO mice of normal 
control did not show obesity and diabetes but exhibited severe fibrosis in 
addition to steatohepatitis. The pattern of fibrosis in TSNO mice resembled 
human NASH, namely, delicate perivenular and perisinusoidal fibrosis. We 
initially hypothesized that hepatic fibrotic change of TSOD mice could be 
enhanced by intake of the HFC diet due to their background of spontane-
ous metabolic syndrome, however, TSNO mice showed much more severe 
fibrosis. It is speculated that fibrosis-prone traits may be enriched in the 
process of selective breeding of non-obese and non-diabetic mice. The 
fibrotic lesions in TSNO mice lasted until 56 weeks of age, but there was 
only one case of onset of liver tumor. It is known that carcinogenesis at-
tenuates background liver pathology including fibrosis and tumor onset 
provides endpoint in experiments assessing fibrosis. Receptor interacting 
protein 3 which promotes cell death by necroptosis was positive in the liver 
of TSNO mice fed with the HFC diet, suggesting that necroptosis pathway 
might upregulate and resulting in low occurrence of liver tumor in this 
model. Because our model persists in fibrosis over a long period without 
carcinogenesis, it can be considered to be a useful model not only for 
preventive but also for therapeutic experiments.
conclusion: The HFC diet-loaded TSNO mice developed NASH with marked 
fibrosis with quite similar pattern of human fibrotic NASH. Our model in-
duced by not genetically modification but simple diet that imitated human 
dietary habits has many advantages that can simply analyse the mecha-
nism of development of liver fibrosis.
disclosure: Nothing to disclose 
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P1392 IdenTIfIcaTIOn Of nOveL MIrnas assOcIaTed WITh 
exPerIMenTaL nafLd PaThOgenesIs
Islam T.1, Simão A.1, Afonso M.1, Rodrigues P.1, Gama-Carvalho M.2, 
Rodrigues C.M.1, Castro R.E.1
1Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, 
Universidade de Lisboa, Lisbon, Portugal, 2BioFIG - Center for Functional 
and Integrative Genomics, Faculty of Sciences, Universidade de Lisboa, 
Lisbon, Portugal
contact e-Mail address: ruieduardocastro@ff.ulisboa.pt
Introduction: microRNAs (miRNAs) are modulated in non-alcoholic fatty 
liver disease (NAFLD) and are being studied as putative diagnostic and 
prognostic biomarkers. Further, as post-transcriptional modulators of 
gene expression, miRNAs appear to contribute to NAFLD pathogenesis 
by regulating distinct cellular pathways, impacting on lipid and glucose 
metabolism, energy homeostasis, cell death, cell proliferation and differ-
entiation, among others.
aims & Methods: Here, we aimed to identify and validate novel me-
tabolism-associated miRNAs modulated during experimental NAFLD. 
C57BL/6N male mice were fed distinct NAFLD-inducing diets, namely a 
methionine and choline deficient diet (MCD; n=30) for 2 and 8 weeks; a 
high fat, 2% cholesterol diet with high fructose - fast-food diet (FF; n=12) 
- for 25 weeks; and a choline-deficient amino acid-defined diet (CDAA; 
n=28) for 32 and 66 weeks. Liver samples were collected and processed 
for histological and miRNA analyses. Liver RNA from 8 week MCD-fed 
mice was analysed using TaqMan™ array microRNA cards, containing se-
quences for ~740 of the most relevant human or rodent miRNAs. qPCR 
array data was analysed using the HTqPCR package in Bioconductor. We 
found significant differences in the expression of 52 miRNAs, with 25 
miRNAs increasing and 27 miRNAs decreasing in the liver of MCD diet-fed 
mice, comparing with chow-fed animals. Differentially expressed miRNAs 
were subjected to an in silico analysis to exclude previously reported as-
sociations with NAFLD or related metabolic liver diseases. Based on this, 
a panel of different upregulated (miRNA-127, miRNA-136, miRNA-411) and 
downregulated (miRNA-107, miRNA-455) miRNAs was selected for down-
stream validation analyses.
results: miR-136 was found to be up-regulated in MCD-fed animals 
alone. In turn, both miRNA-127 and miR-411 were found consistently up-
regulated in both MCD and CDAA diets, but unaffected in the FF diet, sug-
gesting a possible association with liver damage rather than overall me-
tabolism. Interestingly, miRNA-107 and, in particular, miRNA-455, were 
consistently downregulated in all diets, comparing with control diet-fed 
animals, suggesting that they may constitute major regulators of disease 
pathogenesis.
conclusion: In conclusion, we have identified novel miRNAs modulated 
during experimental NAFLD, associating with distinct pathogenic signal-
ling pathways. A better characterization of the role of these miRNAs in 
disease could translate into prospective therapeutic strategies as well as 
putative biomarkers in NAFLD.
disclosure: Nothing to disclose 
P1393 IL-2, IL-15 and sTeM ceLL facTOr enhance cyTOTOxIcITy 
Of cd3-cd56+cd16+ nk ceLLs agaInsT huMan hePaTOceLLuLar 
carcInOMa ceLL LInes
Luo Y.1, Chen H.1,2, Zhou W.1,3, Sha W.1,4
1Guangdong Provincial People’s Hospital, Gastroenterology, Guangzhou, 
China, 2Guangdong general hospital, Guangdong general hospital, 
GuangZhou, China, 3South China University of Technology, Guang Zhou, 
China, 4Guangdong General Hospital Dept. of Gastroenterology, Guangzhou, 
China
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Introduction: Liver cancer is a kind of malignant tumor, which seriously 
affects people’s health.
aims & Methods: To investigate the effects of IL-2, IL-15 and stem cell factor 
(SCF) on the efficiency of expansion, expression of NKG2D and the cytotox-
city of CD3-CD56+CD16+ NK cells against human hepatocellular carcinoma 
cell lines.The CD3-CD56+CD16+ NK cells purified by the sorting method of 
MACS (magnetic microbeads activated cells sorting) were expanded in 
the presence of IL-2 or IL-15 or IL-2/IL-15/SCF with or without anti-NKG2D 
monoclonal antibody. The efficiency of expansion, the expression of NKG2D 
and the cytotoxcity of CD3-CD56+CD16+ NK cells against HepG2, SMMC-7721 
were determined using trypan blue staining, flow cytometry and CCK-8 
assay, respectively.
results: The efficiency of expansion, the expression of NKG2D and the 
cytotoxcity of CD3-CD56+CD16+ NK cells treated with IL-2/IL-15/SCF were 
significantly increased than those in other groups. Most interestingly, the 
cytotoxic effects of CD3-CD56+CD16+ NK cells on HepG2 cells were signifi-
cantly reduced by the pretreatment with anti-NKG2D monoclonal antibody. 
However, the treatment with the same antibody had little influence on the 
cytotoxicity of CD3-CD56+CD16+ NK cells against SMMC-7721 cells.
conclusion: IL-2/IL-15/SCF enhances the efficiency of expansion, the ex-
pression of NKG2D and the cytotoxicity of CD3-CD56+CD16+ NK cells against 
human hepatocellular carcinoma cell lines.. NKG2D plays an important 
role in mediating the cytotoxicity of NK cells on specific types of tumor 
cells.
disclosure: Nothing to disclose 
P1394 gynecOLOgIcaL hIsTOry and Pregnancy OuTcOMes 
In WILsOn’s dIsease PaTIenTs under TheraPy - a BIcenTrIc 
cOnTrOLLed sTudy
Roseira J.1, Lopes R.2, Silva M.J.3, Vieira A.M.4, Sampaio M.1, Calinas F.3
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contact e-Mail address: jsroseira31@gmail.com
Introduction: Untreated Wilson Disease (WD) is associated with menses 
irregularities and obstetric complications. Research in this area is scarce 
and most studies narrowly focus on pregnancy outcomes comparisons be-
tween WD patients with and without treatment.
aims & Methods: aims: Identify menses irregularities in WD; evaluate the 
impact of under treatment WD in pregnancy, compared with two control 
groups (with and without liver disease). 
Data collection was carried in two hospital centers in order to identify the 
maximum number of women diagnosed with WD. For the control groups, 
women with Hepatitis C (controls with liver disease) and women with 
other gastrointestinal conditions (controls without liver disease), were 
consecutively identified from the hepatology and gastroenterology clinics. 
Sociodemographic characterization and gynecological history were col-
lected. Statistics: chi-square test, multinominal logistic regression.
results: We identified 18 women ongoing treatment for WD (11 pregnan-
cies) and 20 women for each control group. Stage of liver disease between 
controls and the study group was adjusted (p = 0.65).
The incidence of menses irregularities was higher in the WD group (late 
menarche, 15 vs. 2 vs. 2 [p < 0.01]), irregular cycles, 18 vs. 4 vs. 4 [p < 0.01], 
amenorrhea, 12 vs. 2 vs. 1 [p < 0.01]).
The logistic regression model identified the WD group as a predictor of 
miscarriage and low birth weight (odds ratio: 9.0 [1.4-57.1], p = 0.02). Con-
cerning “fetal malformations”, the WD group had the highest rate of events 
(3/11) but the difference was not significant (p = 0.51). The type of therapy 
(D-Pencillamine or zinc acetate), and the clinical presentation of the dis-
ease (hepatic or/and neurological) was not associated with the identified 
obstetric complications in WD.
conclusion: There was a higher incidence of menses irregularities in the 
WD group. Also, this work adds to the literature as it suggests that WD un-
der therapy still maintains a higher risk of spontaneous abortion and low 
birth weight, compared to control groups with and without liver disease. 
Despite the theoretical teratogenic potential of the drugs, the risk of fetal 
malformations under chelation therapy (D-Pencillamine 300mg) or zinc 
acetate (150mg) was not significant, which reinforces the need to maintain 
therapy throughout pregnancy.
disclosure: Nothing to disclose 
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P1395 Why gasTrOenTerOLOgIsTs MusT LOOk fOr TyPe 2 
dIaBeTIc PaTIenTs?
Sporea I.1, Mare R.G.2, Sirli R.L.D.3, Popescu A.3, Silviu N.4, Sima A.5, 
Timar R.5
1University of Medicine and Pharmacy Victor Babes Timisoara, 
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3Victor Babes University of Medicine, Gastroenterology and Hepatology, 
Timisoara, Romania, 4Spitalul Clinic Judetean de Urgenta ‘Pius Brinzeu’, 
Gastroenterology, Timisoara, Romania, 5Victor Babes University of Medicine, 
Timisoara, Romania
contact e-Mail address: ruxi2323@yahoo.com
Introduction: Non-alcoholic fatty liver disease and type 2 diabetes com-
monly coexists. The risk of developing NAFLD in these patients is high due 
to high prevalence of obesity.
aims & Methods: The aim of the study was to assess the severity of liver 
fibrosis and steatosis in a cohort of pure type 2 diabetic patients, using 
non-invasive methods: Transient Elastography (TE) and Controlled Attenu-
ation Parameter (CAP).
The study included 704 type 2 diabetic patients, who were prospectively 
randomized evaluated in the same session by means of TE and CAP (Fi-
broScan EchoSens) to assess both liver fibrosis and steatosis. Reliable liver 
stiffness measurements (LSM) were defined as the median value of 10 LSM 
with an IQR/median < 30%. A cut-off value of 10.1 kPa[1] was used to de-
fine severe fibrosis (F≥3). For differentiation between stages of steatosis 
we used the following cut-off values proposed by the manufacturer: S1 
(mild) 230-275, S2(moderate) 275-300 db/m, S3(severe) > 300 db/m.
results: Out of 704 diabetics screened we excluded those with associated 
viral hepatitis, those with an AUDIT-C score ≥8 and those with unreliable 
LSM. 14 patients had associated viral B or C hepatitis (1.9%) ,17 patients an 
AUDIT-C score ≥8 (2.4%) and 15 patients (2.1%) had other hepatopathies 
(autoimmune, toxic, cholestatic). After excluding those with unreliable 
LSM, the final analysis included 546 diabetic patients without other hepa-
topathies (53.8% women, mean age 60 ±9.5; BMI=31.6± 6.1 kg/m2). 59.9% 
of them had BMI ≥ 30kg/m2. Mild, moderate and severe steatosis by means 
of CAP was found in 17 %, 14.5 % and 58.8% cases respectively. The me-
dian CAP value of patients with mild, moderate and severe steatosis was 
260 db/m, 287 db/m and 356 db/m. Severe fibrosis was detected by means 
of TE in 19% (104/546) of subjects and the median value was 12.5 kPa.
conclusion: In our group, approximately 77.6% were diabetic patients 
with reliable LSM. Presence of steatosis was found in 90.3% of patients by 
means of CAP and 19% of them had severe fibrosis suggesting the need 
for further assessment.
references: 1. Petta S et al. Improved Noninvasive prediction of Liver Stiff-
ness Measurement in Patients with Nonalcoholic Fatty Liver Disease Ac-
counting for Controlled Attenuation Parameter Values. Hepatology 2016. 
Doi:10.1002/hep.28843
disclosure: Ioan Sporea: Speakers fees: AbbVie, BMS, Gilead, Janssen, 
Philips, General Electric; Advisory boards: AbbVie, Merck; Siemens, Canon 
Toshiba. Research support: Philips, General Electric Roxana Sirli and Alina 
Popescu had the following conflict of interests: Philips, General Electric, 
Abbvie, AstraZeneca, Zentiva, Neola, Dr. Reddy, BMS, MSD, Mylan. 
P1396 reLaTIOnshIP BeTWeen cOffee cOnsuMPTIOn and 
nOnaLcOhOLIc faTTy LIver dIsease
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Introduction: There is emerging evidence for the positive effects of coffee 
consumption in patients with liver disease. Our aim was to determine the 
effects of coffee intake on a liver enzymes, inflammation parameters, non-
invasive elastographic markers of liver steatosis and fibrosis, as well as to 
degree of NAFLD detect by liver biopsy.
aims & Methods: In this cross-sectional study we have analyzed 575 pa-
tients with NAFLD. There was 273 (47.5%) man and the mean age was 
59±13 years. NAFLD was detected by controlled attenuation parameter 
(CAP) and liver stiffness measurements (LSM) assessed by transient elas-
tography (TE). In part of the patients (113) the liver biopsy was done as 
well. Coffee drinking was recorded using semi-quantitate questionnaire 
and categorized as yes vs. no and as 0, 1, 2, ≥3.
results: The great majority were coffee drinkers (77.6%). Patients were 
divided into four subgroups of patients depending on the number of cups 
of coffee per day (0, 1, 2, ≥3). Firstly we have analyzed the influence of cof-
fee drinking on the elastographic parameters of liver steatosis and fibrosis 
(CAP and LSM). Interestingly, patients that were drinking more cups of 
coffee had higher CAP, while the same group of patients had lower LSM 
values in comparison to nondrinkers or those who were drink only one cup 
of coffee per day, although that was not statistically significant. Next we 
have investigated the influence of coffee drinking on biopsy findings. There 
was no significant difference in the degree of NASH, although patients 
who were not coffee drinkers had lower degree. On the other hand those 
who drank more coffee had the lowest degree of fibrosis, although this 
difference is not statistically significant. Furthermore, drinking coffee had 
no influence on liver enzyme levels. Finally, drinking coffee had beneficial 
influence on ferritin and CRP values as inflammation parameters.
conclusion: According to our results drinking coffee have beneficial effect 
on degree of fibrosis detected by TE (LSM) and liver biopsy, as well as on 
inflammation parameters.
disclosure: Nothing to disclose 
P1397 gender BIas In POLycysTIc LIver dIsease: esTradIOL 
sTIMuLaTes PrOLIferaTIOn and InfLuences esTrOgen 
recePTOr exPressIOn In Prkcsh knOckOuT chOLangIOcyTes
Bernts L.H.P., van Bakel K., Sahin A., te Morsche R.H.M., Drenth J.P.H.
Radboud University Medical Center, Gastroenterology and Hepatology, 
Nijmegen, Netherlands
contact e-Mail address: lucas.bernts@radboudumc.nl
Introduction: Polycystic liver disease (PLD) is a rare genetic disease and 
PRKCSH has been identified as one of the causative genes. In large co-
hort studies, over 80% of patients are female. In addition, the severity 
of PLD correlates with the use of exogenous estrogens [1]. We aimed to 
find experimental evidence for the effect of estradiol on proliferation of 
cholangiocytes ex vivo. Furthermore, we studied the expression of estrogen 
receptor (ER)-α, ER-β and the G protein-coupled estrogen receptor (GPER) 
in cholangiocyte cell lines, organoids and hepatic cyst tissue.
aims & Methods: We used H69 wild type (WT) and H69 PRKCSH knock out 
(KO) cholangiocyte cell lines, patient-derived organoids (n=10) and hepatic 
cyst tissue (n=9). H69 cell lines were incubated in a dilution series of es-
tradiol. A possible additive effect of progesterone was also assessed in a 
dilution series. With the use of WST-1 assays, the effect of the hormones 
on the relative proliferation between treated and non-treated WT and KO 
cholangiocytes was determined. PCNA expression was used to identify 
proliferative effects in organoids. For RNA isolation we cultured WT and 
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KO cholangiocytes, and organoids in medium with either the optimal hor-
mone concentration for proliferation, or vehicle. RNA was isolated using 
Trizol to determine the expression of estrogen receptors (ER-α, ER-β and 
GPER) and PCNA by quantitative polymerase chain reaction (qPCR). The 
relative expression fold change (2-ΔΔCt) between WT and KO cholangiocytes, 
and treated and non-treated cholangiocytes and organoids was measured. 
Finally, we studied the expression of estrogen receptors in hepatic cyst 
tissue obtained from surgical fenestration and patient-derived organoids. 
The organoids were derived from cyst fluid obtained during aspiration or 
tissue during fenestration of hepatic cysts.
results: We found that mainly estradiol, but also progesterone to a minor 
extent, stimulates proliferation in PRKCSH KO and WT cholangiocytes. The 
optimal estradiol concentration was 10 nM. Without estradiol, GPER ex-
pression was higher in KO cholangiocytes compared to WT (2-ΔΔCt = 6.19). 
When treated with estradiol, the relative expression decreased, but was 
still higher in KO compared to WT (2-ΔΔCt = 2.47). This is explained by an 
increase in GPER expression in WT (2-ΔΔCt = 1.58) and reduction of GPER ex-
pression in KO (2-ΔΔCt = 0.63) after estradiol treatment. ER-α and ER-β were 
not detectable with qPCR in the cell lines, nor did we detect any estrogen 
receptor expression in organoids. After addition of estradiol to organoids, 
PCNA expression was 6 times higher, which is indicative of a proliferative 
effect. In 7/9 (78%) cyst tissue samples, expression of any estrogen recep-
tors was found. In 6/9 (66%) samples ER-α was expressed, in 3/9 (33%) 
ER-β and in 7/9 (78%) GPER. We detected both GPER and ER-α in 5/9 
(56%) samples.
conclusion: In this study we provide evidence for the proliferative effect 
of estradiol on cystic cholangiocytes, which may be regulated by multiple 
estrogen receptors in cystic epithelia. With the results of this study, we 
confirm that gender bias in polycystic liver disease is to some extent ex-
plained by estradiol exposure.
references: 1. Sherstha, R., et al., Postmenopausal estrogen therapy selec-
tively stimulates hepatic enlargement in women with autosomal dominant 
polycystic kidney disease. Hepatology, 1997. 26(5): p. 1282-1286.
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Introduction: According to current data connection between nonalcoholic 
fatty liver disease
(NAFLD) and gastroesophageal reflux disease (GERD) is controversial. Our 
aim was to analyze relationship between GERD and NAFLD.
aims & Methods: In this cross-section study we have analyzed 436 patients 
mean age 63.3±13.5 in whom upper gastrointestinal endoscopy (GE) was 
done. There were 215 (49.3%) male patients. On upper GE endoscopy we 
were interested to analyze presence of hiatal hernia, cardiac insufficiency 
and the presence and degree of GERD. NAFLD was diagnosed by liver en-
zymes and transient elastography [controlled attenuation parameter (CAP) 
for detection of liver steatosis and liver stiffness measurements (LSM) for 
liver fibrosis detection]. In part of the patients the liver biopsy was done.
results: Firstly we have analyzed difference between patients with mild 
steatosis (first group had CAP< 268 db/m) and advanced steatosis (sec-
ond group had CAP≥268 db/m). As we expected patients with advanced 
steatosis had higher values of anthropometric parameters of obesity, the 
XL probe was dominantly used and they had higher incidence of dyslip-
idemia. There was no significant difference due to GERD frequency and 
degree as well as frequency of hiatal hernia between two group of pa-
tients, but patients with advanced steatosis had higher incidence of cardiac 
insufficiency (p=0.04). Next, we were interested to analyze is there a differ-
ence in upper GI endoscopy findings between NAFLD patients with normal 
and elevated LSM values. There was no difference in anthropometric pa-
rameters of obesity between NAFLD patients with normal LSM values and 
those with elevated LSM values, while second group of patients had higher 
incidence of other components of the metabolic syndrome. Interestingly 
we didn’t find any significant difference in upper GI endoscopy between 
two groups of patients. Finally we have analyzed what are the difference 
in liver enzymes, elastographic and liver biopsy findings between patients 
with GERD and those without GERD. We didn’t find any significant differ-
ence in liver enzymes, elastographic parameters of steatosis (CAP) and 
fibrosis (LSM) and liver biopsy findings among two group of patients.
conclusion: According to our results and in contrary to recent data, we 
didn’t find the connection between frequency and degree of GERD and 
degree of NAFLD diagnosed by liver enzymes, elastographic parameters of 
steatosis (CAP) and fibrosis (LSM) and liver biopsy findings, except patients 
with advanced steatosis defined by CAP values had higher incidence of 
cardiac insufficiency.
disclosure: Nothing to disclose 
P1399 sIMPLe BIOLOgIcaL scOre fOr dIaBeTOLOgIsTs TO 
IdenTIfy nafLd PaTIenTs WITh sIgnIfIcanT fIBrOsIs
Sporea I.1, Mare R.-G.2, Lupusoru R.2, Silviu N.3, Sirli R.L.D.2, Popescu A.2, 
Sima A.4, Timar R.4
1University of Medicine and Pharmacy Victor Babes, Gastroenterology and 
Hepatology, Timisoara, Romania, 2Victor Babes University of Medicine, 
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contact e-Mail address: isporea@umft.ro
Introduction: Non-alcoholic fatty liver disease is becoming the most com-
mon cause of chronic liver disease.
aims & Methods: The aim of this study was to identify factors associated 
with significant liver disease in a cohort of type 2 diabetes patients and to 
develop a simple score for clinicians to identify more easily patients at risk. 
Patients were recruited prospectively in the study. Every first 6 patients 
who were referred to the Metabolic Disease Outpatient Clinic on a consul-
tation day. Evaluation of liver fibrosis (stiffness) was made using Transient 
Elastography (FibroScan), performed in fasting conditions, with M and XL 
probes. Each patient was evaluated biologically for the presence of viral 
hepatitis (B and C) and an AUDIT-C score was performed to exclude alcohol 
abuse. Also subjects characteristics, epidemiological data and biochemi-
cal tests were recorded. Variables tested for the association with advanced 
liver fibrosis were: age, body mass index (BMI), abdominal circumference, 
hypertension, years after diagnosis of diabetes, glycemia, glycosylate he-
moglobin, AST, ALT. Logistic regression was used for multivariate model to 
assess the association between advanced liver fibrosis and other variables. 
The cut-off value for significant fibrosis was >8.4 kPa [1].
results: The total number of diabetics evaluated was 641. After the exclu-
sion of others conditions, 468 patients with NAFLD were included, mean 
age 60.2±9.2, 55% women and 45% men. Advanced fibrosis was found in 
29.4% (138/468) patients. To assess the advanced fibrosis predicting score, 
all clinical variables associated with significant fibrosis, with p < 0.05 in 
the univariate analysis were considered in a multivariate regression model 
(BMI, glycemia, glycosylate hemoglobin, AST, ALT, abdominal circumfer-
ence) and gave us the following predicting score: 1 point for AST> 30 U/I, 
ALT>35 U/L, BMI> 30, abdominal circumference and 2 points for HbA1c > 
7.5%, glycemia>200mg/dl. The score ranged from 0 to 8 with maximum 
predictability at 8. The best cut-off value for predicting significant fibrosis 
was ≥4, with a sensitivity of 83.3%.
conclusion: A simple score consisting of body mass index (BMI), abdomi-
nal circumference, glycemia, glycosylate hemoglobin, AST, ALT can identify 
NAFLD patients with significant fibrosis.
references: 1.Petta S. et al, The combination of liver stiffness measurement 
and NAFDL fibrosis score improves the non-invasive diagnostic accuracy 
for severe liver fibrosis. Liver Int 2015.
disclosure: oan Sporea: Speakers fees: AbbVie, BMS, Gilead, 
Janssen,Philips, General Electric; Advisory boards: AbbVie, Merck; Sie-
mens, Canon Toshiba. Research support: Philips, General Electric Alina 
Popescu and Roxana Sirli have the following conflicts of interests: Phil-
ips, General Electric, Abbvie, AstraZeneca, Zentiva, Neola, Dr. Reddy, BMS, 
MSD, Mylan. 
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P1400 assessMenT Of nOnaLcOhOLIc faTTy LIver 
dIsease usIng seruM TOTaL ceLL deaTh and aPOPTOsIs 
Markers - cOMParIsOn WITh The LIver BIOPsy
Mikolasevic I.1, Domislovic V.2, Krznaric Z.3, Jakopcic I.4, Delija B.4, 
Skenderević N.4, Mijic A.4, Stevanovic T.4, Klapan M.4, Aralica M.4, 
Bilic-Zulle L.4, Milic S.4, Stimac D.5, Filipec Kanizaj T.6
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contact e-Mail address: ivana.mikolasevic@gmail.com
Introduction: The diagnosis of non-alcoholic fatty liver disease (NAFLD), 
non-alcoholic steatohepatitis (NASH) and fibrosis relies on liver biopsy. 
Non-invasive assessments are urgently needed. Thus, our aim was to eval-
uate cell apoptotic marker cytokeratin-18 M30 and total cell death markers 
cytokeratin-18 M65 for the assessment of NAFLD.
aims & Methods: A cohort of 136 patients mean age 58.3±11.3 with biopsy-
proven NAFLD were enrolled. There was 69 (50.7%) male patients. NAFLD 
was by transient elastography [controlled attenuation parameter (CAP) for 
detection of liver steatosis and liver stiffness measurements (LSM) for liver 
fibrosis detection]. NASH diagnosis was based on Brunt’s criteria and the 
NAFLD activity score (NAS) and the presence of fibrosis were determined. 
The diagnosis of NASH was based on NAS≥5. Biomarkers were determined 
by enzyme-linked immunosorbent assay.
results: Of 136 analyzed patients, 67 patients had NAS≥5 defined as NASH 
(according to the NAS score). Interestingly, there was no significant cor-
relation between the M30 and M65 levels and CAP measurements. On the 
other hand, there was significant positively correlation of M65 and LSM 
measurements (r=0.228; p=0.007), while the correlation between M30 and 
LSM didn’t reach the significant level (r=0.156; p=0.06). There was signifi-
cant positive correlation between NAS score and M30 (r=0.193; p=0.02) and 
M65 (r=0.300; p=0.0004). M30 levels were significantly higher in NASH 
group of patients in the comparison to the non-NASH patients according 
to the NAS score (351.2±655.6 vs. 90.1±62; p=0.001) (figure 1a). Also, M65 
levels were significantly higher in NASH group of patients in the com-
parison to the non-NASH patients according to the NAS score (585.1±886.5 
vs. 207.2±33.2; p=0.0006). M30 levels was a moderate predictor of NASH 
on biopsy with an area under the curve (AUC) of 0.722 (95% Cl 0.639 to 
0.795). A M30 cut-off of >74 had a sensitivity of 52.2%, specificity of 90%in 
NASH diagnosis. Similar, M65 level was a moderate predictor of NASH on 
biopsy with an area under the curve (AUC) of 0.781 (95% Cl 0.595 to 0.759). 
A M65 cut-off of >274 had a sensitivity of 38.8%, specificity of 97.1% in 
NASH diagnosis. Interestingly, M30 levels were significantly higher and in 
patients with significant fibrosis (grade 2-4) in comparison to the patients 
without fibrosis and to those with mild fibrosis (grade 1) (303.6±658.4 
vs. 143.3±197.4; p=0.05). Also, M65 levels were significantly higher in pa-
tients with significant fibrosis (grade 2-4) in comparison to the patients 
without fibrosis and to those with mild fibrosis (grade 1) (494.9±802.7 vs. 
295.6±317.4; p=0.05).
conclusion: Serum biomarkers M30 and M65 had a moderate accuracy in 
detecting NASH. Combination of non-invasive marker could improve the 
sensitivity.
disclosure: Nothing to disclose 
P1401 TreaTMenT Of nOnaLcOhOLIc faTTy LIver 
dIsease WITh vITaMIn d: a dOuBLe- BLInded, randOMIzed, 
PLaceBO-cOnTrOLLed PILOT sTudy
Mikolasevic I.1, Domislovic V.2, Lukenda Zanko V.3, Krznaric Z.4, Bokun T.5, 
Filipec Kanizaj T.6, Skenderević N.3, Kujundzic Dinjar P.3, Ostojic A.7, 
Milic S.3, Orlic L.3
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Introduction: Nonalcoholic fatty liver disease is the most commmon form 
of chronic liver disease that affects around 25% of population. No licensed 
mediacal treatment exists. We investigated efficacy and safety of a 48-
week treatment with vitamin D in patients with transiet elastography (TE) 
defined NAFLD.
aims & Methods: TE defined NAFLD pataients with decreases 25-OH vita-
min D level at baseline recieved vitamin D (1000 IU/per day) or placebo 
orally over a 48-week period. The primary endpoint of this study was the 
changes of elastographic parameter of liver steatosis (controller atenua-
tion parameter - CAP) and fibrosis (liver stifness measurements - LSM) 
from the baseline to the end of treatment. The secondary aim was tthe 
changes of liver enzymes (AST, ALT, GGT) from the baseline to the end of 
treatment.
results: Patients were randomly assigned to intervention (N=175) or pla-
cebo group (N=90). Average age of population was 62.4 years with 42% 
of male participants. There was no significant differences in intervention 
or placebo group in baseline age, gender, BMI, waist, hip and thigh cir-
cumference, but also there was no significant difference in baseline serum 
vitamin D levels in intervention and placebo group (55.7±30.3 vs 50.7±27.9, 
P=0.22). There was significant decrease in CAP (dB/m) values in interven-
tion group through follow up of 12 months (317.5±39.6 vs 277.01±53.35, P< 
0.0001) comparing to placebo group where there was significant increase 
in CAP values (309.2±41.7 vs 323.8±41.5, P=0.019). We have not noticed 
significant changes in LSM (kPa) values in placebo or intervention group, 
however it is important to notice that there was a trend towards lower 
values of LSM in intervention group in the follow-up period (6.23±3.73 vs 
5.65±3.26, P=0.12) comparing to the placebo group (6.13±3.85 vs 6.17±2.7, 
P=0.931).
conclusion: Treatment with 1000 IU of vitamin D over 48 weeks was well 
tolerated and led to a significant improvement of CAP values.
disclosure: Nothing to disclose 
P1402 TranIseT eLasTOgraPhy In The PrOsPecTIve 
evaLuaTIOn Of faTTy LIver dIsease
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Introduction: The aim of this prospective study was to monitor the pro-
gression of elastographic parameters of liver steatosis [controlled attenu-
ation parameter (CAP)] and fibrosis [liver stiffness measurement (LSM)] 
in patients with elastography proven NAFLD using Fibroscan 502 Touch. 
Furthermore, using elastographic parameters in patients with one or more 
MetS components and NAFLD, we were estimating the effects of clinical 
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and laboratory parameters on progression of elastographic parameters of 
steatosis and fibrosis (CAP and LSM). Finally, according to different BMI 
categories.
aims & Methods: For the time period between May 2014 and October 2014 
there were 606 consecutives ambulatory NAFLD patients enrolled in this 
prospective study. During each visit, that is every three months, Transiet 
elastography (TE) examinations were performed in each patient. First of 
all, we were interested in analyzing the time to CAP (i.e. elastographic 
parameter of steatosis) and LSM (i.e. elastographic parameter of fibrosis) 
progression by at least 20% in total population and in identifying indepen-
dent predictors of CAP and LSM progression in total population. Secondly, 
we were interested in analyzing the time to CAP and LSM progression by 
20% in different BMI categories.
results: This cohort consisted of 507 patients, 53.3% males. Median age 
was 62 (63-68) years and median BMI was 29.6 kg/m2, with relatively high 
proportion of overweight (41%, n=208) and obese (45.8%, n=232) patients 
and only 13.2% (n=67) having BMI< 25. There was a high proportion of 
patients with hypertension (71%), T2DM (39.1%), hyperlipidemia (68.6%), 
CKD (24.9%) and MetS (44.6%). Median values of CAP were 305 (269-337) 
and liver stiffness 5.3 (4.3-6.9). The cohort was followed for a mean period 
of 15.46 months (±11.3, range 0.4-41.4 months), corresponding to 663.58 
person years. 
During follow-up in 84 patients (16.5%) progression of liver steatosis for 
20% occurred. On the other hand, in more patients, 201 (39.6%), occurred 
progression of liver fibrosis for 20%. After that we analyzed patients di-
vided into three groups based on BMI status; < 25 (lean), 25-29.9 (over-
weight), and≥30 kg/m2 (obese). When stratified for BMI category, sig-
nificant difference was found in occurrence of fibrosis progression, with 
obese patients having the highest proportion. There was no difference in 
occurrence of steatosis progression, or time to steatosis or time to fibrosis 
progression. 
Obese patients have 1.66 (1.23-2.25) higher risk of developing fibrosis pro-
gression compared to overweight patients which were taken as the refer-
ence category. Kaplan-Meier survival curves stratified per BMI category 
were different (P=0.023) with obese patients having the highest risk of 
liver fibrosis progression. This was not the case for progression of liver 
steatosis. In multivariate Cox-regression analysis significant predictor of 
fibrosis progression was HOMA-IR.
conclusion: By this study we have shown that for the progression of elas-
tographic parameters of steatois and fibrosis (I.e. CAP and LSM) are im-
portant the same factors (i.e. MetS and its individual components) that 
were reported to be associated with NAFLD progression detected by other 
methods. Thus, indicating that by this method we could monitor NAFLD 
progression in everyday clinical practice by patient-friendly method. How-
ever further studies are needed.
disclosure: Nothing to disclose 
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Introduction: The non-alcoholic fatty liver disease (NAFLD) is considered 
to be the most common liver disease in the world in recent years. It is 
closely linked to metabolic disorders and, in the first place, with obesity. 
This greatly impairs the quality of life of the patients, and may also be ac-
companied depressive disorders.
aims & Methods: The aim of the study was to assess depressive disorders 
and health related quality of life of obese patients with NAFLD in the initial 
stages of liver fibrosis( non-cirrhotic NAFLD). 45 patients (20 men and 25 
women, aged 23- 78 years, mean BMI 30,47 kg/m2 ) were devided into 4 
groups : 10 obese without fibrosis(age 48,6±18,4, BMI 32,2±2,4 kg/m2 ), 
obese with 1 stage of fibrosis(age 55,8±13,6, BMI 32,7±4,7 kg/m2), 11 obese 
with 2-3 stage of fibrosis(age 63±3,7, BMI 34,8±3,7 kg/m2 ), and 11 lean 
without fibrosis(control group) (age 49,6±17,7, BMI 22±2,1 kg/m2 ). Liver 
stiffness was measured by share wave elastography, HRQOL was measured 
using the Ukrainian version of the SF-36 Health Survey. 
We assessed the depression with the help of The Beck Depression Inven-
tory (BDI).
results: Main domains of the HRQL score were significantly lower in obese 
patients with NAFLD in comparison to the lean patients: comparing of 
three groups of obese patients with different stages of fibrosis with lean 
patients we found statistically significant difference in Physical health: 
control- F0(t=2,6 p=0,017), in control -F1(t=3,6 p=0,002) and in control - 
F-2-3 groups (t=3,53 p=0,002). Datas of Mental health in the comparing 
group control- F0(t=2,7 p=0,013), control- F1(t=2,5 p=0,019). In comparing 
group with advanced fibrosis no statistically significant difference in Men-
tal health control F2-3 (t1,27 p 0,216).
The depression level is higher in the group of obese patients comparing to 
the lean ans it’s stage is the highest in the F2-F3 group.
conclusion: In obese people HRQL is lower than in lean and it decreases 
with the stage of fibrosis. We suppose that our datas show deterioration 
of the critical assessment of their condition in patients with advanced fi-
brosis.
disclosure: Nothing to disclose 
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Introduction: Lifestyle modification is the only currently recommended 
treatment for nonalcoholic fatty liver disease (NAFLD). Preliminary studies 
of vitamin E and silybin showed beneficial effects on liver function. We 
report on a double-blind clinical trial the effect of Sylimarin and vitamin E 
in patients with NAFLD.
aims & Methods: Randomized, double-blind, clinical trial conducted at 2 
university clinical research centers in 80 patients (aged years) with NAFLD 
conducted between September 2014 and March 2015. All patients were 
randomized to receive vitamins E (400 IU) and Silymarin 280mg daily for 4 
months. Additionally, all patients were given standard weight-loss coun-
seling and encouraged to follow a low fat diet (< 30 fat g/day). Patients 
were obtained at baseline and on after 4 months for measurement of ALT 
and ultrasonography. Given the two planned primary comparisons, P val-
ues of less than 0.05 were considered to indicate statistical significance.
results: There was no significant difference in terms of sex and BMI be-
tween the groups. At the end of the 12-week treatment period there was 
a significant decrease in the serum ALT levels in both treatment groups. 
The mean change in ALT level from baseline to 4 months was 31.6 U/L with 
Sylimarin group vs. -15.1 U/L with vitamin E (P =.07). Therefore, effects in 
the Sylimarin were larger than vitamin E (p < 0.0001). The mean ALT levels 
changed to normal 55.0% (22 of 40 cases) in the Sylimarin group and 
45.0% (18 of 40 patients) vitamin E group (P=0.04). Based ultrasonography 
findings after 4 months in the vitamin E group 4 patients and in the Syli-
marin group 2 cases were normalized. Adverse events (AEs) were gener-
ally transient and included diarrhea, dysgeusia, and pruritus; no serious 
AEs were recorded.
conclusion: In Sylimarin and vitamin E treatment appears to be signifi-
cantly effective in biochemical improvement in decreasing the ALT and 
ultrasonographic measurement, respectively
disclosure: Nothing to disclose 
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P1405 syMPaTheTIc OveracTIvITy and earLy sOdIuM 
reTenTIOn In exPerIMenTaL LIver cIrrhOsIs: a rOLe fOr 
renaLase
Sansoe’ G.1, Aragno M.2, Leone N.1, Berrutti M.1, Ayoubi M.1, Castellino F.1
1Humanitas Gradenigo Hospital, Division of Gastroenterology, Torino, Italy, 
2University of Torino, Department of Clinical and Biological Sciences, Torino, 
Italy
contact e-Mail address: giovannisan@iol.it
Introduction: Sympathetic overactivity promotes sodium retention and 
functional renal failure in liver cirrhosis. Renalase, 38 kDa amine oxidase 
with just 13% aminoacid identity with monoamine oxidase A, is secreted 
into the blood by the kidney and is the only identified form of amine oxi-
dase that clears plasma of circulating catecholamines.
aims & Methods: To study plasma and tissue content and function of 
renalase in experimental preascitic and ascitic cirrhosis. In normal rats 
(group G1), rats with CCl
4
-dependent liver cirrhosis without ascites (G2) 
and with ascites (G3) we evaluated: renalase levels and activity in plasma, 
liver and kidney; renalase gene transcription and immunohistochemical 
localization in liver and kidney; liver histology and matrix deposition, hor-
monal status and kidney function.
results: In plasma, mature (38 kDa) contents and activity, well detected in 
normal rats, were virtually absent in rats with compensated or ascitic cir-
rhosis (all P< 0.01 vs. G1). In G2 and G3 rats, but not in G1, we found large 
amount of enzymatically active high-molecular-weight (78 kDa) renalase 
and very little 38 kDa protein in hepatocytes of regenerative nodules of 
the cirrhotic liver and in kidney tubules. RT-PCR confirmed higher levels 
of renalase gene transcription in both liver and kidney of G2-3 (P< 0.03 vs. 
G1). Rats with preascitic liver damage showed increased plasma catechol-
amines, normal renin-angiotensin system activation and sodium reten-
tion, while ascitic rats had both secondary aldosteronism and increased 
adrenergic activation.
conclusion: High-molecular-weight forms of functional renalase accu-
mulates in diseased liver and kidney, but tissue processing and release 
into blood of mature (38 kDa) renalase is almost absent, contributing to 
increased levels of plasma catecholamines and sodium retention in both 
preascitic and decompensated cirrhosis.
disclosure: Nothing to disclose 
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Introduction: Catecholamines promote proximal tubular fluid retention 
and decrease Na+ and water delivery to the diluting segment of the Henle’s 
loop, thereby reducing renal excretion of solute-free water. In advanced 
cirrhosis, non-osmotic hypersecretion of vasopressin (ADH) has a role in 
causing dilutional hyponatremia, but the advantage of ADH V
2 
receptor an-
tagonists is controversial in the treatment of ascites.
aims & Methods: By means of the use of sympatholytic agents (α2
A 
ad-
renergic receptor agonists), we assessed the hypothesis that adrenergic 
hyperfunction might contribute to water retention in experimental ascitic 
cirrhosis. Hormonal status, renal function and tubular free-water reab-
sorption (TFWR) were evaluated in four groups of rats with ascitic cir-
rhosis: rats with cirrhosis due to 13 weeks of CCl
4
 (group G1); cirrhotic rats 
receiving, from 11th to 13th CCl
4
 week, daily diuretics alone (0.5 mg/kg furo-
semide plus 2 mg/kg K+- canrenoate) (G2), or diuretics plus guanfacine 
oral prodrug (α2
A 
adrenergic receptor agonist and sympatholytic agent) 2 
mg/kg (G3). Group G4 received diuretics plus SSP-004240F1 (V
2
 receptor 
antagonist) 1 mg/kg.
results: Compared to G2, guanfacine plus diuretics (G3) reduced serum 
norepinephrine from 423 ± 22 to 211 ± 41 ng/L and plasma renin activity 
from 35 ± 8 to 9 ± 2 ng/mL/h (all P< 0.03). Compared to G1 and G2, TFWR 
was significantly reduced, and to the same extent, with low-dose guan-
facine plus diuretics (G3) and with V
2 
antagonist plus diuretics (G4) (all 
P< 0.03). TFWR correlated with plasma aldosterone (r=0.51, P< 0.01) and 
urinary potassium excretion (r=0.90, P< 0.001).
conclusion: In ascitic cirrhosis, reduced volaemia, secondary aldosteron-
ism and adrenergic hyperfunction, especially when exacerbated by potas-
sium-depleting diuretics (furosemide), contribute to tubular retention of 
water and dilutional hyponatremia. Low-dose sympatholytic agents are 
as effective as V
2
 antagonists to achieve aquaretic effects in this setting.
disclosure: Nothing to disclose 
P1407 reBaLanced heMOsTasIs In LIver cIrrhOsIs
Pereira F., Azevedo R., Linhares M., Ramos D., Pinto J., Tristan J., 
Banhudo A.
Hospital Amato Lusitano, Gastroenterology, Castelo Branco, Portugal
contact e-Mail address: pereiraflavio14@gmail.com
Introduction: Traditional concepts of liver cirrhosis believed that it present-
ed a pro-haemorrhagic tendency, thought to be the result of laboratory 
abnormalities such as thrombocytopenia and prolongation of the interna-
tional normalised ratio (INR). However, recent evidence indicates that the 
hemostasis in liver cirrhosis is more complex that previously thought. Pro-
duction of both procoagulant and anticoagulant factors is affected, leading 
to a delicate hemostatic rebalance, where a higher risk for both bleeding 
and thrombosis coexists.
aims & Methods: We aimed to investigate the coagulation abnormalities in 
patients with acute decompensated cirrhosis. We conducted a prospective 
observational study including patients admitted with acute decompen-
sated cirrhosis. Measurement of serum level of platelets, von Willebrand 
factor antigen (vWF), prothrombin time (PT), INR, coagulation factors II, V, 
VII, VIII and procoagulant protein C (PC) and antithrombin (AT). Statistical 
analysis with SPSS v25.
results: 55 patients included (91% male; mean age of 61±10 years; 93% 
alcoholic etiology; mean MELD 17±5,6 points; Child-Pugh C 62%). Mean 
serum level values: platelets 115000±64000; PT 20,9±6,9; INR 1,42±0,27; FII 
43,3±15,2 (reference value 50-150); FV 49±22,3 (62-139); FVII 33,5±31,2 (50-
129); FVIII 231±186 (50-150); vWF 491±236 (42-176,3), PC 29,1±17,5 (70-140), 
AT 45,1±25 (83-128). 
Patients with platelet levels below 100 000/uL had higher values of vWF 
(562 vs 405; p<0,05). There was a moderate inverse correlation between 
INR and PC (p<0,05; R=-0,462) and AT (p<0,05; R=-0,434); and there was 
a strong positive correlation between INR and vWF (p<0,001; R=0,544). 
There was also a strong positive correlation between AT and factors V 
(p<0,01; R=0,759) and VII (p< 0,01; R=0,657).
conclusion: This study corroborates the concept that the patient with liver 
cirrhosis presents a complex and fragile hemostatic profile, with prohe-
mostatic and antihemostatic factors that tend to rebalance. Thrombocyto-
penia and prolongation of the INR are compensated by an increase in vWF 
values; a reduction of procoagulant factors (V and VII) is counterbalanced 
by a decrease in PC and AT.
disclosure: Nothing to disclose 
P1408 changes In PLasMa cIrcuLaTIng MIcrOvesIcLes 
In PaTIenTs WITh hcv-reLaTed cIrrhOsIs afTer TreaTMenT 
WITh dIrecT-acTIng anTIvIraLs
Zanetto A.1, Campello E.2, Radu C.M.2, Bulato C.2, Shalaby S.1, Spiezia L.2, 
Franceschet E.1, Burra P.1, Simioni P.2, Russo F.P.1
1Multivisceral Transplant Unit/Gastroenterology, Department of Surgery, 
Oncology and Gastroenterology, Padua University Hospital, Padua, Italy, 
2Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, 
Padua, Italy
contact e-Mail address: sarahshalaby18@gmail.com
Introduction: The eradication of HCV infection by direct-acting antiviral 
agents (DAAs) has been linked to an amelioration of liver synthesis and a 
regression of fibrosis. Although changes in number and type of circulat-
ing microvesicles (MVs) have been reported in cirrhosis, conclusive data 
on the effect of DAAs treatment on MVs profile in HCV cirrhotic patients 
remain scarce.
aims & Methods: To prospectively characterize changes in plasmatic levels 
of endothelial, platelet and hepatocyte MVs, and MVs expressing versican 
core protein (VCAN+) in patients with HCV-related cirrhosis at baseline, 
end of therapy (EOT), at 12, 24 and 48 weeks (W) after EOT by new genera-
tion flow-cytometry, and to correlate these changes with clinical outcome.
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results: Fifty-eight patients were enrolled (86% Child’s A). MVs were in-
creased at EOT versus baseline, though only platelet MVs revealed a sta-
tistically significant difference (p<0.01). MVs levels did not change signifi-
cantly after EOT notwithstanding a steady downward trend towards base-
line levels. In contrast, VCAN+MVs dropped significantly at EOT (p < 0.001) 
and remained low throughout the follow-up. Hepatocyte MVs significantly 
correlated with liver stiffness (r 0.40, p 0.0021). Eight composite outcomes 
occurred during the 1-year follow-up: 3 portal vein thromboses, 2 hepa-
tocellular carcinomas and 3 liver decompensation. Child’s B, the presence 
of F2 oesophageal varices (OR for interaction 19.2 [95%CI 1.45-253.7], p 
0.023) and platelet MVs (OR 1.026 [95%CI 1.00-1.05, p 0.023) correlated 
significantly with clinical outcomes.
conclusion: VCAN+MVs appear to mirror the profibrotic status of the 
cirrhotic disease; hepatocyte MVs correlate with liver stiffness and platelet 
MVs might be associated with a worse clinical outcome.
disclosure: Nothing to disclose 
P1409 sPLeen and LIver sTIffness cOMBIned MOdeL 
fOr PredIcTIng esOPhageaL varIces In PaTIenTs WITh 
cOMPensaTed LIver cIrrhOsIs
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Popescu A.5, Sirli R.L.D.5
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Hepatology, Timisoara, Romania, 2Emergengy County Hospital of Timisoara, 
Hunedoara, Romania, 3University of Medicine and Pharmacy ‘Victor 
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5University of Medicine Victor Babes, Gastroenterology and Hepatology, 
Timisoara, Romania
contact e-Mail address: foncea.camelia@gmail.com
Introduction: Ultrasound based elastography methods and biological 
markers can be used as non-invasive tools for predicting the presence of 
esophageal varices,
aims & Methods: The aim of the study was to formulate and assess the 
usefulness of a new non-invasive score to predict the presence of esopha-
geal varices (EV) in cirrhotic patients.
A prospective study was performed in 77 subjects with compensated liver 
cirrhosis (diagnosed based on clinical, biological and elastographic crite-
ria -Liver transient elastography>12.5kPa[1]), who underwent upper en-
doscopy, abdominal ultrasound, spleen and liver stiffness measurements 
(SSM and LSM, respectively) with a 2D-SWE technique from General Elec-
tric (Logiq E9) and biologic tests in the same session. Reliable SSM and 
LSM were defined as the median value of 10 measurements acquired in a 
homogenous area with IQR/M< 0.30.
results: We obtained reliable SSM in 98.7% (76/77) subjects and reliable 
LSM in 97.4% (75/77). 75 subjects were included in the final analysis, 64% 
(48/75) with EV. The mean SS, LS, spleen size (cm) were significantly higher 
in patients with EV (16.77±2.92 kPa vs. 13.2±2.66 kPa, p< 0.0001; 14.12±2.09 
kPa vs. 11.5±1.56 kPa, p< 0.0001; 14.49±2.09 cm vs. 13.05±1.86 cm, p=0.004, 
respectively). Thrombocytes were significantly fewer in patients with EV 
(90,125±34,425 vs. 135,738 ± 58,905, p=0.0001).
In univariate analysis, SSM, LSM, spleen size and thrombocytes were as-
sociated with the presence of EV, all p< 0.0001. In multivariate analysis, 
the model including SSM, LSM, spleen size and thrombocytes had the fol-
lowing p-values: p=0.01, p=0.01, p=0.03 and p=0.01. Using these factors 
as predictors, by multiple regression analysis, we obtained the follow-
ing score: Presence of EV=0.04*SSM + 0.06*LSM + 0.04*spleen size - 
1*10-6*thrombocytes -1.17. The score had a cut-off value >0.48(AUROC=0.9, 
Se=95.8%, Sp=96.3%, PPV=97.9%, NPV=92.9%) for predicting the pres-
ence of EV.
conclusion: Using the model including SSM, LSM, spleen size and throm-
bocytes we can rule in the presence of EV with a positive predictive value 
of 97%.
references: 1. Castera, L., Forns, X. and Alberti, A. Non-invasive evaluation 
of liver fibrosis using transient elastography. Journal of Hepatology, 2008, 
48(5), pp.835-847.
disclosure: Nothing to disclose 
P1410 sPLeen sTIffness fOr The nOnIvasIve PredIcTIOn 
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Introduction: Ultrasound based elastography methods can be used as non-
invasive tools for predicting the presence of esophageal varices.
aims & Methods: The aim of the study was to establish the usefulness of 
spleen stiffness (SS) values measured by means of two elastographic tech-
niques: point shear wave elastography (pSWE) and 2D-shear wave elas-
tography (2D-SWE) as non-invasive markers for predicting the presence of 
esophageal varices (EV) and to compare their performances.
A prospective study was performed, including 86 subjects with compen-
sated liver cirrhosis who underwent both upper endoscopy and SS mea-
surements (SSM) by means of two elastographic techniques: pSWE - us-
ing virtual touch quantification (VTQ) technology (Acuson S2000-Siemens 
Medical Solutions); and 2D-SWE (LOGIQ E9-General Electric), in the same 
admission. Reliable SSM were defined for both techniques as the median 
value of 10 measurements acquired in a homogenous area with (IQR/M) < 
0.30. Compensated liver cirrhosis was diagnosed based on clinical, biolog-
ical and elastographic criteria (Liver transient elastography>12.5 kPa) [1].
results: We obtained reliable SSM in 98.8% (85/86) by means of 2D-SWE.
GE and in 96.5% (83/86) subjects by means of pSWE-VTQ. 83 subjects were 
included in the final analysis, 63.8% (53/83) of them with EV. The best SS 
cut-off value by 2D-SWE.GE for predicting the presence of EV in our study 
group was 13.4 kPa (AUROC-0.89; sensitivity-85%; specificity- 93.3%; PPV-
95.7%; NPV-77.8%), while for pSWE-VTQ it was 2.8 m/s (AUROC-0.65; 
sensitivity-60%; specificity-70%; PPV-78%; NPV-50%). Based on AUROC 
comparison, 2D-SWE.GE performed significantly better than pSWE-VTQ to 
predict the presence of EV (p=0.0011).
conclusion: Although there are no significant differences between the fea-
sibility of the two methods (p=0.62), it seems that 2D-SWE.GE has a better 
performance in predicting the presence of EV as compared with pSWE-VTQ 
(p=0.0011).
references: 1. Castera, L., Forns, X. and Alberti, A. Non-invasive evaluation 
of liver fibrosis using transient elastography. Journal of Hepatology, 2008, 
48(5), pp.835-847.
disclosure: Nothing to disclose 
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P1411 Is sPLeen sTIffness suPerIOr TO LIver sTIffness 
fOr PredIcTIng POrTaL hyPerTensIOn?
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Introduction: Liver stiffness (LS) and spleen stiffness (SS) are two most 
widely accessible non-invasive parameters for predicting esophageal vari-
ces (EV), but the reported accuracy of the two predictors have been incon-
sistent across studies.
aims & Methods: The aim of the study was to establish the usefulness of 
spleen stiffness (SS) and liver stiffness (LS) values measured by 2D-shear 
wave elastography (2D-SWE.GE) as non-invasive markers for predicting 
the presence of esophageal varices (EV) and to compare their performanc-
es. A prospective study was performed, including 90 subjects with com-
pensated liver cirrhosis who underwent both upper endoscopy and spleen 
and liver stiffness measurements (SSM, LSM) by means of 2D-SWE (LOGIQ 
E9-General Electric), in the same admission. Reliable SSM were defined 
as the median value of 10 measurements acquired in a homogenous area 
with (IQR/M) <0.30. Compensated liver cirrhosis was diagnosed based on 
clinical, biological and elastographic criteria (Liver transient elastogra-
phy>12.5 kPa) [1].
results: We obtained reliable SSM in 96.7% (87/90) and reliable LSM in 
97.7% (88/90) by means of 2D-SWE.GE. 85 subjects were included in the 
final analysis, 63.5% (54/85) of them with EV. The best SS cut-off value 
by 2D-SWE.GE for predicting the presence of EV in our study group was 
13.7 kPa (AUROC-0.88; sensitivity-78%; specificity- 90.3%; PPV-93%; NPV-
66.8%), while the best LS cut-off value was 11.1 kPa (AUROC-0.78; sensi-
tivity-98.1%; specificity-52%; PPV-77,9%; NPV-94,1%). Based on AUROC 
comparison, SS performed significantly better than LS to predict the pres-
ence of EV (p=0.0253).
conclusion: SS seems to be a better tool that LS for predicting the presence 
of EV in cirrhotic patients.
references: 1. Castera, L., Forns, X. and Alberti, A. Non-invasive evaluation 
of liver fibrosis using transient elastography. Journal of Hepatology, 2008, 
48(5), pp.835-847.
disclosure: Nothing to disclose 
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Introduction: The advent of direct-acting antivirals (DAAs) is a major 
breakthrough in hepatology representing the therapeutical standard of 
care in patients with chronic hepatitis C virus infection over the past few 
years. Despite high rates of sustained virological response (SVR), DAAs 
therapy doesn’t eliminate the risk of thrombotic events.
aims & Methods: In our study we aimed to assess the occurrence of throm-
botic events and clinical presentation in patients treated with DAAs and 
sustained virological response. 
We retrospectively analyzed a cohort of patients with HCV-related liver 
cirrhosis treated with PrOD ± ribavirin and LED/SOF ± ribavirin for 12/24 
weeks, in a tertiary gastroenterology center from Romania, between Janu-
ary 1st 2016 and July 1st 2018. All patients with presumption of thrombosis 
were evaluated by vascular Doppler, abdominal ultrasound and confirmed 
by CT scan.
results: The study included 473 HCV-infected cirrhotic patients treated 
with PrOD or LED/SOF, with documented SVR, mean age 69,7 ± 5,5 years, 
predominantly female (59%).Of the total number, 284 (60.04%) received 
PrOD and 189 (39.95%) patients were treated with LED/SOF. Thrombot-
ic complications were reported in 23 (4.86%) patients: 3 (13.04%)with 
deep vein thrombosis, 14 (60.86%) with portal vein thrombosis (PVT), 6 
(26.08%) with malignant PVT. 
All patients had associated cardiovascular (15-65.21%) and metabolic 
comorbidities (8-34.78%). The main clinical manifestations at diagnosis 
were: swelling,edema, erythema and lower limb pain in 3 patients, upper 
digestive haemorrhage in 8 patients, ascitic decompensation in 4 patient, 
abdominal pain in 5 patients and 3 patients were asymptomatic. 
Biologically there was no significant change in prothrombin serum 
levels(baseline values in patients treated with PrOD was 11.67 ± 0.91 versus 
11.70 ± 0.83 at SVR,p=0.993, respectively 11.5 ± 0.84 sec at baseline ver-
sus 11.4 ± 0.68 at SVR, p=0.715 inpatients treated with LED/SOF±RBV) and 
platelet count (126 000 (101 500-162 000) vs. 131000 (101 000-165 000), p= 
0.818 in patients treated with PrOD, respectively 94857.14 ± 32 vs. 92428.57 
± 35, p= 0.853, in patients treated with LED/SOF+RBV).
conclusion: We conclude that thrombotic events in patients with HCV-re-
lated liver cirrhosis treated with DAAs are not influenced by the variations 
of coagulation parameters, rather correspond to the hypercoagulability 
status and the natural evolution of the cirrhotic patient.
disclosure: Nothing to disclose 
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Introduction: Recent studies suggest that follow-up paracentesis, in cases 
of spontaneous bacterial peritonitis (SBP) should only be performed if 
there is a clinical and/or analytic worsening.
aims & Methods: Our aims were to evaluate which patients with SBP ben-
efit from the diagnostic follow-up paracentesis, according to clinical and 
analytical predictive factors of an inadequate response at the third day of 
treatment. 
Retrospective study conducted in a tertiary center, included the patients 
with SBP between January 2011 and June 2018. Clinical/analytical data was 
obtained at baseline and at the third day of antibiotic therapy. An ad-
equate response to therapy, at the third day, was defined by a decrease of 
≥25% in neutrophil count of the ascitic fluid.
results: We included 103 cases of SBP with a mean age of 61±11 years. 
30.1% of cases the patients were under antibiotic prophylaxis for SBP. At 
the third day, 30.1% had an inadequate response to antibiotic therapy. 
At admission, the presence of diabetes mellitus (p=0.034), a higher se-
rum neutrophils count (p=0.043), a lesser level of serum total proteins 
(p=0.040) and a positive culture in ascitic fluid (p< 0.001) were related 
to inadequate response. At day 3, a higher level of serum urea (p=0.018), 
creatinine (p=0.030), CRP (p=0.001), a higher count of serum leucocytes 
(p=0.001) and neutrophyles (p=0.001), the presence of fever (p=0.047) and 
abdominal pain (p< 0.001) were associated to absence of response, too. 
In the multivariate analysis, diabetes mellitus (OR=5.33; 95% CI:1.24-
22.96), positive ascitic fluid culture at admission (OR=15.66; 95% CI:2.41-
101.94), abdominal pain at day 3 (OR=3.94; 95% CI:0.94-16.45; p<0.06) 
and CRP at day 3 (OR=1.02; 95% CI:1.00-1.03) were independently and 
significantly associated to inadequate response at the third day of empiric 
therapy. 
The predictive model presented good accuracy [AUROC of 0.85 (p< 0.001) 
(Fig. 1)] - a cutoff of 0.055 had a sensitivity, specificity, positive predictive 
value, and negative predictive value for absence of response to antibiotic 
of 100%, 35%, 42%, and 100%, respectively. 
With this model cutoff, 24% of repeated paracentesis could be precluded 
in our population sample.
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conclusion: These results evidence that, in approach of SBP, the perfor-
mance of follow-up paracentesis, three days after the beginning of empiric 
therapy, should be individualized, according the conjugation of clinical 
and analytic variables. With our model a considerable number of unnec-
essary procedures may be avoided.
disclosure: Nothing to disclose 
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Introduction: Poor muscle function and sarcopenia has previously been 
shown to be a negative prognostic factor in advanced liver disease (Hanai 
et al, Nutrition 2015). However, the impact of muscle function on prognosis 
in compensated chronic liver disease (CLD) is unknown.
aims & Methods: We aimed to assess the potential prognostic value of 
muscle performance in a cohort of patients with a variety of common CLDs. 
Our primary aims were to assess mortality and transplant-free survival.
We followed a consecutively recruited cohort of patients with compen-
sated CLD (Child- Pugh < B/C) that were enrolled in a study on muscle 
function and CLD in our institution between 2010 and 2014. In all, 270 
CLD outpatients accepted inclusion (52±15 years at baseline,59±15 at follow 
up, mean±SD; 151 females). Twenty-nine patients with a history of hepatic 
decompensation (e.g., ascites) or Fibrosis 4 score (FIB-4) ≥3.25 indicating 
cirrhosis were excluded. Diagnoses in the remaining 241 subjects were 
primary biliary cholangitis (PBC; n=41), primary sclerosing cholangitis 
(PSC; n=42), autoimmune hepatitis (AIH; n=48), and viral hepatitis (HBV, 
n=51; HCV, n=59). All subjects performed four validated tests of muscle 
function: “Timed Up and Go” test (TUG, dichotomized into >10 seconds), 
walking speed (self-chosen and maximal walking speed, 30 m distance; 
m/s), handgrip strength with a dynamometer (maximum and average 
strength over 10 sec; N), and standing heel-rise test (number of heel-
rises). In addition, using a seven-grade scale questionnaire for physical 
activity level, from 0 = no to 6 = regular strenuous physical activity several 
times/week, we dichotomized the study population into those with levels 
0-4 and 5-6. By comparisons with data of an age and gender matched 
reference population we estimated muscle performance as percentage of 
normal and dichotomized patients into groups with normal or impaired 
muscle performance for each muscle test. Follow up data for mortality and 
liver transplantation was obtained through hospital records and Swedish 
population registries.
results: In our population, at baseline muscle function was impaired in 
several tests: standing heel-rise test (n=16 normal test, 7%), maximum 
(n=54, 22% normal test) and average grip strength (n=56, 23% normal 
test), self-chosen (n=169, 70% normal test) and maximum walking speed 
(128, 53% normal test), TUG>10 seconds (n=42, 17%). Physical activity level 
5-6 (n=35, 15%). 
During a follow up of a mean of 6.75±1.4 years, 14 patients died (6%) 
and 10 (4%) patients underwent liver transplantation. TUG over 10 seconds 
was associated with a lower survival (Kaplan-Meier, log rank test p=0.041), 
however not with transplant free survival (p=0.248). The other physical 
functioning tests including physical activity level, self-chosen and maxi-
mum walking speed, maximum and average handgrip strength were not 
significantly associated with mortality or transplant free survival (Kaplan-
Meier, log rank test p>0.05 for all).
conclusion: Timed up and go test was a predictor of mortality in our popu-
lation of compensated chronic liver disease. The prognostic value of this 
test in patients with fully compensated liver disease should be evaluated 
in further trials.
disclosure: Nothing to disclose 
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Introduction: Portal vein thrombosis (PVT) is recognized as one of the com-
plications of liver cirrhosis. Anticoagulation treatment could be indicated 
in patients with PVT, but the efficacy remains unclear.
aims & Methods: We aim to investigate the characteristics of PVT and the 
efficacy of anticoagulation treatment in cirrhotic patients diagnosed with 
PVT. A total of 116 cirrhotic patients who were diagnosed with PVT between 
January 2018 and December 2018 were retrospectively analyzed in this 
study. Complete response (CR) for anticoagulation treatment was defined 
as repermeabilization of PVT assessed by dynamic imaging.
results: The baseline characteristics of all patients were as follows : age, 
61.26±11.33 years old; platelet counts, 90 × 106 /L; ALT, 30 U/L; albumin, 
3.2 g/dL; PT, 64%; D-dimer, 4.6 ng/mL; AT-3 56% and the etiology of the 
liver cirrhosis (viral B hepatitis/ viral C hepatitis/alcoholic/ NASH/other), 
17.2%/33.6%/22.4%/22.4%/4.3%. 
Among patients with liver disease, 51 patients (44.0%) had history of liver 
cancer and the mean MELD score was 15.21±7.11. Almost half of PVT were 
located in the main trunk of portal vein (61/116.) Twenty seven patients 
(23.3%) received an anticoagulant treatment. 
Most of the patients received low weight molecular heparine (59.3%), fol-
lowed by acenocoumarol (25.9%) and only 14.8% of the patients received 
direct oral anticoagulant treatment. During the study period half of the 
patients 58 (50.0%) remained stationary, 40 patients had improvement 
of the PVT (34.5%) and in 18 patients PVT worsened. The anticoagulant 
treatment did not influenced PVT evolution. In 24 patients that received an 
anticoagulant treatment PVT improved or remained stable. 
However, 14 patients (12.1%) died during the study, none of them from 
bleeding complications. The anticoagulant treatment was not associated 
with an increased mortality rate (OR 0.899, CI 0.228-3.440, p=0.862).
conclusion: Anticoagulation treatment for PVT was safe, although did not 
influenced PVT evolution. Careful management should be necessary after 
anticoagulation treatment.
references: 1. Sarin SK, Philips CA, Kamath PS, et al. Toward a compre-
hensive new classification of portal vein thrombosis in patients with cir-
rhosis. Gastroenterology 2016;151:574-577 2. Lisman T, Porte RJ. Nery F, 
Chevret S, Condat B, et al. Groupe d’Etude et de Traitement du Carcinome 
Hépatocellulaire. Causes and consequences of portal vein thrombosis in 
1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 
2015;61:660-667
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Introduction: The non selective beta-blockant (NSBB) treatment in cirrhotic 
patients has several limitations regarding side effects, as arterial hypo-
tension or bradicardia. Caution should be taken in cirrhotic patients with 
refractory ascites, hyponatremia or arterial hypotension, as NSBB could 
precipitated the development of the acute kidney injury.
aims & Methods: The aim of this study was to evaluate the risk of variceal 
bleeding after the NSBB treatment is stopped in patients with refractory 
ascites. All consecutive patients with liver cirrhosis and refractory ascites 
admitted to the Institute of Gastroenterology and Hepatology from January 
2017 to December 2017 were included in this study. The diagnosis of refrac-
tory ascites was established according to the current guidelines.
results: During the study period a total of 57 patients were diagnosed 
with refractory ascites. In more than half of them, 29 patients (50.8%), 
the NSBB treatment was stopped, the main cause of stopping the treat-
ment being systolic blood pressure less than 90 mmHg. The majority of the 
patients were receiving propranolol (86.2%), and only 4 patients (3.8%) 
received carvedilol. Out of the 29 patients that stopped the treatment, 21 
(72.4%) were Child-Pugh class C, and 5 patients (17.2%) developed vari-
ceal bleeding. The risk of variceal bleeding was not increased in cirrhotic 
patients with refractory ascites that stopped the NSBB treatment (OR 1.207, 
CI 0.361-4.039, p=0.796).
conclusion: Stopping the NSBB treatment in patients with refractory asci-
tes is not associated with an increased risk of variceal bleeding , despite 
the severity of liver disease.
references: 1. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Por-
tal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and 
management: 2016 practice guidance by the American Association for the 
study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/
hep.28906. 2. Reiberger T, Mandorfer M. Beta adrenergic blockade and 
decompensated cirrhosis. J Hepatol. 2017 Apr;66(4):849-859. doi: 10.1016/j.
jhep.2016.11.001. Epub 2016 Nov 15. Review. PubMed PMID: 27864004.
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Introduction: Baveno criteria safely identify patients who can avoid variceal 
screening endoscopy: A diagnostic test accuracy meta-analysis.
aims & Methods: This meta-analysis aimed to quantify the safety and ef-
ficacy of these criteria. A systematic search was conducted in nine data-
bases for diagnostic accuracy studies. Eligible papers discussed chronic 
liver diseases (CLD) and tested Baveno criteria against endoscopic variceal 
screening. Our main focus was the predictive power of Baveno criteria for 
varices needing treatment. We calculated pooled spared endoscopy rate, 
sensitivity, specificity, and negative and positive predictive values with 
95% confidence intervals (CIs). Heterogeneity was tested by I2-statistics 
and explored by subgroup analysis (cACLD) and meta-regression.
results: The search yielded 27 eligible papers including 6739 CLD cases. 
Pooled spared endoscopy rate was 26.4% (CI: 21.6-31.5%; I2=95.1%). 
Pooled negative predictive value proved to be 99.3% (CI: 98.4-99.8%; 
I2=21.5%). In the subgroup of cACLD, heterogeneity disappeared while 
negative predictive value was maintained. 
Pooled sensitivity was 97.9% (CI: 95.1-99.7%; I2=49.4%), with an I2=9.8% 
in the subgroup of cACLD. Pooled positive predictive value was 8.1%, 
(CI: 13.3-23.5%; I2=93.0%). Pooled specificity was 31.0% (CI: 23.5-39.0%; 
I2=96.5%). Meta-regression proved that body mass index (p=0.042), the 
percentage of non-alcoholic fatty liver disease (p=0.038), and platelet 
count (p=0.027) correlated positively with specificity.
conclusion: The application of Baveno criteria significantly reduces the 
number of unnecessary variceal screening endoscopies while being safe: 
patients with liver stiffness < 20 kPa and platelet count >150x109 cells/L 
carry a very low risk of having varices needing treatment.
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Introduction: To date few evidences are available on the risk of hepatic 
decompensation (HD) related to portal hypertension (PH) after therapy 
with new direct-acting antivirals (DAAs) in patients with HCV-related ad-
vanced chronic liver disease (ACLD). Furthermore, the predictive role of 
non-invasive markers of PH, such as liver (LSM) and spleen (SSM) stiffness 
measurement after DAA therapy is still debated and should be clarified. 
We previously reported that SSM≥54 kPa was able to predict HD in un-
treated HCV patients, better than LSM.
aims & Methods: The aim of this study is to assess the role LSM and SSM 
in HD prediction after sustained virologic response (SVR). 
A cohort study in 146 ACLD patients treated with DAAs and with available 
LSM and SSM both before and 6 months after end-of treatment (EOT) was 
performed in our centre. Patients were prospectively followed up from EOT 
and PH related events were registered. Time-dependent models for HD 
prediction after SVR were applied to account for changes in LSM and SSM 
after DAA therapy.
results: During a follow-up of 33,5 months a total of 20 (13.7%) patients 
developed at least one episode of HD (among these, 3 presented a sec-
ond HD event). The first decompensating event was ascites in the majority 
(17/20, 85%) of patients. 
Three patients developed a second episode of HD. Besides HD develop-
ment, 18 (12.3%) patients developed hepatocellular carcinoma after DAA 
therapy; 3 (2.1%) developed portal vein thrombosis, 4 (2.7%) underwent 
high-bleeding risk varices prophylaxes, 3 (2.1%) underwent liver trans-
plantation and 7 (4.8%) patients died. 
At the multivariate analysis, previous HD (HR, 8.065; 95%CI 2.806 - 23.180) 
and SSM≥54 kPa (HR, 4.678; 95%IC 1.307-16.744) were independently asso-
ciated with a higher risk of HD development after DAAs treatment. Kaplan-
Meier curves were estimated and drawn by the SSM cut-off of 54 kPa ; in 
term of survival, the difference between the two curves was statistically 
significant (p= 0.0007). The time-dependent model including SSM values 
at baseline and at 6 months after EOT predicted post-SVR HD development 
better than the models including LSM and its changes after therapy.
conclusion: SSM is confirmed to be an accurate surrogate of portal hyper-
tension also after SVR achieved with DAA therapy. Moreover, SSM is able 
to stratify for the risk of HD development after DAA therapy more accurately 
than LSM.
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can predict clinical complications in compensated HCV-related cirrhosis: A 
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Introduction: Portal vein thrombosis (PVT) is being increasingly recog-
nized in patients with advanced cirrhosis and in those undergoing liver 
transplantation. Therapy with low molecular weight heparin and vitamin 
K antagonists has been shown to achieve complete and partial recanaliza-
tion. Although anticoagulation therapy related bleeding is the most feared 
complication, studies are showing no increase in the risk of bleeding re-
lated to coagulation
aims & Methods: Clinical, demographic, and biochemical data were retro-
spectively analyzed from a cohort of 150 consecutive patients with cirrhosis 
and portal vein thrombosis who presented from 2010 until 2018 in Fundeni 
Clinical Institute. The patients were followed until death, liver transplanta-
tion or last contact. Survival models were built based on univariate and 
multivariate Cox regression analysis
results: There were 51% men (77 patients), median age at inclusion 54 
years, the main etiology of LC was viral (69%) , 70 patients having VHB or 
VHB+VHD infection and 34 patients with VHC infection. Portal vein throm-
bosis was complete in 47 (31%) patients and localised at portal trunk in 
72% (109 patients), confluent of the PV 55% (83 patients) and superior 
mesenteric vein 35%. (56 patients). LT was performed in 22 (14.66%) pa-
tients. Therapy with anticoagulants was administered in 80 (53%) patients.
Median overall survival from diagnosis of LC was 57.3 months and median 
survival since diagnosis of PV thrombosis was 16 months. Predictive fac-
tors for death identified by univariate Cox regression analysis were: age 
of the patient, initial lab MELD score at diagnosis of PV thrombosis and 
after 6 months of follow-up, absence of administration of anticoagulants, 
progression of PV thrombosis during follow-up, refractory ascites and 
bleeding complications after PV development. Independent predictors of 
death identified by multivariate analysis were: increased age of the patient 
(HR=1.09, p=0.02), increased MELD score at 6 months after diagnosis of 
PV thrombosis (HR=1.27, p=0.01), occurrence of hemorrhagic complications 
after PV diagnosis (HR=4.47, p=0.004). There was no statistical association 
between administration of anticoagulants/type and occurrence of hemor-
rhagic complications.
conclusion: Anticoagulant therapy should be administered to all patients 
with portal vein thrombosis. Lower survival rates should be expected in 
patients with LC and PV thrombosis that are older at diagnosis and have 
an accelerated impairment of liver function and portal hypertension after 
PV development
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Introduction: Direct acting antivirals (DAAs) are a novel and completely 
oral hepatitis C therapy. DAAs are used in most patients being treated 
for hepatitis C, including those with decompensated cirrhosis. Cirrhotic 
patients should be closely monitored after treatment. HCC is thought to 
develop over time as the liver is exposed to inflammation and develops 
fibrosis.
aims & Methods: 
1. To detect risk factors for HCC in cirrhotic patients after DAAs.
2. To evaluate new score for HCC prediction after DAAs in chronic 
Hepatitis C.
We retrospectively evaluated 1240 patients treated with DAAs but 124 pa-
tients who had fibroscan in virology unit, National Liver Institute, Menoufia 
University after informed written consent. Pre-treatment laboratory data 
were collected after multivariate analysis to data we found risk factors for 
HCC with DAAs (High fibroscan, Diabetus mellitus, low paltates and older 
age) this data show in novel score to detect HCC (Age >60 equal points 2 
or younger 1, Fibroscan > 18.5 kPa equal 2 or other equal 1, presence of DM 
equal 2 or other equal 1 and paltates < 100 Iu/ml equal 2) and calculated 
from (4-8 points).
results: All patients who developed HCC was group (I) (35 patients; 
0.028%) and who did not develop HCC group (II), Risk score was calcu-
lated from 124 patients who had fibroscan at base line assesment with 
AUC (0.90) and significant in table (1); after Demographic, clinical and 
laboratory data were compared between group developed HCC and not 
developed HCC, Multivariate models showed that Age (Age >60 years) (OR 
8.9), CI (2-40.8), presence of DM (OR 8.9) CI(3.1 - 26.1), Fibroscan (OR 37) CI 
(5.6-257), Platlates (OR 3.2)CI(0.99 - 1.1).
Test result 
variable
area std. error
asymptotic 
significance
asymptotic 95% 
confidence Interval
Novel score 0.906 0.027 0.000
Lower Bound (0.853); 
Upper Bound(0.959).
[Novel score Area Under the Curve :]
conclusion: 
1. Novel risk score for HCC after DAAs with cut off level (6) with sensitivity 
(80%) and specificity (85%) can predict HCC with DAAs.
2. Higher LSM by fibroscan, older age, DM and lower paltates are risk fac-
tors for HCC after HCV eradication by DAAs.
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Introduction: Variceal bleeding is one of the most fatal complication in 
patients with liver cirrhosis. A screening esophagogastroduodenoscopy 
(EGD) is recommended in all patients with cirrhosis to detect those pa-
tients at risk of variceal bleeding. 
However, with the progressive introduction of non-invasive methods for 
the diagnosis of cirrhosis, an increasing number of patients are diagnosed 
at an earlier, fully compensated stage of the disease, resulting in a large 
number of unnecessary screening endoscopies [1]. Thus, there is an ur-
gent need for noninvasive screening methods for varices in patients with 
chronic liver disease.
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Two-dimensional shear wave elastography (2D-SWE) is a promising new 
type of shear wave-based ultrasound technique for measuring liver stiff-
ness. The shear waves are generated directly within the tissue, allowing 
measuring stiffness also in patients with ascites. The liver stiffness values 
can be obtained on the basis of anatomic information to control major 
measurement bias [2]. This method has equal or superior diagnostic ac-
curacy for the staging of liver fibrosis and portal hypertension in patients 
with chronic liver disease [3, 4]. 
Primary biliary cholangitis (PBC) is one of cholestatic autoimmune liver 
diseases, rare etiology of chronic liver disease. However, there was also no 
coincident cut-off value for predicting high varices, and only several stud-
ies about SWE evaluating the varices in compensated liver cirrhosis, and 
all of studies with all etiology of cirrhosis and small sample sizes [5, 6]. 
The aim of this study was to investigate the diagnostic performance of 2D-
SWE for predicting high-risk varices in patients with PBC related chronic 
liver disease.
aims & Methods: To investigate the diagnostic performance of 2D-SWE for 
predicting high-risk varices in patients with PBC related chronic liver dis-
ease. Clinical data from 182 patients with PBC related chronic liver disease 
who underwent 2D-SWE and endoscopy were collected consecutively. Liver 
stiffness (LS) was measured by 2D-SWE. The time interval between 2D-
SWE and endoscopy examination no more than 3 months. Comparisons of 
the accuracy of prediction between groups were made by areas under the 
receiver operating characteristic curves (AUROCs).
results: The optimal cutoff value for predicting high-risk varices was 13.65 
kPa, AUROC of LS was 0.886(95% CI: 0.837-0.935), sensitivity was 0.759 
and specificity was 0.898. The optimal cutoff value for predicting high-risk 
varices in PBC patients without ascites was 10.2 kPa, AUROC of LS was 
0.887 (95% CI: 0.816-0.959), sensitivity and specificity were 0.957 and 
0.721, respectively.
conclusion: LS of 2D-SWE is reliable predictor for predicting presence of 
high-risk varices in patients with PBC related chronic liver disease. In ad-
dition, SWE is a reliable noninvasive tool for predicting esophageal varices 
with ascites.
references: 1. de Franchis, R., Evolving consensus in portal hypertension. 
Report of the Baveno IV consensus workshop on methodology of diagno-
sis and therapy in portal hypertension. J Hepatol, 2005. 43(1): p. 167-76. 
2. Muller, M., et al., Quantitative viscoelasticity mapping of human liver 
using supersonic shear imaging: preliminary in vivo feasibility study. Ul-
trasound Med Biol, 2009. 35(2): p. 219-29. 3. Elkrief, L., et al., Prospective 
comparison of spleen and liver stiffness by using shear-wave and transient 
elastography for detection of portal hypertension in cirrhosis. Radiology, 
2015. 275(2): p. 589-98. 4. Paul, S.B., et al., Assessment of liver fibrosis in 
chronic hepatitis: comparison of shear wave elastography and transient 
elastography. Abdom Radiol (NY), 2017. 42(12): p. 2864-2873. 5. Petzold, 
G., et al., Evaluation of liver stiffness by 2D-SWE in combination with non-
invasive parameters as predictors for esophageal varices in patients with 
advanced chronic liver disease. Scand J Gastroenterol, 2019: p. 1-8. 6. Kim, 
T.Y., et al., Diagnostic Performance of Shear Wave Elastography for Pre-
dicting Esophageal Varices in Patients With Compensated Liver Cirrhosis. J 
Ultrasound Med, 2016. 35(7): p. 1373-81.
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Introduction: In liver cirrhosis, especially in advanced stages, portal vein 
thrombosis(PVT) is one of the most common complications and its preva-
lence increases with disease severity. PVT is mainly due to hypercoagu-
lable state and altered dynamic of blood flow in the portal vein. Studies 
reported a prevalence of 10-28% in cirrhotic patients, excluding those with 
HCC. Association between liver cirrhosis and malignancies, especially HCC, 
may increase PVT prevalence up to 44%.
aims & Methods: In our study we aimed to evaluate the prevalence of 
portal vein thrombosis in a cohort of patients with liver cirrhosis based 
on Child Pugh score (CPS). We retrospectively analyzed a cohort of pa-
tients with livercirrhosis in a tertiary gastroenterology referral center from 
North-Eastern Romania, between January 1st 2017 and December 31st 2018. 
All patients with presumption of thrombosis wereevaluated by abdominal 
ultrasound and confirmed by CT scan. Were excluded from patientswith 
thrombophilia.
results: The study included 2734 cirrhotic patients with mean age 56,7 
± 5,3 years,predominantly female (1558 - 57%). Of the total number, 143 
(5.23%) patients presented PVT, of which 21 (14.68%) patients with acute 
PVT and 122 (85.31%) patients with chronic PVT. The main clinical pre-
sentation at diagnosis were variably: upper digestive haemorrhage in 
26 (18.18%) patients, ascitic decompensation in 80 (55.94%) patients, 
abdominal pain in 25(17.48%) patients and 12 (8.39%) patients were as-
ymptomatic. The commonest causes of cirrhosis and PVT were alcoholic 
liver disease (30, 20.97%), viral hepatitis B±D (13, 9.09%)viral hepatitis C 
(74, 51.74%), malignant PVT (19, 13.28%) and other causes (7, 4.89%). Of 
the patients included in study, 12 (8.39%) Child-Pugh class A, 81 (56.64%) 
class B and 50(34.96%) class C cirrhotic patients. PVT prevalence is 2.1% 
in compensated liver cirrhosis and up to 23% in decompensated liver cir-
rhosis. Association between liver cirrhosis and malignancies, especially 
HCC, increased PVT prevalence to 42%.
conclusion: Child-Pugh score was higher in patients with PVT, which con-
firms that the prevalence of PVT increases with the severity of cirrhosis 
liver. Thus, PVT prevalence is low in compensated liver cirrhosis and is 
increased in decompensated liver cirrhosis. In addition, in patients with 
liver cirrhosis and HCC, the PVT prevalence was higher, data confirmed by 
the literature.
disclosure: Nothing to disclose 
P1424 ePIdeMIOLOgIcaL PrOfILe Of cIrrhOTIc PaTIenTs WITh 
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1Hospital Universitário Evangélico Mackenzie, Curitiba, Brazil, 2Faculdade 
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Introduction: Digestive hemorrhages (DH) represent high morbidity and 
mortality clinical emergency¹. They can manifest in the form of hemateme-
sis, melena, enterorrhagia and hematochezia². The main cause of DH 
non related to digestive tract affections is the hypertension of the portal 
system. This clinical syndrome is frequent in the liver cirrhosis and the 
growth of esophageal varices (EV) is one of its main complications, with 
predominance in 60% and 80% of the cases¹. Hemorrhage by rupture of 
EV constitutes a bad prognosis in cirrhosis, with mortality between 17% 
and 57%¹. For proper management, endoscopic treatment is indicated, 
through sclerotherapy and elastic ligature of the esophageal varices³.
aims & Methods: To investigate the clinical and demographic profile of the 
cirrhosis patient hospitalized with DH in a university hospital in the period 
from September 2017 to January 2019. This is a retrospective study, made 
through records’ data collection, of 772 patients attended in the Digestive 
Hemorrhage Department of the Hospital Universitário Evangélico Macken-
zie in this period. In September 2017, this hospital became a unique refer-
ence for acute cases of GIB sent by the Public Health System in Curitiba 
(about 3.5 million people). A descriptive and statistical analysis of preva-
lence by age, sex, transfusion, decease, symptomatology of admission, 
smoking, alcoholism, medicine, comorbidities, clinical-surgical conduct, 
endoscopic diagnosis and endoscopic treatment was made.
results: From the 772 patients with gastrointestinal bleeding, 139 present-
ed with cirrhosis diagnosed. The main etiology was alcoholism (76.2% 
patients), followed by hepatitis C and hepatitis B. The most prevalent 
gender was male (107 patients, 77%). The mean age was 55 years old. 
The age range compromised was between 41-50 years old (29.5%). 43 
patients (30.9%) were deceased throughout the internment, 30 men and 
13 women. The mortality rate was higher between women, 40.6% against 
28% of the men. Red blood cells transfusion was necessary in 81 of the 
patients (58.2%). The most common entry symptom was hematemesis, 
with 123 cases (88.4%) and the most common association was hemateme-
sis and melena with 64 cases (46%). The medium level of hemoglobin at 
admission was 8,9 g/dL (3.2-17.6). Among patients, 76.2% were alcohol-
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ism and 28.7% patients were tobacco users. The most frequent comor-
bidity was systemic arterial hypertension (26.6%) and medication most 
associated with digestive bleeding was the usage of anti-inflammatory, 
9 cases (6.4%). At the endoscopic exam, the most frequent finding was 
esophageal varices, 71/139 (51%) of which 24 (33.8%) needed endoscopic 
treatment by elastic ligature. Besides EV, 35 patients (25.17%) presented 
hypertensive gastropathy and 8 manifested gastric varices (5.75%). Ten 
patients had liver transplants and 3 (33.3%) dead.
conclusion: The profile of the patients with hepatic disease and cirrho-
sis admitted for digestive hemorrhages is represented by a male patient, 
above 55 years, alcoholics and with high mortality risk. The main symptom 
observed is hematemesis and presenting esophageal varices.
references: 1. JASMINS, Luís. Rastreio de varizes esofágicas em doentes 
com hipertensão portal: Haverá lugar para um método não endoscópico? 
J Port Gastrenterol., Lisboa, v. 19, n. 1, p. 10-11, jan. 2012. Available from: 
http://www.scielo.mec.pt/pdf/ge/v19n1/v19n1a02.pdf. 2. OLIVEIRA, Mário 
Ramos de; FANGANIELLO, Mário. Hemorragias de causas digestivas: as-
pectos fisiopatológicos e clínicos. Revista de Medicina, São Paulo, v.44, n. 
4, p. 231-245, nov. 1960. Available from: https://www.revistas.usp.br/re-
vistadc/article/download/57800/60851/ 3. Erwin Biecker, “Gastrointestinal 
Bleeding in Cirrhotic Patients with Portal Hypertension,” ISRN Hepatology, 
vol. 2013, Article ID 541836, 20 pages, 2013. Available from: https://doi.
org/10.1155/2013/541836.
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Chaabouni H.3, Maamouri N.3
1La Rabta Hospital of Tunis, Gastroenterology B, Ariana, Tunisia, 2La Rabta 
Hospital of Tunis, Sousse, Tunisia, 3La Rabta Hospital of Tunis, Tunis, Tunisia, 
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GASTROENTEROLOGY, Tunis, Tunisia
contact e-Mail address: yosrasaid10@yahoo.fr
Introduction: Bacterial infections (BI), which are frequent and late compli-
cations of cirrhosis, increase the frequency of hospitalizations, morbidity 
and mortality.
aims & Methods: Our objective was to determine the prevalence of BI and 
to identify predictive factors for readmission within 30 days for all causes 
in cirrhotic patients treated for first BI.
We performed a retrospective analysis of data from consecutive cirrhotic 
patients hospitalized for an IB, recruited from January 2010 to December 
2017.
results: A total of 252 cirrhotic patients were included. Eighty-one (32,1%) 
of them were hospitalized for an IB with average age of 61,6 years [37-
87] and sex-ratio of 0,39. The etiology of cirrhosis was dominated by viral 
origin in 47% of cases. The infection was Community-Acquired in 70,3% 
and nosocomial in 29,6%. These consisted mainly of urinary tract infection 
(49.4%), respiratory infection (14.1%) and ascitic fluid infection (15,1%) 
with two cases of ascitic fluid tuberculation. Escherichia coli (E. coli) was 
the most common germ (52%). E.coli ESBL (extended spectrum beta-
lactamases) was the predominant germ in nosocomial infections (35,7%). 
The median hospital stay was 31 days [6-90]. sixteen patients (19,7%) died 
during hospitalization. During follow-up, 11 patients (13,5%) were read-
mitted within 30 days of discharge. Predictive factors of early readmission 
in univariate analysis were: anemia (p=0,02), hepatocellular carcinoma 
(HCC) (p=0,01), a history of diabetes (p< 0,05), undernutrition (p< 0,05). In 
multivariate analysis, only anemia and HCC were independent predictors 
of early readmission.
conclusion: In our study, BI were dominated by E.coli urinary tract infec-
tions. These infections may represent a relatively higher risk of early read-
mission with anemia and HCC as predictive factors.
disclosure: Nothing to disclose 
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Introduction: The occurrence of renal failure during viral cirrhosis is fre-
quently associated with a poor prognosis. Since most glomerular filtration 
rate (GFR) formulas in these patients are often inaccurate due to the in-
clusion of serum creatinine, a new more specific formula (RFHCGFR) has 
been proposed.
aims & Methods: Our objective was to evaluate the prognostic impact of 
kidney failure estimated by RFHCGFR during viral cirrhosis C.
We performed a retrospective analysis of data from consecutive patients 
followed in our department for viral cirrhosis C recruited from January 
2010 to December 2017. GFR was estimated by MDRD and RFHCGFR. Sur-
vival associated with GFR was estimated by Kaplan Meier method using 
the Log-rank.
results: A total of 112 patients were included with an average age of 62,9 
years [43-83] and sex-ratio of 0,3. Patients were classified by the Child-
Pugh (CP) score into CP A in 42,8%, CP B in 41,9% and CP C in 15,1% 
of cases. The median GFR was 96,3 ml/min evaluated by MDRD and 72.3 
ml/min/1,732 by RFHCGFR. GFR estimated by RFHCGFR was significantly 
correlated to GFR estimated by MDRD (p < 0.0001). Using RFHCGFR, the 
survival at two years was 73,3% in patients with GFR>30 ml/min/1,732 and 
5,2% in patients with GFR< 30 ml/min/1,732 (p=0,02). For the MDRD, there 
was no difference in survival between patients with GFR>30 ml/min and 
those with GFR< 30 ml/min (p=0,09). A significant correlation was noted 
between kidney failure estimated by RFHCGFR and ascitic decompensation 
(p=0.005), bacterial infections (p=0,05) and early readmission within 30 
days (p=0,03).
conclusion: In our study, renal failure estimated by RFHCGFR was a prog-
nostic factor correlated with survival, ascitic decompensation, bacterial 
infections and early readmission.
disclosure: Nothing to disclose 
P1427 cIrrhOsIs assOcIaTed WITh WOrse OuTcOMes In 
PaTIenTs undergOIng BarIaTrIc surgery
Kroner P.T.1, Wijarnpreecha K.2, Hoogenboom S.2, Taner B.3, Croome K.2, 
Harnois D.2, Pungpapong S.4
1Mayo Clinic, Gastroenterology, Jacksonville, United States, 2Mayo Clinic, 
Jacksonville, United States, 3Mayo Clinic, Transplant Surgery, Jacksonville, 
United States, 4Department of Transplantation, Mayo Clinic, Jacksonville, 
United States
contact e-Mail address: thomaskroner@gmail.com
Introduction: Obesity is directly linked to non-alcoholic steatohepatitis 
(NASH). Bariatric surgery (BS) has emerged as a successful treatment op-
tion for obesity, and used as a way to decrease the BMI and positively 
influence a patient’s NASH. Cirrhosis, a complication of NASH, confers an 
increased risk for a broad range of surgical interventions. Smaller studies 
have shown that BS is safe in compensated (Child A) cirrhosis. However, 
large studies examining bariatric surgical outcomes in patients with cir-
rhosis with and without PVT lack.
aims & Methods: The aim of this study is to determine the inpatient 
outcomes of non-transplant patients with liver cirrhosis undergoing BS. 
Case-control study using the 2012-2016 NIS, the largest public inpatient 
database in the US. All patients with ICD9-10CM procedural codes for 
BS were included. Patients with history of liver transplant (LT) and those 
who underwent LT during that admission were excluded. The cohort was 
stratified into two groups: 1) cirrhosis without PVT and 2) cirrhosis with 
PVT. These groups were compared to non-cirrhotic patients undergoing 
BS. The primary outcome was determining the odds of inpatient mortality 
in the two cohorts. Secondary outcomes included determining inpatient 
morbidity, resource utilization, hospital length of stay (LOS), and inflation-
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adjusted total hospital costs and charges. Multivariate regression analyses 
were used to adjust for age, gender, Charlson Comorbidity Index, income 
in patient zip code, hospital region, location, size and teaching status.
results: 965,595 patients underwent BS in the study period, of which 6,470 
had cirrhosis without PVT and 160 had cirrhosis with coexisting PVT. The 
mean age for patients with cirrhosis and no PVT was 58.8 years, while 
the mean age for patients with cirrhosis and PVT was 59.0 years (53% 
and 31% were female, respectively). For the primary outcome, patients 
with cirrhosis and no PVT had increased inpatient mortality odds of 4.03 
(p< 0.01), while patients with cirrhosis and PVT had inpatient mortality 
odds of 13.86 when compared to patients undergoing BS without cirrhosis. 
For the secondary outcomes, patients with cirrhosis with and without PVT 
displayed increased odds of shock, ICU stay, AKI, and multiorgan failure. 
In addition, both cohorts displayed significantly higher additional hospital 
costs. However only patients with cirrhosis and PVT displayed higher total 
hospitalization charges and LOS compared to patients without cirrhosis 
who underwent BS (Table 1).
variable cirrhosis without PvT cirrhosis with PvT
Mortality 4.03 (3.24,5.03) <0.01 13.86 (5.44,35.32) <0.01
Shock 2.56 (2.10,3.12) <0.01 9.02 (3.64,22.32) <0.01
ICU 2.25 (1.91,2.65) <0.01 7.81 (3.56,17.16) <0.01
AKI 1.71 (1.46,2.02) <0.01 6.74 (3.07,14.83) <0.01
Multi-organ failure 1.93 (1.67,2.23) <0.01 5.81 (2.66,12.71) <0.01
Additional Adjusted Costs $2,549 (368,4729) 0.02 $43,334 (24637,62035) <0.01
Additional Adjusted Charges $8,826 (-742,18394) 0.07 $182,059 (67762,296357) <0.01
Additional Adjusted LOS (days) 0.1 (-0.5,0.7) 0.76 13.3 (7.7,19.0) <0.01
[Adjusted odds ratio and additional adjusted means in patients with cirrhosis 
and no PVT and cirrhosis with PVT undergoing BS.]
conclusion: Patients with cirrhosis with and without PVT had higher as-
sociated inpatient mortality and morbidity odds during the admission for 
bariatric surgery compared to patients without cirrhosis. Patients with cir-
rhosis and PVT had higher mortality and morbidity odds than patients 
with cirrhosis alone. This reflects the risk that cirrhosis in itself confers to 
patients undergoing bariatric surgery. Thus, this should continue to be an 
important consideration in patients with cirrhosis evaluated for bariatric 
surgery. Prospective studies are required to better understand the impact 
of cirrhosis, both compensated and decompensated, on bariatric surgical 
outcomes. 
disclosure: Nothing to disclose 
P1428 evIdence-Based PrOTOcOL fOr dIagnOsIs and 
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Introduction: Hepatorenal syndrome (HRS) is one of the deadliest com-
plications of cirrhosis and carries a high mortality. It is treated with an 
association of terlipressin plus albumin. This treatment is very costly, and 
it is paramount to choose wisely those patients who benefit from it. Our 
hospital had an evidence-based protocol for treatment of HRS instituted as 
standard-of-care in 2013.
aims & Methods: 
Purpose: Analyze variables associated to survival in patients diagnosed 
with HRS.
Study design: Historical cohort.
Methods: A search for every patient who received terlipressin in our hos-
pital from 2010 to 2016 was performed, ranging from three years prior and 
after the institution of the protocol. Every chart was reviewed in order to 
determine the diagnosis of cirrhosis and HRS. The data in these charts was 
reviewed and multiple variables were collected. A cox-regression multi-
variate analysis was performed to determine mortality.
results: It was included 46 patients who were diagnosed with HRS, 20 
pre-protocol and 26 post-protocol. Mean age was 58 years-old and 80% 
were male. Most common cause of cirrhosis was alcohol abuse (76%). 
Respectively, mortality for 30-day, 90-day and 365-day was 75%, 89% and 
89% for the pre-protocol period and 61%, 69% and 80% for the post-pro-
tocol period. In multivariate analysis, AST > 40, pre-protocol period and 
Child-Pugh score were associated with higher 30-day and 90-day overall 
mortality. Also, the total mean dose of terlipressin and albumin used per 
patient reduced with the institution of the protocol, reducing from 27 to 22 
mg of terlipressin and from 236 to 144 g of albumin per patient. This was 
not associated with higher mortality.
conclusion: The use of a evidence-based protocol in the treatment of HRS 
translated in a higher survival. Also, it was associated with lower drug use.
disclosure: Nothing to disclose 
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Introduction: Several studies demonstrated a significant decrease in liv-
ers stiffness (LS) values in most, but not all patients following sustained 
virologic response (SVR).
aims & Methods: The purpose of this study was to highlight the factors 
associated with an increase in LS following SVR. 
The study included 254 patients with genotype HCV hepatitis who had a 
SVR following DAA treatment. All were assessed by transient elastography 
(TE) at the start of treatment and 12 weeks after the end of treatment, 
when SVR was assessed). In each patient, 10 valid LS measurements were 
obtained either with M or XL probes. Reliable LSM were defined as median 
value of 10 measurements with Interquartile range/median (IQR/M)≤30%. 
Demographic, biologic (including FibroMax), ultrasonographic data were 
collected and analyzed.
results: Of the 259 patients evaluated, 47 (22.4%) patients had elevated 
LS values at SVR12 as compared to start point, but in only 27 all data was 
available, so the final analysis included 27 patients. In univariate analysis 
only obesity and elevated transaminases at SVR12 were associated with 
LS increase at SVR12 (p=0.0007 and p=0.0008, respectively). In multivari-
ate analysis, the presence of steatosis on ultrasound, obesity and elevated 
transaminases were independently associated to LS increase at SVR12.
conclusion: Obesity, cytolysis and steatosis were associated with LS in-
crease after SVR in patients with HCV hepatitis treated with DAA.
disclosure: Ioan Sporea: Speakers fees: AbbVie, BMS, Gilead, 
Janssen,Philips, General Electric; Advisory boards: AbbVie, Merck; Sie-
mens, Canon Toshiba. Research support: Philips, General Electric Roxana 
Sirli: Philips, General Electric, Abbvie, AstraZeneca, Zentiva, Neola, Dr. 
Reddy, BMS, MSD. Alina Popescu : Philips, General Electric, Abbvie, Astra-
Zeneca, Zentiva, Neola, Dr. Reddy, BMS, MSD, Mylan. 
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28B and IcaM-1 On resPOnse TO dIrecT anTIvIraL TreaTMenT 
aMOng chrOnIc hePaTITIs c egyPTIan PaTIenTs
Elsheredy A.1, Almaeen A.2, Ghazy A.2,3, Helaly G.1, Amer I.4, Ghazy H.5, 
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Introduction: Complete eradication of HCV virus is one of the most im-
portant goals for antiviral treatment research. New direct antiviral agent 
(DAA) therapy has revolutionized for HCV; with higher efficacy and safety 
than peg IFN-α/RBV. However, easy access to DAAs, availability of reli-
able HCV prognostic tests, and affordable costs still remain important 
goals that must be reached to globally eliminate hepatitis C. Genotyping 
of interleukin-28B (IL28B) and intra-cellular adhesion molecule-1 (ICAM-
1) single nucleotide polymorphisms (SNPs) may be helpful to predict re-
sponse to treatment of HCV infected patients; especially when double or 
triple therapy can be used. Thus they could have a role in predicting early 
virological response to DAA.
aims & Methods: 
The aim of the current study was to investigate the impact of IL-28B rs860, 
rs917 and ICAM-1 rs1437 single nucleotide polymorphisms on response to 
treatment with sofosbuvir + Daclatsvir ± Ribavirin, among chronic hepatitis 
C Egyptian patients.
subjects and Methods: Genomic DNA was extracted from a total of 120 
subjects; including 40 healthy volunteers, 80 chronic HCV patients who 
were subdivided into responder and non-responder to direct antiviral 
drugs. IL-28B and ICAM-1 SNP was assessed by 5’ nuclease assay with 
a TaqMan MGB (minor groove binder) probe using StepOne™ Real-Time 
PCR System (Applied Biosystems, Life Technologies). Liver functions’ tests, 
Anti-HCV antibodies, quantification of HCV-RNA and HCV Sequence analy-
sis were done for all subjects under the study.
results: AST and ALT values showed statistically significant increase 
among non- responder HCV patients compared to the other studied 
groups (P=0.001*) while serum albumin and ALK levels did not show any 
statistically significant differences (P=0.173 and 0.076, respectively). All 
HCV patients were positive for anti-HCV antibodies. All samples of HCV 
patients were successfully genotyped and sub-genotyped; 72 patients 
(90%) have HCV genotype 4a, while the remaining 8 cases (10%) have 
genotype 4l. The frequencies of IL 28B rs860 T and ICAM-1 rs 437 C alleles 
were higher among HCV patients, either responders or non-responders, 
when compared to the control group but statistically insignificant (P= 
0.280, 0.305, respectively). On the other hand, IL 28B rs917 G allele is more 
frequent among healthy controls; suggesting their protective role against 
HCV infection (P= 0.045*). Regarding relation between IL-28B and ICAM-1 
polymorphism and response to treatment with DAA, HCV patients with IL-
28B rs917 GG alleles showed an early viral responder compared to those 
carrying TT alleles; these differences were found to be statistically signifi-
cant (P=0.050*). Also, ICAM-1 rs437 CT alleles were more frequent among 
responders and control groups but statistically insignificant. On the other 
hand, for IL 28B rs860 HCV patients with either CT or TT alleles did not 
show any statistically significant differences among all the studied groups.
conclusion: IL-28Brs917 represents protective genotypes as HCV infected 
patients have a statistically significant lower prevalence of IL-28Brs917 GG 
genotype when compared to uninfected individuals. Considering response 
to DAA treatment, the higher frequency of ICAM-1 rs437 CT genotypes ob-
served among responder HCV patients elucidate that ICAM-1 rs437 geno-
typing could be a useful independent tool for predicting outcome of treat-
ment with DAA.
references: Helaly GF, Elsheredy AG, Bedewy ES and Attia NM. Sequence 
Heterogeneity in the Core and NS5A Region of Hepatitis C Virus (HCV) and 
IL-28B Polymorphisms in Predicting Treatment Response among Chronic 
HCV Genotype 4 Infected Egyptian Patients. Int.J.Curr.Microbiol.App.Sci 
(2017) 6(7): 2382-98. Das D, Pandya M. Recent Advancement of Direct-
acting Antiviral Agents (DAAs)in Hepatitis C Therapy. Mini Rev Med Chem. 
2018;18(7):584-596. Spengler U. Direct antiviral agents (DAAs) - A new 
age in the treatment of hepatitis C virus infection. Pharmacol Ther. 2018 
Mar;183:118-26. Sakhaee F, Ghazanfari M, Vaziri F, Jamnani FR, Davari M, 
Gharibzadeh S, et al. The impact of genetic variation in IL28B, IFNL4 and 
HLA genes on treatment responses against chronic hepatitis C virus infec-
tion. Infect Genet Evol. 2017 Oct;54:330-7. Amany A. Ghazy*, Nour M. El-
Etreby. Relevance of HLA-DP/DQ and ICAM-1 SNPs among ovarian cancer 
patients. Front in Immunology 2016 May; 12:202.
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Introduction: Hepatitis B virus reactivation (HBVr) during immunosuppres-
sive drug therapy (ISDT) is a growing concern; however, prospective long-
term follow-up studies are rare.
aims & Methods: In this cross-sectional, prospective study, we analyzed 
two groups of patients showing hepatitis surface antibody (anti-HBs) posi-
tivity/HBV surface antigen (HBsAg) negativity among 225 patients receiv-
ing immunosuppressive therapy and 157 patients receiving antineoplastic 
therapy in our tertiary care center between January 2016 and January 2018. 
We also analyzed the associated factors and determined the necessity of 
prophylactic antiviral treatment. Baseline hepatitis serology, PCR mea-
surements, liver alanine transaminase (ALT) levels and the international 
normalized ratio (INR) were recorded. Routine monthly follow-up of pa-
tients consisted of a complete physical examination and analyses of liver 
enzymes, the INR and HBV serology. According to the national healthcare 
policy, HBV-DNA levels were measured by PCR every three months. Pa-
tients who were HBsAg (+), HBV-DNA (+), anti-HCV (+), anti-HDV (+) or 
anti-HBc (-) were excluded. Because HBVr typically occurs during the first 
six months of ISDT, patients who discontinued treatment because of HBV-
unrelated reasons and/or died before the six-month follow-up threshold 
were excluded and patients with a history of treatment with interferon 
(IFN) or antiviral drugs were excluded. HBVr criteria defined as: loss of 
HBV immune control in HBsAg (-) / anti-HBc (+) patients (i) receiving ISDT 
for a concomitant medical condition; (ii) a rise in HBV-DNA compared to 
baseline; and (iii) reverse seroconversion (seroreversion) from HBsAg-
negative to HBsAg-positive for HBsAg (-) anti-HBc (+). To examine the as-
sociation between anti-HBs titers and HBVr, anti-HBs (+) patients were 
divided into three subgroups: (i) anti-HBs > 1000 mIU/mL (Group A), (ii) 
anti-HBs between 100 and 1,000 mIU/mL (Group B) and anti-HBs between 
0 and 100 mIU/mL (Group C).
results: Among the 579 patients recruited to this study, 144 were excluded 
according to the above-mentioned criteria (74 patients did not meet the 
criteria, and 70 patients were either lost to follow-up, discontinued the 
treatment or died before the 6-month threshold); thus, 435 patients were 
included The mean follow-up time was 25.8 months. We did not detect any 
cases of HBVr, even among 86 patients receiving rituximab (49 of which 
are anti-HBc positive only) and 132 patients receiving tumor necrosis factor 
inhibitors (84 of which are anti-HBs positive only). Furthermore, we did 
not find an association between anti-HBs changes and HBVr, although a 
role for anti-HBs in reactivation has previously been suggested. A sub-
group analysis showed that during the study period, the antibody levels 
did not change in Group A, changed non-significantly in Group B (p=0.25) 
and significantly declined in Group C (p=0.002). However, despite the 
marked decline in antibody levels in Group C, we did not observe any 
cases of HBVr. Changes in the mean ALT and INR levels were not significant 
(p=0.36 and p=0.54, respectively).
conclusion: The risk of reactivation of HBV infection by immunosuppres-
sive and antineoplastic therapy is lower than that suspected in published 
anecdotal reports.
disclosure: Nothing to disclose 
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P1432 nOn InvasIve assessMenT Of POrTaL hyPerTensIOn 
In PaTIenTs WITh advanced fIBrOsIs due TO hePaTITIs c afTer 
TreaTMenT WITh dIrecT acTIOn anTIvIraLs
Moralejo Lozano O.1, Maroto Castellanos M.1, Suárez P.2, 
Colmenares Bulgheroni M.1, Barrajón Masa A.1, Rey Díaz-Rubio E.1
1Hospital Clínico San Carlos, Gastroenterology Unit, Madrid, Spain, 2Hospital 
Clínico San Carlos, Public health and Preventive Medicine Unit, Madrid, 
Spain
contact e-Mail address: oscarmoralejo@gmail.com
Introduction: Patients with advanced hepatic fibrosis due to chronic hepa-
titis C (HCV) receive successful treatment for hepatitis with direct-acting 
antivirals (DAA); however, many of them are still at risk of decompensa-
tion, mainly at the expense of portal hypertension. There are data that 
reflect a lower risk of decompensation in those who achieve sustained viral 
response (SVR), although they are scarce and in the short term.
aims & Methods: We want to make a comparison using an innocuous and 
widely available indirect method such as abdominal ultrasound of the 
most accessible parameters of portal hypertension before and after treat-
ment with DAA in patients who achieve SVR.
Retrospective study of patients with HCV hepatitis and F4 fibrosis treated 
in our center between 2015 and 2017. Data was collected in 2019. The di-
ameter of the portal vein (PVD), the superior mesenteric and splenic veins 
diameter (SMVD, SVD), the bipolar diameter of the spleen (BPSD), and the 
presence of ascites is compared before (in the previous 12 months) and 
after the end of treatment at the first, second and third year. The variables 
PVD, SMVD, SVD, BPSD and ascites are collected as qualitative variables 
(normal vs. pathological); in the case of pathological PVD and BPSD (≥ 
13mm and ≥ 120mm respectively), they are expressed as quantitative vari-
ables in millimeters.
results: There is a decrease in the incidence of splenomegaly after treat-
ment so that those with enlarged BPSD at the start of treatment normal-
ized it by 21.2% in the first year (p = 0.023), 28.2% in the second (p = 
0.001), and 30.8% in the third (p = 0.000), so that the prevalence of sple-
nomegaly changes from 46.45% to 40.43% after one year, 37.42% after 
the second, and 43.63% after the third. Among those with pathological 
BPSD, a statistically significant decrease of 4.22 (1.50-7.21, 95% CI) mm 
was observed at the first year (p = 0.006), 5.57 (2.80-8.55, 95% CI) at the 
second year (p = 0.001), and 6.61 (2.60-10.63, 95% CI) mm at the third year 
(p = 0.002). With regard to the presence of ascites, among the 10 patients 
who presented it at the beginning of treatment, only 2 presented it after 
one year (with 2 new patients who did not present it before), although this 
difference did not reach statistical significance (p = 0.109). By the second 
year, only 1 patient of the initially decompensated remained this way, and 
none of the patients in the third year (with a total of 3 decompensated 
patients who were not decompensated at the beginning of the treatment 
in both the second and the third year), these differences are not significant 
(p = 0.227, and 0.727 respectively).
With respect to PVD, there are no differences before or after treatment, nor 
are there any differences with SMVD or SVD. Among those with a patho-
logical PVD, its quantitative measurement does not show improvement in 
the first, second or third year.
conclusion: An improvement in BPSD (splenomegaly) is observed. This 
could translate an improvement in the hepatic venous pressure gradient 
(HVPG) with a lower risk of decompensation in these patients, as an in-
direct parameter of portal hypertension and predictor of the existence of 
esophageal varices in cirrhosis. We observed for the first time that this 
change is maintained in the long term (3 years), which could translate 
changes in the hepatic architecture with regression of fibrosis. 
Likewise, the data seem to suggest a lower incidence of ascites, without 
being statistically significant. However, other sonographic parameters 
such as PVD, SMVD, or SVD show no improvement.
references: Thrift AP, El‐Serag HB, Kanwal F. Global epidemiology and 
burden of HCV infection and HCV‐related disease. Nat Rev Gastroenterol 
Hepatol. 2017;14:122‐ 132. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer 
H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, 
Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association 
between sustained virological response and all-cause mortality among 
patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 
308: 2584-2593 Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-
Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A 
Systematic Review and Meta-analysis of the Survival Benefit of Achieving 
a Sustained Virological Response. Clin Infect Dis 2015;61: 730-740 Libânio 
D, Marinho RT. Impact of hepatitis C oral therapy in portal hypertension. 
World J Gastroenterol. 2017;23(26):4669-4674. doi:10.3748/wjg.v23.i26.4669
disclosure: Nothing to disclose 
P1433 gLecaPrevIr/PIBrenTasvIr fOr chrOnIc hePaTITIs c 
In Large reaL WOrLd exPerIence sTudy
Flisiak R.1, Zarębska-Michaluk D.2, Janczewska E.3, Krygier R.4, 
Tomasiewicz K.5, Piekarska A.6, EpiTer-2
1Medical University of Białystok, Department of Infectious Diseases and 
Hepatology, Bialystok, Poland, 2Jan Kochanowski University, Kielce, Poland, 
3Medical University of Silesia, Katowice, Poland, 4NZOZ Gemini, Żychlin, 
Poland, 5Medical University of Lublin, Lublin, Poland, 6Medical University of 
Łódź, Łódź, Poland
contact e-Mail address: robert.flisiak@umwb.edu.pl
Introduction: Aim was to follow patients profile and effectiveness of 
chronic hepatitis C (CHC) treatment with glecaprevir/pibrentasvir (GP) a 
pangenotypic regimen in real world settings.
aims & Methods: Patients treated with GP were selected from 10 161 in-
cluded in the EpiTer2 database of treated for CHC between 2015 and 2018. 
Analysis was carried out in 381 patients which started therapy with GP in 
2018, that was compared to data from general population of treated in 
corresponding period (n=3938).
results: Gender distribution (51% females) and age (49±14 years) of pa-
tients treated with GP were similar to general population. Majority of pa-
tients on GP were infected with genotype 1b (51%) or 3 (39%) and these 
proportions were different than in general population (78% and 13% re-
spectively). Majority of GP patients (69%) were treatment naïve, but it was 
lower than in general population (85%). Proportions of cirrhotics (14%), 
decompensation history (0.5%) and Child-Pugh >A (1.2%) in patients 
treated with GP were similar to general population (15%, 0.8%, 1.1% re-
spectively). Majority of patients received 8 weeks regimen (65%), followed 
by 12 weeks (28%). Since there were three treatment failures, sustained 
virologic response rates available in 111 patients for intent to treat and in 
110 per protocol analysis, were 96% and 97% respectively, that was similar 
to general population data. Much more subpopulation analysis, including 
cirrhotics, genotype 3 infected and failures to previous therapies will be 
available in mid 2019 for possible presentation at the meeting.
conclusion: Glecaprevir/pibrentasvir compared to other regimens, was ad-
ministered more frequently to patients infected with genotype 3 and treat-
ment experienced. Effectiveness of this novel regimen in this real world 
study reached up to 97%.
disclosure: Robert Flisiak, Dorota Zarębska-Michaluk, Ewa Janczewska, 
Krzysztof Tomasiewicz, Anna Piekarska received speakers honoraria from 
AbbVie, MSD, Gilead, Robert Flisiak, Krzysztof Tomasiewicz, Anna Piekar-
ska were advisors to AbbVie, MSD, Gilead. Robert Flisiak received research 
grant from AbbVie, Arbutus, MSD, Gilead, Roche Krzysztof Tomasiewicz 
received research grant from BMS Rafał Krygier - nothing to disclose 
P1434 hcvkId-sTudy: cOMParIsOn fOr PrevaLence Of earLy 
renaL fIndIngs aMOng hePaTITIs-c POsITIve and negaTIve 
POPuLaTIOns usIng urIne and PLasMa BIOMarkers
Kaartinen K.1, Vuoti S.2, Honkanen E.1, Färkkila M.A.3,4
1Helsinki University Central Hospital, Department of Nephrology, Helsinki, 
Finland, 2MSD Finland, Espoo, Finland, 3Helsinki University Hospital, 
Department of Gastroenterology, Helsinki, Finland, 4Helsinki University, 
Helsinki, Finland
contact e-Mail address: martti.farkkila@hus.fi
Introduction: Hepatitis C (HCV) infection is known to cause extrahepatic 
kidney manifestations, which are typically discovered at a late stage. HCV-
related nephropathy may show different histopathologic patterns, as both 
glomerular and tubulointerstitial damage have been described in the lit-
erature. Early identification of patients with kidney derangements would 
be beneficial to enable treatment and to avoid progression to chronic kid-
ney disease.
aims & Methods: The primary objective of the prospective, observational 
HCVKID-study is to evaluate the prevalence of renal manifestations among 
HCV+ patients in Finland and to compare those findings to HCV-negative 
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controls complemented by long-term analyses to identify changes from 
baseline. This is a cross-sectional analysis to compare baseline character-
istics between HCV+ patients and healthy controls. 208 HCV-PCR-positive 
male and female patients (≥ 18 years old) were eligible for the study. The 
HCV-negative control group (n= 492) was enrolled by an occupational 
healthcare provider. Exclusion criteria were HIV or Hepatitis B or other 
underlying diseases that may influence kidney function.
results: The prevalence of any renal finding (abnormal proteinuria, oc-
currence of hematuria or serum creatinine over upper normal limit) was 
significantly more frequent in the HCV+ -population compared to healthy 
controls (41/208 vs. 45/492), p = 0.0002. Occurrence of abnormal pro-
teinuria as evaluated by various methods was the most common urinary 
finding among HCV+ patients. Protein dipstick test was positive in 4/201, 
tubular proteinuria marker A1Miglo in 22/208 and albuminuria marker Al-
bCrea in 8/208. Elevated serum cystatin-C was also prevalent among HCV+ 
-patients (72/208), however s-creatinine was abnormal only in 7/208. Glo-
merular filtration rate (eGFRepi) was significantly lower in the HCV+ popu-
lation with renal findings, albeit within normal limits. Estimated time from 
HCV transmission, infection genotype or stage of liver fibrosis were not 
significantly different between HCV + with renal finding vs. HCV + without 
renal finding. Baseline blood values and liver parameters were similar 
among both HCV+ populations. SVR12 data on 97 patients revealed early 
improvements in liver enzymes and APRI scores, but not in proteinuria 
markers, serum creatinine or cystatin-C.
conclusion: HCV seems to influence both renal tubular and glomerular 
cells as judged by different proteinuria profiles. Tubular cell damage may 
be the earliest sign of renal dysfunction caused by HCV and could poten-
tially be used to identify patients with a higher risk to develop more severe 
renal manifestations.
references: Lai T, Lee MH, Yang HI, You SL, Lu SN, Wang LY, Yuan Y, L’Italien 
G, Chien KL, Chen CJ; REVEAL-HCV Study Group. High hepatitis C viral load 
and genotype 2 are strong predictors of chronic kidney disease. Kidney 
Int. 2017; 92(3):703-709. doi: 10.1016/j.kint.2017.03.021. Ozkok A, Yildiz A: 
Hepatitis C virus associated glomerulopathies. World J Gastroenterol. 
2014;20(24):7544-54 Ferri C, Giuggioli D, Colaci M. Renal manifestations of 
hepatitis C virus. Clin Liver Dis 2017; 21: 487-97
disclosure: Grant from MSD. 
P1435 daPs scOre: PredIcTIve MOdeL fOr sIgnIfIcanT 
fIBrOsIs In Idahs
Sundaram S., Darak H., Bhatia S.
Seth GS Medical College & King Edward Memorial Hospital, Department of 
Gastroenterology, Mumbai, India
contact e-Mail address: drsridharsundaram@gmail.com
Introduction: Up to 20% of Incidentally Detected Asymptomatic Hepatitis 
B patients (IDAHS) have significant fibrosis at presentation. Management 
of IDAHS, especially those with normal Alanine Transaminase (ALT) has 
been a topic of debate. We aimed to study predictors of significant fibrosis 
in IDAHS and to develop a composite clinical score for prediction of sig-
nificant fibrosis.
aims & Methods: A retrospective review of IDAHS referred to the Liver clin-
ic at King Edward Memorial Hospital from May 2018 to December 2018 was 
done. Demographic details of the patients were noted. Patients underwent 
investigations including complete blood count, liver function tests, HBeAg 
assay, HBV DNA PCR and ultrasound of abdomen. Liver stiffness measure-
ments were taken using the Fibroscan 430 Mini machine (Echosens Ltd., 
Paris, France) using the M or XL probe attachments after an overnight fast. 
10 readings were taken with success rate of >80% and interquartile range 
of < 30% as standard. Fibroscan values of >8 kPa were classified as signifi-
cant fibrosis (>F2) as per the APASL criteria and those with values >11 kPa 
were considered as cirrhosis.
results: 299 patients were included, of which 63% were male with mean 
age of 42.6 years. 20% patients were obese as per BMI criteria. 226 
(75.9%) were HBeAg non-reactive. 5 patients had concomitant HCV and 
4 had HIV infection. Significant fibrosis was seen in 82 (27.4%) patients. 
36 patients (12%) were cirrhotic on VCTE. 39 (19.6%) patients with normal 
SGPT had evidence of significant fibrosis. Higher Age, Higher mean SGPT, 
lower platelets and presence of Diabetes was associated with significant 
fibrosis (p<0.05) on Univariate Analysis. HBV DNA levels, HBeAg and pres-
ence of obesity were not associated with significant fibrosis. Multivariate 
analysis revealed higher SGPT, lower platelets, higher age and Diabetes 
were associated with fibrosis. Hence prediction model using Platelets 
(>240000/cu.mm =0, <240000/cu.mm=1 point), Age (<45 yrs =0, >45 yrs =1 
point), presence of Diabetes (No=0, Yes= 1 point) & SGPT (<45 U/L=0, >45 
U/L=1 point) was developed. Patients were sub-stratified based on cumu-
lative score as low risk (0-2 points) and high risk (3-4 points). Those with 
high risk had OR of 14.9 (95% CI- 4.89-45.84) over those with low risk for 
fibrosis. On internal validation, DAPS score had accuracy of 77.3% with 
specificity of 98.2%.
Parameter Points= 0 Points= 1
Associated Diabetes Mellitus No Yes
Age <45 years >45 years
Platelets >240,000/ cu.mm <240,000/ cu.mm
SGPT <45 U/L >45 U/L
  Total score- 0-2 Low risk 3-4 High risk  
[DAPS Score for fibrosis prediction in IDAHS]
conclusion: High proportion of IDAHS have significant fibrosis (27%) at 
presentation. 20% patients with normal SGPT have fibrosis on VCTE. In 
low resource settings where non-invasive assessment of fibrosis is not fea-
sible, DAPS score can be used for prediction of significant fibrosis in IDAHS 
with high specificity.
references: NA
disclosure: Nothing to disclose 
P1436 usefuLness Of shear Wave eLasTOgraPhy BefOre 
and afTer dIrecT-acTIng anTIvIraL TreaTMenT fOr hePaTITIs 
c vIrus
Kasai A., Mawatari S., Taniyama O., Ijuin S., Sakae H., Tabu K., Oda K., 
Kumagai K., Ido A.
Kagoshima University Graduate School of Medical and Dental Sciences, 
Digestive and Lifestyle Diseases, Kagoshima, Japan
contact e-Mail address: a-kasai@m3.kufm.kagoshima-u.ac.jp
Introduction: Direct-acting antivirals (DAA) for hepatitis C virus have 
helped achieve a high sustained virologic response (SVR). While the ideal 
method of determining the risk of hepatocellular carcinoma (HCC) devel-
opment is unclear, some studies have shown an association of liver stiff-
ness and Mac-2 binding protein glycosylation isomer (M2BPGi) with liver 
carcinogenesis. We evaluated the liver stiffness using shear wave elastog-
raphy (SWE) before and after DAA treatment and examined its usefulness 
for predicting HCC development.
aims & Methods: We enrolled 84 patients with hepatitis C virus infection 
who underwent SWE before and after DAA treatment at our hospital and 
examined the relationship between the SWE value and fibrosis markers, 
such as M2BPGi and hyaluronic acid. The SWE value was measured using 
a Logiq E9 (44 cases; General Electric Company) or an Aplio 500 (40 cases; 
TOSHIBA). The SWE value was measured with the same device throughout 
a given patient’ course.
results: The average age was 67 years old (range 43-87), 38 patients were 
men, and 20 had cirrhosis (23.5%). Nine patients (11%) had a history of 
HCC. DAA treatment comprised Daclatasvir and Asunaprevir in 27 cases, 
Sofosbuvir and Ledipsvir in 38 cases, Ombitasvir and Paritaprevir in 1 case, 
Sofosbuvir and Ribavirin in 15 cases, and Elbasvir and Grazoprevir in 3 
cases. The SVR rate with treatment was 92.9%. The pre-treatment SWE 
values measured with the Aplio 500 were positively correlated with the 
FIB-4 index (Correlation coefficient, r = 0.8, p < 0.001), hyaluronic acid 
level (r = 0.515, p = 0.014), M2BPGi level (r = 0.671, p = 0.024), and alpha-
fetoprotein (AFP) level (r = 0.421, p = 0.007). There was a negative correla-
tion with the platelet count (r = −0.652, p < 0.001) and albumin level (r = 
−0.374, p = 0.019). Similarly, the pre-treatment SWE values measured with 
the LogiqE9 were positively correlated with the FIB-4 index (r = 0.353, p = 
0.019), hyaluronic acid level (r = 0.345, p = 0.042), and M2BPGi level (r = 
0.474, p = 0.013). The average SWE value with the Aplio500 was 1.94 m/s in 
cases with an FIB-4 index < 3.25 (equivalent to F0-2) and 2.43 m/s in those 
with a value ≥3.25 (equivalent to F3 or higher); those respective values 
with the Logiq E9 were 1.39 m/s and 1.49 m/s. The SWE value decreased 
in 67.9% of cases after DAA treatment, and the average value before treat-
ment, at the end of treatment (EOT), 6 months after the EOT, 12 months 
after the EOT and 24 months after the EOT were 2.18, 2.18, 2.01, 1.98, and 
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1.86 m/s with the Aplio 500, respectively, and 1.45, 1.36, 1.29, 1.28, and 
1.19 m/s, with the LogiqE9, respectively. We divided patients with SVR who 
had no history of HCC into two groups based on whether or not the SWE 
value decreased after the EOT. We compared the baseline values of ala-
nine aminotransferase, platelet, AFP, and FIB-4 index between these two 
groups but noted no marked differences. However, in the patients whose 
SWE value decreased, the M2BPGi level was significantly lower at 6 and 12 
months after the EOT than at EOT (p < 0.001, 0.002, respectively), with no 
such changes noted in the patients whose SWE value did not decrease (p 
= 0.467, 0.921 respectively).
conclusion: A decrease in the SWE value after DAA therapy likely reflects 
improvement in the liver inflammation. However, there were some pa-
tients in whom the SWE levels did not decrease after the EOT. In those 
patients, the M2BPGi also did not decrease, suggesting that these patients 
may be at risk of liver carcinogenesis.
disclosure: Nothing to disclose 
P1437 sTudy Of The resPOnse and safeTy Of dIrecT acTIng 
anTIvIraL cOMBInaTIOn TheraPy In hePaTITIs c vIrus-reLaTed 
chILd-B LIver cIrrhOsIs
Ibrahim Mohamed H.1, Ahmed Sakr A.2, Reda Mohamed M.3
1Faculty of Medicine-Menoufia University, Tropical Medicine Department, 
Shebeen El-Kom, Egypt, 2Faculty of Medicine-Menoufia University, Tropical 
Medicine Department, Shibin El-kom-Menoufia, Egypt, 3Shibin El-Kom Fever 
Hospital, Hepatology and Gastroenterology Department, Shibin El-Kom, 
Egypt
contact e-Mail address: aymanahmedsakr@gmail.com
Introduction: Direct-acting antiviral drugs (DAAs) have revolutionized the 
treatment for patients with chronic hepatitis C virus (HCV) infection, with 
excellent rates of sustained virologic response(SVR). Patients with HCV-
related Child -B liver cirrhosis are poorly evaluated in the clinical trials 
of DAAs.
aims & Methods: In this cohort multicentral cross-sectional study, we fo-
cused on the effectiveness and safety of DAAs for the treatment of Child 
B- cirrhotic Egyptian patients with chronic HCV infection genotype(GT-4) 
in a routine clinical practice. Child -Pugh score was calculated for all pa-
tients, those with score 7 to 9 was selected(Child-B). All patients’ data 
including demographic, clinical and laboratory measures were recorded. 
Child B patients (hard to treat) with a total number (n=326);269 naïve and 
57 experienced were compared to Child A patients (easy to treat) (n=275), 
all of them were naive.
results: In Child A patients, 260 had sofosbuvir (SOF)and daclatasvir 
(DAC) for 12 weeks,13 had SOF plus simeprevir (SIM) for 12 weeks and 
2 had Ritonavir-Paritaprevir-Ombitasvir-Ribavirin for 12 weeks. While, in 
Child B patients; 86 had SOF-DAC for 24 weeks, 233 patients had SOF-
DAC-RVB for 12 weeks. (98.9%) of Child A patients had completed their 
course and 1.1%stopped treatment due to pregnancy, However, in Child B 
only (91.1%) had completed their course (P< 0.001); 29 stopped treatment 
due to complications (hematemesis 2.8%, jaundice 1.8%, ascites0.6% or 
anemia aggravation2.8%, hepatic encephalopathy0.6%)with statistically 
significant difference between both groups (P- 0.001).SVR-12 achieved 
in 98.5%&86.7%in Child A&B, respectively with statistically significant 
difference(P< 0.001).In both groups, HB, PLT, ALT, AST, s.albumin and bili-
rubin improved post- than pre-treatment levels(p-< 0.001).Regarding the 
risk factors for non-SVR-12; increasing age, male gender, experienced pa-
tients, with SOF-DAC for 12 weeks, moderate to severe ascites and Child 
score 9 were highly statistically significant difference (p-value=0.000). At 
SVR-12 in Child B group,3/297 (1%)patients developed hepatic focal lesions 
(HFLs), 5(1.7%) developed new jaundice,20% has developed new-onset or 
a deterioration of pre-existing ascites and 1.2%developed upper gastroin-
testinal bleeding.
conclusion: Real-world results of generic DAAs combinations in Egyptian 
patients with chronic HCV-Child B were very safe and effective with SVR-
12 (98.5%&86.7%) with very rare reported complications (0.01%,0.9%) in 
Child A&B, respectively.
disclosure: Nothing to disclose 
P1438 The effecT Of InTerferOn TheraPy On naTuraL 
cOurse Of hePaTITIs d
Bakkaloglu O.1, Yildirim O.2, Karaca C.3
1Istanbul University Cerrahpasa, Gastroenterology and Hepatology, Istanbul, 
Turkey, 2Diyarbakir State Hospital, Diyarbakir, Turkey, 3Istanbul University, 
Istanbul, Turkey
contact e-Mail address: o.k.bakkaloglu@gmail.com
Introduction: Hepatitis Delta Virus (HDV) is a defective virus that can only 
cause hepatitis on hosts already infected with Hepatatis B virus (HBV).
Compared with other viral hepatitis; chronic delta hepatitis (CDH) has a 
higher incidence of end stage liver disease and hepatocellular carcinoma.
Treatment goal of HDV infection is either eradication of both HBV and HDV 
or long-term suppression of disease activity. 
Today the only approved treatment opportunity of CDH is alpha inter-
pheron (IFNα). Previous clinical trials claim a high dose long term IFNα 
treatment has a higher chance of virological, biochemical and histological 
response with a ameliorated natural course of disease.
aims & Methods: This study aims to asses long term histological, virologi-
cal and biochemical outcomes of our patients treated with IFNα. Data of 
48 CDH patients who had been treated with IFNα for at least 1 year and 
who were non cirrhotic at the beginning of follow up were assessed ret-
rospectively. . Demographic characteristics, biochemical, serological and 
histological parameters of patients were reviewed. Cirrhosis diagnosis 
was supported with objective findings of portal hypertension. Pre and post 
treatment liver biopsy Ishak fibrosis staging scale scores were compared.
Patients were grouped according to fibrosis score change as increasing, 
decreasing and steady groups. Histological course, virological and bio-
chemical responses were comparatively analyzed.
results: 48 patients were followed for mean 7 years. Post treatment fol-
low up was mean 5 years. 24 of 48 patients were observed to be cirrhotic 
during follow up. Virological response rate of patients treated with clas-
sical IFNα was %37 while patients treated with pegylated IFNα had % 41 
virological response rate. Sustained virological response (SVR) rate among 
patients was %37 at the end of follow up. There was statistical correlation 
in between histological response rates and virological and biochemical 
responses. Biochemical response is accepted as normalized serum ALT 
value. Pre - post treatment liver biopsy fibrosis scores of 24 patients who 
were non cirrhotic at the end of follow up; were compared, the result 
was statistically non - significant (p=0,979). Patients with decreasing or 
steady fibrosis scores are accepted as histological responders. 6 patients 
(%13) were in decreasing fibrosis score group, 10 patients (%21) were in 
steady fibrosis score group while 8 patients (%16) were in increasing fi-
brosis score group of total 24 patients with both pre and post treatment 
liver biopsies.
conclusion: This study revealed long term natural course of patients treat-
ed with IFNα at least for 1 year. IFNα therapy hasn’t changed the natural 
course, however 2 of 3 patients have clinicaly and hystologicaly progressed.
disclosure: Nothing to disclose 
P1439 adherence TO TreaTMenT and TheraPeuTIc success 
In PeOPLe WhO InjecT drugs WITh hePaTIs c vIrus InfecTIOn In 
a TerTIary care hePaTOLOgy cenTer
Bota S., Razpotnik M., Hucke F., Flatscher K., Peck-Radosavljevic M.
Klinikum Klagenfurt am Wörthersee, Department of Internal Medicine and 
Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology and 
Nephrology and Emergency Medicine (ZAE) with Centralized Endoscopy 
Service, Klagenfurt, Austria
contact e-Mail address: bota_simona1982@yahoo.com
Introduction: Hepatitis C therapy with directly-acting antiviral agents (DAA) 
(especially pangenotypic) is associated with a sustained virological re-
sponse (SVR) >95% in a real world setting with almost no adverse events. 
The World Health Association published a strategy to eliminate hepatitis 
C by 2030. People who inject drugs (PWIDs) are often less-compliant to 
treatment and have a high risk of reinfection. Hepatitis C elimination will 
be difficult in this group of patients.
aims & Methods: The aim of this study was to investigate the adherence to 
treatment, SVR rate and reinfection rate in PWIDs with hepatitis C.
Our retrospective study included PWIDs with hepatitis C which were evalu-
ated in our Hepatology outpatients clinic between 2014-2018. 
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The following information was extracted: presence of positive viral load, 
HCV genotype, treatment regimen, SVR achievement, reinfection with hep-
atitis C virus, HIV coinfection, recent (in the last 6 months) i.v. drugs use, on-
going opioid agonist therapy, fibrosis stage according to Transient Elastog-
raphy -TE (Fibroscan). The following TE cutoff values were used (Tsochatzis 
et al - JHepatol 2011; 54: 650-659): F≥2: 7 kPa F≥3: 9.5 kPa and F4: 12 kPa
results: We included 202 PWID with hepatitis C in our analysis with a 
mean age of 34.1±9.6 years (70.7% male). Intravenously drugs use in the 
last 6 months was reported in 20.8% of patients and 51.9% of the whole 
cohort were under opioid substitution therapy. HIV coinfection was diag-
nosed in 1.9% of patients.
Positive HCV viral load was present in 179/202 patients (88.6%). 
HCV genotype distribution was: 1 (subtyping not possible)-1.8%, 1a-30.2%, 
1b-8.4%, 2-1.5%, 3-49.8%, 4-2.8%, 6-2.2%, unknown (viral load very 
low)-2.8%.
TE was available in 145/179 (71.7%) of patients and the following fibrosis 
grades were observed: F0-1-68.9%, F2-16.6%, F3-4.1%, F4-10.4%.
40/179 (22.3%) of patients with a positive viral load were not treated (2.8% 
very low viral load with suspicion of acute hepatitis C in healing, 0.5% 
because of pregnancy and 19% because the patients did not show up to 
start therapy).
The first treatment-regimen used were: DAA-69.1%, DAA+Ribavirin-23.1%, 
PegInterferon+Ribavirin-4.3%, DAA+PegInterferon+Ribavirin-3.5%.
SVR12 was documented after first therapy in 76/139 (54.6%) of patients. 
6/76 (7.9%) patients presented in follow-up with reinfection with hepatitis 
C virus.
Currently, the treatment status of our treated patients is: SVR12 -80/139 
(57.5%), viral load negative by end of treatment (EOT), but patients did 
not show up to SVR12 visit - 40/139 (28.8%), viral load negative at EOT 
and SVR12 visit will follow-10/139 (7.2%), ongoing therapy-5/139 (3.7%), 
therapy discontinued-3/139 (2.1%)(2/3 patients were on DAA therapy and 
did not show up after first prescription was given) and relapse - 1/139 
(0.7%)(after therapy with PegInterfeon+Ribavirin).
Relapse after DAA+/- Ribavirin therapy was observed by 4 patients (geno-
type 1a-2 patients and genotype 3-2 patients). 2/4 patient achieved SVR 
after therapy with another DAA regimen. The other two patients are cur-
rently under therapy.
conclusion: To achieve hepatitis C elimination, better strategies regarding 
PWIDs are needed. In our cohort, around 20% of the patients with positive 
viral load are not treated and they can infect other people, especially by 
sharing needles.
disclosure: Nothing to disclose 
P1441 dO hLa-dP/dq POLyMOrPhIsMs and/Or seruM IP-10 
affecT resPOnse TO dIrecT anTIvIraL drugs TheraPy aMOng 
hePaTITIs c egyPTIan PaTIenTs?
Hydara T.1, Ghazy A.2
1Kafrelshiekh University, Internal Medicine, Tanta, Egypt, 2Kafrelshiekh 
University, Microbiology, Kafr El-Sheikh, Egypt
contact e-Mail address: tamerhydara@yahoo.com
Introduction: Recent genome-wide studies have demonstrated that anti-
gen-presentation genes, particularly HLA class II gene may play an impor-
tant role in pathogenesis and response to antiviral therapy among chronic 
hepatitis C patients. During viral infection, IP-10 is secreted by hepatocytes 
and correlates with hepatic inflammation due to induction of cellular im-
munity. It could predict sustained non-response to antiviral therapy.
aims & Methods: Thus in the current study aimed to investigate the impact 
of HLA-DP/DQ single nucleotide polymorphisms and serum IP-10 levels 
on response to treatment with sofosbuvir + Daclatsvir ± Ribavirin, among 
chronic hepatitis C Egyptian patients. 
Subjects & methods: This study was conducted on 80 HCV infected pa-
tients (40 responder and 40 non-responder) and 40 healthy volunteers. 
History taking, thorough clinical examination, CBC, liver functions tests, 
AFP, anti-HCV antibodies and viral load were done for all subjects under 
the study. Genomic DNA was extracted from a total of 120 subjects, includ-
ing 40 healthy volunteers, 40 HCV responder patients, and 40 HCV non 
responder chronic HCV patients. HLA-DP-rs3077 and HLA-DQ-rs3920 SNP 
was assessed using 5’ nuclease assay with a TaqMan MGB (minor groove 
binder) probe in a StepOne™ Real-Time PCR System. Serum Levels of IP-
10 were measured in all serum samples, using commercial human IP-10 
Instant ELISA kit.
results: Allelic discrimination of HLA-DP-rs3077 and HLA-DQ-rs3920 
SNP revealed a statistical significant correlation between HLA-DP-rs3077 
AA genotype and response to treatment (P= 0.001*). Also, there was a 
statistical significant correlation between HLA-DQ-rs3920 AG variant and 
HCV infection as it was markedly expressed in both responders and non-
responders groups when compared to the controls (P=0.004*); regardless 
the outcome after treatment. 
Moreover, there was statistically significant increase in IP-10 levels among 
the non-responder group when compared with other groups (P = 0.001*) 
and IP-10 showed 95% sensitivity and 15% specificity with area under 
curve (AUC) of 0.889 (95% Confidence Interval=0.776-1.001, P=.00001*); 
indicating a good negative test that is good for catching actual cases of HCV 
but it also comes with some false positives. So, it could be considered the 
excellent for screening test.
conclusion: Our work provides more detail about HLA-DP/DQ gene poly-
morphism and serum IP-10 among chronic hepatitis C patients as new 
independent tools for anticipating HCV infection susceptibility (particularly 
HLA-DQ-rs3920 AG genotype and IP-10) and response to direct antiviral 
drugs (especially HLA-DP-rs3077 AA).
disclosure: Nothing to disclose 
P1442 safeTy and effIcacy Of sOfOsBuvIr Based regIMens 
In hePaTITIs c vIrus recurrence POsT LIver TransPLanTaTIOn
Abbasy M.1, Afifi M.1, Zakareya T.1, Abdelsameea E.1, Al Haddad O.K.2, 
Rewisha E.2, Salman T.3
1National Liver Institute, Menoufia University, Hepatology and 
Gastroenterology, Shebeen El-Kom, Egypt, 2National Liver Institute, Menoufia 
University, Shebeen El-Kom, Egypt, 3National Liver Institute, Menoufia 
University, Hepatology, Shebeen El-Kom, Egypt
contact e-Mail address: mohamed.abbasy@yahoo.com
Introduction: Hepatitis C virus (HCV) recurrence after liver transplantation 
(LT) is universal and associated with an accelerated disease course. Second 
generation direct acting antivirals dramatically improved viral clearance. 
Their use in the post-transplant still needs to be studied.
aims & Methods: we aimed in our study to evaluate safety and efficacy 
of sofosbuvir based regimens in treatment of HCV recurrence after liver 
transplantation.
Sixty patients with HCV recurrence after LT were included. They received 
sofosbuvir (SOF) in combination with: ribavirin (SOF/RBV) for 24 weeks 
(n=20), simeprevir (SOF/SIM) for 12 weeks (n=21), and daclatasvir with or 
without ribavirin (SOF/DCV±RBV) for 12/24 weeks according to the stage of 
liver fibrosis and eligibility for ribavirin (n=19). All patients who received 
(SOF/SIM) were on Tacrolimus or rapamune based immunosuppression
results: Mean age of the studied patients was 52.5±7.9 years (range 28-
68), mostly males (99.7%). All patients achieved end-of-treatment re-
sponse. Sustained virological response at 12 weeks after cessation of treat-
ment (SVR12) was 100% with the SIM/SOF and SOF/DCV±RBV regimens 
and 85% (n=17) with SOF/RBV. The commonest adverse event was fatigue, 
which occurred in 15 (75%), 18 (85.7%) and 0%, followed by hemoglobin 
drop < 9 g/dl in 3 (15%), 1 (4.8%) and 2 (10.5%), and hyperbilirubinemia 
in 2 (10%), 2 (9.5%) and 0% in the SOF/RBV, SIM/SOF and SOF/DCV±RBV 
groups respectively.
conclusion: Sofosbuvir based combinations are safe and effective in the 
treatment of recurrent HCV after LT, especially when combined with an-
other directly acting antiviral.
disclosure: Nothing to disclose 
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P1443 nucLeOs(T)Ide anaLOgues WIThdraWaL In 
aghBe-negaTIve chrOnIc hePaTITIs B: exPerIence Of 
2 years Of fOLLOW-uP
S G.1, Rocha M.2, Gamelas V.3, Silva M.J.3, Calinas F.3
1Centro Hospitalar e Universitário Lisboa Central, Gastroenterology, 
Camarate, Portugal, 2Centro Hospitalar Universitário de Lisboa Central EPE, 
Gastroenterology, Loures, Portugal, 3Centro Hospitalar Universitário de 
Lisboa Central EPE, Gastroenterology, Lisboa, Portugal
contact e-Mail address: veronicagamelas@gmail.com
Introduction: The nucleos(t)ide analogues (NUCs) are the mainstay treat-
ment for chronic hepatitis B (CHB). It was recently recommended to stop 
NUCs in selected patients with HBeAg-positive CHB and without cirrhosis. 
However, it is not yet defined what is the best moment to discontinue NUCs 
neither is clear what are the predictors of remission.
aims & Methods: We aimed to analyse the outcomes after NUC withdrawal 
in a selected group of HBeAg-positive CHB patients. 
Evaluation of all patients that discontinued NUCs and had at least 2 years 
of follow-up in a hepatology unit of a tertiary care hospital. To stop NUCs 
the patients had to have at least 3 years of virus load undetectability, no 
past history of clinical or laboratorial exacerbation of hepatitis and a tran-
sient elastography < 6kPa. Relapse was defined as alanine aminotransfer-
ase (ALT) elevation over 2 times the upper limit of normal and HBV DNA 
levels over 20000 UI/mL.
results: 21 patients were evaluated, 17 men, average age of 59 (±12) years 
old, treated with NUCs for an average time of 103 (±29) months, with an 
average time of undetectability of HBV-DNA levels of 85 (±25) months and 
an average value of ALT before the beginning of NUCs treatment of 187UI/L 
(range: 52-674UI/L). The average value of qAgHBs at the time of NUCs dis-
continuation was 2203 UI/mL (range: 2.9-12804UI/mL). 
Relapse was observed in 10 (52%) patients, in all cases it occur in the first 
6 months after discontinuation of NUCs. These patients had an average 
value of ALT at the hepatitis flare of 349 UI/L (range; 85-873UI/L) and none 
had liver failure. All these patients were restarted on NUCs and it was 
observed AgHBs seroconvertion in 20% (2/10) at 20 and at 26 months after 
NUCs discontinuation. 
In the 11 patients without recurrence, in an average follow-up of 28 
months, there was one case of seroconversion of AgHbs.
In multivariate analysis, none of the variables analysed (duration of treat-
ment, duration of undetectable viral load, ALT before starting NUCs, qA-
gHBs before NUCs discontinuation) pointed out any significant predictor 
for need to restart NUCs or to seroconversion.
conclusion: The NUCs withdrawal in a selected group of patients with 
HBeAg-negative CHB was safe, permitted to stop long-term NUCs therapy 
in most patients and resulted in the seroconversion of the AgHbs in a con-
siderable percentage of patients.
disclosure: Nothing to disclose 
P1444 PerfOrMance Of aBdOMInaL uLTrasOund In The 
PredIcTIOn Of esOPhageaL varIces
Trad N.1, Sabrine S.2, Issaoui D.3, Kchir H.4, Said Y.5, Hajer H.6, 
Chaabouni H.4, Maamouri N.4
1La Rabta Hospital, Gastroenterology B, Ariana, Tunisia, 2La Rabta 
Hospital, Gastroenterology, Tunis, Tunisia, 3La Rabta Hospital, Sousse, 
Tunisia, 4La Rabta Hospital, Tunis, Tunisia, 5Charles Nicolle Hospital, 
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Ben Arous, Tunisia
contact e-Mail address: yosrasaid10@yahoo.fr
Introduction: Portal hypertension (PHT) is the main complication and 
cause of death during cirrhosis. The signs of PHT (collateral circulation) 
in imaging are sufficient, according to BAVENO VI recommendations, to 
affirm the presence of a clinically significant PHT (defined by a hepatic 
venous pressure gradient > 10 mmHg).
aims & Methods: Our objective was to evaluate the performance of imag-
ing, especially abdominal ultrasound (AU), in the prediction of esophageal 
varices (OV).
We performed a retrospective study including, between January 2010 and 
December 2016, all patients with chronic liver disease, followed in our de-
partment and who had within 3 months, upper gastrointestinal endoscopy 
(UGIE) and AU.
results: We included 198 patients (69 men and 129 women) with an aver-
age age of 60.5 years. The main etiologies of chronic liver disease were 
viral infection C (44.9%) and viral infection B (19.7%). OV were found in 116 
patients. Ultrasound signs of PHT were found in 92 patients. A significant 
correlation was noted between the presence of signs of PHT at AU and 
the presence of OV at UGIE (p < 0.001). The sensitivity, specificity, positive 
predictive value, and negative predictive value of AU in OV prediction were 
73.8%, 66%, 79.7%, and 58.2%, respectively, with an area under the curve 
ROC of 0.65 (0.56-0.74).
conclusion: The good sensitivity of AU, which is a non-invasive examina-
tion, in the prediction of OV didn’t exempt the UGIE, but could provide a 
better selection of patients requiring this invasive exploration.
disclosure: Nothing to disclose 
P1445 rOLe Of rIsk sTraTIfIcaTIOn In PrIMary BILIary 
chOLangITIs In PredIcTIng BIOcheMIcaL resPOnse TO 
ursOdesOxychOLIc acId
Ayari M., Ayadi S., Belhadjmabrouk E., Zaimi Y., Said Y., Mouelhi L., 
Debbeche R.
Charles Nicolle Hospital, Gastroenterology, Tunis, Tunisia
contact e-Mail address: ayari.myriam@hotmail.fr
Introduction: Ursodesoxycholic acid (UDCA) remains the mainstay of man-
agement of primary biliary cholangitis (PBC). However the course of this 
disease can be variable. Numerous criteria for predicting outcome of treat-
ment have been studied based on biochemical response to UDCA, though 
it does not take the stage of the disease into account. More recently the 
globe score have been validated to identify patients at risk of poor progno-
sis by estimating transplant-free survival.
aims & Methods: We aimed to assess the prognostic ability of the GLOBE 
score alongside with Paris-2 criteria. We performed a retrospective analy-
sis of data from 53 consecutive patients with PBC from 2009 to 2018. We 
enrolled all patients from our department with PBC and receiving UDCA 
therapy 13-15mg/kg/day. The diagnosis of PBC was done according to EASL 
criteria. The response to treatment was evaluated according to Paris-2 cri-
teria at 1 year of treatment. The GLOBE score was calculated in all patients. 
The parameters of this score are: age at diagnosis and levels of bilirubin, 
alkaline phosphatase, albumin, platelet count at 1 year of treatment with 
UDCA.
results: A total of 53 consecutive patients were included: 45 women and 8 
men (sex ratio F/M=5.6). The mean age at diagnosis was 55 years (range 
19-78 years). The median follow-up was 6 years. Cirrhosis was present 
at the diagnosis in 39% of cases (n=21). The mortality rate was 15% (n = 
8). Factors associated with poor response to UDCA therapy were: stage of 
cirrhosis at diagnosis of PBC (p = 0.04), associated autoimmune disease 
(p = 0.024) and elevated pre-therapy level of total bilirubin (p = 0.01). The 
average Globe score was 2.05 (extremes -0.91-5.55). This score was sig-
nificantly correlated with response to treatment (p < 0.001) and mortality 
(p = 0.04). Patients fulfilling Paris II criteria had a significantly lower score 
globe than those who did not (mean 0.35 vs 2.28; p = 0.028).
conclusion: Our study found a significant association between the globe 
score and the response to the UDCA therapy. The use of this score will 
allow early identification of patients at risk of poor response in order to 
optimize treatment, prevent progression to end stage liver disease and 
improve the prognosis.
references: Scoring systems in primary biliary cholangitis - time to make 
a move. Yang F, Yang Y, Tang R, Gershwin ME, Ma X. Aliment Pharmacol 
Ther [2017]
disclosure: Nothing to disclose 
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P1446 seruM and BILIary PrOTeOMIcs as surrOgaTe 
Markers fOr dIsease PrOgressIOn and rIsk fOr BILIary 
neOPLasIa In PrIMary scLerOsIng chOLangITIs
Färkkila M.A.1, Saraswat M.2, Tohmola T.2, Joenväärä S.2, Tenca A.3, 
Arola J.4, Renkonen R.5
1Helsinki University Hospital, Gastroenterology, Helsinki, Finland, 2Helsinki 
University, Haartman Institute, Helsinki, Finland, 3Clinic of Gastroenterology 
- Helsinki University Hospital, Internal Medicine - Helsinki University, 
Helsinki, Finland, 4HUSLab, Helsinki University Hospital, Pathology, Helsinki, 
Finland, 5Helsinki University, Helsinki, Finland
contact e-Mail address: martti.farkkila@hus.fi
Introduction: Primary sclerosing cholangitis [PSC] is a chronic inflamma-
tory disease leading to strictures of intra- and extrahepatic bile ducts, cho-
lestasis and eventually to biliary cirrhosis (1). The chronic inflammation 
and increased proliferation of biliary epithelial cells are associated with 
development of biliary dysplasia and cholangiocarcinoma [CCA] (2-3), with 
the lifetime risk around 10% (4-5). Several serum surrogate markers (6) 
have been developed to predict the risk for liver cirrhosis, transplantation 
free survival or death, such as decrease of P-ALP (7), IL-8 (8), and ELF® 
(9). However, all of these variables are very late endpoints and not suitable 
for monitoring bile duct inflammation, progression of bile duct disease 
or development of risk of biliary dysplasia - before development of CCA.
aims & Methods: The aim of the study is to evaluate the proteomic profiles 
in serum and bile in PSC patients with 
1) non-advanced, 
2) advanced bile duct disease or 
3) biliary neoplasia to find better markers for disease progression and risk 
for biliary neoplasia.
In total, 79 patients with confirmed PSC referred for ERC for diagnosis and 
surveillance of the disease were included (48 females) and another 12 
patients with CCA. During ERC bile sample was aspirated using balloon 
catheter and then stored in -80oC. Brush cytology (BC) was collected both 
from extra- and intrahepatic bile ducts for Papanicolaou staining for grad-
ing dysplasia. Cholangiographic findings are scored according to modified 
Amsterdam score (Helsinki score). Serum samples are collected at the time 
of ERC.
Label -free quantitative proteomics from serum and bile from the same 
individuals was performed UDMSE mode in Synapt G2-Si with nUPLC-TRI-
ZAIC C18 tile as previously described (10).
results: Quantitative serum and bile proteomics from 43 patients with PSC 
with a small ERC score < 4 were compared to PSC 36 patients with ERC 
score of >4 as a marked of disease progression. The bile proteome was 
significantly different in PSC compared to CCA patients. 93 bile proteins 
showed were significantly (Mann-Whitney) differentially expressed and 
the changes were up to 15-fold. These proteins were enriched on the e.g. 
inflammatory pathways. Concomitantly the serum proteomics showed only 
mild alterations, with only 14 significantly altered proteins with a maximus 
2-fold increase.
Quantitative serum and bile proteomics from 79 patients with PSC, but not 
dysplasia or CCA were compared to 12 serum from patients with CCA. The 
bile proteome was significantly different in PSC compared to CCA patients. 
156 bile proteins showed were significantly (Mann-Whitney) differentially 
expressed and the changes were up to 53-fold. Concomitantly the serum 
proteomics did not show essentially any significantly altered protein ex-
pressions between PSC and CCA patients. The upregulated proteins were 
enriched on e.g. inflammatory and gluconeogenesis/glycolysis.
conclusion: Analyses of bile proteomics showed significant alterations 
during the disease progression of PSC. Similarly the bile proteomics was 
profoundly altered during the progression from an inflammatory disease 
(PSC) to a malignant process (CCA). While the bile proteome was found to 
be modified significantly during these disease states the serum proteomics 
did not display these alterations at the same level.
references: 1. Dyson JK et al Lancet. 2018 2. Bergquist A, et al. J Hepatol. 
2002;36:321-7. 3. Manninen P, et al. Scand J Gastroenterol. 2015;50:423-8 4. 
Boberg KM, et al. Scand J Gastroenterol 2002; 37: 1205-11. 5. Claessen MM. 
J Hepatol. 2009;50:158-64. 6. Ponsioen CY, et al. Hepatology. 2016;63:1357-
67. 7. de Vries EM, et al. Liver Int. 2016;36:1867-75. 8. Vesterhus M, et al.J 
Hepatol. 2017;66:1214-22. 9 deVries EMG. Liver International. 2017;37:1554-
1561. 10 Holm M, et al. PLoS One. 2018;13:e0195354.
disclosure: Nothing to disclose 
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ManIfesTaTIOns : cLInIcaL asPecTs and rOLe In The 
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Introduction: Primary biliary cholangitis (PBC) is an auto-immune disease 
characterized by destructing the biliary ducts. It affects women in their fif-
ties. The actual treatment is the ursodesoxycholic acid (UDCA). Association 
with auto-immunes diseases (AID) has been already established.
aims & Methods: The aim of this study is to describe the different auto-
immune diseases found in a population of PBC and to study their impact 
on the treatment response. 
Methods: Retrospective study from January 2000 to August 2018. All pa-
tients hospitalized in the gastroenterology department for PBC were in-
cluded. PBC diagnosis was based on the EASL criteria. The response to 
treatment was evaluated by the Paris II criteria at one year of treatment.
results: We included 53 patients. The sexe ratio M/F was 0,18. The mean 
age of our patients at the time of the positive diagnosis of PBC was 55 
years old. Family history of auto-immune hepatitis was found in 11,3% of 
the cases. AID were found in the first consult in 60,4% of the patients. The 
different AID were type 1 diabetes (n=1), celiac disease (n=6), hypothyroid-
isms (n=10), systemic lupus erythematosus (n=2), vitilio (n=1), Sjogren syn-
drome (n=13), hemolytic anemia (n=8) and auto-immune hepatitis (n=6). 
13 patients had at least two of these associated AID. The influence of the 
AID on the response to the treatment by UDCA was studied. Diabetes type1, 
hypothyroidism, and celiac disease influenced significantly the response 
to treatment (respenctively p= 0,024, p=0,001, p=0,024). Generally, the 
response to UDCA was better in the group with no AID with a difference 
statistically significant (p< 0,005).
conclusion: Auto-immune diseases, when associated with PBC influence 
the response to UDCA. They need to be researched ant treated since the 
positive diagnosis of PBC to ameliorate the response to the treatment and 
therefore the survival of the patients.
disclosure: Nothing to disclose 
P1449 exOMe-WIde sequencIng sTudy Of PrIMary 
scLerOsIng chOLangITIs - a TWO POPuLaTIOn sTudy
Koskela J.1,2,3, Voskuil M.4, Rivas M.5, Avila B.2, Stevens C.2, Ripatti S.6, 
Xavier R.7, Ananthakrishnan A.N.7, Sokol H.8, Weersma R.K.9, Daly M.2, 
Färkkila M.A.3
1University of Helsinki, Institute for Molecular Medicine Finland, Helsinki, 
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4University Medical Center Groningen, Gastroenterology and Hepatology, 
Groningen, Netherlands, 5Stanford University, Department of Biomedical 
Data Science, Stanford, United States, 6University of Helsinki, Finland, 
Institute for Molecular Medicine Finland, Helsinki, Finland, 7Massachusetts 
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Antoine Hospital, Gastroenterology Department, Paris, France, 9University 
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Introduction: Primary sclerosing cholangitis (PSC) is a rare and progressive 
inflammatory disease of the bile ducts with no effective therapy currently 
available. While the prevalence of PSC has been reported only at 15.3-
32/100,000, PSC is the most common cause of liver transplantations in 
Nordic countries. Additionally, PSC patients are at high risk of cholangio-
carcinoma (up to 1000-fold) compared to population control and substan-
tial risk of colorectal cancer. PSC is commonly associated with inflamma-
tory bowel disease (IBD) as ~70% of PSC-patients present with PSC-IBD. 
When co-occurring with IBD, PSC is most often (80% of cases) associated 
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with ulcerative colitis (UC). So far it is unclear whether PSC-IBD is an inde-
pendent entity or whether it only manifests as an IBD subtype, however up 
to 8% of patients with IBD have diagnostic findings in MRI. A recent (and 
largest) genome wide association study using imputed array data of 4,796 
PSC cases estimated the genetic correlation of IBD and PSC to 29%, while 
confirming most previously reported variants and identifying 4 new loci, as 
up to 19 loci have now been associated with PSC.
aims & Methods: This study aims to assess the (possibly rare and hence 
not captured by array genotyping and imputation) coding mutations rele-
vant to PSC risk. In this present study, we perform the largest exome-wide 
association study on PSC to date, to further extend our understanding of 
genetic determinants of biliary and intestinal inflammation in patients 
with PSC. We are currently analyzing the largest so far whole exome se-
quencing (WES) study on PSC, aiming at meta-analyzing > 1100 patients of 
Finnish (n~720) and European (n~400) ancestry. The Finnish PSC patients 
represent ~15% of total estimated Finnish PSC population. 
In addition to DNA, deep phenotyping and health status information, 
sequential endoscopic retrograde cholangiographic examinations (ERC), 
biliary cytology, bile samples have been collected from the Finnish pa-
tients.
results: Our preliminary analysis focused on a Finnish subset and sug-
gests that out of the 19 loci described so far, we identify nominally signifi-
cant (p<0.05) associations in 8 genes and in 12 loci within a 500kb win-
dow of the previously implicated gene (p<0.01). Additionally, we confirm a 
strong MHC component and replicate 14/312 Finnish signals (p<0.0001) in 
a non-Finnish-European population (p<0.05).
conclusion: The summary statistics-level results of a full meta-analysis will 
be made available online for UEG Week.
disclosure: Nothing to disclose 
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Introduction: The use of obeticholic acid (OCA) is approved as second line 
therapy for patients with primary biliary cholangitis (PBC) with insufficient 
response or intolerance to ursodeoxycholic acid (UCDA).
aims & Methods: To assess the efficacy and safety of obeticholic acid as 
second line therapy in patients with PBC (as monotherapy or add-on to 
UCDA) in a real-world cohort in Austria.
Our study included 33 PBC patients (87.8% women) with a mean age of 
60.7 ± 10.8 years from 10 Austrian centers (Klagenfurt, Villach, Salzburg, 
Linz, Vienna - 2 center, Eisenstadt, Ried, Graz and Innsbruck), who received 
therapy with OCA because of intolerance or insufficient response to the 
maximal dose of UCDA (12.2% monotherapy with OCA, 87.8% combination 
therapy OCA + UCDA). 
We evaluated the response of alkaline phosphatase (AP), alanine trans-
aminase (ALT), gamma-glutamyltransferase (GGT) and bilirubin during 
therapy with OCA. Furthermore, adverse events were assessed.
Fibrosis stage at the start of therapy with OCA was assessed by Transient 
Elastography -TE (Fibroscan, Echosens, France). The following TE cutoff 
values were used (Corpechot et al - Hepatology 2012; 56: 198-208): F ≥1: 7.1 
kPa, F≥2: 8.8 kPa, F≥3: 10.7 kPa and F4: 16.9 kPa
results: The median follow up of therapy with OCA was 13 months (be-
tween 0.5 and 27 months).
TE was available in 26/33 (78.7%) when OCA was started. The fibrosis stag-
es observed were: F0-19.2%, F1-19.2%, F2-7.8%, F3-26.9% and F4-26.9%.
A significant reduction of AP, GGT and ALT was observed with obeticholic 
acid treatment (Table).
 
Baseline 
values 
(n=33)
values 
after 1 
month of 
therapy 
(n=32)
values 
after 3 
months of 
therapy 
(n=28)
values 
after 6 
months of 
therapy 
(n=27)
values 
after 12 
months of 
therapy 
(n=18)
p value
AP (U/l) 
Median 
(IQR)
237 
(204-300)
189 
(168-280)
166 
(144-244)
156 
(116-213)
136 
(100-171)
p<0.05 between 
Baseline and 3,6, 12 
months of therapy
GGT (U/l) 
Median 
(IQR)
180 
(109-432)
98 
(53-219)
76 
(51-159)
73 
(42-152)
41 
(20-82)
p<0.05 between 
Baseline and 3,6, 12 
months of therapy
ALT (U/l) 
Median 
(IQR)
51 
(33-73)
33 
(27-48)
35 
(23-52)
34 
(25-54)
27 
(20-32)
p<0.05 between 
Baseline and 1,3,6, 
12 month of therapy
Bilirubin 
(mg/dl) 
Median 
(IQR)
0.7 
(0.55-1.11)
0.67 
(0.5-1)
0.6 
(0.47-0.85)
0.6 
(0.47-0.95)
0.47 
(0.42-0.74)
p<0.05 between 
Baseline and 12 
month of therapy
[Table]
Adverse events were observed in 18/33 (54.5%) of patients. Adverse events 
recorded were: pruritus 12/33 (36.3%), fatigue 4/33 (12.1%), joint pain 4/33 
(12.1%), abdominal pain 2/33 (6.1%), peripheral edema 1/33 (3.1%), nau-
sea 1/33 (3.1%), exanthem 1/33 (3.1%), and generalized musculoskeletal 
pain 1/33 (3.1%) of patients.The treatment was stopped in 7/33 (21.2%) 
patients: in one case because of increase of AP and bilirubin after 7 months 
of therapy, in one case because non response+pruritus after7 months of 
therapy and in 5 cases because of adverse events (pruritus -2 cases, severe 
joint pain and peripheral edema - 1 case, exanthem-1 case and general-
ized musculoskeletal pain-1 case). One patient was lost to follow-up.
conclusion: The second-line therapy with obeticholic acid is effective and 
safe in patients with PBC also in a real-world setting.
disclosure: Nothing to disclose 
P1451 recurrence Of PrIMary BILIary chOLangITIs afTer 
LIver TransPLanTaTIOn: a sIngLe cenTer exPerIence
Drastich P.1, Bajer L.1, Chmelova K.1, Brezina J.1, Macinga P.1, Sticova E.2, 
Trunecka P.1, Taimr P.1, Spicak J.1
1IKEM, Hepatogastroenterology, Prague, Czech Republic, 2IKEM, Pathology, 
Prague, Czech Republic
contact e-Mail address: lukasbajer1@gmail.com
Introduction: Primary biliary cholangitis (PBC) is a chronic autoimmune 
liver disorder that may progress to cirrhosis and eventually to liver failure 
and death. For those who develop end - stage liver disease, orthotopic 
liver transplantation (OLT) should be considered. Moreover, recurrent form 
of PBC (rPBC) appears in significant proportion of patients after OLT. Re-
current PBC is usually characterized by mild clinical course. In minor group 
of patients however, rPBC may eventually lead to graft loss and liver re - 
transplantation (re - OLT).
aims & Methods: The aim of this study was to evaluate outcome of OLT 
for PBC in our center and to identify recipient risk factors for rPBC. A total 
number of 82 orthotopic liver transplantations for PBC were performed at 
Institute for Clinical and Experimental Medicine, Prague between January 
1995 and January 2017. The diagnosis of rPBC was based on protocolary 
and/or on - demand liver graft biopsies. We retrospectively analyzed all 
relevant medical records from our computed database. Input statistical 
data were analyzed using JMP software. Survival ratio was determined 
from Kaplan - Meier curves. Pearson’s chi-squared test and Fisher’s exact 
test were used to assess the potential risk factors for rPBC. A p-value ≤ 0.05 
was considered as statistically significant.
results: Out of 82 transplanted patients with median 158 (23 - 261) months 
of follow-up, 73 (89 %) were female and 9 (11 %) were male with median 
age of 56.9 (36 - 71) at the time of OLT. 3/82 (3.7 %) had hepatocellular 
carcinoma (HCC) in the liver explant. Except 3 (3.7 %) who received split, 
all patients were transplanted with whole graft. 9/82 (11 %) had overlap-
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ping features of autoimmune hepatitis. 1-, 3-, 5-years patient survival was 
92.7 %, while 10-years survival was 84.6 %. Graft survival was 91.7 % at 
1, 3 and 5 years and 83.7 % at 10 years. 3 (3.7 %) patients received re-
transplant: 1 (1.2 %) for primary graft dysfunction and 2 (2.4 %) for rPBC. 
For analysis of rPBC risk factors, we excluded the patients monitored out-
side our center and those who died sooner than 3 years after OLT. Out of 74 
analyzed patients, 45 (54.9 %) developed rPBC after median time of 46 (11 
- 239) months. 22 (29.7 %) received cyclosporin and 52 (70.3 %) received 
tacrolimus as their primary immunosuppressive agent. 
None of the potential risk factors (age, sex, type of immunosuppression, 
features of AIH prior OLT, AMA and ANA positivity prior OLT) were sig-
nificantly associated with rPBC (p > 0.1). However, the rate of rPBC had 
statistical tendency to be higher in patients who had HCC in their explants 
(p = 0.056).
conclusion: Recurrent PBC is frequent but usually not serious clinical con-
dition. In our cohort, rPBC rate was relatively high, presumably due to long 
median follow - up after OLT.
disclosure: Nothing to disclose 
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hePaTITIs-PrIMary BILIary chOLangITIs and auTOIMMune 
hePaTITIs-PrIMary scLerOsIng chOLangITIs OverLaP PaTIenTs 
cOMPared TO auTOIMMune hePaTITIs PaTIenTs
Biewenga M.1, van der Berg A.P.2, van Buuren H.R.3, van der Meer A.J.P.3, 
Van Nieuwkerk C.M.J.4, De Vos Tot Nederveen Cappel W.5, Brouwer J.6, 
Drenth J.P.H.7, van Hoek B.8
1LUMC, Department of Gastroenterology and Hepatology, Leiden, 
Netherlands, 2UMC Groningen Gastroenterology and Hepatology, 
Groningen, Netherlands, 3Erasmus MC Gastroenterology and Hepatology, 
Rotterdam, Netherlands, 4VU Medical Center, Amsterdam, Netherlands, 
5Isala Clinics, Zwolle, Netherlands, 6Reinier de Graaf Gasthuis, Delft, 
Gastroenterology, Vlaardingen, Netherlands, 7Radboud University Nijmegen 
Medical Centre - Gastroenterology and Hepatology, Radboud University 
Nij, Gastroenterology and Hepatology, Nijmegen, Netherlands, 8Leiden 
University Medical Center, Department of Gastroenterology and Hepatology, 
Leiden, Netherlands
contact e-Mail address: m.biewenga@lumc.nl
Introduction: In 10% of the autoimmune hepatitis (AIH) patients features 
of primary biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC) 
are present, called overlap or variant syndromes. The aim of this study 
was to characterize AIH-PBC and AIH-PSC patients and compare outcome 
to AIH patients.
aims & Methods: In a retrospective cohort study all patients with AIH-PBC 
and AIH-PSC were included in 3 hospitals. AIH-PBC patients had to fulfil 
the strict Paris criteria. AIH-PSC patients needed a definite diagnosis of 
AIH according to the simplified criteria and signs of PSC on ERCP, MRCP 
or onion ring fibrosis on liver biopsy. Characteristics and outcome were 
compared to AIH in a case-control design matched on age and cirrhosis.
results: Twelve AIH-PBC, 25 AIH-PSC and 74 AIH patients were included. 
AIH-PSC patients were more often males compared to AIH patients (56% 
vs 28%; p = 0.007) and had large duct PSC in 92%. AIH-PBC patients had 
higher AF and GGT (p < 0.001 and p = 0.006) and presence of AMA anti-
bodies in 75%. AIH-PSC and AIH-PBC had lower ALAT than AIH at diagno-
sis (p = 0.014) but IgG levels and SMA antibodies did not differ (p = 0.79; 
p = 0.58). 
Treatment with prednisone, azathioprine and ursodeoxycholic acid (UDCA) 
was started in all AIH-PBC and AIH-PSC patients, except UDCA in 2 pa-
tients. Complete AIH remission was obtained in 8 (67%), 16 (64%) and 61 
(82%) of the AIH-PBC, AIH-PSC and AIH patients (p = 0.12). 
The median GLOBE score in AIH-PBC patients was -0.41 (range: -1.6 - 2.9) 
resulting in an expected median 10 year survival of 89% (range: 4-97%). 
The median Amsterdam Oxford score was 2.45 (range: 0.9-3.8) in AIH-PSC 
patients resulting in an expected median 10 year survival of 59% (range: 
14-88%). 
At the end of median follow-up of 107 months (range: 1-353) 4 (33%) AIH-
PBC, 8 (32%) AIH-PSC and 8 (11%) AIH patients had progressed to liver 
transplantation or liver related death (p = 0.023). Four (16%) AIH-PSC de-
veloped a cholangiocarcinoma.
conclusion: In 12 AIH-PBC patients and 25 AIH-PSC patients using strict 
criteria no difference was found regarding IgG, SMA antibodies and re-
sponse to therapy compared to AIH patients. Survival was worse in AIH-
PSC and AIH-PBC patients than AIH patients. Survival of AIH-PBC patients 
was worse than expected according to the GLOBE score and survival of 
AIH-PSC patients was better than expected according to the Amsterdam 
Oxford score although AIH-PSC patients are at risk for developing cholan-
giocarcinoma.
disclosure: Support by unrestricted grants from Zambon Pharma and Chie-
si Pharma were received 
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Introduction: Primary sclerosing cholangitis (PSC) is a rare chronic liver 
disease, with 0.95 cases reported per 100,000 people in Japan. Because of 
its rarity in Japan, the clinical characteristics are still not clear. Recent in-
vestigations have shown that general conditions, such as oxidative stress, 
affect the course of chronic diseases. We investigated the clinical course 
and oxidative stress-related condition of PSC to determine the prognostic 
factors of PSC.
aims & Methods: We analyzed 41 PSC patients who attended our depart-
ment from June 2008 to June 2018. The clinical characteristics, including 
concomitant inflammatory bowel disease (IBD) or bile duct carcinoma and 
liver transplantation experience, were investigated in order to define the 
prognostic factors. The oxidative stress status was evaluated by two types 
of markers and the ratio: serum d-ROM (oxidative stress marker, as re-
flecting serum active-oxygen metabolism) , OXY (antioxidant marker, as 
reflecting anti-oxidation power) and Oxidative Index (Standardized d-ROM 
/ SD - Standardized OXY / SD).
results: The median age was 35 years (14-74 years), and male sex was pre-
dominant (27:14). The average observation period was 1226 days, and 9 pa-
tients died. The Mayo risk score was able to significantly discriminate the 
poor overall survival (p< 0.001). Significant poor prognostic factors were 
higher age, higher Mayo risk score, higher FIB-4 index, lower Child-Pugh 
grade, higher hemoglobin, higher Albumin, lower Bilirubin according to 
the log rank test. A lower anti-oxidant marker OXY was also included as 
a poor prognosis-related factor, while d-ROM was not. In a multivariate 
analysis, while properly excluding confounding factors, FIB-4 index and 
Mayo risk score were the markers proven to be significant (p< 0.01). A 
receiver operating characteristic (ROC) analysis revealed the usefulness of 
Mayo PSC risk score and FIB-4. High AUC (>0.8) indicate FIB-4 index and 
Mayo risk score were indicated very useful markers for predicting the PSC 
prognosis.
conclusion: The FIB-4 index and Mayo risk were shown to be a prognostic 
factor for PSC in our study. Maintaining antioxidant stress will lead to a 
good prognosis and suggests the efficacy of antioxidant treatment.
disclosure: Nothing to disclose 
P1455 cLInIcaL OverLaP Of hePaTOBILIary and 
rheuMaTOLOgIc PaThOLOgy: a reTrOsPecTIve sTudy Of 
PravaLence
Saraiva M.1, Dias E.1, Macedo G.2
1Centro Hospitalar São João, Gastroenterology, Porto, Portugal, 2World 
Gastroenterology Organisation, Milwaukee, Wi, United States
contact e-Mail address: miguelmascarenhassaraiva@gmail.com
Introduction: The rheumatic manifestations of gastrointestinal pathology, 
in particular of hepatobiliary diseases, in addition to being a diagnostic 
challenge, complicate the natural course of the primary disease and worse 
the prognosis due to the multiorganic affection they often have. The aim of 
this study is to characterize the prevalence of confirmed rheumatic disease 
associated with hepatobiliary diseases in a tertiary reference center.
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aims & Methods: All patients with simultaneous diagnosis of hepatobiliary 
pathology and rheumatologic pathology were retrospectively evaluated 
between 2007 and 2017. All patients with the following confirmed rheu-
matologic diagnoses (ICD9) were studied: Rheumatoid arthritis; Undif-
ferentiated polyarthritis; Ankylosing spondylitis; Spondylarthritis; Psoriatic 
Arthritis; Polymyalgia Rheumatica; Diffuse Connective Tissue Diseases; SLE 
- Systemic lupus erythematosus; Systemic Sclerosis; Sjögren’s Syndrome; 
Vasculitis; Behçet’s disease; Drop; Pseudogout; Osteoarthrosis; with a di-
agnosis of concomitant confirmed hepatobiliary disease.
results: From a sample of 2169 consecutive patients, simultaneously in 
consultation with Gastroenterology and Rheumatology, we were able to 
identify 51 patients with the above mentioned requirements, and 3 pa-
tients were excluded after subsequent exclusion of rheumatologic disease. 
The majority of the patients were females (58.3%). The mean age at diag-
nosis was 53.2 years (range 29-91 years). 
Hepatitis C was diagnosed in 26 patients (54%), autoimmune hepatitis in 6 
patients (12.5%), primary biliary cholangitis in 3 patients (6.25%), primary 
sclerosing cholangitis in 2 patients (4.2%), non-alcoholic steatohepatitis 
(4.2%), cryptogenic cirrhosis (4.2%), Wilson’s disease (4.2%), and other 
diagnoses (10.4%) in 5 patients (hepatitis B, alcoholic liver cirrhosis, toxic 
hepatitis, alpha 1 antitrypsin deficiency and hemochromatosis). 
Rheumatoid arthritis was diagnosed in 13 patients (27.1%), spondylarthritis 
in 13 patients (27.1%), ankylosing spondylitis in 5 patients (10.4%), undif-
ferentiated polyarthritis in 4 patients (8.3%), SLE in 4 patients (8.3%), pso-
riatic arthritis in 2 patients (4.2%) and other diagnoses (2.1%) in 7 patients 
(systemic sclerosis, Sjögren’s syndrome, vasculitis, Behçet’s disease, gout, 
osteoarthritis and connective tissue diseases). 
Particularly, regarding the rheumatologic manifestations of Hepatitis C, we 
identified rheumatoid arthritis in 6 patients (23%), spondylarthritis in 6 
patients (23%), undifferentiated polyarthritis in 4 patients (15.4%), and 
ankylosing spondylitis in 4 patients (15.4%). %) SLE in 4 patients (15.4%), 
psoriatic arthritis in 2 patients (4.2%)
It should be noted that 27.1% of this group of patients were currently under 
biological therapy.
conclusion: Given that 2.2% of patients, followed in both specialties, pres-
ent simultaneous digestive and rheumatologic pathology, it is fundamen-
tal to characterize the impact and therapeutic repercussions that come 
from the clinical overlap between pathologies.
disclosure: Nothing to disclose 
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Introduction: Total glucosides of paeony (TGP), an active mixture extracted 
from paeony root, has anti-inflammatory, immune regulatory effects and 
is widely used for the treatment of autoimmune diseases such as rheu-
matoid arthritis. However, the role of TGP in autoimmune hepatitis (AIH) 
is still unknown. Here, we investigate the effect of TGP in concanavalin A 
(Con A) induced experimental autoimmune hepatitis (EAH) and the mo-
lecular mechanisms in vitro.
aims & Methods: C57BL/6 female mice were injected intravenously with 
Con A (20 mg/kg) to generate a model of EAH. TGP (936mg/kg) was ad-
ministered by gavage once daily for 3 days before Con A challenge. The 
levels of serum liver enzymes, variations of immune cells recruited in liver 
including dendritic cells(DCs), T cells, macrophages and myeloid-derived 
suppressor cells (MDSCs), liver pathologic examines were determined 12 h 
after Con A injection. In vitro, the LO2 cell lines were used to examine the 
susceptibility of hepatocyte to Con A and explore the underlying mecha-
nisms. 
We treated the hepatocyte with Con A (10µg/mL)and TGP (100mg/L). Mi-
tochondrial membrane potential (ΔΨm), reactive oxygen species (ROS) 
level, apoptosis related proteins including Bax, Bcl2 and cleaved-Caspase3 
were detected. 
Moreover, immature DCs were generated from mice bone marrow dendrit-
ic cells (BMDCs) and then cultured with GM-CSF, IL-4 and β-ME. We then 
treated the immature BMDCs with Con A (10µg/mL) and TGP(100mg/L) for 
24 hours. The expression of major histocompatibility complex II (MHCII), 
CD11C and CD80 was determined by flow cytometry (FCM).
results: In Con A- induced EAH mice, pretreatment with TGP reduced the 
levels of serum liver enzymes including alanine transaminase (ALT), as-
partate transaminase (AST). Moreover, decreased histopathological dam-
age was detected in the TGP-pretreated condition. Importantly, the FCM 
data showed that pretreatment with TGP reduced the infiltration of mature 
DCs and activated CD4+ T cells in liver. 
In vitro, MTT assay showed that TGP(100mg/L) had protective effect on LO2 
cell lines as compared with cells treated with Con A alone. Pretreatment 
with TGP ameliorated ΔΨm decline, ROS level imbalance and apoptosis 
increase of hepatocytes stimulated by Con A. In addition, The expression of 
Bcl2 was increased during this process, accompanied with decreased level 
of Bax and cleaved-Caspase3. Therefore, TGP might decrease hepatocytes 
apoptosis through a mitochondrial apoptotic pathway. In the meantime, 
the maturation of BMDCs was inhibited by TGP as evidenced by lower lev-
els of MHCII and CD80 as compared with Con A treated cells.
conclusion: TGP could ameliorate Con A-induced EAH by regulating apop-
tosis of hepatocytes and maturation of DCs. It might be a potential com-
pound in treating AIH.
disclosure: Nothing to disclose 
P1457 dO nOn-InvasIve Markers Of fIBrOsIs have a PLace 
In The evaLuaTIOn Of fIBrOsIs In OverLaP syndrOMe?
Elleuch N.1, Moalla M.2, Hammami A.3, Amira H.1, Ben Slama A.4, 
Jaziri H.1, Brahem A.1, Ajmi S.1, Ksiaa M.1, Jmaa A.1
1Sahloul, Sousse, Tunisia, 2Hospital Hedi Chaker, Gastro-Enterology, Sax, 
Tunisia, 3University Hospital Fattouma Bourguiba, Gastroenterology, Sousse, 
Tunisia, 4CHU Sahloul, Gastroenterology, Sousse, Tunisia
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Introduction: The non-invasive markers of fibrosis are currently validated 
in viral hepatopathies but less validated in other dysimmune liver dis-
eases. Very few studies have focused on the place of non-invasive markers 
of fibrosis in the overlap syndrome. The aim of our study is to determine 
the correlation between non-invasive markers of fibrosis and histological 
fibrosis scores in overlap syndrome.
aims & Methods: A retrospective study that collects all patients with an 
overlap syndrome: primary biliary cholangitis - autoimmune hepatitis or 
primary sclerosing cholangitis - autoimmune hepatitis. The APRI and FIB-
4 scores were calculated at the time of diagnosis and one year after treat-
ment. A liver biopsy specifying the degree of fibrosis according to Metavir 
was performed at the time of diagnosis. Liver elastography was done after 
one year of treatment. Fibrosis was considered significant from F2 for he-
patic elastography and Metavir score and a cut-off > 1.5 and > 3.25 for APRI 
and FIB-4, respectively. The Spearman correlation test and the ROC curve 
were used to analyze the data.
results: Our study involved 56 patients divided into 52 women and 4 men 
of average age 51.1 years (30-73 years). Autoimmune hepatitis was as-
sociated with primary biliary cholangitis in 89.3% of cases and primary 
sclerosing cholangitis in 10.7% of cases.Spearman’s correlation analysis 
did not show a correlation between serum markers measured at the time 
of diagnosis and the degree of histological fibrosis (r = 0.5, p = 0.001). 
Among the 52 patients who would have significant fibrosis according to 
the APRI score, 20 patients had no significant histological fibrosis (F0, F1).
Among the 48 patients who would have significant fibrosis according to 
the FIB-4 score, 30 actually had significant fibrosis (> = F2).After one year 
of treatment, 54 patients underwent hepatic elastography, which showed 
significant fibrosis in 70.3% of cases (38 patients). Correlation analysis did 
not show any correlation between serum markers of fibrosis and hepatic 
elastography. Among the 38 patients with significant fibrosis according to 
the measurement of hepatic elastography, 16 patients and 12 others were 
presumed to have no significant fibrosis according to the APRI and FIB-4 
scores, respectively.
conclusion: In our study, we did not find any correlation between the dif-
ferent non-invasive markers of fibrosis and the results of the liver biopsy, 
which remains to this day the gold standard for assessing liver fibrosis in 
dysimmunitary disorders like overlap syndrome.
disclosure: Nothing to disclose 
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P1458 PredIcTIOn Of The PrOgnOsIs Of advanced 
hePaTOceLLuLar carcInOMa PaTIenTs By hTerT PrOMOTer 
MuTaTIOn In cIrcuLaTIng TuMOr dna
Hirai M., Kinugasa H., Nouso K., Terasawa H., Yamamoto S., Oyama A., 
Adachi T., Wada N., Sakata M., Yasunaka T., Onishi H., Shiraha H., 
Takaki A., Okada H.
Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, Gastroenterology and Hepatology, Okayama, Japan
contact e-Mail address: mami_k@live.jp
Introduction: Human telomerase reverse transcriptase (hTERT) promoter 
mutation is found in about 50% of hepatocellular carcinoma (HCC), which 
is the most frequent somatic genetic alteration in HCC. Several clinical 
studies have revealed that the presence of the hTERT promoter mutation 
was closely correlated with poor prognosis in solid tumors such as lung 
and breast cancers. However, the association between the mutation and 
clinicopathologic features in patients with HCC has not been elucidated 
well. Recently, cell-free circulating tumor DNA (ctDNA) in plasma/serum 
has been applied as a noninvasive marker for cancer diagnosis.
aims & Methods: This study was designed to estimate the clinical utility of 
ctDNA for detecting hTERT promotor mutation in patients with advanced 
HCC and to reveal the correlation between hTERT promoter mutation and 
prognosis. Eighty-six patients with advanced HCC who were treated with 
sorafenib or lenvatinib at Okayama University Hospital between Septem-
ber 2013 and September 2018 were enrolled in this study. The plasma or 
serum samples were obtained from their blood prior to the drug admin-
istration. ctDNAs extracted from 1ml of plasma or serum samples with 
QIAamp Circulating Nucleic Acid Kit (QIAGEN, Hilden, Germany) were used 
to detect hTERT promoter mutations by digital droplet PCR (ddPCR; Bio-
Rad, Hercules, CA, USA), and correlations between the presence of the 
mutation and clinical outcome of the patients were analyzed.
results: The median follow-up period was 11 months (interquartile range, 
6.8-17.7months). The median age of the patients was 73 years and 72% 
were male. Clinical stages of 4, 11, 31 and 40 patients were II, III, IVa 
and IVb, respectively. HBs antigen and HCV antibody were detected in 16 
(18.6%) and 37 (43.0%) patients, respectively. As for HCC treatments, 71 
and 15 patients received sorafenib and lenvatinib, respectively. In the 86 
patients examined, 45 patients (52.3%) were positive for hTERT promoter 
mutation in ctDNA. Presence of the hTERT promoter mutation was corre-
lated with low serum albumin (P=0.048), high aspartate aminotransferase 
(P=0.016), high alanine aminotransferase (P=0.022), low prothrombin ac-
tivity (P=0.044), large intrahepatic tumor size (P=0.032), and high PIVKA- 
II (P=0.032). Overall survival (OS) of the patients with the mutation was 
significantly shorter than those without it (p=0.001). Median survival time 
of each group was 11.2 months and 22.2 months, respectively. In univariate 
analysis with Cox’s proportional hazards model, the presence of hTERT 
promoter mutation [Hazard ratio (HR), 2.13; 95% Confidence interval (CI), 
1.20-3.88; P=0.009), low albumin (<3.6 g/dL) (HR, 1.81; 95%CI, 1.03-3.21, 
P=0.040), high aspartate aminotransferase (≧25IU/L) (HR, 1.83; 95%CI, 
1.45-3.28; P=0.034), Child-Pugh class B (HR, 2.54; 95%CI, 1.22-4.92; 
P=0.015), vascular invasion (HR, 2.34; 95% CI, 1.29-4.12; P=0.006) were 
significant factors for poor OS. Multivariate analysis revealed that hTERT 
promoter mutation (HR, 2.01; 95% CI, 1.09-3.83; P=0.025) and vascular 
invasion (HR, 2.57; 95% CI, 1.31-4.97; P=0.006) were significant factors for 
poor OS.
conclusion: hTERT promoter mutation in ctDNA was associated with short 
survival and could be a valuable biomarker for predicting prognosis of the 
patients with advanced HCC treated with molecular target drugs.
disclosure: Nothing to disclose 
P1459 effecT Of MeTfOrMIn On Igf-r-Induced aPOPTOsIs 
and PrOLIferaTIOn In LIver cancer ceLLs
Jung J.H.1, Lee J.2
1Hallym University Dongtan Sacred Heart Hospital, Division of 
Gastroenterology, Department of Internal Medicine, Hwaseong-si, Korea 
(Republic of), 2Hallym University Dongtan Sacred Hospital, Gastroenterology, 
Gyunggi-Do, Korea (Republic of)
contact e-Mail address: jhjung0410@gmail.com
Introduction: Metformin has been well known to have antineoplastic ac-
tivity in hepatocellular carcinoma (HCC) cells. Studies on AMP-activated 
protein kinase (AMPK)-related studies and cell cycle inhibition have been 
reported as HCC inhibitory mechanisms of metformin. Insulin growth fac-
tor 1 receptor (IGF-1R) is a receptor involved in cell proliferation, inhibi-
tion of apoptosis, angiogenesis and tumorigenesis and tumor-associated 
inflammation, and targeted therapies for these have been developed and 
used clinically.
aims & Methods: This study was performed to determine whether met-
formin inhibits survival of HCC cells through IGF-1R pathway. HCC cell line 
HepG2 cells were cultured. In order to investigate the effect of metformin 
on HepG2 cells according to glucose level, cells were cultured in 5mM 
glucose and 25mM glucose medium. 3-(4, 5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assays were performed to determine the 
effect of metformin on the cell proliferation. Apoptosis was measured by 
a cell death detection enzyme-linked immunosorbent assay and a cas-
pase-3 activity assay. Expression levels of various proteins, with or without 
specific small interfering ribonucleic acid-induced gene disruption, were 
measured by Western blot analysis.
results: Metformin induces apoptosis of HepG2 cells and reduces cell vi-
ability. However, the efficacy of metformin-induced apoptosis was reduced 
in the hyperglycemic environment (25mM glucose). Metformin reduced 
IGF-1R activity in HCC cells and decreased IRS-1, PI3K, and Akt activities in 
IGF-1R pathway, leading to increased TSC-2 activity and decreased mTOR 
activity. When AMPK siRNA was also used to block AMPK function, metfor-
min caused HepG2 cell apoptosis. 
In addition, in the normal environment, metformin increased AMPK Thr 
172 activity and decreased AMPK Ser 485 activation. However, AMPK Ser 
485 activity was increased in hyperglycemic environment as well as AMPK 
Thr 172.
conclusion: The inhibitory effect of metformin on HCC cells induces a de-
crease in IGF-1R activity by metformin and thus promotes apoptosis. In the 
hyperglycemic environment, the efficacy of metformin on HCC inhibitory 
effect is decreased, which suggests that the action of mTOR is elevated by 
AMPK Ser485 phosporylation. Therefore, the use of metformin is helpful in 
the treatment of liver cancer, especially in hyperglycemia.
disclosure: Nothing to disclose 
P1461 WIThdraWn
P1460 fIfTeen years Of hePaTOceLLuLar carcInOMa, a 
ParadIgM shIfT frOM InfecTIOus TO nOn-InfecTIOus eTIOLOgy
Pangilinan J.A.R.1, Alcantara-Payawal D.2
1Cardinal Santos Medical Center, Internal Medicine, Quezon City, Philippines, 
2Cardinal Santos Medical Center, Gastroenterology, San Juan City, Philippines
contact e-Mail address: dianapayawal@yahoo.com
Introduction: Hepatocellular carcinoma (HCC) is a malignant tumor that 
is the fifth most common type of cancer and the third leading cause of 
cancer-related death globally. A study in 2009 concluded that in the Philip-
pines, the most common risk factors leading to the disease were chronic 
hepatitis b infection and alcoholic liver disease. With an ever-evolving 
paradigm and change in the trends of diseases, it is imperative to update 
current knowledge with a more recent collection of data providing essen-
tial information on the pre-cursors of Hepatocellular carcinoma.
aims & Methods: This is a single-center retrospective, descriptive study of 
all adult patients with hepatocellular carcinoma at Cardinal Santos Medi-
cal Center (CSMC) in a fifteen-year span (2003-2018). 
Clinical data, including essential demographics such as age, sex, etiology 
of HCC were obtained and analysis was done using chi-square and t-test, 
respectively.
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results: Comparison of data showed a statistically significant change in the 
infectious and non-infectious causes of HCC. Time 1 showed predominance 
of HCC with infectious etiology, representing 67% of all cases, with most 
cases from Hepatitis B. Time 2 showed a 22% decrease in this etiology, 
which could be inferred to be an effect of vaccination readily producing 
this endpoint. But with a predominantly older age group (mean age 64), a 
large segment of the population in time 2, specifically 45% had an infec-
tious etiology. 
An interesting note is the prominent increase in the number of HCC cases 
arising from non-infectious causes, with a modest 21% of cases in time 1, 
to a little over two times of that in time 2. With 73 cases in time 1 and 137 
in time 2 representing a statistically significant two-fold increase in these 
cases, the breakdown shows a shift from a prominent non infectious cause 
from alcoholic disease towards NAFLD. 72% of non infectious cases in time 
2 arose from NAFLD, with ALD, showing significant decrease percentage-
wise with the number of cases seemingly overshadowed by the large in-
crease in cases on NAFLD.
  n = 674 Time 1 (2003-2010) n=378
Time 2 (2010-2018) 
n-296 P - value
Age   63+12.5 66+12.5 1.00
M/F   250/128 255/41 >0.99
HBV   247 104 <0.002*
HCV   7 10 <0.2241
NAFLD   15 99 <0.0000001*
ALD   58 33 <0.035*
Unknown   0 45 NA
DIH   5 0 NA
AIH   0 0 NA
[Table: Results of data from two time periods]
conclusion: Hepatitis B is still the most common etiology of Hepatocel-
lular Carcinoma. There has been a significant increase in the development 
of HCC from non-infectious etiologies. Of the non-infectious etiologies, 
NAFLD seems to be an emerging threat in the development of Liver Cancer.
disclosure: Nothing to disclose 
P1462 c60 fuLLerene: anTIfIBrOTIc, anTITuMOr and 
anTIMeTasTaTIc nanOTheraPeuTIc fOr hePaTOceLLuLar 
carcInOMa TreaTMenT
Kuznietsova H.1, Dziubenko N.1, Herheliuk T.1,2, Hurmach V.1, Lynchak O.3, 
Prylutskyy Y.1, Ritter U.4
1Taras Shevchenko National University of Kyiv, Institute of Biology and 
Medicine, Kyiv, Ukraine, 2Institute for Problems of Cryobiology and 
Cryomedicine, Department of Biotechnical Problems in Diagnostic, Kyiv, 
Ukraine, 3Taras Shevchenko National University of Kyiv, Education and 
Scientific Centre, Institute of Biology, Kyiv, Ukraine, 4Technical University of 
Ilmenau, Institute of Chemistry and Biotechnology, Ilmenau, Germany
contact e-Mail address: biophyz@gmail.com
Introduction: The excessive production of reactive oxygen species is the 
main cause of liver cancer initiation and progression, therefore the use 
of antioxidants could be a promising treatment. Biocompatible pristine 
C
60
 fullerene is the powerful antioxidant demonstrating low toxicity and 
ability to be accumulated in liver, so have a prospect as liver disease 
therapeutic.
aims & Methods: C
60
 fullerene impact on liver fibrosis, tumor growth and 
metastasis were aimed to be discovered using rat hepatocellular carci-
noma (HCC) model. HCC was initiated by N-diethylnitrosamine (DEN, 200 
mg/kg) injection. Two weeks later tumor promotion was achieved by sub-
cutaneous CCl
4
 (0.1 ml/100g) injections twice/week continuously. Pristine 
C
60
 fullerene aqueous colloid solution (C
60
FAS; 0.15 mg/ml, size of aggre-
gates 1.2-100 nm [1]), was administered daily (0.25 mg/kg) starting in 2 
weeks from DEN injection. Its impact on liver fibrosis and cirrhosis was as-
sessed at 10th and 15th week, impact on tumor development and metastasis 
- at 22nd week. Liver injury was evaluated according to [2], by histological 
(HE staining) and biochemical (plasma blood markers) methods. C
60
FAS 
impact on EGFR and pan-cytokeratin expression was assessed in HepG2 
cells (IHC). C
60
 fullerene ability to interact with EGFR, FGFR, PDGFR and 
VEGFR was assessed by molecular docking and molecular dynamics.
results: C
60
FAS attenuated liver steatohepatosis and fibrosis and improved 
liver state in HCC-rats at 10-week stage (as evidenced by histological and 
biochemical assay). In HCC-rats at 15-week stage C
60
FAS also diminished 
liver injury (as evidenced by liver damage score, depression of elevated se-
rum markers and histological assay) and avoided dysplastic cells appear-
ance in pancreas. In HCC-rats at 22-week stage C
60
FAS prevented tumor 
development (no tumors in liver compared to well-developed tumors in 
non-treated rats), attenuated liver injury (liver enzymes decreased, bili-
rubin was levelled, morphology was improved) and prevented metastasis 
(no atypical cells in pancreas compared to neoplastic cells aggregates and 
even well-developed tumors in non-treated animals). Reference 5-fluoro-
uracil demonstrated less efficacy: small single tumors were observed, liver 
enzymes remained elevated, bilirubin retained higher than that in control.
 
 
10 
weeks
 
15 
weeks
 
22 
weeks
   
  HCC
HCC 
+C60FAS
HCC
HCC 
+C60FAS
HCC
HCC 
+C60FAS
HCC 
+5-fluorouracil
Liver damage 
score
8.2* 7.25* 9.2* 7.8* 11.33* 9.25* 10.25*
ALT   307 193 215      
AST   268 185 152 74 54 48
Conjugated 
bilirubin
    133   171   56
Non-
conjugated 
bilirubin
    74   118   49
ALP     345 273      
LDH     2750 1002 150 67 144
GGT     115 49 380 307 384
α-amilase           -91 -56
[Parameters of liver state, specified in per cent compared to control; only 
statistically significant values (p<0.05) are presented, *absolute values]
C
60
FAS applying in 10-100 µmol/ml concentration inhibited EGFR and pan-
cytokeratin expression in HepG2 cells in a dose-dependent manner (by 
39-70%). C
60
 fullerene ability to form complexes with ATP-binding sites of 
EGFR and FGFR but not VEGFR and PDGFR was also demonstrated, which 
let us to suggest the possibility of such impact in in vivo system.
conclusion: C
60
FAS can inhibit fibrogenesis, malignant degeneration and 
metastasis in liver and maintain its functional activity. C
60
 fullerene ability 
to inhibit EGFR and pan-cytokeratin expression and to block EGFR and 
FGFR could contribute to its biological activity.
references: [1] Ritter U, et al. Fuller Nanotub Carbon Nanostruct. 
2015;23(6):530-4 [2] Liu X, et al. BMC Complement Altern Med 2013;13:375
disclosure: Nothing to disclose 
P1463 3-MercaPTOPyruvaTe suLfurTransferase 
rePresses TuMOr PrOgressIOn and PredIcTs PrOgnOsIs 
In hePaTOceLLuLar carcInOMa
Li M., Jin Q., Zhang J., Cen L., Yu C., Li Y.
The First Affiliated Hospital, College of Medicine, Zhejiang University, 
Gastroenterology, Hangzhou, China
contact e-Mail address: lemon2323@126.com
Introduction: The prognosis for hepatocellular carcinoma (HCC) remains 
dismal in terms of overall survival (OS), and its molecular pathogenesis 
has not been completely defined. 3-mercaptopyruvate sulfurtransferase 
(MPST) is one of enzymes to regulate endogenous hydrogen sulfide (H
2
S) 
biosynthesis. The expression and functional role of MPST in HCC has never 
been investigated. We aimed to clarify the role of MPST in HCC.
aims & Methods: MPST protein expression in HCC specimens was mainly 
analyzed by immunohistochemistry (IHC) using a tissue microarray (TMA) 
containing HCC tumor tissue and matched adjacent tissues from 90 pa-
tients. Another 12 paired clinical HCC samples were used for MPST protein 
determination. The effect of MPST on HCC progression was studied in vitro 
and in vivo. A diethylnitrosamine (DEN)-induced liver cancer model was 
used to evaluate the role of MPST in hepatocarcinogenesis.
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results: TMA in 90 cases revealed that MPST was significantly downregu-
lated in 80 HCC clinical specimens compared to their paired non-tumor 
tissues by IHC staining, with negative expression in one case. Clinical-
ly, a low MPST expression was associated with a worse OS (p < 0.05) 
and larger tumor size (p < 0.05). Downregulation of MPST protein was 
further detected in all 12 HCC patients compared with their nontumor 
counterparts. Downregulation of MPST was also investigated in 5 HCC cell 
lines compared with normal human hepatocyte by using both qPCR and 
Western blot analysis. Functional studies showed that overexpression of 
MPST in HCC cells inhibited cell proliferation, clonogenicity and induced 
apoptosis. 
Furthermore, MPST overexpression significantly suppressed the growth of 
tumor xenografts in nude mice, whereas silencing MPST by intratumor de-
livery of siRNA markedly promoted tumor growth. Moreover, DEN-induced 
murine HCC was aggravated by MPST gene knockout. Mechanistically, 
MPST overexpression induced G1-phase arrest via inhibition of pRb/E2F1 
signaling pathway. Consistently, MPST expression correlated negatively 
with pRb in HCC specimens and was associated with HCC outcomes.
conclusion: MPST may function as a tumor suppressor gene that plays an 
essential role in HCC proliferation and liver tumorigenesis. It is a candidate 
predictor of clinical outcome in patients with HCC, with possible use as a 
biomarker and intervention point for new therapeutic strategies.
disclosure: Nothing to disclose 
P1464 vaLue Of seruM endOcan In PredIcTIOn Of 
POsT-aBLaTIOn recurrence Of hePaTITIs c reLaTed 
hePaTOceLLuLar carcInOMa
El-Sadek H.1, Fawzy E.1, Saber S.2, Hassaneen A.3
1Faculty of Medicine, Zagazig University, Gastroenterology & Hepatology 
Unit, Internal Medicine Department, Zagazig, Egypt, 2Faculty of Medicine, 
Zagazig University, Radiology Department, Zagazig, Egypt, 3Faculty of 
Medicine, Zagazig University, Clinical Pathology Department, Zagazig, Egypt
contact e-Mail address: hanyelsadek75@yahoo.com
Introduction: Hepatitis C virus (HCV)-related hepatocellular carcinoma 
(HCC) remains a major global health problem. The recurrence of HCC after 
curative ablation is common, and mandates frequent costly post-ablation 
investigations especially triphasic computerized tomography (TCT). Serum 
endocan (a soluble proteoglycan) has been used as a biomarker to predict 
prognosis in various inflammatory and neoplastic diseases.
aims & Methods: The aim of this study was to assess the performance of 
serum endocan level in prediction of HCC recurrence after curative radio-
frequency ablation (RFA), in a subset of patients with HCV-related HCC. 
In this prospective study, 56 HCV-related HCC patients treated with curative 
RFA were enrolled, and tumor recurrence was evidenced by typical radio-
logic criteria using repetitive TCT (quarter yearly), over a mean follow up 
period of 23.79±7.56 months. Routine clinical and laboratory assessment, 
estimation of liver disease severity as class A/B according to Child-Tur-
cotte-Pugh (CTP) scoring, and tumor staging (0/A) using Barcelona Clinic 
of Liver Cancer (BCLC) system, were performed.
In addition, all studied patients underwent baseline (one month after 
curative RFA) measurement of suggested serum biomarkers of tumor re-
currence including endocan, des-gamma-carboxy prothrombin (DCP) and 
alfa fetoprotein (AFP).
results: There were significant associations between HCC recurrence 
(24/56 patients, 42.86%) and several parameters; tumor size ≥3 cm (p 
0.025), multiple tumor foci (p 0.028), BCLC stage A (P 0.042), CTP class B 
(p 0.005), low serum albumin (p 0.007), high serum bilirubin (p 0.011), as 
well as increased mean values of endocan (p< 0.001), DCP (p 0.004) and 
AFP (p 0.039). 
Using logistic regression analysis, only serum endocan and DCP were in-
dependent predictors of HCC recurrence (p<0.001 and p 0.003, respec-
tively). Serum endocan (at a cut-off level ≥2.09 ng/mL) had the highest 
sensitivity (95.8%) and specificity (87.5%) for prediction of HCC recurrence 
(p<0.001), followed by DCP ≥208.5 mAU/mL (sensitivity 79.2%, specificity 
71.9%, p 0.003), and lastly by AFP ≥75.0 ng/mL (sensitivity 75.0%, specific-
ity 71.9%, p 0.001). Endocan level ≥2.09 ng/mL carries a significantly high 
risk of HCC recurrence (Odds Ratio: 161.0, Confidence Interval: 16.8-1542.3, 
p <0.001). 
Using Kaplan-Meier survival analysis, the mean recurrence-free survival 
time was significantly shorter in patients with endocan level ≥2.09 ng/mL 
than in those with a level <2.09 ng/mL (16.78 vs. 35.24 months, log-rank 
test, p<0.001), and the mean overall survival time was significantly shorter 
in patients with endocan level ≥2.09 ng/mL than in those with a level <2.09 
ng/mL (24.95 vs. 32.58 months, log-rank test, p<0.001).
conclusion: Serum endocan is a useful biomarker that can significantly 
predict HCC recurrence and survival after radiofrequency ablation.
disclosure: Nothing to disclose 
P1465 seruM serOTOnIn as a POTenTIaL dIagnOsTIc Marker 
fOr hePaTOceLLuLar carcInOMa
Attalla M.A.A.1, Mamdouh F.2, Abdelaleem S.1, Abdelaal A.2, E. Salem A.3, 
Rabiee A.3, Elsisi O.2
1Cairo University Hospital (Kasr Al Ainy), Endemic Medicine and Hepatology, 
Cairo, Egypt, 2Cairo University Hospital (Kasr Al Ainy), Clinical and Chemical 
Pathology, Cairo, Egypt, 3Cairo University Hospital (Kasr Al Ainy), Internal 
Medicine Department, Cairo, Egypt
contact e-Mail address: mahmoudabdelalim@yahoo.com
Introduction: Hepatocellular carcinoma (HCC) is a major health problem in 
Egypt and its incidence is increasing ¹. Alpha fetoprotein (AFP), the most 
widely used biomarker for HCC diagnosis, is not sensitive for early HCC de-
tection². So, there was a need for other diagnostic seromarkers to replace, 
or be used in combination with, AFP
aims & Methods: We aimed to assess the potential role of serum sero-
tonin level in HCC diagnosis. This study was conducted on 75 Hepatitis C 
virus (HCV)-positive patients. Twenty five healthy age- and sex-matched 
subjects were included as a control group. Diagnosis of HCC was done ac-
cording to the American Association for the Study of Liver Disease (AASLD) 
guidelines. Staging of patients into early- and late-stage HCC was done 
according to Barcelona Clinic Liver Cancer (BCLC) criteria. 
Subjects were divided into 4 groups: 
Group I (late-stage HCC) included 21 patients with late-stage HCC on top 
of liver cirrhosis. 
Group II (Early-stage HCC) included 28 patients with early-stage HCC on 
top of liver cirrhosis. 
Group III (cirrhotic) included 26 patients with liver cirrhosis with no evi-
dence of HCC. 
Group IV was the Control group. 
Serum serotonin level was determined in all recruited subjects using High 
Performance Liquid Chromatography (HPLC)-fluorescent detection method.
results: AFP had a statistically significant elevation in group I (late-stage 
HCC) with a median of 1300 ng/L (195 - 2544 ng/L) compared to groups II 
and III ( early-stage HCC and cirrhosis) (P ≤ 0.01). Regarding serum se-
rotonin level, it had a statistically significant elevation in group II (Early-
stage HCC) with a median of 275 (204.7-400) compared to groups I, III, 
and IV (Late-stage HCC, Cirrhosis and control) with median of 33 ng/µL 
(30-50 ng/µL), 50 ng/µL (30-60 ng/µL) and 102 (85-150 ng/µL), respectively 
(P=0.001). Receiver operating characteristic (ROC) curve showed that se-
rum serotonin had a sensitivity of 100%, specificity 92.3%, Positive Predic-
tive Value (PPV) 93.3%, Negative Predictive Value (NPV) 96% and accuracy 
of 96.3%, in discriminating early-stage HCC from cirrhosis. The best values 
were obtained when using serotonin at cut -off value of 108 ng/µL. There 
was no correlation between serotonin and AFP.
conclusion: serum serotonin level is a rapid, sensitive, noninvasive diag-
nostic biomarker for the detection of early-stage HCC. It may improve the 
sensitivity of AFP for the detection of early-stage HCC if used in combina-
tion.
references: Omar A, Abou-Alfa GK, Khairy A and Omar H (2013): Risk fac-
tors for developing hepatocellular carcinoma in Egypt. Chin Clin Oncol. 
(4):43 Lou, J., Zhang, L., and Lv, S. (2017): Biomarkers for Hepatocellular 
Carcinoma. Biomarkers in Cancer, 1-9
disclosure: Nothing to disclose 
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P1466 vascuLar endOTheLIaL grOWTh facTOr as a 
PrOgnOsTIc Marker In BOTh cOnvenTIOnaL and drug eLuTIng 
Beads TransarTerIaL cheMOeMBOLIzaTIOn fOr unresecTaBLe 
hePaTOceLLuLar carcInOMa
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contact e-Mail address: doctorhodaelgamal@gmail.com
Introduction: Vascular endothelial growth factor (VEGF) increases in hepa-
tocellular carcinoma (HCC) patients. Many studies had evaluated levels of 
VEGF in conventional transarterial chemoembolization (cTACE) but assess-
ment of VEGF levels in TACE using drug eluting beads (DEB-TACE) versus 
cTACE has not been sufficiently studied.
aims & Methods: Aim of the study was to estimate VEGF levels and their 
relation to response and recurrence in both DEB-TACE and cTACE in pa-
tients with unresectable HCC.
subjects & methods: This parallel concurrent interventional study included 
114 unresectable HCC patients: 58 patients underwent cTACE and 56 pa-
tients underwent DEB-TACE. All included patients were classified as Bar-
celona clinic liver cancer (BCLC) stage B. Three samples of venous blood 
were obtained from all HCC patients one day before, day 1 and day 30 after 
TACE for estimation of VEGF levels. According to response after TACE, pa-
tients in each group were classified into progressive disease (PD), partial 
response (PR), and complete response (CR) which was followed for com-
plete one year. The results were statistically analyzed.
results: VEGF levels at day 1 and day 30 were higher than their basal levels 
in both cTACE and DEB-TACE groups, while no significant difference was 
found in VEGF levels between the two groups. Patients with PD after TACE 
in both groups showed significantly higher VEGF than those with PR and 
CR.
VEGF levels (basal, day 1 and day 30) at cut off values 97.3, 149.8 and 104.1 
pg/ml respectively could discriminate treatment success from disease pro-
gression with area under receiver-operating characteristic curves (AUCs) 
0.806, 0.775, and 0.771 respectively; sensitivity 88.9%, 88.9% and 77.8% 
respectively and specificity 62.5%, 64.6 and 66.7% respectively (table 1), 
but had no relation to HCC recurrence in complete response group after 
12 months.
  Basal vegf vegf at day 1 vefg at day 30
AUC 0.806 0.775 0.771
Diagnostic 
point
VEGF >97.3 pg/ml 
have poor prognosis
VEGF >149.8 pg/ml 
have poor prognosis
VEGF >104.1 pg/ml 
have poor prognosis
sensitivity 88.9% 88.9% 77.8%
specificity 62.5% 64.6% 66.7%
PPV 96.8% 96.9% 91.4%
NPV 30.8% 32% 27.3%
[Diagnostic performance of different VEGF levels]
conclusion: VEGF may predict response to therapy in both DEB-TACE and 
cTACE but it has no relation to HCC recurrence.
disclosure: Nothing to disclose 
P1467 deveLOPMenT Of a scOrIng sysTeM ThaT OuTMaTch 
OTher sPecIfIc scOres In TransarTerIaL cheMOeMBOLIzaTIOn 
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João, Gastroenterology, Oporto, Portugal, 8Centro Hospitalar de São João, 
Gastrenterology, Porto, Portugal
contact e-Mail address: jom_73@hotmail.com
Introduction: Barcelona clinic liver cancer (BCLC) is the most accepted 
staging system in hepatocellular carcinoma (HCC) in Europe. BCLC recom-
mends treatment with transarterial chemoembolization (TACE) in patients 
with intermediate-stage HCC (BCLC B). Despite this, TACE is also used in 
patients with more advanced disease.
aims & Methods: The aim of this study was to develop a prognostic model 
of TACE treated patients, that relates to complete response at 1 month after 
TACE according to the mRECIST criteria, and compare it with other TACE 
specific staging systems. A cohort of 206 patients treated with TACE was 
analyzed. Using univariable analysis, different prognostic factors were 
identified and included in the construction of a prognostic model. Sub-
sequently, we simplified the model by categorizing the albumin and C-
reactive protein variables. The model was constructed using backward cox 
regression. We evaluated the capability of our model to predict complete 
response at 1 month after TACE according to the mRECIST criteria. Finally, 
the model was compared with BCLC and established TACE specific staging 
systems (STATE-score and HAP-score) using ROC curve for prediction of 
mortality at 1 year.
results: Our cohort had a median age of 68.75±0,8 year, 77.2% were male; 
etiology of liver disease was hepatitis C virus in 32%, alcoholic liver dis-
ease in 40% and hepatitis B virus in 10%, other causes in 18%. BCLC-A was 
present in 37,4% of the patients, BCLC-B in 50% and BCLC-C in 12,7%. The 
median survival time was 18,64 months. Patients with mRECIST complete 
response at 1 month survived longer than other patients (37.44 vs 23.42 
months, p=0.034). In Kaplan-Meier analyses presence of portal thrombo-
sis (p=0.009), up-to 7 criteria (p=0.009), C-reactive protein (p< 0.001) and 
albumin (p=0.002) were identified as independent prognostic factors and 
used to construct our model with backward cox regression. By dividing 
in terciles, we identified three different groups of patients, with median 
survival times of 37.86, 22.87 and 9.61 month respectively (p< 0.0001). BCLC 
did not differentiated survival in the Kaplan-Meier analyses (p=0.345). 
HAP-score (p=0.027) and STATE-score (p< 0.001) differentiated survival. 
Using this model, we identify differences in the 3 groups for proportion 
of mRECIST complete response with TACE at 1 month (group A: 19.3%, 
group B: 18%, group C 2.6%; p=0.018). Unlike HAP-score (p=0.41), BCLC 
(p=0.135) and STATE-score (p=845) did not related with mRECIST complete 
response at 1 month. When compared with BCLC (AUC 0.468), HAP-score 
(AUC 0.549) and STATE-score (AUC 0.601), our model presented a stronger 
capacity to predict mortality at 1 year (AUC 0,696).
conclusion: Patients outside the BCLC-B stage might benefit from TACE, 
since survival in patients with BCLC-C was not different from intermediate-
stage in our population. Different staging systems for better patient selec-
tion are necessary. We identified prognostic factors for patients treated 
with TACE. Our model is apparently better at predicting mortality at 1-year 
when compared with BCLC, HAP-score and STATE-score. This model is also 
able to identify patients with poor response to TACE according to mRECIST 
criteria. External validation is necessary to confirm these results.
disclosure: Nothing to disclose 
782 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
P1468 LIver TransPLanTaTIOn fOr hePaTOceLLuLar 
carcInOMa In PaTIenTs Over 65 years Of age In IreLand: 
Is ThIs The BesT use Of Our grafTs?
Murphy A.1, Bourke M.1, O’Brien A.2, Appel J.3, Houlihan D.D.1
1St. Vincent’s University Hospital, Department of Hepatology, Dublin, Ireland, 
2St. Vincent’s University Hospital, Dublin, Ireland, 3University College Dublin 
(UCD), Dublin, Ireland
contact e-Mail address: aislingmurphy_ie@hotmail.com
Introduction: Liver Transplantation (LT) is an established therapy for pa-
tients with hepatocellular carcinoma (HCC) with good long term survival. 
There are however, an increasing number of effective loco-regional thera-
pies (LRT) available with much lower morbidity and mortality risk. It is 
not well established whether older HCC patients (≥65 years) have worse 
outcomes after LT and might be better served with LRT. This might free up 
grafts for patients with decompensated liver disease and reduce waiting 
list mortality.
aims & Methods: 1. Compare the survival of older (≥65 years) and younger 
(< 65 years) patients that received LT for HCC.
2. Compare the survival of older patients following listing for LT to patients 
treated only with LRT and resection. 
Data was collected retrospectively from both, the prospectively maintained 
national liver transplantation database from January 1993 to December 
2017 and our HCC database from January 2014 to December 2018, in St 
Vincent’s University Hospital. Ethical approval for this study was obtained 
from the local ethics committee. LRT included transarterial chemoemboli-
zation, thermal ablation and selective internal radiation therapy. Survival 
was compared by using Kaplan Meier curve and log-rank tests.
results: In total, 156 (n=128 < 65years) patients received LT for HCC in our 
hospital during the study period. The main aetiology of liver disease were 
alcohol 26.9% (n=42), viral 39.7% (n=62), haemochromatosis 12.1% (n=19) 
and non-alcoholic fatty liver 6.4% (n=10). The majority of patients were 
male (83.9%) and the median age at the time of LT was 59 (IQR 53-63). 
Most patients were within Milan criteria (n=111, 86.4%) and this propor-
tion was similar in the older and younger age groups (82.1% and 87.4% 
respectively; p=0.45). Older patients had a worse 4-year survival than 
younger patients (62% vs 78%, p=0.07). We therefore sought to compare 
the survival of elderly patients considered for LT from the time of listing, 
to those treated with LRT or resection only (n=79). There was no survival 
difference between the groups during the follow period (P>0.05). The sur-
vival for both groups was 62% at four years.
conclusion: 
Our data suggest that patients over 65 years have higher peri-operative 
and early mortality following LT compared to younger patients. LRT or re-
section has proven to be an effective alternative treatment at least in the 
short to medium term and offers equivalent survival compared to LT in this 
group. We therefore question the appropriateness of organ allocation to 
elderly patients with HCC.
disclosure: Nothing to disclose 
P1469 vaLIdaTIOn Of aLPha feTO PrOTeIn MOdeL as a 
PredIcTOr Of resPOnse ,recurrence and survIvaL In 
egyPTIan PaTIenTs WITh hePaTOceLLuLar carcInOMa 
underWenT Trans arTerIaL cheMOeMBOLIzaTIOn
Shaker M.K., Abdella H.M., Eltabbakh M., Abu Hashima M.A.
Ain Shams University, Tropical Medicine, Hepatology and Gastroenterology 
Department, Cairo, Egypt
contact e-Mail address: midoatif.2014@gmail.com
Introduction: In Egypt, liver cancer forms 23.81% of the total malignancies.1 
Recently, the French study group for liver transplantation reported on a 
new predictive model for hepatocellular carcinoma(HCC) recurrence post 
liver transplant, namely the alpha feto protein(AFP) model which consid-
ered superior to Milan criteria in predicting recurrence in a training set 
of HCC patients, and was subsequently validated in a cohort of French 
patients followed prospectively under the control of the French organiza-
tion for organ sharing.2
aims & Methods: 
aim: To validate the use of AFP model as a predictor of response, recur-
rence and survival in Egyptian patients with hepatocellular carcinoma un-
dergoing trans arterial chemoembolization(TACE).
Methods: This cohort study was conducted at Tropical Medicine depart-
ment at Ain Shams University Hospitals.We included all newly diagnosed 
patients with HCC who were fit for TACE according to Barcelona Clinic Of 
Liver Cancer(BCLC) 2012 starting from January 2012 till January 2016.The 
AFP model was calculated for each patient enrolled in the study before 
TACE according to the following (Simplified, user-friendly version of the 
AFP model)2:
Largest diameter of hepatic focal lesion (≤ 3cm, 3-6 cm, > 6 cm took points 
0,1, 4 respectively).
Number of nodules (1-3 , ≥4 took points 0 ,2 respectively).
Alpha feto protein level (AFP level (IU/ml) ≤ 100 , 100-1000,> 1000 took 
points 0,2,3 respectively).
Then the patients were classified before intervention into low risk group 
for TACE (total points < 2) and high-risk group for TACE (total points of 2 or 
more).The patients were followed up by AFP level,and triphasic spiral CT 
performed 1 month after TACE to evaluate the response then at 4 months 
and 7 months post TACE to evaluate the local and distant recurrence.
results: One hundred and thirty two patients who underwent TACE were 
included in the study with mean age 57.28 ± 7.46 years and HCV Ab posi-
tive predominance (89.4%).According to alpha feto protein model,the pa-
tients were classified into low risk group for TACE(43.2% of patients)with 
median alpha feto protein model equal zero and high risk group for TACE 
(56.8% of patients) with median alpha feto protein model equal 3.Com-
plete response was achieved in higher percentage of patients in low risk 
group(91.2 %)than high risk group(73.3%)but without reaching statistical 
significance (P=0.057).The one and three years recurrence free survival 
were 50% and 24.1% in low risk group Versus 29.1% and 16.2%in high 
risk group respectively.Also,the one and three years overall survival rate 
were 97% and 37.3% in low risk group Versus 98.1% and 11.6% in high risk 
group respectively but all without reaching statistical significance. On clas-
sifying our patients with alpha feto protein level < 100 IU/ml (79 patients) 
into low risk patients (57 patients) and high risk patients (22 patients) ac-
cording to alpha feto protein model, we found that complete response 
was achieved in significantly higher percentage of patients in low risk 
group(91.2%)than high risk group(69.6%)(P< 0.05).Also, recurrence oc-
curred in a less percentage of patients in low risk group(71.2%)than high 
risk group(81.2%)but without reaching statistically significant difference 
between the 2 groups(P>0.05). Median overall survival was significantly 
higher in low risk group (18 months) than high risk group (16 months) 
(P< 0.01).
conclusion: AFP model could be used as a predictor of response, recur-
rence and survival in HCC patients undergoing TACE especially in patients 
with alpha feto protein level less than 100 IU/ml.
references: 1- Holah NS, El-Azab DS, Aiad HA and Sweed DM. Hepatocel-
lular carcinoma in Egypt: epidemiological and histopathological proper-
ties. Menoufia Med J .2015; 28:718-24. 2-Andrea N, Richard L, Paolo M, et 
al. Validation of the AFP model as a predictor of HCC recurrence in patients 
with viral hepatitis-related cirrhosis who had received a liver transplant for 
HCC: Journal of Hepatology 2017; 66: 552-559.
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P1470 IncIdence Of chOLangIOcarcInOMa and rIsk 
facTOrs: an anaLysIs Of 403295 cOnsecuTIve PaTIenTs
Craviotto V.1, Lleo A.1, Aloise M.2, Ceriani R.2, Colombo M.2, 
Badalamenti S.2, Torzilli G.1, Voza A.2, Aghemo A.3
1Humanitas University, Biomedical Sciences, Milan, Italy, 2Humanitas Clinical 
and Research Center, IRCCS, Milano, Italy, 3Humanitas University, Internal 
Medicine and Hepatology, Pieve Emanuele, Italy
contact e-Mail address: vincenzo.craviotto@humanitas.it
Introduction: Cholangiocarcinomas (CCAs) are a heterogeneous group of 
tumors that arise from the biliary tract epithelia, and account for nearly 
3% of all gastrointestinal tumors. Although CCA is on the rise in most 
countries, the epidemiology of these cancers has been poorly understood.
aims & Methods: We therefore aim to assess the prevalence, demograph-
ics and risk factors of patients with new diagnosis of CCA presenting in the 
Emergency Room (ER) of an Academic Italian Hospital. We retrospectively 
analyzed all ER cases between January 2010 and December 2017 at Hu-
manitas Research Hospital in Milano Italy.
results: From Jannuary 2010 to December 2017 403295 patients entered the 
ER, in 203 (0.05%) of them the diagnosis was CCA. CCA cases increased 
from 38 in the 2010-2011 period (38/102103: 0.03%) to 66 in the 2016-2017 
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period (66/101337: 0.07%) (p=0.007). The most frequent reasons for hos-
pitalization in patients with CCA were jaundice (n=106, 52%), abdominal 
pain (n=30, 15%) and abnormal liver function tests (n=13, 6%). During the 
study period 1224 patients (0.3%) entered the ER for jaundice, CCA ac-
counted for 9% of those cases. Out of the 203 patients with CCA, 109 were 
male (53.7%), the mean age was 68 years (24-88). 
No patient had PSC, only 6 (2.9%) had cirrhosis, while 32 had diabetes 
(15.7%). The anatomical location of the identified CCA was intrahepatic in 
21.6% of the cases, perihilar in 29%, distal in 26.6%, and gallbladder in 
21%. Tumor staging was 1 in 27 (13.3%), 2 in 57 (28.1%), 3 in 29 (14.3%) 
and 4 in 90 patients (44.3%). Treatment of CCA could be analyzed in 135 
patients, 51 patients (38%) received best supportive care, 43 received Che-
motherapy (32%), while 41 underwent surgery (30%). 
The rates of surgery increased during the enrolment period however with-
out reaching significant differences (19.7% in 2010-2011 vs 32.5% in 2016-
2017, p=0.3).
conclusion: CCA is a rare presentation in the ER, however with increasing 
incidence. CCA was found in 9% of all cases presenting with jaundice. 
Importantly, none of the identified CCA patients had PSC. Further, the low 
rate of patients with coexisting liver disease (2.9%), the high prevalence of 
advanced cancer stage (47%) as well as the low rate of surgical treatment 
(30%) reported by our study highlights the need for research in the field.
disclosure: Nothing to disclose 
P1471 The IMPacT Of TheraPy Of hePaTITIs c WITh dIrecT 
anTIvIraLs On The Occurrence Of hePaTOceLLuLar 
carcInOMa - a sIngLe cenTer exPerIence
Muzica C.1,2, Stanciu C.2, Huiban L.1,2, Petrea O.1,2, Girleanu I.1,2, 
Singeap A.M.1,2, Cuciureanu T.1,2, Chiriac S.1,2, Trifan A.-V.1,2
1”Grigore T Popa “ University of Medicine and Pharmacy, Iasi, Romania, 
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Introduction: The advent of direct-acting antiviral agents (DAAs) against 
hepatitis C virus (HCV) with high-sustained virological response rates, rep-
resents a major breakthrough in hepatology. The impact of DAAs on he-
patocellular carcinoma risk after obtaining sustained virological response 
(SVR) in patients with chronic HCV infection and advanced liver fibrosis 
remains to be clarified.
aims & Methods: The aim of our study was to assess the incidence of de 
novo hepatocellular carcinoma in a cohort of patients with SVR after an-
tiviral therapy. We prospectively analyzed a cohort of patients with HCV 
related liver cirrhosis treated with paritaprevir/ritonavir, ombitasvir and 
dasabuvir (PrOD) ± ribavirin for 12 weeks. Patients were followed between 
01 December 2015 and 01 March 2019, in a tertiary referral center from 
North-Eastern Romania. All patients were evaluated pretreatment accord-
ing to our National Protocol.
results: We enrolled in our study 480 patients (mean age 59.1±8.3 years), 
predominantly female (54.8%), with no prior history of hepatocellular car-
cinoma. During the study period we recorded a number of 27 (5.6%) de 
novo hepatocellular carcinoma cases, predominantly males (68%), mean 
age 61±5.9 years. The mean period between SVR and hepatocellular car-
cinoma diagnosis was 28±4 weeks. The sonographic findings revealed the 
predominance of unicentric lesions in 21 (70%) patients and the predomi-
nant localization of the lesions were in the VIII liver segment (23%). Dur-
ing follow-up, the main alpha-fetoprotein levels were significantly higher 
at the time of hepatocellular carcinoma diagnosis compared to baseline 
(68.01±5.72 vs 11.22±2.21, p< 0.0001).
conclusion: In conclusion, obtaining viral clearance does not seem to de-
crease the risk of hepatocellular carcinoma in patients with HCV-related 
liver cirrhosis after obtaining SVR with DAAs, the percentage of 5.6% be-
ing in the range described for the annual incidence of HCC in untreated 
HCV cirrhosis (between 3% and 7%). The impact of the DAA therapy im-
pact on hepatocarcinogenesis remains pivotal.
references: 1. European Association for the Study of the Liver; European 
Organisation for Research and Treatment of Cancer. EASL-EORTC clinical 
practice guidelines: management of hepatocellular carcinoma. J Hepatol. 
2012;56:908-943. 2. Baumert TF, Jühling F, Ono A, Hoshida Y. Hepatitis C-
related hepatocellular carcinoma in the era of new generation antivirals. 
BMC Med. 2017 Mar 14;15(1):52. doi: 10.1186/s12916-017-0815-7. Review. 
PubMed PMID: 28288626; PubMed Central PMCID: PMC5348895. 3. Gigi 
E, Lagopoulos VI, Bekiari E. Hepatocellular carcinoma occurrence in DAA-
treated hepatitis C virus patients: Correlated or incidental? A brief review. 
World J Hepatol. 2018;10(9):595-602. doi:10.4254/wjh.v10.i9.595.
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for Gstroenterology Dept. of Ultrasound, Gastroenterology, Cluj Napoca, 
Romania
contact e-Mail address: zsparchez@gmail.com
Introduction: Immunotherapy in hepatocellular carcinoma (HCC) is a re-
cent and very promising approach, namely the inhibition of the PD/pro-
grammed death-ligand 1 (PD-L1) axis. After tumor ablation or surgical 
treatment the 5 years recurrence rate is beyond 50%. Until now, no serum 
biomarker has proved to accurately discriminate patients who will develop 
recurrence from those who will not.
aims & Methods: In this prospective on-going clinical study we aim to 
investigate the prognostic value of a soluble form of PD-L1 in HCC pa-
tients. During 2016 to 2019 a total number of 267 patients with HCC have 
been evaluated for possible inclusion in the study. In total 123 patients with 
Child-Pugh class A, BCLC class 0 or A treated by either ablation (microwave 
or radiofrequency) or surgery were analyzed. Pre-treatment serum sPD-L1 
levels were measured with an enzyme-linked immunosorbent assay (ELI-
SA). Additionally, in 40 out of 123 patients sPD-L1 was also measured 4-6 
weeks after ablation or surgery.
results: Median sPD-L1 concentrations in patients with HCC was 95 (range 
47.6-305.4) pg/mL. Using the cut-off value of 95 pg/mL patients were strat-
ified into low (< 95 pg/mL) and high sPD-L1 ( ³ 95 pg/mL). 108 out of 123 
had a minimal follow-up of at least 6 months. After a median follow-up 
of 18 months the recurrence rate was 10.63% in patients with low sPD-L1 
compared to 68.85% in patients with high sPD-L1 ( p < 0.001). Disease-free 
survival was 14.2 months compared to 6.3 months in low vs. high sPD-L1 
patients ( p=0.001). In 23 out of 40 patients sPD-L1 increased 4-6 weeks af-
ter treatment while in 17 out of 40 patients it remained stable or decreased.
conclusion: We conclude that a high sPD-L1 level is a possible prognos-
tic indicator for a poor outcome in HCC patients after curative treatment. 
Patients with high sPD-L1 might benefit from combination therapies (e.g. 
tumor ablation and PD-1/PD-L1 inhibitors). Nevertheless, the predictive 
value of sPD-L1 levels for a successful anti-PD1/PD-L1 therapy should be 
investigated in the future.
disclosure: Nothing to disclose 
P1473 BeTTer ManageMenT Of sOrafenIB reLaTed adverse 
evenTs IMPacTs On reasOns LeadIng TO dIscOnTInuaTIOn and 
survIvaL
Tovoli F.1, Ielasi L.2, Benevento F.1, Piscaglia F.1
1Policlinic S. Orsola - Malpighi University of Bologna, Bologna, Italy, 
2Policlinic S. Orsola - Malpighi, Department of Medical and Surgical 
Sciences, Bologna, Italy
contact e-Mail address: luca.ielasi.kr@gmail.com
Introduction: Sorafenib is associated with various adverse events (AEs) po-
tentially leading to permanent drug discontinuation. Common sense sug-
gests that cumulative experience over a long timeframe might improve the 
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management of drug-related AEs, with a potential benefit to the patients. 
However, the actual existence and the full extent of this phenomenon have 
never been investigated.
aims & Methods: We analyzed a large retrospective-prospective database 
gathering the clinical data of 201 patients from our Centre, who were con-
secutively prescribed with sorafenib between 2008 and 2017. We divided 
these patients in two groups according to the start date of sorafenib (2008-
2012 vs 2013-2017), comparing clinical, laboratory and tumor character-
istics. In particular, we verified: treatment duration, medium daily dose, 
reason of sorafenib discontinuation and overall survival (OS).
results: One-hundred-three and 98 patients started sorafenib in 2008-
2012 and 2013-2018, respectively. These groups did not differ in age, sex, 
performance status, liver function, and tumor staging. Due to more fre-
quent dose reductions, the median average daily dose of sorafenib was 
lower in the 2013-2018 group (413 vs 518 mg/day, p<0.001). In parallel, 
the median treatment duration increased in the same group (145 vs 112 
day, p=0.027), with no remarkable difference in the cumulative drug dose 
between the two groups (61.6 vs 58.1 g, p=0.440). The rate of patients per-
manently stopping sorafenib for intolerance dropped from 23.3% in 2008-
2012 to 7.1% in 2013-2017 (p=0.002). The median OS was similar in the two 
groups (11.1 vs 11.6 months), but the rate of long-survivors (OS>3 year) was 
higher in the 2013-2017 group (23.4 vs 9.7%, p=0.001). 
To reduce the influence of deaths due to early progression, we performed 
a subgroup analysis of patients who achieved disease control as their best 
radiologic response. In this case, the OS in the 54 patients treated in 2013-
2017 was significantly higher compared to that of the 51 patients treated 
in 2008-2012 (24.4 vs 20.6 months, HR 0.63, 95%CI 0.42-0.96, p=0.031)
conclusion: Increased experience in the management of sorafenib-related 
AEs may lead to increased treatment duration and better outcomes in 
sorafenib-responsive patients. This factor may be of paramount relevance 
in the era of sequential treatments based on tyrosine- kinase inhibitors, as 
these molecules share a common toxicity-profile.
disclosure: Nothing to disclose 
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TIssue saMPLIng: ex-vIvO cLInIcaL evaLuaTIOn Of 
chOLangIOscOPy-guIded cryOBIOPsy TechnIque
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Introduction: Indeterminate biliary strictures still represent a major chal-
lenge in endoscopic diagnostics today [1], [2]. ERCP, EUS-FNA and cholan-
gioscopic guided biopsy show unsatisfactory sensitivity and may not ex-
clude malignancy [3], [4]. The cryobiopsy technique (CB) is a new method 
for tissue extraction which is already used for endobronchial biopsies in 
clinical routine. Several studies have demonstrated that CB is superior to 
conventional biopsy techniques such as forceps biopsies (FB) [5], [6].
aims & Methods: The aim of this ex-vivo clinical study was to investigate 
feasibility and tissue quality of CB in comparison to FB forceps for the re-
trieval of native and pathologically altered bile duct tissue. 
We Included 14 patients with suspected tumor obstruction of the common 
bile duct who underwent a pancreaticoduodenectomy. Postoperatively, 
the bile duct was exposed by lengthwise incision. Tissue samples were 
then taken either from visibly altered areas or, if not visible, from native 
bile ducts. A new prototype of a cryoprobe with a diameter of 1.1 mm 
(Erbe Elektromedizin GmbH, Tubingen, Germany) that was connected to 
a gas supply device (ERBECRYO2) as well as a standard forceps for the 
gastrointestinal tract (Boston Scientific Radial Jaw 4 Marlborough, Mas-
sachusetts, USA) were used for comparison. CB activation time differed 
from 1 to 6 seconds. A minimum of 3 biopsy attempts per patient were 
performed with each method. All biopsy specimens were assessed by two 
pathologists who were blinded to the biopsy method. Data was collected 
and analyzed for general feasibility, specimen area, and histological as-
sessability (evaluated by using a 7-point Likert scale ranging from 0-6). 
Samples were defined as representative, if the samples were big enough, 
had no or negligible crush artefacts and a score ≥2.
results: In total 76 biopsy attempts were made from 14 patients. Biopsy 
retrieved a macroscopically sufficient tissue sample in 22/30 (73.33%) at-
tempts using standard forceps and 25/46 (54.3%) using CB (p=0.014). The 
success rate of CB was 10/11 (90.90%) when carcinoma tissue was sampled 
compared to FB 6/9 (66.60%; p=0.285). The agreement between the two 
pathologist regarding representativity was good, with Cohen’s Kappa of 
0.69. 
Significantly larger samples were obtained by CB (5.60 ±5.0mm2) com-
pared to FB (3.23 ±5.00 mm²; p=0.005). Superior histologic assessability 
scores were achieved by CB (4.58 ±2.51) compared to FB (3.1 ±1.6; p=0.002). 
More representative samples were obtained by CB (92%) compared to FB 
(58%; p=0.011).
conclusion: CB in the bile duct is feasible and the quality of the obtained 
tissue is high. FB was more successful in retrieving tissue sample from the 
native bile duct than CB. There was no statistically significant difference in 
pathologically altered areas. If CB was successful, larger tissue amounts 
and more representative samples can be retrieved than with a standard 
biopsy forceps. With these promising results, an in-vivo study is justified.
references: [1] Moura et al. 2018. Endoscopic retrograde cholangiopancre-
atography versus endoscopic ultrasound for tissue diagnosis of malignant 
biliary stricture: Systematic review and meta-analysis. Endoscopic ultra-
sound 7, 1, 10-19. [2] Navaneethan et al, 2015. Comparative effectiveness 
of biliary brush cytology and intraductal biopsy for detection of malignant 
biliary strictures: a systematic review and meta-analysis. Gastrointestinal 
endoscopy 81, 1, 168-176 [3] Navaneethan et al, 2015. Single-operator chol-
angioscopy and targeted biopsies in the diagnosis of indeterminate biliary 
strictures: a systematic review. Gastrointestinal endoscopy 82, 4, 608-14.
e2. [4] Weilert et al, 2014. EUS-FNA is superior to ERCP-based tissue sam-
pling in suspected malignant biliary obstruction: results of a prospective, 
single-blind, comparative study. Gastrointestinal endoscopy 80, 1, 97-104. 
[5] Hetzel et al, 2012. Cryobiopsy increases the diagnostic yield of endo-
bronchial biopsy: a multicentre trial. The European respiratory journal 39, 
3, 685-690. [6] Schumann et al, 2010. Cryoprobe biopsy increases the di-
agnostic yield in endobronchial tumor lesions. The Journal of thoracic and 
cardiovascular surgery 140, 2, 417-421
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P1476 synergIsTIc effecTs and PharMacOTheraPeuTIc 
acTIvITy Of geMcITaBIne and cIsPLaTIn cOMBInaTIOn TheraPy 
In BILIary TracT cancer ceLL LInes
Sakamoto Y.1,2, Yamagishi S.3, Okusaka T.1, Ojima H.3,4
1National Cancer Center Hospital, Department of Hepatobiliary and 
Pancreatic Oncology, Tokyo, Japan, 2International University of Health and 
Welfare Atami Hospital, Department of Gastroenterology and Hepatology, 
Atami, Japan, 3Division of Molecular Pathology, National Cancer Center 
Research Institute, Tokyo, Japan, 4Keio University School of Medicine, 
Pathology, Tokyo, Japan
contact e-Mail address: yasakamo@iuhw.ac.jp
Introduction: Gemcitabine (GEM) and cisplatin (CDDP) combination 
therapy (GC) is the primary standard chemotherapy for advanced biliary 
tract cancer (BTC) worldwide; however, its pharmacotherapeutic activity 
remains unclear. This study aimed to assess the effects of GC in several 
BTC cell lines.
aims & Methods: We evaluated the dose-response activity of GEM and 
CDDP in 17 BTC cell lines; the cell lines were stratified into three groups 
based on their sensitivity as effective (IC
50
 of <1µM and calculable ≤IC
70
), 
resistant (IC
50
 could not be determined), and medium (sensitivity ≤ IC
70
) 
using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTS) assay. Eleven cell lines were selected for analysis of GC activity using 
the MTS assay. Synergistic, antagonistic, and additive effects of GEM and 
CDDP were determined by the Bliss additivism model (BM) and combina-
tion index (CI) at a GEM:CDDP molar ratio of 7:1 based on human renal 
clearance. 
The effect with a CI score of >1.25 was categorized as antagonistic, that 
with 0.7-1.25 as additive, that with 0.3-0.7 as synergistic, and that with 
≤0.3 as strongly synergistic. Pharmacotherapeutic effects were evaluated 
by comparison of the IC
50
 value of GEM alone and that of GEM plus CDDP 
at a 7:1 molar ratio.
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results: GEM was effective against four of the BTC cell lines; four cell lines 
were resistant and three had medium sensitivity. The results of BM re-
vealed GC had synergistic effects against all cell lines. The CI values against 
GC at a molar ratio of 7:1 revealed that antagonistic, additive, synergism, 
and strong synergism were 0, 3, 4, 4, respectively. The cell lines, on which 
GC had strong synergistic effect, were all GEM-resistant, and IC
50 
by GC 
was >1 µM. In GEM-sensitive cell lines, the IC
50
 at the 7:1 combination ratio 
was <1µM. The difference in the IC
50
 values for GEM and GC administration 
was small. If the IC
50
 value is low, the drug therapy is effective. A strong 
synergistic effect by GC therapy (molar ratio 7:1) was observed against the 
GEM-resistant cell lines; however, the corresponding sIC
50
 value was high, 
indicating a discrepancy between the CI and IC
50
 values.
conclusion: BM and CI show that GC combination treatment has a high 
synergistic effect. However, the pharmacotherapeutic activity of GC combi-
nation treatment did not considerably differ in GEM-sensitive cells. Strong 
synergy was noted in GEM-resistant cells, but the pharmacotherapeutic ef-
fects were not adequate. To treat advanced BTC more effectively, predictive 
efficacy markers for GEM to select patients who should be treated with GC 
and a third therapeutic agent in the GC combination are needed.
disclosure: Takuji Okusaka received honoraria from Eli Lilly Japan. Yasunari 
Sakamoto, Seri Yamagishi, Takuji Okusaka, and Hidenori Ojima received 
research grant from Eli Lilly Japan outside the submitted work. 
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P1478 BLOOd neuTrOPhIL-LyMPhOcyTe raTIO and 
PLaTeLeT-TO-LyMPhOcyTe raTIO can Be earLy PredIcTOrs 
fOr The severITy Of acuTe PancreaTITIs
Liu C.
Jinglin Hospital, Nanjing University, Gastroenterology and Hepatology, 
Nanjing, China
contact e-Mail address: liuchang_gi@163.com
Introduction: Given the evidence that Neutrophil-lymphocyte ratio (NLR) 
and platelet-to-lymphocyte ratio (PLR) can early predict the severity and 
outcome of many inflammation-association diseases and neoplasm. In this 
study, we aimed to investigate the value of NLR and PLR in early prediction 
of the severity of acute pancreatitis.
aims & Methods: Clinical data of 629 acute pancreatitis patients was col-
lected and then NLR and PLR were calculated on the first admission and 
correlated with subsequent severity. Severe acute pancreatitis (SAP) is de-
fined by persistent organ failure more than 48 hours, while mild severe 
acute pancreatitis (MSAP) and mild acute pancreatitis (MAP) were defined 
into Non-SAP.
results: Among 629 acute pancreatitis patients, 396 were classified into 
Non-SAP and 233 into SAP. NLR was 6.79 (0.73-46.00) in Non-SAP group 
and 16.33 (2.91-96.70) in SAP group, respectively. PLR and NLR were the 
most significant variables after all the data was analyzed. Receiver op-
erating characteristics (ROC) curves of NLR and PLR were performed to 
determine the optimal cut-off value to predict SAP. NLR (AUC 0.789; 95% 
CI: 0.755 to 0.820) combine with PLR (AUC 0.770; 95% CI: 0.729-0.807) can 
get more accurate value (AUC 0.799; 95% CI: 0.760-0.835) for predicting 
SAP. Then the receiver operating characteristic areas between each predic-
tive model was compared, there was no significant difference between 
each group, and NLR combined with PLR (N-PLR) did not have a significant 
better performance than PLR independently. It demonstrated that PLR and 
NLR were two independent predictors for the severity of acute pancreatitis.
conclusion: PLR and NLR can be simple and effective indicators for pre-
dicting SAP in early stage.
disclosure: Nothing to disclose 
P1479 a MuLTIcenTer, InTernaTIOnaL cOhOrT anaLysIs 
Of 1435 PaTIenTs TO suPPOrT cLInIcaL TrIaL desIgn In acuTe 
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Introduction: Despite the lack of specific treatment of acute pancreatitis 
(AP), there are relatively few clinical trials that investigate this disease. 
Our aim was to analyze a large, high-quality, multicenter, international 
cohort to provide necessary information for study feasibility calculation, 
study design, sample size calculation and primary outcome selection for 
clinical trials in AP.
aims & Methods: First, we searched the medical literature for stud-
ies which used C-reactive protein level (CRP) or white blood cell count 
(WBC), to describe their current role in trials on AP. Second, we analyzed 
the data of 1435 patients in our multinational registry of AP. Data on CRP 
and WBC: on admission, within 24 hours form the onset of pain and their 
highest values during hospitalization were analyzed to investigate their 
correlation with severity and mortality of AP. Descriptive statistical tools 
as Kruskal-Wallis, Mann-Whitney U, Levene’s F tests, Receiver Operating 
Characteristic (ROC) curve analysis and AUC (Area Under the Curve) with 
95% confidence interval (CI) were performed.
results: Our literature review showed that CRP is used as an inclusion 
criterion or as a primary outcome or both (17, 10 and 2 studies respectively) 
in the earlier and current clinical trials on AP. Its use is extremely variable 
and not well described. In our cohort, CRP levels on admission predicted 
mortality and severe cases of AP poorly (AUC: 0.669 (CI: 0.569-0.770); 0.681 
(CI: 0.601-0.761) respectively). CRP levels measured within 24 hours from 
the onset of abdominal pain equally failed to predict mortality or severity 
(AUC: 0.741 (CI: 0.627-0.854; AUC: 0.690 (CI: 0.586-0.793) respectively). The 
highest CRP and WBC during the entire hospitalization had equally poor 
predictive accuracy for mortality and severity of AP. However, if CRP within 
24 hours from the onset of pain is an inclusion criterion, then it can mark-
edly elevate the combined even rate of mortality and severe cases of AP 
(13% for CRP>25mg/l and 28% for CRP>200mg/l). WBC did not show the 
same characteristics as CRP.
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conclusion: We found that increasing the CRP as an inclusion criterion 
from the onset of abdominal pain can elevate the event rates of mortal-
ity, and severity. This novel finding may decrease the number of patients 
required for clinical trials in the future. Based on our results, CRP should 
not be used as a primary outcome in clinical trials and WBC should not be 
used as an inclusion criterion or outcome in clinical trials on AP.
disclosure: Nothing to disclose 
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Introduction: Walled-off pancreatic necrosis (WOPN) is a complication of 
acute pancreatitis that affects approximately 20% of patients and still car-
ries high risk of morbidity and mortality. Endoscopic drainage by either 
Lumen Apposing Metal Stents (LAMS), Self Expanding Metal Stents (SEMS) 
or Double Pigtail Stents (DPS) can help to drain the liquid component of 
WOPN. 
However solid debris may remain in the cavity and can act as a source 
of ongoing infection and sepsis-related multi-organ failure. Therefore 
endoscopic debridement is usually recommended but a limitation of 
the approach is the lack of dedicated devices; this results in the need for 
multiple, repetitive and time-consuming procedures to achieve complete 
resolution. A new 3.1 mm flexible mechanized microdebrider catheter can 
now be deployed through a 3.2 mm endoscopic working channel to resect 
and remove solid debris under direct endoscopic visualization, and may 
overcome the limitation.
aims & Methods: The aim of the ongoing prospective international mul-
ticenter study is to explore feasibility and safety of necrosectomy with the 
flexible endoscopic microdebrider in patients with WOPNs. All patients 
underwent prior CT scan which had to show WOPN of ≥ 6cm and ≤ 22cm 
in size with ≥30% solid component. Endoscopic drainage (by either LAMS, 
SEMS or DPS) was carried out at least three days before endoscopic micro-
debrider-assisted necrosectomy was performed through the gastrostoma 
under direct visualization.
Adverse events (AE), procedure times, number of procedures until resolu-
tion, percentage decrease of solid necrosis per session, decrease of WOPN 
size on follow-up CT scans (21 days after final session) and time to dis-
charge were documented.
results: 19 patients with WOPN were screened in the study between 
November 2018 and March 2019. 12 patients underwent microdebrider-
assisted necrosectomy. No microdebrider-associated adverse events, in-
cluding bleeding were reported. However, one patient died during the 
study period not attributed to microdebrider use. A mean of 1.8 interven-
tions (range 1-4) were required with an average microdebrider procedure 
time of 77 minutes and total procedure time of 180 minutes. There was a 
mean 63.0% reduction of solid necrosis after the first session. The mean 
decrease of cavity size was 86.8% in the 5 patients so far reported with 
completed pre- and post-CT scans. Time from microdebrider-assisted ne-
crosectomy to discharge averaged 6 days (range 0-12 days).
conclusion: Microdebrider-assisted necrosectomy for WOPN seems to be 
a feasible and safe procedure that can provide very effective endoscopic 
clearance of solid debris without device-associated adverse events. Com-
pared to endoscopic necrosectomy using conventional, non-dedicated in-
struments endoscopic microdebrider-assisted necrosectomy appears to be 
superior with regard to the number of procedures required for resolution 
and to overall procedure time.
disclosure: Schlag - speakers fee, advisory board, travel grants and fi-
nancial study support from Interscope, Olympus, Medtronic, Esocap, Falk 
Pharma, Adare Pharma; Other authors - no Interscope-related disclosure. 
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Introduction: Acute (necrotizing) pancreatitis may result in disrupted or 
disconnected pancreatic duct syndrome, which is associated with a fur-
ther complicated clinical course. Diagnosis of disconnected pancreatic duct 
syndrome is not standardized in clinical practice or international guide-
lines. We therefore performed a systematic review of the current literature 
on imaging modalities for diagnosing disruption or disconnection of the 
pancreatic duct in patients with acute pancreatitis.
aims & Methods: A systematic search was performed in MEDLINE, Em-
base and Cochrane library databases up to October 2018 to identify all 
studies evaluating diagnostic modalities for the diagnoses of a disrupted 
or disconnected pancreatic duct in acute pancreatitis. All data regarding 
diagnostic accuracy were extracted.
results: We included twelve studies, evaluating 286 relevant patients, re-
porting on five different diagnostic modalities. The overall diagnostic ac-
curacy of amylase-measurement in drain fluids for detecting a disrupted 
pancreatic duct was 65%, with a sensitivity of 100% and a specificity of 
50%. One study evaluated endoscopic retrograde cholangiopancreatogra-
phy (ERCP), as compared with surgically confirmed disruption, showing a 
sensitivity of 100%, with no reported specificity. In a selected study popu-
lation, endoscopic ultrasound (EUS) also demonstrated a 100% sensitiv-
ity in detecting a disrupted pancreatic duct. The sensitivity of (secretin)-
magnetic resonance cholangiopancreatography (MRCP), as compared 
with several other diagnostic modalities, ranged from 83.3%-100%, with a 
specificity of 100%. For secretin-MRCP, sensitivity was 83.3% and specific-
ity was 100%. The sensitivity for computed tomography was 68%.
conclusion: This systematic review suggests that EUS, ERCP and (secretin)-
MRCP are all accurate in diagnosing a disruption or disconnection of the 
pancreatic duct in patients with acute pancreatitis. Given the poor overall 
visualization of the pancreatic duct on EUS and the invasive nature of ERCP, 
however, (secretine)-MRCP would be recommended as first diagnostic 
modality. Further prospective studies are needed to define the optimal 
timing and diagnostic value of (secretin)-MRCP in different subgroups of 
patients with acute (necrotizing) pancreatitis.
disclosure: Nothing to disclose 
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Introduction: Acute pancreatitis (AP) can lead to both endocrine and exo-
crine pancreatic insufficiency. Necrotizing pancreatitis is a severe disease 
that can lead to changes in body composition and earlier findings show 
that necrotizing pancreatitis is associated with a high risk of exocrine in-
sufficiency.
aims & Methods: The aim of this study was to investigate the long-term 
changes in pancreatic function and body composition in patients with AP 
and walled-off pancreatic necrosis (WON) following endoscopic transgas-
tric drainage and necrosectomy (ETDN). 
We prospectively included patients with WON who underwent ETDN. Pa-
tients were evaluated during admission and at 1, 3, 6 and 12 months af-
ter discharge with faecal elastase (f-elastase), Haemoglobin A1c (HBA1c), 
C-peptide, and body composition with dual-energy x-ray absorptiometry 
(DXA). At 12 months Lundh’s test was performed to directly assess exo-
crine function. Before treatment was initiated, all patients underwent a 
computed tomography (CT) scan, and CT severity index (CTSI) as well as 
modified CTSI was calculated.
results: Eighteen patients were included (67% men; median age 63 years; 
44% gallstones; 39% alcohol; 17% other). At 12 months follow-up 57% 
of the patients had exocrine insufficiency based on Lundh’s test and 67% 
based on f-elastase. Two patients (11%) developed signs of endocrine in-
sufficiency, based on both HBA1c and C-peptide, two patients with only 
HBA1c being affected. 
From discharge to up to 3 months after discharge, we found a loss in mean 
total body mass from 78.2 ± 18.4 kilogram (kg) to 73.9 ± 18.1 kg (p=0.03), 
in mean total fat mass from 25.9 ± 11.0 kg to 23.5 ± 9.9 kg (p=0.14) and in 
mean muscle mass from 49.6 ± 10.1 kg to 47.7 ± 10.3 kg (p=0.15). Between 
3- and 12-months follow-up, the mean total body mass increased to 78.6 ± 
13.7 kg (p=0,001), mean muscle mass to 49.6 ± 9.6 kg (p=0.03) and mean 
fat mass to 26.4 ± 7.0 kg (p=0.06). We found no correlation between the 
changes in body composition and endocrine or exocrine function.
conclusion: More than half of the patients in present study developed exo-
crine insufficiency one year after treatment for WON with ETDN. Our results 
support earlier findings, that patients with WON are at risk of developing 
especially exocrine insufficiency and that a minor group develop endocrine 
insufficiency. Although exocrine insufficiency is evident, its influence on 
changes in weight and body composition is questionable as our patients 
regained their weight on 12 months follow-up. Furthermore, our results 
question whether enzyme supplement should be supplemented per se in 
cases of low f-elastase values, or if the clinical decision should include 
other parameters such as changes in weight and in muscle and fat mass.
disclosure: Nothing to disclose 
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Introduction: Endoscopic ultrasound (EUS) has emerged as an important 
tool in diagnostic evaluation of patients with acute pancreatitis (biliary 
or unknown etiology). The current guidelines recommend performance of 
endoscopic retrograde cholangiopancreatography (ERCP) by patients with 
acute biliary pancreatitis only in the presence of cholangitis, dilated biliary 
ducts or confirmed choledocholithiasis.
aims & Methods: The aim of this study was to utility of EUS by patients with 
biliary or unknown etiology of acute pancreatitis.
Our retrospective study included EUS investigations performed between
06/2017-03/2019 in our newly established GI-Department, which features a 
centralized endoscopy-service in a University affiliated tertiary care teach-
ing hospital.
EUS was performed in patients with biliary pancreatitis without cholangi-
tis or dilated biliary ducts in order diagnose/exclude choledocholithiasis. 
Patients with acute pancreatitis of unknown etiology were investigated 
with EUS in order to identify a possible etiology (especially biliary).
results: 60 patients were included in this analysis (33 with biliary pancre-
atitis and 27 with unknown etiology of acute pancreatitis).
Choledocolithiasis was diagnosed in 12/33 (36.3%) patients with acute bili-
ary pancreatitis. All these patients received ERCP and biliary duct stones 
were removed. In one patient with acute pancreatitis and gallstones, but 
without choledocholithiasis, EUS also diagnosed a tumor in the pancreatic 
head (this was not seen in CT scan). A biopsy was performed and showed 
an adenocarcinoma. 
In 1/20 (5%) biliary pancreatitis cases with negative EUS, the patient devel-
oped jaundice on follow-up and ERCP with extraction of bile duct stones 
was performed.
EUS identified an etiology in 16/27 (59.2%) of cases with initially unknown 
etiology of acute pancreatitis: biliary-11/27 (40.7%), autoimmune pancre-
atitis - 2/27 (7.4%), pancreatic tumor (undiagnosed in CT scan)- 1/27 (3.7%), 
pancreaticolithiasis -1/17 (3.7%) and chronic pancreatitis - 1/27 (3.7%).
Magnetic resonance imaging (MRI) was available in 8/11 (72.7%) patients 
with pancreatitis of unknown etiology and negative EUS. Pancreas divisum 
was diagnosed in 1/8 cases. In all other cases MRI was also negative.
Negative MRI was present in 3/16 (18.7%) pancreatitis cases with biliary 
etiology in EUS. No MRI was available in the other cases.
conclusion: EUS is a very sensitive method for diagnosing choledocholi-
thiasis in patients with biliary pancreatitis and provide an etiology in two 
thirds of cases with initially unknown etiology of acute pancreatitis.
disclosure: Nothing to disclose 
P1484 TO cOMPare The cLInIcaL OuTcOMe Of PaTIenTs 
Of acuTe PancreaTITIs (aP) havIng InTra-aBdOMInaL 
hyPerTensIOn (Iah) WITh ThaT Of PaTIenT WITh nOrMaL 
InTra-aBdOMInaL Pressure (IaP)
Singh A.1, Samanta J.1, Rana A.1, Bellam B.L.1, Gupta P.1, Gupta V.2, 
Yadav T.D.2, Sinha S.K.1, Kochhar R.1
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Introduction: Acute pancreatitis patients, mainly severe acute pancreatitis, 
tends to have elevated intra-abdominal pressure which may progress to 
intra-abdominal hypertension (IAH) and abdominal compartment syn-
drome (ACS). ACS is shown to correlate with poor outcome and increased 
mortality in AP. However, outcome of AP with IAH is rarely studied.
aims & Methods: Study was aimed to compare the clinical outcome of 
patients of AP with IAH with those with normal IAP. Retrospectively data 
was analysed of 105 patients of AP from Jan 2016 to May 2018. Parameters 
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measured included the demographic profile, clinical severity scores, CT 
severity score (CTSI), persistent organ failure (OF), hospital and ICU stay, 
need and outcome of percutaneous catheter drainage (PCD), surgery re-
quirement and mortality. Patients were divided into two group based on 
presence or absence of IAH and were analysed.
results: Among 105 patients of AP, IAH was present in 48 (45.7%) patients. 
Both the groups were comparable for clinical characteristics. Patients with 
IAH had more often severe disease, BISAP ≥2, higher APACHE II scores 
and CTSI. IAH group had more often OF (87.5% vs. 70.2%, p value=0.033), 
prolonged ICU stay (12.5 vs. 6.75 days, p value=0.007) and higher mortality 
(52.1% vs. 15.8%, p value < 0.001). In the IAH group, reduction of IAP by 
less than 35% at 48hours post-PCD compared to baseline correlated with 
higher mortality (81.2% vs. 37.5%, p value = 0.004) while in patients with 
normal IAP no correlation with decrease in IAP and mortality was noted. 
Need for PCD, surgery and hospital stay were similar in two groups. On 
multivariate analysis, presence of IAH and CVS failure at presentation were 
independent predictors of mortality (p value < 0.001 and 0.004, respec-
tively). APACHE ≥10 and CTSI ≥8 at presentation was found to predict the 
development of IAH (p value 0.014 and 0.019, respectively) on multivariate 
analysis.
conclusion: IAH is an independent predictor of mortality in AP. Patients 
with APACHE ≥10 and CTSI ≥8 at presentation are likely to develop IAH and 
require IAP monitoring.
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de Ribes, Spain, 8Borsod-Abaúj-Zemplén County Hospital and University 
Teaching Hospital, Székesfehérvár, Hungary, 9University of Debrecen, 
Department of Internal Medicine, Division of Gastroenterology, Debrecen, 
Hungary, 10Szent György Teaching Hospital of County Fejér, 1st Department 
of Internal Medicine, Székesfehérvár, Hungary, 11Bajcsy Zsilinszky Hospital, 
Budapest, Hungary, 12Szent György Teaching Hospital of County Fejér, 
Székesfehérvár, Hungary, 13Heim Pál Children’s Hospital, Budapest, Hungary
contact e-Mail address: foldimarcsi4@gmail.com
Introduction: Pain is the most common symptom in acute pancreatitis (AP), 
and is part of the diagnostic criteria. However, its clinical characteristics in 
AP have not been detailed in the literature. Our aim was to objectify the 
diagnostic and prognostic role of acute abdominal pain in AP.
aims & Methods: Our aim was to objectify the diagnostic and prognostic 
role of acute abdominal pain in AP. The Hungarian Pancreatic Study Group 
(HPSG) has prospectively collected multicenter clinical data of 1432 adult 
patients between 2012 and 2017. The specific pain questionnaire contained 
data in four categories: intensity of pain (Visual Analog Scale; 1-10, mild 
[mild]: 1-3, moderate [modP]: 4-6, severe [sevP]: 7-10), duration of pain 
prior to admission (hours), localization of pain (9 regions of the abdo-
men), and type of pain (sharp, dull, or cramping). These data were com-
pared to parameters on admission and with the outcome of AP. Statistical 
analyses were performed accordingly.
results: Pain contributed to the ‘on admission’ diagnosis in 99.6% 
(n=1426) of cases. It was mostly severe (mildP: 5%, n=38; modP: 25%, 
n=178; sevP: 70%, n=511), cramping (61%, n=705), and epigastric (48%, 
n=687). Severe pain was associated with a more severe disease course 
(p< 0.05); however, it failed to predict mortality (p=0.826). Sharp pain 
was associated with AP severity (p< 0.001), mortality (OR=2.263, 95% CI: 
1.199-4.059), and systemic complications (OR=2.263, 95% CI: 1.550-3.970). 
Localization of pain was not associated with the main outcomes. Throm-
bocyte (r=0.074, p< 0.05), CRP (r=0.322, p< 0.001) alkaline phosphatase 
(r=0.171, p< 0.001), γ-GT (r=0.071, p< 0.05), and total bilirubin (r=0.147, p< 
0.001) were positively correlated with duration of pain prior to admission, 
whereas amylase (r= 0.212, p< 0.001), lipase (r= 0.257, p< 0.001), hemoglo-
bin (r= 0.090, p< 0.05) and triglyceride (r= 0.892, p< 0.05) showed negative 
correlation with the duration of pain. Pain within the first 24 hours was 
accompanied by elevated amylase levels in 78% of cases on admission. 
If pain lasted more than 72 hours, amylase was only increased in 62% of 
cases on admission. Furthermore, longstanding ( >3 days) pain was as-
sociated with milder (p< 0.001) and rather dull pain (p< 0.05), localized in 
the right abdomen (p< 0.005).
conclusion: Pain was associated with the main outcomes and different, 
prognostically or diagnostically important laboratory parameters. Pain 
later in the disease course becomes atypical, and amylase or lipase reach 
the diagnostic level less frequently. Our work comprehensively objectified 
the diagnostic and prognostic role of pain in AP.
disclosure: Nothing to disclose 
P1486 duaL cenTer exPerIence Of earLy PancreaTIc 
necrOsIs LOcaTIOn and acuTe PancreaTITIs severITy
Gulla A.1,2, Samuilis A.3, Bollen T.4, Strupas K.5
1Institute of Clinical Medicine, Faculty of Medicine, Vilnius University/Vilnius 
University Hospital, Department of Surgery, Vilnius, Lithuania, 2Georgetown 
University Hospital, Department of Surgery, Washington DC, United States, 
3Institute of Clinical Medicine, Faculty of Medicine, Vilnius University/
Vilnius University Hospital, Department of Radiology, Vilnius, Lithuania, 
4St. Antonius Ziekenhuis, Nieuwegein, Netherlands, 5Institute of Clinical 
Medicine, Faculty of Medicine, Vilnius University/Vilnius University Hospital, 
Department of Surgery, Gastroenterology, Nephrourology, Vilnius, Lithuania
contact e-Mail address: aistegulla@gmail.com
Introduction: Acute pancreatitis is a severe and frequently a life-threat-
ening disease, which can lead to pancreatic necrosis, acute lung injury, 
SIRS and MODS. In this study, we hypothesized that the early radiologically 
determined location of pancreatic necrosis can serve as a determinant of 
acute pancreatitis severity, thus lead to more systematic complications.
aims & Methods: Acute pancreatitis (n=100) patients in two institutions 
were studied. Contrast CT scan was performed either on admission or be-
tween Days 3-10 during the hospital stay. In addition, CT index, percentage 
of non-enhancement pancreas, Balthazar score, CTSI score and modified 
CTSI score were evaluated. A particular emphasis was to the location of 
non- enhancement pancreas and pattern of pancreatic necrosis. Other 
findings, such as pleural complications, ascites, pericardial effusion, vas-
cular complications, peripancreatic collections, wall and shape of necrosis 
and extra-pancreatic organ involvement were evaluated. All CT scans were 
evaluated by two different radiologists in both institutions.
results: The subjects were selected based on confirmation of acute pan-
creatitis diagnosis. We report the preliminary results of the first ten (10%) 
patients from our cohort. Balthazar score- E-7/10, D-3/10 and CTSI score 
of 10-10%, 6-40%, 8-10%, 4-10%, 3-20% subsequently. While modified 
CTSI score of 10-30%, 8-40%, 6-30%, 8-20%, 4-10% accordingly. The 
presence of pancreatic necrosis was determined by four types of spread 
patterns based on location. Our data demonstrate location of collections 
as: bilateral- 4 (40%), central-7 (70%), right-sided-2 (20%), scattered ne-
crosis-3 (30%), left sided-2 (20%), right sided-1 (10%), extension below 
iliac crest-2 (20%), thus 2 (20%) patients had hyperdense adrenals as sign 
of shock. In addition, non-enhanced pancreas >50%- 1/10, < 30%- 4/10, 
while subtotal necrosis >90%-2/10 patients.
conclusion: Further studies are now underway to analyze the remaining 
cohort to determine whether early identification of location of pancreatic 
necrosis can determine severity of acute pancreatitis disease course, thus 
prevent systemic complications.
references: Types of spread patterns of EXPN (based on the dominant pat-
tern observed, modified from Madry et al 1994 and Ishikawa et al 2006); 
right EXPN, central EXPN, left EXPN, and bilateral EXPN.
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P1487 necrOTIzIng PancreaTITIs: can dIffusIOn-WeIghTed 
MagneTIc resOnance IMagIng heLP In deTerMInIng 
InfecTIOn?
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Introduction: Acute pancreatitis is a common disease worldwide, with the 
majority of patients having a rapidly favorable outcome. Nevertheless, 
20% will develop moderate to severe disease with a high risk of infec-
tion of necrosis and organ failure; in these cases mortality can reach 15%. 
Infected necrosis requires management with antibiotics and invasive in-
terventions. However, differentiating sterile from infected necrosis can be 
challenging. Diffusion-weighted magnetic resonance imaging (DW-MRI) 
has shown promising results regarding the presence of infection or not in 
pancreatic pseudocysts. These results have not been generalized to pan-
creatic necrosis or walled-off necrosis (WON). On the other hand, there is 
limited data regarding microbiology and antibiotic use in these patients.
aims & Methods: The aim of the study is to assess the diagnostic potential 
of DW-MRI to detect infected necrosis, as well as determining the micro-
biology and antibiotic use in patients with necrotizing pancreatitis.This is 
a retrospective study on patients with necrotizing acute pancreatitis ad-
mitted from 2010-2018, having undergone invasive interventions and MRI 
before intervention. Patients with chronic pancreatitis were excluded. Mi-
crobiology results based on fluid collected during drainage and sequential 
antibiotic use were recorded. Gold standard for an infected collection was 
considered when the culture of fluid collected during the initial drainage 
was positive. MRIs were reviewed and infection of the necrosis or WON 
was considered in case of a restricted diffusion signal.
results: Sixty-seven patients were identified. The majority (67.2%) were 
men, and the main etiology was alcoholic in 30/67 (44.6%). Intensive 
care unit admission was required for 37/67(53.8%) who presented with 
organ failure for a median duration of 12 (1-121) days. Median hospital 
stay was 70 (15-345) days. All patients had, at least, one endoscopic drain-
age (overall 2(1-8)). Endoscopic necrosectomy was required in 24/67 (36%) 
and combined percutaneous drainage in 18 (26.9%). DW-MRI was per-
formed in 56 patients; sensitivity of DW-MR to detect infection was 67% 
and specificity 58%. CT revealed air bubbles in 8 patients; sensitivity and 
specificity of this sign was respectively 19% and 100%. Cultures collected 
during the first drainage were positive in 57/67 patients (85%). Microbiol-
ogy results from the first drainage revealed more frequently gram-negative 
rods: E.Coli (n=15), Klebsiella Pneumoniae (n=6) and Pseudomonas aeru-
ginosa (n=3) with already 9 multidrug resistant bacteria, whereas fungi 
were found in 17 patients (candida albicans n=13). All patients were treated 
with antibiotics with a median duration of 43 (1-137) days, with 3 (0-12) 
adaptations according to clinical evolution or further bacteriological find-
ings. Amoxicillin-clavulanic acid was the most used first choice antibiotic 
(n=22), followed by piperacillin-tazobactam (n=14). 35 patients (52%) 
were treated with antifungal therapy, mostly Fluconazole. Mortality during 
the initial hospitalization occurred in 12/67(17.9%) patients.
conclusion: DW-MRI could be a useful additional tool to distinguish be-
tween sterile and infected necrosis. Antibiotics are overused in patients 
with necrotizing acute pancreatitis with suspected infection, resulting in 
an increase of multidrug resistant bacteria and fungal infections.
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P1488 PaTIenT characTerIsTIcs and PredIcTOrs Of 
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Introduction: Discharge Against Medical Advice (DAMA) which is the pa-
tient’s discontinuation or refusal of medical care is a health problem in 
the United States (U.S) contributing to worse morbidity, mortality and fre-
quent re-hospitalizations. Despite the significant burden DAMA imposes 
on healthcare cost and utilization, there is a lack of understanding of the 
characteristics of patients who DAMA and factors associated with DAMA 
especially among hospitalized gastrointestinal patients. Acute pancreatitis 
(AP) on the other hand, is the most frequent gastrointestinal reason for 
hospitalization in the U.S. We therefore aim to examine the characteristics 
of patient who DAMA and determine factors associated with DAMA among 
patients admitted with AP.
aims & Methods: A retrospective study utilizing the 2014 National Inpatient 
Sample (NIS) database was performed. All adult patients admitted with a 
primary or secondary diagnosis of AP were included in this study. Patients 
who died during index hospitalization or transferred to another facility 
were excluded. Patient and hospital level characteristics were obtained. 
Discharge diagnosis and DAMA outcome data were collected. Patient and 
population characteristics of patients who DAMA were examined using de-
scriptive analysis. Multivariable logistic regression was used to determine 
factors associated with DAMA in this population. We adjusted for patient 
and hospital-level characteristics, possible etiologies, type of procedure, 
and complications.
results: A total of 51,607 discharge records met our inclusion criteria. 
N=1,893 (3.5 %) of all discharges were against medical advice. 69% of 
patients were in the 35-65 years age bracket and 60% were Whites. A total 
of 58% had some type of government insurance (Medicare or Medicaid) 
and patients with ≥ 3 co-morbidities had the highest proportion of DAMA 
(43%).
After adjusting for covariates, patients who use tobacco (OR 1.54, 95% CI 
1.31 -1.80), cannabis (OR 1.26, 95% CI 1.01 - 1.59), and other illicit drugs 
(OR 1.50, 95% CI 1.27 - 1.77) were more likely to DAMA compared to non-
smokers, non-cannabis and non-illicit drug users. Patients on government 
insurance (OR 2.28, 95% CI 1.98 - 2.62), and self-pay (OR 2.34, 95% CI 
1.99 -2.78) were more likely to DAMA compared to patients with private 
health insurance. Interestingly, patients with a diagnosis of gallstone (OR 
2.76, 95% CI 1.89 - 4.03) and alcoholic AP (OR 2.31 95% CI 2.01 -2.66) were 
found to be more likely to DAMA compared to AP from other etiologies. 
Other factors associated with DAMA in this population include males (OR 
1.36, 95% CI 1.51 - 1.23), younger patients and patients with less than 3 
comorbidities (OR 1.51, 95% CI 1.79-1.28).
conclusion: In the acute pancreatitis population, factors associated with 
DAMA include younger male patients, the use of tobacco and illicit drugs, 
patients on government insurance, patients with gallstone, alcohol-
induced pancreatitis and patients with fewer number of comorbidities. 
Understanding the characteristics of patients discharged against medical 
advice and the factors that may influence the decision to DAMA may help 
identify specific populations for pre- and in-hospital intervention to help 
reduce the incidence of DAMA and its associated morbidity and mortal-
ity, as well as reduce the overall cost related to re-hospitalizations in this 
patient population.
disclosure: Nothing to disclose 
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P1489 sPecIfIc crysTaLLOId sOLuTIOns versus nOrMaL 
saLIne fOr acuTe PancreaTITIs - MeTa-anaLysIs WITh TrIaL 
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Introduction: Intravenous fluid resuscitation is a cornerstone of treatment 
for pts with acute pancreatitis (AP) directed to prevent hypovolaemia and 
organ hypoperfusion. Specific crystalloid solutions with additional poten-
tial anti-inflammatory and buffer agents such as lactate or acetate, and 
lower chloride levels have been researched in different critically-ill pts 
compared to the use of normale saline, showing potential superiority.
aims & Methods: We aimed to evalute the effects of these specific crystal-
loids in AP pts and assess the level of available evidence. We performed 
electronic searches of Medline, Web of Science, Scopus, and The Cochrane 
Library for randomized controlled trials assessing the use of specific crys-
talloid solutions for treatment of AP. Mortality and organ failure (OF) were 
assessed as primary outcomes. Secondary outcomes included SIRS, pan-
creatic necrosis (PN), infected pancreatic necrosis (IPN), local complica-
tions (LC), and length of hospital stay. TSA was performed for the primary 
outcomes, and secondary outcomes showing a significant result in meta-
analysis, with alpha of 5%, and power of 80%. Results for dichotomous 
outcomes were expressed as risk ratios (RRs) with 95% confidence in-
tervals (CIs), and continuous results were expressed as mean differences 
(MDs) with 95% CIs.
results: Three RCTs with a total of 127 patients were included in the analy-
sis. All trials compared the use of RL (n=) compared to NS (n=). The mor-
tality and OF rates were similar in both groups with RRs 0.36 (95% CI 0.04 
to 3.30;I2=0%) and 0.39 (95% CI 0.09 to 1.76;I2=0%), respectively. Devel-
opment of PN was reduced with RL (RR 0.28; 95% CI 0.09 to 0.91;I2=0%). 
SIRS rates at 24h were lower among pts receiving RL (RR 0.38;95% CI 
0.15 to 0.98;I2=36%) and the length of hospital stay was shorter (MD 
-0.80;95% CI -1.23 to -0.37;I2=78%). TSA was not performed for mortal-
ity due to too little information available. To detect a RR reduction (RRR) 
for OF of 30% and a rate of 20% among controls, a total of 1231 pts are 
required. A 30% RRR with 30% PN rate among controls would require 
a 1151 pts, while a 30% RRR with 40% SIRS rate among controls would 
require 2227 pts. A required information size of 218 pts was calculated 
based on a minimal relevant effect of reducing hospital stay for 1 day 
(SD=1.52). To detect All TSA analyses were performed for the total of 127 
randomized pts.
conclusion: Evidence favoring use of Ringer’s lactate over normal saline 
for treatment of AP is very low. We couldn’t identify RCTs evaluating other 
specific and balanced crystalloid solutions. Further research is needed.
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Introduction: Pseudocysts are a known complication of acute or chronic 
pancreatitis which can require intervention if symptomatic. The drainage 
can be achieved endoscopically, surgically or by Interventional Radiology. 
The endoscopic approach has been shown to be associated with less com-
plications than the other routes.
aims & Methods: We have analysed data from January 2016 to February 
2019 of patients that underwent Hot Axios stent insertion. The data were 
stored in the electronic endoscopic and patient’s record. We collected data 
on gender, age at stent insertion, patient’s background, symptoms that led 
to endoscopy, hospital stay length and outcome.
results: Total of patients that had Hot Axios inserted were 41. 
Mean age at diagnosis was 53 years. 17 (41%) were females and 24 (59%) 
were males. 44% patients presented with abdominal pain and vomiting 
and 22% had associated weight loss. 17% (n 7) had chronic pancreatitis 
and 5% (n 2) had underlying cancer. Length of hospital stay median of 7 
days (0-135). 20 patients had no complications (49%), 4 (10%) reported 
pain, 9 (22%) sepsis, 2 (5%) bleeding. Sepsis was controlled with repeat 
necrosectomies and antibiotics. 
All patients had resolution of symptoms necessitating cystgastrostomy.
In our cohort there were 2 deaths (5%) which were not related to the stent 
insertion.
conclusion: We described our experience over 3 years in a London teaching 
hospital which receives referrals from all over the region. Sepsis appears 
to be a relatively common complication of Hot Axios pancreatic pseudocyst 
drainage necessitating further endoscopic procedures. Accurate selection 
of patient may help to improve clinical outcome and decrease the compli-
cation rate.
disclosure: Nothing to disclose 
P1491 PerfOrMance Of faecaL eLasTase 1 TesT agaInsT 
The “gOLd sTandard” 3 day faecaL faT cOLLecTIOn TesT fOr 
The dIagnOsIs Of PancreaTIc exOcrIne InsuffIcIency (PeI) In 
PaTIenTs WITh chrOnIc PancreaTITIs: IT Is TIMe TO change TO 
cuT-Off vaLue!
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Introduction: Correct diagnosis of pancreatic exocrine insufficiency (PEI) is 
very important as pancreatic enzyme replacement therapy improves pa-
tient’s outcomes. Faecal elastase 1 test is increasingly use as the test of 
choice for establishing the diagnosis, with the cut-off value varies between 
>200 and >100mcg/g. With such cut-off values, although the prevalence 
of PEI in relative benign conditions such as irritable syndromes, diabetes 
mellitus and age has been reported up to 15%, a majority of these patients 
did not have pancreatic abnormality on further evaluation. These findings 
question the validity of the FE1 test and its cut-off values. Validating data of 
FE1 test against the gold-standard 3-day faecal fat test are lacking.
aims & Methods: To assess the performed of FE1 test against the gold 
standard 3-day faecal fat test for diagnosing PEI in patients with chronic 
pancreatitis. 
This was a multicenter study (NCT03481803) that evaluated the presence of 
PEI in patients with a known history as well as imaging changes of chronic 
pancreatitis. All patients underwent a screening test for PEI using the FE1 
test, which was defined as FE1 < 100mcg/g. Only patients who had FE1 
value of less than 100mcg/g underwent further testing with an in-patient 
3-day faecal fat test with standardized high fat meal. Both FE1 and 3-day 
faecal fat tests were evaluated in a centralized laboratory (Sonic, Aus-
tralia). The 3-day faecal fat test was further validated by another tertiary 
laboratory in France. Coefficient of Fat Absorption (CFA) is calculated and 
value of less than 50% indicates the presence of PEI. Descriptive statistics 
as well ROC analyses were performed.
results: Of a total 56 patients with clinical and imaging diagnosis of 
chronic pancreatitis, only 24 (43%) patients had FE1< 100mcg/g. Based on 
the 3-day faecal fat test, only 5 (21%) patient had PEI, with 11 patients had 
CFA≥80% and 8 patients had 80%>CFA≥50%. Even if PEI is defined as CFA 
of less than 75%, PEI is presence in only 9 (37.5%) patients. This would 
give a false positive PEI diagnostic rate by FE1 test of 79% and 64.5%, re-
spectively. Whilst all patients with CFA< 50% had FE1 of less than 20mcg/g, 
10/19 (53%) patients with CFA>50% had FE1< 50mcg/g. Using the ROC 
analyses, the cut-off value of 37.5mcg/g given the best sensitivity (65%) 
and specificity (100%).
conclusion: In patients with clinically proven chronic pancreatitis, only 
21% of patients with FE1 < 100mcg/g have PEI. Even if the PE1 cut-off value 
for PEI is lowered to 50mcg/g, the false positive rate is still 53%. Our study 
suggests that the cut-off value of FE1 to define PEI should be lowered, and 
a value of less than 37.5mcg/g gives the best diagnostic performance and 
negate the risk of false positivity.
disclosure: Nothing to disclose 
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P1492 Pancreas vOLuMe and fecaL eLasTase-1 as 
PrOgnOsTIc Marker fOr PancreaTIc exOcrIne InsuffIcIency 
fOLLOWIng PancreaTIc resecTIOn
Cho Y.W.1, Jung M.K.1, Heo J.2
1Department of Internal Medicine, Kyungpook National University School 
of Medicine, Gastroenterology, Daegu, Korea (Republic of), 2Kyungpook 
National University Hospital/Kyungpook National University, Department of 
Internal Medicine, Daegu, Korea (Republic of)
contact e-Mail address: minky1973@hanmail.net
Introduction: Pancreatic resection can lead to pancreatic exocrine insuf-
ficiency (PEI). Fecal elastase-1 (FE-1) test is an effective marker for assess-
ment of PEI in patients who underwent pancreatic resection. We measured 
pancreas volume, FE-1 level, and BMI of 36 patients who underwent pan-
creatic resection. The aims of this study ware (1) to assess the relevance 
between reduced pancreas volume and decreased FE-1 level, (2) to assess 
the effectiveness of FE-1 level as predictive marker on underweight caused 
by PEI in patients with pancreatic resection.
aims & Methods: 36 Patients who underwent pancreatic resection at 
Kyungpook national university hospital between April 2015 and December 
2018 were enrolled. Pancreas volume, FE-1 level and BMI were measured 
in all 36 patients after pancreatic resection. Patients were divided into 
three groups according to FE-1 level: “normal” (≥200 ㎍/g), “ intermediate 
decrease” (15-199 ㎍/g), “severe decrease” (< 15 ㎍/g). The association of 
pancreas volume, FE-1 level, and BMI was analyzed respectively.
results: Mean FE-1 level was 100.3 ㎍/g. 7 patients (19%) had normal pan-
creatic exocrine function and 29 patients (81%) had PEI in patients who 
underwent pancreatic resection. In PEI patients, 19 patients had “inter-
mediate decrease” FE-1 level and 10 patients had “severe decrease” FE-1 
level. 8 patients had underweight on BMI (BMI < 18.5). Reduction of pan-
creas volume was not significantly associated with decrease of FE-1 level 
and body weight loss as indicated by BMI (P= .14, P= .33, respectively). And 
also, FE-1 level was not significantly associated with BMI (P= .80). How-
ever, decreased FE-1 level has weak correlation with decrease of BMI (P= 
.16). Especially, “severe decrease’ of FE-1 level has the greater correlation 
with decrease of BMI (P= .15).
conclusion: Decrease of FE-1 level is a simple and useful predictive marker 
for PEI in patients who underwent pancreatic resection.
disclosure: Nothing to disclose 
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Introduction: Early diagnosis of chronic pancreatitis (CP) would be impor-
tant in order to stop the disease progression in time. Unfortunately, neither 
definitions nor biomarkers of early CP are available. It has been reported 
that recurrent acute pancreatitis (RAP) can lead to CP, therefore, the num-
ber of previous attacks or RAPassociated parameters may be suitable for 
characterizing early CP. The main aim of this study is to identify biomarkers 
which are significantly different in acute pancreatitis (AP), RAP, and CP. 
Another aim is to understand the modifying effect of the number of acute 
episodes which could be considered as early CP.
aims & Methods: The Hungarian Pancreatic Study group has built up a 
prospective register of subjects with AP. In the last six years, precise clini-
cal data were collected from 1435 patients. In this study, data on the num-
ber of episodes from 1315 patients with high data accuracy were analyzed.
results: In our cohort, 983 (74.75%), 270 (20.53%), 62 (4.72%) patients 
had a single episode of AP, RAP, and CP, respectively. In the RAP group, 173 
patients (64.07%) had 2 episodes, 43 (15.93%) had 3 episodes, 24 (8.89%) 
had 4 episodes, and 30 (11.11%) had 5 or more episodes. Thirteen bio-
markers were significantly different in the first attack of AP and CP. The 
significant difference between AP and CP disappeared after the second 
episode of AP concerning 8 biomarkers (gender, age, biliary etiology, al-
cohol consumption, pseudocyst development, gammaGT, amylase, and red 
blood cell count), as did after the third episode concerning 3 biomarkers 
(biliary etiology, body mass index, ASAT) as did after the fourth and fifth 
episodes concerning 2 biomarkers (ALAT and smoking). As an average, the 
significant differences between AP and CP disappeared from 2.63 attacks. 
The average number of acute episodes of patients with pre existing mor-
phological alterations of the pancreas (CP group) was 4.77.
conclusion: A definition of early CP may be 3 or more previous attacks of 
AP without chronic morphological alterations in the pancreas.
disclosure: Nothing to disclose 
P1494 PhenOTyPIc and genOTyPIc PrOfILes In chrOnIc 
PancreaTITIs assOcIaTed WITh cysTIc fIBrOsIs gene carrIer 
sTaTus
Ahmed A.Y.M.1,2, Mclaughlin J.2, Levison S.1,2, Makin A.3
1Manchester Foundation Trust, Gastroenterology, Manchester, United 
Kingdom, 2Manchester University, Manchester, United Kingdom, 3Manchester 
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Introduction: Pancreatic function has been used in the literature to as-
sess the severity of Cystic Fibrosis Transmembrane Conductance Regu-
lator (CFTR) gene mutations. The mutations are classified from I to VI; 
Class I produce no protein, in class II the protein fails to reach the apical 
membrane, and class III produce protein that fails to respond to cAMP. 
Classes I to III are called severe mutations and associated with pancreatic 
insufficiency. Class IV (reduced conductance) and class V (reduced protein 
synthesis or partially defective) are mild mutations and associated with 
pancreatic sufficiency.
aims & Methods: To examine the relationship between cystic fibrosis mu-
tations classifications and pancreatic function in a cohort of patients with 
chronic pancreatitis and CFTR gene mutations. We conducted a retrospec-
tive analysis of all the genetic and the pancreatic function data for all the 
patients in Manchester Royal infirmary Pancreatology Unit with Chronic 
pancreatitis and CFTR gene carrier status between 1999 to 2018.
results: Analysis of pancreatic function was carried out in 42 chronic pan-
creatitis patients with CFTR mutations. 36 were heterozygous and 6 com-
pound heterozygous. In the heterozygous cohort 30 genes were identified 
as severe mutations (22 F508. 2 G551 1. I148T/7T, 2 D1152H 1. TG115T5, 1. 
1679G, 1 R553X). The overall prevalence of PI is 50%. There was no statisti-
cal difference in this prevalence on further subdividing the genes to class I, 
II, and III. The majority presented as pancreatic sufficient (99%) and later 
on developed PI. The remaining 6 in the heterozygous group carried mild 
mutations (Arg117) class IV. PI prevalence was 66%, 33% were pancreatic 
insufficient at presentation. The prevalence of PI in the 6 compound het-
erozygous group was 66% (4), 3 were combination of severe and mild mu-
tations F508/Arg117 the other 3 combination of severe and severe mutation 
(D1151/F508del and F508/G511). Both groups had the same prevalence of 
PI.
conclusion: Pancreatic function does not correlate with the class or the 
severity type of the mutation in both the heterozygous and the compound 
heterozygous in CFTR patients. In this cohort of patients Presenting with 
pancreatitis most are pancreatic sufficient which implies additional factors 
might play a role in the development of pancreatic insufficiency.
disclosure: Nothing to disclose 
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P1495 eTIOLOgy and MOrPhOLOgy IMPacT cLInIcaL cOurse 
Of chrOnIc PancreaTITIs
Perkhofer L.1, Hann A.1, Seufferlein T.2, Wagner M.1, Kleger A.2, Müller M.3
1Ulm University, Internal Medicine I, Ulm, Germany, 2Universitätsklinikum 
Ulm, Klinik für Innere Medizin I, Ulm, Germany, 3Ulm University Hospital, 
Gastroenterology, Ulm, Germany
contact e-Mail address: martin.mueller42@gmx.de
Introduction: Symptoms caused by chronic pancreatitis (CP) are common 
but often elusive hampering therapeutic decisions. Though correlations of 
morphologic findings in imaging and clinical appearance remain vague. 
We aimed in investigating whether a distinct combination of clinical pa-
rameters can better define the extent of pancreatic insufficiency and dis-
ease burden.
aims & Methods: The aim of the study was to assess the impact of etiology 
and endosonographic morphology on the clinical course of chronic pan-
creatitis. Data from 350 CP patients were evaluated retrospectively from a 
single center data base following predefined criteria: 
(i) Confirmed CP, 
(ii) endoscopic ultrasound (EUS) plus 
(iii) fecal elastase-1 testing, 
(iv) age >18 years, 
(v) Cambridge Score >1 on EUS evaluation.
results: In total 182 patients (137 male, 45 female) fulfilled criteria. Me-
dian age was 52 years (range 19-88 years). Etiology distributed as follows: 
idiopathic 50%, alcohol 42.3%, autoimmune 7.7%. 56.6% of patients suf-
fered from chronic pain that was significantly associated with male sex and 
younger age. Stool elastase-1 activity discriminated exocrine pancreatic 
function in Cambridge IV significantly better than in lower stages. Simi-
larly, the endocrine function was significantly more reduced in Cambridge 
IV CP.
conclusion: A high disease burden is linked to extensive morphological al-
terations in EUS while pain is more frequent in younger and male patients. 
The etiology of CP is a predictor for the extent of exocrine impairment.
disclosure: Nothing to disclose 
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Introduction: Type 1 autoimmune pancreatitis (AIP) is one of the possible 
manifestation of IgG4 related disease (IgG4-RD). A score system to evalu-
ate the IgG4-RD activity (IgG4-RD
responder index - IgG4-RD RI) has been recently published. IgG4-RD RI 
can be used as an outcome measure both for clinical assessment and for 
the evaluation of drug response in clinical trials.
aims & Methods: Aim of the study was to establish the reliability of IgG4-
RD RI before and after steroid treatment compared to clinical remission 
and 1 year relapse. 
We retrospectively studied all patients observed in our center with a di-
agnosis of type 1 AIP based on International Consensus Diagnostic Criteria 
(ICDC) from January 2012 to December 2016. IgG4-RD RI was calculated at 
baseline (before steroid treatment - time 0), 1 month after the beginning 
of the treatment (time 1) and at the end of steroid therapy (time 2). We 
excluded patients who did not undergo MRI and serum IgG4 dosage at 
any time.
results: 33 patients (27 males, 6 females, mean age 60.2±17.2 years) were 
included. IgG4-RD.
RI was 8.9±4 at baseline, 2.5±3.4 at time 1 (p< 0.0001 vs. time 0), and 
4.5±3.9 at time 2 (p=0.029 vs. time 1). IgG4-RD RI was higher at time 0 
in 14 patients who relapsed within 1 year (10.9) vs. 19 who did not (7.4) 
(p=0.009). This difference was not observed at time 1 (3.1 vs. 2.1; p=ns), 
but it was again documented at time 2 (7.1 vs. 2.5; p=0.002). Serum IgG4 
levels were similar at any time in patients who relapsed and in those who 
did not.
conclusion: IgG4-RD RI is a useful tool for the management of patients suf-
fering from IgG4-RD, especially for the early detection of disease relapse 
within 1 year. Its levels seem to correlate with disease activity, whereas 
serum IgG4 levels are not associated neither with disease activity nor with 
the risk of disease relapse. Prospective studies with larger cohorts of pa-
tients are needed to confirm our data.
disclosure: Nothing to disclose 
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Introduction: The timing and frequency of Branch Duct Pancreatic Intra-
ductal Mucinous Neoplasms (BD-IPMN) malignant progression is un-
known. Knowledge of predictive features of advanced histology is funda-
mental in BD-IPMN management (as an indication for resection surgery). 
In addition to the American Gastroenterological Association (AGA) guide-
lines, it was recently published the Fukuoka (2017) and the European Study 
Group on Cystic Tumors of the Pancreas (ESGCTP, 2018) recommendations.
aims & Methods: We aimed to compare the diagnostic yield between AGA, 
Fukuoka and European recommendations in the prediction of advanced 
histology features in patients with BD-IPMN.
For this, we performed a retrospective analysis of the surgical referral cri-
teria according to the previous mentioned guidelines in the cases of BD-
IPMN submitted to surgical resection in a tertiary center between 2010-
2018. Advanced Histology was defined by the presence of either high grade 
dysplasia or adenocarcinoma in the surgical specimen.
results: We reviewed 54 cases (mean age 63.9 ± 14.6 years, 67% were fe-
male). Two-thirds of the lesions were diagnosed incidentally, with a mean 
diameter of 32.3 ± 15.8 mm. After surgical resection, 17 lesions (31.5%) met 
criteria for advanced histology. 
The Fukuoka and AGA guidelines presented a similar probability ratio for 
the presence of advanced histology features (Fukuoka: OR 26.81, p < 0.01; 
AGA: OR 29.87, p < 0.01). 
The presence of a relative or an absolute criteria of the European guide-
lines presented the highest sensitivity for the diagnosis of advanced histol-
ogy between the three guidelines (Fukuoka 76.5%, AGA 82.4%, ESGCTP 
100%), with the lowest positive predictive value (PPV) (Fukuoka 76.5%, 
AGA 74.7%, ESGCTP 50%). 
When considering only the presence of an absolute criteria for surgical 
resection, European guidelines had greater specificity, PPV and odds ratio 
(sensitivity 52.9%, specificity 97.3%, PPV 90%, OR 40.5, p < 0.01). However, 
it also had the higher number of “false negatives” results (Fukuoka n = 4, 
AGA n = 3, ESGCTP n = 8). 
All cases with European absolute criteria also presented with AGA and 
Fukuoka criteria for surgical resection.
conclusion: The new European criteria presented the highest specificity 
for the presence of advanced histology features in the surgical specimen. 
The combination of the European guidelines criteria with Fukuoka or AGA 
criteria allowed the optimization in sensitivity/PPV of the European guide-
lines absolute criteria.
disclosure: Nothing to disclose 
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P1498 cOLOnOscOPy fIndIngs In IPMn PaTIenTs
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Introduction: Intraductal papillary mucinous neoplasms (IPMNs) of the 
pancreas are being increasingly detected on an incidental basis given the 
widespread use and availability of cross-sectional imaging. Given the in-
creased risk of metachronous development of pancreatic cancer, the rec-
ommendations for follow-up pancreatic imaging are becoming clearer. 
However, the association between IPMNs and colorectal polyps and ad-
enocarcinoma is not as clear, resulting in an uncertain recommendation 
for endoscopic examination.
aims & Methods: This retrospective study aims to establish the prevalence 
of endoscopic findings such as polyps and colorectal adenocarcinomas on 
colonoscopy in IPMN patients. The indications for colonoscopy included 
screening in asymptomatic individuals and investigation of non-specific 
abdominal pain. This study also aims to determine whether IPMN char-
acteristics differ according to colonoscopy findings. All IPMNs incidentally 
identified on cross-sectional imaging between 2007 and 2017 in a single-
centre in Malta were included. For those patients who underwent a colo-
noscopy, endoscopic and histology findings were noted. The respective 
IPMN classification (branch-duct: BD or main-duct: MD), size and location 
were recorded.
results: A total of 355 patients with an IPMN were enrolled, 72 of which 
underwent a colonoscopy. Adenomatous polyps found in 50% (n=36) of 
colonoscopies, the majority of which had low-grade dysplasia: 11% had 
either moderate or high-grade dysplasia. Benign hyperplastic polyps were 
present in 14% (n=10), while colorectal adenocarcinoma was present in 
15% (n=11). Colonoscopy was normal in 21% (n=15). 
  colonoscopy finding
  adenomatous Polyps
hyperplastic 
Polyps
colorectal 
adenocarcinoma
normal 
colonoscopy
frequency 
of finding on 
colonoscopy (%)
50 (n=16) 14 (n=10) 15 (n=11) 21 (n=15)
average age 
(min-max) 70; (58-85) 66; (55-80) 69; (49-84) 67; (54-86)
Male:female ratio 1.4:1 1.5:1 1.2:1 1:2
IPMn 
classification
86% BD-IPMNs; 
8% MD-IPMNs; 
6% Mixed-
IPMNs
100% 
BD-IPMNs
100% 
BD-IPMNs
100% 
BD-IPMNs
average IPMn 
size (mm); 
(min-max)
16; (5-46) 12; (5-21) 18; (7-50) 12; (5-23)
IPMn location - 
head & neck of 
pancreas (%)
50 (n=18) 60 (n=6) 64 (n=7) 73 (n=11)
IPMn location - 
body of pancreas 
(%)
31 (n=11) 0 (n=0) 27 (n=3) 0 (n=0)
IPMn location - 
tail of pancreas 19 (n=7) 40 (n=4) 9 (n=1) 27 (n=4)
[IPMN Characteristics According to Colonoscopy Finding]
All IPMN patients with a colonoscopy revealing colorectal adenocarcinoma 
underwent follow-up imaging (staging and monitoring response to treat-
ment). No change in IPMN size was noted over an average follow-up pe-
riod of 22 months. 46% (n=5) of adenocarcinomas were located in the 
caecum and ascending colon, 9% (n=1) in the transverse colon, 18% (n=2) 
in the descending and sigmoid colon, whilst 27% (n=3) were present in 
the rectum.
conclusion: The diagnostic yield of a colonoscopy for an adenomatous pol-
yp or adenocarcinoma in a patient with IPMN is around 65% in our cohort 
of patients. The IPMNs in these patients tend to be of a larger size when 
compared to those with a normal colonoscopy or benign hyperplastic pol-
yp. Female IPMN patients are twice as likely to have a normal colonoscopy 
when compared to males. The location of the IPMN itself does not vary 
significantly between the different groups. These findings are derived from 
a retrospective study and hence are subject to bias, however, given the fact 
that both colorectal adenocarcinomas and IPMNs are epithelial neoplasms 
within the gastrointestinal tract, a possible association between the two 
entities remains to be investigated further with prospective studies. At 
present, recommendations for colonoscopy remain based on conventional 
practice in gastroenterology.
disclosure: Nothing to disclose 
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Introduction: Pancreatic cystic lesions (PCLs) are frequent findings fre-
quently require repeated imaging surveillance. Endoscopic ultrasound 
with fine-needle aspiration (EUS-FNA) for CEA and cytology in pancreatic 
cystic fluid (PCF) is an accurate diagnostic method. Current guidelines rec-
ommend EUS-FNA in PCLs with at least one of these worrisome features 
(size≥3 cm, mural nodule< 5mm, main duct dilation 5-10mm). The value of 
pancreatic cystic fluid (PCF) analysis in small PCLs is not clear.
aims & Methods: To evaluate if patients with PCLs < 3cm, submited to EUS-
FNA for cystic fluid analysis with CEA, amylase and cytology, had adequate 
cyst classification and an alteration in clinical decision.
Methods: Retrospective analysis of a EUS database including 167 patients 
with PCLs < 3 cm evaluated by EUS from 2007-16, of which 115 had ad-
ditional FNA performed for PCF analysis. Clinical, imaging, PCF features 
(cytology, CEA level, amylase), and clinical decision were prospectively 
registered. We defined two groups of lesions, Group A (without mural 
nodule/mass) and Group B (with mural nodule/mass).
results: In 115 patients, 65% were females, with a mean age of 63 ± 12 
years old (33-86), and a mean follow-up time of 37±30months (6-134). Cyst 
location in: head/body/tail/multiple: 45/42/23/5. Mean cyst size=19±6mm, 
with percentage of cysts by size (mm): < 10/10-20/>20 in 8,7%/48,7%/42,6. 
Mass/mural nodule present in 27% (31/115) of PCLs. PCF analysis, with 
CEA level < 5/5-192/>192 in 18,2%/42,4%/39,4%, amylase< 250 in 40%, 
and with cytology acellular/benign or inflammatory/LGD/malignant or 
atypical or NET, in 65%/17%/3%/15% of PCLs. Strategy before EUS-FNA: 
Imaging surveillance/surgery/other: 71%/18%/11%. Strategy after EUS-
FNA: Stop imaging surveillance/imaging surveillance/surgery/other: 
6%/66%/17%/11%. A total of 19 patients, were referred for surgery, includ-
ing 10 in Group A and 9 in Group B. Surgical pathology diagnosis (Group 
A + Group B): PDAC (0+1), IPMN-ADC (1+1) + NETs (2+0), IPMN (3+3), MCN 
(1+1), SCA (2+2), lymphangioma (1+0), pseudocyst (0+1), what corresponds 
to 3 vs 2 malignant, 4 vs 4 pre-malignant cysts, and 3 vs 2 benign cysts 
in Groups A and B, respectively. CEA was < 5 ng/mL in 20% and 14% of 
patients in Groups A and B, respectively. Comparing the group of patients 
referred for surgery with other patients, there was a statistically significant 
difference with a positive cytology and presence of a mural nodule or mass 
in the surgery group, but no significant differences in age, cyst size, and 
presence of septations or CEA level between groups. In Group A, older age 
and malignant/suspicious cytology but not size, CEA or amylase level in 
PCLs were related with a malignant final diagnosis and in Group B only 
a positive cytology correlated with a malignant final diagnosis. In Groups 
A and B, 29% and 22% of PCLs referred for surgery were malignant, cor-
responding to 3/84 (3.6%) in group A and 2/31(6.5%) in Group B.
conclusion: EUS-FNA in small PCLs (< 3cm) allows cytological confirmation 
of malignancy prior to surgery, even in pancreatic cysts without worrisome 
features (mural nodule or mass) and it should not be delayed in small 
cysts because 26% of surgical specimens were malignant lesions. On the 
other hand, low CEA (< 5ng/mL) occurred in about 1 in every 5 patients, 
with a possible opportunity to stop surveillance, particularly in PCLs with-
out mural nodules, but in clinical practice surveillance stopped for 6% of 
patients only.
disclosure: Nothing to disclose 
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P1500 PancreaTIc cysTs: dOes eus-fna adds vaLue Over 
eus MOrPhOLOgy and MrI? exPerIence Of a TerTIary-care 
acadeMIc MedIcaL cenTer
Oria I., Pizzala J., Rivera Flores J., Villaverde A., Pasqua A., Abecia V., 
Marcolongo M.
Hospital Italiano de Buenos Aires, Gastroenterology, Buenos Aires, Argentina
contact e-Mail address: ines.oria@hospitalitaliano.org.ar
Introduction: Endoscopic ultrasound (EUS) and magnetic resonance imag-
ing (MRI) are valuable tools in the assessment of cystic pancreatic lesions 
(CPLs). However, achieving a preoperative diagnosis of CPLs still remains a 
challenge. EUS-guided fine needle aspiration (FNA) provides a method to 
obtain cyst fluid for analysis to gain additional information.
aims & Methods: The aim of our study was to compare the concordance 
between the diagnosis of the cyst by FNA, with that obtained by two diag-
nostic imaging methods (EUS morphology and MRI). In addition, evaluate 
if EUS-FNA offered any benefit in cases of inconclusive MRI.
We performed a retrospective analysis of a prospectively collected data-
base at a tertiary-care academic medical center between January 2015 and 
December 2018. All patients who were referred for EUS were reviewed, 
and patients with diagnosis of pancreatic cysts were included. Imaging, 
pancreatic cyst fluid (PCF) and follow-up were analyzed. Cysts were classi-
fied as mucinous or non-mucinous based on any of the following param-
eters: 1) PCF was grossly mucinous on examination (string sign positive) 2) 
positive citology 3) CEA level was >192 ng/mL.
results: A total of 2238 EUS were performed during the study period and 
319 of them had a final diagnosis of pancreatic cysts (70% women, mean 
age 64.46 +/- 13.35 SD). The most frequent indication was surveillance of 
already known lesions (56%) and inconclusive findings in previous images 
(32%). The most frequent cystic lesions were IPMN 2 and serous cystic 
neoplasms (50% and 17% by EUS and 53% and 17% by MRI). FNA was per-
formed on 139 cysts (37%), according to the presence of suspicious signs of 
malignancy, or at the request of the attending physician. From 139 FNAs, 
62 were diagnosed as mucinous by PCF . The agreement between the di-
agnosis of the cyst by FNA, with that obtained by EUS morphology was 
89.2% (Kappa 0.78, P < 0.001). The concordance between the diagnosis 
of the cyst by FNA and that obtained by MRI was 72.66 (Kappa 0.41. P < 
0.001). In the correlation with the images, of the 62 patients with mucinous 
cysts, 55 had a diagnosis of mucinous by EUS morphology (88% CI 95% 
78.1-95.3), while only 27 had mucinous diagnosis by CRMN (43.5% CI 95% 
31-56.7).
From the 319 patients with pancreatic cysts 60 (18.8%) had inconclusive 
results on MRI and EUS morphology was able to make a diagnosis in 31 of 
them. When we analysed the 139 punctured cysts, MRI was indeterminate 
in 40 patients and FNA diagnosed 36 of the 40 patients (90%): 13 muci-
nous, 18 serous, 4 cystic neuroendocrine tumors (NET) 1 pseudocyst.
conclusion: In our study, EUS with or without FNA was superior to MRI 
specially in cases of inconclusive MRI.
disclosure: Nothing to disclose 
P1501 WIThdraWn
P1502 asPIrIn Is assOcIaTed WITh Increased rIsk Of cancer 
reLaTed deaTh afTer surgery fOr InTraPaPILLary MucInOus 
TuMOrs Of The Pancreas: a Large sIngLe cenTer cOhOrT 
sTudy
Valente R.1, Ateeb Z.2, Capurso G.3, Scandavini C.M.4, Vespasiano F.4, 
Anzillotti G.4, Löhr M.5, Arnelo U.6, Del Chiaro M.7
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Hospital, Milan, Italy, 4Karolinska University Hospital, Stokholm, Sweden, 
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Introduction: Intraductal papillary mucinous neoplasms (IPMNs) are in-
creasingly considered “the polyps of the pancreas”, possibly harboring 
several degrees of cellular atypia up to invasive cancer. If high-grade dys-
plasia/cancer is suspected, the patient should be considered for surgical 
resection. No diagnostic tool can preoperatively predict the degree of dys-
plasia and, on the contrary of other cancer types, no chemoprevention is 
available to slow progression and cancer related death. Aspirin (ASA), Ace 
Inhibitors/Sartans (ACEI/ARB) and Statins (STAT) are widely used in the 
setting of primary and secondary cardiovascular prevention. Such drugs 
seem to play a role in modulating incidence and prognosis of different type 
of tumors such as colon cancer. Such drugs have been suggested to pos-
sibly influence also pancreas cancer incidence and prognosis by inhibiting 
respectively COX 1-2, VEGFR and MAPK cascades. No study has previously 
evaluated their effect on operated IPMNs.
aims & Methods: to evaluate the effect of ASA, ACEI/ARB and STAT on 
cancer related death in a cohort of operated IPMNs patients.
results: single-center retrospective cohort study on prospectively collected 
patients operated for pancreatic IPMN. Known risk factors for PDAC and 
exposure to the target drugs were retrospectively collected. Chi-square, 
t-test, univariate and multivariate logistic and cox hazard regression analy-
sis were applied when needed. 
Results, among 274 operated IPMNs patients, 210 were included in the 
final analysis, 47.61% males. ASA, ACEI/ARB and STAT were used respec-
tively in 29.18%, 51.90% and 36.84% of cases. At univariable cox hazard 
regression analysis ASA users displayed a borderline significantly higher 
risk of cancer related death HR 2.11 (0.90-4.94, 95% CI, p=0.08) while STAT 
and exclusive ACEI/ARB users did not (respectively HR= 0.77, 95% CI 0.32-
1.89, p=0.58 and HR= 1.18, 95% CI 0.49-2.82, p=0.69). At multivariable cox 
hazard regression analysis adjusted for sex, age, clinical factors associated 
with both pancreas cancer and cardiovascular risk (such as smoking, dia-
betes, first degree family history, overweight/obesity and elevated Ca19.9) 
ASA users were confirmed to be associated with increased risk of cancer 
related death (HR=2.70, 95% CI 1.10-6.59, p=0.02).
conclusion: The use of ASA but not STAT and ACEI/ARB is associated to 
cancer related death after surgical resection for pancreatic IPMNs. Further 
studies are needed to investigate if this association is the result of an un-
derling pathophysiologic mechanism or the result to a common and yet 
unknown risk factors exposure.
disclosure: Nothing to disclose 
P1503 vOn hIPPeL-LIndau (vhL) syndrOMe - PresenTaTIOn 
and PancreaTIc fIndIngs Of Our case serIes
Duman D.G., Keklikkıran Ç., Kani H.T., Demirtaş C.&.
Marmara University School of Medicine, Gastroenterology, Istanbul, Turkey
contact e-Mail address: drdenizduman@yahoo.com
Introduction: Von Hippel-Lindau (VHL) disease is a rare autosomal domi-
nantly inherited familial syndrome with an incidence of 2-3 cases per 
100,000 population. This disease is associated with a high morbidity and 
mortality involving different organs and have varying phenotypes from 
family to family. Central nervous system, retina, kidneys and pancreas are 
the main organs affected by the disease. Pancreatic lesions may range 
from benign cystic lesions to malignant solid neoplasms. The discovery 
of any of the syndrome components should raise suspicion of this disease 
and other organ involvements should be investigated. 
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We present seven cases of Von Hippel Lindau syndrome evaluated in our 
pancreas clinic.
aims & Methods: We present seven cases of VHL disease who were ad-
mitted to our pancreas clinic between 2008 and 2018. Three of the seven 
patients referred to us by neurosurgery department following the cranial 
hemangioblastoma diagnosis. Three patients already had a family history 
of VHL disease in their first or second degree relatives. One patient was 
referred to us due to the pancreatic cystic lesions incidentally diagnosed 
with transabdominal ultrasound and endoscopic ultrasound (EUS) showed 
multiple cysts in pancreas varying in size.
results: In our case series, all the patients were female and they were 
evaluated using a linear array EUS prob. Most common pancreatic mani-
festation was multiple cysts with clear fluid content without any solid 
component or debris or calcification in 6/7 patients. Cysts were scattered 
almost all parts of the organ. Their highest diameters range from 21 to 51 
mm. One patient had side branch intraductal papillary mucinous neoplasm 
(IPMN) with solid components. None of the cases had any pancreas related 
mortality throughout our follow up period that range from 6 months to 10 
years. Their age on application to our pancreas clinic range from 28 to 61 
years. One patient had a history of recurrent acute pancreatitis while the 
rest of them were asymptomatic regarding pancreatic disease. 3/7 patients 
had accompanying renal cysts.
conclusion: The hemangioblastomas of the CNS are the most frequent le-
sions in VHL disease seen in 60 - 84% of the cases while it was diagnosed 
in 42% of patients in our series. The average age of diagnosis is 29 years, 
mostly presented as single tumor (58%). Multiple tumors are always asso-
ciated with the VHL syndrome. Pancreatic cysts are the most common form 
of presentation in the VHL syndrome. Pancreatitis and pancreatic insuffi-
ciency are rare complications. In our series only 1 patient was symptomatic 
with recurrent pancreatitis history. The identification of the VHL is impor-
tant as the syndrome cause high risk of complications that can be avoided 
with a proper diagnosis and early treatment. Early recognition of unaffect-
ed family members of patients via genetic testing has contributed to the 
improved prognosis of these patients. Nevertheless, our results showed 
that cysts constitute main pancreatic finding and they live uneventful with 
regard to their pancreatic lesion. One side branch IPMN case in our study 
represent an unusual pancreatic manifestation of VHL disease. Therefore, 
it is wise to avoid unnecessary cyst sampling or drainage attempts in VHL 
disease patients as those interventions may pose risk of infection, hemor-
rhage etc. to the patient unless the suspicion of malignancy is positive.
disclosure: Nothing to disclose 
P1504 IMPacT Of POsT-OPeraTIve InfecTIOus cOMPLIcaTIOn 
On heMaTOgenOus LIver MeTasTasIs afTer curaTIve 
resecTIOn fOr gasTrO-InTesTInaL cancers: esPecIaLLy 
In TerMs Of Pre-MeTasTaTIc nIche fOrMaTIOn ThrOugh 
IMMune-ThrOMBOsIs In The LIver
Ohta T.
Kanazawa University Hospital, Department of Gastroenterological Surgery, 
Kanazawa, Japan
contact e-Mail address: ohtat@staff.kanazawa-u.ac.jp
Introduction: Post-operative infectious complications including anasto-
motic leakage are well known to increase hematogenous liver metastasis 
and long-term mortality after curative resection for gastro-intestinal can-
cers. Many strong innate immune cells including Kupffer, NK, NKT, and 
γδT cells can exist in the liver and eliminate circulating tumor cells (CTC). 
However, liver metastasis often occurs in such a situation and not much is 
known about the mechanism of immune escape of cancer cells.
aims & Methods: We investigated the crucial mechanism of immune es-
cape of cancer cells in the liver. First, in vitro experiment, we co-cultured 
human pancreatic cancer cell line, BxPC-3 (CD44v and epithelial pheno-
type) or BxPC3 treated with 10 nM TGF-β (CD44s and mesenchymal phe-
notype) with activated platelets from both human and mouse, in order to 
clarify the molecular mechanisms of interactive cell to cell adhesion man-
ner between cancer cells and activated platelets, because it is well known 
that activated platelets can express p-selectin on the cell surface and can 
adhere to CD44s, a ligand of p-selectin. 
Next, in vivo experiment using immuno-competent mice (n=10), we ex-
amined whether LPS (1 mg/kg)-mediated intraperitoneal infection could 
induce neutrophil extracellular trap (NETs) in the liver sinusoid and form 
the immuno-thrombosis cooperatively with activated platelets. In addition, 
24hrs after intraperitoneal injection of LPS (1 mg/kg) in immune-compe-
tent mice (n=20), BxPC3 xenografts (n=10) or BxPC3 treated with 10 nM 
TGF-β (n=10) were transplanted intrasplenically. 
Then, each mouse was sacrificed at each time point of 10 min and 90 
min after transplantation of xenografts and subjected to the pathological 
examinations.
results: In vitro experiment, numerous activated platelets from both hu-
man and mouse could be adherent to BxPC3 treated with TGF-β, but not 
much adherent to parental cell line BxPC-3. In vivo experiment using 
immune-competent mice, the heterogeneous NETs formation in the liver 
sinusoid was found in LPS group (n=5), although the liver was not the 
organ of surgical site infection. Numerous activated platelets were also 
present around NETs. However, in saline group (n=5), NETs were not found 
in the liver. In addition, in mouse model of transplanting parental cell line 
BxPC-3 xenografts intrasplenically (n=10), these xenografts were entirely 
eliminated by the innate immune surveillance at the time point of 90 min 
after transplantation, although xenograft cancer cells were present in the 
liver at the time point of 10 min after transplantation. In contrast, some 
clusters of BxPC-3 treated with 10 nM TGF-β were surprisingly found to be 
vigorous in the liver at the time point of 90 min after transplantation and 
these xenografts were surrounded by numerous activated platelets even in 
immune-competent mice (n=5).
conclusion: We demonstrated that intraperitoneal injection of LPS could 
induce NETs in the liver sinusoid and form the immuno-thrombosis coop-
eratively with activated platelets, resulting in the formation of pre-meta-
static niche in the liver through a lot of alarmin which were well known 
to be released from NETs and activated platelets, and have a function to 
recruit myeloid derived suppressor cells (MDSC) from the bone marrow. In 
addition to such a pre-metastatic niche formation as the “soil”, the induc-
tion of epithelial mesenchymal transition (EMT) of cancer cells was con-
sidered to be necessary as the “seed” in order to preferably adhere to the 
activated platelets and escape the innate immune surveillance of the liver 
as a first step of hematogenous liver metastasis.
disclosure: Nothing to disclose 
P1505 decIPherIng The rOLe Of rInT-1 In reguLaTIng 
PancreaTIc ducTaL adenOcarcInOMa (Pdac) hOMeOsTasIs
Arnold F.1, Frappart P.2, Seufferlein T.2, Kleger A.2
1University Ulm, Internal Medicine I, Ulm, Germany, 2Universitätsklinikum 
Ulm, Internal Medicine 1, Ulm, Germany
contact e-Mail address: frank.arnold@uni-ulm.de
Introduction: RINT-1 (RAD50-interacting protein 1) is a multifunctional 
protein playing a role in cell cycle regulation, genomic stability, telomere 
maintenance, ER-Golgi trafficking and autophagy. Beside facilitating cel-
lular homeostasis, rare missense mutation found in RINT-1 and overex-
pression of RINT-1 were associated to increase the risk of development 
of different kind of tumors including breast cancer, colorectal cancer, and 
Lynch-syndrome type cancers.
aims & Methods: To characterize more in details the mechanisms of RINT-1 
regulation and to ultimately identify RINT1-dependent pathways that could 
be targeted in PDAC, an extensive interaction study through yeast-two hy-
brid assay and mass spectrometry was preliminary performed.
results: We discovered hundreds of new RINT1-interaction partners in-
cluding E3 ligases interacting with RINT-1 allowing a better understand-
ing of RINT-1 biological function. In addition, we identify several post-
translational modifications including ubiquitination and sumoylation and 
demonstrated that ubiquitination is a key regulator of RINT-1 stability and 
biological function. 
Hereby, we show that RINT-1-depletion in PDAC cell lines leads to severe 
growth defects in vitro and in vivo associated with massive Golgi frag-
mentation and G2 cell cycle arrest followed by ER-stress and autophagy. 
Complete collapse of cellular homeostasis finally results in activation of 
apoptosis. In addition, subcutaneous xenografts showed strong infiltration 
of B220+ immune cells in RINT- 1-deficient tumors.
conclusion: These data suggest that RINT-1 homeostasis is essential for 
PDAC survival and represents therefore a putative therapeutic target. Al-
together, these data reveal the key role of RINT-1 in PDAC homeostasis.
disclosure: Nothing to disclose 
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P1506 desIgner PancreaTIc cancer generaTed frOM huMan 
PLurIPOTenT sTeM ceLL derIved ducTs
Breunig M.1, Merkle J.2, Seufferlein T.3, Hohwieler M.1, Kleger A.4
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Introduction: Cell bioengineering approaches not only hold great promise 
to replace and regenerate dysfunctional tissue for improved life quality 
of the diseased patient but may also provide more sophisticated disease 
models. Engineering approaches to build human pancreatic tissue resem-
bling acinar, ductal and endocrine tissue have been hampered by the com-
plexity of the pancreas. Human pluripotent stem cells (PSCs) may provide 
the appropriate bioengineering platform for developmental and biomedi-
cal studies due to their capability to differentiate into every cell type in the 
human body. 
However, PSCs typically yield heterogeneous population, while certain 
disease models require homogenous populations. Our initial protocol 
was powered to generate virtually pure cultures of human pancreatic 
progenitor cells followed by spontaneous differentiation in a 3D-culture 
environment to allow acinar ductal commitment (Hohwieler, GUT, 2017). 
Here, we have implemented signals controlling embryonic lineage fate 
bifurcations to efficiently yield the desired cell types through exclusion of 
alternate fates.
aims & Methods: Here, we have implemented signals controlling em-
bryonic lineage fate bifurcations to efficiently yield the desired cell types 
through exclusion of alternate fates: Specifically, we applied signaling 
molecules and growth factors inducing ductal cells, while inhibiting the 
respective counter lineage with inhibitors. Afterwards, we genome edited 
human PSCs to specifically design the core machinery of the pancreatic 
cancer genome. Orthotopic transplantation was additionally incorporated 
into the experimental work flow.
results: This approach yields virtually pure pancreatic duct-like cells gen-
erated from human PSCs resembling key features of adult human pancre-
atic ducts: A robust test battery including functional Carbanhydrase and 
CFTR activity and homogenous ductal marker expression underpinned 
ductal identity. Transcriptional profiles of engineered ducts match the 
one of human mature ducts. In line orthotopic transplantation reveals 
human untransformed ducts in the murine host. Pluripotent stem cells 
armed with oncogenic KRAS were similarly differentiated to the ductal 
lineage followed by oncogene activation in vitro and in vivo. Here, mutant 
KRAS alters ductal organoid polarity as early sign of dysplastic growth 
in vitro, followed by the generation of moderately differentiated human 
PDAC in vivo.
conclusion: Summarized, this novel and unique differentiation platform 
generates human untransformed ducts allowing modelling of plasticity, 
dysplasia and cancer formation in a human and genetically defined back-
ground in the pancreas. Thereby, we also show that human ducts are in-
deed permissive to generate human PDAC. Tailored genome editing strat-
egies mimicking the mutational make-up of human PDAC will open novel 
opportunities to provide a unique and valuable human PDAC model.
disclosure: Nothing to disclose 
P1507 The rOLe Of MMP9 and hIf1 exPressIOn In 
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1University of Parma, Department of Medicine and Surgery, Parma, Italy, 
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Introduction: Pancreatic ductal adenocarcinoma (PDAC) has high invasive-
ness, tendency to locally infiltrate and to show nodal and distant metas-
tasis.
MMPs’ overexpression is frequently associated with high invasiveness re-
lated to ECM degradation. Also HIF1 overexpression, caused by hypoxia 
adaption, is involved in malignant behavior.
aims & Methods: Aim of this study is to explore the relationship between 
MMP9 and/or HIF1 expression and grading, nodal metastasis, perineural 
and angiolymphatic invasiveness.
Based on records from Parma’s Department of Pathology, a database was 
created collecting a series of 73 surgical samples of PDAC, from 2007 to 
2017. On these samples an histological evaluation was performed consid-
ering grading, nodal metastasis and perineural and angiolymphatic inva-
siveness. In addition, to investigate MMP9 and HIF1α histological expres-
sion, an immunohistochemical evaluation was carried out. The positivity 
was evaluated as Tumor-Infiltrating Lymphocytes (TIL) considering three 
grades observing the number of cells/high power field (TIL1< 30/HPF 40x; 
TIL2=30-60/HPF 40x; TIL3>60/HPF 40x).
results: In the assessment of MMP9, TIL1 was 38 (52.1%), TIL2 19 (26%) 
and TIL3 16 (21.9%).
Sorting by tumor grading, 13 out of 16 (81,25%) TIL3 were G3 and all G1 
samples were TIL1 (p=0.03). Perineural infiltration was shown in 55,2% of 
TIL1, 73,6% of TIL2 and 81,25% of TIL3; angiolymphatic invasiveness was 
shown in 26,3% of TIL1, 57,8% of TIL2 and 62,5% of TIL3 (p=0.014). Nodal 
metastasis were detected in 36.8% of TIL1, 57.9% of TIL2 and 68.7% of TIL3 
(p=0.06).
In the achievement of HIF1α, TIL1 was 29 (39.7%), TIL2 21 (28.7%) and TIL3 
23 (31.5%).
Sorting by tumor grading, there were no statistical significance because all 
the gradings were equally distributed. Perineural infiltration was shown 
in 27.5% of TIL1, 52.3% of TIL2 and 52.1% of TIL3; angiolymphatic inva-
siveness was shown in 48.2% of TIL1, 71.4% of TIL2 and 82.6% of TIL3 
(p=0.01). Nodal metastasis was in 31% of TIL1, 52.3% of TIL2 and 69.5% 
of TIL3 (p=0.03).
Moreover, the more MMP9 and HIF1 positivity increase, the more malig-
nant pattern such as perineural and angiolymphatic infiltration and nodal 
metastasis can be detected.
conclusion: The results show that TIL evaluated both with MMP9 and HIF1 
could exert a relevant role in neoplastic invasiveness phenotype, in partic-
ular considering perineural and angiolymphatic infiltration and tendency 
to nodal metastasis. Finally, MMP9 and HIF1 both expressed could charac-
terize a more malignant phenotype.
disclosure: Nothing to disclose 
P1508 angIOgenesIs assessMenT Of PancreaTIc 
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Pathology, Craiova, Romania, 3University of Medicine and Pharmacy of 
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Introduction: Pancreatic cancer (PC) represents one of the major therapeu-
tic challenges because most of the patients are diagnosed in an advanced 
stage, when available therapies barely influence the overall survival rate. 
In PC the vascularization is characterized by a high microvascular density 
and poor perfused vessels with heterogenenous distribution. Confocal la-
ser endomicroscopy (CLE), with various miniprobes available is accessible 
tool for different lesions providing a live diagnosis.
aims & Methods: Angiogenesis assessment in pancreatic adenocarcinoma 
(PDAC) by fluorescently labelled antibodies with confocal laser endomi-
croscopy on fresh harvested samples immediately after surgery.
Materials and method: Ten consecutive patients diagnosed with PDAC fol-
lowing fine needle aspiration - endoscopic ultrasound underwent cura-
tive therapy with tumor resection. Fresh specimens from both normal and 
tumor tissue were washed in saline solution and incubated for one hour 
in the dark at 37 °C, with Alexa-Fluor 488 anti-CD105/Endoglin antibody 
(mouse anti-human IgG2a, Exbio Prague, Czech Republic). And CLE imag-
ing was performed to assess the microvascularazation in an ex vivo setting 
by direct contact with the specimen. We all tested mesothelin as a poten-
tial marker to differentiate between normal and tumor pancreatic tissue. 
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All aquired images were assessed with a dedicated processing software 
to obtain a Z projection of confocal serial stacks. Next we measured the 
vascular density and vessel diameters within 50 µm × 475 µm rectangular 
regions previosuly chosen. We also compared the results with clasic im-
munohistochemistry technique.
results: CD105 expression on CLE was present within PDAC samples with 
a microvascular density of 13.56 ± 6.88 compared to normal pancreatic 
tissue 1.1 ± 0.857 (p< 0.001). Mesothelin was clearly proved to be pres-
ent in every PDAC samples suggesting a potential direct target for future 
oncologic therapies.
conclusion: This pilot study proves that CLE targeted CD105 for tumoral 
vascular network might represents a potential tool for future studies re-
garding PDAC neoangiogenesis and future therapies.
disclosure: Nothing to disclose 
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Introduction: Obestatin is a 23-aminoacid peptide derived from pre-
proghrelin, was first isolated from stomach in 2005 and binds to the GPR39 
receptor. Our group has described obestatin/GPR39 expression in human 
healthy pancreas, as well as in pancreatic adenocarcinomas. These studies 
support the hypothesis that this endogenous system plays a regulatory 
role in the physiology of the exocrine pancreas and in the mechanism of 
the pancreatic regeneration. In addition, this system seems to be involved 
in the pathogenesis and/or pancreatic cancer prognosis.
aims & Methods: The objective of this study is to evaluate the involve-
ment of this system in the proliferation of cell lines of human pancreatic 
cancer with different degrees of differentiation: PANC-1, which comes from 
an undifferentiated carcinoma of ductal origin; RWP-1, a well/moderately 
differentiated ductal adenocarcinoma; and BxPC3, derived from a primary 
adenocarcinoma, which in nude mice produces well/moderately differen-
tiated adenocarcinomas to poorly differentiated.
In vitro study of the obestatin/GPR39 system expression by using immuno-
cytochemical techniques in tumor the cell lines PANC-1, RWP-1 and BxPC3. 
In addition, cell proliferation assays were performed after obestatin treat-
ment (100 and 200 nM) by BrdU and manual counting. 10% FBS was used 
as positive control.
results: The obestatin/GPR39 system was expressed intensely in the three 
pancreatic cancer cells. No immunoreactivity was observed in nega-
tive controls incubated without primary antibody. Obestatin administra-
tion (100 and 200nM) provoked a mitogenic effect in the RWP-1 cell line 
(46,31±3,45% over control; p< 0,05) although less pronounced than in the 
PANC-1 cell line at 48 h (64,12±2,64% over control; p< 0,05). In the case 
of BxPC3, no stimulation of proliferation was observed (-1,05±3,32% over 
control).
conclusion: This study offers two main findings: 1) the obestatin/GPR39 
system was intensely expressed in the human pancreatic tumor cell lines; 
2) exogenous obestatin increased the proliferation of these cell lines. The 
differences observed in the obestatin mitogenic effect may be due to the 
expression differences of key molecules in the signaling pathway of the 
obestatin/GPR39 system, such as the EGF receptor. The obtained results 
showed that the obestatin/GPR39 system was involved in the proliferative 
processes of pancreatic cancer.
disclosure: Nothing to disclose 
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Introduction: The role of immune cells on the pancreatic cancer microenvi-
ronment has increasingly gained attention over the past decade, however, 
whether the invasion of nerves by cancer cells is regulated by the presence 
of tumor-infiltrating leucocytes is still unexplored.
aims & Methods: In this study we aim to uncover novel immune-mediated 
pathways in the pathogenesis of neural invasion in pancreatic cancer.
We performed a comprehensive histopathological analysis of the intratu-
moral and perineural immunological infiltration in a cohort of 40 PDAC-
patients through immunhistochemical and double immunofluorescence 
stainings and automated quantification algorithms. 
Furthermore, using in vitro migration assays we evaluated the influence 
of natural killer (NK) cells and myeloid derived suppresor cells (MDSCs) 
on the chemoattractive gradient towards nerves and analyzed it via digital 
time-lapse microscopy.
results: Among the analysed immune cell types, the intratumoral density of 
MDSCs (p=0,00029), NK cells (p<0,0001) and CD8+ T (p=,0003) cells showed 
the highest correlation with neural invasion. In the perineural niche, the 
presence of neural invasion was associated with the infiltration by MDSCs 
(0,00005562 ± 0,000007588 vs 0,00002839 ± 0,000003435, p=0,0009) and 
NK cells (0,0001881 ± 0,00003231 vs 0,00007007 ± 0,00001280, p=0,0005). 
Mechanistically, the migratory behaviour of pancreatic cancer cells to-
wards neurons was significantly enhanced by the interaction with MD-
SCs (-0,004685 ± 0,0,01074 vs -0,1188 ± 0,01002, p<0,0001) and NK cells 
(0,09274 ± 0,01496 vs -0,1537 ± 0,009966, p<0,0001).
conclusion: MDSCs and NK cells raise as the key regulators in the peri-
neural niche promoting neural invasion, constituting therefore attractive 
targets for immunotherapy aiming to decrease tumor-associated pain and 
cancer spread.
disclosure: Nothing to disclose 
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Introduction: Pancreatic ductal adenocarcinoma (PDAC) is todays 4th lead-
ing cause of cancer-associated death in the Western World with an increas-
ing tendency. Thereby it relies on a core of driver mutations and dozens of 
passenger mutations refining a strong intratumoral heterogeneity. Ataxia-
Telangiectasia Mutated (ATM) is the most frequently mutated DNA-damage 
repair gene and missense mutations can be found in both sporadic and 
familiar pancreatic cancer. We previously showed that ATM levels inversely 
correlate with patient’s prognosis and the deletion of ATM in a mouse 
model of pancreatic cancer (AKC) accelerates tumorigenesis, metastasis 
and leads to genomically instable tumours. The latter characteristic opens 
vulnerability for a synthetic lethal attack using Parp inhibitors.
aims & Methods: However, we faced early resistance and tumour control 
required additional chemotherapy. In the current study, we systematically 
performed combinational screening for synergistic routes based on ac-
tionable perturbations in the DNA damage response to present an ATM 
null tailored targeted therapy at low dosage.
results: Synergistic tumour impact was found upon simultaneous inhibi-
tion of Parp-, Atr-, and DNA-Pkc-signaling (termed PAD) leading to syn-
thetic lethality in AKC cell lines in vivo and in vitro.Mechanistically, PAD 
lead to cytokinesis failure, replication folk stalling, Parp trapping, reversal 
of Atm-induced track lengthening finally leading to p53-mediated apop-
tosis. Chemical and genetic targeting of ATM together with PAD in human 
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PDAC lines and organoid cultures substantiated these data. Additionally, 
we elaborated consequences of Parp1 inhibitor resistance within the AKC 
background. Arising cell clones were aneuploid, highly genomically unsta-
ble and underwent epithelial-mesenchymal transition to boost an intrinsi-
cally program present in Atm-deficient PDAC. These features were associ-
ated with the acquisition of a multi-drug resistant phenotype caused by 
up-regulation of drug-transporters and de-toxification enzymes. Finally, 
exome-sequencing identified Drg1 loss as an additional crucial mediator 
in resistant cells.
conclusion: Thus, we provide coherent understanding of the molecular 
mechanism occurring upon Atm deletion in PDAC to precisely interfere 
with tumor characteristic for therapeutic success in mice and men.
disclosure: Nothing to disclose 
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Introduction: Based on recent studies, current guidelines recommend 
against routine preoperative biliary drainage (PBD) in patients with pan-
creatic head cancer if bilirubin levels are < 250 µmol/l. However, patients 
with higher bilirubin levels still undergo PBD, despite the lack of clini-
cal studies including these patients. To evaluate the rationale for a differ-
ent PBD approach in high bilirubin patients, tumor characteristics, PBD 
technical success- and complication rates, and postoperative complication 
rates were compared in patients with a bilirubin level ≥250 and < 250.
aims & Methods: In this retrospective cohort study, patients diagnosed 
with resectable pancreatic head cancer and cholestasis (bilirubin >40) 
from 2008 until 2018 were identified in three centers of the Regional Aca-
demic Cancer Center Utrecht. Analyses were performed in patients with 
a bilirubin level ≥250 versus < 250 at diagnosis (1) and prior to PBD and 
surgery (2) to reflect the moment of clinical decision making (1) and the 
actual effect of the bilirubin level on procedural outcomes (2). Multivari-
able logistic regression analyses were performed to identify independent 
predictors of PBD complications and severe postoperative complications 
(Clavien-Dindo ≥3), including bilirubin level as a continuous variable.
results: A total of 244 patients were included, 191 with bilirubin < 250 at 
diagnosis and 53 with bilirubin ≥250. PBD was performed in 64% (123/191) 
and 91% (48/53), respectively. Tumor characteristics did not differ between 
patients with bilirubin ≥250 versus < 250 at diagnosis. In patients under-
going PBD, no differences in technical success (83% vs. 81%, p=0.80) and 
complication rates (33% vs. 29%, p=0.60) were found between patients 
with bilirubin ≥250 versus < 250 at diagnosis. The use of metal stents was 
equal between the two groups (40% vs. 36%, p=0.66).
Ultimately, 212/244 (87%) patients underwent surgery, of which 168 pa-
tients had a bilirubin level at diagnosis < 250 and 44 ≥250. PBD was per-
formed in 143/212 (67%) of these patients. The rate of severe postoperative 
complications did not differ between patients with bilirubin ≥250 versus < 
250 at diagnosis (40% vs. 30%, p=0.26). In addition, when analyzing bili-
rubin levels ≥250 versus < 250 directly prior to PBD and surgery, no differ-
ences in PBD technical success and complications and severe postoperative 
complications were found. Bilirubin level at diagnosis was no independent 
predictor for PBD complications (OR 1.00 per 1 µmol/l, 95% CI 1.00-1.00), 
nor for severe postoperative complications (OR 1.00 per 1 µmol/l, 95% CI 
1.00-1.01). Also, no significant association between severe postoperative 
complications and PBD was found (OR 0.77, 95% CI 0.40-1.51).
conclusion: Tumor characteristics, PBD technical success and complica-
tions, and postoperative complications did not differ between patients 
with pancreatic head cancer and a bilirubin level ≥250 and < 250. Al-
though cautious interpretation of these data is mandatory given the retro-
spective nature, our study does not support a different approach regarding 
PBD in patients with severe jaundice and suggests omitting routine PBD 
in these patients either. 
Moreover, the perioperative benefit of PBD in these patients should be 
convincing in order to compensate for the serious drainage related mor-
bidity. Whether a subgroup of patients with pancreatic head cancer and 
cholestasis might benefit from PBD (e.g. in the setting of prehabilitation) 
needs to be further evaluated.
disclosure: Nothing to disclose 
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Introduction: With biomarkers lacking specificity and local symptoms 
appearing late, pancreatic cancer is a silent killer. Although much effort 
has been invested into modern imaging methods and new treatment ap-
proaches in the last decades, the prognosis remains unfavorable, with the 
5-year survival rate of only 5-7%. Therefore, intense research has been 
focusing on the identification of early symptoms and PC-specific mark-
ers. Several approaches have been tested, ranging from the inspection 
of pancreatic stellate cells to the analysis of microRNAs. As the cancerous 
pathology induces alterations of many essential biochemical pathways, the 
affected cells and tissues exhibit altered metabolism. This phenomenon 
may be easily inspected by metabolomics, an analytical platform with the 
ability to detect metabolites. Metabolites are produced by all bodily cells, 
thus, their analysis is usually performed using the tissue with suspected 
pathology or biofluids.
aims & Methods: To ensure minimal invasiveness and, thereby, a minimal 
burden for the patient, we used blood plasma for our metabolomics study. 
The blood plasma is not only easy to obtain, but it also comprises the ma-
jority of metabolites produced by the whole body. In our study, the blood 
plasma of PC patients (stage III-IV) and healthy controls was subjected to 
two sets of experiments. 
First, clinically recognized markers of oxidative stress related to cancer-
ous diseases were detected and quantified. Subsequently, we performed 
a multi-marker screening, i.e. the identification of other metabolites that 
might be considered clinically significant for PC. 
After initial pre-treatment (extraction, homogenization, centrifugation), 
the plasma samples were analyzed using high-performance liquid chro-
matography coupled with electrospray-ionization tandem mass spectrom-
etry in a gradient elution program. 
The clinically recognized markers were quantified after measuring their 
standards; the molecules resulting from the multi-marker screening were 
identified via Human Metabolome Database.
results: We detected multiple markers pointing to oxidative stress caused 
by reactive oxygen species forming during cancer growth, such as ortho-
tyrosine or 8-isoprostane, the levels of which were significantly elevated 
in the plasma of PC patients compared to healthy controls. Damage to the 
genetic information in DNA/RNA was indicated by higher levels of 8-hy-
droxy-2’-deoxyguanosine and 8-hydroxyguanosine, respectively. In the PC 
patients, the multimarker screening revealed enormously decreased levels 
of lysophosphatidylcholine, which means poor control of cell proliferation 
and a major disruption of lipid metabolism. Severe disturbances of lipid 
metabolism during PC were also illustrated by the increase in chenode-
oxycholic acid and carnitine derivatives. The presence of docosahexaenoic 
acid and its metabolites revealed the activation of the immune system.
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conclusion: Apart from markers of oxidative stress, which have been pre-
viously clinically recognized for several cancerous diseases, we identified 
molecules that have not been connected to PC so far. Thus, we believe that 
metabolomic profiling may serve as a reliable platform for the identifica-
tion of a panel of potential biomarkers, which would facilitate the diagno-
sis of pancreatic cancer. 
The study was supported by the Ministry of Health of the Czech Republic 
(project Nr. 16-31028A).
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Introduction: Organotypic cultures derived from pancreatic ductal adeno-
carcinoma (PDAC) termed pancreatic cancer organoids (PDO) recapitulate 
the primary cancer and can be derived from primary or metastatic biopsies. 
Although isolation and culture of patient derived pancreatic organoids have 
been established several years ago, advantages and constrains for individu-
alized medicine have not been comprehensively investigated yet.
aims & Methods: We conducted a feasibility study, systematically comparing 
head-to-head xenografted primary tissue and xenograft-derived organoids 
by rigorous immunohistochemical and molecular characterization. Subse-
quently, a drug testing platform has been set-up and validated in vivo.
results: Firstly, PDAC organoids faithfully recapitulate morphology and 
marker protein expression patterns of the original tumors. 
Secondly, quantitative proteomes from the patient-derived xenografts as 
well as from corresponding organoid cultures showed high concordance. 
Thirdly, genomic alterations as assessed by array-based comparative ge-
nomic hybridization revealed similar results in both groups. 
Fourthly, we established a small-scale, pharmacotyping platform adjusted 
to operate in parallel considering potential obstacles such as culture con-
ditions, timing, drug dosing and interpretation of the results. 
In vitropredictions were successfully validated in an in vivoxenograft trial. 
Finally, the organoid phenotyping outcome was compared with the predic-
tive value of gene mutations obtained by panel sequencing.
conclusion: In conclusion, small-scale drug screening in organoids ap-
pears a feasible, robust and easy-to-handle method to allow response 
predictions in parallel to daily clinical routine. PDO based phenotyping 
faithfully reflects genotypes. Therefore, our fast and cost-efficient assay is 
a reasonable approach in a predictive clinical setting.
disclosure: Nothing to disclose 
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Introduction: The treatment options and survival of locally advanced pan-
creatic cancer (LAPC) have improved in recent years. However, it is un-
known whether elderly patients (i.e. ≥75 years) have benefited from these 
improvements. With the ongoing aging of the patient population and an 
increasing incidence of pancreatic cancer, this patient group deserves 
more attention. This study aims to assess the influence of age on treatment 
and overall survival in patients with LAPC.
aims & Methods: Consecutive patients diagnosed with LAPC were prospec-
tively registered in 14 Dutch centers (April 2015 to December 2017). Patients 
were divided in three groups according to age (< 65, 65-74 and ≥75 years). 
We evaluated the influence of age on type of treatment and overall survival 
by using logistic regression and Cox regression analyses.
results: Overall, 425 patients with LAPC were included; 163 patients 
(38.4%) aged < 65 years, 184 patients (43.3%) aged 65-74 and 78 patients 
(18.4%) aged ≥75 years. Both patients aged < 65 years and 65-74 years 
were in good condition (WHO ps 0-1 in 88.3% and 73.2% respectively) 
and were mostly treated with chemotherapy (87% and 81.3%). Elderly 
patients were in good clinical condition as well (WHO ps 0-1 in 73.2%), 
49.9% was treated with chemotherapy and 43.6% received best supportive 
care. Median overall survival in elderly patients receiving treatment was 
longer as compared to those receiving best supportive care (9.0 vs 3.0 
months). Multivariate logistic regression analysis demonstrated that each 
additional year in age is associated with a decreasing probability to re-
ceive chemotherapy (hazard ratio [HR] 0.948, 95% confidence interval [CI] 
0.903-0.994, p = 0.028). In multivariate analysis an increase in age was 
not associated with a decrease in overall survival (HR 1.001, 95% CI 0.987-
1.015, p = 0.892). A better WHO performance score and receiving treatment 
were predictors for an increased overall survival.
conclusion: Elderly patients with LAPC are less often treated with chemo-
therapy. However, chemotherapy was associated with improved survival 
in elderly patients and age was not independently associated with lower 
survival. Therefore, treatment with chemotherapy should probably be con-
sidered more often in fit elderly patients with LAPC.
disclosure: Nothing to disclose 
P1517 PrOgnOsTIc facTOrs Of unresecTaBLe PancreaTIc 
cancer BefOre cheMOTheraPy
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Shiga University of Medical Science, Division of Gastroenterology, Otsu, Japan
contact e-Mail address: ysk.s1231@gmail.com
Introduction: The prognosis of patients with unresectable pancreatic can-
cer is difficult to predict during the initiation of systemic chemotherapy 
treatment. In most cases, determining the appropriate chemotherapy 
drugs and dosages for each patient is challenging. Recent studies have 
reported that the modified Glasgow prognostic score (mGPS) and neu-
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trophil-to-lymphocyte ratio (NLR), as the indices of the inflammatory re-
sponse of the body and nutritional condition, are associated with cancer 
prognosis. However, only few studies have demonstrated the use of these 
indices in predicting the prognosis of patients with unresectable pancre-
atic cancer. 
This report is a retrospective study on the prognostic factors of unresect-
able pancreatic cancer prior to chemotherapy.
aims & Methods: In this study, 56 patients with unresectable pancreatic 
cancer (stages III and IV as per the General Rules for the Study of Pancreat-
ic Cancer, 7th Edition, edited by Japan Pancreas Society) who were treated 
with chemotherapy from August 2010 to September 2017 were included. In 
accordance with the mGPS definition, we categorised the patients as fol-
lows: both high CRP (>1.0 mg/dL) and low albumin (< 3.5 mg/dL) levels, 2 
points; only high CRP level, 1 point and only low albumin level or neither of 
those, 0 points. We retrospectively discussed sex, age at diagnosis, perfor-
mance status (PS), CRP, CA 19-9, NLR, platelet-to-lymphocyte ratio (PLR), 
CRP-to-albumin ratio (CAR), mGPS and overall survival. Furthermore, we 
predetermined the cut-off value of NLR/PLR/CAR to be 5.0/190/0.09, di-
vided mGPS into 2 groups (0 and 1-2 points).
results: The subjects included 34 men and 22 women, with a mean age 
of 69.1 years, at stage III/IV (13/43), PS (27/28/1/0/0) (PS = 0/1/2/3/4). Using 
univariate analysis for each item (sex, age at diagnosis, CRP, CA 19-9, NLR, 
PLR, CAR and mGPS), PLR (p = 0.06), CAR (p = 0.03) and mGPS (1, 2) (p = 
0.0027) were significantly different. Nonetheless, based on the results of 
the multivariate analysis, mGPS (1, 2) is the only independent significant 
factor among the 3.
conclusion: These findings indicate that mGPS, prior to chemotherapy, can 
be a predicting factor for the prognosis of patients with unresectable pan-
creatic cancer.
disclosure: Nothing to disclose 
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Introduction: Surgery has been shown to improve the survival of patients 
with borderline and locally advanced pancreatic cancer (BR-LAPC). There 
are technical, but no clear biologic criteria how to select which patients 
would benefit from resection.
aims & Methods: To evaluate the impact of elevated Ca 19-9, mGPS, and 
positive aortocaval lymph nodes (ACLN) on survival of resected patients 
with BR-LAPC. Retrospective analysis from a prospectively collected data-
base was done on all patients resected for BR-LAPC at Karolinska Universi-
ty Hospital between 2008-2018. AOCL were routinely sampled for staging, 
but did not preclude resection.
results: Overall 270 patients with BR-LAPC were resected with periopera-
tive mortality of 2.6% (n=7). Mean age was 67 years, male:female ratio 
1.1:1. Positive AOCL were found in 38 patients (14.1%) and had the stron-
gest association with impaired survival: median, 1-,3-,5-year survival of 11 
months, 40%, 7%, 0% and 18 months, 70%, 29%, 19%, respectively. Modi-
fied GPS 0, 1 or 2 was neither associated with the presence of positive ACLN 
nor survival (p=ns). Elevated Ca 19-9 >200, compared to ≤200,showed clear 
association with the presence of positive ACLN (positive:negative ACLN = 
26:58 versus 11:86, respectively, p< 0.05) and impaired survival: median, 
1-,3-,5-year survival of 15 months, 56%, 10%, 7% versus 22 months, 69%, 
35%, 21% (p=0.0005). Adjuvant, but not neoadjuvant, chemotherapy had 
significant positive impact on survival: 24 months, 75%, 34%, 23% versus 
14 months, 55%, 21%, 12%, respectively (p=0.0004).
conclusion: Patients with BR-LAPC and elevated Ca 19-9 might need rou-
tine sampling of ACLN before decision for resection to better select who 
would benefit from surgery
disclosure: Nothing to disclose 
P1519 earLy OnseT PancreaTIc cancer (eOPc): 
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In a Large case-cOnTrOL sTudy
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Introduction: Pancreas cancer (PDAC) is expected to become the 2nd most 
common cause of cancer related death within 2030. Its occurrence is high-
er in the late life, with a peak of incidence is in the seventh decade. Never-
theless, 10% of patients is affected at an age < 50 years. Such population 
identifies the so called “early onset pancreatic cancers” (EOPC). Although 
it is known that EOPC are generally diagnosed in a more advance stage of 
disease and often in a metastatic status already at diagnosis, it is virtually 
unknown whether this poorer prognosis is the epiphenomenon of a dif-
ferent underling pathophysiological mechanisms, or the result of a merely 
delayed diagnosis. So far few, small and heterogeneous series have in-
vestigated the prognosis in EOPC compared to non-early onset pancreatic 
cancer (NOPC). None of them through a strict matching for sex and stage 
of disease (pTNM). Additionally, most of the previous studies relied on 
non-surgical series describing the clinical outcomes of patients who have 
not undergone treatments with curative intent.
aims & Methods: To investigate post-operative survival and possible risk 
factors worse outcome in EOPC and NOPC patients.
A case-control study on consecutive patients operated for PDAC between 
2008 and 2017 at HPB Disease Unit, Karolinska Hospital, Stockholm. Data 
about demographics, known risk factors for PDAC, exposures, pathological 
information, treatment and survival were recorded. Cases: PDAC patients 
aged ≤50 years (EOPC). Controls: 1:5 sex and stage (pTNM) matched pa-
tients consecutively recruited in the same period, aged >50 years (NOPC). 
Chi square was used to analyze categorical variables, t test for continuous 
ones. Survival was assessed through Kaplan Meier method and statistically 
significant results were evaluated through univariable and multivariable 
Cox hazard regression analysis.
results: 24 EOPC and 120 stage controls were recruited. 1,3,5 years overall 
survival was similar in cases and controls (respectively 70.8% vs 72.5%; 
30.1% vs 28.9% and 24.1% vs 12.5%; p=0.63). The use of adjuvant chemo-
therapy was confirmed to improve the outcome in both cases and controls 
(respectively HR=0.30; 95%CI 0.10-0.91, p=0.03 vs HR 0.61; 95% CI 0.36-
1.00, p=0.05). No statistically significant difference was found regarding 
the prevalence of genetic syndromes, exposures and known risk factors 
for PDAC. At univariable cox hazard regression analysis, diabetes (HR= 
1.60; 95CI 0.95-2.69, p=0.07) and underweight (HR=5.59; 95%CI 2.01-15.51, 
p=0.0009) were significantly associated to an increased risk of cancer re-
lated death in controls. Such increased risk was not confirmed in cases. At 
multivariable cox regression analysis underweight was confirmed to be 
significantly associated to an increased risk of mortality in controls (HR 
4.31; 95%CI 1.51-12.30, p=0.006).
conclusion: Overall survival is similar in operated EOPC and NOPC patients. 
Adjuvant chemotherapy was confirmed as a factor positively influencing 
prognosis in both cases and controls. Metabolic and nutritional status play 
a role in influencing prognosis in NOPC but not in EOPC.
disclosure: Nothing to disclose 
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OuTcOMes fOLLOWIng PancreaTIcOduOdenecTOMy In PaTIenTs 
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Introduction: To assess the impact of sarcopenia on the occurrence of 
postoperative complications and mortality after pancreatic resection in 
patients with pancreatic adenocarcinoma.
aims & Methods: This study included 137 patients with pancreatic adeno-
carcinoma, who underwent pancreaticoduodenectomy in our institution in 
the period 2017-2018. Preoperative computed tomography (CT) was per-
formed for all patients. Sarcopenia was quantified using two approaches: 
the Total Psoas Index (TPI) and the Hounsfield Unit Average Calculation 
(HUAC). They were measured at the level of the third lumbar vertebral 
body (L3).
results: Sarcopenia was diagnosed in 49 (39.8%) patients using TPI. 
Postoperative complications occurred in 24 (48.9%) patients, in patients 
without sarcopenia postoperative complications occurred in 23 (31.0%) pa-
tients, (c2 = 4.1, p=0.04). Mortality was 3 (6.1%) and 1 (1.3%) respectively, 
(c2 = 0.09, p=0.7).
In 53 (38.7%) patients sarcopenia was diagnosed using HUAC. Postop-
eretive complications occurred in 25 (47.2%) patients in the group with 
sarcopenia and in 19 (22.6%) patients in the group without sarcopenia 
(c2 = 8.9, p=0.003). Mortality was 3 (5.6%) and 1 (1.2%) respectively (c2 
= 2.2, p=0.1).
In patients with sarcopenia determing by HUAC pancreatic fistula Grade B 
or C occurred in - 14 patients, delayed gastric empting - in у 3, haemor-
rhage- in 6, infections complications occurred in 2 patients.
In patients without sarcopenia pancreatic fistula Grade B or C occurred 
in - 5 patients, delayed gastric empting - in 2, haemorrhage - in 4, infec-
tions complications occurred in 5 patients and lymphorrhea occurred in 
3 patients. We did not find any significant difference in the increase of 
delayed gastric empting (c2 = 0.02, p=0.8), haemorrhage (c2 = 0.05, p=0.8), 
infections complications (c2 = 0.09, p=2.7), but the level of pancreatic fis-
tula Grade B or C was significantly higher in patients with sarcopenia (c2 
= 0.04, p=3.8).
In patients with sarcopenia determing by TPI pancreatic fistula Grade B or 
C occurred in - 12 patients, delayed gastric empting - in у 2, haemorrhage- 
in 6, infections complications occurred in 4 patients.
In patients without sarcopenia pancreatic fistula Grade B or C occurred 
in - 5 patients, delayed gastric empting - in 4, haemorrhage - in 5, infec-
tions complications occurred in 9 patients. We did not find any significant 
difference in the increase in the number of infections complications (c2 = 
2.9, p=0.08), delayed gastric empting (c2 = 0.74, p=0.3) and haemorrhage 
(c2 = 0.07, p=0.8), but the level of pancreatic fistula Grade B or C was also 
significantly higher in patients with sarcopenia (c2 = 4.06, p=0.04).
conclusion: HUAC and TPI could be easily calculated preoperatively in 
patients with pancreatic cancer. Present results suggest that sarcopenia, 
determined by HUAC and TPI is a reliable indicator of the surgical out-
come and significantly affects the level of postoperative complications and 
pancreatic fistula. Determination of sarcopenia can be used to improve 
the selection of patients with pancreatic cancer prior to resection and to 
predict of pancreatic fistula.
disclosure: Nothing to disclose 
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Introduction: Patients with pancreatic cancer are commonly affected by a 
pronounced perioperative sarcopenia and cachexia, which are associated 
with poorer overall survival. The aim of this study is to test the impact of 
pancreatic resection on body composition parameters in pancreatic cancer 
patients.
aims & Methods: Body composition parameters were measured using 
computed tomography (CT) images at L3 vertebral level prior to surgery 
(timepoint 1, T1) as well as 6 (T2) and 12 months (T3) after pancreatic 
resection were assessed using Slice-O-Matic® software version 4.3. Fol-
lowing body compositions parameters were estimated: subcutaneous 
adipose tissue area index (SATI), visceral tissue area index (VATI), intra-
muscular tissue area index (IMATI), total adipose tissue area index (TATI), 
as well as skeletal muscle mass index (SMAI). 
Sarcopenia was defined by consensus thresholds before surgery with the 
cut-off points for SMI (skeletal muscle tissue area index) < 52.4 cm2/m2 
for male and < 38.5 cm2/m2 for female patients. 248 patients with pancre-
atic cancer from cachexia database treated in the Department of Surgery, 
Klinikum Rechts der Isar, 2006-2019, were screened for this retrospective 
study. 
From 219 resected patients with the presence of preoperative CT, only 63 
patients had CTs at T1, T2, and T3. 42 (67%) of these patients were sarco-
penic before surgery; 36 (57%) were sarcopenic 6 months after surgery, 
and 41 (65%) were sarcopenic 12 months after surgery.
results: Median value of TATI decreased from 95 cm/m2 at T1 to 52 cm/m2 
at T2 (p < 0.001) and slightly increased to 62 cm2/m2 at T3 (p < 0.001 T1 vs. 
T2; p = 0.724 T2 vs. T3). Median value of VATI decreased from 35 cm/m2 at 
T1 to 20 cm/m2 at T2 (p < 0.001) and slightly increased to 21 cm2/m2 at T3 
(p < 0.001 T1 vs. T2; p = 0.913 T2 vs. T3). Median value of SATI decreased 
from 53 cm/m2 at T1 to 32 cm/m2 at T2 (p < 0.001) and slightly increased to 
36 cm2/m2 at T3 (p < 0.001 T1 vs. T2; p = 0.576 T2 vs. T3). IMATI and SMAI 
did not change significantly after pancreatic resection.
conclusion: Resected pancreatic cancer patients are affected by a signifi-
cant adipose tissue loss 6 months after surgery, which doesn’t improve 
until 12 months after surgery. Surprisingly, though the most of pancre-
atic cancer patients suffer from sarcopenia before surgery, no additional 
muscle wasting occurs after pancreatic resection.
disclosure: Nothing to disclose 
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P1523 reLaTIve adrenaL InsuffIcIency In decOMPensaTed 
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Introduction: Relative adrenal insufficiency (RAI) is a clinically undetect-
able predisposing factor of poor outcome in cirrhotics.There are no pub-
lished studies regarding presence and effect of RAI in children with de-
compensated cirrhosis.
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aims & Methods: We aimed to study 
1) prevalence of RAI in decompensated cirrhotic children using low dose 
short synacthen test, 
2) assess the surrogatory markers of RAI [interleukin-6 (IL-6) and tumor 
necrosis factor-α (TNF-α)] and serum high density lipoprotein (HDL), pre-
cursor of serum cortisol and 
3) assess outcome over 180 days follow-up.
This is a prospective longitudinal observational study enrolled hemodyam-
ically stable cirrhotic patients with ascites after excluding patients on cor-
ticosteroids, adrenal insufficiency, terminally ill, concurrent infections and 
shock. They were sampled for serum basal cortisol (BC), peak cortisol (PC; 
after 30 minutes of 1 mcg intravenous synacthen), serum TNF-α, IL-6 and 
HDL levels at D1 and D21. Delta cortisol was defined as difference between 
BC and PC. RAI was diagnosed as PC< 500nmol/L. Cohort was analysed in 
terms of severity of liver disease, previous event (hepatic encephalopathy, 
gastrointestinal bleeding, systemic infection and spontaneous bacterial 
peritonitis) in past 180 days, complications (new onset organ failures, in-
fection and hospital readmissions) at follow-up and death.
results: Prevalence of RAI on D1 was 54% in decompensated cirrhosis 
(n=63). Significant differences of D1-RAI patients (n=34) vs normal adre-
nal functions (NAF,n=29) were age (135±43 vs 119±53 mo, p=0.18), platelet 
count (109±63 vs 170±95 x103/µL,p=0.003), BC (275±92 vs 517±135 nmol/
L,p< 0.001), PC (356±93 vs 673±165 nmol/L,p< 0.001) and delta cortisol 
(90±84 vs 174±170 nmol/L, p=0.04), complications in follow up (53% vs 
24%, p=0.023). D1-RAI, significant varices, hypersplenism, serum albu-
min, INR, PELD (pediatric end-stage liver disease) score, serum HDL were 
the statistically significant determinants of follow-up complications on 
regression analysis in decompensated cirrhotics. Independant factors 
on multivariate analysis for follow-up complications and mortality were 
PELD score and hypersplenism. RAI progressed to 61% by D21. Patients 
with RAI (n=34) with or without complications at follow-up were com-
pared (table 1). In this subgroup, INR, PELD score and serum HDL were 
risk factors for complications and death. In RAI patients, PELD >7 pre-
dicted follow-up complications (AUC: 86%, p< 0.001, sensitivity 100%, 
specificity 50%) and PELD >11 predicted death (AUC: 86%, p=0.003, sen-
sitivity 100%, specificity 50%).
conclusion: Half of the decompensated cirrhotic children have RAI. RAI 
determines the follow-up complications. RAI patients with complications 
have higher PELD scores, lower HDL levels and higher mortality.
disclosure: Nothing to disclose 
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Introduction: The natural history of biliary dysplasia (BD) in children and 
young adolescents with primary sclerosing cholangitis (PSC) is lacking.
aims & Methods: Aim of this study was to report the role of endoscopic 
retrograde cholangiography (ERC) with systematic brush cytology (BC) for 
screening and follow-up of BD in this setting of patients.
Study design: Retrospective cohort study.
Population, timing, area: All patients with PSC diagnosed in childhood/
adolescence between 1993-2017 at Helsinki University Hospital (HUH) were 
identified. 
Disease diagnosis: PSC was diagnosed based on: 
1. Elevation of liver enzymes, 
2. Liver biopsy, 
3. ERC. Notably, ERC with BC is performed in all the patients referred for a 
suspicious of PSC regardless the severity of the disease in HUH: 
1. To confirm/exclude the diagnosis and 
2. To assess the individual risk of progression based on BC; patients with 
a repeatedly confirmed BD are referred for liver transplantation (LT). ERC 
images were scored using a modified version of Amsterdam PSC score; a 
global score combing intra- (0-8) and extra- (0-8) hepatic score was ob-
tained (0-4: mild, 5-8: moderate, 9-16: severe changes). Cytology samples 
were graded as benign (i.e., normal or inflammatory/regenerative atypia), 
suspicious (for BD or malignancy) or malignant (i.e., CC). 
Data: Clinical data and lab tests were reviewed.
End-points: A composite of LT + cirrhosis at last follow-up were evaluated. 
Follow-up: All patients were censored by the end of March 2019.
results: Baseline characteristics: 68 patients (42 males, median age at 
diagnosis 16, range: 5-21 years) were included; 22 patients (32%) had an 
overlap with autoimmune hepatitis (AIH) and 57 patients (84%) had con-
comitant inflammatory bowel disease (IBD). 
Follow-up duration: The median follow-up time was 8 (range: 2-25) years. 
At the last follow-up the median age was 23 (range: 10-43) years. 
Screening ERC: At first ERC the global score was: 0-4 in 46 (68%), 5-8 in 
8 (12%) and 9-16 in 14 (20%) patients. Gamma-glutamyltranspeptidase 
(GGT) and Ca 19.9 were higher in patients with more advanced changes 
(p= 0.05 and 0.01), respectively. Suspicious of malignancy (low-grade dys-
plasia, LGD) was detected in four patients (6%) (one was cirrhotic, 2 had 
also aneuploidy): 2 received LT (LGD was confirmed in one and cirrhosis 
without LGD in one) and 2 LGD were not confirmed on following BC. 
Follow-up ERC: A median of 2 (range: 0-11) ERCs with brush cytology were 
performed. Suspicion of malignancy (LGD) was raised in 5 (3% of the 
ERC:s): one was transplanted (LGD was not confirmed, but severe cholan-
gitis) and 4 were not confirmed on following BC but one was listed for LT 
because of cirrhosis. One patient underwent right hepatectomy for a liver 
mass, consistent with biliary LGD.
comparison at d1(baseline), n=34 comparison at d21, n=22
  Complications (n=18) No complications (n=16) p   Complications (n=10) No complications (n=12) p
Previous events, n (%) 15 (83) 8 (50) 0.07 Previous events, n (%) 8 (80) 7 (58) 0.38
PELD score 23.5 ± 12.7 6.9 ± 9.9 <0.001 PELD score 22.8 ± 10.7 8.3 ± 9.9 0.004
D1 basal cortisol (nmol/L) 293 ± 98 256 ± 84 0.24 D21 basal cortisol (nmol/L) 290 ± 119 251 ± 113 0.45
D1 peak cortisol (nmol/L) 369 ± 95 341 ± 89 0.39 D21 peak cortisol (nmol/L) 380 ± 114 351 ± 102 0.53
D1 IL-6 (pg/mL) 29 ± 39 39 ± 73 0.63 D21 IL-6 (pg/mL) 63 ± 96 42 ± 65 0.59
D1 TNF (pg/mL) 4.1 ± 5.4 8 ± 12 0.22 D21 TNF (pg/mL) 10 ± 15 4.3 ± 13 0.38
D1 HDL (mg/dL) 14 ± 11 29 ± 12 0.001 D21 HDL (mg/dL) 20 ± 12 36 ± 14 0.009
Death in 180 days, n (%) 7(39) 0(0) 0.008 Death in next 6 month, n(%) 2(20) 0(0) 0.19
[P1523 Table 1: Comparison of decompensated cirrhotic children with relative adrenal insufficiency with and without future complications at baseline and day]
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End of follow-up: Eight patients (12%) had received LT: 4 for decompensat-
ed cirrhosis (one with biliary LGD), one for a markedly increased S-Ca19-9 
(cirrhosis on histology) and 2 for suspicion of malignancy. Five patients 
(7%) were cirrhotic. No cases of CC were detected.
Survival (Logrank test for trend): Probability for the end-point LT + cirrho-
sis at last follow-up was higher in patients with more advanced bile duct 
disease at their first ERC (p=0.04).
Multiple linear regression: Elevated GGT (p=0.02), ALP (0.01) and bilirubin 
(0.05) at first ERC were independent factors for the end point LT + cirrhosis 
at last follow-up.
conclusion: In patients with a PSC-onset at childhood/adolescence bili-
ary dysplasia may develop within a median time of 3 years necessitating 
thorough follow-up.
disclosure: Nothing to disclose 
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Introduction: Acute recurrent pancreatitis (ARP) is poorly understood in 
children. Several genetic risk factors have been identified in adults with 
ARP. However, literature regarding genetics of ARP is sparse in pediatric 
age group.
aims & Methods: All children (< 18 years) with ARP from Jan 2016 to May 
2018 were prospectively enrolled in the study. Children with a known cause 
of ARP like obstructive, toxic/metabolic and autoimmune were excluded 
from the final analysis. Children with idiopathic ARP (IARP)underwent ge-
netic testing for mutations/polymorphisms in genes known to predispose 
to ARP {SPINK1, PRSS1, CTRC (Chymotrypsin C), CTSB (Cathepsin B), CLDN-
2 (Claudin-2) and CFTR}.
results: A total of 239 children (116 boys, 10.3±3.7 years) were enrolled 
during the study period. Of these, 204 (85.35%) children were identified 
as IARP. Themean age of symptom onset and the average number of acute 
episodes were 8.3±3.7 years and 3.3 ± 1.8, respectively. In 4.6% (11/239) 
family history of pancreatitis was noted. Pancreas divisum was found in 
18.7% (27/144) children. Genetic evaluation was performed in 144 (70.6%) 
children with IARP. Mutations/polymorphisms in at least 1 gene was iden-
tified in 89.5% (129/144) children including SPINK1 in 41.9%, PRSS1 (rs 
10273639) in 58.2%, CTRC in 25.6%, CLDN -2 in 72.9% and CFTR in 2.3%. 
There was no significant in the incidence of genetic mutations/polymor-
phisms in IARP with or without pancreas divisum (95.7 vs 88.4%; p=0.467).
conclusion: Genetic mutations are the most common cause of IARP in 
children. The incidence of genetic mutations is similar in children with or 
without pancreas divisum. The role of pancreas divisum in causing ARP in 
the absence of a genetic mutations should be evaluated in future studies.
disclosure: Nothing to disclose 
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Introduction: The documented incidence of acute pediatric pancreatitis 
(APP) is low, but it shows a rising pattern from Eastern to Western Europe 
and the USA. An American study established close correlation between 
serum pancreas enzyme measurement (sPEM) and the incidence of APP.
aims & Methods: The aim of the PINEAPPLE-R study is to retrospectively 
investigate the diagnostic practice for APP and to estimate the incidence 
of pancreatitis among children suffering from abdominal pain worldwide. 
PINEAPPLE (Pain IN EArly phase of Pediatric Pancreatits) is a registered 
(ISRCTN35618458), observational, multinational clinical trial (http://www.
ncbi.nlm.nih.gov/pubmed/26641250). The PINEAPPLE-R sub-trial is a ret-
rospective review of pediatric ER medical records, collecting symptoms, 
results of abdominal imaging and pancreatic enzyme measurements. We 
have already overviewed 46190 pediatric patient records and obtained the 
requested data from 4 countries’ 15 hospitals for the PINEAPPLE-R trial.
results: Retrospectively 10.4% (4782/46190) of the children appeared at ER 
units had abdominal pain. In case of abdominal pain sPEM was performed 
in 13.8% (662/4782), 23.1% (1104/4782) of the patients had abdominal im-
aging and the incidence of pancreatitis was 0.2% (11/4782). The number 
of sPEM decreased from the USA to Eastern Europe (21.6% to 5.6%) and 
clearly correlated with the incidence of APP (0.5% to 0%, R2=0.958). The 
most accurate diagnostic workup has been performed in Israel, where 
the sPEM was measured in 62.9% (165/262) and the abdominal imaging 
41.6% (109/262) of patients with abdominal pain, resulted in 3 (1.14%) 
diagnosed APP.
conclusion: The PINEAPPLE-R shows that the incidence of APP is 0.2% 
based on the current diagnostic practice. Better awareness of APP results 
1.14% incidence of APP as a reason of abdominal pain. These data strongly 
suggest that the majority (86%) of APP is not diagnosed.
disclosure: Nothing to disclose 
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P1527 underWaTer endOscOPIc MucOsaL resecTIOn fOr 
recurrenT duOdenaL TuMOr: a reTrOsPecTIve case serIes
Shichijo S., Takeuchi Y., Uedo N., Kono M., Fukuda H., 
Shimamoto Y., Ohmori M., Iwagami H., Matsuura N., Nakahira H., 
Maekawa A., Kanesaka T., Higashino K., Ishihara R.
Osaka International Cancer Institute, Department of Gastrointestinal 
Oncology, Osaka, Japan
contact e-Mail address: shichijiyou-tky@umin.ac.jp
Introduction: Endoscopic resection for superficial non-ampullary duode-
nal neoplasms (SNADEN) is gradually spreading, and recurrence after en-
doscopic resection sometimes occurs. However, conventional endoscopic 
mucosal resection (EMR) for recurrent lesion with submucosal saline 
injection is difficult because of submucosal fibrosis. Furthermore, endo-
scopic submucosal dissection (ESD) for duodenal neoplasm accompanies 
a high risk of perforation, and highly advanced skills are demanded to 
perform ESD especially on recurrent lesions. Underwater EMR (UEMR) 
was developed and described by Binmoeller et al in 2012. We previously 
reported the usefulness of UEMR for primary SNADENs.
aims & Methods: We retrospectively analyzed patients diagnosed with re-
current duodenal neoplasm and treated with UEMR at Osaka International 
Cancer Institute from 2015 to March 2019. For UEMR procedure, a waterjet 
endoscope with distal attachment was used. We evacuated air from the 
affected segment of lumen and infused water until the lumen was com-
plete full, then we performed hot snare polypectomy without submucosal 
injection.
results: During the study period, 7 patients (6 men, 1 woman; age, 59-78 
years) were treated with UEMR for recurrent SNADENs. All lesions were 
flat elevated, and located at the descending duodenum. The period from 
previous treatment to the treatment of recurrence were 1.4 ± 1.1 years. 
Tumor size was 2 to 11 mm. En bloc resection was performed in 5 cases 
and piecemeal resection in 2 cases without complications during the pro-
cedure. The procedure time was 18 ± 17 min. 2 patients presented melena 
and were performed endoscopic examination 3 and 4 days after UEMR, 
respectively, and 1 required hemostasis by clipping. Pathological diagno-
sis was intramucosal adenocarcinoma in 4 cases, and tubular adenoma 
in 3.
conclusion: UEMR for recurrent duodenal lesion is feasible and effective, 
which is difficult to be treated with conventional EMR, or ESD.
disclosure: Nothing to disclose 
P1528 The dOuBLe-BITe BIOPsy TechnIque Is fasTer and 
equaLLy accuraTe cOMPared TO The sIngLe-BITe TechnIque 
fOr endOscOPIc surveILLance Of heredITary dIffuse gasTrIc 
cancer
Pappas A.1, Waldock W.1, Richardson S.1, Januszewicz W.2, Roberts G.3, 
O’Donovan M.4, Fitzgerald R.C.5, di Pietro M.1
1University of Cambridge, MRC Cancer Unit, Cambridge, United Kingdom, 
2University of Cambridge, MRC Cancer Unit, Department of Oncology, 
Cambridge, United Kingdom, 3Cambridge University Hospital, Surgery, 
Cambridge, United Kingdom, 4Cambridge University Hospital, Histopathology, 
Cambridge, United Kingdom, 5Medical Research Council Hutchison / MRC 
Research Centre MRC Cancer Unit, Cambridge, United Kingdom
contact e-Mail address: apopapp300@yahoo.com
Introduction: Germline mutation in the E-cadherin gene (CDH1) is found 
in approximately 30% of individuals fulfilling the clinical criteria for he-
reditary diffuse gastric cancer (HDGC) and is an indication for prophylactic 
gastrectomy. However, endoscopic surveillance is recommended for those 
individuals that refuse gastrectomy and prefer to delay it for medical or 
psychosocial reasons, in order to identify foci of intramucosal signet ring 
cell carcinoma (SRCC) and inform the best timing of surgery. The recom-
mended endoscopic protocol involves 30 random mapping biopsies in 6 
gastric anatomical regions (Cambridge protocol), which is tedious and 
time-consuming. In order to save time, two specimens could be taken 
during a single passage of the biopsy forceps (“double-bite” technique). 
Previous studies on the efficacy of this technique, in both the upper and 
lower gastrointestinal tract, have generated conflicting results.
aims & Methods: The aim of this study was to determine the adequacy and 
utility of the “double-bite” technique for mapping biopsies in patients un-
dergoing surveillance for HDGC. The primary outcome was identification of 
SRCC foci in the two arms. The secondary outcomes included time to per-
form biopsy protocol, biopsy size, patients comfort and dose of sedation.
Patients were randomized to the single or double-bite arm. Procedures 
were performed by 3 trained endoscopists with high-resolution white-
light and narrow band imaging with targeted biopsies on visible lesions 
followed by Cambridge protocol biopsies. Randomization was revealed 
to the endoscopist just before the mapping biopsies. The time taken for 
the procedure was recorded between the first and last mapping biopsy. 
A comfort score was assigned by an endoscopy nurse after the procedure, 
according to the modified Gloucester scale. Biopsy specimens were as-
sessed for size and presence of SRCC foci by two upper GI pathologists, 
who had significant experience in identification of SRCC and were blinded 
to study arm. 
This study was powered for the secondary endpoint related to the pro-
cedural time and we estimated that 13 cases at least in each arm were 
required to show a difference with a power of 0.95 at a significance level 
of 0.01.
results: Twenty-five patients were included in the single-bite and 23 in 
the double-bite arm. There was no difference in patient demographics, 
including age and gender. In the mapping biopsies, 2 SRCC foci were de-
tected in the single-bite arm and 5 in the double-bite arm (p=0.24). The 
Cambridge biopsy protocol in the double-bite arm was significantly faster 
compared to the single-bite arm (11±2.7min vs 13±2.4; p=0.004). The mean 
size of the biopsies in the double-bite arm was significantly smaller than 
in the single-bite arm (2.5 vs 3 mm, p=0.001). There was no difference in 
sedation dose and comfort score.
conclusion: The double-bite technique is significantly faster than the sin-
gle-bite method for performing the Cambridge biopsy protocol in patients 
undergoing surveillance for HDGC. Despite the smaller size, the double-
bite technique does not reduce the yield of SRCC.
disclosure: Nothing to disclose 
P1529 TT-j knIfe Increases sPeed Of Per-OraL endOscOPIc 
MyOTOMy: a cOMParIsOn Of uk and jaPanese PracTIce
Patel M.1, Shimamura Y.2, Gulati S.1, Gunasingam N.1, Haji A.3, Hayee B.4, 
Inoue H.5
1King’s Institute of Therapeutic Endoscopy, Gastroenterology, London, 
United Kingdom, 2Showa University Koto Toyosu Hospital, Digestive Disease 
Center, Tokyo, Japan, 3Kings College Hospital, Colorectal Surgery, London, 
United Kingdom, 4Kings College Hospital, Gastroenterology, London, United 
Kingdom, 5Showa University Northern Yokohama Hospital, Digestive Disease 
Center, Yokohama, Japan
contact e-Mail address: mehulpatel1@doctors.org.uk
Introduction: Per-oral endoscopic myotomy (POEM) is an effective treat-
ment for achalasia but requires a high level of technical expertise with 
a steep learning curve limiting its accessibility to select centres. The TTJ 
knife unlike the conventional TT knife offers an integrated water jet during 
tunnelling and submucosal dissection.
aims & Methods: This study aims to determine if the TTJ knife increases 
the speed of myotomy and could be a beneficial tool for less experienced 
endoscopists. Procedure data was retrospectively analysed for 107 cases 
performed at a UK centre (2013-2019) and 1549 cases performed at a more 
experienced Japanese centre (2008-2019). Case matching was executed 
between sites for: prior therapies, sigmoid shape oesophagus, knife (TT/
TTJ) and total myotomy length (+/-5cm). Independent samples t-test was 
undertaken to compare outcome measures (myotomy speed (cm/minute) 
and procedure time (minutes)) for TTJ and TT knives.
results: Mean speed of myotomy for all cases was significantly faster for 
the TTJ knife (0.16 vs 0.21, p< 0.001) and mean procedure time was sig-
nificantly shorter (68.35 vs 88.81, p< 0.001). Differences in mean myotomy 
speed by knife (TTJ vs TT) were greater in the UK cohort (0.21 vs 0.14, p< 
0.001) than the Japanese cohort (0.21 vs 0.17, p< 0.05) but still significantly 
faster in both cohorts. Mean procedure time with TTJ was significantly 
shorter in the UK cohort (57.0 vs 88.7, p< 0.001), while there was no signifi-
cant difference in the Japanese cohort (79.7 vs 89.0, p=0.17). The speed of 
myotomy using the TT knife was significantly faster in the Japanese cohort 
compared to the UK cohort (0.17 vs 0.19, p< 0.05), there was no significant 
difference by centre for the TTJ knife (0.21 vs 0.20, p=0.72).
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conclusion: The TTJ knife increases the speed of myotomy and reduces 
procedure time for all levels of operator. The magnitude of this effect ap-
pears to be smaller for a high-volume centre, but still significantly differ-
ent. Furthermore, myotomy speed with TTJ was the same in both groups 
suggesting a real advantage for a jet-type knife in this scenario.
disclosure: Nothing to disclose 
P1530 OuTcOMes frOM The uk endOscOPIc suBMucOsaL 
dIssecTIOn (uk esd) naTIOnaL regIsTry: MOvIng TOWards an 
aLTernaTIve aPPrOach fOr underTakIng esd In a WesTern 
seTTIng
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Introduction: The practice of endoscopic submucosal dissection (ESD) as a 
viable technique for resection of early gastrointestinal neoplasia has been 
growing in the West. However, its uptake has been slow due to a long 
learning curve, higher complication rate and lack of a reimbursement tar-
iff in many centres.
aims & Methods: The aim of this study was to analyse the ESD practice in 
the UK through the development of the country’s first national ESD registry. 
The registry was established in 2016 with 4 major tertiary referral centres 
performing ESD Data was prospectively collected and captured on a na-
tional electronic database for subsequent analysis. Baseline demograph-
ics, procedure and lesion details as well as en bloc, R0 resection and com-
plication rates were recorded. Both conventional ESD and hybrid (knife 
assisted resection or KAR, where a snare is used) techniques were used.
results: A total of 249 ESD procedures were included. The average age of 
the patients was 70 years with a male:female ratio of 2:1. The ESD comple-
tion rate was 98.4% (245/249). 13.8% of the lesions were scarred from 
previous endoscopic resection attempts. Of the completed procedures, 70 
were undertaken in the oesophagus, 55 rectal, 54 colonic, 64 gastric and 
3 in the duodenum. The average lesion size was 3.2cm. The average pro-
cedure time was 58, 62, 87 and 127 minutes for oesophageal, duodenal, 
colorectal and gastric lesions respectively. 
The majority of the lesions (177/249, 71.1%) were removed using a standard 
ESD technique compared to 72/249 (28.9%) using a KAR technique where 
piecemeal resection was more likely. The table below stratifies the proce-
dure outcomes according to standard ESD versus KAR techniques. 
  standard esd knife assisted resection (kar)
 
En bloc 
resection 
rate
R0 
resection 
rate
Blee-
ding
Perfora-
tion
En bloc 
resection 
rate
R0 
resection 
rate
Blee-
ding
Perfo-
ration
Oesophageal 
(n=70)
60/61
(98.4%)
52/61
(85.2%)
1/61 
(1.6%)
0
9/9 
(100%)
8/9 
(88.9%)
0 0
gastric 
(n=64)
56/57 
(98.2%)
51/57 
(89.5%)
1/57 
(1.8%)
3/57 
(5.3%)
6/7 
(85.7%)
6/7 
(85.7%)
0 0
duodenal 
(n=3) N/A N/A N/A N/A
2/3 
(66.7%)
2/3 
(66.7%)
0
1/3 
(33.3%)
colorectal 
(n=108)
54/55 
(98.2%)
48/55 
(87.3%)
2/55 
(3.6%)
2/55 
(3.6%)
18/53 
(33.9%)
18/53 
(33.9%)
1/53 
(1.9%)
2/53 
(3.8%)
[Analysis of ESD by location and resection method]
The overall stricture rate for oesophageal ESD was 8.6% (6/70, with 2 oc-
curring using KAR and 4 using standard ESD). Notably, the complication 
(bleeding/perforation) rate for oesophageal lesions was lower than that 
of colorectal despite fewer cases being performed. The en bloc resection 
rate using KAR for colorectal lesions was low due to piecemeal removal.
conclusion: This data provides insight into the practice of ESD in the UK 
through a national registry. Overall en bloc resection rates are high when 
conventional ESD is undertaken and complication rates low when a KAR 
approach is used. 
Most of the procedures were carried out in the colorectum and oesopha-
gus reflecting the local pathology burden. Bleeding and perforation rates 
were low and procedure time shortest in oesophageal ESD despite a simi-
lar number of rectal, gastric and oesophageal cases being undertaken. 
This may provide a basis for training in oesophageal ESD in parallel with 
rectal and gastric cases rather than the traditional model of Eastern train-
ing that advocates step wise progression starting with gastric ESD. Tai-
loring this model of practice may increase the uptake of ESD as a safe 
procedure in the West with appropriate training.
disclosure: Nothing to disclose 
P1531 Occurence Of BLack esOPhagus In a sIngLe TerTIary 
cenTer: a reTrOsPecTIve anaLysIs Of 11 years
Orlando D.1, Ruggeri M.2, Di Giulio E.3, Carabotti M.4, Esposito G.5, 
Corleto V.6, Annibale B.7
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Department of Clinical Sciences and Translational Medicine, Rome, Italy, 
5Sant’Andrea Hospital, Sapienza University of Rome, Department of Medical-
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Medicine Surgery, Roma, Italy, 7Ospedale S. Andrea, Medical and Surgical 
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Introduction: Acute esophageal necrosis so called black esophagus (AEN), 
is a rare clinical condition characterized by the endoscopic finding of dif-
fuse, often circumferential, black mucosal pigmentation of esophagus, 
which typically stops at gastro-esophageal junction. Duodenal involve-
ment has been described in this condition. Epidemiological data of AEN 
are scanty, in fact until now only small case series and case reports are 
available.
aims & Methods: To assess the occurrence of AEN in a consecutive endo-
scopic cohort over an 11 years period.
results: 15 patients out of 2.515 emergency esophagogastroduodenoscopy 
[EGDS] (0.59%) were found with AEN. Only 1 out of 23.455 patients were 
diagnosed during elective EGDS (0.004%). Median age was 75 yrs (range 
47-89), 63% were men. Upper gastrointestinal bleeding was the clinical 
presentation and indication for endoscopy in 13 patients (81.25%). In the 
other three cases, anemia, persistent vomiting and dysphagia were the in-
dications for EGDS. Only three patients presented hypotension at the time 
of endoscopy. AEN involved the entire length of esophagus in 7 patients 
(43%); distal third in 5 patients (32%) and inferior two thirds in 4 patients 
(25%). Concomitant duodenal abnormalities were reported in 12 patients 
(75%): 8 patients presented frank duodenal ulcers and 2 patients present-
ed duodenal erosions, whereas the other 2 patients a necrotic aspect of 
duodenum was found. 
Further endoscopic findings included 7 cases of hiatal hernia, one case of 
Mallory-Weiss lesion, one case of oozing bleeding from the distal esopha-
gus, in one case, a gastric volvulus was diagnosed. No gastric endoscopical 
abnormalities were described with the exception of one patient presenting 
necrotic aspect of pylorus.
Laboratory findings showed anemia in 11 patients (68%), neutrophilic 
leucocytosis in 13 patients (81%) elevated creatinine level reported in 12 
patients (75%), hyperglycemia observed in 13 patients (81%). 
All patients reported one or more pre existing comorbidities: 7 patients 
(43%) were diabetic, 5 patients (31%) had history of chronic renal failure, 
3 patients (18%) had cardiovascular disease, 2 patients (12.5%) had active 
malignancy.
Acute events were reported in almost all patients: 7 cases (43%) pneumo-
nia, 6 cases (37%) acute renal failure, 2 cases (12.5%) Clostridium Difficile 
colitis, 1 case acute myocardial infarction and one patient developed AEN 
few days after orthopaedic surgery. Two patients developed AEN as first 
presentation of Zollinger Ellison Syndrome.
conclusion: AEN is a rare cause of upper gastrointestinal bleeding repre-
senting the most common clinical manifestation of this disorder. Concomi-
tant duodenal alterations are associated in two third of cases. Exception-
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ally, AEN is observed in elective endoscopy. Combination of acute events 
and pre-existing comorbities characterize the clinical setting in which AEN 
may arise.
disclosure: Nothing to disclose 
P1532 WIThdraWn
P1533 POLysOMnOgraPhIc assessMenT Of resPIraTOry 
dIsTurBance durIng deeP PrOPOfOL sedaTIOn fOr endOscOPIc 
suBMucOsaL dIssecTIOn Of gasTrIc TuMOrs
Uesato M., Urahama R., Aikawa M., Maruyama T., Matsubara H.
Chiba University Graduate School of Medicine, Frontier Surgery, Chiba, Japan
contact e-Mail address: uesato@faculty.chiba-u.jp
Introduction: Although drug-induced sedation can improve outcomes in 
advanced gastrointestinal endoscopic procedures, sedation-related criti-
cal cardiorespiratory complications are of significant concern, and recent 
guidelines recommend pulse oximetry monitoring during sedation.
aims & Methods: To investigate that polysomnographic monitoring can 
accurately evaluate respiratory disturbance incidence during sedation for 
gastrointestinal endoscopy compare to pulse oximetry alone.This prospec-
tive observational study included 10 elderly patients with early gastric can-
cer undergoing endoscopic submucosal dissection (ESD) under propofol 
sedation. Apart from routine cardiorespiratory monitoring, polysomnog-
raphy measurements were acquired. The primary hypothesis was tested by 
comparing the apnea hypopnea index (AHI), defined as the number of ap-
nea and hypopnea instances per hour during sedation, with and without 
hypoxemia; hypoxemia was defined as the reduction in oxygen saturation 
by ≥3% from baseline.
results: Polysomnography (PSG) detected 207 respiratory disturbances in 
the 10 patients. PSG yielded a significantly greater AHI (10.44 ± 5.68 hour−1) 
compared with pulse oximetry (1.54 ± 1.81 hour−1, p < 0.001), thus support-
ing our hypothesis. Obstructive AHI (9.26 ± 5.44 hour−1) was significantly 
greater than central AHI (1.19 ± 0.90 hour−1, p < 0.001). Compared with 
pulse oximetry, PSG detected the 25 instances of respiratory disturbances 
with hypoxemia 107.4 seconds earlier on average.
conclusion: Compared with pulse oximetry, PSG can better detect respira-
tory irregularities and thus provide superior AHI values, leading to avoid-
ance of fatal respiratory complications during ESD under propofol-induced 
sedation.
disclosure: Nothing to disclose 
P1534 PhOTOdIagnOsIs Of gasTrIc adenOcarcInOMa In raTs
Khorovodov A.1, Kanevskii M.1, Agranovich I.1, Vaschenko T.1, 
Gisbrecht A.2, Navolokin N.1,3, Genova-Hristova T.1,2, Maslyakova G.3, 
Borisova E.1,2, Galitskaya A.1, Konnova S.1, Semyachkina-Glushkovskaya O.1
1Saratov State University, Interdisciplinary Center of Critical Technologies in 
Medicine, Saratov, Russian Federation, 2Institute of Electronics, Bulgarian 
Academy of Sciences, Sofia, Bulgaria, 3Saratov State Medical University, 
Saratov, Russian Federation
contact e-Mail address: matvejkanev@mail.ru
Introduction: Gastric cancer is one of the most common oncological dis-
eases, which is diagnosed only at the last stage1. Photodiagnosis (PDD) is 
a promising method in the diagnosis of stomach cancer2. However, this 
method has drawbacks: similar spectra for inflammation and cancer3. The 
search for effective diagnostic parameters of PDT can give an impulse for 
progress in the early diagnosis of gastric cancer and reduce the mortality 
from this disease. Here we analyzed parameters of PDD that might be ef-
fective for early prognosis of gastric cancer in rats.
aims & Methods: The results were carried out with adult rats using our 
model of gastric adenocarcinoma4,5 induced by combination of two factors: 
1) stress (overpopulation) and 
2) nitrites: toluidine (2g/kg) in food and nitrites (2g/l) in water. 
Rats underwent chronic social stress for 9 months. The upper endoscopy 
was performed using our in-house custom-made multichannel endoscopy 
system. Histological assay was performed to analyze the changes in the 
gastric tissues. Biochemical analysis were used for additional confirma-
tion of oncological changes: the levels of sialic acids, TBA-active products, 
lactic acid were measured by standard methods given in test kits.
Delta-ALA (20 mg/kg) was applied intravenously 2 hours before the spec-
troscopic observation. Excitation source at 405 nm (AFS-405, Polironik 
Ltd., Moscow, Russia) coupled with fiber-optical probe with 25 mW out-
put power on the end of the fiber tip was used for induction of 5-ALA-
PpIX fluorescence in the lesions under interest. Fluorescence emission of 
endogenous autofluorescence (420-630 nm) and exogenous 5-ALA/PpIX 
fluorescence (630-710 nm) was detected using microspectrometer coupled 
to the fiber probe (USB4000, Ocean Optics Inc., Dunedin, USA).
results: Our results demonstrated that in 9 months of observation all rats, 
that underwent chemical and social stress showed development of peptic ul-
cers. In 38% of rats with peptic ulcers were associated with intestinal meta-
plasia of goblet cells, which is morphological pre-cancer symptom. Other 
62% of rats had gastric adenocarcinoma. Tumor lesions were accompanied 
by the migration of cancer cells through the lymphatic vessels to the liver and 
the lungs. The number of metastatic nodes varied from 1 to 5.
Development of gastric adenocarcinoma was confirmed by biochemical 
analysis of blood serum. Levels of sialic acids, TBA-active products, lactic 
acid increased significantly in all animals with gastric cancer.
The spectral measurements were made on normal mucosa and suspicious 
sites. Normal mucosa has significant autofluorescence. The tumor area has 
reduced autofluorescence signal and well pronounced signal at 635 nm 
and 704 nm, typical for 5-ALA/PpIX. Inflammatory areas showed inter-
mediate levels of the fluorescence at 635-704 nm. However, the spectral 
intensity at 635 nm was two times lower than the signal obtained from 
cancerous sites, which allows to differentiate the areas based on the spec-
troscopic detection of exogenous fluorophores.
conclusion: Collectively, our results clearly show that combination of two 
factors as chronic social stress and nitrites in food provoke gastric adeno-
carcinoma formation in rats. The intensity of autofluorescence signal is a 
marker of gastric mucosa injuries. The analysis of two specific maxima of 
laser at 635 nm and 704 nm in PDD demonstrate more effectiveness of 
spectral intensity at 635 nm for early differentiation of areas based on the 
spectroscopic detection of exogenous fluorophores.
This work was supported by Grant of Russian Science Foundation №18-
15-00139.
references: 1) Torre, Lindsey A., et al. “Global cancer statistics, 2012.” CA: a 
cancer journal for clinicians 65.2 (2015): 87‐108; 
2) Namikawa T. et al. Clinical applications of 5-aminolevulinic acid-me-
diated fluorescence for gastric cancer. World J Gastroenterol. 2015 Aug 7; 
21(29): 8769-8775; 
3) Borisova E., et al. 5-ALA Mediated Fluorescence Detection of Gastroin-
testinal Tumors”, Adv Opt Tech, ID 862081, 7 pages doi:10.1155/2008/862081 
(2008) 
4) Ulanova M. et al. “Stress-Induced Stroke and Stomach Cancer: Sex Dif-
ferences in Oxygen Saturation.” Oxygen Transport to Tissue XXXVIII, Ad-
vances in Experimental Medicine and Biology 923, DOI 10.1007/978-3-319-
38810-6_18. 
5) Khorovodov A. et al. The role of stress and nitrosamines in the develop-
ment of gastric cancer: a new model of adenocarcinoma formation with 
metastases in rats / United European Gastroenterology Journal. Vol. 5.5_
suppl.: A837-A875. 2017.
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P1535 PhOTOgraPhIc dOcuMenTaTIOn Of uPPer 
gasTrOInTesTInaL LandMarks aT gasTrOscOPy: 
hOW gOOd Is IT?
Patel R.N., Christie S., Canda R., El-Masry A., Besherdas K.
Royal Free London NHS Trust, Gastroenterology, London, United Kingdom
contact e-Mail address: rajan.patel@nhs.net
Introduction: The British Society of Gastroenterology (BSG) and Associa-
tion of Upper Gastrointestinal Surgeons (AUGIS) recently published a posi-
tion statement in view of the variability of performance of a high-quality 
gastroscopy and an unacceptably high rate of failure to diagnose cancer 
at endoscopy. This set out the minimum expected standards in diagnos-
tic upper gastrointestinal endoscopy. One recommendation is that photo-
documentation should be made of relevant anatomical landmarks and any 
detected lesions. This practice encourages mucosal cleansing, mucosal in-
spection and ensures a complete examination. The European Society of 
Gastrointestinal Endoscopy (ESGE) guidelines describe a systematic ap-
proach to photo-documentation with a recommendation of eight anatomi-
cal landmarks to improve diagnostic endoscopy quality of endoscopy.
807Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
aims & Methods: The aim of this study was to retrospectively assess the 
photo-documentation at gastroscopy in clinical practice and compare this 
to the recommended sites as per the ESGE guidelines. This was a single 
centre, retrospective analysis of 250 consecutive gastroscopies in a district 
general hospital endoscopy unit in London over a two week period from 
2nd April 2019. The gastroscopy reports were scrutinized for photographic 
evidence of the anatomical landmarks. The images capture on the Uni-
soft GI Reporting Tool were analysed and compared to the recommended 
ESGE guidelines. The patient comfort scores of the procedures (0 = no 
discomfort, 1 = one or two episodes, 2 = more than 2 episodes, 3 = sig-
nificant discomfort) were examined in relation to number of photographs 
obtained.
results: Of the 250 gastroscopies performed, the eight anatomical land-
marks were photographed during only 33 procedures (13%). In these 33 
procedures the patient comfort scores were >1 (more than two episodes of 
discomfort) in 3 patients (9%) compared with 60 (28%) in the 217 patients 
with suboptimal photo-documentation (p = 0.02). In the 33 procedures 
where all the landmarks were photographed; 22 patients (66%) had seda-
tion, 11 (33%) patients had xylocaine throat spray.
anatomical site site photographed, n (%)
Upper Oesophagus 77 (31%)
Gastro-Oesophageal 178 (71%)
Fundus in retroflexion 126 (50%)
Body of stomach 130 (52%)
Incisura in retroflexion 70 (28%)
Gastric Antrum 148 (59%)
Duodenal bulb 98 (39%)
Duodenum second part 178 71%)
[Table 1. Frequency of anatomical sites photographed during gastroscopy.]
conclusion: In this study, photographic evidence of anatomical landmarks 
as per ESGE guidelines is only documented in 13%. Better comfort scores 
and procedures under conscious sedation increase compliance with op-
timal photo-documentation. Photographic documentation improves the 
diagnostic quality of endoscopy and acts as a medico-legal record of an 
adequate/complete procedure. There is much room for improvement in 
the photographic documentation of anatomical landmarks during gastros-
copy.
disclosure: Nothing to disclose 
P1536 OdynOPhagIa - Is IT a syMPTOM WOrThy Of urgenT 
gasTrOscOPy?
Patel R.N., Canda R., Haghollahi S., Besherdas K.
Royal Free London NHS Trust, Gastroenterology, London, United Kingdom
contact e-Mail address: rajan.patel@nhs.net
Introduction: Odynophagia is defined as a painful sensation in the oesoph-
ageal region that occurs in relation to swallowing. Endoscopy is the gold 
standard investigation for the diagnosis of mucosal lesions in the oesoph-
agus. Unlike dysphagia, which has historically been an alarm symptom 
of oesophageal cancer, odynophagia does not form part of the suspected 
upper gastrointestinal (GI) cancer referral in the UK.
aims & Methods: We aimed to compare the standard ‘red flag’ indica-
tions for gastroscopy to odynophagia in terms of cancer detection. A ret-
rospective analysis of all patients who underwent upper GI endoscopy for 
standard upper GI ‘two-week-wait’ (2WW) criteria compared with odyno-
phagia as a primary symptom over a 14-year period (2005-2019) within 
an NHS Trust in North London. Data was obtained from the Unisoft En-
doscopy reporting software. The findings at endoscopy for all indications 
were scrutinised.
results: During the study period, a malignant oesophageal tumour was 
identified in 21 patients (4%) endoscoped for odynophagia (total 530 pa-
tients scoped for odynophagia). This compared to Anaemia (17936 endo-
scoped and 94 tumours identified (0.5%)); Dysphagia (10954 endoscoped 
and 562 tumours identified (5%)); Nausea and vomiting (N&V) (6380 en-
doscoped and 64 tumour identified (1%)); Weight loss (6157 endoscoped 
and 119 tumours identified (2%)).
Of the 530 patients who were endoscoped for odynophagia during the 
study period, 240 (45%) had oesophageal mucosal lesions: Reflux 
oesophagitis 193 (36%); Barrett’s oesophagus (26 (5%); Malignant tumour 
21 (4%). 32 (6%) had an oesophageal stricture.
Indication for 
gastroscopy
number of 
endoscopies
Malignant tumour 
identified (%)
Odynophagia 530 4
Dysphagia 10954 5
Anaemia 17936 0.5
Nausea/Vomiting 6380 1
Weight loss 6157 2
[Table 1. Indication for gastroscopy and percentage of cancers detected]
conclusion: From this study, almost half of patients endoscoped for ody-
nophagia have a positive endoscopic mucosal abnormality. 4% of patients 
endoscoped for odynophagia had oesophageal cancer compared with 5% 
of dysphagia patients. Anaemia (0.5%), weight loss (2%) and N&V (1%) 
all have inferior cancer pick up rates. We recommend that odynophagia be 
re-classified as an ‘alarm symptom’ and those presenting with this signifi-
cant symptom undergo an urgent upper GI endoscopy to define the exact 
mucosal abnormality and exclude oesophageal cancer.
disclosure: Nothing to disclose 
P1537 LOng TerM OuTcOMes Of endOscOPIc suBMucOsaL 
dIssecTIOn fOr earLy gasTrIc neOPLasIa: a sIngLe cenTer 
ITaLIan exPerIence
Belletrutti P.J.1, Palma R.1, Maselli R.1, Galtieri P.A.1, Ormando V.M.1, 
Carrara S.1, Anderloni A.1, Fugazza A.1, Pellegatta G.1, Di Leo M.1, 
Romana C.1, Cappello A.1, Spadaccini M.1, D’Amico F.1, Craviotto V.1, 
Lamonaca L.1, Colombo M.1, Capogreco A.1, Attardo S.1, Spaggiari P.2, 
Repici A.1
1Humanitas Clinical and Research Center and Humanitas University, 
Digestive Endoscopy Unit, Rozzano (MI), Italy, 2Humanitas Clinical and 
Research Center and Humanitas University, Rozzano (MI), Italy
contact e-Mail address: rossellapalma89@gmail.com
Introduction: The endoscopic submucosal dissection (ESD) is the treatment 
of choice for most gastric superficial neoplastic lesions owing to its poten-
tial for a curative en bloc resection and low risk of recurrence. At a mini-
mum, ESD allows a complete histopathological evaluation of the lesion. In 
recent years, good clinical outcomes from several studies have expanded 
the indication criteria for gastric ESD.
aims & Methods: The aim of this study is to report the short- and long-term 
outcomes of a cohort of patients from a single Italian center who under-
went gastric ESD. A retrospective analysis of a prospectively mantained reg-
istry of all gastric ESDs performed at Humanitas Research Hospital during 
a 10-year period (January 2010 - January 2019) was performed. Expanded 
indication criteria for gastric ESD were used. Demographic, clinical, endo-
scopic, histological and follow-up data were extracted and analyzed.
results: During the study period, 158 consecutive gastric lesions were 
treated by ESD. On final pathology, 91 lesions were adenocarcinoma 
(57.4%) with a subclassification of pT1a: 56 (61.5%), pT1b: 31 (34.%) and 
pT2: 4 (4.4%). Thirty-eight lesions were diagnosed as high grade dysplasia 
(24.%), 23 were low grade dysplasia only (14.5.%) and 6 were non-adeno-
matous (3.8%). An en-bloc resection was achieved in 136 patients (86%). 
R0 resection was reported in 116 patients (73,4%), while 30 yielded a R1 
resection (19%) and the remaining 12 procedures (7.6%) were classified 
as Rx. Twenty-two patients (14%) experienced a complication (11 early, 10 
delayed, 1 both early and delayed). The most common complication was 
bleeding (17 patients, 10.7%) while 5 perforations (3%) were reported. All 
these complications were successfully treated endoscopically except 3 pa-
tients who required surgery because recurrent bleeding after failure of en-
doscopic treatment and radiologic embolization in 1 case and due to early 
(1 case) or delayed perforation (1 case). No deaths occurred related to the 
ESD procedure. Overall, 23 patients (14.5%) underwent surgery because 
of non-curative resections. Thirteen patients (8.2) were lost at follow-up. 
Mean follow-up was 37.2 months (range 122-3). During follow-up, 6 local 
recurrences of adenoma with LGD at the previous ESD site were diagnosed 
while 2 patients developed a cancer in a site different from ESD and were 
referred to surgery.
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conclusion: In a large western series of ESD for early gastric neoplasia ESD 
was associated with a significant proportion of curative resection and quite 
low rate of complications as well as disease recurrence. Overall, surgery 
was required in 17.7% mostly because of non-curative ESD resection.
disclosure: Nothing to disclose 
P1538 usefuLLness Of TransnasaL hyBrId endOscOPIc 
suBMucOsaL dIssecTIOn
Minato Y., Ohata K., Matsuhashi N.
NTT Medical Center Tokyo, Gastroenterology, Tokyo, Japan
contact e-Mail address: yoheiminato55925@gmail.com
Introduction: Endoscopic Submucosal Dissection (ESD) is technically dif-
ficult and time-consuming procedure which is usually performed under 
sedation. Therefore, ESD has definite risks especially for elderly patients. 
And due to the physiological constriction, the conventional scope is some-
times not reached to the target lesions. In these situations, transanal hy-
brid ESD(T-ESD) maybe alternative therapeutic option for superficial gas-
trointestinal neoplasms.
aims & Methods: We evaluated the clinical outcome of T-ESD. After in-
formed consent, T-ESD was performed without sedation for elderly pa-
tients whose age were over 80 years old or the patient having the trouble 
of physiological constriction. For this study, the target size was defined 
10mm or less intramucosal gastric cancer. And the ulcerative lesions were 
excluded. Clinical characteristics and outcomes were evaluated retrospec-
tively. 13 gastric lesions were resected by T-ESD between April 2016 and 
March 2019. All of the T-ESD steps were performed using EG-580NW2 
endoscope (Fujifilm, Tokyo, Japan), with a diameter of the distal end of 
5.8mm and inner diameter of the instrument channel of 2.4mm and a 
newly developed multifunctional snare ‘SOUTEN’ (Kaneka Medics, Tokyo, 
Japan) which is design to achieve Hybrid ESD which is available through 
the transnasal endoscope. The knobshaped tip attached to the loop top 
helps to stabilize the needle-knife, making it less likely to slip during cir-
cumferential incision and enables partial submucosal dissection. For he-
mostasis, RAICHO(Kaneka Medics, Tokyo, Japan) was used which ensure 
the suction ability of the scope even with the transnasal endoscope.
results: The mean age was 80.5±6.5 years old, the male to female ra-
tion was 8:5. The lesions locations were U/M/L:1/5/7. Mean tumor size 
and resected specimen size were 10.4±3.2mm and 21.1±6.0mm. And mean 
procedure time was 15.3±3.1min. En-bloc R0 resection rate were 100% re-
spectively. In all patients, face scale was 1 and oxygen saturation could 
keep more than 95% during procedure, therefore oxygen administration 
was not needed. Incidence of perforation and postoperative hemorrhage 
were 0% and 7.7%(1/13).
conclusion: We confirmed favorable clinical outcomes of T-ESD. On the 
other hand, We need pay attention to the fact that the weaker suction abil-
ity and lack of the water jet may make hemostasis more difficult to achieve. 
Though we believe this is a useful therapeutic option, additional studies 
would be needed to determine if this modality is also useful for beginners.
disclosure: Nothing to disclose 
P1539 InTernaTIOnaL MuLTIcenTer sTudy On The 
ManageMenT Of PaTIenTs afTer faILed PerOraL endOscOPIc 
MyOTOMy (POeM)
Assis D.1, Brewer Gutierrez O.1, Sloan J.2, Eleftheriadis N.3, 
Albéniz-Arbizu E.4, Vosoughi K.5, Ichkhanian Y.6, Cho J.Y.7, Khashab M.A.8, 
Draganov P.V.9, Familiari P.10, Yang J.5, Barret M.11, Runge T.2, Pioche M.12, 
Marks J.13, AbiMansour J.14, Su B.15, Ujiki M.16, Perbtani Y.17, Bechara R.18, 
Tantau M.V.19, Patel M.20, Velanovich V.21, Haji A.22, Kumta N.23, Sippey M.24, 
Aghaie Meybodi M.25
1Johns Hopkins University, Medicine-Gastroenterology and Hepatology, 
Baltimore, United States, 2Johns Hopkins, Gastroenterology, Baltimore, 
United States, 3Metropolitan Hospital Athens, Athens, Greece, 4Complejo 
Hospitalario de Navarra, Servicio Aparato Digestivo, Pamplona, Spain, 
5Johns Hopkins Medical Institution, Division of Gastroenterology and 
Hepatology, Baltimore, United States, 6The Johns Hopkins Hospital, 
Medicine, Baltimore, United States, 7Soonchunhyang University College of 
Medicine, Seongnam, Korea (Republic of), 8The Johns Hopkins Hospital, 
Baltimore, United States, 9University of Florida, Gainesville, United States, 
10Gemelli University Hospital - IRCSS, Digestive Endoscopy Unit - Department 
of Gastroenterological, Endocrinometabolic and Nephro-Urological Sciences, 
Roma, Italy, 11Cochin Hospital, Gastroenterology, Paris, France, 12Hospices 
Civils de Lyon, Gastroenterology and Endoscopy, Lyon, France, 13Case 
Western, University Hospitals, Cleaveland, United States, 14The Johns Hopkins 
Hospital, Internal Medicine, Baltimore, United States, 15University of Chicago, 
Chicago, United States, 16Northshore University Health System, Highland 
Park, United States, 17University of Florida, Gastroenterology, Gainesville, 
United States, 18Queen’s University Division of Gastroenterology Kingston 
General and Hotel Dieu Hospitals, Kingston, Canada, 19Hepatology Institute 
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Romania, 20King’s Institute of Therapeutic Endoscopy, Gastroenterology, 
London, United Kingdom, 21University of South Florida, Tampa, United States, 
22Kings College Hospital, Colorectal Surgery, London, United Kingdom, 23New 
York Presbyterian Hospital, Gastroenterology, New York, United States, 24Case 
Western, University Hospitals, Cleveland Medical Center, Cleveland, United 
States, 25Johns Hopkins, Baltimore, United States
contact e-Mail address: yichkha1@jhmi.edu
Introduction: Peroral Endoscopic Myotomy (POEM) is considered a primary 
treatment for patients with achalasia and a safe alternative to pneumatic 
dilation (PD) and laparoscopic Heller myotomy (LHM). Although highly ef-
fective, clinical failure may occur. It is currently unknown how patients who 
fail POEM are best managed. Options include conservative management, 
botulinum toxin injection (BTX), redo POEM, PD, and LHM.
aims & Methods: 
(1) To describe a cohort of patients who failed POEM; 
(2) Compare clinical success [Eckardt ≤ 3] and safety [severity of adverse 
events (AEs) per ASGE Lexicon] of the above described treatment modali-
ties in patients with failed POEM. 
This is an international, multicenter, retrospective study at 19 tertiary cen-
ters between 1/2012 and 8/2018. All patients who underwent POEM for 
the treatment of achalasia, esophagogastric junction outflow obstruction 
(EGJOO), hypercontractile esophagus (Jackhammer), and diffuse esopha-
geal spasm (DES), who failed POEM were included. Patients with an Eck-
ardt score >3 after POEM or during follow-up were considered clinical 
failures.
results: A total of 3251 patients underwent POEM and 110 (3.38%) ex-
perienced clinical failure (46.46% F, mean age 51yr). Main type of mo-
tility disorder was achalasia (82.72 %) and most commonly was type 2 
(46.36%). The mean integrated relaxation pressure (IRP) after failed POEM 
was 15.28±11.97 mmHg. The mean Eckardt score prior to retreatment was 
5.64±2.24. A total of 38 (34.5%) patients underwent redo POEM, 28 (25.5%) 
had PD, 4 (3.6%)had standard balloon dilation, not pneumatic, 8 (7.3%) 
LHM, 2 (1.8%)BTX, and 30 (27.3%) were treated conservatively (Table 1). 
Regarding retreatment, in the redo POEM group, the mean length of 
esophageal and gastric myotomy were 6.77±3.25 and 2.8±1.4 cm, respec-
tively, and mean procedure time was 116.43 ± 65.07 min. In the retreatment 
with LHM group, the mean length of esophageal and gastric myotomy 
were 4.4±2.7 and 2.4±0.54 cm, respectively, and the mean procedure time 
was 135 ±17.32 min. In the PD group, mean dilation diameter and proce-
dure time were 32.31±3.53 mm [1 dilation (n=18), 2 dilation (n=10) ses-
sions] and 20.91±21.2 min. Overall, clinical success was achieved in 40/80 
(50%) patients who underwent retreatment during a mean follow-up of 
265.76 days. Two (5.2%) patients had AEs during redo POEM [1 muco-
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sotomy (mild) and 1 esophageal leak (moderate)]. Mean Eckardt score 
post retreatment was 2.83±2.38 [2.19±2.2 in Redo POEM, 3.28±2.4 in PD, 
4.2±2.8 in LHM]. Clinical success was similar between redo POEM, PD and 
LHM (p=0.096). PD had the shortest mean procedure time (p< 0.001), and 
length of hospitalization
(1.1 vs 1.92 vs 2.5 d; p=0.006) (Table 1).
conclusion: This international study comprehensively assessed a cohort of 
patients who failed POEM. Redo POEM, LHM, and PD are equally effective 
and safe retreatment options for these patients.
disclosure: This abstract has been submitted and accepted for oral presen-
tation at the Digestive Disease Week (DDW) 2019. 
P1540 PrOsPecTIve randOMIzed sTudy On The use Of a 
cOMPuTer-Based endOscOPIc sIMuLaTOr fOr TraInIng In 
esOPhagOgasTrOduOdenOscOPy
Ait Errami A.1, Jiddi S.2, Oubaha S.3, Zouhour S.3, Krati K.3
1Mohammed VI, Hepatogastroenterology, Marrakech, Morocco, 2UHC 
Mohammed VI,, Gastroenterology, Marrakech, Morocco, 3UHC Marrakech, 
Marrakech, Morocco
contact e-Mail address: adil.ae@hotmail.fr
Introduction: Computer-based endoscopic simulators have been devel-
oped in recent years, and their usefulness has been reported. There are 
a few reports that have evaluated the effectiveness and drawbacks of a 
computer-based simulator.
aims & Methods: The present study aimed to assess the effectiveness of a 
computer‐based simulator for basic training in EGD.
The GI-Mentor II simulator was used. The subjects were 16 hospital medi-
cal residents. After receiving an explanation regarding the fundamentals 
of endoscopy, 8 trainees were each randomized into a simulator group and 
a non-simulator group. 
The simulator group received 4h of training with the GI-Mentor II plus 
bedside training, while the non-simulator group received bedside train-
ing. Subsequently, each subject performed endoscopy twice for assess-
ment. Performance was evaluated according to a five-grade scale for a 
total of 11 items.
results: The score was significantly higher in the skills required for inser-
tion into the esophagus, passing from the esophagogastric junction (EGJ) 
to the antrum, passing through the pylorus, and examination of the duo-
denal bulb and the fornix.
conclusion: The performance of endoscopy was improved by 4 h of simu-
lator training. The simulator was more effective with regard to the items 
related to manipulation skills. Computer-based simulator training in EGD 
is useful for beginners.
disclosure: Nothing to disclose 
P1541 IMPLIcaTIOns Of randOM uPPer gI endOscOPIc 
BIOPsIes On cOsT; a reTrOsPecTIve cLInIcaL audIT
Ahmed S.1, Amin M.N.1, Saleem M.U.1, Richards C.2, Robinson R.1
1University Hospitals Leicester, Gastroenterology, Leicester, United Kingdom, 
2University Hospitals Leicester, Histopathology Department, Leicester, United 
Kingdom
contact e-Mail address: saeed5198@gmail.com
Introduction: Oesophago-gastro-duodenoscopy is the major tool for inves-
tigation of Upper GI tract symptoms. In view of recent upcoming cancer 
investigation pathways and campaigns the number of biopsies required is 
likely to increase1. Cancer detection rates remained unchanged by random 
non-diagnostic biopsies2.
Non targetted biopsies to investigate Helicobacter Pylori are not cost ef-
fective as cheaper non invasive modalities are readily available.Literature 
review showed that biopsies for weight loss without serological evidence 
of coeliac disease, is diagnostic in less than 1%3.
aims & Methods: This retrospective clinical audit was performed on all 
diagnostic gastroscopies at the University Hospitals of Leicester within the 
month of January in 2018. In the initial audit cycle,practice was compared 
to British Society of Gastroenterology guidelines, recently published rec-
ommendations from the Newcastle group as well as our local biopsy pro-
tocol 4,5. All planned therapeutic procedures as well as incomplete or failed 
procedures were excluded.The local guidelines were updated following 
initial audit results and disseminated across the trust. Practice was then 
re-audited against the updated guidelines. Finally the findings were anal-
ysed to evaluate any cost implications.
results: First cycle: A total 731 gastroscopies were performed during Jan-
uary 2018. Diagnostic biopsies were obtained in 261 out of 570 eligible 
cases.According to study criteria total of 102 (13.95%) out of 731 patients 
were biopsied inappropriately.The assumed cost of a single biopsy set was 
around 145£. The monthly cost of unnecessarybiopsies was 14,790£ (esti-
mated to be 177,480£ annually).
Second cycle: A total of 802 gastroscopies were performed during January 
2019.Diagnostic biopsies were obtained in 253 out of 666 eligible patients.
According to the study criteria 66 (8.2%) out of 802 biopsies were ob-
tained inappropriately. Keeping the assumed cost for the single biopsy set 
remained unchanged.The monthly cost was therefore 9,570£ (estimated to 
be 114,840 annually).
conclusion: We have detected a sizeable number of inappropriate biopsies 
resulting from local and national guidelines not being followed. This has 
a significant cost implication.By updating local protocols and emphasising 
the importance of avoiding unnecessary non targeted biopsies we have 
demonstrated potentially significant cost savings.
references: 1.Teriaky A, AlNasser A, McLean C, et al. The utility of endoscop-
ic biopsies in patients with normal Upper Endoscopy.Can J Gastroenterol-
Hepatol2016;2016:1-7. 2. Cadman B, Dixon MF, Wyatt JI. Value of routine, 
non-targeted biopsies in the diagnosis of gastric neoplasia.J ClinPathol1997; 
50:832-4. 3.Kotha S, Holohan C, Gera A, et alPTH-032 D2 biopsies in weight 
loss referrals - is it necessary and cost effective? Gut 2015;64:A420. 4.Beg 
S, et al. Quality standards in upper gastrointestinal endoscopy a position 
statement of the British Society of Gastroenterology(BSG) an Association 
of upper gastrointestinal surgeons of Great Britain and Ireland(AUGIS).Gut 
2017;0:1-14. doi:10.1136/gutjnl-2017-314109 5.Gibson V, Needham S, Nayer 
M, et alDo non-targeted gastric biopsies affect the management of pa-
tients, and can a simple protocol and education reduce the rate? Frontline 
Gastroenterology 2018;9:67-72.
disclosure: Nothing to disclose 
P1542 cOrreLaTIOn Of endOscOPIc and hIsTOLOgIcaL 
feaTures In aduLTs WITh susPecTed ceLIac dIsease
Salma B.1, Sabbah M.2, Kchaou Ouakaa A.1, Trad D.2, Elloumi H.2, 
Gargouri D.2
1Habib Thameur Hospital, Gastroenterology, Tunis, Tunisia, 2Habib Thameur 
Hospital, Tunis, Tunisia
contact e-Mail address: baghdadi.selma@gmail.com
Introduction: Clinical presentation of celiac disease is extremely variable 
and the diagnosis relies on serologic tests, mucosal intestinal biopsy and 
clinic and serologic response to a gluten-free diet. The aim of our study is 
to correlate the endoscopic and histological aspects of adult patients with 
suspicion of celiac disease and to evaluate the correlation with histological 
findings.
aims & Methods: A retrospective study was conducted between January 
2015 and december 2018. Endoscopic aspects of 61 adult patients were 
evaluated and correlated with the histological features according the 
Marsh classification system.
results: Sixty one patients were included, mean age was 42.9 years[ 16-83] 
and sex ratio was 0.8. No statistically significant correlation was showed 
between the age and gender and pathology features and endoscopy mani-
festations (p>0.05).
The most prevalent clinical data in patients with histological diagnosis of 
CD were iron-deficiency anemia (29.5%), chronic diarrhea (9.8%), and 
malabsorption syndrome (8.2%).
The endoscopic study of the duodenum showed: normal mucosa in 5 
cases (8.2%); scalopping folds in 3 (4.9%), and total villous atrophy in 
52 (85.2%). Among these patients, histological examination showed CD 
in 38(23%) ,intraepithelial lymphocytosis in 40(65.5%)and was normal in 
9(5.4%) We did not observe a significant correlation between endoscopy 
results and pathology features (p=0.235).
conclusion: Our data confirmed Endoscopic markers have disappointing 
sensitivity. Endoscopic markers of villous atrophy are not useful for screen-
ing for celiac disease and duodenal histological assessment remains man-
datory
disclosure: Nothing to disclose 
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P1543 gasTrIc Per OraL endOscOPIc PyLOrOMyOTOMy 
(g POeM) fOr refracTOry gasTrOParesIs: a sIngLe cenTre 
exPerIence
Gunasingam N.1, Patel M.1, Gulati S.1, Haji A.2, Hayee B.3
1King’s Institute of Therapeutic Endoscopy, Gastroenterology, London, 
United Kingdom, 2King’s College Hospital, Colorectal Surgery, London, 
United Kingdom, 3King’s College Hospital, Gastroenterology, London, United 
Kingdom
contact e-Mail address: nishmi@gmail.com
Introduction: Gastroparesis (GP) is a disorder evidenced by delayed gastric 
emptying in the absence of mechanical obstruction, commonly idiopathic 
or secondary to diabetes mellitus. G-POEM has been used to treat refrac-
tory gastroparesis and we present our initial experience with this novel 
endoscopic technique.
aims & Methods: All patients undergoing G-POEM for refractory GP from 
May 2018 onwards were included, with data extracted from the hospi-
tal electronic patient record. Procedures were performed by one endos-
copists at our centre with experience in submucosal endoscopy. Efficacy 
at 3 months was assessed by reduction of symptom score (Gastroparesis 
Cardinal Symptom Index; GCSI), with secondary considerations including 
technical success, procedural complications, hospital length of stay and 
hospitalisations after treatment.
results: 10 patients (10F; mean age 40.3± 15.4 y) were included (5 diabetic, 
5 idiopathic). Mean duration of disease was 9.5± 5.6 y, with 4 months me-
dian duration of follow-up post-procedure. 6 patients had previous treat-
ment with botulinum toxin, and one gastric electrical stimulator. Technical 
success was achieved in all cases while, at 3 months, 8 had improvement 
total GCSI (mean scores 3.978 vs 2.076 (p = 0.008)) and each GCSI subtype 
score: nausea and vomiting (3.63 vs 1.70, p = 0.012); fullness (4.30 vs 2.30, p 
=0.012); bloating (4 vs 2.22, p = 0.28). Mean hospital stay was 9± 13 d, with 
5 patients staying less than 4 days and two with prolonged admission. 
One significant adverse event was recorded: abdominal collection around 
the myotomy site requiring a prolonged hospital admission of 18 days for 
intravenous antibiotics in one patient. 
Only one patient required hospitalisation for gastroparesis symptoms after 
their G-POEM procedure (this was the same patient who did not achieve 
clinical success with reduction in their GCSI scores).
conclusion: G-POEM is a promising therapeutic treatment for patients with 
refractory GP, with significant improvement in symptoms and, in our co-
hort a dramatic reduction in the need for hospitalisation in short-term fol-
low up. A European sham-controlled study is under way and longer-term 
data are required to confidently determine its role in the management of 
such a challenging condition.
disclosure: Nothing to disclose 
P1544 LOng-TerM OuTcOMes afTer Per-OraL endOscOPIc 
MyOTOMy fOr TreaTMenT Of esOPhageaL achaLasIa
Pellegatta G.1, Maselli R.1, Galtieri P.A.1, Belletrutti P.1, Carlani E.1, 
Omodei P.D.2, Preatoni P.1, Castoro C.3, Spadaccini M.1, Fugazza A.1, 
Palma R.1, Ormando V.1, Repici A.1
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Introduction: Per-oral endoscopic myotomy (POEM) is a relatively novel 
endoscopic therapy for esophageal achalasia. The outcome and safety of 
peroral endoscopic myotomy (POEM) in patients with achalasia has been 
mostly reported with relatively short/mid-term follow-up data. As a matter 
of fact, studies reporting long-term clinical outcomes and the incidence of 
gastroesophageal reflux (GER) after POEM are still limited.
aims & Methods: The aim of this study was to assess the long-term out-
comes and the incidence of GER in a cohort of consecutive patients treated 
with POEM for achalasia between June 2012 and December 2015. A retro-
spective analysis of a prospectively maintained procedure database was 
conducted and included clinical assessment in combination with findings 
at interval upper GI endoscopies, manometry and pH monitoring. Sched-
uled follow-up included clinical assessment by Eckardt symptoms, high 
resolution manometry, upper-gastrointestinal endoscopy and pH monitor-
ing at 3-6, 12-24, 36 and 60 months after POEM. A post-POEM Eckardt 
score ≤3 was considered a clinical success. Regarding pH monitoring, a 
percentage of time with esophageal exposure to acid (pH < 4) > 4.2% was 
considered positive for GER .
results: A total of 60 achalasia patients (type I 9.8%, type II 82.3% and 
type III 7.9%) with follow-up longer than 36 months were included. The 
median age of the patients was 54 years (range 17-86); no patients with 
ASA class IV were treated with POEM. Nineteen patients had received prior 
interventional treatment (32.7%) and five patients had a sigmoid esopha-
gus (8,3%). 
Adverse events occurred in 7 patients (11.6%); according to the AGA Lexicon 
classification, 5 were mild, 2 were moderate. Median length of hospital 
stay was 2.1 days (range 1-9). 
The mean pre-POEM Eckardt score was 6.5 (±2.3) and it significantly de-
creased 3-6 months after POEM (0.75±1.5, p< 0.0001), remaining stable 12-
24, 36 and 60 months after POEM (0.74±1.1, 1.11±1.7 and 0.88±1.5, respec-
tively; p< 0.0001). The mean integrated relaxation pressure (IRP) before 
POEM was 26.12±11.2 mmHg and significantly decreased at 3-6 months af-
ter POEM (9.42±3.54 mmHg, p< 0.0001), remaining stable 12-24, 36 and 60 
months after POEM (9.81±3.9, 9.6±5 and 10.6±4.5, respectively; p< 0.0001). 
During follow-up, clinical success was maintained in 95% at 3-6 months, 
93.3% at 12-24 months, 91.6% at 36 months and 90% at 60 months after 
POEM. 
Clinical reflux symptoms occurred in 25%, 28.3%, 23.3% and 17.7% of 
patients, respectively, after 3-6, 12-24, 36 and 60 months after POEM. 
Upper-GI endoscopy revealed erosive esophagitis in 30%, 28.3%, 31.6% 
and 35.0% of patients, respectively, at 3-6, 12-24, 36 and 60 months after 
POEM. Cases of Grade C and D erosive esophagitis were present only 3-6 
months after the procedure. There were no confirmed reflux-related post-
POEM strictures or diagnoses of Barrett esophagus. Twenty-four hour pH 
monitoring studies revealed pathological esophageal acid exposure time 
in 26.3%, 24.2%, 27.6% and 20.0% of patients, respectively, 3-6, 12-24, 36 
and 60 months after POEM.
conclusion: POEM is a highly safe and effective treatment for esophageal 
achalasia with favourable clinical outcomes up to 60 months post-proce-
dure. GER occurs 20-30% of patients post-POEM. Moreover, our results em-
phasize the importance of long-term follow-up in all patients after POEM.
references: Cotton PB, Eisen GM, Aabakken L et al. A lexicon for endoscop-
ic adverse events: report of an ASGE workshop. Gastrointestinal Endos-
copy;71: 446-454. Werner YB, Costamagna G, Swanström LL et al. Clinical 
response to peroral endoscopic myotomy in patients with idiopathic acha-
lasia at a minimum follow-up of 2 years. Gut 2016;65(6):899-906. Repici 
A, Fuccio L, Maselli R et al. GERD after per-oral endoscopic myotomy as 
compared with Heller’s myotomy with fundoplication: a systematic review 
with metaanalysis. Gastrointest Endosc 2018; 87: 934-43.
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P1545 The “Over-The-scOPe-grasPer” - a neW InsTruMenT 
fOr fLexIBLe endOscOPy
Epp S.1, Hann A.1, Meining A.2
1Ulm University, Department of Internal Medicine I, Ulm, Germany, 
2University of Würzburg, Gastroenterology, Würzburg, Germany
contact e-Mail address: sonja.epp@outlook.com
Introduction: Removal of blood clots, necrotic tissue and occasionally for-
eign bodies is a significant problem in flexible endoscopy. There are no 
special gripping instruments for the removal of viscous materials and suc-
tion alone is often limited.
aims & Methods: A special gripping instrument (Over-The-Scope-Grasper: 
OTSG) was designed to overcome those problems. It can be attached to 
the tip of a conventional gastroscope, similar to a conventional cap. Two 
excavator-like jaws are attached to the tip of the cap, which can be opened 
and closed by a pull mechanism running on the outside of the endoscope. 
Thus, the working channel of the endoscope remains available for suction/
irrigation or insertion of additional instruments. The total diameter of the 
system is 13 mm.
results: In one patient, the OTSG was used for necrosectomy after the for-
mation of a gastrocystostomy. In another patient, the OTSG was used to 
remove a large coagulum after ESD in the middle esophagus after removal 
with a Dormia basket ended frustrantly. The insertion of the endoscope 
was possible without any problems when the OTSG was closed. By open-
ing and closing the jaws with simultaneous suction, it was possible to 
remove necrotic material or large parts of the coagulum respectively.
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conclusion: The OTSG was successfully used for the removal of necrotic 
tissue and blood clots. Further evaluation based on a larger case series 
is still pending.
disclosure: Nothing to disclose. 
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Introduction: Endoscopic sleeve gastroplasty (ESG) is a relatively novel 
endoscopic procedure that reduces the gastric lumen with proven less 
complications and almost same 6 months weight loss compared to lapa-
roscopic sleeve gastroplasty (LSG). To our knowledge there are no trials 
investigating the role of multidisciplinary evaluation (ME) before and after 
ESG. 
The aims of the present study were to evaluate the role of ME prior and 
after ESG in terms of weight loss outcomes, quality of live improvements 
and adverse events.
aims & Methods: From May 2016 to April 2019 all patients that underwent 
ESG were retrospectively evaluated from a prospective database. Included 
patients had 2° and 3° degree of obesity or 1° with comorbidities. All pa-
tients underwent upper GI endoscopy to exclude pathologies. Until Sep-
tember 2017 before ESG only psychiatric evaluation was requested, while 
after this date we adopted the guidelines of the Italian Society for Obesity 
Surgery and all patients were evaluated on a multidisciplinary fashion 
prior ESG. 
The ME team was composed by: gastroenterologist, surgeon, psychiatrist, 
endocrinologist and dietitian. Patients were divided in two groups: group 1 
were patients with ESG done before ME while group 2 were patients with 
ESG done after ME. 
We compared this two groups in terms of weight loss outcomes, quality 
of life improvements and adverse events. Quality of live was measured 
with the Bariatric Analysis and Reporting Outcome System (BAROS). ESG 
was done with the Apollo Overstitch suturing system (Apollo Endosurgery) 
and a double channel gastroscope Olympus 2TGIF-160 (Olympus Japan) in 
general anesthesia and with insufflation of CO2. 
All patients had ambulatory visit t 1, 3, 6 and 12 months after ESG and 
weight loss outcomes were measured in terms of Excess Weight Loss 
(%EWL), the Total Body Weight Loss (%TBWL) and BAROS scale were as-
sessed. Statistical analysis was done with chi-square test and < 0.05 value 
was considered significant. 
The study was approved by the local Ethical Committee (N° 19211/18).
results: A totally of 89 ESG were performed. Mean procedure time was 51 
minutes (range 28-92). Mean number of stitches were 4.7/patient (range 
3-8). No procedure related complications were observed. Female were 56 
patients; mean age was 45.4 (range 23-73). Mean BMI at inclusion was 
41.6 (range 31.6-62.4).
Twelve months follow-up was done in 34 patients, 6 months in 26, 3 
months in 10, while in 19 patients follow up was 1-month. Mean %EWL 
and %TBWL at 12 months was 37.6 and 15.6 respectively, at 6 months was 
37.1 and 16.7, at 3 months was 30.6 and 13.8, while for 1 month was 16.9 
and 7.8 respectively. Mean Baros score was 4.6 at 12 and 6 months, 3.9 at 
3 months, while for 1 month was 2.7.
Comparing the two groups (11 patients in group 1 and 78 patients in group 
2) there was significant (P< 0.05) difference in terms of %EWL and %TBWL 
(Table 1) for all periods of follow-up, with better results in group 2. There 
was also a significant improvement in the BAROS scale in the patients in 
group 2 (Table 1). 
conclusion: ME before and after ESG has a fundamental role in terms of 
better procedure outcomes for both weight loss and quality of live in obese 
patients.
disclosure: Nothing to disclose 
  WL (kg) %eWL %TBWL BarOs
 
pre-
Me
post- 
Me
pre-
Me
post- 
Me
pre-
Me
post- 
Me
pre-
Me
post- 
Me p
1 month 
follow-up 5.7 10.8 11.5 19.7 5.2 9.1 1.4 3.3 <0.01
3 months 
follow-up 12.1 18.1 23.7 33.7 11 15.2 2.3 4.7 <0.05
6 months 
follow-up 14.1 22.4 26.5 42.2 14.7 18.8 2.5 5.7 <0.01
12 months 
follow-up 14.1 27.5 25.4 48.8 11.7 22 2.5 6.5 <0.01
WL = Weight Loss; eWL = excess Weight Loss; TBWL = Total Body Weight Loss; BarOs = 
Bariatric analysis and reporting Outcome system.
[Table 1. ESG results on 89 patients pre and post multi-disciplinary 
evaluation (ME)]
P1547 endOscOPIc resecTIOn Of nOn-aMPuLLary duOdenaL 
POLyPs: a reTrOsPecTIve sIngLe cenTre exPerIence
Gunasingam N.1, Patel M.1, Gulati S.1, Haji A.2, Hayee B.3
1King’s Institute of Therapeutic Endoscopy, Gastroenterology, London, 
United Kingdom, 2King’s College Hospital, Colorectal Surgery, London, 
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Introduction: Current literature estimates that complete endoscopic resec-
tion (ER) of duodenal adenomas can be achieved in 79-100% of cases, but 
complication rates are high and adenoma recurrence is encountered in up 
to 37% of cases (Basford & Bhandari, 2012). We present our retrospective 
experience.
aims & Methods: Data from the electronic patient record was analysed for 
all patients who underwent duodenal polyp resection from June 2013 were 
included (excl. familial polyposis cases). Procedures were performed by 
either one of two endoscopists with experience in endoscopic resection. 
Accepted definitions of technical success, major adverse events and recur-
rence were used.
results: 31 patients (15F; mean age 67.9± 10.4 y) were included. The mean 
polyp size was 38.8±23.6 mm, with most (n = 26) located within D2. More 
than half were laterally spreading lesions (n=16). The main method of re-
section was with piecemeal EMR (n=24), with 5 removed by en-bloc EMR 
and 2 by ESD. Histology revealed tubular adenoma low grade dysplasia (n 
= 12), tubulovillous adenoma with low grade dysplasia (n = 11) and neu-
roendocrine tumour (n = 3). ER was successful in 28 / 31 cases (90.3%). 
Mean size in 3 incomplete resections was 93mm, with 1 patient referred 
for surgery, 1 repeat ER and 1 did not proceed due to a more pressing 
medical diagnosis. 
3/31 had peri-procedural complications: endoscopically-treated perfora-
tion in 2 (6%) and minor bleeding in 1. 2/31 patients (6%) experienced 
delayed bleeding, with one patient requiring a repeat OGD but no inter-
vention and the other requiring transfusion of packed red blood cells and 
observation in hospital. There was no procedure related mortality. At time 
of writing 4 patients had not yet had surveillance OGD and to date 5 pa-
tients (20.8%) had recurrence all treated endoscopically.
conclusion: ER of duodenal polyps is feasible and safe. Our single centre 
experience is on par with what is published in the literature in regards to 
technical success and adverse events. A prospective analysis would be of 
value to guide patient selection, optimal treatment and surveillance pro-
tocols.
disclosure: Nothing to disclose 
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P1548 LOng-TerM OuTcOMes Of gasTrIc endOscOPIc 
suBMucOsaL dIssecTIOn In endOscOPIc curaBILITy crITerIa
Konishi H., Kuwai T., Moriuchi R., Wada K., Tao K., Miura R., Tamaru Y., 
Kusunoki R., Yamaguchi A., Kouno H., Kohno H.
National Hospital Organization Kure Medical Center and Chugoku Cancer 
Center, Gastroenterology, Kure, Japan
contact e-Mail address: hirox2x4@gmail.com
Introduction: Endoscopic submucosal dissection (ESD) is one of the most 
useful methods for treating early gastric neoplasms, and its indication is 
becoming expansive. The absolute-indication criteria for gastric ESD have 
been expanded in the Japanese gastric cancer treatment guidelines 2018. 
According to the new guidelines, endoscopic curability A (eCura A) is 1) le-
sions of any size without UL, differentiated-type, and pT1a or 2) lesion size 
≤3cm with UL, differentiated-type, and pT1a; whereas endoscopic curabil-
ity B (eCura B) is 3) lesion size ≤2cm without UL, undifferentiated-type, and 
pT1a or 4) lesion size ≤3cm, differentiated-type, and pT1b(SM1, <500µm). 
The eCura A cases are recommended to be followed up by annual EGD, 
whereas the eCura B cases are recommended to be followed by CT or 
US in addition to annual EGD. However, few studies have compared the 
short-/long-term outcomes of gastric ESD between the new endoscopic 
curability criteria.
aims & Methods: This study aimed to evaluate and compare the clinical 
outcomes of ESD in early gastric cancers with eCura A and B lesions. The 
participants included 476 patients with 554 early gastric cancers, diag-
nosed as having eCura A or B lesions. All patients underwent ESD at our 
hospital between June 2007 and August 2018. The patients were divided 
into 2 groups: eCura A lesions (Group A, 419 patients with 483 lesions) 
and eCura B lesions (Group B, 70 patients with 71 lesions). We evaluated 
the clinicopathological findings; short/long-term outcomes including the 
local, distant, and metachronous recurrence rates, and the overall and 
disease-specific survival (OS and DSS) rates.
results: The mean ages of Groups A and B were 72.9 and 68.5 years, re-
spectively, and the male-to-female ratios in Groups A and B were 319/100 
and 56/14, respectively. The mean tumor sizes in Groups A and B were 
15.5 and 13.6mm, respectively. From the histopathological findings, the 
rates of differentiated-type were 100% (483/483) in Group A and 62.0% 
(44/71) in Group B (p< 0.01). Regarding the tumor depth, intramucosal 
carcinomas were 100% (483/483) in Group A and 38.0% (27/71) in Group 
B (p< 0.01), and shallow submucosal invasive carcinomas (< 500µm) were 
62.0% (44/71) in Group B. The en bloc resection rates and curative resec-
tion rates were 100% in both groups. Adverse events included the inci-
dence of postoperative hemorrhages of Group A and B were 3.11% (15/483) 
and 5.63% (4/71), respectively, and perforations during ESD for Group A 
and B were 0.21% (1/483) and 1.41% (1/71), respectively. Regarding the 
long-term outcomes, the local and distant recurrence rates were 0.41% 
(2/483) and 0% (0/483) in Group A, and 0% (0/71) and0 % (0/71) in Group 
B, respectively (n.s.). The metachronous recurrence rates in Group A and 
B were 6.83% (33/483) and 5.63% (4/71), respectively (n.s.). Regarding 
the survival analysis (using the Kaplan-Meier method and long-rank test), 
the mean follow-up periods for Group A and Group B were 51.6±35.2 and 
49.9±35.3 months, respectively. The 3 and 5 y OS rates were 93.1% and 
90.0% in Group A, and 100% and 90.6% in Group B, respectively. The 
5-year DSS rates were 100% in both groups. There were no significant dif-
ferences observed for the survival rates.
conclusion: The eCura B lesions have an excellent long-term prognosis 
equivalent to that of eCura A lesions. Therefore, the new endoscopic cur-
ability criteria are considered apt, and there is a possibility that eCura B 
lesions could be treated in the same manner as eCura A lesions.
disclosure: Nothing to disclose 
P1549 sequenTIaL TheraPeuTIc aPPrOach fOr PersIsTenT 
gasTrO-cuTaneOus fIsTuLas afTer PercuTaneOus endOscOPIc 
gasTrOsTOMy (Peg) reMOvaL In cancer PaTIenTs
Currais P.1, Faias S.2, Francisco F.3, Sousa L.3, Gramancho J.3, Pereira A.D.3
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Introduction: PEG removal in head and neck cancer patients (HNCPs) is re-
quired after completion of treatment, in case of tumor remission and after 
adequate oral intake is resumed. The PEG tract usually closes spontane-
ously within 48 to 72 hours. Persistent gastro-cutaneous fistula (PGCF) is a 
rare complication after PEG tube removal. The diagnosis is established in 
case of persistent gastric leakage through the fistulous tract for more than 
30 days after PEG removal.
aims & Methods: Our goal was to evaluate the incidence and treatment 
algorithm of PGCF in HNCPs.
This is a retrospective unicentric study of HNPCs referred for PEG removal 
between 2014-2018. The patients with PGCF were evaluated and their se-
quential treatment (medical, endoscopic and surgical) was reviewed, and 
technical and clinical success were assessed.
results: During the study period, 331 PEG tubes, all with 24 French were 
removed. There were 313 (94.7%) male patients, with a mean age of 59 ± 
11 years (18-85), with 19 PGCF (5.7%). Medical therapy (proton-pump in-
hibitors, prokinetics and antibiotics in case of infection, for 2 to 8 weeks) 
was performed with clinical success (definitive closure of the PGCF) in 
12 (63.2%) patients. The remaining 7 patients required endoscopic or 
surgical treatment. In 4 (21.1%), endoscopic treatment had technical and 
clinical success (3 patients with fulguration of the gastric leak edges with 
argon plasma coagulation (APC), silver nitrate in the path and external 
orifice, and closure of the internal orifice with hemoclips: mean num-
ber=6,33±0.47 (range: 6 to 7), and 1 (5.3%) with an over-the-scope-clip 
(OTSC)). Only 3 patients underwent surgery, 1 due to clinical failure of 
sequential endoscopic therapy (hemoclips + OTSC) and 2 underwent di-
rect surgery (one required surgery for another condition and one had a 
PEG-site herniation).
conclusion: PGCF is a rare complication after PEG removal. Medical ther-
apy is usually effective and should be maintained for at least 8 weeks. 
Endoscopic therapy is an effective second-line option and surgery is rarely 
required.
disclosure: Nothing to disclose 
P1550 endOscOPIc TreaTMenT fOr zenker’s dIverTIcuLuM 
WITh The sTag BeeTLe knIfe (sB knIfe) - PreLIMInary resuLTs 
frOM a sIngLe-cenTer exPerIence
Devani M.1, Reati R.2, Bezzio C.3, Saibeni S.4, Omazzi B.5, Arena I.6, 
De Nucci G.7, Della Corte C.6, Manes G.8
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Introduction: Flexible endoscopic treatment of symptomatic Zenker’s di-
verticulum (ZD) is an established treatment option. Over the years, various 
techniques have been developed and many devices have been tested with 
varying results. We report our experience with a scissor-shaped, rotating 
device with two insulated monopolar blades (SB knife) designed primarily 
for endoscopic submucosal dissection. Little data are reported about its 
use for endoscopic treatment of Zenker diverticulum.
aims & Methods: From Febuary 2014 to April 2019, n = 20 patients (pts) 
were treated at ASST-Rhodense with the SB knife junior. The two insulated 
blades allowed to avoid the use of the overtube. The procedures were 
performed with a cap to better evaluate the diverticulum and the septum. 
All patients underwent an esophagram before the procedure and post-
procedure, to rule out perforation and to assess esophageal transit. Symp-
toms (dysphagia, regurgitation, and respiratory symptoms) were analyzed 
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before and at the follow up using a validated scale. Procedure duration, 
rate of complications, symptom changes after the procedure and rate of 
relapsing patients during follow up were also recorded.
results: The procedure was carried out successfully in all patients. The 
mean size of ZD was 3 cm (1-6 cm). Eighteen out of 20 (90%) patients re-
ceived one treatment session. The mean procedure time was 28 min (18-
60 min). In 4 procedures (20%), one to two clips were prophylactically 
placed at the bottom of the resection line. Two patients (10%) required 
a second treatment after a mean of 14 months (2-26) due to symptomatic 
recurrence; both patients were at the very beginning of our experience (pts 
n.2 and n.3) and the recurrence of dysphagia was likely to be as a result 
of an incomplete division of cricopharyngeal fibers of the septum. Two 
minor intraprocedural bleedings were easily treated by the “coagrasper” 
use of the device. No major bleeding or late-onset bleeding developed. 
One minor perforation occurred (minimum free air in the mediastinum, no 
mediastinitis, no leak of hydrophilic medium per os) and was successfully 
treated with medical therapy. 
During a mean follow-up of 27 months (1-60), a significant symptom im-
provement was achieved in all the scores (dysphagia; regurgitation; respi-
ratory symptoms).
conclusion: Flexible endoscopic treatment of ZD with the SB knife is safe, 
effective, and has lasting effects on symptoms also at long term follow up, 
with a relatively low recurrence rate.
disclosure: Nothing to disclose 
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Introduction: Percutaneous endoscopic gastrostomy (PEG) removal is re-
quired in head and neck cancer patients (HNCP), after chemoradiotherapy 
ends and adequate oral intake is reacquired. The PEG tract usually closes 
spontaneously within 48-72 hours. Persistent gastro-cutaneous fistula 
(PGCF) is an uncommon complication of PEG removal.
aims & Methods: Our aim was to compare the incidence of PGCF in two 
groups of HNCP removing PEG under distinct protocols.
We performed a prospective cohort study with a historical control group. 
Group A, with 86 patients who removed PEG in 18-month period (May15-
Dec16) and Group B, a historical control group, with 102 patients who re-
moved PEG in a 14-month period (Jan14-Apr15). There were two different 
PEG tube removal protocols. Group A had 4h of rest and fasting, followed 
by cold liquid diet 4/4h and omeprazole 40mg bid for 4 weeks. Group B 
rested for 6h and initiated oral diet 12h after PEG removal. The study pri-
mary end-point was the incidence of PGCF in both groups and secondary 
end-points were to evaluate predictors and treatment of PGCF.
results: Demographics were identical in Group A and B, 84.9% male with 
a mean of 56±9 years old and 86.3% male with a mean of 53±11 years old, 
respectively. In Group A: 67.4% were smokers; 6.9% had diabetes mellitus 
(DM) and 2.3% used corticosteroids. Median body mass index (BMI) reduc-
tion of 2.25 (0.73-4.11) Kg/m2. PEG complication rate of 13.9%, predomi-
nantly minor infections. Mean PEG placement time was 8.2±4.5 months, 
use PEG for nutrition for 2.4 months on average, with 11.6% of the patients 
not using PEG. Only 2 (2.3%) patients had PGCF after PEG removal, one 
closure with medical therapy (PPI+prokinetic+antibiotic) and other with 
through-the-scope (TTS) clips. 
In Group B: 50% smokers; 5.9% with DM and 2.9% used steroids. Median 
BMI reduction of 2.39 (0.71-4.14) Kg/m2. PEG complication rate of 33.3%, 
most frequently infections. Mean PEG time was 8.5±4.6months, use PEG 
for nutrition for 4.75 months on average, 9.8% of patients not using PEG. 
PGCF occurred in 9 (8.8%) patients, with 7 closures with medical therapy, 
1 with an over-the-scope clip (OTSC) and 1 with surgery.
By multivariable analysis, PEG time (p=0.006; CI95% 1.05-1.26) and pres-
ence of early leak (4h) after PEG removal (p=0.002; CI95% 4.10-9.63) were 
independent predictors of PGCF. The new protocol reduced the number 
of PGCF (2 cases versus 9 in the historical control group), nearly reaching 
statistical significance (p = 0.056, IC95% 0.87-19.57).
conclusion: The new PEG removal protocol showed a tendency to reduc-
tion of PGCF, with less of time in hospital and fewer fasting hours. As 
PEG time is a predictor of PGCF, early removal of PEG is recommended. 
Patients with early leak post-PEG removal should be informed that, if PGCF 
installs, medical treatment is effective, and endoscopy or surgery are rarely 
required.
disclosure: Nothing to disclose 
P1552 a suBMucOsaL fLuId cushIOn PrevenTs MuscLe Layer 
daMage durIng MucOsaL argOn PLasMa cOaguLaTIOn
Maselli R.1, Belletrutti P.J.2, Spadaccini M.2, Stabler T.3, Ederer M.3, 
Neugebauer A.3, Enderle M.3, Galtieri P.A.4, Anderloni A.4, Carrara S.4, 
Fugazza A.4, Di Leo M.1, Pellegatta G.1, Cappello A.2, Romana C.2, 
Palma R.2, Ormando V.2, Repici A.1,2
1Humanitas Clinical and Research Hospital, Rozzano, Italy, 2Humanitas 
University, Biomedical Science, Rozzano, Italy, 3ERBE Elektromedizin GmbH, 
Tubingen, Germany, 4Humanitas Clinical and Research Center, Rozzano, Italy
contact e-Mail address: roberta.maselli@humanitas.it
Introduction: Thermal damage to the muscle layer of the gastrointestinal 
wall can occur during mucosal application of argon plasma coagulation 
(APC). This injury may be mitigated by creating a fluid cushion within the 
submucosal layer. This can be achieved during endoscopy by injecting flu-
ids directly into the submucosa, thus creating a cushion effect, using a 
needle and syringe or a high pressure needleless injection system. The 
fluid cushion physically separates the mucosal layer from the muscle layer 
and suppresses unwanted tissue temperature elevation. This in turn pro-
tects the muscle layer from thermal damage. The coagulative threshold of 
muscle proteins is known to be about 60°C, but there are no published 
systematic assessments of the minimum injection volume needed nor the 
ideal injectate to prevent thermal damage to the muscle layer during mu-
cosal APC ablation.
aims & Methods: Our aims were, firstly, to measure the final temperature 
inside the fluid cushion after mucosal ablation with APC and then to de-
termine any differences in the final temperature between various inject-
able solutions. Secondly, we sought to determine the minimum volume of 
injectate required to protect the muscle layer from thermal damage. 
All experiments were performed in an ex-vivo porcine gastrointestinal 
tract model. Five different fluids (normal saline, Glyceol, Gelafundin, Volu-
ven and Eleview) of different volumes (range 0 - 5mL) were injected into 
the submucosa of the esophagus, stomach (fundus) and rectum to create 
a fluid cushion. APC was applied to the mucosa for a fixed duration (3s) 
at different power settings (ranging from 30 - 120W). Immediately after 
APC treatment, the final temperature was measured by placing a contact 
thermometer inside the fluid cushion, just on top of the muscle layer. The 
minimum volume of fluid needed to protect the muscle layer from thermal 
damage was also determined.
results: There was no significant difference in the temperature measured 
at the surface of the muscle layer between elevation with normal saline, 
Glyceol, Gelafundin, Voluven and Eleview at all 3 tissue locations at equal 
injection volumes and power settings. The experiments showed that the 
temperature rose for each injectate with heightened power settings but 
also decreased with increasing volume of injected fluid. The minimum 
amount of fluid needed to protect the muscle layer from thermal damage 
was 2mL for the esophagus, stomach and rectum in the case of a power 
setting between 30 to 90W and 3mL in the case of 90 to 120W.
conclusion: Normal saline and four commercially available submucosal 
injectates possess similar thermoregulatory effects in terms of acting as 
an insulator of the muscle layer during APC treatment. As opposed to the 
choice of injectate or anatomic location treated, the volume of fluid in-
jected is the main determinant of the final temperature at the level of the 
muscularis propria. To reduce the likelihood of thermal damage to deeper 
layers of the GI tract when APC is applied, a minimum injection volume of 
2mL is recommended if < 90W of power is utilized.
disclosure: Nothing to disclose 
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P1553 s-POeM Is effecTIve TreaTMenT fOr ePIPhrenIc 
dIverTIcuLa assOcIaTed WITh sPasTIc MOTILITy dIsOrders
Demeter M.1, Duricek M.2, Uhrik P.1, Hyrdel R.2, Banovcin P.2
1University Hospital Martin, Department of Gastroenterology, Martin, 
Slovakia, 2Jessenius Faculty of Medicine in Martin, Comenius University, 
Department of Gastroenterology, Martin, Slovakia
contact e-Mail address: michaldemeter@gmail.com
Introduction: Esophageal epiphrenic diverticula are infrequently associ-
ated with achalasia and major disorders of esophageal peristalsis. The 
mainstay of treatment is laparoscopic myotomy and diverticulectomy with 
anterior fundoplication. However, in case of contraindication and/or disap-
proval of the procedure by the patient, there are limited ways of alternative 
treatment. S-POEM (salvage POEM) has gained some evidence as a eligible 
treatment for achalasia and esophageal epiphrenic diverticula. However, 
the effectivity of the procedure has yet been demonstrated only in case 
reports and the data based on the series of patients are lacking.
aims & Methods: We present a case series of 7 symptomatic patients with 
achalasia or spastic motility disorders and large epiphrenic diverticulum 
that have been treated by S-POEM. In these patients Eckhardt score was 
calculated, barium contrast study was performed and the posture and the 
size of the diverticulum was recorded before the procedure. High resolu-
tion manometry (HRM) was performed and in case of the detection of ma-
jor disorder of peristalsis according to the Chicago classification v3.0 POEM 
procedure was performed. Generally, the myotomy was guided on the site 
opposite to the diverticular sack. After 3 months patients were invited for 
checkup, during which the general well-being and Eckhardt score was 
evaluated, upper endoscopy and HRM was performed.
results: 7 patients (3 men, 4women) met the inclusion criteria. Mean age 
was 69 years (range 43-80 y.). HRM revealed achalasia in 6 patients, I. type 
in 5 patients, II type in 1 patient. In one patient we were not able to clas-
sify the motility disorder due to previous intervention. Mean radiological 
size of diverticula was 6 x 4,8cm (range 4x4 - 11x9 cm). The most common 
complaint was dysphagia (mean partial Eckhardt score for dysphagia 2), 
followed by regurgitation (mean partial Eckhardt score for regurgitation 2). 
Posterior POEM procedure was performed in 6 patients, anterior procedure 
in 1 patient. In 3 months follow up we observed significant decrease of 
Eckhardt score (6.6 vs. 0.6, p< 0.0001). There was a significant improvement 
in dysphagia and regurgitation (2 vs. 0.17 p< 0.01, 2 vs. 0.33 p< 0.01). A dra-
matic decrease of IRP was also observed IRP (31.8 vs. 8.8, p< 0.0001). The 
average weight gain was 6.8 kg. There were neither complications related 
to the procedure, nor any aspiration event detected at 3 months follow up.
conclusion: S-POEM provided effective symptomatic improvement and sig-
nificant decrease of the LES relaxation pressure in patients with esopha-
geal epiphrenic diverticula associated with achalasia or spastic motility 
disorders. However, long term follow up in a large cohort of patients is 
required before it is considered equivalent treatment alternative for these 
patients. Supported by U01 DK116311 and VEGA 1/0304/19
disclosure: Nothing to disclose 
P1554 quaLITy In uPPer gasTrOInTesTInaL endOscOPy: 
IMPacT Of cLInIcaL PracTIce guIdeLInes PuBLIcaTIOn
João M., Alves S., Taveira F., Areia M., Elvas L., Brito D., Saraiva S., 
Cadime A.T.
Portuguese Oncology Institute of Coimbra, Gastroenterology, Coimbra, 
Portugal
contact e-Mail address: mafaldacaine@gmail.com
Introduction: Upper gastrointestinal (UGI) endoscopy is the gold standard 
for the diagnosis and treatment of most esophageal, gastric, and small-
bowel disorders. The European Society of Gastrointestinal Endoscopy (ESGE) 
has identified quality of endoscopy as a major priority and has published 
performance measures in the field of a quality improvement initiative.
aims & Methods: Our aim was to evaluate ESGE’s performance measures 
for UGI endoscopy in a tertiary center and assess the effect of their publica-
tion on improving the quality of procedures. 
Retrospective cohort study included all UGI endoscopies performed in a 
single center between 2016 and 2018. We performed a global evaluation 
of performance measures defined by ESGE guideline and a comparative 
analysis between the period previous (2016) and subsequent (2017-2018) 
to their publication using Chi2 test.
results: A total of 3289 procedures were evaluated. Regarding key per-
formance measures, proper fasting instructions were received in 99.9%; 
procedure duration was documented in 97.5%; accurate photo docu-
mentation was reported in 70.6%; standardized terminology was used in 
35.9%; Seattle protocol in Barrett’s surveillance was adopted in 55.9% 
and immediate and delayed complications were monitored in 99.4% and 
77.6%, respectively. As far as minor performance measures are concerned, 
inspection time in the stomach was appropriate in 72.4%; lugol staining in 
esophagus for patients at risk of squamous cell cancer was used in 88.9%; 
biopsy protocol according to MAPS guidelines was applied in 76.1% and 
55.6% of Barrett’s patients entered a registry to monitor the incidence of 
dysplasia. Considering comparative analysis between 2016 and 2017-218, 
we have verified statistically significant improvement in the accurate photo 
documentation (56.6% vs. 76.7%; p< 0.01); in the standardized terminol-
ogy use (24.1% vs. 42.7%; p< 0.01) and in the inspection time in the stom-
ach (70.7% vs. 76.3%; p< 0.01).
conclusion: In our center minimum standards are fulfilled to fasting in-
structions, documentation of procedure duration and registration of im-
mediate and delayed complications after therapeutic endoscopies. The 
remaining measures require improvement and subsequent auditing. Dis-
closure of performance measures, followed by auditing and correction, 
may allow Gastroenterologists to improve UGI endoscopy quality.
disclosure: Nothing to disclose 
P1555 arTIfIcIaL InTeLLIgence MeThOds fOr dIagnOsIs 
Of earLy gasTrIc cancer WITh MagnIfyIng narrOW Band 
IMagIng endOscOPy
Kuvaev R.1,2, Kashin S.V.3, Kraynova E.4, Khryashchev V.5, Stepanova O.5, 
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Introduction: Endoscopic diagnosis of gastric cancer at an earlier stage 
is the single most effective strategy for reducing gastric cancer mortality. 
Magnifying narrow-band (M-NBI) imaging endoscopy significantly im-
proves the diagnostic accuracy of gastric epithelial neoplastic lesions [1]. 
However, effective application of M-NBI endoscopy is difficult due to the 
presence of various changes of gastric mucosal patterns, and therefore 
requires appropriate training. Computer-aided decision support systems 
based on endoscopic image analysis are being designed to assist an en-
doscopist in enhancing the diagnosis and mastering advanced techniques 
that require a high level of expertise [2]. 
Recently convolutional neural networks have become one of the most 
popular and effective approaches in different fields of endoscopic image 
analysis.
aims & Methods: The aim of this study was to develop a system for auto-
matic identification of gastric cancer on M-NBI images using deep learn-
ing through convolutional neural networks (CNN). The database of 1293 
M-NBI endoscopic images was created. It consisted of 357 M-NBI images 
of cancerous lesions and 936 M-NBI images of non-cancerous lesions 
(Olympus Exera II, GIF Q160Z, Lucera GIF, Q260Z, EXERA III, GIF HQ 190). 
The developed image analysis algorithm was based on the application 
of the SSD (Single Shot Multibox Detector) architecture of convolutional 
neural network. The network architecture was implemented using the 
Caffe framework. The neural network was pre-trained on the ImageNet 
[3] image database which was used to initialize part of the weights. The 
weights of the remaining layers were initialized using Xavier initializa-
tion. Neural network training was done simultaneously with 8 GPU video 
cards of the NVIDIA DGX-1 supercomputer. For numerical experiments 100 
images were randomly selected from the endoscopic image database: 24 
images of cancer and 76 images non-cancerous lesions. The videodata of 
M-NBI endoscopic procedures (415 frames which were not presented in 
the database) was blindly analyzed by the designed system and an expert 
endoscopist to compare it with the doctor’s diagnosis. Spatial correlation 
between automated results and experts opinion was assessed.
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results: Average precision for “cancer” class was 0,827, average preci-
sion for “non-cancer” class was 0,923, mean average precision was 0,875. 
Average intersect over union (IoU) score (area of intersection the expert 
frame and the frame obtained using algorithm / total area combining 
these frames) was 0,767 which corresponds to high concordance between 
automated and expert marking of gastric cancer areas.
conclusion: The proposed algorithm of image analysis based on deep 
learning through SSD convolutional neural network allowed to design the 
automated system for NBI-M endoscopic diagnosis of gastric cancer. The 
designed system is able to analyze videodata and can be implemented in 
endoscopic electronic data collecting system for further testing in daily 
clinical practice.
references: 1. Pimentel-Nunes P., Libânio D., Marcos-Pinto R. et al. Man-
agement of epithelial precancerous conditions and lesions in the stomach 
(MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), Euro-
pean Helicobacter and Microbiota Study Group (EHMSG), European Society 
of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva 
(SPED) guideline update 2019. Endoscopy. 2019 Apr;51(4):365-388. 2. Ku-
vaev R., Kashin S., Nikonov E., et al. Computer-aided diagnostic system for 
the real time pathology prediction and clinical decision support during 
narrow band imaging magnification endoscopy in stomach. United Eu-
ropean Gastroenterol J. 2015 Oct; 3(5S):A9 3. Image Net Image Database 
http://www.image-net.org/.
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P1556 TreaTMenT Of gasTrIc varIces By InTravarIceaL 
InjecTIOn Of n-2-BuTyL cyanOacryLaTe: resuLTs Of The fIrsT 
aLgerIan PrOsPecTIve sTudy
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Introduction: Endoscopic intavariceal injection of cyanoacrylate, especially 
of N-2-butyl
cyanoacrylate (NBC) is the treatment of choice for bleeding from type 2 
gastro-esophageal varices (GOV 2) and isolated gastric varices (IGV), 
whether in acute phase or in a secondary prophylaxis setting. This en-
doscopic therapy has not been evaluated in our country. In this study, we 
evaluated the efficacy of this technique in the secondary prophylaxis of 
bleeding from VOG 2 and IGV and we have also estimated hemostasis rates 
and either complications of this technique and predictive factors for recur-
rence.
aims & Methods: A prospective analysis of clinical, biological, endoscopic 
and evolutive parameters was carried out in patients recruited and treated 
consecutively, which we divided into two non-comparative groups: a group 
1 (G1) of patients treated in secondary prophylaxis and a group 2 (G2) of 
patients treated in acute bleeding phase. Statistical analyses were per-
formed using SPSS software (version 22.0; SPSS Inc., Chicago, IL, United 
States). Descriptive data are reported as mean ± SD or as percentage. The 
Student’s t test and the χ 2 test were used to assess differences between 
groups. Forward stepwise logistic regression analyses, both univariate 
and multivariate, and receiver operating characteristic curve (ROC) analy-
sis were used to determine the correlation between factors and clinical 
outcomes;The actuarial survival curve was established by the Kaplan-Meir 
method. The comparisons of survival curves were made using the Logrank 
test. A P value < 0.05 was considered statistically signifcant.
results: 75 patients (37 males, 38 females),sex_ratio=0.9 with a mean age 
of 54.23 ± 3.46 years were enrolled and followed for an average duration 
of 16.27 ± 2 months, 44 patients were G1 and 31 G2 . Gastric varices (GV) 
were GOV 2 in 96% of cases and were related to cirrhosis in 55 patients 
(73%). Immediate and initial hemostasis rates in the G2 were 95% and 
90%, respectively, and the failure rate was about 10% (N=3)in the same 
group. Minor complications were observed in 38.7% in the G2( N=12) and 
29.5%cases in the G1(N=12). Major complications were seen in 9.7% in the 
G2(N=3), including a case of pulmonary embolism and in 2.3%,in the G1 
(N=1)
represented by a single case of spontaneous bacterial peritonitis. Mortal-
ity was estimated at 9.7% in the G2 (N=3) and 0% in the G1(N=0). The G1 
bleeding recurrence rate was estimated at 0% at six weeks and at 9.1% 
at 1 year(N=4) and the mean survival without recurrence was evaluated at 
22.7 months ± 1.24 [20.26-25.13] .In multivariate analysis only the presence 
of ascites at the time of endoscopic treatment was a predictive factor of 
recurrence with an adjusted OR: 13.89 CI 95% [1.07-17.915] .
conclusion: Our study confirms the efficacy and relative safety of NBC in-
jection in the treatment of GV either in secondary prophylaxis and acute 
haemorrhage setting. We confirm its feasibility in our environment with 
satisfactory hemostasis and bleeding recurrence rates and acceptable 
complications.
disclosure: Nothing to disclose 
P1557 cOaTIng Of MeTaLIc sTenTs WITh aceLuLLar BIOMaTrIx 
and nanOfIBers Based scaffOLd cOnTaInIng a sTerOId In 
PrevenTIng esOPhageaL sTrIcTure afTer cIrcuMferenTIaL 
endOscOPIc dIssecTIOn - an exPerIMenTaL sTudy
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Martinek J.5
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Introduction: The major drawback of circumferential endoscopic submu-
cosal dissection (CESD) in the esophagus is development of refractory 
stricture in almost 100% of cases. We have previously shown that a self-
expandable metallic stent (SEMS) covered with acellular biomatrix from 
pig’s dermis resulted in reduced stricture severity and improved quality of 
healing (Dolezel et al. GIE 87.6 (2018): AB266-7).
aims & Methods: To assess the effect of a newly developed drug eluting 
SEMS coated with acellular biomatrix and with a nanofibers-based scaffold 
(from a polymer solution) containing a steroid (Depomedrol 104 mg) in 
preventing the post-CESD esophageal stricture.
An experimental controlled study. CESD were performed in the mid-
esophagus in 14 pigs (control group, A, n=6; interventional group, B, n=8). 
After completing CESD, SEMS were placed alongside the post-CESD defect 
and fixed with a lasso technique. SEMS were removed 21 days after CESD. 
Pigs were euthanatized when a significant stricture developed.
results: The mean length of the defect was 54 ± 15 mm. Significant stric-
tures developed in all pigs after a mean of 12.8 ± 4.3 days. The length of 
stricture was 26.6 ± 14.9 mm in the control group and 17.0 ± 10.4 mm in the 
B group, (p=0.19). The narrowest stricture diameter did not differ between 
the groups (8.8 ± 4.0 mm (A) vs. 8.6 ± 2.1 mm (B), p=0.45). Macroscopic re-
epithelization was not detected in 66% (4/6) of pigs in the control group, 
while it was always present in the B group, p=0.06. The re-epithelization 
length (measured as the longest distance of new epithelization from the 
edge of the defect) was 1100 ± 935 µm in the control group vs. 679 ± 489 µm 
in the interventional group (p=0.39). The re-epithelization width was 105 ± 
115 µm (A) and 236 ± 202 µm in the B group, p=0.24. Thickness of fibrosis 
was 2.3 ± 1.1 mm (A) and 2.0 ± 0,1 mm (B), p=0.36. Histologically, severe 
inflammation was present in all pigs in the control A group, while in no pig 
in the B group (only mild inflammation), p=0,0008.
conclusion: Depomedrol eluted from SEMS covered with acellular bioma-
trix was unable to effectively prevent post-CESD esophageal stricture in the 
experimental model. However, it significantly improved microscopic heal-
ing quality in terms of re-epithelization and less severe inflammation. The 
stent may be a suitable candidate for further development.
references: Supported by the Ministry of Health, Project Reg. No. 16-
27653A, the National Sustainability Program I, project number LO1609 
(Czech Ministry of Education, Youth and Sports), RVO: 67985904 and IP 
1012
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P1558 unsedaTed uPPer gasTrOInTesTInaL endOscOPy: 
dOes TOPIcaL PharyngeaL anesThesIa Make IT MOre 
TOLeraBLe?
Ferchichi I., Sabbah M., Trad D., Ouakaa A., Bibani N., Elloumi H., 
Gargouri D.
Habib Thameur Hospital, Department of Gastroenterology, Tunis, Tunisia
contact e-Mail address: ichrakferchichi.if@gmail.com
Introduction: In many countries, upper gastrointestinal endoscopy (UGIE) 
is commonly performed without sedation, which avoids the cost and risk 
of procedural sedation altogether. Adequate patient tolerance is essential 
for successful completion of a safe examination. As a result, endoscopists 
tend to use a topical pharyngeal anesthesia (TPA) as a pretreatment for 
unsedated UGIE. However its efficiency has not been established.
aims & Methods: The purpose of this study is to assess the tolerance of 
unsedated UGIE and to determine whether TPA has an impact on patients’ 
tolerance level. A prospective study during a period of 6 months (Novem-
ber 2018 - April 2019) was conducted. Patients who underwent unsedated 
UGIE were included and randomly divided into two groups: with and with-
out TPA administration (xylocaine spray). 
A comparision of UGIE tolerance between the two groups was performed. 
Patients who were under psychotropic or analgesic treatment were ex-
cluded from this study. The UGIE tolerance evaluation was based on a pri-
mary criterion: the patient’s acceptance to undergo the examination again 
under the same conditions. 
The secondary criteria were: the occurrence of a suffocation sensation, 
the occurrence of nausea and the level of pain/discomfort measured using 
the visual analog scale (VAS) (0 = no pain/discomfort encountered to 10 = 
extremely painful/uncomfortable).
results: Seventy patients (female=36, male=34, mean age 50 years [18-
82]) were included. UGIE was mostly performed for epigastralgia (48.6%) 
and iron deficiency anemia (17%). UGIE was well tolerated in 65.7% of 
patients: forty-six out of seventy accepted to undergo the same procedure. 
The refusal to repeat the examination was significantly related to suffoca-
tion sensation (p< 0.01), nausea (p< 0.01) and the level of pain/discomfort 
(p< 0.01).
There was no significant difference between the 2 groups in terms of toler-
ance according to the primary and the secondary criteria. The VAS score 
was 4.66/10 for patients who received TPA versus 5.49/10 for those who 
didn’t receive TPA. Unsedated UGIE was less tolerable in female patients 
(p< 0.01) and in less than 40 year-old patients but with no statistical sig-
nificance (p=0.08). Previous endoscopic experience and longer examina-
tion time didn’t seem to interfere with patient’s tolerance level.
conclusion: The use of a Topical pharyngeal anesthesia appears to be ben-
eficial for male and for over 40 year-old patients. Otherwise, TPA doesn’t 
seem to improve unsedated UGIE tolerance.
disclosure: Nothing to disclose 
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On 105 PaTIenTs
Olivier R.1, Brochard C.2, Quénéhervé L.3, Wallenhorst T.4, David G.5, 
Silvain C.6, Bruley Des Varannes S.7, Ropert A.8, Coron E.9
1CHU de Poitiers, Vienne, Poitiers, France, 2CHU Rennes, Services des 
Maladies de L’Appareil Digestif, Rennes, France, 3University Hospital of 
Nantes, Digestive Disease Institute, Nantes, France, 4Pontchaillou University 
Hospital, Rennes, France, 5CHU de Nantes, Nantes, France, 6Hôpital de la 
Milétrie, Hepato-gastroenterology, Poitiers, France, 7Hopital Hotel Dieu, 
Institut des Maladies de l’Appareil Digestif, Nantes, France, 8CHU Rennes, 
Rennes, France, 9University of Nantes Institute of Digestive Disease, Nantes, 
France
contact e-Mail address: raphael.olivier0714@orange.fr
Introduction: Peroral Endoscopic Myotomy (POEM) is part of the modern 
therapeutic arsenal for the management of achalasia. Its effectiveness has 
been widely demonstrated and it is now often offered as a first-line treat-
ment. Nevertheless, the overall impact of previous processing operations 
on the results of this intervention remains to be determined in current 
practice. The purpose of our study was therefore to compare the feasibility, 
morbidity and efficacy of POEM in naïve and naïve patients.
aims & Methods: Clinical, manometric and endoscopic data from patients 
treated for esophageal achalasia with POEM in 2 tertiary centers were col-
lected prospectively and analyzed retrospectively. Esophageal motor disor-
ders were defined according to the Chicago Classification v3.0. Symptoms 
were assessed using Eckardt’s score before POEM, then at 1 and 6 months 
post-procedure. Esophageal manometry data (before the procedure and 
at 6 months), gesture data (procedure duration, myotomy length, number 
of clips), per and postoperative complications (bleeding, infection, hos-
pitalization duration) and efficacy (defined by an Eckardt score ≤3) were 
collected. The data were compared by matched and unpaired t-test or by 
Chi2 test.
results: A total of 105 patients (40 females, 38.1%, median age = 51.2[38.2-
64.8] years) were included between July 2015 and October 2018. Twenty-
five patients (23.8%) had type I achalasia, 63 (60.0%) type II achalasia, 13 
(12.4%) type III achalasia and 4 (3.8%) a variant. Fifty-two (49.5%) pa-
tients were naïve to any treatment and fifty-three (50.5%) had previous 
treatment, (49 patients, had at least one pneumatic dilation, 7 had Heller’s 
myotomy and 4 had botulinum toxin injection). The characteristics of the 
2 groups were comparable in terms of sex, age, type of achalasia, Eckardt 
score, resting pressure of the lower esophageal sphincter (LES) and inte-
grated relaxation pressure (IRP) before POEM. 
With regard to the feasibility and the safety of the gesture, no significant 
differences were found between the two groups concerning: the duration 
of the intervention (naïve = 45[36-60] minutes vs non naïve = 50[35-65] 
minutes; p= 0.1647), the length of the myotomy (naïve = 10[8-10]cm vs. 
non naïve = 9[8-10]cm; p= 0.4275) or the number of clips used to close the 
submucosal tunnel (naïve= 6[5-7] vs. naïve= 6[6-7]; p= 0.3221). There was 
no significant difference concerning per and postoperative complications 
notably for severe complications. Two patients (1.9%) (1 naïve et 1 non 
naïve, no statistical difference p = 1.00) had a mediastinitis of favourable 
progression after endoscopic treatment; associated with surgical drainage 
for one and radiological drainage for the other, without esophagectomy.
Myotomy treatment was considered successful (Eckardt score ≤3) in 77/87 
patients (88.5%) at 6 months. The efficacy of POEM at 6 months was com-
parable between the 2 groups: 39/44 patients (92.9%) in the naïve group 
and in 38/43 (84.4%) in the non naïve group (p=0.1288) Esophageal ma-
nometry data were available for 66/87 patients. There was no significant 
difference in the post-POEM IRP and lower esophageal sphincter resting 
pressure between the 2 groups.
conclusion: This study, conducted on a large number of patients under 
conditions of routine clinical practice, shows that the feasibility, morbidity 
and efficacy of POEM in achalasia at 6 months are comparable between 
naïve and non naïve patients. This technique can therefore be offered to 
patients with severe esophageal achalasia resistant to other therapies.
references: 1- E. Akintoye, N. Kumar, I. Obaitan, Q. A. Alayo, et C. C. 
Thompson, « Peroral endoscopic myotomy: a meta-analysis », Endoscopy, 
vol. 48, no 12, p. 1059-1068, déc. 2016. 2- H. Ø. Kristensen, J. Kirkegård, D. 
W. Kjær, F. V. Mortensen, R. Kunda, et N. C. Bjerregaard, « Long-term out-
come of peroral endoscopic myotomy for esophageal achalasia in patients 
with previous Heller myotomy », Surg. Endosc., vol. 31, no 6, p. 2596-2601, 
juin 2017. 3- T. Ling, H. Guo, et X. Zou, « Effect of peroral endoscopic my-
otomy in achalasia patients with failure of prior pneumatic dilation: a pro-
spective case-control study », J. Gastroenterol. Hepatol., vol. 29, no 8, p. 
1609-1613, août 2014.
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P1560 shOuLd rOuTIne duOdenaL BIOPsIes aLWays Be 
PerfOrMed In eLderLy PaTIenTs WITh aneMIa WIThOuT 
endOscOPIc sIgns Of BLeedIng?
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Introduction: Anemia, a multifactorial condition, occurs in 12.7% of men 
and 30.2% of non-pregnant women worldwide. Specifically, iron-defi-
ciency anemia (prevalence 2-5% of men and postmenopausal women in 
developed countries) is considered a warning sign especially in elderly 
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(colonic or gastric neoplasia), but it may be also due to benign condi-
tions (coeliac disease (CD), duodenal intraepithelial lymphocytosis (DIL), 
chronic atrophic gastritis or H.pylori, poor dietary intake, non-steroidal 
anti-inflammatory drugs. Multimorbidity and polypharmacy may play an 
additional role. Anemia is found in 80-90% of CD, but the need for routine 
duodenal biopsies, independently from age or coeliac serology status, is 
debated. Guidelines from British Society of Gastroenterology recommend 
duodenal biopsies in individuals undergoing upper endoscopy (EGDS) in 
whom CD or alternative mucosal cause of malabsorption is suggested.
aims & Methods: To determine diagnostic yield of routine duodenal bi-
opsies in adult and elderly patients with anemia whose EGDS failed to 
reveal macroscopic causes of bleeding and to identify predictive features of 
duodenal histopathological findings. Single center cross-sectional study; 
between 2015-2018, among consecutive 7968 EGDS performed in our En-
doscopy Unit, 744 were for anemia. Patients with manifest GI bleeding or 
no gastric/duodenal biopsies were excluded. In 469 (F 68%; median age 
60yrs), both gastric and duodenal biopsies, were taken. 
Clinical, endoscopic and histological features were collected and sepa-
rately analyzed in the groups with or without histopathological changes 
of duodenal mucosa (DM). Univariate/multivariate analyses were per-
formed (dependent variable: normal or pathological DM; independent 
variables: gender, outpatient/inpatient, age, endoscopic findings in stom-
ach or duodenum). Different cut-offs for age were considered (>50, >60, 
>70, >80yrs).
results: Of 469 included patients, 40(8.5%) had histopathological chang-
es in DM: 12(2.6%) CD, 25(5.3%) DIL, 3(0.6%) others (2 Giardia Lamblia 
infection, 1 hypereosinophilia). Compared to patients with normal DM, 
they were younger (median age 47.5 yrs, range 20-90 vs 62 yrs, range 17-
93,p=0.0005) and showed more frequently duodenal endoscopic findings 
(22.5% vs 6.7%,p=0.0014), while the stomach was endoscopically normal 
in all cases (0 vs 14.7%,p=0.0182). The frequency of histopathological find-
ings in the DM showed a significantly decreasing trend with increasing 
age, in patients aged < 40, 41-50, 51-60, 61-70, 71-80, and >80yrs, they 
were observed in 25%, 30%, 20%, 12.5%, 10%, and 2.5%, respectively 
(p=0.0010). 
Logistic regression models showed that endoscopically normal DM and 
age >50, >60, and >70yrs were significantly associated with normal DM bi-
opsies. Anemic patients aged >60, >70, or >80yrs with endoscopically nor-
mal DM had a 3- to 4-fold higher probability of having normal duodenal 
histology (OR3.5,95%CI 1.5-82, OR3.6 95%CI 1.6-8.5, OR4.1,95%CI1.8-9.4). 
The strength of association increased with increasing age. Other indepen-
dent variables (gender, outpatient/inpatient, gastric findings) were not as-
sociated.
conclusion: In anemic patients without endoscopic signs of bleeding, pre-
dictors for histologically normal DM were age and endoscopically normal 
DM appearance. In over 70yrs anemic patients infrequent or negligible 
pathological findings in DM were found. 
These results suggest that taking routine duodenal biopsies is question-
able in elderly anemic patients especially in absence of macroscopic duo-
denal alterations of other suspected signs of related intestinal diseases.
disclosure: Nothing to disclose 
P1561 InsuLaTed-TIP knIfe TunneLIng TechnIque fOr 
esOPhageaL endOscOPIc suBMucOsaL dIssecTIOn: an InITIaL 
WesTern exPerIence
Mehta N.1, Jang S.1, Stevens T.1, Raja S.2, McNamara M.3, Sohal D.3, 
Murthy S.2, Saito Y.4, Vargo J.1, Abe S.4, Bhatt A.1
1Cleveland Clinic, Gastroenterology and Hepatology, Cleveland, United States, 
2Cleveland Clinic, Cardiac and Thoracic Surgery, Cleveland, United States, 
3Cleveland Clinic, Hematology-Oncology, Cleveland, United States, 4National 
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contact e-Mail address: mehtan5@ccf.org
Introduction: Esophageal endoscopic submucosal dissection (ESD) can 
be technically challenging due to the narrow lumen and thin wall of the 
esophagus. Device and technique innovation is needed to make esopha-
geal ESD easier to perform, especially in the West where experience and 
procedure volumes are less. The loose submucosa of the esophagus allows 
easy entry of the entire ceramic tip of an insulated tip (IT) knife within it. 
This allows for the backside chip (electrocautery blade on the backside of 
the ceramic tip) to dissect the submucosa, while the ceramic tip protects 
the muscle layer from injury as the knife is advanced. 
This technique is called IT knife tunneling technique and has been de-
scribed in Japan for esophageal ESD. We evaluated the safety and efficien-
cy of the IT knife tunneling technique for esophageal ESD at our Western 
endoscopy center.
aims & Methods: A single center study evaluating consecutive patients 
who underwent esophageal ESD with IT knife tunneling technique be-
tween July 2016-November 2017. This technique was not used on lesions 
with expected severe fibrosis. All ESDs were performed by a single ESD 
expert (AB). Primary aim was to determine safety of the technique, partic-
ularly regarding perforation, intraprocedural (>2-gram hemoglobin drop 
< 48 hours after procedure), and delayed (active bleeding from a post-ESD 
ulcer diagnosed by emergency or planned follow-up endoscopy) bleeding. 
Procedure time, resection speed, en-bloc, R0 (negative vertical and hori-
zontal margins), and curative (R0 resection, well to moderately differenti-
ated histology, absence of lymphovascular invasion, absence of budding, 
and absence of invasion beyond superficial submucosa (< 500 microns) 
for adenocarcinoma or no submucosal invasion for squamous cell cancer) 
resection rates were measured.
results: 19 patients underwent esophageal ESD with IT knife tunneling 
technique [Table]. Median lesion size was 3 cm [25-75 IQR: 2.5-3.3], me-
dian procedure time 70 min [60.5-96.5], and median resection speed 0.364 
cm2/min [0.269-0.482]. No esophageal perforations, strictures, or delayed 
bleeding. One case with intraprocedural bleeding requiring blood trans-
fusion of one unit. En-bloc, R0, and curative resection rate 100% (19/19), 
94.7% (18/19), and 73.7% (14/19), respectively. 4/5 of the non-curative le-
sions were known high-risk lesions; ESD performed because these pa-
tients were deemed non-surgical candidates. 17 patients had Barrett’s-
related neoplasms (5 high-grade dysplasia, 12 adenocarcinoma). Two had 
squamous cell cancer; these two large resections >2/3 esophageal circum-
ference (6 and 7 cm) were injected with Kenalog and prescribed oral fluti-
casone to prevent stricture formation.
  IT knife Tunneling Technique
  N=19
Factor Statistics
Histology  
1) Barrett‘s Associated Neoplasm 17/19 (89.5%)
a) Esophageal Adenocarcinoma 12/17
b) High grade dysplasia 5/17
2) Squamous Cell Cancer 2/19 (10.5%)
Size of resected lesion (cm) 3 [2.5, 3.3]
En-bloc resection rate 70 [60.5, 96.5]
R0 resection rate 0.364 [0.269, 0.482]
Curative resection rate 14/19 (73.7%)
Perforations/Strictures 0/0 (0%/0%)
Significant Intraprocedural Bleed 1/19 (5.3%)
Significant Delayed Bleed 0/19 (0%)
[Table 1. Safety and Efficiency of IT Knife Tunneling Technique ESD Resection]
conclusion: IT knife tunneling technique allowed for safe esophageal ESD 
of non-fibrotic lesions at our endoscopy center. Further use of this tech-
nique in the West is warranted.
disclosure: Nothing to disclose 
P1562 The effecT Of endOscOPIc MucOsaL resecTIOn (eMr) 
vs endOscOPIc suBMucOsaL dIssecTIOn (esd) TechnIque On 
hIsTOLOgIc MargIns fOr endOscOPIcaLLy TreaTed earLy 
esOPhageaL adenOcarcInOMa
Mehta N.1, Li F.1, Young A.2, Robertson S.3, Chahal P.1, Jang S.1, Cruise M.3, 
Vargo J.1, Stevens T.1, Bhatt A.1
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contact e-Mail address: mehtan5@ccf.org
Introduction: Both endoscopic mucosal resection (EMR) and endoscopic 
submucosal dissection (ESD) techniques are used for the treatment of ear-
ly esophageal cancers. ESD has potential advantages including higher en 
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bloc and R0 resection rates, which have been demonstrated for squamous 
cell carcinomas (ESCC) but data for esophageal adenocarcinoma (EAC) 
is more limited. Histologic determination of the horizontal and vertical 
margins is important to determine the completeness of resection and risk 
of recurrence. Larger tumors, especially those that spread laterally may 
exceed with limits of en bloc resectability using standard EMR techniques.
aims & Methods: 
Aim: To determine the effect of EMR vs ESD techniques on the histologic 
margins in endoscopically treated early EAC.
Methods: Our institution’s endoscopy and pathology databases were que-
ried for patients undergoing endoscopic treatment of early EAC. Endo-
scopic and histologic characteristics were collected. Pathology slides were 
re-reviewed by a blinded pathologist to determine status of horizontal 
and vertical margins. All statistical analyses were performed using SAS 
(version 9.4, The SAS Institute, Cary, NC) and a p < 0.05 was considered 
statistically significant.
results: A total of 52 patients with early EAC were analyzed. 23 patients 
underwent ESD and 29 had EMR. Tumors that underwent ESD were sig-
nificantly larger compared to those resected with EMR technique (20.0 
mm [20.0,28.0] vs 11.0 mm [9.0,13.0], p <0.001). Rates of endoscopic en 
bloc resection were not statistically different (EMR 89.7% vs ESD 100%, 
p = 0.25). On the other hand, EMR specimens were significantly more 
likely to have positive lateral margins compared to ESD specimens (48.3% 
vs 8.7%, p=0.003) as well as have lower confidence in determining lat-
eral margins. The reason for lower confidence in the EMR group included 
cautery artifact (37.9%) and difficulty in orientation (20.7%). Interestingly, 
EMR and ESD had similar rates of positive vertical margins (7.1% vs 8.7%, 
p = 0.33).
conclusion: EMR and ESD had similar rates of positive vertical margins but 
rates of positive horizontal margins were significantly higher in the EMR 
group, despite a smaller size of lesion resected in the EMR group. We pos-
tulate that this is a limitation of the EMR technique and there is a certain 
lateral size threshold or Paris classification that is unsuitable for EMR as 
the standard EMR cap assisted technique may not be able to resect enough 
of a “normal” margin to the tumor compared to ESD. Further analysis is 
needed to determine if early EAC below a certain size threshold or tumor 
morphology may be more amenable to EMR technique while other types 
of tumors should undergo ESD to ensure higher rates of negative margins.
disclosure: Nothing to disclose 
P1563 WhaT Is The cause Of MIssed gasTrOInTesTInaL 
cancers and deLays In dIagnOsIs?
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Introduction: A delay in diagnosis in Upper Gastrointestinal Cancer (UGIC) 
and Colorectal Cancer (CRC) are associated with poor outcomes. Multiple 
studies have looked at rates of missed cancers at endoscopy, but few have 
looked at other factors that delay the time to endoscopy. This study looks at 
systematic factors responsible for this delay, and identifies ways in which 
we can reduce this delay in both UGIC and CRC.
aims & Methods: We looked at all patients diagnosed with an UGIC or 
CRC at King’s College Hospital (KCH), London between 2011-2018 inclusive. 
From this group we identified all patients who were seen by a Gastroenter-
ologist or a Colorectal Surgeon in the 36 months prior to diagnosis, either 
in clinic or at endoscopy. Each of these cases was looked at in detail to 
determine whether the cancer was missed due to a ‘Systematic Factor’ or 
was a ‘Post Endoscopy Cancer’.
results: 1,073 cases of GI Cancer were diagnosed in the study period. 60 
of 797 (7.5%) cases of CRC and 28 of 276 (11.3%) UGICs had been seen in 
the last 36 months. 61 patients (5.7%) were determined to have a ‘missed 
cancer’. From this group 10 UGICs and 23 CRCs were determined to be 
‘Post Endoscopy Cancers’ (PEC). The remaining 28 cases were determined 
to be missed secondary to ‘Systematic Factors’. Specific causes of delay in 
diagnosis are shown in Table 1. 
The mean length of delay was longer in the ‘Systematic Factors’ group 
versus the ‘PEC’ group (430 vs. 264 days). The ‘Systematic Factors’ group 
also showed a more advanced TNM staging compared the ‘PEC’ group; 
pT 2.14 vs. 1.39, pN 0.57 vs. 0.45, pM 0.07 vs 0.12. The ‘Systematic Fac-
tors’ group also showed a higher percentage of patients referred routinely, 
rather than via an emergency cancer pathway, compared to the PEC group 
(74.1% vs. 53.8%).
factor leading to delay number of patients
Post Endoscopy Cancers 33
Inadequate Investigation 10
Incomplete endoscopy 2
Poor bowel preparation 5
Missed on radiological investigation 2
Delayed investigation 4
Incomplete Follow up 4
Histology not reviewed 1
[Table 1. Factors leading to Delay of Diagnosis in Gastrointestinal Cancers]
conclusion: Post Endoscopy Cancers are well-established concept, leading 
to delays in diagnosing gastrointestinal cancers. However it is important to 
identify Systematic Factors which also impact on speed to diagnosis. High-
er proportions of missed cancer in the routine pathway imply that we are 
more likely to miss cancers without the pathway driven approach we see 
in Two Week Wait referrals. Systematic Factors are also more likely to con-
tribute to a longer delay to diagnosis and a more advanced clinical picture 
as shown by the TNM staging. Therefore, if we are to improve diagnosis of 
Gastrointestinal Cancers we should focus equally on the Systematic Factors 
leading up to diagnosis as well as the quality of endoscopy.
disclosure: Nothing to disclose 
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Introduction: Ingesting foreign bodies (FB) can be accidental or deliberate. 
It can be serious because of the location or nature of the FB, which makes 
their endoscopic extraction urgent. Prisoners represent a population par-
ticularly affected by this pathology.
aims & Methods: The purpose of our study was to describe the modalities 
of this endoscopic technique as well as to highlight its particularities in the 
inmates. We conducted a comparative retrospective study of consecutive 
patients who had undergone upper digestive endoscopy for foreign body 
extraction between January 1982 and December 2018. We have compared 
prisoners to non incarcerated patients.
results: We included 99 patients (74 men and 25 women) with a mean age 
of 29 years [6 months-66 years]. Endoscopy was performed for all patients. 
Of these patients, 30.3% were inmates. A psychiatric history was found 
more frequently among prisoners than non prisoners (90% versus 24.6%, 
p <0.001). The FB’s ingestion circumstance was more voluntary for the de-
tainee (90%, OR = 29, p <0.001). FBs were more numerous among inmates 
(43.3% versus 13%, p <0.001), with a higher frequency of metallic FB (70% 
versus 13%, p <0.001) and larger dimensions than non-incarcerated pa-
tients (63.6% versus 37.7%, p = 0.02). The success rate of the extraction was 
78% with no statistically significant difference between the two groups. 
Recurrence of FB ingestion was higher in the case of incarceration (13.3% 
versus 5.8%, p = 0.038).
conclusion: The multiple number, the large size of the ingested body and 
the predominance of metallic ones testify the severity of FB ingestion in 
the inmates. These are characteristics to be considered by the practitioner 
before extraction and also for better management of a fragile population 
in order to reduce the recidivism rate.
disclosure: Nothing to disclose 
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P1565 “LIghT BLue cresT” sIgn fOr dIagnOsIs Of gasTrIc 
InTesTInaL MeTaPLasIa usIng MagnIfyIng endOscOPy WITh 
I-scan OPTIcaL enhanceMenT
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Introduction: Gastric intestinal metaplasia (GIM) is considered as a prema-
lignant condition and associated with a high risk for the development of 
gastric cancer [1]. However, conventional white light imaging endoscopic 
features of GIM has a high rate of interobserver variability and correlates 
poorly with the histology. Uedo et al. first described “light blue crest” 
(LBC) sign as highly accurate sign of the presence of histological GIM us-
ing magnifying endoscopy and narrow band imaging (NBI) system with 
a monochrome CCD and rotary RGB filter (Lucera, Olympus) [2]. LBC was 
defined as an optical phenomenon caused by the reflectance of narrowed 
spectrum light on the ciliated surface of the epithelium that can be seen at 
the tangential observation of edge of the surface. However the possibility 
of LBC detection and its efficacy in diagnosis of GIM with other narrowed 
spectrum technologies were not fully investigated.
aims & Methods: The aim of this study was to evaluate the diagnostic ef-
ficacy of LBC in diagnosis of GIM with magnifying i-scan optical enhance-
ment endoscopy (PENTAX Medical, Japan). 86 gastric lesions in 46 patients 
(mean age 52.1 years, SD=10.2, 54% male, 46% female) were observed 
with magnifying i-scan optical enhancement endoscopy (EPK-i7010, endo-
scope EG-2990Zi, PENTAX Medical). Presence of LBC were assessed by two 
endoscopists (R.K. and S.K.), cases with low confidence of LBC diagnosis 
was consulted with developer of the LBC concept (N.U.). LBC was defined 
as a fine, blue-white line on the crests of the epithelial surface/gyri[2]. 
Forceps biopsy was performed for a histological evaluation of lesions.
results: From 86 gastric lesions complete GIM was confirmed in 14 cases, 
incomplete GIM - in 8 cases, mixed GIM - in 9 cases. LBC was diagnosed in 
22 cases (all lesions with confirmed GIM). Sensitivity, specificity, accuracy, 
positive predictive value, negative predictive value for LBC sign in diagno-
sis of GIM were 0.71, 1.00, 0.90, 1.00, 0.86, respectively.
conclusion: Magnifying endoscopy with i-scan optical enhancement tech-
nology provides accurate diagnosis of GIM by using LBC sign. Further stud-
ies are needed to evaluate the efficacy of different previously described 
endoscopic features of IM using new optical technologies.
references: 1. Pimentel-Nunes P., Libânio D., Marcos-Pinto R. et al. Man-
agement of epithelial precancerous conditions and lesions in the stomach 
(MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), Euro-
pean Helicobacter and Microbiota Study Group (EHMSG), European Society 
of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva 
(SPED) guideline update 2019. Endoscopy. 2019 Apr;51(4):365-388. 2. Uedo 
N, Ishihara R, Iishi H et al. A new method of diagnosing gastric intestinal 
metaplasia: narrow-band imaging with magnifying endoscopy. Endos-
copy. 2006 Aug;38(8):819-24.
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Introduction: Endoscopic resection of Superficial Colorectal lesions in close 
proximity to the Appendiceal Orifice (L-PAO) was shown to be feasible but 
is still considered impossible in case of deep invasion into the appendix 
(Toyonaga type 3). We report here a series of Endoscopic Submucosal Dis-
section with double clip and rubber band traction (DCT-ESD) of L-PAO to 
determine the outcomes.
aims & Methods: We reviewed retrospectively all the consecutive DCT-ESD 
resections of L-PAO in 3 french centers. Toyonaga’s classification was de-
scribed for each lesion and type 0 lesions which are not in contact of ap-
pendiceal orifice were excluded. Our primary outcome was En bloc and 
R0 resection rates for L-PAO. Morbidity (bleeding, perforation and acute 
appendicitis) and salvage surgery were recorded.
results: 32 patients underwent DCT-ESD (mean age 67). 11 patients had pre-
vious appendectomy (28.6%). Toyonaga’s type of lesion was type 3 (enter 
deeply in appendiceal orifice) for 22 lesions (68.8%) including 11 (34.4%) 
without history of appendectomy and 11 (34.4%) with previous appendec-
tomy, 7 type 2 (enters orifice, and transition to normal appendiceal mucosa 
is discernible on inspection of the appendiceal lumen) (21.9%) and 3 type 
1 lesions (reaches border of the appendix orifice) (9.4%). Median diameter 
of the specimen was 35 mm (10-110mm) and median resection duration 
was 47 min (10-230 min). En bloc resection was achieved in all cases exclu-
sively with DCT-ESD. Histology confirmed R0 resection in 29 cases (90.6%) 
and R1 in 3 cases but only with lateral contact with low grade dysplasia. 
Finally, 11 perforations occurred per-procedure and were all immediately 
closed with clips. In post-operation, 3 patients (10.7%) underwent delayed 
surgery without stomia for remaining leakage in 2 cases for complications 
related and in 1 case for incomplete resection. No death occurred.
conclusion: DCT-ESD is effective and safe for resection of lesion developed 
into appendiceal orifice. Most procedures allowed En Bloc curative resec-
tion by endoscopic means only avoiding surgery in 90.6% of cases.
disclosure: Nothing to disclose 
P1567 LOng-TerM OuTcOMes Of endOscOPIc resecTIOn 
fOr T1 cOLOrecTaL cancer
Corre F.1, Barret M.1, Terris B.2, Abouali E.1, Belle A.1, Leblanc S.1, 
Coriat R.1, Chaussade S.1
1Cochin Hospital, Gastroenterology, Paris, France, 2Cochin Hospital, 
Pathology, Paris, France
contact e-Mail address: felcorre@gmail.com
Introduction: Endoscopic resection allows treating intramucosal colorec-
tal cancer with a low morbidity and no mortality. However, lymph node 
involvement is found in about 10% of submucosal colorectal carcinomas, 
indicating additional surgical resection. According to the Japanese (JSCCR) 
and European (ESGE) guidelines, the presence of a deep submucosal infil-
tration (beyond 1000µm), poor differentiation, lympho-vascular invasion, 
or grade 2-3 tumor budding should lead to complementary surgery. The 
aim of this study was to assess the safety and long-term outcome of en-
doscopic resection for T1 colorectal carcinoma in a Western population.
aims & Methods: We conducted a retrospective study, from a prospec-
tively collected database including all patients with endoscopic mucosal 
resection or endoscopic submucosal dissection performed at a single 
French tertiary referral center. We included 68 consecutive patients with 
T1 colorectal cancer between February 2014 and May 2018. All patients 
were discussed in a dedicated multidisciplinary meeting for superficial 
gastrointestinal cancers. 
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We collected demographic data, procedural histological data and follow-
up data in order to determine the local and distant recurrence rates and 
overall, progression free and cancer specific survival.
results: The mean age of the population was 71.5 +/- 11.8. 44/68 (64.7%) 
lesions were in the colon and 24/68 (35.3%) in the rectum. 14/68 (20.6%) 
lesions were pedunculated. 26/68 (38,2%) patients had an endoscopic 
mucosal resection (EMR), 22/68 (32.4%) an endoscopic submucosal dis-
section (ESD), 8/68 (11.8%) a hybrid technique, 7/68 (10.3%) a conven-
tional polypectomy and 5/68 (7.4%) a full-thickness resection using a 
dedicated device (FTRD). En bloc resection rate was 49/68 (72.1%), his-
tologically resection rate was 45/68 (66.2%) and curative resection rate 
was 11/68 (16.2%). Overall, 49/68 (72.1%) patients had an indication for 
complementary surgery. 
However, only 29/68 (42.6%) actually underwent the surgery: eight were 
lost to follow-up, seven declined surgery and five were not fit for the 
surgical procedure. Among the patients who underwent surgery, 6/29 
(20.7%) actually had lymph node metastases. The median follow-up was 
32 months (15-41 months). Nine patients were lost to follow-up. During 
follow-up, 3/59 (5.1%) patients had cancer relapse: one patient developed 
a metachronous colorectal cancer with distant metastases, one patient de-
veloped distant metastases after declining complementary surgery, and 
one patient developed lymph node metastasis although the initial endo-
scopic resection was thought to be curative, and was ultimately treated 
with chemoradiotherapy and then surgery. 3/59 (5.1%) patients died, one 
from a distant metastatic relapse of his colorectal cancer and the two oth-
ers from non cancer related other causes. 
Finally, among the 59 patients followed after endoscopic resection for T1 
colorectal cancer, 8 (13.4%) were metastatic: 6 (10.2%) had lymph node 
metastasis on the surgical specimen and 2 (3.4%) developed distant me-
tastases during follow-up.
conclusion: Our data support the validity of the JSCCR guidelines in a 
French monocentric cohort with long-term follow-up: endoscopic resec-
tion of T1 colorectal cancer can be considered safe and curative in the vast 
majority of cases. Given the high proportion of surgical specimens free 
of lymph node metastases, additional criteria to assess the risk of lymph 
node involvement associated with early colorectal cancer are needed.
references: 1) Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, 
Hase K, Matsukuma S, Kanai T, Kurihara H, Ozawa K, Yoshimura K, Bekku 
S: Risk factors for an adverse outcome in early invasive colorectal carci-
noma. Gastroenterology 2004; 127: 385-394. 2) Watanabe, Toshiaki, Kei 
Muro, Yoichi Ajioka, Yojiro Hashiguchi, Yoshinori Ito, Yutaka Saito, Tetsuya 
Hamaguchi, et al. « Japanese Society for Cancer of the Colon and Rectum 
(JSCCR) Guidelines 2016 for the Treatment of Colorectal Cancer ». Interna-
tional Journal of Clinical Oncology 23, nᵒ 1 (february 2018): 1-34.
disclosure: Nothing to disclose 
P1568 BIOPOTenTIaLs fOr cLInIcIan saTIsfacTIOn WITh 
sedaTIOn In cOLOnOscOPy
Hann A.1, Götze S.1, Mehlhase N.1, Gruss S.2, Walter S.2
1Ulm University, Department of Internal Medicine I, Ulm, Germany, 2Ulm 
University, Department of Psychosomatic Medicine and Psychotherapy, Ulm, 
Germany
contact e-Mail address: a.hann@posteo.de
Introduction: Nurse-administered propofol sedation (NAPS) with intermit-
tent bolus applications has become the standard procedure for colonosco-
py in Germany. Although patient satisfaction with this method is high, little 
about the satisfaction of the examiner and factors that might negatively 
influence this satisfaction are available.
aims & Methods: In this ongoing study we hypothesized that the num-
ber of movements or paralinguistic noises during sedation correlate with 
lower overall scores in the Clinician Satisfaction with Sedation Instrument 
(CSSI). Further we aimed to measure different biopotentials of the patient 
in order to accurately identify movements and paralinguistic noises that 
result in administration of sedating drugs.
Consecutive patients scheduled for a colonoscopy or sigmoidoscopy were 
prospectively enrolled. Biopotentials including electromyography of dif-
ferent facial muscles, skin conductance level and body temperature were 
obtained during the procedure. Additionally, events like movements, para-
linguistic noises, dosages of sedatives were recorded with the correspond-
ing event time. Clinician Satisfaction with Sedation Instrument (CSSI) was 
filled out by the examiner after the procedure. Correlation between the 
number of movements and paralinguistic noises and the global values 
of CSSI were calculated. Additionally, biopotentials were evaluated for 
their relationship with the recorded events. ClinicalTrials.gov number: 
NCT03860779.
results: 94 patients were enrolled. Biopotentials were available for 76 pa-
tients. Mean global satisfaction with the sedation was 84 (95% CI; 81-88) 
of 100 points. Combined events of movements and paralinguistic noises 
were mean 7 (95% CI; 6-9) per examination. Lower global satisfaction with 
the sedation values significantly correlated with higher values of move-
ments and paralinguistic noises (p< 0.001). Skin conductance level was 
available for 71 patients. Changes in the conductance level show a first 
relationship between body movements, paralinguistic noises and the ap-
plication of sedatives in 53 (75%) examinations.
conclusion: In this ongoing trial we were able to present that movements 
and paralinguistic noises of the patient during colonoscopy are associated 
with a lower satisfaction with the sedation using the CSSI. Simultaneously 
measured biopotentials - in combination with machine learning algorithm 
- might help to overcome this problem by helping to identify the right tim-
ing for the application of sedatives.
disclosure: Nothing to disclose 
P1569 IMPrOved BI-ManuaL endOscOPIc resecTIOn usIng a 
cusTOMIzaBLe ManIPuLaTOr sysTeM desIgned as an OverTuBe 
fOr sTandard endOscOPes
Walter B.1, Krieger Y.2, Lüth T.2, Meining A.3
1Universitätsklinikum Ulm, Klinik für Innere Medizin I, Ulm, Germany, 
2Technische Universität München, Fakultät für Maschinenwesen, Lehrstuhl 
für Mikrotechnik und Medizingerätetechnik (MiMed), München, Germany, 
3Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, 
Würzburg, Germany
contact e-Mail address: benjamin.walter@uniklinik-ulm.de
Introduction: Endoscopic submucosal dissection (ESD) can be considered 
for en-bloc resection of early cancers in the gastrointestinal tract. A ma-
jor drawback of the current technique is its inability to perform bimanual 
tasks. We have recently designed and evaluated a 3D-printed platform that 
was successfully tested in the living pig model (Zizer et al., Endoscopy 
2015). Nevertheless, we also experienced that complex procedures in an 
angulated position might be difficult to perform using such a system.
aims & Methods: On the basis of an automated design process for the flex-
ible manipulator structures as well as additive manufacturing by means of 
selective laser sintering the overtube manipulator system for ESD was fur-
ther modified. Several subtypes were printed that included a single- and 
dual-arm version, as well as a version for pediatric scopes and standard 
gastroscopes, respectively. Furthermore, manipulators were either small 
or long. 
Focus of the study was to evaluate the feasibility of endoscopic submucosal 
resection with the new systems. ESD was performed in a porcine ex-vivo 
model. 30mm lesion in size were resected located in the upper and lower 
GI tract (corpus, antrum; cecum, rectum).
results: In total, 24 ESD’s were performed (6 antrum, 6 corpus in inversion, 
6 cecum, 6 rectum) with one-arm and two-arm manipulators or small (ᴓ 
5mm) or standard scopes (ᴓ 10mm), respectively. ESD was feasible in 13 
cases. Mean procedure time (min±SD) for ESD was 17.5(±7.1) for the corpus, 
19.2(±8.5) for antral lesions, 20.5(±12.3) for the rectum, and 30.1(±8.5) for 
the cecum. Pediatric scope manipulators were too frail for sufficient resec-
tion working in inversion and for lesions located in the cecum. Resection 
was also impaired in the corpus and rectum using longer sized manipula-
tor-arm systems. Single-arm manipulator equipped standard endoscopes 
offered best results in optimal traction-countertraction during ESD for all 
locations. ESD was feasible in all those 4/4 cases. Mean procedure time 
was rather short with 16.5(±4.6).
conclusion: Based on our preliminary date we conlude that ESD is feasible 
using a customizable manipulator system designed for standard endo-
scopes with a monolithic design in an ex-vivo model. A single-arm ma-
nipulator system attached onto a standard gastroscope appears to offer 
the optimum utilization of traction and counter traction during endoscopic 
resection even in difficult locations. 
This work is supported and founded by the Deutsche Forschungsgemein-
schaft (DFG). DFG-RG 1321
disclosure: Nothing to disclose 
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P1570 cOnsuLTanT TrIage aLOne and cOMBIned cOnsuLTanT 
and endOscOPy nurse TrIage sIgnIfIcanTLy reduce 
InaPPrOPrIaTe endOscOPIes esPecIaLLy urgenT P1 referraLs
Tony A., Kaippilly Naryanan V., Armstrong P., Fauzi N., Yadav A., Hall B., 
Kelly O., Smyth C., Farrell R.
Connolly Hospital,Blanchardstown, Royal College of Surgeons of Ireland, 
Gastroenterology, Dublin, Ireland
contact e-Mail address: ambilymck@gmail.com
Introduction: The Irish public endoscopy service is facing unprecedented 
pressure in terms of a huge increase in endoscopy referrals over the past 
10 years with currently over 20,000 patients on the Inpatient/Daycase Na-
tional GI Endoscopy waiting list. Despite established referral guidelines 
many patients are referred inappropriately from both primary and second-
ary care for urgent and non-urgent endoscopies with high non-attendance 
and cancellation rates. There is a lack of data assessing the impact of con-
sultant triage and endoscopy nurse triage on endoscopy referrals.
aims & Methods: To prospectively compare the effect of consultant triage 
alone (which is relatively less labour intensive) with combined consultant 
and endoscopy nurse triage (which is relatively more labour intensive) on 
endoscopy referrals to our endoscopy unit. 
Methods: All endoscopy referrals including GP letters, direct access and 
Surgical, Medical and ED referrals received over a 28 day period in Febru-
ary 2019 were included in this prospective study. Referrals were stratified 
pre-triage into urgent/priority 1 (P1) within 4 weeks, non-urgent/priority 2 
(P2) within 3 months and surveillance groups before being triaged by 4 GI 
consultants based on established HIQA and BSG endoscopy referral guide-
lines. Any referrals with missing data, alarm symptoms, prior endoscopy/
histology data were subsequently validated by telephone triage by our 
Endoscopy Triage Nurse. Outcomes were compared between pre-triage, 
consultant triage and combined consultant and endoscopy nurse triage. 
Statistical analysis was performed using student Chi Square test.
results: Out of 312 endoscopy referrals during the study period, 12 pa-
tients were excluded as they had already undergone consultant triage. Of 
the 300 patients enrolled (median age 50, range 17-88, M:F 150:150). 142 
(47%) were directly referred from their GP, 101 (34%) from the Surgical 
department, 31 (10.4%) from other Medical departments and 26 (8%) from 
the Emergency Department. Prior to triage 159 patients were referred for 
urgent P1 endoscopy, 125 for non-urgent P2 endoscopy and 16 for surveil-
lance endoscopy. Consultant triage alone reduced P1 endoscopies by 16% 
from 159 to 133 (p=0.02) and combined consultant and endoscopy nurse 
triage reduced P1 endoscopies by a total of 30% to 112 (p=0.0003). Consul-
tant triage increased overall P2 endoscopies marginally from 125 to 129 and 
subsequently to 124 after endoscopy nurse triage (P=0.5(nonsignificant). 
Consultant triage alone reduced all endoscopy referrals by 11% (p< 0.05) 
redirecting referrals to HP testing/OPD/GP follow-up/CT colonography 
while combined consultant and endoscopy nurse triage reduced all en-
doscopy referrals by 21% (p=0.01).
conclusion: Consultant triage alone significantly reduced 16% of urgent 
endoscopy referrals and 11% of all endoscopy referrals while combined 
consultant and endoscopy nurse triage significantly reduced 30% of urgent 
endoscopy referrals and 21% of all endoscopy referrals. Both consultant 
triage alone and combined consultant and endoscopy nurse triage can 
achieve significant reductions and cost savings in endoscopy referrals.
disclosure: Nothing to disclose 
P1571 LesIOn MOrPhOLOgy and TOPOgraPhy InfLuence The 
PredIcTIOn and MIss raTes Of suBMucOsaL InvasIve cancer 
In cOLOrecTaL LaTeraLLy sPreadIng LesIOns
Vosko S.1, Shahidi N.1, Sidhu M.1, Hourigan L.F.2, Singh R.3, Moss A.C.4, 
Van Hattem A.1, Bar-Yishai I.1, Schoeman S.1, Burgess N.5, Bourke M.J.1
1Westmead Hospital, Department of Gastroenterology and Hepatology, 
Westmead, NSW, Australia, 2Princess Alexandra, Department of 
Gastroenterology and Hepatology, Brisbane, Australia, 3Lyell McEwin 
Hospital, Department of Medicine, Adelaide, Australia, 4Western Health, 
Melbourne, Endoscopy Department, Melbourne, Australia, 5Westmead 
Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia
contact e-Mail address: nealshahidi@gmail.com
Introduction: The majority of large (≥ 20mm) colorectal laterally spreading 
lesions (LSLs) are benign and can be effectively managed by piecemeal en-
doscopic mucosal resection (EMR). However, a subgroup harbor submuco-
sal invasive cancer (SMIC) and require en bloc resection by an alternative 
resection technique. Accurately predicting SMIC by optical evaluation is 
critical to inform therapeutic decisions. It is unknown whether LSL mor-
phology, specifically nodular versus flat morphology, and LSL topography 
influence the performance of SMIC prediction.
aims & Methods: Colorectal LSLs ≥ 20mm referred for endoscopic resec-
tion, within a prospective multi-center observational cohort, were consid-
ered for inclusion. As per protocol, optical evaluation was performed prior 
to endoscopic resection and included lesion morphology (Paris classifica-
tion), topography (granular, non-granular, mixed), surface pit pattern and 
surface vascular pattern characterization. SMIC prediction was based on 
the identification of established surface pit pattern and vascular pattern 
features consistent with invasive neoplasia. Rigid/fixed/non-lifting lesions 
and those with a Paris 0-IIc component were excluded, as these features 
are strongly associated with SMIC and are established predictors of it. 
Sensitivity, specificity, accuracy* and miss rates were calculated for SMIC 
prediction with histology as the reference gold standard. Outcomes were 
then stratified by nodular (Paris 0-Is and 0-IIa+Is) versus flat (Paris 0-IIa 
and 0-IIb) morphology and topography 
*Accuracy = correctly predicted lesions for histology (including SMIC and 
non-SMIC) divided by total number of lesions.
results: From July 2013 - March 2019, 1808 colorectal LSLs were identified. 
258 serrated lesions, 39 rigid/fixed/non-lifting lesions, and 79 lesions with 
a Paris 0-IIc component were excluded from analysis. Of the remaining 
1432 LSLs (mean size 37.2m; range 20-120; 665 nodular, 767 flat), SMIC was 
identified in 92 (6.4%). Overall sensitivity, specificity, and accuracy of SMIC 
prediction were 43.5% (95% CI 33.7%-53.7%), 98.4 (95% CI 97.6%-98.9%) 
and 94.8% (95% CI 93.5%-95.8%), respectively. 
Sensitivity decreased when comparing nodular LSLs (37.5%; 95% CI 
25.9%-50.0%) vs. flat LSLs (57.1%; 95% CI 37.4%-74.9%) and non-gran-
ular LSLs (58.6%; 95% CI 40.6%-75.0%) vs. granular LSLs (32.6%; 95% 
CI 20.4%-46.9%). The overall miss rate was 3.6%. This was significantly 
higher amongst nodular vs. flat LSLs (6.4% vs. 1.6%; p< 0.001) with flat 
granular LSLs having the lowest SMIC miss rate (0.7%; 95% CI 0.2-1.9) 
amongst all LSL sub-populations.
variable nodular Lesions % (95% cI)
flat Lesions % 
(95% cI) P-value
Sensitivity All Lesions 37.5 (25.9-50.0) 57.1 (37.4-74.9)  
Sensitivity Granular 30.0 (17.6-45.2) 50.0 (16.7-83.3)  
Sensitivity Non-Granular 55.6 (25.4-82.7) 60 (38.4-78.9)  
Sensitivity Mixed 46.7 (23.9-70.6) 50 (6.1%-93.9)  
Specificity All Lesions 97.3 (95.6-98.4) 99.0 (97.9-99.5)  
Specificity Granular 98.1 (96.5-99.0) 100  
Specificity Non-Granular 94.3 (88.0-97.8) 97.5 (95.2-98.9)  
Specificity Mixed 95.3 (85.9-99.0) 100  
Accuracy 91.6 (89.3-93.5) 97.5 (96.2-98.5) < 0.001
SMIC Missed 6.4 (4.4-8.0) 1.6 (0.9%-2.8%) < 0.001
[Submucosal Invasive Cancer Prediction Performance and Miss Rates]
conclusion: The sensitivity of predicting SMIC by pit pattern and vascu-
lar pattern is limited in large colorectal LSLs, specifically nodular lesions. 
Given their SMIC miss rate, nodular LSLs, in the absence of concerning 
features on optical biopsy, require further risk stratification to accurately 
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identify optimal candidates for en bloc resection techniques. Alternatively, 
flat granular lesions, in the absence of optical features of SMIC, need only 
be removed by EMR.
disclosure: Nothing to disclose 
P1572 a dedIcaTed 12 MOnTh cOMPeTency-Based TraInIng 
PrOgraMMe In endOscOPIc MucOsaL resecTIOn aLLOWs safe 
and effecTIve resecTIOn Of cOMPLex LaTeraLLy sPreadIng 
LesIOns
Sidhu M.1,2, Tate D.J.3, Bourke M.J.1
1Westmead Hospital, Gastroenterology and Hepatology, Sydney, Australia, 
2University of Sydney - Westmead Clinical School, Sydney, Australia, 
3Westmead Hospital, Gastroenterology and Hepatology, Gent, Belgium
contact e-Mail address: drmsidhu16@gmail.com
Introduction: No formal training pathways for endoscopic mucosal resec-
tion (EMR) currently exist and training is often ad-hoc and sporadic. As 
such many endoscopists practice EMR without formal training. This may 
contribute to incomplete polyp resection and referral of large benign 
colorectal neoplasia to surgery. We aimed to investigate the impact of a 
dedicated 12-month EMR training program on trainee competency.
aims & Methods: Prospective data, relating to technical aspects of EMR 
and outcomes, was collected from consecutive directly-supervised proce-
dures commenced by five trainees over a 12-month period at a tertiary 
endoscopic resection centre. All trainees had achieved appropriate com-
petency in colonoscopy (at least 200 independent procedures prior to their 
training year of which at least 50 procedures involved diminutive polyp-
ectomy) and undertook a four-week observation period prior to starting 
cases. Data was analysed in two cohorts divided by procedures performed 
in the first or second six months of their training period.
results: Five trainees (median age - 31yrs) performed 98 EMRs in 98 pa-
tients over 12 months. Median lesion size in the first half was 30mm (in-
terquartile range [IQR] 25-40) and 35mm (IQR 25-50) in the second. The 
complexity of LSL increased in the second half of the cohort [SMSA 4 LSL 
2nd half vs 1st half, 47.2% (26/55) vs. 32.5% (14/43)]. Other important le-
sion characteristics did not vary between the halves of the cohort.
The ability to competently perform dynamic submucosal injection and 
specimen retrieval after EMR was significantly more likely in the second 
six months of training as compared to the first (86.8% vs 54.8%, p=0.001 
and 88.9% vs 60.5%, p=0.002 respectively).
Trainees were significantly more likely to independently complete greater 
than 50% of the EMR procedure in the second six months of their train-
ing as compared to first (81.8% vs 51.2%, p= 0.001, OR - 4.3 (1.7-10.7], 
p= 0.002). The need for consultant intervention was also significantly less 
likely in the second half of the training period (62.8% vs 40%, p=0.004).
Despite the involvement of a trainee and the complexity of the lesions at-
tempted the overall technical success was 96.9% and not statistically dif-
ferent between the two cohorts. There was also no significant difference 
in the rate of adverse events including bleeding and deep mural injury 
(see Table 1). 
Table 1 first half
second 
half Total p
Or (95% cI) 
1st vs 2nd half p
Median Size, mm (IQR)
30 (25-
40)
35 (25-50)        
SMSA Level 2/3/4 13/16/14 12/17/26 25/33/40 0.33    
SMSA-EMR Level: Low 
Risk/ High Risk
15/28 25/30 40/58 0.30    
dynamic submucosal 
injection 17 (54.8) 46 (86.8) 63 0.001 5.6 (1.7-18.0) 0.005
Percentage of 
resection performed 
independently <50% 
v. >50%
21 (48.4) 
vs. 22 
(51.2)
10 (18.2) vs. 
45 (81.8)
31 vs. 67 0.001 4.3 (1.7-10.7) 0.002
consultant takeover 27 (62.8) 22 (40) 63 0.04 2.53 (1.1-5.8) 0.03
Technical success (%)
41 
(95.3%)
54 (98.2%) 95 (96.9) 0.42    
CSPEB 3 7 10 0.35    
Total 43 55 98      
[Lesion Characteristics, Trainee and Procedure Outcomes; CSPEB - clinically 
significant endoscopic bleeding, SMSA - size, morphology, site and access]
conclusion: Endoscopists competent in diminutive polypectomy can be 
trained to perform EMR of complex colorectal lesions safely and without 
detriment to overall outcomes. Key aspects of this programme include a 
focussed, intensive period of training (>6 months) with competency-based 
teaching and introduction of sequentially more complex lesions (identified 
using the SMSA score [1]). 
This study may provide a foundation for the development of a structured, 
competency based training program for endoscopists learning advanced 
tissue resection.
references: [1] Sidhu M, Tate DJ, Desomer L, Brown G, Hourigan LF, Lee 
EYT, Moss A, Raftopoulos S, Singh R, Williams SJ, Zanati S, Burgess N, 
Bourke MJ. The size, morphology, site, and access score predicts critical 
outcomes of endoscopic mucosal resection in the colon. Endoscopy. 2018 
Jul;50(7):684-692. doi: 10.1055/s-0043-124081. Epub 2018 Jan 25. Erratum 
in: Endoscopy. 2018 Jul;50(7):C7. PubMed PMID: 29370584.
disclosure: Nothing to disclose 
P1573 endOscOPIc MucOsaL resecTIOn Is an effecTIve and 
defInITIve TheraPy fOr LaTeraLLy sPreadIng LesIOns aT The 
anOrecTaL juncTIOn
Shahidi N.1,2, Sidhu M.1,3, Vosko S.1, van Hattem A.1, Bar-Yishay I.1, 
Schoeman S.1, Tate D.J.4, Holt B.5, Hourigan L.6, Burgess N.1,3, Bourke M.J.1,3
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Sydney, Australia, 2University of British Columbia, Department of Medicine, 
Vancouver, Canada, 3University of Sydney - Westmead Clinical School, 
Sydney, Australia, 4Westmead Hospital, Gastroenterology and Hepatology, 
Gent, Belgium, 5St. Vincent’s Hospital, Department of Gastroenterology 
and Hepatology, Melbourne, Australia, 6Princess Alexandra Hospital, 
Queensland, Australia
contact e-Mail address: nealshahidi@gmail.com
Introduction: Large (≥ 20mm) laterally spreading lesions (LSLs) at the ano-
rectal junction are most commonly referred for surgery due to the unique 
anatomical, sensory and physiological characteristics of this area. More 
recently, it has been argued that these lesions, if treated endoscopically, 
should be managed by endoscopic submucosal dissection (ESD) or trans-
anal endoscopic microsurgery (TEM). Endoscopic mucosal resection (EMR) 
is well established as a definitive therapy for colorectal LSLs, however, it is 
unknown whether it is an effective and durable treatment for LSLs at the 
ARJ (ARJ-LSLs).
aims & Methods: We evaluated the technical success, short-term and long-
term outcomes of EMR for ARJ-LSLs (defined as distal margin either cross-
ing or within 20mm of the dentate line) in comparison to rectal LSLs within 
a prospective multi-center observational cohort of LSLs ≥ 20mm. 
Technical success was defined as complete removal of all neoplastic tissue 
during index EMR. Safety was evaluated by the frequency of intra-pro-
cedural bleeding, deep mural injury, delayed bleeding and perforation. 
Long-term efficacy was defined by the absence of either endoscopic or 
histological recurrence at surveillance colonoscopy (SC) at recommended 
intervals of 6, 12, 36 and 60 months (SC1 - SC4, respectively).
results: Between July 2008 - April 2019, 109 ARJ-LSLs and 351 rectal LSLs 
were considered for endoscopic resection. Twenty (5 ARJ, 15 rectal) LSLs 
had endoscopic features consistent with deep submucosal invasive cancer 
(SMIC) and were referred directly to surgery. 
One rectal lesion had a concomitant sigmoid cancer and went to surgery. 
Recently, 39 (18 ARJ, 21 rectal) LSLs were enrolled in a selective ESD pro-
tocol and were excluded from analysis. The remaining 86 ARJ-LSLs (mean 
size 48.3mm, range 20 - 100mm) were removed by EMR. Technical success 
was 97.7%. SMIC was present in 3 (3.5%) lesions. 
The frequency of recurrence was 14.9%, 4.7%, 5.3% and 0.0% at SC1-SC4 
and surgery was avoided in all. Amongst 24 ARJ-LSLs which underwent 
margin snare-tip soft coagulation (STSC) to mitigate the risk of recurrence, 
no recurrence was identified at SC1 (0.0% vs. 23.3%; p=0.01), nor at SC2 - 
SC4. The frequencies of technical success, adverse events and recurrence 
were not different between ARJ-LSLs and rectal LSLs.
conclusion: EMR is a safe, efficient, effective and durable therapy for ARJ-
LSLs. EMR should be considered as the primary therapeutic modality for 
the majority of these lesions.
disclosure: Nothing to disclose
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variable arj-LsLs n=86(%) rectal LsLs n=314(%) p-value
Mean age (sd) (years) 64.3 (12.3) 65.7 (12.4)  
Male sex 46 (54.8%) 170 (54.7%)  
Mean size (range) (mm) 48.3 (20 - 100) 43.3 (20 - 120)  
cancer 3 (3.5%) 38 (12.1%)  
successful resection 84 (97.7%) 305 (97.1%) 0.786
Intra-Procedural Bleeding 10 (11.6%) 18 (5.7%) 0.058
Intra-Procedural Perforation 0 (0%) 2 (0.6%) 0.458
delayed Bleeding 9 (10.7%) 24 (7.7%) 0.369
delayed Perforation 0 (0.0%) 1 (0.3%) 0.604
sc1 completed/eligible 67/75 (89.3%) 211/246 (85.8%)  
sc1 recurrence 10 (14.9%) 35 (16.6%) 0.748
sc2 completed/eligible 43/66 (65.2%) 149/213 (70.0%)  
sc2 recurrence 2 (4.7%) 10 (6.7%) 0.623
sc3 completed/eligible 19/39 (48.7%) 73/158 (46.2%)  
sc3 recurrence 1 (5.3%) 1 (1.4%) 0.300
sc4 completed/eligible 5/9 (55.6%) 17/35 (48.6%)  
sc4 recurrence 0 (0.0%) 0 (0.0%) NA
[Patient/Lesion Characteristics and EMR Outcomes of ARJ-LSLs vs. Rectal 
LSLs]
P1574 MuLTIcenTer sTudy Of LInked cOLOr IMagIng fOr 
IMPrOvIng The vIsIBILITy Of fLaT cOLOrecTaL POLyPs By 
endOscOPIsTs and cOLOr dIfference vaLues
Yoshida N.1, Hisabe T.2, Ikematsu H.3, Inoue K.4, Dohi O.5, Itoh Y.6, Saito Y.7
1Kyoto Prefectural University of Medicine, Molecular Gastroenterology 
and Hepatology, Kyto, Japan, 2Fukuoka University Chikushi Hospital, 
Gastroenterolology, Chikushino, Japan, 3National Cancer Center Hospital 
East, Department of Gastroenterology & Endoscopy, Kashiwa, Japan, 4Kyoto 
Pref University of Medicine, Kyoto, Japan, 5Kyoto Prefectural University of 
Medicine, Gastroenterology and Hepatology, Kyoto, Japan, 6Kyoto Prefectural 
University of Medicine, Kyoto, Japan, 7National Cancer Center Hospital 
Endoscopy Division, Endoscopy Division, Tokyo, Japan
contact e-Mail address: naohisa@koto.kpu-m.ac.jp
Introduction: Linked color imaging (LCI) is one of image-enhanced endos-
copies and can visualize gastrointestinal lesions better. We previously re-
ported that LCI improved the visibility of various colorectal lesions includ-
ing diminutive polyps and sessile serrated adenoma and polyps (SSA/P) 
using videos and pictures [1,2]. 
In this study, we analyzed the efficacy of LCI for improving flat polyp’s 
visibility in various situations including fast-withdrawal or large-monitor 
observation utilizing endoscopist’s visibility scoring and color difference 
(CD) value in a multicenter study.
aims & Methods: We recorded videos of flat polyps 2-20 mm in white light 
imaging (WLI), blue laser imaging-bright (BLI-b), and LCI from July 2017 
to December 2017 according to inclusion criteria. All videos were evalu-
ated by 8 endoscopists according to a published polyp visibility score from 
four (excellent) to one (poor). Additionally, 1.5-times-faster videos and 
1.7-times-larger-sized videos were also evaluated. Moreover, we calcu-
lated color difference (CD) value in three modes between each polyp and 
surrounding mucosa.
results: The mean scores of LCI (3.11±0.95) were significantly higher than 
WLI (2.55±1.04, p< 0.001), and were not significantly higher than BLI-b. 
With respect to right-sided location, < 10mm size, and serrated lesions, 
the scores of LCI were significantly higher than WLI. Additionally, the 
scores of faster videos were significantly lower than normal videos in each 
mode. The scores of faster videos in LCI (3.0±1.1) were also significantly 
higher than WLI (2.0±1.0, p< 0.001) and BLI-b (2.8±1.1, p=0.03). The scores 
of larger-sized videos weren’t significantly higher than normal monitor’s 
videos in each mode. The CD value of LCI was significantly higher than WLI 
(18.0±7.7 vs. 11.7±7.0, p< 0.001) and BLI-b (15.8±9.6, p=0.04).
conclusion: Our study showed that LCI significantly improved visibility of 
colorectal polyps in various situations such as faster withdrawal or a larg-
er-sized monitor observation with multicenter study. Moreover, we proved 
LCI’s increase of objective CD value as an objective indicator for polyp vis-
ibility compared to WLI and BLI-b. According to these results, we thought 
LCI is promising for polyp detection. Prospective randomized control stud-
ies are expected in the future for proving this hypothesis. 
references: 1. Yoshida N, Naito Y, Murakami T, et al. Linked color imag-
ing improves the visibility of colorectal polyps: a video study. Endosc Int 
Open 2017; 5: E518-525 2. Yoshida N, Naito Y, Yasuda R, et al. Linked color 
imaging improves the visibility of various featured colorectal polyps in an 
endoscopist’s visibility and color difference value. Int J Colorectal Dis 2017; 
32: 1253-1260
disclosure: This study was performed by a research fund from Fujifilm 
(J162001222). Yoshito Itoh is affiliation with a donation-funded department 
from FUJIFILM Medical Co. Ltd. Naohisa Yoshida received a research grant 
from Fujifilm Co. The other authors have no conflicts of interest to declare. 
P1575 effecTIveness Of an InjecTaBLe, POLy(aMIdOaMIne)
s Based hydrOgeL as suBMucOsaL LIfTIng agenT In cOLOnIc 
esd: In-vIvO anIMaL sTudy
Lim S.G.1,2, Mascagni P.3, Piantanida E.4, Fiorillo C.5, Pizzicannella M.2,6, 
De Cola L.4, Perretta S.7
1Ajou University School of Medicine, Gastroenterology, Suwon, Korea 
(Republic of), 2IHU-Strasbourg, Strasbourg, France, 3IRCAD, IHU-Strasbourg, 
Strasbourg, France, 4Institut de Science et d’Ingeńierie Supramolećulaires, 
CNRS, UMR7006, Université de Strasbourg, Strasbourg, France, 5’A Gemelli’ 
Hospital, Catholic University of Rome, Digestive Surgery, Rome, Italy, 
6Campus Bio-medico University, Endoscopic Unit, Cienzano di Roma, Italy, 
7IRCAD-IHU, Surgery, Strasbourg, France
contact e-Mail address: mdlsk75@gmail.com
Introduction: Endoscopic submucosal dissection (ESD) is a well- estab-
lished technique that allows for en bloc removal of superficial gastro-in-
testinal cancer. To improve the efficacy, safety of endoscopic submucosal 
dissection techniques the quality and duration of the submucosal lift is key. 
Currently available agents are not satisfactory. The objective of this study is 
to assess the safety and efficacy of an injectable, poly(amidoamine)s based 
hydrogel to lift the submucosa in comparison with standard lifting solution 
for colorectal ESD in an in vivo porcine study.
aims & Methods: Prior to ESD proper preparation of the colon was carried 
out. 
ESD of similar size (2x2cm) were performed in the colon 20 to 30cm from 
the anal verge by an experienced endoscopist. Two types of solutions were 
used for submucosal lifting: saline solution in the control group and hy-
drogel. Procedure time, dissection speed, and complications were record-
ed and compared between the two groups.
results: 22 procedures were performed in the colorectum of thirteen pigs 
(10 ESDs in control group and 12 ESDs in hydrogel ESD group). Effective 
procedure times were 2744 seconds in control group and 1496 seconds 
in hydrogel ESD group. In the hydrogel ESD group the dissection speed 
improved significantly after the first five cases (26.77 mm2/min in first five 
cases vs 49.88 mm2/min in later seven cases) and the mean dissection 
speed in last seven cases was significantly faster than that in control group 
(49.83 mm2/min vs 29.13 mm2/min, p=0.019). Perforation occurred in 3 
cases in the control group and in 1 case in the hydrogel ESD group.
conclusion: The use of poly(amidoamine)s based hydrogel as a lifting 
agent significantly improved dissection speed compared to standard saline 
solution in colorectal ESD. Further randomized studies should confirm the 
lower rate of perforation observed in the hydrogel group.
disclosure: Nothing to disclose 
P1576 endOcyTOscOPy-LIke MaxIMuM-MagnIfyIng 
evaLuaTIOn WITh cMOs Laser endOscOPy fOr cOLOrecTaL 
LesIOns Is cLInIcaLLy usefuL
Yasuda M.1,2, Naito Y.2
1Uji-Tokushukai Medical Center, Dept. of Gastroenterology and Hepatology, 
Kyoto, Japan, 2Kyoto Pref University of Medicine Gastroenterology, Dept. of 
Gastroenterology, Kyoto, Japan
contact e-Mail address: koutoku7@fa2.so-net.ne.jp
Introduction: As an endoscopic diagnosis of neoplastic lesions of the co-
lon and rectum, an endoscope capable of ultra-magnifying 520 times has 
been put on the market and is spreading. Developed by Kudo et al., this is 
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an extremely excellent and epoch-making endoscope system that allows 
real-time observation similar to microscopic HE staining by contacting a 
lens of a colonoscope with a lesion after staining the lesion with methy-
lene blue and crystal violet.
However, the endoscope is limited in that it is a little expensive, that it is 
used by a system made by Olympus, and that it requires a little techniques 
to be contacted and observed.
Therefore, we examined how close the conventional magnifying endo-
scope can be to the above-mentioned super-magnifying endoscope Endo-
cytoscope even by non-contact observation, and how much Endocyte-like 
evaluation can be observed with the widely marketed and widespread en-
doscope with laser light source, which is equipped with CMOS image cen-
ter manufactured by FujiFilm Co., optical 135 times, electronic 270 times 
magnification.
aims & Methods: From March 2018 to December 2018, we studied 40 cases 
in which colorectal lesions were observed on Endocyte and CMOS laser 
source endoscopy at our hospital.
The Endocyte system used Olympus’s CF-H 290 ECI endoscope and EVIS 
Elite 290 light source system.
The CMOS laser source endoscope used the Fujifilm endoscope EC-L 600 
ZP and the light source system LASEREO 4450.
When lesions were observed, they were compared by methylene blue-
crystal violet staining with 520 fold magnification for CF-H 290 ECI and 270 
fold magnification for EC-L 600 ZP.
In addition, the established EC classification at the end site was made the 
golden standard, and it was examined in comparison with EC1a, EC1b, EC2, 
EC3a, EC3b, pathology after the lesion cutting.
Observation with a CMOS laser endoscope at a maximum magnification of 
270 times is classified into ECL, a classification similar to EC classification.
Classified as (Meaning of EC-like classification or EC-Laser classification). 
As in the EC classification, ECL 1a, ECL 1b, ECL 2, ECL 3a, and ECL 3b were 
determined according to the shape of the gland lumen and the state of 
nuclear staining.
results: The concordance rate between EC classification and ECL classifica-
tion was 100% for EC1a and ECL 1a, 100% for EC1b and ECL 1b, 95% for 
EC2 and ECL 2, 95% for EC3a and ECL 3a, and 100% for EC3b and ECL 3b. 
However, the EC classification was superior in confidence and strength of 
diagnosis.
conclusion: Endocytoscopy-like maximum-magnifying evaluation with 
CMOS laser endoscopy for colorectal lesions is clinically useful.
Endocytoscopy for colorectal neoplastic lesions is currently the highest 
point of magnification endoscopy, but equipment deployment is still slow. 
When CMOS LASER endoscopes, which are already in wide use to some 
extent, are used at the limits of specifications, it has been found that ap-
proximate results can be obtained to some extent.
disclosure: Nothing to disclose 
P1577 cOMParIsOn Of LOng TerM cLInIcaL OuTcOMes 
BeTWeen cOLd endOscOPIc MucOsaL resecTIOn (c-eMr) 
and cOLd snare POLyPecTOMy (csP) fOr cOLOrecTaL POLyP 
Less Than 15MM In sIze
Moon J.R., Kim H.G., Jeon S.R., Jung Y., Ko B.M., Kim J.O.
Soonchunhyang University Hospital, Internal Medicine-GI/Hepatology, 
Seoul, Korea (Republic of)
contact e-Mail address: ukino816@gmail.com
Introduction: Incomplete resection rate of small polyp was reported as 
6.8% in the CARE study. Several methods of cold polypectomy includ-
ing cold snare polypectomy (CSP) and cold endoscopic mucosal resection 
without electrocautery (C-EMR) have been used for routine polypectomy 
practice. The aim of this study was to assess the long-term efficacy and 
safety of CSP versus C-EMR for colorectal polyps less than 15 mm in size.
aims & Methods: Total 472 patients underwent polypectomy with cold 
methods from July 2015 to December 2017. In this retrospective study, 112 
patients who underwent surveillance colonoscopy after colon polypectomy 
with cold methods were included for analysis. Clinical parameters includ-
ing recurrence, polyp size and shape, complication between two groups 
were compared.
results: Total, 331 colorectal polyps were removed with CSP (n=148) or 
C-EMR (n=183) from 112 patients. Mean age was 60.9 ± 11.1 years old, and 
mean surveillance interval was 458.3 ± 237.3 days. Regarding polyp shape, 
pedunculated polyps (65.4% vs. 34.6%) and flat polyps (69.9% vs. 30.1%) 
were tended to resected by C-EMR more frequently than CSP (p=0.053). 
Mean size was larger in C-EMR group (8.46 ± 1.97 mm) than CSP (6.80 ± 
1.21 mm) group (p< 0.001). In histology, 92.3% (12/13) of sessile serrated 
adenoma and two high-grade dysplasias were removed by C-EMR meth-
od. Recurrence rates were 6.1% (9/148) in CSP group, and 2.2% (4/183) in 
C-EMR group, respectively (p=0.070). Regarding complication, immediate 
bleeding was 4.4% (8/183) in C-EMR group and 2.0% (3/148) in CSP group 
(p=0.237), and delayed bleeding was occurred in one patient after C-EMR 
(0.5%).
conclusion: Both cold methods were feasible in terms of recurrence rate 
and safety. C-EMR was performed more in the flat or pedunculated polyps, 
and larger sized polyp than CSP method with relatively lower recurrence 
rate. Further large-scaled prospective study with long-term surveillance 
is required.
disclosure: Nothing to disclose 
P1578 BOdy Mass Index and The rIsk Of cOLOnIc POLyPs
Popescu A., Chisevescu D., Foncea C.G., Suseanu D., Danila M., Sirli R., 
Sporea I.
Victor Babes University of Medicine, Department of Gastroenterology and 
Hepatology, Timisoara, Romania
contact e-Mail address: alinamircea.popescu@gmail.com
Introduction: Colorectal cancer (CRC) screening is associated with a de-
creased incidence and mortality from CRC. However, patient adherence to 
screening is less than desirable and resources are limited even in devel-
oped countries. Better identification of individuals at a higher risk could 
result in improved screening efforts. Some studies suggest that body mass 
index (BMI) could be associated with higher frequency of colonic polyps 
and consequently CRC [1]. The aim of this study is to assess whether there is 
a relationship between BMI and the presence of colonic polyps.
aims & Methods: A retrospective study was performed including 424 pa-
tients whom underwent colonoscopy for various reasons between January 
2018-December 2018 in a private endoscopy unit. BMI was calculated as 
weight/height2 (kg/m2). Normal weight was defined as BMI 18.5-24.9 kg/
m2, overweight 25 to 29.9 kg/m2 and obesity > 30 kg/m2.The frequency of 
polyps diagnosed at colonoscopy was assessed.
results: From the 424 patients included in the study, 60%(256/424) female 
and 40%(168/424) male, mean age 53±12years, mean BMI 26.8±4.8 kg/
m2. Considering BMI, 33.2% (141/424) were normal, 38.6%(164/424) over-
weight and 28%(119/424) obese. 18% (77/424) patients presented colonic 
polyps: 13%(18/141) in the normal patients, 18%(29/164) in overweight 
patients and 25%(30/119) in obese patients, with significat difference be-
tween normal and overweight plus obese patients (p< 0.0001). Consider-
ing BMI>25 kg/m2 as a threshold for the risk of developing colonic polyps, 
the risk was significantly higher for overweight and obese patients OR 1.79 
CI 95% (1.01-3.18) p=0.043.
conclusion: Subjects with BMI>25 have a significantly higher risk of asso-
ciation with colonic polyps, therefore, BMI as a measure of obesity can be 
a valuable and easy to use tool for optimizing screening methods.
references: 1.Theodore F. Shapero et al. Obesity Increases Prevalence of 
Colonic Adenomas at Screening Colonoscopy: A Canadian Community-
Based Study. Can J Gastroenterol Hepatol. 2017; 2017: 8750967. Published 
online 2017 Jul 11. doi: 10.1155/2017/8750967
disclosure: Nothing to disclose 
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P1579 dIsease-free survIvaL afTer WesTern-Based 
endOscOPIc suBMucOsaL dIssecTIOn fOr cOLOrecTaL 
neOPLasIa
Maselli R.1, Spadaccini M.2, Belletrutti P.J.2, Galtieri P.A.1, Attardo S.3, 
Palma R.2, Anderloni A.1, Fugazza A.1, Di Leo M.2, Carrara S.1, 
Pellegatta G.1, Ormando V.2, Cappello A.2, Romana C.2, Lamonaca L.2, 
Craviotto V.2, Ferrara E.4, Spaggiari P.4, D’Amico F.2, Hassan C.5, Repici A.1,2
1Humanitas Clinical and Research Hospital, Rozzano, Italy, 2Humanitas 
University, Biomedical Science, Rozzano, Italy, 3Istitui Clinici Scientifici 
‘Maugeri’, Pavia, Italy, 4Humanitas Clinical and Research Center, Rozzano, 
Italy, 5Nuovo Regina Margherita Hospital, Gastroenterology, Rome, Italy
contact e-Mail address: roberta.maselli@humanitas.it
Introduction: In Asian countries, the safety and efficacy of endoscopic 
submucosal dissection (ESD) is well-established for the minimally inva-
sive treatment of early colorectal cancer. Large retrospective studies have 
shown favorable long-term outcomes with a disease free survival of 94.6% 
and 92.1% at 3 and 5 years, respectively [1]. On the other hand, the role 
of ESD for colorectal lesions in Western communities is unclear. This may 
be attributed to the limited adoption of ESD in Western centers and disap-
pointing technical outcomes in preliminary studies. In addition, the lack of 
long-term data for Western-based colorectal ESD generates uncertainty as 
to the clinical relevance of such a procedure.
aims & Methods: The aim of this study is to assess the long-term outcomes 
of a large cohort of patients treated with colorectal ESD in a tertiary West-
ern endoscopy centre. Between 2011 and 2018, a retrospective analysis of a 
prospectively maintained procedure database was conducted on patients 
treated by ESD for colorectal lesions at Humanitas Research Hospital in 
Milan, Italy. Both conventional ESD and hybrid-ESD cases were included. 
Short-term outcomes of interest were en-bloc, R0 and curative resection 
rates as well as the occurrence of adverse events. Long-term outcomes of 
interest were adenoma and carcinoma recurrence rates. Uni- and multi-
variable logistic regressions were applied to identify factors associated 
resectional outcomes and adenoma recurrence.
results: Over the study period, 244 consecutive patients with colorectal 
neoplasia underwent colorectal ESD. Conventional ESD was performed 
in 80.3% of cases. Overall, 189 (77.4%) lesions were adenomas and 55 
(22.6%) were cancers (52 adenocarcinomas and 2 neuroendocrine and 1 
squamous carcinoma). Rates of en bloc and R0 resection were 87.3% and 
82.8%, respectively. On multivariate analysis, only hybrid-ESD technique 
was negatively related to en bloc resection (OR 0.02 vs standard ESD 95% 
CI: 0.01-0.08) yet for R0 resection only standard ESD technique (vs hybrid-
ESD) was predictive (OR 4.61 95% CI: 1.41-18.58). 
Nine perforations occurred: 7 (77.8%) were managed endoscopically; 2 
(22.2%) required surgery. Intra- and post-procedural bleeding occurred 
in 9 (3.7%) and 1 (0.4%) patient(s), respectively; all cases were managed 
endoscopically. No ESD-related deaths occurred. In total, 39 patients un-
derwent surgical consultation and/or subsequent resection due to non-cu-
rative ESD (37 patients) or adverse events (perforation in 2 patients). Thus, 
the follow-up analysis included 205 patients with a median follow-up of 
2.9 years (range 0.5-8.0). 
Adenoma recurrence was detected in 5 (2.6%) patients (3 at 6 months, 2 
at 1 year and none at 3 or 5 years). The risk of recurrence was higher for 
patients in the piecemeal resection group than for those in the en-bloc 
resection group (p=0.05). The adenoma recurrence-free probability at 6 
and 12 months from resection was 98.5% (95% CI: 97.0%-100.0%) and 
97.4% (95% CI: 95.2%-99.7%), respectively. No carcinoma recurrences 
were observed.
conclusion: Colorectal ESD is a safe and effective approach for managing 
advanced colorectal neoplasia. Furthermore, in expert hands, colorectal 
ESD can be performed in a Western setting with outcomes comparable to 
published Eastern series.
references: 1. Yamada M, Saito Y, Takamaru H, et al. Long-term clinical 
outcomes of endoscopic submucosal dissection for colorectal neoplasms 
in 423 cases: a retrospective study. Endoscopy. 2017 Jan 20. doi: 10.1055/s-
0042-124366.
disclosure: Nothing to disclose 
P1580 drug deLIvery ThrOugh cOLOnIc TransendOscOPIc 
enTeraL TuBIng: a reaL WOrLd sTudy and MuLTIfacTOrIaL 
anaLysIs
Zhang T., Long C., Ji G., Zhang F.
The Second Affiliated Hospital of Nanjing Medical University, Medical Center 
for Digestive Disease, Nanjing, China
contact e-Mail address: tzhang@njmu.edu.cn
Introduction: Colonic transendoscopic enteral tubing (TET) as a new colon-
ic interventional method has been frequently used for complete delivery 
of fecal microbiota transplantations (FMTs) or whole-colon administration 
of drugs.
aims & Methods: To evaluate the possible factors affecting methodology, 
feasibility and safety of colonic TET. We prospectively recorded patients 
who underwent colonic TET for FMT or medications in our center from 
October 2014 to November 2018. The success rate, adverse events and pa-
tients’ satisfaction, as well as the retaining time of TET tube were evalu-
ated.
results: Totally 224 patients were included for analysis in this real-world 
study. The success rate of TET procedure was 100% (224/224). The median 
retaining time of TET tube was 8.5 (IQR 7 - 11) days in 158 patients with 
the tube falling out naturally. These patients were divided into the short-
retaining group (≤ 8.5 days) and the long-retaining group (> 8.5 days). 
Univariate and multivariate analysis demonstrated that titanium clip type 
(p = 0.001) was an independent influencing factor for the retaining time 
of tube. The number of large titanium clips with longer arms significantly 
affected the retaining time (p = 0.013). No severe adverse event was ob-
served during and after TET.
 
Titanium clip 
number frequency
TeT retaining 
time P-value
Small titanium clip 3 7 6 (4 - 7)  
  4 9 7 (6.5 - 7.5)  
  5 10 7.5 (5 - 10.5)  
  6 9 7 (5.5 - 9.5) 0.498
Large titanium clip 2 14 7.5 (6 - 11)  
  3 72 9 (7 - 11)  
  4 35 11 (8 - 12) 0.013
[Table 1. Correlation between the titanium clip number and TET retaining 
time.]
conclusion: Colonic TET is a feasible, practical, and safe technique with a 
high degree of patients’ satisfaction for multiple FMTs or frequent colonic 
medication administration. Generally, two to four large titanium clips are 
recommended to ensure the fixation of the TET tube onto the colonic wall 
and maintain it for 7-10 days.
disclosure: Nothing to disclose 
P1581 Is POOr BOWeL PreP ever accePTaBLe and WhaT Is The 
effecT Of IndIcaTIOn fOr The TesT?
Archer T.1, Riley S.1, Thoufeeq M.2, YORKER Yorkshire Endoscopy Research 
Group
1Sheffield Teaching Hospitals, Gastroenterology, Sheffield, United Kingdom, 
2Hull Royal Infirmary, Endoscopy/ Gastroenterology, East Yorkshire, United 
Kingdom
contact e-Mail address: thomas.p.archer@outlook.com
Introduction: Bowel preparation is recognised as a key quality indicator 
for colonoscopy. It correlates with the adenoma detection rate (ADR) and 
is used to guide subsequent surveillance period after a normal investiga-
tion. It is also a perennial bug bear of endoscopists, leading to prolonged 
as well as incomplete procedures. The Boston Bowel Preparation Scale 
(BBPS) is a commonly used metric for assessing bowel cleansing and a 
score of 6 is generally regarded as adequate. Evidence demonstrates that 
a score of 6 or higher is associated with a higher ADR and fewer missed 
polyps. However, few studies have addressed the relationship between a 
BBPS of less than 6 and the need for repeat colonoscopy by indication. 
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The aim of this study was to evaluate association between indication for 
colonoscopy and the perceived need of repeat colonoscopy in the setting 
of poor bowel preparation.
aims & Methods: Endoscopists of varying experiences and grades were 
invited to take part in the study during a regional endoscopy research 
meeting. All participants were shown videos of approximately 1 minute 
duration which demonstrated bowel preparation quality in 3 segments of 
the bowel; right, transverse and left. They were informed that no abnor-
malities were seen, and were asked to grade the bowel preparation on a 
dichotomous scale of “adequate for indication” or “inadequate, requiring 
repeat colonoscopy”. All participants also documented their colonoscopy 
experience and whether they were bowel cancer screening programme 
(BCSP) accredited. 
Indications are detailed in the table. 2 videos were presented per indica-
tion in a random order, each with a BBPS of between 3 and 5.
Chi squared tests were used to assess differences.
results: 19 endoscopists participated. 18 of whom graded 10 videos and 
1 who graded 5 videos. 8 were consultants, 7 registrars, 2 fellows and 2 
were nurses. 4 of the consultants were BCSP accredited. Overall 42.2% 
of cases were recorded as inadequate, requiring a rescope. The number 
of cases which the reviewers felt were inadequate ranged from 0/10 to 
7/10 with a median of 4/10 and interquartile range of 3 to 5. 11.1% of the 
scores for case 1 were graded as inadequate, compared with 49.0% for all 
the other cases combined (p< 0.0001). No other indication reached statis-
tical significance. The mean number of inadequate cases rated by BCSP 
accredited endoscopists was 4.75, compared with 3.93 in the non BCSP 
group (p=0.35). There was no significant difference between consultants, 
registrars and nurses.
conclusion: All of the videos were chosen to demonstrate bowel prepara-
tion which was inadequate, as defined by the BBPS < 6. However, only 
42% of examinations were considered sufficiently poor to require a re-
scope. Furthermore there is a considerable variation between endosco-
pists as to whether a patient required a rescope. The indication for colo-
noscopy, however, had little influence on judgement of the adequacy of 
bowel preparation, other than a young patient with possible inflammatory 
bowel disease, whose suboptimal prep was accepted by most.
These results suggest that suboptimal bowel preparation as defined by a 
BBPS < 6 is often accepted in clinical practice.
Case Indication
1
18 year old female with a history of diarrhoea and a family history of ulcerative 
colitis
2 62 year old male patient with positive faecal occult blood in BCSP
3 74 year old female with rectal bleeding mixed with stool
4 60 year old male with 3 small polyps at index colonoscopy 3 years ago
5 80 year old male patient with iron deficiency anaemia
[Indications for cases]
references: 1. Kaminski MF, Wieszczy P, Rupinski M, Wojciechowska U, 
Didkowska J, Kraszewska E, et al. Increased Rate of Adenoma Detection 
Associates With Reduced Risk of Colorectal Cancer and Death. Gastroenter-
ology. 2017;153(1):98-105. 2. Lai EJ, Calderwood AH, Doros G, Fix OK, Jacob-
son BC. The Boston bowel preparation scale: a valid and reliable instru-
ment for colonoscopy-oriented research. Gastrointest Endosc. 2009;69(3 
Pt 2):620-5. 3. Sulz MC, Kröger A, Prakash M, Manser CN, Heinrich H, Mis-
selwitz B. Meta-Analysis of the Effect of Bowel Preparation on Adenoma 
Detection: Early Adenomas Affected Stronger than Advanced Adenomas. 
PLoS One. 2016;11(6):e0154149. 4. Clark BT, Protiva P, Nagar A, Imaeda A, 
Ciarleglio MM, Deng Y, et al. Quantification of Adequate Bowel Prepara-
tion for Screening or Surveillance Colonoscopy in Men. Gastroenterology. 
2016;150(2):396-405; quiz e14-5.
disclosure: Nothing to disclose 
P1582 The effecT Of caseMIx On POLyP deTecTIOn raTe 
and cecuM InTuBaTIOn raTe
Pedersen L.1, Torp-Pedersen C.2,3, Bernstein I.1, Green Carlsen C.4, 
Lindorff-Larsen K.5
1Aalborg University Hospital, Department of Surgical Gastroenterology, 
Aalborg, Denmark, 2Nordsjaellands Hospital, Hillerod, Department of 
Cardiology and Clinical Investigation, Hillerød, Denmark, 3Aalborg University 
Hospital, Department of Cardiology, Aalborg, Denmark, 4Aarhus University 
Hospital, Department of Emergency, Aarhus, Denmark, 5Aalborg University 
Hospital, Nordsim: Center for Skills Training and Simulation, Aalborg, 
Denmark
contact e-Mail address: lasse.pedersen@rn.dk
Introduction: Established markers of good colonoscopy quality such as the 
Cecum Intubation Rate (CIR) and the Polyp Detection Rate (PDR) are known 
by most colonoscopists and performance goals are readily available. Fac-
tors such as patient sex, patient age and colonoscopy indication have the 
potential to affect the CIR or the PDR1. Colonoscopists might not perform 
examinations on an identical casemix. Different casemix could result in 
performance goals being too easy or nearly impossible to reach.
aims & Methods: The primary aim was to introduce a benchmark (based 
on CIR and PDR) that accounted for differences in casemix between colo-
noscopists. The secondary aim was to see if colonoscopist performed dif-
ferent than the benchmark.
Individual colonoscopist casemix (patient age, patient sex and colonoscopy 
indication) were registered on all colonoscopies in a 7-week period at Aal-
borg University Hospital, Denmark (n = 894). Colonoscopists performing 
>40 colonoscopies were analyzed individually. Colonoscopist performing 
<20 colonoscopies and 21-40 colonoscopies were grouped in a very low 
volume and a low volume group, respectively. 
Statistical analysis were conducted using Stata MP 15.1 and R 3.5.1.
Difference in patient age, patient sex and indication were analyzed using 
univariate analysis. 
Predicted CIR and predicted PDR with 95% CI was calculated using boot-
straps. A permutations test was performed to identify whether deviation 
from predicted performance represented low colonoscopy quality or sta-
tistical uncertainty.
results: univariate casemix analysis:
Mean age, [range 61 - 67], Diff. p = 0.36. 
Male sex [range 44% - 72%], Diff. p = 0.25.
Indication (% of screening), [range 1% - 70%], Diff. p < 0.01. 
Individual colonoscopists actual and predicted performance:
colonscopist n Measured cIr%
Predicted 
cIr%(95% cI)
Measured 
Pdr%
Predicted 
Pdr%(95% cI)
A 123 87.0 85.9 (83-88) 20.3 26.5 (23-29)
B 96 81.3 85.9 (83-88) 26.0 27.9 (25-31)
C 85 74.1 85.8 (83-88) 22.4 32.4 (29-35)
D 83 92.8 85.9 (83-88) 26.5 26.9 (24-30)
E 81 96.3 88.9 (87-91) 45.7 41.9 (38-46)
F 62 87.1 86.6 (84-89) 40.3 27.9 (25-31)
G 49 91.8 86.0 (84-88) 36.7 36.8 (34-40)
H 47 83.0 88.0 (86-90) 44.7 39.9 (36-44)
I 43 86.0 89.8 (87-92) 55.8 49.0 (44-54)
Low vol. 
(n 20-40)
98 87.8 89.0 (87-91) 37.8 41.6 (38-46)
Very low vol. 
(n <20)
127 90.6 87.5 (85-90) 37.8 33.0 (30-36)
[Actual and predicted cecum intubation rate (CIR) and poly detection rate 
(PDR)]
The permutation test did not find evidence to support that overall devi-
ance from the predicted performance were related to inferior performance 
(PDR: p = 0.11, CIR: p = 0.81).
conclusion: Predicted performance allow each colonoscopist to see if he/
she performs better or worse than the department average performance 
given his/her unique casemix. 
Actual performance deviated from 95 CI of predicted performance among 
some colonscopist, but the deviation was not significant.
827Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Our study found little variation in predicted CIR [range 85.8-89.8] and 
larger variation in predicted PDR [range 26.5-49.0]. The large variation 
indicates that numeric performance goals should be applied with caution 
when there is a large variations in casemix among colonoscopists. A low 
PDR could simply be related to casemix. Casemix analysis could easily be 
extended too include additional variables available from Electronic Health 
records for more precise estimates.
references: 1) Harris JK, Froehlich F, Wietlisbach V, Burnand B, Gonvers 
JJ, Vader JP. Factors associated with the technical performance of colo-
noscopy: An EPAGE Study. Dig Liver Dis. 2007;39(7):678-689. doi:10.1016/j.
dld.2007.02.012
disclosure: Nothing to disclose 
P1583 resecTIOn Of cOLOrecTaL POLyPs WITh cLIP PLaceMenT 
Leads TO reduced ePIsOdes Of POsT-POLyPecTOMy BLeedIng 
cOMPared TO POLyPecTOMy WIThOuT cLIP PLaceMenT
Skamnelos A.1, Kavvadias A.1, Kartsoli S.1, Mpaltagiannis G.1, 
Theopistos V.1, Katsanos K.H.2, Tzampouras N.3, Christodoulou D.K.4
1University Hospital of Ioannina, Department of Gastroenterology, Ioannina, 
Greece, 2Medical School of Ioannina, Division of Internal Medicine, 
Ioannina, Greece, 3University Hospital of Ioannina, Ioannina, Greece, 
4Gastroenterology Unit University Hospital, 1St Division of Internal Medicine 
and Hepato-Gastroenterology Unit, Ioannina, Greece
contact e-Mail address: alskamnelos@gmail.com
Introduction: Endoscopic polypectomy is the standard of care for most of 
colorectal polyps and has expanded to include larger and sessile polyps. 
We compared the role of clip placement after polypectomy of peduncu-
lated or sessile polyps larger than 2 cm in diameter to prevent postpolyp-
ectomy bleeding.
aims & Methods: Patients who underwent polypectomy of sessile or pe-
dunculated polyps larger than 2 cm were randomized to clip versus no 
clip placement at the base of the polyp. Patients with obvious bleeding 
or visible vessel after polypectomy were excluded from the study. The pa-
tients were followed-up for any signs of postpolypectomy bleeding for one 
month after the therapeutic procedure.
results: In total 50 subsequent patients who underwent polypectomy of 
sessile or pedunculated polyps larger than 2 cm were studied (30 males, 
median age 67 years, range 28-86 years, 32 with sessile polyps, 18 with 
pedunculated polyps). Half of the patients were randomly treated with clip 
placement after the procedure. The aim of the clip was either to strangu-
late the peduncle of pedunculated polyp or close the open wound left after 
the resection of the sessile polyp. None of the patients bled in the group 
of clip placement, while 4 of the 25 patients bled in the group of no clip 
placement (P< 0.05). All bleeding episodes were managed conservatively 
with endoscopy, adrenaline solution injection and clip placement.
conclusion: Clip placement after resection of pedunculated and sessile 
polyps larger than 2 cm can prevent postpolypectomy bleeding. In cases 
of bleeding subsequent endoscopic treatment was effective in all cases.
disclosure: Nothing to disclose 
P1584 rOOT cause anaLysIs Of 424 POTenTIaL POsT 
cOLOnOscOPy cOLOrecTaL cancers usIng The WOrLd 
endOscOPy OrganIzaTIOn aLgOrIThM
Nielsen A., Pedersen L.
Aalborg University Hospital, Department of Surgical Gastroenterology, 
Aalborg, Denmark
contact e-Mail address: andersnielsen1991@gmail.com
Introduction: Root cause analysis of post colonoscopy colorectal cancer 
(PCCRC) is essential to understand and prevent cases of PCCRC. The World 
Endoscopy Organization (WEO) has recently proposed a common method 
when conducting root cause analysis of PCCRC1. The aim of this study was 
to test the feasibility of the WEO algorithm on a large PCCRC dataset and 
to perform sub analysis in each WEO category to identify factors that could 
help avoid PCCRC in the future.
aims & Methods: All colorectal cancers (CRCs) (ICD-10: C.18-C.20) diag-
nosed in North Region, Denmark from 2010-2018 were included in the 
root cause analysis. CRCs were cross-referenced with colonoscopies occur-
ring from 6 months until 4 years from CRC diagnosis. A total of 424 colo-
noscopies on 330 individuals were investigated in journal records and the 
pathology database. Cause was assigned according to the WEO algorithm 
with the most plausible explanation. 
Currently, the root cause analysis is based on 100 out of the 424 potential 
PCCRCs. With later inclusion of the remaining PCCRCs in a complete root 
cause analysis.
results: Exclusion criteria and the distribution of PCCRC-cases according to 
the most plausible cause are found below.
exclusion (n=42)  
Examination cancelled upon scope insertion (solid stool) 4
Metastastic CRC recurrence recurrence ouitside the colon 21
CRC date not registered correctly 13
Incorrect colonoscopy procedure code 3
Appendix tumor 1
Total 42
   
WeO Pccrc cause (n = 58) n (%)
Missed lesion, prior examination adeguate 25 (43)
Missed lesion, prior examination inadequate 23 (40)
Detected lesion not resected 2 (3)
Incomplete resection of detected lesion 6 (10)
Deviation from planned management pathway 2 (3)
[Exclusion criteria and WEO PCCRC causes of PCCRC cases]
The location of missed lesions (adequate and inadequate examinations) 
were: Rectum 33%, Sigmoid: 14%, Descending colon: 0%, Splenic flex: 
2%, Transversal colon: 2%, Hepatic flex: 10%, Ascending colon: 9% and 
the Cecum: 31%.
The main reason for inadequate examinations was the lack of documented 
cecal intubation (18/23).
conclusion: Missed lesions were predominantly located in the rectum or 
the cecum. The cecum can be technically challenging to visualize ade-
quately, and previous studies have found higher risk of missed lesions in 
the cecum.2,3 The high proportion of missed lesions located in the rectum 
may be related to local practices. Mandatory looping in the rectum is not 
required in North Region, Denmark, and rectal looping was only recorded 
in one case of a missed rectal lesion. 
In cases with a previous inadequate examination, lack of evidence for ce-
cal intubation was the dominant factor. In North Region, Denmark photo 
documentation is not required, but no evidence of terminal ileum intuba-
tion nor visualization of the ileocecal valve, the appendix orificium or an 
ileocolonic anastomosis were documented. 
Incomplete resections were usually related to difficult polypectomies with 
multiple colonoscopies, polypectomies and short surveillance intervals 
before a final CRC diagnosis. Only one case of unexpected recurrence was 
identified. 
Deviation from the planned pathway was mostly related to insufficient and 
unclear journal recording. 
The WEO algorithm provides a useful framework to categorize PCCRC. In 
our study 82% of cases are related to missed lesions which are probably 
avoidable. The WEO algorithm is a valuable tool to identify areas in the 
colonoscopy service that could be improved in an attempt to avoid PCCRC.
references: 1) Rutter MD, Beintaris I, Valori R, et al. World Endoscopy Or-
ganization Consensus Statements on Post-Colonoscopy and Post-Imaging 
Colorectal Cancer. Gastroenterology. 2018;155(3):909-925.e3. doi:10.1053/j.
gastro.2018.05.038. 2) Morris EJA, Rutter MD, Finan PJ, Thomas JD, Valori 
R. Post-colonoscopy colorectal cancer (PCCRC) rates vary considerably de-
pending on the method used to calculate them: a retrospective obser-
vational population-based study of PCCRC in the English National Health 
Service. Gut. 2015;64(8):1248-1256. doi:10.1136/gutjnl-2014-308362. 3) Sa-
madder NJ, Curtin K, Tuohy TMF, et al. Characteristics of missed or interval 
colorectal cancer and patient survival: A population-based study. Gastro-
enterology. 2014;146(4):950-960. doi:10.1053/j.gastro.2014.01.013.
disclosure: Nothing to disclose 
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P1585 cOLOnOscOPy frequency In dIfferenT sOcIOecOnOMIc 
grOuPs BefOre and afTer IMPLeMenTaTIOn Of cOLOrecTaL 
cancer screenIng In sTOckhOLM-gOTLand regIOn: 
a naTIOnWIde regIsTer-Based sTudy In sWeden, 2006-2015
Thulin T.1, Hultcrantz R.1, Holmén A.2, Strömberg U.3, Forsberg A.1
1Karolinska Institutet, Medicine, Stockholm, Sweden, 2Region Halland, 
Varberg, Sweden, 3Gothenburg University, Medicine, Gothenburg, Sweden
contact e-Mail address: torbjorn.thulin@ki.se
Introduction: Colorectal cancer (CRC) screening programmes are used 
to prevent CRC by detection of precancerous lesions or CRCs in less ad-
vanced stages. From 2008 and onwards, inhabitants aged 60-69 years in 
the Stockholm-Gotland Region (SGR) have been invited to participate in a 
faecal occult blood test (FOBT) based screening. Individuals with a positive 
FOBT were invited to a colonoscopy. In the rest of Sweden, organised CRC 
screening has not been implemented. We hypothesize the implementation 
of the screening programme in the SGR has accentuated socioeconomic 
disparities in colonoscopy frequency.
aims & Methods: The aim was to study time trends in the colonoscopy 
frequency in different socioeconomic groups and geographical areas, with 
special consideration to the implementation of CRC screening in the SGR 
in 2008, within the age group 60-69 years. All registered colonoscopies in 
Sweden 2006-2015 were collected from Swedish in- and outpatient reg-
isters. In total 576,598 colonoscopies were included. From this cohort we 
selected colonoscopies performed on persons 60-69 years old. Data about 
sex, age, marital status, immigrant status and number of school years 
were collected from Statistics Sweden and linked to each colonoscopy (us-
ing unique personal identification numbers). Groups were categorized ac-
cording to educational level (low, < 9 years in school; intermediate, 10-12 
years; and high, >12 years), immigrant status (Swedish- vs. foreign-born) 
and sex. We compared colonoscopy frequencies in the population aged 
60-69 years before (2006-2007) and after (2010-15) implementation of the 
screening programme.
results: In the pre-screening period, the absolute frequency per 1000 was 
slightly higher in the SGR (8.9 for men, 9.9 for women) than in the rest of 
Sweden (7.5 for men, 8.6 women). In the SGR, the colonoscopy frequency 
was markedly higher among people with high educational level, 14.0 per 
1000 such persons. By contrast, in the rest of Sweden, the frequency was 
somewhat lower among people with high educational level, 5.9 per 1000. 
Between the pre- and post-screening periods the absolute frequency in-
creased by 14.6 units for men and 11.5 for women in the SGR. In the rest 
of Sweden, the corresponding frequency increases were less pronounced; 
4.7 and 5.2, respectively. Comparing the frequency increases for different 
population groups according to educational level revealed the following 
patterns: 7.5 (low educational level), 7.0 (intermediate) and 10.7 (high) in 
the SGR; 4.9, 5.1 and 6.7 in the rest of Sweden. Comparing the frequency 
increases with regard to immigrant status revealed less pronounced dis-
parities: 13.3 (Swedish-born) and 11.3 (foreign-born) in the SGR; 5.0 and 
4.6 in the rest of Sweden.
conclusion: In the pre-screening period, colonoscopy within the popu-
lation aged 60-69 years in the SGR was more common among women 
and among people with high educational level. In the rest of Sweden, 
colonoscopy was not more common among people with high educational 
level. The frequency of colonoscopy have increased most pronouncedly in 
men and in highly educated individuals after the implementation of the 
CRC screening programme in the SGR. The frequency increase was similar 
in Swedish- and foreign-born individuals. Prerequisites for a screening 
programme that creates more equal conditions for attendance need to be 
addressed in further studies.
disclosure: Nothing to disclose 
P1586 Measures TO reduce POsT-POLyPecTOMy BLeedIng 
In PeduncuLaTed POLyPs - dOes a cLIP heLP?
Patel R.N., Moledina S., Hall R., Canda R., Besherdas K.
Royal Free London NHS Trust, Gastroenterology, London, United Kingdom
contact e-Mail address: rajan.patel@nhs.net
Introduction: Immediate and delayed post-polypectomy bleeding (PPB) is 
a serious complication after endoscopic removal of large pedunculated 
polyps. Options to decrease the risk of bleeding include injecting the stalk 
with adrenaline, placing endoscopic clips across the stalk (before or after 
the polypectomy) and placement of a nylon loop around the stalk. The 
principle of closing a defect to reduce complications is well established but 
the cost effectiveness of prophylactic clipping remains controversial. There 
are currently no consensus guidelines.
aims & Methods: We aimed to investigate the use of endoscopic clips dur-
ing polypectomy of pedunculated polyps >10mm and assess its associa-
tion with PPB. We performed a large retrospective study across two sites 
at a tertiary London-based hospital Trust. Endoscopy software (Unisoft GI 
reporting tool) was used to identify pedunculated polyps >10mm in size 
during a 5 year period (January 2014 to March 2019). Patients that did not 
undergo polypectomy were excluded.
results: 657 polypectomies were performed for pedunculated polyps dur-
ing the study period (mean age 65.2 (range 22 - 94), Female 240 (36.5%)). 
Mean pedunculated polyp size 16.4mm (10 - 60mm). 431 (65.6%) in sig-
moid colon. 636 (96.8%) hot snare polypectomy; 264 (40.2%) injected 
with adrenaline. Endoscopic clip used in 191 (29%). Total immediate (< 
6hrs) and delayed bleeding (6hrs to 2 weeks) events were 11 (1.7%) and 14 
(2.1%), respectively. 
 
endoscopic clip 
(n =191)
no endoscopic clip 
(n = 466) p value*
size (mm) 18.1 15.7 0.0002
hot snare (%) 183 (95.8) 453 (97.2) 0.35
adrenaline injection (%) 115 (60.2) 149 (32.0) <0.0001
Immediate bleeding (%) 9 (4.7) 2 (0.4) 0.0001
delayed bleeding (%) 4 (2.1) 10 (2.1) 0.97
[Table 1. Bleeding complications according to use of endoscopic clip]
conclusion: Endoscopic clip use was associated with more immediate 
bleeding events suggesting that it is being used as a treatment strategy 
(not prophylactically) to achieve haemostasis in high risk patients. Endo-
scopic clips are being deployed more often with larger polyps and in com-
bination with adrenaline injection. Overall PPB rates in our cohort remain 
low. There remains considerable variation in practice and the type / size 
of clip to use and the method of clipping remain unanswered questions. 
Whilst there is clear guidance from national and international bodies on 
how to remove sessile polyps, the optimal technique for resection of pe-
dunculated polyp is less clear and this may account for the variability in 
clinical practice.
disclosure: Nothing to disclose 
P1587 POsT-cOLOnOscOPy cOLOrecTaL cancers - shOuLd 
We Be asPIrIng TO BeTTer TargeTs?
Patel R.N., Kumar R., Khurram R., Ang K.M., Hickmott L., Besherdas K.
Royal Free London NHS Trust, Gastroenterology, London, United Kingdom
contact e-Mail address: rajan.patel@nhs.net
Introduction: The British Society of Gastroenterology (BSG), the UK Joint 
Advisory Group (JAG) on GI Endoscopy and the Association of Coloproctol-
ogy of Great Britain and Ireland (ACPGBI) have developed quality assur-
ance measures and key performance indicators for the delivery of colo-
noscopy within the UK. One of these includes aspiring to a target of < 5% 
post-colonoscopy colorectal cancers (PCCRC) at 3 years.
aims & Methods: We performed a retrospective study across two sites at a 
tertiary London-based hospital Trust. Endoscopy software (Unisoft GI re-
porting tool) was used to identify all new colorectal cancers diagnosed 
during colonoscopy during a 16 month period (May 2017 to September 
2018). Interrogation for a prior colonoscopy within 3 and 5 years of the 
date of each colorectal cancer diagnosis was then performed. PCCRC rate 
was defined as the proportion of PCCRC diagnoses amongst all CRC cases 
within a 3 year period. 
We also analysed demographics, time interval (initial to diagnostic colo-
noscopy) and colonoscopist performing the procedure (physician vs. sur-
geon). Quality of bowel preparation was scrutinised in the PCCRC cases 
(excellent, good, fair, inadequate).
results: We identified 282 cases of colorectal cancer diagnosed during 
colonoscopy in the study period. There were a total of 8 cases of PCCRC 
within 3 years giving our Trust a PCCRC rate of 2.8%. Mean age of patients 
with a PCCRC diagnosis was 75.8 (64 - 88). Mean interval from initial to di-
agnostic colonoscopy in PCCRC cases was 2.08 years (0.92 - 3). Of the 8 pa-
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tients with PCCRC; 1 was Dukes’ A, 4 were Dukes’ B2, 2 were Dukes’ C1 and 
1 was Dukes’ C2. 7 of the 8 cases (87.5%) were colonoscopies performed 
by surgeons or external agency endoscopists. 4 of the 8 cases (50%) had 
less than good bowel preparation. Retroflexion in the rectum was not per-
formed in 6 of the 8 cases (75%). When PCCRC diagnoses were extended 
to within 5 years the PCCRC rate was 4.3%.
conclusion: Our study shows that our Trust is within the quality standards 
set by the relevant governing bodies. Root cause analyses identified cae-
cal, sigmoid and anastomotic lesions as high risk sites for missed cancers 
as well as omission of retroflexion in the rectum. Accepting less than good 
bowel preparation is also a factor in half of PCCRC cases. Only 1 patient had 
an endoscopically resectable lesion at diagnostic colonoscopy but there 
were no patients with distant metastases. 
In view of the advances made in the quality of colonoscopy training and 
enhanced endoscopic technology, we suggest raising the bar with regards 
to acceptable PCCRC by either lowering the target or increasing the time 
frame to 5 years.
disclosure: Nothing to disclose 
P1588 nurse-Led educaTIOnaL TeLePhOne InTervenTIOn 
fOr BOWeL PreParaTIOn fOr rePeaT cOLOnOscOPy afTer 
BOWeL PreParaTIOn faILure
Alvarez Gonzalez M.A.1, Pantaleon M.A.2, Bernard Cabredo B.3, 
García-Rodriguez A.4, Frago Larramona S.5, Nogales Rincón O.6, 
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Spain, 6Hospital Gregorio Marañon Dept. de Endoscopia Digestiva, Madrid, 
Spain, 7Universitary Hospital Rio Hortega, Gastroenterology, Vallodolid, 
Spain, 8Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, 
Spain, 9Consorci Sanitari de Terrassa, Terrassa, Spain, 1012 de Octubre 
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13Hospital de Viladecans, Viladecans, Spain, 14Secretaria de Universitats de 
Catalunya, Barcelona, Spain
contact e-Mail address: marcoalgo@gmail.com
Introduction: Up to 20% of bowel preparations for colonoscopy are con-
sidered inadequate and the colonoscopy is not valid. The consequences 
are missed lesions, cancelled procedures, diagnostic delays, and increased 
risks and costs. The most important predictor of inadequate bowel prepa-
ration is a previous failure. There are no standardized recommendations to 
prepare those patients. An educational intervention through a telephone 
call has demonstrated to improve the efficacy of bowel preparation in the 
general population.
aims & Methods: The aim of this study was to analyze the efficacy of a 
nurse-led educational intervention by telephone within the 48 hours be-
fore the colonoscopy, in patients with previous bowel preparation failure. 
This was a multicentre randomized clinical trial with parallel groups (con-
trol and educational intervention), endoscopist-blind. The study was ap-
proved by each of the 11 participant hospitals. Consecutive patients with 
inadequate bowel preparation were included. A sample size of 650 par-
ticipants was calculated to show a 10% improvement in bowel preparation 
adequacy. Both groups received the same bowel prepararation protocol 
including 4 liters of PEG in split dose regimen. The main outcome was 
adequate bowel preparation defined as all segments of the Boston Bowel 
Preparation scale with 2 or 3 points. Participants with no efficacy data were 
considered bowel preparation failures. Intention to treat (ITT) analysis in-
cluded all randomized participants and per protocol (PP) analysis included 
participants that could be contacted by telephone and control cases. Clini-
caltrials identifier: NCT03055689
results: The investigators included, 651 consecutive participants (329 
control and 321 intervention) without differences in the baseline char-
acteristics. In the ITT analysis bowel preparation was inadequate in 97 
(29.6%) control cases and in 77 (23.9%) intervention cases, risk difference 
5.7%. p=0.1. Attendance to colonoscopy was 296 (91.4%) and 297 (92.2%), 
p=0.68 in control and intervention groups. Adenoma detection rate was 
39.2% and 44.4%, p=0.21 in the control and intervention groups respec-
tively. In the intervention group 267 (82.9%) participants could be reached 
by telephone. In the PP analysis the bowel preparation was inadequate in 
45 cases (16.9%) in the intervention group, with a risk difference with the 
control group of 12.7%, p>0.001.
conclusion: In patients with previous failure of bowel preparation a nurse-
led telephone education in the 48 hours before the colonoscopy is not 
effective as intention to treat, due to a limited applicability. However that 
intervention is clearly effective when the patient can be reached by tele-
phone.
disclosure: Nothing to disclose 
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Introduction: Between 2013 and 2014, 63-66% of all patients with newly 
diagnosed colorectal cancer (CRC) in the UK underwent a surgical resec-
tion for their tumour1. Post-resection surveillance colonoscopy for meta-
chronous CRC has become standard practice, as patients with a previous 
CRC may be at greater risk of a secondary CRC diagnosis than age and 
sex-matched controls are of a primary CRC diagnosis2. However, the pro-
tection offered by surveillance colonoscopy may in fact be limited by the 
quality of the colonoscopy performed, and in particular, the ability of the 
colonoscopist conducting the procedure. Key performance indicators (KPIs) 
are markers of colonoscopy quality, and include adenoma detection rate 
(ADR), caecal intubation rate (CIR) and polyp retrieval rate (PRR). Unfortu-
nately, the utility of KPIs for surveillance colonoscopy in patients who have 
undergone surgical resection for CRC is not well described.
aims & Methods: Using KPIs, we aimed to assess the quality of colonos-
copy in a cohort of patients with previous CRC who underwent surveillance 
post-resection at West Middlesex University Hospital (WMUH), and com-
pare these to non-surveillance KPIs by the same colonoscopists to assess 
the relationships between them. We retrospectively assessed colonoscopy 
data for post-resection CRC surveillance at WMUH between 2010 and 2019. 
Patient demographic and colonoscopy data was collected alongside colo-
noscopist non-surveillance KPI data and analysed using the software SPSS. 
All flexible-sigmoidoscopies which did not aim to completely intubate the 
bowel were excluded. We assessed for correlation between surveillance 
and non-surveillance KPIs from the same colonoscopists at the trust, and 
tested for any differences in KPIs between the two cohorts.
results: In total, 641 surveillance colonoscopies for post-resection CRC 
were performed by over 50 colonoscopsists. The overall ADR in the 1st, 2nd, 
3rdand 4th surveillance colonoscopies was 22.0%, 27.0%, 36.8% and 38.5% 
respectively, with an ADR of 26.0% across all colonoscopies. 7 colonosco-
pists performed at least 20 surveillance colonoscopies in our cohort. For 
these 7 colonoscopists, the total ADR was 25.9% (range 13.6%-45.0%), the 
total CIR was 97.4% (range 95.0%-100%), and the total PRR was 90.3% 
(range 76.9-100%). Non-surveillance ADRs correlated with surveillance 
ADRs (R2=0.650, p< 0.05), but non-surveillance CIRs did not correlate 
with surveillance CIRs (R2=0.270, p=0.232), nor did non-surveillance PRRs 
correlate with surveillance PRRs (R2=0.532, p=0.153). There were no sig-
nificant differences between the surveillance and non-surveillance ADRs 
observed in these colonoscopists (p=0.115).
conclusion: Even with a relatively small sample size, we found a clear as-
sociation between surveillance and non-surveillance colonoscopist ADRs 
(the primary marker of colonoscopy quality) in our cohort. Although other 
KPIs including CIR and PRR did not correlate between surveillance and 
non-surveillance cohorts, there may be practical reasons for this, includ-
ing the presence of short bowels in post-resection CRC patients and the 
exclusion of flexible-sigmoidoscopies in our study.
references: 1) Cancer research UK. Available at: https://www.cancerre-
searchuk.org/health-professional/cancer-statistics/statistics-by-cancer-
type/bowel-cancer/diagnosis-and-treatment [Accessed 01/04/2019]. 2) 
Mulder SA, Kranse R, Damhuis RA, Ouwendijk RJ, Kuipers EJ, van Leerdam 
ME. The incidence and risk factors of metachronous colorectal cancer: an 
indication for follow-up. Dis Colon Rectum. 2012;55(5):522-31.
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P1590 IndIcaTOrs Of adequaTe InsPecTIOn Of BOWeL 
MucOsa: can We use OnLy POLyP deTecTIOn raTe (Pdr)?
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Introduction: Adenoma detection rate (ADR) and mean adenoma per colo-
noscopy (APC) are established quality indicators in colonoscopy. Yet they 
are not generally used in European countries. This may be because it is 
rather difficult to obtain them in terms of time and personnel. To improve 
the compliance of endoscopists with quality control, it is essential to sim-
plify the entire monitoring process. Polyp detection rate (PDR) is a user 
friendly alternative of ADR that can be easily evaluated from administrative 
data.
aims & Methods: The aim of our study was to assess whether PDR cor-
relates with ADR and with APC. Our effort was to determine minimal mar-
ginal value for APC. Prospective multicenter study included asymptomatic 
individuals aged 45-75 who underwent preventive colonoscopy in 2012-
2016 as part of Czech study monitoring metabolic risk factors of colorectal 
cancer. Individuals with incomplete colonoscopy and endoscopists with 
less than 30 colonoscopies and/or no detected adenoma in the observed 
group were excluded from the study. Spearman’s correlation coefficient 
was used to assess the relation between individual PDR/ADR and PDR/APC 
resp. The resulting conversion factors to predict ADR (APC) from PDR were 
obtained by linear regression.
results: In total, the study included 1,614 preventive colonoscopies per-
formed by 16 endoscopists. Correlation between PDR and both indicators in 
all preventive colonoscopies was strong and statistically significant (PDR/
ADR: Rs 0.82; p < 0.001; PDR/APC: Rs 0.70; p= 0.0027). We used the same 
methodology to determine gender-specific and indication-specific PDR/
ADR and PDR/APC correlations. In all cases, we demonstrated a strong and 
statistically significant correlation between PDR and ADR (APC resp). We 
obtained conversion factors for both quality indicators: PDR to ADR 0.7185, 
resp. PDR to APC 0.0123.
conclusion: There is a strong correlation between PDR/ADR as well as 
between PDR/APC. Because of better availability, PDR may replace ADR 
and APC in colonoscopy quality assessment. Using our conversion factor 
we obtained minimal marginal value of APC 0.5 based on 40% minimal 
marginal value of PDR as recommended by ESGE.
PDR has the potential to increase compliance of endoscopists to quality 
control, at least until data processing is fully automated. 
Supported by grants MO1012, Progres Q28/LF1 and 17-31909A
disclosure: Nothing to disclose 
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Introduction: The effectiveness of bowel cleansing is essential for a qual-
ity colonoscopy as it affects diagnostic accuracy and adenoma detection 
rate. Inadequate cleansing remains a major challenge, with a suboptimal 
bowel preparation observed in 25% of procedures. 
Among all factors contributing to inadequate preparation, age has been 
shown to be an independent risk factor for poor bowel cleansing. Nev-
ertheless, factors affecting bowel cleansing in the elderly are not fully 
known, and current guidelines do not provide a specific recommendation 
for optimisation of preparation in these patients.
aims & Methods: This study aimed to assess the difference in bowel cleans-
ing in elderly compared to younger patients and to evaluate independent 
factors associated with a cleansing success. 
We retrospectively reviewed a prospective cohort of 1289 in- and out-pa-
tients undergoing a colonoscopy after a standard (afternoon-only) or a 
split (afternoon-morning) preparation with a 1, 2 or 4L PEG-based solu-
tion consecutively enrolled from September 2018 to February 2019 in 5 
Italian centres. The elderly population was defined by an age ≥65 years. 
Bowel cleansing was assessed through the Boston Bowel Preparation 
Scale (BBPS) and a cleansing success was defined as a total BBPS≥6 with 
a partial BBPS≥2 in each segment. Tolerability was evaluated by a semi-
quantitative scale with a score ranging from 0 to 10.
results: All 1289 patients were included in the analysis. Overall 52.8% 
of subjects were male, the meanage was 60.5±14, and 44.6% of patients 
were older than 65 years.
Bowel preparation was performed with a 4L, 2L and 1L PEG solution in 
38.0%, 43.9% and 18.1% of cases, in the absence of serious adverse events. 
Bowel cleansing by BBPS was 6.6±1.4 and 6.3±1.6 (p= 0.006) in the groups 
of patients aged < 65 and ≥65 years and colonoscopy was completed with 
cecal intubation in 97.5% and 95.5% (p=0.05) of patients, respectively. 
Compared to patients < 65 years, patients ≥65 years achieved a lower 
cleansing success: 70.3 vs 77.3% overall, 61.2% vs 69.5% in the subgroup 
of standard preparation and 84.9% vs 90.2% in the subgroup of split 
preparation. 
At multivariate analysis, split regimen (OR=2.49, 95% CI=1.38-4.48; 
p=0.002), adequate cleansing at previous colonoscopy (OR=3.28, 95% 
CI=1.40-7.68; p=0.006) and tolerability score (OR=1.14, 95% CI=1.03-1.26; 
p=0.006) were independently associated with a cleansing success in the 
group of patients aged < 65 years. In the group of patients aged ≥65 years, 
split regimen (OR=2.43, 95% CI=1.34-4.38; p=0.003), adequate cleansing 
at previous colonoscopy (OR=2.29, 95% CI=1.14-4.73; p=0.02), tolerability 
score (OR=1.29, 95% CI=1.16-1.44; p< 0.001), low-fiber diet for at least 3 
days preceding colonoscopy (OR= 2.45, 95% CI=1.42-4.24; p=0.001) and 
colonoscopy within 5 hours after preparation (OR= 2.67, 95% CI=1.28-5.56; 
p=0.008) were independently associated with a bowel cleansing success.
conclusion: Compared to younger patients, achieving adequate cleansing 
in the elderly is more challenging, and it is influenced by a higher num-
ber of external factors. Among these, split preparation, timing of colonos-
copy within 5 hours after preparation, low-fiber diet for at least 3 days 
preceding colonoscopy, adequate cleansing at previous colonoscopy and 
tolerability of preparation were independently associated with a cleans-
ing success. These factors play a crucial role in achieving a proper bowel 
cleansing and need to be properly addressed to optimise the quality of 
preparation in elderly, thus avoiding the discomfort and the risks deriving 
from the repetition of the exam.
disclosure: Nothing to disclose 
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P1592 snare TIP sOfT cOaguLaTIOn Of The MucOsaL defecT 
MargIn fOLLOWIng cOLOnIc endOscOPIc MucOsaL resecTIOn 
(eMr) reduces recurrence In a “reaL LIfe” seTTIng
Abu Arisha M.1,2, Half E.1, Maza I.1, Muaalem R.2, Bana S.2, Awadie H.2, 
Klein A.2,3
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Introduction: Large (>20 mm) colonic lateral spreading lesions (LSL) while 
uncommon, are high risk precursors of CRC, and require Endoscopic Mu-
cosal Resection (EMR) for their safe and efficacious removal. EMR is the 
treatment of choice due to its high success rates, good safety profile and 
multiple advantages compared with surgery. 
A recent randomized study demonstrated that ablation of the post-EMR 
mucosal defect margin significantly reduced polyp recurrence at surveil-
lance. Also, recently studies have shown that endoscopic assessment of 
recurrence is very accurate with a NPP of 99%-100%. 
We aimed to determine the efficacy of this technique for reducing polyp 
recurrence in a “real life” setting.
aims & Methods: Analysis of a prospectively collected database of LSL≥ 20 
mm was performed in two hospitals in Israel. Standard EMR technique 
was used in all cases emphasizing complete snare excision followed by 
thermal ablation of the entire defect margin. Surveillance colonoscopy 
was performed 4-6 month after resection. Recurrence was assessed endo-
scopically with High Definition White Light (HDWL), Narrow Band Imaging 
(NBI) and magnification. Normal appearing scars were randomly biopsied 
as were any scars suspicious for recurrence. The primary endpoint was 
lesion recurrence at first surveillance colonoscopy.
results: Over 34 months 313 LSL in 303 patients were removed by EMR. 
249/313 (81.7%) were removed piecemeal. 233/249 (93.5%) lesions were 
treated with ablation of the margin. 176/233 (75.5%) completed first sur-
veillance colonoscopy. Recurrence was suspected endoscopically and 
confirmed histologically in 4/176 cases. One histological recurrence was 
detected in a biopsy from a normal appearing scar. Overall recurrence oc-
curred in 5/176 (2.8%) cases. Compared to the final histology, endoscopic 
diagnosis was accurate in 98%. We had 6/249 (2.4%) cases of clinical 
significant delayed bleeding all treated conservatively and two cases of 
deep mural injury treated by clips only.
conclusion: Ablation of the mucosal defect margin following EMR in a 
“real life” setting results in very low recurrence rates and low rates of 
complication. STSC should be performed routinely following piecemeal 
colonic EMR.
references: 1. Moss et al; Endoscopic mucosal resection outcomes and 
prediction of submucosal cancer from advanced colonic mucosal neopla-
sia, Gastroenterology 2011 2. Belderbos T.D.G., Leenders M., Moons L. et al; 
Local recurrence after endoscopic mucosal resection of nonpedunculated 
colorectal lesions: systematic review and meta-analysis Endoscopy 2014. 
3. Klein A, Tate DJ, Bourke MJ et al. Thermal Ablation of Mucosal Defect 
Margins Reduces Adenoma Recurrence After Colonic Endoscopic Mucosal 
Resection; Gastroenterology 2019 4. Desomer L et al. Adenoma recurrence 
after piecemeal colonic EMR is predictable: the Sydney EMR recurrence 
tool. Gastrointest Endosc. 2017
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endOscOPy usIng rOuTIne daTa
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Introduction: Detailed stratified estimates of adverse events after endosco-
py would inform clinical decision making about appropriate investigations 
in those at higher risk. This is important due to the ever increasing pro-
portion of the population undergoing diagnostic endoscopy. This abstract 
identified the adjusted total and excess risk of cardiovascular, respiratory, 
gastrointestinal and symptom events in both primary and secondary care 
following low risk day case diagnostic gastroscopy, colonoscopy, sigmoid-
oscopy and double upper and lower procedures.
aims & Methods: Patients undergoing day case diagnostic endoscopy were 
identified in the English population from the Clinical Practice Research 
Datalink hospital data using OPCS-4 coding. Each endoscopy procedure 
was frequency matched with replacement on decade of birth to at 4 con-
trols alive and registered at the time of the endoscopy including those 
who might have an endoscopy at a later date. Follow up was censored on; 
30 days or the earliest diagnosis of cancer, a subsequent gastrointestinal 
event, a subsequent interventional procedure, after the first emergency 
hospital admission, any transfer out the study population, or death. 
The first acute event was defined as either the primary reason for the first 
emergency admission after an endoscopy or a primary care consultation. 
This was coded broadly by their ICD 10 chapter; and more specifically as 
a cardiac, cerebrovascular, respiratory, gastrointestinal bleeding, perfora-
tion or peritonitis event; or as having an episode coding symptoms of nau-
sea, vomiting or abdominal pain without a gastrointestinal diagnosis. Gas-
trointestinal events or symptoms recorded both prior and post procedure 
were censored as likely to be the indication for the procedure. Outcomes 
were identified in the 30 days after the index date, from either linked pri-
mary care consultations, the underlying cause from death certificates, or 
the main diagnosis from emergency hospital admissions. 
The age stratified risk of each type of event following each type of day 
case diagnostic endoscopy was estimated in a Cox regression model ad-
justed for age, gender. and a previously developed measure of pre-existing 
co-morbidity1. Then the stratified absolute excess risks were calculated, 
adjusting for censored and competing events, by using the cumulative in-
cidence functions derived from the Cox model.
results: 277,535 gastroscopies, 172,862 colonoscopies, 22,995 dual proce-
dures and 73.195 flexible sigmoidoscopies were recorded in the linked data 
between 1998 and 2016. Of the outcome events 118,089 were coded as 
cardiorespiratory, 1,463 as gastrointestinal , and 4,213 as pain, nausea or 
vomiting. The absolute excess cardiovascular risk compared to the general 
population decreased with age for colonoscopy and double procedures, 
but increased following gastroscopies and flexible sigmoidoscopies, pos-
sibly reflecting the different case mix of patients referred for these proce-
dures. There was no reduction in the risk of a post procedure event over 
the time course of the study after adjusting for age and co-morbidity. The 
largest annual relative change was for a slight increase in cardiovascular 
events after diagnostic gastroscopy (HR=1.005 (1.001-1.009)) with an aver-
age 30 day risk of 5% for patients over 80 years.
conclusion: This study showed the potential of linked routine data to pro-
vide a comprehensive population based measurement of post endoscopic 
events in primary and secondary care. Cardiovascular events predominate, 
and despite improvements in sedation practice there was no observable 
reduction in post procedure events.
references: Crooks. PLoS One. 2016;11(10):e0165507
disclosure: Nothing to disclose 
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Introduction: The effectiveness of bowel cleansing is a key element for a 
quality colonoscopy as it affects diagnostic accuracy and adenoma detec-
tion rate. A very-low-volume 1L PEG solution NER1006 (Plenvu® Norgine, 
Harefield, UK) has been recently introduced after the publication of three 
phase 3 randomized controlled trials showing non-inferiority respect to 
comparators [1-3]. Despite its proven effectiveness, the safety of NER1006 in 
the elderly has never been assessed in a real-life setting.
aims & Methods: This study aimed to assess the difference of NER1006 
safety profile in elderly compared to younger patients in a real-life set-
ting. We performed a post-hoc analysis of data from a cohort of 1289 pa-
tients undergoing a colonoscopy after a standard (afternoon-only) or a 
split (afternoon-morning) preparation with a 1, 2 or 4L PEG-based solution 
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consecutively enrolled from September 2018 to February 2019 in 5 Italian 
centres. The elderly population was defined by an age ≥65 years. Tolerabil-
ity was evaluated through a semi-quantitative scale with a score ranging 
from 0 to 10. Safety was monitored through adverse event (AE) reporting.
results: Among 1289 patients, 233 subjects undergoing a bowel prepa-
ration with NER1006 were included in the analysis. The mean age was 
59.5±15.9 years, 52.4% of patients were male, and 43.5% were older than 
65 years old. 
Mean age was 48.6±11.9 years (range 18-64) in the group of patients aged 
< 65 years, and 73.7±6.3 years (range 65-91) in the group of patients aged 
≥65 years, while prevalence of hypertension, diabetes and obesity was 13.7 
vs 32.7% (p=0.03), 3.1 vs 9.9% (p=0.001) and 12.2 vs 13.9% (p=0.7) in the 
two groups, respectively. Overall incidence of adverse events was 19.8% 
and 10.9% (p=0.06) in the group of patients aged < 65 and ≥65 years. 
Incidence of nausea, vomit, abdominal pain, dehydration and headache 
was 3.1 vs 3.0% (p=0.9), 9.9 vs 5.9% (p=0.2), 0.8 vs 0.0% (p=0.3) 2.3 vs 
0.0% (p=0.1) and 2.3 vs 0.0% (p=0.1), in the group of patients aged < 65 
and ≥65 years, respectively. No serious adverse events or deaths occurred 
in any of the two groups.
conclusion: In this post-hoc analysis, we did not find any substantial dif-
ference in the safety profile of NER1006 in the elderly compared to younger 
patients. Given the observational nature of our study, an assessment of 
blood electrolyte or creatinine was not feasible. Nevertheless, no clinical 
event attributable to electrolyte imbalance or dehydration was observed 
in any patient. These results confirm the safety of this product even in the 
elderly and in a real-life setting.
references: 1) DeMicco MP, Clayton LB, Pilot J, et al. Novel 1 L polyethyl-
ene glycol-based bowel preparation NER1006 for overall and right-sided 
colon cleansing: a randomized controlled phase 3 trial versus trisulfate. 
GastrointestEndosc. 2018;87:677-687. 2) Bisschops R, Manning J, Clayton 
LB, et al. Colon cleansing efficacy and safety with 1 L NER1006 versus 2 L 
polyethylene glycol + ascorbate: a randomized phase 3 trial. Endoscopy. 
2019 Jan;51(1):60-72. doi: 10.1055/a-0638-8125. 3) Schreiber S, Baumgart 
DC, Drenth JPH, et al. Colon cleansing efficacy and safety with 1 L NER1006 
versus sodium picosulfate with magnesium citrate: a randomized phase 3 
trial. Endoscopy. 2019 Jan;51(1):73-84. doi: 10.1055/a-0639-5070.
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Introduction: Endoscopic mucosal resection (EMR) is a safe and effective 
technique for the resection of large colorectal lesions, but is associated 
with a high risk of local recurrence (LR). Data on the ideal methods and 
outcomes of endoscopic treatment of LR after EMR are scarce, with no 
formal recommendations.
aims & Methods: We intended to evaluate the efficacy, safety and en-
doscopic clearance rate following treatment of LR after piecemeal EMR 
(pEMR).
Retrospective unicentric study based on the analysis of LR after pEMR of 
lesions with ≥20 mm between January/2010 and December/2017, register-
ing its endoscopic, histological, treatment, complications and surveillance 
features.
results: A total of 226 pEMR of lesions measuring ≥20mm (Median 25mm, 
IQR 20-35mm) were evaluated. LR was observed in 71 patients (31.4%). 
Mean age of 66 ± 10 years, male in 45%, 42.2% located distal to the he-
patic flexure.
LR was small (< 5mm) and unifocal in 76% and 86% of cases, respectively. 
It was objectified in the first 6 months after index pEMR in 60.5% and sub-
mitted to en-block resection in 63.1% of the cases. The modalities used to 
resect recurrence were cold snare (49.3%), hot snare (25.4%), cold snare 
and cold-forceps avulsion (11.3%), cold-forceps avulsion alone (3%) and 
endoscopic full-thickness resection (3%). 8.5% (n = 6) of the patients were 
referred for surgery due to an inability to resect recurrence. Histology: 
50.7% displayed tubulovillous adenoma at histopathology and 38.1% high 
grade dysplasia. A second LR was observed in 12.3% (n = 8) patients, all of 
whom underwent piecemeal resection of the first relapse. 1 patient was re-
ferred for surgical resection due to nonresectability of the second relapse.
An endoscopic clearance of recurrent adenoma of 91.1% was obtained.
conclusion: LR after pEMR is often small and can be effectively treated 
using conventional endoscopic techniques with long-term remission rates 
greater than 90%. More complex endoscopic techniques (endoscopic full-
thickness resection/endoscopic submucosal dissection) and surgery are 
only necessary in a small number of patients.
disclosure: Nothing to disclose 
P1596 ManageMenT Of cOLOrecTaL POLyPs In a deveLOPIng 
cOunTry: Is There any dIfference?
Mrabti S., Seddik H., Boutallaka H., Sair A., Berraida R., Sentissi S., 
El koti I., Benkirane A.
Military Instruction Hospital Mohammed V, Gastroenterology II, Rabat, 
Morocco
contact e-Mail address: doc.mrabti@gmail.com
Introduction: Colorectal polyps are very common in general population. 
Endoscopy allows the diagnosis and characterization of the polyp which is 
fundamental to determine the modalities of polyp removal.
aims & Methods: The aim of our study is to determine the incidence of 
rectocolic polyps in our department and thus their adequate management.
This is a retrospective descriptive and analytical study conducted over a 
period of 19 years from January 2000 to April 2019 in our department of 
gastroenterology II of the military teaching hospital of Rabat. We included 
all patients over 18yo whom had less than 4 colorectal polyps of more 
than 3mm each, discovered during a total colonoscopy with a complete 
polyp characterization using white light and narrow band imaging, and 
whom underwent a complete endoscopic removal and retrieval. For all 
patients, we assessed the endoscopic devices used for polypectomies, and 
for complications management. We then performed a statistical analysis 
using SPSS software 24.0.
results: 3,23% (n=214) of patients who had undergone total colonoscopies 
performed during the study period (n=6607) underwent one or multiple 
polypectomies. The mean age of our patients was 55,89+/-14,45years old 
[18-90], with a sex ratio M/F of 2,17 and a history of operated rectocolic 
cancer in 13,2% (n=27). The mean number of polyps in each patient was 
1,32+/-0,66. Colonoscopies indications were dominated by rectal bleeding 
which represented 22,9% (n=47), followed by constipation in 12,2% (n=25), 
iron deficiency anemia in 5% (n=10) and abdominal pain in 5% (n=10).
During the procedure, the major part of polyps were located in left colon 
in 45,1% (n=93) and rectum in 27,7% (n=57), followed by transverse colon 
in 17,6% (n=36), right colon in 15,1% (n=31) and coecum in 5,4% (n=11).
All colorectal polyps were staged according to Paris classification with a 
predominance of sessile polyps (Is) which represented 73,83% (n=158), fol-
lowed by pedunculated ones (Ip) which represented 37,38% (n=80). stages 
IIa , IIb and IIc of Paris classification were less frequent with respectively 
0,46% (n=1), 7,47% (n=7) and 0,46% (n=1).
42.05% (n = 90), polyps were removed by forceps, 32.24% (n = 69) had 
polypectomies using cold snare, 22.89% (n = 49) had endoscopic mucosal 
resection (EMR), and 28.03 % (n = 60) were biopsied and resected later.
Early complication rate defined by the occurrence of bleeding after polyp-
ectomy was 2% (n = 2), and there was no late complication noted.
conclusion: Endoscopic resection of recto-colic polyps is currently an 
alternative to radical surgery, leading to a significantly lower cost and 
morbidity and allowing a decrease of the incidence and mortality due to 
recto-colic cancer. The therapeutic choice depends on good endoscopic 
characterization in real time. Monitoring after polypectomy is necessary 
and depends mainly on histological findings
disclosure: Nothing to disclose 
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P1597 dOes a One-day quaLITy IMPrOveMenT cOnference 
On screenIng cOLOnOscOPy InfLuences quaLITy ParaMeTers? 
- fOLLOW-uP afTer secOnd cOnference
Majcher B.1, Penz D.1, Kammerlander-Waldmann E.1, 
Hinterberger A.1, Pammer D.1, Szymanska A.1, Asaturi A.1, 
Trauner M.2, Ferlitsch M.1, Austrian Society of Gastroenterology 
and Hepatology (OEGGH): Quality Assurance Working Group
1Medical University of Vienna, Department of Internal Medicine III, Division 
of Gastroenterology & Hepatology, Wien, Austria, 2Head of Division of 
Gastroenterology and Hepatology, Department of Medicine III, Wien, Austria
contact e-Mail address: barbara.majcher@meduniwien.ac.at
Introduction: After investigating the impact of a quality improvement con-
ference on screening colonoscopy in 2016, we wanted to analyze if at-
tending a second conference one year later has an influence on quality 
parameters. Thus, our aim of the study was to assess differences in quality 
measures according to the endoscopist’s participation in the conference.
aims & Methods: 69 902 screening colonoscopies from 213 endosco-
pists performed within the Austrian Certificate of Screening Colonoscopy 
were evaluated. The second one-day quality improvement conference on 
screening colonoscopy was also organized within the framework of the 
certificate on September 9th, 2017. We investigated the following quality 
parameters: the adenoma detection rate (ADR), advanced adenoma detec-
tion rate (AADR) and cecal intubation rate (CIR).
results: Data from the year before (September 2016 to August 2017) and 
the year after the conference (October 2017 to September 2018) were com-
pared.
No statistical significance was found in mean ADR, AADR and CIR from the 
year before and after the conference among participants of the certificate 
attending the conference for the second time, first time and those who did 
not participate (table 1).
 
Before 
conference
after 
conference p-value
endoscopists participating 
for 2nd time; n= 24 (11,27%) ADR % (SD) 30,49 (9,39) 32,45 (9,85) 0,2022
  AADR % (SD) 7,83 (6,05) 8,33 (5,87) 0,6064
  CIR % (SD) 97,2 (3,15) 97,46 (2,71) 0,4597
endoscopists participating 
for 1st time; n=15 (7,04%) ADR % (SD) 27,37 (12,82) 28,59 (12,59) 0,5056
  AADR % (SD) 5,81 (3,94) 4,39 (3,0) 0,2621
  CIR % (SD) 98,82 (1,53) 97,71 (3,9) 0,2349
non-participants; n= 174 
(81,69%) ADR % (SD) 24,39 (12,79) 24,38 (12,43) 0,9930
  AADR % (SD) 5,6 (5,02) 5,11 (4,51) 0,1421
  CIR % (SD) 97,51 (3,15) 97,41 (3,19) 0,6520
[Table 1]
conclusion: This study did not show any change in the investigated quality 
parameters among endoscopists who attended the quality improvement 
conference and the ones who did not participate. Endoscopists attend-
ing the conference had higher quality parameters than non-participants 
already before the conference. Therefore, it is important to reach those 
endoscopists who need more improvement and encourage them to take 
part in training.
disclosure: Nothing to disclose 
P1598 endOscOPIc suB MucOsaL dIssecTIOn usIng scIssOr 
TyPe knIfe (sB knIfe) fOr BrOad-Based Or sTaLked cOLOnIc 
POLyPs: a sIngLe cenTre case serIes
Rameshshanker R.1, Rajendran A.2, Wawszczak A.2, Saunders B.P.2
1St Mark’s Hospital, Endoscopy, London, United Kingdom, 2St Mark’s Hospital 
and Academic Institute, London, United Kingdom
contact e-Mail address: rameshshan777@yahoo.co.uk
Introduction: Intra procedural and post polypectomy bleeding is a recog-
nised complication of large broad -based or pedunculated polyp resection. 
Several endoscopic techniques have been applied to prevent bleeding with 
variable success. Furthermore, piecemeal endoscopic mucosal resection 
could lead to incomplete resection and future recurrences.
aims & Methods: We report our preliminary experience in achieving a 
complete en bloc, Endoscopic Sub mucosal Dissection (ESD) using a scis-
sor type SB knife.
A prospective database was analysed including 26 consecutive patients 
(median age 66 years, range 34-80) with 28 broad-based colorectal neo-
plasms resected by ESD between 2015 and 2017.
results: ESD techniqueOnce a broad-based polyp was detected, the 
surface was scrutinised with white light and NBI. Firstly, the base was 
injected with submucosal injection of 0.1% hyaluronate and methylene 
blue and ESD was performed using SB knife junior (monopolar ESD knife, 
Sumius,Tokyo, Japan). Following an initial mucosal incision, submucosal 
(SM) dissection was performed. SM blood vessels (BV) were grasped and 
coagulated to prevent bleeding. A sequence of coagulation and cutting 
was performed repeatedly until the polyp was resected completely. Pol-
ypectomy base was examined and any oozing BV’s were treated with SB 
knife and the base was closed using haemostatic clips. Polyp tissue were 
retrieved and sent for histology.
The median (IQR) polyp size was 3.25cm (2-6cm). 89% (25/28) of the 
polyps were in either rectum or sigmoid colon. Histology showed ade-
noma with low grade dysplasia in 12/28(42.8%), high grade dysplasia in 
28.6%(n=8), T1 adenocarcinoma in 10.7%(n=3), hamartomas in 7.1%(n=2), 
serrated lesions without dysplasia in 7.1% (n=2) and lipoma in 3.6%(n=1) 
of endoscopically resected lesions. Intra procedural bleeding was treated 
either with haemostatic function of SB knife or with snare tip soft coagu-
lation. Base of all polyps, following resection were closed with multiple 
clips. There were no episodes of perforation or delayed post polypectomy 
bleeding. 3 patients (11.5%) were electively admitted post procedure for 
overnight observation and discharged on the following day. The en-bloc, 
histological complete and curative(R0) resection rates were 100%, 89% 
and 85%. Three patients (11.5%) at risk of lymph node metastasis under-
went additional radical surgery. 20/25(80%) of ESD cases had endoscopic 
follow up data over a median duration of 12 months (range 6-36 months) 
and none of them had local recurrences.
conclusion: ESD using scissor type SB knife is efficient and safe in treating 
broad-based or stalked polyps. Our series highlighted a favourable short 
and medium-term outcome.
disclosure: None declared 
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P1600 fuLL ThIckness resecTIOn versus endOscOPIc 
suBMucOsaL dIssecTIOn Of resIduaL/recurrenT cOLOnIc 
LesIOns On scar: a reTrOsPecTIve ITaLIan and jaPanese 
cOMParaTIve sTudy
Barbaro F.1, Hirasawa K.2, Gibiino G.3, Kobayashi R.4, Pecere S.5, 
Fukuchi T.6, Petruzziello L.7, Costamagna G.8
1Gemelli Hospital, Digestive Endoscopy, Roma, Italy, 2Yokohama-City Medical 
Center, Endoscopy, Yokohama, Japan, 3Gemelli University Hospital - IRCCS, 
Digestive Endoscopy Unit - Department of Gastroenterological, Endocrino-
metabolic and Nephro-urological Sciences, Roma, Italy, 4Yokohama 
City University, Medical Center, Yokohama, Japan, 5Catholic University 
of Rome, Gemelli Hospital, Digestive Endoscopy Unit - Department of 
Gastroenterological, Endocrino-metabolic and Nephro-urological Sciences, 
Roma, Italy, 6Yokohama City University Medical Center, Gastroenterological 
Center, Division of Endoscopy, Yokohama, Kanagawa, Japan, 7Policlinico A. 
Gemelli, Endoscopia Digestiva Chirurgica, Rome, Italy, 8Università Cattolica 
del Sacro Cuore, Digestive Endoscopy Unit, Roma, Italy
contact e-Mail address: giulia.gibiino@gmail.com
Introduction: Even if the barriers to the adoption of Endoscopic Submucosal 
Dissection (ESD) in the current practice in Western countries are falling, it 
remains, especially for colonic lesions, challenging and with a high risk of 
adverse events. ESD for residual/recurrent colonic lesions on scar is even 
more technically difficult and it has significant rate of perforations even in 
Japanese expert hands. Nevertheless, in Japanese tertially referral centers 
ESD represents the standard of care in such lesions. Full thickness resection 
(FTR) with a over-the-scope device (FTRD - Ovesco Endoscopy) is a mini-
mally invasive endoscopic technique recently introduced in Western coun-
tries. Even if with some limitations (the major limitation is the maximum 
size of the lesion, 30 mm), it showed to be safe and effective in the resec-
tion of residual/recurrent colonic lesions on scar and, being less technically 
demanding than ESD, it is more applicable among Western endoscopists.
aims & Methods: This study sought to compare, therefore, outcomes for 
endoscopic resection of such lesions between a Japanese and an Italian 
tertially referral centre. From January 2017 to December 2018 a total of 
17 and 48 residual/recurrent colorectal lesions on scar were respectively 
treated by FTR (in the Italian Centre) and ESD (in the Japanese Centre). En-
bloc and R0-resection rates were recorded as primary outcomes and retro-
spectively analysed. Adverse events, median procedure time and residual 
lesions at 3-months follow-up were assessed as secondary outcomes.
results: The proportions of R0 resections were 86.7% in the FTR group 
vs 97.9% in the ESD group. En-bloc resection rate was achieved in 100% 
in both groups. Adverse events were not reported in the first group. ESD 
group Intraoperative perforations rate was 20.8%, all managed conser-
vatively; no delayed perforations were reported and 1 case of bleeding 
occurred, managed endoscopically. There was no significant difference 
in median procedure time (56 min vs 67.5 min). At 3-months follow-up 
relapse was evident in one patient of the FTR group, treated with hybrid 
ESD while no relapse was reported for ESD group. Mean size of specimens 
was 21 mm for FTR (20;35) vs 37 mm (12-48) for ESD group. Histological 
analysis revealed: low-risk adenocarcinoma or adenoma (16 FTR, 46 ESD), 
high-risk adenocarcinoma (1 FTR, 2 ESD group).
conclusion: Despite the few numbers of preliminary data and clear limi-
tations when comparing two techniques with different advancement in 
asiatic and non-asiatic endoscopic centres, FTR showed to be a safe and 
effective procedure in residual/recurrent colonic lesions on scar and could 
become the standard of care in such lesions in Western Countries.
disclosure: Nothing to disclose 
P1601 feasIBILITy Of hyBrId endOscOPIc suBMucOsaL 
dIssecTIOn WITh MuLTIfuncTIOnaL snare ‘sOuTen’
Minato Y., Ohata K., Matsuhashi N.
NTT Medical Center Tokyo, Gastroenterology, Tokyo, Japan
contact e-Mail address: yoheiminato55925@gmail.com
Introduction: Colorectal endoscopic submucosal dissection (ESD) provides 
complete en bloc resection and precise pathological evaluations. However, 
ESD is still technically difficult and time required. Therefore, as an alter-
native option, Hybrid ESD may shorten the procedure time and enable to 
achieve an en bloc resection for relatively large lesions. Recently, a novel 
multifunctional snare (SOUTEN; Kaneka Medics, Tokyo, Japan) was intro-
duced to enable successful hybrid ESD procedures. Since the knob-shaped 
tip helps to stabilize the needle-knife, making it less likely to slip during 
circumferential incision and partial submucosal dissection, all the pro-
cesses can be completed using 1 device.
aims & Methods: The aim of this study is to evaluate the safety and efficacy 
of colorectal hybrid ESD. In this retrospective study, we applied Hybrid ESD 
using the “SOUTEN” for relatively large (20-30mm), non-pedunculated 
colorectal tumors. From June 2016 to December 2018, 46 lesions were re-
moved by Hybrid ESD. Lesions involving the ileocecal valve and/or appen-
diceal orifice were excluded from this study. In addition, lesions with pol-
ypoid growth or converging fold and those suspected of exhibiting severe 
fibrosis were also excluded. The clinical characteristics and outcomes were 
evaluated. To assess the efficacy and safety of the hybrid ESD, we extracted 
the clinical data for patients who received conventional ESD randomly from 
our ESD database performed within the previous year adjusted for tumor 
size, morphology, and location.
results: The patient age was 63.9 ± 8.5 years. All the lesions were success-
fully resected with the hybrid ESD procedure. The tumor locations were 8, 
10, and 28 in the rectum, left-sided colon, and right-sided colon, respec-
tively. The mean procedure time was 16.6 ± 4.8 minutes. The mean diam-
eter of the resected specimen was 28.5 ± 4.7 mm, and the mean tumor size 
was 22.3 ± 3.4 mm. The histological assessment revealed low-grade dyspla-
sia in 24 lesions, high-grade dysplasia in 20 patients and SM invasion in 2 
lesions. En bloc resection was achieved in all the lesions and R0 resection 
was 89.1%(41/46) . Delayed bleeding occurred in 1(2.2%) patient and Per-
foration occurred in 1(2.2%) patient. These complications were controlled 
by endoscopic treatment. No significant differences in the rates of R0 re-
section, curative resection, or adverse events were seen between ESD and 
Hybrid ESD. However, the hybrid ESD group had a significantly shorter 
procedure time than the conventional ESD group (16.6 ± 4.8 minutes vs. 
37.5 ± 21.1 minutes, P > 0.001).
conclusion: Hybrid ESD using a multifunctional snare may enable easy and 
safe resection of relatively large colorectal tumors. In addition, a cutting 
device and additional snare are usually required for hybrid ESD. But we 
could perform all the hybrid ESD steps using the “SOUTEN” snare. There-
fore, multifunctional snare also may provide cost benefit.
disclosure: Nothing to disclose 
P1602 WIThdraWn
P1603 usefuLness Of narrOW Band IMagIng fOr cOMPLeTe 
endOscOPIc resecTIOn Of sessILe serraTed adenOMa/POLyP 
(ssa/P), nasa sTudy: kasId MuLTI-cenTer sTudy
Moon J.R.1, Byeon J.-S.2, Kim H.G.1, Jung Y.1, Jeon S.R.1, Cha J.-M.3, 
Yang H.J.4
1Soonchunhyang University Hospital, Internal Medicine-GI/Hepatology, 
Seoul, Korea (Republic of), 2Asan Medical Center, Dept. of Gastroenterology, 
Seoul, Korea (Republic of), 3Kyung Hee University College of Medicine, 
Internal Medicine, Department of Gastroenterology and Hepatology, Seoul, 
Korea (Republic of), 4Sungkyunkwan University Hospital, Department of 
Gastroenterology and Hepatology, Seoul, Korea (Republic of)
contact e-Mail address: ukino816@gmail.com
Introduction: Sessile serrated adenoma/polyp (SSA/P) is known as high 
risk lesion of incomplete resection. However, there have been very limited 
evidence about how to immediate detect of remnant lesion of SSA/P right 
after the endoscopic resection. We compared Narrow band imaging (NBI) 
and white light endoscopy (WLE) for detection of remnant lesion of SSA/P 
right after the endoscopic resection of SSA/P.
aims & Methods: Prospective randomized multi-center study was done. All 
target lesions were suspicious SSA/P lesions which had 3 or more than 3 
scores out of WLE criteria assigned 1 point on each criterion by observing 
WLE; non-protruding and non-excavated shape, larger than 1 cm in size, 
right colon location, being covered by mucus cap, and varicose vessels 
presence on the surface of the lesion after submucosal injection. After en-
doscopic resection, we performed NBI or WLE inspection by randomiza-
tion for detection of remnant tissue, if detected, additional resection was 
performed. Four directional biopsies for checking the incomplete resection 
were performed on the resection margin after endoscopic resection in-
cluding additional resection for remnant lesion. Primary aim was compar-
ing the detection rate of remnant lesion, the diagnosis rate of SSA/P in the 
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remnant lesion after additional resection, and the incomplete resection 
rate between two groups. Secondary aim was finding accuracy of endo-
scopic WLE criteria for SSA/P diagnosis.
results: Total 145 lesions (NBI inspection group, n=69, WLE inspection 
group, n=76) were removed. The diagnosis rate of SSA/P was 87.6% 
(127/145) by criteria. There were no significant differences of remnant tis-
sue detection rate (14.5% vs. 13.2%, p>0.05), proportion of SSA/P of rem-
nant tissue after additional resection (10.1% vs. 10.5%, p>0.05), and the 
incomplete resection rate (5.8% vs. 9.2%, p>0.05) between NBI and WLE 
groups. The positive predictive value (PPV) of the individual criteria for 
diagnosis of SSA/P were 95.2% (mucus cap), 92.2% (ascending colon and 
cecum location), 92.1% (varicose vessel), and 86.6% (non-protruding and 
non-excavated morphology). In ROC curve analysis, the sensitivity of the 
endoscopic criteria by WLE was 93.7% at the cut-off of 2.5 with 0.741 (95% 
confidence interval 0.588~0.895) of the area under the ROC curve.
conclusion: There was no significant difference for detecting remnant le-
sion and for checking incomplete resection between NBI and WLE after en-
doscopic resection of SSA/P. WLE criteria showed moderate performance 
in diagnosing SSA/P.
disclosure: Nothing to disclose 
P1604 feasIBILITy and accePTaBILITy Of nOveL cOLOnOscOPy 
WITh cOMPuTer aIded earLy dIagnOsIs Of BOWeL cancer
Dolwani S.1, Brain K.1, Ye X.2, Gubala V.3, Howe R.W.4, Davies G.-L.5, 
Smits S.1
1Cardiff University, Population Medicine, Cardiff, United Kingdom, 2University 
of Lincoln, Computer Science, Lincoln, United Kingdom, 3University of Kent, 
Medway School of Pharmacy, Kent, United Kingdom, 4Lostwithiel Surgery, 
Primary Care, Exeter, United Kingdom, 5University College London, Materials 
Chemistry, London, United Kingdom
contact e-Mail address: dolwanis@cardiff.ac.uk
Introduction: Patients with low risk bowel symptoms often triaged to a 
non-urgent pathway have longer diagnostic intervals and later detection 
of cancer. Resource and workforce constraints in delivery of secondary care 
colonoscopy contribute to these delays
aims & Methods: This study presents preliminary data to investigate the 
acceptability and feasibility of a novel type of semi-automated robotic 
colonoscopy (portable with disposable probes not requiring reprocessing 
or decontamination) to potentially overcome delays between presentation, 
referral, diagnosis and treatment decision. 
Participants referred by their GP for direct colonoscopy underwent the new 
procedure (semi-automated robotic colonoscopy) and a parallel (back to 
back design) standard colonoscopy and were later interviewed via tele-
phone to explore their experience and comparison between the two pro-
cedures. Comfort scores and colonoscopy quality indicators and outcomes 
were compared. An online GP survey exploring feasibility of the new pro-
cedure in a primary care setting was also conducted. We also analysed the 
feasibility and accuracy of developing a machine learning tool to interpret 
findings at both novel and standard colonoscopy.
results: Participants (6 M, 9 F) perceived the value, usefulness and pur-
pose of the new procedure, with favourable comparisons made to standard 
colonoscopy, particularly previous experience of pain and recovery. Lack of 
requirement for sedation was a key benefit of the new procedure. Primary 
care was endorsed as a location, with proximity and familiarity viewed fa-
vourably, particularly in overcoming negative aspects of bowel preparation 
and recovery (e.g. not wanting to travel far). Those feeling they would not 
need sedation also viewed primary care positively. Others were indifferent, 
with feelings that it was such an undesirable procedure that location would 
not matter. Twenty-nine GPs completed the online survey. Barriers to the 
new procedure in GP practices included perceived lack of expertise to inter-
pret findings (74% agreement) and not enough space for equipment (59% 
agreement). Nearly all participants felt the new procedure had the potential 
to impact quicker diagnosis (97% agreement), and all participants felt it 
had the potential to achieve early diagnosis in low risk bowel symptoms not 
meeting 2 week wait criteria (100% agreement).
conclusion: Target users found the new procedure acceptable and viewed 
it favourably compared to standard colonoscopy. GPs perceived uses for the 
new procedure in primary care, particularly for low risk patients, however 
expertise and space were a concern. These findings are positive as the new 
procedure has the potential to improve issues with colonoscopy capacity 
and diagnostic workforce in the NHS, with a larger scale study now need-
ed. We have previously published on the training requirements and learn-
ing curve for the novel colonoscopy procedure and will also present data 
on computer aided analysis and interpretation of findings at colonoscopy.
references: Kopczynska M, Smits S, Hopps R, Ramaraj R, Warren N, 
Goddard S, Ye X, Dolwani S. Assessment of technical parameters and 
skills training to inform a simulation-based training program for semi-
automated robotic colonoscopy. Endosc Int Open. 2019 Jan;7(1): E9-E14
disclosure: Nothing to disclose 
P1605 endOscOPIc TreaTMenT Of Large syMPTOMaTIc cOLOn 
LIPOMas: a sysTeMaTIc revIeW and MeTa-anaLysIs
Vandenbroucke A.-M.1, Bronswijk M.2
1University Hospitals Leuven, KU Leuven, General Internal Medicine, Leuven, 
Belgium, 2University Hospitals Leuven, Gastroenterology and Hepatology, 
Heverlee, Belgium
contact e-Mail address: mjh.bronswijk@gmail.com
Introduction: Various techniques have been described for endoscopic re-
section of large symptomatic colon lipomas. Relying on spontaneous in-
traluminal expulsion following partial snare resection, lipoma unroofing 
might provide a safer, more cost effective and easier technique, compared 
to dissection-based techniques, endoscopic mucosal resection (EMR) or 
loop-assisted resection.
aims & Methods: The aim of this systematic review was to compare ef-
ficacy and safety of these four endoscopic techniques. A systematic review 
was performed by AMVB and MB in March 2019, using PubMed, Embase, 
the Cochrane Library and Clinicaltrials.gov. As most outcomes were binary 
in nature and several outcomes did not occur in some studies, routine 
calculation of standard errors in outcome probability was not possible. 
Therefore, original patient data were extracted, after which complete reso-
lution rate, recurrence rates and adverse events were compared.
results: Twenty seven studies between 1979-2019 met selection criteria. In 
total, 119 lesions were identified (45.5% female, mean age 63 years, mean 
lesion size 47.9mm). In total, 5 retrospective analyses, 21 case reports and 1 
prospective study were included. As no higher quality studies were found, 
possible publication bias should be taken into account. Heterogeneity was 
not assessed as most studies were not controlled. Ten patients underwent 
unroofing (8.4%), whereas 27 patients (22.7%), 33 patients (27.7%) and 
48 patients (40.3%) underwent dissection-based technique, EMR or loop-
assisted-snare resection respectively. Complete resolution rate was 80%, 
100%, 100% and 95.8% respectively. A statistically significant increased 
rate of complete resolution was seen only amongst patients receiving EMR 
(OR 19.71 (0.86-450.00 95% CI), p=0.0498), compared to unroofing. As ex-
pected, no recurrence was detected in all four groups. More importantly, 
no adverse events were identified in patients receiving endoscopic treat-
ment by unroofing. Amongst patients who underwent dissection-based 
resection, EMR or loop-assisted techniques, adverse events were identified 
in 7.4%, 12.1% and 6.3% respectively.
conclusion: Compared to unroofing, dissection-based techniques and 
loop-assisted resection did not provide an increased complete resolution 
rate which was statistically significant. Owing to the superior safety profile, 
our data suggest that unroofing should be considered as the primary en-
doscopic technique for resection of giant colonic lipomas, before resorting 
to EMR, dissection-based or loop-assisted techniques. However, due to the 
nature of the studies included, possible publication bias should be taken 
into account
disclosure: Nothing to disclose 
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P1606 BarrIers TO chrOMOendOscOPy: exPerIence In an 
IrIsh TerTIary cenTre
Stack R.1, Layden N.2, Murphy D.1, Uppamuchik Kal P.1, Sheridan J.3, 
Horgan G.4, Mulcahy H.4, Doherty G.A.5, Cullen G.6
1St. Vincent’s University Hospital, Gastroenterology, Dublin, Ireland, 2St. 
Vincent’s University Hospital, Dublin, Ireland, 3St. Vincent’s University 
Hospital Beaumont University Hospital, Dublin, Ireland, 4St. Vincent’s 
Hospital, Gastroenterology, Dublin, Ireland, 5University College Dublin, 
Dublin, Ireland, 6St. Vincent’s Hospital, Dublin, Ireland
contact e-Mail address: stack.roisin@gmail.com
Introduction: Chromoendoscopy, CE, is the optimal choice of surveillance 
for dysplasia in the inflammatory bowel, IBD, disease cohort, particularly 
for primary sclerosing cholangitis, PSC. However, with the pressure of wait-
ing list and busy endoscopy list, CE can be perceived as a cumbersome task.
aims & Methods: To review the IBD colonoscopy surveillance practice in a 
tertiary centre of IBD and PSC patients with regard to CE, highlighting ob-
stacles and perceived barriers. We performed a retrospective review of 121 
surveillance colonoscopies for inflammatory bowel disease in a teaching 
tertiary hospital over a 12month period. Patient demographics including 
age, IBD phenotype and medication were recorded. Endoscopy settings 
such as bowel preparation, withdrawal time and endoscopist expertise 
were recorded along with pre-endoscopy faecal calprotectin. Mode of ex-
amination by CE, targeted biopsies or quadrantic biopsies every 10cm were 
noted.
results: 121 surveillance colonoscopies were performed over 12months. 
Median cohort age: 48years. Male:71(58.6%). 58, 25, 2 and 36 patients 
had Crohn’s Disease, Ulcerative colitis, IBD undetermined and PSC-IBD 
respectively. CE, white band light, WBL, targeted biopsies and quadran-
tic biopsies at 10cm intervals were performed in 30, 74, and 12 patients 
respectively. 5 patients had no biopsies taken due to failed procedures/
poor preparation. 49/121(40.5%) had active disease at time of assessment, 
9/121(7%) having moderate to severe disease. 41 patients had a faecal 
calprotectin, FCP, within the 12 months prior to endoscopy, 11/41(27%) of 
which were >200. 69/121(57%) patients had excellent bowel preparation. 
However, 52/121(42.9%) had reported adequate or poor preparation, not 
compatible with EC. 
Amongst th4 CE cohort, there was no significant predominance in expertise 
of endoscopist, fellow 17/30, consultant 13/30. Average withdrawal time for 
consultants for non-chromo v CE was insignificant; 15.4 v 21 minutes (p val-
ue- 0.0571). Average withdrawal time for fellows for non-chromo v CE was 
significant; 19 v 30 minutes (p value 0.0020). 25/30 patient were reported 
to have excellent bowel preparation. There was a significant difference 
between the incidence of CE amongst hepatologist and gastroenterologist 
endoscopists; 1/17 v 29/91 (p value 0.0020).
Amongst the PSC-IBD cohort, 8/36 patients received chromoendoscopy in 
equal measuring from fellow and consultant endoscopists. 11/36(30%) pa-
tients were reported to have poor bowel preparation not compatible with 
CE. 6/36(17%) patients had active disease not compatible to EC.
conclusion: The quality of surveillance endoscopy is influenced by the de-
gree of bowel preparation, remission of disease and mode of inspection. 
Poor bowel preparation was found to be a significant obstacle to CE, par-
ticularly in the PSC-IBD cohort. Few patients had a recent FCP to ensure 
remission prior to colonoscopy. Both these factors can be optimised pre-
endoscopy to facilitate EC performance. While it may be perceived to be a 
longer procedure, no significance in withdrawal time was seen amongst 
consultant endoscopy performing EC and standard white light colonoscopy 
suggesting initial delays seen amongst fellow endoscopist reflects a learn-
ing curve.
disclosure: Nothing to disclose 
P1607 cOrreLaTIOn BeTWeen surrOgaTe quaLITy 
IndIcaTOrs fOr adenOMa deTecTIOn raTe (adr) and 
adenOMa MIss raTe (aMr) In quaLIfIed cOLOnOscOPy, 
cOre sTudy; kasId MuLTI-cenTer sTudy
Moon J.R.1, Kim H.G.1, Jeon S.R.1, Cha J.-M.2, Kwak M.S.3, Jung Y.1, 
Shin J.E.4, Cho Y.S.5
1Soonchunhyang University Hospital, Internal Medicine-GI/Hepatology, 
Seoul, Korea (Republic of), 2Kyung Hee University College of Medicine, Seoul, 
Korea (Republic of), 3Kyung Hee University College of Medicine, Department 
of Gastroenterology, Seoul, Korea (Republic of), 4Dankook University 
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contact e-Mail address: ukino816@gmail.com
Introduction: Adenoma detection rate (ADR) has been known as a key 
quality indicator of colonoscopy. However, ADR cannot reflect every ad-
enoma detection during colonoscopy and still it is unclear that ADR can 
properly reflect adenoma missing rate (AMR). We evaluated the correla-
tion between AMR and ADR, and other surrogate quality indicators.
aims & Methods: We performed a cross-sectional study of asymptomatic 
examinees aged 50~75 years who underwent back-to-back screening 
colonoscopies by 8 endoscopists. The polyp detection rate including ad-
enoma (PDR), the total number of adenomas per colonoscopy (APC), the 
additional adenomas found after the first adenoma per colonoscopy (ADR-
Plus), the total number of adenomas per positive participant (APP), and 
ADR were calculated for prediction of AMR.
results: Total 371 back-to-back colonoscopies were performed. ADRs were 
64.6% in male, and 51.1% in female examinees (p=0.009). Because there 
was a significant difference in the gender of the examinees by each endos-
copist (p< 0.001), and also was a significant difference of ADRs (65.6, 44, 
64.3, 75.4, 54, 48, 52, and 60%, p=0.024), ADRs were separately obtained 
by gender. There were no significant differences of ADRs of each endos-
copist obtained separately for male (p=0.335) and female (p=0.218) exam-
inees. AMRs not differed between endoscopists (31.3, 9.1, 21.9, 22.1, 10.9, 
12.5, 19.2, 22.9%, p=0.462) for male examinees and for female examinees 
(27.8, 8.7, 0, 18.2, 46.4, 0, 31.8 and 23%, p=0.052). There was no related 
quality indicators with AMR in both male and female examinees. Overall, 
PDR was significantly correlated with ADR (rho 0.826, p=0.011). In female 
participants, PDR (rho 0.904, p=0.002) and APC (rho=0.838, p=0.009) were 
significantly correlated with ADR.
conclusion: High ADRs endoscopists showed varied AMRs. PDR and APC 
may be surrogate quality indicators for ADR. However, further studies 
for surrogate quality indicators to discriminate meticulous endoscopists 
should be performed.
disclosure: Nothing to disclose 
P1608 WhaTsaPP reMInder IMPrOves The quaLITy Of 
cOLOrecTaL cancer screenIng. a sIngLe BLInded randOMIzed 
cOnTrOLLed sTudy
Lam T.Y.T.1, Sung J.J.Y.2, Wu J.2, Luk K.C.A.3
1Chinese University of Hong Kong, Institute of Digestive Disease, Shatin, 
China, 2Chinese University of Hong Kong, Department of Medicine & 
Therapeutics, Hong Kong, China, 3The Chinese University of Hong Kong, 
Hong Kong, Hong Kong, China (SAR)
contact e-Mail address: arthurluk@cuhk.edu.hk
Introduction: Bowel preparation is one of the important factors to ensure 
a high quality colonoscopy. Efforts to improve bowel preparation level 
through traditional communication routines have proven to be useful. 
However, the impact of WhatsApp reminder on the bowel preparation level 
of screening colonoscopy is still unknown.
aims & Methods: We aimed to investigate the effectiveness of WhatsApp 
reminder in bowel preparation level of screening colonoscopy.
Subjects recruited and randomized form a population based CRC screen-
ing program. All subjects would receive both verbal and written instruc-
tions of bowel preparation by a healthcare professional on the day of ap-
pointment making. For subjects randomized to the WhatsApp reminder 
group, they will receive a WhatsApp reminder with same content of the 
written instruction and a video of detailed bowel preparation instruction 4 
days prior colonoscopy. For subjects randomized to usual care group, they 
will not receive any reminder.
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  Whatsapp reminder usual care p-value
  N = 333 N = 333  
Male Gender (%) 197 (59.2) 195 (58.6) 0.875
Age (SD) 65.4 (3.8) 65.7 (3.9) 0.261
Hypertension (%) 133 (39.9) 125 (37.5) 0.525
Diabetes (%) 47 (14.1) 3 (12.9) 0.65
Ischemic heart disease (%) 25 (7.5) 22 (6.6) 0.65
Chronic obstructive pulmonary disease 
(%)
4 (1.2) 3 (0.9) 1
Cirrhosis (%) 2 (0.6) 1 (0.3) 1
Renal impairment (%) 2 (0.6) 5 (1.5) 0.451
Fatty liver (%) 8 (2.4) 5 (1.5) 0.401
Caecal intubation (%) 328 (98.5) 327 (98.2) 0.761
  N = 328 N = 327  
Median withdrawal time in minutes 
(IQR)
11 (7-17) 10 (7-16) 0.399
Median intubation time in minutes (IQR) 6 (4-9) 6 (4-9) 0.579
Satisfactory bowel preparation level (%) 283 (86.3) 257 (78.6) 0.01
Adenoma detection (%) 240 (72.9) 227 (69.4) 0.318
[Demographics and colonoscopy findings between WhatsApp reminder and 
usual care groups]
results: From June 2017 to April 2019, 667 subjects scheduled for screen-
ing colonoscopy because of positive fecal immunochemical test were 
recruited. They were randomized to WhatsApp reminder and usual care 
groups in 1:1 ratio. Demographics between two group was similar. 12 sub-
jects with incomplete colonoscopy were excluded. No difference can be 
observed in median intubation and withdrawal time between two groups. 
When compared to usual care group, more subjects significantly achieved 
satisfactory (excellent or good) bowel preparation level (86.3% vs 78.6%, 
p=0.01) during screening colonoscopy. However, adenoma detection rate 
was similar between two groups (72.9% vs 69.4, p=0.318).
conclusion: WhatsApp reminder shows significant improvement in the 
bowel preparation level of screening colonoscopy.
disclosure: Nothing to disclose 
P1609 TIMe’s uP: faTIgue negaTIveLy IMPacTs cOLOnOscOPy 
adenOMa deTecTIOn raTe
Wu T.1,2, Vandeleur A.3, Rahman T.2,3
1The Royal Brisbane and Women’s Hospital, Brisbane, Queensland, 
Australia, Department of Gastroenterology, Newstead, Australia, 2University 
of Queensland, Medicine, Brisbane, Australia, 3The Prince Charles Hospital, 
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Introduction: The quality of colonoscopy is influenced by patient and op-
erator factors. Various studies on timing of colonoscopy and effect of op-
erator fatigue on adenoma detection (ADR) have yielded conflicting results 
(1-3). This study aims to compare adenoma detection and complication 
rates between elective colonoscopies performed first and last in the list, 
across multiple operators (n=12) in a tertiary public hospital.
aims & Methods: We conducted a case-control study on patients who un-
derwent elective colonoscopies from 2012 to 2017 at the Prince Charles 
Hospital. Time of endoscopy was used as a surrogate marker for operator 
fatigue, whereby colonoscopies performed after 11am on the morning list 
and after 4pm on the afternoon list were identified as cases, and matched 
with those performed before 9am and at or before 1pm as controls. Clini-
cal, endoscopic and histological databases were analysed for baseline pa-
tient characteristics, colonoscopy quality markers, and adverse events from 
a 30-day follow up survey.
results: We report on preliminary analysis of 1216 patients who underwent 
colonoscopies between April and June 2017. The patients were booked in 
no particular sequence and have similar baseline characteristics. Colonos-
copies done later in the list had lower adenoma detection rates (39.7% 
vs 55.7%, OR 0.5, p=0.007) and lower mean adenoma count (1.2 vs 1.9, 
p=0.04). No statistically significant difference was found in SSA detection 
rates, quality of bowel preparation, and complication rates.
conclusion: Preliminary data suggests a significant deterioration in colo-
noscopy quality associated with operator fatigue. Further analysis with 
stratified data for individual operators, and on extended dataset between 
2012-2017 will be carried out to confirm these findings.
references: 1.Almadi MA, Sewitch M, Barkun AN, Martel M, Joseph L. Ad-
enoma detection rates decline with increasing procedural hours in an en-
doscopist’s workload. Canadian Journal of Gastroenterology & Hepatology. 
2015;29(6):304-308. 2.Subramanian S, Psarelli EE, Collins P, et al. Colo-
noscopy performance is stable during the course of an extended three-
session working day. Endoscopy International Open. 2015;3(5):E494-E500. 
doi:10.1055/s-0034-1392523. 3.Lee A, Jensen CD, Marks AR, et al. Endos-
copist fatigue estimates and colonoscopic adenoma detection in a large 
community-based setting. Gastrointestinal endoscopy. 2017;85(3):601-610.
e2. doi:10.1016/j.gie.2016.09.033.
disclosure: Nothing to disclose 
P1610 endOscOPIc TaTTOOIng Of cOLOrecTaL LesIOns aT 
nOTTInghaM unIversITy hOsPITaLs: are We sPOT On?
Oppong P.1, Tan H.2, Ban L.3, Chow C.W.2, Parra-Blanco  A.4
1Royal Derby Hospital, Nottingham, United Kingdom, 2Nottingham University 
Hospital, Gastroenterology, Nottingham, United Kingdom, 3University of 
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Introduction: Endoscopic tattooing is a safe technique useful for locali-
sation of small colorectal lesions, especially in the laparoscopic setting. 
However, many studies have reported variation in tattooing practice, re-
sulting in inaccuracies in diagnosis and management. The aim of this 
study was to review tattooing practice in all patients with colorectal can-
cer and high grade dyplastic polyps who were discussed at the colorectal 
multidisciplinary team meeting (MDT) at Nottingham University Hospitals 
(NUH) in 2016.
aims & Methods: Minutes and colonoscopy reports for all new cases dis-
cussed at the colorectal MDT in 2016 were analysed. Cases discussed at 
the MDT were those with colorectal cancer, polyps with cancer, high grade 
dysplasia, or suspicious for malignancy. Tattooing practice was evaluated 
against the local NUH colon tattoo protocol. This states that all suspected 
cancers identified, excluding those located at the caecum and rectum, 
should be tattooed at 3 radial sites, 3 cm anal to the lesion. Colonic polyps 
>2 cm (excluding caecum and rectum) and/or suspicious for malignancy, 
should be tattooed at at least 1 site 3 cm anal to the lesion. Tattoos and 
their relationship to the lesion should be photo-documented.
Cases discussed at the colorectal MDT were excluded if they had been pre-
viously discussed, the endoscopy report was unavailable, the cancer was 
identified at emergency surgery or on CT only or there was no cancer/
polyp at colonoscopy.
results: The results are shown in table 1.
  n Tattooed (%, 95% cI) Tattooed as per protocol (%, 95% cI)
Colonic cancer 133 96 (72.2, 63.7-79.1) 49 (51.0, 40.6-61.4)
Malignant polyp 14 10 (71.4, 41.9-91.6)
23 (52.3, 36.7-67.5) [all 
polyps]
HGD polyp 55 24 (43.6, 30.3-57.7)  
LGD or other polyp 21 10 (47.6, 25.7-70.2)  
Suspected rectal cancer 116 17 (14.7, 8.8-22.4)  
Suspected caecal cancer 24 7 (29.2, 12.6-51.1)  
[Table 1: Results]
Rates of tattooing were similar across males and females. There was some 
variation by patient age, location of the cancer and who did the index 
colonoscopy. For example, only 59.1% of patients had a tattoo if the index 
colonoscopy was performed by consultant surgeon compared to over 70% 
by other professionals (p>0.05). With regards to tattooing as per local pro-
tocol, the lowest rate (33%) was seen with independent trainee colonos-
copists (p>0.05). No variables however were identified to have statistically 
significant associations with increased rate of tattooing polyps.
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conclusion: How and when to tattoo colonic lesions is becoming increas-
ingly pertinent in the age of minimally invasive surgery. This audit high-
lights the need for improvement in this area and serves as a reminder 
for us to align routine clinical practice with local guidelines. Given these 
findings, we believe there is a role for regular standardised teaching on 
endoscopic tattooing for endoscopists.
We acknowledge the limitations inherent in our study, including the small 
sample size of the study. However, we are undergoing a re-audit for year 
2019 of similar qualitative study to ascertain improvements. As conclusion, 
we consider our findings an important first step towards effective clinical 
management, and prevention of colorectal cancers.
disclosure: Nothing to disclose 
P1611 dO PaTIenTs redeveLOP The saMe LesIOns afTer 
resecTIng TheM?
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Hepatology - Department of Medicine III, Head of Division o, Department of 
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Introduction: Colorectal cancer can arise from nonadvanced adenomas or 
advanced adenomas. Patients with advanced adenomas have higher risk 
to develop CRC (Brenner et al., Gut. 2007). 
Aim of this study was to see if patients redevelop advanced- or nonad-
vanced lesions by comparing diagnosis of baseline colonoscopy with diag-
nosis of surveillance colonoscopy.
aims & Methods: In this retrospective study 5175 patients underwent two 
colonoscopies within 1-10 years. Data stem from the Austrian certificate of 
screening colonoscopy. Diagnosis of patients in first screening colonos-
copy got compared with diagnosis of surveillance colonoscopy with a Chi-
square-test.
results: Mean surveillance interval was 4 years. 372 patients (7,19%) got 
diagnosed with advanced adenomas, 1384 (26,74%) had nonadvanced ad-
enomas and 3419 (66,07%) had no pathological findings in first screening 
colonoscopy. Diagnosis of surveillance colonoscopy per baseline colonos-
copy are shown in table 1. (p=0,0001). Most patients who got diagnosed 
with advanced adenomas in screening colonoscopy had no pathological 
findings or nonadvanced adenomas in surveillance colonoscopy. Patients 
who got diagnosed with nonadvanced adenomas in screening colonoscopy 
had mostly no pathological findings or got diagnosed with nonadvanced 
adenomas again. 
 
advanced 
adenomas in 
surveillance 
colonoscopy
nonadvanced 
adenomas in 
surveillance 
colonoscopy
no pathological 
findings in 
surveillance 
colonoscopy
Advanced adenomas in 
screening colonoscopy
77 (20,70%) 135 (36,29%) 160 (43,01%)
Nonadvanced adenomas 
in screening colonoscopy
93 (6,72%) 580 (41,91%) 711 (51,36%)
No pathological findings 
in screening colonoscopy
208 (6,08%) 680 (19,89%) 2531 (74,03%)
[Table 1]
conclusion: Most of the patients who had advanced- or nonadvanced le-
sions inscreening colonoscopy had no pathological diagnosis in surveil-
lance colonoscopy. Nevertheless, results demonstrate that patients, who 
got diagnosed with advanced- or nonadvanced adenomas, redeveloped 
adenomas, which shows the importance of accurate surveillance colonos-
copy. Chi-square test was significant (p=0,0001).
disclosure: Nothing to disclose 
P1612 InfLuence Of MOOn Phases On BOWeL PreParaTIOn 
quaLITy In a screenIng cOLOnOscOPy cOLLecTIve
Kammerlander-Waldmann E.1,2, Kammerlander A.3, Penz D.1,2, 
Hinterberger A.1,2, Majcher B.1,2, Szymanska A.1,2, Asaturi A.1,2, 
Trauner M.1,2, Ferlitsch M.1,2
1Medical University of Vienna, Dept. of Internal Medicine III, Div. of 
Gastroenterology and Hepatology, Vienna, Austria, 2Quality Assurance 
Working Group, Austrian Society for Gastroenterology and Hepatology, 
Vienna, Austria, 3Medical University of Vienna, Dept. of Cardiology, Vienna, 
Austria
contact e-Mail address: elisabeth.waldmann@meduniwien.ac.at
Introduction: Moon phases, in particular full moon, are often discussed 
to have an impact on sleep and activity behavior as well as various other 
functions of the human body.
aims & Methods: The aim of the present study was to investigate the im-
pact of moon phases on bowel preparation quality. Therefore, we ana-
lyzed bowel preparation quality according to a modified Aronchick Score in 
screening colonoscopies performed between 08/2008 and 12/2018 within 
a national quality assurance program in Austria. Preparation quality rated 
as excellent, good or fair were considered sufficient.
results: 207,593 screening colonoscopies were included in the study. 
50,74% of screenees were woman, mean age was 60.9 years (SD 9.1). 
Bowel preparation quality was sufficient in 95.94% of examinations. Over-
all bowel preparation quality differed significantly between moon phases 
(new/waning/waxing/full moon, p=0.014). 3.12% (n=6,480) of colonosco-
pies were performed the day after a full-moon night. Those patients had a 
significantly higher rate of inadequate bowel preparation as compared to 
other moon phases (relative risk 1.18 [95% CI 1.06-1.32], p=0.004). Notably, 
this effect was only significant in men (5.32% vs. 4.22% insufficient prepa-
ration; p=0.003%, women p=0.26%).
conclusion: If screening colonoscopy is scheduled on a day after a full 
moon night, patients, particularly male patients, should be intensely in-
structed to follow bowel preparation guidelines.
disclosure: Nothing to disclose 
P1613 PrevaLence Of adenOMas aMOng dIMInuTIve 
unresecTed POLyPs In LefT cOLOn
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Introduction: The American Society for Gastrointestinal Endoscopy (ASGE) 
recommends that diminutive polyps located in the distal colon can be left 
in place without any resection if they are predicted to be nonadenomatous 
with a negative predicting value of >90%. However, we know that ap-
proximately 30% of adenomas are located in the left colon. Therefore, aim 
of our study was to assess the prevalence of adenomas among unresected 
diminutive polyps in the distal colon.
aims & Methods: 315.822 screening colonoscopies between 2007 and 
March 2019 performed by 355 endsocopists were analyzed within the 
Austrian quality assurance program. Histopathologic diagnosis of polyps 
under 5mm located in the left colon that were not resected but where 
endoscopists took biopsies to ensure were assessed. Further the nega-
tive predictive value for adenomatous lesions among those polyps was 
analyzed.
results: Overall In 39,24 % (n= 123.942) polyps were detected. 14,18% 
(n=17581) were diminutive and located in the left colon. 3,22% (n=566) of 
those lesions remained unresected but a biopsy was taken. 
Among those 566 unresected diminutive polyps 2,83% (n=16) were ad-
vanced and 21,91% (n=124) nonadvaned adenomas. In 0,35% (n=2) those 
lesions were characterized as SSA and in 0,53% (n=3) as TSA. 421 (74,38%) 
of all unresected left sided diminutive lesions were classified as hyper-
plastic polyps.
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conclusion: In our study cohort there was a high prevalence of adenomas 
(24,74%) among unresected diminutive polyps in the left colon were a 
biopsy was performed. The negative predictive value for adenomas, SSAs, 
as well as TSAs was 74,38% which is lower than recommended. Therefore 
left-sided diminutive lesions that macroscopically appear to be hyperplas-
tic but were the endoscopist decided to take a biopsy should be resected. 
Only in case the endoscopists can characterize the adenomatous lesions 
with high confidence, predict and leave behind strategy may be used.
disclosure: Nothing to disclose 
P1614 effIcacy Of endOscOPIc TreaTMenT In Large BILe 
ducT sTOnes: a revIeW Of a TunIsIan serIes
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Introduction: Therapeutic endoscopic retrograde cholangiopancretography 
(ERCP) is the first approach in the management of bile duct stones. It is 
estimated that bile ducts can be cleared in 90% of the cases with con-
ventional endoscopic methods. Large stones, however, can be sometimes 
challenging to remove.
aims & Methods: The aim of our study was to investigate the management 
and the complications associated with large common bile duct stones. 
We realized a retrospective study including all patients that underwent an 
ERCP between 2013 and January 2018. The patients who had common bile 
duct stones were divided into two groups:
- First group: those who had large common bile duct stones (>=10mm).
- Second group: patients with smaller common bile duct stones.
results: During the study period, 424 ERCPs were performed to remove 
common bile duct stones. The mean age of the patients was 61,3 years 
old (13-98) with a sex ratio (F/M) of 2. Large stones have been found in 
22,16% of the procedures (n=94). In both groups of patients, an acute bili-
ary pancreatitis or cholangitis was associated in 5,3% of the cases. Bile 
duct clearance was obtained respectively in 95,74% and 90,6% within the 
first and second group. Nine patients from the first group needed more 
than one ERCP. When it came to large stones, lithotripsy was performed in 
5 patients, we placed a nasobiliary catheter once and a biliary endopros-
theses in 12 patients. Among the second group, a biliary endoprostheses 
was needed 5 times and one patient had a nasobiliary catheter placed. No 
difference was found in terms of short term ERCP complications between 
the two groups (p=0,349).
conclusion: Large common bile duct stones may require additional tech-
niques while ERCP to be removed but do not cause more short term com-
plications than smaller bile duct stones.
disclosure: Nothing to disclose 
P1615 effIcacy Of InTraMuscuLar dIcLOfenac In The 
PrevenTIOn Of POsT-ercP PancreaTITIs: a PrOsPecTIve, 
randOMIzed, PLaceBO-cOnTrOLLed sTudy
Kim M.C.1, Kim S.B.1, Cho J.H.1, Kim K.H.1, Kim K.O.1, Lee S.H.1, Jang B.I.1, 
Kim T.N.2
1Yeungnam University, College of Medicine, Internal Medicine, Daegu, Korea 
(Republic of), 2Yeungnam University College of Medicine, Internal Medicine, 
Daegu, Korea (Republic of)
contact e-Mail address: tnkim@yu.ac.kr
Introduction: Rectal nonsteroidal anti-inflammatory drugs (NSAIDs) re-
duce the risk and the severity of post-endoscopic retrograde cholangio-
pancreatography (ERCP) pancreatitis (PEP). However, rectal NSAIDs are not 
available in some countries including Korea. Recently, two contrary studies 
about the effect of intramuscular NSAIDs to PEP had been reported. The 
aim of this study was to evaluate the efficacy of intramuscular NSAIDs in 
prevention of PEP.
aims & Methods: This is prospective, randomized, placebo-controlled clin-
ical trial. Patients who underwent ERCP with naïve papilla received single 
dose of intramuscular diclofenac (75mg) or placebo immediately before 
ERCP. The primary outcome was PEP, which was defined as followings; 
newly developed abdominal pain, elevation of serum amylase or lipase at 
least three times the upper normal limits 24 hours after ERCP, and prolon-
gation of hospitalization at least 2 days.
results: Total 171 patients were randomized, and 168 patients were finally 
enrolled in study. Demographic and clinical factors, comorbidities, ERCP 
findings, and types of treatment were similar between two groups. The 
PEP developed in 6 of 73 patients (8.2%) in the diclofenac group and in 5 
of 95 patients (5.3%) in placebo group (p=0.443). While most of PEP had 
mild severity (90.9%), moderate case was only 1 patient of PEP in diclof-
enac group (p=0.338). There was no case of severe PEP in both groups. In 
multivariate logistic regression analysis, factor associated with prevention 
of PEP was endoscopic retrograde pancreatic drainage (odds ratio 0.012; 
95% confidence interval 0.001-0.184; p-value=0.002) and not intramus-
cular diclofenac (odds ratio 0.565; 95% confidence interval 0.114-2.798; 
p-value=0.565).
conclusion: Intramuscular diclofenac does not seem to be effective in pre-
vention of PEP.
disclosure: Nothing to disclose 
P1616 WeIghT-Based dOsIng sTraTegy In recTaL dIcLOfenac 
use Is feasIBLe fOr PrevenTIOn Of POsT-ercP PancreaTITIs In 
a reaL-WOrLd jaPanese POPuLaTIOn
Tomita R.1, Nishida T.1, Hayashi S.1,2, Chang L.1, Kuriki S.1, Aochi K.1, 
Meren E.1, Sakamoto T.1, Higaki Y.1, Osugi N.1, Sugimoto A.1, Takahashi K.1, 
Nakamatsu D.1, Mukai K.1, Matsumoto K.1, Yamamoto M.1, Fukui K.1, 
Inada M.1
1Toyonaka Municipal Hospital, Gastroenterology, Toyonaka, Japan, 2Hayashi 
Clinic, Gastroenterology and Internal Medicine, Suita, Japan
contact e-Mail address: track800ryo@icloud.com
Introduction: Acute pancreatitis is a common complication after endo-
scopic retrograde cholangiopancreatography (ERCP) and called post-ERCP 
pancreatitis (PEP). It is, however, difficult to completely prevent it. ESGE 
guideline 2014 says that nonsteroidal anti-inflammatory drugs (NSAIDs) 
routine rectal administration of 100mg of diclofenac or indomethacin im-
mediately before or after ERCP in all patients without contraindication. 
100 mg of diclofenac is higher than the normal single dose used for the 
Japanese population. However, there are still few evidence of the efficacy 
of a low dosage of rectal diclofenac in a real-world Japanese population. 
The aim of this study was to evaluate the efficacy of low-dose diclofenac 
use based on weight for prevention of PEP.
aims & Methods: This study was a retrospective single-center cohort study 
of consecutive patients underwent ERCP or ERCP-related procedures from 
January 2016 to March 2019. During the study period, procedures were 
conducted to prevent PEP using either 50mg or 25mg of rectal diclofenac 
in patients weighing ≥50kg or < 50kg and intensive intravenous fluid ad-
ministration when post ERCP 2-hour serum amylase level was more than 
2 times of upper limit of normal. Before the study period, we conducted 
the PEP prevention strategy using prophylactic antibiotics and protease in-
hibitor for 3 days without the use of NSAIDs. The PEP rate was 3.9% (95% 
CI: 3.02-5.07) in 1403 patients as historical control (World J Gastrointest 
Endosc. 2016). In the present study, we evaluated the PEP rate of weight-
based dosing strategy in rectal diclofenac use. The following conditions 
were excluded: 1) gallstone pancreatitis, 2) unreachable to papilla, 3) no 
use of diclofenac.
results: A total of 1241 patients (median age 76, female 43%) were en-
rolled. Of them, 181 cases were excluded. Finally, 1060 cases were analyzed 
(native papilla: 514, 48%, diclofenac 25mg: N=561, 53%, 50mg: N=499, 
47%). The median cannulation time was 1 min (range 1-82), and the me-
dian procedure time was 30 min (range 3-120min). PEP developed in 26 
patients (2.4%, 95%CI: 1.7-3.6) including 4 severe acute pancreatitis, and 
perforation and bleeding occurred 0 and 2 patients, respectively. PEP rates 
were similar in both diclofenac 25 mg and 50 mg (2.7% and 2.2%, re-
spectively).
conclusion: Low dose rectal diclofenac use and intensive intravenous flu-
id administration strategy is relatively lower PEP rate than our historical 
control. It seems to be better compared with the strategy using protease 
inhibitor without the use of NSAIDs.
disclosure: Nothing to disclose 
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P1617 ManageMenT Of PancreaTIcOjejunaL anasTOMOTIc 
sTenOsIs fOLLOWIng PancreaTOduOdenecTOMy WITh 
sIngLe-BaLLOOn enTerOscOPy assIsTed endOscOPIc 
reTrOgrade PancreaTOgraPhy (sBe-erP)
Shimizu S., Takaki R., Kobashikawa K.
Urasoe General Hospital, Department of Gastroenterology, Okinawa, Japan
contact e-Mail address: murasachi1004@hotmail.com
Introduction: Pancreaticojejunal anastomostic stenosis (PAS) is recognised 
as one of the long-term complications post pancreatoduodenectomy (PD). 
PAS can cause acute pancreatitis and associated complications such as 
stone formation. Balloon-assisted enteroscopy (BAE) has been available 
since 2003. It’s primary use has been for therapy post hepato-biliary sur-
gery. However, data pertaining to efficacy, safety, and long-term outcomes 
of the optimal enteroscopic approach for PAS is lacking.
aims & Methods: Our aim is to assess the efficacy, safety, and long-term 
outcomes of single-balloon enteroscopy for PAS related acute pancreatitis 
post PD. 8 patients between November 2013 and March 2017 were enrolled 
from our center.The pancreaticojejunal anastomosis was assessed with a 
single balloon enteroscope, using a 3/0 prolene suture for identifying the 
site. We then proceeded to followed by replacing the plastic stent. Follow 
up stent removal were performed at 3 months. We recorded; 
1) the duration of the onset of acute pancreatitis after operation, 
2) success rate of endoscopic treatment, 
3) procedure time, 
4) complication rate, and 
5) recurrence rate of pancreatitis.
results: The median age in these 8 patients are 66 years old, and male/
female are 4/4. All 8 patients underwent pylorus-preserving pancreatico-
duodenectomy (PPPD) for malignancy. The average total observation pe-
riod since PD was 94 (41-151) months, while the period since first treatment 
was 41 (14-61) months.
1) The mean to time of onset of acute pancreatitis after PD was 45 months 
(8-129) months. 
2) 7 out of 8 patients had a successful endoscopic result (88%). 
3) The average procedure time was 86 (56-124) minutes. 
4) Two patients (25%) who had hyper amylasemia and one patient (13%) 
experienced the recurrence of acute pancreatitis due to stent migration. 
However, there were no serious complications in these 8 patients. 
5) 3/7 (42%) cases had recurrence of pancreatitis after recurrent PAS. 
For these 3 recurrent cases, the average duration of recurrent pancreatitis 
was 19 (11-35) months. Despite repeated endoscopic treatment, all three 
patients experienced multiple episodes of acute pancreatitis.
conclusion: The previous reports have mentioned that the rate of pancre-
atitis was 3% after PPPD, with surgical management considered as first 
line therapy. Evidence for BAE-ERP treatments for PAS have been limited 
to case reports. However, reported issues include difficulty in identification 
of the pancoreaticojejunal anastomosis and thus success rate varies. In 
our study, the success rate was as high as 88% due to using 3/0 prolene 
sutures as an indicator for locating pancreaticojejunal anastomosis. We 
had shorter procedure times without signficinat adverse events. Therefore, 
endoscopic treatment is safe, and less invasive technique in this small case 
series. Further prospective, multi-centre studies are required to validate 
our findings.
disclosure: Nothing to disclose 
P1618 endOscOPIc ManageMenT Of MInOr aMPuLLary 
TuMOrs: a MuLTIcenTer case serIes
Aslam R.1, Ahsan N.2, Inamullah M.2, Ayub K.3
1Silver Cross Hospital, Gastroenterology, New Lenox, United States, 
2Southwest Gastroenterology, Oak Lawn, United States, 3Silver Cross Hospital, 
Medicine, Oak Brook, United States
contact e-Mail address: raslam01@nyit.edu
Introduction: Ampullary and duodenal carcinoma are aggressive cancers 
with poor 5 year survival rates. Like colorectal cancer, ampullary and duo-
denal carcinomas are also thought to follow the adenoma-carcinoma se-
quence. Ampullectomy is a well-established treatment for adenoma and 
early stage carcinoma of major ampulla. Several studies have established 
its safety and efficacy in the management of major ampullary adenomas. 
However, adenomas arising in the minor ampulla are relatively rare and 
there are no good case series on endoscopic management of these tumors. 
We report a multicenter case series of endoscopic ampullectomy in the 
management of minor ampullary tumors.
aims & Methods: To establish the safety and efficacy of endoscopic ampul-
lectomy in the management of minor ampullary adenomas. Consecutive 
patients undergoing ampullectomy for minor ampullary tumor at four 
hospitals were included in this study over a period of 5 years. A total of 6 
patients were included in the study and all six patients underwent ERCP 
for purpose of minor ampullectomy. MRCP and EUS was performed on all 
patients prior to ERCP to rule out invasion. Pancreatic stents were placed 
after ampullectomy in 5 patients, 3 F x 8 cm single pigtail stents in 4 pa-
tients, and 5 F x 5 cm straight stent in one patient. All stents were removed 
in approximately 2 weeks.
results: Ampullectomy was technically successful in all 6 patients. One 
patient required two ERCPs for complete ampullectomy. The adenomas 
varied in size from 1 cm to 3 cm. Pathology revealed adenoma in three 
patients, adenoma with high grade dysplasia in one patient, carcinoma 
in one patient, and carcinoid tumor in one patient. One patient (16%) de-
veloped post ERCP pancreatitis; this patient was kept in the hospital for 2 
days. No other major complications were noted. Two patients had abdom-
inal pain for one day post ERCP; this was considered a minor complication. 
Follow-up for these patients ranged from 2 to 5 years with EGD using 
duodenoscope at 3 months, one year and yearly thereafter. One patient 
had recurrence at 2 years which was thought to be recurrent adenoma (4 
mm). This patient was treated with repeat ampullectomy. The patient with 
carcinoma had endoscopies every 3 months for a year followed by yearly 
endoscopy; no recurrence was noted during the 3 years of follow-up. An 
EUS, MRI and PET scans were also performed at 1 year per oncology ad-
vice; all tests were negative. Two out of six patients (33%) had Familial 
Adenomatous Polyposis (FAP). Two patients had Pancreas Divisum, one 
with Type 1, and other with type 3 Divisum.
conclusion: In our pilot study, endoscopic ampullectomy appears safe and 
effective in the management of minor ampullary adenomas.
references: 1.Lapp, Robert T, and Grant F Hutchins. Minor Papilla Ad-
enoma Management in Patients with Pancreas Divisum and Familial 
Adenomatous Polyposis. ACG Case Reports Journal, American College 
of Gastroenterology, 8 Oct. 2013 2.Han J, Kim M-H. Technical Review: 
Endoscopic papillectomy for adenomas of the major duodenal papilla 
(with video). Gastrointestinal Endoscopy. 2006;63:292-301. doi:10.1016/j.
gie.2005.07.022. 3.Irani S, Arai A, Ayub K, et al. Papillectomy for ampullary 
neoplasm: results of a single referral center over a 10-year period. Gas-
trointest Endosc. 2009;70:923-932. 4.Sugiyama M, Kimura W, Muto T, et al. 
Endoscopic resection of adenoma of the minor papilla. Hepatogastroenter-
ology. 1999;46(25):189-192. 5.Lucena JF, Alvarez OA, Gross GW. Endoscopic 
resection of heterotropic pancreas of the minor duodenal papilla: Case 
report and review of the literature. Gastrointest Endosc. 1997;46(1):69-72.
disclosure: Nothing to disclose 
P1619 cOMParaTIve adverse evenT anaLysIs In ercP 
BeTWeen POsT LIver TransPLanT and naTIve hePaTOBILIary 
anaTOMy
Catron T.1, Shipley L.2, Johnson D.2, Mitchell R.1, Kyanam K.1, Harrison D.3, 
Shoreibah M.1, Ahmed A.4
1University of Alabama at Birmingham, Gastroenterology and Hepatology, 
Birmingham, United States, 2University of Alabama at Birmingham, 
Internal Medicine, Birmingham, United States, 3University of Alabama 
at Birmingham, Birmingham, United States, 4University of Alabama at 
Birmingham, Gastroenterology & Hepatology - Interventional Endoscopy, 
Hoover, United States
contact e-Mail address: ali494@gmail.com
Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) 
carries potential for procedure-related adverse events. Several clinical 
variables have been identified in prior studies that increase risk for such 
events. We are reporting data from our ERCP experience to compare ad-
verse events post-ERCP between post-orthotopic liver transplant (pOLT) 
patients and patients with native anatomy (nOLT).
aims & Methods: A retrospective review was conducted with prospectively 
maintained patient data at a single, high-capacity ERCP center. ERCP en-
counters between Dec 2017 and Oct 2018 were identified from endoscopy 
software. During this time outpatients were contacted within 72 hours of 
ERCP to assess for adverse events. Individual patient demographics, clini-
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cal and endoscopy data, and reported outpatient and inpatient adverse 
events were recorded from the electronic medical record. Fisher’s exact 
test was utilized to determine significance between rates of adverse events 
between pOLT patients and nOLT patients.
results: 312 nOLT patients underwent 415 ERCPs and 43 pOLT patients 
underwent 66 ERCPs. 75.6% and 62.8% of nOLT and pOLT patients, re-
spectively, underwent only one ERCP during the study time period; 17.6% 
and 20.9% had two ERCP encounters and 6.7% and 16.3% had three or 
more ERCP encounters. The average age of nOLT and pOLT patients was 
60 and 55 with both groups being mostly male (71.4% and 54%, respec-
tively). 12.1% of nOLT had cirrhosis prior to ERCP. Leading etiologies of 
liver disease in the transplant group included non-alcoholic steatohepati-
tis (28.6%), hepatitis C (21.4%), and alcohol-related (19%). Chronic kidney 
disease ≥ stage III was found in 4.5% (nOLT) and 11.9% (pOLT) of patients. 
13.4% nOLT and no pOLT patients had comorbid pancreaticobiliary malig-
nancy. 19.5% and 4.8% of nOLT and pOLT patients reported a history of 
acute pancreatitis prior to ERCP. The pOLT group had a greater rate of bile 
duct strictures than the nOLT group (54.5% vs. 28.4%, p = 0.0001) while 
the rate of choledocholithiasis was similar (30.3% vs 34.4%, p = 0.58). 
Stent manipulation was performed in a majority of cases (nOLT 69.6% and 
pOLT 90.9%, p = 0.0002). Rectal indomethacin was used more often in 
native anatomy (14.7% vs 1.5%, p = 0.0012). Total adverse event rates were 
similar in both groups (10.1% nOLT and 10.6% pOLT, p = 0.83) and rates of 
post-ERCP pancreatitis in nOLT was 1.9% and in pOLT was 6.1%, p = 0.068). 
Additional ERCP data is described in Table 1.
conclusion: While pOLT status does not appear to independently predict 
overall increased rate of adverse events after ERCP, we observed in our co-
hort that pancreatitis occurs nearly three times more frequently. The trans-
plant group also received indomethacin much less often. A larger prospec-
tive study with to further analyze these differences is recommended.
disclosure: Nothing to disclose 
P1620 LOng-TerM fOLLOW-uP: TransPancreaTIc BILIary 
sPhIncTerOTOMy fOr BILIary access Is safe
Koskensalo V.1,2, Udd M.1,2, Rainio M.1,2, Halttunen J.1,2, Sipilä M.2, 
Lindström O.1,2, Kylänpää L.1,2
1Helsinki University Central Hospital, Abdominal Center, Helsinki, Finland, 
2University of Helsinki, Helsinki, Finland
contact e-Mail address: vilja.koskensalo@helsinki.fi
Introduction: Transpancreatic biliary sphincterotomy (TPBS) is an ad-
vanced cannulation method for access to common bile duct (CBD) in endo-
scopic retrograde cholangiopancreatography (ERCP). If CBD cannulation is 
difficult, endoscopist can open the septum between the pancreatic and the 
biliary duct with a sphincterotome to gain the access. Long-term results of 
this procedure are not well-known. We wanted to evaluate the short- and 
the long-term complications of TPBS on patients with native papilla.
aims & Methods: ERCPs performed during years 2007 to 2013 in Helsinki 
University Hospital Endoscopy unit were reviewed. After exclusion of pri-
mary sclerosing cholangitis, chronic pancreatitis (CP), biliary or pancreatic 
malignancies and deceased patients, there were 170 consecutive TPBS pa-
tients with native papilla and a benign indication for ERCP. For these TPBS 
patients we searched 170 consecutive age- and sex matched controls with 
same inclusion criteria, but with successful biliary access by primary wire-
guided cannulation. Of these groups, 143 (84.1%) patients and 140 (82.6%) 
controls participated the phone survey ≥ 4 years after first ERCP. Data of 
patient demographics, acute post-ERCP pancreatitis (PEP), recurrent pan-
creatitis, CP or symptoms related to CP, upper abdominal pain, new ERCP 
procedures and surgical treatments was collected from patient records.
results: PEP developed to seven patients (4.9%) in TPBS and one patient 
(0.7%) in control group (p=0.067). Other acute complications (cholangitis, 
perforation, bleeding) were not significantly different between the groups 
(Table 1). ERCP ended with no access to biliary tract in four cases (2.8%) 
p=0.122 in TPBS group and all ERCPs in control group were successful. 
Three patients (2.1%) in TPBS and six patients (4.3%) in control group 
(p=0.238) suffered from acute recurrent non-ERCP related pancreatitis 
during the follow-up period. Only one (0.7%) patient in control group de-
veloped CP and there were no patients with CP in TPBS group. Upper ab-
dominal pain was as common in both groups: 10 patients (6.9%) in TPBS 
group and 12 patients (8.6%) in control group suffered from abdominal 
pain daily and six patients (4.2%) in TPBS group and 12 patients (8.6%) in 
control group weekly.
  TPBs group (n=143)
control group 
(n=140) p-value
Age* at ERCP 59 (18-93) 62 (21-89) 0.418
Female 106 (74.1) 99 (70.7) 0.595
BMI* (kg/m²) 26.0 (16.9-70.3) 27.9 (16.0-74.0) 0.222
Indication for ERCP      
Biliary stones 112 (78.3) 104 (74.3) 0.485
Biliary pancreatitis 18 (12.6) 24 (17.1) 0.318
Bile duct injury after cholecystectomy 15 (10.5) 16 (11.4) 0.851
Biliary stricture (non-malignant) 15 (10.5) 11 (7.9) 0.485
Post-ERCP pancreatitis 7 (4.9) 1 (0.7) 0.067
Cholangitis 1 (0.7) 1 (0.7) 1.000
Perforation 3 (2.1) 1 (0.7) 0.622
Bleeding 2 (1.4) 2 (1.4) 1.000
No acute pancreatitis in follow-up 
period 140 (97.9) 134 (95.7) 0.238
Chronic pancreatitis 0 (0) 1 (0.7) 0.495
Abdominal pain during previous year 58 (40.5) 50 (35.7) 0.463
daily 10/143 (6.9) 12/140 (8.6)  
weekly 6/143 (4.2) 12/140 (8.6)  
once a month/seldom 42/143 (29.4) 26/140 (18.6)  
Medication for abdominal pain in 
previous year 30 (21.1) 22 (15.7) 0.283
[Table 1. Patient and procedure characteristics (n=283). Numerical data are 
presented as median (range)* or number of patients (%)]
conclusion: TPBS is a useful procedure with acceptable complication rates. 
There was no significant difference between groups when evaluating the 
short-term or long-term complications. Additionally, there were no sig-
nificant difference during the follow-up period in upper abdominal pain, 
usage of painkillers, recurrent pancreatitis or development of CP.
disclosure: Nothing to disclose 
P1621 WIThdraWn
P1622 cOnscIOus sedaTIOn In ercP: a uk PersPecTIve frOM 
a generaL hOsPITaL
Mohammed O., Raees K., Mahmood Z.
Stepping Hill Hospital, Gastroenterology, Stockport, United Kingdom
contact e-Mail address: omarkadem@yahoo.com
Introduction: Despite the fact, it has been more than 8 years since the 
release of the UK guidelines for the use of propofol for deep sedation of 
adult patients undergoing Endoscopic Retrograde Cholangiopancreatog-
raphy (ERCP) (1) ,yet the lionshare of UK based centres consider conscious 
sedation as the preferred way of sedation.
aims & Methods: The goal of this project is to evaluate ERCP under con-
scious sedation and compare quality indicators with the benchmark stated 
by British society of Gastroenterology (BSG). 
In our centre, we retrospectively analysed all ERCP procedures data from 
hospital-based registry carried out under conscious sedation and general 
anaesthesia (GA) during the period (2016, 2017, and 2018), and reviewed 
related complications during the study period.
Total number of cases 602, 579 were done under conscious sedation, while 
23 cases were done under GA.
results: A total 579 patients had ERCP under conscious sedation during 
these 3 years, Male 42.1% (241) , mean age 71.7 , and range (17-99) , physi-
cal health was assessed via ASA score; 76.1% of our cohort were classi-
fied as ASA II-III. 100% of the procedure was intended for therapy. Deep 
cannulation was achieved in 97.4% (564), and procedure was success-
fully completed in 93.2% (540), incomplete procedure was 4.14% (24), 
and failed 2.6% (15). Complications; Pancreatitis was 2.9% (17), no patient 
had serious bleeding requiring blood transfusion , perforation rate 0.34% 
(2), and mortality related to the procedure 0.17% (1). Sedation wise, mean 
sedation rate for Midazolam for age below 70 was (3.2 mg), while for age 
above 70 was (2.3 mg). Regarding Fentanyl for age below 70, the mean 
rate is (81.8 mg), while above the age of 70, the rate was (57.84 mg), and 
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mean comfort score was (2.5). Antibiotic for incomplete decompression 
of bile duct was given in 100%. While the cases that needed ERCP under 
GA (N=23), 65% of the cases were classified as ASA score 2-3. These cases 
formed 3.8% of the whole ERCP pool during the period of the study.
conclusion: In a summery, we concluded that ERCP under conscious seda-
tion is still safe and effective in vast majority of the cases, and on pars with 
the guidelines (4, 5). However a small number of cases still require GA 
or propofol, this would need discussion and collaboration between gas-
troenterologists and anaesthetists base on each case due to the peculiar 
situation in the UK where propofol should be given only by anaesthetist (1).
references: 1 Guidance for the use of propofol sedation for adult patients 
undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) and 
other complex upper GI endoscopic procedures .April 2011 On behalf of the 
Joint Royal College of Anaesthetists (RCoA) and British Society of Gastroen-
terology (BSG) Working Party. 2 Propofol Sedation for ERCP Procedures: A 
Dilemna? Observations from an Anesthesia Perspective. Hindawi Publish-
ing Corporation, Diagnostic and Therapeutic Endoscopy, Volume 2012, Ar-
ticle ID 639190, 5 pages, doi:10.1155/2012/639190 3 J. Aisenberg, J. V. Brill, 
U. Ladabaum, and L. B. Cohen, “Sedation for gastrointestinal endoscopy: 
new practices, new economics,” American Journal of Gastroenterology, 
vol. 100, no. 5, pp. 996-1000, 2005 4 ASGE : Guidelines for sedation and 
anesthesia in GI endoscopy , GASTROINTESTINAL ENDOSCOPY Volume 87, 
No. 2 : 2018 5 BSG ERCP - The Way Forward, A Standards Framework ,Mark 
Wilkinson, (BSG Endoscopy, working party convenor and chairman) et al. 
June 2014
disclosure: Nothing to disclose 
P1623 PLace Of ercP In hePaTIc hydaTId dIsease WITh 
cysTOBILIary cOMMunIcaTIOn: a 17 years exPerIence
Boutallaka H., Seddik H., Mrabti S., Sair A., Berraida R., Elkoti I., 
Loubaris K., Sentissi S., Benkirane A.
Military Instruction Hospital Mohammed V, Gastroenterology II, Rabat, 
Morocco
contact e-Mail address: hanaeboutallaka@gmail.com
Introduction: Hydatid disease is an infectious disease caused by Echinococ-
cus Granulosus, it affects most commonly the liver. Intrabiliary fistulisa-
tion is one if its rare and severe complications which remains frequently 
misrecognized.
aims & Methods: The aim of our study is to evaluate the efficacy and safety 
of ERCP in management of hepatic hydatid cysts with cystobiliary commu-
nication based on our experience.
We conducted a retrospective bi-centric descriptive and analytical study, 
from january 2002 to march 2019 in both the departments of gastroenter-
ology of military teaching hospital, and Cheikh Zayed Hospital in Rabat, 
including 50 patients with hepatic hydatid cyst communicating with biliary 
tract. Endoscopic retrograde cholangiopancreatography with endoscopic 
sphincterotomy were performed in all our patients. Global success was 
defined by the final clearance of bile ducts and drying up of biliary fistula. 
IBM SPSS software 24.0 was used for statistical analysis of our data.
results: The mean age of our population was 46,2+/-14,9 years old with 
a sex ratio M/F of 2,06. Of the 50 patients enrolled in the study, ERCP was 
performed before surgery in 52,2% cases and post-operatively in 47,8% 
cases. Indications of ERCP included cholangitis due to biliary obstruction 
in 43,5%, and persistant external biliary fistula in 34% of cases. During 
ERCP, mean diameter of common bile duct (CBD) was 10,7+/-4,06 millime-
ters, and median diameter of cyst of 35mm [20-60] measured by leakage 
of contrast into cyst cavity. CBD was filled by defect of varying size in 82,1%, 
and we noted a distal stenosis in 28,6%. Endoscopic sphincterotomy was 
performed in all cases, so that we could empty out hydatid cysts and 
daughter cysts encountered in bile duct using biliary occlusion balloon 
and/or dormia basket in 87% of cases. Nevertheless, 21,7% required na-
sobiliary drainage and 8,7% required biliary stenting due to CBD stricture. 
Global success defined by the final clearance of bile ducts was obtained 
in 100%. Regression of jaundice was noted in 5 to 10 days after ERCP and 
biliary fistula healed in a median of 10 days.
conclusion: ERCP is a safe, effective and conservative procedure to man-
age hepatic hydatid disease with cystobiliary communication. Endoscopic 
sphincterotomy allows the treatment of associated cholangitis and biliary 
obstruction most frequently, It leads to decrease the duration of hospital 
stay and to avoid a heavy surgery in some cases.
disclosure: Nothing to disclose 
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Introduction: Self-expandable metal (SEMS) and plastic stents (PS) place-
ment are the two alternative therapeutic option for the palliative endo-
scopic management of unresectable malignant biliary obstruction. The 
longer stent patency might compensate for the substantially higher cost 
of SEMS compared to PS. Current guidelines recommend the use of SEMS 
if the patient’s life expectancy is more than four months. The aims of this 
study were to compare the therapeutic efficacy and cost-effectiveness of 
SEMS and PS in the treatment of malignant biliary obstruction.
aims & Methods: 135 consecutive patients were retrospectively enrolled 
who underwent endoscopic stent placement due to unresectable malig-
nant biliary obstruction between 2011 and 2017 at University of Szeged. 
Patients were divided into PS (41 patients), primary SEMS (39 patients), 
and secondary SEMS (55 patients) subgroups. The efficacy and cost-ef-
fectiveness of stents were determined on basis of technical and functional 
success rate, stent patency and cumulative cost of treatment.
results: The 135 enrolled patients underwent 111 SEMS and 153 PS place-
ment with similarly high technical (100% vs. 98.69%) and functional suc-
cess rate (90.10% vs. 86.27%) during the study period. The average pa-
tency of SEMS was significantly higher compared with PS (22.16 vs. 10.28 
weeks; p< 0.001). In the PS subgroup multiple stent implantation and larg-
er stent diameter increased the stent patency compared with the 7 Fr stents 
(10.88 vs. 10.55 vs. 7.63). The mean survival of patients was substantially 
higher in the secondary SEMS subgroup (47.07 weeks, range 1-134, med. 
40) compared with the primary SEMS (24.46 weeks, range 2-72, med. 17) 
and PS groups (18.27 weeks, range 3-76, med. 12). There was no difference 
in the average cost of treatment per month between the PS, primary and 
secondary SEMS groups (892.12 EUR vs. 939.12 EUR vs. 788.46 EUR). The 
cumulative cost of first two-months’ treatment was substantially lower in 
the PS group compared with primary and secondary SEMS groups (1645.19 
EUR vs. 1937.82 EUR vs. 1755.82 EUR), however, if the patients’ survival time 
was more than two months, the cost-effectiveness of SEMS was better than 
plastic stents: 4-months cumulative cost was 2325.14 EUR in SP, 1898.96 
EUR in primary SEMS and 2009.02 HUF in secondary SEMS group.
conclusion: Considering the cost of treatment, the burden of patients and 
health care system we recommend the SEMS implantation if the life expec-
tancy of patients is more than two months. In short survival cases or if the 
SEMS not available the multiple plastic stent implantation is recommended.
disclosure: Nothing to disclose 
P1625 TreaTMenT sTraTegy fOr chOLedOchOLIThIasIs In 
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Introduction: Endoscopic sphincterotomy with stone extraction is a wide-
ly accepted standard therapy for choledocholithiasis. Use of endoscopic 
therapy in very elderly patients with common bile duct (CBD) stones has 
increased with the aging society. However, it is sometimes difficult to per-
form lengthy or frequent procedures in elderly patients because of poor 
physical status or comorbidities. Several studies have reported that long-
term biliary stenting is safe and effective for the elderly.
aims & Methods: This study aimed to evaluate strategies for endoscopic 
management of choledocholithiasis in very elderly patients.
This is a retrospective cohort study of very elderly patients (age, ≥85 years) 
who had undergone endoscopic retrograde cholangiopancreatography 
(ERCP)-related procedures for CBD stones at Kyoto Second Red Cross Hos-
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pital between 1998 and 2018. Patients who failed biliary cannulation or 
presented with biliary stricture, post Billroth II reconstruction, Roux-en-Y 
reconstruction, and biliary reconstruction were excluded. 477 very elder-
ly patients were analyzed and divided into two groups according to the 
management strategy: stone extraction group (n=304), patients who un-
derwent endoscopic CBD stone removal; and stent group (n=173), patients 
who underwent endoscopic bile duct stenting without stone removal. Pa-
tient characteristics, treatment, clinical outcomes, long-term outcomes, 
and complications were compared between the groups.
results: There were significant differences between the stone extraction 
and stent group with regard to age (88.7 vs. 91.1 years, p< 0.001), presence 
of multiple (≥5) CBD stones (19.7% vs. 37.6%, p< 0.001), and presence of 
large stone (28.7% vs. 53.3%, p< 0.001). There was no significant differ-
ence in presence of comorbidities and antithrombotic therapy between 
the groups. 
Significantly more ERCP sessions were required during hospital stay in the 
stone extraction group than in stent group (1.7 vs. 1.2, p< 0.001). Total pro-
cedure time were significantly longer in the stone extraction group than in 
the stent group (66.9 vs. 42.2 min, p< 0.001). The rate of complete stone 
removal was 88.7% in the stone extraction group. 
There was no significant difference in the rate of complications during and 
after ERCP between the groups. Kaplan-Meier analysis showed a signifi-
cantly lower rate of CBD stone and/or cholangitis recurrence in the stone 
extraction than in the stent group (p< 0.001).
conclusion: In terms of long-term outcomes, endoscopic stone extraction 
is recommended as the first choice even in very elderly patients. For dif-
ficult common bile duct stones, long-term biliary stenting is a feasible 
option and appropriate in patients with short life expectancy due to old 
age and comorbidities.
disclosure: Nothing to disclose 
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Introduction: Since its first description, endoscopic retrograde cholangio-
pancreatography (ERCP) has evolved into a leading modality in the treat-
ment of the pancreas and biliary tract conditions. Its enormous therapeutic 
potential also carries the possibility of adverse events (AEs) that may be 
associated with a significant morbidity and mortality. Numerous studies 
have helped determine the expected rates of ERCP-related AEs and pos-
sible methods for improving the safety of ERCP, but many of them are 
limited by nonuniformity of definitions, small sample sizes or analyse each 
AE separately.
aims & Methods: The aim of our study was to evaluate the AEs’ prevalence 
after ERCP, and risk factors for its occurrence.
Retrospective cohort study of all patients who underwent ERCP between 
January 2012 and December 2017, in a single tertiary center. Demographic 
and clinical data, including post-procedural AEs, were analysed. Risk fac-
tors for global and individual AEs occurrence were identified using multi-
variate logistic regression analysis.
results: During the study period a total of 2002 ERCPs were performed on 
1492 consecutive patients, 51.4% male, with a median age of 68 years (IQR 
56-79). The main indications for ERCP were choledocolithiasis (37.0%), 
jaundice (11.1%), biliary stenosis (11.4%) and imaging abnormality of the 
bile duct (8.6%).
The overall AE rate was 15.3% [Planned bile duct cannulation with naive 
papilla - 210/1339 (15.7%); Planned bile duct cannulation with previous 
sphincterotomy - 55/499 (11.0%); Planned pancreatic duct cannulation 
with naive papilla - 18/83 (21.7%); Planned pancreatic duct cannulation 
with previous sphincterotomy - 21/70 (30%)]. The main post-ERCP AE was 
pancreatitis (7.5%), followed by cholangitis (4.9%), hemorrhage (1.3%), 
perforation (1.0%), cardiopulmonary events (0.9%) and cholecystitis 
(0.3%). ERCP AE-related mortality rate was 1.0%. 
In the multivariate analysis, ERCP difficulty degree (III/IV vs I/II: OR 1.842, 
p< 0.001), difficult biliary cannulation (OR 1.992, p< 0.001), imaging ab-
normality of the bile duct (OR 1.636, p=0.025), periprocedural haemor-
rhage (OR 3.656, p< 0.001) and ampulectomy (OR 4.681, p=0.018) were 
independently associated with an increased risk of AEs. Naïve papilla (OR 
2.170, p=0.008), pancreatic duct cannulation (OR 1.923, p=0.026), imag-
ing abnormality of the bile duct (OR 2.035, p=0.009), choledocholithiasis 
(OR 0.535, p=0.01), previous post ERCP-pancreatitis (OR 3.434, p=0.003), 
periprocedural haemorrhage (OR 2.432, p=0.022) were independently as-
sociated with pancreatitis. 
Periprocedural haemorrhage (OR 9.747, p<0.001), anti-aggregation plus 
anticoagulant therapy (OR 11.832, p=0.028), sphincteroplasty (OR 3.545, 
p=0.013) and distal common bile duct stricture (OR 8.767, p=0.003) were 
independently associated with postprocedural haemorrhage. Hilar stric-
ture was the only independent factor associated with cholangitis (OR 
8.685, p=0.006). Altered anatomy (OR 9.391, p=0.014) and peripapillary 
diverticulum (OR 3.813, p=0.019) were associated with perforation.
Post-ERCP AEs-related mortality was independently associated with diffi-
cult biliary cannulation (OR 3.160, p=0.020), jaundice (OR 5.071, p=0.006), 
anticoagulation with NOACs (OR 26.660, p=0.007) and ASA score (4 vs 1-3, 
OR 5.273, p=0.008).
conclusion: ERCP AEs’ prevalence is significant. Patient-related risk factors 
assume a non-negligible role for its occurrence. Adequate stratification, 
considering potentially modifiable risk factors, with identification of high-
risk patients and targeted prophylactic management may be important to 
prevent or minimize their occurrence.
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Introduction: Post-cholecystectomy iatrogenic biliary injuries, though 
more uncommon than in the early years of laparoscopic surgery still rep-
resents an important burden of morbidity and mortality. When discovered 
during surgery the injuries can be easily managed, otherwise endoscopic 
retrograde cholangio-pancreatography (ERCP) represents the first choice 
of treatment.
aims & Methods: The aim of this study is to evaluate the role of ERCP in 
the managment of biliary laparoscopic induced lesions after cholecistec-
tomy. We conducted a retrospective study which enrolled the patients with 
iatrogenic biliary injuries after laparoscopic cholecystectomy hospitalized 
in the Clinical Emergency Hospital Bucharest, who underwent ERCP from 
January 2014 to March 2019.
results: The study included 48 patients diagnosed with post laparoscopic 
cholecystectomy iatrogenic injuries or who had a high clinical and imag-
ing suspicion of biliary lesion, and were mainly referred to our tertiary 
center for ERCP. The mean age was 54,5 years (range 20 to 84).
According to S.M. Strasberg classification 72, 91% of the patients had a 
type A lesion, which was associated in half of the cases with main bile 
duct lithiasis. ERCP with plastic stent insertion was used in 22 patients, the 
stent was extracted on average after 30 days with full recovery, while for 13 
patients only sphincterotomy was performed also with full recovery. A type 
D lesion was described during ERCP for 5 patients, 4 of whom were treated 
surgically after an initial ERCP with sphinterotomy, while one patient had a 
full recovery after plastic stent placement. 
More complex type E lesions where described in 8 patients (E1-3 patients; 
E2 - 4 patients; E3- 1 patient), and in all except one patient the first ERCP 
had failed to treat the lesion. 
One patient with type E2 lesion had a plastic stent inserted via ERCP in 
the surgery room and need it another 6 ERCP’s with multiple plastic stent 
exchange for 18 months until full recovery.
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conclusion: ERCP remains a useful treatment tool for Iatrogenic biliary 
lesions after laparoscopic cholecystectomy. Therapeutic ERCP can success-
fully treat low complexity lesions and in some cases can be used in rendez-
vous procedures in the surgery room for very complex injuries.
disclosure: Nothing to disclose 
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Introduction: Single-operator cholangioscopy (SOC) has been a major ad-
vance in indeterminate biliary stricture (IDBS) diagnosis because it has 
made direct visualization and optically guided biopsy of these lesions. 
However, SOC-guided biopsies have shown limited sensitivity. In order 
to overcome this limitation, identifying the cholangioscopic features that 
most strongly suggest malignancy is an interesting way to improve SOC 
diagnostic capabilities; however, no systematic analysis of SOC findings 
has been conducted to date.The aim of our study is to establish endoscopic 
criteria allowing to distinguish between benign and malignant lesions.
aims & Methods: 4 referral centers included 98 Spyglass DS cholangiosco-
py recordings performed for indeterminate biliary strictures (IDBS) whose 
final diagnosis was known by histology or follow-up for more than 1 year. 
7 experts in cholangioscopy participated in the development of a consen-
sual reading grouping 20 semiological criteria. The videos were analyzed 
individually by each expert after randomization according to the reading 
grid. A hypothesis diagnosis was issued for each examination. After a sta-
tistic analysis a second meeting with the same methodology were held for 
criteria validation.
results: 98 IDBS videos from 95 patients of mean age 66 years (13 - 89) 
were analyzed; there were 38 benign and 60 malignant strictures. The 
Sensitivity ranged from 68% to 81% and specificity from 55 to 71%. The 
univariate and multivariate analysis identified 4 significant criteria. One 
for benign lesions: the presence of endobiliary material odds ratio (OR)= 
0.649; 95% confidence interval (CI), 0.427 - 0.988. Three for malignant le-
sions: villous pattern OR = 1.477; 95% CI, 0.98 - 2.21; irregular vessels OR 
= 2.042; 95% CI, 1.35 - 3.08; redish aspect OR = 1.67; 95% CI,1.09 - 2.53.
conclusion: Simple criteria’s could assist malignancy diagnosis and en-
hance The performance of cholangioscopic visual diagnosis of IDBS.
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Introduction: ERCP is a technically challenging and high-risk procedure 
requiring focussed training and experience to maximize technical success 
and minimize adverse outcomes. Quality indicators in ERCP are useful to 
evaluate and monitor technical performance and adverse outcomes.
aims & Methods: The objective of this study was to evaluate the technical 
performance and the fulfillment of quality indicators in ERCP practice in 
a tertiary center.
We retrospectively evaluated 941 consecutive ERCPs that were performed 
at a tertiary hospital between October 2016 and January 2019 and were 
prospectively registered.
We excluded 92 procedures due to lack of an attempt to cannulate the pa-
pilla of Vater (mainly due to duodenal obstruction often due to malignant 
stricture and altered small intestinal anatomy with Roux en Y anastomosis) 
and in 13 procedures due to inadequate post procedure follow-up data. 
Finally, the study cohort included 836 procedures. Intravenous hydration 
with Ringer’s lactate and prophylactic diclofenac suppository were per-
formed in all procedures. Prophylactic post ERCP antibiotic prophylaxis 
was prescribed when indicated.
The technical performance was compared with the quality indicators for 
ERCP recommended by the American Society of Gastrointestinal Endoscopy 
(ASGE) and the European Society of Gastrointestinal Endoscopy (ESGE).
results: The mean age of the study sample was 71 ± 15.8 years and 51% 
(426) of the procedures were performed in men.
The indications for ERCP were as follows: Choledocholithiasis 57% (476); 
malignant biliary stricture 27% (226); benign biliary stricture 6% (48); bili-
ary fistula 4% (30); acute gallstone pancreatitis 2% (17); ampuloma 0.2% 
(2) and others 4.4% (37).
The overall rate of deep cannulation of the main bile duct was 97.8% 
(818/836) and in patients with intact papilla of Vater was 97% (543/560). 
The incidence of post ERCP pancreatitis (PEP) was 2.5% (21), post sphinc-
terotomy haemorrhage 1.1% (9) and perforation 0.2% (2). The technical 
performance indicators of ERCPs compared to those recommended by 
ASGE and ESGE are presented in table 1.
The following variables were not documented in the study: the use of pro-
phylactic antibiotic therapy and the success rate of bile duct stent place-
ment.
  asge esge Technical performance
1)Appropriate indication for ERCP >90%   100%
2)Native papilla deep cannulation rate >90%
>90% 
(>95% ideal)
97%
3)Extraction rate of <1cm common bile 
ducts stones
≥90% >90% 100%
4)Successful biliary stent placement rate ≥90% >95% Not recorded
5)Post-ERCP pancreatitis rate Yes <10% (<5% ideal) 2.5%
[Table 1. Evaluation of technical performance when compared to quality 
indicators of ERCP recommended by ASGE and ESGE]
conclusion: The awareness and use of a prospective database allowed a 
detailed analysis of the performance indicators in ERCP as recommended 
by ASGE and ESGE and may have contributed to the good technical out-
comes and low incidence of adverse outcomes.
disclosure: Nothing to disclose 
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Introduction: Endoscopic retrograde cholangiopancreatography (ERCP) is 
one of the endoscopic techniques with the highest rate of adverse events. 
The expected rate of post-ERCP pancreatitis (PEP) varies between 1% and 
7% for most average-risk patients, haemorrhage post endoscopic sphinc-
terot- omy varies between 0.8% to 2% and perforation varies between 
0.1% to 0.6%
aims & Methods: The objective of this study was to evaluate the incidence 
of adverse events after ERCP and determine risk factors for post-ERCP pan-
creatitis (PEP).
We retrospectively evaluated 941 consecutive ERCPs that were performed 
in a tertiary hospital between October 2016 and January 2019. Data related 
to the procedures was prospectively registered. The indication for ERCP, 
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incidence and predictors of PEP were evaluated. We excluded 92 proce-
dures wherein cannulation of papilla of Vater was not attempted (mainly 
because of duodenal obstruction due to neoplastic stricture, altered small 
intestinal anatomy with Roux en Y anastomosis) and 13 procedures due to 
inadequate follow-up data. The final study sampled included 836 ERCP 
procedures. All patients received intravenous Ringer’s lactate and rectal 
diclofenac 100mg suppository for prophylaxis of PEP.
Patients at high risk for PEP were defined by intact papilla of Vater and 
time to cannulation of the main bile duct > 5mins or ≥2 cannulations of 
the pancreatic duct. Descriptive statistical analysis, chi square and logistic 
regression were realized (SPSSÒ 21).
results: The average age of the study sample was 71±15.8 years with 51% 
(426) being men. The main indications for ERCP were: Choledocholithiasis 
57% (476); Malignant stenosis 27% (226); Benign stenosis 6% (48). The 
cannulation rate of intact papilla of Vater was 97% (543/560). Guide 
wire assisted cannulation was used in 72% (591) and precut papillotomy 
in 13.3% (111). The time to main bile duct cannulation was < 5mins in 
65% (546) patients. The pancreatic duct was cannulated in 24% (202) 
patients. Contrast was injected into the pancreatic duct in 6.2% (52) and a 
prophylactic 5Fr stent placed in the pancreatic duct in 9.1% (76) patients. 
The high-risk group for PEP represented 33% (275) of ERCPs. The overall 
incidence of complications after ERCP was 4.3% (36) with PEP occurring in 
2.5% (21) patients as shown in table 1.
PEP was associated with time until cannulation of main bile duct > 5mins 
(p = 0.01); ≥1 pancreatic duct cannulations (p <0.01) and pancreatic duct 
contrast injection (p < 0.01). The only predictor of PEP was ≥2 cannulations 
of the pancreatic duct (OR: 4.7; 95% CI, 1.29-17.1, p = 0.019).
  Overall study sample (n=836)
native papilla of 
vater (n=560)
Prior sphincterotomy 
(n=276)
Main bile duct 
cannulation rate
97.8% (818) 97% (543 99.6% (275)
PEP 2.5% (21) 3.4% (19) 0.7% (2)
Hemorrhage 1.1% (9) 1.4% (8) 0.4% (1)
Cholangitis 0.5% (4) 1.4% (2) 0.4% (1)
Perforation 0.2% (2) 1.4% (2) 0%
[Table 1. Cannulation rate and incidence of post ERCP adverse events]
conclusion: In our prospective registry, the incidence of ERCP adverse 
events was low with a PEP rate lower than that usually described in pub-
lished literature. The only independent predictor of PEP were ≥2 cannula-
tions of the pancreatic duct.
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Introduction: The severity of post-ERCP pancreatitis (PEP) is a major prob-
lem because of its occasional lethality. However, no predictor of the se-
verity has been identified. In the present multicenter prospective study, 
SOSUI, we investigated potential predictive factors for the severity of PEP.
aims & Methods: We prospectively followed 3,914 patients who underwent 
ERCP between February 2015 and May 2017 at five high-volume centers in 
Kyoto or Shiga prefecture in Japan. 3,661 patients were included after 253 
those who had been complicated by pancreatitis, undergone biliary tract 
reconstruction, or had papilla not reached were excluded.
Of the 3,661 patients, we evaluated 263 patients who developed PEP. We 
compared between the mild and severe cases to examine potential predic-
tors for the severity of PEP. PEP was diagnosed when patients presented 
with at least two of three following manifestation: (1) serum amylase el-
evation (above the upper limits of each center) on the following day, (2) 
abdominal pain lasting for longer than 24 hours and (3) pancreatitis on 
CT. The severity of PEP was assessed based on the severity criteria of the 
Japanese Ministry of Health, Labour and Welfare.
results: 35 (0.9%) and 228 (6.5%) patients developed severe and mild 
PEP. A significant difference was found between patients with severe and 
mild PEP with regard to the serum amylase level at 2 hours after ERCP (P 
=0.0016), abdominal pain immediately and 24 hour after ERCP (P=0.011 
and 0.0024) and performing lithotomy (P=0.031). ROC analysis was con-
ducted on the serum amylase level at 2 hours as a predictive factor for se-
vere PEP, demonstrating that the cutoff value was 3.6 times higher than the 
upper limits of each center (sensitivity: 60%; specificity: 68%; and AUC: 
0.63). In multivariate analysis using logistic regression by dividing the am-
ylase level at 2 hours after ERCP into 3.7 times higher or lower than the ref-
erence values of each center, abdominal pain immediately after ERCP and 
AMY values at 2 hours after ERCP were identified as independent factors.
conclusion: In the present study, abdominal pain immediately after ERCP 
and serum amylase level at 2 hours were identified as predictive factors 
for the severity of PEP. They can be useful for facilitating urgent therapeutic 
intervention. We have to investigate more to identify appropriate treatment 
for preventing PEP.
disclosure: Nothing to disclose 
P1632 dIagnOsTIc accuracy and TheraPeuTIc effIcacy Of 
dIgITaL sIngLe-OPeraTOr chOLangIOscOPy fOr BILIary LesIOns 
and sTenOsIs
Weigand K.1, Küchle M.1, Zuber-Jerger I.1, Müller-Schilling M.2, 
Kandulski A.1
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Introduction: Digital single-operator cholangioscopy (dSOC) has revolu-
tionized bile duct visualization during endoscopic retrograde cholangiog-
raphy (ERC). Visual inspection of suspicious areas and targeted biopsies 
have become possible quick and easy, as well as interventions like electro-
hydraulic or laser lithotripsy. One main indication for dSOC is the evalua-
tion of indeterminate biliary strictures.
aims & Methods: In this study 180 dSOCs performed 2016 till 2017 in a 
high volume tertiary center have been retrospectively analyzed to evaluate 
sensitivity, specificity as well as positive and negative predictive values for 
indeterminate strictures and lesions. Furthermore technical success and 
complications were analyzed.
results: In 92-97% the region of interest was reached and visualized and 
in 83-100% successful biopsies were taken in the biliary tract in this study. 
Only the distal bile duct was less successful with only 84% and 62%, re-
spectively. The procedure was safe with cholangitis as main complication. 
Regarding the diagnostic accuracy of dSOC of indeterminate biliary lesions 
and strictures we found a sensitivity of 0.87 and specificity of 0.88. The 
investigators assessment directly after dSOC had a positive predictive value 
of 0.63 and a very high negative predictive value of 0.97.
conclusion: Our study demonstrates that dSOC has a very high diagnostic 
efficacy as well as a favorable safety profile. Therefore, it should be dis-
cussed as standard of care in addition to ERC for indeterminate biliary 
lesions.
disclosure: Nothing to disclose 
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P1633 endOscOPIc TreaTMenT Of cOMPLIcaTIOns Of hydaTId 
cysTs In The LIver BrOken In The BILe ducTs: exPerIence Of a 
MOrOccan deParTMenT
Jamal S., Seddik H., Loubaris K., El Koti I., Benkirane A.
Military Training Hospital Mohammed V of Rabat, Morocco, Hepatology and 
Gastroenterology, Rabat, Morocco
contact e-Mail address: jamalsara24@gmail.com
Introduction: The Hydatid cyst of the liver is a parasitic disease due to 
the development of the larval form of the Taenia of the dog Echinococcus 
granulosus. By its clinical latency, the Diagnosis is most often at the stage 
of complications. Fistulization of the cyst hydatid in the bile ducts is the 
most common complication. Endoscopy is necessary because of the thera-
peutic problems and risks associated with surgery.
aims & Methods: The objective of our study was to evaluate and analyze 
the effectiveness of ERCP in the diagnosis and treatment of Hydatid cysts of 
the liver broken in the pathways ducts.
This is a 15-year retrospective and descriptive study, ranging from Janu-
ary 2003 to October 2018, focused on patients with fistulized Hydatid cyst 
in the pathways bile duct. ERCP and endoscopic biliary sphincterotomy 
were performed in all patients, 18 times pre-operatively and 21 times post-
operatively.
results: 39 patients with broken Hydatid cyst in the biliary duct, 2.4% of 
the indications ERCP in our series were included. The average age of pa-
tients was 47, with male predominance in 65% of cases. KHF broken in 
the ways galls were complicated by persistent external biliary fistula post 
operatively in 34% of cases. Sphincterotomy was performed in all patients 
allowing removal of Hydatid material by extraction balloon or Dormia bas-
ket. The evolution was marked by the disappearance of jaundice after 5 to 
12 days in average after endoscopic gesture and dryness of external biliary 
fistula after 10 to 12 days.
conclusion: The results of our study confirm the efficacy and safety of ERCP 
and the endoscopic sphincterotomy in biliary complications of echinococ-
cosis hepatic. It makes it possible to shorten the post-operative stay and to 
avoid are operation, often difficult and haemorrhagic.
disclosure: Nothing to disclose 
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Introduction: Colo-rectal neoplasia is one of the most commonly diagnosed 
malignancies, representing in Italy the second cause of overall malignan-
cies in the man, after prostate neoplasia, and in woman, after breast neo-
plasia, with 373.000 new diagnosis/years in 2018. Pre-sacral lesions may 
arise in the follow up after colo-rectal surgery, after adjuvant chemotherapy 
(CT), or neo-adjuvant chemo-radiotherapy. CTscan and pelvic RM are the 
two most used diagnostic tool in these patients, but they can be inconclu-
sive in the diagnosis of pre-sacral lesions. PET scan adds more information 
but, in presence of inflammation, can show false positive results.
aims & Methods: The aim is to critically evaluate the role and the efficacy 
of endoscopy ultrasound (EUS) and Fine Needle Aspiration or Biopsy (FNA/
FNB) in the multimodal restaging of suspected local recurrence or pro-
gression disease in patients with history of rectal cancer. Procedures were 
performed with linear EUS scope. The number of EUS FNA/FNB passes 
was decided by the endoscopist based on the gross morphology of the 
specimen (if core was visible) and or rapid on-site evaluation if available.
results: From September 2015 to March 2019 we retrospective enrolled 
eight patients referred to our units for pre-sacral lesions undergoing en-
doscopy ultrasound (EUS) and Fine Needle Aspiration or Biopsy (FNA/
FNB). In all cases the radiological findings (CT scan and or PET/MRI) were 
inconclusive for a final diagnosis. Table 1 summarizes patients’, lesions’ 
and procedures’ results. In 6 of 8 patients pathological evaluation con-
firmed the suspicion of local recurrence and they were referred for onco-
logical re-treatment. 
In two patients EUS-FNB of lymph-node yielded a diagnosis of inflamma-
tion (at histology) with no tumoral cells at cytology. Radiological follow-up 
for these two patients confirmed benign characteristics. In only two cases 
both cytology and histology were performed, and in both tissue acquisition 
by EUS-FNB allowed to reach a diagnosis. All lesions resembling masses 
resulted in local recurrence. In only one of three cases in which lymph-
nodes were targeted, cytology evaluation on an EUS-FNB of 15 mm lymph-
node showed tumoral cells. Procedures were performed in out-patient 
setting. All patients underwent antibiotic prophylaxis with intra-venous 
cefalosporine one shot before the biopsy. No adverse events or infection 
were observed.
conclusion: EUS plus FNA/FNB should be a mandatory diagnostic tool 
in patients with a history of lower GI neoplasia in case of pre-sacral le-
sions supposed to be local recurrence. EUS-FNB seems to offer a higher 
diagnostic power. High diagnostic accuracy allows to redefine oncologic 
treatment and follow-up strategy. Further and wider retrospective cohort 
studies are warranted to offer more significative results.
disclosure: Nothing to disclose 
P1635 WIThdraWn
P1636 WIThdraWn
sex/age neOPLasIa TnM TreaTMenT
MOnThs 
frOM 
dIagnOsIs
susPIcIOn LesIOn/sIze needLe/Passes cyTOLOgy hIsTOLOgy
M 79 RECTAL ADENOCARCINOMA T3N1 SX + aCT 80 CT scan + PET MASS 10 mm FNB 25GA/2 NA ADENOCARCINOMA
M 74 RECTAL ADENOCARCINOMA T3N1 SX + aCT 26 CT scan + PET MASS 33 mm FNB 22GA/2 NA ADENOCARCINOMA
F 62 SIGMOID ADENOCARCINOMA T3N0 SX 22 CT scan + MRI MASS 30 mm FNB 25GA/3 NA ADENOCARCINOMA
M 78 RECTAL ADENOCARCINOMA T1N0 SX 36 CT scan MASS 22 mm FNB 25GA/3 INADEQUATE NEOPLASTIC CELLS
M 56 RECTAL ADENOCARCINOMA ypT0N0 RT + SX 36 CT scan LN 4 mm FNB 22GA/3 INADEQUATE INFLAMMATION
F 48 ANAL SQUAMOUS CELL CARCINOMA NA CT + RT 3 CT scan LN 15 mm FNA 25GA/3 NEOPLASTIC CELLS NA
M 58 RECTAL ADENOCARCINOMA pT3N1a SX + aCT 19 CT scan + PET MASS 8 mm FNB 25GA/2 NEOPLASTIC CELLS NA
M 72 RECTAL ADENOCARCINOMA pT3N1b SX 12 CT scan + PET LN 6 mm FNB 25GA/2 NO NEOPLASTIC CELLS NA
SX: surgery; CT: chemotherapy; aCT: adjuvant chemotherapy; RT: radiotherapy; LN: Lymph-node; NA: not available.
[P1634 Table 1]
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P1637 PerfOrMance Of eus-guIded TIssue acquIsITIOn In 
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Introduction: EUS-guided tissue acquisition (EUS-TA) is crucial step in the 
differential diagnosis and management of patients with gastrointestinal 
subepithelial lesions (GI-SELs).
aims & Methods: The aim of the study was to evaluate the adequacy of 
EUS-TA performed with standard needles (SN) and with fine needle biopsy 
needles (FNB needles), using a standardized protocol for the management 
of specimens in the diagnosis of GI-SELs.
This retrospective, single center study enrolled patients who underwent 
EUS-TA of upper or lower GI-SELs. A macroscopic on-site evaluation 
(MOSE) was performed by the endoscopist after every needle pass. All 
specimens obtained using either standard or histology needles were pro-
cessed in the same way according to the MOSE.
Specimens were defined as “diagnostic” when sufficient material for his-
tologic or cytologic evaluation was present. If the biopsies did not allow a 
complete evaluation, the specimens were considered as “not adequate”. 
If the patient underwent surgical resection of the SEL, the EUS TA findings 
were compared with the final pathological diagnosis.
results: 86 patients were included in the study (45 males, 52.3%), with 
mean age 64.0 years (SD = 11.6 years). The average size of the lesions 
was 36.3 mm (SD = 23.2 mm). 61.2% of lesions were detected in stomach, 
19.8% in the duodenum, 15.1 % in the esophagus and cardias, and 4.7% 
in the rectum. FNB was used in 53 patients (61.6%), in the remaining 33 
(38.4%) a SN was used. Adequate samples were obtained in in 65 patients 
(75.6%): 59 had adequate histologic samples, 19 had an adequate cytology 
and 13 patients had both adequate histology and cytology samples. 
In terms of adequacy, no statistically significant difference was found 
between standard and FNB samples (69.7% versus 80.0%, respectively, 
p=0.306). (69.7% versus 80.0%, respectively p=0.306). The mean number 
of needle passes was 2.2 (SD = 0.8 passes, range: 1-4 passes). It did not 
differ between the standard needle and the FNB groups (2.2±0.9 passes 
versus 2.3±0.8 passes, respectively, p=0.431), nor the adequacy of the 
specimens not affected by the mean number of needle passes (2.3±0.8 
passes for adequate samples vs 2.1±0.9 passes for inadequate samples 
p=0.400). 
A histological sample was, however, more frequently obtained with FNB 
needles than with standard needles [74.0% versus60.0%, respectively 
(p=0.008)]. The adequacy of histological samples was higher than the 
adequacy of cytological specimens (85.3% versus65.3%, respectively, 
p=0.015). No early adverse events or technical difficulties were registered 
in either group.
Fifty-tree patients (61.6%) underwent surgical resection, of which 40 had 
a diagnostic EUS-TA. In all of them, the final diagnosis confirmed that ob-
tained with EUS-TA. Considering EUS and surgical findings, the final diag-
nosis was: GIST in 68 patients (79.6%), leiomyoma in 6 (6.9%), schwan-
noma in 2 (2.3%) and desmoid tumor in 1 (1.2%). Inadequate specimens 
were obtained, and no subsequent surgery was performed in 8 patients 
(9.6%): considering the lesion characteristics (< 20 mm, without worri-
some features) and/or age >75 years, clinical and imaging follow up alone 
was proposed to these patients.
conclusion: using a standardized protocol based on MOSE for the manage-
ment of specimens from the endoscopy suite to the pathology department 
in an expert center, EUS-TA had a high rate of diagnostic accuracy and 
concordance between biopsy and surgical specimens, with no difference 
between FNBs and SN. FNB needles guaranteed a higher rate of histologi-
cal specimens for ancillary analysis.
disclosure: Nothing to disclose 
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Introduction: Endoscopic ultrasound (EUS) is a specific endoscopic ex-
amination used to diagnose various types of gastrointestinal tumors. An 
important role of the EUS was found in the diagnostics of neuroendocrine 
tumors of the gastrointestinal tract (GEP NETs). In recent years, other mo-
dalities have been developed which, in combination with the EUS, improve 
diagnostics, give detailed description about invasion into surrounding 
structures, and allow prediction of the tumor’s biological behavior. Such 
methods include elastography (EG). EG is based on demonstrating the dif-
ference in tissue stiffness between tumor and reference area. Strain EG 
measures tissue response to external or internal application of a certain 
force. It is based on the fact that the stiffer tissue has a lower elasticity and 
therefore is less deformed upon exposure to pressure. Tissue characteris-
tics are analyzed based on a color qualitative method, or using one of the 
semi-quantitative methods: strain ratio (SR), strain histogram (SH). SR is 
the difference in elasticity between two regions in one region of interest 
(ROI). SH represents the average elasticity value in the defined area.
aims & Methods: The aim of our study was to find a typical image, SR 
and SH of GEP NET in endoscopic elastographic measurement using strain 
qualitative and semi-quantitative methods. In our prospective pilot study, 
patients with subepithelial tumors of the stomach, duodenum and pan-
creas were examined. The lesions were displayed on an endoscopic ul-
trasonography using a convex probe with 7.5-10 MHz. The elastographic 
image contained the entire tumor in the region of interest and the same 
amount of comparison region. For the evaluation of the qualitative picture 
we used the 4-stage EG image rating scale according to WFUMB (World 
Federation for Ultrasound in Medicine and Biology) 2015. SH and SR were 
obtained by three different measurements in each case. The selected refer-
ence area for SR was chosen non-standard. SR was obtained by comparing 
subendothelial tumor with the stomach or duodenal wall, pancreatic NETs 
were compared with the unaffected pancreatic tissue.
results: 30 patients (20 females and 10 males) with histologically con-
firmed GEP NET from 2017 to 2019 were included in the study. The mean 
age of subject was 53.7 years (17 to 74 years). We observed EG qualitative 
image of GEP NETs homogeneous hard, heterogeneous hard, heteroge-
neous soft, homogeneous soft 73.3%, 20.0%, 3.3%, 3.3%, respectively. 
The mean SR observed was 5,17 (95% CI; 5,41 - 10,61) and SH 26,6 (95% CI; 
21,35 - 35,02). Sufficient correlation coefficient in the group with qualita-
tive image - homogeneous hard between SR and SH was reached r=-0,613 
(95% CI; -0,8 to -0,2585; p=0,0024).
conclusion: Endoscopic ultrasonography with elastography allows to eval-
uate changes in tissue elasticity in otherwise poorly accessible locations. 
Gastroenteropancreatic neuroendocrine tumors exhibit considerable ho-
mogeneity in qualitative endoscopic elastographic images. The relatively 
small range of strain ratio and strain histogram measured between tumor 
and healthy tissue in our study, indicates the possibility of using these 
semi-quantitative methods in GEP NETs differential diagnostics.
references: This publication is the result of the project implementation: 
Measurement of ciliary kinetics of the respiratory tract, ITMS: 26220220019 
supported by the Operational Programme Research and Innovation funded 
by the ERDF.
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Introduction: The assessment of bile duct dilatation can be carried out us-
ing many diagnostic modalities including abdominal ultrasonography (US), 
computed tomography (CT), and magnetic resonance cholangiopancrea-
tography (MRCP). However, failure to identify the cause of CBD dilatation 
has been observed in subjects with normal liver function tests and nonspe-
cific abdominal symptoms. EUS has emerged as an important tool for eval-
uation of biliary disease. Some literatures suggest its impact in detection 
of a potential biliary pathology, despite a low pre-test clinical suspicion.
aims & Methods: The aim was to assess the diagnostic value of EUS in 
patients with normal liver blood tests and unexplained dilatation of com-
mon bile duct following other diagnostic modalities including US, CT, and 
MRCP. Methods: we conducted a retrospective study on 56 patients re-
ferred to TBRI (Theodor Bilharz Research Institute) over the period of 2 
years. The patients who had dilated CBD, but evaluation with US, and CT 
or MRCP did not provide a specific cause with normal liver biochemistry 
{alkaline phosphatase,or AST, or ALT} were included in our study. The pa-
tients in whom a diagnosis had been provided by prior imaging (CT/MRCP/
US), those with obscure etiology on CT and/ or US alone, and those with 
previous ERCP or pancreaticobiliary surgery were excluded from this study. 
There were 11 patients had normal alkaline phosphatase (45-120 IU/L), 21 
patients had normal aspartate aminotransferase {AST} (20-40 U/L), and 
24 patients had normal alanine aminotransferase {ALT} (20-50 U/L). All 
patients were enrolled to determine the diagnostic yield of endoscopic 
ultrasound in this condition.
results: Our study revealed that among 11 subjects with normal alkaline 
phosphatase, there were 5 males and 6 females, with a mean (±SD) age 
of 45.18 (±14.58). The diameter of CBD dilatation by abdominal ultrasound 
was 9.96 (±1.13). EUS findings were as follows: 6 cases (54.55%) had stone, 
2 cases (18.18%) had benign stricture, another 2 cases (18.18%) had prom-
inent CBD no obstruction, and 1 case (9.09%) had malignant stricture. 
Among 21 subjects with normal AST, there were 12 males and 9 females, 
with a mean (±SD) age of 50.19 (±11.11). The diameter of CBD dilatation 
by abdominal ultrasound was 11.55 (±2.53). EUS findings were as follows: 
8 cases (38.10%) had stone, another 8 cases (38.10%) had malignant 
stricture, 3 cases (14.29%) had benign stricture, and 2 cases (9.52%) had 
prominent CBD no obstruction. Among 24 subjects with normal ALT, there 
were 11 males and 13 females, with a mean (±SD) age of 50.75 (±13.16). The 
diameter of CBD dilatation by abdominal ultrasound was 11.79 (±2.59). EUS 
findings were as follows: 11 cases (45.83%) had stone, 8 cases (33.33%) 
had malignant stricture, 3 cases (12.50%) had benign stricture, and 2 cases 
(8.33%) had prominent CBD no obstruction. 
   
alkaline 
phosphatase 
(45-120 Iu/L)
asT 
(20-40 u/L)
aLT 
(20-50 u/L)
    N (%) N (%) N (%)
  Stone 6 (54.5%) 8 (38.1%) 11 (45.8%)
eus Benign stricture 2 (18.1%) 3 (14.2%) 3 (12.5%)
  Malignant stricture 1 (9.09%) 8 (38.1%) 8 (33.3%)
 
Prominent CBD dilatation 
without obstruction
2 (18.1%) 2 (9.5%) 2 (8.3%)
Total   11(100%) 21 (100%) 24 (100%)
cBd 
diameter Mean ± SD 9.96 ± 1.13 11.55 ± 2.53 11.79 ± 2.59
age Mean ± SD 45.18 ± 14.58 50.19 ± 11.11 50.75 ± 13.16
[Table 1. Descriptive data of the study]
conclusion: In our study we revealed firstly that CBD dilatation with normal 
liver chemistry is not always a benign condition. Secondly the importance 
of EUS as a diagnostic modality in patients with normal liver blood tests 
and dilated CBD and negative prior imaging tests.
disclosure: Nothing to disclose 
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Introduction: Peritoneal carcinomatosis (PC) is the metastatic seeding of 
malignant cells to peritoneal cavity. It is associated with a dramatic prog-
nosis worsening, with limited therapeutic options. Although cumbersome 
in diagnosing, due to its presentation variability, it should be ruled out 
before starting any invasive treatment modality. Recently, a new through-
the-needle micro-biopsy forceps (Moray Forceps, US Endoscopy) have 
been proposed, allowing micro-histology cores.
aims & Methods: With this novel application, we aimed to evaluate the 
feasibility of MF in the assessment of PC to complete patient diagnostic 
work out. 
All procedures were conducted under moderate sedation, by 2 expert en-
dosonographers. After a complete EUS evaluation, ascites was punctured, 
with a 19G FNA needle. Before suction, the MF was introduced through-
the-needle, and the suspected carcinomatosis nodule was sampled. Mi-
cro-histology specimens were collected in formalin and evaluated by a 
dedicated pathologist.
results: 3 consecutive patients (2 F, 1 M; mean age 72 yo), with ascites and 
suspicion of PC, referred to our center for EUS staging, were sampled with 
MF. Tissue sampling with MF was feasible in all patients, with a technical 
success of 100%. Sample quality was medium-high, in all the cases, giv-
ing the opportunity for immuno-histochemical staining, when necessary. 
No adverse events where observed both during and after the procedure 
in all cases. 
case 1 A 75 yo man underwent investigations for abdominal pain and 
weight loss. A CT scan showed a 70 mm solid lesion of the pancreas tail. A 
subsequent EUS confirmed the lesion and showed the presence of ascites, 
with hypoechoic nodules, suspicious for PC. A FNB of the pancreatic le-
sions was performed, together with ascites sampling and nodules biopsy 
with MF. Pathology evaluation reported extended necrotic carcinoma on 
nodules biopsies, compatible with PC. 
case 2 A 64 yo woman underwent US and CT scan, showing PC, with un-
known primary lesion. After negative EGD and colonoscopy, pt underwent 
EUS, showing ascites with omentum nodules, biopsied with MF. Pathology 
evaluation reported malignant cells on peritoneal nodules. Supplemental 
analysis for immunohistochemistry showed CK7, WT1 positivity and CK20 
negativity, compatible with ovarian primitivity. 
case 3 A 77 yo woman underwent staging EUS for a focal solid lesion of the 
pancreatic tail, with abundant peri-hepatic and pelvic fluid. Since the find-
ing of ascites with irregular peritoneal nodular-like lesions, with hypo-en-
hancement after contrast medium injection, a MF biopsy was performed, 
for micro-histology. Pathology evaluation of both pancreatic lesion FNA 
and MF biopsy showed pancreatic ductal adenocarcinoma.
conclusion: This is the first experience reporting a micro-histology forceps 
in the ascites work-out to rule out PC. The technique, using this through-
the-needle device, is feasible and safe, with technical success rate of 
100%. It allowed to sample peritoneal irregularity, with high quality tissue 
fragments in all the cases, giving the opportunity for additional assess-
ment, as immunoistochemical staining.
disclosure: Nothing to disclose 
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P1641 IMPrOvIng PseudOachaLasIa WOrkuP: rOLe Of 
endOscOPIc uLTrasOund (eus) In addITIOn TO hIgh resOLuTIOn 
ManOMeTry (hrM) and cT IMagIng
Chia C.T.W.1, Nasr I.2, Koumoutsos I.2, DeMartino S.2, Meenan J.2
1Tan Tock Seng Hospital Dept. of Gastroenterology, Gastroenterology & 
Hepatology, Novena, Singapore, 2Guy’s and St Thomas’ Hospital, London, 
United Kingdom
contact e-Mail address: tzechris@gmail.com
Introduction: Pseudoachalasia is an infrequent secondary form of acha-
lasia which can result from malignant or benign tumors, postoperative 
complications or paraneoplastic syndromes. Management can be vastly 
different between achalasia and pseudoachalasia, making it important 
to exclude the latter condition. Esophago-gastro-duodenoscopy (EGD), 
high resolution manometry (HRM), barium esophagram, CT scan and EUS 
play complementary roles to procure a diagnosis of achalasia and exclude 
pseudoachalasia. This is one of the few studies that aims to evaluate the 
role of EUS in excluding pseudoachalasia for patients referred for achala-
sia workup.
aims & Methods: Data was collected retrospectively from hospital elec-
tronic records from 2008 to 2015. Our study group comprised 77 patients 
(female=44, male=33) with a mean age of 62 years. All cases had a prior 
EGD and EUS performed. Only cases with a non-diagnostic EGD (including 
negative esophageal biopsies) were included. Cases with obvious mass 
seen on EGD were excluded. Work up included the following:(A)classic 
achalasia symptoms, (B)normal EGD, (C)positive HRM +/-barium for acha-
lasia/gastro-esophageal junction outflow obstruction (GEJ-OO) and (D)
had CT scan performed. Yield of excluding pseudoachalasia with addi-
tion of EUS was analysed in 4 groups: (1)A+B, (2)A+B+C, (3)A+B+D and (4)
A+B+C+D. Cases referred without information on manometry, barium or 
CT findings were excluded appropriately in the subgroup analysis. Surveil-
lance was performed within 6-12 months to detect any missed cases of 
pseudoachalasia. Statistical analysis was performed using SPSS V20 using 
the McNemar Chi-Square and Cochran’s Q.
results: Almost all patients (98.7%) had dysphagia as one of the main 
symptoms. EGD was non-diagnostic in all cases. EUS was performed in all 
patients. Number of pseudoachalasia cases detected in Group (1)[n=77], 
Group (2)[n=53], Group (3)[n=38] and Group (4)[n=26] were 0, 0, 3 and 0 
respectively. With addition of EUS (Table 1), incremental detection of pseu-
doachalasia in these respective cohorts were 7.8% (p=0.031), 1.9% (p=NS), 
0% (p=NS) and 0% (p=NS). EUS showed a sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV) of 85.7%, 100%, 
100% and 98.6%. There was only 1 case of pseudoachalasia that was not 
picked up which manifested 2 years later. Other modalities (B, C and D) 
complemented each other to give excellent values of sensitivity, specificity 
and NPV (Table 2).
conclusion: In excluding pseudoachalasia, additon of EUS to a well com-
plemented workup (typical symptoms, EGD, HRM and/or CT scan) may not 
yield statistically significant benefit. However, EUS demonstrated good 
sensitivity and excellent specificity, PPV and NPV for pseudoachalasia de-
tection clinically and should be considered on a case-by-case basis espe-
cially in any diagnostic dilemma.
disclosure: Nothing to disclose 
P1642 The ThIckness Of The fna needLe cOnTrIBuTIng TO 
The PrOcedures and hIsTOLOgIcaL resuLTs By eus-fna
Masaki Y., Kawakami Y., Ishigami K., Ito A., Akutsu N., Motoya M., 
Sasaki S., Nakase H.
Sapporo Medical University, Gastroenterology and Hepatology, Sapporo, 
Japan
contact e-Mail address: yoshiharu.masaki@gmail.com
Introduction: Recently, the newly franseen shaped EUS-FNA needle has 
been used in worldwide. However, it remains unclear which gauge nee-
dles are optimal for the improvement of the diagnostic yield with biopsy 
specimens.
aims & Methods: The aim of this study is to whether the thickness of the 
FNA needle affects procedures of EUS-FNA or histopathological diagnosis. 
We retrospectively enrolled the patients whose EUS-FNA were performed 
in our hospital between December 2017 and May 2019. Thirty-two and fifty-
one patients underwent EUS-FNA by using 19G and 22G franseen shaped 
needle, respectively. We investigated the difference in the success rate of 
histopathological diagnosis between these two groups. Additionally, we 
analyzed clinical characteristics (age, sex, clinical diagnosis, target site, 
puncture tract, the number of punctures, the success rate of string like 
tissue sampling, the success rate of histopathological diagnosis) to identify 
the factors contributing to an accurate diagnosis. The Pearson χ test or the 
Fisher exact test was used for the categorical variables, whereas Student’s 
t-test or Mann-Whitney U test was used for continuous data. Multivariate 
analysis was performed for the factors which showed p ≦ 0.20 by univari-
ate analysis.
results: With regard to clinical characteristics, there were no statistical dif-
ferences in age, sex, clinical diagnosis, and target site (p = 0.55, 0.10, 0.70, 
0.06, and 0.06, respectively). In the 19G group, the mean number of punc-
tures was significantly lower than that in the 22G group (1.81 vs 2.21, p = 
0.04). The success rate of string like tissue sampling and histopathological 
diagnosis didn’t show significant differences between these two groups (p 
= 0.94 and 0.21, respectively). We could not identify the significant factors 
by multivariate analysis, while younger age could contribute to accurate 
diagnosis by univariate analysis (p = 0.036).
conclusion: EUS-FNA using 19G franseen shaped needle could have the 
advantage of achieving the accurate histopathological diagnosis by a sig-
nificantly smaller number of punctures in comparison with the 22G fran-
seen needle.
disclosure: Nothing to disclose 
P1643 cyTOLOgIcaL anaLysIs By endOscOPIc 
uLTrasOund-guIded fIne needLe BIOPsy In saMPLIng sOLId 
gasTrOInTesTInaL LesIOns: a feasIBILITy sTudy
Grech M.G., Saliba G., Azzopardi N., Gerada J.
Mater Dei Hospital, Gastroenterology, Msida, Malta
contact e-Mail address: jurgen.gerada@gov.mt
Introduction: Anecdotal results suggest FNB (fine needle biopsy) needles, 
used for tissue acquisition during endoscopic ultrasound (EUS), yield just 
as good results when cytological evaluation was performed, as it does 
with histological analysis.
aims & Methods: We studied the feasibility of FNB needle (ProCore®, 
Cook) to obtain samples for cytology analysis. 29 randomly selected pa-
tients who underwent EUS-guided FNB of a solid gastrointestinal lesion, 
with sampling taken for both cytological and histological analysis, be-
tween 2016 and 2018, were retrospectively enrolled. Positive cytology was 
defined as adequate material for interpretation, following either of these 
cytological techniques: rapid on-site evaluation, sample in fixative or cell 
block. Data was collected through the medical notes.
results: 29 patients (59% males, mean age 66) had EUS-FNB of a gastro-
intestinal lesion (pancreas 80%; others 20%). Positive cytology was ob-
tained in 24/29 cases (83% sensitivity), 23 of which had correct diagnosis 
(23/24; 96% specificity). Positive histology was obtained in 20/29 cases 
(69% sensitivity), 19 of which had correct diagnosis (19/20; 95% specific-
ity). Analysing malignant cases only (20), sensitivity was 90% (18/20) and 
65% (13/20) for cytology and histology respectively. 5 cases were diag-
nosed cytologically but not histologically.
conclusion: This small feasibility study confirms that EUS-FNB needle 
samples can be sent for cytological analysis. The high sensitivity and spec-
ificity of cytology, which in this cohort were even higher than histology, 
suggests that cytology should be included when EUS-FNB is performed. 
Sending samples for cytology and histology using 1 needle would increase 
the yield, while remaining cost-effective. Larger studies are however 
needed to confirm this.
disclosure: Nothing to disclose 
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P1644 facTOrs InfLuencIng dIagnOsTIc accuracy Of 
endOscOPIc uLTrasOund WITh fIne needLe asPIraTIOn 
(eus-fna) In PancreaTO-BILIary TuMOrs
Del Vecchio Blanco G.1, Palmieri G.2, Formica V.3, Portarena I.3, 
Nardecchia A.3, Troncone E.1, Benassi M.4, Giudice E.4, Anselmo A.5, 
Toti L.5, Manzia T.M.5, Tisone G.5, Roselli M.3, Monteleone G.1, Paoluzi O.A.1
1University Tor Vergata, Department of Systems Medicine - Gastroenterology 
Unit, Roma, Italy, 2University Tor Vergata, Department of Biomedicine and 
Prevention - Anatomic Pathology Unit, Rome, Italy, 3University Tor Vergata, 
Department of Oncoemathology - Oncology Unit, Rome, Italy, 4University Tor 
Vergata, Department of Oncoemathology - Radiotherapy Unit, Rome, Italy, 
5University Tor Vergata, Department of Surgery - Transplant Surgery Unit, 
Rome, Italy
contact e-Mail address: giovanna.del.vecchio.blanco@uniroma2.it
Introduction: Endoscopic ultrasound (EUS) with fine needle aspiration 
(FNA) is a well-established technique for assessing lesions of the pan-
creas and biliary tract. Diagnostic yield of EUS-FNA varies according to the 
expertise of endosonographer raging from 65% to >90%. ESGE guideline 
suggests to perform a formal training in EUS before starting supervised 
EUS-FNA. At least 20 to 30 EUS-FNAs with rapid on-site cytopathological 
examination (ROSE) are recommended to reach a diagnostic accuracy of 
80%. Whether the absence of ROSE prolongs the learning period required 
to achieve a diagnostic accuracy ≥90% has not yet been defined.
aims & Methods: Aim of the study was to evaluate the factors, including 
the absence of ROSE, influencing diagnostic accuracy of EUS-FNA in pa-
tients with suspected pancreato-biliary tumors in a tertiary center. From 
2010 to 2018, 557 consecutive EUS-FNAs were carried out by a single op-
erator under conscious/deep sedation using an echo endoscope (Olympus 
GFUCT140 or GFUCT180). EUS FNAs were carried out using a needle of 
different type (Echotip ProCore, Wilson-Cook, Expect TM Boston Scientific, 
Shark Core TM FNB Medtronic, Acquire Boston Scientific) and with differ-
ent size (19, 20, 22 Gauge). All samples were fixed in formalin solution 
for histopathological assessment. In case of absence of clear findings of 
neoplasm, the sample was deemed as not diagnostic. All clinical data, 
sex, age, type and size of the needle, site of the lesion, number of passes, 
and sampling technique (with/without stilet) were prospectively recorded 
in an electronic database. EUS-FNA performance was defined on the basis 
of sensitivity, specificity and diagnostic accuracy calculated according to 
kind and size of the needle, site of the lesion, and progressive experience 
expressed in the number of procedures grouped in blocks of 50. Variables 
associated with diagnostic accuracy were evaluated by multivariate logistic 
regression analysis.
results: Of 557 EUS-FNA, 308 were carried out for pancreato-biliary neo-
plasms. The final diagnosis was pancreatic cancer in 253 patients, cys-
tic pancreatic lesion in 8 patients, primary and metastatic liver cancer in 
5 patients, and cholangiocarcinoma in 17 patients. Overall sensitivity of 
EUS-FNA was 66% (95% CI: 60.8 - 71.8), specificity 100%, and diagnos-
tic accuracy 69% (95% CI: 64.0 - 74.4). When tissue sampling was per-
formed using a new fine needle biopsy (FNB) (Acquire/Shark needles), 
the diagnostic accuracy increased up to 90.5% (95% CI: 80.7 - 99.3). When 
EUS-FNA was targeted to both primary and metastatic lesions (33 patients) 
sensitivity raised to 98% (95% CI: 93.9 - 100). Diagnostic accuracy was 
influenced by the experience of the operator, reaching 87.5% after 250 
procedures (95% CI: 78.8 - 96.2). Variables associated with diagnostic ac-
curacy were FNB needle (OR 3.06; 95% CI: 0.94 - 9.94), operator expertise 
(OR 1.21; 95% CI: 1.02 - 1.43) and EUS-FNA of primary and metastatic sites 
(OR 9.67; 95% CI: 1.27 - 73.75). No EUS-FNA-related complication occurred 
during the study period.
conclusion: EUS-FNA is a safe procedure with high diagnostic accuracy in 
pancreato-biliary neoplasms. The diagnostic accuracy increases during the 
learning curve period, being necessary at least 250 EUS-FNAs to achieve a 
good (>85%) value in the absence of ROSE. The new FNB needles seem to 
strongly improve EUS performance.
disclosure: Nothing to disclose 
P1645 sTudy On cOMPLIcaTIOns Of eus-fna In cases TakIng 
anTIThrOMBOTIc drugs
Tsuneyoshi K., Iwaya H., Hashimoto S., Tanoue S., Ido A.
Kagoshima University Graduate School of Medical and Dental Sciences, 
Digestive and Lifestyle Diseases, Kagoshima, Japan
contact e-Mail address: t-kengo@m3.kufm.kagoshima-u.ac.jp
Introduction: Endoscopic examinations under antithrombotic medica-
tion have been performed with increasing frequency in recent years, and 
there have been a few reports of bleeding after EUS-FNA[Endoscopic Ul-
trasound-Fine Needle Aspiration]. We retrospectively examined bleeding 
and complications after EUS-FNA among users of antithrombotic drugs in 
our institution.
aims & Methods: The subjects were 665 consecutive patients (February 
2013 to January 2019) who underwent EUS-FNA according to the BSG and 
ESGE guidelines 2016 for users of antithrombotic drugs.
(1) We divided the patients into two groups according to the preopera-
tive intake condition,(antithrombotic drug group and non-antithrombotic 
group)and examined the bleeding rate and technique related factors.
(2) The antithrombotic group was further divided into four groups: a con-
tinuation group, a withdrawal group (a withdrawal of more than 24 hours 
before surgery), an aspirin or cilostazol substitution group, and a heparin 
substitution group.
Direct oral anticoagulants (DOAC) are recommended to be discontinued 
for more than 48 hours according to the guidelines, and were included in 
the withdrawal group.
The definition of hemorrhage was a decrease of Hb ≧2 g/dl within 24 h 
after the operation according to the guidelines of the International Society 
for Thrombosis and Hemostasis.
results: The puncture site of the lesion was pancreas in 474, liver in 7, 
lymph node in 67, digestive tract in 83, and other organs in 34.
A total of 98 patients in the antithrombotic group, and 567 in the non-
antithrombotic group, had a significantly higher proportion of men in the 
group (p = 0.002), had a significantly higher proportion of the age in the 
group (p < 0.001). There were no significant differences in the number of 
punctures, in the puncture sites between the 2 administration groups (P = 
0.228, P = 0.248). The overall incidence of FNA complications was 16 cases 
(2.4%), 4 cases of bleeding, 6 cases of hematoma, 2 cases of pseudocyst, 
1 case of pancreatitis, 2 cases of peritonitis, and 1 case of intraabdominal 
abscess. There were 1 case (1.0%) and 3 cases (0.53%) of bleeding in the 
antithrombotic and non-antithrombotic groups, and there was no associa-
tion (P = 0.472). 
(2) The antithrombotic drugs consisted of antiplatelet drugs in 69, antico-
agulants in 25, and concomitant medication in 4. There were 28 patients 
in the continuation group, 34 in the drug holiday group, 18 in the aspirin 
or cilostazol substitution group, and 18 in the heparin substitution group. 
The bleeding rates in the continuation group, withdrawal group, aspirin or 
cilostazol substitution group, and heparin substitution group were 0% (0 
case), 0% (0 case), 5.6% (1 case), 0% (0 case) being highest in the aspirin 
or cilostazol substitution group (P = 0.213). No bleeding was observed in 
patients taking direct oral anticoagulants.
conclusion: Rates of bleeding and complications after EUS-FNA were simi-
lar to those previously reported. Hemorrhaging was more frequent in the 
aspirin or cilostazol replacement group than in the other groups but im-
proved with conservative treatment. Even in patients taking antithrombotic 
drugs, the risk of bleeding is low, and it may be possible to safely perform 
EUS-FNA.
disclosure: Nothing to disclose 
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P1646 IncIdence and rIsk facTOrs assOcIaTed WITh 
BLeedIng POsT endOscOPIc uLTrasOund fIne needLe 
asPIraTIOn/BIOPsy (eus-fna/fnB) Of sOLId and cysTIc 
PancreaTIc Masses
Razpotnik M., Bota S., Essler G., Weber-Eibel J., Peck-Radosavljevic M.
Klinikum Klagenfurt am Wörthersee, Department of Internal Medicine and 
Gastroenterology (IMuG), Hepatology, Endocrinology, Rheumatology and 
Nephrology and Emergency Medicine (ZAE) with Centralized Endoscopy 
Service, Klagenfurt am Wörthersee, Austria
contact e-Mail address: marcel.razpotnik@gmail.com
Introduction: Endoscopic ultrasound fine needle aspiration/biopsy (EUS-
FNA/FNB) is an established technique for pancreatic tumor evaluation and 
considered a high risk bleeding procedure.
aims & Methods: The aim of this study was to assesses the bleeding rate 
of EUS-FNA/FNB of solid and cystic pancreatic masses according to use of 
antithrombotic agents and coagulations parameters (platelet count and 
prothrombin time). 
Our retrospective analysis included EUS-FNA/FNB of solid and cystic pan-
creatic masses performed between 01/2017-03/2019 in our newly estab-
lished GI-Department, which features a centralized endoscopy-service in a 
University affiliated tertiary care teaching hospital.
Bleeding rate was assessed separately for solid pancreatic masses and 
pancreatic cysts. Parameters analyzed regarding the occurrence of bleed-
ing were: age, use of acetylsalicylic acid (ASA), low molecular heparin 
(LMWH) or other antithrombotic/anticoagulant agents, platelets count, 
prothrombin time, and use of EUS-FNB needles.
results: 115 patients were included into this analysis (76 with solid and 
39 with cystic pancreatic masses). Only EUS-FNA was used for pancreatic 
cysts. EUS-FNA was used in 88.1% of cases with solid pancreatic masses.
No bleeding was observed by EUS-FNA of pancreatic cysts. ASA was pres-
ent in medication at EUS-FNA in 9/39 (23.1%) of these patients and LMWH 
in 3/39 (7.7%) cases. Platelets were lower than 100.000/mm3 in one case 
(2.5%) and prothrombin time < 60% in 5/39 (12.8%).
Bleeding with hemodynamic instability was not observed in our cohort 
of EUS-FNA/FNB of solid pancreatic masses. In one case (1.3%) bleeding 
from a vessel from the duodenal wall was observed with Doppler-US and 
immediately treated with a hemoclip. In 8/76(10.5%) cases slight intralu-
minal bleeding with spontaneous termination was registered.
The use of EUS-FNB needles and biopsy in ASA-users trend to increase the 
bleeding rate in patients with solid pancreatic masses.
factor Patients without bleeding (n=67)
Patients with any type of 
bleeding (n=9) p value
Age (years) 65.6±14.1 64.8±16.9 0.88
Use of antithrombotics      
- Acetylsalicylic Acid (%) 16.4 44.4 0.12
- LMWH (%) 13.4 11.1 0.73
Platelets (cells/mm3) 260.9±78.7 266.7±76.7 0.83
Prothrombine time (%) 90.1±15.9 81.3±18.9 0.13
Use of FNB needles (%) 8.9 33.3 0.08
[Table: Risk Factors associated with Bleeding post EUS-FNA/FNB of Solid and 
Cystic Pancreatic Masses]
conclusion: No bleeding was observed post EUS-FNA of pancreatics cysts. 
Slight bleeding was observed in 11.8% of EUS biopsies of solid pancreatic 
masses, but no hemodynamic relavant bleeding occurred. Only in one case 
a hemoclip was needed to stop bleeding. Use of EUS-FNB needle and ASA 
trend to increase the bleeding rate.
disclosure: Nothing to disclose 
P1647 gasTrOInTesTInaL suBePITheLIaL LesIOns (gI seLs): 
OPTIMIzIng unnecessary surveILLance and PaTIenT care 
WITh endOscOPIc uLTrasOund (eus)
Chia C.T.W.1, Lim W.C.2, Vu C.2
1Tan Tock Seng Hospital, Gastroenterology & Hepatology, Novena, Singapore, 
2Tan Tock Seng Hospital, Gastroenterology & Hepatology, Singapore, 
Singapore
contact e-Mail address: tzechris@gmail.com
Introduction: Upper GI subepithelial lesions (SELs) are commonly found 
during oesophagogastroduodenoscopy (OGD) and most are <2cm on av-
erage. Management of these small SELs are often variable by different 
centres. Many patients are routinely brought back for frequent 1-2 yearly 
surveillance despite being asymptomatic and this significantly escalates 
health care cost without benefit to patients or actual improvement in clini-
cal management if the SELs are small and stable.
aims & Methods: We aim to determine the outcome of these small but 
frequently seen SELs based on a retrospective analysis of a cohort of SEL 
cases followed prospectively. Patients with SELs < 2cm and no change in GI 
symptoms from 2007 up to 2016 with OGD and EUS done were analyzed in 
terms of demographic characteristics and size progression of SEL, lymph 
node presence and eventual change in management from first detection 
right up to the last OGD/EUS surveillance. Cases with less than 3 years of 
follow up were excluded for meaningful analysis. Analysis using paired 
sample T-test for mean SEL size was done using SPSS.
results: There was 210 patients ranging from 29-83 years of age, 61% 
being female. Average follow up range from 3 to 11 years with mean of 
6 years. SEL size on index EUS and final EUS range from 3-19mm and 
2-20mm respectively. The SEL distribution comprised 72% gastric and 18% 
esophageal origin. 
Of all cases, 62% , 28% and 10% were found on EUS to arise from muscu-
laris propria (MP), muscularis mucosa (MM) and submucosa of the GI tract 
respectively. About 10% underwent fine needle aspiration (FNA) with none 
being malignancy. Only 1 case demonstrated an increase in size of more 
than 50% but less than 100% over 3 years. All other SELs had fluctuations 
in mean size of < 33% or size regression and was deemed overall stable 
by endosonographer. 
There was no significant difference between the initial mean size of these 
SELs on index EUS compared to final mean size on the last EUS (p=0.288). 
There was 0% mortality related to all these SELs.
conclusion: This study suggests small GI SELs < 2cm can generally adopt 
a longer interval surveillance from baseline and may not need continuous 
yearly/biyearly surveillance if the initial repeat EUS is stable compared to 
the index scope, done within 3 years. A reasonable surveillance sequence 
proposed include 1 year followed by 3 years and then every 5-10 yearly if 
SEL remains stable and patient has no new GI symptoms. This has poten-
tial to reduce health care cost and growing endoscopy burden without 
sacrificing important clinical outcomes for patients.
disclosure: Nothing to disclose 
P1648 effIcacy Of LuMen aPPOsIng MeTaL sTenTs vs 
seLf-exPandaBLe MeTaL sTenTs fOr endOscOPIc 
uLTrasOund-guIded chOLedOchO-duOdenOsTOMy: 
a sysTeMaTIc revIeW and MeTa-anaLysIs
Amato A.1, Buda A.2, Sinagra E.3, Vieceli F.4, Scaramella L.1,5, Belletrutti P.6, 
Fugazza A.7, Repici A.6, Anderloni A.7
1Valduce Hospital, Gastroenterology, Como, Italy, 2UOC Gastroenterology, 
GI Oncological Surgery, Feltre, Italy, 3Fondazione Istituto G. Giglio, 
Gastroenterology and Endoscopy Unit, Cefalù, Italy, 4University Hospital of 
Verona, Gastroenterology and Digestive Endoscopy Unit - Pancreas Center, 
Verona, Italy, 5University of Milan, Pathophysiology and Transplantation, 
Milano, Italy, 6Humanitas University, BioMedical Sciences, Rozzano, Milano, 
Italy, 7Humanitas Research Hospital, Digestive Endoscopy Unit, Division of 
Gastroenterology, Milano, Italy
contact e-Mail address: andrea.anderloni@humanitas.it
Introduction: Endoscopic ultrasound (EUS)-guided biliary drainage (BD) 
is gaining a primary role for endoscopic palliation of malignant common 
bile duct obstruction. Lumen apposing fully covered metal stents (LAMS) 
are now replacing self-expandable metal stents (SEMS), commonly used 
for this procedure in the past.
852 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
aims & Methods: The aim of this systematic review and meta-analysis was 
to evaluate the efficacy and safety of LAMS vs SEMS for biliary drainage via 
endoscopic ultrasound- guided choledocho-duodenostomy.
A meta-analysis was performed using the Preferred Reporting Items for 
Systematic Review and Meta-Analysis (PRISMA) protocols. Three databas-
es (PubMed, EMBASE and Google Scholar) were searched for studies con-
taining data on EUS-guided choledocho-duodenostomy. English language 
articles from inception to 03 February 2019 were checked against our pre-
determined eligibility criteria. Odds ratios (OR) and mean differences (MD) 
were pooled using the random effects model with the DerSimonian-Laird 
estimation and displayed on forest plots.
results: A total of 29 studies were included containing data on 960 pa-
tients. LAMS and SEMS were evaluated in 4 and 25 studies, accounting for 
174 and 786 patients, respectively. Overall, the pooled rate of clinical suc-
cess was 82.1% [95% CI 76.3-86.7], and significantly higher for LAMS than 
SEMS (91.5% [95% CI 86.2-94.9] vs. 71.4% [95% CI 61.2-79.9, p< 0.001). 
The overall technical success rate was 78.2% [95% CI 70.8-84.2], and sig-
nificantly higher for LAMS than SEMS (93.4 % [95% CI 60.5-79.0] vs. 70.6% 
[95% CI 61.2-79.9], p< 0.001). 
Both the procedure-related adverse events (AEs) and re-intervention rates 
were lower for LAMS than SEMS, although the rate of overall AEs was sig-
nificantly higher for LAMS than SEMS (18.4% [95% CI 11.3-28.5] vs. 11.2% 
[95% CI 8.5-14.6], p< 0.001).
conclusion: LAMS outperformed SEMS in terms of efficacy of EUS-guided 
choledocho-duodenostomy for biliary drainage. Their use was associated 
with less procedural AEs and fewer re-interventions when compared to 
SEMS placement, however, more post-procedure AEs occurred with LAMS 
when compared to SEMS. This most critical point requires further inves-
tigation.
disclosure: Nothing to disclose 
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Introduction: Endoscopic ultrasound guided fine needle biopsy (EUS-FNB) 
represents the current standard for obtaining a histological diagnosis 
of a pancreatic mass. 19G stainless steel needles are relatively rigid and 
technical difficulties due to the inability to advance the needle out of the 
endoscope often prevent tissue collection, especially for the transduode-
nal puncture route. Nitinol-based needles are more flexible and might 
decrease technical difficulties and thus increase diagnostic accuracy. In 
this prospective, multicenter, randomized, partially blinded study we com-
pared the diagnostic value of those two needle types in patients with a 
solid pancreatic lesion.
aims & Methods: Consecutive patients with a solid pancreatic mass were 
diagnosed with EUS-FNB using one puncture with each needle in a ran-
domized fashion. Olympus EZ Shot 2 19G were used as steel needles and 
EZ Shot 3 Plus 19G were used for nitinol-based needles. Final diagnosis 
was made by histology and diagnostic procedures during follow up. Pri-
mary endpoint was diagnostic accuracy of each needle. Secondary end-
points included time for puncture, amount of tumor tissue obtained, and 
technical failure. Histological specimen were centrally reviewed by a pa-
thologist blinded to the final needle type and final diagnosis. ClinicalTrials.
gov Identifier: NCT02909530.
results: Out of 46 prospectively recruited patients central pathological ex-
amination was available for 41. Diagnostic accuracy for the two needles 
combined was 87.8%. Diagnostic accuracy was 66% and 68% using the 
stainless steel and nitinol-based needle respectively. Analysis of diagnos-
tic accuracy divided by transduodenal and transgastric route furthermore 
presented no significant difference. Time spent for puncturing was 137 +/- 
61 seconds (mean +/- SD) for the stainless steel and 111 +/- 53 seconds for 
the nitinol-based needle (p<0.001). Technical failure occurred in 3 (6.5%) 
cases using the stainless steel and in none using the nitinol-based needle. 
Postprocedural self-limited bleeding occurred in 2 (4%) cases.
conclusion: Usage of a nitinol-based 19G needle failed to present a signifi-
cant difference regarding diagnostic accuracy compared with a stainless 
steel needle in EUS-FNB of solid pancreatic lesions. Usage of a nitinol-
based needle was faster and resulted in no technical failures.
disclosure: Nothing to disclose 
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Introduction: Current guidelines suggest that the EUS-FNB is equivalent to 
FNA and both tissue acquisition techniques may be utilised for cytopatho-
logical analysis.With the FNB technique there is a possibility of assessing 
tissue adequacy macroscopically obviating the need for ROSE.Possibility of 
immunohistochemistry in these samples aids classification of the neopla-
sia particularly in difficult casesReduction in number of passes would lead 
to fewer complications.
aims & Methods: We performed a retrospective cohort study of patients 
with solid masses or lesions needing EUS-guided core biopsy between 
January 2018 and November 2018. All core biopsies were obtained using 
an Acquire™Fine Needle Biopsy Device- 22 gauge (Boston Scientific Corpo-
ration, Natick MA, USA).This data was compared to the matched popula-
tion in the previous year using the standard 22-25 gauge needle for FNAC.
All patients having EUS-FNAC/FNB were evaluated for the study. Patients 
with cystic lesions based on EUS and other cross-sectional imaging data 
were excluded from the study. Details of the location of the lesion, size 
of the lesion, endoscopic ultrasound findings, type of tissue acquisition 
(transesophageal, transgastric, trans duodenal), tissue acquisition tech-
niques (slow pull, fanning vs. suction),technical success, operator visual 
satisfaction on tissue acquisition, pathologist satisfaction, average passes, 
size of the core in FNB and final cytopathologist or histopathologic diag-
nosis with or without IHC were recorded.
results: A total of 207 patients, 134 (64.7%) male and 73 (35.3%) female 
were included in this study. The mean age of the study population was 
54.3±11 years83 of these patients has FNB and 124 had FNAC.148 (71.4%) 
of the biopsied lesions were located in the pancreas and 59 (28.6%) were 
extrapancreatic in location.Only 3/83 needed repeat biopsy for diagnosis 
in the FNB group vs. 17/124 in the FNAC group with average pass of 1 and 
2.7 respectively.Notably 2/3 repeat biopsies in the FNB group were gastric 
wall thickening? Linitus plastica and the third was a retroperitoneal tu-
mour with extensive necrosis.There were no significant complications in 
either group.
conclusion: FNB sampling provides intact cores that provide better char-
acterization of malignancy and improve the diagnostic accuracy for benign 
lesions. With extrapancreatic lesions (especially gastrointestinal stromal 
tumors, lymphoma, and neuroendocrine tumors), histology is crucial for 
reaching a diagnosis, as cytology alone cannot uniformly provide adequate 
architecture and cellular configuration.We encountered no procedure-re-
lated complications.In this large, single-center study, EUS-FNB performed 
with a novel Franseen-type biopsy needle proved to be an effective mo-
dality for tissue acquisition from all solid lesions.EUS FNB should replace 
FNAC in our opinion.
disclosure: Nothing to disclose 
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Introduction: With the development of the new core needles, fine needle 
biopsy (FNB) has emerged as an alternative to standard fine needle aspi-
ration (FNA) for procurement of larger amounts of tissue. Several studies 
have been published so far on core needles, most of them coming from ex-
pert centers. Our aim was to compare the diagnostic adequacy and yield of 
a core versus standard needle, in a center without on-site cytopathology.
aims & Methods: We enrolled all patients with a diagnosis of pancreatic 
adenocarcinoma admitted in our clinic over a period of 16 months, who 
underwent endoscopic ultrasound (EUS) guided tissue sampling using ei-
ther standard EchoTip, or ProCore needle (Cook Medical). EUS examina-
tions were carried out using a Pentax-Hitachi system using a linear probe. 
Final diagnosis was set by FNA/FNB, repeated FNA/FNB, surgery or long-
term outcome. We compared the diagnostic adequacy of samples and the 
diagnostic yield for malignancy between the two groups - FNA versus FNB 
needle.
results: Altogether 58 patients were enrolled, median age 62 years, 63.8% 
males. FNB using the core needle was done in 19/58 (32.8%) of patients, 
while the other 67.2% were punctured using FNA needle. Mean tumor size 
was 33 mm in the FNA group, and 33.9 mm in the FNB group. More pan-
creatic head tumors were sampled using an FNA needle - 51.3% versus 
31.6%. Also, more 22G needles were used in the FNA group (46% vs. 37%). 
Diagnostic adequacy was achieved in 89% of FNA samples and 94% of 
FNB. Diagnostic yield for malignancy was slightly better for FNB - 89.5%, 
compared to FNA - 82.1%.
conclusion: In our study, high diagnostic performance was achieved with 
both needles without on-site cytopathology, but the core one proved to be 
slightly better.
disclosure: Nothing to disclose 
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Introduction: The fully-covered stents lumen apposing metal stents (LAMS) 
are designed for one step placement and facilitates the direct endoscopic 
necrosectomy into the walled-off pancreatic necrosis (WOPN). However, 
the prediction of the number of necrosectomy sessions in these patients 
is not known.
aims & Methods: To assess the possible prediction for the need of necro-
sectomy according to the amount of necrosis inside the WOPN assessed 
during endosonography (EUS). 
This is a single center prospective analysis at a single tertiary referral cen-
ter. There were enrolled patients with symptomatic WOPN (pain, infection 
or gastric or biliary outlet obstruction) with more than 4 weeks after the 
onset of acute pancreatitis. The amount of necrosis was assessed by EUS 
in the session of LAMS placement . There were noted the clinical suc-
cess regarding LAMS placement , the number of necrosectomies, the need 
for additional drainage (pigtail stents), the complications and the survival 
rate. The need for necrosectomy was performed on-demand when fever 
or inflammatory biological markers raised after LAMS placement. The pa-
tients were discharged when the inflammatory markers normalized and 
they were followed-up monthly by abdominal ultrasound and by CT scan 
at three months.
results: There were 28 patients included and more than half were infect-
ed. The median size of the WOPN was 108mm (IQR: 81-146). LAMS was 
successfully placed in all patients, without immediate complications fol-
lowing the procedure. Necrosis was present in all patients and one third 
of them had more than 50% of the WOPN cavity with necrosis. Necrosec-
tomies were performed in 25/28 (89.2%) patients. The median number of 
endoscopic debridement sessions was 2 (IQR: 1-4). There was no statisti-
cally significant association between the size of the WOPN and number of 
necrosectomies performed (Spearman’s r coefficient =153, p=0.427) or be-
tween the amount of necrosis and the number of necrosectomies (p>0.05). 
The median duration until stent removal was 36 days (IQR: 24 - 55 days). 
Overall, WOPN resolution at 3 months follow up was noted in 24/28 
(85.7%) patients. Two patients died, one due to pseudoaneurysm bleeding 
and another with bleeding from gastric collateral circulation.
conclusion: The size of WOPN and the amount of necrosis prior LAMS 
drainage of WOPN cannot predict the need for on-demand necrosectomy 
sessions.
disclosure: Nothing to disclose 
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Introduction: EUS represent nowadays an essential tool the identification, 
staging sampling and follow-up of benign and malignant bilio-pancreatic 
lesions. Diagnostic endosonography has traditionally been associated with 
a very low rate of complications Perforation stay one of the most deemed 
complication in endoscopy and in EUS, although surgery allows simulta-
neous treatment of the perforation and of an associated biliary or pancre-
atic disorder, surgery is an invasive treatment carrying its own morbidity 
and mortality, especially when undertaken in a context of emergency. We 
wanted to assess the feasibility, efficacy and safety of the immediate endo-
scopic repair of EUS-induced duodenal perforations with over-the-scope 
clips and report our experience to determine whether this procedure can 
be recommended in such cases.
aims & Methods: We performed a retrospective study of patients with EUS 
related iatrogenic perforation observed in our unit from 2011 to 08/2018.
We included all consecutive patients with EUS related perforation with 
immediate diagnosis, and receiving a conservative endoscopic manage-
ment. Patients with primary surgical management and conservative, 
non-interventional management, as well as perforation resulting from an 
endoscopic intervention (eg endoscopic sphicnterotomy, cyst fenestration, 
etc), were excluded.
results: 13 perforations in 8504 EUS procedure occurred (0.15%).
Two patients were excluded, one for a large duodenal tear requiring im-
mediate surgery, the other one for misdiagnosing the perforation leading 
to early discharge and readmission 24h later with peritonitis and emer-
gency surgery.
A total of 11 patients were included, all women. The mean patient age 
was 75 (range 68-88) years. 8/11 (72.7%) perforations were due to a radial 
probe. All procedures were performed at a diagnostic end.
Perforations were located in the superior flexure of the duodenum in 9/11 
(81%), in the descending part of the duodenum 1/11(9%), and in the in-
ferior duodenal flexure 1/11 (9%). The size of the defect was ranged from 
10-15mm. All clipping procedures experienced a technical and clinical suc-
cess. 3/11(27%) had a stay in intensive care unit for less than 72h, total 
hospital stay ranged from 3-22 days.
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conclusion: Although bearing a low rate of specific complications, diag-
nostic EUS is not adverse event-free and observing proper indications is 
necessary, especially in elderly patients. Duodenal perforation is a poten-
tially serious adverse event, but conservative endoscopic treatment with 
over-the-scope clips represents a feasible, efficient and safe treatment that 
can prevent surgery in most instances.
disclosure: Nothing to disclose 
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Introduction: Endoscopic Ultrasound (EUS) guided tissue acquisition of le-
sions adjacent to the gastrointestinal tract has been previously achieved by 
fine needle aspiration (FNA). Recently, core biopsy from EUS guided ap-
proach has been successfully performed with the new tip-modifying nee-
dles, known as fine needle biopsy (FNB) needles. The first of these was the 
reverse bevel needle known as ProCoreTM (Cook Medicine). The more re-
cently developed core needles include the franseen-tip needle (AcquireTM, 
Boston Scientific) and fork-like tip needle (Sharkcore, Metronics). Although 
the use of these core needles obtained more tissue and is associated with a 
better diagnostic yield than the FNA needles, data on diagnostic outcome 
between these core needles are lacking.
aims & Methods: To compare diagnostic outcomes of EUS guided tissue 
acquisition between the 22-gauge Cook ProCoreTM and the 22-gauge Bos-
ton Scientific AcquireTM needles. 
This is a prospective evaluation of consecutive patients who were referred 
for EUS tissue acquisition of lesions of at least 1cm adjacent to the upper 
GI tract. Biopsy was performed without the presence of on-site cytology 
and two needle passes were taken from each lesion, with one pass from a 
22-gauge ProCore needle and one pass from a 22-gauge Acquire needle. 
The order of the needle was randomized. Macroscopic On-Site Evaluation 
(MOSE) was performed to examine the adequacy of the acquired tissue and 
the samples from each needle were sent in separate pots for histology. Core 
was defined as whitish tissue and the length of the core was measured to 
be 3 times that of the width. Final diagnosis was based on either surgical 
specimen or from biopsy specimen with at least 6 months clinical follow up.
results: A total of 78 needle passes were taken from 39 lesions, including 
24 pancreatic lesions, 6 lymph nodes, 4 subepithelial lesions, 3 biliary 
masses, 2 liver lesions and 1 GB mass. The mean size of the lesions was 
27±9mm. Overall, tissue diagnosis was achieved in 38/39 lesions, giving 
a diagnostic accuracy of 97%, which included 21 pancreatic cancers, 8 
metastatic cancers, 2 pancreatic neuroendocrine tumour, 2 GIST, 2 leio-
myoma, 1 focal pancreatitis, and 3 reactive nodes. There was no difference 
in diagnostic yield between the two needles (Procore = 90% (35/39) vs. 
Acquire = 95% (37/39); P=0.97). In 3 patients, the Acquire needle provided 
a diagnostic sample whereas the ProCore did not. In one patient, the Pro-
Core needle provided a diagnostic sample whereas the Acquire did not. 
Both needles were unable to obtain an adequate sample for a retrocardiac 
lymph node. Based on MOSE, the core length of tissue taken from the 
Procore needle was longer than that of the Acquire needle (14.6mm vs. 
12.8mm, P=0.038). This, however, this did not contribute to an increase in 
diagnostic yield
conclusion: This tandem EUS guided biopsy study showed that, even in the 
absence of rapid on-site cytology, the diagnostic accuracy from 2 passes 
of FNB needles is high (97%), and there is no difference in the diagnostic 
yield between the reverse bevel and franseen tip needles. These findings 
support the use of these new FNB needles in routine EUS guided tissue 
acquisition.
references: 1. Iglesias-Garcia, J. et al. Feasibility and yield of a new EUS 
histology needle: results from a multicenter, pooled, cohort study. Gas-
trointest. Endosc. 73, 1189-1196 (2011). 2. Jovani, M., Abidi, W. M. & Lee, 
L. S. Novel fork-tip needles versus standard needles for EUS-guided tis-
sue acquisition from solid masses of the upper GI tract: a matched cohort 
study. Scand. J. Gastroenterol. 52, 784-787 (2017). 3. Leung Ki, E.-L. et al. 
Macroscopic onsite evaluation using endoscopic ultrasound fine needle 
biopsy as an alternative to rapid onsite evaluation. Endosc. Int. Open 07, 
E189-E194 (2019).
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Introduction: Currently, a validated scale for grading small-bowel cleans-
ing in capsule endoscopy (CE) is lacking. The computed assessment score 
of the small-bowel cleansing (CAC) is based on objective measurements 
of color intensities (red over green) in the Rapid Reader® of the PillCam® 
CE system. Areas of adequate mucosal visibility should be associated with 
high values of red intensity and areas of inadequate mucosal visibility as-
sociated with low values of green intensity. The CAC score was adapted to 
Mirocam® MC1200 system by Ponte et al, being considered an objective 
and feasible score in the assessment of small-bowel cleansing. About Ali 
et al, considered a CAC score cut-off of 1.6 to best discriminate adequately 
from inadequately cleansed frames. Recently, Mirocam® system created 
a new informatic software (MC1600) which enables capturing around 6 
frames per second, comparing with the 3 frames per second in MC1200.
aims & Methods: This study aimed to adapt the CAC score to the Miro-
cam® MC1600 system and evaluate the correlation of this computed score 
with Brotz grading scales (Quantitative Index - QI and Qualitative Evalua-
tion - QE) in the old CE MC1200 and in the new CE MC1600. The authors 
performed a retrospective single-center analysis of CE Mirocam® MC1200 
and MC1600. Patients with active bleeding and whose capsule did not 
reach the cecum were excluded from the study. The first duodenal im-
age and the first cecal image were selected from all CE videos, and all 
the remaining findings were deleted. Map View function displays a bar 
circumscribed by a blue line which represents the small bowel images. 
The histogram function of GIMP® was used to measure the mean inten-
sity value of the green and red channels. Afterwards, these values were 
entered into a database and the CAC score were determined according to 
the Weyenberg et al formula. The correlation between the CAC scores and 
the 10 points QI was performed using Spearman’s correlation coefficient. 
The CAC scores and the 4 grades QE were compared using the intra-class 
correlation coefficient (ICC).
results: 73 CE videos were analyzed referring to 73 patients, 53.4% were 
male (n=39), with a mean age of 54.2 (± 18.8) years-old. 58.9% (n=43) of 
the CE videos were performed with the MC1600, and 41.1% (n=30) with the 
MC1200. The main indication was OOGIB in 61.6% (n=45), followed by sus-
pected Crohn’s disease (CD) in 32.9% (n=24). The sex, age and indication to 
perform CE did not show to be different between the 2 softwares (p=0.23, 
p=0.06 and p=0.29, respectively). The QI (New: 8.16 vs. Old: 7.87, p=0.44) 
and a poor QE (New: 11.6% vs. Old: 6.7%, p=0.89) did not differ between the 
2 softwares. On the other hand, the CAC score was higher with the MC1600 
version (5.62 vs. 4.95, p=0.03). With the MC1600 version, a poor correlation 
between QI and CAC score was found with a Spearman’s Rho of 0.36 (p< 
0.05), and a poor correlation between QE and CAC score was found with an 
ICC of 0.15 (CI 95% = -0.11 to 0.44, p = 0.01). With the MC1200 version, a fair 
correlation between QI and CAC score was found with a Spearman’s Rho of 
0.48 (p< 0.01), and a poor correlation between QE and CAC score was found 
with an ICC of 0.21 (CI 95% = -0.18 to 0.56, p = 0.03).
conclusion: The new software (MC1600) presented higher CAC scores, 
which could be of great importance since this score allows a more objec-
tive assessment of small-bowel cleansing. With this new software version, 
the authors were not able to verify a better correlation between this com-
puted assessment and the Brotz grading scales. 
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Introduction: Although small bowel capsule endoscopy (SBCE) has be-
come the best diagnostic modality for small bowel lesion, time-consuming 
and tedious review process leads to low diagnostic yield.
aims & Methods: The aim of this study was to develop a convolutional 
neural network (CNN) algorithm for automatic detection of various small 
bowel lesions. A total of 3,313 still images containing pathology findings 
were collected from 389 SBCE videos. These were classified into two cat-
egories by expert readers: vascular lesion (red spot/angioectasia/active 
bleeding) and depressed lesion (erosion/ulcer/stricture). A VGG-like CNN 
[1] (14 convolutional, 7 max-pooling and 2 fully-connected layers) was 
implemented to extract features which carry principal characteristics of an 
input image in both categories. Then we combined the two different binary 
classification models (normal-vascular and normal-depressed) not only to 
detect two types of lesions from each model, but also to yield conserva-
tive negative. Furthermore, we visualized where the detected lesions are, 
class activation map (CAM), by calculating contributions of each pixel in a 
feature to the classification result [2].
results: The algorithm for detection of vascular lesions yielded a sensitiv-
ity of 88.3%, a specificity of 97.3%, a positive predictive value of 97.0%, a 
negative predictive value of 89.3%, and an accuracy of 92.8%. The algo-
rithm for detection of depressed lesions revealed a sensitivity of 88.9%, 
a specificity of 95.6%, a positive predictive value of 95.2%, a negative 
predictive value of 89.6%, and an accuracy of 90.0%. We combined these 
two algorithms in the way that a normal image was defined when it was 
not classified as a pathology image by either vascular or depressed lesion 
detection algorithm. As a result, the combined algorithm yielded a sensi-
tivity of 91.4%, a specificity of 93.2%, a positive predictive value of 93.1%, 
a negative predictive value of 91.6%, and an accuracy of 92.3%. Further-
more, CAM accurately pinpointed lesion parts from the pathology images, 
which means that it colored the lesion parts red but non-lesion parts blue.
conclusion: Our CNN algorithm showed high diagnostic performances for 
detecting various lesions of SBCE. Visualization of the relevant lesions by 
CAM could help to reduce missed detection with the naked eye.
references: 1. K. Simonyan and A. Zisserman, “Very Deep Convolu-
tional Networks for Large-Scale Image Recognition,” arXiv preprint arX-
iv:1409.15556, 2014. 2. R. R. Selvaraju, A. Das, R. Vedantam, M. Cogswell, 
D. Parikh, and D. Batra, “Grad-cam: Why did you say that? Visual explana-
tions from deep networks via gradient-based localization,” arXiv preprint 
arXiv:1610.02391, 2016.
disclosure: Funding: This research was supported by the Bio & Medical 
Technology Development Program of the National Research Foundation 
(NRF) funded by the Ministry of Science & ICT (NRF-2018M3A9E8021507). 
P1657 OPTIMaL PreParaTIOn fOr sMaLL BOWeL caPsuLe 
endOscOPy
Kametaka D.1, Ito M.1, Shiode J.1, Yoshioka M.2, Nasu J.1
1Okayama Saiseikai General Hospital, Okayama, Japan, 2Okayama Saiseikai 
General Hospital, Dept. of Gastroenterology, Okayama, Japan
contact e-Mail address: johnrambo851@yahoo.co.jp
Introduction: Visualization of the mucosa in Small bowel capsule endos-
copy (SBCE) is frequently impaired by intestinal contents (e.g. food residue, 
air bubbles and unclear turbid intraluminal fluid), more often in the lower 
small intestine where we tend to encounter more endoscopic and patho-
logical findings. A meta-analysis had shown that small-bowel purgative 
preparation (polyethylene glycol solution or sodium phosphate) improves 
the diagnostic yield (Am J Gastroenterol 2009; 104: 219-227). The Canadian 
Association of Gastroenterology (CAG) and the European Society of Gastro-
intestinal Endoscopy (ESGE) does recommend the use of a bowel prepara-
tion (Gastroenterology. 2017 Feb;152(3):497. Endoscopy 2010; 42: 220-227.), 
but no specific preparation regimen is shown.
aims & Methods: The aim of this study was to seek an appropriate 
preparation for SBCE. We reviewed a consecutive 340 patients (201:139/
male:female) who underwent SBCE from Jul. 2009 to Sep. 2017 in Okayama 
Saiseikai General Hospital and assessed retrospectively from the clinical 
record. SBCE was performed using the Given Imaging PillCam SB2 and 
SB3. For each SBCE, two segments of 10 minutes were selected, one at the 
last 10 minutes of the small intestine transit and one at the start of the last 
quartile of the small intestine transit time. Visibility of the SBCE image was 
assessed based on percentage of (or proportion) of 5 elements: (1) visual-
ized mucosa, (2) fluid and debris, (3) bubbles, (4) bile/chyme staining, and 
(5) brightness. 
Among 340 subjects, Group A followed the conventional overnight fast 
(n=58, 17.1%). Group B received 0.9L of magnesium citrate (MC) solution 
after the overnight fast, 2 hours prior to the endoscopy (n=84, 24.7%). 
Group C received 1~2L of polyethylene glycol (PEG) solution after the over-
night fast, 2 hours prior to the endoscopy (n=29, 8.5%). 
Group D received 1~2L of PEG solution after the overnight fast before colo-
noscopy, and SBCE was performed immediately after the negative colonos-
copy, but the duration was not assessable (n=117, 34.4%). 
Group E received 0.18L of MC solution before the overnight fast (n=24, 
7.1%). 28 subjects were excluded, 24 because the visibility was not assess-
able due to massive bleeding, unreached cecum, recording failure and 4 
because of preparation unknown.
results: The use of 0.9L of MC solutions led to a significant improvement 
in (4) bile/chyme staining (P=0.0101) and (5) brightness (P=0.0014). Also, 
(1) visualized mucosa (P=0.0826), (2) fluid and debris (P=0.0515), and (3) 
bubbles (P=0.0592) seemed to show a trend toward visibility improve-
ment. All the patients in Group B were able to ingest the whole 0.9L solu-
tions before the SBCE.
conclusion: Comparatively low volume (0.9L) MC solution improves visual 
quality of SBCE and was feasible.
disclosure: Nothing to disclose 
P1658 caPsuLe endOscOPy fOr sMaLL BOWeL crOhn’s 
dIsease - shOuLd We TrusT In MagneTIc resOnance 
enTerOgraPhy?
Xavier S.1,2,3, Boal Carvalho P.1,2,3, Dias de Castro F.1,2,3, Magalhães J.1,2,3, 
Rosa B.1,2,3, Moreira M.J.1,2,3, Cotter J.1,2,3
1Hospital da Senhora da Oliveira, Guimarães, Gastroenterology, Guimarães, 
Portugal, 2University of Minho, School of Medicine, Braga, Portugal, 
3University of Minho, ICVS/3Bs PT Government Associate Laboratory, Braga/
Guimarães, Portugal
contact e-Mail address: smaxavier@gmail.com
Introduction: Currently, both small bowel capsule endoscopy (SBCE) and 
magnetic resonance enterography (MRE) can be used to assess small bow-
el involvement in Crohn’s disease (CD). However, SBCE appears to be more 
sensitive in the detection of mild and proximal lesions.
aims & Methods: We aimed to compare the diagnostic yield for SBCE and 
MRE.
Adult patients with either confirmed or suspected Crohn’s disease who 
were submitted to both SBCE and MRE were retrospectively reviewed. Only 
patients performing SBCE and MRE within 3 months were included and 
patients with changes in CD therapy during this period were excluded.
Presence of ulcers, villous edema and stenosis were assessed in SBCE, and 
patients with Lewis Score (LS) ≥135 were considered to have significant 
inflammation. SB wall thickening, hyperenhancement, edema, comb sign 
or presence of ulcers were considered signs of active CD in MRE.
results: Included 30 patients (53.3% suspected and 46.7% confirmed CD) 
with a median age of 31±11 years, 56.7% of which were females. Com-
paring SBCE and MRE, SBCE had a significantly higher diagnostic yield 
(90.0% vs 53.3%, p=0.007), with higher detection of ileal lesions (83.3% 
vs 53.3%, p=0.022). 
Even more importantly, only SBCE identified jejunal inflammatory activ-
ity (46.7% vs 0.0%, p< 0.001). Despite the fact that statistical significance 
was not attained, SBCE identified 2 traversable strictures that were not 
identified by MRE (6.7% vs 0.0%, p=0.500) and out of 14 patients with 
suspected Crohn’s disease, SBCE identified significant inflammation in 4 
patients with negative MRE (85.7% vs 57.1%, p=0.289). MRE was more 
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likely to detect findings when SBCE showed moderate to severe inflamma-
tory activity (LS ≥790) compared with those with mild inflammatory activity 
(LS 135-790) (72.7% vs 30.8%, p=0.041).
conclusion: In our cohort, SBCE showed a significant overall higher diag-
nostic yield than MRE, with higher detection of distal lesions and, more 
importantly, SBCE identified proximal lesions in nearly half of examination 
while MRE was unable to identify any case. MRE diagnostic yield was more 
heavily influenced by the severity of inflammatory activity, being signifi-
cantly inferior to SBCE in patients with mild inflammatory activity.
disclosure: Nothing to disclose 
P1659 vIdeO caPsuLe cOLOnOscOPy: May There Be 
PredIcTOrs Of cOLOrecTaL POLyPs fIndIngs afTer IncOMPLeTe 
cOnvenTIOnaL cOLOnOscOPy?
Macedo Silva V.1,2,3, Magalhães R.1,2,3, Rosa B.1,2,3, Boal Carvalho P.1,2,3, 
Moreira M.J.1,2,3, Cotter J.1,2,3
1Hospital Senhora da Oliveira, Gastroenterology Department, Guimarães, 
Portugal, 2Life and Health Sciences Research Institute, University of 
Minho, Braga/Guimarães, Portugal, 3ICVS/3B’s, PT Government Associate 
Laboratory, Braga/Guimarães, Portugal
contact e-Mail address: rui.magalhaes.med@gmail.com
Introduction: Even though conventional colonoscopy remains as the first 
line approach in colorectal polyps detection, Video Capsule Endoscopy 
(VCE) may play an important role on further investigation after an incom-
plete colonoscopy.
aims & Methods: Our aim was to evaluate the existence of predictive fac-
tors for colorectal polyps detection by VCE on patients with previous in-
complete conventional colonoscopy.
For that, a retrospective monocentric study of patients who underwent VCE 
after previous incomplete colonoscopy between April 2015 and January 
2019 was carried out. Analyzed variables included age, gender, capsule’s 
transit time in colon, previous hemoglobin, positive fecal occult blood test, 
personal history of colorectal polyps, familiar history of colorectal cancer, 
smoking habits, obesity, progression level on the incomplete colonoscopy 
and existence of previous complete colonoscopy. Mann-Whitney test was 
used for evaluation of continuous variables and Chi-square test for cat-
egorical variables.
results: 59 patients were included, 49 being females (83.1%), with a me-
dian age of 68 (interquartile range of 18). Colorectal polyps were docu-
mented in 18 patients (30.5%), with sessile polyps prevailing (88.9% of 
the patients with positive findings). 17 of these patients (94.4%) presented 
polyps in locations not previously approached by the incomplete colonos-
copy. Smoking habits (former or current) were significantly associated with 
the detection of colorectal polyps after incomplete colonoscopy (66.7% vs 
26.0%; p=.041). Other analyzed variables did not show any statistically sig-
nificative differences (p>0.05).
conclusion: VCE is a very useful technique to be used on further inves-
tigation of patients with previous incomplete conventional colonoscopy, 
allowing to detect colorectal polyps in around one-third of the evaluated 
patients. There was a significant association between smoking habits and 
colorectal polyps on VCE.
disclosure: Nothing to disclose 
P1660 cLeanLIness scOres fOr sMaLL BOWeL caPsuLe 
endOscOPy: an exTernaL (un)vaLIdaTIOn sTudy
Le Mouel J.-P.1, Houist G.2, Saurin J.C.3, Cholet F.4, Leenhardt R.2, 
Vanbiervliet G.5, Leandri C.6, Rahmi G.7, Kirchgesner J.2, Duburque C.8, 
Dray X.2,9
1CHU Amiens Picardie, Gastroenterology, Amiens, France, 2Sorbonne 
University, Hepato-Gastroenterology and Digestive Endoscopy, APHP, Saint 
Antoine Hospital, Paris, France, 3Hospices Civils de Lyon, Lyon Cedex 03, 
France, 4Chu La Cavale Blanche, Endoscopy Unit, Brest, France, 5CHU, Hôpital 
L’Archet 2, Gastroenterology, Nice, France, 6Cochin University Hospital, 
Gastroenterology, Paris, France, 7Hôpital Européen Georges Pompidou, 
Gastroenterology, Paris, France, 8Groupement des Hopitaux de l’Institut 
Catholique de Lille, Gastroenterology, Lille, France, 9Paris 6 University and 
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contact e-Mail address: jeanphilippe.lemouel@wanadoo.fr
Introduction: Small bowel (SB) capsule endoscopy (CE) is a standard for 
the examination of the SB in patients with occult gastrointestinal bleed-
ing (OGIB) or suspicion of Crohn’s disease. The detection of lesions in CE 
may be dependent on the quality of the visualization of the SB. Brotz et 
al. developed 3 different scores to assess the SB cleanliness: one quantita-
tive score named Qualitative Index (QI); and two qualitative scores named 
Qualitative Evaluation (QE), and Overall Adequacy Assessment (OAA). After 
internal validation these 3 scores were considered as a reference. However, 
no external validation of any of these score has been performed to date. 
The aim of our study was to assess their reproducibility.
aims & Methods: One hundred and fifty-five complete, third-generation 
SB-CE videos were analysed. These videos were extracted from a recent, 
randomized, controlled multicenter trial (PREPINTEST, NCT01267981); 
which evaluated three different modalities of preparation of SB, in 834 
patients with OGIB; by selecting third-generation SB-CE from the 5 larg-
est inclusion centres. All 155 videos were read twice, in a random order, 
at six-week interval, by three SB-CE expert readers. The 3 scores (QI, QE, 
OAA) were determined by each expert independently, using the definitions 
of the initial study: 
- QI was based on a 10-point scale, with 2 points allotted to each of five 
items amongst mucosa visibility, fluid and debris, bubbles, bile/chyme 
staining, brightness; 
- QE based on QI items but simplified, grading the cleansing of the SB as 
poor, fair, good and excellent; 
- OAA was defined by the “adequacy” or “inadequacy” of the preparation. 
Linear weighted Cohen’s Kappa were calculated to assess intra-observer 
and inter-observer reproducibility for each score.
results: Intra-observer reproducibility was fair to moderate, with Kappa 
coefficients varying between 0.37-0.46, 0.41-0.51 and 0.41-0.50 for QI, QE 
and OAA, respectively. 
Inter-observer reproducibility was fair to substantial correlation, with Kap-
pa coefficients between experts varying between 0.40-0.64, 0.29-0.65 and 
0.52-0.71 for QI, QE and OAA, respectively (Table 1). 
 
qualitative index (qI) 
Mean (range)
qualitative evaluation 
(qe) Mean (range)
Overall adequacy 
assessment (Oaa) 
Mean (range)
first reading (at week-0, random order)
expert 1 vs 2 0.49 (0.41 - 0.58) 0.48 (0.37 - 0.59) 0.52 (0.27 - 0.77)
expert 1 vs 3 0.57 (0.49 - 0.66) 0.53 (0.42 - 0.64) 0.70 (0.48 - 0.91)
expert 2 vs 3 0.55 (0.47 - 0.63) 0.65 (0.55 - 0.75) 0.66 (0.45 - 0.88)
second reading (at week-6, random order)
expert 1 vs 2 0.40 (0.30 - 0.49) 0.29 (0.17 - 0.40) 0.52 (0.34 - 0.71)
expert 1 vs 3 0.46 (0.37 - 0.54) 0.43 (0.32 - 0.54) 0.67 (0.51 - 0.82)
expert 2 vs 3 0.64 (0.57 - 0.71) 0.53 (0.42 - 0.65) 0.71 (0.57 - 0.86)
[Table 1: Inter-observer reproducibility of three scores assessing small bowel 
cleanliness in capsule endoscopy]
Specifically, some of the 5 QI items were poorly reproducible, and par-
ticularly the evaluation of the amount of bile and chime, with Kappa coef-
ficient varying from 0.21 to 0.29 and from 0.16 to 0.34, for intra and inter-
observer reproducibility, respectively.
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conclusion: One of the main preparation score used in research studies 
proved to be poorly reproducible wenhever the same or a different reader 
was used as comparator. There is a major need for improved preparation 
scores to allow satisfying data analysis in small bowel capsule endoscopy.
references: Brotz C, et al. Gastrointest Endosc. 2009;69:262-70
disclosure: Nothing to disclose 
P1661 accuracy Of arTIfIcIaL InTeLLIgence aIded rePOrTIng 
In vIdeO caPsuLe endOscOPy
Hong Y.Y.1, Ninh A.2, Corbett G.1
1Cambridge University Hospital, Department of Gastroenterology, Cambridge, 
United Kingdom, 2Docbot, California, United States
contact e-Mail address: hyouyi@yahoo.com
Introduction: Video Capsule Endoscopy (VCE) is primarily used for diag-
nostic examination for the area of small bowel, which cannot be assessed 
by conventional gastroscopy or colonoscopy. VCE offers a variety of ad-
vantages like being non-invasive, easily tolerable with small swallowed 
capsule, painless, sedation free, potentially avoidance of harmful radiation 
and invasive investigations. 
However, the reviewing and examination of each VCE can be a tedious and 
time-consuming process, potentially taking up to 1-2 hours (depending 
on experience) of a Gastroenterologist time. A new Artificial Intelligence 
(AI) algorithm - Docbot CapsuleAI version 1.3, which consists of a multi-
class convolutional neural network and pHash post-processing algorithms, 
was developed to highlight and present the potential clinically significant 
frames, with the aim to reduce the reviewing time and improve the ac-
curacy of VCE reporting.
aims & Methods: To examine the accuracy of this new AI aided reporting 
system (Docbot CapsuleAI version 1.3) in VCE. 
50 anonymized VCEs (pre-reported by Gastroenterologists, inclusive of 
40 VCEs with abnormal findings and 10 VCEs with normal findings) were 
selected to test the diagnostic accuracy of the new AI algorithm (Docbot 
CapsuleAI version 1.3) in aiding the reporting process. All the frames high-
lighted by AI, will be subsequently reviewed by 2 Gastroenterologists, to 
determine the sensitivity, specific and accuracy of the AI aided diagnostic 
system, against the gold standard of human reporting by Gastroenterolo-
gist.
results: Out of the total 50 VCEs, the AI algorithm picked up an average 
total frame of 190 per VCE (Min=27, Max =417). There were lower number of 
average total frames picked up by AI for the normal VCEs = 168 Vs abnor-
mal VCEs =195. For the abnormal VCEs, the average number of abnormal 
frames picked up by AI were 22.
Overall, this AI algorithm has the sensitivity of 95%, specificity of 100% 
with the accuracy of 96%, in picking up the clinically significant frames, 
for the final diagnostic reporting of VCE. 
The AI algorithm has successfully highlighting clinically significant frames 
(ranging from normal, vascular lesion, ulcer, erosion, tumour, stricture, 
and inflammation) in 48 out of 50 VCEs. 2 VCEs with abnormal finding 
which were not picking up by the AI algorithm were small duodenal polyp 
and sub-mucosal lipoma.
conclusion: The new AI algorithm has high sensitivity, specificity and ac-
curacy in highlighting clinically significant frames to clinician, helping to 
improve time spent and accuracy of VCE reporting.
disclosure: Nothing to disclose 
P1662 WOrLd’s LargesT serIes WITh caPsOcaM®. 
feasIBILITy, cOMPLeTIOn and deTecTIOn raTe Of The neW 
generaTIOn Of caPsuLe endOscOPe WITh a 360° LaTeraL 
PanOraMIc vIeW - a sIngLe cenTer reTrOsPecTIve sTudy
Pachofszky T., Holzmüller P., Madl C.
KA Rudolfstiftung, IV. Department of Internal Medicine with 
Gastroenterology, Hepatology, Endoscopy and Oncology, Vienna, Austria
contact e-Mail address: thomas.pachofszky@gmx.at
Introduction: Capsule endoscopy started in 2000 a revolution in diagnos-
ing small bowel diseases. The first capsule endoscope was M2A® with one 
camera at one end of the capsule (Given Imaging, Yoqneam, Israel). It 
was the first time that direct visualization of the entire small bowel was 
possible. From this year onwards, we can see a rising number of examina-
tions and indications for capsule endoscopy. The drawback of the endview 
capsule is the limited view - PillCam SB3®(Medtronics, Dublin, Ireland) 
156°, MiroCam®(IntroMedic, Seoul, Korea), 170°.
With the introduction of CapsoCam®(CapsoVision, Saratoga, CA, USA) with 
a lateral panoramic view of 360°, now we have a total view on the mucosa. 
Because of this 360° lateral panoramic view, we have the chance to get a 
better detection rate for capsule endoscopy.
aims & Methods: The aim of this single center retrospective study was to 
compare the different capsule systems used at the KA Rudolfstiftung, Vi-
enna, Austria (CapsoCam®, PillCam®, MiroCam®), in respect to visibility of 
the Papilla of Vater, completion rate, detection rate (defined as pathology 
identified according to the indication), loss of data because of technical 
problems, image quality, download and reading time of the 360° lateral 
panoramic view of CapsoCam® and the endview systems including Pill-
Cam® and MiroCam®. 
Included are examinations from 2012 to 2018 with the CapsoCam® system 
including the three generations of SV1®, SV2® and CapsoCam Plus®: 852 
(CapsoCam Plus®:516), and the PillCam SB2® and SB3®: 803 and Miro-
Cam®: 315 - a total of 1970 examinations.
results: Visibility of Papilla of Vater: CapsoCam® 81.7%; Endview 9.6%
Complete examination: CapsoCam® 97.4%; Endview 84.8%
Detection rate: CapsoCam® 51.3%; Endview 44.6%; p-value: 0.003901
Loss of data: CapsoCam® 3.1%; Endview 6%
Download time: CapsoCam® 15 min; PillCam SB3® 90 min; MiroCam® 35 min
Reading time: CapsoCam® 15-20 min; PillCam SB3® 30-40 min; MiroCam® 
30-40 min
conclusion: CapsoCam® showed an excellent visibility of the Papilla of 
Vater at more than 80% and a complete examination of the small bowel 
at more than 97%. These numbers are the highest published data to this 
time. In our series, the CapsoCam® is superior in finding relevant patholo-
gies according to the indication with a p-value of 0.0039
The main fear of experts about the loss of data because of the inability to 
retrieve the excreted CapsoCam® can be rejected. In our study we found 
twice the data loss in the endview group because of problems with the 
data recorder, SD-card or the sensor belt. With CapsoCam Plus®we have 
the same image quality as with the PillCam SB3®. Because of these data, 
the fastest download and reading time CapsoCam Plus® have a clear ben-
efit compared with the established endview systems.
disclosure: Consultant for Medtronic, Boston Scientific, CapsoVision 
P1663 hIgh-rIsk facTOrs fOr gasTrIc reTenTIOn In sMaLL 
BOWeL caPsuLe endOscOPy. a sIngLe cenTre reTrOsPecTIve 
cOMParaTIve sTudy
O’Riordan F.1, Reidy M.1, Sim Yan En S.1, McNamara D.1,2, Wong J.1, 
Manoharan T.1, Semenov S.1,2, Omorogbe J.1, Ryan B.1,2, O’Connor A.1,2, 
Breslin N.1,2
1Tallaght Hospital/Trinity College Dublin, Gastroenterology, Dublin, Ireland, 
2Trinity Academic Gastroenterology Group, Clinical Medicine, Dublin, Ireland
contact e-Mail address: fionaoriordan85@gmail.com
Introduction: Certain conditions and medications have been identified 
as risk factors for gastric capsule retention (GCR). ESGE guidance recom-
mends the use a real-time viewer to guide appropriate early preventa-
tive intervention such as prokinetic administration when delayed gastric 
emptying occurs.
aims & Methods: To examine the prevalence and associations of GCR in an 
Irish cohort and to compare findings against a control group. Patients with 
video confirmation of gastric retention for the duration of the study were 
identified from a small bowel capsule endoscopy (SBCE) database of 3078 
cases. Using this database, we also retrospectively identified patients who 
underwent a SBCE immediately after each GCR patient without retention. 
These patients were used as controls. Demographic and clinical data was 
extracted from medical records. Cases and controls were compared using 
a chi2 test, a p value of < 0.05 was considered significant.
results: A total of 70 GCR cases were identified giving an occurrence rate 
of 2.3%. Data was available for 61 GCR and 55 control patients. There 
were more females than males in both groups; 36/61 (59.1%) GCR group 
and the 34/55 (61.8%) control group. The mean age was 58 years in both 
groups. In keeping with standard SBCE practice, the commonest indica-
tions for SBCE were iron deficiency anaemia [32/62(52%) GCR group and 
20/55(36%) control group] and suspected Crohn’s disease [15/61(25%) 
GCR group and 17/55(31%) control group]. 
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There was significantly more patients with hypothyroidism in the GCR 
group 12/61 (20%) vs 4/55 (7%) than in the control group [P = 0.0438]. 
There was no difference in the rate of diabetes [10/61(16%)) GCR group 
vs 9/55(16%) control group [P =1.000]] nor psychotropic medication use 
[14/61 (23%) GCR group vs 16 (29%) control group [P = 0.4630]]. While 
there were over twice as many patients 14/61 (23%) in the GCR group with 
more than one associated risk factor vs the control group 6/55 11%) this 
was not statistically significant [P = 0.0894]. Interestingly, there were sig-
nificantly less current or ex-smokers 18/61 (30%) in the GCR group versus 
28/55 (51%) in the control group [P = 0.0217].
conclusion: GCR was a relatively frequent occurrence in our large cap-
sule population. In our cohort, only hypothyroidism was associated with 
an increased risk of GCR. Contrary to published data, older age, female 
gender, smoking, diabetes and use of psychotropic medications were not 
predictive. Our data suggests current predictive measures of GCR are inad-
equate and unlikely to accurately select patients for real time monitoring 
and appropriate early intervention. The role of multiple risk factors for GCR 
prediction warrants further evaluation.
disclosure: Nothing to disclose 
P1664 effecT Of InTravenOus MeTOcLOPraMIde On sMaLL 
BOWeL TransIT TIMe durIng MagneTIc caPsuLe endOscOPy 
exaMInaTIOn: a PrOsPecTIve, randOMIzed sTudy
Schmiedt P.1, Lovasz B.D.2, Szalai M.1, Kiss E.3, Oczella L.1, Dubravcsik Z.4, 
Madacsy L.1
1Endo-Kapszula Health Center and Endoscopy Unit, Székesfehérvár, Hungary, 
2Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 
3Szent Imre Hospital, Budapest, Hungary, 4Bacs-Kiskun County Hospital, 
Gastroenterology & Endoscopy, Kecskemét, Hungary
contact e-Mail address: endomabt1@gmail.com
Introduction: Diagnostic yield with capsule endoscopy (CE) is limited by 
incomplete study due to slow small-bowel transit and poor view quality 
in the distal bowel. Prokinetics may increase gastric transit time, but cur-
rently, there are conflicting results regarding the effect of metoclopramide 
on small bowel transit time and optimal preparation protocol during CE.
aims & Methods: aim of our present study was to investigate whether in-
travenous metoclopramide accelerates small bowel transit time and in-
creases the completion rate of CE examination.
191 patients who underwent magnetic capsule endoscopy (MACE) after 6 
hours of fasting period were randomized to receive either 5 mg intravenous 
metoclopramide (metoclopramide (MC) group: 103 cases) or no prokinetic 
treatment at all (control (C) group: 88 cases), after the completion of a 30 
min automated gastric mucosal surface robotic examination protocol. Dur-
ing the small bowel examination period all patients in each group received 
1000 ml PEG solution to improve visibility of the distal small bowel.
results: PEG administration during CE resulted in an excellent small bowel 
and distal ileal mucosal visibility which was demonstrated in both patient 
groups without significant differences. Complete small bowel examination 
was detected in 100/103 (97%) in the MC group, and 87/88 (98%) of the C 
group, without significant differences. However, we demonstrated signifi-
cant differences in the small bowel transit time between the MC and the C 
group, 3:07:41+1:57:47 vs. 4:03:01+1:52:19 (p=0,00007), respectively.
conclusion: Intravenous metoclopramide proved to have a significant ef-
fect on shortening the small bowel transit time, but it has no effect on 
the completeness of the entire small bowel visibility, which is due to the 
fact of long-lasting operation time and possibility of active pyloric passage 
of MACE. One liter of PEG administration during the small bowel transit 
period might improve the quality of distal ileal mucosal visibility and have 
an additive effect on the high success rate to accomplish combined gastric 
and small bowel MACE examinations.
disclosure: Nothing to disclose 
P1665 PrevaLence and rIsk facTOrs fOr duOdenaL 
PerfOraTIOn due TO MIgraTed BILIary PLasTIc sTenTs
Stassen P.M.C., de Jong D.M., Poley J.W., Bruno M.J., de Jonge P.J.F.
Erasmus MC, University Medical Center Rotterdam, Department of 
Gastroenterology & Hepatology, Rotterdam, Netherlands
contact e-Mail address: p.stassen@erasmusmc.nl
Introduction: Transpapillary biliary drainage by stent placement through 
endoscopic retrograde cholangiography (ERC) is a well-established treat-
ment for bile duct obstruction. Migrated stent-induced perforation of the 
duodenal wall can be a potentially life-threatening complication. The ac-
tual prevalence of this complication is however unknown and risk factors 
for perforation are unclear.
aims & Methods: We aimed to analyze the prevalence, risk factors and 
clinical course of migrated stent-induced duodenal perforation (MSDP). 
All consecutive patients who underwent an ERC with biliary plastic stent 
placement during the study period January 1st 2014 till December 31st 2017 
in our center were retrospectively analyzed. Data on demographic factors, 
medical history, indication for ERC, biliary stricture and stent characteris-
tics were systematically collected in all patients. In addition, for patients 
who were diagnosed with a MSDP, date of perforation, clinical presenta-
tion at diagnosis, type of treatment of perforation and outcome of treat-
ment were reviewed.
results: During the study period, a total number of 2487 ERCs were per-
formed in 1228 patients (mean age 59 years, 59% male). In 630 patients 
(51%), a biliary plastic stent was placed; in 304 patients (25%), one or 
more stents were placed for perihilar strictures.
A total of 14 MSDPs were diagnosed in 13 patients (mean age 63 years, 79% 
male). All perforations occurred in patients with a perihilar stricture. The 
overall prevalence of MSDP was 1,1% in all patients who underwent an 
ERC, 2,2% for patients who underwent ERC with biliary stent placement 
and 4,6% for patients with a biliary stent for a perihilar stricture.
The median length of the stents was 15 cm (IQR 12-15 cm), perforation did 
not occur with stents shorter than 12 cm. Perforation occurred both with 7 
and 10 French stents (21% and 79% resp.), and with either center or duo-
denal bend type stents (42% and 58% resp.). The stenosis was malignant 
in 8 patients (57%). The majority of perforated stents were deployed with 
the proximal tip in the left intrahepatic ducts (57%). Biliary sphincterotomy 
and stricture balloon dilation were not significantly associated with MSDP. 
Median time to diagnosis of perforation was 13 days (IQR, 4-66 days). In 
71% of the patients (n=10) duodenal perforation was clinically suspected 
due to presentation with abdominal pain, fever and/or laboratory abnor-
malities. 4/14 patients were asymptomatic and MSDP was diagnosed at 
elective stent retrieval. Treatment was either conservative by removal of 
the stent, endoscopic closure with an over the scope clip (OTSC) or surgery 
in respectively 36% (n=5), 57% (n=8) and 7% (n=1) of the patients. Two 
patients died due to ongoing abdominal sepsis (14%), despite repeated 
endoscopic, percutaneous and surgical interventions.
conclusion: This is the first study to report on the prevalence of MSDP in 
patients who undergo ERC. Despite the overall low risk of MSDP, it repre-
sents a potentially life threatening complication of ERC after transpapillary 
drainage for perihilar biliary strictures. The risk of MSDP needs to be ac-
knowledged for this indication and warrants consideration in symptomatic 
patients after ERC.
disclosure: Nothing to disclose 
P1666 sTenT seLecTIOn fOr PreOPeraTIve draInage 
Of a dIsTaL MaLIgnanT BILIary OBsTrucTIOn
Kohisa J., Yoshikawa S., Miida S., Hojo Y., Azumi M., Takeuchi M.
Nagaoka Red Cross Hospital, Nagaoka, Japan
contact e-Mail address: jun-g2588@angel.ocn.ne.jp
Introduction: For stent placement in cases of unresectable distal malig-
nant biliary obstruction, self-expandable metallic stents (SEMS) are rec-
ommended, as they have a longer patency period than plastic stents (PS). 
However, there has been no consensus on the types of stents that should 
be recommended for preoperative drainage. In recent years, preopera-
tive adjuvant therapy has been increasingly adopted in the clinic, and the 
preoperative waiting periods have lengthened in an increasing number of 
cases. This study examined the selection of stents for preoperative drain-
age.
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aims & Methods: For stent placement in cases of unresectable distal ma-
lignant biliary obstruction, self-expandable metallic stents (SEMS) are rec-
ommended, as they have a longer patency period than plastic stents (PS). 
However, there has been no consensus on the types of stents that should 
be recommended for preoperative drainage. In recent years, preopera-
tive adjuvant therapy has been increasingly adopted in the clinic, and the 
preoperative waiting periods have lengthened in an increasing number of 
cases. This study examined the selection of stents for preoperative drain-
age.
results: The median patient age was 72 years, and the sex breakdown was 
37 men and 11 women. The causative diseases included pancreatic cancer 
in 26 cases, bile duct cancer in 14 cases, papillary cancer in 7 cases, and 
intraductal papillary-mucinous carcinoma in one case. Stent malfunction 
was observed in one case in the SEMS group (6.7%) and in eight cases in 
the PS group (24.2%). The mean estimated patency periods that were ob-
tained through the Kaplan-Meier method were 136 days in the SEMS group 
and 74 days in the PS group, and the mean period was significantly longer 
in the SEMS group (p=0.043). The median technical costs were 359,340 JPY 
in the SEMS group and 170,710 JPY in the PS group, which indicates that 
the cost was higher in the SEMS group. On the other hand, in patients who 
received multiple treatments, the median technical cost in the PS group 
was 331,580 JPY, and there was no significant difference from that in the 
SEMS group (p=0.220). Procedural accidents included acute pancreatitis 
in two cases in the SEMS group (13.3%) and acute cholangitis in one case 
in the PS group (3.0%), and both cases were mild. The mean estimated 
preoperative waiting periods were 28 days in the non-NA group and 131 
days in the NA group.
conclusion: As preoperative waiting periods were shorter in the non-NA 
group, the patency period of PS was sufficient for this group. Since the cost 
that is incurred by the use of PS is low, PS is recommended for patients in 
the non-NA group. On the other hand, preoperative waiting periods are 
long in the NA group, and the use of PS for this group would likely require 
multiple treatments. Therefore, from the perspectives of cost and invasive-
ness, SEMS is recommended for patients in the NA group.
disclosure: Nothing to disclose 
P1667 cOncOMITanT MaLIgnanT duOdenaL and BILIary 
sTenOsIs: duOdenaL sTenTIng and hePaTIcOgasTrOsTOMy 
durIng The saMe PrOcedure Is a safeTy PrOcedure 
(saMeTIMe sTudy)
Debourdeau A.1, Caillol F.2, Ratone J.P.2, Zemmour C.1, Decoster C.1, 
Winkler J.1, Pesenti C.2, Bories E.1, Giovannini M.2
1Institute Paoli Calmettes, Marseille, France, 2Institute Paoli Calmettes, 
Endoscopy, Marseille, France
contact e-Mail address: antoinedebourdeau@hotmail.com
Introduction: The concomitant biliary and duodenal malignant stenosis is 
a rare event, reflecting a locally advanced neoplastic process. Endoscopic 
management is usually an association of duodenal and biliary retrograde 
stenting. EUS biliary drainage is an alternative drainage for these patients 
with inaccessible papilla. We conducted a single retrospective study to 
evaluate EUS biliary drainage in association duodenal stenting.
aims & Methods: Patients were included from 01.01.2011 to 31.12.2017. Pa-
tients were included if they had palliative endoscopic management with 
biliary drainage and duodenal stenting in the same time or within 7 days 
or less for concomitant bilio-duodenal malignant stenosis. Patients were 
extracted from our database with ConSore soft.
Patients were divided into several groups for statistical analysis. 
First, according to the timing of biliary drainage: in the SAMETIME drain-
age group if the two procedures were done on the same day and in the 
DEFFERED drainage group if the two procedures were done in different 
days (< 7 days). 
And secondly, depending on the biliary drainage method used: EUS-HG 
if hepaticogastrostomy or DUODENALACCESS if the drainage was done by 
ERCP, radiological or choledoduodenostomy.
results: From 01.01.2011 to 31.12.2017 31 patients were included (19 women, 
mean age=66). Stenosis was related to pancreatic cancer for 17 patients 
(54%), colorectal cancer for 4 (12.9%), breast cancer metastases for 3 
(9.7%), vesicular adenocarcinoma for 3 (9,7%), duodenal adenocarcinoma 
for 1 (3.2%), uterine sarcoma for 1 (3.2%), ovarian cancer metastases for 1 
(3.2%) and one gastric adenocarcinoma (3.2%). Patients had an average 
Karnofsky index of 72%, the average preoperative bilirubin was 143µmol/L. 
Sixteen (52%) patients were in the SAMETIME group, 15 in the DEFFERED: 
11 (35%) with biliary drainage after duodenal stenting and 4 (13%) with 
biliary drainage before duodenal stenting.
Biliary drainage was done by EUS-HG for 11 (35%) patients, by DUODENA-
LACCESS for 20 (65%): percutaneous path for 11 (35%) patients, by ERCP 
for 8 patients (26%) and choledoduodenostomy for 1 patient.
30 of 31 patients died during follow-up. Median survival was 76 days 
(mean 152 days +/-206).
Patients in the group SAMETIME had significantly shorter hospitalization 
than the DEFFERED group: 7.47 days vs 12,5 days (p=0.035). The SAMETIME 
group trended to have a lower rate of significant postoperative complica-
tions (27% VS 56%; p=0.0953).
The EUS-HG group trended to have lower rate of significant postoperative 
complications Dindo-Clavien classification> III (18% VS 55% p=0.065) and 
less biliary endoscopic revision (9% VS 30% p=0.37).
conclusion: In case of double biliary and duodenal obstruction, SAME-
TIME drainage is associated with a halved hospitalization time and prob-
ably with less adverse events than a two procedures drainage. In case 
of double stenosis EUS-HG should be preferred. No more complication 
were described in our study than others drainage and on the contrary a 
tendancy to better patency, less complication, and in current practice an 
easier re-intervention for stent obstruction.
disclosure: Nothing to disclose 
P1668 WIThdraWn
P1669 The effecTIveness and safeTy Of endOscOPIc 
TransPaPILLary gaLLBLadder sTenTIng fOr PaTIenTs 
WITh acuTe chOLecysTITIs
Sekine K., Doi S., Kuniyoshi N., Tsujikawa T., Mabuchi M., Yasuda I.
Teikyo University Mizonokuchi Hospital, Gastroenterology, Kanagawa, Japan
contact e-Mail address: hawaiiantuberider@gmail.com
Introduction: The gold standard definitive therapy for acute cholecystitis 
is cholecystectomy. However, it is not possible to perform cholecystectomy 
all the time, especially in poor performance status patients. In those cases, 
the Endoscopic transpapillary gallbladder stenting (EGBS) is more effective 
rather than other drainage methods. EGBS is relatively new gallbladder 
drainage method for acute cholecystitis. Therefore, the effectiveness and 
safety of EGBS has not been considered enough.
aims & Methods: We evaluate the effectiveness and safety of EGBS for 
acute cholecystitis.
This retrospective cohort study included the patients which had diagnosed 
for acute cholecystitis and underwent EGBS at our institution between 
September 2012 and January 2018. The primary endpoint of this study was 
a technical success rate of EGBS. The adverse events of EGBS and recur-
rence of the cholecystitis after undergoing EGBS were also considered.
results: A total of 111 patients (77 men and 34 women; median age 66 
years) underwent EGBS. The severity assessments of acute cholecystitis 
were 46 mild, 60 moderate, and 5 severe. The technical success rate for 
EGBS was 80.0% (89/111). Among them, 36 patients had common bile duct 
and were performed for endoscopic lithotripsy. The adverse events of EGBS 
were observed in 6 patients. Of these, 3 patients were penetration of cys-
tic duct, 2 patients were pancreatitis, and 1 patient was bleeding during 
Endoscopic sphincterotomy. No recurrence of acute cholecystitis was ob-
served during waiting periods for cholecystectomy after EGBS.
conclusion: The success rate of EGBS was relatively high and recurrence 
of cholecystitis was not observed. In addition, the adverse event rate was 
also low. Therefore, we consider that EGBS is effectiveness and safety, and 
becomes one of the effective treatments for acute cholecystitis.
disclosure: Nothing to disclose 
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P1670 characTerIsTIcs Of MajOr duOdenaL PaPILLa In 
effIcacy and safeTy Of needLe-knIfe fIsTuLOTOMy
Sadeghi A.1, Asadzadeh Aghdaei H.1, Pasharavesh L.2, Zabandan N.3, 
Ahmadi S.4, Zali M.R.1
1Research Center for Gastroenterology and Liver Disease of Shahid Beheshti 
University of Medical Sciences, Tehran, Iran (Islamic Republic of), 2Research 
Center for Gastroenterology and Liver Disease of Shahid Beheshti University 
of Medical Sciences, Liver Disease, Tehran, Iran (Islamic Republic of), 
3Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic 
Republic of), 4Imperial College London, London, United Kingdom
contact e-Mail address: hamid.asadzadeh@gmail.com
Introduction: Needle-knife Fistulotomy (NKF) is a commonly used rescue 
method for biliary cannulation in challenging ERCP cases. The type of Ma-
jor Duodenal Papilla (MDP) is suggested to be an effective factor in selec-
tion of patients suitable for NKF. However, data from clinical studies is 
scarce. In this study we aim to compare the success and complication rates 
of NKF between three types of MDP.
aims & Methods: The study samples were patients who experienced diffi-
cult cannulation during an elective ERCP procedure conducted in an affili-
ated university hospital between September 2017 and March 2018. The suc-
cess and complication rates of NKF administered for these patients were 
compared by the patients’ type of MDP. Three categories of MDP (small, 
bulging, long) were defined based on the anatomical characteristics ob-
served during endoscopy.
results: A total of 72 patients (35 men, 37 women; mean ± SD age 62.3±15.5 
years) underwent NKF and were classified into 3 groups of small (N=24), 
bulging (N=20) and long (N=28) MDP. The overall success rate of NKF was 
70.8%, which was highest in patients in the bulging MDP group (90%), 
followed by the small (75%), and long (53.6%) MDP groups (P=0.02). 
The total complication rate was 59.7%, including post ERCP Pancreatitis 
(13.9%), bleeding (19.4%), perforation (4.2%) and asymptomatic hyper-
amylasemia (25%). Overall complication rates were lowest among pa-
tients in the small MDP (45.8%) followed by budging MDP (55%) groups 
and highest in the long MDP groups (78.6%) (P=0.03).
conclusion: Characteristics of MDP is an important factor for selection pa-
tients for NKF. The best outcome for NKF (highest success and lowest com-
plication rate) was achieved in patients with bulging MDP and the worst 
outcome (lowest success and highest complication rate) was observed in 
patients with long MDP.
disclosure: Nothing to disclose 
P1671 InTraducTaL vs. TransPaPILLary fuLLy cOvered MeTaL 
sTenT PLaceMenT fOr MaLIgnanT BILIary sTrIcTures
Taniguchi Y.
Kobe city Medical Center General Hospital / Japan, Gastroenterology, Kobe, 
Japan
contact e-Mail address: guuguuyouhei@hotmail.com
Introduction: Endoscopic trannspapillary placement of a metal stent (MS) 
for treatment of a malignant biliary stricture has been widely accepted 
as a standard palliative biliary drainage technique. A conventional fully 
covered metal stent is placed across the duodenal papilla. Duodenobiliary 
reflux though a biliary stent placed across the major duodenal papillary is 
considered to be a predisposing factor for stent occlusion and cholangitis. 
Intraductal placement of a biliary stent above the duodenal papilla (inside 
stent) may be associated with longer stent patency and a lower occlusion 
rate because of reduced duodenobiliary reflux.
aims & Methods: The aim of this study was to determine whether intra-
ductal fully covered metal stent placement(IP) or transpapillary fully cov-
ered metal stent placement(TP) is a better therapeutic technique for- ma-
lignant biliary strictures.
From January 2016 to December 2018, a total of 79 patients with malignant 
biliary strictures were retrospectively enrolled in this study. The patients 
were divided into an IP group(n=30) and TP group(n=49). Technical and 
clinical success, complication, and stent patency were compared between 
the two groups.
results: There were no significant differences between the IP and TP 
groups in the rates of technical success(100% vs. 100%), clinical suc-
cess(100% vs. 100%), early complications(10.0% vs. 6.1%), late compli-
cations(0% vs. 4.1%), or stent occlusion(23.3% vs. 20.6%). The average 
patency periods in the IP and TP groups were 150.0 and 103.7 days, respec-
tively. Cumulative stent patency also did not differ significantly between 
the two groups(P=0.680).
conclusion: TP for malignant biliary strictures showed a high technical 
success rate, low complication rate, and no difference in stent patency 
when compared with IP. Long-term follow-up and prospective compara-
tive studies are needed to evaluate the usefulness of IP.
disclosure: Nothing to disclose 
P1672 cOMPLIcaTIOns Of PercuTaneOus TranshePaTIc 
chOLangIOgraPhy and BILIary draInage (PTcd)
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1Radboud University Medical Center, Gastroenterology and Hepatology, 
Nijmegen, Netherlands, 2Radboud University Medical Center, Nijmegen, 
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contact e-Mail address: ayla.turan@radboudumc.nl
Introduction: Percutaneous transhepatic cholangiography and biliary 
drainage (PTCD) is used for treatment for biliary obstruction after failed 
endoscopic biliary cannulation.
aims & Methods: Our aim was to evaluate complication rates and risk 
factors for adverse outcome of PTCD in a real-world population. We per-
formed a multicenter (4 Teaching and 1 University hospitals) cohort study 
in the period 2011-2016. 
Our primary outcome was the incidence of infectious (sepsis, cholangitis, 
abscess or cholecystitis) and non-infectious complications (bile leakage, 
catheter blockage, severe hemorrhage, etc.) and mortality within 30 days 
of a PTCD procedure. Intra Class Correlations (ICC) were calculated to de-
termine variance of outcomes between the five hospitals. Multilevel logis-
tic regression analysis was performed to identify risk factors for predefined 
outcomes.
results: In total, 331 patients with PTCD were analyzed, 251 of whom had 
malignant biliary tract obstruction. Two-hundred-twenty-six patients 
(68.3%) developed a complication after PTCD. 
In 224 patients without pre-existent infection, 114 developed one or more 
infectious complications (40.6%), i.e. cholangitis in 26.3%, sepsis in 
24.6%, abscess in 2.7% and cholecystitis in 1.3%. Non-infectious com-
plications were seen in 167 of 331 patients (50.5%). PTCD-related 30-day 
mortality was 8.5%. 
Risk factors for infectious complications were internal drainage (OR 2.12, 
95% CI 1.03-3.38) and drain obstruction (OR 2.60, 95% CI 1.39-4.88), while 
multiple re-interventions were related to non-infectious complications 
(OR 2.11, 95% CI 1.64-2.71). No risk factors for mortality were identified.
conclusion: This multicenter study shows that PTCD is associated with a 
high number of adverse events and substantial mortality. Infectious com-
plications, in particular cholangitis and sepsis, are common and appear 
to be caused by drain malfunction and internalized drainage. These high 
complication rates should stimulate the search for alternative strategies 
for biliary drainage.
disclosure: Nothing to disclose 
P1673 uncOverIng cLInIcaL gaPs In The ManageMenT Of 
chrOnIc LIver dIsease-assOcIaTed ThrOMBOcyTOPenIa In 
aduLTs requIrIng eLecTIve InvasIve PrOcedures: a cLInIcaL 
PracTIce assessMenT
Fisher G.1, Voorn S.1, Gunesekera D.1, Peck-Radosavljevic M.2
1Medscape, Global Medical Education, London, United Kingdom, 2Klinikum 
Klagenfurt am Wörthersee, Department of Internal Medicine and 
Gastroenterology, Klagenfurt, Austria
contact e-Mail address: geoff@geofishmedicalmarketing.com
Introduction: Optimal implementation of emergent thrombopoetin re-
ceptor agonists (TPO-RA) such as lusutrombopag and avatrombopag is 
anticipated to require significant changes to the treatment paradigm for 
patients with Chronic Liver Disease (CLD)-associated thrombocytopenia 
(TCP) requiring elective invasive procedures (EP). In order to provide clini-
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cians with optimum education, guidance and support to achieve the best 
outcomes with these agents in routine practice, it is important to identify 
current knowledge and clinical gaps that need to be addressed.
aims & Methods: This study determined the readiness of clinicians to im-
plement TPO-RA in practice by exploring understanding of current patient 
selection criteria, the limitations of platelet infusions and the scientific 
rationale and supporting efficacy and safety data for emergent TPO-RA, 
including considerations related to practical application. A 25-question, 
online, continuing medical education (CME) survey was developed that in-
cluded a range of demographic, knowledge and practice-based questions. 
The activity launched on December 20, 2018 and data collected through 
February 6, 2019.
results: 31 gastroenterologists, 47 hematologists, and 30 other physicians 
completed the survey. All were required to be involved in the manage-
ment of patients with CLD-associated TCP undergoing EP. 47% of partici-
pants were from community hospitals, 30% from teaching hospitals and 
the remainder from solo/group community practices. Delay to invasive 
procedures due to TCP was common: 25% of participants reported a de-
lay >40% of the time, 22%, 21-40% of the time, and 41%, 1-20% of the 
time. Only 13% never experienced delays. Lack of awareness/availability 
of newer treatment options (45% participants), lack of evidence-based 
guidelines (20%), and insufficient time to manage TCP before the pro-
cedure (12%) were identified as the current most significant barriers to 
optimal management of patients. Participants were currently only slightly 
(32%) or moderately (39%) confident in application of TPO-RA in practice. 
Only 16% were mostly/very confident. Only 49% of participants correctly 
identified 50,000/mL as the platelet threshold for considering interven-
tion for TCP. Participants were familiar with the role of TPO in the patho-
physiology of TCP (79%) and the mechanism of action of TPO-RA (75%). 
However, participants generally lacked knowledge on a range of questions 
that explored understanding of the clinical evidence for avatrombopag and 
lusutrombopag including identification of eligible patients in terms of type 
of EP and bleeding risk, magnitude and type of efficacy benefit, safety pro-
file, duration of use, and monitoring requirements. 62% failed to identify 
that portal vein thrombosis occurred at a similarly low level in patients 
receiving lusutrombopag or placebo in the LPLUS1/2 trials. Only 22% of 
participants correctly identified that platelet counts should be monitored 
for 4 weeks after initiating treatment with TPO-RA.
conclusion: The findings reveal significant current knowledge and clinical 
gaps amongst clinician specialties involved in the management of CLD-as-
sociated TCP in patients undergoing EP. Whilst this highlights some of the 
key issues and challenges in current practice, and may reflect the current 
lack of access to and clinical experience with TPO-RA, this strongly points 
to a need for education to establish a better understanding of the impact 
of TPO-RA on practice. Clinicians require support with the implementation 
of the paradigm shift that is needed for effective and safe routine applica-
tion of TPO-RA to achieve the best patient outcomes.
disclosure: Markus Peck: Investigator, AbbVie, Arqle-Daiichi, Bayer, BMS, 
Boehringer-Ingelheim, Imclone, Lilly, MSD, Novartis, Roche, Shionogi; 
Speaker, Advisor: AbbVie, Bayer, BMS, Boehringer-Ingelheim, Eisai, Ipsen, 
Lilly, MSD, Roche, Shionogi; Grant Support, AbbVie, Arqle-Daiichi, Bayer, 
MSD, Roche. No others 
P1674 eMergIng TreaTMenTs fOr chrOnIc LIver dIsease-
assOcIaTed ThrOMBOcyTOPenIa In aduLTs requIrIng eLecTIve 
InvasIve PrOcedures: effecT Of OnLIne educaTIOn On 
cLInIcIan knOWLedge, and cOnfIdence
Fisher G.1, Voorn S.2, Gunesekera D.2, Peck-Radosavljevic M.3
1Medscape, Global Medical Education, London, United Kingdom, 2Medscape 
Global Medical Education, London, United Kingdom, 3Klinikum Klagenfurt 
am Wörtersee, Abteilungsvorstand Gastroenterologie & Hepatologie, 
Endokrinologie und Nephrologie, Klagenfurt, Austria
contact e-Mail address: geoff@geofishmedicalmarketing.com
Introduction: Thrombopoetin Receptor agonists (TPO-RA) such as lu-
sutrombopag and avatrombopag are emerging as alternative treatment 
options to platelet transfusions for patients with Chronic Liver Disease 
(CLD)-associated thrombocytopenia requiring elective invasive procedures. 
Optimal implementation of these agents is anticipated to require signifi-
cant changes to the treatment paradigm, so education of clinicians on the 
rationale and supporting data as well as practical application of these 
agents will be important.
aims & Methods: This study determined whether online continuing medi-
cal education (CME) could improve clinicians’ knowledge of the rationale 
behind the development of TPO-RA and the supporting clinical evidence, 
and improve clinicianconfidence with application of these agents in prac-
tice. A 30-minute online video discussion between 2 experts was launched 
for countries in Europe in December 2018, with data collected until Febru-
ary 2019. Educational effect was assessed with a repeated-pairs pre-/post-
assessment study design, where individual participants served as his/her 
own control. 3 multiple-choice, knowledge questions and 1 self-efficacy, 
5-point Likert scale (confidence) question were analyzed. Chi-squared test 
assessed pre- to post-assessment change (5% significance level, P< .05). 
Magnitude of change in total number of correct responses overall, and for 
each question, were determined with Cramer’s V (effect size: < 0.05 mod-
est; 0.06-0.15 noticeable, 0.16-0.30 considerable, >0.30 extensive).
results: 78 gastroenterologist and 72 hematologists completed both pre- 
and post-assessments. An overall positive extensive education effect was 
observed for both specialties (V=.306, p< .001 and V=.281, p< .001, respec-
tively). 
For both specialties significant improvements were observed between pre- 
and post-assessment for all 3 questions which covered identification of 
the complications of platelet infusions, identification of the correct plate-
let count defining eligibility for the ADAPT-1 and ADAPT-2 Phase 3 trials 
of avatrombopag and identification of the correct efficacy and safety data 
from the L-PLUS1 and L-PLUS2 Phase 3 trials of lusutrombopag. Average % 
of correct responses improved from 28% to 88% pre-and post-assessment 
for gastroenterologists and from 43% to 68% for haematologists. 
Both specialties had only modest baseline knowledge of the key data for 
both agents (24-47% gastroenterologists and 49-56% hematologists), with 
significant improvement post-assessment. Improved confidence in the 
ability to treat thrombocytopenia in patients with CLD requiring an elective 
invasive procedure was demonstrated post-assessment, with a total aver-
age confidence improvement of 35% for gastroenterologists and 25% for 
haematologists.
conclusion: This on-demand, online video discussion resulted in a highly 
positive educational effect with improvements in clinician knowledge and 
confidence. However, the study revealed that there is currently only a mod-
est baseline understanding of key data supporting the implementation of 
TPO-RA in practice. In addition, despite the positive educational gains, 
there are persistent knowledge gaps evident post-assessment for a signifi-
cant proportion of clinicians. 
Further education is merited given the important implications of these 
agents to the treatment paradigm. Online medical education is valuable in 
supporting the interpretation of new data and practical application of new 
agents in practice, as well as identifying areas of continued educational 
need
disclosure: Markus Peck: Investigator, AbbVie, Arqle-Daiichi, Bayer, BMS, 
Boehringer-Ingelheim, Imclone, Lilly, MSD, Novartis, Roche, Shionogi; 
Speaker, Advisor: AbbVie, Bayer, BMS, Boehringer-Ingelheim, Eisai, Ipsen, 
Lilly, MSD, Roche, Shionogi; Grant Support, AbbVie, Arqle-Daiichi, Bayer, 
MSD, Roche. No others 
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P1676 cOMBIned uLTrasOund- and fLuOrOscOPy guIded 
TranshePaTIc BILIary draInage Is suPerIOr TO cOnvenTIOnaL 
radIOgraPhy guIded TechnIque
Hollenbach M.1, Schaumburg T.1, Feisthammel J.1, Mössner J.1, Michl P.2, 
Rosendahl J.2, Hoffmeister A.1
1University of Leipzig, Department of Internal Medicine, Neurology and 
Dermatology; Division of Gastroenterology and Rheumatology, Leipzig, 
Germany, 2Martin-Luther-University Halle-Wittenberg, Department of 
Medicine, Clinic for Internal Medicine I, Halle, Germany
contact e-Mail address: marcus.hollenbach@web.de
Introduction: Difficult biliary cannulation (DBC) is a common condition in 
endoscopy and often remains challenging. DBC is related to benign, ma-
lignant or iatrogenic diseases. In case of unsuccessful ERCP, EUS-guided 
or percutaneous transhepatic biliary drainage (PTCD) are standard proce-
dures for alternative bile duct access. PTCD is often performed by ultra-
sound guided puncture (US-PTCD) but also conducted without sonography 
(non-US-PTCD). However, there is no comparative data showing any supe-
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riority for the use of US-PTCD with regard to technical success or compli-
cations. Thus, we performed a retrospective two-center study comparing 
US-PTCD with non-US-PTCD.
aims & Methods: Data of 269 patients who underwent PTCD between 
2002 and 2018 were collected and retrospectively analyzed. Indications, 
outcome, technical efficacy, comorbidities and procedural characteristics 
were analyzed. Fisher’s exact test, Student’s t-test and Chi-Square-test 
were used to identify dispersions between both groups.
results: We identified 200 patients, who were treated by US-PTCD and 69 
by non-US-PTCD. Mean age was 66.3 (US-PTCD) and 67.4 years (non-US-
PTCD) and PTCD was performed mostly in men (64.5% and 66.7%). In both 
groups, right-sided PTCDs were conducted more often than left sided (78% 
and 79%). Main indications for PTCD were palliative (63.5% and 62.2%) 
bile duct drainage due to prior abdominal surgery or unsuccessful ERCP. 
US-PTCD resulted in technical efficacy of 81% compared to 79.7% in non-
US-PTCD (p>0.05). Internal duodenal drainage was achieved in 50.5% 
(US-PTCD) and 36.2% (non-US-PTCD) patients (p=0.05). Interventions 
could be performed without sedation in 19% of patients in US-PTCD but 
only in 3% in non-US-PTCD group (p< 0.001). Minor complications (severe 
pain, dislocation, bleeding, cholangitis and other) occurred in 18.5% of 
US-PTCD and 20.3% of non-US-PTCD (p>0.05) but severe complications 
(pleural or cardiac injuries, perforation and fistula) occurred significantly 
less in US-PTCD (2% vs. 6.2%, p=0.04).
conclusion: US-PTCD and non-US-PTCD showed comparable technical ef-
ficacy but US-PTCD resulted in improved internal duodenal biliary drain-
age, less necessity of sedation and less severe complications compared to 
non-US-PTCD.
disclosure: Nothing to disclose 
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P1677 dOes endOscOPIc OBsTrucTIOn In cOLOrecTaL cancer 
requIre urgenT surgery and resuLT In POOr PrOgnOsTIc 
facTOrs?
Wilasrusmee C., Supsamutchai C., Jirasiritham J.
Faculty of Medicine Ramathibodi Hospital, Mahidol University, Surgery, 
Bangkok, Thailand
contact e-Mail address: chumpon.wil@mahidol.ac.th
Introduction: Colonoscopy is an endoscopic tool for evaluation of colorectal 
cancer, and there is no conclusive evidence of a connection between clini-
cal gut obstructions and obstructed seen in endoscopy (obstructed colo-
noscopy). Unplanned urgent operations in obstructed colorectal cancer by 
endoscopic processes may increase mortality and the possibility of poor 
outcome. The suitable waiting time to complete staging and prepare pa-
tients before surgery has not been reported.
aims & Methods: The aim of the study is to determine the suitable wait-
ing times, incidence of emergency surgery during waiting times, and out-
comes of obstructed colonoscopy. 
Retrospective cohort of obstructed colonoscopies in colorectal cancer was 
analyzed. Patients who refused surgery or failed to attend follow up ap-
pointments were excluded. Data was collected from both emergency and 
elective operation groups, including incidences of emergency surgery, 
waiting times, staging, level of obstruction and outcome.
results: The total of 4,017 colonoscopies were analyzed. There were 211 
(5.25%) unsuccessful procedures due to tumor obstruction. Twelve pa-
tients (7.3%) had emergency operations during waiting for surgery. The 
average waiting time was 25 days. No perioperative deaths were reported. 
5-year survival rate was lower in stage II and III cancer.
conclusion: In this study, we found low incidence (7.3%) of emergency 
surgery in unsuccessful colonoscopy from obstructed colorectal cancer. Pa-
tients are able to wait 2-3 weeks after the date of colonoscopy without risk 
of increased mortality.
disclosure: Nothing to disclose 
P1678 LOng TerM heaLTh reLaTed quaLITy Of LIfe 
fOLLOWIng cOLOrecTaL cancer surgery: PaTIenT rePOrTed 
OuTcOMes In a reMOTe fOLLOW-uP POPuLaTIOn
Malcolm F.1, Banerjea A.1, Whitehead D.1, Gupta A.1, Adiamah A.1, West J.2, 
Humes D.J.3
1University of Nottingham, Digestive Diseases Biomedical Research Centre, 
Nottingham, United Kingdom, 2University of Nottingham, Division of 
Epidemiology and Public Health, Nottingham, United Kingdom, 3University 
of Nottingham, Digestive Diseases Biomedical Research Centre, Dept. of 
Surgery, Nottingham, United Kingdom
contact e-Mail address: francesca.malcolm@nhs.net
Introduction: Remote follow-up (RFU) after colorectal cancer (CRC) surgery 
allows delivery of surveillance tests without the need for regular clinical 
review. However little is known about long term health related quality of 
life (HRQoL) in RFU patients.
aims & Methods: The aim of this cross sectional survey was to investigate 
HRQoL in this patient group. EQ-5D and QLQ-C30 questionnaires were sent 
to all CRC enrolled into RFU between 2011-2016. Primary outcomes were 
HRQoL scores. We analysed HRQoL scores with respect to year of RFU, 
demographics, operation type and stoma.
results: In total 428 of 722 patients responded (59.3%) with a median 
RFU time of 2.6 years. 26.6% of patients reported ‘perfect health’. The 
median EQ-5L index score was 0.785 (IQR: 0.671-1) and QLQ-C30 Global 
HRQoL score was 75 (IQR: 58.3-83.3). HRQoL scores were similar in dif-
ferent years of follow up. Lower HRQoL score were related to having a 
stoma (p< 0.003), cancer recurrence (p=0.009), female gender (p=0.009) 
and right-sided resection (p=0.03). Right-sided resection patients reported 
higher pain severity compared with those who underwent left-sided re-
sections (p=0.037).
conclusion: HRQoL is good in remotely followed up CRC patients. Predic-
tors of lower scores will be a useful in service planning and holistic needs 
assessment. Despite an abundance of literature describing morbidity re-
lated to anterior resection, right-sided resection patients in this cohort re-
ported worse HRQoL and symptoms.
disclosure: Nothing to disclose 
P1679 ILeOanaL POuch cancer: a case serIes
Patel R., Worley G., Allison L., Evans S., Sasikumar A., Jenkins J.T., 
Antoniou A., Faiz O., Corr A., Clark S.K., Latchford A.
St Mark’s Hospital, London, United Kingdom
contact e-Mail address: roshani.patel@nhs.net
Introduction: There are few data detailing management and outcomes of 
ileoanal pouch cancer.
aims & Methods: We aimed to determine the clinical presentation, man-
agement and outcomes for patients with ileoanal pouch cancer with Fa-
milial Adenomatous Polyposis (FAP) and Ulcerative Colitis (UC). Patients 
were identified by a search of two prospectively maintained institutional 
databases: UC pouches (2006-2019) and the Polyposis Registry (1978-2019). 
Endoscopic surveillance and cancer staging and management data were 
retrieved from hospital records.
results: Thirteen cases were identified; three=FAP, nine=UC, one both. Two 
patients were referred to our centre following a diagnosis of pouch can-
cer locally. Five patients were diagnosed at our centre with pouch cancer 
following a referral to our centre for other reasons such as fistula, pouch 
sepsis, and stricture. 
Six patients were diagnosed at our centre whilst on annual surveillance; 
median time to diagnosis of pouch cancer from previous surveillance en-
doscopy was 11.5 months (range 6- 18 months). 3/6 on surveillance at our 
centre had UC; none of whom had any adenomatous or dysplastic lesion 
visible on prior surveillance endoscopy. 
Eleven patients had cuff cancer, one pouch body cancer (FAP) and one had 
an anal canal squamous cell carcinoma (UC). The median time since pouch 
formation was 12 years (3-30) for UC and 30 years (12-34) for FAP. Seven 
(58%) patients were undergoing active annual surveillance.
Five UC cases had dysplasia (n=3) or cancer (n=2) in their proctocolectomy 
specimen. Five UC patients developed anal fistulae before cancer diagno-
sis. Pre-operative imaging was available for review on 11 patients, all of 
whom had margin threatening disease at diagnosis.
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Ten patients had/will be undergoing pouch excision (seven exenteration, 
three abdominoperineal excision). Ten underwent neoadjuvant chemora-
diotherapy. Two had non-operative management (one complete clinical 
response after neoadjuvant therapy; one palliative chemotherapy). One 
patient was lost to follow-up. Kaplan Meier one-year survival: 86% (SE 
0.132).
conclusion: There should be a high index of suspicion for pouch cancer 
in pouch patients with dysplasia or carcinoma at proctocolectomy or late-
developing fistulae in patients who have had a pouch for UC. Surveillance 
does not abolish the risk of developing pouch cancer and adequate cuff 
examination can be challenging. Ileoanal pouch cancers usually are diag-
nosed when they are already locally advanced.
disclosure: Nothing to disclose 
P1680 evaLuaTIOn Of exTended LaTeraL PeLvIc sIdeWaLL 
excIsIOn [eLsIe] fOr LOcaLLy advanced & recurrenT recTaL 
cancer (rcc) InvOLvIng The LaTeraL PeLvIc sIdeWaLL
Pring E.1, Gould L.2, Fletcher J.3, Taylor C.3, Hona T.3, Hellawell G.3, Corr A.4, 
Burling D.5, Aston W.3, Antoniou A.3, Jenkins J.T.5
1St Mark’s Hospital and Imperial College London, Surgery and Cancer, 
London, United Kingdom, 2St Mark’s Hospital, Academic Institute, London, 
United Kingdom, 3The Complex Cancer Clinic, St Marks Hospital, London, 
United Kingdom, 4St Mark’s Hospital, Academic Institute, Middlesex, United 
Kingdom, 5St. Marks Hospital, London, United Kingdom
contact e-Mail address: etpring@doctors.org.uk
Introduction: In the context of locally advanced or recurrent rectal cancer, 
disease extension to the lateral pelvic sidewall is associated with lower 
rates of complete resection and poorer survival overall. Adaptions to surgi-
cal approach may improve complete resection rates but whether improve-
ment in survival will follow is unclear.
aims & Methods: We aimed to assess the outcomes following surgery for 
locally advanced and recurrent rectal cancer with disease extension into 
the pelvic side wall using a novel surgical approach termed ELSiE (Ex-
tended Lateral Pelvic Sidewall Excision)
304 consecutive National Health Service (NHS) patients underwent ex-
enterative surgery in a single UK specialist centre. Where pretreatment 
MRI indicated pelvis sidewall or sciatic notch extension ELSiE was offered 
as a component of the pelvic exenteration surgery (n=111). Retrospective 
analysis of a prospectively maintained database assessed R0 rates, Cla-
vien-Dindo morbidity and overall specific survival (OSS - assessed using 
Kaplan-Meier analysis).
results: 304 patients underwent pelvic exenteration surgery, 111 of these 
were offered and underwent ELSiE. R0 rate in the ELSiE group was 85.3% 
compared to 82.2% non-ELSiE group. 53% of ELSiE procedures were for 
recurrent or re-recurrent rectal cancer compared to 36% in the non-ELSiE 
group. 47% of those who underwent ELSiE had en-bloc Total Perineal Ex-
cision whilst 27% did in the non-ELSiE population. En-bloc sacrectomy 
rate in ELSiE was 32.4% (15.5% non-ELSiE). Major-morbidity in the ELSiE 
group 41.4% and 30% in the non-ELSiE. Morbidity without sacrectomy in 
ELSiE was 35% as opposed to 24% in non-ELSiE. 90-day mortality was 
4.5% ELSiE and 5.0% non-ELSiE. Survival analysis revealed that 70% of 
patients were alive at 1000-days post-operatively with no differences in 
OSS between either group.
conclusion: ELSiE as an adjunct to exenteration surgery for pelvic sidewall 
disease extension in locally advanced, recurrent and re-recurrent rectal 
cancer increased R0 rates with relative improvements in OSS. Morbidity 
remains high in ELSiE and methods to reduce this are required. External 
validation of the ELSiE technique is now required.
disclosure: Nothing to disclose 
P1681 deveLOPMenT Of PaTIenT sPecIfIc 3d vIrTuaL MOdeLs 
fOr PLannIng BeyOnd-TMe resecTIOns In advanced recTaL 
cancer
Fletcher J., Gould L., Pring E., Sahnan K., Burling D., Corr A., Antoniou A., 
Lung P., Miskovic D., Jenkins J.T.
St Mark’s Hospital, London, United Kingdom
contact e-Mail address: jordan.fletcher@nhs.net
Introduction: Advanced rectal cancer is defined by invasion into sur-
rounding structures. Complete tumour clearance (R0), requires radical 
resections going beyond the usual TME plane. Operative approaches 
are bespoke and pre-operative planning essential. Patient specific 3D 
models may be a useful adjunct and enable a personalised operative 
“roadmap”.
aims & Methods: The following complex cases were selected; Extended 
Lateral Side-wall Excision (ELSiE), High Subcortical Sacrectomy (HiSS) and 
posterior exenteration. 
Standard axial and sagittal T2-weighted MRI sequences were obtained. 
DICOM images were imported into open-source software ITK-SNAP1and 
key anatomical structures were manually segmented and exported into 3D 
software, Blender for processing.
results: Segmentation took approximately 60-180 minutes and 20-60 min-
utes for mesh processing. Advanced rendering techniques were employed 
enabling ultra-realistic anatomical visualisation. Surgeons can manipulate 
models in 3D space, hide/reveal or change transparency of different struc-
tures of interest. In each case the precise anatomical relationship of the 
tumour to surrounding structures was clearly visualised.
conclusion: Surgeons currently use a combination of MRI scans, reports 
and discussion with radiologists to better understand anatomy. The use 
of these reconstructions in the MDT, in clinic and in the operating theatre 
could be useful to better communicate complex rectal anatomy, identify 
areas of difficulty and aid surgical planning.
references: Yushkevich PA, Piven J, Hazlett HC, et al. User-guided 3D ac-
tive contour segmentation of anatomical structures: Significantly improved 
efficiency and reliability. Neuroimage. 2006;31(3):1116-1128. doi:10.1016/j.
neuroimage.2006.01.015
disclosure: Nothing to disclose 
P1682 uTILITy Of hIgh suBcOrTIcaL sacraL resecTIOn 
{hIss] fOr LOcaLLy advanced & recurrenT recTaL cancer 
exTendIng OnTO L5/s1/2
Pring E.1, Gould L.2, Fletcher J.3, Taylor C.3, Hona T.3, Aston W.3, Corr A.4, 
Burling D.5, Holloway I.3, Antoniou A.3, Jenkins J.T.5
1St Mark’s Hospital and Imperial College London, Surgery and Cancer, 
London, United Kingdom, 2St Mark’s Hospital, Academic Institute, London, 
United Kingdom, 3Complex Cancer Clinic, St Marks Hospital, London, United 
Kingdom, 4St Mark’s Hospital and Academic Institute, Middlesex, United 
Kingdom, 5St Marks Hospital, London, United Kingdom
contact e-Mail address: etpring@doctors.org.uk
Introduction: In locally advanced and recurrent rectal cancer disease ex-
tension onto the lower lumbar spine and sacrum at L5/S1/2 is regarded as 
surgically unsalvageable, en-bloc bony cortex excision, High Subcortical 
Sacral resection [HiSS], may offer the chance of salvage in patients regard-
ed as unsuitable or at high risk of incomplete resection with conventional 
surgical approaches.
aims & Methods: We aimed to assess whether this technique improved 
outcomes in this group of patients who have been thought to have surgi-
cally unsalvageable disease.
Consecutive National Health Service (NHS) patients undergoing exentera-
tive surgical procedures at a single centre were assessed and those with 
disease extension onto L5/S1/2 assessed for suitability for HiSS. Patients 
suitable for mid-distal S1-S1/2 sacrectomy were preferentially offered this 
option. 
A prospective database of these patients was maintained and retrospec-
tive analysis performed. Outcomes including R0 rates, Clavien-Dindo 
morbidity, length-of-stay and OSS (Kaplan-Meier survival analysis) were 
assessed.
results: 304 consecutive exenterations were performed, of these 30 were 
HiSS procedures and 66 were sacrectomies, 46 classified as high sacrec-
tomies [HS] (above S2/3) and 20 as distal sacrectomies [DS]. 60% of HiSS; 
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28% HS and 50% DS had the diagnosis of primary rectal cancer extending 
beyond the TME (PRbTME). R0 rates were HiSS 81%; HS 87%; DS 75% and 
83% for the non-sacral resection cohort.
Major-morbidity, classified as Clavien-Dindo grades 3 and 4, occurred in 
HiSS 36%; HS 48%; DS 45% and 28% in the non-sacrectomy group.
Median LOS [IQR] varied significantly between the groups p=0.00005: 
non-sacral exenteration 19 days [IQR 11-29]; HiSS 24 days [IQR 13-45]; HS 
35 days [IQR 23-62]; DS 21 days [IQR 11-42]. Survival analysis confirmed no 
differences in OSS between groups -p=0.829, the OSS for HiSS was 70% 
at 1000 days.
conclusion: HiSS may offer an opportunity for radical treatment and im-
prove outcomes for patients previously regards as unsalvageable. The data 
presented here demonstrate that options to optimise R0 rates and reduce 
morbidity are needed these could include 3D reconstruction & image-
enhanced surgery.
disclosure: Nothing to disclose 
P1683 surgIcaL rePaIr Of endOscOPy Induced cOLOnIc 
PerfOraTIOns: a case-MaTched sTudy Of shOrT-TerM 
MOrBIdITy and MOrTaLITy
Daniel F.1, Jabak S.1, Hosni M.1, Tamim H.2, Mailhac A.2, Khalife M.3, 
Faraj W.3, Jamali F.3
1American University of Beirut Medical Center, Division of Gastroenterology, 
Department of Internal Medicine, Beirut, Lebanon, 2American University of 
Beirut Medical Center, Biostatistics Support Unit, Clinical Research Institute, 
Beirut, Lebanon, 3American University of Beirut Medical Center, Surgery, 
Beirut, Lebanon
contact e-Mail address: fd21@aub.edu.lb
Introduction: Iatrogenic perforation of the gastrointestinal tract is mainly 
caused by endoscopic procedures. Surgical repair of endoscopy induced 
colonic perforation have only been evaluated in small case series.
aims & Methods: To study to the short-term morbidity and mortality as-
sociated with surgical repair of endoscopy induced colonic perforations, 
and to compare these outcomes to those of similar surgeries performed 
for other indications on elective or emergency basis.
We studied all patients with endoscopic colonic perforation (ICD 9-10 
codes) who underwent surgical intervention from the 2014-2017 National 
Surgery Quality Improvement Program (NSQIP) participant use data spe-
cific file. NSQIP data base includes prospective validated outcomes and 
anonymized data for patients undergoing major surgery in more than 
500 hospitals. The primary outcome in this study was short term surgical 
morbidity (including wound, cardiac, respiratory, urinary, neurological, 
thromboembolism, and sepsis) and mortality. 
Outcomes were compared between 3 groups of surgical interventions: Su-
turing, open segmental colectomy, and laparoscopic segmental colectomy. 
Then, based on surgery CPT codes, patients (group 1) were matched with 
1:2 ratio to control patients undergoing same surgical interventions for 
other indications on elective (group 2) or emergency basis (group 3). 
We used the chi square test or Fisher’s exact to compare categorical vari-
ables. We used the independent t-test for continuous variables. We per-
formed multivariate analysis to adjust for confounders of 30-day postoper-
ative outcomes between the 3 matched groups. We included confounders 
into the models based on both clinical and statistical significance.
results: Over 4 years, 590 patients underwent surgical intervention to 
repair endoscopy induced colonic perforation. The average age of the pa-
tients was 66.5 ± 13.6 with female gender predominance (381, 64.7%). 
The majority underwent open colectomy (365, 61.8%) while 85 patients 
(14.4%) underwent laparoscopic colectomy and 140 patients (23.7%) un-
derwent surgical suturing. 
Overall mortality occurred in 25 patients (4.2%). No statistically significant 
difference in mortality was found between open colectomy, laparoscopic 
colectomy, and suturing (4.0%, 2.6%, and 5.9% respectively, p=0.48. 
Composite morbidity occurred in 163 patients (27.6%). It was significantly 
lower in laparoscopic colectomy (14.1%) compared to 30.2% and 29.4% 
in open colectomy and suturing approaches (p=0.014). 
Group 1 patients were shown to have better 30-day outcomes compared 
to group 3, regarding mortality (OR=0.66, 95% CI [0.51-0.85], p=0.001), 
sepsis (OR=0.54, 95%CI[0.66-0.91], p=0.002), and bleeding (OR=0.70, 95% 
CI [0.58-0.85], p=0.0003). Compared to group 2, group 1 patient showed 
significantly fewer bleeding complications (OR=0.54, 95% CI [0.35-0.84], 
p=0.0055).
conclusion: Open segmental colectomy was the most frequent approach 
used to repair endoscopy induced colonic perforation in our series. Lapa-
roscopic repair was associated with lower composite morbidity. Post -op-
erative mortality, sepsis and bleeding complications were found to be 
significantly lower than in controls matched for the same procedures per-
formed for other indications on emergency basis.
disclosure: Nothing to disclose 
P1684 endOscOPIc MucOsaL resecTIOn and endOscOPIc 
suBMucOsaL dIssecTIOn Of 161 cases Of LaTeraLLy sPreadIng 
TuMOrs
Sorogin S.1, Kashin S.V.2, Zavialov D.3, Goncharov V.I.4, Kraynova E.2, 
Nadezhin A.4
1Yaroslavl State Medical Academy, Department of General Surgery, Yaroslavl, 
Russian Federation, 2Yaroslavl Clinical Oncology Hospital, Department 
of Endoscopy, Yaroslavl, Russian Federation, 3Yaroslavl Regional Cancer 
Hospital, Department of Endoscopy, Yaroslavl, Russian Federation, 4Yaroslavl 
Regional Cancer Hospital, Yaroslavl, Russian Federation
contact e-Mail address: stassorogin@gmail.com
Introduction: Laterally spreading lesions, which are traditionally treated 
surgically, may be amenable to endoscopic mucosal resection (EMR), often 
using a piecemeal method and Endoscopic submucosal dissection (ESD) 
. Appropriate selection of lesions and a careful technique may enhance 
the efficacy of EMR and ESD for polyps more 10 mm in diameter without 
compromising safety. The aim of this study was to identify the factors that 
may predict the risk of polyp recurrence.
aims & Methods: A retrospective analysis was conducted on the outcome 
of 101 polyps more/20 mm in diameter, treated by piecemeal EMR at a 
single centre using the ‘‘lift and cut’‘ technique or ESD. All records were 
reviewed for polyp size, site, morphology and histology. 
Polypectomy technique, patient treatment, polyp recurrence and surgical 
interventions were also recorded.
results: Over THE 3-year period, 101 colonic polyps measuring more 10 
mm were removed by EMR end ESD. Follow-up data WAS available for 83 
cases (82%) with a mean polyp diameter of 42.9 mm; the total success rate 
of endoscopic polyp removal was 98%. 
There was no statistically significant relationship between the site and re-
currence.
Two patients (2%) underwent surgical intervention after EMR or ESD be-
cause of failed clearance. There were no post-EMR or post-ESD perfora-
tions and significant bleeding was revealed amog only six patients (5.9%). 
Based on clinicopathological analyses of LSTs, the indication for colorectal 
ESD is an LST non-granular type (LST-NG) >20 mm. LST granular type (LST-
G) >30 mm or 40 mm are possible candidates for ESD because they have 
a higher submucosal (SM) invasion rate and are difficult to treat even by 
endoscopic piecemeal mucosal resection (EPMR).En bloc ESD reduces the 
local recurrence rate for large colorectal neoplasias. Piecemeal resection 
is the most important risk factor for local recurrence regardless of the ER 
method used.
conclusion: With careful attention to technique, piecemeal EMR or ESD is 
a safe option for the resection of most sessile and flat colorectal polyps 
more/20 mm in size. A stricter treatment may be required for larger lesions 
because of the higher risk of recurrence.
disclosure: Nothing to disclose 
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P1685 recTaL cancer In adOLescenTs and yOung aduLTs 
(aya): PresenTaTIOn PaTTern and OuTcOMes
Foppa C.1, D’Hoore A.2, Cianchi F.3, Carvello M.4, Wolthuis A.5, 
Montorsi M.4, Rimassa L.6, Bertuzzi A.7, Laghi L.8, Malesci A.7, 
Santoro A.7, Spinelli A.9
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Center, Rozzano, Milano, Italy, 5University Hospital Leuven, Abdominal 
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Rozzano,Milano, Italy, 7Humanitas Clinical And Research Center, Rozzano, 
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Introduction: Rectal cancer in AYA (≤ 39 years) is rare but increasingly di-
agnosed. The aim of our study was to analyze presentation pattern, and 
outcomes in AYA operated for RC.
aims & Methods: Data on rectal cancer resections from 2008 to 2018 were 
collected from the prospectively maintained databases of 3 European re-
ferral centers and compared to a control group of consecutive patients 
over 40 (n=500).
results: 87 patients in AYA group (mean age: 33.5, range 18-39; 53% 
males) were compared to 500 patients in the control group (500). In AYA 
tumors were significantly more advanced (locally advanced 12% vs 4%; 
p=0.005; metastatic 37% vs 14.3%; p=< 0.0001). Accordingly, neoadju-
vant and adjuvant treatment (69% vs 32%, p< 0.0001; 76.2% vs 48.7%; p< 
0.001), more complex and staged surgical procedures (9.3%), open sur-
gery (31.1% vs 4.7%; p< 0.0001) and stomas (68% vs 47.6%; p=0.004) were 
more commonly performed in AYA patients. No differences in periopera-
tive outcomes were reported. At a mean follow-up of 5 years no difference 
in overall survival (p=0.651), while a significantly lower cancer free survival 
was observed in AYA (p< 0.0001).
conclusion: AYA patients undergoing resection for RC are rare, but more 
advanced at presentation, resulting in more complex operations, a faster 
cancer progression and lower cancer free-survival. Our data call for in-
creasing awarenesson rectal cancer in AYA population.
disclosure: Nothing to disclose 
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Parra R.S.1, Zanardi J.V.C.2, Valerio F.P.2, Feitosa M.2, Féres O.3, 
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Introduction: Deep infiltrating endometriosis invading the intestine occurs 
in 8 to 12% of women with endometriosis. Surgery is indicated in patients 
with pelvic pain that do not respond to medical therapy.
aims & Methods: To access the results of laparoscopic surgical treatment 
of bowel endometriosis in a single referral center. A retrospective analysis 
of medical records of patients with intestinal endometriosis submitted to 
laparoscopic surgical treatment. Number of surgeries, conversion rates, 
surgical time, length of hospital stay and complications were evaluated.
results: One-hundred and thirteen patients were included. The mean age 
was 34.6 (ranging from 19 to 53), 62.8% of the patients have previous sur-
geries, the mean body mass index (BMI) was 25.2kg/m2. The main surgical 
indication was chronic pelvic pain (84.9%), followed by infertility (73.5%) 
and dyspareunia (54.9%). All procedures were done by laparoscopy. Sur-
geries performed: retosigmoidectomy (n=49, 43.4%), discoid anterior rec-
tum resection (n=35, 31.0%), rectum shaving (n=26, 23.0%), appendec-
tomy (n=11, 9.7%), and colon and ileal resection or ileal resection (n=8, 
7.1%). Hysterectomy was performed in eleven patients (9.7%) and bladder 
or ureteral lesions with need of resection in 7 patients (6.2%). Thirty-five 
patients (31.0%) had more than one resection at the same laparoscopic 
procedure. The mean surgical time was 122 minutes (retosigmoidectomy: 
149minutes, anterior discoid rectum resection 114minutes and shaving 
87minutes). When more than one procedure was performed at the same 
laparoscopy the mean surgical time increased to 161minutes. 
The mean hospitalization time was 1.5 days (retosigmoidectomy: 1.8 days; 
discoid anterior resection: 1.4 days; shaving 1.0 day; more than one pro-
cedure at same laparoscopy 2.2 days). The conversion rates was 1.8% 
(n=2). Three patients needed temporary stoma (2.6%). The postoperative 
complication rates were 23% including rectal bleeding (n=18, 15.9%; only 
one case needed blood transfusion), wound infection (n=2, 1.8%), anas-
tomotic leakage (n=0, 0%), nonsurgical site infection (n=3, 2.6%), need 
for reoperation (n=2, 1.8%, due to thermal injury; these two patients need 
provisory colostomy), readmission at 30 days (n=3, 2.6%, one due thermal 
injury and other two patients due to abdominal pain and diarrhea), deep 
vein thrombosis (n=1, 0.9%), and mortality at one year (n=0, 0%). Surgi-
cal recurrence occurred in four patients (3.5%) with need of new intestinal 
resection.
conclusion: Laparoscopic surgery is safe and should be offered as the 
first surgical option in patients with deep endometriosis with intestinal 
involvement.
references: Abrão MS, Petraglia F, Falcone T, Keckstein J, Osuga Y, Chap-
ron C. Deep endometriosis infiltrating the recto-sigmoid: critical fac-
tors to consider before management. Hum Reprod Update. 2015 May-
Jun;21(3):329-39. doi: 10.1093/humupd/dmv003. PMID 25618908.
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fOr zenker’s dIverTIcuLuM
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Introduction: The best option of treatment of Zenker’s diverticulum is still 
controversial. Recent data shows that same effectiveness of flexible en-
doscopy and traditional surgery. The only drawback of endoscopic tech-
nique is the limitation of myotomy level, which can result in the relapse 
of symptoms. Driven by new technologies we started to utilize the tunnel 
technique in patients with Zenker’s diverticulum.
aims & Methods: To evaluate the effectiveness of endoscopic cryophar-
ingoesophagomyotomy using a different techniques in the treatment of 
patients with Zenker’s diverticulum.
In the period from July 2014 to April 2019, endoscopic surgery in MCSC 
A.S. Loginov for Zenker’s diverticulum was performed in 113 patients. The 
average age of patients was 65 (from 34 to 86 years). According to the 
traditional method, 35 patients were operated on (I group). The average 
operative time was 42 minutes. According to the tunnel technique, 37 pa-
tients were operated on (group II). The mean operative intervention time 
was 50 minutes. According to the combined method, 42 patients were 
operated on. The average operative time was 32 minutes.
results: The peculiarity of the patients who underwent surgery using the 
new combined method was the almost complete absence of the residual 
cavity of the diverticulum during the X-ray control examination.
Two patients in the group of traditional endoscopic treatment were re-
operated because of complaints recurrence; each of them underwent two 
re-interventions. In two more cases the traditional endoscopic treatment 
was completed in two stages due to the large size of diverticulum. No re-
currence of symptoms was observed after tunnel or combined technique.
conclusion: Combined and tunneled endoscopic surgery for Zenker’s di-
verticulum allows to successfully expand the scope of surgical interven-
tion by performing an extended myotomy and dissection of the mucous 
membrane of the septum. This allows you to create conditions for the pre-
vention of recurrence of the disease, thereby providing the best result of 
treatment.
disclosure: Nothing to disclose 
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P1688 MInIMaL InvasIve TechnIques In The ManageMenT Of 
cOLOrecTaL anasTOMOTIc Leak: a randOMIzed exPerIMenTaL 
sTudy
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Introduction: Anastomotic leak (AL) after low anterior rectal resection rep-
resents dreadful complication, which is associated with significant mor-
bidity, morbidity and affects oncological and functional outcomes. Some of 
recently developed minimal invasive techniques are potentially suitable for 
the treatment of early diagnosed AL. TAMIS (Transanal Minimally Invasive 
Surgery) which was primarily introduced for local rectal excisions is one 
of those. Another option may be to use endoscopic suturing system (Over-
Stitch; Apollo Endosurgery, Inc) providing full thickness closure in hollow 
viscera.
aims & Methods: The aim of our study was to compare feasibility and 
efficacy of two different minimal invasive techniques for early repair of 
anastomotic leak on animal model.
Model of low colorectal anastomotic leak was introduced in 42 male pigs. 
Laparoscopic low anterior resection was performed with anastomosis cre-
ated with 28 mm circular stapler after removing half of the staples. Two 
days later, the animals were randomized for endoscopic closure, TAMIS 
repair or control group with no treatment. 
In endoscopic group a double-channel endoscope was introduced and 
anastomotic defect closed with 2/0 prolene and secured with original 
knotless fixation. 
In TAMIS group a special port (GelPOINT) was inserted transanally and 
pneumorectum established. Standard laparoscopic instruments and 5mm 
camera were then used to close the defect by interrupted 3/0 vicryl suture. 
Three - grade scale (I - closed completely, II - closed with visible gaps, III 
- closure not possible) was introduced to assess the completion of closure. 
The signs of intraabdominal septic complications (IASC) and anastomotic 
healing including the burst test were evaluated after animals being sacri-
ficed on 9th postoperative day. Chi square and Mann-Whitney tests were 
used to compare interventional and control groups. 
This project was approved by local ethical committee in accordance with 
the European Convention on Animal Protection and supported by health 
research grants (AZV 16-31806A, MO 1012)
results: Closure was technically possible in all 28 cases (grades I/II/III - 
11/3/0 in endoscopic and 9/5/0 in TAMIS group; p>0,005). Two animals 
after endoscopic closure died due to peritonitis on 8th and 9th postoperative 
day. There was no difference in operating time - 31 (19-70) min in endo-
scopic and 43 (20-70) min in TAMIS group (p=0,357).
Overall IASC rate was lower after both endoscopic (5/14; p=0,022) and TA-
MIS (4/14; p=0,0079) repair compared to control (11/14). Healed anasto-
mosis with no visible defect was observed in 10/14 (p=0,0023) and 11/14 
(p=0,0068) in endoscopic and TAMIS groups respectively vs. 2/14 in con-
trol group. The burst test confirmed sufficient closure with mean pressure 
of 200 (80-300) mmHg in endoscopic and 235 (25-300) mmHg in TAMIS 
group (p=0,619).
conclusion: Evaluated techniques were proved to be suitable for closure 
of anastomotic defect with similarly high success rates. Both interventions 
reduced intraabdominal septic complications. Endoscopic closure seems 
to require more training since initial procedures were associated with 
peritoneal soiling and peritonitis.
disclosure: Nothing to disclose 
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Introduction: The overall reported rate of parastomal hernias (PSH) in lit-
erature ranges from 44- 56%, and is highest in end colostomies (48%) 
followed by loop colostomies (30.8%), end ileostomies (28.3%) and lowest 
in loop ileostomies (6.2%-16%) [1,2]. Although several risk factors contrib-
uting to the development of PSH have been identified, manipulation of the 
stoma site during surgery has not been studied.
aims & Methods: The primary aim of this study was to identify the influ-
ence of manipulation of the marked stoma-site during surgery (e.g. lapa-
roscopic port placement) on the subsequent development of parastomal 
hernia (PSH).
We analysed data of consecutive patients who underwent colorectal sur-
gery for benign and malignant pathology between January 2017 and De-
cember 2018 at a single tertiary care centre.
results: A total of 408 patients were analysed. Their mean age at surgery 
was 54.6 (SD-17.9) years. Forty-nine(12.0%) developed PSH after surgery. 
The median time to developing a hernia was 222(25 and 75 percentile 147 
and 363, respectively) days. 
Laparotomy was performed in 233 while 127 and 48 had laparoscopy and 
single-incision surgery, respectively. One-hundred-and-ten (28.7%) had 
instrumentation placed through the stoma site during surgery.
A log-rank test was run to determine if there were differences in develop-
ing a PSH if the stoma site was being used as a port site. When the first 
180-days were considered, the PSH formation was significantly different 
(χ2(2)=9,4,p=.002). When the entire follow-up period was considered, 
however, there was no statistically significant difference in PSH formation 
(χ2(2)=1.13,p=.28).
conclusion: Using the stoma site as a port site increases the risk of early 
PSH formation, but this does not lead to an increased risk of PSH formation 
in the long run.
references: 1.Antoniou, S.A., Agresta, F., Garcia Alamino, J.M. et 
al.European Hernia Society guidelines on prevention and treatment of 
parastomal hernias. Hernia (2018) 22: 183. https://doi.org/10.1007/s10029-
017-1697-5 2. Gillern S, Bleier JI. Parastomal hernia repair and reinforce-
ment: the role of biologic and synthetic materials. Clin Colon Rectal Surg. 
2014;27(4):162-71.
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Introduction: The overall reported rate of parastomal hernias (PSH) in the 
literature ranges from 44- 56% and is highest in end colostomies (48%) 
followed by loop colostomies (30.8%), end ileostomies (28.3%) and low-
est in loop ileostomies (6.2%-16%) [1,2]. Single Incision Laparoscopic 
Surgery (SILS) uses a port that is larger than standard laparoscopic ports 
(35-50mm) and therefore exerts a much higher radial force at the stoma 
site compared to other techniques. The short and medium-term effects of 
this have not been studied.
aims & Methods: The primary aim of this study was to identify the inci-
dence of PSH in patients who underwent SILS.
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We analysed data of consecutive patients who underwent colorectal sur-
gery for benign and malignant pathology between January 2017 and De-
cember 2018 at a single tertiary care centre. Patient and procedural data 
were retrieved from a prospectively maintained database.
results: A total of 408 patients were analysed. Their mean age at surgery 
was 54.4 (SD-17.9) years. A total of 45 (11.3%) developed PSH after surgery. 
The median time to developing a hernia was 220 (25 and 75 percentile 146 
and 368, respectively) days. 
Two-hundred-and-thirty-three patients underwent laparotomy while 127 
and 48 had laparoscopy and SILS, respectively, with 27(11.5%), 19(14.9%) 
and 3(6.3%) patients developing PSH. Univariate analysis did not identify 
a statistically significant difference between different surgical techniques 
(Chi-square 2.59, p=.27). 
A log-rank test was run to determine if there were differences in develop-
ing a PSH and the different types of surgery. The survival distributions 
for the surgeries were not statistically significantly different, χ2(2) = 3.06, 
p=.22, but there was a non-significant reduction in PSH in SILS patients.
conclusion: Single Incision Laparoscopic Surgery did not increase the risk 
of PSH. A study with a larger sample size may show a statistically signifi-
cant risk reduction in SILS compared to other techniques.
references: 1.Antoniou, S.A., Agresta, F., Garcia Alamino, J.M. et 
al.European Hernia Society guidelines on prevention and treatment of 
parastomal hernias. Hernia (2018) 22: 183. https://doi.org/10.1007/s10029-
017-1697-5 2. Gillern S, Bleier JI. Parastomal hernia repair and reinforce-
ment: the role of biologic and synthetic materials. Clin Colon Rectal Surg. 
2014;27(4):162-71.
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Introduction: Flexible endoscopic septum division (FESD) is an established 
treatment for Zenker’s diverticulum, however, data on long term outcomes 
are sparse. In addition,treatment of recurrences after surgery stapling can 
be technically challengingand little is known about role of FESD of recur-
rence after surgical recurrence. In this prospective study we aimed to eval-
uate long-term efficacy data for FESD and identify predictors of sustained 
symptom remission (treatment naïve and surgical recurrence).
aims & Methods: Successive patients undergoing FESD for ZD between 
2014-2018 were enrolled in this prospective study. Procedures were per-
formed by a single operator under propofol sedation without endotracheal 
intubation. Symptom severity pre- and post-FESD was recorded using the 
Dysphagia, Regurgitation, Complications (DRC) scale. Symptom remission 
was defined as a total DRC score of ≤1 after index FESD or the latest at-
tempt after planned multi-stage procedures. Symptom-free remission was 
measured using a Kaplan-Meier approach, with univariable analyses per-
formed using Cox-regression models.
results: 69 patients (mean age 74.4 years, SD 11.8, 61% male) were in-
cluded for analysis, of which 60% were categorised American Society of 
Anaesthesiologists (ASA) Grade III or IV. 19 patients (28%) had undergone 
previous stapling treatment. The median cricopharyngeal muscle length 
was 24mm (IQR 17-30mm). The median procedure time was 20 minutes 
(IQR 19-25). The mean number of sessions of FESD therapy per patient 
was 1.4 (SD 0.7). In total, 75.4% of patients achieved symptom remission 
after the last planned FESD procedure. Kaplan-Meier estimated rates of 
symptom recurrence at 12, 24, 36 months were 12.6%, 36.3%, 46.5% re-
spectively. The median time from the latest planned FESD procedure to 
symptom recurrence was 46.7 months (95% CI 18.4-75.0). On univariable 
analysis, factors associated with symptom recurrence included previous 
stapling (hazard ratio [HR] 2.88; P=0.33) and younger age (HR 0.959 per 
year, P=0.030), but not significantly by gender (P=0.699), cricopharyngeal 
muscle length (P=0.059), procedural duration (P=0.241) or combined DRC 
score (P=0.080).
conclusion: Using Kaplan-Meier estimates, the majority of patients de-
velop recurrent ZD symptoms beyond 12 months post-FESD. This risk is 
higher in patients with recurrent ZD and in younger patients. All patients 
undergoing FESD for ZD should have either regular or open access follow-
up arrangements in case symptoms recur.
disclosure: Nothing to disclose 
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Introduction: Experience with endoscopic retrograde cholangiopancrea-
tography (ERCP) in the pediatric setting is still limited especially in infant 
population. Wide heterogeneity of reported safety and efficacy profile and 
lack of systematic and standardized methodologies use exist, thus limiting 
pediatric ERCP use even in specialized centers.
aims & Methods: The aim of this study was to evaluate the efficacy and 
safety of pediatric ERCP and to identify factors associated with procedure-
related adverse events. All consecutive ERCPs performed for any indication 
in patients under the age of 18 from 2005 to 2018 at our single tertiary 
referral center were included in the study. Demographic characteristics of 
patients, indications, technical and clinical success, findings and proce-
dure-related adverse events were retrospectively analyzed. The grade of 
technical complexity of each ERCP and the procedure-related complica-
tions were assessed according to the American Society for Gastrointestinal 
Endoscopy (ASGE) criteria.
results: A total of 117 ERCPs were performed in 57 children (median age 
7.6 (1-17) years; median weight 23.2 kg) by three ERCP expert endosco-
pists under general anaesthesia. The most frequent indications of ERCP 
were as follows: recurrent or chronic pancreatitis (33), post-surgical bile 
duct injury (19), suspected choledocholithiasis (14), and primary scleros-
ing cholangitis (PSC) (9). Therapeutic techniques performed were biliary 
sphincterotomy (32/117), biliary stenting (42/117), biliary stone extraction 
(21/117), pancreatic sphincterotomy (7/117), pancreatic stone extraction 
(5/117) and pancreatic stenting (10/117). Technical success was achieved in 
112/117 (96%) cases and clinical success in 52/57 (92%) patients. ERCP-
related complications consisted of seven episodes of mild pancreatitis 
(6% post-ERCP pancreatitis (PEP) rate) all resolved following conservative 
treatment. No procedure-related mortality was recorded.
conclusion: When performed in experienced hands the use of ERCP in 
newborns, children and adolescents is safe and effective, with complica-
tion rates comparable to those reported in adults. 
However well designed prospective studies are needed to better define 
outcomes.
disclosure: Nothing to disclose 
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P1694 cOhOrT anaLysIs Of PedIaTrIc InTussuscePTIOn 
scOre TO dIagnOse InTussuscePTIOn
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Surgery, Bangkok, Thailand
contact e-Mail address: palittiya.s@chula.ac.th
Introduction: Intussusception is a serious cause of intestinal obstruction in 
young children and delayed diagnosis increases morbidity. Ultrasonogra-
phy (USG) is the gold standard for diagnosis but operator dependence and 
unavailable worldwide.
aims & Methods: The aims of the present study are to study the clinical 
characteristics and treatment outcomes and to evaluate the diagnostic ac-
curacy of abdominal radiography (AR) with and without promising param-
eters to diagnose intussusception. 
Children with suspected intussusception who underwent abdominal USG 
investigation in our center from 2006 to 2018 were recruited. Clinical and 
investigation were evaluated and compared between intussusception and 
non-intussusception groups. AR images were interpreted by a pediatric 
radiologist. Diagnosis of intussusception is composed of compatible USG 
and response with reduction.
results: Ninety-seven children were diagnosed with intussusception 
(2.06±2.67 years, 62.9% male), 37.1% of whom were referrals and 74% 
were < 2 years old. The common manifestations of intussusception were 
irritable or abdominal pain (86.6%), vomiting (58.5%), abdominal dis-
tension (39.2%) and bloody stool (36.1%). The classic triad of intussus-
ception (abdominal pain, bloody stool and palpable mass) had specificity 
of 100% but sensitivity of 11.3%. Children with no clinical fever and no 
palpable abdominal mass could discriminate intussusception from other 
mimics (P< 0.05). The referral cases had more clinical lethargy, bilious 
vomiting, bloody stool and more failure to reduce intussusception than 
non-referral cases (P< 0.05). In the multivariate model, clinical irritability 
and abdominal distension were the significant factors for failure to reduce 
intussusception. The pathologic leading of intussusception were identified 
in 28.8% including lymphoma, diverticulum, polyp, Crohn’s disease, ap-
pendicolith, and enlarged intra-abdominal lymph nodes. AR to diagnose 
intussusception had sensitivity, specificity, PPV, NPV and accuracy of 73%, 
63.6%, 67%, 70% and 68.4%, respectively. However, a combination of 
clinical irritability or abdominal pain, vomiting and age < 2 years with 
compatible AR (the Pediatric Intussusception Score model) had a high di-
agnostic value with a specificity of 93.33%
conclusion: AR had a poor diagnostic value to diagnose intussusception. 
Apart from the well-known triad, the Pediatric Intussusception Score could 
increase the diagnosis accuracy leading to timely specific management.
references: 1. Weihmiller SN, Buonomo C, Bachur R. Risk stratification of 
children being evaluated for intussusception. Pediatrics 2011;127:e296-303. 
2. Territo HM, Wrotniak BH, Qiao H, Lillis K. Clinical signs and symptoms 
associated with intussusception in young children undergoing ultrasound 
in the emergency room. Pediatr Emerg Care 2014;30:718-22.
disclosure: Nothing to disclose 
P1695 effecT Of POrTOsysTeMIc shunT surgery On 
chOLangIOPaThy In chILdren WITh exTrahePaTIc POrTaL 
venOus OBsTrucTIOn
Ravindranath A., Sen Sarma M., Yachha S.K., Lal R., Singh S., 
Srivastava A., Poddar U., Neyaz Z., Behari A.
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Pediatric 
Gastroenterology, Lucknow, India
contact e-Mail address: aathira.r@gmail.com
Introduction: There is paucity of literature on portal cavernoma cholan-
giopathy (PCC) in children and there are a number of unanswered ques-
tions regarding the outcome of PCC especially after porto-systemic shunt 
surgery.
aims & Methods: 
Objectives: To assess the effect of portosystemic shunt surgery on PCC in 
children with EHPVO.
Methods: Children with EHPVO deemed unfit for Meso-Rex shunt with 
splenomegaly-related issues and presence of PCC (symptomatic or as-
ymptomatic) underwent Magnetic resonance cholangiogram (MRC) and 
Magnetic resonance portovenogram (MRPV) just before non-selective 
portosystemic shunt surgery. PCC was graded as per modified Llop clas-
sification.[1] Those with patent shunt were re-evaluated for PCC at least 6 
months after surgery with repeat MRC and compared with pre-shunt im-
ages. Pre and post shunt assessment of peribiliary collateral density was 
made on MRPV and correlated with the vascular anatomy.
results: Twenty five children underwent portosystemic shunt surgery 
(central end to side splenorenal shunt with splenectomy in 24, mesocaval 
shunt in 1). Their duration of disease, age at surgery (pre-surgery PCC 
assessment) and age at re-assessment (post-surgery PCC) were 77 (15-
144) months, 156 (72 - 210) months, 192 (78 to 216) months respectively. 
All showed shunt patency and adequate flow velocity. Pre-surgery MRC 
showed PCC grade I in 11, grade II in 1 and grade III in 13. MRPV showed 
SMV block in 20. Re-assessment for PCC 18 (6 to 54) months after surgery 
showed grade 1 in 6 and grade III in 19. The overall change in grade of PCC 
pre and post-surgery was significant (p=0.04). Thus, PCC was progressive 
in 6 and static in 19 children. Regression was seen in none. The density 
of peribiliary collaterals decreased in 5, increased in 3 and remained un-
changed in 17. Decrease in peribiliary collaterals was seen only in those 
with SMV patency (n=5) and their PCC was static. Splenomegaly-related 
issues, gastroesophageal varices on endoscopy and other intrabdominal 
(esophageal, perisplenic and perigastric) collaterals ameliorated in all.
  Pre-surgery (n=25)
Post-surgery 
(n=25) p-value
Grade I 11 6  
Grade II 1 0  
Grade III 13 19  
Wavy changes 19 17 0.16
Angulations 10 10 1.0
Indentations 7 9 0.56
Strictures 14 19 0.02
Upstream dilatation (Intrahepatic) 12 18 0.01
Upstream dilatation (Extrahepatic) 8 13 0.06
[Comparison of MRC features pre and post-portosystemic shunt surgery]
conclusion: Non-selective porto-systemic shunt surgery decompresses the 
portal hypertension in esophago-gastro-splenic venous circuit effectively 
but fails to ameliorate the cholangiopathy and peribiliary collaterals. The 
peristence of cholangiopathy is attributable to SMV block.
references: [1] Llop E, de Juan C, Seijo S, et al. Portal cholangiopathy: 
radiological classification and natural history. Gut. 2011;60:853-60.
disclosure: Nothing to disclose 
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P1696 dIsTIncTIve MIcrOBIOTa TraITs aLLOW TO 
dIfferenTIaTe BeTWeen cLOsTrIdIuM dIffIcILe InfecTIOn 
and InfLaMMaTOry BOWeL dIsease PaTIenTs In an aMerIcan 
POPuLaTIOn
Amoedo J.1,2, Ramió-Pujol S.1, Park E.3, Pollock N.3, Kelly C.3, 
Serra-Pagès M.1, Guardiola J.4, Moss A.3, Aldeguer X.1,5,6, Garcia-Gil J.1,2
1GoodGut SL, Girona, Spain, 2Universitat de Girona, Microbiology 
department, Girona, Spain, 3Beth Israel Deaconess Medical Center, Boston, 
United States, 4Hospital Universitario de Bellvitge, Gastroenterology, 
L’Hospitalert de LLobregat (Barcelona), Spain, 5Departament de 
Gastroenterologia, Hospital Dr. Josep Trueta, Girona, Girona, Spain, 6Institut 
d’Investigació Biomèdica de Girona, Girona, Spain
contact e-Mail address: joan.amoedo@goodgut.eu
Introduction: Clostridium difficile infection (CDI) incidence has increased in 
recent years and it is the major cause of antibiotic-associated diarrhoea. 
Its manifestations have many similarities to exacerbations of Inflamma-
tory Bowel Disease (IBD). Dysbiosis, a deviation from the normal microbial 
composition, has been widely reported in both CDI and IBD patients.
aims & Methods: The aim of this study was to compare the abundances of 
different bacterial markers in stool samples of CDI and IBD patients, which 
might be used to develop bacterial biomarkers for IBD in symptomatic 
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patients. A cohort consisting of 20 CDI and 22 IBD patients were recruited 
by the Gastroenterology department from Beth Israel Deaconess Medical 
Center (Boston, USA). All CDI and IBD patients presented an active clini-
cal represented by the presence of depositional alteration and abdominal 
pain. The relative abundance of all bacterial markers by qPCR: Faecali-
bacterium prausnitzii (Fpra), Escherichia coli (Eco), F. prausnitzii phylogroup 
I (PHG-I), F. prausnitzii phylogroup II (PHG-II), Akkermansia muciniphila 
(Akk), Ruminococcus sp. (Rum), Lactobacillus sp (Lac), Bacteroidetes (Bac) 
and Methanobrevibacter smithii (Msm) was determined on faecal samples.
results: The relative abundances of Fpra, PHG-I, PHG-II, Rum, Eco and 
Msm were significantly different between CDI and IBD patients. While 
Fpra, PHG-I, PHG-II and Rum were significantly lower in CDI patients when 
compared with IBD patients, the abundance of Eco and Msm were signifi-
cantly higher in CDI patients. No significant differences were found in Akk, 
Lac and Bac.
conclusion: CDI patients exhibit a lower abundance of anaerobic bacterial 
markers such as Ruminococcus, F. prausnitzii and its phylogroups, which 
are considered to be beneficial maintaining gut homeostasis, Instead, spe-
cies with inflammatory properties such as E. coli were increased in CDI. 
These results indicate that conditions with similar phenotypes (symptoms, 
endoscopic appearance) may display significant differences in faecal bac-
terial.
disclosure: Prof. Garcia-Gil, Dr. Aldeguer, Dr. Serra-Pagès, Dr. Ramió-Pu-
jol, Mr. Amoedo, are employees from GoodGut, company who has received 
private and public funding. Prof. Garcia-Gil, Dr. Aldeguer, Dr. Serra-Pagès, 
Dr. Ramió-Pujol and Mr. Amoedo report grants from CDTI, during the con-
duct of the study. Prof. Garcia-Gil, Dr. Aldeguer and Dr. Serra-Pagès are 
also GoodGut shareholders, outside the submitted work. The rest of the 
authors have nothing to disclose. 
P1697 esTaBLIshMenT Of chrOnIc InfLaMMaTIOn MOdeL 
usIng huMan sMaLL InTesTInaL and cOLOnIc OrganOIds
Hibiya S., Tsuchiya K., Katsukura N., Shirasaki T., Watanabe S., 
Nishimura R., Okamoto R., Watanabe M.
Tokyo Medical and Dental University, Gastroenterology and Hepatology, 
Tokyo, Japan
contact e-Mail address: shibiya.gast@tmd.ac.jp
Introduction: Patients with inflammatory bowel disease (IBD) mainly pres-
ent with ulcerative colitis (UC) or Crohn’s disease (CD). Recently, it has 
been recommended that mucosal healing is therapeutic goal of IBD. Fur-
thermore, histological healing is becoming new target to treat IBD, be-
cause dysfunction of epithelial cells such as goblet cell depletion and crypt 
distortion might cause frequent relapse. However, the mechanism for cell 
transformation of intestinal epithelial cells by chronic inflammation re-
mains unknown.
aims & Methods: We have previously reported the irreversible transfor-
mation of intestinal epithelial cells after long-term chronic inflammation 
for over a year by using mice colonic organoids1. We therefore aimed to 
establish human in vitro chronic inflammatory model using human small 
intestinal and colonic organoid because human model might be useful to 
assess the molecular mechanism of pathogenesis. Human small intestinal 
and colonic organoids were isolated from non-inflamed lesion of small 
intestine and colon, respectively. The expression of inflammatory related 
receptors in both organoids were assessed by RT-PCR. Inflammatory re-
sponse of the organoids by each inflammatory reagent was assessed by 
IL-8 expression. The mixture of inflammatory reagents were added into 
medium every other day for 12 weeks. The expression of NF-kB target 
genes IL-8, DUOXA2 was assessed every 3 weeks during 12 weeks stim-
ulation. Microarray analysis was performed at 5 weeks of inflammatory 
stimulation in colonic inflammatory organoids. This study was approved 
by the ethics committee.
results: We identified the difference of the inflammatory related recep-
tors expressed in between human small intestinal and colonic organoids. 
Inflammatory response by each inflammatory reagent was also different 
between small intestinal and colonic organoids. The mixture of inflamma-
tory reagents for small intestinal and colonic organoids has therefore been 
decided respectively for suitable inflammatory response. The stimulation 
by inflammatory reagents showed the significant induction of IL-8 and DU-
OXA2 in both small intestinal and colonic organoids. IL-8 was immediately 
downregulated during 12 weeks stimulation following rapid increase at 3 
hours stimulation in both small intestinal and colonic organoids. In con-
trast, the expression of DUOXA2 gene was persistently increased form 3 
hours to 12 weeks stimulation in both organoids. Microarray analysis in 
colonic organoids showed that the highest induced gene was claudin-18 
(CLDN18), which has been reported to be increased in UC patients. The 
expression of CLDN18 were gradually increased at the late phase of inflam-
matory stimulation for 12 weeks in both organoids, indicating that the ex-
pression pattern of inflammatory induced genes was classified by 3 types; 
tentative, persistent and gradual.
conclusion: Chronic inflammation into the human small intestinal and co-
lonic organoid might mimic the phenotype of IBD. The establishment of in 
vitro human model for IBD might be useful for the identification of chronic 
inflammatory specific genes and developing effective therapy targeted 
mucosal healing. Moreover, the analysis of genes gradually upregulated 
at the late phase of inflammatory stimulation might be useful for under-
standing the pathogenesis of epithelial cell transformation during IBD dis-
ease duration. Furthermore, the identification of the differences between 
in vitro small intestinal and colonic organoids might be necessary for the 
investigation of differences between UC and CD.
references: 1) Hibiya S, Tsuchiya K et al. Long-term inflammation trans-
forms intestinal epithelial cells of colonic organoids. J Crohns Colitis. 
11:621-630, 2017.
disclosure: Nothing to disclose 
P1698 succInaTe acTIvaTes The erk PaThWay and The 
exPressIOn Of WnT LIgands In ePITheLIaL ceLLs
Arastey M.1, Ortiz-Masia D.2, Gisbert Ferrándiz L.3, Macías-Ceja D.C.3, 
Calatayud S.3, Barrachina M.D.3, Cosin-Roger J.4
1Universitat de Valencia, Farmacologia, Valencia, Spain, 2CIBERehd-
Universtat de Valencia, Medicina, Valencia, Spain, 3Universitat de Valencia, 
Pharmacology, Valencia, Spain, 4Unidad Mixta Facultad de Medicina-
Hospital Dr Peset, FISABIO, Pharmacology, Valencia, Spain
contact e-Mail address: jesus.cosin@uv.es
Introduction: Crohn’s disease (CD) is a chronic inflammatory disorder of 
the gastrointestinal tract characterized by initial transmural inflamma-
tion, commonly associated with complications, such as stenosis, abscesses 
and fistulas.The development of fistulas has been associated with the 
epithelial-mesenchymal transition (EMT) which is the process that allows 
to change the phenotype of the epithelial cells to a fibrotic behavior. Under 
inflammatory conditions, the metabolite succinate accumulates and its re-
ceptor, called SUCNR1,activates EMT.
aims & Methods: The objective of this study is to analyze the pathway 
activated by succinate in epithelial cells.Intestinal resections from CD’s pa-
tients (subdivided in B2 and B3 according Montreal’s classification) were 
obtained. Healthy resections from colon carcinoma patients were used as 
controls and succinate levels were measured by using a colorimetric kit. 
HT-29 intestinal epithelial cells were treated with a constant concentra-
tion of 1mM succinate during different times (0 min, 15min, 30min, 1h, 
6h and 24h). We analyzed the expression of p-ERK with respect to total 
ERK by means of Western Blot. The expression of the EMT markers (Snail1, 
Vimentin and E-Cadherin) as well as the expression of Wnt ligands and 
Wnt targets (Wnt1, Wnt4 and Wnt10a, c-myc, lgr5) were analyzed by qPCR 
after treatment with succinate. In some cases cells were treated with an 
inhibitor of the ERK pathway (V0126 10 µM).Results are expressed by mean 
± SEM (n≥3) and as fold induction vs vehicle. Statistical analysis was per-
formed with one-way ANOVA followed by Newman-Keuls test.
results: The succinate concentration is higher in intestinal resections from 
B3 (208.9 ± 26.03) than B2 (127.2 ± 21.66) CD patients. In HT-29 cells, suc-
cinate induces an increase in the expression of p-ERK at 15 min (195.5% 
± 72.83). It also produces an increase in the mRNA expression of Vimentin 
(fold induction of 1.60 ± 0.20), Snail1 (2.12 ± 0.09), Wnt1 (4.76 ± 1.05), Wnt4 
(2.32 ± 0.52), Wnt10a (3.69 ± 0.34), c-myc (1.14 ± 0.10) and lgr5 (1.28 ± 0.12) 
and a decrease in E -cadherin (0.63 ± 0.08). The treatment with V0126 
revert these changes to values that do not differ from that obtained in 
vehicle-treated cells.
conclusion: Succinate is increased specifically in B3 patients. In addition, 
succinate induces the activation of the ERK pathway and the expression 
of Wnt ligands in epithelial cells, which could be involved in the effects of 
succinate on EMT.
disclosure: Nothing to disclose 
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P1699 assOcIaTIOn Of cx3cr1 exPressIOn In The PerIPheraL 
BLOOd WITh MucOsaL InfLaMMaTIOn In IBd: a naTuraL kILLer 
sTOry?
Uniken Venema W.T.C.1, Visser F.1, Hagting M.1, Voskuil M.2, Jansen B.H.1, 
Weersma R.K.2, Festen E.A.M.(.3
1University Medical Center Groningen, Gastroenterology, Groningen, 
Netherlands, 2University Medical Center Groningen, Gastroenterology and 
Hepatology, Groningen, Netherlands, 3University Medical Center Groningen, 
Groningen, Netherlands
contact e-Mail address: w.t.c.uniken.venema@umcg.nl
Introduction: CX3CR1 is a chemokine receptor expressed on various (im-
mune) cell types, and involved in adhesion on and migration of leukocytes 
through epithelial and endothelial cells (1,2). The proportion of CX3CR1+ 
cells within the blood CD4 effector T cell population, has been found to 
be correlated with clinical disease activity in IBD (3). Moreover, blocking 
CX3CR1 has been shown to reduce colitis in mice. This renders CX3CR1 
a promising drug target for IBD and a potential biomarker for disease 
activity. We assessed expression of CX3CR1 on a variety of cell types in the 
blood of IBD patients and healthy controls to find potential target cells for 
CX3CR1-blockade therapy in humans, and questioned whether expression 
of CX3CR1 is associated with histologically proven disease activity in the 
gastrointestinal tract in patients with IBD.
aims & Methods: Peripheral blood from patients with Crohn’s disease (CD, 
n=11), ulcerative colitis (UC, n=11) and healthy controls (HC, n=11) was col-
lected prior to endoscopy. Whole blood was isolated using washing and 
lysis of red blood cells, stained with a panel containing various antibodies 
(CD3, CD8, CD19, CD16, CD14, CD15, CX3CR1, CD56) and subsequently ana-
lyzed using an LSR II FACS analyzer. Disease activity was assessed through 
evaluation of biopsies of macroscopically inflamed areas by a pathologist. 
Using flow cytometry, the proportion of CX3CR1-positive cells as well as 
the level of CX3CR1 expression in a variety of cell types was evaluated. 
Differences between CD, UC and HC, as well as between patients with 
and patients without disease activity in the gastrointestinal tract were as-
sessed.
results: We noted CX3CR1 expression on blood (NK) T cells, NK cells, 
monocytes and granulocytes, but not on B cells. Neutrophils constitute 
the largest proportion of CX3CR1+ cells in the blood (median 3.7% [IQR 
3.3]), whereas within the subpopulations, non-classical monocytes (me-
dian 98% [IQR 2.6]) and NK cells (median 90.3% [IQR 8.7]) had the highest 
proportion of CX3CR1 positive cells. In blood derived from patients with 
histologically active UC, intermediate monocytes showed a significantly 
higher proportion of CX3CR1+ cells (p=0.036), whereas CD4+ NK T cells 
showed upregulation of CX3CR1 on the cell surface (p=0.013), compared to 
patients with UC in remission. In CD, the proportion of CX3CR1+ CD8+ NK 
T cells was higher in patients with inflammation versus patients without 
inflammation (p=0.05).
conclusion: CX3CR1 is expressed on a wide variety of peripheral blood 
cells. Although the proportion of CX3CR1+ cells within the CD4 T cell popu-
lation has previously been reported to be associated with clinical disease 
activity in IBD, we do not find an association between the proportion of 
CX3CR1+ CD4 T cells and histologically proven disease activity in IBD. We do 
find an association between inflammation and CX3CR1+ CD8+ NK T cells in 
CD and CX3CR1+ intermediate monocytes in UC, which highlights the role 
of these cells in IBD. These results provide a baseline for follow-up studies 
on the role of CX3CR1 in IBD.
references: 1. Imai T, Hieshima K, Haskell C, et al. Identification and molec-
ular characterization of fractalkine receptor CX3CR1, which mediates both 
leukocyte migration and adhesion. Cell 1997;91:521-30. 2. Nishimura M, 
Umehara H, Nakayama T, et al. Dual functions of fractalkine/CX3C ligand 
1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes 
that are defined by CX3CR1 expression. J Immunol 2002;168:6173-80. 3. Ko-
bayashi T, Okamoto S, Iwakami Y, et al. Exclusive increase of CX3CR1+CD28-
CD4+ T cells in inflammatory bowel disease and their recruitment as in-
traepithelial lymphocytes. Inflamm Bowel Dis 2007;13:837-46.
disclosure: Nothing to disclose 
P1700 nO dIfference In The dIsTrIBuTIOn Of PaThOgenIc 
facTOrs fOund In escherIchIa cOLI IsOLaTes frOM PaTIenTs 
WITh crOhn’s dIsease and heaLThy IndIvIduaLs
Siniagina M., Markelova M., Laikov A., Boulygina E., Khusnutdinova D., 
Kharchenko A., Fedorova M., Romanova V., Grigoryeva T.
Kazan Federal University, Kazan, Russian Federation
contact e-Mail address: marias25@mail.ru
Introduction: Dysbiosis of the gut microbiome in Crohn’s disease (CD) pa-
tients is associated with reduced bacterial diversity and higher relative 
abundance of Proteobacteria phylum, in particular Escherichia coli. In re-
cent decades, E. coli is thought to be implicated in CD pathogenesis and 
considered as one of the possible causes of the disease occurrence and 
progression.
aims & Methods: The aim of the study was to characterize E. coli strains 
obtained from diagnosed CD patients and individuals (controls), and to 
evaluate their contribution to the pathogenesis of CD.
E. coli strains were isolated from stool samples of 14 patients and 18 con-
trols. Fecal suspensions were inoculated on selective Endo medium and 
colonies were identified by MALDI Biotyper and serological test. Based on 
quadruplex PCR identification according to Clermont et al. (2013), the colo-
nies were assigned to phylogenetic groups. Ninety seven selected isolates 
were sequenced on MiSeq platform. Reads were assembled using SPAdes 
v.3.11.1 followed by assemblies’ annotation using Prokka v.1.9. Serotypes 
were assigned using SerotypeFinder-2.0 tool. Using MLT ENTEROtest 24N 
kit, the strains were tested for the production of H
2
S and the ability to 
utilize various sugars, polyhydric alcohols, glycosides, and amino acids.
results: Out of 97 sequenced isolates, 33 duplicates were revealed using 
the comparative genome analysis, i.e. isolates sequenced more than once 
due to varying colony phenotypes. Sixty four strains had unique genomes - 
27 isolates from CD patients, and 37 isolates from the control group.
The phylogenetic group distribution did not differ significantly between CD 
patients and controls. However, E. coli strains belonged to phylogroups E/
clade 1 and F were identified only in healthy donors. Clinical significance 
of strains belonging to these groups is not well understood.
The pathogenicity and virulence of E. coli strains were explored by search-
ing for 61 previously reported genes of adhesion and invasion system in 
their genomes. We found no statistically significant difference in these 
genes distribution when comparing isolates from both CD and control 
groups. So, there was no evidence for the association between CD status 
and the presence of pathogenic or virulent genes in E. coli strains. Ac-
cording to the classification of E. coli serotypes, among isolated strains 3 
enteroagregative types (EAEC: O17/O44:H18, O15:H18, O126:H27), 3 entero-
pathogenic types (EPEC: O128ac:H12, O88:H25, O154:H9), and 1 enteroinva-
sive type (O112ac:H16) were found. The distribution of these types did not 
differ significantly between CD and control groups, either, though strains 
of these serological subgroups prevailed in fecal samples from individuals 
with CD and constituted a smaller proportion in healthy ones. Prevalence 
of these strains in CD patients may be associated with the development of 
the disease.
Strains from studied cohorts showed no significant difference in ability to 
catalyze sugars, polyhydric alcohols, glycosides and amino acids. It is of 
interest to note, 3 different strains from one CD patient showed ability to 
produce H
2
S. It is supposed that hydrogen sulfide involves in IBD develop-
ment by disrupting the integrity of the intestinal mucosa.
conclusion: The whole genome analysis of E. coli strains in CD patients 
and healthy controls did not reveal any connection between E. coli viru-
lence and pathogenicity and disease status. It may be assumed that the 
development of the disease is associated with altered interaction between 
the bacteria with certain serotypes and human immune system and their 
balance in community.
references: Clermont, O., Christenson, J. K., Denamur, E., Gordon, D. M. 
(2013). The Clermont Escherichia coli phylo‐typing method revisited: im-
provement of specificity and detection of new phylo‐groups. Environmen-
tal microbiology reports, 5(1), 58-65.
disclosure: This work was funded by Russian Foundation for Basic Re-
search (RFBR) according to the research project №17-00-00433 
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P1701 a guT MIcrOBIOTa-derIved MeTaBOLITe rerOuTes 
InTesTInaL exPansIOn Of anTIgen PresenTIng ceLLs frOM 
cIrcuLaTIng MOnOcyTes fOr enhancIng anTI-TuMOraL 
acTIvITy and survIvaL In cOLOrecTaL cancer
Chauvin C.1, Boulard O.1, Perche Q.1, Régnier P.2, Delacre M.1, 
Segura E.3, Waldschmitt N.4, Couturier-Maillard A.1, Darasse-Jèze G.2, 
Chamaillard M.5, Poulin L.1
1Centre of Infection and Immunity of Lille, NLRII, Lille, France, 2Université 
Paris Descartes, Faculté de Médecine Paris Descartes, Paris, France, 3Institut 
Curie, PSL Research University, Paris, France, 4INSERM Lille, Freising, 
Germany, 5Inserm U 1019-7, Inserm U 1019, Lille, France
contact e-Mail address: camille.chauvin@curie.fr
Introduction: The intestinal mucosa inhabits the largest pool of phagocytes 
that fails to be constantly replenished from circulating monocytes in the 
absence of the gut microbiota and to some extent in response to antibiot-
ics. Understanding this paradigm is of importance as long-term compo-
sitional changes in the gut microbiome has been linked to the initiation 
and progression of either inflammatory or neoplastic lesions even later in 
life. We herein investigated whether bacterial muramyl dipeptide (MDP), 
which occurs physiologically in high concentrations within the intestinal 
lumen, may interfere on the functional specialization of circulating mono-
cytes into either dendritic cells or macrophages for intestinal homeostasis.
aims & Methods: The NOD2 gene expression levels of 427 colorectal can-
cer patients was respectively compared to outcome using the cancer ge-
nome atlas database. The transcriptomic data from NOD2hi and NOD2low 
tumors were further analysed for identifying gene pathways that were 
differentially enriched. We next performed multiparametric cell cytometry 
and gene expression analysis by making use of the Azoxymethane (AOM)/
Dextran Sulfate Sodium (DSS) model of mouse colorectal cancer. A mouse 
model of colitis and competitive bone-marrow chimera mice were used for 
evaluating the anti-inflammatory properties and the long-term autonomy 
of M-CSF-derived phagocytes from Nod2-deficient mice respectively. This 
fate mapping of Nod2-deficient bone marrow derived precursors was ad-
dressed by reconstituting Nod2-deficient CD45.2+ animals with an equal 
mixture of wild-type CD45.1+ and congenic Nod2-deficient CD45.2+ cells. 
After these in vivo systems, we used in vitro culture approaches to study the 
impact of MDP on human monocytes differentiation into either dendritic 
cells or macrophages.
results: A shorter median survival time of patients was observed for 
those with the lowest transcript levels of NOD2. Such tumors were mark-
edly characterized by a lowered expression of several genes involved in 
phagocytosis and antigen presentation. Conversely, the intratumoral 
abundance of monocyte-derived phagocytes (CD11b+ CCR2- Ly6C- MHCII+) 
was lowered in tumours from Nod2-deficient animals. Quantitative RT-PCR 
analysis further argued for a specific decrease in the accumulation of an-
tigen presenting cells derived from circulating monocytes despite similar 
abundance of macrophages. The shift towards monocyte-derived dendritic 
cells was also found when treating human peripheral blood monocytes 
with MDP. Adoptive transfer of M-CSF-derived phagocytes alleviated the 
severity of DSS-induced colitis, while the absence of NOD2 gave a lowered 
advantage on the expansion of such cells as determined by competitive 
chimera experiment.
conclusion: Herein, we identified a key role of the major Crohn’s disease 
predisposing NOD2 gene on the ontogeny of monocyte-derived dendritic 
cells that may account for the greater survival of colorectal patients with 
high levels of intratumoral NOD2.
disclosure: Nothing to disclose 
P1702 cIrcuLaTIng vITaMIn d BIndIng PrOTeIn, TOTaL, free 
and BIOavaILaBLe 25-hydrOxyvITaMIn d and TheIr reLaTIOn 
TO InfLaMMaTIOn In InfLaMMaTOry BOWeL dIsease
Aksan A.1,2, Boettger K.1,3, Hein N.3, Caicedo-Zea Y.4, Diehl I.4, 
Schumann C.4, Armbruster F.-P.4, Stein J.1,2,3
1Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt am Main, 
Germany, 2Goethe University, Institute of Pharmaceutical Chemistry, Frankfurt 
am Main, Germany, 3DGD Clinics Sachsenhausen, Teaching Hospital of the 
Goethe University, Gastroenterology and Clinical Nutrition, Frankfurt am 
Main, Germany, 4Immundiagnostik AG, Bensheim, Germany
contact e-Mail address: ayscak@gmail.com
Introduction: There is mounting evidence to suggest that vitamin D levels 
are associated with important clinical parameters and outcomes in pa-
tients with inflammatory bowel disease (IBD). In recent years, additional 
IBD cohort studies have emerged that further support an association be-
tween vitamin D deficiency and clinical disease activity (1-4). However, the 
causal relationship remains unclear. To our knowledge, this is the first 
study in adult patients with IBD to report the influence of vitamin D bind-
ing protein (VDBP) on the association between circulating total, free, and 
bioavailable 25(OH)D and inflammation in IBD.
aims & Methods: This study aimed to provide a better understanding of this 
relationship by more closely examining the relation between inflammation 
and different vitamin D parameters. A comparative, single-centered, cross-
sectional study was conducted in 108 adults with IBD. Blood count, trans-
ferrin, albumin and CRP were determined by routine assays. CRP levels 
≥5mg/dL were considered biochemical evidence of inflammatory activity. 
25(OH)D and VDBP levels were determined by ELISA. Free vitamin D and 
bioavailable vitamin D levels were calculated with the validated formula 
(5). Statistical analysis was performed using IBM SPSS version 25.0.
results: 108 subjects with IBD (54 male, 59 female; 68 CD, 45 UC) with a 
mean age of 41.08 ±12.84 years were recruited to the study. Of these pa-
tients, 32/108 had inflammatory activity (14 male, 18 female; 22 CD, 10 UC; 
39.69 ±13.89 years) while 76/108 had no inflammation (36 male, 40 female; 
44 CD, 32 UC; 41.54 ±12.43 years). The albumin levels were negatively cor-
related with CRP (-0.303, p=0.002) and significantly lower in the presence 
of inflammation (p< 0.05). Average serum 25(OH)D levels were found to 
be similar in inflammatory and non-inflammatory conditions (25.37 ±11.38 
and 23.46 ±10.12 ng/mL respectively, p>0.05). However, VDBP levels were 
significantly higher when inflammation was present (364.26 ±63.26 mg/L 
in inflammatory vs. 335.27 ±67.51 mg/L in non-inflammatory conditions, 
p< 0.05) and also showed a positive correlation with CRP levels (0.288, 
p=0.003). The free/total 25(OH)D ratio was negatively correlated with CRP 
levels (-0.260, p< 0.05). Neither free 25(OH)D nor bioavailable 25(OH)
D levels were correlated with CRP or albumin levels and no significant 
inflammation-related variance in levels was found for either of these pa-
rameters.
conclusion: Although no association between total, free and bioavailable 
25(OH)D and inflammation was observed, high levels of circulating VDBP 
were associated with increased levels of inflammation. Confirming this as-
sociation, the free/total 25(OH)D ratio showed an inverse association with 
inflammation. These findings suggest that VDBP may play a bigger role 
than previously thought in the modulation of the complex relation be-
tween vitamin D and inflammation. Thus, we propose that the simultane-
ous detection and investigation of total, free and bioavailable 25(OH)D and 
VDBP levels in plasma can provide valuable information when studying the 
relationship between vitamin D and IBD-related inflammation.
references: 1. Blanck S, Aberra F. Vitamin d deficiency is associated 
with ulcerative colitis disease activity. Digestive diseases and sciences. 
2013;58(6):1698-702. 2. Ulitsky A, Ananthakrishnan AN, Naik A, Skaros S, 
Zadvornova Y, Binion DG, et al. Vitamin D deficiency in patients with in-
flammatory bowel disease: association with disease activity and quality of 
life. JPEN Journal of parenteral and enteral nutrition. 2011;35(3):308-16. 3. 
Alrefai D, Jones J, El-Matary W, Whiting SJ, Aljebreen A, Mirhosseini N, et 
al. The Association of Vitamin D Status with Disease Activity in a Cohort of 
Crohn’s Disease Patients in Canada. Nutrients. 2017;9(10). 4. Scolaro BL, 
Barretta C, Matos CH, Malluta EF, Almeida IBTd, Braggio LD, et al. Defi-
ciency of vitamin D and its relation with clinical and laboratory activity 
of inflammatory bowel diseases. Journal of Coloproctology. 2018;38(2):99-
104. 5. Bikle DD, Malmstroem S, Schwartz J. Current Controversies: Are 
Free Vitamin Metabolite Levels a More Accurate Assessment of Vitamin D 
Status than Total Levels? Endocrinology and metabolism clinics of North 
America. 2017;46(4):901-18.
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Introduction: Inflammatory bowel disease (IBD) is caused by a complex 
interaction among genetic, immunological, bacterial and environmental 
factors. In this scenario, protein tyrosine phosphatase non-receptor type-
2 (PTPN2) has been recognized as a risk factor for the development of 
IBD and functional studies revealed a major role for this protein in the 
development of experimental colitis through the regulation of the inflam-
masome, among other processes. Similar, the immunoregulatory cytokine 
interleukin-10 (IL-10), which is a master regulator of innate immune cell 
function and controls excessive inflammatory cytokine release, e.g. that 
of the inflammasome product IL-1β, has also been considered a relevant 
player in the control of intestine inflammation.
aims & Methods: Here we aimed to elucidate the interaction between IL-10 
and PTPN2 dysfunction in the development of intestinal inflammation, at 
cellular and molecular level, in order to contribute to the identification of 
new and novel prevention and/or therapeutic approaches. 
DSS colitis and the IL-10-/- immune cell-driven colitis models were per-
formed in mice lacking PTPN2 in myeloid cells (PTPN2fl/flxLysMCre mice 
or PTPN2fl/flxCD11cCre mice). After that, histology studies, flow cytometry, 
expression analysis, ELISA and barrier function experiments were per-
formed. Bone marrow derived macrophages (BMDMs) were used for ex 
vivo studies.
results: Ex vivo experiments using BMDCs showed that recombinant IL-
10 was able to ameliorate the expression of IL1β induced by LPS in WT 
but not in PTPN2CD11cCre BMDCs. The same experiments using BMDMs from 
WT and PTPN2LysMCre mice revealed no differences in the expression of IL1β. 
However, IL-10-induced reduction of the production of mature IL1β was 
impaired in BMDMs from PTPN2LysMCre mice as compared with their WT lit-
termates. Analysis of different well-known signalling pathways involved 
in the regulation of the inflammasome and IL1β expression revealed that 
NFκappaB, Erk and Jnk activation were dysregulated in PTPN2LysMCre BMD-
Ms. Colitis models using IL-10-/- and IL-10-/-xPTPN2LysMcre mice also revealed 
differences in prolapse incidence, histology scores and myeloperoxidase 
activity, being all these parameters increased in the mice lacking PTPN2 
in myeloid cells.
conclusion: PTPN2 contributes to IL-10-related effects on innate immune 
response and development of colitis. These results unravel a novel mo-
lecular mechanism, by which the beneficial effects of IL-10 on intestinal 
inflammation depends on the genetic host factors.
disclosure: Nothing to disclose 
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contact e-Mail address: dai.bingbing@gene.com
Introduction: Therapeutic approaches to treating inflammatory bowel 
diseases (IBD) include targeting integrins that mediate adhesion and 
migration of inflammatory lymphocytes to the gastrointestinal (GI) tract. In 
the era of anti-integrin therapies in IBD, it is important to understand the 
relative contributions of integrin family members to lymphocyte migration 
and retention in the GI tract.
aims & Methods: To dissect the role of β7 integrins in lymphocyte traf-
ficking, we used the KikGR transgenic mouse model which ubiquitously 
expresses a green-to-red photoconvertible protein. After treatment with 
antibodies against α4β7, αEβ7, β7 (which targets both α4β7 and αEβ7), 
or a control, mesenteric lymph nodes (MLNs) were surgically exposed to 
violet light to photo-convert cells from KikG (green fluorescence) to KikR 
(red fluorescence). Frequency of KikR+ CD8+ T cells in the colon lamina 
propria was then analysed by flow cytometry. Statistical testing was con-
ducted using Student’s unpaired t tests.
results: Individual blockade of either α4β7 or αEβ7 integrin reduced CD8+ 
T cell localization to the colon lamina propria from mesenteric lymph 
nodes, whereas blockade of both led to a greater reduction in CD8+ T 
cells (Table). Further, we demonstrate superior reductions in both poly-
clonal and antigen-specific effector T cell accumulation in the intestinal 
mucosa following concurrent inhibition of both β7 integrins as compared 
with single blockade of either α4β7 or αEβ7. Additional experiments using 
intra-vital two-photon microscopy to image mucosal CD8+ T cells from the 
luminal side of the small intestine showed that αEβ7-expressing T cells 
actively migrate within the epithelium and can travel across the basement 
membrane between subepithelial regions and lamina propria compart-
ments. Importantly, blockade of αEβ7 or its ligand E-cadherin reduces T 
cell interactions with the basolateral epithelial surface. Lastly, blockade of 
αEβ7, but not α4β7, reduces the retention time of activated effector T cells 
in the intestinal mucosa. 
comparison Mean ± seM (% of migration relative to control)
Anti-αEβ7 vs control 54.6%±9.5% vs 100%*
Anti-αEβ7 vs control 52.1%±6.7% vs 100%*
Anti-αEβ7 + anti-α4β7 vs control 29.1%±6.7% vs 100%***
Anti-αEβ7 + anti-α4β7 vs anti-αEβ7 29.1%±6.7% vs 54.6%±9.5%*
Anti-αEβ7 + anti-α4β7 vs anti-α4β7 29.1%±6.7% vs 52.1%±6.7%*
Anti-β7 vs control 26.4%±6.4% vs 100%**
Anti-β7 vs anti-αEβ7 26.4%±6.4% vs 54.6%±9.5%*
Anti-β7 vs anti-α4β7 26.4%±6.4% vs 52.1%±6.7%*
MLN, mesenteric lymph node; SEM, standard error.
Data were calculated as percentage of KikR+ CD8+ cells migrated from MLN relative to 
that of the control group. *P < 0.05, **P < 0.01, ***P < 0.001. Data are representative of 
five independent experiments. 
[Table. Trafficking of CD8+ T Cells from MLNs to the Colon Is Reduced by Dual 
Blockade of α4β7 and αEβ7]
conclusion: Taken together, our results suggest a model in which cell mi-
gration to the gut mucosa is mediated through α4β7 while activated ef-
fector T cells are retained in the lamina propria and intra-epithelial space 
via αEβ7:E-cadherin interactions. Co-blockade of α4β7 and αEβ7 leads to 
increased reduction of T cell accumulation in GI tissues through a stepwise 
inhibition of T cell migration and subsequent tissue retention. Our data 
also suggest that a therapeutic blockade of both α4β7 and αEβ7 such as 
that provided by etrolizumab may provide more efficient inhibition of T cell 
trafficking to the gut and potentially their inflammatory effects on the gut 
lining, which could alter the pathogenesis of IBD, than blockade of one 
integrin alone.
disclosure: All authors are employees of Genentech, Inc. 
P1705 InTraceLLuLar survIvaL and rePLIcaTIOn Of 
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Introduction: Adherent-invasive Escherichia coli (AIEC) have been associ-
ated with Crohn’s disease pathogenesis. AIEC pathotype is constituted by 
E. coli able to adhere to and invade intestinal epithelial cells, and able 
to survive and replicate within macrophages without inducing cell death. 
Identification of AIEC is based on in vitro models of infection and lacks 
standardisation. Besides, scarce data exist about the intramacrophage 
survival and replication abilities of non-adherent and non-invasive E. coli 
colonizing the gut mucosa (non-AIEC).
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aims & Methods: We aimed to compare the intracellular survival and rep-
lication abilities of AIEC and non-AIEC strains in two different cell lines 
previously used for AIEC identification. We tested 13 AIEC and 29 non-AIEC 
strains isolated from the intestinal mucosa of Crohn’s disease patients and 
controls using gentamicin protection assays in triplicate. The cell lines test-
ed were the murine macrophages J774 and the human monocytes THP-1, 
the latter was differentiated to macrophages. The results are expressed 
as the percentage of intracellular bacteria after 24h of infection. Indices 
>100% indicate intracellular survival.
results: In J774, AIEC strains clearly showed higher indices of intracellular 
survival/replication than non-AIEC (1143±750% vs 282±175%, p< 0.001). 
However, 85% of non-AIEC were indeed able to survive and replicate 
within this cell line, what can represent an issue in AIEC screening. We 
suggest a new threshold value that could be of assistance, as 85% of 
AIEC strains and only 7% of non-AIEC showed indices over 500% (p< 
0.001). In THP-1, the indices of survival/replication were lower than in 
J774 and no differences were found between strains (AIEC: 90±52%, non-
AIEC: 119±72%). No correlation was found between the data obtained by 
the two models.
conclusion: In conclusion, we suggest that the human cell line THP-1 is not 
suitable for AIEC screening and that a higher threshold value of intracel-
lular survival/replication in J774 may be of assistance in AIEC screening. 
Additional studies using more realistic models such as non-tumour hu-
man cell lines would be of interest.
disclosure: Nothing to disclose 
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and IMPrOves dss cOLITIs In MIce
Rahman S.1, Davids M.2, van Hamersveld P.H.P.1, Welting O.1, 
Meijer S.L.2, Williams D.L.3, van den Wijngaard R.M.1, Hakvoort T.B.M.1, 
de Jonge W.J.1, Heinsbroek S.E.M.1
1Academic Medical Center, Tytgat Institute for Liver and Intestinal Research, 
Amsterdam, Netherlands, 2Academic Medical Center, Amsterdam, 
Netherlands, 3East Tennessee State University, Department of Surgery, 
Johnson City, United States
contact e-Mail address: s.rahman@amsterdamumc.nl
Introduction: β-glucan consumption is known for its beneficial effects 
in reducing inflammation. Humans lack the required enzymes to digest 
β-glucans, but certain intestinal microbiota species can digest β-glucans 
and thus trigger gut microbial changes, improving human health.
aims & Methods: In this study, we determined curdlan (bacterial β-glucan) 
induced microbial changes, and followed its influence on the course of in-
testinal inflammation in the Dextran Sodium Sulfate (DSS) colitis. C57BL/6 
mice were pre-treated with vehicle (5% glucose) or curdlan (10 mg/ml) 
through oral gavage for 14 days. Subsequently, mice were taken off curdlan 
and colitis was induced by administering 2% fresh DSS daily to the drink-
ing water for 7 days. Control (non-colitis) groups received normal drinking 
water. To determine inflammation, colon weight and length was measured 
and histology scoring and gene expression study were performed. Colon 
content was collected for 16S amplicon (V3-V4) sequencing of microbiota 
composition. Differences in amplicon sequence variance (USEARCH) com-
position were visualized based on the Bray-Curtis-Dissimilarity Index. Fold 
differences were studied using DESeq2.
results: In colitis condition, disease activity index, weight loss and inflam-
mation score of the curdlan pre-treated group were improved compared to 
the vehicle treated group. Concomitant with improved colitis, the bacterial 
populations exhibited a higher alpha diversity of the curdlan fed animals 
compared to vehicle. Beta diversity analysis indicated large differences (R2 
= 0.46) in the bacterial community structure (Bray-Curtis) between the 
colitis and non-colitis condition. While curdlan feeding did not induce 
any global community changes, specific taxa did show significant differ-
ences in relative abundance. Interestingly, a specific Bifidobacterium was 
observed to be 10 to 100-fold more prevalent in the curdlan fed group in 
both colitis and non-colitis conditions respectively.
conclusion: Curdlan feeding improved DSS-induced colitis and our data 
suggests that alterations in the gut microbiome may mediate the observed 
beneficial effects.
references: 1. Baldassano S, Accardi G, Vasto S. Beta-glucans and can-
cer: The influence of inflammation and gut peptide. European Journal 
of Medicinal Chemistry. 2017;142:486-92. 2. Wirtz S, Neurath MF. Mouse 
models of inflammatory bowel disease. Advanced drug delivery reviews. 
2007;59(11):1073-83. 3. Asto E, Mendez I, Audivert S, Farran-Codina A, 
Espadaler J. The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and 
Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-
Analysis. Nutrients. 2019;11(2). 4. Schroeder BO, Birchenough GMH, Stahl-
man M, Arike L, Johansson MEV, Hansson GC, et al. Bifidobacteria or Fiber 
Protects against Diet-Induced Microbiota-Mediated Colonic Mucus Dete-
rioration. Cell host & microbe. 2018;23(1):27-40.e7.
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Introduction: Variations in the expression and/or the sequence of outer 
membrane proteins (OMPs) may modulate bacterial virulence. Increased 
OmpC expression and particular mutations in OmpA sequence have been 
related to a better interaction of adherent-invasive Escherichia coli (AIEC) 
strain LF82 with intestinal epithelial cells (IECs).
aims & Methods: We aimed to study in a collection of AIEC and non-ad-
herent and non-invasive E. coli colonizing the gut mucosa (non-AIEC): i) 
the variability of OMPs sequence to look for new variants associated with 
AIEC, and ii) to study the differential gene and protein expression of OMPs 
between the two groups of strains to gain knowledge about the role of 
OMPs in AIEC pathogenicity.
Fourteen AIEC and 30 non-AIEC strains were included in the study. The 
ompA, ompC and ompF genes were sequenced by Sanger method. Dif-
ferential expression of OMPs was studied at the protein level by urea-SDS-
PAGE in strains growing LB medium, and for the first time, at the gene 
level during in vitro infection of intestine-407 cells by RT-qPCR. Two frac-
tions were analysed: i) the bacteria present in the supernatants of infected 
cultures and ii) the bacteria interacting with IECs (either the adhered or 
the intracellular ones).
results: Sequence variants were mostly associated with the phylogenetic 
origin of the strains rather than with the AIEC phenotype. Nonetheless, 
OmpA-A200V, and OmpC-S89N, -V220I and -W231D amino acid substitu-
tions were more frequently found in AIEC than in non-AIEC strains. OMPs 
protein levels were also similar between AIEC and non-AIEC growing in 
conventional culture. However, AIEC showed increased expression of ompA 
and ompF in comparison with non-AIEC when growing in the superna-
tants of infected IECs cultures (p< 0.030). Interestingly, reduced OMPs ex-
pression was observed in AIEC strains infecting IECs (p< 0.032), whereas 
non-AIEC strains did not significantly alter OMPs expression under this 
condition (p>0.577).
conclusion: In conclusion, despite no particular OMPs sequence variants 
have been found as a common and distinctive trait in AIEC, a general trend 
has been observed in terms of OMPs gene expression using in vitro infec-
tion models. This supports the hypothesis that differential expression of 
OMPs proteins could play an important role in AIEC virulence.
disclosure: Nothing to disclose 
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Introduction: Crohn’s disease and ulcerative colitis are inflammatory bow-
el diseases (IBD) leading to abdominal pain, severe diarrhea, fatigue and 
weight loss. Over 1 million Americans and 2.5 million Europeans are esti-
mated to have IBD, with incidence rates rising exponentially in industrial-
ized nations. To date, there is no cure for IBD, making patients dependent 
on lifelong symptomatic treatment aimed to reduce recurrence of intesti-
nal inflammation. Thus, novel and effective treatments for IBD are an ur-
gent and unmet medical need. Selective Inhibitor of Nuclear Export (SINE) 
compounds, that inhibit exportin 1 (XPO1)-mediated nuclear export of over 
200 cargoes, may represent a novel option to treat inflammation, such as 
NfKb and PPAR-g. Eltanexor (KPT-8602), an oral SINE compound, has a 
broad therapeutic window and minimal brain penetration in preclinical 
species associated with reduced toxicities while maintaining efficacy. The 
safety, tolerability, and efficacy of eltanexor is currently being evaluated in 
patients with relapsed/refractory cancer indications (NCT02649790). Our 
preliminary data indicated that eltanexor also has potent anti-inflamma-
tory and cytoprotective effects both in vitro and in vivo, providing clear 
rationale for its utility as a promising therapeutic agent for IBD. This study 
sought to determine the effects of eltanexor during intestinal inflamma-
tion using a dextran sulfate sodium (DSS)-induced colitis mouse model, as 
well as its impact on cytokine expression in bone marrow-derived (BMD) 
macrophages (Mφs).
aims & Methods: Colitis was induced in C57BL6/J mice by 2.5% dextran 
sodium sulfate (DSS) in drinking water for 5 days. Disease progression 
was assessed by a standardized disease activity index (DAI) including body 
weight loss, stool consistency and blood in the faeces. Myeloid cells in-
filtrating the colonic mucosa were analyzed via flow cytometry. To assess 
the therapeutic potential of eltanexor in vivo, 10 and 15 mg/kg of the SINE 
compound were orally administered every other day starting at day 5 of 
DSS colitis. To study the anti-inflammatory effect of eltanexor at gene ex-
pression level, BMDMφs were pre-treated with eltanexor before stimula-
tion with LPS (100 ng/ml) and IFNγ (50 ng/ml).
results: To test the therapeutic potential of eltanexor, mice treatment was 
started at the peak of intestinal inflammation, namely day 5 after DSS. Oral 
administration of 15 mg/kg eltanexor resulted in a rapid and potent reduc-
tion of DAI within 48 hours of administration. Eltanexor treatment resulted 
in recovery of body weight loss, reduced blood in the faeces and normaliza-
tion of stool consistency. This anti-inflammatory effect was accompanied 
by a decreased infiltration of colonic inflammatory myeloid cells including 
neutrophils and monocytes, followed by an increase in mature Mφ. In vi-
tro, eltanexor pre-treatment suppressed expression of pro-inflammatory 
cytokines (IL-1b, IL-1a, NOS2, IL-6 and TNFa) in LPS/IFNγ treated BMDMφs. 
In parallel, eltanexor was able to induce a rapid increase (within 2 hours 
post dosage) in LPS+IFNγ stimulated BMDMφs of IL-10 compared to the 
vehicle pointing towards a strong anti-inflammatory effect.
conclusion: Eltanexor was able to significantly improve the course of mu-
rine DSS-induced colitis. Both in vitro and in vivo, eltanexor demonstrated 
the ability to rapidly decrease inflammation and prevent myeloid cell acti-
vation. These data suggest that blockage of XPO1-mediated nuclear export 
may be a promising therapeutic strategy to favor a rapid remission in IBD 
and further research is warranted.
disclosure: Nothing to disclose 
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Introduction: The dysbiosis displayed by patients with Crohn’s Disease (CD) 
and ulcerative colitis (UC) are different [1]. Although the location of the 
disease is a parameter relevant to clinical practice [2], few studies have 
shown the changes in the microbial community among the subtypes of 
inflammatory bowel disease (IBD) that affect the colon (E1, E2, E3, C-CD 
and IC-CD).
aims & Methods: Our aim was to analyse the richness, diversity and com-
position of the microbiota associated to the colonic mucosa of IBD patients 
with disease located in the colon in order to identify bacterial markers that 
allow their discrimination. 
Colonic biopsies were obtained from 21 patients with UC (5 E1, 6 E2 and 10 
E3) and 22 with CD (12 C-CD and 10 IC-CD). Mucosa-associated microbial 
community was analysed by sequencing the V4 region of the 16S rRNA gene 
by the Illumina MiSeq method (depth 23,611 seqs/sample). Differences be-
tween IBD subtypes according to location have been sought by analysing 
alpha diversity (richness and diversity) and the relative abundance of taxa 
at different taxonomic levels (phylum-genus). The receiver operating char-
acteristic (ROC) curve analysis was performed for the significant taxa, and 
accuracy to discriminate amongst disease locations was measured by the 
area under the ROC curve (AUC). Besides, and given the compositional na-
ture of microbiome data [3], a lineal discriminant analysis was performed 
with selbal [4]. The groups of taxa whose relative abundance allowed the 
best discrimination between diseases was selected to calculate a balance 
to differentiate conditions, using a k-fold cross-validation algorithm.
results: Richness (Sobs=55-288) and diversity (InvSimp=1.9-38.9) of 
the bacterial community were similar among all the disease locations 
compared. Six indicators, that determine a differential microbiological 
signature between IBD locations, have been identified (relative abun-
dance=0.16-20.91%). The abundances of sequences corresponding to indi-
cators 36 and 75 were significantly lower in patients with C-CD compared 
to those with UC of any location (p≤0.040, AUC≥0.726). Besides, indicators 
2, 11 and 69 showed significant differences between E3 and C-CD (p≤0.015, 
AUC≥0.829). Indicators 2 and 11 also showed differences between UC lo-
cations (p≤0.017, AUC≥0.861) while the relative abundance of indicators 
51 and 19 is higher in C-CD compared to IC-CD (p≤0.007, AUC≥0.846). On 
the other side, using the compositional approach, a ratio of two indica-
tors resulted in the best balance to discriminate between diseases, which 
had an apparent AUC=0.857 when measured on the whole dataset (cross-
validation AUC=0.665).
conclusion: Richness and diversity of the microbiota associated to the 
colonic mucosa of IBD patients with colonic disease location is similar. 
However, differential bacterial indicators have been identified and a ratio 
to discriminate between UC and CD with colonic location is proposed. The 
quantification of these taxa would allow to refine the use of microbiomark-
ers to 
(i) support the diagnosis between IBD that affect the same location and/or 
(ii) assess the risk of disease extension.
references: [1]Machiels,K et al.2014.Gut.63(8):1275-83. [2]Satsangi,J et 
al.2006.Gut.55(6):749-753. [3] Gloor, G. et.al. 2017. Front. Microbiol. (8): 
1-6 [4] Rivera-Pinto et al. 2018 mSystems.17;3(4).pii: e00053-18.
disclosure: XA is consultant from AbbVie, Janssen and Takeda, and has 
received honoraria for lectures including services on speakers bureaus 
from AbbVie, MSD, Janssen, Takeda, Shire, Zambon and Ferring. For the 
remaining authors nothing to disclose. 
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P1710 BenefIcIaL effecTs Of 3-OxO-c12:2 n-acyL hOMOserIne 
LacTOne, a neW quOruM sensIng MOLecuLe frOM The guT 
ecOsysTeM, On The InTesTInaL BarrIer funcTIOn
Aguanno D.1, Coquant G.1, Peyrottes A.1,2, Brot L.1, Mallet J.-M.2, 
Carrière V.1, Leturque A.1, Seksik P.1,3, Grill J.-P.1, Thenet S.1,4
1UMRS_938-Centre de Recherche Saint-Antoine, Team Philippe SEKSIK-Harry 
SOKOL ‘Microbiota, Gut & Inflammation’, Paris, France, 2PSL University, 
Sorbonne Université, CNRS, Chemistry Department, École Normale 
Supérieure, Paris, France, 3Gastroenterology & Nutrition Department, 
Gastroenterology and Nutrition Unit, Paris, France, 4Ecole Pratique des 
Hautes Etudes, PSL University, Paris, France
contact e-Mail address: doriane.aguanno@sorbonne-universite.fr
Introduction: N-acyl homoserine lactones (AHLs) are molecules involved 
in quorum sensing, a bacterial communication network, which can also 
impact the host’s physiology. We recently showed the presence of AHLs in 
the human gut ecosystem and identified a new AHL, named 3-oxo-C12:2. 
This molecule was decreased in inflammatory bowel disease subjects dur-
ing flare and its absence was associated with dysbiosis, thus suggesting 
a beneficial role if this new AHL. However, 3-oxo-C12:2 is structurally very 
close of the well-studied AHL 3-oxo-C12, produced by the opportunistic 
pathogen P. aeruginosa, which is known to impair epithelial barriers.
aims & Methods: 
In this context, we aimed to investigate the effects of the 3-oxo-c12:2 ahL 
on the intestinal barrier function, and compare them to those of the 3-oxo-
C12. 
Human Caco-2/TC7 enterocytic cells were exposed on their apical side to 
3-oxo-C12:2 or 3-oxo-C12 AHLs. These treatments were combined or not 
with pro-inflammatory cytokines Interferon-g and Tumor Necrosis Factor-
a, known to have deleterious effects on the barrier function. We assessed 
paracellular permeability by measuring the passage of FITC-dextran 4 kDa 
and analyzed tight junctions (TJ) integrity by immunofluorescence and 
Proximity Ligation assays.
results: Upon exposure to 3-oxoC12, the paracellular permeability is in-
creased and the signal of Occludin and Tricellulin, bicellular and tricellular 
TJ proteins respectively, is decreased. In contrast, 3-oxo-C12:2 AHL modi-
fies neither permeability nor tight junctions integrity. While 3-oxo-C12 po-
tentiates the increase in permeability induced by the pro-inflammatory 
cytokines, 3-oxo-C12:2 does not exacerbate cytokine effects on permeabil-
ity. Moreover, 3-oxo-C12:2 attenuates the deleterious effects of cytokines 
on Occludin and Tricellulin, as well as on their interaction at the plasma 
membrane with their cytoplasmic partner ZO-1. Preliminary results show 
that Occludin and Tricellulin interact with the E3-ubiquitin ligase Itch and 
that the increase in ubiquitination levels of Occludin and Tricellulin caused 
by cytokines is suppressed in the presence of 3-oxo-C12:2, suggesting that 
it prevents their endocytosis or degradation.
conclusion: Our results show that 3-oxo-C12:2, a major AHL in the hu-
man gut, exerts a protective role on the intestinal barrier function in pro-
inflammatory conditions. Given its loss in inflammatory bowel disease 
patients, the beneficial role of the 3-oxo-C12:2 AHL in the gut ecosystem 
leads to interesting perspectives to better understand host-microbiota in-
teractions in this digestive tract pathology.
disclosure: Nothing to disclose 
P1711 Is There a BeTTer Way TO MOnITOr vITaMIn d 
MeTaBOLIsM In InfLaMMaTOry BOWeL dIsease?
Boettger K.1,2, Aksan A.2,3, Hein N.1, Stein J.1,2,3
1DGD Clinics Sachsenhausen, Teaching Hospital of the Goethe University, 
Gastroenterology and Clinical Nutrition, Frankfurt am Main, Germany, 
2Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt am Main, 
Germany, 3Goethe University, Institute of Pharmaceutical Chemistry, Frankfurt 
am Main, Germany
contact e-Mail address: kboettger@khs-ffm.de
Introduction: Vitamin D has traditionally been known as a regulatory fac-
tor in bone metabolism and homeostasis, but emerging evidence suggests 
that it also plays an important role in immune regulation, as indicated by 
the fact that vitamin D deficiency has been associated with the pathogen-
esis of inflammatory bowel disease (IBD) (1). While it is possible that vita-
min D affects the severity of inflammation and the disease course in pa-
tients with IBD, the causal relationship remains uncertain due to the com-
plexity of the interrelationship between vitamin D and inflammation (2-4). 
Most studies have relied on immunoassays measuring 25-hydroxyvitamin 
D (25(OH)D3), which may be less accurate than the accepted gold standard 
of liquid chromatography tandem mass spectrometry (LC-MS/MS). Circu-
lating 25(OH)D3 is hydroxylated to the metabolically active 1,25(OH) 2D3 
by CYP27A1. The alternative pathway involves hydroxylation to the inactive 
24,25(OH)2D3 via the 24-hydroxylase CYP24A1 prior to elimination (5).
aims & Methods: Based on the hypothesis that the ratio of 25(OH)D to 
24,25(OH)2D3 may be a more accurate measure of vitamin D status than 
25(OH)D alone, our study aimed to characterise vitamin D metabolism in pa-
tients with active and inactive IBD using LC-MS/MS. The study was conducted 
as a cross-sectional prospective cohort study. Patients with inflammatory dis-
ease had definite endoscopic evidence of ulceration, and either CRP >5mg/L 
or faecal calprotectin >200mg/kg in stool. Patients who had taken medica-
tions with corticosteroids or vitamin D supplementation in the preceeding 
4 weeks were excluded. Serum was tested for 25(OH)D3, 1,25(OH) 2D3 and 
24,25(OH)2D3 using an LC-MS/MS assay. Spearman’s correlation coefficient 
was used to test correlations and unpaired t-tests to test differences between 
inflammatory and non-inflammatory IBD patient groups.
results: Up to November 2018, 87 consecutive patients with IBD (39 CD; 
48 UC) were recruited; 55% were male. Median age was 36 years (range 
23 to 72 yrs). Fewer patients in the active group were on immunomodu-
lators (40% vs. 61%, p=0.05) or TNF inhibitors (25% vs. 49%, p=0.05). 
There was no difference in serum 25(OH)D3, or 1,25(OH)2D3 between the 
groups. Serum 24,25(OH)22D3 levels were significantly lower in the ac-
tive group (mean 1.9 vs. 2.7ng/mL, p<0.001) and thus the ratio of 25(OH)
D3: 24,25(OH)2D3 was higher (49.4 vs. 26.1, p<0.001). There was an in-
verse correlation between active disease and 24,25(OH)2D3 levels (r2=0.39; 
p=0.01). Dietary vitamin D intake and sunlight exposure did not differ be-
tween the groups.
conclusion: In the context of inflammation, levels of 1,25(OH)2D3 are main-
tained by shifting the metabolism of 25(OH)D to 1,25(OH)2D3 rather than 
24,25(OH)2D3, suggesting a reduction in 24-hydroxylase activity to main-
tain the active metabolite. The ratio of 25(OH)D3:24,25(OH)2D3 is increased 
in active disease and may be a more sensitive marker of vitamin D status 
in patients with CD.
references: 1. Limketkai BN, Bechtold ML, Nguyen DLJCGR. Vitamin D and 
the Pathogenesis of Inflammatory Bowel Disease. 2016;18(10):52. 2. Mouli 
VP, Ananthakrishnan AN. Review article: vitamin D and inflammatory bow-
el diseases. Alimentary pharmacology & therapeutics. 2014;39(2):125-36. 
3. Chetcuti Zammit S, Ellul P, Girardin G, Valpiani D, Nielsen KR, Olsen 
J, et al. Vitamin D deficiency in a European inflammatory bowel disease 
inception cohort: an Epi-IBD study. European journal of gastroenterology 
& hepatology. 2018;30(11):1297-303. 4. Pallav K, Riche D, May WL, Sanchez 
P, Gupta NK. Predictors of vitamin D deficiency in inflammatory bowel dis-
ease and health: A Mississippi perspective. World journal of gastroenterol-
ogy. 2017;23(4):638-45. 5. Christakos S, Dhawan P, Verstuyf A, Verlinden L, 
Carmeliet G. Vitamin D: Metabolism, Molecular Mechanism of Action, and 
Pleiotropic Effects. Physiological reviews. 2016;96(1):365-408.
disclosure: A. Aksan has received financial support for research work from 
Immundiagnostik AG. J. Stein has received payments for consultation and 
lecturing from Immundiagnostik AG. K. Böttger and N. Hein have no con-
flicts of interest. 
P1712 WIThdraWn
P1713 effecT Of eThnIcITy On The faecaL WaTer MeTaBOLIc 
PrOfILes In crOhn’s dIsease
Powles S.T.R.1,2, Chong L.1,2, Gallagher K.I.1, Hicks L.1,2, Swann J.R.3, 
Holmes E.3, Williams H.R.T.1,2, Orchard T.R.1,2
1Imperial College London, Division of Digestive Diseases, London, United 
Kingdom, 2Imperial College Healthcare NHS Trust, Gastroenterology, London, 
United Kingdom, 3Imperial College London, Division of Integrative Systems 
Medicine, London, United Kingdom
contact e-Mail address: s.powles@imperial.ac.uk
Introduction: South Asians (SA) with Crohn’s disease (CD) display a dif-
ferent disease phenotype and course (1), as well as a different urinary 
metabolic profile (2). Metabolic profiling of faecal water has distinguished 
CD from controls previously, but only in Caucasian (Cau) cohorts, charac-
terised by a reduction in short chained fatty acids.
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aims & Methods: The aim of this study was to compare the metabolic pro-
files of faecal water in CD patients and healthy controls (H) from Caucasian 
and South Asian backgrounds. 
Samples from 28 CD patients (15 Cau and 13 SA) and 44 healthy controls (20 
Cau and 24 SA) were analysed by 1H NMR spectroscopy. Data was assessed 
using orthogonal partial least squares discriminant analysis (OPLSDA). 
Hypothesis-led univariate analysis was also performed using metabo-
lites that have been previously shown to distinguish CD from controls (2). 
These metabolites were as follows: acetate, butyrate, propionate, lactate, 
methylamine, glutamine, alanine, taurine, valine, and 2-hydroxybutyrate 
(2HIB).
results: Multivariate analysis (Table 1) demonstrated that the faecal me-
tabolites driving the separation between CD and controls were similar 
regardless of ethnicity, although statistically significant separation could 
not be achieved by multivariate analysis in the smallest group (CD v H in 
Caucasians). 
Univariate analysis demonstrated a statistically significant reduction in 
butyrate, acetate, 2HIB, and methylamine (p < 0.05) in Cau CD patients 
compared to controls consistent with previous studies, but only a reduc-
tion in 2HIB and methylamine was seen with statistical significance in SA 
patients. When directly comparing Cau and SA patients with CD, butyrate 
and 2HIB were significantly different (p = 0.034 and 0.035 respectively) 
between these ethnic groups.
Model 
OPLsda n r2x q2
P value 
cv-anOva
Metabolites driving 
separation in cd
CD : HC All
72 
(28:44)
0.145 0.197 <0.001
acetate↓ butyrate↓ glutamine↓ 
alanine↓ creatine↓ tryptophan↓ 
2HIB↓ methylamine↓
CD : H 
Caucasian
35 
(15:20)
0.122 0.126 0.117
acetate↓ butyrate↓ glutamine↓ 
alanine↓ creatine↓ tryptophan↓ 
2HIB↓ methylamine↓
CD : H South 
Asians
37 
(13:24)
0.196 0.290 0.024
acetate↓ butyrate↓ glutamine↓ 
alanine↓ creatine↓ tryptophan↓ 
2HIB↓ methylamine↓
[Table 1]
conclusion: Despite observing consistent changes in the metabolites driv-
ing separation between Caucasian and SA patients compared to controls, 
univariate analysis reveals differences relating to ethnicity, showing that 
ethnicity influences faecal water metabolic profiles. The effect of ethnicity 
is likely to be a combination of genetics, diet and environment. Ethnicity 
therefore must be accounted for as a potential confounder in this type of 
analysis.
references: (1). Walker, 2011. AJG. (2). Marchesi, 2008. J. Proteome Res.
disclosure: Nothing to disclose 
P1715 TPL2 InhIBITOr TreaTMenT reduces MuLTIPLe 
InfLaMMaTOry endPOInTs In a scId T ceLL Transfer MOdeL 
Of cOLITIs
Hammond A., Cui Z.-H., Zipfel S., Wendt E., Wilbert S., Taylor J., Warr M.
Gilead Sciences, Inc., Foster City, United States
contact e-Mail address: matthew.warr@gilead.com
Introduction: Tumor progression locus 2 (TPL2, also known as MAP3K8) is 
a mitogen-activated protein kinase kinase kinase and the primary regula-
tor of ERK-mediated gene transcription downstream of multiple proin-
flammatory stimuli.1 Converging lines of evidence suggest a critical role 
for TPL2 in IBD. TPL2 RNA is upregulated in IBD patient colon biopsies 
and a TPL2 gain-of-function single nucleotide polymorphism (SNP) is as-
sociated with the development of IBD.2-4 Furthermore, TPL2 deficiency has 
been demonstrated to attenuate disease pathology in murine models of 
IBD, including TNFΔARE and DSS-induced mouse colitis models.5,6 As such, 
TPL2 inhibition represents a potential strategy to modulate inflammation 
in IBD.
aims & Methods: The objective of this work was to determine the effect 
of a highly selective TPL2 inhibitor on chronic intestinal inflammation in a 
severe combined immunodeficient (SCID) T cell transfer model of colitis. A 
highly selective TPL2 inhibitor (TPL2i) was dosed in a SCID T cell transfer 
model. In this model, SCID mice develop chronic intestinal inflammation 
following the transfer of naïve CD4+CD45RBhi T-cells.7 Animals were ran-
domized into treatment groups at day 21 (N=15 vehicle, N=15 20 mg/kg TP-
L2i, N=15 60 mg/kg TPL2i) and orally dosed BID for 28 days. On day 21, prior 
to treatment initiation, 5 naïve and 5 T-cell transferred mice were sacri-
ficed to confirm disease initiation. Following 4 weeks of treatment animals 
were randomized into necropsy groups and sacrificed at 2, 8, or 12h post-
last dose. Plasma TPL2i levels were assessed to estimate target coverage. 
The effect of TPL2 inhibition on colitis was evaluated based on multiple 
histopathological endpoints at necropsy. Three independent transverse co-
lon sections (proximal, middle and distal) were scored to assess histology 
sum score (tabulated from independent inflammation, gland loss, erosion 
and hyperplasia scores), edema (µm), percent PMN, and neutrophil score. 
To assess the effects of TPL2i treatment on TPL2 signaling and proinflam-
matory cytokine levels in the colon, flash frozen colon tissue was analyzed 
by western blot and MesoScale Discovery, respectively. Statistics were per-
formed using a 2-sided Wilcoxon Rank sum test.
results: Plasma TPL2i levels demonstrated that the 60 mg/kg dose 
achieved plasma concentrations sufficient to inhibit TPL2 activity by 50% 
at trough. Treatment with both 20 mg/kg and 60 mg/kg doses of TPL2i 
improved colitis at day 49 as demonstrated by a significant improvement 
in colon weight/length. A statistically significant improvement in multiple 
histopathological endpoints was also observed with 60 mg/kg TPL2i treat-
ment, including an improvement in histology sum, inflammation, gland 
loss, percent PMN and neutrophil scores. Modulation of TPL2 activation 
and a reduction in proinflammatory cytokines were demonstrated in the 
colon of TPL2i treated animals with a significant reduction in phospho-
TPL2 levels (a marker of TPL2 kinase activation) and a clear trend towards 
reduced TNFα, IL-1β, IL-6, KC, IL-12, IFNγ and IL-17 levels in the colon.
conclusion: This work demonstrates that a highly selective TPL2i improves 
colitis and reduces multiple inflammatory markers in a SCID T cell transfer 
model of colitis.
references: 1. Gantke T, Sriskantharajah S, Ley S. Cell Res. 2011;21:131-
145. 2. Arijs, I., et al. Plos One. 2009;4(11):1-10. 3. Jostins, L., et al. Nature. 
2012;491:119-124. 4. Hedl M and Abraham C. Gut. 2016;65:1799-1811. 5. Kon-
toyiannis, D., et al. J. Exp. Med. 2002;196:1563-1574. 6. Lawrenz, M., et al. 
Mucosal Immunol. 2012;5:129-139. 7. Kiesler, P., Fuss, I.J., and W. Strober. 
Cell. Mol. Gastroenterol. Hepatol. 2015;1(2):154-170.
disclosure: Hammond A., Cui Z.-H., Zipfel S., Wendt E., Wilbert S., Taylor 
J., and Warr M are employees of Gilead Sciences, Inc. 
P1716 gs-4875, a fIrsT-In-cLass TPL2 InhIBITOr suPPresses 
Mek-erk InfLaMMaTOry sIgnaLIng and PrOInfLaMMaTOry 
cyTOkIne PrOducTIOn In PrIMary huMan MOnOcyTes
Warr M., Hammond A., Park G., Cui Z.-H., Wright N., Taylor J.
Gilead Sciences, Inc., Foster City, United States
contact e-Mail address: matthew.warr@gilead.com
Introduction: Tumor progression locus 2 (TPL2, also known as MAP3K8) is a 
mitogen-activated protein kinase kinase kinase and the primary regulator 
of ERK-mediated gene transcription downstream of multiple proinflam-
matory stimuli including bacterial products (eg, LPS and bacterial pepti-
doglycans), damage-associated molecular patterns (DAMPs), TNFα, and 
IL-1β.1 TPL2 regulates the expression of several proinflammatory cytokines, 
including TNFα, IL-1β, IL-6 and IL-8. As TPL2 acts on both the production of 
and response to TNFα and IL-1β, it acts to amplify proinflammatory signal-
ing. Dysregulated signaling downstream of these inflammatory signals can 
drive uncontrolled immune cell activation and inflammation, associated 
with IBD and other chronic inflammatory and autoimmune diseases. As 
such, TPL2 inhibition represents a strategy to modulate inflammation in 
IBD and other disease states.
aims & Methods: We evaluated the effect of a highly selective TPL2 inhibi-
tor (GS-4875) on inflammatory signaling and cytokine production in LPS 
and TNFα-stimulated primary human monocytes and monocyte-derived 
dendritic cells. A rat LPS-TNFα acute inflammation model was used to 
establish a PK/PD relationship. A TPL2 kinase assay was used to assess 
GS-4875 biochemical IC
50
. GS-4875 selectivity was screened using a KI-
NOMEscan™ selectivity assay (ScanMAX, DiscoveRx, San Diego, CA) at 
1µM GS-4875. Monocytes or monocyte-derived dendritic cells were pre-
cultured with a GS-4875 and stimulated with LPS or TNFα, and phospho-
signaling and cytokine production was then evaluated at 30 minutes and 
4 hours post stimulation. A431 cells (human epidermoid carcinoma cell 
line) were stimulated with TNFα or EGF and phospho-ERK was evaluated 
after 30 minutes. In vivo PK/PD relationship was established using a rat 
LPS-TNFα model of acute inflammation. In this model, female lewis rats 
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were dosed orally with 3, 10, 30 or 100 mg/kg doses of GS-4875 or 1 mg/
kg dexamethasone followed by IV dosing of 0.01 mg/kg LPS 2 hours later. 
Animals were bled for plasma at multiple time points between 0 and 5h 
after compound dosing and plasma concentrations of TNFα and GS-4875 
were measured.
results: GS-4875 inhibits the TPL2 kinase with an IC50 = 1.3 nM with no 
significant off-target binding activity. GS-4875 selectively inhibited LPS 
and TNFα-stimulated phosphorylation of TPL2, MEK, and ERK, with little 
to no inhibition of phosphorylated p38, JNK or p65 observed. Both the 
RNA production and secretion of TNFα, IL-1β, IL-6, and IL-8 following LPS 
stimulation in primary human monocytes was similarly inhibited with GS-
4875. In monocyte-derived dendritic cells GS-4875 inhibited the secretion 
of TNFα and IL-6 following LPS stimulation. To confirm TPL2 requirement 
for inflammatory, but not Ras-mediated (growth factor stimulated) ERK 
signaling, A431 cells were stimulated with either TNFα or EGF. Although 
TPL2 inhibition reduced TNFα-stimulated pERK, no effect on ERK activa-
tion downstream of EGF was observed. In vivo activity and PK/PD relation-
ship was established using a rat LPS-TNFα model of acute inflammation. 
GS-4875 treatment showed dose and exposure dependent inhibition of 
LPS-stimulated TNFα production at all time points with an estimated EC50 
(±SD) of 667 ±124 nM. Inhibition of TNFα production at the highest dose 
tested inhibited TNFα levels at levels equivalent to that of dexamethasone.
conclusion: This work demonstrates the selective effects of TPL2 inhibition 
on ERK-mediated signaling and proinflammatory cytokine production and 
highlights the potential for TPL2 inhibition to treat IBD and other chronic 
inflammatory and autoimmune diseases.
references: 1. Gantke T, Sriskantharajah S, Ley S. Cell Res. 2011;21:131-145.
disclosure: Warr M., Hammond A., Park G., Cui Z.-H., Wright N., and Taylor 
J. are employees of Gilead Sciences, Inc. 
P1717 PrOsTagLandIn e2 PrOducTIOn By enTerIc gLIaL ceLLs 
reduces cOLITIs deveLOPMenT In feMaLe MIce
Rolli-Derkinderen M.1, Bessard A.2, Durieu E.2, Oullier T.2, Mahé M.2, 
Cenac N.3, Neunlist M.2
1Inserm, TENS, Nantes, France, 2Inserm U 1235, Nantes, France, 3INSERM 
UMR 1220, Digestive Health Research Institute, Toulouse, France
contact e-Mail address: michel.neunlist@univ-nantes.fr
Introduction: Enteric glial cells (EGCs) are involved in the modulation of 
intestinal motility, permeability and inflammation. We have shown that 
these regulations involve the production and release of soluble mediators, 
including omega-3 and -6 derivatives such as prostaglandins. Prostaglan-
din E
2
 (PGE
2
) participates in the control of intestinal functions, but studies 
focusing on the effects of PGE
2
 released specifically by EGC are still lacking. 
We have evaluated in vivo the impact of mPGES1 (PGE
2
 producing enzyme) 
deletion induced specifically in EGC, on intestinal functions and intestinal 
inflammation.
aims & Methods: mPGES1 deletion was induced in 10 to 20 weeks old male 
or female S100bCre-ERT2-mPGES1fl-fl by a daily injection of tamoxifen (tamo) 
for 5 days. Two weeks after the onset of the induction of deletion, we in-
duced, or not, the development of colitis by adding dextran sodium sulfate 
(DSS 4%) in the drinking water during 4 days. The intestinal functions 
measured at the end of the protocol are: (i) the paracellular permeability 
(sulfonic acid flux), (ii) the total transit time (expulsion time of carmine red 
given in gavage) and (iii) the disease Activity Index (DAI =presence of blood 
in the stool and weight loss of the animals). An immunohistological analy-
sis enabled us to verify the induction of mPGES1 after inflammation in the 
EGC of wild type mPGES1 mice (mPGES1fl-fl mice treated with tamo), and its 
deletion in mPGES1 ΔEGC mice (S100bCre-ERT2-mPGES1fl-fl treated with tamo).
results: The increased expression of mPGES1 in glial cells was observed 
after exposure to DSS in the myenteric and submucosal ganglia of male 
and female wild type mPGES1 mice. This induction was absent in mPGES1 
ΔEGC mice. In female, DSS treatment induced increases in permeability and 
DAI, and reduction of transit time only in mPGES1 ΔEGC mice. In contrast, 
mPGES1 deletion has had no impact on intestinal function or inflammation 
in males that behaved like mPGES1 ΔEGC female mice.
conclusion: This work represents the first in vivo evidence of a direct in-
volvement of glial-derived PGE
2
 in the pathophysiology of the intestine. In 
addition it suggest that the resistance to colitis development observed in 
female could be due to an increase PGE
2
 production.
disclosure: nothing to disclose 
P1718 MaTernaL exPOsure TO gOs/InuLIn MIxTure fOsTers 
cOLITIs deveLOPMenT In OffsPrIng MIce
Le A.1, Selle A.2, Aubert P.1, Brosseau C.2, Durieu E.1, Oullier T.1, 
Neunlist M.3, Bodinier M.2, Rolli-Derkinderen M.4
1Inserm U1235, TENS, Nantes, France, 2INRA, BIA, Nantes, France, 3Inserm 
U1235, Nantes, France, 4Inserm, TENS, Nantes, France
contact e-Mail address: amelie.le@etu-univ-nantes.fr
Introduction: An alteration of the gut microbiota is involved in the patho-
genesis of inflammatory bowel disease (IBD) and several probiotic strains 
and/or non-digestible food ingredients such as prebiotics are already used 
as dietary supplements to improve intestinal health. One alternative to 
prevent or reduce colitis development could consist of modulating ma-
ternal immunity and microbiota through prebiotics. For this purpose, we 
studied the effects of prebiotics given to Balb/c mice during gestation on 
the development of colitis in their offspring.
aims & Methods: 8-10 weeks old offspring mice from mothers exposed to 
the GOS/inulin prebiotics mixture (9/1, 4% w/w) during gestation or fed 
with a control diet, were submitted or not to 3 cycles of dextran sodium 
sulfate (DSS) which induces colitis. A cycle consists of 2 days of 4% DSS 
in drinking water followed by 5 days of water. At day 4, 11 and 18 of the 
protocol, the total transit time, the fecal pellet output, the intestinal per-
meability and the disease activity index (stool consistency, weight loss, 
and gross bleeding) were measured in the 4 groups of mice. At day 18, 
the offspring mice were sacrificed and further measurements of intestinal 
segment permeability, tissue remodelling, systemic and intestinal inflam-
mation as well as microbiota sequencing were performed.
results: Offspring from mothers that received GOS/inulin prebiotics pre-
sented no changes in the humidity percentage of feces or total transit time 
before or after DSS cycles. Nevertheless when treated with DSS, offspring 
from mothers that received GOS/inulin prebiotics presented an increased 
disease activity index compared to the DSS group of offspring from moth-
ers with control diet.
conclusion: The enrichment of pregnant mice with non-digestible GOS/
inulin prebiotics promotes a long‐term effect in their offspring that is, un-
expectedly, not a protective one but a sensitization to colitis development. 
Molecular mechanisms involved are under investigation, but our results 
already question about the “health benefit” that GOS/inulin should confer.
disclosure: Nothing to disclose 
P1719 cOMParaTIve anaLysIs Of faecaL caLPrOTecTIn and 
shOrT chaIn faTTy acIds In PaTIenTs WITh uLceraTIve cOLITIs 
and crOhn’s dIsease
Valencise Quaglio A.E.1, Ribeiro Batista G.2, Almeida-Jr L.D.1, Sassaki L.Y.2, 
Di Stasi L.C.1
1São Paulo State University (UNESP), Institute of Biosciences, Department 
of Pharmacology, Botucatu, Brazil, 2São Paulo State University (UNESP), 
Institute of Biosciences, Department of Medical Clinic, Botucatu, Brazil
contact e-Mail address: anaequaglio@hotmail.com
Introduction: Inflammatory bowel disease (IBD) comprises two distinct dis-
eases: Crohn’s disease (CD) and ulcerative colitis (UC). Both are chronic 
diseases with a relapsing course of inflammation in the digestive system. 
The aetiology of these diseases has not been fully elucidated but is currently 
presumed to result from a complex interplay among genetic, environmen-
tal, microbial and immune factors. Intestinal homeostasis also depends on 
genetic, environmental, microbial and immune factors, while dysbiosis has 
been considered an important immunologic aetiology factor in IBD with 
quantitative and qualitative changes in the microbial composition. Short 
chain fatty acids (SCFAs) such as acetic, propionic and butyric acids, arise 
from bacterial fermentation of carbohydrates, proteins, peptides and gly-
coprotein precursors and its levels differ between healthy subjects and IBD 
patients as a results from dysbiosis presented by IBD patients. Endoscopy 
and histopathology are the golden standard methods for detection and as-
sessment of IBD, but a distinct increase of faecal calprotectin level can be 
a useful marker for the diagnosis of IBD. Calprotectin is a calcium- and 
zinc-binding protein, which for practical purposes can be considered to 
be neutrophil-specific. The amount of calprotectin reflects the number of 
participating neutrophils in this inflammation. This aspect has been widely 
confirmed in intestinal inflammatory diseases by significant correlation be-
tween faecal calprotectin levels and other measures of acute inflammation.
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aims & Methods: Based on this, the aim of this work was to analyse and 
correlate faecal calprotectin levels with acetic, propionic and butyric acids 
production in faeces samples from patients with UC (n=55) or CD (n=35). 
For that, calprotectin levels were measured using Quantum Blue® fCAL 
Extended kit (Bühlmann Laboratories) and SCFAs were dosed by chro-
matographic analysis using a GC-MS Thermo Scientific, model FOCUS 
equipped with an automatic liquid sampler (Thermo - triplus DUO), and 
coupled to a Thermo - ISQ 230ST mass detector. All results are represented 
by mean± SEM and statistical significance were considered for p≤0.05
results: Calprotectin value were 401.1±56.66 µg/ml for UC and 276.6±52.90 
µg/ml for CD patients. Acetic, propionic and butiric acid levels were 
0.1367±0.006 mg/ml, 0.2345±0.005mg/ml and 0.069±0.003mg/ml re-
spectively, for UC and 0.1338± 0.006 mg/ml, 0.2500±0.006 mg/ml and 
0.07±0.003 mg/ml for CD patients. There is no correlation between calpro-
tectin and SCFAs values, but, when compared UC and DC SCFAs levels, we 
found major levels of propionic acid in DC patients compared with UC ones 
(p≤0.05). This result could represent the discovery of a new biomarker 
useful for IBD subtypes differentiation.
conclusion: Based on this, SCFAs cannot be used as substitute for calpro-
tectin dosage in IBD patient’s diagnosis; however, SCFAs can represent a 
new biomarker for IBD subtypes differentiation. Additional experiments 
should be performed in order to evaluate SCFAs levels in healthy subjects 
and compare to IBD patients.
Financial support: Fapesp
disclosure: Nothing to disclose 
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Introduction: Crohn’s disease (CD) and ulcerative colitis (UC) are main clin-
ical forms of inflammatory bowel disease. IBD is a chronic inflammatory 
disorder of the intestine and its pathogenesis remains unclear. 
The cause of IBD is unknown, but it is suggested that an aberrant immune 
response toward the commensal microbiota is responsible for the disease 
in genetically predisposed individuals.
aims & Methods: The purpose of the study is to analyze the serum level of 
several proinflammatory cytokines and standard inflammatory biomarkers 
(C reactive protein (CRP) and calprotectin) in patients with CD and UC.A 
total of 286 patients with IBD (156 with UC and 130 with CD) were included 
into the study. 67 healthy volunteers were included into the control group. 
UC patients included 61% females, 39% males, average age was 41,6±12,8; 
43,9% had pancolitis, 36,5% was with left-sided colitis and 19,5% pre-
sented symptoms of proctitis. CD patients included 52,7 % females, 47,2% 
males with average age 34,5±11,7; 25% of patients had localized form, 75% 
- distant form. Serum cytokine levels were analyzed using multiplex im-
munoassay.CRP was measured in serum by ELISA test. Calprotectin was 
analyzed in stool samples. Statistical analysis was performed using STA-
TISTICA 6.0 Software Package.
results: Statistically significant increase of CRP (mg/L) both in UC (8,51±8,17) 
and CD (15,2±24,55) patients compared to controls (1,23±1,61) was revealed 
(p < 0,001). The same trend was observed for calprotectin (ɱg/kg) in UC 
(572,6190±501,0668) and CD (539,80±674,7079) patients compared to con-
trols (34,5±30,98) (p < 0,001).
Besides statistically significant increase of IL1b, IL8, IFNg serum levels was 
observed in UC patients both in acute stage and remission compared to 
control group (p < 0,001). Serum level of proinflammatory IL-6 was not 
increased in UC patients compared to controls (p < 0,001). It was noticed 
statistically significant increase of IL1b, IL6, IFNg in CD patients both in 
acute stage and remission compared to controls (p< 0,05). It was also re-
vealed a correlation between СRP & IL6 (RS=-0,4, p=0,007), СRP &IL8 
(RS=0,34,p=0,02), calprotectin&IFNg (RS=0,3 ,p=0,04), calprotectin&IL1a 
(RS=0,35,p=0,02) in UC patients. Analysis of CD patients showed correla-
tion between СRP&IL12p70 (RS=0,3,p=0,04), СRP&IL1b (RS=0,5,p=0,003), 
calprotectin&IL-4 (RS=0,35, p=0,03), calprotectin & fractalkine (RS=0,5 
,p=0,0009).
conclusion: Thus, proinflammatory cytokines contribute to chronic inflam-
mation in IBD both in acute stage and remission correlatinfg with inflam-
matory biomarkers CRP and calprotectin.
disclosure: Nothing to disclose 
P1721 guT-BraIn axIs In InfLaMMaTOry BOWeL dIseases: 
eMergenT rOLe Of InTesTInaL PerMeaBILITy
Petito C.1, Petito V.2, Ferrarese D.1, Laterza L.1, Schiavoni E.1, Napolitano D.1, 
Gasbarrini A.1,2, Scaldaferri F.1,2
1Fondazione Policlinico Universitario A. Gemelli IRCCS, Gastroenterology, 
Rome, Italy, 2Universitá Cattolica del Sacro Cuore di Roma, Institute of 
Medical Pathology, Rome, Italy
contact e-Mail address: claudia.petito93@gmail.com
Introduction: Inflammatory bowel diseases (IBD) are characterized by 
chronic inflammation of the intestine, malabsorption and loss of protein 
and micronutrients. The pathogenesis of these disorders is not yet defined, 
but numerous evidences allow to hypothesize that it is due to a dysregula-
tion of the mucosal immune response to the antigenic components of the 
intestinal flora. Factors like depression and chronic psychosocial distress 
seem to represent a risk factor for the arise of disease, as well as showing 
an influence on the course of the disease.
Stress can increase intestinal permeability, probably as a result of altera-
tions in the cholinergic nervous system and mucosal mast cell functions.
aims & Methods: The aim of this study is to investigate whether the altera-
tions of the intestinal barrier are associated with psychometric alterations. 
We enrolled 33 IBD patients: 20 CD and 13 UC, with a mean age of 45 years. 
Serum samples were collected for determination of the ZO-1, TNF alpha 
and LPS proteins by ELISA assay to study the alterations of the intestinal 
barrier. Each patient completed a specific questionnaire for mood disor-
ders: Minnesota Multiphasic Personality Inventory-2 (MMPI-2), State-Trait 
Anxiety Inventory (STAI Y1 - Y2), Hospital Anxiety and Depression Scale 
(HADS), Connor-Davidson Resilience Scale (CD-RISC), Barrat Impulsive-
ness Scale (BIS), Aggression Questionnaire (AQ). All study participants 
gave written informed consensus before sampling and data collection.
results: The 61% of patients suffered from anxiety, and 37% from depres-
sion. Despite this, patients maintained good resilience: 94% have CD RISC 
scores > 40. Moreover 88% of patients are positive for some MMPI-2 items, 
in aprticular Schizophrenia (Sc), Psychastenia (Pt), Paranoia (Pa), hypoma-
nia (Ma), depression (D) and hysteria (Hy).Patients were divided by disease 
activity and no significant psychometric profile differences were found. the 
levels of ZO-1 and TNF were elevated in patients with high scores in anxiety 
scales (STAI Y1 and Y2 and HADS) but high LPS levels did not seem to be 
significantly associated with any of the variables examined.
conclusion: This study showed that the prevalence of psychometric altera-
tions in patients with IBD is significant, although the possible alterations 
of behavior are independent of disease activity. Furthermore, the increase 
of intestinal permeability could have a role in the worsening of anxiety. 
Further studies and more patients are necessary to better understand the 
development of mood disorders in course of IBD, and the role of Gut-Brain 
Axis in the medium-long term reactivation of patients, especially in terms 
of response and adherence to therapy.
disclosure: Nothing to disclose 
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Introduction: Microscopic colitis (MC), comprising both collagenous colitis 
(CC) and lymphocytic colitis (LC), currently constitute an emergent cause of 
chronic watery diarrhea. Previously considered as a rare disease, several 
epidemiological studies have documented an increasing incidence of MC 
in Western countries. 
However, there seems to be a significant variation in the reported inci-
dence and prevalence rates among countries. Furthermore, a good esti-
mation of the proportion of MC in patients presenting with chronic diar-
rhea is unclear.
aims & Methods: To provide accurate estimates on the incidence and 
prevalence rate of MC and the frequency of MC in patients presenting with 
chronic diarrhea through a systematic-review and meta-analysis.
MEDLINE and EMBASE databases were searched for studies exploring on 
the epidemiology of MC up to December 2018. A pre-determined protocol 
following the PRISMA criteria was used. 
The pooled incidence and prevalence rates, the pooled frequency of MC 
in chronic diarrhea patients and the geographical distribution of MC were 
calculated with random-effects models. Female/male odds ratios were es-
timated with a random-effects model. Heterogeneity between studies was 
assessed with the chi-square test (Cochran Q statistic) and quantified with 
the I2 statistic.
results: Of the 1,446 citations retrieved, 26 population-based studies from 
North-America and Europe were included for calculating incidence and 
prevalence rates, showing high heterogeneity and most of them (80%) 
providing high quality methodologies. The pooled overall incidence and 
prevalence rates of MC were estimated to be 11.9 (95%CI,9-14.8;I2=99.73%) 
new cases per 100,000 person-year (N=21 studies) and 119 (95%CI,73-
166;I2=97.1%) per 100,000 persons (N=5 studies), respectively. 
For CC, the pooled overall incidence and prevalence rates were 5.2 
(95%CI,4.2-6.2;I2=98.3%) new cases per 100,000 person-year (n=25 stud-
ies) and 50.1 (95%CI,13.7-76.5;I2=98.4%) cases per 100,000 persons (n=6), 
respectively. For LC, this was 5.2 (95%CI,4.1-6.4;I2=97.7%) new cases per 
100,000 person-year (n=21 studies) and 61.7 (95%CI,48.2-75.3;I2=80.6%) 
per 100,000 persons (n=5), respectively. 
There are geographical variations in the incidence of MC (table 1). How-
ever, the relative low number of studies from Southern Europe compared 
to Northern Europe in combination with the different time periods studied, 
impedes direct comparisons. 
geographic regions cc(95%cI) Lc(95%cI) Mc(95%cI) 
Northern Europe 5.9(4.6-7.4) 4.9(3.5-6.2) 12.1(8.3-15.8)
Southern Europe 2.4(0.6-4.1) 3.1(1.4-4.7) 7.5(5.2-9.8)
North America 5.5(3.4-7.4) 8.0 (5.0-11.0) 14.3(8.9-19.8)
[Table 1]
Subgroup analyses on the incidence of MC by sex was possible in 18 stud-
ies and demonstrated that female sex is significantly associated with an in-
creased risk of MC (OR 2.5;95%CI,2.3-2.9;I2=86.7%) as well as for CC and LC 
(OR 3.2;95%CI,3-3.5 and OR 2.0;95%CI,1.8-2.3, respectively) independently 
of the setting, study fashion (retrospective or prospective), level (national, 
regional or local) and geographical region considered. 
The pooled frequency of MC in patients with chronic diarrhea was estimat-
ed to be 12.8% (95%CI:9.9-15.9,I2=93.6%), considering only studies with a 
moderate/high quality and sample size of ≥100 patients (n=14).
conclusion: The population-based incidence and prevalence of MC vary 
widely across individual studies and geographical areas, probably due to 
differences in background populations, environmental exposure, genetic 
background and differences in the awareness on the disease. More pro-
spective, large-scale, and population-based studies are needed to better 
evaluate MC epidemiology.
disclosure: Nothing to disclose 
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Introduction: Inflammatory bowel disease (IBD) impacts on the physical 
and mental wellbeing of patients. Addressing and quantifying disability 
in IBD as part of Patient Reported Outcomes (PROs) is a major therapeutic 
target in IBD.
The IBD-Disk is a visual self- administered, abbreviated version of the IBD 
Disability Index which gives a rapid over view of disability in patients with 
IBD.
aims & Methods: The aim of our study was to assess for correlation be-
tween disability reported by patients with IBD, their endoscopy findings 
and IBD therapy using the IBD Disk. A prospective study was conducted 
over 3 months between July to September 2018. Patients attending the IBD 
clinic were invited to complete the 10 item IBD-Disk questionnaire. Patient 
demographics, endoscopy findings and IBD therapy were also recorded.
results: 58 patients completed the questionnaire. 59% (34) male, age 
range 19-85 years. 59% (34) had ulcerative colitis (UC) and 41% (24) 
crohn’s disease. Low energy levels was the commonest disability reported 
affecting 57% (33), followed by difficulty sleeping at 53% (31). Dissatisfac-
tion with body image, followed by sexual dysfunction accounted for low-
est levels of disability at 24% (14) and 22% (13) respectively. 10% (6) of 
patients had no disability and were receiving either 5- aminosalicylate (5-
ASA) monotherapy or combination with an immunomodulator. 40% (23) 
used 5-ASA alone, 31%(18) used immunomodulators and 26% (15) were 
receiving biologics. 6% (2) had a Mayo Endoscopic score of 3.
conclusion: In our study difficulty sleeping and poor energy levels ac-
counted for the greatest disability among our patients. There was no 
correlation between the degree of disability, endoscopic scores and IBD 
treatments. Disabilities reported were variable, but the IBD Disk rapidly 
highlights patient concerns allowing health care professionals adequately
address them.
disclosure: Nothing to disclose 
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Introduction: Studies since early 1980s have shown the presence of sub-
clinical gut inflammation in up to 60% of the patients with axial spondy-
loarthritis, 6% of which proceed to become inflammatory bowel disease 
(IBD) in 10 years. Here we aim to further explore the presence of gut in-
flammation using acute inflammatory markers in stool and serum and 
correlate the results with disease characteristics.
aims & Methods: A collaborative group comprising of gastroenterologists 
and rheumatologists was formed between 2 healthcare trusts in UK. Clinic 
lists and electronic operating systems were interrogated with appropriate 
ethical approval to identify patients with axSpA with or without IBD (axS-
pA-IBD and axSpA not-IBD, respectively) and psoriatic arthritis as disease 
controls. Eligible patients were called prior to their clinic appointments 
and were sent stool containers. On the day of their clinic appointments, 
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patients were consulted for 15-30 minutes where their disease was care-
fully phenotyped, drug history obtained and they were consented in to 
the study. Stool and blood samples were collected and analysed for faecal 
calprotectin (FC) and ESR and CRP respectively.
results: 116 patients with axial spondyloarthritis (79 axSpA-not IBD, 22 
axSpA-IBD and 15 psoriatic axSpA [axSpA-PsA]) and 22 patients with pso-
riatic peripheral spondyloarthritis (pPsA) were recruited. 
Total of 81 stool samples were analysed. Faecal calprotectin (FC) was el-
evated to above 50ug/g in 36 stool samples; 21 out of 44 (48%) patients 
with axSpA-not IBD (median 72, range 51- 587), 9 out of 18 (50%) patients 
with axSpA-IBD (median 224.5, range 51->2000), 2 out of 7 (29%) patients 
with axSpA-PsA (median 69, range 51-87) and 6 out of 14 (43%) patients 
with pPsA (median 61.5, range 57- 122). Of the elevated FC samples, only 
one patient with known Crohn’s disease had significant GI symptoms. 
10 out of 36 (28%) patients with elevated FC were taking daily NSAIDs 
compared to 4 out of 48 (8%) patients with normal FC. Daily NSAID users 
did not have higher mean FC. 
9 out of 11 (82%) patients who had disease duration of more than 10 years 
had elevated FC. 
13 out of 28 (46%) patients with BASDAI index (axSpA disease activity 
score) of > 4 had elevated FC and 13 out of 33 (39%) with BASDAI < 4. 
BASDAI of above 4 reflects active disease. 
Patients on biological therapy were equally distributed across all cohorts.
conclusion: Significant proportion of axSpA-not IBD patients have gut in-
flammation as evidenced by raised faecal calprotectin however median 
level in axSpA-not IBD is still lower than axSpA-IBD. NSAIDs have relatively 
little impact. There is a correlation between gut inflammation and age 
of symptoms onset, disease duration and serum inflammatory markers. 
There is no correlation between gut inflammation and joint disease activ-
ity. Based on this study, further work is required to delineate at risk popu-
lation with a view to determining those in whom a colonoscopy would be 
a helpful tool.
references: Mielants, H et al. Macroscopic and histological changes of 
the ileum HLA-B27 related diseases: therapeutic consequences. Int J Clin 
Pharmacol Res. 1984;4(6):409-14. Hamilton, L et al. The prevalence of axial 
spondyloarthritis in the UK: a cross-sectional cohort study. BMC Musculo-
skelet Disord. 2015; 16: 392.
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Introduction: Up to 40% of the patients with inflammatory bowel disease 
(IBD) have MRI evidence of axial spondyloarthritis compared to 1.5% in 
the non IBD population. Here we aim to distinguish axial spondyloarthritis 
associated with IBD (axSpA-IBD) from axSpA without IBD (axSpA-not IBD) 
and psoriatic axSpA (axSpA-PsA).
aims & Methods: A collaborative group comprising of gastroenterologists 
and rheumatologists was formed between 2 healthcare trusts in UK. Clinic 
lists and electronic operating systems were interrogated with appropri-
ate ethical approval to identify patients with axSpA-IBD, axSpA-not IBD 
and axSpA-PsA. Patients were contacted prior to their clinic appointments 
and were sent stool containers. On the day of their clinic appointments, 
they were consulted for 15-30 minutes where their diseases were carefully 
phenotyped, drug history obtained, and informed consent taken. Stool and 
blood samples were collected and analysed for faecal calprotectin and 
acute inflammatory markers.
results: 62 patients were analysed for this study; 22 patients (10 Crohn’s/ 
12 UC) with axSpA-IBD, 24 with axSpA-not IBD and 16 patients with axSpA-
PsA. Of the patients with IBD, 13 out of 22 (59%) were diagnosed with IBD 
first. Median duration of IBD before the diagnosis of axSpA was 3.5 years. 
Remaining 9 patients who were diagnosed with axSpA first, the median 
duration of disease before the diagnosis IBD was 3.5 years as well. 
Median age of onset for joint disease in axSpA-IBD is 30 years compared 
to 27 and 22 in axSpA-not IBD and axSpA-PsA cohorts. 
All three cohorts had gender predominance towards the male sex with 
82% in axSpA-IBD, 86% in axSpA-not IBD and 94% in axSpA-PsA. There 
was no ascertainment bias with the male gender when the diagnosis of 
axSpA was given first. 
Association with HLA B*27 is stronger in the axSpA-not IBD group with 
76% patients possessing the polymorphism compared to 50% in axSpA-
IBD and 40% in axSpA-PsA. Median BASDAI (ankylosing spondylitis dis-
ease activity score) for axSpA-IBD, axSpA-not IBD and axSpA-PsA are 4.3, 
3.95 and 3.2 respectively. Scores of above 4 indicate active disease. 
Mean faecal calprotectin in axSpA-IBD is 233.7ug/g compared to 99.1 and 
28.2 in axSpA-not IBD and axSpA-PsA. 
Pearson correlation coefficient between faecal calprotectin and BASDAI 
scores was 0.0451.
conclusion: In our cohort, we have shown that IBD related axial spondy-
loarthritis is different to axSpA-not IBD in terms of its weaker association 
with HLA B*27 antigen, higher degree of gut inflammation and increased 
age of onset for joint disease. Mean faecal calprotectin in axSpA-not IBD 
was still significantly higher than axSpA-PsA. 
Weaker association with HLA B* 27 antigen in axSpA-IBD points to the pos-
sibility of a different genetic loci or mode of aetiopathogenesis. 
Contrary to what we had expected, male gender predominance is simi-
lar across both axSpA-IBD and axSpA-not IBD group. We’ve found similar 
joint disease activity and functional disability across all cohorts. Further 
work is required to compare this study population with previously studied 
population.
references: Harbord, M et al. The First European Evidence-based Con-
sensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. 
Journal of Crohn’s and Colitis, 2016 March; 10 (3): 239-254. Orchard, TR et 
al. The prevalence, clinical features and association of HLA-B27 in sacroili-
itis associated with established Crohn’s disease. Aliment Pharmacol Ther. 
2009 Jan;29(2):193-7.
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Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas 
(CIBEREHD), Madrid, Spain
contact e-Mail address: mjcasanova.g@gmail.com
Introduction: Microscopic colitis (MC) is a common cause of chronic diar-
rhea with an increasing incidence. However, its etiology and pathogenesis 
are not fully understood.
aims & Methods: i) To describe the main epidemiological and clinical 
characteristics of the patients with MC; ii) to evaluate the efficacy of the dif-
ferent treatments for MC; and iii) to determine the relapse rate in patients 
who achieved clinical remission with budesonide. All patients aged over 
18, diagnosed with collagenous colitis (CC) or lymphocytic colitis (CL) at the 
Gastroenterology Department from Hospital Universitario de La Princesa 
from January 1, 2010 to June 31, 2018, were included. Efficacy and loss of 
response to budesonide were evaluated by Kaplan-Meier analysis.
results: 113 patients diagnosed with CC or CL were included (78% female, 
mean age at diagnosis 65 years, 59% had CC). The median time from 
symptoms to diagnosis was 4 months (IQR 2-7). The most frequent symp-
toms were: diarrhea (98%), weight loss (43%), and abdominal pain (31%). 
3% had a family history of inflammatory bowel disease, 44% history of 
smoking, and 19% cancer antecedents. 31% suffered from depression 
and 48% had at least one autoimmune disease associated, the most fre-
quent being thyroid disease (19%), allergic asthma (10%), type 1 diabetes 
mellitus (5%) and celiac disease (4%). At diagnosis, 43% of the patients 
were on proton-pump inhibitors, 34% on statins, 29% on non-steroidal 
anti-inflammatory drugs, 25% on selective serotonin reuptake inhibitors 
and 20% on beta blockers. The diagnostic colonoscopy showed mucosal 
abnormalities in 16% of the patients, the most frequent being: erythe-
ma (13%), edema (10%), loss of vascular pattern (5%) and spontaneous 
bleeding (5%). Only in 12% of all colonoscopies biopsies were taken by 
colon segments and the mean number of biopsies per colonoscopy was 6. 
At the onset of the disease, 30% of the patients experienced a spontane-
ous clinical remission. Of the remaining, 75% received budesonide, 27% 
5-aminosalicylic acid (5-ASA), 7% systemic steroids and 3% thiopurines. 
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93% achieved remission with budesonide, 43% with 5-ASA, 7% with 
loperamide and 100% with systemic steroids (60% became steroid-de-
pendent). 2 patients received thiopurines due to lack of response to other 
treatments and both achieved clinical remission. Of the patients treated 
with budesonide at diagnosis, 19% were unable to discontinue the drug 
and received maintenance therapy. Of the 51 patients who achieved re-
mission with budesonide at diagnosis, 39% relapsed. Of them, 90% re-
sponded again to budesonide. A second relapse after budesonide with-
drawal occurred in 28% and all of these patients achieved remission after 
restart of budesonide. There was no difference in response to budesonide 
between patients with CC and CL (P>0.05). The cumulative incidence of 
loss of response after achieving remission with budesonide at diagnosis 
(median follow-up time of 55 months) was 39% (95% CI 26-54%): 20% at 
1 year, 32% at 2 years, and 46% at 3 years of follow-up. The rate of adverse 
events of the patients treated with budesonide was 4%, leading to drug 
discontinuation in all cases.
conclusion: MC is more frequent in elderly women. Diarrhea, weight loss 
and abdominal pain are the most common symptoms at diagnosis. MC fre-
quently appears in patients with autoimmune disorders, smoking history 
and under treatment with certain drugs. The vast majority (93%) of the 
patients treated with budesonide at diagnosis achieved remission, how-
ever, almost 40% of them lost response subsequently. Retreatment with 
budesonide after relapsing was effective in most cases.
disclosure: Nothing to disclose 
P1727 TOP LIsT Of MaLIgnancIes OBserved In The hungarIan 
POPuLaTIOn WITh uLceraTIve cOLITIs
Molnár T.1, Szántó K.1, Milassin Á.2, Farkas K.2
1University of Szeged, First Department of Internal Medicine, Szeged, 
Hungary, 2University of Szeged, First Department of Medicine, Szeged, 
Hungary
contact e-Mail address: molnar.tamas@med.u-szeged.hu
Introduction: Ulcerative colitis (UC) is associated with an increased risk 
of colorectal cancer (CRC) and the second most common cause of death 
among UC patients is CRC. An increased risk for extraintestinal malignan-
cies are also observed among IBD patients.
aims & Methods: Our aim was to recognize malignancy pattern associated 
with UC using the National Health Insurance Fund social security databas-
es including inpatient-, outpatient care between 2010 and 2016. This is an 
epidemiological study based on a Hungarian national database. Hungar-
ian UC patients were enrolled. Patients were classified as having a certain 
kind of cancer if they have at least two appearances in the in- or outpatient 
care with the corresponding ICD codes.
results: 37795 patients with UC were included in the study during the 
observational period. Investigating all malignant neoplasms of the UC 
population, colorectal cancer (CRC) was found to be the most frequently 
observed cancer. 1424 patients, 3.7% of the total UC population were di-
agnosed with CRC. Colonic localisation (2.16%) was more frequent than 
rectal localisation (1.7%). The second most common malignancy was non-
melanotic skin cancer, in 1.48% of the patients, the third was prostate can-
cer in 0.99% of the patients. Malignant neoplasm of the urogenital tract 
and the breast were diagnosed in 0.54-0.46% of the patients. Malignant 
melanoma of the skin was the fifteenth most common malignancy, 0.21% 
of the patients were diagnosed with malignant melanoma. Among our pa-
tients intestinal non-Hodgkin lymphomas were observed in 0.092% of the 
patients. Malignancies with the least incidence were malignant neoplasm 
of the uvula and testis and bone and articular cartilage, 10-10 UC patients 
were diagnosed with these malignancies.
conclusion: Our results underly that colorectal carcinoma is still a real 
danger in UC patients, highlight that surveillance need to be improved 
in national level. The most common extracolonic malignancies were non-
melanotic skin cancer.
disclosure: Nothing to disclose 
P1728 usefuLness Of naTuraL Language PrOcessIng 
(nLP) cOMBIned WITh deeP MachIne LearnIng as a TOOL fOr 
cLInIcaL research In crOhn’s dIsease. PreMOnITIOn-cd sTudy
Fernandez-Nistal A.1, Martinez V.1, Gomollon Garcia F.2, Tagarro I.1, 
Medrano I.3, Montoto Otero C.1
1Takeda Farmaceutica España, Madrid, Spain, 2Hospital Clínico Universitario 
Lozano Blesa, Servicio de Aparato Digestivo, Zaragoza, Spain, 3Savanamed, 
Madrid, Spain
contact e-Mail address: alonso.fernandez@takeda.com
Introduction: Natural Language Processing (NLP) is a technology that uses 
computer-based linguistics and artificial intelligence to identify and ex-
tract information from free-text data sources such as progress notes, pro-
cedure and pathology reports, and laboratory and radiologic test results1. 
NLP can accurately and efficiently use the vast data resources that have 
been relatively unavailable for meaningful clinical or research use until 
now. However, it is still unknow the full potential and applicability of NLP 
in clinical practice and research2. In this study, we have tried to understand 
if NLP could become another alternative of generating evidence in Crohn’s 
Disease.
aims & Methods: This is a data-driven, observational, retrospective, non-
interventional, study using secondary data captured in Electronic Medical 
Records (EMRs). A data-driven system based on Natural Language Pro-
cessing (NLP) and big data techniques, has been used to conduct the study, 
using the EHRead technology (Savana). Natural Language was extracted 
from EMRs and captured as free text. Medical concepts were detected by 
using computational linguistic techniques and comprehensive clinical 
contents, scientifically validated (like SNOMED Clinical Terms, CT). This 
unstructured data has been treated as big data and analysed with artifi-
cial intelligence. The results presented here belong to an interim analysis 
of data from 3 Spanish hospitals participating in PREMONITION-CD study 
(NCT03668249). The period for extracting the data has been bounded to 
the last available five years of clinical practice contained in the EMRs avail-
able at each site.
results: Using this innovative technology, we have been able to extract 
data from 877 EMRs from Crohn’s Disease (CD) patients. NLP has allowed 
us to determine some of the main descriptive characteristics of these pa-
tients and Health Care Resources Utilization (HCRU) . Therefore, we have 
learned that 50.6% of patients were female and, out of those patients with 
available data about faecal calprotectin, CRP and hemoglobin, mean (SD) 
were 532 (638.8) µg/g, 460.6 (133.4) mg/L and 12.8 (2.1) g/dL respectively. 
Regarding previous medical history, the most common conditions were 
disorders of cardiovascular system (20.3%) and disorder of lipoprotein/
lipid metabolism (13.3%). 
Additionally, NLP also allowed us to gather information about HCRU. For 
example, the average (SD) number of visits/year to GI units has been rel-
atively stable along last years, ranging between 1.5 (2.4) and 2.1 (2.9). 
However, the average number of visits to the hospital day have steadily 
increased over the last years from 6.4 (7) visits in 2013, to 8.3 (8.9) in 2017; 
with a similar trend regarding visits to other specialists: from 6.6 (8.6) in 
2013 to 8.3 (9.7) in 2017.
conclusion: NLP seems to be a promising tool that can be used in specific 
situations to accurately provide meaningful information in patients with 
Inflammatory Bowel Disease. We anticipate it will become more widely 
used within clinical, research, and administrative roles. Quality of clinical 
data contained within EMRs and validation of data extraction process must 
be taken into consideration in order to let NLP become a key resource to 
answer questions that otherwise would be too expensive or time consum-
ing to address with a traditional research methodology.
references: 1. Velupillai S, Suominen H, Liakata M, Roberts A, Shah AD, 
Morley K, Osborn D, Hayes J, Stewart R, Downs J, Chapman W, Dutta R. 
Using clinical Natural Language Processing for health outcomes research: 
Overview and actionable suggestions for future advances. J Biomed In-
form. 2018 Dec; 88:11-19 2. Hou JK, Imler TD, Imperiale TF. Current and 
future applications of natural language processing in the field of digestive 
diseases. Clin Gastroenterol Hepatol. 2014 Aug;12(8):1257-61.
disclosure: PREMONITION-CD study has been sponsored by Takeda 
Farmacéutica España SA 
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P1729 earLy dIsease acceLeraTIOn In PaTIenTs WITh 
neWLy dIagnOsed crOhn’s dIsease In IndIa and IsraeL: 
InsIghTs frOM an easT-WesT IncePTIOn cOhOrT
Goren I.1, Yanai H.2, Pal P.3, Adigopula B.4, Pendyala S.5, Yadgar K.6, 
Banerjee R.7, Dotan I.8, the Indo-Israeli IBD GastroEnterology 
paRtnership (TiiiGER)
1Rabin Medical Cneter, affiliated to Sackler Faculty of Medicine, Tel Aviv 
University, Division of Gastroenterology, Petah Tikva, Israel, 2RABIN 
Medical Center, Dr., Tel Aviv, Israel, 3Department of Gastroenterology, 
Asian institute of Gastroenterology, Dr., Hyderabad, India, 4Department of 
Gastroenterology, Asian institute of Gastroenterology, Hyderabad, India, 
5Asian Inst. of Gastroenterology - Gastroenterology, Hyderabad, India, 
6Rabin Medical Center, Petah Tikva, Israel, 7Asian Inst. of Gastroenterology 
- Gastroenterology, Hyderabad, Israel, 8Rabin Medical Center, Director, 
Division of Gastroenterology, Petah Tikva, Israel
contact e-Mail address: irisdo@clalit.org.il
Introduction: Crohn’s disease (CD) is a progressive disease with variable 
rate of acceleration. An increase in the incidence of CD is evident in Asia 
and specifically in India. Data on clinical presentation and course in the 
Indian population is lacking.
aims & Methods: The Indo-Israeli IBD GastroEnterology paRtnership 
(TiiiGER) aimed to assess patterns of early disease among Indian and Is-
raeli patients with newly diagnosed CD. Prospective observational incep-
tion cohorts were recruited in two large referral centers in India and Israel 
between May 2013 and December 2017. Adults (>18 years) suspected of CD 
or patients with newly diagnosed CD were included. Disease acceleration 
was defined by the first CD-related surgery, hospitalization or recommen-
dation to start steroids, immunomodulators or biologic therapy.
results: Two hundreds sixty patients were included, 104 Indians and 
156 Israelis. Indian patients had male predominance compared with the 
Israeli cohort (65.4% vs. 50.6%, p=0.019). At diagnosis Indian patients 
were older (37.8±12.8 vs. 31.8±12.8, p< 0.0001) and were less likely to be 
active smokers (8.7% vs. 22.4%, p< 0.0001). Indian patients had signifi-
cantly more colonic and upper gastrointestinal disease location (35.6% vs. 
19.2%, p=0.003 and 13.5% vs. 5.1%, p=0.018, respectively), more stenotic 
behavior (36.6% vs. 6.5%, p< 0.0001) and lower rate of perianal disease 
involvement (5.8% vs. 23.7%, p< 0.0001), compared to Israeli patients.
Furthermore, Israeli patients had higher body mass index (23.4±4.5 vs. 
19.9±4.3, p< 0.0001) and significantly more family history of CD (22.4% vs. 
3.8%, p< 0.0001).
Overall during a follow-up period of up to 43 months, disease acceleration 
rate was 50% (52/104) in Indian and 66.7% (104/156) in Israeli patients, 
with median time to disease acceleration of 7.6 (interquartile range [IQR] 
1.9-25.6) and 3.4 (IQR 1.3-23) months, p=0.05, respectively. In multivari-
ate cox regression model, Indian compared to Israeli patients were less 
likely to have disease acceleration or to be treated with steroids, immuno-
modulators or biologic therapy (hazard ratio [HR] 0.598; 95% CI, 0.4-0.8; 
p=0.011 and HR 0.563; 95% CI, 0.373-0.851, p=0.006).
conclusion: In a first indo-Israeli inception cohort of patients with newly 
diagnosed CD more than half of the patients experienced early disease 
acceleration. Distinct demographic and phenotype characteristics at CD di-
agnosis and different rates of disease acceleration were identified. Ethnic 
variations in disease phenotype may help to identify key genetic, environ-
mental & behavioral factors contributing to the development of IBD.
disclosure: This study was partially supported by generous grants from the 
ECCO-AOCC travel grant & the IOIBD travel grant. Idan Goren, MD, grant 
recipient. 
P1730 cOMParIsOn Of dIeTary PaTTerns In IBd PaTIenTs 
BeTWeen The nOrThern and sOuThern PrOvInces Of The 
neTherLands
Peters V.1,2, Spooren C.3, Weersma R.K.1, van Dullemen H.M.1, 
Festen E.A.M.(.1, Visschedijk M.1, Masclee A.A.3, Hendrix E.3, Pierik M.J.4, 
Dijkstra G.1, Jonkers D.M.3, Campmans-Kuijpers M.1
1University Medical Centre Groningen and University of Groningen, 
Department of Gastroenterology and Hepatology, Groningen, Netherlands, 
2University Medical Centre Groningen and University of Groningen, 
Department of Epidemiology, Groningen, Netherlands, 3University Medical 
Centre Maastricht and University of Maastricht, Division Gastroenterology-
Hepatology, Maastricht, Netherlands, 4Maastrich University Medical Center, 
Department of Gastroenterology and Hepatology, Maastricht, Netherlands
contact e-Mail address: v.peters@umcg.nl
Introduction: Evidence-based dietary guidelines are not available for pa-
tients with Inflammatory Bowel Disease (IBD). Therefore, patients tend to 
follow their own “unguided” dietary habits, often leading to unbalanced 
intakes that may further impact disease course. Hence, we aimed to iden-
tify dietary patterns in post-diagnosis habitual dietary intake in 2 separate 
cohorts of Dutch IBD outpatients.
aims & Methods: 489 IBD patients (286 Crohn’s Disease (CD), 203 Ulcer-
ative Colitis (UC)) from Groningen and 236 IBD patients (154 CD, 82 UC) 
from Maastricht with data on demographics and disease phenotype were 
included. Dietary intake, including nutrients and 22 food groups, was 
obtained via semi-validated food frequency questionnaires. Dietary dif-
ferences in macronutrients and food groups, and baseline characteristics 
were analysed between the cohorts using a students’ t-test or X2-test when 
appropriate. A preliminary principal-components analysis (PCA) was con-
ducted on 22 food groups to identify relevant dietary patterns.
results: Compared to the Maastricht cohort, patients in the Groningen co-
hort had a lower age at inclusion and diagnosis, disease duration, and 
less men (all p< 0.05); no differences were observed in phenotype, BMI 
or smoking. The total energy intake including energy from all separate 
macronutrients was significantly lower in the Groningen cohort. Moreover, 
patients in Groningen consumed less legumes, grains, red and processed 
meat, poultry, fish, confectionery, coffee, oils, alcoholic beverages and 
condiments, but more potatoes, dairy, non-alcoholic beverages and pre-
pared meals than patients in Maastricht.
First, a PCA was run in the Groningen cohort to identify dietary patterns. 
This PCA, with an overall Kaiser-Meyer-Olkin (KMO) measure of 0.624 re-
vealed 8 components with eigenvalue >1. Visual inspection of the scree plot 
(Cattell, 1966) and interpretability criteria, indicated that two components 
should be retained, explaining 22.0% of the total variance. The interpreta-
tion of the data was in line with the western and prudent components as 
described before (Stricker, 2013). Condiments, grain products, potatoes, 
oils, processed and red meat, snacks and confectionery contributed to a 
western component; whereas fruits, vegetables, fish, tea, eggs and nuts 
loaded positively, and snacks and non-alcoholic beverages loaded nega-
tively on the prudent component. To confirm the above patterns, a PCA 
was also run on the Maastricht data, with an overall KMO of 0.602 and 
revealing 9 components with an eigenvalue >1. Here, visual inspection of 
the scree plot and interpretability criteria also indicated that two compo-
nents should be retained. These explained 21.8% of the total variance and 
were also consistent with the western and prudent component. The same 
food groups loaded on the western component and prudent component, 
except for snacks and fruits to the prudent component. This might be due 
to smaller sample size in the Maastricht cohort.
conclusion: Our study shows that IBD patients in the Groningen cohort 
mainly use a western or prudent-based diet after diagnosis. These findings 
were confirmed in the geographical distinct Maastricht cohort; as mainly 
the same patterns were extracted. Since, adapting a western dietary pat-
tern may contribute to potentially unintended effects on disease course, 
dietary intervention in these patients might be beneficial.
references: Abstract: V. Peters and C. Spooren are shared first author, D.M. 
Jonkers and M.J.E. Campmans-Kuijpers are shared last author. 
Ref: Cattell, R. B. (1966). The scree test for the number of factors. Multi-
variate Behavioral Research, 1, 245-276. Stricker, M.D. (2013). Dietary pat-
terns derived from principal component- and k-means cluster analysis: 
Long-term association with coronary heart disease and stroke. Nutrition, 
Metabolism & Cardiovascular Diseases, 23, 250e256.
disclosure: Dr. Pierik reports grants from Falk Pharma, non-financial sup-
port from Abbvie, non-financial support from Falk Pharma, nonfinancial 
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support from Johnsen and Johnsen, non-financial support from Takeda, 
non-financial support from Ferring, nonfinancial support from Immuno-
diagnostics, grants from European comission , non-financial support from 
MSD, grants from ZONMW (Dutch national research fund), outside the sub-
mitted work. Dr. Jonkers and Drs. Spooren report a grant from European 
commission outside the submitted work (FP7/SysmedIBD) 
P1731 IncreasIng IncIdence Of crOhn’s dIsease In ePIrus, 
greece: a 30-year PrOsPecTIve sTudy frOM a referraL 
cenTer
Skamnelos A.1, Katsanos K.H.2, Malakos Z.1, Saridi M.1, Albani E.3, 
Lamouri C.3, Mousavere I.1, Kavvadias A.1, Theopistos V.1, 
Mpaltagiannis G.4, Tzampouras N.1, Christodoulou D.K.5
1University Hospital of Ioannina, Department of Gastroenterology, Ioannina, 
Greece, 2Medical School of Ioannina, Division of Internal Medicine, 
Ioannina, Greece, 3University Hospital of Ioannina, Ioannina, Greece, 
4University Hospital and Medical School of Ioannina, Ioannina, Greece, 
5University Hospital, Gastroenterology Unit, 1St Division of Internal Medicine 
and Hepato-Gastroenterology Unit, Ioannina, Greece
contact e-Mail address: alskamnelos@gmail.com
Introduction: The number of individuals affected by inflammatory bowel 
diseases (IBD) has been globally increasing. We have described a low inci-
dence of Crohn’s disease in our area in the past. The aim of this extended 
study was to investigate and update the incidence and prevalence of IBD 
and its subtypes (UC, CD, IBD unclassified) in Epirus which is a well-de-
fined geographical area of Greece with a 30-year observation period of 
these diseases.
aims & Methods: The epidemiological study was conducted in the region 
of Epirus, one of the 13 prefectures of Greece, and in the two neighboring 
islands of the Ionian Sea, Corfu and Lefkada. The study was conducted in 
two periods, 1982-2002 and 2003-2015 so that we could trace any changes 
in the incidence and behavior of IBD during time in our area.
results: The overall incidence of Crohn’s disease was 1.16/100,000 in-
habitants (95% C.I. 0,62 - 1,60) [1,41 (95% C.I. 0.75 - 2.15) for males vs 
1.02 (95% C.I. 0,39 - 1,23) for females] on the first period (1982-2002) and 
2,75/100,000 inhabitants (95% C.I. 1,53 - 3,46) [3,67 (95% C.I. 1,96 - 4,71) 
for males vs 1,85 (95% C.I. 0,77 -2,64) for females] of the second period 
(2003-2015). These observations showed a significant increase of Crohn’s 
disease in both genders in our area. In addition, the prevalence of ul-
cerative colitis per age group showed a decrease of the incidence of UC 
in older ages during the most recent time period compared to the past. 
This decrease was more prominent to male patients over 70 years of age. 
Regarding the age distribution of ulcerative colitis, it appears that there is 
a significantly increasing trend to affect younger ages during the second 
time period (the recent one). At the same time, as mentioned, a notewor-
thy decrease in the incidence of ulcerative colitis after the age of 70 years 
has been documented during the second period of the study.
conclusion: The results of our study confirm the continuing change of epi-
demiology of IBD in our area, with increasing incidence of Crohn’s disease 
and decreasing incidence of ulcerative colitis in elderly patients. In addi-
tion, based on international multicenter studies, patients with IBD and 
particularly CD are expected to increase within the next decades. Aware-
ness of the disease, early diagnosis and consistent and prompt monitoring 
from the time of diagnosis will provide them with a better quality of life 
and prevent complications.
disclosure: Nothing to disclose 
P1732 PrevaLence and PredIcTOrs Of sexuaL and erecTILe 
dysfuncTIOn In PaTIenTs WITh InfLaMMaTOry BOWeL dIsease
Domislovic V.1, Brinar M.2, Barišić A.3, Vujicic L.4, Novosel M.4, Krznaric Z.5
1University Hospital Centre Zagreb, Department of Gastroenterology and 
Hepatology, Zagreb, Croatia, 2University Hospital Centre Zagreb, Department 
of Gastroenterology, Zagreb, Croatia, 3University Hospital Center Zagreb, 
Clinical Nutrition, Zagreb, Croatia, 4Zagreb School of Medicine, Zagreb, 
Croatia, 5KBC Zagreb, Gastroenterology, Zagreb, Croatia
contact e-Mail address: viktor.domislovic@gmail.com
Introduction: Inflammatory Bowel Disease (IBD) has a negative impact on 
quality of life (QOL), and sexuality is one of its major determinants. The 
impact of disease characteristics on sexuality and intimacy is one of the 
main concerns of IBD patients. Despite the obvious relevance of this prob-
lem, knowledge of the extent and the determinants of sexual dysfunction 
in persons with IBD is limited.
aims & Methods: The main goal of the study was to determine the preva-
lence of sexual dysfunction (SD), erectile dysfunction and association with 
quality of life (QOL) and it’s components in patients with IBD, and to search 
for predictors of SD and ED. 
In this cross-sectional study patients fulfilled anonymous validated ques-
tionnaire on their sexual function. In International Index of Erectile Func-
tion (IIEF) for males, five domains were evaluated through questions on 
erectile function, orgasmic function, sexual desire, intercourse satisfac-
tion and overall satisfaction. In women were six domains assessed, desire, 
arousal, lubrication, orgasmic function, satisfaction and pain. For both 
scores, higher scores indicated a better function. Patients also fulfilled 
IBDQ-32, a validated questionnaire for assessing quality of life in IBD pa-
tients. IBDQ-32 score is ranging from 32 to 224 with higher scores repre-
senting better quality of life and consists of four main components (social, 
emotional, systemic and bowel function). Disease activity was defined as 
Crohn’s Disease Activity Index (CDAI) >150 or Partial Mayo Score ≥3 for CD 
and UC, respectively.
results: In this study we have enrolled 202 patients who fulfilled the ques-
tionnaire (133 CD, 69 UC). Among them 122 were men and 80 women. 
Average age of included patients was 39.2±11.02. In women, SD rates were 
75% (N=60), and were significantly higher than 18% (N=22) in men (p< 
0.001). QOL was significantly lower in patients with SD, in which IBDQ-
32 score amounted 167.47±30.4 vs. 182.8±31.9, p=0.01. ED was reported 
by 30% (N=37) of male IBD patients. Patients with ED had lower IBDQ-
32 score comparing to patients without ED (161.4±35.4 vs. 186.6±27.5, p< 
0.001). In univariate analysis, significant positive predictors for SD in total 
IBD population were female gender, UC and impaired social, emotional, 
systemic and bowel function components of IBDQ. Multivariate analysis 
showed that the significant predictors for SD were female gender (OR=17.5, 
95% CI 8.3-37.2) and emotional component of IBDQ (OR=3.5, 95% CI 0.7-
17.05). Disease duration, disease activity, history of lower abdominal sur-
gery, presence of stoma, perianal disease and current biological treatment 
were not significant predictors of SD.
conclusion: The results show that SD is highly prevalent in IBD patients, 
with women to man ratio of almost 4 to 1. Erectile dysfunction is present in 
approximately every third male patient. Patients with both SD and ED have 
lower QOL. Significant and strong predictors for SD are female gender 
and emotional component of IBDQ, which consists of questions regarding 
frustration, depression, tension, worry about surgery, irritation, angriness, 
fear of not finding a toilet, being tearful or upset, feel lack of understand-
ing and satisfaction with personal life. Improvement of QOL is one of the 
main goals in treating IBD patients. Because of its strong connection with 
sexual function and satisfaction, it is important to identify those problems 
and to provide proper psychological support, medical treatment and edu-
cational information.
disclosure: Nothing to disclose 
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P1733 erecTILe dysfuncTIOn In Men WITh neWLy dIagnOsed 
InfLaMMaTOry BOWeL dIsease
Ait Errami A.1, Samlani Z.2, Oubaha S.3, Krati K.3
1Mohammed VI, Hepatogastroenterology, Marrakech, Morocco, 2UHC 
Marrakech, Hepatogastroenterology, Marrakech, Morocco, 3UHC Marrakech, 
Marrakech, Morocco
contact e-Mail address: adil.ae@hotmail.fr
Introduction: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic 
inflammatory bowel diseases (IBDs) that often present between the second 
and fourth decades of life, when sexual identity and relationships are de-
veloping. Sexual function is one of the top concerns expressed by patients 
with IBD yet remains poorly explored by researchers and clinicians.
aims & Methods: Cross-sectional studies on sexual function in men with 
inflammatory bowel disease (IBD). Using a prospective incidence cohort, 
we aimed to describe sexual function at baseline and over time and to 
identify factors associated with impaired sexual function in men with IBD.
18 years and older enrolled between April 2016 and January 2019 in our 
centre with a minimum three months of follow-up were eligible for study. 
Male sexual function was assessed using the International Index of Erectile 
Function (IIEF), a self-administered questionnaire that assesses 5 dimen-
sions of sexual function over the most recent 4 weeks. To assess changes in 
the IIEF per various demographic and clinical factors, linear mixed effects 
models were used.
results: Fifty two of 73 eligible men (71 %) completed the questionnaire 
(19 Crohn’s disease, 33 ulcerative colitis). The mean age (SD) of the cohort 
at diagnosis was 29.4 years. At baseline, 28 % of men had global sexual 
dysfunction, and 85% had erectile dysfunction. Independent factors asso-
ciated with erectile dysfunction are older age and lower physical and men-
tal component summary scores on the Short Form Health Survey (SF-36).
conclusion: In an incident cohort of IBD patients, most men had erectile 
dysfunction. Physicians should be aware of the high prevalence of erectile 
dysfunction and its associated risk factors among men with newly diag-
nosed IBD to direct multidisciplinary treatment planning.
disclosure: Nothing to disclose 
P1734 OBesITy and OsTeOPOrOsIs In InfLaMMaTOry BOWeL 
dIsease PaTIenTs: a naTIOnWIde anaLysIs
Enofe I.1, Aluko A.2, Yam J.3, Khan N.N.1
1Michigan State University, Internal Medicine, Lansing, United States, 
2Michigan State University, East Lansing, United States, 3Michigan State 
University, Gastroenterology, East Lansing, United States
contact e-Mail address: enofeik@yahoo.com
Introduction: Osteoporosis is a major health problem in patients with in-
flammatory bowel disease (IBD) with reported prevalence ranging from 
30-60% among this population in the United States. Obesity on the oth-
er hand has conflicting evidence as it relates to osteoporosis especially 
among IBD patients with some studies reporting a protective effect while 
others demonstrate worsening bone mass effect. Given the rising global 
prevalence of obesity and the poorly understood consequences in IBD pa-
tients, we aimed to examine the relationship between obesity and osteo-
porosis in IBD patients using the largest repository of discharges in the 
united states. We hypothesize that obesity will be associated with osteo-
porosis in IBD patients.
aims & Methods: We performed a retrospective study using the 2014 Na-
tional Inpatient Sample database. All adult patients with a primary or sec-
ondary discharge diagnosis of inflammatory bowel disease were included 
in this study. Data on patient and hospital level characteristics, sociode-
mographic factors, and outcomes were obtained. Diagnosis of both obesity 
and osteoporosis diagnosis were identified using ICD 9 codes. Descriptive 
and inferential analysis was performed. Patient and outcome character-
istics were compared using chi-square and logistic regression. We con-
trolled for sociodemographic factors and patient comorbidities.
results: A total of 273,905 discharge records with inflammatory bowel dis-
ease met our inclusion criteria for this study. The prevalence of obesity was 
significantly higher in patients with Ulcerative colitis compared to Crohn’s 
disease (10.64% versus 10.03 % p-value < 0.05). Using multivariable 
analysis to control for patients age, sex and comorbidities, obese patients 
with Crohn’s disease were 43% significantly less likely to have osteoporosis 
compared to their non-obese counterparts (AOR 0.57, 95% CI 0.46 - 0.71). 
Obese patients with Ulcerative colitis were 16% less likely to have osteo-
porosis compared to non-obese patients (AOR 0.84, 95% CI 0.69 - 1.14), 
however this relationship was not statistically significant.
conclusion: Our study demonstrates a protective effect of obesity against 
osteoporosis in patients with Crohn’s disease but not in patients with Ul-
cerative colitis. Although prior studies have shown conflicting results con-
cerning the role of obesity in IBD, our study further adds to the literature 
demonstrating different effects of osteoporosis in Crohn’s disease versus 
ulcerative colitis. The mechanism by which obesity may possibly protect 
against osteoporosis is poorly understood,
more so, in light of studies that associate obesity predominantly with ac-
tive Crohn’s disease, prospective studies are needed to understand these 
findings better and provide higher level evidence as well as a molecular 
basis for this interaction.
disclosure: Nothing to disclose 
P1735 The OMIs (OcuLar ManIfesTaTIOns In IBd screenIng) 
quesTIOnnaIre: a TOOL fOr cLInIcIans fOr earLy deTecTIOn Of 
OcuLar InvOLveMenT In InfLaMMaTOry BOWeL dIsease
Scrivo B.1, Vadalà M.2, Giuffrida E.1, Davì C.3, Ingrassia Strano G.3, 
Ventura N.2, Cillino S.1, Cammà C.1, Cappello M.1
1University of Palermo, Gastroenterology and Hepatology Section, 
ProMiSe Department, Palermo, Italy, 2University of Palermo, Biomedicine, 
Neuroscienze and Advance Diagnostic Department, Palermo, Italy, 3University 
of Palermo, Palermo, Italy
contact e-Mail address: barbara.scrivo@gmail.com
Introduction: Extraintestinal manifestations (EIM) are common in Inflam-
matory Bowel Disease ( IBD) being reported in up to 50% of patients. 
Among EIMs ocular manifestations are less frequent (less than 15%) but 
may be associated with significant morbidity, including blindness. They 
may be related to active inflammation or have an independent course or 
represent adverse events of pharmacological therapies. Ocular complaints 
are often non specific and are frequently ignored from both physicians and 
patients. Biological therapies, especially anti-TNFs, have been shown ef-
fective on some eye EIMs, probably reducing their prevalence.
aims & Methods: Our aim was to assess the accuracy of a dedicated ques-
tionnaire in patients with IBD treated with biological drugs for the detec-
tion of ocular EIMs in a tertiary IBD referral clinic. We developed a ques-
tionnaire, OMIS (Ocular Manifestations in IBD Screening), after agreement 
between gastroenterologists and ophthalmologists. The questionnaire was 
administered by a non-ophthalmologist physician to 96 IBD patients treat-
ed with biological drugs (anti-TNFs) in the Gastroenterology clinic during 
infusion or in the waiting room.
results: Out of 96 interviewed patients, EIMs were reported in 55 persons 
(57%), mainly as joint menifestations (36%). Thirty-five patients (36.5%) 
tested positive for ocular involvement at screening and were selected for 
ophthalmologic examination. Red eye (12 patients, 34.28%), ocular pain 
(10 patients, 28.57%), photophobia (14 patients, 40%) and visual fogging 
(18 patients, 51.42%). On ophtalmological visit, ocular EIMS were con-
firmed in 29 of 35 patients (82.85%): 4 cases of uveitis (11.42%), all dated 
before the beginning of biologics, 12 cases of dry eye (34.28%) and 13 
cases of cataracts (37.14%), in progress or already treated with surgery.
conclusion: The OMIS questionnaire is a useful tool for non-ophthalmol-
ogist physician in everyday practice during the outpatient visit, in order to 
select patient to be addressed to ophthalmological visit, creating a real 
integrated multidisciplinary clinical equipe, to improve management of 
IBD, to prevent visual disability and guarantee quality of life.
disclosure: Nothing to disclose 
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P1736 uPgraded dIfferenTIaL dIagnOsIs Of MuLTIPLe 
PseudOPOLyPs and PrecancerOus POLyPs: 10 years PracTIce 
Based sTudy
Prymak O.1, Golovchenko O.2, Babiichuk Y.2
1Medical Clinical Investigational Center of Medical Center Health Clinic 
LLC, Gastroenterology, Hepatology and Endocrinology, Vinnytsia, Ukraine, 
2Medical Clinical Investigational Center of Medical Center Health Clinic LLC, 
Vinnytsia, Ukraine
contact e-Mail address: oliaflava@gmail.com
Introduction: It’s common knowledge that the risk of colorectal cancer in 
patients with ulcerative colitis (UC) is greatly increased compared with 
the general population. Pseudopolyps (PP) are considered as a part of UC 
manifestation, in the same time, they can mask adenomatous polyps that 
may become malignant. In case of multiple PP, differential diagnosis with 
the precancerous is subjective by endoscopist evaluation, besides, biopsy 
of all PP and is financially and technically difficult process.
aims & Methods: The aim of the study was to optimize the identifying 
potential precancerous polyps among the multiple PP.
For a 10 years study, 80 patients with moderate to severe UC with endo-
scopic and histologic established multiple PP were undergone CT of ab-
domed, pelvis and enterography on TOSHIBA Aquilion 64 Slice CT Scanner 
with dual contrast (intravenous and oral). Based on conclusion results, 
they were divided into two groups. Group 1 included 28 patients with PP 
that were determined on CT. Other 52 patients were included in Group 2 
as they had no evidence of polyps on CT. Then, all patients were received 
conventional and immunobiological treatment up to achieve clinical and 
laboratory remission (in general 54 patients: 23 (82.1%) in Group 1 and 31 
(59.6%) in Group 2). After that, they were undergone colonoscopy.
results: 1. Group 1 had before treatment the mean size of polyp 1.7+/-0.4 
cm and the affected by PP area 30 +/- 5 % per bowel segment. After treat-
ment, 20 patients (87%) had the same size and affected area (p< 0,05). 
Other 3 patients (13%) got improvement - mean size of polyp decreased 
to 1.2+/-0.3 cm (p< 0,05), affected area left the same. After biopsy of the 
largest PP in each subject, the different type adenoma was found in 10 
(43.5%), hyperplastic in 3 (13%) and chronic inflammation in 10 (43.5%) 
cases.
2. Group 2 had before treatment the mean size of polyp 1.0+/-0.4 cm and 
the affected by PP area 27% +/- 4 % per bowel segment. After treatment, 
24 patients (77.4%) had disappearance of PP (p< 0,05). Other 7 patients 
(22.6%) got improvement - mean size of polyp decreased to 0.6+/-0.2 cm 
(p< 0,05), affected area to 23 % +-3%. After biopsy of the largest PP in 
each subject only chronic inflammation was observed. 
Thus, the most polyps that were determined on CT after biopsy (56%) 
were precancerous, versus polyps that were not (chronic inflammation) 
(p< 0,05). The using of CT is allowed to decrease number of biopsies and 
more accurately determine precancerous polyps.
conclusion: The CT, in the aggregate with standard methods, could be 
used for verification of precancerous polyps among PP.
disclosure: Nothing to disclose 
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Gazouli M.2, Koutroubakis I.1
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Introduction: The presence of antinuclear antibodies (ANA) in serum of in-
flammatory bowel disease (IBD) patients has been associated with a worse 
response to treatment with anti-TNF agents including infliximab (IFX). An 
association between ANA and the development of paradoxical cutaneous 
and rheumatological manifestations in IBD patients under IFX has also 
been reported. However, there is limited data on the direct correlation of 
ANA with the pharmacokinetics of IFX.
aims & Methods: The aim of this study is to investigate the potential as-
sociation of serum ANA with IFX trough levels (IFX-TLs) and IFX antibod-
ies (ATIs) in IBD patients treated with IFX. We studied IBD patients under 
maintenance treatment with IFX retrospectively in whom we had at least 
one IFX-TLs and ATIs measurement and one ANA measurement in the se-
rum. IFX and ATIs as well as clinical disease activity scores (HBI or SCAI), 
biomarkers (CRP) and development of adverse events were compared be-
tween patients with positive and negative ANA.
results: Fifty IBD patients under maintenance therapy with IFX were en-
rolled. Of these, 28 had positive ANA [men 15 (54%), median age 46.8 ± 
12.1 years, 20 with Crohn’s disease (71.4%), median disease time 14.1±11 
years, median IFX therapy time 62.5±51 months, 11 smokers and 7 ex-
smokers, 15 under combination therapy with an immunomodulator AZA/
MTX (53.5%)] and 22 had negative ANA [men 17 (77.2%) mean age 41.8 ± 
17.9, 18 Crohn’s disease (81.8%), median disease time 12.2±7.9 years, me-
dian IFX therapy time 51.9±36.8 months, 7 smokers and 7 ex-smokers, 12 
under combination therapy with AZA/MTX]. The median IFX-TLs (IQR) in 
serum of group 1 was 3.51 µg / ml (1.26-6.74), significantly lower than those 
of group 2 [7.38 µg / ml (4.85-10.18)], P = 0.017. 
In addition, the median ATIs in the 1st group (ANA +) were 2.65 U / mL 
(2.41-3.21) significantly higher than the median ATIs of the 2nd (ANA-), 
[2.35 U / mL (2.12-2.81)], P =0.031. No significant differences in regards of 
clinical activity scores, CRP levels or the development of adverse events 
between positive and negative ANA patients was found (P>0.05). 
Eight patients of the first group also showed positive anti-ds-DNA. Posi-
tive anti-ds-DNA patients did not have a statistically significant difference 
in IFX-TLs versus patients with negative anti-ds-DNA (P>0.05). There was 
also no difference in ATIs levels between patients with positive or negative 
anti-ds-DNA (P>0.05).
conclusion: In IBD patients under maintenance treatment with IFX the 
presence of positive ANA is associated with lower IFX-TLs and higher ATIs 
compared to those with negative ANA. Further study is needed in a larger 
population to evaluate the significance of this finding.
disclosure: Nothing to disclose 
P1738 PrevaLence and rIsk facTOrs fOr nOn-aLcOhOLIc 
faTTy LIver dIsease In crOhn’s dIsease
Ben Mohamed A., Medhioub M., Khsiba A., Mahmoudi M., Hamzaoui L., 
Azzouz M.M.
Faculty of Medecine of Tunis, Tunis, Tunisia
contact e-Mail address: asmabenmed2014@gmail.com
Introduction: Non-alcoholic fatty liver disease (NAFLD) is responsible for 
up to 40% of hepatic alterations diagnosed in inflammatory bowel dis-
eases (IBD).
aims & Methods: We aimed to evaluate the prevalence and risk factors for 
NAFLD in patients with Crohn’s disease (CD).
Methods: This is a comparative retrospective study of 86 cases of CD (42 
men and 44 women, sex-ratio of 0.95) with a mean age of 42.47 years 
(18-88 years). We used as a control group, 50 patients consulting for an 
intestinal functional disorder (29 women and 21 men) whose average age 
was 42 years. 
In both groups, hepatic steatosis was sought by abdominal ultrasound as 
well as calculation of the HSI score (Hepatic Steatosis Index). Patients with 
chronic liver disease whose etiology is different from NAFLD, or daily alco-
hol consumption greater than 20 g/day for women and 30 g/day for men 
were excluded.
results: We collected 86 patients followed for CD, the median duration of 
follow-up was 54 months; 44.2% (36) of patients were smokers, 12% had 
a family history of CD, 25.6% (22) were overweight with an average BMI 
of 22.45 kg/m2 (15-30.47kg/m2), 44.2% (38) had ileal disease, 14% (12) a 
colonic disease and 38.6% (33) ileocolic localization. 
CD was inflammatory in 38.4% of cases, stenotic in 34.9% of cases, fistu- 
lizing in 7% of cases and both stenosing and fistulizing in 17.4% of cases. 
NAFLD based on abdominal ultrasound data and HSI score calculation was 
observed in 21 (24.7%) patients with CD versus 8 cases in the control group 
(16%) (p = 0.04). 
The prevalence of diabetes and overweight was comparable between the 
two groups. Among patients with CD, those with NAFLD were more likely 
to be women (14 women versus 7 men) with an average age greater than 
45 years. BMI was higher in patients with hepatic steatosis. Factors as-
sociated with the presence of hepatic steatosis during CD were overweight 
(BMI > 25 kg/m2) (p = 0.026), smoking (p = 0.006), and cortico- steroid 
therapy (p = 0.032). There was no significant association between history 
of surgery and the concept of fatty liver.
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conclusion: Hepatic steatosis is the most common hepatobiliary event dur-
ing CD. Its screening should be systematic in order to introduce preventive 
measures avoiding its progression towards fibrosis.
disclosure: Nothing to disclose 
P1739 a screenIng TOOL fOr The earLy dIagnOsIs Of 
exTraInTesTInaL ManIfesTaTIOns In InfLaMMaTOry BOWeL 
dIsease: The eMaIL quesTIOnnaIre
Ingrassia Strano G.1, Busacca A.1, Giuffrida E.1, Guida L.1, Carrozza L.1, 
Scrivo B.2, Calvaruso V.3, Cappello M.4
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Introduction: Data on prevalence of extraintestinal manifestations (EIMs) 
in inflammatory bowel disease (IBD) range from 6% up to 47%. Recently, 
several red flags and questionnaires have been proposed for early diagno-
sis of articular manifestations.
aims & Methods: Our aim was to analyze the prevalence of EIMs in a single 
center prospective cohort, using a comprehensive questionnaire devel-
oped by our group to detect all EIMs ( Extraintestinal MAnifestations in In-
flammatory boweL disease , EMAIL) . Patients with IBD attending our Clinic 
from November 2017 to January 2019 were interviewed using a two-part 
questionnaire, the first part for clinical-demographic data and the second 
part for EIMs (date of diagnosis, pharmacological therapies at onset and 
for EIMs, response to therapy, relationship with disease activity). Patients 
positive to screening were referred for multidisciplinary approach.
results: 206 IBD patients were interviewed, 114 (55,3%) Crohn’s disease 
(CD) and 92 (44,7%) ulcerative colitis (UC), 52,4% male, mean age 46,7 
years (SD± 15,2). Familial predisposition for IBD was reported in 28,2% 
(47/206). Smokers were 63 (30,6%). 60 (53%) CD patients and 48 (52%) UC 
patients, in total 108, had history of at least one EIM. 37 patients (18%) had 
more than one EIM. The maximum number of EIMs was 4. Articular EIMs 
were found in 49 pts (24%), 36 (31,6%) with CD; peripheral arthritis was 
found in 14% (29/206), axial arthritis in 9,7% (20/206): 7 pts (3,4%) had 
ankylosing spondylitis, 13 (6,3%) sacroiliitis. Mucocutaneous EIMs were 
detected in 39 pts (19%), 27 (23,7%) with CD; erythema nodosum in 15 pts 
(7,3%), pyoderma gangrenosum in 9 (4,4%), psoriasis in 15 (7,3%), follicu-
litis in 7 (3,4%). Ocular EIMs were observed in 35 pts (17%), 19 (16,6%) with 
CD: uveitis in 7 pts (3,4%), conjunctivitis in 8 (3,9%), optic neuritis in 2, 
glaucoma in 2 pts, cataract in 13 (6,3%), dry eye in 4 (1,9%), central serous 
chorioretinopathy in 1. Hepatobiliary EIMs were observed in 31 pts (15%), 
19 with UC: 26 steatosis (12,6%), 5 (2,4%) primary sclerosing cholangitis. 4 
(2%) pts had DVT. There was a significant correlation between CD and ar-
ticular EIMs (p=0,001) , between axial arthritis and IBD related surgery (p= 
0,001) and age at IBD diagnosis between 16 and 40 years (p= 0,042). Skin 
manifestations were more frequent in female (p=0,002) in CD (p=0,032), 
in pts without perianal disease (p=0,019). There was a strong correlation 
between skin manifestations and IBD activity (p< 0,001). Ocular manifes-
tations were more frequent in pts without perianal disease (p=0,042). 
Hepatobiliary manifestations were more frequent in male (p= 0,017) and 
in UC (P=0,044). There was a significant correlation between DVT and IBD 
activity (p= 0,016). 59,6% of patients with EIM (64/108) were treated with 
biologics, immunomodulators were used in 25/108 patients (23%). Combo 
Therapy was used in 11/108 pts (10%).
conclusion: The questionnaire developed by our group proved to be a 
sensitive screening tool since the prevalence of EIMs in our cohort was 
higher than that reported in the literature. Articular and cutaneous EIMs 
are more frequent in CD, hepatobiliary EIMs are more frequent in UC. A 
gender difference has been found since cutaneous EIMs are more frequent 
in females, hepatobiliary more in males. Cutaneous EIMs and DVT are re-
lated with IBD activity. EIMs require a multidisciplinary approach and the 
frequent use of biologics and immunomodulators, early diagnosis could 
improve response to therapy and positively impact on quality of life.
disclosure: None to declare 
P1740 PredIcTOrs Of negaTIve c-reacTIve PrOTeIn In acTIve 
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Faculty of Medicine of Tunis, Tunis, Tunisia
contact e-Mail address: asmabenmed2014@gmail.com
Introduction: Due to its wide accessibility, fast availability and proven cor-
relation with disease activity, C-reactive protein (CRP) remains an essential 
tool in the management of Crohn’s disease (CD). However, the correlation 
of CRP with CD activity is not per- fect. It is therefore of great importance 
to identify the group of patients with active dis- ease and negative CRP.
aims & Methods: We performed a retrospective case-control study, with 
inclusion of CD patients with proven active disease as demonstrated by en-
doscopic and/or radiologic examinations. The CRP’s cut-off value used to 
separate patients in two groups (cases and controls) was 1 mg/dl. Demo-
graphic, phenotypic and clinical characteristics were collected. Statistical 
analysis was performed with SPSS 20.0.
results: We included 77 patients (38 men, 39 women) with a mean age 
of 40.21 years (18-88 years) and median duration of disease of 58 months 
(24-310 months). Twenty seven (35%) of these patients had negative CRP. 
There weren’t statistically significant differences in CD activity between 
cases and controls, as evaluated by Best index. Upon exploratory analysis, 
there were statistically significant differences regarding gender as 47.36% 
of men vs. 23.07% of women had a negative CRP (p = 0.04). Even though 
location was not a significant predictor, all patients with a negative CRP 
had ileal involvement. On multivariate analysis, gender remained a sig-
nificant predictor (p = 0.02). There was also a tendency to a higher prob-
ability of negative CRP in isolated ileal disease (p = 0.058). There were 
no differences in age, behaviour, disease duration, previous abdominal 
surgery or smoking status.
conclusion: Despite being a useful tool, CRP has some limitations and it 
can be negative in cases of active disease. In patients with the identified 
characteristics: men with ileal disease, other methods should be used to 
exclude with confidence the presence of inflammatory activity.
disclosure: Nothing to disclose 
P1741 degradaTIOn and fOrMaTIOn Of TyPe III, Iv and v 
cOLLagen are assOcIaTed WITh dIsease acTIvITy, dIsease 
severITy and dIsease exTensIOn In PaTIenTs WITh uLceraTIve 
cOLITIs
Mortensen J.H.1, Domislovic V.2, Karsdal M.A.1, Brinar M.2, Krznarić Ž.2, 
Manon-Jensen T.1
1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Clinical 
Hospital Centre, Department of Gastroenterology and Hepatology, Zagreb, 
Croatia
contact e-Mail address: viktor.domislovic@gmail.com
Introduction: Ulcerative colitis (UC) is an idiopathic chronic inflammatory 
bowel disease, where increased matrix metalloproteinases are the major 
contributor to the intestinal tissue remodelling UC. The intestinal base-
ment membrane (main constituent is type IV collagen) is directly posi-
tioned underneath the epithelial cells. The supportive interstitial matrix 
(main constituent are type I, III and V collagens) is mainly produced by fi-
broblasts. Both matrices are important for intestinal health and are highly 
affected in UC.
aims & Methods: We investigated serum biomarkers of collagen degrada-
tion and formation of the respective extracellular matrix (ECM) compart-
ments and their association with disease activity, severity and extension 
in 29 UC patients and 29 healthy donors (HD) were included as a control 
group. A combination of the partial mayo score and biochemical activ-
ity was used to determine disease activity (pMayo>1 and CRP>5). Disease 
severity and extension was assessed by Montreal classification. Biomark-
ers of type III collagen degradation (C3M) and formation (PRO-C3), type 
IV collagen degradation (C4M) and formation (PRO-C4), type V collagen 
formation (PRO-C5) and C-reactive protein (CRP) were measured in serum 
by ELISA. One-way ANOVA (Tukey’s multiple comparisons test), and spear-
man rho correlations were applied for statistical analyses.
results: C4M was significantly elevated in active UC compared to UC in 
remission (P< 0.05) and HD (P< 0.001), and PRO-C4 was also significantly 
elevated in active UC and UC in remission compared to HD (P< 0.01). C3M 
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was significantly elevated in active UC compared to UC in remission (P< 
0.05) and HD (P< 0.05), whereas PRO-C3 was significantly elevated in ac-
tive UC and UC in remission compared to HD (P< 0.001). PRO-C5 was el-
evated in active UC compared to HD (P< 0.01) (figure 1). In addition, C3M 
(r=56,P< 0.01), C4M (r=0.41,P< 0.05), PRO-C4 (r=58,P< 0.001), PRO-C5 
(r=49,P< 0.01), and CRP (r=47,P< 0.01) correlated with disease severity, and 
PRO-C4 (r=48,P< 0.01), PRO-C5 (r=0.38,P< 0.05), and CRP (r=45,P< 0.01) 
correlated with disease extension.
conclusion: The biomarkers C3M and C4M were associated with disease 
activity in UC and disease severity in addition to PRO-C4 and PRO-C5. 
PRO-C4 and PRO-C5 also correlated with disease extension. These data 
demonstrated that ECM remodelling of the intestinal basement membrane 
and interstitial matrix are associated with disease status and progression, 
which can be used to optimize treatment strategies for UC patients.
disclosure: JHM, MAK, and TMJ are full time employees at Nordic Biosci-
ence. MAK and TMJ hold stocks in Nordic Bioscience. 
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Croatia, 3San Matteo Hospital Foundation, University of Pavia, First 
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contact e-Mail address: tmj@nordicbio.com
Introduction: Crohn’s disease (CD) and ulcerative colitis (UC) is marked by 
inflammation of the gastrointestinal tract and characterized by intermittent 
periods of active disease (flares) and inactive disease (remission) resulting 
in impaired intestinal epithelial barrier and induced tissue damage and 
remodeling. Methods for assessment of the intestinal permeability can be 
used to evaluate the disease burden, however, there are only a few non-
invasive biomarkers available. The epithelial cells are positioned directly 
on top of the basement membrane, which is remodeled extensible in IBD. 
The transmembrane collagens connect the epithelial cells to this extra cel-
lular matrix (ECM).
aims & Methods: Since transmembrane collagens have an important role 
in epithelial cell homeostasis, we sought to determine whether type 23 
collagen, a transmembrane collagen expressed in epithelial cells as asso-
ciated with the basement membrane, could serve as surrogate for disease 
activity in patients with CD and UC active disease. 
We developed an enzyme-linked immunosorbent assay (ELISA, named 
PRO-C23) to detect the ectodomain of type 23 collagen in serum, followed 
by evaluation of its levels in both rat dextran sulfate sodium (DSS) model 
and human UC and human CD cohorts. Serum from 44 CD and 29 UC pa-
tients with active and inactive disease based on the simple endoscopic 
score for CD (SES-CD) and on the Mayo score for UC (pMayo), respectively 
were included in this study.
results: In patients, serum levels of PRO-C23 were elevated in CD (p< 0.05, 
Fig. 1A) and UC (p< 0.001, Fig. 1B) patients with active disease compared 
to healthy donors. In the DSS induced rat colitis model, PRO-C23 level was 
significantly increased in the rats with active disease (Fig. 1C) and returned 
to normal level after disease remission.
conclusion: This is the first study that showed type 23 collagen levels were 
elevated in IBD, and consequently that transmembrane collagens and the 
basement membrane axis is important for the pathology of IBD. We dem-
onstrated that biomarker, PRO-C23, was elevated in rats with active colitis 
(proving accuracy) and in CD and UC patients with active disease. This 
indicates that PRO-C23 is associated with a compromised interstitial mu-
cosa, and epithelial cell dysfunction. PRO-C23 may potentially be used as 
non-invasive surrogate of disease activity in CD and UC patients and thus 
aid in the diagnosis and monitoring patients, in combination with other 
biomarkers.
disclosure: JHM, MAK, SS, ML, and TMJ are full time employees at Nordic 
Bioscience. MAK and TMJ hold stocks in Nordic Bioscience. 
P1744 InsIghTs frOM a MuLTIdIscIPLInary referraL cLInIc 
fOr derMaTOLOgIcaL cOMPLIcaTIOns In PaTIenTs WITh 
InfLaMMaTOry BOWeL dIseases: IBd-derMa-cLInIc
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Introduction: Dermatological manifestations are common among patients 
with inflammatory bowel diseases (IBD). They may be driven by the in-
flammatory process, nutritional deficiencies, or medications. As the diag-
nosis and treatment of dermatologic manifestations is often challenging, 
we established a multidisciplinary referral clinic (IBD-DERMA) for joint 
decision making and patient care.
aims & Methods: We aimed to estimate the impact of multidisciplinary care 
in the IBD-DERMA clinic. The clinic functions since 2018. It is conducted by 
an IBD expert and a dermatologist with expertise in immunological disor-
ders. Consecutive patients with IBD who have developed a dermatological 
complication and were referred for consultation by either gastroenterolo-
gists or dermatologists were included. Joint decision making was driven by 
the status of the IBD, past medical history, exposure to medications, and 
the dermatological diagnosis. Mann Whitney or Chi- square tests were 
employed to compare continuous or categorical variables, accordingly.
results: Overall 92 patients were included: 50 males (54.3%), median 
age 34 years (IQR 29-44), and median disease duration of 8 years (IQR 
3-13). Crohn’s disease - 75 patients, most with small bowel involvement, 
and a form of bowel damage (L1- 50%, L3-37%, B2 -24%, B3 27%, B2/3- 
17%), and 43% with perianal involvement. Ulcerative colitis -16 patients, of 
whom 71% had pancolitis. In 23% of the cohort there was a history of IBD-
related surgery, and 48% had at least one extra-intestinal manifestation 
in addition to IBD and dermatologic manifestations. Only 20% of patients 
had a history of dermatological condition prior to IBD diagnosis (mostly 
psoriasis [63%]). Sixty percent of patients were experienced with thiopu-
rines, 12% with methotrexate, and 78.5% with anti-tumor necrosis factor 
agents (ATNFs). At referral 80% of patients had quiescent IBD, most (92%) 
controlled with medications. The most prevalent dermatologic diagnosis 
was skin eruptions induced by ATNFs, complicating 45.6% of the cohort: 
28/42 patients with psoriasiform dermatitis (PD), and 14/42 patients with 
dominant inflammatory alopecia (IA). Characteristics of patients with PD 
and dominant IA were comparable, however therapeutic strategies dif-
fered. Intervention strategies were: (i) topical therapy (steroid ointments/
injections or phototherapy), systemic steroids, combination with metho-
trexate - without discontinuation of the offending ATNF, (ii) discontinuing 
the ATNF, (iii) a biologic switch. Altogether 88% significantly improved. 
Topical treatments were effective in 60.7% of patients with PD but only 
21.4% of those with IA (p=0.023). Discontinuation of the offending ATNF 
was necessary in 93% of the patients with IA compared to 36% of patients 
with PD (p< 0.001). A switch to a different biologic class was needed in 
order to control either the skin condition and/or the IBD in 57.1% of the IA 
patients, compared to only 10.7% of patients with PD (p=0.002).
conclusion: An IBD-DERMA clinic provides expert care for patients with 
IBD and dermatological manifestations. Paradoxical skin eruptions were 
the most prevalent diagnoses. Almost a third of the patients presented with 
dominant IA secondary to ATNF, a condition that has a distinct course, and 
may represent a different pathophysiologic process. Joint decision mak-
ing resulted in improvement in 88% of dermatologic manifestations. The 
IBD-DERMA clinic is a platform enabling professional and personalized 
approach to treat patients with IBD and dermatological manifestations.
disclosure: Nothing to disclose 
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P1745 MucOsaL aBnOrMaLITIes Of The esOPhageaL 
In PaTIenTs WITh IBd: an endOscOPIc sTudy
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Introduction: Crohn’s disease (CD) is generally found in the ileum and/
or colon, albeit, since the 1960s it has become evident that this chronic 
inflammatory disorder of unknown etiology can affect the whole gastroin-
testinal tract from mouth to anus. In 0.5-13% of patients with ileocolonic 
CD, upper gastrointestinal tract is affected, with 0.2 to 1.8% of cases being 
mainly located in the lower third of the esophagus, however, should a 
systematic esophageal biopsy be performed in all patients with IBD?
aims & Methods: The aim of this study is to evaluate the interest of system-
atic esophageal biopsy in every IBD patient’s case, as well as the preva-
lence of esophageal Crohn’s disease in our series.
We conducted a prospective and descriptive study including 64 patients with 
IBD supervised within our department , and who have had an upper eno-
doscopy .Epidemiological, clinical, endoscopic and histological data were 
collected, These patients systematically underwent biopsy esophageal.
results: A total of 64 patients were included , 35 men ( 54 ,68 % ) and 
29 females (45,32%) , with an average age being 39.32 years ( range : 
22-76 ans ). Among them, 39 patients ( 60,9%) had crohn’s disease , 19 
patients (29.6 % ) had ulcerative colitis, and 5 patients ( 7.8 % ) had in-
derterminate colitis .Upper endoscopy was systematically performed on 
58 (90.6 %)patients and was indicated to investigate an upper gastro in-
testinal disorder in 9.3% (6 patients)of cases. It was normal for 55 patients 
(85.9%) and revealed: Esophagitis in five cases (grade A of Los Angeles 
(three patients), grade B (one patient), and grade C (one patient), typical 
manifestations evoking an esophageal localization of crohn’s disease were 
found in 2 patients: superficial ulcerations scattered in the lower third of 
the esophagus and an oval ulcer of 6 mm. These 2 patients are females 
whom respective ages are 35 and 31 years old, they have a low localization 
of Crohn’s disease (L2 and L1 according to the Montreal classification), one 
of them, had an upper gastro intestinal truct symptom: epigastralgia. His-
tological findings were nonspecific, indicating ulcerative esophagitis for 
both patients.For the other patients, histological findings showed chronic 
and hyperplasic esophagitis in 33 cases ( 51.5%), normal esophageal mu-
cosa in 22 cases (34.3%), congestive mucosa in 3 cases (4.6 %), and reflux 
oesophagitis in 3 cases (4.6 %).
conclusion: Our study showed that a systematic esophageal biopsy per-
formed on all IBD patients is far from being profitable, while a systematic 
upper GI endoscopy might be more useful.
disclosure: Nothing to disclose 
P1746 serOLOgIcaL BIOMarkers Of TyPe vI cOLLagen 
reMOdeLLIng refLecT endOscOPIcaLLy and cLInIcaLLy acTIve 
crOhn’s dIsease
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Introduction: The relapsing and transmural inflammation of Crohn’s dis-
ease (CD) may cause intestinal tissue damage that eventually may result 
in surgery. Disease activity in CD patients is assessed by clinical symptoms 
and macroscopic findings of intestinal inflammation at endoscopy. Type VI 
collagen is positioned in the interface of the interstitial matrix and base-
ment membrane in the intestine. It affects epithelial cell-fibronectin in-
teraction that is important for cell proliferation, adhesion, and migration. 
Collagens hold signalling potential, and endotrophin that is released from 
the pro-peptide of type VI collagen during enzymatic processing can itself 
stimulate fibroblasts to produce more extracellular matrix (ECM).
aims & Methods: Type VI collagen is more than just a structural protein 
and we investigated if serum biomarkers of its remodelling could serve as 
surrogate of disease activity in CD patients. 
Serum from 17 CD patients with active (n=10) and inactive (n=7) disease 
based on the simple endoscopic score for CD (SES-CD) were included in 
this study. Two competitive ELISAs were used to estimate serum levels of 
degradation and formation of type VI collagen, respectively. One for a neo-
epitope of matrix metalloproteinase (MMP)-9 mediated degradation of 
type VI collagen α3 chain (C6Ma3) and one for endotrophin; C-terminus of 
released C5 domain of type VI collagen α3 chain (PRO-C6).
results: Serum levels of C6Ma3 were elevated in CD patients with a SES-CD 
above 2 compared to patients with a SES-CD of 0-2. A receiver operat-
ing characteristic (ROC) analysis showed an area under the curve of 1 for 
C6Ma3 with specificity and sensitivity both at 100%. The area under the 
ROC curve for CRP and Fcal were 0.87 and 0.81, respectively. Serum levels 
of PRO-C6 were lower in CD patients with active disease compared to pa-
tients in remission based on the Harvey-Bradshaw Index (HBI) and serum 
PRO-C6 demonstrated an inverse correlation to HBI.
conclusion: Our data show that biomarkers of tissue remodelling reflect 
endoscopically and clinically active CD. MMP mediated destruction of 
type VI collagen (C6Ma3) was associated with endoscopically active CD 
and could separate endoscopically active and inactive patients with 100% 
sensitivity and specificity. Decreased levels of endotrophin (PRO-C6) was 
associated with clinically active CD and showed an inverse relationship 
with HBI. This indicates that remodelling of type VI collagen measured by 
C6Ma3 and PRO-C6 can be used as surrogate markers of endoscopically 
and clinically active CD, and fragments and signalling molecules released 
from type VI collagen are associated with pathological features of CD.
disclosure: ML, MP, JHM, MAK, and TMJ are full time employees at Nordic 
Bioscience. MAK and TMJ hold stocks in Nordic Bioscience. 
P1747 a serOLOgIcaL BIOMarker Of TyPe vIII cOLLagen 
ThaT cOnTaIns The anTI-angIOgenIc sIgnaLLIng MOLecuLe, 
vasTaTIn, Is assOcIaTed WITh The exTensIOn Of dIsease In 
uLceraTIve cOLITIs
Lindholm M.1, Godskesen L.2, Pehrsson M.1, Kjeldsen J.2, Krag A.2, 
Karsdal M.A.1, Manon-Jensen T.1, Mortensen J.H.1
1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2University 
of Southern Denmark, Department of Medical Gastroenterology, Odense, 
Denmark
contact e-Mail address: mpe@nordicbio.com
Introduction: Ulcerative colitis (UC) is characterized by superficial inflam-
mation that starts in the rectum and can extend proximally to affect the 
entire colon. Endoscopy is used to diagnose patients in terms of extension 
of disease, however this is invasive and cannot always be completed e.g. if 
the colon is too severely inflamed. The epithelial and endothelial basement 
membrane (BM) is an abundant extracellular matrix (ECM) of the intestine. 
Type VIII collagen is directly associated with the BM and the C-terminus of 
this collagen contains the anti-angiogenic signalling molecule, vastatin.
aims & Methods: Due to the abundant vasculature in the intestine, we 
investigated if a serum biomarker that targets the vastatin site of type VIII 
collagen was associated with the degree of inflammation in UC.
Serum was collected from 61 UC patients that were endoscopically record-
ed for extension of disease: remission, proctitis, left-sided, pancolitis, and 
unknown. Endoscopy could not be completed in patients with unknown 
extension of disease, however, five out of six unknown patients had at least 
left-sided colitis, but most possibly pancolitis. Rat serum from acute (n=10) 
and chronic dextran sulfate sodium (DSS) colitis (n=39) were included. A 
competitive ELISA for the C-terminus of type VIII collagen (PRO-C8) was 
used to estimate serum levels of type VIII collagen/vastatin.
results: Serum levels were elevated in UC patients with proctitis (P=0.003), 
left-sided (P=0.008), pancolitis (P=0.002) and unknown (P=0.0003) exten-
sion of disease compared to patient in endoscopically remission. In ad-
dition, PRO-C8 serum levels were elevated in unknown (P=0.036) and 
pancolitis (P=0.03) patients compared to proctitis. The levels were also el-
evated in unknowns (P=0.04) compared to left-sided, for which pancolitis 
patients had a tendency (P=0.065) of higher PRO-C8 levels. Serum PRO-C8 
was confirmed to be increased in both acute and chronic DSS colitis.
conclusion: PRO-C8, containing the anti-angiogenic signalling molecule 
vastatin, was associated with extension of disease in UC patients and 
was elevated in patients for which endoscopy could not be completed. 
Increased PRO-C8 was shown to originate from intestinal inflammation 
in DSS colitis in rats. Thus, PRO-C8 may be a serological biomarker that 
reflects intestinal tissue inflammation based on extension of disease. This 
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also indicates that UC patients with broad tissue involvement may have an 
altered collagen signalling and that ECM signals are part of the disease 
pathology.
disclosure: ML, MP, JHM, MAK, and TMJ are full time employees at Nordic 
Bioscience. MAK and TMJ hold stocks in Nordic Bioscience. 
P1748 MucOsaL caPILLary PaTTern recOgnITIOn Based On 
auTOMaTed IMage anaLysIs durIng endOscOPy accuraTeLy 
deTecTs hIsTOLOgIcaL reMIssIOn In uLceraTIve cOLITIs
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Introduction: A treat to target strategy in ulcerative colitis (UC) requires an 
objective evaluation tool to assess remission. The Mayo endoscopic sub-
score (MES) and the ulcerative colitis endoscopic index of severity (UCEIS) 
have important inter-rater variability mainly in evaluating remission. His-
tological remission is the best predictor for sustained clinical remission in 
UC. The infiltration of neutrophils is associated with morphological irregu-
larities of the pericryptal capillaries.
aims & Methods: The aim was to develop a new objective automated tool 
for a prototype colonoscopic system to assess histological remission based 
on the evaluation of the morphology of the pericryptal capillaries during 
endoscopy.
We used a prototype endoscopic system enabling activation of a short 
wave-length monochromatic light through adaptation of a LED system. 
This enables to evaluate in real time the mucosal architecture (crypts, 
pericryptal capillaries, bleeding) up to a depth of around 200µm. In ini-
tial observations histological non-remission was associated with bleeding 
(mucosal/luminal) and capillary congestion. For this, an image analysis 
algorithm was applied to provide a score that quantifies the specific mor-
phology of the mucosal capillaries. The algorithm included two steps. First, 
bleeding (mucosal/luminal) was assessed by pattern recognition. Samples 
with bleedings were automatically classified as non-remission. In case of 
non-bleeding (mucosal/luminal), the degree of congestion of the capil-
laries was measured (maximal localized density estimation after morpho-
logical hessian based vessel recognition) to assess an ideal cut off value to 
identify histological remission (Geboes score (GBS) < 2B.1; no neutrophils 
in the lamina propria). Consecutive UC patients at the University of Leuven 
were evaluated with the MES, UCEIS, visual capillary evaluation based on 
short wave-length monochromatic light and the automated image analy-
sis algorithm. To test the reliability of the algorithm and scores, the results 
were correlated with the GBS. Biopsies were taken in the matching area of 
the endoscopic evaluation.
results: Fifty eight patients with UC (53% male, median age 41y IQR 38-
56, disease duration 7.1y IQR 2.4-16.4) with 113 evaluable segments (89% 
rectum or sigmoid) were included. The correlation between GBS and 
MES, UCEIS and visual short wave-length was good (r= 0.76, 0.75, 0.74, 
respectively). The automated image analysis algorithm detected histologi-
cal remission with a high performance (sens 0.79, spec 0.90) compared 
to UCEIS (sens 0.95, spec 0.69) and MES (sens 0.98, spec 0.61), resulting 
in a positive predictive value of 0.83, 0.65 and 0.59 for the automated im-
age analysis algorithm, UCEIS and MES respectively. The algorithm detects 
histological remission with high accuracy (86%). (table 1)
 
Mayo 
endoscopic 
sub score
ulcerative colitis 
endoscopic index 
of severity
visual 
capillary 
score
Image 
analysis 
algorithm
n 113 113 113 113
accuracy 0,743 0,788 0,876 0,858
sensitivity 0,976 0,952 0,810 0,786
specificity 0,606 0,690 0,915 0,901
Positive predictive value 0,594 0,645 0,850 0,825
Negative predictive value 0,977 0,961 0,890 0,877
[Table 1: performance of the different evaluation tools]
conclusion: Mucosal capillary pattern recognition based on image analysis 
with short wave-length monochromatic light detected histological remis-
sion with high accuracy in UC. This technique provides an objective and 
quantitative tool to assess histological remission, and excludes inter-read-
er variability.
disclosure: Nothing to disclose 
P1749 sysTeMaTIc LIver BIOPsy durIng surgery fOr 
InfLaMMaTOry BOWeL dIsease: WhaT cOnTrIBuTIOn?
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Introduction: Hepatic disorders associated with IBD are frequent and var-
ied according to the type of IBD (Crohn’s disease or ulcerative colitis). The 
abnormalities of biochemical liver tests observed may be transient or last-
ing. The most specific of these is primary sclerosing cholangitis (PSC) with 
a risk of degeneration.
aims & Methods: The objective of our study was to evaluate the prevalence 
of various hepatic histological lesions, especially PSC in patients operated 
for ulcerative ulcerative colitis or Crohn’s disease, and to discuss the value 
of systematic perioperative liver biopsy.
Descriptive and analytical prospective study including 14 patients who had 
surgery for severe acute colitis or complicated Crohn’s disease, consent 
was previously bled by the patients to have their agreement to perform a 
liver biopsy.
results: Fourteen patients (6 women, 8 men) were included in the study. 
9 patients with Crohn’s disease and 5 patients with ulcerative colitis. The 
various histological lesions discovered are: chronic hepatitis in 6 patients 
associated with fibrosis in 5 cases, including 4 cases FI and one case F2 
according to the Metavir score, nonspecific inflammatory lesions compat-
ible with lesions of small duct cholangitis or chronic portitis in 7 patients, 2 
patients had hepatic steatosis and one patient had a hepatic capillary hae-
mangioma. Liver biopsy was normal in only one case. However, no patient 
presented histological lesions suggestive of primary sclerosing cholangitis.
conclusion: Our study (preliminary results) proves that performing a sys-
tematic perioperative liver biopsy can be cost-effective by allowing the di-
agnosis of early-stage histological abnormalities such as hepatic steatosis 
and small channel cholangitis in order to initiate treatment. adequate and 
regular follow-up to avoid complications.
disclosure: Nothing to disclose 
P1750 TheraPeuTIc drug MOnITOrIng In crOhn’s dIsease 
PaTIenTs, a cOMParIsOn BeTWeen hOMOgeneOus MOBILITy 
shIfT assay and POInT Of care MeThOd
Bodini G.1, Demarzo M.G.2, Djahandideh A.3, Baldissarro I.3, 
Savarino E.V.4, Savarino V.5, Jain A.6, Risso P.7, Giannini E.G.8
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Introduction: Therapeutic Drug Monitoring (TDM) is a useful tool to help 
physicians managing patients with Inflammatory Bowel Disease treated 
with anti-tumor necrosis factor (TNF) drugs. Different techniques are cur-
rently available to evaluate serum drug concentration (TL), and various 
studies found an association between drug TL, evaluated either with ELISA 
or HMSA, and IBD activity. However, these techniques are time consum-
ing. Recently, a point-of-care (POC) method has been proposed to evaluate 
drug TL and overcome the limitations inherent to other methodologies.
aims & Methods: The aim of our study was to evaluate the capability of 
POC to discriminate between IBD relapse and remission, and to evaluate 
the concordance of drug TL measured with POC and HMSA. 
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We analyzed with Quantum BlueÒ(Buhlmann Laboratories AG, Schonen-
buch, Switzerland) (POC) 200 Adalimumab (ADA) and 200 Infliximab se-
rum samples of 46 Crohn’s Disease (CD) patients previously assessed with 
HMSA. Blood samples were drawn at standardized time points during 
anti-TNF treatment (2, 6, and every 8 weeks), before anti-TNF administra-
tion. Disease activity was assessed by the Harvey-Bradshaw Index (HBI, 
remission defined by HBI< 5).
results: We evaluated 46 CD patients who responded to anti-TNF induction 
with ADA (n= 25, 54.3%) and IFX (n= 21, 45.6%), with a median follow-up 
of 83 weeks (range 16-144 weeks). 
At week 16, median ADA TL of patients in remission were significantly 
higher as compared to patients in disease relapse using both HMSA [12.7 
mcg/mL (range, 8.9-23.6 mcg/mL) vs 6.6 mcg/mL (range, 0.7-9.6 mcg/mL), 
P=0.0001] and POC [17.8 mcg/mL (range 7.6-35.0 mcg/mL) vs 9.8 mcg/mL 
(range 5.8-11.4 mcg/mL), P=0.0003]. The concordance between the two 
different techniques has been assessed as 0.76 by Choen Kappa. Consider-
ing IFX TL, patients in remission had higher serum drug concentration us-
ing both HMSA [7.0 mcg/mL (range, 0.0-21.8 mcg/mL)] and POC [6.2 mcg/
mL (range 0.4-14.3 mcg/mL)] as compared to patients who experienced 
disease relapse [HMSA, 0.1 mcg/mL (range, 0.0-4.1 mcg/mL), P=0.019; 
POC, 0.45 mcg/mL (range 0.4-3.3 mcg/mL), P=0.0072]. The concordance 
between the two different test for IFX TL was 0.81.
At the end of follow up, median ADA TL of patients in remission were 
significantly higher as compared to patients who experienced disease re-
lapse, using both HMSA and POC [respectively, 10.7 mcg/mL (range, 4.6-
18.3 mcg/mL) and 16.2 mcg/mL (range 5.7-35.0 mcg/mL) vs 5.6 mcg/mL 
(range, 3.1-9.9 mcg/mL) and 6.5 mcg/mL (range 1.3-17.1 mcg/mL) P=0.001 
and P=0.0012] with a concordance of 0.75.
Lastly, considering IFX TL, patients in remission had numerically higher 
serum drug concentration [4.7 mcg/mL (range, 0.1-18.6 mcg/mL) and 
2.4 mcg/mL (range 0.4-11.1 mcg/mL)] compared to patients who experi-
enced disease relapse [0.2 mcg/mL (range, 0.1-6.7 mcg/mL) and 0.5 mcg/
mL (range 0.4-4.8 mcg/mL)] (P=0.13 and P=0.25) using HMSA and POC, 
respectively. The concordance between the two different test we used to 
calculate TL was 0.70.
conclusion: In conclusion, we observed that both POC and HMSA are TL 
tests able to differentiate relapse and remission in IBD patients. The as-
sociation between anti-TNF TL and disease status (remission/relapse) was 
better in ADA-treated patients rather than patients treated with IFX. Lastly, 
we demonstrated a good concordance between HMSA and POC. Anti-drug 
antibody concentrations while available on HMSA were not available on 
POC. This would limit the identification of anti-TNF non-responders on the 
POC test if a percentage of those were anti-drug antibody positive.
disclosure: Nothing to disclose 
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Introduction: Calprotectin, a calcium and zinc binding protein present in 
the cytosol of granulocytes neutrophils, monocytes, and macrophages. Fe-
cal calprotectin (FC), a marker of colonic inflammation, can be used as first 
diagnostic tool and in the follow up of inflammatory Bowel Diseases (IBD). 
Many studies show that fecal calprotectin is useful in IBD diagnosis and in 
specialist settings but its benefit in the clinical practice of general practi-
tioners is still not clear.
aims & Methods: Our aim was to analyze the usefulness of fecal calpro-
tectin indication in a north - east Italy population with lower GI symptoms 
of mild to moderate severity. A cohort of 2487 laboratory exams of fecal 
Calprotectin were selected from January 2018 to December 2018. 2388 of 
these were requested by the General Practitioner (96.0%) and the other 
99 exams by a Gastroenterologist (4.0%), which were excluded from the 
analysis. The study population was thus composed of 937 men (39.2%) and 
1451 women (60.8%), mean age 49.48 years (range 18-96).According to 
the literature, 3 cut off values were selected for this exam: 0-49 µg/g was 
considered negative, 50-149 µg/g was considerate indeterminate and ≥150 
was considerate positive. 
285 of these patients were sent to a Colonoscopy by general practitioners.
results: The results of 2037 fecal calprotectin was divided into: negative 
(0-49 µg/g): n. 1735 (72.7%), indeterminate (50-149 µg/g) n. 493 (20.6%) 
and positive (≥150 µg/g) n. 160 (6.7%). 
The patients who underwent colonoscopy after FC testing were 285 (14.0% 
of the total number of requested FC tests): 155 with negative FC, 81 with 
indeterminate FC, and 49 with positive FC.
Colonoscopic findings in patients with negative FC were: normal in 89 cas-
es (57.4%), diverticular disease in 33 cases (21.3%), polyps in 10 patients 
(6.5%), IBD in 16 cases (10.3%), other types of colitis (ischemic and non-
specific) in 6 patients (3.9%), and colorectal neoplasia in 1 patient (0.6%).
Colonoscopic findings in patients with indeterminate FC were: normal in 37 
cases (45.7%), diverticular disease in 27 patients (33.3%), polyps in 6 cases 
(7.4%), IBD in 3 patients (3.7%), other types of colitis in 7 cases (8.6%) and, 
colorectal neoplasia in 1 case (1.2%).
Colonoscopic findings in patients with positive FC were: normal in 19 
(38.8%) cases, diverticular disease in 4 (8.2%) cases, polyps in 2 patients 
(4.1%), IBD in 17 patients (34.7%), other types of colitis in 5 cases (10.2%) 
and neoplasia in 2 patients (4.1%).
conclusion: Although positive FC values are more frequently associated 
with organic disease, especially IBD, and should therefore prompt colo-
noscopic evaluation, the latter, as well as diverticular disease and even 
colorectal neoplasms can be present with normal FC values. We notice a 
high rate of indeterminate FC in diverticular disease patients, suggesting 
that an early treatment and subsequent FC retesting might be an optimal 
approach. 
Considering FC in association to some clinical data (such as age) can in-
crease the usefulness of the test. Despite the high number of false positive 
cases, Calprotectin alone can be useful in the clinical practice for the gen-
eral practitioner in the management of patients with low GI symptoms, to 
avoid diagnostic delay and to restrict unnecessary invasive and expensive 
exams.
disclosure: Nothing to disclose 
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Introduction: Crohn’s disease (CD) is characterized by episodes of relapse 
and remission and therefore requires continuous evaluation of disease ac-
tivity. Extra Cellular Matrix (ECM) consists of basement membrane (BM) 
and interstitial matrix (IM). BM) is positioned directly underneath the 
epithelial cells and consists mainly of type IV collagen, while IM consists 
mainly of type I, III and V collagen, and is produced by fibroblasts. Patho-
logical environment, such as inflammation and fibrosis, leads to impaired 
remodeling, structure, quality and function of the collagen in the ECM.
aims & Methods: Our aim was to investigate biomarkers of collagen deg-
radation and formation and their association with disease activity and in 
patients with CD.
In this cross-sectional study we measured five biomarkers of ECM remod-
eling in 75 patients with CD (60% males, age 35(IQR 26.5-43.5)), and 29 
healthy controls matched by age and gender. Biomarkers of type III colla-
gen degradation (C3M) and formation (PRO-C3), type IV collagen degrada-
tion (C4M) and formation (PRO-C4), type V collagen formation (PRO-C5) 
and C-reactive protein (CRP) were measured in serum by ELISA. Inflamma-
tory activity was defined as combination of clinical or biochemical disease 
activity (CDAI≥150 or CRP>5). Disease behavior was assessed by Montreal 
classification. One-way ANOVA (Tukey’s multiple comparisons test), and 
ROC analysis was applied in statistical analysis.
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results: Biomarkers of interstitial matrix remodelling showed that C3M 
was significantly elevated in active CD compared to inactive CD (P< 0.05) 
and HD (P< 0.05), whereas PRO-C3 and PRO-C5 were significantly elevated 
in active CD and inactive CD compared to HD (P< 0.001, P< 0.05). (Figure 
1) Turnover type III collagen showed highest diagnostic accuracy for active 
disease (AUC=0.74). Area under curve was for C3M 0.63, PRO-C3 0.36 and 
PRO-C5 0.52. 
Biomarkers of basement membrane remodelling showed significantly 
higher C4M in active CD compared inactive (P< 0.05) and HD (P< 0.001), 
whereas PRO-C4 was significantly elevated in active and inactive CD com-
pared to HD (P< 0.01). Area under curve was for C4M 0.64, C4M/PRO-C4 
ratio 0.57 and PRO-C4 0.56.
conclusion: Both biomarkers of interstitial matrix (C3M) and basement 
membrane (C4M) were associated with disease activity. PRO-C3, PRO-C5 
and PRO-C4 were associated with CD regardless of disease activity. Inter-
stitial matrix biomarkers of turnover type III collagen C3M/PRO-C3 showed 
highest diagnostic accuracy for disease activity. In conclusion, these bio-
markers may be used in monitoring and prediction of disease activity and 
in differentiation between patients with CD and healthy individuals.
disclosure: Nothing to disclose 
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Introduction: Faecal Calprotectin (FCP) has been found to be an accurate 
surrogate marker for post-operative recurrence in Crohn’s disease (CD). 
However, the use of FCP to monitor disease activity in patients with an 
ileostomy due to CD has not been established. The aim of this study was 
to assess the performance characteristics of FCP in patients with CD and 
an ileostomy and to compare this to patients with CD post ileo-colonic 
resection.
aims & Methods: Post-operative patients with CD attending a single aca-
demic centre were identified using a prospectively maintained database 
of >4000 Inflammatory Bowel Disease (IBD) patients. These were cross-
referenced with the local hospital endoscopy reporting system to identify 
patients with small bowel endoscopic assessment from 2014 onwards. 
Endoscopic CD activity was classified using the Rutgeert’s score (RS) and 
RS≥2 was used to define endoscopic recurrence. A FCP cut-off 150µg/g 
was used to define disease activity. MRE assessment was used to classify 
patients as active or inactive CD.
results: 1,896 surgeries for CD were identified from our IBD database. A 
total of 80 (ileostomy: n=27, anastomosis: n=53) contemporaneous endo-
scopic and FCP results in 74 patients were analysed. Median age was 46.9 
(IQR 37.0-57.1)) and did not significantly differ between the two groups. 
Similar numbers of male (n= 30) and female (n=44) were identified in 
both groups. Patients with an ileostomy had significantly higher rates of 
negative disease predictors including younger age at diagnosis (p< 0.05), 
longer disease duration (p=0.001) and a higher proportion of perianal dis-
ease (p=0.01). Patient demographics, disease characteristics and baseline 
biochemistry are outlined in Table 1. 
72% had i0-1 disease, and 28% i2-4 disease in the ileostomy group com-
pared to 47.2% and 52.8% respectively in the anastomosis group, with a 
trend towards more active disease in the anastomosis group (p=0.052). No 
significant correlation was identified between endoscopic scores and FCP 
results in patients with an ileostomy (p=0.109, R=0.328). In the anasto-
mosis group, there was a significant correlation between level of FCP and 
RS≥2 (p=0.012, R=0.343), particularly in patients with FCP >150 (p=0.008, 
R=0.371).
conclusion: Our study confirms the strong correlation between FCP and 
endoscopic activity in post-operative CD and in particular shows a high 
degree of accuracy when 150µg/g is used as a cut off in these patients. 
There was, however, poor correlation in CD patients with an ileostomy. 
FCP is best used with caution in this patient cohort and in conjunction with 
other validated objective tools.
disclosure: Nothing to disclose 
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Introduction: Ulcerative colitis (UC) is an intractable chronic inflammatory 
disease characterized by diffuse inflammation of the colonic mucosa. Cur-
rent indexes to evaluate the severity of UC include blood routine (BR), ESR 
and clinical grading system such as Mayo score and Baron endoscopic 
score[1]. But there is still lack of reliable objective index to assess disease 
severity. Systemic immune-inflammation index (SII) is a newly developed 
composite index based on BR, which is defined as platelet×neutrophil/
lymphocyte[2]. It has been proved to be both convenient and feasible in 
predicting treatment effect and prognosis of small cell lung cancer[3], pan-
creatic cancer[4], colorectal cancer[5] and hepatocellular carcinoma[6]. 
Hence, we analyze the correlation between SII and severity of UC patients, 
and estimate its value in UC diagnosis.
aims & Methods: We retrospectively include patients in our department 
from January 2013 to December 2018. UC patients were diagnosed ac-
cording to Third European Evidence-based Consensus on Diagnosis and 
Management of Ulcerative Colitis. The exclusion criteria include coronary 
heart disease, diabetes, chronic renal failure, hematopathy, hypersplen-
ism, autoimmune disease, pregnancy, carcinoma, radiotherapy, infection, 
antiplatelet or NSAID drug intake. The control group was selected from 
patients who received colorectal polyps ESD. Their medical and family his-
tory were clear and pathological results of ESD samples were hypertrophic 
polyps. Their baseline information, BR, ESR, CRP and Mayo score were 
recorded. Statistical analyses were performed using Graphpad prism 8.
results: There were 79 UC patients and 79 age and sex matched controls. 
The disease duration of UC patients was 45.78±65.31 months. Most patients 
suffered from pancolitis (n=50), while the number of left sided and distal 
colitis patients were 17 and 12, respectly. Mesalazine (n=52) was most com-
monly used in these patients, others were glucocorticoid (n=7), salazo-
sulfapyridine (n=6), azathioprine (n=3), infliximab (n=2) and thalidomide 
(n=1). There were 18 patients who have never used any anti-immune, anti-
inflammatory medicine or have been suspended for over 3 months. Ac-
cording to Mayo scoring system, the patients were classified into remission 
(n=8), mild (n=8), moderate (n=48) and severe (n=15).
There were significant differences between UC patients and controls in 
PLR, NLR and SII (p< 0.0001). Notably, SII was significantly lower between 
remission/mild group and severe group (p=0.012). Moreover, PLR, NLR and 
SII were associated with Mayo score, ESR and CRP. Among them, SII and 
Mayo score are most relevant (r=0.505, p< 0.0001). This revealed the out-
standing ability of SII in estimating disease severity of UC.
NLR and SII shows excellent ability in UC diagnosis (Table). The AUC of NLR 
and SII was 0.808 and 0.858, separately, with cut-off values of 2.535 (p< 
0.0001, SE=0.034, 95% CI [0.742, 0.874]) and 619.1 (p< 0.0001, SE=0.030, 
95% CI [0.800, 0.917]). Similarly, PLR can diagnose UC with a cut-off value 
of 174.5 (AUC=0.755, p< 0.0001, SE=0.030, 95% CI [0.800, 0.917]).
conclusion: This is the first report to demonstrate that SII has great poten-
tial in evaluating UC severity and diagnosis. Properly designed prospective 
studies are needed for further investigation.
references: 1. Schoepfer AM, et al. Ulcerative colitis: correlation of the 
Rachmilewitz endoscopic activity index with fecal calprotectin, clinical ac-
tivity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 
15: 1851-1858 2. Zhong JH, et al. Prognostic role of systemic immune-in-
flammation index in solid tumors: a systematic review and meta-analysis. 
Oncotarget 2017; 8: 75381-75388 3. Hong X, et al. Systemic Immune-in-
flammation Index, Based on Platelet Counts and Neutrophil-Lymphocyte 
Ratio, Is Useful for Predicting Prognosis in Small Cell Lung Cancer. Tohoku 
J Exp Med 2015; 236: 297-304 4. Aziz MH, et al. The Systemic-Immune-
Inflammation Index Independently Predicts Survival and Recurrence in 
Resectable Pancreatic Cancer and its Prognostic Value Depends on Biliru-
bin Levels: A Retrospective Multicenter Cohort Study. Ann Surg 2018, DOI: 
10.1097/sla.0000000000002660: 5. Xie QK, et al. The systemic immune-
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inflammation index is an independent predictor of survival for metastatic 
colorectal cancer and its association with the lymphocytic response to the 
tumor. J Transl Med 2018; 16: 273 6. Hu B, et al. Systemic immune-inflam-
mation index predicts prognosis of patients after curative resection for he-
patocellular carcinoma. Clin Cancer Res 2014; 20: 6212-6222
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Introduction: Inflammatory bowel disease (IBD) is associated with a higher 
risk of colorectal cancer (CRC). However, studies have investigated this risk 
and reported widely varying rates.
aims & Methods: This meta-analysis aims to estimate the risk of colorectal 
cancer in inflammatory bowel disease from multiple aspects.A literature 
search using Medline and Pubmed was conducted for terms related to 
colorectal cancer in inflammatory bowel disease from 1988 to 2018. All 
the full-text articles were searched and studies should meet our inclusion 
criterias ,in which no country restricted, the number of patients was over 
500 and the follow up time was over 5 years. Overall pooled incidence 
rate , with 95% confidence intervals (CI),of colorectal cancer was obtained 
using a random-effects model as well as a cumulative risk at 10 years, 20 
years, and 30 years of disease.
results: Of 3620 studies , 46 articles were included and the total num-
ber of inflammatory bowel disease patients was 142190 in which 38672 
were Crohn’s disease(CD) and 103518 were ulcerative colitis(UC). The over-
all prevalence of CRC in IBD patient was estimated to be 1.17%(95% CI 
1.03-1.31%). The CRC incidence of 71.03/100000 person year duration(pyd) 
in CD patients yielded differently to the incidence of 122.56/100000 pyd 
in UC patients. The CRC incidence rate in CD patients varied in intesti-
nal site, being 34/100000 pyd in colon, 31.2/100000 pyd in caecum and 
25.26/100000 pyd in rectum. The CRC incidence rate in UC also varied in in-
testinal site,being 60.88/100000 pyd in colon, 44.61/100000 pyd in cecum 
and 34.61/100000 pyd in rectum. The worldwide CRC incidence rate varied 
regionally, being 169.03/100000 pyd in North America, 95.05/100000 pyd 
in Europe, 95.05/100000 pyd in Asian , 235.12/100000 pyd in Australia and 
139.78/100000 pyd in South Africa. The risk for CRC was 0.91% (95% CI 
0.63-1.20%) at 10 years, 3.66% (95% 2.42-4.90%) at 20 years, and 12.58% 
(95% CI 5.92-19.23%) at 30 years after IBD diagnosis. Subgroup analysis 
by stratifying the studies according to data source,study design and gender 
of the study did not reveal any significant differences.
conclusion: Using the meta-analysis we determinded the incidence of 
CRC in IBD patients was 1.17% and the higest incidence rate was found 
in Australia in 5 continents. UC patients had a higher risk of CRC than CD 
patients. No matter UC or CD, colon had a higer risk of developing CRC. 
Hence, adherence to colonoscopy is essential. A larger prospective study is 
needed to obtain a better incidence of CRC.
disclosure: Nothing to disclose 
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Introduction: Faecal calprotectin (FC) is a reliable surrogate marker of 
mucosal inflammation in Crohn’s disease (CD). Recent data suggest a 
FC-directed treat-to-target approach results in superior mucosal healing 
compared to a symptom-based treatment approach.1 However, it is un-
known whether normalisation of FC within the first 12 months of diagnosis 
improves long-term outcomes in CD.
aims & Methods: We performed a retrospective cohort study to establish 
if normalisation of FC within 12 months of diagnosis was correlated with 
disease progression. Inclusion criteria were: (a) diagnosis of CD between 
2009-2017; (b) measurement of FC at diagnosis or +/- 2 months and prior 
to any initiation of treatment; (c) a FC value ≥250 µg/g at diagnosis; (d) 
at least 1 additional FC within 12 months after diagnosis; (e) >12 months 
follow up. 
The primary endpoint was a composite of progression in Montreal disease 
behaviour (B1-B2/3, B2-B3 or new perianal disease), resectional IBD sur-
gery or disease related hospitalisation 12 months post-diagnosis onwards.2 
Normalisation of FC was defined as < 250 µg/g. When >1 FC was performed 
in the 12 month post-diagnosis period, the last FC was used to determine 
normalisation. Survival analysis was performed using Kaplan Meier curves 
and groups compared via the log-rank test. Multivariable Cox-regression 
analysis was used to determine independent factors associated with dis-
ease progression.
results: A total of 200 patients met inclusion criteria with a median follow 
up of 4.9 years (IQR 2.9-7.3 years). 46% (92/200) of patients normalised 
FC within 12 months of diagnosis. Normalisation of FC within the first 12 
months of diagnosis was associated with a significantly lower rate of the 
composite endpoint of disease progression (Table 1, log-rank p< 0.001). 
There was no difference in disease characteristics at diagnosis (sex, age, 
Montreal location/behaviour, perianal disease, smoking status, FC) be-
tween patients who normalised FC versus those that did not. FC-normali-
sation was associated with a higher rate of biologic use (37.0% vs 18.5%, 
p< 0.001). Correcting for age, sex, disease location / behaviour and FC 
value at diagnosis; smoking (Hazard Ratio 1.8, 95% CI 1.1-3.0, p=0.03), 
biologic use within 12 months of diagnosis (Hazard Ratio 2.7, 95% CI 1.6-
4.6, p< 0.001) as well as normalisation of FC within 12 months of diagnosis 
(Hazard Ratio 0.2, 95% CI 0.1-0.4, p< 0.001) were independently associ-
ated with disease progression.
conclusion: This study demonstrates that normalisation of mucosal inflam-
mation in the first year of CD will substantially impact long-term outcomes. 
The data indicate that FC is an excellent surrogate marker for this purpose 
and are of immediate clinical utility. 
status at 12 months cumulative progression rates after first 12 months from diagnosis
  1-year 3-years 5-years
FC normalised (<250 µg/g) 7.0% 18.7% 24.4%
FC not normalised (≥250 µg/g) 28.1% 43.2% 63.8%
[Table 1. Cumulative progression rates (composite of progression in Montreal 
disease behaviour or new peri-anal disease/ surgery/ IBD hospitalisation)]
references: 1.Colombel JF, et al. Effect of tight control management on 
Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 tri-
al. Lancet. 2017; 390: 2779 - 2789 2.C Yzet, et al. OP35 Endoscopic and deep 
remission at 1 year prevents disease progression in early Crohn’s disease: 
long-term data from CALM, Journal of Crohn’s and Colitis, 2019; 13 (Issue 
Supplement 1): S024-S025
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CWL has received research support from Gilead, Oshi Health and AbbVie, 
consultancy fees from AbbVie, Pfizer, Dr. Falk, Hospira, MSD, Gilead, Phar-
macosmos, Takeda and Vifor, and speaker fees and travel support from 
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Introduction: Ulcerative colitis is a mucosal inflammatory disease of the 
colon. Depending on the extent and degree of mucosal involvement there 
may not be signs of systemic inflammation like high CRP values. Although 
fecal calprotectin can predict mucosal remission in ulcerative colitis, data 
about CRP level in this context is insufficient
aims & Methods: The aim of this study is to define a CRP level to predict 
mucosal remission in ulcerative colitis. We retrospectively reviewed colo-
noscopy reports of ulcerative colitis patients (who are not on any steroid 
treatment) between December 2016 and March 2019 and also their CRP 
levels which were obtained at the same week of the colonoscopy examina-
tion. Mucosal remission was defined as Mayo score 0 or 1 at colonoscopy. 
The best CRP level for mucosal remission prediction was assesed by ROC 
curve analysis and also by positive and negative predictive values
results: A total of 289 patients were involved. CRP levels which predicts 
mucosal remission is shown at the table. At the ROC curve analysis we 
found that CRP levels between 2.69-2.78 mg/dl can predict mucosal remis-
sion with a 80% sensitivity and specificity. For subgroups with Montreal E2 
and E3 ROC curve analysis suggested 2,1 mg/dl (sen. 80%, spe. 80%) and 
2,95 mg/dl (sen. 83% , spe. 85%) CRP levels can be used for prediction of 
mucosal remission respectively
crp Level mg/dl Mayo 0-1 group Mayo 2-3 group
<5 131 61
>5 7 89
Sens: 0,94; Spec: 0,59; PPV: 0,68; NPV: 0,92
<3 117 30
>3 21 120
Sens: 0,84; Spec: 0,80; PPV: 0,79; NPV: 0,85
<2 94 20
>2 44 130
Sens: 0,68; Spec: 0,86; PPV: 0,82; NPV: 0,74
[Table 1. Sensitivity and specificity values for predicting mucosal remission.]
conclusion: CRP cutoff level of approximately 2.7 mg/dl can predict muco-
sal remission in ulcerative colitis better than standard cutoff of 5 mg /dl
disclosure: Nothing to disclose 
P1758 fecaL eOsInOPhIL-derIved neurOTOxIn/eOsInOPhIL 
PrOTeIn x (edn/ePx) shOWed hIgh sPecIfIcITy and POsITIve 
PredIcTIve vaLue as a BIOMarker fOr deTecTIng dIsease 
acTIvITy In InfLaMMaTOry BOWeL dIsease cOMPare TO faecaL 
caLPrOTecTIn
Lyutakov I.1,2, Penchev P.3, Nakov R.4, Nakov V.5, Valkov H.6, Dimov A.7, 
Chetirska M.8, Asenova B.8, Vatcheva- Dobrevska R.8, Vladimirov B.9
1University Hospital ‘Tsaritsa Yoanna - ISUL’, Gastroenterology, Sofia, 
Bulgaria, 2Medical University – Sofia, Sofia, Bulgaria, 3Medical University 
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Queen Yoanna University Hospital, Gastroenterology, Sofia, Bulgaria, 
5Tsaritsa Joanna University Hospital, Gastroenterology, Sofia, Bulgaria, 
6Isul, Gastroenterology, Sofia, Bulgaria, 7University of National and World 
Economy, Department of Statistics and Econometrics, Sofia, Bulgaria, 
8University Hospital “Tsaritsa Yoanna - ISUL, Department of Microbiology 
and Virosology, Sofia, Bulgaria, 9UMBAL Tsaritsa Joana, Gastroenterology, 
Sofia, Bulgaria
contact e-Mail address: ivan.lutakov@gmail.com
Introduction: Colonoscopy with histological analysis with multiple biopsies 
represents the accepted procedure used to find the diagnosis of patients 
with chronic diarrhea and to assess disease activity and severity. However, 
it is invasive and costly. Fecal calprotectin (FC) is used as a biomarker for 
intestinal inflammation in inflammatory bowel disease (IBD) but there is 
always a search for new biomarker for microscopic colitis (MC). Moreover, 
the best biomarker for distinguishing functional from organic intestinal 
disorders is elucidated. In some studies is demonstrated that, mucosal 
inflammation in IBD and MC is done by eosinophil activation and this need 
to be evaluated in future bigger studies.
aims & Methods: The AIM is to evaluate the diagnostic accuracy of fae-
cal eosinophil-derived neurotoxin/eosinophil protein x (EDN/EPX) and to 
compare it to FC in patients with chronic diarrhoea. In this prospective 
study, we enrolled 109 adult patients with chronic diarrhoea who under-
went standard laboratory test, CRP, colonoscopy, faecal EDN/EPX and FC at 
‘Tsaritsa Yoanna - ISUL’ University Hospital, Sofia, Bulgaria. We divided the 
patients into six groups: 30 patients with active IBD, 21 patients with IBD in 
remission, 21 patients with IBD after surgery (IBD-IL), 23 patients with IBS- 
D, 14 patients with MC and 11 healthy control subjects. We used ELISA to 
detect EDN/EPX and quantitative immunochromatographic to evaluate FC.
results: Of these 109 (90,9%) patients with chronic diarrhea included in 
the analysis, elevated levels of EDN/EPX above 366 ng/ml was confirmed 
in 51 patients (46,8%) and lower levels of 58 patients (53,2%) as using cut-
off level of disease activity compare to 11 (9,1%) healthy controls (p=0,002). 
We found a EDN/EPX cut-off level of 366 ng/ml for IBD active group with 
sensitivity of 80% (95% CI 61.43% to 92.29%), specificity 90,9 % (95% 
CI 58.72% to 99.77%), negative predictive value 62,5% (95% CI 44,3% 
to 77,74%) and positive predictive value (PPV) of 96% (78.6% to 99.37%) 
(p=0,001), compare to FC with sensitivity 78% and specific 72,2%. Mean FC 
levels among the 6 groups were IBD Active (750 µg/g) vs IBD in remission 
(81 µg/g) vs IBD after surgery (375 µg/g) vs IBS-D (47 µg/g) vs MC (221 µg/g) 
vs healthy controls (43 µg/g), respectively (p= 0,002). Mean EDN/EPX levels 
among the 6 groups were IBD Active (2777 ng/ml) vs IBD in remission (412 
µg/g) vs IBD after surgery (1425 µg/g) vs IBS-D (524 µg/g) vs MC (187 µg/g) 
vs healthy controls (179 µg/g), respectively (p= 0,002). We found correla-
tion between EDN/EPX and FC to be moderate (Pearson’s r=0,6, p-value < 
0,01). We estimate higher median levels of EPX/EDN in IBD patients with 
active disease, IBD patients after surgery and lower levels of EPX/EDN in 
MC group and no difference between IBD in remission and IBS-D group.
conclusion: EPX/EDN fecal biomarker could be used as surrogate markers 
for assessing disease activity in IBD patients with active disease and pro-
vided additional discrimination from IBD in remission. EDN/EPX showed 
higher specificity and PPV for detecting disease activity in IBD patients 
compared with FC. Combination of EDN/EPX and FC should be used for 
identifying patients with active IBD and they could possibly be used as bio-
markers for differentiating IBD and MC from IBS-D or healthy subjects with 
high diagnostic accuracy. Both EDN/EPX and FC can be used as a screening 
and monitoring surrogate markers for non-invasive disease activity. Fur-
thermore, bigger studies are needed to establish the efficacy of EDN/EPX.
references: 1. Wagner M, Sjöberg K, Vigren L, Olesen M, Benoni C, Toth 
E, et al. Elevated fecal levels of eosinophil granule proteins predict col-
lagenous colitis in patients referred to colonoscopy due to chronic non-
bloody diarrhea. Scand J Gastroenterol . 2016 Jul 2;51(7):835-41. \ 2. Pisani 
LF, Tontini GE, Marinoni B, Villanacci V, Bruni B, Vecchi M, et al. Biomark-
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ers and Microscopic Colitis: An Unmet Need in Clinical Practice. Front Med. 
2017 May 10;4(May):54. 3. Wagner M, Peterson CGB, Stolt I, Sangfelt P, 
Agnarsdottir M, Lampinen M, et al. Fecal eosinophil cationic protein as a 
marker of active disease and treatment outcome in collagenous colitis: A 
pilot study. Scand J Gastroenterol . 2011 Jul 11;46(7-8):849-54. 4. von Arnim 
U, Wex T, Ganzert C, Malfertheiner P, Schulz C. Fecal calprotectin: a marker 
for clinical differentiation of microscopic colitis and irritable bowel syn-
drome. Clin Exp Gastroenterol . 2016 Apr;9(1):97.
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P1759 BOne MIneraL MeTaBOLIsM In InfLaMMaTOry BOWeL 
dIsease: a crOss-secTIOnaL sTudy
Tulewicz-Marti E.M., Korcz T., Rydzewska-Wyszkowska G.
Centralny Szpital Kliniczny MSWiA w Warszawie, General Medicine and 
Gastroenterology with Inflammatory Bowel Disease Subdivision, Warsaw, 
Poland
contact e-Mail address: e.tulewicz@gmail.com
Introduction: Crohn’s disease (CD) and ulcerative colitis (UC) are the main 
forms of inflammatory bowel disease (IBD), chronic relapsing-remitting 
inflammatory conditions of uncertain origin affecting the gastrointestinal 
tract. Vitamin D plays a key role in gut immunity and maintenance of the 
mucosal barrier and also may be a predictive factor of bone mineralisation.
aims & Methods: The objective of our study was to determine the preva-
lence of vitamin D deficiency and the levels of biochemical markers of 
bone mineral metabolism in patients with IBD. A total of 87 patients with 
IBD were included. Serum calcium, albumin, phosphorus, parathyroid 
hormone, 25-hydroxyvitamin D (25-OHD), Beta-crosslaps (CTX), osteocal-
cine and urine phosphorus levels were evaluated.
results: 57 patients with CD (32% were women) and 30 patients with UC 
(55% women) were enrolled in the study. The mean calcium level was 2,32 
±0,13 mmol/L in CD patients and 2,31±0,34 mmol/L in UC patients. Albumin 
level was 4,14±0,52 g/dL in CD and 4,26±0,45 in UC group. Interestingly 
21% of UC patients and 5% of CD had hypophosphatemia (p< 0,05). Mean 
phosphorus in urine was 59,6±48,1mg/dL in CD and 44,6±36,1 mg/dL in UC 
patients (p=0,179). Deficiency of 25-OHD was very high, with a prevalence 
of 86% in patients with UC and 83% in patients with CD. Hyperparathy-
roidism, defined as a parathyroid hormone level >56,9 pg/mL was present 
in 18% of patients with CD and 14% of patients with UC. Whatmore CTX 
was elevated in 22% of CD patients and 40% of UC. Mean osteocalcin level 
in CD was 23,12±9,8 and 20,74±11 in UC patients. No significant differences 
were observed between CD and UC (p=0,865 for PTH; p=0,140 for CTX and 
p=0,891 osteocalcin).
conclusion: Bone mineral metabolism disorders were common in UC and 
CD patients. Hypophosphatemia and bone turnover markers were more 
frequent in CU group. Vitamin D deficiency was likely to occur in IBD pa-
tients, therefore it should be monitored and supplemented to avoid bone 
damage.
disclosure: Nothing to disclose 
P1760 vITaMIn d defIcIency In PaTIenTs WITh InfLaMMaTOry 
BOWeL dIsease Is assOcIaTed WITh Increased dIsease acTIvITy
Kubesch A., Hausmann J., Amiri M., Sprinzl K., Blumenstein I.
University-Hospital Frankfurt, Department of Internal Medicine 1, Frankfurt 
am Main, Germany
contact e-Mail address: irina.blumenstein@kgu.de
Introduction: Vitamin D has an inhibitory role in the inflammatory signal-
ing pathways and supports the integrity of the intestinal barrier. Due to its 
immunomodulatory effect, vitamin D appears to play a role in the course 
of chronic inflammatory bowel disease (IBD) and a corresponding defi-
ciency is associated with an increased risk of a flare.
aims & Methods: The aim of this study was to investigate to what extent 
the 25(OH)D3 level correlates with clinical and laboratory parameters of 
disease activity and whether a cut-off value for prediction of remission 
could be defined.Patients with IBD treated in the outpatient department 
of the University Hospital Frankfurt were included and analyzed retrospec-
tively. The 25(OH)D3 levels were measured and correlated with clinical and 
laboratory chemical activity parameters. Vitamin D deficiency was defined 
as 25(OH)D3 levels < 30 ng/ml.
results: A total of 481 (218 male,45.5%) patients with IBD were included, 
274 (58.1%) with Crohn’s disease (CD), 198 (41.9%) with ulcerative colitis 
(UC). The median age of the patients was 41.65 (17-84). In 294 patients 
(61%) a vitamin D deficiency was detected. CD patients had significantly 
more vitamin D deficiency than UC patients (p= 0.04). 217 (46.6%) patients 
received oral vitamin D substitution. However,165 of these patients (76%) 
still had a relevant vitamin D deficiency. In the logistic regression analysis 
of the HBI (Harvey Bradshaw Index) in CD patients was inversely associated 
with the 25(OH)D3 serum concentration. A 25(OH)D3 serum concentration 
of 27.5 ng/mL seems to be the optimal cut-off value to predict remission 
in our cohort.
conclusion: In our study, vitamin D levels were inversely associated with 
disease activity. Thus, especially in high-risk patients, close monitoring 
should be established in clinical routine and, if necessary, optimized sub-
stitution should be considered.
disclosure: Nothing to disclose 
P1761 MMP-2 and -8 degraded and cITruLLInaTed-vIMenTIn 
(vIcM) cOrreLaTes TO dIsease acTIvITy In InfLaMMaTOry 
BOWeL dIseases
Godskesen L.E.1, Lindholm M.2, Mortensen J.H.2, Krag A.1, Karsdal M.A.2, 
Manon-Jensen T.2, Kjeldsen J.1
1University of Southern Denmark, Department of Medical Gastroenterology, 
Odense, Denmark, 2Nordic Bioscience, Biomarkers and Research, Herlev, 
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contact e-Mail address: tmj@nordicbio.com
Introduction: Vimentin is a type III intermediate filament protein that sta-
bilises cell architecture, but might be more active involved in intestinal 
inflammation during Crohn’s disease (CD) and ulcerative colitis (UC). In 
lamina propria vimentin is found in mesenchymal cells like fibroblast and 
myofibroblasts, but are also produced by activated macrophages in in-
flammatory diseases. Protein fragments from vimentin turnover can be 
measured by competitive enzyme-linked immunosorbent assay (ELISA)
targeting MMP-2 and -8 degraded and citrullinated-vimentin (VICM) and 
thereby maybe act as aserological biomarker of intestinal inflammation.
aims & Methods: The aim of this study is to evaluate how VICM correlates 
to clinical and endoscopic disease activity in CD and UC.We included 63 
CD patients, 107 UC patients and 20 healthy controls in a prospective study 
aimed at biomarker evaluation. 35% (n=24) of CD patients and 49% (n=52) 
of UC patients with active disease. We recorded Harvey-Bradshaw Index 
(HBI) or Simple Clinical Colitis Activity Index (SCCAI), and measured VICM, 
C-reactive protein (CRP) and faecal calprotectin (FC). 17 CD and 63 UC pa-
tients were evaluated with sigmoidoscopy or colonoscopy from where we 
recorded Simple Endoscopic Score for Crohn’s disease (SES-CD) or Endo-
scopic Mayo Score.
results: VICM was significantly elevated in CD and UC patients compared 
to healthy controls (p=0.0001). VICM correlated positively to SES-CD, SCCAI 
and Endoscopic Mayo Score and, and had a tendency to correlate to HBI 
VICM had a stronger correlation to the endoscopic scores than CRP but not 
as strong a correlation as FC.
conclusion: VICM is significantly elevated in IBD patients in remission and 
IBD patients with active disease compared to healthy controls. Further-
more, VICM correlates significantly to endoscopic disease activity in CD, 
to clinical and endoscopic activity in UC, and have a tendency to correlate 
to clinical disease activity in CD. VICM correlates more to the endoscopic 
scores compared to CRP This might reflect the fact that VICM is produced 
locally in the inflamed gut, whereas CRP is a systemic inflammation mark-
er produced in the liver. VICM might act as a serological biomarker of 
inflammation in the intestinal wall in IBD.
disclosure: ML, JHM, MAK, and TMJ are full time employees at Nordic Bio-
science. MAK and TMJ hold stocks in Nordic Bioscience. 
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P1762 fecaL shOrT-chaIn faTTy acIds In InfLaMMaTOry 
BOWeL dIseases PaTIenTs
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Introduction: Short-chain fatty acids (SCFA) play an important role in 
maintaining colon homeostasis, provide optimal levels of acidity and are 
probably involved in the pathogenesis of various bowel diseases.
aims & Methods: The aim of the study was to determine the level of fecal 
SCFA in patients with ulcerative colitis (UC) and Crohn’s disease (CD). 
Seventy seven IBD patients, including 42 UC and 35 CD patients were in-
cluded into the study. The control group consisted of 42 healthy volunteers. 
Determination of fecal SCFA in IBD patients and control group volunteers 
was carried out by gas-liquid chromatographic analysis.
results: In our study, the ratio of major SCFA was as follows: in the control 
group - C2 (68.5%), C3 (11.8%), C4 (19.7%), in the group of CD patients - 
C2 (62.2%), C3 (17.4%), C4 (20.4%), in UC patients - C2 (63%), C3 (18%), 
C4 (19%). The C2-C4 profile showed an increase of the relative content of 
propionic acid in CD - (0.16±0.07 units) and UC patients - (0.16±0.07 units), 
compared to the control group - (0.13±0.03 units), p=0.0188, p=0.0079, 
respectively, with the unchanged relative content of acetic and butyric 
acids. However, UC and CD patients showed a decrease in the absolute 
content of acetic acid - (3.07±2.02 and 3.65±2.75 mg/g) and butyric acid - 
(0.93±0.81 and 1.20±1.15 mg/g) compared to the control group - (6.32±4.81 
and 1.82±1.56 mg/g, respectively), p< 0.05. Besides we found that CD and 
UC patients had reduced absolute content of isobutyric (IC4) - (0.20±0.23) 
mg/g, (0.18±0.18) mg/g and isovaleric (IC5) acids - (0.25±0.23) mg/g, 
(0.23±0.26) mg/g, as well as isocaproic acid (IC6) level was decreased in UC 
patients- (0.011±0.016) mg/g compared to the control group - (0.33±0.34) 
, mg/g for IC4, (0.41±0.39) mg/g for IC5, (0.006±0.018) mg/g for IC6, p< 
0.05. The sum of all SCFA (C2+C3+C4+C5+C6+IC4+IC5+IC6) was lower in 
UC - (5.51±3.89) mg/g and CD patients - (6.58±5.08) mg/g compared to 
the control group - (10.35±7.7) mg/g, p=0.0018, p=0.0194. There was also a 
tendency to the shift of the anaerobic index to a more negative side in UC 
(-0.56±0.24) u. and CD patients - (-0.55±0.26) u , compared to the control 
group - (-0.47±0.18) u.
conclusion: Reduced absolute content of butyric acid in IBD patients al-
lows to suppose the presence of the link between decreased butyrate level 
and gut inflammation. A shift in the anaerobic index to a more negative 
side indicates the activation of opportunistic bacteria in IBD patients. A 
decrease in the absolute content of particular SCFA and their total number 
in IBD patients may indicate the inhibition of functional activity and the 
number of anaerobic microbiota and/or an increase of the SCFA utilization 
by colonocytes.
disclosure: Nothing to disclose 
P1763 fecaL eOsInOPhIL caTIOnIc PrOTeIn Is a dIagnOsTIc 
and PredIcTIve BIOMarker In yOung aduLTs WITh 
InfLaMMaTOry BOWeL dIsease
Abedin N.1,2, Langen T.1, Groner S.1, Jessica R.1, Tischendorf S.1, Röseler S.3, 
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Introduction: Fecal biomarkers are important non-invasive means for the 
diagnosis, measurement of disease activity and evaluation of treatment ef-
ficiency in inflammatory bowel disease (IBD), but endoscopy remains the 
gold standard for the diagnosis and determination of state of inflamma-
tion and disease activity in inflammatory bowel disease (IBD).
aims & Methods: Here, we evaluate the significance of fecal Eosinophil 
Cationic Protein (fECP) and compare it to the most studied fecal biomarker 
calprotectin (fCal). fECP and fCal were analyzed in fecal samples of pa-
tients with Crohn’s disease (CD, n = 144), Ulcerative colitis (UC, n = 70), 
clostridium difficile infection (CDI, n = 9), primary food allergy (PFA, n = 11), 
secondary pollen-associated food allergy (SFA, n = 25) and non-inflamma-
tory controls (total n = 78; healthy controls n = 37; disease controls n = 13; 
irritable bowel syndrome n = 28). In IBD patients, results were correlated 
with serum CRP and both clinical and endoscopic activity scores. Endos-
copy was performed in 83 IBD patients (CD n = 42; UC n = 41).
results: Compared to controls, fECP was significantly elevated in CD, UC, 
CDI and PFA. fCal was increased in CD, UC and CDI, but not PFA. fECP corre-
lated with disease activity markers in IBD patients; however, ROC analyses 
shows a lower diagnostic accuracy to differentiate between endoscopically 
active and inactive IBD patients (AUC = 0.77) than for fCal (AUC = 0.88). 
In contrast to fCal, fECP correlated negatively with age. fECP elevation in 
IBD patients below the age of 45 years was independent of clinical and 
endoscopic activity (endoscopically inactive IBD vs controls; AUC for fECP 
= 0.86; AUC for fCal = 0.62). Furthermore, in IBD patients < 45 years and 
low inflammatory activity (fCal < 250 mg/kg), fECP is a prognostic marker 
indicating the necessity of change of treatment or surgery (fECP < 200 µg/
kg = 22 %; 200 - 600 µg/kg = 44 %; > 600 µg/kg = 82 % at month 48 of 
follow-up).
conclusion: fECP could serve as a diagnostic marker and indicates disease 
progression in young IBD patients in remission.
disclosure: Nothing to disclose 
P1764 IL-33/sT2 LeveLs and guT MIcrOBIOTa 
characTerIzaTIOn can PredIcT MucOsaL resPOnse 
TO anTI-Tnf TheraPy In uLceraTIve cOLITIs
Lopetuso L.R.1, Petito V.2, Graziani C.3, Quagliariello A.4, Del Chierico F.4, 
Scannone D.5, Putignani L.4, Pizarro T.T.6, Armuzzi A.7, Scaldaferri F.8, 
Gasbarrini A.9
1Catholic University, UOC Internal Medicine, Gastroenterology and 
Hepatology Gastroenterological and Oncological Area, Gastroenterological 
and Endocrino-Metabolical Sciences Department, Rome, Italy, 
2Catholic University of Sacred Heart, Department of Internal Medicine, 
Gastroenterology Divison, Civitavecchia, Italy, 3Gemelli Hospital, Internal 
Medicine and Gastroenterology Division, Rome, Italy, 4Bambino Gesu 
Paediatric Hospital, Microbiome Unit, Rome, Italy, 5Fondazione A. 
Gemelli Hospital IRCCS, Rome, Italy, 6Case Western Reserve University 
School of Medicine, Pathology and Medicine, Cleveland, United States, 
7Catholic University, Complesso Integrato Columbus, Internal Medicine 
and Gastroenterology, Rome, Italy, 8Catholic University, Internal Medicine, 
Gastroenterology Division, IBD Unit, Rome, Italy, 9Catholic University, Gemelli 
University Hospital, Internal Medicine, Gastroenterology and Liver Diseases, 
Rome, Italy
contact e-Mail address: lopetusoloris@libero.it
Introduction: It is now well-established that IL-33/ST2 axis and gut mi-
crobiota are important factors in the pathogenesis of IBD with a potential 
reciprocal influence. Recent evidence has shown that tumor necrosis factor 
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(TNF) inhibitors (anti-TNF) are able to modulate the IL-33/ST2 axis as well 
as gut microbiota in inflammatory conditions. Anti-TNF are considered to 
be effective in inducing mucosal healing in patients with moderate-to-
severe Ulcerative Colitis (UC).
aims & Methods: The aim of our study was to explore the potential role 
of the IL-33/ST2 axis and gut microbiota in the mucosal healing process 
mediated by anti-TNF therapy in UC. Endoscopic MAYO score was calcu-
lated before the first anti-TNF infusion (T0) and after 6 weeks (T2). 26 UC 
patients (MAYO score at T0 ≥ 2), grouped into 14 responders with mucosal 
healing (MAYO score ≤ 1) and 12 non-responders to anti-TNF at T2 (MAYO 
score ≥ 2) were enrolled. 10 healthy controls undergoing routine colonos-
copy for tumor screening were also enrolled. At each time point, serum 
and fecal samples were collected. ELISA and western blot were performed 
to assess IL-33/ST2 protein levels and to evaluate protein isoforms, respec-
tively. Intestinal biopsies were also taken from the rectum and IHC was 
done to evaluate mucosal IL-33/ST2 expression and localization. Genomic 
DNA was extracted from fecal samples and V3-V4 regions of the 16S rRNA 
gene were sequenced by MiSeq Illumina platform for microbiota charac-
terization.
results: IL-33 protein levels were significantly increased in responders vs. 
non-responders, both at T0 and T2. Among responders, IL-33 protein was 
slightly reduced at T2 vs. T0, while unchanged in non-responders. Inter-
estingly, significantly higher levels of ST2 were found in responders vs. 
non-responders at T0, while no differences between groups were found 
at T2. Among responders, ST2 levels were dramatically reduced at T2 vs. 
T0. No significant differences were found in non-responders at both time 
points. Healthy controls showed significantly lower levels of both IL-33 and 
ST2 compared with other groups. Full-length, bioactive IL33 (31 kDa), ST2L 
(76 kDa) and sST2 (52 kDa) were expressed in all experimental groups; 
the cleaved, less active form of IL33 (24 kDa) was increased in only non-
responders vs. responders and healthy controls.
IHC confirmed these observations. In particular, IL-33 and ST2 staining was 
more intense within the inflamed and ulcerated mucosa of responders 
compared to non-responders at T0. After 6 weeks, ST2 staining was even 
more evident in responders, notably localized to the healed mucosa and 
in close proximity to areas of re-epithelialization. Little to no staining for 
both IL-33 and ST2 was present in healthy controls. Microbiota analysis 
showed an increased biodiversity at T0 in responders vs. non respond-
ers. At T0, non responders showed lower levels of Verrucomicrobia (Ak-
kermansia municiphila) and Firmicutes, with an increased abundance of 
Bacteroidetes vs. responders.
conclusion: Our results suggest a possible role for IL-33/ST2 and gut micro-
biota in predicting gut mucosal wound healing in patients with moderate-
to-severe UC treated with anti-TNF. IL-33/ST2 axis and gut microbiota could 
thus represent a useful diagnostic tool to evaluate therapeutical options in 
IBD patients. Further studies are underway to determine mechanisms of 
action that support these findings.
disclosure: Nothing to disclose 
P1765 IMMunOMOduLaTOr and BIOLOgIcaL TheraPy are 
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Introduction: Immune mediated diseases (IMIDs) include a heterogenous 
group of chronic diseases that are characterized by the loss of the immune 
system tolerance causing inflammation and tissue damage in different or-
gans. Inflammatory bowel diseases (IBD) belong to IMIDs group together 
with other autoimme diseases. Literature data showed a IMIDs prevalence 
of 9-15% in IBD, depending of the region studied.
aims & Methods: The aim of our study is to describe the prevalence and 
influence of IMIDs in IBD.
A retrospective and descriptive study was designed to evaluate the influ-
ence of IMIDs in IBD. 1448 IBD patients were studied to evaluate the differ-
ent clinical characteristics and evolution course of the disease depending 
on the associated IMIDs.
results: We included 1448 patients of whom 46.96% (n=680) were di-
agnosed with Crohn’s Disease, 48.34% (n=700) with Ulcerative Colitis 
and 4.7% (n=68) with IBD Unclassified. A IMIDs prevalence of 25.69% 
was present in IBD patients compared to 74.31% (n=1076) of IBD patients 
without IMIDs. The most prevalent IMIDs were intrinsic ashma and skin 
psoriasis following rheumatoid conditions. An increased risk of IMIDs was 
observed in IBD women (OR 1.48 (IC 95%: 1.17 - 1.87) p=0.001). Furthe-
more, more proportion of IMIDs patients was observed in Crohn’s Disease 
compared to Ulcerative Colitis (OR 1.35 (IC 95%1.07-1.70) p=0.02). It is im-
portant to highligh that IMIDs required more immunomodulator (OR 1.61 
(IC 95%: 1.27 -2.03) p=< 0,01) and biological therapy (OR 1.89 (IC 95%: 1.47 
-2.43) p= < 0,01).
conclusion: 
1. There is an increased IMIDs prevalence in IBD patients. 
2. Crohn’s Disease patients and women have a higher risk of associated 
IMIDs to their IBD.
3. IBD patients with associated IMIDs require more immunomodulator 
therapy or biological therapy to control their disease , probably caused by 
a more aggressive course of IBD. 
4. More studies are necessary to increase the knowledge in IBD patients 
with associated IMIDs.
 
IBd with IMIds 
associated (%, n)
IBd without 
IMIds (%, n) Or (Ic) p
gender: men 44.64% (168) 52.34% 1.48 (1.17 - 1.87) 0.001*
Type of disease: 
crohn‘s disease 52.21% (201) 45.06% (478) 1.35 (1.07-1.70) 0.026*
Immunomodulator 
Therapy: yes 48.31% (186) 36.78% (391) 1.61 (1.27 - 2.03) <0.000*
Biological Therapy: 
yes 36.36 % (140) 23.24% (247) 0.89 (1.47 - 2.43) <0.000*
surgery: yes 21.04%(81) 19.59% (208) 1.1 (0.82 - 1.46) 0.536
[Odss ratio of clinical characteristics and therapy.]
disclosure: MJG; MP, CDP, LR and BC have no conflict of interest to declare. 
MR has served as a speaker and advisory member for Abbvie, MSD and 
Janssen. JC is a consultant of Abbvie, Gilead, MSD and Intercept. Also JC 
obtained grants of aforementioned companies. 
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Introduction: Prevalence of overweight and obesity is increasing world-
wide, as well as of Inflammatory Bowel Disease (IBD). However, there is 
lack of evidence about the nutritional habits of patients with IBD and also 
about the relationship between the course of the disease and the body 
mass index (BMI).
aims & Methods: 
1) To determine the healthy and nutritional habits of patients with IBD and 
their adherence to Mediterranean diet (MD). 
2) To analyze the course of the disease, regimens of treatment and quality 
of life depending on body mass index (BMI).
We performed a prospective cohort study that included consecutive pa-
tients with IBD attending our adult IBD clinic in a one-month period. De-
mographic characteristics and disease related factors were obtained from 
Spanish ENEIDA database. Health-related quality of life was measured us-
ing the disease-specific Inflammatory Bowel Disease Questionnaire (IBDQ-
9)1 and anxiety and depression were estimated by the Goldberg Anxiety 
and Depression Scale (GADS). Adherence to MD was evaluated using the 
14-point Mediterranean Diet Adherence Screener from PREDIMED study2. 
The variables were analyzed depending on the BMI (underweight ≤ 18.4, 
normal 18.5-24.9, overweight 25-29.9, obesity ≥ 30 ). Statistical analysis 
was performed using SPSS version 22.0.
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results: A total of 104 patients were included in our study. Mean age was 
47.0±14.4 years and 56.7% of patients (59/ 104) were females); 53.8% 
(56/104) of patients had ulcerative colitis and 46.2% (48/104) Crohn’s dis-
ease. More than half of patients were diagnosed of overweight (41.3% 
(43/104)) or obesity (15.4% (16/104)) with a significantly increase in BMI 
as age does (mean age 41.6±14.7 years in normal-underweight, 49.7±12.3 
years in overweight and, 55.1±13.2 years in obesity; p=0.001). There were 
more former smokers in the group of obese and overweight patients than 
in normal-underweight ones (62.5% (10/16), 55.8% (24/43), 33.3% (15/45), 
respectively, p=0.034). Since IBD diagnosis, 42.3% (44/104) of patients 
have modified their diet with weight changes in 61.4% (27/44) of them 
(55.6% (15/27) of patients lost weight and 44.4% (12/27) gained weight). 
No statistically significant differences were observed between the physical 
activity and the BMI (p=0.269).
47.1% (49/104) of patients had a good adherence to MD, decreasing adher-
ence as the BMI increases, but without reaching statistical significance 
(55.6% (25/45), 41.9% 18/43) and 37.5%(6/16) in normal-underweight, 
overweight and obese; respectively, p=0.308). 
There were no significant differences neither in the disease related factors 
(type, location, extension, activity of the disease, extraintestinal manifesta-
tions or complications) nor in the IBD treatments depending on BMI. 
Concerning quality of life, the mean mark in the IBDQ-9 questionnaire was 
44.8±10 (equivalent to 61.5 in the 0-100 scale) without significantly dif-
ferences between BMI groups. More than half percent of patients (59.6% 
(62/104)) had probably depression based on Golberg questionnaire.
conclusion: Nearly 50% of patients modify their diet after the diagnosis of 
IBD and there is a low adherence to MD, specially in those with obesity. 
No differences were shown in the course of IBD, treatment and outcomes 
depending on BMI. A high number of patients have probably depression 
and quality of life could be improved.
references: (1): Alcala MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. 
Shortened questionnaire on quality of life for inflammatory bowel disease. 
Inflamm Bowel Dis 2004;10:383-91. (2): Estruch R, Ros E, Salas-Salvadó 
J, Covas MI, Corella D, Arós F et al. Primary Prevention of Cardiovascular 
Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive 
Oil or Nuts. N Engl J Med. 2018 Jun 21;378(25)
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Introduction: Spondyloarthritis (SpA) is one of the most common extrain-
testinal manifestations (EIM) of Inflammatory bowel diseases (IBD). The 
diagnosis of SpA in patients with IBD is challenging, treatment strategy 
should be often revised when IBD and SpA coexist.
aims & Methods: The aim of the study is to evaluate factors associated with 
higher risk of axial SpA in patients with IBD. The single-center observa-
tional cross-sectional study included patients with a definite diagnosis of 
IBD and chronic back pain (duration > 3 months). Inflammatory Back Pain 
(IBP) was determined according to ASAS criteria (2009). If suspected with 
SpA, patients underwent X-ray and/or MRI of sacroiliac joints. SpA was di-
agnosed according to ECCO recommendations. All patients diagnosed with 
SpA also fulfilled ASAS criteria for axial SpA. Univariate and multivariate 
logistic regression analysis was performed to assess the factors associated 
with higher risk of being diagnosed with axial SpA.
results: The study included 91 patients (males - 47 (51.6%), mean age - 
40.2±11.7 years, duration of IBD - 7.7±7.6 years) with IBD: 52 (57.1%) with 
ulcerative colitis (UC), 39 (42.9%) with Crohn’s disease (CD). IBP was pres-
ent in 39 (42.9%) patients with IBD, 26 (28.6%) patients were diagnosed 
with axial SpA, among them 14 (15,4%) patients with radiographic axial 
SpA. In the univariate logistic regression model, 4 factors were associated 
with a higher chance of SpA diagnosis: presence of arthritis, arthralgia, 
CD and IBP. The associations remained statistically significant when mul-
tivariate logistic regression model was constructed (Table 1). In particular, 
patients with CD had higher chance of being diagnosed with axial SpA 
compared with UC 3.51 (1.04-11.82).
Parameter univariate analysis, Or (95% cI)
Multivariate analysis; Or 
(95% cI)
Male sex 0.57 (0.23-1.44)  
HLA-B27 4.00 (0.55-29.17)  
Smoking 0.91 (0.26-3.25)  
Arthritis 10.77 (2.26-44.2) 20.03 (3.05-131.69)
Crohn’s Disease 2.92 (1.14-7.48) 3.51 (1.04-11.82)
Arthralgia 4.12 (1.55-10.95)  
Inflammatory back pain 8.07 (2.8-23.23) 16.41 (3.99-67.34)
[Table 1. Factors associated with a higher chance of axial spondyloarthritis]
conclusion: Presence of CD was associated with higher chance of being di-
agnosed with axial SpA compared to UC. Arthritis, arthralgia and IBP were 
also associated with a higher chance of axial SpA diagnosis.
disclosure: Nothing to disclose 
P1768 dOes hIsTOLOgIcaL reMIssIOn (nancy Index) PredIcT 
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Introduction: During the last decades, treatment goals in patients with 
ulcerative colitis (UC) have shifted from clinical remission only to clini-
cal remission combined with mucosal healing. However, yet, the value of 
achieving histological remission remains unclear.
aims & Methods: 
aim: To examine whether histological healing could be a predictor of sus-
tained remission in UC patients with mucosal healing and to investigate 
risk factors for relapse.
Methods: This was a retrospective monocentric study conducted in the De-
partments of Gastroenterology and Pathology of Mohamed Taher Maamouri 
Hospital , between January 2012 to December 2018. Patients diagnosed with 
UC who had been in clinical remission for at least 6 months were evaluated 
for endoscopic remission. Those in endoscopic remission (Mayo score ≤1) 
underwent colonic biopsies. Histological findings were analyzed according 
to Nancy index. Histological remission was defined as a Nancy index of 0 
or 1. Clinical demographics including age, sex, smoking status, history of 
appendectomy, disease extent and use of medications were collected.
results: Sixty one patients had a sustained clinical remission with a dura-
tion ranged from 9 months to 25 years. Of these 61 patients, 28 were in 
endoscopic remission, 18 were female with a median age of 50.82 years. 
Medical therapy included 5-aminosalicylic acid ( 78.6%) and immunosup-
pressive treatments(21.4%). According to the affected areas, proctitis type 
accounted for 21.4 % of the patients , left-sided type for 21.4 % , and pan-
colitis type for 57.1 % . Histological remission was noted in 60.7% (17/28) of 
the patients, while 11 (39.1%) patients still had histologically active disease. 
The remission maintenance rate was higher in the histological healing 
group, without reaching statistical significance (88,3% VS 45,5% ,p=0.2). 
Histological remission did not depend on the disease duration (p=0.5) .
Endoscopic findings were graded as Mayo score 0 in 57.1 % of the patients 
(n = 16) and 1 in 33, 9% (n = 12).The remission maintenance rate was higher 
in the Mayo score 0 group (p= 0.04). Others factors as :age, gender, and 
duration of clinical remission were not found to be statistically significant 
in predicting relapse.
conclusion: In our study histological remission failed to reach statistical 
significance to predict relapse but it showed that patients with Mayo score 
1 may need examination of histological inflammation to improve UC pa-
tients outcomes.
disclosure: Nothing to disclose 
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P1769 cOsT-uTILITy anaLysIs Of MrI and cT In 
radIaTIOn-Induced neOPLasMs In InfLaMMaTOry 
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Introduction: Given the chronic nature of IBD, frequent imaging with CT 
and MRI is often used to assess disease activity and complications. The 
advantages of CT scans include greater accessibility, lower cost and bet-
ter spatial resolution. However, its major disadvantage is ionizing radia-
tion. On the other hand, MRIs do not contain ionizing radiation and have 
improved soft tissue resolution, but are costlier, more time-intensive and 
are less accessible. Currently, CT scans are used more commonly in the 
management of IBD, despite recent studies demonstrating similar sensi-
tivity and specificity in the two imaging modalities. This is of importance, 
given that the lifetime attributable risk of neoplasm and mortality related 
to radiation is directly related to the cumulative radiation exposure. As a 
result, a Markov model was created to ascertain the cost utility of utilizing 
MRI rather than CT in preventing radiation-induced neoplasms in patients 
with inflammatory bowel disease.
aims & Methods: A provincial (Ontario) database of 72 933 IBD patients 
from 1999-2016 was examined. Quarterly rates of CT/MRI utilization were 
extrapolated from this database. The lifetime attributable risk of malig-
nancy related to radiation was taken from the BEIR VII study from the 
National Academies Press (2006). Cost considerations for MRI/CT were 
taken from the American College of Radiology and mortality rates were 
taken from Statistics Canada. A hypothetical population of patients aged 
40 was examined over a 30 year period. An analysis was conducted with 
Markov modeling to examine whether use of MRIs rather than CTs was 
cost effective with regards to increased health utility from reduced rates of 
malignancy and malignancy-related death in IBD patients.
results: In the female group, the aggregate cost of CT and MRI scans was 
$7291.05 and $11023.88, respectively. This represents a $3732.84 cost dif-
ference. The total QALY in the MRI group compared to the CT group was 
29.32 and 29.27, respectively. This represents a difference of 0.049 QALY, 
and an ICER of $75782.53/QALY. A sensitivity analysis was conducted in this 
group and demonstrated that the ICER was < $100000/QALY after 26 years, 
and < $50000/QALY after 35 years. In the male group, the total cost of CT 
and MRI scans was $7257.22 and $10971.06, respectively. There was a cost 
difference of $3713.84. The total QALY in the MRI group compared to the 
CT group was 29.11 and 29.08, respectively. This represents a 0.036 QALY 
difference, and an ICER of $102473.35/QALY. A sensitivity analysis demon-
strated that the ICER was < $100000/QALY after 31 years and < $50000/
QALY after 39 years.
conclusion: A hypothetical Markov model was constructed to evaluate the 
cost-effectiveness of using MRIs rather than CTs in IBD patients, given the 
increased health utility from reduced rates of malignancy and malignancy-
related death. In our analyses, use of MRIs was cost-effective to CTs in 
females and males after 26 and 31 years of imaging, respectively, starting 
at the age of 40. As a result, there may be a role in using MRIs over CT 
scans in patient populations requiring frequent imaging given the cost-
effectiveness of the intervention.
disclosure: Nothing to disclose 
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Introduction: Although fecal calprotectin (Fcal) and fecal immunochemical 
test (FIT) have been to be associated with endoscopic disease activity in ul-
cerative colitis (UC), the values of each marker depending on the mucosal 
status are not well known.
aims & Methods: This study evaluated the differences between two fecal 
markers depending on the mucosal status in UC. A total of 174 results, ob-
tained in simultaneous examination with endoscopy and fecal tests, were 
retrospectively evaluated for 127 UC patients from March 2015 to February 
2018. The usefulness of fecal markers as a surrogate marker of endoscopic 
disease activity and the difference between fecal markers depending on 
the mucosal status was statistically evaluated. Endoscopic disease activity 
was divided into Mayo endoscopic subscore (MES) and ulcerative colitis 
endoscopic index of severity (UCEIS).
results: Both fecal markers showed statistically significant correlation with 
MES (r = 0.678 for Fcal (p < 0.001) and r = 0.635 for FIT (p < 0.001)) and 
UCEIS (r = 0.711 for Fcal (p < 0.001) and r = 0.657 for FIT (p < 0.001)). Fcal 
was significantly superior to FIT in predictive accuracy for endoscopic dis-
ease activity (AUC; 0.863 versus 0.765 in MES (p < 0.001) and AUC; 0.847 
versus 0.757 in UCEIS (p < 0.001). FIT was significantly superior to Fcal 
in sensitivity for complete mucosal healing (98.0% versus 78.4% in MES, 
94.9% versus 74.6% in UCEIS).
conclusion: Both Fcal and FIT were well correlated with endoscopic disease 
activity in UC patients. Fcal was more accurate correlation with endoscopic 
disease activity in patients with active inflammation, while FIT was more 
sensitive in predicting the achievement of complete mucosal healing.
disclosure: Nothing to disclose 
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Introduction: Early detection of postoperative recurrence (POR) remains a 
major concern in patients with Crohn disease (CD).
aims & Methods: We aimed to assess the performances of serial faecal 
calprotectin monitoring within the three first months following ileocolonic 
resection to predict CD endoscopic POR at 6 months.
In this multicenter prospective study, all the patients with CD who un-
derwent ileocolonic resection were consecutively enrolled. Stools samples 
were collected at baseline, at one month (M1) and M3 to measure faecal 
calprotectin level. The stools samples were collected in the morning the 
day before the endoscopy to reduce intraindividual variation, and imme-
diately stored at 4 °C. Faecal calprotectin was measured using quantita-
tive immunoassay . Ileocolonoscopy was performed at M6. The endoscopic 
severity was graded independently according to the Rutgeerts’ index by 
two experienced central readers, blinded from clinical or biological data.
Endoscopic POR was defined as Rutgeerts’ index ≥ i2b.
results: Overall, 48 patients were included. 
Among them, 18 patients (36%) presented with endoscopic POR (Rutgeerts 
score ≥ i2b) 6 months after surgery. We did not observe any significant 
difference between patients with or without early endoscopic POR (M6), 
respectively, regarding the level of faecal calprotectin at baseline (100[50-
190] vs 166 [89-312] µg/g; p=0.15), at M1 (93 [48-104] vs 100 [50-180] µg/g; 
p=0.44) and at M3 (100 [68-328] vs 99 [50-100] µg/g; p=0.28). Faecal cal-
protectin kinetics during the first three months after surgery was signifi-
cantly different between the patients with or without POR at M6 (p=0.021). 
The relative variation (median) between the level of faecal calprotectin at 
baseline and M3 (ΔFcal M3-M0) was significantly higher in patients with 
endoscopic POR +60% IQR[- 47%; + 217%] compared to those without POR 
- 38% IQR[- 64%; 0%] (p=0.01). ΔFcal M3-M0 > +10 % demonstrated the 
best performances to predict endoscopic POR at M6 (AUC=0.73, sensitivity 
= 64.7% CI[41.1-82.7], specificity = 87.5% CI[68.0-96.3], negative predictive 
value = 77.8% CI[57.5-91.4] and positive predictive value = 78.6% CI[49.2-
95.3]).
899Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
conclusion: Faecal calprotectin variation within the first months after il-
eocolonic resection is an accurate predictor of early endoscopic POR in 
CD patients.
disclosure: Nothing to disclose 
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Introduction: The complexity of underlying pathophysiology of IBD and 
the difficulty to understand the relevance of, “-omics” have prompted us 
to asses alternative approaches and technologies. Physiological intermo-
lecular modulation spectroscopy (PIMS), and nematic protein organization 
technic (NPOT) two cutting edge label free technologies that have been 
used to reconcile these “omics” with the clinical relevance. PIMS, stratifies 
patients to responder and non-responder in regard to a treatment. NPOT 
identifies the functional molecular network in responder patients, thus 
paving the way to identify success biomarkers. 
We have therefore in a prospective study used PIMS and NPOT to predict 
responder IBD patients prone to be treated with Vedolizumab and isolated 
their underling functional molecular network.
aims & Methods: In a prospective clinical study, protein extracts of pe-
ripheral blood mononuclear cells (PBMC) of 31 outpatients (female = 17, 
mean age= 55.6 years and men=14, mean age=41.7) diagnosed with UC or 
CD (UC=13, CD= 18) prone to be treated with Vedolizumab were subjected 
to PIMS analysis. 
PIMS analysis were performed blinded on isolated PBMCs from 4 different 
treatment period (week 0, 2, 6 and 14). Patient’s data were blinded. One 
microgram of total protein from each patient’s PBMC was challenged with 
1µM of Vedolizumab. 
After determination of base line, the samples were frozen at -17°C. Dy-
namic changes in macromolecular interaction were registered from -17 to 
5°C. After deblinding IBD patients from each group of responder (n=3) 
and non-responder (n=3) were subjected to Nematic protein Organization 
technique (NPOT) in order to identify the signaling pathways in both group 
respectively.
results: PIMS predictions were in accordance with clinical response to Ve-
dolizumab from treatment on set (week 0) to last treatment (week 14) as 
follow 14 CD 77-92% and UC, 78-100% respectively. NPOT revealed the 
presence of proteins ITGB7, ITGAV, ITG3, PF-4 and ASGH in Vedolizumab 
responder patients whereas no distinct signaling pathway was observed 
in non-responder patients.
conclusion: PIMS could predict responder from non-responder and NPOT 
highlighted the signaling pathway required for positive clinical response 
to Vedolizumab. The combination of these two technologies can pave the 
way in identification of success and resistance biomarkers.
disclosure: Nothing to disclose 
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Introduction: Retrospective and prospective treat-to-target studies have 
shown biological and endoscopic remission are superior to clinical remis-
sion in achieving improved long-term clinical outcomes in patients with 
inflammatory bowel diseases (IBD). Stricter, more rigorous therapeutic 
targets may require higher drug levels.
aims & Methods: We aimed to study whether higher maintenance adali-
mumab drug levels are associated with clinical, biological and endoscopic 
remission. Demographic, clinical, laboratory and endoscopic data were 
collected retrospectively from 66 consecutive IBD patients treated with 
adalimumab who had a C-reactive protein (CRP) and/or stool calprotec-
tin measured and endoscopic evaluation within 12 weeks of adalimumab 
serum trough levels. We defined clinical remission as HBI< 5 or MAYO < 2 
for Crohn’s disease (CD) and ulcerative colitis (UC), respectively; biologic 
remission as CRP < 0.5 mg/dL and/or calprotectin < 250; endoscopic remis-
sion as SESCD ≤3 (for ileal disease) or SESCD ≤4 for a more extensive CD 
or endoscopic Mayo ≤1 for UC. Data was analyzed using STATA statistical 
analysis software. This study was approved by the local IRB.
results: Sixty-six consecutive patients were included in our study. Median 
age was 37 years (range 20 to 79), 50% were male, most patients (86%) 
had CD. Patients who achieved clinical, biologic and endoscopic remission 
had higher serum trough adalimumab levels (ug/mL±StdErr, 8.9±0.9 Vs. 
5.7±1, p=0.016; 8.2±0.8 Vs. 6.6 ±1.1, p=0.023; 9.2±1.0 Vs. 6.1±0.7, p=0.019, 
respectively) .
Increased levels of adalimumab were required to reach deeper levels 
of remission, reaching significance comparing clinical and deep (clini-
cal, biologic and endoscopic) remission (ug/mL±StdErr, 5.9±1 Vs. 11.7±1.5, 
p=0.04).
Patients who achieved remission had lower odds ratio of developing 
disease-related complications (OR=0.4, p=0.04). Lower complications rate 
was also associated with higher maintenance adalimumab serum trough 
levels (8.4±0.8 Vs. 5.7±0.9, p=0.04).
conclusion: Higher adalimumab trough levels may be required to achieve 
better disease control. This study provides additional data to guide thera-
peutic drug monitoring with adalimumab.
disclosure: Nothing to disclose 
P1774 uLceraTIve cOLITIs PaTIenTs WITh LOW seruM LeveLs 
afTer The InducTIOn Of anTI-Tnf drugs dO nOT achIeve 
MucOsaL heaLIng aT One year. a PrOsPecTIve sTudy
Bertani L.1,2, Tapete G.1, Albano E.1, Baiano Svizzero G.1, Mumolo G.2, 
Maltinti S.1, Ramacciotti N.1, Ceccarelli L.2, de Bortoli N.1, Bellini M.1, 
Marchi S.1, Costa F.2
1University of Pisa, Translational Research and New Technologies in 
Medicine and Surgery, Pisa, Italy, 2Pisa University Hospital, General Surgery 
and Gastroenterology, Pisa, Italy
contact e-Mail address: lorenzobertani@gmail.com
Introduction: Anti -Tumor Necrosis Factors (TNF) are currently the most 
commonly used drugs for moderate to severe ulcerative colitis (UC). Ther-
apeutic drug monitoring (TDM) is a promising strategy to optimize the 
health care resources in case of loss of response during anti TNF treatment, 
but a proactive management of TDM is being debated.
aims & Methods: The aim of this prospective study was to evaluate the use 
of Trough Levels (TL) of Infliximab (IFX), Adalimumab (ADA) or Golimumab 
(GOL) at the end of the induction phase as predictors of mucosal healing 
(MH) in patients with UC.
All the patients who started anti-TNF treatment with IFX, ADA or GOL in 
monotherapy at Pisa University Hospital since November 2017 were pro-
spectively enrolled. At the end of the induction (week 6 for IFX or GOL, 
week 8 for ADA) TL were evaluated on serum samples drawn before drug 
administration, by using an ELISA test (Promonitor®, Grifols, Spain). At 
week 54, MH (defined as Mayo Endoscopic Score< 2) and clinical remission 
(CR, defined as a Partial Mayo Score< 2) were evaluated. Statistical correla-
tion between TL and MH or CR was performed using Wilcoxon signed-rank 
test and ROC curves.
results: At present, 61 patients were enrolled: 32 treated with IFX, 15 with 
ADA, 14 with GOL. MH was reached in 30 patients (14 with IFX, 9 with ADA, 
7 with GOL). A collective correlation between TL and MH was found (p < 
0.01), which was confirmed when the 3 drugs were considered separately: 
in particular, patients with low TL were less likely to achieve MH. ROC 
curve analysis, currently performed for IFX, identified a cut-off of 5.4µg/ml 
(AUC 0.885, p< 0.001) in predicting the probability of non-achieving MH.
conclusion: TL in UC patients after the induction of anti-TNF treatment 
were predictors of endoscopic response. For all the drugs evaluated, high 
TL showed a correlation with MH. For IFX, TL less then 5.4µg/ml predicted 
with good accuracy the lack of MH at one year.
disclosure: Nothing to disclose 
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P1775 safeTy Of usTekInuMaB In InfLaMMaTOry BOWeL 
dIseases: InTegraTed safeTy anaLysIs Of resuLTs frOM Phase 
2 and 3 sTudIes In crOhn’s dIsease and uLceraTIve cOLITIs
Ghosh S.1, Sands B.E.2, O’Brien C.D.3, Tikhonov I.3, Zhou Y.3, Volger S.3, 
Marano C.3, Ott E.4, Gasink C.4, Sandborn W.J.5, Danese S.6
1Institute of Translational Medicine, Birmingham, United Kingdom, 
2Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division 
of Gastroenterology, New York, United States, 3Janssen Research & 
Development, LLC, Spring House, United States, 4Janssen Scientific Affairs, 
LLC, Horsham, United States, 5University of California, San Diego, La Jolla, 
United States, 6Humanitas Research Hospital, Milan, Italy
contact e-Mail address: ghoshs@bham.ac.uk
Introduction: Ustekinumab (UST) is a well-established therapy in Crohn’s 
disease (CD) and psoriatic diseases. Recently presented phase 3 data 
showed that UST was safe and effective in ulcerative colitis (UC). Phase 3 
induction and maintenance studies of UST in CD (UNITI, IMUNITI) and UC 
(UNIFI) had similar designs, which allows for integrated analysis across 
both inflammatory bowel disease (IBD) indications.
aims & Methods: We present an analysis of integrated safety data of UST in 
IBD. Data from 6 phase 2/3 CD and UC studies were pooled, and safety was 
evaluated through 1 year of follow-up. In phase 3, CD and UC pts received 
a single IV placebo (PBO) or UST (130mg or ~6mg/kg) induction dose fol-
lowed by SC maintenance doses of PBO or UST (90mg q8 or q12 wks). 
Concomitant immunomodulators (IMM) and corticosteroids were permit-
ted. All pts who received ≥1 dose of UST were included. Safety outcomes 
through 1 year are presented as the number of pts with events per 100 
pt-years (PY) of follow-up
results: At induction baseline (2370 pts in pooled phase 3 IBD studies), 
median age was 38.0 years, 46.9% were receiving corticosteroids, 30.8% 
were receiving IMM, 53.0% had failed biologics, and 37.1% were naïve to 
biologics.
In phase 3 IBD studies, through Wk8 of PBO-controlled induction, 1582 
pts were treated with UST. Pts with ≥1 event (PBO vs UST) were 55.8% vs 
53.9% with AEs, 6.2% vs 4.4% with SAEs, 19.9% vs 19.3% with infections, 
and 1.3% vs 1.1% with serious infections.
Through 1 year in pooled phase 2/3 IBD studies, 2574 pts were treated 
with UST with 1733 PY. The number of patients per 100 PY with AEs (PBO 
165.99 vs UST 118.32), SAEs (27.50 vs 21.23), infections (80.31 vs 64.32), seri-
ous infections (5.53 vs 5.02), malignancies including non-melanoma skin 
cancer (NMSC) (0.50 vs 0.81), and discontinuations of study agent because 
of an AE (13.41 vs 7.73) were similar between UST and PBO. The most fre-
quently occurring AEs (excluding diseases under study) were arthralgia 
(PBO 16.93 vs UST 16.56), headache (16.43 vs 16.50), nausea (13.25 vs 11.94), 
and abdominal pain (14.59 vs 11.54), and infections were nasopharyngitis 
(16.26 vs 18.11) and upper respiratory tract infection (11.40 vs 11.36). Results 
were similar for the CD and UC studies separately (Table shows key safety 
events).
  cd studiesa uc studiesb
  PBOc (n=943) USTd (n=1749) PBOc (n=446) USTd (n=825)
Total PY of follow-up 347 1106 250 627
Adverse events 197.97 (686) 131.52 (1455) 121.65 (304) 95.03 (596)
Serious adverse events 34.05 (118) 25.94 (287) 18.41 (46) 12.91 (81)
Infections 95.52 (331) 72.59 (803) 59.23 (148) 49.75 (312)
Serious infections 6.64 (23) 6.06 (67) 4.00 (10) 3.19 (20)
Discontinuation of study 
agent because of an 
adverse event
13.56 (47) 9.76 (108) 13.21 (33) 4.15 (26)
Malignancies (including 
NMSC)e
0.58 (2) 0.63 (7) 0.40 (1) 1.12 (7)
a. NCT00265122, NCT00771667, NCT01369329, NCT01369342, and NCT01369355
b. NCT02407236
c. The PBO group includes data up to the first UST dose for patients who were initially treated 
with PBO and data at or after 16 wks from the first UST dose for patients who were randomized 
to placebo maintenance.
d. The UST group includes data up to 16 wks from the first UST dose for patients who were 
randomized to placebo maintenance.
e. Malignancies that occurred in patients receiving UST included colon cancer, papillary renal 
cell carcinoma, squamous cell carcinoma, basal cell carcinoma, prostate cancer, small intestine 
adenocarcinoma and incidental carcinoid tumor, and rectal adenocarcinoma.
[Number of pts with key safety events through 1 year of treatment per 100 PY 
of follow-up (number of patients with events) in phase 2/3 CD & UC studies]
Regarding serious infections, the CD-specific manifestation of anal abscess 
occurred in PBO 2.02 and UST 0.90 pts per 100 PY in CD pts. When CD-spe-
cific events were excluded, overall rates of serious infections were similar 
between UC and CD populations.
In pooled phase 2/3 studies, the only malignancy (excluding NMSC) re-
ported in >1 UST-treated pt was prostate cancer; no lymphomas were re-
ported through 1 year. Two pts receiving UST (0.12 per 100 PY; both had 
UC) died from events that investigators considered to be unrelated to study 
agent (esophageal varices hemorrhage and acute respiratory failure dur-
ing thyroid surgery).
conclusion: The safety profile of UST in pts with UC and across integrated 
IBD indications through 1 year was favorable and consistent with the es-
tablished safety profile in pts with CD and psoriatic disease.
disclosure: Drs. Ghosh, Sands, Sandborn, and Danese were investigators 
in clinical trials sponsored by Janssen. Drs. O’Brien, Tikhonov, Zhou, Vol-
ger, Marano, Ott, and Gasink are employees of Janssen. 
P1776 dOes anTI-Tnf Makes dIfference In OsTeOarTIcuLar 
ManIfesTaTIOns assOcIaTed TO InfLaMMaTOry BOWeL dIsease?
Santos A.L.1,2,3, Lopes S.1,2,3, Gaspar R.2,3,4, Andrade P.1,2,3, 
Corte-Real Nunes A.2,3,5, Macedo G.1,2,3
1Centro Hospitalar de São João, Gastroenterology, Porto, Portugal, 2WGO 
Oporto Training Center, Porto, Portugal, 3Porto Medical School, University of 
Porto, Porto, Portugal, 4Hospital São João, Gastrenterology, Porto, Portugal, 
5Centro Hospitalar de São João, Porto, Portugal
contact e-Mail address: anaasantos89@gmail.com
Introduction: Among the extraintestinal manifestations (EIM) related to 
inflammatory bowel disease (IBD), which occur in 15-40% of patients, the 
most prominent are those of osteoarticular spectrum, due to their high 
prevalence (30%) and impact in quality of life.
aims & Methods: With this study, the authors intended to evaluate the 
prevalence of osteoarticular manifestations (OAM) in patients undergoing 
biological therapy and the main factors associated with their development. 
Retrospective and unicentric study, with inclusion of patients followed in 
referral outpatient care of IBD, under anti-TNF at time of the study. De-
mographic characterization with determination of OAM [mechanical com-
plaints (MC), OAM secondary to therapy and IBD-related arthropathy (AD)] 
and the predictor factors related to their development.
results: A total of 422 patients were included [337 with Crohn’s disease 
(CD) and 85 with ulcerative colitis (UC)], with median age of 40 years (IQR 
29-50), 54% of female gender. The OAM prevalence was 23% (89% in DC). 
A higher prevalence of OAM was associated, with statistic significance, 
to female gender in ulcerative colitis (p=0.045) and to age higher than 
40 years in DC (p=0.018). MC were identified in 20% of cases and OAM 
secondary to therapy in 18% (15 osteopenia/osteoporosis and 2 cases of 
arthritis caused by IFX). Among AD’s patients, 56% presented manifesta-
tions of axial predominance (30% of ankylosing spondylitis, 21% of axial 
spondylarthritis related to IBD and 15% sacroileitis), 35% of peripheral 
spondylarthritis and 7% with a enthesopathic component. In 21%, the 
OAM occurred before IBD’s diagnosis. 
The absence of therapy with anti-TNF was risk factor for AD manifestations 
(p<0.001) and, in cases of DC, the higher rate of AD was associated, with 
statistic significance, to a clinical active disease when it appeared (p=0.001). 
The presence of OAM led to therapeutic changes in 86% of patients, the 
most leading to the initiation or dose optimization of anti-TNF.
conclusion: The OAM present higher prevalence in CD patients condition-
ing, frequently, changes in therapeutic strategy. The absence of anti-TNF 
therapeutic and, in CD, absence of clinical remission, was related to AD.
disclosure: Nothing to disclose 
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P1777 eLeMenTaL dIeT TheraPy PLays a sIgnIfIcanT rOLe In 
avOIdIng POsTOPeraTIve surgIcaL recurrence In PaTIenTs 
WITh crOhn’s dIsease In The era Of BIOLOgIcs
Shinozaki M., Takahashi R.
University of Tokyo, Surgery, Tokyo, Japan
contact e-Mail address: mshino@ims.u-tokyo.ac.jp
Introduction: Postoperative recurrence affects most patients with Crohn’s 
disease. Novel therapies have been introduced, including anti-tumour ne-
crosis factor-alpha agents, integrin antagonists, and endoscopic balloon 
dilatation. However, little is known about their efficacy in the long term.
aims & Methods: We aimed to clarify which therapies could decrease 
postoperative surgical recurrence in patients with Crohn’s disease. Seventy 
operations in 46 patients with Crohn’s disease were included in this retro-
spective study. Survival curves were created, and univariate and multivari-
ate analyses were performed.
results: Smokers were significantly more likely to develop recurrences 
(p=0.023). Patients who were administered anti-tumour necrosis factor-
alpha therapy had significantly better prognoses than those who did not 
receive it (p=0.028). Patients who underwent endoscopic balloon dilata-
tion procedures had significantly better prognoses (p=0.017). Immuno-
modulators were significantly more effective at preventing surgical recur-
rences (p=0.046). Patients who maintained an elemental diet (greater than 
900 kcal/day) had significantly better prognoses than those who did not or 
those whose diets were lower in quantity (p< 0.001). However, multivariate 
analysis indicated that the only significant factor for controlling postopera-
tive surgical recurrence was nutritional therapy (p=0.0058).
conclusion: Univariate analyses showed that smoking, anti-tumour necro-
sis factor-alpha therapy, immunomodulator therapy, endoscopic balloon 
dilatation therapy, and elemental diet therapy exerted significant effects 
on postoperative recurrence in patients with Crohn’s disease. However, the 
multivariate analysis revealed that only elemental diet therapy was sig-
nificantly associated with surgical recurrence rates. Elemental diet therapy 
can play a significant role in the management of Crohn’s disease even in 
the era of biological therapies.
disclosure: The author received grant support from Mitsubishi Tanabe 
Pharma Co. Ltd 
P1778 MeThOTrexaTe afTer anTI-Tnf-α faILure In crOhn’s 
dIsease: a reTrOsPecTIve serIes frOM The eneIda regIsTry. 
TeachIng an OLd dOg neW TrIcks?
Mesonero F.1, Castro-Poceiro J.2, Ricart E.2, Benítez J.M.3, Camps Aler B.4, 
Guardiola J.5, Iborra M.6, López-García A.7, Torres Rodríguez P.F.8, 
Esteve M.9, Tosca J.10, Bertoletti F.11, Almela P.12, Calvet X.13, Vera M.I.14, 
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Busquets Casals D.19, Hernandez Camba A.20, Rivero M.21, 
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Spain, 7Hospital del Mar, Barcelona, Spain, 8Hospital Universitari Germans 
Trias i Pujol, Aparell Digestiu, Badalona, Spain, 9Hospital Mutua Terrassa, 
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Universitario Canarias, Tenerife, Spain, 27Hospital Universitario de Torrejón, 
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Introduction: Methotrexate (MTX) is an inmmunomodulator that has 
shown efficacy in Crohn’s disease (CD). Its use is mainly recommended 
to maintain remission in patients with steroid-dependency and failure of, 
or intolerance to, thiopurines. Data on its use as monotherapy in patients 
with failure of anti-TNF-α drugs are limited.
aims & Methods: 
(1) To determine the short and long term efficacy of MTX monotherapy in 
CD patients with previous failure and/or intolerance to anti-TNF-α.
(2) To evaluate the safety profile in this scenario.
(3)To identify factors associated to short- and long-term efficacy.
Multicentre, observational, and retrospective study on the Spanish Na-
tional IBD Registry ENEIDA. Patients with CD who were treated with MTX 
for active disease, defined by Harvey-Bradshaw index (HB) ≥3, with previ-
ous failure and/or intolerance to at least one anti-TNF-α were included. 
Patients with MTX as part of a combined therapy regimen were excluded. 
Short-term results were evaluated between 12 and 16 weeks of therapy. 
Remission was defined as HB< 3, and response as a decrease of 3 points, 
at least, in the HB score, without achieving remission. Long-term success 
was defined as continuation on steroid-free monotherapy at the maximum 
follow-up. Adverse events were specifically registered.
results: 110 patients were included. Demographic and disease-related char-
acteristics are reflected in Table 1. A 77.2% had been exposed to thiopurines. 
All patients had received at least one anti-TNF-α, infliximab (IFX) in 73.6% 
and adalimumab (ADA) in 26.4%, 44.5% had received two anti-TNF-α (ADA 
and IFX), and 1.8% three anti-TNF-α (IFX, ADA, and certolizumab). 
Induction of MTX therapy was done with 25 mg in 80.9% of cases, and 
with SC injection in 93.6%. On induction, mean HB score was 6.6±3, and 
C-reactive protein (CRP) 12.2 ± 10 mg/L. Steroids were associated in 42.6% 
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of cases. In the short term analysis (week 12-16), percentages of remission, 
response, and failure, were 33.0, 31.1%, and 35.9%, respectively. Mean 
CRP at this point was 7.7 ± 6mg/L. Partial or complete steroid withdrawal 
was achieved in 96.3% at week 12-16. Long-term succes was 36.4% with 
a median therapy duration of 36 months (range 4-300). Long-term MTX 
withdrawal was necessary in 73.6%, due to failure (44.5%), adverse events 
(29.1%), or both. Adverse events were registered in 41.2% of cases, mainly 
digestive intolerance (15.5%), weakness/malaise (10.9%), and liver injury 
(7.3%). In 22.7%, these adverse events resulted in drug withdrawal. In the 
multivariate analysis non-smoking status (OR 1.56, CI 1.05-2.33), and the 
use of only one anti-TNF-α before MTX therapy (OR 1.25, CI 1,01-6,08) were 
factors significantly associated to short term remission/response. No pre-
dictors of long-term response could be identified.
Gender (M/F) 43/67 (39,1/60,9%)
Age (years) 47±14
Tobacco use (No/Yes/Former) 53/30/27 (48,1/27,2/24,5%)
Obesity (No/Yes)* 99/11 (90/10%)
Liver disease ( No/Yes )** 103/7 (93,6/6,4%)
Duration of disease (years) 16±10
Disease localization (L1/L2/L3/+L4) 41/22/47/29 (37,2/20/42,7/26,4%)
Disease behaviour (B1/B2/B3) 55/30/25 (50/27,3/22,7%)
Perianal disease ( No/Yes ) 62/48 (55,4/44,6%)
Previous surgery ( No/Yes ) 39/71 (35,5/64,5%)
[Table 1. Demographic and disease-related characteristics. *BMI>30,  
** viral hepatitis/steatosis/cirrhosis]
conclusion: MTX has an acceptable short-term efficacy and safety profile 
in a group of CD patients with previous anti-TNF-α failure or intolerance. 
Although treatment discontinuation due to lack of efficacy and/or side ef-
fects is frequent, a long-term therapeutic benefit is obtained in one third 
of patients.
disclosure: Nothing to disclose 
P1779 BIOLOgIc use In aduLT PaTIenTs neWLy dIagnOsed 
WITh uLceraTIve cOLITIs In The unITed sTaTes, 2010-2013 and 
2014-2016
D’Haens G.R.1, Naegeli A.2, Mahoui M.3, Morton S.3, Dong Y.3, Hunter T.2, 
Farrar M.2, Canavan J.3, Stefani-Hunyady D.4
1AMC Amsterdam Inflammatory Bowel Disease Centre, Amsterdam, 
Netherlands, 2Eli Lilly & Company, Global Patient Outcomes and Real World 
Evidence, Indianapolis, United States, 3Eli Lilly & Company, Indianapolis, 
United States, 4Eli Lilly & Company, Bio-Medicines, Greenwood, United States
contact e-Mail address: naegelian@lilly.com
Introduction: The objective of this research was to characterize treatment 
patterns and sequences of biologic initiation in adult patients newly di-
agnosed with Ulcerative Colitis (UC) in the United States in 2010-2013 and 
2014-2016.
aims & Methods: Adult (18+ years) patients with ≥2 UC diagnosis codes 
(ICD-9: 556.x; ICD-10:K51.x) from October 1, 2010 to September 30, 2016 
were included in this retrospective analysis of medical and pharmacy 
claims data from the IBM Marketscan Commercial, Medicaid, and Medi-
care-Supplemental Claims database. Patients were excluded if they were 
< 18 years old, had a Crohn’s disease (CD) diagnosis two years pre- or 
post-index, had a dual UC and CD diagnosis, or did not have treatment 
throughout the study period. Pathway visualization techniques and sub-
groups analyses were conducted for the 2 years post diagnosis to compare 
biologic use following first diagnosis during 2010-2013 and 2014-2016. 
Two-sample t-tests were conducted to compare continuous variables and 
two-sample proportion tests were used to compare categorical variables 
in two time periods of diagnosis.
results: A cohort of 7,794 UC patients were identified with 4,637 (59.5%) 
diagnosed with UC during 2010-13 and 3,157 (40.5%) diagnosed during 
2014-16. Overall, during both periods of diagnosis, patients were more 
likely to be female (55%). Patients diagnosed during 2014-16 tended to be 
younger when compared to 2010-13 (mean age at diagnosis: 49.2 vs. 46.2 
years; p< .00001). In general, the majority of patients initiated conventional 
treatment (aminosalicylates, immunomodulators, and/or corticosteroids) 
at the time of diagnosis (99%). 231 (5.0%) diagnosed 2010-13 and 304 
(9.6%) diagnosed 2014-16 initiated at least one biologic treatment during 
the 2 year follow-up. The median time to biologic treatment in the 2 years 
post diagnosis was 289 days for those diagnosed 2010-13 versus 223 days 
for those diagnosed during 2014-16 (p< 0.00001). On average, patients ini-
tiated biologic treatment 66 days earlier when receiving a UC diagnosis 
during 2014-16. Infliximab was more frequently identified as the first-line 
biologic in the 2 years post diagnosis for those diagnosed 2010-13, while 
adalimumab was the first-line biologic for those diagnosed 2014-16. How-
ever, pathway visualization Sankey diagrams illustrated limited switching 
from one biologic to another after initiation of biologic therapy during the 
2 years post diagnosis for 2010-13, with no predominant sequence identi-
fied. This trend remained for the 2014-16 cohort (data not shown).
characteristic:
diagnosis in 
2010-2013 
(n=4,637)
diagnosis in 
2014-2016 
(n=3,157)
P-value
Gender
Male; n (%) 2,064 (44.5%) 1,434 (45.4%) 0.427
Female; n (%) 2,573 (55.5%) 1,723 (54.6%) 0.427
Age (years); mean (standard deviation) 49.2 (15.8) 46.2 (16.5) <.00001
Treatment at Diagnosis
Conventional Treatment; n (%) 4,620 (99.8%) 3,137 (99.6%) 0.92
Biologic Treatment; n (%) 9 (0.2%) 14 (0.4%) 0.046
Time to Biologic Treatment (days)*
Median* (Q1, Q3) 289 ( 132, 495) 223 ( 89.5, 389) <.00001
Min-Max 0-715 0-727  
*Wilcoxon rank test, Q1=first quartile, Q3=third quartile, Min=Minimum; Max=Maximum
[Patient Demographics and Clinical Characteristics]
conclusion: Despite recent authorization of safe and effective biologic 
treatments for UC, updated clinical guidelines, and initiatives to treat pa-
tients more aggressively to delay disease progression, conventional treat-
ment is still more common at the time of diagnosis. Biologic use in UC 
remains limited; however, the time to biologic initiation after diagnosis 
is decreasing.
disclosure: Drs Naegeli, Mahoui, Morton, Dong, Hunter, Farrar, and Ste-
fani-Hunyadi are employees and stock holders of Eli Lilly and Company. 
P1780 BIOLOgIc use In aduLT PaTIenTs neWLy dIagnOsed 
WITh crOhn’s dIsease In The unITed sTaTes, 2010-2013 and 
2014-2016
D’Haens G.R.1, Naegeli A.2, Mahoui M.3, Morton S.3, Dong Y.3, Hunter T.2, 
Farrar M.2, Canavan J.3, Stefani-Hunyady D.4
1AMC Amsterdam Inflammatory Bowel Disease Centre, Amsterdam, 
Netherlands, 2Eli Lilly and Company, Global Patient Outcomes and 
Real World Evidence, Indianapolis, United States, 3Eli Lilly & Company, 
Indianapolis, United States, 4Eli Lilly and Co, Bio-Medicines, Greenwood, 
United States
contact e-Mail address: naegelian@lilly.com
Introduction: The objective of this research was to characterize treatment 
patterns and sequences of biologic initiation in adult patients newly di-
agnosed with Crohn’s disease (CD) in the United States in 2010-2013 and 
2014-2016.
aims & Methods: Adult (18+ years) patients with ≥2 CD diagnosis codes 
(ICD-9: 555.x; ICD-10:K50.x) from October 1, 2010 to September 30, 2016 
were included in this retrospective analysis of medical and pharmacy 
claims data from the IBM Marketscan Commercial, Medicaid, and Medi-
care-Supplemental Claims database. Patients were excluded if they were 
< 18 years old, had an Ulcerative Colitis (UC) diagnosis two years pre- or 
post-index, had a dual CD and UC diagnosis, or did not have treatment 
throughout the study period. Pathway visualization techniques and sub-
groups analyses were conducted for the 2 years post diagnosis to compare 
biologic use following first diagnosis during 2010-2013 and 2014-2016. 
Two-sample t-tests were conducted to compare continuous variables and 
two-sample proportion tests were used to compare categorical variables 
between two time periods of diagnosis.
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results: A cohort of 5,460 CD patients were identified with 3,219 (59.0%) 
diagnosed with CD during 2010-13 and 2,241 (41.0%) diagnosed during 
2014-16. Overall, during both periods of diagnosis, patients were more 
likely to be female (55%). Patients diagnosed during 2014-16 tended to be 
younger when compared to 2010-13 (mean age at diagnosis: 44.8 vs. 42.1 
years; p< .00001). In general, the majority of patients initiated conven-
tional treatment (aminosalicylates, immunomodulators, and/or corticoste-
roids) at the time of diagnosis (97%). 468 (14.6%) diagnosed 2010-13 and 
553 (24.7%) diagnosed 2014-16 initiated at least one biologic treatment 
during the 2 year follow-up. The median time to biologic treatment in the 
2 years post diagnosis was 139 days during 2010-13 versus 91 days during 
2014-16 (p< .00001). On average, patients initiated biologic treatment 48 
days earlier when receiving a CD diagnosis during 2014-16. Adalimumab 
was more frequently identified as the first-line biologic in the 2 years post 
diagnosis for those diagnosed 2010-13 and 2014-16. Pathway visualization 
Sankey diagrams illustrated limited switching from one biologic to another 
after initiation of biologic therapy during the 2 years post diagnosis for 
2010-13, with no predominant sequence identified. This trend remained for 
the 2014-16 cohort (data not shown).
characteristic: diagnosis in 2010-2013 (n=3,219)
diagnosis in 
2014-2016 (n=2,241) P-value
Gender
Male; n (%) 1,397 (43.4%) 1,048 (46.8%) 0.014
Female; n (%) 1,822 (56.6%) 1,193 (53.2%) 0.014
Age (years); mean (standard 
deviation)
44.8 (16.3) 42.1 (16.2) <.0001
Treatment at Diagnosis
Conventional Treatment; n (%) 3,128 (97.5%) 2,134 (95.4%) .0002
Biologic Treatment; n (%) 79 (2.5%) 103 (4.6%) .00001
Time to Biologic Treatment (days)
Median* (Q1, Q3) 139 ( 57, 316.2) 91 (42, 243) <.00001
Min-Max 0-728 0-723  
*Wilcoxon rank test, Q1=first quartile, Q3=third quartile, Min=Minimum; Max=Maximum
[Patient Demographics and Clinical Characteristics]
conclusion: Despite recent authorization of safe and effective biologic 
treatments for CD, updated clinical guidelines, and initiatives to treat pa-
tients more aggressively to delay disease progression, conventional treat-
ment is still more common at the time of diagnosis. Biologic use in CD 
remains limited; however, the time to biologic initiation after diagnosis 
is decreasing.
disclosure: Drs Naegeli, Mahoui, Morton, Dong, Hunter, Farrar, and Ste-
fani-Hunyadi are employees and stock holders of Eli Lilly and Company. 
P1781 TreaTMenT WITh ThIOPurInes In PaTIenTs WITh 
uLceraTIve cOLITIs. Is adherence a sIgnIfIcanT facTOr?
Capilla Lozano M.1, Gomez Medina C.1, Ballester Ferre M.P.2, 
Marti Aguado D.3, Bosca Watts M.M.4, Toscá Cuquerella J.5, 
Navarro Cortes P.6, Mora Miguel F.4, Minguez Pérez M.4
1Hospital Clínico Universitario de Valencia, Medicina Digestiva, Valencia, 
Spain, 2University Clinic Hospital of Valencia, Digestive Disease, Valencia, 
Spain, 3University Clinic Hospital of Valencia, Digestive, Valencia, Spain, 
4Hospital Clinico Universitario de Valencia, Valencia, Spain, 5Hospital Clinico 
Valencia, Valencia, Spain, 6Hospital Clinico Universitario de Valencia, 
valencia, Spain
contact e-Mail address: conchin.gome@gmail.com
Introduction: Thiopurines are drugs used as maintenance therapy in pa-
tients with ulcerative colitis (UC). There are dissimilar results regarding the 
relationship between adherence to treatment and risk of relapse.
aims & Methods: To evaluate the percentage of adherence to thiopurines, 
its repercussion in the evolution of the disease and the factors related to it.
Analytical, observational and retrospective study of patients with UC fol-
lowed at University Clinic Hospital of Valencia under treatment with thio-
purines from October 2017 to October 2018. Adult patients registered in the 
ENEIDA database in clinical remission at the beginning of the study were 
included. The adherence was evaluated with an electronic pharmaceutical 
prescription system (GAIA), considering adherence to the dispensation of 
≥80% of the prescribed medication. The study analyzed, according to the 
degree of adherence, clinical variables (age, gender, comorbidity, smok-
ing habit, disease extent, time of evolution, extraintestinal manifestations, 
number and severity of relapses) and therapeutic variables (number of 
tablets, dose, concomitant treatment).
results: Fourty-six patients with UC (67.4% males) were included with 
a median of 43 (IQR 32-55) years old. The adherence was of 74% and 
no correlation with fewer disease relapses was found. A lower dose of 
thiopurines was considered as a predictor of non-adherence. A tendency 
to higher risk of relapse was observed in the non-adherent group after 
the 30th week of follow-up in the Kaplan-Meier curve. Mesalazine and 
biologic therapy was prescribed in 74% and 24% of patients, respectively. 
The adherence to mesalazine correlates with the adherence to thiopurines.
variables nO adherence yes adherence p-value
Gender, n (%): Males // Females
6 (19,4) // 
6 (40)
25 (80,6) // 
9 (60)
0,135
Extraintestinal manifestations, n (%) 5 (31,2) 11 (68,8) 0,560
Adverse reaction to thiopurines, 
n (%)
5 (38,5) 8 (61,5) 0,230
Concomitant treatment related to 
IBD, n (%)
9 (25,7) 26 (74,3) 0,918
Concomitant treatment not related 
to IBD, n (%)
5 (26,3) 14 (73,7) 0,976
Comorbility, n (%) 6 (28,6) 15 (71,4) 0,725
Relapse, n (%) // Mild relapse, n (%) 
// Moderate/severe relapse, n (%)
5 (38,5) // 
2 (28,6) // 3 (50)
8 (61,5) // 
5 (71,4) // 3 (50)
0,230 // 
0,871 // 0,153
Dose/day (mg), x (sd) // No of 
tablets/day, x (sd)
90 (49) // 2 (1) 132 (51) // 3 (1) 0,015 // 0,050
Adherence to mesalazine, n (%) 0 (0) 20 (76,9) <0.001
[Results]
conclusion: The adherence to thiopurines evaluated by the electronic pre-
scription system was of 74%. No relation between adherence and number 
and severity of disease relapse was observed during one year follow-up. 
Dose and adherence to mesalazine were factors related to adherence to 
thiopurines. It may be necessary to extend the follow-up period.
disclosure: This abstract has been previously presented as a poster at a 
national scientific meeting, in the 22th anual meeting of the Spanish Gas-
troenterology Group (AEG). 
P1782 severe faTIgue Is cOMMOn and assOcIaTed WITh 
LOW quaLITy Of LIfe and WOrk PrOducTIvITy LOss In IBd: 
The WOrk-IBd sTudy
Van Gennep S.1, Evers S.W.1, de Boer N.K.2, Rietdijk S.T.3, Gielen M.E.4, 
Gecse K.B.1, Duijvestein M.1, Ponsioen C.Y.1, D’Haens G.R.1, de Boer 
A.G.E.M.5, Löwenberg M.1
1Amsterdam UMC, University of Amsterdam, Gastroenterology and 
Hepatology, Amsterdam, Netherlands, 2Amsterdam UMC, Vrije Universiteit 
Amsterdam, Gastroenterology and Hepatology, Amsterdam, Netherlands, 
3OLVG, Gastroenterology and Hepatology, Amsterdam, Netherlands, 
4Ziekenhuis Amstelland, Gastroenterology and Hepatology, Amstelveen, 
Netherlands, 5Amsterdam UMC, University of Amsterdam, Coronel Institute of 
Occupational Health, Amsterdam, Netherlands
contact e-Mail address: s.vangennep@amc.uva.nl
Introduction: More than 40% of inflammatory bowel disease (IBD) patients 
suffer from fatigue, even during quiescent disease. Associations have been 
reported between anti-TNF use and severe fatigue in IBD,1 which can be 
related to the mode of action, side-effect profile or indirectly to more se-
vere disease.
aims & Methods: One of the aims of the prospective WORK-IBD study was 
to determine the prevalence and burden of severe fatigue and identify 
predictors for severe fatigue in IBD. All Crohn’s disease (CD) and ulcerative 
colitis (UC) patients that attended the outpatient clinic of two non-academ-
ic and two academic hospitals between May 1st and August 31st 2017 were 
invited. Only (self-) employed patients were eligible to participate. Fatigue, 
quality of life, work productivity and disease activity were measured using 
the Multidimensional Fatigue Inventory (range 0-100), Short Inflammatory 
Bowel Disease Questionnaire (range 10-70), Work Productivity and Activity 
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Impairment questionnaire, patient-reported Harvey Bradshaw Index and 
Simple Clinical Colitis Activity Index, respectively. Severe fatigue was de-
fined as a general fatigue score above the 95th percentile of the general 
population adjusted for gender and age.2 Factors with p-value below 0.1 
in univariable analysis, or that were considered clinically relevant, were 
entered into multivariable logistic regression analysis using backward 
elimination (likelihood ratio).
results: In total, 1590 IBD patients were invited out of which 768 (48%) 
responded (119 not eligible, 86 declined participation), and 536 were 
included (58% female, 53% CD) with a median (IQR) age of 45 (33-53) 
years, respectively (table 1). Severe fatigue was reported in 252 patients 
(47%). Considering type of treatment, severe fatigue was reported in 42/113 
(37%) of patients receiving mesalamine (5-ASA), 51/112 (56%) receiving 
immunomodulators (thiopurines, methotrexate), 45/86 (52%) on anti-TNF 
monotherapy, 23/42 (55%) on anti-TNF combination therapy, 15/29 (52%) 
using vedolizumab, 12/16 (75%) using ustekinumab and in 64/138 (46%) 
of patients without maintenance treatment. Patients from academic cen-
ters were more likely to report severe fatigue compared to non-academic 
patients (53% vs 38%, p=0.001). Clinical disease activity (OR 3.6, 95% CI 
1.9-6.8) and arthralgia (OR 1.8, 95% CI 1.0-3.3) were independent risk 
factors for severe fatigue and patients treated with 5-ASA had a signifi-
cant lower risk to report severe fatigue (OR 0.3, 95% CI 0.1-0.8). Patients 
suffering from severe fatigue reported significantly lower quality of life 
(median (IQR) 50 (43-55) vs 60 (55-64), p<0.001) and significantly higher 
percentages work productivity loss (median (IQR) 30% (0-60) vs 0% (0-
10), p<0.001).
  Total (n=536)
no 
treatment 
(n=138)
5-asa 
(n=113)
Immuno-
modulator 
(n=112)
anti-Tnf 
(n=128)
vedoli-
zumab 
(n=29)
usteki-
numab 
(n=16)
crohn’s disease, 
n (%) 286 (53) 83 (60) 12 (11) 66 (59) 91 (71) 19 (66) 15 (94)
disease 
duration, 
median years 
(Iqr)
11 (5-20) 12 (6-21)
10 (4-
20)
11 (5-20) 12 (6-20) 14 (5-20) 11 (7-15)
Prior bowel 
resection, n (%) 143 (27) 57 (41) 3 (3) 26 (23) 40 (31) 7 (24) 10 (63)
disease activity, 
n (%) 122 (23) 28 (20) 17 (15) 28 (25) 32 (25) 7 (24) 10 (63)
arthralgia, 
n (%) 179 (34) 42 (30) 37 (33) 40 (36) 43 (34) 10 (35) 7 (44)
severe fatigue, 
n (%) 252 (47) 64 (46) 42 (37) 51 (46) 68 (53) 15 (52) 12 (75)
[Table 1. Baseline characteristics]
conclusion: In this large IBD cohort, 47% of patients reported severe fa-
tigue. Clinical disease activity and arthralgia were significantly associ-
ated with severe fatigue, whereas 5-ASA treatment was associated with 
a lower incidence. The latter may be due to the favorable safety profile 
or a mild disease course. In contrast to prior studies, no higher risk for 
severe fatigue was found for patients treated with anti-TNF. Severe fatigue 
was associated with reduced quality of life and higher percentage of work 
productivity loss.
references: 1. Williet N, Sarter H, Gower-Rousseau C, et al. Patient-re-
ported Outcomes in a French Nationwide Survey of Inflammatory Bowel 
Disease Patients. J Crohns Colitis. 2017;11(2):165-174. doi:10.1093/ecco-jcc/
jjw145. 2. Schwarz R, Krauss O, Hinz A. Fatigue in the general population. 
Onkologie. 2003;26(2):140-144. doi:10.1159/000069834.
disclosure: This work was sponsored by dr. Falk Pharma Benelux B.V. 
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Introduction: Therapeutic drug monitoring is being incorporated into ev-
eryday clinical management with anti-TNF therapy; however, measure-
ment of serum drug and antibody levels of vedolizumab (VDZ) is less clear 
to guide drug dosing in the clinical practice. According to all available 
data, serum trough levels alone seem to be inadequate to predict clinical 
response with VDZ therapy. At present, no data is available on the potential 
correlation between mucosal or fecal VDZ concentration and therapeutic 
response to VDZ.
aims & Methods: The aim of this study is to assess the correlation between 
serum, mucosal and fecal VDZ concentrations to get a better view on the 
pharmacokinetic-pharmacodynamic relationships of the drug in inflam-
matory bowel disease (IBD-Crohn’s disease [CD], ulcerative colitis [UC]) 
patients receiving maintenance therapy. 
Patients and methods: Patients with luminal CD and UC receiving main-
tenance VDZ therapy were enrolled in the study. Clinical disease activ-
ity was assessed, blood samples and fecal specimens were collected and 
colonoscopy with biopsy samples was performed in every patient. Biopsy 
samples were obtained from inflamed and uninflamed tissue from the co-
lon. Serum, mucosal and fecal VDZ levels were determined by ELISA assay.
results: Data of 26 patients (8 CD, 18 UC) have been available so far. The 
mean duration of VDZ therapy was 5.8 months. Seven patients were naive 
to biological therapy at induction. Twenty patients had endoscopic activity 
during colonoscopy. Mucosal drug level did not show difference between 
either samples obtained from the inactive vs. active part of the bowel 
(0.54 vs. 0.39 µg/g, p=0,28), or between samples obtained from patients 
with endoscopic activity vs. mucosal healing (0.44 vs. 0.86 µg/g, p=0.11). 
Similarly, median serum trough level did not differ significantly between 
patients with endoscopic activity and remission (31.96 µg/ml vs. 28.99 µg/
ml, p=0.3). However, median fecal concentration of VDZ was significantly 
lower in patients with endoscopic activity compared to those showing 
mucosal healing (0.22 µg/ml vs. 0.55 µg/ml, p< 0.001). Fecal drug level 
showed significant correlation with tissue drug levels obtained from both 
inflamed and uninflamed region of the colon (r=0.80, p=0.001 and r=0.78, 
p=0.0003), however no correlation was shown between serum and fecal 
and between serum and tissue drug levels.
conclusion: Our study would be the first that simultaneously examine se-
rum, mucosal and fecal concentrations of VDZ comparing with endoscopic 
activities. Our data suggest that determination of fecal drug concentra-
tion may be promising in the evaluation of endoscopic response to VDZ 
therapy and may help to identify a useful surrogate marker of tissue drug 
concentration.
disclosure: Nothing to disclose 
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P1784 safeTy and effIcacy Of endOscOPIc dILaTaTIOn 
Of sMaLL BOWeL crOhn’s dIsease sTrIcTures By 
BaLLOOn-assIsTed enTerOscOPy: a POOLed anaLysIs Of 
IndIvIduaL daTa frOM 219 PaTIenTs
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and Herpetology, Münster, Germany, 3Cleveland Clinic Foundation, Lerner 
Research Institute, Department of Quantitative Health Sciences, Cleveland, 
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Introduction: Strictures are a common complication of Crohn’s disease 
(CD). While colonoscopy has been proven suitable and effective for dila-
tion therapy of CD-associated strictures of the ileocecum, the published 
evidence on safety and efficacy of balloon-assisted enteroscopy (BAE) for 
balloon dilation therapy of CD strictures of the small intestine is scarce.
aims & Methods: In the present study we performed a pooled safety and 
efficacy analysis based on individual patient data. Therefore, a systematic 
literature review was performed to assess all relevant citations found in 
Embase, Medline and the Cochrane library regarding BAE used for EBD of 
small intestinal CD strictures. In addition, conference proceedings includ-
ing DDW, ECCO, UEGW, A-IBD, AGA and German Gastroenterology Con-
gress were screened for additional data. Study authors were contacted to 
provide individual patient data. Descriptive statistics were used to sum-
marize patients’ characteristics. Univariate cox proportional hazards re-
gression model was applied to find out possible risk factors for need for 
re-dilation and surgery. Backward model selection procedure was used 
and multi-variate cox model were built.
results: 19 publications with a total of 468 CD patients and 1194 performed 
dilation procedures were included. 25.1% of strictures were anastomotic 
strictures (74.9% de novo, respectively). Technical success rate was 88.1%, 
resulting in clinical efficacy in 78% of patients. Major complications de-
fined as perforation, bleeding or dilation-related surgery occurred in 3.7% 
of all procedures. During a mean follow-up period of 16 months, 45.7% of 
patients reported symptomatic recurrence, while 38.1% of patients needed 
to undergo re-dilation and 27.5% required surgical intervention.
Multivariate analysis of 219 individual patients identified a 73% higher haz-
ard of re-dilation in CD patients with clinical symptoms compared to as-
ymptomatic patients and a 40% lower hazard in patients with prestenotic 
dilation compared with patients with no prestenotic dilation. Additionally, 
increased CRP values at dilation (elevation of CRP per 0.1 increased the 
hazard for surgery by 8.6%) and inflamed mucosa at dilation (2.8 times 
increased hazard as compared with non-inflamed mucosa) were identified 
as risk factors for the need for surgery.
conclusion: Balloon-assisted enteroscopy for dilatation therapy of CD-
associated strictures of the small intestine possesses a high rate of short-
term technical and clinical success with acceptable complication rates. 
Main predictors for intermediate therapeutic failure are clinical symptoms, 
non-stenotic dilation, increased CRP values and mucosal inflammation at 
the time of dilation. Endoscopic dilation by BAE is a valuable alternative 
to surgery in selected patients with small bowel CD associated strictures.
disclosure: Nothing to disclose 
P1785 cOMParaTIve assessMenT Of fecaL MIcrOBIOTa 
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Introduction: For patients with non-responding or refractory to standard 
treatment ulcerative colitis (UC), tofacitinib and biologic agents pose an 
additional alternative. Emerging evidence suggest that fecal microbiota 
transplantation (FMT) can also induce remission of UC.
aims & Methods: We performed a systematic review and network meta-
analysis to compare FMT to current therapies with regard to safety and 
efficacy in induction of remission of UC. We searched Medline, Embase, 
CENTRAL and grey literature sources up to November 2018. We included 
randomized controlled trials (RCTs) in patients with active UC that com-
pared FMT, infliximab, adalimumab, golimumab, vedolizumab and tofaci-
tinib to each other or placebo as induction therapies. Efficacy outcomes 
included clinical remission, clinical response and endoscopic remission. 
Safety was assessed with the incidence of any adverse event (AE), serious 
AEs and infections. We conducted random-effects network meta-analysis 
and ranked treatments based on the surface under the cumulative rank-
ing (SUCRA) probabilities. We estimated Predictive intervals (PrIs), which 
indicate the interval within which the relative effect of a future study is 
expected to be, to facilitate interpretation of the results in the light of the 
magnitude of heterogeneity.
results: Twenty placebo-controlled trials (FMT 5 trials) with 4634 patients 
were included in the network meta-analysis. FMT was superior to placebo 
in clinical remission (OR 2.80; 95% CI 1.46-5.36) and response (OR 2.53; 
95% CI 1.52-4.23), however there was no difference in terms of endoscopic 
remission (OR 1.91; 95% CI 0.62-5.86). No indirect comparisons between 
FMT and licensed treatments reached statistical significance in any effi-
cacy outcome. Results remained stable when PrIs were applied. On SUCRA 
analysis, infliximab (SUCRA 0.94, 0.73 and 0.87) and tofacitinib (SUCRA 
0.79, 0.86 and 0.87) were ranked highest while adalimumab (SUCRA 0.28, 
0.25 and 0.28) was ranked lowest in terms of response, clinical and en-
doscopic remission, respectively. FMT (SUCRA 0.64, 0.60 and 0.53) had 
comparable SUCRA values with golimumab (SUCRA 0.45, 0.56 0.46) and 
vedolizumab (SUCRA 0.40, 0.49 and 0.46). Regarding safety, there was 
no increase in the rates of any AEs for FMT and licensed therapies (data 
on infliximab were not available) and no differences in indirect compari-
sons. Vedolizumab (SUCRA 0.78) was the safest option, followed by tofaci-
tinib (SUCRA 0.57). FMT (SUCRA 0.38) had comparable SUCRA values with 
adalimumab (SUCRA 0.38) and golimumab (SUCRA 0.49). Only tofacitinib 
increased the incidence of infections compared to placebo (OR 1.51; 95%CI 
1.05-2.19, SUCRA 0.06), but the risk was not retained when Prls were in-
cluded in the analysis. Based on SUCRAs, FMT (SUCRA 0.85) was safest 
in terms of infections followed by golimumab (SUCRA 0.55), adalimumab 
(SUCRA 0.52) and vedolizumab (SUCRA 0.49). There was no difference be-
tween treatments regarding incidence of serious AEs, however FMT was 
ranked lowest (SUCRA 0.10). Lack of efficacy data in FMT trials based on 
prior anti-TNF exposure precluded evidence synthesis separately for anti-
TNF naïve and anti-TNF experienced patients.
conclusion: Preliminary evidence suggest that FMT could be an alternative 
induction therapy for ulcerative colitis with comparable efficacy and safety 
to licensed pharmacological treatments. Nevertheless, due to the absence 
of head-to-head trials, the short duration of studies and the limited size 
of FMT trials (277 patients) conclusions must be interpreted with caution.
disclosure: Nothing to disclose 
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P1786 The ecOnOMIc Burden Of crOhn’s dIsease In eurOPe: 
fIndIngs frOM a sysTeMaTIc LITeraTure revIeW
Purser M.1, Bhaila R.2, Hartley L.2, Earnshaw S.1, Nag A.3
1RTI Health Solutions, Research Triangle Park, NC, United States, 2RTI 
Health Solutions, Manchester, United Kingdom, 3Shire, a Takeda Company, 
Lexington, MA, United States
contact e-Mail address: arpita.nag@takeda.com
Introduction: Crohn’s disease (CD) is an inflammatory bowel disease char-
acterized by chronic inflammation of the gut. As new treatments become 
available, analyses of the cost to healthcare systems, patients, and their 
caregivers incurred by CD are increasingly important. The aim of this sys-
tematic literature review (SLR) was to identify and summarize the costs 
and healthcare resource utilization associated with CD in Europe from a 
societal perspective.
aims & Methods: An SLR was conducted to identify studies reporting 
healthcare resource use and direct and indirect costs associated with 
CD, published in English from 1 January 2012 to 22 June 2018. Literature 
searches were conducted using MEDLINE, Embase, EconLit, and the Co-
chrane library databases. Conference abstracts from the past 2 years were 
reviewed, and bibliographic lists of relevant SLRs were interrogated. Study 
selection was guided by prespecified inclusion and exclusion criteria. Cur-
rency values were adjusted using purchase price parity values and infla-
tion data using EU28 values (OECD, 2019).
results: A total of 40 studies presenting resource use, productivity and/or 
cost data were identified. Twenty-seven studies reported healthcare re-
source use data, 23 studies assessed direct costs, and 15 studies estimated 
indirect costs/lost productivity, 3 of which specifically assessed caregiver 
economic burden. 
Various methodologies including prospective questionnaires, database 
claims analysis, surveys, observational studies, and randomized controlled 
trials were used to estimate the direct cost of CD. Medication use (n = 20) 
and hospitalizations (n = 15) were the most frequently reported resources. 
The proportion of patients hospitalized ranged from 9.3% in patients on 
a biologic to 66% in patients with perianal disease. In addition, the mean 
hospital length of stay ranged from 2 days reported for a patient popula-
tion in which only 14% of patients presented with active disease to 23 days 
in a study of patients with perianal disease. Total annual direct costs per 
patient varied widely across Europe, ranging from €4639 for a newly diag-
nosed patient population in Italy to €24 374 for a Spanish patient popula-
tion receiving 12 months of biologic treatment. 
Before the introduction of biologics, the main components of the direct 
cost of CD across European healthcare systems were related to surgery and 
hospitalizations: after the introduction of biologics, the main cost driver 
was that associated with anti-tumor necrosis factor (TNF) therapies. Indi-
rect costs such as productivity loss, sick leave, travel expenses, and out of 
pocket expenses contributed between €665 and €7591 per patient per year 
to the economic burden of CD.
conclusion: This systematic review indicates that the direct costs and 
healthcare resource use associated with CD present a considerable eco-
nomic burden in Europe. Although surgery and hospitalizations can have 
a substantial impact on costs, more recent studies show that the cost of 
biologics is now the main cost driver in CD patients across Europe.
disclosure: Medical writing support was provided by Emily Colbeck, of 
PharmaGenesis London, London, UK, and funded by Shire, a Takeda com-
pany. Molly Purser, Rikal Bhaila, Louise Hartley, and Stephanie Earnshaw 
are employees of RTI Health Solutions, an independent research organi-
zation, which received research funding from Shire, a Takeda company, 
for this and other studies and from other pharmaceutical companies that 
market drugs for the treatment of patients with Crohn’s disease and other 
medical conditions. Arpita Nag is an employee of Shire, a Takeda com-
pany. 
P1787 IMPrOveMenT Of syMPTOMs and quaLITy Of LIfe 
afTer rePeaTed faecaL MIcrOBIOTa TransPLanTaTIOn fOr 
TreaTMenT Of chrOnIc POuchITIs
Kousgaard S.1, Kirk K.F.2, Nielsen H.L.3, Thorlacius-Ussing O.4
1Aalborg University Hospital, Department of Gastrointestinal Surgery, 
Aalborg, Denmark, 2Aalborg University Hospital, Department of Infectious 
Diseases, Aalborg, Denmark, 3Aalborg University Hospital, Department 
of Clinical Microbiology, Aalborg, Denmark, 4Aalborg University Hospital, 
Department of Gastrointestinale Surgery, Aalborg, Denmark
contact e-Mail address: s.kousgaard@rn.dk
Introduction: Pouchitis is a common long-term complication after restor-
ative proctocolectomy with ileal pouch-anal anastomosis (IPAA) in the 
surgical treatment of Ulcerative Colitis (UC) (1). Many theories have been 
proposed, but the exact disease mechanism of pouchitis is still uncertain. 
Current evidence suggest that the gut microbiota could be a significant 
factor in the aetiology of pouchitis (2). During the last decades, interest in 
faecal microbiota transplantation (FMT) has grown rapidly. 
This intervention as a new ‘ecological’ therapy for several diseases includ-
ing chronic pouchitis. Studies have shown that FMT may restore the in-
testinal microbial balance in treated patients - re-establishing an almost 
normal intestinal microbial environment (3-4). However, evidence to use 
repeated FMT for treatment of chronic pouchitis is still lacking.
aims & Methods: To investigate the clinical effect of FMT in treatment of 
patients with chronic pouchitis, we performed a 2-week FMT treatment 
pilot study. The study was designed as an open-label cohort study with 
a 2-week intervention period and a 6-month follow-up period. Patients 
diagnosed with chronic pouchitis were included in the study. All patients 
were allocated to treatment with FMT delivered by enema daily for two 
consecutive weeks. FMT material was obtained from healthy faecal donors 
recruited from the Blood Bank and screened according to international 
guidelines (5). 
Disease severity was accessed before and after FMT using the Pouchi-
tis Disease Activity Index (PDAI) score. A PDAI score < 7 was considered 
equivalent to clinical remission. The clinical PDAI score (cPDAI) was used 
in the 6-month follow-up period. Quality of life was measured using the 
Short Inflammatory Bowel Disease Questionnaire (SIBDQ) before and af-
ter FMT.
results: Ten patients were included of whom one was excluded before 
the FMT intervention. Nine patients completed the 2-week FMT treatment 
period. At 30-day follow-up, 44% of the patients had clinical remission 
with a PDAI score < 7. A non-significant improvement of the PDAI score 
was found between inclusion and 30-day follow-up, mean 7.0 (SD 3.13) 
before FMT and mean 5.2 (SD 4.02) after FMT, p=0.81. The clinical effect 
lasted to end of follow-up at 6 months in 33% of the patients. The cPDAI 
score improved from mean 2.7 (SD 1.25) at inclusion to mean 0.7 (SD 0.47) 
at 6-month follow-up, p=0.07. The SIBDQ score showed a non-significant 
improvement between inclusion (mean 43.0 (SD 13.43)) and 30-day follow-
up (mean 48.0 (SD 8.37)), p=0.29.
conclusion: In this study, we found that FMT induced clinical remission in 
44% of patients with chronic pouchitis with improvement of symptoms 
and quality of life. Although our study showed no significant clinical re-
mission of pouchitis symptoms after FMT, we still believe that FMT can be 
a new treatment of chronic pouchitis. Several factors might influence the 
effect of FMT, such as the route used for FMT administration and dura-
tion of FMT treatment. Approaches in FMT treatment of chronic pouchitis 
need to be explored. This includes length of treatment, use of maintenance 
treatment, FMT donor-mix versus single donor, and if antimicrobial ther-
apy should be administered prior to FMT treatment. Finally, a randomized 
controlled study is required to examine the true role of FMT in treating 
chronic pouchitis.
references: (1) Hata K, Ishihara S, Nozawa H et al. Pouchitis after ileal 
pouch-anal anastomosis in ulcerative colitis: Diagnosis, management, 
risk factors, and incidence. Dig Endosc. 2017 Jan;29(1):26-34. doi: 10.1111/
den.12744. (2) Segal JP, Oke S, Hold GL et al. Systematic review: ileoanal 
pouch microbiota in health and disease. Aliment Pharmacol Ther. 2018 
Feb;47(4):466-477. doi: 10.1111/apt.14454. (3) Fang S, Kraft CS, Dhere T et al. 
Successful treatment of chronic Pouchitis utilizing fecal microbiota trans-
plantation (FMT): a case report. Int J Colorectal Dis. 2016 May;31(5):1093-
1094. doi: 10.1007/s00384-015-2428-y. (4) Stallmach A, Lange K, Buening 
J et al. Fecal Microbiota Transfer in Patients With Chronic Antibiotic-Re-
fractory Pouchitis. Am J Gastroenterol. 2016 Mar;111(3):441-3. doi: 10.1038/
ajg.2015.436. (5) Cammarota G, Ianiro G, Tilg H et al.; European FMT Work-
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ing Group. European consensus conference on faecal microbiota trans-
plantation in clinical practice. Gut. 2017 Apr;66(4):569-580. doi: 10.1136/
gutjnl-2016-313017.
disclosure: Nothing to disclose 
P1788 ecOnOMIc evaLuaTIOns Of BIOLOgIcaL TreaTMenTs 
fOr MOderaTe-TO-severe crOhn’s dIsease: fIndIngs frOM a 
sysTeMaTIc LITeraTure revIeW
Purser M.1, Bhaila R.2, Hartley L.2, Earnshaw S.1, Nag A.3
1RTI Health Solutions, Research Triangle Park, United States, 2RTI Health 
Solutions, Manchester, United Kingdom, 3Shire, a Takeda Company, 
Lexington, United States
contact e-Mail address: arpita.nag@takeda.com
Introduction: Moderate-to-severe Crohn’s disease (CD) is a chronic, pro-
gressive disease characterized by inflammation of the lining of the gut. 
Treatment options include targeted biological therapies such as tumor 
necrosis factor (TNF)-alpha inhibitors (e.g. infliximab, adalimumab) and 
anti-integrin and anti-IL-23 treatments (vedolizumab, ustekinumab). With 
increasing treatment options, understanding economic evaluations of 
different therapies is crucial to inform clinical practice. The aim of this 
systematic literature review (SLR) was to summarize published economic 
evaluation models of biologic treatments for CD in Europe.
aims & Methods: An SLR was conducted to identify studies (economic 
analyses, systematic literature reviews, meta-analyses, and health tech-
nology assessments [HTAs]) of biological therapies in patients with moder-
ate-to-severe CD, published in English from 1 January 2012 to 22 June 2018. 
Literature searches were performed in MEDLINE, Embase, EconLit, and the 
Cochrane library databases. Conference abstracts from the past 2 years 
were reviewed, along with key HTA websites. Bibliographic lists of relevant 
SLRs were also interrogated. Study selection was guided by prespecified 
inclusion and exclusion criteria.
results: Thirteen economic analyses were identified, of which 10 com-
pared biological treatment with biological and/or conventional therapy, 
1 compared biological treatment with surgery and 2 focused on clinical 
management of CD. Biologics considered included infliximab, infliximab 
biosimilar, adalimumab, vedolizumab, and ustekinumab. Ten analyses 
were performed from a health systems perspective while three studies 
presented data from a societal perspective. Economic models utilized in 
the studies included decision tree models, Markov models, or hybrid de-
cision tree-Markov approaches. The models were built around key end-
points of response and remission. Efficacy of first- and second-generation 
biologics when compared with one another was estimated primarily us-
ing network meta-analyses. The time horizon of analyses ranged from 48 
weeks to lifetime. Key health states considered include remission, mild 
disease, moderate/severe disease, surgery, and death. The value of sec-
ond-generation biologics (vedolizumab and ustekinumab) was examined 
separately in anti-TNF naïve and anti-TNF failure patient populations in 
five studies. These biologics were more cost effective in the anti-TNF fail-
ure population than the anti-TNF naïve group. Sequencing of biologics 
was considered in two analyses.
conclusion: Several modelling structures have been used to model CD us-
ing various time horizons. As treatment options for CD increase in Europe, 
economic evaluations comparing biologics to each other has become in-
creasingly important. In addition, as more treatments are approved, the 
impact of sequencing of biologics may need to be considered and may in 
turn dictate analyses of longer time horizons.
disclosure: Medical writing support was provided by Emily Colbeck, of 
PharmaGenesis London, London, UK, and funded by Shire, a Takeda com-
pany. Molly Purser, Rikal Bhaila, Louise Hartley, and Stephanie Earnshaw 
are employees of RTI Health Solutions, an independent research organi-
zation, which received research funding from Shire, a Takeda company, 
for this and other studies and from other pharmaceutical companies that 
market drugs for the treatment of patients with Crohn’s disease and other 
medical conditions. Arpita Nag is an employee of Shire, a Takeda company. 
P1789 cIrcuLaTIng cd8 α4β7+ MeMOry T ceLLs as earLy 
BIOMarkers Of reMIssIOn TO vedOLIzuMaB In uLceraTIve 
cOLITIs
González M.1, Lund Tiirikainen M.K.2, Lopez Garcia A.3, 
Murciano Gonzalo M.F.1, Abril Rodriguez L.1, Canillas Alaves L.1, 
de Jesús Gil C.2, Ruiz-Romeu E.2, Sans L.2, Santamaria-Babí L.F.2, 
Márquez Mosquera L.1
1Hospital del Mar, Gastroenterology, Barcelona, Spain, 2Parc Científic de 
Barcelona (PCB/UB). Universitat de Barcelona, Traslational Immunology, 
Barcelona, Spain, 3H.Sant Joan Despi-Moises Broggi, Gastroenterology, Sant 
Joan Despi, Spain
contact e-Mail address: mariagvivo@gmail.com
Introduction: Vedolizumab (VDZ) is a humanized monoclonal antibody 
targeting the α
4
β
7
 integrin us in ulcerative colitis (UC). So far, no VDZ 
response biomarker has been identified.
aims & Methods: aim: to assess whether baseline circulating CD4+ and CD8+ 
memory T lymphocytes subpopulations could be biomarkers of response 
to VDZ treatment in patients with UC.Prospective study, n=15 patients with 
active UC defined as Ulcerative Colitis Disease Activity Index (UCDAI) >3, 
Mayo endoscopic subscore >1 and fecal calprotectin >250 mcg/g. Treatment 
with VDZ (300mg iv) was scheduled as standard induction regime.
Peripheral blood samples were obtained before the first dose of VDZ. 
Purification of circulating memory T cells (CD45RO+) and simultaneous 
analysis of CD4+ and CD8+ lymphocytic subpopulations (α
4
β
7
+/-, HLA-DR+/-, 
IL23R+/-, CCR9+/-, IL17A+/-, IL-23R+/-, IL-9+/-, β
7
 +/-) by flow citometry were 
performed. 
Clinical response and remission, faecal calprotectin levels and Mayo 
endoscopic subscore were evaluated at week 14.
results: 8 females, median of age was 45 (IQR=32) years, disease extent 
(Montreal - E1: 2 patients, E2: 8 patients, E3: 5 patients), 7 severe colitis 
(UCDAI > 9). Most patients (14) had prior failure to antiTNF-α: primary 
non-response in 8 patients and loss of response in 6. 
Washout period were: 1 month for infliximab, 2 weeks for adalimumab. 
Vedolizumab treatment combined with steroids (prednisone 1 mg/kg/day 
PO) was started in 13 patients. 
At week 14: 10 patients achieved steroid-free clinical remission, 9 
patients had fecal calprotectin levels < 250mcg/g and 9 patients achieved 
biochemical and/or endoscopic remission (calprotectin levels < 250 mcg/g 
and/or Mayo endoscopic subscore < 1).
Patients with steroid-free clinical remission presented baseline absolute 
account of CD8 α4β7+ memory T cells significantly higher when compared 
with patients with no VDZ response (table 1). Patients with biochemical 
and/or endoscopic remission at week 14 presented baseline absolute 
account of CD8 α4β7+ T cells significantly higher and CD8 CCR9+ T cells 
significantly lower than non-responders. 
No differences were identified according to flare severity, the extent of 
disease or the type of antiTNF-α failure. No statistically differences were 
found in the other lymphocyte subpopulations included in the study.
Baseline lymphocytes 
(absolute account/ml)
cLInIcaL reMIssIOn 
14Wk
nOn cLInIcaL 
reMIssIOn 14Wk p value
CD4 394,47 327,66 0,026
CD8 α4β7+ 19,265 11,4 0,026
Baseline lymphocytes 
(absolute account/ml)
BIOCHEMICAL 
AND/OR ENDOSCOPIC 
REMISSION 14W
NON BIOCHEMICAL 
AND/OR ENDOSCOPIC 
REMISSION 14W
p value
CD8CCR9+ 0,33 1,12 0,041
CD8 α4β7+ 24,1 10,57 0,007
[Analysis of baseline T cells subpopulations]
conclusion: The absolute account of CD8 α4β7+ memory T cells before 
starting VDZ therapy could be an early biomarker of remission and 
therefore help us to select a subset of responders.
disclosure: Investigator Initiated Sponsored Research by Takeda 
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P1790 cOMBInaTIOn Of BIOMarkers refLecTIng TyPe Iv 
cOLLagen degradaTIOn and cITruLLInaTed vIMenTIn PredIcTs 
resPOnse TO adaLIMuMaB WITh hIgh dIagnOsTIc accuracy, In 
PaTIenTs WITh crOhn’s dIsease
Mortensen J.H.1, Karsdal M.A.1, Grønbæk H.2, Hvas C.L.2, Dige A.2, 
Manon-Jensen T.1
1Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, 2Aarhus 
University Hospital, Department of Hepatology and Gastroenterology, 
Aarhus, Denmark
contact e-Mail address: jhm@nordicbio.com
Introduction: In inflammatory bowel diseases (IBD), up to 40% of patients 
do not respond to biologic treatment, e.g. anti-TNFα antibodies. A person-
alized medicine approach may facilitate the best possible treatment option 
for IBD patients. Currently, no biomarkers have sufficient sensitivity to sep-
arate responders from non-responders within the first weeks of anti-TNFα 
therapy, which limits the personalized medicine approach for IBD patients.
aims & Methods: We investigated serum biomarkers that reflect basement 
membrane degradation (C4M: MMP mediated degradation of type IV col-
lagen) and citrullinated vimentin (VICM: activated macrophages), and their 
ability to predict response to anti-TNFα treatment in Crohn’s disease. 
This was a single-centre cohort study. We measured clinical responses 
to adalimumab at week 8 after treatment induction in 22 patients with 
Crohn’s disease, using the Harvey Bradshaw Index (HBI). Response was 
defined as clinical remission (HBI< 5) at week 8. ELISA was applied to 
quantify the degradation of type IV collagen (C4M) and macrophages ac-
tivity (VICM). Inflammation was estimated by C-reactive protein (CRP). The 
biomarkers were combined in a backwards multivariate regression model 
to increase the prediction value for non-response to anti-TNF.
results: At baseline, C4M serum levels was significantly higher in non-
responders compared with responders (AUC: 0.81 [CI: 0.58-1.00], p=0.027). 
VICM serum levels were not significantly different at baseline between 
responders and non-responders but was modulated in patients who re-
sponded to anti-TNF and was significantly lower at week 1 compared with 
non-responders (AUC=0.89 [CI: 0.69-1.00], p=0.007). CRP did not demon-
strate any predictive value at baseline (AUC=0.65 [CI:0.42-0.89], p=0.301) 
or week 1 (AUC=0.66 [CI: 0.38-0.94], p=0.282). C4M and VICM were in-
cluded in the final model. The combination of C4M and VICM increased 
the predicted value to identify patients that do not respond to anti-TNF 
treatment (AUC=0.94 [CI: 0.75-1.00], p=0.005), with an odds ratio of 22 
(CI: 2.70-313).
conclusion: The combination of baseline serum levels of C4M and week 
1 serum levels of VICM demonstrated high accuracy to predict who will 
respond to anti-TNFα treatment in Crohn’s disease, and was superior to 
CRP. Thus, baseline levels of C4M in combination with week 1 levels of 
VICM may be used to predict response to anti-TNF and may therefore aid 
in a more personalized treatment approach.
disclosure: JHM, MAK, and TMJ are full time employees at Nordic 
Bioscience. MAK and TMJ hold stocks in Nordic Bioscience. 
P1791 dIfference In cLInIcaL effIcacy and safeTy 
In crOhn’s dIsease PaTIenTs TreaTed WITh InfLIxIMaB 
accOrdIng TO TIMIng fOr addITIOn Of ThIOPurIne
Zeze K.1, Hirano A.1, Torisu T.1, Esaki M.2
1Kyushu University, Department of Medicine and Clinical Science, Fukuoka, 
Japan, 2Saga University Hospital, Department of Endoscopic Diagnostics and 
Therapeutics, Saga, Japan
contact e-Mail address: kzeze@intmed2.med.kyushu-u.ac.jp
Introduction: Although clinical efficacy of combination therapy with inflix-
imab (IFX) and thiopurine has been demonstrated in Crohn’s disease (CD), 
it remains uncertain when to add thiopurine in CD patients treated with 
IFX. The present study aimed to clarify appropriate timing for the addition 
of thiopurine in CD patients treated with IFX.
aims & Methods: We performed a retrospective analysis of CD patients 
treated with IFX as the first-line biologic during the period between June 
2002 and July 2018 at our institution. Patients were classified into early 
combination (EC) group and late combination (LC) group; EC group in-
cludes patients who were initiated thiopurine prior to IFX or simultane-
ously. LC group includes patients who were initiated IFX monotherapy or 
those who were added thiopurine after losing response to IFX. We then 
compared continuation rate of IFX between EC and LC groups using the 
Kaplan-Meier method and the log-rank test. We also compared adverse 
events (AEs) rates between the two groups.
results: A total of 176 patients were included in the present study [64% 
men, median age, 23 (10-75) years], and the mean observation period 
was 76.8 months [range; 1-182 months]. 49 patients were classified into EC 
group and 127 patients were into LC group. The mean observation period 
and CRP level at the start of IFX were not significantly different between 
the two groups (64 months vs. 71 months; p=0.61, 0.55 mg/dl vs. 0.47 mg/
dl; p=0.77). The mean period of taking thiopurine were significantly longer 
in EC group than LC group (53 months vs. 0 months; p< 0.0001). The cumu-
lative IFX continuation rates showed no significant difference between the 
two groups (p= 0.25). 19 patients (38.7%) in the EC group and 28 patients 
(22%) in the LC group experienced AEs, and the rate was significantly 
higher in the EC group compared to LC group (p= 0.03). Serious AEs in-
cluding pneumonia and pancreatitis requiring hospitalization were identi-
fied in 4 cases (8.2%) in the EC group, and 6 cases (4.7%) in the LC group, 
whereas the rate was not different between the two groups (p= 0.36).
conclusion: The addition of thiopurine after loss of response to IFX mono-
therapy might be an alternative to the early combination therapy in CD 
when considering safety profile during treatments, whereas more precise 
analysis with regard to disease control should be necessary.
disclosure: Nothing to disclose 
P1792 eOTaxIn-1 and MucOsaL eOsInOPhIL aBundance 
PredIcT TreaTMenT resPOnse TO vedOLIzuMaB In 
InfLaMMaTOry BOWeL dIsease
Gabriëls R.Y.1, Bourgonje A.R.1, von Martels J.Z.H.1, Trentadue G.1, 
Blokzijl T.1, van Dullemen H.M.1, Festen E.A.M.1, Visschedijk M.C.1, 
Weersma R.K.1, Kats-Ugurlu G.2, Faber K.N.3, Dijkstra G.1
1University Medical Center Groningen, Gastroenterology and Hepatology, 
Groningen, Netherlands, 2University Medical Center Groningen, Pathology 
and Medical Biology, Groningen, Netherlands, 3University Medical Center 
Groningen, Laboratory Medicine, Groningen, Netherlands
contact e-Mail address: r.y.gabriels@umcg.nl
Introduction: Vedolizumab, an antibody against α4β7-integrin capable of 
blocking immune cell migration across intestinal endothelia expressing 
MADCAM-1, is a second-line biological treatment for moderate-to-severe 
inflammatory bowel disease (IBD). Because of moderate response rates 
to this drug, there is an urgent need for predictive markers to identify pa-
tients who are likely to benefit from vedolizumab. Our aim was to explore 
the predictive value of selected serum inflammatory biomarkers regarding 
response to vedolizumab induction therapy.
aims & Methods: 76 IBD patients (Crohn’s disease (CD), n=33, ulcerative 
colitis (UC), n=43) completed vedolizumab induction therapy and 10 serum 
inflammatory biomarkers were quantified prior to vedolizumab treatment 
(CRP, SAA, TNF-α, IFN-γ, IL-6, IL-8, IL-10, IL-17A, eotaxin-1 and eotaxin-3). 
Eosinophils were quantified in serum and in non-inflamed colon tissue 
(numbers per High Power Field (HPF 0.24 mm²)) prior to treatment. Eo-
sinophil numbers were quantified up to 60/HPF and when ≥60 were set 
at 60. Clinical response was defined as a decrease of at least 3 points in 
the Harvey Bradshaw Index (HBI) for CD or Simple Clinical Colitis Activity 
Index (SCCAI) for UC.
results: Baseline serum eotaxin-1 levels were significantly higher in ve-
dolizumab responders, compared to primary non-responders (0.31 [0.22-
0.46] vs. 0.20 [0.16-0.29] ng/mL, P< 0.05). Doubling of baseline serum 
eotaxin-1 levels was significantly associated with increased odds of attain-
ing clinical response or remission at week 14 (adjusted OR: 3.28, P< 0.05). 
The final prediction model based on serum eotaxin-1 levels showed an 
adjusted area under the receiver operating characteristics curve (AuROC) 
of 0.81, with an optimally balanced cut-off value for serum eotaxin-1 >0.49 
ng/mL with a sensitivity of 75.0% and specificity of 76.7% (Youden’s index 
0.52). A significant inverse correlation was observed between serum eo-
taxin-1 levels and serum eosinophil count (P< 0.01). As eotaxin-1 regulates 
the migration of eosinophilic granulocytes into the intestinal mucosa, we 
also analyzed mucosal eosinophilic granulocyte abundance in a subset 
of 24 IBD patients (10 CD and 14 UC) prior to treatment. Baseline me-
dian eosinophil numbers in non-inflamed tissue were significantly higher 
in responders compared to non-responders (60 ± 12 vs. 25 ± 7.5 eosino-
phils/HPF, P< 0.001). Patients with >30 eosinophils/HPF achieved clinical 
response in 83.3% of cases (n=12), whereas only 8.3% of patients with 
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< 30 eosinophils showed therapy response (n=12). Preliminary analyses 
(in 15 patients) revealed a positive correlation between serum eotaxin-1 
and mucosal eosinophil abundance, though this was not significant yet in 
this small sub cohort. None of the other tested serum biomarkers showed 
significant predictive value for response or non-response to vedolizumab 
in this patient cohort.
conclusion: Serum eotaxin-1 and mucosal eosinophil abundance in non-
inflamed colon tissue are reliable predictors for vedolizumab response in 
IBD patients. Our findings await further validation in an independent pa-
tient cohort.
disclosure: Nothing to disclose 
P1793 azaThIOPrIne cO-MedIcaTIOn has nO IMPacT On 
vedOLIzuMaB PharMacOkIneTIcs
Kadleckova B.1, Polakovicova V.2, Lucenicova J.3, Mikus P.4, Zelinkova Z.5
1IBD Centre ASSIDUO, Gastroenterological, Bratislava, Slovakia, 2Gastro 
Centrum, Mytna, Bratislava, Slovakia, 3St Michael’s Hospital, Laboratory of 
Clinical Biochemistry&Haematology, Bratislava, Slovakia, 4Pharmaceutical 
Faculty of Comenius University, Bratislava, Slovakia, 5St Michael`s Hospital, 
Dpt of Gastroenterology, Bratislava, Slovakia
contact e-Mail address: zuzana.zelinkova@nsmas.sk
Introduction: It is now well established that response to anti-tumor ne-
crosis factor (antiTNF) biologics in inflammatory bowel disease (IBD) is 
dependent on their pharmacokinetics. Azathioprine (AZA) co-medication 
has been associated with higher rate of therapeutic levels of antiTNF bio-
logics. Vedolizumab (VDZ) has recently enriched the therapeutic options 
for IBD and the data on its pharmacokinetics, especially in the setting of 
AZA co-medication are scarce.
aims & Methods: Therefore, the aims of this study were first, to determine 
the association of vedolizumab trough levels with clinical response to ve-
dolizumab. Second, to analyze the impact of azathioprine co-medication 
on vedolizumab pharmacokinetics. 
All IBD patients treated with vedolizumab for at least 6 months in two 
referral IBD centra between September 2015 and October 2019 were in-
cluded. Sera were collected in a prospective manner from each patient 
prior the first maintenance infusion. VDZ levels were determined by ELISA 
(Ridascreen®, Biopharm) and the differences in VDZ levels between re-
sponders and non-responders as well as between patients with AZA co-
medication vs. patients on VDZ monotherapy were analyzed statistically.
results: In total, 42 IBD patients (28 with Crohn`s disease and 14 with 
ulcerative colitis) were included. There were 25 (59.5%) responders at 6 
months of the treatment. Responders had significantly higher VDZ levels 
compared with non-responders (respective means±SEM - 15.08±2.475 µg/
ml vs. 6.853±0.982 µg/ml; p=0.0118). The clinical response rate did not sig-
nificantly differ between patients with AZA co-medication and patients on 
VDZ monotherapy (67% vs. 55%, p=n.s.). There was no difference in VDZ 
levels between these two groups of patients (13.2±2.859 µmol/l among 
AZA users vs. 11±2.26 µmol/l in VDZ monotherapy group; p=n.s.).
conclusion: Clinical response to vedolizumab is associated with higher 
trough levels of vedolizumab during the maintenance phase of treatment. 
In contrast to antiTNF biologics, vedolizumab pharmacokinetics do not 
seem to be influenced by azathioprine co-medication.
disclosure: This study has been supported by a grant from Slovak Research 
Agency 
P1794 a french naTIOnWIde PrOsPecTIve sTudy Of 
InfLIxIMaB BIOsIMILar cT-P13 use In reaL LIfe (refLecT): 
a TWO-year fOLLOW-uP
Nancey S.1, Laharie D.2, Mammar N.3, Bouhnik Y.4
1CHU Lyon, Gastroenterology, Lyon, France, 2CHU Bordeaux-Hôpital Haut-
Lévêque, Gastroenterology, Pessac, France, 3Pfizer France, Medical Dept., Paris, 
France, 4CHU Beaujon, Gastroenterology- IBD and Nutrition, Clichy, France
contact e-Mail address: yoram.bouhnik@bjn.aphp.fr
Introduction: Reflect study has been carried out to assess in real life the 
use of CT-P13, the first monoclonal antibody biosimilar to infliximab (IFX) 
approved in France. Long-term real-life data on CT-P13 use are limited in 
patients (pts) suffering from Inflammatory bowel diseases and rheumatic 
diseases.
aims & Methods: Reflect is a multicenter, prospective, observational study 
conducted in France which aims to describe characteristics of pts’ receiv-
ing CT-P13 and to assess safety and effectiveness in real-life conditions. 
Pts (age ≥ 6 years) with Crohn’s disease (CD), ulcerative colitis (UC) and 
rheumatic diseases treated with CT-P13 were eligible for enrolment, in-
cluding IFX naive pts (IFXn) or those having switched from IFX originator 
to CT-P13 (IFXs). Complementary data after a two-year follow-up period 
in pts suffering from CD and UC using descriptive statistical analyses are 
presented here.
results: From 3rd October 2018 to 31st January 2019, of the 1321 included pts, 
680 pts with inflammatory bowel disease were analyzed in the present sub 
analysis [480 CD pts (48.3% males; mean age: 37.1 ± 14.1 years; median 
disease duration: 6.9 years) and 200 UC pts (54.5%; 41.2 ± 17.5 years; 5.4 
years)]. Previous biologics other than IFX were taken by 40,3% of CD and 
41,8% of UC pts. At baseline, a minority of pts (21.8% of CD and 18.5% of 
UC) have been switched from the IFX originator to CT-P13; more pts have 
an active disease in IFXn 79,5% for UC and 52,2% of CD comparing to 
IFXs pts 37.5% and 15,4% respectively (p=0.002 and p< 0.001). In UC pts, 
median Mayo score were 7.5 and 1.5 in IFXn and IFXs pts at baseline and, 
it decreased by 3 and 5 points at 12 and 24 months in IFXn pts. In CD pts, 
median Harvey-Bradshaw Index (HBI) were 4 and 1 in IFXn and IFXs pts 
respectively and, it decreased by 2 and 1 points in at 12 and 24 months IFXn 
pts. In IFXs pts, there was no change in both UC and CD median disease ac-
tivity scores at 12 and 24 months except for the HBI which increased slightly 
at 24 months by 1 point. The treatment with CT-P13 has been withdrawn 
due to treatment failure or safety reason in 5,6 % of CD pts and 12,7 % UC 
pts in IFXn pts and in 2,1% and 2,9% of IFXs pts. 
conclusion: The two years follow-up data suggest that CT-P13 was effective 
in inducing and maintaining remission in CD and UC in both naive and 
switched patients. This real-life study did not identify new safety concerns.
disclosure: The authors disclose the following: Stephane Nancey has re-
ceived board or lectures fees from AbbVie, Ferring, Janssen, MSD,Novartis, 
Pfizer, Takeda, Tillots, HAC Pharma, and Norgine; David Laharie has re-
ceived board or lectures fees from AbbVie, Cel-gene, Ferring, Janssen, 
MSD, Novartis, Pfizer, Roche, and Takeda; Nadir Mammar is an employee 
of Pfizer France; Yoram Bouhnik: lecture and consulting fees for Abbvie, 
Bio-garan, Boehringer Ingelheim, CTMA, Ferring, Gilead, Hospira, ICON, 
InceptionIBD, Janssen, Lilly, Mayoli Spindler, Merck, MSD, Norgine, Pfizer, 
RobartsClinical Trials, Roche, Sanofi, Shire, Takeda, UCB, Vifor Pharma. 
P1795 reaL LIfe exPerIence Of fIrsT LIne anTI-Tnf In 
crOhn’s dIsease PaTIenTs In sPaIn: dO We have daTa TO 
chOOse BeTWeen InfLIxIMaB and adaLIMuMaB?
Marín-Jiménez I.1, Bastida G.2, Fores A.3, Argüelles-Arias F.4, Tagarro I.5, 
Fernandez A.5, Montoto Otero C.5, Aguas M.6, Ferreiro Iglesias R.7, 
Merino O.8, Santos Fernández J.9, Cortes X.10, Mesonero Gismero F.11, 
Barreiro de Acosta M.12
1Hospital Gregorio Marañón, Gastroenterology, Madrid, Spain, 2Hospital La 
Fe, Valencia, Spain, 3Hospital General de Castelló, Castellón, Spain, 4HUV 
Macarena, UGC DIGESTIVO, Sevilla, Spain, 5Takeda Farmaceutica España, 
Madrid, Spain, 6La Fe Universitary and Politecnic Hospital, Gastroenterology 
Unit, Valencia, Spain, 7University Hospital of Santiago de Compostela, 
Santiago de Compostela, Spain, 8Cruces, Bilbao, Spain, 9Rio Hortega, 
Gastroenterology, Valladolid, Spain, 10Hospital of Sagunto, Sagunto, Spain, 
11Hospital Ramon y Cajal, Gastroenterology, Los Santos de la Humosa, Spain, 
12University Hospital of Santiago, Gastroenterology, Santiago de Compostela, 
Spain
contact e-Mail address: drnachomarin@hotmail.com
Introduction: Anti-TNFs represent a key treatment strategy for the manage-
ment of IBD. However, it would be important to have more data about their 
use with the aim of facilitating the right choice in clinical practice. One of 
the aims of this study was to learn about the patterns of use of two anti-
TNFs, adalimumab and infliximab, when used in biologic-naïve patients 
for the treatment of Crohn’s disease (CD).
aims & Methods: This was a retrospective, observational study, conducted 
in 24 hospitals in Spain. IBD patients who started first anti-TNF treatment 
between June 2011 and June 2013 were included consecutively in the par-
ticipating centres. Data about anti-TNF management were collected. Ka-
plan Meier analyses were used to evaluate time to treatment intensifica-
tion and time to discontinuation in CD with adalimumab and infliximab. 
Data are presented descriptively
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results: One hundred and ninety-four CD patients were included (n=85 
treated with infliximab and n=109 treated with adalimumab). Median age 
was 43.0 years (range: 20.0-74.0) and most patients presented ileum and 
colon (L3=44.6%) or terminal ileum location (L1=37.3%). The most com-
mon disease behaviour was inflammatory (B1=44.6%). Median follow up 
time (from treatment initiation until informed consent signed) was 59.7 
(range: 43.5 - 76.2) and 60.2 (range: 45.3 - 74.9) months for adalimumab 
and infliximab respectively. 
Dose intensification was recorded in 29.4% of patients treated with adali-
mumab and 28.2% of patients treated with infliximab. Median time to 
first dose intensification was similar with adalimumab, 15.1 months (range 
1.3-61.8) and infliximab, 14.1 months (range 0.2-59.5).
Regarding treatment discontinuation, it occurred in 56.0% of patients 
treated with adalimumab, and in 63.5% with infliximab. Median time to 
treatment discontinuation was 27.4 months (range 0.9-66.9) with adalim-
umab, and 23.0 months with infliximab (range 0.0-58.9).
Concomitant use of corticosteroids at any time during maintenance was 
similar with adalimumab (31.2%) compared with infliximab (28.2%) being 
the mean number of cycles needed was similar (adalimumab 1.5, SD 0.8 vs 
infliximab 1.2, SD 0.5). The use of immunosuppressants at any time during 
maintenance was similar among the two products (adalimumab: 60.5% 
vs infliximab: 76.5%) being the mean number of required cycles was also 
comparable (adalimumab 1.3, SD 0.9 vs infliximab 2.2, SD 8.4).
conclusion: Similar proportions of patients with CD received dose inten-
sification with infliximab and adalimumab, and the discontinuation rates 
with both anti-TNFs were also similar. 
Dose intensification with both anti-TNFs was required in around one in 
every three patients, and after a similar median time (slightly longer than 
1 year).
More than half of patients treated with adalimumab and infliximab discon-
tinued treatment during the follow-up, and this occurred after a compa-
rable median time (slightly longer than 2 years).
Although a significant proportion of patients required concomitant use of 
corticosteroids and/or immunosuppressants, the average number of re-
quired cycles was low. 
Despite the common use of anti-TNFs as the first biologic in CD, we have 
not found any major difference between adalimumab and infliximab that 
could lead to a preferred treatment option.
disclosure: VERNE Study has been sponsored by Takeda Farmacéutica Es-
paña 
P1796 TOfacITInIB InducTIOn effIcIency and InTraceLLuLar 
cyTOkIne dynaMIcs In uLceraTIve cOLITIs: resuLTs frOM 
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Machkova N.1, Hruba V.1, Mitrova K.1, Vasatko M.1, Lukas M.1,2
1ISCARE I.V.F. a.s., IBD Clinical and Research Center, Prague, Czech 
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Medicine, Prague, Czech Republic, 3First Faculty of Medicine, Charles 
University and Military University Hospital, Department of Internal Medicine, 
Prague, Czech Republic, 4First Faculty of Medicine, Charles University and 
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Republic
contact e-Mail address: martin.kolar@gmail.com
Introduction: Tofacitinib is an oral JAK inhibitor with intracellular mecha-
nism of action, approved for the treatment of ulcerative colitis (UC). Its 
efficiency was proven in registration trials, however data from clinical 
practice are insufficient. Our aim was to evaluate response to tofacitinib 
after 8 weeks in UC patients, and to assess potential predictors of response 
including early cytokine production shifts.
aims & Methods: Data from consecutive UC patients who started tofacitinib 
10 mg b.i.d. between January and April 2019 were evaluated. Disease ac-
tivity was assessed by Mayo score including endoscopic Mayo at baseline 
and week 8 together with C-reactive protein (CRP) and fecal calprotectin 
(FC). Production of IL-4, IL-10, IL-17, TNFα and IFNγ in T-helper cells was 
determined at baseline and week 4 by flow cytometry after lymphocyte 
activation. 
At week 8, patients with total Mayo 0-5 with endoscopic subscore 0-1 
(corresponding to mucosal healing) were considered responders. Adverse 
events were registered at every visit (weeks 2, 4 and 8).
results: 24 patients (41.7% males, 58.3% females), mean age 35.3±11.8 
years were included. Mean disease duration was 8.3±5.2 years. In median, 
the patients were previously treated with 2 biologic agents, however, 25% 
of the patients were naive to any biologic therapy. Systemic corticosteroids 
were present in 41.7% patients at baseline and no patient had concomi-
tant biologic or other immunosuppressive therapy. At week 8, 52.9% of 
patients responded to therapy. Total Mayo decreased in responders from 
mean 5.9±3.5 to 1.1±1.3 (p=0.01), while in nonresponders it changed from 
8.0±2.5 to 8.9±2.1 (p=0.86). Endoscopic subscore decreased from 2.0±1.0 
to 0.6±0.7 (p=0.02) in responders, however remained stationary in non-
responders (2.9). CRP and FC dropped significantly in responders (6.7±6.2 
vs. 2.0±2.2 mg/L, p=0.04; 1195±1189 vs. 578±654 µg/g, p=0.05), but not in 
nonresponders. The responding and nonresponding groups differed sig-
nificantly in baseline triglycerides, which were higher in nonresponders. 
Other baseline parameters were comparable including corticotherapy, 
previous biologic therapy, disease duration and laboratory values, how-
ever, nonresponders tended to have more active disease at baseline and 
there were more females in the responding group (62.5% vs. 18.2%, 
p=0.07). Significant difference was observed in shifts of production of cy-
tokines IL-4 and IL-10 in T-helper cells. In responders, there was a sig-
nificant decrease in IL-4 and no change in IL-10, while in nonresponders, 
there was no change in IL-4 and significant decrease in IL-10. Interestingly, 
there was also a significant increase of intracellular TNFα in all patients. 
Tofacitinib was stopped in 23.5% of patients at week 8 due to insufficient 
response. Two patients reported headaches after treatment initiation and 
single events of CMV colitis, C. diff. colitis and oral candidiasis occurred.
conclusion: Tofacitinib was efficient in inducing clinical response with mu-
cosal healing in about 50% of UC patients after 8 weeks of therapy in clini-
cal practice. There was no clear baseline predictor of response, however, 
considering limited sample, there was also no indication of even multiple 
biologics failure negatively affecting response. Tofacitinib might thus be 
an option in respective patients. Preliminary results of cytokine dynamics 
suggest early IL-4 decrease as a potential biomarker of response, warrant-
ing further investigation.
disclosure: Nothing to disclose 
P1797 MadcaM1 exPressIOn Is sTaBLe OverTIMe and Is nOT 
InfLuenced By IMMune suPPressIve MedIcaTIOn
Podmanicky D.1, Berakova K.2, Kadleckova B.3, Zelinkova Z.4
1St Michael`s Hospital, Dept. of Surgery, Bratislava, Slovakia, 2Martinske 
Biopticke Centrum, Pathology, Zilina, Slovakia, 3IBD Centre ASSIDUO, 
Gastroenterological, Bratislava, Slovakia, 4St Michael`s Hospital, Dept. of 
Gastroenterology, Bratislava, Slovakia
contact e-Mail address: zuzana.zelinkova@nsmas.sk
Introduction: Approximately one third of inflammatory bowel disease (IBD) 
patients are primary non-responders to vedolizumab, a monoclonal anti-
body against α4β7 integrin receptor. Activated lymphocytes are homing to 
the gut mucosa through binding to mucosal vascular adressin cell adhe-
sion molecule 1 (MAdCAM1) localised on the intestinal endothelial cells. 
MAdCAM1 expression is subject to great interindividual variability which 
may impact the efficacy of vedolizumab. If stable overtime decreased or 
absent MAdCAM1 expression might be one of the determinants of primary 
non-response to vedolizumab.
aims & Methods: The aim of this study was thus to determine the stabil-
ity of MAdCAM1 expression on intestinal endothelial cells of IBD patients 
overtime and the influence of immune suppressive therapy on this expres-
sion. 
From all IBD patients who underwent bowel resection in one referral cen-
ter between January 2016 and March 2019 the resection specimens were 
randomly selected for assessment of MAdCAM1 expression in lamina pro-
pria endothelial vessels. The expression was determined by immunohisto-
chemistry and was arbitrarily assigned into three categories: negative, low 
and high (0%, up to 30% and above 30% of MAdCAM1 positive lamina 
propria vessels, respectively). For patients with serial specimens, resection 
or biopsies, the changes in MAdCAM1 expression overtime were assessed. 
The medication used in the last 30 days before resection was noted and 
the differences between the respective groups according to MAdCAM1 ex-
pression were analyzed.
results: There were in total 112 resections performed, out of which 52 re-
section specimens (38, 73% with Crohn`s disease, 14, 27% with ulcerative 
colitis; 48% of males) were randomly selected for MAdCAM1 expression 
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assessment. There were 6 pts (12%) with negative MAdCAM1 expression, 
10 (19%) had low and 36 (69%) had high MAdCAM1 expression. There 
were no differences in rates of respective immune suppressive therapies 
used preceding the surgery; the systemic steroids, azathioprine and bio-
logics were equally distributed among all three groups. 
For fifteen patients, serial specimens were available. Among these pa-
tients, there were 11 patients with high MAdCAM1 expression and 4 with 
low expression. All patients with high MAdCAM1 expression had concor-
dant levels of expression overtime. From four patients with low MAdCAM1 
expression, one patient had negative expression in one and low expression 
in a second specimen, other three had low MAdCAM1 expression in all 
serial specimens.
conclusion: One fifth of IBD patients do not express or have low expression 
of MAdCAM1. The expression of MAdCAM1 is stable overtime and is not in-
fluenced by immune suppressive medication. Further studies are needed 
to determine whether this low MAdCAM1 expression might underly the 
primary non-response to vedolizumab.
disclosure: ZZ received lecture fees from Takeda. 
P1798 ManageMenT Of anTI-Tnf anTIBOdy TheraPy fOr 
LOng-TerM reMIssIOn Of crOhn’s dIsease
Kitamura K., Okafuji H., Matsukawa H., Seishima J., Miyazawa M., 
Asahina Y., Hayashi T., Iida N., Takatori H., Kaneko S.
Kanazawa University, Dept of Gastroenterology, Kanazawa, Japan
contact e-Mail address: kazuyak2010@gmail.com
Introduction: To maintain the long-term remission of Crohn’s disease, it is 
important to sustain the effects of anti-tumor necrosis factor (TNF) anti-
body therapy. Here we examined risk factors related to primary or second-
ary failure of anti-TNF therapy.
aims & Methods: We analyzed 127 patients with Crohn’s disease who treat-
ed with anti-TNF antibody as maintenance therapy at our hospital, and 
the frequency of primary as well as secondary failure of anti-TNF antibody 
therapy was determined. In addition, factors related to primary or second-
ary failure during the treatment were examined retrospectively.
results: Among subjects, 100 patients were treated with infliximab (IFX) 
and 27 patients were treated with adalimumab (ADA) as first biologics. 
Primary failure was observed in 6 patients (6%) treated with IFX and 3 
patients (11%) treated with ADA, with no differences among the drugs. We 
further examined 118 patients excluding primary failure, secondary failure 
was observed in 53 patients (56%) treated with IFX and 3 patients (13%) 
treated with ADA. Thiopurines were administered in 62 patients (66%) 
treated with IFX and 15 patients (63%) treated with ADA. The cumulative 
rate of secondary failure was 5% for 1 year, 28% for 3 years, and 47% 
for 5 years. We next examined risk factors related to secondary failure by 
Kaplan-Meier method and log-rank test. Thiopurine administration prior 
to anti-TNF antibody (p = 0.01) and C-reactive protein (CRP) less than 0.3 
mg/dl at the start of treatment (p = 0.02) showed significantly longer prog-
nosis of primary therapy. In multivariate analysis by proportional hazards 
model, the time to secondary failure was significantly longer in the cases 
with prior administration of thiopurine (p = 0.03), whose hazard ratio was 
3.3. Finally, 55 cases were examined whether the single nucleotide poly-
morphism of Fcγ receptor could be a predictor of primary or secondary 
failure of anti-TNF therapy. The frequency of primary failure of IFX was 
significantly higher in the cases with single nucleotide polymorphisms of 
FCGR2A and FCGR3A (p = 0.006).
conclusion: Continuation of primary treatment is important for maintain-
ing long-term remission of Crohn’s disease, and prior administration of 
thiopurine was considered to be useful to avoid secondary failure of an-
ti-TNF therapy. In addition, it has been suggested that single nucleotide 
polymorphism of Fcγ receptor may be a predictor to IFX primary failure.
disclosure: Nothing to disclose 
P1799 The MeThOdOLOgy, feasIBILITy and safeTy Of 
cOLOnIc TransendOscOPIc enTeraL TuBIng: a MuLTIcenTer, 
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Wen Q.1, Cui B.1, Li P.1, Zhang J.1, Wu X.1, Tu H.2, Yuan Y.3, Zhang F.1
1The Second Affiliated Hospital of Nanjing Medical University, Medical Center 
for Digestive Diseases, Nanjing, China, 2Hubei Provincial Hospital of TCM, 
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Introduction: Colonic transendoscopic enteral tubing (TET) is a novel, safe 
and quick technology for microbiota transplantation (MT) and whole co-
lon administration. During the TET procedure, this technique needs insert 
colonoscope twice, the first time is for inserting the TET tube，the second 
time is for affixing the TET tube to the intestinal wall using titanium clips. 
However, it is difficult to find the cavity during the second time after insert-
ed tube for some patients because of the gather of colonic folds and acute 
angle of colonic cavity caused by the TET tube pulling. It is well known that 
cap assisted colonoscope is easier to flatten the haustral folds and improve 
mucosal exposure. Here we establish the hypothesis that using cap as-
sisted colonoscope can decrease the second cecal intubation time which 
not only improve work efficiency, but also save procedure time.
aims & Methods: We designed a prospective multicenter, randomized con-
trolled trial to compare the effect of with or without cap assisted colonos-
copy for the second insertion on colonic TET procedure in order to perform 
the colonic TET faster and more convenient. All subjects who underwent 
colonic TET were included at three centers in China from August 2018 
to March 2019. Subjects were randomly assigned to cap assisted group 
(n=105) and non-cap assisted group (n=106). The primary outcome was the 
second cecal intubation time. Secondary outcomes included TET procedure 
time, success rate, single titanium clip fixation time, retaining time of TET 
tube, maximum insertion pain score and all related adverse events (AEs).
results: Baseline characteristics were comparable between the two groups 
(P>0.05). The TET tubes were used in 50 patients for MT and whole colon 
administration, 127 patients for MT, and 6 healthy volunteers for sampling. 
The success rate of TET procedure was 100% in two groups. The median 
second cecal intubation time in the cap assisted group was shorter in com-
parison with non-cap assisted group (2.6 (IQR: 1.7-3.4) min vs 3.0 (IQR: 
2.0-4.1) min, P=0.019). The difference of mean second cecal intubation 
time was more obvious in two groups among patients with constipation 
(cap vs non-cap: 2.9±1.2 min vs 4.0±2.0 min, P=0.017). The mean second 
cecal intubation time in cap assisted group was shorter than that of non-
cap assisted group among patients with ulcerative colitis, however, there 
was no statistical difference (2.5±1.2 min vs 3.2±2.1 min, P= 0.137). The 
median TET procedure time was shorter in cap assisted group, but there 
was no significant difference between the groups (8.9 (IQR 7.5-11.9) min vs 
9.1 (IQR 7.0-10.9) min, P=0.352). The median single titanium clip fixation 
time was also no significant difference between the groups (1.2 (IQR 0.9-
1.5) min vs 1.2 (IQR 1.0-1.4) min, P=0.777). Their maximum insertion pain 
scores were lower in cap assisted group, but there was no significant dif-
ference (4.6±2.6 vs 5.2±1.9, P=0.573). 3 subjects had anal discomfort and 1 
subject had anal pain in cap assisted group, and 1 subject had anal pain 
in non-cap assisted group after TET. AEs were no significant difference 
between the groups (4.5% vs 1.0%, P=0.201). No severe AEs was observed 
during and after TET.
conclusion: This study confirms that cap assisted colonoscopy for TET pro-
cedure can shorten the second cecal intubation time, and is a safe and ef-
fective method. Therefore, it is recommended to insert colonoscope in the 
second time with cap assisted in TET procedure to improve work efficiency 
and reduce procedure time, especially for patients with constipation.
references: [1]Peng Z, Xiang J, He Z, et al. Colonic transendoscopic enteral 
tubing: A novel way of transplanting fecal microbiota[J]. Endosc Int Open, 
2016, 4(6): E610-3. [2]Zhang F, Zhang T, Zhu H, et al. Evolution of Fecal 
Microbiota Transplantation in Methodology and Ethical Issues[J]. Curr Opin 
Pharmacol, 2019. DOI: 10.1016/j.coph.2019.04.004. [3]Ding X, Li Q, Li P, et 
al. Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active 
Ulcerative Colitis[J]. Drug Saf, 2019.
disclosure: Nothing to disclose 
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P1800 PaTIenT saTIsfacTIOn and adherence TO fecaL 
MIcrOBIOTa TransPLanT On LOng-TerM cLInIcaL OuTcOMe 
Of uLceraTIve cOLITIs
Li Q., Zhang T., Ding X.
the Second Affiliated Hospital of Nanjing Medical University, Medical Center 
for Digestive Disease, Nanjing, China
contact e-Mail address: xding@njmu.edu.cn
Introduction: Ulcerative colitis (UC), a phenol type of inflammatory bowel 
disease (IBD), is a chronic relapsing and remitting inflammatory disorder 
of the gastrointestinal tract. Although the pathophysiology of UC remains 
unknown, growing evidence suggests that the changes in gut microbiota 
composition may be a key element in gut inflammatory processes1. Fecal 
microbiota transplantation (FMT), which involves the infusion of fecal mi-
crobiota from a healthy donor into a patient’s intestine for reconstructing 
gut microbiota, has become an option for the treatment of UC.The way to 
improve the long-term efficacy of FMT remains unclear.
aims & Methods: This study aimed to evaluate the UC patients’ satisfac-
tion with FMT and the role of adherence to scheduled FMT for long-term 
clinical outcomes.Patients with UC who underwent FMT at our center from 
November 2012 to September 2018 were evaluated. We assessed patient 
satisfaction with post-FMT outcomes, adherence to the second course of 
FMT, and attitude towards delivering ways of FMT.
results: 176 patients were included into the final analysis. At one week, 
one month, three months, and six months after FMT, the clinical response 
rate was 48.9%, 69.3%, 49.4%, and 32.7%, respectively. Patients’ quality 
of life was significantly higher one year after FMT than that before FMT 
(P < 0.001). Partial Mayo score at one month post-FMT (P < 0.001) was 
an independent factor of patients’ satisfaction. The laboratory preparation 
process was related to the incidence of adverse events (P < 0.05). 76.2% 
(93/122) of patients exhibited poor adherence to the treatment of sequen-
tial FMTs while 23.8% (29/122) of patients followed our recommendation 
for the second course of FMT. Patients achieved longer clinical response in 
the good adherence group as compared with the poor adherence group 
(P < 0.001). Patients preferred to choose colonic transendoscopic enteral 
tubing (TET) as the FMT delivery route.
conclusion: Patients’ good adherence to scheduled FMT is an important 
factor to maintain long-term clinical benefits achieved from FMT.
disclosure: Dr. Faming Zhang invented the concept of GenFMTer and tran-
sendoscopic enteral tubing and devices related to it. 
P1801 a PrOPensITy scOre-WeIghTed cOMParIsOn Of 
vedOLIzuMaB, adaLIMuMaB, and gOLIMuMaB In PaTIenTs 
WITh uLceraTIve cOLITIs: reaL-LIfe daTa frOM The sIcILIan 
neTWOrk fOr InfLaMMaTOry BOWeL dIsease (sn-IBd)
Macaluso F.S.1, Ventimiglia M.1, Fries W.2, Viola A.2, Cappello M.3, 
Scrivo B.3, Magnano A.4, Pluchino D.4, Camilleri S.5, Garufi S.5, 
Di Mitri R.6, Mocciaro F.6, Magrì G.7, Ferracane C.7, Citrano M.8, 
Graziano F.8, Bertolami C.9, Renna S.1, Orlando R.1, Rizzuto G.1, 
Cottone M.1, Orlando A.1, Sicilian Network for Inflammatory Bowel 
Disease (SN-IBD)
1’Villa Sofia-Cervello’ Hospital, IBD Unit, Palermo (Pa), Italy, 2Inflammatory 
Bowel Disease Unit, A.O.U. Policlinico ‘G. Martino”, Messina, Italy, 3UOC 
Gastroenterologia ed Epatologia Di.Bi.Mis - University of Palermo, Palermo, 
Italy, 4Gastroenterology Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, 
Italy, 5Gastroenterology Unit, A.O.O.R. “S. Elia- M. Raimondi”, Caltanissetta, 
Italy, 6ARNAS Civico-Di Cristina-Benfratelli, Gastroenterology and Endoscopy 
Unit, Palermo, Italy, 7Gastroenterology Unit, A.O. “Santa Marta e S. Venera”, 
Acireale, Italy, 8Pediatrics Unit, A.O.O.R. “Villa Sofia-Cervello”, Palermo, Italy, 
9A.O. Papardo di Messina, Messina, Italy
contact e-Mail address: fsmacaluso@gmail.com
Introduction: The recent VARSITY trial showed that Vedolizumab (VDZ) was 
superior to Adalimumab (ADA) in achieving clinical remission and muco-
sal healing in patients with ulcerative colitis (UC). Conversely, no real-life 
data on the comparative effectiveness of VDZ, ADA, and Golimumab (GOL) 
in UC have been published yet.
aims & Methods: Data of consecutive patients with UC treated with VDZ, 
ADA, and GOL from June 2015 to December 2018 were extracted from the 
cohort of the Sicilian Network for Inflammatory Bowel Disease (SN-IBD). 
A three-arms propensity score-adjusted analysis was performed to reduce 
bias caused by imbalanced covariates at baseline, including the propor-
tion of TNF-α inhibitor naïve and non-naïve patients, using the Inverse 
Probability of Treatment Weighting (IPTW) approach. The effectiveness 
was evaluated at 8 weeks, 52 weeks, and as treatment persistence at the 
end of follow up. The clinical endpoints were steroid-free clinical remis-
sion (partial Mayo score < 2 without steroid use) and clinical response 
(reduction of the partial Mayo Score ≥2 points with a concomitant decrease 
of steroid dosage compared with baseline). The sum of the two outcomes 
was defined as clinical benefit. The achievement of mucosal healing (en-
doscopic Mayo score 0-1) was assessed after at least 6 months of biological 
treatment.
results: A total of 463 treatments (187 VDZ; 168 ADA; 108 GOL) were includ-
ed, with a median follow-up of 47.6 weeks (IQR 20.0-85.9). At 8 weeks, a 
clinical benefit was achieved in 70.6% patients treated with VDZ, in 68.5% 
patients treated with ADA, and in 67.6% patients treated with GOL (p = 
n.s. for all comparisons); at 52 weeks, VDZ showed better rates of clinical 
benefit compared with both ADA (71.6% vs. 47.5; OR: 2.79, 95% CI 1.63-4.79, 
p< 0.001) and GOL (71.6% vs. 40.2%; OR: 3.77, 95% CI 2.08-6.80, p< 0.001), 
while the difference between ADA and GOL was not significant. Cox sur-
vival analysis demonstrated that patients treated with VDZ had a reduced 
probability of treatment discontinuation compared to those treated with 
ADA (HR: 0.42, 95% CI 0.28-0.64, p< 0.001) and GOL (HR: 0.30, 95% CI 
0.19-0.46, p< 0.001), while patients treated with ADA had a significantly 
reduced risk of treatment discontinuation compared to those treated with 
GOL (HR: 0.71, 95% CI 0.50-1.00, p=0.048). Post-treatment mucosal healing 
rates showed a numerical but non-significant difference in favour of VDZ 
(48.1%) compared with ADA and GOL (38.0% and 34.6%, respectively).
conclusion: In the first study comparing at the same time the clinical effec-
tiveness of VDZ, ADA, and GOL in UC patients via propensity score-adjusted 
analysis, VDZ was superior to both subcutaneous agents at 52 weeks and 
as treatment persistence, while ADA showed a superior treatment persis-
tence compared to GOL.
disclosure: Fabio Salvatore Macaluso served as an advisory board mem-
ber for MSD and Biogen, and received lecture grants from MSD, AbbVie, 
and Takeda Pharmaceuticals. Maria Cappello served as an advisory board 
member for AbbVie, MSD, Takeda Pharmaceuticals, and received lecture 
grants from AbbVie, MSD, Chiesi, and Takeda Pharmaceuticals. Filippo 
Mocciaro served as an advisory board member for AbbVie and MSD Phar-
maceuticals, and received lecture grants from AbbVie, MSD and Takeda 
Pharmaceuticals. Sara Renna served as an advisory board member for 
AbbVie and MSD Pharmaceuticals, and received lecture grants from Ab-
bVie, MSD and Takeda Pharmaceuticals Ambrogio Orlando served as an 
advisory board member for AbbVie, MSD, Takeda Pharmaceuticals, and 
received lecture grants from AbbVie, MSD, Sofar, Chiesi, and Takeda Phar-
maceuticals. 
P1802 The frequency Of fecaL MIcrOBIOTa 
TransPLanTaTIOn fOr MaInTenance Of LOng-TerM effIcacy 
In PaTIenTs WITh uLceraTIve cOLITIs: a PILOT sTudy
Li Q.1, Zhang T.1, Ding X.2
1The Second Affiliated Hospital of Nanjing Medical University, Medical Center 
for Digestive Disease, Nanjing, China, 2the Second Affiliated Hospital of 
Nanjing Medical University, Medical Center for Digestive Disease, Nanjing, 
China
contact e-Mail address: xding@njmu.edu.cn
Introduction: Ulcerative colitis (UC), a phenol type of inflammatory bowel 
disease (IBD), is a chronic relapsing and remitting inflammatory disorder 
of the gastrointestinal tract. Although the pathophysiology of UC remains 
unknown, growing evidence suggests that the changes in gut microbiota 
composition may be a key element in gut inflammatory processes1. Fecal 
microbiota transplantation (FMT), which involves the infusion of fecal mi-
crobiota from a healthy donor into a patient’s intestine for reconstructing 
gut microbiota, has become an option for the treatment of UC.Increasing 
evidence has shown that fecal microbiota transplantation (FMT) is emerg-
ing as a novel therapy for ulcerative colitis (UC).
aims & Methods: To study the frequency of fecal microbiota transplan-
tation for maintenance of long-term efficacy in patients with ulcerative 
colitis.Patients were recruited from November 2012 to September 2018. 122 
patients who achieved clinical response at one month after first course of 
FMT were included into the final analysis. The risk factors of the efficacy 
maintenance time and readmission for FMT were assessed by Chi-square 
test or non-parametric test.
913Vol. 7 | October 2019
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results: The median time of maintaining clinical response to the first course 
of FMT in total 77 patients was 90 days (IQR, 30-150). The time of maintain-
ing clinical response to the second course of FMT in 25 of 77 patients was 
180 days (IQR, 97.5-297.5). Compared with the time of maintaining clinical 
response to the first course FMT, the second course of FMT achieved promi-
nently longer maintenance time in the 25 patients (p <0.05). No severe 
adverse event related to the FMT was observed during and after the FMT 
procedure, as well as during the long-term follow-up. The volume of fe-
cal microbiota did not affect the clinical response maintenance time (p = 
0.562). The patients with readmission attained remarkably longer time of 
maintaining efficacy than those without readmission (p <0.0001) and they 
had significantly better efficacy at 3 months after the first course of FMT 
comparing with the patients who were not readmission (p <0.0001).
conclusion: This study demonstrated that patients with UC could be ad-
ministered the second course of FMT less than 3 months after the first FMT 
and they were advised to get the third course of FMT less than 6 months 
after the second one for maintaining the long-term clinical benefits from 
the FMT. Readmission for next course of FMT was valuable to maintain 
long-term efficacy.
disclosure: Dr. Faming Zhang invented the concept of GenFMTer and tran-
sendoscopic enteral tubing and devices related to it. 
P1803 assOcIaTIOn Of usTekInuMaB seruM cOncenTraTIOns 
and PerIanaL fIsTuLa resOLuTIOn In The crOhn’s dIsease 
unITI PrOgraM
Sands B.E.1, Kramer B.2, Gasink C.2, Jacobstein D.3, Gao L.-L.2, Ma T.2, 
Adedokun O.J.4, Colombel J.-F.5, Schwartz D.A.6
1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New 
York, United States, 2Janssen Scientific Affairs, LLC, Horsham, United States, 
3Janssen Research & Development, Immunology Development GI, Spring 
House, United States, 4Janssen Research & Development, LLC, Spring House, 
United States, 5Icahn School of Medicine at Mount Sinai, Gastroenterology, 
New York, United States, 6Vanderbilt University Medical Center, Nashville, 
United States
contact e-Mail address: bruce.sands@mssm.edu
Introduction: Previous studies have demonstrated the efficacy and safety 
of ustekinumab (UST) IV induction and SC maintenance in Crohn’s disease. 
Analysis from the Phase 2 and 3 UST trials also demonstrated possible 
benefit in fistula resolution at week 8 [14.1% (10/71) PBO vs 24.7% (37/150) 
all UST doses combined] despite a small proportion (10.8 to 15.5% across 
the studies) of patients with active perianal fistulas at baseline (Sands et 
al DDW 2017). Here we examine the relationship between perianal fistula 
resolution at induction week 8 (maintenance week 0) and maintenance 
week 44 based on serum UST levels at maintenance weeks 0 and 24 in 
patients receiving IV UST induction and SC UST maintenance.
aims & Methods: Patients in UNITI-1 and 2 induction studies were random-
ized to IV PBO or UST (130mg or ~6mg/kg). Patients with open, draining 
perianal fistulas at baseline had their fistulas assessed by physical exam 
(including gentle compression). Patients were analyzed for complete fis-
tula resolution (100% reduction) at subsequent study visits. Fistula resolu-
tion at induction week 8 was also analyzed based on week 8 UST serum 
concentration quartiles, while fistula resolution at maintenance week 44 
was analyzed based on maintenance week 24 UST serum concentration 
quartiles (incorporating non-randomized and randomized groups). Pa-
tients who started a prohibited medication (e.g. another biologic) were 
considered not to be in fistula resolution.
results: In observed data, among randomized patients with open, drain-
ing perianal fistulas at baseline of UNITI-1/2 27.5% (11/40) receiving 130mg, 
23.7% (9/38) receiving ~6mg/kg UST and 25.6% (20/78) combined UST had 
fistula resolution induction week 8 compared to 9.3% (4/43) in the PBO 
group (p=0.03, 0.08, and 0.03, respectively). At week 44, 85.7% (6/7) and 
71.4% (5/7) patients randomized to UST maintenance (90mg Q8W or Q12W) 
had perianal fistula resolution, compared to 44.4% (4/9) of patients ran-
domized to PBO (p=0.15 and 0.36, respectively). Incorporating all patients 
(randomized and non-randomized) treated with UST maintenance, peri-
anal fistula resolution occurred in 42% (21/50) of patients. In the induction 
week 8 quartile analysis, perianal fistula resolution was 38.9% (7/18) in 
Q1, 11.8% (2/17) in Q2, 27.8% (5/18) in Q3, and 29.4% (5/17) in Q4 for all 
UST treated patients (Table 1). Fistula resolution at maintenance week 44 
based on week 24 concentration quartiles also did not show any exposure 
response relationship (Table 1).
fistula resolution at Week 8 Post Induction (Week 0 Maintenance) by serum 
concentrations at Week 8 Post Induction (Week 0 Maintenance)
UST Concentration Quartiles WK 0
a
130mg UST
b
~6mg/kg
c
Combined
Q1 33.3% (3/9) 44.4% (4/9) 38.9% (7/18)
Q2 11.1% (1/9) 12.5% (1/8) 11.8% (2/17)
Q3 44.4% (4/9) 11.1% (1/9) 27.8% (5/18)
Q4 33.3% (3/9) 25.0% (2/8) 29.4% (5/17)
fistula resolution at Week 44 Post Maintenance by usT serum concentrations at Week 
24 Post Maintenance
UST Concentration Quartiles WK 24a 90 mg Q8Wd
90mg Q8W or 
Q12W
e
-
Q1 85.7% (6/7) 75% (9/12) -
Q2 57.1% (4/7) 50% (6/12) -
Q3 28.6 (2/7) 25% (3/12) -
Q4 14.3% (1/7) 27.3% (3/11) -
a Patients in fistula resolution with missing PK data were excluded from this analysis
b Q1: <1.18 µg/ml; Q2 >1.18 µg/ml <1.62 µg/ml; Q3: >1.62 µg/ml <2.84 µg/ml; Q4 >2.84 µg/ml
c Q1 <3.40 µg/ml; Q2 >3.40 µg/ml <5.04 µg/ml; Q3 >5.04 µg/ml <9.30 µg/ml; Q4 >9.30 µg/ml
d Q1: <1.34 µg/ml; Q2: >1.34 µg <1.99 µg/ml; Q3: >1.99 µg/ml< 3.01 µg/ml; Q4 > 3.01 µg/mL
e Q1: <1.25 µg/ml; Q2: >1.25 µg <2.31 µg/ml; Q3: >2.31 µg/ml< 3.47 µg/ml; Q4 > 3.47 µg/mL
[Table 1: Fistulation Resolution at Induction Week 8 and Maintenance  
Week 44]
conclusion: Some evidence of efficacy in perianal fistula resolution is pres-
ent with UST in both induction and maintenance, despite a relatively small 
number of patients with perianal fistulas. However, perianal fistula reso-
lution did not appear to be associated with higher UST serum concentra-
tions.
disclosure: Bruce E Sands, Jean-Frederic Colombel, David Schwartz are all 
investigators for Janssen Research & Development, LLC Brian C. Kramer 
Christopher Gasink are employees of Janssen Scientific Affairs, LLC Doug-
las Jacobstein, Long-Long Gao, Tony Ma, and Omoniyi J Adedokun are all 
employees of Janssen Research & Development, LLC 
P1804 LOWer Tnf-α InhIBITOr drug survIvaL In feMaLe 
PaTIenTs WITh InfLaMMaTOry BOWeL dIsease Is reaLTed TO a 
greaTer rIsk Of sIde effecTs
Schultheiss J.P.D., Brand E.C., Lamers E., van der Berg W.C.M., 
Van Schaik F., Oldenburg B., Fidder H.H.
UMC Utrecht, Gastroenterology, Utrecht, Netherlands
contact e-Mail address: j.p.d.schultheiss-7@umcutrecht.nl
Introduction: Approximately 11% of patients fail to respond to induc-
tion therapy with anti-tumour necrosis factor-α (TNF-α) (primary non-
responders) and 25-40% of primary responders discontinue treatment 
because of loss of response or side effects over time. Identification of pa-
tient-specific factors related to drug discontinuation is therefore important 
to aid physicians in clinical decision making. In rheumatoid arthritis and 
psoriasis female sex has been shown to be associated with discontinua-
tion of anti-tumour necrosis factor-α (TNF-α) therapy. We assessed the 
association between sex and TNF-α drug survival in patients with inflam-
matory bowel disease (IBD).
aims & Methods: All IBD patients treated with infliximab (IFX), adalim-
umab (ADA) or golimumab (GOL) between January 2011 and December 
2017 were retrospectively identified in the hospital’s pharmacy’s record. 
Patients with a follow-up time of less than 12 months at our hospital were 
excluded. Patient and treatment characteristics and reasons for anti-TNF-α 
discontinuation (primary non-response, secondary loss of response, side 
effects and ‘other’ discontinuation reasons) were recorded.
The primary analyses were done by multilevel Cox proportional hazards 
regression models with random intercepts per patient. Univariable hazard 
ratios for overall discontinuation were estimated. Subsequently the asso-
ciation between sex and overall anti-TNF-α discontinuation was multi-
variable assessed. Competing risks Cox proportional hazards models were 
fitted to assess uni- and multivariable hazard ratios for the discontinuation 
reasons separately.
results: In total 529 patients were included (50.1% female, 631 treatment 
episodes - 357 IFX, 240 ADA, 34 GOL - and 2280 TNF-α inhibitor treat-
ment years). Female sex (adjusted hazard ratio [aHR] 1.42, 95% CI 1.16 
- 1.74), higher age at start of therapy per decade (aHR 1.15, 95% CI 1.04 
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- 1.27) and dose escalation (aHR 3.74, 95% CI 2.78 - 5.02) were associated 
with anti-TNF-α therapy discontinuation in both primary and sensitivity 
analyses. Total cohort cause-specific analysis identified female sex to be 
associated with side-effects but not with other reasons for discontinua-
tion (aHR 4.05, 95% CI 2.36 - 6.98). Adalimumab (aHR 1.70, 95% CI 1.11 
- 2.60) and golimumab (aHR 4.97, 95% CI 2.30 - 10.74) use and dose-
escalation (aHR 7.71, 95% CI 5.28 - 11.26) were associated with secondary 
loss of response.
conclusion: Drug survival of anti-TNF-α therapy is lower in females as 
compared to males, mainly because of higher rates of discontinuation for 
side effects in females. Understanding the sex-specific differences in effec-
tiveness and safety of anti-TNF-α compounds can aid physicians in clinical 
decision-making.
disclosure: E.C. Brand has received unrestricted research funding from 
Pfizer BV as co-investigator; B. Oldenburg has received research support 
and grants from MSD BV, Abbvie BV, Ferring BV, Takeda BV and Pfizer 
BV and is an advisory board member of MSD BV, Abbvie BV, Ferring BV, 
Takeda BV, Janssen BV and Pfizer BV; and H.H. Fidder has done consulta-
tion for Abbvie BV, Janssen BV, Ferring BV and Takeda BV. The remaining 
authors disclose no conflicts. 
P1805 earLy vedOLIzuMaB TrOugh LeveLs PredIcT 
TreaTMenT PersIsTence Over The fIrsT year In 
InfLaMMaTOry BOWeL dIsease
Guidi L.1, Pugliese D.1, Panici Tonucci T.1, Bertani L.2, Costa F.2, 
Privitera G.1, Gremese E.3, Tolusso B.3, Di Mario C.3, Papa A.1, 
Gasbarrini A.4, Rapaccini G.L.1, Armuzzi A.1
1Fondazione Policlinico Universitario A. Gemelli IRCCS Università Cattolica 
del Sacro Cuore, IBD Unit Presidio Columbus, Roma, Italy, 2University 
of Pisa, Translational Research and New Technologies in Medicine and 
Surgery, Pisa, Italy, 3Fondazione Policlinico Universitario A. Gemelli 
IRCCS Università Cattolica del Sacro Cuore, Division of Rheumatology, 
Roma, Italy, 4Fondazione Policlinico A. Gemelli Universitario A. Gemelli 
Università Cattolica del Sacro Cuore, Department of Internal Medicine and 
Gastroenterology, Roma, Italy
contact e-Mail address: danipug@libero.it
Introduction: The role of Therapeutic Drug Monitoring widely validated for 
anti TNF-α drugs, especially in case of loss of response, remains debated 
with Vedolizumab.
aims & Methods: We investigated the utility of early serum Vedolizumab 
trough levels for predicting the first-year Vedolizumab therapy outcome 
and identifying patients at higher risk of therapy failure. We included con-
secutive patients affected by Crohn’s disease and Ulcerative Colitis, who 
started Vedolizumab therapy at two hospitals in Italy. Vedolizumab trough 
levels and anti-Vedolizumab antibodies were assayed by ELISA at week 6 
and 14. Clinical remission (according to Harvey Bradshaw Index and Par-
tial Mayo Score, as appropriate) was assessed at week 6, 14, 22 and 54. 
The primary endpoint was to explore the correlation between early Ve-
dolizumab trough levels and Vedolizumab persistence over the first year 
of treatment, defined as the maintenance of therapy because of sustained 
clinical benefit.
results: 101 patients (82% exposed to anti TNF-α drugs) were included. 
Median VTL were 28.3 µg/mL (IQR 16.9-39.8) at week 6 and 18.4 µg/mL (IQR 
11.8-25) at week 14 after the first infusion of vedolizumab. A cut-off TL of 
16.55 µg/ml at week 14 predicted Vedolizumab persistence within the first 
year of therapy with a sensitivity of 73.3 % and a specificity of 59.4% (p 
=0.0009, AUROC 0.686, 95% CI 0.581-0.779). 
Week 14 Vedolizumab trough levels were significantly higher in patients 
with clinical remission at week 14, 22, 54, as well as in those patients 
achieving mucosal healing within 54 weeks. Early Vedolizumab trough 
levels were significantly correlated with serum albumin levels (Spear-
man’s rho=0.204, p=0.0107).
conclusion: High VTL at week 14 were associated with a higher probability 
of maintaining Vedolizumab therapy over the first year because of a sus-
tained clinical benefit.
disclosure: Nothing to disclose 
P1806 IMPacT Of The sWITch frOM OrIgInaL adaLIMuMaB TO 
BIOsIMILar adaLIMuMaB sB5 On seruM drug TrOugh LeveLs, 
cLInIcaL and BIOLOgIcaL dIsease acTIvITy In PaTIenTs WITh IBd
Lukas M.1,2, Pesinova V.1, Bortlik M.1,3,4, Duricova D.1, Machkova N.1, 
Hruba V.1, Lukas M.1, Vasatko M.1, Malickova K.1,2
1ISCARE I.V.F. a.s., IBD Clinical and Research Center, Prague, Czech 
Republic, 2General University Hospital and First Faculty of Medicine, Charles 
University, Institute of Medical Biochemistry and Laboratory Medicine, 
Prague, Czech Republic, 3First Faculty of Medicine, Charles University and 
Military University Hospital, Department of Internal Medicine, Prague, 
Czech Republic, 4First Faculty of Medicine, Charles University and Military 
University Hospital, Institute of Pharmacology, Prague, Czech Republic
contact e-Mail address: milan.lukas@email.cz
Introduction: Biosimilar adalimumab SB5 is a biosimilar monoclonal an-
tibody for the treatment of patients with autoimmune diseases such as 
inflammatory bowel disease (IBD). Generally, biosimilars are biological 
products showing high resemblance to the reference biological products, 
and they exhibit no clinically meaningful differences in terms of safety and 
effectiveness. 
Since monitoring of adalimumab serum trough levels hold an important 
significance in treatment modalities, insufficient data about monitoring 
of drug serum trough levels in IBD patients treated with SB5 are present 
to date.
variable
Total cohort
all discontinuations
univariable
Total cohort
all discontinuations
Multivariable
Total cohort
loss of response
univariable
Total cohort
loss of response
Multivariable
Total cohort
side effects
univariable
Total cohort
side effects
Multivariable
Total cohort
‘other’ discontinuations
univariable
Total cohort
‘other’ discontinuations
Multivariable
female sex (male 
reference)
1.37
(1.10-1.70)
1.42 
(1.16-1.74)
1.13
(0.87-1.46)
1.17 
(0.91-1.51)
4.01 
(2.35-6.85)
4.05 
(2.36-6.98)
1.03 
(0.67-1.58)
1.00 
(0.64-1.55)
age at start per decade 1.15 
(1.05-1.27)
1.15 
(1.04-1.27)
1.06
(0.95-1.19)
1.10 
(0.97-1.26)
1.24 
(1.06-1.45)
1.23 
(1.00-1.52)
1.25 
(1.04-1.50)
1.20 
(0.96-1.52)
second and later 
treatment episode
1.08 
(0.81-1.45)
0.97 
(0.70-1.36)
1.41
(0.98-2.02)
0.86 
(0.56-1.33)
1.34 
(0.77-2.34)
1.36 
(0.70-2.67)
1.55 
(0.81-2.97)
1.38 
(0.64-2.95
adalimumab therapy 
(infliximab reference)
0.98 
(0.74-1.29)
1.08 
(0.78-1.49)
1.24
(0.87-1.77)
1.70 
(1.11-2.60)
0.94 
(0.54-1.63)
0.61 
(0.32-1.16)
1.26 
(0.67-2.37)
1.03 
(0.50-2.12)
golimumab therapy 
(infliximab reference)
2.25 
(1.27-3.99)
1.95 
(1.06-3.61)
3.64
(1.88-7.03
4.97 
(2.30-10.74)
2.05 
(0.68-6.20)
1.05 
(0.29-3.77)
3.64 
(0.99-13.38)
2.01 
(0.47-8.50)
duration of disease (yrs) 1.01 
(1.00-1.03)
1.00 
(0.98-1.02)
1.00
(0.98-1.02)
0.99 
(0.97-1.02)
1.03 
(1.00-1.06)
1.01 
(0.98-1.04)
1.03 
(1.00-1.06)
1.01 
(0.97-1.05)
current smoker 0.94 
(0.61-1.44)
0.93 
(0.62-1.40)
0.92
(0.55-1.55)
0.87 
(0.52-1.47)
1.20 
(0.60-2.41)
0.94 
(0.45-1.95)
0.94 
(0.38-2.33)
Removed from model
dose escalation 3.54 
(2.64-4.76)
3.74 
(2.78-5.02)
6.88
(4.77-9.92)
7.71 
(5.28-11.26)
1.22 
(0.61-2.44)
1.39 
(0.67-2.87)
0.60 
(0.27-1.35)
Removed from model
concomitant 
immunomodulator use
0.95 
(0.72-1.27)
0.94 
(0.71-1.24)
0.98
(0.69-1.41)
0.89 
(0.62-1.28)
0.72 
(0.42-1.22)
0.76 
(0.44-1.34)
1.14 
(0.61-2.12)
Removed from model
[P1804 Table. Total cohort & total cohort cause-specific analysis]
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aims & Methods: In this study, we applied original adalimumab-validated 
ELISA based on TNFa as a target antigen to determine drug serum levels of 
SB5. The primary objective of current study was to compare serum trough 
levels of original adalimumab and SB5 before and after switching from 
the original to the biosimilar drug. Secondary aims were to assess clini-
cal effectiveness of biological treatment after the switching from original 
adalimumab to SB5 by symptom activity indexes (Harvey-Bradshaw index 
(HBI) in Crohn’s disease, and partial Mayo score (pMayo) in ulcerative coli-
tis and response as assessed by systemic and local inflammatory markers 
(C-reactive protein, CRP; and fecal calprotectin, FC).
Eighty-seven IBD patients, responders in maintenance adalimumab treat-
ment period, after the switching from original adalimumab to SB5, with 
known previous three measurements of the original adalimumab trough 
levels, were included. Sera form IBD Blood Bank established according to 
the Ethics Committee of ISCARE (Nr 2015/Ia) were used, and patient data 
were anonymously processed according to the latest version of the Helsinki 
Declaration of Human Research Ethics.
Biosimilar adalimumab trough levels at W10 after the switching were 
measured by enzyme immunoassay (ADALIMUMAB ELISA ImmunoGuide, 
REF: IG-AA103). CRP serum concentrations measured by immunoneph-
elometry and fecal calprotectin levels measured by fluoroimmmunoassay 
on switching day were compared with W10 values after the switching.
results: Of 87 patients, 47 were women and 40 were men; 77 with Crohn’s 
disease and 10 with ulcerative colitis; median age 39.5 (23 to 70) years. No 
differences in CRP and FC values before and after the switching were ob-
served (Spearman’s rank correlation coefficients r = 0.320 (p = 0.0048) and 
r = 0.833 (p < 0.0001), respectively). Similarly, no significant differences 
were found in HBI and pMayo values: Kruskal-Wallis H-test have shown 
p = 0.824 for HBI and p = 0.855 for pMayo indexes. Moreover, excellent 
quantitative agreement was observed between mean adalimumab trough 
levels before and after the switching from the original drug to SB5: Spear-
man’s rank coefficient values were r = 0.756 and p < 0.0001.
conclusion: TNFa-based ELISA kit for measuring adalimumab trough lev-
els showed similar overall performance in the detection of original and 
biosimilar adalimumab-containing sera. Clinical effectiveness of adalim-
umab treatment after the switching from the original to the biosimilar 
adalimumab SB5 assessed by symptom activity indexes and by systemic 
and local inflammatory markers remained identical after the switching.
disclosure: Supported by the IBD-Comfort Endowment Fund. 
P1807 cLInIcaL decIsIOn suPPOrT TOOL PredIcTs rIsk Of 
InfecTIOn In PaTIenTs WITh InfLaMMaTOry BOWeL dIsease 
TreaTed WITh vedOLIzuMaB
Dulai P.1, Feng D.2, Lasch K.2
1University of California San Diego, La Jolla, United States, 2Takeda 
Pharmaceuticals USA Inc, Deerfield, United States
contact e-Mail address: pdulai@ucsd.edu
Introduction: Disease activity is an independent predictor of infections 
while patients are receiving biologic therapy; however, prior studies have 
not taken into consideration the persistence of disease activity due to inef-
fectiveness of therapy when attempting to identify predictors of infectious 
complication. We hypothesized that a clinical decision support tool (CDST) 
that predicts treatment effectiveness would also predict the risk of devel-
oping an infection while on therapy.
aims & Methods: Two previously built and externally validated CDSTs that 
predict the treatment effectiveness of vedolizumab in ulcerative colitis (UC) 
and Crohn’s disease (CD) were used in combination with the phase 3 clini-
cal trial data sets (GEMINI). UC and CD patients were stratified by baseline 
variables using the CDSTs into low, intermediate, or high probability of re-
sponse to vedolizumab. Time-to-event with Cox proportional hazard mod-
els was used to compare the risk of infection across groups and to identify 
independent predictors of infections among subgroups.
results: A total of 618 UC and 1,023 CD patients were included. Among 
both UC and CD patients, those categorized as having a low-intermediate 
probability of response (n=479 UC, n=814 CD) to vedolizumab were more 
likely to develop infectious complications while on therapy than those cat-
egorized as having a high probability (n=139 UC, n=209 CD) of response 
to vedolizumab (UC: hazard ratio [HR] 1.383, 95% confidence interval [CI] 
1.024-1.868; CD: HR 1.458, 95% CI 1.124-1.893). The proportion of patients 
developing a serious infection was 1% of UC and 3% of CD patients in the 
high-probability groups versus 2% of UC and 5% of CD patients in the low-
intermediate probability of response groups. Among the low-intermediate 
probability of response UC group, independent predictors of developing 
an infection were baseline extraintestinal manifestation (no versus yes; HR 
0.755, 95% CI 0.569-1.001), previous tumour necrosis factor (TNF) antago-
nist exposure (no versus yes; HR 0.671, 95% CI 0.497-0.906), and baseline 
faecal calprotectin (log transformed; HR 1.135, 95% CI 1.016-1.268). Among 
the low-intermediate probability of response CD group, an independent 
predictor of developing an infection was previous TNF antagonist exposure 
(no versus yes; HR 0.727, 95% CI 0.553-0.957).
conclusion: Vedolizumab is an overall safe and well-tolerated biologic 
therapy in both UC and CD. We observed that patients with a low-inter-
mediate probability of response to vedolizumab have an increased risk for 
developing infectious complications. These data suggest that persistence 
of disease activity due to lack of efficacy may be a primary determinant of 
safety, as opposed to drug-related mechanisms.
disclosure: Parambir Dulai reports steering committee membership and 
speaking honoraria from Takeda, travel support and consulting fees from 
Takeda and Janssen, and grant support from Takeda and Pfizer. Ding Feng 
reports employment at Takeda. Karen Lasch reports employment at Takeda. 
P1808 sOrBIcILLIn fracTIOn Of PenIcILLIuM fLavIgenuM fOr 
The TreaTMenT Of InfLaMMaTOry BOWeL dIsease: In vITrO 
and In vIvO sTudIes
Dovbynchuk T.1, Ivashchenko O.1, Dikmen M.2, Zholos A.1, Öztürk Y.2, 
Canturk Z.2, Tolstanova G.1,3
1Taras Shevchenko National University of Kyiv, ESC Institute of Biology and 
Medicine, Kyiv, Ukraine, 2Anadolu University, Pharmacy Faculty, Eskisehir, 
Turkey, 3Taras Shevchenko National University of Kyiv, Institute of High 
Technology, Kyiv, Ukraine
contact e-Mail address: mtaisa80@gmail.com
Introduction: Inflammatory bowel diseases (IBD) are chronic relapsing in-
testinal inflammation that often require to treat patients over years and to 
adapt the therapy repeatedly with respect to side effects or loss of previous 
medication effect. By so, we constantly need to search for a new non-toxic 
compound to better optimize the current IBD treatment.
aims & Methods: The aim of the present study is to test the effects of sec-
ondary metabolite sorbicillin of Penicillium flavigenum in vitro and in vivo 
model of IBD. 
1) Aqueous fraction of sorbicillin was extracted from Penicillium flavigenum 
isolated from Lake Salt (Konya, Turkey) and analysed on LC-MS. 
2) The cytotoxicity, cell proliferation and apoptotic effects of sorbicillin and 
mesalazine (positive control) (500, 250, 125, 62.5 and 31.25 µg/mL) were 
investigated on Caco2 colorectal adenocarcinoma cells after 24 h incuba-
tion by WST-1 assay, xCELLigence RTCA-DP Real Time Cell Analyzer and An-
nexinV-PI assay, respectively. IL-1β production by LPS (1 µg/mL)-stimulated 
THP-1 human monocyte cells was analysied by flow cytometry. 
3) Ulcerative colitis (UC) was induced in unfasted Wistar rats by 6% iodo-
acetamide (IA) in 1% methylcellulose or vehicle - control (0.1 ml/rat, given 
intracolonically). 
Sorbicillin (50, 100 and 200 mg/kg) dissolved in H
2
O or placebo (sterile 
H
2
O) were gavaged daily for 5 days after IA enema, followed by autopsy 
on the 7th day. Body weight, lethargy and diarrhea were recorded daily. 
Damage score of colonic lesions; MPO activity by H
2
O
2
-dependent oxida-
tion of o-dianisidine hydrochloride; colonic vascular permeability by the 
extravasation of Evans blue injected intravenously 15 min prior euthanasia; 
glycoproteins levels in colonic mucus by PAS staining on PVDF membrane; 
and cecum weight were recorded.
results: Sorbicillin and mesalazine did not show cytotoxic and apoptotic 
effects at all studied concentrations on Caco2 cells. Whereas treatment of 
LPS-stimulated THP-1 cells with 500 µg/mL of Sorbicillin or mesalazine for 
24 h reduced the levels of IL-1β from 28.4% in control to 6.6 and 6.7 %, 
respectively. Sorbicillin in dose 50 and 100 mg/kg did not induce significat 
effect on clinical and morphological signs of IA-UC. While, rats treated 
with sorbicillin 200 mg/kg had the same pattern of body weight gain as 
the control rats (15% IA+sorbicillin vs 4% in IA+placebo). Sorbicillin in 
dose 200 mg/kg significantly (p< 0.05) reduced lesioned area, loss of ru-
gae, dilatation, weight of colon/100 g, ceacum weight/100 g and colonic 
MPO activity vs. IA+placebo group. Moreover, sorbicillin (200 mg/kg) re-
duced 2-fold (p< 0.05) the colonic vascular permeability and increased 
1.5-fold (p< 0.05) glycoproteins levels in colonic mucus in rats with IA-UC 
vs. IA+placebo group.
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conclusion: Sorbicillin-containing aqueous fraction of Penicillium flavige-
num does not have cytotoxic and apoptotic effects on Caco-2 cell, but has 
anti-inflammatory effect by reducing IL-1β levels in LPS-stimulated THP1 
cells. Sorbicillin ameliorates iodoacetamide-induced UC in rats. The res-
toration of mucosal barrier and resolving inflammation are the potential 
mechanism of sorbicillin beneficial effect. Acknowledgement: This study 
was supported by Mevlana Project Based International Exchange Programme 
(Project number: D26-MEVLANA-01).
disclosure: Nothing to disclose 
P1809 reverse sWITchIng TO OrIgInaTOr InfLIxIMaB May Be 
cOnsIdered In PaTIenTs WITh InfLaMMaTOry BOWeL dIseases 
exPerIencIng neW sIde effecTs Or LOss Of resPOnse afTer 
sWITchIng TO a cT-P13 BIOsIMILar
Mahmmod S.1, Schultheiss J.P.D.1, Mahmmod N.2, Tan A.C.3, Dijkstra G.4, 
Fidder H.H.1
1UMC Utrecht, Gastroenterology, Utrecht, Netherlands, 2Antonius Ziekenhuis 
Gastroenterology, Zeist, Netherlands, 3Canisius Wilhelmina Hospital Dept. 
of Hepatogastroenterology, Nijmegen, Netherlands, 4UMC Groningen 
Gastroenterology and Hepatology, Groningen, Netherlands
contact e-Mail address: j.p.d.schultheiss-7@umcutrecht.nl
Introduction: In current clinical practice, patients with inflammatory bowel 
disease (IBD) treated with originator infliximab (IFX) have been or are be-
ing switched to biosimilar infliximab because of lower costs and seemingly 
similar effectiveness of biosimilars. Over a one-year follow-up 7%-26% of 
the patients discontinued biosimilar IFX treatment, which is comparable 
to originator IFX. Common reasons for discontinuation of biosimilar IFX 
treatment are (subjective) loss of response or side effects. As a result of 
newly experienced side effects or loss of response while using biosimi-
lar infliximab, patients are occasionally switched back to treatment with 
originator IFX. However, not much is currently known regarding reverse 
switching to originator IFX.
aims & Methods: Our aim was to assess the prevalence of and the specific 
reasons for reverse switching to originator infliximab within 52-weeks af-
ter an initial conversion from originator infliximab to a CT-P13 biosimilar in 
patients with IBD. Additionally, we evaluated whether reinitiating origina-
tor infliximab led to the desired favorable effect.
In this retrospective, observational, multi-centre cohort study, data of IBD 
patients from two tertiary care centres and two large general hospitals in 
the Netherlands were collected. Adult patients with IBD were eligible for 
inclusion if they had been switched from infliximab originator to the CT-
P13 biosimilar and had a follow up time of at least 52 weeks after initial 
conversion. Reasons for re-switching were categorised into side effects or 
loss of response to the biosimilar.
results: A total of 254 patients with IBD were switched (165 Crohn’s dis-
ease, 52 Ulcerative colitis and 2 IBD-Unclassified). Reverse switching oc-
curred in 35/254 (13.8%) of the patients after a mean of 23.6 weeks. Re-
verse switchers were more often female (48.9% versus 68.6%, p = 0.02) 
than those who stayed on biosimilar treatment.
Thirty-two patients (91.4%) switched back to the originator because of 
newly experienced side effects and only three (8.6%) because of loss of 
response on biosimilar IFX. Most frequently reported side effects were skin 
reactions in 37.1% of patients (13/35), an increase in IBD related symptoms 
37.1% (13/35) of patients and fatigue in 25.7% (9/35) of patients. Three 
patients had by calprotectin (>250 mg/L) objectified loss of response on in-
fliximab biosimilar. In 75% (24/32) of the patients experiencing side effects 
and 100% (3/3) of the patients with loss of response, reverse switching to 
originator IFX led to the desired effect of improvement of the side effect or 
regaining of response to IFX therapy. 
conclusion: Switching back to originator infliximab seems effective in 
patients with IBD, who experience side effects or loss of response after 
switching from originator to biosimilar infliximab. Switching patients back 
to originator infliximab may therefore be justified in case patients experi-
ence new side effects or loss of response after switching to a biosimilar 
IFX.
disclosure: G. Dijkstra has received unrestricted research Grants from Ab-
bVie and Takeda. He has served as a member of the advisory board for 
Mundipharma and Pharmacosmos and has received speaker fees from 
Takeda, Pfizer and Janssen.H.H. Fidder has done consultation for Abbvie 
BV, Janssen BV, Ferring BV and Takeda BV. The remaining authors disclose 
no conflicts. 
demographics Patients remaining on biosimilar (n=219)
Patients switched back 
to originator (n=35) p-value
sex 
- female, n (%)
- Male, n (%)
107 (48.9%)
112 (51.1%)
24 (68.6%) 
11 (31.4%)
0.02
age at diagnosis (years), 
mean (sd) ζ 27.5 (±13.9) 27.7 (±13.7) N.S. 
∞ 
age at initial switch 
(years), mean (sd) ζ 40.7 (±15.8) 40.2 (±16.9) N.S. 
∞ 
Months on originator 
infliximab, mean (sd) ζ 62.2 (±35.5) 59.0 (±39.5) N.S. 
∞ 
Type of IBd, n (%)
- crohn‘s disease
- ulcerative colitis
- IBd-unclassified
165(75.3)
52(23.7)
2(0.9)
28(80)
7(20.0)
0(0)
N.S. ∞ 
smoking, n (%)
- Missing
- never
- In the past
- currently
12(5.5)
128(58.4)
27(12.3)
52(23.7)
1 (2.9)
18(51.4)
8(22.9)
8(22.9)
N.S. ∞ 
hospital, n (%)*
- uMcu
- azn
- cWz
- uMcg
86(39.3)
94(42.9)
25(11.4)
14(6.4)
15(42.9)
13(37.1)
3(8.6)
4(11.4)
N.S. ∞ 
ζ : standard deviation; *uMcu: university Medical centre utrecht; azn: st. antonius 
hospital nieuwegein; cWz: canisius Wilhelmina hospital; uMcg: university Medical 
centre groningen; ∞ : not significant
[Comparison of demographics between patients who did and did not switch 
back to originator infliximab]
P1810 shOrT- and LOng-TerM effIcacy Of vedOLIzuMaB 
TheraPy On cLInIcaL and endOscOPIc acTIvITy In PaTIenTs 
WITh anTI-TuMOr necrOsIs facTOr aLPha resIsTanT 
InfLaMMaTOry BOWeL dIsease
Bor R.1, Farkas K.1, Miheller P.2, Palatka K.3, Szamosi T.4, Vincze A.5, 
Matuz M.6, Rutka M.7, Szántó K.7, Tóth T.1, Balint A.1, Szepes Z.G.1, 
Nagy F.8, Milassin Á.1, Fabian A.1, Zsigmond F.4, Bajor J.9, Lakner L.L.10, 
Katalin M.11, Müllner K.12, Papp M.13, Szabone Salamon Á.14, Horváth G.15, 
Fülöpné Sarang K.16, Vitális Z.17, Schäfer E.18, Sarlós P.19, Molnár T.7
1University of Szeged, 1st Dept. of Medicine, Szeged, Hungary, 2Semmelweis 
University, 2nd Dept. of Medicine, Budapest, Hungary, 3University of 
Debrecen, Medical and Health Science Center, Div Gastroenterology, Dept. 
of Gastroenterology, Debrecen, Hungary, 4MHEK, Budapest, Hungary, 
5University of Pécs, 1st Dept. of Medicine, Pécs, Hungary, 6University 
of Szeged, Dept. of Clinical Pharmacy, Szeged, Hungary, 7University of 
Szeged, 1st Dept. of Internal Medicine, Szeged, Hungary, 8SZTE ÁOK I. sz. 
Belgyógyászati Klinika, 1st Dept. of Medinine, Szeged, Hungary, 9University 
of Pécs, Medical School, 1st Dept. of Medicine, Division of Gastroenterology, 
Pécs, Hungary, 10Markusovszky Kórház, Szombathely, Hungary, 
11’Semmelweis Egyetem II. Belgyógyászati Klinika, 2nd Dept. of Medicine, 
Budapest, Hungary, 12Semmelweis University, 2nd Dept. of Internal Medicine, 
Budapest, Hungary, 13University of Debrecen, MHSC Institute of Medicine, 
Division of Gastroenterology, Debrecen, Hungary, 14Balassa Janos Hospital, 
Dept. of Gastroenterology, Szekszard, Hungary, 15Budai Hepatológiai 
Centrum, Budapest, Hungary, 16Markusovszky Hospital, Szombathely, 
Hungary, 17DEOEC Debreceni Egyetem Klinikai Központ, Debrecen, Hungary, 
18AEK, Budapest, Hungary, 19University of Pécs, 1st Dept. of Internal Medicine, 
Pécs, Hungary
contact e-Mail address: bor.reni86@gmail.com
Introduction: Vedolizumab (VDZ) therapy as alternative option in the man-
agement of moderate and severe IBD has been registered since 2016 in 
Hungary, however all newly initiated VDZ therapy was individualized, it 
should be approved by the steering committee of five Hungarian IBD-spe-
cialist up to 2019. This situation resulted that only those patients could be 
received VDZ treatment whose longstanding disease showed inadequate 
response to the conventional anti-TNF-alpha and/or immunosuppressant 
therapy. The aim of our observational study was to assess the efficacy of 
short- and long-term VDZ therapy on clinical and endoscopic activity in 
moderate and severe active IBD in real-life setting.
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aims & Methods: Our non-interventional multicenter cohort study en-
rolled all adult IBD patients with moderate and severe activity who re-
ceived VDZ therapy between July 2016 and December 2018 in our entire 
country. The therapeutic response was assessed based on the changes of 
clinical (Crohn’s Disease Activity Index [CDAI], Mayo score) and endoscopic 
(Simple Endoscopic Score for Crohn Disease [SES-CD], endoscopic Mayo 
score) scores. Clinical response was defined as >3 points decrease in the 
total Mayo score or >100 decrease in CDAI score from baseline. Remission 
was defined as Mayo score ≤2, with no individual subscores >1, or as CDAI 
score ≤150. Mucosal healing was defined as Mayo endoscopic subscore ≤1 
or as SES CD score ≤4.
results: 83 Crohn’s disease (CD) and 121 ulcerative colitis (UC) patients 
completed VDZ induction therapy. The mean age was 39.9 years (range 
18-78; median 36) and the average disease duration was 9.6 years (range 
1-36; median 8). Extraintestinal manifestations occurred in 57 patients 
(27.9%), and in 11 cases (5.4%) IBD was associated with primary sclerosing 
cholangitis (PSC). The mean value of activity scores significantly decreased 
by the end of short-term treatment period both in CD (SES-CD: 20.93 vs. 
13.55; p< 0.00001; CDAI: 303.58 vs. 167.66; p< 0.00001) and UC (Mayo: 9.74 
vs. 4.33; p< 0.00001; eMayo: 2.80 vs. 1.41;su p< 0.00001) subgroups. The 
rate of clinical response during the short-term VDZ therapy was substan-
tially higher in the UC group compared with CD group (84.3% vs. 61.5%; 
p< 0.0001). No significant difference in terms of the proportion of clinical 
remission and steroid-free remission was observed between the UC and 
CD subgroups (49.6% vs. 51.8%, p=0.777; and 27.3% vs. 37.4%, p=0.169). 
In 124 cases (72 UC and 52 CD) the first-year VDZ treatment could have 
been completed during the study period, however in 32 cases (25.8%) 
primary non-response for induction therapy was observed. 92 patients (60 
UC and 32 CD) received maintenance VDZ therapy. The rate of response, 
clinical remission and steroid-free remission were substantially higher 
in UC (65.3%, 47.2% and 44.4%) compared with CD (42.3%, 32.7% and 
30.8%) by the end of first-year therapy (p< 0.001). Significant difference 
was observed between UC and CD subgroups in terms of mucosal healing 
both by the end of induction and by the end of first-year therapy (52.9% 
and 21.7%, p< 0.0001vs. 51.4%and 21.2%, p=0.015).
conclusion: Our results suggest that both the short-term and the one-year 
long maintenance VDZ therapy is effective and safe therapeutic option in 
anti-TNF-alpha failure or intolerant IBD patients with moderate or severe 
disease activity, however significant difference was observed between the 
UC and CD subgroups. Mucosal healing was achievable in every second UC 
and in only every fifth CD patients both by the end of the induction and by 
the end of first-year treatment in this difficult-to-treat population.
disclosure: Nothing to disclose 
P1811 effIcacy and safeTy Of ThIOguanIne as 
rescue TreaTMenT fOr InfLaMMaTOry BOWeL dIsease: 
a MuLTI-cenTre sTudy
Bayoumy A.1, van Liere E.1, Ansari A.2
1VUMC, Gastroenterology & Hepatology, Amsterdam, Netherlands, 2East 
Surrey Hospital, Gastroenterology, London, United Kingdom
contact e-Mail address: a.b.bayoumy@amc.uva.nl
Introduction: Thioguanine (TG) is an alternative thiopurine therapy which 
has been used for patients with inflammatory bowel disease (IBD) who 
have failed azathioprine or 6-mercaptopurine due to side effects or sub-
optimal response. Its widespread use has been hampered from concerns 
about safety of TG due to reports of liver toxicity, especially nodular regen-
erative hyperplasia (NRH), when TG was used in higher doses.
aims & Methods: The aim of this study was to investigate the long-term 
efficacy and safety of low-dose TG in IBD after failure of prior conventional 
therapy in an English cohort. 
A retrospective multicentre chart study was performed on IBD patients 
who were treated with TG from 2006 to 2019 in three hospitals in the 
United Kingdom. Both patients’ characteristics and drug history as well as 
the efficacy and safety profile of TG therapy were reviewed in the patients’ 
medical records. Clinical, radiological and laboratory parameters were 
collected; to assess NRH liver biopsies and MRI results were assessed. 
Clinical remission was defined as: no (re)initiation of corticosteroids, no 
initiation of biological therapy and no surgical intervention.
results: In total 193 patients (57% female and Crohn’s disease in 64%) 
were included, with a median daily TG dose of 20 mg (range: 20-40 mg), 
a median treatment duration of 23 months (range: 0-155 months) and a 
median follow-up of 36 months (range: 1-155 months). 71% of the patients 
showed clinical remission to TG within 6 months and 54% of the patients 
were still using TG at final follow-up. Forty-three patients (22%) stopped 
TG due to intolerance(s) and 15 patients (8%) stopped due to resistance. 
Intolerances to TG occurred in 28% of the patients (n = 54), primarily 
consisting of elevated liver enzymes (n = 9, 5%), myelotoxicity (n = 9, 
5%) and rash (n = 9, 5%). Pancreatitis only occurred in one patient with 
a history of thiopurine-induced pancreatitis. NRH was diagnosed in two 
patients (1%).
conclusion: Long-term follow-up shows that thioguanine was effective 
and well-tolerated in 54% patients who had failed conventional therapy. 
The occurrence of pancreatitis and NRH was very little in this study.
disclosure: Nothing to disclose 
P1812 The OuTcOMe Of resecTed crOhn’s dIsease PaTIenTs 
WITh nO POsTOPeraTIve TreaTMenT BuT under cLOse 
endOscOPIc fOLLOW uP and acceLeraTed sTeP uP TreaTMenT 
In case Of endOscOPIc reLaPse: a TerTIary referraL cenTer 
PILOT sTudy
Erzin Y.Z.1, Yildirim S.2, Bozcan S.3, Gulturk I.4, Eskazan T.5, Bakkaloglu O.6, 
Kurt E.A.3, Hatemi A.I.1, Demir N.3, Celik A.F.3
1Istanbul University Cerrahpasa, School of Medicine, Gastroenterology, 
Istanbul, Turkey, 2Istanbul University Cerrahpasa, Medical Faculty, 
Gastroenterology, Istanbul, Turkey, 3Istanbul University Cerrahpasa, School of 
Medicine, Istanbul, Turkey, 4Istanbul University Cerrahpasa, Medical Faculty, 
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Medicine, Division of Gastroenterology, Istanbul, Turkey, 6Istanbul University 
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Introduction: According to POCER study, postop. endoscopic follow up at 
6 mo. and relevant treatment (tx) escalation of resected CD patients might 
decrease endoscopic relapse rates at 18 mo. compared to those getting 
the best postop. tx according to their risk stratification without endoscopic 
follow up. However after minimizing the inflammatory load in the postop. 
setting there might be still a group of unnecessaryly overtreated patients. 
So our aim was to determine the outcome of resected CD patients with no 
initial postop. tx independent of risk status.
aims & Methods: Starting in 2012 we closely followed up each CD pa-
tient after their first ileocecal resection with colonoscopy at 3-6-12-18-24 
mo. and then annually. Active smoking, resection for penetrating disease 
were accepted as risk factors for relapse but both high or low risk groups 
were followed up without any initial tx. If relapse was detected at any 
colonoscopy an accelerated step up tx. was applied starting with 5-ASA+ 
budesonide, continuing with AZA and ending up with biologics in an add 
on fashion. 
All patients’ demographic features like age, age at onset, operation, sex, 
disease duration, location, behaviour, reason for resection, smoking sta-
tus, Rutgeerts score at each colonoscopy were noted. Patients with active 
perianal disease and upper GI involvement were excluded.
results: A total of 45 patients [mean age 40.40±10.66 yr, 24 being female, 
29 (65%) with high risk] were enrolled into the study. Mean follow up time 
was 54.46±18.83 mo. The overall endoscopic relapse rate during whole 
follow up was 36/45 (80%), median time to relapse being 3 mo. Relapse 
rate showed no relation with parameters like age, age at onset, and op-
eration, sex, disease location, and established risk factors for postop. re-
lapse (active smoking, penetrating disease). After starting the step up tx 
the percentage of relapsers decreased to 23 out of 36 at the very last visit. 
Nine out of 45(20%) never had a relapse although six of them actually 
having risk factors.
conclusion: In light of previous POCER study the relapse rate at 18 mo. was 
50% when the best tx immidiately was started and managed according to 
postop. colonoscopy at 6 mo. In the present study the endoscopic relapse 
rate was the same despite a longer follow up time of 54 mo., although 
none of them had an immidiate postop. tx. but received the appropriate 
tx. in an accelerated step up manner. These results make us question the 
defined postop. risk factors and we think that our approach could help 
tailoring individual tx. and avoiding unnecessary tx. at least in a subgroup 
of patients.
disclosure: Nothing to disclose 
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P1813 MeTaanaLysIs Of earLy surgery versus InITIaL 
MedIcaL TheraPy WITh Or WIThOuT deLayed surgery In 
PaTIenTs WITh ILeOcOLOnIc crOhn’s dIsease
Ryan É.J.1,2, Orsi G.1, Syed A.Z.1, Boland M.R.1, Creavin B.2,3, Kelly M.E.2,3, 
Sheahan K.2, Neary P.C.1, Kavanagh D.O.1,4, McNamara D.4,5, Winter D.C.2,3, 
O Riordan J.M.1,4
1Tallaght University Hospital, Tallaght, Dublin 24, Department of Surgery, 
Dublin, Ireland, 2University College Dublin (UCD), School of Medicine, 
Dublin, Ireland, 3St Vincents University Hospital, Department of Surgery, 
Dublin, Ireland, 4Trinity College Dublin, School of Medicine, Dublin, 
Ireland, 5Tallaght University Hospital, Tallaght, Dublin 24, Department of 
Gastroenterology, Dublin, Ireland
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Introduction: Previous studies have demonstrated that early bowel resec-
tion (EBR) in ileocolonic Crohn’s disease (CD) can result in an improved 
clinical course compared to initial medical treatment (IMT), including es-
calation to biologic therapy
aims & Methods: We sought to compare the safety and efficacy of EBR ver-
sus IMT for the management of patients with ileocolonic CD. A systematic 
search was performed to identify studies that compared EBR (performed 
< 1yr from initial diagnosis) or IMT for the management of ileocolonic CD. 
Log hazard ratios (InHR) for recurrence free survival (RFS) and their stan-
dard errors were calculated from Kaplan-Meier plots and pooled using 
the inverse variance method. Dichotomous variables were pooled as odds 
ratios (OR). Quality assessment of the included studies was performed us-
ing the Newcastle-Ottawa (NOS) and Jadad scales
results: 7 studies of 1863 CD patients (EBR n= 581, 31.2%; IMT n= 1282, 
68.8%) were eligible for inclusion. The studies had a moderate to high risk 
of bias. The median NOS was 8 (range 7-9). There was a reduced likelihood 
of overall (OR 0.53 95% Confidence interval [95% CI]: 0.34, 0.83, p=0.005) 
and surgical (OR 0.47, 95% CI 0.24, 0.91, p=0.03) recurrence with EBR 
than with IMT. There was also a less requirement for maintenance biologic 
therapy (OR 0.24, 95% CI 0.14, 0.42, p< 0.0001). 
Patients who underwent EBR had a significantly improved RFS than those 
who underwent IMT (HR, 0.62 95% CI 0.52, 0.73, p< 0.001). There was no 
difference in morbidity (OR 1.67, 95% CI 0.44, 6.36, p=0.45) between the 
groups.
conclusion: Surgery is associated with reduced recurrence and need for 
maintenance biologic therapy in CD. It is critical that both a surgeon and a 
gastroenterologist review patients early, at the time of diagnosis, to facili-
tate informed management decisions.
disclosure: Nothing to disclose 
P1814 hOMe-deLIvered InfLIxaMaB InfusIOn: safeTy daTa 
frOM 373 hOMe InfusIOns Over 4 years
Shaikh F.A.1, Goodoory V.2, Shenderey R.2, McConnell J.3
1Airedale general Hospital Keighley, Gastroenterology, Keighley, United 
Kingdom, 2Airedale Hospital NHS Foundation Trust, Gastroenterology, 
Keighley, United Kingdom, 3Airedale Hospital NHS Foundation Trust, 
Keighley, United Kingdom
contact e-Mail address: f_shaikh88@hotmail.com
Introduction: Treatment with infliximab for patients with Inflammatory 
Bowel Disease (IBD) in the UK consists of intravenous infusions usually 
delivered in hospital via a nurse-led service. Several studies have proven 
the safety of infliximab infusions at home which also eases the capacity 
for hospital infusions. However, the uptake in clinical practice has been 
slow in the UK. We aim to evaluate the safety and patient satisfaction of 
home infliximab infusions in a district general hospital 4 years after its 
introduction.
aims & Methods: This is a retrospective audit of all IBD patients enrolled 
in a home infliximab infusion programme from July 2014 to July 2018. Data 
were collected from the electronic database and case notes. Data collected 
included serious adverse reactions requiring hospital admission and num-
ber of times home infusions were put on hold/stopped because of safety 
concerns. Patients currently on the home infliximab infusion programmed 
were interviewed by telephone by 2 Gastroenterology specialist trainees. 
Satisfaction rate (out of 10) were collected for adequate communication, 
delivery times, customer service, driver assistance/attitude, nurse support 
service, clinical waste collection and overall satisfaction.
results: A total of 41 patients were included in the analysis (3 excluded due 
to insufficient follow up data): median age was 42 years, 19 (46.3%) were 
women, 9 (22%) had ulcerative colitis and 32 (78%) had crohn’s disease. 
Three hundred and seventy three (373) infliximab infusions were given at 
home: there were no deaths and no adverse reactions requiring hospital 
admission. There were 3 (0.8%) instances where home infliximab infu-
sions were put on hold or stopped as shown in table 1. Patients were given 
a median number of 7 doses of infliximab in hospital before moving to the 
home infliximab infusion. The median follow up time on home infliximab 
was 14 months and the median number of doses given at home was 7. 
Eighteen (69.2%) out of 26 patients on home infliximab in July 2018 re-
sponded to a telephone interview. Mean and median satisfaction rates 
were 9.7 and 10 (out of 10).
conclusion: A home infliximab infusion programme for patients with IBD 
is safe with all adverse reactions being minor and managed in the com-
munity. Patient satisfaction rate is high.
disclosure: Nothing to disclose 
P1815 The duBLIn InfLaMMaTOry Burden scOre PredIcTs 
earLy cLInIcaL and BIOcheMIcaL resPOnse TO gOLIMuMaB 
TreaTMenT In uc; earLy resuLTs Of The gOaL-arc sTudy
Egan C.1, Jones F.2, Sheridan J.3, Coe A.4, Doran P.5, Cullen G.6, Leyden J.7, 
Galligan M.5, Mccarthy J.8, O’Toole A.9, Kevans D.10, Egan L.11, Doherty G.A.5
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Beaumont University Hospital, Dublin, Ireland, 4St. Vincents University 
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Introduction: Golimumab (GLM) is an anti-TNF monoclonal antibody li-
censed for the treatment of Ulcerative Colitis. Higher trough levels are as-
sociated with enhanced response to therapy. (GOAL-ARC) is a randomized 
multi-centered trial of the impact of personalized dosing of Golimumab 
based on inflammatory burden (assessed by FCP - faecal calprotectin) and 
therapeutic drug monitoring versus standard of care (with dosing accord-
ing to label). We aimed to evaluate the impact of inflammatory burden in 
UC on drug levels and early response to GLM treatment.
aims & Methods: All study participants had a diagnosis of UC, with moder-
ate to severe disease activity (Mayo 6-12), with an endoscopic sub-score 
of ≥2. Clinical response was defined as a decrease in baseline modified 
partial mayo score of 2 points or a decrease of ≥30% from baseline. GLM 
was administered at 200mg at week 0, 100mg at week 2 in all patients in 
advance of week 6 assessment.
Induction data was analyzed to week 6 including baseline inflammatory 
burden (DUBLIN Score - Rowan et al, JCC 2019), FCP and modified partial 
mayo scores and week 6 trough GLM levels.
results: 70 patients have been recruited to GOAL-ARC. 90% have com-
pleted the induction phase to week 6. Moderate disease activity was pres-
ent in 79% with a Mayo endoscopic sub-score of 2 at screening. 56% had 
a weight < 80Kg.
Pre and post induction data was available on 51 patients,. Clinical response 
was achieved in 57% at week 6. The median modified partial mayo score 
decreased from 4(IQR 3-5) at baseline to 2(IQR 1-3) at week 6 (p< 0.001). 
Median FCP reduced from 1380 (IQR 685-3000) at baseline to 180 (IQR 15-
1122) at week 6 (p=0.001). A lower baseline DUBLIN score was associated 
with clinical response at week 6 (p=0.048).
Median GLM level at week 6 was 3.97 (IQR 2.3-5.8). Higher week 6 drug 
levels were associated with clinical response. (p=0.012). Week 6 GLM level 
was inversely proportional to week 6 FCP(p=0.001). Baseline DUBLIN score 
was inversely proportional to week 6 drug levels (p=0.021).
conclusion: Early results of GOAL-ARC demonstrate the majority (57%) of 
UC patients treated with GLM show early clinical response (by week 6). 
Significant improvements are observed in modified partial Mayo scores 
and FCP by week 6, with higher drug levels being significantly associ-
ated with achieving clinical response and reductions in faecal calprotectin. 
Lower baseline DUBLIN (inflammatory burden) scores are associated with 
higher trough drug levels and clinical response at week 6 indicating that a 
higher inflammatory burden is associated with poorer outcomes.
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  Baseline Week 6 p value
Faecal Calprotectin µg/g Median (IQR) 1380 (685-3000) 179.5 (15-1122) 0.001
Modified Partial Mayo score median 
(IQR)
4 (3-5) 2 (1-3) <0.001
[Table 1. Comparison of baseline and week 6 median faecal calprotectin and 
modified partial mayo scores following induction with Golimumab]
references: 1. Rowan CR, Cullen G, Mulcahy HE, Sheridan J, Moss AC, Ryan 
EJ, et al. DUBLIN (Degree of Ulcerative colitis Burden of Luminal INflamma-
tion) score, a simple method to quantify inflammatory burden in Ulcerative 
Colitis. J Crohns Colitis 2019 Mar.
disclosure: GD has received research and/or unrestricted educational 
funding from; Abbvie, MSD, Pfizer, Janssen, Takeda, Tillott’s, Shire GD has 
received speaker fees or participated in advisory boards for; Abbvie, MSD, 
Pfizer, Janssen, Amgen, Mylan, Shire, Dr Falk 
P1816 earLy ‘reaL WOrLd’ exPerIence WITh TOfacITInIB fOr 
MOderaTe TO severe uLceraTIve cOLITIs
Honap S., Sharma E., Ray S., Begum Y., Tamilarasan A.G., 
Cunningham G., Luber R., Mawdsley J., Anderson S., Sanderson J., 
Irving P.M.
IBD Centre, St. Thomas’ Hospital, London, United Kingdom
contact e-Mail address: honap@hotmail.co.uk
Introduction: Tofacitinib is an oral, small molecule Janus kinase inhibi-
tor, which received NICE approval for the treatment of moderate to severe 
treatment-refractory ulcerative colitis in late 2018. We present early clinical 
and biomarker outcome data for a cohort of new starters in a tertiary IBD 
referral centre.
aims & Methods: A retrospective cohort analysis of patients was under-
taken using prospectively maintained records. Patients commenced on 
tofacitinib between October 2018 to April 2019 were included. Clinical dis-
ease activity was measured at baseline and at four and eight weeks using 
the Simple Clinical Colitis Activity Index (SCCAI). Faecal calprotectin (FCAL) 
and C-reactive protein (CRP) were measured at baseline and eight weeks. 
Descriptive statistics and Wilcoxon signed rank test were calculated using 
GraphPad Prism version 8.0.
results: Twenty five patients commenced tofacitinib, median age 32 (range 
19-74) and median disease duration of 7 years (range 0.4-20). All patients 
had previously failed biologic therapy (24 anti-TNF, 1 vedolizumab and 13 
both). Paired outcome data was available for n=20 at week 4 and n=15 
at week 8. Median baseline SCCAI fell from 8 (range 2-14) to 3 (1-7) af-
ter four weeks (n=20), further decreasing to 2 (0-6) at week 8 (n=15) (p< 
0.0001). Median baseline FCAL (n=15) fell from 451(63-6020) to 95(5-1420) 
(p< 0.0001). There was no significant change in CRP following induction 
therapy. One patient discontinued due to non-response. Tofacitinib was 
well tolerated in our cohort with only one patient ceasing therapy after two 
weeks due to headaches. No significant haematological or biochemical 
abnormalities were noted.
conclusion: Our early experience with tofacitinib for those with disease 
refractory to one or more biologic agents, is encouraging. Real life effec-
tiveness appears to be at least as good as the efficacy demonstrated in the 
trial programme and tolerance is also reassuring, albeit in a small cohort 
with limited follow up.
disclosure: SH: Lecture fees: Janssen. Financial support for education/
training: Janssen, Vifor Pharma, Falk. PMI: Lecture fees: Abbvie, Warner 
Chilcott, Ferring, Falk Pharma, Takeda, MSD, Johnson and Johnson, Shire. 
Financial support for research: MSD, Takeda Advisory fees: Abbvie, Warner 
Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos, Topivert, Genentech, 
Hospira, Samsung Bioepis 
P1817 PredIcTIve facTOrs fOr The resPOnse TO InTravenOus 
cOrTIcOsTerOId TheraPy In severe acuTe cOLITIs
Tamzaourte M., Berrag S., Jamal S., Mourabit S., Aourarh A.
Mohammed V Teaching Military Hospital, Gastroenterology 1 Departement, 
Rabat, Morocco
contact e-Mail address: mouna.tamzaourte@gmail.com
Introduction: Acute severe colitis can be a revelation or occur in the course 
of a known chronic inflammatory bowel disease, especially ulcerative 
colitis. Intravenous corticosteroid therapy (IVC) is the first-line medical 
treatment of acute severe colitis. The aim of our work is to evaluate the 
predictors of the response to intravenous corticosteroid therapy in severe 
acute colitis
aims & Methods: This is a two-year observational study of 27 cases of acute 
colitis collected in our department. acute severe colitis was defined by a 
Lichtiger score greater than 10. Clinical, biological, endoscopic and radio-
logical data were collected and analyzed by SPSS20 software.
results: The average age of our patients is 37.9 ± 17.1 years with a clear 
female predominance (21/27). 6 patients (22.2%) had known IBD. The aver-
age Lichtiger score was 13 ± 1.45. 9 patients (33.3%) were naive steroids. 9 
patients (33.3%) had endoscopic severity criteria. 19/20 of the patients in 
failure with the CO received the IFX, a patient was operated for colectasie. 
In univariate analysis, the factors significantly associated with the failure 
of CO IV were: CRP elevated on D3 (>45mg / l), presence of blood on D3, 
pancreatic involvement, non-naive status with corticosteroids . In multi-
variate analysis and adjusting to the above factors, only CRP >45mg / l to 
J3 is significantly associated with CO IV failure (OR = 1.3, p = 0.02).
conclusion: Our study confirms the data in the literature on the importance 
of the CRP assay at D3 to evaluate the response or failure to intravenous 
corticosteroid therapy in the initial management of severe acute colitis.
disclosure: Nothing to disclose 
P1818 The effIcacy and The safeTy Of vedOLIzuMaB 
In a grOuP Of anTI-Tnf exPerIenced PaTIenTs WITh IBd; 
a reaL-LIfe daTa frOM Turkey
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1Ankara Utf Ibn-I Sina Hastanesi, Ankara, Turkey, 2İstanbul University 
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Introduction: Vedolizumab is a new agent acting as an anti-Integrin which 
has been started to be use in treatment of Crohn’s disease (CD) and Ul-
cerative Colitis (UC). In this retrospective study we aimed to examine the 
safety and effectiveness of vedolizumab treatment in anti-TNF experienced 
patients with CD and UC. In addition we aimed to show whether there is a 
role for thiopurines in vedolizumab treatment.
aims & Methods: : Chart review was performed retrospectively in patients 
with UC and CD in Cerrahpasa University, Ankara University and Acıbadem 
University IBD outpatient clinics. Clinical response and clinical remission 
rates were calculated by using Harvey-Bradshaw Index and Partial Mayo 
score.
results: Total of 101 patients [mean age 39,4±12,7 yr, 51 Male, 57 CD (56%) 
] were enrolled into the study. The clinical response rates were 66%, 62% 
and 44% in 3, 6 and 12 months of vedolizumab treatment in CD patients. 
The Clinical remission rates were 22%,34% and 36% in the same intervals 
in CD patients. The clinical response rates were 59%, 62% and 36% in 
3, 6 and 12 months of vedolizumab treatment in UC patients. The Clini-
cal remission rates were 25%,39% and 33% in the same intervals in UC 
patients. There was no correlation found between thiopurin use, disease 
duration, clinical response and clinical remission rates in either diseases.
No serious side effects were recorded during vedolizumab treatment.
conclusion: Vedolizumab treatment is effective and safe in patients who 
were previously treated with anti-TNF agents. Thiopurins did not show any 
beneficiary effect over Vedolizumab treatment.
disclosure: Nothing to disclose 
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P1819 5-aMInOsaLIcyLaTe InTOLerance Is assOcIaTed WITh 
a POOr PrOgnOsIs In PaTIenTs WITh uLceraTIve cOLITIs
Fujii T.1, Hibiya S.1, Saito E.1, Takenaka K.1, Suzuki K.1, Motobayashi M.1, 
Shimizu H.1, Nagahori M.1, Ohtsuka K.1, Yauchi T.2, Kurosaki M.3, 
Watanabe M.1
1Tokyo Medical and Dental University, Gastroenterology and Hepatology, 
Tokyo, Japan, 2Soka Municipal Hospital, Gastroenterology, Soka, Japan, 
3Musashino Red Cross Hospital, Gastroenterology and Hepatology, Tokyo, 
Japan
contact e-Mail address: tfujii.gast@tmd.ac.jp
Introduction: 5-aminosalicylates(5-ASA) are the key drugs in induction 
and maintenance therapy in ulcerative colitis (UC). Some UC patients are 
involved in 5-ASA intolerance after induction of oral 5-ASA compounds. 
There are no evidence of the prognosis including the risk of colectomy in 
5-ASA intolerant UC patients.
aims & Methods: The aim of this study is to establish the prognosis of 
5-ASA intolerant UC patients in multicenter cohort study.A retrospective 
review of a prospective multicenter database (2014-2018) of 1,208 UC 
patients was carried out and a total of 1,064 patients treated with oral 
5-ASA compounds were enrolled. We compared the risk of colectomy and 
biologics induction between patients (i) tolerant to first 5-ASA compound 
(880), (ii) intolerant to first 5-ASA compound but tolerant to other 5-ASA 
compound (96) and (iii) intolerant to 5-ASA compound and withdrawal of 
5-ASA (88).
results: We identified 1,064 patients with UC, of which 32 patients (3%) 
resulted in colectomy and 211 patients (20%) treated with biologics. Col-
ectomy rate in patients (iii)intolerant to 5-ASA and withdrawal of 5-ASA 
were higher than (i) tolerant to first 5-ASA and (ii) intolerant to first 5-ASA 
but tolerant to other 5-ASA (6.1%, 3.1%, 2.1%, respectively). (iii) Patients 
withdrawal of 5-ASA showed higher risk of colectomy compared with (i) 
tolerant to first 5-ASA (Hazard ratio (HR) 3.02, 95% Concidence interval 
(CI): 1.08-8.45). The risk of colectomy among (ii) patients intolerant to first 
5-ASA but tolerant to other 5-ASA showed no significant difference com-
pared with (i) tolerant to first 5-ASA (HR 0.72, 95% CI: 0.16-3.10). The bio-
logics induction rate in (iii) patients withdrawal of 5-ASA was significantly 
higher than (i) tolerant to first 5-ASA and (ii) intolerant to first 5-ASA but 
tolerant to other 5-ASA (39%, 21%, 17%, respectively). Also (iii) patients 
withdrawal of 5-ASA showed higher risk of induction with biologics com-
pared with (i) tolerant to first 5-ASA (HR 2.10, 95% CI: 1.28-3.45). Those 
risk among (ii) patients intolerant to first 5-ASA but tolerant to other 5-ASA 
showed no significant difference compared with (i) tolerant to first 5-ASA 
(HR 0.72, 95% CI: 0.40-3.45).
conclusion: Patients with UC who had 5-ASA intolerance and withdrew 
from 5-ASA showed poor prognosis. We should consider trying other 
5-ASA compounds even if the patients had intolerance to one 5-ASA com-
pound.
disclosure: TF received research support from AbbVie, Alfresa, Boehringer 
Ingelheim, Celgene, EA Pharma, Eisai, Eli Lilly, Gilead Sciences, Janssen 
Pharma 
P1820 audIT Of sTerOId excess In InfLaMMaTOry BOWeL 
dIsease In The era Of BIOLOgIcs
Parry R.1, Durai D.2, Hawthorne B.2, Siddique N.2, Evans R.2, Datta K.2
1Cardiff University, Department of Gastroenterology, Cardiff, United Kingdom, 
2University Hospital Wales, Gastroenterology, Cardiff, United Kingdom
contact e-Mail address: parryrj2@cardiff.ac.uk
Introduction: Currently systemic corticosteroids are key treatments in the 
induction of remission of inflammatory bowel disease (IBD). Steroid ex-
cess can cause significant adverse side effects. Steroid dependency, excess 
and appropriateness have each been defined within ECCO guidelines, but 
currently there is no agreed benchmark on what is an acceptable rate of 
steroid use in IBD(1-2). A large study from the United Kingdom (UK) found 
a steroid use of 30% and excess in 14.9% in patients seen in IBD clin-
ics(3). The aim of this study is to evaluate the rates of steroid use/excess 
in patients attending a large tertiary IBD clinic in the era of increasing 
biologics usage.
aims & Methods: Data was collected over 16 weeks from unselected pa-
tients seen in our IBD clinic in Wales, UK, where over 4000 patients attend. 
A steroid assessment tool was used to determine patients’ steroid use. Oral 
steroid (Prednisolone/Budesonide) data was collected from the patients 
at clinic and cross referenced with the hospital patient records, hospital 
pharmacy database and primary care records. Each set of results were 
evaluated against ECCO guidelines, steroid excess or dependency was de-
fined as a patient requiring >2 courses of steroids in the past 12 months 
or a disease flare with tapering of a steroid course or a relapse within 3 
months of stopping steroids. Prescriptions were evaluated to determine 
their appropriateness. Current and prior drug usage including all immu-
nosuppressants (IS) were collected.
results: 258 patients were analysed in total, 60.9% of these had Crohn’s 
disease(CD), 33.7% Ulcerative Colitis(UC) and 5.4% Inflammatory bowel 
disease unclassified (IBDU). Mean age 45 years, Male 50% Female 50%. 
Disease severity was assessed and 58.9% of patients had inactive disease, 
26.0% mild, 14.0% moderate and 1.1% severe. Drug usage:
5ASA Thiopurine Other IS Anti-TNF Anti-integrin Anit-IL23
Current Past Current Past Current Past Current Past Current Past Current 
Past
UC 21.3% 9.7% 7.0% 7.4% 0.8% 1.2% 3.1% 2.3% 0.8% 0.8% 0% 0%
Crohn’s 5.0% 19.4% 13.1% 29.5% 2.7% 10.8% 13.6% 10.9% 1.2% 2.7% 
4.3% 0.4%
IBD-U 2.3% 2.7% 0.4% 1.6% 0.4% 0.4% 0.4% 1.2% 0% 0.8% 0% 0%
Total 28.6% 31.8% 20.5% 38.5% 3.9% 12.4% 17.1% 14.4% 2.0% 4.3% 
4.3% 0.4%
In the preceding 12 months 34.1% of patients had received at least 1 course 
of oral corticosteroids, 16.7% patients were in steroid excess/dependency. 
The dependency/excess occurred more frequently in Crohn’s patients (CD 
17.8%, UC 14.9%). Of the people in steroid excess the percentage on each 
drug were 5ASA 14.0%, Thiopurine 14.0%, Other IS 4.7%, Anti-TNF 14.0%, 
Anti -integrin 2.3%, Anti -IL23 9.3%
conclusion: High proportion of IBD patients seen in clinic were exposed to 
steroids in the preceding year. In comparison to previous study(3) the use 
of steroids seems higher despite increasing use of biologics. When evalu-
ating steroid excess it is essential to include primary care and hospital 
pharmacy records. Future studies should evaluate steroid use in all IBD 
service set up including patient directed self management service.
references: 1. Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, 
Barreiro-de Acosta M et al.Third European evidence based consensus on 
diagnosis and management of ulcerative colitis. Part 1: definitions, di-
agnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, 
surgery, and ileo-anal pouch disorders. Journal of Crohn’s and Colitis 
2017;11:649-670. 2. Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, 
Lindsay JO et al.3rd European evidence based consensus on the diagnosis 
and management of Crohn’s disease 2016: part 1: diagnosis and medical 
management. Journal of Crohn’s and Colitis. 2017;11:3-25. 3. Selinger CP, 
Parkes GC, Bassi A, Fogden E, Hayee B, Limdi JK, et al. A multi-centre audit 
of excess steroid use in 1176 patients with inflammatory bowel disease. 
Alimentary pharmacology & therapeutics. 2017;46(10):964-73.
disclosure: Nothing to disclose 
P1821 vedOLIzuMaB In The TreaTMenT Of chrOnIc 
refracTOry POuchITIs - a sysTeMaTIc revIeW
Lim W.-C., Lin H.
Tan Tock Seng Hospital, Gastroenterology and Hepatology, Singapore, 
Singapore
contact e-Mail address: huiyu_lin@ttsh.com.sg
Introduction: Approximately 50% of patients with ileal pouch anal anasto-
mosis (IPAA) develop pouchitis, with 10-15% of acute pouchitis developing 
chronic pouchitis(CP). Whilst the majority responds to antibiotic therapy, 
treatment options for chronic antibiotic refractory pouchitis(CARP) include 
combination antibiotic therapy, budesonide, immunomodulators(IM) or 
anti-tumour necrosis factor (TNF) antibodies. There is limited data on the 
role of vedolizumab(VZB), an a4b7 integrin antagonist, in the treatment 
of CP. We performed a systematic review of the literature to explore the 
efficacy of VZB in CP
aims & Methods: A systematic literature search in MEDLINE (1966-Novem-
ber 2018), Cochrane Central Register of Clinical Trials, and abstracts from 
recent major gastroenterology meetings (Digestive Disease Week, United 
European Gastroenterology Week and Congress of European Crohn’s and 
Colitis Organisation) was performed using the following terms: “integ-
rin”, “vedolizumab”, “pouchitis”. Only English language publications and 
abstracts on the efficacy of VZB for CP in ulcerative colitis patients with 
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IPAA were included; Crohn’s disease of the pouch was excluded. Addi-
tional trials were identified through review of reference list of included 
articles
results: 6 case reports (n=6)1-6 and 3 retrospective case series8-10 (2 in ab-
stract form, n=51) were included; 1 case series (Philpott J 2017)7 was ex-
cluded (duplicate). Only 1 ongoing randomised-controlled phase IV study 
(NCT02790138) was found whose data has yet to be reported. 
All patients (n=57) had chronic antibiotic refractory/ dependent pouchitis 
and received VZB after failing prior therapy, including IM and anti-TNF. In 
the case reports, 6 patients (mean age 36yrs, M:F 1:1) with CARP received 
induction/maintenance VZB; symptom improvement was seen as early as 
6 wks and pouchoscopy at 14-33 wks reported near/complete resolution 
of pouchitis. 
In the 3 retrospective case series, 64-75% achieved improvement/clinical 
remission(CR) at 12-14 wks, with 58.3% still in CR at 46 wks:(a) 14 of 19 
(73.7%) with CARP who received at least 1 dose of VZB had improvement 
of modified Pouchitis Disease Activity Index (mPDAI) at 12 wks (median 
decrease 2 units, p=0.031) ;(b) 9 of 12 (75%) who received induction/main-
tenance VZB achieved CR (mPDAI< 5 + decrease of >=2) at 14 wks, with 7 
(58.3%) still in CR at median 46(14-105) wks ;(c) after 3-4 doses of VZB, 
64% with CARP/antibiotic dependent pouchitis achieved CR (PDAI< 7) at 14 
wks. Minor adverse events were reported in 10-16%
conclusion: From uncontrolled studies and case reports, VZB appears to 
be efficacious and safe for the treatment of CP refractory to antibiotics and 
other therapy including anti-TNF. Controlled data is needed to confirm its 
efficacy in this group of patients.
references: 1. Martins D, Ministro P, Silva A. Port J Gastroenterol 
2018;25:340-341. 2. Orfanoudaki E, Foteinogiannopoulou K, Koutroubakis 
LE. Annals of Gastroenterology 2018;31(3):379. 3. Coletta M, Paroni M, Cap-
rioli F. J Crohns Colitis 2017;11:1507-1508 4. Mir F, Yousef MH, Partyka EK, 
Tahan V. Int J Colorectal Dis 2017;32(10):1517-1518. 5. Bethege J, Meffert S, 
Ellrichmann M, Conrad C, Nikolaus S, Schreiber S. BMJ Open Gastroenterol 
2017;4(1): e000127 6. Schmid M, Frick JS, Malek N, Goetz M. Int J Colorectal 
Dis 2017;32(4):597-598. 7. Philpott J, Ashburn J, Shen B. Inflamm Bowel 
Dis. 2017 Jan;23(1):E5-E6. doi: 10.1097/MIB.0000000000000992. PubMed 
PMID: 27930413 8. Bar F, Kuhbacher T, Dietrich NA et al. Aliment Pharmacol 
Ther 2018;47(5):581-587. 9. Amandeep Singh, Freeha Khan, Rocio Lopez, 
Bo Shen, Jessica Philpott. Gastroenterology 2018; 154 (6) Supplement 1: 
S-411, Sa1829. 10.Verstockt B, Claeys C, Van Assche G, D’Hoore A, Wolthuis 
A, Vermeire S, Ferrante M. J Crohns Colitis 2018;12(supplement 1): S425 
11.Phase 4 Study to Evaluate the Efficacy and Safety of Vedolizumab in the 
Treatment of Chronic Pouchitis. Https://clinicaltrials.gov/show/nct0279013
disclosure: Nothing to disclose 
P1822 sysTeMaTIc revIeW Of caLcIneurIn InhIBITOrs (cnI) 
and vedOLIzuMaB (vdz) cOMBInaTIOn TheraPy In acuTe 
severe uLceraTIve cOLITIs (asuc)
Lin H., Lim W.-C.
Tan Tock Seng Hospital, Gastroenterology and Hepatology, Singapore, 
Singapore
contact e-Mail address: huiyu_lin@ttsh.com.sg
Introduction: Patients with acute severe ulcerative colitis (ASUC) may 
be refractory to treatment with steroids and anti-tumour necrosis factor 
agents (anti-TNF). Ciclosporin inhibitors (CNI) have been used effectively 
as a fast-acting bridge to slower-onset immunomodulators in thiopurine-
naïve patients; however concerns over toxicity limit prolonged use of CNI 
as maintenance therapy. Patients who are azathioprine-exposed or anti-
TNF-refractory have limited medical treatment options, often resulting in 
colectomy. 
Combination of CNI as induction therapy, together with slower-acting but 
potentially safer vedolizumab (VDZ) has recently been used in patients 
with severe inflammatory bowel disease (IBD). We aim to review the utility 
of this combination treatment in ASUC.
aims & Methods: A systematic bibliographic review was conducted on 
PubMed using the keywords “vedolizumab”, “calcineurin inhibitors”, 
“inflammatory bowel disease”, and “severe ulcerative colitis”. Additional 
studies were identified by manual search of reference lists. 
6 articles were identified within the period 2013 to March 2019. Only Eng-
lish language publications and abstracts on use of combination CNI+VDZ 
in adult ASUC patients were included. 1 paediatric study (1), 1 case report(6) 
and 1 abstract (2) (ASUC data not reported) were excluded.
results: There were 2 prospective observational studies(3,4) [N= 30] and 1 
retrospective study (5) [N=39]. Patients were refractory to conventional treat-
ment with steroids [1 study, N=17] and/or anti-TNF therapy [N=48]. CNI (ci-
closporin or tacrolimus) was used for induction of remission in majority 
of cases, or as rescue agent in those failing induction with Vedolizumab 
[subgroup of 1 study, N=7]. 
In 2 studies, IV cyclosporine 2 mg/kg titrated to goal trough level 300-
400 or Tacrolimus 0.05mg-0.1mg/kg/d with target levels 10-14ng/mL was 
started; a week later, CNI-responsive patients were given vedolizumab (IV 
300mg at week 0,2,6 then maintenance 8-weekly) and CNIs were stopped 
after 8-12 weeks per protocol. In another study, VDZ was initiated on aver-
age 30days after CNI, with average combination CNI+VDZ of 64 days. 
Combination CNI+VDZ showed good short-term efficacy (1 study: 14/15 in 
remission). At 1 year, there was a respectable colectomy-free rate of 75% 
(2 studies, N=39/52), comparable to other studies with infliximab/ciclospo-
rin combined with azathioprine. In those receiving steroids at baseline, 
Steroid-free remission was achieved in 18/36 = 50% at week 14. Serious 
adverse events (N=7) were attributed to CNIs; there were no deaths.
conclusion: Preliminary studies of combination CNI and VDZ in patients 
with ASUC appear promising. However, the methodology in these limited 
studies was heterogenous. Further prospective trials are needed for the 
confirmation of the utility and efficacy of this treatment strategy in the 
management of ASUC.
references: [1] Hamel B et al. , (2018), Outcome of tacrolimus and vedoli-
zumab after corticosteroid and antiTNF failure in paediatric severe colitis 
[2] M. Rutka, (2017), Efficacy of combination therapy with cyclosporin and 
vedolizumab in inflammatory bowel diseases refractory to anti TNF agents 
[3] D. Tarabar , (2017), Combination therapy of cyclosporine and vedoli-
zumab is effective and safe for severe, steroid  resistant ulcerative colitis 
patients: A prospective study [4] B. Christensen, (2019), Safety and Efficacy 
of Combination Treatment With Calcineurin Inhibitors and Vedolizumab in 
Patients With Refractory Inflammatory Bowel Disease [5] Pellet G, (2019), 
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in 
Combination with Vedolizumab in Patients With Refractory Ulcerative Coli-
tis [6] W. Alana, (2014), Novel Use of Cyclosporine Induction Therapy as a 
Bridge to Vedolizumab in Severe Ulcerative Colitis [7] Laharie D, (2018), 
Long term outcome of patients with steroid refractory acute severe UC 
treated with ciclosporin or infliximab.
disclosure: Nothing to disclose 
P1823 OraL curcuMIn Is nOT MOre effecTIve Than PLaceBO 
TO PrevenT endOscOPIc POsTOPeraTIve recurrence In 
PaTIenTs WITh crOhn’s dIsease TreaTed WITh cOncOMITanT 
ThIOPurInes
Bommelaer G.1, Laharie D.2, Nancey S.3, Hebuterne X.4, Roblin X.5, 
Maria N.6, Peyrin-Biroulet L.7, Fumery M.8, Pereira B.9, Goutte M.10, 
Buisson A.11
1Chu Estaing, Clermont-Ferrand, France, 2CHU de Bordeaux Hopital Haut-
Leveque Dept. de Gastroenterologie, Pessac Cedex, France, 3HCL Lyon, Lyon, 
France, 4Hospital Arche 2, Nice, Nice, France, 5University of St. Etienne Dept. 
de Gastroenterologie, Saint Etienne, France, 6CHRU Lille, Gastroenterology, 
Courbevoie Cedex, France, 7Nancy University Hospital Inserm U954 Dept. of 
Hepato-Gastroenterology, Department of Gastroenterology, Vandoeuvre les 
Nancy, France, 8Amiens University Hospital, Gastroenterology Department, 
Amiens, France, 9CHU Clermont Ferrand Service de Médecine Digestive 
et Hépato-biliaire, Clermont-Ferrand, France, 10NHE - CHU de Clermont-
Ferrand, Digestive Disease/M2iSH Laboratory, Clermont-Ferrand, France, 
11CHU Estaing Clermont-Ferrand, Dept. of Gastroenterology, Clermont-
Ferrand, France
contact e-Mail address: vguastella@chu-clermontferrand.fr
Introduction: Postoperative recurrence is a major concern in patients with 
Crohn’s disease (CD). Curcumin exhibited antiinflammatory and antioxi-
dative properties in cellular and rodent models. Recently, a randomized 
controlled trial demonstrated that oral curcumin was more effective than 
placebo to induce clinical and endoscopic remission in patients with ulcer-
ative colitis failing to mesalamine [1].
aims & Methods: We aimed to assess the efficacy of oral curcumin com-
pared to placebo to prevent endoscopic POR in patients with CD receiving 
concomitant thiopurines therapy. We conducted a double-blind, random-
ized, placebo-controlled trial in eight IBD centers. All patients with CD (> 18 
years-old) undergoing bowel resection were consecutively enrolled within 
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15 days after the surgery or the closure of diverting stoma. All macroscopic 
lesions had to be removed and the anastomosis had to be reached by colo-
noscopy. The patients were randomized to be treated with azathioprine 
2.5mg/kg, and either placebo (placebo group) or oral curcumin (3g/day) 
(curcumin group).
The primary endpoint was endoscopic POR at 6 months (M6), defined as 
Rutgeerts’ index ≥ i2a.
Secondary endpoints were severe endoscopic POR (≥ i3), clinical POR 
(CDAI > 150), quality of life (IBDQ) and safety. An intermediary analysis 
was planned after the enrollment of 50% of the patients (n=62 patients).
results: Overall, 62 patients were enrolled (mean age 36.3 ± 12.0 years, 
mean CD duration 8.1 ans ± 8.0 years, 67.2 % female genders, 37.8% smok-
ers, 8.2 % with perianal lesions, 45.9 % with structuring CD, 36.1 % with 
fistulizing CD, 45.9 % with prior bowel resection, 18.0 % of anti-TNF na-
ïve patients). In intermediary analysis (intent-to-treat), curcumin was not 
more effective than placebo to prevent endoscopic POR at M6: 67.7 % (21/31) 
vs 58.1 % (18/31) (p=0.60), in curcumin and placebo groups, respectively 
(Figure 1). The rate of severe endoscopic POR was significantly higher in 
patients treated with curcumin (17/31, 54.8%) compared to placebo (8/31, 
25.8 %) (p= 0.02). The rate of clinical POR was not different between the 
two groups: 38.7 % (12/31) in curcumin group vs 45.2 % (14/31) in placebo 
group (p = 0.80). IBDQ was similar between the two groups (178.5 in the 
curcumin group vs 181.5 in the placebo group; p=0.63). The rate of adverse 
events was not different between the two groups.
conclusion: Oral curcumin was not more effective than placebo to prevent 
endoscopic postoperative recurrence (POR) in patients with CD receiving 
concomitant thiopurines therapy.
references: [1] Lang A et al. Clin Gastroenterol Hepatol 2015.
disclosure: Nothing to disclose 
P1824 IMPacT Of PaTIenT educaTIOn On sWITch accePTance 
In IBd PaTIenTs In reMIssIOn, WITh InfLIxIMaB OrIgInaTOr 
sWITched fOr an InfLIxIMaB BIOsIMILar: a PrOsPecTIve sTudy
Hastier-De Chelle A.1, Cluzeau V.1, Condat J.1, Arab N.1, Hebuterne X.2, 
Filippi J.3
1CHU of Nice, Gastroenterology and Clinical Nutrition, Nice, France, 2Hospital 
Archet 2, Nice, Department of Gastroenterology and Clinical Nutrition, Nice, 
France, 3Hopital de lAchet, Dept. de Gastroenterlogie Dept. de Nutrition 
Oncologie, Nice Cedex 3, France
contact e-Mail address: hastier-dechelle.a@chu-nice.fr
Introduction: CT-P13, the first biosimilar to infliximab (IFX), has an efficacy 
and tolerance profile comparable to IFX originator, at a lower cost. Physi-
cians are thus strongly encouraged to propose a biosimilar. However, for 
patients, the switch from IFX originator to a biosimilar is not always ac-
cepted.
aims & Methods: The aim of this study was to evaluate the impact of pa-
tient education (PE) on the acceptance of a switch from IFX originator to 
biosimilar in IBD patients treated with IFX originator. In a monocentric pro-
spective study, all IBD adult patients treated with IFX originator between 
June 2017 and June 2018, in clinical remission for at least 6 months, were 
asked to complete a questionnaire specifically designed for this study, to 
assess their knowledge on biosimilars and their acceptance of a switch-
ing strategy. Patients had the choice whether or not to accept the switch, 
with or without PE. The primary endpoint was the percentage of patients 
who accepted the switch, after receiving a PE session due to an initial 
refusal. Secondary endpoints were the evaluation of patient knowledge 
and feeling regarding biosimilar treatment; clinical remission, based on 
the Harvey-Bradshaw Index (score < 4) for CD and the partial Mayo score 
(< 2) for UC; biological remission: C reactive protein (N< 5 mg/l) and fae-
cal calprotectin (N< 150 µg/g stool) and immunogenicity after the switch, 
trough levels of IFX (TLI) and anti- IFX antibodies (ATI).
results: 86 patients (median age: 44 years [19-79]) were included (36% UC 
and 64% CD). The switch was initially refused by 47% of patients. In this 
subgroup, 78% agreed to participate in an educational interview with the 
PE nurse; 68% finally accepted the switch.
At Week 16, the persistence on biosimilar was 91%. At weeks 0, 8 and 
16, respectively, Mayo score was 0.68 ± 0.69, 0.81 ± 0.95 and 0.57 ± 0.76 
(p = 0.733) and Harvey-Bradshaw score was 0.88 ± 1.70, 1.95 ± 2.27 and 
2.14 ± 2.36 (p = 0.134); CRP was 2.92 ± 4.52, 3.48 ± 5.99 and 4.33 ± 10.82 
(p = 0.724); faecal calprotectin was 291 ± 402, 418 ± 596 and 427 ± 459 (p 
= 0.745); TLI was 5.00 ± 3.98, 4.81 ± 3.97 and 4.44 ± 3.34 (p = 0.642); no 
patients had immunisation after the switch; IBDQ was 182.61 ± 28 at W0 
and 175 ± 34 for at W16 (p = 0.494). The evaluation on the knowledge of 
biosimilars at W0 showed that 77% of patients had never heard about it, 
85% were in favour of the switch and 61% expressed fears about their use. 
At Week 16, the same evaluation showed that 84% of patients said they 
knew about biosimilars, 93% were in favour of the switch and 39% were 
still concerned about their use.
conclusion: This study confirms the safety of switching infliximab by CT-
P13 and demonstrates for the first time that PE plays a key role in switch 
acceptance by patients.
disclosure: The study was funded by Pfizer, France 
P1825 PersIsTenT OBesITy afTer TreaTMenT WITh WeIghT 
LOss MedIcaTIOns Or BarIaTrIc surgery Is a rIsk facTOr fOr 
deveLOPMenT Of InfLaMMaTOry BOWeL dIsease
Kochhar G.1, Syed A.2, El-hachem S.1, Abdal-Baki H.1, Chintamaneni P.1, 
Singh S.3, Loftus E.4, Thakkar S.1, Shen B.5, Dulai P.3
1Allegheny Health Network, Pittsburgh, United States, 2Allegheny Health 
Network, Gastroenterology, Pittsburgh, United States, 3UCSD, San Diego, 
United States, 4Mayo Clinic, Rochester, United States, 5Cleveland Clinic 
Foundation, Cleveland, United States
contact e-Mail address: drkochhar@gmail.com
Introduction: An association between bariatric surgery and risk of new-
onset inflammatory bowel disease (IBD) has been suggested, however, the 
epidemiology of this association is not well characterized.
aims & Methods: Using IBD Explorys, a HIPPA-enabled web platform that 
includes clinical data from over 62 million unique individuals with ac-
companying lab data, we aimed to quantify the risk for new-onset IBD 
among patients undergoing bariatric surgery (roux-en-y gastrojejunos-
tomy, sleeve gastrectomy or resection, stomach stapling, gastric banding), 
versus patients being treated with weight loss medications (orlistat, phen-
termine + topiramate, lorcaserin, naltrexone + bupropion, liraglutide), 
and the general population (without prior bariatric surgery, weight loss 
medication exposure, or IBD diagnosis upon entry into Explorys). We fur-
ther explored the association between persistence of obesity, defined as a 
BMI > 30 up to 6 months after exposure to bariatric surgery or weight loss 
medication, and the risk of new-onset IBD. IBD was diagnosed based on 
a combination of ICD-9 codes + at least 1 prescription for an IBD specific 
medication (5-ASA,immunomodulator, biologic). Relative risks (RR) with 
95% Confidence Intervals (CI) are reported.
results: A total of 59,630 and 198,270 patients were exposed to bariat-
ric surgery and weight loss medications respectively, with 640 and 2,240 
developing new-onset IBD after exposure. The prevalence of new-onset 
IBD after exposure to bariatric surgery (1,073/100,000 persons) was com-
parable with exposure to weight loss medications (1,130/100,000 persons, 
p=0.222), and both were significantly higher than the prevalence of new-
onset IBD in the general population (512/100,000, {RR 2.14, [95% CI 1.98, 
2.31] p<0.001}and weight loss medication {RR 2.40, [95% CI 2.30, 2.49]
p<0.001}). Among patients who developed new-onset IBD after exposure 
to bariatric surgery or weight loss medications, >80% of them had a BMI 
>30 up to 6 months after treatment of obesity (p<0.001). None of the new-
onset IBD post bariatric surgery had zinc or selenium deficiency.
characteristic all IBd [n = 319,610]
Post-Bs IBd 
[n = 640] relative risk p
Age, n(%) 18-65 
years
203,920 (64) 520(81) 2.67 [2.45, 2.91] < 0.0001
Race: Caucasian 
African american 
Hispanic
263,140 [82] 3
2,660 [10] 
4,610 [1]
560(88) 
80(13)
2.23 [1.05, 2.42] 
2.56 [2.06, 3.19]
< 0.0001
Subtypes, n(%) 
CD US
135,080 [42] 
110,850 [35]
300 [47 
220 [34]
2.32 [2.08, 2.60] 
2.08 [1.82, 2.37]
< 0.0001
IBD associated 
surgery: Colectomy 
Proctocolectomy 
Ileostomy
39,000 [12] 
2,890 [1] 
17,030 [5]
100 [16] - 
50 [8]
2.68 [2.21, 3.26] - 
3.07 [2.33, 4.05]
< 0.0001
All cause mortality 16,780 [5] 30 [5] 1.87 [1.31, 2.68] 0.0006
[Demographics and surgical outcomes]
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conclusion: Exposure to bariatric surgery and weight loss medications is 
associated with an increased risk for new-onset IBD compared to the gen-
eral population, and this is predominately seen among those who fail to 
normalize their BMI up to 6 months after treatment.
disclosure: Nothing to disclose 
P1826 surgery and BIOLOgIc PrescrIPTIOn raTes fOr 
crOhn’s dIsease In LOThIan, scOTLand 2000-2017; a POPuLaTIOn 
Based cOhOrT
Jenkinson P.1, Jones G.R.1, Plevris N.1, Lyons M.2, Burgess C.3, Wilson D.C.4, 
Arnott I.D.1, Lees C.W.1
1NHS Lothian, Gastroenterology, Edinburgh, United Kingdom, 2University of 
Edinburgh, Edinburgh, United Kingdom, 3Royal Hospital for Sick Children, 
Gastroenterology, Edinburgh, United Kingdom, 4University of Edinburgh 
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Introduction: Recent years have seen a shift in Crohn’s disease (CD) man-
agement to earlier initiation of biologic therapy using a treat to target 
strategy. However, the effect on long-term outcomes, in particular surgical 
resection, remains unclear.
aims & Methods: The aim of this study was to describe trends in rates of 
surgery and biologic prescription in CD over time in a population-based 
cohort. All incident CD cases (adult and paediatric) diagnosed between 
01/01/00 and 31/12/17 were identified from the Lothian IBD registry (Jones 
G, ECCO 2019). Abdominal surgeries were identified from Scottish coding 
data. All data were manually validated using the EHR and pathology re-
cords. Kaplan-Meier methods were used to generate incidence curves for 
first IBD surgery, repeat surgery, permanent stoma formation and first bio-
logic prescription. To compare surgical resection rates over time the cohort 
was divided into quartiles by date of diagnosis: 00-04, 05-08, 09-13 and 
14-17; analysis was performed using the log rank test.
results: 532/1753 (30.3%) incident CD cases underwent surgery during the 
study period. 170/532 (32.0%) patients had surgery at diagnosis and were 
excluded from survival analysis. The overall cumulative incidence rates of 
first surgery at 1, 5, and 10 years were 7.6% (95% CI, 4.5%-11.7%), 16.9% 
(13.3%-20.9%), and 25.7% (21.7%- 29.9%) respectively. When comparing 
temporal trends there was a significant reduction in surgical rates by date 
of diagnosis (logrank p < 0.001; see table).
A total of 601/1753 patients (34.3%) were prescribed biologics. The rates 
of first biologic prescription at 1, 5, and 10 years were 8.8% (CI:, 5.9%- 
12.3%), 20.3% (17.2%-23.7%), and 29.5% (26.4%-32.8%), respectively. 
When comparing temporal trends there was a significant increase in bio-
logic prescription rates by date of diagnosis (logrank p < 0.001; see table). 
Biologic prescription in the first year after diagnosis rose significantly over 
time from 1.0% in the first cohort to 19.0% in the latest. 
date of 
diagnosis
cumulative incidence 
of surgery
cumulative incidence of 
biologic prescription
  1 year 5 years 10 years 1 year 5 years 10 years
2000-2004 10.0% 22.0% 32.7% 1.0% 5.7% 14.9%
2005-2008 6.4% 18.3% 27.2% 2.8% 12.2% 25.8%
2009-2013 7.7% 15.5% 21.1% 6.1% 22.0% 43.0%
2014-2017 5.2% 13.7%* - 19.0% 44.9%* -
[Table 1. Cumulative incidence of first surgery and first biologic prescription 
(Kaplan Meier analysis, *censored).]
conclusion: In our population based cohort the earlier use of biologics in 
CD has been paralleled by a significant reduction in surgical rate and time 
to first operation.
references: Jones G et al, ECCO 2019, DOP87. Multi-parameter datasets are 
required to identify the true prevalence of IBD: The Lothian IBD Regis-
try (LIBDR) [Internet]. [cited 2019 Mar 20]. Available from: https://www.
ecco-ibd.eu/publications/congress-abstract-s/abstracts-2019/item/dop87-
multi-parameter-datasets-are-required-to-identify-the-true-prevalence-
of-ibd-the-lothian-ibd-
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and Norgine. IDA has received consultancy fees from Vifor and travel sup-
port from Takeda and Dr Falk. CWL has received research support from 
Gilead, Oshi Health and AbbVie, consultancy fees from AbbVie, Pfizer, Dr. 
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P1827 InvesTIgaTIOns PrIOr TO sTOMa reversaL In crOhn’s 
dIsease: WhaT Is Our currenT PracTIce and dOes IT affecT 
OuTcOMes?
Meade S.1, Cargill Z.1, Darakhshan A.2, Williams A.2, Mawdsley J.1, Ray S.1, 
Anderson S.1, Sanderson J.1, Irving P.3
1Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, 
United Kingdom, 2Guy’s and St Thomas’ NHS Foundation Trust, Colorectal 
Surgery, London, United Kingdom, 3Guy’s and St Thomas’ Hospital, 
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contact e-Mail address: meadesc@yahoo.co.uk
Introduction: Temporary stomas are commonly used during surgery for 
Crohn’s disease to reduce the risk of anastomotic leaks. There is limited 
data on pre-operative evaluation prior to reversal and whether this pre-
dicts adverse outcomes.
aims & Methods: We performed a retrospective review of patients with 
Crohn’s disease being considered for stoma reversal between January 2012 
and July 2018 in a tertiary inflammatory bowel disease centre. Investiga-
tions and results prior to stoma reversal were evaluated. Notes review 
clarified whether investigations altered management. We also collected 
data on pre- and post-operative medical management and time to first 
flare.
results: 48 patients (age range 15-78y, 21 females:27 males) were evalu-
ated. Montreal classification was; 19% L1 (n=9, 89% B2, 11% B3), 4% L2 
disease (n=2 B3), 77% L3 (n=37, 27% B2, 73% B3). 23% also had perianal 
disease. Investigations performed prior to stoma reversal included faecal 
calprotectin (2%, n=1), rigid sigmoidoscopy (2%, n=1), endoscopy (27%, 
n=13), cross-sectional imaging 33% (23%, n=10 MR Enterography, and 
10%, n=5 CT enterography), contrast studies 83% (54%, n=26 loopogram, 
and 30%, n=14 water soluble enema) and examination under anaesthesia 
(5%, n=2). 19% (n=9) investigation findings changed management; ex-
pedited closure n=3, delayed closure n=1, intraoperative endoscopy n=2, 
reversal indefinitely postponed due to active disease n=3. Time with stoma 
ranged from 32-1806 (median 192) days. Time with stoma was similar for 
elective and emergency stoma-forming operations. 
Of the patients whose stomas were reversed (n=45), 9 patients had flares 
within a year of reversal and 28 did not. Contrast studies were requested 
in 78% (flare) and 79% (no flare) of cases whereas disease activity was 
assessed in 33% and 54% of cases respectively. The characteristics of each 
group (those that flared under a year and those that did not flare) dif-
fered in terms of disease phenotype (67% vs 36% B2 and 33% vs 64% 
B3 respectively). There was no significant differences between historical 
treatments and post-reversal therapy (33% vs 29% no therapy, 56% vs 
40% thiopurine monotherapy and 11% vs 32% biologic therapy). Three 
patients were not reversed; one had obvious symptoms of active disease 
and supporting investigations, two had abnormal investigation findings 
(in the absence of obvious symptoms of active disease) resulting in a deci-
sion against surgery.
conclusion: There are no current guidelines to advise how patients with 
Crohn’s disease should be assessed prior to stoma reversal. Practice is 
variable and investigations focus on anatomical abnormalities (exclusion 
of strictures) rather than objective measures of disease activity. As clinical 
symptoms do not always mirror disease activity, failure to assess disease 
activity may have an association with adverse outcomes post-operatively 
and deserves further research.
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P1828 OPTIMaL TIMIng Of ILeOcecaL resecTIOn In crOhn’s 
dIsease: nO dIfference In cLInIcaL OuTcOMe afTer earLy and 
LaTe surgery
Beelen E.M.J.1, Sleutjes J.A.M.1, de Graaf E.J.R.2, Bodelier A.G.L.3, 
Hoentjen F.4, Dijkstra G.5, de Boer N.K.6, Romberg-Camps M.7, 
van der Woude C.J.1, de Vries A.C.1, the Dutch Initiative on Crohn 
and Colitis (ICC)
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Rotterdam, Netherlands, 2Ijsselland Hospital, Surgery, Capelle aan den Ijssel, 
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Netherlands, 4Radboud University Medical Center, Gastroenterology and 
Hepatology, Nijmegen, Netherlands, 5University Medical Center Groningen 
(UMCG), Gastroenterology and Hepatology, Groningen, Netherlands, 
6Amsterdam UMC, Vrije Universiteit Amsterdam, Gastroenterology and 
Hepatology, Amsterdam, Netherlands, 7Zuyderland Medical Center, 
Gastroenterology and Hepatology, Sittard-Geleen, Netherlands
contact e-Mail address: e.beelen@erasmusmc.nl
Introduction: Early ileocecal resection (ICR) in Crohn’s disease (CD) may 
prolong clinical remission and reduce the risk of complications. Optimal 
timing of ICR is yet unknown as long-term data comparing the clinical 
outcome after ICR at different CD stages are lacking. In this study, we aim 
to compare the disease course in CD patients following acute, early and 
late ICR.
aims & Methods: CD patients aged 16 years and older who underwent 
primary ICR between 2000 and 2018 in 4 academic and 2 teaching hospi-
tals were included. Patients were identified in a local pathology database 
and demographic, clinical and surgical data were collected from medical 
charts. The study population was divided in 3 groups according to the tim-
ing of resection: ICR at first CD manifestation or within 1 month after diag-
nosis (surgery at diagnosis), within 1 year after diagnosis (early surgery) 
or more than 1 year after diagnosis (late surgery). The primary outcome 
was clinical recurrence, defined as the start or switch of CD medication 
for symptomatic disease. Secondary outcomes were endoscopic recur-
rence (Rutgeerts score ≥i2b) and/or radiologic recurrence (echo, CT and 
MRI), surgical recurrence (re-resection) and hospitalization. Early surgery 
and late surgery cohorts were matched using propensity score matching 
(1:1) accounting for sex, disease localization, disease behaviour, peri-anal 
fistulas, smoking, calendar year of ICR, and the use of prophylactic postop-
erative biologicals or thiopurines. Kaplan Meier survival analysis and Cox 
proportional hazard analysis were performed.
results: A total of 513 CD patients (320 females (62%), median age 30.8 
(IQR 23.5 - 42.3)) were included. ICR was performed at first CD manifesta-
tion or within 1 month after CD diagnosis in 48 patients (9%), early surgery 
was performed in 103 patients (20%, after median 5.1 months, range 1.1 
- 11.9) and late surgery in 361 patients (70%, after median 62.3 months, 
range 12.5 - 562.6). The cumulative probability of clinical recurrence after 
surgery at diagnosis was 18.8%, 33.4% and 47.7% after 1, 5 and 10 years 
respectively, which was significantly lower as compared to 25.6%, 57.1% 
and 77.6% after early surgery (p =0.005) and 28.4%, 63.6% and 80.6% 
after late surgery (p=0.001). Endoscopic and/or radiologic recurrence rates 
were also significantly lower in patients with an acute resection at diagno-
sis as compared to early and late surgery (p=0.023). No significant differ-
ences were observed between groups regarding hospitalization (p = 0.578) 
and re-resection (p=0.327). 
After propensity score matching, clinical recurrence rates for the matched 
early surgery group (n=99) were 25.5%, 56.9% and 77.6% after 1, 5 and 
10 years and 24.0%, 63.1% and 74.8% after 1, 5 and 10 years (p=0.849) 
in the late surgery group (n=99). No significant differences were found in 
endoscopic and/or radiologic recurrence, hospitalization or re-resection.
conclusion: The long-term outcome of acute ICR at CD diagnosis is charac-
terized by lower rates of clinical recurrence as compared to early and late 
surgery. When accounting for known risk factors for postoperative recur-
rence and prophylactic postoperative medication use, no differences were 
observed in clinical, endoscopic or surgical recurrence rates in early versus 
late ICR in CD.
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Kingdom, 5Humanitas Research Hospital, Rozzano, Milano, Italy, 6Consultant 
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Healthcare NHS Trust, London, United Kingdom, 7Humanitas University, 
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Introduction: Crohn’s disease (CD) is a relapsing and remitting disorder 
with an annual incidence of 3 to 20 per 100,000. Ileocecal involvement 
is the commonest disease pattern in Crohn’s disease (CD) and is seen in 
over half of the patients [1]. Surgery is required when medical manage-
ment fails or when secondary complications develop. The probability of 
requiring surgery for CD is 78% and 90% after 20 and 30 years of disease, 
respectively [2].
aims & Methods: The primary aim of this study was to identify factors 
associated with laparoscopic procedures requiring conversion to open sur-
gery in patients undergoing minimally invasive ileocolic resection (MIICR) 
for Crohn’s disease (CD).
We analysed data of consecutive patients who underwent MIICR between 
January 2005 and May 2018 for CD at 2 European tertiary care centres. 
A Logistic regression analysis was performed to identify statistically signifi-
cant factors associated with conversion to an open approach.
results: Three hundred and ninety-two patients (M:F 185:207) underwent 
MIICR. Their mean age at surgery was 48.3 (SD-14.5) years. Seventy-two 
(18.4%) patients required conversion to an open approach. 
The regression model was statistically significant (p< 0.0001) and clas-
sified 84.5% of the cases accurately. The multivariate analysis identified 
age at surgery (odds ratio 1.03), males (OR 2.8), prior resection (OR 2.9), 
diversion of stool (OR 4.3) and simultaneous colon resection (OR 2.5) to be 
associated with a higher risk of conversion to open surgery.
Ethnicity, ASA grade, smoking, diabetes, use of biologics, albumin level, 
perianal disease, stricturoplasty, or duration of disease did not affect con-
version.
conclusion: Males, older patients, prior resection and stool diversion were 
associated with a higher chance of conversion to open approach. This 
finding should be considered during the preoperative informed consent 
process.
references: 1. Y., L., et al., A laparoscopic approach reduces short-term 
complications and length of stay following ileocolic resection in Crohn’s 
disease: an analysis of outcomes from the NSQIP database. Colorectal Dis-
ease, 2012. 14(5): p. 572-577. 2. Coffey, J.C., et al., Inclusion of the mesen-
tery in ileocolic resection for Crohn’s disease is associated with reduced 
surgical recurrence. J Crohns Colitis, 2018.
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Introduction: Crohn’s disease (CD) is a relapsing and remitting disorder 
with an annual incidence of 3 to 20 per 100,000. Ileocecal involvement 
is the commonest disease pattern in Crohn’s disease (CD) and is seen in 
over half of the patients [1]. Surgery is required when medical manage-
ment fails or when secondary complications develop. The probability of 
requiring surgery for CD is 78% and 90% after 20 and 30 years of dis-
ease, respectively [2]. A prolonged hospital stay after surgery has health, 
economical and social implications. Enhanced recovery pathways aim to 
optimise the hospital stay.
aims & Methods: The primary aim of this study was to identify pre- and 
perioperative factors associated with a prolonged length of stay (LOS) after 
ileocolic resection in CD.
We analysed data of consecutive patients who underwent surgery for CD 
between January 2005 and May 2018 at 2 European tertiary care centres. 
A logistic regression analysis was performed to identify statistically signifi-
cant factors associated with a prolonged hospital stay.
results: A total of 628 patients (M: F 326:302) were included in the analy-
sis. Their mean age at surgery was 44.1(SD-15.0) years. The median length 
of stay was 6-days (interquartile range 5-9). 
The regression model was statistically significant (p< 0.0001) and clas-
sified 66.3% of the cases accurately. The multivariate analysis identified 
open surgery (Odds ratio 2.2), strictureplasty (OR 2.5), longer disease du-
ration (OR 1.03) and Asian ethnicity (OR 3.1) to be significantly associated 
with a hospital stay of ≥7 days. 
Age at surgery, sex, ASA grade, smoking, diabetes, use of biologics, albu-
min level, perianal disease, prior bowel resections, simultaneous bowel 
resection or laparoscopic conversion did not increase the LOS.
conclusion: Patients undergoing open surgery, strictureplasty and longer 
disease duration were more likely to require a hospital stay greater than 
seven days. Such factors should be taken into consideration in any en-
hanced recovery pathway in order to tailor the patient journey.
references: 1. Y., L., et al., A laparoscopic approach reduces short‐term 
complications and length of stay following ileocolic resection in Crohn’s 
disease: an analysis of outcomes from the NSQIP database. Colorectal Dis-
ease, 2012. 14(5): p. 572-577. 2. Coffey, J.C., et al., Inclusion of the mesen-
tery in ileocolic resection for Crohn’s disease is associated with reduced 
surgical recurrence. J Crohns Colitis, 2018.
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Introduction: Crohn’s disease (CD) is a relapsing and remitting disorder 
with an annual incidence of 3 to 20 per 100,000. Ileocecal involvement 
is the commonest disease pattern in Crohn’s disease (CD) and is seen in 
over half of the patients [1]. Surgery is required when medical manage-
ment fails or when secondary complications develop. The probability of 
requiring surgery for CD is 78% and 90% after 20 and 30 years of disease, 
respectively [2]. Although most patients do not require a stoma at the pri-
mary operation, there is no way to predict the likelihood of a stoma. This 
ambiguity affects pre-operative informed consent. Injudicious avoidance 
of a stoma can increase the risk of anastomotic complications and need for 
additional interventions.
aims & Methods: The primary aim of this study was to identify factors 
leading to primary stoma formation after ileocolic resection for Crohn’s 
disease (CD).
We analysed data of consecutive patients who underwent surgery for CD 
between January 2005 and May 2018 in 2 European tertiary care centres. 
A Logistic regression analysis was performed to identify statistically sig-
nificant factors associated with stoma formation in patients undergoing 
ileocolic resection for CD.
results: A total of 628 patients (M: F 326:302) underwent surgery. Their 
mean age at surgery was 44.1(SD-15.0) years. Eighty-one patients (12.8%) 
had stomas created at the primary operation. Forty-three(53.1%) were 
end-ileostomies the rest were defunctioning stomas. 
The regression model was statistically significant (p< 0.0001) and clas-
sified 86.3% of the cases accurately. The multivariate analysis identified 
lower pre-op albumin (odds ratio 0.89), males (OR 2), simultaneous co-
lonic (OR 7.3) resection and prior resection (OR 2.8 per previous surgery) 
to be significantly associated with stoma formation.
Age at surgery, ethnicity, use of biologics, smoking, perianal disease, 
emergency surgery or simultaneous strictureplasty or small bowel resec-
tion were not associated with a higher chance of stoma formation.
Of the patients who did not have a stoma at the primary operation, 11 (2%) 
needed subsequent surgery for anastomotic leaks in the post-operative 
course. Fifty-five (67.9%) had their stomas reversed.
conclusion: Low albumin, previous resections, males and simultaneous 
colonic resection were associated with a higher chance of primary stoma 
formation. Preoperative strategy planning including the approach to pri-
mary-stoma might reduce the need for reintervention.
references: 1. Y., L., et al., A laparoscopic approach reduces short‐term 
complications and length of stay following ileocolic resection in Crohn’s 
disease: an analysis of outcomes from the NSQIP database. Colorectal Dis-
ease, 2012. 14(5): p. 572-577. 2. Coffey, J.C., et al., Inclusion of the mesen-
tery in ileocolic resection for Crohn’s disease is associated with reduced 
surgical recurrence. J Crohns Colitis, 2018.
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P1832 hOW TO OPTIMIze The MedIcO-surgIcaL ManageMenT 
Of PerIanaL fIsTuLIzIng crOhn’s dIsease TO Increase The 
raTe Of fIsTuLa cLOsure?
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Peyrin-Biroulet L.1, Bouguen G.2
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Introduction: Perianal fistulizing Crohn’s disease (PCD) remains a chal-
lenge to treat, despite the use of TNF antagonists. Several guidelines 
agreed to recommend a medico-surgical management but half of patients 
with PCD would still suffer from persistent disease. The aim of the study 
was to assess the best medico-surgical strategy for treating PCD.
aims & Methods: The medical records of all patients with fistulizing peri-
anal Crohn’s disease treated with TNF antagonists in two referral centers 
between 1998 and 2018 were reviewed. The therapeutic persistence was 
performed to compare infliximab and adalimumab treatment using a Ka-
plan-Meier method. The cumulative incidences of complete fistula closure 
were estimated using the Kaplan-Meier method. Medical and surgical 
predictors of long-term outcomes were identified using a Cox proportional 
hazards model and used to propose the optimal medico-surgical manage-
ment.
results: A total of 200 patients were included. At PCD diagnosis, 19% of 
patients were B3 and 44.5% were L3 according to the Montreal classi-
fication. A total of 41% of patients had associated proctitis. The overall 
cumulative probabilities of fistula closure were 26.8% and 69.8% at 1 and 
5 years, respectively. Infliximab were more likely to be used compared to 
adalimumab (73.5% vs 26.5%, respectively). The therapeutic persistence 
of TNF antagonist was of 138.73 weeks without difference between adalim-
umab and infliximab. Of note patients treated with ADA were more likely to 
experience treatment optimization (60.4% vs 30.6% in IFX group). 
Regarding the medical treatment, the combination of TNF antagonist with 
an immunosuppressant (HR=1.55, p=0.03) and the presence of a proctitis 
(HR=1.74, p=0.0086) were independently associated with fistula closure. B1 
phenotype was associated with lower rate of fistula closure. When consid-
ering the perianal surgery, the initial drainage of the fistula with a seton 
and an additional surgery during the follow-up were also associated with 
an increase of fistulas closure. No difference was observed between the 
type of additional surgery (seton insertion, fistulotomy, rectal advance-
ment flap and others). However, this effect was only observed when the 
complementary surgery was performed within the first year of TNF an-
tagonist treatment.
Finally, the best management of the PCD was the association of a combi-
nation therapy following a first drainage with a seton and then a comple-
mentary surgery within the first year. The cumulative probabilities of fistu-
la closure in this setting were 44% and 98% at 1 and 5 years, respectively.
conclusion: The combination of medical and surgical treatment is required 
for the management of patients with PCD. Both part of the treatment 
should be early and proactively optimized to increase the rate of fistula 
closure.
disclosure: Nothing to disclose 
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Introduction: In light of the global growth in the spread of antibiotic-resis-
tance in microorganisms, commensal bacteria require serious attention, 
particularly the key representatives of the human intestinal microbiota in 
view of their genome plasticity, reservoirs of antibiotic resistance, resis-
tance mechanisms in vivo and in vitro, as well as the ability to transfer 
resistance modules. Bacteria of the genus Lactobacillus, including L. plan-
tarum, are important residents of human gut, oral cavity, and urogenital 
tract, and are widely used for correction of the intestinal microbiota com-
position. However, the information of the antibiotics effects on genomic 
profile and drug sensitivity of these microorganisms is rare and contradic-
tory.
aims & Methods: The aim of our research was to elucidate the effects of 
clarithromycin (Clr) and amoxicillin (Amx) used for the eradication therapy 
of Helicobacter pylori on the L. plantarum genomic profile and sensitivity to 
these antibiotics. The object of the study was the strain L. plantarum 8P-
A3, isolated from the probiotic supplement “Lactobacterin dry” (Biomed 
Perm Research and Manufacturing Association, Russia), and the clinical 
strain L. plantarum HP227-5, isolated from the intestinal microbiota of a 
patient who underwent H. pylori eradication treatment according to the 
Maastricht Protocol (amoxicillin 1000 mg bid, clarithromycin 500 mg bid, 
proton pump inhibitor and bismuthate tripotassium dicitrate 240 mg bid 
for 14 days). Both strains were cultivated at 37°C on Man-Rogosa-Sharpe 
(MRS) medium. In order to obtain the resistant strain, sequential cultiva-
tion of the initial L. plantarum 8P-A3 with an increasing antibiotics concen-
tration to clinically significant levels was performed. Total DNA extracted 
from strains was sequenced on the MiSeq platform (Illumina). The reads 
were assembled using SPAdes v.3.11.1, the SNP calling was performed us-
ing SNPEff v.3.6.
results: As a result of selection of the initial laboratory strain L. plantarum 
8P-A3 (MIC of Clr and Amx was 0.04 µg/ml and 0.01 µg/ml, respectively) 
the strain L. plantarum 8P-A3Clr+Amx with high resistance to both clarithromy-
cin and amoxicillin (Clr concentration of 5.5 µg/ml and Amx concentration 
of 14.5 µg/ml) was obtained. Ten mutations were found in the genome of 
L. plantarum 8P-A3Clr+Amx, including 4 mutations in antibiotics target genes 
(rplD, rplV, penA, pbpB) and 6 novel mutations in genes which were not 
mentioned earlier as determinants of clarithromycin and amoxicillin resis-
tance in bacteria: transcriptional termination factor Rho (rho), PhoH-like 
protein, teichoic acid ribitol-phosphate polymerase (tarL), GDP-mannose 
4,6-dehydratase (gdpP), transcriptional regulatory protein (walR) and one 
hypothetical protein. However, mutations identified in L. plantarum 8P-
A3Clr+Amx were not detected in the genome of L.plantarum HP227-5, and no 
resistance to clarithromycin and amoxicillin was revealed in the clinical 
isolate.
conclusion: Our data suggests that the antibiotic therapy used in the Maas-
tricht Protocol for H. pylori eradication does not cause the development of 
antibiotic resistance in clinical isolate L.plantarum, and the mechanisms 
for adapting to antimicrobials in vitro and in vivo may vary significantly 
in these bacteria. To confirm this assumption, it is necessary to conduct 
a study with a large cohort of patients. The ability of L. plantarum str. 8P-
A3Clr+Amx to transfer clarithromycin and amoxicillin resistance genes to other 
bacteria also requires further research.
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Introduction: Fusobacterium nucleatum has long been found to cause op-
portunistic infections and has recently been implicated in colorectal cancer 
(CRC), which brings great attentions widely. However, the mechanism is 
still largely unknown. We found that the relative abundance of F. nuclea-
tum in fecal microbiota was significantly increased in colorectal cancer 
patients in our previous study. To explore the causative role it may have in 
CRC development, we inoculated C57BL/6 mice with one clinical F. nuclea-
tum strain isolated from a CRC patient’s fecal sample, and then evaluated 
the structure of colon microbiota, colon pathology and gut barrier function 
after F. nucleatum infection.
aims & Methods: We isolated one clinical strain (FN16) enriched in relative 
abundance 3% of the CRC patient’s gut mucosa bacteria, and identified 
it as F. nucleatum by biochemical tests and 16S ribosomal RNA gene se-
quencing. Four groups of mice were then compared to reveal difference, 
i.e., control group, F. nucleatum infection group (FUSO), Azoxymethane-
induced CRC group (AOM) and AOM+FUSO infection group. To establish in-
fection, we infused 108 cells of FN16 every day for two weeks into C57BL/6J 
mice by gastric gavage. Body weight, length of colon, colorectal tumor for-
mation ratio, colorectal barrier function and gut microbiota structure were 
assessed to explore the potential role of FN16 in the development of CRC.
results: The body weight, colon length and colorectal tumor formation ra-
tio profiles exhibited significant differences among the four groups. FUSO 
group showed significantly reduced body weight and shorter colon length 
compared with the control group. And AOM+FUSO showed the highest tu-
mor formation ratio and the worst body weight among the four groups. 
What’s more, colon pathology was the most serious in the AOM+FUSO 
group, which was confirmed by hematoxylin-eosin staining. The colon 
mucosa of FUSO mice developed obvious inflammation phenotype with 
the higher level of IL-6 (P< 0.01) and TNF-α(P< 0.01) by the RT-PCR results. 
The AOM+FUSO group showed the same pattern compared with the AOM 
group, and the mRNA expression of IL-6 (P< 0.05) and TNF-α(P< 0.01) in 
colon tissue of AOM+FUSO group were significantly higher. In addition, the 
mRNA expression of ZO-1 (P< 0.05) and Claudin-1 (P< 0.01) in colon mu-
cosa of FUSO group were reduced, indicating the dysfunction of gut bar-
rier. To explore the reason of F. nucleatum-caused colon inflammation and 
gut barrier damage, we profiled the structure of mucosa microbiota of the 
four groups. We found that the structure of colon microbiota changed a lot 
after F. nucleatum infection; striking differences in fecal microbial popula-
tion patterns were observed between FUSO and control group, AOM+FUSO 
and AOM group. Inflammation-inducing genus Bacteroides was enriched 
in the mucosa microbiota of FUSO and AOM+FUSO group, whereas the 
genera Lactobacollus and Ruminococcus were significantly less abundant. 
The dysbiosis of colon mucosa microbiota, characterized by the enrich-
ment of inflammation-inducing pathogens and the decreased in probiotics 
members, therefore represent a specific microbial signature of F. nuclea-
tum infection, which may provide new sights into the role of this bacteria 
in promoting colorectal cancer.
conclusion: The CRC mice with infection of F. nucleatum FN16 isolated from 
the CRC patient shows aggravated intestinal inflammatory conditions and 
dysbiosis of colon microbiota, suggesting that the F. nucleatum may be a 
contributing factor to CRC, rather than a bystander.
references: Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer 
Patients. Na Wu, Xi Yang, Ruifen Zhang, Jun Li, Xue Xiao, Yongfei Hu, Yan-
fei Chen, Fengling Yang, Na Lu, Zhiyun Wang, Chunguang Luan, Yulan Liu, 
Baohong Wang, Charlie Xiang, Yuezhu Wang, Fangqing Zhao, George F. 
Gao, Shengyue Wang, Lanjuan Li, Haizeng Zhang, Baoli Zhu. August 2013, 
Volume 66, Issue 2, pp 462-470
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Introduction: Obviously H.pylori eradication therapy can lead to changes of 
gut microbiota composition. However, there is limited data concerning the 
influence of eradication therapy on functional potential of the human gut 
microbiota that is probably more important in maintaining human health.
aims & Methods: The aim of the study was to evaluated influence of 
H.pylori eradication therapy on gut microbiota metabolic potential. 
Stool samples from 102 H.pylori-positive patients before and immediately 
after eradication therapy (proton pump inhibitor, amoxicillin 1000 mg, 
clarithromycin 500 mg and bismuthate tripotassium dicitrate 240 mg bid 
for 14 days) and 29 samples 1 month after therapy from the same patients 
were collected. Stool samples total DNA was sequenced on SOLiD 5500xl-
W. Reads were mapped to ChocoPhlAn using the HUMAnN2 algorithm 
for functional profiling. Relative abundances of metabolic pathways (MP) 
were calculated as “cpm” - a number of reads mapped to pathway divided 
by a total number of mapped reads, p< 0.05 was considered as significant. 
MP were categorized by MetaCyc database.
results: Serious alterations of the gut micriobiota functional potential 
were observed due to H.pylori eradication therapy: significant differences 
were found in the relative abundance of 180 MP. Most of the changes were 
observed for biosynthesis pathways: immediately after the therapy 97 MP 
[biosynthesis of amino acids (6), carbohydrates (9), cell structures (4), co-
factors, prosthetic groups, electron carriers (45), fatty acids and lipids (23), 
nucleosides and nucleotides (7), metabolic regulators (2), siderophores 
(1)] and 1 tRNA processing MP were more represented in the gut micro-
biota than initially. However, 8 biosynthesis MP [amino acids (2), cofactors, 
prosthetic groups and electron carriers (2), fatty acids and lipids (1), nucle-
osides and nucleotides (1)] became less represented compared to baseline.
Changes in abundance of Degradation/Utilization/Assimilation pathways 
were observed immediately after the therapy, including increased repre-
sentation of 43 MP [alcohols (2), aldehydes (1), amines and polyamines (4), 
amino acids (4), aromatic compounds (8), carboxylates (3), secondary me-
tabolites (4), carbohydrates (8), inorganic nutrients (5), nucleosides and 
nucleotides (1), fatty acids and lipids (3)] while 4 pathways [degradation of 
pyrimidine nucleotides (1), carbohydrates (2) and formaldehyde assimila-
tion (1)] became less represented after eradication than before therapy. 
Similar changes were noted for Generation of Precursor Metabolite and 
Energy processes: abundance of 6 MP decreased, however, abundance of 
21 MP increased immediately after the therapy compared to initial level, 
including fermentation processes, acetyl-CoA biosynthesis, pentose phos-
phate pathway, TCA cycle, aerobic respiration, glycolysis.
By the end of the month after eradication therapy a tendency to return 
to the initial level was observed for most of functional potential changes. 
However, changes in abundance of 28 MP: Biosynthesis (22), Degradation/
Utilization/Assimilation (4) and Generation of Precursor Metabolites and 
Energy (2) still persisted. Most of these pathways were more represented 
in the gut microbiota one month after the end of therapy than initially.
conclusion: So H.pylori eradication therapy caused significant changes in 
the gut microbiota metabolic potential, some of which persisted even one 
month after the end of therapy. An increased abundance of most pathways 
could be associated with stress response of the gut microbiota on the back-
ground of antibacterial therapy.
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Introduction: Butyrate is a major energy source for colonocytes and plays 
an important role in maintaining the stability of the gut microbiota, pre-
vention of inflammation and gene expression regulation. Current data 
suggest a wide spectrum of positive effects of butyrate with a high poten-
tial for a therapeutic use. Antibacterial therapy is known to alter composi-
tion and functional potential of the gut microbiota.
aims & Methods: The aim of the study was to assess the influence of 
H.pylori eradication therapy on the gut microbiota functional state with 
respect to short-chain fatty acids production.
Stool samples were collected from 102 H.pylori-positive patients before 
(the baseline) and immediately after eradication therapy (amoxicillin (1000 
mg), clarithromycin (500 mg), proton pump inhibitor, bismuthate tripotas-
sium dicitrate (240 mg) bid for 14 days), as well as 29 stool samples were 
collected one month after the end of treatment from the same patients. To-
tal DNA extracted from stool samples was sequenced on SOLiD 5500xl-W 
platform (whole genome sequencing). For metabolic profiling reads were 
aligned to ChocoPhlAn database using the HUMAnN2 algorithm. Relative 
abundances of pathway were calculated as “cpm” - a number of reads 
mapped to pathway divided by a total number of mapped reads. Differ-
ences were assessed using Wilcoxon signed-rank test (p-value< 0.05 was 
considered statistically significant). Metabolic pathways were classified ac-
cording to MetaCyc database.
results: The pronounced functional changes of the gut microbiota, includ-
ing metabolic pathways of fermentation to short-chain fatty acids were 
revealed immediately after the eradication therapy. Abundance of follow-
ing pathways - fermentation to lactate (ANAEROFRUCAT-PWY: homolactic 
fermentation; P122-PWY: heterolactic fermentation), to acetate (P161-PWY: 
acetylene degradation), to propionate (PWY-7013: L-1,2-propanediol deg-
radation) was increased comparing with baseline - 83.58±46.16 cpm vs. 
61.87±33.04 cpm, 12.52±25.28 cpm vs. 4.24±9.02 cpm, 19.80±35.60 cpm vs. 
7.99±10.58 cpm and 16.95±63.10 cpm vs. 2.88±8.09 cpm, respectively.
However the abundance of metabolic pathways related to butyrate pro-
duction - CENTFERM-PWY: pyruvate fermentation to butanoate and PWY-
5676: acetyl-CoA fermentation to butanoate II - was decreased in the 
gut microbiota after therapy compared to initial level: 1.92±2.18 cpm vs. 
3.12±3.62 cpm and 15.39±13.18 cpm vs. 17.88±9.72 cpm, respectively. Abun-
dance of following metabolic pathways - PWY-7288 fatty acid β-oxidation, 
PWY66-391: fatty acid β-oxidation VI, where butyrate could be consumed 
as the initial agent of the reaction was increased after therapy compar-
ing to baseline, 0.04±0.09 cpm vs. 0.03±0.17 cpm and 0.07±0.17 cpm vs. 
0.05±0.25 cpm, respectively. Representation of PWY-6803: phosphati-
dylcholine acyl editing pathway, in which butyrate derivatives could be 
produced was increased immediately after the eradication treatment com-
pared to initial level, 22.00±42.54 cpm vs. 6.45±16.12 cpm. 
No significant changes were observed in the relative abundance of meta-
bolic pathways involved in butyrate formation in the gut microbiota one 
month after eradication therapy compared to the baseline level that may 
be due to the compensatory possibilities of the gut microbiota.
conclusion: So H.pylori eradication therapy leads to alteration of butyrate-
producing metabolic pathways in the human gut microbiota, changes re-
turn to the initial level one month after the treatment.
disclosure: Nothing to disclose 
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Introduction: Very little is known about the variation in the mucosa-associ-
ated microbiota (MAM) along the human gastrointestinal (GI) tract.
aims & Methods: We aimed to determine the bacterial communities in dif-
ferent parts of the GI tract and compare patients without gastrointestinal 
disease with patients with Crohn’s disease (CD) and Ulcerative colitis (UC).
We recruited 72 patients undergoing upper GI endoscopy and colonoscopy 
for the assessment of a positive FOBT with normal results of the endoscop-
ic investigations (other than small adenoma) and no symptoms reported 
utilising a standardised assessment of gastrointestinal symptoms (SAGIS). 
In addition, we recruited 44 patients with CD and 50 patients with UC. 
Utilising the Brisbane Aseptic Biopsy Device, we obtained biopsies from 
the proximal small intestine, terminal ileum, ascending colon and rec-
tum without cross contamination from luminal contents or other regions 
of the GI tract. Biopsy samples were immediately placed under aseptic 
conditions into a sterile tube containing RNA later (Qiagen). Samples were 
allowed to incubate at room temperature for 30 minutes, then frozen and 
stored at -80°C. Total DNA was extracted from biopsies, and sample free 
reagent controls, using a repeated bead-beating based method. Samples 
were profiled by high-throughput amplicon sequencing with dual-index 
barcoding using the Illumina MiSeq platform, targeting the V6-V8 region 
of the gene encoding 16S ribosomal RNA. The libraries were sequenced on 
an Illumina MiSeq platform and the data were quality assessed, trimmed 
and filtered, then processed using the Quantitative Insights into Microbial 
Ecology version 2 (QIIME2) software. Microbiota and statistical analyses 
were performed in QIIME2 and R. Significant differences in Shannon and 
Chao1 alpha diversity metrics between sample types, and between disease 
states for each sample type, were calculated using Kruskal-Wallis and un-
paired Wilcox rank sum tests. Differentially abundant taxa were identified 
with DESeq2 using a likelihood ratio test while correcting for age, BMI 
and gender.
results: Across all patient groups, the three most abundant genera in the 
duodenum were Streptococcus, Pseudomonas and Prevotella. However, 
in the terminal ileum, right colon and rectum, Faecalibacterium, Bacte-
roides, and Escherichia-Shigella were the three most abundant bacterial 
taxa. There were significant differences in the Shannon and Chao1 diversity 
scores of the mucosa-associated microbiota (MAM) present in the duode-
num and terminal ileum (P< 0.001-0.05) between UC and CD, and UC and 
controls, with greater diversity found for the control subjects. In the right 
colon and rectum, significantly lower Shannon diversities were observed 
in UC and CD vs controls (P< 0.05).
conclusion: There are marked differences in the three most abundant bac-
teria in the upper and lower gut. Similarly, MAM from different parts of 
the human GI tract reveal distinct characteristics in the relation to the most 
prevalent bacterial taxa and the alpha diversity observed at these sites. 
Interestingly, both UC and CD patients have different MAM profiles in both 
proximal and distal sites of the GI, and these are different from those ob-
served for healthy asymptomatic controls.
disclosure: Nothing to disclose 
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Introduction: Decreased microbial diversity of the fecal microbiota is rec-
ognized as a part of gut dysbiosis[1] and hence treatments increasing 
microbial diversity, such as fecal microbiota transplantation (FMT) have 
attracted much attention within recent years.
FMT has, in many studies, improved the fecal alpha-diversity which has 
also been correlated with improved clinical effects [2].
FMT treatment by capsules has emerged as a possible way to continuously 
transfer fecal material giving lower doses of fecal material, delivered on 
a daily basis.
aims & Methods: The aim of our research was to investigate if, and poten-
tially when, FMT delivered through capsules changes the fecal microbiota 
diversity in patients with Irritable Bowel Syndrome (IBS), and to investi-
gate if the effects diminish over time.
To investigate this we analysed samples from a previously published 
placebo-controlled randomized clinical trial investigating the effects of 12 
days of 25 daily multidonor FMT capsules treating 52 patients with IBS [3]. 
We tested fecal samples from baseline, and at 15 days, 1, 3 and 6 months 
following the commencement of treatment using 16S RNA sequencing. 
Wilcoxon signed-rank tests (p≤0.05) were used to compare alpha-diversity 
levels at each time-point after baseline with the levels at baseline.
results: From a median fecal alpha-diversity (Chao1 index) of 306,5 at 
baseline the median diversity increased at all the following timepoints. 
The increase was significant after 15 days (404,3, p=0,005), 1 month (433,4 
p=0,005) and 3 months (421,3 p=0,0002), but was no longer statistically 
significant after 6 months (379,1, p=0,08). The placebo group did not sig-
nificantly change their median fecal alpha-diversity at any timepoint. From 
a baseline level of 342,1 the median fecal alpha diversity was between 
324,6 and 376,9 at the following timepoints. 
The increases in fecal alpha-diversity was significant when compared to 
the changes in the placebo group after 15 days (p=0,03) and 3 months 
(p=0,004).
conclusion: Twelve days of daily FMT treatment given by capsules signifi-
cantly increases the fecal microbiological alpha-diversity of patients with 
IBS and this persists for at least three months.
However, the increased alpha-diversity was in general not associated with 
a beneficial clinical effect in the FMT group when compared to the placebo 
group. Future studies must assess if FMT might improve symptoms in some 
patients with IBS and in particular in patients with low fecal microbial 
diversity.
references: 1. Kriss M, Hazleton KZ, Nusbacher NM, et al. Low diversity gut 
microbiota dysbiosis: drivers, functional implications and recovery. Cur-
rent opinion in microbiology. 2018 Aug;44:34-40. 2. Rossen NG, Fuentes 
S, van der Spek MJ, et al. Findings From a Randomized Controlled Trial of 
Fecal Transplantation for Patients With Ulcerative Colitis. Gastroenterology. 
2015 Jul;149(1):110-118. 3. Halkjær SI, Christensen AH, Lo BZS, et al. Faecal 
microbiota transplantation alters gut microbiota in patients with irritable 
bowel syndrome: Results from a randomised, double-blind placebo-con-
trolled study. Gut. 2018;67(12):2107-2115.
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Introduction: Autism Spectrum Disorder (ASD) is a neurodevelopmental 
disorder in which dysfunctions of the microbiota-gut-brain axis are in-
creasingly recognized. In particular, alterations in gut microbiota or their 
metabolites, such as secondary biliary acids, have been suggested to con-
tribute to ASD pathology. In order to study how dysbiosis could affect gut 
functions and enteric nervous system (ENS) homeostasis, we used fecal 
supernatant (FS) prepared from ASD patients and healthy controls (HC). 
Specifically, we studied the impact of FS on intestinal epithelial barrier 
functions and ENS phenotype.
aims & Methods: Antibiotic-treated mice received enema of FS from ASD 
patients (n=16) and from healthy controls (n=10). Paracellular and transcel-
lular gut permeability were measured in vivo and ex vivo in proximal colon. 
Gene and protein expression for glial (S100b, GFAP), neuronal (GAP43, 
synapsin1) and inflammatory molecules (IL-1β, TNFα) were analyzed in 
proximal colon, brain and primary culture of ENS treated with FS from 
ASD patients or HC. Finally, concentrations of several bacterial metabolites 
(short chain fatty acids and biliary acids) were measured in FS by mass 
spectrometry. 16S metasequencing of the intestinal microbiota was per-
formed for ASD patients and HC.
results: No change of in vivo permeability was observed in mice treated with 
FS from ASD patients while ex vivo transcellular and paracellular permeabili-
ty of proximal colon was decreased as compared to HC. FS from ASD patients 
induced a decrease of mRNA expression of TNFα, IL-1β, and an increase for 
S100β and GAP43 in the colon. This latter result was reproduced in primary 
cultures of ENS. In addition, the protein expression of the synaptic marker 
synapsin1 was decreased in the colon and showed a trend of reduction in 
the brain (amygdala) of mice treated with FS from ASD patients compared to 
controls. The concentration of the secondary bile acid deoxycholic acid was 
higher in the FS from ASD patients as compared to HC. Changes in bacterial 
proportion are observed in ASD patients as compared to HC, with a relative 
increase of Bacteroidetes and decrease of Firmicutes.
conclusion: FS from ASD patients alter intestinal permeability and expres-
sion of inflammatory and ENS molecules. The factors in FS from ASD pa-
tients responsible for these changes remain to be identified.
This project was supported by “Fondation pour la Recherche Médicale”.
disclosure: Nothing to disclose 
P1840 esTaBLIshMenT Of a sTOOL Bank In a cOunTry WITh 
LOWer huMan deveLOPMenT Index
Nakov R.1, Lyutakov I.2, Petkova V.3, Kaneva R.3, Penchev P.4, 
Vatcheva-Dobrevska R.5, Vladimirov B.6, Nakov V.7
1Clinic of Gastroenterology, Queen Yoanna University Hospital, 
Gastroenterology, Sofia, Bulgaria, 2University Hospital ‘Tsaritsa Yoanna - 
ISUL’, Gastroenterology, Sofia, Bulgaria, 3Medical University Sofia, Molecular 
Medicine Center, Sofia, Bulgaria, 4Medical University Sofia, Gastroenterology, 
Sofia, Bulgaria, 5Medical University Sofia, Microbiology and Virology, Sofia, 
Bulgaria, 6UMBAL Tsaritsa Joana, Gastroenterology, Sofia, Bulgaria, 7Tsaritsa 
Joanna University Hospital, Gastroenterology, Sofia, Bulgaria
contact e-Mail address: radislav.nakov@gmail.com
Introduction: Fecal Microbiota transplantation (FMT) is a novel therapy, 
with proven efficacy against recurrent Clostridium difficile infection (CDI). 
For safe implementation and broader application of FMT, quality con-
trolled stool banking is a must. Establishing a stool bank is a complex, 
time-consuming and expensive process, making it a real challenge in a 
country with lower Human Development Index (HDI)
930 UEG Journal | Abstract Book
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aims & Methods: We aimed to establish the first stool bank in an Eastern 
European country - Bulgaria. A multidisciplinary team of gastroenterolo-
gists, medical microbiologists, infectious diseases specialist and geneti-
cists was set up. We used a questionnaire based on the First European FMT 
Consensus (1) in order to recruit possible stool donors. Microbiota analysis 
was performed on all selected donors.
results: Between October 2018 and April 2019, 112 donor volunteers com-
pleted a questionnaire; 70 (62.5%) were excluded, mainly because age 
above 50, an unhealthy BMI and risk behavior. Fourty-two (37.5%) donor 
candidates were invited for laboratory testing of blood and feces of which 
12 (28.6%) passed this screening. Presence of Helicobacter pylori fecal an-
tigen and Multi Drug Resistant Organisms were the most observed exclu-
sion criteria. Of 12 donors, 4 (33%) failed at a following screening test, 
which is performed every three months. Finally, 8 (7.14%) active donors 
were enrolled.
conclusion: Even though we found many healthy volunteers, only a low 
percentage (7.14%) of them are suitable to become feces donors. Estab-
lishing of a stool bank in a country with lower HDI is important for mak-
ing FMT saver and more popular as a treatment method, finding further 
implementation and regulation of FMT and supporting physicians offering 
this treatment to their patients.
references: 1. Cammarota G, Ianiro G, Tilg H, et al. European consensus 
conference on faecal microbiota transplantation in clinical practice. Gut. 
2017 Apr;66(4):569-580.
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Introduction: An urgent problem of modern urology is the increase in the 
number and rejuvenation of the age of patients suffering from urolithiasis. 
It has been established that from 70 to 80% of stones excreted during uro-
lithiasis are calcium oxalate, and the level of oxaluria depends in a certain 
way on the composition and functional activity of intestinal microbiota, in 
particular on the ability to degrade oxalates. Except for Oxalabacter formi-
genes, a number of normobiote representatives are capable to metabo-
lize oxalate salts (e.g. Lactobacillus spp., Bifidobacterium spp., Eubacterium 
lentum, Bacillus spp, Enterococcus faecalis,). The anbibiotics decreased the 
quantity of oxalate-degrading bacteria (ODB) but there is no available data 
and approaches to evaluate the total oxalate-degrading activity (ODA) of 
fecal microbiota (without isolation of pure culture).
aims & Methods: The aim of the present study was to develop approach 
for evaluation of total ODA of fecal microbiota and to assess the dynamics 
changes in the ODA of fecal microbiota after broad-spectrum antibiotic 
ceftriaxone treatment in rats. The object of the study was fecal microbi-
ota of male Wistar rats (200-300 g, n = 6). Ceftriaxone (300 mg/kg, CJSC 
“Darnitsa”, Ukraine) was injected intramuscularly for 7 days. Faeces were 
collected before antibiotic treatment and on the 1st, 14th and 56th days af-
ter antibiotic withdrawal. The quantity of ODB was determined by culture 
method on a highly selective Oxalate Medium (g/L): K
2
HPO
4 
- 0.25; KH
2
PO
4 
- 0.25; (NH4)
2
SO
4 
- 0.5; MgSO
4
·7H
2
O - 0.025; CH
3
COON - 0.82; yeast extract 
- 1.0; rezazurin - 0,001; Na
2
CO
3 
- 4; L-cysteine-HCl - 0.5; Trace element so-
lution SL-10 - 1 ml with the following composition per L: HCl (25%; 7.7 M) 
- 10.00 ml, FeCl
2
 x 4H
2
O - 1.50 g, ZnCl
2 
- 70.00 mg, MnCl
2
 x 4H
2
O - 100.00 
mg, H
3
BO
3 
- 6.00 mg, CoCl
2
 x 6H
2
O - 190.00 mg, CuCl
2
 x 2H
2
O - 2.00 mg, 
NiCl
2
 x 6H
2
O - 24.00 mg, Na
2
MoO
4
 x 2H
2
O - 36.00 mg; та Na
2
C
2
O
4 
- 5 mg 
(cultivated anaerobically at 37°C for 48 hours). The redoximetric titration 
(with KMnO4) was adopted to evaluate the total ODA of faecal microbiota. 
The results were expressed in % degradation of oxalate for 0.01 g of feces.
results: At the 1st day after ceftriaxone withdrawal, we observed increase 
a number of ODB from lg 8.02±0.25 CFU/g to lg 9.47±0.17 CFU/g (p< 0.05) 
and fecal microbiota ODA from 9.50±1.78 % to 11.67±2.99 %. At the 14th day 
there was a significant decrease a number of ODB by more than 2 orders of 
magnitude (from lg 8.02±0.25 CFU/g to lg 5.72±0.48 CFU/g, p< 0.05), that 
was accompanied diminish the fecal ODA - from 9.50±1.78 % to 6.3±1.46 
%. By the 56th day, a number of ODB was almost unchanged vs. 14th day 
of experiment (lg 5,28±0,45 CFU/g, p< 0.05), but fecal ODA continued de-
crease (from 9.50±1.78 % to 4.67 ± 1.87%, p< 0.05).
conclusion: 1) The redoximetric titration (with KMnO4) is the reliable meth-
od for evaluation of total ODA of the fecal microbiota without isolation of 
pure culture and might have clinical application. 2) Ceftriaxone treatment 
reduced the total oxalate-degrading activity of fecal microbiota indepen-
dently on number of ODB.
disclosure: Nothing to disclose 
P1842 The dynaMIcs Of MucOsa-assOcIaTe BacTerIa In 
IrrITaBLe BOWeL dIsease
Inoue J., Hayashi H., Oyama K., Ikegawa T., Tanaka S., Tanaka T., 
Kodama Y.
Kobe University Graduate School of Medicine, Gastroenterology, Kobe, Japan
contact e-Mail address: juninoue@med.kobe-u.ac.jp
Introduction: The gut microbiota between individuals varies greatly, while 
the composition of gut microbiota within individual slightly changes over 
time. Fecal samples can be easily collected and are often used to analyzing 
gut microbiota. 
On the other hand, the composition of mucosal bacteria differs from that 
of luminal bacteria. Though mucosal bacteria are considered to be impor-
tant in the pathophysiology of intestinal disease including irritable bowel 
disease (IBS), there are small numbers of study investigating the dynamic 
analysis of mucosa-associated bacteria because of the difficulty of collect-
ing the sample comparing to fecal samples.
aims & Methods: The purpose of this study is to analysis the dynamics 
of mucosa-associated bacteria over time in patient with IBS. The mucus 
samples including mucosal bacteria were collected from terminal ileum, 
cecum, transverse colon, sigmoid colon and rectum in same patient with 
IBS three times at the examination with lower endoscopy using cytology 
blush. After extracting DNA from mucus samples, 16S metagenome were 
performed by Miseq platform(Illumina). Sequence data were quality fil-
tered and microbial composition, alpha and beta diversities were analyzed 
using QIIME open-source software.
results: The microbial composition of mucosal samples collected by blush 
were comparable to that of mucosal samples collected by mucosal biopsy 
and microbial DNA amount in the mucus samples collected by blush were 
more than 1000 times larger than that of from biopsy samples. Though the 
microbial composition of mucosal bacteria were different from that of fecal 
samples, there were not big different change when comparing between 
each mucosal samples collected from terminal ileum, cecum, transverse 
colon, sigmoid colon and rectum. 
Compared to luminal bacteria, the proportion of Sutterella, Enterobacteri-
aceae, Delftia and Pseudomonas were increased in the mucus samples on 
the other hands Phascolarctobacterium, Blautia, Lachnospiraceae, Para-
bacteroides were decreased. Interestingly PCoA analysis revealed that the 
microbial composition of mucosa-associate bacteria had slightly changed 
over time as with the fecal microbial composition.
conclusion: In this study there are small dynamic changes of mucosa-asso-
ciate bacteria as with luminal bacteria within the individuals in IBS patient 
over time and may constantly contribute to the pathophysiology of IBS.
disclosure: Nothing to disclose 
P1843 PeOPLe’s MOTIvaTIOn ThrOugh sOcIaL neTWOrks 
cOuLd Increase ParTIcIPaTIOn In cOLOrecTaL cancer 
screenIng caMPaIgns
Koivogui A.1, Levi S.2, Lewkowicz S.3, Gombeaud T.4, Le Mab G.1, 
Benamouzig R.5
1Comite Departemental Des Cancer, Bondy, France, 2MEDORION, Tel Aviv, 
Israel, 3Zav-Menia NGO, Tel Aviv, Israel, 4Association de Dépistage du Cancer 
Colorectal (ADCCR), Seine-Saint-Denis, Bobigny, France, 5Hopital Avicenne, 
Service de Gastroenterologie, Bobigny, France
contact e-Mail address: robert.benamouzig@aphp.fr
Introduction: Colorectal cancer (CRC) screening using fecal occult blood 
testing results in reduced CRC mortality. However participation rates in 
organized campaign remains low and rarely exceed 50% in most French 
departments. The Colorectal Cancer Screening Association in Seine-Saint-
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Denis considered outreach via social networks to people aged 50-74 living 
in deprived target areas with a high proportion of NPAI (mail invitation 
campaign not distributed).
aims & Methods: The purpose of this analysis was to describe the proce-
dure and initial results of the pilot study.
67,000 people aged 50 to 74 years from six municipalities with low socio-
economic background and a proportion of NPAI over 10% were consid-
ered. Accounting to the biannual frequency of departmental screening 
campaigns, the average participation rate in these area was only 25% in 
2017 with a 19% exclusion rate due to medical reasons (previous colonos-
copy, high risk patients…) and 11% NPAI. A pilot Facebook campaign ran 
for 2 months. Facebook presented the ads as defined by the scientific com-
mittee to the target population. The team operated using a simple web-
based healthcare engagement platform designed to increase participation 
developed by Medorion©, Israel. No special computer skills are required 
and training is a simple 2-hour web seminar. The Facebook campaign 
does not require names, Emails or any predefined contact information. 
The rate of engagement can be adjusted to the capacity of the team as well 
as the project budget. In this campaign, 33,000 Facebook users living in 
this area were targeted. All data collected is stored outside of Facebook in 
a HIPAA and GDPR compliant platform according to European legislation.
results: Over a two-month engagement period, 4317 people click on the 
CRC screening advertising and 298 people applied for a test kit. Overall, 
84% of requests were made outside working hours (9 a.m-5 p.m) and 
100% provided an email, postal address, and a phone number (100% mo-
bile). Of these, 160 (53.7%) were eligible for CRC screening after verifica-
tion on a dedicated regional eligibility site (www.neonetidf.org). Ineligible 
population included 38 people who resided outside Seine-Saint-Denis, 
16 people who were outside the age range, 48 people that could not be 
verified because to inaccurate information provided, 30 people who had 
recent CRC screening, and 6 who had recent or ongoing colon disease. 
The average age of the 160 eligible people was 54 yrs and among them 
64 (40%) carried out the screening test to date, higher than the 25% best 
effort so far. For the other 96 at 60 days after the Facebook campaign 
closure, a weekly email reminder is still sent to increase this participation.
conclusion: Extrapolating to a possible year-long project, this method can 
easily reach a 3 to 5% increase in CRC screening within this target popula-
tion, which has a history of non-compliance and have not been responsive 
to previous attempts. It is important to note that the results are based on 
modest pilot settings, small budget, no specific creative, and not backed by 
a state trusted entity promoting the screening, making these results even 
more significant.
disclosure: Nothing to disclose 
P1844 changes In cOLOrecTaL cancer IncIdence In yOung 
aduLTs In engLand: a POPuLaTIOn Based sTudy 1974 - 2015
Dixon S.1,2, Chambers A.C.1, White P.3, Williams A.C.1, Thomas M.4, 
Messenger D.4
1University of Bristol, Cell & Molecular Medicine, Bristol, United Kingdom, 
2Bristol Royal Infirmary, Department of Gastroenterology, Bristol, United 
Kingdom, 3University of the West of England, Department of Engineering, 
Design & Mathematics, Bristol, United Kingdom, 4Bristol Royal Infirmary, 
Department of Colorectal Surgery, Bristol, United Kingdom
contact e-Mail address: stevewdixon@doctors.net.uk
Introduction: Colorectal cancer (CRC) remains a major cause of cancer-
related mortality worldwide. Recent reports from the United States[1,2], 
Canada[3] & Australia[4] have suggested that the incidence of CRC in 
young adults is rising. Using a novel dataset from the English population 
we aimed to determine the temporal changes in CRC incidence trends by 
age group and cohort.
aims & Methods: This was a retrospective, population-based cohort study 
of all patients aged 20 years and above diagnosed with CRC between 1974 
and 2015 in England. Data were obtained from the National Cancer Reg-
istration and Analysis Service operated by Public Health England using 
ICD-9 and -10 codes for CRC. Mid-year population estimates were obtained 
from the Office for National Statistics and used to calculate age-specific in-
cidence rates for ten age groups that were age-adjusted to the 2013 Euro-
pean Standard Population. Join-point regression analysis was performed 
to analyse the magnitude and direction of temporal changes in age-spe-
cific incidence rates. Age-period-cohort modelling was used to assess the 
independent effects of age, period and cohort on CRC incidence rates.
results: Between 1974 and 2015 a total of 1,145,639 diagnosis of CRC were 
made (726887 colon, 418752 rectum). Since 1966 there has been a marked 
rise in the incidence rate ratio (IRR) for both colon and rectal cancer: com-
pared with the reference year 1926, the IRR has doubled (1.92, 95% CI 
1.08-3.43) for colon and tripled (3.07, 95% CI 1.79-5.26) for rectal cancer. 
Strikingly, since 2001 the incidence rate among 20-29 year olds has risen 
by 20.7% per year and by 12.7% per year among 30 - 39 year olds. CRC 
incidence initially rose following the introduction of the Bowel Cancer 
Screening Programme in 2006 but this has subsequently plateaued. The 
incidence rates of CRC among other age groups has remained largely un-
changed.
conclusion: This novel data from England mirrors the recently described 
trends in reported in other economically developed countries of rising inci-
dence of CRC in young adults. Work is required to elucidate the underlying 
causes to allow public health measures required to slow or reverse the 
current trend which is likely to place further strain on already stretched 
healthcare resources in England. 
Furthermore, understanding the mechanisms underpinning the trends 
described herein may allow risk stratification for screening tests in young-
er adults who would not otherwise qualify for testing. Any such expansion 
of screening practices is likely to have a significant impact on the cost and 
service provision requirement within the confines of the English National 
Health System.
references: [1] Siegel, R.L., et al., Colorectal Cancer Incidence Patterns in 
the United States, 1974-2013. J Natl Cancer Inst, 2017. 109(8). [2] Patel, P. and 
P. De, Trends in colorectal cancer incidence and related lifestyle risk fac-
tors in 15-49-year-olds in Canada, 1969-2010. Cancer Epidemiol, 2016. 42: 
p. 90-100. [3] Brenner, D.R., et al., Increasing colorectal cancer incidence 
trends among younger adults in Canada. Prev Med, 2017. 105: p. 345-349. 
[4] Boyce, S., et al., Young-onset colorectal cancer in New South Wales: a 
population-based study. Med J Aust, 2016. 205(10): p. 465-470.
disclosure: Nothing to disclose 
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P1846 cOLOrecTaL cancer POPuLaTIOn-Based screenIng 
PrOgraM In a POrTuguese dIsTrIcT - PreLIMInary resuLTs
Martins da Cunha C.1, Gago T.1, Roseira J.2, Campelo P.1, Peixe B.1, 
Cardoso C.3, Caldeira P.1, Correia F.3, Guerreiro H.1
1Centro Hospitalar Universitário do Algarve, Serviço de Gastrenterologia, 
Faro, Portugal, 2Centro Hospitalar Universitário do Algarve, Serviço de 
Gastrenterologia, Portimão, Portugal, 3Núcleo de Rastreios da Administração 
Regional de Saúde do Algarve, Algarve, Portugal
contact e-Mail address: anacdacunha@gmail.com
Introduction: Colorectal cancer (CCR) is a leading cause of death world-
wide. Since there is a strong correlation between mortality and the dis-
ease stage, focus on the preclinical phase to recognize and treat precursor 
lesions is the main priority. Organized screening programs for CCR are 
emerging in Europe to face the overall growing incidence.
aims & Methods: The aim of this study was to evaluate the diagnostic 
performance of the program and to define potential adjustments to the 
strategy adopted. 
Observational study from a pilot population-based screening program for 
CCR in a Portuguese district based on fecal immunochemical test (FIT) with 
a cut-off level of 100 ng/mL. Colonoscopy was the standard diagnostic fol-
low-up test. Preliminary data were collected from January 2018 to March 
2019 to analyze screening measures and quality indicators according with 
national advices adapted from the European Union guidelines. Advanced 
adenoma (AA) was defined as any adenoma with at least one of the fol-
lowing features: ≥10 mm in size, villous or tubulo-villous component, high 
grade dysplasia.
results: The tested population consisted of 6636 individuals and the posi-
tivity rate was 4% (n=257). Of all those who tested positive, 55% (n=142) 
underwent colonoscopy. In total, 153 colonoscopies were performed, in-
cluding 11 repeated for diagnostic/therapeutic purposes, with an overall 
adequate bowel preparation of 91%. The cecal intubation rate was 92%. 
The polyp and adenoma detection rates were 57% and 43%, respectively. 
The AA detection rate was 22% matching 51% of all detected adenomas 
with a true-positive rate of 24% and a false-positive rate of 32%. Neopla-
sia was diagnosed in 6 cases.
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conclusion: The AA detection rate was substantially high when compared 
with data published in literature alongside with an unexpected low posi-
tivity rate. These findings could justify lowering the FIT cut-off level, in 
order to increase the diagnostic yield, and carrying out actions to improve 
the colonoscopy participation rate.
disclosure: Nothing to disclose 
P1847 PaTTern Of dIsTanT MeTasTases In rIghT versus LefT 
cOLOrecTaL cancer: a seer Based sTudy
Hassan M., Uthman I., Hafez M., Elrawy B.
Suez Canal University Hospital, Ismailia, Egypt
contact e-Mail address: mariamdarweesh11@gmail.com
Introduction: Colorectal carcinoma (CRC) is one of the common malignan-
cies with escalating incidence and mortality. Today, it is considered a dou-
ble-faced disease; each face has a unique pathology, management, and 
prognosis. Immense efforts are applied to explore the behavior of CRC in 
both sides of the colon; therefore, in this study we focus on the metastatic 
pattern of CRC in right and left sides.
aims & Methods: We identified 10714 patients who have been diagnosed 
with stage 4 CRC from 2010 to 2013 through Surveillance, Epidemiology 
and End Results (SEER) database. Metastatic pattern for liver, peritoneum, 
lung, bone and brain was analyzed.
results: We found 6805 and 3909 patients had left and right CRC, respec-
tively. Right CRC had higher incidence rate of liver and peritoneum metas-
tases than left CRC (92.9 % vs. 89.7 % and 30% % vs. 27.3 % respectively, 
P= 0.003). While, on the other hand, left CRC had a higher incidence rate 
of lung metastases (31.5% vs. 25.6%) than right CRC. No statistical signifi-
cance difference was found regarding pattern of bone or brain metastases 
between both colon sides. Males with right CRC were more susceptible to 
the five sites of metastases than females. Albeit males with left CRC were 
the least to develop peritoneum, lung and brain metastases compared to 
females. Concerning the survival rates, patients with tumors arising from 
left colon had better 1-year survival rates in comparison to those with tu-
mors from right colon (64.7% and 49% respectively, p < 0.001).
conclusion: Right CRC patients are more vulnerable to liver and perito-
neum metastases; however, those with left CRC have higher probability 
to develop lung metastases, furthermore, they have better survival rates.
disclosure: Nothing to disclose 
P1848 are gI cancers BeIng dIagnOsed frOM OuTsIde 
The ‘urgenT cancer’ referraL PaThWay?
Mehta A., Hong S., Sachdeva A., Patel R.N., Tariq Z., King J., Besherdas K.
Royal Free London NHS Trust, Gastroenterology, London, United Kingdom
contact e-Mail address: rajan.patel@nhs.net
Introduction: The UK lags behind Europe in the diagnosis, treatment and 
survival rates of cancer. To improve on this and diagnose cancer early, pa-
tients with alarm symptoms from primary care are referred on a ‘Two week 
wait’ (2WW) urgent pathway. Previous data indicates that the majority of 
cancers diagnosed in the UK are from outside the 2WW pathway. However, 
demand for upper and lower GI endoscopy via the 2WW has risen dramati-
cally above and beyond the steady increase in overall GI cancer incidence.
aims & Methods: We aimed to study the diagnostic pathways via which 
GI cancers are diagnosed. We reviewed the common luminal upper and 
lower GI cancers diagnosed at endoscopy at a single centre between 
February 2017 and September 2018 via Unisoft GI Reporting Tool. Known 
malignancies and diagnoses made at other Trusts were excluded (n= 72). 
Retrospective analysis of 317 patients with 332 GI cancers was performed.
results: 332 GI cancers (oesophagus 44 (13.9%), stomach 21 (6.6%), duo-
denum 6 (1.9%), colon 174 (54.9%), rectum 87 (27.4%)). Mean age 71.1 
(range 24 - 97), Female 133 (42.0%). Median time to diagnosis (i.e. presen-
tation to endoscopy) was 22 days (IQR 14 to 34). 
Referral pathways included: 202 (63.7%) GP Target 2WW, 45 (14.2%) In-
patient, 30 (9.5%) Urgent 2WW from clinic/hospital discharge, 21 (6.6%) 
Abnormal imaging, 17 (5.4%) Routine clinic, 2 (0.6%) Surveillance.
Only 48 (15.1%) GI cancer patients went ‘Straight To Test’ (STT) whereas 
198 (62.5%) were seen in clinic first. The mean time to diagnosis in those 
referred via the GP Target 2WW was 25.4 days (STT) versus 32.2 days (clinic 
review), (p = 0.05). 
conclusion: In this study, we conclude that two thirds of GI cancers were 
diagnosed following referral via the 2WW pathway but only one third of 
gastric cancers. Of the 2WW patients, two thirds had a clinic review prior 
to endoscopy which resulted in a 7 day delay in cancer diagnosis compared 
to STT patients. We conclude that more patients with cancer are diagnosed 
on the 2WW pathway than previously documented and triaging patients 
STT speeds up the diagnosis further by 7 days. We recommend that the 
majority of 2WW patients be triaged STT so that earlier diagnosis of can-
cer may result in improved survival and reduce the gap compared to our 
European counterparts.
disclosure: Nothing to disclose
 
all gI 
cancers 
(n=332)
Oesopha-
gus n=44
gastric 
n=21
colon 
n=174
rectum 
n=87 p value
age (mean, s.d) 71.1 
(13.5)
73.8 
(11.6)
71.8 
(17.8)
71.5 
(13.2)
68.0 
(13.7)
0.10
Time to diagnosis 
(median, Iqr)
22 
(14-34)
19 
(7-28)
11 
(5-28)
24.5 
(17-38.75)
23 
(16-33)
0.27
gP ‚2WW’ 
Pathway (%)
202 
(63.7)
25 
(56.8)
7 
(33.3)
109 
(62.6)
69 
(79.3)
0.0003
sTT (%) 48 
(15.1)
9 
(20.5)
2 
(9.5)
24 
(13.8)
13 
(14.9)
0.63
curative 
Treatment (%)
204 
(64.4)
13 
(29.5)
2 
(9.5)
129 
(74.1)
65 
(74.7)
<0.00001
[Table 1. Pathways to diagnosis for individual GI cancers (+ STT/clinic/A&E)]
P1849 Ten-year cOLOrecTaL cancer MOrTaLITy afTer 
adenOMa reMOvaL
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Värmlands Nysäter & Centre for Clinical Research, Värmlands Nysäter, 
Sweden, 5Karolinska Institute, Department of Medical Epidemiology and 
Biostatistics, Stockholm, Sweden, 6Cancer Registry of Norway, Oslo, Norway, 
7Sørlandet Hospital Trust, Department of Medicine, Kristiansand, Norway, 
8Frontier Science Foundation, Boston, United States
contact e-Mail address: h.c.jodal@medisin.uio.no
Introduction: Patients who have had adenomas removed are believed to 
be at increased risk for colorectal cancer (CRC). Dependent on adenoma 
characteristics, these patients are recommended surveillance colonosco-
py at regular intervals. Previously, we did not find increased risk for CRC 
among patients with previous adenoma 7.7 years after polypectomy (1). We 
have updated the results with more than 10 years follow-up, in accordance 
with the time horizon of current surveillance guidelines.
aims & Methods: We identified all patients without a prior diagnosis of 
CRC who had adenomas removed in Norway from 1993 to 2007 through the 
Cancer Registry of Norway (1). Norwegian guidelines recommended colo-
noscopy surveillance after 10 years after removal of high-risk adenomas, 
and no surveillance after removal of low-risk adenomas. We calculated 
standardised incidence-based mortality ratios (SMRs) using age-, sex- and 
period-specific rates for the Norwegian population as comparison. High-
risk adenomas were defined as multiple adenomas (two or more) and 
adenomas with either villous growth-pattern or high-grade dysplasia.
results: We included 40,824 patients who had colorectal adenomas re-
moved. During a median follow-up of 10.7 years (maximum 23.0 years), 
1820 patients were diagnosed with and 520 died of CRC. Overall, adenoma 
patients had a similar risk of CRC death to the general population (SMR 
0.98; 95 % confidence interval (CI) 0.90-1.07). Patients with high-risk ad-
enomas had increased risk of CRC death (SMR 1.23; 95 % CI 1.09-1.39), 
while patients with low-risk adenomas had reduced risk (SMR 0.82; 95 
% CI 0.72-0.92). The absolute risk of CRC death for patients with low-risk 
adenomas was 1.1 %, and 1.6 % for those with high-risk adenomas.
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conclusion: Patients with low-risk adenomas have a lower risk of CRC 
death than the general population and do not need surveillance. The risk 
for patients with high-risk adenomas is only marginally increased and sur-
veillance should be discussed.
references: 1. Loberg M, Kalager M, Holme O, Hoff G, Adami HO, Bretthau-
er M. Long-term colorectal-cancer mortality after adenoma removal. N 
Engl J Med. 2014;371(9):799-807.
disclosure: Nothing to disclose 
P1850 shOuLd yOung PaTIenTs WITh IncIdenTaLLy deTecTed 
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recOMMendaTIOns? rIsk Of MeTachrOnOus neOPLasIa and 
reaL surveILLance PracTIces
Chang H.E., Lee H.H., Choi Y.H., Kim S.-J., Cho Y.K., Park J.-M., Lee B.-I., 
Cho Y., Lee I.-S., Choi M.-G.
Catholic University of Korea Seoul St. Mary’s Hospital, Department of Internal 
Medicine, Seoul, Korea (Republic of)
contact e-Mail address: lia1999@naver.com
Introduction: The current guidelines for colonoscopy surveillance after 
screening and polypectomy are for patients aged 50 and older. It is not 
well known whether post-polypectomy surveillance recommendations are 
appropriate for young patients less than age 40 years with incidentally 
detected adenomas.
aims & Methods: The aims of the study were to identify the occurrence of 
metachronous advanced neoplasia in young patients < 40 years and to 
investigate whether surveillance recommendations by endoscopists com-
plied with the current national guidelines. We retrospectively analyzed 
the medical record obtained from the Catholic University of Korea Seoul 
St.Mary’s Hospital and health screening center. Patients under the age of 
40 with ≥1 adenoma removed on colonoscopy between January 2010 and 
December 2017 were eligible.
results: Among a total of 8,168 subjects who underwent colonoscopy dur-
ing the study period, 723 were eligible after excluding those with no neo-
plastic lesion (n=7,414), familial adenomatous polyposis (n=10), colorectal 
cancer (n=10), and neuroendocrine tumor (n=11). Of these 723 patients, 140 
(19.4%) had high risk adenoma, which consisted of 3 or more adenomas 
(n=25), any adenoma larger than 10 mm (n=35), any tubulovillous or vil-
lous adenoma (n=7), any adenoma with high-grade dysplasia (n=52), and 
any serrated polyps larger than 10 mm (n=21). The high risk patients were 
younger (32 vs. 34 years, P = 0.015), more female (42.9% vs. 31.7%, P = 
0.016) and had lower BMI (22.8 vs. 24.2, P = 0.001) compared to the low 
risk patients. Surveillance colonoscopy was performed in 22.3% (130/583) 
of the low risk patients and 35.7% (50/140) of the high risk patients (P = 
0.001). Metachronous advanced neoplasia was identified in 1.5% (2/130) of 
the low risk patients and 12.0% (6/50) of the high risk patients (P = 0.002). 
Furthermore, we could confirm the record of endoscopist surveillance 
recommendation in 142 patients. The compliance rates with the national 
guidelines were 25.0% for the low risk neoplasia and 55.0% for high risk 
neoplasia. Almost all noncompliant patients underwent follow up colo-
noscopy earlier than recommended.
conclusion: Even in young patients less than age 40 years, a shorter in-
terval of surveillance colonoscopy should be applied to the patients with 
high risk adenoma to detect the metachronous advanced neoplasia. Most 
noncompliant patients were observed to undergo surveillance colonos-
copy earlier than recommended.
disclosure: Nothing to disclose 
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Introduction: Colorectal cancer (CRC) is one of the most common cancers 
in Europe. Recently the American Cancer Society published a qualified rec-
ommendation advocating the start of CRC screening at 45 years, based on 
the increase in the incidence of CRC in individuals with <55 years (45-49 
years: 31/100,000; 50-54 years: 58/100.000), in contrast to a reduction in 
individuals with >65 years. Mortality rate (MR) was stable in patients <55 
years (45-49 years: 8/100,000; 50-54 years: 13/100,000) and decreased af-
ter 55 years.
aims & Methods: We intended to evaluate if the changes in the CRC inci-
dence/mortality observed in the USA also occur in Portugal and perform 
a cost-effectiveness analysis of CRC screening starting at 45 years of age. 
We evaluated the incidence of CRC by age group using data from the Na-
tional Cancer Registry and MR according to the National Statistics Institute 
between 1993-2010 and 2003-2016, respectively. Cost-effectiveness analy-
sis performed with a decision tree from a societal perspective compar-
ing biennial faecal immunochemical test (FIT) or one single colonoscopy 
screening versus non-screening at the age of 45 years-old in Portugal. 
Efficacy was measured in quality-adjusted life years (QALY). For the base-
case scenario, the incidence rate used for the age of 45-50 years-old was 
30/100,000, the FIT cost was €3 with a 50% acceptance rate and the colo-
noscopy cost was €397 with a 38% acceptance rate. The threshold was 
set at €39,760/QALY and the primary outcome was the incremental cost-
effectiveness ratio (ICER).
results: In Portugal, between 1993 and 2010, there was an increase in 
CRC incidence of 17% (25/100,000 vs. 30/100,000), 35% (39/100,000 vs. 
54/100,000) and 71% (52/100,000 vs. 97/100,000) in patients with 45-49 
years, 50-54 years and 55-59 years, respectively. The MR of patients with 
45-54 years remained stable between 2003 and 2016 (12/100,000) as a 
counterpoint to a moderate decrease in individuals with 55-64 (38/100,000 
vs. 35/100,000) and a sharp reduction in 65-75 (93/100,000 vs. 75/100,000). 
Screening for CRC at the age of 45 was not cost-effective with the present 
incidence. FIT screening provided an ICER of €57,995/QALY while colonos-
copy provided an ICER of €2,117,564/QALY. In one-way sensitivity analysis 
FIT screening would be cost-effective at the present cost and acceptance 
rates if the incidence rate rises above 38/100,000 (current rates for people 
aged ≥50 years-old); colonoscopy at this age was never cost-effective de-
spite changes in costs and/or incidence rates.
conclusion: In Portugal the incidence of CRC in patients aged 45-55 years 
has been increasing, with stable MR, contrary to the decrease in MR in the 
age groups covered by CRC screening programs. This scenario is similar 
to what has been described in the United States of America. However, 
CRC screening in Portugal, at the age of 45 years-old at present is not 
cost-effective and will only be cost-effective if the incidence rates rises to 
38/100,000. The current CRC screening strategy, starting at the age of 50 
years-old, by biennial FIT, is clearly cost-effective as the incidence rate is 
already 55/100,000.
disclosure: Nothing to disclose 
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P1852 screenIng fOr cOLOrecTaL cancer. dIfferences 
BeTWeen MaLes and feMaLes In Our hOsPITaL. resuLTs In 
84559 suBjecTs
Hontoria Bautista G.1, Jiménez Moreno M.A.2, Bernad Cabredo B.2, 
Moncada Urdaneta A.C.2, Sicília Aladrén B.3, Gomez Camarero J.2, 
Pereda García R.2, Sanz Sánchez J.2, Saiz Chumillas R.2, 
Saez-Royuela Gonzalo F.2
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Spain, 2Hospital Universitario de Burgos, Burgos, Spain, 3H Universitario de 
Burgos, Gastroenterology, Burgos, Spain
contact e-Mail address: gadeva@hotmail.com
Introduction: Worldy, Colorectal Cancer (CRC) is the thirth cancer more fre-
quent in males and the second in women. Screening programmes have 
demonstrated the detection of CRC in early stages allowing a more effec-
tive treatment.
aims & Methods: 
- To describe the findings and the differences in neoplastic findings be-
tween sexes in the asymptomatic participants. 
- Screening programme for CRC was introduced in our hospital in octo-
ber 2014. We collected data until March 2019. Men and women between 
50 and 69 years old were invited to undergo a Faecal Occult Blood Test 
(FOBT). Those who obtained a positive result were offered to perform a 
colonoscopy. 
The following results have been calculated from the data base CRC Screen-
ing Programme of Junta de Castilla y León in Burgos.
results: In total, 84559 subjects were invited to take part in the program. 
Of these, 32871 provided a faecal sample resulting in a 38.9% participation 
rate (52,2% females). FOBT was positive in 3228 individuals (9.8%), 58.1% 
of them were males; 2649 (82.1%) of them underwent a colonoscopy.
Of those 2649, colonoscopies were negative or had non neoplasic find-
ings in 422 (27.6%) males and 572 (51.1%) females. We detected low-risk 
adenomas (LRA) in 393 (25.7%) males and in 270 (24.1%) females, p < 
0.01; medium-risk adenoma (MRA) in 383 (25%) males and 177 (15.8%) 
females, p = 0.1; and high-risk adenomas (HRA) in 186 (12.2%) males and 
52 (4.6%) females, p = 0,0001. Adenoma detection rate (ADR) resulted in 
55.2%. 194 invasive CRC were found (9.4% of males and 4.4% of females). 
The probability of being diagnosed of adenoma (RR 1.35, 95% IC 1.26 - 
1.45; p < 0.0001) and CRC (RR 2.16, 95% IC 1.59 - 2.94; p < 0.0001) was 
higher in males.
conclusion: Participation rate of the screening programme in our hospital 
is very low, remaining below 45%, established as the acceptable rate in 
European Guidelines. On the other hand, colonoscopy acceptance rate was 
82,1%. However, there are an unknown percentage of people, who decide 
to perform FOBT and/or colonoscopies in private centres. 
FOBT positivity rate was 9.8%, slightly higher than in the rest of Spain 
(6.8%). 
ADR was 55.2%, more than 25% required by European quality guidelines.
In more than half of participants, neoplasic adenomas were resected 
avoiding their progression to advanced neoplasia. CRC, LRA and HRA were 
more frequent in males with similar rates described in bibliography.
disclosure: Nothing to disclose 
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Introduction: Colorectal cancer (CRC) screening is important because sur-
vival mainly depends on the stage at diagnosis.
aims & Methods: We aimed to analyze the impact of annual fecal immuno-
chemical test-triggered colonoscopy (FIT-C) compared to screening colo-
noscopy (SCR-C) on the detection rates of low-risk adenomas (LRA), high-
risk adenoma (HRA) and CRC among individuals with average CRC risk. 
Two prospective population based CRC screening strategies, annual FIT 
screening vs. SCR-C were compared within a province of Austria. All as-
ymptomatic individuals, who underwent FIT-C or SCR-C between 01/2003 
and 12/2014, were included in this population-based screening study. We 
excluded individuals with a history of inflammatory bowel disease or he-
reditary CRC syndromes. The lesions were classified in three groups: CRC, 
HRA and LRA including tubular adenoma ≤ 1cm.
results: Fourteen thousand four hundred thirteen individuals (median age 
62; 53% males) with FIT-C were compared to 10.083 individuals (median 
age 60; 52% males) with SCR-C.
The CRC detection rates were 1.26% (confidence interval (CI): 1.05; 1.48) 
in FIT-C compared to 0.54% (CI: 0.39; 0.68) SCR-C (p<0.001). The HRA 
detection rates were 14.22% (CI: 13.65; 14.79) in FIT-C compared to 6.84% 
(CI: 6.43; 7.25) in SCR-C (p<0.001). The LRA detection rates were 16.98% 
(CI: 16.25; 17.72) in FIT-C compared to 12.95% (CI: 12.3; 13.61) in SCR-C 
(p<0.001).
conclusion: FIT-C presents an effective CRC-screening method in subjects 
with average CRC-risk as this population-based study demonstrated that 
FIT-C doubles detection rate of HRA and CRC in head-to-head comparison 
with SCR-C.
disclosure: Nothing to disclose 
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Introduction: Non-polyposis colorectal cancer (CRC) in young adults (aged 
≤ 50 years) represents 10-15% of all CRC. Current clinical guidelines recom-
mend performing tumour mismatch repair deficiency testing in all CRC pa-
tients (by immunohistochemistry (IHC) for MLH1, MSH2, MSH6 and PMS2), 
as a screening for Lynch syndrome (so-called universal strategy). When 
IHC reveals loss of protein expression, guidelines recommend performing 
germline genetic analyses to confirm Lynch syndrome 1. However, recent 
studies in early-onset CRC cases suggest the existence of germline muta-
tions in MMR or other genes in which IHC study may not be altered 2.
aims & Methods: To describe the diagnostic yield of performing univer-
sal germline genetic testing in patients with non-polyposis CRC aged 50 
years or less in order to improve the identification of hereditary CRC syn-
dromes. 
A total of 253 patients, corresponding to all patients aged ≤ 50 years with 
non-polyposis CRC patients visited in the High-Risk CRC Clinic of Hospital 
Clinic de Barcelona between 2008 and 2018, were included., Until June 
2016, 182 patients were included and studied by IHC. 
If the study showed loss of protein expression or was inconclusive, muta-
tions in MMR genes (MLH1, MSH2, MSH6, PMS2) were analysed by Sanger 
Sequencing and MLPA, while if IHC was normal MUTYH gene was evalu-
ated (prevalent mutations in Caucasian population). 
From July 2016 until the end of the study, 70 patients were included and 
performed multigene panel by Next Generation Sequencing, including 
MLH1, MSH2, MSH6, PMS2, BRCA1, BRCA2 and MUTYH, regardless of the 
IHC result.
results: IHC for MMR proteins was performed in 235 cases, showing loss 
of expression in 56 (23.8%) of which 35 (62%) patients were diagnosed 
of Lynch syndrome:16 (46%) had mutation in MLH1, 13 (37%) in MSH2, 3 
(8.5%) in MSH6 and 3 (8.5%) in PMS2. Of the remaining 197 patients with 
normal IHC study (n = 179) or without IHC study (n = 18), in 7 (3.6%) a 
germline mutation was found: 4 biallelic mutations in MUTYH and 3 diag-
noses of Lynch syndrome with normal IHC (2 mutations in MSH6 and 1 in 
MSH2). Of the 42 patients with Lynch syndrome, 7 (16.7%) were diagnosed 
by a genetic study not directed by IHC.
conclusion: Up to 17% of young patients with CRC carry germinal muta-
tions in mismatch repair genes or MUTYH gene. In almost 20% of these 
patients, the mutation would not have been diagnosed with the standard 
strategy based on universal IHC. These results support the use of multi-
gene panel testing in all patients with CRC ≤50 years.
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references: 1. Guía práctica clínica diagnóstico y prevención cáncer 
colorectal. Asociación Española Gastroenterología. 2018. 2. Pearlman R, et 
al. Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mu-
tations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol. 
2017; 3(4): 464-471.
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Introduction: Autophagy is a key pathway involved in cellular homeo-
stasis by orchestrating the degradation of cytoplasmic macromolecular 
constituents elicited by various stress stimuli (e.g. starvation). It has been 
suggested that proficient autophagy is involved in mounting an appropri-
ate DNA damage response (DDR). The IBD risk gene ATG16L1is a criti-
cal component of the autophagic machinery and absence of ATG16L1 has 
severe consequences for intestinal epithelial cell survival and function, 
however a potential role of the protein for DDR is unknown. We have pre-
viously shown that deficiency in the enzyme RNase H2b leads to impaired 
ribonucleotide excision repair and induces spontaneous DNA damage 
with subsequent p53-dependent suppression of stem cell proliferation. 
Absence of p53 and RNAseH2b in the intestinal epithelium leads to ac-
cumulation of somatic mutations and spontaneous intestinal carcinogen-
esis. The aim of our study was to test the role of Atg16l1 in coordinating 
DNA repair and epithelial cell fate decisions in this newly established DNA 
damage model.
aims & Methods: Murine intestinal epithelial ModeK cells were gene si-
lenced using siRNA (Atg16l1, Ctrl.) stimulated with the DNA-damaging 
agent Cytarabin A (AraC) and subjected to gene expression analyses, FACS 
cell death assays and immunoblot analyses. A conditional intestinal epi-
thelial knockout of Atg16l1, Rnaseh2b and the combined DKO was estab-
lished by crossing VillinCre mice with mice floxed for Atg16l1, Rnaseh2bor 
both. Intestinal organoids of WT, Atg16l1ΔIEC, Rnaseh2bΔIECand Rnaseh2b/
Atg16l1ΔIECmice were derived by culturing small intestinal crypt cells in a 
collagen matrix and then used for immunoblot analyses, colony forma-
tion assays, RNA sequencing and transcriptome analysis. WT, Atg16l1ΔIEC, 
Rnaseh2bΔIECand Rnaseh2b/Atg16l1ΔIECmice simultaneously delivered conve-
nient in-vivomodels for basal phenotyping, aging experiments and acute 
or chronic DSS-colitis models. Post mortemanalyses included fluorescence 
or IHC stainings, western blot analyses and gene expression analyses.
results: AraC stimulation let to profound induction of autophagy in IECs, 
which was dependent on Atg16l1. Vice versa knockdown of Atg16l1 led to 
increased AraC induced cell death, as shown by propidium idodide stain-
ing. In-vivo we observed that co-deletion of Atg16l1 in Atg16l1/H2bdIECmice 
led to increased epithelial cell death and consecutive increase of histo-
pathological inflammation. Likewise DSS induced colitis led to a strong 
manifestation of particular small intestinal inflammation, which was as-
sociated with increased cell death and DNA damage. Importantly, Atg16l1-
deficiency completely impaired DNA damage induced suppression of stem 
cell proliferation, as small intestinal crypts in Atg16l1/H2bdIECmice presented 
with increased numbers of Ki67 and BrdU+ cells, compared to H2bdIECmice. 
In-vitro this finding was validated as intestinal organoids from Atg16l1/H2b-
dIECmice showed significantly increased colony forming ability, compared 
to H2bdIEC. Mechanistically RNA sequencing reveals that Atg16l1 governs a 
distinct transcriptional programme involved with rescued epithelial pro-
liferation.
conclusion: We show that Atg16l1is a critical component of physiological 
DDR and is involved in fate decisions of epithelial cells towards DNA dam-
age-induced dell death. Importantly, we show that Atg16l1-deficiency im-
pairs DNA damage-induced suppression of stem cell proliferation despite 
ongoing epithelial cell death. Hence, Atg16l1 licenses an essential step of 
genome surveillance, which might point towards a novel role of the gene 
in intestinal carcinogenesis.
disclosure: Nothing to disclose 
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Introduction: Colorectal cancer (CRC) is the third most common type of 
cancer in the world, and its incidence continues to rise. SLC39A7 (ZIP7) is a 
zinc transporter that plays a key role in intestinal epithelial self-renewal. 
However, whether or not SLC39A7 is involved in human colorectal cancer 
remains unclear.
aims & Methods: To assess the biological function of SLC39A7 in colorec-
tal cancer, we constructed CRISPR/Cas9-based gene knockout. The SW620 
and HCT116 cell lines were infected with the constructed virus, then cell 
proliferation, cell apoptosis and migration assays were detected to de the 
inhibition efficiency of the adenovirus on hepatoma cells. Immunohisto-
chemical analysis was performed to determine SLC39A7 protein expression 
levels in the cancer tissues.
results: Our results showed that the SLC39A7 protein expression levels in 
the CRC tissues were significantly higher than those in the adjacent normal 
mucosa, and was positively correlated with the lymph node metastasis. 
Knockout of SLC39A7 exhibited a significant decrease in cell viability and 
proliferation of colorectal cancer cells. It was also shown that knockout of 
SLC39A7 boosted apoptosis in colorectal cancer cells. Furthermore, down-
regulation of SLC39A7 suppressed Nrf2 expression. In addition, migration 
assays further demonstrated that knockdown of Zn2+ significantly reduced 
the migration and invasion ability in both SW620 and HCT116 cells.
conclusion: In conclusion, our results suggest that SLC39A7 plays a crucial 
role in the proliferation and invasion of colorectal cancer cells, which pro-
vides evidence that SLC39A7 might be as a potential therapeutic target for 
colorectal cancer treatment.
references: [1]Baltaci A K, Yuce K. Zinc Transporter Proteins.[J]. Neuro-
chemical Research, 2017, 43(3):1-14. [2]Wei Y , Dong J , Li F , et al. Knock-
down of SLC39A7 suppresses cell proliferation, migration and invasion 
in cervical cancer[J]. EXCLI J. 2017, 16:1165-1176. [3]Taylor K, Vichova P N, 
Hiscox S, et al. ZIP7-mediated intracellular zinc transport contributes to 
aberrant growth factor signaling in antihormone-resistant breast cancer 
Cells.[J]. Endocrinology, 2008, 149(10):4912-4920. [4]Ohashi W, Kimura 
S, Iwanaga T, et al. Zinc Transporter SLC39A7/ZIP7 Promotes Intestinal 
Epithelial Self-Renewal by Resolving ER Stress:[J]. Plos Genetics, 2016, 
12(10):e1006349.
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Introduction: Bariatric surgery effectively induces weight loss in obese pa-
tients, decreasing obesity-related co-morbidities and overall cancer risk.1 
While a recent meta-analysis demonstrated a 27% decrease in CRC risk 
following bariatric surgery, a large cohort study showed an increase in the 
standardized incidence ratio of CRC with longer follow-up intervals after 
bariatric surgery.2,3 By preferentially modulating epigenetic modifications 
versus de novo chromosomal mutations, the complex physiologic changes 
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following bariatric surgery may in fact drive CRC via the sessile serrated 
adenomas (SSA) pathway or conventional adenoma-carcinoma sequence, 
respectively.4-7 
aims & Methods: Our aim was to examine the risk of CRC precursors in 
post-bariatric surgery patients as compared to the general population. We 
conducted a single center retrospective case-control study using 2007-2019 
data from the electronic medical record. Cases were defined as patients 
age 40 to 50 at time of bariatric surgery, with subsequent documented 
initial screening colonoscopy and pathology. Cases were excluded if they 
underwent a diagnostic colonoscopy or had a family history of CRC (1st-
degree relative age< 60 years, or two 1st-degree relatives at any age). 88 
patients met both inclusion and exclusion criteria. Cases were matched 1:1 
by age ± 2 years and gender to controls with BMI ≥ 25 undergoing average-
risk screening colonoscopy during the same time period. Chi-square and 
t-tests were performed to compare anatomic and histologic distribution of 
adenomas between groups.
results: Among cases, bariatric procedures consisted of Roux-en-Y (51%), 
laparoscopic gastric band placement (28%), and vertical sleeve gastrec-
tomy (20%). Mean BMI pre-surgery was 42 kg/m2, compared to 33 kg/m2 
at initial screening colonoscopy (Table 1). Average time from surgery to 
colonoscopy was 4.5 years (SD 2.5 years), with 45% undergoing colonos-
copy ≥ 5 years post-surgery. 
There was no significant difference in adenoma detection rate (ADR) be-
tween surgical and control groups (35% vs. 40%, p=0.34). SSA detection 
rate was significantly higher in post-surgery patients (9.1%) compared to 
controls (3.9%, p< 0.01). Of all detected adenomas, SSA proportion was 
significantly higher in surgical (15%) vs. control patients (8.2%, p=0.03). 
Rectal adenomas were more common in the surgical vs. control groups 
(12.3% vs 3.0%, p< 0.01), but otherwise we observed no difference in the 
proportion of adenomas by anatomic location or advanced adenomas. 
Neither group had high-grade dysplasia or CRC.
conclusion: SSAs are more common among average-risk obese patients 
after bariatric surgery compared to non-surgical controls. By anatomic 
location, adenomas are more common in the rectum compared to non-
surgical controls, but the overall distribution of adenomas was similar. 
Mucosal, metabolic, and microbiome-related changes associated with 
bariatric surgery may alter profile of CRC precursors. Further studies are 
needed to understand the risk of CRC following bariatric surgery.
  Bariatric surgery (n=88)
control 
(n=102) P-value
Female 67 (76%) 70 (67%) p=0.13
Mean Age at Colonoscopy 51.5 +/- 2.2 52.2 +/- 2.4 p=0.07
Mean BMI at Colonoscopy 33 +/- 6 31 +/- 6 p=0.07
Adenoma detection rate 35.2% 40.2% p=0.34
Percent SSA 15.1% 8.2% p=0.03
Percent Tubular Adenoma 84.9% 91.8% p=0.03
SSA detection rate 9.1% 3.9% p=<0.01
Adenomatous polyps by location      
Percent adenomas right-sided 63.0% 62.0% p=0.81
Percent adenomas left-sided 37.0% 38.4% p=0.81
Percent adenomas rectal 12.3% 3.0% p=<0.01
[Population Demographics and Adenoma Characteristics]
references: 1. Shah M, Simha V, Garg A. Long-Term Impact of Bariatric 
Surgery on Body Weight, Comorbidities, and Nutritional Status. J Clin 
Endocrinol Metab. 2006;91(11):4223-4231. doi:10.1210/jc.2006-0557 
2. Derogar M, Hull MA, Kant P, Ostlund M, Lu Y, Lagergren J. Increased 
Risk of Colorectal Cancer After Obesity Surgery. 2013. doi:10.1097/
SLA.0b013e318288463a 3. Afshar S, Kelly SB, Seymour K, Lara J, Woodcock 
S, Mathers JC. The Effects of Bariatric Surgery on Colorectal Cancer Rsik: 
Systematic Review and Meta-analysis. Obes Surg. 2014;24(10):1793-1799. 
doi:10.1007/s11695-014-1359-y 4. Strum WB. Colorectal Adenomas. N 
Engl J Med. 2016;375(4):387-390. doi:10.1056/NEJMc1604867 5. Rex DK, 
Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review 
and recommendations from an expert panel. Am J Gastroenterol. 
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P1858 asPIrIn TreaTMenT changes OxyLIPIn LeveLs In 
MurIne and huMan cOLOn TIssue
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Introduction: Although prevention and treatment of colorectal cancer 
(CRC) have improved during recent years due to screening colonoscopies, 
new chemotherapeutic and antibody approaches, CRC still ranks second 
in cancer mortality in 2018 worldwide. Therefore, research needs to focus 
on the prevention of neoplastic colonic lesions. Epidemiological studies 
showed that regular use of acetylsalicylic acid (ASA) is associated with a 
preventive effect on the development of CRC [1]. The mechanisms underly-
ing this chemopreventive effect are still unclear, however ASA-mediated 
inhibition of cyclooxygenase (COX)-1 and COX-2, leading to suppression of 
prostaglandin biosynthesis, is the primary focus of interest. Recently, we 
detected significantly lower tissue eicosanoid levels of most COX derived 
metabolites in ASA treated individuals in healthy colonic mucosal tissue 
samples obtained during routine colonoscopy. Furthermore, we observed 
that LOX- and CYP-pathway product concentrations remained unaffected 
by ASA treatment [2]. Following the hypothesis that ASA could inhibit CRC 
development via lipid mediator modification, we now aim to investigate 
the effect of ASA chemoprevention on colon tumorigenesis.
aims & Methods: Using liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS), we quantified a broad spectrum of omega-6 and ome-
ga-3 polyunsaturated fatty acid (PUFA)-derived lipid mediators in normal 
colonic mucosa and colon tumor tissue. The murine AOM/DSS-induced 
model of colitis-associated colorectal cancer (CAC) was employed to in-
vestigate lipid mediator changes in healthy versus neoplastic mucosa in 
ASA-naive mice. We then analyzed the effect of ASA treatment on colon 
tumorigenesis and lipid mediator formation in mice. In order to assess the 
relevance of these findings in humans, lipid metabolite changes were also 
analyzed in colorectal adenoma and carcinoma tissues procured during 
routine colonoscopy examination.
results: In murine colon tumors we confirmed increases of a variety of 
COX-metabolites such as PGE
2
 and 11-HETE in tumor tissue as compared 
to normal mucosa and these increases were dampened by aspirin treat-
ment in the murine AOM/DSS model. Aspirin led to a significant reduction 
of tumor incidence but not size in the AOM/DSS model. Furthermore, we 
detected strongly elevated levels of 5-LOX and 12-LOX pathway products 
in murine tumor tissues. A trend showing similar changes of lipid media-
tor profiles due to aspirin treatment were also found in human colorectal 
adenoma and carcinoma biopsy samples.
conclusion: The data presented here provides insight into lipid metabolite 
profile changes in murine colonic tumorigenesis. Furthermore, these data 
confirm a chemopreventive anti-tumor effect of ASA treatment which is 
accompanied by specific changes particularly of COX-1 derived lipid media-
tors. Pointing towards the relevance of these animal data in humans, we 
were able to show similar lipid mediator changes in biopsies from patients 
with colon adenomas and colon carcinoma.
references: 1. Giovannucci, E., et al., Aspirin and the risk of colorectal can-
cer in women. N Engl J Med, 1995. 333(10): p. 609-614. 2. Gottschall, H., 
et al., Aspirin alone and combined with a statin suppresses eicosanoid 
formation in human colon tissue. J Lipid Res, 2018. 59(5): p. 864-871.
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P1859 dna reMeThyLaTIOn, rePaIr and aLTeraTIOn Of 
ePITheLIaL-MesenchyMaL TransITIOn In cOLOrecTaL cancer 
ceLL LInes By s-adenOsyLMeThIOnIne TreaTMenT
Zsigrai S.1, Kalmár A.1,2, Szigeti K.A.1, Nagy Z.B.1, Barták B.K.1, Valcz G.1,2, 
Galamb O.1,2, Dankó T.3, Tulassay Z.1,2, Igaz P.1,2, Molnár B.1,2
1Semmelweis University, 2nd Department of Internal Medicine, Budapest, 
Hungary, 2Hungarian Academy of Sciences, Molecular Medicine Research 
Group, Budapest, Hungary, 3Semmelweis University, 1st Department of 
Pathology and Experimental Cancer Research, Budapest, Hungary
contact e-Mail address: zsigrai.sara@gmail.com
Introduction: Global DNA hypomethylation can be observed along aging of 
normal cells, and it is also related to genomic instability and the activation 
of proto-oncogenes during tumor development. S-adenosylmethionine 
(SAM) is a universal methyl donor molecule, used as a dietary supple-
ment. SAM is involved in DNA methylation processes, thereby it may have 
a favorable effect on DNA remethylation, repair and remodeling.
aims & Methods: Our aim was to analyze the effect of SAM treatment on 
global DNA methylation level, gene expression, DNA integrity and cell 
cycle of two different colorectal cancer cell lines (HT-29, SW480). HT-
29 and SW480 cells were treated with SAM in different concentrations 
(0, 0.5, 1 mmol/l) for 48 hours. The global DNA methylation status was 
analyzed by immunohistochemistry and bisulfite pyrosequencing of long 
interspersed nuclear element-1 (LINE-1) retrotransposons. The gene ex-
pression changes were detected using Human Transcriptome Array 2.0 
(HTA 2.0). Double-strand DNA break analysis was performed with γH2AX 
ELISA and immunostaining. Cell-free DNA level of the medium collected 
at the end of the treatments was quantified following DNA isolation. Flow 
cytometry measurements were assessed for cell cycle and apoptosis de-
termination.
results: DNA remethylation, elevated expression (p<0.05) of DNA-repair-
related genes and decreased expression (p<0.05) of genes, that are in-
volved in epithelial-mesenchymal transition were observed after SAM 
treatment. Increased phosphorylation of H2AX (74.9, 166.5, 200.6 pM) 
resulted by different SAM concentrations was also referred to the activa-
tion of reparative processes. Moreover, elevation of apoptotic cell num-
ber and cell-free DNA level (0.23, 0.26, 0.63 ng/ul) were also detected. 
Proportion of cells was decreased in both G0/G1 (48.4, 28.5, 20.4%) and 
G2/M (6.0, 10.7, 12.5%) phases by SAM; however, it was increased in S 
(45.7, 61.7, 67.0%) phase, where the double-strand DNA break checkpoint 
is located.
conclusion: SAM can induce DNA methylation and activation of DNA repair 
processes, while inhibiting epithelial-mesenchymal transition. According 
to the results of our study, we suppose that DNA can be released from 
treated cells and apoptosis is also induced by initiating DNA repair. Tumor 
cells could be targeted by SAM through different pathways; therefore, it 
might be a potential agent in cancer treatment.
disclosure: Nothing to disclose 
P1860 β6-InTegrIn acceLeraTes TuMOr grOWTh and 
decreases T-ceLL InfILTraTIOn In a cecuM InjecTIOn MOdeL 
Of cOLOn cancer
Busenhart P., Atrott K., Hering L., Katkeviciute E., Rogler G., Spalinger M., 
Scharl M.
University Hospital Zürich, University of Zürich, Department of 
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contact e-Mail address: philipp.busenhart@usz.ch
Introduction: Integrins are receptors for extracellular matrix proteins and 
are involved in many critical cellular processes such as cell adhesion, mi-
gration, proliferation, differentiation and cell death. The β6-integrin sub-
unit (ITGB6) is hardly ever detectable in normal epithelial tissues, whereas 
it is highly induced in epithelial cells during embryogenesis, wound re-
pair as well as during tumorigenesis of many epithelial tumors such as 
colorectal cancer (CRC). 
In CRC, patients with high ITGB6 expression in the tumor present with 
a more aggressive disease and reduced survival rates. ITGB6 is upregu-
lated during epithelial-to-mesenchymal transition (EMT) and activates la-
tent TGFβ that is present in the extracellular matrix. Since TGFβ has been 
shown to drive immune evasion in mouse colon tumors, TGFβ activation 
through ITGB6 might lead to a reduced immune response to the tumor, 
explaining the reduced survival of patients with ITGB6 expressing tumors. 
In this study, we aimed at investigating the effect of ITGB6 overexpression 
on colon cancer growth in vivo.
aims & Methods: To assess the effect of ITGB6 on tumor growth in vivo, we 
overexpressed ITGB6 in two mouse colon cancer cell lines, namely CT-26 
and MC-38, derived from Balb/c (CT-26) or C57/Bl6 mice (MC-38) using 
lentiviral vectors. Control cells were transduced with the empty control vec-
tor. These cell lines were injected into the cecum wall of Balb/c or C57/Bl6 
mice and the mice were sacrificed after 2-3 weeks. Tumors were cut out of 
the cecum and weighted to determine tumor mass. Cytokine and cytolytic 
enzyme expression in the tumor was measured by RT-qPCR. T-Cell infiltra-
tion was determined by immunohistochemical (IHC) stainings for CD3, CD4 
and CD8.
results: In both cell lines ITGB6 overexpression accelerated tumor growth 
in vivo, resulting in significantly larger tumors than in control cell tumors 
at day of sacrifice. RT-qPCR analysis of RNA isolated from the tumors 
showed decreased IFNγ, TNFα, Granzyme B and Perforin expression upon 
ITGB6 overexpression, indicating an effect on the tumor immune response. 
IHC staining of the tumors showed a significant decrease in the number of 
CD3, CD4 and CD8 positive T-cells in the ITGB6 overexpressing tumors. Ki67 
expression was not altered by ITGB6 overexpression, demonstrating that 
the difference in tumor growth was not caused by enhanced cell prolifera-
tion. Therefore, the differences in tumor size are likely to be a consequence 
of an altered immune response and less tumor cell killing through cyto-
toxic CD8+ T-cells.
conclusion: ITGB6 promotes tumor growth in vivo and reduces T-cell in-
filtration into the tumor. Because of its exclusive expression in epithelial 
tumors, the tumor growth promoting ITGB6 is an excellent drug target. 
Therefore, inhibiting ITGB6 alone or as part of a combination therapy 
might be a promising therapy approach for CRC patients.
disclosure: Nothing to disclose 
P1861 hyPOxIc TuMOr MIcrOenvIrOnMenT reguLaTes 
grhL2 vIa reducIng ceLL adhesIOn and IncreasIng 
ePITheLIaL-MesenchyMaL-TransITIOn (eMT) TO PrOMOTe 
cOLOn cancer ceLL InvasIOn and MIgraTIOn
Zhou F.1, Zou X.2
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Introduction: Grainyhead-like 2 (GRHL2) was reported to maintain the 
epidermal barrier by directly regulating expression of Cdh1 and Cldn4. 
Hypoxic microenvironment was important in promoting drug resistance 
of tumor stem cells. While colorectal cancer (CRC) originates from dyspla-
sia in the epithelial stem cells and forms hypoxic microenvironment when 
expanding.
aims & Methods: We aimed in this study to demonstrate the roles of GRHL2 
in colorectal cancer in hypoxic environment. To create hypoxic microenvi-
ronment, cells were incubated in hypoxic incubator with 1% O
2
 and 5% 
CO
2
. Then to investigate functional significance of GRHL2, human HCT116 
cell lines with steady decreased GRHL2 expression was generated by 
lentiviral transfection, meanwhile, overexpressed GRHL2 expression was 
generated in SW620 cell lines by TrueORF cDNA transfection followed by 
monoclonal collection. CCK8, colony-formation and transwell assays were 
applied to evaluate the proliferation and metastasis of colon cancer cell 
lines. Real-time qPCR and western blotting were used to determine the 
expression level of EMT markers. Dual Luciferase Reporter Assay was used 
to examine transcription activity of given sequences in vitro. Chromatin Im-
munoprecipitation (ChIP) assay was applied to determine whether Hif-1α 
can functionally bind to promoter region of GRHL2 to inhibit its transcrip-
tion. For in vivo study, cells were transplanted into wild-type mice through 
orthotopic or tail vein injection in order to test the function of GRHL2 in 
two major tumor-associated scenarios: primary tumor growth and remote 
metastasis.
results: HCT116, HT29 and SW480 (all initiated from primary tumors) 
showed relatively higher GRHL2 expression, while SW620 (derived from 
metastasis lymph node) had a low GRHL2 level. All cell lines exhibited a 
decrease in GRHL2 expression under hypoxic environment (1% O
2
, 24h). 
Functional knockdown of GRHL2 in HCT116 demonstrated mesenchymal 
morphology, increased migration, but reduced colony formation ability. 
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While overexpressed GRHL2 in SW620 showed increased proliferation, 
but lower migration ability. Western Blot also indicated EMT in shGRHL2 
HCT116 (lower E-cadherin and higher Vimentin expression). Also in vivo, 
lower GRHL2 expression led to reduced orthotopic implantations prolif-
eration, but higher metastasis intendancy. To understand the mechanism 
of down-regulation of GRHL2 in hypoxia, using Jaspar database, we pre-
dicted a Hif-1α binding site within the promoter region of GRHL2 after 
excluding methylation in GRHL2 promoter. Luciferase results also showed 
decreased transcription activity of this region, possibly leading to down-
regulation of GRHL2. Further CHIP assay validated that Hif-1α can directly 
bind to the promoter region (-533~-523bp) of GRHL2.
conclusion: Collectively, our findings identify that hypoxia promotes colon 
cancer metastasis via regulating GRHL2 expression, which may represent a 
rational therapeutic target in CRC.
disclosure: Nothing to disclose 
P1862 PaTIenTs WITh MuLTIPLe adenOMas In unITed 
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Introduction: Approximately one in twenty cases of colorectal cancer (CRC) 
are associated with germline mutations that confer higher susceptibility to 
the disease. Guidelines recommend that patients with ten or more adeno-
mas be referred for genetic testing1, with evidence that suggests >9% of 
these patients with 10-19 adenomas have a highly penetrant CRC predis-
position syndrome2.
aims & Methods: The primary aim of this study was to quantify patients 
with ten or more adenomas in the West London (WL) and North Central 
London (NCL) Bowel Cancer Screening program (BCSP) centres. The sec-
ondary aim was to determine what proportion of these multiple adenoma 
patients were referred for genetic screening.
A retrospective cross-sectional study was performed of patients who un-
derwent colonoscopy following a positive faecal occult blood test (FOBt) as 
part of the WL and NCL BCSPs between May 2007 & June 2018. All polyps 
were examined histologically and only confirmed adenomas were includ-
ed. Clinicopathological data including age and gender was recorded from 
BCSP patient records. Referrals to regional clinical genetics services were 
ascertained. Statistical analysis was performed in Graphpad Prism.
results: 11,337 patients underwent colonoscopy following positive FOBt 
and 5,650 (49.8%) had 1 or more adenomas. 107 patients (0.94%) had 10 
or more adenomas. The proportion of patients with 10 or more adenomas 
was higher in NCL BCSP (1.1%) than in WL BCSP (0.7%) (p=0.02; χ2 test). 42 
patients presented with 10 or more metachronous adenomas at the index 
colonoscopy or following an early follow up procedure; the remaining 65 
patients undergoing excision of a total of 10 or more metachronous adeno-
mas after subsequent surveillance colonoscopy. An accurate family history 
was not routinely collected in this population. Of the 107 patients with 10 or 
more adenomas, only 3 (2.8%) were referred to a clinical genetics service.
conclusion: In two London BCSP centres, patients with ten or more meta-
chronous adenomas are an uncommon finding. Despite guidelines advis-
ing genetic testing in this group, referral rates are low. A referral pathway 
and management strategies should be established to address this patient 
population.
references: 1. Hampel H, Bennett RL, Buchanan A, et al. A practice guide-
line from the American College of Medical Genetics and Genomics and 
the National Society of Genetic Counselors: referral indications for cancer 
predisposition assessment. Genet Med 2015;17:70-87. 2. Grover S, Kastrinos 
F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mu-
tations in patients with multiple colorectal adenomas. Jama 2012;308:485-
492.
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Introduction: Participation rates for colorectal cancer (CRC) screening us-
ing faecal occult blood tests are suboptimal in many countries. There is 
therefore a need for the development of other test types that may improve 
screening uptake. The aim of this study was to evaluate the performance 
of a blood test for methylation-specific detection of circulating tumor DNA 
(ctDNA) in a study population with the full range of neoplastic and non-
neoplastic pathologies encountered in the colon and rectum.
aims & Methods: Study participants (n=1,621) had blood collected prior to 
colonoscopy or colonic surgery (median age, 64.2y (18-88yo), 56% males). 
Circulating cell-free DNA was extracted from plasma, bisulphite convert-
ed and assayed for the presence of methylated ctDNA using a multiplex, 
methylation-specific real-time PCR assay for detection of methylation in 
the genes BCAT1, IKZF1 and IRF4. Detection of methylation for any of the 
three genes deemed a specimen positive for ctDNA. Adenomas were clas-
sified as High- (HRA), Medium- (MRA) or Low-Risk Adenoma (LRA) as 
previously described (1). CRC was staged according to AJCC 7th Edition. The 
ctDNA blood test performance estimates were calculated from true- and 
false-positive rates for cancer.
results: The 3-gene methylation ctDNA blood test had an overall sensitiv-
ity for CRC of 73.9% (136/184, 95%CI: 67.1-79.1) with a better detection of 
later, 81.0%, (68/84; 71.3-87.9) versus earlier stage cancer, 67.3% (66/98; 
57.6-75.8; p=0.0375). The ctDNA test sensitivity for stage II, III and IV were 
87.7% (50/57; 76.8-93.9), 78.4% (40/51; 60.8-89.5) and 84.8% (28/33; 69.1-
93.3), respectively, and were not significantly different. However, the test 
had a reduced sensitivity for stage I (16/41, 39.0%; 25.7-54.3, p< 0.0001). 
To determine whether the apparent lower sensitivity for Stage I CRC was 
a biologically-determined issue, we examined the relationship between 
test positivity and tumor depth of invasion. Including only cases with no 
disseminated disease, a significant linear trend (p< 0.0001) was observed 
between assay positivity and T stage determined at surgery: T1N0M0, 
25% (6/24, 12.0-44.9); T2N0M0, 58.8% (10/17, 36.0-78.4); T3N0M0, 85.7% 
(42/49, 73.3-92.9); T4N0M0, 100% (8/8, 67.6-100). Lesion location of cancer 
did not influence assay positivity rates (proximal, 38/50; distal, 89/117, p 
= 0.9920). The estimated specificity for cancer was 90.1% (81/820, 88.0-
92.0), of which 82.7% (67/81) were methylation positive in a single gene 
only. Gender, smoking, family history and age were not significant predic-
tors of test positivity. The sensitivity of the ctDNA blood test for adenoma 
detection was low (LRA, 9.3%, (26/280, 6.4-13.3); MRA 15.0% (27/180, 10.5-
20.9); HRA, 16.6% (26/157, 11.6-23.2)), although a positive trend was ob-
served with the HRA having the highest positivity rate of all the adenoma 
subtypes (p=0.0290).
conclusion: With a specificity of 90.1%, the 3-gene methylation ctDNA 
blood test had an overall sensitivity for CRC of 73.9% and was positive for 
67.3% of early stage cancer (stage I and II). The overall cancer positivity 
rate appears to be a function of tumor invasiveness. Based on the data 
reported herein, it is justified to proceed to validation of this ctDNA assay 
in true screening populations.
references: 1. Vieth M et al. Endoscopy 2012;44:Suppl 3:131-9. 2. Pedersen 
S et al. BMC Cancer 2015; 15: 654.
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P1864 vOLaTILe OrganIc cOMPOunds In BreaTh can 
serve as nOn-InvasIve dIagnOsTIc BIOMarkers fOr The 
deTecTIOn Of advanced adenOMas and cOLOrecTaL cancer: 
PrOOf-Of-PrIncIPLe sTudy
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1Radboudumc, Gastroenterology, Utrecht, Netherlands, 2Medisch Spectrum 
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5Radboud University Medical Center, Nijmegen, Netherlands
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Introduction: Colorectal cancer (CRC) is the third most common cancer 
diagnosis in the Western world. Unfortunately, a non-invasive screening 
tool with the ability to accurately detect (pre-)malignant colon lesions is 
still lacking. 
The aim of this study was to evaluate if exhaled volatile organic com-
pounds (VOCs) can serve as non-invasive biomarkers for the detection of 
CRC and its precursor lesions using an electronic nose (e-nose).
aims & Methods: This multicenter study was conducted in two hospitals in 
the Netherlands. All consecutive colonoscopy patients aged ≥18 years old, 
without inflammatory bowel disease or (previous) malignancy, were invit-
ed for breath testing. A random sample of two-thirds of the breath samples 
was used to train the artificial neural network to recognize disease-specific 
mixtures of VOCs. These training models for CRC and advanced adenomas 
(AAs) were then used to blindly predict the diagnosis of the remaining pa-
tients. Lastly, final disease-specific models were developed using all avail-
able data to further improve the discriminatory power of the algorithms.
results: Breath samples of 511 patients were collected. Sixty-four patients 
were excluded due to an inadequate breath test (n=51), incomplete colo-
noscopy (n=8), or colitis (n=5). Classification was based on the most ad-
vanced lesion detected. Seventy patients were diagnosed with CRC, 117 had 
≥1 AA, and 128 patients had normal colonoscopy. The training model for 
CRC had a sensitivity and specificity of 83% and 60%, respectively, and 
predicted the blinded data with similar accuracy. The final disease-specific 
model for CRC had an AUC of 0.84, with a sensitivity of 95% and specificity 
of 64%. The final disease-specific model for AAs had an AUC of 0.73, with 
a sensitivity of 79% and specificity of 59%.
conclusion: This study suggests that exhaled VOCs could potentially serve 
as non-invasive biomarkers for the detection of CRC and AA using e-nose 
technology. Future studies including more patients could further improve 
the discriminatory potential of VOCs for the detection of premalignant and 
malignant colorectal lesions.
disclosure: The eNose company supplied the eNoses for free 
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Introduction: Cell-free DNA (cfDNA) level increases in several pathologi-
cal processes including colorectal cancer (CRC). In addition, genetic (e.g. 
mutations) and epigenetic (e.g. DNA methylation) modifications of cfDNA 
molecules can be also observed; as DNA can originate from tumorous cells 
hence it carries cancer-specific DNA alterations. Identification of these 
quantitative and qualitative changes in peripheral blood - especially with 
the usage of automated methods - offers a promising tool for CRC screen-
ing or detection, however, differing results were reported in the case of 
several markers.
aims & Methods: Our aim was to test different blood collection tubes, 
manual and automated cfDNA extraction methods in order to assess 
whether these factors influence the cfDNA yield and the methylation pat-
tern of four previously described methylation markers in plasma samples 
of normal, adenoma and CRC patients. 
Besides standard K3EDTA tubes (n=30), Streck Cell-Free DNA BCT® (n=10) 
and Roche Cell-Free DNA (n=30) collection tubes were tested. In addition 
to manual cfDNA isolation (n=121), the MagNA Pure 96 (Roche) (n=30) and 
InviGenius (STRATEC Biomedical AG) (n=69) systems were used for auto-
mated cfDNA extraction from plasma specimens. After cfDNA quantifica-
tion and bisulfite conversion steps, methylation pattern of SFRP1, SFRP2, 
SDC2 and PRIMA1 genes was determined using MethyLight PCR containing 
multiplex preamplification.
results: Slightly higher cfDNA levels were noticed in case of both auto-
mated cfDNA extraction method compared to manual isolation. However, 
no significant difference was observed in the cfDNA amount after using 
different blood collection tubes. The methylation level of SFRP1, SFRP2, 
SDC2 and PRIMA1 showed continuous increase along normal - adenoma 
- carcinoma sequence after manual cfDNA preparation with methylation 
percentage values of 22%, 7%, 12% and 14% in CRC samples, respectively. 
Based on the methylation pattern of the 4 genes, CRC and AD specimens 
could be distinguished from normal controls with 91.5% and 89.2% sen-
sitivity, and 97.3% and 86.5% specificity values. Interestingly, lower meth-
ylation frequencies and levels were observed in the case of all biomarkers 
using the automated instruments, however, methylation differences have 
been found between the clinical groups.
conclusion: Automated isolation techniques may contribute to wide-
spread, screening applications of methylation markers; however, further 
developments are needed in order to make the results comparable with 
manual extraction in respect to cfDNA yield and methylation analysis.
disclosure: Nothing to disclose 
P1866 gLOBaL dna hyPOMeThyLaTIOn In TIssue and LIquId 
BIOPsy saMPLes In cOLOrecTaL cancer PrOgressIOn Is caused 
By decreased MeThyL-dOnOrs
Szigeti K.A.1, Galamb O.1,2, Kalmar A.1,2, Valcz G.1,2, Zsigrai S.1, Bartak B.K.1, 
Nagy Z.B.1, Tulassay Z.1,2, Igaz P.1,2, Molnar B.1,2
1Semmelweis University, 2nd Department of Internal Medicine, Budapest, 
Hungary, 2Hungarian Academy of Sciences, Molecular Medicine Research 
Group, Budapest, Hungary
contact e-Mail address: kri.szigeti@gmail.com
Introduction: In cancerous diseases global DNA hypomethylation is char-
acteristic, which can lead to genetic instability through the active mobile 
genetic elements. Alterations of DNA methyltransferase (DNMT) expression 
and level of methyl-donor molecules (folic acid (FA), S-adenosylmethio-
nine (SAM)) can lead to aberrant global DNA hypomethylation.
aims & Methods: Our aim was to examine global DNA methylation chang-
es along aging and colorectal normal-adenoma-carcinoma sequence and 
in inflammatory bowel disease in tissue and liquid biopsy samples for 
diagnostic purposes. Moreover, we aimed to explore the reasons of global 
hypomethylation on gene expression level and methyl-donor molecule 
content. 
Bisulfite treatment was performed on DNA isolated from 30 normal (N), 
10 adenoma (Ad), 10 colorectal carcinoma (CRC), 10 colitis ulcerosa (UC) 
tissue samples and on 11 N, 10 Ad, 15 CRC, 12 UC plasma specimens. 30 N 
samples contained different age groups derived from under 20 to 70 years 
old healthy controls for examination of aging process. LINE-1 PCR product 
was generated and pyrosequenced. Whole genome expression level of 60 
biopsy samples was evaluated by HTA 2.0 RNA microarraychip (Affyme-
trix). In situ tissue appearance of 5-methylcytosine, FA, SAM and expres-
sion of DNMTs were analysed by immunohistochemistry staining (IHC).
results: According to LINE-1 bisulfite sequencing results, DNA methyla-
tion was 72,6±1% in samples of healthy controls under 50 years old and 
71,6±1,8% in specimens of patients over 50 years old. 
Significant DNA hypomethylation was found in CRC (62,9±8,7%; p< 0,001), 
Ad (66,7±5,1%; p< 0,001) tissue samples in comparison with N samples 
(72±1,4%). Significant decrease of DNA methylation was observed in CRC 
(78,8±1,7%; p< 0,02), Ad (80,1±1,7%; p< 0,02) plasma samples compared to 
N specimens (82,2±1,8%). Global DNA hypomethylation was not detected 
in UC samples. 
Significantly elevated RNA expression of enzymes connected to nucleotide 
synthesis was observed in Ad and CRC samples compared to N (p< 0,05), 
while no changes were detected in the RNA levels of DNA methylation-
related proteins. RNA expression of enzymes in DNA repair was found up-
regulated in Ad and CRC specimens. The intensity of 5-mC labelling of CRC 
and Ad samples was lower than in N tissue samples. Decreased FA and 
SAM levels were detected in CRC compared to N specimens and no expres-
sion changes of DNMT enzymes.
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conclusion: Significant decrease in DNA methylation level was found in tis-
sue and liquid biopsy samples of colorectal normal-adenoma-carcinoma 
sequence, but not in UC specimens. Our results suggest that determina-
tion of global DNA hypomethylation could have prognostic and diagnostic 
value as well, and reduction of DNA methylation level could be linked to 
decreased FA and SAM availability and not to methylation related activity.
disclosure: Nothing to disclose 
P1867 The assOcIaTIOn Of TOLL-LIke recePTOr (TLr) 
PaThWay POLyMOrPhIsMs and cOLOrecTaL cancer rIsk: 
a MeTa-anaLysIs
Lagrue D.1, Aggarwal N.2, Monahan K.J.3
1Imperial College School of Medicine, London, United Kingdom, 2Imperial 
College London, Medicine, Westcliff on Sea, United Kingdom, 3West 
Middlesex Hospital, Family Cancer Clinic, London, United Kingdom
contact e-Mail address: dl2813@ic.ac.uk
Introduction: Colorectal cancer (CRC) is the third commonest cancer world-
wide. Approximately 35% of CRC risk is due to heritable factors but 5% 
attributed to associated with known syndromes. Single Nucleotide Poly-
morphisms (SNPs) are common, low penetrance gene variants that may 
contribute to the remaining heritable risk. The toll-like receptor (TLR) sig-
nalling pathway is a key mediator of inflammation and has unique roles in 
the gut due to the presence of commensal microbiota. It is also suggested 
to have a significant role in colorectal carcinogenesis. This systematic re-
view and meta-analysis aims to investigate the association of polymor-
phisms in the TLR signalling pathway with CRC.
aims & Methods: A systematic literature review of Pubmed, Ovid MEDLINE 
and HuGENet databases was conducted. Specific inclusion and exclusion 
criteria were used to select relevant papers. A per-allele, pooled odds ratio 
was used to assess the risk of each variant. Heterogeneity was investigated 
using Cochrane’s Q test and I2. Publication bias was assessed through fun-
nel plot asymmetry. Statistical analysis was conducted using the Metafor 
package in R.
results: Sixty-seven SNPs were identified in published literature in 14 TLR 
pathway genes associated with CRC risk, of which 12 SNPs in five genes 
were eligible for meta-analysis. Two SNPs showed a significant association 
with CRC risk: TLR4 rs7873784 (Odds ratio = 1.356, p=0.011, 95% C.I. 1.07-
1.71) and TLR4 rs5030728 (Odds ratio = 0.916, p=0.025, 95% C.I. 0.86-0.99). 
Funnel plots demonstrated no evidence of publication bias.
conclusion: The TLR pathway is an potential target for CRC therapy and 
risk assessment. This study identifies two SNPs in the TLR4 gene associated 
with CRC risk. In order that conclusions might be made about the role of 
this pathway in colorectal carcinogenesis, adequately powered studies of 
greatly increased population size must be conducted.
disclosure: Nothing to disclose 
P1868 ceLL-free dna quanTITy and quaLITy aLTeraTIOns 
In dIfferenT PhysIOLOgIcaL and PaThOLOgIcaL cOndITIOns
Bartak B.K.1, Szigeti K.A.1, Orbán-Márkus E.1, Kalmár A.1,2, Galamb O.1,2, 
Nagy Z.B.1, Zsigrai S.1, Tulassay Z.1,2, Igaz P.1,2, Molnár B.1,2
1Semmelweis University, 2nd Department of Internal Medicine, Budapest, 
Hungary, 2Hungarian Academy of Sciences, Molecular Medicine Research 
Group, Budapest, Hungary
contact e-Mail address: bartak.barbara@gmail.com
Introduction: Elevation of cell-free DNA (cfDNA) level in peripheral blood 
was observed in certain physiological conditions, such as pregnancy, ag-
ing or high physical activity. Furthermore, altered cfDNA concentration 
can also be detected in some pathological processes, as autoimmune or 
inflammatory diseases, and different cancer types including colorectal 
cancer (CRC). However, to date, studies about quality changes of cfDNA 
molecules aimed to analysing the fragment profile and global methylation 
pattern of cfDNA are lacking.
aims & Methods: Our aim was to define the quantity and quality changes 
of cfDNA, including concentration, fragment length and global DNA meth-
ylation level during high physical exercise, and in neoplastic and inflam-
matory colorectal diseases. Moreover, we aimed to monitor treatment 
response in metastatic CRC patients analysing the above-mentioned pa-
rameters during therapy. 
Plasma fraction was separated from blood samples of 6 healthy athletes 
before, during and after physical training, and from healthy (n=16), ad-
enoma (n=13), IBD (n=19), and CRC (n=16) patients. Moreover, plasma 
longitudinal assessment was performed in the case of 10 metastatic CRC 
patients treated with chemotherapy. After cfDNA isolation, it was quanti-
fied using Qubit 1.0 fluorimeter (Thermo Fisher Scientific), and fragment 
length distribution was examined with Bioanalyzer 2100 (Agilent). Global 
DNA methylation analysis was performed by bisulfite pyrosequencing of 
long interspersed nuclear element-1 (LINE-1) (Qiagen).
results: Elevated cfDNA levels have been found in plasma of adenoma 
(72,1±37,5ng), IBD (78,0±50,9ng) and CRC (84,5±70,1ng) patients, com-
pared to controls (36,2±11,3ng). Moreover, high increase of cfDNA amount 
was observed during physical exercise (198,5±90ng), in comparison with 
control phase (86,3±40,6ng), and then in restitution period significantly 
lower cfDNA level (155,6±119,3ng) was detected. CfDNA fragment length 
distribution showed different pattern in each sample group. Slightly de-
creasing tendency of global DNA methylation was noticed along normal-
colorectal adenoma-carcinoma sequence. Interestingly, the amount and 
global methylation level alteration of cfDNA revealed negative correlation 
in CRC patients during therapy and progression.
conclusion: Characteristic cfDNA level, fragment length and global DNA 
methylation level were identified in the different sample groups that might 
contribute to the diagnosis and therapy response analysis of colorectal 
disorders.
disclosure: Nothing to disclose 
P1869 sequenTIaL use Of fecaL IMMunOcheMIcaL TesT fOr 
heMOgLOBIn and fecaL caLPrOTecTIn In cOLOrecTaL cancer 
screenIng
Hultcrantz R.1, Fritzell K.2, Forsberg A.3, Seki Y.4, Ichiyanagi T.5, Taguchi H.5, 
Watanabe K.5, Andersson G.6, Löwbeer C.6
1Karolinska Institutet, Medicine, Stockholm, Sweden, 2Karolinska Institutet, 
Neurobiology, Care Sciences and Society, Stockholm, Sweden, 3Karolinska 
Institutet, Institution of Medicine Solna, Stockholm, Sweden, 4EIKEN 
Chemical, Tokyo, Japan, 5EIKEN, International Marketing, Tokyo, Japan, 
6Aleris Medilab, Stockholm, Sweden
contact e-Mail address: rolf.hultcrantz@ki.se
Introduction: Fecal immunochemical test for hemoglobin (FIT) is widely 
used in colorectal cancer (CRC) screening, in order to select screening par-
ticipants more likely to have advanced adenoma (AA) or CRC. Fecal calpro-
tectin (FC) or its subunits have been reported to show high sensitivity and 
negative predictive value for CRC. We developed an FC reagent adapted to 
sampling device designated for FIT, in order consecutively analyze FIT and 
FC from the same samples.
aims & Methods: To better identify participants with CRC and AA in a 
screening program by combining FIT and FC in order to lower the need 
for colonoscopy.
We selected 801 out of 6,000 fecal samples collected with sampling de-
vices for FIT, OC-Auto Sampling Bottle 3, in the SCREESCO study. They had 
all FIT > 10 ug/g and had been subjected to colonoscopy. The samples had 
been stored at -80 oC. We determined fecal hemoglobin and calprotectin 
concentrations, in the same sample consecutively by OC-SENSOR PLEDIA. 
Of 801 analyzed, 13 were not possible to analyze because of sample short-
age. Sensitivity (Se), specificity (Sp), positive predictive value (PPV) and 
negative predictive value (NPV) of FC test were analysed at different FIT 
cut-offs.
results: 54 participants had CRC (6.9%) and 152 had AA (19.3%) in the 788 
subjects, the other had a normal colonoscopy or one adenoma < 5 mm.. 
In the participants with CRC the data for Se, Sp, PPV and NPV at FIT >15 
ug/g FIT cut-off were 94.1%, 87.4%, 7.1%, 96.8%.. At FIT > 20 ug/g the val-
ues were 88.5%, 85.3%, 7.0%, 94.6%, and at FIT > 40ug/g 73.1%, 73.5%, 
6.8%, 93.1%, on consecutive FC test. 
For participants with AA, the same values at FIT > 15ug/g Hb were 83.1%, 
89.0%, 18.3%, 73.1%, At FIT > 20 ug/g: 81.1%, 86.6%, 18.3%, 74.8% and at 
FIT > 40 µg/g, 64.9%, 75.6%, 17.1%, 74.4%, on consecutive FC test. 
For the group CRC and AA, the values at FIT > 15ug/g were 85.4%, 88.6%, 
23.5%, 71.0%, respectively, at FIT >20ug/g: 82.2%, 86.6%, 23.2%, 70.3% 
and at FIT > 40ug/g: 65.4%, 76.1%, 21.5%, 68.5%. 
In cases with cut-off values of FIT between 10 and 20 µg/g, FC test follow-
ing FIT had more than 90% of negative predictive value for CRC at cut-off 
values between 15 to 100 µg/g FC.
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conclusion: FC test following FIT positivity had more than 90 % of NPV 
with any cut-off values, and around 90% of sensitivity at 15 or 20 µg/g of 
FC cut-off. Our data suggest that FC test following FIT positivity have good 
sensitivity for CRC among average-risk population. For AA, the sequential 
FIT and FC test possibly has better performance than FIT alone with higher 
cut-off levels. Thus the combination of FIT and FC may be of use in reduc-
ing the number of colonoscopies needed in CRC screening.
disclosure: The study was sponsored by Eiken Chemical. 
P1870 dIagnOsTIc yIeLd usIng arTIfIcIaL InTeLLIgence 
assIsTed endOcyTOscOPy fOr sessILe serraTed adenOMa/
POLyP
Ogawa Y.1, Kudo S.1, Mori Y.2, Misawa M.1, Mochizuki K.1, Maeda Y.3, 
Ichimasa K.1, Nakamura H.1, Ishigaki T.4, Ogata N.5, Kudo T.1, 
Wakamura K.1, Hayashi T.1, Ishida F.1, Itoh H.6, Oda M.6, Mori K.6
1Showa University Northern Yokohama Hospital, Digestive Disease Center, 
Yokohama, Japan, 2Showa University Northern Yokohama Hospital, Digestive 
Disease Center, Tokyo, Japan, 3Showa University Northern Yokohama 
Hospital, Digestive Disease Center, Kanagawa Yokohamashi, Japan, 4Showa 
University, Northern Yokohama Hospital, Yokohama, Japan, 5Showa 
University Northern Yokohama Hospital, Digestive Disease Center, Northern 
Yokohama Hospital, Yokohama, Japan, 6Nagoya University, Graduate School 
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contact e-Mail address: sunny.onet@gmail.com
Introduction: Sessile serrated adenoma/polyps (SSA/Ps) are known to be 
precursors of CRCs. 
Therefore, accurate endoscopic criteria to differentiate SSA/Ps from hyper-
plastic polyps (HPs) are needed. However endoscopic differentiation with 
endoscopists’ eyes is considered difficult.
aims & Methods: In this study, we evaluated the performance of the arti-
ficial intelligence (AI) combined with endocytoscopy in endoscopic iden-
tification of SSA/Ps. We developed the AI system based on the previously 
proposed model.
The AI system was combined with endocytoscopy (CF-H290ECI from Olym-
pus Co.). which enables in vivo observation of cellular images at 500-fold 
magnification. The diagnostic algorithm of the AI consisted of the se-
quence of image acquisition, extraction of 312 visual features from nuclear 
images and contrast difference of the whole image, and classification into 
the two pathological groups (SSA/P and Non-neoplastic). We designed this 
retrospective study to assess the performance of the AI system for predic-
tion of SSA/Ps by using 30 SSA/Ps (822 images) and 69 Non-neoplastic le-
sions (Total 1574 images) including 66 HPs (1524 images), 1 juvenile polyps 
(17 images) and 2 inflammatory polyps (33 images) resected between Jul. 
2018 and Feb. 2019. Machine learning for the AI was performed by using 
14222 images which were acquired and selected from Jan. 2016 to Jun. 
2018. The main outcome measures were diagnostic sensitivity specificity, 
accuracy of the AI system in identifying SSA/P in the image-based analysis 
and the lesion-based analysis. In the lesion-based analysis, diagnosis of 
the target lesion was defined as SSA/P when the AI system shown at least 
one SSA/P output.
results: The AI system automatically output the pathological prediction of 
1667 images (SSA/P 510 images, HP 1157 images) out of total 2396 images 
immediately with high confidence (probability>=80%). 
In the image-based analysis, the AI system showed sensitivity of 19.0% 
(97/510), specificity of 98.7% (1143/1157) and accuracy 74.4%(1240/1667).
However, in the lesion-based analysis AI system showed sensitivity of 
66.6% (20/30), specificity of 89.9% (62/69) and accuracy 82.8% (82/99).
conclusion: This study revealed AI system diagnosed SSA/P with high 
specificity.
However further accumulation of endoscopic images for machine learning 
is required to make more robust model for diagnosing SSA/Ps.
references: Mori Y, Kudo SE, Chiu PW et al. Impact of an automated system 
for endocytoscopic diagnosis of small colorectal lesions: an international 
web-based study. Endoscopy 2016; 48: 1110 - 1118
disclosure: Nothing to disclose 
P1871 nOn-InvasIve deTecTIOn Of cOLOrecTaL cancer and 
advanced adenOMa usIng cancer-sPecIfIc MeThyLaTIOn 
sIgnaTures In PLasMa cTdna
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9Zhongshan Hospital, Endoscopy, Shanghai, China
contact e-Mail address: zhu.boqun@zs-hospital.sh.cn
Introduction: Colorectal cancer (CRC) is a common malignant tumor of the 
digestive tract and one of the leading causes of cancerdeath worldwide. 
The five-year survival rate of CRC drops from above 90% at stage I to less 
than 10% at stage IV. Therefore, colonoscopy is recommended as a screen-
ing method, but patient compliance can be low due to its invasiveness. 
Non-invasive biomarker tests have also been developed for years, but are 
limited in sensitivity and specificity, especially for early-stage CRC and pre-
cancerous adenomas. We have established a highly accurate, next genera-
tion sequencing (NGS)-based, machine-learning guided screening assay 
(ColonES) detecting ctDNA methylation signatures in plasma.
aims & Methods: In this study, we organized a multi-center prospective 
study to evaluate the clinical performance and utility of ColonES. 
Blood samples were collected in EDTA tubes and centrifuged within 4 hrs 
to separate plasma. ColonES, an NGS based bisulfite sequencing assay 
covering approximately 2,181 genomic regionswas employed to identify 
pre-cancerous lesion and CRC. Patient samples were separated into three 
groups based on colonoscopy results. The high risk group includes CRC, 
advanced adenoma (AA), and cases with more than three adenomas; the 
low risk group include healthy individuals or patients with non-malignant 
diseases; the indeterminate group include non-AA with a sizes under 1cm. 
Before this study, a separate cohort of 400 samples was used to train the 
classification model, and a cohort of 514 samples was used to validate the 
model. This study will enroll approximately 2000 patients covering a full 
spectrum of clinical conditions to evaluate the accuracy and reproducibility 
of the assay.
results: The enrolled 2000 patients are divided equally between different 
categories. The first phase of the study, which is comprised of 259 patients, 
hasbeen completed.Sensitivity and specificity of different categories were 
determined using this group of samples.The sensitivities of stage 0/1 CRC, 
AA and multi-adenoma are 91.7%, 81.6% and 80.0%, respectively. Symp-
tomatic patients free of neoplasm were divided into two groups: group 
with no findings in colonoscopy, and the group with pathologically benign 
condition(s) including inflammation, polypus, or ulcus. The specificities of 
these groups are 82.9% and 80.8%, respectively. Interestingly, 52.6% of 
non-AA patients were called positive, suggesting that cfDNA from these 
patients may contain cancer-specific methylation signals. In-depth analy-
sis of the data revealed that the methylation scores, which are used to 
categorize the patients, are different in CRC patients of different stages 
and in CRC patients with different lesion sizes. In AA patients, methylation 
scores vary depending on sizes in tubular adenoma sub-category, but not 
in other AA sub-categories.
conclusion: We demonstrated that cancer-specific methylation signatures 
can be used for CRC and AA detection in plasma samples with high sen-
sitivity and specificity. This will provide a valuable tool for CRC and AA 
diagnosis and screening, especially in populations who cannot or are un-
willing to undergo colonoscopy.
disclosure: Hui Wang, Athurva Gore, Hai-Biao Gong and Rui Liu are em-
ployees of Singlera Genomics Inc., the product of which was used in this 
study. No other conflict of interest is declared. 
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P1872 age and cOLOnOscOPy InTervaL afTer 
TransPLanTaTIOn Is The rIsk Of advanced cOLOnIc 
neOPLasIa In renaL TransPLanT recIPIenTs
Choe Y.1, Park J.M.2
1Seoul St. Mary’s Hospital, College of Medicine, The Catholic University 
of Korea, Internal Medicine, Seoul, Korea (Republic of), 2Seoul St. Mary’s 
Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea 
(Republic of)
contact e-Mail address: choeyounghee29@gmail.com
Introduction: Organ transplantation has a higher risk for malignancies 
compared to general subjects.
aims & Methods: The purpose of this study was to investigate the inci-
dence of colorectal neoplasms in renal transplant recipients and to find 
risk factors for the development of advanced colonic neoplasias in renal 
transplant recipients. 
Between 1992 and 2015, colorectal neoplasm screening was performed 
in renal transplant recipients with colonoscopic evaluation. The incidence 
of colorectal cancer was compared with that of the general population 
registered in the National Cancer Registration Statistics. To determine the 
risk factors for the development of advanced colonic neoplasia, we inves-
tigated demographics, body mass index, types of main immunosuppres-
sive agents, and the interval of the first endoscopic evaluation from the 
transplantation.
results: Among 1,828 renal transplant recipients, 748 patients underwent 
colonoscopic evaluation between 1992 and 2017. Colorectal neoplasms oc-
curred in 191 patients (25.5%): non-advanced adenoma in 105 (14.0%), 
advanced adenoma in 70 (9.4%), cancer in 16 patients (2.1%). The inci-
dence of colorectal cancer in 2016 Korean National Cancer Statistics was 
0.06%, showing a higher incidence of colorectal cancer in renal transplant 
recipients. In multivariate analysis, age over 40 and more than five years 
interval between transplant and the first colonoscopy were independent 
risk factors for advanced colonic neoplasia. The risk of advanced neoplasia 
development in age over 40 was increased compared to under 40 (OR 8.7, 
95% CI 2.01-34.33; P=.003). The risk of advanced neoplasia was high if 
colonoscopy is performed more than 5 years after transplantation (OR 1.1, 
95% CI 1.02-1.16; P=.016).
  univariate analysis Multivariate analysis
Variables Odd ratio (95% CI) p value Odd ratio (95% CI) p value
Age (≥40 years) 8.7 (2.12-36.03) 0.003 8.3 (2.01-34.33) 0.003
Male sex 1.4 (0.88-2.27) 0.151 - -
Obesity 1.5 (0.87-2.65) 0.139 - -
DDKT/LDKT* 1.1 (0.94-1.20) 0.313 - -
CyS/TAC** 1.4 (0.86-2.21) 0.182 - -
Colonoscopy interval (≥5yrs) 1.1 (1.02-1.17) 0.008 1.1 (1.02-1.16) 0.016
* DDKT: Deceased donor at kidney transplantation, LDKT: Living donor at kidney 
transplantation ** CyS: Cyclosporine, TAC: Tacrolimus
[Risk factors for Advanced colonic neoplasia after renal transplantation]
conclusion: Renal transplant recipients had a higher incidence of colorec-
tal neoplasms. Colon cancer screening should be recommended before 40 
years in these patients.
disclosure: Nothing to disclose 
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P1874 sTudyIng TradITIOnaL serraTed 
adenOMas - endOscOPIc and PaThOLOgIcaL sIgns 
Of nOnserraTed TyPes Of cOLOn LesIOns
Ageykina N.1, Oleynikova N.2, Malkov P.2, Danilova N.2, Kharlova O.2, 
Fedorov E.2,3
1Medsi Clinic, Endoscopy, Moscow, Russian Federation, 2Lomonosov Moscow 
State University, Moscow, Russian Federation, 3Pirogov Russian National 
Research Medical University, Moscow, Russian Federation
contact e-Mail address: ageykina.natalia@yandex.ru
Introduction: Exact endoscopic and morphological criteria of traditional 
serrated adenomas (TSAs) of the colon are still not indicated. We exam-
ined features of TSAs in patients of our population.
aims & Methods: To characterize the endoscopic and histological features 
of traditional serrated adenomas and compare with nonserrated colorectal 
polyps.
Of the 500 epithelial lesions, removed via colonoscope in 265 patients, 
14/500 (2.8%) TSAs with different degrees of dysplasia and focus of adeno-
carcinoma in 1/14 (7.1%) were histologically identified. The key endoscopic 
and pathological features of TSAs and immunohistochemical studies with 
CD44, Ki67, Msi-1 and 1-and 3 - claudins antibodies were evaluated.
results: Polyps were located in the both parts of the colon, but most of 
them were located in the left colon (9/14; 64.3%), exactly in the rectum 
(7/14; 50%). Drew attention to their red color (13/14; 92.9%). The polyps 
size was 0.5-4.5 cm, while 2 (14.3%) polyps did not exceed 0.5 cm and 3 
(21.6%) polyps were more than 2.5 cm. Macroscopically, 5/14 (35.7%) le-
sions were flat-elevated Type 0-IIa; 9/14 (64.3%) polyps were protruding 
Type 0-Is, 0-Isp, 0-I. Two (14,3%) polyps were covered with a mucus cap. 
Three (21.4%) flat-elevated TSAs had pit-pattern II and only one of them 
presented as dark-green colors on auto fluorescence imaging (AFI) colo-
noscopy that are similar to the normal surrounding mucosa. This polyps 
type difficult to differentiate from hyperplastic polyps (HP) and sessile ser-
rated adenomas (SSA); 11/14 (78.6%) had pit-pattern IV and presented as 
magenta color tone on AFI colonoscopy. This endoscopic features are more 
typical for adenoma tubular-villous (ATV) and adenoma villous (AV). Im-
munohistochemically TSA is close to AT/ATV and fundamentally different 
from HP/ SSA, despite the fact that in current classification they belong to 
the group of serrated lesions. Statistically significant differences are:
· similar distribution of CD44 (surface) of the AT, ATV and TSA;
· similar levels of Msi-1 cytoplasmic response in AT, ATV and TSA; 
· similar levels of Claudine-1 and -3 expression in ATV and TSA.
conclusion: Often TSA are located in the rectum and corresponds to red 
protruding type lesions with pit-pattern IV. The TSA diagnosis based on 
AFI based on changes in magenta color tone. These endoscopic futures are 
the classical for nonserrated polyps with villous structure. The presence 
of characteristic ectopic crypts is almost impossible to distinguish from 
the branching of crypts in any ATV or AV, and there is no consensus on 
the number of ectopic crypts required for TSA verification. Given the low 
incidence of TSA, the similarity of endoscopic features and the absence of 
immunohistochemical differences between TSA and AT/ATV, the feasibility 
of TSA allocation in a separate classification group is debated and requires 
further study.
disclosure: Nothing to disclose 
943Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
P1875 cOMPLIcaTIOns afTer endOscOPIc resecTIOn Of T1 
cOLOrecTaL carcInOMas
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Uden, Netherlands, 19University Medical Center Utrecht, Pathology, Utrecht, 
Netherlands, 20University Medical Center Utrecht, Gastroenterology and 
Hepatology, Utrecht, Netherlands, 21Jeroen Bosch Hospital, Gastroenterology 
and Hepatology, ‘s-Hertogenbosch, Netherlands
contact e-Mail address: s.vandeven@erasmusmc.nl
Introduction: In contrast to the complication risk of endoscopic resection 
(ER) of adenomas, the intra-procedural and post-procedural complication 
risk of ER of T1 colorectal cancer (CRC) is scarcely reported in literature. 
One might hypothesize that ER of these early CRCs is associated with an 
increased complication risk, as these tumors grow into the submucosal 
layer and sometimes show incomplete lifting.
aims & Methods: We aimed to identify the complication rate after primary 
ER of T1 CRCs and to identify risk factors associated with these complica-
tions. Medical records were reviewed of all patients diagnosed with T1 
CRC between January 2000 and December 2014 within 15 hospitals in the 
Netherlands. Patients that underwent ER (with or without adjuvant sur-
gery) were selected. Primary outcome was the occurrence of endoscopy 
related complications (i.e., bleeding, perforation, polypectomy electro-
coagulation syndrome (PPES)) requiring re-colonoscopy, surgery, pro-
longed hospital stay, readmission, or other interventions such as antibiotic 
therapy or blood transfusion. Secondary outcome was the identification of 
independent risk factors associated with these complications. Additional 
information on treatment of complications, and intra-procedural hemoclip 
placement for prophylaxis was collected of all patients with complications 
and random controls (sub-cohort) from our total cohort in a 1:3 ratio. For 
the analysis of possible risk factors, the sub-cohort was used. Multivariate 
logistic regression was performed.
results: From a retrospective cohort of 1879 T1 CRC patients, 1069 patients 
with ER of T1 CRC were selected. Endoscopic complications occurred in 
59/1069 (5.5%) of patients, among which 37.3% of complications was clas-
sified as mild, 59.3% as moderate, and 3.4% as severe. These complica-
tions were delayed bleeding (N=40, 3.7%), perforation (N=13, 1.2%) and 
PPES (N=6, 0.6%). No fatal complications were observed. Independent 
predictors for complications were; age > 70 years (OR=2.111; 95% confi-
dence interval (CI)=1.124-3.964), and tumor size >20mm (OR=2.224, 95% 
CI=1.054-4.694). Age > 70 years was also associated with an increased risk 
for delayed bleeding (OR=2.616; 95% CI=1.236-5.537).
conclusion: In this large multicenter retrospective cohort study, complica-
tion rate of ER of T1 CRC (5.5%) was comparable with reported complica-
tion rates of ER of adenomas in current literature. These data supporting 
the relative safety of ER for T1 CRCs. More caution is warranted for ER of T1 
CRC in patients older than 70 years, and large lesions (>20mm).
disclosure: Nothing to disclose 
P1876 LOW dOse 5-aMInOsaLIcyLIc acId (5-asa) suPPresses 
grOWTh Of huMan cOLOrecTaL adenOMa derIved ceLLs In 
3-dIMensIOnaL cuLTure: IMPLIcaTIOns fOr PrevenTIOn
Dixon S.1,2, Creed T.2, Williams A.C.1
1University of Bristol, Cell & Molecular Medicine, Bristol, United Kingdom, 
2Bristol Royal Infirmary, Department of Gastroenterology, Bristol, United 
Kingdom
contact e-Mail address: stevewdixon@doctors.net.uk
Introduction: 5-aminosalicylic acid (5-ASA) is a well-tolerated and inex-
pensive salicylate used in the treatment of ulcerative colitis and epidemio-
logical data suggests that regular use reduces the risk of colitis-associated 
cancer[1]. Although aspirin (acetylsalicylic acid) has shown promise as a 
chemoprophylactic agent in patients with high colorectal polyp burden[2, 
3] it is unknown if 5-ASA has the same benefit. Interestingly 5-ASA has 
been shown to suppress Wnt/b-catenin signalling, deregulation of which 
is a key event in the initiation of colorectal cancer (CRC) tumorigenesis. 
Here we demonstrate that 5-ASA can repress the stem potential of hu-
man adenoma cells in a 3D organoid culture system and suggest this drug 
has potential as a chemoprophylactic agent in patients with a high polyp 
burden.
aims & Methods: The human colonic adenoma cell line PC/AA/C1 was 
seeded as a single-cell suspension into Matrigel®(Corning Life Sciences, 
USA) extracellular matrix and incubated with advanced DMEM/F12 (Sig-
ma-Aldrich, UK) media supplemented with 0.1% bovine serum albumin 
(Sigma-Aldrich), 2mM glutamine (Gibco), 10mM HEPES (Sigma-Aldrich), 
penicillin & streptomycin (Life Technologies, UK), 1% N2 (Gibco, UK), 2% 
B27 (Gibco, UK), 0.2% N-acetylcysteine (Gibco, UK) and EGF (Peprotech, 
UK). 5-ASA (Sigma-Aldrich) was dissolved in this culture medium and pH 
balanced to 7.35 - 7.45. 
Clinically achievable colonic luminal 5-ASA concentrations using oral 
preparations is 12 - 25mM[4]; we tested efficacy of lower doses in this 3D 
system. Serial images through the Matrigel hemispheres were acquired 
as a Z-stack using a DMI6000 widefield microscope (Leica, Germany) & 
LAS-X software (Leica) and analysed using a custom in-house MatLab pro-
gramme to estimate spheroid number and size. 
In parallel, cells were grown in T25 flasks (Corning, USA) and treated with 
5-ASA before protein lysates were taken for SDS-PAGE and Western blot-
ting for the stem cell marker and Wnt target leucine-rich G protein coupled 
receptor 5 (LGR5, Abcam, UK).
results: Adenoma cells exposed to low doses of 5-ASA once seeded into 
Matrigel established fewer viable organoids than control cells: control 
mean 95 organoids (95% confidence intervals 49 - 141)), 2mM 5-ASA 
mean 84 organoids (95% CI 36 - 131) & 5mM 5-ASA mean 30 organoids 
(95% CI 16 - 43; p < 0.005). After 21 days in culture, adenoma-derived or-
ganoids were significantly smaller than control: Control median 58800µm 
(inter-quartile range 4692 - 171560µm), 2mM median 1951µm (IQR 1207 
- 3331µm), 5mM median 1540µm (IQR 1139 - 2304µm)). Cells exposed to 
5mM 5-ASA at the time of seeding did not grow over 21 days of culture, 
but did form organoids if 5-ASA was removed from culture medium by day 
11. Where 5-ASA treatment was delayed to day 7 of culture, 5-ASA slowed 
but did not abrogate growth. Western blots of cell lysates demonstrated 
downregulation of LGR5 at higher (but clinically achievable) doses but 
LGR5 expression returned to normal within 8 hours of removing 5-ASA 
from culture medium.
conclusion: In these experiments we demonstrate that at low dose 5-ASA 
reduces the colony forming efficiency and growth of human colonic ad-
enoma cells in 3-dimensional culture system, implying that 5-ASA sup-
presses stemness, further supported by observed downregulation of the 
putative cancer stem cell marker LGR5. 
This data suggests that 5-ASA would be able to prevent formation and/or 
growth of adenomas in predisposed individuals. Clinical trials are required 
to establish if this affordable and well-tolerated drug could reduce polyp 
burden and cancer risk.
references: [1] Qiu, X., et al., Chemopreventive effects of 5-aminosalicylic 
acid on inflammatory bowel disease-associated colorectal cancer and dys-
plasia: a systematic review with meta-analysis. Oncotarget, 2016. [2] Hull, 
M.A., et al., Eicosapentaenoic acid and aspirin, alone and in combina-
tion, for the prevention of colorectal adenomas (seAFOod Polyp Prevention 
trial): a multicentre, randomised, double-blind, placebo-controlled, 2 x 2 
factorial trial. Lancet, 2018. 392(10164): p. 2583-2594. [3] Burn, J., et al., A 
randomized placebo-controlled prevention trial of aspirin and/or resistant 
starch in young people with familial adenomatous polyposis. Cancer Prev 
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Res (Phila), 2011. 4(5): p. 655-65. [4] Desreumaux, P. and S. Ghosh, Review 
article: mode of action and delivery of 5-aminosalicylic acid - new evi-
dence. Aliment Pharmacol Ther, 2006. 24 Suppl 1: p. 2-9.
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P1877 PrOgnOsTIc IMPacT Of neuTrOPhIL-TO-LyMPhOcyTe 
raTIO and TransfOrMIng grOWTh facTOr β recePTOr On 
cOLOrecTaL cancer survIvaL In a LeBanese POPuLaTIOn
Yazbeck C.1, Yazbeck Y.2, Ibrahim T.3, Massoud M.4, Chahine G.5
1Notre Dame des Secours University Hospital, GI, Jbeil, Lebanon, 2USEK, Jbeil, 
Lebanon, 3Saint Joseph University, Beirut, Lebanon, 4Notre Dame des Secours 
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Introduction: Colorectal cancer (CRC) is the third cancer in prevalence and 
in mortality worldwide. Inflammatory and genetic factors appear to play a 
role in the prognosis of CRC. A high neutrophil-to-lymphocyte ratio (NLR) 
is thought to be a predictor of poor prognosis in colorectal cancer. In addi-
tion, some authors consider that Transforming Growth Factor Beta Recep-
tor (TGFβR) polymorphism may have prognostic significance in colorectal 
cancer.
aims & Methods: Our primary objective is to assess the prognostic impact of 
NLR and TGFβR polymorphism, independently, on the 3-years and 5-years 
overall survival rates and on disease-free survival rates in colorectal cancer. 
Our secondary objective is to assess the prognostic impact of NLR¸ depend-
ing on the TGFβR polymorphism, on the 3-years and 5-years overall sur-
vival rates and on disease-free survival rates in colorectal cancer.
This is a retrospective cross-sectional multivariate study conducted in two 
hospitals in Lebanon. A total of 91 patients diagnosed with colorectal ade-
nocarcinoma prior to 2011, positive for either polymorphism TGFβR*6A/9A 
or TGFβR*9A/9A by genetic analysis DNA on blood samples and having a 
complete blood count at diagnosis prior to any treatment, were included 
in this study.
results: The impact of NLR on the survival of CRC was statistically signifi-
cant with a p-Value < 0.05: low NLR was associated with better 3-years 
and 5-years overall survival rates and with better disease-free survival 
rates compared to high NLR. The impact of TGFβR polymorphism was not 
significant: TGFβR*9A/6A polymorphism was not associated with neither 
decreased overall survival rates nor decreased disease-free survival rates. 
To our knowledge, this is the first multivariate study to evaluate the impact 
of NLR and TGFβR polymorphism at the same time.
conclusion: NLR is a simple, non-invasive and unexpansive tool which can 
be easily used to classify patients and adapt disease management and fol-
low up in order to optimize outcomes. 
It would be interesting, in future studies, to evaluate the exact mechanism 
of the immunological response in CRC and the elaborate the role of cyto-
kines of lymphocytes.
references: Kuipers EJ, Grady WM, Lieberman D, et al. COLORECTAL CAN-
CER. Nat Rev Dis Primer. 2015;1:15065. doi:10.1038/nrdp.2015.65 2. Marley 
AR, Nan H. Epidemiology of colorectal cancer. Int J Mol Epidemiol Genet. 
2016;7(3):105-114. 3. Bhurgri H, Samiullah S. Colon Cancer Screening - Is 
It Time Yet? J Coll Physicians Surg--Pak JCPSP. 2017;27(6):327-328. doi:2629
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P1878 PrevaLence and IMPacT Of anaeMIa fOLLOWIng 
TheraPeuTIc InTervenTIOn fOr cOLOrecTaL cancer
Dru R.C.1, Court E.L.2, Curtis N.J.2, Spencer C.2, Allison A.2, Dalton R.2, 
Dennison G.2, Ockrim J.B.2, Francis N.K.2
1Yeovil District Hospital NHS Foundation Trust, General Surgery, Yeovil, United 
Kingdom, 2Yeovil District Hospital, General Surgery, Yeovil, United Kingdom
contact e-Mail address: rebecca.dru@ydh.nhs.uk
Introduction: Anaemia is common in patients with colorectal cancer and 
can be worsened by surgical blood loss. Preoperative optimisation aims to 
correct preoperative anaemia with comparably little attention given to the 
prevalence and consequences of postoperative anaemia.
aims & Methods: The aim of this study was to investigate the frequency of 
postoperative anaemia and any associated short and long-term impacts of 
anaemia at discharge following laparoscopic colorectal cancer resection.
A dedicated, prospectively populated database of elective laparoscopic 
colorectal cancer procedures with curative intent within a fully implemented 
ERAS protocol was utilised. Patient demographics, tumour characteristics, 
and operative details were captured. The primary endpoint was anaemia at 
discharge. Anaemia was defined as haemoglobin (Hb) level of < 120g/L for 
women and < 135g/L for men. Secondary endpoints were anaemia at time 
of hospital admission, length of stay (LoS), postoperative complications, 
and overall survival. Median follow up was 61 months with overall survival 
calculated with the Kaplan-Meier log rank method stratifying for tumour 
stage. Data was analysed using the IBM SPSS® statistical tool.
results: Complete data of 532 patients were included with median age of 
72 years and BMI 26. 389 were male while 161(24.1%) were ASA III. 46.4% 
were anaemic preoperatively. Median operative time was 180min (inter-
quartile range 150-250) with 100ml (0-200) median estimated blood loss. 
At discharge most patients were anaemic (76.6%, Hb 115 g/L (106-125), 
p< 0.001). 16.7% experienced postoperative complication(s) with a lower 
discharge Hb seen in this group (110g/L (105-120) vs. 116g/L (107-127), 
p=0.001). Anaemia at discharge was significantly associated with a lon-
ger stay (7 (5-11) vs. 6 (5-8), p=0.037) while preoperative anaemia was 
not (7 (5-10) vs. 7 (5-9), p=0.063). Admission and discharge anaemia 
were independently associated with worse overall survival (p=0.027 and 
p=0.018 respectively) and remained significant after adjusting for tu-
mour stage.
conclusion: Anaemia at time of discharge following elective laparoscopic 
colorectal cancer surgery is commonplace with associated negative im-
pacts upon short-term outcomes and overall survival.
disclosure: Nothing to disclose 
P1879 The verIfIcaTIOn Of The vaLIdITy Of aMBuLaTOry 
hOT snare eMr and POLyPecTOMy fOr cOLOnIc neOPLasIa
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Introduction: Hot snare endoscopic mucosal resection (EMR) and pol-
ypectomy is an efficacious endoscopic therapy for colorectal neoplasia. 
Due to the complication such as delayed bleeding and perforation, these 
procedures generally need hospitalization. Ambulatory EMR and polyp-
ectomy are easier to manage and can be performed earlier compared to 
those with hospitalization. However, the curability and safety of ambula-
tory treatment is not clarified. Thus the aim of this study was to verify 
the validity of ambulatory hot snare EMR and polypectomy for colonic 
neoplasia.
aims & Methods: From January 2007 to November 2018, 97 patients who 
underwent ambulatory hot snare EMR and polypectomy for colonic neo-
plasia (ambulatory group. male:female, 67:30; age, 64.3 ± 12.5; 173 le-
sions), and 1184 patients who underwent those procedure for colonic neo-
plasia with hospitalization (hospitalization group. male:female, 813:371; 
age 66.2 ± 10.8 ; 2752 lesions) in Chiba university hospital were included 
in this study. The curative resection rate, procedure-related complications 
were compared between the ambulatory group and hospitalization group 
retrospectively.
results: Median tumor size (mm) was 7 (range 3-30) in the ambulatory 
group and 7 (range 2-50) in the hospitalization group. There was no sig-
nificant difference. The breakdown of SSA/P / low grade intra-mucosal 
neoplasia/ high grade intra-mucosal dysplasia/ cancer was 10/ 105/ 57/ 1 
and 109/ 1774/ 822/ 47 respectively. The curative resection rate was 82.1% 
in the ambulatory group and 75.5% in the hospitalization group (p=0.051 
chi-square test). The number of the patients with the history of use of 
anticoagulants and/or antiplatelet drugs was 11 (11.3 %) and 226 (19.1%) 
respectively, and the difference was not significant. 
Mean period of hospital stay in hospitalization group was 4.1 ± 2.9 days. 
Perforation occurred in 0 (0%) patient and 2 (0.2%) patients respectively. 
Delayed bleeding occurred in 1 (1.0%) patient and 32 (2.7%) patients re-
spectively, and the differences were not significant. 
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One patient with delayed bleeding in ambulatory group underwent endo-
scopic hemostasis without hospitalization 2 days after EMR.
conclusion: Ambulatory hot snare EMR and polypectomy for colonic neo-
plasia can be performed safely with equivalent curability to those with 
hospitalization even if the patients had the history of use of anticoagulants 
and/or antiplatelet drugs.
disclosure: Nothing to disclose 
P1880 MrI cOMBIned WITh a sTrucTured rePOrT 
TeMPLaTe as a Pre-seLecTIOn TOOL PrIOr TO endOscOPy 
TO IdenTIfy PaTIenTs fOr Organ-PreservaTIOn afTer 
cheMOradIOTheraPy In recTaL cancer
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Introduction: MRI and endoscopy are currently the main tools used to 
assess response and identify potential candidates for organ preserving 
treatments after chemoradiotherapy (CRT) for rectal cancer. For logistical 
reasons and when there is limited expertise in endoscopic imaging for 
restaging, MRI could play a role as a pre-selection tool to identify patients 
who would benefit from additional endoscopy to differentiate between po-
tential complete responders who may be candidates for organ preserva-
tion and poor responders in whom surgery is unavoidable.
aims & Methods: Aim of this study was to evaluate the performance of MRI 
(for readers with varying expertise levels) using a simplified structured 
report template in this specific setting. 
Seven independent readers with varying expertise levels retrospectively 
evaluated 63 patients who routinely underwent a restaging MRI with Dif-
fusion-Weighted Imaging (MRI-DWI). Using a simplified structured report 
template taking into account the morphologic response on T2W-MRI and 
the signal pattern on DWI, patients were categorized as: 
[1] good - potential complete responders (i.e., would benefit from endos-
copy to identify complete responders), 
[2] intermediate responders - residual tumour most likely (i.e., endoscopy 
potentially useful to confirm residual tumour), and 
[3] poor responders - highly suspicious of tumour (i.e., endoscopy not re-
quired, surgery unavoidable). 
The final response outcome of all patients was determined by histopathol-
ogy in the operated patients or by long term follow-up (local recurrence 
free follow up of ≥ 1 year) in the patients with a sustained complete re-
sponse undergoing watch-and-wait.
results: The median number of patients categorized into the “poor re-
sponders” group by the 7 readers was 13(21%) (range 8-24). The vast ma-
jority of these patients had confirmed residual tumour at histopathology, 
with a low rate of “missed complete responders” varying from 0-4% for 
the different readers. The median number of patients categorized into the 
“intermediate responders” group was 31 (49%) (range 14-36). The rate of 
missed complete responders in this group ranged from 0-24% for the dif-
ferent readers. In the group categorized as the “good - potential complete 
responders” (median 18 (29%), range 14-26 per reader), the majority of 
patients (44-67%) were confirmed complete responders. When combining 
the MR poor-intermediate response group together, the risk of missing 
complete responders ranged from 3-12% for the 7 readers.
conclusion: MRI using a simplified structured report template can aid in 
pre-selecting patients for immediate surgery, regardless of radiologists’ 
experience level:
- When applying a stringent pre-selection (MR-poor responders only), the 
risk for missing complete responders is almost negligible (0-4%) and ap-
proximately 21% of patients can be safely referred for direct surgery. 
- With a more conservative approach (including both MR-poor and -in-
termediate responders), around 71% of patients may be referred for direct 
surgery without endoscopic evaluation, at the cost of missing 3-12% of 
complete responders.
Using MRI in such a way, can thus facilitate a more selective use of endos-
copy to identify the good responding patients and further select candidates 
for organ preservation.
disclosure: Nothing to disclose 
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Introduction: Although endoscopic submucosal dissection (ESD) of gastro-
intestinal (GI) neuroendocrine tumor (NETs) is an increasingly performed 
minimally invasive technique allowing complete en-bloc resection of mu-
cosal and submucosal lesions, data on efficacy and safety outcome is lim-
ited. The aim of this study is to review three European centers experience 
of endoscopic treatment of superficial GI NET by ESD.
aims & Methods: Clinical and technical data of patients treated by ESD 
from three tertiary European centers were prospectively collected from 
October 2014 to March 2019. Complete resection (R0) was defined as clear 
lateral and vertical margins.
results: Thirty ESDs of NETs were performed in 28 patients (females 
60.7%), median age of 61 years. Twenty-one NETs (70%) were removed 
from the stomach, 6 from the rectum (20%), 2 from the duodenum (6.6%) 
and 1 from the esophagus (3.33%). Seventeen out of 21 (80.9%) gastric 
NETs were associated with atrophic gastritis, 15 (88.2%) of which of auto-
immune etiology. Moreover, 8 out of 21 patients (38.1%) with gastric NET 
had history of multiples NETs. Among them, 6 patients had been diagnosed 
with autoimmune atrophic gastritis (75%), 1 patient with helicobacter py-
lori related gastritis (12.5%) and 1 patient with gastritis of unknown origin 
(12.5%). En-bloc resection was achieved in all patients (100%). R0 resec-
tion rate was 80% (93.3% clear lateral and 80% clear vertical margins). 
Lymphovascular infiltration was diagnosed in three cases (10%).
Median ESD duration time, recorded in 21 procedures, was 60 min (range 
20-240). One case of rectal and one case of duodenal NET removal, pre-
sented small perforations, treated conservatively by antibiotics and clip 
closure. The median specimen size was of 26 mm (range 12-65). Patho-
logical examination showed 17 (56.6%) grade 1, 12 (40%) grade 2 and 
1 (3.3%) grade 3 NETs. Sixty-nine percent of lesions were characterized 
as pT1 and 30.4% as pT2. Three patients were candidates for additional 
treatment: one had endoscopic mucosal resection for additional known 
lesions, one underwent surgery with oncological lymph node resection (fi-
nally pT2N1) and one refused systemic therapy. Follow up was performed 
in 21 patients. At the end of a median follow-up of 554 days, two cases of 
recurrence were identified: one was managed endoscopically, the second 
refused treatment.
conclusion: Our series of ESD for selected GI NETs showed favorable re-
sults in term of efficacy and safety. However, further studies are needed to 
determine the role of ESD compared to other resection modalities.
disclosure: Dr Despott and Dr Murino receive research/ education sup-
port from Aquilant Medical, Fujifilm, Olympus, Pentax Medical, Boston 
scientific and GI supply. All others authors have no conflicts of interest to 
disclosure. 
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P1882 endOscOPIc suBMucOsaL dIssecTIOn In dysPLasTIc 
LesIOns In LOng-sTandIng uLceraTIve cOLITIs: resuLTs Of a 
TerTIary endOscOPIc referraL cenTer
Manta R.1, Bachetti F.1, Castellani D.1, Antonelli E.1, Caruso A.2, 
Germani U.1, Bertani H.2, Grande G.2, Reggiani Bonetti L.3, Villanacci V.4, 
Bassotti G.5, Conigliaro R.2, Clerici C.1
1Perugia Hospital, Gastroenterology and Digestive Endoscopy Unit, 
Perugia, Italy, 2Nuovo Ospedale Civile Sant’Agostino Estense, Baggiovara, 
Gastroenterology and Digestive Endoscopy Unit, Modena, Italy, 3Policlinico 
di Modena, University of Modena and Reggio Emilia, Pathology, Modena, 
Italy, 4Spedali Civili Brescia, Pathology, Brescia, Italy, 5Perugia University, 
Medicine, Gastroenterology Unit, Perugia, Italy
contact e-Mail address: fra.bachetti89@gmail.com
Introduction: Endoscopic resection of superficial polypoid lesions in ul-
cerative colitis (UC) patients is appropriate if a complete resection can be 
achieved. However, endoscopic mucosal resection (EMR) is ineffective for 
large, nonpolypoid neoplasms (NPL) in UC, due to submucosal fibrosis and 
poor data are available on the efficacy of endoscopic submucosal dissec-
tion (ESD).
aims & Methods: The aim of this study is to assess ESD feasibility and 
efficacy for large, NPL in UC patients in two tertiary endoscopic referral 
center.From April 2009 to October 2017 superficial NPL >20 mm within the 
colonic mucosa of ulcerative colitic patients, were retrospectively evalu-
ated, in a tertiary italian endoscopic referral center. Pre resection staging 
of NPLs was achieved by WLE+cromoendoscopy + NBI (Olympus Comp.) 
or I-scan System (Pentax Comp.). ESD was performed according to the 
standard technique, by using CO2 insufflation. Dual knife and Hook knife 
were used as ablation tools. A hyperosmotic solution (plasma expander 
+ epinephrine + indigo carminio) was used to obtained the lifting of le-
sion. All endoscopic procedures were performd under conscious sedation 
(fentanyl + midazolam).
results: Twenty-three patients (15M and 8F) were considered in the study; 
median age at time of resection was 62 (30-81). The colonic disease du-
ration was 18 years (1-44) and 87% of the patients had extensive coli-
tis (E3); 13% left side colitis (E2). Twelve of the 23 patients were under 
5-aminosalicylic acid, 10 under biologics and 1 patient under azathioprine 
therapy. Mean lesion size was 38.6 ±22.1 (20-50) mm. En bloc resection 
was achieved in n=22 patients (95.6%), in 1 patients piecemeal was per-
formed and there were no severe complications. All lesions removed were 
non polypoid with distinct margins, and no ulceration was observed. In all 
resected lesions low-grade dysplasia was diagnosticated histopathologi-
cally. No patient was referred for colectomy.
conclusion: In this study, ESD of large non polypoid lesions associated with 
UC seems to be feasible, safe and curative option. These data support the 
potential role of advanced endoscopic therapeutic tecnique for a manage-
ment of dyspalsia associated colitis in selected patients.
disclosure: Nothing to disclose 
P1883 Lynch syndrOMe - unIversaL screenIng sTraTegy 
IMPLeMenTaTIOn
Cortez-Pinto J.1, Rosa I.2, Lage P.3, Claro I.4, Fonseca R.5, Pereira A.D.3, 
Grupo Multidisciplinar de Cancro Colo-Rectal do IPOLFG
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Gastroenterology, Lisboa, Portugal, 2Instituto Portugues de Oncologia 
de Lisboa, EPE Dept. de Gastroenterologie, Gastroenterology, Lisboa, 
Portugal, 3Instituto Português de Oncologia de Lisboa Francisco Gentil, 
Gastroenterology, Lisboa, Portugal, 4Portuguese Institute Oncology 
Gastroenterology, Gastroenterology, Lisboa, Portugal, 5Instituto Português de 
Oncologia de Lisboa Francisco Gentil, Pathology, Lisboa, Portugal
contact e-Mail address: isaalr9@zonmail.pt
Introduction: Revised Bethesda Criteria (BC) are used to select patients 
with colorectal cancer (CRC) for Lynch Syndrome (LS) screening - selective 
strategy.
Given the low sensitivity of these criteria, screening for loss of expression 
of DNA repair proteins (DRP) / microsatellite instability (MSI) in all patients 
with CRC diagnosis, or in those < 70 years is currently recommended - 
universal strategy.
aims & Methods: Our aim was to evaluate the benefits of applying the 
universal strategy in the identification of patients with LS.
Single-center cohort study. All patients < 70 years with an initial diagnosis 
of CRC discussed in a multidisciplinary appointment (07/2016 - 12/2017) 
and submitted to surgery were evaluated.
Clinical data, tumor features (including DRP expression), and genetic / 
epigenetic studies results were analysed (descriptive statistics).
results: 105 patients were evaluated [57.1% males, mean age at diagnosis: 
58.5 years (15-69)]. 7.7% of the tumours were mucinous or had signet ring 
cells. In 30% lymphocytic infiltrate was observed.
2.9% met the Amsterdam Criteria and 27.6% BC.
There was loss of DRP expression in 8.6% of tumours (7/9 MLH1 / PMS2; 
1/9 MSH2 / MSH6; 1/9 MSH2). In the subgroup of patients with loss of DRP 
expression, one had a positive genetic diagnosis -LS (patient with MSH2 / 
MSH6 loss), 5 have ongoing studies (hipermethylation or genetic diagno-
sis), 2 died before being tested and one refused genetic diagnosis (patient 
with loss of MSH2). The patient with LS diagnosis fulfilled BC (age < 50 
years). Of the remaining 8 patients,3 did not fulfil BC and would not have 
been investigated by the selective strategy.
conclusion: The preliminary results of our study demonstrate the impor-
tance of the universal strategy widespread implementation for screening 
of loss of DRP expression/ MSI in CRC.
disclosure: Nothing to disclose 
P1884 LOng TerM fOLLOW-uP Of recTaL cancer PaTIenTs 
WITh a cOMPLeTe resPOnse fOLLOWed In a WaIT-and-see 
aPPrOach, Is There an Increased rIsk fOr MeTasTasIs?
Haak H.E.1,2, van der Sande M.E.1,2, Lambregts D.M.J.3, Beets-Tan R.G.H.2,3, 
Melenhorst J.4, Beets G.L.1,2, Maas M.3, the Dutch Watch-and-Wait 
Consortium
1Netherlands Cancer Institute - Antoni van Leeuwenhoek Ziekenhuis, 
Department of Surgery, Amsterdam, Netherlands, 2GROW School for 
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contact e-Mail address: h.haak@nki.nl
Introduction: Patients with a regrowth in a wait-and-see-program are re-
ported to have a higher risk for metastases. This is probably related to an 
inherent higher risk of incomplete responders, but it cannot be excluded 
that metastases can arise from the regrowth.
aims & Methods: The aim of this study was to evaluate the risk of dis-
tant metastasis in wait-and-see patients with a clinical(near)complete 
response (cCR) after neoadjuvant chemoradiation (CRT) for rectal cancer, 
according to local regrowth and timing of inclusion. 
Patients were included in a wait and see program between 2004 and 2019 
when a three modality approach with digital rectal examination, endosco-
py and MRI showed a (near) cCR. Patients were followed with frequent en-
doscopy and MRI every 3 months during the first year, and every 6 months 
thereafter. Oncological outcomes were assessed with Kaplan-Meier curves 
and a log rank test.
results: We analyzed 313 patients with a median FU of 39 months (range 
2-158) of which the majority (n=191) were prospectively analyzed. 52% 
(n=161) patients had an immediate cCR at restaging and 47%(n=147)pa-
tients had a near cCR during restaging with a cCR after reassessment of 
3 months. 19% of the patients developed a local regrowth within 3 years 
(n=57, 49 luminal, 3 nodal, 5 both luminal and nodal). 9 patients with 
local regrowth developed distant metastasis (20%, 95%CI 62-90) within 
3 years compared to 11 patients with distant metastasis without LR (5%, 
95%CI:92-98) (p < 0,001). 7/9 patients developed a local regrowth first 
before detection of metastasis, 1 patient developed local regrowth and me-
tastasis simultaneously and 1 patient developed metastasis 6 months prior 
to detection of local regrowth. Patients with a near CR and local regrowth 
tend to develop more metastasis compared to immediate complete re-
sponders who had a local regrowth. 3-year overall survival in patients with 
local regrowth was 93%(95%CI:80-98) vs. 97%(95%CI:94-99) in patients 
without local regrowth (p=0.25).
conclusion: Rectal cancer patients selected for a wait-and-see-program who 
develop a regrowth have a higher risk of developing distant metastasis, es-
pecially in near CR. It is hypothesized that this is related to tumour biology 
but it remains unsure if metastasis arise from a regrowth. Overall survival 
outcomes in patients with and without regrowth did not differ significantly.
disclosure: Nothing to disclose 
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P1885 OuTcOMes fOLLOWIng surgery fOr cOMPLeTeLy 
reMOved cOLOnIc LaTeraL sPreadIng LesIOns cOnTaInIng 
suB-MucOsaL InvasIve cancer
Abu Arisha M.1,2, Half E.1, Maza I.1, Awadie H.2, Muaalem R.2, Bana S.2, 
Kariv R.3, Haj-Yahya M.3, Khuri W.1, Klein A.1,2
1Rambam Health Care Campus, Gastronterology, Haifa, Israel, 2Holy Family 
Hospital Nazareth, Department of Gastroenterology, Nazareth, Israel, 3Tel 
Aviv Sourasky Medical Center, Tel Aviv, Israel
contact e-Mail address: m_abu-arisha@rmc.gov.il
Introduction: Management of malignant colorectal polyps can be en-
doscopic or surgical and the best approach has yet to be defined since 
prospective data is lacking. Endoscopic mucosal resection (EMR) is the 
treatment of choice for large (>20 mm) lateral spreading colonic polyps 
(LSL) with high success rates, good safety profile and clinical and economic 
advantages compared with surgery. There is no data on the outcome and 
management of malignant LSL (M-LSL) following complete removal by 
piecemeal EMR.
aims & Methods: We aimed to determine if salvage surgery for M-LSL fol-
lowing complete EMR resection is necessary. We analyzed data from a 
prospectively collected database of patients who underwent EMR at three 
hospitals In Israel. Patients with M-LSL were identified and their surgical 
and pathological data was reviewed for the presence of residual neoplastic 
tissue and complication. The primary end-point was the presence of re-
sidual localo-regional cancer.
results: Over 34 months 313 LSL in 303 patients were removed by EMR. 
249/313 (81.7%) were removed piecemeal. Complete endoscopic resection 
was achieved in 249/249 (100%) which endoscopically were not suspicious 
for containing deep submucosal invasive cancer. The final EMR pathology 
showed invasive cancer in 23/249 (9.2%). 
After multidisciplinary meeting (MDT), 5 cases were not sent to surgery 
(curative resection or high operative risk). 18 cases were referred for sur-
gery following MDT because EMR was considered non-curative (presence 
of LVI/tumor budding/submucosal invasion>1mm/poor tumor differen-
tiation/absence of clear margins or a combination thereof). In all cases, 
18/18 (100%) patients underwent laparoscopic oncological resection with 
no major complications. There was no evidence of residual cancer in the 
resected colons or lymph nodes in all patients.
conclusion: Colonic LSL removed by piecemeal EMR, may not require sur-
gery even when submucosal invasive cancer is present in the resected EMR 
specimen. Further research may define specific criteria for avoiding sur-
gery.
disclosure: Nothing to disclose 
P1886 The IMPOrTance Of InTrOducIng cOLOnOscOPy 
screenIng In The aduLT cysTIc fIBrOsIs PaTIenTs: a sIngLe 
TerTIary referraL cenTre anaLysIs
Doherty J.1, Zulquernain S.1, Plant B.2
1Cork University Hospital, Department of Gastroentrology, Cork, Ireland, 2Cork 
University Hospital, Cork Centre for Cystic Fibrosis, Cork, Ireland
contact e-Mail address: jaynedohertie@hotmail.com
Introduction: The risk of colorectal cancer (CRC) in patients with cystic fi-
brosis (PWCF) is 10times greater than the general population and 30times 
greater post-transplant. Due to this increased risk new screening guide-
lines were published in Gastroenterology by the CF Colorectal Cancer 
Screening Task Force in 2018.
aims & Methods: Our aim was to benchmark current practise at our centre 
against current guidelines. Our endoscopy database was interrogated from 
2012 to present to identify PWCF who received a previous colonoscopy.
results: 
group 1: PWcf non-transplant cohort; 
161 patients were included. 26 were >40years. 4 patients had a previous 
colonoscopy (total number colonoscopies = 4). No colonoscopies were 
done for screening, all as patients were symptomatic. One patient had a 
polyp at colonoscopy. Adenoma detection rate (ADR) was 25%.
21 patients >40 have no previous colonoscopy. Surveillance for CRC in this 
cohort has yet to be implemented with 0% compliance to date. 
group 2: PWcf post solid-organ transplant;
16 patients were included. 13 were >30 years. 11 patients had a previous 
colonoscopy (total number colonoscopies = 20). 
Reasons for index colonoscopy: 5 screening, 3 symptomatic, 3 no indica-
tion on report. 
10 colonoscopies in total were done for screening. 
3 patients had polyps found at index colonoscopy (2 adenomas high grade 
dysplasia, 4 adenomas low grade dysplasia) and surveillance colonosco-
pies were arranged subsequently. ADR was 27.27%. Current practise in the 
post transplant cohort is close to new recommendations with 84% compli-
ance, however only 45.45% of index colonoscopies were done initially for 
screening.
conclusion: Current guidelines are only in existence just over 12months. 
Our analysis suggests there is an awareness of the need for CRC screening 
in the post-transplant cohort but there is need for improvement. In PWCF 
with no previous transplant screening has not been a priority and needs to 
be implemented. Currently we are implementing a screening programme 
in keeping with current guidelines.
disclosure: Nothing to disclose 
P1887 InaPPrOPrIaTe nOn-InvasIve cOLOrecTaL cancer 
referraL TO surgery: a screenIng POPuLaTIOn-Based 
OBservaTIOnaL sTudy
Iacopini F.1, Hassan C.2, Ceci V.3, Frontespezi S.4, Brighi S.5, Fedeli P.6, 
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Introduction: Performance key measures of endoscopic resection and sur-
gery referral are indefinite but heterogeneous operative skills can have a 
heavy impact on organized colorectal cancer screening programs.
aims & Methods: Retrospective, observational 2-year study. Consecutive 
patients referred to surgery for colorectal neoplasms diagnosed in an 
organized screening program. Primary outcome: non-invasive neoplasm 
rates stratified on endoscopic staging (superficial vs. deep) and resection 
attempt. Invasive cancer was defined as cancer invading the submucosa 
(SM) or beyond on endoscopic and/or surgical specimens. Data were re-
trieved both from the county registry and cross-checked with date prospec-
tively collected in endoscopy databases.
results: A total of 468 patients were referred to surgery from 13 centers. 
Mean age was 64 (range 56-74); males 256 (58%); 213 (47%) from rural 
areas. 
According to endoscopic morphology and approach before surgery, neo-
plasms were stratified in three groups: superficial underwent endoscopic 
resection (n.92, Sup-ER); superficial underwent biopsies (n.96, Sup-B); 
deep underwent biopsies (n.280, Deep-B). Sup-ER were significantly 
smaller (< 0.0001), more frequently pedunculated (< 0.0001) and in the left 
colon (< 0.0001) than Sup-B. Sup-ER underwent complete resection were 
significantly smaller (0.0059) and more frequently pedunculated (0.0433) 
than incomplete resections.
The non-invasive cancer rate was 11% for Sup-ER, 40% for Sub-B, and 
9% for Deep-B. However, non-invasive cancer rate for mass ulcer-negative 
Deep-B (20%) was significantly higher than thos in stricturing and ulcer-
positive (3% and 5%, respectively: P=0.0002).
Centers showed significantly different rates of Sup-ER underwent com-
plete resection (57% to 100%, P=0.0001), quite significantly different over-
all non-invasive rates (P=0.0549), and significantly different non-invasive 
rates in Sup-B (P=0.0187). Overall non-invasive cancer rates in the 13 cen-
ters ranged from 0% to 30% (P=0.0581), being < 10% and >20% in 5 
(29%) centers, respectively.
Non-invasive cancer rate of sup-B was significantly different ranging from 
0% (in 5 centers) to >60% in 3 centers.
conclusion: The rate of noninvasive cancers referred to surgery in screen-
ing programs should be measured because rates can be high and center 
performances widely heterogeneous. Most of noninvasive cancer referred 
to surgery can be related to suboptimal resection skill or unavailability 
of advanced techniques that would guarantee an en bloc resection and 
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accurate histology. Corrective actions should consider: improvement in 
endoscopic characterization in all centers; expert 2nd-look in endoscopic 
referral centers in which hybrid EMR and/or ESD can be performed. Rate of 
noninvasive cancers referred to surgery should be a quality measure both 
for endoscopic and surgical screening centers.
disclosure: Nothing to disclose 
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On grade ≥ 3 TOxIcITy In PaTIenTs receIvIng fIrsT-LIne 
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Introduction: Malnutrition is frequent and negative in cancer patients. In 
particular, protein-energy malnutrition is associated with increased com-
plications of chemotherapy.
aims & Methods: This study aimed at assessing the benefits of an early 
and active individualized dietary counseling (DC) in patients receiving 1st-
line chemotherapy for metastatic colorectal cancer (CRC). In a prospective 
multicentre study, non-malnourished patients were randomised to benefit 
(G1) or not (G2) from individualised DC by a dietician at treatment initiation 
and every 2 wk thereafter. ONS or EN/PN were prescribed based on guide-
lines. The primary endpoint was grade ≥3 toxicity over a 1-y follow-up. To 
show a 20% difference with a power of 80% and α=0.05, 80 patients per 
group were needed. Statistics were performed with logistic regressions 
and Chi-2 tests.
results: 173 patients were analysed in ITT: G1 (n=85, F/M:31/54, 64±13 y); 
G2 (n=88, F/M:34/54; 63±12 y). The number of metastatic sites, PS, BMI 
(25±4 vs 26±4), and treatment protocols were similar. A grade ≥3 toxic-
ity was seen in 49.4% of G1 and 67.0% of G2 patients (RR=0.367; 95%CI: 
0.186-0.722; p= 0.0037) with a median delay of 359 (182- …) vs 169 d (118-
252). 9.4% of G1 and 19.3% of G2 patients died (p=0.065). Energy and pro-
tein intake of G1 patients exceeded those of G2 patients by 222±76 kcal/d 
and 11.4±4.8 g/d (p=0.004). Weight variations favoured G1 (p=0.007): at 
M3, G1 patients had a stable weight and G2 patients had lost 1,2 ± 0,6 kg. 
At M6, 14.8% of G1 and 30.8% of G2 patients (p=0.03) were malnourished. 
ONS were prescribed in 48.2% of G1 and 61.4% of G2 patients (p=0.08) and 
EN/PN in 7.1% of G1 and 14.8% of G2 patients (p=0,105).
conclusion: An early and active DC reduces the risk of developing a grade 
≥3 toxicity during the first-line chemotherapy of metastatic CRC. Even if 
further studies are needed in order to allow extrapolations, this work ad-
vocates a systematic dietary counselling in cancer patients receiving che-
motherapy.
disclosure: Nothing to disclose 
P1889 evaLuaTIOn Of The enTerIc nervOus sysTeM By 
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Introduction: The enteric nervous system (ENS) in dysmotility has been 
studied by classical light microscopy including immunohistochemistry. 
However, the procedure is rather time-consuming and only small compo-
nents of the ENS in two dimensions can be analyzed. Novel x-ray imaging 
techniques, employed in this study, allow to obtain high-resolution three-
dimensional scans of soft biological tissue over a longer segment with an 
overview of interganglionar neural connections, and different intragan-
glionar cell types, which would normally show no contrast with standard 
x-ray absorption microtomography.
aims & Methods: The aim of the present study was to evaluate the ENS in 
a three-dimensional manner, to get a more complete architecture of the 
neural tissue in sickness and health. Full-thickness biopsies of ileum from 
a patient with Ehlers-Danlos syndrome and secondary severe gastrointes-
tinal dysmotility and from a healthy resection border of proximal colon due 
to resection of the colonic carcinoma were embedded in paraffin and sec-
tioned. Representative areas of the ENS with presence of myenteric ganglia 
and submucosal ganglia were identified in Hematoxylin & Eosin stained 
microscopic sections. By a 1-mm punch, a biopsy was extracted from the 
paraffin block and put into a plastic tube. 
The samples were scanned, without any further preparation, in two differ-
ent tomography instruments developed at the Institute for X-ray Physics of 
Georg-August-Universität, Göttingen [1]. The first instrument, a laboratory 
setup, allowed to image the whole 1-mm sample with a ~1mm effective 
voxel size during 8 hours with a microscope coupled sCMOS, enabling an 
identification of the neural tissue structure. Phase retrieval suitable for low 
coherence sources was performed using the Bronnikov Aided Correction 
scheme, and cone beam tomographic reconstruction were implement-
ed based on the ASTRA toolbox. Selected regions of interest were then 
scanned in the second instrument, a synchrotron-based instrument (GINI-
X, P10, DESY, Hamburg), which allows to image regions of 320x320x320 
mm3 with an effective voxel size of 176 nm. At this resolution, individual 
cells inside the ganglia can be distinguished.
From the coarser-resolution tomographic scans, the neural tissue struc-
ture has been extracted with semi-automatic segmentation methods. Pre-
liminary digital quantification of the volume of the neural tissue over total 
biopsy volume, were performed from the segmented volumes. A more-in-
depth digital analysis, currently in progress, will allow to measure param-
eters such as the length and average diameter of the ganglia.
results: The myenteric ganglia from the control were normal regarding 
both size and cellularity. Neurons and glia cells could be recognized. Be-
tween the ganglia, the nerve-bundles were thick and sharply demarcated. 
In contrast, the ganglia from the patient were smaller and the intergan-
glional nerves were uneven/irregular with alternating thin and “small 
nodular” regions. Preliminary digital quantification showed that the ratio 
of neural tissue volume over total biopsy volume in the patient (0.9%) was 
significantly diminished compared to the control (7.3%).
conclusion: Three-dimensional nanotomography may be a useful tool and 
can give valuable information on the changes of the size and intergangli-
onar neural connections of the ENS in dysmotility diseases which cannot 
be obtained/received by classical methods.
references: [1] Töpperwien, M., van der Meer, F., Stadelmann, C. and 
Salditt, T., 2018. Three-dimensional virtual histology of human cerebellum 
by X-ray phase-contrast tomography. Proceedings of the National Academy 
of Sciences, 115(27), pp.6940-6945.
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P1890 The sIgnIfIcance Of ILeus In The POsT-kIdney 
TransPLanT seTTIng: a heaLThcare uTILIzaTIOn PersPecTIve
Kroner P.T.1, Kesler A.M.2, Corral J.E.3, Lukens F.3
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Introduction: Ileus is a known early complication following kidney trans-
plant (KTx). Approximately 16,000 KTx surgeries are performed each year 
in the US, thus it is imperative to study and find solutions to potential 
hospital complications post-transplant. There is limited data largely from 
case reports documenting the occurrence of ileus in KTx patients. Poten-
tial risk factors include post-operative setting, steroid withdrawal, or even 
peritoneal sclerosis in patients with a history of peritoneal dialysis (PD).
aims & Methods: The aim of this study is to assess inpatient prevalence 
and outcomes of ileus in the same admission as the KTx occurred. 
Case-control study using the NIS 2012-2016, the largest publically available 
inpatient database in the US. The ICD9-10CM procedural codes for kidney 
transplant were used to identify all patients that underwent KTx during 
the same admission. None were excluded. Patients with associated ileus 
were identified using ICD9-10CM diagnostic codes. The primary outcome 
was determining the odds of ileus in post-KTx patients. Secondary out-
comes were inpatient mortality, postoperative complications, measured by 
shock, ICU stay, resource utilization, length of hospital stay (LOS), total 
hospitalization charges and costs. Propensity score matching was used to 
create a matching population for gender, age and Charlson Comorbidity 
Index. Multivariate regression analyses were used to adjust for income 
in patients’ zip code, hospital region, location, size and teaching status.
results: A total of 89,065 KTx patients were identified, of which 16,880 
were propensity score matched for the selected covariates. The mean pa-
tient age was 50 years, and 40% were female. On multivariate analysis, 
the odds of ileus in the KTx cohort was 3.90 (p< 0.01) compared to patients 
who did not undergo KTx surgery. When patients that underwent KTx and 
developed ileus during the admission, they had greater adjusted odds of 
shock 6.22 (p< 0.01), TPN 11.24 (p< 0.01), AKI 1.97 (p< 0.01), multi-organ 
failure 1.85 (p< 0.01), post-op infection 17.7 (p< 0.01), Deep Vein Throm-
bosis 2.3 (p=0.02), Pulmonary Embolism 2.79 (p=0.02), and bleeding 
2.44(p=0.04) compared to patients with no KTx. In addition, those who 
developed ileus had greater hospitals costs, charges, and length of stay 
(LOS) (Table 1).
variable aOr 95%cI p-value
Ileus in patients with KTx 3.90 3.41-4.46 <0.01
Inpatient Mortality 2.94 0.67-12.83 0.15
ICU 1.60 0.68-3.73 0.27
TPN 11.24 2.43-52.10 <0.01
AKI 1.97 1.28-3.03 <0.01
Post-op infection 17.70 4.12-75.98 <0.01
DVT 2.30 1.12-4.75 0.02
PE 2.79 1.16-6.74 0.02
Post op Shock 2.96 0.69-12.68 0.14
Variable Adjusted Means 95%CI p-value
Additional Adjusted Costs $40,182 21216-59147 <0.01
Additional Adjusted Charges $129,933 52424-207441 <0.01
Additional Adjusted LOS (days) 13.1 5.1-21.1 <0.01
[Table 1 - Adjusted odds ratio and additional means to the evaluated 
variables in patients with kidney transplant surgery that develop ileus]
conclusion: Patients undergoing kidney transplant are more likely to de-
velop ileus than patients who did not have kidney transplant surgery, con-
firming known reports documenting ileus in the early post-operative pe-
riod. This cohort of patients who developed ileus following transplant have 
greater odds of post-operative complications, as well as increased morbid-
ity, resource utilization and economic burden. Future studies should focus 
on elucidating the etiology of ileus following kidney transplant, as well as 
associated factors, and creating strategies to address it.
disclosure: Nothing to disclose 
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Introduction: Despite advances in Ulcerative Colitis (UC) therapies, many 
patients suffer refractory symptoms in the absence of active inflammation. 
For this group, treatment remains challenging, with a paucity of therapeu-
tic options. In this prospective, ongoing study, we aim to determine the 
prevalence and burden of functional colorectal disorders inpatients with 
quiescent UC using validated questionnaires.
aims & Methods: In a cross-sectional study, consecutive patients with UC 
attending Inflammatory Bowel Disease (IBD) clinics were invited to par-
ticipate. Patients completed a series of validated questionnaires; includ-
ing Hospital Anxiety and Depression Scale (HADS), the Rome IV diagnostic 
questionnaire for functional gastrointestinal disorders (FGIDs), an IBD-QoL 
score and the IBD-control questionnaire. Participants were requested to 
return a Faecal Calprotectin (FCP) within 2 weeks of completing ques-
tionnaires. Quiescent UC was defined as IBD-control 8 score ≥13 and IBD-
control-VAS ≥85, and/or FCP levels ≤250 (where available, FCP data were 
used in preference to IBD-control to classify UC activity). Based on Rome 
IV diagnosis and UC disease activity (active or quiescent), patients were 
divided into groups and data compared using non-parametric tests.
results: Overall, n=97 UC patients (n=50 males, mean age 48 (range 18-
82)) participated. 41/97, (42%) UC patients met the Rome IV diagnostic 
criteria for ≥1 FGIDs (irritable bowel syndrome n=26, functional constipa-
tion n=6 and faecal incontinence (FI) n=22). Disease activity data (IBD-
control and/or FCP) were available for all patients, and based on these 
61/97, 63% had quiescent UC. Within the quiescent UC group, 25/61 (41%) 
met the Rome IV diagnostic criteria for ≥1 FGIDs (irritable bowel syndrome 
n=14, functional constipation n=3 and FI n=13). Within the active UC group, 
those with co-existing FGIDs, compared to those without FGIDs, had sig-
nificantly worse median QoL scores (P=0.02), higher HADS-depression 
(P=0.005) and HADS-anxiety (P=0.05). By contrast, in those with quiescent 
UC, those with an FGID did not have different median HADS scores (de-
pression P=0.15, anxiety P=0.62) or IBD-QoL scores (P=0.20), compared 
those without FGIDs.
conclusion: This study is one of the first to use Rome IV criteria in UC and 
confirms that the prevalence of FGIDs is high. Patients with active disease 
and overlapping functional symptoms appear to have worse QoL and more 
psychological distress compared to those with quiescent disease. Clinicians 
should therefore be vigilant to this functional overlap and treat both func-
tional and inflammatory driven symptoms.
disclosure: Nothing to disclose 
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Introduction: Transanal irrigation (TAI) is a safe technique designed to as-
sist the evacuation of faeces from the bowel in a controlled manner by 
introducing water via the anus. This is a widely accepted alternative to 
950 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
conventional management strategies and is intended to allow people with 
bowel dysfunction to flush out the distal colon as part of their bowel man-
agement strategy, promoting the rehabilitation of bowel function. This 
also enables the users to choose the time and place of evacuation and to 
develop a consistent bowel routine.
aims & Methods: 
aim: To assess how TAI modifies Quality of Life (QoL) of patients with func-
tional constipation (FC), fecal incontinence (FI) and low anterior resection 
syndrome (LARS).
Methods: Between 1/2016 and 12/2018 patients suffering from FC, FI or 
LARS were treated with TAI in 11 Italian centers. The primary endpoint was 
QoL, measured through VAS (all patients) and through validated question-
naires such as Pac-QoL (FC), FI-QoL (FI), Wexner score (FC, FI) and LARS 
score (LARS); secondary endpoint included patient’s compliance analysing 
dropout rate.
results: Results concern 195 patients (FI, N=14; FC, N=101; LARS, N=80). The 
Wexner score after 6 months dropped from 13±5 to 1±2 in FI patients (p< 
0.001) and, after 12 months, from 16.6±6.5 to 11.2±3.1 in FC ones (p< .001). 
The VAS score increased significantly after 1 month (5.6±3.3 vs. 7.8±2.1 for 
FI patients; 3.8±2.7 vs. 6.8±1.9 for FC patients and 2.3±1.4 vs. 6.8±2.1 for 
LARS patients, p< .001 in all cases) and further improved over time. LARS 
patients experienced a drop in the LARS score from 33.7±10.4 to 11.3±12.5 
(p< .001) on the first month and at 24 months their LARS score was 0.5±3.1. 
The average dropout rate at the last follow up was 20.4%.
conclusion: Patients suffering from IF, FC or LARS were compliant to TAI 
and experienced significant QoL improvement.
references: 1.Role of transanal irrigation in the treatment of anterior re-
section syndrome. Tech Coloproctol. 2018 Jul;22(7):519-527. 2.Trans-anal 
irrigation should be offered to patients with severe bowel dysfunction. Br 
J Gen Pract. 2019 Mar;69(680):136 3.American College of Gastroenterol-
ogy Chronic Constipation Task Force An evidence-based approach to the 
management of chronic constipation in north america. Am J Gastroenterol. 
2005;100:1-4. 4.Trans-anal irrigation therapy to treat adult chronic func-
tional constipation: systematic review and meta-analysis. BMC Gastroen-
terol. 2015
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Introduction: Central sensitization (CS) has been proposed to be an im-
portant mechanism for symptom generation in functional gastrointestinal 
disorders (FGID). In this study, we explore the association between symp-
toms and CS in patients with FGID, and in volunteers with no or mild GI 
symptoms.
aims & Methods: Patients with FGID according to Rome IV and volunteers 
completed questionnaires assessing central sensitization (CSI), sensory 
processing sensitivity (HSP), GI symptoms (GSRS-IBS), psychological dis-
tress (HAD) and non-GI symptoms (PHQ-12). The validated cut-off of CSI 
(≥40) distinguished between persons with and without reported CS.
results: We included 77 FGID patients and 79 volunteers (median age 
30 [26-39] vs. 25 [22-32] years (p< 0.001); females 57 (74%) vs. 41 (52%) 
(p=0.007)). 
Thirty-three (43%) patients and one (1%) volunteer reported CS. Patients 
with CS were older (36 [27-47] years vs. 28 [24-33] years, p=0.02), had 
more severe overall GI symptoms (4.0 [3.8-4.5] vs. 3.7 [3.2-4.2], p=0.03) 
and non-GI symptoms (9 [8-10] vs. 6 [4-8], p< 0.001) than patients without 
CS, but with no significant differences in psychological distress or sensory 
processing sensitivity. Linear trend analyses in all study subjects (divided 
into CS quintiles) demonstrated gradual increase of GI symptom severity 
with increasing severity of CS with large effect sizes (Table 1). Furthermore, 
moderate to strong correlations were seen between CS and GI symptoms 
(total: rho=0.68; abdominal pain: rho=0.64; bloating: rho=0.65; constipa-
tion: rho=0.56; diarrhoea: rho=0.58; satiety: rho=0.55, all p< 0.001). 
gsrs-IBs domain p-value Partial η 2
Total score <0.001 0.44
Pain syndrome <0.001 0.40
Bloating syndrome <0.001 0.40
Constipation syndrome <0.001 0.26
Diarrhoea syndrome <0.001 0.29
Satiety syndrome <0.001 0.27
[Table 1: Linear relationships between increasing level of central  
sensitization and gastrointestinal symptoms.]
conclusion: Central sensitization is common in patients with functional 
gastrointestinal disorders, and clearly associated with GI symptom sever-
ity, indicating that it seems to be an important factor for GI symptom gen-
eration.
disclosure: Irina Midenfjord: No competing interest. Cecilia Grinsvall: No 
competing interest. Peter Koj: No competing interest. Hans Törnblom has 
served as Consultant/Advisory Board member for Allergan, Allmiral and 
Shire. Magnus Simrén has received unrestricted research grants from Da-
none Nutricia and Ferring Pharmaceuticals, and served as a Consultant/
Advisory Board member for AstraZeneca, Danone Nutricia, Nestlé, Almi-
rall, Allergan, Albireo, Menarini, Glycom and Shire, and as a speaker for 
Tillotts, Takeda, Shire, Menarini, AlfaSigma, Biocodex, Alimentary Health, 
Allergan and Almirall. 
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Introduction: Functional constipation (FC) is a prevalent disorder in elderly 
people. It impacts on healthcare and quality of life (QoL). The frail pheno-
type is associated to poor health outcomes including disability, hospital-
ization, and mortality.
aims & Methods: To determine the prevalence, pathophysiology and 
symptoms of FC among older people, and its association with frailty.
This was an epidemiological study of individuals over 70 years of age, 
stratified into robust, pre-frail and frail (Fried criteria (2)), and recruited 
from the community, an acute hospital and a nursing-home. Variables 
collected were sociodemographic data, frailty, Rome III symptoms (1), Br-
sitol scale for faecal consistency, dependence, cognitive status, and QoL. 
Anorectal manometry and CTT were performed on a second sample of 56 
community-living patients with FC, and 25 hospitalized patients under-
went a balloon expulsion test (BET).
results: The study included 416 patients, 50.2% men, with a mean age 
of 79.64±6.8. Prevalence of FC was 26.8% (32.4% women, 21.8% men; 
p=0.019). Excessive strain (89.3%) and hard stools (75.7%) were the most 
prevalent symptoms in FC, 20.4% showed < 3 bowel movements/week. 
Patients with FC showed poorer results in QoL. Prevalence of FC was high-
er in the frail group (41.7%) than pre-frail (33.9%) or robust (24.2%) (p< 
0.001). 
Obstructive defecation symptoms were very prevalent in frail and pre-frail 
(53.5% and 48.6%, respectively). In robust the most prevalent subtype was 
mixed. 
Regarding pathophysiology, All robust patients showed dyssynergic defeca-
tion, and delayed CCT in 40%. Only 17.3% of the pre-frail had normal BET.
conclusion: The prevalence of FC in older people, especially women, is 
very high, and is associated with frailty and poor QoL. Its pathophysiology 
is mainly associated with dyssynergic defecation and hard stools. 
FC differs between gender, age and functional status. Management should 
be tailored to patient characteristics and underlying pathophysiology.
references: 1. Drossman DA, Douglas A. The Functional Gastrointestinal Dis-
orders and the Rome III Process. Gastroenterology 2006; 130:1377-1390. 2. 
Xue QL, Bandera Roche K, Varadhan R, Zhou J, Fried L. Initial Manifestation 
of Frailty Criteria and the Development of Frailty Phenotype in the Women ‘s 
Health and Aging Study II. Journal of Gerontology 2008;63: 984-99
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POsTPrandIaL cycLIc MeaL resPOnse Of The cOLOn In a 
randOMIzed Three-Way crOssOver hIgh-resOLuTIOn cOLOn 
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Introduction: Opioid induced constipation (OIC) is a prevalent condition 
amongst patients treated with opioids for chronic pain. Constipation and 
other side effects can be as prevalent as 40-90% resulting in non-compli-
ance and quality of life reduction. The effects of opioids on colonic motor 
function and their reversal by opioid antagonists have been poorly studied. 
We therefore conducted a crossover trial to study effects of codeine and the 
peripheral µ-opioid receptor antagonist naloxegol on colonic manometry 
patterns in healthy volunteers (HV).
aims & Methods: On each of three study visits, participants underwent 
a colonoscopy (conscious sedation with midazolam 2-5mg IV) after half-
standard PEG preparation for colonic manometry catheter (40-sensor 
high-resolution manometry catheter 2.5 cm spacing, Laborie, Mississauga, 
Canada) placement. Colonic motility was evaluated during 2 hours after a 
standardized bread meal (645 kcal). After waking up, HV received nalox-
egol (25mg)/placebo, placebo/codeine (60mg followed by 30mg one hour 
after the meal) or naloxegol/codeine by oral administration in a random-
ized, double-blind crossover fashion. Symptom registration for abdominal 
pain, discomfort, bloating, gas, desire to defecate and urge was performed 
every 15 minutes during the entire measurement on a visual analogue 
scale (VAS). A total symptom score was calculated for each symptom by 
adding the scores for the entire measurement. The data were analysed us-
ing mixed-models analysis in SAS with post-hoc analysis after correction 
for multiple testing.
results: Ten HV [3 male, aged 26.5 (range 20 - 63) years] finalized all three 
study visits. 
Data on motor pattern prevalence are presented in Table 1 [data are re-
ported as median (interquartile range). (a) p< 0.01 vs. placebo/codeine, 
(b) p< 0.05 vs. placebo/codeine, (c) p< 0.05 vs. naloxegol/placebo]. Long 
anterograde propagating waves (PW) were significantly decreased in the 
codeine/placebo compared to codeine/naloxegol condition. No significant 
differences were found for short anterograde PW or short retrograde PW. 
The postprandial cyclic patterns were significantly altered by the treat-
ment condition. First, the cyclic anterograde PW were lower in the pla-
cebo/codeine compared to the naloxegol/placebo and naloxegol/codeine 
treatment. Second, the cyclic retrograde were significantly more frequent 
in placebo/codeine compared to the two other treatment groups. Finally, 
significantly less cyclic simultaneous PW were present in the naloxegol/
placebo vs. placebo/codeine condition.
The total score for abdominal discomfort was significantly less in the 
placebo/codeine condition compared to the naloxegol/codeine condition 
(p=0.046). No significant differences were found for bloating, gas, desire 
to defecate, urge or abdominal pain. 
  naloxegol/Placebo Placebo/codeine naloxegol/codeine
p-value 
main 
effect
Short antero-
grade PW
3.0 (2.00-5.50) 2.5 (1.00-4.50) 4.0 (2.00-7.00) 0.307
Short retrogra-
de PW
6.0 (2.75-15.00) 3.5 (2.00-4.00) 4.0 (3.25-7.75) 0.544
Long antero-
grade PW
2.0 (0.75-7.00) 1.5 (0-3.00) 3.5 (2.00-12.00)a 0.005
Cyclic antero-
grade PW
14.5 (7.25-21.75)b 7.0 (3.75-13.50) 15.0 (5.25-23.00)b 0.013
Cyclic retrogra-
de PW
43.5 (20.75-65.00)b 78.0 (43.50-84.50) 37.5 (17.75-52.75)a,c 0.003
Cyclic simulta-
neous PW
7.0 (2.25-16.25)a 17.5 (6.25-50) 10.0 (5.25-13.00) 0.006
Simultaneous 
PW
3.0 (0.75-6.50) 2.0 (0.75-3.25) 2.5 (2.00-7.25) 0.361
[Overview of colonic motor pattern prevalence in the postprandial period 
after codeine and naloxegol administration. (PW: Pressure wave)]
conclusion: Codeine administration increased cyclic retrograde activity 
and decreased cyclic anterograde activity in the postprandial period and 
this effect was reversed by naloxegol. These observations enhance our un-
derstanding of the mechanism of OIC and its treatment with peripheral 
µ-opioid receptor antagonists.
disclosure: Nothing to disclose 
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Introduction: Anorectal biofeedback (BF) is a well-established treatment 
for patients with constipation and functional defaecation disorders, how-
ever demand greatly exceeds supply. There is some evidence that pre-
treatment clinical or physiological factors may predict success of treat-
ment1. As biofeedback is a form of behavioural therapy, we hypothesised 
that psychological traits could help predict response to BF in constipation
aims & Methods: To describe pre-BF treatment psychological traits of 
constipated patients and to evaluate these as predictors of favourable re-
sponse to treatment.
77 consecutive constipated patients undergoing anorectal BF completed a 
pre-treatment computer-based questionnaire of multiple emotional state 
and cognitive psychology measures, in addition to baseline clinical and 
anorectal physiology testing. Patients underwent weekly BF visits over 6 
weeks. The main outcome measure was physician-assessed response to 
BF (moderately-greatly improved), blinded to baseline psychological eval-
uation results. Secondary outcome measures included change in patient-
rated visual analog scales of impact of bowel dysfunction on quality of 
life (VAS QOL), feeling of control (VAS control) and satisfaction with bowel 
motions (VAS satisfaction).
results: 69 (90%) patients completed BF (mean age 51+-17 yrs, 62 female). 
Patients with paradoxical anal contraction on push were more likely to re-
spond to BF (OR 5.3, 95% CI 1.2-24, p=0.3), as well as patients with higher 
self-efficacy scores (OR 1.2, 95% CI 1.1-1.4, p=0.002), higher treatment ef-
ficacy expectancy (OR 1.1, 95% CI 1.1-1.2, p=0.03), higher internal health 
locus of control (OR 2.2, 95% CI 1.2-4.1, p=0.01), and lower perceived stress 
sub-score of worries (OR 0.4, 95% CI 0.2-0.9, p=0.03). On multivariate 
analysis incorporating all baseline physiology and psychological predic-
tors, internal health locus of control was the only predictor of a favourable 
response to BF.
Psychological and cognitive measures also predicted all VAS secondary 
outcomes. For example, lower scores on perceived stress sub-scores of 
worries again predicted more improvement in VAS QOL (coef -2.7,, 95% CI 
-4.4 - (-1.1), p< 0.01) and VAS control (coef. -2.7, 95% CI -4.4 - (-0.9)), while 
higher treatment efficacy expectancy predicted more improvement in VAS 
satisfaction (coef. +0.3, 95% CI 0.2-0.4, p< 0.001) and VAS control (coef. 
+0.2, 95% CI 0.1-0.3, p=0.03).
conclusion: Success of anorectal biofeedback therapy for constipated pa-
tients is dependent on patients’ psychological and coping strategies. Ad-
dressing potential psychological barriers prior to BF might optimise future 
patient outcomes
references: 1. Shim L, Jones M, Prott G, Morris L, Kellow J, Malcolm A. 
Predictors of outcome of anorectal biofeedback therapy in patients with 
constipation. Aliment Pharmacol Ther. 2011 Jun;33(11):1245-51.
disclosure: Nothing to disclose 
952 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
P1897 vOLuMeTrIc recTaL sensaTIOn TesTIng: 
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Introduction: Research based rectal sensory testing using a barostat and 
infinitely compliant balloon, has previously revealed correlations between 
disease states and both rectal hypo- and hyper- sensitivity1. Similar data 
for the volumetric only sensation testing methods employed in clinical 
practice (using a compliant balloon) are lacking, and differences between 
the commonly measured thresholds for first sensation, urge and maximal 
tolerated volume (MTV) are unknown.
aims & Methods: Our aims were, therefore, to determine: (1) Does volu-
metric rectal balloon sensation testing correlate with disease states? (2) 
Which, if any, of the three sensory thresholds tested is most relevant for 
each disease state?
1251 patients (mean age 53+-18, 92% female) referred for volumetric rectal 
balloon sensation testing as part of anorectal manometry were included 
in the study. All patients completed the Rome and hospital anxiety and de-
pression (HAD) questionnaires. Data regarding possible factors associated 
with alterations in rectal sensation were prospectively collected, including 
relevant surgical, medical and obstetric history. Univariate analysis of all 
factors was followed by multivariate analysis of positive variables, with 
sensation thresholds used as continuous outcome measures. Next, volu-
metric rectal sensitivity values were categorised into low, normal or high 
using data derived from 44 healthy female volunteers, and distribution of 
disease states across the categories was compared in a subgroup of female 
patients (n=1107).
results: Presenting symptoms of constipation, older age and longer bal-
loon expulsion time (BET) were associated with higher thresholds for all 
sensations (p< 0.05 for all comparisons). Presenting symptoms of faecal 
incontinence (FI) was associated with lower thresholds for all sensations 
(p< 0.001 for all comparisons). The presence of connective tissue disease 
was associated with lower urge to defecate and lower MTV, while previous 
pelvic radiation therapy and irritable bowel syndrome (IBS) were associ-
ated with lower values on MTV only (p< 0.05 for all). 
Using normal values for reference in the female subgroup, older age was 
associated with hyposensitivity (higher than normal values) on first (OR 
1.03, 95% CI 1.02-1.04), urge (OR 1.03, 95% CI 1.02-1.04), and MTV thresh-
olds (OR 1.03, 95% CI 1.01-1.03, respectively) (p< 0.01 for all). Patients pre-
senting with constipation were more likely to be hyposensitive on MTV (OR 
2.6, 95% CI 1.8-3.7, p< 0.001), while FI were hypersensitive (lower than 
normal values) on urge (OR 0.3, 95% CI 0.2-0.5, p< 0.001). Hypersensitiv-
ity on first sensation was associated with inflammatory bowel disease (OR 
0.3, 95% CI 0.1-0.9, p=0.03), and hypersensitivity on urge sensation with 
connective tissue disease (OR 0.4, 95% CI 0.2-0.9, p=0.04).
conclusion: Volumetric sensory testing as commonly practiced is corre-
lated with some disease states known to affect rectal sensation, and thus 
has clinical relevance. Several conditions, such as IBS, inflammatory bowel 
disease and connective tissue disease, were correlated with only two or 
even a single abnormal threshold, suggesting the three sensation thresh-
olds may measure different pathophysiological pathways and should con-
tinue to be used in clinical practice.
references: 1. Remes-Troche J, Rao S. Neurophysiological testing in ano-
rectal disorders. Expert Rev Gastroenterol Hepatol. 2008 June ; 2(3): 323-
335.
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Introduction: Manual abdominal massage has been shown to be effective 
in treating slow transit constipation even burdensome. To improve care 
efficacy, Bamk-001, a device for automatic abdominal massage, was newly 
developed.
aims & Methods: The purpose of this study was to assess the effect of 
Bamk-001 on symptom profiles and the colonic transit time (CTT) in pa-
tients with chronic constipation. 
Thirty seven patients with functional constipation diagnosed by Rome IV 
criteria were enrolled prospectively from December 2018 to Feburary 2019. 
All of the patients received device assisted-automatic abdominal massage 
for 15minutes twice a day once in the morning before breakfast and once 
at night in 14days. CTT was done before and end of the study periods. 
Symptom profile including spontaneous bowel movements, straining, 
stool form, feeling of incomplete emptying, anorectal blockage, abdomi-
nal discomfort, overall defecation satisfaction, and device related adverse 
events were analyzed.
results: Thirty seven patients were finally enrolled. Bamk-001 statistically 
significantly improved CTT from 54.0[33.6-75.6] hour to 28.8[18.0-52.8] 
(p=0.001). Both of left sided and rectosigmoid segmental CTT also sig-
nificantly improved from 21.6[12.6-41.7] to 13.2[3.3-26.7] and from 15.0[6.9-
26.7] to 3.6[0.0-13.2], respectively. Moreover, all of the patients’ symptom 
profiles were alleviated after treating. No serious adverse events were 
reported.
conclusion: Bamk-001, newly developed device for automatic abdomi-
nal massage, showed excellent care efficacies including improved CTTs 
and symptom profiles in patients with functional constipations. Device 
assisted-automatic abdominal massage, as an adjunct to management of 
constipation, offers an acceptable and potentially beneficial intervention to 
patients with chronic constipation.
references: 1. Sommers T, Mitsuhashi S, Singh P, et al. Prevalence of 
Chronic Constipation and Chronic Diarrhea in Diabetic Individuals in the 
United States. Am J Gastroenterol 2018. 2. Choung RS, Branda ME, Chitkara 
D, et al. Longitudinal direct medical costs associated with constipation in 
women. Aliment Pharmacol Ther 2011;33:251-60. 3. Almario CV, Ballal ML, 
Chey WD, et al. Burden of Gastrointestinal Symptoms in the United States: 
Results of a Nationally Representative Survey of Over 71,000 Americans. 
Am J Gastroenterol 2018;113:1701-1710. 4. Heidelbaugh JJ, Stelwagon M, 
Miller SA, et al. The spectrum of constipation-predominant irritable bowel 
syndrome and chronic idiopathic constipation: US survey assessing
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P1899 uTILITy Of cT cOLOnOgraPhy as a dIagnOsTIc 
PrOcedure fOr IrrITaBLe BOWeL syndrOMe
Wada T.1, Kubota E.2, Yamada T.1, Ohara A.1, Kamiya T.2, Kataoka H.2
1Okazaki City Medical Association, Public Health Center, Okazaki, Japan, 
2Nagoya City University Graduate School of Medical Sciences, Department of 
Gastroenterology and Metabolism, Nagoya, Japan
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Introduction: Computed tomography colonography (CTC) has been devel-
oped as a less invasive alternative method to colonoscopy for colorectal 
cancer screening. Some subjects who underwent CTC reported abdomi-
nal pain induced by carbon dioxide gas injection during examination. We 
speculated that pain perception during CTC might reflect visceral hyper-
sensitivity related to irritable bowel syndrome (IBS).
aims & Methods: A prospective study of consecutively registered patients 
who underwent CTC for colorectal cancer screening between April 2018 
and March 2019 in a single medical center was conducted. IBS was diag-
nosed using the Rome IV criteria, and patients with IBS were classified 
into IBS subgroups according to the predominant stool pattern experi-
enced by the patient. In addition, all subjects completed the IBS Severity 
Scale (IBS-SS) and IBS-QOL questionnaire. Pain perception during CTC 
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was quantified using the visual analog scale (VAS) at six time points dur-
ing the CTC as follows: (1) before CTC, (2) immediately after carbon diox-
ide gas injection, (3) until the injection pressure reached a plateau (18 
mmHg), (4) in the prone position after carbon dioxide gas injection, (5) in 
the supine position after carbon dioxide gas injection, and (6) after CTC. 
We also evaluated the association between the VAS and IBS-SS scores.In 
this study, we investigated whether pain perception induced by carbon di-
oxide gas injection during CTC is different between patients with IBS and 
healthy controls. Furthermore, we evaluated the correlation between the 
pain score during CTC and the severity of the IBS symptom or the quality 
of life of patients with IBS.
results: One hundred twenty-three subjects who underwent CTC were en-
rolled in this study. Thirteen subjects were excluded because of incomplete 
questionnaires (n = 10) or a diagnosis of colorectal cancer with CTC (n = 3). 
Fifteen patients were diagnosed as having IBS on the basis of the Rome IV 
criteria for IBS. Patients with IBS were classified into the following groups: 
IBS with diarrhea (IBS-D, n = 1), IBS with constipation (IBS-C, n = 3), mixed 
IBS (IBS-M, n = 3), and unspecified IBS (IBS-U, n = 8). 
No significant differences in background characteristics, including age, 
sex, alcohol consumption, and smoking habit, were found between the 
IBS and control groups. The volume of carbon dioxide gas injected during 
CTC did not show a significant difference between the two groups. The 
total colon length was not significantly different between the two groups. 
The VAS score of the IBS groups was significantly higher than that of the 
control group at two time points, (2) immediately after carbon dioxide gas 
injection (p < 0.01) and (3) until the injection pressure reached a plateau 
(18 mmHg; p < 0.01). The maximum VAS score during CTC was also sig-
nificantly higher in the IBS groups than in the control group (p < 0.05). 
Although the IBS-SS score was significantly higher in the IBS groups than 
in the control group, we found no significant correlation between the VAS 
and IBS-SS scores in the IBS groups. The IBS-QOL score also did not show 
any significant correlation with the VAS score.
conclusion: Our study indicates that pain perception evaluated using the 
VAS during CT colonography might be a potential diagnostic method for 
IBS. Further study is necessary to clarify the association between pain per-
ception induced by CT colonography and IBS severity.
disclosure: Nothing to disclose 
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Introduction: Diamine Oxidase (DAO) is the extracellular enzyme for his-
tamine degradation pathway. It was recently reported that DAO is an ac-
curate marker of intestinal mucosal integrity in intestinal diseases (Garcia 
Martin 2007) and after chemotherapy (Motoori 2017) and it was shown in 
rats that duodenal lipid infusion increases intestinal DAO activity (Ji 2013), 
suggesting its use to detect intestinal permeability alterations.
aims & Methods: The aims of the study was the measurement of serum 
DAO levels in patients with IBS, IBD and HV to ascertain whether it could 
suggest intetsinal barrier defects. We enrolled 31 IBS patients (12 F, mean 
age 28±4 yrs; 22 IBS-D and 9 IBS-D) and 21 HV (12 F, mean age 27±5 yrs). 
Moreover, as pathologic control group, 10 IBD patients in remission were 
also enrolled (4 F, mean age 31±4 yrs, 5 CD and 5 RCU). Serum samples 
were collected after an overnight fast and serum DAO was measured (DAO 
ELISA Listarfish, Italy). In all the subjects, intestinal permeability was de-
tected with lactulose/mannitol test. Lactulose/mannitol % dose urinary 
recovery was determined after oral administration of 1g of mannitol and 
5 g of lactulose.
results: In HV, serum DAO was significantly higher than in IBS and IBD 
patients (9.5±1.7, 5.7±2.9, and 4.1±1.8 U ml, respectively, p< 0.01). In IBS, 
the subgroup of patients with postprandial symptoms showed lower 
DAO levels than the subgroup without postprandial symptoms (2.3±1.0 vs 
6.3±4.6 U ml, respectively, p< 0.01). In IBS patients, serum DAO was slightly 
correlated with %LMER (r=0.41). Serum DAO levels did not correlate with 
gender, age, severity of symptoms, duration of disease.
conclusion: Serum DAO is reduced in both IBS and IBD patients, suggest-
ing a role in the detection of intestinal permeability defects. Moreover, the 
reduced levels in IBS patients with postprandial symptoms may suggest a 
role of meal ingestion also in the pathophysiology of IBS symptoms.
disclosure: Nothing to disclose 
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Introduction: Patients with functional bowel disorders (FBD) are classified 
using the Rome criteria. However, this classification does not take account 
the intensity of symptoms and bloating.
aims & Methods: 
The purpose of this study is to evaluate whether the intensity of the cardi-
nal signs of FBD (constipation, diarrhea, bloating, abdominal pain) could 
be used to identify homogeneous groups of patients regardless the Rome 
criteria.
In this observational study, 1729 consecutive ambulatory FBD patients (73% 
females) completed the Rome III questionnaire and 10-point Likert scales 
for the intensity of constipation, diarrhea, bloating and abdominal pain 
during the week preceding the consultation.
A Gaussian mixture model was used to aggregate patients according to the 
cardinal signs of FBD without prior information. A classification tree using 
the intensity of the cardinal signs of FBD was proposed. The comparison of 
these two classifications were analyzed using ANOVA and logistic regres-
sion.
results: According to the Rome criteria, 707 patients (41%) were classi-
fied as having irritable bowel syndrome (IBS) (234 (14%) IBS-Constipation, 
225 (13%) IBD-Diarrhea, 126 (7%) SII-Mixed, 122 (7%) IBS-Nonspecific), 
374 (22%) functional constipation, 215 (12%) functional diarrhea, 101 (6%) 
bloating and 194 (11%) non-specific.
According to the intensity of cardinal signs of FBD, patients were divided 
into 8 clusters named according to their main symptomatology: “painful 
constipation” (285, 16%), “mild pain constipation” (236, 14%), “painful 
diarrhea” (166, 10%), “mild-pain diarrhea” (178, 10%), “mixed transit” 
(126, 7%), “bloating” (255, 15%), “abdominal pain” (89, 5%) and “non-
specific”(394, 23%).
The study of the relationship between the Rome III classification and this 
new classification showed that IBS-Constipation is associated with “pain-
ful constipation” (P < 0.01), SII-Diarrhea with “painful diarrhea” (P < 0.01) 
and “mild pain diarrhea”(P < 0.01), SII-Mixed with” mixed transit “(P < 
0.01), SII-nonspecific with “bloating” (P < 0.01), functional constipation 
with “painful constipation”(P < 0.01) and” mild pain constipation “(P < 
0.01), functional diarrhea with “mild pain diarrhea” (P < 0.01) and “non-
specific” (P < 0.01), bloating with “bloating” (P < 0.01) and nonspecific (P 
< 0.01), non-specific FBD with “non-specific” (P < 0.01) and functional ab-
dominal pain with “bloating” (P < 0.01) and “abdominal pain” (P < 0.01).
conclusion: This study conducted in a large FBD population shows that the 
symptomatic phenotype is partially associated with the Rome III criteria. 
This new classification can be used in addition with the Rome criteria to 
specify these criteria in clinical or therapeutic studies.
disclosure: Nothing to disclose 
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Introduction: Accurate measurement of gastrointestinal symptoms is es-
sential for understanding the severity of disease. Traditionally, gastroin-
testinal symptoms have been recorded through patient recall of symptoms 
elicited through standardized instruments, such as the widely used gas-
trointestinal symptom rating scale1 (GSRS). Recently our group has shown 
that symptoms as recalled differ substantially from those elicited prospec-
tively through a diary2. Recall questionnaires also attempt to elicit average 
level of symptoms but generally make no attempt at capturing within-sub-
ject variation in symptom levels. Since it is known that functional gastro-
intestinal disorders (FGIDs) are relapsing and remitting disorders it would 
be clinically appropriate to also measure the variation in symptoms over 
time within patients.
aims & Methods: This study set out to understand the relationship be-
tween gastrointestinal symptom burden as measured through the GSRS 
and as measured prospectively via a smart phone app using a method 
known as ecological momentary assessment3 (EMA) in which individuals 
are asked symptom and other questions once per day over a 14-day period. 
We also sought to understand the incremental utility of EMA in differen-
tiating gastrointestinal health from disorder versus the GSRS. EMA mea-
sures included current mood, gastrointestinal and non-gastrointestinal 
pain and interference in daily activities, all measured on a 7-point scale, 
where higher is better mood or worse symptoms. Average level of each 
measure was calculated across the week along with the within-person 
variance. Explained variance in GSRS was by calculated through multiple 
linear regression (Table 1) with bootstrapped statistical inference due to 
violation of the Normality assumption. Discrimination of GI disorder from 
health utilised unconditional logistic regression.
results: 28 GI symptomatic and 27 asymptomatic individuals were recruit-
ed from the community. Symptomatic individuals reported higher average 
symptom scores and greater temporal variability in scores than asymptom-
atic individuals (Table 1). They also reported higher (better) average mood 
scores but did not differ in mood variability. The EMA-derived measures of 
average symptom and mood scores together with within-individual tem-
poral variation in scores accounts for 64% of the variance in GSRS scores. 
The same EMA-derived measures provided good discrimination between 
GI symptomatic and asymptomatic groups with an AUC of 0.90. Adding 
GSRS score to the model increased the AUC to 0.92, indicating little in-
cremental value over and above the EMA-derived measures. GSRS score 
alone yields an AUC of 0.84.
Measure symptomatic mean (sd)
asymptomatic 
mean (sd) regression b (se) p
GI pain mean 2.52 (1.30) 0.82 (1.35) 1.70 (0.37) <.001
GI pain SD 2.04 (0.83) 0.90 (0.95) 1.14 (0.23) <.001
GI pain interference mean 1.35 (1.15) 0.36 (0.61) 0.99 (0.25) <.001
GI pain interference SD 1.60 (0.82) 0.55 (0.72) 1.05 (0.20) <.001
Non-GI pain mean 2.56 (1.43) 0.90 (1.36) 1.66 (0.37) <.001
Non-GI pain SD 1.91 (0.78) 0.93 (1.10) 0.98 (0.25) <.001
Non-GI pain interference mean 1.39 (1.19) 0.47 (0.85) 0.93 (0.27) .001
Non-GI pain interference SD 1.56 (0.88) 0.66 (1.07) 0.90 (0.27) .001
Current mood mean 5.20 (1.14) 6.35 (1.59) -1.16 (0.37) .002
Current mood SD 1.73 (0.68) 1.67 (0.88) 0.07 (0.21) 0.7
GSRS 3.30 (1.12) 1.90 (0.96) 1.39 (0.26) <.001
[Table 1. Discrimination of GI symptomatic from asymptomatic individuals]
conclusion: EMA-derived measures of symptoms and mood provide su-
perior discrimination of GI disorder from health compared with a widely 
used validated recall questionnaire, and add useful quantification of the 
variation that patients experience over time while avoiding potential re-
call bias. This makes EMA a useful tool worth considering in research and 
clinical practice.
references: 1. Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale 
for gastrointestinal symptoms in patients with irritable bowel syndrome 
and peptic ulcer disease. Digestive diseases and sciences. 1988;33(2):129-
134. 2. Jones MP, Walter S, Faresjo A, et al. Gastrointestinal recall question-
naires compare poorly with prospective patient diaries for gastrointestinal 
symptoms: data from population and primary health centre samples. Eur 
J Gastroenterol Hepatol. 2019;31(2):163-169. 3. Mujagic Z, Leue C, Vork L, et 
al. The Experience Sampling Method--a new digital tool for momentary 
symptom assessment in IBS: an exploratory study. Neurogastroenterology 
and motility : the official journal of the European Gastrointestinal Motility 
Society. 2015;27(9):1295-1302.
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Introduction: Irritable Bowel Syndrome (IBS) is a highly prevalent func-
tional gastrointestinal disorder. Earlier studies have shown that IBS can 
affect work life, limiting ability to perform at work and leading to ab-
senteeism. However, there are few studies focusing on work experiences 
based on patients’ narratives. Further, factors that influence performance 
have not yet been fully explored.
aims & Methods: The aim of this study was to construct a theory for how 
persons with IBS maintain their work life. A qualitative study was con-
ducted using constructivist grounded theory. Semi-structured interviews 
with 15 women and 8 men with IBS were conducted. The participants were 
recruited at an outpatient clinic specialized in functional gastrointestinal 
disorders and were between 26 and 64 years of age. Of the participants, 
5 had mild IBS, 10 had moderate IBS and 8 had severe IBS. Fourteen 
worked full-time, 6 worked part-time and 3 were currently on sick leave. 
In accordance with grounded theory, the data collection and analysis were 
conducted simultaneously. The interviews were transcribed verbatim and 
coded line-by-line, incident-by-incident and thereafter focused coding 
was done. From the data and codes, categories were generated. Finally, a 
core category was constructed.
results: A core category, balancing work life and living with IBS, was de-
veloped and interpreted as being constituted of four categories illustrating 
the process of maintaining work life while constantly being under threat of 
symptoms. Persons with IBS coped with being under threat of symptoms by 
restricting impact of IBS on work by using strategies and upholding daily 
routines; being ahead by exerting control over work life; and reconciling IBS 
with work life, which was understood as a successful outcome from being 
ahead and restricting impact, but also influenced by the individual’s outlook 
on life. These were ongoing processes that took place both during and out-
side of work hours, and that served to limit the influence of IBS on work by 
symptoms being milder, perceived as less frequent, or not as bothersome. 
Adjusting to other people in work life interfered with the strategies of being 
ahead, restricting impact and reconciling, that aimed to limit influence of 
IBS on work, leaving persons with IBS more susceptible to symptoms.
conclusion: This study deepens the understanding of the work situation of 
persons with IBS, and the impact of IBS on work. Health care professionals 
can use the results of this study in the patient meeting when discussing 
IBS in regard to work ability and sick leave. The results imply that although 
balancing work life with living with IBS can be a struggle, there are ways 
for persons with IBS to reduce impact on work on several different levels.
disclosure: Nothing to disclose 
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Introduction: Irritable bowel syndrome (IBS) is highly prevalent in primary 
care, although characteristics of patients diagnosed with IBS by general 
practitioners, still remain to be studied. Therefore, the objective of this 
study was to evaluate IBS symptom severity, quality of life, and work pro-
ductivity in IBS patients diagnosed by general practitioners.
aims & Methods: IBS patients, included by 62 general practitioners, com-
pleted questionnaires evaluating demographics, stool types, Rome IV 
criteria, IBS symptom severity (IBS-SSS), quality of life (IBS-QoL), anxiety 
(GAD), depression (PHQ9), somatization (PHQ15), and work productivity 
and activity impairment (WPAI). Patients were subdivided into severity cat-
egories based on their IBS-SSS scores: normal < 75, mild 75-175, moderate 
175-300, severe ≥300.
results: 299 primary care IBS patients (75% females, mean age 42±0.9 
years, mean BMI 24±0.3) were included and characterized by the following 
stool types: constipation (22%), diarrhea (26%), mixed stool type (40%), 
and normal (11%). Normal, mild, moderate, and severe IBS-SSS were rep-
resented in 3, 17, 40, and 40% of all patients respectively. Patients with 
severe IBS-SSS differed significantly from the other IBS-SSS subgroups 
in QoL, GAD, PHQ9, PHQ15, and WPAI with all p-values lower than 0.05. 
Symptom severity scores were positively correlated with IBS-QoL (R=0.55), 
GAD (R=0.35), PHQ9 (R=0.38), PHQ15 (R=0.60), and WPAI (R=0.46).
The Rome IV criteria were fulfilled by 70 percent of all patients (Rome+). 
Rome+ patients were characterized by a significantly higher IBS-SSS score 
(290±6 vs. 194±10, p< 0.0001), IBS-QoL (35±1.2 vs. 23±1.5, p< 0.0001), GAD 
(7±0.4 vs. 5±0.4, p=0.0002), PHQ9 (7±0.3 vs. 5±0.5, p=0.005), and PHQ15 
(13±0.3 vs. 10±0.5, p< 0.0001) compared to Rome-. In addition, the work 
productivity was more affected in the Rome+ group (3.1±0.2) compared to 
Rome- (1.7±0.3, p=0.0004).
conclusion: In IBS patients, diagnosed by general practitioners, more than 
two thirds fulfill the Rome IV criteria. Symptom severity, quality of life, 
anxiety, depression, somatization, and work productivity were significantly 
different between the Rome + and Rome - group and the group with se-
vere IBS-SSS compared to normal, mild, and moderate IBS-SSS.
disclosure: Nothing to disclose 
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Kishino T.
Nara City Hospital, Center for Digestive and Liver Disease, Nara, Japan
contact e-Mail address: t-kishino@nara-jadecom.jp
Introduction: The current standard treatment for diverticular hemorrhage 
is endoscopic hemostasis by clipping, endoscopic band ligation (EBL), or 
injection therapy. EBL has been used more frequently than clipping be-
cause the early recurrent bleeding rate after EBL is lower than that after 
clipping. However, adverse events, such as diverticulitis and perforation, 
after EBL have been reported, albeit rarely. On the other hand, the endo-
clip approach offers the theoretical advantage of causing less injury to 
adjacent tissues. However, the efficacy of endoclips for diverticular hemor-
rhage is unclear.
aims & Methods: To retrospectively evaluate the safety and efficacy of en-
doclips versus EBL for the treatment of colonic diverticular hemorrhage.
Study population: At Nara City Hospital, 93 patients with colonic diverticu-
lar hemorrhage with stigmata of recent hemorrhage (SRH) were treated 
using endoclips or EBL between January 2013 and December 2018. SRH 
was defined as a densely adherent clot despite vigorous irrigation, a non-
bleeding visible vessel, or active hemorrhage visualized on colonoscopy. 
Colonoscopic examinations: All patients received standard supportive 
medical care for lower gastrointestinal bleeding, including hemodynamic 
monitoring and fluid resuscitation. Packed red blood cells were transfused 
to correct severe anemia if necessary. Bowel preparation with polyethyl-
ene glycol or glycerin enema was performed before colonoscopic exami-
nations. All patients underwent colonoscopy using water-jet scopes with 
a tip hood (PCF-Q260AZI or GIF-Q260 J: Olympus Optical Company Ltd, 
Tokyo, Japan), and a water-jet system was used for vigorous irrigation. 
To improve endoscopic visualization of colonic diverticula, we observed 
the colonic diverticulum under full water immersion (Digestive Endoscopy 
2018; 30: 121-122) since 2016.
Endoscopic hemostasis with endoclips: We classified the patients treated 
by endoclips into the direct clipping group and indirect clipping group. 
Endoclips were placed directly onto the vessel if technically feasible (direct 
clipping group). When direct placement of endoclips onto the vessel was 
not possible, the diverticulum was closed in a zipper fashion (indirect clip-
ping group).
Endoscopic hemostasis with endoscopic band ligation: At our institution, 
we introduced EBL for colonic diverticular hemorrhage in February 2016. 
After the site of bleeding had been marked with endoclips, the colono-
scope was removed and subsequently reinserted after attachment of a 
band-ligator device. The diverticulum was pulled via suction into the cup 
of the endoscopic ligator, and the elastic O-ring was released.
Evaluation items: Rate of early rebleeding within 30 days after initial treat-
ment, and complications were retrospectively evaluated.
results: Of the 93 patients, 34, 28, and 31 were in the direct clipping group, 
indirect clipping group, and EBL group, respectively. The rate of early re-
bleeding in the direct clipping, indirect clipping, and EBL groups was 5.9% 
(2/34), 35.7% (10/28), and 6.5% (2/31), respectively (p=0.001: direct clip-
ping group vs indirect clipping group, p=1: direct clipping group vs EBL 
group, Chi-squared test). No complications occurred in all groups. All early 
rebleeding cases in the direct clipping group stopped with EBL.
conclusion: Direct clip placement is acceptable as the first treatment choice 
for colonic diverticular hemorrhage. When direct placement of endoclips is 
not possible, EBL should be performed instead of indirect clipping.
disclosure: Nothing to disclose 
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Yeoh K.-G.2, Gwee K.A.6
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Introduction: Singapore is a multi-ethnic country that has undergone rapid 
development over the last few decades, with increasing influence of west-
ern culture, and also faces a rapidly aging population. However, recent 
data on the prevalence of colonic diverticulosis is lacking.
aims & Methods: This study aims to evaluate the prevalence of colonic 
diverticulosis in Singapore and determine its risk factors and association 
with common gastrointestinal symptoms. We also aim to evaluate any ra-
cial differences amongst the three main races in Singapore - the Chinese, 
Malays and Indians. 
We retrospectively reviewed data obtained from the endoscopy database 
for colonoscopies performed between 2006 to 2016 in National University 
Hospital Singapore. Colonoscopies were included if they had at least one of 
the following indications: screening, diarrhea, abdominal pain and consti-
pation. Patients below the age of 21, or with a history of colorectal cancer, 
colonic surgery, inflammatory bowel disease and Lynch syndrome were 
excluded. Patients with incomplete or repeated colonoscopies done during 
the study period were also excluded.
results: We reviewed 55,679 colonoscopies from 2006 to 2016. After ex-
cluding 35,284 colonoscopies, a total of 20,395 were included. The overall 
prevalence of diverticulosis was 19.6%, and its prevalence has progressive-
ly increased from 2006 to 2016 (14.9% vs 23.9%, adjusted trend< 0.001). 
Patients with diverticulosis were older and had higher BMI. Diverticulosis 
was significantly more prevalent in Chinese compared to Malay and Indian 
races (20.5% vs 18.9% vs 15.5%, p<0.05), and in males compared to fe-
males (21.5% vs 17.6%, p<0.05). There was no significant trend difference 
in terms of age, ethnicity and gender distribution of colonic diverticulosis 
patients recruited from 2006 to 2016. Right-sided diverticulosis was more 
common than left-sided or pan-diverticulosis (16.2% vs 8.3% vs 4.8%, 
p<0.05). Multivariate regression analysis revealed age (odds ratio [OR], 
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1.054; 95% confidence interval [CI], 1.048-1.059), BMI (OR, 1.049; 95% CI, 
1.035-1.063), male gender (OR, 1.269; 95% CI, 1.135-1.419), Chinese ethnic-
ity (OR, 1.307; 95% CI, 1.080-1.582), alcohol consumption (OR, 1.227; 95% 
CI, 1.012-1.487), presence of adenoma (OR, 1.168; 95% CI, 1.032-1.322) and 
abdominal pain symptom (OR, 1.218; 95% CI, 1.055-1.408) as independent 
risk factors for colonic diverticulosis. Constipation was negatively associ-
ated with diverticulosis (OR, 0.698; 95% CI, 0.573-0.852).
variable Odds ratio (Or) 95% confidence Interval (cI) P-value
Age 1.054 1.048-1.059 <0.001
BMI 1.049 1.035-1.063 <0.001
Male Gender 1.269 1.135-1.419 <0.001
Ethnicity (Chinese) 1.307 1.080-1.582 0.006
Alcohol consumption 1.227 1.012-1.487 0.037
Presence of adenoma 1.168 1.032-1.322 0.014
Diarrhea symptom 1.096 0.899-1.336 0.366
Constipation symptom 0.698 0.573-0.852 <0.001
Abdominal pain symptom 1.218 1.055-1.408 0.007
[Multivariate logistic regression for association between colonic 
diverticulosis and risk factors]
conclusion: The overall prevalence of colonic diverticulosis in Singapore 
was 19.6% with a significant increase of 9.0% from 2006 to 2016. There 
were no significant differences in age, gender and ethnicity distribution of 
patients with diverticulosis over the years suggesting that there may be 
other risk factors that contribute to the increasing prevalence of diverticu-
losis. The most common form of diverticulosis in our Singaporean cohort 
remained predominantly right-sided. Age, male gender, Chinese ethnicity, 
elevated BMI, alcohol consumption, colonic adenoma and abdominal pain 
symptom are associated with diverticulosis.
disclosure: Nothing to disclose 
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Of The cOLOn: an anaLysIs frOM The InTernaTIOnaL, 
MuLTIcenTer, PrOsPecTIve sTudy
Tursi A.1, Brandimarte G.2, Di Mario F.3, Elisei W.4, Picchio M.5, 
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Introduction: Diverticulosis of the colon is the most frequent anatomi-
cal alteration detected during colonoscopy. The endoscopic classification 
called “DICA” (Diverticular Inflammation and Complication Assessment) 
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has been recently developed in order to have an objective endoscopic de-
scription of the colon harbouring diverticula. Retrospective study found 
a significant relationship between severity of DICA score and clinical and 
demographic characteristics of people having diverticulosis/diverticular 
disease.
aims & Methods: Aim of this multicentre, international, prospective study 
was to assess the predictive value of this classification in term of acute 
diverticulitis and surgery occurrence on a 1-year observational follow-up 
period. 
2215 prospective patients at the first diagnosis of diverticular disease were 
enrolled after exclusion of radiological signs of acute diverticulitis; inflam-
matory bowel diseases; ischemic colitis; prior colonic resection; patients 
with severe liver failure (Child-Pugh C) or severe kidney failure; pregnant 
women; patients who are currently using or who have received any laxa-
tive agents or mesalazine or probiotics or antibiotics < 2 weeks prior to the 
enrollment; inability to comply with study protocol and to give informed 
consensus to the procedure; patients with or history of cancer, of any ori-
gin, within 5 years before enrollment; history of alcohol, drug, or chemical 
abuse. All patients were classified according to DICA classification.
results: 1377 (62.15%) patients were classified as DICA 1, 599 (27,04%) as 
DICA 2, and 239 (10.80%) as DICA 3. 
The risk of acute diverticulitis occurrence/recurrence, as well as the risk 
of surgery, were significantly linked to the severity of DICA score at entry.
Overall, acute diverticulitis occurred in 79 (3,6%) patients: it occurred in 17 
(1.38%) DICA 1, 30 (5.11%) DICA 2 and 30 (12.82%) DICA 3 patients respec-
tively (p< 0,0001). 
Overall, surgery occurred in 29 (1,3%) patients: it occurred in 2 (0.14%) 
DICA1, 11 (1.87%) DICA 2 and 16 (6.83%) DICA 3 patients respectively (p< 
0,0001).
conclusion: The 1-year results of this prospective study seems to confirm 
that DICA endoscopic classification has a significant prognostic role on the 
risk of acute diverticulitis occurrence/recurrence and on the risk of surgery 
in people having colonic diverticulosis detected at colonoscopy.
disclosure: Nothing to disclose 
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Introduction: Diverticulosis is considered one of the most common and 
burdensome GI disorders. Several observations hold that certain epide-
miological and etiological characteristics are shared between colonic di-
verticulosis and colorectal cancer (CRC), suggesting a possible association 
between these two conditions. This connection is of paramount clinical 
relevance, as several reports demonstrated that patients with diverticular 
disease have a higher risk of harboring CRC as well as adenomas. How-
ever, data are still controversial and inconclusive, as other recent studies 
failed to confirm this association. Uunraveling the dilemma appears to 
be clinically relevant, as tailored screening or surveillance intervals for 
CRC and polyp follow up could be of benefit in patients with diverticular 
disease.
aims & Methods: The present study aims to compare the CRC detection 
rate and location as well as polyp detection rate between patients with di-
verticular disease and a matched group. In this retrospective single center 
study, patients diagnosed with diverticulosis on colonoscopy over a 10-
year period were included. Each diverticulosis patient was matched with 
1 control by age, gender, setting (inpatient/outpatient) and procedure’s 
indication. CRC and polyp detection rates were recorded and compared 
between the groups before and after adjustment for bowel preparation 
quality and exam completion (cecal intubation).
results: A cohort of 13680 patients (6840 patients with diverticulosis and 
6840 matched controls) were included. Diverticulosis was located mainly 
to the sigmoid and left colon (88.5%). The CRC diagnosis rate was lower 
in the diverticulosis group (2% vs. 4.5%, odds ratio=0.472, p< 0.001 and 
95%CI=0.382-0.584). Moreover, location of CRC was unrelated to diver-
ticulosis location, as more CRCs in the diverticulosis group were located 
proximal to the splenic flexure as compared to control group (42.5% vs 
29.5% respectively; P=0.03). Diverticulosis, however, was associated with 
increased polyp detection rate compared to controls (30.5% vs. 25.5%; 
odds ratio=1.2, P< 0.001 and 95%CI=1.11-1.299). These trends were kept 
also after multivariate analysis.
conclusion: Diverticulosis was not linked with increased risk for CRC, nor 
was its location correlated with CRC location.
disclosure: Nothing to disclose 
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Introduction: A variety of drugs have been suggested to act as potential 
risk factors or protective against complications in diverticular disease (DD).
aims & Methods: Aim of this study was to assess the role of clinical fea-
tures and drug use potentially predisposing to [non-steroidal anti-inflam-
matory drugs (NSAIDs), antiplatelets, anticoagulants] or protective against 
[statins] the development of complications such as acute diverticulitis (AD) 
or diverticular bleeding (DB) in a cohort of patients with DD.
The REMAD Registry (Diverticular Disease Registry) is an ongoing 5-year 
prospective, observational, cohort study, involving 47 centres (Trials.gov: 
NCT03325829). 
For the purpose of this analysis, patients were categorized in: a) patients 
without history of DD complications; b) patient with past AD (without di-
verticular bleeding); c) patients with past DB.
Demographic, clinical features and use of drugs assumed before the DD 
diagnosis [frequent use of NSAIDs (at least once a week: aspirin, NSAIDs, 
COX-2 inhibitors), antiplatelets (aspirin, ticlopidine, clopidogrel), antico-
agulants (heparin, warfarin, factor X and thrombin inhibitors), and statins] 
were collected in order to identify factors associated with DD complica-
tions.
results: Out of 1217 patients (45.7% female; 75.4% age≥60yrs; 15.9%BMI≥30 
kg/m2; 14.4% Charlson index≥3; 21% family history for DD), 998 (82%) had 
no history of DD complications, 194 (15.9%) had a past episode of AD and 
25 (2.1%) had a past DB. 
Compared to patients with no history of DD complications, age ≥60yrs was 
inversely (OR=0.48; 95%CI:0.34-0.67) whereas first degree family history 
for DD was positively (OR=1.68;95%CI:1.17-2.41) associated to patients with 
past AD. On the other hand, age ≥60yrs (OR=4.30; 95%CI:1.16-15.94) and 
Charlson index ≥3 (OR=2.58; 95%CI:1.07-6.23) were associated to history 
of past DB. 
Regarding drugs potentially predisposing to DD complications, no signifi-
cant differences were found regarding assumption of frequent NSAIDs and 
chronic antiplatelets in mono or dual therapy [5.3%, 2.6%, 8.3% (NSAIDs: 
P>0.05) and 8.7%, 15.8%, 29.2% (antiplatelets: P>0.05) in patients with-
out DD complications, past AD and past DB, respectively]. By considering 
only ticlopidine assumption, it was significantly associated with past his-
tory of AD (3.2%) compared with patient without DD complications (0.9%) 
(OR 4.0; 95%CI:1.25-12.85). 
Anticoagulants were more frequently taken in patients with past DB (12.5%) 
compared to patients with past AD (2.1%) (P=0.035); particularly warfarin 
use, was associated to patients with past DB (12.5%) compared to both 
patients without history of DD complications (2.4%; OR 4.86;95%CI:1.32-
17.87) and patients with past AD (1%; OR 9.53; 95%CI: 1.1-79.10). Regarding 
drugs potentially protective against DD complications, no significant dif-
ferences were found regarding use of statins (15.2%, 13.5%, 20.8% in pa-
tients without DD complication, past AD and past DB respectively; P>0.05).
conclusion: This Registry study showed that some distinctive clinical fea-
tures distinguish patients with two different kinds of DD complications: 
younger age and first degree family history for DD were associated to AD 
958 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
whereas older age and higher Charlson index were associated to DB. Re-
garding drugs, since ticlopidine use was associated with past AD whereas 
use of anticoagulants (particularly warfarin) was associated with past DB, 
clinicians should pay particular attention at complications in using drugs 
in DD patients.
disclosure: Nothing to disclose 
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Introduction: Following an attack of acute diverticulitis ( AD) many pa-
tients suffer from persistent symptoms and impaired quality of life. These 
patients are diagnosed as suffering from symptomatic uncomplicated di-
verticular disease ( SUDD). Few treatment strategies exist in order to im-
prove patients’ symptoms. However, there is no validated clinical score for 
standardized patients’ assessment.
aims & Methods: Our aim was to develop and validate a simplified easy 
to use diverdticular clinical score. Data from long term prospective study 
of 261 patients AD was reviewed. Patients’ most relevant clinical symp-
toms were recorded and processed. A simplified questionnaire based on 
these clinical symptoms and relevant validated questionnaires for pain as-
sessment ( VAS ) and inflammatory bowel disease activity (IBD control ) 
was designed. Validation was performed using a pilot study focus group 
containing 20 patients suffering from SUDD after a documented attack of 
(AD). Personal interview with all patients was conducted using structured 
cognitive interview questions. Thereafter, a validation cohort consists of 48 
patients suffering from SUDD post AD attack was established. Question-
naire’s results were compared to physicians’ global assessment for disease 
severity obtained during the visit and to inflammatory markers. question-
naire consists of 9 basic questions, assessing frequency, duration and se-
verity of the abdominal pain, additional symptoms, missed plans activities, 
mood disturbances and desire for treatment.
results: A total of 52 questionnaires were filled by 48 patients. Correlation 
between single questions and total score to disease severity and inflam-
matory markers is shown in table 1. Correlation matrix demonstrates a very 
strong correlation between the total score of the questionnaire and the 
elevation of inflammatory markers (ρ= 0.84). 
Cronbach’s alpha for measuring internal consistency was 0.91. The area 
under a ROC curve examining the overall ability of the test to discriminate 
between patients with/without active disease produced AUC = 0.989.
 
abdomi-
nal pain- 
frequency
abdomi-
nal pain- 
duration
abdomi-
nal pain- 
severity
additio-
nal sym-
ptoms
Missed 
activities
Total 
score
disease 
activity
Inflamm-
atory 
markers
Abdominal 
pain- 
frequency
1 0.77 0.93 0.74 0.88 0.94 0.9 0.85
Abdominal 
pain- 
duration
0.77 1 0.82 0.56 0.68 0.8 0.74 0.7
Abdominal 
pain- 
severity
0.93 0.82 1 0.7 0.85 0.95 0.9 0.86
Additional 
symptoms
0.74 0.56 0.7 1 0.67 0.82 0.57 0.53
Missed 
activities
0.88 0.68 0.85 0.67 1 0.85 0.92 0.88
Total score 0.94 0.8 0.95 0.82 0.85 1 0.86 0.84
Disease 
activity
0.9 0.74 0.9 0.57 0.92 0.86 1 0.96
Inflammato-
ry markers
0.85 0.7 0.86 0.53 0.88 0.84 0.96 1
[Correlation between single questions and total score to disease severity and 
inflammatory markers]
conclusion: Patients suffering from SUDD post AD express a wide range 
of symptoms. Following further research the new DICS questionnaire may 
help in monitoring those symptoms, facilitate patients’ stratification and 
support therapeutic decisions. 
disclosure: Nothing to disclose 
P1912 The PrOgnOsTIc vaLue Of a neW endOscOPIc 
cLassIfIcaTIOn fOr dIverTIcuLar dIsease: dIca (dIverTIcuLar 
InfLaMMaTIOn and cOMPLIcaTIOn assessMenT)
Cambiè G.1, Violi A.1, Tursi A.2, Brandimarte G.3, Miraglia C.1, Elisei W.4, 
Rodriguez-Castro K.I.5, Ferronato A.6, Baldassarre G.5, Crafa P.1, Cuoco L.5, 
Di Mario F.1
1University of Parma, Department of Medicine and Surgery, Parma, Italy, 2ASL 
BAT Gastroenterology Service, Andria, Italy, 3Hospital ‘Cristo Re’, Dept. of 
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Introduction: .Colonic Diverticulosis is one of the most common anatomic 
alterations found in the clinical practice. This condition has 60% incidence 
in the population over 60 years old. About 20% of patients with this con-
dition will develop Diverticular Disease, and 5% of them will evolve into 
Diverticulitis. Recently the first endoscopic classification of Diverticular 
Disease, useful for the clinical management of those patients, has been 
proposed: DICA.
aims & Methods: The aim of the study is to analyze the distribution of the 
severity according to DICA score amongst patients with diagnosis of colonic 
Diverticulosis in relation to age, gender, the occurrence-recurrence of di-
verticulitis, other associated complications, and the necessity of surgical 
procedures, as well as the duration and the economic cost of the hospi-
talization. We analysed and classified 5635 cases identified at colonoscopy 
according to the DICA score, in the period between January 2012 and April 
2018. Hospital discharge forms for all patients with hospital admitions for 
diverticular disease or its complications during the same time interval 
were retrieved.
results: 69.9% of patients had a DICA score of 1, while 21% and 9.1% 
of patients have a DICA 2 or DICA 3 score, respectively. Aging increased 
the frequency and severity of diverticular disease (mean ages for each 
DICA score being 65.8 years, 67.0 years, and 69.6 years for DICA 1, 2, and 
3, respectively). Higher severity scores were found in female patients 
(DICA1=44.6%, DICA2=50.8%, DICA3=57.8%). The occurrence of overall 
complications was 5.4%, being 3.5%, 7.7% and 14.2% for DICA scores 
1, 2, and 3, respectively. Diverticular disease was not complicated diver-
ticular disease (DICA1=1%, DICA2=1.8%, DICA3=3.5%); not complicated 
diverticulitis (DICA1=2.1%, DICA2=4.7%, DICA3=6.4%); bleeding in diver-
ticulitis (DICA1=0.4%, DICA2=1.2%, DICA3=4.5%); diverticular perforation 
(DICA1=0.0%, DICA2=0.1%, DICA3=0.4%). The complications that needed 
a surgical procedure were for DICA1 about 0.2%, for DICA2 0.8% and for 
DICA3 2.5%. As well, the average of the occupant days in the hospital and 
the cost, respectively, was for DICA1, 8.5 days and 2300 Euro, for DICA2, 9.5 
days and 3080 Euro, for DICA 3, 13 days and 4090 Euro.
conclusion: In conclusion, the majority of the patients with Diverticular 
Disease belonged to the severity score DICA1 and the patients classified 
with DICA3 were mainly female and older than 69 years old. The study 
confirmed the prognostic value of the endoscopic classification DICA since 
the occurrence of complication resulted in a statistically significant relation 
with the score DICA3. DICA classification was able to discriminate, based 
on endoscopic records, the patients that could develop complications for 
Diverticular Disease.
disclosure: Nothing to disclose 
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P1913 evaLuaTIOn Of rIsk facTOrs fOr cOLOnIc 
dIverTIcuLOsIs In easTern and cenTraL eurOPean 
POPuLaTIOn
Lukosiene J.I.1, Reichert M.C.2, Tamelis A.3, Pampikas S.1, Kiudelis G.1, 
Jonaitis L.1, Kupcinskas L.1, Lammert F.2, Kupcinskas J.1
1Lithuanian University of Health Sciences, Department of Gastroenterology, 
Kaunas, Lithuania, 2Saarland University Medical Center, Department of 
Internal Medicine II, Homburg, Germany, 3Lithuanian University of Health 
Sciences, Department of Surgery, Kaunas, Lithuania
contact e-Mail address: j_kupcinskas@yahoo.com
Introduction: Colonic diverticulosis (CD) is a frequent condition of the large 
intestine and an important cause of hospital admissions in Western and 
industrialized nations [1, 2, 3]. Several factors have been associated with 
increased risk of CD and its related complications including advanced age, 
obesity, physical inactivity, and a low-fiber diet [4-8]. Nevertheless, re-
ported data are conflicting and high-powered comprehensive analysis 
on different dietary and lifestyle factors linked with CD is lacking [1, 4]. 
Therefore,we set out to investigate the association between potential risk 
factors and the prevalence of CD using inclusive data from a colonoscopy-
based cross-sectional study in eastern and central European population.
aims & Methods: Study cohort was conducted at two tertiary referral cen-
ters in Germany and Lithuania (the Saarland University Medical Center in 
Homburg and the University Hospital of Kaunas). The local Ethics Com-
mittee and National Data Protection Committee approved the study. Adult 
participants underwent routine colonoscopy and completed a detailed 
questionnaire on diet, bowel habits and various lifestyle aspects. We con-
sidered multiple risk factors for diverticulosis including diet (portion size, 
amount of meals per day, amount of fluids, amount of fish and red meat 
per week etc.), frequency of bowel movements, various symptoms of con-
stipation, tobacco use, alcohol use, nonsteroidal anti-inflammatory drug 
(NSAID) use, education, obesity and gender. Link between risk factors and 
CD was assessed using logistic regression and standard hypothesis testing 
methods where pertinent.
results: The study included 1333 patients, 634 (47,6%) males with a mean 
age of 61,89 years and 698 females with a mean age of 62,95 years. CD was 
diagnosed in 858 (64,4%) of patients. Univariate analysis revealed that 
age (OR 1,073, 95% CI, 1,062-1,085, p< 0,05) and obesity (OR 1,529, 95% CI, 
1,155-2,025, p=0,003) were associated with colonic diverticulosis in accor-
dance with prior findings. Our analysis also revealed new risk factors re-
lated with CD including frequency of bowel movements (OR 0,131, 95% CI, 
0,040-0,426, p=0,001) and rectal tenesmus (OR 1,922, 95% CI, 1,19-3,104, 
p=0,008). We used a multivariate analysis to re-affirm obtained results. 
Univariate analysis also showed a significant association between CD and 
education (p=0,004), working night shifts (p<0,05), amount of meals per 
day (p=0,006) and previous abdominal surgery (p=0,028); however, these 
associations were not significant in the multivariate logistic regression. 
Likewise, we did not find a significant association between CD and gender, 
NSAID use, alcohol and tobacco use, various symptoms of constipation, 
education and different dietary aspects.
conclusion: Our analysis using large population cohort establish older 
age, obesity, frequency of bowel movements and rectal tenesmus as the 
main risk factors associated with CD.
references: 1. Tursi A. Diverticulosis today: unfashionable and still un-
der-researched. Therap Adv Gastroenterol. 2016;9(2):213-228. 2. Delvaux 
M. Diverticular disease of the colon in Europe: Epidemiology, impact on 
citizen health and prevention. Aliment Pharmacol Ther 2003;18:71-4. DOI: 
10.1046/j.0953-0673.2003.01720.x 3. Manousos N, Truelove S, Lumsden 
K. Prevalence of colonic diverticulosis in general population of Oxford 
area. Br Med J 1967;3:762-3. 4. Kruis W, Spiller RC, Papagrigoriadis S, et 
al. Diverticular disease: a fresh approach to a neglected disease. Dig Dis 
2012;30:5-5. 5. Strate LL, Liu YL, Aldoori WH, et al. Obesity increases the 
risks of diverticulitis and diverticular bleeding. Gastroenterology 2009; 
136:115-122. 6. Rosemar A, Angeras U, Rosengren A. Body mass index and 
diverticular disease: a 28-year follow-up study in men. Dis Colon Rectum 
2008;51:450-455. 7. Peery AF, Sandler RS, Ahnen DJ, et al. Constipation and 
a low-fiber diet are not associated with diverticulosis. Clin Gastroenterol 
Hepatol 2013;11:1622-7. 8. Kopylov U, Gen-Horin S, Lahat A, et al. Obesity, 
metabolic syndrome and the risk of development of colonic diverticulosis. 
Digestion 2012;86:201-5. DOI: 10.1159/000339881.
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P1914 nuTrITIOnaL characTerIsTIcs Of PaTIenTs WITh 
dIverTIcuLar dIsease: resuLTs frOM The reMad regIsTry
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Surgical Sciences, Bologna, Italy, 6Ospedale S. Andrea, Medical and 
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Introduction: Several evidences suggest that diet has a critical role in the 
pathophysiology of diverticular disease (DD). However, no data are avail-
able regarding nutritional status of patients with DD and diverticulosis.
aims & Methods: The aim of this study was to investigate the nutritional 
characteristics of patients with DD and diverticulosis.
Diverticular Disease Registry (REMAD) is an ongoing 5-years prospec-
tive, observational, multicentre, cohort study, involving 47 Centers (Trials.
gov:NCT03325829). Patients were categorized according to the following 
criteria: i) Diverticulosis: presence of diverticula in the absence of abdomi-
nal symptoms; ii) Symptomatic uncomplicated diverticular disease (SUDD): 
recurrent abdominal symptoms as abdominal pain and/or changes in 
bowel habit, attributed to diverticula in the absence of overt inflammation; 
iii) Previous diverticulitis (PD): patients who experienced at least 1 episode 
of diverticulitis in the past. 
At the baseline, 1217 [45.7% female, age 66±10 y] patients were enrolled. 
705 (58%), 300 (24.7%) and 212 (17.3%) patients fulfilled criteria for diver-
ticulosis, SUDD and PD, respectively.
All patients who were asked to fill in a food frequency questionnaire to as-
sess energy and nutritional intake. In order to compare results, 100 heathy 
subjects (HS) were asked fill in food frequency questionnaire. WinFood 
software was used for the estimation of nutrient and caloric intake.
results: 332 patients with diverticulosis, 147 with SUDD and 83 with PD ac-
cepted to fill in self-administered nutritional questionnaire. In order to re-
duce age-related differences, 205 patients with diverticulosis, 100 patients 
with SUDD, 73 with PD and 82 HS were included in the analysis (62.6±8.1, 
62.5±8.9, 62.2±9.5 and 62.1±7.5 years, respectively; p=0.965).
Patients with PD and SUDD showed a lower calorie intake compared to 
patients with diverticulosis and HS (1416±405 and 1582±519 vs 1642±554 
and 1778±439 kCal; p< 0.001). 
Consumption of fat was lower in PD group compared to diverticulosis, 
SUDD and HS groups (53±18 vs. 60±23, 63±27 and 75±22 g/die; p< 0.001), 
whereas protein consumption was lower in PD group only compared to 
diverticulosis group (71±22 vs. 83±27 g/die; p=0.007). No differences were 
observed in terms of carbohydrate consumption among the four groups. 
Compared to diverticulosis, SUDD and HS groups, patients with PD re-
ported a lower intake of total fiber (18±7, 18±7 and 20±6 vs. 15±6 g/die; 
p< 0.001), soluble fibers (4.4±1.7, 4.5±1.9 and 4.9±1.7 vs. 3.7±1.6 g/die; p< 
0.001) and insoluble fibers (12±5 12±5 14±4 vs. 10±4 g/die; p< 0.001). Lastly, 
patients with PD also reported a reduced intake of Vitamin A, Vitamin C, 
Vitamin D, Vitamin E and Polyphenols (data not shown).
conclusion: Our data showed that patients with diverticular disease, in 
particular patients with PD, have a modified intake of calories, fiber and 
some macronutrients compared to other groups included HS. Moreover, 
these patients also showed nutritional deficiencies of molecules with 
anti-oxidant effects, predisposing to recurrence of diverticulitis. If these 
changes are the consequence of diet modifications after acute diverticulitis 
needs to be clarified. These data rise attention on dietary interventions in 
the management of DD.
disclosure: Nothing to disclose 
960 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Paediatric: Lower gI III
09:00-14:00 / Poster Exhibition - Hall 7
P1915 uPPer gasTrOInTesTInaL TracT fIndIngs 
In PedIaTrIc IBd: PrevaLence and assOcIaTIOn WITh 
OTher dIsease feaTures
Repo M.1, Pessi J.1, Wirtanen E.1, Hiltunen P.2, Ruuska T.2, Kivelä L.1, 
Kurppa K.2
1Tampere University, Centre of Child Health Research, Tampere, Finland, 
2Tampere University Hospital Dept. of Pediatrics, Tampere, Finland
contact e-Mail address: marleena.repo@fimnet.fi
Introduction: During the past few decades, prevalence of pediatric inflam-
matory bowel diseases (IBD) has increased and diagnostic methods im-
proved. However, data on the frequency and significance of upper gastro-
intestinal tract (UGT) findings remain limited.
aims & Methods: Comprehensive medical data of 2395 consecutive chil-
dren who had undergone gastrointestinal endoscopy with systematic 
biopsy sampling were collected. Next, IBD patients (n=129) were divided 
to those with and without histological UGT findings in esophagogastro-
duodenoscopy for comparisons of the disease features and treatment 
response. Control group comprised corresponding children who did not 
receive any diagnosis in endoscopic and other investigations (n=178).
results: UGT findings were more common in IBD patients than in controls 
(70% vs 32%, p< 0.001). Of IBD patients, 19% had findings in esophagus, 
63% in ventricle and 11% in duodenum, while corresponding figures for 
controls were 18%, 17% and 5%. Fifty-five percent of IBD patients had 
ulcerative colitis (UC), 34% Crohn’s disease (CD) and 11% IBD unclassified 
(IBD-U). The findings were more common in CD (84%) than in UC (62%) 
and IBD-U (64%) (p=0.038). Four CD patients had UGT granulomas, while 
the other histological findings did not affect to the IBD diagnostics. IBD 
patients with and without UGT findings did not differ in gender or age 
distribution, family history, or laboratory results other than albumin at 
diagnosis (Table 1). The groups were also comparable in the distribution 
of colonic involvement and clinical presentation at diagnosis, but children 
with UGT findings showed more often primary treatment response (83% 
vs. 64%, p=0.024). 
  ugT findings n=90 no ugT findings n=39 P value
  n % n %  
Girls 41 45.6 14 35.9 0.308
IBD in 
relatives
13 14.4 8 20.5 0.391
Positive 
calprotectin (1)
55 90.2 24 88.9 0.856
  n:o of data Median (q1,q3) n:o of data
Median 
(q1,q3)  
Age, years 90 13 (11, 14) 39 12 (8, 14) 0.150
ESR, mm 85 18 (12, 34) 37 20 (9, 34) 0.956
Albumin, g/l 56 36 (31, 40) 27 39 (36, 41) 0.020
(1) Data available for 61 patients with and 27 patients without UGT findings.
[Table 1. Baseline characteristics and diagnoses of 129 IBD children with and 
without upper gastrointestinal tract (UGT) findings.]
conclusion: UGT findings are common in pediatric IBD, especially in CD 
patients and in ventricle and, in some cases, may affect the diagnosis. 
However, they do not seem to associate with more severe disease presen-
tation or poorer initial treatment response.
disclosure: Nothing to disclose 
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Introduction: Crohn’s disease (CD) is a chronic disease often originating 
in childhood and requiring daily attention. We aimed to assess the health 
literacy (HL), quality of life (QoL) and related outcomes in CD patients pro-
spectively followed in the Belgian Crohn’s disease registry (BELCRO), com-
pared to young type 1 diabetes mellitus (DM) patients.
aims & Methods: Demographics, clinical data (including Crohn’s Disease 
Activity Index (CDAI) for CD) and validated HL and QoL questionnaires 
(HLS-EU-Q16, EQ-5D-5L and WPAI) were obtained from young adult CD 
and DM patients diagnosed in childhood and followed in the BELCRO or 
Diabetes Clinic UZ Brussel. HL was scored as inadequate (0-8), problem-
atic (9-12) or sufficient (13-16). QoL was dichotomized into ‘problems’ (EQ-
5D levels 2 to 5) or ‘no problems’ (level 1). Work productivity and activity 
impairment (WPAI) were scored as percentages. Univariate non-paramet-
ric (Mann-Whitney U and chi-squared test) and correlation (Spearman) 
analyses were performed.
results: In total, 46 CD (median (IQR) age 25 (24-27) years, 63% male) and 
50 DM (age 20 (19-22) years, 50% male) patients were included. Median 
CDAI-score in CD patients was 67 (30-138). Median HL was the same in CD 
and DM patients (both 14 (11-15), p=0.81) with similar proportions of inad-
equate, problematic and sufficient HL (all p>0.05) in CD vs. DM patients. 
Median QoL was similar in CD and DM patients (both 75 (65-80), p=0.47) 
with similar proportions of problems with mobility, self-care, usual activi-
ties and anxiety/depression but a significance for higher pain/discomfort 
in CD vs. DM patients (53 vs. 32%, p=0.04). Median work (10 (0-30) vs. 
20 (10-40)%, p=0.45) and activity impairment (20 (0-40) vs. 20 (10-40)%, 
p=0.95) was similar in CD and DM. HL correlated positively with QoL in CD 
and DM (both r=0.6, p< 0.01) and negatively with work impairment in CD 
(r=-0.4, p=0.02) but not DM patients. Work impairment for CD correlated 
with the CDAI (r=0.5, p=0.01) and number of hospitalizations and surgeries 
in the last 3 years (r=0.4, p=0.03). CD patients with recent hospitalization 
and surgery (22%) had a trend for higher CDAI (107 (58-252) vs. 41 (20-114), 
p=0.07) with lower HL (11.5 (10-12) vs. 14 (11-16), p=0.06) and QoL (68 (60-
75) vs. 80 (70-85), p=0.02) compared to those without.
conclusion: In the studied populations, HL is sufficient in the majority of 
cases. Despite a comparable QoL and WPAI to DM patients, young CD pa-
tients with recent hospitalizations and surgeries have lower QoL and HL 
than those without. Interventions and programs aimed at improving HL 
and QoL in children and adolescents with CD should be installed to in-
crease health-related outcomes in early adult life.
disclosure: This study was supported by a grant from MSD to BESPGHAN. 
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P1917 LaTenT TuBercuLOsIs TesTIng In PaedIaTrIc 
PaTIenTs WITh InfLaMMaTOry BOWeL dIsease TreaTed 
WITh anTI-TuMOur necrOsIs facTOr agenTs: dO We need 
neW TesTIng recOMMendaTIOns?
Henriques A., Mourão F., Monteiro J., Espinheira M.C., Pinto Pais I., 
Fernandes R., Campos L., Trindade E., Amil Dias J.
Unidade de Gastrenterologia Pediátrica, Centro Hospitalar e Universitário de 
S. João, Porto, Porto, Portugal
contact e-Mail address: andremartinshenriques@gmail.com
Introduction: Anti-tumour necrosis factor (anti-TNF) agents are one of 
the therapeutic cornerstones in inflammatory bowel disease (IBD). These 
agents increase the risk of reactivation of latent infections. Latent tubercu-
losis (LT) testing is recommended prior to anti-TNF therapy in paediatric 
patients with IBD. In the European Union, Portugal is one of the countries 
with the highest prevalence of tuberculosis, and the country’s northern 
region has the third highest national notification rate registered in 2017: 
20,6 cases per 100.000 inhabitants. Our department is Portugal’s northern 
region paediatric gastroenterology reference centre.
aims & Methods: We performed a retrospective and descriptive analysis 
of paediatric patients with IBD eligible for anti-TNF therapy followed at 
our department during the last 2 years. This study aimed to evaluate the 
prevalence of LT and active tuberculosis in this group of patients.
results: Clinical data from 273 paediatric patients with IBD was analysed. 
120 of these patients were eligible for anti-TNF therapy (77,5% Crohn’s dis-
ease, 21,7% Ulcerative Colitis, 0,8% IBD unclassified). The median age was 
13 years. LT prevalence was 7,3% (n=9): positive Tuberculin skin test (TST) 
in 5 cases and positive Interferon-gamma release arrays (IGRA) in 4. In 2 
cases initial IGRA testing was negative. A single patient had contact with a 
case of active tuberculosis. All patients diagnosed with LT were treated with 
isoniazid. Follow up after treatment of LT varied between 28 and 1496 days. 
We had no cases of complications or development of active tuberculosis.
conclusion: Testing for LT prior to anti-TNF therapy is mandatory. Repeat-
ing this testing process while under anti-TNF therapy is dependent on a 
case-by-case analysis. Even in the absence of contact with active tuber-
culosis its important to test and treat LT. We believe that further studies 
are needed to formulate new recommendations for LT testing / testing 
repetition.
disclosure: Nothing to disclose 
P1918 gasTrOInTesTInaL grafT-versus-hOsT dIsease In 
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Introduction: Graft-versus-host disease (GVHD) is a life-threatening mul-
tisystemic complication of allogeneic hematopoietic cell transplantation.
aims & Methods: The aim of this retrospective study was to describe the 
features of the hematopoietic stem cell transplanted (HSCT) patients diag-
nosed with Gastrointestinal (GI) GVHD. Paediatric patients (< 18y of age) 
that had received an HSCT from January 2014 to November 2018 were in-
cluded. Diagnosis, epidemiological and clinical data were compared be-
tween patients who developed GVHD and the rest of patients with HSCT.
results: A total of 177 patients received HSCT and 28 (14.2%) of them de-
veloped GVHD, 50% were women. At the moment of the HSCT, the average 
age was 8.85 years old (±5.9 y) and GVHD was diagnosed at the age of 9.4 
y (±5.8 y). The type of HSCT and the underlying conditions for which HSCT 
was indicated in patients who developed GVHD (n=28), versus those who 
did not develop GVHD (n=149) are shown in Table 1. 
The most common symptoms of GI GVHD were vomiting in 21 patients 
(75%), diarrhoea and anorexia in 19 (67.9%) respectively, abdominal 
and pain in 18 (64.3%), weight loss in 16 (57.1%) and hepatomegaly in 8 
(28.6%). 
A total of 19 (67.9%) presented cutaneous GVHD demonstrated by biopsy, 
9 (32.1%) bronchiolitis obliterans and 14 (50%) had clinical criteria of he-
patic GVHD. The diagnosis of GI GVHD was made by upper endoscopy in 11 
(39.3%), lower endoscopy in 9 (32.1%) and both of them in 8 (28.6%). No 
side effects of the endoscopy were notified.
The types of GVHD were classic acute GVHD in 14 (50%), acute and persis-
tent or recurrent GVHD in 3 (10.7%), classic chronic GVHD in 4 (14.3%), and 
overlap (both acute and chronic GVHD were present) in 7 (25%). 
Most of the patients received several treatments, including methylpred-
nisolone in 26 (92.8%), budesonide in 7 (25%), beclomethasone in 2 (7%), 
photopheresis in 19 (67.9%), etanercept in 17 (60.7%), calcineurin inhibi-
tors in 13 (46.4%), ruxolitinib in 7 (25%), mycophenolate mofetil, anti-
thymocyte globulin and mesenchymal stem cells infusion and immuno-
globulin in 3 patients (10.7%) respectively, and sirolimus in 1 (3.6%). These 
treatments were totally effective in 15 patients (53.6%), partially effective 
in 8 (28.6%) and non-effective or refractory in 5 (17.9%).
   
Transplanted 
patients who 
developed gvhd 
(n=28)
Transplanted 
patients who did 
not develop gvhd 
(n=149)
p
Type of HSCT
Haploindentical 
allogeneic
11 (39,3%) 59 (39,6%) 0,8625
 
HLA-matched allogeneic 
related
5 (17,9%) 27 (18,1%) 0,8231
  HLA-mismatched related 0 2 (1,3%) 1
 
HLA-matched allogeneic 
non-related
10 (35,7%) 13 (8,7%) 0,0003
 
HLA-mismatched 
unrelated
2 (7,1%) 9 (6%) 0,8415
Underlying 
condition
Acute lymphoblastic 
leukemia (ALL)
11 (39,3%) 38 (25,5%) 0,2059
 
Acute myeloid leukemia 
(AML)
12 (42,9%) 29 (19,5%) 0,0400*
  Hodgkin Lymphoma 1 (3,6%) 5 (3,4%) 1
 
Myelodysplastic 
syndrome
1 (3,6%) 8 (5,4%) 1
  Immunodeficiency 1 (3,6%) 1 (0,7%) 0,3001
  Hurler syndrome 1 (3,6%) 3 (2%) 0,5011*
  Medullary aplasia 1 (3,6%) 3 (2%) 0,5011
  Other 0 62 (41,6%) 0,0001*
[Table 1]
conclusion: The treatments for GI GVHD are not always effective.A higher 
percentage of patients who received an HLA-identical unrelated allogeneic 
HSCT and who had ALL in the group that developed GVHD when compared 
to those who did not develop GVHD was observed (differences statistically 
significant), suggesting a possible association with these factors. Most pa-
tients with GI GVHD also presented cutaneous GVHD.
references: Jaramillo-Esparza, C et al. (2018). Gastrointestinal tract and 
liver graft-versus-host disease in pediatric patients with hematopoietic 
progenitor cell transplantation at a tertiary care center in Mexico. Revista 
De Gastroenterología De México 83(4), 385-392. Levine et al. (2013). Low 
Paneth cell numbers at onset of gastrointestinal graft-versus-host disease 
identify patients at high risk for nonrelapse mortality. Blood, 122(8), 1505-
1509. Ma, C., Maluf, H., & Liu, T. (2015). Acute graft-versus-host disease is 
more prevalent and severe in the lower than the upper gastrointestinal 
tract. Human Pathology, 46(10), 1480-1487. Myerson, D. et al (2017). Graft-
versus-Host Disease of the Gut: A Histologic Activity Grading System and 
Validation. Biology Of Blood And Marrow Transplantation, 23(9), 1573-1579. 
Rodriguez-Otero, P et al. (2012). Fecal calprotectin and alpha-1 antitrypsin 
predict severity and response to corticosteroids in gastrointestinal graft-
versus-host disease. Blood, 119(24), 5909-5917. Sultan, M. et al(2012). En-
doscopic Diagnosis of Pediatric Acute Gastrointestinal Graft-Versus-Host 
Disease. Journal Of Pediatric Gastroenterology And Nutrition, 55(4), 417-
420. Washington, K. et al (2009). Pathology of graft-versus-host disease in 
the gastrointestinal tract. Human Pathology, 40(7), 909-917.
disclosure: Nothing to disclose 
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P1919 The dynaMIcs Of chInese guT MIcrOBIaL cOMMunITIes: 
The exPedITIOn In TrInIdad and TOBagO
Liu H.1, Dong F.1, Wu J.2
1Capital Medical University, Beijing Shijitan Hospital, Gastroenterology, 
Beijing, China, 2Beijing Shijitan Hospital, CMU, Digestive System, Beijing, 
China
contact e-Mail address: liuhong1118@126.com
Introduction: The human gut microbiome consists of trillions of micro-
biota and the majority of these microbiota reside in the gut. Many pre-
vious researches have received considerable attention to the association 
between gut metagenome and chronic diseases, such as obesity, inflam-
matory bowel disease, and other diseases. The roles of gut microbiota 
in human health not only in influencing the normal processes, but also 
associating with the occurrence and development of disease. With the 
increasing number of Chinese travelers around the world, there is un-
doubtedly drastic change of their diet as well as living environment, which 
would profoundly affect the gut microbial communities of these Chinese 
travelers. In general, when a person to a new environment, his/her may 
be feel inadaptability and the body has discomfort with a few symptoms, 
such as dizzy, flummoxed and emesis, and the time of inadaptability vary 
from person to person. We human are known to be inadaptable for the 
changing environments and foods. However, the mechanisms behind the 
inadaptability phenomenon remain unclear. Researches have already re-
vealed that for short-term travelers, our gut microbial communities have 
been profoundly affected by the changing environments, and they have 
also asserted powerful feedbacks for our adaptation. Yet for mid- or long-
term stays, the effect of changing environments on gut microbial commu-
nities as well as their feedback remain elusive.
aims & Methods: In this study, we have followed a Chinese medical team’s 
expedition from China to Trinidad and Tobago, stay in half a year, and 
come back again. During the whole monitoring duration of more than 9 
months, we have collected 184 feces samples from Chinese medical team, 
28 feces samples from native of Trinidad and Tobago and 5 food and water 
samples from Trinidad and Tobago, as well as 57 feces samples from native 
of Beijing, China. To characterize the taxonomic profile of the gut micro-
biome, the V4 hypervariable region of the bacterial 16S rRNA gene were 
amplified using the universal bacterial/archaeal primers 515F (5’- GTGC-
CAGCMGCCGCGGTAA-3’) and 806R (5’- GGACTACHVGGGTWTCTAAT-3’). To 
characterize gut microbiome functional potential, 61 faecal samples were 
selected and performed shotgun metagenome sequencing, mainly includ-
ing the faecal samples of MT3, MT6, and MT10 people.
results: The number of OTUs and PD_whole_tree varied from 511 to 6,695 
and from 42.21 to 330.42, respectively. Whilst, the Shannon index and 
Simpson index ranged from 1.51 to 7.06 and 0.58 to 0.98, respectively. 
These differences revealed that the most significant changes of the gut 
microbiota occur directly after the shift of diet and locations. The mantel 
test between composition data (taxonomical composition and functional 
composition) and diet information showed that the changes of the gut 
microbiota community was strongly associated with diet, especially dairy 
products, pickled food, salty snack and sodas.
conclusion: Based on which taxonomical structure profiling and associa-
tion studies have been conducted, we have found that (i) the most signifi-
cant changes of the gut microbiota occur directly after the shift of diet and 
locations; (ii) the stable states of the gut microbiota were diet dependent, 
while those states were related more with hosts than with enterotype; (iii) 
there were obvious differences in gut microbiota between Chinese groups 
with short stay and those with long stay in Trinidad and Tobago; (iv) there 
were obvious differences in gut microbiota between Chinese (with short 
and long stay in Trinidad and Tobago) and those natives.
disclosure: On behalf of all the authors ,there is no conflict of the interest 
P1920 screenIng fOr h. PyLOrI and cLarIThrOMycIn 
resIsTance By Pcr frOM gasTrIc BIOPsIes: cOMParaTIve 
sTudy Of 2 kITs, aMPLIdIag h. PyLOrI+cLarIr (MOBIdIag) and 
rIdagen heLIcOBacTer PyLOrI (r-BIOPharM)
Gibaud-Papin S.1, Persyn E.1, Musquer N.2, Mosnier J.-F.3, Le Rhun M.2, 
Chapelle N.2, Crémet L.1, Coron E.2, Matysiak-Budnik T.2
1CHU de Nantes, Bacteriology, Nantes, France, 2CHU de Nantes Hôtel Dieu, 
Hépato-Gastroentérologie & Oncologie Digestive, Nantes Cedex, France, 
3CHU de Nantes Hôtel Dieu, Anatomie et Cytologie Pathologiques, Nantes 
Cedex, France
contact e-Mail address: sophieanne.gibaud@chu-nantes.fr
Introduction: Because of the increasing rate of clarithromycin- resistant He-
licobacter pylori strains in France, the HAS French guidelines recommend 
antimicrobial susceptibility testing before starting the first-line eradication 
treatment. We evaluated the feasibility of this new approach in our hospi-
tal by studying 2 qualitative PCR kits : Amplidiag H. pylori+clariR kit (MO-
BIDIAG) targeting the 23S rRNA gene and SNPs in 2142 and 2143 positions, 
mostly involved in clarithromycin resistance, and RIDAGENE Helicobacter 
pylori kit (r-biopharm) targeting 16S rRNA and 23S rRNA genes.
aims & Methods: Patients with indication for endoscopy with gastric bi-
opsies were included in this study. Two antral and 2 corpus biopsies were 
analysed by PCR, and 2 additional biopsies were used for histological 
analysis. The 4 biopsies dedicated for PCR, were pooled, extracted on an 
iPrep extractor, and DNA amplifications were performed on a Rotorgene 
thermocycler.
results: Among the 50 screened patients, 37 were H. pylori negative with 
both PCR kits (35 were confirmed negative and 1 was found positive by his-
tology, 1 had no histological analysis), 13 were H. pylori positive with both 
PCR kits without detection of clarithromycin resistance (12 were confirmed 
positive and 1 was found negative by histological analysis).
conclusion: Preliminary results of this study prove the feasibility of H. pylori 
and clarithromycin resistance screening by PCR from gastric biopsies, and 
show a good correlation between the 2 kits and histology results. They are 
both easy to use and give rapid results (1h45 for MOBIDIAG kit and 70 min 
for RIDAGEN kit). Samples can be tested in triplicate with the MOBIDIAG 
kit. We are currently working to complete these results with additional 
samples, to evaluate the PCR performances for clarithromycin resistance 
detection.
disclosure: Nothing to disclose 
P1921 seLecTIve MIcrOBIOTa TransPLanTaTIOn Induces 
radIaTIOn enTerITIs IMPrOveMenT: a PILOT sTudy
Ding X., Li Q., Li P., Zhang T., Xiang L., Zhang F.
Second Affiliated Hospital of Nanjing Medical University, Medical Center for 
Digestive Disease, Nanjing, China
contact e-Mail address: xding@njmu.edu.cn
Introduction: The intestinal microbiota is implicated in the pathogenesis 
of radiation-induced bowel toxicity. Microbiota transplantation might be a 
therapeutic option for radiation enteritis.
aims & Methods: This study aimed to assess the efficacy and safety of se-
lective microbiota transplantation (SMT) through mid-gut in patients with 
radiation enteritis through a prospective cohort study. Eighteen patients 
with a median age of 56 (IQR, 49.8-63.5) years, were included after in-
formed consent and institutional ethics approval according to registered 
trial (NCT03516461). The prepared 200ml selective microbiota suspension 
(mixed species of cultured bacteria) was infused daily into the distal duo-
denum through the nasojejunal transendoscopic enteral tubing (TET) tube 
for 3 days. Clinical and endoscopic data were collected during the follow-
up. Endoscopic evaluations were assessed using the Vienna Rectoscopy 
Score (VRS). Fecal metatranscriptomes and metagenomes analysis were 
performed to assess associated microbial changes. The urinary metabolic 
profiles of those patients were generated using nuclear magnetic reso-
nance (NMR) spectroscopy.
results: 66.7 (12/18), 66.7% (12/18), 61.1% (11/18) and 44.4% (8/18) pa-
tients responded to SMT [ ≥1 grade reduction in Radiation Therapy Oncol-
ogy Group (RTOG) European Organization for Research and Treatment of 
Cancer (EORTC) Radiation Toxicity Scales] at week 1, 2, 3 and 4 weeks, 
respectively. The stool frequency per day reduced from 5.9 ± 0.7 (mean 
± SE) to 3.4 ± 0.6 four weeks after SMT (p < 0.001). The improvements in 
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quality of life was demonstrated by a decreased European Organization for 
Research and Treatment of Cancer Quality of Life Module for Proctitis-21 
items questionnaire (EORTC QLQ PRT21) score from 56.8 ± 2.0 to 47.8 ± 
3.1 four weeks after SMT (p = 0.001). Patients with VRS ≤ 2 at baseline 
achieved significantly more response than those with VRS ≥ 3 [100 % (5/5) 
vs. 23.1% (3/13), p = 0.007]. SMT was associated with a significantly higher 
response rate in patients with EORTC QLQ PRT21 score ≤ 63 at baseline than 
those > 63 [61.5% (8/13) vs. 0.0 % (0/5), P = 0.029]. Microbiota analysis 
showed that SMT altered the composition greatly. SMT induced significant 
alterations in urinary metabolic profiles. No serious adverse event related 
to SMT occurred during treatment and follow-up.
conclusion: SMT induces clinical and endoscopic improvement in radiation 
enteritis and is associated with distinct microbial and metabolic changes 
that relate to outcome. SMT is a promising novel therapeutic option for 
radiation enteritis.
disclosure: Nothing to disclose 
P1922 a POLIT sTudy Of an uPPer gasTrOInTesTInaL 
MOnITOrIng sysTeM fOr TrackIng uPPer gasTrOInTesTInaL 
BLeedIng
Chuang C.-H.1, Chen C.-C.2, Kuo H.-Y.3, Hong M.-Y.4, Wu J.-H.3, Kang J.-W.3, 
Huang C.-J.3
1National Cheng-Kung University, Department of Internal Medicine, Tainan, 
Taiwan, 2National Cheng Kung University, Medical Device Innovation Center, 
Tainan, Taiwan, 3National Cheng-Kung University Hospital, Tainan, Taiwan, 
4National Cheng-Kung University Hospital, Department of Emergency 
Medicine, Tainan, Taiwan
contact e-Mail address: hannhannhann@yahoo.com.tw
Introduction: Second-look endoscopy would be scheduled, if rebleeding is 
suspected after primary endoscopic hemostasis of upper gastrointestinal 
(UGI) bleeding. However, the routine second-look endoscopy is a high-cost 
intervention and could even increase unnecessary risk. Thus, we aimed to 
develop a novel continuous UGI monitoring system to improve the tracking 
of UGI bleeding.
aims & Methods: The UGI monitoring system consisted of a tiny and thin 
tube camera, a wearable host device, and a mobile display device. The 
tube camera was connected to the host device and then inserted into 
stomach via nasal tunnel. The host device was set to acquire images ev-
ery minute and sent the images to the mobile device, in which an image 
analysis application was installed for rebleeding detection. 
Patients with Rockall scores ≥ 3 were eligible for this study. They were put 
on the UGI monitoring system by the trained medical staff. The monitoring 
period was ≤ 3 days because most of rebleeding occurred within 3 days. 
The comfort level was scaled from 0 to 5 by the patients.
results: Eight patients who had UGI bleeding and received primary endos-
copy hemostasis were included in this study (age 41±83, 6 males, Rockall 
score 3-9) and the trial is still ongoing. From the images, how the con-
tents inside the stomach changed over time was observed. Coffee-ground, 
blood clots, red blood, and food contents were photographed. Up to date, 
the included patient had not rebleeding during the system monitoring. 
However, this system could confirm no active bleeding in stomach 1-4 days 
earlier than observation of melena. Moreover, the comfort level of using 
the UGI monitoring system was less than 2 in average.
conclusion: This UGI monitoring system could confirm no active gastric 
bleeding earlier. It is potential to evaluate various scenarios in the UGI tract 
with an endurable comfort level.
disclosure: Nothing to disclose 
P1923 BLeedIng afTer gasTrIc endOscOPIc suBMucOsaL 
dIssecTIOn and necessITy Of endOscOPIc exaMInaTIOn 
(2nd LOOk) On The fOLLOWIng day
Itoh T.1, Kawauara K.1, Azukisawa S.1, Kamai J.1, Kobayashi R.1, Hamada K.1, 
Okamura H.1,2, Urashima S.1,2, Yamada S.3, Kitakata H.1
1Kanazwa Medical University Dept. of Endoscopy, Gastroenterological 
Endoscopy, Kahoku District, Japan, 2Kanazawa Medical University Himi 
Municipal Hospital, Gastroenterology, Himi, Japan, 3Kanazwa Medical 
University, Pathology and Laboratory Medicine, Kahoku District, Japan
contact e-Mail address: itotohru@kanazawa-med.ac.jp
Introduction: Endoscopic submucosal dissection (ESD) has become the 
standard treatment for early gastric cancer in Japan. Hemorrhage is often 
encountered after ESD, and endoscopic hemostasis is required in some 
cases. Some institutions do not perform upper gastrointestinal endoscopy 
after ESD (hereinafter referred to as 2nd look), and some authors have 
reported that 2nd look on the day after ESD is unnecessary. In our de-
partment, however, exposed blood vessels and blood clots without active 
bleeding in the post-dissection ulcer floor have been recognized in addi-
tion to active bleeding after resection. In addition to active bleeding, we 
consider that exposed and/or observable vessel findings and clots on the 
ulcer floor after resection are important risk factors for hemorrhage. Here, 
we report comparison and examination of the frequency of active bleed-
ing and “ulcer after resection with a risk of bleeding” on the day after ESD 
in relation to their risk factors. We also discuss the necessity of 2nd look 
after ESD.
aims & Methods: In this paper, 2nd look refers to upper gastrointestinal 
endoscopy examination on the day after ESD. We examined 447 cases with 
2nd look retrospectively in patients treated with ESD in our department 
during the period from August 2008 to March 2018. Active bleeding was 
examined in 447 cases. After excluding 51 cases with active bleeding, the 
occurrence of ulcers after resection with a risk of bleeding was examined 
in 396 cases. Patient background and pathological findings were checked 
on electronic medical records, and images and endoscopic findings were 
checked using a device for recording images of endoscopic findings 
(Solemio ENDO; Olympus, Tokyo, Japan).
results: Active bleeding was seen in 51 cases (11.4%). Site of lesion, re-
sected specimen size, and history with/without antithrombotic drug ad-
ministration were found to be factors that significantly determined the 
occurrence of active bleeding. In cases with upper body lesions, hazard 
ratio (HR) was 0.259 (P = 0.0256) with a low risk of bleeding. For speci-
mens resected by ESD exceeding 30 mm in size, HR was 2.736 (P = 0.0019) 
indicating a higher risk of bleeding. This suggested that larger specimens 
are associated with higher risk of bleeding. Patients with a history of anti-
thrombotic drug administration showed an increased risk of active bleed-
ing (HR = 1.957, P = 0.0477). We found 88 cases (22.2%) of “post-dissection 
ulcer floor with a risk of bleeding.” HR was 0.318 (P = 0.0074) for upper 
body lesions. Thus the frequency of “post-dissection ulcer floor with a risk 
of bleeding” was low. Conversely, HR was 1.868 (P = 0.0120) for lesions in 
the antrum with a higher risk of bleeding. HR for specimen length >30 mm 
was 1.982 (P = 0.0060), and the frequency of “post-resection ulcer with a 
risk of bleeding” was high.
conclusion: The results of this study indicated that the frequencies of active 
bleeding after ESD and “ulcer with a risk of bleeding” were higher than 
expected. In addition, their risk factors were elucidated. We believe that 
2nd look is necessary to safely discharge patients.
references: none
disclosure: no any Conflict of Interest 
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P1924 effecTIveness Of The TreaTMenT WITh sOMaTOsTaTIn 
anaLOgues and / Or ThaLIdOMIde fOr InTesTInaL 
angIOdysPLasIas In cLInIcaL PracTIce
Mauriz-Barreiro V.1,2, de la Iglesia-Garcia D.1,2, Baston Rey I.2,3, 
González J.4, Castro A.4, Carroceda S.1, Iglesias-Garcia J.1,2, 
Dominguez-Muñoz J.E.1,2
1University Hospital of Santiago de Compostela, Gastroenterology, Santiago 
de Compostela, Spain, 2Health Research Institute of Santiago de Compostela, 
Santiago de Compostela, Spain, 3University Hospital of Santiago de 
Compostela, Gastroenterology and Hepatology, Santiago de Compostela, 
Spain, 4University Hospital of Santiago de Compostela, Pharmacy, Santiago 
de Compostela, Spain
contact e-Mail address: julio.iglesias.garcia@sergas.es
Introduction: Pharmacological therapy with thalidomide or somatostatin 
analogues is indicated in patients with intestinal angiodysplasias, who did 
not respond to standard endoscopic treatment with argon-plasma coagu-
lation. Previous studies support the efficacy of these therapies, but this has 
not been proven in real clinical practice.
aims & Methods: The aim of this study was to evaluate the effectiveness 
of thalidomide and/or octreotide-LAR in patients with intestinal angiodys-
plasias not responding to standard endoscopic therapy in the daily clinical 
practice.
Methods: A retrospective, single-center, cohort study was designed. Pa-
tients diagnosed with intestinal angiodysplasias between 2012 and 2018 
at the University Hospital of Santiago de Compostela, Spain, who were 
treated with thalidomide and/or octreotide-LAR were included. Hemoglo-
bin levels, transfusion needs (red blood cells units per month), intravenous 
iron, and bleeding episodes were analyzed. Results are shown in percent-
ages, mean and standard deviation, and analyzed by Student-t or U-Mann 
Whitney test.
results: 31 patients were included (19 males, median age 77.3 years). 
25% of the patients suffered from liver cirrhosis, 32% had chronic re-
nal injury, 13% ischemic heart disease, and 25% aortic stenosis. Three 
patients were initially treated with thalidomide 100mg/24h, and 28 with 
octreotide-LAR 20mg/month. Eight patients, who did not respond to 
octreotide-LAR switched to thalidomide. Compared with baseline before 
treatment, hemoglobin levels increased with octreotide-LAR (0.98, 95%CI 
0-1.97, p=0.05). However, needs per month of packed red blood cells 
(0.29, 95%CI -0.60-1.19, p>0.05), intravenous iron (-0.01, 95%CI -0.49-
0.47, p>0.05) and bleeding episodes (-0.03, 95%CI -0.16-0.10, p>0.05) 
did not decrease.
No significant benefit was either observed after thalidomide therapy 
(needs of packed red blood cells per month 1.47, 95%CI -1.77-4.72, p>0.05; 
hemoglobin levels 0.59, 95%CI -0.64-1.82, p>0.05 and bleeding episodes 
per month 0.05, 95%CI -0.29-0.18, p>0.05). There were two mild adverse 
reactions in patients with octreotide-Lar and four with Thalidomide.
conclusion: Effectiveness of pharmacological treatment with octreotide 
analogues or thalidomide of intestinal angiodysplasias refractory to endo-
scopic therapy in clinical practice is questionable. These results have to be 
confirmed in larger multicenter studies.
disclosure: Nothing to disclose 
P1925 aTP-dePendenT POTassIuM channeLs, sOLuBLe 
guanyLyL cycLase and endOgenOus PrOsTagLandIns In 
carBOn MOnOxIde-MedIaTed PrevenTIOn agaInsT OxIdaTIve 
IscheMIa/rePerfusIOn-Induced gasTrIc daMage
Magierowska K.1, Korbut E.1, Bakalarz D.1,2, Wójcik D.1, 
Hubalewska-Mazgaj M.1, Surmiak M.1, Buszewicz G.3, Sliwowski Z.1, 
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1Jagiellonian University Medical College, Department of Physiology, Cracow, 
Poland, 2Institute of Forensic Research, Department of Forensic Toxicology, 
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contact e-Mail address: m.magierowski@uj.edu.pl
Introduction: Carbon monoxide (CO), produced endogenously or released 
from tricarbonyldichlororuthenium (II) dimer (CORM-2) was shown to pro-
tect gastric mucosa against injury caused by NSAIDs or stress. However, 
the role of this gaseous transmitter in prevention of oxidative ischemia/
reperfusion (I/R)-induced gastric damage has not been extensively eluci-
dated. Therefore, we determined the effect of pretreatment with CORM-2 
on gastric lesions formation induced by 30 min of I followed by 3 h of R.
aims & Methods: Thirty minutes before I/R, male Wistar rats were pre-
treated i.g. withvehicle, CORM-2 (1-10 mg/kg) or ZnPP (10 mg/kg) as an 
inhibitor of endogenous CO-producing heme oxygenase (HO) adminis-
tered alone or combined with ODQ (10 mg/kg i.p.), inhibitor of soluble 
guanylyl cyclase (sGC), indomethacin (5 mg/kg), non-selective inhibitor of 
cyclooxygenases (COXs), L-NNA (15 mg/kg), inhibitor of nitric oxide (NO) 
synthase or glibenclamide (10 mg/kg), ATP-dependent potassium chan-
nels (K-ATP) blocker. Gastric lesions area, mucus production and gastric 
blood flow (GBF) were assessed by planimetry, AB/PAS staining and laser 
flowmetry, respectively. Gastric mucosal mRNA and/or proteinexpression 
for HO-1, HO-2 and Nrf-2, but also COX-1, COX-2, iNOS, TNF-a, IL-1b, K-
ATP subunits Sur2 and Kir6.1 and sGC subunits alpha-1 and beta-1 were 
determined by real-time PCR and/or Western blot or IHC. 8-hydroxydeoxy-
guanosine (OHG) level in gastric mucosa as a molecular marker of oxida-
tive DNA damage and PGE2 concentration were determined by ELISA. CO 
content in gastric mucosa was determined by gas chromatography. Serum 
concentration of 11 pro- and anti-inflammatory cytokines and TGFb1-3 was 
determined by Luminex platform.
results: Pretreatment with CORM-2 (5 mg/kg) but not ZnPP increased CO 
content in gastric mucosa, decreased I/R-induced gastric damage, in-
creased GBF, decreased OHG, increased PGE2 content and mRNA expres-
sion of COX-2, iNOS, TNF-a, IL-1bmRNA as compared with vehicle-control. 
CORM-2 maintained physiological mucus production. Glibenclamide and 
L-NNA but not indomethacin or ODQ reversed gastroprotective effects of 
CORM-2. Exposure to I/R decreased gastric mucosal mRNA expression 
for Sur2 and Kir6.1 previously decreased by exposure to I/R. CORM-2 de-
creased blood concentration of 11 cytokines and TGFb3 elevated by I/R.
conclusion: We conclude that CO released from CORM-2 prevented gas-
tric mucosa against oxidative I/R-induced damage by the maintenance of 
gastric microcirculation only in part dependently on sGC activity. These 
gastroprotective and hyperemic effects of CO against I/R-injury involve 
biosynthesis of endogenous NO but not co-activity of COXs. However, CO 
maintained physiological level of protective PGE2 under I/R conditions. 
Since increased bioavailability of CO did not modulated mRNA expression 
for K-ATP subunits and pharmacological blockade of these channels re-
versed protective and hyperemic effect of CORM-2 we conclude that this 
molecule acts via K-ATP activity. CO attenuated I/R-induced inflammatory 
response and DNA oxidation in gastric mucosa and on systemic level con-
firming its strong anti-inflammatory and anti-oxidative properties. [Fund-
ing source: National Science Centre, Poland (UMO-2016/23/N/NZ4/01890)].
disclosure: Nothing to disclose 
P1926 BaLLOOn TaMPOnade In The ManageMenT Of 
uncOnTrOLLed varIceaL haeMOrrhage - a 12 years 
reTrOsPecTIve sTudy
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Introduction: Variceal hemorrhage is a life-threatening emergency and 
a major cause of death. Currently, the use of Sengstaken-blakemore (SB) 
tube is recommended as a temporary measure in uncontrolled variceal 
bleeding when endoscopic therapy fails or is not possible. Even though 
it is recommended, there are no recent studies about the outcomes of 
its use.
aims & Methods: The aim of this study was to evaluate the safety and ef-
ficacy of SB tube placement, as well as the rebleeding rate and associated 
mortality. We also sought to identify associated predictors of hemostasis 
and mortality.
It was done a retrospective analysis of all the patients treated with SB tube 
for uncontrolled variceal hemorrhage at a single tertiary care hospital be-
tween 01/01/2007 and 31/12/2018.
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results: Over a twelve-year period, 34 patients underwent SB tube place-
ment, 26 males, average age of 56 (±13.5) years old, 88% (30/34) had por-
tal hypertension due to cirrhosis with an average Child-Pugh score of 10.6 
(±2.1) and average MELD-Na score of 20.9 (±7.6). 86% of these patients had 
alcohol-related cirrhosis and 50% had active alcohol consumption. 
At the time of the insertion of the SB tube, all the patients were medicated 
with a vasoactive drug and 94% (32/34) had active hemorrhage. Success-
ful initial hemostasis was achieved in 62% (21/34) of the cases, despite 
rebleeding in 43% (9/21). The SB tube use was associated with complica-
tions in 32% of the cases, 8% of them was severe. The overall mortality 
rate within 30 days was 70% and within 1 year was 84%.
Univariate analysis indicated as potential predictors of mortality at 1 year 
the octreotide use (vs terlipressina; p = 0,02), hepatocellular carcinoma 
(p=0,006), and active alcohol consumption (p=0,04). Multivariate analysis 
did not point out any predictor of hemostasis or mortality.
conclusion: SB tube seems to be a beneficial option as a rescue therapy 
for uncontrolled variceal bleeding but it is associated with a high rate of 
complications and bleeding recurrence.
disclosure: Nothing to disclose 
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Introduction: Mallory-Weiss syndrome (MWS) is characterized by super-
ficial non-perforated mucosal laceration, commonly at gastroesophageal 
junction, and is estimated to be the cause of 8% to 15% of upper gastro-
intestinal bleeding of non-varicose origin1,2. The mechanism behind the 
injury is the sudden and repeated increase in intra-abdominal pressure 
caused by nausea, vomiting, hiccups, tension, coughing, abdominal or 
thoracic trauma2. Laceration originates at the gastroesophageal junction 
and may extend proximally into the esophagus or distally into the stom-
ach1. The main predisposing factor is alcoholism, present in 30% to 70% 
of cases2,3. The severity of bleeding appears to be greater in the presence of 
portal hypertension and esophageal varices. Other related causes include 
bulimia nervosa, hyperemesis gravidarum and gastroesophageal reflux 
disease1. In most cases, it has a self-limiting course and does not require 
emergency endoscopy or surgical intervention.
aims & Methods: Characterize the epidemiological profile of the patient in 
a university hospital that presents gastrointestinal bleeding due to MWS, 
from September 2017 to January 2019. A retrospective study was carried 
out with data collection of medical records and the protocol implanted 
in 772 patients of the Digestive Hemorrhage Service. In September 2017, 
this hospital became a unique reference for acute cases of gastrointestinal 
bleeding in Curitiba-PR and metropolitan region. Descriptive and statisti-
cal analysis of the prevalences according to age, sex, need for transfusion, 
death, symptomatology of entry, smoking, alcoholism, medications, co-
morbidities, clinical-surgical management, endoscopic diagnosis, endo-
scopic treatment was made.
results: Of the 772 patients evaluated, 15 (1.9%) presented endoscopic re-
ports confirming MWS, composing the sample. The most prevalent gender 
was male (13 patients) and the most affected age group was between 61-
70 years (26.7%). The median age was 52 years (SD16.5). One man died 
(6.7%), non-related to MWS. Transfusion of red blood cells was necessary 
in 4 patients (26.7%), all male. The most present entry symptom was he-
matemesis with 14 cases (93.3%) and the most common association was 
hematemesis and melena with 4 cases (26.7%). The mean hemoglobin 
level at admission was 11.7 g / dL (5.1 - 16.4). Of the 15 patients, 10 were 
alcoholics, all men, for 27 years on average. As for smoking, 5 people 
smoked and 2 were ex-smokers, accounting for 46.7% of the sample. 
Cirrhosis was observed in only one individual, having the alcoholism as 
the etiology. The continuous medication more associated with bleeding 
was the use of anti-inflammatory drugs with 2 cases (13.3%). The most 
prevalent diagnosed etiology os MWS was alcoholism, corresponding to 8 
cases (53.3%), followed by unidentified causes in 3 patients (20%), acute 
gastroenterocolitis and gastroesophageal reflux disease, each with 2 cases 
(13.3%). At the endoscopy exam, in addition to MWS, 3 patients presented 
with enanthematous gastritis, one with erosive gastritis, one with esopha-
geal varices and another with healing gastric ulcer.
conclusion: The results set the profile of patients with MWS as men, alco-
holics, presenting with hematemesis associated or not with melena and 
median age of 52 years. It is important to recognize this entity in cases of 
upper gastrointestinal bleeding, especially of non-varicose origin in alco-
holic patients.
references: 1. Rawla P, Devasahayam J. Mallory Weiss Syndrome. [Updat-
ed 2019 Mar 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls 
Publishing; 2019 Jan-. Available from: https://www.ncbi.nlm.nih.gov/
books/NBK538190/ 2. Rich K. Overview of Mallory-Weiss syndrome. J Vasc 
Nurs [Internet]. 2018;36(2):91-3. Available from: https://doi.org/10.1016/j.
jvn.2018.04.001 3. Cybułka B. Mallory-Weiss Syndrome based on own ex-
perience-diagnostics and modern principles of management. Pol Prz Chir 
Polish J Surg. 2016;88(2):77-86
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Introduction: Acute upper gastrointestinal haemorrhage secondary to pep-
tic ulcer disease carries a significant mortality risk. The management of 
peptic ulcers with adherent clots (Forrest IIB) remains uncertain. ESGE 
recommends consideration of endoscopic clot removal. We aim to describe 
the demographics and outcomes of patients with adherent clots at a dis-
trict general hospital.
aims & Methods: Data for patients admitted to our Trust and diagnosed 
with a peptic ulcer over the last 3 years was obtained from the coding de-
partment using ICD-10 codes (K25.0, K25.2, K26.0, K26.2, K27.0 and K27.2). 
89 patients that had undergone inpatient endoscopy were identified.
results: 89 patients; female 28 (31.5%), mean age 72.9 (23 - 96). 17 (19.1%) 
patients were taking anticoagulants/antiplatelets (8 warfarin, 4 DOACs, 5 
clopidogrel / ticagrelor). Mean length of stay 12.7 days. 6 (6.7%) patients 
had rebleeds, 2 (2.2%) patients underwent surgery and 6 (6.7%) patients 
died. 
29 (32.6%) patients had adherent clots found at endoscopy. 
Of 29 patients with adherent clots; 3 (10.3%) had documented endoscopic 
removal; 14 (48.3%) had documented not removal and 12 (41.4%) had no 
documentation of adherent clot management. 13 of the 14 adherent clots 
(93%) that were not removed were located in D1. 8 (27.6%) patients with 
an adherent clot received monotherapy. 
  adherent clot (n=29) no adherent clot (n=60) *p value
Indication (haematemesis 
& Melaena), n (%) 15 (51.7) 10 (16.7) 0.0006
size (cm), mean (range) 1.5 (0.5 - 5) 1.1 (0.5 - 3) 0.009
Transfused, n (%) 26 (89.7) 42 (70.0) 0.04
[Table 1. Adherent Clot versus No Adherent Clot - Demographics and ulcer 
outcomes]
conclusion: Patients with adherent clots presented with more severe 
symptoms, had larger ulcers and required more transfusions. Only 10% of 
adherent clots had documentation of endoscopic removal and almost half 
of adherent clots were not removed. Clearer documentation is required for 
future practice. Ambiguous guidelines could be contributing to variability 
in practice and suboptimal management.
disclosure: Nothing to disclose 
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Introduction: With increasing advances and complexity of endoscopic 
therapy, there is an increased risk of post procedure bleeding. Hemospray 
(Cook Medical, North Carolina, USA) is a novel haemostatic powder for GI 
bleeding. The aim of this study is to look at outcomes in patients with up-
per Gastrointestinal bleeds (UGIBs) following endoscopic therapy treated 
with hemospray in 14 centres worldwide.
aims & Methods: Data was prospectively collected on the use of hemo-
spray from specialist centres (Jan’16-September’18). Hemospray was used 
during emergency endoscopy for UGIBs post endoscopic therapy at the 
discretion of the endoscopist as a monotherapy, dual-therapy with stan-
dard haemostatic techniques or rescue therapy once standard methods 
have failed. Haemostasis was defined as the cessation of bleeding within 
5 minutes of the application of hemospray. Rebleeding was defined as a 
sustained drop in Hb (>2g/l), haematemesis or melaena with haemody-
namic instability after the index endoscopy.
results: 59 patients had UGIBs post endoscopic therapy (41 male,18 fe-
male, 34/59 (58%) post Endoscopic mucosal resection (EMR), 5/59 (9%) 
post ESD, 5/59 (9%) post biliary sphincterotomy). The median Blatchford 
score at baseline was 4 (IQR,0-8). The average Rockall score was 6 
(IQR, 5-7).
Haemostasis following the application of hemospray was achieved in 
60/60 (100%) of patients. 14/59 (24%) patients had monotherapy with 
hemospray, 32/59 (54%) had combination therapy and 13/59 (22%) had 
rescue therapy. 2/46 (4%) had a rebleed post hemospray, one was follow-
ing oesophageal EMR and the other post duodenal EMR. There were no 
patients’ deaths within 30 days.
conclusion: Hemospray is effective in achieving immediate hoemostasis 
following endoscopic therapy, with a low rebleed rate and no 30-day mor-
tality.
disclosure: Nothing to disclose 
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Introduction: Acute upper gastrointestinal bleeding is a common condition 
in the emergency unit and has significant associated morbidity and mor-
tality. Worldwide the most common causes of UGIB are nonvariceal, from 
peptic ulcers, Mallory Weiss syndrome, angiodysplesia or malignancy of 
the upper GI tract. ESGE guideline recommends performing early endos-
copy (< 24 hours) after hemodynamic resuscitation. Very early endoscopy 
(< 12 hours) is recommended in patients with high risk clinical features like 
persistent hypotension and tachycardia after volume resuscitation.
aims & Methods: The aim of the study was to evaluate the causes of UGIB, 
assess the time for early endoscopy and the hemostatic techniques used. 
We performed a retrospective study between 1st September 2018 to 31th 
December 2018 and included 182 patients who were admitted in our de-
partment with upper gastrointestinal bleeding.. We divided them into vari-
ceal bleeding (69 patients) and nonvariceal bleeding (113 patients).
results: The mean age in the variceal bleeding lot was 55 years old, the 
youngest being 28 years old and the oldest 79 years old. 8 patients had 
bleeding from gastric varices GOV I and in one case was used injection of 
Glubran and in the other 7 patients band ligation. 61 patients had haemor-
rhage from esophageal varices and band ligation was performed. 
The average time passed from presentation until the performance of the 
therapeutic endoscopy in patients with variceal bleeding was 3 hours and 
55 minutes and the hospitalization period was around 3 days. From 69 
patients with variceal bleeding 7 died, but they were having important 
comorbidities related mainly to advanced cirrhosis ( hepatic cirrhosis Child 
B or C and hepatocarcinoma) .
In the non variceal lot, the average age was 59 years old, the youngest 
being 18 years old and the oldest patient being 90 years old. The most 
common causes were gastric ulcer (30 cases ) or duodenal ulcer (35 cas-
es), followed by 16 patients with Mallory Weiss lesions, 7 with Dieulafoy 
lesions and 6 with bleeding from gastric angiodysplasia. Rare causes of 
UGIB were haemorrhage from vater ampullary cancer, gastric polyps and 
hemosuccus pancreaticus. The therapeutic tools used in UGIB from ulcers 
were injection of epinephrine 1:10.000 in saline, followed by a second he-
mostatic procedure, like electrocoagulation using GoldProbe and applica-
tion of endoscopic hemoclips
In patients with bleeding from Dieulafoy lesions and gastric angiodyspla-
sia we used diluted epinephrine injection followed by electrocoagulation 
with GoldProbe and in Mallory Weiss lesions we frequently used dilute 
adrenaline injection and hemoclips.
The time passed from presentation until we performed the therapeutic 
endoscopy in the nonvariceal group was on average 5 hours, and the du-
ration of hospitalization was on average 4 days. We had 8 deaths, 5 with 
duodenal ulcer and 3 with Dieulafoy lesion, related to cardiovascular co-
morbidities and anticoagulation drugs.
conclusion: Very early endoscopic approachment seems to lowers the 
mortality rate and the duration of hospitalization, especially in patients 
with active bleeding or important comorbidities. From our experience, a 
good patient orientated rapid hemeodynamic echilibration and early en-
doscopy seems to be the best management for the UGIB.
disclosure: I have nothing to disclose. 
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Introduction: Acute haemorrhage from ruptured esophageal varices is 
most probably the most serious consequence of uncontrolled portal hyper-
tension in cirrhotic patients, with a significant mortality. Overall survival 
is improving, due to new therapeutic approaches and improved medical 
care. However, early mortality after an episode of acute variceal bleeding 
remains high.
aims & Methods: The aim of this study was to evaluate the risk factors 
affecting 5-day mortality rate after acute variceal bleeding in unselected 
cirrhotic patients.
537 cirrhotic patients admitted in our department with variceal bleed-
ing were evaluated, 351 men and 186 women, with a mean age of 58.8 
years, during a 7 years period. We divided the group of patients into three 
groups: group A, who died due to severe variceal bleeding (n=32), group 
B, the survivors (n=452), and group C, patients who died from other com-
plications (n=53).
We tried to identify prognostic factors for massive, uncontrollable vari-
ceal hemorrhage by comparing patients’ characteristics among the three 
groups.
results: Total in hospital mortality rate was 15.8% (n=85), with a death 
rate of 5.9% (n=32) due to severe bleeding, while 9.8% of patients died 
from other complications.
There were no significant differences regarding the proportion of grade 3 
EV and grade 2 EV in group A vs. group B vs. group C, nor regarding the 
mean age. The proportion of class Child Pugh class C in group A was sig-
nificantly higher than in group B, but similar to group C. The MELD score 
was significantly higher in group A than in group B, but similar to group 
C. Severe thrombocytopenia (< 50.000/mmc) and haemorrhagic shock at 
admission were significantly more frequent in group A than in group B, 
but similar to group C.
characteristics group a (32p) vs. group B (452p)
group a (32p) vs. group c 
(53p)
EV grade 3 11/32 vs. 195/452 p= NS 11/32 vs. 22/53 p= NS
EV grade 2 20/32 vs. 257/452 p= NS 20/32 vs. 31/53 p= NS
Age 58 y/o vs. 59 y/o p= NS 58 y/o vs. 59 y/o p= NS
Child Pugh Class C 22/32 vs. 151/452 p=0.0006 22/32 vs. 31/53 p= NS
Meld score 24.5 vs. 17.4 p= 0.0005 24.5 vs. 24.8 p= NS
Severe thrombocytopenia 10/32 vs. 76/452   p< 0.0001 10/32 vs. 11/52 p= NS
Haemorrhagic shock 24/32 vs. 12/452    p< 0.0001 24/32 vs. 13/53 p= NS
[Table]
conclusion: Liver failure, severe thrombocytopenia and haemorrhagic 
shock at admission were the risk factors we identified for in hospital 5-day 
mortality rate due to variceal bleeding.
disclosure: Nothing to disclose 
P1932 evaLuaTIOn Of Our In-PaTIenT endOscOPy WOrkLOad 
and MeeTIng naTIOnaL sTandards fOr The ManageMenT Of 
uPPer gasTrOInTesTInaL BLeedIng In a unIversITy hOsPITaL
Samani S.1, Lee H.L.1, Wurm P.1, Ramiah R.D.2
1University Hospitals of Leicester NHS Trust, Gastroenterology, Leicester, 
United Kingdom, 2University Hospitals Leicester, Dept. of Gastroenterology, 
Leicester, United Kingdom
contact e-Mail address: eddysamani@gmail.com
Introduction: The 2015 United Kingdom (UK) National Confidential Enquiry 
into Patient Outcome and Death (NCEPOD) report, ‘Time to get control’ and 
National Institute for Health and Care Excellence (NICE) clinical guideline 
(CG141), England highlighted the need for endoscopy within 24 hours for 
patients presenting with suspected acute upper gastrointestinal bleeding 
(AUGIB). However, endoscopy demand has increased in recent years. We 
set out to evaluate our in-patient endoscopy procedure mix, workload, 
assess the timeliness of endoscopy and intervention rates for patients with 
AUGIB following a revised service arrangement. The updated service offers 
gastroenterology in-reach ward rounds on the acute medical units and 
once daily dedicated emergency inpatient endoscopy list at the University 
Hospitals of Leicester, UK NHS Trust which serves a catchment population 
of 1.1 million.
aims & Methods: Patients referred for inpatient endoscopy from 1st of Janu-
ary to 31st of December 2017 were retrospectively identified via our online 
Integrated Clinical Environment (ICE) referral system, inpatient endoscopy 
procedure books and consultant’s call out time sheets. ICE referrals and 
endoscopy database records were reviewed and cross referenced. Basic 
demographics, indications, number and type of endoscopic procedures 
including intervention rates for AUGIB were analysed. Time to endoscopy 
was defined as time of ICE referral to time of completion of endoscopy 
report. Simple regression analysis and Chi-Square test were used for sta-
tistical analysis.
results: The total number of in-patient endoscopic procedure performed 
was 2033 with a mean number of 169 (1400 OGDs, 585 flexible-sigmoid-
oscopies, and 48 colonoscopies). 745 OGDs were performed for suspected 
AUGIB with a mean number of 61 procedures per month. Median and 
mean time to endoscopy was 5.2 hours (Interquartile Range [IQR] 3-21.9h) 
and 13.1 hours respectively. 84% of OGDs for AUGIB were performed within 
24 hours. Overall intervention rate was 27.2%. The intervention rate was 
lower for procedures done outside of 24 hours compared to procedures 
done within 24 hours (17.6% versus 29.2% p = 0.010). 81.9% of ICE refer-
rals were logged during in hours (9:00 to 17:00) and 18.1% were logged 
out of hours (17:00 to 08:00). We did not find an association between the 
timing of referral with timing of endoscopy (p = 0.912).
conclusion: Despite proactive emergency working arrangements, a large 
proportion of endoscopies for patients with AUGIB were performed out-
side the time frames set by NICE guidelines and the NCEPOD report. Over-
all intervention rate was high but lower in procedures performed outside 
of 24 hours suggesting a degree of triage in utilizing the in-patient en-
doscopy list. To meet the 24 hour standard, an all-day rolling emergency 
endoscopy list maybe needed, a luxury few UK NHS Trusts can afford at 
times of severe constraints on endoscopy services.
disclosure: Nothing to disclose 
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eMergency TerTIary care hOsPITaL: a sIngLe-cenTer cOhOrT 
sTudy
Rinja E., Diaconu I.-G., Sandru V., Nedelcu I.C., Plotogea O.M., 
Hortopan A., Oprita R., Chioncel C., Pestroiu Calescu D., Ilie M., 
Constantinescu G.
Bucharest Clinical Emergency Hospital, Gastroenterology, Bucharest, 
Romania
contact e-Mail address: ecaterina.rinja@gmail.com
Introduction: Upper gastrointestinal bleeding (UGIB) represents the main 
endoscopic emergency worldwide and despite the development of new 
therapeutic methods its treatment can still be very challenging.
aims & Methods: The aim of this paper is to assess the patients with UGIB, 
both variceal and non-variceal who underwent early endoscopic treatment 
(< 12 hours) in a tertiary care emergency hospital. This is a retrospective 
analysis that enrolled patients with UGIB from January 2015 to December 
2018, hospitalized in the Bucharest Clinical Emergency Hospital in Roma-
nia. Both the variceal and non-variceal bleeding were evaluated in terms 
of the type of lesion and the follow-up of the endoscopic treatment: re-
bleeding, admission in Intensive Care Unit (ICU), surgical treatment and 
death.
results: The study included a total of 1677 patients, which were separated 
into two groups, non-variceal bleeding (1066 patients) and variceal bleed-
ing (611 patients). In the non-variceal bleeding group, 32.74% had gastric 
ulcer, 30.86% had duodenal ulcer, 10.22% had Mallory-Weiss lesions, 
7.61% of patients were bleeding from vascular lesions (angiodysplasias 
and Dieulafoy lesions), 6.56% from tumours (oesophagial, gastric and 
968 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
duodenal tumours), 3.29% from esophageal ulcers, 3.19% had endoscopic 
retrograde cholangio-pancreatography (ERCP) post-sphincterotomy bleed-
ing, 3.18% had acute hemorrhagic gastroduodenitis, while smaller per-
centages had acute necrotizing oesophagus (1.03%), post-gastric polypec-
tomy bleeding (0.94%) and arterial fistulas or aneurysms (0.38%). Only 
85.55% required endoscopic treatment and all patients received proton 
pump inhibitors drugs. Rebleeding was assessed in 48 patients (5.26%), 
mostly from gastric ulcers (24 patients), duodenal ulcers (14 patients) 
and ERCP post-sphincterotomy (3 patients). ICU admission was needed 
in 7.42% of total cases. A mortality rate of 12.29% (131 patients deceased) 
was recorded, mostly because of major comorbidities. Emergency surgery 
was needed in 22.92% of the patients with rebleeding, of which 27.27% of 
patients had good outcome and 72.73% of patients had deceased. 
In the variceal bleeding group, from the total of 611 patients receiving en-
doscopic treatment in our unit, 529 had esophageal varices (EV), 49 had 
gastroesophageal varices type 1 (GOV1), 20 had gastroesophageal varices 
type 2 (GOV2) and 13 had isolated gastric varices (IGV). All the patients 
received adequate endoscopic treatment as well as medical treatment (va-
soactive drugs such as terlipressin). The rebleeding rate was of 2.12% and 
was evaluated considering each type of varices: 8 patients with EV, 3 pa-
tients with IGV, 1 patient with GOV1 and 1 patient with GOV2. Sengstaken-
Blakemore tube was necessary in 9 patients (1.47%) and admission in the 
ICU was required in 5% of the patients. We assessed the outcome of these 
patients: 94.44% had a positive outcome and were discharged and 5.56% 
deceased.
conclusion: Our experience as an emergency tertiary care center with UGIB 
emphasizes the importance of early endoscopic approach as a safe and ef-
fective procedure with a high success rate, reducing the need for surgery. 
However, the mortality rate in both variceal and non-variceal bleeding 
remains high, therefore a multidisciplinary management (endoscopists, 
surgeons and anesthesiologists) is still considered the best approach for 
these patients.
disclosure: Nothing to disclose 
P1935 gasTrOInTesTInaL BLeedIng In PaTIenTs On OraL 
anTIcOaguLaTIOn TheraPy: cLInIcaL and deMOgraPhIc 
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Introduction: There is frequent and growing use of medications that pre-
vent abnormal blood clotting, including anticoagulants and antiplatelets¹. 
However, their therapeutic benefits must be balanced against the risks². 
The reported incidence of hemorrhagic complications in patients treated 
with anticoagulated drugs ranges from 12 to 40%³. The commonest site of 
significant bleeding is the gastrointestinal tract.
aims & Methods: The aim of this study was to assess the clinical and de-
mographic characteristics of anticoagulated patients hospitalized with 
gastrointestinal bleeding in a university hospital. A retrospective study 
was carried out with data collection of medical records and the protocol 
implanted in 772 patients of the Digestive Hemorrhage Service. From Sep-
tember 2017 to January 2019, 39 patients with gastrointestinal bleeding 
(GIB) were hospitalized while on oral anticoagulants. The patients were 
categorized according to age, sex, need for transfusion, death, symptom-
atology of entry, alcoholism, medications, comorbidities, endoscopic di-
agnosis, endoscopic treatment. The clinical outcome of these patients was 
compared with those of 591 patients hospitalized in the same time with 
GIB who were not taking anticoagulation or antiplatelets.
results: 39 patients used oral anticoagulants (5%). The most prevalent 
gender was the female (51%). The mean age was 74 years (19-91). Eleven 
patients died (28.3%), mostly men (9). Transfusion of red blood cells was 
necessary in 27 patients (69.2%) and the higher international normalized 
ratio (INR) didn’t increase the number of blood bags or the mortality. The 
most common entry symptoms were hematemesis with 24 cases (61.5%) 
and melena (53.8%). The mean hemoglobin level at admission was 8.8 g 
/ dL (4.1-17.2). Warfarin was the mostly used anticoagulant (50%). Of the 
39 patients, 10 were alcoholics (25.6%), all men. Cirrhosis was observed 
in only one individual, having the alcoholism as its etiology. The most 
frequent comorbidity was systemic arterial hypertension (64%). At endo-
scopic examination, 21 presented mucosal lesions (53.8%), 9 with peptic 
ulcers (23%), 2 with duodenal ulcers, 1 with esophageal ulcer, 2 with gas-
tric varices and one sclerotherapy was needed. We found no significant 
difference between the death rate between anticoagulated (28.3%) and 
non-anticoagulated patients (20.3%; p=0.22).
conclusion: Acute gastrointestinal bleeding is a severe complication in 
patients receiving long-term oral anticoagulant therapy, with high mor-
tality. These patients usually bleed from mucosal disease, a non-varicose 
cause. However, in this study, there was no statistically significant differ-
ence between the death rate between anticoagulated and non-anticoag-
ulated.
references: 1. Pedro Raquel, Sobral Maria Ana. Novos anticoagulan-
tes orais e risco de hemorragia gastrointestinal: uma realidade? Rev 
Port Med Geral Fam [Internet]. 2015 Ago; 31(4 ): 286-288. Available 
from: http://www.scielo.mec.pt/scielo.php?script=sci_arttext&pid=S2182-
51732015000400009&lng=pt. 2. Chang HY, Zhou M, Tang W, Alexander GC, 
Singh S. Risk of gastrointestinal bleeding associated with oral anticoagu-
lants: population based retrospective cohort study. BMJ [Internet]. 2015 Apr 
24;350:h1585. Available from: http://dx.doi.org/10.1136/bmj.h1585 3. Levine 
MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of an-
ticoagulant treatment. Chest. 2001;119(1 Suppl.):108S-21S. Available from: 
https://doi.org/10.1378/chest.119.1_suppl.108S
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Introduction: Upper gastrointestinal bleeding (UGIB), defined as bleed-
ing from lesions in the digestive tract proximal to the Treitz ligament is a 
medical emergency with high mortality rates1. Of the cases of UGIB, 10% 
to 30% have varicose origin, and these varicose veins are present in 50% 
of cirrhotic patients2. Volemic reposition is used as the initial manage-
ment of UGIB and should be more carefully chosen in patients with vari-
cose UGIB, as they have a persistente state of hypervolemic circulation, 
with splanchnic vasodilation and low effective arterial volume, tending 
to arterial hypotension. Formal platelet transfusion indications are bone 
marrow failure or secondary hemorrhagic manifestations treatment3. 
There is no consensus, however, some authors indicate that values above 
50,000 platelets/mm3 are safe for performing invasive procedures3, and 
at least 20,000 platelets/mm3 for performing non-invasive procedures. 
Transfusion, therefore, is only indicated below 50,000 platelets/mm3 in 
invasive procedures and below 20,000 platelets/mm3 in non-invasive 
procedures. There is no indication of prophylactic transfusion in cases 
other than these.
aims & Methods: To characterize the need for platelet transfusion in the cir-
rhotic patient with gastrointestinal bleeding treated in a university hospital 
from September 2017 to January 2019. This is a retrospective study with 
data gathering from the 772 patients of the Digestive Hemorrhage Depart-
ment of the Hospital Universitário Evangélico Mackenzie, Curitiba, Brazil. In 
September 2017, this hospital became a unique reference for acute cases of 
gastrointestinal bleeding in Curitiba. Descriptive and statistical analysis was 
made of the prevalences according to age, sex, need for transfusion, death, 
symptomatology of entry, smoking, alcoholism, comorbidities, clinical-sur-
gical management, endoscopic diagnosis, endoscopic treatment.
results: Of the 772 patients, 12 presented with cirrhosis and were subject 
to platelet transfusion (1.5%), composing the sample 10 men (83.3%) and 
2 women (16.7%). At admission, the average platelet count of these pa-
tients was 98,000/mm3 (15,000-285,000). Only one patient had platelets 
below 20,000/mm3 (8.3%) and other 3 patients had platelets equal to or 
below 50,000/mm3 (33.3%). Therefore, there were 8 platelets transfusions 
without indication (66.6%). The median age was 51.5 years (SD = 8.8). 4 
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patients died (33.3%). The mean hemoglobin level at admission was 7.4 g/
dL (3.7-9.7). Red blood cell transfusion was required in 11 patients (91.6%). 
The most present entry symptom was hematemesis with 11 cases (91.6%) 
and the most common association was hematemesis and melena with 7 
cases (58.3%). Of the 12 patients, 9 were alcoholics (75%), all of them 
cirrhotic. At endoscopic examination, the most prevalent cause of UGIB 
was esophageal varices, corresponding to 10 cases (83.3%), of which 3 
needed elastic ligature, followed by portal hypertensive gastropathy with 
4 patients (33.3%).
conclusion: The profile of the cirrhotic patient with gastrointestinal bleed-
ing and platelet transfusion need is of men with a mean age of 51.5 years, 
alcoholics, presenting with hematemesis. The Department, facing so 
many platelet transfusions without indication, decided to better educate 
residents and attending physicians, as well as to restrict transfusion to 
extreme thrombocytopenia (less than 15,000 platelets/mm3) and to wait 
for the improvement of platelet metrics with drugs, to perform procedures, 
invasive or not.
references: 1. Lourenço, K., & Oliveira, R. (2003). ABORDAGEM DO PACI-
ENTE COM HEMORRAGIA DIGESTIVA ALTA NÃO VARICOSA. Medicina (Ri-
beirao Preto. Online), 36(2/4), 261-265. 2. LUZ, Haroldo Luiz Jordelino da et 
al. FATORES PROGNÓSTICOS E MORTALIDADE EM PACIENTES CIRRÓTICOS 
QUE FORAM INTERNADOS COM HEMORRAGIA DIGESTIVA ALTA VARICOSA 
EM UM HOSPITAL PÚBLICO. Arquivos Catarinenses de Medicina, [S.l.], v. 
46, n. 1, p. 97-106, jul. 2017. ISSN 18064280. Disponível em: 3. Ministério da 
Saúde. Guia para Uso de Hemocomponentes 2010, 1ª Edição.
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Introduction: Dyspepsia is common in the community, causing a substan-
tial impact on quality of life for sufferers as well as financial implications 
for society. The initial management of dyspepsia in primary care is a classi-
cal medical decision-making problem, with a number of competing strat-
egies for the physician to consider. However, there is equipoise between 
some of these, and current guidelines do not agree on which approach 
should be used first-line.
aims & Methods: Our aim was to conduct a network meta-analysis to 
compare the effectiveness of first-line strategies for the management of 
patients with uninvestigated dyspepsia. 
MEDLINE, EMBASE, EMBASE Classic, the Cochrane central register of con-
trolled trials, and clinicaltrials.gov were searched through March 2019 to 
identify randomised controlled trials (RCTs) assessing effectiveness of five 
management strategies (prompt endoscopy, “test and treat”, “test and 
scope”, empirical acid suppression, or symptom-based management) for 
uninvestigated dyspepsia. Trials reporting a dichotomous assessment of 
symptom status at final point of follow-up (≥12 months) were included.
Data were pooled using a random effects model. Effectiveness was re-
ported as a pooled relative risk of remaining symptomatic at final follow-
up, with 95% confidence intervals (CIs) to summarise effectiveness of each 
comparison tested, and ranked according to P-score. We also analysed 
likelihood of patients in each treatment arm requiring endoscopy, dissatis-
faction with management, and rates of upper gastrointestinal cancer.
results: We identified 15 eligible RCTs, containing 6162 patients. Of the five 
strategies, “test and treat” was ranked first, using both an intention-to-
treat and per protocol analysis (P-score 0.79 for both) (Figure), but none 
of the strategies were significantly less effective than “test and treat”, or 
more effective than each other, on direct or indirect comparison. Prompt 
endoscopy ranked second, but performed similarly (P-score 0.71 and 0.69 
on intention-to-treat and per protocol analysis). 
Patients assigned to “test and treat” were significantly less likely to require 
subsequent endoscopy (P-score 0.98), compared with all other strate-
gies on indirect comparison. Dissatisfaction rates were significantly lower 
among patients randomised to prompt endoscopy, compared with “test 
and treat” and empirical acid suppression on indirect comparison. Only 
20 upper gastrointestinal cancers (0.4%) were detected in 11 RCTs report-
ing this endpoint, containing 5028 patients. Detection rates were broadly 
similar between treatment arms.
conclusion: In a network meta-analysis of RCTs, “test and treat” and 
prompt endoscopy performed similarly in terms of effect on symptoms at 
last point of follow-up, but “test and treat” was ranked first, and led to 
significantly fewer endoscopies than all other approaches. This suggests, 
of the five management strategies we studied, “test and treat” is the likely 
to be the most cost-effective.
disclosure: Nothing to disclose 
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Introduction: The epidemiology including the prevalence and risk factors 
of dyspepsia varies in different population. Moreover, functional dyspepsia 
(FD), though is commoner than organic in hospital studies, community 
data, particularly from rural areas, are lacking in Asia due to difficulty in 
performing endoscopy in the community. Hence, we performed a rural 
community study in Bangladesh with the following aims: 
(1) to study the prevalence of uninvestigated dyspepsia (UD), FD and struc-
tured dyspepsia (SD) in the community, 
(2) to evaluate the frequency of H. pylori in FD and peptic ulcer (PU), 
(3) to study its virulence-associated genes (CagA, vacA and specifically the 
vacA allelic variants) among patients with FD as compared to PU, and 
(4) to determine the risk factors for dyspepsia.
aims & Methods: This prospective cross-sectional house-to-house survey 
was undertaken by trained field interviewers among adult population 
(>18-y) in three villages (Charcharia, Churain of Dhaka district and Kharrah 
of Munshiganj district of Bangladesh) using enhanced Asian Rome III 
questionnaire and General Health Questionnaire-28 translated and vali-
dated in Bengali language. Dyspepsia, functional heartburn (FH) and IBS 
were defined by Rome III criteria. 
Dyspeptic subjects were offered an upper gastrointestinal endoscopy in-
cluding tests for H. pylori (rapid urease test, histology and multiplex poly-
merase chain reaction, PCR; infection was diagnosed if PCR or two other 
tests were positive) and its genotyping by PCR for CagA, vacA and specifi-
cally the vacA allelic variants. SD was diagnosed in presence of duodenitis 
or erosions, PU and erosive esophagitis.
results: 3351/3559 subjects responded [(94.15%), mean age 40.41±16.05 
y, female, 1924 (57.4%)]. 547 (16.3%) had UD [female 346 (18%) vs male 
201 (14%); p=0.002)]. 201 (6%), 88 (2.6 %,) and 258 (7.7%) had postpran-
dial distress syndrome (PDS), epigastric pain syndrome (EPS) and PDS-EPS 
overlap, respectively. 
On multivariate analysis increasing age, female gender, being married, 
lower education of less than class V, lower family income, use of non-ste-
roidal anti-inflammatory drugs, history of acute gastroenteritis in last year 
and presence of psychological distress were found as risk factors for UD. 
Of 346 (63.25%) agreeing for endoscopy; 232 (67.05%) and 114 (32.95%) 
had FD and SD [PU 99 (28.61%); EE, 13 (3.76%) and both peptic ulcer and 
EE, 4 (1.16%)] respectively. Of 232 FD subjects, 35 (15%), 73 (31%) and 124 
(54%) had EPS only, PDS only and EPS-PDS overlap, respectively. H pylori 
was positive among 266/342 (78%) dyspeptics [FD, 173 /230 (75.2%) vs SD, 
92/114 (82.1%) (p=0.169)]. H. pylori infected patients with PU had higher 
frequency of Cag A and vac A genotype s1m1 positivity than those with FD 
(p< 0.05). Of the 547 UD subjects, 203 (37%) had FH, 110 (20%) had IBS and 
52 (9.5 %) had both FH and IBS.
970 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
conclusion: 16%, 11% and 5% rural adult population of Bangladesh had 
UD, FD and PU, respectively. About half of the patients with dyspepsia 
had PDS-EPS overlap and 20% had overlap with IBS. About third of the 
subjects with UD had SD, mostly PU. Patients with PU had more virulent H. 
pylori compared to those with FD.
disclosure: Nothing to disclose 
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Introduction: Functional dyspepsia (FD) is a disorder of the brain-gut axis 
characterised by symptoms of abdominal discomfort. Mindfulness-based 
therapies use meditation and relaxation to achieve a state of conscious-
ness, mindfulness, during which one consciously attends to his or her 
moment-to-moment experience. Its efficacy for FD treatment is uncertain.
aims & Methods: To determine the effectiveness of group mindfulness 
based intervention in improving the symptoms and quality of life in pa-
tients with functional dyspepsia. We performed an assessor-blinded ran-
domised treatment-as-usual waitlist controlled trial. Patients who fulfilled 
Rome-3 FD were prospectively recruited from a tertiary care gastroenter-
ology unit in Singapore and randomised to undergo Mindfulness Based 
Cognitive Therapy (MBCT) or Treatment-as-Usual (TAU). Subjects in the 
MBCT arm underwent weekly 2-hour-long standardised MBCT sessions 
for 8 weeks and 1 half-day retreat conducted by 2 accredited psychologists. 
Outcomes were assessed using Short Form Nepean Dyspepsia Index (NDI-
SF) and the EuroQOL VAS scale which were administered pre and post 
treatment by assessors blinded to the treatment assignment. The Primary 
outcome was change in NDI-SF and EuroQoL at end of treatment compared 
to baseline. Ethics Board review was obtained.
results: Fifty three patients were referred and 27 (59.9%) patients were 
recruited over 3 months. Amongst those who did not agree to recruitment, 
10 were not fluent in English, 10 cited time constraints and unsuitability of 
the MBCT schedules, and 6 had no cited reasons. 21 of 27 patients (78%) 
completed the intervention. Of those who withdrew, 5 found difficulty in 
attending the intervention schedule due to time commitments, 1 had dif-
ficulty in following with the intervention instructions, 1 lost interest, and 2 
were unable to complete “homework” due to time constraints. 
There was significant difference in change of NDI-SF at end of treatment 
compared to baseline between MBCT and TAU (mean change: -11.33 (7.53) 
Vs -2.0 (9.16), p< 0.01) (see table) indicating that participants in the MBCT 
arm experienced a greater symptom improvement as compared to those in 
the TAU arm. There was no significant difference in change of EuroQOL VAS 
scale between baseline and post-treatment assessment between groups. 
    Mean Baseline (sd)
Mean end of 
MBcT (sd)
Mean change 
baseline to 
end (sd)
Mean difference 
between MBcT 
and Tau (sd)
p
NDI-SF MBCT 28.14 (9.54) 16.81 (4.75) -11.33 (7.53) 6.19 (8.38) <0.01
  TAU 25.00 (8.72) 23.00 (9.58) -2.0 (9.16)    
EuroQoL-
VAS
MBCT 57.79 (21.43) 61.45 (15.34) 3.66 (18.64) 1.8 (18.45) 0.53
  TAU 62.69 (16.91) 63.25 (19.50) 0.56 (18.25)    
[Table of Results]
conclusion: FD patients who underwent MBCT experienced a greater im-
provement in their symptoms compared to those in the TAU arm. Language 
proficiency and time constraints were the major barriers to attendance of 
MBCT. Modifications to the intervention to address these limitations and 
careful patient selection should be considered in future studies.
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Hepatology, Nijmegen, Netherlands
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Introduction: Digital educational tools hold several advantages over 
non-digital information. Patient engagement in self-management is an 
important application of digital tools. Dyspepsia is a condition primarily 
managed by lifestyle intervention, making patient engagement and edu-
cational motivation essential. Adoption of an educational tool depends on 
its development process and information transfer methods. We provide 
a detailed description of a successful dyspepsia e-learning development 
process.
aims & Methods: We assessed users’ needs by focus groups and inter-
views, followed by scientific validation of information against a systematic 
literature review. Subsequently, we developed the content based on most 
important themes, provided by the focus group participants and current 
literature. All content was organized into chapters and we supplemented 
information with text, videos, and 3D visualizations. The e-learning was 
pilot-tested and adjusted accordingly.
results: We performed a focus group both with dyspeptic patients (n = 
5) and general practitioners (n = 5). Main themes revealed were 1) Reas-
surance; 2) Pathophysiology of dyspepsia; 3) Prevalence, symptoms and 
prognosis of dyspepsia; 4) Lifestyle interventions; 5) Availability and value 
of therapy and diagnostics; 6) Psychosocial factors in dyspepsia, and 7) 
Peers’ experiences. We wrote short text blocks providing information per 
item and added videos of a gastroenterologist, dietician and patient, ex-
plaining gastric function, dietary interventions and patient experiences. 
We created 3D visualizations of dyspepsia prevalence, upper gastrointesti-
nal endoscopy procedure, gastric anatomy, function and mucosal damage, 
and pharmacological mechanisms of acid-reducing drugs.
conclusion: The dyspepsia e-learning is a novel multi-media educational 
tool to assist patients and physicians in management of dyspepsia. This 
tool may be deployed to stimulate patient engagement and improve health 
outcomes. The presented protocol can be used to guide development of 
future e-learnings for dyspepsia, or similar conditions. 
https://elearning-gastroscopiestaging.medify.eu/mdl/index_elearning-
cwz_nl.html
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Introduction: Upper gastro-intestinal (GI) endoscopy is frequently per-
formed in dyspeptic patients. Diagnostic yield is low and clinical implica-
tions are limited. Therefore, dyspeptic patients are exposed to an avoid-
able invasive procedure. Symptom comprehension and lifestyle modifica-
tions potentially reduce patients’ need for upper GI endoscopy.
aims & Methods: Our aim was to study whether education of dyspeptic 
patients by e-learning reduces upper GI endoscopies in patients referred 
for direct-access upper GI endoscopy. We performed a multi-center, ran-
domized, controlled trial in dyspeptic patients aged 18-70 years, referred 
for direct-access upper GI endoscopy. We excluded patients with alarming 
features or family history of upper GI malignancy. We recruited patients 
from four district hospitals in the Netherlands and randomly assigned (1:1 
ratio) patients to receive either e-learning education (intervention) or en-
doscopy (control). Primary outcome was the difference in proportion of 
cancelled upper GI endoscopies at 12 weeks. Secondary outcomes included 
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symptom type and severity (PAGI-SYM), dyspepsia-related quality of life 
(SF-NDI) and health anxiety (SHAI). NCT03205319.
results: We randomized a total of 119 patients (median age 48 yrs [IQR:37-
56], male 40%, Western European ethnicity 90%, use of acid-suppressive 
drugs 74%, previous upper GI endoscopy 24%). There were no baseline 
differences between study groups (intervention n=62; control n=57) with 
respect to symptom type/severity, quality of life and health anxiety. At 12 
weeks, 61% of patients in the intervention group had cancelled endoscopy, 
vs. 14% of controls (RR 0.44 [95% CI 0.31-0.62], p < 0.001). No GI malig-
nancy was detected.
conclusion: E-learning education of dyspeptic patients effectively and 
safely reduces 47% of upper GI endoscopies. Education by e-learning may 
be broadly implemented in clinical practice to improve efficient use of up-
per GI endoscopies.
disclosure: Nothing to disclose 
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Introduction: Opioid-induced constipation (OIC), a common side effect of 
opioids, is due to the activation by opioids of the µ-opioid receptors in the 
enteric nervous system1. Peripherally acting µ-opioid receptor antagonists 
(PAMORAs) can reverse OIC by blocking the peripheral action of opioids in 
the gastrointestinal tract without affecting centrally mediated analgesia2. 
Naldemedine3 is a PAMORA indicated for OIC in adult patients with chronic 
non-cancer pain in the US, in patients with chronic non-cancer pain and 
cancer in Japan and in adult patients who have previously been treated 
with a laxative in EU.
aims & Methods: This study evaluated the in vitro and in vivo pharma-
cological profiles of naldemedine compared with those of naloxone and 
naloxegol.
In vitro binding affinity, antagonistic activity, Schild plot analysis of antag-
onism, and binding kinetics were evaluated for naldemedine, naloxegol, 
and naloxone. In vivo effects of each opioid antagonist on rat small intesti-
nal transit (SIT) as well as withdrawal symptoms in morphine-dependent 
rats were also evaluated.
    naldemedine naloxone naloxegol
Binding affinities/ 
Antagonist activities
µ (nM) 0.34/ 0.50 1.52/ 4.05 5.04/ 38.35
  δ (nM) 0.43/ 0.27 56.90/ 41.74 99.16/ 145.93
  κ (nM) 0.94/ 0.44 2.63/ 18.43 40.78/ 38.51
Shild analysis of 
antagonism
Schild slope 1.42 0.88 0.93
Binding kinetics to 
humanµ-opioid receptor
Kon(nM-1min-1) 0.041 0.350 0.056
  Koff(min-1) 0.023 0.290 0.390
  T1/2(min) 30.78 2.44 1.78
[Summary of in vitro pharmacological profile of naledemedine compared 
with naloxone and naloxegol in human opioid receptors]
results: In vitro, the antagonist activity of naldemedine at human µ, δ or 
k opioid receptors were 0.50, 0.27 or 0.44 nM, respectively. These values 
are more potent compared with those of other compounds. The Schild plot 
analysis indicated that naldemedine antagonized the effect of opioid ago-
nist in a non-competitive manner while other compounds antagonized in 
a competitive manner. In receptor binding kinetics analysis, naldemedine 
showed slower K
on
 and K
off
 profile than other compounds. In vivo, nalde-
medine dose-dependently ameliorated the morphine-induced SIT inhibi-
tion. This effect was not dependent on the dose of morphine between 1 
and 3 mg/kg. On the contrary, the dose-response curve of naloxegol was 
significantly shifted between the doses of morphine. This difference in in-
hibition pattern of naldemedine and naloxegol could be attributed to type 
of antagonism. In morphine-dependent rats, naldemedine caused periph-
eral and central withdrawal symptoms at doses higher than 0.3 and 3 mg/
kg, respectively, while the ED
50
 for preventive effect of constipation was 
0.03 mg/kg. Naldemedine showed slower onset and lower severity of diar-
rhea, which is a peripheral withdrawal symptom, than other compounds 
at each ED
50
 in the SIT model. These differences could be attributed to 
binding kinetics.
conclusion: Naldemedine acted differently with the mu-opioid receptor 
when compared with naloxegol and naloxone as demonstrated by slower 
kinetics and acting as a non-competitive antagonist. These results may 
explain the clinical profile observed in the clinical trials with naldeme-
dine.
references: 1 Bell T, Annunziata K, and Leslie JB (2009) Opioid-induced 
constipation negatively impacts pain management, productivity, and 
health-related quality of life: findings from the National Health and Well-
ness Survey. J Opioid Manag 5:137-44. 2 Streicher JM, Bilsky EJ (2017) Pe-
ripherally Acting µ-Opioid Receptor Antagonists for the Treatment of Opi-
oid-Related Side Effects: Mechanism of Action and Clinical Implications. 
J Pharm Pract. 31:658-669 3 Kanemasa T, Koike K, Arai T, Ono H, Horita 
N, Chiba H, Nakamura A, Morioka Y, Kihara T, Hasegawa M (2019) Phar-
macologic effects of naldemedine, a peripherally acting µ-opioid receptor 
antagonist, in in vitro and in vivo models of opioid-induced constipation. 
Neurogastroenterol Motil. 31:e13563
disclosure: TK: Participated in research design KK: Conducted experiments 
and performed data analysis KT: Conducted experiments and performed 
data analysis TA: Conducted experiments and performed data analysis AN: 
Participated in research design YM: Participated in research design MH: 
Participated in research design 
P1943 effecT Of naLdeMedIne On frequency Of 
sPOnTaneOus BOWeL MOveMenTs and assOcIaTed syMPTOMs
Wild J.1, Hale M.2, Yamada T.3, Ferreira J.C.A.3
1Upstate Clinical Research Associates, Williamsville, United States, 2Gold 
Coast Research LLC, Plantation, United States, 3Shionogi Inc, Florham Park, 
United States
contact e-Mail address: jwild@roadrunner.com
Introduction: Opioid-induced constipation (OIC) is a well-known side ef-
fect of opioid therapy. NAL is a peripherally-acting µ-opioid receptor an-
tagonist approved for the treatment of OIC in patients with chronic non-
cancer pain.
aims & Methods: To assess the effect of naldemedine (NAL) 0.2 mg once 
daily vs placebo (PBO) on the frequency of bowel movements (BMs), spe-
cifically the frequency of spontaneous BMs (SBMs), complete spontaneous 
BMs (CSBMs), SBMs without straining, and SBMs with a Bristol Stool Scale 
(BSS) score of 3 or 4 based on pooled results from the COMPOSE-1 and 
COMPOSE-2 studies during 12 weeks of treatment.
Two randomized, double-blind PBO controlled 12-week studies 
(NCT01965158 and NCT01993940), assessed the effect over time of NAL 0.2 
mg once daily vs PBO in the frequency of SBMs, CSBMs, defined as SBMs 
with a perception of complete evacuation, SBMs without straining, and 
SBMs with a BSS score of 3 or 4 in adult (age 18-80 years) subjects with 
chronic non-cancer pain and OIC. Subjects were required to not be on 
laxatives at screening or to agree to discontinue laxatives upon signing in-
formed consent. The mean changes in the frequency per week from base-
line to each week was compared between NAL and PBO, with a mixed-
effects model repeated measures with opioid dose strata and study as a 
covariate and treatment group, time, time-by-treatment group interaction 
as fixed effects. Safety was assessed based on the incidence of adverse 
events (AEs).
results: In the two studies pooled, 1095 subjects were randomized 1:1 to 
NAL (N=549) or PBO (N=546) for 12 weeks. In all four endpoints, NAL was 
associated with a significantly (P≤0.0001) greater improvement from base-
line at each week relative to PBO, starting at Week 1 and up to Week 12. The 
overall incidence of AEs was generally similar between groups. Treatment 
with NAL was associated with a greater incidence of gastrointestinal AEs 
(abdominal pain, diarrhea, nausea) compared with PBO.
conclusion: Treatment with NAL over 12 weeks compared with placebo 
improved the frequency of bowel movements as well as the signs and 
symptoms of OIC frequently reported with bowel movements including 
perception of incomplete evacuation, need for straining, and hard stools. 
NAL was generally well tolerated.
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disclosure: James Wild received a one-time stipend from Shionogi for per-
forming a review of the clinical study report. Martin Hale was a consultant 
to Shionogi Inc. and received a stipend for review of the clinical study 
report. Tadaaki Yamada is an employee of Shionogi Inc. who may or may 
not own stock options. Juan Camilo Arjona Ferreira was an employee of 
Shionogi Inc. at the time the work was performed. 
P1944 safeTy and effIcacy Of naLdeMedIne fOr The 
TreaTMenT Of OPIOId-Induced cOnsTIPaTIOn In PaTIenTs 
WITh chrOnIc nOn-cancer PaIn receIvIng OPIOId TheraPy: 
a suBgrOuP anaLysIs Of PaTIenTs ≥65 years Of age
Wild J.1, Webster L.2, Yamada T.3, Hale M.4
1Upstate Clinical Research Associates, Williamsville, United States, 2PRA 
Health Sciences, Salt Lake City, United States, 3Shionogi Inc, Florham Park, 
United States, 4Gold Coast Research LLC, Plantation, United States
contact e-Mail address: jwild@roadrunner.com
Introduction: Chronic non-cancer pain (CNCP) is commonly managed with 
opioid analgesics, yet opioid-induced constipation (OIC), one of the most 
common side effects, is under-recognized and undertreated in elderly pa-
tients. Naldemedine (NAL), an oral peripherally acting µ-opioid receptor 
antagonist, is indicated for treatment of OIC in adult patients with CNCP in 
the US and in patients with CNCP and cancer in Japan.
aims & Methods: To evaluate the safety and efficacy of NAL for up to 12 
weeks in a subgroup of elderly patients from an integrated analysis across 
3 global phase 3 trials.
Results up to 12 weeks from 3 double-blind, randomized, placebo (PBO)-
controlled trials were integrated. Patients aged 18-80 years (y) with CNCP 
treated with opioids for ≥3 months and OIC received oral NAL 0.2 mg or 
PBO once daily. Patients aged ≥65 y were included in this subgroup analy-
sis. Safety assessments from the 3 studies up to 12 weeks (safety popu-
lation) included overall incidence of treatment-emergent adverse events 
(TEAEs), TEAEs in Gastrointestinal (GI) Disorders System Organ Class (SOC), 
and TEAEs of opioid withdrawal (OW) or possible OW. Efficacy was based 
on the primary endpoint from the two 12-week studies (intent-to-treat 
population), ie, proportion of responders. A responder was defined as 
having ≥3 spontaneous bowel movements (SBMs)/week and ≥1 SBM/week 
increase from baseline (BL) for ≥9 of 12 weeks and ≥3 of the last 4 weeks.
results: At BL, 14.8% (344/2328) of patients in the safety population were 
≥65 y. The incidence of TEAEs in the NAL vs PBO groups was 45.9% vs 
51.6% (≥65 y) and 47.1% vs 45.6% (overall), and the incidence of GI disor-
der SOC TEAEs in the NAL vs PBO groups was 20.2% vs 16.1% (≥65 y) and 
21.8% vs 13.8% (overall), respectively. The incidence of TEAEs of OW in 
the NAL vs PBO groups was 1.1% vs 0% (≥65 y) and 1.0% vs 0.6% (over-
all), and the incidence of TEAEs of possible OW was 1.1% vs 0.6% (≥65 
y) and 1.6% vs 0.5% (overall), respectively. The proportion of responders 
was higher in the NAL vs PBO groups for patients ≥65 y (51.8% vs 37.6%; 
difference [95% confidence interval]: 12.6 [−2.3, 27.5]) and overall (50.1% 
vs 34.1%; 16.0% [10.2, 21.8]), respectively.
conclusion: This integrated analysis across 3 phase 3 clinical trials up to 12 
weeks confirmed that OIC treatment with NAL 0.2 mg was generally well 
tolerated and effective in patients aged ≥65 y with CNCP. The incidence of 
OW and possible OW was low and similar between NAL and PBO. Safety 
and efficacy results were consistent with the overall population.
disclosure: James Wild received a one-time stipend from Shionogi for per-
forming a review of the clinical study report. Lynn Webster was a consul-
tant and received travel reimbursement from Shionogi Inc. Tadaaki Yama-
da is an employee of Shionogi Inc. who may or may not own stock options. 
Martin Hale was a consultant to Shionogi Inc. and received a stipend for 
review of the clinical study report. 
P1945 safeTy Of naLdeMedIne fOr The TreaTMenT Of 
OPIOId-Induced cOnsTIPaTIOn In suBjecTs WITh chrOnIc 
nOn-cancer PaIn receIvIng OPIOId TheraPy: resuLTs Of 
Three gLOBaL Phase 3 cLInIcaL TrIaLs
Webster L.1, Magazine H.I.2, Yamada T.2
1PRA Health Sciences, Salt Lake City, United States, 2Shionogi Inc, Florham 
Park, United States
contact e-Mail address: lrwebstermd@gmail.com
Introduction: Opioid-induced constipation (OIC) is a common side effect 
of opioids in the treatment of chronic non-cancer pain (CNCP). Effective 
treatment of OIC can be impacted by how particular treatments are tol-
erated. Nalemedine (NAL), an oral, peripherally acting µ-opioid recep-
tor antagonist, is approved for the treatment of OIC in adult patients with 
CNCP in the US.
aims & Methods: To evaluate the safety and tolerability of NAL from inte-
grated analysis across three global phase 3 trials up to 12 weeks. 
Results from three phase 3, double-blind, randomized, placebo (PBO)-
controlled trials were integrated to evaluate the safety and tolerability of 
NAL up to 12 weeks. Subjects 18 to 80 years old, with CNCP and OIC, tak-
ing opioids for ≥3 months, received either NAL 0.2 mg (N=1163) or PBO 
(N=1165) taken orally once daily with or without food. Tolerability and ad-
verse events, including potential opioid withdrawal (OW) were analyzed.
results: The majority of subjects completed the trial (NAL, 88.7%, PBO, 
88.4%) and the proportion that discontinued was similar across treatment 
groups. The duration of treatment was similar across treatment groups 
with a mean exposure of 76.6 and 77.2 days in the NAL and PBO groups 
respectively, approaching the maximal possible exposure of 84 days for the 
12-weeks of study. Adverse Drug Reactions were reported more frequently 
in the NAL group compared with PBO across the studies and in the pooled 
population (NAL, 20.1%, PBO, 13.6%, 95% CI of difference: 3.4, 9.5). The 
assessment of summary measures of Treatment Emergent Adverse Events 
(TEAEs) demonstrated that the overall incidence was similar between 
groups in all studies and associated primarily with the gastrointestinal 
system. TEAEs reported for ≥1% of subjects in at least one treatment group 
and at a higher incidence in the NAL group compared to PBO are shown in 
Table 1. TEAEs with ≥ 1% difference between the NAL and PBO groups were 
limited to abdominal pain, diarrhea, and nausea. In general, TEAEs were 
mild to moderate in severity and short in duration. The majority of reports 
of diarrhea occurred early in the study, reports of abdominal pain occurred 
early and only once, and nausea generally occurred early but with reports 
throughout the study. The incidence of OW was low in the NAL and PBO 
groups (NAL, 1.0%, PBO, 0.6%).
conclusion: An integrated analysis across three Phase 3 trials demonstrat-
ed that treatment of OIC with NAL in subjects with CNCP was well tolerated 
with the majority of TEAEs occurring early, of short duration, mild to mod-
erate in nature and generally limited to the gastrointestinal system. Fur-
thermore, the incidence of OW was low and similar between NAL and PBO.
Treatment emergent adverse events naldemedine 0.2 mg (%) Placebo (%)
Diarrhea 7.7 2.4
Abdominal Pain 6.4 1.9
Nausea 5.3 3.3
Abdominal Pain - Upper 2.7 1.5
Back Pain 2.7 2.2
Headache 2.2 2.1
Vomiting 2.3 1.4
Nasopharyngitis 1.8 1.6
Abdominal Distension 1.7 1.6
Hyperhydrosis 1.5 0.7
Arthralgia 1.5 1.2
Viral Gastroenteritis 1.4 0.6
Influenza 1.1 0.9
Drug Withdrawal Syndrome 1.0 0.6
Bronchitis 1.0 0.9
[Treatment Emergent Adverse Events reported for ≥1% of subjects]
disclosure: Lynn Webster was a consultant and received travel reimburse-
ment from Shionogi Inc. Harold I. Magazine is an employee of Shionogi 
Inc. Tadaaki Yamada is an employee of Shionogi Inc. who may or may not 
own stock options. 
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    systemic sclerosis (n=55)
amyloidosis 
(n=27)
Paraneoplastic syndromes 
(n=18)
Sex Male, Female 29.1%(n=16), 70.9%(n=39) 74%(n=20), 26%(n=7) 55.6%(n=10), 44.4%(n=8)
Age at pseudo-obstruction   52.8(12.1) 60(13.5) 52.6(20.2)
Clinical features
Bloating, Distension, Pain, Nausea, 
Vomiting, Constipation, Diarrhea, 
>5%weight loss
82.7%(n=52), 69.2%(n=52), 
71.2%(n=52), 82.7%(n=52), 
73.1%(n=52), 51.9%(n=52), 
67.3%(n=52), 77.6%(n=49)
80.8%(n=26), 73.0%(n=26), 
53.8%(n=26), 61.5%(n=26), 
46.2%(n=26), 30.8%(n=26), 
80.8%(n=26), 30.8%(n=26)
72.2%(n=18), 72.2%(n=18), 
72.2%(n=18), 61.1%(n=18), 
50%(n=18), 44.4%(n=18), 
27.8%(n=18), 11.1%(n=18)
Diameter of dilated small bowel in cm (SD) 
(n=no. of dilated bowels/total no. of observations)
Duodenum, Jejunum, Ileum
4.4(1.6)(n=46/47), 4.5(1.6)
(n=44/47), 4.5(1.7)(n=42/47)
3.6(1.2)(n=13/25), 4.0(1.2)
(n=13/25), 4.0(1.1)(n=12/25)
3.7(0.8)(n=9/18), 4.4(1.3)
(n=9/18), 4.2(0.9)(n=7/18)
Diameter of dilated large bowel in cm (SD) 
(n=no. of dilated bowels/total no. of observations)
Caecum, Ascending colon, 
Transverse colon, Descending colon, 
Sigmoid colon
7.3(2.1)(n=8/47) 6.5(3.1)(n=8/47) 
7.0(3.1)(n=7/47) 4.3(0.9)(n=4/47) 
5.2(1)(n=4/35)
8.1(4)(n=13/25) 6.6(3)(n=13/25) 
8.7(4.8)(n=12/25) 13.3(5.5)
(n=4/25) 5.1(n=1/25)
7.8(2.5)(n=9/18) 6.5(1.1)
(n=9/18) 7.6(2.8)(n=9/18) 
6.5(2.8)(n=5/18) 4.9(n=1/18)
Gastric emptying, % 1 hr, 2 hrs, 4 hrs
24%(23%), 45%(32%), 
71%(29%)
25%(29%), 46%(34%), 
70%(28%)
27%(12%), 53%(17%), 
84%(17%)
Small bowel transit, colonic filling 6 hrs 28%(34%) 16%(12%) 35%(21%)
Colonic transit, geometric center, GC 4 hrs, 24 hrs, 48 hrs 0.4(0.8), 1.7(1.3), 1.8(1.6) 0.10(0.1), 0.57(0.7), 0.95 (0.5) 0.2(0.2), 2.1(0.4), 2.7 (0.6)
Manometry findings  
Total 8: 7 were abnormal (5 
myopathic type, 1 neuropathic, 
1 both)
Only 1 finding is available 
which is abnormal 
(neuropathic type)
Total 5: 4 were abnormal (3 
neuropathic, 1 mechanical)
[P1946 Table 1]
P1946 cLInIcaL, IMagIng and PhysIOLOgIcaL 
characTerIsTIcs Of chrOnIc InTesTInaL PseudO-OBsTrucTIOn 
In sysTeMIc scLerOsIs, aMyLOIdOsIs and ParaneOPLasTIc 
syndrOMes: a TerTIary care cenTer exPerIence
Pamarthy R.1, Breen-Lyles M.1, Sundt W.1, Makol A.2, Grover M.1
1Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United 
States, 2Mayo Clinic, Division of Rheumatology, Rochester, United States
contact e-Mail address: grover.madhusudan@mayo.edu
Introduction: Chronic intestinal pseudo-obstruction (CIPO) is a rare dis-
abling disorder characterized by a severe impairment of intestinal motil-
ity, mimicking mechanical obstruction in the absence of an obstructing 
luminal lesion.
aims & Methods: To describe the clinical correlates, imaging findings, 
and physiological studies (scintigraphic transit and manometry) in pseu-
do-obstruction associated with systemic sclerosis (SSc), amyloidosis and 
paraneoplastic syndromes evaluated at a single large tertiary referral cen-
ter. A retrospective cohort of patients with intestinal pseudo-obstruction 
associated with SSc, amyloidosis or paraneoplastic syndromes treated at 
our institution between Jan 1, 2008-Aug 1, 2018 was assembled. Subjects 
with an alternative luminal or systemic etiology for bowel dilatation were 
excluded. Demographics, clinical characteristics, autoimmune serologies, 
imaging, physiological testing and biopsy results were abstracted from 
electronic medical records using a standardized data abstraction form.
results: We identified 100 cases of pseudo-obstruction {mean age 58 y, 
54% female, 86% Caucasian}; 55 associated with SSc, 27 with amyloidosis 
and 18 with paraneoplastic syndromes. The clinical features, radiological 
and physiological study findings were as listed in the table below. Female 
preponderance was seen in SSc, in comparison to male dominance in the 
other two groups. The most common symptom was abdominal bloating in 
all 3 groups. Vomiting and weight loss were more common in SSc com-
pared to the other two groups. Diarrhea was less common in paraneo-
plastic syndromes compared to the other two groups. Only small bowel 
dilation was seen in 70%, 32% & 44% of patients in SSc, amyloidosis and 
paraneoplastic, respectively. Only large bowel dilation was seen in 44% & 
44% of patients in amyloidosis and paraneoplastic, respectively. Remain-
ing had both small and large bowel dilations. 5/8 were myopathic in SSc 
group and 3/5 were neuropathic in paraneoplastic group on gastroduode-
nal manometry.
conclusion: Small bowel is more commonly involved than large bowel 
both on imaging and transit studies in SSc patients, whereas both small 
and large bowel showed equal involvement in the other 2 groups. Myo-
pathic involvement was more common in SSc, whereas neuropathic in-
volvement was more common in paraneoplastic syndromes.
disclosure: Nothing to disclose 
P1947 ManOMeTry daTa Of The LOWer esOPhageaL 
sPhIncTer LInearLy cOrreLaTe WITh cLInIcaL severITy 
In TyPe I and II achaLasIa
Bancila I.1, Dimitriu A.2, Iacob R.3, Gheorghe C.1
1Fundeni Clinical Institute, Gastroenteroloy and Hepatology, Bucharest, 
Romania, 2Fundeni Clinical Institute, Gastroenterology - Endoscopy, 
Bucharest, Romania, 3Fundeni Clinical Institute, Bucharest, Romania
contact e-Mail address: ibancila@yahoo.com
Introduction: Achalasia is a very heterogeneous disease, with no obvious 
correlation between symptom duration, symptom severity, radiology and 
manometric data. The aim of our study was to investigate possible cor-
relations between symptom severity (Eckardt score) and manometric data.
aims & Methods: We analysed a cohort of 61 consecutive patients with 
achalasia, diagnosed according to the Chicago classification v 3.0; 41 pa-
tients had achalasia type II, 17 had type I and only 3 patients had achalasia 
type III. Due to the low number of type III achalasia patients we included 
in the analysis only patients with type I and II. The patients were divided 
according to the Eckardt score in two groups, with a score ≤ 6 and with a 
score > 6 (representing clinically severe achalasia). The manometric data 
of the two groups were compared using Mann-Whitney U-testand student 
t-test and multivariate analysis. A p < 0.05 was considered significant.
results: All the manometric variables of the esophagogastric junction [LES 
resting (LESP) and residual (LESRP) pressure and integrated relaxation 
pressure (IRP)] showed differences between the two groups, in the sense 
of higher values  corresponding to the Eckardt score > 6 (p = 0.029 for LESP, 
p = 0.0009 for LESRP, p = 0.003 for IRP). The univariate analysis showed 
linear correlations between IRP (r² = 0,17; p = 0,004), LESRP (r² = 0,26; p = 
0,0004), LESP (r² = 0,08; p = 0,048) and the Eckardt score. The multivariate 
analysis of the correlations between the Eckardt score and the manometric 
variables at the level of the LES was done by multiple regression and found 
that LES resting pressure is not an independent predictor for the sever-
ity of the Eckardt score (regression coefficient -0.03, p = 0.08), while IRP 
(regression coefficient 0.04; p = 0.0004) and LESRP (regression coefficient 
0.09; p = 0.002) are independent predictors of the Eckardt score. The distal 
contractility integral showed no significant differences between the two 
groups (p = 0.97).
conclusion: Our resuts have shown that in type I and II achalasia there is 
a linear correlation between the degree of incompleteness of LES relax-
ation and the clinical severity measured by the Eckardt score. These results 
validate the Eckardt score as a sensitive tool in determining the severity 
of achalasia before treatment and underline that the main determinant 
of symptoms in achalasia is the absence of relaxation of the LES, with a 
superior pathophysiological importance compared to that of aperistalsis.
disclosure: Nothing to disclose 
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P1948 deLayed esOPhagO-gasTrIc juncTIOn reLaxaTIOn 
In PaTIenTs WITh jackhaMMer esOPhagus suggesTs ThaT 
The hyPercOnTracTILe PerIsTaLsIs May Be a cOMPensaTOry 
MechanIsM
Valdovinos Garcia L.R.1,2, Horsley-Silva J.1, Crowell M.D.3, 
Valdovinos Díaz M.A.4, Vela M.F.5
1Mayo Clinic, Gastroenterology and Hepatology, Scottsdale, United States, 
2Instituto Nacional de Ciencias Medicas y Nutricion ‘Salvador Zubiran’, 
Gastroenterología, Mexico City, Mexico, 3Mayo Clinic Arizona, Scottdale, 
United States, 4INNSZ, Gastroenterology, Mexico City, Mexico, 5Mayo Clinic, 
Gastroenterology and Hepatology, Phoenix, United States
contact e-Mail address: drprapul@gmail.com
Introduction: Jackhammer esophagus (JE) is a major disorder of esopha-
geal motility, characterized by hypercontractile peristalsis, diagnosed by 
high resolution manometry (HRM) showing ≥ 20% swallows with in-
creased contractile vigor (distal contractile integral (DCI) > 8000 mmHg/s/
cm). We hypothesize that the hypercontractile peristalsis in JE could be a 
compensatory mechanism for impaired EGJ relaxation, which even when 
integrated relaxation pressure (IRP) is normal (< 15 mmHg) may be ex-
pressed by a delayed onset of relaxation.
aims & Methods: Our aim was to assess and compare time to onset of EGJ 
relaxation in JE patients with normal IRP, “control” patients (presenting for 
evaluation of esophageal symptoms) with normal HRM, and asymptomatic 
healthy volunteers. 
We evaluated time to onset of EGJ relaxation in 44 patients (24 with JE, 
20 with normal HRM) who presented to our motility lab for evaluation of 
esophageal symptoms, and in 21 asymptomatic healthy volunteers who 
underwent HRM. Demographic characteristics and validated esophageal 
questionnaires (GERDQ, BEDQ, Eckardt) were collected for all subjects. 
HRM was performed with a solid-state catheter with 36 pressure sensors; 
ten 5-ml liquid swallows administered, Chicago Classification version 3.0 
used to diagnose JE and normal esophageal motility. Time to onset of EGJ 
relaxation after swallow initiation was measured in seconds, from the 
time of upper esophageal sphincter opening to EGJ opening. EGJ opening 
was determined at an isobaric contour of 23 mmHg, based on analysis in 
the healthy volunteers showing persistent EGJ effacement at this value in 
100% of the volunteers. Median times to onset of relaxation for the study 
groups were compared by Wilcoxon rank sum test.
results: Demographics and questionnaire scores are shown in Table 1; pa-
tients were older and had higher scores compared to healthy volunteers. 
HRM metrics were different among the study groups with the exception of 
DL (Table 1). Median times to onset of relaxation after swallow initiation 
are shown in figure 1. There was no significant difference in median time 
to onset of relaxation for healthy volunteers compared to patient controls 
with normal HRM (0.20 s versus 0.90 s, p = 0.149). Median time to onset 
of relaxation was significantly longer in JE patients compared to healthy 
volunteers and patient controls (3.30s vs 0.20 s vs 0.90 s, p=0.001).
  healthy volunteers control patients with normal hrM
jackhammer 
esophagus p
Age 35 (28 - 41) 55 (40 - 67) 64.5 (59.5 - 71) 0.001
BMI 24.34 (23.01 - 28.08) 25.40 (21.75 - 29.17) 27.26 (24.36 - 29.57) 0.543
BEDQ 0 ( 0 - 0) 0 (0 - 4) 8 (0.5 - 17) 0.001
GERDQ 0 (0 - 0) 7.50 (1.50 - 15.50) 10 (4 - 18.5) 0.001
Eckardt 0 (0 - 0) 2.5 (1 - 3.5) 2 (2 - 3.5) 0.001
IRP 8 (3.30 - 13.30) 4.95 (4.95 - 6.95) 9.10 (5.85 - 13.70) 0.044
DCI 1081 (568 - 1676) 1635 (1409 - 2128) 8635 (7143 - 11370) 0.001
DL 6.50 (5.60 - 7.30) 6.35 (5.75 - 7) 6.35 (5.80 - 7.65) 0.779
EGJ 22.4 (14.5 - 27.9) 23 (21.75 - 29.15) 36.95 (29.05 - 52.10) 0.001
Seconds 0.20 (0 - 3.30) 0.90 (0.30 - 2.50) 3.30 (2.80 - 5.30) 0.001
[Table 1]
conclusion: Patients with Jackhammer esophagus and normal EGJ relax-
ation by IRP have significantly delayed onset of EGJ relaxation compared 
to healthy subjects and control patients with normal HRM. These findings 
suggest that hypercontractile peristalsis in these JE patients could be a 
compensatory mechanism to overcome outflow obstruction manifested as 
delayed EGJ relaxation. Therefore, if our findings are confirmed, therapies 
to address impaired EGJ relaxation could be considered for these patients.
disclosure: Nothing to disclose 
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cOnTracTILe Index In The dIagnOsIs Of egj OuTLeT 
OBsTrucTIOn
Wang K.1, Xu Z.2, Ge Y.2, Xia Z.-W.2, Duan L.-P.2
1Peking University Third Hospital, Department of Gastroenterology, Beijing, 
China, 2Peking University Third Hospital, Beijing, China
contact e-Mail address: wangkun55555@sina.com
Introduction: The diagnosis of EGJ outlet obstruction (EGJOO) is mainly 
based the high 4 second integrated relaxation pressure (IRP4s) with peri-
staltic contraction during wet swallows. In some situations, the IRP4s was 
hard to get because patients couldn’t well accomplish the wet swallows. 
EGJ contractile index (EGJCI) is a newly defined metric to reflect the func-
tion of EGJ in resting state.
aims & Methods: The aims of this study were to analyze the values of EGJCI 
in the diagnosis of EGJOO. 
One hundred and seven EGJOO patients and 103 non-EGJOO subjects were 
enrolled in this study. All subjects completed the CRF questionnaire, blood 
tests, gastroendoscopy and HRM. The values of EGJCI were compared be-
tween the two groups. The correlations between EGJCI, LES rest pressure 
and IRP4s were analyzed respectively and furtherly the AUC value of EGJCI 
in diagnosing EGJOO was analyzed by ROC curve.
results: There was significant difference of the EGJCI values between the 
EGJOO group and the non-EGJOO subjects (34.85±2.95 vs. 14.42±1.38, P< 
0.001). Among these 210 subjects, significant positive correlation between 
ECJCI and IRP4s was found (r=0.574, P< 0.001) while no significant correla-
tion was found between IRP4s and LES rest pressure (r=0.107, p=0.085). 
Further analysis showed the AUC of EGJCI was 0.778. And the cutoff value 
of EGJCI was 14.02 to differentiate the EGJOO and non EGJOO with sensitiv-
ity of 0.804 and specificity of 0.66.
conclusion: EGJCI is an effective metric to represent the EGJ function of 
both resting state and the swallowing state. When the cutoff was 14.02, 
EGJCI can help to differentiate the EGJOO patients from non-EGJOO subjects 
with a high sensitivity.
disclosure: Nothing to disclose 
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Introduction: Gold standard for diagnosis of gastroparesis is gastric emp-
tying scintigraphy. Unfortunately, the association between symptoms and 
results of scintigraphy is poor. The Motilis 3D-Transit system allows mini-
mally invasive and completely ambulatory description of transit patterns 
throughout the whole gastrointestinal tract.
aims & Methods: The aim was to establish normative data for gastric emp-
tying time and contractility patterns assessed with the 3D-Transit system 
and determine if gastric emptying time and contractility patterns were af-
fected by age, BMI, gender or the content of the test meal.
3D transit recordings from 130 healthy were reanalysed using newly de-
veloped software.
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results: The median gastric emptying time was 2.7hours (range 0.1-21). In 
90% the capsule passed the pylorus within the fasting period of 6 hours 
after ingestion. The median contraction frequency in the stomach was 
3.1 contractions pr. Minute (range 2.6-3.9). The frequency was highest in 
women and increased with age (p< 0.05). The median amplitudes was 
35°(range 4-85) based on rotation of the capsule and 11mm (range 6-31) 
based on capsule position. The amplitude based on rotation higher in 
women and decreased with increasing BMI (p< 0.05). The amplitude was 
higher in women, increased with the total amount of calories in the test 
meal and decreased with increasing BMI and age (p< 0.05). We did not 
find any systematical day-to-day variation (p>0.05). Inter-rater variability 
was minimal.
conclusion: The 3D-Transit is a safe, minimally invasive, radiation free and 
ambulatory system for assessment of GE. Vi have established normative 
data on gastric emptying and motility. In future studies with 3D-transit, 
gender, age, BMI should be matched and the test meal should also be 
standardized.
disclosure: Schlageter V is co-owner of Motilis Medica SA and has been 
technical partner in terms of improving and creating new system software 
but had no influence on the study itself. Other authors have no competing 
interests. 
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Introduction: Esophagogastric junction outflow obstruction (EGJOO) is a 
high-resolution manometry (HRM) derived diagnosis with unclear clini-
cal implications; some require invasive therapy similar to achalasia, while 
others are of little significance. We hypothesized that adjunctive testing 
during HRM (free drinking and solids) would help determine EGJOO that is 
relevant and warrants therapy.
aims & Methods: Between July 2015 and December 2018, all those with 
EGJOO on HRM at a tertiary center in London were assessed. HRM was 
performed with ten 5mL water swallows followed routinely by a rapid 
drink challenge (RDC; 200mL water drunk freely) and then solid swal-
lows (either five 1cm3 buttered bread or 200g rice). EGJOO was defined as 
raised integrated relaxation pressure (IRP) during 5mL swallows (median 
IRP >15mmHg), RDC (IRP>8mmHg) and/or solid swallows (IRP>25mmHg 
in at least 2 swallows) with preserved peristalsis.1 EGJOO was divided into 
Functional or Secondary (anatomic/mucosal disorder). Eckardt symptom 
score, stasis on barium swallow, presence of peristaltic dysfunction and 
therapeutic outcome were assessed.
results: From a total of 1705 HRM studies performed, 78 subjects (4.6%) 
were identified as having EGJOO (median age 55y; 29 males). Dysphagia 
was the primary symptom in 54 (69%). Hiatus hernia >2cm was present in 
30 (38%). Fifty-four (70%) had functional EGJOO, of whom 19 were opioid 
users. 17 had Secondary etiologies; post-fundoplication (N=7), crural dia-
phragm impingement within a hernia (N=3), stricture (N=3) and eosino-
philic esophagitis (N=4). Secondary EGJOO had a significantly lower mean 
IRP during single water swallows compared to functional EGJOO (12.1 vs 
18.2mmHg, P< 0.01). 
In 26 patients (31%), raised IRP was evident only with RDC or solids 
and not with 5mL water; this occurred in a larger proportion of Second-
ary compared to Functional EGJOO subjects (65% vs. 25% respectively; 
P=0.003). 7 received endoscopic therapy with significant improvement in 
median Eckardt score (6 pre and 2 post-therapy; P=0.02). On the other 
hand, 13 (17%) with raised IRP during 5mL water swallows had normal IRP 
with RDC/solids, 11 of whom had no concomitant peristaltic abnormalities 
or holdup of barium at the EGJ and did not require any form of therapy.
Fifty-two subjects (69%) had normal esophageal body motility, while 24 
(31%) exhibited hypertensive, fragmented or ineffective patterns with any 
swallow modality. Of the 55 who had subsequent barium studies, patients 
with peristaltic abnormalities exhibited holdup of contrast significantly 
more often than those with normal peristalsis (42% vs. 16% respectively; 
P=0.02).
19 (35%) of Functional EGJOO patients had endoscopic therapy (7 botuli-
num toxin, 13 pneumatic dilatation and 1 per-oral endoscopic myotomy) 
leading to a reduction in mean Eckardt score from 5.9 to 1.0 at a minimum 
of 3 months post-therapy (P<0.0001). Of the Secondary EGJOO subjects, 5 
(29%) received endoscopic therapy: 2 balloon or Savary-Gilliard dilatation 
(mucosal stricture) and 3 pneumatic dilatation (tight fundoplication). This 
led to a reduction in mean Eckardt score from 6.2 to 3.0 at a minimum of 
3 months post-therapy (P=0.03).
conclusion: The addition of adjunctive testing to the HRM protocol (RDC/
solids) increases the likelihood of identifying clinically relevant EGJOO, by 
increasing both sensitivity and specificity of its diagnosis. These findings, 
along with abnormalities in esophageal motor pattern during RDC and 
solid swallows as a further discriminating factor may assist in better de-
termining who might benefit from therapy.
references: 1. Hollenstein M, Thwaites P, Bütikofer S, Heinrich H, Sauter 
M, Ulmer I, Pohl D, Ang D, Eberli D, Schwizer W, Fried M, Distler O, Fox 
M, Misselwitz B. Pharyngeal swallowing and oesophageal motility during 
a solid meal test: a prospective study in healthy volunteers and patients 
with major motility disorders. Lancet Gastroenterology & Hepatology 2017; 
2(9):644-653
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Introduction: Gastroparesis (GP) is a chronic debilitating condition. Cur-
rent pylorus-targeted procedures are either invasive or have questionable 
efficacy. Gastric per-oral pyloromyotomy (G-POEM) has been proposed as 
a minimally invasive intervention for refractory GP.
aims & Methods: We performed a systematic review and pooled analysis 
to evaluate the efficacy and safety of G-POEM for GP. 
Electronic databases (Medline, Scopus, EMBASE) were searched up to Jan-
uary 2019. Only studies including patients who underwent G-POEM for GP 
were eligible. The primary outcome of interest was the technical success 
rate. Secondary outcomes included the mean procedural time, the rate of 
clinical success and the rate of adverse events, namely intra- and post- 
procedural bleeding, perforations and strictures. The pre- and post- pro-
cedural Gastroparesis Cardinal Symptom Index (GCSI) scores and results 
of Gastric Emptying Scintigraphy (GES), if provided, were also assessed. 
Procedural, clinical and safety outcomes were assessed by pooling data 
by means of a random- or fixed-effect models according to the degree of 
heterogeneity to obtain a proportion with a 95% confidence interval (CI).
results: Ten studies were eligible for inclusion (292 patients), only 2 of 
which were prospective. Seven studies were performed in the United 
States, 2 in France and 1 in China. All studies but 2 were single-center 
experiences. Endoscopic pyloromyotomy was technically successful in all 
patients. Significant symptomatic improvement was achieved after 83.9% 
of the procedures (mean follow up period 7.8±5.5 months). Six studies 
reported the pre- and post- procedural Gastroparesis Cardinal Symptom 
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Index score: the mean pre-procedural GCSI score was 3.3±0.6 and dropped 
to 1.61±0.61 after G-POEM (p<0.001). When comparing the mean values 
of pre- and post-procedural scintigraphic evaluation, there was a signifi-
cant decrease in the residual percentage at both 2 and 4 hours: 74.9±5.2 
% vs 52.5±10.8 % (p<0.001) and 44.1±13.0 % vs 20.6±9.5 % (p<0.001), 
respectively. The overall adverse event rate was 6.8%. Immediate and 
post-procedural bleeding occurred in 1.9% (I2=27.8%) and 2.6% (I2=0%) 
of procedures, respectively. Gastric ulcers were reported in 5 cases, with 
a pooled rate of 2.3% (I2=0%). Moreover, perforations were reported in 
3 cases and a peritoneal abscess occurred in 1 case. Late events such as 
pyloric strictures were reported after 1% (I2=0%) of cases.
conclusion: In the short-term, G-POEM appears to be a promising tech-
nique in terms of safety and efficacy outcomes. While comparison to other 
pylorus-directed interventions in large controlled trials is awaited, G-
POEM should be considered as a therapeutic option when dealing with 
refractory gastroparesis.
disclosure: Nothing to disclose 
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Introduction: There is literature suggesting an association between oesoph-
ageal motility disorders and eosinophilic oesophagitis (EoE) with a few 
cases reporting patients with co-existing oesophageal achalasia and EoE.1-3
aims & Methods: The aim of this study was to undertake a histological 
evaluation for the presence of eosinophils in oesophageal biopsies (muco-
sal and muscle) in patients with achalasia who underwent POEM to deter-
mine if any association of eosinophilic oesophagitis and achalasia existed 
in our cohort. 
All patients undergoing POEM for achalasia from 2013 onwards were in-
cluded, with data extracted from the hospital electronic patient record. Pa-
tients had routine pre-treatment assessment with high resolution manom-
etry, barium swallow and Eckardt score. Results of oesophageal biopsies 
(mucosal and oesophageal) that were taken were recorded. 
Histology samples were processed by our local histopathology depart-
ment. Samples were routinely fixed in formalin and embedded in paraffin 
wax before sectioning onto glass slides for review.
results: 105 patients underwent POEM at our institution from November 
2013 onwards (45F; mean age 51± 14 yrs). Mean duration of disease was 
4.9± 4.5 yrs and the most common sub-type of achalasia according to Chi-
cago Classification was Type II (71 patients). The mean Eckardt score pre-
POEM was 8±2 points. 
44 (42%) patients underwent oesophageal biopsies (39 mucosal, 5 mus-
cle) in our cohort. 21 patients underwent oesophageal biopsies prior to 
undergoing POEM, 5 had oesophageal biopsies taken during POEM and 18 
underwent oesophageal biopsies post POEM (during their Day 1 post POEM 
oesophagogastroduodenoscopy). 
31 patients had both lower and mid oesophageal biopsies, 6 only had low-
er oesophageal biopsies and 2 only mid oesophageal biopsies. The 5 that 
had muscle biopsies taken had their sample taken from mid oesophagus. 
No patient had oesophageal biopsies that contained eosinophils. 20 sam-
ples were reported as normal, 19 biopsies chronic inflammation, 2 biop-
sies with diathermy effect and therefore not interpretable, 1 fibrosis and 2 
with other diagnoses (leukoplakia and candidiasis).
conclusion: In our cohort no oesophageal biopsies reported eosinophils. 
Most biopsies either had evidence of chronic inflammation or no abnor-
mality. Our study could not identify a link between eosinophilic oesopha-
gitis and achalasia. The main finding of chronic inflammation is in keep-
ing with stasis related inflammation that occurs in achalasia. Our finding 
could challenge the need to do routine oesophageal biopsies in work up 
endoscopy for achalasia patients who already have a confirmed diagnosis 
with high resolution manometry. This could have significant cost and time 
saving benefits. Further research is required to determine the utility of 
oesophageal muscle biopsies, a novel resource uncovered by submucosal 
endoscopy.
references: 1.Cools-Lartigue, J., Chang, S. Y., Mckendy, K., Mayrand, S., 
Marcus, V., Fried, G. M., & Ferri, L. E. (2013). Pattern of esophageal eo-
sinophilic infiltration in patients with achalasia and response to Heller 
myotomy and Dor fundoplication. Diseases of the Esophagus, 26(8), 766-
775. 2. Savarino, E., Gemignani, L., Zentilin, P., De Bortoli, N., Malesci, A., 
Mastracci, L., ... & Savarino, V. (2011). Achalasia with dense eosinophilic in-
filtrate responds to steroid therapy. Clinical gastroenterology and hepatol-
ogy, 9(12), 1104-1106. 3. Mandaliya, R., DiMarino, A. J., & Cohen, S. (2013). 
Association of achalasia and eosinophilic esophagitis. Indian Journal of 
Gastroenterology, 32(1), 54-57.
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Introduction: Non-cardiac chest pain (NCCP) is one of major symptoms in 
patients with esophageal motility disorders (EMDs) or gastroesophageal 
reflux disease (GERD), but, the symptom profile of NCCP in different dis-
eases is not fully understood.
aims & Methods: A total of 91 consecutive patients (57 females, mean age: 
54 years) with NCCP who underwent esophageal manometry using high 
resolution manometry (HRM) between March 2009 and February 2018 at 
Gunma University Hospital were enrolled. Most of the patients (92%) had 
dysphagia as well as NCCP. NCCP was assessed by a questionnaire con-
cerning location, time and duration of NCCP. Esophagogastroduodenos-
copy (EGD) was performed in all patients. When reflux esophagitis was 
seen on EGD or when a proton pump inhibitor (PPI) was effective, patients 
were diagnosed as GERD. When eosinophil infiltration (≥15/HPF) in the 
esophageal mucosa was seen, patients were diagnosed as eosinophilic 
esophagitis (EoE) regardless of presence of EMDs or GERD. Esophageal 
motility was assessed retrospectively according to the Chicago classifica-
tion v3.0. Major EMDs were divided into five groups based on HRM find-
ings: Achalasia type I or II, achalasia type III, esophago-gastric junction 
outflow obstruction (EGJOO), spastic esophageal motility disorders (SMDs) 
and absent contractility (AC). When major EMDs were found, it was con-
sidered that NCCP was caused by EMDs. When a PPI was not effective 
and there was no abnormal finding on both EGD and HRM, a 24-hour 
esophageal pH-impedance monitoring was performed. When abnormal 
esophageal acid exposure or positive symptom association were found, 
patients were diagnosed as GERD. When neither of those was present, 
patients were diagnosed as functional chest pain (FCP).
results: There were 33 achalasia (type I or II), 8 achalasia (type III), 8 EG-
JOO, 7 SMDs, 3 AC, 7 EoE, 22 GERD and 3 FCP. Fifty seven (63%), 45 (49%), 
32 (35%) and 27 (30%) patients had pain in the lower part, middle part, 
back or upper part of the chest, respectively. The location of pain was not 
significantly different among patient groups. The time of pain was signifi-
cantly different among groups (p<0.05). 
  Within 1 minute
1-5 
minutes
5-10 
minutes
10-30 
minutes
More than 
30 minutes
Type I or II achalasia 27% 18% 21% 9% 24%
Type III achalasia 0% 50% 25% 13% 13%
Esophago-gastric junction 
outflow obstruction
13% 50% 13% 13% 13%
Spastic esophageal motility 
disorders
29% 29% 29% 14% 14%
Absent contractility 0% 33% 0% 33% 33%
Eosinophilic esophagitis 14% 14% 14% 29% 29%
Gastroesophageal reflux 
disease
27% 9% 9% 0% 55%
Functional chest pain 33% 0% 33% 0% 33%
[Duration of chest pain among groups]
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Most patients had pain between meals or during or after meals. Some pa-
tients with achalasia or EoE had pain in the wake-up period; patients with 
EGJOO or SMDs did not have pain in the wake-up period. Patients with type 
I or II achalasia tended to have pain during nighttime as well as during 
post prandial periods. The duration of pain was also significantly differ-
ent among groups (p<0.05, Table). It was shorter in patients with type 
III achalasia, EGJOO or SMDs, while, it was longer in patients with GERD.
conclusion: The symptom profile of NCCP was different among patient 
groups. The NCCP profile may represent pathophysiology of diseases.
disclosure: Nothing to disclose 
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Introduction: Opioid induced oesophageal dysfunction is increasingly rec-
ognized. The inability to discontinue opioids pauses a challenge in the 
management of these patients. Opioids mainly affect organization of peri-
stalsis and relaxation of the lower oesophageal sphincter. The relationship 
between type of opioids intake, symptoms and manometric pattern is still 
unclear.
aims & Methods: To record the prevalence of major and minor oesopha-
geal disorders in patients using opioids and compare this to non-users.
We identified 155 patients on opioids registered on our HRM database 
between October 2013 and March 2019. Type of opioids, symptoms and 
manometric features were reviewed and compared between opioids users 
and non-users (n= 6465). Patients with an incomplete test, studied follow-
ing fundoplication or with a known major motility disorder were excluded.
results: The prevalence of opioid use in our patient population was 2.3%. 
Opioids used included Tramadol (n=50), Codeine (n=45), Morphine Sul-
phate (n=12), Co-dydramol (n=9), Fentanyl (n=7), Oxycodone (n= 6) and 
Combination therapy (n=26). The commonest reason for opioid use was 
a musculoskeletal disorder (55%). The main complaint was dysphagia in 
21%, chest pain in 10%, heartburn and regurgitation in 35%, cough in 8% 
and other (abdominal pain, vomiting, belching, globus) in 26%. Another 
42.5% reported dysphagia as secondary symptom. Compared to non-users 
of opioids, dysphagia was the main complaint in 13.5% and chest pain 
in 4.8%, whilst another 21% reported dysphagia as secondary symptom. 
There was a significant difference in the prevalence of all major and mi-
nor manometric abnormalities between opioid users and non-users (p< 
0.0001). The incidence of GOJ obstruction was 11.6% vs 1.6% respectively, 
Jackhammer oesophagus and Distal Oesophageal Spasm 4.5% vs 1.2%, 
Achalasia type 3 1.9% vs 0.18%, Absent peristalsis 1.3% vs 0.09%, Nut-
cracker oesophagus 3.9% vs 0.17%, IEM 29.6% vs 10%. Amongst opioid 
users whose main complaint was dysphagia or chest pain, Achalasia type 
3 was present in 6% and GOJ obstruction in 19%. Although numbers are 
relatively small, more portent opiates (Fentanyl, Oxycodone) and combina-
tions of opiates appeared associated with a greater risk of major motility 
disorders.
conclusion: The prevalence of symptoms and oesophageal dysmotility 
was higher in opioids users. This highlights the awareness physicians 
and physiologists should have about an increasing problem in our patient 
group.
disclosure: Nothing to disclose 
P1956 PaThOPhysIOLOgy Of sWaLLOWIng dysfuncTIOn 
and dOPaMInergIc effecTs In ParkInsOn’s dIsease
Nascimento W.1, Arreola V.2, Sanz P.3, Necati E.4, Bolivar-Prados M.2, 
Clavé P.2,5
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and Rehabilitation, Mersin, Turkey, 5CiBER de Enfermedades Hepáticas y 
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Introduction: The pathophysiology of OD and the effect of dopaminergic 
medication on swallowing dysfunction are not fully understood in Parkin-
son’s disease.
aims & Methods: Our aim was to describe the pathophysiology of impaired 
safety of swallow in Parkinson’s disease (PD) and to assess whether the 
OFF/ ON state related to dopaminergic medication affects swallow func-
tion.
We studied 50 patients with PD and 12 healthy volunteers (HV). Videofluo-
roscopic (VFS) signs and kinematics of swallow response were assessed. In 
40 patients with PD, all tests were performed in OFF (12 hours without any 
medication) and ON (1 hour after usual dopaminergic medication) state.
results: Mean age of PD patients was 70.46±10.03yr (24 women), mean 
time of disease 5.094±3.86yr, the Hoehn-Yahr stage 2.32±0.81 and mean 
dose of dopamine 567.10±302.35mg. Mean age of HV was 40.20±2.50 yr 
(six women). PD Patients had high prevalence of impaired safety of swal-
low (36% of penetrations in PD, higher PAS mean 2.16± (1.35), delayed 
laryngeal vestibule closure time (LVC, 293.33±90.07ms) when compared 
to HV (164.00±39.78ms), both unaffected by dopaminergic treatment 
(305.00±105.90ms). A cutoff level of delayed LVC≥380.00ms predicts un-
safe swallow with sensitivity=0.67; specificity=0.79 and AUC of 0.80. There 
was no significant difference in swallow between OFF and ON states for 
VFS signs of efficacy and safety, or kinematics of swallow response. In both 
situations patients presented similar high prevalence of oral residue (OFF: 
92.50%; ON: 90.00%), piecemeal swallow (OFF: 75.00%; ON: 80.00%) 
and pharyngeal residue (OFF: 85.00%; ON: 85.00%).
conclusion: Swallowing function appears to be severely impaired in the 
initial stages of PD and do not improve by dopaminergic treatment. Pa-
tients with PD require new strategies for active treatment of the severe 
swallowing dysfunction they suffer from the initial stages of the disease.
disclosure: Nothing to disclose 
P1957 cOMParIsOn Of safeTy Of TreaTMenT OPTIOns fOr 
end-sTage achaLasIa Or sIgMOId esOPhagus: a sysTeMaTIc 
revIeW and MeTa-anaLysIs
Gopalakrishnan Ravikumar N.P.1, Ravindran A.1, Thota P.2, Raja S.3, 
Sanaka M.3
1University at Buffalo, Internal Medicine, Buffalo, United States, 2Cleveland 
Clinic Foundation Digestive Disease Institute, Gastroenterology, Cleveland, 
United States, 3Cleveland Clinic Foundation Digestive Disease Institute, 
Cleveland, United States
contact e-Mail address: ravikumar.naveen1@gmail.com
Introduction: End-stage achalasia is characterized by massive esopha-
geal dilatation with loss of the esophageal straight axis giving rise to a 
sigmoid appearance. Several effective treatment options are available for 
early achalasia. However, these interventions might be technically difficult 
and associated with higher complication rates in the management of end-
stage achalasia.
aims & Methods: We aimed to compare the relative safety of various treat-
ment modalities used in patients with end-stage achalasia and sigmoid 
esophagus through a systematic review and meta-analysis.The meta-anal-
ysis was performed using the Preferred Reporting Items for Systematic 
Reviews for Meta-analyses (PRISMA) guidelines. We searched PubMed, 
Embase, Cochrane library, Medline, Google Scholar, and Science Citation 
Index to identify relevant studies between January 2012 and January 2018. 
Keywords used were “sigmoid esophagus”, “end stage achalasia”, “acha-
lasia”, ”Laparoscopic Heller myotomy (LHM)”, ”esophagectomy”, ”esopha-
geal resection”, ”peroral endoscopic myotomy (POEM)” and “advanced 
achalasia”. Statistical analysis was performed using Review Manager Ver-
sion 5.3 (RevMan) software.
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results: Using the predefined search strategy, 33 studies were included 
in the meta-analysis. A total of 1987 patients were included of which 1497 
underwent esophagectomy, 386 had LHM and 104 had POEM. Based on 
the meta-analysis, POEM was found to be most effective treatment option 
in terms of major complications [OR = 0.51, 95% confidence interval (CI) = 
0.28 to 0.89], length of hospital stay [standardized mean difference (SMD) 
= -1.1, 95% CI = - 1.18 to - 0.07] and operative time [SMD = - 1.82, 95% 
CI - 2.76 to - 0.11] (table 1). P score ranking result showed that POEM was 
ranked top in major complications, hospital stay and operative time (P 
score = 0.907, 0.996, 0.991, respectively)(table 2).
Treatments Major complications hospital stay Operative time
Esophagectomy 0.438 0.428 0.456
LHM 0.176 0.478 0.526
POEM 0.907 0.996 0.991
[P score rankings]
conclusion: Our results show that POEM is safer and is associated with 
shorter length of hospital stay compared to esophagectomy and LHM in 
treating sigmoid esophagus or end-stage achalasia. We believe this is the 
first meta-analysis to compare the safety of treatment options in end-stage 
achalasia with sigmoid esophagus. Further studies are needed to assess 
the efficacy of these interventions in this patient population.
disclosure: Nothing to disclose 
P1958 OuTcOMe Of Per OraL endOscOPIc MyOTOMy fOr 
TreaTMenT Of achaLasIa - nOrWegIan sIngLe cenTer 
exPerIence WITh MedIan fOLLOWIng-uP Of 24 MOnThs
Pham K.D.-C.1,2, Havre R.F.3, Gilja O.H.4, Hatlebakk J.G.5
1Haukeland University Hospital, Medicine, Bergen, Norway, 2University of 
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Department of Medicine and University of Bergen, Department of Clinical 
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contact e-Mail address: phamkdc@gmail.com
Introduction: Long term effects of Per Oral Endoscopic Myotomy (POEM) 
are still unknown. The aim of this study was to investigate and report the 
feasibility, safety, efficacy and complications of POEM from the introduc-
tory phase in a tertiary referral center in Norway.
aims & Methods: Collected prospective data from the first 68 patients with 
achalasia who underwent POEM at Haukeland University Hospital from 
February 2014 until December 2017 were analyzed. The patients were fol-
lowed up for 12 months with respect to acute and delayed complications, 
and efficiency of the treatment. The diagnosis was based on findings on 
high resolution manometry (HRM) and timed barium swallow X-ray (TBS). 
We repeated HRM, TBS, in addition to impedance and 24-hours pH mea-
surement 12 months after POEM. Reflux was regarded as pathological if 
the acid exposure (pH< 4) time was more than 6%. Eckardt score was 
used for symptom evaluation before, and at 6, 12 and up to 56 months 
after POEM.
results: 41 males and 27 females with symptomatic achalasia and Eckardt 
score ≥6 were included. The mean age was 44,6y. Based on HRM, 15 pa-
tients had achalasia type I, 34 type II and 19 with type III. 36 patients (53%) 
were naïve to other treatment, while 11 (16%) had been previously treated 
with botulinum toxin injection, 14 (22%) with pneumatic balloon dilata-
tion, and 10 (15%) with Heller’s myotomy. The average resting pressure 
over lower esophageal sphincter (LES) was median 25 mmHg (0-72) prior 
to POEM, and 6,5 mmHg (0-23.1) after. Dysphagia improved in all patients 
on follow up. The Eckardt score was significantly reduced from median 7 
(4-12) before POEM to 1 (0-9) at 12 months after POEM (p < 0.0001). The 
median myotomy length was 11 cm (4-20). 43 patients (63%) patients had 
posterior myotomy, while 25 (27%) anterior. The procedure time was mean 
130 min, and admission time was mean 3 days. We did not experience any 
serious complications but observed capnoperitoneum and capnothorax in 
10 patients (15%). 3 patients (4%) required peritoneal decompression dur-
ing POEM (Grade 2 complication). At 12 months, 86.8% had Eckard score 
≤3, and 75,5% Eckardt score ≤2. 24 -hours pH monitoring was recorded 
on 55 patients (80%). 12 months post-POEM pathological reflux was mea-
sured in 45%, but only 37% reported reflux symptoms, 22% needed proton 
pump inhibitors (PPI) daily while 9% needed PPI occasionally.
conclusion: Results with 12-56 months following-up from our cohort of 
consecutive patients show that POEM is safe and relieves symptoms of 
achalasia significantly, but the risk of reflux is higher than what is previ-
ously reported in the literature. Further studies are needed to confirm the 
findings in a long-term follow-up.
disclosure: Nothing to disclose 
P1959 can OesOPhageaL hyPOMOTILITy exPLaIn underLyIng 
cause Of sMaLL InTesTInaL BacTerIaL OvergrOWTh?
Wolak A.1, De Silva M.2, Wong T.3, Zeki S.S.4, Alavi S.5, Jafari J.6
1Guy’s and St Thomas Hospital London, London, United Kingdom, 2Guy’s and 
St Thomas Hospital London, london, United Kingdom, 3St Thomas Hospital, 
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Introduction: It is known that Small Intestinal Bacterial Overgrowth (SIBO) 
is linked with gut hypomotility as well as long term use of acid suppres-
sants. However, due to difficulties for investigating small intestinal motil-
ity, identifying the underlying cause for SIBO in patients remains mainly 
unknown and speculative.
aims & Methods: The aim of this study is to investigate the relation of oe-
sophageal motility findings with SIBO, as an indicator of gut hypomotility. 
Methodology
Patients referred to Guy’s Hospital London for upper GI investigation who 
completed oesophageal high resolution manometry, lactulose test to rule 
out SIBO and also 24hr impedance-pH reflux monitoring from June 2017 
to Dec. 2018. Diagnoses were made based on: Chicago classification for 
oesophageal motility disorders v3 [1], the North American consensus 
guideline for Hydrogen and Methane breath testing 2017 [2], and the Lyon 
consensus on reflux monitoring 2017 [3]. 
Statistical analysis was made using Graphpad Prism tool to obtain ROC 
analysis, two tailed Fisher’s exact test and demographic analysis. P value 
< 0.05 was considered significant.
results: 71 patients completed both HRM and SIBO testing (F:M= 46:25, 
median age 49, 25-70 years old). 25/71 patients were diagnosed with SIBO 
out of whom 17 (68%) had also ineffective oesophageal motility, 6 (24%) 
normal oesophageal motility and 2 (8%) oesophagogastric outflow ob-
struction. 
57 patients completed both 24hr impedance-pH reflux monitoring and 
SIBO test. 20/57 diagnosed with SIBO of whom, pathological gastro-
esophageal reflux was confirmed in 5 (20%). ROC curve analysis revealed 
that detection of distal contractile integral (DCI) < 450mmHg.cm.s has a 
sensitivity of 63.64% and specificity of 52% in predicting SIBO (95% CI: 
47%-77%). 
There was statistically significant different number of patients with SIBO 
diagnosed with IOM as opposed to having normal motility (P < 0.004). 
However majority of the SIBO patients were not suffering from GORD 
(GORD vs having no GORD: P < 0.008). Lower oesophageal sphincter basal 
pressure and DCI were not significantly different between patients with 
and without SIBO. 
Gender had a slight impact on presence of SIBO (female with SIBO 39%, 
male with SIBO 24%). Highest prevalence of SIBO was detected in patients 
in their 50s (50%) but there was a dramatic reduction beyond the age 60 
(18%).
conclusion: SIBO is significantly associated with poor oesophageal body 
motility. This can be due to underlying poor small intestinal motility in a 
group of patients with IOM. A further study with larger sample size and 
concomitant investigation of small intestinal as well as oesophageal mo-
tility testing is required to further confirm these findings before use of 
oesophageal motility as a surrogate to determine small intestinal motility.
references: [1] Neurogastroenterol Motil. 2015 Feb;27(2):160-74. doi: 10.1111/
nmo.12477. Epub 2014 Dec 3. The Chicago Classification of esophageal 
motility disorders, v3.0 [2] Am J Gastroenterol. 2017 May;112(5):775-784. 
doi: 10.1038/ajg.2017.46. Epub 2017 Mar 21. Hydrogen and Methane-Based 
Breath Testing in Gastrointestinal Disorders: The North American Consen-
sus. [3] Gut. 2018 Jul;67(7):1351-1362. doi: 10.1136/gutjnl-2017-314722. Epub 
2018 Feb 3. Modern diagnosis of GERD: the Lyon Consensus.
disclosure: Nothing to disclose 
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P1960 funcTIOnaL dysPePsIa and duOdenaL eOsInOPhILIa 
are assOcIaTed WITh IncIdenT anxIeTy: PrOsPecTIve 10 year 
fOLLOW-uP Of The kaLIxanda sTudy
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Introduction: Functional dyspepsia (FD) is a common condition in the pop-
ulation. It is associated with duodenal eosinophilia1 and it has been shown 
that anxiety at baseline is associated with new-onset functional dyspepsia 
in long term.2 Innate immunity response is linked with gut-brain/brain-gut 
regulation and psychological distress.3
aims & Methods: Our aim was to investigate whether FD (Rome III) is 
associated with new-onset anxiety and/or depression and if this can be 
predicted by duodenal inflammation in a population based 10-year follow-
up study. 
Participants of the study (n=3000) were randomly selected from the na-
tional Swedish population register and surveyed in 1998 by a validated ab-
dominal symptom questionnaire (ASQ) and hospital anxiety and depres-
sion scale (HADS). 1000 individuals were randomly selected to complete 
an esophagogastroduodenoscopy in 1999-2001. All eligible from the latter 
cohort (n=887, response rate 79%) were invited to a follow-up in 2010 with 
the ASQ and HADS. In a case-control study of 213 subjects (FD vs. healthy 
controls), histology from the oesophagus, stomach and the duodenum was 
evaluated at baseline (the pre-specified cut off being the mean, 23 eo-
sinophils in duodenal bulb (D1) and 24 eosinophils in second part of the 
duodenum (D2)). The cut off for gastric eosinophilia was also the mean, 
11 eosinophils in all three locations: cardia, corpus and antrum. The pos-
sible association of FD and duodenal eosinophilia to incident anxiety was 
analysed. Data were analyzed by Fisher’s exact test and logistic regression.
results: FD was reported by 89 subjects (42%), duodenal eosinophilia in 
D1 was found in 78 subjects (37%) and in 84 subjects in D2 (39%) at base-
line. Incident anxiety was found in 12 subjects (6%) and depression only 
in 2 subjects (1%). None of the study subjects had oesophageal eosino-
philia. Duodenal eosinophilia was not associated with gastric eosinophilia 
(OR=0.18, 95 CI 0.02-1.70, P=0.135). 
Incident anxiety was associated with baseline functional dyspepsia (10/83 
vs. 2/116, p=0.004), especially postprandial distress syndrome (10/65 vs. 
2/134, p< 0.001) but not with epigastric pain syndrome (1/27 vs. 11/172, 
p=1.0). Incident anxiety was also associated with duodenal eosinophilia in 
D1 at baseline (9/75 vs. 3/124, p=0.011, OR=5.2, 95% CI 1.31-20.4, adjusting 
for age, gender and FD).
conclusion: : Incident anxiety is significantly associated with baseline FD 
and duodenal eosinophilia is associated with a 5-fold increased risk of 
anxiety in a 10-year follow-up supporting the concept that mucosal im-
mune system can regulate the bidirectional gut-brain communication.
references: 1. Talley, N.J., Walker, M.M., Aro, P., et al. Non-ulcer dyspepsia 
and duodenal eosinophilia: an adult endoscopic population-based case-
control study. Clin Gastroenterol Hepatol 5, 1175-1183 (2007). 2. Aro, P., 
Talley, N.J., Johansson, S.E., Agreus, L. & Ronkainen, J. Anxiety Is Linked 
to New-Onset Dyspepsia in the Swedish Population: A 10-Year Follow-up 
Study. Gastroenterology 148, 928-937 (2015). 3. Powell, N., Walker, M.M. 
& Talley, N.J. The mucosal immune system: master regulator of bidirec-
tional gut-brain communications. Nat Rev Gastroenterol Hepatol 14, 143-
159 (2017).
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Introduction: There are no population-based studies determine the preva-
lence of gastrointestinal symptoms and associated diseases, in Turkey. It 
is necessary to know the prevalence of the diseases in the community for 
health professionals and their providers, in order to establish forward-
looking targets and to use the resources correctly. Therefore, this study was 
designed to determine the frequency of the most common gastrointestinal 
system (GIS) symptoms, and diseases in a community-based sample.
aims & Methods: The study is a cross-sectional cohort study. The ‘‘Cap-
padocia cohort’‘ consisting of Avanos and Gülşehir districts of Nevşehir is 
shown to represent exactly the Turkey, in terms of population distribution. 
Therefore, it was found appropriate for the sample. The study was con-
ducted between October 2017 and July 2018. Volunteers over 18 years of 
age were included in the study. The ‘’Gastrointestinal Symptom Question-
naire’’ consisting of 16 questions for the upper GIS and 18 questions for the 
lower GIS was applied by the contracted research company by phone or 
face to face. It was accepted that the symptom was present if the symptom 
severity was ≥2 on a 6 scale, and gastrointestinal disease was accepted 
if the symptoms were present in at least 3 areas. The questionnaire was 
questioned for the last month. Body mass indexes were calculated.
results: A GI symptom questionnaire was performed in 3369 (81.7%) of 
total 5042 people, who met the study criteria and accepted to participate, 
and 2797 people (67.8%) were evaluated for height and weight. The 39% 
of the participants were male , 61% were female and the median age was 
52 years. The median BMI was 29.6 kg/m2 and 35% of the participants 
were overweight and 45% were obese. The rate of smokers was 24%, 
and the rate of alcohol drinkers was 5.2%. The use of aspirin and NSAIDs 
was 52%, PPI use was 25.5%, and the rate of H2RA use was 6.2%. The 
70.5% of the population had at least one GIS symptom. The most common 
symptoms of upper GIS were bloating, burning and pain, and the most 
common symptoms of lower GIS were abnormal defecation, gurgling and 
swelling. The presence of upper GIS disease associated with symptom 
severity was 32.7%, the presence of lower GI disease was 12.9%, and the 
presence of both were 9.9%. The frequency was significantly higher in 
women (p < 0.001). The presence of symptoms and the presence of upper 
GIS disease were directly proportional to BMI. There was a significant 
decrease in upper gastrointestinal symptoms and upper GIS disease fre-
quency with age.
conclusion: This community-based cross-sectional cohort study, evaluat-
ing the gastrointestinal symptoms and the burden of disease, which was 
held in Turkey for the first time, has revealed that gastrointestinal symp-
toms were 70% among the community. The study showed that 1/3 of the 
population had upper GIS disease, 1/10 had lower GIS disease, and this fre-
quency increased significantly in women. There was a linear relationship 
between weight gain and symptoms and presence of upper GI disease. It 
has been found that the prevalence of gastroenterological diseases is high 
and they are serious in terms of public health in Turkey.
disclosure: Nothing to disclose 
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Moccia F.1, Sabattini L.1, Franzoni L.1, Di Mario F.1
1University of Parma, Department of Medicine and Surgery, Parma, Italy, 
2ULSS7 Alto Vicentino, Digestive Endoscopy Unit, Santorso, Italy
contact e-Mail address: michele.russo@studenti.unipr.it
Introduction: Gastroesophageal reflux disease (GERD) is claimed to be a 
multifactorial disease involving both environmental and dietary factors [1]
[2], but the scientific literature on this topic is lacking.
aims & Methods: Aim of the study is to assess the impact of such factors 
in the outcome of GERD in a population of patients in a secondary care 
setting.
We enrolled 208 GERD patients in a private gastroenterological ward in 
North-East Italy; we selected GERD patients with problems at work (ha-
rassment, mobbing, interpersonal conflict, bullying, low motivation and 
job satisfaction, discrimination, etc.)or who did night work or smokers ( 10 
to 20 cigarettes per day) or heavy coffee drinkers (3 or more daily). Patients 
were singled out in 4 groups according to the factors involved in their clini-
cal history: group A in which problems at work played an important role, 
group B that experienced discomfort due to night shifts; group C with the 
smokers and group D composed of heavy coffee drinkers. The observation 
time was divided into 2 periods marked by 3 symptom evaluations car-
ried out with the Visual Analogue Scale (VAS) (ranged from 0 to 10 with 
increasing gravity of pain) and with a Symptomatic Score (SS) that consid-
ered only heartburn and regurgitation (the score ranged from 0 to 6 with 
the single symptom score ranging from 0 to 3 with increasing gravity); the 
first period lasted 6 months, in which all patients performed therapy with 
antacids or PPI only when needed; symptoms were assessed at baseline 
and at the end of 6 months; in the second period, which lasted 6 months, 
patients were made to change their habits, changing profession, being 
diverted to daily shifts, quit smoking and stop drinking coffee. The clinical 
outcome of GERD has been evaluated through VAS and Symptomatic Score 
modifications.
results: We selected 208 pts (M: 108, mean age 48 years, range 19-73 
years) divided into 4 groups according with the study design: group A: 43 
pts (M: 19, mean age 46 years, range 19-52) that have changed their oc-
cupation during the follow-up; group B: 37 pts (M: 28, mean age 41 years, 
range 24-54) that changed shift; group C: 61 pts (M: 27, mean age 52 years, 
range 25-73) that quit smoking and group D: 67 pts (M: 34, mean age 54 
years, range 23-71) that stopped drinking coffee. Table 1 summarizes the 
results (expressed as mean value (m.v.)) before and after the critical envi-
ronmental event.
conclusion: The study seems to confirm the importance of environmental 
factors on GERD outcome, focusing on the crucial role of break through life 
events like shift and carrier changes; dietary and voluptuous factors such 
as drinking coffee and smoking seem to be less important in improving 
these patients’ quality of life.
  T0 (Baseline) T1 (environmental event) T2 (after 6 months)
group a vas m.v. 5 6 2
group a ss m.v. 5 5 1
group B vas m.v. 5 6 1
group B ss m.v. 4 5 1
group c vas m.v. 5 6 5
group c ss m.v. 4 5 6
group d vas m.v. 6 5 5
group d ss m.v. 5 4 5
[Table 1.]
references: [1] Bradley, Laurence A., et al. “The relationship between stress 
and symptoms of gastroesophageal reflux: the influence of psychological 
factors.” American Journal of Gastroenterology88.1 (1993). [2] Sonnenberg, 
Amnon. “Effects of environment and lifestyle on gastroesophageal reflux 
disease.” Digestive Diseases 29.2 (2011): 229-234.
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PaTIenTs WITh TyPe 3 sPhIncTer Of OddI dysfuncTIOn
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Introduction: Type 3 Sphincter of Oddi dysfunction, or biliary visceral hy-
persensitivity, causes considerable morbidity. However in the wake of the 
EPISOD study, which refuted the role of sphincterotomy, there is lack of 
clarity regarding whether any endoscopic intervention is beneficial. We 
therefore performed a retrospective single centre study of papillary in-
jection of botulinum toxin for management of Type 3 Sphincter of Oddi 
dysfunction.
aims & Methods: Electronic endoscopy records were searched from 2015-
2018 for cases of botulinum toxin injection for Type 3 Sphincter of Oddi 
dysfunction. All had received injections of 100 units of botulinum toxin 
into the papilla, during duodenoscopy. Electronic patient records were 
retrospectively reviewed for symptomatic response, duration of response, 
further procedures and adverse events.
results: 19 patients were identified. All underwent at least one procedure, 
with 11 undergoing repeat procedures . Following first procedure, (63.2% 
N=12/19) reported complete resolution of symptoms)and (15.7%, N=3/19) 
reported a partial response. Median duration of response was 4 months 
(IQR 4-4.5). Following repeat procedures, (36.4%, N= 4/11) reported total 
response, and (18.2%, N=2/11) reported partial response. There were no 
serious adverse events identified.
conclusion: 78.9% patients reported symptomatic improvement following 
first injection with botulinum toxin. 54.6% reported improvement after a 
follow up procedure. Papillary botulinum toxin injection may be a useful 
and relatively safe treatment option for Type 3 Sphincter of Oddi dysfunc-
tion, however placebo controlled trials are required to further evaluate 
benefit, especially regarding repeat procedures.
disclosure: Nothing to disclose 
P1964 hOW LOng shaLL We Make MyOTOMy fOr gasTrIc 
sIde TO PrevenT refLax esOPhagITIs afTer POeM?
Takahashi A., Oyama T.
Saku Central Hospital Advanced Care Center, Endoscopy, Nagano, Japan
contact e-Mail address: aurevoireurope@yahoo.co.jp
Introduction: According to guideline of Peroral endoscopic myotomy 
(POEM), the endopoint of the myotomy is recommended from 1 to 2cm 
into the gastric side. GERD after POEM is one of adverse event, because 
fundoplication is not performed in POEM as compared with Heller-Dor 
operation. Previous papers have reported that GERD occurs 13 to 60% after 
POEM.
aims & Methods: The aim of this study is to evaluate the effect of short 
length myotomy for gastric side.
Forty-two cases of Achalasia or non-achalasia esophageal motility disor-
ders treated by POEM from December 2012 to December 2017 were en-
rolled in this study.
The length of myotomy was decided by esophagography and/or high reso-
lution manometry (HRM). 1cm myotomy was performed for gastric side. 
When balloon dilatation (BD) and/or re POEM were performed, it was de-
fined as recurrence. 
Gender (Male / Female) was 24 and 18, respectively. Median age was 55 
(19-92) years old. Previous treatment is as follows; BD: 10, medication: 10, 
medication plus BD: 2, BD plus operation: 1. Type of disease is as follow; 
Achalasia: 31 (Type I: 9, Type II: 12, unknown type: 10 because of without 
HRM), DES: 5, Jackhammer esophagus: 1, others: 5. Median duration of 
symptoms was 48 (1-480) months. Median follow up periods was 19 (1-72) 
months.
results: 
1. Median procedure time was 58 (28-131) mins. 
2. Median length of myotomy was 7 (4-19) cm. 
3. Complication: a. Four cases (9.5%) had the mucosal laceration. Three 
cases were treated by endo clip and/or PGA sheet, and one case was treat-
ed by laparoscopic drainage. b. There was no severe bleeding.
4. Median eckardt score (ES) of pre-POEM and post-POEM were 5 (1-11) and 
0 (0-4), respectively. Clinical success rate (ES≦2 or reduced more than 4 
points) was 95% (40/42).
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5. EGD was performed 1 year after POEM. Nine cases (24%) had GERD-A, 
and 5 cases (14%) had GERD-B.
6. Only two cases (5%) had heart burn. Both cases had GERD-B. 
7. Three cases (7%) had recurrence. BD was performed, and 2 cases were 
improved. However, BD for 1 case was not effective, and re-POEM was 
performed.
8. Peristalsis was partially recovered in 19% of the patients after POEM. 
Median length of myotomy for these cases was 6(4-10) cm.
conclusion: Clinical success rate of short gastric myotomy was fare, and 
GERD was lower as compared with previous reports. Therefore, short gas-
tric myotomy is acceptable.
references: None
disclosure: Nothing to disclose 
P1965 InsuffIcIenT rOMe crITerIa TO dIagnOse Pure 
funcTIOnaL aBdOMInaL PaIn and ePIgasTrIc PaIn syndrOMe: 
The need Of ruLIng OuT chrOnIc aBdOMInaL WaLL PaIn
Song K.-H.1, Huh K.-C.2, Kim S.M.1, Koo H.S.1, Lee T.H.1, Choi Y.W.1, 
Kang Y.W.1, Ryu K.1, Rim C.B.1
1Konyang University Hospital, Gastroenterology & Hepatology, Deajon, Korea 
(Republic of), 2Konyang University Hospital, Gastroenterology, Daejeon, 
Korea (Republic of)
contact e-Mail address: postit2@daum.net
Introduction: There is firm evidence that chronic abdominal wall pain 
(CAWP) is one of the major cause of chronic abdominal pain. CAWP has 
been easily ignored and the physician may misdiagnose CAWP as function-
al abdominal pain syndrome (FAPS) or even as epigastric pain syndrome 
(EPS). We investigated whether there is a difference between clinical re-
sponse for local anesthetic injection or a somatic nerve block (a major 
therapeutic option for CAWP) in CAWP alone and in CAWP-FAPS overlap.
aims & Methods: From January 2012 to April 2017, patients complaining 
of abdominal pain were undergone relevant studies. CAWP with negative 
screening exams were enrolled. Greenbaum’s criteria were adopted to di-
agnose CAWP while FAPS was diagnosed according to the Rome III criteria. 
For eligible patients, Rome IV criteria of EPS were surveyed also if they 
were Rome III-based EPS. CAWP alone group and CAWP-FAPS overlap 
group were treated by tap block. Baseline and post-treatment pain sore 
were recorded by 10-Likert scale. The 0.1% lidocaine mixture was used for 
the local anesthetic injection. After the local treatment, the responsiveness 
was assessed and 1 or 2 sessions of additional injection were performed if 
it is warranted. Clinical responsiveness was defined by over 50% degree 
reduction in symptom score.
results: A total of 595 Patients complained with chronic abdominal pain 
were underwent EGD, colonoscopy, blood exam and imaging study (US or 
CT scan). Among them, 49 participants without obvious abnormal result 
to explain the pain were enrolled (11 of overlap, 38 of CAWP only). Mean 
age was 49.5+/-11.2 and female were predominant by 1.45 fold. The most 
frequently affected area was epigastrium followed by right iliac in both 
groups. Kaplan-Meiser analysis of unresponsiveness after the local treat-
ment revealed no significant difference between the two groups (p= 0.781). 
The responsiveness at 3 months after the treatment also was not signifi-
cantly different. When we diagnosed with Rome III criteria, EPS-CAWP 
overlap was less common (p= 0.035, McNemar test).
conclusion: Clinical responsiveness to the local anesthetic injection was 
not different between CAWP-FAPS overlap and CAWP alone. Rome III cri-
teria of EPS is more suitable to discriminate EPS from CAWP than Rome 
IV criteria.
disclosure: Nothing to disclose 
P1966 anaLysIs Of POsT-POeM refLux PredIcTOrs and PPI 
cOnsuMPTIOn
Estremera-Arevalo F.1,2, Albéniz-Arbizu E.2,3, Ezquer S.4, Areste I.1, 
Zúñiga Ripa A.1, Rullan Iriarte M.5, Iglesias R.1, Macias E.1, Vila J.J.6
1Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain, 
2Fundacion Miguel Servet, Pamplona, Spain, 3Complejo Hospitalario 
de Navarra, Servicio Aparato Digestivo, Pamplona, Spain, 4Complejo 
Hospitalario de Navarra, Nursing, Pamplona, Spain, 5Complejo Hospitalario 
de Navarra, Gastroenterology, Sarriguren, Spain, 6Complejo Hospitalario de 
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Introduction: Post-POEM reflux (reflux) appears in 16-68% of the patients 
and it is the main burden after POEM. There is scarce evidence of factors 
predicting reflux.
aims & Methods: 22 patients with complete pre and post-POEM procedure 
work up - upper endoscopy, high-resolution manometry (MMS®, 22 chan-
nels water perfused), barium swallow, 24 h pH testing - were selected 
from our POEM prospective cohort (june 2016-april 2019, n=52). OGJ-CI 
as by Nicodeme. Symptoms: Eckardt and GERDQ score. Reflux diagnosis: 
Lyon consensus criteria. Parametric data expressed as mean, ±SD, t-test 
for mean comparison. Non-parametric data expressed as median (IQR), 
Mann-Whitney test for median comparison. Pearson test was used for cor-
relation analysis. Significant variables p < 0.05, possibly associated vari-
ables p < 0.2.
results: POEM was successful in all patients except one, who needed a 
second POEM procedure due to a mistaken manometric diagnosis. Reflux 
was found in 11/22 (50%) patients. Age was significantly associated with 
reflux, with older patients within this group. Post-POEM body mass index 
(BMI) was also higher in patients with reflux. Gender, time from symptoms 
onset, previous BMI, BMI increment, previous treatments, anaesthetic risk 
and antiplatelet agents intake were not different between groups. Basal 
(pre-POEM) reflux symptoms were lower in patients with reflux, howev-
er, no differences were noticed after POEM with a GERDQ median of 1 in 
patients with reflux and 3 in non-reflux patients. Only one patient with 
reflux scored more than 3 in GERD-Q. No differences were shown in tun-
nel length nor oesophageal/gastric myotomy. Reflux incidence was unaf-
fected by learning curve since it was equal in the first eleven procedures 
compared to the second half. Basal mean lower oesophageal sphincter 
pressure (LOSP) was lower in the reflux group, as well as the basal OGJ-CI 
and the basal 4sIRP. Manometric diagnosis, post-POEM LOSP, decrease of 
LOSP, post-POEM 4sIRP, decrease of 4sIRP, post-POEM OGJ-CI and decrease 
of OGJ-CI were similar between groups. Post-POEM 5 min barium column, 
but not basal nor decrease of barium column, was lower in reflux patients. 
See table 1. The most significant correlations were found for age (p 0.065) 
and post-POEM BMI (p 0.078) with distal oesophageal acid exposure time. 
Endoscopic studies revealed grade A oesophagitis in 2 patients and grade 
C in 1 patient. All patients controlled reflux symptoms with a single PPI 
dose. 4 patients consumed PPI because of antiplatelet agent treatment. 
Overall, there were fewer patients on PPI after POEM procedure - 14/22 vs 
18/22. 7 non-reflux and 1 reflux patients ceased PPI consumption.
conclusion: PostPOEM procedure reflux is common. Older age and a low 
basal GERD-Q score are associated with reflux appearance. There are no 
significantly associated variables in the work-up test, observing lower 
basal LOSP, 4s-IRP pressures and shorter post-POEM barium column in 
the reflux group. Reflux burden is debatable, since globally there were 
less reflux related symptoms after the procedure and the PPI consump-
tion decreased. All patients controlled their symptoms with a single dose 
of PPI.
variable (unit) non-reflux reflux p
Age (years) 46 (11) 65 (22) 0.01
Post BMI (kg/m2) 24.1 ± 5 28.8 ± 4 0.135
Basal GERD-Q 6.9 ± 2.5 4.3 ± 2 0.035
Basal LOSP (mmHg) 37.8 ± 14.7 28.3 ± 12.2 0.125
Basal 4s-IRP (mmHg) 22.5 ± 14 15.8 ± 6.2 0.171
Basal OGJ-CI (mmHg/cm) 51.3 ± 32 29 ± 23 0.096
Post POEM barium column (cm) 2.6 (6.5) 0 (0) 0.161
[Table 1. Significant and possibly associated with reflux variables.]
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references: 1. Estremera-Arevalo F, Albeniz E, Rullan M et al. Efficacy of 
peroral endoscopic myotomy compared with other invasive treatment op-
tions for the different esophageal motor disorders. Rev Esp Enferm Dig. 
2017 Aug;109(8):578-586. doi: 10.17235/reed.2017.4773/2016. 2. Nicodème F, 
Pipa-Muniz M, Khanna K et al. Quantifying esophagogastric junction con-
tractility with a novel HRM topographic metric, the EGJ-Contractile Inte-
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Neurogastroenterol Motil. 2014 Mar;26(3):353-60. doi: 10.1111/nmo.12267. 
Epub 2013 Dec 3. 3. Wang D, Xu H, Tang T et al. Assessment of the esopha-
gogastric junction (EGJ) using the EGJ contractile integral (EGJ-CI) follow-
ing per-oral endoscopic myotomy (POEM) in achalasia. Rev Esp Enferm 
Dig. 2018 Nov;110(11):706-711. doi: 10.17235/reed.2018.5560/2018.
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P1967 MacrOPhage PLasTIcITy and POLarIzaTIOn In 
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Introduction: In gastroesophageal reflux disease (GERD) the refluxate pro-
vokes active esophageal mucosa inflammation with moderate immune 
cells infiltration, which includes macrophages (M), obtaining M1 or M2 
phenotype. Considering the modern concept of immune response devel-
opment, changes of M phenotype strongly correlate with Th1/Th2 systemic 
immune response. So, M of different phenotypes can greatly influence 
esophageal mucosa inflammation and affect GERD clinical variants.
aims & Methods: Analysis of M polarization and phenotypic plasticity in 
patients with different clinical variants of GERD. 
Patients with non-erosive reflux disease (NERD; n=26; 41.2±3.6 y.o.), ero-
sive reflux disease (ERD; n=25; 41.9±3.1 y.o.), and Barrett’s esophagus 
(BE; n=19; 43.7±4.2 y.o.) were included in the study. M phenotype and 
polarization was assessed by in vitro model included adding refluxates 
of patients (n=70) with different pH (4.6-8.1) to peritoneal M of C57/BL6 
mice (n=70) culturing in standard conditions for 36 hours. M polarization 
analysis included secretory function assessment (Th1/Th2 cytokines in cul-
ture medium, Antigenix, USA), receptor characteristics - typical M1/M2 CD 
markers (CD80 / CD206, respectively) performed by flow cytometry (FC500, 
Beckman Coulter). Phenotypic plasticity was measured as changes of CD 
expression (CD80/CD206) and cytokine production (IL-12p70/IL-10) during 
36 hours of M reprogramming in the presence of 0%, 10%, 40% standard 
FBS. Changes in 0% FBS vs 10% FBS reflected plasticity towards M1 phe-
notype, in 40% FBS vs 10% FBS - to M2 phenotype. Mean pH values of 
refluxates were assessed for all patients’ groups.
results: Analysis of M polarization in different variants of GERD by cy-
tokine production and CD markers expression revealed the prevalence 
of Th1 and Th1/Th2 bivalent cytokines and M1 markers expression in all 
groups with variable changes of indices probably due to various mean 
pH values of the refluxates (6.53±0.41 in ERD, 5.52±0.24 in BE, 5.44±0.32 
in NERD). Analysis of macrophage plasticity showed the ability of macro-
phages to change their phenotype both towards M1 and M2 in all groups, 
but max changes were observed in production of IL-10 in 40% FBS in all 
groups (increased as compared to 10% FBS standard conditions in 3.77 
in NERD group, 3.8 - in BE and 3.4 - in ERD). The level of CD markers 
expression also changed in various FBS concentrations, but the changes 
were significant only for CD206 in 40% FBS in all groups. The data were 
comparable between the groups: CD206 expression increased in 1.6 in 
NERD, in 1.5 in BE, in 1.6 ERD.
conclusion: Analysis of macrophage polarization in different variants of 
GERD showed that secretion and receptor profile of the cells is typical for 
M1 phenotype with some variations of different cytokines production and 
CD markers expression that may be due to the type and pH value of the 
refluxate influencing macrophages. Macrophages in all GERD variants can 
change their phenotype according to the micro-environment. Phenotypic 
plasticity of the cells was confirmed by changing the cytokine production 
and CD markers expression. The highest phenotypic plasticity was shown 
towards M2 phenotype for macrophages in all groups. These data can 
indicate the possibility to influence macrophage-mediated immune re-
sponse in different clinical variants of GERD.
disclosure: Nothing to disclose 
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Introduction: Patients with gastroesophageal reflux disease (GERD) often 
have nocturnal symptoms. However, pathophysiology of nocturnal symp-
toms is not fully understood.
aims & Methods: A total 25 subjects were enrolled (11 females, median age 
58 year-old). Subjects were divided into five controls, six reflux esophagitis 
(RE) patients without nocturnal reflux symptoms and 14 RE patients with 
nocturnal reflux symptoms. We evaluated esophageal motility, and gas-
troesophageal reflux (GER) and esophago-pharyngeal reflux (EPR) events 
with a high-resolution impedance manometry system using a Unisensor 
catheter. The system has 36 pressure sensors and 16 impedance measure-
ment sites. Pharyngeal and esophageal pH sensors were located 1.5 cm 
above the proximal border of the upper esophageal sphincter (UES) and 
5 cm above the proximal border of the lower esophageal sphincter (LES) 
to detect EPR and GER events. Sleep stages were assessed using poly-
somnogram. These measurements were concurrently recorded for about 
6-hours post-prandially in the supine position during sleep. Subjects, who 
took proton pump inhibitors (PPIs), were made to stop taking PPIs at least 
one week prior to the study. Subjects had a standard meal (1000 kcal) 
before recording. The presence of RE was evaluated by esophagogastro-
duodenoscopy and the severity of nocturnal symptoms was assessed by 
nocturnal gastro-esophageal reflux disease symptom severity and impact 
questionnaire (N-GSSIQ) in all subjects. The number of transient LES relax-
ation (TLESR), GER, EPR events and the length of proximal extent of liquid 
refluxate from the proximal border of the LES in each liquid or mixed GER 
event were evaluated. Data is shown as median (25%, 75%).
results: Most GER events were associated with TLESR events and they oc-
curred during awakening or just after arousals. There was no acid EPR 
event. The incidences of TLESR, TLESR with liquid or mixed GER, TLESR 
with acid GER and TLESR with UES relaxation were not different among 
three groups (Table). The length of the proximal extent of liquid reflux-
ate in RE patients with nocturnal symptoms was significantly longer than 
other groups (p< 0.05).
  controls
re patients without 
nocturnal reflux 
symptoms
re patients with 
nocturnal reflux 
symptoms
Number of subjects 5 6 14
Number of TLESR events 11 (6, 20) 19 (14, 25) 12 (9, 18)
Number of TLESR events 
with liquid or mixed GER 
events
8 (4, 14) 14 (6, 18) 11 (8, 18)
Number of TLESR events 
with acid GER
0 (0, 6) 2 (0, 6) 5 (0, 8)
Number of TLESR events 
with UES relaxation
1 (1, 4) 3 (0, 6) 0 (0, 1)
Length of proximal extent 
of liquid refluxate
5 (4, 11) 5 (3, 13) 8 (5, 14)*
[Number of events among groups]
conclusion: Nocturnal reflux symptoms are related to the proximal extent 
of liquid refluxate during nighttime. Acid EPR event is not common during 
nighttime.
disclosure: Nothing to disclose 
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P1969 The rOLe Of esOPhageaL ePITheLIaL InTegrITy 
On PrOTOn PuMP InhIBITOr resPOnse In PaTIenTs WITh 
gasTrOesOPhageaL refLux dIsease
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contact e-Mail address: pelinergun@yahoo.com
Introduction: 20-30% of patients with gastroesophageal reflux disease 
(GERD) do not adequately respond to proton pump inhibitors (PPI). It is 
not known whether esophageal epithelial integrity is one of the determi-
nant of the response.
aims & Methods: We evaluated the relationship between PPI response rate 
and esophageal epithelial integrity in GERD patients.
24 healthy controls (HC) 16 functional heartburn, 11 reflux hypersensitivity, 
35 true non-erosive reflux (NERD), 48 erosive GERD A-B (ERD AB) and 12 
erosive GERD C-D (ERD CD) in total 146 subjects were included. GERD and 
QoL questionnaires, high-resolution esophageal manometry, off-PPI intra-
esophageal 24-h impedance-pH monitoring, upper gastrointestinal en-
doscopy with distal esophageal biopsies performed in all patients. Esoph-
ageal epithelial resistance (TEER) and tissue permeability via fluorescein 
diffusion within 2 hours were measured by mini-Ussing chamber system. 
Patients were analysed according to phenotypes and PPI responses; >80% 
very good, 50-79% good, < 50% no response.
results: TEER of all GERD patients were significantly lower than the 
healthy controls. TEER of all GERD groups were decreased compared to HC 
however only ERD groups were significant. The tissue permeability of all 
phenotypes and functional heartburn was significantly higher than con-
trols. According to PPI response, TEER was significantly lower and tissue 
permeability was significantly higher than the controls. Tissue permeabil-
ity in >80% responder group was significantly lower compared to “good” 
and “no response” groups. While TEER results of “17-34” age group were 
higher but insignificant than older patients (>55 yo) (p=0.072), tissue per-
meability was significantly lower. In addition, the tissue permeability of 
patients ≤50 yo healthy controls was significantly lower than older healthy 
controls.
  Teer (ohm) Permeability (pmols)
Healthy controls 166,8 ± 46,2 36,9 ± 13,5
PPI response ≥80% 147,0 ± 39,1** 45,9 ± 23,8*
PPI response 50-79% 136,0 ± 37,6** 57,6 ± 33,1* ^^
No response <50% 138,9 ± 51,8** 60,1 ± 38,9** ^
ERD (all) 129,3 ± 33,3* 51,7 ± 30,7 **
ERD A/B 133,7 ± 34,1* ¥¥ 46,9 ± 28,1***
ERD C/D 112,1 ± 37,1* ¥ 60,1 ± 38,9**
NERD 151,4 ± 48,0 57,5 ± 32,9**
Reflux hypersensitivity 153,6 ± 46,5 65,4 ± 34,1**
Functional heartburn 159,5 ± 55,1 54,5 ± 34,1***
All patients 141,8 ± 39,4** 55,0 ± 32,8*
GERD patients 17-34 yo 150,1 ± 39,4 50,4 ± 25∞
GERD patients >55 yo 133,0 ± 51,6 67,5 ± 43,2
* p≤ 0.001 vs HC, ** p<0.01 vs HC, *** p<0.05 vs HC ¥ p≤ 0.01 vs NERD, ¥¥ p<0.05 vs 
NERD ^ p≤ 0.01 vs Very good PPI response, ^^ p≤ 0.05 vs Very good PPI response ∞ p< 
0.05 vs >55 aged
[Transepithelial resistance and permeability results of the groups]
conclusion: Tissue resistance was lower and tissue permeability higher 
in all GERD patients compared to healthy controls implicates that tissue 
integrity decreases in GERD. Although the PPI response criteria in the lit-
erature have been determined in “50% and above” range; this rate is not 
adequate at the clinical level. We found that a higher and clinically more 
significant level which is >80% range was significantly related with a bet-
ter epithelial integrity. This finding implicates that lower ion (H+) perme-
ability might be related with higher PPI response. The tissue permeability 
of older healthy controls was higher than younger subjects implicates the 
importance of aging by itself.
disclosure: Nothing to disclose 
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Introduction: The crural diaphragm is an essential component of the 
esophagogastric junction (EGJ). Inspiratory EGJ pressure is lower in GERD 
and patients fail to increase EGJ pressure during graded increase in in-
spiratory resistance. Also, some reflux esophagitis patients may have a 
weaker and thinner crural diaphragm. Inflammation is an important factor 
of muscle dysfunction. One of the most common causes of human inflam-
mation is the infection by Helicobacter pylori, which has a complex rela-
tionship with GERD.
aims & Methods: The aim of this study is to measure the thickness of the 
crural diaphragm in GERD patients and analyze its relation to symptoms, 
gastric inflammation, and the infection with H. Pylori. Thirty patients (18 
females, age 46.7 yr, weight 71.5 kg, in average) with GERD (distal esopha-
geal acid exposure > 4.2%) were studied after approval by the local ethi-
cal committee (HUWC-Ceará Federal University, Fortaleza, Brazil). The 
right crus of the diaphragm (RC) is easily identified with an endoscopic 
ultrasound (EUS) probe positioned in the EGJ region during expiration (12 
MHz, radial probe, Fujinon, Japan). The RC images were stored for poste-
rior blinded measurement of its ortogonal section, in mm. GERD patients 
were categorized according to the RC thickness (cutoff=4mm, lower limit 
of our laboratory 95%CI). During the endoscopic procedure, biopsies of 
the antrum and gastric corpus (five different sites) were taken for blinded, 
four-points (0-3), hystologic analysis for each of the following items: in-
flammation, inflammatory activity (neutrofil infiltration), metaplasia, atro-
phy, and H. pylori infection. The total score of each hystologic item were 
summed up for statistical analysis. The maximal inspiratory oral pressure 
(maxIP, in cmH
2
O) was measured with a digital manometer during maxi-
mal isometric inhalation in sitting position with nostrils closed, as marker 
of inspiratory muscles strength. The volunteers also completed two GERD 
questionnaires: RSI for atypical and RDQ for typical symptoms. Data were 
analyzed with Student t or Mann-Whitney Tests. Results are presented in 
mean ± SEM or median (minimum-maximum).
results: Age and weight did not differ between patients with normal 
(n=23) or abnormal (n=7) RC thickness. Symptoms total scores did not 
differ significantly between the two groups: RDQ (9 (2-30) vs 20 (2-25), 
p=0,10) and RSI (13 (1-42) vs 21 (6-38), p=0.17). However, the epigastric 
burning sensation (RDQ item) and the respiratory difficulty (RSI item) were 
higher in the group with a thinner RC (0 (0-5) vs 3 (0-5), p=0.03; 0 (0-5) 
vs 5 (0-5), p=0.023; respectively). Inflammation, inflammatory activity, and 
H. pylori infecction scores were significantly higher in the patients with a 
thinner RC (5 (1-8) vs 5 (5-6), p=0.042; 0 (0-9) vs 5 (0-10), p= 0.003; 0 (0-13 
vs 8 (0-15), p=0.008; respectively). Atrophy and metaplasia did not differ 
between the groups. The positivity of the rapid urease test was also higher 
in the patients with abnormal RC thickness (p=0.008). Acid exposure in the 
distal esophagus did not differ between the two groups of GERD patients. 
The maxIP were less negative in the patients with abnormal RC thickness 
(-75.5±7.5 cmH
2
O vs -56.1±3.9 cmH
2
0).
conclusion: In GERD patients, the thickness of the RC and the strength 
of inspiratory muscles were associated with gastric inflammation due to 
the infection with H. Pylori. The esophageal acid exposure and the typical 
symptoms of the two groups of GERD patients did not differ. These results 
brings about new evidence that may help interpret the complex relation-
ship between H. Pylori infection and GERD.
references: Souza et al, Am. J. Physiol., DOI: 10.1152/ajpgi.00054.2013 
Souza et al, NG&M, DOI: 10.1111/nmo.12899
disclosure: Nothing to disclose 
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P1971 The InfLuence Of cruraL dIaPhragM On 
esOPhagOgasTrIc juncTIOn funcTIOn and gasTrOesOPhageaL 
refLux dIsease feaTures. a PrOsPecTIve sTudy WITh hIgh 
resOLuTIOn ManOMeTry and IMPedance-Ph MOnITOrIng
Tolone S.1, Parisi S.2, Savarino E.V.3, De Bortoli N.4, Frazzoni M.5, 
Penagini R.S.6, Della Coletta M.7, Savarino V.8, Docimo L.9
1University of Campania, Surgery, Naples, Italy, 2Università della Campania 
Luigi Vanvitelli, Naples, Italy, 3University of Padua, Department of 
Surgery, Oncology and Gastroenterology, Padua, Italy, 4University of Pisa, 
Dept. of Gastroenterology, Pisa, Italy, 5Baggiovara Hospital, Digestive 
Pathophysiology Unit, Modena, Italy, 6Università degli Studi di Milano 
Dipto. di Gastroenterologia, Dipartimento di Scienze Mediche, Milan, Italy, 
7University of Padua, Division of Gastroenterology, Department of Surgery, 
Oncology and Gastroenterology, Padua, Italy, 8Universita di Genova, Dept 
Internal Medecine, Genova, Italy, 9University of Campania ‘Luigi Vanvitelli’, 
Naples, Italy
contact e-Mail address: salvatore.tolone@unicampania.it
Introduction: A normal function and morphology of the esophagogastric 
junction (EGJ) is essential in preventing gastroesophageal reflux disease 
(GERD). Crural diaphragm (CD) is responsible for a part of the antireflux 
barrier. High-resolution manometry (HRM) provides information on axial 
separation between lower esophageal sphincter (LES) and CD and can 
evaluate the EGJ antireflux barrier using the EGJ contractile integral (EGJ-
CI). However, comprehensive data about the correlation between presence 
of LES-CD separation, EGJ-CI and GERD features determined at imped-
ance-pH monitoring (MII-pH) are scarce.
aims & Methods: To verify if a increasing distance of LES-CD separation 
and a decreasing EGJ-CI could better correlate with a positive MII-pH test-
ing, with symptoms and the presence of esophagitis. 
Consecutive patients with predominant typical GERD symptoms (heart-
burn and/or regurgitation) and a recent upper endoscopy were enrolled. 
Esophagitis was defined according to Los Angeles classification. The pres-
ence of further symptoms and PPIs response were recorded. All patients 
underwent HRM to assess the EGJ morphology, the EGJ-CI and 10 single 
water swallows to evaluate peristalsis and EGJ function, according to the 
Chicago Classification (CC) 3.0. EGJ Type I was further divided into Type 
I-CO, a complete overlap of LES and CD, and Type I-MS, a minimal separa-
tion, with LES located from the upper border of CD (in correspondence of 
pressure inversion point, 0.0 cm) to 1 cm above. Also, intra-hernia pres-
sure and contractile integral of CD (CD-CI, when distinguishable from LES) 
were recorded.
The patients then underwent impedance-pH testing off-therapy. We re-
corded the esophageal acid exposure time (AET), number of total reflux 
episodes, mean nocturnal baseline impedance (MNBI), post-reflux swal-
low-induced peristaltic wave index (PSPW + if< 53%) and symptom asso-
ciation analysis using symptom association probability (SAP+ if ≥95%) and 
symptom index (SI+ if ≥50%). 
McNemar test and Anova test were performed among groups determined 
according to LES-CD separation.
 
egj Type 
I-cO 
(n=72)
egj Type 
I-Ms 
(n=54)
egj Type 
II (n=42)
egj Type 
III (n=35) P value
Patients with 
GERD (%)
33.3 70.3 76.1 94.2
0.001* 
(n.s. type I-MS vs Type II)
Total number 
of reflux 
(mean ± S.D.)
29±15 48± 29 49±21 79±28
0.001* 
(n.s. type I-MS vs Type II)
AET % 
(mean ± S.D.)
2.7±0.8 4.8±2.2 11±12 17±13 0.001*
PSPW%
(mean ± S.D.)
68± 25 45± 32 50± 37 28± 13
0.001* 
(n.s. type I-MS vs Type II)
MNBI 
(mean ± S.D.)
3211±895 1811±676 1796±943 1279±1285
0.001* 
(n.s. type I-MS vs Type II)
Patients with 
positive symptom 
association (%)
26 55 70.2 86.6 0.001*
EGJ-CI 21±8 15±11 15±14 5±10
0.001* 
(n.s. type I-MS vs Type II)
[Table 1]
results: We enrolled 203 [96M/107F; mean age 46] consecutive patients 
and identified 72 (35.4%) patients with EGJ Type I-CO, 54 (26.6%) Type 
I-MS, 42 (20.7%) Type II and 35 (17.2%) Type III. Patients with Type III EGJ 
had lower EGJ-CI, decreased mean DCI, a higher median number of reflux 
episodes, a greater mean AET, a lower MNBI and PSPW and had more 
frequently a positive symptoms association compared to patients with Type 
II and Type I-CO/MS (Table 1). Type I-MS had a higher number of reflux 
episodes (48 vs. 29, p< 0.03), a greater mean AET (4.8 vs. 2.7, p< 0.05) and 
a greater positive symptom association (55% vs. 26%, p< 0.02) compared 
to Type I-CO. At Anova, PPI response was significantly linked to EGJ Type III, 
whereas dysphagia was linked to higher intra-hernia pressure and CD-CI 
values.
conclusion: With increasing separation between LES and CD, patients had 
a gradually and significantly increase of reflux episodes and esophageal 
acid exposure. Even a minimal separation can be responsible for GERD 
development and supports the role of CD in preventing reflux.
disclosure: Nothing to disclose 
P1972 a nOveL suscePTIBILITy LOcus near grIk2 assOcIaTed 
WITh erOsIve esOPhagITIs In a kOrean cOhOrT
Jin E.H.1, Kim Y.-S.2, Jung S.-A.3
1Seoul National University Hospital Healthcare System Gangnam Center, 
Department of Internal Medicine, Healthcare Research Institute, Seoul, Korea 
(Republic of), 2Seoul National University Hospital Gangnam Center Dept. 
of Internal Medicine, Dept. of Internal Medicine, Seoul, Korea (Republic 
of), 3College of Medicine, Ewha Womans University, Department of Internal 
Medicine, Seoul, Korea (Republic of)
contact e-Mail address: icetea0414@gmail.com
Introduction: Erosive esophagitis is defined as esophageal mucosal breaks 
proven by endoscopy because of gastroesophageal reflux exposure. Through 
Genome-Wide Association Studies (GWAS), we aimed to identify genetic 
factors associated with erosive esophagitis, especially gender differences.
aims & Methods: The GWAS was conducted with 4,242 healthy participants 
who underwent upper endoscopies for health check-ups; 3,620 subjects 
comprised the discovery set and 622 subjects comprised the replication 
set. Erosive esophagitis was diagnosed by endoscopy and assessed for se-
verity. After the quality control and imputation, we used the multivariable 
linear regression and SNPs with p < 5.0 × 10-8 were considered significant 
genome-wide.
results: We detected six genome wide significant SNPs associated with 
erosive esophagitis in male subjects; rs518309 (p = 2.12 x 10-8), rs654455 
(p = 2.12 x 10-8), rs562589 (p = 2.504 x 10-8), rs594589 (p = 2.786 x 10-8), 
rs513126 (p = 2.93 x 10-8), and rs4445064 (p = 5.864 x 10-8). All the SNPs 
were replicated in the replicated set (p < 0.05). We could predict the se-
verity of erosive esophagitis based on genetic risk score established by 
these SNPs. These SNPs were located in topologically associated domain 
of glutamate ionotropic receptor kainite type subunit 2 (GRIK2) gene on 
chromosome 6q16.3.
conclusion: This is the first GWAS to identify SNPs associated erosive 
esophagitis diagnosed by endoscopy. We found six genome wide signifi-
cant SNPs associated with erosive esophagitis and these variation could 
help predict its severity.
disclosure: Nothing to disclose 
P1973 gasTrIn eLevaTIOn durIng LOng TerM PrOTOn PuMP 
InhIBITOr TheraPy and fundIc gLand POLyPs
Kroupa R., Packova B., Konecny S., Dastych M., Dolina J.
University Hospital and Faculty of Medicine Masaryk’s University, 
Department of Internal Medicine and Gastroenterology, Brno, Czech Republic
contact e-Mail address: dolina.jiri@fnbrno.cz
Introduction: Proton pump inhibitor (PPI) therapy is usually associated 
with serum gastrin elevation. Prolonged use of PPI may promote a devel-
opment of fundic gland polyps (FGPs). Concerns have been raised about 
the course of chronic gastrin elevation and relations to FGPs grow. Pub-
lished studies regarding long term PPI use exceed 5 years interval rarely.
aims & Methods: The aim of this study was to analyze the time evolution of 
gastrin elevation during long term PPI therapy of gastroesophageal reflux 
disease and consequences in FGPs development. 
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This prospective observational study included patients with gastroesopha-
geal reflux disease (GERD) on long term PPI therapy. Patients followed 8 
years and longer were selected for analysis. The level of serum gastrin 
during follow up was compared to dose of PPI, sex, H. pylori and presence 
of FGPs on endoscopy.
results: The data from 109 patients (51 males) were available. Mean fol-
low up was 10.9 years. Median serum gastrin level gently fluctuates about 
upper limit of gastrin (115 ng/l) during the period, without any significant 
progression in time. Mean gastrin was non-significantly higher in females 
than males (160 vs 109 (p 0,5)). In 55 patients FGPs were found on gas-
troscopy. 
The mean serum gastrin in patients with and without FGPs was not differ-
ent (131 vs 140 ng/l (p=0,82)). Lower than standard, standard and higher 
PPI doses were related to different gastrin elevation (mean 65 vs 125 vs 192 
ng/l). Neither neuroendocrine tumor nor gastric cancer was recorded in 
the study cohort.
conclusion: Gastrin elevation is mild without any significant progression in 
time during more than 10 years of PPI therapy of GERD. Although chronic 
PPI use is associated with development of fundic gland polyps, this was not 
related to serum gastrin level. The correlation between serum gastrin and 
PPI dose was observed.
disclosure: Nothing to disclose 
P1974 eThnIc cOMParIsOn Of PharMacOkIneTIcs 
and PharMacOdynaMIcs Of dWP14012, a neW 
POTassIuM-cOMPeTITIve acId BLOcker, aMOng kOrean, 
caucasIan and jaPanese
Hwang J.1, Oh J.1, Cho J.2, Lee S.1, Jang I.-J.1
1Seoul National University Hospotal, Clinical Pharmacology and 
Therapeutics, Seoul, Korea (Republic of), 2Daewoong Pharmaceutical Co., 
Ltd., Seoul, Korea (Republic of)
contact e-Mail address: leejh413@snu.ac.kr
Introduction: A potassium-competitive acid blocker (P-CAB), DWP14012, 
is under development for the treatment of acid-related esophageal-gas-
tric disease. This study aimed to compare the pharmacokinetics (PK), 
pharmacodynamics (PD) and safety of DWP14012 among different ethnic 
groups.
aims & Methods: A randomized, double-blind, placebo-controlled, single- 
and multiple-dose study was conducted in Korean, Caucasian and Japa-
nese healthy subjects. Ten subjects in each dose group randomly received 
DWP14012 or placebo in a ratio of 8:2. Each subject was orally received 
DWP14012 (40 mg, 60 mg or 80 mg in Korean; 40 mg or 80 mg in Cau-
casian; 20 mg, 40 mg or 80 mg in Japanese) or placebo once-daily for 7 
consecutive days. Serial blood samples were collected for PK evaluation. 
For PD evaluation, a 24-hour intra-gastric pH monitoring was performed 
at baseline (a day prior to first dose), after a single dose and steady-state 
after multiple doses. Safety profiles were assessed throughout the study. 
A general linear model was developed to compare PK and PD parameters. 
Geometric mean ratios (GMRs) and its 90% confidence intervals (CIs) of 
PK parameters for Caucasian and Japanese over Korean were calculated 
and the mean differences and its 90% CIs of PD parameters between each 
ethnic group was also calculated.
results: After multiple treatment of 40 mg of DWP14012, the plasma 
concentration of DWP14012 and the gastric acid suppression was similar 
among the ethnic groups. The GMR (90% CI) of area under the curve with-
in a dosing interval at steady-state (AUC
tau
) for Caucasian and Japanese to 
Korean were 1.08 (0.76-1.53) and 1.07 (0.76-1.52), respectively. The mean 
percentages of time pH above 4.0 for DWP14012 in Korean, Caucasian and 
Japanese were 64.3%, 62.8% and 70.3%, respectively, and the mean dif-
ference of PD parameter for Caucasian and Japanese compared to Korean 
were not statistically significant (both P > 0.05).
After multiple treatment of 80 mg of DWP14012, the GMR (90% CI) of AUC
tau
 
for Caucasian and Japanese were 0.70 (0.49-0.99) and 0.73 (0.52-1.04), 
respectively. . However, the gastric acid suppression was similar between 
each ethnic group (both P > 0.05); The mean percentages of time pH above 
4.0 for DWP14012 in Korean, Caucasian and Japanese were 94.8%, 90. 6% 
and 90.6%, respectively. 
The increased gastric acid suppression according to dose of DWP14012 and 
clear exposure-response relationship were observed in all ethnic groups. 
There were no serious adverse events and no clinically significant changes 
in tolerability parameters in all dose groups in every ethnicity.
conclusion: After 7-day multiple administration of DWP14012 40 and 80 
mg, the gastric acid suppression and the exposure-response relationship 
were similar among Korean, Caucasian and Japanese. These results sug-
gested that the gastric acid suppression of DWP14012 may not be sensitive 
to ethnic factors.
disclosure: Nothing to disclose 
P1975 On-deMand versus haLf-dOse cOnTInuOus 
TheraPy WITh vOnOPrazan as MaInTenance TheraPy 
fOr gasTrOesOPhageaL refLux dIsease
Tamaki H., Morita M., Noda T., Atsushi K., Ogawa C., Matsunaka T., 
Shibatoge M.
Takamatsu Red Cross Hospital, Department of Gastroenterology, Takamatsu, 
Japan
contact e-Mail address: h-tama@gc4.so-net.ne.jp
Introduction: Although symptomatic gastroesophageal reflux disease 
(GERD) is a chronic clinical condition treated with initial and maintenance 
therapies, there has been no established consensus for a long-term main-
tenance therapy. Several studies have reported the efficacy of vonoprazan 
(VPZ), a novel potassium-competitive acid blocker, as an initial therapy for 
GERD; however, an optimal maintenance therapy with VPZ remains to be 
evaluated.
aims & Methods: The aim of this study was to evaluate the efficacy of an 
on-demand therapy with VPZ as a maintenance therapy for mild symptom-
atic GERD. A retrospective observational study of case data from patients 
with upper gastrointestinal endoscopy-proven symptomatic GERD (defined 
as modified Los Angeles [LA] classification grades A or B, and more than 
8 points on the Frequency Scale for the symptoms of GERD [FSSG]) was 
conducted. We included patients who achieved symptomatic remission, 
which was defined as an FSSG score ≤8 points, after receiving an initial 
therapy with 20 mg VPZ for 8 weeks. These patients were then treated 
with on-demand therapy by taking 20 mg VPZ only when reflux symptoms 
occurred (on-demand group), or with continuous therapy with 10 mg VPZ 
(continuous group) as maintenance therapy. Clinical symptoms were ret-
rospectively compared between the two groups using the FSSG question-
naire at the start of the maintenance therapy, and after 4, 8, 12, 24, 48, and 
52 weeks. An endoscopic evaluation using the modified LA classification 
system was also performed at 12 weeks in both the groups. Furthermore, 
health related quality of life (HRQOL) was assessed using reflex esophagitis 
specific HRQOL questionnaires at 52 weeks.
results: Forty-eight patients (22 men, 26 women; mean age, 72.5 years 
[range, 32-88 years]; on-demand group, 31 patients; continuous group, 
17 patients) completed the study. FSSG scores, modified LA classification 
grades at diagnosis of GERD, and FSSG scores at the start of the mainte-
nance therapy were similar in both the groups (12.0 ± 3.5 vs. 12.8 ± 3.5, P 
= 0.20, grade A; 61.3% vs. 47.1%, P = 0.34; 3.3 ± 2.3 vs. 2.8 ± 2.2, P = 0.20; 
respectively). There was no significant difference in the persistence rate of 
maintenance therapy at week 52 between the groups (85.9% vs. 88.2%, P 
= 0.68). Two patients (6.5%) dropped out because of worsening of symp-
toms, and 3 patients (9.7%) changed regimen to continuous therapy on 
their own volition at remission state in the on-demand group. Moreover, 
two patients (11.8%) dropped out because of worsening of symptoms in 
the continuous group. The average number of VPZ tablets taken per week 
during the 28-52 weeks tended to be lower than that during the 0-28 
weeks in the on-demand group (1.6 tablets ± 0.15 vs. 1.3 tablets ± 0.2, P = 
0.13). Although FSSG scores after 4, 8, 24, 48, and 52 weeks were signifi-
cantly higher in the on-demand group than in the continuous group, there 
was no significant difference in the endoscopic severity, evaluated by the 
modified LA classification system, after 12 weeks between the two groups 
(grade M; 75.0% in the on-demand group vs. 93.8% in the continuous 
group, P = 0.12), and no patients experienced symptomatic recurrence at 
52 weeks in the on-demand group. Furthermore, there was no significant 
difference in HRQOL assessed by reflex esophagitis HRQOL questionnaires 
at 52 weeks between the two groups.
conclusion: On-demand therapy with 20 mg VPZ was an effective alterna-
tive maintenance therapy for mild GERD that was comparable to half-dose 
continuous therapy with a sufficient persistence rate, symptom control 
rate, and HRQOL.
disclosure: Nothing to disclose 
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P1976 a nOveL endOscOPIc fundOPLIcaTIOn fOr 
gasTrOesOPhageaL refLux dIsease: anTI-refLux MucOsaL 
aBLaTIOn (arMa)
Tanabe M., Abad M.R.A., Iwaya Y., Fujiyoshi Y., Quarta Colosso B.M., 
Nishikawa Y., Ueno A., Shimamura Y., Sumi K., Tomida H., Ikeda H., 
Onimaru M., Inoue H.
Showa University Koto Toyosu Hospital, Digestive Diseases Center, Tokyo, 
Japan
contact e-Mail address: mayo.tanabe@gmail.com
Introduction: As a treatment for gastroesophageal reflux disease (GERD), 
proton pump inhibitors (PPIs) are the mainstay of medical therapy. Howev-
er, up to 40% of patients are reported to have persistent GERD symptoms 
despite PPI therapy. Several endoscopic procedures have been attempted 
but no procedure has been widely accepted as the standard endoscopic 
treatment for GERD. We developed Anti-reflux mucosal ablation (ARMA) 
as a minimally invasive treatment.
aims & Methods: The aim of this study is to clarify the efficacy and safety 
of ARMA. The indication of ARMA is PPI refractory GERD patient without 
prominent sliding hernia. The purpose of ARMA is to narrow the space of 
hiatus hernia by performing ablation to the mucosa at the gastric cardia. 
Step 1: marking of scheduled ablation area on the mucosa. Mucosal ab-
lation is scheduled along the gastric cardia in butterfly shape to avoid 
stenosis. Markings on the mucosa were placed using Triangle Tip Knife J 
connected to the electrocautery generator (VIO300D ERBE) in soft coagula-
tion mode, 50 W, effect1. 
Step 2: Saline with indigo carmine dye was injected into submucosa along 
the markings using 25-Gauge needle. Correct submucosal saline injection 
was confirmed by lifting of the mucosal surface. 
Step 3: Near circumferential (butterfly shape) mucosal ablation was made 
using Triangle Tip Knife J in spray coagulation mode, 50W, effect2. 
The efficacy of ARMA was evaluated using the objective findings (flap valve 
grade: Ⅰ/Ⅱ/Ⅲ/Ⅳ as point 0/1/2/3, 24-hour multi-channel intraluminal im-
pedance-pH monitoring) and subjective findings (Frequent Scale for the 
Symptoms of GERD:FSSG, and GERD-HRQL).
results: A total of 12 patients with median age of 54.5 (29-75), Female 
5: Male 7, with PPI-refractory GERD were enrolled in this study between 
May 2018 and March 2019. The procedure time was 40.3 (20-69) minutes 
without any immediate complications. GERD-HRQL score improved sig-
nificantly from median of 30.5 to 12 (p=0.0005), and the FSSG was sig-
nificantly improved from median of 25 to 10.5 (p=0.0078) both at 2-month 
follow-up. The Hill’s flap valve grade score significantly improved from 
1.91 to 0.5 (p< 0.001). The DeMeester composite score improved from 33.5 
to 2.8 (p=0.0547) and percent time clearance pH improved from 9 to 0.5 
(p=0.0781) after ARMA. ARMA was successful in all cases and mild stenosis 
was observed in one patient which was managed by balloon dilatation, 
and no bleeding nor perforation were observed.
conclusion: This case series suggests that endoscopic anti-reflux mucosal 
ablation (ARMA) may represent an effective anti-reflux procedure safely, 
with the added advantage of simplicity, low cost, less invasive, and leaving 
no artificial prostheses in situ. Larger studies with long-term follow up are 
warranted to confirm this result.
disclosure: Nothing to disclose 
P1977 fIxed cOMBInaTIOn Of hyaLurOnIc acId, 
chOndrOITIn-suLPhaTe and aLuMInuM hydrOxIde resTOres 
esOPhageaL MucOsaL InTegrITy In PaTIenTs WITh PrOven 
gasTrOesOPhageaL refLux dIsease - a randOMIzed, 
cOnTrOLLed, PaThOPhysIOLOgIcaL and cLInIcaL sTudy
Savarino E.V.1, Ghisa M.2, Della Coletta M.3, Lorenzon G.1, Marinelli C.1, 
Rigato M.4, Zingone F.1, Savarino V.5
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Introduction: Esophageal intraluminal baseline impedance (BI) is deter-
mined by the conductivity of esophageal wall and is considered a sur-
rogate marker of mucosal integrity, which impairment is associated to the 
development of gastro-esophageal reflux disease (GERD). Indeed, patients 
with GERD exhibit decreased distal BI as compared to healthy controls and 
this finding has been correlated with abnormal distal esophageal acid ex-
posure time (AET). Current research is being focused on novel compounds 
able to protect the esophageal mucosa and restore its integrity. Recently, 
a new medical device based on a combination of hyaluronic acid, chon-
droitin-sulphate and aluminum hydroxide, in a single melt in mouth tablet 
(GERDOFF®, Sofar) has been marketed
aims & Methods: We aimed to investigate whether GERDOFF® was able 
to modify the esophageal mucosal integrity in patients with GERD. This 
was a prospective, single center, randomized, controlled study (EC ap-
proval 4203/AO/17). Within 1-5 days from the upper endoscopy carried 
out off-therapy, 32 patients with typical reflux symptoms and evidence 
of erosive esophagitis greater than Los Angeles (LA) grade B, completed 
the Reflux Disease Questionnaire (RDQ) to assess severity and frequency 
of GERD symptoms, the GERD health-related quality of life (GERD-HRQL) 
and underwent high-resolution impedance manometry (HRIM) followed 
by a 10 minutes impedance-pH recording. Thereafter, they were random-
ized in a 1:1 ratio to receive GERDOFF®, 6 tablets per day, to be admin-
istered after each daily meal, at mid-morning and mid-afternoon and at 
bedtime (Group A), or an oral antacid or alginate on as needed basis for 
14±2 days (Group B). Thereafter, patients repeated the questionnaires, 
filled in a VAS scale to measure the palatability of GERDOFF® and un-
derwent a 24-hour impedance-pH monitoring. Tracings were blindly and 
manually reviewed and BI was measured at distal (at 3cm), mid (at 9cm) 
and proximal (at 15cm) esophagus off-therapy (10 minutes recording) and 
after 14±2 days of treatment. Secondary study parameters were: symp-
toms relief after 14±2 days of treatment, palatability, safety and toler-
ability of GERDOFF®.
results: Two patients did not complete the study and were excluded. So 
far, data from 30 patients [18M/12F; mean age 54 (27-72) years; mean BMI 
26 (18-34)] were further analyzed. Seventeen patients had Grade B, 4 grade 
C, 2 grade D esophagitis and 7 had short-segment Barrett Esophagus. De-
mographic, clinical and conventional impedance-pH features did not differ 
between Group A and Group B (p=ns). Also BI at distal, mid and proximal 
esophagus was similar (p=ns) between the two groups (1553Ω vs. 1284Ω, 
1639Ω vs. 1769Ω, 2140Ω vs. 2303Ω, respectively). In contrast, after treatment 
BI at distal, mid and proximal esophagus was different (p<0.05) between 
the two groups (2093Ω vs. 1247Ω, 2337Ω vs. 1751Ω, 2785Ω vs. 2212Ω, respec-
tively). Twelve out of 15 (80%) patients treated with GERDOFF® showed 
a significant increase of BI after treatment, whereas only 2/15 (14%) had 
a similar effect (p<0.0007). The palatability, safety and palatability of 
GERDOFF® were good.
conclusion: Our data showed that in patients with proven GERD, 
GERDOFF® treatment for two weeks is able to restore the esophageal mu-
cosal integrity in the majority of the patients, at both distal and proximal 
esophagus. These data provide a clear rationale for GERDOFF® use in the 
management of GERD.
disclosure: Edoardo Savarino served as consultant for SOFAR 
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P1978 fIxed cOMBInaTIOn Of hyaLurOnIc acId, 
chOndrOITIn-suLPhaTe and aLuMInuM hydrOxIde IMPrOves 
refLux syMPTOMs and quaLITy Of LIfe In PaTIenTs WITh 
PrOven gasTrOesOPhageaL refLux dIsease - a randOMIzed, 
cOnTrOLLed, PaThOPhysIOLOgIcaL and cLInIcaL sTudy
Savarino E.V.1, Marinelli C.1, Lorenzon G.2, Della Coletta M.3, Ghisa M.4, 
Rigato M.5, Zingone F.1, Savarino V.6
1University of Padua, Department of Surgery, Oncology and Gastroenterology, 
Padua, Italy, 2University of Padua, Padua, Italy, 3University of Padua, 
Division of Gastroenterology, Department of Surgery, Oncology and 
Gastroenterology, Padua, Italy, 4Azienda Ospedaliera di Padova, DISCOG 
- UOC Gastroenterologia, Vedelago (Treviso), Italy, 5Azienda Ospedaliera 
- Universita di Padova, Padua, Italy, 6Universita di Genova, Dept Internal 
Medecine, Genova, Italy
contact e-Mail address: edoardo.savarino@gmail.com
Introduction: Proton pump inhibitors represents the current mainstay of 
gastroesophageal reflux disease (GERD) treatment. However, there is in-
creasing evidence of their failure (i.e. 20-40% of the cases) and adverse 
events. Thus, current research is being focused on novel compounds able 
to protect the esophageal mucosa and reduce the damaging effect of the 
refluxate. Recently, a new medical device based on a combination of hy-
aluronic acid, chondroitin-sulphate and aluminum hydroxide, in a single 
melt in mouth tablet (GERDOFF®, Sofar) has been marketed.
aims & Methods: We aimed to investigate whether GERDOFF® was able to 
modify the esophageal mucosal integrity in patients with GERD. This was 
a prospective, single center, randomized, controlled study (EC approval 
4203/AO/17). Secondary study parameters were: symptoms relief after 14±2 
days of treatment, palatability, safety and tolerability of GERDOFF®. With-
in 1-5 days from the upper endoscopy carried out off-therapy, 32 patients 
with typical reflux symptoms and evidence of erosive esophagitis greater 
than Los Angeles (LA) grade B, completed the Reflux Disease Question-
naire (RDQ) to assess severity and frequency of GERD symptoms, the GERD 
health-related quality of life (GERD-HRQL) and underwent high-resolution 
impedance manometry (HRIM) followed by a 10 minutes impedance-
pH recording. Thereafter, they were randomized in a 1:1 ratio to receive 
GERDOFF®, 6 tablets per day, to be administered after each daily meal, 
at mid-morning and mid-afternoon and at bedtime (Group A), or an oral 
antacid or alginate on as needed basis for 14±2 days (Group B). Thereafter, 
patients repeated the questionnaires, filled in a VAS scale to measure the 
palatability of GERDOFF® and underwent a 24-hour impedance-pH moni-
toring. Tracings were blindly and manually reviewed and BI was measured 
at distal (at 3cm), mid (at 9cm) and proximal (at 15cm) esophagus off-
therapy (10 minutes recording) and after 14±2 days of treatment.
results: Two patients did not complete the study and were excluded. So 
far, data from 30 patients [18M/12F; mean age 54 (27-72) years; mean BMI 
26 (18-34)] were further analyzed. Demographic, clinical and conventional 
impedance-pH features did not differ between Group A and Group B. In 
particular, mean RDQ [28.6 (15-45) vs. 27.6 (4-42), p=0.7800] and mean 
GERD-HQRL [20.2 (3-35) vs. 22.2 (4-35), p=0.864] were similar at base-
line. In contrast, after treatment mean RDQ [28.6 (15-45) vs.16.9 (1-36), 
p=0.0054] and mean GERD-HQRL [20.2 (3-35) vs.12.3 (2-24), p< 0.0030] 
decreased compared to baseline only in the GERDOFF® group, whereas 
no variation was observed in the control group [27.6 (4-42) vs. 31.5 (5-70) 
and 22.2 (4-35) vs. 22.9 (0-33), p=0.1767 and p=0.6451, respectively]. The 
palatability [6.6 (2-10)], safety and tolerabilty of GERDOFF® were good
conclusion: Our data showed that in patients with proven GERD, 
GERDOFF® treatment for two weeks is able to improve GERD-related 
symptoms and quality of life. Larger studies are necessary to confirm these 
preliminary clinical data
disclosure: Edoardo Savarino serve as consultant for SOFAR 
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P1980 MeasureMenT Of seruM gasTrIn LeveLs and 
hIsTOLOgIc evaLuaTIOn Of The degree Of ParIeTaL ceLL 
degeneraTIOn and ecL ceLL hyPerPLasIa are The MOsT 
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1Jikei University, School of Medicine, Department of Internal Medicine, 
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contact e-Mail address: takusan.yamasan@gmail.com
Introduction: The situation surrounding upper gastrointestinal tract dis-
eases is about to change completely due to the decrease in H. pylori infec-
tion rate and the spread of eradication in Japan. In the future, it is expected 
that the use of gastric acid secretion inhibitors will continue to increase 
due to the further increase of gastroesophageal reflux disease (GERD). 
On the other hand, the negative effect and verification of safety associ-
ated with more potent acid suppression and long-term acid suppression 
have not been sufficiently obtained. Potassium Competitive Acid Blocker 
(P-CAB) is the most potent acid secretion suppressant among similar acid 
secretion inhibitors (PPIs and H2 blockers), the use of P-CAB has been 
increasing rapidly in Japan and some countries. But, the negative effect 
of P-CAB (for example progression to neuroendocrine tumors (NET) have 
been remain unknown, so it is necessary to pay attention to the unknown 
side effects of P-CAB
aims & Methods: We aimed to find out an index for avoiding the risk of 
developing neuroendocrine tumor (NET) under the long time use of gastric 
acid secretion inhibitors. We think hypergastrinemia as one of the side ef-
fects of acid secretion inhibitors is the most important factor of NET induc-
tion. In addition, the appearance of ECL cells hyperplasia and degenera-
tion of parietal cells are important precursors of NET, and the presence of 
ECL micronest may be considered as a preneoplastic status of NET onset.
We examined the serum gastrin levels (normal range≦200 pg / ml) and 
gastric biopsy specimens in 55 cases using gastric acid secretion inhibitors 
for GERD from April 2017 to March 2019. We compared the serum gastrin 
levels and the presence of parietal cell degeneration and ECL cell hyper-
plasia on each drug. We examined whether it could be an important index 
for avoiding the risk of developing NET.
results: All 55 cases were divided into 20 cases in the P-CAB group and 
35 cases in the PPI group, we compared the serum gastrin levels in fast-
ing conditions. In the P-CAB group the serum gastrin levels were signifi-
cantly higher (160~35,000 median 2,600) than in the PPI group (40~2,000 
median 280) (p < 0.01). Furthermore, in 26 cases (10 cases in the P-CAB 
group and 16 cases in the PPI group) where stomach biopsy specimens 
were present, 90% (9/10) of the P-CAB group and 50% (8/16) of PPI group 
showed the presence of parietal cell degeneration and ECL cell hyper-
plasia. In addition, the results of comparing the degree of parietal cell 
degeneration and ECL cell hyperplasia showed severe changes in P-CAB 
group 67% (6/9) rather than PPI group 25% (2/8). Two cases of short-term 
use of P-CAB (6 months) were included, it was suggested that histological 
changes due to short-term use of P-CAB occurred in the gastric gland. In 
summary, significant hypergastrinemia associated with strong inhibition 
of gastric acid secretion was revealed, and histologically, parietal cell de-
generation and ECL cell hyperplasia had been occurred at high rates. Fur-
thermore, it became clear that more pronounced changes appeared due 
to the stronger suppression of acid secretion. We believe that long-term 
potent inhibition of acid secretion may increase the risk of developing NET.
conclusion: More potent gastric acid secretion suppression resulted in 
marked hypergastrinemia, hyperplasia of ECL cells and degeneration of 
parietal cells. Therefore, when continuing strong suppression of gastric 
acid secretion, it is recommended that serum gastrin levels and histologic 
evaluation be performed to reduce the risk of developing NET.
disclosure: Nothing to disclose 
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P1981 aLTered guT MIcrOBIOTa In candIdaTes fOr 
anTIrefLux surgery
Haworth J.1, Vales A.2, Boyle N.3, Hobson A.1,2,3
1The Functional Gut Clinic, Manchester, United Kingdom, 2The Functional 
Gut Clinic, London, United Kingdom, 3RefluxUK, London, United Kingdom
contact e-Mail address: jordan@functionalgutdiagnostics.com
Introduction: Antireflux surgery is an option for patients with symptoms 
of gastroesophageal reflux disease (GORD) who have an unsatisfactory re-
sponse to proton pump inhibitor (PPI) therapy or seek an alternative to 
lifelong medication. However, long-term PPI therapy is associated with an 
altered gut microbiota.1,2 Candidates for antireflux surgery are not routinely 
screened for dysbiosis of the gut microbiota. We performed a hydrogen 
and methane breath test (HMBT) in patients under consideration for anti-
reflux surgery with a history of PPI use.
aims & Methods: 138 patients on long-term PPIs (>6 months) and referred 
for antireflux surgery performed a lactulose HMBT. A positive result for 
small intestinal bacterial overgrowth (SIBO) and/or excessive methane 
production was indicative of dysbiosis (determined by a rise in hydrogen 
≥10 ppm above baseline within 60 minutes after ingestion of substrate and 
determined by methane levels ≥10 ppm at any interval, respectively). Pa-
tients who underwent a complete 24-hour ambulatory pH study and HMBT 
were analysed for association with GORD (determined by a distal acid ex-
posure time of >4%) and reflux symptom association (determined by a 
symptom index of ≥50% and symptom association probability of ≥95%) 
statistically using Pearson Chi-Square test.
results: In total 59.4% of subjects (82/138) had gut dysbiosis (25.3% were 
positive for SIBO, 19.6% were positive for excessive methane production 
and 14.5% had concomitant SIBO and excessive methane). 63 patients pro-
vided a complete 24-hour pH study and HMBT. The presence of dysbiosis 
was not associated with an abnormal AET (p=>0.05) but was associated 
with a positive reflux-symptom association (p=0.001). Belching and re-
gurgitation were the most frequently reported symptoms associated with 
reflux episodes.
conclusion: A large proportion of patients considering antireflux surgery 
as a management strategy present with altered gut microbiota as deter-
mined by HMBT. Those patients with dysbiosis are more likely to have a 
positive association between reflux episodes and symptoms. Breath test-
ing may be a useful adjunctive test in the pre/post-operative assessment 
of antireflux surgery. Although, further prospective study is required to 
determine the impact of altered gut microbiota on clinical outcomes fol-
lowing antireflux surgery.
references: 1. Jackson MA, Goodrich JK, Maxan M-E, Freedberg DE, Abrams 
JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut 
microbiota. Gut. 2016;65(5):749. 2. Imhann F, Bonder MJ, Vich Vila A, Fu J, 
Mujagic Z, Vork L, et al. Proton pump inhibitors affect the gut microbiome. 
Gut. 2016;65(5):740.
disclosure: Nothing to disclose 
P1982 rIsk facTOrs fOr erOsIve TOOTh Wear In PaTIenTs 
WITh gasTrOesOPhageaL refLux dIsease (gOrd) syMPTOMs: 
a PrOsPecTIve crOss-secTIOnaL case cOnTrOL sTudy
Alharthi R.1,2, Moazzez R.1, Bartlett D.1, Jafari J.3
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London, United Kingdom, 2Pirincess Noura bnt Abdulrahman University, 
Riyadh, Saudi Arabia, 3Guy’s and St Thomas Hospital, London, United 
Kingdom
contact e-Mail address: rasha.alharthi@kcl.ac.uk
Introduction: The most common oral manifestations of patients with GORD 
symptoms is erosive toot wear (ETW). It is not clear why a group of patients 
with GORD symptoms develop ETW whereas others don’t. The aim of this 
study is to assess the risk factors associated with developing ETW in pa-
tients with GORD symptoms, and to identify the predictive factors for ETW.
aims & Methods: Consecutive patients referred for assessment of GORD 
to the Oesophageal Laboratory at Guy’s Hospital were recruited (REC Ref 
18/NE/0099). After consenting, validated self-reported Reflux Symptom 
Questionnaire 7-day recall (RESQ-7) was used to assess the frequency and 
intensity of GORD symptoms. Patients underwent 24hr impedance-pH re-
flux monitoring; acid exposure times, Symptoms index (SI) and symptoms 
association probability (SAP) were reported.
A clinical assessment of ETW was done using Basic Erosive Tooth Wear 
Examination (BEWE) protocol; a validated index in which the mouth is 
divided into 6 areas each scored from 0 to 3 (0= no ETW, 1= initial loss of 
surface texture, 2= loss of hard tissue < 50% of surface area and 3= loss of 
hard tissue ≥ 50% of surface area). Those with a cumulative score of ≥12 
and at least 1 oral area scoring 3 were included in the ETW group (ETW) 
and the rest were included in the NETW group (No ETW).
Data were analysed using STATA software, mean (SD), t-test analysis and 
ROC curve analysis were applied. P< o.o5 was considered significant.
results: 121 patients were recruited: ETW (n=64), NETW (n=57). Patients 
reported a range of 9 symptoms more commonly: heartburn, chest pain, 
regurgitation, cough, hoarseness, acid taste, throat burning, belching 
and epigastric pain. (mean±SD) of intensity and frequency of individual 
symptoms of heartburn, hoarseness and coughing were significantly 
higher in ETW group: 
Heartburn intensity (ETW: 12.7±0.9 vs NETW: 9.7±0.9; P= 0.03), frequency 
(ETW: 14.3 ±1.0 vs NETW: 10.3 ±1.0; P= 0.007). Hoarseness intensity (ETW: 
2.25±0.2 vs NETW: 1.32 ±0.2; P= 0.004), frequency (ETW: 2.8 ±0.2 vs NETW: 
1.5±0.2; P= 0.0004). Coughing intensity (ETW: 3.0 ±0.2 vs NETW: 1.6± 0.2; 
P= 0.004, frequency (ETW: 3.5 ±0.2 vs NETW: 1.98 ±0.2; P= 0.0001).
ROC curve analysis, considering all symptoms on RESQ-7, showed that 
patients with total frequency of >25 (54.01% were correctly classified with a 
specificity of 30.88% and sensitivity of 76.8%) and/or total intensity of >36 
(61.36% were correctly classified with a specificity of 81.5% and sensitivity 
of 41.8%) are more likely to develop ETW amongst GORD patients.
119/121 patients completed impedance-pH testing, total acid exposure time 
was significantly higher in ETW (1.48± 0.06) patients vs NETW (1.28±0.06); 
P=0.02. However, there was no significant difference between the two 
groups when upright and/or supine acid exposure time was considered 
individually.
conclusion: This study demonstrates that there are three predictive values 
of developing ETW in GORD patients:
1) Heartburn, hoarseness and coughing as opposed to other reflux 
symptoms. Hoarseness and cough may indicate progression of reflux to 
proximal oesophagus and oral cavity.
2) Abnormal total acid exposure time, regardless of the body position or 
diurnal changes, on reflux monitoring.
3) Total frequency >25 and/or intensity >36 of all symptoms on RESQ-7; 
although not yielding in high accuracy.
disclosure: Nothing to disclose 
P1983 The naTuraL hIsTOry Of LOW-grade dysPLasIa In 
PaTIenTs WITh BarreTT’s OesOPhagus: a TerTIary cenTre 
exPerIence
Hussein M.1,2, Sehgal V.1, Magee C.3, Sami S.2,4, Banks M.5, Sweis R.1, 
Graham D.1, Morris D.1, Rodriguez M.1, Jansen M.1, Novelli M.1, Lovat L.2, 
Haidry R.1,2
1University College London Hospital, Gastroenterology, London, United 
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College London Hospital NHS Trust (UCLH), Endoscopy Unit, Gastrointestinal 
Services, London, United Kingdom
contact e-Mail address: mohamed.hussein3@nhs.net
Introduction: Barrett’s Oesophagus (BE) is associated with increased risk of 
oesophageal cancer (EAC). The optimal management of low-grade dyspla-
sia (LGD) arising in BE remains controversial. We performed a retrospec-
tive study from a tertiary referral centre for BE neoplasia, to estimate time 
to progression in patients with confirmed LGD compared to down-staged 
LGD.
aims & Methods: We carried out retrospective analysis of tertiary BE LGD 
referrals in a single tertiary centre (July ‘06-October ‘18). Patients under-
went high definition white light endoscopy with chromoendoscopy with 
targeted and Seattle protocol biopsies following referral. All biopsies were 
reviewed by at least two expert pathologists. We carried out analysis in 
ablation naïve patients with at least one follow-up endoscopy post index 
procedure. The primary end point was time to progression to high grade 
dysplasia (HGD)/EAC.
results: 141 LGD patients were included.13 were diagnosed during surveil-
lance at our centre. 128 were tertiary referrals. 43/128(34%) were upstaged 
at index endoscopy after referral to HGD/intramucosal adenocarcinoma 
989Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
(IMC). 12 were upstaged to IMC, all had endoscopic mucosal resections 
at index.
44/128(34%) were down-staged, 28/128(34%) to non-dysplastic Barrett’s 
oesophagus (NDBO), 15/128(12%) to indefinite for dysplasia (IND), one had 
no BE on index endoscopy. In the NDBO/IND group, 34 had no ablations 
and at least one follow-up endoscopy during surveillance at our cen-
tre, 5/34(15%) progressed to HGD/IMC over a median time of 36 months 
(IQR,13-42).
41/128(32%) of all referrals had confirmed LGD at index endoscopy. There 
was 54/141(38%) confirmed “true” LGD including patients diagnosed un-
der our surveillance programme. In this cohort 34 had no ablations and at 
least one follow-up endoscopy during follow-up surveillance. 10/34(32%) 
progressed to HGD/IMC over a median time of 10 months (IQR,4-16). The 
remainder of this cohort had a median follow up of 27 months (IQR,14-45), 
and average number of 2 follow-up endoscopies with biopsies. 
  ‘True’ Lgd (n=34)
Ind (n=13) 
(downstaged cohort)
ndBO (n=21) 
(downstaged cohort)
Mean age, years 66 71 69
Male sex 30/34 (88%) 12/13 (92%) 16/21 (76%)
Medan progression time 
to hgd/IMc (months) 10 (IQR, 4-16) 19 (IQR, 11-28) 42 (IQR, 28-72)
Median months of 
follow-up 17 (IQR, 6-39) 31 (IQR, 15-46) 17 (IQR, 6-31)
[Analysis of ablation treatment naive patients]
conclusion: Our data shows the variability in the diagnosis of LGD from re-
ferring centres, with 32% of referrals with confirmed LGD. The cumulative 
incidence of progression to HGD/IMC and time to progression varied across 
subgroups. Confirmed LGD had a shorter progression time compared to 
the down-staged group (NDBO/IND). It is important to differentiate these 
subgroups so that decisions on surveillance/endotherapy can be more 
personalised and resources utilised more wisely.
disclosure: Nothing to disclose 
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Introduction: Barrett’s oesophagus (BE) is the main risk factor for oe-
sophageal adenocarcinoma (OAC). The presence of dysplasia significantly 
increases the risk of BE malignant progression, hence, endoscopic treat-
ment such as radiofrequency ablation (RFA) is recommended in those 
cases. After RFA, random 4-quadrant biopsies at the gastro-oesophageal 
junction (GOJ) are taken to detect residual disease. It is debatable wheth-
er intestinal metaplasia (IM) at the GOJ is a reliable marker of residual 
disease since it is subjective and patchy in nature. We have previously 
shown that methylation panel is accurate in identifying IM within the oe-
sophageal tissue1.
aims & Methods: In this single-centre, retrospective study we aimed to 
investigate whether a methylation panel in GOJ biopsies could be used 
to stratify patients after RFA. We analysed paraffin-embedded 4-quad-
rant BE and GOJ biopsies from adult patients with BE who underwent 
RFA, achieved remission, and had at least 2 follow-up endoscopies with 
biopsies taken at the GOJ. Biopsy sets from each treatment time-point 
(pre-RFA, 1st and 2nd follow-up) were included. The extent of IM was 
classified using a dedicated 4-tier histological score (IM-Score) and im-
munochemistry score using trefoil factor-3 staining (TFF3-score). The 
IM-Score was based on number of glands with goblet cells (1, 2-5 or >5 
glands) and number of biopsies with IM (0=no IM, 1=focal, 2=moderate 
and 3=extensive) and a total score of 0-1 was regarded as ‘focal IM’ and 
2-3 as ‘diffuse IM’. TFF-3 was scored as positive in the presence of intense 
cytoplasmic staining. Promoter methylation at 3 genes (ZNF345, TFP12, 
ZNF569) was assessed by Methylight and a mean value was generated 
(Meth-Score). Methylation levels were compared using one-way ANOVA 
and Wilcoxon test, where appropriate. The accuracy of methylation panel 
in predicting diffuse IM after RFA treatment was assessed by calculating 
the area under the receiver operating characteristic curve (AUC). The cor-
relation between Meth-score and IM-Score / TFF3 was assessed using 
Spearman’s method.
results: We included 45 patients, who achieved endoscopic remission af-
ter RFA. The pre-RFA grades included: non-dysplastic BE (NDBE; 24.4%), 
low-grade dysplasia (LGD; 31.1%), and high-grade dysplasia/intramucosal 
carcinoma (HGD/IMC; 44.4%). Overall, the methylation levels correlated 
with the degree of dysplasia, with a Meth-Score of 40.5%, 63.0% and 
80.6% in NDBE, LGD, HGD/IMC, respectively (P<0.001). One-hundred-and-
five GOJ biopsy sets (post-RFA) were analysed, of which 87 (82.9%) had 
focal IM, and 18 (17.1%) had wide-spread IM, with corresponding mean 
methylation levels of 2.4% and 35.5%, respectively (P=.018). The accuracy 
of methylation panel in predicting wide-spread IM at the GOJ was high 
(AUC 91.6%, 95%CI 87.0%-96.2%). Within the GOJ biopsy sets we found 
a significant correlation between methylation levels and amount of IM, 
measured both with IM-Score (rho=66.0%, P<0.001) and TFF3 positivity 
(rho=75.6%, P<0.001).
conclusion: The methylation panel can differentiate grades of dysplasia in 
Barrett’s and significantly correlates with the extent of IM at the GOJ. We 
propose the Meth-Score as an objective measure of residual and recurrent 
disease following RFA.
references: 1) Chettouh H, Mowforth O, Galeano-Dalmau N, et al. Methyla-
tion panel is a diagnostic biomarker for Barrett’s oesophagus in endoscopic 
biopsies and non-endoscopic cytology specimens. Gut. 2018;67:1942-1949.
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1University College London Hospital, Gastroenterology, London, United 
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Introduction: Barrett’s Oesophagus (BE) is associated with an increased 
risk of oesophageal cancer (EAC). The optimal management of patient’s 
with low-grade dysplasia (LGD) arising in BE remains controversial. In the 
past 3 years there is a shift toward offering endoscopic eradication therapy 
to avoid cancer progression. We performed a retrospective study from a 
tertiary referral centre for BE neoplasia, our aim was to look at risk factors 
for progression of ‘true’ low grade dysplasia (LGD confirmed at endoscopy 
by two expert Barrett’s histopathologists).
aims & Methods: We carried out a retrospective analysis of all confirmed 
LGD BE in a single tertiary centre (July 2006-October 2018) and assessed 
risk factors which may affect rates of progression. Extent was defined as 
unifocal (One endoscopic level of LGD) or multifocal (>1 endoscopic level 
of LGD in BE segment). All patients underwent high definition white light 
endoscopy with chromoendoscopy with targeted and Seattle protocol bi-
opsies following referral. All biopsies were reviewed by at least two expert 
pathologists. The primary end point was time to progression to high grade 
dysplasia (HGD)/EAC.
results: A total of 54 patients had confirmed low grade dysplasia follow-
ing index endoscopy, 34 patients (30m, 4f) were ablation treatment naïve 
and had at least one follow-up endoscopy. The average age of this cohort 
was 66 . Patients had an average of 2 (IQR,1-3) follow-up endoscopies with 
biopsies following index endoscopy at our centre. Their median follow-up 
time was 22 months (IQR,8-39).
16/34 (47%) patients had multifocal low-grade dysplasia. 8(50%) of these 
patients progressed to HGD/EAC over a median time of 14 months (IQR,6-
19). 2/18 (11%) patients with unifocal low grade dysplasia progressed to 
HGD/EAC over a median time of 2 months (IQR, 2-3). There was significant 
difference in numbers that progressed between both groups (P < 0.05).
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6/34 (18%) patients had nodularity in Barrett’s at baseline. 4/6 (67%) of 
these patients progressed to HGD/EAC over a median time of 8 months 
(IQR, 3-14). Most of these patients (75%) had an endoscopic mucosal re-
section for staging. 6/28 (21%) patients with no nodularity progressed to 
HGD/EAC over a median time of 11 months (IQR,5-21). There was a signifi-
cant difference in the numbers that progressed between the two cohorts 
(P < 0.005).
5/34 (15%) patients had a short segment of Barrett’s (< 3cm). 1/5 (20%) of 
these patients progressed to EAC after one month. 9/29 (31%) patients with 
a long segment of BE (≥ 3cm) progressed to HGD/EAC over a median follow 
up time of 13 months (IQR, 4-17). 
 
unifocal 
Lgd
Multifo-
cal Lgd
short Be 
segment
Long Be 
segment
nodula-
rity
no 
nodularity
Male female
Number 
progressed 
to HGD/
EAC (%)
2/18 
(11%)
8/16 
(50%)
1/5 (20%)
9/29 
(31%)
4/6 
(67%)
6/28 
(21%)
9/30 
(30%)
1/4 
(25%)
P- value P < 0.05 P = 0.6 P < 0.05 P = 0.8
[Analysis of radio frequency ablation naive patients]
conclusion: LGD in BE can be difficult to accurately diagnose pathologi-
cally and therefore management can often be variable. Robust prognostic 
markers are needed to differentiate those patients that need surveillance 
or endotherapy. Multifocal LGD and nodularity were associated with a sig-
nificant risk of progression to HGD/EAC. The presence of a longer segment 
of BE was associated with a higher progression risk.
There is an argument that the treatment of LGD with endotherapy should 
be indivualised given the possible risks associated. Identifying key risk fac-
tors of progression will tailor treatment in a specific, higher risk cohort.
disclosure: Nothing to disclose 
P1986 cOLuMnar ePITheLIuM MOrPhOLOgy afTer 
esOPhagecTOMy: cLInIcaL InsIghT InTO The deveLOPMenT 
Of BarreTT’s esOPhagus
Iizuka T.1, Ohkura Y.2, Ueno M.2
1Toranomon Hospital, Gastroenterology, Tokyo, Japan, 2Toranomon Hospital, 
Gastrointestinal Surgery, Tokyo, Japan
contact e-Mail address: t-iizuka@toranomon.gr.jp
Introduction: The mechanism of development of Barrett’s esophagus (BE) 
has been investigated in animal experiments; however, clinical studies 
are rare. Acid reflux is considered to play a major role in the develop-
ment of BE, but there is little evidence to prove this. Given that changes 
in columnar epithelium due to acid reflux are used as a surrogate marker 
of BE, we investigated the link between the development of BE and acid 
reflux.
aims & Methods: This retrospective study involved 158 patients who un-
derwent esophagectomy in a single institution between 2004 and 2018. 
Patients without detailed data such as operative method, patients without 
an intact stomach, and patients without endoscopic follow-up were ex-
cluded. Patients were divided into two groups. The first group comprised 
106 patients who had undergone esophagectomy and gastric pull-up re-
construction (St), while the second group comprised 52 patients who had 
undergone esophagectomy and ileocolic interposition (Ic). The incidence 
of BE, the interval between surgery and the development of BE, and the 
severity of BE and reflux esophagitis were analyzed. BE was defined as 
an endoscopic columnar epithelium extending to the oral side from the 
site of anastomosis. Scheduled endoscopic examination was performed as 
follow-up once or twice a year.
results: Clinical characteristics were as follows: mean age 64.7 years in St, 
61.3 years in Ic (p=0.017); male patients 95 (90%) and 43 (83%), respec-
tively (p=0.31); mean follow-up period 67.6 and 51.3 months, respectively 
(p=0.013); and mean number of endoscopic examinations 8.8 and 7.7, re-
spectively (p=0.17). Occurrence of BE was seen in 47 cases (44.3%) and 1 
case (1.9%), respectively (p< 0.01). Reflux was observed in 68 cases and 
1 case, respectively (p< 0.01). The median interval to development of BE 
was 524 (168-3002) days. The mean length of BE was 11.7 mm. Univariate 
and multiple logistic analysis revealed that the method of reconstructive 
surgery (odds ratio 22.6) and reflux (odds ratio 4.91) were independent 
risk factors. There was no incidence of Barrett’s adenocarcinoma during 
follow-up.
conclusion: The development of BE is closely linked to reflux, including 
gastric acid reflux, and is rarely observed in ileocolic interposition.
disclosure: Nothing to disclose 
P1987 dIagnOsTIc yIeLd Of seaTTLe PrOTOcOL and TargeTed 
BIOPsy - cOMParaTIve sTudy In BarreTT’s esOPhagus 
surveILLance
Silva J.C., Fernades C., Pinho R., Proença L., Silva A.P., Sousa M., 
Gomes A.C., Afeto E., Carvalho J.
Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de 
Gaia, Portugal
contact e-Mail address: catarina.rib.gomes@gmail.com
Introduction: Endoscopic surveillance in Barrett’s Esophagus (BE) is rec-
ommended according to the Seattle protocol (SP) with random 4-quadrant 
biopsy specimens obtained every 1-2 cm to detect dysplasia, complement-
ed with targeted biopsies (TB) of suspicious lesions.
Narrow-Band Imaging (NBI) has the potential to increase diagnostic acu-
ity, although it is not routinely recommended. The main limitations of SP 
are sampling error and costs associated with histology.
aims & Methods: The main aim was compare diagnostic yield (DY), de-
fined by dysplasia in the histology, of SP with TB alone.
Cross-sectional study, which consecutively included patients undergoing 
BE surveillance between 2015 and 2018. Exams were executed with high 
resolution scopes under white light (WL) or NBI according to endoscopist’s 
preference and experience. Surveillance of BE was made according to SP 
in all patients. TB were performed if suspected focal lesions were identi-
fied.
results: A total of 127 surveillance exams referring to 94 patients were in-
cluded. Mean age was 60±15 years and most patients were male (74.5%). 
WL evaluation was complemented with NBI in 40.2% (n=51). Random bi-
opsies were performed in 112 (88.2%) and targeted biopsies in 15 (11.8%). 
DY of SP was very low (2.7%, n=3) and dysplasia was confirmed in a sub-
sequent examination in only 1 case (0.9%). TB demonstrated a significantly 
higher DY (40%; n=6) (p < 0.001). Considering only patients in whom WL 
evaluation was complemented with NBI, SP maintained a significantly 
lower DY (SP-2.6%, TB-41.70%, p=0.002). There was a significant associa-
tion between TB surveillance and dysplasia identification in histology, both 
in WL (p < 0.001) and NBI assessment (p = 0.002).
conclusion: Targeted biopsies had a significantly higher diagnostic yield, 
either under WL or with NBI, compared to Seattle Protocol.
disclosure: Nothing to disclose 
P1988 BarreTT’s OesOPhagus surveILLance aT a Large 
unIversITy hOsPITaL In The unITed kIngdOM
Mak J.K.C., Nar R., Boulton R., Butt M.A.
Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham 
NHS Foundation Trust, Department of Gastroenterology, Birmingham, United 
Kingdom
contact e-Mail address: ralph.boulton@uhb.nhs.uk
Introduction: Barrett’s oesophagus represents the most important risk fac-
tor for the development of oesophageal cancer. According to NICE, sur-
veillance should be considered for Barrett’s diagnosed endoscopically and 
on biopsy1. British Society of Gastroenterology (BSG) guidelines recom-
mend Barrett’s surveillance to be performed at specific prescribed inter-
vals dependent upon the length and histology2. Additionally, the BSG has 
proposed the use of a Minimum Endoscopic Dataset (MED) for reporting 
endoscopic findings2.
aims & Methods: The main aims of this service improvement project were 
to:
1. Evaluate whether Barrett’s surveillance is being conducted within rec-
ommended levels of tolerance at our hospital.
2. Assess the standard of our endoscopy reporting in comparison to the 
BSG MED.
A total of 137 Barrett’s cases diagnosed endoscopically at Queen Elizabeth 
Hospital Birmingham (QEHB) between 2015 and 2018 were identified. The 
QEHB serves as the primary teaching hospital for the University of Bir-
mingham and is one of the largest single-site NHS hospitals in the UK.
Patients found to have Barrett’s with dysplasia were excluded from sur-
veillance. In addition, patients who were subsequently diagnosed with 
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oesophageal cancer (as identified from the Somerset Cancer Registry) 
were excluded. Adherence of the endoscopy report findings to the criteria 
outlined in the BSG MED was assessed including documentation of the 
Prague endoscopic classification and concordance with Seattle protocols 
for biopsy.
results: Of the 137 Barrett’s cases, 50 (36%) were excluded from the sur-
veillance programme. As shown in Table 1, these included 23 patients with 
dysplasia and a single patient with subsequent oesophageal cancer diag-
nosed on biopsy. 57 of the remaining 87 patients (66%) were identified 
to be overdue for surveillance. Of these 57 cases, 11 (19%) had the Prague 
classification documented, while 2 (4%) had biopsies taken.
Total no. of Barrett’s cases: 137 Proportion of cases
no. excluded: 50/137 36%
-Dysplasia 23/50 46%
-Subsequent diagnosis of oesophageal cancer 1/50 2%
-Previous diagnosis of oesophageal cancer (i.e. under 
cancer surveillance)
2/50 4%
-Endoscopy report unavailable 11/50 22%
-Other (e.g. failed endoscopy or inconclusive Barrett‘s) 13/50 26%
no. eligible for surveillance: 87/137 64%
no. with surveillance overdue: 57/87 66%
-Prague classification 11/57 19%
-Biopsies 2/57 4%
[Table 1: Breakdown of Barrett’s cases diagnosed at QEHB in 2015-18]
It is clear that a significant proportion of Barrett’s patients at our hospital 
are overdue their surveillance endoscopy outside of tolerance. Further-
more, most of them have neither been properly reported nor sampled 
according to BSG standards at their last endoscopy. The latest National 
Oesophago-cancer Gastric Audit reported a decreased number of Bar-
rett’s patients diagnosed with dysplasia in 2012-17 in the West Midlands 
(in contrast to the rest of the UK)3. Our results suggest that poor Barrett’s 
surveillance at our hospital in recent years could have at least partially 
contributed to this decline.
conclusion: An unacceptable number of Barrett’s patients at our hospital 
are overdue their surveillance as per BSG guidelines. Efforts to imple-
ment a co-ordinated surveillance programme and improve our standard 
of endoscopy reporting are now underway. Barrett’s patients identified to 
have surveillance overdue have been entered into a prospective database 
for prioritised follow-up in order to bring our Barrett’s surveillance service 
back to tolerance.
references: 1. Gastro-oesophageal reflux disease and dyspepsia in adults: 
investigation and management. NICE Clinical Guideline 2014 [CG184] 2. 
British Society of Gastroenterology guidelines on the diagnosis and man-
agement of Barrett’s oesophagus. Fitzgerald RC, di Pietro M, Ragunath K, 
et al. Gut 2014;63:7-42 3. National Oesophago-cancer Gastric Audit - An-
nual Report 2017
disclosure: Nothing to disclose 
P1989 narrOW Band IMagIng In screenIng Of BarreTT’s 
esOPhagus In gasTrOesOPhageaL refLux dIsease PaTIenTs
Elsheaita A.1, Nouh H.2, Elbially M.1, Shamseya M.M.1, Shawky Ahmed S.3, 
Madkour M.A.1, Shamseya A.4, Khalil H.4
1Medical Research Institute, Alexandria University, Experimental and Clinical 
Internal Medicine, Alexandria, Egypt, 2Alexandria Faculty of Medicine, 
Internal Medicine, Alexandria, Egypt, 3Medical Research Institute, Alexandria 
University, Pathology, Alexandria, Egypt, 4Alexandria Faculty of Medicine, 
Alexandria, Egypt
contact e-Mail address: mougazi@hotmail.com
Introduction: Seattle protocol described as targeted and random four-
quadrant biopsies every 2 cm has long been considered as the gold stan-
dard of screening and surveillance of Barrett’s esophagus (BE) to minimize 
sampling error (1), however its difficulty limits its applicability in practice 
specially as a screening tool for BE among specific populations. With the 
rising need to do selective screening in gastroesophageal reflux disease 
(GERD) patients with certain risk factors other protocols as Narrow band 
imaging (NBI) guided biopsy need to be investigated.
aims & Methods: To validate the utility of NBI guided biopsy as a screening 
protocol for BE among certain GERD patients compared to Seattle protocol.
Endoscopy and biopsy taking was done in 2 different sessions 2 weeks 
apart to allow mucosa to heal for 100 patients in Alexandria, Egypt. In 
the first session Seattle protocol was applied and in the second session 
NBI guided biopsy was done. Patients had at least one of the following: 
Chronic Gastroesophageal reflux disease (more than 5 years), frequent 
Gastroesophageal reflux disease (more than once weekly), two or more of 
the following risk factors for Barrett’s esophagus: Old age >50 years, cen-
tral obesity (waist circumference >102 cm in males and >88 cm in females), 
current or past history of smoking and family history of BE or esophageal 
adenocarcinoma (EAC) and family history of BE or EAC (2). All patients 
with known Barrett’s esophagus were excluded. Suspicious lesions were 
defined as follows: in Seattle protocol mucosal irregularities (e.g. nodules/
ulcers) (3), in NBI suspicious lesions were defined as per Barrett Interna-
tional NBI Group (BING) classification as any lesion with irregular/absent 
mucosal pattern and/or any lesion with irregular vascular pattern (focally 
or diffusely distributed vessels not following normal architecture of the 
mucosa) (4).
results: Considering the overall worst diagnosis by histopathology as the 
true diagnosis, Of the 100 consecutive GERD patients, 17 patients had Bar-
rett’s esophagus either by one of the two techniques or by both, 35.3% by 
both methods, 41.2% by narrow band imaging alone and 23.5% by Seattle 
protocol alone (p< 0.001, ĸ= 0.461). Sensitivity, specificity, negative predic-
tive value and positive predictive value for Seattle protocol were 58.8%, 
100%, 92.2%, 100% vs 76.5%, 100%, 95.4%, 100% respectively for narrow 
band imaging. A mean of 7.73 samples/patient were taken in Seattle pro-
tocol vs 3.42 samples in narrow band imaging (p< 0.001). A mean of 8.63 
minutes was consumed in Seattle protocol vs 2.65 minutes in narrow band 
imaging (p< 0.001). No statistically significant difference in the detection 
rate of dysplasia between the two techniques was found.
conclusion: Though this study has some limitations due to the relatively 
small number of patients beside the lack of magnifying NBI which leaded 
to some difficulty in detection of abnormal vascular pattern, this study 
indicates that NBI guided biopsy might be a valid alternative to Seattle 
protocol and further multicentric larger studies are needed.
references: 1. Gould JC, Wendling MR, Oeschlager BK, Mittal SK, Koman-
duri S, Perry KA, et al. Advances in the Diagnosis and Treatment of Bar-
rett’s Esophagus and Early Esophageal Cancer; Summary of the Kelly and 
Carlos Pellegrini SSAT/SAGES Luncheon Symposium. J Gastrointest Surg. 
2017;21(8):1342-9. 2. Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clini-
cal Guideline: Diagnosis and Management of Barrett’s Esophagus. Am J 
Gastroenterol. 2016;111(1):30-50; quiz 1. 3. Wolfsen HC, Crook JE, Krishna 
M, Achem SR, Devault KR, Bouras EP, et al. Prospective, controlled tandem 
endoscopy study of narrow band imaging for dysplasia detection in Bar-
rett’s Esophagus. Gastroenterology. 2008;135(1):24-31. 4. Sharma P, Berg-
man JJ, Goda K, Kato M, Messmann H, Alsop BR, et al. Development and 
Validation of a Classification System to Identify High-Grade Dysplasia and 
Esophageal Adenocarcinoma in Barrett’s Esophagus Using Narrow-Band 
Imaging. Gastroenterology. 2016;150(3):591-8
disclosure: Nothing to disclose 
P1990 an auTOMaTed, quanTITaTIve MuLTIPLex 
IMMunOfLuOrescence assay accuraTeLy rIsk sTraTIfIes 
BarreTT’s esOPhagus PaTIenTs WITh a cOMMunITy-Based 
dIagnOsIs Of LOW-grade dysPLasIa aT a raTe cOMParaBLe 
TO exPerT PaThOLOgIsTs
Frei N.1, Konté K.1, Bossart E.A.2, Zhang Y.2, Critchley-Thorne R.J.2, 
Pouw R.E.1, Bergman J.J.1
1Academic Medical Centre, Gastroenterology and Hepatology, Amsterdam, 
Netherlands, 2Cernostics, Inc., Pittsburgh, United States
contact e-Mail address: nicola.frei@gmx.net
Introduction: Low-grade dysplasia (LGD) in Barrett’s esophagus (BE), is the 
strongest predictor of malignant progression, yet an accurate histological 
diagnosis of LGD is challenging. The majority of community-based LGD 
diagnoses are down-staged to non-dysplastic (ND)BE when reviewed by 
an expert pathologist, whereas patients in whom the diagnosis of LGD 
is confirmed have a 10% annual risk of progression to high-grade dys-
plasia (HGD) or cancer (Ca), justifying the consideration of prophylactic 
endoscopic ablation. Although guidelines recommend expert pathologist 
review of all LGD cases, expert review is poorly defined, prone to observer 
992 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
variation, and not widely available. Recent studies suggest that an au-
tomated, quantitative multiplex immunofluorescence assay may identify 
NDBE patients with an increased risk of malignant progression. We in-
vestigated if this assay also allows objective risk stratification for cases 
with a community-based diagnosis of LGD at a rate comparable to expert 
pathologists.
aims & Methods: A blinded nested case-control cohort was derived from 
the screening cohort of the SURF-study, a randomized controlled trial of 
SUrveillance vs. RadioFrequency ablation for BE patients with LGD. 60 pa-
tients with a community-based diagnosis of LGD of whom 30 progressed 
to HGD/EAC (progressors) and 30 patients who did not progress (non-pro-
gressors) were matched for age, sex and maximal BE length. All random 
biopsy levels of the baseline endoscopy and subsequent endoscopies were 
independently reviewed by 3 expert pathologists with an international 
reputation. All levels of the baseline endoscopy were additionally tested 
by a multiplex biomarker assay (TissueCypher Barrett’s Esophagus Assay, 
Cernostics). The assay integrates quantitative biomarker and morphol-
ogy scores extracted from whole slide images of multiplex immunofluo-
rescence-labeled standard formalin-fixed paraffin-embedded biopsies to 
classify patients as low-risk (LR), intermediate-risk (IR) and high-risk for 
progression to HGD/EAC within 5 years. A histological revision diagnosis of 
NDBE was considered as low- (LR), while indefinite for dysplasia (IND) and 
LGD were considered as high-risk (HR) for progression.
results: 60 BE patients (52 male), mean age 63±9 years, were studied. 
Clinical characteristics were similar between progressors and non-pro-
gressors. Median time between baseline endoscopy and progression was 
2.5 years (1.3-5.4). Accuracy, sensitivity and specificity of the biomarker as-
say vs. the 3 expert pathologists were 73% vs 72-77%, 66% vs 77-80% and 
80% vs 63-77%, respectively. 20/26 (78%) patients classified as IR/HR by 
the biomarker panel and 69-77% classified as HR (IND/LGD) by the 3 expert 
pathologists progressed to HGD/EAC.
conclusion: A quantitative multiplex immunofluorescence assay risk strati-
fied BE patients with a community-based diagnosis of LGD with an accu-
racy comparable to three renowned expert pathologists. The assay allows 
for automated, objective risk stratification which may be a practical and 
effective solution to the lack of standardization of expert pathology review 
of LGD as advocated by all guidelines.
disclosure: R.J. Critchley-Thorne and E.A. Bossart have ownership interest 
(stock or stock options) in, and are salaried employees at Cernostics, Inc. 
Y. Zhang is a paid consultant to Cernostics, Inc. 
P1991 safeTy and effIcacy Of MuLTI-Band MucOsecTOMy 
fOr vIsIBLe LesIOns In BarreTT’s esOPhagus: a sysTeMaTIc 
revIeW WITh POOLed anaLysIs
Spadaccini M.1, Maselli R.2, Attardo S.3, Thoguluva-Chandrasekar V.4, 
Belletrutti P.J.1, Carrara S.2, Di Leo M.1, Fugazza A.2, Anderloni A.2, 
Galtieri P.A.2, Pellegatta G.2, Lamonaca L.1, Craviotto V.1, D’Amico F.1, 
Palma R.1, Ormando V.1, Cappello A.1, Romana C.1, Dal Buono A.1, 
Colombo M.1, Hassan C.5, Sharma P.4, Repici A.1,2
1Humanitas University, Biomedical Science, Rozzano, Italy, 2Humanitas 
Clinical and Research Hospital, Rozzano, Italy, 3Istitui Clinici Scientifici 
‘Maugeri’, Pavia, Italy, 4University of Kansas School of Medicine, 
Gastroenterology, Leawood, United States, 5Nuovo Regina Margherita 
Hospital, Gastroenterology, italy, Italy
contact e-Mail address: marco.spadaccini@humanitas.it
Introduction: The incidence of esophageal adenocarcinoma (EAC) has 
been increasing over the past decades. Current consensus states that all 
visible lesions in the context of Barrett’s Esophagus (BE) should be en-
doscopically resected due to the high likelihood of containing significant 
pathology. Conversely, extensive resection aiming for metaplasia eradica-
tion should not be preferred over ablation strategies given the higher risk 
of subsequent stricturing. Current methods of mucosal resection include 
the cap-assisted technique and more recently multi-band mucosectomy 
(MBM). Since its first description, several prospective and retrospective se-
ries have been published, but data on efficacy and safety of MBM has yet 
to be systematically reviewed.
aims & Methods: We performed a systematic review with pooled-analysis 
to evaluate the efficacy and safety of MBM in patients with BE. Electronic 
databases (Medline, Scopus, EMBASE) were searched up to March 2019. 
Studies including patients with BE who underwent MBM were eligible. 
The primary outcome was the rate of adverse events such as intra- and 
post- procedural bleeding, perforation and stricture. Of note, we devel-
oped subgroup meta-analytic models selecting a priori variables which 
could affect the outcomes, such as the indication for performing MBM 
(focal lesion resection vs metaplasia eradication). Secondary outcomes 
were focused on MBM performed for resecting visible lesions. The rates of 
complete resections and R0 resections were assessed. The endoscopic re-
section was considered macroscopically complete if the visible lesion was 
entirely removed. The absence of neoplastic invasion at deep and lateral 
margins of the resected specimens was considered as an R0 resection for 
lesions resected in an en-bloc fashion. In cases of piecemeal resections, 
R0 at the deep margin of all resected specimens derived from a single 
lesion was required. Primary and secondary outcomes were assessed by 
pooling data by means of a random- or fixed-effect model according to 
the degree of heterogeneity to obtain a proportion with a 95% confidence 
interval (CI).
results: Thirteen studies were eligible for inclusion, providing data on 
1334 procedures performed in 986 patients; 839 out of 1334 procedures 
were performed in order to resect focal lesions on BE. Ten studies were 
performed in Europe and 3 in North America. All studies but 3 had a 
retrospective design. According to data reported by 6 studies, there was a 
mean number of 4.2±1.6 specimens per procedure. Considering the his-
tological findings, 52.2% of the lesions were adenocarcinomas and 31.3% 
were HGD. The overall adverse event rate was 5.3%(I2:83.4%). Immediate 
and post-procedural bleeding occurred in 0.2% (I2 :0%) and 0.7% (I2:0%) 
of procedures, respectively. Moreover, perforations and strictures were 
reported in 0.3% (I2 :0%) and 3.9% (I2: 80.4%) of procedures, respec-
tively. 
The sensitivity analysis focused on focal lesion resection (8 studies, 584 
procedures) reported an overall adverse event rate of 5.5% (I2=0%), with 
rates of bleeding, perforation and stricture of 1.6%, 1.0% and 3.3%, re-
spectively. Focal lesions were resected at a complete rate of 97.6%(I2: 
49.9%) with an R0 resection rate of 94.1% (I2 81.7%).
conclusion: Our results confirm MBM as a safe and effective technique to 
treat visible lesions in patients with Barrett’s esophagus. Further studies 
with longer follow-up periods are still necessary to provide definitive reas-
surance in terms of long term efficacy.
disclosure: Nothing to disclose 
P1992 The rIsk Of PrevaLenT and IncIdenT neOPLasIa 
In PaTIenTs WITh a dIagnOsIs Of BarreTT’s esOPhagus 
IndefInITe fOr dysPLasIa
Januszewicz W.1,2, Phillips R.3, O’Donovan M.4, Sawas T.5, Katzka D.A.5, 
Fitzgerald R.C.6, di Pietro M.7
1University of Cambridge, MRC Cancer Unit, Department of Oncology, 
Cambridge, United Kingdom, 2Medical Center for Postgraduate Education, 
Department of Gastroenterology, Hepatology and Clinical Oncology, Warsaw, 
Poland, 3MRC Cancer Unit, University of Cambridge, Cambridge, United 
Kingdom, 4Addenbrooke’s Hospital, University of Cambridge, Department 
of Histopathology, Cambridge, United Kingdom, 5Mayo Clinic, Rochester, 
Minnesota, United States, 6Medical Research Council Hutchison / MRC 
Research Centre MRC Cancer Unit, Cambridge, United Kingdom, 7University of 
Cambridge, MRC Cancer Unit, Cambridge, United Kingdom
contact e-Mail address: w.januszewicz@gmail.com
Introduction: Barrett’s esophagus (BE) is a well-established precursor 
condition to esophageal adenocarcinoma and the presence of dysplasia is 
the main risk factor for malignant progression. The BE with indefinite for 
dysplasia (BE-IND) diagnosis is used when the significance of epithelial 
abnormalities is uncertain due to inflammation or technical artifact. The 
natural behaviour of BE-IND is poorly understood.
aims & Methods: In this retrospective, single-center study we aimed to 
characterize the risk of prevalent and incident neoplasia in patients with 
BE-IND. We reviewed the BE research database to identify patients di-
agnosed with BE-IND. We excluded patients under 18 years old, with a 
follow-up of less than 1 year, with a previous diagnosis of definitive dys-
plasia, and previous endoscopic therapy. Times and rates of progression 
to neoplasia were calculated and categorized as prevalent neoplasia when 
the progression occurred within 1 year of follow-up (FU), and incident neo-
plasia, for progression after >1 year FU. A multivariable regression model 
adjusted for age, sex, length of BE segment, the extent of IND (focal vs 
multifocal) and baseline IND diagnosis was used to identify risk factors for 
both prevalent and incident neoplasia.
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results: In total, 345 patients with ≥1 diagnosis of BE-IND were identi-
fied between 1999 and 2018, of which 147 (42.6%) were excluded, and the 
remaining 198 (57.4%) were analyzed. Hundred-fifty-one patients (76.3%) 
showed regression to a non-dysplastic epithelium at the first follow-up 
biopsies and 19 patients (9.6%) had prevalent dysplasia of any grade in-
cluding 17 low-grade dysplasia (LGD) and two cases of advanced neoplasia 
(1.0%): 1 high-grade dysplasia (HGD) and 1 intramucosal cancer (IMC). 
Twenty-eight patients (14.1%) had incident dysplasia progressing to LGD 
(21), HGD (5), and IMC (2) after a median FU of 32.8 months (range 12.3 - 
124.5), yielding an incidence rate of dysplasia (any grade) and advanced 
neoplasia (HGD/IMC) of 3.9 and 1.3 cases per 100 patient-years, respec-
tively. The length of BE segment was associated with the increased risk 
of prevalent dysplasia (odds ratio 1.14; 95%CI 1.00-1.30, P=.046), however 
not incident dysplasia, for which none of the analyzed risk factors were 
found predictive.
conclusion: Patients with BE-IND, especially with a long segment of BE, 
should be closely monitored as nearly 10% harbor prevalent dysplasia. 
A significant proportion of patients with BE-IND will progress to more 
advanced stages and molecular biomarkers are required for stratifica-
tion, as clinical criteria to predict patients at high-risk for progression 
are lacking.
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Introduction: While esophagectomy is the standard treatment for submu-
cosal (T1b) esophageal adenocarcinoma (EAC) and squamous cell cancer 
(SCC), many elderly patients -the age group that esophageal cancer tends 
to affect- are not candidates for surgery. 
Endoscopic submucosal dissection (ESD) is a minimally invasive procedure 
that allows for en-bloc resection of early esophageal cancer and allows for 
precise histopathologic staging of the tumor. ESD could be curative in sub-
mucosal cancer without lymph node metastasis, and it allows for precise 
histopathologic staging.
aims & Methods: We aimed to evaluate the long-term outcomes of ESD in 
patients with EUS-staged T1b esophageal cancer. 
A retrospective multicenter study was performed at three academic hos-
pitals in the U.S. Patients who underwent ESD with a pre-procedural or 
post-procedural histopathologic diagnosis of T1b N0 M0 EAC or SCC were 
included in the study. Data was collected on demographics, tumor and 
procedure characteristics, procedure pathology, and follow-up. Local re-
currence was confirmed by endoscopic findings and pathological analysis. 
Metastasis was confirmed by cross-sectional imaging. 
The main outcome was a composite of rate of metastasis and local re-
currence. Follow-up time was defined as months from initial procedure 
to recurrence or last follow-up visit if recurrence-free. A time-to-event 
analysis was performed to evaluate recurrence. A Cox proportional haz-
ard ratio regression analysis was performed to identify predictors of re-
currence.
results: Thirty-seven patients underwent ESD (mean age 70 years +/-9; 25 
males; median tumor size 25 mm). Based on available comorbidity data, 
42% patients were not fit for surgery, as determined by an age-adjusted 
Charlson Comorbidity Index > 6. En bloc and R0 rates were 73% and 52%, 
respectively. Twenty tumors (54%) were found to be HGD or T1a on post-
ESD specimen analysis, while one was staged as T2. Immediately after 
ESD, 4 patients were referred for surgery, 2 underwent chemoradiation 
therapy, and 4 radiation alone. Patients were followed for a median of 9 
months, and the calculated 12- and 48-month recurrence rate was 13% 
and 30%, respectively. Not achieving en bloc resection was identified as a 
predictor for recurrence.
conclusion: This multicenter trial showed that ESD for T1b esophageal can-
cer can be acceptable for patients who deemed not surgical candidates. 
However, close follow up is necessary. ESD can also serve as a staging 
procedure, as our data confirms inaccurate EUS-staging of T1b cancer, with 
54% of tumors being down-staged to T1a, as has been previously reported.
disclosure: Nothing to disclose 
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Introduction: In gatekeeper healthcare systems, an efficient diagnostic 
process in primary care is pivotal for reducing cancer related disease bur-
den.
aims & Methods: This study aims to explore reasons for long time to refer-
ral for upper gastrointestinal (GI) cancer patients in Dutch primary care.
A retrospective cohort study, using anonymized free text primary care re-
cords of 6 routine primary care databases in the Netherlands. Patients 
diagnosed with oesophageal- or gastric cancer (2010-2015), who symp-
tomatically presented in primary care, were included. Based on manual 
free text exploration, time from presentation to referral in primary care 
was determined. Duration was calculated per characteristic (median, IQR).
We performed uni- and multivariable log-binomial regression analyses to 
find associations of patient- and presentation characteristics with relatively 
“long duration” (≥75th percentile value). Routes to referral of patients with 
relatively “longest durations” (≥90th percentile value) were explored using 
thematic free text analyses.
results: 174 symptomatic oesophageal cancer patients and 138 symptom-
atic gastric cancer patients were included. Longer median durations and/
or univariable association with ≥P75 were found for; 
(1) patients without alarm symptoms (both types), 
(2) female sex, higher socio-economic status score (SES) and psychiatric 
comorbidity (oesophageal cancer), 
(3) youngest age category (gastric cancer). In multivariable analysis, pre-
sentation without alarm symptoms showed a statistically significant asso-
ciation with “long duration” (≥P75) for both cancer types. For oesophageal 
cancer, high SES was associated with long duration. Thematic exploration 
of routes to diagnosis for patients with “longest durations” (≥P90) showed 
one dominating theme: “an initial low clinical suspicion of cancer”, and 
only few preventable factors for long duration.
conclusion: The main reason for long time to referral of oesophageal and 
gastric cancer patients is an initial low cancer suspicion. Absence of alarm 
symptoms is the main contributor to this lower suspicion and therefore, 
the longer times to referral. 
Only few preventable factors for delayed referral could be identified. These 
findings reflect a well-functioning gatekeeper system, with most to be 
gained from improving upper GI cancer recognition among those with 
non-alarm symptoms.
disclosure: Nothing to disclose 
P1995 a PrOsPecTIve sTudy Of sM2 carcInOMa dIagnOsIs 
usIng The exTenT Of TyPe B2 vesseLs In The jaPan esOPhageaL 
sOcIeTy cLassIfIcaTIOn
Takeuchi M., Azumi M., Kohisa J.
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Japan
contact e-Mail address: yasuzuka2000@yahoo.co.jp
Introduction: Although the Japan Esophageal Society (JES) classification 
for superficial squamous cell carcinoma has been simplified and is now 
widely used, the low diagnostic accuracy of invasion depth on the basis of 
type B2 vessels is a topic of concern. Based on the fact that in pSM2 car-
cinoma type B2 vessels appear at a similarly high rate to type B3 vessels, 
and the larger the area they cover, the higher the possibility of invasion, 
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we have previously reported that the extent of type B2 vessels in cases of 
pSM2 carcinoma is significantly larger than that in cases of pMM/pSM1 
carcinoma, and that the appropriate cut-off value is 7 mm.
aims & Methods: In the present study, we carried out a prospective study 
of the accuracy of the diagnosis of invasion depth based on the extent of 
these type B2 vessels. We examined 99 lesions in 78 patients who un-
derwent endoscopic submucosal dissection in our department between 
April 2016 and September 2018. The patients were 71 men and 7 women 
of median age 70 years (range 50-89 years). The main macroscopic tumor 
type was IIa in 12 cases, IIb in 35, IIc in 47, Is in 4, and III in 1; the main 
tumor location was the cervical esophagus (Ce) in 4 cases, the upper tho-
racic esophagus (Ut) in 9, the middle thoracic esophagus (Mt) in 57, the 
lower thoracic esophagus (Lt) in 27, and the abdominal esophagus (Ae) 
in 2; the circumferential ratio was < 1/2 the circumference of the esopha-
gus in 61 cases, < 2/3 of the circumference in 13, ≥2/3 of the circumfer-
ence in 21, and circumferential in 4; and the mean tumor diameter was 
20 mm (range 3-100 mm). The region of interest containing the highest 
concentration of atypical vessels was marked with two points, the invasion 
depth at this point was diagnosed, and the diagnostic accuracy was inves-
tigated. For type B2 vessels in particular, both ends of the largest region 
were marked, and the distance between these marks was then measured 
by using biopsy forceps. The largest diameter was also measured under 
stereoscopic microscopy. In this study, type B2 vessels were defined as 
irregularly branched vessels corresponding to type 4 vessels in the Arima 
classification.
results: The vessels in the region of interest were type B1 in 75 lesions, 
type B2 in 21, and type B3 in 3. Of the 75 lesions with type B1 vessels, 
the tumor had invaded to EP or LPM in 69 cases, MM in 4, and SM2 in 2, 
and the diagnostic accuracy was 92% (69/75). All 3 lesions with type B3 
vessels had invaded the submucosa to a depth of ≥200 mm (SM2), and 
the diagnostic accuracy was 100% (3/3). Both these results were similar 
to those of previous studies. However, of the 21 lesions with type B2 ves-
sels, 14 had invaded either the MM or the submucosa to a depth of < 200 
mm (SM1) and 7 were SM2, and following the conventional procedure the 
diagnostic accuracy was only 66.7% (14/21). However, when the extent of 
the vessels was taken into account, 15 lesions had type B2 vessels with an 
extent of < 7 mm. The invasion depth for these 15 lesions was MM/SM1 in 
14 and SM2 in 1, and the diagnostic accuracy was 93% (14/15). The inva-
sion depth of all 6 lesions with type B2 vessels with an extent of ³7 mm 
was SM2, and the diagnostic accuracy was 100% (6/6). Taking the extent 
of type B2 vessels into account significantly improved diagnostic accuracy 
from 68% to 95% (p < 0.01).
conclusion: Although our prospective study involved only a small number 
of cases, it suggested that the extent of type B2 vessels may be useful for 
the diagnosis of invasion depth. The designation of irregularly branched 
vessels as type B2 may also be an important assessment criterion.
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Introduction: Obesity was known to be the risk factor of the incidence of 
Barrett’s esophagus (BE) and Barrett’s esophageal adenocarcinoma (BEA). 
Especially excessive visceral fat have recently reported to promote some 
cancers, including BEA, development and progression because of meta-
bolic disruption. It elaborates cytokines, adipokines and growth factors, 
resulting in systemic inflammation which could be carcinogenesis. To our 
best knowledge, there is no report to mention to the differences of rela-
tionship between abdominal fat distribution and progression of BEA based 
on the length of BE.
aims & Methods: This study aimed to clarify the impact of abdominal fat 
distribution on progression of BE to adenocarcinoma in long-segment BE 
(LSBE) and short-segment BE (SSBE).
Study 1: We retrospectively reviewed the 124 patients with pathologically 
defined superficial BEA who underwent endoscopic resection, including 4 
endoscopic mucosal resection (EMR) and 85 endoscopic submucosal dis-
section (ESD), or surgical operation (35 esophagectomy) in our institution 
between January 2004 and December 2018. 124 BEA cases included 34 
LSBE (length ≥3 cm) cases and 90 SSBE (length ≥1 and < 3 cm) cases. Us-
ing computed tomography volumetry, we measured areas of visceral (VFA) 
and subcutaneous (SFA) fat at the level of the umbilicus, and calculated 
the VFA/SFA ratio in each patient, defining high-VFA/SFA ratio (≧1.0) and 
low-VFA/SFA ratio ( < 1.0). We also measured body mass index (BMI) and 
waist circumference (WC). VFA/SFA ratio, BMI and WC in the patients were 
compared and analyzed between BEA with LSBE group and BEA with SSBE 
group. 
Study2: We divided 62 patients who had LSBE into two groups based on 
prognosis of BEA; BEA with LSBE (34 patients) and non-BEA with LSBE 
group (18 patients). Abovementioned parameters were compared and 
analyzed between these two groups.
results: Study1: High VS ratio were seen in 22 (64.7%) patients among BEA 
with LSBE group and 34 (37.8%) patients among BEA with SSBE group, 
which is statistically significant (p = 0.0072). However, difference of BMI 
or WC were not significant between BEA with LSBE group and BEA with 
SSBE group as follow; median BMI (range) 24.2 (13.1-31.8) kg/m² vs. 23.2 
(16.2-36.9) kg/m², WC (range) 85.8 (59.8-122.6) cm vs. 86.0 (62.4-151.4) cm. 
Study2: In non-BEA with LSBE group, BMI (range) and WC (range) were 
23.7kg/m² (18.8-26.8) kg/m² and 86.1 (77.0-104.9) cm. These were not sig-
nificant either, compared to BEA with LSBE group. High VS ratio were seen 
in 6 (33.3%) patients among non-BEA with LSBE group. This result was 
statistically significant compared to BEA with LSBE group (0.038).
conclusion: High VFA/SFA ratio was significantly associated with progres-
sion of long-segment Barrett’s esophagus to esophageal adenocarcinoma.
references: [1]Beddy P, Howard J, McMahon C, Knox M, de Blacam C, Ravi 
N, et al. Association of visceral adiposity with oesophageal and junctional 
adenocarcinomas. Br J Surg2010; 97:1028-1034. [2] Long E, Beales L.P. I . 
The role of obesity in oesophageal cancer development Therap Adv Gastro-
enterol. 2014 Nov; 7(6): 247-268.
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Introduction: ESD for pharyngeal SCC (PSCC) is difficult, because of nar-
row space and poor maneuverability. Especially, ESD for PSCC located in 
the anterior side of epiglottis is extremely difficult. Because, the intubated 
tube elevates the epiglottis, and working space of anterior side of epiglot-
tis will become narrow.
aims & Methods: The aim of this study is to clarify the usefulness of ESD 
for pharyngeal SCC, especially located in the anterior side of epiglottis. 
119 pharyngeal SCC in 91 patients treated by ESD from Apr. 2006 to Mar. 
2019 in Saku Central Hospital Advanced Care Center were enrolled to this 
retrospective study. 
Male/Female was 90/1. Mean age was 68.5 (40-92). Mean size of tumor 
and specimen were 20.0 (1 - 51) and 29.1 (8 - 90) mm, respectively.　 
Location: pyriform sinus, middle pharynx epiglottis, and were 55, 58 and 
6. 
All ESD was performed by a hook knife under intubated general anesthe-
sia. 
ESD for the SCC located in anterior side of epiglottis: An intubated tube 
elevated epiglottis, and the approach to anterior side of epiglottis becomes 
impossible. Therefore, a temporary tracheotomy was performed before 
ESD. Clip with line was used to get enough traction. Autocut mode was 
used for dissection to prevent burning effect to the cartilage of epiglottis. 
Surveillance: 1 - 2 endoscopy, CT scan and neck US were performed as 
surveillance after ESD.
results: 
1. En bloc resection rate was 100%. R0 resection (En bloc + lateral margin 
negative) rate was 96.6% (115/119) 
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2. Complication: Delayed bleeding rate was 1.1% (1/91). Re-intubation was 
needed for the hemostasis. Dysphasia was shown in 3.3% (3/91). Two pa-
tients had mild dysphagia and improved in two weeks. The remaining one 
patient had severe dysphagia. The patient had a big SCC, 50mm in size, 
and the SCC extend from light piriform sinus to ary-epiglotic fold. 
3. Invasion depth: Epithelial (EP) and subepithelial (SEP) SCC were 57% 
(68/119) and 43% (51/119), respectively. 
4. The rate of lymph-duct involvement of EP and SEP were 0% and 5.7% 
(5/119), respectively. 
5.The rate of venous involvement of EP and SEP were 0% and 2.9% (1/35), 
respectively. The only patient who had venous involvement was 92 years 
old, and followed up without an additional therapy. 
6. Local recurrent rate was 0 %. 
7. LNM rate of EP and SEP was 0% and 4.7% (2/43 cases), respectively. A 
cervical LNM was diagnosed 6 months after ESD. Lymph node dissection 
and CRT was performed for the patient. The patient died of other disease 
without recurrence of pharyngeal SCC. The other patient also had a cervi-
cal LNM and treated by LND + CRT. The patient is alive without recurrence 
for 10 years. 
8. Prognosis and distant metastasis 
One patient died of lung metastasis. The patient had SEP SCC with lymph 
duct involvement. 
9. ESD for SCC in anterior side of epiglottis 
A temporary tracheotomy was performed before ESD. Clip with line was 
used to get enough traction for all cases. All of six cases were completed 
successfully without any complications.
conclusion: ESD is a safe and useful treatment for superficial pharyngeal 
SCC, even if SCC located in anterior side of epiglottis. We have to observe 
carefully to detect such superficial pharyngeal SCC when we insert endo-
scope.
disclosure: Nothing to disclose 
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Introduction: Achalasia of the esophagus is a benign disease caused by 
dyskinesia of an esophageal motor disorder characterized by insufficient 
relaxation of the lower esophageal sphincter and the absence of progres-
sive peristalsis. Achalasia is presumed to be a premalignant lesion and 
esophageal carcinoma is the most serious late complication clinically. 
Chronic inflammation by retained food may induce carcinogenesis of the 
esophageal squamous epithelium. Carcinoma may develop progressively 
from hyperplastic and dysplastic changes of esophageal achalasia. How-
ever, the detailed mechanism of carcinogenesis in achalasia patients has 
not been clarified yet.
aims & Methods: We analyzed 21 cases of achalasia-associated carcinoma 
of the esophagus clinically, and examined pathological and morphological 
characteristics of carcinogenesis in achalasia, surgically or endoscopically 
resected, using endoscopic, histological and immunohistochemical proce-
dures. The invasive parts of each carcinoma, in situ carcinoma, dysplasia 
as well as hyperplasia were examined for histological mapping, and with 
immunohistochemical expression for p53 protein.
results: The patients ranged in age from 43 to 76 years, with a mean age 
of 60 years. The mean interval between the diagnosis of achalasia and 
carcinoma was 21.7 years. Nine of the 21 cases were superficial cancers, 
and the other 12 cases were advanced cancers invading the adventitia. 
Radiographically, 10 of the 21 cases were sigmoid type, the other 11 cases 
were straight (flask) type. Six cases were grade III, the other 15 cases were 
grade II, and none was grade I. Surgical treatment for achalasia was 12 
cases, balloon dilatable bouginage was 6 cases, and 3 cases were no treat-
ment. Endoscopically, 8 cases of carcinomas were protruding type, and the 
others were superficial depressed type and ulcerative type. Twelve cases 
were composed of squamous cell carcinoma and the other one was ba-
saloid-squamous carcinoma. Histological mapping of the resected speci-
mens demonstrated marked hyperplastic changes of stratified squamous 
epithelium and multiple foci of dysplastic changes. The squamous cell 
carcinomas showed well to moderately differentiated type with low-grade 
atypia, closely associated with dysplastic foci. Immunohistochemical over-
expression of p53 was detected in the invasive parts of the carcinoma, in 
situ carcinoma, and dysplasia, and was not detected in the hyperplastic 
epithelium.
conclusion: Chronic inflammatory irritation by retained food in achalasia 
may induce chronic hyperplastic esophagitis and eventually malignant 
transformation of esophageal epithelial cells, associated with dysplasia-
carcinoma sequence. Achalasia seems to be a risk factor for developing 
squamous cell carcinoma of the esophagus, even if after surgically treated. 
Careful long-term follow-up to detect and treat early stage cancer for pa-
tients with achalasia by endoscopic screening is recommended.
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Introduction: Esophagectomy is a standard treatment for patients with 
‘high-risk’ early esophageal cancer (EEC) despite a growing evidence that 
endoscopic treatment could be a safe alternative even for these patients.
aims & Methods: The aims were 1. to prospectively assess results of endo-
scopic vs. surgical treatment in consecutive patients with ‘high-risk’ EEC 
and 2. to determine lymph node (LN) metastases and micrometastases 
(including risk factors) in those who underwent surgery. Firstly, patients 
with EEC underwent endoscopic resection (ER) or submucosal dissection 
(ESD). Those patients with ‘high-risk’ EEC without contraindications were 
referred to surgery, the remaining patients continued in endoscopic treat-
ment, if necessary. ‘High-risk’ cancer was defined as any cancer with sm 
invasion or mucosal cancer with at least one of the following: poor differ-
entiation (G3/G4), invasion to blood (A+) or lymphatic vessels (L+) and high 
tumor cell dissociation (TCD3). The patients have been followed up for a 
median of 32,5 months (range 1-171). LNs were processed as a sentinel LN, 
thus it was completely cut into 2-3 mm thick slices and embedded into par-
affin blocks. Serial levels were stained for hematoxylin-eosin to evaluate 
metastases and for immunohistochemistry to evaluate micrometastases 
and isolated tumor cells.
results: A total of 67 patients was included, 18 (26,9%) had T1a cancer 
with ‘high-risk’ features and 49 (73,1%) had T1b cancer with sm invasion; 
48 had adenocarcinoma (EAC), 18 had squamous carcinoma (SCC) and 1 
had mixed adenoneuroendocrine carcinoma (MANEC); 27 patients (40,3%) 
were referred to surgery and 40 (59,7%) continued in endoscopic treat-
ment. 
Endoscopy: Complete local remission (CLR) was achieved in 35/40 patients 
(87,5%). Four patients without CLR continued endoscopic therapy with a 
palliative intent and one patient died due to other comorbidity. Tumor 
generalization occurred in 2 patients (1 EAC and 1 SCC, both with sm3 inva-
sion, G3, TCD3, A+ and L+) and local relapse occurred in 1 patient (EAC, 
sm1, G3, TCD3). All of the remaining patients with CLR (n=32; 21 EAC, 10 
SCC, 1 MANEC) have not experienced either local relapse or generalization. 
Tumor-free survival was 28,5 months (range 1-131). 
Surgery: Among 27 patients who were referred for esophagectomy, one 
patient had generalization revealed during the operation. The remaining 
26 patients underwent esophagectomy; local residua of malignancy were 
present in 5/26 patients (19,2%, expected residua as these patients did 
not achieved CLR). A total of 532 LNs were evaluated, LN metastases were 
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detected in 1 (16 LNs) (EAC: G3-4, sm3, TCD3, A+, L+) and micrometastases 
in another 2 patients (EAC: sm3, G3, TCD 2, A+, L+; SCC: sm2, G2, TCD1, 
A+). Surgery related mortality was 3,9% (1/26, the cause of death was 
anastomotic dehiscence).
conclusion: Endoscopic treatment provided long-term remission (or cure) 
in considerable number of patients with high risk EAC and it may represent 
a valid alternative to surgery. The risk of LNs metastases/micrometastases 
was low. The risk of metastatic progression increased with rising amount 
of risk features (Prob > |t| 0.0366). None of the patients with sm1 invasion 
or well-differentiated tumor (G1) have experienced generalization, thus 
advanced sm invasion (sm2, sm3) and poor differentiation may be crucial 
factors.
disclosure: Nothing to disclose 
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Introduction: Endoscopic ultrasound (EUS) and EUS-guided fine-needle 
aspiration (FNA) are potential tools for detection of residual disease af-
ter neoadjuvant chemoradiotherapy (nCRT) in patients with esophageal 
cancer. This is the first prospective study that investigated the yield of 
EUS and FNA for detection of malignant lymph nodes (LNs) 10-12 weeks 
after nCRT.
aims & Methods: EUS was performed 10-12 weeks after nCRT. 18F-FDG PET-
CT was used to guide targeting of suspicious LNs. If suspicious LN were 
identified with radial EUS, a linear EUS was performed with concurrent 
FNA-sampling. Endoscopic nodal staging was compared to histopatholog-
ical examination of the resection specimen (ypN). Primary outcome was 
the proportion of correctly identified patients with malignant LNs (ypN+).
results: 101 consecutive patients were included. Seventy-nine patients had 
ypN- residual disease, of whom 62 were classified correctly by EUS (speci-
ficity 78%). Twenty-two patients had ypN+ residual disease of whom 11 
were identified by EUS (sensitivity 50%). Six of these patients had ≥1 LN 
not fulfilling the EUS-criteria for malignant LNs (round, hypo-echogenic, 
>5mm). Malignant LNs in falsely negative patients were predominantly lo-
cated at the distal LN stations. Specificity and sensitivity of FNA were 100% 
(10/10) and 75% (3/4), respectively.
  ypn- ypn+ Total
yun- 62 11 73
yun+ 17 11 28
Total 79 22 101
[Positive and negative findings by EUS (yuN) and histopathological 
examination of the resection specimen (ypN).]
conclusion: EUS detected 50% of ypN+ patients 10-12 weeks after nCRT. 
Remarkably, in 55% (6/11) of these patients ≥1 suspect LNs did not meet 
EUS-criteria for malignant LNs. To optimize sensitivity and minimize the 
risk of missing residual disease after nCRT, FNA of local LNs should be 
performed even in cases of low suspicion.
disclosure: Nothing to disclose 
P2001 effIcacy and safeTy Of endOscOPIc suBMucOsaL 
dIssecTIOn fOr esOPhageaL LesIOns under generaL 
anesThesIa
Maruyama T.1, Uesato M.1, Urahama R.1, Suito H.2, Yamaguchi Y.3, 
Yonemoto S.3, Matsubara H.1
1Chiba University Graduate School of Medicine, Frontier Surgery, Chiba, 
Japan, 2Chiba university, Ffrontier surgery, Chiba, Japan, 3Chiba university, 
Frontier surgery, Chiba, Japan
contact e-Mail address: t.maruyama@chiba-u.jp
Introduction: Endoscopic submucosal dissection (ESD) is a well-estab-
lished treatment for early-stage malignant lesions of the stomach, esoph-
agus, and colorectum with no risk of lymphatic metastasis. ESD requires 
precise and complicated maneuvers. But the esophageal wall is thinner 
than the stomach and moves with respiration and heartbeat, swallow-
ing, peristalsis in a narrow space. It couses difficult maneuverability of 
devices. 
Therefore, intraoperative management of the patient’s general condition is 
very important during esophageal ESD. In Japan, ESD is usually performed 
under conscious sedation in the endoscopy room. 
However, it is difficult to control patient movement completely because of 
insufficient effect of sedation, and it has a risk of aspiration pneumonia. 
Any patient movement during the procedure can result in complications 
such as perforation and hemorrhage. Therefore, we perform ESD under 
general anesthesia with mechanical ventilation.
aims & Methods: The aim of this presentation is to evaluate the effect and 
safety of Esophageal ESD under general anesthesia.
In the past 10 years from January 2008 to December 2017, 371 lesions (277 
patients) had undergone ESD under general anesthesia for diseases of 
the esophagus. We retrospectively investigated the efficacy and safety of 
esophageal ESD under general anesthesia.
results: The male: female ratio was 244:33 (88.1%:11.9%) and the patients’ 
average age was 68.1 ± 8.5 years (42-89 years). The diameter of the resect-
ed specimen was 43.0 ± 18.3 mm (8-115 mm) and average circumference 
rate of resected specimen was three-fifth (one-fifth to whole circumfer-
ence). The en bloc resection rate was 89.0%. The average operating time 
was 113.8 ± 62.3 min (25-340 min), and the average anesthesia time was 
146.4 ± 67.6 min (50-370 min). The location of the lesion was cervical in 20 
lesions, upper esophagus in 53 lesions, middle esophagus in 169 lesions, 
lower esophagus in 97 lesions, esophagogastric junction in 32 lesions. The 
pathological findings was squamous cell carcinoma in 280 lesions and 
adenocarcinoma in 20 lesions, neoplasia in 56 lesions, others in 11 le-
sions. The invasion depth of carcinoma was M in 266 lesions, SM in 34 
lesions. Average postoperative hospital stay was 7.7 days (2-64). Average 
years of experience as a doctor was 13 years (6-21). About one-third of the 
patients were performed ESD by a non-expert doctor (6-8 years of experi-
ence as a doctor). With regard to complications, intraoperative perforation 
occurred in 3 (1.1%) patients, delayed perforation occurred in 1 (0.4%), 
delayed bleeding occurred in 4 (1.4%). These complications were occurred 
in patient performed ESD by expert doctor (over 11 years of experience as 
a doctor), because of difficulty factor to perform ESD (location, size, severe 
comorbidities, etc).
conclusion: For ordered management of accidental events during esopha-
geal ESD, general anesthesia might be a crucial option for a better clinical 
outcome even when administered by non-experienced operators.
disclosure: Nothing to disclose 
P2002 a nOveL MagnIfIed endOscOPIc fIndIng fOr The 
dIfferenTIaL dIagnOsIs BeTWeen InfLaMMaTIOn and 
suPerfIcIaL esOPhageaL squaMOus ceLL carcInOMa
Takahashi A., Oyama T.
Saku Central Hospital Advanced Care Center, Endoscopy, Nagano, Japan
contact e-Mail address: aurevoireurope@yahoo.co.jp
Introduction: Magnified endoscopic findings were subclassified into type 
B1, B2 and B3 in Japanese esophageal society (JES) classification to diag-
nose invasion depth of esophageal superficial squamous cell carcinoma 
(ESCC). Type B2 is defined as irregular vessels without a loop-like forma-
tion, and it diagnoses as T1aMM/T1bSM1 SCC. 
Sometimes T1aESCC has erosion / inflammation, and NBI magnified en-
doscopy revealed non loop irregular vessels. If it is judged as JES type B2, 
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the lesion was overdiagnosed as T1aMM/T1bSM1. Therefore, we have to 
investigate the differential diagnosis between SCC and erosion, when non 
loop irregular vessels were observed.
aims & Methods: The aim of this study is to investigate the characteristics 
of type B2 vessels.
Four hundred ninety-nine ESCC in 298 patients were treated by ESD from 
January 2011 to May 2018. Precise comparison between magnified endo-
scopic findings and histology is necessary to measure the target vessels 
correctly. We selected consecutive 53 ESCC in 51 patients which had type 
B2, and precious comparison was possible.
The distance between top of IPCL and surface, the density and minor axis 
of type B2 using CD34 staining were investigated.
Based on endoscopic findings, we subclassified B2 into B2 pure and B2 
inflammation (B2 i.) B2 pure was defined as non-loop irregular vessels. 
B2 i was defined as thin vessels with high density. 
B2 pure was 44 lesions, and B2 i was 9 lesions. Macroscopic type; 0-IIa, 
0-IIb, 0-IIc and 0-III were 10, 2, 31, 1 and 0, 0, 9, 0 respectively. Location; 
Ce, Ut, Mt, Lt and Ae were 6, 4, 26, 6, 2 and 0, 0, 7, 2, 0, respectively. Mean 
tumor size was 37mm and 39mm, respectively. There was no significant 
difference in background between B2 pure and B2 i.
results: 
1. Histological findings of B2 area: All of the pathological diagnosis in 44 
lesions which showed B2 pure were SCC. Pathological diagnosis of 9 le-
sions which showed B2 i were SCC in 2, and erosion or inflammation in 
7 lesions.
2. How deep can we observe by NBI magnified endoscopy? The distance 
between top of IPCL and surface was measured in 66 points of non-neo-
plastic squamous epithelium randomly. The mean distance was 88 (31-174) 
µm. Therefore, we concluded that we can observe at least 100 µm under 
the surface.
3. Maicrovessles which exist 100 µm under the surface in B2 i (n=6) and B2 
pure (n=16) were investigated. 
a. Density was calculated using CD34 staining. The mean density was 3.35/
mm in B2 pure and 8.22 /mm in B2 i, respectively (p=0.001). 
b. Minor axis of vessels was measured using CD34 staining. The mean 
minor axis of vessels was 12.3 µm and 6.65 µm, respectively. (p=0.0028). 
B2 i has thin vessels with high density, and B2 pure has thick vessels with 
low density.
conclusion: B2i is an important parameter to show erosion in superficial 
ESCC. B2 should be subclassified into B2 pure and B2 i to prevent over-
diagnosis.
disclosure: Nothing to disclose 
P2003 TuMOr sIze Increases The rIsk fOr LyMPh nOde 
MeTasTases In T1B esOPhageaL adenOcarcInOMa
Sadaps M.1, Mehta N.2, Jang S.2, Vargo J.2, McNamara M.1, Sohal D.1, 
Raja S.3, Khorana A.1, Bhatt A.2, Murthy S.3
1Cleveland Clinic, Hematology-Oncology, Cleveland, United States, 2Cleveland 
Clinic, Gastroenterology and Hepatology, Cleveland, United States, 3Cleveland 
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contact e-Mail address: sadapsm@ccf.org
Introduction: The decision to give adjuvant therapy after endoscopic resec-
tion of T1b esophageal adenocarcinoma (EAC) who are not surgical candi-
dates is largely based on a lesion’s risk of lymph node metastasis (LNM). 
However, risk factors for LNM in esophageal T1b EAC are still not clearly 
defined.
aims & Methods: The aim of this study is to evaluate risk factors for LNM 
in T1b EAC patients who underwent esophagectomy or endoscopic resec-
tion with ≥ 5 years of follow-up post-procedurally. This was a single cen-
ter, retrospective analysis carried out at a large tertiary referral center. 
Our pathology database assisted in identifying patients who underwent 
esophagectomy or ER with ≥ 5 years follow-up, with histologically proven 
T1b EAC between 2010 and 2017. 
Patients were excluded from the study if they (a) received chemoradiation 
prior to esophagectomy (b) received chemoradiation before or after ER (c) 
had any other primary cancer treated within the preceding 5 years. LNM 
was considered positive if there was histologically or radiologically con-
firmed metastasis (a) in esophagectomy specimens or (b) within 5 years of 
follow up post ER. All pathologic specimens were reviewed by an expert 
gastrointestinal pathologist for T1b accuracy and depth of submucosal in-
vasion.
results: A total of 40 patients [median age 69y (IQR 61.5-76); 87% males] 
formed the study cohort of which 36 patients (90%) underwent esopha-
gectomy and 4 patients who were not surgical candidates (10%) under-
went endoscopic resection. Of the total, seven (17.5%) patients developed 
LNM per study criteria (Table 1). Tumor size was significantly (p-value 
0.019) associated with the risk of LNM. Applying a non-parametric ROC 
curve, 3 cm is the optimal threshold at which the size of the tumor is posi-
tively associated with metastasis. No other risk factors including lympho-
vascular invasion, differentiation on pathology, macroscopic appearance, 
infiltration growth pattern, or tumor distance from the gastroesophageal 
junction were significant risk factors for LNM.
conclusion: In T1b esophageal adenocarcinoma, tumor size greater than 3 
cm appears to be the variable with the most potential as a risk factor for 
metastasis at five years following surgical or endoscopic resection. Ad-
juvant therapy should be considered in patients with tumor size greater 
than 3 cm.
disclosure: Nothing to disclose 
P2004 MIca has a PrOTecTIve effecTIve TO nOn-sTerOIdaL 
anTI-InfLaMMaTOry drugs enTerOPaThy vIa reguLaTIng LOng 
nOn-cOdIng rna-ncruPar and Par2
Wang Y., Ye F., Zhang S.
The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 
China
contact e-Mail address: zhangshuotcm@126.com
Introduction: NSAIDs (non-steroid anti-inflammatory drugs) have a wide 
range of clinical applications. Studies have shown that the incidence of 
small intestine injury in patients with long-term NSAIDs is about 70%. 
Currently, the prevention and treatment methods are limited, thus it is of 
great significance to elucidate its pathogenesis for the safe clinical ap-
plication of NSAIDs.
aims & Methods: Caco-2 cells were cultured and divided into the following 
six groups: 
Group A: blank control group; 
Group B: diclofenac sodium treatment group; 
Group C: Control RNAa group; 
Group D: ncRuPAR over expression group; 
Group E: diclofenac sodium+mica containing serum group; and
Group F: diclofenac sodium treatment+PAR-2 (proteinase-activated recep-
tor-2) blocker FSLLRY-NH2 group. 
Transwell detected the intestinal epithelial cell permeability, western-blot 
detected the expression of PAR-2, Occludin and Claudin-1, and qRT-PCR 
detected the expression of ncRuPAR and PAR-2 mRNA.
results: After diclofenac sodium treatment, intestinal epithelial cell per-
meability increased (143.02±1.70 vs 100±4.43, P< 0.05), the expression of 
Occludin (0.29±0.02 vs 0.45±0.01, P< 0.05) and Claudin-1 (0.20±0.01 vs 
0.31±0.01, P< 0.05) decreased. The expression of ncRuPAR mRNA (7.01±1.17 
vs 1.17±0.81, P< 0.05) and PAR-2 mRNA (5.52±0.92 vs 1.03±0.29, P< 0.05) 
also increased. Mica medicated serum and PAR-2 blocker FSLLRY-NH2 in-
hibited the increase of intestinal epithelial cell permeability induced by 
diclofenac sodium (108.18±1.96 ; 111.29±4.23, P< 0.05), as well as its effect 
on the expression of ncRuPAR mRNA (3.40±1.89; 4.18±0.35, P< 0.05), PAR-
2 mRNA (2.73±0.39; 3.60±0.69, P< 0.05), Occludin (0.38±0.02;0.35±0.01, P< 
0.05) and Claudin-1 (0.25±0.01;0.24±0.02, P< 0.05). After ncRuPAR over 
expression, intestinal epithelial cell permeability increased (147.93±1.96, P< 
0.05), the expression of PAR-2 mRNA (24.71±4.17, P< 0.05) and ncRuPAR 
mRNA (4686.48±1191.9, P< 0.05) increased, while the expression of oc-
cludin (0.35±0.02, P< 0.05) and claudin-1 (0.18±0.01, P< 0.05) decresed.
conclusion: Small intestinal epithelial cell permeability increased and 
mucosal mechanical barrier function is impaired in NSAIDs enteropathy. 
NcRuPAR affect the mechanical barrier function of intestinal mucosa by 
regulating the expression of PAR-2, and mica may play a preventive role by 
affecting the expression of ncRuPAR.
disclosure: Nothing to disclose 
998 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
P2005 IMPLeMenTaTIOn Of PrOTOn PuMP InhIBITOr 
dePrescrIPTIOn PrOTOcOL aT hOsPITaL dIscharge: 
The de-PIBP PrOjecT
García Cámara P.1, Lamuela L.J.1, Llorente-Barrio M.1, Sierra O.1, 
Monzón M.R.1, Alcedo J.1,2, Arbones-Mainar J.M.2,3, Bernal V.1,2
1Hospital Miguel Servet, Department of Gastroenterology, Zaragoza, Spain, 
2Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain, 3Unidad 
de Investigación Traslacional. Hospital Universitario Miguel Servet, Instituto 
Aragonés de Ciencias de la Salud (IACS), CIBEROBN, Instituto de Salud 
Carlos III, Madrid, Spain
contact e-Mail address: paulagarciacamara@gmail.com
Introduction: Proton pump inhibitors (PPIs) are among the most pre-
scribed drugs. Despite a safe profile, their prolonged use has been associ-
ated with some complications such as enteric infections and fractures. It is 
hence recommended to adjust their prescription according to the existing 
guidelines of scientific societies.
aims & Methods: Objectives: To evaluate the applicability of a deprescrip-
tion algorithm in hospitalized patients with chronic consumption of PPIs, 
and to determine the number of patients who maintain deprescription 
after 4, 12 and 24 weeks, as well as the factors associated with the lack of 
compliance with the deprescription algorithm. 
Methodology: prospective study with consecutive inclusion of patients who 
were under PPI treatment for at least 8 weeks and had been admitted to 
the Gastroenterology Department (GED) of the University Hospital Miguel 
Servet (Zaragoza, Spain). PPI prescription was classified as adequate or 
inadequate according to the criteria of the Spanish Association of Gastro-
enterology. Those with inadequate prescription who agreed to participate 
in the study completed the Spanish version of the Gastrointestinal Short 
Form Questionnaire (GSF-Q). Exclusion criteria were: GSF ≥13, occasional 
use of PPI (≤2 times / week), severe comorbidity (ASA IV or higher), ad-
vanced cognitive impairment, pregnancy, and hospital stay less than 24 
hours. Patients without exclusion criteria were included in the deprescrip-
tion protocol based on the recommendations of the Canadian Primary Care 
Society, with follow-up at 4, 12 and 24 weeks to assess the reappearance 
of symptoms, necessity to reintroduce PPIs and why. The protocol was ap-
proved by the Ethics Committee.
results: Between September 2018 and April 2019, 1173 patients were ad-
mitted more than 24 hours to the GED, of whom 513 (43.73%) consumed 
PPIs chronically. 142 met some other exclusion criteria. 371 patients were 
included, 54% males, with mean age 74.4 (SD 12.5) years. The prescrip-
tion was considered adequate in 284 patients (76.55%), being over 60 
year old individuals taking antiaggregant drugs the most frequent group 
(76.05%). The prescription was inadequate in 87 patients (23.45%), the 
majority because of polypharmacy (52%). 12 patients refused to participate 
in the deprescription protocol. 35 patients stopped PPI treatment imme-
diately while 26 gradually reduced the treatment, 7 switch to on-demand 
treatment and 7 decreased dosed indefinitely. Sex was not a risk factor for 
inadequate prescription (p = 0.251), while age> 75 years was indeed as-
sociated with inadequate prescription(p = 0.025). Follow-up information, 
which was available at 4 weeks for 64 patients, showed that 53 individuals 
(82.81%) complied with the deprescription protocol while 11 subjects had 
reintroduced PPIs again at the previous dose (7 without justified cause). At 
12 weeks, 32 out of 45 patients (71.1%) with follow-up information com-
plied with the deprescription protocol. No patient presented serious ad-
verse effects attributable to deprescription.
conclusion: Inadequate indication of PPI is very common in patients ad-
mitted to a Gastroenterology ward. The application of algorithm of depre-
scription is a safe and effective strategy to reduce the inadequate con-
sumption of PPIs in the medium term.
disclosure: Nothing to disclose 
P2006 PrOTOn PuMP InhIBITOrs: IMPLeMenTaTIOn Of a 
de-PrescrIBIng sTraTegy
Campillo A.1, Erviti J.2, Celaya M.C.3, Bolado F.4, Irisarri R.5
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2Servicio Navarro de Salud-Osasunbidea, Sección de Innovación y 
Organización, Pamplona, Spain, 3Servicio Navarro de Salud-Osasunbidea, 
Subdirección de Farmacia, Pamplona, Spain, 4Complejo Hospitalario de 
Navarra, Gastroenterology and Hepathology, Pamplona, Spain, 5Hospital 
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contact e-Mail address: campilloarregui@gmail.com
Introduction: Proton pump inhibitors (PPI) are the most consumed drugs 
in Spain. Prescribing a PPI without indication contributes to polypharmacy 
and drug interactions.
aims & Methods: Our objective was to develop a strategy in order to op-
timize the use of PPI in a northern region of Spain (616,758 inhabitants). 
Methods: A so-called “PPI optimization strategy” was implemented in-
cluding the following activities: 
1) A multidisciplinary group (gastroenterologists, general practitioners 
(GPs) and primary care pharmacists (PCP)) was established to design the 
strategy; 
2) Evidence on PPIs and gastroprotection was assessed; 
3) Criteria for selection of candidates for intervention was agreed (patients 
with PPI prescribed for more than 12 months without authorized indica-
tion); 
4) Pharmacists presented the program and gave a training session to GPs 
and nurses. 
5) Patient-oriented support materials were provided to doctors (explana-
tory leaflets for candidates and general public too); 
6) Candidates for intervention were retrieved through an in-house devel-
oped software called Observa (Observatory of medication safety), that in-
teracts with all clinical records in our province; 
7) A message was sent through this tool to GPs whose patients met the 
inclusion criteria asking to withdraw the drug in November’17 for patients 
>65 years. In June’18 a message was sent for patients < 65 years meeting 
the inclusion criteria and a second message to those patients > 65 years for 
whom there had not been an answer after the first invitation; 
8) A mass media campaign supporting the strategy was launched that 
included press release for local newspapers. 
9) PPIs withdrawal was monitored and evaluated.
results: A total of 15,794 patients were candidates for the intervention; 
9,325 >65 years and 6,469 patients < 65 years. A 53% (n: 8,293) of depre-
scription invitations were answered; 40% were accepted, 11% rejected and 
2% non-valid. 
Among patients >65 years, who were invited twice to withdraw PPIs, 62% 
of deprescription invitations were answered (n: 5,735) and 47% of all the 
proposals were accepted, 76% of those answered. (n: 4,631). In patients 
younger than 65 years, who got a single invitation, there were a 40% of 
answers (n:2,558) and a 30% of proposals were accepted (n:1,912), 74% of 
those that had been answered.
The strategy was started in the end of 2017. During 2018 the amount of 
defined daily dose (DDD) for PPIs in our region descended a 13% compared 
to 2017.
conclusion: There is a high use of PPI in general population, quite often 
without meeting any medical criteria for it. The use of web tools such as 
Observa can contribute to the optimization of pharmacotherapy and avoids 
PPI overuse. A 75% of the evaluated proposals of de-prescribing were ac-
cepted, which has had an impact on the consume of PPIs in our region.
disclosure: Nothing to disclose 
999Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
P2007 cLInIcOPaThOLOgIcaL and IMMunOhIsTOcheMIcaL 
sTudy Of The MechanIsM Of sPOradIc fundIc gLand POLyP 
PrOLIferaTIOn and enLargeMenT In LOng-TerM PPI-users
Matsumura M., Tsuji N., Yoshida S., Tomooka M., Umehara Y., Kudo M.
Kindai University Faculty of Medicine Gastroenterology and Hepatology, 
Osaka-Sayama, Japan
contact e-Mail address: mariko.tarte@gmail.com
Introduction: An association between sporadic fundic gland polyps (SFGP) 
and long-term PPI use has previously been suggested, and SFGP with dys-
plasia-carcinoma in rare cases has recently been reported.
aims & Methods: To investigate the relationship between SFGP and PPI, 
we enrolled 86 SFGP patients (32 PPI-users of more than 6 months and 
54 non-users) and compared clinical and endoscopic characteristics and 
histological findings including parietal cell protrusion (PCP), number and 
size of microcysts, parietal cell nuclear density, and MIB1 and β-catenin 
immunohistochemistry of biopsy specimens.
results: All patients were H. pylori-negative, with no or slight gastric atro-
phy. The proportion of patients with cobble stone-like appearance in back-
ground mucosa and with more than 20 polyps were significantly higher 
among PPI-users (66% of users vs. 6% of non-users and 63% of users 
vs. 19% of non-users, respectively).The maximum diameter of the polyps 
was significantly larger in PPI-users than non-users (5.3 mm vs. 3.6 mm, 
respectively). Histologically, the number of microcysts and ratio of patients 
with PCP was significantly greater in PPI-users than non-users (8.4 vs. 4.9 
and 53% vs. 13%, respectively). There was no difference in the maximum 
diameter of microcysts, parietal cell nuclear density, or MIB1-index be-
tween the two groups. At no point was nuclear accumulation of β-catenin 
observed.
conclusion: Our results suggest that an increased number of microcysts 
drives the enlargement and proliferation of SFGP in long-term PPI-users. 
The proliferative activity of the neck zone and β-catenin immunohisto-
chemistry did not differ between users and non-users. There was no pa-
rietal cell hyperplasia; however, parietal cell hypertrophy was found in 
PPI-associated SFGP.
disclosure: Nothing to disclose 
P2008 quanTIfyIng earLy gasTrIc cancer In ausTraLIa: 
WhaT Is The POTenTIaL need fOr gasTrIc esd In The WesT?
Yang L.1,2, Taylor A.1,2, Thompson A.1,2, Desmond P.1,2, Holt B.1,2
1St Vincent’s Hospital, Gastroenterology, Fitzroy, Australia, 2The University of 
Melbourne, Melbourne, Australia
contact e-Mail address: lindaviva0912@gmail.com
Introduction: Endoscopic submucosal dissection (ESD) can be curative in 
early gastric cancer (EGC), particularly in lesions with favourable histology.
(1) ESD provides an en bloc specimen, enabling accurate staging, and has 
significantly lower morbidity and mortality compared to gastrectomy.(2) 
It is the recommended treatment for EGC in multiple international guide-
lines and is widely performed in Asia where gastric cancer has high preva-
lence.(3-5) ESD is not commonly performed in Western countries.(6) 
One proposed reason is that a lower proportion of gastric cancer present 
at early stage than in high prevalence regions. To assess the potential need 
for ESD, the incidence of EGC must be established.
aims & Methods: This study aims to evaluate the proportion of gastric 
cancer that met histological criteria for EGC, and proportion of EGC that 
were suitable for and treated by endoscopic resection in a Western popu-
lation.
This is a retrospective analysis of all gastric cancers reported to Victorian 
Cancer Registry, a mandatory reporting process of new cancer diagnoses 
in the state of Victoria (26% of the population).(6) All EGCs (T1a and T1b le-
sions) diagnosed between January 2011 to December 2016 were identified 
from histological reports. Demographic, tumour characteristics and treat-
ment data were collected. Japanese and European ESD guidelines (3,5) 
were applied to assess the number of potential ESD candidates.
results: 1779 gastric cancers were reported. 237 (13.3%) were EGCs, with 
mean annual incidence of 47 cases. 33 endoscopic and 149 surgical resec-
tion specimens were available. On application of ESD resection criteria, 132 
(72.5%) met extended and 84 (46.2%) met standard criteria. Of these, 26 
(19.7%) were treated endoscopically and 106 (80.3%) by surgery. Tumour 
location, depth and involvement of pathologic margins was significantly 
different between treatment strategies (Table 1). Endoscopic resections 
were performed using snare-based technique and ESD in 93.4% and 
6.6%, respectively. 
   
surgical, 
n = 149
endoscopic, 
n = 33 P value
Age at diagnosis 
(median, range)
  68.7 (25.5 - 92.9) 70.9 (50.9 - 87.8) 0.168
Male (n, %)   105 (70.5) 23 (69.7) 0.690
Location of tumour 
(n, %)
Antrum/Incisura 60 (40.3) 3 (9.09) <0.005
  Lesser curvature 6 (4.0) 4 (12.1) <0.005
  Greater curvature 27 (18.1) 2 (6.06) ns
  Fundus 5 (3.4) 1 (3.03) ns
  GOJ/cardia 42 (28.2) 16 (48.5) <0.005
Depth of tumour 
(n, %)
Tis 3 (2.0) 4 (12.1) ns
  T1a 55 (36.9) 20 (60.6) ns
  T1b 91 (61.1) 9 (27.3) <0.005
Differentiation (n, %) Well/Moderate 64 (43.0) 15 (45.4) 0.205
  Poor 37 (24.8) 3 (9.09) 0.145
  Not reported 48 (32.2) 15 (45.5) 0.305
Diameter (mm, 
median, range
  21.2 (0.2 - 65) 17.6 (6 - 90) 0.179
Lymphovascular 
invasion (n, %)
  24/146 (16.4)* 4/31 (12.9)* 0.346
Perineural invasion 
(n, %)
  4/134 (3.0)* 0/24 (0)* 0.015
Pathologic margins 
clear (n, %)
  143 (96) 23/30 (76.7)* <0.005
*not reported in all cases. NS; not significant
[Table 1. Comparison of early gastric cancers treated with surgical versus 
endoscopic resection]
conclusion: In this State Cancer Registry study, 237 EGCs were diagnosed 
over a 5-year period, representing 13.3% of gastric cancers. Within limi-
tations of retrospective analysis, most EGCs fulfilled criteria for ESD. Ad-
vanced resection techniques should be considered part of the management 
algorithm for EGC, ideally after discussion at a multidisciplinary meeting 
involving an Interventional Endoscopist. To increase the utilisation of ESD, 
patients should be referred to centres with expertise in lesion assessment 
and advanced endoscopic resection, and systems implemented to improve 
training, accreditation and access to ESD.
references: 1. Yada T, Yokoi C, Uemura N. The current state of diagnosis and 
treatment for early gastric cancer. Diagn Ther Endosc. 2013;2013:241320. 2. 
Choi MK, Kim GH, Park DY, Song GA, Kim DU, Ryu DY, et al. Long-term 
outcomes of endoscopic submucosal dissection for early gastric cancer: a 
single-center experience. Surg Endosc. 2013;27(11):4250-8. 3. Hu J, Zhao Y, 
Ren M, Li Y, Lu X, Lu G, et al. The Comparison between Endoscopic Submu-
cosal Dissection and Surgery in Gastric Cancer: A Systematic Review and 
Meta-Analysis. Gastroenterol Res Pract. 2018;2018:4378945. 4. Pimentel-
Nunes P, Dinis-Ribeiro M, Ponchon T, Repici A, Vieth M, De Ceglie A, et al. 
Endoscopic submucosal dissection: European Society of Gastrointestinal 
Endoscopy (ESGE) Guideline. Endoscopy. 2015;47(9):829-54. 5. Japanese 
Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 
4). Gastric Cancer. 2017;20(1):1-19. 6. Ono H, Yao K, Fujishiro M, Oda I, 
Nimura S, Yahagi N, et al. Guidelines for endoscopic submucosal dissec-
tion and endoscopic mucosal resection for early gastric cancer. Dig Endosc. 
2016;28(1):3-15. 7. Statistics ABo. Australian Demographic Statistics, Sep 
2018. Canberra, Australia2019.
disclosure: Nothing to disclose 
1000 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
P2009 endOscOPIc surveILLance afTer TOTaL gasTrecTOMy 
fOr gasTrIc cancer: Is IT necessary?
Lee J.S., Na H.K., Ahn J.Y., Choi K.D., Jung K.W., Kim D.H., Song H.J., 
Lee G.H., Jung H.-Y., Lee J.H.
Asan Medical Center, University of Ulsan College of Medicine, Division of 
Gastroenterology, Department of Internal Medicine, Seoul, Korea (Republic of)
contact e-Mail address: spaceplag@gmail.com
Introduction: Endoscopic surveillance after total gastrectomy for gastric 
cancer is routinely performed for detecting tumor recurrence or adverse 
effects of surgery.1 But, there were only a few reports for clinical benefits 
of endoscopic surveillance.2-5
aims & Methods: We investigated the necessity for endoscopic surveillance 
after total gastrectomy for gastric cancer. We reviewed the medical records 
of 385 patients who underwent total gastrectomy for gastric cancer be-
tween January 2011 and December 2011 in single tertiary hospital. Finally, 
we enrolled 143 early gastric cancer (EGC) patients and 175 advanced gas-
tric cancer (AGC) patients who received surveillance programs after total 
gastrectomy including endoscopy and abdominopelvic computed tomog-
raphy with contrast (APCT).
results: Median follow-up period of APCT was 58.4 months and endosco-
py was 55.5 months. We performed an R0 resection in 313 of 318 patients. 
Tumor recurrence was confirmed in 59 patients (19%), all of which were 
confirmed by APCT. Of 59 patients, four patients were EGC and 55 patients 
were AGC patients. The sites of recurrences were as follows: peritoneum 
in twenty-five, distant metastasis in twenty-one, loco-regional recurrence 
in six, and mixed recurrence in seven. Endoscopically confirmed recur-
rences were in five patients. Only one patient was confirmed recurrence 
by endoscopy earlier than APCT. This patient was performed R1 resec-
tion with the involvement of proximal margin. The postoperative benign 
stricture was confirmed by endoscopy in 2 patients (1%) without symptom 
and endoscopically passage disturbance. Other postoperative adverse ef-
fects including surgical stump or anastomosis site leakage, jejunal intus-
susception, and mechanical ileus were confirmed by APCT in 7 patients 
(2%).
conclusion: Endoscopic surveillance after total gastrectomy with R0 re-
section for gastric cancer is a limited role for detecting tumor recurrence 
or adverse effects of surgery. Abdominopelvic computed tomography with 
contrast is maybe sufficient for surveillance modality after total gastrec-
tomy with R0 resection for gastric cancer.
references: 1. NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines), Gastric Cancer, Version 1.2019, NCCN.org. 2. Kodera Y, Ito S, 
Yamamura Y, et al. Follow-up surveillance for recurrence after curative 
gastric cancer surgery lacks survival benefit. Annals of surgical oncology. 
2003;10(8):898-902. 3. Bennett JJ, Gonen M, D’Angelica M, Jaques DP, 
Brennan MF, Coit DG. Is detection of asymptomatic recurrence after cura-
tive resection associated with improved survival in patients with gastric 
cancer? Journal of the American College of Surgeons. 2005;201(4):503-510. 
4. Park SJ, Park YS, Jung IS, et al. Is endoscopic surveillance necessary 
for patients who undergo total gastrectomy for gastric cancer? PLOS ONE. 
2018;13(6):e0196170. 5. Lee SY, Lee JH, Hwang NC, et al. The role of follow-
up endoscopy after total gastrectomy for gastric cancer. European journal 
of surgical oncology : the journal of the European Society of Surgical Oncol-
ogy and the British Association of Surgical Oncology. 2005;31(3):265-269.
disclosure: Nothing to disclose 
P2010 rIsk facTOrs Of gasTrIc cancer afTer eradIcaTIOn 
Of Helicobacter pylori evaLuaTed frOM The BackgrOund gasTrIc 
MucOsa: a PrOPensITy scOre-MaTched case-cOnTrOL sTudy
Obayashi Y.1, Kawano S.1, Okamoto Y.1, Baba Y.1, Hamada K.1, Sakae H.1, 
Abe M.1, Kanzaki H.1, Iwamuro M.1, Kawahara Y.1, Tanaka T.2, Okada H.1
1Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, Department of Gastroenterology and Hepatology, 
Okayama, Japan, 2Okayama University Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Department of Pathology, Okayama, 
Japan
contact e-Mail address: buttersand14@yahoo.co.jp
Introduction: It is well known that eradication of Helicobacter pylori (H. 
pylori) reduces the risk of gastric cancer (GC) development. In contrast, 
H. pylori eradication does not prevent gastric cancer development in all 
individuals. There would be some risk factors in the background gastric 
mucosa after eradication of H. pylori. However, it is still unclear that histo-
logical features of the background gastric mucosa would be a predictable 
marker for the development of GC after eradication of H. pylori. Thus, we 
investigated risk factors of early GC development after eradication of H. 
pylori based on the histological characteristics of gastric mucosa.
aims & Methods: 61 patients who underwent endoscopic submucosal dis-
section of GC after successful H. pylori eradication (defined as group A), 
and 122 patients without developing gastric neoplasm over 3 years after 
successful H. pylori eradication for control group, (defined as group B) 
were analyzed. Moreover, we used propensity score-matching analysis to 
adjust significant differences in the baseline clinical characteristics of pa-
tients. Before and after propensity score-matching, we compared the score 
in the histological evaluation of these enrolled patients between group 
A and group B. Three biopsy specimens were obtained from the greater 
curvature of the antrum, the lesser curvature of the corpus, and the greater 
curvature of the corpus.
Gastric mucosa samples were evaluated according to the updated Sydney 
system.
results: Comparison of clinical characteristics between two groups re-
vealed that males, elderly patients were significantly higher, and years 
after successful eradication were longer, although not significantly, in 
group A.
Updated Sydney system scores of group A were significantly higher than 
group B at all site except for intestinal metaplasia (IM) in the greater cur-
vature of the corpus. However, there may be some bias, because of the dif-
ference depending on gender, age, and years after successful eradication. 
Therefore, we matched to reduce the influence of confounding these fac-
tors. After propensity score-matching, 54 patients with gastric cancer and 
54 patients without gastric cancer were included in each group. Inflam-
mation (mononuclear cells infiltration) in background gastric mucosa of 
Group A were significantly higher than the scores for the matched group B 
with the greater curvature of the antrum (0.78±0.57 vs 0.28±0.45, p< 0.01), 
the lesser curvature of the corpus (0.89±0.42 vs 0.64±0.59, p< 0.01) and 
greater curvature of the corpus (0.59±0.60 vs 0.35±0.48, p=0.03). Other 
significant differences were observed in atrophy of the greater curvature 
of the antrum (1.13±0.87 vs 0.64±0.77, p< 0.01), the lesser curvature of the 
corpus (1.61±1.01 vs 0.92±1.01, p< 0.01), and in IM of the greater curvature 
of the antrum (0.78±0.82 vs 0.46±0.77, p=0.02), the lesser curvature of the 
corpus (1.57±1.19 vs 0.85±0.98, p< 0.01).
conclusion: Continuous high level of inflammation in the background gas-
tric mucosa would be a risk factor of gastric cancer onset after H. pylori 
eradication.
disclosure: Nothing to disclose 
P2011 The effecTs Of WarfarIn and dIrecT OraL 
anTIcOaguLanT In endOscOPIc suBMucOsaL dIssecTIOn cases 
fOr gasTrIc neOPLasM
Ueki N.1, Kirita K.2, Agawa S.1, Ikeda G.2, Noda H.3, Higuchi K.2, 
Akimoto T.2, Yamawaki H.1, Kodaka Y.1, Kawagoe T.2, Futagami S.1, 
Iwakiri K.2
1Nippon Medical School Musashikosugi Hospital, Gastroenterology, 
Kawasaki, Japan, 2Nippon Medical School, Gastroenterology, Tokyo, Japan, 
3Nippon Medical School Hospital, Gastroenterology, Tokyo, Japan
contact e-Mail address: nobue@nms.ac.jp
Introduction: The number of the cases who take warfarin or direct oral 
anticoagulant (DOAC) is increasing because they have cardiovascular dis-
eases. Japanese guidelines for gastroenterological endoscopy have rec-
ommended continuation of warfarin and temporary withdrawal of DOAC 
on the day of endoscopic submucosal dissection (ESD). However, antico-
agulants were temporarily withdrawn until the guidelines were revised 
in 2017. In Japan, DOAC has been used since 2011, however, the effect on 
endoscopic treatment is not clear. In this study, we evaluated the effect of 
warfarin and DOAC.
aims & Methods: 417 patients with gastric neoplasms underwent ESD at 
the Nippon Medical School from January 2012 to February 2018. We ex-
cluded 32 patients who underwent injection of triamcinolone into ulcer 
after ESD, 27 patients who took NSAIDs, and 9 patients who had been on 
dialysis. Among them, 96 cases were taking antithrombotic drugs. 21 pa-
tients taking anticoagulant drugs were divided into two groups; warfarin 
group (13 patients; male 10) and DOAC group (8 patients; male 8). The 
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types of DOAC were dabigatran, apixaban, edoxaban or rovaroxaban. We 
compared retrospectively the post-bleeding rate, blood data, and compli-
cations between two groups.
results: The post-bleeding rate were no differences between warfarin 
group (15.3%; 2/13) and DOAC group (12.5%; 1/8). No perforation occurred 
in both groups. The warfarin group had a slight longer ESD procedure 
time than the DOAC group. There were no differences in the rate of in-
crease on the next day after ESD with platelet counts, PT (%) and APTT, 
but D-dimer was significantly increased in the warfarin group (61.0% vs 
15.4%; p = 0.04). There were no complications such as thromboembolism 
in both groups.
conclusion: Although there was no thromboembolism, withdrawing war-
farin made anticoagulant action unstable and may be risk of thromboem-
bolism.
disclosure: Nothing to disclose 
P2012 endOscOPIc uLTrasOund In The dIagnOsIs 
and fOLLOW-uP Of gasTrIc suBePITheLIaL LesIOns: 
resuLTs frOM a regIOnaL cenTre
Haddock R.1, Tham J.2, Paterson S.3, Stanley A.J.2
1NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United 
Kingdom, 2Glasgow Royal Infirmary GI Unit, Department of Gastroenterology, 
Glasgow, United Kingdom, 3NHS Forth Valley, Gastroenterology, Larbert, 
United Kingdom
contact e-Mail address: rosiehaddock1@doctors.org.uk
Introduction: Gastric subepithelial lesions (SEL) found on conventional 
endoscopy or CT have a broad differential including malignant disease. 
Endoscopic ultrasound (EUS) +/- fine needle aspiration (FNA) has become 
an important modality in assessing SELs and guiding management. The 
optimum assessment and follow-up strategy for smaller lesions remains 
unclear. Our aim was to assess outcomes of patients undergoing EUS for 
gastric SELs in our regional centre. Secondary aims included assessing the 
use of EUS FNA, surveillance strategy and outcomes by lesion size (<10, 
10-20 and >20mm).
aims & Methods: We undertook a retrospective analysis of our prospec-
tively collated regional EUS database, to identify patients who underwent 
EUS for SELs. Electronic patient records were analysed to obtain relevant 
data including imaging, cytopathology and follow-up. Patients with SELs 
out-with the stomach and patients undergoing EUS for investigation of 
known (or strongly suspected) malignancy were excluded.
results: Between 1/1/14 and 31/12/17, 70 patients were referred for EUS due 
to the identification of an SEL on endoscopy (97%) or CT scan (3%). Mean 
age was 60 years with 44% (n=31) male. 56% (n=38) patients also under-
went endoscopic biopsy together with EUS. All patients were followed up 
for a minimum of 12 months. Mean lesion size on EUS was 24.8mm. 15.7% 
(n=11), 42.9% (n=30) and 40% (n=28) of lesions were < 10mm, 10-20mm 
and >20mm respectively. One patient had mucosal thickening only, and 
one patient had incidental lung adenocarcinoma diagnosed at EUS. Table 
1 shows the EUS diagnosis according to size of lesion. 
31.4% (n=22) patients underwent FNA of lesion, (0%,4.2% and 27.1% pa-
tients for lesion size < 10mm 10-20mm and >20mm respectively). 4.2% 
(n=3) patients had biopsies within biopsies and 5.7% (n=4) patients were 
not sampled due to patient factors. 
68% (n=15) of EUS-FNAs were diagnostic. 62.5% (n=10) FNAs were di-
agnostic of GIST, with 12.5% (n=2) leiomyoma, and one each adenocarci-
noma, lymphoma, and lipoma. 
All patients with lesions < 20mm (n=42) were alive and well with at least 
one-year follow-up, or had died of unrelated causes. 19 underwent repeat 
EUS or surveillance CT/endoscopy, 19 had no planned follow up due to 
lesions being deemed low risk or patient choice, one had a resection and 
two died of other causes. Of the 27 patients with lesions >20mm, 11 un-
derwent resection/received Imatinib and 11 underwent EUS/CT/endoscopy 
surveillance due to patient co-morbidities or lesion being deemed low risk 
on EUS, with static size of lesion. Three lesions >20mm were cysts requir-
ing no follow-up, two received other chemotherapy/surgery and one died 
of unrelated causes.
conclusion: EUS is a useful tool in the assessment, diagnosis and follow-
up of small SELs. Management of lesions < 2cm remains controversial, 
however in our series, patients with SEL within this size range had no 
clinical sequelae and no EUS findings of concern during follow-up of at 
least one-year.
eus imaging diagnosis (n) size of lesion <10mm
size of lesion 
10-20mm
size of lesion 
>20mm Total
Probable GIST 1 6 14 21
Benign lesion 5 15 1 21
Indeterminate 0 0 4 4
Pancreatic rest 1 5 0 6
Lipoma 1 3 1 5
Suspicion of malignancy 0 0 5 5
Cyst 0 0 3 3
Normal 1 0 0 1
Polyp 1 2 0 3
[Table 1. EUS results according to size]
disclosure: Nothing to disclose 
P2013 cLInIcaL IMPacT Of endOscOPIc suBMucOsaL 
dIssecTIOn usIng cLuTch cuTTer WITh Over-The-scOPe-cLIP 
cLOsure fOr suPerfIcIaL nOn-aMPuLLary duOdenaL 
ePITheLIaL TuMOr
Dohi O.1, Yoshida N.1, Ishida T.2, Takayama S.1, Nakano T.1, Majima A.3, 
Inoue K.1, Kamada K.1, Takagi T.2, Konishi H.1, Naito Y.4, Itoh Y.1
1Kyoto Prefectural University of Medicine, Gastroenterology and Hepatology, 
Kyoto, Japan, 2Kyoto Prefectural University of Medicine, Molecular 
Gastroenterology and Hepatology, Kyoto, Japan, 3Omihachiman Community 
Medical Center, Gastroenterology and Hepatology, Omihachiman, Japan, 
4Kyoto Prefectural University of Medicine, Gastroenterology, Kyoto, Japan
contact e-Mail address: osamu-d@koto.kpu-m.ac.jp
Introduction: Endoscopic submucosal dissection (ESD) for superficial non-
ampullary duodenal epithelial tumor (SNADET)is often caused high rate 
of delayed complications.We reported that ESD using a scissor-type knife 
was efficient for gastrointestinal tumors andESD with prophylactic laparo-
scopic closure is one of the minimally invasive treatments for SNADET. In 
contrast, there have been some reports with regard to the usefulness of the 
over-the-scope clip (OTSC) for prevention of delayed complications after 
endoscopic treatment.
aims & Methods: The consecutive patients with SNADET who underwent 
ESD at the hospital of Kyoto Prefectural University of Medicine were retro-
spectively enrolled between January 2009 and April 2019.The inclusion cri-
teria were SNADETs larger than 10mm without submucosal invasion with 
a low risk for lymph node metastasis clinically. We had mainly performed 
ESD using a needle-type knife (Flush Knife) between January 2009 and 
September 2017, or using a scissor-type (Clutch Cutter) between October 
2017 and April 2019. The mucosal defect was prophylactically closed using 
conventional clips, laparoscopic hand-saw suturing, or OTSC.
The primary endpoint was to evaluate the rate of en block resection, intra-
operative complications (perforation and bleeding) between Flush Knife 
cases and Clutch Cutter cases. The secondary end point was to evaluate the 
rate of delayed complications among three closing methods. All patients 
provided written informed consent. 
This study was approved by the ethical committee of Kyoto Prefectural Uni-
versity of Medicine.
results: A total of 77 lesions in 75 patients (male/female 54/23 and median 
age 67 years) were resected by ESD. There were 37 and 40 cases resected 
using the Flush Knife and the Clutch Cutter, respectively. Moreover, there 
were 14, 13, and 50 cases using conventional clip, laparoscopic hand-sewn 
suturing, and OTSC for prophylactic closure of the mucosal defect after 
ESD, respectively. Histopathological diagnosis (adenoma/ T1a cancer/ T1b 
cancer) in Flush Knife and Clutch Cutter cases revealed 2/33/2 and 1/34/5, 
respectively. In Flush Knife and Clutch Cutter cases, the rate of R0 resection 
was 83.8% and 97.5%, respectively, with no significant difference. Median 
resection time in Clutch Cutter cases was significantly shorter than that 
in Flush Knife cases (40 min and 54 min, respectively, P< 0.01). The rates 
of complete closurewere 78.6%, 92.3%, and 98.0% for the conventional 
clip, the laparoscopic closure, and OTSC, respectively, with no significant 
difference (P=0.13). 
However, the closing time for OTSC was significantly shorter than that 
of the conventional clip and the laparoscopic closure (P< 0.01). Adverse 
events such as delayed perforation and delayed perforation was 15.4%, 
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7.7%, and 2.3%, and 0%, 0%, and 2.3% for the conventional clip, the 
laparoscopic closure, and OTSC, respectively, with no significant difference 
(P=0.56 and P=1).
conclusion: ESD using Clutch Cutter with OTSC closure is safe and feasible 
for the less invasive treatment of SNADET.
disclosure: Yuji Naito received collaboration research funding from Fuji-
film Medical Co., Ltd. (J132001115, J132001139). Naohisa Yoshida received 
a research grant from Fujifilm Medical Co., Ltd. (J162001222). Yoshito Itoh 
were affiliated with a department that was partially funded by Fujifilm 
Medical Co., Ltd. (J082003006). 
P2014 PrecedIng endOscOPIc suBMucOsaL dIssecTIOn 
dOes nOT affecT fOr The PrOgnOsIs Of PaTIenTs WITh 
gasTrIc carcInOMa WITh suBMucOsaL deeP InvasIOn afTer 
addITIOnaL surgery: a PrOPensITy scOre-MaTched anaLysIs
Kuroki K.1, Oka S.2, Tanaka S.3, Yorita N.1, Hata K.1, Kotachi T.1, 
Ninomiya Y.1, Boda T.1, Ito M.2, Arihiro K.4, Chayama K.2
1Hiroshima University Hospital, Endoscopy, Hiroshima, Japan, 2Hiroshima 
University Hospital, Gastroenterology and Metabolism, Hiroshima, Japan, 
3Hiroshima University, Endoscopy and Medicine, Hiroshima, Japan, 
4Hiroshima University Hospital, Anatomical Pathology, Hiroshima, Japan
contact e-Mail address: d163308@hiroshima-u.ac.jp
Introduction: In Japan, the guidelines for gastric cancer treatment specify 
several criteria for curative resection of endoscopic submucosal dissection 
(ESD), and additional surgery after endoscopic ESD is recommended for all 
patients who did not meet the curative criteria for gastric cancer. The sub-
mucosal deep invasion (SM-d; depth of submucosal invasion≧500µm) is 
one of the risk factors for the predicted lymph node metastasis, and is used 
in the new curative criteria “eCura system” in the Japanese Gastric Cancer 
Treatment guidelines 2018 (ver.5). However, the data about the long-term 
outcomes of the preceding ESD for the patients with pathological SM-d 
(pSM-d) gastric cancer is insufficient. In this study, we analyzed the influ-
ence of preceding ESD on the prognosis of patients with pSM-d gastric 
cancer after additional surgery using propensity score-matching.
aims & Methods: We retrospectively assessed 316 consecutive patients with 
319 pSM-d gastric cancers who underwent ESD prior to additional surgery 
or surgery alone between February 2002 and February 2017 at the Hiro-
shima University Hospital. Of the patients after ESD, patients who did not 
meet curative criteria of the guidelines were advised to undergo additional 
surgery. Of the 316 patients, 63 patients were treated by ESD alone be-
cause of various reasons (refusal to surgery, comorbidity and/or advanced 
age), and they were excluded. Finally, 248 patients with pSM-d gastric 
cancer who underwent ESD prior to additional surgery (Group A: n=101) 
or surgical resection alone (Group B: n= 147) were included in this study. 
Propensity score-matching was used to control for potential confounders. 
After matching the propensity scores, we analyzed pathological character-
istics between the 2 groups and the prognoses of patients with≧60 month 
follow-up period was analyzed.
results: The baseline characteristics before propensity score matching 
were following: There were significantly more male in Group A than Group 
B, and the patients in Group A were significantly older than the patients in 
Group B. A higher proportion of patients in group B had tumors located in 
the middle third of the stomach. Likewise, depressed type tumors and un-
differentiated type tumors in Group B were significantly more than tumors 
in Group A, the mean tumor diameter in Group B were significantly larger 
than that in Group B and the mean depth of submucosal invasion in Group 
B was significantly deeper than in Group A. The en bloc resection rates in 
Group A were 91% (93/102) and the rates of vertical margin positive were 
23% (23/102). Perforation occurred in 5% (5/102) and all cases could be 
improved by conservative treatment. Local recurrence had not occurred 
but metastasis to lymph nodes or other organs occurred in 2% (2/102) in 
Group A and 3% (4/147) in Group B. Propensity scores were calculated us-
ing a logistic regression model, and the variables included in the model 
were age, sex, tumor size, and gross type in Group A. After propensity 
score-matching, 80 patients in group A and 80 patients in group B were 
picked up. There were no significant differences in 5-year overall survival 
rates (87.5% vs. 91.2%) and 5-year disease-specific survival rates (96.3% 
vs. 96.4%) after treatment of pSM-d gastric cancer between 2 groups.
conclusion: Preceding ESD for patients with pSM-d gastric cancer did not 
affect their clinical outcomes adversely after additional surgery.
disclosure: Nothing to disclose 
P2015 gerMLIne MuTaTIOns In TWO faMILIaL earLy-OnseT 
gasTrIc cancer faMILIes
Zhou F.
Nanjing Drum Tower Hospital affiliated with Medical School of Nanjing 
University, Department of Gastroenterology, Nanjing, China
contact e-Mail address: zhoufan24@hotmail.com
Introduction: Gastric cancer (GC) is highly heterogeneous and most cases 
are sporadic. While only 10% cases showed family aggregation overall, the 
frequency of hereditary GC can rise up to 25% in early-onset GC patients. 
At present, the only known cause of hereditary diffuse gastric cancer is 
CDH1 germline mutation in the Caucasian population. Recent studies us-
ing next-generation sequencing have identified several recurrent somatic 
genes mutated in sporadic GC. However, germline mutations of familial 
gastric cancer (FGC) have not been thoroughly investigated in Chinese pa-
tients.
aims & Methods: We searched our previously published cohorts of 152 
young GC patients1 and identified two FGC families. In each family, two 
patients were re-admitted to our hospital. Patients’ demographics, clinical 
results, detailed family history, and endoscopic-pathological findings were 
gathered and analyzed. Patients’ peripheral blood was collected to extract 
DNA for whole-genome sequencing. The sequencing data were aligned 
with the reference genome sequence, filtered out synonymous alterations, 
and compared with previously published results in the literature and the 
TCGA data of the Unites Stated National Institute of Health.
results: In four patients (two male patients and two female probands, 
average age: 50.2 years), three had poorly differentiated adenocarcinoma 
with mixed mucinous and signet ring carcinoma components; the oth-
er was moderately differentiated adenocarcinoma in the cardia. Tumor 
stages ranged from pI to pIIA. All 4 patients were well at the last follow 
up. Whole-genome sequencing demonstrated 8 shared non-synonymous 
SNPs and Indels among all four patients, 4 unique variations shared in 
the first family and 7 in the second family. Go analysis showed that the 
genes for cytoskeleton, actin binding, myosin complex, keratin filament, 
cytoskeletal protein binding and intercellular non-membrane-bounded 
organelle terms were significantly associated with FGC. Two germline 
genes, 1) Leukocyte immunoglobulin-like receptor subfamily A member 4 
(LILRA4) with a missense mutation (NM_012276.4:c.953-2A>G), 2) Myome-
sin-2 (MYOM2) with a missense mutation (NM_003970.3:c.3695A>G), were 
validated by PCR Sanger Sequencing. No CDH1 mutation or p53 alterations 
were found in any 4 Chinese patients.
conclusion: These findings showed that 2 germline genes, LILRA4 and 
MYOM2, may act as tumor suppressor genes and might be used as a diag-
nostic marker for FGC. Further validation of these two genes mutations in 
FGC is obligatory and on-going.
references: 1 Fan Zhou#, Jiong Shi, Cheng Fang, Xiaoping Zou*, Qin 
Huang*. Gastric Carcinomas in Young (Younger than 40 Years) Chinese Pa-
tients: Clinicopathology, Family History, and Postresection Survival, Medi-
cine (Baltimore), 2016, 95(9): e2873.
disclosure: Nothing to disclose 
P2016 The PrevaLence and sIgnIfIcance Of jejunaL 
POLyPOsIs afTer duOdenecTOMy In faMILIaL adenOMaTOus 
POLyPOsIs
Yoon J.Y.1, Mehta N.2, Burke C.2, Augustin T.3, O’Malley M.4, Laguardia L.4, 
Cruise M.5, Mankaney G.2, Church J.4, Kalady M.4, Walsh R.M.3, Bhatt A.2
1Cleveland Clinic, Internal Medicine, Cleveland, United States, 2Cleveland 
Clinic, Gastroenterology and Hepatology, Cleveland, United States, 3Cleveland 
Clinic, General Surgery, Cleveland, United States, 4Cleveland Clinic, Colorectal 
Surgery, Cleveland, United States, 5Cleveland Clinic, Pathology, Cleveland, 
United States
contact e-Mail address: jiyoon.y@gmail.com
Introduction: Duodenal adenocarcinoma is the second leading cause of 
cancer in familial adenomatous polyposis (FAP). Spigelman stage (SS) of 
duodenal polyposis predicts cancer risk. Advanced SS requires consider-
ation of duodenal resection. Post-duodenectomy data indicate polyps oc-
cur in the post-anastomotic jejunum, distal to the flow of bile, but limited 
data exists regarding their significance. Our study aims to evaluate the 
prevalence, natural history, and severity of polyposis of the jejunum after 
duodenectomy in patients with FAP.
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aims & Methods: We identified consecutive FAP patients following duo-
denal resection, including Whipple procedure, pancreas-sparing duode-
nectomy (PSD), or segmental duodenectomy, at Cleveland Clinic between 
08/1978 and 01/2018 from the David G. Jagelman Inherited Colon Cancer 
Registries. Patients without endoscopic follow up data were excluded. 
Medical records were used to determine demographics, time to diagnosis 
of jejunal polyps, length of post-operative endoscopic follow up, and maxi-
mal SS of jejunal polyposis (neo-Spigelman stage). The Spigelman and 
neo-Spigelman stage (0-IV) was calculated according to cumulative points 
(1,2,3) for each category within the following characteristic: largest polyp 
size (1-4 mm, 5-10 mm, > 10 mm), polyp number (1-4, 5-20, > 20), histol-
ogy (tubular adenoma, tubulovillous adenoma, villous adenoma), degree 
of dysplasia (1 for low grade, 3 for high grade). Stage I is 1-4 points, II is 
5-6 points, III is 7-8 points and IV is 9-12 points.
results: 64 patients were identified; mean age 61.7 ±12.3 years, 53% male, 
83% white. 28% underwent Whipple, 61% PSD, and 11% segmental duo-
denectomy. Advanced polyposis (81%, SS III-IV) was the most common in-
dication for surgery. Post-operatively 38/64 (59%) developed jejunal pol-
yposis (Table 1), with median time to diagnosis of 55 months and follow up 
time of 127 months. On most recent endoscopy, neo-Spigelman stage was 
I in 29%, II in 50%, III in 18.4%, and IV in 2.6%. No cases of high-grade 
dysplasia or carcinoma were noted during surveillance. 48% of jejunal 
polyps were treated with endoscopic resection or ablation. One patient 
with neo-Spigelman stage III jejunal polyposis had Whipple procedure 21 
years after initial PSD for progressive polyposis of the jejunum, with surgi-
cal specimen demonstrating high grade dysplasia. 
    number of patients (%)
Time to diagnosis, median months [Q1, Q3] 55 [22, 84]
Duration of post-operative endoscopic follow up, median 
months [Q1, Q3]
127 [78, 175]
Neo-Spigelman stage Stage I 11 (29)
  Stage II 19 (50)
  Stage III 7 (18.4)
  Stage IV 1 (2.6)
Carcinoma/ HGD on surveillance biopsy 0
Management of jejunal 
polyposis
Surveillance 18 (47.4)
  Endoscopic resection/ ablation 19 (50)
  Surgical resection 1 (2.6)
Q1 first quartile; Q3 third quartile; HGD high grade dysplasia
[Table 1. Jejunal polyposis detected on post-operative surveillance (N=38)]
conclusion: In spite of surgical management of duodenal polyposis, je-
junal polyposis occurs in the majority of patients after surgical duode-
nectomy and is advanced in 1 in 5 patients. Further studies are required 
to evaluate the significance and risk of polyposis of the jejunum in FAP 
patients. In the meantime, continued endoscopic surveillance is indicated.
disclosure: Nothing to disclose 
P2017 The PrevaLence and sIgnIfIcance Of duOdenaL BuLB 
POLyPOsIs afTer duOdenecTOMy In PaTIenTs WITh faMILIaL 
adenOMaTOus POLyPOsIs
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Cleveland, United States, 5Cleveland Clinic Foundation, Colorectal Surgery, 
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Introduction: Consideration of prophylactic duodenal surgery is recom-
mended in patients with Familial Adenomatous Polyposis (FAP) and Spi-
gelman stage IV duodenal polyposis to prevent cancer. Pylorus-sparing 
approaches of pancreatoduodenectomy (PD) and pancreas-sparing duo-
denectomy (PSD) are often performed over a complete Whipple procedure. 
Pylorus-sparing techniques, with the benefit of reduced rates of gastric 
dumping syndrome, create a duodeno-jejunal anastomosis at the apex of 
the duodenal bulb, which remains at risk of recurrent adenoma. Our study 
aims to evaluate the prevalence and severity of polyposis of the duodenal 
bulb after pylorus-sparing duodenectomy.
aims & Methods: We identified consecutive FAP patients following duode-
nal resection (PD, PSD, or segmental duodenectomy) at Cleveland Clinic, 
between 05/1992 and 01/2018 from the David G. Jagelman Inherited Co-
lon Cancer Registries. Those who had a pylorus-sparing procedure with 
a remnant duodenal bulb on post-operative anatomy were included in 
the study. Those without endoscopic follow up data after surgery were 
excluded. Medical records data was used to determine time to occurrence, 
maximal size, histology, and dysplasia of duodenal bulb polyps in patients 
after duodenal resection.
results: 55 FAP patients had a pylorus-sparing duodenal resection and 
were included in the study (20% PD, 69% PSD, 11% segmental duode-
nectomy). Mean age was 61.5 ±12.6 years, 56% were male, and 82% were 
white. 6/55 (11%) patients with duodenal bulb polyposis were identified 
(Table 1). All patients were post-PSD. Median time to polyp occurrence in 
the duodenal bulb was 43 months [IQR 19-62]. All 6 patients developed 
large polyps > 20 mm. 1 of 6 had tubulovillous adenoma, the remainder 
tubular adenoma on biopsy. Endoscopic resection with submucosal injec-
tion was attempted on 5 of 6 cases, and complete resection was achieved 
in one case. The remaining 4 lesions demonstrated no lift on submucosal 
injection. In one case, initial endoscopic resection was successful, but re-
current adenoma at the site of resection after 12 months was not amenable 
to resection due to fibrosis. There were no cases of carcinoma or surgical 
resection for duodenal bulb polyps. 
Patient
Time to 
polyp detection 
(months)
no. of 
post operative 
egds
Maximal 
size (mm)
Maximal 
histology
success of 
endoscopic 
therapy
1 19 16 60 TA No
2 43 4 20 TA Yes
3 56 2 40 TA No
4 62 12 50 TA No
5 14 7 25 TVA No
6 105 9 35 TA Not attempted
[Table 1: Bulb polyp characteristics (N=6)]
conclusion: A minority of patients develop polyps in the duodenal bulb 
after pylorus-sparing duodenectomy. They are difficult to manage endo-
scopically due to failure of endoscopic resection with frequent non-lifting 
with submucosal injection. This could be secondary to the proximity to the 
surgical anastomosis, prevalence of Brunner’s glands in the proximal duo-
denum, and previous attempted removal. Optimal approaches to prevent 
duodenal bulb polyps after pylorus-sparing duodenectomy are needed.
disclosure: Nothing to disclose 
P2018 vOnOPrazan versus PrOTOn PuMP InhIBITOrs fOr 
The ManageMenT Of gasTrIc endOscOPIc suBMucOsaL 
dIssecTIOn-Induced arTIfIcIaL uLcer: a sysTeMaTIc revIeW 
WITh MeTa-anaLysIs
Kim B.J.1, Kang H.2, Kim J.G.3, Choi G.2
1Chung-Ang University College of Medicine, Internal Medicine 
(Gastroenterology), Seoul, Korea (Republic of), 2Chung-Ang Univ. Hospital, 
Anesthesiology, Seoul, Korea (Republic of), 3Chung-Ang Univ. Hospital, 
Internal Medicine (Gastroenterology), Seoul, Korea (Republic of)
contact e-Mail address: kimbj@cau.ac.kr
Introduction: Vonoprazan, a novel potassium-competitive acid block-
ing agent, has been used in the management of endoscopic submucosal 
dissection (ESD)-induced artificial ulcers. This study aimed to perform a 
systematic review and meta-analysis for the comparison of the effects of 
vonoprazan and proton pump inhibitors (PPI) in treating ESD-induced ar-
tificial ulcers and preventing delayed bleeding in randomized controlled 
trial and cohort studies.
aims & Methods: We searched OVID-MEDLINE, EMBASE, Cochrane Central 
Register of Controlled Trials (CENTRAL), Google Scholar, and clinical trial 
registries in April 2018 to identify all studies that assess and compare the 
effects of vonoprazan and PPI in treating ESD-induced artificial ulcers and 
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preventing delayed bleeding. Primary outcome of ulcer healing rate and 
secondary outcomes of shrinkage rate, ulcer size, and delayed bleeding 
were studied.
results: A total of 1265 patients from 12 studies was included in the final 
analysis. Healing rate at 4 weeks post-ESD was significantly higher in the 
vonoprazan group than in the PPI group (RR 1.20 (1.03-1.40)). However, 
healing rate at 8 weeks post-ESD was significantly higher in the PPI group 
than in the vonoprazan group (RR 0.68 (0.48-0.97)). 
There was no evidence of significant difference between groups in shrink-
age rate at 4 weeks post-ESD, shrinkage rate at 8 weeks post-ESD, delayed 
bleeding, ulcer size at 0 weeks post-ESD, and ulcer size at 8 weeks post-
ESD.
conclusion: There was no substantial difference in ulcer healing and post-
ESD bleeding between vonoprazan and PPIs. However, vonoprazan more 
rapidly and effectively treated artificial ulcers after ESD than did PPIs.
references: J Neurogastroenterol Motil. 2019 Jan 31;25(1):6-14. doi: 10.5056/
jnm18139. Mori H, Suzuki H. Role of Acid Suppression in Acid-related Dis-
eases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker. J 
Neurogastroenterol Motil. 2019 Jan 31;25(1):6-14.
disclosure: Nothing to disclose 
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1Royal Hallamshire Hospital, Academic Unit of Gastroenterology and 
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Introduction: The United Kingdom BSG and AUGIS quality standards in up-
per gastrointestinal endoscopy recommend taking biopsies for histological 
examination to diagnose inflammatory, pre- or malignant lesions which 
may or may not be visible to the naked eye [Beg, Gut 2018]. This may 
increase the duration and cost of the procedure and potentially reduce the 
focus on mucosal inspection. This study aimed to investigate the diagnostic 
value (changes in diagnosis and contribution to management) added by 
histology and its cost.
aims & Methods: Patients under going consecutive diagnostic gastrosco-
pies performed by four fellows were recruited. Incomplete, surveillance 
or therapeutic procedures, procedures for dysphagia and those arranged 
in order to obtain histology (eg. positive coeliac serology) were excluded. 
Biopsies were performed according to BSG quality standards [Beg, Gut 
2018]. The utility of biopsies (changes in diagnosis and contribution to 
management) were examined from endoscopic and histological findings.
results: Of 509 patients examined, 314 were included. Gastroscopies was 
performed for dyspepsia (66%), anaemia (26%), weight loss (16%), diar-
rhoea (2%) and vomiting (1%). Biopsies occurred in 86% of patients with 
an mean of 1.5 samples per patient biopsied. Biopsy sampling provided 
additional pathological information not evident at endoscopy in 28% of 
cases. However, if benign pathologies are excluded (mostly chemical or 
Helicobacter gastritis or duodenitis), this falls to 6.7% (n=18: dysplasia 
n=3, adenocarcinoma n=1, gastric intestinal metaplasia (GIM) n=7, villous 
atrophy (VA) n=2, Barretts n=5). In total, management change occurred in 
19% consequent on histological findings, but this falls to 12% (n=34: ad-
enocarcinoma n=2, dysplasia n=3, GIM, n=10, Barretts n=15, VA n=3, peptic 
stricture n=1) where Helicobacter pylori (which can be detected by other 
non-invasive methods) eradication is excluded. 
Fifty seven focal lesions were biopsied where dysplasia or cancer was di-
agnosed in 7% (1/14 oesophageal, 2/35 gastric and 1/8 duodenal). Bar-
retts (58% vs 0% p=0.02), GIM (81% vs 18% p=0.05) and VA (20% vs 1% 
p=0.02) were found more commonly in abnormal compared to normal 
mucosa. The overall cost of tissue sampling approximates to £17,100 (£82 
per person). Routine biopsies of patients with only normal mucosa costed 
over £3,500.
conclusion: Although 86% undergoing gastroscopy have biopsies taken, 
contributing to aetiopathological understanding in 28%, only a small mi-
nority (6.7%) have pre-malignant or malignant pathologies and result in a 
change in management in only 12%. Non-targeted biopsies are of limited 
value and costly when sampled from normal mucosa.
references: Beg S, Ragunath K, Wyman A, et al. Quality standards in up-
per gastrointestinal endoscopy: a position statement of the British Society 
of Gastroenterology (BSG) and Association of Upper Gastrointestinal Sur-
geons of Great Britain and Ireland (AUGIS). Gut 2017; 66(11): 1886-99.
disclosure: Nothing to disclose 
P2021 rOuTIne exaMInaTIOn Of sTOMach and duOdenuM In 
PaTIenTs aTTendIng fOr BarreTT’s surveILLance- Is IT reaLLy 
IndIcaTed?
Shaikh F.K.1, Mundre P.2
1Bradford Teaching Hospitals NHS Trust, Gastroenterology, Bradford, United 
Kingdom, 2Bradford Teaching Hospitals NHS Trust, Leeds, United Kingdom
contact e-Mail address: pradeepmundre@gmail.com
Introduction: Patients undergoing OGD for Barrett’s surveillance have ex-
amination upto D2 before detailed examination of Barrett’s mucosa and 
Seattle protocol biopsies. This may lead to less time dedicated to examine 
Barrett’s segment potentially leading to reduction in the yield of dyspla-
sia. Most patients undergo such procedures with throat spray or sedation, 
hence potentially reducing the compliance of patients towards the end of 
procedure when examination of Barrett’s segment is performed in routine 
practice.
aims & Methods: Our aim is to find out what percentage of surveillance 
OGDs incidentally pick up significant pathologies in stomach and duode-
num (cancer, pyloric stenosis, polyp with dysplasia, benign ulcer and varix) 
compared with their index procedures; whether we could potentially avoid 
examination of stomach and duodenum during surveillance procedures 
and focus this time on longer inspection of Barrett’s segment 
We retrospectively analysed all OGD reports retrieved from hospital’s En-
doscopy reporting tool for patients who underwent OGD within last 10 
years (January 2009- December 2018) for Barrett’s surveillance. Data was 
extracted electronically using the endoscopy audit tool on the reporting 
system. We analysed all these OGDs for presence of significant pathologies 
in stomach and duodenum that were found incidentally. Procedures with 
Barrett’s oesophagus as index diagnosis or OGD earlier than the proposed 
surveillance interval for other indications were excluded. Reports of all 
procedures with a diagnosis of Barrett’s oesophagus over a period of one 
year(2018) were individually validated manually to confirm accuracy of the 
electronic data set and to get a gross estimate of surveillance procedures 
over 10 years.
results: Yearly procedure count was 155 patients undergoing Barrett’s sur-
veillance OGD which approximates to about 1550 procedures over 10 years. 
The median age was 68 years. Average surveillance interval was 3.45± 
1.12 years. There were no cases of gastric or duodenal cancer, however 1 
patient had incidental follicular lymphoma (0.06%), single case of gastric 
adenoma with focal HGD (0.06%) and 2 patients with duodenal adenoma 
(0.1%) were found over 10 years. Incidental benign ulcers (gastric and du-
odenal) were found in 4% (n =61) and gastric varices in 5 patients (0.3%, 
all with known chronic liver disease).
conclusion: Our study demonstrates that incidental findings of significant 
pathology during surveillance OGD for Barrett’s oesophagus is very rare. 
Hence in patients undergoing Barrett’s surveillance, a focussed examina-
tion of oesophagus and gastro-oesophageal junction rather than examina-
tion of stomach and duodenum may be more appropriate with an aim to 
increase pick up rates of dysplasia. Previous studies have demonstrated 
that longer inspection time is associated with increase in detection rate of 
high grade dysplasia and cancer (1).
A shortcoming in our study is the retrospective nature of data. We also 
noted a longer surveillance interval than what we expected. This could be 
explained by surveillance procedures performed outside our local author-
ity, but this would not have influenced our results other than the overall 
numbers. We do not have any data regarding separate time intervals for 
the completion of OGD and examination of Barrett’s segment. We would 
recommend detailed prospective data collection for these aspects. Multi-
centre data may further validate the above results.
references: 1. Longer inspection time is associated with increased detec-
tion of high-grade dysplasia and esophageal adenocarcinoma in Barrett’s 
esophagus. Gupta, Neil et al. GIE , Volume 76 , Issue 3 , 531 - 538
disclosure: Nothing to disclose 
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1Université Libre de Bruxelles, Faculty of Psychology, Bruxelles, Belgium, 
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Oncology, Brussels, Belgium
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Introduction: Recent guidelines on quality in endoscopy recommend a 
regular assessment of patient experience. Nevertheless, there is a paucity 
of data in this research area. Most studies did not question the experi-
ence from the patient perspective. The aim of this study was to develop a 
satisfaction questionnaire in order to identify the main elements affecting 
patient experience and satisfaction during an upper-endoscopy.
aims & Methods: Based on literature review and information collected 
from exploratory interviews with patients, before and after the examina-
tion, a satisfaction questionnaire was created. This questionnaire includes 
an interactive part with 11 variables about patient experience classified 
by importance by the patients. This questionnaire was administered by 
the same interviewer to outpatients undergoing upper-endoscopy after 
discharge from Saint-Pierre Hospital, Brussels, Belgium from the 14th of 
march to the 4th of april 2019. An informed consent validated by local eth-
ics committee was presented before each interview. The statistical analy-
ses were performed with IBM SPSS.
results: Out of the 54 consecutive interviewed patients, 52 fully responded 
(35 women). 46.1% of the sample was aged between 26 and 45 years old. 
The mean of the global satisfaction was 8.82 out of 10 with a standard de-
viation of 0.989. Perceived « Kindness of the care team », « Professionalism 
of the care team » and « Explanation of the results right after the exami-
nation » were considered as the 3 most important factors influencing the 
global satisfaction of the patient, by respectively 84.6%, 57.7% and 50% of 
the sample. On the other hand, « Fasting the day of the exam », « Waiting 
time before the exam » and « Pain » were considered as the 3 least im-
portant factors influencing the global satisfaction of the patient, by respec-
tively 57.7 %, 57.7% and 36.5%. There is a statistically significant difference 
in rank between both the 11 variables (p< 0.001), and the 3 most important 
factors (p=0.001). There is a significant difference between « Kindness of 
the care team » and « Professionalism of the care team » (p=0.006).
conclusion: Patient satisfaction is a key quality indicator of upper-endos-
copy. It is necessary to draw attention on how patients feel before and 
after an endoscopy procedure and not only focus on the exam itself. Our 
interesting results show that kindness and communication stand out as 
the most important factors of patient satisfaction during upper-endoscopy. 
Larger studies should confirm these results in order to design a validated 
questionnaire.
references: Bisschops, R., Areia, M., Coron, E., Dobru, D., Kaskas, B., 
Kuvaev, R., Pech, O., Ragunath, K., Weusten, B., Familiari, P., Domagk, 
D., Valori, R., Kaminski, M., Spada, C., Bretthauer, M., Bennett, C., Se-
nore, C., Dinis-Ribeiro, M. and Rutter, M. (2016). Performance measures 
for upper gastrointestinal endoscopy: a European Society of Gastrointes-
tinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy, 48(09), 
pp.843-864. Brown, S., Bevan, R., Rubin, G., Nixon, C., Dunn, S., Panter, 
S., & Rees, C. (2015). Patient-derived measures of GI endoscopy: a meta-
narrative review of the literature. Gastrointestinal Endoscopy, 81(5), 1130-
1140.e9.
disclosure: Nothing to disclose 
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P2023 dIfferenTIaL heLIcOBacTer PyLOrI PLasTIcITy In The 
gasTrIc nIche Of suBjecTs aT Increased gasTrIc cancer rIsk
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di Aviano (CRO) IRCCS, Cancer Epidemiology Unit, Aviano, Italy, 3Centro di 
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Introduction: Histopathological changes in gastric mucosa during Helico-
bacter pylori (HP) infection can be associated with HP fitness adaptation 
through genetic events leading to reduced virulence as precancerous le-
sions develop.
aims & Methods: In this study we dissected the heterogeneity of the HP 
genotypes in patients (pts) at higher gastric cancer (GC) risk to understand 
if they exploit an increased genetic stability and consequent virulence. 14 
Autoimmune Gastritis (AG), 25 First Degree Relatives of GC pts (FDR), 39 GC 
and 13 Dyspeptic pts without familiarity (D) were investigated. Gastric bi-
opsies were grown in HP selective medium; HP was identified by standard 
methods. As representation of HP strain heterogeneity, 10-12 colonies-
forming-unit (CFU)/pt were isolated and analyzed by PCR. A total of 915 
CFU were examined. Three CagPAI loci (cagA, cagE, virB11) were studied as 
proxy marker of CagPAI plasticity. VacA s, i and m regions, homB/A alleles 
were also evaluated as markers of additional virulence. A stable CagPAI 
was defined by simultaneous presence of virB11, cagE, cagA genes in ≥9 
isolated CFU/pt. Increased virulence was determined with ≥9CFU with vacA 
s1i1mx aplotype (vs. sxi2m2 or vacA deletion) or ≥9CFU with homB gene. 
Histological grading of gastritis was made by Sidney system. OR and 95% 
confidence intervals (C.I.) were calculated.
results: FDR status was associated with significant higher atrophy (OR=6.3, 
95%C.I.:1.2-31.9) and neutrophil infiltration (activity) (OR=7.2, 95%C.I.:1.2-
44.7) than D, while metaplasia and mononuclear cell infiltration were 
comparable. Moreover, FDR showed a reduced risk to host mixed infec-
tions (OR=2.7, 95%C.I.:0.03-0.81). Additionally, FDR exhibited a higher fre-
quency of subtypes carrying the CagPAI-vacA s1i1mx-homB positive profile 
(OR=2.7, 95%C.I.:1.7-4.4). Conversely, AG patients presented a lower fre-
quency of subtypes carrying a stable CagPAI and vacA s1i1mx.
conclusion: These results underline H. pylori different plasticity in the gas-
tric niche of populations at risk of GC, suggesting a different host-bacte-
rium interaction capacity that might affect the outcome of the infection.
disclosure: Nothing to disclose 
P2024 heLIcOBacTer PyLOrI caga PrOMOTes gasTrIc cancer 
TuMOrIgenesIs vIa The P-erk/auf1/gkn1 PaThWay
Yanlei G.1, Shigang D.2
1Peking University Third Hospital, Gastroenterology, Beijng, China, 2Peking 
University Third Hospital, Beijng, China
contact e-Mail address: guoyanleidr@163.com
Introduction: Helicobacter pylori (HP) was the carcinogen of gastric cancer 
,especially the cagA-positive HP. Gastrokine1(GKN1), an important tumor 
suppressor, is downregulated in HP infected gastric mucosa. However, the 
underlying mechanism that HP cagA promotes carcinogenesis by influenc-
ing the anti-tumor gene GKN1 was not clearly elucidated.
aims & Methods: We investigated whether GKN1 was downregulated dur-
ing HP infection in vivo and in vitro by real-time PCR , western blot and 
immunohistochemistry. The AUF1 gene was knocked down in GES-1 and 
BGC-823 cells , we measured GKN1 expression by real-time PCR and west-
ern blot to find their inner relationship. 
In addition , we conducted RNA-Protein Pull-Down and RNA-immunopre-
cipitation to judge whether AUF1 can bind GKN1. By measuring turnover 
and luciferase activity ,we explored the GKN1mRNA stability while AUF1 
was knockdown. During HP infection ,we measured AUF1, GKN1 and p-ERK 
expression. We also observed the cell proliferation, migration, cell cycle 
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when AUF1 was knockdown. Furthermore, we conducted the cagA knock-
out HP and measured the expression of AUF1, GKN1 and p-ERK.
results: we suggested that GKN1 was downregulated during HP infection. 
In addition, GKN1 expression was negatively correlated with AUF1. RNA-
Protein Pull-Down and RNA-immunoprecipitation experiment proved 
AUF1 can bind with GKN1mRNA. Further investigation revealed that AUF1 
can influence the GKN1mRNA stability to regulate its expression. Moreover, 
We observed AUF1 was induced during HP infection and biological function 
studies demonstrated that AUF1 can promote cell proliferation ,migration 
and accelerated G1/S phase transition. What’s more, HP cagA can activate 
the p-ERK/AUF1/GKN1 pathway and the expression of AUF1 and GKN1 can 
be rescued by p-ERK inhibitor.
conclusion: These data showed that HP cagA may promote gastric cancer 
tumorigenesis via the p-ERK/AUF1/GKN1 pathway. The AUF1/GKN1 axis 
might serve as a prognostic biomarker as well as a novel potential target 
in the treatment of gastric cancer.
disclosure: Nothing to disclose 
P2025 OPTIMuM secOnd-LIne regIMens fOr heLIcOBacTer 
PyLOrI eradIcaTIOn: InTerIM resuLTs Of an On-gOIng 
cOchrane sysTeMaTIc revIeW
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7Universidad Francisco de Vitoria, Facultad de Ciencias de la Salud, Madrid, 
Spain, 8Universidad Antonio de Nebrija, Fundación San Juan de Dios, Centro 
Universitario de CC de la Salud San Rafael, Madrid, Spain, 9Universidad 
Francisco de Vitoria (UFV), Faculty of Medicine, Madrid, Spain, 10Hospital 
Clínico San Carlos, Anesthesiology, Madrid, Spain, 11Hospital Universitario 
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contact e-Mail address: opnyssen@gmail.com
Introduction: H. pylori infection represents a significant healthcare burden, 
and first-line eradication treatment often fails, mainly due to antibiotic 
resistance.
aims & Methods: To evaluate the effects of second-line treatments on H. 
pylori (Hp) eradication through systematic review of randomised controlled 
trials (RCTs).
We searched electronic databases and other sources up to January 2019. 
Selection criteria: RCTs comparing the efficacy of at least two different sec-
ond-line Hp treatments. The previous failed first-line regimen should have 
contained at least two antibiotics. We excluded studies assessing a sec-
ond-line therapy based on bacterial antibiotic susceptibility or resistance 
or the use of any type of adjuvant in any of the treatments. We determined 
the effects on Hp eradication rates based on intention-to-treat analysis. 
We attempted to combine results by meta-analysing risk differences (RD). 
We stratified results by first-line therapy used. Meta-analysis was con-
ducted with at least two studies based on the Mantel-Haenszel method. 
We planned to explore sources of heterogeneity by subgroup analysis. We 
assessed risk of bias of the included studies with the Cochrane risk-of-bias 
tool for RCTs.
results: Up to now, the review has included 41 RCTs. In total, we have 
evaluated 39 comparisons of second-line different antibiotic combinations, 
which are stratified by five different first-line therapy failures. Effects on 
Hp eradication rates: The table below summarises the meta-analyses per-
formed for the 9 second-line therapy comparisons after failure of a first-
line standard triple therapy. Two comparisons improved eradication rates. 
Triple therapy with amoxicillin and metronidazole was more effective than 
triple with amoxicillin and levofloxacin (2 studies, I2=0%; High risk of bias). 
Also, standard bismuth quadruple therapy during 14 days was more effec-
tive as compared to 7 days (3 studies, I2=53%; High risk of bias).
experimental arm control arm rd [95%cI] nº of studies1
PPI + A + M PPI + A 0.01 [-0.23, 0.22] 3
PPI + A + M PPI + A + L 0.21 [0.09, 0.33]* 2
PPI + A + Ma PPI + A + Mb 0.03 [-0.08, 0.14] 3
E + A + Mox E + M + Tc + TDB 0.03 [-0.16, 0.09] 3
O + Bs + A + M O + A + Tc + Bs 0.12 [-0.01, 0.24] 2
PPI + M + Tc + Bs (14 days) PPI + M + Tc + Bs (7 days) 0.16 [0.07, 0.26]* 3
PPI + L + Azit PPI + M + Tc + Bs -0.08 [-0.40, 0.24] 2
PPI + L + T PPI + M + Tc + Bs 0.04 [-0.36, 0.45] 2
PPI + A + L PPI + M + Tc + Bs 0.04 [-0.27, 0.36] 3
1- Number of studies included in each comparison; RD-risk difference; CI-confidence 
interval; PPI-proton pomp inhibitor; A-amoxicillin; Azit- azithromycin; Bs-bismuth salts; 
C-clarithromycin; E-esomeprazole; L-levofloxacin; Mox-moxifloxacin; M-metronidazole; 
Ma-metronidazole 750mg; Mb-metronidazole 500mg; O-omeprazole; T-tinidazole; Tc-
tetracycline; TDB-tripotassium dicitrate bismuthate; * significance level p≤0.05
[Meta-analyses for the 9 second-line therapy comparisons after failure of a 
first-line standard triple therapy]
conclusion: There is an amalgam of anti-H. pylori second-line treatments 
used in the clinical setting. After a first-line standard triple therapy (PPI, 
clarithromycin and amoxicillin) failure, triple therapy with a PPI, amoxicil-
lin and metronidazole showed higher eradication rates than the combina-
tion of a PPI, amoxicillin and levofloxacin. Standard quadruple therapy 
during 14 days, as compared to 7 days, showed better results. However, 
these are preliminary results and need to be read cautiously due to the 
limited number of studies included for each comparison and their high 
risk of bias.
disclosure: Nothing to disclose 
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Sgouras D.4, Mentis A.4, Zampeli E.1, Baxevanis P.1, Michopoulos S.1
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Introduction: Helicobacter pylori (Hp) eradication is challenging, espe-
cially in high clarithromycin (Cla)-resistant areas where the classical triple 
therapy has to be abandoned.
aims & Methods: Evaluation of real-life data for Hp eradication in patients 
who applied Maastricht V treatment guidelines in a high Cla-resistant 
area. Consecutive patients evaluated prospectively for Hp eradication after 
receiving 1st, 2nd or 3rd line treatments according to Maastricht V guidelines 
during a period of 31 months (08/2016-03/2019). Cla-resistance was 30% 
in our population by means of culture and/or PCR. Hp eradication was 
evaluated with 13C urea breath test (UBT) at least 4 weeks after treatment. 
Medications offered for 1st line treatment were: Esomeprazole (Eso) 40mg, 
Amoxicillin (Amo) 1gr, Metronidazole (Metro) 500mg and Cla 500mg all 
bid in different quadruple combinations or a commercial combination of 
Bismuth subcitrate potassium, Metro, Tetracycline hydrochloride (BMT) 3 
pills qid administered with Eso 40mg bid. For 2nd line they received either 
Eso and Amo bid plus Levofloxacin 500mg (Levo) qd (Eso/Amo/Levo) or 
Eso/BMT for 10 days and for 3rd line: only Eso/BMT for 10 days. Results 371 
out of 387 patients received treatment according to Maastricht V guide-
lines, mean age 55.8±14.8 years, 46% males. Overall Hp eradication after 
the 3 lines of treatment was achieved in 306 patients with an intention to 
treat (ITT) and per protocol (PP) analysis success rates of 82.5% (95% C.I. 
78.6-86.4) and 89.7% (86.5-93.0) respectively. For 1st line treatment 252 re-
ceived Eso/Amo/Cla/Metro bid for 10 days (CONCO10), 27 received Eso/Amo 
bid for 7days and then Eso/Cla/Metro bid for another 7 days (SEQ14), 44 
received Eso/Amo bid for 7days and then Eso/Amo/Cla/Metro bid for an-
other 7 days (HYBRID14) and 6 received Eso/BMT for 10 days. For 2nd line 
treatment 34 patients received Eso/Amo/Levo for 10 days and 2 Eso/BMT 
for 10 days while for 3rd line treatment all 6 received Eso/BMT for 10 days.
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results: Overall 1st line eradication rates for 329 patients were 82.7 (95% 
C.I. 78.6 - 86.8) in ITT and 90.1 (95% C.I. 86.7-93.4) in PP analysis. Details 
are depicted in the table. 
  cOncO10 (252) seq14 (27) hyBrId14 (44) esO/BMT(6)
ITT%(95%C.I.) 84.5(80.1-89.0) 88.9 (77.0 -100) 65.9(51.9-79.9) 100
PP%(95% C.I.) 90.0 (86.5-94.0) 88.9 (77.0 -100) 87.9(76.7 - 99) 100
[1st Line Treatment]
For second line 26 eradicated with Eso/Amo/Levo [ITT = 76.5% (95% C.I. 
62.2-90.7) and PP = 83.9% (95% C.I. 70.9-96.8)] and all 2 (100%) with 
Eso/BMT while in the 3rd line 6 out of 6 eradicated Hp (100%) with Eso/
BMT. Univariate analysis revealed that younger age (OR=3.4) and alcohol 
consumption (OR=2.12) were associated with non-compliance regarding 
reevaluation with UBT. 19.6 % of patients reported side effects (16 % dys-
geusia, 12% nausea, 8% soft or frequent bowel movements, 1% rush). No 
patient discontinued treatment due to side effects.
conclusion: 
1) Real life Hp eradication rates are satisfactory in high clarithromycin re-
sistant areas when Maastricht V guidelines are applied 
2) The most frequently used 1st line treatment regimen is ten day concomi-
tant with a high eradication rate 
3) Bismuth subcitrate combination had a success rate of 100% in all 3 lines 
of treatment when administered, although limited by low availability in 
many countries.
disclosure: Nothing to disclose 
P2027 cOncOMITanT TheraPy, sequenTIaL TheraPy Or hIgh 
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Introduction: The resistance of Helicobacter pylori to antibiotics has in-
creased the need for new first line treatment. The aim of this study was 
to assess and compare the efficacy and safety of concomitant treatment 
with sequential therapy and dual therapy with high dose esomeprazole 
and amoxicillin.
aims & Methods: This prospective randomized study was performed dur-
ing July 2016 to September 2018. Consecutive naïve helicobacter pylori 
infected patients were included. Patients included were randomized and 
divided into 3 groups using a high dose PPI based on esomeprazole 40mg 
twice daily:
*BT group: dual therapy= PPI + amoxicillin 1g 3*/d for 14 days
*SQ group: sequential therapy= PPI + amoxicillin 1g twice daily for 5 days 
followed by PPI + clarithromycin 500mg and metronidazole 500mg twice 
daily for 5 days.
*CT group: concomitant therapy= PPI + amoxicillin 1g + clarithromycin 
500mg + metronidazole 500mg twice daily for 10 days.
At the end of the treatment, compliance to therapy and reported side 
effect were evaluated. At least 6 weeks after the end of the treatment a 
C13 urea breath test (UBT) was performed to assess H. pylori eradication 
rate.
results: A total of 393 patients agreed to participate in the study. The Mean 
age of patients was 43.9 +/- 15 years (16-90 years). Sex ratio was= 1. Groups 
BT, SQ and CT included respectively 130, 132 and 131 patients. They were 
comparable in terms of age, sex, clinical and endoscopic presentation. The 
eradication rate in intention to treat (ITT) was 63.1%, 86. 4% and 90.8% 
respectively in the BT, SQ and CT groups (P = 0.0001). 
The corresponding rate of eradication by protocol was 67. 7%, 88.5% and 
95.3% (P = 0.00016). No significant results were seen in the eradication 
rate between CT and SQ both in PP analysis and in ITT analysis (P= 0.09). 
The prevalence of the side effects following the concomitant treatment was 
38. 2% significantly higher (P = 0.001) than BT group (13. 80%) and SQ 
group (22%). Therapeutic compliance was 94%, 98.5% and 95. 4% re-
spectively in patients receiving the BT, SQ and CT protocol (P= 0.16).
conclusion: This study demonstrated that concomitant therapy led to a 
non-statistically significant over sequential therapy, with higher side ef-
fects.
disclosure: Nothing to disclose 
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Introduction: Antimicrobial resistance may reduce response to Helico-
bacter pylori (HP) eradication therapy. Recently, a prospective multicenter 
clinical study revealed high rates of clarithromycin (21%) and/or chinolone 
(13%) resistant Helicobacter pylori (HP) species in a large treatment-naïve 
Austrian patient population.
aims & Methods: The aim of this subsequent study was to assess the clini-
cal impact of this antimicrobial resistance on the actual HP-eradication 
treatment success of study subjects. Follow-up data of patients participat-
ing in the afore mentioned prospective clinical trial were analyzed regard-
ing HP-eradication treatment regimen, treatment success rates and subse-
quent HP-eradication therapies. Of note, results of antimicrobial resistance 
testing (as assessed by real-time PCR in the previous study) were not yet 
available when subjects underwent individual HP-eradication therapy.
results: Four study centers provided their follow-up data on a total of 116 
HP-positive patients. 108/116 pts. (93%) received HP-eradication treatment: 
sequential therapy, 58/108 (54%); clarithromycin triple therapy, 26/108 
(24%); levofloxacin sequential therapy, 20/108 (19%). Treatment response 
was tested in 54/108 pts. (50%) by histology, stool antigen or urea breath 
test. Among these 54 patients, 20 subjects (37%) had been identified to 
have clarithromycin (15/54, 28%) and/or quinolone (6/54, 11%) resistant 
HP species. Nevertheless, eradication was successful in 50/54 pts. (93%) 
including 10 patients with proven antimicrobial resistance against anti-
biotic compounds used for eradication. Those 4/54 pts. (7%) who failed 
initial HP-eradication (most likely due to proven clarithromycin resistance) 
underwent another treatment course of the same eradication regimen and 
cleared HP upon final investigation.
conclusion: This follow-up study revealed high success rates of standard 
HP-eradication therapy despite proven antimicrobial resistance against 
antibiotic compounds used for eradication. Although reporting a small 
number of subjects, these results warrant further investigation regarding 
selection of compounds and treatment duration for HP-eradication therapy 
in the future.
references: Bilgilier C, Stadlmann A, Makristathis A, Thannesberger J, 
Kastner MT, Knoflach P, et al. Prospective multicentre clinical study on 
inter- and intrapatient genetic variability for antimicrobial resistance of 
Helicobacter pylori. Clin Microbiol Infect. 2018 Mar;24(3):267-272.
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P2029 fOurTeen day sequenTIaL TheraPy cOnTaInIng 
raBePrazOLe versus 10 and 14 day cOncOMITanT TheraPy In 
The fIrsT LIne TreaTMenT Of heLIcOBacTer PyLOrI InfecTIOn: 
an OPen LaBeL, sIngLe cenTer, randOMIzed cLInIcaL TrIaL
Boutallaka H., Seddik H., Berrag S., Mrabti S., Sair A., Elkoti I., 
Berraida R., Loubaris K., Sentissi S., Benkirane A.
Military Instruction Hospital Mohammed V, Gastroenterology II, Rabat, 
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contact e-Mail address: hanaeboutallaka@gmail.com
Introduction: Helicobacter Pylori infection remains currently a common 
infection worldwide.
The decline in the efficacy of traditional triple therapies has generated 
since 2010 new combinations of antibiotics. The last guidelines of Maas-
tricht V recommend concomitant quadritherapy or bismuth quadritherapy 
to reach an eradication rate of at least 90%. These values remain higher 
than those obtained with standard sequential therapy, but with a higher 
cost and more adverse effects.
aims & Methods: We aimed to compare a modified sequential therapy to 
10 and 14 day quadritherapies currently recommended in terms of efficacy, 
incidence of adverse effects and cost.
We conducted an open-label prospective study at gastroenterology II de-
partment in Military teaching hospital of Rabat from January 2016 to March 
2019 and randomized patients with confirmed Helicobacter pylori infection 
to 3 groups (1:1:1): The first group received quadruple therapy of twice-
daily (bid) Omeprazole 20mg, Amoxicillin 1g, Clarythromycin 500mg and 
Metronidazol 500mg for 10days (QT-10), the second group received a 14 
day quadruple therapy following the same regimen (QT-14), and the third 
received an optimized sequential therapy consisting on a bid Rabeprazole 
20 mg plus amoxicillin 1g for 7 days, followed by bid Rabeprazole 20 mg, 
clarithromycin 500 mg and metronidazole 500mg for the next 7days (OST-
14). Adverse events (AEs) were recorded throughout the study, and the 
H.pylori eradication rate was determined 6 weeks after treatment using 
the 13C urea breath test.
results: There was no significant difference in relation to demographic, 
clinical, endoscopic and histologic findings between the three groups.
In intention to treat analysis (ITT), eradication rate was 87%, 92,3% and 
95,8% respectively in QT-10, QT-14 and OST-14 groups, with no significant 
difference between the groups. In the per protocol analysis, and compared 
to QT-10, QT-14 and OST-14 showed a significant higher eradication rate 
with 91,2%, 95% and 96,8% respectively (p=0,03). The overall incidence 
of AEs was also significantly lower in the OST-14 group, compared to QT-10 
and QT-14 groups (21,2%, 37,2% and 41,6% respectively, p=0,02).
conclusion: Optimizing standard sequential therapy in terms of duration 
and using a second-generation Proton Pomp Inhibitor is a safe and effec-
tive alternative that allows an eradication rate comparable to those cur-
rently recommended by the Maastricht V guidelines, while causing fewer 
adverse effects and allowing a gain in term of cost. Further studies are 
needed to substantiate these findings.
disclosure: Nothing to disclose 
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contact e-Mail address: rahulhshah@hotmail.com
Introduction: Functional dyspepsia (FD) is classically defined as continu-
ous or frequently recurring epigastric pain or discomfort centred in upper 
abdomen for which no organic cause can be determined. The last Consen-
sus of an International panel of clinical investigators on gastroduodenal 
functional disorders (Rome III) recommended Helicobacter Pylori (HP) 
eradication in all infected patients with non ulcer dyspepsia diagnosed 
at upper endoscopy, also suggesting non-invasive testing followed by HP 
eradication (test and treat) in those patients with no alarm features, al-
though many infected patients with FD may not gain symptomatic benefit.
aims & Methods: Effect of eradication of HP on symptoms of functional 
dyspepsia is uncertain, and the data in Asian scenario are scanty. The 
study aimed to see HP positivity rate in patients of functional dyspepsia 
and primarily the effect of its eradication on symptoms.All patients who 
were diagnosed with functional dyspepsia of more than 3 months duration 
were enrolled into this study. Patients of functional dyspepsia were tested 
for HP infection by the urease breath test by Heliprobe analyser, Sweden. 
These patients had no alarm symptoms, red flags to warrant an endoscopy. 
Symptoms were documented on our standard Performa and symptoms on 
a seven-point Likert scale, ranging from extremely improved compared 
with the baseline period to extremely aggravated compared with the base-
line period.HP positive patients were treated with standard triple therapy 
for 15 days with amoxicillin, ornidazole and clarithromycin.
results: HP positivity rate in functional dyspepsia was 274/994 (27.5%).
Repeat UBT was performed between 12-14 weeks (off PPI for 2 weeks) 19 
patients were lost to follow up in the treatment arm and 86 patients in the 
HP negative arm at 6 months.At 12 weeks, the eradication rate for HP in 
triple therapy was 201/255 (78.8%).The patients who were H pylori nega-
tive were treated with standard dose PPI and prokinetic (domperidone).
On intention-to-treat analysis, the symptom resolution at 24 weeks in the 
HP positive group and negative group was (187/255) [73.3%] and 136/634 
[21.4%] respectively (X=209.380; p value< 0.001). Symptom resolution/ im-
provement was defined as a 3 point reduction in the Likert scale.
conclusion: 187/255 (73.3%) patients who had helicobacter pylori eradica-
tion had resolution of symptoms vs. the population of HP negative pa-
tients 136/634 (21.4%) at 6 months (p value< 0.001). Complete resolution 
of symptoms occured in 38/187 (20.3%) of the HP treated patients.Of the 
various upper GI symptom clusters epigastric pain resolved the most and 
bloating the least on Likert scale.There is a high HP positivity rate in pa-
tients of a presumed diagnosis of functional dyspepsia. The eradication 
of H pylori seems to resolve the symptoms (albeit partially) of functional 
dyspepsia.The number needed to treat/harm is 2.
disclosure: Nothing to disclose 
1009Vol. 7 | October 2019
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
P2031 effIcacy In secOnd-LIne regIMens In sPaIn: 
resuLTs frOM The eurOPean regIsTry On h. PyLOrI 
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Universitario Río Hortega, Valladolid, Spain, 14Hospital Clínico Universitario 
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Introduction: The use of an optimal second-line regimen to eradicate 
Helicobacter pylori (H. pylori) infection refractory to the previous treat-
ment prescribed is crucial in order to save antibiotics for future infec-
tions, specially considering the relevance of antibiotic resistance growth 
worldwide.
aims & Methods: The aim was to evaluate the efficacy of the second-line 
treatments more frequently prescribed in a Spanish cohort arising from 
routine clinical practice. We conducted an observational, prospective, 
multicenter study, carried out in 48 Spanish hospitals as part of the ‘Pan-
European Registry on H. pylori management’. The project was provided by 
AEG-REDCap. Patients were included from February 2013 to January 2018 
by Spanish gastroenterologists. A multivariate analysis was performed 
considering the most efficacious therapies. The sex of the patient, type 
of PPI (first vs. second-generation), type of PPI dose (simple vs. double), 
treatment duration (10 vs. 14 days), compliance and penicillin allergy, were 
considered for evaluation.
results: 1,868 patients received a second-line eradication therapy in our 
cohort: 67% of them were women, 6% had penicillin allergy and their 
median age was 50±14 years. 90% of the patients had previously received 
a therapy containing clarithromycin. The therapies most frequently pre-
scribed were (all of them including a proton pump inhibitor, PPI): triple 
therapy comprising levofloxacin and amoxicillin (T-LA, 43%), quadruple 
therapy adding bismuth to the triple therapy mentioned (Q-BLA, 22%), 
three-in-one single capsule bismuth containing metronidazole, bismuth 
and tetracycline (Q-SINGLE, 15%), triple therapy combining moxifloxacin 
and amoxicillin (T-MXA, 5%), and the non-bismuth quadruple concomi-
tant therapy (Q-NBCT, 5%). 10% of the remaining patients received other 
minority therapies. Efficacy of these therapies was analyzed on a modi-
fied ITT (mITT) and PP basis. Results are shown in Table 1, depending on 
treatment duration. Good compliance was associated with higher efficacy 
in Q-BLA and T-LA therapies (p< 0.05). The longer treatment duration (14 
days) was also associated with higher efficacy in T-LA therapy (p< 0.001).
    mITT efficacy PP efficacy
 
duration 
(days) n included mITT (95% c.I) n included PP (95% c.I)
T-La 10 593 70% (66-74%) 564 73% (69-76%)
  14 193 86% (80-90%) 180 92% (87-95%)
q-BLa 14 408 86% (82-89%) 375 91% (87-93%)
q-sIngLe 10 263 82% (77-87%) 232 92% (88-95%)
T-Mxa 14 69 86% (75-93%) 66 89% (79-96%)
q-nBcT 10 39 77% (61-89%) 37 78% (62-90%)
  14 46 80% (66-91%) 45 82% (68-92%)
[Table 1: Efficacy obtained in mITT and PP basis with the five more common 
treatments used as second-line regimens.]
conclusion: The best efficacy results (closer to 90%) as second-line thera-
pies were obtained using quadruple therapy combining levofloxacin and 
bismuth, and triple therapies with amoxicillin and a quinolone (levofloxa-
cin/moxifloxacin), all of them prescribed for 14 days.
disclosure: Dr. Gisbert has served as a speaker, a consultant and advisory 
member for or has received research funding from Casen Recordati, Mayo-
ly, Allergan, Advia, Diasorin. Dr McNicholl has received retributions from 
Allergan and MSD for training activities, and he is an advisor for Mayoly. 
The rest of co-authors have no conflict of interests to declare. 
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P2032 Pan-eurOPean regIsTry On h. PyLOrI ManageMenT 
(hP-eureg): fIrsT-LIne TreaTMenT use and effIcacy Trends 
In 2013-2018
Perez Nyssen O.1, McNicholl A.G.2, Bordin D.S.3, Tepeš B.4, 
Perez Aisa M.&.5, Dino V.6, Caldas Alvarez M.7, 
Bujanda Fernández de Piérola L.8, Castro Fernandez M.9, Lerang F.10, 
Leja M.11, Rodrigo Sáez L.R.12, Rokkas T.13, Kupcinskas L.14, 
Perez-Lasala J.15, Jonaitis L.16, Shvets O.17, Gasbarrini A.18, Şimşek H.19, 
Axon A.20, Buzás G.M.21, Machado J.C.L.22, Niv Y.23, Boyanova L.24, 
Goldis E.-A.25, Lamy V.26, Katicic M.27, Przytulski K.28, Beglinger C.29, 
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Spain, 16Lithuanian University of Health Sciences Dept. of Gastroenterology, 
Gastroenterology, Kaunas, Lithuania, 17O.Bohomolets National Medical 
University, Internal Medicine No.1, Kyiv, Ukraine, 18Catholic University, 
Gemelli University Hospital, Internal Medicine, Gastroenterology and Liver 
Diseases, Rome, Italy, 19Hacettepe University Faculty of Medicine, Ankara, 
Turkey, 20University of Leeds, Dept. of Medicine, Nidd, North Yorkshire, 
United Kingdom, 21Ferencvaros Health Centre, Budapest, Hungary, 22Institute 
of Molecular Pathology and Immunology of the University of Porto - 
Diagnostics, Institute, Diagnostics, Porto, Portugal, 23Rabin Medical Center, 
Tel Aviv University Gastroenterology, Dept. of Gastroenterology, Petach 
Tikva, Israel, 24Medical University of Sofia, Sofia, Bulgaria, 25County Hospital 
Timisoara Gastroenterology, Dept. of Gastroenterology, Timisoara, Romania, 
26CHU de Charleroi - Hôpital Marie Curie, Dept. Of Gastroenterology and 
Hepatology, Charleroi, Belgium, 27University Hospital Merkur Polyclinic Nola, 
Zagreb, Croatia, 28Gastroenterology Foundation, Endoscopy, Warszawa, 
Poland, 29University Hospital Basel, Division of Gastroenterology, Basel, 
Switzerland, 30Otto-von-Guericke University, Department of Gastroenterology 
Hepatology and Infectious Diseases, Magdeburg, Germany, 31University of 
Copenhagen, Dept. of Gastroenterology, Copenhagen, Denmark, 32Meander 
MC, Gastroenterology And Hepatology, Soest, Netherlands, 33University 
of Belgrade Clinical Center of Serbia Gastroenterology and Hepatolog, 
Gastroenterology and Hepatology, Belgrade, Serbia, 34Herttoniemi Hospital 
Dept. of Internal Medicine, Dept. of Internal Medicine, Helsinki, Finland, 
35Hospital San Pedro de Alcantara, Gastroenterology, Caceres, Spain, 
36Gastrocentr, Perm, Moscow, Russian Federation, 37Ukrainian Academy of 
Medical Sciences, Kyiv, Ukraine, 38Hospital Lozano Blesa, Zaragoza, Spain, 
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Surgical sciences, Bologna, Italy, 40Hospital Universitario de La Princesa and 
Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain, 41Hopital 
Pellegrin, Laboratoire de Bacteriologie, Inserm U1053, Bordeaux Cedex, 
France, 42Trinity College Dublin - Faculty of Health Sciences, Trinity College 
Dublin; Dublin/IE, Faculty of Health Sciences, Dublin, Ireland, 43Hospital 
Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa 
(IP) and Centro, Digestive Services, Madrid, Spain, 44Centro de Investigación 
Biomédica en Red de Enfermedades Hepáticas y Digestivas (Ciberehd), 
Madrid, Spain
contact e-Mail address: opnyssen@gmail.com
Introduction: The impact of consensus, prescription choices and efficacy 
trends on clinical practice over time has not been studied in depth.
aims & Methods: International multicenter prospective non-interventional 
registry starting in 2013 aimed to evaluate the decisions and outcomes of 
H. pylori management by European gastroenterologists. All infected adult 
patients were systematically registered at AEG-REDCap e-CRF. Variables in-
cluded: Patient’s demographics, previous eradication attempts, prescribed 
treatment, adverse events, and outcomes. Intention-to-treat analyses were 
performed. Data monitoring was performed to ensure the quality of the 
data.
results: So far 25,256 patients from 27 European countries have been in-
cluded, 19,754 (77%) were naïve empirical prescriptions. Although, overall, 
the most common prescribed treatments in the 2013-18 period were triple 
therapies, a shift in antibiotic regimens was identified. Triple therapies 
decreased from over 50% of prescription in 2013/14 to less than 25% in 
2017/18 while Pylera® has increased from 0-1% (2014/2015) to 25% (2018). 
Full description of most common treatments is shown in Table 1. Regard-
ing the efficacy of each treatment no trend has been identified (data now 
shown), however there has been a 5% overall improve in first-line efficacy 
(Table 1).
conclusion: European gastroenterological practice is constantly adapting 
to the newest published evidence and recommendations, and although 
this shift is delayed and slow, it improves clinical practice outcomes.
Treatment 2013 2014 2015 2016 2017 2018
Triple c+M 116 271 317 262 41 8
Triple c+a 1,541 2,192 1,478 1,127 1,002 196
Triple a+M 164 181 75 31 19 1
Triple a+L 76 104 117 75 11 1
sequential c+a+T 231 263 236 61 302 69
sequential c+a+M 354 156 54 21 6 1
quadruple M+Tc+B 70 83 12 2 6 1
quadruple c+a+T 6 31 91 34 8 7
quadruple c+a+M 753 910 943 786 663 65
quadruple c+a+B 42 83 195 766 408 148
Pylera 1 1 21 502 788 183
Other 136 189 239 200 174 47
mITT 85.8% 86.3% 86.2% 88.3% 89.7% 90.4%
[Treatment prescription and overall eradication trends 2013-2018  
(Hp-EuReg)]
disclosure: Dr McNicholl has received retributions from Allergan and MSD 
for training activities, and he is an advisor for Mayoly. Dr. Gisbert has 
served as a speaker, a consultant and advisory member for or has received 
research funding from Casen Recordati, Mayoly, Allergan, Advia, Diasorin. 
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Introduction: The best approach for Helicobacter pylori management re-
mains unclear. Audit processes are essential to ensure that clinical practice 
is aligned with best standards of care.
aims & Methods: International multicenter prospective non-interventional 
registry starting in 2013 aimed to evaluate the decisions and outcomes of 
H. pylori management by European gastroenterologists. All infected adult 
patients were systematically registered at AEG-REDCap e-CRF. Variables 
included: Patient’s demographics, previous eradication attempts, pre-
scribed treatment, adverse events, and outcomes. Intention-to-treat and 
per-protocol analyses were performed. Data monitoring was performed to 
ensure the quality of the data.
results: So far, 21,487 first-line prescriptions from 27 European countries 
have been evaluated. Average age was 49 years, 60% women, and 18% 
had peptic ulcer. Pre-treatment resistance rates were: 24% to clarithromy-
cin, 34% metronidazole, and 14% both. Drug prescription and efficacy is 
shown in the table. Triple therapy with amoxicillin and clarithromycin was 
the most commonly prescribed(45%), achieving, overall, < 80% eradica-
tion rate. Over 90% eradication was obtained only with 10-day bismuth 
quadruple therapies or 14-day concomitant treatment. Longer treatment 
duration, higher acid inhibition and compliance were associated with 
higher eradication rates in the multivariate analysis.
conclusion: Triple therapies account for the majority of prescriptions, how-
ever, only quadruple therapies lasting at least ten days are able to achieve 
over 90% eradication rates.
Treatment n % use ITT mITT PP
PPI + c+a 8,374 39% 68.4% 84.2% 84.7%
PPI + c+a+M 4,156 19% 86.1% 90.0% 90.5%
PPI + c+a+B 1,525 7.1% 78.6% 92.8% 93.1%
PPI + M+Tc+B s.c. 1,520 7.1% 82.9% 94.7% 95.3%
PPI + c+a+T seq 1,166 5.5% 76.9% 91.3% 91.9%
PPI + c+M 1,043 4.9% 70.0% 81.1% 81.5%
PPI + c+a+M seq 608 2.8% 74.8% 81.0% 83.2%
PPI + a+M 560 2.6% 65.8% 85.4% 85.5%
PPI + a+L 404 1.9% 76.6% 81.4% 81.8%
PPI + M+Tc+B 188 1.3% 77.6% 93.1% 93.7%
PPI + c+a+T 172 0.9% 83.6% 94.9% 96.1%
ITT - intention to treat, PP - per-protocol, 95%cI - 95% confidence interval, PPI - proton 
pump inhibitor, seq - sequential, c - clarithromycin, M - metronidazole, T - tinidazole, 
a - amoxicillin, L - levofloxacin, B - bismuth , Tc - tetracycline, s.c. - single capsule
[Overall first-line eradication rate per by treatment]
disclosure: Prof. Gisbert has served as a speaker, consultant and advi-
sor to, or has received research funding from, Almirall, Nycomed, Astra-
Zeneca, Casen Recordati, Mayoly, and Allergan. Dr McNicholl has received 
retributions from Allergan and MSD for training activities, and he is an 
advisor for Mayoly. 
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P2035 aPPLIcaTIOn Of screenIng and scOrIng sysTeM 
fOr The anaLysIs Of a neW TyPe Of gasTrIc cancer
Jinyong H.1, Ali R.W.1, Xiaojun H.1, Shanshan M.2, Kai X.2, Manan A.3, 
Akram M.A.3, Ahmad I.4, Yaoping Z.2, Haiyan W.2
1Lanzhou University Second Hospital, Internal Medicine/Gastroenterology, 
Lanzhou, China, 2Lanzhou University Second Hospital, Lanzhou, China, 
3Lanzhou University, School of Life Science, Lanzhou, China, 4Fudan 
University, School of Medicine, Shanghai, China
contact e-Mail address: rjwqrali@yahoo.com
Introduction: Approximately 500,000 deaths from gastric cancer reports 
in china annually. In addition, almost 680,000 new cases - half of which 
globally - attributed to the low rate of early screening and detection. High-
risk groups over the age of 40 get screening for gastric cancer every year. 
Risk factors include having previously gastric illnesses suffering, immedi-
ate family member with gastric cancer, or antibodies for the Helicobacter 
pylori (Hp) bacteria. In China, almost 90 percent of the patients when de-
tected for gastric cancer are already in the progressive stage.
aims & Methods: To explore the screening and scoring system of a new 
type of gastric cancer and its application in gastric cancer screening for 
comprehensive analysis.
The 451 screened patients at gastric cancer risk from April 2018 to October 
2018 were selected. According to the survey, serum pepsinogen (PGI, PGII, 
PGI/PGII) and gastrin 17 (G17) were determined by enzyme-linked immu-
nosorbent assay. Helicobacter pylori positive rate was tested by a 13C urea 
breath test. According to the “China Early Gastric Cancer Screening Process 
Expert (of Shanghai) Consensus, 2017” scoring standard, the patients were 
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divided into three groups, i.e. low-risk groups (n=306), intermediate risk 
group (n=130) and high-risk group (n=15). All patients underwent gas-
troscopy, biopsy and pathological diagnosis for suspicious lesions under 
endoscopy.
results: In the low-risk group, we detected 11 cases of low-grade intra-
epithelial neoplasia (detection rate was 3.6%). In case of the intermedi-
ate-risk group, one was differentiated with adenocarcinoma (progressive 
phase), four were high-grade tumors (detection rate 3.1%) and 23 were 
found low-grade tumors (detection rate 17.7%). While in the high-risk 
group, there were two high-grade tumors (detection rate 13.3%) and nine 
low-grade tumors (detection rate 60%). Among them, the infection rate 
of Helicobacter pylori for the low-risk group, intermediate-risk group and 
high-risk group found was 33%, 51%, and 60%, respectively that showed 
an upward trend.
groups
Total 
cases
hp
hp Infec-
tion rate
  Main Pathology
 
Posi-
tive
Nega-
tive
 
Ad-
vanced 
Cancer
High Level 
Intra-epithelial 
Neoplasia
Low Level 
Intra-epithelial 
Neoplasia
Atrophic 
Gastritis
low-risk 
group
306 204 102 0.333333 / / 11 227
Interme-
diate-risk 
group
130 64 66 0.507692 1 4 23 80
High-risk 
group
15 6 9 0.6 / 2 9 4
[Statistical Results: ]
conclusion: According to our study, the high-risk groups of new gastric 
cancer screening and scoring system can effectively improve the detection 
rate of early gastric cancer. Furthermore, it will be helpful to secure a large 
number of therapeutic assets/resources in gastric cancer screening.
disclosure: Nothing to disclose 
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Introduction: Early detection and adequate surveillance of gastric precan-
cerous lesions (GPL) may prevent the development of gastric cancer (GC) 
and reduce GC-related mortality. However, some patients with GPL are lost 
for follow up. The aims of this prospective study were: 
1) to evaluate the feasibility and efficacy of a “phone-call” strategy to res-
cue the patients lost for follow-up, and 
2) to assess the evolution of GPL in these patients.
aims & Methods: Among all the patients diagnosed with GPL (atrophic 
gastritis, AG, intestinal metaplasia, IM, low grade dysplasia, LGD) in our 
center between January 2000 and December 2015, we identified those who 
according to the European MAPS guidelines [1]should undergo a surveil-
lance endoscopy, who were under the age of 80, and who had no severe 
comorbidities. They were all contacted by phone (three calls) by a medi-
cal doctor, and invited to undergo a surveillance endoscopy. In those who 
accepted, the upper endoscopy was performed during which 5 random 
gastric biopsies (2 from the antrum, 1 from the angulus, and 2 from the 
corpus) were obtained for histological analysis performed by an expert 
pathologist with the evaluation of the presence of GPL and their severity. 
The results were compared to those of the initial endoscopy.
results: Among the 535 patients with a GPL,134 fulfilled the inclusion crite-
ria and were contacted by telephone. Among them, 62 could not be joined, 
16 were followed in another center, 8 agreed to participate but never came, 
8 refused endoscopy, and 3 had endoscopy but without biopsies. Thus fi-
nally, 36 patients (27%) were included in the analysis. There were 22 males 
(61%), the mean age was 57 years at index endoscopy and 63 years at 
inclusion, and the mean duration of follow up was 65 months. At index 
endoscopy, 3 patients had AG, 27 IM, and 6 LGD. Nine patients (25%) were 
H. pylori positive and in all of them the bacterium was successfully eradi-
cated. During the follow up, 7 patients (19%) showed a progression of GPL 
[(1 from AG to IM, 4 from antrum- or corpus-limited IM to pangastric IM, 1 
from IM to LGD, and 1 from extensive IM to GC which could be treated cu-
ratively (pT2pN0)]. Eleven patients (31%) showed regression of GPL (1 from 
AG to normal mucosa, 6 from IM to normal mucosa, 1 from pangastric- to 
corpus limited-IM, 3 from LGD to IM), and 18 patients (50%) showed sta-
bility of the lesions.
conclusion: This study shows that: 
1) despite several phone calls, a follow-up endoscopy could only be per-
formed in a quarter of patients who had indication for control endoscopy 
according to the current guidelines, and 
2) most of the patients showed stability of the GPL, but one patient pro-
gressed to GC and thanks to this strategy, he could be diagnosed on time 
and successfully treated.
references: Dinis-Ribeiro M, Areia M, de Vries A, Marcos-Pinto R, Mon-
teiro-Soares M, O’Connor A, et al. Management of precancerous condi-
tions and lesions in the stomach (MAPS): guideline from the European 
Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study 
Group (EHSG), European Society of Pathology (ESP), and the Sociedade 
Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74-94. 
doi:10.1055/s-0031-1291491
disclosure: Nothing to disclose 
P2037 LOng-TerM OuTcOMe Of WaTch and WaIT sTraTegy 
fOr gasTrIc anTIBIOTIc-resIsTanT MucOsa-assOcIaTed 
LyMPhOId TIssue LyMPhOMa
Matsuno Y.1, Torisu T.1, Fuyuno Y.1, Okamoto Y.1, Fujioka S.1, Hirano A.1, 
Umeno J.1, Moriyama T.1, Kitazono T.1, Esaki M.2
1Kyushu University, Department of Medicine and Clinical Science, Fukuoka, 
Japan, 2Saga University Hospital, Department of Endoscopic Diagnostics and 
Therapeutics, Saga, Japan
contact e-Mail address: ymatsuno@intmed2.med.kyushu-u.ac.jp
Introduction: Although Helicobacter pylori (HP) eradication therapy (anti-
biotic therapy) has been established as the first line therapy for gastric 
mucosa-associated lymphoid tissue (MALT) lymphoma regardless of their 
HP infection status, therapeutic strategy for superficial gastric MALT lym-
phoma in patients not responding to antibiotic therapy (non-responders) 
has been an important issue to be solved. Watch & wait strategy has been 
assumed to be a choice after antibiotic therapy, however, the malignant 
potential of the disease remains uncertain.
aims & Methods: We analyzed the long-term outcome of watch & wait 
strategy for non-responders. During the period between January 1995 
and January 2017, 119 patients received antibiotic therapy as the first-line 
therapy for superficial gastric MALT lymphoma. Among them, we selected 
45 patients who met the inclusion criteria; 
a) the first-line therapy of antibiotic therapy could not lead complete re-
sponse of the disease, 
b) watch & wait strategy was subsequently applied for at least a year in 
case no disease progression, 
c) the disease confined to either mucosal layer or submucosal layer under 
endoscopic ultrasonography. 
Clinical data were collected by reviewing electrical medical records, and 
long-term outcome of superficial gastric MALT lymphoma occurring in HP-
negative patients (HP-negative disease) was analyzed by comparing the 
outcome occurring in HP-positive patients (HP-positive disease). 
Overall survival rate (OSR) and progression free survival rate (PFSR) were 
calculated by the Kaplan-Meier method and the values were compared 
using the log-rank test. We also compared clinicopathological features be-
tween HP-negative and HP-positive diseases.
results: The study subjects comprised 25 HP-negative disease and 20 HP-
positive disease, and the mean follow-up period was 56 months [range; 
9-224 months]. OSR of the study subjects at 5 and 10 years after HP eradica-
tion were 100% and 92%, and PFSR at 5 years was 53%. PFSR was signifi-
cantly higher in HP-negative disease than in HP-positive disease (PFSR at 5 
years; 73% vs 27%, p=0.0026). Age ≤ 60 years (16/25 vs 5/20), the disease 
confined to the mucosal layer (20/25 vs 8/20), and superficially spreading 
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type in morphology (22/25, 11/20) were significantly more frequent in HP-
negative disease than in HP-positive disease. Eleven patients (55%) in HP-
positive disease and 4 patients (16%) in HP-negative disease experienced 
disease progression. Interestingly, the progression pattern was obviously 
different between HP-positive disease and HP-negative disease (enlarge-
ment of gastric leision/extra-gastric leision, 10/1 vs 0/4, p=0.0027)
conclusion: Careful follow-up by EGD seems appropriate to monitor dis-
ease progression of superficial gastric MALT lymphoma in non-responders. 
In HP-negative patients with MALT lymphoma, watch & wait strategy can 
be reasonable after antibiotic therapy, however, careful follow-up using 
systemic imaging modalities should be necessary.
disclosure: Nothing to disclose 
P2038 PrOsPecTIve sTudy shOWIng The cOrreLaTIOn 
BeTWeen The severITy Of hP gasTrITIs and Pre-neOPLasTIc 
LesIOns In a MOrOccan POPuLaTIOn
Jamal S., Seddik H., Loubaris K., Berraida R., El Koti I., Benkirane A.
Military Training Hospital Mohammed V of Rabat, Morocco, Hepatology and 
Gastroenterology, Rabat, Morocco
contact e-Mail address: jamalsara24@gmail.com
Introduction: Helicobacter pylori (Hp) is a pathogenic bacterium that con-
tributes to an inflammatory reaction of the gastric mucosa. The extent and 
severity of gastric mucosal inflammation, as well as the occurrence of pre-
neoplastic lesions (atrophy and intestinal metaplasia), depend on a num-
ber of factors that are related to the bacterium, host, and environmental 
factors.
aims & Methods: The aim of this work is to study the gastric lesions associ-
ated with Hp infection, and to determine the relationship between bacte-
rial density and the appearance of gastric histological lesions.
We performed a single-centric prospective study from March 2014 and 
March 2019. We included 406 patients who benefited from high endoscopy 
and who had Hp infection documented on a histological study of gastric 
biopsies.
results: The average age of patients was 43.9 years (range, 15 to 87 years). 
The sex ratio (H / F) was 1.23. Chronic smoking was found in 17.9% of cas-
es. The frequency of antritis and moderate to severe chronic funditis was 
78.5% and 40.5% respectively. Moderate to severe activity was noted in 
48.5% at the antrum in 21% at the fundus. The incidence of gastric atrophy 
and intestinal metaplasia was 12.7% and 7.2%, respectively. The density of 
HP was higher in the antrum than in the fundus (67.2% vs. 26.8% respec-
tively). In univariate analysis, only antral and fundic gastritis activity was 
significantly associated with bacterial density (OR: 4.3, 95% CI (2.7 - 6.8) p 
< 0.001, OR: 5.9. 95% CI (3.5 - 9.9) p < 0.001 respectively).
conclusion: In our study the density of Helicobacter pylori significantly in-
fluences the activity of gastritis. We found no correlation between bacterial 
density and gastric pre-neoplastic lesions. Other studies with large case 
series including other factors, including the genetic profile of Helicobacter 
pylori, are needed.
disclosure: Nothing to disclose 
P2039 Is IT WOrTh TO screen The PaTIenTs fOr 
PreneOPLasTIc gasTrIc LesIOns and heLIcOBacTer PyLOrI?
Bataga S.M.1, Macarie M.2, Negovan A.2
1Clinical Emergency County Hospital, First Clinic of Gastroenterology, Targu 
Mures, Romania, 2University of Medicine and Pharmacy, Targu-Mures, 
Romania
contact e-Mail address: simonabataga@yahoo.com
Introduction: In spite of declining incidence in the last years, gastric cancer 
(GC) is still the fifth most common cancer in the world, however, GC is the 
third worldwide cause of mortality from malignant diseases. 
The prevention of GC includes the primary prevention: eradication of Heli-
cobacter pylori(HP) and secondary prevention: the detection, surveillance 
and/or treatment of the preneoplastic lesions.
As it is known, the first step in carcinogenesis initiation process is the 
colonization of the gastric mucosa with HP. Identifying and surveillance 
in patients with these gastric preneoplastic lesions leads to early diagno-
sis of gastric cancer with more treatment options and an improvement in 
survival rate.
aims & Methods: The purpose of this study was to determinate the inci-
dence of gastric preneoplastic lesions from several points of view: gender, 
age, histopathology type, and the presence of the HP and to evaluate the 
best time for screening.
Upper digestive endoscopy has been performed in 12541 patients with dys-
peptic syndrome in First Gastroenterology Clinic from Târgu Mureș, from 
2014-2018. Patients with hemorrhage were excluded from the study. In all 
the patients gastric biopsies and histopatological exam were made, OLGA 
classification was used.
results: In 2131 patients (52,9% males and 47,1% females) were found gas-
tric changes. Histopathologically, 32,7% of the patients had atrophic gas-
tritis, 43,1% intestinal metaplasia (23,7% complete metaplasia and 19,4% 
incomplete metaplasia) and 0,7% dysplasia. Active gastritis/pangastrits 
with HP was identified in 59,3% of the patients. In 4,8% of cases there 
were revealed polyps (hyperplastic, adenomatous) and were removed. 
The incidences of preneoplastic lesions reported to the total numbers of 
patients were: 5.55% atrophic gastritis, 7.30% intestinal metaplasia and 
0,11% dysplasia.
The premalignant lesions were present mostly in the patients between 60 
and 70 years. There was no statistically significant difference between males 
and females (P>0.05) regarding the incidence of preneoplastic lesions.
conclusion: HP was identified in more than half of the patients, so HP has 
still a high incidence in Romania. After the age of 60 is worth to screen the 
patients by endoscopy or to perform non-invasive tests like pepsinogen. 
Women are as much exposed as man to premalignant gastric lesions after 
60 years
references: 1. Malfertheiner P, Megraud F, O’Morain CA, et al. Manage-
ment of Helicobacter pylori infection-the Maastricht V/Florence Consen-
sus Report. Gut. 2017;66:6-30. 2. Dinis-Ribeiro M, Areia M, de Vries AC, 
et al. Management of precancerous conditions and lesions in the stomach 
(MAPS): Endoscopy. 2012;44:74-94. 3. Shiotani A, Cen P, Graham DY. Eradi-
cation of gastric cancer is now both possible and practical. Semin Cancer 
Biol. 2013;23:492-501
disclosure: Nothing to disclose 
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P2040 a sPecIaLTy PharMacy cOhOrT sTudy evaLuaTIng The 
effecTIveness Of TedugLuTIde In suBgrOuPs Of shOrT BOWeL 
syndrOMe PaTIenTs receIvIng ParenTeraL suPPOrT defIned 
By BOWeL anaTOMy
Chen K.1, Yang H.2, Zhao J.2, Briggs A.2
1Shire Human Genetic Therapies, Inc., a Member of the Takeda Group of 
Companies, Cambridge, United States, 2Analysis Group, Inc., Boston, United 
States
contact e-Mail address: kristina.chen@takeda.com
Introduction: This specialty pharmacy cohort study assessed the effective-
ness of teduglutide in reducing parenteral support (PS) in patients with 
short bowel syndrome-associated intestinal failure (SBS-IF) across anat-
omy subgroups.
aims & Methods: Adult patients with SBS-IF who received PS and teduglu-
tide (2013Q1-2017Q2) from Option Care, a specialty pharmacy in the United 
States, were classified into anatomy subgroups as defined in Jeppesen et 
al. 2018: 1) stoma group (defined as 0% colon remaining, stoma, and no 
colon-in-continuity), 2) ≥50% colon remaining group (defined as ≥ 50% 
colon remaining, no stoma, and colon-in-continuity), 3) >0-< 50% colon 
remaining group. Response (≥20% reduction in weekly PS volume) and 
weaned off (weekly PS volume of 0) rates during follow-up and time to 
first response/weaned off were summarised.
results: The 23 patients in the study included 10 in the stoma group 
(mean±SD age, 57.2±9.0 years) and 13 in the ≥50% colon remaining group 
(54.2±16.2 years). No patients had colon remaining between 0% and 
50%. Crohn’s disease was the most common reason for bowel resection 
in patients with stoma (70.0%) and patients with ≥50% colon remaining 
(36.4%). Before teduglutide initiation, mean duration of SBS was 11.4±10.6 
and 12.2±12.6 years, duration of PS was 4.4±2.5 and 9.5±10.7 years, and 
PS volume was 12.4±6.3 and 11.5±5.5 L/week in patients with stoma and 
≥50% colon remaining, respectively. After teduglutide initiation, among 
10 patients with stoma (mean follow-up duration 24.2±18.1 months), 7 
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(70.0%) achieved response and 5 (50.0%) weaned off PS; mean time to 
first response and weaning off was 9.8±11.5 and 17.7±14.7 months, respec-
tively. Among 13 patients with ≥50% colon remaining (mean follow-up 
duration, 32.0±14.8 months), 10 (76.9%) achieved response and 6 (46.2%) 
weaned off PS; mean time to first response and weaning off was 2.7±2.6 
and 10.2±14.2 months, respectively.
conclusion: Teduglutide reduced weekly PS volume and patients with SBS-
IF achieved weaning off across anatomy subgroups. The response rate to 
teduglutide is consistent with findings from prior clinical trials but time to 
response and PS-wean off differ, which may reflect differences in SBS-IF 
management between clinical trials and real world use, and care with 
or without the expertise of a Center of Excellence multidisciplinary team. 
Further research is warranted to confirm current findings.
references: Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C. Factors 
associated with response to teduglutide in patients with short-bowel syn-
drome and intestinal failure. Gastroenterology. 2018;154(4):874-885.
disclosure: K Chen is an employee of Shire Human Genetic Therapies, Inc., 
a member of the Takeda group of companies. H Yang, J Zhao, and A Briggs 
are employee of Analysis Group, Inc., which received payment for con-
tracted research from Shire Human Genetic Therapies, Inc., a member of 
the Takeda group of companies. This research was funded by Shire Human 
Genetic Therapies, Inc., a member of the Takeda group of companies. 
P2041 PredIcTIve POTenTIaL Of BIOMarkers Of InTesTInaL 
BarrIer funcTIOn fOr TheraPeuTIc ManageMenT WITh 
TedugLuTIde In PaTIenTs WITh shOrT BOWeL syndrOMe
Büttner J.1, Maasberg S.1,2, Bochow B.1, Naranjo S.1, Werich M.1, 
Pape U.-F.1,2
1Charité-Universitätsmedizin Berlin Campus Mitte, Medizinische Klinik mS 
Gastroenterologie, Berlin, Germany, 2Asklepios Klinik St. Georg, Innere 
Medizin und Gastroenterologie, Hamburg, Germany
contact e-Mail address: ul.pape@asklepios.com
Introduction: Teduglutide, an analog of glucagon-like peptide 2, improves 
intestinal rehabilitation in chronic intestinal failure frequently caused by 
short bowel syndrome (SBS). However, the mechanisms in the intestinal 
barrier related to regulation of intestinal permeability (IP) during adap-
tive response or therapy are not well understood. We analyzed whether 
measurement of IP or gene expression analysis from mucosal biopsies of 
selected candidate genes likely associated with IP are useful biomarkers 
to describe the regulation mechanisms in the intestinal barrier in patients 
with SBS with or without teduglutide therapy.
aims & Methods: IP was assessed using a sugar drink test containing 
lactulose and mannitol and urinary recovery rate was used to determine 
lactulose/mannitol ratio. Gene expression analyses of mucosal biopsies 
was performed using qRT-PCR Quantitec Primer Assays for tight junction 
genes and epithelial markers.
results: SBS patients (n=29) showed increased Lac/Man ratio compared to 
healthy controls (HC, n=34),(p=0.0001). Mannitol recovery was decreased 
in SBS (Mean HC 13.8% vs. SBS 5.4%, p= 0.0001), whereas lactulose re-
covery was similar to HC (mean HC 0.21% vs. SBS 0.36% p= 0.2). qRT-
PCR analyses showed significant differences in gene expression between 
SBS patients (n=30) and HC (n=7) for YBX3 p=0.048, CRB3 p=0.009, CDK4 
p=0.048, CASK p=0.03, and SI p=0.02.
For 12 patients, gene expression data were analyzed before and after up to 
12 month of teduglutide treatment. Significant differences in gene expres-
sion were received for CASK p=0.01 and SI p=0.028. Further, analysis of 
citrullin levels in this cohort showed increased citrullin levels in patients 
with teduglutide therapy (p=0.012).
conclusion: The analysis of IP gave first insights into changes of intestinal 
sugar absorption but has not yet been established in SBS patients. Further 
paired and controlled studies are required to evaluate the specifc influ-
ence of both altered bowel anatomy and/or changes in barrier function. 
Furthermore, altered specific gene expression was shown for both, tight 
junction formation and genes involved in nutrient transport and should be 
further analyzed.
disclosure: Nothing to disclose 
P2042 gOThenBurg InTesTInaL TransPLanT endOscOPy 
scOre: a PrOsPecTIve, sIngLe cenTer evaLuaTIOn
Varkey J.1,2, Herlenius G.3, Pischel A.1, Yamamoto S.1, Oltean M.3
1Sahlgrenska Universitetssjukhuset, Division of Gastroenterology, 
Department of Internal Medicine, Göteborg, Sweden, 2Cambridge University 
Hospitals NHS Foundation Trust, Cambridge Intestinal Failure and 
Transplant, Cambridge, United Kingdom, 3Sahlgrenska University Hospital, 
Transplantation Institute, Göteborg, Sweden
contact e-Mail address: jonas.varkey@nhs.net
Introduction: The results of intestinal transplantation have drastically im-
proved during the last decade. However, the major factor that influences 
the survival is the presence of acute rejection. In the absence of timely 
treatment rejection may rapidly evolve towards mucosal loss, which is as-
sociated with a poor outcome. 
Microscopic examination of the endoscopic biopsies forms the basis of 
acute cellular rejection monitoring today. Nevertheless, the findings dur-
ing endoscopy in acute cellular rejection (ACR) are well-known, but a 
grading system for its severity is lacking. Gothenburg Intestinal Transplant 
Endoscopy Score (GITES) is a novel, five-stage endoscopic score construct-
ed by us aiming to describe and categorize the endoscopic findings after 
intestinal transplantation1. In theory, this system could result in a more 
objective evaluation of the visual findings and subsequently a faster diag-
nosis of rejection
aims & Methods: We prospectively graded the endoscopic findings with 
GITES in 13 adult patients (3 isolated intestinal grafts,10 multivisceral 
grafts) at one single center using white light high definition endoscopy 
systems. The scoring was performed by the endoscopist at the time of 
endoscopy and later we correlated the results with histology. Our aim with 
this study was to establish the usefulness of GITES in diagnosing acute 
cellular rejection.
results: Eighty-five ileoscopies were performed between January 2015 to 
feb 2019. In 52 (61%) cases the endoscopic findings were normal. Twenty-
three (69%) out of the 33 abnormal endoscopies revealed mild alterations 
represented by mild/moderate edema, erythema or blunted villi (GITES 
1 and 2). Acute rejection was found in biopsies from 11 (14%) endoscopy 
sessions (4 mild & 7 moderate/severe) and in three specimens the biopsies 
revealed CMV enteritis. GITES above 1 (erythema, edematous villi) had 91% 
sensitivity and 94% specificity for ACR whereas positive (PPV) and negative 
predictive values (NPVs) were 78% and 98%, respectively. During moder-
ate and severe ACR, GITES revealed an 87% sensitivity and 94% specificity 
whereas positive (PPV) and negative predictive values (NPVs) were 78% 
and 98% respectively
conclusion: This study suggest that evaluation of the endoscopic findings 
with GITES results in a satisfactory identification and stratification of rejec-
tion. A prospective, multicentre evaluation is needed.
references: Varkey J, Stotzer PO, Simren M, Herlenius G, Oltean M. The 
endoscopic surveillance of the transplanted small intestine: a single cen-
ter experience and a proposal for a grading score. Scand J Gastroenterol. 
2018;53(2):134-139.
disclosure: Nothing to disclose 
P2043 PrevenTIve effecT Of LacTOBacILLus saLIvarIus WB21 
On sMaLL BOWeL InjurIes In suBjecTs WhO Take BOTh nsaId 
and PPI: a randOMIzed, dOuBLe-BLInd, PLaceBO-cOnTrOLLed 
TrIaL
Okamoto Y.1, Esaki M.2, Morishita T.1, Hara Y.3, Hirano A.1, Umeno J.1, 
Maehata Y.4, Kobayashi H.3, Ishikawa H.5, Torisu T.1, Matsumoto T.6, 
Kitazono T.1
1Kyushu University, Department of Medicine and Clinical Science, Fukuoka, 
Japan, 2Saga University Hospital, Department of Endoscopic Diagnostics 
and Therapeutics, Saga, Japan, 3International University of Health and 
Welfare Fukuoka Sanno Hospital, Division of Gastroenterology, Fukuoka, 
Japan, 4Maehata Clinic, Kagoshima, Japan, 5Kyoto Prefectural University of 
Medicine, Department of Molecular-Targeting Cancer Prevention, Osaka, 
Japan, 6Iwate Medical University, Division of Gastroenterology, Department of 
Internal Medicine, Morioka, Japan
contact e-Mail address: yokamoto@intmed2.med.kyushu-u.ac.jp
Introduction: We previously demonstrated an exacerbating effect of pro-
ton pump inhibitors (PPI) on small bowel injuries by nonsteroidal anti-
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inflammatory drugs (NSAID) in the randomized, double-blind, placebo-
controlled trial [1]. However, when considering the prevention of upper GI 
damage by NSAIDs, simultaneous medication of NSAID and PPI is reason-
able. Thus, preventive measures for small bowel injuries by NSAID and PPI 
need to be determined.
aims & Methods: We aimed to ascertain the influence of Lactobacillus sali-
varius WB21 on small bowel injuries using capsule endoscopy (CE) in sub-
jects who take both NSAID and PPI.
Sixty healthy subjects were randomly assigned into two groups; one given 
celecoxib (200 mg, twice daily), rabeprazole (20 mg, once daily) and pla-
cebo for 2 weeks (placebo group, n=30), and the other given celecoxib, 
rabeprazole and Lactobacillus salivarius WB21 (7.0×108CFU, twice daily) 
for 2 weeks (WB21 group, n=30). The subjects completed questionnaires 
about GI symptoms, and laboratory tests and CE before and after 2 weeks’ 
medication. We then compared the incidence and the numbers of small 
bowel mucosal lesions determined by second CE between WB21 and pla-
cebo groups. We also compared positive rates of GI symptoms and anemia 
between the two groups. In the present study, patients in whom small 
bowel mucosal lesions were identified by initial CE were omitted in the 
data analysis.
results: Fifty-seven patients (27 subjects in the WB21 group and 30 sub-
jects in the placebo group) underwent the full analysis. The incidence rate 
of small bowel ulcers was significantly lower in the WB21 group than the 
placebo group (14.8% vs. 40.0% respectively; P= 0.043). In addition, the 
mean number of ulcers was significantly smaller in the WB21 group than 
the placebo group (0.7 vs. 1.1 respectively; P=0.049). However, the inci-
dence rates and the mean number of small bowel erosion did not differ 
between the two groups. GI symptom score by Gastrointestinal Symptom 
Rating Scale did not differ between the two groups, and no subject devel-
oped anemia after the medication.
conclusion: Lactobacillus salivarius WB21 seems to exert preventive effect 
on small bowel mucosal injuries in subjects taking NSAID and PPI simul-
taneously. 
UMIN clinical trial registry number: UMIN000026358
references: 1. Washio E, et al. Clin Gastroenterol Hepatol 2016; 14: 809-815.
disclosure: Nothing to disclose 
P2044 resuLTs Of a MuLTIcenTrIc reTrOLecTIve sTudy Of 
TedugLuTIde TreaTMenT In BenIgn shOrT BOWeL syndrOMe 
In gerMany
Pevny S.1, Wehkamp J.2, Zopf Y.3, Herrmann H.J.3, Blumenstein I.4, 
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Introduction: Teduglutide (TED) is a medical treatment for functional re-
habilitation of short bowel syndrome (SBS) in patients with chronic intes-
tinal failure (cIF). Its application and effectivity is routinely monitored by 
a structured home care service program within a multicentric approach 
in Germany.
aims & Methods: From these prospectively documented data, a retrolec-
tive data base was generated in order to study treatment characteristics 
and outcome parameters in a clinical routine setting of TED-treated cIF-
patients. An interim analysis for TED treatment characteristics up to one 
year is presented. Statistical analyses were performed with SPSS by using 
Friedman-Test with subsequent Bonferroni-adjusted post-hoc analyses 
and Spearman’s Rank-Order Correlation.
results: So far, 44 patients (f:26 / m:18, median age 53 years) were in-
cluded in this interim analysis. Causes of SBS included vascular (n=13) 
and inflammatory diseases (n=16), ileus (n=6), injury (n=5) and others 
(n=4). Median time on parenteral support (PS) before TED was 31 (range 
3 - 301) months. At TED start, 64% of patients (28/44) received individu-
ally compounded parenteral nutrition (PN), 18% (8/44) received standard-
ized PN; the remaining patients received either no parenteral support al-
though medically indicated (n=3), solely intravenous fluid support (n=3) 
or support details were unknown (n=2). PS was administered by patients 
themselves (n=17), by relatives (n=3), by nurses (n=13) or others/unknown 
(n=3/5). TED treatment resulted in a significant reduction in PN calories 
and volume requirements as well as reduced infusion days per week and 
shortened infusion times (see Table 1). 
 
i.v.-Volume per 
week [L]
i.v.-Energy per 
week [kcal]
PN-Infusion time 
per serving [h]
PN days per 
week
Baseline 12.8 (±7.5) 7,119 (±4,475) 10.6 (±3.8) 5.0 (±2.4)
Week 12 ± 1 11.3 (±7.1) 6,315 (±4,454) 10.3 (±4.0) 4.4 (±2.3)*
Week 24 ± 3 10.4 (±6.8) ** 5,425 (±4,517) ** 9.5 (±4.9) 3.8 (±2.6)***
Week 49 ± 6 9.6 (±7.3) ** 5,254 (±4,719) ** 7.9 (±5.5) ** 3.6 (±2.8)***
[Parenteral support characteristics on teduglutide treatment. n=34; p<0.05, 
** p<0.01, *** p<0.001 vs. baseline; PN = parenteral nutrition; Mean (SD)]
The reduction of infusion time was positively correlated with the reduction 
of PN volume (p< 0.001; r=0.63) and calories (p=0.001; r=0.58) after one 
year of TED treatment. After one year, 29 of 39 patients (74%) were con-
sidered responders to TED treatment (with a minimum of 20% i.v.-volume 
reduction).
conclusion: In this multicentric real-world analysis of PS-dependent SBS/
cIF-patients, TED shows effectivity in improving intestinal absorptive func-
tion as indicated by significantly reduced weekly i.v.-volume and calorie 
requirements. In addition, the findings demonstrate a reduction of effec-
tive infusion days and times, which both importantly affect patients’ well-
being. These data indicate the effectivity of TED treatment in a national 
routine treatment setting in concordance with clinical trial data and guide-
line recommendations.
disclosure: S. Pevny, J. Wehkamp, I. Blumenstein, M.W. von Websky, I. 
Schiefke S. Maasberg and U.-F. Pape: Consultant for Shire; U.-F. Pape: 
Grant / Research Support from Shire 
P2045 BOne MarrOW MesenchyMaL sTeM ceLL cOndITIOned 
MedIuM WITh InfLaMMaTOry acTIvaTIOn fOr rePaIr Of 
radIaTIOn-Induced Iec-6 ceLL Injury
Chen H.1,2, Luo Y.1, Sha W.1,3
1Guangdong Provincial People’s Hospital and Guangdong Academy of 
Medical Sciences, Gastroenterology, Guangzhou, China, 2Guangdong 
General Hospital, GuangZhou, China, 3Guangdong General Hospital Dept. of 
Gastroenterology, Gastroenterology, Guangzhou, China
contact e-Mail address: 464695938@qq.com
Introduction: Conditioned medium from mesenchymal stem cells (MSC-
CM) may represent a promising alternative to MSCs transplantation. Our 
previous study has demonstrated that MSC-CM with inflammatory activa-
tion improves the structural and functional restoration of the small intes-
tine after radiation-induced intestinal injury, improve the survival status of 
rats with acute radiation injury, but its potential cellular mechanism has 
not been further explored.
aims & Methods: To observe the effect of MSC-CM with inflammatory 
activation on the proliferation and apoptosis of intestinal epithelial cells 
(IEC-6) after radiation injury and to investigate the cellular mechanism 
of pre-activated MSC-CM in repairing the small intestinal mucosa. : IEC-6 
cells were divided into four groups: control group, radiation injury group, 
normal MSC-CM (MSC-CMIEC-6(NOR)) group and inflammatory pre-ac-
tivated MSC-CM (MSC-CMIEC-6(IR)) group. IEC-6 cells in the latter three 
groups were exposed to 10 Gy X-ray irradiation and cultured in DMEM-
F12 medium, MSC-CMIEC-6(IR) and MSC-CMIEC-6(NOR) respectively. Cells 
in the control group were only cultured in DMEM-12 medium. Cultured 
cells were collected at 3 days after radiation to observe the proliferation of 
IEC-6 cells by using proliferating cell nuclear antigen immunofluorescence 
staining, and to observe the apoptosis by using TUNEL apoptosis staining 
and western blot assay.
results: Compared with the radiation injury group, in the MSC-CMIEC-6(IR) 
group, the number of cells positive for proliferating cell nuclear antigen 
increased significantly (P<0.05), the number of TUNEL positive cells de-
creased significantly (P<0.05), and the expression of Caspases-3 decreased 
significantly (P<0.05), However, there was no significant difference be-
tween the MSC-CMIEC-6(NOR) group and radiation injury group (P>0.05).
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conclusion: Taken together, MSC-CMIEC-6(IR), but not non-activated 
MSC-CM, significantly promotes the proliferation and reduces apoptosis 
of intestinal epithelial cells after radiation injury and therefore repair the 
injured intestinal tissue.
disclosure: Nothing to disclose 
P2046 gInsenOsIde rg1 enhances The ParacrIne effecTs 
Of BM-Mscs On radIaTIOn Induced InTesTInaL Injury
Luo Y.1, Chen H.1,2, Sha W.1,3
1Guangdong Provincial People’s Hospital, Gastroenterology, Guangzhou, 
China, 2Guangdong general hospital, Guangdong general hospital, 
GuangZhou, China, 3Guangdong General Hospital Dept. of Gastroenterology, 
Gastroenterology, Guangzhou, China
contact e-Mail address: 464695938@qq.com
Introduction: Radiation induced intestinal injury(RIII) is commonly seen 
in patients with intra-abdominal and/or pelvic malignancy.However, there 
are still no effective stategies in treating this life-threatening disease.stem 
cell therapy using pleiotropic mesenchymal stromal cell(MSCs) seems to 
be one of the most promising therapies for treating the adverse effects 
related to the radiotherapy,However, the amounts of active molecules se-
creted by MSCs under normal condition are too low to reach the effective 
therapeutic concentrations, and thus couldn’t exert its beneficial effect on 
tissue reparation.Ginsenoside Rg1 is available to promote proliferation 
and differentiation of stem cells and plays an important role in tissue re-
pair. Therefore, it’s becoming an ideal stimulatory factor for stem cells to 
enhance the therapeutic effect of MSCs[18, 19]. There were few studies re-
porting that RG1 could increase the concentrations of VEGF, G-CSF around 
the damaging tissue, raising the idea of its potential on regulating para-
crine[18, 20, 21].Therefore, we used RG1 to stimulate MSC and explored 
whether the paracrine effect was improved and if there’s any therapeutic 
benefits on RIII.
aims & Methods: We used RG1 to stimulate MSC and explored whether the 
paracrine effect was improved and if there’s any therapeutic benefits on 
RIII. For all the vivo experiments, 2 ml DMEM-F12 or concentrated condi-
tioned medium with different concentrations of RG1, RG1 with or without 
neutralizing antibodies were injected intraperitoneally,
results: Systemic infusion of Rg1-MSC-CM, but not MSC-CM, significantly 
improved intestinal damage and survival of RIII rats,we found that the 
level of VEGF and IL-6 were significantly higher in RG1-MSC-CM than MSC-
CM. Further antibody neutralizing investigations confirmed that VEGF and 
IL-6 were two most key factors in RG1-MSC-CM-mediated tissue repair. we 
explored the mechanism and enhancing effects of RG1 on MSC paracrine. 
It has been found that PI3K/Akt signaling pathway is essential in epithelial 
survival and neoangiogenesis[24]. What’s more, the activation of PIK3-AKT 
pathway can enhance the expression of VEGF and IL-6[25]. Some investi-
gators found that RG1 could activate thePI3K-AKT pathway by binding to 
glucocorticoid receptor[20, 27]. As expected, through examing the related 
molecules involved in this pathway, we found that the concentration of 
phosphorylated-AKT, IKK increased significantly with the utilization of RG1.
In addition, nuclear translocation was enhanced by activating NF-kB. On 
the contrary, after using the corresponding inhibitor of NF-kB(BAY11-7082), 
the increased expression of IL-6 and VEGF and even the therapeutic effect 
of RG1-MSC-CM were canceled out. This suggested that the PI3K-AKT/NF-
kB pathway was critical in the RG1-mediated paracrine enhancement of 
MSC. Further investigation on CHIP studies showed that there were several 
binding sites for NF-kB on the gene promoter of VEGF and IL-6, which 
further confirmed the hypothesis that RG1 could activate NF-kB via the 
PI3K-AKT pathway, increase the expression of VEGF and IL-6 secreted by 
MSC and thus paly a role in RIII.
conclusion: The present study showed that RG1 could enhance the para-
crine effect of MSC for VEGF and IL-6, which helped to promote tissue re-
pair in RIII. This indicated that RG1 could be served as a promoter in stem 
cell therapy for treating RIIII.
disclosure: Nothing to disclose 
P2047 In aduLT cOeLIac dIsease hIsTOLOgIcaL recOvery 
and PersIsTenT vILLOus aTrOPhy seeM sIMILar afTer 1 and 
2-3 years Of adequaTe gLuTen-free dIeT
Galli G.1, Conti L.1, Lahner E.1, Cazzato M.1, Esposito G.1, Magi L.1, 
Pilozzi E.2, Annibale B.1
1Sant’Andrea Hospital, Sapienza University of Rome, Department of Medical-
Surgical Sciences and Translational Medicine, Rome, Italy, 2Sant’Andrea 
Hospital, Sapienza University of Rome, Pathology Unit, Department of 
Clinical and Molecular Medicine, Rome, Italy
contact e-Mail address: lau88.conti@gmail.com
Introduction: In adult coeliac disease (CD) the gold standard to assess duo-
denal mucosal recovery after gluten-free diet (GFD) should be histological 
control through duodenal biopsies taken by esophagogastroduodenosco-
py. Timing and effective need of this follow-up is nowadays debated. Only 
a limited percentage of CD patients achieve complete histological recovery 
after 1 year of adequate GFD1. Refractory CD is defined as persistent villous 
atrophy associated to malabsorptive signs or symptoms despite adequate 
GFD for more than 12 months, but data on the timing and occurrence after 
GFD are scarce and conflicting 2,3
aims & Methods: The study’s first aim was to verify if longer histologi-
cal control is able to obtain higher percentage of complete histological 
recovery. Second aim was to determine number of patients with refractory 
coeliac disease at 1 and 2-3 years of follow-up.
Longitudinal cohort study of 168 CD adult patients (F=72%; median age=38, 
range18-71 years) followed from 2009 to 2018, who randomly underwent 
endoscopic/histological control after adequate GFD (Biagi-questionnaire 
score 3-4) at 1 year (Group 1 n=113 patients; mean follow-up 13+1.6 months) 
or 2-3 years (Group 2 n= 55 patients; mean follow-up 27.2+4.8 months). 
Anthropometric, clinical, serological data and duodenal histology (at 
baseline and follow-up) were compared between Group 1 and Group 2. 
Total histological recovery was defined as absence of villous atrophy and 
< 30/100 intraepithelial lymphocytes, partial histological recovery as im-
provement of at least one grade of the Marsh classification while no his-
tological recovery as the total absence of improvement compared to the 
baseline histology at CD diagnosis. Refractory coeliac disease was defined 
as persistence of villous atrophy associated to gastrointestinal symptoms 
and biochemical alterations, when excluded other causes of villous atro-
phy.
results: Total and partial histological recovery were similar in Group 1 and 
Group 2 (Total recovery: 61.9% vs 54.5%, respectively; p=0.40; partial re-
covery 36.3% vs 38.2%, respectively; p=0.86). No histological recovery was 
slightly more frequent in Group 2 although statistical significance was not 
reached (1.8% in Group 1 vs 7.3% in Group 2; p=0.09). Features at baseline 
and at follow-up (gender, median age, GI symptoms, CD specific antibod-
ies and Marsh 3C) were similar between groups. Villous atrophy persisted 
in 27 (23.9%) Group 1 patients and in 14 (25.5%) Group 2 patients (p=0.84). 
In 1 (0.9%) Group 1 patient and 1 (1.8%) Group 2 patient (p=0.59) with 
persisting villous atrophy, presence of severe gastrointestinal symptoms, 
antibodies positivity and/or biochemical alterations were associated, thus 
displaying a clinical picture of refractory CD. Between patients with no 
histological recovery, 2 (100%) patients in Group 1 and 3 patients (75%) in 
Group 2 reported improvement or resolution of their diagnosis symptoms.
conclusion: Total, partial and no histological recovery similarly occurs af-
ter 1 and 2-3 years of adequate GFD. Villous atrophy persists in about one 
forth of patients in both Groups. Features of refractory celiac disease are 
infrequent (1.2% of the total population) and occur in similar proportions 
after 1 or 2-3 years of adequate GFD. Thus, in adult CD patients histological 
recovery and occurrence of refractory CD after adequate GFD seem not to 
be time-dependent, and the first histological follow-up after 2-3 years of 
adequate GFD seems to be safe.
references: 1) Galli G, Esposito G, Lahner E, et al. Histological recovery and 
gluten-free diet adherence: a prospective 1-year follow-up study of adult 
patients with coeliac disease. Aliment Pharmacol Ther. 2014 Sep;40(6):639-
47 2) Rubio-Tapia A, Hill ID, Kelly CP et al. ACG clinical guidelines: di-
agnosis and management of celiac disease. Am J Gastroenterol. 2013 
May;108(5):656-76 3) Alberto Rubio-Tapia and Joseph Murray. Classifica-
tion and management of refractory celiac disease. Gut 2010 Apr;59(4): 
547-557
disclosure: Nothing to disclose 
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P2048 undersTandIng ceLIac dIsease OuTcOMes and 
MOnITOrIng PaTTerns afTer dIagnOsIs: a MuLTInaTIOnaL 
reaL-WOrLd sTudy
Lundin K.E.A.1, Kelly C.P.2, Sanders D.3, Wang S.4, Kayaniyil S.5, Wang S.5, 
Sambrook R.5, Barrett C.2, Yoosuf S.2, Pettersen E.S.1, Leffler D.A.4
1K. G. Jebsen Coeliac Disease Research Centre, University of Oslo and 
Oslo University Hospital, Oslo, Norway, 2Beth Israel Deaconess Medical 
Center, Harvard Medical School, Boston, United States, 3Royal Hallamshire 
Hospital and University of Sheffield, Sheffield, United Kingdom, 4Takeda 
Pharmaceuticals International Co., Cambridge, United States, 5ICON plc., 
Vancouver, Canada
contact e-Mail address: knut.lundin@medisin.uio.no
Introduction: The objective of the study is to describe celiac disease (CeD) 
outcomes and monitoring patterns in patients with CeD in the United King-
dom (UK), USA, and Norway.
aims & Methods: A retrospective medical chart review study was per-
formed at three gastroenterology centres. Data from medical charts of 
patients with biopsy-confirmed CeD, who were diagnosed between 2008 
and 2012 and who had at least one follow-up before December 31, 2017, 
were collected. Patients were classified into four groups at diagnosis and 
follow up: 1: no symptoms & normal duodenal histology; 2: no symptoms 
& abnormal duodenal histology; 3: symptoms & normal duodenal histol-
ogy; and 4: symptoms & abnormal duodenal histology. Any biopsy results 
other than normal or increased intraepithelial lymphocytes were consid-
ered abnormal. Symptoms included in this classification were diarrhoea, 
abdominal pain/distention, poor appetite, weight loss, tiredness/lethargy, 
brain fog, malabsorption and bloating.
results: To date, 200 eligible patients were included (100 in Norway, 100 in 
the USA). Data collection is currently ongoing at the UK site. Patients were 
72.5% female with a median age at diagnosis of 35 years (IQR: 23-48), and 
a median follow-up of 26.5 months (IQR: 12-51.5). Overall, 52% presented 
with diarrhoea, 49% had abdominal pain, 38.5% had nutritional deficien-
cies, 32% experienced bloating and 11.5% presented with anaemia. At di-
agnosis, 17.5% and 82.5% were in class 2 and 4 respectively. All patients 
were advised to commence a gluten free diet (GFD) after diagnosis, and 
4 patients discontinued the GFD during follow-up. Adherence to the GFD 
was not assessed. Ninety-three (46.5%) patients reported symptoms fol-
lowing acute gluten exposure while attempting to follow a GFD. 
After esophagogastroduodenoscopy (55%), bone densitometry was the 
next most frequent (33.5%) procedure performed during follow-up, where 
45% of US patients received this procedure compared to 22% of Norwe-
gian patients. One hundred and eight (54%) patients underwent at least 
one follow-up duodenal biopsy, which comprised 26% and 82% of US and 
Norwegian patients respectively. Of these 108 patients, 4% of US patients 
and 25% of Norwegian patients had ≥ 2 follow-up biopsies after diag-
nosis. However, the US site had a greater number of follow-up visits and 
longer follow-up duration compared to the Norway centre. During follow-
up, 68% had persistent CeD-related gastrointestinal symptoms, 40.5% had 
nutritional deficiencies, and 26.5% had tiredness/lethargy indicated in 
their charts. Of the patients with a follow-up biopsy, the median follow-up 
time from diagnosis to last biopsy result within the study period was 25.5 
months (IQR: 12-45), and 38 patients (36%) had persistent villous atrophy 
at this time regardless of symptoms (Table 1). Patients with persistent at-
rophy were significantly older at diagnosis (43 vs. 35 years old, p<0.01). 
    during follow-up, n (%)
Baseline disease class n† class 1 class 2 class 3 class 4
Class 2 (n=35) 18 9 (50%) 2 (11.1%) 4 (22.2%) 3 (16.7%)
Class 4 (n=165) 88 34 (38.6%) 14 (15.9%) 21 (23.9%) 19 (21.6%)
Class 1: No symptoms & normal duodenal histology; Class 2: No symptoms & abnormal 
duodenal histology; Class 3: Symptoms & normal duodenal histology; Class 4: Symptoms & 
abnormal duodenal histology. *Considered only the last symptoms and biopsy results available 
during the follow-up period. 17 subjects in class 2 and 75 subjects in class 4 at baseline did 
not have any available biopsy results during the follow-up period. †2 subjects with follow-up 
biopsy results as ‚other‘ were excluded from this analysis.
[Changes in celiac disease class from baseline through follow-up (N=108)*]
conclusion: Follow-up biopsy is not universally conducted even at large 
referral centres. Initial findings suggest a large proportion of patients 
continue to have abnormal duodenal histology and/or ongoing symptoms 
after diagnosis despite GFD. Further, the majority of patients continue to 
experience gastrointestinal symptoms after diagnosis.
disclosure: Song W and DL: Takeda employees; KL and DS: Takeda consul-
tancy; CK: Consultancy for Cour Pharma, Glutenostics, Innovate, Immuno-
genx and Takeda; Sisi W, SK and RS: ICON employees receiving research 
funds from Takeda; CB and SY: Beth Israel Deaconess Medical Center em-
ployees; EP: Oslo University Hospital employee 
P2049 Burden Of ILLness and TreaTMenT exPerIences 
In ceLIac dIsease - resuLTs frOM a MuLTI-cOunTry PaTIenT 
survey sTudy
Lebwohl B.1, Sanders D.S.2, Urwin H.3, Geller M.G.4, Wang S.5, Clifford S.6, 
Lewis H.B.7, Cho M.6, Latibeaudiere D.7, Ong V.6, Leffler D.A.5
1Celiac Disease Center, Columbia University Medical Center, New York, United 
States, 2Royal Hallamshire Hospital and University of Sheffield, Sheffield, 
United Kingdom, 3Coeliac UK, Bucks, United Kingdom, 4Celiac Disease 
Foundation, Woodland Hills, United States, 5Takeda Pharmaceuticals 
International Co., Cambridge, United States, 6ICON plc., San Francisco, 
United States, 7ICON plc., London, United Kingdom
contact e-Mail address: song.wang@takeda.com
Introduction: Strict adherence to a gluten-free diet (GFD) is the sole treat-
ment option for patients with celiac disease (CeD). Many patients still ex-
perience symptoms and develop complications of the disease, as well as 
bear additional burden due to maintaining the GFD (1-6).
aims & Methods: The objective of the study is to assess the burden of 
CeD and treatment experiences through a multi-country patient survey. 
A cross-sectional survey was developed, in collaboration with patient 
advocates, clinicians, outcomes researchers and patients with CeD. Sur-
vey questions included socio-demographic and clinical characteristics, 
symptoms, and patient-reported outcome (PRO) measures, e.g., the Celiac 
Symptom Index (CSI), Celiac Dietary Adherence Test (CDAT), and Work Pro-
ductivity and Activity Impairment Questionnaire (WPAI). CeD severity was 
self-reported as mild, moderate, severe, or very severe. Adult participants 
were eligible if they had self-reported biopsy-confirmed CeD (or serology 
with family history of CeD) and on a GFD for ≥6 months. Participants are 
being recruited through patient advocacy groups and patient panels in the 
US, UK, Spain, and Germany.
results: To date, 101 UK and 100 US patients have completed the survey. 
The UK sample’s mean age was 35.5 years, with 73% female and 84% 
White-British. The US sample’s mean age was 37.2 years, with 60% fe-
male and 78% White/Caucasian-American. Most patients were diagnosed 
by biopsy (80% of UK, 80% of US). Seventy three percent of US patients 
and 85.2% of UK patients self-reported their CeD severity as “moderate”, 
“severe” or “very severe”. 
    uk (n=101) us (n=100)
Method of diagnosis: Biopsy via endoscopy 40% 19.8%
 
Blood tests for serology/
antibodies related to CD
20% 19.8%
  Biopsy and blood tests 40% 60.4%
self reported ced 
severity: Mild 14.9% 27%
  Moderate 30.7% 30%
  Severe 30.7% 31%
  Very Severe 23.8% 12%
csI means score (sd) 41.9 (11.4) 41.7 (11.8)
cdaT mean score (sd) 16.0 (4.1) 15.6 (4.7)
WPaI mean score (sd): Impairment at Work 35% (25.1%) 39.9% (27.8%)
  Work Productivity Loss 41.3% (29.4%) 47.4% (30.9%)
  Overall Activity Impairment 36.6% (25.4%) 44% (26.4%)
[US and UK Demographics and PRO scores]
The majority of patients (72.2% of UK, 75% of US) reported having CeD-
related symptoms more than once a month, with 63% of UK patients and 
57% of US patients reporting at least one episode of symptomatic sus-
pected gluten exposure within the last month. 19.8% of UK patients and 
23% of US patients experienced CeD-related symptoms at daily basis, and 
more patients (37.6% of UK, 30% of US) reported having a couple of symp-
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toms at weekly basis. The most frequently reported symptoms experienced 
in the past month for both US and UK patients included abdominal pain, 
tiredness, flatulence, diarrhoea, and bloating, with the most bothersome 
being tiredness, abdominal pain and concentration issues. 
Table 1 illustrates that only 18 (17.8%) UK and 31 US patients (31%) were 
considered to have excellent/very good adherence (CDAT< 13). Mean WPAI 
scores indicated relatively high work productivity and activity impairment 
reported in both US and UK patients’ prior week. The US general popu-
lation estimates for average percent lost productivity at work was 14%, 
(absenteeism=4%, presenteeism=10%) 7. 
conclusion: In this preliminary analysis of an on-going patient survey, the 
large majority of adult patients with CeD in the US and UK have significant 
burden of disease including frequent symptoms, challenges with GFD ad-
herence, and diminished work productivity.
references: 1. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray 
JA. ACG clinical guidelines: diagnosis and management of celiac disease. 
Am J Gastroenterol 2013;108:656-76. 2. Guandalini S, Tundia N, Thak-
kar R, Macaulay D, Essenmacher K, Fuldeore M. Direct costs in patients 
with celiac disease in the USA: a retrospective claims analysis. Dig Dis 
Sci 2016;61:2823-30. 3. Ukkola A, Kurppa K, Collin P, et al. Use of health 
care services and pharmaceutical agents in coeliac disease: a prospective 
nationwide study. BMC Gastroenterol 2012;12:136. 4. Mattila E, Kurppa K, 
Ukkola A, et al. Burden of illness and use of health care services before 
and after celiac disease diagnosis in children. J Pediatr Gastroenterol Nutr 
2013;57:53-6. 5. Missbach B, Schwingshackl L, Billmann A, et al. Gluten-
free food database: the nutritional quality and cost of packaged gluten-free 
foods. PeerJ 2015;3:e1337. 6. Burden M, Mooney PD, Blanshard RJ, White 
WL, Cambray-Deakin DR, Sanders DS. Cost and availability of gluten-free 
food in the UK: in store and online. Postgrad Med J 2015;91:622-6. 7. Tundia 
N, Hass S, Fuldeore M, Wang L.L, Cavanaugh T, Boone J, Heaton P, Valida-
tion and U.S. population norms of health-related productivity question-
naire, Value in Health, Volume 18, Issue 3, May 2015, Page-A24
disclosure: SW and Daniel L: Takeda employees; BL: Consultancy for Take-
da and Innovate Biopharmaceuticals; DS, HU and MG: Takeda consultancy; 
SC, HL, MC, Diandra L and VO: ICON employee receiving research funds 
from Takeda 
P2050 Increased serOreacTIvITy TO MIcrOBIaL Markers 
In fIrsT-degree reLaTIves Of ceLIac dIsease PaTIenTs
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Lindfors K.6, Kurppa K.1
1Tampere University and Tampere University Hospital, Tampere Centre for 
Child Health Research, Tampere, Finland, 2University of Helsinki and Helsinki 
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Introduction: Relatives of celiac disease (CD) patients are at higher risk of 
developing the disease due to genetic predisposition and possible envi-
ronmental factors. We have previously reported increased seropositivity to 
Saccharomyces cerevisiae (anti-Saccharomyces cerevisiae antibodies, ASCA), 
Pseudomonas fluorescence (anti-I2 antibodies) and Bacteroides Caccae (an-
ti-OmpW antibodies) in CD.
aims & Methods: We hypothesized that also relatives of CD patients could 
show hyperreactivity to these three microbial markers. Frequency of sero-
positivity and concentrations of ASCA IgA and IgG, IgA-class anti-I2 and 
anti-OmpW antibodies were compared between 463 first-degree relatives 
of CD patients, 58 untreated and 55 treated CD patients and 80 non-CD 
controls. In addition, CD-associated HLA haplotypes and tissue transglu-
taminase (tTGab) and endomysium (EmA) antibodies were determined.
results: Altogether 49 relatives of CD patients were positive for tTGab and/
or EmA and were analyzed as a separate group. Among the 414 CD autoan-
tibody negative relatives, one or more of the three microbial markers was 
positive in 73%, in 97% of untreated and in 87% of treated CD patients and 
44% of non-CD controls. The relatives also had higher median ASCA IgA 
(8.90 vs 4.50 U/ml, p< 0.001), ASCA IgG (8.37 vs 5.75 U/ml, p< 0.001) and 
anti-I2 antibody (absorbance 0.71 vs 0.32, p<0.001) concentrations than the 
controls. The percentage of seropositivity (86%) and concentrations of mi-
crobial markers were somewhat higher in the autoantibody positive group 
(median ASCA IgA 11.1 U/ml, ASCA IgG 12.8 U/ml, median absorbance for 
anti-I2 antibodies 0.93 and for anti-OmpW antibodies 1.00). In this sub-
group, also anti-OmpW antibody concentrations were higher than in the 
control group. There was a weak positive correlation between tTGab and 
ASCA IgA (r=0.31, p<0.001). Seropositivity of relatives was not significantly 
associated with HLA genotypes (DQ2.5, DQ8, DQ2.2, DQ2+DQ8 or DQ2 and 
DQ8 negative).
conclusion: Relatives of CD patients demonstrated higher frequency of se-
ropositivity and increased concentrations of ASCA, anti-I2 and anti-OmpW 
antibodies compared with non-CD controls. These findings were not asso-
ciated with HLA DQ2 or DQ8, suggesting the role of environmental factors 
and other genetic variants.
disclosure: Nothing to disclose 
P2051 facTOrs assOcIaTed WITh nOn adherenece TO gLuTen 
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Gonczarowski Institute of Gastroenterology and Liver Diseases, Zerifin, Israel
contact e-Mail address: danazelnik@gmail.com
Introduction: The cornerstone of the recommended treatment for celiac 
disease (CD) is a lifelong strict gluten-free diet (GFD). We aimed to identify 
prospectively the demographic, clinical, social and psychological profile 
associated with non adherence to a GFD in adult CD patients in Israel
aims & Methods: An anonymous online questionnaire has been sent via 
the Israeli Celiac association and through social networks. Only CD pa-
tients≥18 years old were included. Socio-demographic, laboratory and 
clinical data as well as anxiety and depression score were reported. Ad-
herence to GFD was assessed by Biagi questionnaire.
results: 301 patients completed the questionnaire, mean age of 37.5 ± 14.9 
years, 79.2% female. The most common presenting symptoms were: ane-
mia (59.7%), abdominal pain (50.8%) and diarrhea (42.8%). According to 
the Biagi score, 82% of patients were found to be high adherent to GFD 
(Biagi 3-4) and 18% were low adherent (Biagi-0-2). Univariate analysis 
revealed that: age of patient, age at diagnosis, duration of disease, edu-
cation, income level, origin, smoking, gastroenterological follow up and 
membership in a supporting group, were all significantly associated with 
adherence to GFD.However in multivariate analysis, only age at diagno-
sis and smoking were significantly associated with adherence to GFD (HR 
1.083, 0.287, respectively).
conclusion: Understanding risk factors for non adherence in celiac disease 
in an important issue. Intervention strategies in young adult celiac patients 
as well as in smokers might improve adherence and reduce future compli-
cations with better quality of life.
disclosure: Has been accepted to present as well in the international celiac 
disease symposiun ICDS 2019 in Paris. 
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P2052 heMOrheOLOgIcaL aLTeraTIOns In ceLIac dIsease 
and InfLaMMaTOry BOWeL dIsease
Szakács Z.1, Csiszár B.2, Kenyeres P.2, Sarlós P.3, Erőss B.1, Hussain A.4, 
Nagy Á.4, Kőszegi B.5, Veczák I.3, Farkas N.6, Nagy M.1, Márta K.1, 
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Introduction: Hemorheological changes predispose to the development of 
arterial thrombotic events; however, limited information is available on 
the status of these changes in celiac disease (CeD) and inflammatory bowel 
disease (IBD).
aims & Methods: In this study, we aimed to describe the hemorheologi-
cal profile of CeD and IBD patients to investigate whether any alterations 
contribute to elevated cardiovascular risk. This is a case-control study in-
volving newly diagnosed and followed CeD and IBD patients with non-CeD, 
non-IBD subjects. In addition to routine laboratory parameters, hemorhe-
ological parameters i.e. erythrocyte deformability and aggregation (with 
LORCA), viscosity of whole blood and plasma (with Brookfield viscometer) 
were measured from venous blood. We calculated mean±standard devia-
tion (for continuous variables) and frequencies (for categorical variables) 
and used two-sample t-test and linear correlation in the statistical analy-
sis. Registration number: ISRCTN49677481.
results: Study participants included 52 CeD, 41 IBD (73% with Crohn’s 
disease) and 54 control patients. There was no difference in age and 
gender distribution between CeD and control patients, nor in hemato-
crit (41.2±3.5% vs. 41.4±3.6%, respectively; p=0.717), viscosity of plazma 
(1.24±0.16 mPa·s vs. 1.27±0.14 mPa·s, respectively; p=0.253), viscosity of 
whole blood (4.07±0.43 mPa·s vs. 4.13±0.46 mPa·s, respectively; p=0.534) 
and erythrocyte aggregation. In contrast, erythrocyte deformability was 
impaired at three different levels of shear. Patients with IBD were younger 
than controls (36±14 years vs. 44±17 years, respectively; p=0.013) with male 
dominance (46.3% vs. 62.9%, respectively; p=0.029), there was no dif-
ference in hematocrit (40.3±3.9% vs. 41.4±3.6%, respectively; p=0.159), 
viscosity of plasma (1.31±0.17 mPa·s vs. 1.27±0.14 mPa·s, respectively; 
p=0.234), viscosity of whole blood (4.14±0.49 mPa·s vs. 4.13±0.46 mPa·s, 
respectively; p=0.896) and erythrocyte aggregation between groups. In 
contrast, aggregation index and γ were higher (p=0.008), while t
1/2
 was 
lower in IBD patients (p=0.024). In Crohn’s disease, viscosity of plasma 
positively correlated with disease activity (rho=+0.579, p=0.001).
conclusion: An impaired erythrocyte deformability in CeD, an increased 
aggregability in IBD, and an activity-dependent increase in viscosity of the 
plasma in Crohn’s disease may predispose to thrombus formation.
disclosure: Nothing to disclose 
P2053 effecT Of BIfIdOBacTerIuM InfanTIs nsL suPer 
sTraIn In hIghLy syMPTOMaTIc ceLIac dIsease PaTIenTs On 
LOng-TerM gLuTen-free dIeT. a PILOT sTudy
Smecuol E.G.1, Temprano M.D.l.P.1, Acosta F.2, Sugai E.2, Moreno M.L.2, 
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Introduction: A strict gluten-free diet (GFD) is currently the only recom-
mended treatment for celiac disease (CeD). Despite apparent compliance 
with the diet, 30-50% of treated patients have gastrointestinal (GI) symp-
toms. A recent DBPC trial showed that oral administration of Bifidobacte-
rium infantisNLS super strain (B. infantis NSL-SS) alleviated symptoms in 
newly diagnosed CeD patients consuming gluten, and that this effect could 
be attributed to the modulation of innate immunity.
aims & Methods: 
aim: We explore the effect of a three-week course of B. infantis NSL-SS 
on persistent symptoms in patients with CeD following a long-term GFD.
Methods: We conducted a prospective, randomized, cross-over, double-
blind, placebo-controlled trial. Adult patients were enrolled if they were on 
a GFD for at least two years and were symptomatic at screening according 
to the GI symptom rate score (GSRS) (>3 points in the mean global score or 
>2 for any individual syndromes). Patients voluntarily consuming gluten, 
with complications, other treatments that might have affected results, or 
limitations for following protocol or collecting stool or urine samples were 
excluded. After a one-week run-in period, patients were randomized to 
receive B. infantis NSL-SS (Natren LIFE START 2 Natren Inc. CA.) (2 capsules 
3 t.i.d.; 2 x 10 CFU/capsule) or placebo for 3 weeks. After a 2-week wash-
out period, patients switched treatment for the next 3 weeks. Outcome 
was assessed based on changes (Δ) in the celiac symptoms index (CSI) for 
each treatment. Stool and urine samples were also collected at the end of 
each period for detection of gluten immunogenic peptide (GIP) excretion.
results: Eighteen patients were enrolled; 2 were excluded due to inten-
tional transgressions and 4 due to inconsistence in symptoms question-
naire reports. In the per protocol analysis (n=12), there were no signifi-
cant changes in the CSI total score and subscales comparing probiotics 
vs. placebo. However, there was a significant improvement of specific CeD 
symptoms in B. infantis treatment compared to placebo (median Δ [range]: 
5.0 points [0 to 9] vs. 2.5 [-7 to 4], respectively; p<0.03; Mann-Whitney) 
when this analysis was restricted to patients with total CSI scores above 
the median. There was a significant placebo effect in general health sub-
scale (p<0.04). Globally, we observed a non-significant carryover effect 
when probiotics was the first treatment. GIP excretion in stools and urine 
was similar in both treatments. No side effects were detected in either 
intervention.
conclusion: This exploratory study suggests that B. infantis NSL-SS may 
improve specific CeD symptoms in a subgroup of GFD treated patients with 
higher symptomatic
disclosure: Nothing to disclose 
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P2054 reaL LIfe PaTTerns Of gLuTen-free dIeT adherence 
In ceLIac PaTIenTs usIng gIP excreTIOn
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Introduction: Patients with celiac disease (CeD) treated with a gluten-free 
diet (GFD) are often exposed to gluten contamination. However, the fre-
quency of such transgressions in a real life scenario is unclear.
aims & Methods: aim: To explore the pattern of fecal and urinary excre-
tion of gluten immunogenic peptide (GIP) during a 4-week period in CeD 
patients on long-term GFD.
Methods: This prospective study enrolled consecutive series of adult CeD 
patients on a GFD for more than two years. At baseline, patients com-
pleted a celiac symptom index (CSI) questionnaire to determine presence 
of symptoms. Patients collected stool and urine samples for 4 weeks. The 
collection protocol was designed to ensure coverage of gluten excretion 
during week-days and week-ends. 
Thus, the last stool on Fridays, and two urine samples during Sunday 
morning and evening, were collected. Urine samples were pooled in one 
single week-end assay. An ELISA test for stool (iVYLISA GIP-S , Biomedal 
S.L. Spain) and point-of-care tests (GlutenDetect; Biomedal S.L., Spain) for 
urine were used for GIP detection.
results: We enrolled 23 patients who were on a GFD for a median time 
of 7 yrs. The median number of transgressions for the overall population 
was 3/4w. (IQR: 1-5). GIP excretion in week-end (urine samples) was pos-
itive in 21/23 patients (91.3%), while GIP in stools collected during week-
days was detected in 11/23 patients (47.8%) (Fisher’s Exact test: p<0.004). 
While 41/92 (44.6%) GIP determinations in urine were positive, GIP was 
detected in 24/92 (26.0%) of stools (Chi square test: p<0.02). Frequency 
of GIP excretion for each of the 4 weeks, progressively increased as the 
study progressed (1 vs. 4 week GIP excretion in either stool and/or urine: 
p<0.05). 
No differences were observed comparing symptomatic (CSI scores >35 
points) vs. asymptomatic patients. A significant correlation was observed 
between frequency of transgressions and baseline serology (rho: vs. IgA 
tTG p<0.04; vs. IgA DGP p<0.0009).
conclusion: The study shows evidence of a high frequency of dietary indis-
cretions in CeD patients on long term treatment with GFD, independently 
of the presence of symptoms. Ingestion of gluten was notably more fre-
quent during week-end than during week-days. We show evidence of a 
relaxation of dietary control along the 4-week study.
disclosure: Nothing to disclose 
P2055 InTrOducIng a dIrecT access gasTrOscOPy PaThWay 
fOr PrIMary care PhysIcIans sIgnIfIcanTLy reduces deLays 
In dIagnOsIs Of cOeLIac dIsease
Manji Z.1, Sim M.1, Donald K.1, Mccann S.1, Jafar W.2
1Stockport NHS Foundation Trust, Stockport, United Kingdom, 2Stockport NHS 
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contact e-Mail address: zafir.manji@stockport.nhs.uk
Introduction: UK guidelines recommend that patients with suspected co-
eliac disease should have endoscopy and biopsy within 6 weeks of referral. 
This helps to avoid adult patients abstaining from gluten products prior to 
establishing a histological diagnosis. Our unit traditionally receives writ-
ten referrals from primary care for a specialist review prior to gastroscopy 
and biopsy. This resulted in diagnostic delays leading to non-compliance 
with the national 6-week target. Therefore, we have introduced a new 
direct access gastroscopy service for primary care physicians to bypass the 
first specialist consultation with the aim of streamlining the process, thus 
improving patient experience and meeting the national target.
aims & Methods: We retrospectively reviewed cases of newly elevated TTGs 
from primary and secondary care between 2014 and 2018 (n=108). Of these, 
52 patients were referred for specialist review for probable coeliac disease. 
43 of these were referred from primary care physicians (the other 9 were 
excluded as they were internal hospital referrals) however 1 of the direct 
access referrals refused endoscopy. We then compared the performance of 
the new direct access gastroscopy service to the traditional referral route, 
using an unpaired t-test to compare time to endoscopy.
results: Patients referred via the traditional pathway (n=21) took a mean 
time of 94.4 days (95% C.I. 46.58 to 142.22) to undergo a gastroscopy 
and biopsy. Conversely, patients referred on the direct access gastroscopy 
pathway (n=21) took a mean of 39.7 days (95% C.I. 16.63 to 62.77), which 
was significantly quicker than the traditional pathway (p=0.04). 17 patients 
(81%) seen on the direct access pathway and 16 patients (76.1%) on the 
indirect access pathway demonstrated a positive histology.
conclusion: The direct access gastroscopy pathway enabled the unit to 
meet national standards and improve the patient experience by instigating 
earlier introduction of gluten free diet.
disclosure: Nothing to disclose 
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Introduction: Celiac disease (CD) is autoimmune, genetic pathology of dy-
gestive system, that characterized by primary or secondary dysbiosis.
aims & Methods: 
aim: To investigate of fecal microbiota composition and to identify candi-
date biomarkers of CD by serum metabolomics analysis. 
Methods: Fresh fecal samples were collected from 43 CD patients on a 
gluten-free diet and 42 healthy controls (HC). The quantitative real-time 
polymerase chain reaction (qRT-PCR) was used for fecal microbiota as-
sessment. Serum metabolomic assays were conducted using the GC-MS.
results: CD patients had lower butyrate-producing Faecalibacterium 
prausnitzii and Bifidobacterium spp. counts than HC. Taxonomic dysbiosis 
in CD was characterized by a higher Bacteroides fragilis/Faecalibacterium 
prausnitzii ratio compared to HC. Serum of CD patients showed significant 
increases in stearic acid, 2-hydroxyisovaleric acid (2-HIVA), succinate, fu-
marate and benzoate compared to HC. The ratio of arachidonic acid (AA) 
to eicosadienoic acid (EDA) (C20:4n-6/C20:2n-6) was increased in CD. Oral 
butyrate plus inulin (as supplement for 28 days) significantly enhanced 
fecal butyrate-producing bacteria (evaluated as BCoAT gene content), re-
duced elevated baseline B. fragilis/F. prausnitzii ratio and lowered serum 
levels of pro-inflammatory succinate and 2-HIVA in CD patients.
conclusion: An increased B. fragilis/F. prausnitzii ratio can serve as avail-
able biomarker for intestinal proinflammatory dysbiosis in CD. Low counts 
of butyrate-producing F. prausnitzii suggest the desirability of co-treatment 
with oral butyrate or butyrate-enhancing agents (probiotics, prebiotics, 
metabiotics) in CD. Treatment that increases colonic bifidobacteria (e.g., 
some Bifidobacterium probiotics or inulin-type prebiotics) can be con-
sidered in CD. Significant changes in serum levels of microbial and en-
dogenous metabolites, reflecting some metabolic pathways disturbances 
(glycolysis, TCA cycle, fatty acid metabolism, ketone body metabolism, 
phenylalanine, tyrosine and tryptophan metabolism, microbial metabo-
lism) are observed in CD. Some metabolites (e.g., a microbial metabolite 
2-HIVA), as well as a new metabolomic index (AA/EDA ratio), reflecting the 
balance between pro-inflammatory and anti-inflammatory components of 
the omega-6 fatty acid pool, may be considered as candidate biomarkers 
of chronic intestinal inflammation and metabolic dysbiosis in CD.
disclosure: No Conflict of Interest 
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P2058 endOscOPIc resecTIOn Of aMPuLLary and duOdenaL 
adenOMas: are We dOIng IT rIghT?
Hossain E.1, Abdelrahim M.2, Varytimiadis L.3, Arndtz S.4, Al Kandari A.5, 
Goggin P.5, Bhandari P.6
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Introduction: Duodenal and ampullary adenomas have the potential for 
malignant transformation to carcinomas by an adenoma-to-carcinoma se-
quence as seen elsewhere in the gastrointestinal tract. Endoscopic resec-
tion of these lesions is increasingly being used in place of invasive surgery. 
However, endoscopic resection in the duodenum can be challenging due 
to its anatomy and may be associated with a higher risk of complications. 
This study aims to evaluate the safety and efficacy of endoscopic resection 
of such lesions.
aims & Methods: All patients with ampullary and large non-ampullary 
(>10mm) duodenal polyps who underwent endoscopic resection in a ter-
tiary referral centre were included in the study. A retrospective analysis on 
data including demographics, size, histology, location, method of resec-
tion and complications was performed.
results: A total of 122 patients underwent endoscopic resection of duode-
nal polyps. Out of these 37 underwent ampullectomy and 85 underwent 
resection for non-ampullary duodenal polyps >10mm.
Ampullary Adenomas
There were a total of 37 patients who underwent ampullectomy ( median 
age 66 years [IQR 50-83]. 27 (73%) had a submucosal injection, whereas 
pancreato-duodenal stent was placed in 26 (73%) of the patients. 7 (20%) 
patients had adjunct tissue ablation (APC). 62% of the lesions were pure 
ampullary, whereas 38% polyps involved the duodenum.
The mean polyp size was 21.6mm [IQR5-80]. 75.7% (28/37) of the polyps 
were removed in a single session with an en-bloc resection rate of 43.2%.
.Non Ampullary Duodenal Adenomas
A total of 85 patients with polyps >10mm referred for endoscopic therapy 
(median age 64 years, [IQR] 27-87 years, 52% male). 58 (70%) underwent 
endoscopic mucosal resection (EMR) and 27 (30%) had knife assisted re-
section (KAR). The histology revealed 63 (77%) low grade dysplasia, 14 
(14%) high grade dysplasia, 2(3%) carcinoids, 1(1%) Brunner gland hy-
perplasia and 5 (5%) hyperplastic polyps. The majority of the lesions were 
found in D2 (70,82%). 8/85 patients (10%) had a diagnosis of familial ad-
enomatous polyposis syndrome. 
The mean polyp size was 25.3 mm [IQR 10-80]. 93.5% (80/85) of the polyps 
were removed in a single session with an en-bloc resection rate of 40%. 
Table 1 shows the complication and recurrence rates stratified by lesion 
size (< 30mm vs >30mm) for both ampullary as well as non ampullary 
lesions.
 
non ampullary duodenal 
adenomas ampullary adenomas
Lesion size < 30 mm > 30 mm < 30 mm > 30mm
Number 53 32 28 9
Delayed Bleeding 2 ( 4%) 5 (16%) 1 (4%) 1 (11%)
Perforation 1 (2%) 1 (3%) 0 (0%) 0 (0%)
Pancreatitis 0 (0%) 0 (0%) 0 (0%) 1 ( 11%)
Recurrence 1 (2%) 5 (16%) 4 (14%) 3 (33%)
[Table 1]
The bleed rate was significantly higher in larger lesions. All complications 
in this series were managed endoscopically. The mean follow up period 
was 38 months for non ampullary duodenal adenomas and 16 months for 
ampullary adenomas. Recurrence rate was higher in the larger lesions in 
both sub groups and a majority of the recurrences ( 70%) were treated 
endoscopically.
conclusion: Endoscopic resection of duodenal lesions is a safe and effec-
tive technique for complete removal of these polyps. Lesion assessment is 
crucial in patient selection for endoscopic removal as noted by the absence 
P2057 cLInIcOPaThOLOgIcaL feaTures Of The MucIn 
PhenOTyPes In sPOradIc nOn-aMPuLLary duOdenaL 
suBMucOsaL InvasIve carcInOMa
Matsueda K.1, Kanzaki H.2, Takenaka R.3, Nakagawa M.4, Matsueda K.5, 
Tanaka T.6, Okada H.7
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Introduction: We previously revealed the clinicopathological difference of 
non-ampullary duodenal neoplasia between the oral and anal side of the 
papilla of Vater. However, the reason of the difference by tumor location 
is not clarified. There are some reports about the differences of mucin 
phenotype of non-ampullary duodenal epithelial neoplasia depending on 
tumor location. However, previous studies have targeted only superficial 
tumors, like adenoma and mucosal carcinoma.
aims & Methods: We tried to reveal the clinicopathological features and 
the significance of mucin phenotype in carcinoma with submucosal inva-
sion. We retrospectively collected all the case of non-ampullary duodenal 
carcinoma (NADC) which invaded into submucosal layer at 4 institutions 
in Japan between January 2003 and December 2018. Moreover, we inves-
tigated consecutive mucosal NADCs in Okayama University Hospital as a 
control group during the same period. The mucin expression of MUC5AC, 
MUC6, MUC2, CDX2, and CD10 and the proliferative activity of Ki-67 were 
evaluated in both submucosal and mucosal carcinomas by immunohisto-
chemistry. Tumors were classified into gastric, gastric and intestinal mixed, 
and intestinal phenotype according to combination of mucin expression. 
We measured the distribution of tumor cells stained for Ki-67 to assess the 
proliferative activities of tumor cells.
results: There were 11 submucosal carcinomas at 4 institution, and 12 mu-
cosal carcinomas in Okayama University Hospital. Among the patients with 
submucosal carcinoma, 8, 1, and 2 received radical resection with lymph-
adenectomy, partial resection without lymphadenectomy, and endoscopic 
resection, respectively. There were no significant differences in sex, age, 
tumor size, macroscopic type, or histological type between the submucosal 
and mucosal groups. 
However, all the submucosal carcinomas were located on the oral side 
of the papilla of Vater (oral-Vater), and the proportion of NADCs on oral-
Vater was significantly higher in submucosal carcinoma than mucosal car-
cinoma (100% vs. 58.3%, P = 0.0016). These lesions were classified gastric 
type (n=8) and mixed type (n=3), and no lesions were intestinal type. The 
proportion of gastric and mixed type was significantly higher in submu-
cosal carcinoma than in mucosal carcinoma (100% vs. 41.7%, P = 0.0024). 
The distribution of Ki-67 expression showed that the diffusely stained pat-
tern was more frequently seen in submucosal carcinoma than mucosal 
carcinoma (66.7% vs. 9.1%, P = 0.0047).
 
submucosal 
(n=11)
Mucoal 
(n=12) P-value
Tumor location (oral-Vater/anal-Vater) (%) 11/0 (100/0) 7/5 (58.3/41.7) 0.016
Mucin phenotype (gastric+mixed/intestinal) 
(%)
11/0 (100/0) 5/7 (41.7/58.3) 0.0024
Ki-67 (superficial type/diffuse type) (%) 1/10 (9.1/90.9) 8/4 (66.7/33.3) 0.0047
[Table. Comparison of clinicopathological features between submucosal and 
mucosal carcinomas]
conclusion: Our date clarified the differences in the clinicopathological 
features such as tumor location, mucin phenotype, and proliferation be-
havior of tumor between submucosal and mucosal carcinoma. That might 
suggest there is different origin and pathway in the carcinogenesis of sub-
mucosal invasive carcinoma from mucosal carcinoma.
references: Matsueda et al. J Gastroenetrol Hepatol. 2019 Epub ahead of 
print.
disclosure: Nothing to disclose 
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P2060 an evaLuaTIOn Of The rIsks and BenefITs Of BIOPsy 
Of The PaPILLa In PaTIenTs WITh faMILIaL adenOMaTOus 
POLyPOsIs (faP)
Mehta N.1, Yoon J.2, Shah R.2, O’Malley M.1, Laguardia L.1, Mankaney G.1, 
Bhatt A.1, Burke C.1
1Cleveland Clinic, Gastroenterology and Hepatology, Cleveland, United States, 
2Cleveland Clinic, Internal Medicine, Cleveland, United States
contact e-Mail address: mehtan5@ccf.org
Introduction: Nearly all patients with FAP will develop duodenal adeno-
mas. Ampullary and duodenal cancer are the leading cause of death in 
patients with FAP after colectomy. The risk of duodenal cancer can be pre-
dicted by the Spigelman stage of duodenal polyposis. International and 
national guidelines recommend upper endoscopic surveillance with for-
ward and side viewing scopes to evaluate the duodenum and visualize the 
papilla for patients with FAP at a frequency according to the Spigelman 
stage. There is no consensus whether the papilla should be routinely biop-
sied or included in the Spigelman staging system of duodenal polyposis. 
Some endoscopists refrain from biopsy of the papilla due to a theoretical 
risk of pancreatitis. No data is available to support the risk of pancreatitis 
related to biopsy of the papilla.
aims & Methods: We aim to identify the rate of pancreatitis after biopsy 
of the papilla in FAP patients and the effect of biopsy on Spigelman stage. 
This is a retrospective cohort study identifying consecutive FAP patients 
at the Cleveland Clinic, between 05/1992 and 01/2018 from the David G. 
Jagelman Inherited Colon Cancer Registries. All FAP patients who have 
undergone at least one endoscopy with biopsy of the duodenal papilla 
were included. Patients with previous history of ampullary carcinoma or 
in whom pathology results were not available were excluded. Medical 
records were used to determine demographics, endoscopic history, risk 
factors for pancreatitis, and Spigelman staging with and without biopsy. 
Post-procedural pancreatitis was defined as two out of three of: 
i) typical symptoms of pancreatitis 
ii) lipase three times the upper limit of normal or 
iii) presence of radiography consistent with pancreatitis within 7 days of 
esophagogastroduodenoscopy (EGD).
results: 77 FAP patients (51.9% male) were identified with a total of 120 
individual upper endoscopies (range: 1-6 biopsies per patient) resulting 
in biopsy of the duodenal papilla. 1.6% (2/120) developed pancreatitis af-
ter ampullary biopsy. Normal papilla was biopsied in 49/120 EGDs. No 
patients with endoscopically normal appearing papilla developed pan-
creatitis. 71 abnormal duodenal papilla were biopsied with 2 episodes of 
pancreatitis post-biopsy. Both episodes of acute pancreatitis occurred in 
the same patient. Biopsy of the normal papilla changed Spigelman stage 
in 3 patients: 
i) stage 1 to 2 
ii) stage 2 to 3 
iii) stage 3 to 4. 
In the patient who was up-staged from Spigelman III to IV due to normal 
papilla biopsy underwent pancreas-sparing duodenectomy.
conclusion: No FAP patients with biopsies of endoscopically normal pa-
pilla developed pancreatitis. Biopsy of normal duodenal papilla in FAP 
does have the potential to change management by increasing Spigelman 
stage. It should be further studied if multiple biopsies of the papilla affect 
this risk-benefit ratio.
disclosure: Nothing to disclose 
of cancers in this cohort. The risk of complications, particularly bleeding 
is significantly higher in lesions greater than 3cm in size. Similarly, recur-
rence rates are also higher in this group. Nevertheless, we demonstrated 
that all complications and most recurrences were successfully managed 
endoscopically.
disclosure: Nothing to disclose 
P2059 a 20-year sIngLe-cenTer exPerIence Of TuMOr 
BLeedIng In duOdenaL gasTrOInTesTInaL sTrOMaL TuMOr
Pih G.Y., Ahn J.Y., Na H.K., Lee J.H., Jung K.W., Kim D.H., Choi K.D., 
Song H.J., Lee G.H., Jung H.-Y.
Asan Medical Center, Gastroenterology, Seoul, Korea (Republic of)
contact e-Mail address: lalila721@gmail.com
Introduction: Upper gastrointestinal bleeding (UGIB) is one of the major 
manifestations of gastrointestinal stromal tumor (GIST)of gastrointestinal 
tract. Several studies have reported that GIST bleeding is associated with 
poor prognosis. However, only few reports have reported the prognosis of 
duodenal GIST and its hemostasis modalities for tumor bleeding.
aims & Methods: To identify clinical outcome of duodenal GIST bleeding, 
we analyzed risk factors and prognosis of hemorrhagic duodenal GIST 
evaluating hemostasis methods. Total 179 patients histopathologically di-
agnosed with primary duodenal GIST between January 1998 and Decem-
ber 2017 were enrolled to this study and medical records were reviewed, 
retrospectively.
results: Of 179 total patients, 49 (27.4%) patients showed UGIB. Endoscop-
ic intervention and transarterial embolization were performed for initial 
hemostasis in 17 and 1 patients, respectively and other 31 were treated 
conservatively. In endoscopic treatment group, re-bleeding was found in 
6 cases (35.3%) and all of the patients finally received surgery. Over a 
median of 48 months of follow-up, 7 patients in the bleeding group and 
20 patients in the non-bleeding group died; the 5-year survival rate was 
83.3% in the bleeding group and 85.7% in the non-bleeding group (P = 
0.431). Multivariate analysis showed that significant risk factors for duode-
nal GIST bleeding was P53 positivity (hazard ratio [HR] = 2.601, P = 0.019) 
and risk factors for overall survival were old age (HR = 1.070, P = 0.004), 
large maximal diameter (HR = 1.197, P = 0.002), and mitotic count > 5/HPF 
(HR 5.029, P = 0.002). A tumor diameter of 5 cm was cut-off value in pre-
dicting overall survival with a sensitivity of 81.0 % and specificity of 65.3%.
  Total (n=179) Bleeding group (n=49)
non-bleeding 
group (n=130) P value
Age (median, IQR) 55 (44-64) 55 (44-63) 55 (44-64) 0.792
Sex (male/female) 91/88 34/15 57/73 0.003
Size of tumor, cm 4.0 (3.0-6.0) 4.0 (3.0-6.0) 4.0 (3.0-6.0) 0.938
Mitotic count 2.0 (1.0-4.3) 3.0 (1.0-5.0) 2.0 (1.0-4.0) 0.112
Antithrombotic drugs 14 (7.8%) 4 (8.2%) 10 (7.7%) 1.000
Recurrence 27/163 (15.1%) 7/47 (14.9%) 20/116 (17.2%) 0.196
Recurrence free survival, months 40 (19-76) 49 (19-88) 39 (19-69) 0.226
Death 27 (15.1%) 7 (14.3%) 20 (15.4%) 1.000
Median survival, months 48 (21-77) 49 (23-99) 43 (20-75) 0.196
[Table. Clinicopathologic characteristics.]
conclusion: Surgical removal of duodenal GIST should be considered when 
tumor bleeding is detected because re-bleeding rate is somewhat high 
after endoscopic hemostasis. And, in duodenal GIST patients with old age, 
large tumor diameter, and mitotic count > 5/HPF, managements should be 
performed carefully due to the poor prognosis.
disclosure: Nothing to disclose 
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P2062 POssIBLe IMPacT Of vagOTOMy On POsTOPeraTIve 
WeIghT LOss afTer seLecTed BarIaTrIc surgery PrOcedures. 
IMPOrTance Of The MOduLaTIOn Of The secreTIOn Of 
gasTrOInTesTInaL hOrMOnes Based On anIMaL exPerIMenTaL 
MOdeLs
Wierdak M.1,2,3, Hubalewska-Mazgaj M.3, Magierowska K.3, Wójcik D.3, 
Brzozowski T.4, Korbut E.3, Budzynski A.2, Magierowski M.3
1Jagiellonian University of Cracow, Department of Gastroenterology, Cracow, 
Poland, 2Jagiellonian University Medical College, 2nd Department of Surgery, 
Cracow, Poland, 3Jagiellonian University Medical College, Department of 
Physiology, Cracow, Poland, 4Jagiellonian University Collegium Medicum, 
Physiology, Crakow, Poland
contact e-Mail address: mateusz.wierdak@uj.edu.pl
Introduction: Obesity is one of the major health problems in the developed 
countries and bariatric surgery procedures are effective in the treatment 
of this disorder. Nevertheless, all present bariatric surgery procedures, 
with the exception of intra-gastric balloon insertion, have significant im-
pact on the innervation of the vagus nerve. Many experimental studies 
have shown, that signals from the vagus nerve play an important role in 
the gastrointestinal hormones regulation and transmission of information 
between enteric nervous system and brain centers responsible for food 
intake regulation.
aims & Methods: Therefore, we aimed to determine the effect of vagal 
innervation on the regulation of food intake and secretion of enterohor-
mones in the pathophysiology of simple obesity as well as the change of 
these parameters after selected bariatric surgery procedures.
Male Wistar rats were fed with a high-caloric diet for 8 weeks to induce 
obesity (DIO). Next, sleeve gastrectomy (LSG), truncal varotomy with py-
loroplasty (VAG) and intra-gastric balloon insertion were performed 
alone (BAL) or in combination with truncal vagotomy (VAG + BAL). Ani-
mals weight was monitored weekly. After 12 weeks, rats were sacrificed 
and gastrointestinal biopsies and serum samples from portal vein were 
collected. Glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide 
(GIP), peptide YY (PYY), ghrelin, glucagon, insulin, leptin and pancreatic 
polypeptide (PP) concentration was measured using Luminex platform or 
ELISA.
results: In rats with VAG, LSG, and BAL+VAG significant weight loss was 
observed during 4 and 12 weeks after surgery. However, in animals with 
BAL temporal reduction of weight observed after 4 weeks was reversed 
after 12 weeks. VAG alone decreased serum content of ghrelin, GIP, PYY 
and PP but did not affect glucagon, leptin or GLP-1 as compared with intact 
DIO. BAL increased GLP-1, GIP, decreased ghrelin but did not affect serum 
concentration of other enterohormones. LSG decreased content of ghrelin, 
PYY and PP. BAL combined with VAG decreased GLP-1, GIP, PYY, PP as 
compared with BAL alone.
conclusion: We assume that the effect of VAG on weight loss was mediat-
ed by the modulation of particular enterohormones release. We conclude 
that VAG increased the effectivness of BAL implementation maintaining 
its weight loss effect 12 weeks after surgery via modulation of PYY and 
PP concentration possibly affecting food intake in these animals. [Fund-
ing source: National Science Centre, Poland (UMO-2016/23/N/NZ4/03252)].
disclosure: Nothing to disclose 
P2063 PreOPeraTIve uPPer endOscOPy PLays an IMPOrTanT 
rOLe In asyMPTOMaTIc PaTIenTs undergOIng BarIaTrIc 
surgery
Laudanno O.1, Ahumarán G.2, Thome M.3,4, Gollo P.2, Gonzalez P.5
1Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos 
Aires, Gastroenterology, Ciudad Autónoma de Buenos Aires, Argentina, 
2Hospital Bocalandro, Gastroenterology, Buenos Aires, Argentina, 3Swiss 
Medical, Gastroenterology, Buenos Aires, Argentina, 4Hospital Eva Perón, 
Gastroenterology, Buenos Aires, Argentina, 5Sanatorio La Trinidad, Buenos 
Aires, Argentina
contact e-Mail address: olaudanno@intramed.net.ar
Introduction: Obesity is a global epidemic and is associated with greater 
morbidity and mortality. Surgically induced weight loss has become the 
best treatment for morbidly obese patients. Obesity has been shown to 
be an important risk factor for several gastrointestinal diseases. Many of 
these conditions can be clinically relevant and have a significant impact on 
nutrition III
09:00-14:00 / Poster Exhibition - Hall 7
P2061 rOux-en-y gasTrIc ByPass and PrevIOus BarIaTrIc 
surgery are rIsk facTOrs fOr syMPTOMaTIc chOLeLIThIasIs 
afTer BarIaTrIc surgery
Abu Sneineh M.1, Harel L.2, Shirin H.2
1Shamir (Assaf Harofeh) Medical Center, Surgery ‘A’, Zerifin, Israel, 2Institute of 
Gastroenterology, Liver, Shamir (Assaf Harofeh) Medical Center, Zerifin, Israel
contact e-Mail address: haimsh@asaf.health.gov.il
Introduction: Bariatric surgery predisposes patients to development of cho-
lelithiasis and therefore the need of a subsequent cholecystectomy; how-
ever, the incidence of cholecystectomy after bariatric surgery is debated.
aims & Methods: Medical records of 601 patients hospitalized for bariatric 
surgery between January 1, 2010 and July 1, 2018 were reviewed. Our aim 
was to evaluate the incidence of cholecystectomy following different types 
of common bariatric procedures. 
All patients who developed cholelithiasis and a subsequent cholecystec-
tomy were included. Cholelithiasis was diagnosed by clinical criteria and 
characteristic ultrasound findings. We used the Israeli community medical 
data system “Ofek” in order to find patients’ missing data. Twenty-one 
patients were excluded because of missing data. 
Categorical variables were summarized with frequencies and percentages. 
Continuous variables were summarized using sample size, Mean, Stan-
dard deviation, Median, Minimum, Maximum and 95% C.I. Correlations 
between categorical variables and Incidence of cholelithiasis after surgery 
were tested for significance using the Chi-Square test. Correlations be-
tween Continuous variables and incidence of cholelithiasis after surgery 
were tested for significance using the independent T-Test.
results: We evaluated retrospectively 580 patients with an average follow-
up of 12 months (range 6-24 months). Mean age was 48±19 years (78% 
females). Twenty-nine patients (5%) underwent laparoscopic cholecystec-
tomy (LC) before the bariatric surgery and 58 patients (10%) performed 
concomitant LC with the bariatric procedure due to symptomatic gallstone 
disease (including stones, sludge and polyps). There were 203 laparoscop-
ic sleeve gastrectomy (SG) (35%), 175 laparoscopic gastric band (LAGB) 
(30%), 55 Roux-en-Y gastric bypass (RYGB) (9.5%) and 147 (25%) mini 
gastric bypass (MGB) procedures during the study period. At the follow-up 
period 36 patients (6.2%) developed symptomatic cholelithiasis while the 
most common clinical presentation was biliary colic. 
Statistically, there was a significant difference between the type of the bar-
iatric operation and the incidence of cholelithiasis after the operation. The 
incidence of symptomatic gallstones formation in patients who underwent 
RYGB was 14.5 %. This was significantly higher comparing to 4.4% fol-
lowing SG, 4.1% following LAGB and 7.5% following MGB (p=0.04). We 
did not find any predictive risk factors including smoking, BMI at surgery, 
change in BMI, comorbidities such as diabetes, hyperlipidemia, hyperten-
sion and COPD for gallstone formation or a subsequent cholecystectomy. 
Interestingly, previous bariatric surgery was a risk factor for gallstone for-
mation and cholecystectomy [15.8% (13/82 patients) in those with previous 
bariatric surgery compared to 4.6% (23/492 patients) among those with-
out previous bariatric operation (P< 0.001)].
conclusion: Our data demonstrate that patients with previous bariatric 
surgery or patients planned for RYGB are at high risk to develop post-
operative symptomatic gallbladder disease. Concomitant cholecystectomy 
during the bariatric procedure should be considered in those asymptom-
atic patients with cholelithiasis.
disclosure: Nothing to disclose 
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results: We obtained a total of 13,352 (V3-V4) and 14,379 (V1-V2) high-
quality sequences per sample representing 370±76 OTUs and 255±55 OTUs, 
respectively, with a Shannon diversity of 4.71±0.37 and 3.99±0.37. Permu-
tational multivariate analysis identified 46 subject-related variables that 
significantly explained nearly one third of the variations in gut microbiota 
profiles. Besides triglyceride concentration in blood and body weight, rural 
versus urban habitats strongly influenced compositional profiles (explain-
ing 0.9% variations). Unsupervised clustering identified three distinct mi-
crobiota profiles characterized by significant differences in richness and in 
the relative abundance of dominant bacterial genera, including Prevotella 
(C1), Bacteroides (C2) and Ruminococcus (C3). Richness was highest in C1 
(423±65 OTUs) associated with a significantly reduced prevalence of obese 
(p=0.004) and T2D individuals (p=0.015). Lowest diversity and richness was 
observed in C3 (333±72 OTUs). Richness and Shannon diversity was signifi-
cantly reduced in obese individuals (BMI > 30). 
Interestingly, microbiota profiles of T2D compared to metabolically healthy 
individuals revealed significantly reduced richness and Shannon diversity 
in populations with a BMI > 30. Paired analysis of 701 prospective samples 
are in the process aiming to validate microbial risk profiles for the develop-
ment of T2D. 
conclusion: The microbial ecosystem in the human gut is characterized 
by a large variation influenced by environmental factors associated with 
geographic regions, lifestyle, and health conditions. BMI is an important 
variable to stratify the microbiota profiles of T2D. The prospective fecal mi-
crobiota analysis in KORA will allow the identification of microbial profiles 
that can be predictive of T2D development.
disclosure: Nothing to disclose 
P2065 InTragasTrIc BaLLOOn - hOW IMPOrTanT Is 
MuLTIdIscIPLInary TeaM TO PrevenT WeIghT regaIn 
afTer IgB use?
Sander B.1, Scarparo J.I.B.2, Sander M.1, Matz F.3, Ramos F.3, 
Santos Paiva D.1, Alberti L.4
1Sander Medical Center, Bariatric Endoscopy, Belo Horizonte, Brazil, 2Clinica 
Scarparo Scopia, São Paulo, Brazil, 3Endodiagnostic, Rio de Janeiro, Brazil, 
4Universidade Federal de Minas Gerais, Surgery, Belo Horizonte, Brazil
contact e-Mail address: brunosander@hotmail.com
Introduction: Intragastric Ballon (IGB) has gained popularity recently, 
however, studies addressing long-term weight loss with IGB are scarce in 
the current literature. Although different studies cite the importance of the 
multidisciplinary team in the control and prevention of weight regimen, 
there are still no studies that quantify the benefits of this follow-up. 
Thus, the objective of this study was to evaluate the long-term weight regi-
men, in a cohort of patients who underwent IGB, among those who did or 
did not follow the treatment with the multidisciplinary team.
aims & Methods: Obese patients treated with intragastric balloon (IGB) 
for a six-month period who underwent balloon removal at least two years 
before the collection of data, were invited to participate in the study. Pa-
tients were stratified based on length of follow-up after IGB removal on 
the date of interview (2, 3, and 4 years), and relevant factors to weight con-
trol as well as behavioral habits were analyzed (A survey was conducted 
to evaluate the frequency and adherence of the behaviors stipulated by 
the psychologist and nutritionist, as well as the rhythm of physical activity, 
in all years of follow-up), and compared by using a logistic multivariate 
analysis.
results: A total of 224 patients were included in the study. The mean 
weight regain was 4.66±4.91 kg, 8.66±6.96 kg, and 9.99±8.44 kg at follow-
up on 2, 3 and 4 years, respectively. Multivariate logistic analysis deter-
mined risk factors for weight regain according to time span after IGB re-
moval. After 2 years of balloon removal, the significant risk factor was lack 
of follow-up with a psychologist during treatment; increasing the chance 
of weight regain 1.13 times compared with those subjects that received 
psychological follow up (ODDS for 2 years: 1.13; p=0.02; IC95%: 0.55-1.89). 
An independent and significant risk factor for weight regain after 3 years 
of IGB removal was the lack of follow-up with a nutritionist after the use 
of IGB. Chance of weight regain was 3.36 times higher in this group than 
in individuals who did the nutritional follow-up (ODDS for 3 years: 3.36; 
p<0.01; IC95%: 1.42-7.94). After 4 years of IGB removal, sedentary behavior 
was an independent and significant risk factor, increasing the chance of 
weight regain 3.86 times compared with physically active behavior (ODDS 
for 4years: 3.86; p=0.03; IC95%: 1.13-12.67).
patients undergoing bariatric surgery. The indication Esophagogastroduo-
denoscopy ( EGD ) prior to bariatric surgery is controversial in particular in 
asymptomatic patients. ASMBS and ASGE recommends preoperative en-
doscopy in patients with symptoms and individualized H. Pylori screening 
however, most studies recommend its implementation in all patients. A 
lack of correlation between patient symptoms and endoscopic findings has 
been documented by many authors. However, considering the relatively 
weak clinical relevance of the majority of lesions discovered on routine 
EGDS and the cost and invasiveness of the procedure, several authors have 
instead advocated a non-endoscopic approach for asymptomatic patient. 
Furthermore, many surgeons consider reflux esophagitis or Barrett’s oe-
sophagus a contraindication to Laparoscopic Sleeve Gastrectomy (LSG)
aim: The purpose of this study was to compare the prevalence of abnor-
mal relevant findings and HP status in preoperative EGD before bariatric 
surgery in asymptomatic and symptomatic patients undergoing bariatric 
surgery. 
Methods: Data was collected from a prospective database of a consecutive 
series of 212 obese patients undergoing bariatric surgery. The patients were 
divided into two groups according to gastrointestinal symptoms. Group 1: 
Upper gastrointestinal symptoms Group 2: asymptomatic. The endoscopic 
findings were classified by clinical relevance in: Not relevant findings (did 
not change the surgical approach) or Relevant findings (change surgical 
approach or postpone surgery). Moreover, Helicobacter Pylori (HP) assess-
ment by histology was performed in all the patients. Gastric biopsies were 
performed in elective patients according to the endoscopic findings
results: In the Group 1 (symptomatic, 72 patients) 20% of the patients had 
a normal endoscopy and 37 % of the patients had relevant findings (mainly 
hiatus hernia, reflux esophagitis) that changed the surgical approach, 10 
% of the patients had another major finding (gastric adenoma, Barrett’s 
oesophagus, celiac disease). 62% were HP positive. 10% had intestinal 
metaplasia. In the Group 2 (asymptomatic, 140 patients) 25 % of the pa-
tients had a normal endoscopy and 32 % of the patients had relevant find-
ings (mainly hiatus hernia, reflux esophagitis). 12 % of the patients had 
another relevant finding (gastric adenoma, ulcers and Barrett’s esopha-
gus, celiac disease). 12% had intestinal metaplasia. 68% were HP positive.
conclusion: Preoperative EGD in asymptomatic and symptomatic patients 
undergoing bariatric surgery revealed significant pathology in many pa-
tients that alter the medical and surgical management. Similar rates of 
relevant findings were found in asymptomatic and symptomatic patients. 
Our results support routine EGD in asymptomatic patients undergoing bar-
iatric surgery
disclosure: Nothing to disclose 
P2064 guT MIcrOBIOTa PrOfILIng In a PrOsPecTIve 
POPuLaTIOn cOhOrT In reLaTIOn TO MeTaBOLIc heaLTh
Reitmeier S.1, Clavel T.2, Neuhaus K.1, Grallert H.3, Peters A.4, Haller D.5
1Technical University Munich, Core Facility Microbiome, Freising, Germany, 
2Institute for Medical Microbiology, RWTH Aachen, Functional Microbiome 
Research Group, Aachen, Germany, 3Helmholtz Zentrum München Research 
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Epidemiology, Munich, Germany, 5Technical University Munich, Chair of 
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Introduction: .Population-based studies have identified regional variations 
in individual compositions of the fecal microbiota, limiting the relevance 
of disease-associated signatures from currently available cross-sectional 
cohorts. KORA is a regionally confined and prospectively followed popula-
tion study with a focus on cardiometabolic health. In an interval of 5-years, 
microbiota profiling was performed on consecutive stool samples using 
high-throughput sequencing
aims & Methods: Bacterial profiling of two sampling time points (t
1
=1,976 
and t
2
=701 samples) was performed by amplicon sequencing of the V3/
V4 and V1/V2 regions of 16S rRNA genes. Data were adjusted to control 
over confounding variables such as metformin intake, physical activity, vi-
tamin D, PPI, age and gender. To assess shifts in the microbiota linked to 
metabolic conditions, individuals were stratified based on body mass in-
dex (BMI), impaired glucose tolerance (HOMA, fasting glucose and OGTT) 
to discriminate between healthy, prediabetic and Type-2 diabetes (T2D) 
conditions.
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conclusion: Weight regain occurs commonly after intragastric balloon re-
moval in up to two-thirds of patients. Lack of psychological and nutritional 
follow up during and after treatment, as well as sedentary behavior are 
important risk factors for weight regain.
references: Moura D, Oliveira J, De Moura EG, et al. Effectiveness of intra-
gastric balloon for obesity: A systematic review and meta-analysis based 
on randomized control trials. Surg Obes Relat Dis 2016;12:420-9. Genco A, 
Cipriano M, Bacci V, et al. Intragastric balloon followed by diet vs intra-
gastric balloon followed by another balloon: a prospective study on 100 
patients. Obes Surg 2010;20:1496-500. Genco A, Maselli R, Frangella F, 
et al. Intragastric balloon for obesity treatment: results of a multicentric 
evaluation for balloons left in place for more than 6 months. Surg Endosc 
2015;29:2339-43. Crea N, Pata G, Della Casa D, et al. Improvement of meta-
bolic syndrome following intragastric balloon: 1 year follow-up analysis. 
Obes Surg 2009;19:1084-8.
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Sander B.1, Sander M.1, Santos Paiva D.1, Scarparo J.I.B.2, Matz F.3, 
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Introduction: The intragastric balloon (IGB) has been used for more than 
20 years in Brazil as an endoscopic method for assisting weight loss, and 
some intercurrences were observed during more than 10,000 procedures 
performed. One of these intercurrences is the presence of fungi in the IGB, 
increasing the friability of the silicone and inducing the premature rupture 
of the IGB, as well as gas hyperinflation.
aims & Methods: To evaluate the effectiveness of the use of antifungal 
(Nystatin), diluted in intragastric balloon filling saline solution, in order 
to prevent the appearance of fungi in silicon, 120 patients (76.7% women) 
who underwent adjustable intragastric balloon Spatz3 throughout the year 
2017.
Patients were divided into two groups by randomized clinical trial: 60 pa-
tients had 50 nystatin mililiters (100,000 IU / ML) mixed with saline solu-
tion with Methylen Blue in the IGB filling and the other 60 patients had 
their IGB filled with saline solution and Methylene Blue. Only the nursing 
team knew which patients had received antifungals in the filling of the 
balloon (double-blind study).
The initial volume of IGB filling in all patients was 700ml.
Initial BMI started at 27 kg/m2 and IGB maximum period implant was 12 
months.
When the IGB was removed, the Endoscopist described whether there was 
fungal colonization on the silicone surface and, when there was, divided 
the colonization on the silicone surface in 4 stages: less than 10% (insig-
nificant), between 10% and 25% (light), between 20 and 50% (moderate) 
and more than 50% (accentuated). When there was insignificant coloniza-
tion (up to 10%) it was described as normal in the database.
results: 19 patients (15.84%) were excluded from the final analysis: 2 
(1.66%) due to early removal, 15 (12.5%) did volume adjustment during 
the IGB and 2 (1,66%) balloon spontaneous deflation or leakage.
Among the 101 patients analyzed, 54 had antifungal in the IGB and 47 only 
saline and methylene blue.
In the group with antifungal the incidence of fungal colonization was 
9.25% (n = 5).
In these 5 IGBs with fungal colonization, 4 (80%) presented light coloniza-
tion (between 10% and 25% of the surface) and 1 (20%) with moderate 
colonization (between 25% and 50% of the surface).
In the group without the use of antifungal the incidence of fungal colo-
nization was 19.15% (n = 9). In these 9 IGBs with fungal colonization, 4 
(44.5%) presented light colonization (between 10% and 25% of the sur-
face), 3 (33.3%) with moderate colonization (between 25% and 50% of the 
surface) and 2 (22.2%) with accentuated colonization (more than 50% of 
the surface). 
There was no significant difference in outcomes between men and women 
and mean age was 30.49 years. 
The mean weight loss was -20.64kg (+/- 16.8kg).
conclusion: The use of mixed nystatin to the saline solution in the IGB fill-
ing reduced the fungal colonization in the silicone coating by half, demon-
strating that this practice has a positive effect with low cost and significant 
difference in fungal prevention.
However, even associated with IGB friability, fungal colonization does not 
prove to be of such importance since balloon spontaneous deflation or 
leakage corresponded to only 1.66% of the total initial sample and the 
14 patients who presented fungi in the IGB (13.86 %) did not present any 
clinical symptoms.
references: Crea N, Pata G, Della Casa D, et al. Improvement of metabolic 
syndrome following intragastric balloon: 1 year follow-up analysis. Obes 
Surg 2009;19:1084-8. 2.Mazure RA, Salgado G, Villarreal P, et al. Intragas-
tric balloon and multidisciplinary team. Nutr Hosp 2009;24:282-7. 3.Sallet 
JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intra-
gastric balloon. Obes Surg 2004;14:991-8
disclosure: Nothing to disclose 
P2067 WIThdraWn
P2068 vITaMIn d LeveLs In PaTIenTs WITh InfLaMMaTOry 
BOWeL dIsease
Stojkovic Lalosevic M.1, Markovic A.2, Stankovic S.3, Dragasevic S.4, 
Vojnovic M.2, Rankovic I.5, Stulic M.6, Muhovic D.7, Culafic D.3, Pejic N.8, 
Toncev L.9, Stojkovic M.10
1Clinical Center of Serbia, Gastroenterology and Hepatology, Belgrade, 
Serbia, 2Clinical Center of Serbia, Clinic for Gastroenterology and Hepatology, 
Belgrade, Serbia, 3Clinical Center of Serbia, Belgrade, Serbia, 4Clinical 
Center Serbia, School of Medicine, University of Belgrade, Clinic for 
Gastroenterology and Hepatology, Belgrade, Serbia, 5Clinical Centre of Serbia 
- Clinic for Gastroenterology, Belgrade, Serbia, 6Clinical center of Serbia, 
Clinic of gastroenterology and hepatology, Belgrade, Serbia, 7Clinical center 
of Montenegro, Podgorica, Montenegro, 8Clinical center of Serbia, Belgrade, 
Serbia, 9Clinical Center of Serbia, Clinic for gastroenterology and hepatology, 
Belgrade, Serbia, 10Kc Srbije, Belgrade, Serbia
contact e-Mail address: drmilicastojkovic@gmail.com
Introduction: Recently it has been shown that Vitamin D has a role in im-
munomodulation processes. Namely it promotes differentiation of lym-
phocytes as well as different interleukins such as IL-10, and it may have an 
effect on production of interferon γ.
aims & Methods: We aimed to assess Vitamin D levels in inflammatory 
bowel disease (IBD) patients as well as healthy individuals, and to exam-
ine is there a correlation of Vitamin D levels with disease activity. Com-
plete medical records of all patients with histologically diagnosed IBD 
were evaluated. As a control group we analyzed medical records of age 
and sex matched healthy volunteers, who had done their annual health 
check up. A case-control study was preformed among 45 newly diagnosed 
IBD patients and the same number age, sex matched healthy controls. All 
patients underwent a total colonoscopy with ileoscopy. Complete blood 
count was obtained in addition to inflammatory markers (CRP, erythrocyte 
sedimentation rate-ESR) and serum levels of 25-hydroxyVitamin D. Mayo 
score, UCEIS and CDAI respectively were calculated for each patient.
results: Vitamin D deficiency was noted in 60% of patients with IBD and 
32% healthy individuals. Serum levels of Vitamin D were significantly 
lower (P< 0.05) in IBD patients than controls. There were no significant 
differences in values of Vitamin D in relation to age or gender (P>0.05), al-
though the average values were lower in women. Additionally we have not 
found statistically significant differences in levels of Vitamin D in patients 
with UC compared to CD. Moreover serum levels of Vitamin D negatively 
correlated with CRP and ESR (P< 0.05). Additionally lower levels of Vitamin 
D negatively correlated with CDAI, UCEIS and Mayo score (P< 0.05).
conclusion: Our results suggest that IBD patients may have micronutrient 
deficiency more common than assumed. Additionally patients with active 
disease have significantly lower levels of Vitamin D, so there is a need for 
adequate supplementation.
disclosure: Nothing to disclose 
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P2069 The cLInIcaL sIgnIfIcance Of hyPOPhOsPhaTaeMIa 
afTer InTravenOus IrOn InfusIOns fOr IrOn defIcIency 
anaeMIa
Fragkos K.1, Sehgal V.1, Rogers J.1, Arulrajan S.2, Pavanerathan P.2, 
Barragry J.1, Sebepos-Rogers G.3, Mehta S.1, Di Caro S.1, Rahman F.1
1University College London Hospitals NHS Foundation Trust, GI Services, 
London, United Kingdom, 2University College London, Medical School, 
London, United Kingdom, 3Royal London Hospital, Gastroenterology, London, 
United Kingdom
contact e-Mail address: konstantinos.fragkos@nhs.net
Introduction: Intravenous (IV) iron is commonly used to treat iron deficien-
cy in patients with severe symptomatic anaemia or intolerance to oral iron 
supplements [1]. Ferric carboxymaltose (FCM) is a high dose IV iron known 
to cause a drop in serum phosphate level that often leads to hypophos-
phatemia [2]. Hypophosphataemia following FCM administration has been 
reported to be up 75%, but its clinical significance remains unknown [3].
aims & Methods: The purpose of this study was to investigate the propor-
tion of patients developing hypophosphataemia following FCM adminis-
tration and the potential clinical sequel in a tertiary university hospital. 
The medical records of inpatients that received an FCM infusion between 
Apr-2016 and Dec-2017 were retrospectively examined. Data on basic de-
mographics, haematinics, phosphate and related biochemistry, were col-
lected at baseline and five follow-up time points.
results: A total of 321 patients received FCM during the audit period; 61.4% 
were females. Mean weight ± SD at baseline was 66.7 ± 20.3 kg, age 54.3 ± 
23.8 years, haemoglobin 92.2 ± 0.8 g/L, ferritin 163.1 ± 288.5 µg/L, transfer-
rin saturation 13. 2± 13.5%. 25% of patients had inflammatory bowel dis-
ease (IBD). Mean iron dose per administration was 902.8 ± 177.4 mg, and 
19/321 (5.9%) of patients experienced a hypersensitivity reaction, of which 
3/321 (0.9%) requiring IV steroids. Mean baseline phosphate was 1.1 ± 0.3 
mmol/L and dropped to 0.97 ± 0.3 following FCM administration. 94/216 
(43.5%) of patients with available records had a phosphate level of < 0.8 
mmol/L, 63/216 (29.2%) < 0.65 mmol/L and 6/216 (2.8%) < 0.33 mmol/L at 
any time point up 90 days post-infusion. The temporal trend of phospate 
reduction is shown in Table 1. 
Patients that had a phosphate of <0.65 mmol/L 
at any point hypophosphataemia (n=63)
% of patients with 
phosphate of <0.8 
mmol/L
% of patients 
with phosphate 
of <0.65 mmol/L
0-7 days post FCM infusion (n with available 
data = 51)
42/51 (82.4%) 37/51 (72.6%)
8-14 days post FCM infusion (n with available 
data = 38)
25/38 (65.7%) 19/38 (50%)
15-29 days post FCM infusion (n with available 
data = 35)
23/35 (65.7%) 16/35 (54.3%)
30-60 days post FCM infusion (n with available 
data = 35)
27/35 (77.1%) 22/35 (62.8%)
>60 days post FCM infusion (n with available 
data = 11)
6/11 (54.5%) 5/11 (45.5%)
[Temporal trend of hypophospahatemia]
Of those developing hypophosphataemia, 11/94 (11.7%) received oral phos-
phate and 45/94 (47.9%) IV phosphate. Mean alkaline phosphatase in-
creased from 113.3 IU/L at baseline to 130.0 IU/L at 0-7 days and 146.7 IU/L 
at 8-14 days post iron infusion (p< 0.05).
conclusion: In the population examined, a high proportion of patients de-
veloped hypophosphataemia following FCM administration. In almost half 
of the cases that developed hypophosphataemia treatment with Oral/IV 
phosphate was necessary. A high proportion of those developing hypo-
phosphataemia had a low phosphate up to 90 days post iron infusion. Our 
data suggest that FCM-induced hypophosphataemia is persistent and has 
important clinical consequences.
references: [1] Koduru P, Abraham BP. The role of ferric carboxymaltose in 
the treatment of iron deficiency anemia in patients with gastrointestinal 
disease. Therapeutic advances in Gastroenterology. 2016 Jan;9(1):76-85. 
[2] Hardy S, Vandemergel X. Intravenous iron administration and hypo-
phosphatemia in clinical practice. International Journal of Rheumatology. 
2015;2015. [3] Fang W, McMahon LP, Bloom S, Garg M. Symptomatic severe 
hypophosphatemia after intravenous ferric carboxymaltose. JGH Open. 
2019.
disclosure: Nothing to disclose 
P2070 a eurOPean e-deLPhI survey: exPerT cOnsensus On 
ManageMenT Of IrOn defIcIency anaeMIa In PaTIenTs WITh 
gasTrOInTesTInaL BLeedIng
Schiefke I.1, Aksan A.2,3, Wehkamp J.4, Teich N.5, Keshav S.6, Stein J.2,3,7, 
For the Delphi Study Group
1Klinik für Gastroenterologie, Hepatologie, Diabetologie und Endokrinologie, 
Leipzig, Germany, 2Interdisciplinary Crohn Colitis Centre Rhein-Main, 
Frankfurt am Main, Germany, 3Goethe University, Institute of Pharmaceutical 
Chemistry, Frankfurt am Main, Germany, 4Medizinische Universitätsklinik, 
Innere Medizin I, Tübingen, Germany, 5Gastroenterologische 
Gemeinschaftspraxis, Leipzig, Germany, 6Oxford University Hospital, 
Nuffield Department of Medicine, Oxford, United Kingdom, 7DGD 
Clinics Sachsenhausen, Teaching Hospital of the Goethe University, 
Gastroenterology and Clinical Nutrition, Frankfurt/Main, Germany
contact e-Mail address: ayscak@gmail.com
Introduction: Gastrointestinal bleeding (GIB) is a common complication of 
many gastrointestinal conditions with a high mortality rate (5-11%), and 
one of the the most common causes of iron deficiency anaemia (IDA) (1, 
2). While IDA is known to occur in different gastrointestinal disorders, re-
cording and characterising GIB-related IDA (GIB-IDA) in heterogeneous 
GI conditions is challenging. Therefore, data are scarce and guidelines for 
diagnosis and management are lacking.
aims & Methods: This study aimed to use Delphi methodology to obtain 
an expert consensus on the optimal management of GIB-IDA. An e-Delphi 
Survey was conducted among 26 European experts in gastroenterology 
and IDA. Potential participants were chosen based on publications, es-
tablished clinical expertise and seniority in the workplace, and asked to 
complete a narrative questionnaire about their clinical practice and opin-
ion on GIB-IDA management. Questionnaires were qualitatively analysed 
to identify unique propositions for optimal management of GIB-IDA, which 
were used to formulate a Delphi Questionnaire with 13 different categories 
including 126 core statements. Here, we present data from the 5 main 
categories (with 54 statements): 1) Iron treatment for iron deficiency and 
IDA; 2) Oral iron (reasons to use); 3) Oral iron (reasons not to use); 4) Intra-
venous (IV) iron (reasons to use); 5) IV iron (reasons not to use). Consensus 
was defined as at least 75% agreement on the proposition.
results: Consensus was reached in support of 17 of the 54 statements pro-
posed. The 5 statements with the strongest (>91%) consensus were: 1) In 
mild anaemia, oral iron may suffice; 2) Clinical findings which suggest 
the use of IV iron as part of the treatment of IDA include a history of mal-
absorption states associated with poor absorption of oral iron, such as 
coeliac disease; 3) First line IV iron treatment should be considered when 
adverse effects of oral iron occur; 4) The price of IV iron formulations is 
mostly the reason to use oral iron first line to treat anaemia due to GI 
bleeding, and 5) A consensus on methods for administration of available 
IV iron products is needed to reduce inappropriate blood transfusion.
conclusion: Our study suggests that current use of iron therapy by experts 
in the field is driven by clinical and cost-orientated considerations, rather 
than by clinical assessment and therapeutic targets or treatment thresh-
olds. Although experts recognise the importance and effectiveness of IV 
iron products, consensus is lacking regarding the use of IV iron as first-line 
therapy in patients with GIB-IDA, although studies show that it may be 
faster and more cost-effective than oral iron.1,2 New guidance is therefore 
needed concerning the optimal therapy of GIB-IDA, including recommen-
dations on the use of IV iron formulations.
references: 1. Pasha SF, Hara AK, Leighton JA. Diagnostic evaluation and 
management of obscure gastrointestinal bleeding: a changing para-
digm. Gastroenterology & hepatology. 2009;5(12):839-50. 2. Rollhauser 
C, Fleischer DE. Nonvariceal upper gastrointestinal bleeding. Endoscopy. 
2004;36(1):52-8.
disclosure: A. Aksan has received congress expenses from Vifor Pharma. J. 
Stein has received fees for consultancy and lecturing from Pharmacosmos, 
and Vifor. 
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results: 49 in-patients were identified over the 3month period, an an-
nualised PN workload of approx. 200 pts/yr. Mean age was 69.2y (46-93), 
mean weight prior to commencing PN 75.3kg (41.1-114.8kg). 22/49 pts were 
surgical, 1/49 medical and 16/49 on intensive care. 25/49 pts had a clearly 
documented indication (ITU 5/16, medicine 10/11, surgery 10/22) but only 1 
patient had a documented anticipated duration for PN. Mean duration was 
10 days (1-32) and mean length of inpatient stay was 21 days (4-53). Only 
7/49 pts were reviewed by a Nutritional MDT team, although all pts were 
regularly reviewed by Dieticians. 
Reasons for discontinuing PN: oral feeding resumed in 28 pts, death/end 
of life care commenced in 10 pts, NG/NJ/PEG feeding commenced in 6 pts, 
patient refusal in 2 pts and 3 pts transferred to a tertiary service. 
Complications: Abnormal LFTs in 3 pts, abnormal electrolytes in 33 pts and 
1 midline associated thrombophlebitis. 16/49 pts had daily testing of serum 
biochemistry. 30 day all-cause mortality from commencing PN was 18% 
(9/49).
conclusion: Our study shows the need for a quality improvement program 
for PN including documentation of indications and goals of PN treatment. 
Patients commencing PN should be reviewed by a Nutrition MDT to im-
prove initial assessment and monitoring. A decreased compliance with 
daily serum biochemistry correlates with an increased incidence of elec-
trolyte abnormality.
disclosure: Nothing to disclose 
P2073 PreLIMInary anaLysIs Of The quaLITy Of LIfe and 
nuTrITIOnaL sTaTus In PaTIenTs referred fOr PercuTaneOus 
endOscOPIc gasTrOsTOMy: BenefIcence Or nOn-MaLefIcence?
Santos A.L.1,2,3, Ramalho R.1,2,3, Coelho R.1,2,3, Macedo G.1,2,3
1Centro Hospitalar de São João, Gastroenterology, Porto, Portugal, 2WGO 
Oporto Training Center, Porto, Portugal, 3Porto Medical School, University of 
Porto, Porto, Portugal
contact e-Mail address: anaasantos89@gmail.com
Introduction: The Percutaneous Endoscopic Gastrostomy (PEG) is an option 
for long-term enteric feeding, specially in patients with neurologic condi-
tions that affect swallowing or with oropharyngeal malignancies.
aims & Methods: With this study, we intend to determine how the PEG af-
fect health-related quality of life (HRQoL) and the nutritional status (NS) in 
patients who were submitted to the procedure. Prospective and unicentric 
study, designed to assessment HRQoL and NS in patients who received 
PEG between November 2018 and February 2019 as well as the impact of 
the procedure in these variables. The HRQoL was assessed with the por-
tuguese version of EQ-5D questionnaire and the NS with Mini Nutritional 
Assessment (MNA), that were performed to the patient or his/her caregiver 
(in case of response incapacity of the patient), at the time of PEG perform 
and 2-3 months after that.
results: A total of 21 patients were included, 52% of male gender, with 
a mean age of 71±18 years. The nasogastric tube was the main form of 
feeding (76%), with a median time of use of 5 months (IQR 2-12). In 31% 
of cases, the body mass index (BMI) was lower than normal (mean BMI 
of 20±4 kg/m2). According to MNA, 60% of patients were undernourished 
and 33% with risk of that; among these two groups, an early age was as-
sociated to undernourished (p=0.024). In 43% of cases, the health status 
was considered worse when compared with 12 months before the PEG 
perform. Nine patients were contacted after received the PEG, in a mean 
time of 3±1 months; 10% of cases were death, due to causes not related to 
the procedure. It was verified an improvement in NS with a paired increase 
of the mean value of MNA after PEG placement (p=0.027). In EQ-5D, it 
was verified an improvement in capacity of perform daily routine activi-
ties (p=0.046). Moreover, a subjective improvement in terms of physical, 
psychological and emotional welfare was reported (100%, 86% and 71%, 
respectively).
conclusion: PEG placement was associated to an improvement in NS and 
also to one factor in terms of HRQoL. The subjective assessment, in terms 
of welfare, was overall positive.
disclosure: Nothing to disclose 
P2071 PrOTeIn energy MaLnuTrITIOn aLTers 
ePITheLIa-MIcrOBe InTeracTIOns In The InTesTInaL TracT 
WITh LOng-LasTIng cOnsequences fOr InfLaMMaTOry 
suscePTIBILITy
Sommer F.1, Hamm J.2, Häsler R.1, Thingholm L.1, Klischies K.1, 
Sommer N.1, Franke A.1, Rosenstiel P.3
1Kiel University, Institute of Clinical Molecular Biology, Kiel, Germany, 
2University Hospital Schleswig Holstein, Institute of Clinical Molecular 
Biology, Kiel, Germany, 3Kiel University, University Hospital Schleswig-
Holstein, Institute of Clinical Molecular Biology (IKMB), Kiel, Germany
contact e-Mail address: f.sommer@ikmb.uni-kiel.de
Introduction: Maintaining health requires a homeostatic equilibrium be-
tween the microbial community and the intestinal epithelium that serves 
as the regulatory interface with the host. Nutritional stressors such as mal-
nutrition, starvation or caloric restriction disturb this equilibrium and thus 
provoke changes in the function of the intestinal microbiota and intestinal 
mucosa.
aims & Methods: We aimed to elucidate the mechanisms underlying the 
complex tripartite interplay between microbiota, the intestinal epithelium 
and the environment (nutritional stressors). We therefore developed ex-
perimental protein energy malnutrition (PEM) models to investigate the 
effects of adult, postnatal and prenatal PEM on the microbiota and host 
physiology, in particular inflammatory susceptibility.
results: We found that PEM induced drastic modifications of the host’s 
gastrointestinal tract but also systemic immunity and metabolism. A single 
episode of PEM extensively changed the overall microbiota composition 
enriching for Gammaproteobacteria and Bacteroidaceae while deplet-
ing for Actinobacteria and Verrucomicrobia along with the functional 
metagenomic repertoire. The intestinal epithelial transcriptome was also 
largely reprogrammed in response to PEM. PEM-induced changes in the 
microbiota and epithelial transcriptome partially remained upon switch-
ing to control diet, indicating a “memory effect”. Most important, the long 
lasting PEM-induced microbiome and transcriptome changes also altered 
the inflammatory susceptibility in an experimental colitis model in vivo. 
On-going experiments aim at determining whether PEM phenotypes are 
transmissible, for example from the mother to offspring or solely through 
the altered microbiome.
conclusion: Our data identified alterations in the microbiome and epithe-
lial transcriptome as potential molecular mechanisms underlying the long 
lasting physiologic consequences of PEM, thus paving the way to develop 
probiotic therapeutic interventions for malnutrition.
disclosure: Nothing to disclose 
P2072 deLIverIng ParenTeraL nuTrITIOn - reaL WOrLd 
chaLLenges
Rayner D., Harkess S., McFarland D., Lee S., Dhar A.
Darlington Memorial & Bishop Auckland Hospitals, Gastroenterology, Co. 
Durham, United Kingdom
contact e-Mail address: daniellerayner@nhs.net
Introduction: Parenteral nutrition (PN) is widely used to intravenously de-
liver nutrition to patients with non-functioning or inaccessible gut. The 
National Confidential Enquiry into Patient Outcome and Death (NCEPOD) 
report in 2010, “A Mixed Bag” found good practice regarding PN in only 
19% of cases. It recommended an urgent need to deliver high quality nu-
trition to all patients in hospital.
aims & Methods: This audit was designed to evaluate our Parenteral Nu-
trition Service against NCEPOD review. The primary aim was to establish 
whether the key recommendations of the NCEPOD report are being ad-
hered to: documentation of indication and its appropriateness, consider-
ation of enteral options, clinical and biochemical monitoring during PN, 
duration of PN and any complications. All adult inpatients who received PN 
at Darlington Memorial Hospital and University Hospital of North Durham 
between June- August 2018 were identified from 2 electronic databases 
viz. referrals to dietetics and electronic prescribing software. 
Data collection was done from case notes, inpatient electronic prescrip-
tion charts and pathology results. Baseline demographics, documented 
indication for PN, anticipated and actual duration of PN, reason for dis-
continuing PN and associated complications were recorded and analysed 
using Excel®.
1028 UEG Journal | Abstract Book
W
ed
ne
sd
ay
, O
ct
ob
er
 2
3,
 2
01
9
Tu
es
da
y,
 O
ct
ob
er
 2
2,
 2
01
9
M
on
da
y,
 O
ct
ob
er
 2
1,
 2
01
9
aims & Methods: To give clinical, endoscopic and morphological charac-
teristics of various variants of chronic inflammatory pathology of the stom-
ach and duodenum in children.
Patients and methods. 112 children aged 6 - 17 with chronic inflammatory 
pathology of the stomach and duodenum were examined.
results: Chronic inflammatory disorders of the stomach and duodenum in 
children presents 4 variants: isolated duodenitis, duodenogastric, antrum 
gastritis and pangastritis. In isolated duodenitis in children (17.9 %), mor-
phologically, moderate or severe inflammation in the duodenum mucosa 
in the intact body and the antral region of the stomach is determined. 
Duodenogastric (19.6 %) characterizes by the appearance of a slight su-
perficial inflammation in the antrum. In antrum-gastritis (10.7 %), it has a 
moderate or severe degree, and in some patients can be combined with 
an initial process in the body of the stomach. 
Pangastritis (51.8 %) is characterized by the presence of moderate or se-
vere common inflammation often hyperplasic with follicular or erosive 
bulbitis. Colonization of the gastric mucosa Hp has differences, depending 
on the topical version. In the body of the stomach, it is absent or insignifi-
cant in patients with the first three options, in pangastritis. Hp is deter-
mined in the body in all cases, and in a third of patients (34.4 %) a moder-
ate or severe degree of colonization Of Hp of the body of the stomach is 
recorded. In antrum-gastritis and pangastritis 83.2 % of children found 
highly pathogenic strains of Hp. A common feature of all topic variants is 
the presence of chronic duodenitis. Insulated gastritis without involving in 
process of the mucosa of the duodenum in children is not detected. There 
are no significant differences in clinical manifestations of certain topical 
variants of chronic inflammatory pathology of the stomach and duodenum 
in children.
conclusion: Chronic inflammatory disorders of the stomach and duode-
num in children is heterogeneous and includes 4 variants: isolated duo-
denitis, duodenogastric, antrum gastritis and pangastritis. In the absence 
of differences in clinical manifestations, each variant is characterized by 
features of pathomorphology of the mucosa of the stomach and duode-
num, as well as colonization of Hp.
disclosure: Nothing to disclose 
P2076 safeTy and effIcacy Of The raPId reaL TIMe 13c-uBT 
dIagnOsTIc fOr h. PyLOrI deTecTIOn In chILdren
Shirin H.1, Shalem T.1, Sunny Z. H.2, Leung D.3, Raj P.4, Troendle D.M.5, 
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Introduction: Helicobacter pylori (H. pylori) infection in children is often 
acquired in the first five years of life and differs from that in adults.
The ELISA stool antigen test is considered convenient for use in children 
due to lack of a more convenient method. The performance of the Urease 
breath test (UBT) was reported to be with a sensitivity of only 76.2%, due 
to antibiotic and PPI consumption.
aims & Methods: Our aim was to investigate the safety and efficacy of the 
Exalenz Bioscience 13C-Urea Breath Test using the BreathID® Hp systems 
compared to the stool antigen test in the pediatric population.
Fifty three (53) children were enrolled to perform the 13C-Urea Breath Test 
via both the BreathID® Hp Point-of Care (POC) System and the BreathID® 
Hp Lab System means of breath collection. Results of both breath collec-
tion methods were compared with stool antigen testing
results: BreathID® Hp POC System sensitivity was 93.3% [95% CI (68.05%; 
99.83%)] and specificity was 100% [95% CI (86.77%; 100.00%)] compared 
to stool antigen. The overall agreement in detection of H.pylori using the 
BreathID® Hp POC System breath test compared to the stool antigen test 
was 97.56% [95% CI (87.14%; 99.94%)]. BreathID® Hp Lab System sen-
sitivity was 93.3% [95% CI (68.05%; 99.83%)] and specificity was 100% 
[95% CI (87.23%; 100.00%)]compared to stool antigen. The overall agree-
P2074 sIMPLe BedsIde PredIcTOrs Of PercuTaneOus 
gasTrOsTOMy TuBe InserTIOn fOr shOrT-TerM MOrTaLITy
Khoury T.1, Kadah A.2, Mahamid M.3, Mari A.4, Salman A.5, Sbeit W.2
1Galilee Medical Center, Gastroenterology, Naharia, Israel, 2Galilee Medical 
Center, Gastroenterology, Nahariya, Israel, 3Sharee Zedek Medical Center 
and the Nazareth Hospital EMMS, Gastroenterology and Liver Disaeses, 
Jerusalem, Israel, 4Nazareth EMMS Hospital, Gastroenterology, Qalansawa, 
Israel, 5Galilee Medical Center, Internal Medicine, Nahariya, Israel
contact e-Mail address: tawfik.khoury.83@gmail.com
Introduction: Percutaneous endoscopic gastrostomy (PEG) tube insertion 
has become the most common method for oral enteral nutrition and is 
mainly reserved for patients who are unable to maintain long-term ad-
equate oral feeding for at least 2-3 weeks and for malnourished patients 
who are unable to satisfy the body energy requirements. The American 
Gastroenterological Association recommend PEG insertion in patients who 
are expected to survive for more than 1 month after the procedure.
aims & Methods: We aimed to explore simple easily available clinical and 
laboratory predictors for shor-term survival (within 1- month) after PEG 
insertion. We performed a single center retrospective study of all patients 
18 years old or older who underwent primary PEG insertion for various 
clinical indication at Galilee Medical Center from January 1st 2014 to De-
cember 30th 2018. Primary comparison was performed between patients 
who survived more than 1 month after PEG insertion (long-term survival 
)to patients who died within 1 month of the procedure (short-term mor-
tality).
results: A total of 272 patients who underwent primary PEG insertion. Six-
ty-four patients (23.5%) died within one month after PEG insertion (group 
A), compared to 208 patients (76.5%) survived more than 1 month (group 
B). The mean age in group A was 77.3 ± 14 years as compared to 70.4 ± 
17 years in group B. Thirty-two patients (11.8%) were males in group A, 
compared to 103 patients (37.8%) in group B. The most common two indi-
cations for primary PEG insertion in groups A and B were dementia (43.7% 
vs. 34.6%) and stroke (40.6% vs. 35.6%), respectively. 
In univariate regression analysis, only serum albumin and hemoglobin 
levels were positively correlated with long-term survival following PEG 
insertion (more than 1-month) (OR 2.973, 95% CI 1.641-5.387, P=0.0003, 
OR 1.294, 95% CI 1.101-1.520, P=0.0018), respectively. On the other hand, 
several predictors identified showed negative correlation with long-term 
survival. Older age (OR 0.971, 95% CI 0.952-0.991, P=0.005), ischemic 
heart disease (OR 0.494, 95% CI 0.273-0.893, P=0.0197), higher creati-
nine level (OR 0.438, 95% CI 0.249-0.772, P=0.0043), elevated CRP level 
(OR 0.992, 95% CI 0.988-0.996, P< 0.0001) and CRP to albumin ratio (OR 
0.9, 95% CI 0.970 - 0.989, P< 0.0001). On multivariate logistic analysis, 
older age (OR 0.9, 95% CI 0.952-0.996, P=0.019), higher creatinine level 
(OR 0.63, 95% CI 0.379-1.046, P=0.074), and elevated albumin to CRP 
ratio (OR 0.9, 95% CI 0.974-0.994, P=0.002) correlated with short-term 
mortality after PEG insertion, while hemoglobin level remained positively 
correlated with long-term survival (OR 1.18 95% CI 0.995-1.401, P=0.05), 
with ROC of 0.7274.
conclusion: We have showed that simple clinical and laboratory bedside 
parameters including old age, higher creatinine level and elevated CRP to 
albumin ratio could be useful aid in avoiding gratuitous PEG insertion in 
these patients population with high risk for short-term mortality.
disclosure: Nothing to disclose 
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P2075 varIanTs Of The chrOnIc hP-assOTIeTed 
InfLaMMaTOry PaThOLOgy Of The sTOMach and duOdenuM 
In chILdren
Eugeny S., I.S.Akkuratova, E.M.Spivak, R.M.Levit,
Yaroslavl State Medical University, Paediatric, Yaroslavl, Russian Federation
contact e-Mail address: spivak58@mail.ru
Introduction: The detailed location of the process in chronic inflammatory 
pathology of the stomach and duodenum it is important, because differ-
ent variants of location have their own etiopathogenetic mechanisms and 
prognosis.
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ment in detection of H.pylori using the BreathID® Hp Lab System breath 
test compared to the stool antigen test was 97.62% [95% CI (87.43%; 
99.94%)]. One minor possibly related adverse event was recorded
conclusion: The 13C-Urea Breath Test is an accurate, safe, easy to perform, 
non-invasive method, which aids in confirming the presence or eradica-
tion of H. pylori infection. Both breath sample collection methods -the 
BreathID® Hp POC System and the BreathID® Hp Lab System- are safe 
and efficacious diagnostic tests in children, without serious adverse events 
(SAE). The substrate dose used in children is safe.
disclosure: Nothing to disclose 
P2077 The InfLuence Of dIagnOsTIc deLays On grOWTh Of 
chILdren WITh cOeLIac dIsease In cenTraL eurOPe
Riznik P.1, De Leo L.2, Dolinsek J.3, Gyimesi J.4, Klemenak M.1, Koletzko B.5,6, 
Koletzko S.6, Korponay-Szabó I.R.4,7, Krencnik T.1, Not T.2, Palcevski G.8, 
Sblattero D.9, Werkstetter K.J.6, Dolinsek J.1,10
1University Medical Centre Maribor, Department of Paediatrics, Maribor, 
Slovenia, 2IRCCS Burlo Garofolo Trieste, Institute for Maternal and Child 
Health, Trieste, Italy, 3Municipality of Maribor, Project Office, Maribor, 
Slovenia, 4Heim Pál National Paediatric Institute, Coeliac Disease Centre, 
Budapest, Hungary, 5Dr. von Hauner Children’s Hospital, LMU Munich, 
Stiftung Kindergesundheit (Child Health Foundation), Munich, Germany, 
6Dr. von Hauner Children’s Hospital, LMU, Munich, Clinical Medical Centre, 
Munich, Germany, 7University of Debrecen, Faculty of Medicine, Department 
of Paediatrics, Debrecen, Hungary, 8University Hospital Rijeka, Department 
for Gastroenterology, Paediatric clinic, Rijeka, Croatia, 9University of Trieste, 
Trieste, Italy, 10Universtiy of Maribor, Faculty of Medicine, Department of 
Paediatrics, Maribor, Slovenia
contact e-Mail address: petra.riznik@gmail.com
Introduction: Coeliac disease (CD) is one of the most common systemic 
immune-mediated disorders. Undiagnosed and untreated CD can seri-
ously affect nutritional status and growth of affected children.
aims & Methods: The aim of our study was to assess the influence of diag-
nostic delays on growth in newly diagnosed children with CD in the Central 
European (CE) region.
We conducted an anonymised multi-centre web-based survey that was 
filled out by paediatric gastroenterologists from five CE countries, provid-
ing us with data from medical records of CD patients aged < 19 years with 
CD diagnosis in 2016. Z-scores for weight and height of children with CD 
at the time of diagnosis were calculated, based on the WHO reference, 
and related to diagnostic delays measured as the time interval from the 
symptom onset to confirmation of the diagnosis. Statistical analysis was 
performed using IBM SPSS Statistics 22.0 for Windows.
results: Data from 393 symptomatic children (65% female) diagnosed at a 
median age of 7 years (range 7m-18.5y) from Croatia, Hungary, Germany, 
Italy and Slovenia were included. The median delay from onset of symp-
toms to confirmation of the diagnosis was 6m (range 0m-10y). At the time 
of CD diagnosis, median z-score for weight was -0.44 (min -4.59; max 
3.53) and for height -0.07 (min -4.60; max 7.29). No differences were found 
between girls and boys. Twenty-six of the included children (6.6%) had 
diagnostic delays longer than 3 years (Table 1). They had lower weight and 
shorter stature compared to those with the delays of less than one year (z-
score for weight: -0.93 and -0.39 respectively, p< 0.05; z-score for height: 
-0.50 and -0.04 respectively; NS). There was a weak negative correlation 
between diagnostic delays and z-scores for weight (r=-0.105) and height 
(r=-0.115) (both p< 0.05).
dIagnOsTIc 
deLay
number of patients 
(%)
Weight z-score 
(median)
height z-score 
(median)
0-12 months 288 (73.3%) -0.39 -0.04
13-24 months 58 (14.8%) -0.45 -0.27
25-36 months 21 (5.3%) -0.78 -0.29
>36 months 26 (6.6%) -0.93* -0.50
*significant difference vs. 0-12m delays (p<0.05)
[The influence of diagnostic delays on weight and height of children with 
coeliac disease.]
conclusion: Children with CD had slightly lower body mass at the time of 
diagnosis but similar height compared to healthy children. Longer diag-
nostic delays lead to progressively lower body mass and, to a lesser de-
gree, also to shorter stature. Efforts are needed to prevent long diagnostic 
delays and resulting complications, which may permanently affect child 
development as well as final height and health in adulthood. 
*Study was co-financed by Interreg CE programme (CE 111, Focus IN CD)
disclosure: Nothing to disclose 
P2078 hOW LOng shOuLd We fOLLOW chILdren WhO have 
a fIrsT-degree reLaTIve WITh cOeLIac dIsease ?
Korponay-Szabó I.R.1,2, Gyimesi J.3, Koletzko S.4, Mearin L.5, Dolinsek J.6, 
PreventCD, Focus in CD
1University of Debrecen Faculty of Medicine, Paediatrics, Debrecen, Hungary, 
2Heim Pál National Pediatric Institute, Coeliac Disease Centre, Budapest, 
Hungary, 3Heim Pal Childrens Hospital, Coeliac Disease Centre, Budapest, 
Hungary, 4Medizin. Universität München Dr. v. Hauner Kinderklinik, Ped. 
Gastroenterologie, München, Germany, 5LUMC, WAKZ, Leiden, Netherlands, 
6UMC Maribor, Pediatric department, Maribor, Slovenia
contact e-Mail address: ilma.korponay-szabo@uta.fi
Introduction: Family members of patients with coeliac disease (CeD) have 
10-40% risk of CeD during lifetime and most affected subjects develop 
the disease between the age of 2-6 years according to prospective cohort 
studies. In this study we investigated whether 9 and 12 years old children 
have new seroconversion and whether gluten consumption habits influ-
ence the prevalence.
aims & Methods: First-degree family members (FDR) presenting for screen-
ing were prospectively enrolled and followed by measuring serum trans-
glutaminase 2-specific (TGA) and endomysial (EMA) antibodies at age 3 
and 6 years. Children currently aged 9 and 12 years were called for new 
blood drawings. The investigated cohorts included 134 children from the 
PREVENTCD study (www.preventcd.com) with randomised early gluten in-
troduction at age 4 or 6 months, a wild cohort (n=302) born in the same 
years but starting gluten as wished by parents, and other FDR persons with 
multiple screenings. CeD diagnosis was confirmed by histology showing 
Marsh III lesions. Results were compared with prevalence data of cross-
sectional FDR screening performed first time at the specified age time-
points. HLA-DQ testing was performed if a genetic sample was available.
results: Altogether 1007 FDR children at risk had an evaluation by TGA 
testing at age 9 (n=506) or 12 (n=501), or both. No cases occurred in chil-
dren who were negative for both HLA-DQ2 and DQ8 alleles and gluten in-
troduction time did not influence prevalence. From the children who were 
still negative at age 3, 10.2% (19/185) developed CeD by age 6, and from 
those still negative at age 6, 12.0% (3/25) developed CeD by age 9, but no 
new cases occurred between 9 and 12 years of age. Higher proportions of 
positives were found at 9 years of age (66/362, 18.2%) or 12 years of age 
(51/326, 15.6%, p< 0.01), if screening has not been implemented before 
these timepoints or the index patient was diagnosed only at that time.
conclusion: Periodic screening of children at risk should be continued until 
the age of 9 years. 
Grant support: GINOP-2.3.2-15-2016-00015, NKFI 120392, EFOP-3.6.1-16-
2016-00022, CE111 Interreg Focus in CD.
disclosure: Nothing to disclose 
P2079 exPLOrIng The PrOfILe Of ceLIac dIsase BeTWeen 
aduLT and PedIaTrIc ceLIac PaTIenTs
Zelnik Yovel D.1, Broide E.2, Shirin H.2
1Shamir (Assaf Harofeh) Medical Center, Department of Internal Medicine 
‘C’, Zerifin, Israel, 2Shamir (Assaf Harofeh) Medical Center, The Kamila 
Gonczarowski Institute of Gastroenterology and Liver Diseases, Zerifin, Israel
contact e-Mail address: danazelnik@gmail.com
Introduction: Past studies reported differences in disease expression, epi-
demiology, coexisting diseases, complications, and association with obe-
sity, between pediatric and adult patients with celiac disease (CD). The 
purpose of this study was to compare demographic, clinical and social 
data as well as adherence status between pediatric and adults celiac dis-
ease patients.
aims & Methods: An anonymous online questionnaire has been sent via 
the Israeli Celiac association and through social networks. Socio-demo-
graphic and clinical data were reported. Adherence to GFD was assessed 
by Biagi questionnaire.
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results: 445 patients were included in the study, mean age 25.7±17.5 years, 
71.9% female. Patients were divided into 6 different age groups- under 6 
years old (134 patients) , 6-12 (79 patients), 12-18 (41 patients), 18-30 (81 
patients), 30-45 (79 patients) and 45 + years old (23 patients). Abdominal 
pain, diarrhea, distended abdomen, anemia, TSH abnormalities and short 
stature had different prevalence among the different age groups. We found 
significant differences in - Gender (more females in the adult group- 78% 
vs 63%, P< 0.001) as well as in ethnicity (more Ashkenazy Jew in the adult 
group, 62% vs 45%, P< 0.001). The pediatric group had more frequent 
gastroenterology and dietitian follow up (p< 0.001 in both). Pediatric pa-
tients reported to be more frequent a part of a supporting group compared 
to adults (p=0.002). Finally, pediatric patients were found to be more com-
pliant to GFD compared to adults (p< 0.001).
conclusion: there are differences in the clinical profile of celiac disease 
between children and adults. Pediatric celiac patients are more adherent 
to GFD. Different management approach should be considered in the dif-
ferent age groups.
disclosure: Has been accepted to present as well in the international celiac 
disease symposiun ICDS 2019 in Paris. 
P2080 dOes shOrT segMenT cOeLIac dIsease cOnfIned 
TO The duOdenaL BuLB have a unIque cLInIcaL, serOLOgIcaL 
Or hIsTOLOgIcaL PrOfILe?
Broide E.1, Paz H.2, Shalem T.3, Zelnik Yovel D.4, Shirin H.1
1Shamir (Assaf Harofeh) Medical Center, The Kamila Gonczarowski Institute 
of Gastroenterology and Liver Diseases, Zerifin, Israel, 2Shamir (Assaf 
Harofeh) Medical Center, Pediatric Division, Zerifin, Israel, 3Shamir (Assaf 
Harofeh) Medical Center, The Jecheskiel Sigi Gonczarowski Pediatric 
Gastroenterology Unit, Zerifin, Israel, 4Shamir (Assaf Harofeh) Medical 
Center, Department of Internal Medicine ‘C’, Zerifin, Israel
contact e-Mail address: danazelnik@gmail.com
Introduction: Coeliac disease (CD) is a common autoimmune enteropathy 
with increased prevalence worldwide. The diagnosis is based on positive 
serological tests with proved histological findings in the duodenum. Due 
to possible patchy villous atrophy pattern, the histological features may be 
presented only at the duodenal bulb in about 11% of CD patients. So far, 
any possible association between isolated CD of the duodenal bulb and 
unique profile of such patients has not been fully explored. 
We aimed in this study to investigate whether short segment coeliac dis-
ease (SSCD) confined only to the duodenal bulb in pediatric patients has a 
unique demographic, clinical, laboratory or histological profile at the time 
of diagnosis compared to more extensive CD.
aims & Methods: We conducted a retrospective study which included all 
children, aged 1-18 years who underwent upper endoscopy with duodenal 
biopsies for a suspicious CD at the Pediatric Gastroenterology Unit in “As-
saf Harofhe” Medical Center, Israel. Endoscopies were done between Janu-
ary 2013 and august 2108. The diagnosis of CD was made in accordance 
with the ESPGHAN criteria. Demographic, clinical data (celiac-associated 
symptoms), family history of CD and laboratory results (hemoglobin, fer-
ritin, and coeliac serology) at diagnosis as well as histological data were 
recorded. Histological severity was assessed by MARSH classification.
results: Out of 160 suspected CD patients, 22 and 19 children were ex-
cluded due to lack of serology or a diagnosis of potential CD respectively. 
Twenty two out of the remaining 113 children had disease confined only to 
the duodenal bulb-SSCD (19%). The only difference between SSCD to more 
extensive CD was that children diagnosed with SSCD had lower serum level 
of anti-TTG antibodies at presentation (p< 0.01). 
No significant differences between the two groups were documented in 
the demographic, clinical and histological features.
conclusion: SSCD is more common than previously reported in the litera-
ture. Despite lower serology titer the histological severity is similar. More 
prospective studies are needed to illuminate this issue.
disclosure: Nothing to disclose 
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